doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_head	arg_protein	arg_domain	arg_site	arg_sugar	arg_head_offset	arg_base_np	arg_base_np_offset	arg_np	arg_np_offset	sent_text
33073321	0	0	from	glycopeptides	32:44	arg1	patients					63:70	kidney cancer patients	49:70	kidney cancer patients	49:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	6	1	theme	complement	1618:1627	arg1	process					1640:1646	complement activation process	1618:1646	complement activation process	1618:1646	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	2	theme	Further	1302:1308	arg1	analysis					1324:1331	Further gene ontology analysis	1302:1331	Further gene ontology analysis of molecular function and biological process	1302:1376	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	3	theme	original	1395:1402	arg1	glycoproteins					1404:1416	13 original glycoproteins	1392:1416	13 original glycoproteins of the identified glycopeptides from urine of patients	1392:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	4	theme	facile	286:291	arg1	strategy					315:322	a facile one-step modification strategy	284:322	a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique	284:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	4	5	theme	BSA	938:940	arg1	digests					942:948	BSA digests	938:948	BSA digests	938:948	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	1	6	theme	magnetic	214:221	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	6	theme	magnetic	214:221	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	6	7	theme	process	1370:1376	arg1	analysis					1324:1331	Further gene ontology analysis	1302:1331	Further gene ontology analysis of molecular function and biological process	1302:1376	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	8	theme	organic	229:235	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	8	theme	organic	229:235	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	5	9	theme	kidney	1149:1154	arg1	cancer					1156:1161	kidney cancer	1149:1161	kidney cancer	1149:1161	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	6	10	theme	biological	1359:1368	arg1	process					1370:1376	biological process	1359:1376	biological process	1359:1376	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	11	theme	antigen	1597:1603	arg1	binding					1605:1611	antigen binding	1597:1611	antigen binding	1597:1611	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	12	theme	Zr-MOF	252:257	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	12	theme	Zr-MOF	252:257	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	0	13	from	patients	63:70	arg1	Recognition					0:10	Recognition	0:10	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate	0:98	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	6	14	theme	function	1346:1353	arg1	analysis					1324:1331	Further gene ontology analysis	1302:1331	Further gene ontology analysis of molecular function and biological process	1302:1376	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	5	15	theme	people	1124:1129	arg1	urine					1107:1111	urine	1107:1111	urine of healthy people	1107:1129	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	3	16	theme	straightforward	670:684	arg1	manner					699:704	a straightforward coordination manner	668:704	a straightforward coordination manner	668:704	Hydroxyl-rich glucose-6-phosphate was immobilized onto the Zr-MOF via a straightforward coordination manner to regulate its surface property, for the purpose of enhancing its hydrophilicity.
33073321	4	17	theme	detection	983:991	arg1	0.1 fmol μL-1					994:1006	0.1 fmol μL-1	994:1006	0.1 fmol μL-1	994:1006	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	17	theme	detection	983:991	arg1	selectivity					892:902	good selectivity	887:902	good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200)	887:964	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	17	theme	detection	983:991	arg1	limit					974:978	low limit	970:978	low limit of detection (0.1 fmol μL-1)	970:1007	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	18	theme	Zr-MOF	820:825	arg1	merits					810:815	the merits	806:815	the merits of Zr-MOF and glucose-6-phosphate	806:849	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	6	19	theme	identified	1425:1434	arg1	glycopeptides					1436:1448	the identified glycopeptides	1421:1448	the identified glycopeptides from urine of patients	1421:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	3	20	theme	surface	722:728	arg1	property					730:737	its surface property	718:737	its surface property	718:737	Hydroxyl-rich glucose-6-phosphate was immobilized onto the Zr-MOF via a straightforward coordination manner to regulate its surface property, for the purpose of enhancing its hydrophilicity.
33073321	1	21	gly	glycopeptide	338:349	arg2	glycopeptide					338:349	selective glycopeptide capture	328:357	selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique	328:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	4	22	theme	standard	1055:1062	arg1	samples					1064:1070	standard samples	1055:1070	standard samples	1055:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	6	23	theme	ontology	1315:1322	arg1	analysis					1324:1331	Further gene ontology analysis	1302:1331	Further gene ontology analysis of molecular function and biological process	1302:1376	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	24	theme	collagen	1546:1553	arg1	binding					1555:1561	collagen binding	1546:1561	collagen binding	1546:1561	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	0	25	theme	hydrophilic	75:85	arg1	carbohydrate					87:98	hydrophilic carbohydrate	75:98	hydrophilic carbohydrate	75:98	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	1	26	theme	hydrophilic	372:382	arg1	chromatography					396:409	hydrophilic interaction chromatography	372:409	hydrophilic interaction chromatography technique	372:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	6	27	theme	diverse	1502:1508	arg1	process					1640:1646	complement activation process	1618:1646	complement activation process	1618:1646	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	27	theme	diverse	1502:1508	arg1	events					1528:1533	diverse cancer-associated events	1502:1533	diverse cancer-associated events	1502:1533	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	27	theme	diverse	1502:1508	arg1	binding					1605:1611	antigen binding	1597:1611	antigen binding	1597:1611	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	27	theme	diverse	1502:1508	arg1	binding					1588:1594	immunoglobulin receptor binding	1564:1594	immunoglobulin receptor binding	1564:1594	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	27	theme	diverse	1502:1508	arg1	binding					1555:1561	collagen binding	1546:1561	collagen binding	1546:1561	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	28	theme	carbohydrate	186:197	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	28	theme	carbohydrate	186:197	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	0	29	from	Recognition	0:10	arg1	patients					63:70	kidney cancer patients	49:70	kidney cancer patients	49:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	6	30	theme	cancer-associated	1510:1526	arg1	process					1640:1646	complement activation process	1618:1646	complement activation process	1618:1646	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	30	theme	cancer-associated	1510:1526	arg1	events					1528:1533	diverse cancer-associated events	1502:1533	diverse cancer-associated events	1502:1533	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	30	theme	cancer-associated	1510:1526	arg1	binding					1605:1611	antigen binding	1597:1611	antigen binding	1597:1611	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	30	theme	cancer-associated	1510:1526	arg1	binding					1588:1594	immunoglobulin receptor binding	1564:1594	immunoglobulin receptor binding	1564:1594	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	30	theme	cancer-associated	1510:1526	arg1	binding					1555:1561	collagen binding	1546:1561	collagen binding	1546:1561	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	31	theme	chromatography	396:409	arg1	technique					411:419	hydrophilic interaction chromatography technique	372:419	hydrophilic interaction chromatography technique	372:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	4	32	theme	glycopeptides	1036:1048	arg1	recognition					1021:1031	the recognition	1017:1031	the recognition of glycopeptides from standard samples	1017:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	33	theme	good	887:890	arg1	selectivity					892:902	good selectivity	887:902	good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200)	887:964	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	0	34	theme	metal	124:128	arg1	framework					138:146	magnetic metal organic framework	115:146	magnetic metal organic framework combined with LC-MS/MS	115:169	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	5	35	dep	spectrometry	1266:1277	arg1	technology					1279:1288	technology	1279:1288	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	5	35	dep	spectrometry	1266:1277	arg1	LC-MS/MS					1291:1298	LC-MS/MS	1291:1298	LC-MS/MS	1291:1298	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	4	36	theme	glucose-6-phosphate	831:849	arg1	merits					810:815	the merits	806:815	the merits of Zr-MOF and glucose-6-phosphate	806:849	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	2	37	theme	hydrophilic	437:447	arg1	layer					456:460	The inherently hydrophilic Zr-MOF layer	422:460	The inherently hydrophilic Zr-MOF layer	422:460	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	1	38	theme	one-step	293:300	arg1	strategy					315:322	a facile one-step modification strategy	284:322	a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique	284:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	2	39	theme	pore	503:506	arg1	structures					508:517	selective size-sieving pore structures	480:517	selective size-sieving pore structures	480:517	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	2	40	theme	selective	480:488	arg1	structures					508:517	selective size-sieving pore structures	480:517	selective size-sieving pore structures	480:517	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	0	41	theme	urinary	15:21	arg1	glycopeptides					32:44	urinary N-linked glycopeptides	15:44	urinary N-linked glycopeptides in kidney cancer patients	15:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	7	42	dep	abstract	1659:1666	arg1	Graphical					1649:1657	Graphical	1649:1657	Graphical	1649:1657	Graphical abstract.
33073321	4	43	gly	glycopeptides	1036:1048	arg1	samples					1064:1070	standard samples	1055:1070	standard samples	1055:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	43	gly	glycopeptides	1036:1048	arg2	glycopeptides					1036:1048	glycopeptides	1036:1048	glycopeptides from standard samples	1036:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	2	44	theme	specific	541:548	arg1	area					558:561	large specific surface area	535:561	large specific surface area	535:561	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	6	45	theme	receptor	1579:1586	arg1	binding					1588:1594	immunoglobulin receptor binding	1564:1594	immunoglobulin receptor binding	1564:1594	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	46	theme	selective	328:336	arg1	capture					351:357	selective glycopeptide capture	328:357	selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique	328:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	0	47	theme	glycopeptides	32:44	arg1	Recognition					0:10	Recognition	0:10	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate	0:98	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	5	48	gly	glycopeptides	1090:1102	arg2	glycopeptides					1090:1102	glycopeptides	1090:1102	glycopeptides in urine of healthy people	1090:1129	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	5	49	theme	spectrometry/mass	1248:1264	arg1	spectrometry					1266:1277	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	4	50	theme	digests	927:933	arg1	to1:200					957:963	to1:200	957:963	to1:200	957:963	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	50	theme	digests	927:933	arg1	ratio					914:918	the mass ratio	905:918	the mass ratio of HRP digests to BSA digests	905:948	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	0	51	theme	kidney	49:54	arg1	patients					63:70	kidney cancer patients	49:70	kidney cancer patients	49:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	6	52	from	urine	1455:1459	arg1	glycoproteins					1404:1416	13 original glycoproteins	1392:1416	13 original glycoproteins of the identified glycopeptides from urine of patients	1392:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	52	from	urine	1455:1459	arg1	glycopeptides					1436:1448	the identified glycopeptides	1421:1448	the identified glycopeptides from urine of patients	1421:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	5	53	theme	healthy	1116:1122	arg1	people					1124:1129	healthy people	1116:1129	healthy people	1116:1129	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	1	54	theme	@	258:258	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	54	theme	@	258:258	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	4	55	theme	mass	909:912	arg1	to1:200					957:963	to1:200	957:963	to1:200	957:963	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	55	theme	mass	909:912	arg1	ratio					914:918	the mass ratio	905:918	the mass ratio of HRP digests to BSA digests	905:948	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	6	56	theme	immunoglobulin	1564:1577	arg1	binding					1588:1594	immunoglobulin receptor binding	1564:1594	immunoglobulin receptor binding	1564:1594	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	1	57	from	capture	351:357	arg1	virtue					362:367	virtue	362:367	virtue of hydrophilic interaction chromatography technique	362:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	6	58	theme	activation	1629:1638	arg1	process					1640:1646	complement activation process	1618:1646	complement activation process	1618:1646	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	0	59	link	N-linked	23:30	arg1	glycopeptides					32:44	urinary N-linked glycopeptides	15:44	urinary N-linked glycopeptides in kidney cancer patients	15:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	4	60	from	recognition	1021:1031	arg1	samples					1064:1070	standard samples	1055:1070	standard samples	1055:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	6	61	gly	glycopeptides	1436:1448	arg1	urine					1455:1459	urine	1455:1459	urine of patients	1455:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	61	gly	glycopeptides	1436:1448	arg2	glycopeptides					1436:1448	the identified glycopeptides	1421:1448	the identified glycopeptides from urine of patients	1421:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	3	62	theme	Hydroxyl-rich	598:610	arg1	glucose-6-phosphate					612:630	Hydroxyl-rich glucose-6-phosphate	598:630	Hydroxyl-rich glucose-6-phosphate	598:630	Hydroxyl-rich glucose-6-phosphate was immobilized onto the Zr-MOF via a straightforward coordination manner to regulate its surface property, for the purpose of enhancing its hydrophilicity.
33073321	5	63	from	glycopeptides	1090:1102	arg1	urine					1107:1111	urine	1107:1111	urine of healthy people	1107:1129	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	1	64	theme	functionalized	199:212	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	64	theme	functionalized	199:212	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	65	theme	metal	223:227	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	65	theme	metal	223:227	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	5	66	theme	liquid	1221:1226	arg1	spectrometry					1266:1277	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	6	67	gly	glycoproteins	1404:1416	arg1	glycoproteins					1404:1416	13 original glycoproteins	1392:1416	13 original glycoproteins of the identified glycopeptides from urine of patients	1392:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	68	theme	patients	1464:1471	arg1	urine					1455:1459	urine	1455:1459	urine of patients	1455:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	3	69	theme	coordination	686:697	arg1	manner					699:704	a straightforward coordination manner	668:704	a straightforward coordination manner	668:704	Hydroxyl-rich glucose-6-phosphate was immobilized onto the Zr-MOF via a straightforward coordination manner to regulate its surface property, for the purpose of enhancing its hydrophilicity.
33073321	4	70	dep	selectivity	892:902	arg1	to1:200					957:963	to1:200	957:963	to1:200	957:963	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	70	dep	selectivity	892:902	arg1	ratio					914:918	the mass ratio	905:918	the mass ratio of HRP digests to BSA digests	905:948	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	1	71	theme	Mag	248:250	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	71	theme	Mag	248:250	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	5	72	theme	chromatography-mass	1228:1246	arg1	spectrometry					1266:1277	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	4	73	theme	low	970:972	arg1	0.1 fmol μL-1					994:1006	0.1 fmol μL-1	994:1006	0.1 fmol μL-1	994:1006	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	73	theme	low	970:972	arg1	limit					974:978	low limit	970:978	low limit of detection (0.1 fmol μL-1)	970:1007	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	6	74	theme	molecular	1336:1344	arg1	function					1346:1353	molecular function	1336:1353	molecular function	1336:1353	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	75	theme	glycopeptides	1436:1448	arg1	glycoproteins					1404:1416	13 original glycoproteins	1392:1416	13 original glycoproteins of the identified glycopeptides from urine of patients	1392:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	5	76	from	patients	1135:1142	arg1	urine					1107:1111	urine	1107:1111	urine of healthy people	1107:1129	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	6	77	theme	gene	1310:1313	arg1	analysis					1324:1331	Further gene ontology analysis	1302:1331	Further gene ontology analysis of molecular function and biological process	1302:1376	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	6	78	from	glycoproteins	1404:1416	arg1	urine					1455:1459	urine	1455:1459	urine of patients	1455:1471	Further gene ontology analysis of molecular function and biological process revealed that 13 original glycoproteins of the identified glycopeptides from urine of patients significantly participate in diverse cancer-associated events, including collagen binding, immunoglobulin receptor binding, antigen binding, and complement activation process.
33073321	5	79	theme	combined	1212:1219	arg1	spectrometry					1266:1277	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS)	1208:1299	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	1	80	theme	hydrophilic	174:184	arg1	G6P					259:261	Mag Zr-MOF@G6P	248:261	Mag Zr-MOF@G6P	248:261	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	1	80	theme	hydrophilic	174:184	arg1	framework					237:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework	172:245	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P)	172:262	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	2	81	theme	surface	550:556	arg1	area					558:561	large specific surface area	535:561	large specific surface area	535:561	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	0	82	theme	magnetic	115:122	arg1	framework					138:146	magnetic metal organic framework	115:146	magnetic metal organic framework combined with LC-MS/MS	115:169	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	1	83	theme	interaction	384:394	arg1	chromatography					396:409	hydrophilic interaction chromatography	372:409	hydrophilic interaction chromatography technique	372:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	4	84	theme	as-designed	856:866	arg1	composite					868:876	the as-designed composite	852:876	the as-designed composite	852:876	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	5	85	with	patients	1135:1142	arg1	cancer					1156:1161	kidney cancer	1149:1161	kidney cancer	1149:1161	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33073321	0	86	theme	organic	130:136	arg1	framework					138:146	magnetic metal organic framework	115:146	magnetic metal organic framework combined with LC-MS/MS	115:169	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	1	87	theme	technique	411:419	arg1	virtue					362:367	virtue	362:367	virtue of hydrophilic interaction chromatography technique	362:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	2	88	theme	abundant	573:580	arg1	sites					591:595	abundant affinity sites	573:595	abundant affinity sites	573:595	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	2	89	theme	affinity	582:589	arg1	sites					591:595	abundant affinity sites	573:595	abundant affinity sites	573:595	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	0	90	theme	N-linked	23:30	arg1	glycopeptides					32:44	urinary N-linked glycopeptides	15:44	urinary N-linked glycopeptides in kidney cancer patients	15:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	1	91	theme	modification	302:313	arg1	strategy					315:322	a facile one-step modification strategy	284:322	a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique	284:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	2	92	theme	size-sieving	490:501	arg1	structures					508:517	selective size-sieving pore structures	480:517	selective size-sieving pore structures	480:517	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	2	93	theme	large	535:539	arg1	area					558:561	large specific surface area	535:561	large specific surface area	535:561	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	0	94	theme	cancer	56:61	arg1	patients					63:70	kidney cancer patients	49:70	kidney cancer patients	49:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	1	95	theme	glycopeptide	338:349	arg1	capture					351:357	selective glycopeptide capture	328:357	selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique	328:419	A hydrophilic carbohydrate functionalized magnetic metal organic framework (Mag Zr-MOF@G6P) was synthesized via a facile one-step modification strategy for selective glycopeptide capture in virtue of hydrophilic interaction chromatography technique.
33073321	4	96	theme	HRP	923:925	arg1	digests					927:933	HRP digests	923:933	HRP digests	923:933	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	0	97	gly	glycopeptides	32:44	arg2	glycopeptides					32:44	urinary N-linked glycopeptides	15:44	urinary N-linked glycopeptides in kidney cancer patients	15:70	Recognition of urinary N-linked glycopeptides in kidney cancer patients by hydrophilic carbohydrate functionalized magnetic metal organic framework combined with LC-MS/MS.
33073321	4	98	from	samples	1064:1070	arg1	glycopeptides					1036:1048	glycopeptides	1036:1048	glycopeptides from standard samples	1036:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	4	98	from	samples	1064:1070	arg1	recognition					1021:1031	the recognition	1017:1031	the recognition of glycopeptides from standard samples	1017:1070	Benefitting from the merits of Zr-MOF and glucose-6-phosphate, the as-designed composite exhibits good selectivity (the mass ratio of HRP digests to BSA digests was up to1:200) and low limit of detection (0.1 fmol μL-1) towards the recognition of glycopeptides from standard samples.
33073321	2	99	theme	Zr-MOF	449:454	arg1	layer					456:460	The inherently hydrophilic Zr-MOF layer	422:460	The inherently hydrophilic Zr-MOF layer	422:460	The inherently hydrophilic Zr-MOF layer not only provides selective size-sieving pore structures but also offers large specific surface area to afford abundant affinity sites.
33073321	5	100	with	glycopeptides	1090:1102	arg1	cancer					1156:1161	kidney cancer	1149:1161	kidney cancer	1149:1161	More excitingly, glycopeptides in urine of healthy people and patients with kidney cancer were successfully enriched and identified by the combined liquid chromatography-mass spectrometry/mass spectrometry technology (LC-MS/MS).
33014431	8	0	theme	GABAARα2	1126:1133	arg1	membrane					1135:1142	GABAARα2 membrane	1126:1142	GABAARα2 membrane	1126:1142	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	10	1	theme	GABAAR	1428:1433	arg1	function					1435:1442	GABAAR function	1428:1442	GABAAR function	1428:1442	Overall, these results reveal that ALG13 may be involved in the occurrence of epilepsy through the regulation of GABAAR function, and may provide new insight into epilepsy prevention and treatment.
33014431	10	2	theme	epilepsy	1478:1485	arg1	prevention					1487:1496	epilepsy prevention	1478:1496	epilepsy prevention	1478:1496	Overall, these results reveal that ALG13 may be involved in the occurrence of epilepsy through the regulation of GABAAR function, and may provide new insight into epilepsy prevention and treatment.
33014431	0	3	theme	mouse	75:79	arg1	models					81:86	mouse models	75:86	mouse models	75:86	ALG13 participates in epileptogenesis via regulation of GABAA receptors in mouse models.
33014431	10	4	theme	new	1461:1463	arg1	insight					1465:1471	new insight	1461:1471	new insight into epilepsy prevention and treatment	1461:1510	Overall, these results reveal that ALG13 may be involved in the occurrence of epilepsy through the regulation of GABAAR function, and may provide new insight into epilepsy prevention and treatment.
33014431	6	5	theme	inhibitory	837:846	arg1	transmission					857:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	9	6	theme	protein	1220:1226	arg1	interactions					1228:1239	protein interactions	1220:1239	protein interactions between ALG13 and GABAARα2	1220:1266	Furthermore, protein interactions between ALG13 and GABAARα2 were observed in the cortex of wild-type mice.
33014431	10	7	theme	epilepsy	1393:1400	arg1	occurrence					1379:1388	the occurrence	1375:1388	the occurrence of epilepsy	1375:1400	Overall, these results reveal that ALG13 may be involved in the occurrence of epilepsy through the regulation of GABAAR function, and may provide new insight into epilepsy prevention and treatment.
33014431	7	8	theme	GABAA	953:957	arg1	receptors					959:967	GABAA receptors	953:967	GABAA receptors	953:967	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	8	9	theme	membrane	1135:1142	arg1	expression					1112:1121	the expression	1108:1121	the expression of GABAARα2 membrane and total protein	1108:1160	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	7	10	theme	allosteric	929:938	arg1	modulator					940:948	a positive allosteric modulator	918:948	a positive allosteric modulator of GABAA receptors	918:967	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	8	11	theme	protein	1154:1160	arg1	expression					1112:1121	the expression	1108:1121	the expression of GABAARα2 membrane and total protein	1108:1160	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	7	12	with	treatment	884:892	arg1	diazepam					908:915	low-dose diazepam	899:915	low-dose diazepam (a positive allosteric modulator of GABAA receptors)	899:968	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	1	13	link	N-linked	170:177	arg1	glycosylation					179:191	N-linked glycosylation	170:191	N-linked glycosylation	170:191	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	6	14	theme	marked	765:770	arg1	decrease					772:779	a marked decrease	763:779	a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	763:868	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	9	15	located	observed	1273:1280	arg1	cortex					1289:1294	the cortex	1285:1294	the cortex of wild-type mice	1285:1312	Furthermore, protein interactions between ALG13 and GABAARα2 were observed in the cortex of wild-type mice.
33014431	9	15	located	observed	1273:1280	arg2	interactions					1228:1239	protein interactions	1220:1239	protein interactions between ALG13 and GABAARα2	1220:1266	Furthermore, protein interactions between ALG13 and GABAARα2 were observed in the cortex of wild-type mice.
33014431	6	16	from	decrease	772:779	arg1	transmission					857:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	8	17	theme	total	1148:1152	arg1	protein					1154:1160	total protein	1148:1160	total protein	1148:1160	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	0	18	from	regulation	42:51	arg1	models					81:86	mouse models	75:86	mouse models	75:86	ALG13 participates in epileptogenesis via regulation of GABAA receptors in mouse models.
33014431	8	19	theme	GABAARα2	1197:1204	arg1	level					1188:1192	transcription level	1174:1192	transcription level of GABAARα2	1174:1204	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	8	20	dep	influenced	1097:1106	arg1	may					1093:1095	may	1093:1095	may	1093:1095	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	6	21	theme	synaptic	848:855	arg1	transmission					857:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	7	22	theme	ALG13KO	1063:1069	arg1	mice					1071:1074	ALG13KO mice	1063:1074	ALG13KO mice	1063:1074	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	7	23	theme	positive	920:927	arg1	modulator					940:948	a positive allosteric modulator	918:948	a positive allosteric modulator of GABAA receptors	918:967	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	2	24	theme	human	292:296	arg1	disorder					306:313	a rare human genetic disorder	285:313	a rare human genetic disorder with defective glycosylation	285:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	2	24	theme	human	292:296	arg1	type					269:272	glycosylation type I	255:274	glycosylation type I (CDG-I)	255:282	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	9	25	theme	wild-type	1299:1307	arg1	mice					1309:1312	wild-type mice	1299:1312	wild-type mice	1299:1312	Furthermore, protein interactions between ALG13 and GABAARα2 were observed in the cortex of wild-type mice.
33014431	1	26	theme	N-linked	170:177	arg1	glycosylation					179:191	N-linked glycosylation	170:191	N-linked glycosylation	170:191	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	3	27	theme	congenital	378:387	arg1	disorders					389:397	congenital disorders	378:397	congenital disorders of glycosylation type I (CDG-I)	378:429	Epilepsy is commonly observed in congenital disorders of glycosylation type I (CDG-I).
33014431	4	28	theme	spontaneous	509:519	arg1	seizures					521:528	spontaneous seizures	509:528	spontaneous seizures	509:528	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	10	29	theme	function	1435:1442	arg1	regulation					1414:1423	the regulation	1410:1423	the regulation of GABAAR function	1410:1442	Overall, these results reveal that ALG13 may be involved in the occurrence of epilepsy through the regulation of GABAAR function, and may provide new insight into epilepsy prevention and treatment.
33014431	2	30	theme	rare	287:290	arg1	disorder					306:313	a rare human genetic disorder	285:313	a rare human genetic disorder with defective glycosylation	285:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	2	30	theme	rare	287:290	arg1	type					269:272	glycosylation type I	255:274	glycosylation type I (CDG-I)	255:282	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	1	31	theme	glycosylation	179:191	arg1	process					159:165	the process	155:165	the process of N-linked glycosylation	155:191	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	7	32	theme	seizures	1051:1058	arg1	severity					1029:1036	severity	1029:1036	severity of epileptic seizures	1029:1058	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	6	33	theme	ALG13KO	745:751	arg1	mice					753:756	ALG13KO mice	745:756	ALG13KO mice	745:756	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	4	34	theme	EEG	594:596	arg1	recording					598:606	a simultaneous video and intracranial EEG recording	556:606	recording	598:606	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	8	35	theme	transcription	1174:1186	arg1	level					1188:1192	transcription level	1174:1192	transcription level of GABAARα2	1174:1204	Moreover, ALG13 may influenced the expression of GABAARα2 membrane and total protein by changing transcription level of GABAARα2.
33014431	2	36	with	disorder	306:313	arg1	glycosylation					330:342	defective glycosylation	320:342	defective glycosylation	320:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	1	37	theme	asparagine-linked	96:112	arg1	ALG13					89:93	ALG13	89:93	ALG13 (asparagine-linked glycosylation 13)	89:130	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	1	37	theme	asparagine-linked	96:112	arg1	glycosylation					114:126	asparagine-linked glycosylation 13	96:129	asparagine-linked glycosylation 13	96:129	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	4	38	theme	intracranial	581:592	arg1	recording					598:606	a simultaneous video and intracranial EEG recording	556:606	recording	598:606	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	3	39	theme	glycosylation	402:414	arg1	CDG-I					424:428	CDG-I	424:428	CDG-I	424:428	Epilepsy is commonly observed in congenital disorders of glycosylation type I (CDG-I).
33014431	3	39	theme	glycosylation	402:414	arg1	type					416:419	glycosylation type I	402:421	glycosylation type I (CDG-I)	402:429	Epilepsy is commonly observed in congenital disorders of glycosylation type I (CDG-I).
33014431	2	40	gly	glycosylation	330:342	arg1	disorder					306:313	a rare human genetic disorder	285:313	a rare human genetic disorder with defective glycosylation	285:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	2	40	gly	glycosylation	330:342	arg1	type					269:272	glycosylation type I	255:274	glycosylation type I (CDG-I)	255:282	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	6	41	theme	-mediated	827:835	arg1	transmission					857:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission	784:868	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	2	42	theme	congenital	231:240	arg1	disorders					242:250	congenital disorders	231:250	congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation	231:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	3	43	theme	type	416:419	arg1	disorders					389:397	congenital disorders	378:397	congenital disorders of glycosylation type I (CDG-I)	378:429	Epilepsy is commonly observed in congenital disorders of glycosylation type I (CDG-I).
33014431	4	44	theme	ALG13KO	479:485	arg1	mice					496:499	adult ALG13KO knockout mice	473:499	adult ALG13KO knockout mice	473:499	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	7	45	theme	epileptic	1041:1049	arg1	seizures					1051:1058	epileptic seizures	1041:1058	epileptic seizures	1041:1058	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	0	46	theme	GABAA	56:60	arg1	receptors					62:70	GABAA receptors	56:70	GABAA receptors	56:70	ALG13 participates in epileptogenesis via regulation of GABAA receptors in mouse models.
33014431	4	47	theme	adult	473:477	arg1	mice					496:499	adult ALG13KO knockout mice	473:499	adult ALG13KO knockout mice	473:499	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	1	48	link	asparagine-linked	96:112	arg1	ALG13					89:93	ALG13	89:93	ALG13 (asparagine-linked glycosylation 13)	89:130	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	1	48	link	asparagine-linked	96:112	arg1	glycosylation					114:126	asparagine-linked glycosylation 13	96:129	asparagine-linked glycosylation 13	96:129	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	2	49	theme	gene	217:220	arg1	Mutations					194:202	Mutations	194:202	Mutations of the ALG13 gene	194:220	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	9	50	theme	mice	1309:1312	arg1	cortex					1289:1294	the cortex	1285:1294	the cortex of wild-type mice	1285:1312	Furthermore, protein interactions between ALG13 and GABAARα2 were observed in the cortex of wild-type mice.
33014431	2	51	theme	defective	320:328	arg1	glycosylation					330:342	defective glycosylation	320:342	defective glycosylation	320:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	4	52	theme	mice	496:499	arg1	mice					496:499	adult ALG13KO knockout mice	473:499	adult ALG13KO knockout mice	473:499	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	4	52	theme	mice	496:499	arg1	%					468:468	about 20%	460:468	about 20% of adult ALG13KO knockout mice	460:499	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	5	53	theme	ALG13	636:640	arg1	unknown					684:690	unknown	684:690	unknown	684:690	However, the mechanisms of ALG13 by which deficiency leads to epilepsy are unknown.
33014431	5	53	theme	ALG13	636:640	arg1	mechanisms					622:631	the mechanisms	618:631	the mechanisms of ALG13 by which deficiency leads to epilepsy	618:678	However, the mechanisms of ALG13 by which deficiency leads to epilepsy are unknown.
33014431	2	54	theme	ALG13	211:215	arg1	gene					217:220	the ALG13 gene	207:220	the ALG13 gene	207:220	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	4	55	theme	knockout	487:494	arg1	mice					496:499	adult ALG13KO knockout mice	473:499	adult ALG13KO knockout mice	473:499	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	2	56	theme	type	269:272	arg1	disorders					242:250	congenital disorders	231:250	congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation	231:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	6	57	theme	patch-clamp	704:714	arg1	recordings					716:725	Whole-cell patch-clamp recordings	693:725	Whole-cell patch-clamp recordings	693:725	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	7	58	theme	low-dose	899:906	arg1	diazepam					908:915	low-dose diazepam	899:915	low-dose diazepam (a positive allosteric modulator of GABAA receptors)	899:968	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	4	59	theme	simultaneous	558:569	arg1	video					571:575	a simultaneous video and intracranial EEG recording	556:606	video	571:575	In our study, we found that about 20% of adult ALG13KO knockout mice display spontaneous seizures, which were identified in a simultaneous video and intracranial EEG recording.
33014431	7	60	theme	GABAAR	986:991	arg1	function					993:1000	GABAAR function	986:1000	GABAAR function	986:1000	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	3	61	located	observed	366:373	arg2	Epilepsy					345:352	Epilepsy	345:352	Epilepsy	345:352	Epilepsy is commonly observed in congenital disorders of glycosylation type I (CDG-I).
33014431	3	61	located	observed	366:373	arg1	disorders					389:397	congenital disorders	378:397	congenital disorders of glycosylation type I (CDG-I)	378:429	Epilepsy is commonly observed in congenital disorders of glycosylation type I (CDG-I).
33014431	2	62	theme	glycosylation	255:267	arg1	CDG-I					277:281	CDG-I	277:281	CDG-I	277:281	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	2	62	theme	glycosylation	255:267	arg1	disorder					306:313	a rare human genetic disorder	285:313	a rare human genetic disorder with defective glycosylation	285:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	2	62	theme	glycosylation	255:267	arg1	type					269:272	glycosylation type I	255:274	glycosylation type I (CDG-I)	255:282	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	6	63	theme	Whole-cell	693:702	arg1	recordings					716:725	Whole-cell patch-clamp recordings	693:725	Whole-cell patch-clamp recordings	693:725	Whole-cell patch-clamp recordings demonstrated that ALG13KO mice show a marked decrease in gamma-aminobutyric acid A receptor (GABAAR)-mediated inhibitory synaptic transmission.
33014431	2	64	theme	genetic	298:304	arg1	disorder					306:313	a rare human genetic disorder	285:313	a rare human genetic disorder with defective glycosylation	285:342	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	2	64	theme	genetic	298:304	arg1	type					269:272	glycosylation type I	255:274	glycosylation type I (CDG-I)	255:282	Mutations of the ALG13 gene underlie congenital disorders of glycosylation type I (CDG-I), a rare human genetic disorder with defective glycosylation.
33014431	1	65	theme	crucial	138:144	arg1	roles					146:150	crucial roles	138:150	crucial roles	138:150	ALG13 (asparagine-linked glycosylation 13) plays crucial roles in the process of N-linked glycosylation.
33014431	0	66	theme	receptors	62:70	arg1	regulation					42:51	regulation	42:51	regulation of GABAA receptors in mouse models	42:86	ALG13 participates in epileptogenesis via regulation of GABAA receptors in mouse models.
33014431	7	67	theme	receptors	959:967	arg1	modulator					940:948	a positive allosteric modulator	918:948	a positive allosteric modulator of GABAA receptors	918:967	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
33014431	7	68	dep	diazepam	908:915	arg1	modulator					940:948	a positive allosteric modulator	918:948	a positive allosteric modulator of GABAA receptors	918:967	Furthermore, treatment with low-dose diazepam (a positive allosteric modulator of GABAA receptors), which enhances GABAAR function, also markedly ameliorates severity of epileptic seizures in ALG13KO mice.
32935560	0	0	theme	Tier	70:73	arg1	Viruses					77:83	Tier 2 Viruses	70:83	Tier 2 Viruses	70:83	HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses.
32935560	4	1	theme	PSC	679:681	arg1	RANTES					683:688	PSC RANTES	679:688	PSC RANTES	679:688	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	1	theme	PSC	679:681	arg1	inhibitors					657:666	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	1	2	theme	therapy	131:137	arg1	ability					153:159	the virus' ability	142:159	the virus' ability to rapidly escape antibody responses	142:196	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	1	2	theme	therapy	131:137	arg1	concern					96:102	A primary concern	86:102	A primary concern of an antibody-based HIV-1 therapy	86:137	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	5	3	from	absence	947:953	arg1	position					925:932	position N413	925:937	position N413	925:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	4	attach	presence	885:892	arg1	N332					958:961	N332	958:961	N332	958:961	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	4	attach	presence	885:892	arg2	motif					916:920	an N-linked glycan motif	897:920	an N-linked glycan motif at position N413	897:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	8	5	theme	HIV-1	1479:1483	arg1	control					1485:1491	HIV-1 control	1479:1491	HIV-1 control	1479:1491	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	2	6	from	infectivity	310:320	arg1	viruses					338:344	13 subtype C viruses	325:344	13 subtype C viruses	325:344	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	2	7	theme	subtype	328:334	arg1	viruses					338:344	13 subtype C viruses	325:344	13 subtype C viruses	325:344	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	6	8	theme	C	1052:1052	arg1	viruses					1054:1060	200 subtype C viruses	1040:1060	200 subtype C viruses	1040:1060	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	9	9	theme	long-term	1574:1582	arg1	intervention					1599:1610	any long-term antibody-based intervention	1570:1610	any long-term antibody-based intervention	1570:1610	Therefore, for any long-term antibody-based intervention to be globally relevant, it must elicit responses that limit the occurrence of resistance.
32935560	8	10	theme	intervention	1368:1379	arg1	context					1339:1345	the context	1335:1345	the context of an antibody-based intervention	1335:1379	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	2	11	from	phenotype	295:303	arg1	viruses					338:344	13 subtype C viruses	325:344	13 subtype C viruses	325:344	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	2	12	theme	neutralization	261:274	arg1	sensitivity					276:286	antibody neutralization sensitivity	252:286	antibody neutralization sensitivity	252:286	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	2	13	theme	C	336:336	arg1	viruses					338:344	13 subtype C viruses	325:344	13 subtype C viruses	325:344	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	5	14	theme	subtype	848:854	arg1	viruses					858:864	82 subtype C viruses	845:864	82 subtype C viruses	845:864	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	3	15	theme	tier	465:468	arg1	viruses					472:478	the tier 2 viruses	461:478	the tier 2 viruses	461:478	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	5	16	theme	motif	916:920	arg1	predictors					987:996	the most important predictors	968:996	the most important predictors of neutralization resistance	968:1025	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	16	theme	motif	916:920	arg1	presence					885:892	the presence	881:892	the presence of an N-linked glycan motif at position N413	881:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	16	theme	motif	916:920	arg1	absence					947:953	its absence	943:953	its absence at N332	943:961	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	17	theme	C	856:856	arg1	viruses					858:864	82 subtype C viruses	845:864	82 subtype C viruses	845:864	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	2	18	theme	antibody	252:259	arg1	sensitivity					276:286	antibody neutralization sensitivity	252:286	antibody neutralization sensitivity	252:286	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	6	19	dep	tier	1103:1106	arg1	viruses					1116:1122	viruses	1116:1122	viruses	1116:1122	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	3	20	theme	tier	412:415	arg1	viruses					419:425	the seven tier 3 viruses	402:425	the seven tier 3 viruses	402:425	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	3	21	theme	neutralization	504:517	arg1	resistance					519:528	higher neutralization resistance	497:528	higher neutralization resistance	497:528	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	1	22	theme	virus	146:150	arg1	ability					153:159	the virus' ability	142:159	the virus' ability to rapidly escape antibody responses	142:196	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	1	22	theme	virus	146:150	arg1	concern					96:102	A primary concern	86:102	A primary concern of an antibody-based HIV-1 therapy	86:137	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	0	23	theme	Subtype	6:12	arg1	Viruses					23:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses.
32935560	5	24	theme	glycan	909:914	arg1	motif					916:920	an N-linked glycan motif	897:920	an N-linked glycan motif at position N413	897:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	25	from	N332	958:961	arg1	predictors					987:996	the most important predictors	968:996	the most important predictors of neutralization resistance	968:1025	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	25	from	N332	958:961	arg1	presence					885:892	the presence	881:892	the presence of an N-linked glycan motif at position N413	881:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	25	from	N332	958:961	arg1	absence					947:953	its absence	943:953	its absence at N332	943:961	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	2	26	theme	HeLa	354:357	arg1	assay					378:382	a HeLa transfectant-based assay	352:382	a HeLa transfectant-based assay	352:382	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	0	27	theme	HIV-1	0:4	arg1	Viruses					23:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses.
32935560	3	28	contain	have	538:541	arg1	resistance					519:528	higher neutralization resistance	497:528	higher neutralization resistance	497:528	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	3	28	contain	have	538:541	arg2	cost					563:566	a substantial entry cost	543:566	a substantial entry cost	543:566	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	6	29	theme	different	1194:1202	arg1	epitopes					1204:1211	three different epitopes	1188:1211	three different epitopes	1188:1211	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	5	30	from	presence	885:892	arg1	position					925:932	position N413	925:937	position N413	925:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	3	31	theme	substantial	545:555	arg1	cost					563:566	a substantial entry cost	543:566	a substantial entry cost	543:566	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	6	32	from	resistant	1088:1096	arg1	viruses					1054:1060	200 subtype C viruses	1040:1060	200 subtype C viruses	1040:1060	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	6	32	from	resistant	1088:1096	arg1	set					1033:1035	a set	1031:1035	a set of 200 subtype C viruses	1031:1060	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	0	33	theme	Tier	16:19	arg1	Viruses					23:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses.
32935560	6	34	theme	several	1127:1133	arg1	antibodies					1167:1176	several broadly neutralizing monoclonal antibodies	1127:1176	several broadly neutralizing monoclonal antibodies targeting three different epitopes	1127:1211	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	5	35	theme	N-linked	900:907	arg1	motif					916:920	an N-linked glycan motif	897:920	an N-linked glycan motif at position N413	897:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	2	36	theme	viral	289:293	arg1	phenotype					295:303	viral phenotype	289:303	viral phenotype	289:303	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	6	37	from	set	1033:1035	arg1	resistant					1088:1096	resistant	1088:1096	resistant	1088:1096	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	3	38	theme	higher	437:442	arg1	infectivity					444:454	higher infectivity	437:454	higher infectivity	437:454	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	0	39	theme	C	14:14	arg1	Viruses					23:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses	0:29	HIV-1 Subtype C Tier 3 Viruses Have Increased Infectivity Compared to Tier 2 Viruses.
32935560	3	40	theme	higher	497:502	arg1	resistance					519:528	higher neutralization resistance	497:528	higher neutralization resistance	497:528	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	8	41	theme	increased	1412:1420	arg1	infectivity					1422:1432	increased infectivity	1412:1432	increased infectivity	1412:1432	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	6	42	theme	subtype	1044:1050	arg1	viruses					1054:1060	200 subtype C viruses	1040:1060	200 subtype C viruses	1040:1060	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	4	43	theme	neutralization	603:616	arg1	resistance					618:627	neutralization resistance	603:627	neutralization resistance	603:627	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	8	44	theme	viruses	1515:1521	arg1	entry					1499:1503	entry	1499:1503	entry of tier 3 viruses	1499:1521	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	4	45	theme	entry	651:655	arg1	RANTES					683:688	PSC RANTES	679:688	PSC RANTES	679:688	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	45	theme	entry	651:655	arg1	T20					715:717	the fusion inhibitor T20	694:717	the fusion inhibitor T20	694:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	45	theme	entry	651:655	arg1	inhibitors					657:666	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	45	theme	entry	651:655	arg1	Maraviroc					668:676	Maraviroc	668:676	Maraviroc	668:676	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	8	46	with	viruses	1399:1405	arg1	infectivity					1422:1432	increased infectivity	1412:1432	increased infectivity	1412:1432	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	4	47	theme	neutralization	736:749	arg1	resistance					751:760	neutralization resistance	736:760	neutralization resistance	736:760	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	5	48	theme	important	977:985	arg1	predictors					987:996	the most important predictors	968:996	the most important predictors of neutralization resistance	968:1025	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	48	theme	important	977:985	arg1	presence					885:892	the presence	881:892	the presence of an N-linked glycan motif at position N413	881:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	48	theme	important	977:985	arg1	absence					947:953	its absence	943:953	its absence at N332	943:961	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	9	49	theme	antibody-based	1584:1597	arg1	intervention					1599:1610	any long-term antibody-based intervention	1570:1610	any long-term antibody-based intervention	1570:1610	Therefore, for any long-term antibody-based intervention to be globally relevant, it must elicit responses that limit the occurrence of resistance.
32935560	1	50	theme	antibody	179:186	arg1	responses					188:196	antibody responses	179:196	antibody responses	179:196	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	8	51	theme	tier	1508:1511	arg1	viruses					1515:1521	tier 3 viruses	1508:1521	tier 3 viruses	1508:1521	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	3	52	theme	entry	557:561	arg1	cost					563:566	a substantial entry cost	543:566	a substantial entry cost	543:566	We observed that the seven tier 3 viruses exhibited higher infectivity than the tier 2 viruses, suggesting that higher neutralization resistance did not have a substantial entry cost.
32935560	1	53	theme	primary	88:94	arg1	ability					153:159	the virus' ability	142:159	the virus' ability to rapidly escape antibody responses	142:196	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	1	53	theme	primary	88:94	arg1	concern					96:102	A primary concern	86:102	A primary concern of an antibody-based HIV-1 therapy	86:137	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	5	54	link	N-linked	900:907	arg1	motif					916:920	an N-linked glycan motif	897:920	an N-linked glycan motif at position N413	897:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	55	theme	neutralization	1001:1014	arg1	resistance					1016:1025	neutralization resistance	1001:1025	neutralization resistance	1001:1025	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	6	56	theme	monoclonal	1156:1165	arg1	antibodies					1167:1176	several broadly neutralizing monoclonal antibodies	1127:1176	several broadly neutralizing monoclonal antibodies targeting three different epitopes	1127:1211	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	7	57	theme	single	1290:1295	arg1	epitope					1297:1303	a single epitope	1288:1303	a single epitope	1288:1303	This suggests that it is unlikely that resistance to antibodies targeting a single epitope drives overall resistance.
32935560	8	58	theme	resistant	1389:1397	arg1	viruses					1399:1405	highly resistant viruses	1382:1405	highly resistant viruses	1382:1405	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32935560	9	59	theme	resistance	1691:1700	arg1	occurrence					1677:1686	the occurrence	1673:1686	the occurrence of resistance	1673:1700	Therefore, for any long-term antibody-based intervention to be globally relevant, it must elicit responses that limit the occurrence of resistance.
32935560	5	60	theme	resistance	1016:1025	arg1	predictors					987:996	the most important predictors	968:996	the most important predictors of neutralization resistance	968:1025	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	60	theme	resistance	1016:1025	arg1	presence					885:892	the presence	881:892	the presence of an N-linked glycan motif at position N413	881:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	60	theme	resistance	1016:1025	arg1	absence					947:953	its absence	943:953	its absence at N332	943:961	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	6	61	theme	neutralizing	1143:1154	arg1	antibodies					1167:1176	several broadly neutralizing monoclonal antibodies	1127:1176	several broadly neutralizing monoclonal antibodies targeting three different epitopes	1127:1211	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	5	62	from	patterns	833:840	arg1	viruses					858:864	82 subtype C viruses	845:864	82 subtype C viruses	845:864	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	4	63	theme	inhibitor	705:713	arg1	T20					715:717	the fusion inhibitor T20	694:717	the fusion inhibitor T20	694:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	63	theme	inhibitor	705:713	arg1	inhibitors					657:666	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	5	64	from	position	925:932	arg1	predictors					987:996	the most important predictors	968:996	the most important predictors of neutralization resistance	968:1025	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	64	from	position	925:932	arg1	motif					916:920	an N-linked glycan motif	897:920	an N-linked glycan motif at position N413	897:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	64	from	position	925:932	arg1	presence					885:892	the presence	881:892	the presence of an N-linked glycan motif at position N413	881:937	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	5	64	from	position	925:932	arg1	absence					947:953	its absence	943:953	its absence at N332	943:961	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	6	65	theme	tier	1063:1066	arg1	strains					1070:1076	tier 3 strains	1063:1076	tier 3 strains	1063:1076	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	4	66	dep	inhibitors	657:666	arg1	RANTES					683:688	PSC RANTES	679:688	PSC RANTES	679:688	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	66	dep	inhibitors	657:666	arg1	T20					715:717	the fusion inhibitor T20	694:717	the fusion inhibitor T20	694:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	66	dep	inhibitors	657:666	arg1	inhibitors					657:666	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	66	dep	inhibitors	657:666	arg1	Maraviroc					668:676	Maraviroc	668:676	Maraviroc	668:676	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	67	theme	fusion	698:703	arg1	T20					715:717	the fusion inhibitor T20	694:717	the fusion inhibitor T20	694:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	4	67	theme	fusion	698:703	arg1	inhibitors					657:666	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20	651:717	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	2	68	from	sensitivity	276:286	arg1	viruses					338:344	13 subtype C viruses	325:344	13 subtype C viruses	325:344	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	6	69	theme	viruses	1054:1060	arg1	viruses					1054:1060	200 subtype C viruses	1040:1060	200 subtype C viruses	1040:1060	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	6	69	theme	viruses	1054:1060	arg1	set					1033:1035	a set	1031:1035	a set of 200 subtype C viruses	1031:1060	In a set of 200 subtype C viruses, tier 3 strains were more resistant than tier 2 or 1B viruses to several broadly neutralizing monoclonal antibodies targeting three different epitopes.
32935560	4	70	theme	target	792:797	arg1	sites					799:803	these inhibitor target sites	776:803	these inhibitor target sites	776:803	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	5	71	theme	glycosylation	819:831	arg1	patterns					833:840	glycosylation patterns	819:840	glycosylation patterns in 82 subtype C viruses	819:864	By analyzing glycosylation patterns in 82 subtype C viruses, we found that the presence of an N-linked glycan motif at position N413 and its absence at N332 were the most important predictors of neutralization resistance.
32935560	1	72	theme	antibody-based	110:123	arg1	therapy					131:137	an antibody-based HIV-1 therapy	107:137	an antibody-based HIV-1 therapy	107:137	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	2	73	theme	transfectant-based	359:376	arg1	assay					378:382	a HeLa transfectant-based assay	352:382	a HeLa transfectant-based assay	352:382	Therefore, we investigated the relationships between antibody neutralization sensitivity, viral phenotype, and infectivity in 13 subtype C viruses using a HeLa transfectant-based assay.
32935560	7	74	theme	overall	1312:1318	arg1	resistance					1320:1329	overall resistance	1312:1329	overall resistance	1312:1329	This suggests that it is unlikely that resistance to antibodies targeting a single epitope drives overall resistance.
32935560	4	75	theme	inhibitor	782:790	arg1	sites					799:803	these inhibitor target sites	776:803	these inhibitor target sites	776:803	There was no relationship between neutralization resistance and susceptibility to entry inhibitors Maraviroc, PSC RANTES, or the fusion inhibitor T20, indicating that neutralization resistance may not alter these inhibitor target sites.
32935560	1	76	theme	HIV-1	125:129	arg1	therapy					131:137	an antibody-based HIV-1 therapy	107:137	an antibody-based HIV-1 therapy	107:137	A primary concern of an antibody-based HIV-1 therapy is the virus' ability to rapidly escape antibody responses.
32935560	8	77	theme	antibody-based	1353:1366	arg1	intervention					1368:1379	an antibody-based intervention	1350:1379	an antibody-based intervention	1350:1379	In the context of an antibody-based intervention, highly resistant viruses with increased infectivity, circulating in the population, could hinder HIV-1 control since entry of tier 3 viruses is not always selected against.
32719124	1	0	theme	T	139:139	arg1	peptides					157:164	CD8+ T cell-activating peptides	134:164	CD8+ T cell-activating peptides	134:164	The source proteins from which CD8+ T cell-activating peptides are derived remain enigmatic.
32719124	5	1	theme	peptide	916:922	arg1	display					924:930	peptide display	916:930	peptide display	916:930	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	1	2	theme	cell-activating	141:155	arg1	peptides					157:164	CD8+ T cell-activating peptides	134:164	CD8+ T cell-activating peptides	134:164	The source proteins from which CD8+ T cell-activating peptides are derived remain enigmatic.
32719124	0	3	theme	viral	88:92	arg1	epitope					94:100	a single viral epitope	79:100	a single viral epitope	79:100	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	0	4	theme	single	81:86	arg1	epitope					94:100	a single viral epitope	79:100	a single viral epitope	79:100	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	4	5	theme	cell	772:775	arg1	responses					777:785	suboptimal CD8+ T cell responses	754:785	suboptimal CD8+ T cell responses	754:785	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	5	6	theme	generation	816:825	arg1	system					798:803	This dual system	788:803	This dual system of peptide generation	788:825	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	2	7	theme	trafficking	281:291	arg1	routes					293:298	several potential trafficking routes	263:298	several potential trafficking routes within the cell	263:314	Glycoproteins are particularly challenging in this regard owing to several potential trafficking routes within the cell.
32719124	5	8	theme	peptide	808:814	arg1	generation					816:825	peptide generation	808:825	peptide generation	808:825	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	5	9	theme	display	924:930	arg1	antigenicity					883:894	antigenicity	883:894	antigenicity	883:894	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	5	9	theme	display	924:930	arg1	kinetics					904:911	the kinetics	900:911	the kinetics of peptide display	900:930	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	5	10	theme	dual	793:796	arg1	system					798:803	This dual system	788:803	This dual system of peptide generation	788:825	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	2	11	theme	potential	271:279	arg1	routes					293:298	several potential trafficking routes	263:298	several potential trafficking routes within the cell	263:314	Glycoproteins are particularly challenging in this regard owing to several potential trafficking routes within the cell.
32719124	0	12	theme	distinct	12:19	arg1	pathways					32:39	Kinetically distinct processing pathways	0:39	Kinetically distinct processing pathways	0:39	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	4	13	theme	suboptimal	754:763	arg1	responses					777:785	suboptimal CD8+ T cell responses	754:785	suboptimal CD8+ T cell responses	754:785	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	3	14	theme	T	438:438	arg1	expansion					445:453	optimal CD8+ T cell expansion	425:453	optimal CD8+ T cell expansion	425:453	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	15	gly	glycosylation	386:398	arg2	site					400:403	an N-linked glycosylation site	374:403	an N-linked glycosylation site	374:403	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	16	theme	cell	440:443	arg1	expansion					445:453	optimal CD8+ T cell expansion	425:453	optimal CD8+ T cell expansion	425:453	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	17	theme	glycosylation	386:398	arg1	site					400:403	an N-linked glycosylation site	374:403	an N-linked glycosylation site	374:403	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	18	theme	protein	562:568	arg1	fraction					550:557	the exceedingly minor fraction	528:557	the exceedingly minor fraction of protein mislocalized to the cytosol	528:596	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	5	19	theme	cell	843:846	arg1	participation					848:860	CD8+ T cell participation	836:860	CD8+ T cell participation	836:860	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	0	20	theme	processing	21:30	arg1	pathways					32:39	Kinetically distinct processing pathways	0:39	Kinetically distinct processing pathways	0:39	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	4	21	theme	CD8+	765:768	arg1	responses					777:785	suboptimal CD8+ T cell responses	754:785	suboptimal CD8+ T cell responses	754:785	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	3	22	theme	optimal	425:431	arg1	expansion					445:453	optimal CD8+ T cell expansion	425:453	optimal CD8+ T cell expansion	425:453	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	23	theme	minor	544:548	arg1	fraction					550:557	the exceedingly minor fraction	528:557	the exceedingly minor fraction of protein mislocalized to the cytosol	528:596	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	24	theme	CD8+	433:436	arg1	expansion					445:453	optimal CD8+ T cell expansion	425:453	optimal CD8+ T cell expansion	425:453	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	5	25	theme	CD8+	836:839	arg1	cell					843:846	CD8+ T cell	836:846	CD8+ T cell participation	836:860	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	4	26	theme	T	770:770	arg1	responses					777:785	suboptimal CD8+ T cell responses	754:785	suboptimal CD8+ T cell responses	754:785	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	0	27	theme	T	60:60	arg1	response					67:74	the CD8+ T cell response	51:74	the CD8+ T cell response to a single viral epitope	51:100	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	1	28	attach	derived	170:176	arg1	proteins					114:121	The source proteins	103:121	The source proteins from which CD8+ T cell-activating peptides are derived	103:176	The source proteins from which CD8+ T cell-activating peptides are derived remain enigmatic.
32719124	1	28	attach	derived	170:176	arg2	peptides					157:164	CD8+ T cell-activating peptides	134:164	CD8+ T cell-activating peptides	134:164	The source proteins from which CD8+ T cell-activating peptides are derived remain enigmatic.
32719124	4	29	attach	derived	621:627	arg2	peptides					612:619	peptides	612:619	peptides derived from the much larger fraction that undergoes translocation and quality control	612:706	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	4	29	attach	derived	621:627	arg1	fraction					650:657	the much larger fraction	634:657	the much larger fraction that undergoes translocation and quality control	634:706	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	4	30	theme	delayed	726:732	arg1	kinetics					734:741	delayed kinetics	726:741	delayed kinetics	726:741	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	0	31	theme	CD8+	55:58	arg1	response					67:74	the CD8+ T cell response	51:74	the CD8+ T cell response to a single viral epitope	51:100	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	1	32	theme	source	107:112	arg1	proteins					114:121	The source proteins	103:121	The source proteins from which CD8+ T cell-activating peptides are derived	103:176	The source proteins from which CD8+ T cell-activating peptides are derived remain enigmatic.
32719124	2	33	theme	several	263:269	arg1	routes					293:298	several potential trafficking routes	263:298	several potential trafficking routes within the cell	263:314	Glycoproteins are particularly challenging in this regard owing to several potential trafficking routes within the cell.
32719124	3	34	link	glycoprotein-derived	334:353	arg1	epitope					355:361	a glycoprotein-derived epitope	332:361	a glycoprotein-derived epitope to contain an N-linked glycosylation site	332:403	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	3	35	link	N-linked	377:384	arg1	site					400:403	an N-linked glycosylation site	374:403	an N-linked glycosylation site	374:403	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	4	36	theme	quality	692:698	arg1	control					700:706	quality control	692:706	quality control	692:706	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	3	37	theme	glycoprotein-derived	334:353	arg1	epitope					355:361	a glycoprotein-derived epitope	332:361	a glycoprotein-derived epitope to contain an N-linked glycosylation site	332:403	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32719124	4	38	theme	larger	643:648	arg1	fraction					650:657	the much larger fraction	634:657	the much larger fraction that undergoes translocation and quality control	634:706	In contrast, peptides derived from the much larger fraction that undergoes translocation and quality control are produced with delayed kinetics and induce suboptimal CD8+ T cell responses.
32719124	0	39	theme	cell	62:65	arg1	response					67:74	the CD8+ T cell response	51:74	the CD8+ T cell response to a single viral epitope	51:100	Kinetically distinct processing pathways diversify the CD8+ T cell response to a single viral epitope.
32719124	5	40	theme	T	841:841	arg1	cell					843:846	CD8+ T cell	836:846	CD8+ T cell participation	836:860	This dual system of peptide generation enhances CD8+ T cell participation in diversifying both antigenicity and the kinetics of peptide display.
32719124	1	41	theme	CD8+	134:137	arg1	peptides					157:164	CD8+ T cell-activating peptides	134:164	CD8+ T cell-activating peptides	134:164	The source proteins from which CD8+ T cell-activating peptides are derived remain enigmatic.
32719124	3	42	theme	N-linked	377:384	arg1	site					400:403	an N-linked glycosylation site	374:403	an N-linked glycosylation site	374:403	By engineering a glycoprotein-derived epitope to contain an N-linked glycosylation site, we determined that optimal CD8+ T cell expansion and function were induced by the peptides that are rapidly produced from the exceedingly minor fraction of protein mislocalized to the cytosol.
32714760	10	0	theme	protein	1455:1461	arg1	N-glycosylation					1463:1477	protein N-glycosylation	1455:1477	protein N-glycosylation in oocytes	1455:1488	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	6	1	from	reduction	746:754	arg1	glycosylation					759:771	glycosylation	759:771	glycosylation of ZP proteins	759:786	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	10	2	theme	specific	1538:1545	arg1	control					1547:1553	specific control	1538:1553	specific control of oocyte development	1538:1575	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	10	3	theme	female	1507:1512	arg1	fertility					1514:1522	female fertility	1507:1522	female fertility in mammals by specific control of oocyte development	1507:1575	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	4	4	theme	female	526:531	arg1	subfertility					533:544	female subfertility	526:544	female subfertility	526:544	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly) causes female subfertility without grossly affecting other functions.
32714760	8	5	dep	Pttgt1	1166:1171	arg1	e.g.					1160:1163	e.g.	1160:1163	e.g.	1160:1163	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	1	6	theme	many	187:190	arg1	processes					197:205	many life processes	187:205	many life processes	187:205	Post-translational modification of proteins by N-linked glycosylation is crucial for many life processes.
32714760	4	7	dep	mutation	484:491	arg1	497A>G					497:502	c. 497A>G	494:502	c. 497A>G; p. Asp166Gly	494:516	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly) causes female subfertility without grossly affecting other functions.
32714760	3	8	theme	protein	377:383	arg1	N-glycosylation					385:399	protein N-glycosylation	377:399	protein N-glycosylation	377:399	Here, DPAGT1, the enzyme that catalyzes the first step of protein N-glycosylation, is identified to be indispensable for oocyte development in mice.
32714760	9	9	theme	Dpagt1	1299:1304	arg1	knockout					1287:1294	knockout	1287:1294	knockout	1287:1294	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	8	10	theme	number	1064:1069	arg1	downregulation					1044:1057	the downregulation	1040:1057	the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed	1040:1259	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	6	11	theme	developmental	806:818	arg1	competence					820:829	poor developmental competence	801:829	poor developmental competence after fertilization	801:849	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	7	12	theme	first	889:893	arg1	meiosis					895:901	the first meiosis	885:901	the first meiosis	885:901	Moreover, completion of the first meiosis is accelerated in mutant oocytes, which is coincident with the elevation of aneuploidy.
32714760	8	13	from	development	1147:1157	arg1	oocytes					1207:1213	mutant oocytes	1200:1213	mutant oocytes	1200:1213	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	3	14	theme	N-glycosylation	385:399	arg1	step					369:372	the first step	359:372	the first step of protein N-glycosylation	359:399	Here, DPAGT1, the enzyme that catalyzes the first step of protein N-glycosylation, is identified to be indispensable for oocyte development in mice.
32714760	5	15	theme	defective	632:640	arg1	development					642:652	defective development	632:652	defective development of growing follicles	632:673	Mutant females ovulate fewer eggs owing to defective development of growing follicles.
32714760	6	16	gly	glycosylation	759:771	arg1	proteins					779:786	ZP proteins	776:786	ZP proteins	776:786	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	0	17	from	Oocyte	61:66	arg1	Mice					96:99	Mice	96:99	Mice	96:99	DPAGT1-Mediated Protein N-Glycosylation Is Indispensable for Oocyte and Follicle Development in Mice.
32714760	8	18	theme	transcripts	1074:1084	arg1	number					1064:1069	a number	1062:1069	a number	1062:1069	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	6	19	theme	poor	801:804	arg1	competence					820:829	poor developmental competence	801:829	poor developmental competence after fertilization	801:849	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	1	20	theme	life	192:195	arg1	processes					197:205	many life processes	187:205	many life processes	187:205	Post-translational modification of proteins by N-linked glycosylation is crucial for many life processes.
32714760	5	21	theme	growing	657:663	arg1	follicles					665:673	growing follicles	657:673	growing follicles	657:673	Mutant females ovulate fewer eggs owing to defective development of growing follicles.
32714760	9	22	theme	complete	1392:1399	arg1	infertility					1401:1411	complete infertility	1392:1411	complete infertility	1392:1411	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	0	23	theme	Protein	16:22	arg1	N-Glycosylation					24:38	DPAGT1-Mediated Protein N-Glycosylation	0:38	DPAGT1-Mediated Protein N-Glycosylation	0:38	DPAGT1-Mediated Protein N-Glycosylation Is Indispensable for Oocyte and Follicle Development in Mice.
32714760	9	24	theme	Dpagt1	1358:1363	arg1	females					1372:1378	Dpagt1 mutant females	1358:1378	Dpagt1 mutant females	1358:1378	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	5	25	theme	follicles	665:673	arg1	development					642:652	defective development	632:652	defective development of growing follicles	632:673	Mutant females ovulate fewer eggs owing to defective development of growing follicles.
32714760	8	26	theme	transcriptomic	1008:1021	arg1	analysis					1023:1030	transcriptomic analysis	1008:1030	transcriptomic analysis	1008:1030	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	0	27	theme	DPAGT1-Mediated	0:14	arg1	N-Glycosylation					24:38	DPAGT1-Mediated Protein N-Glycosylation	0:38	DPAGT1-Mediated Protein N-Glycosylation	0:38	DPAGT1-Mediated Protein N-Glycosylation Is Indispensable for Oocyte and Follicle Development in Mice.
32714760	8	28	theme	essential	1086:1094	arg1	transcripts					1074:1084	transcripts	1074:1084	transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes	1074:1213	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	5	29	theme	fewer	612:616	arg1	eggs					618:621	fewer eggs	612:621	fewer eggs owing to defective development of growing follicles	612:673	Mutant females ovulate fewer eggs owing to defective development of growing follicles.
32714760	1	30	theme	Post-translational	102:119	arg1	modification					121:132	Post-translational modification	102:132	Post-translational modification of proteins by N-linked glycosylation	102:170	Post-translational modification of proteins by N-linked glycosylation is crucial for many life processes.
32714760	6	31	theme	zona	715:718	arg1	ZP					731:732	ZP	731:732	ZP	731:732	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	6	31	theme	zona	715:718	arg1	pellucida					720:728	fragile zona pellucida	707:728	fragile zona pellucida (ZP)	707:733	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	8	32	theme	mutant	1200:1205	arg1	oocytes					1207:1213	mutant oocytes	1200:1213	mutant oocytes	1200:1213	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	4	33	theme	other	572:576	arg1	functions					578:586	other functions	572:586	other functions	572:586	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly) causes female subfertility without grossly affecting other functions.
32714760	8	34	theme	meiotic	1107:1113	arg1	progression					1115:1125	oocyte meiotic progression	1100:1125	oocyte meiotic progression	1100:1125	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	6	35	theme	proteins	779:786	arg1	glycosylation					759:771	glycosylation	759:771	glycosylation of ZP proteins	759:786	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	6	36	theme	fragile	707:713	arg1	ZP					731:732	ZP	731:732	ZP	731:732	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	6	36	theme	fragile	707:713	arg1	pellucida					720:728	fragile zona pellucida	707:728	fragile zona pellucida (ZP)	707:733	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	9	37	from	oocytes	1309:1315	arg1	knockout					1287:1294	knockout	1287:1294	knockout	1287:1294	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	4	38	dep	497A>G	497:502	arg1	Asp166Gly					508:516	Asp166Gly	508:516	Asp166Gly	508:516	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly) causes female subfertility without grossly affecting other functions.
32714760	8	39	theme	oocyte	1100:1105	arg1	progression					1115:1125	oocyte meiotic progression	1100:1125	oocyte meiotic progression	1100:1125	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	4	40	theme	missense	475:482	arg1	mutation					484:491	Dpagt1 missense mutation	468:491	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly)	468:517	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly) causes female subfertility without grossly affecting other functions.
32714760	10	41	theme	oocyte	1558:1563	arg1	development					1565:1575	oocyte development	1558:1575	oocyte development	1558:1575	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	7	42	with	coincident	946:955	arg1	elevation					966:974	the elevation	962:974	the elevation of aneuploidy	962:988	Moreover, completion of the first meiosis is accelerated in mutant oocytes, which is coincident with the elevation of aneuploidy.
32714760	6	43	contain	have	691:694	arg1	oocytes					683:689	Mutant oocytes	676:689	Mutant oocytes	676:689	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	6	43	contain	have	691:694	arg2	ZP					731:732	ZP	731:732	ZP	731:732	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	6	43	contain	have	691:694	arg2	pellucida					720:728	fragile zona pellucida	707:728	fragile zona pellucida (ZP)	707:733	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	6	43	contain	have	691:694	arg2	thin					698:701	thin	698:701	thin	698:701	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	4	44	theme	Dpagt1	468:473	arg1	mutation					484:491	Dpagt1 missense mutation	468:491	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly)	468:517	Dpagt1 missense mutation (c. 497A>G; p. Asp166Gly) causes female subfertility without grossly affecting other functions.
32714760	2	45	theme	mammalian	262:270	arg1	reproduction					279:290	mammalian female reproduction	262:290	mammalian female reproduction	262:290	However, the exact contribution of N-glycosylation to mammalian female reproduction remains largely undefined.
32714760	3	46	theme	oocyte	440:445	arg1	development					447:457	oocyte development	440:457	oocyte development in mice	440:465	Here, DPAGT1, the enzyme that catalyzes the first step of protein N-glycosylation, is identified to be indispensable for oocyte development in mice.
32714760	9	47	theme	mutant	1365:1370	arg1	females					1372:1378	Dpagt1 mutant females	1358:1378	Dpagt1 mutant females	1358:1378	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	0	48	from	Development	81:91	arg1	Mice					96:99	Mice	96:99	Mice	96:99	DPAGT1-Mediated Protein N-Glycosylation Is Indispensable for Oocyte and Follicle Development in Mice.
32714760	6	49	theme	ZP	776:777	arg1	proteins					779:786	ZP proteins	776:786	ZP proteins	776:786	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	10	50	from	N-glycosylation	1463:1477	arg1	oocytes					1482:1488	oocytes	1482:1488	oocytes	1482:1488	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	1	51	link	N-linked	149:156	arg1	glycosylation					158:170	N-linked glycosylation	149:170	N-linked glycosylation	149:170	Post-translational modification of proteins by N-linked glycosylation is crucial for many life processes.
32714760	0	52	theme	Follicle	72:79	arg1	Development					81:91	Follicle Development	72:91	Follicle Development	72:91	DPAGT1-Mediated Protein N-Glycosylation Is Indispensable for Oocyte and Follicle Development in Mice.
32714760	2	53	theme	N-glycosylation	243:257	arg1	contribution					227:238	the exact contribution	217:238	the exact contribution of N-glycosylation to mammalian female reproduction	217:290	However, the exact contribution of N-glycosylation to mammalian female reproduction remains largely undefined.
32714760	1	54	theme	proteins	137:144	arg1	modification					121:132	Post-translational modification	102:132	Post-translational modification of proteins by N-linked glycosylation	102:170	Post-translational modification of proteins by N-linked glycosylation is crucial for many life processes.
32714760	9	55	from	knockout	1287:1294	arg1	oocytes					1309:1315	oocytes	1309:1315	oocytes	1309:1315	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	8	56	theme	preimplantation	1131:1145	arg1	development					1147:1157	preimplantation development	1131:1157	preimplantation development	1131:1157	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	7	57	theme	mutant	921:926	arg1	oocytes					928:934	mutant oocytes	921:934	mutant oocytes	921:934	Moreover, completion of the first meiosis is accelerated in mutant oocytes, which is coincident with the elevation of aneuploidy.
32714760	2	58	theme	exact	221:225	arg1	contribution					227:238	the exact contribution	217:238	the exact contribution of N-glycosylation to mammalian female reproduction	217:290	However, the exact contribution of N-glycosylation to mammalian female reproduction remains largely undefined.
32714760	5	59	theme	Mutant	589:594	arg1	females					596:602	Mutant females	589:602	Mutant females	589:602	Mutant females ovulate fewer eggs owing to defective development of growing follicles.
32714760	1	60	theme	N-linked	149:156	arg1	glycosylation					158:170	N-linked glycosylation	149:170	N-linked glycosylation	149:170	Post-translational modification of proteins by N-linked glycosylation is crucial for many life processes.
32714760	9	61	located	observed	1346:1353	arg1	females					1372:1378	Dpagt1 mutant females	1358:1378	Dpagt1 mutant females	1358:1378	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	9	61	located	observed	1346:1353	arg2	phenotypes					1335:1344	the phenotypes	1331:1344	the phenotypes observed in Dpagt1 mutant females	1331:1378	Furthermore, conditional knockout of Dpagt1 in oocytes recapitulates the phenotypes observed in Dpagt1 mutant females, and causes complete infertility.
32714760	3	62	from	development	447:457	arg1	mice					462:465	mice	462:465	mice	462:465	Here, DPAGT1, the enzyme that catalyzes the first step of protein N-glycosylation, is identified to be indispensable for oocyte development in mice.
32714760	10	63	gly	N-glycosylation	1463:1477	arg1	female					1507:1512	female fertility	1507:1522	female fertility in mammals by specific control of oocyte development	1507:1575	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	10	63	gly	N-glycosylation	1463:1477	arg1	oocytes					1482:1488	oocytes	1482:1488	oocytes	1482:1488	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	8	64	from	progression	1115:1125	arg1	oocytes					1207:1213	mutant oocytes	1200:1213	mutant oocytes	1200:1213	Mechanistically, transcriptomic analysis reveals the downregulation of a number of transcripts essential for oocyte meiotic progression and preimplantation development (e.g., Pttgt1, Esco2, Orc6, and Npm2) in mutant oocytes, which could account for the defects observed.
32714760	10	65	theme	development	1565:1575	arg1	control					1547:1553	specific control	1538:1553	specific control of oocyte development	1538:1575	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	6	66	theme	Mutant	676:681	arg1	oocytes					683:689	Mutant oocytes	676:689	Mutant oocytes	676:689	Mutant oocytes have a thin and fragile zona pellucida (ZP) due to the reduction in glycosylation of ZP proteins, and display poor developmental competence after fertilization in vitro.
32714760	10	67	from	fertility	1514:1522	arg1	mammals					1527:1533	mammals	1527:1533	mammals	1527:1533	Taken together, these data indicate that protein N-glycosylation in oocytes is essential for female fertility in mammals by specific control of oocyte development.
32714760	3	68	theme	first	363:367	arg1	step					369:372	the first step	359:372	the first step of protein N-glycosylation	359:399	Here, DPAGT1, the enzyme that catalyzes the first step of protein N-glycosylation, is identified to be indispensable for oocyte development in mice.
32714760	2	69	theme	female	272:277	arg1	reproduction					279:290	mammalian female reproduction	262:290	mammalian female reproduction	262:290	However, the exact contribution of N-glycosylation to mammalian female reproduction remains largely undefined.
32714760	7	70	theme	aneuploidy	979:988	arg1	elevation					966:974	the elevation	962:974	the elevation of aneuploidy	962:988	Moreover, completion of the first meiosis is accelerated in mutant oocytes, which is coincident with the elevation of aneuploidy.
32714760	7	71	theme	meiosis	895:901	arg1	completion					871:880	completion	871:880	completion of the first meiosis	871:901	Moreover, completion of the first meiosis is accelerated in mutant oocytes, which is coincident with the elevation of aneuploidy.
32531122	10	0	theme	glomerular	1467:1476	arg1	destabilization					1478:1492	eventual glomerular destabilization	1458:1492	eventual glomerular destabilization	1458:1492	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	4	1	theme	nephrin	480:486	arg1	expression					466:475	the expression	462:475	the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes	462:549	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	10	2	theme	eventual	1458:1465	arg1	destabilization					1478:1492	eventual glomerular destabilization	1458:1492	eventual glomerular destabilization	1458:1492	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	0	3	from	IgG	15:17	arg1	patients					22:29	patients	22:29	patients with kidney transplants	22:53	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	8	4	theme	N-linked	977:984	arg1	residues					995:1002	N-linked glycosyl residues	977:1002	N-linked glycosyl residues from these IgG	977:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	9	5	theme	translational	1149:1161	arg1	value					1163:1167	The translational value	1145:1167	The translational value of these findings	1145:1185	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
32531122	4	6	theme	changes	543:549	arg1	expression					466:475	the expression	462:475	the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes	462:549	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	4	7	theme	transplant	379:388	arg1	recipients					390:399	kidney transplant recipients	372:399	kidney transplant recipients with TG	372:407	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	7	8	theme	podocyte-damaging	884:900	arg1	effects					902:908	the podocyte-damaging effects	880:908	the podocyte-damaging effects of IgG from patients with TG	880:937	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	8	9	theme	residues	995:1002	arg1	removal					966:972	removal	966:972	removal of N-linked glycosyl residues from these IgG	966:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	7	10	theme	neonatal	833:840	arg1	FcRn					855:858	FcRn	855:858	FcRn	855:858	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	7	10	theme	neonatal	833:840	arg1	Receptor					845:852	Silencing neonatal Fc Receptor	823:852	Silencing neonatal Fc Receptor (FcRn)	823:859	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	7	11	theme	Silencing	823:831	arg1	FcRn					855:858	FcRn	855:858	FcRn	855:858	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	7	11	theme	Silencing	823:831	arg1	Receptor					845:852	Silencing neonatal Fc Receptor	823:852	Silencing neonatal Fc Receptor (FcRn)	823:859	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	9	12	theme	patients	1252:1259	arg1	podocytes					1239:1247	podocytes	1239:1247	podocytes of patients with TG	1239:1267	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
32531122	5	13	theme	increased	582:590	arg1	expression					592:601	increased expression	582:601	increased expression of calcium/calmodulin kinase IV (CAMK4)	582:641	These changes are preceded by increased expression of calcium/calmodulin kinase IV (CAMK4).
32531122	4	14	from	recipients	390:399	arg1	IgG					363:365	IgG	363:365	IgG from kidney transplant recipients with TG, but not from those without TG,	363:439	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	7	15	theme	Fc	842:843	arg1	FcRn					855:858	FcRn	855:858	FcRn	855:858	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	7	15	theme	Fc	842:843	arg1	Receptor					845:852	Silencing neonatal Fc Receptor	823:852	Silencing neonatal Fc Receptor (FcRn)	823:859	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	1	16	theme	major	162:166	arg1	glomerulopathy					137:150	Transplant glomerulopathy	126:150	Transplant glomerulopathy (TG)	126:155	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	1	16	theme	major	162:166	arg1	cause					168:172	a major cause	160:172	a major cause of late allograft loss	160:195	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	10	17	theme	transplant	1498:1507	arg1	glomerulopathy					1509:1522	transplant glomerulopathy	1498:1522	transplant glomerulopathy	1498:1522	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	4	18	from	reduction	449:457	arg1	expression					466:475	the expression	462:475	the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes	462:549	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	6	19	theme	Wnt	751:753	arg1	pathway					755:761	the Wnt pathway	747:761	the Wnt pathway	747:761	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	8	20	theme	podocyte	1128:1135	arg1	injury					1137:1142	podocyte injury	1128:1142	podocyte injury	1128:1142	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	8	21	from	IgG	1015:1017	arg1	residues					995:1002	N-linked glycosyl residues	977:1002	N-linked glycosyl residues from these IgG	977:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	8	21	from	IgG	1015:1017	arg1	removal					966:972	removal	966:972	removal of N-linked glycosyl residues from these IgG	966:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	5	22	theme	calcium/calmodulin	606:623	arg1	kinase					625:630	calcium/calmodulin kinase IV	606:633	calcium/calmodulin kinase IV (CAMK4)	606:641	These changes are preceded by increased expression of calcium/calmodulin kinase IV (CAMK4).
32531122	5	22	theme	calcium/calmodulin	606:623	arg1	CAMK4					636:640	CAMK4	636:640	CAMK4	636:640	These changes are preceded by increased expression of calcium/calmodulin kinase IV (CAMK4).
32531122	7	23	theme	IgG	913:915	arg1	effects					902:908	the podocyte-damaging effects	880:908	the podocyte-damaging effects of IgG from patients with TG	880:937	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	2	24	from	ratio	233:237	arg1	TG					242:243	TG	242:243	TG	242:243	Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte loss.
32531122	0	25	theme	N-glycosylated	0:13	arg1	IgG					15:17	N-glycosylated IgG	0:17	N-glycosylated IgG in patients with kidney transplants	0:53	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	5	26	theme	kinase	625:630	arg1	expression					592:601	increased expression	582:601	increased expression of calcium/calmodulin kinase IV (CAMK4)	582:641	These changes are preceded by increased expression of calcium/calmodulin kinase IV (CAMK4).
32531122	4	27	theme	kidney	372:377	arg1	recipients					390:399	kidney transplant recipients	372:399	kidney transplant recipients with TG	372:407	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	2	28	theme	Increased	198:206	arg1	ratio					233:237	Increased urine podocin/creatinine ratio	198:237	Increased urine podocin/creatinine ratio in TG	198:243	Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte loss.
32531122	1	29	theme	late	177:180	arg1	loss					192:195	late allograft loss	177:195	late allograft loss	177:195	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	4	30	with	recipients	390:399	arg1	TG					406:407	TG	406:407	TG	406:407	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	4	31	theme	cytoskeleton	516:527	arg1	expression					466:475	the expression	462:475	the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes	462:549	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	10	32	theme	podocyte	1387:1394	arg1	injury					1396:1401	podocyte injury	1387:1401	podocyte injury in patients with kidney transplants	1387:1437	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	1	33	theme	allograft	182:190	arg1	loss					192:195	late allograft loss	177:195	late allograft loss	177:195	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	4	34	theme	motility	534:541	arg1	changes					543:549	motility changes	534:549	motility changes	534:549	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	9	35	theme	findings	1178:1185	arg1	value					1163:1167	The translational value	1145:1167	The translational value of these findings	1145:1185	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
32531122	10	36	with	patients	1406:1413	arg1	transplants					1427:1437	kidney transplants	1420:1437	kidney transplants	1420:1437	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	1	37	theme	loss	192:195	arg1	glomerulopathy					137:150	Transplant glomerulopathy	126:150	Transplant glomerulopathy (TG)	126:155	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	1	37	theme	loss	192:195	arg1	cause					168:172	a major cause	160:172	a major cause of late allograft loss	160:195	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	0	38	theme	kidney	36:41	arg1	transplants					43:53	kidney transplants	36:53	kidney transplants	36:53	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	10	39	theme	kidney	1420:1425	arg1	transplants					1427:1437	kidney transplants	1420:1437	kidney transplants	1420:1437	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	0	40	gly	N-glycosylated	0:13	arg1	IgG					15:17	N-glycosylated IgG	0:17	N-glycosylated IgG in patients with kidney transplants	0:53	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	9	41	with	patients	1252:1259	arg1	TG					1266:1267	TG	1266:1267	TG	1266:1267	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
32531122	4	42	theme	significant	489:499	arg1	cytoskeleton					516:527	significant podocyte actin cytoskeleton	489:527	significant podocyte actin cytoskeleton	489:527	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	4	43	from	those	423:427	arg1	IgG					363:365	IgG	363:365	IgG from kidney transplant recipients with TG, but not from those without TG,	363:439	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	0	44	from	kinase	84:89	arg1	podocytes					97:105	podocytes	97:105	podocytes	97:105	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	0	45	with	patients	22:29	arg1	transplants					43:53	kidney transplants	36:53	kidney transplants	36:53	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	9	46	theme	other	1305:1309	arg1	forms					1311:1315	other forms	1305:1315	other forms of renal dysfunction	1305:1336	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
32531122	10	47	theme	novel	1357:1361	arg1	considerations					1363:1376	novel considerations	1357:1376	novel considerations	1357:1376	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	7	48	with	patients	922:929	arg1	TG					936:937	TG	936:937	TG	936:937	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	2	49	theme	podocin/creatinine	214:231	arg1	ratio					233:237	Increased urine podocin/creatinine ratio	198:237	Increased urine podocin/creatinine ratio in TG	198:243	Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte loss.
32531122	4	50	theme	actin	510:514	arg1	cytoskeleton					516:527	significant podocyte actin cytoskeleton	489:527	significant podocyte actin cytoskeleton	489:527	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	3	51	theme	podocyte	310:317	arg1	injury					319:324	podocyte injury	310:324	podocyte injury in TG	310:330	The mechanisms that lead to podocyte injury in TG remain unclear.
32531122	3	52	from	injury	319:324	arg1	TG					329:330	TG	329:330	TG	329:330	The mechanisms that lead to podocyte injury in TG remain unclear.
32531122	2	53	theme	urine	208:212	arg1	ratio					233:237	Increased urine podocin/creatinine ratio	198:237	Increased urine podocin/creatinine ratio in TG	198:243	Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte loss.
32531122	1	54	theme	Transplant	126:135	arg1	glomerulopathy					137:150	Transplant glomerulopathy	126:150	Transplant glomerulopathy (TG)	126:155	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	1	54	theme	Transplant	126:135	arg1	cause					168:172	a major cause	160:172	a major cause of late allograft loss	160:195	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	1	54	theme	Transplant	126:135	arg1	TG					153:154	TG	153:154	TG	153:154	Transplant glomerulopathy (TG) is a major cause of late allograft loss.
32531122	4	55	theme	podocyte	501:508	arg1	cytoskeleton					516:527	significant podocyte actin cytoskeleton	489:527	significant podocyte actin cytoskeleton	489:527	We report that IgG from kidney transplant recipients with TG, but not from those without TG, cause a reduction in the expression of nephrin, significant podocyte actin cytoskeleton, and motility changes.
32531122	6	56	theme	repressor	806:814	arg1	SNAIL					816:820	the nephrin transcriptional repressor SNAIL	778:820	the nephrin transcriptional repressor SNAIL	778:820	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	2	57	theme	podocyte	267:274	arg1	loss					276:279	accelerated podocyte loss	255:279	accelerated podocyte loss	255:279	Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte loss.
32531122	6	58	theme	kinase	721:726	arg1	GSK3β					696:700	GSK3β	696:700	GSK3β (glycogen synthase kinase 3 beta)	696:734	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	6	58	theme	kinase	721:726	arg1	beta					730:733	glycogen synthase kinase 3 beta	703:733	glycogen synthase kinase 3 beta	703:733	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	6	59	theme	transcriptional	790:804	arg1	SNAIL					816:820	the nephrin transcriptional repressor SNAIL	778:820	the nephrin transcriptional repressor SNAIL	778:820	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	2	60	theme	accelerated	255:265	arg1	loss					276:279	accelerated podocyte loss	255:279	accelerated podocyte loss	255:279	Increased urine podocin/creatinine ratio in TG signifies accelerated podocyte loss.
32531122	6	61	theme	synthase	712:719	arg1	kinase					721:726	glycogen synthase kinase 3	703:728	glycogen synthase kinase 3 beta	703:733	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	8	62	from	removal	966:972	arg1	IgG					1015:1017	these IgG	1009:1017	these IgG	1009:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	10	63	dep	offer	1351:1355	arg1	lead					1450:1453	lead	1450:1453	may lead to eventual glomerular destabilization and transplant glomerulopathy	1446:1522	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	6	64	theme	nephrin	782:788	arg1	SNAIL					816:820	the nephrin transcriptional repressor SNAIL	778:820	the nephrin transcriptional repressor SNAIL	778:820	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	10	65	from	injury	1396:1401	arg1	patients					1406:1413	patients	1406:1413	patients with kidney transplants	1406:1437	Our results offer novel considerations to limit podocyte injury in patients with kidney transplants, which may lead to eventual glomerular destabilization and transplant glomerulopathy.
32531122	6	66	theme	glycogen	703:710	arg1	kinase					721:726	glycogen synthase kinase 3	703:728	glycogen synthase kinase 3 beta	703:733	Mechanistically, we found that CAMK4 phosphorylates GSK3β (glycogen synthase kinase 3 beta), activates the Wnt pathway and stabilizes the nephrin transcriptional repressor SNAIL.
32531122	8	67	link	N-linked	977:984	arg1	residues					995:1002	N-linked glycosyl residues	977:1002	N-linked glycosyl residues from these IgG	977:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	9	68	theme	renal	1320:1324	arg1	dysfunction					1326:1336	renal dysfunction	1320:1336	renal dysfunction	1320:1336	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
32531122	0	69	theme	calcium/calmodulin	65:82	arg1	kinase					84:89	calcium/calmodulin kinase IV	65:92	calcium/calmodulin kinase IV in podocytes	65:105	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury.
32531122	8	70	theme	glycosyl	986:993	arg1	residues					995:1002	N-linked glycosyl residues	977:1002	N-linked glycosyl residues from these IgG	977:1017	Furthermore, we show that removal of N-linked glycosyl residues from these IgG did not interfere with its entry into the podocytes but eliminated its ability to upregulate CAMK4 and cause podocyte injury.
32531122	7	71	from	patients	922:929	arg1	effects					902:908	the podocyte-damaging effects	880:908	the podocyte-damaging effects of IgG from patients with TG	880:937	Silencing neonatal Fc Receptor (FcRn) or CAMK4 prevented the podocyte-damaging effects of IgG from patients with TG.
32531122	9	72	theme	dysfunction	1326:1336	arg1	forms					1311:1315	other forms	1305:1315	other forms of renal dysfunction	1305:1336	The translational value of these findings is signified by the fact that CAMK4 is increased in podocytes of patients with TG but not in those without TG despite other forms of renal dysfunction.
34510715	0	0	theme	OGT	85:87	arg1	expression					89:98	OGT expression	85:98	OGT expression	85:98	P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.
34510715	6	1	theme	gain-	891:895	arg1	studies					918:924	gain- and loss-of-function studies	891:924	gain- and loss-of-function studies	891:924	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	6	2	from	axis	994:997	arg1	progression					1006:1016	the progression	1002:1016	the progression of HCC	1002:1023	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	1	3	theme	tumour	164:169	arg1	capacity					183:190	the tumour suppressive capacity	160:190	the tumour suppressive capacity of microRNA-15a	160:206	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	12	4	theme	study	1776:1780	arg1	findings					1760:1767	The key findings	1752:1767	The key findings of our study	1752:1780	The key findings of our study highlight a promising novel therapeutic strategy for the treatment of HCC.
34510715	1	5	theme	hepatocellular	240:253	arg1	carcinoma					255:263	hepatocellular carcinoma	240:263	hepatocellular carcinoma (HCC)	240:269	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	1	5	theme	hepatocellular	240:253	arg1	HCC					266:268	HCC	266:268	HCC	266:268	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	10	6	theme	in	1481:1482	arg1	study					1489:1493	our in vivo study	1477:1493	our in vivo study	1477:1493	The results of our in vivo study provided evidence demonstrating that P53 could suppress the development of HCC via the miR-15a/OGT/EZH2 axis.
34510715	4	7	theme	Bioinformatics	494:507	arg1	analysis					509:516	Bioinformatics analysis	494:516	Bioinformatics analysis	494:516	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	12	8	theme	HCC	1852:1854	arg1	treatment					1839:1847	the treatment	1835:1847	the treatment of HCC	1835:1854	The key findings of our study highlight a promising novel therapeutic strategy for the treatment of HCC.
34510715	1	9	theme	suppressive	171:181	arg1	capacity					183:190	the tumour suppressive capacity	160:190	the tumour suppressive capacity of microRNA-15a	160:206	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	7	10	theme	HCC	1167:1169	arg1	tissues					1171:1177	the HCC tissues	1163:1177	the HCC tissues	1163:1177	Our results demonstrated that the miR-15a expression was decreased in the HCC tissues and cells.
34510715	8	11	dep	proliferation	1246:1258	arg1	the					1242:1244	the	1242:1244	the	1242:1244	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	8	12	theme	G0/G1	1340:1344	arg1	arrest					1363:1368	a G0/G1 cell cycle phase arrest	1338:1368	a G0/G1 cell cycle phase arrest	1338:1368	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	4	13	theme	molecular	588:596	arg1	approaches					598:607	molecular approaches	588:607	molecular approaches	588:607	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	5	14	theme	PUGNAc	734:739	arg1	treatment					741:749	PUGNAc treatment	734:749	PUGNAc treatment	734:749	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	2	15	from	role	335:338	arg1	HCC					354:356	HCC	354:356	HCC	354:356	This study aimed to investigate the role of miR-15a in HCC and the associated underlying mechanism.
34510715	2	16	theme	miR-15a	343:349	arg1	role					335:338	the role	331:338	the role of miR-15a in HCC	331:356	This study aimed to investigate the role of miR-15a in HCC and the associated underlying mechanism.
34510715	2	16	theme	miR-15a	343:349	arg1	mechanism					388:396	the associated underlying mechanism	362:396	the associated underlying mechanism	362:396	This study aimed to investigate the role of miR-15a in HCC and the associated underlying mechanism.
34510715	9	17	theme	P53	1445:1447	arg1	effect					1435:1440	the effect	1431:1440	the effect of P53 and miR-15a	1431:1459	OGT stabilized EZH2 via catalysing O-GlcNAc, which reversed the effect of P53 and miR-15a.
34510715	4	18	theme	O-linked	677:684	arg1	GlcNAc					707:712	GlcNAc	707:712	GlcNAc	707:712	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	4	18	theme	O-linked	677:684	arg1	N-acetylglucosamine					686:704	O-linked N-acetylglucosamine	677:704	O-linked N-acetylglucosamine (GlcNAc) transferase (OGT)	677:731	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	2	19	theme	underlying	377:386	arg1	mechanism					388:396	the associated underlying mechanism	362:396	the associated underlying mechanism	362:396	This study aimed to investigate the role of miR-15a in HCC and the associated underlying mechanism.
34510715	0	20	theme	EZH2	104:107	arg1	stabilization					109:121	EZH2 stabilization	104:121	EZH2 stabilization	104:121	P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.
34510715	2	21	theme	associated	366:375	arg1	mechanism					388:396	the associated underlying mechanism	362:396	the associated underlying mechanism	362:396	This study aimed to investigate the role of miR-15a in HCC and the associated underlying mechanism.
34510715	1	22	theme	microRNA-15a	195:206	arg1	capacity					183:190	the tumour suppressive capacity	160:190	the tumour suppressive capacity of microRNA-15a	160:206	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	11	23	theme	HCC	1747:1749	arg1	development					1732:1742	the development	1728:1742	the development of HCC	1728:1749	P53 was found to inhibit the OGT expression by promoting the expression of miR-15a, which destabilized EZH2 and suppressed the development of HCC.
34510715	6	24	theme	loss-of-function	901:916	arg1	studies					918:924	gain- and loss-of-function studies	891:924	gain- and loss-of-function studies	891:924	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	10	25	theme	miR-15a/OGT/EZH2	1582:1597	arg1	axis					1599:1602	the miR-15a/OGT/EZH2 axis	1578:1602	the miR-15a/OGT/EZH2 axis	1578:1602	The results of our in vivo study provided evidence demonstrating that P53 could suppress the development of HCC via the miR-15a/OGT/EZH2 axis.
34510715	7	26	theme	miR-15a	1127:1133	arg1	expression					1135:1144	the miR-15a expression	1123:1144	the miR-15a expression	1123:1144	Our results demonstrated that the miR-15a expression was decreased in the HCC tissues and cells.
34510715	6	27	theme	in	1038:1039	arg1	experiments					1046:1056	in vivo experiments	1038:1056	in vivo experiments based on tumour-bearing nude mice	1038:1090	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	12	28	theme	novel	1804:1808	arg1	strategy					1822:1829	a promising novel therapeutic strategy	1792:1829	a promising novel therapeutic strategy for the treatment of HCC	1792:1854	The key findings of our study highlight a promising novel therapeutic strategy for the treatment of HCC.
34510715	1	29	dep	highlighted	148:158	arg1	miR-15a					209:215	miR-15a	209:215	miR-15a	209:215	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	8	30	theme	phase	1357:1361	arg1	arrest					1363:1368	a G0/G1 cell cycle phase arrest	1338:1368	a G0/G1 cell cycle phase arrest	1338:1368	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	12	31	theme	therapeutic	1810:1820	arg1	strategy					1822:1829	a promising novel therapeutic strategy	1792:1829	a promising novel therapeutic strategy for the treatment of HCC	1792:1854	The key findings of our study highlight a promising novel therapeutic strategy for the treatment of HCC.
34510715	4	32	theme	reporter	568:575	arg1	assay					577:581	dual-luciferase reporter assay	552:581	dual-luciferase reporter assay	552:581	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	12	33	theme	promising	1794:1802	arg1	strategy					1822:1829	a promising novel therapeutic strategy	1792:1829	a promising novel therapeutic strategy for the treatment of HCC	1792:1854	The key findings of our study highlight a promising novel therapeutic strategy for the treatment of HCC.
34510715	6	34	dep	in	1038:1039	arg1	vivo					1041:1044	vivo	1041:1044	vivo	1041:1044	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	6	35	theme	HCC	1021:1023	arg1	progression					1006:1016	the progression	1002:1016	the progression of HCC	1002:1023	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	0	36	theme	hepatocellular	34:47	arg1	carcinoma					49:57	hepatocellular carcinoma	34:57	hepatocellular carcinoma	34:57	P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.
34510715	4	37	theme	dual-luciferase	552:566	arg1	assay					577:581	dual-luciferase reporter assay	552:581	dual-luciferase reporter assay	552:581	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	6	38	from	role	957:960	arg1	progression					1006:1016	the progression	1002:1016	the progression of HCC	1002:1023	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	4	39	link	O-linked	677:684	arg1	GlcNAc					707:712	GlcNAc	707:712	GlcNAc	707:712	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	4	39	link	O-linked	677:684	arg1	N-acetylglucosamine					686:704	O-linked N-acetylglucosamine	677:704	O-linked N-acetylglucosamine (GlcNAc) transferase (OGT)	677:731	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	8	40	theme	miR-15a	1206:1212	arg1	expression					1214:1223	miR-15a expression	1206:1223	miR-15a expression	1206:1223	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	5	41	theme	homolog	864:870	arg1	enhancer					846:853	the enhancer	842:853	the enhancer of zeste homolog 2 (EZH2)	842:879	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	8	42	theme	cycle	1351:1355	arg1	arrest					1363:1368	a G0/G1 cell cycle phase arrest	1338:1368	a G0/G1 cell cycle phase arrest	1338:1368	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	12	43	theme	key	1756:1758	arg1	findings					1760:1767	The key findings	1752:1767	The key findings of our study	1752:1780	The key findings of our study highlight a promising novel therapeutic strategy for the treatment of HCC.
34510715	5	44	theme	enhancer	846:853	arg1	O-GlcNAc					808:815	O-GlcNAc	808:815	O-GlcNAc	808:815	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	5	44	theme	enhancer	846:853	arg1	stabilization					825:837	the stabilization	821:837	the stabilization of the enhancer of zeste homolog 2 (EZH2)	821:879	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	10	45	theme	HCC	1570:1572	arg1	development					1555:1565	the development	1551:1565	the development of HCC	1551:1572	The results of our in vivo study provided evidence demonstrating that P53 could suppress the development of HCC via the miR-15a/OGT/EZH2 axis.
34510715	1	46	from	role	232:235	arg1	carcinoma					255:263	hepatocellular carcinoma	240:263	hepatocellular carcinoma (HCC)	240:269	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	1	46	from	role	232:235	arg1	HCC					266:268	HCC	266:268	HCC	266:268	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	10	47	theme	study	1489:1493	arg1	results					1466:1472	The results	1462:1472	The results of our in vivo study	1462:1493	The results of our in vivo study provided evidence demonstrating that P53 could suppress the development of HCC via the miR-15a/OGT/EZH2 axis.
34510715	3	48	theme	HCC	471:473	arg1	tissues					475:481	HCC tissues	471:481	HCC tissues	471:481	Initially, RT-qPCR was performed to detect the expression of miR-15a in HCC tissues and cells.
34510715	0	49	theme	carcinoma	49:57	arg1	progression					19:29	the progression	15:29	the progression of hepatocellular carcinoma	15:57	P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization.
34510715	4	50	theme	correlation	527:537	arg1	coefficient					539:549	Pearson correlation coefficient	519:549	Pearson correlation coefficient	519:549	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	10	51	dep	in	1481:1482	arg1	vivo					1484:1487	vivo	1484:1487	vivo	1484:1487	The results of our in vivo study provided evidence demonstrating that P53 could suppress the development of HCC via the miR-15a/OGT/EZH2 axis.
34510715	8	52	theme	cells	1291:1295	arg1	invasion					1275:1282	invasion	1275:1282	invasion	1275:1282	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	8	52	theme	cells	1291:1295	arg1	migration					1261:1269	migration	1261:1269	migration	1261:1269	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	8	52	theme	cells	1291:1295	arg1	proliferation					1246:1258	proliferation	1246:1258	proliferation	1246:1258	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	3	53	from	expression	446:455	arg1	cells					487:491	cells	487:491	cells	487:491	Initially, RT-qPCR was performed to detect the expression of miR-15a in HCC tissues and cells.
34510715	3	53	from	expression	446:455	arg1	tissues					475:481	HCC tissues	471:481	HCC tissues	471:481	Initially, RT-qPCR was performed to detect the expression of miR-15a in HCC tissues and cells.
34510715	1	54	theme	Existing	124:131	arg1	literature					133:142	Existing literature	124:142	Existing literature	124:142	Existing literature has highlighted the tumour suppressive capacity of microRNA-15a (miR-15a); however, its role in hepatocellular carcinoma (HCC) remains relatively unknown.
34510715	4	55	theme	Pearson	519:525	arg1	coefficient					539:549	Pearson correlation coefficient	519:549	Pearson correlation coefficient	519:549	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	3	56	theme	miR-15a	460:466	arg1	expression					446:455	the expression	442:455	the expression of miR-15a in HCC tissues and cells	442:491	Initially, RT-qPCR was performed to detect the expression of miR-15a in HCC tissues and cells.
34510715	8	57	theme	cell	1346:1349	arg1	arrest					1363:1368	a G0/G1 cell cycle phase arrest	1338:1368	a G0/G1 cell cycle phase arrest	1338:1368	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	8	58	theme	HCC	1287:1289	arg1	cells					1291:1295	HCC cells	1287:1295	HCC cells	1287:1295	P53 upregulated miR-15a expression, which inhibited the proliferation, migration and invasion of HCC cells, while inducing apoptosis and triggering a G0/G1 cell cycle phase arrest.
34510715	6	59	theme	nude	1082:1085	arg1	mice					1087:1090	tumour-bearing nude mice	1067:1090	tumour-bearing nude mice	1067:1090	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	9	60	theme	miR-15a	1453:1459	arg1	effect					1435:1440	the effect	1431:1440	the effect of P53 and miR-15a	1431:1459	OGT stabilized EZH2 via catalysing O-GlcNAc, which reversed the effect of P53 and miR-15a.
34510715	5	61	theme	cycloheximide	755:767	arg1	assay					775:779	cycloheximide (CHX) assay	755:779	cycloheximide (CHX) assay	755:779	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	2	62	from	mechanism	388:396	arg1	HCC					354:356	HCC	354:356	HCC	354:356	This study aimed to investigate the role of miR-15a in HCC and the associated underlying mechanism.
34510715	6	63	theme	tumour-bearing	1067:1080	arg1	mice					1087:1090	tumour-bearing nude mice	1067:1090	tumour-bearing nude mice	1067:1090	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	5	64	theme	zeste	858:862	arg1	homolog					864:870	zeste homolog 2	858:872	zeste homolog 2 (EZH2)	858:879	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	5	64	theme	zeste	858:862	arg1	EZH2					875:878	EZH2	875:878	EZH2	875:878	PUGNAc treatment and cycloheximide (CHX) assay were performed to evaluate O-GlcNAc and the stabilization of the enhancer of zeste homolog 2 (EZH2).
34510715	11	65	theme	miR-15a	1680:1686	arg1	expression					1666:1675	the expression	1662:1675	the expression of miR-15a, which destabilized EZH2 and suppressed the development of HCC	1662:1749	P53 was found to inhibit the OGT expression by promoting the expression of miR-15a, which destabilized EZH2 and suppressed the development of HCC.
34510715	6	66	theme	P53	965:967	arg1	axis					994:997	the miR-15a/OGT/EZH2 axis	973:997	the miR-15a/OGT/EZH2 axis in the progression of HCC	973:1023	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	6	66	theme	P53	965:967	arg1	role					957:960	the role	953:960	the role of P53	953:967	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
34510715	4	67	theme	N-acetylglucosamine	686:704	arg1	OGT					728:730	OGT	728:730	OGT	728:730	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	4	67	theme	N-acetylglucosamine	686:704	arg1	transferase					715:725	O-linked N-acetylglucosamine (GlcNAc) transferase	677:725	O-linked N-acetylglucosamine (GlcNAc) transferase (OGT)	677:731	Bioinformatics analysis, Pearson correlation coefficient, dual-luciferase reporter assay, and molecular approaches were all conducted to ascertain the interaction between miR-15a and O-linked N-acetylglucosamine (GlcNAc) transferase (OGT).
34510715	11	68	theme	OGT	1634:1636	arg1	expression					1638:1647	the OGT expression	1630:1647	the OGT expression	1630:1647	P53 was found to inhibit the OGT expression by promoting the expression of miR-15a, which destabilized EZH2 and suppressed the development of HCC.
34510715	6	69	theme	miR-15a/OGT/EZH2	977:992	arg1	axis					994:997	the miR-15a/OGT/EZH2 axis	973:997	the miR-15a/OGT/EZH2 axis in the progression of HCC	973:1023	Finally, gain- and loss-of-function studies were employed to elucidate the role of P53 and the miR-15a/OGT/EZH2 axis in the progression of HCC, followed by in vivo experiments based on tumour-bearing nude mice.
33789105	0	0	theme	Notch	88:92	arg1	signaling					94:102	Notch signaling	88:102	Notch signaling	88:102	Ogt controls neural stem/progenitor cell pool and adult neurogenesis through modulating Notch signaling.
33789105	5	1	theme	O-GlcNAc	774:781	arg1	modification					783:794	the O-GlcNAc modification	770:794	the O-GlcNAc modification of Notch TM/ICD fragment	770:819	Mechanistic studies show that Ogt directly interacts with Notch1 and catalyzes the O-GlcNAc modification of Notch TM/ICD fragment.
33789105	4	2	theme	Ogt	578:580	arg1	deficiency					582:591	Ogt deficiency	578:591	Ogt deficiency	578:591	RNA sequencing reveals that Ogt deficiency alters the transcription of genes relating to cell cycle, neurogenesis, and neuronal development.
33789105	6	3	theme	O-GlcNAc	832:839	arg1	modification					841:852	Decreased O-GlcNAc modification	822:852	Decreased O-GlcNAc modification of TM/ICD	822:862	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	7	4	theme	neurogenic	977:986	arg1	defects					988:994	neurogenic defects	977:994	neurogenic defects induced by Ogt deficiency in vitro and in vivo	977:1041	Itch knockdown rescues neurogenic defects induced by Ogt deficiency in vitro and in vivo.
33789105	8	5	theme	essential	1068:1076	arg1	roles					1078:1082	the essential roles	1064:1082	the essential roles	1064:1082	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	6	6	theme	Decreased	822:830	arg1	modification					841:852	Decreased O-GlcNAc modification	822:852	Decreased O-GlcNAc modification of TM/ICD	822:862	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	3	7	theme	Ogt	346:348	arg1	deficiency					350:359	Ogt deficiency	346:359	Ogt deficiency	346:359	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	8	theme	neurogenesis	478:489	arg1	diminishment					434:445	the diminishment	430:445	the diminishment of the aNSPC pool and aberrant neurogenesis	430:489	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	9	theme	pool	460:463	arg1	diminishment					434:445	the diminishment	430:445	the diminishment of the aNSPC pool and aberrant neurogenesis	430:489	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	6	10	theme	Itch	909:912	arg1	binding					878:884	the binding	874:884	the binding of E3 ubiquitin ligase Itch to TM/ICD	874:922	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	4	11	theme	cell	639:642	arg1	cycle					644:648	cell cycle	639:648	cell cycle	639:648	RNA sequencing reveals that Ogt deficiency alters the transcription of genes relating to cell cycle, neurogenesis, and neuronal development.
33789105	1	12	dep	N-acetylglucosamine	128:146	arg1	O-GlcNAc					166:173	O-GlcNAc	166:173	O-GlcNAc	166:173	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	1	12	dep	N-acetylglucosamine	128:146	arg1	O-GlcNAcylation					149:163	O-GlcNAcylation	149:163	O-GlcNAcylation	149:163	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	1	13	theme	important	185:193	arg1	function					195:202	an important function	182:202	an important function	182:202	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	3	14	theme	neural	383:388	arg1	aNSPCs					413:418	aNSPCs	413:418	aNSPCs	413:418	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	14	theme	neural	383:388	arg1	cells					406:410	adult neural stem/progenitor cells	377:410	adult neural stem/progenitor cells (aNSPCs)	377:419	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	6	15	theme	ligase	902:907	arg1	Itch					909:912	E3 ubiquitin ligase Itch	889:912	E3 ubiquitin ligase Itch	889:912	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	8	16	theme	Ogt	1102:1104	arg1	mechanisms					1088:1097	mechanisms	1088:1097	mechanisms	1088:1097	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	8	16	theme	Ogt	1102:1104	arg1	roles					1078:1082	the essential roles	1064:1082	the essential roles	1064:1082	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	4	17	theme	neuronal	669:676	arg1	development					678:688	neuronal development	669:688	neuronal development	669:688	RNA sequencing reveals that Ogt deficiency alters the transcription of genes relating to cell cycle, neurogenesis, and neuronal development.
33789105	3	18	theme	stem/progenitor	390:404	arg1	aNSPCs					413:418	aNSPCs	413:418	aNSPCs	413:418	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	18	theme	stem/progenitor	390:404	arg1	cells					406:410	adult neural stem/progenitor cells	377:410	adult neural stem/progenitor cells (aNSPCs)	377:419	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	6	19	theme	E3	889:890	arg1	Itch					909:912	E3 ubiquitin ligase Itch	889:912	E3 ubiquitin ligase Itch	889:912	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	0	20	theme	stem/progenitor	20:34	arg1	pool					41:44	neural stem/progenitor cell pool	13:44	neural stem/progenitor cell pool	13:44	Ogt controls neural stem/progenitor cell pool and adult neurogenesis through modulating Notch signaling.
33789105	4	21	theme	RNA	550:552	arg1	sequencing					554:563	RNA sequencing	550:563	RNA sequencing	550:563	RNA sequencing reveals that Ogt deficiency alters the transcription of genes relating to cell cycle, neurogenesis, and neuronal development.
33789105	8	22	theme	O-GlcNAc	1110:1117	arg1	modification					1119:1130	O-GlcNAc modification	1110:1130	O-GlcNAc modification	1110:1130	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	3	23	from	function	526:533	arg1	mice					544:547	adult mice	538:547	adult mice	538:547	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	1	24	theme	Ogt	105:107	arg1	N-acetylglucosamine					128:146	Ogt catalyzed O-linked N-acetylglucosamine	105:146	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc)	105:174	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	7	25	dep	deficiency	1011:1020	arg1	in vitro					1022:1029	in vitro	1022:1029	in vitro	1022:1029	Itch knockdown rescues neurogenic defects induced by Ogt deficiency in vitro and in vivo.
33789105	3	26	theme	aNSPC	454:458	arg1	pool					460:463	the aNSPC pool	450:463	the aNSPC pool	450:463	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	27	theme	adult	377:381	arg1	aNSPCs					413:418	aNSPCs	413:418	aNSPCs	413:418	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	27	theme	adult	377:381	arg1	cells					406:410	adult neural stem/progenitor cells	377:410	adult neural stem/progenitor cells (aNSPCs)	377:419	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	6	28	theme	ubiquitin	892:900	arg1	Itch					909:912	E3 ubiquitin ligase Itch	889:912	E3 ubiquitin ligase Itch	889:912	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	1	29	theme	catalyzed	109:117	arg1	N-acetylglucosamine					128:146	Ogt catalyzed O-linked N-acetylglucosamine	105:146	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc)	105:174	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	1	30	theme	biological	215:224	arg1	processes					226:234	diverse biological processes	207:234	diverse biological processes	207:234	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	3	31	from	deficiency	350:359	arg1	aNSPCs					413:418	aNSPCs	413:418	aNSPCs	413:418	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	31	from	deficiency	350:359	arg1	cells					406:410	adult neural stem/progenitor cells	377:410	adult neural stem/progenitor cells (aNSPCs)	377:419	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	0	32	theme	cell	36:39	arg1	pool					41:44	neural stem/progenitor cell pool	13:44	neural stem/progenitor cell pool	13:44	Ogt controls neural stem/progenitor cell pool and adult neurogenesis through modulating Notch signaling.
33789105	5	33	theme	Notch	799:803	arg1	fragment					812:819	Notch TM/ICD fragment	799:819	Notch TM/ICD fragment	799:819	Mechanistic studies show that Ogt directly interacts with Notch1 and catalyzes the O-GlcNAc modification of Notch TM/ICD fragment.
33789105	0	34	theme	adult	50:54	arg1	neurogenesis					56:67	adult neurogenesis	50:67	adult neurogenesis	50:67	Ogt controls neural stem/progenitor cell pool and adult neurogenesis through modulating Notch signaling.
33789105	8	35	theme	mammalian	1146:1154	arg1	neurogenesis					1156:1167	mammalian neurogenesis	1146:1167	mammalian neurogenesis	1146:1167	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	3	36	from	depletion	364:372	arg1	aNSPCs					413:418	aNSPCs	413:418	aNSPCs	413:418	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	3	36	from	depletion	364:372	arg1	cells					406:410	adult neural stem/progenitor cells	377:410	adult neural stem/progenitor cells (aNSPCs)	377:419	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	5	37	theme	Mechanistic	691:701	arg1	studies					703:709	Mechanistic studies	691:709	Mechanistic studies	691:709	Mechanistic studies show that Ogt directly interacts with Notch1 and catalyzes the O-GlcNAc modification of Notch TM/ICD fragment.
33789105	1	38	theme	O-linked	119:126	arg1	N-acetylglucosamine					128:146	Ogt catalyzed O-linked N-acetylglucosamine	105:146	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc)	105:174	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	5	39	theme	fragment	812:819	arg1	modification					783:794	the O-GlcNAc modification	770:794	the O-GlcNAc modification of Notch TM/ICD fragment	770:819	Mechanistic studies show that Ogt directly interacts with Notch1 and catalyzes the O-GlcNAc modification of Notch TM/ICD fragment.
33789105	6	40	mod	modification	841:852	arg1	TM/ICD					857:862	TM/ICD	857:862	TM/ICD	857:862	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	6	40	mod	modification	841:852	arg3	O-GlcNAc					832:839	Decreased O-GlcNAc modification	822:852	Decreased O-GlcNAc modification of TM/ICD	822:862	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	7	41	theme	Itch	954:957	arg1	knockdown					959:967	Itch knockdown	954:967	Itch knockdown	954:967	Itch knockdown rescues neurogenic defects induced by Ogt deficiency in vitro and in vivo.
33789105	1	42	link	O-linked	119:126	arg1	N-acetylglucosamine					128:146	Ogt catalyzed O-linked N-acetylglucosamine	105:146	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc)	105:174	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	2	43	theme	Ogt	272:274	arg1	roles					263:267	the roles	259:267	the roles of Ogt in regulating neurogenesis	259:301	However, the roles of Ogt in regulating neurogenesis remain largely unknown.
33789105	3	44	theme	adult	538:542	arg1	mice					544:547	adult mice	538:547	adult mice	538:547	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	6	45	theme	TM/ICD	857:862	arg1	modification					841:852	Decreased O-GlcNAc modification	822:852	Decreased O-GlcNAc modification of TM/ICD	822:862	Decreased O-GlcNAc modification of TM/ICD increases the binding of E3 ubiquitin ligase Itch to TM/ICD and promotes its degradation.
33789105	3	46	theme	aberrant	469:476	arg1	neurogenesis					478:489	aberrant neurogenesis	469:489	aberrant neurogenesis	469:489	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	1	47	theme	diverse	207:213	arg1	processes					226:234	diverse biological processes	207:234	diverse biological processes	207:234	Ogt catalyzed O-linked N-acetylglucosamine (O-GlcNAcylation, O-GlcNAc) plays an important function in diverse biological processes and diseases.
33789105	3	48	theme	cognitive	516:524	arg1	function					526:533	cognitive function	516:533	cognitive function in adult mice	516:547	Here, we show that Ogt deficiency or depletion in adult neural stem/progenitor cells (aNSPCs) leads to the diminishment of the aNSPC pool and aberrant neurogenesis and consequently impairs cognitive function in adult mice.
33789105	5	49	theme	TM/ICD	805:810	arg1	fragment					812:819	Notch TM/ICD fragment	799:819	Notch TM/ICD fragment	799:819	Mechanistic studies show that Ogt directly interacts with Notch1 and catalyzes the O-GlcNAc modification of Notch TM/ICD fragment.
33789105	0	50	theme	neural	13:18	arg1	pool					41:44	neural stem/progenitor cell pool	13:44	neural stem/progenitor cell pool	13:44	Ogt controls neural stem/progenitor cell pool and adult neurogenesis through modulating Notch signaling.
33789105	7	51	theme	Ogt	1007:1009	arg1	deficiency					1011:1020	Ogt deficiency in vitro and in vivo	1007:1041	deficiency	1011:1020	Itch knockdown rescues neurogenic defects induced by Ogt deficiency in vitro and in vivo.
33789105	8	52	theme	modification	1119:1130	arg1	mechanisms					1088:1097	mechanisms	1088:1097	mechanisms	1088:1097	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	8	52	theme	modification	1119:1130	arg1	roles					1078:1082	the essential roles	1064:1082	the essential roles	1064:1082	Our findings reveal the essential roles and mechanisms of Ogt and O-GlcNAc modification in regulating mammalian neurogenesis and cognition.
33789105	4	53	theme	genes	621:625	arg1	transcription					604:616	the transcription	600:616	the transcription of genes relating to cell cycle, neurogenesis, and neuronal development	600:688	RNA sequencing reveals that Ogt deficiency alters the transcription of genes relating to cell cycle, neurogenesis, and neuronal development.
33486096	10	0	theme	O-GlcNAc	1267:1274	arg1	signaling					1276:1284	O-GlcNAc signaling	1267:1284	O-GlcNAc signaling	1267:1284	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	5	1	theme	hypertrophy-induced	633:651	arg1	suppression					653:663	hypertrophy-induced suppression	633:663	hypertrophy-induced suppression of PGC-1α	633:673	We hypothesized that hypertrophy-induced suppression of PGC-1α was at least partially regulated by O-GlcNAc signaling.
33486096	2	2	dep	partially	342:350	arg1	at					333:334	at	333:334	at	333:334	Its activity is suppressed during pressure overload induced cardiac hypertrophy and such suppression at least partially contributes to the associated morbidity.
33486096	6	3	theme	neonatal	744:751	arg1	myocytes					765:772	neonatal rat cardiac myocytes	744:772	neonatal rat cardiac myocytes	744:772	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	7	4	theme	oxidation/mitochondrial	1000:1022	arg1	genes					1024:1028	PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes	950:1028	PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes	950:1028	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	14	5	theme	cardiac	1904:1910	arg1	diseases					1912:1919	cardiac diseases	1904:1919	cardiac diseases	1904:1919	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	13	6	theme	O-GlcNAc	1648:1655	arg1	signaling					1657:1665	O-GlcNAc signaling	1648:1665	O-GlcNAc signaling	1648:1665	Furthermore, O-GlcNAc signaling may mediate constitutive suppression of PGC-1α activity in the heart.
33486096	8	7	theme	Transverse	1031:1040	arg1	constriction					1049:1060	Transverse aortic constriction	1031:1060	Transverse aortic constriction in mice	1031:1068	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	10	8	with	augmentation	1251:1262	arg1	glucosamine					1291:1301	glucosamine	1291:1301	glucosamine	1291:1301	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	10	8	with	augmentation	1251:1262	arg1	inhibitor					1328:1336	a O-GlcNAcase inhibitor	1314:1336	a O-GlcNAcase inhibitor	1314:1336	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	10	8	with	augmentation	1251:1262	arg1	PUGNAC					1306:1311	PUGNAC	1306:1311	PUGNAC	1306:1311	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	3	9	link	glucose-derived	488:502	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	9	link	glucose-derived	488:502	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	10	theme	proteins	474:481	arg1	O-GlcNAc					461:468	O-GlcNAc	461:468	O-GlcNAc	461:468	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	10	theme	proteins	474:481	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	10	theme	proteins	474:481	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	12	11	theme	O-GlcNAc	1536:1543	arg1	signaling					1545:1553	O-GlcNAc signaling	1536:1553	O-GlcNAc signaling	1536:1553	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	2	12	theme	associated	371:380	arg1	morbidity					382:390	the associated morbidity	367:390	the associated morbidity	367:390	Its activity is suppressed during pressure overload induced cardiac hypertrophy and such suppression at least partially contributes to the associated morbidity.
33486096	12	13	theme	activity	1598:1605	arg1	regulator					1578:1586	a potentially novel regulator	1558:1586	a potentially novel regulator of PGC-1α activity	1558:1605	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	12	13	theme	activity	1598:1605	arg1	recruitment					1521:1531	the recruitment	1517:1531	the recruitment of O-GlcNAc signaling	1517:1553	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	7	14	theme	genes	1024:1028	arg1	downregulation					932:945	a downregulation	930:945	a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes	930:1028	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	3	15	theme	β-N-acetylglucosamine	406:426	arg1	O-GlcNAc					461:468	O-GlcNAc	461:468	O-GlcNAc	461:468	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	15	theme	β-N-acetylglucosamine	406:426	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	15	theme	β-N-acetylglucosamine	406:426	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	4	16	theme	PGC-1α	561:566	arg1	activity					568:575	PGC-1α activity	561:575	PGC-1α activity	561:575	The relationship between O-GlcNAc, and PGC-1α activity in cardiac hypertrophy is unknown.
33486096	12	17	theme	signaling	1545:1553	arg1	recruitment					1521:1531	the recruitment	1517:1531	the recruitment of O-GlcNAc signaling	1517:1553	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	12	17	theme	signaling	1545:1553	arg1	regulator					1578:1586	a potentially novel regulator	1558:1586	a potentially novel regulator of PGC-1α activity	1558:1605	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	8	18	theme	aortic	1042:1047	arg1	constriction					1049:1060	Transverse aortic constriction	1031:1060	Transverse aortic constriction in mice	1031:1068	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	1	19	theme	normal	207:212	arg1	function					222:229	normal cardiac function	207:229	normal cardiac function	207:229	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	3	20	theme	post-translational	428:445	arg1	O-GlcNAc					461:468	O-GlcNAc	461:468	O-GlcNAc	461:468	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	20	theme	post-translational	428:445	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	20	theme	post-translational	428:445	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	4	21	theme	cardiac	580:586	arg1	hypertrophy					588:598	cardiac hypertrophy	580:598	cardiac hypertrophy	580:598	The relationship between O-GlcNAc, and PGC-1α activity in cardiac hypertrophy is unknown.
33486096	6	22	with	Treatment	731:739	arg1	phenylephrine					779:791	phenylephrine	779:791	phenylephrine (an inducer of cardiomyocyte hypertrophy)	779:833	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	14	23	theme	new	1762:1764	arg1	possibilities					1766:1778	new possibilities	1762:1778	new possibilities regarding the inter-regulation of O-GlcNAc signaling	1762:1831	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	1	24	theme	peroxisome	92:101	arg1	receptor-gamma					126:139	The peroxisome proliferator-activated receptor-gamma coactivator-1α	88:154	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α)	88:163	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	1	24	theme	peroxisome	92:101	arg1	PGC-1α					157:162	PGC-1α	157:162	PGC-1α	157:162	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	1	24	theme	peroxisome	92:101	arg1	essential					193:201	essential	193:201	essential	193:201	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	6	25	theme	hypertrophy	822:832	arg1	inducer					797:803	an inducer	794:803	an inducer of cardiomyocyte hypertrophy	794:832	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	1	26	theme	cardiac	214:220	arg1	function					222:229	normal cardiac function	207:229	normal cardiac function	207:229	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	7	27	with	PGC-1α	950:955	arg1	suppression					974:984	concomitant suppression	962:984	concomitant suppression of fatty acid	962:998	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	1	28	theme	proliferator-activated	103:124	arg1	receptor-gamma					126:139	The peroxisome proliferator-activated receptor-gamma coactivator-1α	88:154	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α)	88:163	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	1	28	theme	proliferator-activated	103:124	arg1	PGC-1α					157:162	PGC-1α	157:162	PGC-1α	157:162	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	1	28	theme	proliferator-activated	103:124	arg1	essential					193:201	essential	193:201	essential	193:201	The peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) regulates metabolism and is essential for normal cardiac function.
33486096	6	29	theme	cardiomyocyte	808:820	arg1	hypertrophy					822:832	cardiomyocyte hypertrophy	808:832	cardiomyocyte hypertrophy	808:832	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	0	30	theme	Cardiac	0:6	arg1	hypertrophy					8:18	Cardiac hypertrophy	0:18	Cardiac hypertrophy	0:18	Cardiac hypertrophy drives PGC-1α suppression associated with enhanced O-glycosylation.
33486096	9	31	theme	downstream	1218:1227	arg1	genes					1229:1233	its downstream genes	1214:1233	its downstream genes	1214:1233	Reduction of O-GlcNAc signaling alleviated suppression of PGC-1α and most of its downstream genes.
33486096	12	32	theme	novel	1572:1576	arg1	regulator					1578:1586	a potentially novel regulator	1558:1586	a potentially novel regulator of PGC-1α activity	1558:1605	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	12	32	theme	novel	1572:1576	arg1	recruitment					1521:1531	the recruitment	1517:1531	the recruitment of O-GlcNAc signaling	1517:1553	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	7	33	theme	fatty	989:993	arg1	acid					995:998	fatty acid	989:998	fatty acid	989:998	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	0	34	theme	PGC-1α	27:32	arg1	suppression					34:44	PGC-1α suppression	27:44	PGC-1α suppression associated with enhanced O-glycosylation	27:85	Cardiac hypertrophy drives PGC-1α suppression associated with enhanced O-glycosylation.
33486096	7	35	theme	concomitant	962:972	arg1	suppression					974:984	concomitant suppression	962:984	concomitant suppression of fatty acid	962:998	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	10	36	theme	glucose	1347:1353	arg1	upregulation					1381:1392	glucose starvation-induced PGC-1α upregulation	1347:1392	glucose starvation-induced PGC-1α upregulation	1347:1392	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	14	37	theme	signaling	1823:1831	arg1	inter-regulation					1794:1809	the inter-regulation	1790:1809	the inter-regulation of O-GlcNAc signaling	1790:1831	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	12	38	theme	PGC-1α	1591:1596	arg1	activity					1598:1605	PGC-1α activity	1591:1605	PGC-1α activity	1591:1605	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	7	39	theme	acid	995:998	arg1	suppression					974:984	concomitant suppression	962:984	concomitant suppression of fatty acid	962:998	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	3	40	mod	modification	447:458	arg1	proteins					474:481	proteins	474:481	proteins	474:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	40	mod	modification	447:458	arg3	β-N-acetylglucosamine					406:426	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	13	41	from	suppression	1692:1702	arg1	heart					1730:1734	the heart	1726:1734	the heart	1726:1734	Furthermore, O-GlcNAc signaling may mediate constitutive suppression of PGC-1α activity in the heart.
33486096	3	42	link	O-linked	397:404	arg1	O-GlcNAc					461:468	O-GlcNAc	461:468	O-GlcNAc	461:468	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	42	link	O-linked	397:404	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	42	link	O-linked	397:404	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	43	theme	glucose-derived	488:502	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	43	theme	glucose-derived	488:502	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	7	44	theme	PGC-1α	950:955	arg1	genes					1024:1028	PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes	950:1028	PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes	950:1028	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	8	45	from	constriction	1049:1060	arg1	mice					1065:1068	mice	1065:1068	mice	1065:1068	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	14	46	theme	O-GlcNAc	1814:1821	arg1	signaling					1823:1831	O-GlcNAc signaling	1814:1831	O-GlcNAc signaling	1814:1831	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	8	47	theme	basal	1084:1088	arg1	expression					1090:1099	the basal expression	1080:1099	the basal expression of PGC-1α and its downstream genes	1080:1134	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	13	48	theme	PGC-1α	1707:1712	arg1	activity					1714:1721	PGC-1α activity	1707:1721	PGC-1α activity	1707:1721	Furthermore, O-GlcNAc signaling may mediate constitutive suppression of PGC-1α activity in the heart.
33486096	3	49	theme	metabolic	504:512	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	49	theme	metabolic	504:512	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	10	50	theme	starvation-induced	1355:1372	arg1	upregulation					1381:1392	glucose starvation-induced PGC-1α upregulation	1347:1392	glucose starvation-induced PGC-1α upregulation	1347:1392	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	10	51	dep	hypertrophy	1417:1427	arg1	absence					1406:1412	absence	1406:1412	absence	1406:1412	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	10	51	dep	hypertrophy	1417:1427	arg1	the					1402:1404	the	1402:1404	the	1402:1404	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	9	52	theme	signaling	1159:1167	arg1	Reduction					1137:1145	Reduction	1137:1145	Reduction of O-GlcNAc signaling	1137:1167	Reduction of O-GlcNAc signaling alleviated suppression of PGC-1α and most of its downstream genes.
33486096	8	53	theme	PGC-1α	1104:1109	arg1	expression					1090:1099	the basal expression	1080:1099	the basal expression of PGC-1α and its downstream genes	1080:1134	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	13	54	theme	activity	1714:1721	arg1	suppression					1692:1702	constitutive suppression	1679:1702	constitutive suppression of PGC-1α activity in the heart	1679:1734	Furthermore, O-GlcNAc signaling may mediate constitutive suppression of PGC-1α activity in the heart.
33486096	0	55	theme	enhanced	62:69	arg1	O-glycosylation					71:85	enhanced O-glycosylation	62:85	enhanced O-glycosylation	62:85	Cardiac hypertrophy drives PGC-1α suppression associated with enhanced O-glycosylation.
33486096	9	56	theme	O-GlcNAc	1150:1157	arg1	signaling					1159:1167	O-GlcNAc signaling	1150:1167	O-GlcNAc signaling	1150:1167	Reduction of O-GlcNAc signaling alleviated suppression of PGC-1α and most of its downstream genes.
33486096	4	57	from	relationship	526:537	arg1	hypertrophy					588:598	cardiac hypertrophy	580:598	cardiac hypertrophy	580:598	The relationship between O-GlcNAc, and PGC-1α activity in cardiac hypertrophy is unknown.
33486096	10	58	theme	PGC-1α	1374:1379	arg1	upregulation					1381:1392	glucose starvation-induced PGC-1α upregulation	1347:1392	glucose starvation-induced PGC-1α upregulation	1347:1392	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	2	59	theme	pressure	266:273	arg1	overload					275:282	pressure overload	266:282	pressure overload	266:282	Its activity is suppressed during pressure overload induced cardiac hypertrophy and such suppression at least partially contributes to the associated morbidity.
33486096	14	60	contain	have	1846:1849	arg2	implications					1856:1867	some implications	1851:1867	some implications for metabolic dysregulation during cardiac diseases	1851:1919	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	14	60	contain	have	1846:1849	arg1	findings					1742:1749	Such findings	1737:1749	Such findings	1737:1749	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	5	61	theme	PGC-1α	668:673	arg1	suppression					653:663	hypertrophy-induced suppression	633:663	hypertrophy-induced suppression of PGC-1α	633:673	We hypothesized that hypertrophy-induced suppression of PGC-1α was at least partially regulated by O-GlcNAc signaling.
33486096	14	62	theme	Such	1737:1740	arg1	findings					1742:1749	Such findings	1737:1749	Such findings	1737:1749	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	5	63	theme	O-GlcNAc	711:718	arg1	signaling					720:728	O-GlcNAc signaling	711:728	O-GlcNAc signaling	711:728	We hypothesized that hypertrophy-induced suppression of PGC-1α was at least partially regulated by O-GlcNAc signaling.
33486096	6	64	dep	phenylephrine	779:791	arg1	inducer					797:803	an inducer	794:803	an inducer of cardiomyocyte hypertrophy	794:832	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	7	65	theme	real-time	898:906	arg1	analysis					912:919	Quantitative real-time PCR analysis	885:919	Quantitative real-time PCR analysis	885:919	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	12	66	theme	cardiac	1614:1620	arg1	hypertrophy					1622:1632	cardiac hypertrophy	1614:1632	cardiac hypertrophy	1614:1632	Together, these results reveal the recruitment of O-GlcNAc signaling as a potentially novel regulator of PGC-1α activity during cardiac hypertrophy.
33486096	8	67	theme	genes	1130:1134	arg1	expression					1090:1099	the basal expression	1080:1099	the basal expression of PGC-1α and its downstream genes	1080:1134	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	13	68	theme	constitutive	1679:1690	arg1	suppression					1692:1702	constitutive suppression	1679:1702	constitutive suppression of PGC-1α activity in the heart	1679:1734	Furthermore, O-GlcNAc signaling may mediate constitutive suppression of PGC-1α activity in the heart.
33486096	6	69	theme	myocytes	765:772	arg1	Treatment					731:739	Treatment	731:739	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy)	731:833	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	7	70	theme	PCR	908:910	arg1	analysis					912:919	Quantitative real-time PCR analysis	885:919	Quantitative real-time PCR analysis	885:919	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
33486096	8	71	theme	downstream	1119:1128	arg1	genes					1130:1134	its downstream genes	1115:1134	its downstream genes	1115:1134	Transverse aortic constriction in mice decreased the basal expression of PGC-1α and its downstream genes.
33486096	6	72	theme	O-GlcNAc	865:872	arg1	signaling					874:882	global O-GlcNAc signaling	858:882	global O-GlcNAc signaling	858:882	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	10	73	theme	O-GlcNAcase	1316:1326	arg1	glucosamine					1291:1301	glucosamine	1291:1301	glucosamine	1291:1301	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	10	73	theme	O-GlcNAcase	1316:1326	arg1	inhibitor					1328:1336	a O-GlcNAcase inhibitor	1314:1336	a O-GlcNAcase inhibitor	1314:1336	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	6	74	theme	cardiac	757:763	arg1	myocytes					765:772	neonatal rat cardiac myocytes	744:772	neonatal rat cardiac myocytes	744:772	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	9	75	theme	PGC-1α	1195:1200	arg1	suppression					1180:1190	suppression	1180:1190	suppression of PGC-1α	1180:1200	Reduction of O-GlcNAc signaling alleviated suppression of PGC-1α and most of its downstream genes.
33486096	3	76	theme	O-linked	397:404	arg1	O-GlcNAc					461:468	O-GlcNAc	461:468	O-GlcNAc	461:468	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	76	theme	O-linked	397:404	arg1	modification					447:458	The O-linked β-N-acetylglucosamine post-translational modification	393:458	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins	393:481	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	3	76	theme	O-linked	397:404	arg1	signal					514:519	a glucose-derived metabolic signal	486:519	a glucose-derived metabolic signal	486:519	The O-linked β-N-acetylglucosamine post-translational modification (O-GlcNAc) of proteins is a glucose-derived metabolic signal.
33486096	10	77	theme	signaling	1276:1284	arg1	augmentation					1251:1262	augmentation	1251:1262	augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor)	1251:1337	Interestingly, augmentation of O-GlcNAc signaling with glucosamine or PUGNAC (a O-GlcNAcase inhibitor) reduced glucose starvation-induced PGC-1α upregulation even in the absence of hypertrophy.
33486096	2	78	theme	cardiac	292:298	arg1	hypertrophy					300:310	cardiac hypertrophy	292:310	cardiac hypertrophy	292:310	Its activity is suppressed during pressure overload induced cardiac hypertrophy and such suppression at least partially contributes to the associated morbidity.
33486096	6	79	theme	global	858:863	arg1	signaling					874:882	global O-GlcNAc signaling	858:882	global O-GlcNAc signaling	858:882	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	14	80	theme	metabolic	1873:1881	arg1	dysregulation					1883:1895	metabolic dysregulation	1873:1895	metabolic dysregulation during cardiac diseases	1873:1919	Such findings illuminate new possibilities regarding the inter-regulation of O-GlcNAc signaling and also may have some implications for metabolic dysregulation during cardiac diseases.
33486096	6	81	theme	rat	753:755	arg1	myocytes					765:772	neonatal rat cardiac myocytes	744:772	neonatal rat cardiac myocytes	744:772	Treatment of neonatal rat cardiac myocytes with phenylephrine (an inducer of cardiomyocyte hypertrophy) significantly enhanced global O-GlcNAc signaling.
33486096	7	82	theme	Quantitative	885:896	arg1	analysis					912:919	Quantitative real-time PCR analysis	885:919	Quantitative real-time PCR analysis	885:919	Quantitative real-time PCR analysis revealed a downregulation of PGC-1α with concomitant suppression of fatty acid oxidation/mitochondrial genes.
34726173	4	0	from	aureus	961:966	arg1	structures					925:934	the crystal structures	913:934	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	0	from	aureus	961:966	arg1	structures					988:997	multiple structures	979:997	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	2	1	gly	glycosylation	296:308	arg1	domain					332:337	the long-chain SDR domain	313:337	the long-chain SDR domain mediated by SdgB and SdgA	313:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	2	theme	O-linked	287:294	arg1	factor					384:389	a key virulence factor	368:389	a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response	368:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	2	theme	O-linked	287:294	arg1	glycosylation					296:308	The O-linked glycosylation	283:308	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA	283:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	7	3	theme	mechanistic	1717:1727	arg1	insights					1729:1736	new mechanistic insights	1713:1736	new mechanistic insights	1713:1736	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	3	theme	mechanistic	1717:1727	arg1	point					1806:1810	a starting point	1795:1810	a starting point for the development of antibacterial drugs against staphylococcal infections	1795:1887	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	4	4	theme	glycosylated	1104:1115	arg1	products					1094:1101	products	1094:1101	products (glycosylated SDR peptides)	1094:1129	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	4	theme	glycosylated	1104:1115	arg1	peptides					1121:1128	glycosylated SDR peptides	1104:1128	glycosylated SDR peptides	1104:1128	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	2	5	theme	long-chain	317:326	arg1	domain					332:337	the long-chain SDR domain	313:337	the long-chain SDR domain mediated by SdgB and SdgA	313:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	1	6	theme	adhesive	201:208	arg1	proteins					210:217	staphylococcal adhesive proteins	186:217	staphylococcal adhesive proteins	186:217	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	1	6	theme	adhesive	201:208	arg1	ClfA					277:280	ClfA	277:280	ClfA	277:280	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	2	7	theme	staphylococcal	547:560	arg1	agglutination					562:574	staphylococcal agglutination	547:574	staphylococcal agglutination	547:574	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	7	8	gly	glycosylation	1743:1755	arg1	domain					1768:1773	the SDR domain	1760:1773	the SDR domain	1760:1773	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	4	9	theme	SdgA	948:951	arg1	structures					925:934	the crystal structures	913:934	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	9	theme	SdgA	948:951	arg1	structures					988:997	multiple structures	979:997	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	3	10	theme	response	797:804	arg1	avoidance					761:769	avoidance	761:769	avoidance	761:769	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	3	10	theme	response	797:804	arg1	pathogenicity					743:755	pathogenicity	743:755	pathogenicity	743:755	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	1	11	theme	repeat	247:252	arg1	domains					260:266	serine-aspartate repeat (SDR) domains	230:266	serine-aspartate repeat (SDR) domains	230:266	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	3	12	theme	innate	783:788	arg1	response					797:804	the host innate immune response	774:804	the host innate immune response	774:804	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	4	13	from	structures	925:934	arg1	complex					1010:1016	complex	1010:1016	complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	1010:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	1	14	theme	host	127:130	arg1	tissues					132:138	host tissues	127:138	host tissues	127:138	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	7	15	theme	acceptor	1675:1682	arg1	substrates					1684:1693	donor and acceptor substrates	1665:1693	donor and acceptor substrates	1665:1693	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	16	theme	donor	1665:1669	arg1	substrates					1684:1693	donor and acceptor substrates	1665:1693	donor and acceptor substrates	1665:1693	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	0	17	theme	staphylococcal	62:75	arg1	proteins					86:93	staphylococcal adhesive proteins	62:93	staphylococcal adhesive proteins	62:93	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	4	18	gly	glycosylated	1104:1115	arg1	products					1094:1101	products	1094:1101	products (glycosylated SDR peptides)	1094:1129	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	18	gly	glycosylated	1104:1115	arg1	peptides					1121:1128	glycosylated SDR peptides	1104:1128	glycosylated SDR peptides	1104:1128	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	2	19	theme	successful	483:492	arg1	colonization					501:512	successful tissue colonization	483:512	successful tissue colonization	483:512	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	0	20	theme	proteins	86:93	arg1	glycosylation					45:57	SdgB- and SdgA-mediated glycosylation	21:57	SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins	21:93	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	3	21	theme	molecular	832:840	arg1	basis					842:846	the molecular basis	828:846	the molecular basis of their activity	828:864	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	2	22	theme	strong	635:640	arg1	response					651:658	a strong antibody response	633:658	a strong antibody response	633:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	3	23	theme	activity	857:864	arg1	basis					842:846	the molecular basis	828:846	the molecular basis of their activity	828:864	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	3	23	theme	activity	857:864	arg1	structures					813:822	their structures	807:822	their structures	807:822	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	2	24	theme	proteolytic	444:454	arg1	attack					456:461	host proteolytic attack	439:461	host proteolytic attack	439:461	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	0	25	theme	adhesive	77:84	arg1	proteins					86:93	staphylococcal adhesive proteins	62:93	staphylococcal adhesive proteins	62:93	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	5	26	theme	SDR	1328:1330	arg1	region					1332:1337	the long SDR region	1319:1337	the long SDR region in SDR proteins	1319:1353	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	2	27	theme	virulence	374:382	arg1	factor					384:389	a key virulence factor	368:389	a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response	368:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	27	theme	virulence	374:382	arg1	glycosylation					296:308	The O-linked glycosylation	283:308	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA	283:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	0	28	theme	Structural	0:9	arg1	basis					11:15	Structural basis	0:15	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.	0:94	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	7	29	theme	antibacterial	1835:1847	arg1	drugs					1849:1853	antibacterial drugs	1835:1853	antibacterial drugs against staphylococcal infections	1835:1887	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	30	theme	putative	1607:1614	arg1	role					1616:1619	the putative role	1603:1619	the putative role of the three domains of SdgB in recognizing donor and acceptor substrates	1603:1693	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	2	31	theme	SDR	418:420	arg1	proteins					422:429	the adhesive SDR proteins	405:429	the adhesive SDR proteins	405:429	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	5	32	theme	biophysical	1164:1174	arg1	analyses					1192:1199	biophysical and biochemical analyses	1164:1199	biophysical and biochemical analyses	1164:1199	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	1	33	theme	infection	114:122	arg1	initiation					100:109	The initiation	96:109	The initiation of infection of host tissues by Staphylococcus aureus	96:163	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	4	34	theme	SdgB	1002:1005	arg1	structures					925:934	the crystal structures	913:934	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	34	theme	SdgB	1002:1005	arg1	structures					988:997	multiple structures	979:997	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	7	35	theme	starting	1797:1804	arg1	insights					1729:1736	new mechanistic insights	1713:1736	new mechanistic insights	1713:1736	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	35	theme	starting	1797:1804	arg1	point					1806:1810	a starting point	1795:1810	a starting point for the development of antibacterial drugs against staphylococcal infections	1795:1887	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	36	theme	domain	1768:1773	arg1	glycosylation					1743:1755	glycosylation	1743:1755	glycosylation of the SDR domain	1743:1773	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	4	37	from	structures	988:997	arg1	complex					1010:1016	complex	1010:1016	complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	1010:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	6	38	from	open	1433:1436	arg1	transition					1414:1423	a transition	1412:1423	a transition from an open to a closed conformation upon ligand binding	1412:1481	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	4	39	theme	example	1043:1049	arg1	UDP					1051:1053	example UDP	1043:1053	example UDP	1043:1053	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	3	40	theme	glycosyltransferases	710:729	arg1	significance					684:695	the biological significance	669:695	the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response	669:804	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	5	41	theme	biochemical	1180:1190	arg1	analyses					1192:1199	biophysical and biochemical analyses	1164:1199	biophysical and biochemical analyses	1164:1199	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	7	42	theme	new	1713:1715	arg1	insights					1729:1736	new mechanistic insights	1713:1736	new mechanistic insights	1713:1736	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	42	theme	new	1713:1715	arg1	point					1806:1810	a starting point	1795:1810	a starting point for the development of antibacterial drugs against staphylococcal infections	1795:1887	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	4	43	theme	SDR	1117:1119	arg1	products					1094:1101	products	1094:1101	products (glycosylated SDR peptides)	1094:1129	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	43	theme	SDR	1117:1119	arg1	peptides					1121:1128	glycosylated SDR peptides	1104:1128	glycosylated SDR peptides	1104:1128	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	44	with	complex	1010:1016	arg1	products					1094:1101	products	1094:1101	products (glycosylated SDR peptides)	1094:1129	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	44	with	complex	1010:1016	arg1	ions					1144:1147	phosphate ions	1134:1147	phosphate ions	1134:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	44	with	complex	1010:1016	arg1	substrates					1027:1036	its substrates	1023:1036	its substrates (for example UDP, N-acetylglucosamine or SDR peptides)	1023:1091	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	44	with	complex	1010:1016	arg1	peptides					1121:1128	glycosylated SDR peptides	1104:1128	glycosylated SDR peptides	1104:1128	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	6	45	with	heterodimer	1537:1547	arg1	SdgA					1554:1557	SdgA	1554:1557	SdgA	1554:1557	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	2	46	theme	SDR	328:330	arg1	domain					332:337	the long-chain SDR domain	313:337	the long-chain SDR domain mediated by SdgB and SdgA	313:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	6	47	theme	diverse	1493:1499	arg1	forms					1501:1505	diverse forms	1493:1505	diverse forms	1493:1505	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	1	48	theme	staphylococcal	186:199	arg1	proteins					210:217	staphylococcal adhesive proteins	186:217	staphylococcal adhesive proteins	186:217	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	1	48	theme	staphylococcal	186:199	arg1	ClfA					277:280	ClfA	277:280	ClfA	277:280	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	2	49	theme	immunodominant	606:619	arg1	epitope					621:627	an immunodominant epitope	603:627	an immunodominant epitope for a strong antibody response	603:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	3	50	theme	host	778:781	arg1	response					797:804	the host innate immune response	774:804	the host innate immune response	774:804	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	1	51	theme	proteins	210:217	arg1	family					176:181	a family	174:181	a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA	174:280	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	2	52	link	O-linked	287:294	arg1	factor					384:389	a key virulence factor	368:389	a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response	368:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	52	link	O-linked	287:294	arg1	glycosylation					296:308	The O-linked glycosylation	283:308	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA	283:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	6	53	theme	ligand	1468:1473	arg1	binding					1475:1481	ligand binding	1468:1481	ligand binding	1468:1481	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	1	54	theme	serine-aspartate	230:245	arg1	SDR					255:257	SDR	255:257	SDR	255:257	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	1	54	theme	serine-aspartate	230:245	arg1	repeat					247:252	serine-aspartate repeat	230:252	serine-aspartate repeat (SDR) domains	230:266	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	4	55	theme	SdgB	939:942	arg1	structures					925:934	the crystal structures	913:934	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	55	theme	SdgB	939:942	arg1	structures					988:997	multiple structures	979:997	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	3	56	theme	immune	790:795	arg1	response					797:804	the host innate immune response	774:804	the host innate immune response	774:804	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	6	57	from	changes	1379:1385	arg1	structure					1394:1402	its structure	1390:1402	its structure	1390:1402	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	1	58	theme	tissues	132:138	arg1	infection					114:122	infection	114:122	infection of host tissues	114:138	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	4	59	theme	crystal	917:923	arg1	structures					925:934	the crystal structures	913:934	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	4	60	theme	phosphate	1134:1142	arg1	ions					1144:1147	phosphate ions	1134:1147	phosphate ions	1134:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	6	61	theme	dynamic	1371:1377	arg1	changes					1379:1385	dynamic changes	1371:1385	dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding	1371:1481	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	6	61	theme	dynamic	1371:1377	arg1	transition					1414:1423	a transition	1412:1423	a transition from an open to a closed conformation upon ligand binding	1412:1481	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	2	62	theme	tissue	494:499	arg1	colonization					501:512	successful tissue colonization	483:512	successful tissue colonization	483:512	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	5	63	theme	structural	1207:1216	arg1	work					1218:1221	this structural work	1202:1221	this structural work	1202:1221	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	5	64	theme	novel	1237:1241	arg1	mechanism					1243:1251	the novel mechanism	1233:1251	the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins	1233:1353	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	4	65	theme	multiple	979:986	arg1	structures					988:997	multiple structures	979:997	the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions	913:1147	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	7	66	theme	staphylococcal	1863:1876	arg1	infections					1878:1887	staphylococcal infections	1863:1887	staphylococcal infections	1863:1887	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	67	theme	SdgB	1645:1648	arg1	SdgB					1645:1648	SdgB	1645:1648	SdgB	1645:1648	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	67	theme	SdgB	1645:1648	arg1	domains					1634:1640	the three domains	1624:1640	the three domains of SdgB	1624:1648	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	2	68	theme	antibody	642:649	arg1	response					651:658	a strong antibody response	633:658	a strong antibody response	633:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	7	69	theme	drugs	1849:1853	arg1	development					1820:1830	the development	1816:1830	the development of antibacterial drugs against staphylococcal infections	1816:1887	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	7	70	theme	domains	1634:1640	arg1	role					1616:1619	the putative role	1603:1619	the putative role of the three domains of SdgB in recognizing donor and acceptor substrates	1603:1693	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	5	71	theme	long	1323:1326	arg1	region					1332:1337	the long SDR region	1319:1337	the long SDR region in SDR proteins	1319:1353	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	5	72	from	region	1332:1337	arg1	proteins					1346:1353	SDR proteins	1342:1353	SDR proteins	1342:1353	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	2	73	theme	host	439:442	arg1	attack					456:461	host proteolytic attack	439:461	host proteolytic attack	439:461	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	74	theme	key	370:372	arg1	factor					384:389	a key virulence factor	368:389	a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response	368:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	74	theme	key	370:372	arg1	glycosylation					296:308	The O-linked glycosylation	283:308	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA	283:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	0	75	theme	SdgB-	21:25	arg1	glycosylation					45:57	SdgB- and SdgA-mediated glycosylation	21:57	SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins	21:93	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	5	76	theme	glycosyl-transfer	1290:1306	arg1	process					1308:1314	the glycosyl-transfer process	1286:1314	the glycosyl-transfer process	1286:1314	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
34726173	2	77	theme	adhesive	409:416	arg1	proteins					422:429	the adhesive SDR proteins	405:429	the adhesive SDR proteins	405:429	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	0	78	theme	SdgA-mediated	31:43	arg1	glycosylation					45:57	SdgB- and SdgA-mediated glycosylation	21:57	SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins	21:93	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	3	79	theme	biological	673:682	arg1	significance					684:695	the biological significance	669:695	the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response	669:804	Despite the biological significance of these two glycosyltransferases involved in pathogenicity and avoidance of the host innate immune response, their structures and the molecular basis of their activity have not been investigated.
34726173	1	80	contain	containing	219:228	arg2	domains					260:266	serine-aspartate repeat (SDR) domains	230:266	serine-aspartate repeat (SDR) domains	230:266	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	1	80	contain	containing	219:228	arg1	proteins					210:217	staphylococcal adhesive proteins	186:217	staphylococcal adhesive proteins	186:217	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	1	80	contain	containing	219:228	arg1	ClfA					277:280	ClfA	277:280	ClfA	277:280	The initiation of infection of host tissues by Staphylococcus aureus requires a family of staphylococcal adhesive proteins containing serine-aspartate repeat (SDR) domains, such as ClfA.
34726173	2	81	theme	domain	332:337	arg1	factor					384:389	a key virulence factor	368:389	a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response	368:658	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	2	81	theme	domain	332:337	arg1	glycosylation					296:308	The O-linked glycosylation	283:308	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA	283:363	The O-linked glycosylation of the long-chain SDR domain mediated by SdgB and SdgA is a key virulence factor that protects the adhesive SDR proteins against host proteolytic attack in order to promote successful tissue colonization, and has also been implicated in staphylococcal agglutination, which leads to sepsis and an immunodominant epitope for a strong antibody response.
34726173	6	82	theme	closed	1443:1448	arg1	conformation					1450:1461	a closed conformation	1441:1461	a closed conformation upon ligand binding	1441:1481	SdgB undergoes dynamic changes in its structure such as a transition from an open to a closed conformation upon ligand binding and takes diverse forms, both as a homodimer and as a heterodimer with SdgA.
34726173	0	83	gly	glycosylation	45:57	arg1	proteins					86:93	staphylococcal adhesive proteins	62:93	staphylococcal adhesive proteins	62:93	Structural basis for SdgB- and SdgA-mediated glycosylation of staphylococcal adhesive proteins.
34726173	7	84	theme	SDR	1764:1766	arg1	domain					1768:1773	the SDR domain	1760:1773	the SDR domain	1760:1773	Overall, these findings not only elucidate the putative role of the three domains of SdgB in recognizing donor and acceptor substrates, but also provide new mechanistic insights into glycosylation of the SDR domain, which can serve as a starting point for the development of antibacterial drugs against staphylococcal infections.
34726173	4	85	theme	SDR	1079:1081	arg1	peptides					1083:1090	SDR peptides	1079:1090	SDR peptides	1079:1090	This study reports the crystal structures of SdgB and SdgA from S. aureus as well as multiple structures of SdgB in complex with its substrates (for example UDP, N-acetylglucosamine or SDR peptides), products (glycosylated SDR peptides) or phosphate ions.
34726173	5	86	theme	SDR	1342:1344	arg1	proteins					1346:1353	SDR proteins	1342:1353	SDR proteins	1342:1353	Together with biophysical and biochemical analyses, this structural work uncovered the novel mechanism by which SdgB and SdgA carry out the glycosyl-transfer process to the long SDR region in SDR proteins.
32970321	4	0	theme	CO2	880:882	arg1	content					884:890	oxygen and CO2 content	869:890	oxygen and CO2 content	869:890	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	0	1	link	N-linked	99:106	arg1	glycosylation					108:120	N-linked glycosylation	99:120	N-linked glycosylation	99:120	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	1	2	theme	hamster	275:281	arg1	cells					295:299	Chinese hamster ovary (CHO) cells	267:299	Chinese hamster ovary (CHO) cells	267:299	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	1	2	theme	hamster	275:281	arg1	system					337:342	the preferred expression system	312:342	the preferred expression system for monoclonal antibody protein production	312:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	7	3	theme	protein	1512:1518	arg1	synthesis					1520:1528	protein synthesis	1512:1528	protein synthesis	1512:1528	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	7	4	theme	tricarboxylic	1469:1481	arg1	cycle					1488:1492	tricarboxylic acid cycle	1469:1492	tricarboxylic acid cycle	1469:1492	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	4	5	theme	oxygen	869:874	arg1	content					884:890	oxygen and CO2 content	869:890	oxygen and CO2 content	869:890	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	1	6	theme	CHO	290:292	arg1	cells					295:299	Chinese hamster ovary (CHO) cells	267:299	Chinese hamster ovary (CHO) cells	267:299	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	1	6	theme	CHO	290:292	arg1	system					337:342	the preferred expression system	312:342	the preferred expression system for monoclonal antibody protein production	312:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	6	7	theme	products	1278:1285	arg1	accumulation					1242:1253	accumulation	1242:1253	accumulation of the N-glycosylation products in the extracellular environment	1242:1318	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	6	7	theme	products	1278:1285	arg1	reaction					1328:1335	one reaction	1324:1335	one reaction to correlate cell degradation	1324:1365	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	2	8	contain	have	471:474	arg2	applications					486:497	extensive applications	476:497	extensive applications	476:497	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	2	8	contain	have	471:474	arg1	production					453:462	monoclonal antibodies production	431:462	monoclonal antibodies production	431:462	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	0	9	theme	biopharmaceutical	136:152	arg1	manufacturing					154:166	industrial biopharmaceutical manufacturing	125:166	industrial biopharmaceutical manufacturing	125:166	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	7	10	theme	phosphate	1428:1436	arg1	pathway					1438:1444	pentose phosphate pathway	1420:1444	pentose phosphate pathway	1420:1444	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	4	11	theme	dissolved	897:905	arg1	oxygen					907:912	dissolved oxygen	897:912	dissolved oxygen	897:912	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	12	theme	Experimental	728:739	arg1	data					741:744	Experimental data	728:744	Experimental data of 25 different fed-batch bioprocesses	728:783	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	6	13	theme	cell	1350:1353	arg1	degradation					1355:1365	cell degradation	1350:1365	cell degradation	1350:1365	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	3	14	theme	cellular	588:595	arg1	metabolism					597:606	cellular metabolism	588:606	cellular metabolism	588:606	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	6	15	from	accumulation	1242:1253	arg1	environment					1308:1318	the extracellular environment	1290:1318	the extracellular environment	1290:1318	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	5	16	theme	reaction	1051:1058	arg1	pathways					1060:1067	the reaction pathways	1047:1067	the reaction pathways	1047:1067	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	1	17	theme	Experimental	169:180	arg1	work					195:198	Experimental and modeling work	169:198	Experimental and modeling work	169:198	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	0	18	theme	ovary	65:69	arg1	metabolism					76:85	Chinese hamster ovary cell metabolism	49:85	Chinese hamster ovary cell metabolism	49:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	5	19	theme	additional	1126:1135	arg1	reactions					1137:1145	additional reactions	1126:1145	additional reactions	1126:1145	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	1	20	theme	modeling	186:193	arg1	work					195:198	Experimental and modeling work	169:198	Experimental and modeling work	169:198	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	0	21	theme	metabolism	76:85	arg1	modeling					37:44	Dynamic multiscale metabolic network modeling	0:44	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism	0:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	0	22	theme	N-linked	99:106	arg1	glycosylation					108:120	N-linked glycosylation	99:120	N-linked glycosylation	99:120	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	1	23	theme	antibody	359:366	arg1	production					376:385	monoclonal antibody protein production	348:385	monoclonal antibody protein production	348:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	5	24	theme	proposed	963:970	arg1	network					982:988	our proposed metabolic network	959:988	our proposed metabolic network	959:988	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	4	25	theme	different	752:760	arg1	bioprocesses					772:783	25 different fed-batch bioprocesses	749:783	25 different fed-batch bioprocesses	749:783	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	0	26	theme	Dynamic	0:6	arg1	modeling					37:44	Dynamic multiscale metabolic network modeling	0:44	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism	0:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	5	27	theme	glycoforms	1184:1193	arg1	accumulation					1155:1166	the accumulation	1151:1166	the accumulation of the produced glycoforms	1151:1193	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	0	28	gly	glycosylation	108:120	arg1	manufacturing					154:166	industrial biopharmaceutical manufacturing	125:166	industrial biopharmaceutical manufacturing	125:166	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	2	29	theme	monoclonal	431:440	arg1	antibodies					442:451	monoclonal antibodies	431:451	monoclonal antibodies production	431:462	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	4	30	theme	bioprocesses	772:783	arg1	data					741:744	Experimental data	728:744	Experimental data of 25 different fed-batch bioprocesses	728:783	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	2	31	theme	hosts	421:425	arg1	one					402:404	one	402:404	one	402:404	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	2	31	theme	hosts	421:425	arg1	hosts					421:425	the primary hosts	409:425	the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine	409:556	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	0	32	theme	metabolic	19:27	arg1	modeling					37:44	Dynamic multiscale metabolic network modeling	0:44	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism	0:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	1	33	theme	cells	295:299	arg1	pathway					256:262	the metabolic pathway	242:262	the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production	242:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	2	34	theme	extensive	476:484	arg1	applications					486:497	extensive applications	476:497	extensive applications	476:497	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	8	35	theme	applied	1607:1613	arg1	procedure					1624:1632	the applied modeling procedure	1603:1632	the applied modeling procedure	1603:1632	With the applied modeling procedure, different operational scenarios and fed-batch techniques can be tested.
32970321	3	36	theme	network	659:665	arg1	modeling					623:630	in silico modeling	613:630	in silico modeling of a microkinetic reaction network	613:665	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	5	37	theme	chemical	1014:1021	arg1	reactions					1023:1031	132 chemical reactions	1010:1031	132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms	1010:1193	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	3	38	theme	microkinetic	637:648	arg1	network					659:665	a microkinetic reaction network	635:665	a microkinetic reaction network	635:665	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	0	39	theme	Chinese	49:55	arg1	ovary					65:69	Chinese hamster ovary	49:69	Chinese hamster ovary cell metabolism	49:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	1	40	theme	expression	326:335	arg1	cells					295:299	Chinese hamster ovary (CHO) cells	267:299	Chinese hamster ovary (CHO) cells	267:299	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	1	40	theme	expression	326:335	arg1	system					337:342	the preferred expression system	312:342	the preferred expression system for monoclonal antibody protein production	312:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	8	41	theme	different	1635:1643	arg1	scenarios					1657:1665	different operational scenarios	1635:1665	different operational scenarios	1635:1665	With the applied modeling procedure, different operational scenarios and fed-batch techniques can be tested.
32970321	4	42	theme	process	820:826	arg1	parameters					828:837	multiple process parameters	811:837	multiple process parameters	811:837	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	42	theme	process	820:826	arg1	content					884:890	oxygen and CO2 content	869:890	oxygen and CO2 content	869:890	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	42	theme	process	820:826	arg1	pH					848:849	pH	848:849	pH	848:849	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	42	theme	process	820:826	arg1	speed					862:866	agitation speed	852:866	agitation speed	852:866	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	42	theme	process	820:826	arg1	oxygen					907:912	dissolved oxygen	897:912	dissolved oxygen	897:912	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	6	43	from	reaction	1328:1335	arg1	environment					1308:1318	the extracellular environment	1290:1318	the extracellular environment	1290:1318	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	7	44	theme	biomass	1531:1537	arg1	production					1539:1548	biomass production	1531:1548	biomass production	1531:1548	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	8	45	theme	fed-batch	1671:1679	arg1	techniques					1681:1690	fed-batch techniques	1671:1690	fed-batch techniques	1671:1690	With the applied modeling procedure, different operational scenarios and fed-batch techniques can be tested.
32970321	1	46	theme	Chinese	267:273	arg1	cells					295:299	Chinese hamster ovary (CHO) cells	267:299	Chinese hamster ovary (CHO) cells	267:299	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	1	46	theme	Chinese	267:273	arg1	system					337:342	the preferred expression system	312:342	the preferred expression system for monoclonal antibody protein production	312:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	3	47	theme	unique	699:704	arg1	results					719:725	unique experimental results	699:725	unique experimental results	699:725	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	1	48	theme	ovary	283:287	arg1	cells					295:299	Chinese hamster ovary (CHO) cells	267:299	Chinese hamster ovary (CHO) cells	267:299	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	1	48	theme	ovary	283:287	arg1	system					337:342	the preferred expression system	312:342	the preferred expression system for monoclonal antibody protein production	312:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	6	49	theme	Additional	1196:1205	arg1	reactions					1213:1221	Additional eight reactions	1196:1221	Additional eight reactions	1196:1221	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	6	50	theme	extracellular	1294:1306	arg1	environment					1308:1318	the extracellular environment	1290:1318	the extracellular environment	1290:1318	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	7	51	theme	lipid	1495:1499	arg1	synthesis					1501:1509	lipid synthesis	1495:1509	lipid synthesis	1495:1509	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	4	52	theme	agitation	852:860	arg1	speed					862:866	agitation speed	852:866	agitation speed	852:866	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	7	53	theme	acid	1483:1486	arg1	cycle					1488:1492	tricarboxylic acid cycle	1469:1492	tricarboxylic acid cycle	1469:1492	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	3	54	dep	in	613:614	arg1	silico					616:621	silico	616:621	silico	616:621	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	7	55	theme	nucleotide	1447:1456	arg1	synthesis					1458:1466	nucleotide synthesis	1447:1466	nucleotide synthesis	1447:1466	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	1	56	theme	preferred	316:324	arg1	cells					295:299	Chinese hamster ovary (CHO) cells	267:299	Chinese hamster ovary (CHO) cells	267:299	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	1	56	theme	preferred	316:324	arg1	system					337:342	the preferred expression system	312:342	the preferred expression system for monoclonal antibody protein production	312:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	7	57	theme	pentose	1420:1426	arg1	pathway					1438:1444	pentose phosphate pathway	1420:1444	pentose phosphate pathway	1420:1444	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	0	58	theme	cell	71:74	arg1	metabolism					76:85	Chinese hamster ovary cell metabolism	49:85	Chinese hamster ovary cell metabolism	49:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	3	59	theme	in	613:614	arg1	modeling					623:630	in silico modeling	613:630	in silico modeling of a microkinetic reaction network	613:665	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	2	60	theme	multiple	502:509	arg1	fields					511:516	multiple fields	502:516	multiple fields like biochemistry, biology and medicine	502:556	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	3	61	dep	approach	568:575	arg1	explain					580:586	explain	580:586	to explain cellular metabolism with in silico modeling of a microkinetic reaction network	577:665	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	1	62	theme	monoclonal	348:357	arg1	production					376:385	monoclonal antibody protein production	348:385	monoclonal antibody protein production	348:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	0	63	theme	industrial	125:134	arg1	manufacturing					154:166	industrial biopharmaceutical manufacturing	125:166	industrial biopharmaceutical manufacturing	125:166	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	1	64	theme	protein	368:374	arg1	production					376:385	monoclonal antibody protein production	348:385	monoclonal antibody protein production	348:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	5	65	theme	metabolic	972:980	arg1	network					982:988	our proposed metabolic network	959:988	our proposed metabolic network	959:988	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	7	66	theme	following	1372:1380	arg1	pathways					1382:1389	The following pathways	1368:1389	The following pathways	1368:1389	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	0	67	theme	multiscale	8:17	arg1	modeling					37:44	Dynamic multiscale metabolic network modeling	0:44	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism	0:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	5	68	theme	metabolites	930:940	arg1	total					917:921	A total	915:921	A total of 151 metabolites	915:940	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	2	69	theme	antibodies	442:451	arg1	production					453:462	monoclonal antibodies production	431:462	monoclonal antibodies production	431:462	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	2	70	theme	CHO	388:390	arg1	cells					392:396	CHO cells	388:396	CHO cells	388:396	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	0	71	theme	network	29:35	arg1	modeling					37:44	Dynamic multiscale metabolic network modeling	0:44	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism	0:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	6	72	theme	N-glycosylation	1262:1276	arg1	products					1278:1285	the N-glycosylation products	1258:1285	the N-glycosylation products	1258:1285	Additional eight reactions are considered for accumulation of the N-glycosylation products in the extracellular environment and one reaction to correlate cell degradation.
32970321	8	73	theme	modeling	1615:1622	arg1	procedure					1624:1632	the applied modeling procedure	1603:1632	the applied modeling procedure	1603:1632	With the applied modeling procedure, different operational scenarios and fed-batch techniques can be tested.
32970321	3	74	theme	reaction	650:657	arg1	network					659:665	a microkinetic reaction network	635:665	a microkinetic reaction network	635:665	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	4	75	theme	fed-batch	762:770	arg1	bioprocesses					772:783	25 different fed-batch bioprocesses	749:783	25 different fed-batch bioprocesses	749:783	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	2	76	theme	primary	413:419	arg1	hosts					421:425	the primary hosts	409:425	the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine	409:556	CHO cells are one of the primary hosts for monoclonal antibodies production, which have extensive applications in multiple fields like biochemistry, biology and medicine.
32970321	0	77	theme	hamster	57:63	arg1	ovary					65:69	Chinese hamster ovary	49:69	Chinese hamster ovary cell metabolism	49:85	Dynamic multiscale metabolic network modeling of Chinese hamster ovary cell metabolism integrating N-linked glycosylation in industrial biopharmaceutical manufacturing.
32970321	7	78	theme	membrane	1578:1585	arg1	transport					1587:1595	membrane transport	1578:1595	membrane transport	1578:1595	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	8	79	theme	operational	1645:1655	arg1	scenarios					1657:1665	different operational scenarios	1635:1665	different operational scenarios	1635:1665	With the applied modeling procedure, different operational scenarios and fed-batch techniques can be tested.
32970321	5	80	theme	produced	1175:1182	arg1	glycoforms					1184:1193	the produced glycoforms	1171:1193	the produced glycoforms	1171:1193	A total of 151 metabolites were involved in our proposed metabolic network, which consisted of 132 chemical reactions that describe the reaction pathways, and include 25 reactions describing N-glycosylation and additional reactions for the accumulation of the produced glycoforms.
32970321	4	81	theme	multiple	811:818	arg1	parameters					828:837	multiple process parameters	811:837	multiple process parameters	811:837	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	81	theme	multiple	811:818	arg1	content					884:890	oxygen and CO2 content	869:890	oxygen and CO2 content	869:890	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	81	theme	multiple	811:818	arg1	pH					848:849	pH	848:849	pH	848:849	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	81	theme	multiple	811:818	arg1	speed					862:866	agitation speed	852:866	agitation speed	852:866	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	4	81	theme	multiple	811:818	arg1	oxygen					907:912	dissolved oxygen	897:912	dissolved oxygen	897:912	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32970321	1	82	theme	metabolic	246:254	arg1	pathway					256:262	the metabolic pathway	242:262	the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production	242:385	Experimental and modeling work, described in this article, is focused on the metabolic pathway of Chinese hamster ovary (CHO) cells, which are the preferred expression system for monoclonal antibody protein production.
32970321	7	83	theme	anaplerotic	1551:1561	arg1	reactions					1563:1571	anaplerotic reactions	1551:1571	anaplerotic reactions	1551:1571	The following pathways were considered: glycolysis, pentose phosphate pathway, nucleotide synthesis, tricarboxylic acid cycle, lipid synthesis, protein synthesis, biomass production, anaplerotic reactions, and membrane transport.
32970321	3	84	theme	experimental	706:717	arg1	results					719:725	unique experimental results	699:725	unique experimental results	699:725	Here, an approach to explain cellular metabolism with in silico modeling of a microkinetic reaction network is presented and validated with unique experimental results.
32970321	4	85	theme	parameters	828:837	arg1	variation					798:806	the variation	794:806	the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen	794:912	Experimental data of 25 different fed-batch bioprocesses included the variation of multiple process parameters, such as pH, agitation speed, oxygen and CO2 content, and dissolved oxygen.
32296440	9	0	theme	Increasing	1284:1293	arg1	SR-F1					1295:1299	Increasing SR-F1	1284:1299	Increasing SR-F1	1284:1299	Increasing SR-F1 negatively modulated the uptake of apoptotic cells.
32296440	3	1	theme	collagen-like	646:658	arg1	region					660:665	its collagen-like region	642:665	its collagen-like region	642:665	C1q measured affinity was in the 100 nM range and C1q interaction occurs via its collagen-like region.
32296440	10	2	theme	mock-transfected	1449:1464	arg1	cells					1466:1470	mock-transfected cells	1449:1470	mock-transfected cells	1449:1470	Indeed, THP-1 cells overexpressing SR-F1 displayed a lower phagocytic capacity as compared with mock-transfected cells, which could be partially restored by addition of C1q in the extracellular milieu.
32296440	5	3	theme	N-linked	832:839	arg1	glycans					841:847	SR-F1 N-linked glycans	826:847	SR-F1 N-linked glycans	826:847	The role of SR-F1 N-linked glycans was also tested by mutating each of the three glycosylated asparagines.
32296440	2	4	theme	calreticulin	545:556	arg1	binding					470:476	the binding	466:476	the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT)	466:562	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	1	5	theme	range	233:237	arg1	internalization					207:221	the internalization	203:221	the internalization of a wide range of ligands	203:248	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32296440	10	6	theme	lower	1406:1410	arg1	capacity					1423:1430	a lower phagocytic capacity	1404:1430	a lower phagocytic capacity	1404:1430	Indeed, THP-1 cells overexpressing SR-F1 displayed a lower phagocytic capacity as compared with mock-transfected cells, which could be partially restored by addition of C1q in the extracellular milieu.
32296440	5	7	theme	glycans	841:847	arg1	role					818:821	The role	814:821	The role of SR-F1 N-linked glycans	814:847	The role of SR-F1 N-linked glycans was also tested by mutating each of the three glycosylated asparagines.
32296440	7	8	theme	overexpressing	1115:1128	arg1	macrophages					1130:1140	SR-F1 overexpressing macrophages	1109:1140	SR-F1 overexpressing macrophages	1109:1140	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	7	9	located	observed	1173:1180	arg2	C1q/SR-F1					1148:1156	C1q/SR-F1	1148:1156	C1q/SR-F1 colocalization observed in some membrane areas	1148:1203	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	7	9	located	observed	1173:1180	arg1	areas					1199:1203	some membrane areas	1185:1203	some membrane areas	1185:1203	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	8	10	theme	SR-F1	1271:1275	arg1	cells					1277:1281	THP-1 SR-F1 cells	1265:1281	THP-1 SR-F1 cells	1265:1281	We also observed a higher level of CRT internalization for THP-1 SR-F1 cells.
32296440	1	11	theme	ligands	242:248	arg1	range					233:237	a wide range	226:237	a wide range of ligands	226:248	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32296440	2	12	theme	lipoprotein	504:514	arg1	binding					470:476	the binding	466:476	the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT)	466:562	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	8	13	theme	higher	1225:1230	arg1	level					1232:1236	a higher level	1223:1236	a higher level of CRT internalization for THP-1 SR-F1 cells	1223:1281	We also observed a higher level of CRT internalization for THP-1 SR-F1 cells.
32296440	8	14	theme	THP-1	1265:1269	arg1	cells					1277:1281	THP-1 SR-F1 cells	1265:1281	THP-1 SR-F1 cells	1265:1281	We also observed a higher level of CRT internalization for THP-1 SR-F1 cells.
32296440	5	15	theme	glycosylated	895:906	arg1	asparagines					908:918	the three glycosylated asparagines	885:918	the three glycosylated asparagines	885:918	The role of SR-F1 N-linked glycans was also tested by mutating each of the three glycosylated asparagines.
32296440	6	16	theme	binding	948:954	arg1	activities					956:965	binding activities	948:965	binding activities	948:965	The three mutants retained binding activities for both AcLDL and C1q.
32296440	2	17	theme	density	496:502	arg1	AcLDL					517:521	AcLDL	517:521	AcLDL	517:521	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	2	17	theme	density	496:502	arg1	lipoprotein					504:514	low density lipoprotein	492:514	acetylated low density lipoprotein (AcLDL)	481:522	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	4	18	theme	C-terminal	783:792	arg1	moiety					794:799	the C-terminal moiety	779:799	the C-terminal moiety	779:799	We identified two different binding regions on SR-F1: the N-terminal moiety interacts with C1q and CRT whereas the C-terminal moiety binds AcLDL.
32296440	1	19	theme	scavenger	156:164	arg1	SR-F1					175:179	The scavenger receptor SR-F1	152:179	The scavenger receptor SR-F1	152:179	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32296440	2	20	theme	low	492:494	arg1	AcLDL					517:521	AcLDL	517:521	AcLDL	517:521	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	2	20	theme	low	492:494	arg1	lipoprotein					504:514	low density lipoprotein	492:514	acetylated low density lipoprotein (AcLDL)	481:522	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	9	21	theme	cells	1346:1350	arg1	uptake					1326:1331	the uptake	1322:1331	the uptake of apoptotic cells	1322:1350	Increasing SR-F1 negatively modulated the uptake of apoptotic cells.
32296440	10	22	theme	extracellular	1533:1545	arg1	milieu					1547:1552	the extracellular milieu	1529:1552	the extracellular milieu	1529:1552	Indeed, THP-1 cells overexpressing SR-F1 displayed a lower phagocytic capacity as compared with mock-transfected cells, which could be partially restored by addition of C1q in the extracellular milieu.
32296440	1	23	theme	receptor	166:173	arg1	SR-F1					175:179	The scavenger receptor SR-F1	152:179	The scavenger receptor SR-F1	152:179	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32296440	11	24	from	role	1587:1590	arg1	efferocytosis					1604:1616	efferocytosis	1604:1616	efferocytosis	1604:1616	Our data shed some light on the role of SR-F1 in efferocytosis, through its capacity to bind C1q and CRT, two proteins involved in this process.
32296440	2	25	from	role	458:461	arg1	binding					470:476	the binding	466:476	the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT)	466:562	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	2	26	theme	acetylated	481:490	arg1	AcLDL					517:521	AcLDL	517:521	AcLDL	517:521	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	2	26	theme	acetylated	481:490	arg1	lipoprotein					504:514	low density lipoprotein	492:514	acetylated low density lipoprotein (AcLDL)	481:522	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	4	27	theme	different	686:694	arg1	regions					704:710	two different binding regions	682:710	two different binding regions	682:710	We identified two different binding regions on SR-F1: the N-terminal moiety interacts with C1q and CRT whereas the C-terminal moiety binds AcLDL.
32296440	0	28	theme	Molecular	0:8	arg1	Interactions					23:34	Molecular and Cellular Interactions	0:34	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q	0:82	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	10	29	theme	THP-1	1361:1365	arg1	cells					1367:1371	THP-1 cells	1361:1371	THP-1 cells overexpressing SR-F1	1361:1392	Indeed, THP-1 cells overexpressing SR-F1 displayed a lower phagocytic capacity as compared with mock-transfected cells, which could be partially restored by addition of C1q in the extracellular milieu.
32296440	7	30	theme	stable	993:998	arg1	line					1011:1014	A stable THP-1 cell line	991:1014	A stable THP-1 cell line overexpressing SR-F1	991:1035	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	3	31	theme	C1q	615:617	arg1	interaction					619:629	C1q interaction	615:629	C1q interaction	615:629	C1q measured affinity was in the 100 nM range and C1q interaction occurs via its collagen-like region.
32296440	7	32	theme	THP-1	1000:1004	arg1	line					1011:1014	A stable THP-1 cell line	991:1014	A stable THP-1 cell line overexpressing SR-F1	991:1035	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	9	33	theme	apoptotic	1336:1344	arg1	cells					1346:1350	apoptotic cells	1336:1350	apoptotic cells	1336:1350	Increasing SR-F1 negatively modulated the uptake of apoptotic cells.
32296440	2	34	theme	factor-like	415:425	arg1	modules					427:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	2	35	theme	complement	525:534	arg1	C1q					536:538	complement C1q	525:538	complement C1q	525:538	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	8	36	theme	internalization	1245:1259	arg1	level					1232:1236	a higher level	1223:1236	a higher level of CRT internalization for THP-1 SR-F1 cells	1223:1281	We also observed a higher level of CRT internalization for THP-1 SR-F1 cells.
32296440	5	37	gly	glycosylated	895:906	arg1	asparagines					908:918	the three glycosylated asparagines	885:918	the three glycosylated asparagines	885:918	The role of SR-F1 N-linked glycans was also tested by mutating each of the three glycosylated asparagines.
32296440	2	38	theme	epidermal	398:406	arg1	modules					427:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	2	39	theme	growth	408:413	arg1	modules					427:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	7	40	theme	cell	1006:1009	arg1	line					1011:1014	A stable THP-1 cell line	991:1014	A stable THP-1 cell line overexpressing SR-F1	991:1035	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	3	41	theme	100	598:600	arg1	nM					602:603	nM	602:603	nM	602:603	C1q measured affinity was in the 100 nM range and C1q interaction occurs via its collagen-like region.
32296440	4	42	theme	binding	696:702	arg1	regions					704:710	two different binding regions	682:710	two different binding regions	682:710	We identified two different binding regions on SR-F1: the N-terminal moiety interacts with C1q and CRT whereas the C-terminal moiety binds AcLDL.
32296440	2	43	theme	C-terminal	387:396	arg1	modules					427:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	0	44	theme	Scavenger	39:47	arg1	SR-F1					58:62	Scavenger Receptor SR-F1	39:62	Scavenger Receptor SR-F1	39:62	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	10	45	theme	C1q	1522:1524	arg1	addition					1510:1517	addition	1510:1517	addition of C1q	1510:1524	Indeed, THP-1 cells overexpressing SR-F1 displayed a lower phagocytic capacity as compared with mock-transfected cells, which could be partially restored by addition of C1q in the extracellular milieu.
32296440	3	46	theme	nM	602:603	arg1	range					605:609	the 100 nM range	594:609	the 100 nM range	594:609	C1q measured affinity was in the 100 nM range and C1q interaction occurs via its collagen-like region.
32296440	1	47	theme	several	270:276	arg1	processes					292:300	several immunological processes	270:300	several immunological processes	270:300	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32296440	5	48	link	N-linked	832:839	arg1	glycans					841:847	SR-F1 N-linked glycans	826:847	SR-F1 N-linked glycans	826:847	The role of SR-F1 N-linked glycans was also tested by mutating each of the three glycosylated asparagines.
32296440	0	49	with	Interactions	23:34	arg1	C1q					80:82	Complement C1q	69:82	Complement C1q	69:82	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	7	50	theme	SR-F1	1109:1113	arg1	macrophages					1130:1140	SR-F1 overexpressing macrophages	1109:1140	SR-F1 overexpressing macrophages	1109:1140	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	0	51	theme	SR-F1	58:62	arg1	Interactions					23:34	Molecular and Cellular Interactions	0:34	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q	0:82	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	1	52	theme	immunological	278:290	arg1	processes					292:300	several immunological processes	270:300	several immunological processes	270:300	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32296440	0	53	theme	Cells	145:149	arg1	Clearance					122:130	the Clearance	118:130	the Clearance of Apoptotic Cells	118:149	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	2	54	theme	SR-F1	327:331	arg1	ectodomain					333:342	recombinant SR-F1 ectodomain	315:342	recombinant SR-F1 ectodomain	315:342	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	0	55	theme	Receptor	49:56	arg1	SR-F1					58:62	Scavenger Receptor SR-F1	39:62	Scavenger Receptor SR-F1	39:62	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	0	56	theme	Apoptotic	135:143	arg1	Cells					145:149	Apoptotic Cells	135:149	Apoptotic Cells	135:149	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	0	57	from	Role	110:113	arg1	Clearance					122:130	the Clearance	118:130	the Clearance of Apoptotic Cells	118:149	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	7	58	with	macrophages	1130:1140	arg1	C1q/SR-F1					1148:1156	C1q/SR-F1	1148:1156	C1q/SR-F1 colocalization observed in some membrane areas	1148:1203	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	7	59	theme	macrophages	1130:1140	arg1	surface					1098:1104	the surface	1094:1104	the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas	1094:1203	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	2	60	theme	recombinant	315:325	arg1	ectodomain					333:342	recombinant SR-F1 ectodomain	315:342	recombinant SR-F1 ectodomain	315:342	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	11	61	theme	SR-F1	1595:1599	arg1	role					1587:1590	the role	1583:1590	the role of SR-F1 in efferocytosis	1583:1616	Our data shed some light on the role of SR-F1 in efferocytosis, through its capacity to bind C1q and CRT, two proteins involved in this process.
32296440	2	62	theme	C1q	536:538	arg1	binding					470:476	the binding	466:476	the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT)	466:562	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	4	63	theme	N-terminal	726:735	arg1	moiety					737:742	the N-terminal moiety	722:742	the N-terminal moiety	722:742	We identified two different binding regions on SR-F1: the N-terminal moiety interacts with C1q and CRT whereas the C-terminal moiety binds AcLDL.
32296440	10	64	theme	phagocytic	1412:1421	arg1	capacity					1423:1430	a lower phagocytic capacity	1404:1430	a lower phagocytic capacity	1404:1430	Indeed, THP-1 cells overexpressing SR-F1 displayed a lower phagocytic capacity as compared with mock-transfected cells, which could be partially restored by addition of C1q in the extracellular milieu.
32296440	7	65	theme	membrane	1190:1197	arg1	areas					1199:1203	some membrane areas	1185:1203	some membrane areas	1185:1203	A stable THP-1 cell line overexpressing SR-F1 was generated and C1q was shown to bind more strongly to the surface of SR-F1 overexpressing macrophages, with C1q/SR-F1 colocalization observed in some membrane areas.
32296440	0	66	theme	Complement	69:78	arg1	C1q					80:82	Complement C1q	69:82	Complement C1q	69:82	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	8	67	theme	CRT	1241:1243	arg1	internalization					1245:1259	CRT internalization	1241:1259	CRT internalization	1241:1259	We also observed a higher level of CRT internalization for THP-1 SR-F1 cells.
32296440	2	68	theme	last	375:378	arg1	modules					427:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	the last 2 or 5 C-terminal epidermal growth factor-like modules	371:433	We produced recombinant SR-F1 ectodomain and fragments deleted from the last 2 or 5 C-terminal epidermal growth factor-like modules and investigated their role in the binding of acetylated low density lipoprotein (AcLDL), complement C1q, and calreticulin (CRT).
32296440	0	69	theme	Cellular	14:21	arg1	Interactions					23:34	Molecular and Cellular Interactions	0:34	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q	0:82	Molecular and Cellular Interactions of Scavenger Receptor SR-F1 With Complement C1q Provide Insights Into Its Role in the Clearance of Apoptotic Cells.
32296440	5	70	theme	SR-F1	826:830	arg1	glycans					841:847	SR-F1 N-linked glycans	826:847	SR-F1 N-linked glycans	826:847	The role of SR-F1 N-linked glycans was also tested by mutating each of the three glycosylated asparagines.
32296440	1	71	theme	wide	228:231	arg1	range					233:237	a wide range	226:237	a wide range of ligands	226:248	The scavenger receptor SR-F1 binds to and mediates the internalization of a wide range of ligands, and is involved in several immunological processes.
32281790	6	0	theme	Rat	1140:1142	arg1	IgG2a					1144:1148	anti-CD47 Rat IgG2a	1130:1148	anti-CD47 Rat IgG2a	1130:1148	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	0	theme	Rat	1140:1142	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	1	theme	mosaic	1280:1285	arg1	TMVlys					1294:1299	TMVlys	1294:1299	TMVlys	1294:1299	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	1	theme	mosaic	1280:1285	arg1	virus					1287:1291	tobacco mosaic virus	1272:1291	tobacco mosaic virus (TMVlys)	1272:1300	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	9	2	theme	antibody-VNP	1659:1670	arg1	conjugates					1672:1681	antibody-VNP conjugates	1659:1681	antibody-VNP conjugates	1659:1681	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	4	3	from	glycan	737:742	arg1	region					754:759	the Fc region	747:759	the Fc region	747:759	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	6	4	theme	lysine	1255:1260	arg1	mutant					1262:1267	the lysine mutant	1251:1267	the lysine mutant of tobacco mosaic virus (TMVlys)	1251:1300	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	4	5	theme	glycan	737:742	arg1	cleavage					716:723	(1) cleavage	712:723	(1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase	712:903	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	9	6	theme	Trastuzumab-displaying	1704:1725	arg1	VNPs					1727:1730	Trastuzumab-displaying VNPs	1704:1730	Trastuzumab-displaying VNPs	1704:1730	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	7	7	theme	antibody-VNP	1391:1402	arg1	conjugates					1404:1413	stable and functional antibody-VNP conjugates	1369:1413	stable and functional antibody-VNP conjugates	1369:1413	Site-specific conjugation resulted in stable and functional antibody-VNP conjugates.
32281790	6	8	theme	bacteriophage	1313:1325	arg1	Qβ					1327:1328	bacteriophage Qβ	1313:1328	the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ	1053:1328	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	2	9	theme	heterogeneous	279:291	arg1	display					302:308	heterogeneous antibody display	279:308	heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles	279:423	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	2	10	with	display	302:308	arg1	aggregation					347:357	aggregation	347:357	aggregation	347:357	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	2	10	with	display	302:308	arg1	activity					335:342	hindered biological activity	315:342	hindered biological activity	315:342	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	9	11	theme	SKOV-3	1755:1760	arg1	cells					1783:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	8	12	theme	heterobifunctional	1446:1463	arg1	linkers					1465:1471	heterobifunctional linkers	1446:1471	heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively,	1446:1541	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	9	13	theme	ovarian	1768:1774	arg1	cells					1783:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	6	14	theme	mosaic	1227:1232	arg1	CPMV					1241:1244	CPMV	1241:1244	CPMV	1241:1244	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	14	theme	mosaic	1227:1232	arg1	virus					1234:1238	the plant virus cowpea mosaic virus	1204:1238	the plant virus cowpea mosaic virus (CPMV)	1204:1245	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	4	15	contain	containing	831:840	arg1	linker					823:828	a chemically reactive linker	801:828	a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase	801:903	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	15	contain	containing	831:840	arg2	handle					862:867	an azide functional handle	842:867	an azide functional handle	842:867	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	2	16	theme	hindered	315:322	arg1	activity					335:342	hindered biological activity	315:342	hindered biological activity	315:342	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	6	17	theme	virus	1214:1218	arg1	CPMV					1241:1244	CPMV	1241:1244	CPMV	1241:1244	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	17	theme	virus	1214:1218	arg1	virus					1234:1238	the plant virus cowpea mosaic virus	1204:1238	the plant virus cowpea mosaic virus (CPMV)	1204:1245	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	5	18	theme	antibodies	942:951	arg1	Conjugation					906:916	Conjugation	906:916	Conjugation of the azide-functional antibodies to several VNPs	906:967	Conjugation of the azide-functional antibodies to several VNPs was achieved by making use of strain-promoted azide-alkyne cycloaddition.
32281790	5	19	theme	several	956:962	arg1	VNPs					964:967	several VNPs	956:967	several VNPs	956:967	Conjugation of the azide-functional antibodies to several VNPs was achieved by making use of strain-promoted azide-alkyne cycloaddition.
32281790	6	20	dep	isotypes	1099:1106	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	20	dep	isotypes	1099:1106	arg1	κ					1198:1198	κ	1198:1198	κ	1198:1198	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	20	dep	isotypes	1099:1106	arg1	IgG2a					1144:1148	anti-CD47 Rat IgG2a	1130:1148	anti-CD47 Rat IgG2a	1130:1148	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	20	dep	isotypes	1099:1106	arg1	IgG					1115:1117	human IgG	1109:1117	human IgG from sera	1109:1127	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	20	dep	isotypes	1099:1106	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	20	dep	isotypes	1099:1106	arg1	κ					1151:1151	κ	1151:1151	κ	1151:1151	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	1	21	theme	conjugate	142:150	arg1	antibodies					152:161	conjugate antibodies	142:161	conjugate antibodies to pharmaceuticals or nanoparticles	142:197	Amine/thiol-reactive chemistries are commonly used to conjugate antibodies to pharmaceuticals or nanoparticles.
32281790	10	22	theme	methods	1844:1850	arg1	portfolio					1831:1839	the portfolio	1827:1839	the portfolio of methods that can be used for designing functional antibody-VNP conjugates	1827:1916	This bioconjugation strategy adds to the portfolio of methods that can be used for designing functional antibody-VNP conjugates.
32281790	5	23	theme	cycloaddition	1028:1040	arg1	use					992:994	use	992:994	use of strain-promoted azide-alkyne cycloaddition	992:1040	Conjugation of the azide-functional antibodies to several VNPs was achieved by making use of strain-promoted azide-alkyne cycloaddition.
32281790	4	24	theme	reactive	814:821	arg1	linker					823:828	a chemically reactive linker	801:828	a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase	801:903	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	3	25	theme	conjugation	511:521	arg1	strategy					523:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	4	26	theme	2	783:783	arg1	conjugation					786:796	a glycosidase and (2) conjugation	764:796	conjugation	786:796	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	3	27	theme	driven	495:500	arg1	strategy					523:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	0	28	theme	Site-Specific	0:12	arg1	Strategy					35:42	Site-Specific Antibody Conjugation Strategy	0:42	Site-Specific Antibody Conjugation Strategy	0:42	Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.
32281790	4	29	theme	Fc	637:638	arg1	region					640:645	the Fc region	633:645	the Fc region of a set of immunoglobulins using a two-step enzymatic reaction	633:709	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	3	30	theme	virus-based	549:559	arg1	VNPs					576:579	VNPs	576:579	VNPs	576:579	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	3	30	theme	virus-based	549:559	arg1	nanoparticles					561:573	virus-based nanoparticles	549:573	virus-based nanoparticles (VNPs)	549:580	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	0	31	theme	Conjugation	23:33	arg1	Strategy					35:42	Site-Specific Antibody Conjugation Strategy	0:42	Site-Specific Antibody Conjugation Strategy	0:42	Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.
32281790	5	32	theme	strain-promoted	999:1013	arg1	cycloaddition					1028:1040	strain-promoted azide-alkyne cycloaddition	999:1040	strain-promoted azide-alkyne cycloaddition	999:1040	Conjugation of the azide-functional antibodies to several VNPs was achieved by making use of strain-promoted azide-alkyne cycloaddition.
32281790	10	33	theme	antibody-VNP	1894:1905	arg1	conjugates					1907:1916	functional antibody-VNP conjugates	1883:1916	functional antibody-VNP conjugates	1883:1916	This bioconjugation strategy adds to the portfolio of methods that can be used for designing functional antibody-VNP conjugates.
32281790	4	34	theme	functional	851:860	arg1	handle					862:867	an azide functional handle	842:867	an azide functional handle	842:867	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	0	35	theme	Virus-Based	61:71	arg1	Nanoparticles					73:85	Virus-Based Nanoparticles	61:85	Virus-Based Nanoparticles	61:85	Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.
32281790	10	36	theme	functional	1883:1892	arg1	conjugates					1907:1916	functional antibody-VNP conjugates	1883:1916	functional antibody-VNP conjugates	1883:1916	This bioconjugation strategy adds to the portfolio of methods that can be used for designing functional antibody-VNP conjugates.
32281790	6	37	theme	plant	1208:1212	arg1	CPMV					1241:1244	CPMV	1241:1244	CPMV	1241:1244	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	37	theme	plant	1208:1212	arg1	virus					1234:1238	the plant virus cowpea mosaic virus	1204:1238	the plant virus cowpea mosaic virus (CPMV)	1204:1245	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	2	38	theme	unfavorable	250:260	arg1	display					302:308	heterogeneous antibody display	279:308	heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles	279:423	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	2	38	theme	unfavorable	250:260	arg1	outcomes					262:269	unfavorable outcomes	250:269	unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles	250:423	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	2	39	theme	antibody	398:405	arg1	nanoparticles					411:423	nanoparticles	411:423	nanoparticles	411:423	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	2	39	theme	antibody	398:405	arg1	interactions					378:389	multivalent interactions	366:389	multivalent interactions of the antibody	366:405	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	4	40	dep	cleavage	716:723	arg1	1					713:713	1	713:713	1	713:713	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	41	theme	enzymatic	692:700	arg1	reaction					702:709	a two-step enzymatic reaction	681:709	a two-step enzymatic reaction	681:709	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	6	42	theme	virus	1287:1291	arg1	mutant					1262:1267	the lysine mutant	1251:1267	the lysine mutant of tobacco mosaic virus (TMVlys)	1251:1300	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	42	theme	virus	1287:1291	arg1	CPMV					1241:1244	CPMV	1241:1244	CPMV	1241:1244	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	42	theme	virus	1287:1291	arg1	virus					1234:1238	the plant virus cowpea mosaic virus	1204:1238	the plant virus cowpea mosaic virus (CPMV)	1204:1245	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	4	43	theme	set	652:654	arg1	region					640:645	the Fc region	633:645	the Fc region of a set of immunoglobulins using a two-step enzymatic reaction	633:709	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	6	44	theme	tobacco	1272:1278	arg1	TMVlys					1294:1299	TMVlys	1294:1299	TMVlys	1294:1299	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	44	theme	tobacco	1272:1278	arg1	virus					1287:1291	tobacco mosaic virus	1272:1291	tobacco mosaic virus (TMVlys)	1272:1300	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	2	45	theme	due	359:361	arg1	activity					335:342	hindered biological activity	315:342	hindered biological activity	315:342	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	4	46	theme	immunoglobulins	659:673	arg1	immunoglobulins					659:673	immunoglobulins	659:673	immunoglobulins using a two-step enzymatic reaction	659:709	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	46	theme	immunoglobulins	659:673	arg1	set					652:654	a set	650:654	a set of immunoglobulins using a two-step enzymatic reaction	650:709	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	6	47	from	sera	1124:1127	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	47	from	sera	1124:1127	arg1	κ					1198:1198	κ	1198:1198	κ	1198:1198	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	47	from	sera	1124:1127	arg1	IgG2a					1144:1148	anti-CD47 Rat IgG2a	1130:1148	anti-CD47 Rat IgG2a	1130:1148	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	47	from	sera	1124:1127	arg1	IgG					1115:1117	human IgG	1109:1117	human IgG from sera	1109:1127	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	47	from	sera	1124:1127	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	47	from	sera	1124:1127	arg1	κ					1151:1151	κ	1151:1151	κ	1151:1151	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	10	48	theme	bioconjugation	1795:1808	arg1	strategy					1810:1817	This bioconjugation strategy	1790:1817	This bioconjugation strategy	1790:1817	This bioconjugation strategy adds to the portfolio of methods that can be used for designing functional antibody-VNP conjugates.
32281790	4	49	from	cleavage	716:723	arg1	region					754:759	the Fc region	747:759	the Fc region	747:759	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	50	theme	microbial	878:886	arg1	transglutaminase					888:903	a microbial transglutaminase	876:903	a microbial transglutaminase	876:903	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	51	theme	N-linked	728:735	arg1	glycan					737:742	N-linked glycan	728:742	N-linked glycan in the Fc region	728:759	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	2	52	theme	multivalent	366:376	arg1	interactions					378:389	multivalent interactions	366:389	multivalent interactions of the antibody	366:405	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	6	53	theme	recombinant	1170:1180	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	53	theme	recombinant	1170:1180	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	2	54	theme	antibody	293:300	arg1	display					302:308	heterogeneous antibody display	279:308	heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles	279:423	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	9	55	theme	HER2-positive	1741:1753	arg1	cells					1783:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	8	56	theme	linkers	1465:1471	arg1	use					1439:1441	the use	1435:1441	the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively,	1435:1541	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	7	57	theme	functional	1380:1389	arg1	conjugates					1404:1413	stable and functional antibody-VNP conjugates	1369:1413	stable and functional antibody-VNP conjugates	1369:1413	Site-specific conjugation resulted in stable and functional antibody-VNP conjugates.
32281790	9	58	theme	human	1762:1766	arg1	cells					1783:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	7	59	theme	stable	1369:1374	arg1	conjugates					1404:1413	stable and functional antibody-VNP conjugates	1369:1413	stable and functional antibody-VNP conjugates	1369:1413	Site-specific conjugation resulted in stable and functional antibody-VNP conjugates.
32281790	2	60	theme	biological	324:333	arg1	activity					335:342	hindered biological activity	315:342	hindered biological activity	315:342	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	10	61	used	used	1864:1867	arg2	methods					1844:1850	methods	1844:1850	methods that can be used for designing functional antibody-VNP conjugates	1844:1916	This bioconjugation strategy adds to the portfolio of methods that can be used for designing functional antibody-VNP conjugates.
32281790	6	62	theme	humanized	1182:1190	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	62	theme	humanized	1182:1190	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	63	theme	IgG	1094:1096	arg1	IgG2a					1144:1148	anti-CD47 Rat IgG2a	1130:1148	anti-CD47 Rat IgG2a	1130:1148	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	63	theme	IgG	1094:1096	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	63	theme	IgG	1094:1096	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	63	theme	IgG	1094:1096	arg1	IgG					1115:1117	human IgG	1109:1117	human IgG from sera	1109:1127	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	9	64	theme	cancer	1776:1781	arg1	cells					1783:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	HER2-positive SKOV-3 human ovarian cancer cells	1741:1787	We demonstrate that antibody-VNP conjugates were functional, and Trastuzumab-displaying VNPs targeted HER2-positive SKOV-3 human ovarian cancer cells.
32281790	6	65	theme	cowpea	1220:1225	arg1	CPMV					1241:1244	CPMV	1241:1244	CPMV	1241:1244	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	65	theme	cowpea	1220:1225	arg1	virus					1234:1238	the plant virus cowpea mosaic virus	1204:1238	the plant virus cowpea mosaic virus (CPMV)	1204:1245	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	4	66	theme	glycosidase	766:776	arg1	conjugation					786:796	a glycosidase and (2) conjugation	764:796	conjugation	786:796	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	5	67	theme	azide-functional	925:940	arg1	antibodies					942:951	the azide-functional antibodies	921:951	the azide-functional antibodies	921:951	Conjugation of the azide-functional antibodies to several VNPs was achieved by making use of strain-promoted azide-alkyne cycloaddition.
32281790	6	68	theme	immunoglobulin	1078:1091	arg1	IgG2a					1144:1148	anti-CD47 Rat IgG2a	1130:1148	anti-CD47 Rat IgG2a	1130:1148	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	68	theme	immunoglobulin	1078:1091	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	68	theme	immunoglobulin	1078:1091	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	68	theme	immunoglobulin	1078:1091	arg1	IgG					1115:1117	human IgG	1109:1117	human IgG from sera	1109:1127	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	7	69	theme	Site-specific	1331:1343	arg1	conjugation					1345:1355	Site-specific conjugation	1331:1355	Site-specific conjugation	1331:1355	Site-specific conjugation resulted in stable and functional antibody-VNP conjugates.
32281790	4	70	theme	Fc	751:752	arg1	region					754:759	the Fc region	747:759	the Fc region	747:759	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	8	71	from	amines	1494:1499	arg1	antibodies					1508:1517	the antibodies	1504:1517	the antibodies	1504:1517	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	8	71	from	amines	1494:1499	arg1	VNPs					1523:1526	VNPs	1523:1526	VNPs	1523:1526	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	8	72	theme	stark	1419:1423	arg1	contrast					1425:1432	stark contrast	1419:1432	stark contrast	1419:1432	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	5	73	theme	azide-alkyne	1015:1026	arg1	cycloaddition					1028:1040	strain-promoted azide-alkyne cycloaddition	999:1040	strain-promoted azide-alkyne cycloaddition	999:1040	Conjugation of the azide-functional antibodies to several VNPs was achieved by making use of strain-promoted azide-alkyne cycloaddition.
32281790	1	74	theme	Amine/thiol-reactive	88:107	arg1	chemistries					109:119	Amine/thiol-reactive chemistries	88:119	Amine/thiol-reactive chemistries	88:119	Amine/thiol-reactive chemistries are commonly used to conjugate antibodies to pharmaceuticals or nanoparticles.
32281790	8	75	from	thiols	1483:1488	arg1	antibodies					1508:1517	the antibodies	1504:1517	the antibodies	1504:1517	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	8	75	from	thiols	1483:1488	arg1	VNPs					1523:1526	VNPs	1523:1526	VNPs	1523:1526	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	3	76	theme	strategy	523:530	arg1	application					446:456	the application	442:456	the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs)	442:580	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	0	77	theme	Antibody	14:21	arg1	Strategy					35:42	Site-Specific Antibody Conjugation Strategy	0:42	Site-Specific Antibody Conjugation Strategy	0:42	Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.
32281790	3	78	theme	antibody	502:509	arg1	strategy					523:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	6	79	theme	human	1109:1113	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	79	theme	human	1109:1113	arg1	IgG					1115:1117	human IgG	1109:1117	human IgG from sera	1109:1127	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	80	theme	isotypes	1099:1106	arg1	conjugation					1057:1067	the conjugation	1053:1067	the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ	1053:1328	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	80	theme	isotypes	1099:1106	arg1	Qβ					1327:1328	bacteriophage Qβ	1313:1328	the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ	1053:1328	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	8	81	theme	nonspecific	1569:1579	arg1	coupling					1597:1604	nonspecific and multivalent coupling	1569:1604	nonspecific and multivalent coupling between the antibodies and VNPs	1569:1636	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	2	82	theme	conjugation	211:221	arg1	strategies					223:232	these conjugation strategies	205:232	these conjugation strategies	205:232	Yet, these conjugation strategies often result in unfavorable outcomes such as heterogeneous antibody display with hindered biological activity or aggregation due to multivalent interactions of the antibody and nanoparticles.
32281790	4	83	theme	azide	845:849	arg1	handle					862:867	an azide functional handle	842:867	an azide functional handle	842:867	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	6	84	theme	Trastuzumab	1158:1168	arg1	IgG1					1192:1195	Trastuzumab recombinant humanized IgG1	1158:1195	Trastuzumab recombinant humanized IgG1	1158:1195	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	6	84	theme	Trastuzumab	1158:1168	arg1	isotypes					1099:1106	three immunoglobulin (IgG) isotypes	1072:1106	three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ)	1072:1199	We report the conjugation of three immunoglobulin (IgG) isotypes (human IgG from sera, anti-CD47 Rat IgG2a, κ, and Trastuzumab recombinant humanized IgG1, κ) to the plant virus cowpea mosaic virus (CPMV) and the lysine mutant of tobacco mosaic virus (TMVlys) as well as bacteriophage Qβ.
32281790	3	85	theme	site-specific	463:475	arg1	strategy					523:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	a site-specific and enzymatically driven antibody conjugation strategy	461:530	Here, we report the application of a site-specific and enzymatically driven antibody conjugation strategy to functionalize virus-based nanoparticles (VNPs).
32281790	8	86	theme	multivalent	1585:1595	arg1	coupling					1597:1604	nonspecific and multivalent coupling	1569:1604	nonspecific and multivalent coupling between the antibodies and VNPs	1569:1636	In stark contrast, the use of heterobifunctional linkers targeting thiols and amines on the antibodies and VNPs, respectively, led to aggregation due to nonspecific and multivalent coupling between the antibodies and VNPs.
32281790	4	87	link	N-linked	728:735	arg1	glycan					737:742	N-linked glycan	728:742	N-linked glycan in the Fc region	728:759	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	1	88	used	used	134:137	arg2	chemistries					109:119	Amine/thiol-reactive chemistries	88:119	Amine/thiol-reactive chemistries	88:119	Amine/thiol-reactive chemistries are commonly used to conjugate antibodies to pharmaceuticals or nanoparticles.
32281790	4	89	theme	two-step	683:690	arg1	reaction					702:709	a two-step enzymatic reaction	681:709	a two-step enzymatic reaction	681:709	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	90	theme	linker	823:828	arg1	conjugation					786:796	a glycosidase and (2) conjugation	764:796	conjugation	786:796	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
32281790	4	91	from	region	754:759	arg1	cleavage					716:723	(1) cleavage	712:723	(1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase	712:903	Specifically, an azide-handle was introduced into the Fc region of a set of immunoglobulins using a two-step enzymatic reaction: (1) cleavage of N-linked glycan in the Fc region by a glycosidase and (2) conjugation of a chemically reactive linker (containing an azide functional handle) using a microbial transglutaminase.
31945375	7	0	theme	absolute	1245:1252	arg1	requirement					1254:1264	an absolute requirement	1242:1264	an absolute requirement for undecorated d-mannopyranose in the -1 subsite	1242:1314	In addition, using two differential derivatization methods, we have shown that there is an absolute requirement for undecorated d-mannopyranose in the -1 subsite.
31945375	3	1	theme	strains	502:508	arg1	sequences					445:453	the genome sequences	434:453	the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM	434:550	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	5	2	from	pombe	947:951	arg1	YMs					889:891	structurally distinct YMs	867:891	structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe	867:951	Purified recombinant BtGH76-MD40 displayed activity on structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe.
31945375	9	3	theme	monosaccharide	1732:1745	arg1	end					1709:1711	the reducing end	1696:1711	the reducing end of the undecorated monosaccharide	1696:1745	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	1	4	theme	yeast	261:265	arg1	walls					272:276	yeast cell walls	261:276	yeast cell walls	261:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	1	5	link	N-linked	215:222	arg1	α-mannan					179:186	Yeast α-mannan	173:186	Yeast α-mannan (YM)	173:191	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	1	5	link	N-linked	215:222	arg1	glycan					224:229	a densely branched N-linked glycan	196:229	a densely branched N-linked glycan that decorates the surface of yeast cell walls	196:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	2	6	theme	high	292:295	arg1	degree					297:302	the high degree	288:302	the high degree of branching	288:315	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31945375	6	7	theme	Linkage	954:960	arg1	analysis					962:969	Linkage analysis	954:969	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan	954:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	10	8	theme	enzymes	1810:1816	arg1	acquisition					1791:1801	acquisition	1791:1801	acquisition of new enzymes within extant pathways	1791:1839	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	9	9	theme	side	1548:1551	arg1	chains					1553:1558	extended side chains	1539:1558	extended side chains in the +1 and -2 subsites	1539:1584	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	9	10	theme	and -2	1570:1575	arg1	subsites					1577:1584	the +1 and -2 subsites	1563:1584	the +1 and -2 subsites	1563:1584	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	3	11	theme	tandem	574:579	arg1	pair					581:584	a tandem pair	572:584	a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism	572:667	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	1	12	theme	branched	206:213	arg1	α-mannan					179:186	Yeast α-mannan	173:186	Yeast α-mannan (YM)	173:191	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	1	12	theme	branched	206:213	arg1	glycan					224:229	a densely branched N-linked glycan	196:229	a densely branched N-linked glycan that decorates the surface of yeast cell walls	196:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	0	13	theme	Yeast	158:162	arg1	Mannans					164:170	Diverse Yeast Mannans	150:170	Diverse Yeast Mannans	150:170	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	5	14	theme	distinct	880:887	arg1	YMs					889:891	structurally distinct YMs	867:891	structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe	867:951	Purified recombinant BtGH76-MD40 displayed activity on structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe.
31945375	8	15	theme	branched	1432:1439	arg1	substrate					1462:1470	a branched alpha-mannopentatose substrate	1430:1470	a branched alpha-mannopentatose substrate	1430:1470	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	8	16	theme	X-ray	1350:1354	arg1	superimposition					1389:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	0	17	theme	Linkage	58:64	arg1	Chemistry					66:74	Reaction Product Linkage Chemistry	41:74	Reaction Product Linkage Chemistry	41:74	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	7	18	theme	differential	1177:1188	arg1	methods					1205:1211	two differential derivatization methods	1173:1211	two differential derivatization methods	1173:1211	In addition, using two differential derivatization methods, we have shown that there is an absolute requirement for undecorated d-mannopyranose in the -1 subsite.
31945375	5	19	theme	BtGH76-MD40 displayed	833:853	arg1	activity					855:862	recombinant BtGH76-MD40 displayed activity	821:862	recombinant BtGH76-MD40 displayed activity	821:862	Purified recombinant BtGH76-MD40 displayed activity on structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe.
31945375	6	20	from	S. cerevisiae	1013:1025	arg1	products					999:1006	released oligosaccharide products	974:1006	released oligosaccharide products from S. cerevisiae and S. pombe mannan	974:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	6	20	from	S. cerevisiae	1013:1025	arg1	analysis					962:969	Linkage analysis	954:969	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan	954:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	8	21	theme	structure and	1364:1376	arg1	superimposition					1389:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	1	22	theme	Yeast	173:177	arg1	YM					189:190	YM	189:190	YM	189:190	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	1	22	theme	Yeast	173:177	arg1	α-mannan					179:186	Yeast α-mannan	173:186	Yeast α-mannan (YM)	173:191	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	1	22	theme	Yeast	173:177	arg1	glycan					224:229	a densely branched N-linked glycan	196:229	a densely branched N-linked glycan that decorates the surface of yeast cell walls	196:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	6	23	theme	oligosaccharide	983:997	arg1	products					999:1006	released oligosaccharide products	974:1006	released oligosaccharide products from S. cerevisiae and S. pombe mannan	974:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	6	24	from	S. pombe	1031:1038	arg1	products					999:1006	released oligosaccharide products	974:1006	released oligosaccharide products from S. cerevisiae and S. pombe mannan	974:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	6	24	from	S. pombe	1031:1038	arg1	analysis					962:969	Linkage analysis	954:969	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan	954:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	8	25	theme	superimposition	1389:1403	arg1	Determination					1317:1329	Determination	1317:1329	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition	1317:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	8	25	theme	superimposition	1389:1403	arg1	docking					1419:1425	molecular docking	1409:1425	molecular docking of a branched alpha-mannopentatose substrate	1409:1470	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	0	26	theme	Conserved	86:94	arg1	Substrate					105:113	a Conserved Cleavage Substrate	84:113	a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans	84:170	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	2	27	theme	coupled	372:378	arg1	action					380:385	the coupled action	368:385	the coupled action of side-chain-cleaving enzymes	368:416	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31945375	8	28	theme	molecular	1409:1417	arg1	docking					1419:1425	molecular docking	1409:1425	molecular docking of a branched alpha-mannopentatose substrate	1409:1470	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	4	29	from	family	787:792	arg1	endo-mannanase					742:755	a predicted endo-mannanase	730:755	a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40)	730:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	29	from	family	787:792	arg1	one					708:710	one	708:710	one	708:710	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	29	from	family	787:792	arg1	enzymes					721:727	these enzymes	715:727	these enzymes	715:727	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	1	30	theme	cell	267:270	arg1	walls					272:276	yeast cell walls	261:276	yeast cell walls	261:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	2	31	theme	side-chain-cleaving	390:408	arg1	enzymes					410:416	side-chain-cleaving enzymes	390:416	side-chain-cleaving enzymes	390:416	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31945375	4	32	theme	one	708:710	arg1	activity					696:703	the activity	692:703	the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40)	692:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	33	theme	hydrolase	772:780	arg1	family					787:792	glycoside hydrolase (GH) family 76	762:795	glycoside hydrolase (GH) family 76 (BtGH76-MD40)	762:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	33	theme	hydrolase	772:780	arg1	BtGH76-MD40					798:808	BtGH76-MD40	798:808	BtGH76-MD40	798:808	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	0	34	theme	Active	12:17	arg1	Architecture					24:35	Active Site Architecture	12:35	Active Site Architecture	12:35	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	6	35	from	analysis	962:969	arg1	S. cerevisiae					1013:1025	S. cerevisiae	1013:1025	S. cerevisiae	1013:1025	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	6	35	from	analysis	962:969	arg1	S. pombe					1031:1038	S. pombe	1031:1038	S. pombe	1031:1038	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	8	36	theme	substrate	1462:1470	arg1	Determination					1317:1329	Determination	1317:1329	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition	1317:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	8	36	theme	substrate	1462:1470	arg1	docking					1419:1425	molecular docking	1409:1425	molecular docking of a branched alpha-mannopentatose substrate	1409:1470	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	0	37	theme	Architecture	24:35	arg1	Analysis					0:7	Analysis	0:7	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry	0:74	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	9	38	from	chains	1553:1558	arg1	subsites					1577:1584	the +1 and -2 subsites	1563:1584	the +1 and -2 subsites	1563:1584	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	4	39	theme	GH	783:784	arg1	family					787:792	glycoside hydrolase (GH) family 76	762:795	glycoside hydrolase (GH) family 76 (BtGH76-MD40)	762:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	39	theme	GH	783:784	arg1	BtGH76-MD40					798:808	BtGH76-MD40	798:808	BtGH76-MD40	798:808	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	3	40	theme	bovine-adapted	458:471	arg1	strains					502:508	bovine-adapted Bacteroides thetaiotaomicron strains	458:508	bovine-adapted Bacteroides thetaiotaomicron strains	458:508	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	0	41	theme	Reaction	41:48	arg1	Chemistry					66:74	Reaction Product Linkage Chemistry	41:74	Reaction Product Linkage Chemistry	41:74	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	4	42	theme	predicted	732:740	arg1	endo-mannanase					742:755	a predicted endo-mannanase	730:755	a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40)	730:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	42	theme	predicted	732:740	arg1	one					708:710	one	708:710	one	708:710	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	42	theme	predicted	732:740	arg1	enzymes					721:727	these enzymes	715:727	these enzymes	715:727	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	8	43	theme	alpha-mannopentatose	1441:1460	arg1	substrate					1462:1470	a branched alpha-mannopentatose substrate	1430:1470	a branched alpha-mannopentatose substrate	1430:1470	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	2	44	theme	branching	307:315	arg1	degree					297:302	the high degree	288:302	the high degree of branching	288:315	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31945375	1	45	theme	N-linked	215:222	arg1	α-mannan					179:186	Yeast α-mannan	173:186	Yeast α-mannan (YM)	173:191	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	1	45	theme	N-linked	215:222	arg1	glycan					224:229	a densely branched N-linked glycan	196:229	a densely branched N-linked glycan that decorates the surface of yeast cell walls	196:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	9	46	theme	reducing	1700:1707	arg1	end					1709:1711	the reducing end	1696:1711	the reducing end of the undecorated monosaccharide	1696:1745	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	6	47	theme	diverse	1131:1137	arg1	substrates					1142:1151	structurally diverse YM substrates	1118:1151	structurally diverse YM substrates	1118:1151	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	5	48	from	cerevisiae	912:921	arg1	YMs					889:891	structurally distinct YMs	867:891	structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe	867:951	Purified recombinant BtGH76-MD40 displayed activity on structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe.
31945375	7	49	theme	undecorated	1270:1280	arg1	d-mannopyranose					1282:1296	undecorated d-mannopyranose	1270:1296	undecorated d-mannopyranose in the -1 subsite	1270:1314	In addition, using two differential derivatization methods, we have shown that there is an absolute requirement for undecorated d-mannopyranose in the -1 subsite.
31945375	3	50	theme	thetaiotaomicron	485:500	arg1	strains					502:508	bovine-adapted Bacteroides thetaiotaomicron strains	458:508	bovine-adapted Bacteroides thetaiotaomicron strains	458:508	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	9	51	theme	undecorated	1720:1730	arg1	monosaccharide					1732:1745	the undecorated monosaccharide	1716:1745	the undecorated monosaccharide	1716:1745	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	3	52	theme	YM	655:656	arg1	metabolism					658:667	YM metabolism	655:667	YM metabolism	655:667	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	10	53	theme	functional	1860:1869	arg1	abilities					1871:1879	the functional abilities	1856:1879	the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems	1856:1948	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	10	54	theme	new	1806:1808	arg1	enzymes					1810:1816	new enzymes	1806:1816	new enzymes within extant pathways	1806:1839	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	7	55	from	d-mannopyranose	1282:1296	arg1	subsite					1308:1314	the -1 subsite	1301:1314	the -1 subsite	1301:1314	In addition, using two differential derivatization methods, we have shown that there is an absolute requirement for undecorated d-mannopyranose in the -1 subsite.
31945375	10	56	theme	bacteria	1898:1905	arg1	abilities					1871:1879	the functional abilities	1856:1879	the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems	1856:1948	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	9	57	theme	extended	1539:1546	arg1	chains					1553:1558	extended side chains	1539:1558	extended side chains in the +1 and -2 subsites	1539:1584	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	10	58	theme	saccharolytic	1884:1896	arg1	bacteria					1898:1905	saccharolytic bacteria	1884:1905	saccharolytic bacteria persisting in complex digestive ecosystems	1884:1948	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	9	59	theme	single	1607:1612	arg1	residue					1633:1639	a single alpha-1,6-mannosyl residue	1605:1639	a single alpha-1,6-mannosyl residue	1605:1639	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	9	59	theme	single	1607:1612	arg1	prerequisite					1646:1657	a prerequisite	1644:1657	a prerequisite for activity	1644:1670	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	0	60	theme	Diverse	150:156	arg1	Mannans					164:170	Diverse Yeast Mannans	150:170	Diverse Yeast Mannans	150:170	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	10	61	theme	digestive	1929:1937	arg1	ecosystems					1939:1948	complex digestive ecosystems	1921:1948	complex digestive ecosystems	1921:1948	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	9	62	theme	the +1	1563:1568	arg1	subsites					1577:1584	the +1 and -2 subsites	1563:1584	the +1 and -2 subsites	1563:1584	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	3	63	theme	genes	589:593	arg1	pair					581:584	a tandem pair	572:584	a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism	572:667	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	0	64	theme	Chemistry	66:74	arg1	Analysis					0:7	Analysis	0:7	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry	0:74	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	5	65	theme	recombinant	821:831	arg1	activity					855:862	recombinant BtGH76-MD40 displayed activity	821:862	recombinant BtGH76-MD40 displayed activity	821:862	Purified recombinant BtGH76-MD40 displayed activity on structurally distinct YMs from Saccharomyces cerevisiae and Schizosaccharomyces pombe.
31945375	8	66	theme	BtGH76-MD40	1338:1348	arg1	superimposition					1389:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	6	67	theme	products	999:1006	arg1	analysis					962:969	Linkage analysis	954:969	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan	954:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	8	68	theme	crystal	1356:1362	arg1	superimposition					1389:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	0	69	theme	Cleavage	96:103	arg1	Substrate					105:113	a Conserved Cleavage Substrate	84:113	a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans	84:170	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	9	70	theme	alpha-1,6-mannosyl	1614:1631	arg1	residue					1633:1639	a single alpha-1,6-mannosyl residue	1605:1639	a single alpha-1,6-mannosyl residue	1605:1639	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	9	70	theme	alpha-1,6-mannosyl	1614:1631	arg1	prerequisite					1646:1657	a prerequisite	1644:1657	a prerequisite for activity	1644:1670	In contrast, BtGH76-MD40 can accommodate extended side chains in the +1 and -2 subsites, highlighting that a single alpha-1,6-mannosyl residue is a prerequisite for activity, and cleavage occurs at the reducing end of the undecorated monosaccharide.
31945375	6	71	theme	released	974:981	arg1	products					999:1006	released oligosaccharide products	974:1006	released oligosaccharide products from S. cerevisiae and S. pombe mannan	974:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	6	72	dep	S. cerevisiae	1013:1025	arg1	mannan					1040:1045	mannan	1040:1045	mannan	1040:1045	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	8	73	theme	structural	1378:1387	arg1	superimposition					1389:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	the BtGH76-MD40 X-ray crystal structure and structural superimposition	1334:1403	Determination of the BtGH76-MD40 X-ray crystal structure and structural superimposition and molecular docking of a branched alpha-mannopentatose substrate supported these findings.
31945375	4	74	theme	enzymes	721:727	arg1	endo-mannanase					742:755	a predicted endo-mannanase	730:755	a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40)	730:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	74	theme	enzymes	721:727	arg1	one					708:710	one	708:710	one	708:710	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	74	theme	enzymes	721:727	arg1	enzymes					721:727	these enzymes	715:727	these enzymes	715:727	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	7	75	theme	derivatization	1190:1203	arg1	methods					1205:1211	two differential derivatization methods	1173:1211	two differential derivatization methods	1173:1211	In addition, using two differential derivatization methods, we have shown that there is an absolute requirement for undecorated d-mannopyranose in the -1 subsite.
31945375	6	76	theme	specific	1080:1087	arg1	linkage					1089:1095	a specific linkage	1078:1095	a specific linkage that is conserved in structurally diverse YM substrates	1078:1151	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	2	77	theme	enzymes	410:416	arg1	action					380:385	the coupled action	368:385	the coupled action of side-chain-cleaving enzymes	368:416	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31945375	2	78	theme	YM	346:347	arg1	backbone					334:341	the backbone	330:341	the backbone of YM	330:347	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31945375	0	79	theme	Site	19:22	arg1	Architecture					24:35	Active Site Architecture	12:35	Active Site Architecture	12:35	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	1	80	theme	walls	272:276	arg1	surface					250:256	the surface	246:256	the surface of yeast cell walls	246:276	Yeast α-mannan (YM) is a densely branched N-linked glycan that decorates the surface of yeast cell walls.
31945375	3	81	theme	orphan	612:617	arg1	pathway					619:625	an orphan pathway	609:625	an orphan pathway predicted to be involved in YM metabolism	609:667	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	3	82	theme	genome	438:443	arg1	sequences					445:453	the genome sequences	434:453	the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM	434:550	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	4	83	theme	glycoside	762:770	arg1	family					787:792	glycoside hydrolase (GH) family 76	762:795	glycoside hydrolase (GH) family 76 (BtGH76-MD40)	762:809	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	4	83	theme	glycoside	762:770	arg1	BtGH76-MD40					798:808	BtGH76-MD40	798:808	BtGH76-MD40	798:808	Here, we investigated the activity of one of these enzymes, a predicted endo-mannanase from glycoside hydrolase (GH) family 76 (BtGH76-MD40).
31945375	0	84	theme	Product	50:56	arg1	Chemistry					66:74	Reaction Product Linkage Chemistry	41:74	Reaction Product Linkage Chemistry	41:74	Analysis of Active Site Architecture and Reaction Product Linkage Chemistry Reveals a Conserved Cleavage Substrate for an Endo-alpha-mannanase within Diverse Yeast Mannans.
31945375	7	85	theme	the -1	1301:1306	arg1	subsite					1308:1314	the -1 subsite	1301:1314	the -1 subsite	1301:1314	In addition, using two differential derivatization methods, we have shown that there is an absolute requirement for undecorated d-mannopyranose in the -1 subsite.
31945375	3	86	theme	Bacteroides	473:483	arg1	strains					502:508	bovine-adapted Bacteroides thetaiotaomicron strains	458:508	bovine-adapted Bacteroides thetaiotaomicron strains	458:508	Upon examining the genome sequences of bovine-adapted Bacteroides thetaiotaomicron strains, isolated for their ability to degrade YM, we have identified a tandem pair of genes inserted into an orphan pathway predicted to be involved in YM metabolism.
31945375	10	87	theme	complex	1921:1927	arg1	ecosystems					1939:1948	complex digestive ecosystems	1921:1948	complex digestive ecosystems	1921:1948	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	6	88	theme	YM	1139:1140	arg1	substrates					1142:1151	structurally diverse YM substrates	1118:1151	structurally diverse YM substrates	1118:1151	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	6	89	dep	BtGH76-MD40	1058:1068	arg1	targets					1070:1076	targets	1070:1076	targets a specific linkage that is conserved in structurally diverse YM substrates	1070:1151	Linkage analysis of released oligosaccharide products from S. cerevisiae and S. pombe mannan determined BtGH76-MD40 targets a specific linkage that is conserved in structurally diverse YM substrates.
31945375	10	90	theme	extant	1825:1830	arg1	pathways					1832:1839	extant pathways	1825:1839	extant pathways	1825:1839	Collectively these results demonstrate how acquisition of new enzymes within extant pathways contributes to the functional abilities of saccharolytic bacteria persisting in complex digestive ecosystems.
31945375	2	91	theme	backbone	334:341	arg1	cleavage					318:325	cleavage	318:325	cleavage of the backbone of YM	318:347	Owing to the high degree of branching, cleavage of the backbone of YM appears to rely on the coupled action of side-chain-cleaving enzymes.
31657490	3	0	theme	L-cysteine	538:547	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	0	theme	L-cysteine	538:547	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	6	1	theme	enrichment	952:961	arg1	process					963:969	the actual enrichment process	941:969	the actual enrichment process	941:969	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	6	2	from	RESULTS	930:936	arg1	process					963:969	the actual enrichment process	941:969	the actual enrichment process	941:969	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	3	3	theme	oxide	585:589	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	3	theme	oxide	585:589	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	8	4	gly	glycopeptide	1460:1471	arg2	glycopeptide					1460:1471	glycopeptide analysis	1460:1480	glycopeptide analysis	1460:1480	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	3	5	theme	@	608:608	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	5	theme	@	608:608	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	6	6	theme	@	994:994	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	1	7	gly	Glycosylation	131:143	arg1	proteins					148:155	proteins	148:155	proteins	148:155	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	3	8	theme	@	604:604	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	8	theme	@	604:604	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	6	9	theme	@	991:991	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	9	10	with	materials	1578:1586	arg1	properties					1611:1620	better enrichment properties	1593:1620	better enrichment properties in the future	1593:1634	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	5	11	theme	enriched	737:744	arg1	peptides					746:753	The enriched peptides	733:753	The enriched peptides	733:753	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	0	12	theme	hydrophilic	30:40	arg1	composites					42:51	zwitterionic hydrophilic composites	17:51	zwitterionic hydrophilic composites	17:51	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	6	13	theme	@	978:978	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	7	14	from	enrichment	1219:1228	arg1	biosamples					1260:1269	complex biosamples	1252:1269	complex biosamples	1252:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	3	15	theme	@	621:621	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	15	theme	@	621:621	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	6	16	theme	@	974:974	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	8	17	theme	@	1402:1402	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	4	18	gly	glycopeptide	708:719	arg2	glycopeptide					708:719	glycopeptide enrichment	708:730	glycopeptide enrichment	708:730	The obtained material was used for glycopeptide enrichment.
31657490	8	19	dep	L-Cys	1419:1423	arg1	GO					1396:1397	GO	1396:1397	GO	1396:1397	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	7	20	theme	complex	1252:1258	arg1	biosamples					1260:1269	complex biosamples	1252:1269	complex biosamples	1252:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	1	21	theme	important	166:174	arg1	role					176:179	an important role	163:179	an important role	163:179	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	4	22	theme	glycopeptide	708:719	arg1	enrichment					721:730	glycopeptide enrichment	708:730	glycopeptide enrichment	708:730	The obtained material was used for glycopeptide enrichment.
31657490	0	23	theme	glycopeptides	89:101	arg1	enrichment					66:75	enhanced enrichment	57:75	enhanced enrichment of N-linked glycopeptides from human serum	57:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	1	24	gly	glycopeptides	246:258	arg2	glycopeptides					246:258	naturally occurring glycopeptides	226:258	naturally occurring glycopeptides	226:258	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	9	25	theme	new	1554:1556	arg1	ideas					1558:1562	new ideas	1554:1562	new ideas for synthetic materials with better enrichment properties in the future	1554:1634	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	6	26	theme	high	1025:1028	arg1	1:1000					1043:1048	1:1000	1043:1048	1:1000	1043:1048	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	6	26	theme	high	1025:1028	arg1	selectivity					1030:1040	high selectivity	1025:1040	high selectivity (1:1000)	1025:1049	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	0	27	theme	human	108:112	arg1	serum					114:118	human serum	108:118	human serum	108:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	9	28	gly	glycopeptides	1527:1539	arg2	glycopeptides					1527:1539	glycopeptides	1527:1539	glycopeptides	1527:1539	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	2	29	gly	glycopeptides	416:428	arg2	glycopeptides					416:428	glycopeptides	416:428	glycopeptides	416:428	Therefore, selective enrichment of glycopeptides before mass spectrometry has turned into an urgent problem to be resolved.
31657490	9	30	contain	has	1486:1488	arg2	potential					1496:1504	great potential	1490:1504	great potential in the enrichment of glycopeptides	1490:1539	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	9	30	contain	has	1486:1488	arg1	It					1483:1484	It	1483:1484	It	1483:1484	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	8	31	theme	@	1398:1398	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	7	32	theme	good	1195:1198	arg1	performance					1200:1210	good performance	1195:1210	good performance	1195:1210	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	9	33	theme	better	1593:1598	arg1	properties					1611:1620	better enrichment properties	1593:1620	better enrichment properties in the future	1593:1634	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	7	34	gly	glycopeptides	1233:1245	arg2	glycopeptides					1233:1245	glycopeptides	1233:1245	glycopeptides from complex biosamples	1233:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	7	34	gly	glycopeptides	1233:1245	arg1	biosamples					1260:1269	complex biosamples	1252:1269	complex biosamples	1252:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	0	35	theme	zwitterionic	17:28	arg1	composites					42:51	zwitterionic hydrophilic composites	17:51	zwitterionic hydrophilic composites	17:51	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	1	36	theme	microfacies	309:319	arg1	heterogeneity					321:333	microfacies heterogeneity	309:333	microfacies heterogeneity	309:333	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	1	37	contain	has	305:307	arg1	glycosylation					291:303	glycosylation	291:303	glycosylation	291:303	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	1	37	contain	has	305:307	arg2	heterogeneity					321:333	microfacies heterogeneity	309:333	microfacies heterogeneity	309:333	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	1	38	theme	RATIONALE	121:129	arg1	Glycosylation					131:143	RATIONALE Glycosylation	121:143	RATIONALE Glycosylation of proteins	121:155	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	8	39	theme	@	1415:1415	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	0	40	theme	composites	42:51	arg1	Postsynthesis					0:12	Postsynthesis	0:12	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.	0:119	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	5	41	theme	time-of-flight	824:837	arg1	MALDI-TOFMS					858:868	MALDI-TOFMS	858:868	MALDI-TOFMS	858:868	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	5	41	theme	time-of-flight	824:837	arg1	spectrometry					844:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry	780:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS)	780:869	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	8	42	dep	CONCLUSIONS	1347:1357	arg1	showed					1384:1389	showed	1384:1389	showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis	1384:1480	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	7	43	theme	human	1316:1320	arg1	serum					1322:1326	human serum	1316:1326	human serum using MALDI-TOFMS	1316:1344	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	5	44	theme	matrix-assisted	780:794	arg1	MALDI-TOFMS					858:868	MALDI-TOFMS	858:868	MALDI-TOFMS	858:868	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	5	44	theme	matrix-assisted	780:794	arg1	spectrometry					844:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry	780:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS)	780:869	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	8	45	theme	@	1418:1418	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	0	46	theme	enhanced	57:64	arg1	enrichment					66:75	enhanced enrichment	57:75	enhanced enrichment of N-linked glycopeptides from human serum	57:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	1	47	theme	direct	339:344	arg1	spectrometry					351:362	direct mass spectrometry	339:362	direct mass spectrometry	339:362	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	0	48	link	N-linked	80:87	arg1	glycopeptides					89:101	N-linked glycopeptides	80:101	N-linked glycopeptides from human serum	80:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	6	49	theme	glycopeptides	1138:1150	arg1	enrichment					1124:1133	the enrichment	1120:1133	the enrichment of glycopeptides	1120:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	1	50	theme	occurring	236:244	arg1	glycopeptides					246:258	naturally occurring glycopeptides	226:258	naturally occurring glycopeptides	226:258	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	6	51	theme	outstanding	1052:1062	arg1	sensitivity					1064:1074	outstanding sensitivity	1052:1074	outstanding sensitivity (0.5 fmol)	1052:1085	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	6	51	theme	outstanding	1052:1062	arg1	fmol					1081:1084	0.5 fmol	1077:1084	0.5 fmol	1077:1084	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	3	52	theme	functionalized	549:562	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	52	theme	functionalized	549:562	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	53	theme	zwitterionic	525:536	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	53	theme	zwitterionic	525:536	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	7	54	from	biosamples	1260:1269	arg1	glycopeptides					1233:1245	glycopeptides	1233:1245	glycopeptides from complex biosamples	1233:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	7	54	from	biosamples	1260:1269	arg1	enrichment					1219:1228	the enrichment	1215:1228	the enrichment of glycopeptides from complex biosamples	1215:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	6	55	theme	excellent	1092:1100	arg1	repeatability					1102:1114	excellent repeatability	1092:1114	excellent repeatability for the enrichment of glycopeptides	1092:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	6	56	theme	actual	945:950	arg1	process					963:969	the actual enrichment process	941:969	the actual enrichment process	941:969	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	3	57	theme	graphene	576:583	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	57	theme	graphene	576:583	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	1	58	theme	life	184:187	arg1	activities					189:198	life activities	184:198	life activities	184:198	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	5	59	theme	desorption	802:811	arg1	MALDI-TOFMS					858:868	MALDI-TOFMS	858:868	MALDI-TOFMS	858:868	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	5	59	theme	desorption	802:811	arg1	spectrometry					844:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry	780:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS)	780:869	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	7	60	theme	glycopeptides	1233:1245	arg1	enrichment					1219:1228	the enrichment	1215:1228	the enrichment of glycopeptides from complex biosamples	1215:1269	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	3	61	theme	PDA	605:607	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	61	theme	PDA	605:607	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	5	62	theme	material	920:927	arg1	performance					901:911	the enrichment performance	886:911	the enrichment performance of the material	886:927	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	6	63	theme	L-Cys	995:999	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	4	64	theme	obtained	677:684	arg1	material					686:693	The obtained material	673:693	The obtained material	673:693	The obtained material was used for glycopeptide enrichment.
31657490	3	65	theme	GO	602:603	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	65	theme	GO	602:603	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	6	66	theme	Au	992:993	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	8	67	theme	glycopeptide	1460:1471	arg1	analysis					1473:1480	glycopeptide analysis	1460:1480	glycopeptide analysis	1460:1480	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	3	68	theme	Au	622:623	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	68	theme	Au	622:623	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	5	69	theme	enrichment	890:899	arg1	performance					901:911	the enrichment performance	886:911	the enrichment performance of the material	886:927	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	6	70	theme	MIL-125-NH2	979:989	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	3	71	theme	MIL-125-NH2	609:619	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	71	theme	MIL-125-NH2	609:619	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	6	72	theme	PDA	975:977	arg1	nanomaterials					1001:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials	974:1013	@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides	974:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	1	73	theme	proteins	148:155	arg1	Glycosylation					131:143	RATIONALE Glycosylation	121:143	RATIONALE Glycosylation of proteins	121:155	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	9	74	from	properties	1611:1620	arg1	future					1629:1634	future	1629:1634	future	1629:1634	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	0	75	from	serum	114:118	arg1	glycopeptides					89:101	N-linked glycopeptides	80:101	N-linked glycopeptides from human serum	80:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	0	75	from	serum	114:118	arg1	enrichment					66:75	enhanced enrichment	57:75	enhanced enrichment of N-linked glycopeptides from human serum	57:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	0	76	theme	N-linked	80:87	arg1	glycopeptides					89:101	N-linked glycopeptides	80:101	N-linked glycopeptides from human serum	80:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	9	77	theme	glycopeptides	1527:1539	arg1	enrichment					1513:1522	the enrichment	1509:1522	the enrichment of glycopeptides	1509:1539	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	5	78	theme	laser	796:800	arg1	MALDI-TOFMS					858:868	MALDI-TOFMS	858:868	MALDI-TOFMS	858:868	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	5	78	theme	laser	796:800	arg1	spectrometry					844:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry	780:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS)	780:869	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	3	79	dep	METHODS	505:511	arg1	prepared					636:643	prepared	636:643	was prepared via a postsynthetic method	632:670	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	0	80	from	enrichment	66:75	arg1	serum					114:118	human serum	108:118	human serum	108:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	8	81	theme	experimental	1363:1374	arg1	results					1376:1382	The experimental results	1359:1382	The experimental results	1359:1382	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	0	82	gly	glycopeptides	89:101	arg1	serum					114:118	human serum	108:118	human serum	108:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	0	82	gly	glycopeptides	89:101	arg2	glycopeptides					89:101	N-linked glycopeptides	80:101	N-linked glycopeptides from human serum	80:118	Postsynthesis of zwitterionic hydrophilic composites for enhanced enrichment of N-linked glycopeptides from human serum.
31657490	2	83	theme	glycopeptides	416:428	arg1	enrichment					402:411	selective enrichment	392:411	selective enrichment of glycopeptides before mass spectrometry	392:453	Therefore, selective enrichment of glycopeptides before mass spectrometry has turned into an urgent problem to be resolved.
31657490	2	84	theme	urgent	474:479	arg1	problem					481:487	an urgent problem	471:487	an urgent problem	471:487	Therefore, selective enrichment of glycopeptides before mass spectrometry has turned into an urgent problem to be resolved.
31657490	6	85	gly	glycopeptides	1138:1150	arg2	glycopeptides					1138:1150	glycopeptides	1138:1150	glycopeptides	1138:1150	RESULTS In the actual enrichment process, GO@PDA@MIL-125-NH2 @Au@L-Cys nanomaterials exhibited high selectivity (1:1000), outstanding sensitivity (0.5 fmol), and excellent repeatability for the enrichment of glycopeptides.
31657490	7	86	theme	proposed	1170:1177	arg1	material					1179:1186	the proposed material	1166:1186	the proposed material	1166:1186	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	7	87	gly	glycopeptides	1275:1287	arg2	glycopeptides					1275:1287	56 glycopeptides	1272:1287	56 glycopeptides	1272:1287	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	4	88	used	used	699:702	arg2	material					686:693	The obtained material	673:693	The obtained material	673:693	The obtained material was used for glycopeptide enrichment.
31657490	9	89	theme	enrichment	1600:1609	arg1	properties					1611:1620	better enrichment properties	1593:1620	better enrichment properties in the future	1593:1634	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	7	90	theme	serum	1322:1326	arg1	2 μL					1308:1311	2 μL	1308:1311	2 μL of human serum using MALDI-TOFMS	1308:1344	In addition, the proposed material showed good performance in the enrichment of glycopeptides from complex biosamples; 56 glycopeptides were detected from 2 μL of human serum using MALDI-TOFMS.
31657490	9	91	theme	synthetic	1568:1576	arg1	materials					1578:1586	synthetic materials	1568:1586	synthetic materials with better enrichment properties in the future	1568:1634	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	3	92	theme	postsynthetic	651:663	arg1	method					665:670	a postsynthetic method	649:670	a postsynthetic method	649:670	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	8	93	theme	PDA	1399:1401	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	2	94	theme	selective	392:400	arg1	enrichment					402:411	selective enrichment	392:411	selective enrichment of glycopeptides before mass spectrometry	392:453	Therefore, selective enrichment of glycopeptides before mass spectrometry has turned into an urgent problem to be resolved.
31657490	5	95	theme	ionization	813:822	arg1	MALDI-TOFMS					858:868	MALDI-TOFMS	858:868	MALDI-TOFMS	858:868	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	5	95	theme	ionization	813:822	arg1	spectrometry					844:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry	780:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS)	780:869	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	9	96	theme	great	1490:1494	arg1	potential					1496:1504	great potential	1490:1504	great potential in the enrichment of glycopeptides	1490:1539	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	8	97	theme	MIL-125-NH2	1403:1413	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	2	98	theme	mass	437:440	arg1	spectrometry					442:453	mass spectrometry	437:453	mass spectrometry	437:453	Therefore, selective enrichment of glycopeptides before mass spectrometry has turned into an urgent problem to be resolved.
31657490	5	99	theme	mass	839:842	arg1	MALDI-TOFMS					858:868	MALDI-TOFMS	858:868	MALDI-TOFMS	858:868	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	5	99	theme	mass	839:842	arg1	spectrometry					844:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry	780:855	matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS)	780:869	The enriched peptides were then detected using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOFMS) to demonstrate the enrichment performance of the material.
31657490	9	100	from	potential	1496:1504	arg1	enrichment					1513:1522	the enrichment	1509:1522	the enrichment of glycopeptides	1509:1539	It has great potential in the enrichment of glycopeptides and provides new ideas for synthetic materials with better enrichment properties in the future.
31657490	8	101	theme	Au	1416:1417	arg1	L-Cys					1419:1423	@PDA@MIL-125-NH2 @Au@L-Cys	1398:1423	GO@PDA@MIL-125-NH2 @Au@L-Cys	1396:1423	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	1	102	theme	mass	346:349	arg1	spectrometry					351:362	direct mass spectrometry	339:362	direct mass spectrometry	339:362	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	3	103	theme	@	624:624	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	103	theme	@	624:624	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	1	104	theme	glycopeptides	246:258	arg1	concentration					209:221	the concentration	205:221	the concentration of naturally occurring glycopeptides	205:258	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	1	104	theme	glycopeptides	246:258	arg1	low					282:284	low	282:284	low	282:284	RATIONALE Glycosylation of proteins plays an important role in life activities, but the concentration of naturally occurring glycopeptides is usually relatively low, and glycosylation has microfacies heterogeneity, so direct mass spectrometry is not feasible.
31657490	8	105	theme	excellent	1435:1443	arg1	performance					1445:1455	excellent performance	1435:1455	excellent performance	1435:1455	CONCLUSIONS The experimental results showed that GO@PDA@MIL-125-NH2 @Au@L-Cys exhibited excellent performance on glycopeptide analysis.
31657490	3	106	theme	hydrophilic	564:574	arg1	composite					591:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite	521:599	the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys)	521:630	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
31657490	3	106	theme	hydrophilic	564:574	arg1	L-Cys					625:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	GO@PDA@MIL-125-NH2 @Au@L-Cys	602:629	METHODS Herein, the zwitterionic L-cysteine functionalized hydrophilic graphene oxide composite (GO@PDA@MIL-125-NH2 @Au@L-Cys) was prepared via a postsynthetic method.
33381907	2	0	link	N-linked	294:301	arg1	glycosylation					303:315	N-linked glycosylation	294:315	N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid	294:387	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	9	1	theme	urinary	1519:1525	arg1	albumin					1527:1533	urinary albumin	1519:1533	urinary albumin	1519:1533	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	2	2	theme	amino	329:333	arg1	acid					335:338	the 14th amino acid	320:338	the 14th amino acid	320:338	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	4	3	theme	islet	526:530	arg1	cells					532:536	islet cells	526:536	islet cells in the pancreas	526:552	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	5	4	theme	diabetes	818:825	arg1	DM					837:838	DM	837:838	DM	837:838	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	5	4	theme	diabetes	818:825	arg1	mellitus					827:834	diabetes mellitus	818:834	diabetes mellitus (DM)	818:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	5	5	with	patients	804:811	arg1	DM					837:838	DM	837:838	DM	837:838	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	5	5	with	patients	804:811	arg1	mellitus					827:834	diabetes mellitus	818:834	diabetes mellitus (DM)	818:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	2	6	from	glycosylation	303:315	arg1	acid					335:338	the 14th amino acid	320:338	the 14th amino acid	320:338	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	2	6	from	glycosylation	303:315	arg1	cysteine					346:353	a cysteine	344:353	a cysteine conjugated to the 18th amino acid	344:387	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	1	7	theme	angiotensin-related	143:161	arg1	peptide					163:169	an angiotensin-related peptide	140:169	an angiotensin-related peptide isolated from human urine	140:195	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	1	7	theme	angiotensin-related	143:161	arg1	angiotensin-25					114:127	Big angiotensin-25	110:127	Big angiotensin-25 (Bang-25)	110:137	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	9	8	from	concentration	1418:1430	arg1	urine					1439:1443	the urine	1435:1443	the urine	1435:1443	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	6	9	theme	Homogeneous	893:903	arg1	Assay					905:909	Luminescent Proximity Homogeneous Assay	871:909	Luminescent Proximity Homogeneous Assay	871:909	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	7	10	theme	urine	1214:1218	arg1	samples					1220:1226	urine samples	1214:1226	healthy volunteers' urine samples	1194:1226	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	10	11	theme	urinary	1591:1597	arg1	Bang-25					1599:1605	urinary Bang-25	1591:1605	urinary Bang-25	1591:1605	This assay could provide a useful tool for determining urinary Bang-25, which may prove an important biomarker for diabetic kidney disease.
33381907	5	12	from	patients	804:811	arg1	concentrations					775:788	the urinary concentrations	763:788	the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM)	763:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	7	13	theme	healthy	1194:1200	arg1	volunteers					1202:1211	healthy volunteers	1194:1211	healthy volunteers' urine samples	1194:1226	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	6	14	theme	Ang	1025:1027	arg1	N-terminus					1011:1020	the N-terminus	1007:1020	the N-terminus of Ang II	1007:1030	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	14	theme	Ang	1025:1027	arg1	C-terminus					1040:1049	the C-terminus	1036:1049	the C-terminus of Bang-25	1036:1060	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	15	theme	Proximity	883:891	arg1	Assay					905:909	Luminescent Proximity Homogeneous Assay	871:909	Luminescent Proximity Homogeneous Assay	871:909	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	4	16	from	cells	532:536	arg1	kidney					575:580	the kidney	571:580	the kidney	571:580	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	4	16	from	cells	532:536	arg1	pancreas					545:552	the pancreas	541:552	the pancreas	541:552	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	9	17	theme	different	1457:1465	arg1	perspective					1467:1477	a different perspective	1455:1477	a different perspective on disease status from that provided by urinary albumin	1455:1533	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	6	18	theme	Bang-25	1054:1060	arg1	N-terminus					1011:1020	the N-terminus	1007:1020	the N-terminus of Ang II	1007:1030	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	18	theme	Bang-25	1054:1060	arg1	C-terminus					1040:1049	the C-terminus	1036:1049	the C-terminus of Bang-25	1036:1060	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	2	19	theme	angiotensinogen	264:278	arg1	N-terminus					250:259	the N-terminus	246:259	the N-terminus of angiotensinogen (Aogen)	246:286	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	4	20	theme	production	637:646	arg1	system					648:653	the Ang II production system	626:653	the Ang II production system	626:653	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	5	21	from	Bang-25	793:799	arg1	patients					804:811	patients	804:811	patients with diabetes mellitus (DM)	804:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	5	22	used	used	744:747	arg2	we					698:699	we	698:699	we	698:699	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	6	23	theme	Japan	965:969	arg1	AlphaLISA					939:947	AlphaLISA	939:947	AlphaLISA	939:947	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	23	theme	Japan	965:969	arg1	method					931:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method	857:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan	857:969	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	24	theme	Luminescent	871:881	arg1	Assay					905:909	Luminescent Proximity Homogeneous Assay	871:909	Luminescent Proximity Homogeneous Assay	871:909	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	25	dep	-based	918:923	arg1	Assay					905:909	Luminescent Proximity Homogeneous Assay	871:909	Luminescent Proximity Homogeneous Assay	871:909	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	2	26	theme	N-terminus	250:259	arg1	acids					237:241	the first 25 amino acids	218:241	the first 25 amino acids of the N-terminus of angiotensinogen (Aogen)	218:286	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	5	27	theme	specific	713:720	arg1	assay					722:726	a specific assay	711:726	a specific assay for Bang-25	711:738	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	8	28	with	patients	1264:1271	arg1	DM					1278:1279	DM	1278:1279	DM	1278:1279	In patients with DM, the urinary Bang-25 concentration was significantly higher than in healthy volunteers.
33381907	6	29	theme	Amplified	861:869	arg1	AlphaLISA					939:947	AlphaLISA	939:947	AlphaLISA	939:947	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	29	theme	Amplified	861:869	arg1	method					931:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method	857:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan	857:969	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	10	30	theme	kidney	1660:1665	arg1	disease					1667:1673	diabetic kidney disease	1651:1673	diabetic kidney disease	1651:1673	This assay could provide a useful tool for determining urinary Bang-25, which may prove an important biomarker for diabetic kidney disease.
33381907	9	31	from	that	1502:1505	arg1	status					1490:1495	disease status	1482:1495	disease status from that provided by urinary albumin	1482:1533	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	5	32	theme	urinary	767:773	arg1	concentrations					775:788	the urinary concentrations	763:788	the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM)	763:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	4	33	theme	human	501:505	arg1	cells					532:536	islet cells	526:536	islet cells in the pancreas	526:552	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	4	33	theme	human	501:505	arg1	tissues					507:513	human tissues	501:513	human tissues	501:513	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	4	33	theme	human	501:505	arg1	podocytes					558:566	podocytes	558:566	podocytes in the kidney	558:580	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	10	34	theme	useful	1563:1568	arg1	tool					1570:1573	a useful tool	1561:1573	a useful tool for determining urinary Bang-25, which may prove an important biomarker for diabetic kidney disease	1561:1673	This assay could provide a useful tool for determining urinary Bang-25, which may prove an important biomarker for diabetic kidney disease.
33381907	10	35	theme	diabetic	1651:1658	arg1	disease					1667:1673	diabetic kidney disease	1651:1673	diabetic kidney disease	1651:1673	This assay could provide a useful tool for determining urinary Bang-25, which may prove an important biomarker for diabetic kidney disease.
33381907	1	36	theme	human	185:189	arg1	urine					191:195	human urine	185:195	human urine	185:195	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	0	37	theme	novel	17:21	arg1	ImmunoAssay					33:43	a novel AlphaLISA ImmunoAssay	15:43	a novel AlphaLISA ImmunoAssay for Big angiotensin-25	15:66	Development of a novel AlphaLISA ImmunoAssay for Big angiotensin-25.
33381907	1	38	attach	isolated	171:178	arg2	peptide					163:169	an angiotensin-related peptide	140:169	an angiotensin-related peptide isolated from human urine	140:195	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	1	38	attach	isolated	171:178	arg2	angiotensin-25					114:127	Big angiotensin-25	110:127	Big angiotensin-25 (Bang-25)	110:137	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	1	38	attach	isolated	171:178	arg1	urine					191:195	human urine	185:195	human urine	185:195	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	2	39	theme	14th	324:327	arg1	acid					335:338	the 14th amino acid	320:338	the 14th amino acid	320:338	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	9	40	theme	Bang-25	1410:1416	arg1	concentration					1418:1430	the Bang-25 concentration	1406:1430	the Bang-25 concentration in the urine	1406:1443	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	2	41	theme	amino	378:382	arg1	acid					384:387	the 18th amino acid	369:387	the 18th amino acid	369:387	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	0	42	theme	ImmunoAssay	33:43	arg1	Development					0:10	Development	0:10	Development of a novel AlphaLISA ImmunoAssay for Big angiotensin-25.	0:67	Development of a novel AlphaLISA ImmunoAssay for Big angiotensin-25.
33381907	4	43	theme	Ang	630:632	arg1	system					648:653	the Ang II production system	626:653	the Ang II production system	626:653	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	7	44	theme	AlphaLISA	1067:1075	arg1	ImmunoAssay					1077:1087	The AlphaLISA ImmunoAssay	1063:1087	The AlphaLISA ImmunoAssay	1063:1087	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	7	45	dep	volunteers	1202:1211	arg1	samples					1220:1226	urine samples	1214:1226	healthy volunteers' urine samples	1194:1226	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	0	46	theme	AlphaLISA	23:31	arg1	ImmunoAssay					33:43	a novel AlphaLISA ImmunoAssay	15:43	a novel AlphaLISA ImmunoAssay for Big angiotensin-25	15:66	Development of a novel AlphaLISA ImmunoAssay for Big angiotensin-25.
33381907	7	47	located	detected	1182:1189	arg2	I.					1167:1168	I.	1167:1168	I.	1167:1168	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	7	47	located	detected	1182:1189	arg2	Aogen					1154:1158	Aogen	1154:1158	Aogen	1154:1158	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	7	47	located	detected	1182:1189	arg1	volunteers					1202:1211	healthy volunteers	1194:1211	healthy volunteers' urine samples	1194:1226	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	2	48	theme	first	222:226	arg1	acids					237:241	the first 25 amino acids	218:241	the first 25 amino acids of the N-terminus of angiotensinogen (Aogen)	218:286	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	6	49	theme	ELISA	925:929	arg1	AlphaLISA					939:947	AlphaLISA	939:947	AlphaLISA	939:947	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	49	theme	ELISA	925:929	arg1	method					931:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method	857:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan	857:969	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	0	50	theme	Big	49:51	arg1	angiotensin-25					53:66	Big angiotensin-25	49:66	Big angiotensin-25	49:66	Development of a novel AlphaLISA ImmunoAssay for Big angiotensin-25.
33381907	7	51	theme	plasma	1245:1250	arg1	samples					1252:1258	their plasma samples	1239:1258	their plasma samples	1239:1258	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	1	52	theme	Big	110:112	arg1	peptide					163:169	an angiotensin-related peptide	140:169	an angiotensin-related peptide isolated from human urine	140:195	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	1	52	theme	Big	110:112	arg1	Bang-25					130:136	Bang-25	130:136	Bang-25	130:136	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	1	52	theme	Big	110:112	arg1	angiotensin-25					114:127	Big angiotensin-25	110:127	Big angiotensin-25 (Bang-25)	110:137	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	6	53	used	used	852:855	arg2	assay					846:850	The assay	842:850	The assay	842:850	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	8	54	theme	healthy	1349:1355	arg1	volunteers					1357:1366	healthy volunteers	1349:1366	healthy volunteers	1349:1366	In patients with DM, the urinary Bang-25 concentration was significantly higher than in healthy volunteers.
33381907	1	55	theme	angiotensin-25	114:127	arg1	discovery					97:105	the discovery	93:105	the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine	93:195	We previously described the discovery of Big angiotensin-25 (Bang-25), an angiotensin-related peptide isolated from human urine.
33381907	8	56	theme	Bang-25	1294:1300	arg1	higher					1334:1339	higher	1334:1339	higher	1334:1339	In patients with DM, the urinary Bang-25 concentration was significantly higher than in healthy volunteers.
33381907	8	56	theme	Bang-25	1294:1300	arg1	concentration					1302:1314	the urinary Bang-25 concentration	1282:1314	the urinary Bang-25 concentration	1282:1314	In patients with DM, the urinary Bang-25 concentration was significantly higher than in healthy volunteers.
33381907	9	57	theme	disease	1482:1488	arg1	status					1490:1495	disease status	1482:1495	disease status from that provided by urinary albumin	1482:1533	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	8	58	theme	urinary	1286:1292	arg1	higher					1334:1339	higher	1334:1339	higher	1334:1339	In patients with DM, the urinary Bang-25 concentration was significantly higher than in healthy volunteers.
33381907	8	58	theme	urinary	1286:1292	arg1	concentration					1302:1314	the urinary Bang-25 concentration	1282:1314	the urinary Bang-25 concentration	1282:1314	In patients with DM, the urinary Bang-25 concentration was significantly higher than in healthy volunteers.
33381907	6	59	theme	-based	918:923	arg1	AlphaLISA					939:947	AlphaLISA	939:947	AlphaLISA	939:947	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	6	59	theme	-based	918:923	arg1	method					931:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method	857:936	the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan	857:969	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	2	60	gly	glycosylation	303:315	arg1	acid					335:338	the 14th amino acid	320:338	the 14th amino acid	320:338	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	2	60	gly	glycosylation	303:315	arg1	cysteine					346:353	a cysteine	344:353	a cysteine conjugated to the 18th amino acid	344:387	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	10	61	theme	important	1627:1635	arg1	biomarker					1637:1645	an important biomarker	1624:1645	an important biomarker for diabetic kidney disease	1624:1673	This assay could provide a useful tool for determining urinary Bang-25, which may prove an important biomarker for diabetic kidney disease.
33381907	2	62	theme	N-linked	294:301	arg1	glycosylation					303:315	N-linked glycosylation	294:315	N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid	294:387	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	4	63	from	podocytes	558:566	arg1	kidney					575:580	the kidney	571:580	the kidney	571:580	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	4	63	from	podocytes	558:566	arg1	pancreas					545:552	the pancreas	541:552	the pancreas	541:552	Because Bang-25 is widely distributed in human tissues, including islet cells in the pancreas and podocytes in the kidney, we hypothesized that it may participate in the Ang II production system in these tissues.
33381907	9	64	from	perspective	1467:1477	arg1	status					1490:1495	disease status	1482:1495	disease status from that provided by urinary albumin	1482:1533	Moreover, the results indicated that the Bang-25 concentration in the urine may offer a different perspective on disease status from that provided by urinary albumin.
33381907	5	65	from	concentrations	775:788	arg1	patients					804:811	patients	804:811	patients with diabetes mellitus (DM)	804:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33381907	6	66	theme	specific	995:1002	arg1	antibodies					984:993	antibodies	984:993	antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25	984:1060	The assay used the Amplified Luminescent Proximity Homogeneous Assay (Alpha)-based ELISA method (AlphaLISA) of PerkinElmer Japan and included antibodies specific to the N-terminus of Ang II and the C-terminus of Bang-25.
33381907	2	67	theme	amino	231:235	arg1	acids					237:241	the first 25 amino acids	218:241	the first 25 amino acids of the N-terminus of angiotensinogen (Aogen)	218:286	Bang-25 consists of the first 25 amino acids of the N-terminus of angiotensinogen (Aogen), with N-linked glycosylation on the 14th amino acid and a cysteine conjugated to the 18th amino acid.
33381907	7	68	contain	had	1125:1127	arg1	ImmunoAssay					1077:1087	The AlphaLISA ImmunoAssay	1063:1087	The AlphaLISA ImmunoAssay	1063:1087	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	7	68	contain	had	1125:1127	arg2	cross-reactivity					1132:1147	no cross-reactivity	1129:1147	no cross-reactivity	1129:1147	The AlphaLISA ImmunoAssay specifically recognized Bang-25 and had no cross-reactivity with Aogen or Ang I. Bang-25 was detected in healthy volunteers' urine samples but not in their plasma samples.
33381907	5	69	theme	Bang-25	793:799	arg1	concentrations					775:788	the urinary concentrations	763:788	the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM)	763:839	To test this hypothesis, we developed a specific assay for Bang-25 and used it to examine the urinary concentrations of Bang-25 in patients with diabetes mellitus (DM).
33268543	4	0	theme	human	689:693	arg1	neurons					695:701	human neurons	689:701	human neurons	689:701	However, it remained unclear how these mutations might alter the molecular properties of NLGN4 and affect synaptic transmission in human neurons.
33268543	2	1	theme	amino	343:347	arg1	sequence					354:361	a unique amino acid sequence	334:361	a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents	334:424	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
33268543	9	2	theme	male	1333:1336	arg1	lines					1348:1352	male stem cell lines	1333:1352	male stem cell lines	1333:1352	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	8	3	from	retention	1243:1251	arg1	reticulum					1272:1280	the endoplasmic reticulum	1256:1280	the endoplasmic reticulum	1256:1280	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	8	3	from	retention	1243:1251	arg1	apparatus					1292:1300	Golgi apparatus	1286:1300	Golgi apparatus	1286:1300	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	2	4	theme	unique	336:341	arg1	sequence					354:361	a unique amino acid sequence	334:361	a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents	334:424	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
33268543	4	5	from	transmission	673:684	arg1	neurons					695:701	human neurons	689:701	human neurons	689:701	However, it remained unclear how these mutations might alter the molecular properties of NLGN4 and affect synaptic transmission in human neurons.
33268543	1	6	theme	synapse	263:269	arg1	function					271:278	synapse function	263:278	synapse function	263:278	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	6	7	theme	R101Q	860:864	arg1	mutation					866:873	the R101Q mutation	856:873	the R101Q mutation in NLGN4	856:882	When expressed in HEK293 cells, the R101Q mutation in NLGN4 did not affect its binding affinity for NRXNs or its capacity to form homodimers.
33268543	7	8	theme	N-linked	1045:1052	arg1	glycosylation					1054:1066	N-linked glycosylation	1045:1066	N-linked glycosylation	1045:1066	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	8	9	theme	endoplasmic	1260:1270	arg1	reticulum					1272:1280	the endoplasmic reticulum	1256:1280	the endoplasmic reticulum	1256:1280	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	4	10	theme	NLGN4	647:651	arg1	properties					633:642	the molecular properties	619:642	the molecular properties of NLGN4	619:651	However, it remained unclear how these mutations might alter the molecular properties of NLGN4 and affect synaptic transmission in human neurons.
33268543	9	11	theme	cell	1343:1346	arg1	lines					1348:1352	male stem cell lines	1333:1352	male stem cell lines	1333:1352	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	0	12	theme	Human	114:118	arg1	Neurons					120:126	Human Neurons	114:126	Human Neurons	114:126	An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons.
33268543	9	13	theme	NLGN4	1426:1430	arg1	localization					1410:1421	the synaptic localization	1397:1421	the synaptic localization of NLGN4	1397:1430	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	3	14	with	patients	497:504	arg1	disorders					547:555	other neurodevelopmental disorders	522:555	other neurodevelopmental disorders	522:555	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	3	14	with	patients	497:504	arg1	autism					511:516	autism	511:516	autism	511:516	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	3	15	theme	other	522:526	arg1	disorders					547:555	other neurodevelopmental disorders	522:555	other neurodevelopmental disorders	522:555	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	6	16	from	mutation	866:873	arg1	NLGN4					878:882	NLGN4	878:882	NLGN4	878:882	When expressed in HEK293 cells, the R101Q mutation in NLGN4 did not affect its binding affinity for NRXNs or its capacity to form homodimers.
33268543	10	17	theme	trafficking	1498:1508	arg1	defect					1510:1515	This mutation-induced trafficking defect	1476:1515	This mutation-induced trafficking defect	1476:1515	This mutation-induced trafficking defect substantially diminished the ability of NLGN4 to form excitatory synapses and modulate their functional properties.
33268543	11	18	theme	synaptic	1735:1742	arg1	dysfunction					1744:1754	synaptic dysfunction	1735:1754	synaptic dysfunction in autism	1735:1764	Viewed together, our findings suggest that the R101Q mutation is pathogenic for NLGN4 and can lead to synaptic dysfunction in autism.
33268543	9	19	attach	derived	1320:1326	arg2	neurons					1312:1318	human neurons	1306:1318	human neurons derived from male stem cell lines	1306:1352	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	9	19	attach	derived	1320:1326	arg1	lines					1348:1352	male stem cell lines	1333:1352	male stem cell lines	1333:1352	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	9	20	theme	R101Q	1359:1363	arg1	mutation					1365:1372	the R101Q mutation	1355:1372	the R101Q mutation	1355:1372	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	1	21	theme	cell	177:180	arg1	molecules					191:199	postsynaptic cell adhesion molecules	164:199	postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function	164:278	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	7	22	theme	adjacent	1074:1081	arg1	N102					1092:1095	N102	1092:1095	N102	1092:1095	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	7	22	theme	adjacent	1074:1081	arg1	residue					1083:1089	an adjacent residue	1071:1089	an adjacent residue (N102)	1071:1096	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	1	23	theme	adhesion	182:189	arg1	molecules					191:199	postsynaptic cell adhesion molecules	164:199	postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function	164:278	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	0	24	theme	Autism-Associated	3:19	arg1	Mutation					21:28	An Autism-Associated Mutation	0:28	An Autism-Associated Mutation	0:28	An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons.
33268543	6	25	theme	HEK293	842:847	arg1	cells					849:853	HEK293 cells	842:853	HEK293 cells	842:853	When expressed in HEK293 cells, the R101Q mutation in NLGN4 did not affect its binding affinity for NRXNs or its capacity to form homodimers.
33268543	7	26	theme	NLGN4	1017:1021	arg1	protein					1023:1029	NLGN4 protein	1017:1029	NLGN4 protein	1017:1029	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	5	27	theme	autistic	733:740	arg1	patient					747:753	a severely autistic male patient	722:753	a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene	722:821	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	2	28	theme	family	311:316	arg1	NLGN4					281:285	NLGN4	281:285	NLGN4	281:285	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
33268543	2	28	theme	family	311:316	arg1	member					292:297	a member	290:297	a member of the NLGN family	290:316	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
33268543	1	29	theme	molecules	191:199	arg1	class					155:159	a class	153:159	a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function	153:278	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	1	29	theme	molecules	191:199	arg1	Neuroligins					129:139	Neuroligins	129:139	Neuroligins (NLGNs)	129:147	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	10	30	theme	NLGN4	1557:1561	arg1	ability					1546:1552	the ability	1542:1552	the ability of NLGN4 to form excitatory synapses and modulate their functional properties	1542:1630	This mutation-induced trafficking defect substantially diminished the ability of NLGN4 to form excitatory synapses and modulate their functional properties.
33268543	7	31	theme	protein	1023:1029	arg1	maturation					1003:1012	the maturation	999:1012	the maturation of NLGN4 protein	999:1029	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	2	32	from	sequence	354:361	arg1	humans					366:371	humans	366:371	humans	366:371	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
33268543	2	33	theme	NLGN	306:309	arg1	family					311:316	the NLGN family	302:316	the NLGN family	302:316	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
33268543	8	34	theme	R101Q	1149:1153	arg1	substitution					1155:1166	the R101Q substitution	1145:1166	the R101Q substitution	1145:1166	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	5	35	theme	NLGN4	812:816	arg1	gene					818:821	the NLGN4 gene	808:821	the NLGN4 gene	808:821	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	8	36	theme	NLGN4	1219:1223	arg1	trafficking					1204:1214	the surface trafficking	1192:1214	the surface trafficking of NLGN4	1192:1223	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	8	36	theme	NLGN4	1219:1223	arg1	result					1137:1142	a result	1135:1142	a result	1135:1142	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	3	37	theme	neurodevelopmental	528:545	arg1	disorders					547:555	other neurodevelopmental disorders	522:555	other neurodevelopmental disorders	522:555	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	7	38	link	N-linked	1045:1052	arg1	glycosylation					1054:1066	N-linked glycosylation	1045:1066	N-linked glycosylation	1045:1066	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	8	39	theme	Golgi	1286:1290	arg1	apparatus					1292:1300	Golgi apparatus	1286:1300	Golgi apparatus	1286:1300	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	7	40	dep	inhibiting	1034:1043	arg1	conserved					1108:1116	conserved	1108:1116	is conserved in all NLGNs	1105:1129	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	1	41	theme	postsynaptic	164:175	arg1	molecules					191:199	postsynaptic cell adhesion molecules	164:199	postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function	164:278	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	10	42	theme	excitatory	1571:1580	arg1	synapses					1582:1589	excitatory synapses	1571:1589	excitatory synapses	1571:1589	This mutation-induced trafficking defect substantially diminished the ability of NLGN4 to form excitatory synapses and modulate their functional properties.
33268543	6	43	theme	binding	903:909	arg1	affinity					911:918	its binding affinity	899:918	its binding affinity for NRXNs	899:928	When expressed in HEK293 cells, the R101Q mutation in NLGN4 did not affect its binding affinity for NRXNs or its capacity to form homodimers.
33268543	0	44	from	Transmission	98:109	arg1	Neurons					120:126	Human Neurons	114:126	Human Neurons	114:126	An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons.
33268543	1	45	theme	presynaptic	220:230	arg1	NRXNs					243:247	NRXNs	243:247	NRXNs	243:247	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	1	45	theme	presynaptic	220:230	arg1	neurexins					232:240	presynaptic neurexins	220:240	presynaptic neurexins (NRXNs)	220:248	Neuroligins (NLGNs) are a class of postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) and regulate synapse function.
33268543	0	46	theme	Neuroligin-4	38:49	arg1	Glycosylation					51:63	Neuroligin-4 Glycosylation	38:63	Neuroligin-4 Glycosylation	38:63	An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons.
33268543	5	47	theme	single	766:771	arg1	R101Q					798:802	R101Q	798:802	R101Q	798:802	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	5	47	theme	single	766:771	arg1	substitution					784:795	a single amino acid substitution	764:795	a single amino acid substitution (R101Q)	764:803	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	8	48	theme	surface	1196:1202	arg1	trafficking					1204:1214	the surface trafficking	1192:1214	the surface trafficking of NLGN4	1192:1223	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	8	48	theme	surface	1196:1202	arg1	result					1137:1142	a result	1135:1142	a result	1135:1142	As a result, the R101Q substitution significantly decreased the surface trafficking of NLGN4 and increased its retention in the endoplasmic reticulum and Golgi apparatus.
33268543	3	49	theme	NLGN4	446:450	arg1	gene					452:455	The human-specific NLGN4 gene	427:455	The human-specific NLGN4 gene	427:455	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	5	50	theme	amino	773:777	arg1	R101Q					798:802	R101Q	798:802	R101Q	798:802	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	5	50	theme	amino	773:777	arg1	substitution					784:795	a single amino acid substitution	764:795	a single amino acid substitution (R101Q)	764:803	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	5	51	theme	male	742:745	arg1	patient					747:753	a severely autistic male patient	722:753	a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene	722:821	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	9	52	theme	synaptic	1401:1408	arg1	localization					1410:1421	the synaptic localization	1397:1421	the synaptic localization of NLGN4	1397:1430	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	5	53	theme	acid	779:782	arg1	R101Q					798:802	R101Q	798:802	R101Q	798:802	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	5	53	theme	acid	779:782	arg1	substitution					784:795	a single amino acid substitution	764:795	a single amino acid substitution (R101Q)	764:803	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	10	54	theme	mutation-induced	1481:1496	arg1	defect					1510:1515	This mutation-induced trafficking defect	1476:1515	This mutation-induced trafficking defect	1476:1515	This mutation-induced trafficking defect substantially diminished the ability of NLGN4 to form excitatory synapses and modulate their functional properties.
33268543	11	55	theme	R101Q	1680:1684	arg1	pathogenic					1698:1707	pathogenic	1698:1707	pathogenic	1698:1707	Viewed together, our findings suggest that the R101Q mutation is pathogenic for NLGN4 and can lead to synaptic dysfunction in autism.
33268543	11	55	theme	R101Q	1680:1684	arg1	mutation					1686:1693	the R101Q mutation	1676:1693	the R101Q mutation	1676:1693	Viewed together, our findings suggest that the R101Q mutation is pathogenic for NLGN4 and can lead to synaptic dysfunction in autism.
33268543	11	56	from	dysfunction	1744:1754	arg1	autism					1759:1764	autism	1759:1764	autism	1759:1764	Viewed together, our findings suggest that the R101Q mutation is pathogenic for NLGN4 and can lead to synaptic dysfunction in autism.
33268543	9	57	theme	human	1306:1310	arg1	neurons					1312:1318	human neurons	1306:1318	human neurons derived from male stem cell lines	1306:1352	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	9	58	theme	stem	1338:1341	arg1	lines					1348:1352	male stem cell lines	1333:1352	male stem cell lines	1333:1352	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	9	59	theme	loss-of-function	1448:1463	arg1	phenotype					1465:1473	a loss-of-function phenotype	1446:1473	a loss-of-function phenotype	1446:1473	In human neurons derived from male stem cell lines, the R101Q mutation also similarly reduced the synaptic localization of NLGN4, resulting in a loss-of-function phenotype.
33268543	10	60	theme	functional	1610:1619	arg1	properties					1621:1630	their functional properties	1604:1630	their functional properties	1604:1630	This mutation-induced trafficking defect substantially diminished the ability of NLGN4 to form excitatory synapses and modulate their functional properties.
33268543	4	61	theme	synaptic	664:671	arg1	transmission					673:684	synaptic transmission	664:684	synaptic transmission in human neurons	664:701	However, it remained unclear how these mutations might alter the molecular properties of NLGN4 and affect synaptic transmission in human neurons.
33268543	7	62	gly	glycosylation	1054:1066	arg1	N102					1092:1095	N102	1092:1095	N102	1092:1095	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	7	62	gly	glycosylation	1054:1066	arg1	residue					1083:1089	an adjacent residue	1071:1089	an adjacent residue (N102)	1071:1096	This mutation, however, impaired the maturation of NLGN4 protein by inhibiting N-linked glycosylation at an adjacent residue (N102), which is conserved in all NLGNs.
33268543	0	63	theme	Synaptic	89:96	arg1	Transmission					98:109	Excitatory Synaptic Transmission	78:109	Excitatory Synaptic Transmission in Human Neurons	78:126	An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons.
33268543	4	64	theme	molecular	623:631	arg1	properties					633:642	the molecular properties	619:642	the molecular properties of NLGN4	619:651	However, it remained unclear how these mutations might alter the molecular properties of NLGN4 and affect synaptic transmission in human neurons.
33268543	3	65	theme	human-specific	431:444	arg1	gene					452:455	The human-specific NLGN4 gene	427:455	The human-specific NLGN4 gene	427:455	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	3	66	theme	many	492:495	arg1	patients					497:504	many patients	492:504	many patients with autism and other neurodevelopmental disorders	492:555	The human-specific NLGN4 gene has been reported to be mutated in many patients with autism and other neurodevelopmental disorders.
33268543	0	67	theme	Excitatory	78:87	arg1	Transmission					98:109	Excitatory Synaptic Transmission	78:109	Excitatory Synaptic Transmission in Human Neurons	78:126	An Autism-Associated Mutation Impairs Neuroligin-4 Glycosylation and Enhances Excitatory Synaptic Transmission in Human Neurons.
33268543	5	68	contain	carrying	755:762	arg2	R101Q					798:802	R101Q	798:802	R101Q	798:802	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	5	68	contain	carrying	755:762	arg1	patient					747:753	a severely autistic male patient	722:753	a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene	722:821	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	5	68	contain	carrying	755:762	arg2	substitution					784:795	a single amino acid substitution	764:795	a single amino acid substitution (R101Q)	764:803	Here, we describe a severely autistic male patient carrying a single amino acid substitution (R101Q) in the NLGN4 gene.
33268543	2	69	theme	acid	349:352	arg1	sequence					354:361	a unique amino acid sequence	334:361	a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents	334:424	NLGN4 is a member of the NLGN family and consists of a unique amino acid sequence in humans that is not evolutionarily well conserved in rodents.
32306345	0	0	theme	Receptor	60:67	arg1	Agonist					69:75	a Toll-Like Receptor Agonist	48:75	a Toll-Like Receptor Agonist	48:75	MIC4 from Toxoplasma gondii: A Lectin Acting as a Toll-Like Receptor Agonist.
32306345	0	1	from	Toxoplasma	10:19	arg1	MIC4					0:3	MIC4	0:3	MIC4 from Toxoplasma gondii: A Lectin Acting as a Toll-Like Receptor Agonist.	0:76	MIC4 from Toxoplasma gondii: A Lectin Acting as a Toll-Like Receptor Agonist.
32306345	1	2	theme	gondii	131:136	arg1	forms					111:115	infective forms	101:115	infective forms of Toxoplasma gondii	101:136	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32306345	1	2	theme	gondii	131:136	arg1	Tachyzoites					78:88	Tachyzoites	78:88	Tachyzoites	78:88	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32306345	0	3	theme	Toll-Like	50:58	arg1	Agonist					69:75	a Toll-Like Receptor Agonist	48:75	a Toll-Like Receptor Agonist	48:75	MIC4 from Toxoplasma gondii: A Lectin Acting as a Toll-Like Receptor Agonist.
32306345	6	4	theme	recombinant	859:869	arg1	rMIC4					877:881	rMIC4	877:881	rMIC4	877:881	Therefore, this section details the protocol for prokaryotic expression, production, and purification of recombinant MIC4 (rMIC4) and for experimental assays to confirm its biological activity.
32306345	6	4	theme	recombinant	859:869	arg1	MIC4					871:874	recombinant MIC4	859:874	recombinant MIC4 (rMIC4)	859:882	Therefore, this section details the protocol for prokaryotic expression, production, and purification of recombinant MIC4 (rMIC4) and for experimental assays to confirm its biological activity.
32306345	5	5	from	T.	665:666	arg1	Obtention					642:650	Obtention	642:650	Obtention of MIC4 from T. gondii	642:673	Obtention of MIC4 from T. gondii requires several purification steps, is time-consuming and provides low yield.
32306345	4	6	dep	TLR2-	471:475	arg1	glycans					495:501	N-linked glycans	486:501	N-linked glycans	486:501	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	2	7	theme	regulated	245:253	arg1	Central					214:220	Central	214:220	Central	214:220	Central to this process is the regulated release of micronemes organelles contents.
32306345	2	7	theme	regulated	245:253	arg1	release					255:261	the regulated release	241:261	the regulated release of micronemes organelles contents	241:295	Central to this process is the regulated release of micronemes organelles contents.
32306345	4	8	theme	innate	538:543	arg1	cells					552:556	cell innate immune cells	533:556	cell innate immune cells	533:556	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	4	9	link	N-linked	486:493	arg1	glycans					495:501	N-linked glycans	486:501	N-linked glycans	486:501	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	4	10	theme	cell	533:536	arg1	cells					552:556	cell innate immune cells	533:556	cell innate immune cells	533:556	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	5	11	theme	several	684:690	arg1	steps					705:709	several purification steps	684:709	several purification steps	684:709	Obtention of MIC4 from T. gondii requires several purification steps, is time-consuming and provides low yield.
32306345	5	12	theme	purification	692:703	arg1	steps					705:709	several purification steps	684:709	several purification steps	684:709	Obtention of MIC4 from T. gondii requires several purification steps, is time-consuming and provides low yield.
32306345	3	13	contain	has	329:331	arg2	property					337:344	the property to recognize galactosides residues linked to glycoproteins on the host cell surface	333:428	the property to recognize galactosides residues linked to glycoproteins on the host cell surface	333:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	3	13	contain	has	329:331	arg1	protein					312:318	microneme protein 4	302:320	The microneme protein 4 (MIC4)	298:327	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	3	13	contain	has	329:331	arg1	MIC4					323:326	MIC4	323:326	MIC4	323:326	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	2	14	theme	organelles	277:286	arg1	contents					288:295	micronemes organelles contents	266:295	micronemes organelles contents	266:295	Central to this process is the regulated release of micronemes organelles contents.
32306345	1	15	theme	actinomyosin	149:160	arg1	system					162:167	their actinomyosin system	143:167	their actinomyosin system	143:167	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32306345	2	16	theme	micronemes	266:275	arg1	contents					288:295	micronemes organelles contents	266:295	micronemes organelles contents	266:295	Central to this process is the regulated release of micronemes organelles contents.
32306345	3	17	attach	linked	381:386	arg2	residues					372:379	galactosides residues	359:379	galactosides residues linked to glycoproteins on the host cell surface	359:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	3	17	attach	linked	381:386	arg1	glycoproteins					391:403	glycoproteins	391:403	glycoproteins on the host cell surface	391:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	3	18	theme	cell	417:420	arg1	surface					422:428	the host cell surface	408:428	the host cell surface	408:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	5	19	theme	MIC4	655:658	arg1	Obtention					642:650	Obtention	642:650	Obtention of MIC4 from T. gondii	642:673	Obtention of MIC4 from T. gondii requires several purification steps, is time-consuming and provides low yield.
32306345	6	20	theme	MIC4	871:874	arg1	expression					815:824	prokaryotic expression	803:824	prokaryotic expression	803:824	Therefore, this section details the protocol for prokaryotic expression, production, and purification of recombinant MIC4 (rMIC4) and for experimental assays to confirm its biological activity.
32306345	3	21	theme	galactosides	359:370	arg1	residues					372:379	galactosides residues	359:379	galactosides residues linked to glycoproteins on the host cell surface	359:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	6	22	theme	experimental	892:903	arg1	assays					905:910	experimental assays	892:910	experimental assays	892:910	Therefore, this section details the protocol for prokaryotic expression, production, and purification of recombinant MIC4 (rMIC4) and for experimental assays to confirm its biological activity.
32306345	6	23	theme	prokaryotic	803:813	arg1	expression					815:824	prokaryotic expression	803:824	prokaryotic expression	803:824	Therefore, this section details the protocol for prokaryotic expression, production, and purification of recombinant MIC4 (rMIC4) and for experimental assays to confirm its biological activity.
32306345	3	24	theme	host	412:415	arg1	surface					422:428	the host cell surface	408:428	the host cell surface	408:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	5	25	theme	low	743:745	arg1	yield					747:751	low yield	743:751	low yield	743:751	Obtention of MIC4 from T. gondii requires several purification steps, is time-consuming and provides low yield.
32306345	4	26	theme	N-linked	486:493	arg1	glycans					495:501	N-linked glycans	486:501	N-linked glycans	486:501	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	6	27	theme	biological	927:936	arg1	activity					938:945	its biological activity	923:945	its biological activity	923:945	Therefore, this section details the protocol for prokaryotic expression, production, and purification of recombinant MIC4 (rMIC4) and for experimental assays to confirm its biological activity.
32306345	1	28	theme	infective	101:109	arg1	forms					111:115	infective forms	101:115	infective forms of Toxoplasma gondii	101:136	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32306345	1	28	theme	infective	101:109	arg1	Tachyzoites					78:88	Tachyzoites	78:88	Tachyzoites	78:88	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32306345	4	29	theme	cells	552:556	arg1	activation					519:528	the activation	515:528	the activation of cell innate immune cells	515:556	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	4	29	theme	cells	552:556	arg1	secretion					562:570	secretion	562:570	secretion of inflammatory cytokines	562:596	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	3	30	gly	glycoproteins	391:403	arg1	glycoproteins					391:403	glycoproteins	391:403	glycoproteins on the host cell surface	391:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	2	31	theme	contents	288:295	arg1	Central					214:220	Central	214:220	Central	214:220	Central to this process is the regulated release of micronemes organelles contents.
32306345	2	31	theme	contents	288:295	arg1	release					255:261	the regulated release	241:261	the regulated release of micronemes organelles contents	241:295	Central to this process is the regulated release of micronemes organelles contents.
32306345	4	32	theme	immune	545:550	arg1	cells					552:556	cell innate immune cells	533:556	cell innate immune cells	533:556	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	4	33	theme	cytokines	588:596	arg1	activation					519:528	the activation	515:528	the activation of cell innate immune cells	515:556	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	4	33	theme	cytokines	588:596	arg1	secretion					562:570	secretion	562:570	secretion of inflammatory cytokines	562:596	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	4	34	theme	inflammatory	575:586	arg1	cytokines					588:596	inflammatory cytokines	575:596	inflammatory cytokines	575:596	This property allows that MIC4 binds to TLR2- and TLR4 N-linked glycans and promote the activation of cell innate immune cells and secretion of inflammatory cytokines, acting on resistance against the parasite.
32306345	1	35	theme	host	202:205	arg1	cells					207:211	host cells	202:211	host cells	202:211	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32306345	3	36	theme	microneme	302:310	arg1	protein					312:318	microneme protein 4	302:320	The microneme protein 4 (MIC4)	298:327	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	3	36	theme	microneme	302:310	arg1	MIC4					323:326	MIC4	323:326	MIC4	323:326	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	0	37	dep	MIC4	0:3	arg1	Lectin					31:36	A Lectin	29:36	MIC4 from Toxoplasma gondii: A Lectin Acting as a Toll-Like Receptor Agonist.	0:76	MIC4 from Toxoplasma gondii: A Lectin Acting as a Toll-Like Receptor Agonist.
32306345	3	38	from	glycoproteins	391:403	arg1	surface					422:428	the host cell surface	408:428	the host cell surface	408:428	The microneme protein 4 (MIC4) has the property to recognize galactosides residues linked to glycoproteins on the host cell surface.
32306345	1	39	theme	Toxoplasma	120:129	arg1	gondii					131:136	Toxoplasma gondii	120:136	Toxoplasma gondii	120:136	Tachyzoites, which are infective forms of Toxoplasma gondii, use their actinomyosin system to move over surfaces and invade host cells.
32191460	4	0	contain	contains	674:681	arg1	B					668:668	Swinhopeptolide B	652:668	Swinhopeptolide B (2)	652:672	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	4	0	contain	contains	674:681	arg2	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	4	0	contain	contains	674:681	arg1	2					671:671	2	671:671	2	671:671	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	0	1	theme	Theonella	63:71	arg1	swinhoei					73:80	the Sponge Theonella swinhoei	52:80	the Sponge Theonella swinhoei	52:80	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	5	2	theme	significant	839:849	arg1	inhibition					851:860	significant inhibition	839:860	significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively	839:942	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	2	3	attach	attached	376:383	arg3	N-terminus					392:401	the N-terminus	388:401	the N-terminus	388:401	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	2	3	attach	attached	376:383	arg2	residues					333:340	11 diverse amino acid residues	311:340	11 diverse amino acid residues	311:340	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	5	4	theme	μM	927:928	arg1	values					905:910	IC50 values	900:910	IC50 values	900:910	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	4	5	theme	2,6,8-trimethyldeca-	708:727	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	4	6	theme	undescribed	696:706	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	2	7	contain	contain	303:309	arg1	They					293:296	They	293:296	They	293:296	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	2	7	contain	contain	303:309	arg2	moieties					367:374	13-carbon polyketide moieties	346:374	13-carbon polyketide moieties	346:374	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	2	7	contain	contain	303:309	arg2	residues					333:340	11 diverse amino acid residues	311:340	11 diverse amino acid residues	311:340	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	4	8	theme	2E,4E,6E	729:736	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	2	9	dep	contain	303:309	arg1	each					298:301	each	298:301	each	298:301	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	5	10	theme	Ras/Raf	869:875	arg1	pathway					887:893	the Ras/Raf signaling pathway	865:893	the Ras/Raf signaling pathway	865:893	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	3	11	theme	cis/trans	469:477	arg1	isomerism					479:487	cis/trans isomerism	469:487	cis/trans isomerism of the proline residue	469:510	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	2	12	theme	13-carbon	346:354	arg1	moieties					367:374	13-carbon polyketide moieties	346:374	13-carbon polyketide moieties	346:374	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	0	13	theme	Ras/Raf	95:101	arg1	Interaction					103:113	Ras/Raf Interaction	95:113	Ras/Raf Interaction	95:113	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	4	14	theme	-trienoic	738:746	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	5	15	with	inhibition	851:860	arg1	values					905:910	IC50 values	900:910	IC50 values	900:910	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	1	16	dep	swinhopeptolides	151:166	arg1	swinhopeptolides					151:166	swinhopeptolides A (1) and B (2)	151:182	swinhopeptolides A (1) and B (2)	151:182	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	1	16	dep	swinhopeptolides	151:166	arg1	B					178:178	B (2)	178:182	B (2)	178:182	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	1	16	dep	swinhopeptolides	151:166	arg1	A					168:168	A (1)	168:172	A (1)	168:172	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	5	17	theme	pathway	887:893	arg1	inhibition					851:860	significant inhibition	839:860	significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively	839:942	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	2	18	theme	acid	328:331	arg1	residues					333:340	11 diverse amino acid residues	311:340	11 diverse amino acid residues	311:340	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	3	19	from	conformers	440:449	arg1	DMSO-d6					454:460	DMSO-d6	454:460	DMSO-d6 due to cis/trans isomerism of the proline residue	454:510	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	3	20	theme	proline	496:502	arg1	residue					504:510	the proline residue	492:510	the proline residue	492:510	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	5	21	theme	IC50	900:903	arg1	values					905:910	IC50 values	900:910	IC50 values	900:910	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	4	22	theme	acid	748:751	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	0	23	from	swinhoei	73:80	arg1	Depsipeptides					33:45	Cyclic Depsipeptides	26:45	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.	0:114	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	3	24	theme	residue	504:510	arg1	isomerism					479:487	cis/trans isomerism	469:487	cis/trans isomerism of the proline residue	469:510	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	4	25	theme	Swinhopeptolide	652:666	arg1	B					668:668	Swinhopeptolide B	652:668	Swinhopeptolide B (2)	652:672	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	4	25	theme	Swinhopeptolide	652:666	arg1	2					671:671	2	671:671	2	671:671	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	0	26	theme	Cyclic	26:31	arg1	Depsipeptides					33:45	Cyclic Depsipeptides	26:45	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.	0:114	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	3	27	theme	chemical	603:610	arg1	degradation					612:622	chemical degradation	603:622	chemical degradation	603:622	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	4	28	theme	serine	783:788	arg1	residue					790:796	a terminal serine residue	772:796	a terminal serine residue	772:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	4	29	link	N-linked	760:767	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	1	30	theme	marine	212:217	arg1	sponge					219:224	the marine sponge	208:224	the marine sponge	208:224	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	4	31	theme	terminal	774:781	arg1	residue					790:796	a terminal serine residue	772:796	a terminal serine residue	772:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	2	32	theme	polyketide	356:365	arg1	moieties					367:374	13-carbon polyketide moieties	346:374	13-carbon polyketide moieties	346:374	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	1	33	theme	Papua	275:279	arg1	Guinea					285:290	Papua New Guinea	275:290	Papua New Guinea	275:290	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	3	34	theme	derivatization	628:641	arg1	studies					643:649	derivatization studies	628:649	derivatization studies	628:649	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	1	35	attach	isolated	194:201	arg2	A					168:168	A (1)	168:172	A (1)	168:172	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	1	35	attach	isolated	194:201	arg2	swinhopeptolides					151:166	swinhopeptolides A (1) and B (2)	151:182	swinhopeptolides A (1) and B (2)	151:182	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	1	35	attach	isolated	194:201	arg1	sponge					219:224	the marine sponge	208:224	the marine sponge	208:224	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	1	35	attach	isolated	194:201	arg2	B					178:178	B (2)	178:182	B (2)	178:182	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	1	36	theme	New	281:283	arg1	Guinea					285:290	Papua New Guinea	275:290	Papua New Guinea	275:290	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	5	37	theme	signaling	877:885	arg1	pathway					887:893	the Ras/Raf signaling pathway	865:893	the Ras/Raf signaling pathway	865:893	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	4	38	theme	N-linked	760:767	arg1	moiety					753:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety	683:758	a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue	683:796	Swinhopeptolide B (2) contains a previously undescribed 2,6,8-trimethyldeca-(2E,4E,6E)-trienoic acid moiety N-linked to a terminal serine residue.
32191460	3	39	theme	extensive	564:572	arg1	analyses					578:585	extensive NMR analyses	564:585	extensive NMR analyses complemented by chemical degradation and derivatization studies	564:649	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	1	40	theme	new	120:122	arg1	depsipeptides					131:143	Two new cyclic depsipeptides	116:143	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei	116:243	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	3	41	theme	NMR	574:576	arg1	analyses					578:585	extensive NMR analyses	564:585	extensive NMR analyses complemented by chemical degradation and derivatization studies	564:649	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32191460	1	42	theme	cyclic	124:129	arg1	depsipeptides					131:143	Two new cyclic depsipeptides	116:143	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei	116:243	Two new cyclic depsipeptides named swinhopeptolides A (1) and B (2) have been isolated from the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea.
32191460	0	43	theme	Sponge	56:61	arg1	swinhoei					73:80	the Sponge Theonella swinhoei	52:80	the Sponge Theonella swinhoei	52:80	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	5	44	dep	Swinhopeptolides	799:814	arg1	Swinhopeptolides					799:814	Swinhopeptolides A (1) and B (2)	799:830	Swinhopeptolides A (1) and B (2)	799:830	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	5	44	dep	Swinhopeptolides	799:814	arg1	B					826:826	B (2)	826:830	B (2)	826:830	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	5	44	dep	Swinhopeptolides	799:814	arg1	A					816:816	A (1)	816:820	A (1)	816:820	Swinhopeptolides A (1) and B (2) showed significant inhibition of the Ras/Raf signaling pathway with IC50 values of 5.8 and 8.5 μM, respectively.
32191460	2	45	theme	amino	322:326	arg1	residues					333:340	11 diverse amino acid residues	311:340	11 diverse amino acid residues	311:340	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	0	46	dep	Swinhopeptolides	0:15	arg1	Swinhopeptolides					0:15	Swinhopeptolides A and B	0:23	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.	0:114	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	0	46	dep	Swinhopeptolides	0:15	arg1	B					23:23	B	23:23	B	23:23	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	0	46	dep	Swinhopeptolides	0:15	arg1	Depsipeptides					33:45	Cyclic Depsipeptides	26:45	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.	0:114	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	0	46	dep	Swinhopeptolides	0:15	arg1	A					17:17	A	17:17	A	17:17	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge Theonella swinhoei That Inhibit Ras/Raf Interaction.
32191460	2	47	theme	diverse	314:320	arg1	residues					333:340	11 diverse amino acid residues	311:340	11 diverse amino acid residues	311:340	They each contain 11 diverse amino acid residues and 13-carbon polyketide moieties attached at the N-terminus.
32191460	3	48	dep	Compounds	404:412	arg1	each					422:425	each	422:425	each	422:425	Compounds 1 and 2 each exist as two conformers in DMSO-d6 due to cis/trans isomerism of the proline residue, and their structures were successfully assigned by extensive NMR analyses complemented by chemical degradation and derivatization studies.
32028683	0	0	theme	N-Glycosylation	85:99	arg1	Inhibition					63:72	Inhibition	63:72	Inhibition of Protein N-Glycosylation	63:99	Curcumin Derivative GT863 Inhibits Amyloid-Beta Production via Inhibition of Protein N-Glycosylation.
32028683	4	1	theme	finding	467:473	arg1	derivatives					475:485	finding derivatives	467:485	finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	467:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	5	2	theme	curcumin	701:708	arg1	GT863/PE859					721:731	the curcumin derivative GT863/PE859	697:731	the curcumin derivative GT863/PE859	697:731	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	5	2	theme	curcumin	701:708	arg1	effective					828:836	effective	828:836	effective	828:836	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	7	3	theme	N-linked	1079:1086	arg1	glycosylation					1088:1100	N-linked glycosylation	1079:1100	N-linked glycosylation	1079:1100	We further found that GT863 suppressed N-linked glycosylation, including that of the γ-secretase subunit nicastrin.
32028683	2	4	theme	important	255:263	arg1	targets					277:283	important therapeutic targets	255:283	important therapeutic targets for AD	255:290	Aβ production, aggregation, and clearance are thought to be important therapeutic targets for AD.
32028683	6	5	theme	γ-secretase	938:948	arg1	activity					950:957	γ-secretase activity	938:957	γ-secretase activity	938:957	We further found that GT863 inhibited neither β- nor γ-secretase activity, but did suppress γ-secretase-mediated cleavage in a substrate-dependent manner.
32028683	5	6	theme	derivative	710:719	arg1	GT863/PE859					721:731	the curcumin derivative GT863/PE859	697:731	the curcumin derivative GT863/PE859	697:731	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	5	6	theme	derivative	710:719	arg1	effective					828:836	effective	828:836	effective	828:836	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	4	7	theme	derivative	432:441	arg1	library					443:449	a curcumin derivative library	421:449	a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	421:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	8	theme	present	368:374	arg1	study					376:380	the present study	364:380	the present study	364:380	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	9	theme	curcumin	559:566	arg1	bioavailability					540:554	improved bioavailability	531:554	improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	531:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	10	theme	curcumin	423:430	arg1	library					443:449	a curcumin derivative library	421:449	a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	421:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	8	11	theme	N-glycosylation	1238:1252	arg1	step					1230:1233	the mannose trimming step	1209:1233	the mannose trimming step of N-glycosylation	1209:1252	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	8	12	theme	trimming	1221:1228	arg1	step					1230:1233	the mannose trimming step	1209:1233	the mannose trimming step of N-glycosylation	1209:1252	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	8	13	with	treatment	1332:1340	arg1	GT863					1347:1351	GT863	1347:1351	GT863	1347:1351	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	8	14	theme	mannose	1213:1219	arg1	trimming					1221:1228	mannose trimming	1213:1228	the mannose trimming step of N-glycosylation	1209:1252	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	0	15	theme	Derivative	9:18	arg1	GT863					20:24	Curcumin Derivative GT863	0:24	Curcumin Derivative GT863	0:24	Curcumin Derivative GT863 Inhibits Amyloid-Beta Production via Inhibition of Protein N-Glycosylation.
32028683	1	16	theme	Amyloid-β	102:110	arg1	peptides					117:124	Amyloid-β (Aβ) peptides	102:124	Amyloid-β (Aβ) peptides	102:124	Amyloid-β (Aβ) peptides play a crucial role in the pathogenesis of Alzheimer's disease (AD).
32028683	7	17	link	N-linked	1079:1086	arg1	glycosylation					1088:1100	N-linked glycosylation	1079:1100	N-linked glycosylation	1079:1100	We further found that GT863 suppressed N-linked glycosylation, including that of the γ-secretase subunit nicastrin.
32028683	4	18	theme	human	648:652	arg1	cells					676:680	human neuroblastoma SH-SY5Y cells	648:680	human neuroblastoma SH-SY5Y cells	648:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	0	19	theme	Curcumin	0:7	arg1	GT863					20:24	Curcumin Derivative GT863	0:24	Curcumin Derivative GT863	0:24	Curcumin Derivative GT863 Inhibits Amyloid-Beta Production via Inhibition of Protein N-Glycosylation.
32028683	8	20	theme	treatment	1332:1340	arg1	result					1322:1327	a result	1320:1327	a result of treatment with GT863	1320:1351	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	4	21	dep	curcumin	559:566	arg1	using					568:572	using	568:572	using CHO cells that stably express human amyloid-β precursor protein	568:636	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	21	dep	curcumin	559:566	arg1	using					642:646	using	642:646	using human neuroblastoma SH-SY5Y cells	642:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	3	22	theme	anti-amyloidogenic	328:345	arg1	effect					347:352	an anti-amyloidogenic effect	325:352	an anti-amyloidogenic effect	325:352	Curcumin has been known to have an anti-amyloidogenic effect on AD.
32028683	4	23	theme	Aβ	512:513	arg1	production					515:524	Aβ production	512:524	Aβ production	512:524	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	8	24	theme	similar	1284:1290	arg1	fashion					1292:1298	a similar fashion	1282:1298	a similar fashion	1282:1298	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	4	25	with	library	443:449	arg1	aim					460:462	the aim	456:462	the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	456:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	8	26	theme	mannosidase	1175:1185	arg1	inhibitors					1187:1196	mannosidase inhibitors	1175:1196	mannosidase inhibitors that block the mannose trimming step of N-glycosylation	1175:1252	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	4	27	theme	human	604:608	arg1	protein					630:636	human amyloid-β precursor protein	604:636	human amyloid-β precursor protein	604:636	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	28	theme	improved	531:538	arg1	bioavailability					540:554	improved bioavailability	531:554	improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	531:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	2	29	theme	therapeutic	265:275	arg1	targets					277:283	important therapeutic targets	255:283	important therapeutic targets for AD	255:290	Aβ production, aggregation, and clearance are thought to be important therapeutic targets for AD.
32028683	2	30	dep	Aβ	195:196	arg1	Aβ					195:196	Aβ production, aggregation, and clearance	195:235	Aβ production, aggregation, and clearance	195:235	Aβ production, aggregation, and clearance are thought to be important therapeutic targets for AD.
32028683	2	30	dep	Aβ	195:196	arg1	aggregation					210:220	aggregation	210:220	aggregation	210:220	Aβ production, aggregation, and clearance are thought to be important therapeutic targets for AD.
32028683	2	30	dep	Aβ	195:196	arg1	clearance					227:235	clearance	227:235	clearance	227:235	Aβ production, aggregation, and clearance are thought to be important therapeutic targets for AD.
32028683	2	30	dep	Aβ	195:196	arg1	production					198:207	production	198:207	production	198:207	Aβ production, aggregation, and clearance are thought to be important therapeutic targets for AD.
32028683	4	31	theme	screening	396:404	arg1	analysis					406:413	screening analysis	396:413	screening analysis	396:413	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	32	theme	precursor	620:628	arg1	protein					630:636	human amyloid-β precursor protein	604:636	human amyloid-β precursor protein	604:636	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	0	33	theme	Amyloid-Beta	35:46	arg1	Production					48:57	Amyloid-Beta Production	35:57	Amyloid-Beta Production	35:57	Curcumin Derivative GT863 Inhibits Amyloid-Beta Production via Inhibition of Protein N-Glycosylation.
32028683	4	34	theme	effective	487:495	arg1	derivatives					475:485	finding derivatives	467:485	finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	467:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	7	35	theme	γ-secretase	1125:1135	arg1	nicastrin					1145:1153	the γ-secretase subunit nicastrin	1121:1153	the γ-secretase subunit nicastrin	1121:1153	We further found that GT863 suppressed N-linked glycosylation, including that of the γ-secretase subunit nicastrin.
32028683	9	36	theme	production	1463:1472	arg1	suppression					1445:1455	suppression	1445:1455	suppression of Aβ production	1445:1472	Collectively, these results suggest that GT863 downregulates N-glycosylation, resulting in suppression of Aβ production without affecting secretase activity.
32028683	7	37	theme	subunit	1137:1143	arg1	nicastrin					1145:1153	the γ-secretase subunit nicastrin	1121:1153	the γ-secretase subunit nicastrin	1121:1153	We further found that GT863 suppressed N-linked glycosylation, including that of the γ-secretase subunit nicastrin.
32028683	4	38	theme	amyloid-β	610:618	arg1	protein					630:636	human amyloid-β precursor protein	604:636	human amyloid-β precursor protein	604:636	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	39	theme	derivatives	475:485	arg1	aim					460:462	the aim	456:462	the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells	456:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	9	40	theme	Aβ	1460:1461	arg1	production					1463:1472	Aβ production	1460:1472	Aβ production	1460:1472	Collectively, these results suggest that GT863 downregulates N-glycosylation, resulting in suppression of Aβ production without affecting secretase activity.
32028683	5	41	theme	inhibitory	766:775	arg1	effect					777:782	an inhibitory effect	763:782	an inhibitory effect	763:782	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	5	42	theme	Aβ	871:872	arg1	secretion					874:882	Aβ secretion	871:882	Aβ secretion	871:882	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	3	43	contain	have	320:323	arg1	Curcumin					293:300	Curcumin	293:300	Curcumin	293:300	Curcumin has been known to have an anti-amyloidogenic effect on AD.
32028683	3	43	contain	have	320:323	arg2	effect					347:352	an anti-amyloidogenic effect	325:352	an anti-amyloidogenic effect	325:352	Curcumin has been known to have an anti-amyloidogenic effect on AD.
32028683	9	44	theme	secretase	1492:1500	arg1	activity					1502:1509	secretase activity	1492:1509	secretase activity	1492:1509	Collectively, these results suggest that GT863 downregulates N-glycosylation, resulting in suppression of Aβ production without affecting secretase activity.
32028683	6	45	theme	γ-secretase-mediated	977:996	arg1	cleavage					998:1005	γ-secretase-mediated cleavage	977:1005	γ-secretase-mediated cleavage	977:1005	We further found that GT863 inhibited neither β- nor γ-secretase activity, but did suppress γ-secretase-mediated cleavage in a substrate-dependent manner.
32028683	5	46	contain	have	758:761	arg1	GT863/PE859					721:731	the curcumin derivative GT863/PE859	697:731	the curcumin derivative GT863/PE859	697:731	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	5	46	contain	have	758:761	arg2	effect					777:782	an inhibitory effect	763:782	an inhibitory effect	763:782	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	5	46	contain	have	758:761	arg1	effective					828:836	effective	828:836	effective	828:836	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	6	47	theme	substrate-dependent	1012:1030	arg1	manner					1032:1037	a substrate-dependent manner	1010:1037	a substrate-dependent manner	1010:1037	We further found that GT863 inhibited neither β- nor γ-secretase activity, but did suppress γ-secretase-mediated cleavage in a substrate-dependent manner.
32028683	1	48	theme	crucial	133:139	arg1	role					141:144	a crucial role	131:144	a crucial role	131:144	Amyloid-β (Aβ) peptides play a crucial role in the pathogenesis of Alzheimer's disease (AD).
32028683	4	49	theme	CHO	574:576	arg1	cells					578:582	CHO cells	574:582	CHO cells that stably express human amyloid-β precursor protein	574:636	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	0	50	theme	Protein	77:83	arg1	N-Glycosylation					85:99	Protein N-Glycosylation	77:99	Protein N-Glycosylation	77:99	Curcumin Derivative GT863 Inhibits Amyloid-Beta Production via Inhibition of Protein N-Glycosylation.
32028683	8	51	theme	Aβ	1265:1266	arg1	production					1268:1277	Aβ production	1265:1277	Aβ production	1265:1277	We also found that mannosidase inhibitors that block the mannose trimming step of N-glycosylation suppressed Aβ production in a similar fashion, as was observed as a result of treatment with GT863.
32028683	5	52	theme	tau	794:796	arg1	aggregation					798:808	tau aggregation	794:808	tau aggregation	794:808	We found that the curcumin derivative GT863/PE859, which has been shown to have an inhibitory effect on Aβ and tau aggregation in vivo, was more effective than curcumin itself in reducing Aβ secretion.
32028683	4	53	theme	SH-SY5Y	668:674	arg1	cells					676:680	human neuroblastoma SH-SY5Y cells	648:680	human neuroblastoma SH-SY5Y cells	648:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
32028683	4	54	theme	neuroblastoma	654:666	arg1	cells					676:680	human neuroblastoma SH-SY5Y cells	648:680	human neuroblastoma SH-SY5Y cells	648:680	In the present study, we performed screening analysis using a curcumin derivative library with the aim of finding derivatives effective in suppressing Aβ production with improved bioavailability of curcumin using CHO cells that stably express human amyloid-β precursor protein and using human neuroblastoma SH-SY5Y cells.
33727825	4	0	theme	bioinformatics	454:467	arg1	analysis					469:476	bioinformatics analysis	454:476	bioinformatics analysis	454:476	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	1	1	link	N-linked	188:195	arg1	glycosylation					197:209	the N-linked glycosylation	184:209	the N-linked glycosylation of multiple proteins	184:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	8	2	theme	significant	931:941	arg1	correlation					952:962	a significant positive correlation	929:962	a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa	929:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	2	3	from	phenotype	283:291	arg1	tumors					304:309	several tumors	296:309	several tumors	296:309	RPN2 was reported to be associated with malignant phenotype in several tumors.
33727825	8	4	from	metastasis	1031:1040	arg1	patients					1095:1102	38 patients	1092:1102	38 patients with BCa	1092:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	6	5	theme	gene	782:785	arg1	GSEA					812:815	GSEA	812:815	GSEA	812:815	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	6	5	theme	gene	782:785	arg1	analysis					802:809	gene set enrichment analysis	782:809	gene set enrichment analysis (GSEA)	782:816	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	7	6	theme	normal	894:899	arg1	tissues					910:916	normal adjacent tissues	894:916	normal adjacent tissues	894:916	RESULTS We found that RPN2 was highly expressed in human BCa compared with normal adjacent tissues.
33727825	8	7	theme	RPN2	979:982	arg1	levels					989:994	higher RPN2 mRNA levels	972:994	higher RPN2 mRNA levels	972:994	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	8	theme	higher	972:977	arg1	levels					989:994	higher RPN2 mRNA levels	972:994	higher RPN2 mRNA levels	972:994	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	3	9	theme	RPN2	337:340	arg1	function					325:332	the function	321:332	the function of RPN2 in bladder cancer (BCa)	321:364	However, the function of RPN2 in bladder cancer (BCa) remains unclear.
33727825	8	10	from	patients	1095:1102	arg1	degree					1050:1055	the degree	1046:1055	the degree of pathological differentiation in 38 patients with BCa	1046:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	10	from	patients	1095:1102	arg1	stage					1008:1012	tumor T stage	1000:1012	tumor T stage	1000:1012	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	10	from	patients	1095:1102	arg1	levels					989:994	higher RPN2 mRNA levels	972:994	higher RPN2 mRNA levels	972:994	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	10	from	patients	1095:1102	arg1	metastasis					1031:1040	lymph node (LN) metastasis	1015:1040	lymph node (LN) metastasis	1015:1040	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	11	theme	mRNA	984:987	arg1	levels					989:994	higher RPN2 mRNA levels	972:994	higher RPN2 mRNA levels	972:994	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	5	12	theme	RPN2	580:583	arg1	expression					585:594	RPN2 expression	580:594	RPN2 expression	580:594	qRT-PCR was performed to explore the correlation between RPN2 expression and various clinical features in 38 patients.
33727825	2	13	theme	malignant	273:281	arg1	phenotype					283:291	malignant phenotype	273:291	malignant phenotype in several tumors	273:309	RPN2 was reported to be associated with malignant phenotype in several tumors.
33727825	10	14	theme	RPN2	1259:1262	arg1	knockdown					1264:1272	RPN2 knockdown	1259:1272	RPN2 knockdown	1259:1272	Western blotting revealed that RPN2 knockdown suppressed epithelial-mesenchymal transition (EMT) and inhibited the PI3K-Akt pathway.
33727825	8	15	theme	pathological	1060:1071	arg1	differentiation					1073:1087	pathological differentiation	1060:1087	pathological differentiation in 38 patients with BCa	1060:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	1	16	gly	glycoprotein	159:170	arg1	glycoprotein					159:170	a highly conserved glycoprotein	140:170	a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins	140:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	1	16	gly	glycoprotein	159:170	arg1	Ribophorin					116:125	BACKGROUND Ribophorin II	105:128	BACKGROUND Ribophorin II (RPN2)	105:135	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	6	17	theme	potential	752:760	arg1	mechanisms					762:771	its potential mechanisms	748:771	its potential mechanisms based on gene set enrichment analysis (GSEA)	748:816	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	6	18	theme	biological	681:690	arg1	activity					692:699	the biological activity	677:699	the biological activity of BCa both in vitro and in vivo	677:732	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	5	19	theme	various	600:606	arg1	features					617:624	various clinical features	600:624	various clinical features	600:624	qRT-PCR was performed to explore the correlation between RPN2 expression and various clinical features in 38 patients.
33727825	5	20	theme	clinical	608:615	arg1	features					617:624	various clinical features	600:624	various clinical features	600:624	qRT-PCR was performed to explore the correlation between RPN2 expression and various clinical features in 38 patients.
33727825	7	21	theme	human	870:874	arg1	BCa					876:878	human BCa	870:878	human BCa	870:878	RESULTS We found that RPN2 was highly expressed in human BCa compared with normal adjacent tissues.
33727825	8	22	dep	significant	931:941	arg1	positive					943:950	positive	943:950	positive	943:950	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	1	23	theme	conserved	149:157	arg1	glycoprotein					159:170	a highly conserved glycoprotein	140:170	a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins	140:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	1	23	theme	conserved	149:157	arg1	Ribophorin					116:125	BACKGROUND Ribophorin II	105:128	BACKGROUND Ribophorin II (RPN2)	105:135	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	10	24	theme	PI3K-Akt	1343:1350	arg1	pathway					1352:1358	the PI3K-Akt pathway	1339:1358	the PI3K-Akt pathway	1339:1358	Western blotting revealed that RPN2 knockdown suppressed epithelial-mesenchymal transition (EMT) and inhibited the PI3K-Akt pathway.
33727825	1	25	gly	glycosylation	197:209	arg1	proteins					223:230	multiple proteins	214:230	multiple proteins	214:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	7	26	dep	RESULTS	819:825	arg1	found					830:834	found	830:834	found that RPN2 was highly expressed in human BCa compared with normal adjacent tissues	830:916	RESULTS We found that RPN2 was highly expressed in human BCa compared with normal adjacent tissues.
33727825	6	27	theme	RPN2	669:672	arg1	effects					658:664	the effects	654:664	the effects of RPN2 on the biological activity of BCa both in vitro and in vivo	654:732	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	10	28	theme	Western	1228:1234	arg1	blotting					1236:1243	Western blotting	1228:1243	Western blotting	1228:1243	Western blotting revealed that RPN2 knockdown suppressed epithelial-mesenchymal transition (EMT) and inhibited the PI3K-Akt pathway.
33727825	5	29	from	features	617:624	arg1	patients					632:639	38 patients	629:639	38 patients	629:639	qRT-PCR was performed to explore the correlation between RPN2 expression and various clinical features in 38 patients.
33727825	8	30	theme	tumor	1000:1004	arg1	stage					1008:1012	tumor T stage	1000:1012	tumor T stage	1000:1012	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	11	31	theme	prognostic	1474:1483	arg1	factor					1485:1490	a promising prognostic factor	1462:1490	a promising prognostic factor	1462:1490	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	2	32	theme	several	296:302	arg1	tumors					304:309	several tumors	296:309	several tumors	296:309	RPN2 was reported to be associated with malignant phenotype in several tumors.
33727825	3	33	theme	bladder	345:351	arg1	BCa					361:363	BCa	361:363	BCa	361:363	However, the function of RPN2 in bladder cancer (BCa) remains unclear.
33727825	3	33	theme	bladder	345:351	arg1	cancer					353:358	bladder cancer	345:358	bladder cancer (BCa)	345:364	However, the function of RPN2 in bladder cancer (BCa) remains unclear.
33727825	11	34	from	target	1508:1513	arg1	BCa					1518:1520	BCa	1518:1520	BCa	1518:1520	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	0	35	theme	Poor	14:17	arg1	Prognosis					19:27	Poor Prognosis	14:27	Poor Prognosis	14:27	RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.
33727825	3	36	from	function	325:332	arg1	BCa					361:363	BCa	361:363	BCa	361:363	However, the function of RPN2 in bladder cancer (BCa) remains unclear.
33727825	3	36	from	function	325:332	arg1	cancer					353:358	bladder cancer	345:358	bladder cancer (BCa)	345:364	However, the function of RPN2 in bladder cancer (BCa) remains unclear.
33727825	6	37	from	effects	658:664	arg1	activity					692:699	the biological activity	677:699	the biological activity of BCa both in vitro and in vivo	677:732	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	11	38	theme	therapeutic	1496:1506	arg1	target					1508:1513	therapeutic target	1496:1513	therapeutic target in BCa	1496:1520	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	8	39	theme	node	1021:1024	arg1	metastasis					1031:1040	lymph node (LN) metastasis	1015:1040	lymph node (LN) metastasis	1015:1040	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	40	from	degree	1050:1055	arg1	patients					1095:1102	38 patients	1092:1102	38 patients with BCa	1092:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	1	41	theme	N-linked	188:195	arg1	glycosylation					197:209	the N-linked glycosylation	184:209	the N-linked glycosylation of multiple proteins	184:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	8	42	theme	lymph	1015:1019	arg1	LN					1027:1028	LN	1027:1028	LN	1027:1028	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	42	theme	lymph	1015:1019	arg1	node					1021:1024	lymph node	1015:1024	lymph node (LN) metastasis	1015:1040	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	4	43	theme	adjacent	421:428	arg1	tissues					430:436	adjacent tissues	421:436	adjacent tissues	421:436	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	8	44	from	levels	989:994	arg1	patients					1095:1102	38 patients	1092:1102	38 patients with BCa	1092:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	0	45	theme	Cancer	50:55	arg1	Growth					57:62	Bladder Cancer Growth	42:62	Bladder Cancer Growth	42:62	RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.
33727825	0	46	theme	PI3K-Akt	87:94	arg1	Pathway					96:102	the PI3K-Akt Pathway	83:102	the PI3K-Akt Pathway	83:102	RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.
33727825	1	47	theme	BACKGROUND	105:114	arg1	glycoprotein					159:170	a highly conserved glycoprotein	140:170	a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins	140:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	1	47	theme	BACKGROUND	105:114	arg1	Ribophorin					116:125	BACKGROUND Ribophorin II	105:128	BACKGROUND Ribophorin II (RPN2)	105:135	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	1	47	theme	BACKGROUND	105:114	arg1	RPN2					131:134	RPN2	131:134	RPN2	131:134	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	0	48	theme	Bladder	42:48	arg1	Growth					57:62	Bladder Cancer Growth	42:62	Bladder Cancer Growth	42:62	RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.
33727825	6	49	theme	enrichment	791:800	arg1	GSEA					812:815	GSEA	812:815	GSEA	812:815	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	6	49	theme	enrichment	791:800	arg1	analysis					802:809	gene set enrichment analysis	782:809	gene set enrichment analysis (GSEA)	782:816	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	6	50	theme	set	787:789	arg1	GSEA					812:815	GSEA	812:815	GSEA	812:815	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	6	50	theme	set	787:789	arg1	analysis					802:809	gene set enrichment analysis	782:809	gene set enrichment analysis (GSEA)	782:816	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	11	51	dep	CONCLUSION	1361:1370	arg1	suggest					1383:1389	suggest	1383:1389	suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa	1383:1520	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	11	52	from	factor	1485:1490	arg1	BCa					1518:1520	BCa	1518:1520	BCa	1518:1520	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	4	53	theme	Western	505:511	arg1	blotting					513:520	Western blotting	505:520	Western blotting	505:520	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	4	54	from	Expression	391:400	arg1	BCa					413:415	BCa	413:415	BCa	413:415	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	4	54	from	Expression	391:400	arg1	tissues					430:436	adjacent tissues	421:436	adjacent tissues	421:436	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	4	55	theme	METHODS	383:389	arg1	Expression					391:400	METHODS Expression	383:400	METHODS Expression of RPN2 in BCa and adjacent tissues	383:436	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	8	56	from	differentiation	1073:1087	arg1	patients					1095:1102	38 patients	1092:1102	38 patients with BCa	1092:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	7	57	theme	adjacent	901:908	arg1	tissues					910:916	normal adjacent tissues	894:916	normal adjacent tissues	894:916	RESULTS We found that RPN2 was highly expressed in human BCa compared with normal adjacent tissues.
33727825	8	58	theme	differentiation	1073:1087	arg1	degree					1050:1055	the degree	1046:1055	the degree of pathological differentiation in 38 patients with BCa	1046:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	58	theme	differentiation	1073:1087	arg1	stage					1008:1012	tumor T stage	1000:1012	tumor T stage	1000:1012	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	58	theme	differentiation	1073:1087	arg1	levels					989:994	higher RPN2 mRNA levels	972:994	higher RPN2 mRNA levels	972:994	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	58	theme	differentiation	1073:1087	arg1	metastasis					1031:1040	lymph node (LN) metastasis	1015:1040	lymph node (LN) metastasis	1015:1040	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	8	59	with	patients	1095:1102	arg1	BCa					1109:1111	BCa	1109:1111	BCa	1109:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	4	60	theme	RPN2	405:408	arg1	Expression					391:400	METHODS Expression	383:400	METHODS Expression of RPN2 in BCa and adjacent tissues	383:436	METHODS Expression of RPN2 in BCa and adjacent tissues was compared by bioinformatics analysis, immunohistochemistry, and Western blotting.
33727825	10	61	theme	epithelial-mesenchymal	1285:1306	arg1	EMT					1320:1322	EMT	1320:1322	EMT	1320:1322	Western blotting revealed that RPN2 knockdown suppressed epithelial-mesenchymal transition (EMT) and inhibited the PI3K-Akt pathway.
33727825	10	61	theme	epithelial-mesenchymal	1285:1306	arg1	transition					1308:1317	epithelial-mesenchymal transition	1285:1317	epithelial-mesenchymal transition (EMT)	1285:1323	Western blotting revealed that RPN2 knockdown suppressed epithelial-mesenchymal transition (EMT) and inhibited the PI3K-Akt pathway.
33727825	1	62	theme	multiple	214:221	arg1	proteins					223:230	multiple proteins	214:230	multiple proteins	214:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	9	63	theme	RPN2	1143:1146	arg1	silencing					1148:1156	RPN2 silencing	1143:1156	RPN2 silencing	1143:1156	We further demonstrated that RPN2 silencing inhibited the growth and metastasis of BCa both in vitro and in vivo.
33727825	6	64	theme	BCa	704:706	arg1	activity					692:699	the biological activity	677:699	the biological activity of BCa both in vitro and in vivo	677:732	We assessed the effects of RPN2 on the biological activity of BCa both in vitro and in vivo, and explored its potential mechanisms based on gene set enrichment analysis (GSEA).
33727825	5	65	from	expression	585:594	arg1	patients					632:639	38 patients	629:639	38 patients	629:639	qRT-PCR was performed to explore the correlation between RPN2 expression and various clinical features in 38 patients.
33727825	11	66	theme	promising	1464:1472	arg1	factor					1485:1490	a promising prognostic factor	1462:1490	a promising prognostic factor	1462:1490	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	1	67	theme	proteins	223:230	arg1	glycosylation					197:209	the N-linked glycosylation	184:209	the N-linked glycosylation of multiple proteins	184:230	BACKGROUND Ribophorin II (RPN2) is a highly conserved glycoprotein involved in the N-linked glycosylation of multiple proteins.
33727825	9	68	theme	BCa	1197:1199	arg1	metastasis					1183:1192	metastasis	1183:1192	metastasis	1183:1192	We further demonstrated that RPN2 silencing inhibited the growth and metastasis of BCa both in vitro and in vivo.
33727825	9	68	theme	BCa	1197:1199	arg1	growth					1172:1177	growth	1172:1177	growth	1172:1177	We further demonstrated that RPN2 silencing inhibited the growth and metastasis of BCa both in vitro and in vivo.
33727825	8	69	theme	T	1006:1006	arg1	stage					1008:1012	tumor T stage	1000:1012	tumor T stage	1000:1012	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33727825	11	70	theme	tumor	1437:1441	arg1	development					1443:1453	tumor development	1437:1453	tumor development	1437:1453	CONCLUSION These data suggest that RPN2 functions as an oncogene to promote tumor development and is a promising prognostic factor and therapeutic target in BCa.
33727825	8	71	from	stage	1008:1012	arg1	patients					1095:1102	38 patients	1092:1102	38 patients with BCa	1092:1111	There was a significant positive correlation between higher RPN2 mRNA levels and tumor T stage, lymph node (LN) metastasis and the degree of pathological differentiation in 38 patients with BCa.
33710874	3	0	theme	reagents	561:568	arg1	use					524:526	use	524:526	use of cysteine directed conjugation reagents	524:568	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	3	0	theme	reagents	561:568	arg1	residues					398:405	Cysteine residues	389:405	Cysteine residues	389:405	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	3	0	theme	reagents	561:568	arg1	route					432:436	a route	430:436	a route to site-selectively modify proteins	430:472	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	1	1	theme	biology	261:267	arg1	field					243:247	the field	239:247	the field of chemical biology	239:267	Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology.
33710874	6	2	theme	motif	976:980	arg1	application					941:951	the application	937:951	the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue	937:1088	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	11	3	theme	environments	2096:2107	arg1	range					2073:2077	a range	2071:2077	a range of physiological environments	2071:2107	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	11	4	theme	physiological	2082:2094	arg1	environments					2096:2107	physiological environments	2082:2107	physiological environments	2082:2107	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	1	5	theme	proteins	205:212	arg1	synthesis					172:180	the site-selective synthesis	153:180	the site-selective synthesis of chemically modified proteins	153:212	Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology.
33710874	4	6	theme	thiol	685:689	arg1	present					691:697	thiol present	685:697	thiol present in blood	685:706	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	2	7	theme	pharmacokinetic	319:333	arg1	profiles					335:342	advantageous pharmacokinetic profiles	306:342	advantageous pharmacokinetic profiles	306:342	Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo.
33710874	8	8	link	linked	1413:1418	arg1	thio-bioconjugates					1420:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	11	9	theme	unique	1972:1977	arg1	control					1979:1985	unique control	1972:1985	unique control over linker cleavability toward thiols	1972:2024	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	8	10	theme	Thiol	1355:1359	arg1	appraisal					1374:1382	Thiol cleavability appraisal	1355:1382	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates	1355:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	11	11	theme	thiol	1920:1924	arg1	use					1911:1913	the use	1907:1913	the use of a thiol	1907:1924	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	11	11	theme	thiol	1920:1924	arg1	amine					1932:1936	an amine	1929:1936	an amine for functionalization	1929:1958	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	5	12	theme	site-selective	772:785	arg1	attachment					787:796	the site-selective attachment	768:796	the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	768:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	8	13	dep	linked	1413:1418	arg1	C-N					1409:1411	C-N	1409:1411	C-N	1409:1411	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	9	14	dep	motifs	1679:1684	arg1	motifs					1679:1684	clinically relevant motifs	1659:1684	clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide	1659:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	14	dep	motifs	1679:1684	arg1	peptide					1749:1755	a model peptide	1741:1755	a model peptide	1741:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	14	dep	motifs	1679:1684	arg1	chain					1730:1734	a polyethylene glycol chain	1708:1734	a polyethylene glycol chain	1708:1734	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	14	dep	motifs	1679:1684	arg1	fluorescein					1695:1705	fluorescein	1695:1705	fluorescein	1695:1705	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	14	dep	motifs	1679:1684	arg1	biotin					1687:1692	biotin	1687:1692	biotin	1687:1692	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	11	15	theme	novel	2041:2045	arg1	linker					2047:2052	this novel linker	2036:2052	this novel linker	2036:2052	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	9	16	theme	plug-and-play	1593:1605	arg1	platform					1621:1628	The plug-and-play trifunctional platform	1589:1628	The plug-and-play trifunctional platform	1589:1628	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	7	17	theme	dual	1128:1131	arg1	work					1146:1149	previously documented dual modification work	1106:1149	previously documented dual modification work	1106:1149	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	10	18	theme	site-selective	1857:1870	arg1	fashion					1872:1878	a site-selective fashion	1855:1878	a site-selective fashion	1855:1878	This platform provides a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion.
33710874	8	19	theme	glutathione	1576:1586	arg1	excess					1566:1571	an excess	1563:1571	an excess of glutathione	1563:1586	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	8	20	theme	C-S	1401:1403	arg1	thio-bioconjugates					1420:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	0	21	theme	Cysteine	60:67	arg1	Bioconjugates					69:81	Trifunctional Cysteine Bioconjugates	46:81	Trifunctional Cysteine Bioconjugates	46:81	A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability.
33710874	5	22	theme	cysteine-targeting	733:750	arg1	reagents					752:759	only a few cysteine-targeting reagents	722:759	only a few cysteine-targeting reagents	722:759	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	6	23	theme	cysteine	1073:1080	arg1	residue					1082:1088	a single cysteine residue	1064:1088	a single cysteine residue	1064:1088	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	7	24	from	point	1241:1245	arg1	scaffold					1270:1277	the pyridazinedione scaffold	1250:1277	the pyridazinedione scaffold	1250:1277	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	8	25	theme	thio-bioconjugates	1420:1437	arg1	appraisal					1374:1382	Thiol cleavability appraisal	1355:1382	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates	1355:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	9	26	theme	relevant	1670:1677	arg1	motifs					1679:1684	clinically relevant motifs	1659:1684	clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide	1659:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	26	theme	relevant	1670:1677	arg1	peptide					1749:1755	a model peptide	1741:1755	a model peptide	1741:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	26	theme	relevant	1670:1677	arg1	chain					1730:1734	a polyethylene glycol chain	1708:1734	a polyethylene glycol chain	1708:1734	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	26	theme	relevant	1670:1677	arg1	fluorescein					1695:1705	fluorescein	1695:1705	fluorescein	1695:1705	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	26	theme	relevant	1670:1677	arg1	biotin					1687:1692	biotin	1687:1692	biotin	1687:1692	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	8	27	theme	C-S	1452:1454	arg1	linkers					1471:1477	C-S functionalized linkers	1452:1477	C-S functionalized linkers	1452:1477	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	11	28	theme	linker	1992:1997	arg1	cleavability					1999:2010	linker cleavability	1992:2010	linker cleavability toward thiols	1992:2024	Furthermore, by selecting the use of a thiol or an amine for functionalization, we provide unique control over linker cleavability toward thiols, allowing this novel linker to be applied in a range of physiological environments.
33710874	5	29	theme	functionalities	810:824	arg1	attachment					787:796	the site-selective attachment	768:796	the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	768:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	0	30	theme	Bioconjugates	69:81	arg1	Formation					33:41	the Formation	29:41	the Formation of Trifunctional Cysteine Bioconjugates	29:81	A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability.
33710874	5	31	theme	blood	887:891	arg1	functionalities					810:824	multiple functionalities	801:824	multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	801:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	31	theme	blood	887:891	arg1	extension					903:911	therapeutic blood half-life extension	875:911	therapeutic blood half-life extension	875:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	4	32	theme	maleimide-thiol	613:627	arg1	conjugates					629:638	maleimide-thiol conjugates	613:638	maleimide-thiol conjugates	613:638	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	9	33	theme	polyethylene	1710:1721	arg1	motifs					1679:1684	clinically relevant motifs	1659:1684	clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide	1659:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	33	theme	polyethylene	1710:1721	arg1	chain					1730:1734	a polyethylene glycol chain	1708:1734	a polyethylene glycol chain	1708:1734	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	3	34	theme	cysteine	531:538	arg1	reagents					561:568	cysteine directed conjugation reagents	531:568	cysteine directed conjugation reagents	531:568	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	7	35	theme	additional	1221:1230	arg1	point					1241:1245	an additional reactive point	1218:1245	an additional reactive point on the pyridazinedione scaffold	1218:1277	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	7	35	theme	additional	1221:1230	arg1	group					1209:1213	group	1209:1213	group	1209:1213	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	4	36	theme	used	589:592	arg1	linkers					594:600	commonly used linkers	580:600	commonly used linkers	580:600	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	4	36	theme	used	589:592	arg1	conjugates					629:638	maleimide-thiol conjugates	613:638	maleimide-thiol conjugates	613:638	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	6	37	theme	site-selective	992:1005	arg1	attachment					1007:1016	site-selective attachment	992:1016	site-selective attachment of three functionalities to a protein bearing a single cysteine residue	992:1088	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	9	38	theme	model	1743:1747	arg1	motifs					1679:1684	clinically relevant motifs	1659:1684	clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide	1659:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	38	theme	model	1743:1747	arg1	peptide					1749:1755	a model peptide	1741:1755	a model peptide	1741:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	4	39	theme	low	663:665	arg1	concentrations					667:680	the low concentrations	659:680	the low concentrations of thiol present in blood	659:706	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	7	40	theme	aniline	1291:1297	arg1	derivative					1299:1308	a thiol or aniline derivative	1280:1308	derivative	1299:1308	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	3	41	theme	conjugation	549:559	arg1	reagents					561:568	cysteine directed conjugation reagents	531:568	cysteine directed conjugation reagents	531:568	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	1	42	theme	chemical	252:259	arg1	biology					261:267	chemical biology	252:267	chemical biology	252:267	Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology.
33710874	2	43	theme	advantageous	306:317	arg1	profiles					335:342	advantageous pharmacokinetic profiles	306:342	advantageous pharmacokinetic profiles	306:342	Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo.
33710874	6	44	theme	pyridazinedione	960:974	arg1	motif					976:980	the pyridazinedione motif	956:980	the pyridazinedione motif	956:980	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	5	45	theme	theranostics	858:869	arg1	fields					848:853	the fields	844:853	the fields of theranostics	844:869	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	10	46	from	functionalities	1823:1837	arg1	protein					1844:1850	a protein	1842:1850	a protein	1842:1850	This platform provides a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion.
33710874	4	47	from	blood	702:706	arg1	concentrations					667:680	the low concentrations	659:680	the low concentrations of thiol present in blood	659:706	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	1	48	theme	modified	196:203	arg1	proteins					205:212	chemically modified proteins	185:212	chemically modified proteins	185:212	Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology.
33710874	4	49	from	present	691:697	arg1	blood					702:706	blood	702:706	blood	702:706	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	5	50	theme	half-life	893:901	arg1	functionalities					810:824	multiple functionalities	801:824	multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	801:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	50	theme	half-life	893:901	arg1	extension					903:911	therapeutic blood half-life extension	875:911	therapeutic blood half-life extension	875:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	2	51	theme	in	380:381	arg1	efficacy					371:378	increased efficacy	361:378	increased efficacy in vivo	361:386	Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo.
33710874	1	52	theme	great	221:225	arg1	interest					227:234	great interest	221:234	great interest	221:234	Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology.
33710874	6	53	theme	functionalities	1027:1041	arg1	attachment					1007:1016	site-selective attachment	992:1016	site-selective attachment of three functionalities to a protein bearing a single cysteine residue	992:1088	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	4	54	theme	present	691:697	arg1	concentrations					667:680	the low concentrations	659:680	the low concentrations of thiol present in blood	659:706	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	7	55	theme	modification	1133:1144	arg1	work					1146:1149	previously documented dual modification work	1106:1149	previously documented dual modification work	1106:1149	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	6	56	attach	attachment	1007:1016	arg2	functionalities					1027:1041	three functionalities	1021:1041	three functionalities	1021:1041	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	6	56	attach	attachment	1007:1016	arg1	protein					1048:1054	a protein	1046:1054	a protein bearing a single cysteine residue	1046:1088	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	5	57	dep	functionalities	810:824	arg1	functionalities					810:824	multiple functionalities	801:824	multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	801:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	57	dep	functionalities	810:824	arg1	extension					903:911	therapeutic blood half-life extension	875:911	therapeutic blood half-life extension	875:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	57	dep	functionalities	810:824	arg1	tool					836:839	a useful tool	827:839	a useful tool in the fields of theranostics	827:869	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	8	58	theme	cleavability	1361:1372	arg1	appraisal					1374:1382	Thiol cleavability appraisal	1355:1382	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates	1355:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	7	59	theme	documented	1117:1126	arg1	work					1146:1149	previously documented dual modification work	1106:1149	previously documented dual modification work	1106:1149	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	5	60	from	tool	836:839	arg1	fields					848:853	the fields	844:853	the fields of theranostics	844:869	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	2	61	theme	Homogenous	270:279	arg1	bioconjugates					281:293	Homogenous bioconjugates	270:293	Homogenous bioconjugates	270:293	Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo.
33710874	5	62	from	extension	903:911	arg1	fields					848:853	the fields	844:853	the fields of theranostics	844:869	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	9	63	theme	trifunctional	1607:1619	arg1	platform					1621:1628	The plug-and-play trifunctional platform	1589:1628	The plug-and-play trifunctional platform	1589:1628	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	4	64	from	concentrations	667:680	arg1	blood					702:706	blood	702:706	blood	702:706	However, commonly used linkers, including maleimide-thiol conjugates, are not stable to the low concentrations of thiol present in blood.
33710874	8	65	theme	resultant	1391:1399	arg1	thio-bioconjugates					1420:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	5	66	theme	useful	829:834	arg1	functionalities					810:824	multiple functionalities	801:824	multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	801:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	66	theme	useful	829:834	arg1	tool					836:839	a useful tool	827:839	a useful tool in the fields of theranostics	827:869	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	1	67	theme	site-selective	157:170	arg1	synthesis					172:180	the site-selective synthesis	153:180	the site-selective synthesis of chemically modified proteins	153:212	Linkers that enable the site-selective synthesis of chemically modified proteins are of great interest to the field of chemical biology.
33710874	7	68	theme	thiol	1282:1286	arg1	derivative					1299:1308	a thiol or aniline derivative	1280:1308	derivative	1299:1308	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	6	69	theme	single	1066:1071	arg1	residue					1082:1088	a single cysteine residue	1064:1088	a single cysteine residue	1064:1088	Herein, we demonstrate the application of the pyridazinedione motif to enable site-selective attachment of three functionalities to a protein bearing a single cysteine residue.
33710874	10	70	dep	three	1817:1821	arg1	to					1814:1815	to	1814:1815	to	1814:1815	This platform provides a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion.
33710874	8	71	theme	linked	1413:1418	arg1	thio-bioconjugates					1420:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	the resultant C-S and C-N linked thio-bioconjugates	1387:1437	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	0	72	theme	Thiol	113:117	arg1	Cleavability					119:130	Thiol Cleavability	113:130	Thiol Cleavability	113:130	A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability.
33710874	3	73	theme	Cysteine	389:396	arg1	use					524:526	use	524:526	use of cysteine directed conjugation reagents	524:568	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	3	73	theme	Cysteine	389:396	arg1	residues					398:405	Cysteine residues	389:405	Cysteine residues	389:405	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	3	73	theme	Cysteine	389:396	arg1	route					432:436	a route	430:436	a route to site-selectively modify proteins	430:472	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	3	74	theme	many	479:482	arg1	therapeutics					506:517	many successfully approved therapeutics	479:517	many successfully approved therapeutics	479:517	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	0	75	theme	Plug-and-Play	2:14	arg1	Platform					16:23	A Plug-and-Play Platform	0:23	A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability.	0:131	A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability.
33710874	8	76	theme	functionalized	1456:1469	arg1	linkers					1471:1477	C-S functionalized linkers	1452:1477	C-S functionalized linkers	1452:1477	Thiol cleavability appraisal of the resultant C-S and C-N linked thio-bioconjugates demonstrated C-S functionalized linkers to be cleavable and C-N functionalized linkers to be noncleavable when incubated in an excess of glutathione.
33710874	5	77	theme	therapeutic	875:885	arg1	functionalities					810:824	multiple functionalities	801:824	multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	801:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	77	theme	therapeutic	875:885	arg1	extension					903:911	therapeutic blood half-life extension	875:911	therapeutic blood half-life extension	875:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	2	78	dep	in	380:381	arg1	vivo					383:386	vivo	383:386	vivo	383:386	Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo.
33710874	10	79	theme	rare	1783:1786	arg1	opportunity					1788:1798	a rare opportunity	1781:1798	a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion	1781:1878	This platform provides a rare opportunity to combine up to three functionalities on a protein in a site-selective fashion.
33710874	7	80	theme	reactive	1232:1239	arg1	point					1241:1245	an additional reactive point	1218:1245	an additional reactive point on the pyridazinedione scaffold	1218:1277	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	7	80	theme	reactive	1232:1239	arg1	group					1209:1213	group	1209:1213	group	1209:1213	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33710874	3	81	theme	approved	497:504	arg1	therapeutics					506:517	many successfully approved therapeutics	479:517	many successfully approved therapeutics	479:517	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	0	82	theme	Trifunctional	46:58	arg1	Bioconjugates					69:81	Trifunctional Cysteine Bioconjugates	46:81	Trifunctional Cysteine Bioconjugates	46:81	A Plug-and-Play Platform for the Formation of Trifunctional Cysteine Bioconjugates that also Offers Control over Thiol Cleavability.
33710874	9	83	theme	glycol	1723:1728	arg1	motifs					1679:1684	clinically relevant motifs	1659:1684	clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide	1659:1755	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	9	83	theme	glycol	1723:1728	arg1	chain					1730:1734	a polyethylene glycol chain	1708:1734	a polyethylene glycol chain	1708:1734	The plug-and-play trifunctional platform was exemplified by attaching clinically relevant motifs: biotin, fluorescein, a polyethylene glycol chain, and a model peptide.
33710874	3	84	theme	directed	540:547	arg1	reagents					561:568	cysteine directed conjugation reagents	531:568	cysteine directed conjugation reagents	531:568	Cysteine residues have been exploited as a route to site-selectively modify proteins, and many successfully approved therapeutics make use of cysteine directed conjugation reagents.
33710874	5	85	theme	multiple	801:808	arg1	functionalities					810:824	multiple functionalities	801:824	multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension	801:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	85	theme	multiple	801:808	arg1	extension					903:911	therapeutic blood half-life extension	875:911	therapeutic blood half-life extension	875:911	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	5	85	theme	multiple	801:808	arg1	tool					836:839	a useful tool	827:839	a useful tool in the fields of theranostics	827:869	Furthermore, only a few cysteine-targeting reagents enable the site-selective attachment of multiple functionalities: a useful tool in the fields of theranostics and therapeutic blood half-life extension.
33710874	2	86	theme	increased	361:369	arg1	efficacy					371:378	increased efficacy	361:378	increased efficacy in vivo	361:386	Homogenous bioconjugates often show advantageous pharmacokinetic profiles and consequently increased efficacy in vivo.
33710874	7	87	theme	pyridazinedione	1254:1268	arg1	scaffold					1270:1277	the pyridazinedione scaffold	1250:1277	the pyridazinedione scaffold	1250:1277	Extending upon previously documented dual modification work, here we demonstrate that by exploiting a bromide leaving group as an additional reactive point on the pyridazinedione scaffold, a thiol or aniline derivative can be added to a protein, post-conjugation.
33442744	7	0	from	structures	1025:1034	arg1	micelles					1100:1107	micelles	1100:1107	micelles	1100:1107	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	6	1	from	Met18	893:897	arg1	Mutation					864:871	Mutation	864:871	Mutation of any residue from Met18 to Ile24 of Ost4	864:914	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
33442744	6	1	from	Met18	893:897	arg1	residue					880:886	any residue	876:886	any residue from Met18	876:897	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
33442744	7	2	theme	Ost4V23D	1088:1095	arg1	simulations					1064:1074	molecular dynamics (MD) simulations	1040:1074	molecular dynamics (MD) simulations	1040:1074	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	7	2	theme	Ost4V23D	1088:1095	arg1	structures					1025:1034	solution nuclear magnetic resonance structures	989:1034	solution nuclear magnetic resonance structures	989:1034	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	9	3	contain	containing	1355:1364	arg1	complex					1347:1353	the membrane-bound OST complex	1324:1353	the membrane-bound OST complex containing either WT or V23D mutant	1324:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	9	3	contain	containing	1355:1364	arg2	mutant					1384:1389	either WT or V23D mutant	1366:1389	mutant	1384:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	9	3	contain	containing	1355:1364	arg2	WT					1373:1374	either WT or V23D mutant	1366:1389	WT	1373:1374	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	2	4	theme	reaction	347:354	arg1	step					334:337	the central step	322:337	the central step of this reaction	322:354	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	6	5	theme	residue	880:886	arg1	Mutation					864:871	Mutation	864:871	Mutation of any residue from Met18 to Ile24 of Ost4	864:914	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
33442744	7	6	theme	Ost4	1079:1082	arg1	simulations					1064:1074	molecular dynamics (MD) simulations	1040:1074	molecular dynamics (MD) simulations	1040:1074	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	7	6	theme	Ost4	1079:1082	arg1	structures					1025:1034	solution nuclear magnetic resonance structures	989:1034	solution nuclear magnetic resonance structures	989:1034	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	9	7	theme	V23D	1379:1382	arg1	mutant					1384:1389	either WT or V23D mutant	1366:1389	mutant	1384:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	8	8	theme	point	1146:1150	arg1	mutation					1152:1159	the point mutation	1142:1159	the point mutation	1142:1159	Our studies revealed that while the point mutation did not impact the structure of the protein, it affected its position and solvent exposure in the membrane mimetic environment.
33442744	4	9	theme	multisubunit	660:671	arg1	OST					681:683	OST	681:683	OST	681:683	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	4	9	theme	multisubunit	660:671	arg1	enzyme					673:678	a membrane-associated multisubunit enzyme	638:678	a membrane-associated multisubunit enzyme	638:678	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	7	10	theme	MD	1060:1061	arg1	simulations					1064:1074	molecular dynamics (MD) simulations	1040:1074	molecular dynamics (MD) simulations	1040:1074	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	5	11	theme	OST	859:861	arg1	activity					847:854	activity	847:854	activity	847:854	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	11	theme	OST	859:861	arg1	stability					833:841	stability	833:841	stability	833:841	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	10	12	theme	OST	1558:1560	arg1	complex					1562:1568	the OST complex	1554:1568	the OST complex	1554:1568	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	1	13	from	modification	270:281	arg1	eukaryotes					286:295	eukaryotes	286:295	eukaryotes	286:295	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	13	from	modification	270:281	arg1	prokaryotes					306:316	some prokaryotes	301:316	some prokaryotes	301:316	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	3	14	theme	oligosaccharyltransferase	540:564	arg1	function					572:579	oligosaccharyltransferase (OST) function	540:579	oligosaccharyltransferase (OST) function	540:579	Complete loss of oligosaccharyltransferase (OST) function is lethal in eukaryotes.
33442744	9	15	theme	hydrophobic	1423:1433	arg1	interactions					1447:1458	most hydrophobic helix-helix interactions	1418:1458	most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12	1418:1498	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	0	16	theme	Ost4	121:124	arg1	function					69:76	the function	65:76	the function of yeast oligosaccharyltransferase subunit Ost4	65:124	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	9	17	theme	interactions	1447:1458	arg1	disruption					1404:1413	disruption	1404:1413	disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12	1404:1498	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	9	17	theme	interactions	1447:1458	arg1	TM13					1504:1507	TM13	1504:1507	TM13 of Stt3	1504:1515	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	6	18	theme	Ost4	911:914	arg1	Ile24					902:906	Ile24	902:906	Ile24 of Ost4	902:914	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
33442744	8	19	theme	solvent	1235:1241	arg1	exposure					1243:1250	solvent exposure	1235:1250	solvent exposure	1235:1250	Our studies revealed that while the point mutation did not impact the structure of the protein, it affected its position and solvent exposure in the membrane mimetic environment.
33442744	10	20	theme	solvent	1577:1583	arg1	exposure					1585:1592	solvent exposure	1577:1592	solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions	1577:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	7	21	theme	resonance	1015:1023	arg1	structures					1025:1034	solution nuclear magnetic resonance structures	989:1034	solution nuclear magnetic resonance structures	989:1034	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	3	22	theme	function	572:579	arg1	loss					532:535	Complete loss	523:535	Complete loss of oligosaccharyltransferase (OST) function	523:579	Complete loss of oligosaccharyltransferase (OST) function is lethal in eukaryotes.
33442744	4	23	theme	endoplasmic	703:713	arg1	reticulum					715:723	the endoplasmic reticulum	699:723	the endoplasmic reticulum	699:723	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	7	24	theme	nuclear	998:1004	arg1	resonance					1015:1023	solution nuclear magnetic resonance	989:1023	solution nuclear magnetic resonance structures	989:1034	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	9	25	theme	transmembrane	1481:1493	arg1	TM12					1495:1498	transmembrane TM12	1481:1498	transmembrane TM12	1481:1498	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	5	26	contain	contains	754:761	arg2	critical					804:811	critical	804:811	critical	804:811	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	26	contain	contains	754:761	arg1	Ost4					748:751	Ost4	748:751	Ost4	748:751	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	26	contain	contains	754:761	arg2	helix					790:794	a single membrane-spanning helix	763:794	a single membrane-spanning helix that is critical for maintaining the stability and activity of OST	763:861	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	26	contain	contains	754:761	arg1	subunit					739:745	The smallest subunit	726:745	The smallest subunit	726:745	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	8	27	theme	membrane	1259:1266	arg1	environment					1276:1286	the membrane mimetic environment	1255:1286	the membrane mimetic environment	1255:1286	Our studies revealed that while the point mutation did not impact the structure of the protein, it affected its position and solvent exposure in the membrane mimetic environment.
33442744	0	28	theme	mutation	53:60	arg1	impact					34:39	the impact	30:39	the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4	30:124	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	11	29	theme	Ost4	1720:1723	arg1	subunit					1725:1731	yeast Ost4 subunit	1714:1731	yeast Ost4 subunit	1714:1731	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	0	30	from	impact	34:39	arg1	function					69:76	the function	65:76	the function of yeast oligosaccharyltransferase subunit Ost4	65:124	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	1	31	link	N-linked	174:181	arg1	glycosylation					183:195	N-linked glycosylation	174:195	N-linked glycosylation	174:195	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	3	32	from	eukaryotes	594:603	arg1	lethal					584:589	lethal	584:589	lethal	584:589	Complete loss of oligosaccharyltransferase (OST) function is lethal in eukaryotes.
33442744	5	33	theme	smallest	730:737	arg1	Ost4					748:751	Ost4	748:751	Ost4	748:751	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	33	theme	smallest	730:737	arg1	subunit					739:745	The smallest subunit	726:745	The smallest subunit	726:745	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	10	34	theme	residue	1605:1611	arg1	exposure					1585:1592	solvent exposure	1577:1592	solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions	1577:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	0	35	theme	MD	8:9	arg1	simulations					11:21	MD simulations	8:21	MD simulations	8:21	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	7	36	from	simulations	1064:1074	arg1	micelles					1100:1107	micelles	1100:1107	micelles	1100:1107	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	1	37	link	Asparagine-linked	127:143	arg1	glycosylation					145:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	37	link	Asparagine-linked	127:143	arg1	modification					270:281	an essential and highly conserved co- and post-translational protein modification	201:281	an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes	201:316	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	3	38	from	lethal	584:589	arg1	eukaryotes					594:603	eukaryotes	594:603	eukaryotes	594:603	Complete loss of oligosaccharyltransferase (OST) function is lethal in eukaryotes.
33442744	2	39	theme	lipid-linked	401:412	arg1	donor					414:418	a lipid-linked donor	399:418	a lipid-linked donor	399:418	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	9	40	theme	MD	1306:1307	arg1	simulations					1309:1319	our MD simulations	1302:1319	our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant	1302:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	10	41	from	residue	1605:1611	arg1	pocket					1632:1637	the hydrophobic pocket	1616:1637	the hydrophobic pocket created by these interactions	1616:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	2	42	theme	asparagine	453:462	arg1	side-chain					427:436	the side-chain	423:436	the side-chain of a consensus asparagine in a nascent protein	423:483	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	5	43	theme	membrane-spanning	772:788	arg1	helix					790:794	a single membrane-spanning helix	763:794	a single membrane-spanning helix that is critical for maintaining the stability and activity of OST	763:861	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	43	theme	membrane-spanning	772:788	arg1	critical					804:811	critical	804:811	critical	804:811	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	2	44	from	side-chain	427:436	arg1	protein					477:483	a nascent protein	467:483	a nascent protein	467:483	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	9	45	theme	membrane-bound	1328:1341	arg1	complex					1347:1353	the membrane-bound OST complex	1324:1353	the membrane-bound OST complex containing either WT or V23D mutant	1324:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	10	46	from	pocket	1632:1637	arg1	exposure					1585:1592	solvent exposure	1577:1592	solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions	1577:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	2	47	theme	carbohydrate	359:370	arg1	moiety					372:377	a carbohydrate moiety	357:377	a carbohydrate moiety	357:377	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	9	48	theme	complex	1347:1353	arg1	simulations					1309:1319	our MD simulations	1302:1319	our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant	1302:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	10	49	from	complex	1562:1568	arg1	disengagement					1523:1535	This disengagement	1518:1535	This disengagement of Ost4V23D from the OST complex	1518:1568	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	11	50	theme	complex	1809:1815	arg1	destabilization					1782:1796	the destabilization	1778:1796	the destabilization of the OST complex	1778:1815	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	6	51	from	Mutation	864:871	arg1	Met18					893:897	Met18	893:897	Met18	893:897	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
33442744	3	52	theme	Complete	523:530	arg1	loss					532:535	Complete loss	523:535	Complete loss of oligosaccharyltransferase (OST) function	523:579	Complete loss of oligosaccharyltransferase (OST) function is lethal in eukaryotes.
33442744	1	53	theme	protein	262:268	arg1	glycosylation					145:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	53	theme	protein	262:268	arg1	modification					270:281	an essential and highly conserved co- and post-translational protein modification	201:281	an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes	201:316	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	10	54	from	exposure	1585:1592	arg1	pocket					1632:1637	the hydrophobic pocket	1616:1637	the hydrophobic pocket created by these interactions	1616:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	10	55	theme	Ost4V23D	1540:1547	arg1	disengagement					1523:1535	This disengagement	1518:1535	This disengagement of Ost4V23D from the OST complex	1518:1568	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	2	56	theme	nascent	469:475	arg1	protein					477:483	a nascent protein	467:483	a nascent protein	467:483	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	1	57	theme	N-linked	174:181	arg1	glycosylation					183:195	N-linked glycosylation	174:195	N-linked glycosylation	174:195	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	8	58	theme	protein	1197:1203	arg1	structure					1180:1188	the structure	1176:1188	the structure of the protein	1176:1203	Our studies revealed that while the point mutation did not impact the structure of the protein, it affected its position and solvent exposure in the membrane mimetic environment.
33442744	7	59	theme	molecular	1040:1048	arg1	simulations					1064:1074	molecular dynamics (MD) simulations	1040:1074	molecular dynamics (MD) simulations	1040:1074	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	9	60	theme	most	1418:1421	arg1	interactions					1447:1458	most hydrophobic helix-helix interactions	1418:1458	most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12	1418:1498	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	6	61	theme	enzyme	933:938	arg1	complex					940:946	the enzyme complex	929:946	the enzyme complex	929:946	Mutation of any residue from Met18 to Ile24 of Ost4 destabilizes the enzyme complex, affecting its activity.
33442744	2	62	from	protein	477:483	arg1	side-chain					427:436	the side-chain	423:436	the side-chain of a consensus asparagine in a nascent protein	423:483	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	4	63	theme	membrane-associated	640:658	arg1	OST					681:683	OST	681:683	OST	681:683	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	4	63	theme	membrane-associated	640:658	arg1	enzyme					673:678	a membrane-associated multisubunit enzyme	638:678	a membrane-associated multisubunit enzyme	638:678	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	9	64	theme	helix-helix	1435:1445	arg1	interactions					1447:1458	most hydrophobic helix-helix interactions	1418:1458	most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12	1418:1498	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	7	65	theme	magnetic	1006:1013	arg1	resonance					1015:1023	solution nuclear magnetic resonance	989:1023	solution nuclear magnetic resonance structures	989:1034	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	0	66	theme	subunit	113:119	arg1	Ost4					121:124	yeast oligosaccharyltransferase subunit Ost4	81:124	yeast oligosaccharyltransferase subunit Ost4	81:124	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	7	67	theme	solution	989:996	arg1	resonance					1015:1023	solution nuclear magnetic resonance	989:1023	solution nuclear magnetic resonance structures	989:1034	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	11	68	theme	yeast	1714:1718	arg1	subunit					1725:1731	yeast Ost4 subunit	1714:1731	yeast Ost4 subunit	1714:1731	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	0	69	theme	V23D	48:51	arg1	mutation					53:60	the V23D mutation	44:60	the V23D mutation	44:60	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	1	70	theme	Asparagine-linked	127:143	arg1	glycosylation					145:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	70	theme	Asparagine-linked	127:143	arg1	modification					270:281	an essential and highly conserved co- and post-translational protein modification	201:281	an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes	201:316	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	4	71	located	localized	686:694	arg2	enzyme					673:678	a membrane-associated multisubunit enzyme	638:678	a membrane-associated multisubunit enzyme	638:678	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	4	71	located	localized	686:694	arg1	reticulum					715:723	the endoplasmic reticulum	699:723	the endoplasmic reticulum	699:723	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	4	71	located	localized	686:694	arg2	OST					681:683	OST	681:683	OST	681:683	This reaction is carried out by a membrane-associated multisubunit enzyme, OST, localized in the endoplasmic reticulum.
33442744	7	72	theme	dynamics	1050:1057	arg1	simulations					1064:1074	molecular dynamics (MD) simulations	1040:1074	molecular dynamics (MD) simulations	1040:1074	Here, we report solution nuclear magnetic resonance structures and molecular dynamics (MD) simulations of Ost4 and Ost4V23D in micelles.
33442744	8	73	theme	mimetic	1268:1274	arg1	environment					1276:1286	the membrane mimetic environment	1255:1286	the membrane mimetic environment	1255:1286	Our studies revealed that while the point mutation did not impact the structure of the protein, it affected its position and solvent exposure in the membrane mimetic environment.
33442744	1	74	dep	conserved	225:233	arg1	post-translational					243:260	post-translational	243:260	post-translational	243:260	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	74	dep	conserved	225:233	arg1	co-					235:237	co-	235:237	co-	235:237	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	9	75	theme	Stt3	1512:1515	arg1	disruption					1404:1413	disruption	1404:1413	disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12	1404:1498	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	9	75	theme	Stt3	1512:1515	arg1	TM13					1504:1507	TM13	1504:1507	TM13 of Stt3	1504:1515	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	2	76	from	asparagine	453:462	arg1	protein					477:483	a nascent protein	467:483	a nascent protein	467:483	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	11	77	theme	subunit	1725:1731	arg1	mutant					1741:1746	its mutant	1737:1746	its mutant	1737:1746	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	11	77	theme	subunit	1725:1731	arg1	structures					1700:1709	the structures	1696:1709	the structures of yeast Ost4 subunit	1696:1731	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	0	78	theme	yeast	81:85	arg1	Ost4					121:124	yeast oligosaccharyltransferase subunit Ost4	81:124	yeast oligosaccharyltransferase subunit Ost4	81:124	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	10	79	theme	D23	1601:1603	arg1	residue					1605:1611	the D23 residue	1597:1611	the D23 residue in the hydrophobic pocket created by these interactions	1597:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	11	80	theme	reduced	1821:1827	arg1	activity					1833:1840	reduced OST activity	1821:1840	reduced OST activity	1821:1840	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	1	81	theme	conserved	225:233	arg1	glycosylation					145:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	81	theme	conserved	225:233	arg1	modification					270:281	an essential and highly conserved co- and post-translational protein modification	201:281	an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes	201:316	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	10	82	theme	hydrophobic	1620:1630	arg1	pocket					1632:1637	the hydrophobic pocket	1616:1637	the hydrophobic pocket created by these interactions	1616:1667	This disengagement of Ost4V23D from the OST complex led to solvent exposure of the D23 residue in the hydrophobic pocket created by these interactions.
33442744	5	83	theme	single	765:770	arg1	helix					790:794	a single membrane-spanning helix	763:794	a single membrane-spanning helix that is critical for maintaining the stability and activity of OST	763:861	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	5	83	theme	single	765:770	arg1	critical					804:811	critical	804:811	critical	804:811	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	2	84	theme	consensus	443:451	arg1	asparagine					453:462	a consensus asparagine	441:462	a consensus asparagine in a nascent protein	441:483	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	2	85	link	lipid-linked	401:412	arg1	donor					414:418	a lipid-linked donor	399:418	a lipid-linked donor	399:418	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	11	86	theme	OST	1805:1807	arg1	complex					1809:1815	the OST complex	1801:1815	the OST complex	1801:1815	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33442744	5	87	dep	stability	833:841	arg1	the					829:831	the	829:831	the	829:831	The smallest subunit, Ost4, contains a single membrane-spanning helix that is critical for maintaining the stability and activity of OST.
33442744	2	88	theme	central	326:332	arg1	step					334:337	the central step	322:337	the central step of this reaction	322:354	In the central step of this reaction, a carbohydrate moiety is transferred from a lipid-linked donor to the side-chain of a consensus asparagine in a nascent protein as it is synthesized at the ribosome.
33442744	9	89	theme	OST	1343:1345	arg1	complex					1347:1353	the membrane-bound OST complex	1324:1353	the membrane-bound OST complex containing either WT or V23D mutant	1324:1389	Furthermore, our MD simulations of the membrane-bound OST complex containing either WT or V23D mutant demonstrated disruption of most hydrophobic helix-helix interactions between Ost4V23D and transmembrane TM12 and TM13 of Stt3.
33442744	1	90	theme	essential	204:212	arg1	glycosylation					145:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation	127:157	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	1	90	theme	essential	204:212	arg1	modification					270:281	an essential and highly conserved co- and post-translational protein modification	201:281	an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes	201:316	Asparagine-linked glycosylation, also known as N-linked glycosylation, is an essential and highly conserved co- and post-translational protein modification in eukaryotes and some prokaryotes.
33442744	0	91	theme	oligosaccharyltransferase	87:111	arg1	Ost4					121:124	yeast oligosaccharyltransferase subunit Ost4	81:124	yeast oligosaccharyltransferase subunit Ost4	81:124	NMR and MD simulations reveal the impact of the V23D mutation on the function of yeast oligosaccharyltransferase subunit Ost4.
33442744	11	92	theme	OST	1829:1831	arg1	activity					1833:1840	reduced OST activity	1821:1840	reduced OST activity	1821:1840	Our study not only solves the structures of yeast Ost4 subunit and its mutant but also provides a basis for the destabilization of the OST complex and reduced OST activity.
33326789	5	0	theme	Fc-profiling	769:780	arg1	approach					782:789	a comprehensive antibody Fc-profiling approach	744:789	a comprehensive antibody Fc-profiling approach	744:789	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	1	1	attach	linked	111:116	arg1	inflammation					121:132	inflammation	121:132	inflammation	121:132	Changes in antibody glycosylation are linked to inflammation across several diseases.
33326789	1	1	attach	linked	111:116	arg2	Changes					73:79	Changes	73:79	Changes in antibody glycosylation	73:105	Changes in antibody glycosylation are linked to inflammation across several diseases.
33326789	3	2	theme	antibody	467:474	arg1	biology					479:485	antibody Fc biology	467:485	antibody Fc biology	467:485	However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear.
33326789	1	3	from	Changes	73:79	arg1	glycosylation					93:105	antibody glycosylation	84:105	antibody glycosylation	84:105	Changes in antibody glycosylation are linked to inflammation across several diseases.
33326789	3	4	theme	Fc	476:477	arg1	biology					479:485	antibody Fc biology	467:485	antibody Fc biology	467:485	However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear.
33326789	2	5	theme	cancer	289:294	arg1	relapse					296:302	gastric cancer relapse	281:302	gastric cancer relapse	281:302	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	6	6	theme	promising	1022:1030	arg1	marker					1049:1054	a promising, simply measured marker	1020:1054	a promising, simply measured marker to track reservoir reactivation	1020:1086	Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
33326789	5	7	theme	antibody	818:825	arg1	N-galactosylation					830:846	HIV-specific antibody Fc N-galactosylation	805:846	HIV-specific antibody Fc N-galactosylation	805:846	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	3	8	theme	rebound	513:519	arg1	time					521:524	reservoir rebound time	503:524	reservoir rebound time	503:524	However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear.
33326789	2	9	theme	gastric	281:287	arg1	relapse					296:302	gastric cancer relapse	281:302	gastric cancer relapse	281:302	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	4	10	theme	viral	708:712	arg1	strategies					726:735	promising HIV viral eradication strategies	694:735	promising HIV viral eradication strategies	694:735	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	5	11	theme	independent	942:952	arg1	cohorts					954:960	three independent cohorts	936:960	three independent cohorts	936:960	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	0	12	theme	HIV	0:2	arg1	Glycosylation					25:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.
33326789	2	13	theme	reservoir	372:380	arg1	size					382:385	HIV reservoir size	368:385	HIV reservoir size on therapy	368:396	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	0	14	theme	Antibody	4:11	arg1	Glycosylation					25:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.
33326789	2	15	theme	HIV	368:370	arg1	reservoir					372:380	HIV reservoir	368:380	HIV reservoir size on therapy	368:396	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	2	16	theme	HIV	415:417	arg1	infections					427:436	HIV and HCV infections	415:436	HIV and HCV infections	415:436	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	3	17	from	changes	456:462	arg1	biology					479:485	antibody Fc biology	467:485	antibody Fc biology	467:485	However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear.
33326789	1	18	theme	antibody	84:91	arg1	glycosylation					93:105	antibody glycosylation	84:105	antibody glycosylation	84:105	Changes in antibody glycosylation are linked to inflammation across several diseases.
33326789	0	19	theme	N-Linked	16:23	arg1	Glycosylation					25:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.
33326789	4	20	theme	strategies	726:735	arg1	improvement					679:689	iterative improvement	669:689	iterative improvement	669:689	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	4	20	theme	strategies	726:735	arg1	downselection					651:663	downselection	651:663	downselection	651:663	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	4	21	theme	rebound	603:609	arg1	time					611:614	viral rebound time	597:614	viral rebound time	597:614	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	0	22	theme	Fc	13:14	arg1	Glycosylation					25:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation	0:37	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.
33326789	4	23	theme	viral	597:601	arg1	time					611:614	viral rebound time	597:614	viral rebound time	597:614	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	2	24	theme	antibody	179:186	arg1	galactosylation					188:202	bulk antibody galactosylation	174:202	bulk antibody galactosylation	174:202	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	4	25	theme	iterative	669:677	arg1	improvement					679:689	iterative improvement	669:689	iterative improvement	669:689	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	2	26	theme	bulk	174:177	arg1	galactosylation					188:202	bulk antibody galactosylation	174:202	bulk antibody galactosylation	174:202	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	5	27	theme	Fc	827:828	arg1	N-galactosylation					830:846	HIV-specific antibody Fc N-galactosylation	805:846	HIV-specific antibody Fc N-galactosylation	805:846	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	2	28	from	Alterations	159:169	arg1	galactosylation					188:202	bulk antibody galactosylation	174:202	bulk antibody galactosylation	174:202	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	5	29	theme	treatment	903:911	arg1	discontinuation					913:927	treatment discontinuation	903:927	treatment discontinuation across three independent cohorts	903:960	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	5	30	theme	antibody	760:767	arg1	approach					782:789	a comprehensive antibody Fc-profiling approach	744:789	a comprehensive antibody Fc-profiling approach	744:789	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	4	31	theme	HIV	704:706	arg1	strategies					726:735	promising HIV viral eradication strategies	694:735	promising HIV viral eradication strategies	694:735	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	2	32	theme	HCV	423:425	arg1	infections					427:436	HIV and HCV infections	415:436	HIV and HCV infections	415:436	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	6	33	theme	antibody	983:990	arg1	glycosylation					992:1004	virus-specific antibody glycosylation	968:1004	virus-specific antibody glycosylation	968:1004	Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
33326789	2	34	from	size	382:385	arg1	therapy					390:396	therapy	390:396	therapy	390:396	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	4	35	theme	promising	694:702	arg1	strategies					726:735	promising HIV viral eradication strategies	694:735	promising HIV viral eradication strategies	694:735	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	6	36	theme	virus-specific	968:981	arg1	glycosylation					992:1004	virus-specific antibody glycosylation	968:1004	virus-specific antibody glycosylation	968:1004	Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
33326789	2	37	theme	rheumatic	216:224	arg1	flares					226:231	rheumatic flares	216:231	rheumatic flares	216:231	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	4	38	dep	downselection	651:663	arg1	the					647:649	the	647:649	the	647:649	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	4	39	theme	eradication	714:724	arg1	strategies					726:735	promising HIV viral eradication strategies	694:735	promising HIV viral eradication strategies	694:735	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	2	40	theme	immune	254:259	arg1	activation					261:270	immune activation	254:270	immune activation	254:270	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	2	41	theme	biological	316:325	arg1	age					327:329	biological age	316:329	biological age	316:329	Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV infections.
33326789	4	42	theme	biomarker	567:575	arg1	identification					547:560	The identification	543:560	The identification of a biomarker that could forecast viral rebound time	543:614	The identification of a biomarker that could forecast viral rebound time could significantly accelerate the downselection and iterative improvement of promising HIV viral eradication strategies.
33326789	5	43	theme	comprehensive	746:758	arg1	approach					782:789	a comprehensive antibody Fc-profiling approach	744:789	a comprehensive antibody Fc-profiling approach	744:789	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	6	44	dep	promising	1022:1030	arg1	measured					1040:1047	measured	1040:1047	measured	1040:1047	Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
33326789	1	45	theme	several	141:147	arg1	diseases					149:156	several diseases	141:156	several diseases	141:156	Changes in antibody glycosylation are linked to inflammation across several diseases.
33326789	6	46	theme	reservoir	1065:1073	arg1	reactivation					1075:1086	reservoir reactivation	1065:1086	reservoir reactivation	1065:1086	Thus virus-specific antibody glycosylation may represent a promising, simply measured marker to track reservoir reactivation.
33326789	0	47	theme	Viral	58:62	arg1	Rebound					64:70	Viral Rebound	58:70	Viral Rebound	58:70	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.
33326789	3	48	theme	reservoir	503:511	arg1	time					521:524	reservoir rebound time	503:524	reservoir rebound time	503:524	However, whether changes in antibody Fc biology also track with reservoir rebound time remains unclear.
33326789	5	49	theme	N-galactosylation	830:846	arg1	level					796:800	the level	792:800	the level of HIV-specific antibody Fc N-galactosylation	792:846	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33326789	5	50	theme	HIV-specific	805:816	arg1	N-galactosylation					830:846	HIV-specific antibody Fc N-galactosylation	805:846	HIV-specific antibody Fc N-galactosylation	805:846	Using a comprehensive antibody Fc-profiling approach, the level of HIV-specific antibody Fc N-galactosylation is significantly associated with time to rebound after treatment discontinuation across three independent cohorts.
33085102	0	0	theme	different	75:83	arg1	species					95:101	different mammalian species	75:101	different mammalian species	75:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	1	from	identification	14:27	arg1	pathways					133:140	biological pathways	122:140	biological pathways which support infant growth	122:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	1	from	identification	14:27	arg1	milk					65:68	milk	65:68	milk from different mammalian species	65:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	5	2	theme	glycoproteome	749:761	arg1	profiling					763:771	The glycoproteome profiling	745:771	The glycoproteome profiling	745:771	The glycoproteome profiling demonstrates that glycosylated proteins are higher in caprine milk compared to other samples.
33085102	3	3	from	samples	496:502	arg1	Proteins					465:472	Proteins	465:472	Proteins from these three milk samples	465:502	Proteins from these three milk samples are separated and analyzed using two-dimensional gel electrophoresis (2-DE).
33085102	6	4	theme	N-glycosylated	929:942	arg1	proteins					944:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	Analysis using LC/MS-QTOF identified 42 O-glycosylated and 56 N-glycosylated proteins, respectively.
33085102	1	5	from	mother	293:298	arg1	transfer					247:254	the transfer	243:254	the transfer of immunological components from the mother to the baby	243:310	Milk serves as the sole nutrition for newborns, as well as a medium for the transfer of immunological components from the mother to the baby.
33085102	2	6	theme	infant	450:455	arg1	growth					457:462	infant growth	450:462	infant growth	450:462	This study reveals different glycoprotein profiles obtained from human, bovine, and caprine milk and their potential roles in supporting infant growth.
33085102	0	7	from	Isolation	0:8	arg1	pathways					133:140	biological pathways	122:140	biological pathways which support infant growth	122:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	7	from	Isolation	0:8	arg1	milk					65:68	milk	65:68	milk from different mammalian species	65:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	7	8	theme	human	992:996	arg1	milk					998:1001	human milk	992:1001	human milk	992:1001	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	6	9	theme	O-glycosylated	907:920	arg1	proteins					944:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	Analysis using LC/MS-QTOF identified 42 O-glycosylated and 56 N-glycosylated proteins, respectively.
33085102	9	10	theme	ruminant	1424:1431	arg1	proteomes					1438:1446	ruminant milk proteomes	1424:1446	ruminant milk proteomes	1424:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	0	11	theme	mammalian	85:93	arg1	species					95:101	different mammalian species	75:101	different mammalian species	75:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	12	from	glycoproteins	48:60	arg1	species					95:101	different mammalian species	75:101	different mammalian species	75:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	12	from	glycoproteins	48:60	arg1	milk					65:68	milk	65:68	milk from different mammalian species	65:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	9	13	theme	milk	1433:1436	arg1	proteomes					1438:1446	ruminant milk proteomes	1424:1446	ruminant milk proteomes	1424:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	9	14	from	presence	1350:1357	arg1	form					1380:1383	the form	1376:1383	the form of immunoglobulins that are lacking in ruminant milk proteomes	1376:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	3	15	theme	milk	491:494	arg1	samples					496:502	these three milk samples	479:502	these three milk samples	479:502	Proteins from these three milk samples are separated and analyzed using two-dimensional gel electrophoresis (2-DE).
33085102	9	16	theme	human	1328:1332	arg1	babies					1334:1339	human babies	1328:1339	human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes	1328:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	9	17	with	babies	1334:1339	arg1	presence					1350:1357	the presence	1346:1357	the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes	1346:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	8	18	theme	vesicle-mediated	1231:1246	arg1	transport					1248:1256	vesicle-mediated transport	1231:1256	vesicle-mediated transport	1231:1256	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	19	theme	important	1186:1194	arg1	system					1266:1271	immune system	1259:1271	immune system	1259:1271	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	19	theme	important	1186:1194	arg1	transport					1248:1256	vesicle-mediated transport	1231:1256	vesicle-mediated transport	1231:1256	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	19	theme	important	1186:1194	arg1	pathways					1213:1220	important human biological pathways	1186:1220	important human biological pathways	1186:1220	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	19	theme	important	1186:1194	arg1	pathways					1288:1295	hemostasis pathways	1277:1295	hemostasis pathways	1277:1295	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	0	20	from	O-	32:33	arg1	species					95:101	different mammalian species	75:101	different mammalian species	75:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	20	from	O-	32:33	arg1	milk					65:68	milk	65:68	milk from different mammalian species	65:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	2	21	gly	glycoprotein	342:353	arg1	glycoprotein					342:353	different glycoprotein profiles	332:362	different glycoprotein profiles obtained from human, bovine, and caprine milk	332:408	This study reveals different glycoprotein profiles obtained from human, bovine, and caprine milk and their potential roles in supporting infant growth.
33085102	0	22	link	N-linked	39:46	arg1	glycoproteins					48:60	N-linked glycoproteins	39:60	N-linked glycoproteins in milk from different mammalian species	39:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	8	23	theme	immune	1259:1264	arg1	system					1266:1271	immune system	1259:1271	immune system	1259:1271	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	7	24	gly	glycoproteins	1010:1022	arg1	glycoproteins					1010:1022	17 glycoproteins	1007:1022	17 glycoproteins	1007:1022	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	3	25	theme	two-dimensional	537:551	arg1	2-DE					574:577	2-DE	574:577	2-DE	574:577	Proteins from these three milk samples are separated and analyzed using two-dimensional gel electrophoresis (2-DE).
33085102	3	25	theme	two-dimensional	537:551	arg1	electrophoresis					557:571	two-dimensional gel electrophoresis	537:571	two-dimensional gel electrophoresis (2-DE)	537:578	Proteins from these three milk samples are separated and analyzed using two-dimensional gel electrophoresis (2-DE).
33085102	2	26	theme	glycoprotein	342:353	arg1	profiles					355:362	different glycoprotein profiles	332:362	different glycoprotein profiles obtained from human, bovine, and caprine milk	332:408	This study reveals different glycoprotein profiles obtained from human, bovine, and caprine milk and their potential roles in supporting infant growth.
33085102	2	27	theme	caprine	397:403	arg1	milk					405:408	caprine milk	397:408	caprine milk	397:408	This study reveals different glycoprotein profiles obtained from human, bovine, and caprine milk and their potential roles in supporting infant growth.
33085102	5	28	theme	glycosylated	791:802	arg1	proteins					804:811	glycosylated proteins	791:811	glycosylated proteins	791:811	The glycoproteome profiling demonstrates that glycosylated proteins are higher in caprine milk compared to other samples.
33085102	4	29	from	samples	612:618	arg1	proteins					594:601	Glycosylated proteins	581:601	Glycosylated proteins from all samples	581:618	Glycosylated proteins from all samples are enriched by affinity chromatography using lectins from the seeds of Artocarpus integer before analysis using LC/MS-QTOF.
33085102	5	30	theme	caprine	827:833	arg1	milk					835:838	caprine milk	827:838	caprine milk	827:838	The glycoproteome profiling demonstrates that glycosylated proteins are higher in caprine milk compared to other samples.
33085102	8	31	from	milk	1149:1152	arg1	glycoproteins					1124:1136	Only glycoproteins	1119:1136	Only glycoproteins from human milk	1119:1152	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	32	theme	human	1143:1147	arg1	milk					1149:1152	human milk	1143:1152	human milk	1143:1152	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	1	33	theme	sole	190:193	arg1	nutrition					195:203	the sole nutrition	186:203	the sole nutrition for newborns	186:216	Milk serves as the sole nutrition for newborns, as well as a medium for the transfer of immunological components from the mother to the baby.
33085102	1	33	theme	sole	190:193	arg1	Milk					171:174	Milk	171:174	Milk	171:174	Milk serves as the sole nutrition for newborns, as well as a medium for the transfer of immunological components from the mother to the baby.
33085102	1	34	theme	immunological	259:271	arg1	components					273:282	immunological components	259:282	immunological components	259:282	Milk serves as the sole nutrition for newborns, as well as a medium for the transfer of immunological components from the mother to the baby.
33085102	4	35	theme	affinity	636:643	arg1	chromatography					645:658	affinity chromatography	636:658	affinity chromatography using lectins from the seeds of Artocarpus integer before analysis using LC/MS-QTOF	636:742	Glycosylated proteins from all samples are enriched by affinity chromatography using lectins from the seeds of Artocarpus integer before analysis using LC/MS-QTOF.
33085102	0	36	theme	O-	32:33	arg1	identification					14:27	identification	14:27	identification	14:27	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	36	theme	O-	32:33	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	36	theme	O-	32:33	arg1	roles					113:117	their roles	107:117	their roles in biological pathways which support infant growth	107:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	1	37	theme	components	273:282	arg1	transfer					247:254	the transfer	243:254	the transfer of immunological components from the mother to the baby	243:310	Milk serves as the sole nutrition for newborns, as well as a medium for the transfer of immunological components from the mother to the baby.
33085102	0	38	theme	biological	122:131	arg1	pathways					133:140	biological pathways	122:140	biological pathways which support infant growth	122:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	39	from	milk	65:68	arg1	identification					14:27	identification	14:27	identification	14:27	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	39	from	milk	65:68	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	39	from	milk	65:68	arg1	roles					113:117	their roles	107:117	their roles in biological pathways which support infant growth	107:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	8	40	theme	biological	1202:1211	arg1	system					1266:1271	immune system	1259:1271	immune system	1259:1271	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	40	theme	biological	1202:1211	arg1	transport					1248:1256	vesicle-mediated transport	1231:1256	vesicle-mediated transport	1231:1256	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	40	theme	biological	1202:1211	arg1	pathways					1213:1220	important human biological pathways	1186:1220	important human biological pathways	1186:1220	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	40	theme	biological	1202:1211	arg1	pathways					1288:1295	hemostasis pathways	1277:1295	hemostasis pathways	1277:1295	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	41	gly	glycoproteins	1124:1136	arg1	glycoproteins					1124:1136	Only glycoproteins	1119:1136	Only glycoproteins from human milk	1119:1152	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	5	42	theme	other	852:856	arg1	samples					858:864	other samples	852:864	other samples	852:864	The glycoproteome profiling demonstrates that glycosylated proteins are higher in caprine milk compared to other samples.
33085102	0	43	theme	glycoproteins	48:60	arg1	identification					14:27	identification	14:27	identification	14:27	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	43	theme	glycoproteins	48:60	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	43	theme	glycoproteins	48:60	arg1	roles					113:117	their roles	107:117	their roles in biological pathways which support infant growth	107:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	9	44	theme	antibodies	1362:1371	arg1	presence					1350:1357	the presence	1346:1357	the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes	1346:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	3	45	theme	gel	553:555	arg1	2-DE					574:577	2-DE	574:577	2-DE	574:577	Proteins from these three milk samples are separated and analyzed using two-dimensional gel electrophoresis (2-DE).
33085102	3	45	theme	gel	553:555	arg1	electrophoresis					557:571	two-dimensional gel electrophoresis	537:571	two-dimensional gel electrophoresis (2-DE)	537:578	Proteins from these three milk samples are separated and analyzed using two-dimensional gel electrophoresis (2-DE).
33085102	4	46	theme	Glycosylated	581:592	arg1	proteins					594:601	Glycosylated proteins	581:601	Glycosylated proteins from all samples	581:618	Glycosylated proteins from all samples are enriched by affinity chromatography using lectins from the seeds of Artocarpus integer before analysis using LC/MS-QTOF.
33085102	0	47	theme	N-linked	39:46	arg1	glycoproteins					48:60	N-linked glycoproteins	39:60	N-linked glycoproteins in milk from different mammalian species	39:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	9	48	theme	Human	1298:1302	arg1	milk					1304:1307	Human milk	1298:1307	Human milk	1298:1307	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	5	49	gly	glycosylated	791:802	arg1	proteins					804:811	glycosylated proteins	791:811	glycosylated proteins	791:811	The glycoproteome profiling demonstrates that glycosylated proteins are higher in caprine milk compared to other samples.
33085102	8	50	theme	Only	1119:1122	arg1	glycoproteins					1124:1136	Only glycoproteins	1119:1136	Only glycoproteins from human milk	1119:1152	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	8	51	dep	important	1186:1194	arg1	human					1196:1200	human	1196:1200	human	1196:1200	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	9	52	attach	presence	1350:1357	arg2	antibodies					1362:1371	antibodies	1362:1371	antibodies	1362:1371	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	9	52	attach	presence	1350:1357	arg1	form					1380:1383	the form	1376:1383	the form of immunoglobulins that are lacking in ruminant milk proteomes	1376:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	4	53	theme	integer	703:709	arg1	seeds					683:687	the seeds	679:687	the seeds of Artocarpus integer before analysis using LC/MS-QTOF	679:742	Glycosylated proteins from all samples are enriched by affinity chromatography using lectins from the seeds of Artocarpus integer before analysis using LC/MS-QTOF.
33085102	6	54	gly	O-glycosylated	907:920	arg1	proteins					944:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	Analysis using LC/MS-QTOF identified 42 O-glycosylated and 56 N-glycosylated proteins, respectively.
33085102	0	55	theme	infant	156:161	arg1	growth					163:168	infant growth	156:168	infant growth	156:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	56	from	species	95:101	arg1	milk					65:68	milk	65:68	milk from different mammalian species	65:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	56	from	species	95:101	arg1	O-					32:33	O-	32:33	O-	32:33	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	56	from	species	95:101	arg1	glycoproteins					48:60	N-linked glycoproteins	39:60	N-linked glycoproteins in milk from different mammalian species	39:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	4	57	theme	Artocarpus	692:701	arg1	integer					703:709	Artocarpus integer	692:709	Artocarpus integer before analysis using LC/MS-QTOF	692:742	Glycosylated proteins from all samples are enriched by affinity chromatography using lectins from the seeds of Artocarpus integer before analysis using LC/MS-QTOF.
33085102	9	58	theme	immunoglobulins	1388:1402	arg1	form					1380:1383	the form	1376:1383	the form of immunoglobulins that are lacking in ruminant milk proteomes	1376:1446	Human milk remains unique for human babies with the presence of antibodies in the form of immunoglobulins that are lacking in ruminant milk proteomes.
33085102	7	59	contain	has	1003:1005	arg1	milk					998:1001	human milk	992:1001	human milk	992:1001	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	7	59	contain	has	1003:1005	arg2	glycoproteins					1010:1022	17 glycoproteins	1007:1022	17 glycoproteins	1007:1022	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	8	60	theme	hemostasis	1277:1286	arg1	pathways					1288:1295	hemostasis pathways	1277:1295	hemostasis pathways	1277:1295	Only glycoproteins from human milk have shown positive matching to important human biological pathways, such as vesicle-mediated transport, immune system and hemostasis pathways.
33085102	2	61	theme	different	332:340	arg1	profiles					355:362	different glycoprotein profiles	332:362	different glycoprotein profiles obtained from human, bovine, and caprine milk	332:408	This study reveals different glycoprotein profiles obtained from human, bovine, and caprine milk and their potential roles in supporting infant growth.
33085102	7	62	contain	have	1090:1093	arg1	caprine					1071:1077	caprine	1071:1077	caprine	1071:1077	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	7	62	contain	have	1090:1093	arg2	1					1102:1102	1	1102:1102	1	1102:1102	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	7	62	contain	have	1090:1093	arg2	10					1095:1096	10	1095:1096	10	1095:1096	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	7	62	contain	have	1090:1093	arg1	bovine					1083:1088	bovine	1083:1088	bovine	1083:1088	Among those identified, human milk has 17 glycoproteins, which are both O- and N-glycosylated, whereas caprine and bovine have 10 and 1, respectively.
33085102	2	63	theme	potential	420:428	arg1	roles					430:434	their potential roles	414:434	their potential roles in supporting infant growth	414:462	This study reveals different glycoprotein profiles obtained from human, bovine, and caprine milk and their potential roles in supporting infant growth.
33085102	0	64	gly	glycoproteins	48:60	arg1	glycoproteins					48:60	N-linked glycoproteins	39:60	N-linked glycoproteins in milk from different mammalian species	39:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	6	65	gly	N-glycosylated	929:942	arg1	proteins					944:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	42 O-glycosylated and 56 N-glycosylated proteins	904:951	Analysis using LC/MS-QTOF identified 42 O-glycosylated and 56 N-glycosylated proteins, respectively.
33085102	0	66	from	roles	113:117	arg1	pathways					133:140	biological pathways	122:140	biological pathways which support infant growth	122:168	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
33085102	0	66	from	roles	113:117	arg1	milk					65:68	milk	65:68	milk from different mammalian species	65:101	Isolation and identification of O- and N-linked glycoproteins in milk from different mammalian species and their roles in biological pathways which support infant growth.
34469156	2	0	theme	24+·	559:562	arg1	2·					568:569	V4(H)24+·(Cl-)2·	554:569	V4(H)24+·(Cl-)2·(I-)2	554:574	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	0	theme	24+·	559:562	arg1	I-					571:572	I-	571:572	I-	571:572	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	3	1	theme	charge-transfer	891:905	arg1	transition					912:921	the intramolecular charge-transfer (CT) transition	872:921	the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety	872:977	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	2	2	dep	Derivatives	498:508	arg1	2·					568:569	V4(H)24+·(Cl-)2·	554:569	V4(H)24+·(Cl-)2·(I-)2	554:574	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	2	dep	Derivatives	498:508	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	2	dep	Derivatives	498:508	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	2	dep	Derivatives	498:508	arg1	I-					571:572	I-	571:572	I-	571:572	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	3	theme	V4	825:826	arg1	13+					830:832	V4(H)13+	825:832	V4(H)13+	825:832	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	4	theme	acid-base	628:636	arg1	titration					638:646	their UV-vis acid-base titration	615:646	their UV-vis acid-base titration	615:646	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	5	theme	UV-vis	621:626	arg1	titration					638:646	their UV-vis acid-base titration	615:646	their UV-vis acid-base titration	615:646	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	6	theme	base	682:685	arg1	addition					668:675	addition	668:675	addition of a base	668:685	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	7	theme	H	805:805	arg1	1+					807:808	P6(H)1+	802:808	P6(H)1+	802:808	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	4	8	theme	LiI	1212:1214	arg1	addition					1200:1207	addition	1200:1207	addition of LiI	1200:1214	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	3	9	theme	viologen	963:970	arg1	moiety					972:977	the pyridinium or viologen moiety	945:977	moiety	972:977	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	3	10	from	phenoxide	932:940	arg1	transition					912:921	the intramolecular charge-transfer (CT) transition	872:921	the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety	872:977	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	5	11	theme	useful	1270:1275	arg1	derivative					1236:1245	this derivative	1231:1245	this derivative	1231:1245	Consequently, this derivative can be considered as a useful host for the recognition and sensing of lithium cations.
34469156	5	11	theme	useful	1270:1275	arg1	host					1277:1280	a useful host	1268:1280	a useful host for the recognition and sensing of lithium cations	1268:1331	Consequently, this derivative can be considered as a useful host for the recognition and sensing of lithium cations.
34469156	2	12	theme	due	744:746	arg1	nm					726:727	at 487, 583, and 686 nm	705:727	at 487, 583, and 686 nm	705:727	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	1	13	theme	arene	402:406	arg1	22+					413:415	p-pyridiniumcalix[6]arene P6(H)22+	382:415	p-pyridiniumcalix[6]arene P6(H)22+	382:415	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	2	14	dep	show	576:579	arg1	while					609:613	while	609:613	while	609:613	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	4	15	theme	solution	1151:1158	arg1	color					1125:1129	the color	1121:1129	the color of its acetonitrile solution	1121:1158	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	2	16	theme	H	557:557	arg1	2·					568:569	V4(H)24+·(Cl-)2·	554:569	V4(H)24+·(Cl-)2·(I-)2	554:574	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	16	theme	H	557:557	arg1	I-					571:572	I-	571:572	I-	571:572	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	17	dep	species	794:800	arg1	13+					830:832	V4(H)13+	825:832	V4(H)13+	825:832	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	17	dep	species	794:800	arg1	1+					807:808	P6(H)1+	802:808	P6(H)1+	802:808	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	17	dep	species	794:800	arg1	13+					816:818	V6(H)13+	811:818	V6(H)13+	811:818	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	1	18	theme	P6	408:409	arg1	22+					413:415	p-pyridiniumcalix[6]arene P6(H)22+	382:415	p-pyridiniumcalix[6]arene P6(H)22+	382:415	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	4	19	theme	acetonitrile	1138:1149	arg1	solution					1151:1158	its acetonitrile solution	1134:1158	its acetonitrile solution	1134:1158	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	3	20	theme	pyridinium	949:958	arg1	moiety					972:977	the pyridinium or viologen moiety	945:977	moiety	972:977	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	1	21	theme	rare	315:318	arg1	example					320:326	A rare example	313:326	A rare example of an anionic conformational template	313:364	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	0	22	theme	Chromogenic	0:10	arg1	Properties					12:21	Chromogenic Properties	0:21	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes	0:65	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes and Their Cation-Sensing Abilities.
34469156	1	23	theme	chloride	481:488	arg1	anions					490:495	chloride anions	481:495	chloride anions	481:495	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	2	24	theme	H	513:513	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	24	theme	H	513:513	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	25	theme	betainic	768:775	arg1	species					794:800	betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+	768:832	betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+	768:832	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	1	26	theme	H	411:411	arg1	22+					413:415	p-pyridiniumcalix[6]arene P6(H)22+	382:415	p-pyridiniumcalix[6]arene P6(H)22+	382:415	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	0	27	theme	p-Pyridinium-	26:38	arg1	Properties					12:21	Chromogenic Properties	0:21	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes	0:65	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes and Their Cation-Sensing Abilities.
34469156	0	27	theme	p-Pyridinium-	26:38	arg1	Abilities					92:100	Their Cation-Sensing Abilities	71:100	Their Cation-Sensing Abilities	71:100	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes and Their Cation-Sensing Abilities.
34469156	1	28	theme	anions	490:495	arg1	presence					469:476	the presence	465:476	the presence of chloride anions	465:495	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	3	29	theme	cations	1018:1024	arg1	presence					1006:1013	the presence	1002:1013	the presence of cations	1002:1024	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	2	30	theme	new	688:690	arg1	bands					692:696	new bands	688:696	new bands	688:696	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	31	theme	H	828:828	arg1	13+					830:832	V4(H)13+	825:832	V4(H)13+	825:832	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	32	theme	P6	510:511	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	32	theme	P6	510:511	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	3	33	theme	new	841:843	arg1	bands					845:849	These new bands	835:849	These new bands	835:849	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	0	34	theme	p-Viologen-Calixarenes	44:65	arg1	Properties					12:21	Chromogenic Properties	0:21	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes	0:65	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes and Their Cation-Sensing Abilities.
34469156	0	34	theme	p-Viologen-Calixarenes	44:65	arg1	Abilities					92:100	Their Cation-Sensing Abilities	71:100	Their Cation-Sensing Abilities	71:100	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes and Their Cation-Sensing Abilities.
34469156	2	35	theme	Cl-	520:522	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	35	theme	Cl-	520:522	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	36	theme	H	530:530	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	36	theme	H	530:530	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	37	theme	monodeprotonated	777:792	arg1	species					794:800	betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+	768:832	betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+	768:832	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	5	38	dep	recognition	1290:1300	arg1	the					1286:1288	the	1286:1288	the	1286:1288	Consequently, this derivative can be considered as a useful host for the recognition and sensing of lithium cations.
34469156	4	39	theme	P6	1058:1059	arg1	1+					1063:1064	P6(H)1+	1058:1064	P6(H)1+	1058:1064	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	2	40	theme	Cl-	537:539	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	40	theme	Cl-	537:539	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	41	theme	V4	554:555	arg1	2·					568:569	V4(H)24+·(Cl-)2·	554:569	V4(H)24+·(Cl-)2·(I-)2	554:574	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	41	theme	V4	554:555	arg1	I-					571:572	I-	571:572	I-	571:572	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	5	42	theme	lithium	1317:1323	arg1	cations					1325:1331	lithium cations	1317:1331	lithium cations	1317:1331	Consequently, this derivative can be considered as a useful host for the recognition and sensing of lithium cations.
34469156	1	43	theme	anionic	334:340	arg1	template					357:364	an anionic conformational template	331:364	an anionic conformational template	331:364	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	5	44	theme	cations	1325:1331	arg1	sensing					1306:1312	sensing	1306:1312	sensing	1306:1312	Consequently, this derivative can be considered as a useful host for the recognition and sensing of lithium cations.
34469156	5	44	theme	cations	1325:1331	arg1	recognition					1290:1300	recognition	1290:1300	recognition	1290:1300	Consequently, this derivative can be considered as a useful host for the recognition and sensing of lithium cations.
34469156	4	45	theme	hard	1100:1103	arg1	cation					1109:1114	a hard Li+ cation	1098:1114	a hard Li+ cation	1098:1114	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	2	46	dep	2·	541:542	arg1	V6					527:528	V6	527:528	V6	527:528	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	4	47	theme	H	1061:1061	arg1	1+					1063:1064	P6(H)1+	1058:1064	P6(H)1+	1058:1064	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	1	48	theme	conformational	342:355	arg1	template					357:364	an anionic conformational template	331:364	an anionic conformational template	331:364	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	4	49	theme	1+	1063:1064	arg1	band					1040:1043	the band	1036:1043	the band at 487 nm of P6(H)1+	1036:1064	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	4	50	from	nm	1052:1053	arg1	band					1040:1043	the band	1036:1043	the band at 487 nm of P6(H)1+	1036:1064	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	1	51	theme	template	357:364	arg1	example					320:326	A rare example	313:326	A rare example of an anionic conformational template	313:364	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	2	52	theme	P6	802:803	arg1	1+					807:808	P6(H)1+	802:808	P6(H)1+	802:808	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	53	theme	negative	583:590	arg1	solvatochromism					592:606	a negative solvatochromism	581:606	a negative solvatochromism	581:606	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	4	54	theme	cation	1109:1114	arg1	presence					1086:1093	the presence	1082:1093	the presence of a hard Li+ cation	1082:1114	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	2	55	theme	22+·	515:518	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	55	theme	22+·	515:518	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	56	theme	species	794:800	arg1	formation					755:763	the formation	751:763	the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+	751:832	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	57	theme	H	814:814	arg1	13+					816:818	V6(H)13+	811:818	V6(H)13+	811:818	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	58	theme	Cl-	564:566	arg1	2·					568:569	V4(H)24+·(Cl-)2·	554:569	V4(H)24+·(Cl-)2·(I-)2	554:574	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	58	theme	Cl-	564:566	arg1	I-					571:572	I-	571:572	I-	571:572	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	4	59	theme	Li+	1105:1107	arg1	cation					1109:1114	a hard Li+ cation	1098:1114	a hard Li+ cation	1098:1114	In fact, the band at 487 nm of P6(H)1+ was quenched in the presence of a hard Li+ cation, and the color of its acetonitrile solution was changed from pink to colorless upon addition of LiI.
34469156	3	60	theme	CT	908:909	arg1	transition					912:921	the intramolecular charge-transfer (CT) transition	872:921	the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety	872:977	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	2	61	theme	24+·	532:535	arg1	I-					544:545	I-	544:545	I-	544:545	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	2	61	theme	24+·	532:535	arg1	2·					541:542	P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·	510:542	2·	541:542	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34469156	1	62	theme	1,3,5-alternate	433:447	arg1	conformation					449:460	a 1,3,5-alternate conformation	431:460	a 1,3,5-alternate conformation	431:460	A rare example of an anionic conformational template is reported for p-pyridiniumcalix[6]arene P6(H)22+, which adopts a 1,3,5-alternate conformation in the presence of chloride anions.
34469156	0	63	theme	Cation-Sensing	77:90	arg1	Abilities					92:100	Their Cation-Sensing Abilities	71:100	Their Cation-Sensing Abilities	71:100	Chromogenic Properties of p-Pyridinium- and p-Viologen-Calixarenes and Their Cation-Sensing Abilities.
34469156	3	64	theme	intramolecular	876:889	arg1	transition					912:921	the intramolecular charge-transfer (CT) transition	872:921	the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety	872:977	These new bands were attributable to the intramolecular charge-transfer (CT) transition from the phenoxide to the pyridinium or viologen moiety and were responsive to the presence of cations.
34469156	2	65	theme	V6	811:812	arg1	13+					816:818	V6(H)13+	811:818	V6(H)13+	811:818	Derivatives P6(H)22+·(Cl-)2, V6(H)24+·(Cl-)2·(I-)2, and V4(H)24+·(Cl-)2·(I-)2 show a negative solvatochromism, while their UV-vis acid-base titration evidenced that upon addition of a base, new bands appear at 487, 583, and 686 nm, respectively, due to the formation of betainic monodeprotonated species P6(H)1+, V6(H)13+, and V4(H)13+.
34223877	6	0	link	N-linked	1125:1132	arg1	glycans					1134:1140	N-linked glycans	1125:1140	N-linked glycans	1125:1140	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	7	1	theme	MCP-1	1513:1517	arg1	secretion					1479:1487	the secretion	1475:1487	the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium	1475:1556	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	4	2	theme	cytokines	749:757	arg1	secretion					736:744	endothelial secretion	724:744	endothelial secretion of cytokines MCP-1 (CCL2) and IL-6	724:779	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	2	3	theme	peanut	349:354	arg1	consumption					356:366	peanut consumption	349:366	peanut consumption	349:366	PNA is highly resistant to cooking and digestion and is rapidly detectable in the blood after peanut consumption.
34223877	7	4	theme	metastasis-promoting	1492:1511	arg1	MCP-1					1513:1517	MCP-1	1513:1517	MCP-1	1513:1517	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	5	5	theme	endothelial	1039:1049	arg1	formation					1058:1066	endothelial tubule formation	1039:1066	endothelial tubule formation	1039:1066	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	6	6	theme	surface	1099:1105	arg1	CD146					1113:1117	CD146	1113:1117	CD146	1113:1117	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	6	6	theme	surface	1099:1105	arg1	MCAM					1107:1110	endothelial surface MCAM	1087:1110	endothelial surface MCAM (CD146)	1087:1118	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	0	7	from	Appearance	0:9	arg1	circulation					45:55	the blood circulation	35:55	the blood circulation after peanut ingestion	35:78	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	2	8	from	detectable	319:328	arg1	blood					337:341	the blood	333:341	the blood after peanut consumption	333:366	PNA is highly resistant to cooking and digestion and is rapidly detectable in the blood after peanut consumption.
34223877	3	9	theme	cell	574:577	arg1	spreading					590:598	circulating tumour cell metastatic spreading	555:598	circulating tumour cell metastatic spreading	555:598	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	7	10	theme	IL-6	1523:1526	arg1	secretion					1479:1487	the secretion	1475:1487	the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium	1475:1556	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	4	11	theme	circulating	630:640	arg1	PNA					642:644	circulating PNA	630:644	circulating PNA	630:644	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	0	12	theme	endothelial	89:99	arg1	secretion					101:109	endothelial secretion	89:109	endothelial secretion of metastasis-promoting cytokines	89:143	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	7	13	theme	vascular	1537:1544	arg1	endothelium					1546:1556	the vascular endothelium	1533:1556	the vascular endothelium	1533:1556	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	3	14	theme	metastatic	579:588	arg1	spreading					590:598	circulating tumour cell metastatic spreading	555:598	circulating tumour cell metastatic spreading	555:598	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	2	15	from	blood	337:341	arg1	detectable					319:328	detectable	319:328	detectable	319:328	PNA is highly resistant to cooking and digestion and is rapidly detectable in the blood after peanut consumption.
34223877	3	16	theme	cell-associated	521:535	arg1	MUC1					537:540	tumour cell-associated MUC1	514:540	tumour cell-associated MUC1	514:540	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	0	17	theme	metastasis-promoting	114:133	arg1	cytokines					135:143	metastasis-promoting cytokines	114:143	metastasis-promoting cytokines	114:143	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	5	18	theme	increased	992:1000	arg1	adhesion					1026:1033	increased tumour cell-endothelial adhesion	992:1033	increased tumour cell-endothelial adhesion	992:1033	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	3	19	theme	circulating	555:565	arg1	spreading					590:598	circulating tumour cell metastatic spreading	555:598	circulating tumour cell metastatic spreading	555:598	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	5	20	theme	cell	909:912	arg1	integrins					951:959	integrins	951:959	integrins	951:959	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	20	theme	cell	909:912	arg1	molecules					931:939	endothelial cell surface adhesion molecules	897:939	endothelial cell surface adhesion molecules including integrins, VCAM and selectin	897:978	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	3	21	with	interaction	497:507	arg1	MUC1					537:540	tumour cell-associated MUC1	514:540	tumour cell-associated MUC1	514:540	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	3	22	theme	tumour	567:572	arg1	spreading					590:598	circulating tumour cell metastatic spreading	555:598	circulating tumour cell metastatic spreading	555:598	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	1	23	theme	carbohydrate-binding	175:194	arg1	protein					196:202	a carbohydrate-binding protein	173:202	a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight	173:252	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	1	23	theme	carbohydrate-binding	175:194	arg1	agglutinin					153:162	Peanut agglutinin	146:162	Peanut agglutinin (PNA)	146:168	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	7	24	theme	cell	1350:1353	arg1	spreading					1355:1363	tumour cell spreading	1343:1363	tumour cell spreading	1343:1363	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	5	25	theme	adhesion	922:929	arg1	integrins					951:959	integrins	951:959	integrins	951:959	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	25	theme	adhesion	922:929	arg1	molecules					931:939	endothelial cell surface adhesion molecules	897:939	endothelial cell surface adhesion molecules including integrins, VCAM and selectin	897:978	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	26	theme	cytokines	836:844	arg1	secretion					817:825	The increased secretion	803:825	The increased secretion of these cytokines	803:844	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	27	theme	surface	914:920	arg1	integrins					951:959	integrins	951:959	integrins	951:959	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	27	theme	surface	914:920	arg1	molecules					931:939	endothelial cell surface adhesion molecules	897:939	endothelial cell surface adhesion molecules including integrins, VCAM and selectin	897:978	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	28	theme	molecules	931:939	arg1	expression					883:892	the expression	879:892	the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin	879:978	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	0	29	theme	agglutinin	21:30	arg1	Appearance					0:9	Appearance	0:9	Appearance of peanut agglutinin in the blood circulation after peanut ingestion	0:78	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	6	30	theme	N-linked	1125:1132	arg1	glycans					1134:1140	N-linked glycans	1125:1140	N-linked glycans	1125:1140	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	5	31	theme	tumour	1002:1007	arg1	adhesion					1026:1033	increased tumour cell-endothelial adhesion	992:1033	increased tumour cell-endothelial adhesion	992:1033	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	3	32	theme	protein	475:481	arg1	galectin-3					483:492	endogenous galactoside-binding protein galectin-3	444:492	endogenous galactoside-binding protein galectin-3	444:492	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	0	33	theme	peanut	14:19	arg1	agglutinin					21:30	peanut agglutinin	14:30	peanut agglutinin	14:30	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	4	34	theme	present	605:611	arg1	study					613:617	The present study	601:617	The present study	601:617	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	0	35	theme	cytokines	135:143	arg1	secretion					101:109	endothelial secretion	89:109	endothelial secretion of metastasis-promoting cytokines	89:143	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	6	36	theme	MCP-1	1255:1259	arg1	secretion					1242:1250	PNA-induced secretion	1230:1250	PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium	1230:1292	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	5	37	theme	cell-endothelial	1009:1024	arg1	adhesion					1026:1033	increased tumour cell-endothelial adhesion	992:1033	increased tumour cell-endothelial adhesion	992:1033	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	7	38	from	endothelium	1546:1556	arg1	secretion					1479:1487	the secretion	1475:1487	the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium	1475:1556	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	3	39	theme	galectin-3	483:492	arg1	actions					433:439	the actions	429:439	the actions of endogenous galactoside-binding protein galectin-3	429:492	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	3	40	theme	circulating	406:416	arg1	PNA					418:420	circulating PNA	406:420	circulating PNA	406:420	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	6	41	theme	signalling	1189:1198	arg1	Binding					1069:1075	Binding	1069:1075	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans,	1069:1141	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	6	41	theme	signalling	1189:1198	arg1	activation					1158:1167	subsequent activation	1147:1167	subsequent activation of PI3K-AKT-PREAS40 signalling	1147:1198	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	4	42	theme	macro-vascular	679:692	arg1	cells					706:710	micro- as well as macro-vascular endothelial cells	661:710	micro- as well as macro-vascular endothelial cells	661:710	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	7	43	theme	tumour	1385:1390	arg1	MUC1					1408:1411	tumour cell-associated MUC1	1385:1411	tumour cell-associated MUC1	1385:1411	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	3	44	theme	endogenous	444:453	arg1	galectin-3					483:492	endogenous galactoside-binding protein galectin-3	444:492	endogenous galactoside-binding protein galectin-3	444:492	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	5	45	theme	increased	807:815	arg1	secretion					817:825	The increased secretion	803:825	The increased secretion of these cytokines	803:844	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	7	46	with	interaction	1368:1378	arg1	MUC1					1408:1411	tumour cell-associated MUC1	1385:1411	tumour cell-associated MUC1	1385:1411	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	7	47	theme	cell-associated	1392:1406	arg1	MUC1					1408:1411	tumour cell-associated MUC1	1385:1411	tumour cell-associated MUC1	1385:1411	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	4	48	theme	micro-	661:666	arg1	cells					706:710	micro- as well as macro-vascular endothelial cells	661:710	micro- as well as macro-vascular endothelial cells	661:710	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	3	49	theme	galactoside-binding	455:473	arg1	galectin-3					483:492	endogenous galactoside-binding protein galectin-3	444:492	endogenous galactoside-binding protein galectin-3	444:492	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	6	50	theme	PI3K-AKT-PREAS40	1172:1187	arg1	signalling					1189:1198	PI3K-AKT-PREAS40 signalling	1172:1198	PI3K-AKT-PREAS40 signalling	1172:1198	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	0	51	theme	blood	39:43	arg1	circulation					45:55	the blood circulation	35:55	the blood circulation after peanut ingestion	35:78	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	3	52	theme	tumour	514:519	arg1	MUC1					537:540	tumour cell-associated MUC1	514:540	tumour cell-associated MUC1	514:540	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	7	53	theme	circulating	1414:1424	arg1	PNA					1426:1428	circulating PNA	1414:1428	circulating PNA	1414:1428	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	6	54	theme	vascular	1273:1280	arg1	endothelium					1282:1292	vascular endothelium	1273:1292	vascular endothelium	1273:1292	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	6	55	theme	endothelial	1087:1097	arg1	CD146					1113:1117	CD146	1113:1117	CD146	1113:1117	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	6	55	theme	endothelial	1087:1097	arg1	MCAM					1107:1110	endothelial surface MCAM	1087:1110	endothelial surface MCAM (CD146)	1087:1118	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	1	56	theme	Peanut	146:151	arg1	protein					196:202	a carbohydrate-binding protein	173:202	a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight	173:252	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	1	56	theme	Peanut	146:151	arg1	PNA					165:167	PNA	165:167	PNA	165:167	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	1	56	theme	Peanut	146:151	arg1	agglutinin					153:162	Peanut agglutinin	146:162	Peanut agglutinin (PNA)	146:168	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	1	57	theme	~0.15	233:237	arg1	%					238:238	%	238:238	%	238:238	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	5	58	theme	tubule	1051:1056	arg1	formation					1058:1066	endothelial tubule formation	1039:1066	endothelial tubule formation	1039:1066	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	7	59	theme	tumour	1343:1348	arg1	spreading					1355:1363	tumour cell spreading	1343:1363	tumour cell spreading	1343:1363	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	4	60	dep	cytokines	749:757	arg1	cytokines					749:757	cytokines MCP-1 (CCL2) and IL-6	749:779	cytokines MCP-1 (CCL2) and IL-6	749:779	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	4	60	dep	cytokines	749:757	arg1	CCL2					766:769	CCL2	766:769	CCL2	766:769	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	4	60	dep	cytokines	749:757	arg1	IL-6					776:779	IL-6	776:779	IL-6	776:779	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	4	60	dep	cytokines	749:757	arg1	MCP-1					759:763	MCP-1	759:763	MCP-1 (CCL2)	759:770	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	1	61	from	protein	196:202	arg1	peanuts					207:213	peanuts	207:213	peanuts	207:213	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	6	62	theme	subsequent	1147:1156	arg1	activation					1158:1167	subsequent activation	1147:1167	subsequent activation of PI3K-AKT-PREAS40 signalling	1147:1198	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	1	63	theme	%	238:238	arg1	weight					247:252	~0.15% peanut weight	233:252	~0.15% peanut weight	233:252	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	0	64	theme	peanut	63:68	arg1	ingestion					70:78	peanut ingestion	63:78	peanut ingestion	63:78	Appearance of peanut agglutinin in the blood circulation after peanut ingestion promotes endothelial secretion of metastasis-promoting cytokines.
34223877	5	65	theme	endothelial	897:907	arg1	integrins					951:959	integrins	951:959	integrins	951:959	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	5	65	theme	endothelial	897:907	arg1	molecules					931:939	endothelial cell surface adhesion molecules	897:939	endothelial cell surface adhesion molecules including integrins, VCAM and selectin	897:978	The increased secretion of these cytokines autocrinely/paracrinely enhances the expression of endothelial cell surface adhesion molecules including integrins, VCAM and selectin, leading to increased tumour cell-endothelial adhesion and endothelial tubule formation.
34223877	6	66	theme	IL-6	1265:1268	arg1	secretion					1242:1250	PNA-induced secretion	1230:1250	PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium	1230:1292	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	6	67	theme	PNA-induced	1230:1240	arg1	secretion					1242:1250	PNA-induced secretion	1230:1250	PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium	1230:1292	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	7	68	dep	influence	1320:1328	arg1	addition					1304:1311	addition	1304:1311	addition	1304:1311	Thus, in addition to its influence on promoting tumour cell spreading by interaction with tumour cell-associated MUC1, circulating PNA might also influence metastasis by enhancing the secretion of metastasis-promoting MCP-1 and IL-6 from the vascular endothelium.
34223877	4	69	theme	endothelial	694:704	arg1	cells					706:710	micro- as well as macro-vascular endothelial cells	661:710	micro- as well as macro-vascular endothelial cells	661:710	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	1	70	theme	peanut	240:245	arg1	weight					247:252	~0.15% peanut weight	233:252	~0.15% peanut weight	233:252	Peanut agglutinin (PNA) is a carbohydrate-binding protein in peanuts that accounts for ~0.15% peanut weight.
34223877	3	71	theme	previous	373:380	arg1	studies					382:388	Our previous studies	369:388	Our previous studies	369:388	Our previous studies have shown that circulating PNA mimics the actions of endogenous galactoside-binding protein galectin-3 by interaction with tumour cell-associated MUC1 and promotes circulating tumour cell metastatic spreading.
34223877	4	72	theme	endothelial	724:734	arg1	secretion					736:744	endothelial secretion	724:744	endothelial secretion of cytokines MCP-1 (CCL2) and IL-6	724:779	The present study shows that circulating PNA interacts with micro- as well as macro-vascular endothelial cells and induces endothelial secretion of cytokines MCP-1 (CCL2) and IL-6 in vitro and in vivo.
34223877	6	73	theme	PNA	1080:1082	arg1	Binding					1069:1075	Binding	1069:1075	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans,	1069:1141	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34223877	6	73	theme	PNA	1080:1082	arg1	activation					1158:1167	subsequent activation	1147:1167	subsequent activation of PI3K-AKT-PREAS40 signalling	1147:1198	Binding of PNA to endothelial surface MCAM (CD146), via N-linked glycans, and subsequent activation of PI3K-AKT-PREAS40 signalling is here shown responsible for PNA-induced secretion of MCP-1 and IL-6 by vascular endothelium.
34102146	1	0	theme	matrix-assisted	268:282	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	5	1	theme	technique	1157:1165	arg1	slices					1123:1128	the tissue slices	1112:1128	the tissue slices	1112:1128	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	5	1	theme	technique	1157:1165	arg1	sensitivity					1138:1148	the sensitivity	1134:1148	the sensitivity of our technique	1134:1165	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	5	2	theme	S-	1012:1013	arg1	glycopeptides					1015:1027	S- glycopeptides	1012:1027	S- glycopeptides	1012:1027	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	1	3	theme	laser	284:288	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	0	4	theme	glioma	110:115	arg1	landscape					132:140	canine glioma glycoproteomic landscape	103:140	canine glioma glycoproteomic landscape	103:140	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	5	5	theme	diverse	1070:1076	arg1	array					1078:1082	the diverse array	1066:1082	the diverse array of glycosylation present	1066:1107	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	1	6	theme	desorption	290:299	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	0	7	theme	canine	103:108	arg1	landscape					132:140	canine glioma glycoproteomic landscape	103:140	canine glioma glycoproteomic landscape	103:140	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	1	8	theme	resolved	375:382	arg1	glycoproteomics					384:398	spatially resolved glycoproteomics	365:398	spatially resolved glycoproteomics	365:398	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	1	9	gly	glycoproteins	193:205	arg1	glycoproteins					193:205	N-linked glycoproteins	184:205	N-linked glycoproteins	184:205	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	4	10	theme	glycan	865:870	arg1	imaging					872:878	glycan imaging	865:878	glycan imaging	865:878	Results identified haptoglobin as the protein associated with HexNAc4-Hex5-NeuAc2, thus directly linking glycan imaging with intact glycopeptide identification.
34102146	1	11	theme	ionization	301:310	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	0	12	theme	landscape	132:140	arg1	dysregulation					86:98	global dysregulation	79:98	global dysregulation of canine glioma glycoproteomic landscape	79:140	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	4	13	theme	intact	885:890	arg1	identification					905:918	intact glycopeptide identification	885:918	intact glycopeptide identification	885:918	Results identified haptoglobin as the protein associated with HexNAc4-Hex5-NeuAc2, thus directly linking glycan imaging with intact glycopeptide identification.
34102146	6	14	theme	proof-of-principle	1185:1202	arg1	work					1204:1207	this proof-of-principle work	1180:1207	this proof-of-principle work	1180:1207	Ultimately, this proof-of-principle work demonstrates that spatially resolved glycoproteomics greatly complement MALDI-MSI in understanding dysregulated glycosylation.
34102146	0	15	theme	glycoproteomic	117:130	arg1	landscape					132:140	canine glioma glycoproteomic landscape	103:140	canine glioma glycoproteomic landscape	103:140	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	5	16	theme	glycosylation	1087:1099	arg1	present					1101:1107	glycosylation present	1087:1107	glycosylation present	1087:1107	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	1	17	theme	N-linked	184:191	arg1	glycoproteins					193:205	N-linked glycoproteins	184:205	N-linked glycoproteins	184:205	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	2	18	theme	necrotic	552:559	arg1	regions					561:567	necrotic regions	552:567	necrotic regions of high-grade canine gliomas	552:596	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	6	19	theme	dysregulated	1308:1319	arg1	glycosylation					1321:1333	dysregulated glycosylation	1308:1333	dysregulated glycosylation	1308:1333	Ultimately, this proof-of-principle work demonstrates that spatially resolved glycoproteomics greatly complement MALDI-MSI in understanding dysregulated glycosylation.
34102146	2	20	theme	glioma	414:419	arg1	biopsies					421:428	glioma biopsies	414:428	glioma biopsies	414:428	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	0	21	theme	On-tissue	0:8	arg1	glycoproteomics					29:43	On-tissue spatially resolved glycoproteomics	0:43	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging	0:70	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	1	22	link	N-linked	184:191	arg1	glycoproteins					193:205	N-linked glycoproteins	184:205	N-linked glycoproteins	184:205	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	3	23	theme	manual	728:733	arg1	analysis					750:757	manual glycoproteomic analysis	728:757	manual glycoproteomic analysis	728:757	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	1	24	theme	MALDI	313:317	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	3	25	from	regions	655:661	arg1	sections					682:689	adjacent tissue sections	666:689	adjacent tissue sections	666:689	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	2	26	theme	canine	583:588	arg1	gliomas					590:596	high-grade canine gliomas	572:596	high-grade canine gliomas	572:596	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	0	27	theme	resolved	20:27	arg1	glycoproteomics					29:43	On-tissue spatially resolved glycoproteomics	0:43	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging	0:70	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	5	28	gly	glycopeptides	1015:1027	arg1	proteins					1042:1049	over 30 proteins	1034:1049	over 30 proteins	1034:1049	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	5	28	gly	glycopeptides	1015:1027	arg2	glycopeptides					1015:1027	S- glycopeptides	1012:1027	S- glycopeptides	1012:1027	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	3	29	theme	underlying	616:625	arg1	sialo-glycoprotein					627:644	the underlying sialo-glycoprotein	612:644	the underlying sialo-glycoprotein	612:644	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	5	30	theme	glycoproteomics	954:968	arg1	technique					970:978	our spatially resolved glycoproteomics technique	931:978	our spatially resolved glycoproteomics technique	931:978	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	4	31	gly	glycopeptide	892:903	arg2	glycopeptide					892:903	intact glycopeptide identification	885:918	intact glycopeptide identification	885:918	Results identified haptoglobin as the protein associated with HexNAc4-Hex5-NeuAc2, thus directly linking glycan imaging with intact glycopeptide identification.
34102146	1	32	theme	N-glycan	320:327	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	2	33	theme	PNGaseF	443:449	arg1	digestion					451:459	on-tissue PNGaseF digestion	433:459	on-tissue PNGaseF digestion	433:459	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	1	34	theme	spatial	224:230	arg1	localization					232:243	their spatial localization	218:243	their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	218:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	1	35	theme	mass	329:332	arg1	spectrometry					334:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry	268:345	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	2	36	theme	gliomas	590:596	arg1	regions					561:567	necrotic regions	552:567	necrotic regions of high-grade canine gliomas	552:596	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	3	37	theme	adjacent	666:673	arg1	sections					682:689	adjacent tissue sections	666:689	adjacent tissue sections	666:689	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	2	38	theme	on-tissue	433:441	arg1	digestion					451:459	on-tissue PNGaseF digestion	433:459	on-tissue PNGaseF digestion	433:459	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	2	39	theme	glycan	494:499	arg1	HexNAc4-Hex5-NeuAc2					501:519	the glycan HexNAc4-Hex5-NeuAc2	490:519	the glycan HexNAc4-Hex5-NeuAc2	490:519	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
34102146	1	40	theme	spectrometry	334:345	arg1	MSI					356:358	MSI	356:358	MSI	356:358	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	1	40	theme	spectrometry	334:345	arg1	imaging					347:353	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging	268:353	matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	268:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	3	41	theme	various	647:653	arg1	regions					655:661	various regions	647:661	various regions in adjacent tissue sections	647:689	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	0	42	theme	N-glycan	55:62	arg1	imaging					64:70	N-glycan imaging	55:70	N-glycan imaging	55:70	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	1	43	theme	imaging	347:353	arg1	combination					253:263	a combination	251:263	a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI)	251:359	Here, we present an approach to identify N-linked glycoproteins and deduce their spatial localization using a combination of matrix-assisted laser desorption ionization (MALDI) N-glycan mass spectrometry imaging (MSI) and spatially resolved glycoproteomics.
34102146	3	44	gly	sialo-glycoprotein	627:644	arg1	sialo-glycoprotein					627:644	the underlying sialo-glycoprotein	612:644	the underlying sialo-glycoprotein	612:644	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	5	45	theme	present	1101:1107	arg1	array					1078:1082	the diverse array	1066:1082	the diverse array of glycosylation present	1066:1107	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	3	46	theme	glycoproteomic	735:748	arg1	analysis					750:757	manual glycoproteomic analysis	728:757	manual glycoproteomic analysis	728:757	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	4	47	theme	glycopeptide	892:903	arg1	identification					905:918	intact glycopeptide identification	885:918	intact glycopeptide identification	885:918	Results identified haptoglobin as the protein associated with HexNAc4-Hex5-NeuAc2, thus directly linking glycan imaging with intact glycopeptide identification.
34102146	6	48	theme	resolved	1237:1244	arg1	glycoproteomics					1246:1260	spatially resolved glycoproteomics	1227:1260	spatially resolved glycoproteomics	1227:1260	Ultimately, this proof-of-principle work demonstrates that spatially resolved glycoproteomics greatly complement MALDI-MSI in understanding dysregulated glycosylation.
34102146	5	49	from	proteins	1042:1049	arg1	O-					1004:1005	O-	1004:1005	O-	1004:1005	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	5	49	from	proteins	1042:1049	arg1	N-					1000:1001	400 N-	996:1001	400 N-	996:1001	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	5	49	from	proteins	1042:1049	arg1	glycopeptides					1015:1027	S- glycopeptides	1012:1027	S- glycopeptides	1012:1027	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	0	50	theme	global	79:84	arg1	dysregulation					86:98	global dysregulation	79:98	global dysregulation of canine glioma glycoproteomic landscape	79:140	On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.
34102146	3	51	theme	tissue	675:680	arg1	sections					682:689	adjacent tissue sections	666:689	adjacent tissue sections	666:689	To determine the underlying sialo-glycoprotein, various regions in adjacent tissue sections were subjected to microdigestion and manual glycoproteomic analysis.
34102146	5	52	theme	resolved	945:952	arg1	technique					970:978	our spatially resolved glycoproteomics technique	931:978	our spatially resolved glycoproteomics technique	931:978	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	5	53	theme	tissue	1116:1121	arg1	slices					1123:1128	the tissue slices	1112:1128	the tissue slices	1112:1128	In total, our spatially resolved glycoproteomics technique identified over 400 N-, O-, and S- glycopeptides from over 30 proteins, demonstrating the diverse array of glycosylation present on the tissue slices and the sensitivity of our technique.
34102146	2	54	theme	high-grade	572:581	arg1	gliomas					590:596	high-grade canine gliomas	572:596	high-grade canine gliomas	572:596	We subjected glioma biopsies to on-tissue PNGaseF digestion and MALDI-MSI and found that the glycan HexNAc4-Hex5-NeuAc2 was predominantly expressed in necrotic regions of high-grade canine gliomas.
33609912	11	0	theme	glycosylation	1643:1655	arg1	profiles					1657:1664	Different glycosylation profiles	1633:1664	Different glycosylation profiles	1633:1664	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	6	1	theme	purified	946:953	arg1	IgG1					977:980	purified IgG1 and neutralizing IgG1	946:980	purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme	946:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	11	2	theme	Fab	1688:1690	arg1	fragments					1699:1707	Fab and Fc fragments	1688:1707	fragments	1699:1707	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	5	3	link	N-linked	792:799	arg1	chain					817:821	The N-linked oligosaccharide chain	788:821	The N-linked oligosaccharide chain of the purified IgG antibody	788:850	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	2	4	dep	in	578:579	arg1	vitro					581:585	vitro	581:585	vitro	581:585	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	1	5	theme	IgG	177:179	arg1	antibodies					181:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	10	6	theme	sialic	1598:1603	arg1	acid					1605:1608	sialic acid	1598:1608	sialic acid	1598:1608	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	7	7	theme	human	1149:1153	arg1	IgG					1155:1157	human IgG	1149:1157	human IgG	1149:1157	The purified IgG1 showed an electrophoretic pattern compatible with human IgG.
33609912	5	8	theme	lectins	921:927	arg1	panel					906:910	a panel	904:910	a panel of seven lectins	904:927	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	2	9	theme	in	578:579	arg1	activities					609:618	in vitro antibody neutralizing activities	578:618	in vitro antibody neutralizing activities	578:618	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	10	10	theme	fucose	1587:1592	arg1	residues					1610:1617	fucose and sialic acid residues	1587:1617	fucose and sialic acid residues	1587:1617	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	7	11	theme	compatible	1133:1142	arg1	pattern					1125:1131	an electrophoretic pattern	1106:1131	an electrophoretic pattern compatible with human IgG	1106:1157	The purified IgG1 showed an electrophoretic pattern compatible with human IgG.
33609912	6	12	theme	F	1007:1007	arg1	enzyme					1009:1014	PNGase F enzyme	1000:1014	PNGase F enzyme	1000:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	7	13	theme	electrophoretic	1109:1123	arg1	pattern					1125:1131	an electrophoretic pattern	1106:1131	an electrophoretic pattern compatible with human IgG	1106:1157	The purified IgG1 showed an electrophoretic pattern compatible with human IgG.
33609912	8	14	theme	non-neutralizing	1264:1279	arg1	IgG1					1281:1284	non-neutralizing IgG1	1264:1284	non-neutralizing IgG1	1264:1284	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	3	15	theme	Specific	621:628	arg1	IgG1					630:633	Specific IgG1	621:633	Specific IgG1	621:633	Specific IgG1 were purified from human serum using affinity chromatography.
33609912	6	16	theme	IgG1	977:980	arg1	activity					934:941	The activity	930:941	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme	930:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	2	17	theme	antibody	587:594	arg1	activities					609:618	in vitro antibody neutralizing activities	578:618	in vitro antibody neutralizing activities	578:618	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	11	18	theme	deglycosylated	1767:1780	arg1	IgG1					1782:1785	the deglycosylated IgG1	1763:1785	the deglycosylated IgG1	1763:1785	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	7	19	theme	purified	1085:1092	arg1	IgG1					1094:1097	The purified IgG1	1081:1097	The purified IgG1	1081:1097	The purified IgG1 showed an electrophoretic pattern compatible with human IgG.
33609912	1	20	theme	Rabies	139:144	arg1	antibodies					181:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	11	21	located	observed	1676:1683	arg1	fragments					1699:1707	Fab and Fc fragments	1688:1707	fragments	1699:1707	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	11	21	located	observed	1676:1683	arg2	profiles					1657:1664	Different glycosylation profiles	1633:1664	Different glycosylation profiles	1633:1664	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	0	22	theme	human	59:63	arg1	antibodies					70:79	human IgG1 antibodies	59:79	human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis	59:136	Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.
33609912	6	23	theme	focus	1058:1062	arg1	test					1075:1078	the rapid fluorescent focus inhibition test	1036:1078	the rapid fluorescent focus inhibition test	1036:1078	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	2	24	theme	pre-exposure	505:516	arg1	prophylaxis					518:528	pre-exposure prophylaxis	505:528	pre-exposure prophylaxis to human rabies	505:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	11	25	theme	neutralizing	1796:1807	arg1	activity					1809:1816	its neutralizing activity	1792:1816	its neutralizing activity	1792:1816	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	0	26	theme	antibodies	70:79	arg1	activity					47:54	the neutralizing activity	30:54	the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis	30:136	Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.
33609912	12	27	theme	different	1942:1950	arg1	profile					1966:1972	a different glycosylation profile	1940:1972	a different glycosylation profile than non-neutralizing IgG1	1940:1999	Our results suggest that antibody glycosylation is important for neutralizing RABV in vitro, since neutralizing IgG1 has a different glycosylation profile than non-neutralizing IgG1.
33609912	6	28	theme	rapid	1040:1044	arg1	test					1075:1078	the rapid fluorescent focus inhibition test	1036:1078	the rapid fluorescent focus inhibition test	1036:1078	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	0	29	theme	human	89:93	arg1	rabies					95:100	human rabies	89:100	human rabies induced by pre-exposure prophylaxis	89:136	Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.
33609912	13	30	theme	IgG1	2101:2104	arg1	antibodies					2106:2115	IgG1 antibodies	2101:2115	IgG1 antibodies following vaccination	2101:2137	Further research will be needed to better evaluate the differential glycosylation patterns between IgG1 antibodies following vaccination.
33609912	5	31	theme	N-linked	792:799	arg1	chain					817:821	The N-linked oligosaccharide chain	788:821	The N-linked oligosaccharide chain of the purified IgG antibody	788:850	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	9	32	theme	WFA	1351:1353	arg1	lectins					1375:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	0	33	theme	neutralizing	34:45	arg1	activity					47:54	the neutralizing activity	30:54	the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis	30:136	Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.
33609912	2	34	theme	neutralizing	455:466	arg1	IgG1					489:492	both neutralizing and non-neutralizing IgG1	450:492	both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies	450:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	10	35	theme	Non-neutralizing	1491:1506	arg1	IgG1					1508:1511	Non-neutralizing IgG1	1491:1511	Non-neutralizing IgG1	1491:1511	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	0	36	theme	IgG1	65:68	arg1	antibodies					70:79	human IgG1 antibodies	59:79	human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis	59:136	Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.
33609912	2	37	theme	effector	388:395	arg1	functions					397:405	its effector functions	384:405	its effector functions	384:405	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	9	38	theme	ECA	1356:1358	arg1	lectins					1375:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	2	39	theme	glycosylation	424:436	arg1	patterns					438:445	the glycosylation patterns	420:445	the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies	420:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	5	40	theme	lectin-based	874:885	arg1	assay					893:897	a lectin-based ELISA assay	872:897	a lectin-based ELISA assay with a panel of seven lectins	872:927	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	9	41	theme	WGA	1361:1363	arg1	lectins					1375:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	10	42	from	UEA-1	1558:1562	arg1	binding					1547:1553	strong binding	1540:1553	strong binding	1540:1553	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	11	43	theme	neutralizing	1714:1725	arg1	IgG1					1748:1751	neutralizing and non-neutralizing IgG1	1714:1751	neutralizing and non-neutralizing IgG1	1714:1751	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	5	44	theme	IgG	839:841	arg1	antibody					843:850	the purified IgG antibody	826:850	the purified IgG antibody	826:850	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	10	45	from	SNA	1568:1570	arg1	binding					1547:1553	strong binding	1540:1553	strong binding	1540:1553	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	12	46	theme	antibody	1844:1851	arg1	glycosylation					1853:1865	antibody glycosylation	1844:1865	antibody glycosylation	1844:1865	Our results suggest that antibody glycosylation is important for neutralizing RABV in vitro, since neutralizing IgG1 has a different glycosylation profile than non-neutralizing IgG1.
33609912	7	47	with	compatible	1133:1142	arg1	IgG					1155:1157	human IgG	1149:1157	human IgG	1149:1157	The purified IgG1 showed an electrophoretic pattern compatible with human IgG.
33609912	2	48	theme	non-neutralizing	472:487	arg1	IgG1					489:492	both neutralizing and non-neutralizing IgG1	450:492	both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies	450:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	3	49	theme	affinity	672:679	arg1	chromatography					681:694	affinity chromatography	672:694	affinity chromatography	672:694	Specific IgG1 were purified from human serum using affinity chromatography.
33609912	13	50	theme	glycosylation	2070:2082	arg1	patterns					2084:2091	the differential glycosylation patterns	2053:2091	the differential glycosylation patterns between IgG1 antibodies following vaccination	2053:2137	Further research will be needed to better evaluate the differential glycosylation patterns between IgG1 antibodies following vaccination.
33609912	2	51	theme	carbohydrate	346:357	arg1	chain					359:363	the antibody's carbohydrate chain	331:363	the antibody's carbohydrate chain	331:363	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	11	52	theme	non-neutralizing	1731:1746	arg1	IgG1					1748:1751	neutralizing and non-neutralizing IgG1	1714:1751	neutralizing and non-neutralizing IgG1	1714:1751	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	11	53	theme	Different	1633:1641	arg1	profiles					1657:1664	Different glycosylation profiles	1633:1664	Different glycosylation profiles	1633:1664	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	9	54	theme	different	1404:1412	arg1	N-acetylgalactosamine					1414:1434	possible different N-acetylgalactosamine	1395:1434	possible different N-acetylgalactosamine	1395:1434	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	6	55	theme	neutralizing	964:975	arg1	IgG1					977:980	purified IgG1 and neutralizing IgG1	946:980	purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme	946:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	11	56	from	IgG1	1748:1751	arg1	fragments					1699:1707	Fab and Fc fragments	1688:1707	fragments	1699:1707	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	1	57	theme	RABV-specific	253:265	arg1	antibodies					267:276	the RABV-specific antibodies	249:276	the RABV-specific antibodies	249:276	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	6	58	theme	IgG1	955:958	arg1	IgG1					977:980	purified IgG1 and neutralizing IgG1	946:980	purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme	946:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	8	59	contain	had	1226:1228	arg1	IgG1					1221:1224	neutralizing IgG1	1208:1224	neutralizing IgG1	1208:1224	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	8	59	contain	had	1226:1228	arg2	%					1256:1256	RAI = 80%	1248:1256	RAI = 80%	1248:1256	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	8	59	contain	had	1226:1228	arg2	avidity					1239:1245	a higher avidity	1230:1245	a higher avidity (RAI = 80%)	1230:1257	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	8	60	theme	neutralizing	1208:1219	arg1	IgG1					1221:1224	neutralizing IgG1	1208:1224	neutralizing IgG1	1208:1224	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	6	61	gly	deglycosylated	982:995	arg1	IgG1					977:980	purified IgG1 and neutralizing IgG1	946:980	purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme	946:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	1	62	theme	neutralizing	164:175	arg1	antibodies					181:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	10	63	theme	acid	1605:1608	arg1	residues					1610:1617	fucose and sialic acid residues	1587:1617	fucose and sialic acid residues	1587:1617	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	9	64	theme	mannose	1473:1479	arg1	contents					1481:1488	mannose contents	1473:1488	mannose contents	1473:1488	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	8	65	theme	higher	1232:1237	arg1	avidity					1239:1245	a higher avidity	1230:1245	a higher avidity (RAI = 80%)	1230:1257	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	8	65	theme	higher	1232:1237	arg1	%					1256:1256	RAI = 80%	1248:1256	RAI = 80%	1248:1256	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	8	66	dep	had	1226:1228	arg1	%					1295:1295	RAI = 30%	1287:1295	RAI = 30%	1287:1295	All of the antibodies recognized RABV, although neutralizing IgG1 had a higher avidity (RAI = 80%) than non-neutralizing IgG1 (RAI = 30%).
33609912	13	67	theme	Further	2002:2008	arg1	research					2010:2017	Further research	2002:2017	Further research	2002:2017	Further research will be needed to better evaluate the differential glycosylation patterns between IgG1 antibodies following vaccination.
33609912	5	68	theme	ELISA	887:891	arg1	assay					893:897	a lectin-based ELISA assay	872:897	a lectin-based ELISA assay with a panel of seven lectins	872:927	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	1	69	theme	rabies	216:221	arg1	vaccination					223:233	rabies vaccination	216:233	rabies vaccination	216:233	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	12	70	theme	non-neutralizing	1979:1994	arg1	IgG1					1996:1999	non-neutralizing IgG1	1979:1999	non-neutralizing IgG1	1979:1999	Our results suggest that antibody glycosylation is important for neutralizing RABV in vitro, since neutralizing IgG1 has a different glycosylation profile than non-neutralizing IgG1.
33609912	6	71	theme	PNGase	1000:1005	arg1	F					1007:1007	PNGase F	1000:1007	PNGase F enzyme	1000:1014	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	2	72	theme	neutralizing	596:607	arg1	activities					609:618	in vitro antibody neutralizing activities	578:618	in vitro antibody neutralizing activities	578:618	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	4	73	theme	indirect	746:753	arg1	ELISA					755:759	indirect ELISA	746:759	indirect ELISA	746:759	Purity and avidity were analyzed by SDS-PAGE and indirect ELISA using NH4SCN respectively.
33609912	3	74	theme	human	654:658	arg1	serum					660:664	human serum	654:664	human serum	654:664	Specific IgG1 were purified from human serum using affinity chromatography.
33609912	5	75	theme	oligosaccharide	801:815	arg1	chain					817:821	The N-linked oligosaccharide chain	788:821	The N-linked oligosaccharide chain of the purified IgG antibody	788:850	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	9	76	theme	neutralizing	1303:1314	arg1	IgG1					1316:1319	The neutralizing IgG1	1299:1319	The neutralizing IgG1	1299:1319	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	1	77	theme	lyssavirus	146:155	arg1	antibodies					181:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	6	78	theme	inhibition	1064:1073	arg1	test					1075:1078	the rapid fluorescent focus inhibition test	1036:1078	the rapid fluorescent focus inhibition test	1036:1078	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	12	79	theme	glycosylation	1952:1964	arg1	profile					1966:1972	a different glycosylation profile	1940:1972	a different glycosylation profile than non-neutralizing IgG1	1940:1999	Our results suggest that antibody glycosylation is important for neutralizing RABV in vitro, since neutralizing IgG1 has a different glycosylation profile than non-neutralizing IgG1.
33609912	1	80	theme	RABV	158:161	arg1	antibodies					181:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies	139:190	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	6	81	theme	fluorescent	1046:1056	arg1	test					1075:1078	the rapid fluorescent focus inhibition test	1036:1078	the rapid fluorescent focus inhibition test	1036:1078	The activity of purified IgG1 and neutralizing IgG1 deglycosylated by PNGase F enzyme were analyzed using the rapid fluorescent focus inhibition test.
33609912	0	82	theme	pre-exposure	113:124	arg1	prophylaxis					126:136	pre-exposure prophylaxis	113:136	pre-exposure prophylaxis	113:136	Glycosylation is required for the neutralizing activity of human IgG1 antibodies against human rabies induced by pre-exposure prophylaxis.
33609912	2	83	gly	glycosylation	424:436	arg1	IgG1					489:492	both neutralizing and non-neutralizing IgG1	450:492	both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies	450:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	9	84	theme	higher	1333:1338	arg1	binding					1340:1346	higher binding	1333:1346	higher binding to WFA, ECA, WGA, and ConA lectins	1333:1381	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	2	85	theme	human	533:537	arg1	rabies					539:544	human rabies	533:544	human rabies	533:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	11	86	gly	deglycosylated	1767:1780	arg1	IgG1					1782:1785	the deglycosylated IgG1	1763:1785	the deglycosylated IgG1	1763:1785	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	10	87	theme	other	1521:1525	arg1	hand					1527:1530	the other hand	1517:1530	the other hand	1517:1530	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	5	88	theme	purified	830:837	arg1	antibody					843:850	the purified IgG antibody	826:850	the purified IgG antibody	826:850	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	2	89	theme	IgG1	489:492	arg1	patterns					438:445	the glycosylation patterns	420:445	the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies	420:544	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	5	90	with	assay	893:897	arg1	panel					906:910	a panel	904:910	a panel of seven lectins	904:927	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	11	91	theme	Fc	1696:1697	arg1	fragments					1699:1707	Fab and Fc fragments	1688:1707	fragments	1699:1707	Different glycosylation profiles were also observed in Fab and Fc fragments from neutralizing and non-neutralizing IgG1, although the deglycosylated IgG1 lost its neutralizing activity.
33609912	1	92	dep	confer	192:197	arg1	although					236:243	although	236:243	although	236:243	Rabies lyssavirus (RABV) neutralizing IgG antibodies confer protection after rabies vaccination, although how the RABV-specific antibodies neutralize the virus is still unknown.
33609912	13	93	theme	differential	2057:2068	arg1	patterns					2084:2091	the differential glycosylation patterns	2053:2091	the differential glycosylation patterns between IgG1 antibodies following vaccination	2053:2137	Further research will be needed to better evaluate the differential glycosylation patterns between IgG1 antibodies following vaccination.
33609912	5	94	theme	antibody	843:850	arg1	chain					817:821	The N-linked oligosaccharide chain	788:821	The N-linked oligosaccharide chain of the purified IgG antibody	788:850	The N-linked oligosaccharide chain of the purified IgG antibody was evaluated using a lectin-based ELISA assay with a panel of seven lectins.
33609912	9	95	theme	ConA	1370:1373	arg1	lectins					1375:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	WFA, ECA, WGA, and ConA lectins	1351:1381	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
33609912	10	96	theme	strong	1540:1545	arg1	binding					1547:1553	strong binding	1540:1553	strong binding	1540:1553	Non-neutralizing IgG1, on the other hand, showed strong binding at UEA-1 and SNA, which bind to fucose and sialic acid residues respectively.
33609912	2	97	from	influence	565:573	arg1	activities					609:618	in vitro antibody neutralizing activities	578:618	in vitro antibody neutralizing activities	578:618	As changes in the antibody's carbohydrate chain can interfere with its effector functions, we compared the glycosylation patterns of both neutralizing and non-neutralizing IgG1 induced by pre-exposure prophylaxis to human rabies and analyzed their influence on in vitro antibody neutralizing activities.
33609912	9	98	theme	possible	1395:1402	arg1	N-acetylgalactosamine					1414:1434	possible different N-acetylgalactosamine	1395:1434	possible different N-acetylgalactosamine	1395:1434	The neutralizing IgG1 also showed higher binding to WFA, ECA, WGA, and ConA lectins, indicating possible different N-acetylgalactosamine, galactose, N-acetylglucosamine, and mannose contents.
34154738	3	0	theme	increasing	682:691	arg1	concentrations					693:706	increasing concentrations	682:706	increasing concentrations up to 50μM	682:717	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	15	1	theme	2FF	2162:2164	arg1	concentration					2176:2188	the 2FF inhibitor concentration	2158:2188	the 2FF inhibitor concentration	2158:2188	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	9	2	theme	expressing	1375:1384	arg1	clones					1390:1395	High expressing RMD clones	1370:1395	High expressing RMD clones	1370:1395	High expressing RMD clones reduced the fucosylation of the antibody glycan to as low as 16%.
34154738	12	3	theme	concentrations	1863:1876	arg1	addition					1840:1847	addition	1840:1847	addition of increasing concentrations of 2FF	1840:1883	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	15	4	gly	non-fucosylated	2255:2269	arg1	antibody					2271:2278	non-fucosylated antibody	2255:2278	non-fucosylated antibody	2255:2278	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	15	5	from	decrease	2308:2315	arg1	2FF					2365:2367	15 μM 2FF	2359:2367	15 μM 2FF	2359:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	3	6	theme	first	520:524	arg1	method					526:531	The first method	516:531	The first method	516:531	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	8	7	theme	Stable	1203:1208	arg1	clones					1210:1215	Stable clones	1203:1215	Stable clones from transfected pools	1203:1238	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	7	8	theme	6-deoxy-D-lyxo-4-hexulose	1044:1068	arg1	gene					1086:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene	1025:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1025:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	3	9	theme	FUT	560:562	arg1	fucose					600:605	2- fluoro peracetylated fucose	576:605	2- fluoro peracetylated fucose (2FF)	576:611	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	3	9	theme	FUT	560:562	arg1	inhibitor					565:573	a fucosyltransferase (FUT) inhibitor	538:573	a fucosyltransferase (FUT) inhibitor	538:573	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	6	10	theme	17.5	933:936	arg1	%					928:928	%	928:928	%	928:928	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	10	11	theme	RMD	1504:1506	arg1	clones					1508:1513	these RMD clones	1498:1513	these RMD clones	1498:1513	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	7	12	theme	prokaryotic	1027:1037	arg1	gene					1086:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene	1025:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1025:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	3	13	theme	fucosyltransferase	540:557	arg1	fucose					600:605	2- fluoro peracetylated fucose	576:605	2- fluoro peracetylated fucose (2FF)	576:611	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	3	13	theme	fucosyltransferase	540:557	arg1	inhibitor					565:573	a fucosyltransferase (FUT) inhibitor	538:573	a fucosyltransferase (FUT) inhibitor	538:573	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	0	14	theme	glycoengineering	18:33	arg1	strategies					35:44	two glycoengineering strategies	14:44	two glycoengineering strategies	14:44	Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
34154738	9	15	theme	antibody	1429:1436	arg1	glycan					1438:1443	the antibody glycan	1425:1443	the antibody glycan	1425:1443	High expressing RMD clones reduced the fucosylation of the antibody glycan to as low as 16%.
34154738	12	16	theme	fucosylation	1803:1814	arg1	pattern					1816:1822	the fucosylation pattern	1799:1822	the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF	1799:1883	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	10	17	theme	fucosylation	1527:1538	arg1	level					1540:1544	the fucosylation level	1523:1544	the fucosylation level	1523:1544	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	11	18	theme	RMD	1694:1696	arg1	cells					1698:1702	the RMD cells	1690:1702	the RMD cells	1690:1702	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	7	19	theme	producing	1004:1012	arg1	cells					1014:1018	the EG2-hFc producing cells	992:1018	the EG2-hFc producing cells	992:1018	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	6	20	dep	%	928:928	arg1	to					930:931	to	930:931	to	930:931	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	15	21	theme	fucose	2326:2331	arg1	peak					2333:2336	the 2 fucose peak	2320:2336	the 2 fucose peak to insignificance at 15 μM 2FF	2320:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	6	22	theme	total	902:906	arg1	fucosylation					908:919	total fucosylation	902:919	total fucosylation from 80% to 17.5%	902:937	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	9	23	gly	fucosylation	1409:1420	arg1	glycan					1438:1443	the antibody glycan	1425:1443	the antibody glycan	1425:1443	High expressing RMD clones reduced the fucosylation of the antibody glycan to as low as 16%.
34154738	8	24	theme	flow	1264:1267	arg1	cytometry					1269:1277	flow cytometry	1264:1277	flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene	1264:1367	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	15	25	theme	peak	2333:2336	arg1	decrease					2308:2315	a gradual decrease	2298:2315	a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF	2298:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	13	26	theme	concentration-	1944:1957	arg1	manner					1982:1987	a concentration- dependent and specific manner	1942:1987	a concentration- dependent and specific manner	1942:1987	This showed that 2FF inhibits the addition of fucose in a concentration- dependent and specific manner with the inhibition of fucose occurring one fucose at a time.
34154738	8	27	from	pools	1234:1238	arg1	clones					1210:1215	Stable clones	1203:1215	Stable clones from transfected pools	1203:1238	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	1	28	theme	N-linked	127:134	arg1	glycan					136:141	an Fc N-linked glycan	121:141	an Fc N-linked glycan	121:141	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	11	29	theme	step-wise	1645:1653	arg1	mM					1683:1684	up to 1 mM	1675:1684	up to 1 mM	1675:1684	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	11	29	theme	step-wise	1645:1653	arg1	addition					1655:1662	step-wise addition	1645:1662	step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%	1645:1765	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	3	30	theme	peracetylated	586:598	arg1	2FF					608:610	2FF	608:610	2FF	608:610	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	3	30	theme	peracetylated	586:598	arg1	fucose					600:605	2- fluoro peracetylated fucose	576:605	2- fluoro peracetylated fucose (2FF)	576:611	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	3	30	theme	peracetylated	586:598	arg1	inhibitor					565:573	a fucosyltransferase (FUT) inhibitor	538:573	a fucosyltransferase (FUT) inhibitor	538:573	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	8	31	theme	green	1289:1293	arg1	GFP					1316:1318	GFP	1316:1318	GFP	1316:1318	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	8	31	theme	green	1289:1293	arg1	protein					1307:1313	green fluorescent protein	1289:1313	the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene	1285:1367	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	6	32	gly	reduced	894:900	arg1	2FF					947:949	20μM 2FF	942:949	20μM 2FF	942:949	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	3	33	dep	50μM	714:717	arg1	up					708:709	up	708:709	up	708:709	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	1	34	theme	effector	160:167	arg1	functions					169:177	antibody effector functions	151:177	antibody effector functions	151:177	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	0	35	theme	antibody	90:97	arg1	fucosylation					61:72	the fucosylation	57:72	the fucosylation of a monoclonal antibody	57:97	Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
34154738	15	36	theme	non-fucosylated	2255:2269	arg1	antibody					2271:2278	non-fucosylated antibody	2255:2278	non-fucosylated antibody	2255:2278	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	2	37	theme	EGFR	501:504	arg1	receptor					506:513	the EGFR receptor	497:513	the EGFR receptor	497:513	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	14	38	theme	fucose	2125:2130	arg1	moieties					2132:2139	two fucose moieties	2121:2139	two fucose moieties	2121:2139	Control cultures showed the presence of a predominant peak indicating two fucose moieties per antibody.
34154738	11	39	theme	%	1765:1765	arg1	maximum					1752:1758	a maximum	1750:1758	a maximum of 87%	1750:1765	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	13	40	theme	fucose	2012:2017	arg1	inhibition					1998:2007	the inhibition	1994:2007	the inhibition of fucose	1994:2017	This showed that 2FF inhibits the addition of fucose in a concentration- dependent and specific manner with the inhibition of fucose occurring one fucose at a time.
34154738	15	41	theme	μM	2362:2363	arg1	2FF					2365:2367	15 μM 2FF	2359:2367	15 μM 2FF	2359:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	2	42	theme	antibody	442:449	arg1	fucosylation					404:415	core fucosylation	399:415	core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor	399:513	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	13	43	theme	dependent	1959:1967	arg1	manner					1982:1987	a concentration- dependent and specific manner	1942:1987	a concentration- dependent and specific manner	1942:1987	This showed that 2FF inhibits the addition of fucose in a concentration- dependent and specific manner with the inhibition of fucose occurring one fucose at a time.
34154738	2	44	theme	heavy	430:434	arg1	chain					436:440	a camelid heavy chain	420:440	a camelid heavy chain antibody	420:449	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	14	45	theme	predominant	2093:2103	arg1	peak					2105:2108	a predominant peak	2091:2108	a predominant peak indicating two fucose moieties per antibody	2091:2152	Control cultures showed the presence of a predominant peak indicating two fucose moieties per antibody.
34154738	7	46	theme	de	1122:1123	arg1	pathway					1130:1136	the fucose de novo pathway	1111:1136	the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1111:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	1	47	theme	increased	277:285	arg1	binding					287:293	increased binding	277:293	increased binding to the Fcγ receptors	277:314	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	1	48	theme	glycan	136:141	arg1	fucosylation					105:116	Core fucosylation	100:116	Core fucosylation of an Fc N-linked glycan	100:141	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	6	49	from	%	937:937	arg1	fucosylation					908:919	total fucosylation	902:919	total fucosylation from 80% to 17.5%	902:937	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	4	50	theme	cell	774:777	arg1	growth					779:784	cell growth	774:784	cell growth	774:784	At this concentration there was no observed effect on cell growth.
34154738	10	51	theme	antibody	1572:1579	arg1	glycan					1581:1586	the antibody glycan	1568:1586	the antibody glycan	1568:1586	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	0	52	theme	strategies	35:44	arg1	Comparison					0:9	Comparison	0:9	Comparison of two glycoengineering strategies	0:44	Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
34154738	11	53	theme	incremental	1592:1602	arg1	increase					1604:1611	An incremental increase	1589:1611	An incremental increase in fucosylation	1589:1627	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	8	54	theme	RMD	1360:1362	arg1	gene					1364:1367	the RMD gene	1356:1367	the RMD gene	1356:1367	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	11	55	theme	fucosylation	1718:1729	arg1	level					1731:1735	the fucosylation level	1714:1735	the fucosylation level	1714:1735	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	1	56	theme	Fcγ	302:304	arg1	receptors					306:314	the Fcγ receptors	298:314	the Fcγ receptors	298:314	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	3	57	theme	cell	633:636	arg1	cultures					638:645	cell cultures	633:645	cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM	633:717	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	15	58	theme	inhibitor	2166:2174	arg1	concentration					2176:2188	the 2FF inhibitor concentration	2158:2188	the 2FF inhibitor concentration	2158:2188	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	10	59	theme	2FF	1479:1481	arg1	addition					1467:1474	The addition	1463:1474	The addition of 2FF to cultures of these RMD clones	1463:1513	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	2	60	theme	different	354:362	arg1	approaches					364:373	two different approaches	350:373	two different approaches	350:373	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	1	61	theme	dependent	228:236	arg1	ADCC					257:260	ADCC	257:260	ADCC	257:260	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	1	61	theme	dependent	228:236	arg1	cytotoxicity					243:254	the antibody dependent cell cytotoxicity	215:254	the antibody dependent cell cytotoxicity (ADCC) response	215:270	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	4	62	from	effect	764:769	arg1	growth					779:784	cell growth	774:784	cell growth	774:784	At this concentration there was no observed effect on cell growth.
34154738	3	63	theme	EG2-hFc	662:668	arg1	antibody					670:677	the EG2-hFc antibody	658:677	the EG2-hFc antibody	658:677	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	1	64	theme	cytotoxicity	243:254	arg1	response					263:270	the antibody dependent cell cytotoxicity (ADCC) response	215:270	the antibody dependent cell cytotoxicity (ADCC) response	215:270	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	14	65	theme	Control	2051:2057	arg1	cultures					2059:2066	Control cultures	2051:2066	Control cultures	2051:2066	Control cultures showed the presence of a predominant peak indicating two fucose moieties per antibody.
34154738	7	66	theme	RMD	1081:1083	arg1	gene					1086:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene	1025:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1025:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	9	67	theme	High	1370:1373	arg1	clones					1390:1395	High expressing RMD clones	1370:1395	High expressing RMD clones	1370:1395	High expressing RMD clones reduced the fucosylation of the antibody glycan to as low as 16%.
34154738	7	68	theme	reductase	1070:1078	arg1	gene					1086:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene	1025:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1025:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	9	69	theme	RMD	1386:1388	arg1	clones					1390:1395	High expressing RMD clones	1370:1395	High expressing RMD clones	1370:1395	High expressing RMD clones reduced the fucosylation of the antibody glycan to as low as 16%.
34154738	12	70	theme	increasing	1852:1861	arg1	concentrations					1863:1876	increasing concentrations	1852:1876	increasing concentrations of 2FF	1852:1883	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	7	71	theme	GDP-	1039:1042	arg1	gene					1086:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene	1025:1089	a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1025:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	10	72	theme	clones	1508:1513	arg1	cultures					1486:1493	cultures	1486:1493	cultures of these RMD clones	1486:1513	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	12	73	gly	fucosylation	1803:1814	arg1	EG2-hFc					1827:1833	EG2-hFc	1827:1833	EG2-hFc	1827:1833	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	5	74	theme	Glycan	787:792	arg1	analysis					794:801	Glycan analysis	787:801	Glycan analysis	787:801	Glycan analysis was performed on antibodies collected from culture samples using HILIC-HPLC.
34154738	12	75	theme	EG2-hFc	1827:1833	arg1	pattern					1816:1822	the fucosylation pattern	1799:1822	the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF	1799:1883	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	13	76	theme	specific	1973:1980	arg1	manner					1982:1987	a concentration- dependent and specific manner	1942:1987	a concentration- dependent and specific manner	1942:1987	This showed that 2FF inhibits the addition of fucose in a concentration- dependent and specific manner with the inhibition of fucose occurring one fucose at a time.
34154738	8	77	dep	protein	1307:1313	arg1	marker					1321:1326	marker	1321:1326	the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene	1285:1367	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	6	78	theme	80	926:927	arg1	%					928:928	%	928:928	%	928:928	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	8	79	theme	transfected	1222:1232	arg1	pools					1234:1238	transfected pools	1222:1238	transfected pools	1222:1238	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	7	80	theme	EG2-hFc	996:1002	arg1	cells					1014:1018	the EG2-hFc producing cells	992:1018	the EG2-hFc producing cells	992:1018	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	9	81	theme	glycan	1438:1443	arg1	fucosylation					1409:1420	the fucosylation	1405:1420	the fucosylation of the antibody glycan to as low as 16%	1405:1460	High expressing RMD clones reduced the fucosylation of the antibody glycan to as low as 16%.
34154738	13	82	theme	fucose	1932:1937	arg1	addition					1920:1927	the addition	1916:1927	the addition of fucose	1916:1937	This showed that 2FF inhibits the addition of fucose in a concentration- dependent and specific manner with the inhibition of fucose occurring one fucose at a time.
34154738	7	83	theme	second	956:961	arg1	method					963:968	The second method	952:968	The second method	952:968	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	1	84	theme	Fc	124:125	arg1	glycan					136:141	an Fc N-linked glycan	121:141	an Fc N-linked glycan	121:141	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	15	85	from	2FF	2365:2367	arg1	peak					2333:2336	the 2 fucose peak	2320:2336	the 2 fucose peak to insignificance at 15 μM 2FF	2320:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	15	85	from	2FF	2365:2367	arg1	decrease					2308:2315	a gradual decrease	2298:2315	a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF	2298:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	11	86	theme	fucose	1667:1672	arg1	mM					1683:1684	up to 1 mM	1675:1684	up to 1 mM	1675:1684	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	11	86	theme	fucose	1667:1672	arg1	addition					1655:1662	step-wise addition	1645:1662	step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%	1645:1765	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	12	87	used	used	1776:1779	arg2	We					1768:1769	We	1768:1769	We	1768:1769	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	11	88	dep	1	1681:1681	arg1	to					1678:1679	to	1678:1679	to	1678:1679	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	3	89	theme	fluoro	579:584	arg1	2FF					608:610	2FF	608:610	2FF	608:610	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	3	89	theme	fluoro	579:584	arg1	fucose					600:605	2- fluoro peracetylated fucose	576:605	2- fluoro peracetylated fucose (2FF)	576:611	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	3	89	theme	fluoro	579:584	arg1	inhibitor					565:573	a fucosyltransferase (FUT) inhibitor	538:573	a fucosyltransferase (FUT) inhibitor	538:573	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	5	90	theme	culture	846:852	arg1	samples					854:860	culture samples	846:860	culture samples using HILIC-HPLC	846:877	Glycan analysis was performed on antibodies collected from culture samples using HILIC-HPLC.
34154738	0	91	theme	monoclonal	79:88	arg1	antibody					90:97	a monoclonal antibody	77:97	a monoclonal antibody	77:97	Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
34154738	15	92	theme	gradual	2300:2306	arg1	decrease					2308:2315	a gradual decrease	2298:2315	a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF	2298:2367	As the 2FF inhibitor concentration was increased peaks corresponding to one fucose per antibody and non-fucosylated antibody predominated with a gradual decrease of the 2 fucose peak to insignificance at 15 μM 2FF.
34154738	1	93	theme	antibody	151:158	arg1	functions					169:177	antibody effector functions	151:177	antibody effector functions	151:177	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	2	94	theme	CHO	473:475	arg1	cells					477:481	CHO cells	473:481	CHO cells which targets the EGFR receptor	473:513	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	7	95	dep	de	1122:1123	arg1	novo					1125:1128	novo	1125:1128	novo	1125:1128	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	12	96	with	pattern	1816:1822	arg1	addition					1840:1847	addition	1840:1847	addition of increasing concentrations of 2FF	1840:1883	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	0	97	gly	fucosylation	61:72	arg1	antibody					90:97	a monoclonal antibody	77:97	a monoclonal antibody	77:97	Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
34154738	6	98	theme	20μM	942:945	arg1	2FF					947:949	20μM 2FF	942:949	20μM 2FF	942:949	The inhibitor reduced total fucosylation from 80% to 17.5% at 20μM 2FF.
34154738	2	99	gly	fucosylation	404:415	arg1	EG2-hFc					452:458	EG2-hFc	452:458	EG2-hFc expressed in CHO cells which targets the EGFR receptor	452:513	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	2	99	gly	fucosylation	404:415	arg1	antibody					442:449	a camelid heavy chain antibody	420:449	a camelid heavy chain antibody	420:449	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	8	100	theme	fluorescent	1295:1305	arg1	GFP					1316:1318	GFP	1316:1318	GFP	1316:1318	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	8	100	theme	fluorescent	1295:1305	arg1	protein					1307:1313	green fluorescent protein	1289:1313	the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene	1285:1367	Stable clones from transfected pools were isolated following flow cytometry using the green fluorescent protein (GFP) marker which was co-expressed with the RMD gene.
34154738	1	101	gly	fucosylation	105:116	arg1	antibody					151:158	antibody effector functions	151:177	antibody effector functions	151:177	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	1	101	gly	fucosylation	105:116	arg1	glycan					136:141	an Fc N-linked glycan	121:141	an Fc N-linked glycan	121:141	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	1	101	gly	fucosylation	105:116	arg1	effector					160:167	antibody effector functions	151:177	antibody effector functions	151:177	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	11	102	from	increase	1604:1611	arg1	fucosylation					1616:1627	fucosylation	1616:1627	fucosylation	1616:1627	An incremental increase in fucosylation was obtained by step-wise addition of fucose (up to 1 mM) to the RMD cells, in which the fucosylation level increased to a maximum of 87%.
34154738	2	103	theme	chain	436:440	arg1	EG2-hFc					452:458	EG2-hFc	452:458	EG2-hFc expressed in CHO cells which targets the EGFR receptor	452:513	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	2	103	theme	chain	436:440	arg1	antibody					442:449	a camelid heavy chain antibody	420:449	a camelid heavy chain antibody	420:449	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	14	104	theme	peak	2105:2108	arg1	presence					2079:2086	the presence	2075:2086	the presence of a predominant peak indicating two fucose moieties per antibody	2075:2152	Control cultures showed the presence of a predominant peak indicating two fucose moieties per antibody.
34154738	7	105	theme	fucose	1115:1120	arg1	pathway					1130:1136	the fucose de novo pathway	1111:1136	the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan	1111:1200	The second method involved transfecting the EG2-hFc producing cells with a prokaryotic GDP- 6-deoxy-D-lyxo-4-hexulose reductase (RMD) gene in order to deflect the fucose de novo pathway into producing rhamnose which is not incorporated into a glycan.
34154738	1	106	theme	Core	100:103	arg1	fucosylation					105:116	Core fucosylation	100:116	Core fucosylation of an Fc N-linked glycan	100:141	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	2	107	theme	camelid	422:428	arg1	chain					436:440	a camelid heavy chain	420:440	a camelid heavy chain antibody	420:449	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	10	108	theme	glycan	1581:1586	arg1	%					1563:1563	3%	1562:1563	3% of the antibody glycan	1562:1586	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	10	108	theme	glycan	1581:1586	arg1	glycan					1581:1586	the antibody glycan	1568:1586	the antibody glycan	1568:1586	The addition of 2FF to cultures of these RMD clones reduced the fucosylation level even further to 3% of the antibody glycan.
34154738	1	109	theme	fucose	198:203	arg1	absence					187:193	the absence	183:193	the absence of fucose	183:203	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	2	110	theme	core	399:402	arg1	fucosylation					404:415	core fucosylation	399:415	core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor	399:513	The work presented here compares two different approaches to incrementally reduce core fucosylation of a camelid heavy chain antibody, EG2-hFc expressed in CHO cells which targets the EGFR receptor.
34154738	1	111	link	N-linked	127:134	arg1	glycan					136:141	an Fc N-linked glycan	121:141	an Fc N-linked glycan	121:141	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	3	112	theme	2-	576:577	arg1	fluoro					579:584	fluoro	579:584	fluoro	579:584	The first method uses a fucosyltransferase (FUT) inhibitor, 2- fluoro peracetylated fucose (2FF), which was added to cell cultures expressing the EG2-hFc antibody in increasing concentrations up to 50μM.
34154738	12	113	theme	2FF	1881:1883	arg1	concentrations					1863:1876	increasing concentrations	1852:1876	increasing concentrations of 2FF	1852:1883	We also used ESI-MS to analyze the fucosylation pattern of EG2-hFc with addition of increasing concentrations of 2FF.
34154738	4	114	theme	observed	755:762	arg1	effect					764:769	no observed effect	752:769	no observed effect on cell growth	752:784	At this concentration there was no observed effect on cell growth.
34154738	1	115	theme	cell	238:241	arg1	ADCC					257:260	ADCC	257:260	ADCC	257:260	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34154738	1	115	theme	cell	238:241	arg1	cytotoxicity					243:254	the antibody dependent cell cytotoxicity	215:254	the antibody dependent cell cytotoxicity (ADCC) response	215:270	Core fucosylation of an Fc N-linked glycan affects antibody effector functions, as the absence of fucose increases the antibody dependent cell cytotoxicity (ADCC) response with increased binding to the Fcγ receptors.
34575972	0	0	theme	Sp1	93:95	arg1	O-GlcNAcylation					97:111	Sp1 O-GlcNAcylation	93:111	Sp1 O-GlcNAcylation	93:111	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	4	1	theme	insulin	899:905	arg1	treatment					907:915	insulin treatment	899:915	insulin treatment	899:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	3	2	theme	sterol	557:562	arg1	protein					591:597	sterol regulatory element-binding protein 1	557:599	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription	522:670	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	3	2	theme	sterol	557:562	arg1	SREBP1					602:607	SREBP1	602:607	SREBP1	602:607	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	4	3	theme	ACC1	832:835	arg1	expression					838:847	SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression	799:847	SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	799:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	4	theme	carboxylase	817:827	arg1	expression					838:847	SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression	799:847	SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	799:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	5	5	theme	cell	1040:1043	arg1	survival					1045:1052	cell survival	1040:1052	cell survival	1040:1052	Moreover, glutamine deprivation induced LD formation through GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling and supported cell survival.
34575972	5	6	theme	O-GlcNAc-Sp1/SREBP1/ACC1	991:1014	arg1	signaling					1016:1024	GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling	979:1024	GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling	979:1024	Moreover, glutamine deprivation induced LD formation through GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling and supported cell survival.
34575972	7	7	theme	liver	1369:1373	arg1	cells					1393:1397	liver and breast cancer cells	1369:1397	liver and breast cancer cells	1369:1397	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	4	8	theme	SREBP1/acetyl-CoA	799:815	arg1	expression					838:847	SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression	799:847	SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	799:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	5	9	theme	GS-mediated	979:989	arg1	signaling					1016:1024	GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling	979:1024	GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling	979:1024	Moreover, glutamine deprivation induced LD formation through GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling and supported cell survival.
34575972	0	10	theme	Lipid	126:130	arg1	Formation					140:148	Lipid Droplet Formation	126:148	Lipid Droplet Formation in Cancer Cells	126:164	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	4	11	theme	protein	770:776	arg1	O-GlcNAcylation					734:748	O-GlcNAcylation	734:748	O-GlcNAcylation	734:748	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	11	theme	protein	770:776	arg1	N-acetylglucosaminylation					707:731	the O-linked N-acetylglucosaminylation	694:731	the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	694:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	12	theme	O-linked	698:705	arg1	O-GlcNAcylation					734:748	O-GlcNAcylation	734:748	O-GlcNAcylation	734:748	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	12	theme	O-linked	698:705	arg1	N-acetylglucosaminylation					707:731	the O-linked N-acetylglucosaminylation	694:731	the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	694:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	13	theme	LD	877:878	arg1	accumulation					881:892	lipid droplet (LD) accumulation	862:892	lipid droplet (LD) accumulation upon insulin treatment	862:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	6	14	theme	Sp1	1186:1188	arg1	O-GlcNAcylation					1190:1204	Sp1 O-GlcNAcylation	1186:1204	Sp1 O-GlcNAcylation	1186:1204	These findings demonstrate that insulin and glutamine deprivation induces SREBP1 that transcriptionally activates GS, resulting in Sp1 O-GlcNAcylation.
34575972	7	15	theme	feedforward	1305:1315	arg1	loop					1317:1320	a feedforward loop	1303:1320	a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells	1303:1397	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	0	16	theme	Glutamine	15:23	arg1	Synthetase					25:34	SREBP1-Induced Glutamine Synthetase	0:34	SREBP1-Induced Glutamine Synthetase	0:34	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	3	17	dep	factor	550:555	arg1	protein					591:597	sterol regulatory element-binding protein 1	557:599	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription	522:670	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	3	17	dep	factor	550:555	arg1	SREBP1					602:607	SREBP1	602:607	SREBP1	602:607	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	2	18	theme	GS	405:406	arg1	role					397:400	the role	393:400	the role of GS in regulating lipogenesis	393:432	Studies have demonstrated that glutamine synthetase (GS) boosts glutamine-dependent anabolic processes for nucleotide and protein synthesis, but the role of GS in regulating lipogenesis remains unclear.
34575972	0	19	theme	SREBP1-Induced	0:13	arg1	Synthetase					25:34	SREBP1-Induced Glutamine Synthetase	0:34	SREBP1-Induced Glutamine Synthetase	0:34	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	1	20	theme	important	196:204	arg1	lipids					181:186	lipids	181:186	lipids	181:186	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	1	20	theme	important	196:204	arg1	Glutamine					167:175	Glutamine	167:175	Glutamine	167:175	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	1	20	theme	important	196:204	arg1	components					206:215	two important components	192:215	two important components of proliferating cancer cells	192:245	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	4	21	theme	droplet	868:874	arg1	accumulation					881:892	lipid droplet (LD) accumulation	862:892	lipid droplet (LD) accumulation upon insulin treatment	862:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	2	22	theme	anabolic	332:339	arg1	processes					341:349	glutamine-dependent anabolic processes	312:349	glutamine-dependent anabolic processes	312:349	Studies have demonstrated that glutamine synthetase (GS) boosts glutamine-dependent anabolic processes for nucleotide and protein synthesis, but the role of GS in regulating lipogenesis remains unclear.
34575972	3	23	theme	glutamine	490:498	arg1	deprivation					500:510	glutamine deprivation	490:510	glutamine deprivation	490:510	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	0	24	theme	Droplet	132:138	arg1	Formation					140:148	Lipid Droplet Formation	126:148	Lipid Droplet Formation in Cancer Cells	126:164	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	2	25	theme	glutamine-dependent	312:330	arg1	processes					341:349	glutamine-dependent anabolic processes	312:349	glutamine-dependent anabolic processes	312:349	Studies have demonstrated that glutamine synthetase (GS) boosts glutamine-dependent anabolic processes for nucleotide and protein synthesis, but the role of GS in regulating lipogenesis remains unclear.
34575972	0	26	theme	Feedforward	47:57	arg1	Loop					59:62	a Feedforward Loop	45:62	a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation	45:111	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	3	27	theme	transcription	536:548	arg1	factor					550:555	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1)	522:608	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription	522:670	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	0	28	theme	Cancer	153:158	arg1	Cells					160:164	Cancer Cells	153:164	Cancer Cells	153:164	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	4	29	theme	lipid	862:866	arg1	accumulation					881:892	lipid droplet (LD) accumulation	862:892	lipid droplet (LD) accumulation upon insulin treatment	862:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	1	30	theme	proliferating	220:232	arg1	cells					241:245	proliferating cancer cells	220:245	proliferating cancer cells	220:245	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	7	31	theme	SREBP1	1282:1287	arg1	expression					1268:1277	the expression	1264:1277	the expression of SREBP1	1264:1287	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	6	32	theme	glutamine	1099:1107	arg1	deprivation					1109:1119	glutamine deprivation	1099:1119	glutamine deprivation	1099:1119	These findings demonstrate that insulin and glutamine deprivation induces SREBP1 that transcriptionally activates GS, resulting in Sp1 O-GlcNAcylation.
34575972	1	33	theme	cancer	234:239	arg1	cells					241:245	proliferating cancer cells	220:245	proliferating cancer cells	220:245	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	4	34	link	O-linked	698:705	arg1	O-GlcNAcylation					734:748	O-GlcNAcylation	734:748	O-GlcNAcylation	734:748	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	34	link	O-linked	698:705	arg1	N-acetylglucosaminylation					707:731	the O-linked N-acetylglucosaminylation	694:731	the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	694:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	3	35	theme	lipogenic	526:534	arg1	factor					550:555	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1)	522:608	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription	522:670	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	7	36	from	lipogenesis	1337:1347	arg1	cells					1393:1397	liver and breast cancer cells	1369:1397	liver and breast cancer cells	1369:1397	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	3	37	theme	GS	628:629	arg1	promoter					631:638	the GS promoter	624:638	the GS promoter	624:638	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	2	38	theme	protein	370:376	arg1	synthesis					378:386	protein synthesis	370:386	protein synthesis	370:386	Studies have demonstrated that glutamine synthetase (GS) boosts glutamine-dependent anabolic processes for nucleotide and protein synthesis, but the role of GS in regulating lipogenesis remains unclear.
34575972	7	39	theme	breast	1379:1384	arg1	cancer					1386:1391	breast cancer	1379:1391	breast cancer	1379:1391	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	7	40	theme	cancer	1386:1391	arg1	cells					1393:1397	liver and breast cancer cells	1369:1397	liver and breast cancer cells	1369:1397	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	1	41	theme	cells	241:245	arg1	lipids					181:186	lipids	181:186	lipids	181:186	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	1	41	theme	cells	241:245	arg1	Glutamine					167:175	Glutamine	167:175	Glutamine	167:175	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	1	41	theme	cells	241:245	arg1	components					206:215	two important components	192:215	two important components of proliferating cancer cells	192:245	Glutamine and lipids are two important components of proliferating cancer cells.
34575972	5	42	theme	LD	958:959	arg1	formation					961:969	LD formation	958:969	LD formation	958:969	Moreover, glutamine deprivation induced LD formation through GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling and supported cell survival.
34575972	2	43	theme	glutamine	279:287	arg1	GS					301:302	GS	301:302	GS	301:302	Studies have demonstrated that glutamine synthetase (GS) boosts glutamine-dependent anabolic processes for nucleotide and protein synthesis, but the role of GS in regulating lipogenesis remains unclear.
34575972	2	43	theme	glutamine	279:287	arg1	synthetase					289:298	glutamine synthetase	279:298	glutamine synthetase (GS)	279:303	Studies have demonstrated that glutamine synthetase (GS) boosts glutamine-dependent anabolic processes for nucleotide and protein synthesis, but the role of GS in regulating lipogenesis remains unclear.
34575972	5	44	theme	glutamine	928:936	arg1	deprivation					938:948	glutamine deprivation	928:948	glutamine deprivation	928:948	Moreover, glutamine deprivation induced LD formation through GS-mediated O-GlcNAc-Sp1/SREBP1/ACC1 signaling and supported cell survival.
34575972	7	45	theme	LD	1353:1354	arg1	formation					1356:1364	LD formation	1353:1364	LD formation	1353:1364	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	7	46	from	formation	1356:1364	arg1	cells					1393:1397	liver and breast cancer cells	1369:1397	liver and breast cancer cells	1369:1397	Subsequently, O-GlcNAc-Sp1 transcriptionally upregulates the expression of SREBP1, resulting in a feedforward loop that increases lipogenesis and LD formation in liver and breast cancer cells.
34575972	3	47	theme	regulatory	564:573	arg1	protein					591:597	sterol regulatory element-binding protein 1	557:599	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription	522:670	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	3	47	theme	regulatory	564:573	arg1	SREBP1					602:607	SREBP1	602:607	SREBP1	602:607	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	0	48	from	Formation	140:148	arg1	Cells					160:164	Cancer Cells	153:164	Cancer Cells	153:164	SREBP1-Induced Glutamine Synthetase Triggers a Feedforward Loop to Upregulate SREBP1 through Sp1 O-GlcNAcylation and Augments Lipid Droplet Formation in Cancer Cells.
34575972	3	49	theme	element-binding	575:589	arg1	protein					591:597	sterol regulatory element-binding protein 1	557:599	the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription	522:670	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	3	49	theme	element-binding	575:589	arg1	SREBP1					602:607	SREBP1	602:607	SREBP1	602:607	This study identified that insulin and glutamine deprivation activated the lipogenic transcription factor sterol regulatory element-binding protein 1 (SREBP1) that bound to the GS promoter and increased its transcription.
34575972	4	50	theme	specificity	758:768	arg1	protein					770:776	the specificity protein 1	754:778	the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment	754:915	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
34575972	4	50	theme	specificity	758:768	arg1	Sp1					781:783	Sp1	781:783	Sp1	781:783	Notably, GS enhanced the O-linked N-acetylglucosaminylation (O-GlcNAcylation) of the specificity protein 1 (Sp1) that induced SREBP1/acetyl-CoA carboxylase 1 (ACC1) expression resulting in lipid droplet (LD) accumulation upon insulin treatment.
33846785	12	0	theme	lung	1814:1817	arg1	cells					1826:1830	lung cancer cells	1814:1830	lung cancer cells	1814:1830	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	4	1	theme	present	558:564	arg1	study					566:570	the present study	554:570	the present study	554:570	In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo.
33846785	11	2	theme	uridine	1649:1655	arg1	UDP‑GlcNAc					1690:1699	UDP‑GlcNAc	1690:1699	UDP‑GlcNAc	1690:1699	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	11	2	theme	uridine	1649:1655	arg1	substrate					1638:1646	the donor substrate	1628:1646	the donor substrate	1628:1646	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	11	2	theme	uridine	1649:1655	arg1	5‑diphospho‑N‑acetylglucosamine					1657:1687	uridine 5‑diphospho‑N‑acetylglucosamine	1649:1687	uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc)	1649:1700	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	13	3	theme	OGA	1972:1974	arg1	activity					1955:1962	the activity	1951:1962	the activity of OGT, OGA and AMPK in vitro and in vivo	1951:2004	On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.
33846785	2	4	link	O‑linked	332:339	arg1	O‑GlcNAc					364:371	O‑GlcNAc	364:371	O‑GlcNAc	364:371	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	2	4	link	O‑linked	332:339	arg1	β‑N‑acetylglucosamine					341:361	O‑linked β‑N‑acetylglucosamine	332:361	O‑linked β‑N‑acetylglucosamine (O‑GlcNAc)	332:372	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	7	5	theme	enzymatic	1106:1114	arg1	activity					1116:1123	the enzymatic activity	1102:1123	the enzymatic activity of OGT in H1299 cells	1102:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	10	6	theme	present	1356:1362	arg1	study					1364:1368	The present study	1352:1368	The present study	1352:1368	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	8	7	theme	cisplatin	1212:1220	arg1	exposure					1222:1229	cisplatin exposure	1212:1229	cisplatin exposure in H1299 cells	1212:1244	On the contrary, the activation of OGA decreased in response to cisplatin exposure in H1299 cells.
33846785	11	8	theme	GFAT1	1584:1588	arg1	activation					1590:1599	Cisplatin‑induced GFAT1 activation	1566:1599	Cisplatin‑induced GFAT1 activation	1566:1599	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	3	9	theme	molecular	513:521	arg1	mechanisms					523:532	the relevant molecular mechanisms	500:532	the relevant molecular mechanisms in cancer cells	500:548	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	1	10	theme	dynamic	153:159	arg1	modification					195:206	a dynamic and reversible post‑translational modification	151:206	a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA)	151:288	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	1	10	theme	dynamic	153:159	arg1	O‑GlcNAcylation					132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	4	11	theme	protein	660:666	arg1	modification					677:688	protein O‑GlcNAc modification	660:688	protein O‑GlcNAc modification	660:688	In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo.
33846785	7	12	theme	significant	1075:1085	arg1	enhancement					1087:1097	the significant enhancement	1071:1097	the significant enhancement of the enzymatic activity of OGT in H1299 cells	1071:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	13	13	theme	OGT	1967:1969	arg1	activity					1955:1962	the activity	1951:1962	the activity of OGT, OGA and AMPK in vitro and in vivo	1951:2004	On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.
33846785	1	14	theme	reversible	165:174	arg1	modification					195:206	a dynamic and reversible post‑translational modification	151:206	a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA)	151:288	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	1	14	theme	reversible	165:174	arg1	O‑GlcNAcylation					132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	4	15	theme	protein	613:619	arg1	O‑GlcNAcylation					621:635	protein O‑GlcNAcylation	613:635	protein O‑GlcNAcylation	613:635	In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo.
33846785	0	16	theme	non‑small	98:106	arg1	cells					125:129	human non‑small cell lung cancer cells	92:129	human non‑small cell lung cancer cells	92:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	0	17	theme	lung	113:116	arg1	cells					125:129	human non‑small cell lung cancer cells	92:129	human non‑small cell lung cancer cells	92:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	1	18	theme	proteins	211:218	arg1	modification					195:206	a dynamic and reversible post‑translational modification	151:206	a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA)	151:288	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	1	18	theme	proteins	211:218	arg1	O‑GlcNAcylation					132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	4	19	theme	cisplatin	724:732	arg1	activity					712:719	the antitumor activity	698:719	the antitumor activity of cisplatin	698:732	In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo.
33846785	5	20	from	levels	885:890	arg1	in vivo					942:948	in vivo	942:948	in vivo	942:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	5	20	from	levels	885:890	arg1	in vitro					929:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	5	21	theme	cells	923:927	arg1	in vitro					929:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	5	22	theme	H1299	899:903	arg1	in vitro					929:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	10	23	theme	glutamine‑fructose‑6‑phosphate	1429:1458	arg1	GFAT1					1494:1498	GFAT1	1494:1498	GFAT1	1494:1498	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	10	23	theme	glutamine‑fructose‑6‑phosphate	1429:1458	arg1	isomerizing					1478:1488	glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1	1429:1491	glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation	1429:1515	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	5	24	theme	Hep	906:908	arg1	G2					910:911	Hep G2	906:911	Hep G2	906:911	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	2	25	from	Alterations	291:301	arg1	expression					318:327	the protein expression	306:327	the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc)	306:372	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	6	26	theme	expression	994:1003	arg1	levels					1005:1010	the protein and mRNA expression levels	973:1010	levels	1005:1010	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	7	27	from	cells	1141:1145	arg1	enhancement					1087:1097	the significant enhancement	1071:1097	the significant enhancement of the enzymatic activity of OGT in H1299 cells	1071:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	13	28	theme	AMPK	1980:1983	arg1	in vitro					1985:1992	AMPK in vitro	1980:1992	AMPK in vitro	1980:1992	On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.
33846785	13	29	theme	protein	1915:1921	arg1	O‑GlcNAcylation					1923:1937	protein O‑GlcNAcylation	1915:1937	protein O‑GlcNAcylation	1915:1937	On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.
33846785	9	30	theme	AMP‑activated	1283:1295	arg1	AMPK					1313:1316	AMPK	1313:1316	AMPK	1313:1316	Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio.
33846785	9	30	theme	AMP‑activated	1283:1295	arg1	kinase					1305:1310	AMP‑activated protein kinase	1283:1310	AMP‑activated protein kinase (AMPK)	1283:1317	Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio.
33846785	13	31	theme	present	1864:1870	arg1	study					1872:1876	the present study	1860:1876	the present study	1860:1876	On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.
33846785	9	32	theme	kinase	1305:1310	arg1	activity					1271:1278	the activity	1267:1278	the activity of AMP‑activated protein kinase (AMPK)	1267:1317	Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio.
33846785	6	33	from	levels	1005:1010	arg1	cells					1036:1040	H1299 cells	1030:1040	H1299 cells	1030:1040	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	0	34	theme	protein	19:25	arg1	O‑GlcNAcylation					27:41	protein O‑GlcNAcylation	19:41	protein O‑GlcNAcylation	19:41	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	6	35	from	protein	977:983	arg1	cells					1036:1040	H1299 cells	1030:1040	H1299 cells	1030:1040	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	3	36	theme	chemotherapeutic	453:468	arg1	agents					470:475	chemotherapeutic agents	453:475	chemotherapeutic agents	453:475	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	3	37	from	effects	442:448	arg1	cells					544:548	cancer cells	537:548	cancer cells	537:548	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	3	37	from	effects	442:448	arg1	O‑GlcNAcylation					480:494	O‑GlcNAcylation	480:494	O‑GlcNAcylation	480:494	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	10	38	theme	GFAT1	1559:1563	arg1	activity					1547:1554	the activity	1543:1554	the activity of GFAT1	1543:1563	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	5	39	theme	O‑GlcNAc	876:883	arg1	levels					885:890	global protein O‑GlcNAc levels	861:890	global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo	861:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	12	40	theme	cancer	1819:1824	arg1	cells					1826:1830	lung cancer cells	1814:1830	lung cancer cells	1814:1830	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	7	41	theme	activity	1116:1123	arg1	enhancement					1087:1097	the significant enhancement	1071:1097	the significant enhancement of the enzymatic activity of OGT in H1299 cells	1071:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	11	42	theme	donor	1632:1636	arg1	substrate					1638:1646	the donor substrate	1628:1646	the donor substrate	1628:1646	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	11	42	theme	donor	1632:1636	arg1	5‑diphospho‑N‑acetylglucosamine					1657:1687	uridine 5‑diphospho‑N‑acetylglucosamine	1649:1687	uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc)	1649:1700	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	2	43	theme	O‑linked	332:339	arg1	O‑GlcNAc					364:371	O‑GlcNAc	364:371	O‑GlcNAc	364:371	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	2	43	theme	O‑linked	332:339	arg1	β‑N‑acetylglucosamine					341:361	O‑linked β‑N‑acetylglucosamine	332:361	O‑linked β‑N‑acetylglucosamine (O‑GlcNAc)	332:372	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	1	44	theme	O‑GlcNAc	241:248	arg1	transferase					250:260	O‑GlcNAc transferase	241:260	O‑GlcNAc transferase (OGT)	241:266	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	1	44	theme	O‑GlcNAc	241:248	arg1	OGT					263:265	OGT	263:265	OGT	263:265	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	13	45	theme	in vitro	1985:1992	arg1	activity					1955:1962	the activity	1951:1962	the activity of OGT, OGA and AMPK in vitro and in vivo	1951:2004	On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.
33846785	3	46	theme	relevant	504:511	arg1	mechanisms					523:532	the relevant molecular mechanisms	500:532	the relevant molecular mechanisms in cancer cells	500:548	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	5	47	theme	protein	868:874	arg1	levels					885:890	global protein O‑GlcNAc levels	861:890	global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo	861:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	12	48	theme	OGT	1768:1770	arg1	inhibition					1754:1763	the inhibition	1750:1763	the inhibition of OGT and OGA	1750:1778	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	10	49	theme	decreased	1393:1401	arg1	activation					1408:1417	the decreased AMPK activation	1389:1417	the decreased AMPK activation	1389:1417	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	5	50	theme	levels	885:890	arg1	enhancement					846:856	an enhancement	843:856	an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo	843:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	12	51	theme	OGA	1776:1778	arg1	inhibition					1754:1763	the inhibition	1750:1763	the inhibition of OGT and OGA	1750:1778	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	0	52	theme	cell	108:111	arg1	cells					125:129	human non‑small cell lung cancer cells	92:129	human non‑small cell lung cancer cells	92:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	11	53	theme	Cisplatin‑induced	1566:1582	arg1	activation					1590:1599	Cisplatin‑induced GFAT1 activation	1566:1599	Cisplatin‑induced GFAT1 activation	1566:1599	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	3	54	theme	cancer	537:542	arg1	cells					544:548	cancer cells	537:548	cancer cells	537:548	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	1	55	theme	post‑translational	176:193	arg1	modification					195:206	a dynamic and reversible post‑translational modification	151:206	a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA)	151:288	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	1	55	theme	post‑translational	176:193	arg1	O‑GlcNAcylation					132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation	132:146	O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA).
33846785	8	56	theme	H1299	1234:1238	arg1	cells					1240:1244	H1299 cells	1234:1244	H1299 cells	1234:1244	On the contrary, the activation of OGA decreased in response to cisplatin exposure in H1299 cells.
33846785	2	57	theme	protein	310:316	arg1	expression					318:327	the protein expression	306:327	the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc)	306:372	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	0	58	theme	cancer	118:123	arg1	cells					125:129	human non‑small cell lung cancer cells	92:129	human non‑small cell lung cancer cells	92:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	12	59	theme	O‑GlcNAc	1731:1738	arg1	levels					1740:1745	the O‑GlcNAc levels	1727:1745	the O‑GlcNAc levels by the inhibition of OGT and OGA	1727:1778	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	8	60	theme	OGA	1183:1185	arg1	activation					1169:1178	the activation	1165:1178	the activation of OGA	1165:1185	On the contrary, the activation of OGA decreased in response to cisplatin exposure in H1299 cells.
33846785	8	61	from	exposure	1222:1229	arg1	cells					1240:1244	H1299 cells	1234:1244	H1299 cells	1234:1244	On the contrary, the activation of OGA decreased in response to cisplatin exposure in H1299 cells.
33846785	5	62	theme	G2	910:911	arg1	in vitro					929:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	4	63	theme	antitumor	702:710	arg1	activity					712:719	the antitumor activity	698:719	the antitumor activity of cisplatin	698:732	In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo.
33846785	5	64	from	enhancement	846:856	arg1	in vivo					942:948	in vivo	942:948	in vivo	942:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	5	64	from	enhancement	846:856	arg1	in vitro					929:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	the H1299, Hep G2 and MCF‑7 cells in vitro	895:936	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	5	65	theme	MCF‑7	917:921	arg1	cells					923:927	MCF‑7 cells	917:927	MCF‑7 cells	917:927	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	6	66	theme	OGA	1023:1025	arg1	levels					1005:1010	the protein and mRNA expression levels	973:1010	levels	1005:1010	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	6	66	theme	OGA	1023:1025	arg1	protein					977:983	the protein and mRNA expression levels	973:1010	protein	977:983	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	0	67	theme	OGT	71:73	arg1	activity					59:66	the activity	55:66	the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells	55:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	6	68	theme	OGT	1015:1017	arg1	levels					1005:1010	the protein and mRNA expression levels	973:1010	levels	1005:1010	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	6	68	theme	OGT	1015:1017	arg1	protein					977:983	the protein and mRNA expression levels	973:1010	protein	977:983	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	12	69	from	alterations	1712:1722	arg1	levels					1740:1745	the O‑GlcNAc levels	1727:1745	the O‑GlcNAc levels by the inhibition of OGT and OGA	1727:1778	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	4	70	theme	O‑GlcNAc	668:675	arg1	modification					677:688	protein O‑GlcNAc modification	660:688	protein O‑GlcNAc modification	660:688	In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo.
33846785	0	71	theme	OGA	76:78	arg1	activity					59:66	the activity	55:66	the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells	55:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	3	72	from	mechanisms	523:532	arg1	cells					544:548	cancer cells	537:548	cancer cells	537:548	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	3	72	from	mechanisms	523:532	arg1	O‑GlcNAcylation					480:494	O‑GlcNAcylation	480:494	O‑GlcNAcylation	480:494	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	0	73	theme	AMPK	84:87	arg1	activity					59:66	the activity	55:66	the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells	55:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	6	74	theme	mRNA	989:992	arg1	levels					1005:1010	the protein and mRNA expression levels	973:1010	levels	1005:1010	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	0	75	from	activity	59:66	arg1	cells					125:129	human non‑small cell lung cancer cells	92:129	human non‑small cell lung cancer cells	92:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	10	76	theme	AMPK	1403:1406	arg1	activation					1408:1417	the decreased AMPK activation	1389:1417	the decreased AMPK activation	1389:1417	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	0	77	theme	human	92:96	arg1	cells					125:129	human non‑small cell lung cancer cells	92:129	human non‑small cell lung cancer cells	92:129	Cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in human non‑small cell lung cancer cells.
33846785	9	78	theme	protein	1297:1303	arg1	AMPK					1313:1316	AMPK	1313:1316	AMPK	1313:1316	Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio.
33846785	9	78	theme	protein	1297:1303	arg1	kinase					1305:1310	AMP‑activated protein kinase	1283:1310	AMP‑activated protein kinase (AMPK)	1283:1317	Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio.
33846785	10	79	theme	isomerizing	1478:1488	arg1	phosphorylation					1501:1515	glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation	1429:1515	glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation	1429:1515	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	5	80	theme	cisplatin	811:819	arg1	treatment					821:829	cisplatin treatment	811:829	cisplatin treatment	811:829	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	10	81	theme	aminotransferase	1460:1475	arg1	GFAT1					1494:1498	GFAT1	1494:1498	GFAT1	1494:1498	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	10	81	theme	aminotransferase	1460:1475	arg1	isomerizing					1478:1488	glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1	1429:1491	glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation	1429:1515	The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1.
33846785	7	82	from	enhancement	1087:1097	arg1	cells					1141:1145	H1299 cells	1135:1145	H1299 cells	1135:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	2	83	theme	multiple	392:399	arg1	factors					401:407	multiple factors	392:407	multiple factors	392:407	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33846785	7	84	theme	H1299	1135:1139	arg1	cells					1141:1145	H1299 cells	1135:1145	H1299 cells	1135:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	6	85	theme	H1299	1030:1034	arg1	cells					1036:1040	H1299 cells	1030:1040	H1299 cells	1030:1040	Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells.
33846785	7	86	theme	OGT	1128:1130	arg1	activity					1116:1123	the enzymatic activity	1102:1123	the enzymatic activity of OGT in H1299 cells	1102:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	9	87	theme	AMP/ATP	1337:1343	arg1	ratio					1345:1349	the AMP/ATP ratio	1333:1349	the AMP/ATP ratio	1333:1349	Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio.
33846785	12	88	theme	cells	1826:1830	arg1	sensitivity					1799:1809	the sensitivity	1795:1809	the sensitivity of lung cancer cells to cisplatin	1795:1843	However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin.
33846785	7	89	from	activity	1116:1123	arg1	cells					1141:1145	H1299 cells	1135:1145	H1299 cells	1135:1145	Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells.
33846785	3	90	theme	agents	470:475	arg1	mechanisms					523:532	the relevant molecular mechanisms	500:532	the relevant molecular mechanisms in cancer cells	500:548	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	3	90	theme	agents	470:475	arg1	effects					442:448	the effects	438:448	the effects of chemotherapeutic agents on O‑GlcNAcylation	438:494	However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells.
33846785	5	91	from	in vivo	942:948	arg1	enhancement					846:856	an enhancement	843:856	an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo	843:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	11	92	theme	substrate	1638:1646	arg1	production					1614:1623	the production	1610:1623	the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc)	1610:1700	Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc).
33846785	5	93	from	in vitro	929:936	arg1	enhancement					846:856	an enhancement	843:856	an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo	843:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	5	94	theme	global	861:866	arg1	levels					885:890	global protein O‑GlcNAc levels	861:890	global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo	861:948	The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo.
33846785	2	95	theme	β‑N‑acetylglucosamine	341:361	arg1	expression					318:327	the protein expression	306:327	the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc)	306:372	Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors.
33251387	7	0	theme	miR-7-5p	838:845	arg1	OGT					812:814	OGT	812:814	OGT	812:814	Bioinformatic analysis indicated that OGT is a direct target of miR-7-5p.
33251387	7	0	theme	miR-7-5p	838:845	arg1	target					828:833	a direct target	819:833	a direct target of miR-7-5p	819:845	Bioinformatic analysis indicated that OGT is a direct target of miR-7-5p.
33251387	14	1	theme	high	1606:1609	arg1	expression					1611:1620	high expression	1606:1620	high expression in H522, H460, and H1299 cell lines	1606:1656	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	8	2	theme	luciferase	913:922	arg1	assay					933:937	luciferase reporter assay	913:937	luciferase reporter assay	913:937	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	4	3	theme	lung	570:573	arg1	lines					587:591	various lung cancer cell lines	562:591	various lung cancer cell lines	562:591	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	11	4	theme	lung	1323:1326	arg1	growth					1335:1340	lung cancer growth	1323:1340	lung cancer growth	1323:1340	The role of miR-7-5p in lung cancer growth was measured by MTS assays.
33251387	17	5	theme	control	1881:1887	arg1	group					1889:1893	the control group	1877:1893	the control group	1877:1893	miR-181a-5p transfection induced expression levels of OGT were diminished compared to those in the control group.
33251387	11	6	theme	miR-7-5p	1311:1318	arg1	role					1303:1306	The role	1299:1306	The role of miR-7-5p in lung cancer growth	1299:1340	The role of miR-7-5p in lung cancer growth was measured by MTS assays.
33251387	17	7	theme	miR-181a-5p	1782:1792	arg1	levels					1826:1831	miR-181a-5p transfection induced expression levels	1782:1831	miR-181a-5p transfection induced expression levels of OGT	1782:1838	miR-181a-5p transfection induced expression levels of OGT were diminished compared to those in the control group.
33251387	5	8	theme	expression	612:621	arg1	level					623:627	The expression level	608:627	The expression level of miR-7-5p	608:639	The expression level of miR-7-5p was confirmed by qRT-PCR in lung cancer cell lines.
33251387	16	9	theme	miR-7-5p	1735:1742	arg1	Overexpression					1717:1730	Overexpression	1717:1730	Overexpression of miR-7-5p	1717:1742	Overexpression of miR-7-5p also diminished anaerobic glycolysis.
33251387	17	10	theme	induced	1807:1813	arg1	levels					1826:1831	miR-181a-5p transfection induced expression levels	1782:1831	miR-181a-5p transfection induced expression levels of OGT	1782:1838	miR-181a-5p transfection induced expression levels of OGT were diminished compared to those in the control group.
33251387	19	11	theme	cell	2004:2007	arg1	growth					2009:2014	lung cancer cell growth	1992:2014	lung cancer cell growth	1992:2014	Moreover, the overexpression of miR-7-5a suppressed lung cancer cell growth.
33251387	5	12	theme	cancer	674:679	arg1	lines					686:690	lung cancer cell lines	669:690	lung cancer cell lines	669:690	The expression level of miR-7-5p was confirmed by qRT-PCR in lung cancer cell lines.
33251387	1	13	theme	critical	199:206	arg1	role					208:211	a critical role	197:211	a critical role	197:211	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	14	14	theme	low	1577:1579	arg1	expression					1581:1590	low expression	1577:1590	low expression	1577:1590	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	17	15	theme	OGT	1836:1838	arg1	levels					1826:1831	miR-181a-5p transfection induced expression levels	1782:1831	miR-181a-5p transfection induced expression levels of OGT	1782:1838	miR-181a-5p transfection induced expression levels of OGT were diminished compared to those in the control group.
33251387	1	16	theme	complementary	99:111	arg1	enzyme					113:118	a complementary enzyme	97:118	a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming	97:300	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	16	theme	complementary	99:111	arg1	Transferase					76:86	O-GlcNAc Transferase	67:86	O-GlcNAc Transferase (OGT)	67:92	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	9	17	theme	miR-7-5p	967:974	arg1	role					959:962	the role	955:962	the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells	955:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	12	18	theme	release	1429:1435	arg1	assay					1437:1441	an in vitro release assay	1417:1441	an in vitro release assay of PLGA-miR-7-5p	1417:1458	To identify the delivery of miR-7-5p via PLGA, an in vitro release assay of PLGA-miR-7-5p was done.
33251387	4	19	dep	cell	519:522	arg1	metabolism					535:544	metabolism	535:544	metabolism	535:544	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	4	19	dep	cell	519:522	arg1	growth					524:529	growth	524:529	growth	524:529	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	1	20	theme	O-linked	135:142	arg1	O-GlcNAcylation					170:184	O-GlcNAcylation	170:184	O-GlcNAcylation	170:184	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	20	theme	O-linked	135:142	arg1	N-acetylglucosaminylation					144:168	O-linked N-acetylglucosaminylation	135:168	O-linked N-acetylglucosaminylation(O-GlcNAcylation)	135:185	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	15	21	theme	miR-7a-5p	1692:1700	arg1	binding					1681:1687	binding	1681:1687	binding of miR-7a-5p to the 3'-UTR	1681:1714	OGT were repressed by binding of miR-7a-5p to the 3'-UTR.
33251387	0	22	from	role	16:19	arg1	O-GlcNAcylation					28:42	O-GlcNAcylation	28:42	O-GlcNAcylation	28:42	MicroRNA-7-5p's role in the O-GlcNAcylation and cancer metabolism.
33251387	0	22	from	role	16:19	arg1	cancer					48:53	cancer	48:53	cancer	48:53	MicroRNA-7-5p's role in the O-GlcNAcylation and cancer metabolism.
33251387	20	23	dep	10	2058:2059	arg1	to					2055:2056	to	2055:2056	to	2055:2056	miR-7-5p was released via PLGA for up to 10 days.
33251387	9	24	theme	non-small	1004:1012	arg1	cancer					1024:1029	non-small cell lung cancer	1004:1029	non-small cell lung cancer (NSCLC) cells	1004:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	9	24	theme	non-small	1004:1012	arg1	NSCLC					1032:1036	NSCLC	1032:1036	NSCLC	1032:1036	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	9	25	theme	ATP	1208:1210	arg1	assay					1231:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	12	26	theme	in	1420:1421	arg1	assay					1437:1441	an in vitro release assay	1417:1441	an in vitro release assay of PLGA-miR-7-5p	1417:1458	To identify the delivery of miR-7-5p via PLGA, an in vitro release assay of PLGA-miR-7-5p was done.
33251387	9	27	theme	lung	1019:1022	arg1	cancer					1024:1029	non-small cell lung cancer	1004:1029	non-small cell lung cancer (NSCLC) cells	1004:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	9	27	theme	lung	1019:1022	arg1	NSCLC					1032:1036	NSCLC	1032:1036	NSCLC	1032:1036	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	3	28	theme	in-silico	427:435	arg1	approach					437:444	the in-silico approach	423:444	the in-silico approach	423:444	In the in-silico approach, OGT is the predicted target of miR-7-5p.
33251387	9	29	theme	inhibitor	1221:1229	arg1	assay					1231:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	8	30	theme	binding	852:858	arg1	miR-7-5p					869:876	miR-7-5p	869:876	miR-7-5p	869:876	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	8	30	theme	binding	852:858	arg1	sites					860:864	The binding sites	848:864	The binding sites of miR-7-5p in the OGT 3' UTR	848:894	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	21	31	theme	present	2074:2080	arg1	study					2082:2086	the present study	2070:2086	the present study	2070:2086	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	2	32	theme	cancer	374:379	arg1	cells					381:385	lung cancer cells	369:385	lung cancer cells	369:385	In our previous study we found that miR-7-5p was downregulated at lung cancer cells with highly metastatic capacity.
33251387	7	33	theme	Bioinformatic	774:786	arg1	analysis					788:795	Bioinformatic analysis	774:795	Bioinformatic analysis	774:795	Bioinformatic analysis indicated that OGT is a direct target of miR-7-5p.
33251387	9	34	theme	glucose	1174:1180	arg1	uptake					1182:1187	glucose uptake	1174:1187	glucose uptake	1174:1187	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	1	35	theme	metabolic	278:286	arg1	reprogramming					288:300	metabolic reprogramming	278:300	metabolic reprogramming	278:300	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	12	36	theme	miR-7-5p	1398:1405	arg1	delivery					1386:1393	the delivery	1382:1393	the delivery of miR-7-5p via PLGA	1382:1414	To identify the delivery of miR-7-5p via PLGA, an in vitro release assay of PLGA-miR-7-5p was done.
33251387	12	37	dep	in	1420:1421	arg1	vitro					1423:1427	vitro	1423:1427	vitro	1423:1427	To identify the delivery of miR-7-5p via PLGA, an in vitro release assay of PLGA-miR-7-5p was done.
33251387	11	38	theme	MTS	1358:1360	arg1	assays					1362:1367	MTS assays	1358:1367	MTS assays	1358:1367	The role of miR-7-5p in lung cancer growth was measured by MTS assays.
33251387	2	39	theme	metastatic	399:408	arg1	capacity					410:417	highly metastatic capacity	392:417	highly metastatic capacity	392:417	In our previous study we found that miR-7-5p was downregulated at lung cancer cells with highly metastatic capacity.
33251387	19	40	theme	cancer	1997:2002	arg1	growth					2009:2014	lung cancer cell growth	1992:2014	lung cancer cell growth	1992:2014	Moreover, the overexpression of miR-7-5a suppressed lung cancer cell growth.
33251387	8	41	theme	OGT	885:887	arg1	UTR					892:894	the OGT 3' UTR	881:894	the OGT 3' UTR	881:894	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	10	42	theme	protein	1253:1259	arg1	level					1261:1265	O-GlcNAcylated protein level	1238:1265	O-GlcNAcylated protein level	1238:1265	O-GlcNAcylated protein level was determined by Western blot.
33251387	13	43	theme	low	1519:1521	arg1	expression					1523:1532	low expression	1519:1532	low expression in H358, H827	1519:1546	miR-7-5p was highly expressed whereas OGT showed low expression in H358, H827.
33251387	3	44	theme	predicted	458:466	arg1	OGT					447:449	OGT	447:449	OGT	447:449	In the in-silico approach, OGT is the predicted target of miR-7-5p.
33251387	3	44	theme	predicted	458:466	arg1	target					468:473	the predicted target	454:473	the predicted target of miR-7-5p	454:485	In the in-silico approach, OGT is the predicted target of miR-7-5p.
33251387	1	45	theme	various	216:222	arg1	phenotypes					231:240	various cancer phenotypes	216:240	various cancer phenotypes	216:240	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	45	theme	various	216:222	arg1	invasion					253:260	invasion	253:260	invasion	253:260	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	45	theme	various	216:222	arg1	reprogramming					288:300	metabolic reprogramming	278:300	metabolic reprogramming	278:300	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	45	theme	various	216:222	arg1	migration					263:271	migration	263:271	migration	263:271	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	4	46	theme	cancer	575:580	arg1	lines					587:591	various lung cancer cell lines	562:591	various lung cancer cell lines	562:591	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	6	47	theme	blot	701:704	arg1	assays					706:711	Western blot assays	693:711	Western blot assays	693:711	Western blot assays and qRT-PCR were performed to demonstrate miR-7-5p's effect.
33251387	19	48	theme	miR-7-5a	1972:1979	arg1	overexpression					1954:1967	the overexpression	1950:1967	the overexpression of miR-7-5a	1950:1979	Moreover, the overexpression of miR-7-5a suppressed lung cancer cell growth.
33251387	9	49	from	role	959:962	arg1	metabolism					990:999	the cancer metabolism	979:999	the cancer metabolism of non-small cell lung cancer (NSCLC) cells	979:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	8	50	theme	reporter	924:931	arg1	assay					933:937	luciferase reporter assay	913:937	luciferase reporter assay	913:937	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	3	51	from	target	468:473	arg1	approach					437:444	the in-silico approach	423:444	the in-silico approach	423:444	In the in-silico approach, OGT is the predicted target of miR-7-5p.
33251387	5	52	theme	miR-7-5p	632:639	arg1	level					623:627	The expression level	608:627	The expression level of miR-7-5p	608:639	The expression level of miR-7-5p was confirmed by qRT-PCR in lung cancer cell lines.
33251387	4	53	theme	various	562:568	arg1	lines					587:591	various lung cancer cell lines	562:591	various lung cancer cell lines	562:591	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	9	54	theme	miR-7-5p	1116:1123	arg1	effect					1106:1111	the effect	1102:1111	the effect of miR-7-5p on cancer metabolism	1102:1144	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	2	55	theme	previous	310:317	arg1	study					319:323	our previous study	306:323	our previous study	306:323	In our previous study we found that miR-7-5p was downregulated at lung cancer cells with highly metastatic capacity.
33251387	7	56	theme	direct	821:826	arg1	OGT					812:814	OGT	812:814	OGT	812:814	Bioinformatic analysis indicated that OGT is a direct target of miR-7-5p.
33251387	7	56	theme	direct	821:826	arg1	target					828:833	a direct target	819:833	a direct target of miR-7-5p	819:845	Bioinformatic analysis indicated that OGT is a direct target of miR-7-5p.
33251387	17	57	theme	transfection	1794:1805	arg1	levels					1826:1831	miR-181a-5p transfection induced expression levels	1782:1831	miR-181a-5p transfection induced expression levels of OGT	1782:1838	miR-181a-5p transfection induced expression levels of OGT were diminished compared to those in the control group.
33251387	5	58	theme	lung	669:672	arg1	lines					686:690	lung cancer cell lines	669:690	lung cancer cell lines	669:690	The expression level of miR-7-5p was confirmed by qRT-PCR in lung cancer cell lines.
33251387	9	59	theme	cancer	1128:1133	arg1	metabolism					1135:1144	cancer metabolism	1128:1144	cancer metabolism	1128:1144	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	16	60	theme	anaerobic	1760:1768	arg1	glycolysis					1770:1779	anaerobic glycolysis	1760:1779	anaerobic glycolysis	1760:1779	Overexpression of miR-7-5p also diminished anaerobic glycolysis.
33251387	17	61	theme	expression	1815:1824	arg1	levels					1826:1831	miR-181a-5p transfection induced expression levels	1782:1831	miR-181a-5p transfection induced expression levels of OGT	1782:1838	miR-181a-5p transfection induced expression levels of OGT were diminished compared to those in the control group.
33251387	11	62	theme	cancer	1328:1333	arg1	growth					1335:1340	lung cancer growth	1323:1340	lung cancer growth	1323:1340	The role of miR-7-5p in lung cancer growth was measured by MTS assays.
33251387	5	63	theme	cell	681:684	arg1	lines					686:690	lung cancer cell lines	669:690	lung cancer cell lines	669:690	The expression level of miR-7-5p was confirmed by qRT-PCR in lung cancer cell lines.
33251387	11	64	from	role	1303:1306	arg1	growth					1335:1340	lung cancer growth	1323:1340	lung cancer growth	1323:1340	The role of miR-7-5p in lung cancer growth was measured by MTS assays.
33251387	21	65	theme	cancer	2170:2175	arg1	growth					2133:2138	growth	2133:2138	growth	2133:2138	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	21	65	theme	cancer	2170:2175	arg1	cancer					2144:2149	cancer	2144:2149	cancer	2144:2149	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	12	66	theme	PLGA-miR-7-5p	1446:1458	arg1	assay					1437:1441	an in vitro release assay	1417:1441	an in vitro release assay of PLGA-miR-7-5p	1417:1458	To identify the delivery of miR-7-5p via PLGA, an in vitro release assay of PLGA-miR-7-5p was done.
33251387	8	67	from	sites	860:864	arg1	UTR					892:894	the OGT 3' UTR	881:894	the OGT 3' UTR	881:894	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	9	68	from	effect	1106:1111	arg1	metabolism					1135:1144	cancer metabolism	1128:1144	cancer metabolism	1128:1144	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	9	69	theme	cancer	983:988	arg1	metabolism					990:999	the cancer metabolism	979:999	the cancer metabolism of non-small cell lung cancer (NSCLC) cells	979:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	9	70	theme	mitochondrial	1194:1206	arg1	assay					1231:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	21	71	theme	OGT	2103:2105	arg1	inhibition					2089:2098	inhibition	2089:2098	inhibition of OGT by miR-7-5p	2089:2117	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	9	72	theme	cell	1014:1017	arg1	cancer					1024:1029	non-small cell lung cancer	1004:1029	non-small cell lung cancer (NSCLC) cells	1004:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	9	72	theme	cell	1014:1017	arg1	NSCLC					1032:1036	NSCLC	1032:1036	NSCLC	1032:1036	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	14	73	from	expression	1611:1620	arg1	H522					1625:1628	H522	1625:1628	H522	1625:1628	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	14	73	from	expression	1611:1620	arg1	lines					1652:1656	H1299 cell lines	1641:1656	H1299 cell lines	1641:1656	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	14	73	from	expression	1611:1620	arg1	H460					1631:1634	H460	1631:1634	H460	1631:1634	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	9	74	theme	synthase	1212:1219	arg1	assay					1231:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	mitochondrial ATP synthase inhibitor assay	1194:1235	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	1	75	theme	O-GlcNAc	67:74	arg1	enzyme					113:118	a complementary enzyme	97:118	a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming	97:300	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	75	theme	O-GlcNAc	67:74	arg1	OGT					89:91	OGT	89:91	OGT	89:91	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	75	theme	O-GlcNAc	67:74	arg1	Transferase					76:86	O-GlcNAc Transferase	67:86	O-GlcNAc Transferase (OGT)	67:92	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	76	theme	cancer	224:229	arg1	phenotypes					231:240	various cancer phenotypes	216:240	various cancer phenotypes	216:240	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	76	theme	cancer	224:229	arg1	invasion					253:260	invasion	253:260	invasion	253:260	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	76	theme	cancer	224:229	arg1	reprogramming					288:300	metabolic reprogramming	278:300	metabolic reprogramming	278:300	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	76	theme	cancer	224:229	arg1	migration					263:271	migration	263:271	migration	263:271	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	9	77	theme	cancer	1024:1029	arg1	cells					1039:1043	non-small cell lung cancer (NSCLC) cells	1004:1043	non-small cell lung cancer (NSCLC) cells	1004:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	2	78	theme	lung	369:372	arg1	cells					381:385	lung cancer cells	369:385	lung cancer cells	369:385	In our previous study we found that miR-7-5p was downregulated at lung cancer cells with highly metastatic capacity.
33251387	21	79	dep	growth	2133:2138	arg1	metabolism					2151:2160	metabolism	2151:2160	metabolism	2151:2160	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	21	79	dep	growth	2133:2138	arg1	the					2129:2131	the	2129:2131	the	2129:2131	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	9	80	theme	cells	1039:1043	arg1	metabolism					990:999	the cancer metabolism	979:999	the cancer metabolism of non-small cell lung cancer (NSCLC) cells	979:1043	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33251387	14	81	contain	had	1602:1604	arg1	OGT					1598:1600	OGT	1598:1600	OGT	1598:1600	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	14	81	contain	had	1602:1604	arg2	expression					1611:1620	high expression	1606:1620	high expression in H522, H460, and H1299 cell lines	1606:1656	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	19	82	theme	lung	1992:1995	arg1	growth					2009:2014	lung cancer cell growth	1992:2014	lung cancer cell growth	1992:2014	Moreover, the overexpression of miR-7-5a suppressed lung cancer cell growth.
33251387	8	83	theme	miR-7-5p	869:876	arg1	miR-7-5p					869:876	miR-7-5p	869:876	miR-7-5p	869:876	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	8	83	theme	miR-7-5p	869:876	arg1	sites					860:864	The binding sites	848:864	The binding sites of miR-7-5p in the OGT 3' UTR	848:894	The binding sites of miR-7-5p in the OGT 3' UTR were verified by luciferase reporter assay.
33251387	1	84	link	O-linked	135:142	arg1	O-GlcNAcylation					170:184	O-GlcNAcylation	170:184	O-GlcNAcylation	170:184	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	1	84	link	O-linked	135:142	arg1	N-acetylglucosaminylation					144:168	O-linked N-acetylglucosaminylation	135:168	O-linked N-acetylglucosaminylation(O-GlcNAcylation)	135:185	O-GlcNAc Transferase (OGT) is a complementary enzyme that regulates O-linked N-acetylglucosaminylation(O-GlcNAcylation) and plays a critical role in various cancer phenotypes, including invasion, migration, and metabolic reprogramming.
33251387	4	85	from	role	511:514	arg1	cell					519:522	cell growth and metabolism	519:544	cell growth and metabolism	519:544	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	14	86	theme	H1299 cell	1641:1650	arg1	lines					1652:1656	H1299 cell lines	1641:1656	H1299 cell lines	1641:1656	However, miR-7-5p exhibited low expression while OGT had high expression in H522, H460, and H1299 cell lines.
33251387	0	87	dep	O-GlcNAcylation	28:42	arg1	metabolism					55:64	metabolism	55:64	metabolism	55:64	MicroRNA-7-5p's role in the O-GlcNAcylation and cancer metabolism.
33251387	0	87	dep	O-GlcNAcylation	28:42	arg1	the					24:26	the	24:26	the	24:26	MicroRNA-7-5p's role in the O-GlcNAcylation and cancer metabolism.
33251387	21	88	theme	lung	2165:2168	arg1	cancer					2170:2175	lung cancer	2165:2175	lung cancer	2165:2175	In the present study, inhibition of OGT by miR-7-5p decreased the growth and cancer metabolism of lung cancer.
33251387	10	89	theme	O-GlcNAcylated	1238:1251	arg1	level					1261:1265	O-GlcNAcylated protein level	1238:1265	O-GlcNAcylated protein level	1238:1265	O-GlcNAcylated protein level was determined by Western blot.
33251387	3	90	theme	miR-7-5p	478:485	arg1	OGT					447:449	OGT	447:449	OGT	447:449	In the in-silico approach, OGT is the predicted target of miR-7-5p.
33251387	3	90	theme	miR-7-5p	478:485	arg1	target					468:473	the predicted target	454:473	the predicted target of miR-7-5p	454:485	In the in-silico approach, OGT is the predicted target of miR-7-5p.
33251387	6	91	theme	Western	693:699	arg1	assays					706:711	Western blot assays	693:711	Western blot assays	693:711	Western blot assays and qRT-PCR were performed to demonstrate miR-7-5p's effect.
33251387	4	92	theme	cell	582:585	arg1	lines					587:591	various lung cancer cell lines	562:591	various lung cancer cell lines	562:591	To identify miR-7-5p's role in cell growth and metabolism, we transfected various lung cancer cell lines with miR-7-5p.
33251387	10	93	theme	Western	1285:1291	arg1	blot					1293:1296	Western blot	1285:1296	Western blot	1285:1296	O-GlcNAcylated protein level was determined by Western blot.
33251387	13	94	from	expression	1523:1532	arg1	H358					1537:1540	H358	1537:1540	H358	1537:1540	miR-7-5p was highly expressed whereas OGT showed low expression in H358, H827.
33251387	13	94	from	expression	1523:1532	arg1	H827					1543:1546	H827	1543:1546	H827	1543:1546	miR-7-5p was highly expressed whereas OGT showed low expression in H358, H827.
33251387	9	95	theme	NSCLC	1085:1089	arg1	cells					1091:1095	NSCLC cells	1085:1095	NSCLC cells	1085:1095	To investigate the role of miR-7-5p in the cancer metabolism of non-small cell lung cancer (NSCLC) cells, mimic of miR-7-5p was transfected into NSCLC cells, and the effect of miR-7-5p on cancer metabolism was analyzed by LDH assays, glucose uptake, and mitochondrial ATP synthase inhibitor assay.
33215629	2	0	theme	expression	629:638	arg1	regulator					568:576	a key regulator	562:576	a key regulator of trophoblast serotonin synthesis and OGT protein expression	562:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	2	0	theme	expression	629:638	arg1	target					522:527	mechanistic target	510:527	mechanistic target of rapamycin (mTOR) signaling	510:557	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	1	1	theme	adverse	455:461	arg1	neurodevelopment					463:478	adverse neurodevelopment	455:478	adverse neurodevelopment in mice	455:486	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	2	2	theme	OGT	617:619	arg1	expression					629:638	OGT protein expression	617:638	OGT protein expression	617:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	10	3	theme	mTOR	1847:1850	arg1	signaling					1852:1860	mTOR signaling	1847:1860	mTOR signaling	1847:1860	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	10	3	theme	mTOR	1847:1850	arg1	regulator					1871:1879	a key regulator	1865:1879	a key regulator of trophoblast serotonin synthesis and OGT protein expression	1865:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	8	4	theme	serotonin	1618:1626	arg1	concentration					1628:1640	serotonin concentration	1618:1640	serotonin concentration	1618:1640	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	9	5	theme	PHT	1773:1775	arg1	secretion					1792:1800	cultured PHT cell serotonin secretion	1764:1800	cultured PHT cell serotonin secretion	1764:1800	Inhibition of mTORC2, but not mTORC1, increased cultured PHT cell serotonin secretion.
33215629	10	6	theme	key	1867:1869	arg1	signaling					1852:1860	mTOR signaling	1847:1860	mTOR signaling	1847:1860	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	10	6	theme	key	1867:1869	arg1	regulator					1871:1879	a key regulator	1865:1879	a key regulator of trophoblast serotonin synthesis and OGT protein expression	1865:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	1	7	from	response	287:294	arg1	down-regulation					197:211	particular down-regulation	186:211	particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection	186:416	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	8	theme	particular	186:195	arg1	down-regulation					197:211	particular down-regulation	186:211	particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection	186:416	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	4	9	theme	human	941:945	arg1	cells					965:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	3	10	theme	elective	755:762	arg1	terminations					764:775	elective terminations	755:775	elective terminations at 8-22 weeks of gestation	755:802	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	1	11	theme	maternal	399:406	arg1	infection					408:416	maternal infection	399:416	maternal infection	399:416	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	3	12	theme	gestation	794:802	arg1	weeks					785:789	8-22 weeks	780:789	8-22 weeks of gestation	780:802	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	0	13	theme	human	136:140	arg1	placenta					142:149	the human placenta	132:149	the human placenta	132:149	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	6	14	theme	normal	1361:1366	arg1	vein					1383:1386	platelet-depleted normal term umbilical vein	1343:1386	platelet-depleted normal term umbilical vein	1343:1386	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	1	15	theme	O-linked	226:233	arg1	O-GlcNAc					256:263	O-GlcNAc	256:263	O-GlcNAc	256:263	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	15	theme	O-linked	226:233	arg1	N-acetylglucosamine					235:253	placental O-linked N-acetylglucosamine	216:253	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress	216:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	2	16	theme	synthesis	603:611	arg1	regulator					568:576	a key regulator	562:576	a key regulator of trophoblast serotonin synthesis and OGT protein expression	562:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	2	16	theme	synthesis	603:611	arg1	target					522:527	mechanistic target	510:527	mechanistic target of rapamycin (mTOR) signaling	510:557	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	1	17	from	down-regulation	197:211	arg1	response					287:294	response	287:294	response to maternal stress	287:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	3	18	theme	OGT	869:871	arg1	levels					859:864	the protein levels	847:864	the protein levels of OGT and enzymes involved in serotonin synthesis	847:915	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	2	19	theme	trophoblast	581:591	arg1	synthesis					603:611	trophoblast serotonin synthesis	581:611	trophoblast serotonin synthesis	581:611	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	10	20	theme	protein	1924:1930	arg1	expression					1932:1941	OGT protein expression	1920:1941	OGT protein expression	1920:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	8	21	theme	umbilical	1698:1706	arg1	artery					1708:1713	the umbilical artery	1694:1713	the umbilical artery	1694:1713	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	2	22	theme	rapamycin	532:540	arg1	signaling					549:557	rapamycin (mTOR) signaling	532:557	rapamycin (mTOR) signaling	532:557	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	4	23	theme	mTOR	1119:1122	arg1	Complex					1124:1130	mTOR Complex 1	1119:1132	mTOR Complex 1 (mTORC1)	1119:1141	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	23	theme	mTOR	1119:1122	arg1	mTORC1					1135:1140	mTORC1	1135:1140	mTORC1	1135:1140	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	1	24	theme	secretion	339:347	arg1	down-regulation					197:211	particular down-regulation	186:211	particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection	186:416	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	6	25	theme	platelet-depleted	1343:1359	arg1	vein					1383:1386	platelet-depleted normal term umbilical vein	1343:1386	platelet-depleted normal term umbilical vein	1343:1386	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	4	26	dep	raptor	1102:1107	arg1	inhibits					1110:1117	inhibits	1110:1117	inhibits mTOR Complex 1 (mTORC1)	1110:1141	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	27	theme	term	997:1000	arg1	n=27					1012:1015	n=27	1012:1015	n=27	1012:1015	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	27	theme	term	997:1000	arg1	placenta					1002:1009	normal term placenta	990:1009	normal term placenta (n=27)	990:1016	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	3	28	from	weeks	785:789	arg1	terminations					764:775	elective terminations	755:775	elective terminations at 8-22 weeks of gestation	755:802	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	0	29	theme	O-GlcNAc	76:83	arg1	transferase					85:95	O-GlcNAc transferase	76:95	O-GlcNAc transferase	76:95	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	1	30	theme	serotonin	352:360	arg1	secretion					339:347	increased placental secretion	319:347	increased placental secretion of serotonin into the fetal circulation	319:387	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	30	theme	serotonin	352:360	arg1	OGT					279:281	OGT	279:281	OGT	279:281	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	30	theme	serotonin	352:360	arg1	transferase					266:276	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase	216:276	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress	216:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	31	theme	placental	163:171	arg1	function					173:180	placental function	163:180	placental function	163:180	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	3	32	theme	enzymes	877:883	arg1	levels					859:864	the protein levels	847:864	the protein levels of OGT and enzymes involved in serotonin synthesis	847:915	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	2	33	theme	signaling	549:557	arg1	regulator					568:576	a key regulator	562:576	a key regulator of trophoblast serotonin synthesis and OGT protein expression	562:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	2	33	theme	signaling	549:557	arg1	target					522:527	mechanistic target	510:527	mechanistic target of rapamycin (mTOR) signaling	510:557	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	4	34	theme	mTOR	1165:1168	arg1	Complex					1170:1176	mTOR Complex 2	1165:1178	mTOR Complex 2 (mTORC2)	1165:1187	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	34	theme	mTOR	1165:1168	arg1	mTORC2					1181:1186	mTORC2	1181:1186	mTORC2	1181:1186	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	7	35	theme	PHT	1477:1479	arg1	cells					1481:1485	PHT cells	1477:1485	PHT cells	1477:1485	Both mTORC1 and mTORC2 inhibition down-regulated OGT levels in PHT cells.
33215629	0	36	theme	serotonin	111:119	arg1	release					121:127	serotonin release	111:127	serotonin release in the human placenta	111:149	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	6	37	theme	term	1368:1371	arg1	vein					1383:1386	platelet-depleted normal term umbilical vein	1343:1386	platelet-depleted normal term umbilical vein	1343:1386	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	10	38	with	consistent	1816:1825	arg1	model					1836:1840	the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression	1832:1941	the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression	1832:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	9	39	theme	mTORC2	1730:1735	arg1	Inhibition					1716:1725	Inhibition	1716:1725	Inhibition of mTORC2, but not mTORC1,	1716:1752	Inhibition of mTORC2, but not mTORC1, increased cultured PHT cell serotonin secretion.
33215629	5	40	theme	PHT	1227:1229	arg1	lysates					1236:1242	PHT cell lysates	1227:1242	PHT cell lysates	1227:1242	Subsequently, conditioned media and PHT cell lysates were collected.
33215629	0	41	theme	mechanistic	14:24	arg1	target					26:31	mechanistic target	14:31	mechanistic target of rapamycin signaling	14:54	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	7	42	theme	OGT	1463:1465	arg1	levels					1467:1472	OGT levels	1463:1472	OGT levels	1463:1472	Both mTORC1 and mTORC2 inhibition down-regulated OGT levels in PHT cells.
33215629	4	43	attach	isolated	976:983	arg1	n=27					1012:1015	n=27	1012:1015	n=27	1012:1015	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	43	attach	isolated	976:983	arg1	placenta					1002:1009	normal term placenta	990:1009	normal term placenta (n=27)	990:1016	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	43	attach	isolated	976:983	arg2	cells					965:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	9	44	theme	mTORC1	1746:1751	arg1	Inhibition					1716:1725	Inhibition	1716:1725	Inhibition of mTORC2, but not mTORC1,	1716:1752	Inhibition of mTORC2, but not mTORC1, increased cultured PHT cell serotonin secretion.
33215629	0	45	theme	signaling	46:54	arg1	target					26:31	mechanistic target	14:31	mechanistic target of rapamycin signaling	14:54	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	1	46	theme	increased	319:327	arg1	secretion					339:347	increased placental secretion	319:347	increased placental secretion of serotonin into the fetal circulation	319:387	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	3	47	from	women	826:830	arg1	n=46					744:747	n=46	744:747	n=46	744:747	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	3	47	from	women	826:830	arg1	homogenates					731:741	Placental homogenates	721:741	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women	721:830	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	1	48	theme	N-acetylglucosamine	235:253	arg1	OGT					279:281	OGT	279:281	OGT	279:281	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	48	theme	N-acetylglucosamine	235:253	arg1	transferase					266:276	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase	216:276	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress	216:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	4	49	theme	scramble	1073:1080	arg1	control					1092:1098	control	1092:1098	control	1092:1098	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	49	theme	scramble	1073:1080	arg1	sequence					1082:1089	a scramble sequence	1071:1089	a scramble sequence (control)	1071:1099	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	8	50	theme	synthesis	1511:1519	arg1	TPH-1					1552:1556	TPH-1	1552:1556	TPH-1	1552:1556	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	8	50	theme	synthesis	1511:1519	arg1	hydroxylase					1539:1549	serotonin synthesis enzyme tryptophan hydroxylase	1501:1549	serotonin synthesis enzyme tryptophan hydroxylase (TPH-1)	1501:1557	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	1	51	attach	linked	445:450	arg2	Changes					152:158	Changes	152:158	Changes	152:158	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	51	attach	linked	445:450	arg1	neurodevelopment					463:478	adverse neurodevelopment	455:478	adverse neurodevelopment in mice	455:486	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	8	52	theme	early	1573:1577	arg1	placentas					1596:1604	early gestation female placentas	1573:1604	early gestation female placentas	1573:1604	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	10	53	theme	synthesis	1906:1914	arg1	signaling					1852:1860	mTOR signaling	1847:1860	mTOR signaling	1847:1860	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	10	53	theme	synthesis	1906:1914	arg1	regulator					1871:1879	a key regulator	1865:1879	a key regulator of trophoblast serotonin synthesis and OGT protein expression	1865:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	9	54	theme	serotonin	1782:1790	arg1	secretion					1792:1800	cultured PHT cell serotonin secretion	1764:1800	cultured PHT cell serotonin secretion	1764:1800	Inhibition of mTORC2, but not mTORC1, increased cultured PHT cell serotonin secretion.
33215629	8	55	theme	tryptophan	1528:1537	arg1	TPH-1					1552:1556	TPH-1	1552:1556	TPH-1	1552:1556	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	8	55	theme	tryptophan	1528:1537	arg1	hydroxylase					1539:1549	serotonin synthesis enzyme tryptophan hydroxylase	1501:1549	serotonin synthesis enzyme tryptophan hydroxylase (TPH-1)	1501:1557	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	8	56	theme	female	1589:1594	arg1	placentas					1596:1604	early gestation female placentas	1573:1604	early gestation female placentas	1573:1604	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	1	57	theme	transferase	266:276	arg1	down-regulation					197:211	particular down-regulation	186:211	particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection	186:416	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	2	58	theme	protein	621:627	arg1	expression					629:638	OGT protein expression	617:638	OGT protein expression	617:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	1	59	from	neurodevelopment	463:478	arg1	mice					483:486	mice	483:486	mice	483:486	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	4	60	dep	transfected	1032:1042	arg1	n=8					1045:1047	n=8	1045:1047	n=8	1045:1047	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	6	61	theme	culture	1322:1328	arg1	media					1330:1334	cell culture media	1317:1334	cell culture media	1317:1334	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	2	62	theme	mechanistic	510:520	arg1	regulator					568:576	a key regulator	562:576	a key regulator of trophoblast serotonin synthesis and OGT protein expression	562:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	2	62	theme	mechanistic	510:520	arg1	target					522:527	mechanistic target	510:527	mechanistic target of rapamycin (mTOR) signaling	510:557	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	6	63	theme	Free	1260:1263	arg1	concentration					1275:1287	Free serotonin concentration	1260:1287	Free serotonin concentration	1260:1287	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	4	64	theme	Primary	933:939	arg1	cells					965:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	1	65	from	transferase	266:276	arg1	response					287:294	response	287:294	response to maternal stress	287:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	66	theme	placental	216:224	arg1	O-GlcNAc					256:263	O-GlcNAc	256:263	O-GlcNAc	256:263	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	66	theme	placental	216:224	arg1	N-acetylglucosamine					235:253	placental O-linked N-acetylglucosamine	216:253	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress	216:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	4	67	theme	trophoblast	947:957	arg1	cells					965:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	10	68	theme	trophoblast	1884:1894	arg1	synthesis					1906:1914	trophoblast serotonin synthesis	1884:1914	trophoblast serotonin synthesis	1884:1914	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	8	69	theme	umbilical	1671:1679	arg1	vein					1681:1684	the umbilical vein	1667:1684	the umbilical vein	1667:1684	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	2	70	theme	serotonin	593:601	arg1	synthesis					603:611	trophoblast serotonin synthesis	581:611	trophoblast serotonin synthesis	581:611	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	0	71	from	release	121:127	arg1	placenta					142:149	the human placenta	132:149	the human placenta	132:149	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	5	72	theme	conditioned	1205:1215	arg1	media					1217:1221	conditioned media	1205:1221	conditioned media	1205:1221	Subsequently, conditioned media and PHT cell lysates were collected.
33215629	10	73	theme	OGT	1920:1922	arg1	expression					1932:1941	OGT protein expression	1920:1941	OGT protein expression	1920:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	6	74	theme	cell	1317:1320	arg1	media					1330:1334	cell culture media	1317:1334	cell culture media	1317:1334	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	3	75	theme	healthy-term	813:824	arg1	women					826:830	healthy-term women	813:830	healthy-term women	813:830	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	0	76	theme	transferase	85:95	arg1	levels					66:71	levels	66:71	levels of O-GlcNAc transferase	66:95	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	3	77	theme	serotonin	897:905	arg1	synthesis					907:915	serotonin synthesis	897:915	serotonin synthesis	897:915	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	4	78	theme	normal	990:995	arg1	n=27					1012:1015	n=27	1012:1015	n=27	1012:1015	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	4	78	theme	normal	990:995	arg1	placenta					1002:1009	normal term placenta	990:1009	normal term placenta (n=27)	990:1016	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	1	79	link	O-linked	226:233	arg1	O-GlcNAc					256:263	O-GlcNAc	256:263	O-GlcNAc	256:263	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	79	link	O-linked	226:233	arg1	N-acetylglucosamine					235:253	placental O-linked N-acetylglucosamine	216:253	placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress	216:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	2	80	theme	human	678:682	arg1	placenta					684:691	the human placenta	674:691	the human placenta	674:691	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	3	81	theme	protein	851:857	arg1	levels					859:864	the protein levels	847:864	the protein levels of OGT and enzymes involved in serotonin synthesis	847:915	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	4	82	theme	PHT	960:962	arg1	cells					965:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells	933:969	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	10	83	theme	expression	1932:1941	arg1	signaling					1852:1860	mTOR signaling	1847:1860	mTOR signaling	1847:1860	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	10	83	theme	expression	1932:1941	arg1	regulator					1871:1879	a key regulator	1865:1879	a key regulator of trophoblast serotonin synthesis and OGT protein expression	1865:1941	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	1	84	theme	fetal	371:375	arg1	circulation					377:387	the fetal circulation	367:387	the fetal circulation	367:387	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	2	85	theme	key	564:566	arg1	regulator					568:576	a key regulator	562:576	a key regulator of trophoblast serotonin synthesis and OGT protein expression	562:638	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	2	85	theme	key	564:566	arg1	target					522:527	mechanistic target	510:527	mechanistic target of rapamycin (mTOR) signaling	510:557	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	1	86	from	Changes	152:158	arg1	function					173:180	placental function	163:180	placental function	163:180	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	1	86	from	Changes	152:158	arg1	down-regulation					197:211	particular down-regulation	186:211	particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection	186:416	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	8	87	theme	gestation	1579:1587	arg1	placentas					1596:1604	early gestation female placentas	1573:1604	early gestation female placentas	1573:1604	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	3	88	from	terminations	764:775	arg1	n=46					744:747	n=46	744:747	n=46	744:747	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	3	88	from	terminations	764:775	arg1	homogenates					731:741	Placental homogenates	721:741	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women	721:830	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	2	89	theme	fetal	702:706	arg1	circulation					708:718	the fetal circulation	698:718	the fetal circulation	698:718	We hypothesized that mechanistic target of rapamycin (mTOR) signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression and that serotonin is secreted by the human placenta into the fetal circulation.
33215629	6	90	theme	umbilical	1373:1381	arg1	vein					1383:1386	platelet-depleted normal term umbilical vein	1343:1386	platelet-depleted normal term umbilical vein	1343:1386	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	0	91	theme	target	26:31	arg1	Inhibition					0:9	Inhibition	0:9	Inhibition of mechanistic target of rapamycin signaling	0:54	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	5	92	theme	cell	1231:1234	arg1	lysates					1236:1242	PHT cell lysates	1227:1242	PHT cell lysates	1227:1242	Subsequently, conditioned media and PHT cell lysates were collected.
33215629	0	93	theme	rapamycin	36:44	arg1	signaling					46:54	rapamycin signaling	36:54	rapamycin signaling	36:54	Inhibition of mechanistic target of rapamycin signaling decreases levels of O-GlcNAc transferase and increases serotonin release in the human placenta.
33215629	1	94	theme	maternal	299:306	arg1	stress					308:313	maternal stress	299:313	maternal stress	299:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	6	95	theme	serotonin	1265:1273	arg1	concentration					1275:1287	Free serotonin concentration	1260:1287	Free serotonin concentration	1260:1287	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	1	96	from	secretion	339:347	arg1	response					287:294	response	287:294	response to maternal stress	287:313	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	10	97	theme	serotonin	1896:1904	arg1	synthesis					1906:1914	trophoblast serotonin synthesis	1884:1914	trophoblast serotonin synthesis	1884:1914	Our data are consistent with the model that mTOR signaling is a key regulator of trophoblast serotonin synthesis and OGT protein expression.
33215629	6	98	dep	vein	1383:1386	arg1	n=38					1407:1410	n=38	1407:1410	n=38	1407:1410	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	6	98	dep	vein	1383:1386	arg1	plasma					1399:1404	plasma	1399:1404	plasma (n=38)	1399:1411	Free serotonin concentration was measured using ELISA in cell culture media and in platelet-depleted normal term umbilical vein and artery plasma (n=38).
33215629	8	99	theme	serotonin	1501:1509	arg1	TPH-1					1552:1556	TPH-1	1552:1556	TPH-1	1552:1556	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	8	99	theme	serotonin	1501:1509	arg1	hydroxylase					1539:1549	serotonin synthesis enzyme tryptophan hydroxylase	1501:1549	serotonin synthesis enzyme tryptophan hydroxylase (TPH-1)	1501:1557	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	1	100	theme	placental	329:337	arg1	secretion					339:347	increased placental secretion	319:347	increased placental secretion of serotonin into the fetal circulation	319:387	Changes in placental function, in particular down-regulation of placental O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) in response to maternal stress and increased placental secretion of serotonin into the fetal circulation following maternal infection, have been mechanistically linked to adverse neurodevelopment in mice.
33215629	7	101	theme	mTORC2	1430:1435	arg1	inhibition					1437:1446	mTORC2 inhibition	1430:1446	mTORC2 inhibition	1430:1446	Both mTORC1 and mTORC2 inhibition down-regulated OGT levels in PHT cells.
33215629	9	102	theme	cultured	1764:1771	arg1	secretion					1792:1800	cultured PHT cell serotonin secretion	1764:1800	cultured PHT cell serotonin secretion	1764:1800	Inhibition of mTORC2, but not mTORC1, increased cultured PHT cell serotonin secretion.
33215629	8	103	theme	enzyme	1521:1526	arg1	TPH-1					1552:1556	TPH-1	1552:1556	TPH-1	1552:1556	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	8	103	theme	enzyme	1521:1526	arg1	hydroxylase					1539:1549	serotonin synthesis enzyme tryptophan hydroxylase	1501:1549	serotonin synthesis enzyme tryptophan hydroxylase (TPH-1)	1501:1557	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	4	104	dep	rictor	1148:1153	arg1	inhibits					1156:1163	inhibits	1156:1163	inhibits mTOR Complex 2 (mTORC2)	1156:1187	Primary human trophoblast (PHT) cells were isolated from normal term placenta (n=27), cultured and transfected (n=8) with siRNA targeting a scramble sequence (control), raptor (inhibits mTOR Complex 1 (mTORC1)), or rictor (inhibits mTOR Complex 2 (mTORC2)).
33215629	9	105	theme	cell	1777:1780	arg1	secretion					1792:1800	cultured PHT cell serotonin secretion	1764:1800	cultured PHT cell serotonin secretion	1764:1800	Inhibition of mTORC2, but not mTORC1, increased cultured PHT cell serotonin secretion.
33215629	8	106	theme	hydroxylase	1539:1549	arg1	level					1492:1496	The level	1488:1496	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1)	1488:1557	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	8	106	theme	hydroxylase	1539:1549	arg1	higher					1563:1568	higher	1563:1568	higher	1563:1568	The level of serotonin synthesis enzyme tryptophan hydroxylase (TPH-1) was higher in early gestation female placentas and at term serotonin concentration was three-fold higher in the umbilical vein than in the umbilical artery.
33215629	3	107	theme	Placental	721:729	arg1	n=46					744:747	n=46	744:747	n=46	744:747	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
33215629	3	107	theme	Placental	721:729	arg1	homogenates					731:741	Placental homogenates	721:741	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women	721:830	Placental homogenates (n=46) from elective terminations at 8-22 weeks of gestation and from healthy-term women were sexed and the protein levels of OGT and enzymes involved in serotonin synthesis was determined.
32417172	12	0	theme	SIGNIFICANCE	1545:1556	arg1	study					1562:1566	GENERAL SIGNIFICANCE Our study	1537:1566	GENERAL SIGNIFICANCE Our study	1537:1566	GENERAL SIGNIFICANCE Our study provided a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein.
32417172	6	1	from	GalNAz	963:968	arg1	cells					1020:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	5	2	theme	representative	712:725	arg1	protein					745:751	a representative nucleocytoplasmic protein	710:751	a representative nucleocytoplasmic protein	710:751	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	9	3	theme	Ser121	1288:1293	arg1	residue					1295:1301	Ser121 residue	1288:1301	Ser121 residue	1288:1301	Ser121 residue was one of the glycosylated sites on p53.
32417172	6	4	theme	UDP-Gal/UDP-GalNAc	973:990	arg1	cells					1020:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	11	5	dep	CONCLUSIONS	1437:1447	arg1	revealed					1463:1470	revealed	1463:1470	revealed that the O-GalNAc glycosylation was a novel modification on p53	1463:1534	CONCLUSIONS These results revealed that the O-GalNAc glycosylation was a novel modification on p53.
32417172	0	6	link	O-linked	0:7	arg1	modification					31:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	6	7	gly	glycosylation	1053:1065	arg1	p53					1070:1072	p53	1070:1072	p53	1070:1072	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	9	8	theme	glycosylated	1318:1329	arg1	sites					1331:1335	the glycosylated sites	1314:1335	the glycosylated sites on p53	1314:1342	Ser121 residue was one of the glycosylated sites on p53.
32417172	2	9	theme	O-GalNAc	323:330	arg1	glycosylation					332:344	O-GalNAc glycosylation	323:344	O-GalNAc glycosylation	323:344	Recently several evidences suggest that nuclear or cytoplasmic proteins might also have O-GalNAc glycosylation.
32417172	1	10	theme	secretory	215:223	arg1	proteins					225:232	secretory proteins	215:232	secretory proteins	215:232	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	10	11	from	Ser121	1375:1380	arg1	at					1372:1373	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	10	11	from	Ser121	1375:1380	arg1	O-GalNAc					1349:1356	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	10	11	from	Ser121	1375:1380	arg1	glycosylation					1358:1370	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	7	12	theme	glycosylated	1157:1168	arg1	sites					1170:1174	the glycosylated sites	1153:1174	the glycosylated sites	1153:1174	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	7	13	theme	spectrometry	1086:1097	arg1	analysis					1099:1106	mass spectrometry analysis	1081:1106	mass spectrometry analysis	1081:1106	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	5	14	from	existence	615:623	arg1	proteins					685:692	nucleocytoplasmic proteins	667:692	nucleocytoplasmic proteins in cell	667:700	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	3	15	theme	nucleocytoplasmic	361:377	arg1	proteins					379:386	nucleocytoplasmic proteins	361:386	nucleocytoplasmic proteins	361:386	However, what nucleocytoplasmic proteins are O-GalNAc glycosylated and what the biological function of this modification in cells are still poorly understood.
32417172	0	16	theme	suppressor	68:77	arg1	p53					79:81	the tumor suppressor p53	58:81	the tumor suppressor p53	58:81	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	6	17	with	blotting	787:794	arg1	O-glycosidase					904:916	O-glycosidase	904:916	O-glycosidase	904:916	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	17	with	blotting	787:794	arg1	lectins					817:823	GalNAc specific lectins	801:823	GalNAc specific lectins	801:823	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	17	with	blotting	787:794	arg1	GalNAz					963:968	un-O-acetylated GalNAz	947:968	un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	947:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	17	with	blotting	787:794	arg1	β1					872:873	core 1 β1	865:873	core 1 β1	865:873	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	17	with	blotting	787:794	arg1	3-galactosyltransferase					876:898	3-galactosyltransferase	876:898	3-galactosyltransferase	876:898	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	17	with	blotting	787:794	arg1	O-GlcNAcase					852:862	O-GlcNAcase	852:862	O-GlcNAcase	852:862	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	4	18	theme	suppressor	540:549	arg1	p53					551:553	the tumor suppressor p53	530:553	the tumor suppressor p53	530:553	Previously, we reported the tumor suppressor p53 could be O-GalNAc glycosylated in vitro.
32417172	7	19	gly	glycosylated	1157:1168	arg1	sites					1170:1174	the glycosylated sites	1153:1174	the glycosylated sites	1153:1174	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	10	20	theme	O-GalNAc	1349:1356	arg1	Ser121					1375:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	4	21	dep	glycosylated	573:584	arg1	O-GalNAc					564:571	O-GalNAc	564:571	O-GalNAc	564:571	Previously, we reported the tumor suppressor p53 could be O-GalNAc glycosylated in vitro.
32417172	5	22	theme	O-GalNAc	641:648	arg1	glycosylation					650:662	O-GalNAc glycosylation	641:662	O-GalNAc glycosylation	641:662	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	7	23	theme	glycosylation	1214:1226	arg1	functions					1192:1200	the functions	1188:1200	the functions of O-GalNAc glycosylation on p53	1188:1233	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	12	24	theme	O-GalNAc	1603:1610	arg1	glycosylation					1612:1624	the O-GalNAc glycosylation	1599:1624	the O-GalNAc glycosylation	1599:1624	GENERAL SIGNIFICANCE Our study provided a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein.
32417172	0	25	located	present	47:53	arg1	p53					79:81	the tumor suppressor p53	58:81	the tumor suppressor p53	58:81	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	0	25	located	present	47:53	arg2	modification					31:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	1	26	theme	BACKGROUND	84:93	arg1	O-glycosylation					106:120	BACKGROUND Mucin-type O-glycosylation	84:120	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation)	84:160	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	1	26	theme	BACKGROUND	84:93	arg1	O-glycosylation					183:197	the most abundant O-glycosylation	165:197	the most abundant O-glycosylation on membrane and secretory proteins	165:232	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	3	27	theme	biological	427:436	arg1	function					438:445	the biological function	423:445	the biological function of this modification in cells	423:475	However, what nucleocytoplasmic proteins are O-GalNAc glycosylated and what the biological function of this modification in cells are still poorly understood.
32417172	8	28	dep	RESULTS	1236:1242	arg1	glycosylated					1265:1276	glycosylated	1265:1276	was O-GalNAc glycosylated in cells	1252:1285	RESULTS The p53 was O-GalNAc glycosylated in cells.
32417172	10	29	theme	at	1372:1373	arg1	Ser121					1375:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	0	30	theme	O-linked	0:7	arg1	modification					31:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	4	31	gly	glycosylated	573:584	arg1	p53					551:553	the tumor suppressor p53	530:553	the tumor suppressor p53	530:553	Previously, we reported the tumor suppressor p53 could be O-GalNAc glycosylated in vitro.
32417172	5	32	from	proteins	685:692	arg1	cell					697:700	cell	697:700	cell	697:700	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	3	33	gly	glycosylated	401:412	arg1	proteins					379:386	nucleocytoplasmic proteins	361:386	nucleocytoplasmic proteins	361:386	However, what nucleocytoplasmic proteins are O-GalNAc glycosylated and what the biological function of this modification in cells are still poorly understood.
32417172	6	34	theme	un-O-acetylated	947:961	arg1	GalNAz					963:968	un-O-acetylated GalNAz	947:968	un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	947:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	3	35	theme	modification	455:466	arg1	function					438:445	the biological function	423:445	the biological function of this modification in cells	423:475	However, what nucleocytoplasmic proteins are O-GalNAc glycosylated and what the biological function of this modification in cells are still poorly understood.
32417172	10	36	theme	p53	1432:1434	arg1	activity					1420:1427	activity	1420:1427	activity	1420:1427	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	10	36	theme	p53	1432:1434	arg1	stability					1406:1414	stability	1406:1414	stability	1406:1414	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	12	37	theme	pilot	1579:1583	arg1	evidence					1585:1592	a pilot evidence	1577:1592	a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein	1577:1661	GENERAL SIGNIFICANCE Our study provided a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein.
32417172	3	38	dep	glycosylated	401:412	arg1	O-GalNAc					392:399	O-GalNAc	392:399	O-GalNAc	392:399	However, what nucleocytoplasmic proteins are O-GalNAc glycosylated and what the biological function of this modification in cells are still poorly understood.
32417172	6	39	theme	core	865:868	arg1	β1					872:873	core 1 β1	865:873	core 1 β1	865:873	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	11	40	theme	O-GalNAc	1481:1488	arg1	glycosylation					1490:1502	the O-GalNAc glycosylation	1477:1502	the O-GalNAc glycosylation	1477:1502	CONCLUSIONS These results revealed that the O-GalNAc glycosylation was a novel modification on p53.
32417172	11	40	theme	O-GalNAc	1481:1488	arg1	modification					1516:1527	a novel modification	1508:1527	a novel modification on p53	1508:1534	CONCLUSIONS These results revealed that the O-GalNAc glycosylation was a novel modification on p53.
32417172	6	41	theme	GalNAc	801:806	arg1	lectins					817:823	GalNAc specific lectins	801:823	GalNAc specific lectins	801:823	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	42	theme	knockout	1011:1018	arg1	cells					1020:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	43	with	treatments	836:845	arg1	O-glycosidase					904:916	O-glycosidase	904:916	O-glycosidase	904:916	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	43	with	treatments	836:845	arg1	lectins					817:823	GalNAc specific lectins	801:823	GalNAc specific lectins	801:823	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	43	with	treatments	836:845	arg1	GalNAz					963:968	un-O-acetylated GalNAz	947:968	un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	947:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	43	with	treatments	836:845	arg1	β1					872:873	core 1 β1	865:873	core 1 β1	865:873	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	43	with	treatments	836:845	arg1	3-galactosyltransferase					876:898	3-galactosyltransferase	876:898	3-galactosyltransferase	876:898	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	43	with	treatments	836:845	arg1	O-GlcNAcase					852:862	O-GlcNAcase	852:862	O-GlcNAcase	852:862	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	1	44	gly	O-glycosylation	183:197	arg1	membrane					202:209	membrane	202:209	membrane	202:209	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	1	44	gly	O-glycosylation	183:197	arg1	proteins					225:232	secretory proteins	215:232	secretory proteins	215:232	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	6	45	theme	GALE	1005:1008	arg1	cells					1020:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	10	46	gly	glycosylation	1358:1370	arg1	Ser121					1375:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	10	46	gly	glycosylation	1358:1370	arg2	Ser121					1375:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	5	47	dep	existence	615:623	arg1	the					611:613	the	611:613	the	611:613	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	11	48	theme	novel	1510:1514	arg1	glycosylation					1490:1502	the O-GalNAc glycosylation	1477:1502	the O-GalNAc glycosylation	1477:1502	CONCLUSIONS These results revealed that the O-GalNAc glycosylation was a novel modification on p53.
32417172	11	48	theme	novel	1510:1514	arg1	modification					1516:1527	a novel modification	1508:1527	a novel modification on p53	1508:1534	CONCLUSIONS These results revealed that the O-GalNAc glycosylation was a novel modification on p53.
32417172	7	49	theme	O-GalNAc	1205:1212	arg1	glycosylation					1214:1226	O-GalNAc glycosylation	1205:1226	O-GalNAc glycosylation	1205:1226	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	6	50	theme	4-epimerase	992:1002	arg1	cells					1020:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	973:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	51	theme	enzymatic	826:834	arg1	treatments					836:845	enzymatic treatments	826:845	enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase	826:916	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	1	52	theme	abundant	174:181	arg1	O-glycosylation					106:120	BACKGROUND Mucin-type O-glycosylation	84:120	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation)	84:160	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	1	52	theme	abundant	174:181	arg1	O-glycosylation					183:197	the most abundant O-glycosylation	165:197	the most abundant O-glycosylation on membrane and secretory proteins	165:232	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	9	53	from	sites	1331:1335	arg1	p53					1340:1342	p53	1340:1342	p53	1340:1342	Ser121 residue was one of the glycosylated sites on p53.
32417172	12	54	theme	GENERAL	1537:1543	arg1	SIGNIFICANCE					1545:1556	GENERAL SIGNIFICANCE	1537:1556	GENERAL SIGNIFICANCE Our study	1537:1566	GENERAL SIGNIFICANCE Our study provided a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein.
32417172	0	55	attach	present	47:53	arg1	p53					79:81	the tumor suppressor p53	58:81	the tumor suppressor p53	58:81	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	0	55	attach	present	47:53	arg2	modification					31:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	9	56	gly	glycosylated	1318:1329	arg1	sites					1331:1335	the glycosylated sites	1314:1335	the glycosylated sites on p53	1314:1342	Ser121 residue was one of the glycosylated sites on p53.
32417172	6	57	theme	O-GalNAc	1044:1051	arg1	glycosylation					1053:1065	the O-GalNAc glycosylation	1040:1065	the O-GalNAc glycosylation on p53	1040:1072	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	9	58	theme	sites	1331:1335	arg1	one					1307:1309	one	1307:1309	one	1307:1309	Ser121 residue was one of the glycosylated sites on p53.
32417172	9	58	theme	sites	1331:1335	arg1	sites					1331:1335	the glycosylated sites	1314:1335	the glycosylated sites on p53	1314:1342	Ser121 residue was one of the glycosylated sites on p53.
32417172	5	59	theme	nucleocytoplasmic	727:743	arg1	protein					745:751	a representative nucleocytoplasmic protein	710:751	a representative nucleocytoplasmic protein	710:751	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	11	60	from	modification	1516:1527	arg1	p53					1532:1534	p53	1532:1534	p53	1532:1534	CONCLUSIONS These results revealed that the O-GalNAc glycosylation was a novel modification on p53.
32417172	2	61	theme	several	244:250	arg1	evidences					252:260	Recently several evidences	235:260	Recently several evidences	235:260	Recently several evidences suggest that nuclear or cytoplasmic proteins might also have O-GalNAc glycosylation.
32417172	7	62	theme	site-directed	1112:1124	arg1	mutagenesis					1126:1136	site-directed mutagenesis	1112:1136	site-directed mutagenesis	1112:1136	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	5	63	from	function	629:636	arg1	proteins					685:692	nucleocytoplasmic proteins	667:692	nucleocytoplasmic proteins in cell	667:700	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	2	64	theme	cytoplasmic	286:296	arg1	proteins					298:305	nuclear or cytoplasmic proteins	275:305	nuclear or cytoplasmic proteins	275:305	Recently several evidences suggest that nuclear or cytoplasmic proteins might also have O-GalNAc glycosylation.
32417172	10	65	dep	stability	1406:1414	arg1	the					1402:1404	the	1402:1404	the	1402:1404	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	1	66	theme	O-GalNAc	138:145	arg1	glycosylation					147:159	O-GalNAc glycosylation	138:159	O-GalNAc glycosylation	138:159	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	12	67	dep	evidence	1585:1592	arg1	existed					1626:1632	existed	1626:1632	existed on nucleocytoplasmic protein	1626:1661	GENERAL SIGNIFICANCE Our study provided a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein.
32417172	2	68	theme	nuclear	275:281	arg1	proteins					298:305	nuclear or cytoplasmic proteins	275:305	nuclear or cytoplasmic proteins	275:305	Recently several evidences suggest that nuclear or cytoplasmic proteins might also have O-GalNAc glycosylation.
32417172	7	69	theme	mass	1081:1084	arg1	analysis					1099:1106	mass spectrometry analysis	1081:1106	mass spectrometry analysis	1081:1106	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	10	70	theme	glycosylation	1358:1370	arg1	Ser121					1375:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121	1345:1380	The O-GalNAc glycosylation at Ser121 was associated with the stability and activity of p53.
32417172	1	71	from	O-glycosylation	183:197	arg1	membrane					202:209	membrane	202:209	membrane	202:209	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	1	71	from	O-glycosylation	183:197	arg1	proteins					225:232	secretory proteins	215:232	secretory proteins	215:232	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	12	72	theme	nucleocytoplasmic	1637:1653	arg1	protein					1655:1661	nucleocytoplasmic protein	1637:1661	nucleocytoplasmic protein	1637:1661	GENERAL SIGNIFICANCE Our study provided a pilot evidence that the O-GalNAc glycosylation existed on nucleocytoplasmic protein.
32417172	8	73	dep	glycosylated	1265:1276	arg1	O-GalNAc					1256:1263	O-GalNAc	1256:1263	O-GalNAc	1256:1263	RESULTS The p53 was O-GalNAc glycosylated in cells.
32417172	1	74	dep	O-glycosylation	106:120	arg1	referred					123:130	referred	123:130	referred to as O-GalNAc glycosylation	123:159	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	5	75	theme	glycosylation	650:662	arg1	function					629:636	function	629:636	function	629:636	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	5	75	theme	glycosylation	650:662	arg1	existence					615:623	existence	615:623	existence	615:623	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	6	76	theme	lectin	780:785	arg1	blotting					787:794	lectin blotting	780:794	lectin blotting with GalNAc specific lectins	780:823	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	5	77	theme	nucleocytoplasmic	667:683	arg1	proteins					685:692	nucleocytoplasmic proteins	667:692	nucleocytoplasmic proteins in cell	667:700	To investigate the existence and function of O-GalNAc glycosylation on nucleocytoplasmic proteins in cell, p53 as a representative nucleocytoplasmic protein was studied.
32417172	6	78	with	labeling	933:940	arg1	O-glycosidase					904:916	O-glycosidase	904:916	O-glycosidase	904:916	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	78	with	labeling	933:940	arg1	lectins					817:823	GalNAc specific lectins	801:823	GalNAc specific lectins	801:823	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	78	with	labeling	933:940	arg1	GalNAz					963:968	un-O-acetylated GalNAz	947:968	un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	947:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	78	with	labeling	933:940	arg1	β1					872:873	core 1 β1	865:873	core 1 β1	865:873	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	78	with	labeling	933:940	arg1	3-galactosyltransferase					876:898	3-galactosyltransferase	876:898	3-galactosyltransferase	876:898	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	78	with	labeling	933:940	arg1	O-GlcNAcase					852:862	O-GlcNAcase	852:862	O-GlcNAcase	852:862	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	4	79	theme	tumor	534:538	arg1	p53					551:553	the tumor suppressor p53	530:553	the tumor suppressor p53	530:553	Previously, we reported the tumor suppressor p53 could be O-GalNAc glycosylated in vitro.
32417172	0	80	theme	N-acetylgalactosamine	9:29	arg1	modification					31:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification	0:42	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	3	81	from	function	438:445	arg1	cells					471:475	cells	471:475	cells	471:475	However, what nucleocytoplasmic proteins are O-GalNAc glycosylated and what the biological function of this modification in cells are still poorly understood.
32417172	1	82	theme	Mucin-type	95:104	arg1	O-glycosylation					106:120	BACKGROUND Mucin-type O-glycosylation	84:120	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation)	84:160	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	1	82	theme	Mucin-type	95:104	arg1	O-glycosylation					183:197	the most abundant O-glycosylation	165:197	the most abundant O-glycosylation on membrane and secretory proteins	165:232	BACKGROUND Mucin-type O-glycosylation (referred to as O-GalNAc glycosylation) is the most abundant O-glycosylation on membrane and secretory proteins.
32417172	7	83	from	functions	1192:1200	arg1	p53					1231:1233	p53	1231:1233	p53	1231:1233	Using mass spectrometry analysis and site-directed mutagenesis, we identified the glycosylated sites and studied the functions of O-GalNAc glycosylation on p53.
32417172	2	84	contain	have	318:321	arg1	proteins					298:305	nuclear or cytoplasmic proteins	275:305	nuclear or cytoplasmic proteins	275:305	Recently several evidences suggest that nuclear or cytoplasmic proteins might also have O-GalNAc glycosylation.
32417172	2	84	contain	have	318:321	arg2	glycosylation					332:344	O-GalNAc glycosylation	323:344	O-GalNAc glycosylation	323:344	Recently several evidences suggest that nuclear or cytoplasmic proteins might also have O-GalNAc glycosylation.
32417172	6	85	from	glycosylation	1053:1065	arg1	p53					1070:1072	p53	1070:1072	p53	1070:1072	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	0	86	theme	tumor	62:66	arg1	p53					79:81	the tumor suppressor p53	58:81	the tumor suppressor p53	58:81	O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53.
32417172	6	87	theme	metabolic	923:931	arg1	labeling					933:940	metabolic labeling	923:940	metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells	923:1024	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	6	88	theme	specific	808:815	arg1	lectins					817:823	GalNAc specific lectins	801:823	GalNAc specific lectins	801:823	METHODS Using lectin blotting with GalNAc specific lectins, enzymatic treatments with O-GlcNAcase, core 1 β1, 3-galactosyltransferase and O-glycosidase, and metabolic labeling with un-O-acetylated GalNAz in UDP-Gal/UDP-GalNAc 4-epimerase (GALE) knockout cells, we validated the O-GalNAc glycosylation on p53.
32417172	8	89	gly	glycosylated	1265:1276	arg1	cells					1281:1285	cells	1281:1285	cells	1281:1285	RESULTS The p53 was O-GalNAc glycosylated in cells.
32417172	8	89	gly	glycosylated	1265:1276	arg1	p53					1248:1250	The p53	1244:1250	The p53	1244:1250	RESULTS The p53 was O-GalNAc glycosylated in cells.
32417172	8	89	gly	glycosylated	1265:1276	arg2	p53					1248:1250	The p53	1244:1250	The p53	1244:1250	RESULTS The p53 was O-GalNAc glycosylated in cells.
32417172	8	89	gly	glycosylated	1265:1276	arg1	RESULTS					1236:1242	RESULTS	1236:1242	RESULTS The p53 was O-GalNAc glycosylated in cells.	1236:1286	RESULTS The p53 was O-GalNAc glycosylated in cells.
33801653	0	0	theme	O-GlcNAc	98:105	arg1	Homeostasis					107:117	Intracellular O-GlcNAc Homeostasis	84:117	Intracellular O-GlcNAc Homeostasis	84:117	Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
33801653	5	1	theme	lung	963:966	arg1	cells					975:979	lung cancer cells	963:979	lung cancer cells	963:979	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	6	2	theme	expression	1063:1072	arg1	regulation					1045:1054	the regulation	1041:1054	the regulation of OGA expression	1041:1072	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	0	3	theme	Intracellular	84:96	arg1	Homeostasis					107:117	Intracellular O-GlcNAc Homeostasis	84:117	Intracellular O-GlcNAc Homeostasis	84:117	Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
33801653	8	4	theme	O-GlcNAc	1638:1645	arg1	levels					1647:1652	intracellular O-GlcNAc levels	1624:1652	intracellular O-GlcNAc levels	1624:1652	The results provide additional insight into the molecular mechanisms through which cells may fine-tune intracellular O-GlcNAc levels to maintain homeostasis.
33801653	6	5	theme	OGT	1162:1164	arg1	expression					1166:1175	OGT expression	1162:1175	OGT expression	1162:1175	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	2	6	theme	O-GlcNAc	401:408	arg1	transferase					410:420	O-GlcNAc transferase	401:420	O-GlcNAc transferase (OGT)	401:426	Two enzymes are responsible for O-GlcNAc cycling on substrate proteins: O-GlcNAc transferase (OGT) catalyzes the addition while O-GlcNAcase (OGA) helps the removal of GlcNAc.
33801653	2	6	theme	O-GlcNAc	401:408	arg1	OGT					423:425	OGT	423:425	OGT	423:425	Two enzymes are responsible for O-GlcNAc cycling on substrate proteins: O-GlcNAc transferase (OGT) catalyzes the addition while O-GlcNAcase (OGA) helps the removal of GlcNAc.
33801653	2	7	from	cycling	370:376	arg1	proteins					391:398	substrate proteins	381:398	substrate proteins	381:398	Two enzymes are responsible for O-GlcNAc cycling on substrate proteins: O-GlcNAc transferase (OGT) catalyzes the addition while O-GlcNAcase (OGA) helps the removal of GlcNAc.
33801653	1	8	theme	numerous	292:299	arg1	proteins					319:326	numerous nucleocytoplasmic proteins	292:326	numerous nucleocytoplasmic proteins	292:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	8	9	theme	intracellular	1624:1636	arg1	levels					1647:1652	intracellular O-GlcNAc levels	1624:1652	intracellular O-GlcNAc levels	1624:1652	The results provide additional insight into the molecular mechanisms through which cells may fine-tune intracellular O-GlcNAc levels to maintain homeostasis.
33801653	3	10	theme	cell	600:603	arg1	physiology					605:614	cell physiology	600:614	cell physiology	600:614	O-GlcNAcylation modifies protein functions; therefore, dysregulation of O-GlcNAcylation affects cell physiology and contributes to pathogenesis.
33801653	1	11	theme	nucleocytoplasmic	301:317	arg1	proteins					319:326	numerous nucleocytoplasmic proteins	292:326	numerous nucleocytoplasmic proteins	292:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	6	12	from	alterations	1009:1019	arg1	O-GlcNAcylation					1024:1038	O-GlcNAcylation	1024:1038	O-GlcNAcylation	1024:1038	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	5	13	from	expression	949:958	arg1	cells					975:979	lung cancer cells	963:979	lung cancer cells	963:979	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	3	14	theme	protein	529:535	arg1	functions					537:545	protein functions	529:545	protein functions	529:545	O-GlcNAcylation modifies protein functions; therefore, dysregulation of O-GlcNAcylation affects cell physiology and contributes to pathogenesis.
33801653	7	15	theme	initiation	1267:1276	arg1	factor					1278:1283	the eukaryotic translation initiation factor	1240:1283	the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)	1240:1313	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	3	16	theme	O-GlcNAcylation	576:590	arg1	dysregulation					559:571	dysregulation	559:571	dysregulation of O-GlcNAcylation	559:590	O-GlcNAcylation modifies protein functions; therefore, dysregulation of O-GlcNAcylation affects cell physiology and contributes to pathogenesis.
33801653	7	17	theme	O-GlcNAcylation-site	1402:1421	arg1	mutant					1423:1428	the S5A/S6A O-GlcNAcylation-site mutant	1390:1428	the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1	1390:1438	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	4	18	theme	OGT	738:740	arg1	regulation					724:733	feedback regulation	715:733	feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels	715:805	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	7	19	theme	Further	1209:1215	arg1	analyses					1217:1224	Further analyses	1209:1224	Further analyses	1209:1224	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	1	20	attach	attachment	203:212	arg1	groups					262:267	the hydroxyl groups	249:267	the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	249:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	20	attach	attachment	203:212	arg1	residues					280:287	Ser/Thr residues	272:287	Ser/Thr residues	272:287	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	20	attach	attachment	203:212	arg2	GlcNAc					238:243	GlcNAc	238:243	GlcNAc	238:243	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	20	attach	attachment	203:212	arg2	N-acetylglucosamine					217:235	N-acetylglucosamine	217:235	N-acetylglucosamine (GlcNAc)	217:244	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	7	21	theme	translation	1255:1265	arg1	factor					1278:1283	the eukaryotic translation initiation factor	1240:1283	the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)	1240:1313	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	1	22	theme	N-acetylglucosamine	217:235	arg1	attachment					203:212	the attachment	199:212	the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	199:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	7	23	theme	eukaryotic	1244:1253	arg1	factor					1278:1283	the eukaryotic translation initiation factor	1240:1283	the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)	1240:1313	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	7	24	theme	O-GlcNAcylation	1504:1518	arg1	role					1496:1499	an important role	1483:1499	an important role of O-GlcNAcylation	1483:1518	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	7	25	theme	OGT	1352:1354	arg1	downregulation					1334:1347	the downregulation	1330:1347	the downregulation of OGT induced by hyper-O-GlcNAcylation	1330:1387	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	4	26	theme	OGA	746:748	arg1	regulation					724:733	feedback regulation	715:733	feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels	715:805	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	0	27	theme	Feedback	0:7	arg1	Regulation					9:18	Feedback Regulation	0:18	Feedback Regulation of O-GlcNAc Transferase through Translation Control	0:70	Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
33801653	4	28	theme	levels	800:805	arg1	fluctuations					775:786	fluctuations	775:786	fluctuations of O-GlcNAc levels	775:805	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	2	29	theme	O-GlcNAc	361:368	arg1	cycling					370:376	O-GlcNAc cycling	361:376	O-GlcNAc cycling on substrate proteins	361:398	Two enzymes are responsible for O-GlcNAc cycling on substrate proteins: O-GlcNAc transferase (OGT) catalyzes the addition while O-GlcNAcase (OGA) helps the removal of GlcNAc.
33801653	5	30	theme	OGA	945:947	arg1	expression					949:958	OGA expression	945:958	OGA expression in lung cancer cells	945:979	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	0	31	theme	O-GlcNAc	23:30	arg1	Transferase					32:42	O-GlcNAc Transferase	23:42	O-GlcNAc Transferase	23:42	Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
33801653	8	32	theme	additional	1541:1550	arg1	insight					1552:1558	additional insight	1541:1558	additional insight into the molecular mechanisms through which cells may fine-tune intracellular O-GlcNAc levels to maintain homeostasis	1541:1676	The results provide additional insight into the molecular mechanisms through which cells may fine-tune intracellular O-GlcNAc levels to maintain homeostasis.
33801653	1	33	theme	Protein	120:126	arg1	modification					176:187	a dynamic post-translational modification	147:187	a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	147:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	33	theme	Protein	120:126	arg1	O-GlcNAcylation					128:142	Protein O-GlcNAcylation	120:142	Protein O-GlcNAcylation	120:142	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	4	34	theme	molecular	839:847	arg1	mechanisms					849:858	the molecular mechanisms	835:858	the molecular mechanisms involved	835:867	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	5	35	theme	cancer	968:973	arg1	cells					975:979	lung cancer cells	963:979	lung cancer cells	963:979	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	7	36	theme	S5A/S6A	1394:1400	arg1	mutant					1423:1428	the S5A/S6A O-GlcNAcylation-site mutant	1390:1428	the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1	1390:1438	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	6	37	theme	epigenetic	1119:1128	arg1	mechanisms					1130:1139	epigenetic mechanisms	1119:1139	epigenetic mechanisms	1119:1139	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	5	38	theme	O-GlcNAc-feedback	905:921	arg1	regulation					923:932	the O-GlcNAc-feedback regulation	901:932	the O-GlcNAc-feedback regulation of OGT	901:939	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	0	39	theme	Transferase	32:42	arg1	Regulation					9:18	Feedback Regulation	0:18	Feedback Regulation of O-GlcNAc Transferase through Translation Control	0:70	Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
33801653	6	40	theme	OGA	1059:1061	arg1	expression					1063:1072	OGA expression	1059:1072	OGA expression	1059:1072	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	8	41	theme	molecular	1569:1577	arg1	mechanisms					1579:1588	the molecular mechanisms	1565:1588	the molecular mechanisms through which cells may fine-tune intracellular O-GlcNAc levels to maintain homeostasis	1565:1676	The results provide additional insight into the molecular mechanisms through which cells may fine-tune intracellular O-GlcNAc levels to maintain homeostasis.
33801653	7	42	theme	important	1486:1494	arg1	role					1496:1499	an important role	1483:1499	an important role of O-GlcNAcylation	1483:1518	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	1	43	theme	hydroxyl	253:260	arg1	groups					262:267	the hydroxyl groups	249:267	the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	249:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	43	theme	hydroxyl	253:260	arg1	residues					280:287	Ser/Thr residues	272:287	Ser/Thr residues	272:287	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	2	44	theme	GlcNAc	496:501	arg1	removal					485:491	the removal	481:491	the removal of GlcNAc	481:501	Two enzymes are responsible for O-GlcNAc cycling on substrate proteins: O-GlcNAc transferase (OGT) catalyzes the addition while O-GlcNAcase (OGA) helps the removal of GlcNAc.
33801653	5	45	from	regulation	923:932	arg1	cells					975:979	lung cancer cells	963:979	lung cancer cells	963:979	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	4	46	theme	O-GlcNAc	791:798	arg1	levels					800:805	O-GlcNAc levels	791:805	O-GlcNAc levels	791:805	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	0	47	theme	Translation	52:62	arg1	Control					64:70	Translation Control	52:70	Translation Control	52:70	Feedback Regulation of O-GlcNAc Transferase through Translation Control to Maintain Intracellular O-GlcNAc Homeostasis.
33801653	7	48	theme	4E-BP1	1433:1438	arg1	mutant					1423:1428	the S5A/S6A O-GlcNAcylation-site mutant	1390:1428	the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1	1390:1438	Further analyses revealed that the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) contributes to the downregulation of OGT induced by hyper-O-GlcNAcylation; the S5A/S6A O-GlcNAcylation-site mutant of 4E-BP1 cannot support this regulation, suggesting an important role of O-GlcNAcylation.
33801653	6	49	theme	translation	1188:1198	arg1	control					1200:1206	translation control	1188:1206	translation control	1188:1206	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	1	50	from	groups	262:267	arg1	proteins					319:326	numerous nucleocytoplasmic proteins	292:326	numerous nucleocytoplasmic proteins	292:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	51	theme	dynamic	149:155	arg1	modification					176:187	a dynamic post-translational modification	147:187	a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	147:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	51	theme	dynamic	149:155	arg1	O-GlcNAcylation					128:142	Protein O-GlcNAcylation	120:142	Protein O-GlcNAcylation	120:142	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	4	52	theme	cellular	676:683	arg1	O-GlcNAcylation					685:699	cellular O-GlcNAcylation	676:699	cellular O-GlcNAcylation	676:699	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	1	53	theme	post-translational	157:174	arg1	modification					176:187	a dynamic post-translational modification	147:187	a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	147:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	53	theme	post-translational	157:174	arg1	O-GlcNAcylation					128:142	Protein O-GlcNAcylation	120:142	Protein O-GlcNAcylation	120:142	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	2	54	theme	substrate	381:389	arg1	proteins					391:398	substrate proteins	381:398	substrate proteins	381:398	Two enzymes are responsible for O-GlcNAc cycling on substrate proteins: O-GlcNAc transferase (OGT) catalyzes the addition while O-GlcNAcase (OGA) helps the removal of GlcNAc.
33801653	4	55	theme	feedback	715:722	arg1	regulation					724:733	feedback regulation	715:733	feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels	715:805	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	4	56	dep	OGT	738:740	arg1	expression					750:759	expression	750:759	expression	750:759	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	6	57	theme	expression	1166:1175	arg1	modulation					1148:1157	modulation	1148:1157	modulation of OGT expression	1148:1175	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	5	58	theme	OGT	937:939	arg1	expression					949:958	OGA expression	945:958	OGA expression in lung cancer cells	945:979	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	5	58	theme	OGT	937:939	arg1	regulation					923:932	the O-GlcNAc-feedback regulation	901:932	the O-GlcNAc-feedback regulation of OGT	901:939	In this study, we investigated the O-GlcNAc-feedback regulation of OGT and OGA expression in lung cancer cells.
33801653	1	59	theme	Ser/Thr	272:278	arg1	residues					280:287	Ser/Thr residues	272:287	Ser/Thr residues	272:287	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	4	60	theme	O-GlcNAcylation	685:699	arg1	homeostasis					661:671	homeostasis	661:671	homeostasis of cellular O-GlcNAcylation	661:699	To maintain homeostasis of cellular O-GlcNAcylation, there exists feedback regulation of OGT and OGA expression responding to fluctuations of O-GlcNAc levels; yet, little is known about the molecular mechanisms involved.
33801653	6	61	theme	mRNA	1088:1091	arg1	level					1093:1097	the mRNA level	1084:1097	the mRNA level	1084:1097	Results suggest that, upon alterations in O-GlcNAcylation, the regulation of OGA expression occurs at the mRNA level and likely involves epigenetic mechanisms, while modulation of OGT expression is through translation control.
33801653	1	62	theme	residues	280:287	arg1	groups					262:267	the hydroxyl groups	249:267	the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins	249:326	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
33801653	1	62	theme	residues	280:287	arg1	residues					280:287	Ser/Thr residues	272:287	Ser/Thr residues	272:287	Protein O-GlcNAcylation is a dynamic post-translational modification involving the attachment of N-acetylglucosamine (GlcNAc) to the hydroxyl groups of Ser/Thr residues on numerous nucleocytoplasmic proteins.
34957216	11	0	theme	antivirals	1628:1637	arg1	design					1618:1623	the design	1614:1623	the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2	1614:1683	Our results can be of therapeutic importance in the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2.
34957216	0	1	with	Affinity	90:97	arg1	SARS-CoV-2					120:129	SARS-CoV-2	120:129	SARS-CoV-2	120:129	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	9	2	theme	viral	1426:1430	arg1	isolate					1432:1438	the 2003-2004 viral isolate	1412:1438	the 2003-2004 viral isolate	1412:1438	In addition, the mutations of L472P and F360S destabilized the 2003-2004 viral isolate.
34957216	4	3	theme	energy	656:661	arg1	calculations					663:674	the structure-based energy calculations	636:674	the structure-based energy calculations	636:674	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	8	4	theme	mutation	1188:1195	arg1	analysis					1197:1204	The viral mutation analysis	1178:1204	The viral mutation analysis of the two different SARS-CoV-1 isolates	1178:1245	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	4	5	with	affinity	771:778	arg1	hACE2					785:789	hACE2	785:789	hACE2	785:789	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	3	6	theme	SARS-CoV-1	565:574	arg1	protein					554:560	the S protein	548:560	the S protein of SARS-CoV-1	548:574	Here, we per-formed computational saturation mutagenesis of the S protein of SARS-CoV-1 to identify the residues crucial for its functions.
34957216	5	7	theme	SARS-CoV-1	875:884	arg1	proteins					863:870	the S proteins	857:870	the S proteins of SARS-CoV-1 and SARS-CoV-2	857:899	The sequence and structure alignment showed similarities between the S proteins of SARS-CoV-1 and SARS-CoV-2.
34957216	6	8	theme	acids	967:971	arg1	mutations					938:946	target mutations	931:946	target mutations of S protein amino acids	931:971	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	7	9	theme	SARS-CoV-1	1076:1085	arg1	G839W					1067:1071	G839W	1067:1071	G839W of SARS-CoV-1	1067:1085	For example, G839W of SARS-CoV-1 corresponds to G857W of SARS-CoV-2, which decrease the stability of their S glycoproteins.
34957216	3	10	theme	protein	554:560	arg1	mutagenesis					533:543	computational saturation mutagenesis	508:543	computational saturation mutagenesis of the S protein of SARS-CoV-1	508:574	Here, we per-formed computational saturation mutagenesis of the S protein of SARS-CoV-1 to identify the residues crucial for its functions.
34957216	1	11	theme	host	207:210	arg1	surface					217:223	the host cell surface	203:223	the host cell surface	203:223	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	6	12	theme	protein	953:959	arg1	acids					967:971	S protein amino acids	951:971	S protein amino acids	951:971	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	4	13	with	stability	745:753	arg1	hACE2					785:789	hACE2	785:789	hACE2	785:789	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	1	14	theme	receptor	377:384	arg1	receptor					377:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	14	theme	receptor	377:384	arg1	glycoprotein					308:319	its spike glycoprotein	298:319	its spike glycoprotein (S)	298:323	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	14	theme	receptor	377:384	arg1	RBD					290:292	RBD	290:292	RBD	290:292	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	14	theme	receptor	377:384	arg1	domain					282:287	the receptor-binding domain	261:287	the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor	261:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	7	15	theme	S	1161:1161	arg1	glycoproteins					1163:1175	their S glycoproteins	1155:1175	their S glycoproteins	1155:1175	For example, G839W of SARS-CoV-1 corresponds to G857W of SARS-CoV-2, which decrease the stability of their S glycoproteins.
34957216	11	16	from	importance	1600:1609	arg1	design					1618:1623	the design	1614:1623	the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2	1614:1683	Our results can be of therapeutic importance in the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2.
34957216	8	17	theme	SARS-CoV-1	1227:1236	arg1	isolates					1238:1245	the two different SARS-CoV-1 isolates	1209:1245	the two different SARS-CoV-1 isolates	1209:1245	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	4	18	theme	missense	706:713	arg1	mutations					715:723	the missense mutations	702:723	the missense mutations	702:723	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	6	19	theme	target	931:936	arg1	mutations					938:946	target mutations	931:946	target mutations of S protein amino acids	931:971	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	8	20	theme	S-hACE2	1300:1306	arg1	binding					1308:1314	the S-hACE2 binding	1296:1314	the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate	1296:1350	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	4	21	used	used	631:634	arg2	We					628:629	We	628:629	We	628:629	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	1	22	theme	Acute	139:143	arg1	SARS-CoV-1					179:188	SARS-CoV-1	179:188	SARS-CoV-1	179:188	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	22	theme	Acute	139:143	arg1	coronavirus					166:176	Severe Acute respiratory syndrome coronavirus	132:176	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1)	132:189	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	10	23	gly	glycoprotein	1552:1563	arg1	glycoprotein					1552:1563	the S glycoprotein	1546:1563	the S glycoprotein	1546:1563	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	9	24	theme	2003-2004	1416:1424	arg1	isolate					1432:1438	the 2003-2004 viral isolate	1412:1438	the 2003-2004 viral isolate	1412:1438	In addition, the mutations of L472P and F360S destabilized the 2003-2004 viral isolate.
34957216	5	25	theme	SARS-CoV-2	890:899	arg1	proteins					863:870	the S proteins	857:870	the S proteins of SARS-CoV-1 and SARS-CoV-2	857:899	The sequence and structure alignment showed similarities between the S proteins of SARS-CoV-1 and SARS-CoV-2.
34957216	0	26	theme	Binding	82:88	arg1	Affinity					90:97	Binding Affinity	82:97	Binding Affinity	82:97	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	8	27	theme	isolate	1344:1350	arg1	binding					1308:1314	the S-hACE2 binding	1296:1314	the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate	1296:1350	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	1	28	theme	human	333:337	arg1	hACE2					370:374	hACE2	370:374	hACE2	370:374	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	28	theme	human	333:337	arg1	enzyme					362:367	the human Angiotensin-converting enzyme	329:367	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	6	29	theme	similar	982:988	arg1	effects					990:996	similar effects	982:996	similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2	982:1051	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	6	30	from	effects	990:996	arg1	stabilities					1007:1017	their stabilities	1001:1017	their stabilities between SARS-CoV-1 and SARS-CoV-2	1001:1051	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	1	31	theme	enzyme	362:367	arg1	receptor					377:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	4	32	theme	SARS-CoV-1	732:741	arg1	stability					745:753	the SARS-CoV-1 S stability	728:753	the SARS-CoV-1 S stability	728:753	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	0	33	theme	Computational	0:12	arg1	Mutagenesis					25:35	Computational Saturation Mutagenesis	0:35	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein	0:68	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	7	34	theme	glycoproteins	1163:1175	arg1	stability					1142:1150	the stability	1138:1150	the stability of their S glycoproteins	1138:1175	For example, G839W of SARS-CoV-1 corresponds to G857W of SARS-CoV-2, which decrease the stability of their S glycoproteins.
34957216	0	35	dep	Stability	71:79	arg1	Mutagenesis					25:35	Computational Saturation Mutagenesis	0:35	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein	0:68	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	10	36	theme	N-linked	1485:1492	arg1	sites					1508:1512	N-linked glycosylation sites	1485:1512	N-linked glycosylation sites	1485:1512	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	0	37	theme	SARS-CoV-1	40:49	arg1	Glycoprotein					57:68	SARS-CoV-1 Spike Glycoprotein	40:68	SARS-CoV-1 Spike Glycoprotein	40:68	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	1	38	attach	attaches	191:198	arg2	SARS-CoV-1					179:188	SARS-CoV-1	179:188	SARS-CoV-1	179:188	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	38	attach	attaches	191:198	arg2	coronavirus					166:176	Severe Acute respiratory syndrome coronavirus	132:176	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1)	132:189	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	38	attach	attaches	191:198	arg1	surface					217:223	the host cell surface	203:223	the host cell surface	203:223	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	0	39	theme	Glycoprotein	57:68	arg1	Mutagenesis					25:35	Computational Saturation Mutagenesis	0:35	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein	0:68	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	1	40	theme	glycoprotein	308:319	arg1	receptor					377:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	40	theme	glycoprotein	308:319	arg1	glycoprotein					308:319	its spike glycoprotein	298:319	its spike glycoprotein (S)	298:323	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	40	theme	glycoprotein	308:319	arg1	RBD					290:292	RBD	290:292	RBD	290:292	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	40	theme	glycoprotein	308:319	arg1	domain					282:287	the receptor-binding domain	261:287	the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor	261:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	41	theme	syndrome	157:164	arg1	SARS-CoV-1					179:188	SARS-CoV-1	179:188	SARS-CoV-1	179:188	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	41	theme	syndrome	157:164	arg1	coronavirus					166:176	Severe Acute respiratory syndrome coronavirus	132:176	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1)	132:189	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	10	42	theme	glycoprotein	1552:1563	arg1	stability					1533:1541	the stability	1529:1541	the stability of the S glycoprotein	1529:1563	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	7	43	gly	glycoproteins	1163:1175	arg1	glycoproteins					1163:1175	their S glycoproteins	1155:1175	their S glycoproteins	1155:1175	For example, G839W of SARS-CoV-1 corresponds to G857W of SARS-CoV-2, which decrease the stability of their S glycoproteins.
34957216	8	44	theme	isolates	1238:1245	arg1	analysis					1197:1204	The viral mutation analysis	1178:1204	The viral mutation analysis of the two different SARS-CoV-1 isolates	1178:1245	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	4	45	from	effects	691:697	arg1	stability					745:753	the SARS-CoV-1 S stability	728:753	the SARS-CoV-1 S stability	728:753	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	4	45	from	effects	691:697	arg1	affinity					771:778	the binding affinity	759:778	the binding affinity with hACE2	759:789	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	7	46	theme	SARS-CoV-2	1111:1120	arg1	G857W					1102:1106	G857W	1102:1106	G857W	1102:1106	For example, G839W of SARS-CoV-1 corresponds to G857W of SARS-CoV-2, which decrease the stability of their S glycoproteins.
34957216	1	47	theme	receptor-binding	265:280	arg1	receptor					377:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	47	theme	receptor-binding	265:280	arg1	glycoprotein					308:319	its spike glycoprotein	298:319	its spike glycoprotein (S)	298:323	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	47	theme	receptor-binding	265:280	arg1	RBD					290:292	RBD	290:292	RBD	290:292	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	47	theme	receptor-binding	265:280	arg1	domain					282:287	the receptor-binding domain	261:287	the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor	261:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	0	48	with	Stability	71:79	arg1	SARS-CoV-2					120:129	SARS-CoV-2	120:129	SARS-CoV-2	120:129	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	3	49	theme	saturation	522:531	arg1	mutagenesis					533:543	computational saturation mutagenesis	508:543	computational saturation mutagenesis of the S protein of SARS-CoV-1	508:574	Here, we per-formed computational saturation mutagenesis of the S protein of SARS-CoV-1 to identify the residues crucial for its functions.
34957216	5	50	theme	S	861:861	arg1	proteins					863:870	the S proteins	857:870	the S proteins of SARS-CoV-1 and SARS-CoV-2	857:899	The sequence and structure alignment showed similarities between the S proteins of SARS-CoV-1 and SARS-CoV-2.
34957216	4	51	theme	structure-based	640:654	arg1	calculations					663:674	the structure-based energy calculations	636:674	the structure-based energy calculations	636:674	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	0	52	with	Comparison	104:113	arg1	SARS-CoV-2					120:129	SARS-CoV-2	120:129	SARS-CoV-2	120:129	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	8	53	theme	viral	1182:1186	arg1	analysis					1197:1204	The viral mutation analysis	1178:1204	The viral mutation analysis of the two different SARS-CoV-1 isolates	1178:1245	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	10	54	gly	glycosylation	1494:1506	arg2	sites					1508:1512	N-linked glycosylation sites	1485:1512	N-linked glycosylation sites	1485:1512	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	3	55	theme	S	552:552	arg1	protein					554:560	the S protein	548:560	the S protein of SARS-CoV-1	548:574	Here, we per-formed computational saturation mutagenesis of the S protein of SARS-CoV-1 to identify the residues crucial for its functions.
34957216	6	56	theme	amino	961:965	arg1	acids					967:971	S protein amino acids	951:971	S protein amino acids	951:971	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	1	57	theme	cell	212:215	arg1	surface					217:223	the host cell surface	203:223	the host cell surface	203:223	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	6	58	theme	S	951:951	arg1	acids					967:971	S protein amino acids	951:971	S protein amino acids	951:971	Interestingly, we found that target mutations of S protein amino acids generate similar effects on their stabilities between SARS-CoV-1 and SARS-CoV-2.
34957216	8	59	theme	different	1217:1225	arg1	isolates					1238:1245	the two different SARS-CoV-1 isolates	1209:1245	the two different SARS-CoV-1 isolates	1209:1245	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	10	60	from	mutations	1472:1480	arg1	sites					1508:1512	N-linked glycosylation sites	1485:1512	N-linked glycosylation sites	1485:1512	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	1	61	theme	Severe	132:137	arg1	SARS-CoV-1					179:188	SARS-CoV-1	179:188	SARS-CoV-1	179:188	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	61	theme	Severe	132:137	arg1	coronavirus					166:176	Severe Acute respiratory syndrome coronavirus	132:176	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1)	132:189	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	4	62	theme	mutations	715:723	arg1	effects					691:697	the effects	687:697	the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2	687:789	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	3	63	theme	crucial	601:607	arg1	residues					592:599	the residues	588:599	the residues crucial for its functions	588:625	Here, we per-formed computational saturation mutagenesis of the S protein of SARS-CoV-1 to identify the residues crucial for its functions.
34957216	1	64	theme	respiratory	145:155	arg1	SARS-CoV-1					179:188	SARS-CoV-1	179:188	SARS-CoV-1	179:188	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	64	theme	respiratory	145:155	arg1	coronavirus					166:176	Severe Acute respiratory syndrome coronavirus	132:176	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1)	132:189	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	65	gly	glycoprotein	308:319	arg1	S					322:322	S	322:322	S	322:322	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	65	gly	glycoprotein	308:319	arg1	glycoprotein					308:319	its spike glycoprotein	298:319	its spike glycoprotein (S)	298:323	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	2	66	theme	antiviral	465:473	arg1	development					475:485	the antiviral development	461:485	the antiviral development	461:485	SARS-CoV-1 mutates frequently because of its RNA genome, which challenges the antiviral development.
34957216	8	67	theme	SARS-CoV-1	1333:1342	arg1	isolate					1344:1350	the 2003-2004 SARS-CoV-1 isolate	1319:1350	the 2003-2004 SARS-CoV-1 isolate	1319:1350	The viral mutation analysis of the two different SARS-CoV-1 isolates showed that mutations, T487S and L472P, weakened the S-hACE2 binding of the 2003-2004 SARS-CoV-1 isolate.
34957216	10	68	link	N-linked	1485:1492	arg1	sites					1508:1512	N-linked glycosylation sites	1485:1512	N-linked glycosylation sites	1485:1512	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	1	69	theme	Angiotensin-converting	339:360	arg1	hACE2					370:374	hACE2	370:374	hACE2	370:374	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	69	theme	Angiotensin-converting	339:360	arg1	enzyme					362:367	the human Angiotensin-converting enzyme	329:367	the human Angiotensin-converting enzyme (hACE2) receptor	329:384	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	10	70	theme	many	1467:1470	arg1	mutations					1472:1480	many mutations	1467:1480	many mutations on N-linked glycosylation sites	1467:1512	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	4	71	theme	binding	763:769	arg1	affinity					771:778	the binding affinity	759:778	the binding affinity with hACE2	759:789	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	5	72	theme	sequence	796:803	arg1	alignment					819:827	The sequence and structure alignment	792:827	The sequence and structure alignment	792:827	The sequence and structure alignment showed similarities between the S proteins of SARS-CoV-1 and SARS-CoV-2.
34957216	2	73	theme	RNA	432:434	arg1	genome					436:441	its RNA genome	428:441	its RNA genome	428:441	SARS-CoV-1 mutates frequently because of its RNA genome, which challenges the antiviral development.
34957216	5	74	theme	structure	809:817	arg1	alignment					819:827	The sequence and structure alignment	792:827	The sequence and structure alignment	792:827	The sequence and structure alignment showed similarities between the S proteins of SARS-CoV-1 and SARS-CoV-2.
34957216	10	75	theme	glycosylation	1494:1506	arg1	sites					1508:1512	N-linked glycosylation sites	1485:1512	N-linked glycosylation sites	1485:1512	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	4	76	theme	S	743:743	arg1	stability					745:753	the SARS-CoV-1 S stability	728:753	the SARS-CoV-1 S stability	728:753	We used the structure-based energy calculations to analyze the effects of the missense mutations on the SARS-CoV-1 S stability and the binding affinity with hACE2.
34957216	0	77	theme	Spike	51:55	arg1	Glycoprotein					57:68	SARS-CoV-1 Spike Glycoprotein	40:68	SARS-CoV-1 Spike Glycoprotein	40:68	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	11	78	theme	therapeutic	1588:1598	arg1	importance					1600:1609	therapeutic importance	1588:1609	therapeutic importance	1588:1609	Our results can be of therapeutic importance in the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2.
34957216	1	79	theme	spike	302:306	arg1	S					322:322	S	322:322	S	322:322	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	1	79	theme	spike	302:306	arg1	glycoprotein					308:319	its spike glycoprotein	298:319	its spike glycoprotein (S)	298:323	Severe Acute respiratory syndrome coronavirus (SARS-CoV-1) attaches to the host cell surface to initiate the interaction between the receptor-binding domain (RBD) of its spike glycoprotein (S) and the human Angiotensin-converting enzyme (hACE2) receptor.
34957216	3	80	theme	computational	508:520	arg1	mutagenesis					533:543	computational saturation mutagenesis	508:543	computational saturation mutagenesis of the S protein of SARS-CoV-1	508:574	Here, we per-formed computational saturation mutagenesis of the S protein of SARS-CoV-1 to identify the residues crucial for its functions.
34957216	9	81	theme	L472P	1383:1387	arg1	mutations					1370:1378	the mutations	1366:1378	the mutations of L472P and F360S	1366:1397	In addition, the mutations of L472P and F360S destabilized the 2003-2004 viral isolate.
34957216	10	82	theme	S	1550:1550	arg1	glycoprotein					1552:1563	the S glycoprotein	1546:1563	the S glycoprotein	1546:1563	We further predicted that many mutations on N-linked glycosylation sites would increase the stability of the S glycoprotein.
34957216	11	83	theme	vaccines	1642:1649	arg1	design					1618:1623	the design	1614:1623	the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2	1614:1683	Our results can be of therapeutic importance in the design of antivirals or vaccines against SARS-CoV-1 and SARS-CoV-2.
34957216	0	84	theme	Saturation	14:23	arg1	Mutagenesis					25:35	Computational Saturation Mutagenesis	0:35	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein	0:68	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.
34957216	9	85	theme	F360S	1393:1397	arg1	mutations					1370:1378	the mutations	1366:1378	the mutations of L472P and F360S	1366:1397	In addition, the mutations of L472P and F360S destabilized the 2003-2004 viral isolate.
34274643	9	0	used	used	1471:1474	arg2	methods					1434:1440	The separation and analysis methods	1406:1440	methods	1434:1440	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	6	1	theme	Con	962:964	arg1	A					966:966	Con A	962:966	Con A microcolumns	962:979	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	7	2	theme	N-linked	1200:1207	arg1	glycans					1209:1215	the N-linked glycans	1196:1215	the N-linked glycans	1196:1215	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	5	3	dep	non-retained	822:833	arg1	fractions					852:860	fractions	852:860	fractions	852:860	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	0	4	theme	Glycoprotein	0:11	arg1	analysis					13:20	Glycoprotein analysis	0:20	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis	0:76	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	1	5	theme	high-performance	205:220	arg1	microcolumns					231:242	high-performance affinity microcolumns	205:242	high-performance affinity microcolumns	205:242	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	9	6	theme	AGP	1509:1511	arg1	AGP					1509:1511	AGP	1509:1511	AGP	1509:1511	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	9	6	theme	AGP	1509:1511	arg1	amounts					1498:1504	relatively small amounts	1481:1504	relatively small amounts of AGP	1481:1511	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	2	7	theme	model	407:411	arg1	glycoprotein					374:385	Human alpha1-acid glycoprotein	356:385	Human alpha1-acid glycoprotein (AGP)	356:391	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	7	theme	model	407:411	arg1	analyte					413:419	a model analyte	405:419	a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids	405:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	9	8	theme	small	1492:1496	arg1	AGP					1509:1511	AGP	1509:1511	AGP	1509:1511	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	9	8	theme	small	1492:1496	arg1	amounts					1498:1504	relatively small amounts	1481:1504	relatively small amounts of AGP	1481:1511	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	2	9	theme	Human	356:360	arg1	AGP					388:390	AGP	388:390	AGP	388:390	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	9	theme	Human	356:360	arg1	glycoprotein					374:385	Human alpha1-acid glycoprotein	356:385	Human alpha1-acid glycoprotein (AGP)	356:391	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	9	theme	Human	356:360	arg1	analyte					413:419	a model analyte	405:419	a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids	405:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	1	10	theme	capillary	248:256	arg1	electrophoresis					258:272	capillary electrophoresis	248:272	capillary electrophoresis	248:272	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	8	11	theme	Sialic	1287:1292	arg1	residues					1299:1306	Sialic acid residues	1287:1306	Sialic acid residues	1287:1306	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	3	12	dep	lectins	636:642	arg1	A					657:657	concanavalin A	644:657	concanavalin A (Con A)	644:665	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	12	dep	lectins	636:642	arg1	lectin					687:692	Aleuria aurantia lectin	670:692	Aleuria aurantia lectin (AAL)	670:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	12	dep	lectins	636:642	arg1	A					664:664	Con A	660:664	Con A	660:664	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	12	dep	lectins	636:642	arg1	lectins					636:642	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	12	dep	lectins	636:642	arg1	AAL					695:697	AAL	695:697	AAL	695:697	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	7	13	from	present	1271:1277	arg1	AGP					1282:1284	AGP	1282:1284	AGP	1282:1284	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	8	14	theme	branching	1350:1358	arg1	residues					1376:1383	branching and more fucose residues	1350:1383	branching and more fucose residues	1350:1383	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	4	15	with	combination	753:763	arg1	electrophoresis					780:794	capillary electrophoresis	770:794	capillary electrophoresis	770:794	These microcolumns were used with one another or in combination with capillary electrophoresis.
34274643	7	16	from	AGP	1282:1284	arg1	present					1271:1277	present	1271:1277	present	1271:1277	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	16	from	AGP	1282:1284	arg1	degree					1247:1252	a high degree	1240:1252	a high degree of branching	1240:1265	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	0	17	dep	Characterization	79:94	arg1	analysis					13:20	Glycoprotein analysis	0:20	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis	0:76	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	8	18	attach	present	1390:1396	arg2	degrees					1339:1345	higher degrees	1332:1345	higher degrees of branching and more fucose residues	1332:1383	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	8	18	attach	present	1390:1396	arg1	AGP					1401:1403	AGP	1401:1403	AGP	1401:1403	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	9	19	theme	other	1545:1549	arg1	glycoproteins					1558:1570	other intact glycoproteins	1545:1570	other intact glycoproteins	1545:1570	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	2	20	theme	sialic	542:547	arg1	acids					549:553	sialic acids	542:553	sialic acids	542:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	8	21	theme	residues	1376:1383	arg1	degrees					1339:1345	higher degrees	1332:1345	higher degrees of branching and more fucose residues	1332:1383	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	3	22	theme	Con	660:662	arg1	A					657:657	concanavalin A	644:657	concanavalin A (Con A)	644:665	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	22	theme	Con	660:662	arg1	A					664:664	Con A	660:664	Con A	660:664	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	5	23	theme	electrospray	919:930	arg1	spectrometry					948:959	nanoflow electrospray ionization mass spectrometry	910:959	nanoflow electrospray ionization mass spectrometry	910:959	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	2	24	theme	number	532:537	arg1	degree					493:498	its degree	489:498	its degree of branching, fucosylation, and number of sialic acids	489:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	1	25	theme	2.1 mm	193:198	arg1	I.D.					200:203	2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis	193:272	I.D.	200:203	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	0	26	theme	glycoprotein	111:122	arg1	Characterization					79:94	Characterization	79:94	Characterization of alpha1-acid glycoprotein by combined separation methods	79:153	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	2	27	theme	heterogeneous	432:444	arg1	glycosylation					446:458	its heterogeneous glycosylation	428:458	its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids	428:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	0	28	theme	combined	127:134	arg1	methods					147:153	combined separation methods	127:153	combined separation methods	127:153	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	8	29	from	present	1390:1396	arg1	AGP					1401:1403	AGP	1401:1403	AGP	1401:1403	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	6	30	contain	contained	1023:1031	arg1	AGP					1014:1016	AGP	1014:1016	AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans	1014:1124	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	6	30	contain	contained	1023:1031	arg2	N-glycans					1046:1054	bi-antennary N-glycans	1033:1054	bi-antennary N-glycans	1033:1054	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	5	31	theme	AGP	848:850	arg1	analysis					806:813	N-Glycan analysis	797:813	N-Glycan analysis of the non-retained and retained AGP fractions	797:860	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	7	32	from	methods	1157:1163	arg1	Results					1127:1133	Results	1127:1133	Results from these separation methods	1127:1163	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	2	33	used	used	397:400	arg2	analyte					413:419	a model analyte	405:419	a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids	405:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	33	used	used	397:400	arg2	AGP					388:390	AGP	388:390	AGP	388:390	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	33	used	used	397:400	arg2	glycoprotein					374:385	Human alpha1-acid glycoprotein	356:385	Human alpha1-acid glycoprotein (AGP)	356:391	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	4	34	theme	capillary	770:778	arg1	electrophoresis					780:794	capillary electrophoresis	770:794	capillary electrophoresis	770:794	These microcolumns were used with one another or in combination with capillary electrophoresis.
34274643	1	35	theme	glycoprotein	342:353	arg1	glycoforms					318:327	the glycoforms	314:327	the glycoforms of an intact glycoprotein	314:353	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	6	36	theme	fucose-containing	1098:1114	arg1	N-glycans					1116:1124	fucose-containing N-glycans	1098:1124	fucose-containing N-glycans	1098:1124	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	5	37	theme	PNGase	887:892	arg1	digestion					896:904	PNGase F digestion	887:904	PNGase F digestion	887:904	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	9	38	theme	separation	1410:1419	arg1	methods					1434:1440	The separation and analysis methods	1406:1440	methods	1434:1440	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	3	39	theme	Aleuria	670:676	arg1	AAL					695:697	AAL	695:697	AAL	695:697	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	39	theme	Aleuria	670:676	arg1	lectin					687:692	Aleuria aurantia lectin	670:692	Aleuria aurantia lectin (AAL)	670:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	39	theme	Aleuria	670:676	arg1	lectins					636:642	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	1	40	dep	I.D.	200:203	arg1	microcolumns					231:242	high-performance affinity microcolumns	205:242	high-performance affinity microcolumns	205:242	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	0	41	theme	capillary	52:60	arg1	electrophoresis					62:76	capillary electrophoresis	52:76	capillary electrophoresis	52:76	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	9	42	theme	analysis	1425:1432	arg1	methods					1434:1440	The separation and analysis methods	1406:1440	methods	1434:1440	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	8	43	located	present	1390:1396	arg2	degrees					1339:1345	higher degrees	1332:1345	higher degrees of branching and more fucose residues	1332:1383	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	8	43	located	present	1390:1396	arg1	AGP					1401:1403	AGP	1401:1403	AGP	1401:1403	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	2	44	gly	glycoprotein	374:385	arg1	AGP					388:390	AGP	388:390	AGP	388:390	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	44	gly	glycoprotein	374:385	arg1	glycoprotein					374:385	Human alpha1-acid glycoprotein	356:385	Human alpha1-acid glycoprotein (AGP)	356:391	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	44	gly	glycoprotein	374:385	arg1	analyte					413:419	a model analyte	405:419	a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids	405:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	7	45	link	N-linked	1200:1207	arg1	glycans					1209:1215	the N-linked glycans	1196:1215	the N-linked glycans	1196:1215	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	5	46	theme	F	894:894	arg1	digestion					896:904	PNGase F digestion	887:904	PNGase F digestion	887:904	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	7	47	theme	glycans	1209:1215	arg1	fucosylation					1180:1191	fucosylation	1180:1191	fucosylation of the N-linked glycans	1180:1215	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	6	48	theme	A	966:966	arg1	microcolumns					968:979	Con A microcolumns	962:979	Con A microcolumns	962:979	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	2	49	from	variations	475:484	arg1	degree					493:498	its degree	489:498	its degree of branching, fucosylation, and number of sialic acids	489:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	5	50	theme	N-Glycan	797:804	arg1	analysis					806:813	N-Glycan analysis	797:813	N-Glycan analysis of the non-retained and retained AGP fractions	797:860	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	1	51	theme	I.D.	200:203	arg1	combinations					177:188	combinations	177:188	combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis	177:272	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	8	52	theme	acid	1294:1297	arg1	residues					1299:1306	Sialic acid residues	1287:1306	Sialic acid residues	1287:1306	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	7	53	theme	separation	1146:1155	arg1	methods					1157:1163	these separation methods	1140:1163	these separation methods	1140:1163	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	1	54	theme	affinity	222:229	arg1	microcolumns					231:242	high-performance affinity microcolumns	205:242	high-performance affinity microcolumns	205:242	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	2	55	theme	alpha1-acid	362:372	arg1	AGP					388:390	AGP	388:390	AGP	388:390	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	55	theme	alpha1-acid	362:372	arg1	glycoprotein					374:385	Human alpha1-acid glycoprotein	356:385	Human alpha1-acid glycoprotein (AGP)	356:391	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	55	theme	alpha1-acid	362:372	arg1	analyte					413:419	a model analyte	405:419	a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids	405:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	5	56	theme	mass	943:946	arg1	spectrometry					948:959	nanoflow electrospray ionization mass spectrometry	910:959	nanoflow electrospray ionization mass spectrometry	910:959	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	3	57	theme	concanavalin	644:655	arg1	A					657:657	concanavalin A	644:657	concanavalin A (Con A)	644:665	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	57	theme	concanavalin	644:655	arg1	A					664:664	Con A	660:664	Con A	660:664	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	57	theme	concanavalin	644:655	arg1	lectins					636:642	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	1	58	theme	electrophoresis	258:272	arg1	combinations					177:188	combinations	177:188	combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis	177:272	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	7	59	attach	present	1271:1277	arg2	degree					1247:1252	a high degree	1240:1252	a high degree of branching	1240:1265	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	59	attach	present	1271:1277	arg1	AGP					1282:1284	AGP	1282:1284	AGP	1282:1284	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	59	attach	present	1271:1277	arg2	present					1271:1277	present	1271:1277	present	1271:1277	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	60	gly	fucosylation	1180:1191	arg1	glycans					1209:1215	the N-linked glycans	1196:1215	the N-linked glycans	1196:1215	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	1	61	used	used	293:296	arg2	Separations					156:166	Separations	156:166	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis	156:272	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	1	62	gly	glycoprotein	342:353	arg1	glycoprotein					342:353	an intact glycoprotein	332:353	an intact glycoprotein	332:353	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	9	63	theme	intact	1551:1556	arg1	glycoproteins					1558:1570	other intact glycoproteins	1545:1570	other intact glycoproteins	1545:1570	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	5	64	theme	nanoflow	910:917	arg1	spectrometry					948:959	nanoflow electrospray ionization mass spectrometry	910:959	nanoflow electrospray ionization mass spectrometry	910:959	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	6	65	theme	AAL	1063:1065	arg1	microcolumns					1067:1078	AAL microcolumns	1063:1078	AAL microcolumns	1063:1078	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	8	66	theme	fucose	1369:1374	arg1	residues					1376:1383	branching and more fucose residues	1350:1383	branching and more fucose residues	1350:1383	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	0	67	theme	alpha1-acid	99:109	arg1	glycoprotein					111:122	alpha1-acid glycoprotein	99:122	alpha1-acid glycoprotein	99:122	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	5	68	theme	ionization	932:941	arg1	spectrometry					948:959	nanoflow electrospray ionization mass spectrometry	910:959	nanoflow electrospray ionization mass spectrometry	910:959	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	6	69	theme	bi-antennary	1033:1044	arg1	N-glycans					1046:1054	bi-antennary N-glycans	1033:1054	bi-antennary N-glycans	1033:1054	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	9	70	gly	glycoproteins	1558:1570	arg1	glycoproteins					1558:1570	other intact glycoproteins	1545:1570	other intact glycoproteins	1545:1570	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	0	71	theme	separation	136:145	arg1	methods					147:153	combined separation methods	127:153	combined separation methods	127:153	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	2	72	theme	acids	549:553	arg1	fucosylation					514:525	fucosylation	514:525	fucosylation	514:525	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	72	theme	acids	549:553	arg1	number					532:537	number	532:537	number	532:537	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	72	theme	acids	549:553	arg1	branching					503:511	branching	503:511	branching	503:511	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	5	73	theme	retained	839:846	arg1	AGP					848:850	retained AGP	839:850	retained AGP	839:850	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	4	74	used	used	725:728	arg2	microcolumns					707:718	These microcolumns	701:718	These microcolumns	701:718	These microcolumns were used with one another or in combination with capillary electrophoresis.
34274643	0	75	gly	glycoprotein	111:122	arg1	glycoprotein					111:122	alpha1-acid glycoprotein	99:122	alpha1-acid glycoprotein	99:122	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	9	76	with	use	1536:1538	arg1	glycoproteins					1558:1570	other intact glycoproteins	1545:1570	other intact glycoproteins	1545:1570	The separation and analysis methods that were developed could be used with relatively small amounts of AGP and can be adapted for use with other intact glycoproteins.
34274643	0	77	theme	lectin	28:33	arg1	microcolumns					35:46	lectin microcolumns	28:46	lectin microcolumns	28:46	Glycoprotein analysis using lectin microcolumns and capillary electrophoresis: Characterization of alpha1-acid glycoprotein by combined separation methods.
34274643	1	78	theme	intact	335:340	arg1	glycoprotein					342:353	an intact glycoprotein	332:353	an intact glycoprotein	332:353	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	1	79	gly	glycoforms	318:327	arg1	glycoprotein					342:353	an intact glycoprotein	332:353	an intact glycoprotein	332:353	Separations based on combinations of 2.1 mm I.D. high-performance affinity microcolumns and capillary electrophoresis were developed and used to characterize the glycoforms of an intact glycoprotein.
34274643	4	80	dep	one	735:737	arg1	another					739:745	another	739:745	another	739:745	These microcolumns were used with one another or in combination with capillary electrophoresis.
34274643	3	81	contain	contained	622:630	arg1	microcolumns					604:615	microcolumns	604:615	microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	604:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	81	contain	contained	622:630	arg2	lectin					687:692	Aleuria aurantia lectin	670:692	Aleuria aurantia lectin (AAL)	670:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	81	contain	contained	622:630	arg2	A					657:657	concanavalin A	644:657	concanavalin A (Con A)	644:665	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	81	contain	contained	622:630	arg2	lectins					636:642	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	82	theme	aurantia	678:685	arg1	AAL					695:697	AAL	695:697	AAL	695:697	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	82	theme	aurantia	678:685	arg1	lectin					687:692	Aleuria aurantia lectin	670:692	Aleuria aurantia lectin (AAL)	670:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	3	82	theme	aurantia	678:685	arg1	lectins					636:642	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL)	632:698	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	2	83	gly	fucosylation	514:525	arg1	acids					549:553	sialic acids	542:553	sialic acids	542:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	2	84	theme	fucosylation	514:525	arg1	degree					493:498	its degree	489:498	its degree of branching, fucosylation, and number of sialic acids	489:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	7	85	located	present	1271:1277	arg2	degree					1247:1252	a high degree	1240:1252	a high degree of branching	1240:1265	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	85	located	present	1271:1277	arg1	AGP					1282:1284	AGP	1282:1284	AGP	1282:1284	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	85	located	present	1271:1277	arg2	present					1271:1277	present	1271:1277	present	1271:1277	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	86	theme	branching	1257:1265	arg1	present					1271:1277	present	1271:1277	present	1271:1277	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	86	theme	branching	1257:1265	arg1	degree					1247:1252	a high degree	1240:1252	a high degree of branching	1240:1265	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	5	87	theme	non-retained	822:833	arg1	analysis					806:813	N-Glycan analysis	797:813	N-Glycan analysis of the non-retained and retained AGP fractions	797:860	N-Glycan analysis of the non-retained and retained AGP fractions was carried out by using PNGase F digestion and nanoflow electrospray ionization mass spectrometry.
34274643	2	88	theme	branching	503:511	arg1	degree					493:498	its degree	489:498	its degree of branching, fucosylation, and number of sialic acids	489:553	Human alpha1-acid glycoprotein (AGP) was used as a model analyte due to its heterogeneous glycosylation resulting from variations in its degree of branching, fucosylation, and number of sialic acids.
34274643	6	89	with	AGP	1089:1091	arg1	N-glycans					1116:1124	fucose-containing N-glycans	1098:1124	fucose-containing N-glycans	1098:1124	Con A microcolumns were found to selectively enrich AGP that contained bi-antennary N-glycans, while AAL microcolumns retained AGP with fucose-containing N-glycans.
34274643	3	90	theme	separation	562:571	arg1	formats					573:579	Three separation formats	556:579	Three separation formats	556:579	Three separation formats were examined based on microcolumns that contained the lectins concanavalin A (Con A) or Aleuria aurantia lectin (AAL).
34274643	8	91	from	AGP	1401:1403	arg1	present					1390:1396	present	1390:1396	present	1390:1396	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	8	92	theme	higher	1332:1337	arg1	degrees					1339:1345	higher degrees	1332:1345	higher degrees of branching and more fucose residues	1332:1383	Sialic acid residues were more abundant when higher degrees of branching and more fucose residues were present in AGP.
34274643	7	93	theme	high	1242:1245	arg1	present					1271:1277	present	1271:1277	present	1271:1277	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274643	7	93	theme	high	1242:1245	arg1	degree					1247:1252	a high degree	1240:1252	a high degree of branching	1240:1265	Results from these separation methods indicated that fucosylation of the N-linked glycans was more abundant when a high degree of branching was present in AGP.
34274480	4	0	theme	porcine	577:583	arg1	genes					590:594	the four porcine CBLN genes	568:594	the four porcine CBLN genes	568:594	In this study, I present a molecular characterization of the four porcine CBLN genes.
34274480	12	1	contain	contain	1521:1527	arg1	ends					1479:1482	The amino terminal ends	1460:1482	The amino terminal ends of both the CBLN1 and CBLN3 proteins	1460:1519	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	12	1	contain	contain	1521:1527	arg2	sites					1567:1571	three possible N-linked glycosylation sites	1529:1571	three possible N-linked glycosylation sites	1529:1571	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	9	2	theme	residues	1132:1139	arg1	sequence					1117:1124	a putative signal sequence	1099:1124	a putative signal sequence of 21 residues, two conserved cysteine residues,	1099:1173	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	2	theme	residues	1132:1139	arg1	residues					1132:1139	21 residues	1129:1139	21 residues	1129:1139	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	2	theme	residues	1132:1139	arg1	domain					1183:1188	C1q domain	1179:1188	C1q domain	1179:1188	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	7	3	theme	open	874:877	arg1	frame					887:891	an open reading frame	871:891	an open reading frame of 582 nucleotides	871:910	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	8	4	theme	deduced	958:964	arg1	acid					972:975	The deduced amino acid	954:975	The deduced amino acid of the porcine CBLN1 protein	954:1004	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	8	4	theme	deduced	958:964	arg1	identical					1014:1022	identical	1014:1022	identical	1014:1022	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	4	5	theme	genes	590:594	arg1	characterization					548:563	a molecular characterization	536:563	a molecular characterization of the four porcine CBLN genes	536:594	In this study, I present a molecular characterization of the four porcine CBLN genes.
34274480	11	6	theme	acid	1350:1353	arg1	sequence					1355:1362	The deduced amino acid sequence	1332:1362	The deduced amino acid sequence of the porcine CBLN3 protein	1332:1391	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	11	6	theme	acid	1350:1353	arg1	identical					1401:1409	identical	1401:1409	identical	1401:1409	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	10	7	theme	amino	1319:1323	arg1	acids					1325:1329	205 amino acids	1315:1329	205 amino acids	1315:1329	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	11	8	theme	deduced	1336:1342	arg1	sequence					1355:1362	The deduced amino acid sequence	1332:1362	The deduced amino acid sequence of the porcine CBLN3 protein	1332:1391	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	11	8	theme	deduced	1336:1342	arg1	identical					1401:1409	identical	1401:1409	identical	1401:1409	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	9	9	theme	cysteine	1156:1163	arg1	residues					1165:1172	two conserved cysteine residues	1142:1172	two conserved cysteine residues	1142:1172	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	9	theme	cysteine	1156:1163	arg1	residues					1132:1139	21 residues	1129:1139	21 residues	1129:1139	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	2	10	theme	cell	233:236	arg1	synapses					238:245	the parallel fiber-Purkinje cell synapses	205:245	the parallel fiber-Purkinje cell synapses	205:245	Cerebellin-1 (CBLN1) is active in synapse formation and functions at the parallel fiber-Purkinje cell synapses.
34274480	7	11	theme	CBLN1	850:854	arg1	clone					856:860	the CBLN1 clone	846:860	the CBLN1 clone	846:860	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	15	12	theme	precerebellin	1831:1843	arg1	genes					1845:1849	the porcine precerebellin genes	1819:1849	the porcine precerebellin genes	1819:1849	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	12	13	theme	CBLN1	1496:1500	arg1	proteins					1512:1519	both the CBLN1 and CBLN3 proteins	1487:1519	proteins	1512:1519	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	8	14	theme	CBLN1	992:996	arg1	protein					998:1004	the porcine CBLN1 protein	980:1004	the porcine CBLN1 protein	980:1004	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	11	15	theme	human	1447:1451	arg1	CBLN3					1453:1457	human CBLN3	1447:1457	human CBLN3	1447:1457	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	1	16	theme	C1qTNF	73:78	arg1	proteins					80:87	C1qTNF proteins	73:87	C1qTNF proteins	73:87	Cerebellins (CBLN1-4), together with C1qTNF proteins, belong to the CBLN subfamily of C1q proteins.
34274480	9	17	theme	C1q	1179:1181	arg1	residues					1132:1139	21 residues	1129:1139	21 residues	1129:1139	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	17	theme	C1q	1179:1181	arg1	domain					1183:1188	C1q domain	1179:1188	C1q domain	1179:1188	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	7	18	theme	nucleotide	823:832	arg1	sequence					834:841	The nucleotide sequence	819:841	The nucleotide sequence of the CBLN1 clone	819:860	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	7	18	theme	nucleotide	823:832	arg1	protein					926:932	a protein	924:932	a protein of 193 amino acids	924:951	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	12	19	theme	CBLN3	1506:1510	arg1	proteins					1512:1519	both the CBLN1 and CBLN3 proteins	1487:1519	proteins	1512:1519	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	3	20	with	proteins	336:343	arg1	neurexins					291:299	neurexins	291:299	neurexins	291:299	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	5	21	theme	CBLN1-4	725:731	arg1	localization					693:704	chromosomal localization	681:704	chromosomal localization	681:704	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	5	21	theme	CBLN1-4	725:731	arg1	expression					711:720	expression	711:720	expression	711:720	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	5	21	theme	CBLN1-4	725:731	arg1	structure					670:678	gene structure	665:678	gene structure	665:678	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	5	22	theme	chromosomal	681:691	arg1	localization					693:704	chromosomal localization	681:704	chromosomal localization	681:704	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	2	23	theme	synapse	170:176	arg1	formation					178:186	synapse formation	170:186	synapse formation	170:186	Cerebellin-1 (CBLN1) is active in synapse formation and functions at the parallel fiber-Purkinje cell synapses.
34274480	11	24	theme	mouse	1414:1418	arg1	CBLN3					1420:1424	mouse CBLN3	1414:1424	mouse CBLN3	1414:1424	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	2	25	theme	parallel	209:216	arg1	synapses					238:245	the parallel fiber-Purkinje cell synapses	205:245	the parallel fiber-Purkinje cell synapses	205:245	Cerebellin-1 (CBLN1) is active in synapse formation and functions at the parallel fiber-Purkinje cell synapses.
34274480	1	26	theme	CBLN	104:107	arg1	subfamily					109:117	the CBLN subfamily	100:117	the CBLN subfamily of C1q proteins	100:133	Cerebellins (CBLN1-4), together with C1qTNF proteins, belong to the CBLN subfamily of C1q proteins.
34274480	15	27	theme	GenBank	2053:2059	arg1	cDNA					2047:2050	CBLN3 cDNA	2041:2050	CBLN3 cDNA (GenBank ID: EF577505)	2041:2073	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	27	theme	GenBank	2053:2059	arg1	ID					2061:2062	GenBank ID: EF577505	2053:2072	GenBank ID: EF577505	2053:2072	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	12	28	theme	amino	1464:1468	arg1	ends					1479:1482	The amino terminal ends	1460:1482	The amino terminal ends of both the CBLN1 and CBLN3 proteins	1460:1519	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	15	29	theme	GenBank	2091:2097	arg1	cDNA					2085:2088	CBLN4 cDNA	2079:2088	CBLN4 cDNA (GenBank ID: FJ196070)	2079:2111	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	29	theme	GenBank	2091:2097	arg1	ID					2099:2100	GenBank ID: FJ196070	2091:2110	GenBank ID: FJ196070	2091:2110	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	13	30	theme	porcine	1607:1613	arg1	CBLN1					1615:1619	porcine CBLN1	1607:1619	porcine CBLN1	1607:1619	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	1	31	theme	proteins	126:133	arg1	subfamily					109:117	the CBLN subfamily	100:117	the CBLN subfamily of C1q proteins	100:133	Cerebellins (CBLN1-4), together with C1qTNF proteins, belong to the CBLN subfamily of C1q proteins.
34274480	10	32	theme	nucleotide	1195:1204	arg1	sequence					1206:1213	The nucleotide sequence	1191:1213	The nucleotide sequence of the CBLN3 cDNA clone	1191:1237	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	10	32	theme	nucleotide	1195:1204	arg1	protein					1304:1310	a protein	1302:1310	a protein of 205 amino acids	1302:1329	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	7	33	theme	amino	941:945	arg1	acids					947:951	193 amino acids	937:951	193 amino acids	937:951	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	10	34	theme	open	1252:1255	arg1	frame					1265:1269	an open reading frame	1249:1269	an open reading frame of 618 nucleotides	1249:1288	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	2	35	from	formation	178:186	arg1	active					160:165	active	160:165	active	160:165	Cerebellin-1 (CBLN1) is active in synapse formation and functions at the parallel fiber-Purkinje cell synapses.
34274480	13	36	theme	genomic	1578:1584	arg1	similar					1639:1645	similar	1639:1645	similar	1639:1645	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	13	36	theme	genomic	1578:1584	arg1	organization					1586:1597	The genomic organization	1574:1597	The genomic organization of both porcine CBLN1 and CBLN3	1574:1629	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	10	37	theme	clone	1233:1237	arg1	sequence					1206:1213	The nucleotide sequence	1191:1213	The nucleotide sequence of the CBLN3 cDNA clone	1191:1237	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	10	37	theme	clone	1233:1237	arg1	protein					1304:1310	a protein	1302:1310	a protein of 205 amino acids	1302:1329	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	15	38	theme	genes	1845:1849	arg1	cDNAs					1855:1859	cDNAs	1855:1859	cDNAs	1855:1859	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	38	theme	genes	1845:1849	arg1	sequences					1806:1814	The sequences	1802:1814	The sequences of the porcine precerebellin genes	1802:1849	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	10	39	theme	CBLN3	1222:1226	arg1	clone					1233:1237	the CBLN3 cDNA clone	1218:1237	the CBLN3 cDNA clone	1218:1237	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	14	40	theme	CBLN1	1727:1731	arg1	transcripts					1743:1753	CBLN1 and CBLN3 transcripts	1727:1753	CBLN1 and CBLN3 transcripts	1727:1753	The expression analyses demonstrated that CBLN1 and CBLN3 transcripts are predominantly expressed in the cerebellum.
34274480	8	41	theme	mouse	1032:1036	arg1	CBLN1					1038:1042	both mouse CBLN1	1027:1042	both mouse CBLN1	1027:1042	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	5	42	theme	in	619:620	arg1	analyses					629:636	in silico analyses	619:636	in silico analyses	619:636	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	4	43	theme	molecular	538:546	arg1	characterization					548:563	a molecular characterization	536:563	a molecular characterization of the four porcine CBLN genes	536:594	In this study, I present a molecular characterization of the four porcine CBLN genes.
34274480	12	44	gly	glycosylation	1553:1565	arg2	sites					1567:1571	three possible N-linked glycosylation sites	1529:1571	three possible N-linked glycosylation sites	1529:1571	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	12	44	gly	glycosylation	1553:1565	arg2	three					1529:1533	three	1529:1533	three	1529:1533	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	10	45	theme	reading	1257:1263	arg1	frame					1265:1269	an open reading frame	1249:1269	an open reading frame of 618 nucleotides	1249:1288	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	0	46	theme	cerebellin	12:21	arg1	family					28:33	The porcine cerebellin gene family	0:33	The porcine cerebellin gene family	0:33	The porcine cerebellin gene family.
34274480	9	47	contain	contains	1090:1097	arg2	residues					1132:1139	21 residues	1129:1139	21 residues	1129:1139	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	47	contain	contains	1090:1097	arg1	protein					1082:1088	The deduced CBLN1 protein	1064:1088	The deduced CBLN1 protein	1064:1088	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	47	contain	contains	1090:1097	arg2	sequence					1117:1124	a putative signal sequence	1099:1124	a putative signal sequence of 21 residues, two conserved cysteine residues,	1099:1173	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	47	contain	contains	1090:1097	arg2	domain					1183:1188	C1q domain	1179:1188	C1q domain	1179:1188	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	48	theme	CBLN1	1076:1080	arg1	protein					1082:1088	The deduced CBLN1 protein	1064:1088	The deduced CBLN1 protein	1064:1088	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	12	49	theme	N-linked	1544:1551	arg1	sites					1567:1571	three possible N-linked glycosylation sites	1529:1571	three possible N-linked glycosylation sites	1529:1571	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	3	50	theme	cell-adhesion	395:407	arg1	role					372:375	a role	370:375	a role	370:375	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	50	theme	cell-adhesion	395:407	arg1	molecules					409:417	trans-synaptic cell-adhesion molecules	380:417	trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development	380:508	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	11	51	theme	protein	1385:1391	arg1	sequence					1355:1362	The deduced amino acid sequence	1332:1362	The deduced amino acid sequence of the porcine CBLN3 protein	1332:1391	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	11	51	theme	protein	1385:1391	arg1	identical					1401:1409	identical	1401:1409	identical	1401:1409	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	14	52	theme	expression	1689:1698	arg1	analyses					1700:1707	The expression analyses	1685:1707	The expression analyses	1685:1707	The expression analyses demonstrated that CBLN1 and CBLN3 transcripts are predominantly expressed in the cerebellum.
34274480	8	53	theme	human	1051:1055	arg1	CBLN1					1057:1061	human CBLN1	1051:1061	human CBLN1	1051:1061	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	15	54	theme	CBLN3	2006:2010	arg1	gene					2012:2015	CBLN3 gene	2006:2015	CBLN3 gene (GenBank ID: FJ621566)	2006:2038	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	54	theme	CBLN3	2006:2010	arg1	ID					2026:2027	GenBank ID: FJ621566	2018:2037	GenBank ID: FJ621566	2018:2037	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	5	55	dep	in	619:620	arg1	silico					622:627	silico	622:627	silico	622:627	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	3	56	dep	proteins	336:343	arg1	GluD1					345:349	GluD1	345:349	GluD1	345:349	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	56	dep	proteins	336:343	arg1	proteins					336:343	the glutamate-receptor-related proteins	305:343	the glutamate-receptor-related proteins GluD1 and GluD2	305:359	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	56	dep	proteins	336:343	arg1	GluD2					355:359	GluD2	355:359	GluD2	355:359	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	10	57	theme	nucleotides	1278:1288	arg1	frame					1265:1269	an open reading frame	1249:1269	an open reading frame of 618 nucleotides	1249:1288	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	3	58	theme	brain	492:496	arg1	development					498:508	brain development	492:508	brain development	492:508	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	9	59	theme	putative	1101:1108	arg1	sequence					1117:1124	a putative signal sequence	1099:1124	a putative signal sequence of 21 residues, two conserved cysteine residues,	1099:1173	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	15	60	theme	ID	1956:1957	arg1	FJ621565					1960:1967	GenBank ID: FJ621565	1948:1967	GenBank ID: FJ621565	1948:1967	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	60	theme	ID	1956:1957	arg1	gene					1942:1945	CBLN1 gene	1936:1945	CBLN1 gene (GenBank ID: FJ621565)	1936:1968	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	7	61	theme	nucleotides	900:910	arg1	frame					887:891	an open reading frame	871:891	an open reading frame of 582 nucleotides	871:910	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	15	62	theme	GenBank	1983:1989	arg1	ID					1991:1992	GenBank ID: EF577504	1983:2002	GenBank ID: EF577504	1983:2002	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	62	theme	GenBank	1983:1989	arg1	cDNA					1977:1980	CBLN1 cDNA	1971:1980	CBLN1 cDNA (GenBank ID: EF577504)	1971:2003	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	6	63	dep	cerebellins	757:767	arg1	cerebellins					757:767	the cerebellins CBLN1 and CBLN3	753:783	the cerebellins CBLN1 and CBLN3	753:783	Two cDNAs encoding the cerebellins CBLN1 and CBLN3 were RT-PCR cloned and sequenced.
34274480	6	63	dep	cerebellins	757:767	arg1	CBLN3					779:783	CBLN3	779:783	CBLN3	779:783	Two cDNAs encoding the cerebellins CBLN1 and CBLN3 were RT-PCR cloned and sequenced.
34274480	6	63	dep	cerebellins	757:767	arg1	CBLN1					769:773	CBLN1	769:773	CBLN1	769:773	Two cDNAs encoding the cerebellins CBLN1 and CBLN3 were RT-PCR cloned and sequenced.
34274480	15	64	theme	accession	1917:1925	arg1	numbers					1927:1933	the following accession numbers	1903:1933	the following accession numbers	1903:1933	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	8	65	theme	amino	966:970	arg1	acid					972:975	The deduced amino acid	954:975	The deduced amino acid of the porcine CBLN1 protein	954:1004	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	8	65	theme	amino	966:970	arg1	identical					1014:1022	identical	1014:1022	identical	1014:1022	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	11	66	theme	amino	1344:1348	arg1	sequence					1355:1362	The deduced amino acid sequence	1332:1362	The deduced amino acid sequence of the porcine CBLN3 protein	1332:1391	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	11	66	theme	amino	1344:1348	arg1	identical					1401:1409	identical	1401:1409	identical	1401:1409	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	5	67	theme	gene	665:668	arg1	structure					670:678	gene structure	665:678	gene structure	665:678	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	10	68	theme	acids	1325:1329	arg1	sequence					1206:1213	The nucleotide sequence	1191:1213	The nucleotide sequence of the CBLN3 cDNA clone	1191:1237	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	10	68	theme	acids	1325:1329	arg1	protein					1304:1310	a protein	1302:1310	a protein of 205 amino acids	1302:1329	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	7	69	theme	reading	879:885	arg1	frame					887:891	an open reading frame	871:891	an open reading frame of 582 nucleotides	871:910	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	14	70	theme	CBLN3	1737:1741	arg1	transcripts					1743:1753	CBLN1 and CBLN3 transcripts	1727:1753	CBLN1 and CBLN3 transcripts	1727:1753	The expression analyses demonstrated that CBLN1 and CBLN3 transcripts are predominantly expressed in the cerebellum.
34274480	4	71	theme	CBLN	585:588	arg1	genes					590:594	the four porcine CBLN genes	568:594	the four porcine CBLN genes	568:594	In this study, I present a molecular characterization of the four porcine CBLN genes.
34274480	12	72	link	N-linked	1544:1551	arg1	sites					1567:1571	three possible N-linked glycosylation sites	1529:1571	three possible N-linked glycosylation sites	1529:1571	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	9	73	theme	conserved	1146:1154	arg1	residues					1165:1172	two conserved cysteine residues	1142:1172	two conserved cysteine residues	1142:1172	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	9	73	theme	conserved	1146:1154	arg1	residues					1132:1139	21 residues	1129:1139	21 residues	1129:1139	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	2	74	from	active	160:165	arg1	formation					178:186	synapse formation	170:186	synapse formation	170:186	Cerebellin-1 (CBLN1) is active in synapse formation and functions at the parallel fiber-Purkinje cell synapses.
34274480	8	75	theme	porcine	984:990	arg1	protein					998:1004	the porcine CBLN1 protein	980:1004	the porcine CBLN1 protein	980:1004	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	6	76	dep	cloned	797:802	arg1	RT-PCR					790:795	RT-PCR	790:795	RT-PCR	790:795	Two cDNAs encoding the cerebellins CBLN1 and CBLN3 were RT-PCR cloned and sequenced.
34274480	15	77	theme	porcine	1823:1829	arg1	genes					1845:1849	the porcine precerebellin genes	1819:1849	the porcine precerebellin genes	1819:1849	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	7	78	theme	clone	856:860	arg1	sequence					834:841	The nucleotide sequence	819:841	The nucleotide sequence of the CBLN1 clone	819:860	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	7	78	theme	clone	856:860	arg1	protein					926:932	a protein	924:932	a protein of 193 amino acids	924:951	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	8	79	theme	protein	998:1004	arg1	acid					972:975	The deduced amino acid	954:975	The deduced amino acid of the porcine CBLN1 protein	954:1004	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	8	79	theme	protein	998:1004	arg1	identical					1014:1022	identical	1014:1022	identical	1014:1022	The deduced amino acid of the porcine CBLN1 protein was 99% identical to both mouse CBLN1 and to human CBLN1.
34274480	4	80	attach	present	528:534	arg2	I					526:526	I	526:526	I	526:526	In this study, I present a molecular characterization of the four porcine CBLN genes.
34274480	4	80	attach	present	528:534	arg1	study					519:523	this study	514:523	this study	514:523	In this study, I present a molecular characterization of the four porcine CBLN genes.
34274480	15	81	theme	GenBank	2018:2024	arg1	gene					2012:2015	CBLN3 gene	2006:2015	CBLN3 gene (GenBank ID: FJ621566)	2006:2038	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	81	theme	GenBank	2018:2024	arg1	ID					2026:2027	GenBank ID: FJ621566	2018:2037	GenBank ID: FJ621566	2018:2037	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	12	82	theme	proteins	1512:1519	arg1	ends					1479:1482	The amino terminal ends	1460:1482	The amino terminal ends of both the CBLN1 and CBLN3 proteins	1460:1519	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	1	83	dep	together	59:66	arg1	with					68:71	with	68:71	with	68:71	Cerebellins (CBLN1-4), together with C1qTNF proteins, belong to the CBLN subfamily of C1q proteins.
34274480	2	84	theme	fiber-Purkinje	218:231	arg1	synapses					238:245	the parallel fiber-Purkinje cell synapses	205:245	the parallel fiber-Purkinje cell synapses	205:245	Cerebellin-1 (CBLN1) is active in synapse formation and functions at the parallel fiber-Purkinje cell synapses.
34274480	3	85	theme	tripartite	265:274	arg1	complexes					276:284	tripartite complexes	265:284	tripartite complexes with neurexins	265:299	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	12	86	theme	terminal	1470:1477	arg1	ends					1479:1482	The amino terminal ends	1460:1482	The amino terminal ends of both the CBLN1 and CBLN3 proteins	1460:1519	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	3	87	theme	glutamate-receptor-related	309:334	arg1	GluD1					345:349	GluD1	345:349	GluD1	345:349	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	87	theme	glutamate-receptor-related	309:334	arg1	proteins					336:343	the glutamate-receptor-related proteins	305:343	the glutamate-receptor-related proteins GluD1 and GluD2	305:359	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	87	theme	glutamate-receptor-related	309:334	arg1	GluD2					355:359	GluD2	355:359	GluD2	355:359	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	13	88	theme	human	1665:1669	arg1	counterparts					1671:1682	their human counterparts	1659:1682	their human counterparts	1659:1682	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	15	89	theme	following	1907:1915	arg1	numbers					1927:1933	the following accession numbers	1903:1933	the following accession numbers	1903:1933	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	1	90	theme	C1q	122:124	arg1	proteins					126:133	C1q proteins	122:133	C1q proteins	122:133	Cerebellins (CBLN1-4), together with C1qTNF proteins, belong to the CBLN subfamily of C1q proteins.
34274480	13	91	theme	CBLN1	1615:1619	arg1	similar					1639:1645	similar	1639:1645	similar	1639:1645	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	13	91	theme	CBLN1	1615:1619	arg1	organization					1586:1597	The genomic organization	1574:1597	The genomic organization of both porcine CBLN1 and CBLN3	1574:1629	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	15	92	theme	CBLN3	2041:2045	arg1	cDNA					2047:2050	CBLN3 cDNA	2041:2050	CBLN3 cDNA (GenBank ID: EF577505)	2041:2073	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	92	theme	CBLN3	2041:2045	arg1	ID					2061:2062	GenBank ID: EF577505	2053:2072	GenBank ID: EF577505	2053:2072	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	5	93	theme	Experimental	597:608	arg1	data					610:613	Experimental data	597:613	Experimental data	597:613	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	15	94	theme	CBLN1	1971:1975	arg1	ID					1991:1992	GenBank ID: EF577504	1983:2002	GenBank ID: EF577504	1983:2002	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	94	theme	CBLN1	1971:1975	arg1	cDNA					1977:1980	CBLN1 cDNA	1971:1980	CBLN1 cDNA (GenBank ID: EF577504)	1971:2003	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	13	95	theme	CBLN3	1625:1629	arg1	similar					1639:1645	similar	1639:1645	similar	1639:1645	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	13	95	theme	CBLN3	1625:1629	arg1	organization					1586:1597	The genomic organization	1574:1597	The genomic organization of both porcine CBLN1 and CBLN3	1574:1629	The genomic organization of both porcine CBLN1 and CBLN3 is very similar to those of their human counterparts.
34274480	7	96	theme	acids	947:951	arg1	protein					926:932	a protein	924:932	a protein of 193 amino acids	924:951	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	7	96	theme	acids	947:951	arg1	sequence					834:841	The nucleotide sequence	819:841	The nucleotide sequence of the CBLN1 clone	819:860	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	12	97	theme	glycosylation	1553:1565	arg1	sites					1567:1571	three possible N-linked glycosylation sites	1529:1571	three possible N-linked glycosylation sites	1529:1571	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	10	98	theme	cDNA	1228:1231	arg1	clone					1233:1237	the CBLN3 cDNA clone	1218:1237	the CBLN3 cDNA clone	1218:1237	The nucleotide sequence of the CBLN3 cDNA clone comprises an open reading frame of 618 nucleotides and encodes a protein of 205 amino acids.
34274480	0	99	theme	porcine	4:10	arg1	family					28:33	The porcine cerebellin gene family	0:33	The porcine cerebellin gene family	0:33	The porcine cerebellin gene family.
34274480	11	100	theme	CBLN3	1379:1383	arg1	protein					1385:1391	the porcine CBLN3 protein	1367:1391	the porcine CBLN3 protein	1367:1391	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	3	101	with	complexes	276:284	arg1	neurexins					291:299	neurexins	291:299	neurexins	291:299	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	5	102	dep	structure	670:678	arg1	the					661:663	the	661:663	the	661:663	Experimental data and in silico analyses collectively describes the gene structure, chromosomal localization, and expression of CBLN1-4.
34274480	0	103	theme	gene	23:26	arg1	family					28:33	The porcine cerebellin gene family	0:33	The porcine cerebellin gene family	0:33	The porcine cerebellin gene family.
34274480	15	104	theme	GenBank	1948:1954	arg1	FJ621565					1960:1967	GenBank ID: FJ621565	1948:1967	GenBank ID: FJ621565	1948:1967	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	104	theme	GenBank	1948:1954	arg1	gene					1942:1945	CBLN1 gene	1936:1945	CBLN1 gene (GenBank ID: FJ621565)	1936:1968	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	9	105	theme	deduced	1068:1074	arg1	protein					1082:1088	The deduced CBLN1 protein	1064:1088	The deduced CBLN1 protein	1064:1088	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
34274480	11	106	theme	porcine	1371:1377	arg1	protein					1385:1391	the porcine CBLN3 protein	1367:1391	the porcine CBLN3 protein	1367:1391	The deduced amino acid sequence of the porcine CBLN3 protein was 88% identical to mouse CBLN3 and 94% identical to human CBLN3.
34274480	12	107	theme	possible	1535:1542	arg1	sites					1567:1571	three possible N-linked glycosylation sites	1529:1571	three possible N-linked glycosylation sites	1529:1571	The amino terminal ends of both the CBLN1 and CBLN3 proteins contain three possible N-linked glycosylation sites.
34274480	15	108	theme	CBLN1	1936:1940	arg1	FJ621565					1960:1967	GenBank ID: FJ621565	1948:1967	GenBank ID: FJ621565	1948:1967	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	108	theme	CBLN1	1936:1940	arg1	gene					1942:1945	CBLN1 gene	1936:1945	CBLN1 gene (GenBank ID: FJ621565)	1936:1968	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	3	109	theme	synapse	454:460	arg1	formation					462:470	synapse formation	454:470	synapse formation	454:470	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	110	theme	trans-synaptic	380:393	arg1	role					372:375	a role	370:375	a role	370:375	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	3	110	theme	trans-synaptic	380:393	arg1	molecules					409:417	trans-synaptic cell-adhesion molecules	380:417	trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development	380:508	Cerebellins form tripartite complexes with neurexins and the glutamate-receptor-related proteins GluD1 and GluD2, playing a role as trans-synaptic cell-adhesion molecules that critically contribute to both synapse formation and functioning and brain development.
34274480	15	111	theme	CBLN4	2079:2083	arg1	cDNA					2085:2088	CBLN4 cDNA	2079:2088	CBLN4 cDNA (GenBank ID: FJ196070)	2079:2111	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	15	111	theme	CBLN4	2079:2083	arg1	ID					2099:2100	GenBank ID: FJ196070	2091:2110	GenBank ID: FJ196070	2091:2110	The sequences of the porcine precerebellin genes and cDNAs were submitted to DDBJ/EMBL/GenBank under the following accession numbers: CBLN1 gene (GenBank ID: FJ621565), CBLN1 cDNA (GenBank ID: EF577504), CBLN3 gene (GenBank ID: FJ621566), CBLN3 cDNA (GenBank ID: EF577505) and CBLN4 cDNA (GenBank ID: FJ196070).
34274480	7	112	contain	contains	862:869	arg1	protein					926:932	a protein	924:932	a protein of 193 amino acids	924:951	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	7	112	contain	contains	862:869	arg1	sequence					834:841	The nucleotide sequence	819:841	The nucleotide sequence of the CBLN1 clone	819:860	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	7	112	contain	contains	862:869	arg2	frame					887:891	an open reading frame	871:891	an open reading frame of 582 nucleotides	871:910	The nucleotide sequence of the CBLN1 clone contains an open reading frame of 582 nucleotides and encodes a protein of 193 amino acids.
34274480	9	113	theme	signal	1110:1115	arg1	sequence					1117:1124	a putative signal sequence	1099:1124	a putative signal sequence of 21 residues, two conserved cysteine residues,	1099:1173	The deduced CBLN1 protein contains a putative signal sequence of 21 residues, two conserved cysteine residues, and C1q domain.
33812558	9	0	theme	recombinant	1639:1649	arg1	toxins					1651:1656	spider recombinant toxins	1632:1656	spider recombinant toxins	1632:1656	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	6	1	theme	chondroitin	1050:1060	arg1	sulphate					1062:1069	chondroitin sulphate	1050:1069	chondroitin sulphate	1050:1069	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	1	theme	chondroitin	1050:1060	arg1	LiHyal2					970:976	LiHyal2	970:976	LiHyal2	970:976	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	1	theme	chondroitin	1050:1060	arg1	protein					1004:1010	a 45 kDa protein	995:1010	a 45 kDa protein	995:1010	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	1	theme	chondroitin	1050:1060	arg1	acid					1036:1039	hyaluronic acid	1025:1039	hyaluronic acid (HA)	1025:1044	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	1	2	theme	spreading	230:238	arg1	factors					240:246	spreading factors	230:246	spreading factors	230:246	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	0	3	theme	insect	85:90	arg1	cells					92:96	baculovirus-infected insect cells	64:96	baculovirus-infected insect cells	64:96	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	4	4	theme	high	666:669	arg1	identity					671:678	high identity	666:678	high identity	666:678	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	5	5	theme	molecular	859:867	arg1	model					869:873	the molecular model	855:873	the molecular model of LiHyal2	855:884	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	9	6	theme	specific	1759:1766	arg1	treatment					1768:1776	a more specific treatment	1752:1776	a more specific treatment of envenomation victims	1752:1800	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	0	7	from	Production	0:9	arg1	cells					92:96	baculovirus-infected insect cells	64:96	baculovirus-infected insect cells	64:96	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	3	8	theme	baculovirus-insect	502:519	arg1	system					537:542	a baculovirus-insect cell expression system	500:542	a baculovirus-insect cell expression system	500:542	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	4	9	theme	scorpions	721:729	arg1	hyaluronidases					685:698	hyaluronidases	685:698	hyaluronidases of other spiders and scorpions	685:729	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	7	10	theme	N-linked	1245:1252	arg1	carbohydrates					1254:1266	high mannose N-linked carbohydrates	1232:1266	high mannose N-linked carbohydrates	1232:1266	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	6	11	theme	gel	1116:1118	arg1	electrophoresis					1120:1134	agarose gel electrophoresis	1108:1134	agarose gel electrophoresis	1108:1134	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	2	12	theme	matrix	276:281	arg1	components					283:292	extracellular matrix components	262:292	extracellular matrix components	262:292	By degrading extracellular matrix components, these enzymes favor the diffusion of toxins in the affected tissue and at systemic level.
33812558	3	13	theme	cell	521:524	arg1	system					537:542	a baculovirus-insect cell expression system	500:542	a baculovirus-insect cell expression system	500:542	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	7	14	theme	carbohydrates	1254:1266	arg1	addition					1220:1227	the addition	1216:1227	the addition of high mannose N-linked carbohydrates	1216:1266	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	7	15	mod	modified	1204:1211	arg1	LiHyal2					1172:1178	LiHyal2	1172:1178	LiHyal2	1172:1178	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	7	15	mod	modified	1204:1211	arg3	addition					1220:1227	the addition	1216:1227	the addition of high mannose N-linked carbohydrates	1216:1266	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	2	16	theme	toxins	332:337	arg1	diffusion					319:327	the diffusion	315:327	the diffusion of toxins	315:337	By degrading extracellular matrix components, these enzymes favor the diffusion of toxins in the affected tissue and at systemic level.
33812558	5	17	theme	human	810:814	arg1	hyaluronidases					836:849	LiHyal2, human, and honeybee venom hyaluronidases	801:849	LiHyal2, human, and honeybee venom hyaluronidases	801:849	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	5	18	theme	venom	830:834	arg1	hyaluronidases					836:849	LiHyal2, human, and honeybee venom hyaluronidases	801:849	LiHyal2, human, and honeybee venom hyaluronidases	801:849	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	2	19	theme	extracellular	262:274	arg1	components					283:292	extracellular matrix components	262:292	extracellular matrix components	262:292	By degrading extracellular matrix components, these enzymes favor the diffusion of toxins in the affected tissue and at systemic level.
33812558	5	20	theme	major	893:897	arg1	similarities					899:910	major similarities	893:910	major similarities	893:910	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	5	21	theme	honeybee	821:828	arg1	venom					830:834	honeybee venom	821:834	honeybee venom	821:834	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	9	22	theme	envenomation	1781:1792	arg1	victims					1794:1800	envenomation victims	1781:1800	envenomation victims	1781:1800	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	5	23	theme	binding	756:762	arg1	residues					775:782	The catalytic and sugar binding amino acid residues	732:782	residues	775:782	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	6	24	theme	agarose	1108:1114	arg1	electrophoresis					1120:1134	agarose gel electrophoresis	1108:1134	agarose gel electrophoresis	1108:1134	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	4	25	theme	recombinant	576:586	arg1	enzyme					588:593	This recombinant enzyme	571:593	This recombinant enzyme	571:593	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	2	26	theme	systemic	369:376	arg1	level					378:382	systemic level	369:382	systemic level	369:382	By degrading extracellular matrix components, these enzymes favor the diffusion of toxins in the affected tissue and at systemic level.
33812558	7	27	theme	blot	1144:1147	arg1	analysis					1149:1156	Lectin blot analysis	1137:1156	Lectin blot analysis	1137:1156	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	5	28	theme	sugar	750:754	arg1	residues					775:782	The catalytic and sugar binding amino acid residues	732:782	residues	775:782	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	4	29	theme	Hyaluronidase	633:645	arg1	isoform					647:653	Loxosceles intermedia Hyaluronidase isoform 2	611:655	Loxosceles intermedia Hyaluronidase isoform 2	611:655	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	4	29	theme	Hyaluronidase	633:645	arg1	LiHyal2					602:608	LiHyal2	602:608	LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2)	602:656	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	3	30	theme	novel	393:397	arg1	isoform					399:405	a novel isoform	391:405	a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom	391:473	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	9	31	theme	mechanisms	1711:1720	arg1	elucidation					1677:1687	the elucidation	1673:1687	the elucidation of brown spider venom mechanisms	1673:1720	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	4	32	theme	spiders	709:715	arg1	hyaluronidases					685:698	hyaluronidases	685:698	hyaluronidases of other spiders and scorpions	685:729	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	1	33	theme	active	178:183	arg1	role					222:225	an important role	209:225	an important role as spreading factors	209:246	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	1	33	theme	active	178:183	arg1	molecules					185:193	highly active molecules	171:193	highly active molecules	171:193	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	0	34	theme	novel	16:20	arg1	hyaluronidase					47:59	a novel recombinant brown spider hyaluronidase	14:59	a novel recombinant brown spider hyaluronidase	14:59	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	9	35	theme	brown	1692:1696	arg1	mechanisms					1711:1720	brown spider venom mechanisms	1692:1720	brown spider venom mechanisms	1692:1720	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	8	36	theme	L.	1396:1397	arg1	venom					1410:1414	L. intermedia venom	1396:1414	L. intermedia venom	1396:1414	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	3	37	theme	expression	526:535	arg1	system					537:542	a baculovirus-insect cell expression system	500:542	a baculovirus-insect cell expression system	500:542	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	3	38	theme	intermedia	438:447	arg1	venom					469:473	Loxosceles intermedia Mello-Leitão (1934) venom	427:473	Loxosceles intermedia Mello-Leitão (1934) venom	427:473	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	5	39	theme	LiHyal2	801:807	arg1	hyaluronidases					836:849	LiHyal2, human, and honeybee venom hyaluronidases	801:849	LiHyal2, human, and honeybee venom hyaluronidases	801:849	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	9	40	theme	spider	1698:1703	arg1	mechanisms					1711:1720	brown spider venom mechanisms	1692:1720	brown spider venom mechanisms	1692:1720	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	8	41	from	increase	1440:1447	arg1	permeability					1462:1473	capillary permeability	1452:1473	capillary permeability triggered by this PLD	1452:1495	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	1	42	theme	low	118:120	arg1	Hyaluronidases					99:112	Hyaluronidases	99:112	Hyaluronidases	99:112	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	1	42	theme	low	118:120	arg1	toxins					132:137	low expressed toxins	118:137	low expressed toxins of brown spider venoms	118:160	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	3	43	theme	Mello-Leitão	449:460	arg1	venom					469:473	Loxosceles intermedia Mello-Leitão (1934) venom	427:473	Loxosceles intermedia Mello-Leitão (1934) venom	427:473	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	0	44	theme	brown	34:38	arg1	hyaluronidase					47:59	a novel recombinant brown spider hyaluronidase	14:59	a novel recombinant brown spider hyaluronidase	14:59	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	6	45	theme	HA	1090:1091	arg1	zymography					1093:1102	HA zymography	1090:1102	HA zymography	1090:1102	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	9	46	theme	venom	1705:1709	arg1	mechanisms					1711:1720	brown spider venom mechanisms	1692:1720	brown spider venom mechanisms	1692:1720	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	7	47	theme	high	1232:1235	arg1	carbohydrates					1254:1266	high mannose N-linked carbohydrates	1232:1266	high mannose N-linked carbohydrates	1232:1266	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	4	48	theme	intermedia	622:631	arg1	isoform					647:653	Loxosceles intermedia Hyaluronidase isoform 2	611:655	Loxosceles intermedia Hyaluronidase isoform 2	611:655	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	4	48	theme	intermedia	622:631	arg1	LiHyal2					602:608	LiHyal2	602:608	LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2)	602:656	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	0	49	theme	recombinant	22:32	arg1	hyaluronidase					47:59	a novel recombinant brown spider hyaluronidase	14:59	a novel recombinant brown spider hyaluronidase	14:59	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	5	50	theme	amino	764:768	arg1	residues					775:782	The catalytic and sugar binding amino acid residues	732:782	residues	775:782	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	8	51	theme	In	1269:1270	arg1	experiments					1277:1287	In vivo experiments	1269:1287	In vivo experiments	1269:1287	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	3	52	theme	Loxosceles	427:436	arg1	venom					469:473	Loxosceles intermedia Mello-Leitão (1934) venom	427:473	Loxosceles intermedia Mello-Leitão (1934) venom	427:473	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	0	53	theme	hyaluronidase	47:59	arg1	Production					0:9	Production	0:9	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.	0:97	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	7	54	link	N-linked	1245:1252	arg1	carbohydrates					1254:1266	high mannose N-linked carbohydrates	1232:1266	high mannose N-linked carbohydrates	1232:1266	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	8	55	theme	intermedia	1399:1408	arg1	venom					1410:1414	L. intermedia venom	1396:1414	L. intermedia venom	1396:1414	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	8	56	theme	recombinant	1359:1369	arg1	phospholipase-D					1371:1385	a recombinant phospholipase-D	1357:1385	a recombinant phospholipase-D (PLD) of L. intermedia venom	1357:1414	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	8	56	theme	recombinant	1359:1369	arg1	PLD					1388:1390	PLD	1388:1390	PLD	1388:1390	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	1	57	theme	expressed	122:130	arg1	Hyaluronidases					99:112	Hyaluronidases	99:112	Hyaluronidases	99:112	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	1	57	theme	expressed	122:130	arg1	toxins					132:137	low expressed toxins	118:137	low expressed toxins of brown spider venoms	118:160	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	0	58	theme	spider	40:45	arg1	hyaluronidase					47:59	a novel recombinant brown spider hyaluronidase	14:59	a novel recombinant brown spider hyaluronidase	14:59	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	8	59	theme	capillary	1452:1460	arg1	permeability					1462:1473	capillary permeability	1452:1473	capillary permeability triggered by this PLD	1452:1495	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	1	60	theme	venoms	155:160	arg1	Hyaluronidases					99:112	Hyaluronidases	99:112	Hyaluronidases	99:112	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	1	60	theme	venoms	155:160	arg1	toxins					132:137	low expressed toxins	118:137	low expressed toxins of brown spider venoms	118:160	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	3	61	theme	venom	469:473	arg1	hyaluronidase					410:422	hyaluronidase	410:422	hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom	410:473	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	7	62	theme	mannose	1237:1243	arg1	carbohydrates					1254:1266	high mannose N-linked carbohydrates	1232:1266	high mannose N-linked carbohydrates	1232:1266	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	9	63	theme	spider	1632:1637	arg1	toxins					1651:1656	spider recombinant toxins	1632:1656	spider recombinant toxins	1632:1656	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	4	64	theme	other	703:707	arg1	spiders					709:715	other spiders	703:715	other spiders	703:715	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	5	65	theme	crystal	923:929	arg1	site					964:967	the active site	953:967	the active site	953:967	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	5	65	theme	crystal	923:929	arg1	structures					931:940	their crystal structures	917:940	their crystal structures	917:940	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	6	66	theme	45 kDa	997:1002	arg1	LiHyal2					970:976	LiHyal2	970:976	LiHyal2	970:976	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	66	theme	45 kDa	997:1002	arg1	sulphate					1062:1069	chondroitin sulphate	1050:1069	chondroitin sulphate	1050:1069	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	66	theme	45 kDa	997:1002	arg1	protein					1004:1010	a 45 kDa protein	995:1010	a 45 kDa protein	995:1010	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	66	theme	45 kDa	997:1002	arg1	acid					1036:1039	hyaluronic acid	1025:1039	hyaluronic acid (HA)	1025:1044	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	5	67	theme	active	957:962	arg1	site					964:967	the active site	953:967	the active site	953:967	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	5	68	theme	LiHyal2	878:884	arg1	model					869:873	the molecular model	855:873	the molecular model of LiHyal2	855:884	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	8	69	theme	venom	1410:1414	arg1	phospholipase-D					1371:1385	a recombinant phospholipase-D	1357:1385	a recombinant phospholipase-D (PLD) of L. intermedia venom	1357:1414	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	8	69	theme	venom	1410:1414	arg1	PLD					1388:1390	PLD	1388:1390	PLD	1388:1390	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	8	70	dep	In	1269:1270	arg1	vivo					1272:1275	vivo	1272:1275	vivo	1272:1275	In vivo experiments showed that LiHyal2 potentialize dermonecrosis and edema induced by a recombinant phospholipase-D (PLD) of L. intermedia venom, as well as enhance the increase in capillary permeability triggered by this PLD, indicating that these toxins act synergistically during envenomation.
33812558	1	71	theme	brown	142:146	arg1	venoms					155:160	brown spider venoms	142:160	brown spider venoms	142:160	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	9	72	theme	victims	1794:1800	arg1	treatment					1768:1776	a more specific treatment	1752:1776	a more specific treatment of envenomation victims	1752:1800	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	1	73	theme	important	212:220	arg1	role					222:225	an important role	209:225	an important role as spreading factors	209:246	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	1	73	theme	important	212:220	arg1	molecules					185:193	highly active molecules	171:193	highly active molecules	171:193	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	0	74	theme	baculovirus-infected	64:83	arg1	cells					92:96	baculovirus-infected insect cells	64:96	baculovirus-infected insect cells	64:96	Production of a novel recombinant brown spider hyaluronidase in baculovirus-infected insect cells.
33812558	4	75	theme	Loxosceles	611:620	arg1	isoform					647:653	Loxosceles intermedia Hyaluronidase isoform 2	611:655	Loxosceles intermedia Hyaluronidase isoform 2	611:655	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	4	75	theme	Loxosceles	611:620	arg1	LiHyal2					602:608	LiHyal2	602:608	LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2)	602:656	This recombinant enzyme, named LiHyal2 (Loxosceles intermedia Hyaluronidase isoform 2), shares high identity with hyaluronidases of other spiders and scorpions.
33812558	6	76	theme	hyaluronic	1025:1034	arg1	LiHyal2					970:976	LiHyal2	970:976	LiHyal2	970:976	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	76	theme	hyaluronic	1025:1034	arg1	sulphate					1062:1069	chondroitin sulphate	1050:1069	chondroitin sulphate	1050:1069	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	76	theme	hyaluronic	1025:1034	arg1	protein					1004:1010	a 45 kDa protein	995:1010	a 45 kDa protein	995:1010	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	76	theme	hyaluronic	1025:1034	arg1	HA					1042:1043	HA	1042:1043	HA	1042:1043	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	6	76	theme	hyaluronic	1025:1034	arg1	acid					1036:1039	hyaluronic acid	1025:1039	hyaluronic acid (HA)	1025:1044	LiHyal2 was expressed as a 45 kDa protein and degraded hyaluronic acid (HA) and chondroitin sulphate as demonstrated by HA zymography and agarose gel electrophoresis.
33812558	1	77	theme	spider	148:153	arg1	venoms					155:160	brown spider venoms	142:160	brown spider venoms	142:160	Hyaluronidases are low expressed toxins of brown spider venoms, but, as highly active molecules, they present an important role as spreading factors.
33812558	3	78	theme	hyaluronidase	410:422	arg1	isoform					399:405	a novel isoform	391:405	a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom	391:473	Here, a novel isoform of hyaluronidase of Loxosceles intermedia Mello-Leitão (1934) venom was cloned, expressed in a baculovirus-insect cell expression system and fully active purified.
33812558	5	79	theme	acid	770:773	arg1	residues					775:782	The catalytic and sugar binding amino acid residues	732:782	residues	775:782	The catalytic and sugar binding amino acid residues are conserved in LiHyal2, human, and honeybee venom hyaluronidases and the molecular model of LiHyal2 shares major similarities with their crystal structures, including the active site.
33812558	7	80	theme	Lectin	1137:1142	arg1	analysis					1149:1156	Lectin blot analysis	1137:1156	Lectin blot analysis	1137:1156	Lectin blot analysis revealed that LiHyal2 is post-translationally modified by the addition of high mannose N-linked carbohydrates.
33812558	2	81	theme	affected	346:353	arg1	tissue					355:360	the affected tissue	342:360	the affected tissue	342:360	By degrading extracellular matrix components, these enzymes favor the diffusion of toxins in the affected tissue and at systemic level.
33812558	9	82	theme	novel	1606:1610	arg1	approach					1612:1619	a novel approach	1604:1619	a novel approach to express spider recombinant toxins	1604:1656	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
33812558	9	83	theme	treatment	1768:1776	arg1	development					1737:1747	the development	1733:1747	the development of a more specific treatment of envenomation victims	1733:1800	Altogether, these results introduce a novel approach to express spider recombinant toxins, contribute to the elucidation of brown spider venom mechanisms and add to the development of a more specific treatment of envenomation victims.
34204801	10	0	theme	intramitochondrial	1210:1227	arg1	generation					1233:1242	intramitochondrial ROS generation	1210:1242	intramitochondrial ROS generation	1210:1242	Elevated mOGT expression affected the mitochondrial transmembrane potential and increased intramitochondrial ROS generation.
34204801	12	1	theme	many	1329:1332	arg1	proteins					1348:1355	many mitochondrial proteins	1329:1355	many mitochondrial proteins	1329:1355	We identified many mitochondrial proteins as mOGT substrates.
34204801	12	1	theme	many	1329:1332	arg1	substrates					1365:1374	mOGT substrates	1360:1374	mOGT substrates	1360:1374	We identified many mitochondrial proteins as mOGT substrates.
34204801	7	2	theme	Proteomic	733:741	arg1	approaches					743:752	Proteomic approaches	733:752	Proteomic approaches	733:752	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	13	3	from	matrix	1435:1440	arg1	localized					1404:1412	localized	1404:1412	localized	1404:1412	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	14	4	theme	mitochondrial	1668:1680	arg1	proteins					1682:1689	many mitochondrial proteins	1663:1689	many mitochondrial proteins	1663:1689	Our findings suggest that mOGT interacts with and modifies many mitochondrial proteins, and its dysregulation affects cellular bioenergetics and mitochondria function.
34204801	1	5	theme	cell	184:187	arg1	sensor					197:202	a cell glucose sensor	182:202	a cell glucose sensor	182:202	O-GlcNAcylation is a cell glucose sensor.
34204801	1	5	theme	cell	184:187	arg1	O-GlcNAcylation					163:177	O-GlcNAcylation	163:177	O-GlcNAcylation	163:177	O-GlcNAcylation is a cell glucose sensor.
34204801	0	6	theme	Mitochondrial	107:119	arg1	Function					121:128	Mitochondrial Function	107:128	Mitochondrial Function	107:128	Mitochondrial O-GlcNAc Transferase Interacts with and Modifies Many Proteins and Its Up-Regulation Affects Mitochondrial Function and Cellular Energy Homeostasis.
34204801	10	7	theme	mOGT	1129:1132	arg1	expression					1134:1143	Elevated mOGT expression	1120:1143	Elevated mOGT expression	1120:1143	Elevated mOGT expression affected the mitochondrial transmembrane potential and increased intramitochondrial ROS generation.
34204801	13	8	from	membrane	1470:1477	arg1	localized					1404:1412	localized	1404:1412	localized	1404:1412	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	14	9	theme	many	1663:1666	arg1	proteins					1682:1689	many mitochondrial proteins	1663:1689	many mitochondrial proteins	1663:1689	Our findings suggest that mOGT interacts with and modifies many mitochondrial proteins, and its dysregulation affects cellular bioenergetics and mitochondria function.
34204801	6	10	theme	cancer	612:617	arg1	cells					619:623	breast cancer cells	605:623	breast cancer cells	605:623	We performed studies using breast cancer cells with up-regulated mOGT or its catalytic inactive mutant to identify proteins specifically modified by mOGT.
34204801	13	11	theme	mitochondrial	1421:1433	arg1	matrix					1435:1440	the mitochondrial matrix	1417:1440	the mitochondrial matrix	1417:1440	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	13	12	from	localized	1404:1412	arg1	membrane					1470:1477	the inner mitochondrial membrane	1446:1477	the inner mitochondrial membrane	1446:1477	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	13	12	from	localized	1404:1412	arg1	matrix					1435:1440	the mitochondrial matrix	1417:1440	the mitochondrial matrix	1417:1440	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	14	13	theme	cellular	1722:1729	arg1	function					1762:1769	cellular bioenergetics and mitochondria function	1722:1769	cellular bioenergetics and mitochondria function	1722:1769	Our findings suggest that mOGT interacts with and modifies many mitochondrial proteins, and its dysregulation affects cellular bioenergetics and mitochondria function.
34204801	8	14	theme	biochemical	1035:1045	arg1	assays					1047:1052	biochemical assays	1035:1052	biochemical assays	1035:1052	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	4	15	theme	them	413:416	arg1	them					413:416	them	413:416	them	413:416	One of them is targeted to mitochondria (mOGT).
34204801	4	15	theme	them	413:416	arg1	One					406:408	One	406:408	One	406:408	One of them is targeted to mitochondria (mOGT).
34204801	5	16	theme	cancer	496:501	arg1	biology					509:515	cancer cells biology	496:515	cancer cells biology	496:515	Although the impact of O-GlcNAcylation on cancer cells biology is well documented, mOGT's role remains poorly investigated.
34204801	1	17	theme	glucose	189:195	arg1	sensor					197:202	a cell glucose sensor	182:202	a cell glucose sensor	182:202	O-GlcNAcylation is a cell glucose sensor.
34204801	1	17	theme	glucose	189:195	arg1	O-GlcNAcylation					163:177	O-GlcNAcylation	163:177	O-GlcNAcylation	163:177	O-GlcNAcylation is a cell glucose sensor.
34204801	10	18	theme	transmembrane	1172:1184	arg1	potential					1186:1194	the mitochondrial transmembrane potential	1154:1194	the mitochondrial transmembrane potential	1154:1194	Elevated mOGT expression affected the mitochondrial transmembrane potential and increased intramitochondrial ROS generation.
34204801	11	19	theme	cellular	1295:1302	arg1	level					1308:1312	cellular ATP level	1295:1312	cellular ATP level	1295:1312	Moreover, mOGT up-regulation caused a decrease in cellular ATP level.
34204801	2	20	theme	N-acetylglucosamine	286:304	arg1	OGT					319:321	OGT	319:321	OGT	319:321	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	2	20	theme	N-acetylglucosamine	286:304	arg1	transferase					306:316	O-Linked N-acetylglucosamine transferase	277:316	the O-Linked N-acetylglucosamine transferase (OGT)	273:322	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	5	21	theme	cells	503:507	arg1	biology					509:515	cancer cells biology	496:515	cancer cells biology	496:515	Although the impact of O-GlcNAcylation on cancer cells biology is well documented, mOGT's role remains poorly investigated.
34204801	0	22	theme	O-GlcNAc	14:21	arg1	Transferase					23:33	Mitochondrial O-GlcNAc Transferase	0:33	Mitochondrial O-GlcNAc Transferase	0:33	Mitochondrial O-GlcNAc Transferase Interacts with and Modifies Many Proteins and Its Up-Regulation Affects Mitochondrial Function and Cellular Energy Homeostasis.
34204801	10	23	theme	mitochondrial	1158:1170	arg1	potential					1186:1194	the mitochondrial transmembrane potential	1154:1194	the mitochondrial transmembrane potential	1154:1194	Elevated mOGT expression affected the mitochondrial transmembrane potential and increased intramitochondrial ROS generation.
34204801	8	24	theme	assays	1047:1052	arg1	variety					1024:1030	a variety	1022:1030	a variety of biochemical assays	1022:1052	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	8	24	theme	assays	1047:1052	arg1	assays					1047:1052	biochemical assays	1035:1052	biochemical assays	1035:1052	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	11	25	theme	ATP	1304:1306	arg1	level					1308:1312	cellular ATP level	1295:1312	cellular ATP level	1295:1312	Moreover, mOGT up-regulation caused a decrease in cellular ATP level.
34204801	7	26	theme	mass	892:895	arg1	spectrometry					897:908	mass spectrometry	892:908	mass spectrometry	892:908	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	0	27	theme	Mitochondrial	0:12	arg1	Transferase					23:33	Mitochondrial O-GlcNAc Transferase	0:33	Mitochondrial O-GlcNAc Transferase	0:33	Mitochondrial O-GlcNAc Transferase Interacts with and Modifies Many Proteins and Its Up-Regulation Affects Mitochondrial Function and Cellular Energy Homeostasis.
34204801	7	28	theme	mitochondria-enriched	831:851	arg1	fraction					853:860	mitochondria-enriched fraction	831:860	mitochondria-enriched fraction	831:860	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	13	29	theme	mitochondrial	1498:1510	arg1	respiration					1512:1522	mitochondrial respiration	1498:1522	mitochondrial respiration	1498:1522	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	10	30	theme	Elevated	1120:1127	arg1	expression					1134:1143	Elevated mOGT expression	1120:1143	Elevated mOGT expression	1120:1143	Elevated mOGT expression affected the mitochondrial transmembrane potential and increased intramitochondrial ROS generation.
34204801	14	31	theme	mitochondria	1749:1760	arg1	function					1762:1769	cellular bioenergetics and mitochondria function	1722:1769	cellular bioenergetics and mitochondria function	1722:1769	Our findings suggest that mOGT interacts with and modifies many mitochondrial proteins, and its dysregulation affects cellular bioenergetics and mitochondria function.
34204801	3	32	theme	spliced	384:390	arg1	isoforms					396:403	differentially spliced OGT isoforms	369:403	differentially spliced OGT isoforms	369:403	OGT is encoded by a single gene that yields differentially spliced OGT isoforms.
34204801	10	33	theme	ROS	1229:1231	arg1	generation					1233:1242	intramitochondrial ROS generation	1210:1242	intramitochondrial ROS generation	1210:1242	Elevated mOGT expression affected the mitochondrial transmembrane potential and increased intramitochondrial ROS generation.
34204801	0	34	theme	Energy	143:148	arg1	Homeostasis					150:160	Cellular Energy Homeostasis	134:160	Cellular Energy Homeostasis	134:160	Mitochondrial O-GlcNAc Transferase Interacts with and Modifies Many Proteins and Its Up-Regulation Affects Mitochondrial Function and Cellular Energy Homeostasis.
34204801	3	35	theme	OGT	392:394	arg1	isoforms					396:403	differentially spliced OGT isoforms	369:403	differentially spliced OGT isoforms	369:403	OGT is encoded by a single gene that yields differentially spliced OGT isoforms.
34204801	7	36	theme	proteins	817:824	arg1	isolation					763:771	isolation	763:771	isolation of mOGT protein partners and O-GlcNAcylated proteins	763:824	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	0	37	theme	Cellular	134:141	arg1	Homeostasis					150:160	Cellular Energy Homeostasis	134:160	Cellular Energy Homeostasis	134:160	Mitochondrial O-GlcNAc Transferase Interacts with and Modifies Many Proteins and Its Up-Regulation Affects Mitochondrial Function and Cellular Energy Homeostasis.
34204801	7	38	dep	included	754:761	arg1	followed					862:869	followed	862:869	followed by their analysis by mass spectrometry	862:908	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	6	39	theme	inactive	665:672	arg1	mutant					674:679	its catalytic inactive mutant	651:679	its catalytic inactive mutant	651:679	We performed studies using breast cancer cells with up-regulated mOGT or its catalytic inactive mutant to identify proteins specifically modified by mOGT.
34204801	8	40	theme	mOGT	947:950	arg1	dysregulation					952:964	mOGT dysregulation	947:964	mOGT dysregulation	947:964	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	13	41	theme	fatty	1525:1529	arg1	metabolism					1536:1545	fatty acid metabolism	1525:1545	fatty acid metabolism	1525:1545	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	5	42	theme	O-GlcNAcylation	477:491	arg1	impact					467:472	the impact	463:472	the impact of O-GlcNAcylation on cancer cells biology	463:515	Although the impact of O-GlcNAcylation on cancer cells biology is well documented, mOGT's role remains poorly investigated.
34204801	13	43	theme	mtDNA	1587:1591	arg1	processes					1593:1601	mtDNA processes	1587:1601	mtDNA processes	1587:1601	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	14	44	theme	bioenergetics	1731:1743	arg1	function					1762:1769	cellular bioenergetics and mitochondria function	1722:1769	cellular bioenergetics and mitochondria function	1722:1769	Our findings suggest that mOGT interacts with and modifies many mitochondrial proteins, and its dysregulation affects cellular bioenergetics and mitochondria function.
34204801	0	45	theme	Many	63:66	arg1	Proteins					68:75	Many Proteins	63:75	Many Proteins	63:75	Mitochondrial O-GlcNAc Transferase Interacts with and Modifies Many Proteins and Its Up-Regulation Affects Mitochondrial Function and Cellular Energy Homeostasis.
34204801	7	46	theme	O-GlcNAcylated	802:815	arg1	proteins					817:824	O-GlcNAcylated proteins	802:824	O-GlcNAcylated proteins	802:824	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	2	47	theme	target	242:247	arg1	protein					249:255	target protein	242:255	target protein	242:255	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	8	48	theme	dysregulation	952:964	arg1	impact					937:942	the impact	933:942	the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism	933:1014	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	7	49	theme	protein	781:787	arg1	partners					789:796	mOGT protein partners	776:796	mOGT protein partners	776:796	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	2	50	theme	moieties	230:237	arg1	addition					209:216	The addition	205:216	The addition of O-GlcNAc moieties to target protein	205:255	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	5	51	from	impact	467:472	arg1	biology					509:515	cancer cells biology	496:515	cancer cells biology	496:515	Although the impact of O-GlcNAcylation on cancer cells biology is well documented, mOGT's role remains poorly investigated.
34204801	12	52	theme	mitochondrial	1334:1346	arg1	proteins					1348:1355	many mitochondrial proteins	1329:1355	many mitochondrial proteins	1329:1355	We identified many mitochondrial proteins as mOGT substrates.
34204801	12	52	theme	mitochondrial	1334:1346	arg1	substrates					1365:1374	mOGT substrates	1360:1374	mOGT substrates	1360:1374	We identified many mitochondrial proteins as mOGT substrates.
34204801	6	53	theme	catalytic	655:663	arg1	mutant					674:679	its catalytic inactive mutant	651:679	its catalytic inactive mutant	651:679	We performed studies using breast cancer cells with up-regulated mOGT or its catalytic inactive mutant to identify proteins specifically modified by mOGT.
34204801	7	54	theme	partners	789:796	arg1	isolation					763:771	isolation	763:771	isolation of mOGT protein partners and O-GlcNAcylated proteins	763:824	Proteomic approaches included isolation of mOGT protein partners and O-GlcNAcylated proteins from mitochondria-enriched fraction followed by their analysis by mass spectrometry.
34204801	2	55	theme	O-GlcNAc	221:228	arg1	moieties					230:237	O-GlcNAc moieties	221:237	O-GlcNAc moieties	221:237	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	2	56	theme	O-Linked	277:284	arg1	OGT					319:321	OGT	319:321	OGT	319:321	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	2	56	theme	O-Linked	277:284	arg1	transferase					306:316	O-Linked N-acetylglucosamine transferase	277:316	the O-Linked N-acetylglucosamine transferase (OGT)	273:322	The addition of O-GlcNAc moieties to target protein is catalyzed by the O-Linked N-acetylglucosamine transferase (OGT).
34204801	8	57	theme	mitochondrial	969:981	arg1	activity					983:990	mitochondrial activity	969:990	mitochondrial activity	969:990	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	12	58	theme	mOGT	1360:1363	arg1	proteins					1348:1355	many mitochondrial proteins	1329:1355	many mitochondrial proteins	1329:1355	We identified many mitochondrial proteins as mOGT substrates.
34204801	12	58	theme	mOGT	1360:1363	arg1	substrates					1365:1374	mOGT substrates	1360:1374	mOGT substrates	1360:1374	We identified many mitochondrial proteins as mOGT substrates.
34204801	9	59	theme	mitochondrial	1069:1081	arg1	expression					1087:1096	mitochondrial OGT expression	1069:1096	mitochondrial OGT expression	1069:1096	We found that mitochondrial OGT expression is glucose-dependent.
34204801	11	60	theme	mOGT	1255:1258	arg1	up-regulation					1260:1272	mOGT up-regulation	1255:1272	mOGT up-regulation	1255:1272	Moreover, mOGT up-regulation caused a decrease in cellular ATP level.
34204801	8	61	theme	cellular	996:1003	arg1	metabolism					1005:1014	cellular metabolism	996:1014	cellular metabolism	996:1014	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	9	62	theme	OGT	1083:1085	arg1	expression					1087:1096	mitochondrial OGT expression	1069:1096	mitochondrial OGT expression	1069:1096	We found that mitochondrial OGT expression is glucose-dependent.
34204801	11	63	from	decrease	1283:1290	arg1	level					1308:1312	cellular ATP level	1295:1312	cellular ATP level	1295:1312	Moreover, mOGT up-regulation caused a decrease in cellular ATP level.
34204801	8	64	from	impact	937:942	arg1	activity					983:990	mitochondrial activity	969:990	mitochondrial activity	969:990	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	8	64	from	impact	937:942	arg1	metabolism					1005:1014	cellular metabolism	996:1014	cellular metabolism	996:1014	Moreover, we analyzed the impact of mOGT dysregulation on mitochondrial activity and cellular metabolism using a variety of biochemical assays.
34204801	13	65	theme	acid	1531:1534	arg1	metabolism					1536:1545	fatty acid metabolism	1525:1545	fatty acid metabolism	1525:1545	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	13	66	theme	inner	1450:1454	arg1	membrane					1470:1477	the inner mitochondrial membrane	1446:1477	the inner mitochondrial membrane	1446:1477	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
34204801	3	67	theme	single	345:350	arg1	gene					352:355	a single gene	343:355	a single gene that yields differentially spliced OGT isoforms	343:403	OGT is encoded by a single gene that yields differentially spliced OGT isoforms.
34204801	6	68	theme	breast	605:610	arg1	cells					619:623	breast cancer cells	605:623	breast cancer cells	605:623	We performed studies using breast cancer cells with up-regulated mOGT or its catalytic inactive mutant to identify proteins specifically modified by mOGT.
34204801	6	69	theme	up-regulated	630:641	arg1	mOGT					643:646	up-regulated mOGT	630:646	up-regulated mOGT	630:646	We performed studies using breast cancer cells with up-regulated mOGT or its catalytic inactive mutant to identify proteins specifically modified by mOGT.
34204801	13	70	theme	mitochondrial	1456:1468	arg1	membrane					1470:1477	the inner mitochondrial membrane	1446:1477	the inner mitochondrial membrane	1446:1477	Most of these proteins are localized in the mitochondrial matrix and the inner mitochondrial membrane and participate in mitochondrial respiration, fatty acid metabolism, transport, translation, apoptosis, and mtDNA processes.
33997890	0	0	theme	protein	105:111	arg1	modifications					27:39	Variable posttranslational modifications	0:39	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.	0:112	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	11	1	theme	point-of-care	1853:1865	arg1	diagnostics					1867:1877	point-of-care diagnostics	1853:1877	point-of-care diagnostics	1853:1877	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	9	2	theme	native	1305:1310	arg1	Protein					1314:1320	the native N Protein	1301:1320	the native N Protein model	1301:1326	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	4	3	theme	phosphorylation	666:680	arg1	Reports					655:661	Reports	655:661	Reports of phosphorylation of N protein	655:693	Reports of phosphorylation of N protein have failed to provide detailed site-specific information.
33997890	10	4	theme	Recent	1509:1514	arg1	studies					1516:1522	Recent studies	1509:1522	Recent studies	1509:1522	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	0	5	theme	nucleocapsid	92:103	arg1	protein					105:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	11	6	theme	detailed	1682:1689	arg1	characterization					1702:1717	detailed structural characterization	1682:1717	detailed structural characterization of N protein	1682:1730	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	10	7	theme	protective	1647:1656	arg1	responses					1665:1673	protective immune responses	1647:1673	protective immune responses	1647:1673	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	5	8	theme	comprehensive	772:784	arg1	glycomics					786:794	comprehensive glycomics	772:794	comprehensive glycomics	772:794	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	10	9	theme	N	1544:1544	arg1	protein					1546:1552	N protein	1544:1552	N protein	1544:1552	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	10	9	theme	N	1544:1544	arg1	immunogen					1626:1634	a major immunogen	1618:1634	a major immunogen	1618:1634	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	10	9	theme	N	1544:1544	arg1	marker					1591:1596	an important diagnostic marker	1567:1596	an important diagnostic marker for COVID-19	1567:1609	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	6	10	theme	SP	984:985	arg1	sequence					988:995	a signal peptide (SP) sequence	966:995	a signal peptide (SP) sequence	966:995	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	6	11	theme	HEK293	904:909	arg1	cells					911:915	HEK293 cells	904:915	HEK293 cells	904:915	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	3	12	theme	posttranslational	533:549	arg1	PTMs					566:569	PTMs	566:569	PTMs	566:569	N Protein has been suggested in the literature as having posttranslational modifications (PTMs), and accurately defining these PTMs is critical for its potential use in medicine.
33997890	3	12	theme	posttranslational	533:549	arg1	modifications					551:563	posttranslational modifications	533:563	posttranslational modifications (PTMs)	533:570	N Protein has been suggested in the literature as having posttranslational modifications (PTMs), and accurately defining these PTMs is critical for its potential use in medicine.
33997890	11	13	theme	useful	1744:1749	arg1	insights					1751:1758	useful insights	1744:1758	useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics	1744:1877	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	10	14	theme	important	1570:1578	arg1	protein					1546:1552	N protein	1544:1552	N protein	1544:1552	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	10	14	theme	important	1570:1578	arg1	marker					1591:1596	an important diagnostic marker	1567:1596	an important diagnostic marker for COVID-19	1567:1609	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	6	15	theme	peptide	975:981	arg1	sequence					988:995	a signal peptide (SP) sequence	966:995	a signal peptide (SP) sequence	966:995	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	4	16	theme	site-specific	727:739	arg1	information					741:751	detailed site-specific information	718:751	detailed site-specific information	718:751	Reports of phosphorylation of N protein have failed to provide detailed site-specific information.
33997890	9	17	theme	commercial	1443:1452	arg1	protein					1454:1460	any commercial protein	1439:1460	any commercial protein	1439:1460	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	4	18	theme	protein	687:693	arg1	phosphorylation					666:680	phosphorylation	666:680	phosphorylation of N protein	666:693	Reports of phosphorylation of N protein have failed to provide detailed site-specific information.
33997890	7	19	theme	protein	1149:1155	arg1	preparations					1157:1168	the two N protein preparations	1139:1168	the two N protein preparations	1139:1168	Our results show completely different PTMs on the two N protein preparations.
33997890	4	20	theme	N	685:685	arg1	protein					687:693	N protein	685:693	N protein	685:693	Reports of phosphorylation of N protein have failed to provide detailed site-specific information.
33997890	5	21	theme	protein	859:865	arg1	preparations					867:878	two different N protein preparations	843:878	two different N protein preparations	843:878	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	10	22	theme	major	1620:1624	arg1	protein					1546:1552	N protein	1544:1552	N protein	1544:1552	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	10	22	theme	major	1620:1624	arg1	immunogen					1626:1634	a major immunogen	1618:1634	a major immunogen	1618:1634	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	5	23	theme	N	857:857	arg1	preparations					867:878	two different N protein preparations	843:878	two different N protein preparations	843:878	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	5	24	theme	glycomics	786:794	arg1	experiments					828:838	comprehensive glycomics, glycoproteomics and proteomics experiments	772:838	comprehensive glycomics, glycoproteomics and proteomics experiments	772:838	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	7	25	theme	different	1121:1129	arg1	PTMs					1131:1134	completely different PTMs	1110:1134	completely different PTMs	1110:1134	Our results show completely different PTMs on the two N protein preparations.
33997890	2	26	theme	potential	411:419	arg1	target					421:426	a potential target	409:426	a potential target for both vaccine and point-of-care diagnostics	409:473	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	1	27	theme	coronavirus	189:199	arg1	disease					201:207	coronavirus disease 2019	189:212	coronavirus disease 2019 (COVID-19)	189:223	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	1	27	theme	coronavirus	189:199	arg1	COVID-19					215:222	COVID-19	215:222	COVID-19	215:222	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	0	28	theme	posttranslational	9:25	arg1	modifications					27:39	Variable posttranslational modifications	0:39	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.	0:112	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	2	29	theme	point-of-care	449:461	arg1	diagnostics					463:473	both vaccine and point-of-care diagnostics	432:473	diagnostics	463:473	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	11	30	theme	vaccine	1819:1825	arg1	design					1827:1832	vaccine design	1819:1832	vaccine design	1819:1832	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	9	31	theme	N	1312:1312	arg1	Protein					1314:1320	the native N Protein	1301:1320	the native N Protein model	1301:1326	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	0	32	theme	Variable	0:7	arg1	modifications					27:39	Variable posttranslational modifications	0:39	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.	0:112	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	6	33	theme	signal	968:973	arg1	sequence					988:995	a signal peptide (SP) sequence	966:995	a signal peptide (SP) sequence	966:995	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	11	34	theme	structural	1691:1700	arg1	characterization					1702:1717	detailed structural characterization	1682:1717	detailed structural characterization of N protein	1682:1730	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	1	35	theme	Severe	114:119	arg1	coronavirus					148:158	Severe acute respiratory syndrome coronavirus 2	114:160	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	114:173	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	1	35	theme	Severe	114:119	arg1	SARS-CoV-2					163:172	SARS-CoV-2	163:172	SARS-CoV-2	163:172	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	8	36	link	O-linked	1221:1228	arg1	glycosylation					1230:1242	O-linked glycosylation	1221:1242	O-linked glycosylation	1221:1242	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	5	37	theme	glycoproteomics	797:811	arg1	experiments					828:838	comprehensive glycomics, glycoproteomics and proteomics experiments	772:838	comprehensive glycomics, glycoproteomics and proteomics experiments	772:838	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	2	38	theme	Nucleocapsid	294:305	arg1	protein					307:313	Nucleocapsid protein	294:313	Nucleocapsid protein (N protein)	294:325	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	2	38	theme	Nucleocapsid	294:305	arg1	protein					318:324	N protein	316:324	N protein	316:324	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	9	39	theme	protein	1454:1460	arg1	provenance					1425:1434	the provenance	1421:1434	the provenance of any commercial protein to be used for scientific or clinical studies	1421:1506	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	5	40	theme	proteomics	817:826	arg1	experiments					828:838	comprehensive glycomics, glycoproteomics and proteomics experiments	772:838	comprehensive glycomics, glycoproteomics and proteomics experiments	772:838	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	1	41	theme	global	277:282	arg1	pandemic					284:291	a global pandemic	275:291	a global pandemic	275:291	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	6	42	dep	in-house	926:933	arg1	expressed					935:943	expressed	935:943	expressed	935:943	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	6	42	dep	in-house	926:933	arg1	purified					949:956	purified	949:956	purified	949:956	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	1	43	theme	respiratory	127:137	arg1	coronavirus					148:158	Severe acute respiratory syndrome coronavirus 2	114:160	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	114:173	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	1	43	theme	respiratory	127:137	arg1	SARS-CoV-2					163:172	SARS-CoV-2	163:172	SARS-CoV-2	163:172	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	3	44	dep	defining	588:595	arg1	critical					611:618	critical	611:618	critical	611:618	N Protein has been suggested in the literature as having posttranslational modifications (PTMs), and accurately defining these PTMs is critical for its potential use in medicine.
33997890	0	45	theme	acute	51:55	arg1	protein					105:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	10	46	theme	immune	1658:1663	arg1	responses					1665:1673	protective immune responses	1647:1673	protective immune responses	1647:1673	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	7	47	theme	N	1147:1147	arg1	preparations					1157:1168	the two N protein preparations	1139:1168	the two N protein preparations	1139:1168	Our results show completely different PTMs on the two N protein preparations.
33997890	8	48	contain	contained	1194:1202	arg2	O-phosphorylation					1255:1271	O-phosphorylation	1255:1271	extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393	1204:1286	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	8	48	contain	contained	1194:1202	arg1	product					1186:1192	The commercial product	1171:1192	The commercial product	1171:1192	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	8	48	contain	contained	1194:1202	arg2	glycosylation					1230:1242	O-linked glycosylation	1221:1242	O-linked glycosylation	1221:1242	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	8	48	contain	contained	1194:1202	arg2	N-					1214:1215	extensive N-	1204:1215	extensive N-	1204:1215	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	8	49	theme	O-linked	1221:1228	arg1	glycosylation					1230:1242	O-linked glycosylation	1221:1242	O-linked glycosylation	1221:1242	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	11	50	theme	diagnostics	1867:1877	arg1	development					1838:1848	development	1838:1848	development of point-of-care diagnostics	1838:1877	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	11	50	theme	diagnostics	1867:1877	arg1	pathogenesis					1805:1816	viral pathogenesis	1799:1816	viral pathogenesis	1799:1816	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	11	50	theme	diagnostics	1867:1877	arg1	design					1827:1832	vaccine design	1819:1832	vaccine design	1819:1832	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	0	51	theme	severe	44:49	arg1	protein					105:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	2	52	theme	vaccine	437:443	arg1	diagnostics					463:473	both vaccine and point-of-care diagnostics	432:473	diagnostics	463:473	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	9	53	theme	Protein	1314:1320	arg1	model					1322:1326	the native N Protein model	1301:1326	the native N Protein model	1301:1326	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	8	54	from	glycosylation	1230:1242	arg1	site					1276:1279	site Thr393	1276:1286	site Thr393	1276:1286	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	4	55	theme	detailed	718:725	arg1	information					741:751	detailed site-specific information	718:751	detailed site-specific information	718:751	Reports of phosphorylation of N protein have failed to provide detailed site-specific information.
33997890	0	56	theme	syndrome	69:76	arg1	protein					105:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	11	57	from	roles	1782:1786	arg1	development					1838:1848	development	1838:1848	development of point-of-care diagnostics	1838:1877	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	11	57	from	roles	1782:1786	arg1	pathogenesis					1805:1816	viral pathogenesis	1799:1816	viral pathogenesis	1799:1816	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	11	57	from	roles	1782:1786	arg1	design					1827:1832	vaccine design	1819:1832	vaccine design	1819:1832	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	1	58	from	2019	237:240	arg1	China					245:249	China	245:249	China	245:249	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	3	59	from	use	638:640	arg1	medicine					645:652	medicine	645:652	medicine	645:652	N Protein has been suggested in the literature as having posttranslational modifications (PTMs), and accurately defining these PTMs is critical for its potential use in medicine.
33997890	1	60	theme	syndrome	139:146	arg1	coronavirus					148:158	Severe acute respiratory syndrome coronavirus 2	114:160	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	114:173	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	1	60	theme	syndrome	139:146	arg1	SARS-CoV-2					163:172	SARS-CoV-2	163:172	SARS-CoV-2	163:172	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	0	61	theme	respiratory	57:67	arg1	protein					105:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	11	62	theme	PTMs	1791:1794	arg1	roles					1782:1786	the roles	1778:1786	the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics	1778:1877	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	2	63	from	protein	372:378	arg1	coronaviruses					383:395	coronaviruses	383:395	coronaviruses	383:395	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	3	64	theme	N	476:476	arg1	Protein					478:484	N Protein	476:484	N Protein	476:484	N Protein has been suggested in the literature as having posttranslational modifications (PTMs), and accurately defining these PTMs is critical for its potential use in medicine.
33997890	11	65	theme	viral	1799:1803	arg1	pathogenesis					1805:1816	viral pathogenesis	1799:1816	viral pathogenesis	1799:1816	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	8	66	from	N-	1214:1215	arg1	site					1276:1279	site Thr393	1276:1286	site Thr393	1276:1286	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	9	67	theme	scientific	1477:1486	arg1	studies					1500:1506	scientific or clinical studies	1477:1506	scientific or clinical studies	1477:1506	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	1	68	theme	acute	121:125	arg1	coronavirus					148:158	Severe acute respiratory syndrome coronavirus 2	114:160	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	114:173	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	1	68	theme	acute	121:125	arg1	SARS-CoV-2					163:172	SARS-CoV-2	163:172	SARS-CoV-2	163:172	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), started in 2019 in China and quickly spread into a global pandemic.
33997890	9	69	theme	no	1364:1365	arg1	glycosylation					1367:1379	no glycosylation	1364:1379	no glycosylation	1364:1379	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	3	70	theme	potential	628:636	arg1	use					638:640	its potential use	624:640	its potential use in medicine	624:652	N Protein has been suggested in the literature as having posttranslational modifications (PTMs), and accurately defining these PTMs is critical for its potential use in medicine.
33997890	9	71	contain	had	1328:1330	arg1	model					1322:1326	the native N Protein model	1301:1326	the native N Protein model	1301:1326	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	9	71	contain	had	1328:1330	arg2	O-phosphorylation					1332:1348	O-phosphorylation	1332:1348	O-phosphorylation	1332:1348	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	8	72	from	O-phosphorylation	1255:1271	arg1	site					1276:1279	site Thr393	1276:1286	site Thr393	1276:1286	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	2	73	theme	N	316:316	arg1	protein					307:313	Nucleocapsid protein	294:313	Nucleocapsid protein (N protein)	294:325	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	2	73	theme	N	316:316	arg1	protein					318:324	N protein	316:324	N protein	316:324	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	8	74	theme	extensive	1204:1212	arg1	N-					1214:1215	extensive N-	1204:1215	extensive N-	1204:1215	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	8	75	theme	commercial	1175:1184	arg1	product					1186:1192	The commercial product	1171:1192	The commercial product	1171:1192	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	8	76	gly	glycosylation	1230:1242	arg1	site					1276:1279	site Thr393	1276:1286	site Thr393	1276:1286	The commercial product contained extensive N- and O-linked glycosylation as well as O-phosphorylation on site Thr393.
33997890	5	77	theme	different	847:855	arg1	preparations					867:878	two different N protein preparations	843:878	two different N protein preparations	843:878	We have performed comprehensive glycomics, glycoproteomics and proteomics experiments on two different N protein preparations.
33997890	9	78	theme	clinical	1491:1498	arg1	studies					1500:1506	scientific or clinical studies	1477:1506	scientific or clinical studies	1477:1506	Conversely, the native N Protein model had O-phosphorylation at Ser176 and no glycosylation, highlighting the importance of knowing the provenance of any commercial protein to be used for scientific or clinical studies.
33997890	6	79	theme	secretory	1074:1082	arg1	pathway					1084:1090	the secretory pathway	1070:1090	the secretory pathway	1070:1090	Both were expressed in HEK293 cells; one was in-house expressed and purified without a signal peptide (SP) sequence, and the other was commercially produced with a SP channeling it through the secretory pathway.
33997890	2	80	theme	abundant	363:370	arg1	protein					372:378	the most abundant protein	354:378	the most abundant protein in coronaviruses	354:395	Nucleocapsid protein (N protein) is highly conserved and is the most abundant protein in coronaviruses and is thus a potential target for both vaccine and point-of-care diagnostics.
33997890	11	81	theme	N	1722:1722	arg1	protein					1724:1730	N protein	1722:1730	N protein	1722:1730	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33997890	0	82	theme	coronavirus	78:88	arg1	protein					105:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	severe acute respiratory syndrome coronavirus 2 nucleocapsid protein	44:111	Variable posttranslational modifications of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein.
33997890	10	83	theme	diagnostic	1580:1589	arg1	protein					1546:1552	N protein	1544:1552	N protein	1544:1552	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	10	83	theme	diagnostic	1580:1589	arg1	marker					1591:1596	an important diagnostic marker	1567:1596	an important diagnostic marker for COVID-19	1567:1609	Recent studies have indicated that N protein can serve as an important diagnostic marker for COVID-19 and as a major immunogen by priming protective immune responses.
33997890	11	84	theme	protein	1724:1730	arg1	characterization					1702:1717	detailed structural characterization	1682:1717	detailed structural characterization of N protein	1682:1730	Thus, detailed structural characterization of N protein may provide useful insights for understanding the roles of PTMs on viral pathogenesis, vaccine design and development of point-of-care diagnostics.
33206215	4	0	theme	intra-	746:751	arg1	cross-linking					772:784	intra- and intermolecular cross-linking	746:784	intra- and intermolecular cross-linking	746:784	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	1	1	theme	imaging	173:179	arg1	method					199:204	a multiplexed imaging mass spectrometry method	159:204	a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections	159:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	1	2	theme	formalin-fixed	285:298	arg1	sections					325:332	formalin-fixed paraffin-embedded tissue sections	285:332	formalin-fixed paraffin-embedded tissue sections	285:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	0	3	theme	enzyme	79:84	arg1	digests					86:92	serial enzyme digests	72:92	serial enzyme digests from formalin-fixed paraffin-embedded tissue sections	72:146	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	6	4	theme	components	1101:1110	arg1	buildup					1086:1092	the buildup	1082:1092	the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans,	1082:1187	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	5	5	theme	collagenase	962:972	arg1	digestion					983:991	collagenase type III digestion	962:991	collagenase type III digestion	962:991	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	1	6	theme	mass	181:184	arg1	method					199:204	a multiplexed imaging mass spectrometry method	159:204	a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections	159:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	1	7	theme	paraffin-embedded	300:316	arg1	sections					325:332	formalin-fixed paraffin-embedded tissue sections	285:332	formalin-fixed paraffin-embedded tissue sections	285:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	0	8	theme	formalin-fixed	99:112	arg1	sections					139:146	formalin-fixed paraffin-embedded tissue sections	99:146	formalin-fixed paraffin-embedded tissue sections	99:146	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	7	9	theme	MALDI-IMS	1393:1401	arg1	applications					1403:1414	MALDI-IMS applications	1393:1414	MALDI-IMS applications	1393:1414	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	6	10	dep	other	1112:1116	arg1	than					1118:1121	than	1118:1121	than	1118:1121	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	2	11	dep	proteins	390:397	arg1	1					379:379	1	379:379	1	379:379	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	5	12	theme	N-glycan	1015:1022	arg1	removal					1024:1030	N-glycan removal	1015:1030	N-glycan removal via PNGaseF digest	1015:1049	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	1	13	theme	tissue	318:323	arg1	sections					325:332	formalin-fixed paraffin-embedded tissue sections	285:332	formalin-fixed paraffin-embedded tissue sections	285:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	2	14	from	hydroxylation	482:494	arg1	lysines					512:518	lysines	512:518	lysines	512:518	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	14	from	hydroxylation	482:494	arg1	prolines					499:506	prolines	499:506	prolines	499:506	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	5	15	dep	both	994:997	arg1	alone					999:1003	alone	999:1003	alone	999:1003	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	7	16	theme	serial	1285:1290	arg1	strategy					1299:1306	a novel serial enzyme strategy	1277:1306	a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications	1277:1414	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	2	17	theme	extracellular	339:351	arg1	ECM					361:363	ECM	361:363	ECM	361:363	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	17	theme	extracellular	339:351	arg1	matrix					353:358	The extracellular matrix	335:358	The extracellular matrix (ECM)	335:364	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	6	18	theme	fibrotic	1064:1071	arg1	tissues					1073:1079	fibrotic tissues	1064:1079	fibrotic tissues	1064:1079	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	0	19	theme	tissue	132:137	arg1	sections					139:146	formalin-fixed paraffin-embedded tissue sections	99:146	formalin-fixed paraffin-embedded tissue sections	99:146	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	5	20	theme	desorption	858:867	arg1	MALDI-IMS					907:915	MALDI-IMS	907:915	MALDI-IMS	907:915	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	20	theme	desorption	858:867	arg1	spectrometry					893:904	matrix-assisted laser desorption ionization imaging mass spectrometry	836:904	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	21	theme	PNGaseF	1036:1042	arg1	digest					1044:1049	PNGaseF digest	1036:1049	PNGaseF digest	1036:1049	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	7	22	from	section	1381:1387	arg1	PTMs					1354:1357	PTMs	1354:1357	PTMs	1354:1357	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	1	23	theme	spectrometry	186:197	arg1	method					199:204	a multiplexed imaging mass spectrometry method	159:204	a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections	159:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	0	24	theme	paraffin-embedded	114:130	arg1	sections					139:146	formalin-fixed paraffin-embedded tissue sections	99:146	formalin-fixed paraffin-embedded tissue sections	99:146	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	5	25	theme	type	974:977	arg1	digestion					983:991	collagenase type III digestion	962:991	collagenase type III digestion	962:991	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	2	26	from	proteins	390:397	arg1	lysines					512:518	lysines	512:518	lysines	512:518	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	26	from	proteins	390:397	arg1	prolines					499:506	prolines	499:506	prolines	499:506	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	27	from	proteoglycans	557:569	arg1	lysines					512:518	lysines	512:518	lysines	512:518	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	27	from	proteoglycans	557:569	arg1	prolines					499:506	prolines	499:506	prolines	499:506	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	6	28	theme	collagen-type	1123:1135	arg1	elastin					1157:1163	elastin	1157:1163	elastin	1157:1163	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	6	28	theme	collagen-type	1123:1135	arg1	glycosaminoglycans					1169:1186	glycosaminoglycans	1169:1186	glycosaminoglycans	1169:1186	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	6	28	theme	collagen-type	1123:1135	arg1	proteins					1137:1144	collagen-type proteins	1123:1144	collagen-type proteins	1123:1144	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	0	29	theme	imaging	12:18	arg1	spectrometry					25:36	Multiplexed imaging mass spectrometry	0:36	Multiplexed imaging mass spectrometry of the extracellular matrix	0:64	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	6	30	theme	proteins	1137:1144	arg1	buildup					1086:1092	the buildup	1082:1092	the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans,	1082:1187	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	5	31	theme	previous	800:807	arg1	studies					809:815	previous studies	800:815	previous studies	800:815	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	6	32	theme	enzyme	1219:1224	arg1	efficacy					1196:1203	efficacy	1196:1203	efficacy of any single enzyme to access the complex ECM	1196:1250	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	0	33	theme	Multiplexed	0:10	arg1	spectrometry					25:36	Multiplexed imaging mass spectrometry	0:36	Multiplexed imaging mass spectrometry of the extracellular matrix	0:64	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	6	34	theme	single	1212:1217	arg1	enzyme					1219:1224	any single enzyme	1208:1224	any single enzyme	1208:1224	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	5	35	theme	collagen	940:947	arg1	peptides					949:956	collagen peptides	940:956	collagen peptides	940:956	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	4	36	theme	Conventional	640:651	arg1	analysis					661:668	Conventional peptide analysis	640:668	Conventional peptide analysis via trypsin	640:680	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	5	37	theme	ionization	869:878	arg1	MALDI-IMS					907:915	MALDI-IMS	907:915	MALDI-IMS	907:915	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	37	theme	ionization	869:878	arg1	spectrometry					893:904	matrix-assisted laser desorption ionization imaging mass spectrometry	836:904	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	2	38	theme	O-linked	447:454	arg1	glycosylation					456:468	O-linked glycosylation	447:468	O-linked glycosylation	447:468	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	0	39	theme	mass	20:23	arg1	spectrometry					25:36	Multiplexed imaging mass spectrometry	0:36	Multiplexed imaging mass spectrometry of the extracellular matrix	0:64	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	6	40	theme	complex	1240:1246	arg1	ECM					1248:1250	the complex ECM	1236:1250	the complex ECM	1236:1250	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	2	41	theme	fibrous	382:388	arg1	PTM					431:433	PTM	431:433	PTM	431:433	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	41	theme	fibrous	382:388	arg1	proteins					390:397	fibrous proteins	382:397	fibrous proteins	382:397	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	5	42	theme	laser	852:856	arg1	MALDI-IMS					907:915	MALDI-IMS	907:915	MALDI-IMS	907:915	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	42	theme	laser	852:856	arg1	spectrometry					893:904	matrix-assisted laser desorption ionization imaging mass spectrometry	836:904	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	6	43	theme	ECM	1097:1099	arg1	components					1101:1110	ECM components	1097:1110	ECM components other than collagen-type proteins, including elastin and glycosaminoglycans,	1097:1187	However, in fibrotic tissues, the buildup of ECM components other than collagen-type proteins, including elastin and glycosaminoglycans, limits efficacy of any single enzyme to access the complex ECM.
33206215	8	44	dep	Abstract	1427:1434	arg1	Graphical					1417:1425	Graphical	1417:1425	Graphical	1417:1425	Graphical Abstract.
33206215	4	45	theme	ECM	705:707	arg1	peptides					709:716	ECM peptides	705:716	ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs	705:794	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	4	46	theme	due	718:720	arg1	peptides					709:716	ECM peptides	705:716	ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs	705:794	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	5	47	theme	imaging	880:886	arg1	MALDI-IMS					907:915	MALDI-IMS	907:915	MALDI-IMS	907:915	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	47	theme	imaging	880:886	arg1	spectrometry					893:904	matrix-assisted laser desorption ionization imaging mass spectrometry	836:904	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	0	48	theme	matrix	59:64	arg1	spectrometry					25:36	Multiplexed imaging mass spectrometry	0:36	Multiplexed imaging mass spectrometry of the extracellular matrix	0:64	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	2	49	theme	glycosaminoglycan-decorated	529:555	arg1	proteoglycans					557:569	(2) glycosaminoglycan-decorated proteoglycans	525:569	(2) glycosaminoglycan-decorated proteoglycans	525:569	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	1	50	from	matrix	275:280	arg1	sections					325:332	formalin-fixed paraffin-embedded tissue sections	285:332	formalin-fixed paraffin-embedded tissue sections	285:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	3	51	theme	unique	611:616	arg1	challenge					629:637	a unique analytical challenge	609:637	a unique analytical challenge	609:637	Accessing all these components poses a unique analytical challenge.
33206215	4	52	theme	intermolecular	757:770	arg1	cross-linking					772:784	intra- and intermolecular cross-linking	746:784	intra- and intermolecular cross-linking	746:784	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	0	53	theme	extracellular	45:57	arg1	matrix					59:64	the extracellular matrix	41:64	the extracellular matrix	41:64	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	3	54	theme	analytical	618:627	arg1	challenge					629:637	a unique analytical challenge	609:637	a unique analytical challenge	609:637	Accessing all these components poses a unique analytical challenge.
33206215	7	55	theme	extracellular	1322:1334	arg1	matrix					1336:1341	the extracellular matrix	1318:1341	the extracellular matrix	1318:1341	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	4	56	theme	peptide	653:659	arg1	analysis					661:668	Conventional peptide analysis	640:668	Conventional peptide analysis via trypsin	640:680	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	5	57	dep	digestion	983:991	arg1	removal					1024:1030	N-glycan removal	1015:1030	N-glycan removal via PNGaseF digest	1015:1049	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	57	dep	digestion	983:991	arg1	both					994:997	both	994:997	both	994:997	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	2	58	link	O-linked	447:454	arg1	glycosylation					456:468	O-linked glycosylation	447:468	O-linked glycosylation	447:468	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	59	dep	modified	421:428	arg1	PTM					431:433	PTM	431:433	PTM	431:433	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	2	59	dep	modified	421:428	arg1	proteins					390:397	fibrous proteins	382:397	fibrous proteins	382:397	The extracellular matrix (ECM) consists of (1) fibrous proteins, post-translationally modified (PTM) via N- and O-linked glycosylation, as well as hydroxylation on prolines and lysines, and (2) glycosaminoglycan-decorated proteoglycans.
33206215	4	60	theme	low	731:733	arg1	abundance					735:743	their low abundance	725:743	their low abundance	725:743	Conventional peptide analysis via trypsin inefficiently captures ECM peptides due to their low abundance, intra- and intermolecular cross-linking, and PTMs.
33206215	1	61	theme	extracellular	261:273	arg1	matrix					275:280	the extracellular matrix	257:280	the extracellular matrix on formalin-fixed paraffin-embedded tissue sections	257:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	0	62	theme	serial	72:77	arg1	digests					86:92	serial enzyme digests	72:92	serial enzyme digests from formalin-fixed paraffin-embedded tissue sections	72:146	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
33206215	7	63	theme	tissue	1374:1379	arg1	section					1381:1387	a single tissue section	1365:1387	a single tissue section for MALDI-IMS applications	1365:1414	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	5	64	theme	spectrometry	893:904	arg1	techniques					918:927	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	7	65	theme	enzyme	1292:1297	arg1	strategy					1299:1306	a novel serial enzyme strategy	1277:1306	a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications	1277:1414	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	7	66	theme	single	1367:1372	arg1	section					1381:1387	a single tissue section	1365:1387	a single tissue section for MALDI-IMS applications	1365:1414	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	5	67	theme	matrix-assisted	836:850	arg1	MALDI-IMS					907:915	MALDI-IMS	907:915	MALDI-IMS	907:915	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	67	theme	matrix-assisted	836:850	arg1	spectrometry					893:904	matrix-assisted laser desorption ionization imaging mass spectrometry	836:904	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	68	theme	mass	888:891	arg1	MALDI-IMS					907:915	MALDI-IMS	907:915	MALDI-IMS	907:915	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	5	68	theme	mass	888:891	arg1	spectrometry					893:904	matrix-assisted laser desorption ionization imaging mass spectrometry	836:904	matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques	836:927	In previous studies, we have developed matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI-IMS) techniques to capture collagen peptides via collagenase type III digestion, both alone and after N-glycan removal via PNGaseF digest.
33206215	1	69	theme	multiplexed	161:171	arg1	method					199:204	a multiplexed imaging mass spectrometry method	159:204	a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections	159:332	We report a multiplexed imaging mass spectrometry method which spatially localizes and selectively accesses the extracellular matrix on formalin-fixed paraffin-embedded tissue sections.
33206215	7	70	theme	novel	1279:1283	arg1	strategy					1299:1306	a novel serial enzyme strategy	1277:1306	a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications	1277:1414	Here, we have developed a novel serial enzyme strategy to define the extracellular matrix, including PTMs, from a single tissue section for MALDI-IMS applications.
33206215	0	71	from	sections	139:146	arg1	digests					86:92	serial enzyme digests	72:92	serial enzyme digests from formalin-fixed paraffin-embedded tissue sections	72:146	Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections.
32494619	0	0	theme	regulatory	95:104	arg1	factor-5					106:113	interferon regulatory factor-5	84:113	interferon regulatory factor-5	84:113	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	5	1	theme	glucose	892:898	arg1	levels					876:881	higher levels	869:881	higher levels of blood glucose in IAV-infected patients	869:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	5	2	from	levels	876:881	arg1	patients					916:923	IAV-infected patients	903:923	IAV-infected patients	903:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	5	3	theme	IAV-infected	903:914	arg1	patients					916:923	IAV-infected patients	903:923	IAV-infected patients	903:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	0	4	theme	interferon	84:93	arg1	factor-5					106:113	interferon regulatory factor-5	84:113	interferon regulatory factor-5	84:113	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	6	5	theme	IAV	1031:1033	arg1	infection					1035:1043	IAV infection	1031:1043	IAV infection	1031:1043	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	6	6	from	importance	1063:1072	arg1	storm					1120:1124	IAV-induced cytokine storm	1099:1124	IAV-induced cytokine storm	1099:1124	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	5	7	from	patients	916:923	arg1	levels					876:881	higher levels	869:881	higher levels of blood glucose in IAV-infected patients	869:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	4	8	theme	IRF5	648:651	arg1	O-GlcNAcylation					629:643	O-GlcNAcylation	629:643	O-GlcNAcylation of IRF5	629:651	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	5	9	from	glucose	892:898	arg1	patients					916:923	IAV-infected patients	903:923	IAV-infected patients	903:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	4	10	theme	cytokine	718:725	arg1	production					727:736	subsequent cytokine production	707:736	subsequent cytokine production	707:736	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	1	11	theme	influenza	280:288	arg1	virus					292:296	influenza A virus	280:296	influenza A virus	280:296	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	6	12	theme	metabolism	1085:1094	arg1	importance					1063:1072	the importance	1059:1072	the importance of glucose metabolism in IAV-induced cytokine storm	1059:1124	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	3	13	from	O-GlcNAcylation	590:604	arg1	serine-430					617:626	serine-430	617:626	serine-430	617:626	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	2	14	theme	protein	373:379	arg1	O-GlcNAcylation					381:395	protein O-GlcNAcylation	373:395	protein O-GlcNAcylation	373:395	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	5	15	theme	higher	810:815	arg1	levels					817:822	higher levels	810:822	higher levels of proinflammatory cytokines	810:851	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	1	16	theme	hexosamine	176:185	arg1	HBP					209:211	HBP	209:211	HBP	209:211	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	16	theme	hexosamine	176:185	arg1	pathway					200:206	the hexosamine biosynthesis pathway	172:206	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	17	dep	-induced	303:310	arg1	virus					292:296	influenza A virus	280:296	influenza A virus	280:296	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	6	18	theme	IRF5	1010:1013	arg1	function					1015:1022	IRF5 function	1010:1022	IRF5 function	1010:1022	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	6	19	theme	cytokine	1111:1118	arg1	storm					1120:1124	IAV-induced cytokine storm	1099:1124	IAV-induced cytokine storm	1099:1124	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	1	20	theme	biosynthesis	187:198	arg1	HBP					209:211	HBP	209:211	HBP	209:211	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	20	theme	biosynthesis	187:198	arg1	pathway					200:206	the hexosamine biosynthesis pathway	172:206	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	0	21	theme	O-GlcNAc	0:7	arg1	transferase					9:19	O-GlcNAc transferase	0:19	O-GlcNAc transferase	0:19	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	1	22	theme	A	290:290	arg1	virus					292:296	influenza A virus	280:296	influenza A virus	280:296	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	23	link	O-linked	225:232	arg1	signaling					267:275	-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling	213:275	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	24	theme	pathway	200:206	arg1	function					160:167	an essential function	147:167	an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	147:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	0	25	theme	influenza	30:38	arg1	storm					65:69	influenza A virus-induced cytokine storm	30:69	influenza A virus-induced cytokine storm	30:69	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	3	26	theme	interferon	540:549	arg1	IRF5					572:575	IRF5	572:575	IRF5	572:575	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	3	26	theme	interferon	540:549	arg1	factor-5					562:569	interferon regulatory factor-5	540:569	interferon regulatory factor-5 (IRF5)	540:576	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	2	27	theme	IAV-induced	407:417	arg1	production					428:437	IAV-induced cytokine production	407:437	IAV-induced cytokine production	407:437	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	2	28	theme	cytokine	419:426	arg1	production					428:437	IAV-induced cytokine production	407:437	IAV-induced cytokine production	407:437	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	3	29	theme	regulatory	551:560	arg1	IRF5					572:575	IRF5	572:575	IRF5	572:575	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	3	29	theme	regulatory	551:560	arg1	factor-5					562:569	interferon regulatory factor-5	540:569	interferon regulatory factor-5 (IRF5)	540:576	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	5	30	theme	cytokines	843:851	arg1	levels					817:822	higher levels	810:822	higher levels of proinflammatory cytokines	810:851	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	0	31	theme	virus-induced	42:54	arg1	storm					65:69	influenza A virus-induced cytokine storm	30:69	influenza A virus-induced cytokine storm	30:69	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	6	32	theme	HBP-mediated	971:982	arg1	O-GlcNAcylation					984:998	HBP-mediated O-GlcNAcylation	971:998	HBP-mediated O-GlcNAcylation	971:998	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	2	33	theme	key	358:360	arg1	transferase					337:347	O-GlcNAc transferase	328:347	O-GlcNAc transferase (OGT)	328:353	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	2	33	theme	key	358:360	arg1	enzyme					362:367	a key enzyme	356:367	a key enzyme for protein O-GlcNAcylation	356:395	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	6	34	theme	glucose	1077:1083	arg1	metabolism					1085:1094	glucose metabolism	1077:1094	glucose metabolism	1077:1094	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	0	35	theme	A	40:40	arg1	storm					65:69	influenza A virus-induced cytokine storm	30:69	influenza A virus-induced cytokine storm	30:69	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	1	36	from	signaling	267:275	arg1	storm					321:325	influenza A virus (IAV)-induced cytokine storm	280:325	influenza A virus (IAV)-induced cytokine storm	280:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	37	dep	pathway	200:206	arg1	signaling					267:275	-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling	213:275	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	38	theme	-associated	213:223	arg1	signaling					267:275	-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling	213:275	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	39	theme	-induced	303:310	arg1	storm					321:325	influenza A virus (IAV)-induced cytokine storm	280:325	influenza A virus (IAV)-induced cytokine storm	280:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	0	40	theme	cytokine	56:63	arg1	storm					65:69	influenza A virus-induced cytokine storm	30:69	influenza A virus-induced cytokine storm	30:69	O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5.
32494619	1	41	theme	cytokine	312:319	arg1	storm					321:325	influenza A virus (IAV)-induced cytokine storm	280:325	influenza A virus (IAV)-induced cytokine storm	280:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	6	42	theme	IAV-induced	1099:1109	arg1	storm					1120:1124	IAV-induced cytokine storm	1099:1124	IAV-induced cytokine storm	1099:1124	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	4	43	theme	IRF5	698:701	arg1	ubiquitination					680:693	K63-linked ubiquitination	669:693	K63-linked ubiquitination of IRF5	669:701	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	4	43	theme	IRF5	698:701	arg1	production					727:736	subsequent cytokine production	707:736	subsequent cytokine production	707:736	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	6	44	theme	molecular	942:950	arg1	mechanism					952:960	a molecular mechanism	940:960	a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm	940:1124	We identified a molecular mechanism by which HBP-mediated O-GlcNAcylation regulates IRF5 function during IAV infection, highlighting the importance of glucose metabolism in IAV-induced cytokine storm.
32494619	5	45	theme	blood	886:890	arg1	glucose					892:898	blood glucose	886:898	blood glucose in IAV-infected patients	886:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	2	46	theme	O-GlcNAc	328:335	arg1	transferase					337:347	O-GlcNAc transferase	328:347	O-GlcNAc transferase (OGT)	328:353	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	2	46	theme	O-GlcNAc	328:335	arg1	enzyme					362:367	a key enzyme	356:367	a key enzyme for protein O-GlcNAcylation	356:395	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	2	46	theme	O-GlcNAc	328:335	arg1	OGT					350:352	OGT	350:352	OGT	350:352	O-GlcNAc transferase (OGT), a key enzyme for protein O-GlcNAcylation, mediated IAV-induced cytokine production.
32494619	4	47	link	K63-linked	669:678	arg1	ubiquitination					680:693	K63-linked ubiquitination	669:693	K63-linked ubiquitination of IRF5	669:701	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	1	48	theme	O-linked	225:232	arg1	signaling					267:275	-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling	213:275	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	3	49	theme	IRF5	609:612	arg1	O-GlcNAcylation					590:604	O-GlcNAcylation	590:604	O-GlcNAcylation of IRF5 on serine-430	590:626	Upon investigating the mechanisms driving this event, we determined that IAV induced OGT to bind to interferon regulatory factor-5 (IRF5), leading to O-GlcNAcylation of IRF5 on serine-430.
32494619	5	50	theme	higher	869:874	arg1	levels					876:881	higher levels	869:881	higher levels of blood glucose in IAV-infected patients	869:923	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	4	51	theme	subsequent	707:716	arg1	production					727:736	subsequent cytokine production	707:736	subsequent cytokine production	707:736	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	1	52	theme	β-N-acetylglucosamine	234:254	arg1	signaling					267:275	-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling	213:275	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	5	53	theme	clinical	751:758	arg1	samples					760:766	clinical samples	751:766	clinical samples	751:766	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	5	54	theme	proinflammatory	827:841	arg1	cytokines					843:851	proinflammatory cytokines	827:851	proinflammatory cytokines	827:851	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	4	55	theme	K63-linked	669:678	arg1	ubiquitination					680:693	K63-linked ubiquitination	669:693	K63-linked ubiquitination of IRF5	669:701	O-GlcNAcylation of IRF5 is required for K63-linked ubiquitination of IRF5 and subsequent cytokine production.
32494619	5	56	theme	samples	760:766	arg1	Analysis					739:746	Analysis	739:746	Analysis of clinical samples	739:766	Analysis of clinical samples revealed that IRF5 is O-GlcNAcylated, and higher levels of proinflammatory cytokines correlated with higher levels of blood glucose in IAV-infected patients.
32494619	1	57	theme	essential	150:158	arg1	function					160:167	an essential function	147:167	an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	147:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32494619	1	58	theme	O-GlcNAc	257:264	arg1	signaling					267:275	-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling	213:275	the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm	172:325	In this study, we demonstrated an essential function of the hexosamine biosynthesis pathway (HBP)-associated O-linked β-N-acetylglucosamine (O-GlcNAc) signaling in influenza A virus (IAV)-induced cytokine storm.
32790257	20	0	theme	%	3008:3008	arg1	%					3015:3015	%E fat/%	3008:3015	%E fat/%E carbohydrates	3008:3030	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	25	1	dep	prevent	3861:3867	arg1	both					3907:3910	both	3907:3910	both	3907:3910	The results obtained should be taken into account when developing measures to prevent and reduce the prevalence of obesity, both at the population and individual levels.
32790257	14	2	located	found	2058:2062	arg1	men					2067:2069	men	2067:2069	men (p<0.001 when comparing all BMI groups)	2067:2109	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	14	2	located	found	2058:2062	arg2	increase					1931:1938	A linear increase	1922:1938	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity	1922:2052	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	7	3	theme	project	994:1000	arg1	rounds					980:985	7 rounds	978:985	7 rounds of the project	978:1000	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	19	4	theme	E	2707:2707	arg1	frequency					2736:2744	the frequency	2732:2744	the frequency of consumption of more than 10%E due to sugar	2732:2790	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	19	4	theme	E	2707:2707	arg1	Consumption					2691:2701	Consumption	2691:2701	Consumption of %E due to added sugar	2691:2726	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	11	5	theme	various	1640:1646	arg1	fractions					1648:1656	various fractions	1640:1656	various fractions of carbohydrates	1640:1673	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	19	6	theme	E	2777:2777	arg1	consumption					2749:2759	consumption	2749:2759	consumption of more than 10%E due to sugar	2749:2790	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	15	7	theme	BMI	2183:2185	arg1	groups					2187:2192	BMI groups	2183:2192	BMI groups	2183:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	2	8	theme	many	256:259	arg1	factors					275:281	many environmental factors	256:281	many environmental factors	256:281	However, many environmental factors can contribute to or restrain the development of obesity.
32790257	18	9	theme	%	2587:2587	arg1	E					2588:2588	%E	2587:2588	%E	2587:2588	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	8	10	theme	dependent	1046:1054	arg1	variables					1056:1064	dependent variables	1046:1064	dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI)	1046:1285	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	6	11	theme	RLMS	834:837	arg1	Russian					793:799	Russian	793:799	Russian	793:799	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	6	11	theme	RLMS	834:837	arg1	project					839:845	RLMS project	834:845	RLMS project	834:845	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	24	12	theme	direct	3723:3728	arg1	association					3730:3740	no direct association	3720:3740	no direct association with the prevalence of these conditions	3720:3780	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	8	13	theme	%	1109:1109	arg1	E					1110:1110	%E	1109:1110	%E	1109:1110	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	13	theme	%	1109:1109	arg1	percentage					1097:1106	a percentage	1095:1106	a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar)	1095:1193	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	22	14	theme	%	3357:3357	arg1	E					3358:3358	%E	3357:3358	%E of protein, total fat, saturated fatty acids	3357:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	24	15	from	role	3568:3571	arg1	prevalence					3620:3629	the prevalence	3616:3629	the prevalence of overweight and obesity	3616:3655	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	25	16	theme	population	3919:3928	arg1	levels					3945:3950	the population and individual levels	3915:3950	levels	3945:3950	The results obtained should be taken into account when developing measures to prevent and reduce the prevalence of obesity, both at the population and individual levels.
32790257	12	17	theme	%	1735:1735	arg1	protein					1738:1744	the %E protein	1731:1744	the %E protein	1731:1744	A direct association of the %E protein and the BMI category has been established.
32790257	20	18	from	effect	2891:2896	arg1	consumption					2912:2922	the consumption	2908:2922	the consumption of %E of fat and carbohydrates	2908:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	22	19	theme	E	3430:3430	arg1	quartiles					3416:3424	lowest quartiles	3409:3424	lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3409:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	19	theme	E	3430:3430	arg1	quartiles					3344:3352	highest quartiles	3336:3352	highest quartiles of %E of protein, total fat, saturated fatty acids	3336:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	6	20	theme	population	715:724	arg1	Assessment					626:635	Assessment	626:635	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population	626:724	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	25	21	theme	individual	3934:3943	arg1	levels					3945:3950	the population and individual levels	3915:3950	levels	3945:3950	The results obtained should be taken into account when developing measures to prevent and reduce the prevalence of obesity, both at the population and individual levels.
32790257	12	22	theme	protein	1738:1744	arg1	association					1716:1726	A direct association	1707:1726	A direct association of the %E protein and the BMI category	1707:1765	A direct association of the %E protein and the BMI category has been established.
32790257	22	23	theme	lowest	3409:3414	arg1	quartiles					3416:3424	lowest quartiles	3409:3424	lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3409:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	12	24	theme	direct	1709:1714	arg1	association					1716:1726	A direct association	1707:1726	A direct association of the %E protein and the BMI category	1707:1765	A direct association of the %E protein and the BMI category has been established.
32790257	0	25	from	prevalence	68:77	arg1	macronutrients					49:62	macronutrients	49:62	macronutrients	49:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	4	26	theme	adult	586:590	arg1	population					592:601	Russian adult population	578:601	Russian adult population	578:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	15	27	located	observed	2199:2206	arg2	differences					2148:2158	statistically significant differences	2122:2158	statistically significant differences in %E of fat intake in BMI groups	2122:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	15	27	located	observed	2199:2206	arg1	women					2115:2119	women	2115:2119	women	2115:2119	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	7	28	theme	aged	948:951	arg1	adults					897:902	adults	897:902	adults of both sexes (24 767 men and 30 040 women) aged 19-60 years	897:963	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	24	29	contain	has	3716:3718	arg1	energy					3668:3673	the energy	3664:3673	the energy of carbohydrates, including added sugar,	3664:3714	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	24	29	contain	has	3716:3718	arg2	association					3730:3740	no direct association	3720:3740	no direct association with the prevalence of these conditions	3720:3780	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	20	30	theme	E	3016:3016	arg1	carbohydrates					3018:3030	%E fat/%E carbohydrates	3008:3030	%E fat/%E carbohydrates	3008:3030	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	16	31	theme	E	2269:2269	arg1	lower					2301:2305	lower	2301:2305	lower	2301:2305	In men, the consumption of %E due to total carbohydrates is lower in groups with overweight and obesity compared with normal and malnutrition.
32790257	16	31	theme	E	2269:2269	arg1	consumption					2253:2263	the consumption	2249:2263	the consumption of %E due to total carbohydrates	2249:2296	In men, the consumption of %E due to total carbohydrates is lower in groups with overweight and obesity compared with normal and malnutrition.
32790257	8	32	theme	mass	1270:1273	arg1	BMI					1282:1284	BMI	1282:1284	BMI	1282:1284	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	32	theme	mass	1270:1273	arg1	index					1275:1279	body mass index	1265:1279	body mass index (BMI)	1265:1285	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	20	33	from	ratio	2999:3003	arg1	people					3035:3040	people	3035:3040	people with overweight and obesity	3035:3068	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	19	34	dep	E	2777:2777	arg1	%					2776:2776	%	2776:2776	%	2776:2776	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	8	35	theme	total	1128:1132	arg1	carbohydrates					1134:1146	total carbohydrates	1128:1146	total carbohydrates	1128:1146	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	35	theme	total	1128:1132	arg1	fat					1114:1116	fat	1114:1116	fat	1114:1116	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	22	36	theme	saturated	3383:3391	arg1	acids					3399:3403	saturated fatty acids	3383:3403	saturated fatty acids	3383:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	36	theme	saturated	3383:3391	arg1	protein					3363:3369	protein	3363:3369	protein	3363:3369	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	25	37	theme	obesity	3898:3904	arg1	prevalence					3884:3893	the prevalence	3880:3893	the prevalence of obesity	3880:3904	The results obtained should be taken into account when developing measures to prevent and reduce the prevalence of obesity, both at the population and individual levels.
32790257	18	38	from	consumption	2651:2661	arg1	persons					2666:2672	persons	2666:2672	persons with normal BMI	2666:2688	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	19	39	theme	consumption	2749:2759	arg1	frequency					2736:2744	the frequency	2732:2744	the frequency of consumption of more than 10%E due to sugar	2732:2790	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	19	39	theme	consumption	2749:2759	arg1	Consumption					2691:2701	Consumption	2691:2701	Consumption of %E due to added sugar	2691:2726	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	4	40	with	obesity	528:534	arg1	intake					568:573	the macronutrients' energy intake	541:573	the macronutrients' energy intake of Russian adult population	541:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	1	41	from	development	166:176	arg1	adults					207:212	adults	207:212	adults	207:212	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	20	42	theme	%	2927:2927	arg1	E					2928:2928	%E	2927:2928	%E of fat and carbohydrates	2927:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	17	43	theme	mono-	2424:2428	arg1	E					2411:2411	%E	2410:2411	%E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity	2410:2531	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	17	43	theme	mono-	2424:2428	arg1	consumption					2453:2463	the consumption	2449:2463	the consumption	2449:2463	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	15	44	from	groups	2187:2192	arg1	E					2164:2164	%E	2163:2164	%E of fat intake in BMI groups	2163:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	11	45	theme	macronutrients	1514:1527	arg1	values					1504:1509	the absolute values	1491:1509	the absolute values of macronutrients' intake	1491:1535	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	18	46	theme	E	2588:2588	arg1	consumption					2572:2582	consumption	2572:2582	consumption of %E due to polysaccharides and natural sugar	2572:2629	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	4	47	with	overweight	513:522	arg1	intake					568:573	the macronutrients' energy intake	541:573	the macronutrients' energy intake of Russian adult population	541:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	7	48	theme	adults	897:902	arg1	survey					887:892	a survey	885:892	a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years	885:963	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	17	49	theme	disaccharides	2434:2446	arg1	E					2411:2411	%E	2410:2411	%E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity	2410:2531	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	17	49	theme	disaccharides	2434:2446	arg1	consumption					2453:2463	the consumption	2449:2463	the consumption	2449:2463	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	24	50	theme	added	3703:3707	arg1	sugar					3709:3713	added sugar	3703:3713	added sugar	3703:3713	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	22	51	theme	fractions	3476:3484	arg1	E					3430:3430	%E	3429:3430	%E of total carbohydrates and their individual fractions, including added sugar	3429:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	7	52	from	survey	887:892	arg1	data					875:878	data	875:878	data	875:878	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	22	53	theme	E	3358:3358	arg1	quartiles					3416:3424	lowest quartiles	3409:3424	lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3409:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	53	theme	E	3358:3358	arg1	quartiles					3344:3352	highest quartiles	3336:3352	highest quartiles of %E of protein, total fat, saturated fatty acids	3336:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	0	54	theme	prevalence	68:77	arg1	[Analysis					0:8	[Analysis	0:8	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population	0:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	11	55	with	obesity	1590:1596	arg1	exception					1608:1616	the exception	1604:1616	the exception of the consumption of various fractions of carbohydrates	1604:1673	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	18	56	theme	normal	2679:2684	arg1	BMI					2686:2688	normal BMI	2679:2688	normal BMI	2679:2688	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	24	57	theme	diet	3594:3597	arg1	component					3603:3611	the diet fat component	3590:3611	the diet fat component	3590:3611	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	4	58	theme	study	449:453	arg1	aim					438:440	The aim	434:440	The aim of the study	434:453	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	20	59	with	people	3035:3040	arg1	obesity					3062:3068	obesity	3062:3068	obesity	3062:3068	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	20	59	with	people	3035:3040	arg1	overweight					3047:3056	overweight	3047:3056	overweight	3047:3056	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	8	60	theme	added	1182:1186	arg1	sugar					1188:1192	added sugar	1182:1192	added sugar	1182:1192	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	60	theme	added	1182:1186	arg1	fat					1114:1116	fat	1114:1116	fat	1114:1116	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	14	61	theme	BMI	1995:1997	arg1	category					1999:2006	the BMI category	1991:2006	the BMI category	1991:2006	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	11	62	theme	%	1541:1541	arg1	E					1542:1542	%E	1541:1542	%E	1541:1542	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	0	63	theme	overweight	82:91	arg1	prevalence					68:77	prevalence	68:77	prevalence of overweight and obesity among the Russian population	68:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	0	63	theme	overweight	82:91	arg1	association					17:27	the association	13:27	the association of diet energy from macronutrients	13:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	14	64	from	increase	1931:1938	arg1	proportion					1947:1956	the proportion	1943:1956	the proportion of %E of fat with an increase in the BMI category	1943:2006	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	14	64	from	increase	1931:1938	arg1	malnutrition					2030:2041	malnutrition	2030:2041	malnutrition	2030:2041	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	14	64	from	increase	1931:1938	arg1	direction					2015:2023	the direction	2011:2023	the direction from malnutrition to obesity	2011:2052	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	22	65	theme	carbohydrates	3441:3453	arg1	E					3430:3430	%E	3429:3430	%E of total carbohydrates and their individual fractions, including added sugar	3429:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	66	theme	quartiles	3344:3352	arg1	quartiles					3416:3424	lowest quartiles	3409:3424	lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3409:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	66	theme	quartiles	3344:3352	arg1	groups					3326:3331	the groups	3322:3331	the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3322:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	66	theme	quartiles	3344:3352	arg1	quartiles					3344:3352	highest quartiles	3336:3352	highest quartiles of %E of protein, total fat, saturated fatty acids	3336:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	0	67	theme	obesity	97:103	arg1	prevalence					68:77	prevalence	68:77	prevalence of overweight and obesity among the Russian population	68:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	0	67	theme	obesity	97:103	arg1	association					17:27	the association	13:27	the association of diet energy from macronutrients	13:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	9	68	theme	total	1361:1365	arg1	age					1391:1393	age	1391:1393	age	1391:1393	The total daily energy intake and age were used as covariates in the model.
32790257	9	68	theme	total	1361:1365	arg1	intake					1380:1385	The total daily energy intake	1357:1385	The total daily energy intake	1357:1385	The total daily energy intake and age were used as covariates in the model.
32790257	9	68	theme	total	1361:1365	arg1	covariates					1408:1417	covariates	1408:1417	covariates	1408:1417	The total daily energy intake and age were used as covariates in the model.
32790257	12	69	theme	category	1758:1765	arg1	association					1716:1726	A direct association	1707:1726	A direct association of the %E protein and the BMI category	1707:1765	A direct association of the %E protein and the BMI category has been established.
32790257	14	70	dep	men	2067:2069	arg1	p<0.001					2072:2078	p<0.001	2072:2078	p<0.001 when comparing all BMI groups	2072:2108	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	6	71	theme	dietary	640:646	arg1	intake					648:653	dietary intake	640:653	dietary intake	640:653	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	11	72	theme	carbohydrates	1661:1673	arg1	fractions					1648:1656	various fractions	1640:1656	various fractions of carbohydrates	1640:1673	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	15	73	theme	fat	2169:2171	arg1	intake					2173:2178	fat intake	2169:2178	fat intake in BMI groups	2169:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	9	74	theme	energy	1373:1378	arg1	age					1391:1393	age	1391:1393	age	1391:1393	The total daily energy intake and age were used as covariates in the model.
32790257	9	74	theme	energy	1373:1378	arg1	intake					1380:1385	The total daily energy intake	1357:1385	The total daily energy intake	1357:1385	The total daily energy intake and age were used as covariates in the model.
32790257	9	74	theme	energy	1373:1378	arg1	covariates					1408:1417	covariates	1408:1417	covariates	1408:1417	The total daily energy intake and age were used as covariates in the model.
32790257	8	75	dep	percentage	1097:1106	arg1	mono-					1157:1161	natural mono-	1149:1161	natural mono-	1149:1161	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	75	dep	percentage	1097:1106	arg1	disaccharides					1167:1179	disaccharides	1167:1179	disaccharides	1167:1179	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	75	dep	percentage	1097:1106	arg1	carbohydrates					1134:1146	total carbohydrates	1128:1146	total carbohydrates	1128:1146	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	75	dep	percentage	1097:1106	arg1	sugar					1188:1192	added sugar	1182:1192	added sugar	1182:1192	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	75	dep	percentage	1097:1106	arg1	fat					1114:1116	fat	1114:1116	fat	1114:1116	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	75	dep	percentage	1097:1106	arg1	protein					1119:1125	protein	1119:1125	protein	1119:1125	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	14	76	theme	fat	1967:1969	arg1	E					1962:1962	%E	1961:1962	%E of fat	1961:1969	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	6	77	theme	monitoring	814:823	arg1	surveys					825:831	monitoring surveys	814:831	monitoring surveys	814:831	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	17	78	theme	%	2410:2410	arg1	E					2411:2411	%E	2410:2411	%E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity	2410:2531	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	14	79	theme	E	1962:1962	arg1	proportion					1947:1956	the proportion	1943:1956	the proportion of %E of fat with an increase in the BMI category	1943:2006	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	11	80	theme	normal	1688:1693	arg1	values					1699:1704	normal BMI values	1688:1704	normal BMI values	1688:1704	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	21	81	theme	respondents	3154:3164	arg1	distribution					3138:3149	distribution	3138:3149	distribution of respondents with overweight and obesity	3138:3192	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	24	82	theme	overweight	3634:3643	arg1	prevalence					3620:3629	the prevalence	3616:3629	the prevalence of overweight and obesity	3616:3655	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	22	83	theme	highest	3336:3342	arg1	quartiles					3344:3352	highest quartiles	3336:3352	highest quartiles of %E of protein, total fat, saturated fatty acids	3336:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	11	84	theme	daily	1477:1481	arg1	energy					1483:1488	total daily energy	1471:1488	total daily energy	1471:1488	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	0	85	theme	energy	37:42	arg1	prevalence					68:77	prevalence	68:77	prevalence of overweight and obesity among the Russian population	68:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	0	85	theme	energy	37:42	arg1	association					17:27	the association	13:27	the association of diet energy from macronutrients	13:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	0	86	from	association	17:27	arg1	macronutrients					49:62	macronutrients	49:62	macronutrients	49:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	24	87	theme	obesity	3649:3655	arg1	prevalence					3620:3629	the prevalence	3616:3629	the prevalence of overweight and obesity	3616:3655	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	6	88	dep	longitudinal	801:812	arg1	surveys					825:831	monitoring surveys	814:831	monitoring surveys	814:831	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	3	89	theme	value	427:431	arg1	composition					371:381	the composition	367:381	the composition of the diet	367:393	These, of course, include the composition of the diet and the structure of its energy value.
32790257	3	89	theme	value	427:431	arg1	structure					403:411	the structure	399:411	the structure of its energy value	399:431	These, of course, include the composition of the diet and the structure of its energy value.
32790257	13	90	theme	BMI	1909:1911	arg1	groups					1913:1918	all BMI groups	1905:1918	all BMI groups	1905:1918	This relationship is more pronounced in men, but statistically significant in women as well (p<0.001 when comparing all BMI groups).
32790257	6	91	theme	households	771:780	arg1	survey					761:766	a cross-sectional survey	743:766	a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project)	743:846	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	14	92	from	malnutrition	2030:2041	arg1	increase					1931:1938	A linear increase	1922:1938	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity	1922:2052	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	14	92	from	malnutrition	2030:2041	arg1	direction					2015:2023	the direction	2011:2023	the direction from malnutrition to obesity	2011:2052	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	13	93	from	significant	1852:1862	arg1	women					1867:1871	women	1867:1871	women	1867:1871	This relationship is more pronounced in men, but statistically significant in women as well (p<0.001 when comparing all BMI groups).
32790257	11	94	theme	absolute	1495:1502	arg1	values					1504:1509	the absolute values	1491:1509	the absolute values of macronutrients' intake	1491:1535	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	14	95	theme	BMI	2099:2101	arg1	groups					2103:2108	all BMI groups	2095:2108	all BMI groups	2095:2108	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	11	96	theme	fractions	1648:1656	arg1	consumption					1625:1635	the consumption	1621:1635	the consumption of various fractions of carbohydrates	1621:1673	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	22	97	theme	%	3429:3429	arg1	E					3430:3430	%E	3429:3430	%E of total carbohydrates and their individual fractions, including added sugar	3429:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	21	98	with	respondents	3154:3164	arg1	overweight					3171:3180	overweight	3171:3180	overweight	3171:3180	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	21	98	with	respondents	3154:3164	arg1	obesity					3186:3192	obesity	3186:3192	obesity	3186:3192	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	13	99	dep	as	1873:1874	arg1	p<0.001					1882:1888	p<0.001	1882:1888	p<0.001 when comparing all BMI groups	1882:1918	This relationship is more pronounced in men, but statistically significant in women as well (p<0.001 when comparing all BMI groups).
32790257	22	100	theme	total	3372:3376	arg1	protein					3363:3369	protein	3363:3369	protein	3363:3369	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	100	theme	total	3372:3376	arg1	fat					3378:3380	total fat	3372:3380	total fat	3372:3380	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	6	101	theme	parameters	674:683	arg1	Assessment					626:635	Assessment	626:635	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population	626:724	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	2	102	theme	obesity	332:338	arg1	development					317:327	the development	313:327	the development of obesity	313:338	However, many environmental factors can contribute to or restrain the development of obesity.
32790257	21	103	theme	macronutrients	3210:3223	arg1	quartiles					3197:3205	quartiles	3197:3205	quartiles of macronutrients' %E differentiated by gender	3197:3252	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	24	104	theme	carbohydrates	3678:3690	arg1	energy					3668:3673	the energy	3664:3673	the energy of carbohydrates, including added sugar,	3664:3714	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	18	105	with	persons	2666:2672	arg1	BMI					2686:2688	normal BMI	2679:2688	normal BMI	2679:2688	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	4	106	theme	overweight	513:522	arg1	prevalence					499:508	the prevalence	495:508	the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population	495:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	22	107	theme	protein	3363:3369	arg1	E					3358:3358	%E	3357:3358	%E of protein, total fat, saturated fatty acids	3357:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	6	108	theme	cross-sectional	745:759	arg1	survey					761:766	a cross-sectional survey	743:766	a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project)	743:846	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	2	109	theme	environmental	261:273	arg1	factors					275:281	many environmental factors	256:281	many environmental factors	256:281	However, many environmental factors can contribute to or restrain the development of obesity.
32790257	1	110	theme	energy	239:244	arg1	balance					228:234	a positive balance	217:234	a positive balance of energy	217:244	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	1	110	theme	energy	239:244	arg1	cause					152:156	The fundamental cause	136:156	The fundamental cause for the development of overweight and obesity in adults	136:212	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	20	111	theme	opposite	2882:2889	arg1	effect					2891:2896	The opposite effect	2878:2896	The opposite effect of BMI on the consumption of %E of fat and carbohydrates	2878:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	4	112	theme	obesity	528:534	arg1	prevalence					499:508	the prevalence	495:508	the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population	495:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	13	113	from	women	1867:1871	arg1	significant					1852:1862	significant	1852:1862	significant	1852:1862	This relationship is more pronounced in men, but statistically significant in women as well (p<0.001 when comparing all BMI groups).
32790257	19	114	theme	%	2706:2706	arg1	E					2707:2707	%E	2706:2707	%E due to added sugar	2706:2726	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	12	115	theme	BMI	1754:1756	arg1	category					1758:1765	the BMI category	1750:1765	the BMI category	1750:1765	A direct association of the %E protein and the BMI category has been established.
32790257	24	116	theme	fat	3599:3601	arg1	component					3603:3611	the diet fat component	3590:3611	the diet fat component	3590:3611	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	20	117	theme	carbohydrates	3018:3030	arg1	ratio					2999:3003	the ratio	2995:3003	the ratio of %E fat/%E carbohydrates in people with overweight and obesity	2995:3068	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	4	118	theme	population	592:601	arg1	intake					568:573	the macronutrients' energy intake	541:573	the macronutrients' energy intake of Russian adult population	541:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	0	119	from	macronutrients	49:62	arg1	prevalence					68:77	prevalence	68:77	prevalence of overweight and obesity among the Russian population	68:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	0	119	from	macronutrients	49:62	arg1	association					17:27	the association	13:27	the association of diet energy from macronutrients	13:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	0	119	from	macronutrients	49:62	arg1	energy					37:42	diet energy	32:42	diet energy from macronutrients	32:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	8	120	theme	variables	1056:1064	arg1	Association					1031:1041	Association	1031:1041	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status,	1031:1321	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	15	121	from	differences	2148:2158	arg1	E					2164:2164	%E	2163:2164	%E of fat intake in BMI groups	2163:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	22	122	theme	quartiles	3416:3424	arg1	quartiles					3416:3424	lowest quartiles	3409:3424	lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3409:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	122	theme	quartiles	3416:3424	arg1	groups					3326:3331	the groups	3322:3331	the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar	3322:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	122	theme	quartiles	3416:3424	arg1	quartiles					3344:3352	highest quartiles	3336:3352	highest quartiles of %E of protein, total fat, saturated fatty acids	3336:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	19	123	theme	sexes	2822:2826	arg1	people					2807:2812	people	2807:2812	people of both sexes	2807:2826	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	0	124	theme	Russian	115:121	arg1	population					123:132	the Russian population	111:132	the Russian population	111:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	6	125	theme	adult	709:713	arg1	population					715:724	the adult population	705:724	the adult population	705:724	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	1	126	theme	overweight	181:190	arg1	development					166:176	the development	162:176	the development of overweight and obesity in adults	162:212	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	12	127	theme	E	1736:1736	arg1	protein					1738:1744	the %E protein	1731:1744	the %E protein	1731:1744	A direct association of the %E protein and the BMI category has been established.
32790257	16	128	theme	%	2268:2268	arg1	E					2269:2269	%E	2268:2269	%E due to total carbohydrates	2268:2296	In men, the consumption of %E due to total carbohydrates is lower in groups with overweight and obesity compared with normal and malnutrition.
32790257	8	129	theme	body	1265:1268	arg1	BMI					1282:1284	BMI	1282:1284	BMI	1282:1284	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	129	theme	body	1265:1268	arg1	index					1275:1279	body mass index	1265:1279	body mass index (BMI)	1265:1285	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	6	130	from	households	771:780	arg1	Russia					785:790	Russia	785:790	Russia	785:790	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	1	131	theme	obesity	196:202	arg1	development					166:176	the development	162:176	the development of overweight and obesity in adults	162:212	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	20	132	theme	E	3009:3009	arg1	%					3015:3015	%E fat/%	3008:3015	%E fat/%E carbohydrates	3008:3030	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	24	133	theme	significant	3556:3566	arg1	role					3568:3571	a more significant role	3549:3571	a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity	3549:3655	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	8	134	theme	index	1275:1279	arg1	gender					1238:1243	gender	1238:1243	gender	1238:1243	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	134	theme	index	1275:1279	arg1	categories					1251:1260	4 categories	1249:1260	4 categories of body mass index (BMI)	1249:1285	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	19	135	dep	%	2776:2776	arg1	10					2774:2775	10	2774:2775	10	2774:2775	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	4	136	theme	Russian	578:584	arg1	population					592:601	Russian adult population	578:601	Russian adult population	578:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	6	137	from	Russia	785:790	arg1	survey					761:766	a cross-sectional survey	743:766	a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project)	743:846	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	19	138	theme	normal	2845:2850	arg1	direction					2835:2843	the direction normal	2831:2850	the direction normal	2831:2850	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	21	139	theme	%	3226:3226	arg1	E					3227:3227	%E	3226:3227	macronutrients' %E differentiated by gender	3210:3252	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	22	140	theme	fatty	3393:3397	arg1	acids					3399:3403	saturated fatty acids	3383:3403	saturated fatty acids	3383:3403	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	140	theme	fatty	3393:3397	arg1	protein					3363:3369	protein	3363:3369	protein	3363:3369	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	20	141	theme	%	3015:3015	arg1	carbohydrates					3018:3030	%E fat/%E carbohydrates	3008:3030	%E fat/%E carbohydrates	3008:3030	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	16	142	theme	total	2278:2282	arg1	carbohydrates					2284:2296	total carbohydrates	2278:2296	total carbohydrates	2278:2296	In men, the consumption of %E due to total carbohydrates is lower in groups with overweight and obesity compared with normal and malnutrition.
32790257	24	143	theme	conditions	3771:3780	arg1	prevalence					3751:3760	the prevalence	3747:3760	the prevalence of these conditions	3747:3780	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	15	144	from	intake	2173:2178	arg1	groups					2187:2192	BMI groups	2183:2192	BMI groups	2183:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	14	145	with	proportion	1947:1956	arg1	increase					1979:1986	an increase	1976:1986	an increase in the BMI category	1976:2006	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	19	146	theme	added	2716:2720	arg1	sugar					2722:2726	added sugar	2716:2726	added sugar	2716:2726	Consumption of %E due to added sugar and the frequency of consumption of more than 10%E due to sugar are reduced in people of both sexes in the direction normal, overweight, and obesity.
32790257	15	147	theme	%	2163:2163	arg1	E					2164:2164	%E	2163:2164	%E of fat intake in BMI groups	2163:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	24	148	theme	energy	3580:3585	arg1	role					3568:3571	a more significant role	3549:3571	a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity	3549:3655	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	21	149	dep	macronutrients	3210:3223	arg1	E					3227:3227	%E	3226:3227	macronutrients' %E differentiated by gender	3210:3252	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	20	150	from	increase	2983:2990	arg1	ratio					2999:3003	the ratio	2995:3003	the ratio of %E fat/%E carbohydrates in people with overweight and obesity	2995:3068	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	21	151	theme	variance	3083:3090	arg1	Analysis					3071:3078	Analysis	3071:3078	Analysis of variance	3071:3090	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	7	152	theme	sexes	912:916	arg1	adults					897:902	adults	897:902	adults of both sexes (24 767 men and 30 040 women) aged 19-60 years	897:963	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	8	153	theme	nutritional	1303:1313	arg1	status					1315:1320	nutritional status	1303:1320	nutritional status	1303:1320	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	154	theme	natural	1149:1155	arg1	mono-					1157:1161	natural mono-	1149:1161	natural mono-	1149:1161	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	154	theme	natural	1149:1155	arg1	fat					1114:1116	fat	1114:1116	fat	1114:1116	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	22	155	theme	overweight	3272:3281	arg1	higher					3312:3317	higher	3312:3317	higher	3312:3317	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	155	theme	overweight	3272:3281	arg1	frequency					3259:3267	The frequency	3255:3267	The frequency of overweight and obesity	3255:3293	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	1	156	theme	fundamental	140:150	arg1	balance					228:234	a positive balance	217:234	a positive balance of energy	217:244	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	1	156	theme	fundamental	140:150	arg1	cause					152:156	The fundamental cause	136:156	The fundamental cause for the development of overweight and obesity in adults	136:212	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	15	157	theme	significant	2136:2146	arg1	differences					2148:2158	statistically significant differences	2122:2158	statistically significant differences in %E of fat intake in BMI groups	2122:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	22	158	theme	individual	3465:3474	arg1	sugar					3503:3507	added sugar	3497:3507	added sugar	3497:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	158	theme	individual	3465:3474	arg1	fractions					3476:3484	their individual fractions	3459:3484	their individual fractions	3459:3484	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	11	159	theme	macronutrients	1547:1560	arg1	intake					1530:1535	the absolute values of macronutrients' intake	1491:1535	the absolute values of macronutrients' intake	1491:1535	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	11	159	theme	macronutrients	1547:1560	arg1	E					1542:1542	%E	1541:1542	%E	1541:1542	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	11	159	theme	macronutrients	1547:1560	arg1	higher					1580:1585	higher	1580:1585	higher	1580:1585	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	11	159	theme	macronutrients	1547:1560	arg1	intake					1461:1466	The intake	1457:1466	The intake of total daily energy	1457:1488	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	17	160	from	malnutrition	2509:2520	arg1	range					2498:2502	the range	2494:2502	the range from malnutrition to obesity	2494:2531	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	20	161	theme	BMI	2901:2903	arg1	effect					2891:2896	The opposite effect	2878:2896	The opposite effect of BMI on the consumption of %E of fat and carbohydrates	2878:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	6	162	theme	anthropometric	659:672	arg1	parameters					674:683	anthropometric parameters	659:683	anthropometric parameters (height, weight)	659:700	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	24	163	with	association	3730:3740	arg1	prevalence					3751:3760	the prevalence	3747:3760	the prevalence of these conditions	3747:3780	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	20	164	theme	carbohydrates	2941:2953	arg1	E					2928:2928	%E	2927:2928	%E of fat and carbohydrates	2927:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	14	165	from	increase	1979:1986	arg1	category					1999:2006	the BMI category	1991:2006	the BMI category	1991:2006	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	24	166	theme	component	3603:3611	arg1	energy					3580:3585	the energy	3576:3585	the energy of the diet fat component	3576:3611	The data obtained indicate a more significant role of the energy of the diet fat component in the prevalence of overweight and obesity, while the energy of carbohydrates, including added sugar, has no direct association with the prevalence of these conditions.
32790257	13	167	from	men	1829:1831	arg1	pronounced					1815:1824	pronounced	1815:1824	pronounced	1815:1824	This relationship is more pronounced in men, but statistically significant in women as well (p<0.001 when comparing all BMI groups).
32790257	6	168	theme	intake	648:653	arg1	Assessment					626:635	Assessment	626:635	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population	626:724	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	14	169	theme	%	1961:1961	arg1	E					1962:1962	%E	1961:1962	%E of fat	1961:1969	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	9	170	theme	daily	1367:1371	arg1	age					1391:1393	age	1391:1393	age	1391:1393	The total daily energy intake and age were used as covariates in the model.
32790257	9	170	theme	daily	1367:1371	arg1	intake					1380:1385	The total daily energy intake	1357:1385	The total daily energy intake	1357:1385	The total daily energy intake and age were used as covariates in the model.
32790257	9	170	theme	daily	1367:1371	arg1	covariates					1408:1417	covariates	1408:1417	covariates	1408:1417	The total daily energy intake and age were used as covariates in the model.
32790257	6	171	from	survey	761:766	arg1	Russia					785:790	Russia	785:790	Russia	785:790	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	16	172	with	groups	2310:2315	arg1	obesity					2337:2343	obesity	2337:2343	obesity	2337:2343	In men, the consumption of %E due to total carbohydrates is lower in groups with overweight and obesity compared with normal and malnutrition.
32790257	16	172	with	groups	2310:2315	arg1	overweight					2322:2331	overweight	2322:2331	overweight	2322:2331	In men, the consumption of %E due to total carbohydrates is lower in groups with overweight and obesity compared with normal and malnutrition.
32790257	7	173	dep	adults	897:902	arg1	women					941:945	040 women	937:945	30 040 women	934:945	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	7	173	dep	adults	897:902	arg1	men					926:928	767 men	922:928	24 767 men	919:928	For analysis, we selected data from a survey of adults of both sexes (24 767 men and 30 040 women) aged 19-60 years, obtained in 7 rounds of the project during the period 2000-2012.
32790257	3	174	theme	diet	390:393	arg1	composition					371:381	the composition	367:381	the composition of the diet	367:393	These, of course, include the composition of the diet and the structure of its energy value.
32790257	3	174	theme	diet	390:393	arg1	structure					403:411	the structure	399:411	the structure of its energy value	399:431	These, of course, include the composition of the diet and the structure of its energy value.
32790257	0	175	theme	association	17:27	arg1	[Analysis					0:8	[Analysis	0:8	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population	0:132	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	18	176	theme	natural	2617:2623	arg1	sugar					2625:2629	natural sugar	2617:2629	natural sugar	2617:2629	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	15	177	theme	intake	2173:2178	arg1	E					2164:2164	%E	2163:2164	%E of fat intake in BMI groups	2163:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	20	178	theme	E	2928:2928	arg1	consumption					2912:2922	the consumption	2908:2922	the consumption of %E of fat and carbohydrates	2908:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	6	179	dep	Russia	785:790	arg1	Russian					793:799	Russian	793:799	Russian	793:799	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	6	179	dep	Russia	785:790	arg1	project					839:845	RLMS project	834:845	RLMS project	834:845	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	22	180	theme	obesity	3287:3293	arg1	higher					3312:3317	higher	3312:3317	higher	3312:3317	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	180	theme	obesity	3287:3293	arg1	frequency					3259:3267	The frequency	3255:3267	The frequency of overweight and obesity	3255:3293	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	11	181	theme	energy	1483:1488	arg1	intake					1530:1535	the absolute values of macronutrients' intake	1491:1535	the absolute values of macronutrients' intake	1491:1535	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	11	181	theme	energy	1483:1488	arg1	E					1542:1542	%E	1541:1542	%E	1541:1542	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	11	181	theme	energy	1483:1488	arg1	higher					1580:1585	higher	1580:1585	higher	1580:1585	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	11	181	theme	energy	1483:1488	arg1	intake					1461:1466	The intake	1457:1466	The intake of total daily energy	1457:1488	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	8	182	theme	independent	1200:1210	arg1	variables					1221:1229	independent (factor) variables	1200:1229	independent (factor) variables	1200:1229	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	3	183	theme	energy	420:425	arg1	value					427:431	its energy value	416:431	its energy value	416:431	These, of course, include the composition of the diet and the structure of its energy value.
32790257	0	184	theme	diet	32:35	arg1	energy					37:42	diet energy	32:42	diet energy from macronutrients	32:62	[Analysis of the association of diet energy from macronutrients and prevalence of overweight and obesity among the Russian population].
32790257	15	185	from	E	2164:2164	arg1	groups					2187:2192	BMI groups	2183:2192	BMI groups	2183:2192	In women, statistically significant differences in %E of fat intake in BMI groups were observed only between obesity and normal.
32790257	20	186	theme	fat	2933:2935	arg1	E					2928:2928	%E	2927:2928	%E of fat and carbohydrates	2927:2953	The opposite effect of BMI on the consumption of %E of fat and carbohydrates is clearly manifested in an increase in the ratio of %E fat/%E carbohydrates in people with overweight and obesity.
32790257	11	187	theme	total	1471:1475	arg1	energy					1483:1488	total daily energy	1471:1488	total daily energy	1471:1488	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	8	188	theme	factor	1213:1218	arg1	variables					1221:1229	independent (factor) variables	1200:1229	independent (factor) variables	1200:1229	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	11	189	theme	BMI	1695:1697	arg1	values					1699:1704	normal BMI values	1688:1704	normal BMI values	1688:1704	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	14	190	theme	linear	1924:1929	arg1	increase					1931:1938	A linear increase	1922:1938	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity	1922:2052	A linear increase in the proportion of %E of fat with an increase in the BMI category in the direction from malnutrition to obesity was found in men (p<0.001 when comparing all BMI groups).
32790257	17	191	theme	natural	2416:2422	arg1	mono-					2424:2428	natural mono-	2416:2428	natural mono-	2416:2428	The exception is only for %E of natural mono- and disaccharides, the consumption of which in men increases in the range from malnutrition to obesity.
32790257	22	192	theme	added	3497:3501	arg1	sugar					3503:3507	added sugar	3497:3507	added sugar	3497:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	193	theme	total	3435:3439	arg1	carbohydrates					3441:3453	total carbohydrates	3435:3453	total carbohydrates	3435:3453	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	22	193	theme	total	3435:3439	arg1	sugar					3503:3507	added sugar	3497:3507	added sugar	3497:3507	The frequency of overweight and obesity is significantly higher in the groups of highest quartiles of %E of protein, total fat, saturated fatty acids and lowest quartiles of %E of total carbohydrates and their individual fractions, including added sugar.
32790257	11	194	theme	consumption	1625:1635	arg1	exception					1608:1616	the exception	1604:1616	the exception of the consumption of various fractions of carbohydrates	1604:1673	The intake of total daily energy, the absolute values of macronutrients' intake and %E of macronutrients are significantly higher in obesity (with the exception of the consumption of various fractions of carbohydrates) compared to normal BMI values.
32790257	6	195	dep	parameters	674:683	arg1	height					686:691	height	686:691	height	686:691	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	6	195	dep	parameters	674:683	arg1	weight					694:699	weight	694:699	weight	694:699	Assessment of dietary intake and anthropometric parameters (height, weight) of the adult population were obtained in a cross-sectional survey of households in Russia (Russian longitudinal monitoring surveys, RLMS project).
32790257	8	196	dep	variables	1056:1064	arg1	gender					1238:1243	gender	1238:1243	gender	1238:1243	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	8	196	dep	variables	1056:1064	arg1	categories					1251:1260	4 categories	1249:1260	4 categories of body mass index (BMI)	1249:1285	Association of dependent variables of macronutrients' energy as a percentage (%E) (fat, protein, total carbohydrates, natural mono- and disaccharides, added sugar), and independent (factor) variables namely gender and 4 categories of body mass index (BMI), characterizing nutritional status, was investigated using the ANOVA.
32790257	21	197	theme	distribution	3138:3149	arg1	frequency					3125:3133	the frequency	3121:3133	the frequency of distribution of respondents with overweight and obesity	3121:3192	Analysis of variance was confirmed when assessing the frequency of distribution of respondents with overweight and obesity in quartiles of macronutrients' %E differentiated by gender.
32790257	9	198	used	used	1400:1403	arg2	age					1391:1393	age	1391:1393	age	1391:1393	The total daily energy intake and age were used as covariates in the model.
32790257	9	198	used	used	1400:1403	arg2	intake					1380:1385	The total daily energy intake	1357:1385	The total daily energy intake	1357:1385	The total daily energy intake and age were used as covariates in the model.
32790257	9	198	used	used	1400:1403	arg2	covariates					1408:1417	covariates	1408:1417	covariates	1408:1417	The total daily energy intake and age were used as covariates in the model.
32790257	4	199	theme	energy	561:566	arg1	intake					568:573	the macronutrients' energy intake	541:573	the macronutrients' energy intake of Russian adult population	541:601	The aim of the study was to explore the relationship between the prevalence of overweight and obesity with the macronutrients' energy intake of Russian adult population.
32790257	13	200	from	pronounced	1815:1824	arg1	men					1829:1831	men	1829:1831	men	1829:1831	This relationship is more pronounced in men, but statistically significant in women as well (p<0.001 when comparing all BMI groups).
32790257	18	201	with	women	2537:2541	arg1	obesity					2563:2569	obesity	2563:2569	obesity	2563:2569	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	18	201	with	women	2537:2541	arg1	overweight					2548:2557	overweight	2548:2557	overweight	2548:2557	In women with overweight and obesity, consumption of %E due to polysaccharides and natural sugar doesn't differ from consumption in persons with normal BMI.
32790257	1	202	theme	positive	219:226	arg1	balance					228:234	a positive balance	217:234	a positive balance of energy	217:244	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
32790257	1	202	theme	positive	219:226	arg1	cause					152:156	The fundamental cause	136:156	The fundamental cause for the development of overweight and obesity in adults	136:212	The fundamental cause for the development of overweight and obesity in adults is a positive balance of energy.
34422587	12	0	theme	positive	1659:1666	arg1	HRos					1684:1687	HRos	1684:1687	HRos	1684:1687	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	0	theme	positive	1659:1666	arg1	expression					1672:1681	positive sTn expression	1659:1681	positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010)	1659:1776	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	11	1	theme	markers	1532:1538	arg1	expression					1513:1522	concomitant high expression	1496:1522	concomitant high expression of both markers	1496:1538	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	1	2	gly	sialylated	169:178	arg1	glycans					189:195	mucin-type sialylated O-linked glycans	158:195	mucin-type sialylated O-linked glycans	158:195	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	3	3	theme	expression	497:506	arg1	effects					482:488	the clinicopathological and prognostic effects	443:488	the clinicopathological and prognostic effects of sTn expression	443:506	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	3	3	theme	expression	497:506	arg1	relationship					516:527	its relationship	512:527	its relationship with PD-L1 expression in BC tissues	512:563	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	1	4	theme	Siglec	259:264	arg1	receptors					266:274	Siglec receptors	259:274	Siglec receptors	259:274	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	14	5	theme	BC	2157:2158	arg1	patients					2160:2167	BC patients	2157:2167	BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials	2157:2261	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	12	6	theme	multivariate	1611:1622	arg1	model					1639:1643	The multivariate Cox regression model	1607:1643	The multivariate Cox regression model	1607:1643	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	11	7	theme	highest	1548:1554	arg1	risk					1556:1559	the highest risk	1544:1559	the highest risk of relapse (P<0.001) and mortality (P<0.001)	1544:1604	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	9	8	theme	sTn	1132:1134	arg1	expression					1146:1155	sTn and PD-L1 expression	1132:1155	sTn and PD-L1 expression in tumor tissues	1132:1172	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
34422587	12	9	theme	positive	1782:1789	arg1	expression					1797:1806	positive PD-L1 expression	1782:1806	positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014)	1782:1901	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	9	theme	positive	1782:1789	arg1	HRos					1809:1812	HRos	1809:1812	HRos	1809:1812	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	10	theme	regression	1628:1637	arg1	model					1639:1643	The multivariate Cox regression model	1607:1643	The multivariate Cox regression model	1607:1643	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	11	theme	HRpfs	1855:1859	arg1	3.212					1837:1841	3.212	1837:1841	3.212	1837:1841	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	11	theme	HRpfs	1855:1859	arg1	3.110					1884:1888	3.110	1884:1888	3.110	1884:1888	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	11	theme	HRpfs	1855:1859	arg1	Pos=0.017					1844:1852	Pos=0.017	1844:1852	Pos=0.017	1844:1852	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	11	theme	HRpfs	1855:1859	arg1	%					1824:1824	95% CI: 1.138	1822:1834	95% CI: 1.138	1822:1834	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	11	theme	HRpfs	1855:1859	arg1	%					1871:1871	95% CI: 1.116	1869:1881	95% CI: 1.116	1869:1881	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	11	theme	HRpfs	1855:1859	arg1	Ppfs=0.014					1891:1900	Ppfs=0.014	1891:1900	Ppfs=0.014	1891:1900	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	10	12	theme	node	1445:1448	arg1	metastasis					1450:1459	positive lymph node metastasis	1430:1459	positive lymph node metastasis (P=0.002)	1430:1469	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	12	theme	node	1445:1448	arg1	P=0.002					1462:1468	P=0.002	1462:1468	P=0.002	1462:1468	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	9	13	theme	PD-L1	1140:1144	arg1	expression					1146:1155	sTn and PD-L1 expression	1132:1155	sTn and PD-L1 expression in tumor tissues	1132:1172	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
34422587	1	14	theme	O-linked	180:187	arg1	glycans					189:195	mucin-type sialylated O-linked glycans	158:195	mucin-type sialylated O-linked glycans	158:195	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	14	15	theme	dual	2129:2132	arg1	blockade					2134:2141	dual blockade	2129:2141	dual blockade	2129:2141	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	10	16	theme	high	1356:1359	arg1	density					1361:1367	high density	1356:1367	high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028)	1356:1423	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	16	theme	high	1356:1359	arg1	TILs					1409:1412	TILs	1409:1412	TILs	1409:1412	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	16	theme	high	1356:1359	arg1	P=0.028					1416:1422	P=0.028	1416:1422	P=0.028	1416:1422	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	17	theme	advanced	1324:1331	arg1	P<0.001					1346:1352	P<0.001	1346:1352	P<0.001	1346:1352	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	17	theme	advanced	1324:1331	arg1	stage					1339:1343	advanced tumor stage	1324:1343	advanced tumor stage (P<0.001)	1324:1353	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	13	18	theme	BC	2025:2026	arg1	patients					2028:2035	CONCLUSIONS BC patients	2013:2035	CONCLUSIONS BC patients who expressed both sTn and PD-L1	2013:2068	CONCLUSIONS BC patients who expressed both sTn and PD-L1 had poorer survival.
34422587	4	19	theme	invasive	627:634	arg1	patients					639:646	380 invasive BC patients	623:646	380 invasive BC patients	623:646	METHODS We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014.
34422587	5	20	theme	follow-up	696:704	arg1	January					715:721	January	715:721	January	715:721	The last follow-up time was January 31, 2019 with a median follow-up of 62 months.
34422587	5	20	theme	follow-up	696:704	arg1	time					706:709	The last follow-up time	687:709	The last follow-up time	687:709	The last follow-up time was January 31, 2019 with a median follow-up of 62 months.
34422587	3	21	theme	BC	554:555	arg1	tissues					557:563	BC tissues	554:563	BC tissues	554:563	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	14	22	with	patients	2160:2167	arg1	/PD-L1					2180:2185	/PD-L1	2180:2185	/PD-L1	2180:2185	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	14	22	with	patients	2160:2167	arg1	sTn					2174:2176	sTn	2174:2176	sTn	2174:2176	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	14	22	with	patients	2160:2167	arg1	expression					2190:2199	expression	2190:2199	expression	2190:2199	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	4	23	theme	patients	639:646	arg1	data					615:618	the clinical data	602:618	the clinical data of 380 invasive BC patients between January 2011 and January 2014	602:684	METHODS We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014.
34422587	8	24	dep	lower	1057:1061	arg1	%					1085:1085	41.8%	1081:1085	41.8%	1081:1085	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	4	25	dep	METHODS	566:572	arg1	analyzed					593:600	analyzed	593:600	analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014	593:684	METHODS We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014.
34422587	1	26	theme	recent	133:138	arg1	study					140:144	A recent study	131:144	A recent study	131:144	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	14	27	theme	future	2240:2245	arg1	trials					2256:2261	future clinical trials	2240:2261	future clinical trials	2240:2261	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	0	28	from	prognosis	92:100	arg1	cancer					112:117	breast cancer	105:117	breast cancer	105:117	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	0	29	theme	poor	78:81	arg1	prognosis					92:100	poor clinical prognosis	78:100	poor clinical prognosis in breast cancer	78:117	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	8	30	theme	expression	1015:1024	arg1	lower					1057:1061	lower	1057:1061	lower	1057:1061	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	8	30	theme	expression	1015:1024	arg1	rate					1026:1029	the positive expression rate	1002:1029	the positive expression rate of PD-L1 (20.5%)	1002:1046	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	1	31	theme	mucin-type	158:167	arg1	glycans					189:195	mucin-type sialylated O-linked glycans	158:195	mucin-type sialylated O-linked glycans	158:195	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	12	32	theme	progression-free	1966:1981	arg1	survival					1983:1990	progression-free survival	1966:1990	progression-free survival	1966:1990	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	3	33	from	expression	540:549	arg1	tissues					557:563	BC tissues	554:563	BC tissues	554:563	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	12	34	theme	overall	1940:1946	arg1	OS					1958:1959	OS	1958:1959	OS	1958:1959	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	34	theme	overall	1940:1946	arg1	survival					1948:1955	poor overall survival	1935:1955	poor overall survival (OS)	1935:1960	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	34	theme	overall	1940:1946	arg1	PFS					1993:1995	PFS	1993:1995	PFS	1993:1995	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	10	35	theme	CD8+	1372:1375	arg1	lymphocytes					1396:1406	CD8+ tumor-infiltrating lymphocytes	1372:1406	CD8+ tumor-infiltrating lymphocytes	1372:1406	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	12	36	theme	poor	1935:1938	arg1	OS					1958:1959	OS	1958:1959	OS	1958:1959	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	36	theme	poor	1935:1938	arg1	survival					1948:1955	poor overall survival	1935:1955	poor overall survival (OS)	1935:1960	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	36	theme	poor	1935:1938	arg1	PFS					1993:1995	PFS	1993:1995	PFS	1993:1995	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	10	37	theme	sTn	1222:1224	arg1	expression					1226:1235	High sTn expression	1217:1235	High sTn expression	1217:1235	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	0	38	theme	breast	105:110	arg1	cancer					112:117	breast cancer	105:117	breast cancer	105:117	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	7	39	theme	clinicopathological	921:939	arg1	features					941:948	features	941:948	features	941:948	Correlations between sTn/PD-L1 expression and clinicopathological features and prognoses were analyzed.
34422587	0	40	theme	Mucin-type	0:9	arg1	antigen					21:27	Mucin-type sialyl-Tn antigen	0:27	Mucin-type sialyl-Tn antigen	0:27	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	6	41	dep	sTn	792:794	arg1	PD-L1					808:812	PD-L1	808:812	PD-L1	808:812	The expression of the sTn antigen and PD-L1 in 380 tumor specimens was assessed by immunohistochemistry.
34422587	6	41	dep	sTn	792:794	arg1	antigen					796:802	antigen	796:802	antigen	796:802	The expression of the sTn antigen and PD-L1 in 380 tumor specimens was assessed by immunohistochemistry.
34422587	12	42	dep	HRos	1684:1687	arg1	Pos=0.028					1719:1727	Pos=0.028	1719:1727	Pos=0.028	1719:1727	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	42	dep	HRos	1684:1687	arg1	1.941					1690:1694	1.941	1690:1694	1.941	1690:1694	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	42	dep	HRos	1684:1687	arg1	%					1699:1699	95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010	1697:1775	%	1699:1699	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	42	dep	HRos	1684:1687	arg1	Ppfs=0.010					1766:1775	Ppfs=0.010	1766:1775	Ppfs=0.010	1766:1775	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	10	43	theme	lymphocytes	1396:1406	arg1	P<0.001					1314:1320	P<0.001	1314:1320	P<0.001	1314:1320	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	P=0.028					1416:1422	P=0.028	1416:1422	P=0.028	1416:1422	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	P<0.001					1346:1352	P<0.001	1346:1352	P<0.001	1346:1352	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	metastasis					1450:1459	positive lymph node metastasis	1430:1459	positive lymph node metastasis (P=0.002)	1430:1469	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	P=0.002					1462:1468	P=0.002	1462:1468	P=0.002	1462:1468	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	TILs					1409:1412	TILs	1409:1412	TILs	1409:1412	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	expression					1269:1278	negative ER expression	1257:1278	negative ER expression (P<0.001)	1257:1288	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	stage					1339:1343	advanced tumor stage	1324:1343	advanced tumor stage (P<0.001)	1324:1353	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	density					1361:1367	high density	1356:1367	high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028)	1356:1423	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	status					1306:1311	positive HER-2 status	1291:1311	positive HER-2 status (P<0.001)	1291:1321	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	43	theme	lymphocytes	1396:1406	arg1	P<0.001					1281:1287	P<0.001	1281:1287	P<0.001	1281:1287	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	12	44	dep	HRos	1809:1812	arg1	1.912					1815:1819	1.912	1815:1819	1.912	1815:1819	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	44	dep	HRos	1809:1812	arg1	3.212					1837:1841	3.212	1837:1841	3.212	1837:1841	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	44	dep	HRos	1809:1812	arg1	3.110					1884:1888	3.110	1884:1888	3.110	1884:1888	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	44	dep	HRos	1809:1812	arg1	Pos=0.017					1844:1852	Pos=0.017	1844:1852	Pos=0.017	1844:1852	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	44	dep	HRos	1809:1812	arg1	%					1824:1824	95% CI: 1.138	1822:1834	95% CI: 1.138	1822:1834	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	44	dep	HRos	1809:1812	arg1	%					1871:1871	95% CI: 1.116	1869:1881	95% CI: 1.116	1869:1881	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	44	dep	HRos	1809:1812	arg1	Ppfs=0.014					1891:1900	Ppfs=0.014	1891:1900	Ppfs=0.014	1891:1900	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	11	45	theme	relapse	1564:1570	arg1	risk					1556:1559	the highest risk	1544:1559	the highest risk of relapse (P<0.001) and mortality (P<0.001)	1544:1604	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	2	46	theme	antigen	354:360	arg1	PD-L1					372:376	PD-L1	372:376	PD-L1	372:376	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	2	46	theme	antigen	354:360	arg1	expression					315:324	the expression	311:324	the expression of the mucin-type sialyl-Tn antigen (sTn)	311:366	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	0	47	theme	PD-L1	48:52	arg1	expression					54:63	PD-L1 expression	48:63	PD-L1 expression	48:63	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	10	48	theme	ER	1266:1267	arg1	P<0.001					1281:1287	P<0.001	1281:1287	P<0.001	1281:1287	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	48	theme	ER	1266:1267	arg1	expression					1269:1278	negative ER expression	1257:1278	negative ER expression (P<0.001)	1257:1288	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	2	49	theme	mucin-type	333:342	arg1	sTn					363:365	sTn	363:365	sTn	363:365	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	2	49	theme	mucin-type	333:342	arg1	antigen					354:360	the mucin-type sialyl-Tn antigen	329:360	the mucin-type sialyl-Tn antigen (sTn)	329:366	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	7	50	theme	sTn/PD-L1	896:904	arg1	expression					906:915	sTn/PD-L1 expression	896:915	sTn/PD-L1 expression	896:915	Correlations between sTn/PD-L1 expression and clinicopathological features and prognoses were analyzed.
34422587	10	51	theme	lymph	1439:1443	arg1	metastasis					1450:1459	positive lymph node metastasis	1430:1459	positive lymph node metastasis (P=0.002)	1430:1469	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	51	theme	lymph	1439:1443	arg1	P=0.002					1462:1468	P=0.002	1462:1468	P=0.002	1462:1468	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	11	52	theme	high	1508:1511	arg1	expression					1513:1522	concomitant high expression	1496:1522	concomitant high expression of both markers	1496:1538	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	12	53	theme	PD-L1	1791:1795	arg1	expression					1797:1806	positive PD-L1 expression	1782:1806	positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014)	1782:1901	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	53	theme	PD-L1	1791:1795	arg1	HRos					1809:1812	HRos	1809:1812	HRos	1809:1812	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	54	theme	sTn	1668:1670	arg1	HRos					1684:1687	HRos	1684:1687	HRos	1684:1687	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	54	theme	sTn	1668:1670	arg1	expression					1672:1681	positive sTn expression	1659:1681	positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010)	1659:1776	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	5	55	theme	median	739:744	arg1	follow-up					746:754	a median follow-up	737:754	a median follow-up of 62 months	737:767	The last follow-up time was January 31, 2019 with a median follow-up of 62 months.
34422587	3	56	theme	sTn	493:495	arg1	expression					497:506	sTn expression	493:506	sTn expression	493:506	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	12	57	theme	Cox	1624:1626	arg1	model					1639:1643	The multivariate Cox regression model	1607:1643	The multivariate Cox regression model	1607:1643	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	3	58	theme	PD-L1	534:538	arg1	expression					540:549	PD-L1 expression	534:549	PD-L1 expression in BC tissues	534:563	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	8	59	theme	BC	990:991	arg1	tissues					993:999	BC tissues	990:999	BC tissues	990:999	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	1	60	theme	sialylated	169:178	arg1	glycans					189:195	mucin-type sialylated O-linked glycans	158:195	mucin-type sialylated O-linked glycans	158:195	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	3	61	with	effects	482:488	arg1	expression					540:549	PD-L1 expression	534:549	PD-L1 expression in BC tissues	534:563	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	10	62	theme	tumor	1333:1337	arg1	P<0.001					1346:1352	P<0.001	1346:1352	P<0.001	1346:1352	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	62	theme	tumor	1333:1337	arg1	stage					1339:1343	advanced tumor stage	1324:1343	advanced tumor stage (P<0.001)	1324:1353	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	13	63	theme	CONCLUSIONS	2013:2023	arg1	patients					2028:2035	CONCLUSIONS BC patients	2013:2035	CONCLUSIONS BC patients who expressed both sTn and PD-L1	2013:2068	CONCLUSIONS BC patients who expressed both sTn and PD-L1 had poorer survival.
34422587	8	64	theme	positive	1006:1013	arg1	lower					1057:1061	lower	1057:1061	lower	1057:1061	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	8	64	theme	positive	1006:1013	arg1	rate					1026:1029	the positive expression rate	1002:1029	the positive expression rate of PD-L1 (20.5%)	1002:1046	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	5	65	theme	last	691:694	arg1	January					715:721	January	715:721	January	715:721	The last follow-up time was January 31, 2019 with a median follow-up of 62 months.
34422587	5	65	theme	last	691:694	arg1	time					706:709	The last follow-up time	687:709	The last follow-up time	687:709	The last follow-up time was January 31, 2019 with a median follow-up of 62 months.
34422587	9	66	theme	tumor	1160:1164	arg1	tissues					1166:1172	tumor tissues	1160:1172	tumor tissues	1160:1172	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
34422587	12	67	theme	2.847	1759:1763	arg1	%					1746:1746	1.739, 95% CI: 1.063	1737:1756	%	1746:1746	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	1	68	theme	increased	214:222	arg1	expression					224:233	the increased expression	210:233	the increased expression of PD-L1	210:242	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	4	69	theme	BC	636:637	arg1	patients					639:646	380 invasive BC patients	623:646	380 invasive BC patients	623:646	METHODS We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014.
34422587	9	70	theme	high	1189:1192	arg1	P<0.001					1207:1213	P<0.001	1207:1213	P<0.001	1207:1213	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
34422587	9	70	theme	high	1189:1192	arg1	correlation					1194:1204	a high correlation	1187:1204	a high correlation (P<0.001)	1187:1214	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
34422587	14	71	theme	clinical	2247:2254	arg1	trials					2256:2261	future clinical trials	2240:2261	future clinical trials	2240:2261	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	9	72	from	expression	1146:1155	arg1	tissues					1166:1172	tumor tissues	1160:1172	tumor tissues	1160:1172	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
34422587	11	73	with	patients	1482:1489	arg1	expression					1513:1522	concomitant high expression	1496:1522	concomitant high expression of both markers	1496:1538	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	0	74	theme	clinical	83:90	arg1	prognosis					92:100	poor clinical prognosis	78:100	poor clinical prognosis in breast cancer	78:117	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	14	75	theme	further	2217:2223	arg1	examination					2225:2235	further examination	2217:2235	further examination in future clinical trials	2217:2261	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	8	76	theme	PD-L1	1034:1038	arg1	lower					1057:1061	lower	1057:1061	lower	1057:1061	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	8	76	theme	PD-L1	1034:1038	arg1	rate					1026:1029	the positive expression rate	1002:1029	the positive expression rate of PD-L1 (20.5%)	1002:1046	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	10	77	theme	HER-2	1300:1304	arg1	P<0.001					1314:1320	P<0.001	1314:1320	P<0.001	1314:1320	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	77	theme	HER-2	1300:1304	arg1	status					1306:1311	positive HER-2 status	1291:1311	positive HER-2 status (P<0.001)	1291:1321	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	14	78	with	therapy	2116:2122	arg1	blockade					2134:2141	dual blockade	2129:2141	dual blockade	2129:2141	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	12	79	theme	independent	1908:1918	arg1	indicators					1920:1929	independent indicators	1908:1929	independent indicators for poor overall survival (OS) and progression-free survival (PFS)	1908:1996	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	11	80	contain	had	1540:1542	arg2	risk					1556:1559	the highest risk	1544:1559	the highest risk of relapse (P<0.001) and mortality (P<0.001)	1544:1604	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	11	80	contain	had	1540:1542	arg1	patients					1482:1489	patients	1482:1489	patients with concomitant high expression of both markers	1482:1538	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	6	81	from	expression	774:783	arg1	specimens					827:835	380 tumor specimens	817:835	380 tumor specimens	817:835	The expression of the sTn antigen and PD-L1 in 380 tumor specimens was assessed by immunohistochemistry.
34422587	1	82	dep	BACKGROUND	120:129	arg1	showed					146:151	showed	146:151	showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors	146:274	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	10	83	theme	High	1217:1220	arg1	expression					1226:1235	High sTn expression	1217:1235	High sTn expression	1217:1235	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	0	84	theme	sialyl-Tn	11:19	arg1	antigen					21:27	Mucin-type sialyl-Tn antigen	0:27	Mucin-type sialyl-Tn antigen	0:27	Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
34422587	12	85	dep	%	1699:1699	arg1	3.223					1712:1716	3.223	1712:1716	3.223	1712:1716	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	85	dep	%	1699:1699	arg1	%					1746:1746	1.739, 95% CI: 1.063	1737:1756	%	1746:1746	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	12	85	dep	%	1699:1699	arg1	HRpfs					1730:1734	HRpfs	1730:1734	HRpfs	1730:1734	The multivariate Cox regression model revealed that positive sTn expression (HRos: 1.941, 95% CI: 1.168, 3.223, Pos=0.028; HRpfs: 1.739, 95% CI: 1.063, 2.847, Ppfs=0.010) and positive PD-L1 expression (HRos: 1.912, 95% CI: 1.138, 3.212, Pos=0.017; HRpfs: 1.863, 95% CI: 1.116, 3.110, Ppfs=0.014) were independent indicators for poor overall survival (OS) and progression-free survival (PFS), respectively.
34422587	13	86	theme	poorer	2074:2079	arg1	survival					2081:2088	poorer survival	2074:2088	poorer survival	2074:2088	CONCLUSIONS BC patients who expressed both sTn and PD-L1 had poorer survival.
34422587	1	87	link	O-linked	180:187	arg1	glycans					189:195	mucin-type sialylated O-linked glycans	158:195	mucin-type sialylated O-linked glycans	158:195	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	10	88	theme	negative	1257:1264	arg1	P<0.001					1281:1287	P<0.001	1281:1287	P<0.001	1281:1287	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	88	theme	negative	1257:1264	arg1	expression					1269:1278	negative ER expression	1257:1278	negative ER expression (P<0.001)	1257:1288	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	89	theme	positive	1291:1298	arg1	P<0.001					1314:1320	P<0.001	1314:1320	P<0.001	1314:1320	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	89	theme	positive	1291:1298	arg1	status					1306:1311	positive HER-2 status	1291:1311	positive HER-2 status (P<0.001)	1291:1321	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	8	90	dep	RESULTS	979:985	arg1	lower					1057:1061	lower	1057:1061	lower	1057:1061	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	8	90	dep	RESULTS	979:985	arg1	rate					1026:1029	the positive expression rate	1002:1029	the positive expression rate of PD-L1 (20.5%)	1002:1046	RESULTS In BC tissues, the positive expression rate of PD-L1 (20.5%) was much lower than that of sTn (41.8%).
34422587	3	91	theme	clinicopathological	447:465	arg1	effects					482:488	the clinicopathological and prognostic effects	443:488	the clinicopathological and prognostic effects of sTn expression	443:506	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	3	92	with	relationship	516:527	arg1	expression					540:549	PD-L1 expression	534:549	PD-L1 expression in BC tissues	534:563	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	6	93	theme	tumor	821:825	arg1	specimens					827:835	380 tumor specimens	817:835	380 tumor specimens	817:835	The expression of the sTn antigen and PD-L1 in 380 tumor specimens was assessed by immunohistochemistry.
34422587	10	94	theme	tumor-infiltrating	1377:1394	arg1	lymphocytes					1396:1406	CD8+ tumor-infiltrating lymphocytes	1372:1406	CD8+ tumor-infiltrating lymphocytes	1372:1406	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	2	95	theme	breast	397:402	arg1	cancer					404:409	breast cancer	397:409	breast cancer (BC)	397:414	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	2	95	theme	breast	397:402	arg1	BC					412:413	BC	412:413	BC	412:413	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	5	96	theme	months	762:767	arg1	follow-up					746:754	a median follow-up	737:754	a median follow-up of 62 months	737:767	The last follow-up time was January 31, 2019 with a median follow-up of 62 months.
34422587	14	97	from	examination	2225:2235	arg1	trials					2256:2261	future clinical trials	2240:2261	future clinical trials	2240:2261	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	11	98	theme	mortality	1586:1594	arg1	risk					1556:1559	the highest risk	1544:1559	the highest risk of relapse (P<0.001) and mortality (P<0.001)	1544:1604	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	14	99	theme	combinational	2102:2114	arg1	therapy					2116:2122	combinational therapy	2102:2122	combinational therapy with dual blockade	2102:2141	Therefore, combinational therapy with dual blockade might benefit BC patients with sTn(+)/PD-L1(+) expression, which requires further examination in future clinical trials.
34422587	2	100	theme	sialyl-Tn	344:352	arg1	sTn					363:365	sTn	363:365	sTn	363:365	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	2	100	theme	sialyl-Tn	344:352	arg1	antigen					354:360	the mucin-type sialyl-Tn antigen	329:360	the mucin-type sialyl-Tn antigen (sTn)	329:366	However, the relationship between the expression of the mucin-type sialyl-Tn antigen (sTn) and PD-L1 remains unclear in breast cancer (BC).
34422587	4	101	theme	clinical	606:613	arg1	data					615:618	the clinical data	602:618	the clinical data of 380 invasive BC patients between January 2011 and January 2014	602:684	METHODS We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014.
34422587	11	102	theme	concomitant	1496:1506	arg1	expression					1513:1522	concomitant high expression	1496:1522	concomitant high expression of both markers	1496:1538	Moreover, patients with concomitant high expression of both markers had the highest risk of relapse (P<0.001) and mortality (P<0.001).
34422587	3	103	theme	prognostic	471:480	arg1	effects					482:488	the clinicopathological and prognostic effects	443:488	the clinicopathological and prognostic effects of sTn expression	443:506	Therefore, we investigate the clinicopathological and prognostic effects of sTn expression and its relationship with PD-L1 expression in BC tissues.
34422587	1	104	theme	PD-L1	238:242	arg1	expression					224:233	the increased expression	210:233	the increased expression of PD-L1	210:242	BACKGROUND A recent study showed that mucin-type sialylated O-linked glycans could induce the increased expression of PD-L1 via binding to Siglec receptors.
34422587	13	105	contain	had	2070:2072	arg1	patients					2028:2035	CONCLUSIONS BC patients	2013:2035	CONCLUSIONS BC patients who expressed both sTn and PD-L1	2013:2068	CONCLUSIONS BC patients who expressed both sTn and PD-L1 had poorer survival.
34422587	13	105	contain	had	2070:2072	arg2	survival					2081:2088	poorer survival	2074:2088	poorer survival	2074:2088	CONCLUSIONS BC patients who expressed both sTn and PD-L1 had poorer survival.
34422587	6	106	theme	sTn	792:794	arg1	expression					774:783	The expression	770:783	The expression of the sTn antigen and PD-L1 in 380 tumor specimens	770:835	The expression of the sTn antigen and PD-L1 in 380 tumor specimens was assessed by immunohistochemistry.
34422587	4	107	dep	January	656:662	arg1	2011					664:667	2011	664:667	January 2011	656:667	METHODS We retrospectively analyzed the clinical data of 380 invasive BC patients between January 2011 and January 2014.
34422587	10	108	theme	positive	1430:1437	arg1	metastasis					1450:1459	positive lymph node metastasis	1430:1459	positive lymph node metastasis (P=0.002)	1430:1469	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	10	108	theme	positive	1430:1437	arg1	P=0.002					1462:1468	P=0.002	1462:1468	P=0.002	1462:1468	High sTn expression was associated with negative ER expression (P<0.001), positive HER-2 status (P<0.001), advanced tumor stage (P<0.001), high density of CD8+ tumor-infiltrating lymphocytes (TILs) (P=0.028), and positive lymph node metastasis (P=0.002).
34422587	9	109	theme	contingency	1099:1109	arg1	analysis					1111:1118	Pearson's contingency analysis	1089:1118	Pearson's contingency analysis	1089:1118	Pearson's contingency analysis showed that sTn and PD-L1 expression in tumor tissues demonstrated a high correlation (P<0.001).
33231560	9	0	theme	SPC	1800:1802	arg1	MIRI					1815:1818	SPC restrained MIRI	1800:1818	SPC restrained MIRI	1800:1818	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	4	1	theme	2	639:639	arg1	h					641:641	h	641:641	h	641:641	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	6	2	theme	co-immunoprecipitation	985:1006	arg1	experiments					1008:1018	co-immunoprecipitation experiments	985:1018	co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation	985:1093	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	7	3	theme	protein	1269:1275	arg1	kinase					1323:1328	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3	1248:1330	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	3	theme	protein	1269:1275	arg1	RIPK3					1333:1337	RIPK3	1333:1337	RIPK3	1333:1337	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	1	4	contain	have	200:203	arg2	effects					216:222	protective effects	205:222	protective effects	205:222	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	1	4	contain	have	200:203	arg1	anesthetics					162:172	Inhalation anesthetics	151:172	Inhalation anesthetics	151:172	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	6	5	theme	necrotic	862:869	arg1	myocardium					871:880	necrotic myocardium	862:880	necrotic myocardium	862:880	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	1	6	theme	myocardial	232:241	arg1	reperfusion					252:262	myocardial ischemia reperfusion	232:262	myocardial ischemia reperfusion injury (MIRI)	232:276	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	1	7	theme	reperfusion	252:262	arg1	MIRI					272:275	MIRI	272:275	MIRI	272:275	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	1	7	theme	reperfusion	252:262	arg1	injury					264:269	myocardial ischemia reperfusion injury	232:269	myocardial ischemia reperfusion injury (MIRI)	232:276	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	9	8	theme	mediated	1859:1866	arg1	O-GlcNAcylation					1868:1882	OGT mediated O-GlcNAcylation	1855:1882	OGT mediated O-GlcNAcylation of RIPK3	1855:1891	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	7	9	theme	histopathological	1209:1225	arg1	changes					1227:1233	histopathological changes	1209:1233	histopathological changes	1209:1233	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	8	10	theme	SPC	1415:1417	arg1	transferase					1441:1451	SPC up-regulated O-GlcNAc transferase	1415:1451	SPC up-regulated O-GlcNAc transferase (OGT)	1415:1457	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	8	10	theme	SPC	1415:1417	arg1	OGT					1454:1456	OGT	1454:1456	OGT	1454:1456	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	2	11	theme	GlcNAcylation	288:300	arg1	modifications					313:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications have been shown to protect against MIRI.
33231560	8	12	theme	O-GlcNAc	1432:1439	arg1	transferase					1441:1451	SPC up-regulated O-GlcNAc transferase	1415:1451	SPC up-regulated O-GlcNAc transferase (OGT)	1415:1457	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	8	12	theme	O-GlcNAc	1432:1439	arg1	OGT					1454:1456	OGT	1454:1456	OGT	1454:1456	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	7	13	theme	hemodynamic	1175:1185	arg1	performance					1187:1197	hemodynamic performance	1175:1197	hemodynamic performance	1175:1197	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	9	14	theme	cardioprotective	1624:1639	arg1	effects					1641:1647	SPC mediated cardioprotective effects	1611:1647	SPC mediated cardioprotective effects	1611:1647	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	2	15	link	O-linked	279:286	arg1	modifications					313:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications have been shown to protect against MIRI.
33231560	7	16	theme	myocardial	1108:1117	arg1	size					1130:1133	myocardial infarction size	1108:1133	myocardial infarction size	1108:1133	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	17	theme	MLKL	1374:1377	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	2	18	theme	O-GlcNAc	303:310	arg1	modifications					313:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications have been shown to protect against MIRI.
33231560	9	19	theme	OGT	1663:1665	arg1	up-regulation					1676:1688	OGT mediated up-regulation	1663:1688	OGT mediated up-regulation of O-GlcNAcylation	1663:1707	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	9	20	theme	complex	1937:1943	arg1	formulation					1911:1921	the formulation	1907:1921	the formulation of RIPK3/MLKL complex	1907:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	4	21	theme	sevoflurane	570:580	arg1	group					589:593	the SHAM and sevoflurane (SEVO) group	557:593	the SHAM and sevoflurane (SEVO) group	557:593	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	7	22	theme	domain-like	1361:1371	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	1	23	theme	Inhalation	151:160	arg1	anesthetics					162:172	Inhalation anesthetics	151:172	Inhalation anesthetics	151:172	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	0	24	theme	O-GlcNAcylated	129:142	arg1	RIPK3					144:148	OGT-mediated O-GlcNAcylated RIPK3	116:148	OGT-mediated O-GlcNAcylated RIPK3	116:148	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	9	25	theme	O-GlcNAcylation	1693:1707	arg1	down-regulation					1713:1727	down-regulation	1713:1727	down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex	1713:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	9	25	theme	O-GlcNAcylation	1693:1707	arg1	up-regulation					1676:1688	OGT mediated up-regulation	1663:1688	OGT mediated up-regulation of O-GlcNAcylation	1663:1707	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	3	26	theme	cardioprotective	512:527	arg1	effects					529:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	This study aimed to investigate whether O-GlcNAcylation and necroptosis signaling were important for sevoflurane postconditioning (SPC) induced cardioprotective effects.
33231560	4	27	theme	SHAM	561:564	arg1	group					589:593	the SHAM and sevoflurane (SEVO) group	557:593	the SHAM and sevoflurane (SEVO) group	557:593	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	6	28	theme	function	756:763	arg1	parameters					765:774	cardiac function parameters	748:774	cardiac function parameters	748:774	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	9	29	theme	RIPK3	1732:1736	arg1	proteins					1747:1754	RIPK3 and MLKL proteins	1732:1754	RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex	1732:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	4	30	theme	30	611:612	arg1	min					614:616	min	614:616	min	614:616	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	7	31	theme	kinase	1323:1328	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	9	32	theme	MLKL	1742:1745	arg1	proteins					1747:1754	RIPK3 and MLKL proteins	1732:1754	RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex	1732:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	6	33	theme	infarction	731:740	arg1	size					742:745	myocardial infarction size	720:745	myocardial infarction size	720:745	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	7	34	theme	/receptor-interacting	1293:1313	arg1	kinase					1323:1328	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3	1248:1330	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	34	theme	/receptor-interacting	1293:1313	arg1	RIPK3					1333:1337	RIPK3	1333:1337	RIPK3	1333:1337	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	0	35	theme	ischemia	48:55	arg1	reperfusion					57:67	myocardial ischemia reperfusion	37:67	myocardial ischemia reperfusion injury-induced necroptosis	37:94	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	6	36	theme	necroptosis	933:943	arg1	biomarkers					945:954	necroptosis biomarkers	933:954	necroptosis biomarkers	933:954	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	3	37	theme	sevoflurane	469:479	arg1	effects					529:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	This study aimed to investigate whether O-GlcNAcylation and necroptosis signaling were important for sevoflurane postconditioning (SPC) induced cardioprotective effects.
33231560	0	38	theme	injury-induced	69:82	arg1	necroptosis					84:94	myocardial ischemia reperfusion injury-induced necroptosis	37:94	myocardial ischemia reperfusion injury-induced necroptosis	37:94	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	6	39	theme	protein	904:910	arg1	levels					923:928	protein expression levels	904:928	protein expression levels of necroptosis biomarkers	904:954	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	7	40	theme	kinase	1354:1359	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	41	theme	kinase	1277:1282	arg1	kinase					1323:1328	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3	1248:1330	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	41	theme	kinase	1277:1282	arg1	RIPK3					1333:1337	RIPK3	1333:1337	RIPK3	1333:1337	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	6	42	theme	lactic	788:793	arg1	LDH					810:812	LDH	810:812	LDH	810:812	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	42	theme	lactic	788:793	arg1	dehydrogenase					795:807	myocardial lactic dehydrogenase	777:807	myocardial lactic dehydrogenase (LDH) content	777:821	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	9	43	theme	restrained	1804:1813	arg1	MIRI					1815:1818	SPC restrained MIRI	1800:1818	SPC restrained MIRI	1800:1818	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	7	44	theme	mediated	1380:1387	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	45	theme	receptor-interacting	1248:1267	arg1	kinase					1323:1328	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3	1248:1330	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	45	theme	receptor-interacting	1248:1267	arg1	RIPK3					1333:1337	RIPK3	1333:1337	RIPK3	1333:1337	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	9	46	theme	mediated	1667:1674	arg1	up-regulation					1676:1688	OGT mediated up-regulation	1663:1688	OGT mediated up-regulation of O-GlcNAcylation	1663:1707	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	4	47	theme	h	641:641	arg1	reperfusion					643:653	2 h reperfusion	639:653	2 h reperfusion	639:653	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	7	48	theme	RIPK1	1287:1291	arg1	kinase					1323:1328	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3	1248:1330	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	48	theme	RIPK1	1287:1291	arg1	RIPK3					1333:1337	RIPK3	1333:1337	RIPK3	1333:1337	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	9	49	dep	SPC.	1767:1770	arg1	demonstrated					1782:1793	demonstrated	1782:1793	demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex	1782:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	1	50	theme	ischemia	243:250	arg1	reperfusion					252:262	myocardial ischemia reperfusion	232:262	myocardial ischemia reperfusion injury (MIRI)	232:276	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	9	51	theme	OGT	1855:1857	arg1	O-GlcNAcylation					1868:1882	OGT mediated O-GlcNAcylation	1855:1882	OGT mediated O-GlcNAcylation of RIPK3	1855:1891	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	4	52	from	rats	549:552	arg1	group					589:593	the SHAM and sevoflurane (SEVO) group	557:593	the SHAM and sevoflurane (SEVO) group	557:593	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	6	53	theme	histopathological	835:851	arg1	changes					853:859	myocardium histopathological changes	824:859	myocardium histopathological changes	824:859	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	9	54	theme	OGT	1586:1588	arg1	OSMI-1					1575:1580	OSMI-1	1575:1580	OSMI-1	1575:1580	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	9	54	theme	OGT	1586:1588	arg1	inhibitor					1590:1598	an OGT inhibitor	1583:1598	an OGT inhibitor	1583:1598	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	6	55	gly	O-GlcNAcylation	883:897	arg1	addition					710:717	addition	710:717	addition	710:717	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	9	56	theme	RIPK3	1887:1891	arg1	O-GlcNAcylation					1868:1882	OGT mediated O-GlcNAcylation	1855:1882	OGT mediated O-GlcNAcylation of RIPK3	1855:1891	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	7	57	theme	/mixed	1339:1344	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	2	58	theme	O-linked	279:286	arg1	modifications					313:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications	279:325	O-linked GlcNAcylation (O-GlcNAc) modifications have been shown to protect against MIRI.
33231560	7	59	theme	cardiac	1148:1154	arg1	function					1156:1163	cardiac function	1148:1163	cardiac function	1148:1163	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	9	60	theme	mediated	1615:1622	arg1	effects					1641:1647	SPC mediated cardioprotective effects	1611:1647	SPC mediated cardioprotective effects	1611:1647	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	8	61	theme	up-regulated	1419:1430	arg1	transferase					1441:1451	SPC up-regulated O-GlcNAc transferase	1415:1451	SPC up-regulated O-GlcNAc transferase (OGT)	1415:1457	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	8	61	theme	up-regulated	1419:1430	arg1	OGT					1454:1456	OGT	1454:1456	OGT	1454:1456	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	6	62	theme	myocardial	720:729	arg1	size					742:745	myocardial infarction size	720:745	myocardial infarction size	720:745	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	7	63	theme	protein	1315:1321	arg1	kinase					1323:1328	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3	1248:1330	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	63	theme	protein	1315:1321	arg1	RIPK3					1333:1337	RIPK3	1333:1337	RIPK3	1333:1337	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	7	64	theme	infarction	1119:1128	arg1	size					1130:1133	myocardial infarction size	1108:1133	myocardial infarction size	1108:1133	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	9	65	theme	RIPK3/MLKL	1926:1935	arg1	complex					1937:1943	RIPK3/MLKL complex	1926:1943	RIPK3/MLKL complex	1926:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	7	66	theme	lineage	1346:1352	arg1	necroptosis					1389:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis	1248:1399	SPC reduced myocardial infarction size, ameliorated cardiac function, restored hemodynamic performance, improved histopathological changes, and reduced receptor-interacting protein kinase 1 (RIPK1)/receptor-interacting protein kinase 3 (RIPK3)/mixed lineage kinase domain-like (MLKL) mediated necroptosis.
33231560	0	67	theme	OGT-mediated	116:127	arg1	RIPK3					144:148	OGT-mediated O-GlcNAcylated RIPK3	116:148	OGT-mediated O-GlcNAcylated RIPK3	116:148	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	1	68	theme	protective	205:214	arg1	effects					216:222	protective effects	205:222	protective effects	205:222	Inhalation anesthetics have been demonstrated to have protective effects against myocardial ischemia reperfusion injury (MIRI).
33231560	0	69	theme	RIPK3	144:148	arg1	up-regulation					99:111	up-regulation	99:111	up-regulation of OGT-mediated O-GlcNAcylated RIPK3	99:148	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	5	70	theme	Cardiac	656:662	arg1	hemodynamics					664:675	Cardiac hemodynamics	656:675	Cardiac hemodynamics	656:675	Cardiac hemodynamics and function were determined.
33231560	3	71	theme	necroptosis	428:438	arg1	signaling					440:448	necroptosis signaling	428:448	necroptosis signaling	428:448	This study aimed to investigate whether O-GlcNAcylation and necroptosis signaling were important for sevoflurane postconditioning (SPC) induced cardioprotective effects.
33231560	6	72	theme	myocardial	777:786	arg1	LDH					810:812	LDH	810:812	LDH	810:812	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	72	theme	myocardial	777:786	arg1	dehydrogenase					795:807	myocardial lactic dehydrogenase	777:807	myocardial lactic dehydrogenase (LDH) content	777:821	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	8	73	theme	O-GlcNAcylated	1495:1508	arg1	RIPK3					1510:1514	O-GlcNAcylated RIPK3	1495:1514	O-GlcNAcylated RIPK3	1495:1514	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	0	74	theme	postconditioning	12:27	arg1	Sevoflurane					0:10	Sevoflurane postconditioning	0:27	Sevoflurane postconditioning	0:27	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	4	75	theme	min	614:616	arg1	ischemia					618:625	30 min ischemia	611:625	30 min ischemia followed by 2 h reperfusion	611:653	Apart from rats in the SHAM and sevoflurane (SEVO) group, rats underwent 30 min ischemia followed by 2 h reperfusion.
33231560	6	76	theme	cardiac	748:754	arg1	parameters					765:774	cardiac function parameters	748:774	cardiac function parameters	748:774	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	3	77	theme	induced	504:510	arg1	effects					529:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	This study aimed to investigate whether O-GlcNAcylation and necroptosis signaling were important for sevoflurane postconditioning (SPC) induced cardioprotective effects.
33231560	0	78	theme	myocardial	37:46	arg1	reperfusion					57:67	myocardial ischemia reperfusion	37:67	myocardial ischemia reperfusion injury-induced necroptosis	37:94	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	0	79	theme	reperfusion	57:67	arg1	necroptosis					84:94	myocardial ischemia reperfusion injury-induced necroptosis	37:94	myocardial ischemia reperfusion injury-induced necroptosis	37:94	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3.
33231560	6	80	theme	biomarkers	945:954	arg1	parameters					765:774	cardiac function parameters	748:774	cardiac function parameters	748:774	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	80	theme	biomarkers	945:954	arg1	content					815:821	myocardial lactic dehydrogenase (LDH) content	777:821	myocardial lactic dehydrogenase (LDH) content	777:821	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	80	theme	biomarkers	945:954	arg1	levels					923:928	protein expression levels	904:928	protein expression levels of necroptosis biomarkers	904:954	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	80	theme	biomarkers	945:954	arg1	size					742:745	myocardial infarction size	720:745	myocardial infarction size	720:745	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	80	theme	biomarkers	945:954	arg1	myocardium					871:880	necrotic myocardium	862:880	necrotic myocardium	862:880	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	80	theme	biomarkers	945:954	arg1	O-GlcNAcylation					883:897	O-GlcNAcylation	883:897	O-GlcNAcylation	883:897	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	80	theme	biomarkers	945:954	arg1	changes					853:859	myocardium histopathological changes	824:859	myocardium histopathological changes	824:859	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	9	81	theme	proteins	1747:1754	arg1	down-regulation					1713:1727	down-regulation	1713:1727	down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex	1713:1943	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	9	81	theme	proteins	1747:1754	arg1	up-regulation					1676:1688	OGT mediated up-regulation	1663:1688	OGT mediated up-regulation of O-GlcNAcylation	1663:1707	However, OSMI-1, an OGT inhibitor, abolished SPC mediated cardioprotective effects and inhibited OGT mediated up-regulation of O-GlcNAcylation and down-regulation of RIPK3 and MLKL proteins induced by SPC. Our study demonstrated that SPC restrained MIRI induced necroptosis via regulating OGT mediated O-GlcNAcylation of RIPK3 and lessening the formulation of RIPK3/MLKL complex.
33231560	3	82	theme	SPC	499:501	arg1	effects					529:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	This study aimed to investigate whether O-GlcNAcylation and necroptosis signaling were important for sevoflurane postconditioning (SPC) induced cardioprotective effects.
33231560	6	83	theme	myocardium	824:833	arg1	changes					853:859	myocardium histopathological changes	824:859	myocardium histopathological changes	824:859	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	6	84	theme	necroptosis	1055:1065	arg1	pathway					1067:1073	the necroptosis pathway	1051:1073	the necroptosis pathway	1051:1073	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	3	85	theme	postconditioning	481:496	arg1	effects					529:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	sevoflurane postconditioning (SPC) induced cardioprotective effects	469:535	This study aimed to investigate whether O-GlcNAcylation and necroptosis signaling were important for sevoflurane postconditioning (SPC) induced cardioprotective effects.
33231560	8	86	theme	RIPK3	1550:1554	arg1	association					1535:1545	the association	1531:1545	the association of RIPK3 and MLKL	1531:1563	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	6	87	theme	expression	912:921	arg1	levels					923:928	protein expression levels	904:928	protein expression levels of necroptosis biomarkers	904:954	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33231560	8	88	theme	MLKL	1560:1563	arg1	association					1535:1545	the association	1531:1545	the association of RIPK3 and MLKL	1531:1563	In addition, SPC up-regulated O-GlcNAc transferase (OGT) mediated O-GlcNAcylation, increased O-GlcNAcylated RIPK3, and inhibited the association of RIPK3 and MLKL.
33231560	6	89	theme	dehydrogenase	795:807	arg1	content					815:821	myocardial lactic dehydrogenase (LDH) content	777:821	myocardial lactic dehydrogenase (LDH) content	777:821	In addition, myocardial infarction size, cardiac function parameters, myocardial lactic dehydrogenase (LDH) content, myocardium histopathological changes, necrotic myocardium, O-GlcNAcylation, and protein expression levels of necroptosis biomarkers were measured, together with co-immunoprecipitation experiments using proteins associated with the necroptosis pathway and O-GlcNAcylation.
33184803	0	0	theme	Immune-Mediated	89:103	arg1	Purpura					133:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	3	1	with	patients	632:639	arg1	iTTP					646:649	iTTP	646:649	iTTP	646:649	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	1	with	patients	632:639	arg1	history					689:695	no history	686:695	no history of iTTP and other hematological disorders	686:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	6	2	theme	ANKRD36	1076:1082	arg1	family					1084:1089	The ANKRD36 family	1072:1089	The ANKRD36 family of proteins	1072:1101	The ANKRD36 family of proteins have been implicated in inflammation.
33184803	3	3	theme	disorders	729:737	arg1	history					689:695	no history	686:695	no history of iTTP and other hematological disorders	686:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	8	4	theme	binding	1453:1459	arg1	properties					1461:1470	their binding properties	1447:1470	their binding properties	1447:1470	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	8	5	gly	glycosylation	1299:1311	arg1	disease					1328:1334	disease onset	1328:1340	disease onset	1328:1340	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	8	6	theme	clearance	1491:1499	arg1	kinetics					1501:1508	clearance kinetics	1491:1508	clearance kinetics of hemostatic and inflammatory proteins	1491:1548	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	0	7	theme	Thrombocytopenic	116:131	arg1	Purpura					133:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	8	8	theme	hemostatic	1513:1522	arg1	proteins					1541:1548	hemostatic and inflammatory proteins	1513:1548	hemostatic and inflammatory proteins	1513:1548	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	3	9	theme	whole	574:578	arg1	WES					598:600	WES	598:600	WES	598:600	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	9	theme	whole	574:578	arg1	sequencing					586:595	whole exome sequencing	574:595	whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	574:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	0	10	theme	Thrombotic	105:114	arg1	Purpura					133:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	0	11	from	ANKRD36C	63:70	arg1	Patients					75:82	Patients	75:82	Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura	75:139	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	0	12	with	Patients	75:82	arg1	Purpura					133:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Immune-Mediated Thrombotic Thrombocytopenic Purpura	89:139	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	3	13	theme	exome	580:584	arg1	WES					598:600	WES	598:600	WES	598:600	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	13	theme	exome	580:584	arg1	sequencing					586:595	whole exome sequencing	574:595	whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	574:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	6	14	theme	proteins	1094:1101	arg1	family					1084:1089	The ANKRD36 family	1072:1089	The ANKRD36 family of proteins	1072:1101	The ANKRD36 family of proteins have been implicated in inflammation.
33184803	8	15	theme	inflammatory	1528:1539	arg1	proteins					1541:1548	hemostatic and inflammatory proteins	1513:1548	hemostatic and inflammatory proteins	1513:1548	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	8	16	theme	proteins	1541:1548	arg1	kinetics					1501:1508	clearance kinetics	1491:1508	clearance kinetics of hemostatic and inflammatory proteins	1491:1548	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	3	17	with	subjects	672:679	arg1	iTTP					646:649	iTTP	646:649	iTTP	646:649	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	17	with	subjects	672:679	arg1	history					689:695	no history	686:695	no history of iTTP and other hematological disorders	686:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	2	18	theme	iTTP	542:545	arg1	pathogenesis					526:537	the pathogenesis	522:537	the pathogenesis of iTTP	522:545	However, the mechanism underlying anti-ADAMTS13 autoantibody formation is not known, nor it is known how genetic aberrations contribute to the pathogenesis of iTTP.
33184803	0	19	from	Glycosylation	45:57	arg1	Patients					75:82	Patients	75:82	Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura	75:139	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	4	20	from	variations	761:770	arg1	glycosylation					839:851	O-linked glycosylation	830:851	O-linked glycosylation	830:851	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	4	20	from	variations	761:770	arg1	genes					779:783	the genes	775:783	the genes	775:783	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	7	21	theme	dramatic	1170:1177	arg1	alternation					1179:1189	a dramatic alternation	1168:1189	a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls	1168:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	3	22	from	patients	632:639	arg1	samples					610:616	DNA samples	606:616	DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	606:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	22	from	patients	632:639	arg1	WES					598:600	WES	598:600	WES	598:600	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	22	from	patients	632:639	arg1	sequencing					586:595	whole exome sequencing	574:595	whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	574:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	2	23	theme	autoantibody	431:442	arg1	formation					444:452	anti-ADAMTS13 autoantibody formation	417:452	anti-ADAMTS13 autoantibody formation	417:452	However, the mechanism underlying anti-ADAMTS13 autoantibody formation is not known, nor it is known how genetic aberrations contribute to the pathogenesis of iTTP.
33184803	3	24	theme	local	658:662	arg1	subjects					672:679	15 local healthy subjects	655:679	15 local healthy subjects	655:679	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	25	theme	hematological	715:727	arg1	disorders					729:737	other hematological disorders	709:737	other hematological disorders	709:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	4	26	theme	major	862:866	arg1	pathway					868:874	a major pathway	860:874	a major pathway affected in patients with iTTP	860:905	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	8	27	from	onset	1336:1340	arg1	ways					1369:1372	various ways	1361:1372	various ways	1361:1372	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	5	28	theme	ANKRD	936:940	arg1	family					947:952	the ANKRD gene family	932:952	the ANKRD gene family	932:952	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	2	29	theme	anti-ADAMTS13	417:429	arg1	formation					444:452	anti-ADAMTS13 autoantibody formation	417:452	anti-ADAMTS13 autoantibody formation	417:452	However, the mechanism underlying anti-ADAMTS13 autoantibody formation is not known, nor it is known how genetic aberrations contribute to the pathogenesis of iTTP.
33184803	0	30	theme	Exome	0:4	arg1	Sequencing					6:15	Exome Sequencing	0:15	Exome Sequencing	0:15	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	9	31	theme	novel	1582:1586	arg1	insights					1588:1595	novel insights	1582:1595	novel insights into plausible mechanisms underlying the pathogenesis of iTTP	1582:1657	Together, our findings provide novel insights into plausible mechanisms underlying the pathogenesis of iTTP.
33184803	9	32	theme	iTTP	1654:1657	arg1	pathogenesis					1638:1649	the pathogenesis	1634:1649	the pathogenesis of iTTP	1634:1657	Together, our findings provide novel insights into plausible mechanisms underlying the pathogenesis of iTTP.
33184803	1	33	with	metalloproteinase	317:333	arg1	member					371:376	member 13	371:379	member 13	371:379	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	33	with	metalloproteinase	317:333	arg1	motif					364:368	a thrombospondin type 1 motif	340:368	a thrombospondin type 1 motif	340:368	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	5	34	theme	gene	942:945	arg1	family					947:952	the ANKRD gene family	932:952	the ANKRD gene family	932:952	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	1	35	theme	fatal	229:233	arg1	disorder					241:248	a potentially fatal blood disorder	215:248	a potentially fatal blood disorder	215:248	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	35	theme	fatal	229:233	arg1	purpura					197:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura	142:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP)	142:210	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	5	36	from	variations	918:927	arg1	family					947:952	the ANKRD gene family	932:952	the ANKRD gene family	932:952	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	3	37	dep	METHODS	548:554	arg1	performed					564:572	performed	564:572	performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	564:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	4	38	theme	O-linked	830:837	arg1	glycosylation					839:851	O-linked glycosylation	830:851	O-linked glycosylation	830:851	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	1	39	theme	blood	235:239	arg1	disorder					241:248	a potentially fatal blood disorder	215:248	a potentially fatal blood disorder	215:248	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	39	theme	blood	235:239	arg1	purpura					197:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura	142:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP)	142:210	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	7	40	from	alternation	1179:1189	arg1	profile					1214:1220	plasma glycoprotein profile	1194:1220	plasma glycoprotein profile in patients with iTTP compared with the healthy controls	1194:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	9	41	theme	plausible	1602:1610	arg1	mechanisms					1612:1621	plausible mechanisms	1602:1621	plausible mechanisms underlying the pathogenesis of iTTP	1602:1657	Together, our findings provide novel insights into plausible mechanisms underlying the pathogenesis of iTTP.
33184803	7	42	theme	plasma	1194:1199	arg1	profile					1214:1220	plasma glycoprotein profile	1194:1220	plasma glycoprotein profile in patients with iTTP compared with the healthy controls	1194:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	1	43	theme	thrombospondin	342:355	arg1	type					357:360	thrombospondin type 1	342:362	a thrombospondin type 1 motif	340:368	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	44	dep	ADAMTS13	289:296	arg1	metalloproteinase					317:333	metalloproteinase	317:333	metalloproteinase	317:333	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	44	dep	ADAMTS13	289:296	arg1	disintegrin					301:311	a disintegrin	299:311	a disintegrin	299:311	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	3	45	theme	samples	610:616	arg1	WES					598:600	WES	598:600	WES	598:600	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	45	theme	samples	610:616	arg1	sequencing					586:595	whole exome sequencing	574:595	whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	574:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	5	46	from	prevalent	1010:1018	arg1	controls					1062:1069	the healthy controls	1050:1069	the healthy controls	1050:1069	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	5	46	from	prevalent	1010:1018	arg1	patients					1023:1030	patients	1023:1030	patients with iTTP	1023:1040	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	8	47	theme	CONCLUSION	1280:1289	arg1	glycosylation					1299:1311	CONCLUSION Altered glycosylation	1280:1311	CONCLUSION Altered glycosylation	1280:1311	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	4	48	with	patients	888:895	arg1	iTTP					902:905	iTTP	902:905	iTTP	902:905	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	1	49	theme	type	357:360	arg1	member					371:376	member 13	371:379	member 13	371:379	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	49	theme	type	357:360	arg1	motif					364:368	a thrombospondin type 1 motif	340:368	a thrombospondin type 1 motif	340:368	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	7	50	theme	Mass	1141:1144	arg1	spectrometry					1146:1157	Mass spectrometry	1141:1157	Mass spectrometry	1141:1157	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	8	51	dep	onset	1336:1340	arg1	the					1324:1326	the	1324:1326	the	1324:1326	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	1	52	with	disintegrin	301:311	arg1	member					371:376	member 13	371:379	member 13	371:379	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	52	with	disintegrin	301:311	arg1	motif					364:368	a thrombospondin type 1 motif	340:368	a thrombospondin type 1 motif	340:368	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	2	53	theme	genetic	488:494	arg1	aberrations					496:506	genetic aberrations	488:506	genetic aberrations	488:506	However, the mechanism underlying anti-ADAMTS13 autoantibody formation is not known, nor it is known how genetic aberrations contribute to the pathogenesis of iTTP.
33184803	5	54	from	controls	1062:1069	arg1	prevalent					1010:1018	prevalent	1010:1018	prevalent	1010:1018	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	8	55	theme	ADAMTS13	1413:1420	arg1	autoantibodies					1422:1435	ADAMTS13 autoantibodies	1413:1435	ADAMTS13 autoantibodies	1413:1435	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	3	56	theme	other	709:713	arg1	disorders					729:737	other hematological disorders	709:737	other hematological disorders	709:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	1	57	theme	BACKGROUND	142:151	arg1	disorder					241:248	a potentially fatal blood disorder	215:248	a potentially fatal blood disorder	215:248	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	57	theme	BACKGROUND	142:151	arg1	iTTP					206:209	iTTP	206:209	iTTP	206:209	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	57	theme	BACKGROUND	142:151	arg1	purpura					197:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura	142:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP)	142:210	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	3	58	theme	iTTP	700:703	arg1	history					689:695	no history	686:695	no history of iTTP and other hematological disorders	686:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	7	59	from	profile	1214:1220	arg1	patients					1225:1232	patients	1225:1232	patients with iTTP compared with the healthy controls	1225:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	3	60	theme	DNA	606:608	arg1	samples					610:616	DNA samples	606:616	DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	606:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	7	61	theme	glycoprotein	1201:1212	arg1	profile					1214:1220	plasma glycoprotein profile	1194:1220	plasma glycoprotein profile in patients with iTTP compared with the healthy controls	1194:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	1	62	theme	Immune-mediated	153:167	arg1	disorder					241:248	a potentially fatal blood disorder	215:248	a potentially fatal blood disorder	215:248	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	62	theme	Immune-mediated	153:167	arg1	iTTP					206:209	iTTP	206:209	iTTP	206:209	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	62	theme	Immune-mediated	153:167	arg1	purpura					197:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura	142:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP)	142:210	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	3	63	from	sequencing	586:595	arg1	subjects					672:679	15 local healthy subjects	655:679	15 local healthy subjects	655:679	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	63	from	sequencing	586:595	arg1	patients					632:639	40 adult patients	623:639	40 adult patients with iTTP	623:649	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	5	64	from	patients	1023:1030	arg1	prevalent					1010:1018	prevalent	1010:1018	prevalent	1010:1018	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	4	65	theme	protein	797:803	arg1	glycosylation					805:817	protein glycosylation	797:817	protein glycosylation	797:817	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	1	66	theme	thrombotic	169:178	arg1	disorder					241:248	a potentially fatal blood disorder	215:248	a potentially fatal blood disorder	215:248	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	66	theme	thrombotic	169:178	arg1	iTTP					206:209	iTTP	206:209	iTTP	206:209	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	66	theme	thrombotic	169:178	arg1	purpura					197:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura	142:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP)	142:210	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	8	67	theme	various	1361:1367	arg1	ways					1369:1372	various ways	1361:1372	various ways	1361:1372	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	3	68	theme	healthy	664:670	arg1	subjects					672:679	15 local healthy subjects	655:679	15 local healthy subjects	655:679	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	7	69	gly	glycoprotein	1201:1212	arg1	glycoprotein					1201:1212	plasma glycoprotein profile	1194:1220	plasma glycoprotein profile in patients with iTTP compared with the healthy controls	1194:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	5	70	theme	healthy	1054:1060	arg1	controls					1062:1069	the healthy controls	1050:1069	the healthy controls	1050:1069	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
33184803	1	71	theme	thrombocytopenic	180:195	arg1	disorder					241:248	a potentially fatal blood disorder	215:248	a potentially fatal blood disorder	215:248	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	71	theme	thrombocytopenic	180:195	arg1	iTTP					206:209	iTTP	206:209	iTTP	206:209	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	1	71	theme	thrombocytopenic	180:195	arg1	purpura					197:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura	142:203	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP)	142:210	BACKGROUND Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13).
33184803	7	72	theme	healthy	1262:1268	arg1	controls					1270:1277	the healthy controls	1258:1277	the healthy controls	1258:1277	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	4	73	link	O-linked	830:837	arg1	glycosylation					839:851	O-linked glycosylation	830:851	O-linked glycosylation	830:851	RESULTS WES revealed variations in the genes involved in protein glycosylation, including O-linked glycosylation, to be a major pathway affected in patients with iTTP.
33184803	7	74	with	patients	1225:1232	arg1	iTTP					1239:1242	iTTP	1239:1242	iTTP	1239:1242	Mass spectrometry revealed a dramatic alternation in plasma glycoprotein profile in patients with iTTP compared with the healthy controls.
33184803	8	75	theme	disease	1328:1334	arg1	onset					1336:1340	disease onset	1328:1340	disease onset	1328:1340	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	8	76	from	progression	1346:1356	arg1	ways					1369:1372	various ways	1361:1372	various ways	1361:1372	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	3	77	from	subjects	672:679	arg1	samples					610:616	DNA samples	606:616	DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	606:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	77	from	subjects	672:679	arg1	WES					598:600	WES	598:600	WES	598:600	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	3	77	from	subjects	672:679	arg1	sequencing					586:595	whole exome sequencing	574:595	whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders	574:737	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	0	78	from	Abnormalities	28:40	arg1	Glycosylation					45:57	Glycosylation	45:57	Glycosylation	45:57	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	0	78	from	Abnormalities	28:40	arg1	ANKRD36C					63:70	ANKRD36C	63:70	ANKRD36C	63:70	Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.
33184803	3	79	theme	adult	626:630	arg1	patients					632:639	40 adult patients	623:639	40 adult patients with iTTP	623:649	METHODS Here we performed whole exome sequencing (WES) of DNA samples from 40 adult patients with iTTP and 15 local healthy subjects with no history of iTTP and other hematological disorders.
33184803	8	80	theme	Altered	1291:1297	arg1	glycosylation					1299:1311	CONCLUSION Altered glycosylation	1280:1311	CONCLUSION Altered glycosylation	1280:1311	CONCLUSION Altered glycosylation may affect the disease onset and progression in various ways: it may predispose patients to produce ADAMTS13 autoantibodies or affect their binding properties; it may also alter clearance kinetics of hemostatic and inflammatory proteins.
33184803	5	81	with	patients	1023:1030	arg1	iTTP					1037:1040	iTTP	1037:1040	iTTP	1037:1040	Moreover, variations in the ANKRD gene family, particularly ANKRD36C and its paralogs, were also more prevalent in patients with iTTP than in the healthy controls.
32993960	2	0	theme	opposing	445:452	arg1	effects					454:460	opposing effects	445:460	opposing effects on HA synthesis	445:476	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	4	1	from	position	764:771	arg1	site					752:755	a phosphorylation site	734:755	a phosphorylation site	734:755	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	1	2	theme	membrane	134:141	arg1	synthase					101:108	Hyaluronan synthase 2	90:110	Hyaluronan synthase 2 (HAS2)	90:117	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	1	2	theme	membrane	134:141	arg1	protein					143:149	an integral membrane protein	122:149	an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop)	122:236	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	0	3	theme	hyaluronan	68:77	arg1	synthesis					79:87	hyaluronan synthesis	68:87	hyaluronan synthesis	68:87	Phosphorylation of Thr328 in hyaluronan synthase 2 is essential for hyaluronan synthesis.
32993960	6	4	theme	mock	1242:1245	arg1	cells					1247:1251	mock cells	1242:1251	mock cells	1242:1251	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	0	5	from	Phosphorylation	0:14	arg1	synthase					40:47	hyaluronan synthase 2	29:49	hyaluronan synthase 2	29:49	Phosphorylation of Thr328 in hyaluronan synthase 2 is essential for hyaluronan synthesis.
32993960	8	6	theme	essential	1391:1399	arg1	phosphorylation					1369:1383	Thr328 phosphorylation	1362:1383	Thr328 phosphorylation	1362:1383	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	8	6	theme	essential	1391:1399	arg1	factor					1401:1406	an essential factor	1388:1406	an essential factor for HA synthesis by HAS2	1388:1431	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	2	7	theme	phorbol	276:282	arg1	13-acetate					297:306	phorbol 12-myristate 13-acetate	276:306	phorbol 12-myristate 13-acetate (PMA)	276:312	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	7	theme	phorbol	276:282	arg1	PMA					309:311	PMA	309:311	PMA	309:311	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	8	8	theme	HA	1412:1413	arg1	synthesis					1415:1423	HA synthesis	1412:1423	HA synthesis by HAS2	1412:1431	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	3	9	theme	mass	701:704	arg1	spectrometry					706:717	mass spectrometry	701:717	mass spectrometry	701:717	In this study, we constructed an expression vector for the HAS2-loop and analyzed its post-translational modification by PMA and 4-MU using mass spectrometry.
32993960	4	10	theme	phosphorylation	736:750	arg1	site					752:755	a phosphorylation site	734:755	a phosphorylation site	734:755	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	4	11	located	detected	841:848	arg2	site					752:755	a phosphorylation site	734:755	a phosphorylation site	734:755	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	4	11	located	detected	841:848	arg1	cells					857:861	the cells	853:861	the cells	853:861	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	2	12	link	O-linked	501:508	arg1	β-N-acetylglucosaminylation					510:536	O-linked β-N-acetylglucosaminylation	501:536	O-linked β-N-acetylglucosaminylation	501:536	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	6	13	theme	full-length	1065:1075	arg1	HAS2					1077:1080	full-length HAS2	1065:1080	full-length HAS2	1065:1080	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	5	14	theme	mutagenesis	943:953	arg1	cells					977:981	T328A site-directed mutagenesis construct-transfected cells	923:981	T328A site-directed mutagenesis construct-transfected cells	923:981	We next prepared T328A site-directed mutagenesis construct-transfected cells and investigated HA synthesis.
32993960	6	15	theme	T328A	1176:1180	arg1	construct					1208:1216	the T328A site-directed mutagenesis construct	1172:1216	the T328A site-directed mutagenesis construct	1172:1216	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	2	16	theme	HA	465:466	arg1	synthesis					468:476	HA synthesis	465:476	HA synthesis	465:476	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	8	17	theme	HAS2	1504:1507	arg1	synthesis					1509:1517	HAS2 synthesis	1504:1517	HAS2 synthesis	1504:1517	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	4	18	theme	HAS2	825:828	arg1	position					801:808	the Thr328 position	790:808	the Thr328 position of full-length HAS2	790:828	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	5	19	theme	construct-transfected	955:975	arg1	cells					977:981	T328A site-directed mutagenesis construct-transfected cells	923:981	T328A site-directed mutagenesis construct-transfected cells	923:981	We next prepared T328A site-directed mutagenesis construct-transfected cells and investigated HA synthesis.
32993960	2	20	theme	hyaluronan	370:379	arg1	synthesis					357:365	the synthesis	353:365	the synthesis of hyaluronan (HA) in human skin fibroblasts	353:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	8	21	theme	physiological	1522:1534	arg1	conditions					1553:1562	physiological and pathological conditions	1522:1562	physiological and pathological conditions	1522:1562	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	7	22	theme	phosphorylation	1259:1273	arg1	site					1275:1278	This phosphorylation site	1254:1278	This phosphorylation site	1254:1278	This phosphorylation site corresponded with the casein kinase 1 substrate motif.
32993960	6	23	theme	HA	1131:1132	arg1	same					1226:1229	same	1226:1229	same	1226:1229	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	6	23	theme	HA	1131:1132	arg1	HA					1131:1132	HA	1131:1132	HA	1131:1132	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	6	23	theme	HA	1131:1132	arg1	amount					1121:1126	the amount	1117:1126	the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct	1117:1216	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	1	24	theme	multi-membrane-spanning	163:185	arg1	regions					187:193	multi-membrane-spanning regions	163:193	multi-membrane-spanning regions	163:193	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	4	25	theme	4-MU	900:903	arg1	presence					881:888	the presence	877:888	the presence of PMA or 4-MU	877:903	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	1	26	theme	Hyaluronan	90:99	arg1	synthase					101:108	Hyaluronan synthase 2	90:110	Hyaluronan synthase 2 (HAS2)	90:117	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	1	26	theme	Hyaluronan	90:99	arg1	HAS2					113:116	HAS2	113:116	HAS2	113:116	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	1	26	theme	Hyaluronan	90:99	arg1	protein					143:149	an integral membrane protein	122:149	an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop)	122:236	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	7	27	theme	casein	1302:1307	arg1	motif					1328:1332	the casein kinase 1 substrate motif	1298:1332	the casein kinase 1 substrate motif	1298:1332	This phosphorylation site corresponded with the casein kinase 1 substrate motif.
32993960	8	28	theme	synthesis	1509:1517	arg1	regulation					1490:1499	the regulation	1486:1499	the regulation of HAS2 synthesis in physiological and pathological conditions	1486:1562	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	4	29	theme	PMA	893:895	arg1	presence					881:888	the presence	877:888	the presence of PMA or 4-MU	877:903	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	2	30	theme	13-acetate	297:306	arg1	effect					266:271	the effect	262:271	the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts	262:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	31	theme	human	389:393	arg1	fibroblasts					400:410	human skin fibroblasts	389:410	human skin fibroblasts	389:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	32	theme	skin	395:398	arg1	fibroblasts					400:410	human skin fibroblasts	389:410	human skin fibroblasts	389:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	6	33	dep	increased	1035:1043	arg1	compared					1082:1089	compared	1082:1089	compared to in mock cells	1082:1106	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	6	33	dep	increased	1035:1043	arg1	whereas					1109:1115	whereas	1109:1115	whereas	1109:1115	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	2	34	theme	12-myristate	284:295	arg1	13-acetate					297:306	phorbol 12-myristate 13-acetate	276:306	phorbol 12-myristate 13-acetate (PMA)	276:312	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	34	theme	12-myristate	284:295	arg1	PMA					309:311	PMA	309:311	PMA	309:311	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	5	35	theme	site-directed	929:941	arg1	mutagenesis					943:953	T328A site-directed mutagenesis	923:953	T328A site-directed mutagenesis construct-transfected cells	923:981	We next prepared T328A site-directed mutagenesis construct-transfected cells and investigated HA synthesis.
32993960	5	36	theme	T328A	923:927	arg1	mutagenesis					943:953	T328A site-directed mutagenesis	923:953	T328A site-directed mutagenesis construct-transfected cells	923:981	We next prepared T328A site-directed mutagenesis construct-transfected cells and investigated HA synthesis.
32993960	2	37	theme	O-linked	501:508	arg1	β-N-acetylglucosaminylation					510:536	O-linked β-N-acetylglucosaminylation	501:536	O-linked β-N-acetylglucosaminylation	501:536	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	6	38	theme	HA	1028:1029	arg1	HA					1028:1029	HA	1028:1029	HA	1028:1029	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	6	38	theme	HA	1028:1029	arg1	amount					1018:1023	The amount	1014:1023	The amount of HA	1014:1029	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	1	39	theme	large	201:205	arg1	HAS2-loop					227:235	HAS2-loop	227:235	HAS2-loop	227:235	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	1	39	theme	large	201:205	arg1	loop					221:224	a large intracellular loop	199:224	a large intracellular loop (HAS2-loop)	199:236	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	0	40	theme	hyaluronan	29:38	arg1	synthase					40:47	hyaluronan synthase 2	29:49	hyaluronan synthase 2	29:49	Phosphorylation of Thr328 in hyaluronan synthase 2 is essential for hyaluronan synthesis.
32993960	7	41	theme	kinase	1309:1314	arg1	motif					1328:1332	the casein kinase 1 substrate motif	1298:1332	the casein kinase 1 substrate motif	1298:1332	This phosphorylation site corresponded with the casein kinase 1 substrate motif.
32993960	4	42	theme	Thr328	794:799	arg1	position					801:808	the Thr328 position	790:808	the Thr328 position of full-length HAS2	790:828	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	2	43	contain	have	440:443	arg1	TPA					427:429	TPA	427:429	TPA	427:429	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	43	contain	have	440:443	arg1	4-MU					435:438	4-MU	435:438	4-MU	435:438	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	43	contain	have	440:443	arg2	effects					454:460	opposing effects	445:460	opposing effects on HA synthesis	445:476	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	1	44	theme	intracellular	207:219	arg1	HAS2-loop					227:235	HAS2-loop	227:235	HAS2-loop	227:235	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	1	44	theme	intracellular	207:219	arg1	loop					221:224	a large intracellular loop	199:224	a large intracellular loop (HAS2-loop)	199:236	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	8	45	from	regulation	1490:1499	arg1	conditions					1553:1562	physiological and pathological conditions	1522:1562	physiological and pathological conditions	1522:1562	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	8	46	theme	pathological	1540:1551	arg1	conditions					1553:1562	physiological and pathological conditions	1522:1562	physiological and pathological conditions	1522:1562	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	2	47	from	effects	454:460	arg1	synthesis					468:476	HA synthesis	465:476	HA synthesis	465:476	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	4	48	theme	full-length	813:823	arg1	HAS2					825:828	full-length HAS2	813:828	full-length HAS2	813:828	We identified a phosphorylation site at the position corresponding to the Thr328 position of full-length HAS2, which was detected in the cells regardless of the presence of PMA or 4-MU.
32993960	2	49	from	synthesis	357:365	arg1	fibroblasts					400:410	human skin fibroblasts	389:410	human skin fibroblasts	389:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	6	50	theme	mutagenesis	1196:1206	arg1	construct					1208:1216	the T328A site-directed mutagenesis construct	1172:1216	the T328A site-directed mutagenesis construct	1172:1216	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	2	51	theme	4-methylumbelliferone	321:341	arg1	effect					266:271	the effect	262:271	the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts	262:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	52	from	effect	266:271	arg1	synthesis					357:365	the synthesis	353:365	the synthesis of hyaluronan (HA) in human skin fibroblasts	353:410	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	5	53	theme	HA	1000:1001	arg1	synthesis					1003:1011	HA synthesis	1000:1011	HA synthesis	1000:1011	We next prepared T328A site-directed mutagenesis construct-transfected cells and investigated HA synthesis.
32993960	3	54	theme	post-translational	647:664	arg1	modification					666:677	its post-translational modification	643:677	its post-translational modification by PMA and 4-MU	643:693	In this study, we constructed an expression vector for the HAS2-loop and analyzed its post-translational modification by PMA and 4-MU using mass spectrometry.
32993960	6	55	theme	site-directed	1182:1194	arg1	construct					1208:1216	the T328A site-directed mutagenesis construct	1172:1216	the T328A site-directed mutagenesis construct	1172:1216	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	8	56	theme	Thr328	1362:1367	arg1	phosphorylation					1369:1383	Thr328 phosphorylation	1362:1383	Thr328 phosphorylation	1362:1383	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	8	56	theme	Thr328	1362:1367	arg1	factor					1401:1406	an essential factor	1388:1406	an essential factor for HA synthesis by HAS2	1388:1431	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	2	57	theme	HAS2	541:544	arg1	β-N-acetylglucosaminylation					510:536	O-linked β-N-acetylglucosaminylation	501:536	O-linked β-N-acetylglucosaminylation	501:536	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	2	57	theme	HAS2	541:544	arg1	phosphorylation					481:495	phosphorylation	481:495	phosphorylation	481:495	We previously examined the effect of phorbol 12-myristate 13-acetate (PMA) and/or 4-methylumbelliferone (4-MU) on the synthesis of hyaluronan (HA) in human skin fibroblasts and found that TPA and 4-MU have opposing effects on HA synthesis by phosphorylation and O-linked β-N-acetylglucosaminylation of HAS2, respectively.
32993960	3	58	theme	expression	594:603	arg1	vector					605:610	an expression vector	591:610	an expression vector for the HAS2-loop	591:628	In this study, we constructed an expression vector for the HAS2-loop and analyzed its post-translational modification by PMA and 4-MU using mass spectrometry.
32993960	6	59	theme	mock	1097:1100	arg1	cells					1102:1106	mock cells	1097:1106	mock cells	1097:1106	The amount of HA was increased in cells expressing full-length HAS2 compared to in mock cells, whereas the amount of HA synthesized by cells transfected with the T328A site-directed mutagenesis construct was the same as that in mock cells.
32993960	8	60	theme	HAS2-loop	1449:1457	arg1	useful					1466:1471	useful	1466:1471	useful	1466:1471	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	8	60	theme	HAS2-loop	1449:1457	arg1	role					1441:1444	the role	1437:1444	the role of HAS2-loop	1437:1457	These results suggest that Thr328 phosphorylation is an essential factor for HA synthesis by HAS2 and the role of HAS2-loop may be useful in analyzing the regulation of HAS2 synthesis in physiological and pathological conditions.
32993960	7	61	theme	substrate	1318:1326	arg1	motif					1328:1332	the casein kinase 1 substrate motif	1298:1332	the casein kinase 1 substrate motif	1298:1332	This phosphorylation site corresponded with the casein kinase 1 substrate motif.
32993960	0	62	theme	Thr328	19:24	arg1	Phosphorylation					0:14	Phosphorylation	0:14	Phosphorylation of Thr328 in hyaluronan synthase 2	0:49	Phosphorylation of Thr328 in hyaluronan synthase 2 is essential for hyaluronan synthesis.
32993960	1	63	theme	integral	125:132	arg1	synthase					101:108	Hyaluronan synthase 2	90:110	Hyaluronan synthase 2 (HAS2)	90:117	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
32993960	1	63	theme	integral	125:132	arg1	protein					143:149	an integral membrane protein	122:149	an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop)	122:236	Hyaluronan synthase 2 (HAS2) is an integral membrane protein composed of multi-membrane-spanning regions and a large intracellular loop (HAS2-loop).
34452516	4	0	theme	comparative	852:862	arg1	studies					864:870	comparative studies	852:870	comparative studies	852:870	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	8	1	theme	CAP3	1633:1636	arg1	cystovirus					1638:1647	the CAP3 cystovirus	1629:1647	the CAP3 cystovirus	1629:1647	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	6	2	theme	segments	1262:1269	arg1	sequencing					1232:1241	Genome sequencing	1225:1241	Genome sequencing of the three dsRNA segments of the isolated cystoviruses	1225:1298	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	8	3	theme	low	1695:1697	arg1	weight					1709:1714	a low molecular weight	1693:1714	a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide	1693:1836	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	9	4	theme	receptors	1961:1969	arg1	determination					1933:1945	the determination	1929:1945	the determination of their cell receptors	1929:1969	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	9	4	theme	receptors	1961:1969	arg1	isolation					1877:1885	the isolation	1873:1885	the isolation of new Acinetobacter-infecting phages	1873:1923	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	3	5	theme	unique	520:525	arg1	CAP3-7					553:558	CAP3-7	553:558	CAP3-7	553:558	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	5	theme	unique	520:525	arg1	cystoviruses					539:550	five unique dsRNA lytic cystoviruses	515:550	five unique dsRNA lytic cystoviruses (CAP3-7)	515:559	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	1	6	theme	knowledge	245:253	arg1	gaps					255:258	vast knowledge gaps	240:258	vast knowledge gaps in our understanding of phage diversity and phage-host interactions	240:326	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	4	7	theme	genomic	828:834	arg1	sequencing					836:845	genomic sequencing	828:845	genomic sequencing	828:845	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	6	8	theme	Genome	1225:1230	arg1	sequencing					1232:1241	Genome sequencing	1225:1241	Genome sequencing of the three dsRNA segments of the isolated cystoviruses	1225:1298	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	7	9	with	capsids	1514:1520	arg1	membrane					1537:1544	the inner membrane	1527:1544	the inner membrane from the infected host	1527:1567	In Pseudomonas, the cystoviruses are known to be enveloped phages surrounding their capsids with the inner membrane from the infected host.
34452516	1	10	theme	biological	187:196	arg1	Bacteriophages					123:136	Bacteriophages	123:136	Bacteriophages (phages)	123:145	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	1	10	theme	biological	187:196	arg1	entity					198:203	the most ubiquitous biological entity	167:203	the most ubiquitous biological entity on earth	167:212	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	10	11	theme	new	2010:2012	arg1	genus					2014:2018	a new genus	2008:2018	a new genus of Cystoviruses	2008:2034	Further, we describe the genomes of a new genus of Cystoviruses and perform an initial characterization of membrane-associated glycoconjugates.
34452516	1	12	from	entity	198:203	arg1	earth					208:212	earth	208:212	earth	208:212	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	3	13	theme	lytic	533:537	arg1	CAP3-7					553:558	CAP3-7	553:558	CAP3-7	553:558	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	13	theme	lytic	533:537	arg1	cystoviruses					539:550	five unique dsRNA lytic cystoviruses	515:550	five unique dsRNA lytic cystoviruses (CAP3-7)	515:559	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	6	14	theme	low	1309:1311	arg1	levels					1313:1318	low levels	1309:1318	low levels of homology	1309:1330	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	6	15	theme	cystoviruses	1287:1298	arg1	segments					1262:1269	the three dsRNA segments	1246:1269	the three dsRNA segments of the isolated cystoviruses	1246:1298	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	8	16	theme	bacterial	1808:1816	arg1	lipooligosaccharide					1818:1836	bacterial lipooligosaccharide	1808:1836	bacterial lipooligosaccharide	1808:1836	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	10	17	theme	membrane-associated	2079:2097	arg1	glycoconjugates					2099:2113	membrane-associated glycoconjugates	2079:2113	membrane-associated glycoconjugates	2079:2113	Further, we describe the genomes of a new genus of Cystoviruses and perform an initial characterization of membrane-associated glycoconjugates.
34452516	1	18	theme	phage-host	304:313	arg1	interactions					315:326	phage-host interactions	304:326	phage-host interactions	304:326	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	3	19	theme	dsDNA	570:574	arg1	LH6					692:694	all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6	606:694	all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6	606:694	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	19	theme	dsDNA	570:574	arg1	SLAP1					598:602	SLAP1	598:602	SLAP1	598:602	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	19	theme	dsDNA	570:574	arg1	siphovirus					586:595	one dsDNA lysogenic siphovirus	566:595	one dsDNA lysogenic siphovirus (SLAP1)	566:603	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	10	20	theme	initial	2051:2057	arg1	characterization					2059:2074	an initial characterization	2048:2074	an initial characterization of membrane-associated glycoconjugates	2048:2113	Further, we describe the genomes of a new genus of Cystoviruses and perform an initial characterization of membrane-associated glycoconjugates.
34452516	0	21	theme	Resistant	72:80	arg1	LH6					118:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	7	22	theme	infected	1555:1562	arg1	host					1564:1567	the infected host	1551:1567	the infected host	1551:1567	In Pseudomonas, the cystoviruses are known to be enveloped phages surrounding their capsids with the inner membrane from the infected host.
34452516	4	23	theme	bacterial	737:745	arg1	mutagenesis					747:757	bacterial mutagenesis	737:757	bacterial mutagenesis	737:757	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	0	24	theme	radioresistens	96:109	arg1	LH6					118:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	5	25	theme	podovirus	1100:1108	arg1	CAP1					1110:1113	the lytic podovirus CAP1	1090:1113	the lytic podovirus CAP1	1090:1113	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	0	26	theme	Multidrug	62:70	arg1	LH6					118:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	4	27	theme	transmission	703:714	arg1	microscopy					725:734	transmission electron microscopy	703:734	transmission electron microscopy	703:734	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	5	28	theme	LH6	928:930	arg1	PglC					972:975	PglC	972:975	PglC	972:975	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	5	28	theme	LH6	928:930	arg1	Mutation					912:919	Mutation	912:919	Mutation of the LH6 initiating glycosyltransferase homolog	912:969	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	6	29	theme	Pseudomonas	1409:1419	arg1	species					1421:1427	Pseudomonas species	1409:1427	Pseudomonas species	1409:1427	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	8	30	link	lipid-linked	1716:1727	arg1	glycoconjugate					1729:1742	lipid-linked glycoconjugate	1716:1742	a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide	1693:1836	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	5	31	theme	glycosyltransferase	943:961	arg1	homolog					963:969	glycosyltransferase homolog	943:969	glycosyltransferase homolog	943:969	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	0	32	theme	Unique	16:21	arg1	Properties					23:32	Unique Properties	16:32	Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6	16:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	0	32	theme	Unique	16:21	arg1	RNA					0:2	RNA	0:2	RNA	0:2	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	9	33	theme	new	1890:1892	arg1	phages					1918:1923	new Acinetobacter-infecting phages	1890:1923	new Acinetobacter-infecting phages	1890:1923	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	8	34	used	used	1676:1679	arg2	staining					1663:1670	carbohydrate staining	1650:1670	carbohydrate staining	1650:1670	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	3	35	theme	typical	473:479	arg1	podoviruses					493:503	two typical dsDNA lytic podoviruses	469:503	two typical dsDNA lytic podoviruses (CAP1-2)	469:512	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	35	theme	typical	473:479	arg1	CAP1-2					506:511	CAP1-2	506:511	CAP1-2	506:511	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	6	36	theme	reported	1375:1382	arg1	cystoviruses					1384:1395	the only other reported cystoviruses	1360:1395	the only other reported cystoviruses that infect Pseudomonas species	1360:1427	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	5	37	theme	protein	1144:1150	arg1	mutation					1122:1129	mutation	1122:1129	mutation of the pilin protein, PilA,	1122:1157	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	5	38	theme	polysaccharide	1032:1045	arg1	biosynthesis					1053:1064	both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis	992:1064	biosynthesis	1053:1064	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	9	39	theme	phages	1918:1923	arg1	determination					1933:1945	the determination	1929:1945	the determination of their cell receptors	1929:1969	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	9	39	theme	phages	1918:1923	arg1	isolation					1877:1885	the isolation	1873:1885	the isolation of new Acinetobacter-infecting phages	1873:1923	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	4	40	theme	infectivity	766:776	arg1	assays					778:783	phage infectivity assays	760:783	phage infectivity assays	760:783	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	8	41	theme	carbohydrate	1650:1661	arg1	staining					1663:1670	carbohydrate staining	1650:1670	carbohydrate staining	1650:1670	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	7	42	theme	enveloped	1479:1487	arg1	cystoviruses					1450:1461	the cystoviruses	1446:1461	the cystoviruses	1446:1461	In Pseudomonas, the cystoviruses are known to be enveloped phages surrounding their capsids with the inner membrane from the infected host.
34452516	7	42	theme	enveloped	1479:1487	arg1	phages					1489:1494	enveloped phages	1479:1494	enveloped phages surrounding their capsids with the inner membrane from the infected host	1479:1567	In Pseudomonas, the cystoviruses are known to be enveloped phages surrounding their capsids with the inner membrane from the infected host.
34452516	3	43	theme	capable	610:616	arg1	LH6					692:694	all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6	606:694	all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6	606:694	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	43	theme	capable	610:616	arg1	siphovirus					586:595	one dsDNA lysogenic siphovirus	566:595	one dsDNA lysogenic siphovirus (SLAP1)	566:603	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	2	44	theme	DNA	379:381	arg1	viruses					383:389	Approximately one hundred Acinetobacter-infecting DNA viruses	329:389	Approximately one hundred Acinetobacter-infecting DNA viruses	329:389	Approximately one hundred Acinetobacter-infecting DNA viruses have been identified, and in this report, we describe eight more.
34452516	5	45	theme	O-linked	997:1004	arg1	glycoprotein					1006:1017	both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis	992:1064	glycoprotein	1006:1017	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	5	46	theme	pilin	1138:1142	arg1	protein					1144:1150	the pilin protein	1134:1150	the pilin protein	1134:1150	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	5	46	theme	pilin	1138:1142	arg1	PilA					1153:1156	PilA	1153:1156	PilA	1153:1156	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	3	47	theme	lytic	487:491	arg1	podoviruses					493:503	two typical dsDNA lytic podoviruses	469:503	two typical dsDNA lytic podoviruses (CAP1-2)	469:512	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	47	theme	lytic	487:491	arg1	CAP1-2					506:511	CAP1-2	506:511	CAP1-2	506:511	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	9	48	theme	cell	1956:1959	arg1	receptors					1961:1969	their cell receptors	1950:1969	their cell receptors	1950:1969	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	3	49	theme	multidrug	635:643	arg1	isolate					655:661	the multidrug resistant isolate	631:661	the multidrug resistant isolate	631:661	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	6	50	theme	dsRNA	1256:1260	arg1	segments					1262:1269	the three dsRNA segments	1246:1269	the three dsRNA segments of the isolated cystoviruses	1246:1298	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	1	51	theme	vast	240:243	arg1	gaps					255:258	vast knowledge gaps	240:258	vast knowledge gaps in our understanding of phage diversity and phage-host interactions	240:326	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	8	52	theme	molecular	1699:1707	arg1	weight					1709:1714	a low molecular weight	1693:1714	a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide	1693:1836	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	1	53	theme	diversity	290:298	arg1	understanding					267:279	our understanding	263:279	our understanding of phage diversity and phage-host interactions	263:326	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	1	54	from	gaps	255:258	arg1	understanding					267:279	our understanding	263:279	our understanding of phage diversity and phage-host interactions	263:326	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	8	55	theme	lipid-linked	1716:1727	arg1	glycoconjugate					1729:1742	lipid-linked glycoconjugate	1716:1742	a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide	1693:1836	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	1	56	theme	ubiquitous	176:185	arg1	Bacteriophages					123:136	Bacteriophages	123:136	Bacteriophages (phages)	123:145	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	1	56	theme	ubiquitous	176:185	arg1	entity					198:203	the most ubiquitous biological entity	167:203	the most ubiquitous biological entity on earth	167:212	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	5	57	link	O-linked	997:1004	arg1	glycoprotein					1006:1017	both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis	992:1064	glycoprotein	1006:1017	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	10	58	theme	genus	2014:2018	arg1	genomes					1997:2003	the genomes	1993:2003	the genomes of a new genus of Cystoviruses	1993:2034	Further, we describe the genomes of a new genus of Cystoviruses and perform an initial characterization of membrane-associated glycoconjugates.
34452516	6	59	theme	homology	1323:1330	arg1	levels					1313:1318	low levels	1309:1318	low levels of homology	1309:1330	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	3	60	theme	dsRNA	527:531	arg1	CAP3-7					553:558	CAP3-7	553:558	CAP3-7	553:558	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	60	theme	dsRNA	527:531	arg1	cystoviruses					539:550	five unique dsRNA lytic cystoviruses	515:550	five unique dsRNA lytic cystoviruses (CAP3-7)	515:559	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	10	61	theme	Cystoviruses	2023:2034	arg1	genus					2014:2018	a new genus	2008:2018	a new genus of Cystoviruses	2008:2034	Further, we describe the genomes of a new genus of Cystoviruses and perform an initial characterization of membrane-associated glycoconjugates.
34452516	6	62	theme	isolated	1278:1285	arg1	cystoviruses					1287:1298	the isolated cystoviruses	1274:1298	the isolated cystoviruses	1274:1298	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	5	63	theme	CPS	1048:1050	arg1	biosynthesis					1053:1064	both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis	992:1064	biosynthesis	1053:1064	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	3	64	theme	lysogenic	576:584	arg1	LH6					692:694	all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6	606:694	all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6	606:694	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	64	theme	lysogenic	576:584	arg1	SLAP1					598:602	SLAP1	598:602	SLAP1	598:602	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	64	theme	lysogenic	576:584	arg1	siphovirus					586:595	one dsDNA lysogenic siphovirus	566:595	one dsDNA lysogenic siphovirus (SLAP1)	566:603	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	6	65	theme	other	1369:1373	arg1	cystoviruses					1384:1395	the only other reported cystoviruses	1360:1395	the only other reported cystoviruses that infect Pseudomonas species	1360:1427	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	6	66	theme	conserved	1337:1345	arg1	synteny					1347:1353	conserved synteny	1337:1353	conserved synteny	1337:1353	Genome sequencing of the three dsRNA segments of the isolated cystoviruses revealed low levels of homology, but conserved synteny with the only other reported cystoviruses that infect Pseudomonas species.
34452516	0	67	theme	Acinetobacter	82:94	arg1	LH6					118:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	1	68	theme	interactions	315:326	arg1	understanding					267:279	our understanding	263:279	our understanding of phage diversity and phage-host interactions	263:326	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	0	69	theme	Strain	111:116	arg1	LH6					118:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	Multidrug Resistant Acinetobacter radioresistens Strain LH6	62:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	10	70	theme	glycoconjugates	2099:2113	arg1	characterization					2059:2074	an initial characterization	2048:2074	an initial characterization of membrane-associated glycoconjugates	2048:2113	Further, we describe the genomes of a new genus of Cystoviruses and perform an initial characterization of membrane-associated glycoconjugates.
34452516	5	71	theme	lytic	1094:1098	arg1	CAP1					1110:1113	the lytic podovirus CAP1	1090:1113	the lytic podovirus CAP1	1090:1113	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	5	72	gly	glycoprotein	1006:1017	arg1	glycoprotein					1006:1017	both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis	992:1064	glycoprotein	1006:1017	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	8	73	dep	weight	1709:1714	arg1	glycoconjugate					1729:1742	lipid-linked glycoconjugate	1716:1742	a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide	1693:1836	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	4	74	theme	electron	716:723	arg1	microscopy					725:734	transmission electron microscopy	703:734	transmission electron microscopy	703:734	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	7	75	theme	inner	1531:1535	arg1	membrane					1537:1544	the inner membrane	1527:1544	the inner membrane from the infected host	1527:1567	In Pseudomonas, the cystoviruses are known to be enveloped phages surrounding their capsids with the inner membrane from the infected host.
34452516	4	76	theme	carbohydrate	786:797	arg1	staining					799:806	carbohydrate staining	786:806	carbohydrate staining	786:806	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	0	77	theme	Bacteriophages	37:50	arg1	Properties					23:32	Unique Properties	16:32	Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6	16:120	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	0	77	theme	Bacteriophages	37:50	arg1	RNA					0:2	RNA	0:2	RNA	0:2	RNA and Sugars, Unique Properties of Bacteriophages Infecting Multidrug Resistant Acinetobacter radioresistens Strain LH6.
34452516	1	78	theme	phage	284:288	arg1	diversity					290:298	phage diversity	284:298	phage diversity	284:298	Bacteriophages (phages) are predicted to be the most ubiquitous biological entity on earth, and yet, there are still vast knowledge gaps in our understanding of phage diversity and phage-host interactions.
34452516	7	79	from	host	1564:1567	arg1	membrane					1537:1544	the inner membrane	1527:1544	the inner membrane from the infected host	1527:1567	In Pseudomonas, the cystoviruses are known to be enveloped phages surrounding their capsids with the inner membrane from the infected host.
34452516	5	80	theme	capsular	1023:1030	arg1	biosynthesis					1053:1064	both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis	992:1064	biosynthesis	1053:1064	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	9	81	theme	Acinetobacter-infecting	1894:1916	arg1	phages					1918:1923	new Acinetobacter-infecting phages	1890:1923	new Acinetobacter-infecting phages	1890:1923	Together, this study demonstrates the isolation of new Acinetobacter-infecting phages and the determination of their cell receptors.
34452516	3	82	theme	dsDNA	481:485	arg1	podoviruses					493:503	two typical dsDNA lytic podoviruses	469:503	two typical dsDNA lytic podoviruses (CAP1-2)	469:512	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	3	82	theme	dsDNA	481:485	arg1	CAP1-2					506:511	CAP1-2	506:511	CAP1-2	506:511	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	5	83	theme	necessary	978:986	arg1	PglC					972:975	PglC	972:975	PglC	972:975	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	5	83	theme	necessary	978:986	arg1	Mutation					912:919	Mutation	912:919	Mutation of the LH6 initiating glycosyltransferase homolog	912:969	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	8	84	theme	membrane-associated	1590:1608	arg1	glycoconjugates					1610:1624	any membrane-associated glycoconjugates	1586:1624	any membrane-associated glycoconjugates	1586:1624	To characterize any membrane-associated glycoconjugates in the CAP3 cystovirus, carbohydrate staining was used to identify a low molecular weight lipid-linked glycoconjugate subsequently identified by mutagenesis and mass-spectrometry as bacterial lipooligosaccharide.
34452516	4	85	theme	phage	760:764	arg1	assays					778:783	phage infectivity assays	760:783	phage infectivity assays	760:783	Using transmission electron microscopy, bacterial mutagenesis, phage infectivity assays, carbohydrate staining, mass-spectrometry, genomic sequencing, and comparative studies, we further characterized these phages.
34452516	5	86	theme	lytic	1205:1209	arg1	cystoviruses					1211:1222	the lytic cystoviruses	1201:1222	the lytic cystoviruses	1201:1222	Mutation of the LH6 initiating glycosyltransferase homolog, PglC, necessary for both O-linked glycoprotein and capsular polysaccharide (CPS) biosynthesis, prevented infection by the lytic podovirus CAP1, while mutation of the pilin protein, PilA, prevented infection by CAP3, representing the lytic cystoviruses.
34452516	3	87	theme	resistant	645:653	arg1	isolate					655:661	the multidrug resistant isolate	631:661	the multidrug resistant isolate	631:661	We isolated two typical dsDNA lytic podoviruses (CAP1-2), five unique dsRNA lytic cystoviruses (CAP3-7), and one dsDNA lysogenic siphovirus (SLAP1), all capable of infecting the multidrug resistant isolate Acinetobacter radioresistens LH6.
34452516	2	88	theme	Acinetobacter-infecting	355:377	arg1	viruses					383:389	Approximately one hundred Acinetobacter-infecting DNA viruses	329:389	Approximately one hundred Acinetobacter-infecting DNA viruses	329:389	Approximately one hundred Acinetobacter-infecting DNA viruses have been identified, and in this report, we describe eight more.
33006605	0	0	theme	receptor-binding	86:101	arg1	affinity					103:110	receptor-binding affinity	86:110	receptor-binding affinity	86:110	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	7	1	theme	protein	1178:1184	arg1	stability					1159:1167	the stability	1155:1167	the stability of the S protein	1155:1184	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	4	2	theme	mutations	703:711	arg1	total					687:691	A total	685:691	A total of 18 354 mutations in S protein	685:724	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	8	3	from	mutations	1221:1229	arg1	ACE2					1279:1282	human ACE2	1273:1282	human ACE2	1273:1282	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	3	from	mutations	1221:1229	arg1	RBD					1245:1247	SARS-CoV-2 RBD	1234:1247	SARS-CoV-2 RBD	1234:1247	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	1	4	theme	acute	150:154	arg1	coronavirus					177:187	severe acute respiratory syndrome coronavirus 2	143:189	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	143:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	4	theme	acute	150:154	arg1	SARS-CoV-2					192:201	SARS-CoV-2	192:201	SARS-CoV-2	192:201	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	8	5	theme	human	1273:1277	arg1	ACE2					1279:1282	human ACE2	1273:1282	human ACE2	1273:1282	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	0	6	from	effects	9:15	arg1	SARS-CoV-2					42:51	SARS-CoV-2	42:51	SARS-CoV-2	42:51	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	7	7	theme	many	1095:1098	arg1	mutations					1100:1108	many mutations	1095:1108	many mutations in N-linked glycosylation sites	1095:1140	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	1	8	theme	respiratory	156:166	arg1	coronavirus					177:187	severe acute respiratory syndrome coronavirus 2	143:189	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	143:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	8	theme	respiratory	156:166	arg1	SARS-CoV-2					192:201	SARS-CoV-2	192:201	SARS-CoV-2	192:201	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	9	9	theme	potential	1453:1461	arg1	sites					1470:1474	potential target sites	1453:1474	potential target sites in the development of drugs and vaccines against COVID-19	1453:1532	The findings comprehensively provide potential target sites in the development of drugs and vaccines against COVID-19.
33006605	1	10	theme	permissive	242:251	arg1	cells					253:257	the permissive cells	238:257	the permissive cells	238:257	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	6	11	theme	entire	1067:1072	arg1	protein					1076:1082	the entire S protein	1063:1082	the entire S protein	1063:1082	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	8	12	from	mutations	1260:1268	arg1	ACE2					1279:1282	human ACE2	1273:1282	human ACE2	1273:1282	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	12	from	mutations	1260:1268	arg1	RBD					1245:1247	SARS-CoV-2 RBD	1234:1247	SARS-CoV-2 RBD	1234:1247	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	0	13	gly	glycoprotein	59:70	arg1	glycoprotein					59:70	glycoprotein stability	59:80	glycoprotein stability	59:80	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	4	14	from	total	687:691	arg1	protein					718:724	S protein	716:724	S protein	716:724	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	6	15	theme	S	974:974	arg1	variations					985:994	384 experimentally verified S missense variations	946:994	384 experimentally verified S missense variations	946:994	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	5	16	theme	S	913:913	arg1	stability					923:931	S protein stability	913:931	S protein stability	913:931	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	9	17	theme	vaccines	1508:1515	arg1	development					1483:1493	the development	1479:1493	the development of drugs and vaccines against COVID-19	1479:1532	The findings comprehensively provide potential target sites in the development of drugs and vaccines against COVID-19.
33006605	3	18	theme	sequence-based	540:553	arg1	predictions					569:579	sequence-based pathogenicity predictions	540:579	sequence-based pathogenicity predictions	540:579	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	3	19	theme	computational	441:453	arg1	mutagenesis					466:476	computational saturation mutagenesis	441:476	computational saturation mutagenesis	441:476	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	4	20	theme	18 354	696:701	arg1	mutations					703:711	18 354 mutations	696:711	18 354 mutations in S protein	696:724	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	4	21	theme	S	716:716	arg1	protein					718:724	S protein	716:724	S protein	716:724	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	2	22	theme	receptor-binding	264:279	arg1	domain					281:286	The receptor-binding domain	260:286	The receptor-binding domain (RBD) of SARS-CoV-2 S protein	260:316	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	22	theme	receptor-binding	264:279	arg1	protein					310:316	SARS-CoV-2 S protein	297:316	SARS-CoV-2 S protein	297:316	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	22	theme	receptor-binding	264:279	arg1	RBD					289:291	RBD	289:291	RBD	289:291	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	1	23	theme	syndrome	168:175	arg1	coronavirus					177:187	severe acute respiratory syndrome coronavirus 2	143:189	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	143:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	23	theme	syndrome	168:175	arg1	SARS-CoV-2					192:201	SARS-CoV-2	192:201	SARS-CoV-2	192:201	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	6	24	theme	verified	965:972	arg1	variations					985:994	384 experimentally verified S missense variations	946:994	384 experimentally verified S missense variations	946:994	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	5	25	theme	SARS-CoV-2	880:889	arg1	RBD					891:893	SARS-CoV-2 RBD	880:893	SARS-CoV-2 RBD	880:893	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	9	26	from	sites	1470:1474	arg1	development					1483:1493	the development	1479:1493	the development of drugs and vaccines against COVID-19	1479:1532	The findings comprehensively provide potential target sites in the development of drugs and vaccines against COVID-19.
33006605	8	27	theme	neighbor	1310:1317	arg1	D355					1360:1363	D355	1360:1363	D355	1360:1363	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	27	theme	neighbor	1310:1317	arg1	residues					1319:1326	SARS-CoV-2 neighbor residues G496 and F497	1299:1340	SARS-CoV-2 neighbor residues G496 and F497	1299:1340	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	27	theme	neighbor	1310:1317	arg1	F497					1337:1340	F497	1337:1340	F497	1337:1340	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	27	theme	neighbor	1310:1317	arg1	Y41					1369:1371	Y41	1369:1371	Y41	1369:1371	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	27	theme	neighbor	1310:1317	arg1	G496					1328:1331	G496	1328:1331	G496	1328:1331	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	5	28	dep	residues	854:861	arg1	residues					854:861	residues G431 and S514	854:875	residues G431 and S514 in SARS-CoV-2 RBD	854:893	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	5	28	dep	residues	854:861	arg1	S514					872:875	S514	872:875	S514	872:875	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	5	28	dep	residues	854:861	arg1	G431					863:866	G431	863:866	G431	863:866	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	1	29	theme	coronavirus	177:187	arg1	glycoprotein					127:138	The spike (S) glycoprotein	113:138	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	113:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	29	theme	coronavirus	177:187	arg1	responsible					207:217	responsible	207:217	responsible	207:217	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	3	30	theme	structure-based	500:514	arg1	calculations					523:534	structure-based energy calculations	500:534	structure-based energy calculations	500:534	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	7	31	gly	glycosylation	1122:1134	arg2	sites					1136:1140	N-linked glycosylation sites	1113:1140	N-linked glycosylation sites	1113:1140	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	2	32	theme	SARS-CoV-2	297:306	arg1	protein					310:316	SARS-CoV-2 S protein	297:316	SARS-CoV-2 S protein	297:316	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	0	33	theme	Systemic	0:7	arg1	effects					9:15	Systemic effects	0:15	Systemic effects of missense mutations on SARS-CoV-2	0:51	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	7	34	theme	glycosylation	1122:1134	arg1	sites					1136:1140	N-linked glycosylation sites	1113:1140	N-linked glycosylation sites	1113:1140	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	5	35	theme	protein	915:921	arg1	stability					923:931	S protein stability	913:931	S protein stability	913:931	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	0	36	theme	missense	20:27	arg1	mutations					29:37	missense mutations	20:37	missense mutations	20:37	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	3	37	theme	pathogenicity	555:567	arg1	predictions					569:579	sequence-based pathogenicity predictions	540:579	sequence-based pathogenicity predictions	540:579	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	4	38	theme	entire	810:815	arg1	protein					819:825	the entire S protein	806:825	the entire S protein	806:825	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	2	39	theme	host	398:401	arg1	membrane					408:415	the host cell membrane	394:415	the host cell membrane	394:415	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	40	theme	cell	403:406	arg1	membrane					408:415	the host cell membrane	394:415	the host cell membrane	394:415	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	3	41	theme	energy	516:521	arg1	calculations					523:534	structure-based energy calculations	500:534	structure-based energy calculations	500:534	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	3	42	theme	protein	653:659	arg1	structure					661:669	SARS-CoV-2 S protein structure	640:669	SARS-CoV-2 S protein structure	640:669	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	1	43	theme	spike	117:121	arg1	glycoprotein					127:138	The spike (S) glycoprotein	113:138	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	113:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	43	theme	spike	117:121	arg1	responsible					207:217	responsible	207:217	responsible	207:217	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	9	44	theme	drugs	1498:1502	arg1	development					1483:1493	the development	1479:1493	the development of drugs and vaccines against COVID-19	1479:1532	The findings comprehensively provide potential target sites in the development of drugs and vaccines against COVID-19.
33006605	7	45	theme	N-linked	1113:1120	arg1	sites					1136:1140	N-linked glycosylation sites	1113:1140	N-linked glycosylation sites	1113:1140	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	9	46	theme	target	1463:1468	arg1	sites					1470:1474	potential target sites	1453:1474	potential target sites in the development of drugs and vaccines against COVID-19	1453:1532	The findings comprehensively provide potential target sites in the development of drugs and vaccines against COVID-19.
33006605	1	47	gly	glycoprotein	127:138	arg1	glycoprotein					127:138	The spike (S) glycoprotein	113:138	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	113:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	47	gly	glycoprotein	127:138	arg1	responsible					207:217	responsible	207:217	responsible	207:217	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	3	48	theme	systemic	598:605	arg1	effects					607:613	the systemic effects	594:613	the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function	594:682	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	3	49	from	effects	607:613	arg1	function					675:682	function	675:682	function	675:682	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	3	49	from	effects	607:613	arg1	structure					661:669	SARS-CoV-2 S protein structure	640:669	SARS-CoV-2 S protein structure	640:669	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	6	50	theme	pandemic	1027:1034	arg1	form					1036:1039	the dominant pandemic form	1014:1039	the dominant pandemic form	1014:1039	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	6	50	theme	pandemic	1027:1034	arg1	D614G					1042:1046	D614G	1042:1046	D614G	1042:1046	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	0	51	theme	mutations	29:37	arg1	effects					9:15	Systemic effects	0:15	Systemic effects of missense mutations on SARS-CoV-2	0:51	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	6	52	theme	missense	976:983	arg1	variations					985:994	384 experimentally verified S missense variations	946:994	384 experimentally verified S missense variations	946:994	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	3	53	theme	SARS-CoV-2	640:649	arg1	structure					661:669	SARS-CoV-2 S protein structure	640:669	SARS-CoV-2 S protein structure	640:669	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	3	54	used	used	436:439	arg2	we					433:434	we	433:434	we	433:434	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	6	55	theme	dominant	1018:1025	arg1	form					1036:1039	the dominant pandemic form	1014:1039	the dominant pandemic form	1014:1039	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	6	55	theme	dominant	1018:1025	arg1	D614G					1042:1046	D614G	1042:1046	D614G	1042:1046	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	3	56	theme	S	651:651	arg1	structure					661:669	SARS-CoV-2 S protein structure	640:669	SARS-CoV-2 S protein structure	640:669	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	7	57	link	N-linked	1113:1120	arg1	sites					1136:1140	N-linked glycosylation sites	1113:1140	N-linked glycosylation sites	1113:1140	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	3	58	theme	saturation	455:464	arg1	mutagenesis					466:476	computational saturation mutagenesis	441:476	computational saturation mutagenesis	441:476	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	2	59	theme	human	346:350	arg1	enzyme					375:380	human angiotensin-converting enzyme 2	346:382	the human angiotensin-converting enzyme 2 (ACE2)	342:389	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	59	theme	human	346:350	arg1	ACE2					385:388	ACE2	385:388	ACE2	385:388	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	4	60	theme	S	817:817	arg1	protein					819:825	the entire S protein	806:825	the entire S protein	806:825	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	1	61	theme	S	124:124	arg1	glycoprotein					127:138	The spike (S) glycoprotein	113:138	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	113:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	61	theme	S	124:124	arg1	responsible					207:217	responsible	207:217	responsible	207:217	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	3	62	theme	mutations	627:635	arg1	effects					607:613	the systemic effects	594:613	the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function	594:682	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	8	63	theme	ACE2	1346:1349	arg1	residues					1351:1358	ACE2 residues	1346:1358	ACE2 residues	1346:1358	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	2	64	theme	protein	310:316	arg1	domain					281:286	The receptor-binding domain	260:286	The receptor-binding domain (RBD) of SARS-CoV-2 S protein	260:316	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	64	theme	protein	310:316	arg1	protein					310:316	SARS-CoV-2 S protein	297:316	SARS-CoV-2 S protein	297:316	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	64	theme	protein	310:316	arg1	RBD					289:291	RBD	289:291	RBD	289:291	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	4	65	from	protein	718:724	arg1	total					687:691	A total	685:691	A total of 18 354 mutations in S protein	685:724	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	8	66	theme	SARS-CoV-2	1234:1243	arg1	RBD					1245:1247	SARS-CoV-2 RBD	1234:1247	SARS-CoV-2 RBD	1234:1247	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	67	theme	RBD-ACE2	1394:1401	arg1	interaction					1403:1413	the RBD-ACE2 interaction	1390:1413	the RBD-ACE2 interaction	1390:1413	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	68	theme	SARS-CoV-2	1299:1308	arg1	D355					1360:1363	D355	1360:1363	D355	1360:1363	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	68	theme	SARS-CoV-2	1299:1308	arg1	residues					1319:1326	SARS-CoV-2 neighbor residues G496 and F497	1299:1340	SARS-CoV-2 neighbor residues G496 and F497	1299:1340	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	68	theme	SARS-CoV-2	1299:1308	arg1	F497					1337:1340	F497	1337:1340	F497	1337:1340	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	68	theme	SARS-CoV-2	1299:1308	arg1	Y41					1369:1371	Y41	1369:1371	Y41	1369:1371	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	68	theme	SARS-CoV-2	1299:1308	arg1	G496					1328:1331	G496	1328:1331	G496	1328:1331	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	5	69	from	residues	854:861	arg1	RBD					891:893	SARS-CoV-2 RBD	880:893	SARS-CoV-2 RBD	880:893	Specifically, residues G431 and S514 in SARS-CoV-2 RBD are important for S protein stability.
33006605	2	70	theme	S	308:308	arg1	protein					310:316	SARS-CoV-2 S protein	297:316	SARS-CoV-2 S protein	297:316	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	6	71	theme	S	1074:1074	arg1	protein					1076:1082	the entire S protein	1063:1082	the entire S protein	1063:1082	We analyzed 384 experimentally verified S missense variations and revealed that the dominant pandemic form, D614G, can stabilize the entire S protein.
33006605	8	72	dep	residues	1319:1326	arg1	D355					1360:1363	D355	1360:1363	D355	1360:1363	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	72	dep	residues	1319:1326	arg1	residues					1319:1326	SARS-CoV-2 neighbor residues G496 and F497	1299:1340	SARS-CoV-2 neighbor residues G496 and F497	1299:1340	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	72	dep	residues	1319:1326	arg1	F497					1337:1340	F497	1337:1340	F497	1337:1340	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	72	dep	residues	1319:1326	arg1	Y41					1369:1371	Y41	1369:1371	Y41	1369:1371	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	8	72	dep	residues	1319:1326	arg1	G496					1328:1331	G496	1328:1331	G496	1328:1331	In addition, we investigated 3705 mutations in SARS-CoV-2 RBD and 11 324 mutations in human ACE2 and found that SARS-CoV-2 neighbor residues G496 and F497 and ACE2 residues D355 and Y41 are critical for the RBD-ACE2 interaction.
33006605	2	73	theme	angiotensin-converting	352:373	arg1	enzyme					375:380	human angiotensin-converting enzyme 2	346:382	the human angiotensin-converting enzyme 2 (ACE2)	342:389	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	2	73	theme	angiotensin-converting	352:373	arg1	ACE2					385:388	ACE2	385:388	ACE2	385:388	The receptor-binding domain (RBD) of SARS-CoV-2 S protein directly interacts with the human angiotensin-converting enzyme 2 (ACE2) on the host cell membrane.
33006605	0	74	theme	glycoprotein	59:70	arg1	stability					72:80	glycoprotein stability	59:80	glycoprotein stability	59:80	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity.
33006605	7	75	from	mutations	1100:1108	arg1	sites					1136:1140	N-linked glycosylation sites	1113:1140	N-linked glycosylation sites	1113:1140	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
33006605	3	76	theme	missense	618:625	arg1	mutations					627:635	missense mutations	618:635	missense mutations	618:635	In this study, we used computational saturation mutagenesis approaches, including structure-based energy calculations and sequence-based pathogenicity predictions, to quantify the systemic effects of missense mutations on SARS-CoV-2 S protein structure and function.
33006605	1	77	theme	severe	143:148	arg1	coronavirus					177:187	severe acute respiratory syndrome coronavirus 2	143:189	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	143:202	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	1	77	theme	severe	143:148	arg1	SARS-CoV-2					192:201	SARS-CoV-2	192:201	SARS-CoV-2	192:201	The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the binding to the permissive cells.
33006605	4	78	from	mutations	703:711	arg1	protein					718:724	S protein	716:724	S protein	716:724	A total of 18 354 mutations in S protein were analyzed, and we discovered that most of these mutations could destabilize the entire S protein and its RBD.
33006605	7	79	theme	S	1176:1176	arg1	protein					1178:1184	the S protein	1172:1184	the S protein	1172:1184	Moreover, many mutations in N-linked glycosylation sites can increase the stability of the S protein.
32715591	1	0	theme	large	167:171	arg1	gap					196:198	large singlet-triplet energy gap	167:198	large singlet-triplet energy gap	167:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	4	1	theme	block	879:883	arg1	type					859:862	the type	855:862	the type of oxoverdazyl block (C-linked or N-linked)	855:906	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	1	2	theme	singlet-triplet	173:187	arg1	gap					196:198	large singlet-triplet energy gap	167:198	large singlet-triplet energy gap	167:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	5	3	with	diradicals	931:940	arg1	state					966:970	the triplet ground state	947:970	the triplet ground state	947:970	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	5	4	theme	inter-diradical	1052:1066	arg1	coupling					1082:1089	weak inter-diradical ferromagnetic coupling	1047:1089	weak inter-diradical ferromagnetic coupling	1047:1089	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	2	5	theme	nitroxide	339:347	arg1	units					349:353	nitronyl nitroxide units	330:353	nitronyl nitroxide units	330:353	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	4	6	theme	interaction	768:778	arg1	sign					747:750	The sign	743:750	The sign of the exchange interaction	743:778	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	5	7	theme	unique	977:982	arg1	chains					1017:1022	unique one-dimensional exchange-coupled chains	977:1022	unique one-dimensional exchange-coupled chains	977:1022	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	2	8	theme	nitronyl	330:337	arg1	units					349:353	nitronyl nitroxide units	330:353	nitronyl nitroxide units	330:353	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	5	9	theme	triplet	951:957	arg1	state					966:970	the triplet ground state	947:970	the triplet ground state	947:970	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	4	10	theme	bridging	806:813	arg1	moiety					815:820	the bridging moiety	802:820	the bridging moiety (para- or meta-phenylene)	802:846	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	1	11	theme	energy	189:194	arg1	gap					196:198	large singlet-triplet energy gap	167:198	large singlet-triplet energy gap	167:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	5	12	theme	exchange-coupled	1000:1015	arg1	chains					1017:1022	unique one-dimensional exchange-coupled chains	977:1022	unique one-dimensional exchange-coupled chains	977:1022	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	2	13	theme	gold	471:474	arg1	complex					479:485	a nitronyl nitroxide-2-ide gold(I) complex	444:485	a nitronyl nitroxide-2-ide gold(I) complex with high yields	444:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	0	14	theme	Coupled	18:24	arg1	Chains					30:35	Ferromagnetically Coupled S=1 Chains	0:35	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.	0:90	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	2	15	with	complex	479:485	arg1	yields					497:502	high yields	492:502	high yields	492:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	4	16	theme	oxoverdazyl	867:877	arg1	block					879:883	oxoverdazyl block	867:883	oxoverdazyl block (C-linked or N-linked)	867:906	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	5	17	theme	strong	1029:1034	arg1	intra-					1036:1041	strong intra-	1029:1041	strong intra-	1029:1041	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	1	18	theme	stable	102:107	arg1	diradicals					117:126	Thermally stable organic diradicals	92:126	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap	92:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	2	19	theme	nitroxide-2-ide	455:469	arg1	complex					479:485	a nitronyl nitroxide-2-ide gold(I) complex	444:485	a nitronyl nitroxide-2-ide gold(I) complex with high yields	444:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	0	20	theme	Ferromagnetically	0:16	arg1	Chains					30:35	Ferromagnetically Coupled S=1 Chains	0:35	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.	0:90	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	1	21	theme	organic	109:115	arg1	diradicals					117:126	Thermally stable organic diradicals	92:126	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap	92:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	1	22	theme	significant	205:215	arg1	potential					217:225	significant potential	205:225	significant potential for advanced technological applications	205:265	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	4	23	theme	exchange	759:766	arg1	interaction					768:778	the exchange interaction	755:778	the exchange interaction	755:778	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	5	24	theme	ground	959:964	arg1	state					966:970	the triplet ground state	947:970	the triplet ground state	947:970	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	3	25	theme	high	528:531	arg1	stability					533:541	high stability	528:541	high stability	528:541	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	0	26	theme	S=1	26:28	arg1	Chains					30:35	Ferromagnetically Coupled S=1 Chains	0:35	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.	0:90	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	5	27	theme	one-dimensional	984:998	arg1	chains					1017:1022	unique one-dimensional exchange-coupled chains	977:1022	unique one-dimensional exchange-coupled chains	977:1022	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	3	28	theme	inert	570:574	arg1	atmosphere					576:585	an inert atmosphere	567:585	an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed	567:740	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	2	29	theme	cross-coupling	398:411	arg1	reaction					413:420	a palladium-catalyzed cross-coupling reaction	376:420	a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields	376:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	1	30	contain	have	200:203	arg1	diradicals					117:126	Thermally stable organic diradicals	92:126	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap	92:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	1	30	contain	have	200:203	arg2	potential					217:225	significant potential	205:225	significant potential for advanced technological applications	205:265	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	2	31	theme	nitronyl	446:453	arg1	complex					479:485	a nitronyl nitroxide-2-ide gold(I) complex	444:485	a nitronyl nitroxide-2-ide gold(I) complex with high yields	444:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	1	32	theme	advanced	231:238	arg1	applications					254:265	advanced technological applications	231:265	advanced technological applications	231:265	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	3	33	theme	ΔEST	642:645	arg1	AF					638:639	substantial AF	626:639	substantial AF (ΔEST ≈-64 cm-1 )	626:657	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	3	33	theme	ΔEST	642:645	arg1	≈-64 cm-1					647:655	ΔEST ≈-64 cm-1	642:655	ΔEST ≈-64 cm-1	642:655	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	1	34	theme	technological	240:252	arg1	applications					254:265	advanced technological applications	231:265	advanced technological applications	231:265	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	0	35	theme	Verdazyl-Nitronyl	52:68	arg1	Diradicals					80:89	Verdazyl-Nitronyl Nitroxide Diradicals	52:89	Verdazyl-Nitronyl Nitroxide Diradicals	52:89	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	3	36	theme	ΔEST	667:670	arg1	≥25					672:674	ΔEST ≥25	667:674	ΔEST ≥25	667:674	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	3	37	theme	substantial	626:636	arg1	AF					638:639	substantial AF	626:639	substantial AF (ΔEST ≈-64 cm-1 )	626:657	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	3	37	theme	substantial	626:636	arg1	≈-64 cm-1					647:655	ΔEST ≈-64 cm-1	642:655	ΔEST ≈-64 cm-1	642:655	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	4	38	dep	block	879:883	arg1	N-linked					898:905	N-linked	898:905	N-linked	898:905	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	4	38	dep	block	879:883	arg1	C-linked					886:893	C-linked	886:893	C-linked	886:893	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	2	39	with	iodoverdazyls	425:437	arg1	complex					479:485	a nitronyl nitroxide-2-ide gold(I) complex	444:485	a nitronyl nitroxide-2-ide gold(I) complex with high yields	444:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	5	40	theme	ferromagnetic	1068:1080	arg1	coupling					1082:1089	weak inter-diradical ferromagnetic coupling	1047:1089	weak inter-diradical ferromagnetic coupling	1047:1089	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	1	41	theme	triplet	135:141	arg1	state					150:154	a triplet ground state	133:154	a triplet ground state along with large singlet-triplet energy gap	133:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	2	42	with	diradicals	298:307	arg1	oxoverdazyl					314:324	oxoverdazyl	314:324	oxoverdazyl	314:324	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	2	42	with	diradicals	298:307	arg1	units					349:353	nitronyl nitroxide units	330:353	nitronyl nitroxide units	330:353	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	3	43	theme	exchange	706:713	arg1	interactions					715:726	intramolecular exchange interactions	691:726	intramolecular exchange interactions	691:726	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	5	44	theme	weak	1047:1050	arg1	coupling					1082:1089	weak inter-diradical ferromagnetic coupling	1047:1089	weak inter-diradical ferromagnetic coupling	1047:1089	Upon crystallization, diradicals with the triplet ground state form unique one-dimensional exchange-coupled chains with strong intra- and weak inter-diradical ferromagnetic coupling.
32715591	1	45	theme	ground	143:148	arg1	state					150:154	a triplet ground state	133:154	a triplet ground state along with large singlet-triplet energy gap	133:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	2	46	theme	diradicals	298:307	arg1	series					270:275	A series	268:275	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units	268:353	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	3	47	dep	diradicals	609:618	arg1	observed					733:740	observed	733:740	were observed	728:740	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	2	48	theme	palladium-catalyzed	378:396	arg1	reaction					413:420	a palladium-catalyzed cross-coupling reaction	376:420	a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields	376:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	0	49	theme	Diradicals	80:89	arg1	Crystals					40:47	Crystals	40:47	Crystals of Verdazyl-Nitronyl Nitroxide Diradicals	40:89	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	3	50	dep	FM	663:664	arg1	≥25					672:674	ΔEST ≥25	667:674	ΔEST ≥25	667:674	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	3	50	dep	FM	663:664	arg1	100 cm-1					680:687	100 cm-1	680:687	100 cm-1	680:687	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	2	51	theme	phenylene-bridged	280:296	arg1	diradicals					298:307	phenylene-bridged diradicals	280:307	phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units	280:353	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	2	52	theme	iodoverdazyls	425:437	arg1	reaction					413:420	a palladium-catalyzed cross-coupling reaction	376:420	a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields	376:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	3	53	dep	AF	638:639	arg1	interactions					715:726	intramolecular exchange interactions	691:726	intramolecular exchange interactions	691:726	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	3	54	theme	intramolecular	691:704	arg1	interactions					715:726	intramolecular exchange interactions	691:726	intramolecular exchange interactions	691:726	The diradicals exhibit high stability and do not decompose in an inert atmosphere up to 180 °C. For the diradicals, both substantial AF (ΔEST ≈-64 cm-1 ) and FM (ΔEST ≥25 and 100 cm-1 ) intramolecular exchange interactions were observed.
32715591	0	55	theme	Nitroxide	70:78	arg1	Diradicals					80:89	Verdazyl-Nitronyl Nitroxide Diradicals	52:89	Verdazyl-Nitronyl Nitroxide Diradicals	52:89	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	0	56	from	Chains	30:35	arg1	Crystals					40:47	Crystals	40:47	Crystals of Verdazyl-Nitronyl Nitroxide Diradicals	40:89	Ferromagnetically Coupled S=1 Chains in Crystals of Verdazyl-Nitronyl Nitroxide Diradicals.
32715591	2	57	theme	high	492:495	arg1	yields					497:502	high yields	492:502	high yields	492:502	A series of phenylene-bridged diradicals with oxoverdazyl and nitronyl nitroxide units were synthesized via a palladium-catalyzed cross-coupling reaction of iodoverdazyls with a nitronyl nitroxide-2-ide gold(I) complex with high yields.
32715591	1	58	with	diradicals	117:126	arg1	state					150:154	a triplet ground state	133:154	a triplet ground state along with large singlet-triplet energy gap	133:198	Thermally stable organic diradicals with a triplet ground state along with large singlet-triplet energy gap have significant potential for advanced technological applications.
32715591	4	59	dep	moiety	815:820	arg1	para-					823:827	para-	823:827	para-	823:827	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32715591	4	59	dep	moiety	815:820	arg1	meta-phenylene					832:845	meta-phenylene	832:845	meta-phenylene	832:845	The sign of the exchange interaction is determined both by the bridging moiety (para- or meta-phenylene) and by the type of oxoverdazyl block (C-linked or N-linked).
32636304	0	0	theme	multivalent	61:71	arg1	fashion					73:79	a multivalent fashion	59:79	a multivalent fashion	59:79	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	8	1	theme	recombinant	1506:1516	arg1	gp120					1518:1522	recombinant gp120	1506:1522	recombinant gp120	1506:1522	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	2	2	theme	Carbohydrate-binding	335:354	arg1	lectins					395:401	mannose-binding lectins	379:401	particularly mannose-binding lectins	366:401	Carbohydrate-binding proteins, particularly mannose-binding lectins, have also been shown to bind these glycans.
32636304	2	2	theme	Carbohydrate-binding	335:354	arg1	proteins					356:363	Carbohydrate-binding proteins	335:363	Carbohydrate-binding proteins	335:363	Carbohydrate-binding proteins, particularly mannose-binding lectins, have also been shown to bind these glycans.
32636304	7	3	theme	conserved	1372:1380	arg1	site					1382:1385	a secondary conserved site	1360:1385	a secondary conserved site	1360:1385	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	1	4	theme	most	218:221	arg1	antibodies					236:245	most neutralizing antibodies	218:245	most neutralizing antibodies	218:245	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	7	5	theme	multivalent	1260:1270	arg1	mode					1272:1275	This multivalent mode	1255:1275	This multivalent mode of binding	1255:1286	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	1	6	theme	neutralizing	223:234	arg1	antibodies					236:245	most neutralizing antibodies	218:245	most neutralizing antibodies	218:245	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	6	7	theme	shorter	1090:1096	arg1	saccharides					1098:1108	shorter saccharides	1090:1108	shorter saccharides	1090:1108	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	8	8	with	interaction	1477:1487	arg1	affinity					1544:1551	high affinity	1539:1551	high affinity	1539:1551	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	4	9	dep	vulgare	622:628	arg1	lectin					630:635	lectin	630:635	Hordeum vulgare lectin	614:635	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	0	10	dep	high-affinity	91:103	arg1	specific					106:113	specific	106:113	specific	106:113	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	5	11	theme	mannooligosaccharides	938:958	arg1	branching					925:933	branching	925:933	branching	925:933	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	5	11	theme	mannooligosaccharides	938:958	arg1	length					914:919	length	914:919	length	914:919	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	4	12	theme	such	586:589	arg1	lectin					591:596	one such lectin	582:596	one such lectin	582:596	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	7	13	theme	binding	1280:1286	arg1	mode					1272:1275	This multivalent mode	1255:1275	This multivalent mode of binding	1255:1286	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	8	14	theme	high	1539:1542	arg1	affinity					1544:1551	high affinity	1539:1551	high affinity	1539:1551	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	5	15	dep	length	914:919	arg1	the					910:912	the	910:912	the	910:912	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	0	16	theme	high-affinity	91:103	arg1	inhibition					115:124	high-affinity, specific inhibition	91:124	high-affinity, specific inhibition of cellular HIV infection	91:150	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	4	17	theme	Hordeum	614:620	arg1	horcolin					604:611	horcolin	604:611	horcolin (Hordeum vulgare lectin)	604:636	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	4	17	theme	Hordeum	614:620	arg1	vulgare					622:628	Hordeum vulgare lectin	614:635	Hordeum vulgare lectin	614:635	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	1	18	located	found	279:283	arg1	gp120					327:331	the surface envelope glycoprotein-120 (gp120)	288:332	the surface envelope glycoprotein-120 (gp120)	288:332	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	1	18	located	found	279:283	arg2	glycans					271:277	the high-mannose glycans	254:277	the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120)	254:332	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	7	19	theme	mannosyl	1337:1344	arg1	residues					1346:1353	core mannosyl residues	1332:1353	core mannosyl residues	1332:1353	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	1	20	theme	N-Linked	153:160	arg1	glycans					162:168	N-Linked glycans	153:168	N-Linked glycans	153:168	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	8	21	from	concentrations	1598:1611	arg1	inhibition					1557:1566	inhibition	1557:1566	inhibition of HIV infection at nanomolar concentrations without mitogenicity	1557:1632	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	8	21	from	concentrations	1598:1611	arg1	interaction					1477:1487	the interaction	1473:1487	the interaction of horcolin with recombinant gp120 and gp140 with high affinity	1473:1551	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	4	22	from	sites	733:737	arg1	divergence					678:687	the divergence	674:687	the divergence in the residues at its carbohydrate-binding sites	674:737	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	4	22	from	sites	733:737	arg1	residues					696:703	the residues	692:703	the residues at its carbohydrate-binding sites	692:737	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	5	23	theme	total	976:980	arg1	valency					982:988	the total valency	972:988	the total valency	972:988	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	7	24	from	site	1382:1385	arg1	protein					1394:1400	the protein	1390:1400	the protein	1390:1400	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	5	25	theme	calorimetry	846:856	arg1	experiments					858:868	Extensive isothermal titration calorimetry experiments	815:868	Extensive isothermal titration calorimetry experiments	815:868	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	0	26	theme	barley	4:9	arg1	lectin					11:16	The barley lectin	0:16	The barley lectin	0:16	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	0	26	theme	barley	4:9	arg1	horcolin					19:26	horcolin	19:26	horcolin	19:26	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	7	27	theme	exponential	1417:1427	arg1	increase					1429:1436	an exponential increase	1414:1436	an exponential increase in affinity	1414:1448	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	2	28	theme	mannose-binding	379:393	arg1	lectins					395:401	mannose-binding lectins	379:401	particularly mannose-binding lectins	366:401	Carbohydrate-binding proteins, particularly mannose-binding lectins, have also been shown to bind these glycans.
32636304	2	28	theme	mannose-binding	379:393	arg1	proteins					356:363	Carbohydrate-binding proteins	335:363	Carbohydrate-binding proteins	335:363	Carbohydrate-binding proteins, particularly mannose-binding lectins, have also been shown to bind these glycans.
32636304	6	29	with	interactions	1173:1184	arg1	sites					1248:1252	the primary carbohydrate-binding sites	1215:1252	the primary carbohydrate-binding sites	1215:1252	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	8	30	theme	horcolin	1492:1499	arg1	inhibition					1557:1566	inhibition	1557:1566	inhibition of HIV infection at nanomolar concentrations without mitogenicity	1557:1632	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	8	30	theme	horcolin	1492:1499	arg1	interaction					1477:1487	the interaction	1473:1487	the interaction of horcolin with recombinant gp120 and gp140 with high affinity	1473:1551	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	7	31	theme	residues	1346:1353	arg1	interactions					1316:1327	interactions	1316:1327	interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity	1316:1448	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	1	32	theme	high-mannose	258:269	arg1	glycans					271:277	the high-mannose glycans	254:277	the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120)	254:332	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	6	33	theme	higher	1134:1139	arg1	glycans					1141:1147	higher glycans	1134:1147	higher glycans	1134:1147	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	6	34	theme	monovalent	1068:1077	arg1	binding					1079:1085	a monovalent binding	1066:1085	a monovalent binding to shorter saccharides	1066:1108	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	6	35	theme	binding	1057:1063	arg1	mode					1125:1128	a bivalent mode	1114:1128	a bivalent mode for higher glycans	1114:1147	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	6	35	theme	binding	1057:1063	arg1	modes					1048:1052	two distinct modes	1035:1052	two distinct modes of binding	1035:1063	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	6	35	theme	binding	1057:1063	arg1	binding					1079:1085	a monovalent binding	1066:1085	a monovalent binding to shorter saccharides	1066:1108	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	8	36	theme	infection	1575:1583	arg1	inhibition					1557:1566	inhibition	1557:1566	inhibition of HIV infection at nanomolar concentrations without mitogenicity	1557:1632	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	8	36	theme	infection	1575:1583	arg1	interaction					1477:1487	the interaction	1473:1487	the interaction of horcolin with recombinant gp120 and gp140 with high affinity	1473:1551	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	7	37	with	interactions	1316:1327	arg1	site					1382:1385	a secondary conserved site	1360:1385	a secondary conserved site	1360:1385	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	4	38	theme	carbohydrate-binding	712:731	arg1	sites					733:737	its carbohydrate-binding sites	708:737	its carbohydrate-binding sites	708:737	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	3	39	theme	therapeutic	462:472	arg1	potency					474:480	their therapeutic potency	456:480	their therapeutic potency	456:480	Despite their therapeutic potency, their ability to cause lymphocyte proliferation limits their application.
32636304	8	40	theme	HIV	1571:1573	arg1	infection					1575:1583	HIV infection	1571:1583	HIV infection	1571:1583	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	6	41	theme	carbohydrate-binding	1227:1246	arg1	sites					1248:1252	the primary carbohydrate-binding sites	1215:1252	the primary carbohydrate-binding sites	1215:1252	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	5	42	theme	Extensive	815:823	arg1	experiments					858:868	Extensive isothermal titration calorimetry experiments	815:868	Extensive isothermal titration calorimetry experiments	815:868	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	8	43	with	inhibition	1557:1566	arg1	affinity					1544:1551	high affinity	1539:1551	high affinity	1539:1551	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	7	44	from	increase	1429:1436	arg1	affinity					1441:1448	affinity	1441:1448	affinity	1441:1448	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	1	45	theme	infection	190:198	arg1	cycle					200:204	the infection cycle	186:204	the infection cycle of HIV	186:211	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	5	46	theme	titration	836:844	arg1	calorimetry					846:856	isothermal titration calorimetry	825:856	Extensive isothermal titration calorimetry experiments	815:868	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	8	47	theme	nanomolar	1588:1596	arg1	concentrations					1598:1611	nanomolar concentrations	1588:1611	nanomolar concentrations without mitogenicity	1588:1632	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	6	48	theme	Modeling	991:998	arg1	studies					1015:1021	Modeling and simulation studies	991:1021	studies	1015:1021	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	5	49	theme	isothermal	825:834	arg1	calorimetry					846:856	isothermal titration calorimetry	825:856	Extensive isothermal titration calorimetry experiments	815:868	Extensive isothermal titration calorimetry experiments reveal that the lectin was sensitive to the length and branching of mannooligosaccharides and thereby the total valency.
32636304	0	50	theme	high-mannose	35:46	arg1	glycans					48:54	high-mannose glycans	35:54	high-mannose glycans	35:54	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	0	51	theme	HIV	138:140	arg1	infection					142:150	cellular HIV infection	129:150	cellular HIV infection	129:150	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	4	52	theme	anti-HIV	799:806	arg1	candidate					767:775	a promising candidate	755:775	a promising candidate for exploration	755:791	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	4	52	theme	anti-HIV	799:806	arg1	agent					808:812	an anti-HIV agent	796:812	an anti-HIV agent	796:812	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	1	53	theme	surface	292:298	arg1	gp120					327:331	the surface envelope glycoprotein-120 (gp120)	288:332	the surface envelope glycoprotein-120 (gp120)	288:332	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	0	54	theme	cellular	129:136	arg1	infection					142:150	cellular HIV infection	129:150	cellular HIV infection	129:150	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	6	55	theme	primary	1219:1225	arg1	sites					1248:1252	the primary carbohydrate-binding sites	1215:1252	the primary carbohydrate-binding sites	1215:1252	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	7	56	theme	core	1332:1335	arg1	residues					1346:1353	core mannosyl residues	1332:1353	core mannosyl residues	1332:1353	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	1	57	theme	envelope	300:307	arg1	gp120					327:331	the surface envelope glycoprotein-120 (gp120)	288:332	the surface envelope glycoprotein-120 (gp120)	288:332	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	4	58	theme	promising	757:765	arg1	candidate					767:775	a promising candidate	755:775	a promising candidate for exploration	755:791	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	4	58	theme	promising	757:765	arg1	agent					808:812	an anti-HIV agent	796:812	an anti-HIV agent	796:812	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	6	59	theme	bivalent	1116:1123	arg1	mode					1125:1128	a bivalent mode	1114:1128	a bivalent mode for higher glycans	1114:1147	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	0	60	theme	infection	142:150	arg1	inhibition					115:124	high-affinity, specific inhibition	91:124	high-affinity, specific inhibition of cellular HIV infection	91:150	The barley lectin, horcolin, binds high-mannose glycans in a multivalent fashion, enabling high-affinity, specific inhibition of cellular HIV infection.
32636304	6	61	theme	multiple	1189:1196	arg1	arms					1205:1208	multiple glycan arms	1189:1208	multiple glycan arms	1189:1208	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	1	62	theme	HIV	209:211	arg1	cycle					200:204	the infection cycle	186:204	the infection cycle of HIV	186:211	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	6	63	theme	distinct	1039:1046	arg1	modes					1048:1052	two distinct modes	1035:1052	two distinct modes of binding	1035:1063	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	6	64	theme	arms	1205:1208	arg1	interactions					1173:1184	simultaneous interactions	1160:1184	simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites	1160:1252	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	6	65	theme	simultaneous	1160:1171	arg1	interactions					1173:1184	simultaneous interactions	1160:1184	simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites	1160:1252	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	3	66	theme	lymphocyte	506:515	arg1	proliferation					517:529	lymphocyte proliferation	506:529	lymphocyte proliferation	506:529	Despite their therapeutic potency, their ability to cause lymphocyte proliferation limits their application.
32636304	4	67	from	divergence	678:687	arg1	sites					733:737	its carbohydrate-binding sites	708:737	its carbohydrate-binding sites	708:737	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	4	67	from	divergence	678:687	arg1	residues					696:703	the residues	692:703	the residues at its carbohydrate-binding sites	692:737	In this study, we report one such lectin named horcolin (Hordeum vulgare lectin), seen to lack mitogenicity owing to the divergence in the residues at its carbohydrate-binding sites, which makes it a promising candidate for exploration as an anti-HIV agent.
32636304	1	68	theme	glycoprotein-120	309:324	arg1	gp120					327:331	the surface envelope glycoprotein-120 (gp120)	288:332	the surface envelope glycoprotein-120 (gp120)	288:332	N-Linked glycans are critical to the infection cycle of HIV, and most neutralizing antibodies target the high-mannose glycans found on the surface envelope glycoprotein-120 (gp120).
32636304	6	69	theme	glycan	1198:1203	arg1	arms					1205:1208	multiple glycan arms	1189:1208	multiple glycan arms	1189:1208	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32636304	8	70	with	horcolin	1492:1499	arg1	gp140					1528:1532	gp140	1528:1532	gp140	1528:1532	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	8	70	with	horcolin	1492:1499	arg1	gp120					1518:1522	recombinant gp120	1506:1522	recombinant gp120	1506:1522	Finally, we confirmed the interaction of horcolin with recombinant gp120 and gp140 with high affinity and inhibition of HIV infection at nanomolar concentrations without mitogenicity.
32636304	7	71	theme	secondary	1362:1370	arg1	site					1382:1385	a secondary conserved site	1360:1385	a secondary conserved site	1360:1385	This multivalent mode of binding was further strengthened by interactions of core mannosyl residues with a secondary conserved site on the protein, leading to an exponential increase in affinity.
32636304	6	72	theme	simulation	1004:1013	arg1	studies					1015:1021	Modeling and simulation studies	991:1021	studies	1015:1021	Modeling and simulation studies demonstrate two distinct modes of binding, a monovalent binding to shorter saccharides and a bivalent mode for higher glycans, involving simultaneous interactions of multiple glycan arms with the primary carbohydrate-binding sites.
32602701	7	0	theme	Ala	996:998	arg1	substitution					1000:1011	Ala substitution	996:1011	Ala substitution of either site	996:1026	Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper protein folding; Ala substitution of either site inhibited protein secretion.
32602701	8	1	theme	Cys-142	1091:1097	arg1	substitutions					1074:1086	Ala substitutions	1070:1086	Ala substitutions of Cys-142, Cys-194, or both	1070:1115	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	1	2	theme	metabolic	168:176	arg1	function					178:185	metabolic function	168:185	metabolic function	168:185	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	7	3	theme	protein	979:985	arg1	folding					987:993	proper protein folding	972:993	proper protein folding	972:993	Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper protein folding; Ala substitution of either site inhibited protein secretion.
32602701	4	4	theme	glycosylation	569:581	arg1	sites					583:587	all four potential Asn glycosylation sites	546:587	all four potential Asn glycosylation sites	546:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	10	5	theme	C194A	1507:1511	arg1	mutant					1513:1518	the C194A mutant	1503:1518	the C194A mutant	1503:1518	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	1	6	dep	known	124:128	arg1	also					119:122	also	119:122	also	119:122	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	10	7	theme	higher-order	1353:1364	arg1	structures					1366:1375	higher-order structures	1353:1375	higher-order structures	1353:1375	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	4	8	theme	Asn	565:567	arg1	sites					583:587	all four potential Asn glycosylation sites	546:587	all four potential Asn glycosylation sites	546:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	1	9	with	hormone	155:161	arg1	role					193:196	a role	191:196	a role in stress erythropoiesis	191:221	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	1	9	with	hormone	155:161	arg1	function					178:185	metabolic function	168:185	metabolic function	168:185	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	1	10	from	function	178:185	arg1	erythropoiesis					208:221	stress erythropoiesis	201:221	stress erythropoiesis	201:221	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	11	11	theme	myonectin	1614:1622	arg1	myonectin					1614:1622	myonectin	1614:1622	myonectin	1614:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	11	11	theme	myonectin	1614:1622	arg1	domain					1604:1609	the short collagen domain	1585:1609	the short collagen domain of myonectin	1585:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	11	12	theme	triple	1692:1697	arg1	helix					1699:1703	the collagen triple helix	1679:1703	the collagen triple helix	1679:1703	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	5	13	theme	myonectin	741:749	arg1	secretion					751:759	myonectin secretion	741:759	myonectin secretion	741:759	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	4	14	theme	N-linked	448:455	arg1	glycosylation					457:469	Abolishing N-linked glycosylation	437:469	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites	437:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	2	15	theme	protein	309:315	arg1	characterization					285:300	biochemical characterization	273:300	biochemical characterization of the protein	273:315	Despite its importance in physiologic processes, biochemical characterization of the protein is lacking.
32602701	2	16	from	importance	236:245	arg1	processes					262:270	physiologic processes	250:270	physiologic processes	250:270	Despite its importance in physiologic processes, biochemical characterization of the protein is lacking.
32602701	10	17	theme	intermolecular	1381:1394	arg1	bonds					1406:1410	intermolecular disulfide bonds	1381:1410	intermolecular disulfide bonds	1381:1410	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	3	18	theme	protein	357:363	arg1	modifications					365:377	multiple protein modifications	348:377	multiple protein modifications	348:377	Here, we show that multiple protein modifications are critical for myonectin secretion and multimerization.
32602701	4	19	theme	glutamine	519:527	arg1	substitutions					529:541	glutamine substitutions	519:541	glutamine substitutions	519:541	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	8	20	theme	protein	1135:1141	arg1	secretion					1143:1151	protein secretion	1135:1151	protein secretion	1135:1151	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	4	21	theme	Abolishing	437:446	arg1	glycosylation					457:469	Abolishing N-linked glycosylation	437:469	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites	437:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	8	22	theme	both	1112:1115	arg1	substitutions					1074:1086	Ala substitutions	1070:1086	Ala substitutions of Cys-142, Cys-194, or both	1070:1115	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	6	23	theme	endoplasmic	878:888	arg1	reticulum					890:898	the endoplasmic reticulum	874:898	the endoplasmic reticulum	874:898	Although Asn-319 is not identified as glycosylated, Gln substitution caused protein misfolding and retention in the endoplasmic reticulum.
32602701	10	24	theme	disulfide	1396:1404	arg1	bonds					1406:1410	intermolecular disulfide bonds	1381:1410	intermolecular disulfide bonds	1381:1410	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	7	25	theme	protein	1038:1044	arg1	secretion					1046:1054	protein secretion	1038:1054	protein secretion	1038:1054	Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper protein folding; Ala substitution of either site inhibited protein secretion.
32602701	5	26	theme	Asn	712:714	arg1	sites					716:720	Asn sites	712:720	Asn sites	712:720	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	10	27	theme	HMW	1536:1538	arg1	formation					1549:1557	HMW oligomer formation	1536:1557	HMW oligomer formation	1536:1557	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	4	28	gly	glycosylation	569:581	arg2	sites					583:587	all four potential Asn glycosylation sites	546:587	all four potential Asn glycosylation sites	546:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	4	28	gly	glycosylation	569:581	arg2	four					550:553	four	550:553	four	550:553	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	5	29	dep	substituting	694:705	arg1	both					707:710	both	707:710	both	707:710	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	0	30	theme	Protein	0:6	arg1	Modifications					8:20	Protein Modifications	0:20	Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly	0:90	Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly.
32602701	8	31	theme	Cys-194	1100:1106	arg1	substitutions					1074:1086	Ala substitutions	1070:1086	Ala substitutions of Cys-142, Cys-194, or both	1070:1115	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	11	32	theme	collagen	1683:1690	arg1	helix					1699:1703	the collagen triple helix	1679:1703	the collagen triple helix	1679:1703	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	12	33	theme	collagen	1751:1758	arg1	domain					1760:1765	the collagen domain	1747:1765	the collagen domain	1747:1765	Inhibiting Pro hydroxylation or deleting the collagen domain markedly reduced the rate of protein secretion.
32602701	13	34	theme	myonectin	1884:1892	arg1	folding					1894:1900	myonectin folding	1884:1900	myonectin folding	1884:1900	Together, our results reveal key determinants that are important for myonectin folding, secretion, and multimeric assembly and provide a basis for future structure-function studies.
32602701	12	35	theme	Pro	1717:1719	arg1	hydroxylation					1721:1733	Pro hydroxylation	1717:1733	Pro hydroxylation	1717:1733	Inhibiting Pro hydroxylation or deleting the collagen domain markedly reduced the rate of protein secretion.
32602701	8	36	theme	endoplasmic	1165:1175	arg1	reticulum					1177:1185	endoplasmic reticulum	1165:1185	endoplasmic reticulum retention that facilitates myonectin oligomer assembly	1165:1240	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	8	37	theme	Ala	1070:1072	arg1	substitutions					1074:1086	Ala substitutions	1070:1086	Ala substitutions of Cys-142, Cys-194, or both	1070:1115	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	11	38	theme	collagen	1595:1602	arg1	myonectin					1614:1622	myonectin	1614:1622	myonectin	1614:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	11	38	theme	collagen	1595:1602	arg1	domain					1604:1609	the short collagen domain	1585:1609	the short collagen domain of myonectin	1585:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	1	39	theme	stress	201:206	arg1	erythropoiesis					208:221	stress erythropoiesis	201:221	stress erythropoiesis	201:221	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	3	40	theme	myonectin	396:404	arg1	secretion					406:414	myonectin secretion	396:414	myonectin secretion	396:414	Here, we show that multiple protein modifications are critical for myonectin secretion and multimerization.
32602701	9	41	theme	Secreted	1243:1250	arg1	myonectin					1252:1260	Secreted myonectin	1243:1260	Secreted myonectin	1243:1260	Secreted myonectin consists of trimers, hexamers, and high-molecular weight (HMW) oligomers.
32602701	11	42	theme	Pro	1565:1567	arg1	residues					1569:1576	Most Pro residues	1560:1576	Most Pro residues within the short collagen domain of myonectin	1560:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	11	43	theme	Most	1560:1563	arg1	residues					1569:1576	Most Pro residues	1560:1576	Most Pro residues within the short collagen domain of myonectin	1560:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	13	44	theme	key	1844:1846	arg1	determinants					1848:1859	key determinants	1844:1859	key determinants that are important for myonectin folding, secretion, and multimeric assembly and provide a basis for future structure-function studies	1844:1994	Together, our results reveal key determinants that are important for myonectin folding, secretion, and multimeric assembly and provide a basis for future structure-function studies.
32602701	4	45	theme	glucosamine	487:497	arg1	supplementation					499:513	glucosamine supplementation	487:513	glucosamine supplementation	487:513	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	2	46	theme	physiologic	250:260	arg1	processes					262:270	physiologic processes	250:270	physiologic processes	250:270	Despite its importance in physiologic processes, biochemical characterization of the protein is lacking.
32602701	7	47	theme	conserved	913:921	arg1	cysteines					923:931	the four conserved cysteines	904:931	the four conserved cysteines	904:931	Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper protein folding; Ala substitution of either site inhibited protein secretion.
32602701	0	48	theme	Myonectin/Erythroferrone	35:58	arg1	Secretion					60:68	Myonectin/Erythroferrone Secretion	35:68	Myonectin/Erythroferrone Secretion	35:68	Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly.
32602701	8	49	theme	reticulum	1177:1185	arg1	retention					1187:1195	endoplasmic reticulum retention	1165:1195	endoplasmic reticulum retention that facilitates myonectin oligomer assembly	1165:1240	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	10	50	theme	structures	1366:1375	arg1	formation					1340:1348	The formation	1336:1348	The formation of higher-order structures via intermolecular disulfide bonds	1336:1410	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	13	51	theme	structure-function	1969:1986	arg1	studies					1988:1994	future structure-function studies	1962:1994	future structure-function studies	1962:1994	Together, our results reveal key determinants that are important for myonectin folding, secretion, and multimeric assembly and provide a basis for future structure-function studies.
32602701	10	52	theme	C142A	1455:1459	arg1	mutant					1461:1466	the C142A mutant	1451:1466	the C142A mutant	1451:1466	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	0	53	theme	Oligomer	74:81	arg1	Assembly					83:90	Oligomer Assembly	74:90	Oligomer Assembly	74:90	Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly.
32602701	4	54	theme	sites	583:587	arg1	glycosylation					457:469	Abolishing N-linked glycosylation	437:469	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites	437:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	13	55	theme	future	1962:1967	arg1	studies					1988:1994	future structure-function studies	1962:1994	future structure-function studies	1962:1994	Together, our results reveal key determinants that are important for myonectin folding, secretion, and multimeric assembly and provide a basis for future structure-function studies.
32602701	5	56	theme	Mass	618:621	arg1	spectrometry					623:634	Mass spectrometry	618:634	Mass spectrometry	618:634	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	1	57	dep	Myonectin/erythroferrone	93:116	arg1	known					124:128	known	124:128	known as CTRP15	124:138	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	9	58	theme	weight	1312:1317	arg1	oligomers					1325:1333	high-molecular weight (HMW) oligomers	1297:1333	high-molecular weight (HMW) oligomers	1297:1333	Secreted myonectin consists of trimers, hexamers, and high-molecular weight (HMW) oligomers.
32602701	12	59	theme	protein	1796:1802	arg1	secretion					1804:1812	protein secretion	1796:1812	protein secretion	1796:1812	Inhibiting Pro hydroxylation or deleting the collagen domain markedly reduced the rate of protein secretion.
32602701	6	60	theme	protein	838:844	arg1	misfolding					846:855	protein misfolding	838:855	protein misfolding	838:855	Although Asn-319 is not identified as glycosylated, Gln substitution caused protein misfolding and retention in the endoplasmic reticulum.
32602701	10	61	theme	oligomer	1540:1547	arg1	formation					1549:1557	HMW oligomer formation	1536:1557	HMW oligomer formation	1536:1557	The formation of higher-order structures via intermolecular disulfide bonds depended on Cys-142 and Cys-194; while the C142A mutant formed almost exclusively trimers, the C194A mutant was impaired in HMW oligomer formation.
32602701	4	62	link	N-linked	448:455	arg1	glycosylation					457:469	Abolishing N-linked glycosylation	437:469	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites	437:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	4	63	theme	myonectin	597:605	arg1	secretion					607:615	myonectin secretion	597:615	myonectin secretion	597:615	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	8	64	theme	oligomer	1224:1231	arg1	assembly					1233:1240	myonectin oligomer assembly	1214:1240	myonectin oligomer assembly	1214:1240	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	7	65	theme	site	1023:1026	arg1	substitution					1000:1011	Ala substitution	996:1011	Ala substitution of either site	996:1026	Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper protein folding; Ala substitution of either site inhibited protein secretion.
32602701	5	66	with	substituting	694:705	arg1	Gln					727:729	Gln	727:729	Gln	727:729	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	7	67	theme	proper	972:977	arg1	folding					987:993	proper protein folding	972:993	proper protein folding	972:993	Of the four conserved cysteines, Cys-273 and Cys-278 were required for proper protein folding; Ala substitution of either site inhibited protein secretion.
32602701	5	68	gly	glycosylated	676:687	arg1	Asn-281					663:669	Asn-281	663:669	Asn-281	663:669	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	5	68	gly	glycosylated	676:687	arg1	Asn-229					651:657	Asn-229	651:657	Asn-229	651:657	Mass spectrometry confirmed that Asn-229 and Asn-281 were glycosylated, and substituting both Asn sites with Gln prevented myonectin secretion.
32602701	8	69	theme	myonectin	1214:1222	arg1	assembly					1233:1240	myonectin oligomer assembly	1214:1240	myonectin oligomer assembly	1214:1240	In contrast, Ala substitutions of Cys-142, Cys-194, or both markedly enhanced protein secretion, suggesting endoplasmic reticulum retention that facilitates myonectin oligomer assembly.
32602701	12	70	theme	secretion	1804:1812	arg1	rate					1788:1791	the rate	1784:1791	the rate of protein secretion	1784:1812	Inhibiting Pro hydroxylation or deleting the collagen domain markedly reduced the rate of protein secretion.
32602701	2	71	theme	biochemical	273:283	arg1	characterization					285:300	biochemical characterization	273:300	biochemical characterization of the protein	273:315	Despite its importance in physiologic processes, biochemical characterization of the protein is lacking.
32602701	1	72	from	role	193:196	arg1	erythropoiesis					208:221	stress erythropoiesis	201:221	stress erythropoiesis	201:221	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	1	73	theme	secreted	146:153	arg1	Myonectin/erythroferrone					93:116	Myonectin/erythroferrone	93:116	Myonectin/erythroferrone (also known as CTRP15)	93:139	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	1	73	theme	secreted	146:153	arg1	hormone					155:161	a secreted hormone	144:161	a secreted hormone with metabolic function and a role in stress erythropoiesis	144:221	Myonectin/erythroferrone (also known as CTRP15) is a secreted hormone with metabolic function and a role in stress erythropoiesis.
32602701	9	74	theme	high-molecular	1297:1310	arg1	HMW					1320:1322	HMW	1320:1322	HMW	1320:1322	Secreted myonectin consists of trimers, hexamers, and high-molecular weight (HMW) oligomers.
32602701	9	74	theme	high-molecular	1297:1310	arg1	weight					1312:1317	high-molecular weight	1297:1317	high-molecular weight (HMW) oligomers	1297:1333	Secreted myonectin consists of trimers, hexamers, and high-molecular weight (HMW) oligomers.
32602701	13	75	theme	multimeric	1918:1927	arg1	assembly					1929:1936	multimeric assembly	1918:1936	multimeric assembly	1918:1936	Together, our results reveal key determinants that are important for myonectin folding, secretion, and multimeric assembly and provide a basis for future structure-function studies.
32602701	6	76	theme	Gln	814:816	arg1	substitution					818:829	Gln substitution	814:829	Gln substitution	814:829	Although Asn-319 is not identified as glycosylated, Gln substitution caused protein misfolding and retention in the endoplasmic reticulum.
32602701	11	77	theme	short	1589:1593	arg1	myonectin					1614:1622	myonectin	1614:1622	myonectin	1614:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	11	77	theme	short	1589:1593	arg1	domain					1604:1609	the short collagen domain	1585:1609	the short collagen domain of myonectin	1585:1622	Most Pro residues within the short collagen domain of myonectin were also hydroxylated, a modification that stabilized the collagen triple helix.
32602701	3	78	theme	multiple	348:355	arg1	modifications					365:377	multiple protein modifications	348:377	multiple protein modifications	348:377	Here, we show that multiple protein modifications are critical for myonectin secretion and multimerization.
32602701	4	79	theme	potential	555:563	arg1	sites					583:587	all four potential Asn glycosylation sites	546:587	all four potential Asn glycosylation sites	546:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
32602701	0	80	theme	Critical	22:29	arg1	Modifications					8:20	Protein Modifications	0:20	Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly	0:90	Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly.
32602701	4	81	gly	glycosylation	457:469	arg1	sites					583:587	all four potential Asn glycosylation sites	546:587	all four potential Asn glycosylation sites	546:587	Abolishing N-linked glycosylation by tunicamycin, glucosamine supplementation, or glutamine substitutions of all four potential Asn glycosylation sites blocked myonectin secretion.
34689907	8	0	theme	glycosylation	1722:1734	arg1	disorders					1709:1717	congenital disorders	1698:1717	congenital disorders of glycosylation (CDG) diagnosis	1698:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	5	1	theme	signal	1186:1191	arg1	enhancement					1193:1203	a 200-fold signal enhancement	1175:1203	a 200-fold signal enhancement	1175:1203	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	4	2	theme	higher	870:875	arg1	degree					877:882	higher degree	870:882	higher degree of polymerization (DP) of glucose oligomers (18 vs 15)	870:937	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	8	3	theme	Human	1624:1628	arg1	G					1645:1645	Human Immunoglobulin G	1624:1645	Human Immunoglobulin G	1624:1645	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	3	theme	Human	1624:1628	arg1	glycoprotein					1610:1621	a model glycoprotein	1602:1621	a model glycoprotein (Human Immunoglobulin G)	1602:1646	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	5	4	theme	coated	1134:1139	arg1	capillaries					1141:1151	neutrally coated capillaries	1124:1151	neutrally coated capillaries	1124:1151	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	8	5	theme	N-linked	1562:1569	arg1	oligosaccharides					1571:1586	N-linked oligosaccharides	1562:1586	N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis	1562:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	1	6	theme	detection	159:167	arg1	sensitivity					169:179	detection sensitivity	159:179	detection sensitivity	159:179	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	6	7	theme	pH	1274:1275	arg1	adjustment					1277:1286	pH adjustment	1274:1286	pH adjustment as in conventional methods	1274:1313	This approach is based on variation of the buffer's IS, rather than pH adjustment as in conventional methods, for EOF modulation or quasi-total reduction.
34689907	4	8	theme	polymer-free	769:780	arg1	strategy					782:789	our polymer-free strategy	765:789	our polymer-free strategy	765:789	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	3	9	theme	flow	515:518	arg1	suppression					485:495	suppression	485:495	suppression of electroosmotic flow (EOF)	485:524	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	3	9	theme	flow	515:518	arg1	stacking					472:479	sample stacking	465:479	sample stacking	465:479	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	4	10	theme	glycans	756:762	arg1	CE-LIF					708:713	CE-LIF	708:713	CE-LIF of glucose-oligosaccharides and released glycans	708:762	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	11	theme	glucose-oligosaccharides	718:741	arg1	CE-LIF					708:713	CE-LIF	708:713	CE-LIF of glucose-oligosaccharides and released glycans	708:762	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	3	12	dep	200	656:658	arg1	to					653:654	to	653:654	to	653:654	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	3	13	from	strengths	636:644	arg1	acid					581:584	triethanolamine/citric acid	558:584	triethanolamine/citric acid	558:584	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	3	13	from	strengths	636:644	arg1	acid					613:616	triethanolamine/acetic acid	590:616	triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM)	590:662	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	7	14	theme	efficient	1448:1456	arg1	preconcentration					1458:1473	efficient preconcentration	1448:1473	efficient preconcentration	1448:1473	This strategy allows selecting with high flexibility the best pH conditions to perform efficient preconcentration and separation.
34689907	4	15	theme	degree	877:882	arg1	visualization					853:865	visualization	853:865	visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15)	853:937	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	15	theme	degree	877:882	arg1	improvement					812:822	5-fold improvement	805:822	5-fold improvement of detection sensitivity	805:847	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	16	theme	released	747:754	arg1	glycans					756:762	released glycans	747:762	released glycans	747:762	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	3	17	dep	mM	660:661	arg1	200					656:658	200	656:658	200	656:658	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	4	18	theme	conventional	681:692	arg1	protocols					694:702	the conventional protocols	677:702	the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans	677:762	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	19	theme	sensitivity	837:847	arg1	visualization					853:865	visualization	853:865	visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15)	853:937	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	19	theme	sensitivity	837:847	arg1	improvement					812:822	5-fold improvement	805:822	5-fold improvement of detection sensitivity	805:847	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	8	20	link	N-linked	1562:1569	arg1	oligosaccharides					1571:1586	N-linked oligosaccharides	1562:1586	N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis	1562:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	21	theme	congenital	1698:1707	arg1	disorders					1709:1717	congenital disorders	1698:1717	congenital disorders of glycosylation (CDG) diagnosis	1698:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	5	22	theme	electroosmotic	1071:1084	arg1	modulation					1086:1095	electroosmotic modulation	1071:1095	electroosmotic modulation	1071:1095	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	4	23	theme	detection	827:835	arg1	sensitivity					837:847	detection sensitivity	827:847	detection sensitivity	827:847	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	8	24	theme	model	1604:1608	arg1	G					1645:1645	Human Immunoglobulin G	1624:1645	Human Immunoglobulin G	1624:1645	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	24	theme	model	1604:1608	arg1	glycoprotein					1610:1621	a model glycoprotein	1602:1621	a model glycoprotein (Human Immunoglobulin G)	1602:1646	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	3	25	dep	strengths	636:644	arg1	IS					647:648	IS	647:648	IS	647:648	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	6	26	theme	EOF	1320:1322	arg1	modulation					1324:1333	EOF modulation	1320:1333	EOF modulation	1320:1333	This approach is based on variation of the buffer's IS, rather than pH adjustment as in conventional methods, for EOF modulation or quasi-total reduction.
34689907	3	27	theme	best	436:439	arg1	performance					441:451	The best performance	432:451	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF)	432:524	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	0	28	theme	sensitivity	5:15	arg1	electrophoresis					27:41	High sensitivity capillary electrophoresis	0:41	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping	0:87	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping.
34689907	7	29	theme	high	1397:1400	arg1	flexibility					1402:1412	high flexibility	1397:1412	high flexibility	1397:1412	This strategy allows selecting with high flexibility the best pH conditions to perform efficient preconcentration and separation.
34689907	1	30	theme	peak	185:188	arg1	capacity					190:197	peak capacity	185:197	peak capacity	185:197	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	0	31	theme	High	0:3	arg1	electrophoresis					27:41	High sensitivity capillary electrophoresis	0:41	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping	0:87	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping.
34689907	1	32	theme	glucose	282:288	arg1	oligomers					290:298	glucose oligomers	282:298	glucose oligomers	282:298	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	8	33	theme	oligosaccharides	1571:1586	arg1	analysis					1550:1557	the analysis	1546:1557	the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis	1546:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	5	34	theme	detection	963:971	arg1	sensitivity					973:983	the detection sensitivity	959:983	the detection sensitivity	959:983	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	2	35	theme	background	380:389	arg1	BGE					404:406	BGE	404:406	BGE	404:406	This is based on a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans.
34689907	2	35	theme	background	380:389	arg1	electrolyte					391:401	a polymer-free background electrolyte	365:401	a polymer-free background electrolyte (BGE)	365:407	This is based on a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans.
34689907	1	36	theme	oligomers	290:298	arg1	CE-LIF					271:276	CE-LIF	271:276	CE-LIF	271:276	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	1	36	theme	oligomers	290:298	arg1	detection					260:268	laser induced fluorescent detection	234:268	laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans	234:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	4	37	theme	glucose	910:916	arg1	15					935:936	15	935:936	15	935:936	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	37	theme	glucose	910:916	arg1	18					929:930	18	929:930	18	929:930	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	37	theme	glucose	910:916	arg1	oligomers					918:926	glucose oligomers	910:926	glucose oligomers (18 vs 15)	910:937	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	5	38	theme	preconcentration	1007:1022	arg1	strategy					1024:1031	a new electrokinetic preconcentration strategy	986:1031	a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries	986:1151	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	2	39	theme	glycans	423:429	arg1	CE-LIF					413:418	CE-LIF	413:418	CE-LIF of glycans	413:429	This is based on a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans.
34689907	3	40	from	performance	441:451	arg1	terms					456:460	terms	456:460	terms of sample stacking and suppression of electroosmotic flow (EOF)	456:524	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	3	41	theme	suppression	485:495	arg1	terms					456:460	terms	456:460	terms of sample stacking and suppression of electroosmotic flow (EOF)	456:524	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	5	42	theme	electrokinetic	992:1005	arg1	strategy					1024:1031	a new electrokinetic preconcentration strategy	986:1031	a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries	986:1151	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	1	43	theme	capillary	203:211	arg1	electrophoresis					213:227	capillary electrophoresis	203:227	capillary electrophoresis	203:227	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	0	44	theme	fluorescent	48:58	arg1	detection					60:68	fluorescent detection	48:68	fluorescent detection	48:68	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping.
34689907	1	45	theme	released	304:311	arg1	glycans					313:319	released glycans	304:319	released glycans	304:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	8	46	from	serum	1688:1692	arg1	N-glycans					1667:1675	N-glycans	1667:1675	N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis	1667:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	4	47	theme	5-fold	805:810	arg1	improvement					812:822	5-fold improvement	805:822	5-fold improvement of detection sensitivity	805:847	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	8	48	dep	oligosaccharides	1571:1586	arg1	released					1588:1595	released	1588:1595	released from a model glycoprotein (Human Immunoglobulin G)	1588:1646	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	48	dep	oligosaccharides	1571:1586	arg1	applied					1652:1658	applied	1652:1658	applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis	1652:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	1	49	theme	glycans	313:319	arg1	CE-LIF					271:276	CE-LIF	271:276	CE-LIF	271:276	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	1	49	theme	glycans	313:319	arg1	detection					260:268	laser induced fluorescent detection	234:268	laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans	234:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	4	50	theme	oligomers	918:926	arg1	DP					903:904	DP	903:904	DP	903:904	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	4	50	theme	oligomers	918:926	arg1	polymerization					887:900	polymerization	887:900	polymerization (DP) of glucose oligomers (18 vs 15)	887:937	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	3	51	theme	ionic	630:634	arg1	strengths					636:644	elevated ionic strengths	621:644	elevated ionic strengths (IS up to 200 mM)	621:662	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	5	52	theme	new	988:990	arg1	strategy					1024:1031	a new electrokinetic preconcentration strategy	986:1031	a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries	986:1151	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	0	53	with	electrophoresis	27:41	arg1	detection					60:68	fluorescent detection	48:68	fluorescent detection	48:68	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping.
34689907	1	54	attach	present	93:99	arg2	We					90:91	We	90:91	We	90:91	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	1	54	attach	present	93:99	arg1	study					109:113	this study	104:113	this study	104:113	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	6	55	theme	conventional	1294:1305	arg1	methods					1307:1313	conventional methods	1294:1313	conventional methods	1294:1313	This approach is based on variation of the buffer's IS, rather than pH adjustment as in conventional methods, for EOF modulation or quasi-total reduction.
34689907	5	56	theme	200-fold	1177:1184	arg1	enhancement					1193:1203	a 200-fold signal enhancement	1175:1203	a 200-fold signal enhancement	1175:1203	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	1	57	dep	sensitivity	169:179	arg1	the					155:157	the	155:157	the	155:157	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	2	58	theme	new	341:343	arg1	approach					345:352	a new approach	339:352	a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans	339:429	This is based on a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans.
34689907	4	59	theme	polymerization	887:900	arg1	degree					877:882	higher degree	870:882	higher degree of polymerization (DP) of glucose oligomers (18 vs 15)	870:937	Compared to the conventional protocols for CE-LIF of glucose-oligosaccharides and released glycans, our polymer-free strategy offered up to 5-fold improvement of detection sensitivity and visualization of higher degree of polymerization (DP) of glucose oligomers (18 vs 15).
34689907	3	60	theme	triethanolamine/citric	558:579	arg1	acid					581:584	triethanolamine/citric acid	558:584	triethanolamine/citric acid	558:584	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	3	61	theme	electroosmotic	500:513	arg1	EOF					521:523	EOF	521:523	EOF	521:523	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	3	61	theme	electroosmotic	500:513	arg1	flow					515:518	electroosmotic flow	500:518	electroosmotic flow (EOF)	500:524	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	1	62	theme	novel	117:121	arg1	strategy					123:130	a novel strategy	115:130	a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans	115:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	6	63	from	adjustment	1277:1286	arg1	methods					1307:1313	conventional methods	1294:1313	conventional methods	1294:1313	This approach is based on variation of the buffer's IS, rather than pH adjustment as in conventional methods, for EOF modulation or quasi-total reduction.
34689907	7	64	theme	pH	1423:1424	arg1	conditions					1426:1435	the best pH conditions	1414:1435	the best pH conditions	1414:1435	This strategy allows selecting with high flexibility the best pH conditions to perform efficient preconcentration and separation.
34689907	8	65	theme	Immunoglobulin	1630:1643	arg1	G					1645:1645	Human Immunoglobulin G	1624:1645	Human Immunoglobulin G	1624:1645	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	65	theme	Immunoglobulin	1630:1643	arg1	glycoprotein					1610:1621	a model glycoprotein	1602:1621	a model glycoprotein (Human Immunoglobulin G)	1602:1646	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	66	dep	glycosylation	1722:1734	arg1	diagnosis					1742:1750	diagnosis	1742:1750	glycosylation (CDG) diagnosis	1722:1750	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	67	gly	glycoprotein	1610:1621	arg1	G					1645:1645	Human Immunoglobulin G	1624:1645	Human Immunoglobulin G	1624:1645	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	67	gly	glycoprotein	1610:1621	arg1	glycoprotein					1610:1621	a model glycoprotein	1602:1621	a model glycoprotein (Human Immunoglobulin G)	1602:1646	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	3	68	theme	sample	465:470	arg1	stacking					472:479	sample stacking	465:479	sample stacking	465:479	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	1	69	theme	laser	234:238	arg1	CE-LIF					271:276	CE-LIF	271:276	CE-LIF	271:276	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	1	69	theme	laser	234:238	arg1	detection					260:268	laser induced fluorescent detection	234:268	laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans	234:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	7	70	theme	best	1418:1421	arg1	conditions					1426:1435	the best pH conditions	1414:1435	the best pH conditions	1414:1435	This strategy allows selecting with high flexibility the best pH conditions to perform efficient preconcentration and separation.
34689907	5	71	theme	large	1037:1041	arg1	sample					1050:1055	large volume sample	1037:1055	large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries	1037:1151	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	3	72	theme	elevated	621:628	arg1	strengths					636:644	elevated ionic strengths	621:644	elevated ionic strengths (IS up to 200 mM)	621:662	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	8	73	theme	new	1495:1497	arg1	applicable					1531:1540	applicable	1531:1540	applicable	1531:1540	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	8	73	theme	new	1495:1497	arg1	approach					1499:1506	The new approach	1491:1506	The new approach	1491:1506	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	3	74	theme	stacking	472:479	arg1	terms					456:460	terms	456:460	terms of sample stacking and suppression of electroosmotic flow (EOF)	456:524	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	6	75	theme	quasi-total	1338:1348	arg1	reduction					1350:1358	quasi-total reduction	1338:1358	quasi-total reduction	1338:1358	This approach is based on variation of the buffer's IS, rather than pH adjustment as in conventional methods, for EOF modulation or quasi-total reduction.
34689907	1	76	theme	induced	240:246	arg1	CE-LIF					271:276	CE-LIF	271:276	CE-LIF	271:276	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	1	76	theme	induced	240:246	arg1	detection					260:268	laser induced fluorescent detection	234:268	laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans	234:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	5	77	theme	volume	1043:1048	arg1	sample					1050:1055	large volume sample	1037:1055	large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries	1037:1151	To further improve the detection sensitivity, a new electrokinetic preconcentration strategy via large volume sample stacking with electroosmotic modulation without having recourse to neutrally coated capillaries is proposed, offering a 200-fold signal enhancement.
34689907	3	78	theme	triethanolamine/acetic	590:611	arg1	acid					613:616	triethanolamine/acetic acid	590:616	triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM)	590:662	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
34689907	2	79	theme	polymer-free	367:378	arg1	BGE					404:406	BGE	404:406	BGE	404:406	This is based on a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans.
34689907	2	79	theme	polymer-free	367:378	arg1	electrolyte					391:401	a polymer-free background electrolyte	365:401	a polymer-free background electrolyte (BGE)	365:407	This is based on a new approach exploiting a polymer-free background electrolyte (BGE) for CE-LIF of glycans.
34689907	1	80	theme	fluorescent	248:258	arg1	CE-LIF					271:276	CE-LIF	271:276	CE-LIF	271:276	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	1	80	theme	fluorescent	248:258	arg1	detection					260:268	laser induced fluorescent detection	234:268	laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans	234:319	We present in this study a novel strategy to drastically improve the detection sensitivity and peak capacity for capillary electrophoresis with laser induced fluorescent detection (CE-LIF) of glucose oligomers and released glycans.
34689907	0	81	theme	glycan	74:79	arg1	mapping					81:87	glycan mapping	74:87	glycan mapping	74:87	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping.
34689907	0	82	theme	capillary	17:25	arg1	electrophoresis					27:41	High sensitivity capillary electrophoresis	0:41	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping	0:87	High sensitivity capillary electrophoresis with fluorescent detection for glycan mapping.
34689907	8	83	theme	human	1682:1686	arg1	serum					1688:1692	human serum	1682:1692	human serum	1682:1692	The new approach was demonstrated to be applicable for the analysis of N-linked oligosaccharides released from a model glycoprotein (Human Immunoglobulin G) and applied to map N-glycans from human serum for congenital disorders of glycosylation (CDG) diagnosis.
34689907	3	84	dep	IS	647:648	arg1	mM					660:661	mM	660:661	mM	660:661	The best performance in terms of sample stacking and suppression of electroosmotic flow (EOF) was found for a BGE composed of triethanolamine/citric acid and triethanolamine/acetic acid at elevated ionic strengths (IS up to 200 mM).
32790871	0	0	theme	inhibitory	87:96	arg1	activity					98:105	Plasmodium falciparum inhibitory activity	65:105	Plasmodium falciparum inhibitory activity	65:105	A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
32790871	1	1	theme	research	148:155	arg1	efforts					157:163	research efforts	148:163	research efforts	148:163	Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01.
32790871	0	2	theme	falciparum	76:85	arg1	activity					98:105	Plasmodium falciparum inhibitory activity	65:105	Plasmodium falciparum inhibitory activity	65:105	A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
32790871	2	3	theme	Plasmodium	330:339	arg1	falciparum					341:350	Plasmodium falciparum	330:350	Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	330:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	2	3	theme	Plasmodium	330:339	arg1	Pf					353:354	Pf	353:354	Pf	353:354	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	7	4	theme	vaccines	1155:1162	arg1	generation					1131:1140	the next generation	1122:1140	the next generation of CSP-based vaccines	1122:1162	Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
32790871	5	5	from	epitope	760:766	arg1	N-CSP					771:775	N-CSP	771:775	N-CSP	771:775	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	3	6	theme	N-terminal	508:517	arg1	PfCSP					529:533	PfCSP	529:533	PfCSP (N-CSP)	529:541	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	3	6	theme	N-terminal	508:517	arg1	domain					519:524	the N-terminal domain	504:524	the N-terminal domain of PfCSP (N-CSP)	504:541	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	3	7	theme	PfCSP	529:533	arg1	PfCSP					529:533	PfCSP	529:533	PfCSP (N-CSP)	529:541	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	3	7	theme	PfCSP	529:533	arg1	domain					519:524	the N-terminal domain	504:524	the N-terminal domain of PfCSP (N-CSP)	504:541	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	6	8	theme	Pf	974:975	arg1	sporozoites					977:987	live Pf sporozoites	969:987	live Pf sporozoites	969:987	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	5	9	theme	1.85-Å	705:710	arg1	resolution					712:721	1.85-Å resolution	705:721	1.85-Å resolution	705:721	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	7	10	theme	N-CSP	1103:1107	arg1	epitope					1109:1115	the 5D5 N-CSP epitope	1095:1115	the 5D5 N-CSP epitope	1095:1115	Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
32790871	2	11	theme	falciparum	341:350	arg1	protein					374:380	Plasmodium falciparum (Pf) circumsporozoite protein	330:380	Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	330:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	2	11	theme	falciparum	341:350	arg1	PfCSP					383:387	PfCSP	383:387	PfCSP	383:387	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	6	12	theme	live	969:972	arg1	sporozoites					977:987	live Pf sporozoites	969:987	live Pf sporozoites	969:987	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	4	13	theme	antibody	666:673	arg1	recognition					597:607	molecular recognition	587:607	molecular recognition	587:607	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32790871	4	13	theme	antibody	666:673	arg1	efficacy					624:631	functional efficacy	613:631	functional efficacy	613:631	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32790871	3	14	theme	repeat	440:445	arg1	region					447:452	the repeat region	436:452	the repeat region	436:452	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	7	15	theme	5D5	1099:1101	arg1	epitope					1109:1115	the 5D5 N-CSP epitope	1095:1115	the 5D5 N-CSP epitope	1095:1115	Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
32790871	5	16	theme	antibody	881:888	arg1	glycan					899:904	an antibody N-linked glycan	878:904	an antibody N-linked glycan	878:904	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	5	17	theme	α-helical	750:758	arg1	epitope					760:766	an α-helical epitope	747:766	an α-helical epitope in N-CSP	747:775	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	6	18	theme	sporozoite	1001:1010	arg1	inhibition					1012:1021	sporozoite inhibition	1001:1021	sporozoite inhibition	1001:1021	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	3	19	theme	well-studied	410:421	arg1	responses					423:431	the well-studied responses	406:431	the well-studied responses to the repeat region and the C-terminus	406:471	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	0	20	theme	high-affinity	2:14	arg1	antibody					16:23	A high-affinity antibody	0:23	A high-affinity antibody against the CSP N-terminal domain	0:57	A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
32790871	6	21	theme	low	950:952	arg1	binding					958:964	low 5D5 binding	950:964	low 5D5 binding to live Pf sporozoites	950:987	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	7	22	theme	next	1126:1129	arg1	generation					1131:1140	the next generation	1122:1140	the next generation of CSP-based vaccines	1122:1162	Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
32790871	2	23	theme	circumsporozoite	357:372	arg1	protein					374:380	Plasmodium falciparum (Pf) circumsporozoite protein	330:380	Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	330:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	2	23	theme	circumsporozoite	357:372	arg1	PfCSP					383:387	PfCSP	383:387	PfCSP	383:387	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	5	24	theme	high	782:785	arg1	affinity					787:794	high affinity	782:794	high affinity	782:794	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	5	25	theme	unusual	855:861	arg1	utilization					863:873	the unusual utilization	851:873	the unusual utilization of an antibody N-linked glycan	851:904	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	4	26	theme	molecular	587:595	arg1	recognition					597:607	molecular recognition	587:607	molecular recognition	587:607	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32790871	5	27	theme	glycan	899:904	arg1	utilization					863:873	the unusual utilization	851:873	the unusual utilization of an antibody N-linked glycan	851:904	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	5	27	theme	glycan	899:904	arg1	shape					814:818	extensive shape and charge complementarity	804:845	shape	814:818	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	5	27	theme	glycan	899:904	arg1	complementarity					831:845	extensive shape and charge complementarity	804:845	complementarity	831:845	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	6	28	theme	5D5	954:956	arg1	binding					958:964	low 5D5 binding	950:964	low 5D5 binding to live Pf sporozoites	950:987	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	5	29	from	resolution	712:721	arg1	structure					692:700	The crystal structure	680:700	The crystal structure at 1.85-Å resolution	680:721	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	2	30	theme	comprehensive	259:271	arg1	understanding					273:285	a comprehensive understanding	257:285	a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	257:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	1	31	theme	superior	190:197	arg1	vaccine					199:205	a superior vaccine	188:205	a superior vaccine to RTS,S/AS01	188:219	Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01.
32790871	0	32	theme	CSP	37:39	arg1	domain					52:57	the CSP N-terminal domain	33:57	the CSP N-terminal domain	33:57	A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
32790871	2	33	theme	response	313:320	arg1	understanding					273:285	a comprehensive understanding	257:285	a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	257:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	5	34	theme	crystal	684:690	arg1	structure					692:700	The crystal structure	680:700	The crystal structure at 1.85-Å resolution	680:721	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	4	35	theme	monoclonal	655:664	arg1	antibody					666:673	the N-CSP-specific monoclonal antibody 5D5	636:677	the N-CSP-specific monoclonal antibody 5D5	636:677	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32790871	7	36	theme	epitope	1109:1115	arg1	inclusion					1082:1090	the inclusion	1078:1090	the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines	1078:1162	Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
32790871	4	37	dep	recognition	597:607	arg1	the					583:585	the	583:585	the	583:585	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32790871	5	38	theme	charge	824:829	arg1	complementarity					831:845	extensive shape and charge complementarity	804:845	complementarity	831:845	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	5	39	theme	N-linked	890:897	arg1	glycan					899:904	an antibody N-linked glycan	878:904	an antibody N-linked glycan	878:904	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	0	40	theme	N-terminal	41:50	arg1	domain					52:57	the CSP N-terminal domain	33:57	the CSP N-terminal domain	33:57	A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
32790871	6	41	theme	functional	921:930	arg1	studies					932:938	functional studies	921:938	functional studies	921:938	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	7	42	theme	CSP-based	1145:1153	arg1	vaccines					1155:1162	CSP-based vaccines	1145:1162	CSP-based vaccines	1145:1162	Overall, our data do not support the inclusion of the 5D5 N-CSP epitope into the next generation of CSP-based vaccines.
32790871	1	43	theme	global	121:126	arg1	concern					135:141	a global health concern	119:141	a global health concern	119:141	Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01.
32790871	1	43	theme	global	121:126	arg1	Malaria					108:114	Malaria	108:114	Malaria	108:114	Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01.
32790871	5	44	link	N-linked	890:897	arg1	glycan					899:904	an antibody N-linked glycan	878:904	an antibody N-linked glycan	878:904	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	3	45	dep	responses	423:431	arg1	contrast					394:401	contrast	394:401	contrast	394:401	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	1	46	theme	health	128:133	arg1	concern					135:141	a global health concern	119:141	a global health concern	119:141	Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01.
32790871	1	46	theme	health	128:133	arg1	Malaria					108:114	Malaria	108:114	Malaria	108:114	Malaria is a global health concern, and research efforts are ongoing to develop a superior vaccine to RTS,S/AS01.
32790871	6	47	theme	inhibition	1012:1021	arg1	binding					958:964	low 5D5 binding	950:964	low 5D5 binding to live Pf sporozoites	950:987	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	6	47	theme	inhibition	1012:1021	arg1	lack					993:996	lack	993:996	lack of sporozoite inhibition	993:1021	Nevertheless, functional studies indicated low 5D5 binding to live Pf sporozoites and lack of sporozoite inhibition in vitro and in vivo.
32790871	2	48	theme	immunogen	231:239	arg1	design					241:246	guide immunogen design	225:246	guide immunogen design	225:246	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	2	49	theme	protective	294:303	arg1	response					313:320	the protective humoral response	290:320	the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	290:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	2	50	theme	humoral	305:311	arg1	response					313:320	the protective humoral response	290:320	the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP)	290:388	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	0	51	theme	Plasmodium	65:74	arg1	falciparum					76:85	Plasmodium falciparum	65:85	Plasmodium falciparum inhibitory activity	65:105	A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity.
32790871	2	52	theme	guide	225:229	arg1	design					241:246	guide immunogen design	225:246	guide immunogen design	225:246	To guide immunogen design, we seek a comprehensive understanding of the protective humoral response against Plasmodium falciparum (Pf) circumsporozoite protein (PfCSP).
32790871	5	53	theme	extensive	804:812	arg1	shape					814:818	extensive shape and charge complementarity	804:845	shape	814:818	The crystal structure at 1.85-Å resolution revealed that 5D5 binds an α-helical epitope in N-CSP with high affinity through extensive shape and charge complementarity and the unusual utilization of an antibody N-linked glycan.
32790871	3	54	theme	antibody	478:485	arg1	response					487:494	the antibody response	474:494	the antibody response against the N-terminal domain of PfCSP (N-CSP)	474:541	In contrast to the well-studied responses to the repeat region and the C-terminus, the antibody response against the N-terminal domain of PfCSP (N-CSP) remains obscure.
32790871	4	55	theme	functional	613:622	arg1	efficacy					624:631	functional efficacy	613:631	functional efficacy	613:631	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32790871	4	56	theme	N-CSP-specific	640:653	arg1	antibody					666:673	the N-CSP-specific monoclonal antibody 5D5	636:677	the N-CSP-specific monoclonal antibody 5D5	636:677	Here, we characterized the molecular recognition and functional efficacy of the N-CSP-specific monoclonal antibody 5D5.
32130226	4	0	from	processing	807:816	arg1	ER					825:826	the ER	821:826	the ER	821:826	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	1	1	theme	substrates	376:385	arg1	activity					342:349	activity	342:349	activity	342:349	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	1	theme	substrates	376:385	arg1	localization					356:367	localization	356:367	localization	356:367	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	1	theme	substrates	376:385	arg1	stability					331:339	stability	331:339	stability	331:339	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	2	theme	endoplasmic	287:297	arg1	reticulum					299:307	the endoplasmic reticulum	283:307	the endoplasmic reticulum (ER)	283:312	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	2	theme	endoplasmic	287:297	arg1	ER					310:311	ER	310:311	ER	310:311	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	0	3	theme	ER	88:89	arg1	proteostasis					91:102	ER proteostasis	88:102	ER proteostasis	88:102	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	3	4	theme	immune-regulatory	698:714	arg1	kinase					730:735	immune-regulatory PMK-1/p38 MAP kinase	698:735	immune-regulatory PMK-1/p38 MAP kinase	698:735	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	1	5	theme	OST	201:203	arg1	complex					214:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	2	6	theme	many	397:400	arg1	proteins					416:423	many OST substrate proteins	397:423	many OST substrate proteins	397:423	Although many OST substrate proteins have been identified, the physiological role of the OST complex remains incompletely understood.
32130226	0	7	theme	p38-dependent	115:127	arg1	protection					129:138	p38-dependent protection	115:138	p38-dependent protection against pathogenic bacteria	115:166	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	0	8	from	Inhibition	0:9	arg1	elegans					63:69	Caenorhabditis elegans	48:69	Caenorhabditis elegans	48:69	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	4	9	theme	complex	782:788	arg1	inhibition					760:769	genetic inhibition	752:769	genetic inhibition of the OST complex	752:788	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	5	10	theme	critical	969:976	arg1	protein					960:966	an OST-dependent glycosylated protein	930:966	an OST-dependent glycosylated protein	930:966	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	5	10	theme	critical	969:976	arg1	VIT-6					921:925	vitellogenin VIT-6	908:925	vitellogenin VIT-6	908:925	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	5	11	gly	glycosylated	947:958	arg1	protein					960:966	an OST-dependent glycosylated protein	930:966	an OST-dependent glycosylated protein	930:966	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	5	11	gly	glycosylated	947:958	arg1	VIT-6					921:925	vitellogenin VIT-6	908:925	vitellogenin VIT-6	908:925	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	0	12	from	elegans	63:69	arg1	Inhibition					0:9	Inhibition	0:9	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis	0:102	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	1	13	link	N-linked	235:242	arg1	glycosylation					244:256	the N-linked glycosylation	231:256	the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates	231:385	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	7	14	theme	pathogenic	1263:1272	arg1	bacteria					1274:1281	pathogenic bacteria	1263:1281	pathogenic bacteria	1263:1281	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	4	15	theme	OST	778:780	arg1	complex					782:788	the OST complex	774:788	the OST complex	774:788	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	5	16	theme	OST-dependent	933:945	arg1	protein					960:966	an OST-dependent glycosylated protein	930:966	an OST-dependent glycosylated protein	930:966	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	5	16	theme	OST-dependent	933:945	arg1	VIT-6					921:925	vitellogenin VIT-6	908:925	vitellogenin VIT-6	908:925	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	4	17	theme	ER	856:857	arg1	UPRER					886:890	UPRER	886:890	UPRER	886:890	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	4	17	theme	ER	856:857	arg1	response					876:883	ER unfolded protein response	856:883	ER unfolded protein response (UPRER)	856:891	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	4	18	theme	protein	799:805	arg1	processing					807:816	protein processing	799:816	protein processing	799:816	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	6	19	theme	signaling	1088:1096	arg1	up-regulation					1065:1077	up-regulation	1065:1077	up-regulation of PMK-1 signaling upon infection with PA14	1065:1121	We also showed that the OST complex was required for up-regulation of PMK-1 signaling upon infection with PA14.
32130226	2	20	theme	OST	477:479	arg1	complex					481:487	the OST complex	473:487	the OST complex	473:487	Although many OST substrate proteins have been identified, the physiological role of the OST complex remains incompletely understood.
32130226	7	21	theme	crucial	1193:1199	arg1	complex					1184:1190	an evolutionarily conserved OST complex	1152:1190	an evolutionarily conserved OST complex	1152:1190	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	1	22	theme	protein	206:212	arg1	complex					214:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	0	23	from	transferase	33:43	arg1	elegans					63:69	Caenorhabditis elegans	48:69	Caenorhabditis elegans	48:69	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	4	24	theme	protein	868:874	arg1	UPRER					886:890	UPRER	886:890	UPRER	886:890	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	4	24	theme	protein	868:874	arg1	response					876:883	ER unfolded protein response	856:883	ER unfolded protein response (UPRER)	856:891	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	7	25	theme	defense	1236:1242	arg1	mechanisms					1244:1253	host defense mechanisms	1231:1253	host defense mechanisms	1231:1253	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	5	26	theme	glycosylated	947:958	arg1	protein					960:966	an OST-dependent glycosylated protein	930:966	an OST-dependent glycosylated protein	930:966	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	5	26	theme	glycosylated	947:958	arg1	VIT-6					921:925	vitellogenin VIT-6	908:925	vitellogenin VIT-6	908:925	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	2	27	theme	substrate	406:414	arg1	proteins					416:423	many OST substrate proteins	397:423	many OST substrate proteins	397:423	Although many OST substrate proteins have been identified, the physiological role of the OST complex remains incompletely understood.
32130226	6	28	theme	OST	1036:1038	arg1	complex					1040:1046	the OST complex	1032:1046	the OST complex	1032:1046	We also showed that the OST complex was required for up-regulation of PMK-1 signaling upon infection with PA14.
32130226	1	29	gly	glycosylation	244:256	arg1	reticulum					299:307	the endoplasmic reticulum	283:307	the endoplasmic reticulum (ER)	283:312	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	29	gly	glycosylation	244:256	arg1	proteins					271:278	substrate proteins	261:278	substrate proteins	261:278	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	29	gly	glycosylation	244:256	arg1	ER					310:311	ER	310:311	ER	310:311	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	3	30	theme	ER	585:586	arg1	homeostasis					596:606	ER protein homeostasis	585:606	ER protein homeostasis	585:606	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	2	31	theme	OST	402:404	arg1	proteins					416:423	many OST substrate proteins	397:423	many OST substrate proteins	397:423	Although many OST substrate proteins have been identified, the physiological role of the OST complex remains incompletely understood.
32130226	0	32	theme	oligosaccharyl	18:31	arg1	transferase					33:43	the oligosaccharyl transferase	14:43	the oligosaccharyl transferase in Caenorhabditis elegans	14:69	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	4	33	theme	genetic	752:758	arg1	inhibition					760:769	genetic inhibition	752:769	genetic inhibition of the OST complex	752:788	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	2	34	theme	physiological	451:463	arg1	role					465:468	the physiological role	447:468	the physiological role of the OST complex	447:487	Although many OST substrate proteins have been identified, the physiological role of the OST complex remains incompletely understood.
32130226	0	35	theme	pathogenic	148:157	arg1	bacteria					159:166	pathogenic bacteria	148:166	pathogenic bacteria	148:166	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	5	36	theme	vitellogenin	908:919	arg1	protein					960:966	an OST-dependent glycosylated protein	930:966	an OST-dependent glycosylated protein	930:966	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	5	36	theme	vitellogenin	908:919	arg1	VIT-6					921:925	vitellogenin VIT-6	908:925	vitellogenin VIT-6	908:925	We identified vitellogenin VIT-6 as an OST-dependent glycosylated protein, critical for maintaining survival on PA14.
32130226	1	37	theme	N-linked	235:242	arg1	glycosylation					244:256	the N-linked glycosylation	231:256	the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates	231:385	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	7	38	theme	host	1231:1234	arg1	mechanisms					1244:1253	host defense mechanisms	1231:1253	host defense mechanisms	1231:1253	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	0	39	theme	transferase	33:43	arg1	Inhibition					0:9	Inhibition	0:9	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis	0:102	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	7	40	theme	conserved	1170:1178	arg1	complex					1184:1190	an evolutionarily conserved OST complex	1152:1190	an evolutionarily conserved OST complex	1152:1190	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	7	41	theme	OST	1180:1182	arg1	complex					1184:1190	an evolutionarily conserved OST complex	1152:1190	an evolutionarily conserved OST complex	1152:1190	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	1	42	from	glycosylation	244:256	arg1	reticulum					299:307	the endoplasmic reticulum	283:307	the endoplasmic reticulum (ER)	283:312	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	1	42	from	glycosylation	244:256	arg1	ER					310:311	ER	310:311	ER	310:311	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	7	43	theme	ER	1205:1206	arg1	homeostasis					1208:1218	ER homeostasis	1205:1218	ER homeostasis	1205:1218	Our study demonstrates that an evolutionarily conserved OST complex, crucial for ER homeostasis, regulates host defense mechanisms against pathogenic bacteria.
32130226	2	44	theme	complex	481:487	arg1	role					465:468	the physiological role	447:468	the physiological role of the OST complex	447:487	Although many OST substrate proteins have been identified, the physiological role of the OST complex remains incompletely understood.
32130226	3	45	theme	protein	588:594	arg1	homeostasis					596:606	ER protein homeostasis	585:606	ER protein homeostasis	585:606	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	4	46	theme	unfolded	859:866	arg1	UPRER					886:890	UPRER	886:890	UPRER	886:890	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	4	46	theme	unfolded	859:866	arg1	response					876:883	ER unfolded protein response	856:883	ER unfolded protein response (UPRER)	856:891	We found that genetic inhibition of the OST complex impaired protein processing in the ER, which in turn up-regulated ER unfolded protein response (UPRER).
32130226	0	47	theme	Caenorhabditis	48:61	arg1	elegans					63:69	Caenorhabditis elegans	48:69	Caenorhabditis elegans	48:69	Inhibition of the oligosaccharyl transferase in Caenorhabditis elegans that compromises ER proteostasis suppresses p38-dependent protection against pathogenic bacteria.
32130226	3	48	dep	bacteria	654:661	arg1	aeruginosa					675:684	Pseudomonas aeruginosa	663:684	pathogenic bacteria Pseudomonas aeruginosa (PA14)	643:691	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	3	48	dep	bacteria	654:661	arg1	PA14					687:690	PA14	687:690	PA14	687:690	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	1	49	theme	substrate	261:269	arg1	proteins					271:278	substrate proteins	261:278	substrate proteins	261:278	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	3	50	theme	pathogenic	643:652	arg1	bacteria					654:661	pathogenic bacteria Pseudomonas aeruginosa (PA14)	643:691	pathogenic bacteria Pseudomonas aeruginosa (PA14)	643:691	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	3	51	theme	OST	544:546	arg1	crucial					573:579	crucial	573:579	crucial	573:579	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	3	51	theme	OST	544:546	arg1	complex					548:554	the OST complex	540:554	the OST complex in C. elegans	540:568	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	1	52	theme	proteins	271:278	arg1	glycosylation					244:256	the N-linked glycosylation	231:256	the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates	231:385	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	6	53	with	infection	1103:1111	arg1	PA14					1118:1121	PA14	1118:1121	PA14	1118:1121	We also showed that the OST complex was required for up-regulation of PMK-1 signaling upon infection with PA14.
32130226	3	54	theme	PMK-1/p38	716:724	arg1	kinase					730:735	immune-regulatory PMK-1/p38 MAP kinase	698:735	immune-regulatory PMK-1/p38 MAP kinase	698:735	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	1	55	theme	oligosaccharyl	173:186	arg1	complex					214:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	6	56	theme	PMK-1	1082:1086	arg1	signaling					1088:1096	PMK-1 signaling	1082:1096	PMK-1 signaling	1082:1096	We also showed that the OST complex was required for up-regulation of PMK-1 signaling upon infection with PA14.
32130226	3	57	with	infection	628:636	arg1	bacteria					654:661	pathogenic bacteria Pseudomonas aeruginosa (PA14)	643:691	pathogenic bacteria Pseudomonas aeruginosa (PA14)	643:691	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	3	58	theme	MAP	726:728	arg1	kinase					730:735	immune-regulatory PMK-1/p38 MAP kinase	698:735	immune-regulatory PMK-1/p38 MAP kinase	698:735	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
32130226	1	59	theme	transferase	188:198	arg1	complex					214:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex	169:220	The oligosaccharyl transferase (OST) protein complex mediates the N-linked glycosylation of substrate proteins in the endoplasmic reticulum (ER), which regulates stability, activity, and localization of its substrates.
32130226	3	60	from	complex	548:554	arg1	elegans					562:568	C. elegans	559:568	C. elegans	559:568	Here we show that the OST complex in C. elegans is crucial for ER protein homeostasis and defense against infection with pathogenic bacteria Pseudomonas aeruginosa (PA14), via immune-regulatory PMK-1/p38 MAP kinase.
34259368	2	0	theme	quantitative	432:443	arg1	yield					445:449	nearly quantitative yield	425:449	nearly quantitative yield	425:449	FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield.
34259368	7	1	theme	SuFEx	1019:1023	arg1	chemistry					1025:1033	the SuFEx chemistry	1015:1033	the SuFEx chemistry	1015:1033	The scope of the SuFEx chemistry is largely expanded thereby and the facile entry to these phosphate-like connections should prove useful to click chemistry across diverse fields.
34259368	1	2	theme	reliable	135:142	arg1	linker					162:167	a reliable bis-electrophilic linker	133:167		133:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	2	theme	reliable	135:142	arg1	isocyanate					88:97	Fluorosulfuryl isocyanate	73:97	Fluorosulfuryl isocyanate (FSI, FSO2 NCO)	73:113	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	6	3	theme	covalent	919:926	arg1	capture					928:934	potential covalent capture	909:934	potential covalent capture of proteins	909:946	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	1	4	theme	R	293:293	arg1	"					800:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	7	5	theme	chemistry	1025:1033	arg1	scope					1006:1010	The scope	1002:1010	The scope of the SuFEx chemistry	1002:1033	The scope of the SuFEx chemistry is largely expanded thereby and the facile entry to these phosphate-like connections should prove useful to click chemistry across diverse fields.
34259368	1	6	theme	bis-electrophilic	144:160	arg1	linker					162:167	a reliable bis-electrophilic linker	133:167		133:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	6	theme	bis-electrophilic	144:160	arg1	isocyanate					88:97	Fluorosulfuryl isocyanate	73:97	Fluorosulfuryl isocyanate (FSI, FSO2 NCO)	73:113	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	6	7	theme	potential	909:917	arg1	capture					928:934	potential covalent capture	909:934	potential covalent capture of proteins	909:946	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	7	8	theme	phosphate-like	1093:1106	arg1	connections					1108:1118	these phosphate-like connections	1087:1118	these phosphate-like connections	1087:1118	The scope of the SuFEx chemistry is largely expanded thereby and the facile entry to these phosphate-like connections should prove useful to click chemistry across diverse fields.
34259368	6	9	theme	reactivity	823:832	arg1	phenomenon					834:843	This "on water" interfacial reactivity phenomenon	795:843	This "on water" interfacial reactivity phenomenon	795:843	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	5	10	theme	best	733:736	arg1	yield					738:742	the best yield	729:742	the best yield of the S-N linked products	729:769	In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone.
34259368	6	11	from	discovery	991:999	arg1	important					965:973	important	965:973	important	965:973	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	6	11	from	discovery	991:999	arg1	reactivity					878:887	the latent reactivity	867:887	the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery	867:999	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	6	12	theme	interfacial	811:821	arg1	phenomenon					834:843	This "on water" interfacial reactivity phenomenon	795:843	This "on water" interfacial reactivity phenomenon	795:843	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	4	13	theme	great	642:646	arg1	complexities					659:670	the great structural complexities	638:670	the great structural complexities in diverse products	638:690	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	6	14	theme	probe	899:903	arg1	important					965:973	important	965:973	important	965:973	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	6	14	theme	probe	899:903	arg1	reactivity					878:887	the latent reactivity	867:887	the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery	867:999	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	1	15	theme	Fluorosulfuryl	73:86	arg1	NCO					110:112	NCO	110:112	NCO	110:112	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	15	theme	Fluorosulfuryl	73:86	arg1	isocyanate					88:97	Fluorosulfuryl isocyanate	73:97	Fluorosulfuryl isocyanate (FSI, FSO2 NCO)	73:113	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	15	theme	Fluorosulfuryl	73:86	arg1	linker					162:167	a reliable bis-electrophilic linker	133:167		133:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	2	16	theme	isocyanate	315:324	arg1	motif					326:330	FSI's isocyanate motif	309:330	FSI's isocyanate motif	309:330	FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield.
34259368	6	17	theme	drug	986:989	arg1	discovery					991:999	today's drug discovery	978:999	today's drug discovery	978:999	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	6	18	theme	water	804:808	arg1	"					809:809	water"	804:809	water"	804:809	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	7	19	theme	facile	1071:1076	arg1	entry					1078:1082	the facile entry	1067:1082	the facile entry to these phosphate-like connections	1067:1118	The scope of the SuFEx chemistry is largely expanded thereby and the facile entry to these phosphate-like connections should prove useful to click chemistry across diverse fields.
34259368	5	20	theme	step-2	700:705	arg1	reaction					707:714	the step-2 reaction	696:714	the step-2 reaction with amines	696:726	In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone.
34259368	3	21	theme	carbamate	520:528	arg1	fragment					530:537	the FSI-derived fluorosulfuryl carbamate fragment	489:537	the FSI-derived fluorosulfuryl carbamate fragment to amines	489:547	A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed.
34259368	4	22	from	step-1	602:607	arg1	motifs					590:595	The resulting SVI -F motifs	569:595	The resulting SVI -F motifs from step-1	569:607	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	4	22	from	step-1	602:607	arg1	stable					624:629	stable	624:629	stable	624:629	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	1	23	theme	stepwise	173:180	arg1	attachment					182:191	stepwise attachment	173:191		173:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	0	24	theme	Fluorosulfuryl	0:13	arg1	Isocyanate					15:24	Fluorosulfuryl Isocyanate	0:24	Fluorosulfuryl Isocyanate	0:24	Fluorosulfuryl Isocyanate Enabled SuFEx Ligation of Alcohols and Amines.
34259368	6	25	theme	-F	896:897	arg1	probe					899:903	SVI -F probe	892:903	SVI -F probe for potential covalent capture of proteins	892:946	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	6	26	from	important	965:973	arg1	discovery					991:999	today's drug discovery	978:999	today's drug discovery	978:999	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	0	27	theme	SuFEx	34:38	arg1	Ligation					40:47	SuFEx Ligation	34:47	SuFEx Ligation of Alcohols and Amines	34:70	Fluorosulfuryl Isocyanate Enabled SuFEx Ligation of Alcohols and Amines.
34259368	1	28	theme	new	262:264	arg1	module					266:271	a new module	260:271		260:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	3	29	theme	FSI-derived	493:503	arg1	fragment					530:537	the FSI-derived fluorosulfuryl carbamate fragment	489:537	the FSI-derived fluorosulfuryl carbamate fragment to amines	489:547	A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed.
34259368	4	30	theme	-F	587:588	arg1	motifs					590:595	The resulting SVI -F motifs	569:595	The resulting SVI -F motifs from step-1	569:607	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	4	30	theme	-F	587:588	arg1	stable					624:629	stable	624:629	stable	624:629	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	5	31	theme	linked	755:760	arg1	products					762:769	the S-N linked products	747:769	the S-N linked products	747:769	In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone.
34259368	3	32	theme	fluorosulfuryl	505:518	arg1	fragment					530:537	the FSI-derived fluorosulfuryl carbamate fragment	489:537	the FSI-derived fluorosulfuryl carbamate fragment to amines	489:547	A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed.
34259368	1	33	theme	RO-C	273:276	arg1	"					800:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	34	theme	alcohol	199:205	arg1	module					215:220	an alcohol bearing module	196:220	an alcohol bearing module	196:220	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	6	35	theme	latent	871:876	arg1	important					965:973	important	965:973	important	965:973	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	6	35	theme	latent	871:876	arg1	reactivity					878:887	the latent reactivity	867:887	the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery	867:999	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	1	36	attach	attachment	182:191	arg2	module					215:220	an alcohol bearing module	196:220	an alcohol bearing module	196:220	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	36	attach	attachment	182:191	arg1	amine					228:232	an amine	225:232		225:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	1	37	theme	bearing	207:213	arg1	module					215:220	an alcohol bearing module	196:220	an alcohol bearing module	196:220	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	2	38	theme	fluorosulfuryl	396:409	arg1	carbamates					411:420	fluorosulfuryl carbamates	396:420	fluorosulfuryl carbamates	396:420	FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield.
34259368	1	39	theme	=O	278:279	arg1	"					800:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	0	40	theme	Alcohols	52:59	arg1	Ligation					40:47	SuFEx Ligation	34:47	SuFEx Ligation of Alcohols and Amines	34:70	Fluorosulfuryl Isocyanate Enabled SuFEx Ligation of Alcohols and Amines.
34259368	1	41	dep	module	266:271	arg1	created					-1:5		-1:5		845:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	3	42	theme	new	454:456	arg1	reagent					458:464	A new reagent	452:464	A new reagent	452:464	A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed.
34259368	4	43	theme	structural	648:657	arg1	complexities					659:670	the great structural complexities	638:670	the great structural complexities in diverse products	638:690	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	1	44	theme	-NH-SO2	281:287	arg1	"					800:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	4	45	theme	diverse	675:681	arg1	products					683:690	diverse products	675:690	diverse products	675:690	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	3	46	dep	reagent	458:464	arg1	deliver					481:487	deliver	481:487	to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines	478:547	A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed.
34259368	1	47	theme	module	215:220	arg1	attachment					182:191	stepwise attachment	173:191		173:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	5	48	link	linked	755:760	arg1	products					762:769	the S-N linked products	747:769	the S-N linked products	747:769	In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone.
34259368	4	49	from	complexities	659:670	arg1	products					683:690	diverse products	675:690	diverse products	675:690	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	6	50	theme	proteins	939:946	arg1	capture					928:934	potential covalent capture	909:934	potential covalent capture of proteins	909:946	This "on water" interfacial reactivity phenomenon is crucial, revealing the latent reactivity of SVI -F probe for potential covalent capture of proteins in vivo which is important in today's drug discovery.
34259368	3	51	link	FSI-derived	493:503	arg1	fragment					530:537	the FSI-derived fluorosulfuryl carbamate fragment	489:537	the FSI-derived fluorosulfuryl carbamate fragment to amines	489:547	A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed.
34259368	1	52	dep	module	242:247	arg1	module					266:271	a new module	260:271		260:5	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	5	53	theme	products	762:769	arg1	yield					738:742	the best yield	729:742	the best yield of the S-N linked products	729:769	In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone.
34259368	4	54	theme	resulting	573:581	arg1	motifs					590:595	The resulting SVI -F motifs	569:595	The resulting SVI -F motifs from step-1	569:607	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	4	54	theme	resulting	573:581	arg1	stable					624:629	stable	624:629	stable	624:629	The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products.
34259368	0	55	theme	Amines	65:70	arg1	Ligation					40:47	SuFEx Ligation	34:47	SuFEx Ligation of Alcohols and Amines	34:70	Fluorosulfuryl Isocyanate Enabled SuFEx Ligation of Alcohols and Amines.
34259368	1	56	theme	-NR	289:291	arg1	"					800:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	RO-C(=O)-NH-SO2 -NR'R'' is created. FSI's isocyanate motif fuses directly and quickly with alcohols and phenols, affording fluorosulfuryl carbamates in nearly quantitative yield. A new reagent and process to deliver the FSI-derived fluorosulfuryl carbamate fragment to amines are also developed. The resulting SVI -F motifs from step-1 are remarkably stable, given the great structural complexities in diverse products. In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone. This "	273:800	Fluorosulfuryl isocyanate (FSI, FSO2 NCO) is established as a reliable bis-electrophilic linker for stepwise attachment of an alcohol bearing module to an amine bearing module and thence a new module RO-C(=O)-NH-SO2 -NR'R'' is created.
34259368	5	57	with	reaction	707:714	arg1	amines					721:726	amines	721:726	amines	721:726	In the step-2 reaction with amines, the best yield of the S-N linked products arise with water alone.
34259368	7	58	theme	diverse	1166:1172	arg1	fields					1174:1179	diverse fields	1166:1179	diverse fields	1166:1179	The scope of the SuFEx chemistry is largely expanded thereby and the facile entry to these phosphate-like connections should prove useful to click chemistry across diverse fields.
34259368	7	59	theme	click	1143:1147	arg1	chemistry					1149:1157	click chemistry	1143:1157	click chemistry across diverse fields	1143:1179	The scope of the SuFEx chemistry is largely expanded thereby and the facile entry to these phosphate-like connections should prove useful to click chemistry across diverse fields.
34004320	7	0	theme	cord	1251:1254	arg1	VNC					1257:1259	ventral nerve cord (VNC)	1237:1260	ventral nerve cord (VNC)	1237:1260	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	7	0	theme	cord	1251:1254	arg1	eyestalk					1220:1227	the eyestalk	1216:1227	the eyestalk	1216:1227	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	8	1	theme	PpelOT/VP-like	1447:1460	arg1	receptor					1470:1477	the PpelOT/VP-like peptide receptor	1443:1477	the PpelOT/VP-like peptide receptor gene expression	1443:1493	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	2	from	peptide	1361:1367	arg1	crabs					1399:1403	immature and mature female crabs	1372:1403	immature and mature female crabs	1372:1403	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	10	3	theme	peptide	1722:1728	arg1	gene					1730:1733	this peptide gene	1717:1733	this peptide gene	1717:1733	Changes in expression of this peptide gene, but not its receptor, might result in ovarian steroid release inhibition.
34004320	9	4	theme	crabs	1652:1656	arg1	VNC					1636:1638	the VNC	1632:1638	the VNC of immature crabs	1632:1656	In contrast, the PpelOT/VP-like peptide gene was shown to significantly express higher in the VNC of immature crabs and in the ovary of mature crabs.
34004320	3	5	theme	peptide	538:544	arg1	receptor					546:553	the PpelOT/VP-like peptide receptor	519:553	the PpelOT/VP-like peptide receptor	519:553	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	5	6	theme	OT/VP-like	904:913	arg1	receptors					915:923	invertebrate OT/VP-like receptors	891:923	invertebrate OT/VP-like receptors	891:923	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	7	7	theme	neuronal	1195:1202	arg1	clusters					1204:1211	all neuronal clusters	1191:1211	all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC),	1191:1261	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	4	8	theme	N-linked	706:713	arg1	residues					729:736	-two N-linked glycosylation residues	701:736	-two N-linked glycosylation residues located before the first transmembrane domain (TM I)	701:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	8	9	from	difference	1429:1438	arg1	CNS					1526:1528	CNS	1526:1528	CNS	1526:1528	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	9	from	difference	1429:1438	arg1	ovary					1535:1539	ovary	1535:1539	ovary	1535:1539	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	9	from	difference	1429:1438	arg1	system					1518:1523	the central nervous system	1498:1523	the central nervous system (CNS)	1498:1529	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	4	10	theme	seven	659:663	arg1	transmembrane					665:677	transmembrane	665:677	transmembrane	665:677	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	0	11	theme	crab	113:116	arg1	ovary					86:90	ovary	86:90	ovary	86:90	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	0	11	theme	crab	113:116	arg1	system					75:80	the central nervous system	55:80	the central nervous system	55:80	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	11	12	theme	detailed	1823:1830	arg1	mechanism					1832:1840	the detailed mechanism	1819:1840	the detailed mechanism of this peptide in reproduction regulation	1819:1883	However, the detailed mechanism of this peptide in reproduction regulation will be included in our further studies.
34004320	9	13	theme	mature	1678:1683	arg1	crabs					1685:1689	mature crabs	1678:1689	mature crabs	1678:1689	In contrast, the PpelOT/VP-like peptide gene was shown to significantly express higher in the VNC of immature crabs and in the ovary of mature crabs.
34004320	4	14	link	N-linked	706:713	arg1	residues					729:736	-two N-linked glycosylation residues	701:736	-two N-linked glycosylation residues located before the first transmembrane domain (TM I)	701:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	1	15	theme	peptide	228:234	arg1	presence					173:180	presence	173:180	presence	173:180	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	1	15	theme	peptide	228:234	arg1	distribution					186:197	distribution	186:197	distribution	186:197	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	6	16	located	found	1116:1120	arg2	abundance					1106:1114	highest abundance	1098:1114	highest abundance found in brain tissue	1098:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	6	16	located	found	1116:1120	arg1	tissue					1131:1136	brain tissue	1125:1136	brain tissue	1125:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	4	17	theme	first	757:761	arg1	TM					785:786	TM I	785:788	TM I	785:788	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	4	17	theme	first	757:761	arg1	domain					777:782	the first transmembrane domain	753:782	the first transmembrane domain (TM I)	753:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	1	18	from	distribution	186:197	arg1	pelagicus					248:256	Portunus pelagicus	239:256	Portunus pelagicus	239:256	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	8	19	theme	receptor	1470:1477	arg1	expression					1484:1493	the PpelOT/VP-like peptide receptor gene expression	1443:1493	the PpelOT/VP-like peptide receptor gene expression	1443:1493	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	10	20	theme	steroid	1782:1788	arg1	inhibition					1798:1807	ovarian steroid release inhibition	1774:1807	ovarian steroid release inhibition	1774:1807	Changes in expression of this peptide gene, but not its receptor, might result in ovarian steroid release inhibition.
34004320	1	21	from	presence	173:180	arg1	pelagicus					248:256	Portunus pelagicus	239:256	Portunus pelagicus	239:256	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	8	22	theme	expression	1484:1493	arg1	difference					1429:1438	no significant difference	1414:1438	no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary	1414:1539	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	23	theme	gene	1300:1303	arg1	expressions					1305:1315	Comparative gene expressions	1288:1315	Comparative gene expressions between this receptor	1288:1337	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	0	24	theme	nervous	67:73	arg1	system					75:80	the central nervous system	55:80	the central nervous system	55:80	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	6	25	theme	gene	1020:1023	arg1	transcript					1025:1034	this receptor gene transcript	1006:1034	this receptor gene transcript	1006:1034	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	8	26	theme	nervous	1510:1516	arg1	CNS					1526:1528	CNS	1526:1528	CNS	1526:1528	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	26	theme	nervous	1510:1516	arg1	system					1518:1523	the central nervous system	1498:1523	the central nervous system (CNS)	1498:1529	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	5	27	dep	V1R	967:969	arg1	the					963:965	the	963:965	the	963:965	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	0	28	theme	blue	99:102	arg1	crab					113:116	the blue swimming crab	95:116	the blue swimming crab	95:116	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	5	29	from	V1R	967:969	arg1	receptor					855:862	the PpelOT/VP-like peptide receptor	828:862	the PpelOT/VP-like peptide receptor	828:862	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	29	from	V1R	967:969	arg1	distinguishable					942:956	distinguishable	942:956	distinguishable	942:956	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	0	30	from	mRNA	47:50	arg1	ovary					86:90	ovary	86:90	ovary	86:90	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	0	30	from	mRNA	47:50	arg1	system					75:80	the central nervous system	55:80	the central nervous system	55:80	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	2	31	theme	full-length	363:373	arg1	receptor					375:382	the full-length receptor	359:382	the full-length receptor of this peptide	359:398	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	31	theme	full-length	363:373	arg1	receptor					442:449	oxytocin/vasopressin-like peptide receptor	408:449	namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor)	401:483	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	6	32	theme	swimming	1079:1086	arg1	crab					1088:1091	the blue swimming crab	1070:1091	the blue swimming crab with highest abundance found in brain tissue	1070:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	2	33	theme	peptide	434:440	arg1	receptor					442:449	oxytocin/vasopressin-like peptide receptor	408:449	namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor)	401:483	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	33	theme	peptide	434:440	arg1	receptor					375:382	the full-length receptor	359:382	the full-length receptor of this peptide	359:398	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	33	theme	peptide	434:440	arg1	receptor					475:482	PpelOT/VP-like peptide receptor	452:482	PpelOT/VP-like peptide receptor	452:482	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	8	34	theme	immature	1372:1379	arg1	crabs					1399:1403	immature and mature female crabs	1372:1403	immature and mature female crabs	1372:1403	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	1	35	dep	presence	173:180	arg1	the					169:171	the	169:171	the	169:171	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	0	36	theme	peptide	30:36	arg1	pelagicus					128:136	Portunus pelagicus	119:136	Portunus pelagicus	119:136	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	0	36	theme	peptide	30:36	arg1	mRNA					47:50	The oxytocin/vasopressin-like peptide receptor mRNA	0:50	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab	0:116	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	6	37	with	crab	1088:1091	arg1	abundance					1106:1114	highest abundance	1098:1114	highest abundance found in brain tissue	1098:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	9	38	theme	peptide	1574:1580	arg1	gene					1582:1585	the PpelOT/VP-like peptide gene	1555:1585	the PpelOT/VP-like peptide gene	1555:1585	In contrast, the PpelOT/VP-like peptide gene was shown to significantly express higher in the VNC of immature crabs and in the ovary of mature crabs.
34004320	8	39	theme	mature	1385:1390	arg1	crabs					1399:1403	immature and mature female crabs	1372:1403	immature and mature female crabs	1372:1403	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	2	40	theme	peptide	392:398	arg1	receptor					375:382	the full-length receptor	359:382	the full-length receptor of this peptide	359:398	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	40	theme	peptide	392:398	arg1	receptor					442:449	oxytocin/vasopressin-like peptide receptor	408:449	namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor)	401:483	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	1	41	theme	steroid	314:320	arg1	release					322:328	ovarian steroid release	306:328	ovarian steroid release	306:328	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	2	42	theme	peptide	467:473	arg1	receptor					442:449	oxytocin/vasopressin-like peptide receptor	408:449	namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor)	401:483	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	42	theme	peptide	467:473	arg1	receptor					475:482	PpelOT/VP-like peptide receptor	452:482	PpelOT/VP-like peptide receptor	452:482	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	1	43	attach	presence	173:180	arg2	peptide					228:234	oxytocin/vasopressin-like peptide	202:234	oxytocin/vasopressin-like peptide	202:234	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	1	43	attach	presence	173:180	arg1	pelagicus					248:256	Portunus pelagicus	239:256	Portunus pelagicus	239:256	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	5	44	theme	PpelOT/VP-like	832:845	arg1	receptor					855:862	the PpelOT/VP-like peptide receptor	828:862	the PpelOT/VP-like peptide receptor	828:862	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	44	theme	PpelOT/VP-like	832:845	arg1	distinguishable					942:956	distinguishable	942:956	distinguishable	942:956	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	1	45	dep	inhibit	298:304	arg1	Saetan					331:336	Saetan	331:336	Saetan	331:336	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	4	46	theme	glycosylation	715:727	arg1	residues					729:736	-two N-linked glycosylation residues	701:736	-two N-linked glycosylation residues located before the first transmembrane domain (TM I)	701:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	7	47	theme	In	1139:1140	arg1	hybridization					1147:1159	In situ hybridization	1139:1159	In situ hybridization	1139:1159	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	3	48	theme	coding	502:507	arg1	region					509:514	The coding region	498:514	The coding region of the PpelOT/VP-like peptide receptor	498:553	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	3	49	theme	receptor	546:553	arg1	region					509:514	The coding region	498:514	The coding region of the PpelOT/VP-like peptide receptor	498:553	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	9	50	theme	immature	1643:1650	arg1	crabs					1652:1656	immature crabs	1643:1656	immature crabs	1643:1656	In contrast, the PpelOT/VP-like peptide gene was shown to significantly express higher in the VNC of immature crabs and in the ovary of mature crabs.
34004320	3	51	theme	PpelOT/VP-like	523:536	arg1	receptor					546:553	the PpelOT/VP-like peptide receptor	519:553	the PpelOT/VP-like peptide receptor	519:553	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	5	52	theme	invertebrate	891:902	arg1	receptors					915:923	invertebrate OT/VP-like receptors	891:923	invertebrate OT/VP-like receptors	891:923	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	10	53	from	Changes	1692:1698	arg1	expression					1703:1712	expression	1703:1712	expression of this peptide gene	1703:1733	Changes in expression of this peptide gene, but not its receptor, might result in ovarian steroid release inhibition.
34004320	10	54	theme	gene	1730:1733	arg1	expression					1703:1712	expression	1703:1712	expression of this peptide gene	1703:1733	Changes in expression of this peptide gene, but not its receptor, might result in ovarian steroid release inhibition.
34004320	5	55	theme	receptors	915:923	arg1	group					882:886	the group	878:886	the group of invertebrate OT/VP-like receptors	878:923	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	55	theme	receptors	915:923	arg1	receptors					915:923	invertebrate OT/VP-like receptors	891:923	invertebrate OT/VP-like receptors	891:923	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	4	56	theme	-two	701:704	arg1	residues					729:736	-two N-linked glycosylation residues	701:736	-two N-linked glycosylation residues located before the first transmembrane domain (TM I)	701:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	7	57	dep	In	1139:1140	arg1	situ					1142:1145	situ	1142:1145	situ	1142:1145	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	3	58	theme	amino	615:619	arg1	acids					621:625	499 amino acids	611:625	499 amino acids	611:625	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	1	59	theme	oxytocin/vasopressin-like	202:226	arg1	peptide					228:234	oxytocin/vasopressin-like peptide	202:234	oxytocin/vasopressin-like peptide	202:234	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	9	60	theme	crabs	1685:1689	arg1	ovary					1669:1673	the ovary	1665:1673	the ovary of mature crabs	1665:1689	In contrast, the PpelOT/VP-like peptide gene was shown to significantly express higher in the VNC of immature crabs and in the ovary of mature crabs.
34004320	8	61	theme	peptide	1462:1468	arg1	receptor					1470:1477	the PpelOT/VP-like peptide receptor	1443:1477	the PpelOT/VP-like peptide receptor gene expression	1443:1493	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	4	62	theme	transmembrane	665:677	arg1	characteristics					679:693	its seven transmembrane characteristics	655:693	its seven transmembrane characteristics	655:693	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	8	63	theme	gene	1479:1482	arg1	expression					1484:1493	the PpelOT/VP-like peptide receptor gene expression	1443:1493	the PpelOT/VP-like peptide receptor gene expression	1443:1493	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	10	64	theme	release	1790:1796	arg1	inhibition					1798:1807	ovarian steroid release inhibition	1774:1807	ovarian steroid release inhibition	1774:1807	Changes in expression of this peptide gene, but not its receptor, might result in ovarian steroid release inhibition.
34004320	6	65	theme	several	1052:1058	arg1	organs					1060:1065	several organs	1052:1065	several organs of the blue swimming crab with highest abundance found in brain tissue	1052:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	4	66	theme	transmembrane	763:775	arg1	TM					785:786	TM I	785:788	TM I	785:788	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	4	66	theme	transmembrane	763:775	arg1	domain					777:782	the first transmembrane domain	753:782	the first transmembrane domain (TM I)	753:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	7	67	theme	ventral	1237:1243	arg1	VNC					1257:1259	ventral nerve cord (VNC)	1237:1260	ventral nerve cord (VNC)	1237:1260	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	7	67	theme	ventral	1237:1243	arg1	eyestalk					1220:1227	the eyestalk	1216:1227	the eyestalk	1216:1227	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	10	68	theme	ovarian	1774:1780	arg1	inhibition					1798:1807	ovarian steroid release inhibition	1774:1807	ovarian steroid release inhibition	1774:1807	Changes in expression of this peptide gene, but not its receptor, might result in ovarian steroid release inhibition.
34004320	8	69	theme	central	1502:1508	arg1	CNS					1526:1528	CNS	1526:1528	CNS	1526:1528	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	69	theme	central	1502:1508	arg1	system					1518:1523	the central nervous system	1498:1523	the central nervous system (CNS)	1498:1529	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	8	70	theme	Comparative	1288:1298	arg1	expressions					1305:1315	Comparative gene expressions	1288:1315	Comparative gene expressions between this receptor	1288:1337	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	5	71	theme	phylogenetic	796:807	arg1	tree					809:812	The phylogenetic tree	792:812	The phylogenetic tree	792:812	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	4	72	theme	located	738:744	arg1	residues					729:736	-two N-linked glycosylation residues	701:736	-two N-linked glycosylation residues located before the first transmembrane domain (TM I)	701:789	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	7	73	theme	eyestalk	1220:1227	arg1	clusters					1204:1211	all neuronal clusters	1191:1211	all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC),	1191:1261	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	5	74	theme	vertebrates	987:997	arg1	OTR					980:982	OTR	980:982	OTR	980:982	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	74	theme	vertebrates	987:997	arg1	V2R					972:974	V2R	972:974	V2R	972:974	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	74	theme	vertebrates	987:997	arg1	V1R					967:969	V1R	967:969	V1R	967:969	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	6	75	theme	receptor	1011:1018	arg1	transcript					1025:1034	this receptor gene transcript	1006:1034	this receptor gene transcript	1006:1034	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	11	76	from	mechanism	1832:1840	arg1	regulation					1874:1883	reproduction regulation	1861:1883	reproduction regulation	1861:1883	However, the detailed mechanism of this peptide in reproduction regulation will be included in our further studies.
34004320	0	77	theme	swimming	104:111	arg1	crab					113:116	the blue swimming crab	95:116	the blue swimming crab	95:116	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	6	78	theme	highest	1098:1104	arg1	abundance					1106:1114	highest abundance	1098:1114	highest abundance found in brain tissue	1098:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	11	79	theme	reproduction	1861:1872	arg1	regulation					1874:1883	reproduction regulation	1861:1883	reproduction regulation	1861:1883	However, the detailed mechanism of this peptide in reproduction regulation will be included in our further studies.
34004320	5	80	theme	peptide	847:853	arg1	receptor					855:862	the PpelOT/VP-like peptide receptor	828:862	the PpelOT/VP-like peptide receptor	828:862	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	80	theme	peptide	847:853	arg1	distinguishable					942:956	distinguishable	942:956	distinguishable	942:956	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	8	81	from	expressions	1305:1315	arg1	crabs					1399:1403	immature and mature female crabs	1372:1403	immature and mature female crabs	1372:1403	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	6	82	theme	crab	1088:1091	arg1	organs					1060:1065	several organs	1052:1065	several organs of the blue swimming crab with highest abundance found in brain tissue	1052:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	8	83	theme	corresponding	1347:1359	arg1	peptide					1361:1367	its corresponding peptide	1343:1367	its corresponding peptide in immature and mature female crabs	1343:1403	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	11	84	theme	peptide	1850:1856	arg1	mechanism					1832:1840	the detailed mechanism	1819:1840	the detailed mechanism of this peptide in reproduction regulation	1819:1883	However, the detailed mechanism of this peptide in reproduction regulation will be included in our further studies.
34004320	0	85	theme	receptor	38:45	arg1	pelagicus					128:136	Portunus pelagicus	119:136	Portunus pelagicus	119:136	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	0	85	theme	receptor	38:45	arg1	mRNA					47:50	The oxytocin/vasopressin-like peptide receptor mRNA	0:50	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab	0:116	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	9	86	theme	PpelOT/VP-like	1559:1572	arg1	gene					1582:1585	the PpelOT/VP-like peptide gene	1555:1585	the PpelOT/VP-like peptide gene	1555:1585	In contrast, the PpelOT/VP-like peptide gene was shown to significantly express higher in the VNC of immature crabs and in the ovary of mature crabs.
34004320	11	87	theme	further	1909:1915	arg1	studies					1917:1923	our further studies	1905:1923	our further studies	1905:1923	However, the detailed mechanism of this peptide in reproduction regulation will be included in our further studies.
34004320	6	88	theme	blue	1074:1077	arg1	crab					1088:1091	the blue swimming crab	1070:1091	the blue swimming crab with highest abundance found in brain tissue	1070:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	2	89	theme	oxytocin/vasopressin-like	408:432	arg1	receptor					442:449	oxytocin/vasopressin-like peptide receptor	408:449	namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor)	401:483	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	89	theme	oxytocin/vasopressin-like	408:432	arg1	receptor					375:382	the full-length receptor	359:382	the full-length receptor of this peptide	359:398	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	89	theme	oxytocin/vasopressin-like	408:432	arg1	receptor					475:482	PpelOT/VP-like peptide receptor	452:482	PpelOT/VP-like peptide receptor	452:482	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	6	90	located	detected	1040:1047	arg1	organs					1060:1065	several organs	1052:1065	several organs of the blue swimming crab with highest abundance found in brain tissue	1052:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	6	90	located	detected	1040:1047	arg2	transcript					1025:1034	this receptor gene transcript	1006:1034	this receptor gene transcript	1006:1034	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	1	91	theme	ovarian	306:312	arg1	release					322:328	ovarian steroid release	306:328	ovarian steroid release	306:328	The authors recently reported the presence and distribution of oxytocin/vasopressin-like peptide in Portunus pelagicus as well as demonstrated its function to inhibit ovarian steroid release (Saetan et al., 2018).
34004320	0	92	theme	central	59:65	arg1	system					75:80	the central nervous system	55:80	the central nervous system	55:80	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	2	93	theme	PpelOT/VP-like	452:465	arg1	receptor					442:449	oxytocin/vasopressin-like peptide receptor	408:449	namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor)	401:483	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	2	93	theme	PpelOT/VP-like	452:465	arg1	receptor					475:482	PpelOT/VP-like peptide receptor	452:482	PpelOT/VP-like peptide receptor	452:482	Here, the full-length receptor of this peptide, namely oxytocin/vasopressin-like peptide receptor (PpelOT/VP-like peptide receptor) is reported.
34004320	3	94	contain	contained	555:563	arg1	region					509:514	The coding region	498:514	The coding region of the PpelOT/VP-like peptide receptor	498:553	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	3	94	contain	contained	555:563	arg2	1497 bp					565:571	1497 bp	565:571	1497 bp which translationally corresponded to 499 amino acids	565:625	The coding region of the PpelOT/VP-like peptide receptor contained 1497 bp which translationally corresponded to 499 amino acids.
34004320	8	95	theme	female	1392:1397	arg1	crabs					1399:1403	immature and mature female crabs	1372:1403	immature and mature female crabs	1372:1403	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	5	96	from	OTR	980:982	arg1	receptor					855:862	the PpelOT/VP-like peptide receptor	828:862	the PpelOT/VP-like peptide receptor	828:862	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	96	from	OTR	980:982	arg1	distinguishable					942:956	distinguishable	942:956	distinguishable	942:956	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	4	97	theme	Sequence	628:635	arg1	analysis					637:644	Sequence analysis	628:644	Sequence analysis	628:644	Sequence analysis revealed its seven transmembrane characteristics, with -two N-linked glycosylation residues located before the first transmembrane domain (TM I).
34004320	5	98	from	V2R	972:974	arg1	receptor					855:862	the PpelOT/VP-like peptide receptor	828:862	the PpelOT/VP-like peptide receptor	828:862	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	5	98	from	V2R	972:974	arg1	distinguishable					942:956	distinguishable	942:956	distinguishable	942:956	The phylogenetic tree revealed that the PpelOT/VP-like peptide receptor was placed in the group of invertebrate OT/VP-like receptors, and was clearly distinguishable from the V1R, V2R and OTR of vertebrates.
34004320	6	99	theme	brain	1125:1129	arg1	tissue					1131:1136	brain tissue	1125:1136	brain tissue	1125:1136	Also, this receptor gene transcript was detected in several organs of the blue swimming crab with highest abundance found in brain tissue.
34004320	7	100	theme	nerve	1245:1249	arg1	VNC					1257:1259	ventral nerve cord (VNC)	1237:1260	ventral nerve cord (VNC)	1237:1260	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	7	100	theme	nerve	1245:1249	arg1	eyestalk					1220:1227	the eyestalk	1216:1227	the eyestalk	1216:1227	In situ hybridization exhibited its distribution in all neuronal clusters of the eyestalk, brain, ventral nerve cord (VNC), as well as in the ovary.
34004320	8	101	theme	significant	1417:1427	arg1	difference					1429:1438	no significant difference	1414:1438	no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary	1414:1539	Comparative gene expressions between this receptor and its corresponding peptide in immature and mature female crabs revealed no significant difference of the PpelOT/VP-like peptide receptor gene expression in the central nervous system (CNS) and ovary.
34004320	0	102	theme	oxytocin/vasopressin-like	4:28	arg1	pelagicus					128:136	Portunus pelagicus	119:136	Portunus pelagicus	119:136	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
34004320	0	102	theme	oxytocin/vasopressin-like	4:28	arg1	mRNA					47:50	The oxytocin/vasopressin-like peptide receptor mRNA	0:50	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab	0:116	The oxytocin/vasopressin-like peptide receptor mRNA in the central nervous system and ovary of the blue swimming crab, Portunus pelagicus.
33712585	4	0	from	species	581:587	arg1	present					559:565	present	559:565	present	559:565	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	4	0	from	species	581:587	arg1	enzymes					475:481	The enzymes	471:481	The enzymes	471:481	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	1	1	theme	cellular	142:149	arg1	bioenergetics					151:163	cellular bioenergetics	142:163	cellular bioenergetics	142:163	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	6	2	theme	ADP-ribosyl	903:913	arg1	cyclases					915:922	ADP-ribosyl cyclases	903:922	ADP-ribosyl cyclases	903:922	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	5	3	theme	homodimeric	623:633	arg1	protein					648:654	the homodimeric A. fumigatus protein	619:654	the homodimeric A. fumigatus protein	619:654	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	5	4	link	N-linked	692:699	arg1	glycosylation					701:713	N-linked glycosylation	692:713	N-linked glycosylation	692:713	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	5	5	theme	A.	635:636	arg1	protein					648:654	the homodimeric A. fumigatus protein	619:654	the homodimeric A. fumigatus protein	619:654	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	6	6	theme	substrate	807:815	arg1	analogue					817:824	a substrate analogue	805:824	a substrate analogue	805:824	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	2	7	theme	rapid	302:306	arg1	death					313:317	rapid cell death	302:317	rapid cell death	302:317	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	1	8	from	molecule	130:137	arg1	signalling					169:178	signalling	169:178	signalling	169:178	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	1	8	from	molecule	130:137	arg1	bioenergetics					151:163	cellular bioenergetics	142:163	cellular bioenergetics	142:163	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	2	9	theme	NAD+	275:278	arg1	pool					280:283	the host's NAD+ pool	264:283	the host's NAD+ pool	264:283	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	1	10	theme	key	126:128	arg1	dinucleotide					102:113	Nicotinamide adenine dinucleotide	81:113	Nicotinamide adenine dinucleotide (NAD)	81:119	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	1	10	theme	key	126:128	arg1	molecule					130:137	a key molecule	124:137	a key molecule in cellular bioenergetics and signalling	124:178	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	0	11	from	present	50:56	arg1	species					72:78	pathogenic species	61:78	pathogenic species	61:78	Discovery of fungal surface NADases predominantly present in pathogenic species.
33712585	5	12	theme	1.6 Å	594:598	arg1	structure					606:614	The 1.6 Å X-ray structure	590:614	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein	590:654	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	7	13	theme	fungal	958:963	arg1	NADases					965:971	fungal NADases	958:971	fungal NADases	958:971	We propose that fungal NADases may convey advantages during interaction with the host or competing microorganisms.
33712585	5	14	theme	X-ray	600:604	arg1	structure					606:614	The 1.6 Å X-ray structure	590:614	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein	590:654	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	1	15	theme	Nicotinamide	81:92	arg1	dinucleotide					102:113	Nicotinamide adenine dinucleotide	81:113	Nicotinamide adenine dinucleotide (NAD)	81:119	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	1	15	theme	Nicotinamide	81:92	arg1	molecule					130:137	a key molecule	124:137	a key molecule in cellular bioenergetics and signalling	124:178	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	1	15	theme	Nicotinamide	81:92	arg1	NAD					116:118	NAD	116:118	NAD	116:118	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	3	16	theme	pathogen	402:409	arg1	fumigatus					423:431	the pathogen Aspergillus fumigatus	398:431	the pathogen Aspergillus fumigatus	398:431	Here, we report the identification of NADases on the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa.
33712585	3	17	theme	NADases	358:364	arg1	identification					340:353	the identification	336:353	the identification of NADases	336:364	Here, we report the identification of NADases on the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa.
33712585	1	18	theme	adenine	94:100	arg1	dinucleotide					102:113	Nicotinamide adenine dinucleotide	81:113	Nicotinamide adenine dinucleotide (NAD)	81:119	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	1	18	theme	adenine	94:100	arg1	molecule					130:137	a key molecule	124:137	a key molecule in cellular bioenergetics and signalling	124:178	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	1	18	theme	adenine	94:100	arg1	NAD					116:118	NAD	116:118	NAD	116:118	Nicotinamide adenine dinucleotide (NAD) is a key molecule in cellular bioenergetics and signalling.
33712585	6	19	theme	known	888:892	arg1	NADases					894:900	known NADases	888:900	known NADases	888:900	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	0	20	theme	surface	20:26	arg1	Discovery					0:8	Discovery	0:8	Discovery of fungal surface	0:26	Discovery of fungal surface NADases predominantly present in pathogenic species.
33712585	4	21	located	present	559:565	arg1	species					581:587	pathogenic species	570:587	pathogenic species	570:587	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	4	21	located	present	559:565	arg2	enzymes					475:481	The enzymes	471:481	The enzymes	471:481	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	4	21	located	present	559:565	arg2	present					559:565	present	559:565	present	559:565	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	6	22	from	structure	779:787	arg1	complex					792:798	complex	792:798	complex with a substrate analogue	792:824	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	0	23	theme	fungal	13:18	arg1	surface					20:26	fungal surface	13:26	fungal surface	13:26	Discovery of fungal surface NADases predominantly present in pathogenic species.
33712585	5	24	theme	N-linked	692:699	arg1	glycosylation					701:713	N-linked glycosylation	692:713	N-linked glycosylation	692:713	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	2	25	theme	Various	181:187	arg1	pathogens					199:207	Various bacterial pathogens	181:207	Various bacterial pathogens	181:207	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	5	26	theme	Ca2+-binding	721:732	arg1	site					734:737	a Ca2+-binding site	719:737	a Ca2+-binding site whose occupancy regulates activity	719:772	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	2	27	theme	host	241:244	arg1	cell					246:249	the host cell	237:249	the host cell that deplete the host's NAD+ pool	237:283	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	3	28	theme	Aspergillus	411:421	arg1	fumigatus					423:431	the pathogen Aspergillus fumigatus	398:431	the pathogen Aspergillus fumigatus	398:431	Here, we report the identification of NADases on the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa.
33712585	3	29	theme	fungi	384:388	arg1	surface					373:379	the surface	369:379	the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa	369:468	Here, we report the identification of NADases on the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa.
33712585	4	30	theme	necrotizing	506:516	arg1	domain					530:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	0	31	from	species	72:78	arg1	present					50:56	present	50:56	present	50:56	Discovery of fungal surface NADases predominantly present in pathogenic species.
33712585	7	32	theme	host	1023:1026	arg1	microorganisms					1041:1054	the host or competing microorganisms	1019:1054	microorganisms	1041:1054	We propose that fungal NADases may convey advantages during interaction with the host or competing microorganisms.
33712585	6	33	with	complex	792:798	arg1	analogue					817:824	a substrate analogue	805:824	a substrate analogue	805:824	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	4	34	theme	tuberculosis	493:504	arg1	domain					530:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	5	35	theme	protein	648:654	arg1	structure					606:614	The 1.6 Å X-ray structure	590:614	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein	590:654	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	4	36	theme	TNT	525:527	arg1	domain					530:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	7	37	theme	competing	1031:1039	arg1	microorganisms					1041:1054	the host or competing microorganisms	1019:1054	microorganisms	1041:1054	We propose that fungal NADases may convey advantages during interaction with the host or competing microorganisms.
33712585	2	38	theme	cell	308:311	arg1	death					313:317	rapid cell death	302:317	rapid cell death	302:317	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	6	39	from	those	879:883	arg1	mechanism					847:855	a catalytic mechanism	835:855	a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases	835:939	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	6	39	from	those	879:883	arg1	distinct					865:872	distinct	865:872	distinct	865:872	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	2	40	theme	NADase	217:222	arg1	enzymes					224:230	NADase enzymes	217:230	NADase enzymes	217:230	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	4	41	theme	toxin	518:522	arg1	domain					530:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	a tuberculosis necrotizing toxin (TNT) domain	491:535	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	5	42	theme	unique	664:669	arg1	site					734:737	a Ca2+-binding site	719:737	a Ca2+-binding site whose occupancy regulates activity	719:772	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	5	42	theme	unique	664:669	arg1	properties					671:680	unique properties	664:680	unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity	664:772	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	5	42	theme	unique	664:669	arg1	glycosylation					701:713	N-linked glycosylation	692:713	N-linked glycosylation	692:713	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	6	43	theme	catalytic	837:845	arg1	mechanism					847:855	a catalytic mechanism	835:855	a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases	835:939	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	6	43	theme	catalytic	837:845	arg1	distinct					865:872	distinct	865:872	distinct	865:872	The structure in complex with a substrate analogue suggests a catalytic mechanism that is distinct from those of known NADases, ADP-ribosyl cyclases and transferases.
33712585	3	44	theme	saprophyte	441:450	arg1	crassa					463:468	the saprophyte Neurospora crassa	437:468	the saprophyte Neurospora crassa	437:468	Here, we report the identification of NADases on the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa.
33712585	3	45	theme	Neurospora	452:461	arg1	crassa					463:468	the saprophyte Neurospora crassa	437:468	the saprophyte Neurospora crassa	437:468	Here, we report the identification of NADases on the surface of fungi such as the pathogen Aspergillus fumigatus and the saprophyte Neurospora crassa.
33712585	4	46	theme	pathogenic	570:579	arg1	species					581:587	pathogenic species	570:587	pathogenic species	570:587	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	2	47	theme	bacterial	189:197	arg1	pathogens					199:207	Various bacterial pathogens	181:207	Various bacterial pathogens	181:207	Various bacterial pathogens release NADase enzymes into the host cell that deplete the host's NAD+ pool, thereby causing rapid cell death.
33712585	4	48	attach	present	559:565	arg1	species					581:587	pathogenic species	570:587	pathogenic species	570:587	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	4	48	attach	present	559:565	arg2	enzymes					475:481	The enzymes	471:481	The enzymes	471:481	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	4	48	attach	present	559:565	arg2	present					559:565	present	559:565	present	559:565	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33712585	0	49	theme	pathogenic	61:70	arg1	species					72:78	pathogenic species	61:78	pathogenic species	61:78	Discovery of fungal surface NADases predominantly present in pathogenic species.
33712585	7	50	with	interaction	1002:1012	arg1	microorganisms					1041:1054	the host or competing microorganisms	1019:1054	microorganisms	1041:1054	We propose that fungal NADases may convey advantages during interaction with the host or competing microorganisms.
33712585	5	51	dep	A.	635:636	arg1	fumigatus					638:646	fumigatus	638:646	fumigatus	638:646	The 1.6 Å X-ray structure of the homodimeric A. fumigatus protein reveals unique properties including N-linked glycosylation and a Ca2+-binding site whose occupancy regulates activity.
33712585	4	52	from	present	559:565	arg1	species					581:587	pathogenic species	570:587	pathogenic species	570:587	The enzymes harbour a tuberculosis necrotizing toxin (TNT) domain and are predominately present in pathogenic species.
33912181	5	0	theme	MICs	704:707	arg1	ability					687:693	the ability	683:693	the ability of these MICs to induce macrophages to produce IL-10	683:746	Herein, we show that the ability of these MICs to induce macrophages to produce IL-10 depends on TLR4 internalization from the cell surface.
33912181	8	1	theme	MIC4-stimulated	1071:1085	arg1	macrophages					1087:1097	MIC1- or MIC4-stimulated macrophages	1062:1097	MIC1- or MIC4-stimulated macrophages	1062:1097	Furthermore, MIC1- or MIC4-stimulated macrophages gained transient tolerance to LPS.
33912181	4	2	theme	unknown	653:659	arg1	mechanisms					635:644	mechanisms	635:644	mechanisms as yet unknown	635:659	Interestingly, MIC1 and MIC4 also trigger secretion of the anti-inflammatory cytokine IL-10 through mechanisms as yet unknown.
33912181	6	3	theme	endocytosis	840:850	arg1	blockade					828:835	blockade	828:835	blockade of endocytosis by Dynasore	828:862	Macrophages subjected to blockade of endocytosis by Dynasore continued to release TNF-α, but failed to produce IL-10, in response to MIC1 or MIC4 exposure.
33912181	1	4	theme	host	166:169	arg1	responses					176:184	host cell responses	166:184	host cell responses	166:184	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	9	5	theme	undiscovered	1157:1168	arg1	mechanism					1170:1178	a previously undiscovered mechanism	1144:1178	a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response	1144:1258	We report a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response.
33912181	8	6	theme	transient	1106:1114	arg1	tolerance					1116:1124	transient tolerance	1106:1124	transient tolerance to LPS	1106:1131	Furthermore, MIC1- or MIC4-stimulated macrophages gained transient tolerance to LPS.
33912181	0	7	from	gondii	43:48	arg1	Proteins					10:17	Microneme Proteins 1 and 4	0:25	Microneme Proteins 1 and 4 From Toxoplasma gondii	0:48	Microneme Proteins 1 and 4 From Toxoplasma gondii Induce IL-10 Production by Macrophages Through TLR4 Endocytosis.
33912181	6	8	dep	MIC1	936:939	arg1	response					924:931	response	924:931	response	924:931	Macrophages subjected to blockade of endocytosis by Dynasore continued to release TNF-α, but failed to produce IL-10, in response to MIC1 or MIC4 exposure.
33912181	6	8	dep	MIC1	936:939	arg1	exposure					949:956	exposure	949:956	exposure	949:956	Macrophages subjected to blockade of endocytosis by Dynasore continued to release TNF-α, but failed to produce IL-10, in response to MIC1 or MIC4 exposure.
33912181	1	9	from	organelles	278:287	arg1	proteins					253:260	proteins	253:260	proteins from its apical organelles	253:287	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	1	10	theme	cell	171:174	arg1	responses					176:184	host cell responses	166:184	host cell responses	166:184	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	0	11	theme	TLR4	97:100	arg1	Endocytosis					102:112	TLR4 Endocytosis	97:112	TLR4 Endocytosis	97:112	Microneme Proteins 1 and 4 From Toxoplasma gondii Induce IL-10 Production by Macrophages Through TLR4 Endocytosis.
33912181	4	12	theme	anti-inflammatory	594:610	arg1	IL-10					621:625	the anti-inflammatory cytokine IL-10	590:625	the anti-inflammatory cytokine IL-10	590:625	Interestingly, MIC1 and MIC4 also trigger secretion of the anti-inflammatory cytokine IL-10 through mechanisms as yet unknown.
33912181	9	13	theme	host	1233:1236	arg1	response					1251:1258	a host inflammatory response	1231:1258	a host inflammatory response	1231:1258	We report a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response.
33912181	7	14	theme	Dynasore-conditioned	996:1015	arg1	macrophages					1036:1046	Dynasore-conditioned T. gondii-infected macrophages	996:1046	Dynasore-conditioned T. gondii-infected macrophages	996:1046	Similarly, IL-10 was not produced by Dynasore-conditioned T. gondii-infected macrophages.
33912181	3	15	from	glycans	454:460	arg1	TLR4					474:477	TLR4	474:477	TLR4	474:477	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	3	15	from	glycans	454:460	arg1	TLR2					465:468	TLR2	465:468	TLR2	465:468	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	0	16	theme	Microneme	0:8	arg1	Proteins					10:17	Microneme Proteins 1 and 4	0:25	Microneme Proteins 1 and 4 From Toxoplasma gondii	0:48	Microneme Proteins 1 and 4 From Toxoplasma gondii Induce IL-10 Production by Macrophages Through TLR4 Endocytosis.
33912181	7	17	theme	T.	1017:1018	arg1	macrophages					1036:1046	Dynasore-conditioned T. gondii-infected macrophages	996:1046	Dynasore-conditioned T. gondii-infected macrophages	996:1046	Similarly, IL-10 was not produced by Dynasore-conditioned T. gondii-infected macrophages.
33912181	7	18	theme	gondii-infected	1020:1034	arg1	macrophages					1036:1046	Dynasore-conditioned T. gondii-infected macrophages	996:1046	Dynasore-conditioned T. gondii-infected macrophages	996:1046	Similarly, IL-10 was not produced by Dynasore-conditioned T. gondii-infected macrophages.
33912181	4	19	theme	IL-10	621:625	arg1	secretion					577:585	secretion	577:585	secretion of the anti-inflammatory cytokine IL-10	577:625	Interestingly, MIC1 and MIC4 also trigger secretion of the anti-inflammatory cytokine IL-10 through mechanisms as yet unknown.
33912181	1	20	theme	apical	271:276	arg1	organelles					278:287	its apical organelles	267:287	its apical organelles	267:287	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	2	21	dep	proteins	334:341	arg1	4					356:356	4	356:356	4	356:356	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	2	21	dep	proteins	334:341	arg1	1					350:350	1	350:350	1	350:350	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	5	22	theme	TLR4	759:762	arg1	internalization					764:778	TLR4 internalization	759:778	TLR4 internalization from the cell surface	759:800	Herein, we show that the ability of these MICs to induce macrophages to produce IL-10 depends on TLR4 internalization from the cell surface.
33912181	2	23	theme	cell	389:392	arg1	responses					394:402	pro-inflammatory host cell responses	367:402	pro-inflammatory host cell responses	367:402	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	9	24	theme	well-defined	1189:1200	arg1	components					1212:1221	well-defined T. gondii components	1189:1221	well-defined T. gondii components	1189:1221	We report a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response.
33912181	2	25	theme	host	384:387	arg1	responses					394:402	pro-inflammatory host cell responses	367:402	pro-inflammatory host cell responses	367:402	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	4	26	theme	cytokine	612:619	arg1	IL-10					621:625	the anti-inflammatory cytokine IL-10	590:625	the anti-inflammatory cytokine IL-10	590:625	Interestingly, MIC1 and MIC4 also trigger secretion of the anti-inflammatory cytokine IL-10 through mechanisms as yet unknown.
33912181	9	27	theme	T.	1202:1203	arg1	components					1212:1221	well-defined T. gondii components	1189:1221	well-defined T. gondii components	1189:1221	We report a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response.
33912181	2	28	theme	pro-inflammatory	367:382	arg1	responses					394:402	pro-inflammatory host cell responses	367:402	pro-inflammatory host cell responses	367:402	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	3	29	link	N-linked	445:452	arg1	glycans					454:460	N-linked glycans	445:460	N-linked glycans on TLR2 and TLR4	445:477	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	3	30	dep	lectins	409:415	arg1	lectins					409:415	The lectins MIC1 and MIC4	405:429	The lectins MIC1 and MIC4	405:429	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	3	30	dep	lectins	409:415	arg1	MIC4					426:429	MIC4	426:429	MIC4	426:429	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	3	30	dep	lectins	409:415	arg1	MIC1					417:420	MIC1	417:420	MIC1	417:420	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	0	31	theme	Toxoplasma	32:41	arg1	gondii					43:48	Toxoplasma gondii	32:48	Toxoplasma gondii	32:48	Microneme Proteins 1 and 4 From Toxoplasma gondii Induce IL-10 Production by Macrophages Through TLR4 Endocytosis.
33912181	2	32	theme	microneme	324:332	arg1	MICs					344:347	MICs	344:347	MICs	344:347	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	2	32	theme	microneme	324:332	arg1	proteins					334:341	microneme proteins	324:341	microneme proteins (MICs) 1 and 4	324:356	Some of these proteins, including microneme proteins (MICs) 1 and 4, trigger pro-inflammatory host cell responses.
33912181	8	33	theme	MIC1-	1062:1066	arg1	macrophages					1087:1097	MIC1- or MIC4-stimulated macrophages	1062:1097	MIC1- or MIC4-stimulated macrophages	1062:1097	Furthermore, MIC1- or MIC4-stimulated macrophages gained transient tolerance to LPS.
33912181	1	34	from	success	199:205	arg1	stage					220:224	the early stage	210:224	the early stage of infections	210:238	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	1	35	theme	protozoan	119:127	arg1	gondii					149:154	The protozoan parasite Toxoplasma gondii	115:154	The protozoan parasite Toxoplasma gondii	115:154	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	1	36	theme	early	214:218	arg1	stage					220:224	the early stage	210:224	the early stage of infections	210:238	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	1	37	theme	parasite	129:136	arg1	gondii					149:154	The protozoan parasite Toxoplasma gondii	115:154	The protozoan parasite Toxoplasma gondii	115:154	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	3	38	theme	N-linked	445:452	arg1	glycans					454:460	N-linked glycans	445:460	N-linked glycans on TLR2 and TLR4	445:477	The lectins MIC1 and MIC4 interact with N-linked glycans on TLR2 and TLR4, activating NF-κB and producing IL-12, TNF-α, and IL-6.
33912181	0	39	theme	IL-10	57:61	arg1	Production					63:72	IL-10 Production	57:72	IL-10 Production by Macrophages	57:87	Microneme Proteins 1 and 4 From Toxoplasma gondii Induce IL-10 Production by Macrophages Through TLR4 Endocytosis.
33912181	5	40	theme	cell	789:792	arg1	surface					794:800	the cell surface	785:800	the cell surface	785:800	Herein, we show that the ability of these MICs to induce macrophages to produce IL-10 depends on TLR4 internalization from the cell surface.
33912181	1	41	theme	Toxoplasma	138:147	arg1	gondii					149:154	The protozoan parasite Toxoplasma gondii	115:154	The protozoan parasite Toxoplasma gondii	115:154	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33912181	9	42	theme	inflammatory	1238:1249	arg1	response					1251:1258	a host inflammatory response	1231:1258	a host inflammatory response	1231:1258	We report a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response.
33912181	5	43	from	surface	794:800	arg1	internalization					764:778	TLR4 internalization	759:778	TLR4 internalization from the cell surface	759:800	Herein, we show that the ability of these MICs to induce macrophages to produce IL-10 depends on TLR4 internalization from the cell surface.
33912181	9	44	dep	T.	1202:1203	arg1	gondii					1205:1210	gondii	1205:1210	gondii	1205:1210	We report a previously undiscovered mechanism by which well-defined T. gondii components inhibit a host inflammatory response.
33912181	1	45	theme	infections	229:238	arg1	stage					220:224	the early stage	210:224	the early stage of infections	210:238	The protozoan parasite Toxoplasma gondii modulates host cell responses to favor its success in the early stage of infections by secreting proteins from its apical organelles.
33244686	1	0	theme	glycosylation	306:318	arg1	s					325:325	multiple glycosylation site(s)	297:326	multiple glycosylation site(s)	297:326	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	7	1	theme	low-level	1937:1945	arg1	O-glycosylation					1947:1961	low-level O-glycosylation	1937:1961	low-level O-glycosylation	1937:1961	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	3	2	theme	better	619:624	arg1	identification					639:652	better glycopeptide identification	619:652	better glycopeptide identification	619:652	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	6	3	theme	Fc-domain	1653:1661	arg1	protein					1670:1676	an Fc-domain fusion protein	1650:1676	an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode	1650:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	3	theme	Fc-domain	1653:1661	arg1	meanwhile					1785:1793	meanwhile	1785:1793	meanwhile	1785:1793	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	5	4	theme	detection	1291:1299	arg1	sensitivity					1301:1311	the MS detection sensitivity	1284:1311	the MS detection sensitivity for glycopeptides up to ~ 50-fold	1284:1345	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	2	5	theme	different	440:448	arg1	stages					450:455	different stages	440:455	different stages of drug development	440:475	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	4	6	theme	spectrometry	947:958	arg1	detection					965:973	mass spectrometry (MS) detection	942:973	mass spectrometry (MS) detection	942:973	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	3	7	theme	mobile	853:858	arg1	phases					860:865	the mobile phases	849:865	the mobile phases with ion-pairing agents (IP-HILIC)	849:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	1	8	theme	fusion	233:238	arg1	proteins					240:247	Fc-domain fusion proteins	223:247	Fc-domain fusion proteins	223:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	5	9	dep	~ 50-fold	1337:1345	arg1	up					1331:1332	up	1331:1332	up	1331:1332	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	2	10	theme	glycan	343:348	arg1	characterization					358:373	Site-specific glycan profile characterization	329:373	Site-specific glycan profile characterization	329:373	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	6	11	theme	IgG4	1629:1632	arg1	mAbs					1634:1637	IgG4 mAbs	1629:1637	IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile,	1629:1794	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	7	12	gly	O-glycosylation	1947:1961	arg1	mAbs					2000:2003	mAbs	2000:2003	mAbs	2000:2003	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	4	13	theme	spectrometry	1015:1026	arg1	signal					1028:1033	mass spectrometry signal	1010:1033	mass spectrometry signal	1010:1033	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	1	14	theme	glycan	271:276	arg1	contents					278:285	heterogeneous glycan contents	257:285	heterogeneous glycan contents	257:285	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	6	15	theme	comparable	1804:1813	arg1	results					1828:1834	comparable quantitative results	1804:1834	comparable quantitative results	1804:1834	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	3	16	theme	effective	665:673	arg1	separation					675:684	the effective separation	661:684	the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC)	661:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	6	17	theme	N-glycosylation	1695:1709	arg1	sites					1711:1715	five N-glycosylation sites	1690:1715	five N-glycosylation sites	1690:1715	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	18	link	N-linked	1598:1605	arg1	glycans					1607:1613	site-specific N-linked glycans	1584:1613	site-specific N-linked glycans	1584:1613	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	5	19	theme	MS	1288:1289	arg1	sensitivity					1301:1311	the MS detection sensitivity	1284:1311	the MS detection sensitivity for glycopeptides up to ~ 50-fold	1284:1345	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	5	20	theme	ion-suppression	1366:1380	arg1	effect					1382:1387	the ion-suppression effect	1362:1387	the ion-suppression effect of an ion-pairing agent	1362:1411	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	8	21	dep	abstract	2063:2070	arg1	Graphical					2053:2061	Graphical	2053:2061	Graphical	2053:2061	Graphical abstract.
33244686	6	22	theme	enhanced	1492:1499	arg1	sensitivity					1511:1521	enhanced detection sensitivity	1492:1521	enhanced detection sensitivity	1492:1521	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	4	23	theme	trifluoroacetic	1077:1091	arg1	TFA					1099:1101	TFA	1099:1101	TFA	1099:1101	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	4	23	theme	trifluoroacetic	1077:1091	arg1	acid					1093:1096	the trifluoroacetic acid	1073:1096	the trifluoroacetic acid (TFA)	1073:1102	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	0	24	theme	hydrophilic	104:114	arg1	chromatography					128:141	hydrophilic interaction chromatography	104:141	hydrophilic interaction chromatography mass spectrometry	104:159	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	0	25	theme	chromatography	128:141	arg1	spectrometry					148:159	hydrophilic interaction chromatography mass spectrometry	104:159	hydrophilic interaction chromatography mass spectrometry	104:159	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	6	26	theme	data-dependent	1752:1765	arg1	mode					1779:1782	the data-dependent acquisition mode	1748:1782	the data-dependent acquisition mode	1748:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	27	theme	traditional	1854:1864	arg1	methods					1866:1872	the traditional methods	1850:1872	the traditional methods	1850:1872	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	5	28	gly	glycopeptides	1317:1329	arg2	glycopeptides					1317:1329	glycopeptides	1317:1329	glycopeptides	1317:1329	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	6	29	gly	N-glycosylation	1695:1709	arg2	sites					1711:1715	five N-glycosylation sites	1690:1715	five N-glycosylation sites	1690:1715	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	29	gly	N-glycosylation	1695:1709	arg2	five					1690:1693	five	1690:1693	five	1690:1693	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	3	30	dep	agents	884:889	arg1	IP-HILIC					892:899	IP-HILIC	892:899	IP-HILIC	892:899	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	1	31	gly	glycosylation	306:318	arg2	s					325:325	multiple glycosylation site(s)	297:326	multiple glycosylation site(s)	297:326	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	31	gly	glycosylation	306:318	arg2	site					320:323	multiple glycosylation site(s)	297:326	multiple glycosylation site(s)	297:326	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	5	32	theme	separation	1445:1454	arg1	capacity					1456:1463	excellent separation capacity	1435:1463	excellent separation capacity	1435:1463	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	3	33	theme	interaction	490:500	arg1	HILIC					518:522	HILIC	518:522	HILIC	518:522	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	33	theme	interaction	490:500	arg1	chromatography					502:515	Hydrophilic interaction chromatography	478:515	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC)	478:605	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	5	34	theme	TFA-containing	1244:1257	arg1	phases					1266:1271	the TFA-containing mobile phases	1240:1271	the TFA-containing mobile phases	1240:1271	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	6	35	theme	MS/MS-based	1726:1736	arg1	search					1738:1743	MS/MS-based search	1726:1743	MS/MS-based search	1726:1743	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	7	36	from	N-glycosylation	1981:1995	arg1	mAbs					2000:2003	mAbs	2000:2003	mAbs	2000:2003	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	5	37	theme	ion-pairing	1395:1405	arg1	agent					1407:1411	an ion-pairing agent	1392:1411	an ion-pairing agent	1392:1411	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	6	38	from	mAbs	1634:1637	arg1	mode					1779:1782	the data-dependent acquisition mode	1748:1782	the data-dependent acquisition mode	1748:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	39	from	protein	1670:1676	arg1	mode					1779:1782	the data-dependent acquisition mode	1748:1782	the data-dependent acquisition mode	1748:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	2	40	theme	development	465:475	arg1	stages					450:455	different stages	440:455	different stages of drug development	440:475	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	7	41	theme	LC-MS	2037:2041	arg1	analysis					2043:2050	LC-MS analysis	2037:2050	LC-MS analysis	2037:2050	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	3	42	theme	non-glycosylated	779:794	arg1	peptides					796:803	high-abundance non-glycosylated peptides	764:803	high-abundance non-glycosylated peptides	764:803	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	43	theme	separation	542:551	arg1	method					553:558	an orthogonal separation method	528:558	an orthogonal separation method	528:558	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	7	44	theme	prior	2028:2032	arg1	enrichment					2017:2026	any enrichment	2013:2026	any enrichment prior to LC-MS analysis	2013:2050	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	7	45	theme	non-consensus	1967:1979	arg1	N-glycosylation					1981:1995	non-consensus N-glycosylation	1967:1995	non-consensus N-glycosylation	1967:1995	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	2	46	theme	molecules	423:431	arg1	quality					406:412	the quality	402:412	the quality of these molecules	402:431	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	6	47	theme	glycans	1607:1613	arg1	number					1574:1579	an increased number	1561:1579	an increased number of site-specific N-linked glycans for IgG1	1561:1622	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	4	48	theme	ion-pairing	1125:1135	arg1	agent					1137:1141	an ion-pairing agent	1122:1141	an ion-pairing agent	1122:1141	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	3	49	gly	glycopeptides	745:757	arg2	glycopeptides					745:757	glycopeptides	745:757	glycopeptides	745:757	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	50	theme	liquid	578:583	arg1	chromatography					585:598	reversed-phase liquid chromatography	563:598	reversed-phase liquid chromatography (RPLC)	563:605	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	50	theme	liquid	578:583	arg1	RPLC					601:604	RPLC	601:604	RPLC	601:604	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	6	51	theme	site-specific	1584:1596	arg1	glycans					1607:1613	site-specific N-linked glycans	1584:1613	site-specific N-linked glycans	1584:1613	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	1	52	theme	multiple	297:304	arg1	s					325:325	multiple glycosylation site(s)	297:326	multiple glycosylation site(s)	297:326	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	2	53	theme	Site-specific	329:341	arg1	characterization					358:373	Site-specific glycan profile characterization	329:373	Site-specific glycan profile characterization	329:373	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	1	54	theme	site	320:323	arg1	s					325:325	multiple glycosylation site(s)	297:326	multiple glycosylation site(s)	297:326	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	7	55	used	used	1920:1923	arg2	IP-HILIC-MS					1901:1911	IP-HILIC-MS	1901:1911	IP-HILIC-MS	1901:1911	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	1	56	theme	Fc-domain	223:231	arg1	proteins					240:247	Fc-domain fusion proteins	223:247	Fc-domain fusion proteins	223:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	7	57	gly	N-glycosylation	1981:1995	arg1	mAbs					2000:2003	mAbs	2000:2003	mAbs	2000:2003	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	4	58	theme	mass	942:945	arg1	MS					961:962	MS	961:962	MS	961:962	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	4	58	theme	mass	942:945	arg1	spectrometry					947:958	mass spectrometry	942:958	mass spectrometry (MS) detection	942:973	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	2	59	theme	profile	350:356	arg1	characterization					358:373	Site-specific glycan profile characterization	329:373	Site-specific glycan profile characterization	329:373	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	3	60	from	peptides	796:803	arg1	separation					675:684	the effective separation	661:684	the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC)	661:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	60	from	peptides	796:803	arg1	separation					731:740	the separation	727:740	the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC)	661:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	1	61	theme	heterogeneous	257:269	arg1	contents					278:285	heterogeneous glycan contents	257:285	heterogeneous glycan contents	257:285	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	4	62	theme	mass	1010:1013	arg1	spectrometry					1015:1026	mass spectrometry	1010:1026	mass spectrometry signal	1010:1033	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	6	63	theme	quantitative	1815:1826	arg1	results					1828:1834	comparable quantitative results	1804:1834	comparable quantitative results	1804:1834	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	1	64	theme	Many	162:165	arg1	antibodies					202:211	monoclonal antibodies	191:211	monoclonal antibodies (mAb)	191:217	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	64	theme	Many	162:165	arg1	biotherapeutics					167:181	Many biotherapeutics	162:181	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins	162:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	64	theme	Many	162:165	arg1	proteins					240:247	Fc-domain fusion proteins	223:247	Fc-domain fusion proteins	223:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	6	65	contain	containing	1679:1688	arg2	sites					1711:1715	five N-glycosylation sites	1690:1715	five N-glycosylation sites	1690:1715	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	65	contain	containing	1679:1688	arg1	protein					1670:1676	an Fc-domain fusion protein	1650:1676	an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode	1650:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	65	contain	containing	1679:1688	arg1	meanwhile					1785:1793	meanwhile	1785:1793	meanwhile	1785:1793	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	3	66	theme	ion-pairing	872:882	arg1	agents					884:889	ion-pairing agents	872:889	ion-pairing agents (IP-HILIC)	872:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	67	theme	glycopeptide	626:637	arg1	identification					639:652	better glycopeptide identification	619:652	better glycopeptide identification	619:652	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	68	gly	glycopeptide	626:637	arg2	glycopeptide					626:637	better glycopeptide identification	619:652	better glycopeptide identification	619:652	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	6	69	theme	detection	1501:1509	arg1	sensitivity					1511:1521	enhanced detection sensitivity	1492:1521	enhanced detection sensitivity	1492:1521	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	3	70	theme	individual	694:703	arg1	glycoforms					705:714	individual glycoforms	694:714	individual glycoforms	694:714	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	1	71	theme	monoclonal	191:200	arg1	antibodies					202:211	monoclonal antibodies	191:211	monoclonal antibodies (mAb)	191:217	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	71	theme	monoclonal	191:200	arg1	mAb					214:216	mAb	214:216	mAb	214:216	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	0	72	theme	interaction	116:126	arg1	chromatography					128:141	hydrophilic interaction chromatography	104:141	hydrophilic interaction chromatography mass spectrometry	104:159	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	6	73	theme	fusion	1663:1668	arg1	protein					1670:1676	an Fc-domain fusion protein	1650:1676	an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode	1650:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	73	theme	fusion	1663:1668	arg1	meanwhile					1785:1793	meanwhile	1785:1793	meanwhile	1785:1793	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	1	74	contain	contain	249:255	arg2	biotherapeutics					167:181	Many biotherapeutics	162:181	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins	162:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg1	one					290:292	one	290:292	one	290:292	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg1	antibodies					202:211	monoclonal antibodies	191:211	monoclonal antibodies (mAb)	191:217	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg1	s					325:325	multiple glycosylation site(s)	297:326	multiple glycosylation site(s)	297:326	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg1	proteins					240:247	Fc-domain fusion proteins	223:247	Fc-domain fusion proteins	223:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg2	antibodies					202:211	monoclonal antibodies	191:211	monoclonal antibodies (mAb)	191:217	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg1	biotherapeutics					167:181	Many biotherapeutics	162:181	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins	162:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg2	contents					278:285	heterogeneous glycan contents	257:285	heterogeneous glycan contents	257:285	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	1	74	contain	contain	249:255	arg2	proteins					240:247	Fc-domain fusion proteins	223:247	Fc-domain fusion proteins	223:247	Many biotherapeutics such as monoclonal antibodies (mAb) and Fc-domain fusion proteins contain heterogeneous glycan contents at one or multiple glycosylation site(s).
33244686	0	75	theme	mass	143:146	arg1	spectrometry					148:159	hydrophilic interaction chromatography mass spectrometry	104:159	hydrophilic interaction chromatography mass spectrometry	104:159	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	6	76	theme	acquisition	1767:1777	arg1	mode					1779:1782	the data-dependent acquisition mode	1748:1782	the data-dependent acquisition mode	1748:1782	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	4	77	theme	signal	1028:1033	arg1	suppression					995:1005	the suppression	991:1005	the suppression of mass spectrometry signal	991:1033	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	5	78	theme	optimized	1165:1173	arg1	condition					1188:1196	an optimized experimental condition	1162:1196	an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity	1162:1463	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	7	79	from	O-glycosylation	1947:1961	arg1	mAbs					2000:2003	mAbs	2000:2003	mAbs	2000:2003	We also demonstrated that IP-HILIC-MS can be used to identify low-level O-glycosylation and non-consensus N-glycosylation on mAbs without any enrichment prior to LC-MS analysis.
33244686	4	80	theme	electrospray	1042:1053	arg1	ionization					1055:1064	electrospray ionization	1042:1064	electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent	1042:1141	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	5	81	theme	excellent	1435:1443	arg1	capacity					1456:1463	excellent separation capacity	1435:1463	excellent separation capacity	1435:1463	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	0	82	theme	additive	8:15	arg1	Glycine					0:6	Glycine additive	0:15	Glycine additive	0:15	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	0	83	theme	site-specific	29:41	arg1	glycosylation					43:55	site-specific glycosylation profiling	29:65	site-specific glycosylation profiling of biopharmaceuticals	29:87	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	5	84	theme	mobile	1259:1264	arg1	phases					1266:1271	the TFA-containing mobile phases	1240:1271	the TFA-containing mobile phases	1240:1271	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	3	85	with	phases	860:865	arg1	agents					884:889	ion-pairing agents	872:889	ion-pairing agents (IP-HILIC)	872:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	5	86	theme	agent	1407:1411	arg1	effect					1382:1387	the ion-suppression effect	1362:1387	the ion-suppression effect of an ion-pairing agent	1362:1411	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	3	87	theme	orthogonal	531:540	arg1	method					553:558	an orthogonal separation method	528:558	an orthogonal separation method	528:558	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	0	88	theme	profiling	57:65	arg1	glycosylation					43:55	site-specific glycosylation profiling	29:65	site-specific glycosylation profiling of biopharmaceuticals	29:87	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	3	89	theme	Hydrophilic	478:488	arg1	HILIC					518:522	HILIC	518:522	HILIC	518:522	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	89	theme	Hydrophilic	478:488	arg1	chromatography					502:515	Hydrophilic interaction chromatography	478:515	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC)	478:605	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	2	90	theme	drug	460:463	arg1	development					465:475	drug development	460:475	drug development	460:475	Site-specific glycan profile characterization is critical for monitoring the quality of these molecules during different stages of drug development.
33244686	0	91	theme	biopharmaceuticals	70:87	arg1	glycosylation					43:55	site-specific glycosylation profiling	29:65	site-specific glycosylation profiling of biopharmaceuticals	29:87	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	5	92	theme	experimental	1175:1186	arg1	condition					1188:1196	an optimized experimental condition	1162:1196	an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity	1162:1463	Here, we reported an optimized experimental condition for IP-HILIC-MS where glycine is added in the TFA-containing mobile phases to enhance the MS detection sensitivity for glycopeptides up to ~ 50-fold by eliminating the ion-suppression effect of an ion-pairing agent while still retaining excellent separation capacity.
33244686	3	93	theme	high-abundance	764:777	arg1	peptides					796:803	high-abundance non-glycosylated peptides	764:803	high-abundance non-glycosylated peptides	764:803	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	4	94	theme	online	915:920	arg1	IP-HILIC					922:929	an online IP-HILIC	912:929	an online IP-HILIC coupled to mass spectrometry (MS) detection	912:973	However, an online IP-HILIC coupled to mass spectrometry (MS) detection may suffer from the suppression of mass spectrometry signal during electrospray ionization due to the trifluoroacetic acid (TFA), commonly used as an ion-pairing agent.
33244686	3	95	theme	reversed-phase	563:576	arg1	chromatography					585:598	reversed-phase liquid chromatography	563:598	reversed-phase liquid chromatography (RPLC)	563:605	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	95	theme	reversed-phase	563:576	arg1	RPLC					601:604	RPLC	601:604	RPLC	601:604	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	0	96	gly	glycosylation	43:55	arg1	biopharmaceuticals					70:87	biopharmaceuticals	70:87	biopharmaceuticals	70:87	Glycine additive facilitates site-specific glycosylation profiling of biopharmaceuticals by ion-pairing hydrophilic interaction chromatography mass spectrometry.
33244686	3	97	gly	non-glycosylated	779:794	arg1	peptides					796:803	high-abundance non-glycosylated peptides	764:803	high-abundance non-glycosylated peptides	764:803	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	98	theme	glycopeptides	745:757	arg1	separation					675:684	the effective separation	661:684	the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC)	661:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	3	98	theme	glycopeptides	745:757	arg1	separation					731:740	the separation	727:740	the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC)	661:900	Hydrophilic interaction chromatography (HILIC) as an orthogonal separation method to reversed-phase liquid chromatography (RPLC) can achieve better glycopeptide identification due to the effective separation between individual glycoforms as well as the separation of glycopeptides from high-abundance non-glycosylated peptides, which can be further improved by modifying the mobile phases with ion-pairing agents (IP-HILIC).
33244686	6	99	theme	increased	1564:1572	arg1	number					1574:1579	an increased number	1561:1579	an increased number of site-specific N-linked glycans for IgG1	1561:1622	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
33244686	6	100	theme	N-linked	1598:1605	arg1	glycans					1607:1613	site-specific N-linked glycans	1584:1613	site-specific N-linked glycans	1584:1613	We demonstrated that with enhanced detection sensitivity, IP-HILIC-MS can confidently identify an increased number of site-specific N-linked glycans for IgG1, and IgG4 mAbs as well as an Fc-domain fusion protein (containing five N-glycosylation sites) through MS/MS-based search in the data-dependent acquisition mode, meanwhile, achieve comparable quantitative results compared with the traditional methods.
32943699	3	0	theme	nano-LC-ESI-Qq-TOF	739:756	arg1	analysis					776:783	nano-LC-ESI-Qq-TOF mass spectrometry analysis	739:783	nano-LC-ESI-Qq-TOF mass spectrometry analysis	739:783	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	2	1	theme	glycosylation	604:616	arg1	patterns					618:625	antibody glycosylation patterns	595:625	antibody glycosylation patterns	595:625	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	1	2	theme	passive	248:254	arg1	immunity					256:263	passive immunity	248:263	passive immunity	248:263	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	2	3	theme	region	482:487	arg1	glycosylation					458:470	N-linked glycosylation	449:470	N-linked glycosylation of the Fc region	449:487	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	3	4	theme	glycosylation	690:702	arg1	profile					704:710	the murine IgG Fc glycosylation profile	672:710	the murine IgG Fc glycosylation profile during early life	672:728	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	2	5	theme	antibody	595:602	arg1	patterns					618:625	antibody glycosylation patterns	595:625	antibody glycosylation patterns	595:625	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	3	6	theme	age	890:892	arg1	5-60 days					877:885	5-60 days	877:885	5-60 days of age	877:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	3	7	theme	BALB/c	860:865	arg1	mice					867:870	BALB/c mice	860:870	BALB/c mice	860:870	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	0	8	theme	murine	98:103	arg1	system					112:117	the murine immune system	94:117	the murine immune system	94:117	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	0	9	from	Changes	0:6	arg1	glycosylation					36:48	subclass-specific IgG Fc glycosylation	11:48	subclass-specific IgG Fc glycosylation	11:48	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	7	10	theme	glycosylation	1408:1420	arg1	importance					1387:1396	the importance	1383:1396	the importance of IgG Fc glycosylation	1383:1420	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	7	10	theme	glycosylation	1408:1420	arg1	association					1430:1440	its association	1426:1440	its association with inflammation	1426:1458	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	5	11	theme	agalactosylated	1041:1055	arg1	structures					1080:1089	significantly reduced agalactosylated and monogalactosylated structures	1019:1089	significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age	1019:1164	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	3	12	used	used	734:737	arg2	we					731:732	we	731:732	we	731:732	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	4	13	theme	proinflammatory	945:959	arg1	glycosylation					964:976	proinflammatory Fc glycosylation	945:976	proinflammatory Fc glycosylation in all IgG subclasses	945:998	From birth to adulthood, we observed a decline in proinflammatory Fc glycosylation in all IgG subclasses.
32943699	1	14	theme	immune	350:355	arg1	system					357:362	a fully functioning immune system	330:362	a fully functioning immune system	330:362	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	2	15	link	N-linked	449:456	arg1	glycosylation					458:470	N-linked glycosylation	449:470	N-linked glycosylation of the Fc region	449:487	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	6	16	theme	neonatal	1222:1229	arg1	life					1231:1234	neonatal life	1222:1234	neonatal life	1222:1234	This information indicates that the transition between neonatal life and adulthood in mice is accompanied by reduction of inflammatory IgG antibodies.
32943699	0	17	theme	system	112:117	arg1	maturation					80:89	the postnatal maturation	66:89	the postnatal maturation of the murine immune system	66:117	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	1	18	theme	system	357:362	arg1	competence					316:325	the competence	312:325	the competence of a fully functioning immune system	312:362	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	2	19	theme	postnatal	640:648	arg1	life					650:653	early postnatal life	634:653	early postnatal life	634:653	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	7	20	theme	different	1467:1475	arg1	stages					1482:1487	different life stages	1467:1487	different life stages	1467:1487	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	7	21	theme	life	1477:1480	arg1	stages					1482:1487	different life stages	1467:1487	different life stages	1467:1487	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	6	22	from	transition	1203:1212	arg1	mice					1253:1256	mice	1253:1256	mice	1253:1256	This information indicates that the transition between neonatal life and adulthood in mice is accompanied by reduction of inflammatory IgG antibodies.
32943699	1	23	theme	critical	163:170	arg1	period					177:182	a critical time period	161:182	a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system	161:362	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	0	24	theme	immune	105:110	arg1	system					112:117	the murine immune system	94:117	the murine immune system	94:117	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	2	25	theme	early	634:638	arg1	life					650:653	early postnatal life	634:653	early postnatal life	634:653	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	1	26	theme	time	172:175	arg1	period					177:182	a critical time period	161:182	a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system	161:362	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	2	27	theme	N-linked	449:456	arg1	glycosylation					458:470	N-linked glycosylation	449:470	N-linked glycosylation of the Fc region	449:487	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	6	28	theme	inflammatory	1289:1300	arg1	antibodies					1306:1315	inflammatory IgG antibodies	1289:1315	inflammatory IgG antibodies	1289:1315	This information indicates that the transition between neonatal life and adulthood in mice is accompanied by reduction of inflammatory IgG antibodies.
32943699	4	29	theme	IgG	985:987	arg1	subclasses					989:998	all IgG subclasses	981:998	all IgG subclasses	981:998	From birth to adulthood, we observed a decline in proinflammatory Fc glycosylation in all IgG subclasses.
32943699	4	30	theme	Fc	961:962	arg1	glycosylation					964:976	proinflammatory Fc glycosylation	945:976	proinflammatory Fc glycosylation in all IgG subclasses	945:998	From birth to adulthood, we observed a decline in proinflammatory Fc glycosylation in all IgG subclasses.
32943699	3	31	theme	spectrometry	763:774	arg1	analysis					776:783	nano-LC-ESI-Qq-TOF mass spectrometry analysis	739:783	nano-LC-ESI-Qq-TOF mass spectrometry analysis	739:783	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	3	32	theme	murine	676:681	arg1	profile					704:710	the murine IgG Fc glycosylation profile	672:710	the murine IgG Fc glycosylation profile during early life	672:728	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	5	33	theme	monogalactosylated	1061:1078	arg1	structures					1080:1089	significantly reduced agalactosylated and monogalactosylated structures	1019:1089	significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age	1019:1164	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	2	34	theme	inflammatory	369:380	arg1	capability					382:391	The inflammatory capability	365:391	The inflammatory capability of both maternal and neonatal antibodies	365:432	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	0	35	theme	IgG	29:31	arg1	glycosylation					36:48	subclass-specific IgG Fc glycosylation	11:48	subclass-specific IgG Fc glycosylation	11:48	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	1	36	theme	protective	277:286	arg1	antibodies					297:306	protective maternal antibodies	277:306	protective maternal antibodies	277:306	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	3	37	from	5-60 days	877:885	arg1	patterns					835:842	subclass specific Asn-297 glycosylation patterns	795:842	subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age	795:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	3	37	from	5-60 days	877:885	arg1	serum					851:855	the serum	847:855	the serum of BALB/c mice from 5-60 days of age	847:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	2	38	theme	antibodies	423:432	arg1	capability					382:391	The inflammatory capability	365:391	The inflammatory capability of both maternal and neonatal antibodies	365:432	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	0	39	theme	subclass-specific	11:27	arg1	glycosylation					36:48	subclass-specific IgG Fc glycosylation	11:48	subclass-specific IgG Fc glycosylation	11:48	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	1	40	theme	maternal	288:295	arg1	antibodies					297:306	protective maternal antibodies	277:306	protective maternal antibodies	277:306	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	5	41	theme	increased	1105:1113	arg1	sialylation					1115:1125	increased sialylation	1105:1125	increased sialylation after weaning at 45 and 60 days of age	1105:1164	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	2	42	theme	neonatal	414:421	arg1	antibodies					423:432	both maternal and neonatal antibodies	396:432	both maternal and neonatal antibodies	396:432	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	2	43	theme	Fc	479:480	arg1	region					482:487	the Fc region	475:487	the Fc region	475:487	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	3	44	theme	mass	758:761	arg1	analysis					776:783	nano-LC-ESI-Qq-TOF mass spectrometry analysis	739:783	nano-LC-ESI-Qq-TOF mass spectrometry analysis	739:783	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	4	45	from	decline	934:940	arg1	glycosylation					964:976	proinflammatory Fc glycosylation	945:976	proinflammatory Fc glycosylation in all IgG subclasses	945:998	From birth to adulthood, we observed a decline in proinflammatory Fc glycosylation in all IgG subclasses.
32943699	7	46	theme	literature	1361:1370	arg1	body					1353:1356	a growing body	1343:1356	a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages	1343:1487	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	1	47	theme	developing	197:206	arg1	system					224:229	the developing neonatal immune system	193:229	the developing neonatal immune system	193:229	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	0	48	theme	Fc	33:34	arg1	glycosylation					36:48	subclass-specific IgG Fc glycosylation	11:48	subclass-specific IgG Fc glycosylation	11:48	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	3	49	theme	subclass	795:802	arg1	patterns					835:842	subclass specific Asn-297 glycosylation patterns	795:842	subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age	795:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	4	50	from	glycosylation	964:976	arg1	subclasses					989:998	all IgG subclasses	981:998	all IgG subclasses	981:998	From birth to adulthood, we observed a decline in proinflammatory Fc glycosylation in all IgG subclasses.
32943699	5	51	theme	reduced	1033:1039	arg1	structures					1080:1089	significantly reduced agalactosylated and monogalactosylated structures	1019:1089	significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age	1019:1164	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	7	52	with	association	1430:1440	arg1	inflammation					1447:1458	inflammation	1447:1458	inflammation	1447:1458	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	1	53	theme	neonatal	208:215	arg1	system					224:229	the developing neonatal immune system	193:229	the developing neonatal immune system	193:229	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	3	54	theme	specific	804:811	arg1	patterns					835:842	subclass specific Asn-297 glycosylation patterns	795:842	subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age	795:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	2	55	theme	little	566:571	arg1	information					573:583	little information	566:583	little information regarding antibody glycosylation patterns during early postnatal life	566:653	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	2	56	gly	glycosylation	458:470	arg1	region					482:487	the Fc region	475:487	the Fc region	475:487	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	1	57	theme	functioning	338:348	arg1	system					357:362	a fully functioning immune system	330:362	a fully functioning immune system	330:362	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	3	58	theme	IgG	683:685	arg1	profile					704:710	the murine IgG Fc glycosylation profile	672:710	the murine IgG Fc glycosylation profile during early life	672:728	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	6	59	theme	IgG	1302:1304	arg1	antibodies					1306:1315	inflammatory IgG antibodies	1289:1315	inflammatory IgG antibodies	1289:1315	This information indicates that the transition between neonatal life and adulthood in mice is accompanied by reduction of inflammatory IgG antibodies.
32943699	1	60	theme	Early	120:124	arg1	life					136:139	Early postnatal life	120:139	Early postnatal life	120:139	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	3	61	from	patterns	835:842	arg1	5-60 days					877:885	5-60 days	877:885	5-60 days of age	877:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	3	61	from	patterns	835:842	arg1	serum					851:855	the serum	847:855	the serum of BALB/c mice from 5-60 days of age	847:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	3	62	theme	Fc	687:688	arg1	profile					704:710	the murine IgG Fc glycosylation profile	672:710	the murine IgG Fc glycosylation profile during early life	672:728	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	7	63	theme	IgG	1401:1403	arg1	glycosylation					1408:1420	IgG Fc glycosylation	1401:1420	IgG Fc glycosylation	1401:1420	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	1	64	theme	postnatal	126:134	arg1	life					136:139	Early postnatal life	120:139	Early postnatal life	120:139	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	4	65	gly	glycosylation	964:976	arg1	subclasses					989:998	all IgG subclasses	981:998	all IgG subclasses	981:998	From birth to adulthood, we observed a decline in proinflammatory Fc glycosylation in all IgG subclasses.
32943699	1	66	theme	immune	217:222	arg1	system					224:229	the developing neonatal immune system	193:229	the developing neonatal immune system	193:229	Early postnatal life is characterized by a critical time period in which the developing neonatal immune system transitions from passive immunity, induced by protective maternal antibodies, to the competence of a fully functioning immune system.
32943699	7	67	with	importance	1387:1396	arg1	inflammation					1447:1458	inflammation	1447:1458	inflammation	1447:1458	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	6	68	theme	antibodies	1306:1315	arg1	reduction					1276:1284	reduction	1276:1284	reduction of inflammatory IgG antibodies	1276:1315	This information indicates that the transition between neonatal life and adulthood in mice is accompanied by reduction of inflammatory IgG antibodies.
32943699	7	69	theme	Fc	1405:1406	arg1	glycosylation					1408:1420	IgG Fc glycosylation	1401:1420	IgG Fc glycosylation	1401:1420	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	3	70	theme	mice	867:870	arg1	serum					851:855	the serum	847:855	the serum of BALB/c mice from 5-60 days of age	847:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	0	71	theme	postnatal	70:78	arg1	maturation					80:89	the postnatal maturation	66:89	the postnatal maturation of the murine immune system	66:117	Changes in subclass-specific IgG Fc glycosylation associated with the postnatal maturation of the murine immune system.
32943699	2	72	theme	maternal	401:408	arg1	antibodies					423:432	both maternal and neonatal antibodies	396:432	both maternal and neonatal antibodies	396:432	The inflammatory capability of both maternal and neonatal antibodies is governed by N-linked glycosylation of the Fc region, and though this has been examined extensively in adults, there is currently little information regarding antibody glycosylation patterns during early postnatal life.
32943699	7	73	theme	growing	1345:1351	arg1	body					1353:1356	a growing body	1343:1356	a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages	1343:1487	Our study contributes to a growing body of literature indicating the importance of IgG Fc glycosylation and its association with inflammation during different life stages.
32943699	5	74	theme	age	1162:1164	arg1	60 days					1151:1157	60 days	1151:1157	60 days of age	1151:1164	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	5	74	theme	age	1162:1164	arg1	weaning					1133:1139	weaning	1133:1139	weaning at 45	1133:1145	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	3	75	theme	Asn-297	813:819	arg1	patterns					835:842	subclass specific Asn-297 glycosylation patterns	795:842	subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age	795:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	5	76	from	45	1144:1145	arg1	60 days					1151:1157	60 days	1151:1157	60 days of age	1151:1164	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	5	76	from	45	1144:1145	arg1	weaning					1133:1139	weaning	1133:1139	weaning at 45	1133:1145	This was shown by significantly reduced agalactosylated and monogalactosylated structures combined with increased sialylation after weaning at 45 and 60 days of age.
32943699	3	77	theme	early	719:723	arg1	life					725:728	early life	719:728	early life	719:728	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32943699	3	78	theme	glycosylation	821:833	arg1	patterns					835:842	subclass specific Asn-297 glycosylation patterns	795:842	subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age	795:892	To characterize the murine IgG Fc glycosylation profile during early life, we used nano-LC-ESI-Qq-TOF mass spectrometry analysis to assess subclass specific Asn-297 glycosylation patterns in the serum of BALB/c mice from 5-60 days of age.
32839225	10	0	theme	activity	1774:1781	arg1	loss					1756:1759	complete loss	1747:1759	complete loss of aconitase activity	1747:1781	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	7	1	dep	aconitase	1196:1204	arg1	ACO2					1207:1210	ACO2	1207:1210	ACO2	1207:1210	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	4	2	theme	mouse	721:725	arg1	capacitation					733:744	mouse sperm capacitation	721:744	mouse sperm capacitation	721:744	Here we characterize sialylation during mouse sperm capacitation.
32839225	9	3	theme	recombinant	1606:1616	arg1	protein					1618:1624	N612D recombinant protein	1600:1624	N612D recombinant protein tagged with both His and GFP	1600:1653	The latter was confirmed by N612D recombinant protein tagged with both His and GFP.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	EL					1034:1035	EL	1034:1035	EL	1034:1035	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	protein					1005:1011	C4b-binding protein	993:1011	C4b-binding protein	993:1011	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg2	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg2	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	proteases					1046:1054	serine proteases 39 and 52	1039:1064	proteases	1046:1054	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	protein					1084:1090	testis-expressed protein 101	1067:1094	testis-expressed protein 101	1067:1094	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	lipase					1026:1031	endothelial lipase	1014:1031	endothelial lipase (EL)	1014:1036	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	4	gly	sialoglycopeptides	969:986	arg1	zonadhesin					1100:1109	zonadhesin	1100:1109	zonadhesin	1100:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	7	5	theme	mitochondrial	1161:1173	arg1	hydratase					1185:1193	mitochondrial aconitate hydratase	1161:1193	mitochondrial aconitate hydratase (aconitase; ACO2)	1161:1211	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	7	5	theme	mitochondrial	1161:1173	arg1	aconitase					1196:1204	aconitase	1196:1204	aconitase	1196:1204	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	7	5	theme	mitochondrial	1161:1173	arg1	enzyme					1226:1231	a TCA cycle enzyme	1214:1231	a TCA cycle enzyme	1214:1231	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	9	6	theme	N612D	1600:1604	arg1	protein					1618:1624	N612D recombinant protein	1600:1624	N612D recombinant protein tagged with both His and GFP	1600:1653	The latter was confirmed by N612D recombinant protein tagged with both His and GFP.
32839225	0	7	theme	Possible	93:100	arg1	Mechanism					102:110	a Possible Mechanism	91:110	Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis	65:170	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	7	8	from	increase	1266:1273	arg1	content					1282:1288	Sia content	1278:1288	Sia content during capacitation	1278:1308	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	13	9	theme	oxidative	2080:2088	arg1	phosphorylation					2090:2104	oxidative phosphorylation	2080:2104	oxidative phosphorylation	2080:2104	These findings suggest that the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation may come about through sialylation of ACO2.
32839225	6	10	from	protein	1084:1090	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	10	from	protein	1084:1090	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	7	11	theme	cycle	1220:1224	arg1	hydratase					1185:1193	mitochondrial aconitate hydratase	1161:1193	mitochondrial aconitate hydratase (aconitase; ACO2)	1161:1211	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	7	11	theme	cycle	1220:1224	arg1	enzyme					1226:1231	a TCA cycle enzyme	1214:1231	a TCA cycle enzyme	1214:1231	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	13	12	gly	sialylation	2181:2191	arg1	ACO2					2196:2199	ACO2	2196:2199	ACO2	2196:2199	These findings suggest that the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation may come about through sialylation of ACO2.
32839225	6	13	from	proteases	1046:1054	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	13	from	proteases	1046:1054	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	14	from	zonadhesin	1100:1109	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	14	from	zonadhesin	1100:1109	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	7	15	theme	only	1242:1245	arg1	protein					1247:1253	the only protein	1238:1253	the only protein	1238:1253	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	0	16	from	Phosphorylation	142:156	arg1	Switch					120:125	the Switch	116:125	the Switch from Oxidative Phosphorylation to Glycolysis	116:170	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	12	17	theme	alpha	1944:1948	arg1	helix					1950:1954	the alpha helix	1940:1954	the alpha helix	1940:1954	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	8	18	theme	stereospecific	1473:1486	arg1	isomerization					1488:1500	stereospecific isomerization	1473:1500	stereospecific isomerization of citrate to isocitrate	1473:1525	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	10	19	theme	charged	1698:1704	arg1	acid					1715:1718	the negatively charged Aspartic acid	1683:1718	the negatively charged Aspartic acid in the N612D mutant	1683:1738	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	7	20	theme	aconitate	1175:1183	arg1	hydratase					1185:1193	mitochondrial aconitate hydratase	1161:1193	mitochondrial aconitate hydratase (aconitase; ACO2)	1161:1211	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	7	20	theme	aconitate	1175:1183	arg1	aconitase					1196:1204	aconitase	1196:1204	aconitase	1196:1204	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	7	20	theme	aconitate	1175:1183	arg1	enzyme					1226:1231	a TCA cycle enzyme	1214:1231	a TCA cycle enzyme	1214:1231	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	8	21	theme	citrate	1505:1511	arg1	isomerization					1488:1500	stereospecific isomerization	1473:1500	stereospecific isomerization of citrate to isocitrate	1473:1525	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	6	22	from	lipase	1026:1031	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	22	from	lipase	1026:1031	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	7	23	theme	TCA	1216:1218	arg1	hydratase					1185:1193	mitochondrial aconitate hydratase	1161:1193	mitochondrial aconitate hydratase (aconitase; ACO2)	1161:1211	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	7	23	theme	TCA	1216:1218	arg1	enzyme					1226:1231	a TCA cycle enzyme	1214:1231	a TCA cycle enzyme	1214:1231	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	3	24	theme	single	545:550	arg1	study					552:556	no single study	542:556	no single study	542:556	Regardless of its importance, to date, no single study has ever identified nor quantified which glycoproteins bearing terminal sialic acid (Sia) are altered during capacitation.
32839225	5	25	theme	potential	869:877	arg1	modifications					879:891	potential modifications	869:891	potential modifications on their sialylated oligosaccharides	869:928	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	12	26	theme	function	2026:2033	arg1	loss					2018:2021	complete loss	2009:2021	complete loss of function	2009:2033	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	12	27	from	change	1930:1935	arg1	helix					1950:1954	the alpha helix	1940:1954	the alpha helix	1940:1954	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	5	28	theme	liquid	776:781	arg1	chromatography					783:796	liquid chromatography	776:796	liquid chromatography (LC-MS/MS)	776:807	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	5	28	theme	liquid	776:781	arg1	LC-MS/MS					799:806	LC-MS/MS	799:806	LC-MS/MS	799:806	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	12	29	theme	Sia	1896:1898	arg1	introduction					1880:1891	The introduction	1876:1891	The introduction of Sia	1876:1898	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	2	30	gly	sialylation	384:394	arg1	sperm-oocyte					477:488	proper sperm-oocyte interaction	470:500	proper sperm-oocyte interaction	470:500	Several post-translational modifications occur during capacitation, including sialylation, which despite being limited to a few proteins, seems to be essential for proper sperm-oocyte interaction.
32839225	6	31	theme	endothelial	1014:1024	arg1	EL					1034:1035	EL	1034:1035	EL	1034:1035	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	31	theme	endothelial	1014:1024	arg1	lipase					1026:1031	endothelial lipase	1014:1031	endothelial lipase (EL)	1014:1036	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	8	32	from	decrease	1434:1441	arg1	activity					1450:1457	the activity	1446:1457	the activity of ACO2	1446:1465	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	13	33	theme	ACO2	2196:2199	arg1	sialylation					2181:2191	sialylation	2181:2191	sialylation of ACO2	2181:2199	These findings suggest that the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation may come about through sialylation of ACO2.
32839225	0	34	dep	Capacitation	77:88	arg1	Mechanism					102:110	a Possible Mechanism	91:110	Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis	65:170	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	1	35	theme	mammalian	192:200	arg1	spermatozoa					202:212	mammalian spermatozoa	192:212	mammalian spermatozoa	192:212	After ejaculation, mammalian spermatozoa must undergo a process known as capacitation in order to successfully fertilize the oocyte.
32839225	12	36	theme	conformational	1915:1928	arg1	change					1930:1935	a large conformational change	1907:1935	a large conformational change in the alpha helix	1907:1954	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	5	37	theme	nonreductant	823:834	arg1	peptides					836:843	142 nonreductant peptides	819:843	142 nonreductant peptides	819:843	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	6	38	from	protein	1005:1011	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	38	from	protein	1005:1011	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	2	39	theme	post-translational	314:331	arg1	modifications					333:345	Several post-translational modifications	306:345	Several post-translational modifications	306:345	Several post-translational modifications occur during capacitation, including sialylation, which despite being limited to a few proteins, seems to be essential for proper sperm-oocyte interaction.
32839225	6	40	theme	testis-expressed	1067:1082	arg1	protein					1084:1090	testis-expressed protein 101	1067:1094	testis-expressed protein 101	1067:1094	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	0	41	theme	Asparagine	15:24	arg1	Sialylation					0:10	Sialylation	0:10	Sialylation of Asparagine 612	0:28	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	2	42	theme	Several	306:312	arg1	modifications					333:345	Several post-translational modifications	306:345	Several post-translational modifications	306:345	Several post-translational modifications occur during capacitation, including sialylation, which despite being limited to a few proteins, seems to be essential for proper sperm-oocyte interaction.
32839225	10	43	theme	Aspartic	1706:1713	arg1	acid					1715:1718	the negatively charged Aspartic acid	1683:1718	the negatively charged Aspartic acid in the N612D mutant	1683:1738	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	8	44	theme	phospholipase	1405:1417	arg1	activity					1422:1429	its phospholipase A1 activity	1401:1429	its phospholipase A1 activity	1401:1429	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	0	45	theme	Aconitase	39:47	arg1	Activity					49:56	Aconitase Activity	39:56	Aconitase Activity	39:56	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	6	46	theme	C4b-binding	993:1003	arg1	protein					1005:1011	C4b-binding protein	993:1011	C4b-binding protein	993:1011	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	0	47	theme	Oxidative	132:140	arg1	Phosphorylation					142:156	Oxidative Phosphorylation	132:156	Oxidative Phosphorylation	132:156	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	8	48	theme	A1	1419:1420	arg1	activity					1422:1429	its phospholipase A1 activity	1401:1429	its phospholipase A1 activity	1401:1429	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	8	49	from	reduction	1388:1396	arg1	activity					1422:1429	its phospholipase A1 activity	1401:1429	its phospholipase A1 activity	1401:1429	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	3	50	gly	glycoproteins	599:611	arg1	glycoproteins					599:611	glycoproteins	599:611	glycoproteins bearing terminal sialic acid (Sia)	599:646	Regardless of its importance, to date, no single study has ever identified nor quantified which glycoproteins bearing terminal sialic acid (Sia) are altered during capacitation.
32839225	11	51	theme	Computer	1805:1812	arg1	modeling					1814:1821	Computer modeling	1805:1821	Computer modeling	1805:1821	Computer modeling show that N612 sits atop the catalytic site of ACO2.
32839225	3	52	theme	terminal	621:628	arg1	acid					637:640	terminal sialic acid	621:640	terminal sialic acid (Sia)	621:646	Regardless of its importance, to date, no single study has ever identified nor quantified which glycoproteins bearing terminal sialic acid (Sia) are altered during capacitation.
32839225	3	52	theme	terminal	621:628	arg1	Sia					643:645	Sia	643:645	Sia	643:645	Regardless of its importance, to date, no single study has ever identified nor quantified which glycoproteins bearing terminal sialic acid (Sia) are altered during capacitation.
32839225	2	53	theme	few	430:432	arg1	proteins					434:441	a few proteins	428:441	a few proteins	428:441	Several post-translational modifications occur during capacitation, including sialylation, which despite being limited to a few proteins, seems to be essential for proper sperm-oocyte interaction.
32839225	2	54	theme	sperm-oocyte	477:488	arg1	interaction					490:500	proper sperm-oocyte interaction	470:500	proper sperm-oocyte interaction	470:500	Several post-translational modifications occur during capacitation, including sialylation, which despite being limited to a few proteins, seems to be essential for proper sperm-oocyte interaction.
32839225	5	55	theme	tandem	753:758	arg1	MS					760:761	tandem MS	753:761	tandem MS coupled with liquid chromatography (LC-MS/MS)	753:807	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	5	56	gly	sialylated	902:911	arg1	oligosaccharides					913:928	their sialylated oligosaccharides	896:928	their sialylated oligosaccharides	896:928	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	10	57	theme	complete	1747:1754	arg1	loss					1756:1759	complete loss	1747:1759	complete loss of aconitase activity	1747:1781	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	13	58	from	phosphorylation	2090:2104	arg1	switch					2068:2073	the switch	2064:2073	the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation	2064:2156	These findings suggest that the switch from oxidative phosphorylation, over to glycolysis that occurs during capacitation may come about through sialylation of ACO2.
32839225	2	59	theme	proper	470:475	arg1	interaction					490:500	proper sperm-oocyte interaction	470:500	proper sperm-oocyte interaction	470:500	Several post-translational modifications occur during capacitation, including sialylation, which despite being limited to a few proteins, seems to be essential for proper sperm-oocyte interaction.
32839225	6	60	theme	N-linked	960:967	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	60	theme	N-linked	960:967	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	8	61	dep	occurred	1528:1535	arg1	N612					1565:1568	N612	1565:1568	N612	1565:1568	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	4	62	theme	sperm	727:731	arg1	capacitation					733:744	mouse sperm capacitation	721:744	mouse sperm capacitation	721:744	Here we characterize sialylation during mouse sperm capacitation.
32839225	10	63	theme	aconitase	1764:1772	arg1	activity					1774:1781	aconitase activity	1764:1781	aconitase activity	1764:1781	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	8	64	dep	isomerization	1488:1500	arg1	i.e.					1468:1471	i.e.	1468:1471	i.e.	1468:1471	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	6	65	link	N-linked	960:967	arg1	sialoglycopeptides					969:986	N-linked sialoglycopeptides	960:986	N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin	960:1109	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	6	65	link	N-linked	960:967	arg1	such					954:957	such	954:957	such	954:957	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	10	66	theme	N612D	1727:1731	arg1	mutant					1733:1738	the N612D mutant	1723:1738	the N612D mutant	1723:1738	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	12	67	theme	large	1909:1913	arg1	change					1930:1935	a large conformational change	1907:1935	a large conformational change in the alpha helix	1907:1954	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	8	68	theme	Sia	1347:1349	arg1	loss					1339:1342	the loss	1335:1342	the loss of Sia within EL (N62)	1335:1365	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	5	69	from	modifications	879:891	arg1	oligosaccharides					913:928	their sialylated oligosaccharides	896:928	their sialylated oligosaccharides	896:928	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	10	70	from	acid	1715:1718	arg1	mutant					1733:1738	the N612D mutant	1723:1738	the N612D mutant	1723:1738	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	12	71	theme	complete	2009:2016	arg1	loss					2018:2021	complete loss	2009:2021	complete loss of function	2009:2033	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	0	72	theme	Sperm	71:75	arg1	Capacitation					77:88	Mouse Sperm Capacitation	65:88	Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis	65:170	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	5	73	theme	them	856:859	arg1	them					856:859	them	856:859	them	856:859	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	5	73	theme	them	856:859	arg1	9					851:851	9	851:851	9	851:851	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32839225	3	74	theme	sialic	630:635	arg1	acid					637:640	terminal sialic acid	621:640	terminal sialic acid (Sia)	621:646	Regardless of its importance, to date, no single study has ever identified nor quantified which glycoproteins bearing terminal sialic acid (Sia) are altered during capacitation.
32839225	3	74	theme	sialic	630:635	arg1	Sia					643:645	Sia	643:645	Sia	643:645	Regardless of its importance, to date, no single study has ever identified nor quantified which glycoproteins bearing terminal sialic acid (Sia) are altered during capacitation.
32839225	11	75	theme	ACO2	1870:1873	arg1	ACO2					1870:1873	ACO2	1870:1873	ACO2	1870:1873	Computer modeling show that N612 sits atop the catalytic site of ACO2.
32839225	11	75	theme	ACO2	1870:1873	arg1	site					1862:1865	the catalytic site	1848:1865	the catalytic site of ACO2	1848:1873	Computer modeling show that N612 sits atop the catalytic site of ACO2.
32839225	10	76	theme	Sia	1675:1677	arg1	replacement					1660:1670	The replacement	1656:1670	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant	1656:1738	The replacement of Sia for the negatively charged Aspartic acid in the N612D mutant caused complete loss of aconitase activity compared with the WT.
32839225	11	77	theme	catalytic	1852:1860	arg1	ACO2					1870:1873	ACO2	1870:1873	ACO2	1870:1873	Computer modeling show that N612 sits atop the catalytic site of ACO2.
32839225	11	77	theme	catalytic	1852:1860	arg1	site					1862:1865	the catalytic site	1848:1865	the catalytic site of ACO2	1848:1873	Computer modeling show that N612 sits atop the catalytic site of ACO2.
32839225	6	78	theme	serine	1039:1044	arg1	proteases					1046:1054	serine proteases 39 and 52	1039:1064	proteases	1046:1054	As such, N-linked sialoglycopeptides from C4b-binding protein, endothelial lipase (EL), serine proteases 39 and 52, testis-expressed protein 101 and zonadhesin were reduced following capacitation.
32839225	0	79	theme	Mouse	65:69	arg1	Capacitation					77:88	Mouse Sperm Capacitation	65:88	Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis	65:170	Sialylation of Asparagine 612 Inhibits Aconitase Activity during Mouse Sperm Capacitation; a Possible Mechanism for the Switch from Oxidative Phosphorylation to Glycolysis.
32839225	8	80	theme	ACO2	1462:1465	arg1	activity					1450:1457	the activity	1446:1457	the activity of ACO2	1446:1465	Interestingly, although the loss of Sia within EL (N62) was accompanied by a reduction in its phospholipase A1 activity, a decrease in the activity of ACO2 (i.e. stereospecific isomerization of citrate to isocitrate) occurred when sialylation increased (N612).
32839225	7	81	theme	Sia	1278:1280	arg1	content					1282:1288	Sia content	1278:1288	Sia content during capacitation	1278:1308	In contrast, mitochondrial aconitate hydratase (aconitase; ACO2), a TCA cycle enzyme, was the only protein to show an increase in Sia content during capacitation.
32839225	12	82	theme	active	1985:1990	arg1	site					1992:1995	the active site	1981:1995	the active site	1981:1995	The introduction of Sia causes a large conformational change in the alpha helix, essentially, distorting the active site, leading to complete loss of function.
32839225	5	83	theme	sialylated	902:911	arg1	oligosaccharides					913:928	their sialylated oligosaccharides	896:928	their sialylated oligosaccharides	896:928	Using tandem MS coupled with liquid chromatography (LC-MS/MS), we found 142 nonreductant peptides, with 9 of them showing potential modifications on their sialylated oligosaccharides during capacitation.
32791352	8	0	theme	human	1151:1155	arg1	expression					1164:1173	transient human PDGFRA expression	1141:1173	transient human PDGFRA expression	1141:1173	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	2	1	theme	receptor	348:355	arg1	gpPDGFRA					364:371	gpPDGFRA	364:371	gpPDGFRA	364:371	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	1	theme	receptor	348:355	arg1	alpha					357:361	receptor alpha	348:361	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	8	2	theme	PDGFRA	1157:1162	arg1	expression					1164:1173	transient human PDGFRA expression	1141:1173	transient human PDGFRA expression	1141:1173	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	8	3	theme	potential	1218:1226	arg1	infection					1205:1213	GPCMV(PC-) infection	1194:1213	GPCMV(PC-) infection	1194:1213	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	8	3	theme	potential	1218:1226	arg1	basis					1228:1232	a potential basis	1216:1232	a potential basis for viral species specificity	1216:1262	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	6	4	link	N-linked	839:846	arg1	inhibition					871:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	3	5	from	interaction	543:553	arg1	absence					592:598	absence	592:598	absence of gO	592:604	Immunoprecipitation assays demonstrated direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO.
32791352	5	6	from	expression	734:743	arg1	cells					782:786	adjacent cells	773:786	adjacent cells	773:786	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	2	7	link	Platelet-derived	317:332	arg1	receptor					451:458	the putative receptor	438:458	the putative receptor for PC-independent GPCMV infection	438:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	7	link	Platelet-derived	317:332	arg1	factor					341:346	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	1	8	gly	glycoprotein	216:227	arg1	glycoprotein					216:227	homolog glycoprotein complexes	208:237	homolog glycoprotein complexes	208:237	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	0	9	theme	cell	89:92	arg1	fusion					94:99	cell fusion	89:99	cell fusion	89:99	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	6	10	theme	tyrosine	914:921	arg1	TK					931:932	TK	931:932	TK	931:932	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	6	10	theme	tyrosine	914:921	arg1	kinase					923:928	blocking tyrosine kinase	905:928	blocking tyrosine kinase (TK) transduction	905:946	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	2	11	dep	factor	341:346	arg1	gpPDGFRA					364:371	gpPDGFRA	364:371	gpPDGFRA	364:371	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	11	dep	factor	341:346	arg1	alpha					357:361	receptor alpha	348:361	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	1	12	dep	pig	136:138	arg1	GPCMV					157:161	GPCMV	157:161	GPCMV	157:161	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	12	dep	pig	136:138	arg1	cytomegalovirus					140:154	cytomegalovirus	140:154	Species-specific guinea pig cytomegalovirus (GPCMV)	112:162	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	13	theme	gH-based	263:270	arg1	gH/gL/gO					280:287	gH/gL/gO	280:287	gH/gL/gO	280:287	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	13	theme	gH-based	263:270	arg1	trimer					272:277	gH-based trimer	263:277	gH-based trimer (gH/gL/gO)	263:288	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	8	14	theme	GPCMV	1194:1198	arg1	infection					1205:1213	GPCMV(PC-) infection	1194:1213	GPCMV(PC-) infection	1194:1213	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	8	14	theme	GPCMV	1194:1198	arg1	basis					1228:1232	a potential basis	1216:1232	a potential basis for viral species specificity	1216:1262	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	6	15	theme	blocking	905:912	arg1	TK					931:932	TK	931:932	TK	931:932	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	6	15	theme	blocking	905:912	arg1	kinase					923:928	blocking tyrosine kinase	905:928	blocking tyrosine kinase (TK) transduction	905:946	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	7	16	theme	viral	1111:1115	arg1	infection					1117:1125	viral infection	1111:1125	viral infection	1111:1125	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	4	17	theme	viral	621:625	arg1	gB					627:628	viral gB	621:628	viral gB	621:628	Expression of viral gB also resulted in precipitation of gB/gH/gL/gO/gpPDGFRA complex.
32791352	8	18	theme	viral	1238:1242	arg1	specificity					1252:1262	viral species specificity	1238:1262	viral species specificity	1238:1262	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	5	19	theme	gH/gL/gO	761:768	arg1	expression					734:743	expression	734:743	expression of gpPDGFRA and gH/gL/gO in adjacent cells	734:786	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	5	20	theme	cell	796:799	arg1	fusion					801:806	cell fusion	796:806	cell fusion	796:806	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	6	21	theme	glycosylation	857:869	arg1	inhibition					871:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	3	22	theme	direct	536:541	arg1	interaction					543:553	direct interaction	536:553	direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO	536:604	Immunoprecipitation assays demonstrated direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO.
32791352	1	23	theme	congenital	171:180	arg1	CMV					182:184	congenital CMV	171:184	congenital CMV	171:184	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	0	24	theme	pig	7:9	arg1	gH/gL/gO					42:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	7	25	from	mutant	1020:1025	arg1	trophoblast					1030:1040	trophoblast	1030:1040	trophoblast	1030:1040	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	7	25	from	mutant	1020:1025	arg1	cells					1056:1060	epithelial cells	1045:1060	epithelial cells	1045:1060	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	2	26	theme	GPCMV	479:483	arg1	infection					485:493	PC-independent GPCMV infection	464:493	PC-independent GPCMV infection	464:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	4	27	theme	gB/gH/gL/gO/gpPDGFRA	664:683	arg1	complex					685:691	gB/gH/gL/gO/gpPDGFRA complex	664:691	gB/gH/gL/gO/gpPDGFRA complex	664:691	Expression of viral gB also resulted in precipitation of gB/gH/gL/gO/gpPDGFRA complex.
32791352	0	28	theme	Guinea	0:5	arg1	pig					7:9	Guinea pig	0:9	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	8	29	theme	species	1244:1250	arg1	specificity					1252:1262	viral species specificity	1238:1262	viral species specificity	1238:1262	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	0	30	theme	trimer	27:32	arg1	gH/gL/gO					42:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	3	31	theme	gH/gL/gO	558:565	arg1	interaction					543:553	direct interaction	536:553	direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO	536:604	Immunoprecipitation assays demonstrated direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO.
32791352	4	32	theme	gB	627:628	arg1	Expression					607:616	Expression	607:616	Expression of viral gB	607:628	Expression of viral gB also resulted in precipitation of gB/gH/gL/gO/gpPDGFRA complex.
32791352	0	33	theme	cytomegalovirus	11:25	arg1	gH/gL/gO					42:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	6	34	theme	limited	886:892	arg1	effect					894:899	limited effect	886:899	limited effect	886:899	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	2	35	theme	fibroblast	391:400	arg1	cells					402:406	fibroblast cells	391:406	fibroblast cells	391:406	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	36	theme	putative	442:449	arg1	receptor					451:458	the putative receptor	438:458	the putative receptor for PC-independent GPCMV infection	438:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	36	theme	putative	442:449	arg1	factor					341:346	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	37	theme	Platelet-derived	317:332	arg1	receptor					451:458	the putative receptor	438:458	the putative receptor for PC-independent GPCMV infection	438:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	37	theme	Platelet-derived	317:332	arg1	factor					341:346	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	0	38	theme	complex	34:40	arg1	gH/gL/gO					42:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO	0:49	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	2	39	attach	present	380:386	arg2	receptor					451:458	the putative receptor	438:458	the putative receptor for PC-independent GPCMV infection	438:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	39	attach	present	380:386	arg2	factor					341:346	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	39	attach	present	380:386	arg1	cells					402:406	fibroblast cells	391:406	fibroblast cells	391:406	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	1	40	theme	homolog	208:214	arg1	virus					194:198	the virus	190:198	the virus	190:198	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	40	theme	homolog	208:214	arg1	trimer					272:277	gH-based trimer	263:277	gH-based trimer (gH/gL/gO)	263:288	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	40	theme	homolog	208:214	arg1	complexes					229:237	homolog glycoprotein complexes	208:237	homolog glycoprotein complexes	208:237	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	40	theme	homolog	208:214	arg1	pentamer-complex					294:309	pentamer-complex	294:309	pentamer-complex (PC)	294:314	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	3	41	with	interaction	543:553	arg1	gpPDGFRA					572:579	gpPDGFRA	572:579	gpPDGFRA	572:579	Immunoprecipitation assays demonstrated direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO.
32791352	5	42	theme	adjacent	773:780	arg1	cells					782:786	adjacent cells	773:786	adjacent cells	773:786	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	7	43	theme	epithelial	1045:1054	arg1	cells					1056:1060	epithelial cells	1045:1060	epithelial cells	1045:1060	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	2	44	theme	growth	334:339	arg1	receptor					451:458	the putative receptor	438:458	the putative receptor for PC-independent GPCMV infection	438:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	44	theme	growth	334:339	arg1	factor					341:346	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	6	45	theme	kinase	923:928	arg1	transduction					935:946	blocking tyrosine kinase (TK) transduction	905:946	blocking tyrosine kinase (TK) transduction	905:946	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	7	46	theme	non-susceptible	1073:1087	arg1	trophoblast					1030:1040	trophoblast	1030:1040	trophoblast	1030:1040	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	6	47	theme	gpPDGFRA	848:855	arg1	inhibition					871:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	1	48	theme	Species-specific	112:127	arg1	pig					136:138	Species-specific guinea pig cytomegalovirus (GPCMV)	112:162	Species-specific guinea pig cytomegalovirus (GPCMV)	112:162	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	8	49	theme	PC-	1200:1202	arg1	infection					1205:1213	GPCMV(PC-) infection	1194:1213	GPCMV(PC-) infection	1194:1213	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	8	49	theme	PC-	1200:1202	arg1	basis					1228:1232	a potential basis	1216:1232	a potential basis for viral species specificity	1216:1262	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	5	50	theme	Cell-cell	694:702	arg1	assays					711:716	Cell-cell fusion assays	694:716	Cell-cell fusion assays	694:716	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	6	51	theme	N-linked	839:846	arg1	inhibition					871:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	1	52	theme	guinea	129:134	arg1	pig					136:138	Species-specific guinea pig cytomegalovirus (GPCMV)	112:162	Species-specific guinea pig cytomegalovirus (GPCMV)	112:162	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	53	theme	glycoprotein	216:227	arg1	virus					194:198	the virus	190:198	the virus	190:198	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	53	theme	glycoprotein	216:227	arg1	trimer					272:277	gH-based trimer	263:277	gH-based trimer (gH/gL/gO)	263:288	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	53	theme	glycoprotein	216:227	arg1	complexes					229:237	homolog glycoprotein complexes	208:237	homolog glycoprotein complexes	208:237	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	1	53	theme	glycoprotein	216:227	arg1	pentamer-complex					294:309	pentamer-complex	294:309	pentamer-complex (PC)	294:314	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32791352	5	54	theme	fusion	704:709	arg1	assays					711:716	Cell-cell fusion assays	694:716	Cell-cell fusion assays	694:716	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	6	55	contain	had	948:950	arg1	transduction					935:946	blocking tyrosine kinase (TK) transduction	905:946	blocking tyrosine kinase (TK) transduction	905:946	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	6	55	contain	had	948:950	arg2	impact					955:960	no impact	952:960	no impact	952:960	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	5	56	theme	gpPDGFRA	748:755	arg1	expression					734:743	expression	734:743	expression of gpPDGFRA and gH/gL/gO in adjacent cells	734:786	Cell-cell fusion assays determined that expression of gpPDGFRA and gH/gL/gO in adjacent cells enabled cell fusion, which was not enhanced by gB.
32791352	8	57	theme	transient	1141:1149	arg1	expression					1164:1173	transient human PDGFRA expression	1141:1173	transient human PDGFRA expression	1141:1173	In contrast, transient human PDGFRA expression did not complement GPCMV(PC-) infection, a potential basis for viral species specificity.
32791352	6	58	contain	had	882:884	arg1	inhibition					871:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition	839:880	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	6	58	contain	had	882:884	arg2	effect					894:899	limited effect	886:899	limited effect	886:899	N-linked gpPDGFRA glycosylation inhibition had limited effect and blocking tyrosine kinase (TK) transduction had no impact on infection.
32791352	0	59	theme	universal	66:74	arg1	receptor					76:83	universal receptor	66:83	universal receptor for cell fusion and entry	66:109	Guinea pig cytomegalovirus trimer complex gH/gL/gO uses PDGFRA as universal receptor for cell fusion and entry.
32791352	2	60	theme	present	380:386	arg1	receptor					451:458	the putative receptor	438:458	the putative receptor for PC-independent GPCMV infection	438:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	2	60	theme	present	380:386	arg1	factor					341:346	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA)	317:372	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	3	61	theme	gO	603:604	arg1	absence					592:598	absence	592:598	absence of gO	592:604	Immunoprecipitation assays demonstrated direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO.
32791352	7	62	theme	TK-domain	1010:1018	arg1	mutant					1020:1025	TK-domain mutant	1010:1025	TK-domain mutant	1010:1025	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	3	63	theme	Immunoprecipitation	496:514	arg1	assays					516:521	Immunoprecipitation assays	496:521	Immunoprecipitation assays	496:521	Immunoprecipitation assays demonstrated direct interaction of gH/gL/gO with gpPDGFRA but not in absence of gO.
32791352	7	64	from	gpPDGFRA	998:1005	arg1	trophoblast					1030:1040	trophoblast	1030:1040	trophoblast	1030:1040	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	7	64	from	gpPDGFRA	998:1005	arg1	cells					1056:1060	epithelial cells	1045:1060	epithelial cells	1045:1060	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	2	65	theme	PC-independent	464:477	arg1	infection					485:493	PC-independent GPCMV infection	464:493	PC-independent GPCMV infection	464:493	Platelet-derived growth factor receptor alpha (gpPDGFRA), only present on fibroblast cells, was identified via CRISPR as the putative receptor for PC-independent GPCMV infection.
32791352	7	66	theme	expressed	988:996	arg1	gpPDGFRA					998:1005	Ectopically expressed gpPDGFRA	976:1005	Ectopically expressed gpPDGFRA	976:1005	Ectopically expressed gpPDGFRA or TK-domain mutant in trophoblast or epithelial cells previously non-susceptible to GPCMV(PC-) enabled viral infection.
32791352	4	67	theme	complex	685:691	arg1	precipitation					647:659	precipitation	647:659	precipitation of gB/gH/gL/gO/gpPDGFRA complex	647:691	Expression of viral gB also resulted in precipitation of gB/gH/gL/gO/gpPDGFRA complex.
32791352	1	68	theme	human	242:246	arg1	CMV					248:250	human CMV	242:250	human CMV	242:250	Species-specific guinea pig cytomegalovirus (GPCMV) causes congenital CMV and the virus encodes homolog glycoprotein complexes to human CMV, including gH-based trimer (gH/gL/gO) and pentamer-complex (PC).
32041787	4	0	from	lines	996:1000	arg1	monocytes					1011:1019	human monocytes	1005:1019	human monocytes	1005:1019	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	0	from	lines	996:1000	arg1	neutrophils					1032:1042	murine neutrophils	1025:1042	murine neutrophils	1025:1042	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	1	theme	bacterial	730:738	arg1	motility					740:747	bacterial motility	730:747	bacterial motility	730:747	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	5	2	theme	N-linked	1402:1409	arg1	chains					1418:1423	surface N-linked glycan chains	1394:1423	surface N-linked glycan chains (N-glycans)	1394:1435	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	5	2	theme	N-linked	1402:1409	arg1	N-glycans					1426:1434	N-glycans	1426:1434	N-glycans	1426:1434	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	2	3	theme	phagocytic	515:524	arg1	resistance					526:535	phagocytic resistance	515:535	phagocytic resistance	515:535	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	5	4	theme	CD18	1525:1528	arg1	integrins					1530:1538	CD18 integrins	1525:1538	CD18 integrins in trans	1525:1547	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	5	5	theme	initial	1459:1465	arg1	interaction					1467:1477	the initial interaction	1455:1477	the initial interaction of bacteria with monocytes	1455:1504	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	5	6	with	interaction	1467:1477	arg1	monocytes					1496:1504	monocytes	1496:1504	monocytes	1496:1504	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	4	7	theme	strains	925:931	arg1	mutants					898:904	motile and isogenic nonmotile deletion mutants	859:904	motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa	859:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	6	8	theme	aeruginosa	1669:1678	arg1	uptake					1638:1643	uptake	1638:1643	uptake	1638:1643	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	3	9	theme	adhesion	589:596	arg1	type					609:612	a leukocyte adhesion deficiency type 1	577:614	a leukocyte adhesion deficiency type 1 (LAD-I) patient	577:630	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	9	theme	adhesion	589:596	arg1	LAD-I					617:621	LAD-I	617:621	LAD-I	617:621	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	7	10	theme	phagocytic	1843:1852	arg1	recognition					1854:1864	recognition	1854:1864	recognition	1854:1864	These findings provide novel insights into the cellular determinants for phagocytic recognition and uptake of P. aeruginosa.
32041787	0	11	theme	aeruginosa	99:108	arg1	Binding					45:51	Binding	45:51	Binding	45:51	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa.
32041787	0	11	theme	aeruginosa	99:108	arg1	Internalization					68:82	Phagocytic Internalization	57:82	Phagocytic Internalization of Pseudomonas aeruginosa	57:108	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa.
32041787	3	12	theme	direct	756:761	arg1	engagement					763:772	direct engagement	756:772	direct engagement with CD18-containing integrins	756:803	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	4	13	theme	independent	913:923	arg1	strains					925:931	two independent strains	909:931	two independent strains of P. aeruginosa	909:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	14	theme	deficiency	598:607	arg1	type					609:612	a leukocyte adhesion deficiency type 1	577:614	a leukocyte adhesion deficiency type 1 (LAD-I) patient	577:630	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	14	theme	deficiency	598:607	arg1	LAD-I					617:621	LAD-I	617:621	LAD-I	617:621	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	4	15	theme	CD18	1189:1192	arg1	expression					1194:1203	CD18 expression	1189:1203	CD18 expression	1189:1203	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	16	dep	aeruginosa	706:715	arg1	remains					805:811	remains	805:811	remains unknown	805:819	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	4	17	theme	nonmotile	879:887	arg1	mutants					898:904	motile and isogenic nonmotile deletion mutants	859:904	motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa	859:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	5	18	theme	bacteria	1482:1489	arg1	interaction					1467:1477	the initial interaction	1455:1477	the initial interaction of bacteria with monocytes	1455:1504	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	1	19	theme	aeruginosa	177:186	arg1	control					154:160	host control	149:160	host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival	149:342	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	4	20	theme	human	1005:1009	arg1	monocytes					1011:1019	human monocytes	1005:1019	human monocytes	1005:1019	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	21	theme	CHO	1361:1363	arg1	cells					1365:1369	CHO cells	1361:1369	CHO cells	1361:1369	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	22	theme	isogenic	870:877	arg1	mutants					898:904	motile and isogenic nonmotile deletion mutants	859:904	motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa	859:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	7	23	theme	novel	1793:1797	arg1	insights					1799:1806	novel insights	1793:1806	novel insights into the cellular determinants for phagocytic recognition and uptake of P. aeruginosa	1793:1892	These findings provide novel insights into the cellular determinants for phagocytic recognition and uptake of P. aeruginosa.
32041787	3	24	theme	leukocyte	579:587	arg1	type					609:612	a leukocyte adhesion deficiency type 1	577:614	a leukocyte adhesion deficiency type 1 (LAD-I) patient	577:630	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	24	theme	leukocyte	579:587	arg1	LAD-I					617:621	LAD-I	617:621	LAD-I	617:621	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	25	theme	CD18-containing	779:793	arg1	integrins					795:803	CD18-containing integrins	779:803	CD18-containing integrins	779:803	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	4	26	theme	mutants	898:904	arg1	use					852:854	the use	848:854	the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa	848:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	27	theme	murine	1025:1030	arg1	neutrophils					1032:1042	murine neutrophils	1025:1042	murine neutrophils	1025:1042	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	2	28	theme	motility	410:417	arg1	adaptation					374:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	2	28	theme	motility	410:417	arg1	loss					392:395	the loss	388:395	the loss	388:395	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	0	29	theme	Distinct	0:7	arg1	Contributions					9:21	Distinct Contributions	0:21	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa	0:108	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa.
32041787	4	30	theme	deletion	889:896	arg1	mutants					898:904	motile and isogenic nonmotile deletion mutants	859:904	motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa	859:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	31	theme	mechanistic	1155:1165	arg1	studies					1167:1173	mechanistic studies	1155:1173	mechanistic studies	1155:1173	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	2	32	theme	bacterial	400:408	arg1	motility					410:417	bacterial motility	400:417	bacterial motility	400:417	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	0	33	theme	CD18	26:29	arg1	Integrins					31:39	CD18 Integrins	26:39	CD18 Integrins	26:39	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa.
32041787	5	34	link	N-linked	1402:1409	arg1	chains					1418:1423	surface N-linked glycan chains	1394:1423	surface N-linked glycan chains (N-glycans)	1394:1435	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	5	34	link	N-linked	1402:1409	arg1	N-glycans					1426:1434	N-glycans	1426:1434	N-glycans	1426:1434	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	4	35	theme	CRISPR-generated	959:974	arg1	lines					996:1000	CRISPR-generated CD18-deficient cell lines	959:1000	CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils	959:1042	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	36	theme	host	1271:1274	arg1	cells					1276:1280	the host cells	1267:1280	the host cells	1267:1280	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	37	theme	type	609:612	arg1	patient					624:630	a leukocyte adhesion deficiency type 1 (LAD-I) patient	577:630	a leukocyte adhesion deficiency type 1 (LAD-I) patient	577:630	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	38	from	patient	624:630	arg1	phagocytes					561:570	phagocytes	561:570	phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient	561:630	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	1	39	theme	Gram-negative	198:210	arg1	pathogen					237:244	a motile Gram-negative, opportunistic bacterial pathogen	189:244	pathogen	237:244	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	1	39	theme	Gram-negative	198:210	arg1	aeruginosa					177:186	Pseudomonas aeruginosa	165:186	Pseudomonas aeruginosa	165:186	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	6	40	from	role	1720:1723	arg1	process					1761:1767	this process	1756:1767	this process	1756:1767	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	5	41	theme	bacteria	1579:1586	arg1	internalization					1560:1574	internalization	1560:1574	internalization of bacteria	1560:1586	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	4	42	theme	receptor	1341:1348	arg1	expression					1316:1325	ectopic expression	1308:1325	ectopic expression of complement receptor 3 (CR3)	1308:1356	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	43	theme	Previous	538:545	arg1	studies					547:553	Previous studies	538:553	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient	538:630	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	6	44	theme	CD18	1729:1732	arg1	signaling					1743:1751	CD18 integrin signaling	1729:1751	CD18 integrin signaling	1729:1751	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	4	45	theme	CD18	1050:1053	arg1	expression					1055:1064	CD18 expression	1050:1064	CD18 expression	1050:1064	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	2	46	theme	relevant	365:372	arg1	adaptation					374:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	2	46	theme	relevant	365:372	arg1	loss					392:395	the loss	388:395	the loss	388:395	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	4	47	theme	cell	991:994	arg1	lines					996:1000	CRISPR-generated CD18-deficient cell lines	959:1000	CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils	959:1042	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	1	48	theme	opportunistic	213:225	arg1	pathogen					237:244	a motile Gram-negative, opportunistic bacterial pathogen	189:244	pathogen	237:244	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	1	48	theme	opportunistic	213:225	arg1	aeruginosa					177:186	Pseudomonas aeruginosa	165:186	Pseudomonas aeruginosa	165:186	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	4	49	theme	complement	1330:1339	arg1	receptor					1341:1348	complement receptor 3	1330:1350	complement receptor 3 (CR3)	1330:1356	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	49	theme	complement	1330:1339	arg1	CR3					1353:1355	CR3	1353:1355	CR3	1353:1355	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	1	50	theme	motile	191:196	arg1	pathogen					237:244	a motile Gram-negative, opportunistic bacterial pathogen	189:244	pathogen	237:244	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	1	50	theme	motile	191:196	arg1	aeruginosa					177:186	Pseudomonas aeruginosa	165:186	Pseudomonas aeruginosa	165:186	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	2	51	theme	chronic	436:442	arg1	infections					444:453	chronic infections	436:453	chronic infections	436:453	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	0	52	theme	Integrins	31:39	arg1	Contributions					9:21	Distinct Contributions	0:21	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa	0:108	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa.
32041787	5	53	from	integrins	1530:1538	arg1	trans					1543:1547	trans	1543:1547	trans	1543:1547	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	4	54	theme	CD18-deficient	976:989	arg1	lines					996:1000	CRISPR-generated CD18-deficient cell lines	959:1000	CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils	959:1042	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	55	theme	surface	667:673	arg1	CD18					643:646	CD18	643:646	CD18	643:646	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	55	theme	surface	667:673	arg1	receptor					675:682	a putative cell surface receptor	651:682	a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown	651:819	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	6	56	theme	talin-1	1599:1605	arg1	proteins					1621:1628	talin-1 and kindlin-3 proteins	1599:1628	talin-1 and kindlin-3 proteins	1599:1628	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	5	57	theme	glycan	1411:1416	arg1	chains					1418:1423	surface N-linked glycan chains	1394:1423	surface N-linked glycan chains (N-glycans)	1394:1435	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	5	57	theme	glycan	1411:1416	arg1	N-glycans					1426:1434	N-glycans	1426:1434	N-glycans	1426:1434	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	1	58	theme	bacterial	227:235	arg1	pathogen					237:244	a motile Gram-negative, opportunistic bacterial pathogen	189:244	pathogen	237:244	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	1	58	theme	bacterial	227:235	arg1	aeruginosa					177:186	Pseudomonas aeruginosa	165:186	Pseudomonas aeruginosa	165:186	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	2	59	theme	antibiotic	490:499	arg1	tolerance					501:509	increased antibiotic tolerance	480:509	increased antibiotic tolerance	480:509	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	4	60	theme	motile	859:864	arg1	mutants					898:904	motile and isogenic nonmotile deletion mutants	859:904	motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa	859:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	5	61	theme	surface	1394:1400	arg1	chains					1418:1423	surface N-linked glycan chains	1394:1423	surface N-linked glycan chains (N-glycans)	1394:1435	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	5	61	theme	surface	1394:1400	arg1	N-glycans					1426:1434	N-glycans	1426:1434	N-glycans	1426:1434	Our data support that surface N-linked glycan chains (N-glycans) likely facilitate the initial interaction of bacteria with monocytes and cooperate with CD18 integrins in trans to promote internalization of bacteria.
32041787	6	62	theme	integrin	1734:1741	arg1	signaling					1743:1751	CD18 integrin signaling	1729:1751	CD18 integrin signaling	1729:1751	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	7	63	theme	cellular	1817:1824	arg1	determinants					1826:1837	the cellular determinants	1813:1837	the cellular determinants for phagocytic recognition and uptake of P. aeruginosa	1813:1892	These findings provide novel insights into the cellular determinants for phagocytic recognition and uptake of P. aeruginosa.
32041787	2	64	theme	increased	480:488	arg1	tolerance					501:509	increased antibiotic tolerance	480:509	increased antibiotic tolerance	480:509	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	4	65	theme	ectopic	1308:1314	arg1	expression					1316:1325	ectopic expression	1308:1325	ectopic expression of complement receptor 3 (CR3)	1308:1356	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	66	theme	aeruginosa	706:715	arg1	uptake					688:693	uptake	688:693	uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown	688:819	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	4	67	theme	bacteria	1255:1262	arg1	attachment					1237:1246	the initial attachment	1225:1246	the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells	1225:1369	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	1	68	theme	key	131:133	arg1	mechanism					135:143	the key mechanism	127:143	the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival	127:342	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	1	68	theme	key	131:133	arg1	Phagocytosis					111:122	Phagocytosis	111:122	Phagocytosis	111:122	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	4	69	dep	aeruginosa	1121:1130	arg1	revealed					1175:1182	revealed	1175:1182	revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells	1175:1369	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	2	70	located	observed	420:427	arg2	adaptation					374:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	2	70	located	observed	420:427	arg2	loss					392:395	the loss	388:395	the loss	388:395	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	2	70	located	observed	420:427	arg1	infections					444:453	chronic infections	436:453	chronic infections	436:453	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	3	71	theme	putative	653:660	arg1	CD18					643:646	CD18	643:646	CD18	643:646	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	71	theme	putative	653:660	arg1	receptor					675:682	a putative cell surface receptor	651:682	a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown	651:819	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	4	72	theme	aeruginosa	1121:1130	arg1	uptake					1082:1087	the uptake	1078:1087	the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells	1078:1369	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	73	theme	aeruginosa	939:948	arg1	strains					925:931	two independent strains	909:931	two independent strains of P. aeruginosa	909:948	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	3	74	theme	cell	662:665	arg1	CD18					643:646	CD18	643:646	CD18	643:646	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	3	74	theme	cell	662:665	arg1	receptor					675:682	a putative cell surface receptor	651:682	a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown	651:819	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	6	75	theme	kindlin-3	1611:1619	arg1	proteins					1621:1628	talin-1 and kindlin-3 proteins	1599:1628	talin-1 and kindlin-3 proteins	1599:1628	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	2	76	theme	such	349:352	arg1	adaptation					374:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation	345:383	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	2	76	theme	such	349:352	arg1	loss					392:395	the loss	388:395	the loss	388:395	One such clinically relevant adaptation is the loss of bacterial motility, observed within chronic infections, that is associated with increased antibiotic tolerance and phagocytic resistance.
32041787	7	77	theme	aeruginosa	1883:1892	arg1	recognition					1854:1864	recognition	1854:1864	recognition	1854:1864	These findings provide novel insights into the cellular determinants for phagocytic recognition and uptake of P. aeruginosa.
32041787	7	77	theme	aeruginosa	1883:1892	arg1	uptake					1870:1875	uptake	1870:1875	uptake	1870:1875	These findings provide novel insights into the cellular determinants for phagocytic recognition and uptake of P. aeruginosa.
32041787	4	78	attach	attachment	1237:1246	arg2	bacteria					1255:1262	the bacteria	1251:1262	the bacteria	1251:1262	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	4	78	attach	attachment	1237:1246	arg1	cells					1276:1280	the host cells	1267:1280	the host cells	1267:1280	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
32041787	6	79	theme	murine	1683:1688	arg1	neutrophils					1690:1700	murine neutrophils	1683:1700	murine neutrophils	1683:1700	Moreover, talin-1 and kindlin-3 proteins promote uptake, but not binding, of P. aeruginosa by murine neutrophils, which supports a role for CD18 integrin signaling in this process.
32041787	1	80	theme	host	149:152	arg1	control					154:160	host control	149:160	host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival	149:342	Phagocytosis is the key mechanism for host control of Pseudomonas aeruginosa, a motile Gram-negative, opportunistic bacterial pathogen which frequently undergoes adaptation and selection for traits that are advantageous for survival.
32041787	3	81	with	engagement	763:772	arg1	integrins					795:803	CD18-containing integrins	779:803	CD18-containing integrins	779:803	Previous studies using phagocytes from a leukocyte adhesion deficiency type 1 (LAD-I) patient identified CD18 as a putative cell surface receptor for uptake of live P. aeruginosa However, how bacterial motility alters direct engagement with CD18-containing integrins remains unknown.
32041787	0	82	theme	Phagocytic	57:66	arg1	Internalization					68:82	Phagocytic Internalization	57:82	Phagocytic Internalization of Pseudomonas aeruginosa	57:108	Distinct Contributions of CD18 Integrins for Binding and Phagocytic Internalization of Pseudomonas aeruginosa.
32041787	4	83	theme	initial	1229:1235	arg1	attachment					1237:1246	the initial attachment	1225:1246	the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells	1225:1369	Here we demonstrate, with the use of motile and isogenic nonmotile deletion mutants of two independent strains of P. aeruginosa and with CRISPR-generated CD18-deficient cell lines in human monocytes and murine neutrophils, that CD18 expression facilitates the uptake of both motile and nonmotile P. aeruginosa However, unexpectedly, mechanistic studies revealed that CD18 expression was dispensable for the initial attachment of the bacteria to the host cells, which was validated with ectopic expression of complement receptor 3 (CR3) by CHO cells.
33453988	8	0	theme	oral	1292:1295	arg1	GlcNAc					1297:1302	oral GlcNAc	1292:1302	oral GlcNAc	1292:1302	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	4	1	theme	N-glycan	560:567	arg1	branching					569:577	N-glycan branching	560:577	N-glycan branching	560:577	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	8	2	theme	myelin	1261:1266	arg1	repair					1268:1273	myelin repair	1261:1273	myelin repair	1261:1273	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	2	3	theme	glycoprotein	415:426	arg1	clustering					428:437	glycoprotein clustering	415:437	glycoprotein clustering	415:437	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	4	4	theme	cell	683:686	arg1	endocytosis					688:698	platelet-derived growth factor receptor-α cell endocytosis	641:698	platelet-derived growth factor receptor-α cell endocytosis	641:698	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	8	5	from	diseases	1344:1351	arg1	neuroprotective					1311:1325	neuroprotective	1311:1325	neuroprotective	1311:1325	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	4	6	link	platelet-derived	641:656	arg1	factor					665:670	platelet-derived growth factor	641:670	platelet-derived growth factor	641:670	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	1	7	theme	multiple	197:204	arg1	MS					217:218	MS	217:218	MS	217:218	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	1	7	theme	multiple	197:204	arg1	sclerosis					206:214	multiple sclerosis	197:214	multiple sclerosis (MS)	197:219	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	4	8	theme	receptor-α	672:681	arg1	endocytosis					688:698	platelet-derived growth factor receptor-α cell endocytosis	641:698	platelet-derived growth factor receptor-α cell endocytosis	641:698	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	5	9	theme	newborn	771:777	arg1	pups					779:782	newborn pups	771:782	newborn pups	771:782	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	5	10	theme	oral	711:714	arg1	GlcNAc					716:721	oral GlcNAc	711:721	oral GlcNAc	711:721	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	5	11	theme	N-glycan	843:850	arg1	branching					852:860	N-glycan branching	843:860	N-glycan branching	843:860	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	2	12	theme	receptors	322:330	arg1	Modification					293:304	Modification	293:304	Modification of cell surface receptors with branched N-glycans	293:354	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	6	13	theme	myelin	1013:1018	arg1	repair					1020:1025	myelin repair	1013:1025	myelin repair	1013:1025	In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.
33453988	5	14	theme	lactating	726:734	arg1	mice					736:739	lactating mice	726:739	lactating mice	726:739	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	2	15	theme	surface	314:320	arg1	receptors					322:330	cell surface receptors	309:330	cell surface receptors	309:330	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	6	16	with	mice	910:913	arg1	demyelination					946:958	toxin (cuprizone)-induced demyelination	920:958	toxin (cuprizone)-induced demyelination	920:958	In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.
33453988	5	17	dep	drives	741:746	arg1	whereas					814:820	whereas	814:820	whereas	814:820	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	7	18	theme	serum	1055:1059	arg1	levels					1068:1073	endogenous serum GlcNAc levels	1044:1073	endogenous serum GlcNAc levels	1044:1073	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	2	19	theme	cell	309:312	arg1	receptors					322:330	cell surface receptors	309:330	cell surface receptors	309:330	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	3	20	theme	N-glycan	509:516	arg1	branching					518:526	N-glycan branching	509:526	N-glycan branching	509:526	GlcNAc is a rate-limiting metabolite for N-glycan branching.
33453988	8	21	theme	demyelinating	1330:1342	arg1	diseases					1344:1351	demyelinating diseases	1330:1351	demyelinating diseases like MS	1330:1359	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	7	22	theme	GlcNAc	1061:1066	arg1	levels					1068:1073	endogenous serum GlcNAc levels	1044:1073	endogenous serum GlcNAc levels	1044:1073	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	2	23	theme	cell	368:371	arg1	growth					373:378	cell growth	368:378	cell growth	368:378	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	3	24	theme	rate-limiting	480:492	arg1	GlcNAc					468:473	GlcNAc	468:473	GlcNAc	468:473	GlcNAc is a rate-limiting metabolite for N-glycan branching.
33453988	3	24	theme	rate-limiting	480:492	arg1	metabolite					494:503	a rate-limiting metabolite	478:503	a rate-limiting metabolite for N-glycan branching	478:526	GlcNAc is a rate-limiting metabolite for N-glycan branching.
33453988	4	25	theme	platelet-derived	641:656	arg1	factor					665:670	platelet-derived growth factor	641:670	platelet-derived growth factor	641:670	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	5	26	theme	primary	748:754	arg1	myelination					756:766	primary myelination	748:766	primary myelination in newborn pups	748:782	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	6	27	theme	adult	904:908	arg1	mice					910:913	adult mice	904:913	adult mice with toxin (cuprizone)-induced demyelination	904:958	In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.
33453988	1	28	theme	important	122:130	arg1	role					132:135	an important role	119:135	an important role	119:135	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	7	29	theme	endogenous	1044:1053	arg1	levels					1068:1073	endogenous serum GlcNAc levels	1044:1073	endogenous serum GlcNAc levels	1044:1073	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	8	30	from	neuroprotective	1311:1325	arg1	diseases					1344:1351	demyelinating diseases	1330:1351	demyelinating diseases like MS	1330:1359	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	31	theme	critical	1214:1221	arg1	GlcNAc					1204:1209	GlcNAc	1204:1209	GlcNAc	1204:1209	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	31	theme	critical	1214:1221	arg1	regulators					1223:1232	critical regulators	1214:1232	critical regulators of primary myelination and myelin repair	1214:1273	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	31	theme	critical	1214:1221	arg1	branching					1190:1198	N-glycan branching	1181:1198	N-glycan branching	1181:1198	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	2	32	theme	branched	337:344	arg1	N-glycans					346:354	branched N-glycans	337:354	branched N-glycans	337:354	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	0	33	theme	oligodendrocyte	53:67	arg1	differentiation					84:98	oligodendrocyte precursor cell differentiation	53:98	oligodendrocyte precursor cell differentiation	53:98	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.
33453988	4	34	theme	growth	658:663	arg1	factor					665:670	platelet-derived growth factor	641:670	platelet-derived growth factor	641:670	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	8	35	theme	primary	1237:1243	arg1	myelination					1245:1255	primary myelination	1237:1255	primary myelination	1237:1255	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	6	36	theme	neuro-axonal	982:993	arg1	damage					995:1000	neuro-axonal damage	982:1000	neuro-axonal damage	982:1000	In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.
33453988	4	37	from	cells	621:625	arg1	oligodendrogenesis					587:604	oligodendrogenesis	587:604	oligodendrogenesis from precursor cells	587:625	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	4	38	theme	precursor	611:619	arg1	cells					621:625	precursor cells	611:625	precursor cells	611:625	Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-α cell endocytosis.
33453988	2	39	gly	glycoprotein	415:426	arg1	glycoprotein					415:426	glycoprotein clustering	415:437	glycoprotein clustering	415:437	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	7	40	theme	damage	1155:1160	arg1	measures					1109:1116	imaging measures	1101:1116	imaging measures of demyelination and microstructural damage	1101:1160	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	0	41	theme	cell	79:82	arg1	differentiation					84:98	oligodendrocyte precursor cell differentiation	53:98	oligodendrocyte precursor cell differentiation	53:98	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.
33453988	1	42	theme	cognitive	140:148	arg1	development					150:160	cognitive development	140:160	cognitive development	140:160	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	0	43	theme	precursor	69:77	arg1	differentiation					84:98	oligodendrocyte precursor cell differentiation	53:98	oligodendrocyte precursor cell differentiation	53:98	N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.
33453988	5	44	from	myelination	756:766	arg1	pups					779:782	newborn pups	771:782	newborn pups	771:782	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	8	45	theme	myelination	1245:1255	arg1	GlcNAc					1204:1209	GlcNAc	1204:1209	GlcNAc	1204:1209	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	45	theme	myelination	1245:1255	arg1	regulators					1223:1232	critical regulators	1214:1232	critical regulators of primary myelination and myelin repair	1214:1273	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	45	theme	myelination	1245:1255	arg1	branching					1190:1198	N-glycan branching	1181:1198	N-glycan branching	1181:1198	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	6	46	theme	oral	961:964	arg1	GlcNAc					966:971	oral GlcNAc	961:971	oral GlcNAc	961:971	In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.
33453988	8	47	theme	N-glycan	1181:1188	arg1	GlcNAc					1204:1209	GlcNAc	1204:1209	GlcNAc	1204:1209	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	47	theme	N-glycan	1181:1188	arg1	regulators					1223:1232	critical regulators	1214:1232	critical regulators of primary myelination and myelin repair	1214:1273	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	47	theme	N-glycan	1181:1188	arg1	branching					1190:1198	N-glycan branching	1181:1198	N-glycan branching	1181:1198	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	7	48	theme	MS	1031:1032	arg1	patients					1034:1041	MS patients	1031:1041	MS patients	1031:1041	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	2	49	with	Modification	293:304	arg1	N-glycans					346:354	branched N-glycans	337:354	branched N-glycans	337:354	Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.
33453988	8	50	theme	repair	1268:1273	arg1	GlcNAc					1204:1209	GlcNAc	1204:1209	GlcNAc	1204:1209	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	50	theme	repair	1268:1273	arg1	regulators					1223:1232	critical regulators	1214:1232	critical regulators of primary myelination and myelin repair	1214:1273	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	8	50	theme	repair	1268:1273	arg1	branching					1190:1198	N-glycan branching	1181:1198	N-glycan branching	1181:1198	Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.
33453988	7	51	theme	microstructural	1139:1153	arg1	damage					1155:1160	microstructural damage	1139:1160	microstructural damage	1139:1160	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	1	52	theme	remyelination	239:251	arg1	failure					228:234	failure	228:234	failure of remyelination	228:251	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	5	53	theme	breast	801:806	arg1	milk					808:811	breast milk	801:811	breast milk	801:811	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	6	54	theme	-induced	937:944	arg1	demyelination					946:958	toxin (cuprizone)-induced demyelination	920:958	toxin (cuprizone)-induced demyelination	920:958	In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.
33453988	7	55	theme	demyelination	1121:1133	arg1	measures					1109:1116	imaging measures	1101:1116	imaging measures of demyelination and microstructural damage	1101:1160	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	1	56	theme	demyelinating	169:181	arg1	diseases					183:190	demyelinating diseases	169:190	demyelinating diseases	169:190	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	1	57	theme	permanent	262:270	arg1	damage					285:290	permanent neuro-axonal damage	262:290	permanent neuro-axonal damage	262:290	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
33453988	5	58	theme	primary	880:886	arg1	myelination					888:898	primary myelination	880:898	primary myelination	880:898	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	5	59	from	secretion	788:796	arg1	milk					808:811	breast milk	801:811	breast milk	801:811	Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.
33453988	7	60	theme	imaging	1101:1107	arg1	measures					1109:1116	imaging measures	1101:1116	imaging measures of demyelination and microstructural damage	1101:1160	In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.
33453988	1	61	theme	neuro-axonal	272:283	arg1	damage					285:290	permanent neuro-axonal damage	262:290	permanent neuro-axonal damage	262:290	Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.
32921312	2	0	from	carbamoylation	544:557	arg1	proteome					582:589	the HDL proteome	574:589	the HDL proteome	574:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	1	theme	dyslipidemia	326:337	arg1	management					312:321	The management	308:321	The management of dyslipidemia, hypertension and other traditional risk factors	308:386	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	7	2	theme	greater	1625:1631	arg1	ability					1633:1639	a greater ability	1623:1639	a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group	1623:1755	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	3	from	changes	563:569	arg1	proteome					582:589	the HDL proteome	574:589	the HDL proteome	574:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	1	4	theme	kidney	253:258	arg1	function					260:267	kidney function	253:267	kidney function	253:267	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
32921312	3	5	theme	nondialysis	698:708	arg1	subjects					710:717	nondialysis subjects	698:717	nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER)	698:840	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	7	6	theme	eGFR< 60 + A3	1593:1605	arg1	group					1607:1611	the eGFR< 60 + A3 group	1589:1611	the eGFR< 60 + A3 group	1589:1611	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	1	7	theme	kidney	182:187	arg1	disease					189:195	Diabetic kidney disease	173:195	Diabetic kidney disease	173:195	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
32921312	7	8	theme	antioxidant	1497:1507	arg1	role					1509:1512	The antioxidant role	1493:1512	The antioxidant role of HDL (lag time for LDL oxidation)	1493:1548	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	7	8	theme	antioxidant	1497:1507	arg1	similar					1554:1560	similar	1554:1560	similar	1554:1560	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	4	9	theme	AER	919:921	arg1	eGFR< 60					953:960	eGFR< 60	953:960	eGFR< 60	953:960	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	9	theme	AER	919:921	arg1	A3					967:968	A3 (n = 25)	967:977	A3 (n = 25)	967:977	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	9	theme	AER	919:921	arg1	stages					923:928	eGFR> 60 mL/min/1.73 m2 plus AER stages	890:928	eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25)	890:977	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	9	theme	AER	919:921	arg1	A2					937:938	A2	937:938	A2	937:938	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	9	theme	AER	919:921	arg1	A1					930:931	A1	930:931	A1	930:931	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	3	10	theme	filtration	778:787	arg1	eGFR					795:798	eGFR	795:798	eGFR	795:798	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	3	10	theme	filtration	778:787	arg1	rate					789:792	the estimated glomerular filtration rate	753:792	the estimated glomerular filtration rate (eGFR)	753:799	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	0	11	theme	kidney	120:125	arg1	disease					127:133	diabetic kidney disease	111:133	diabetic kidney disease without dialysis	111:150	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	8	12	theme	HDL	1840:1842	arg1	modification					1853:1864	the HDL chemical modification	1836:1864	the HDL chemical modification	1836:1864	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	3	13	theme	estimated	757:765	arg1	eGFR					795:798	eGFR	795:798	eGFR	795:798	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	3	13	theme	estimated	757:765	arg1	rate					789:792	the estimated glomerular filtration rate	753:792	the estimated glomerular filtration rate (eGFR)	753:799	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	4	14	theme	eGFR> 60 mL/min/1.73 m2	890:912	arg1	eGFR< 60					953:960	eGFR< 60	953:960	eGFR< 60	953:960	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	14	theme	eGFR> 60 mL/min/1.73 m2	890:912	arg1	A3					967:968	A3 (n = 25)	967:977	A3 (n = 25)	967:977	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	14	theme	eGFR> 60 mL/min/1.73 m2	890:912	arg1	stages					923:928	eGFR> 60 mL/min/1.73 m2 plus AER stages	890:928	eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25)	890:977	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	14	theme	eGFR> 60 mL/min/1.73 m2	890:912	arg1	A2					937:938	A2	937:938	A2	937:938	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	14	theme	eGFR> 60 mL/min/1.73 m2	890:912	arg1	A1					930:931	A1	930:931	A1	930:931	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	15	with	Individuals	851:861	arg1	DKD					868:870	DKD	868:870	DKD	868:870	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	5	16	theme	apolipoprotein	1225:1238	arg1	apoD					1243:1246	apoD	1243:1246	apoD	1243:1246	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	5	16	theme	apolipoprotein	1225:1238	arg1	D					1240:1240	apolipoprotein D	1225:1240	apolipoprotein D (apoD)	1225:1247	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	5	16	theme	apolipoprotein	1225:1238	arg1	RESULTS					1039:1045	RESULTS	1039:1045	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.	1039:1260	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	2	17	theme	risk	483:486	arg1	factors					488:494	nontraditional risk factors	468:494	nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality	468:607	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	17	theme	risk	483:486	arg1	products					527:534	advanced glycation end products	504:534	advanced glycation end products (AGEs)	504:541	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	3	18	theme	excretion	821:829	arg1	AER					837:839	AER	837:839	AER	837:839	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	3	18	theme	excretion	821:829	arg1	rate					831:834	urinary albumin excretion rate	805:834	urinary albumin excretion rate (AER)	805:840	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	6	19	from	macrophages	1439:1449	arg1	14C-cholesterol					1418:1432	14C-cholesterol	1418:1432	14C-cholesterol from macrophages (33%)	1418:1455	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	2	20	theme	end	523:525	arg1	AGEs					537:540	AGEs	537:540	AGEs	537:540	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	20	theme	end	523:525	arg1	carbamoylation					544:557	carbamoylation	544:557	carbamoylation	544:557	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	20	theme	end	523:525	arg1	products					527:534	advanced glycation end products	504:534	advanced glycation end products (AGEs)	504:541	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	20	theme	end	523:525	arg1	functionality					595:607	functionality	595:607	functionality	595:607	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	20	theme	end	523:525	arg1	changes					563:569	changes	563:569	changes in the HDL proteome	563:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	0	21	from	Enrichment	0:9	arg1	proteome					66:73	the HDL proteome	58:73	the HDL proteome	58:73	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	3	22	theme	urinary	805:811	arg1	excretion					821:829	urinary albumin excretion	805:829	urinary albumin excretion rate (AER)	805:840	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	4	23	dep	stages	923:928	arg1	stages					923:928	eGFR> 60 mL/min/1.73 m2 plus AER stages	890:928	eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25)	890:977	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	23	dep	stages	923:928	arg1	A1					930:931	A1	930:931	A1	930:931	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	23	dep	stages	923:928	arg1	eGFR< 60					953:960	eGFR< 60	953:960	eGFR< 60	953:960	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	23	dep	stages	923:928	arg1	A2					937:938	A2	937:938	A2	937:938	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	23	dep	stages	923:928	arg1	A3					967:968	A3 (n = 25)	967:977	A3 (n = 25)	967:977	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	23	dep	stages	923:928	arg1	n = 10					941:946	n = 10	941:946	n = 10	941:946	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	7	24	from	macrophages	1710:1720	arg1	secretion					1656:1664	the secretion	1652:1664	the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages	1652:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	25	theme	advanced	504:511	arg1	AGEs					537:540	AGEs	537:540	AGEs	537:540	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	25	theme	advanced	504:511	arg1	carbamoylation					544:557	carbamoylation	544:557	carbamoylation	544:557	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	25	theme	advanced	504:511	arg1	products					527:534	advanced glycation end products	504:534	advanced glycation end products (AGEs)	504:541	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	25	theme	advanced	504:511	arg1	functionality					595:607	functionality	595:607	functionality	595:607	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	25	theme	advanced	504:511	arg1	changes					563:569	changes	563:569	changes in the HDL proteome	563:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	26	theme	factors	380:386	arg1	management					312:321	The management	308:321	The management of dyslipidemia, hypertension and other traditional risk factors	308:386	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	0	27	theme	HDL	94:96	arg1	functions					98:106	HDL functions	94:106	HDL functions in diabetic kidney disease without dialysis	94:150	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	6	28	from	group	1289:1293	arg1	HDL					1262:1264	HDL	1262:1264	HDL from the eGFR< 60 + A3 group	1262:1293	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	7	29	theme	lag	1522:1524	arg1	time					1526:1529	lag time	1522:1529	lag time for LDL oxidation	1522:1547	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	8	30	dep	CONCLUSION	1758:1767	arg1	contribute					1808:1817	contribute	1808:1817	could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD	1802:1958	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	2	31	theme	traditional	363:373	arg1	factors					380:386	other traditional risk factors	357:386	other traditional risk factors	357:386	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	7	32	theme	HDL	1517:1519	arg1	role					1509:1512	The antioxidant role	1493:1512	The antioxidant role of HDL (lag time for LDL oxidation)	1493:1548	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	7	32	theme	HDL	1517:1519	arg1	similar					1554:1560	similar	1554:1560	similar	1554:1560	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	0	33	theme	apolipoprotein	14:27	arg1	A-IV					29:32	apolipoprotein A-IV	14:32	apolipoprotein A-IV	14:32	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	8	34	theme	chemical	1844:1851	arg1	modification					1853:1864	the HDL chemical modification	1836:1864	the HDL chemical modification	1836:1864	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	7	35	theme	IL-6	1669:1672	arg1	secretion					1656:1664	the secretion	1652:1664	the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages	1652:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	8	36	theme	HDL	1915:1917	arg1	loss					1919:1922	HDL loss	1915:1922	HDL loss of function in well-established DKD	1915:1958	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	5	37	dep	Targeted	1047:1054	arg1	quantified					1075:1084	quantified	1075:1084	quantified	1075:1084	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	5	37	dep	Targeted	1047:1054	arg1	RESULTS					1039:1045	RESULTS	1039:1045	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.	1039:1260	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	4	38	dep	METHODS	843:849	arg1	Individuals					851:861	Individuals	851:861	METHODS Individuals with DKD	843:870	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	5	39	dep	RESULTS	1039:1045	arg1	apoD					1243:1246	apoD	1243:1246	apoD	1243:1246	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	5	39	dep	RESULTS	1039:1045	arg1	apoA-IV					1253:1259	apoA-IV	1253:1259	apoA-IV	1253:1259	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	5	39	dep	RESULTS	1039:1045	arg1	D					1240:1240	apolipoprotein D	1225:1240	apolipoprotein D (apoD)	1225:1247	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	5	39	dep	RESULTS	1039:1045	arg1	RESULTS					1039:1045	RESULTS	1039:1045	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.	1039:1260	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	3	40	with	subjects	710:717	arg1	DKD					724:726	DKD	724:726	DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER)	724:840	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	8	41	from	loss	1919:1922	arg1	DKD					1956:1958	well-established DKD	1939:1958	well-established DKD	1939:1958	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	3	42	theme	chemical	641:648	arg1	modification					650:661	chemical modification	641:661	chemical modification	641:661	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	4	43	theme	control	1003:1009	arg1	subjects					1011:1018	control subjects	1003:1018	control subjects (eGFR> 60; n = 8)	1003:1036	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	4	43	theme	control	1003:1009	arg1	n = 8					1031:1035	n = 8	1031:1035	n = 8	1031:1035	METHODS Individuals with DKD were divided into eGFR> 60 mL/min/1.73 m2 plus AER stages A1 and A2 (n = 10) and eGFR< 60 plus A3 (n = 25) and matched by age with control subjects (eGFR> 60; n = 8).
32921312	5	44	from	HDL	1114:1116	arg1	groups					1125:1130	all groups	1121:1130	all groups	1121:1130	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	2	45	theme	HDL	578:580	arg1	proteome					582:589	the HDL proteome	574:589	the HDL proteome	574:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	0	46	theme	D	53:53	arg1	Enrichment					0:9	Enrichment	0:9	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome	0:73	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	6	47	attach	remove	1411:1416	arg2	ability					1400:1406	a reduced ability	1390:1406	a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls	1390:1490	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	47	attach	remove	1411:1416	arg1	controls					1483:1490	controls	1483:1490	controls	1483:1490	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	48	theme	reduced	1392:1398	arg1	ability					1400:1406	a reduced ability	1390:1406	a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls	1390:1490	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	1	49	theme	Diabetic	173:180	arg1	disease					189:195	Diabetic kidney disease	173:195	Diabetic kidney disease	173:195	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
32921312	0	50	theme	diabetic	111:118	arg1	disease					127:133	diabetic kidney disease	111:133	diabetic kidney disease without dialysis	111:150	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	6	51	theme	total	1322:1326	arg1	AGEs					1328:1331	total AGEs	1322:1331	total AGEs (20%)	1322:1337	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	51	theme	total	1322:1326	arg1	%					1336:1336	20%	1334:1336	20%	1334:1336	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	8	52	from	increase	1773:1780	arg1	apoA-IV					1794:1800	apoA-IV	1794:1800	apoA-IV	1794:1800	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	8	52	from	increase	1773:1780	arg1	apoD					1785:1788	apoD	1785:1788	apoD	1785:1788	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	0	53	from	functions	98:106	arg1	disease					127:133	diabetic kidney disease	111:133	diabetic kidney disease without dialysis	111:150	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	3	54	theme	glomerular	767:776	arg1	eGFR					795:798	eGFR	795:798	eGFR	795:798	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	3	54	theme	glomerular	767:776	arg1	rate					789:792	the estimated glomerular filtration rate	753:792	the estimated glomerular filtration rate (eGFR)	753:799	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	7	55	from	TNF-alpha	1678:1686	arg1	macrophages					1710:1720	LPS-elicited macrophages	1697:1720	LPS-elicited macrophages	1697:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	0	56	theme	HDL	62:64	arg1	proteome					66:73	the HDL proteome	58:73	the HDL proteome	58:73	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	2	57	theme	factors	488:494	arg1	participation					451:463	the participation	447:463	the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality	447:607	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	7	58	dep	HDL	1517:1519	arg1	time					1526:1529	lag time	1522:1529	lag time for LDL oxidation	1522:1547	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	5	59	theme	eGFR< 60 + A3	1183:1195	arg1	group					1197:1201	the eGFR< 60 + A3 group	1179:1201	the eGFR< 60 + A3 group	1179:1201	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	6	60	theme	eGFR< 60 + A3	1275:1287	arg1	group					1289:1293	the eGFR< 60 + A3 group	1271:1293	the eGFR< 60 + A3 group	1271:1293	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	61	theme	higher	1305:1310	arg1	levels					1312:1317	higher levels	1305:1317	higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x)	1305:1384	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	2	62	theme	nontraditional	468:481	arg1	factors					488:494	nontraditional risk factors	468:494	nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality	468:607	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	62	theme	nontraditional	468:481	arg1	products					527:534	advanced glycation end products	504:534	advanced glycation end products (AGEs)	504:541	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	7	63	theme	control	1743:1749	arg1	group					1751:1755	the control group	1739:1755	the control group	1739:1755	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	64	theme	glycation	513:521	arg1	AGEs					537:540	AGEs	537:540	AGEs	537:540	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	64	theme	glycation	513:521	arg1	carbamoylation					544:557	carbamoylation	544:557	carbamoylation	544:557	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	64	theme	glycation	513:521	arg1	products					527:534	advanced glycation end products	504:534	advanced glycation end products (AGEs)	504:541	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	64	theme	glycation	513:521	arg1	functionality					595:607	functionality	595:607	functionality	595:607	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	2	64	theme	glycation	513:521	arg1	changes					563:569	changes	563:569	changes in the HDL proteome	563:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	3	65	theme	albumin	813:819	arg1	excretion					821:829	urinary albumin excretion	805:829	urinary albumin excretion rate (AER)	805:840	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	7	66	theme	LDL	1535:1537	arg1	oxidation					1539:1547	LDL oxidation	1535:1547	LDL oxidation	1535:1547	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	67	theme	risk	375:378	arg1	factors					380:386	other traditional risk factors	357:386	other traditional risk factors	357:386	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	6	68	theme	pentosidine	1340:1350	arg1	ability					1400:1406	a reduced ability	1390:1406	a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls	1390:1490	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	68	theme	pentosidine	1340:1350	arg1	levels					1312:1317	higher levels	1305:1317	higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x)	1305:1384	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	5	69	theme	proteomic	1056:1064	arg1	analyses					1066:1073	proteomic analyses	1056:1073	proteomic analyses	1056:1073	RESULTS Targeted proteomic analyses quantified 28 proteins associated with HDL in all groups, although only 2 were more highly expressed in the eGFR< 60 + A3 group than in the controls: apolipoprotein D (apoD) and apoA-IV.
32921312	7	70	dep	group	1751:1755	arg1	comparison					1725:1734	comparison	1725:1734	comparison	1725:1734	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	1	71	dep	BACKGROUND	153:162	arg1	disease					189:195	Diabetic kidney disease	173:195	Diabetic kidney disease	173:195	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
32921312	2	72	theme	other	357:361	arg1	factors					380:386	other traditional risk factors	357:386	other traditional risk factors	357:386	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	0	73	theme	A-IV	29:32	arg1	Enrichment					0:9	Enrichment	0:9	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome	0:73	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	7	74	theme	LPS-elicited	1697:1708	arg1	macrophages					1710:1720	LPS-elicited macrophages	1697:1720	LPS-elicited macrophages	1697:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	7	75	from	secretion	1656:1664	arg1	macrophages					1710:1720	LPS-elicited macrophages	1697:1720	LPS-elicited macrophages	1697:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	76	theme	CVD	416:418	arg1	complications					420:432	CVD complications	416:432	CVD complications	416:432	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	0	77	theme	apolipoprotein	38:51	arg1	D					53:53	apolipoprotein D	38:53	apolipoprotein D	38:53	Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.
32921312	1	78	theme	cardiovascular	281:294	arg1	risk					302:305	cardiovascular (CVD) risk	281:305	cardiovascular (CVD) risk	281:305	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
32921312	7	79	from	IL-6	1669:1672	arg1	macrophages					1710:1720	LPS-elicited macrophages	1697:1720	LPS-elicited macrophages	1697:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	80	from	functionality	595:607	arg1	proteome					582:589	the HDL proteome	574:589	the HDL proteome	574:589	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	3	81	theme	HDL	614:616	arg1	composition					618:628	The HDL composition	610:628	The HDL composition	610:628	The HDL composition, proteome, chemical modification and functionality were analyzed in nondialysis subjects with DKD categorized according to the estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER).
32921312	6	82	theme	AGEs	1328:1331	arg1	ability					1400:1406	a reduced ability	1390:1406	a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls	1390:1490	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	82	theme	AGEs	1328:1331	arg1	levels					1312:1317	higher levels	1305:1317	higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x)	1305:1384	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	1	83	theme	CVD	297:299	arg1	risk					302:305	cardiovascular (CVD) risk	281:305	cardiovascular (CVD) risk	281:305	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
32921312	8	84	theme	function	1927:1934	arg1	loss					1919:1922	HDL loss	1915:1922	HDL loss of function in well-established DKD	1915:1958	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	7	85	theme	TNF-alpha	1678:1686	arg1	secretion					1656:1664	the secretion	1652:1664	the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages	1652:1720	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	8	86	theme	well-established	1939:1954	arg1	DKD					1956:1958	well-established DKD	1939:1958	well-established DKD	1939:1958	CONCLUSION The increase in apoD and apoA-IV could contribute to counteracting the HDL chemical modification by AGEs and carbamoylation, which contributes to HDL loss of function in well-established DKD.
32921312	6	87	theme	carbamoylation	1363:1376	arg1	ability					1400:1406	a reduced ability	1390:1406	a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls	1390:1490	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	6	87	theme	carbamoylation	1363:1376	arg1	levels					1312:1317	higher levels	1305:1317	higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x)	1305:1384	HDL from the eGFR< 60 + A3 group presented higher levels of total AGEs (20%), pentosidine (6.3%) and carbamoylation (4.2 x) and a reduced ability to remove 14C-cholesterol from macrophages (33%) in comparison to HDL from controls.
32921312	7	88	from	group	1607:1611	arg1	HDL					1580:1582	HDL	1580:1582	HDL from the eGFR< 60 + A3 group	1580:1611	The antioxidant role of HDL (lag time for LDL oxidation) was similar among groups, but HDL from the eGFR< 60 + A3 group presented a greater ability to inhibit the secretion of IL-6 and TNF-alpha (95%) in LPS-elicited macrophages in comparison to the control group.
32921312	2	89	theme	hypertension	340:351	arg1	management					312:321	The management	308:321	The management of dyslipidemia, hypertension and other traditional risk factors	308:386	The management of dyslipidemia, hypertension and other traditional risk factors does not completely prevent CVD complications, bringing up the participation of nontraditional risk factors such as advanced glycation end products (AGEs), carbamoylation and changes in the HDL proteome and functionality.
32921312	1	90	theme	lipid	222:226	arg1	derangements					228:239	lipid derangements	222:239	lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk	222:305	BACKGROUND AND AIMS Diabetic kidney disease (DKD) is associated with lipid derangements that worsen kidney function and enhance cardiovascular (CVD) risk.
34785590	1	0	theme	O-linked	189:196	arg1	attachment					198:207	the O-linked attachment	185:207	the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc)	185:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	1	1	theme	neurodegenerative	286:302	arg1	diseases					304:311	neurodegenerative diseases	286:311	neurodegenerative diseases	286:311	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	5	2	theme	MJD	826:828	arg1	cell					830:833	MJD cell and animal models	826:851	cell	830:833	By analyzing MJD cell and animal models, we provide evidence that OGT is dysregulated in MJD, therefore compromising the O-GlcNAc cycle.
34785590	8	3	theme	incurable	1530:1538	arg1	MJD					1540:1542	the yet incurable MJD	1522:1542	the yet incurable MJD	1522:1542	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	5	4	theme	O-GlcNAc	934:941	arg1	cycle					943:947	the O-GlcNAc cycle	930:947	the O-GlcNAc cycle	930:947	By analyzing MJD cell and animal models, we provide evidence that OGT is dysregulated in MJD, therefore compromising the O-GlcNAc cycle.
34785590	3	5	theme	target	557:562	arg1	proteins					564:571	target proteins	557:571	target proteins	557:571	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	8	6	from	ataxin-3	1399:1406	arg1	disease					1422:1428	disease	1422:1428	disease	1422:1428	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	6	from	ataxin-3	1399:1406	arg1	health					1411:1416	health	1411:1416	health	1411:1416	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	6	7	theme	proteasome-dependent	1033:1052	arg1	manner					1054:1059	a proteasome-dependent manner	1031:1059	a proteasome-dependent manner	1031:1059	Moreover, we demonstrate that wild-type ataxin-3 modulates OGT protein levels in a proteasome-dependent manner, and we present OGT as a substrate for ataxin-3.
34785590	1	8	gly	O-GlcNAcylation	116:130	arg1	diseases					304:311	neurodegenerative diseases	286:311	neurodegenerative diseases	286:311	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	2	9	theme	neuronal	337:344	arg1	substrates					359:368	substrates	359:368	substrates for O-GlcNAcylation	359:388	However, although many neuronal proteins are substrates for O-GlcNAcylation, this process has not been extensively investigated in polyglutamine disorders.
34785590	2	9	theme	neuronal	337:344	arg1	proteins					346:353	many neuronal proteins	332:353	many neuronal proteins	332:353	However, although many neuronal proteins are substrates for O-GlcNAcylation, this process has not been extensively investigated in polyglutamine disorders.
34785590	7	10	theme	ataxin-3	1152:1159	arg1	aggregates					1161:1170	ataxin-3 aggregates	1152:1170	ataxin-3 aggregates	1152:1170	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	2	11	theme	many	332:335	arg1	substrates					359:368	substrates	359:368	substrates for O-GlcNAcylation	359:388	However, although many neuronal proteins are substrates for O-GlcNAcylation, this process has not been extensively investigated in polyglutamine disorders.
34785590	2	11	theme	many	332:335	arg1	proteins					346:353	many neuronal proteins	332:353	many neuronal proteins	332:353	However, although many neuronal proteins are substrates for O-GlcNAcylation, this process has not been extensively investigated in polyglutamine disorders.
34785590	4	12	theme	neurodegenerative	616:632	arg1	condition					634:642	a neurodegenerative condition	614:642	a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate	614:810	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	4	12	theme	neurodegenerative	616:632	arg1	MJD					607:609	MJD	607:609	MJD	607:609	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	8	13	from	development	1491:1501	arg1	MJD					1540:1542	the yet incurable MJD	1522:1542	the yet incurable MJD	1522:1542	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	7	14	theme	disease	1316:1322	arg1	model					1303:1307	zebrafish model	1293:1307	zebrafish model of the disease	1293:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	7	15	from	model	1303:1307	arg1	reminiscent					1252:1262	motor impairment reminiscent	1235:1262	motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease	1235:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	4	16	theme	stretch	715:721	arg1	expansion					686:694	the expansion	682:694	the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate	682:810	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	3	17	theme	enzyme	495:500	arg1	OGT					524:526	OGT	524:526	OGT	524:526	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	3	17	theme	enzyme	495:500	arg1	transferase					511:521	the enzyme O-GlcNAc transferase	491:521	the enzyme O-GlcNAc transferase (OGT)	491:527	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	7	18	theme	motor	1235:1239	arg1	reminiscent					1252:1262	motor impairment reminiscent	1235:1262	motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease	1235:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	3	19	theme	Machado-Joseph	577:590	arg1	disease					592:598	Machado-Joseph disease	577:598	Machado-Joseph disease (MJD)	577:604	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	3	19	theme	Machado-Joseph	577:590	arg1	MJD					601:603	MJD	601:603	MJD	601:603	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	3	20	theme	O-GlcNAc	502:509	arg1	OGT					524:526	OGT	524:526	OGT	524:526	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	3	20	theme	O-GlcNAc	502:509	arg1	transferase					511:521	the enzyme O-GlcNAc transferase	491:521	the enzyme O-GlcNAc transferase (OGT)	491:527	We aimed to evaluate the enzyme O-GlcNAc transferase (OGT), which attaches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).
34785590	7	21	theme	ataxia	1267:1272	arg1	reminiscent					1252:1262	motor impairment reminiscent	1235:1262	motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease	1235:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	7	22	theme	OGT	1120:1122	arg1	levels					1124:1129	OGT levels	1120:1129	OGT levels	1120:1129	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	1	23	theme	Aberrant	107:114	arg1	modification					161:172	a protein posttranslational modification	133:172	a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc)	133:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	1	23	theme	Aberrant	107:114	arg1	O-GlcNAcylation					116:130	Aberrant O-GlcNAcylation	107:130	Aberrant O-GlcNAcylation	107:130	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	1	24	theme	monosaccharide	216:229	arg1	O-GlcNAc					252:259	O-GlcNAc	252:259	O-GlcNAc	252:259	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	1	24	theme	monosaccharide	216:229	arg1	N-acetylglucosamine					231:249	the monosaccharide N-acetylglucosamine	212:249	the monosaccharide N-acetylglucosamine (O-GlcNAc)	212:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	0	25	theme	Pathophysiological	0:17	arg1	interplay					19:27	Pathophysiological interplay	0:27	Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.	0:105	Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.
34785590	4	26	theme	increased	778:786	arg1	propensity					788:797	increased propensity	778:797	increased propensity to aggregate	778:810	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	1	27	theme	N-acetylglucosamine	231:249	arg1	attachment					198:207	the O-linked attachment	185:207	the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc)	185:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	0	28	theme	O-GlcNAc	37:44	arg1	transferase					46:56	O-GlcNAc transferase	37:56	O-GlcNAc transferase	37:56	Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.
34785590	6	29	theme	protein	1013:1019	arg1	levels					1021:1026	OGT protein levels	1009:1026	OGT protein levels	1009:1026	Moreover, we demonstrate that wild-type ataxin-3 modulates OGT protein levels in a proteasome-dependent manner, and we present OGT as a substrate for ataxin-3.
34785590	1	30	link	O-linked	189:196	arg1	attachment					198:207	the O-linked attachment	185:207	the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc)	185:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	5	31	theme	animal	839:844	arg1	models					846:851	MJD cell and animal models	826:851	models	846:851	By analyzing MJD cell and animal models, we provide evidence that OGT is dysregulated in MJD, therefore compromising the O-GlcNAc cycle.
34785590	7	32	from	patients	1281:1288	arg1	model					1303:1307	zebrafish model	1293:1307	zebrafish model of the disease	1293:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	6	33	theme	OGT	1009:1011	arg1	levels					1021:1026	OGT protein levels	1009:1026	OGT protein levels	1009:1026	Moreover, we demonstrate that wild-type ataxin-3 modulates OGT protein levels in a proteasome-dependent manner, and we present OGT as a substrate for ataxin-3.
34785590	4	34	dep	condition	634:642	arg1	caused					672:677	caused	672:677	caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate	672:810	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	4	34	dep	condition	634:642	arg1	characterized					644:656	characterized	644:656	characterized by ataxia	644:666	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	4	35	theme	deubiquitinase	734:747	arg1	ataxin-3					749:756	the deubiquitinase ataxin-3	730:756	the deubiquitinase ataxin-3	730:756	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	7	36	theme	impairment	1241:1250	arg1	reminiscent					1252:1262	motor impairment reminiscent	1235:1262	motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease	1235:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	7	37	from	reminiscent	1252:1262	arg1	model					1303:1307	zebrafish model	1293:1307	zebrafish model of the disease	1293:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	4	38	theme	polyglutamine	701:713	arg1	stretch					715:721	a polyglutamine stretch	699:721	a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate	699:810	MJD is a neurodegenerative condition characterized by ataxia and caused by the expansion of a polyglutamine stretch within the deubiquitinase ataxin-3, which then present increased propensity to aggregate.
34785590	7	39	theme	cell	1204:1207	arg1	viability					1209:1217	cell viability	1204:1217	cell viability	1204:1217	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	8	40	theme	promising	1466:1474	arg1	target					1476:1481	a promising target	1464:1481	a promising target for the development of therapeutics in the yet incurable MJD	1464:1542	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	40	theme	promising	1466:1474	arg1	cycle					1455:1459	the O-GlcNAc cycle	1442:1459	the O-GlcNAc cycle	1442:1459	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	0	41	theme	Machado-Joseph	66:79	arg1	ataxin-3					97:104	the Machado-Joseph disease protein ataxin-3	62:104	the Machado-Joseph disease protein ataxin-3	62:104	Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.
34785590	6	42	theme	wild-type	980:988	arg1	ataxin-3					990:997	wild-type ataxin-3	980:997	wild-type ataxin-3	980:997	Moreover, we demonstrate that wild-type ataxin-3 modulates OGT protein levels in a proteasome-dependent manner, and we present OGT as a substrate for ataxin-3.
34785590	7	43	theme	MJD	1277:1279	arg1	patients					1281:1288	MJD patients	1277:1288	MJD patients in zebrafish model of the disease	1277:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	1	44	theme	protein	135:141	arg1	modification					161:172	a protein posttranslational modification	133:172	a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc)	133:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	1	44	theme	protein	135:141	arg1	O-GlcNAcylation					116:130	Aberrant O-GlcNAcylation	107:130	Aberrant O-GlcNAcylation	107:130	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	7	45	theme	protein	1182:1188	arg1	clearance					1190:1198	protein clearance	1182:1198	protein clearance	1182:1198	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	1	46	theme	posttranslational	143:159	arg1	modification					161:172	a protein posttranslational modification	133:172	a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc)	133:260	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	1	46	theme	posttranslational	143:159	arg1	O-GlcNAcylation					116:130	Aberrant O-GlcNAcylation	107:130	Aberrant O-GlcNAcylation	107:130	Aberrant O-GlcNAcylation, a protein posttranslational modification defined by the O-linked attachment of the monosaccharide N-acetylglucosamine (O-GlcNAc), has been implicated in neurodegenerative diseases.
34785590	8	47	from	OGT	1391:1393	arg1	disease					1422:1428	disease	1422:1428	disease	1422:1428	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	47	from	OGT	1391:1393	arg1	health					1411:1416	health	1411:1416	health	1411:1416	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	48	theme	O-GlcNAc	1446:1453	arg1	target					1476:1481	a promising target	1464:1481	a promising target for the development of therapeutics in the yet incurable MJD	1464:1542	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	48	theme	O-GlcNAc	1446:1453	arg1	cycle					1455:1459	the O-GlcNAc cycle	1442:1459	the O-GlcNAc cycle	1442:1459	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	49	theme	therapeutics	1506:1517	arg1	development					1491:1501	the development	1487:1501	the development of therapeutics in the yet incurable MJD	1487:1542	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	8	50	theme	direct	1364:1369	arg1	interaction					1371:1381	a direct interaction	1362:1381	a direct interaction between OGT and ataxin-3 in health and disease	1362:1428	Taken together, our results point to a direct interaction between OGT and ataxin-3 in health and disease and propose the O-GlcNAc cycle as a promising target for the development of therapeutics in the yet incurable MJD.
34785590	0	51	theme	protein	89:95	arg1	ataxin-3					97:104	the Machado-Joseph disease protein ataxin-3	62:104	the Machado-Joseph disease protein ataxin-3	62:104	Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.
34785590	7	52	theme	zebrafish	1293:1301	arg1	model					1303:1307	zebrafish model	1293:1307	zebrafish model of the disease	1293:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
34785590	2	53	theme	polyglutamine	445:457	arg1	disorders					459:467	polyglutamine disorders	445:467	polyglutamine disorders	445:467	However, although many neuronal proteins are substrates for O-GlcNAcylation, this process has not been extensively investigated in polyglutamine disorders.
34785590	0	54	theme	disease	81:87	arg1	ataxin-3					97:104	the Machado-Joseph disease protein ataxin-3	62:104	the Machado-Joseph disease protein ataxin-3	62:104	Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.
34785590	7	55	theme	patients	1281:1288	arg1	reminiscent					1252:1262	motor impairment reminiscent	1235:1262	motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease	1235:1322	Targeting OGT levels and activity reduced ataxin-3 aggregates, improved protein clearance and cell viability, and alleviated motor impairment reminiscent of ataxia of MJD patients in zebrafish model of the disease.
32365408	0	0	theme	preformed	104:112	arg1	fibrils					114:120	α-synuclein preformed fibrils	92:120	α-synuclein preformed fibrils	92:120	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	7	1	theme	OGA	1208:1210	arg1	inhibition					1194:1203	inhibition	1194:1203	inhibition of OGA	1194:1210	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	7	2	located	observed	1263:1270	arg2	concentration-					1221:1234	concentration-	1221:1234	concentration-	1221:1234	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	7	2	located	observed	1263:1270	arg1	neurons					1328:1334	mouse primary cortical neurons	1305:1334	mouse primary cortical neurons	1305:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	7	2	located	observed	1263:1270	arg1	lines					1289:1293	multiple cell lines	1275:1293	multiple cell lines including mouse primary cortical neurons	1275:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	7	2	located	observed	1263:1270	arg2	reductions					1142:1151	These reductions	1136:1151	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA	1136:1210	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	6	3	theme	expression	1085:1094	arg1	knockdown					1068:1076	genetic knockdown	1060:1076	genetic knockdown of OGA expression	1060:1094	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	1	4	theme	α-synuclein	244:254	arg1	forms					235:239	aggregated forms	224:239	aggregated forms of α-synuclein (α-syn)	224:262	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	0	5	theme	α-synuclein	92:102	arg1	fibrils					114:120	α-synuclein preformed fibrils	92:120	α-synuclein preformed fibrils	92:120	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	10	6	theme	OGA	1683:1685	arg1	inhibitors					1687:1696	OGA inhibitors	1683:1696	OGA inhibitors	1683:1696	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	4	7	theme	potential	677:685	arg1	exploitation					687:698	their downstream potential exploitation	660:698	their downstream potential exploitation	660:698	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	8	8	theme	OGT	1375:1377	arg1	5SGlcNHex					1390:1398	5SGlcNHex	1390:1398	5SGlcNHex	1390:1398	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	8	8	theme	OGT	1375:1377	arg1	inhibitor					1379:1387	the OGT inhibitor	1371:1387	the OGT inhibitor	1371:1387	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	7	9	theme	mouse	1305:1309	arg1	neurons					1328:1334	mouse primary cortical neurons	1305:1334	mouse primary cortical neurons	1305:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	2	10	theme	α-syn	277:281	arg1	aggregates					283:292	These toxic α-syn aggregates	265:292	These toxic α-syn aggregates	265:292	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	2	11	dep	cell	323:326	arg1	cell					315:318	cell	315:318	cell	315:318	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	6	12	theme	nucleocytoplasmic	969:985	arg1	levels					987:992	increased nucleocytoplasmic levels	959:992	increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	959:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	0	13	theme	fibrils	114:120	arg1	internalization					73:87	cellular internalization	64:87	cellular internalization of α-synuclein preformed fibrils	64:120	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	6	14	link	O-linked	997:1004	arg1	N-acetylglucosamine					1006:1024	O-linked N-acetylglucosamine	997:1024	O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	997:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	6	14	link	O-linked	997:1004	arg1	O-GlcNAc					1027:1034	O-GlcNAc	1027:1034	O-GlcNAc	1027:1034	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	2	15	theme	toxic	271:275	arg1	aggregates					283:292	These toxic α-syn aggregates	265:292	These toxic α-syn aggregates	265:292	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	6	16	theme	increased	959:967	arg1	levels					987:992	increased nucleocytoplasmic levels	959:992	increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	959:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	10	17	theme	protective	1716:1725	arg1	effects					1727:1733	their protective effects	1710:1733	their protective effects	1710:1733	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	6	18	theme	proteins	1046:1053	arg1	levels					987:992	increased nucleocytoplasmic levels	959:992	increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	959:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	8	19	theme	cells	1360:1364	arg1	treatment					1347:1355	treatment	1347:1355	treatment of cells with the OGT inhibitor, 5SGlcNHex,	1347:1399	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	6	20	theme	genetic	1060:1066	arg1	knockdown					1068:1076	genetic knockdown	1060:1076	genetic knockdown of OGA expression	1060:1094	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	4	21	theme	high	642:645	arg1	interest					647:654	high interest	642:654	high interest for their downstream potential exploitation	642:698	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	4	22	theme	new	569:571	arg1	pathways					573:580	new pathways	569:580	new pathways that hinder the internalization of such α-syn fibrils	569:634	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	7	23	theme	primary	1311:1317	arg1	neurons					1328:1334	mouse primary cortical neurons	1305:1334	mouse primary cortical neurons	1305:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	0	24	theme	Pharmacological	0:14	arg1	inhibition					16:25	Pharmacological inhibition	0:25	Pharmacological inhibition	0:25	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	6	25	theme	OGA	1081:1083	arg1	expression					1085:1094	OGA expression	1081:1094	OGA expression	1081:1094	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	1	26	theme	Lewy	180:183	arg1	bodies					185:190	Lewy bodies	180:190	Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn)	180:262	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	1	26	theme	Lewy	180:183	arg1	hallmark					140:147	The pathological hallmark	123:147	The pathological hallmark of Parkinson's disease (PD)	123:175	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	7	27	theme	α-syn	1170:1174	arg1	fibrils					1176:1182	α-syn fibrils	1170:1182	α-syn fibrils	1170:1182	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	3	28	theme	pathology	502:510	arg1	spreading					485:493	spreading	485:493	spreading of the pathology throughout the brain	485:531	This process leads to spreading of the pathology throughout the brain in a prion-like manner.
32365408	4	29	theme	disease-modifying	719:735	arg1	therapeutics					737:748	disease-modifying therapeutics	719:748	disease-modifying therapeutics for PD	719:755	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	5	30	theme	hydrolase	857:865	arg1	OGA					880:882	OGA	880:882	OGA	880:882	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	5	30	theme	hydrolase	857:865	arg1	O-GlcNAcase					867:877	the glycoside hydrolase O-GlcNAcase	843:877	the glycoside hydrolase O-GlcNAcase (OGA)	843:883	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	2	31	theme	subsequent	423:432	arg1	uptake					434:439	their subsequent uptake	417:439	their subsequent uptake by neighboring cells	417:460	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	3	32	theme	prion-like	538:547	arg1	manner					549:554	a prion-like manner	536:554	a prion-like manner	536:554	This process leads to spreading of the pathology throughout the brain in a prion-like manner.
32365408	4	33	dep	way	705:707	arg1	create					712:717	create	712:717	to create disease-modifying therapeutics for PD	709:755	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	9	34	theme	unknown	1560:1566	arg1	mechanism					1568:1576	an unknown mechanism	1557:1576	an unknown mechanism that does not involve well-characterized endocytotic pathways	1557:1638	Notably, this effect is mediated through an unknown mechanism that does not involve well-characterized endocytotic pathways.
32365408	2	35	theme	dying	355:359	arg1	neurons					361:367	dying neurons	355:367	dying neurons	355:367	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	10	36	theme	potential	1813:1821	arg1	approach					1841:1848	a potential disease-modifying approach	1811:1848	a potential disease-modifying approach to treat PD	1811:1860	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	10	36	theme	potential	1813:1821	arg1	exploration					1778:1788	exploration	1778:1788	exploration of OGA inhibitors	1778:1806	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	5	37	theme	fibrils	922:928	arg1	uptake					906:911	the cellular uptake	893:911	the cellular uptake of α-syn fibrils	893:928	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	4	38	theme	α-syn	622:626	arg1	fibrils					628:634	such α-syn fibrils	617:634	such α-syn fibrils	617:634	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	5	39	theme	α-syn	916:920	arg1	fibrils					922:928	α-syn fibrils	916:928	α-syn fibrils	916:928	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	10	40	theme	disease-modifying	1823:1839	arg1	approach					1841:1848	a potential disease-modifying approach	1811:1848	a potential disease-modifying approach to treat PD	1811:1860	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	10	40	theme	disease-modifying	1823:1839	arg1	exploration					1778:1788	exploration	1778:1788	exploration of OGA inhibitors	1778:1806	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	8	41	theme	α-syn	1434:1438	arg1	PFFs					1440:1443	α-syn PFFs	1434:1443	α-syn PFFs	1434:1443	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	1	42	theme	pathological	127:138	arg1	bodies					185:190	Lewy bodies	180:190	Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn)	180:262	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	1	42	theme	pathological	127:138	arg1	hallmark					140:147	The pathological hallmark	123:147	The pathological hallmark of Parkinson's disease (PD)	123:175	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	4	43	theme	such	617:620	arg1	fibrils					628:634	such α-syn fibrils	617:634	such α-syn fibrils	617:634	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	0	44	theme	O-GlcNAcase	44:54	arg1	knockdown					31:39	knockdown	31:39	knockdown	31:39	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	0	44	theme	O-GlcNAcase	44:54	arg1	inhibition					16:25	Pharmacological inhibition	0:25	Pharmacological inhibition	0:25	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	7	45	theme	fibrils	1176:1182	arg1	uptake					1160:1165	the uptake	1156:1165	the uptake of α-syn fibrils caused by inhibition of OGA	1156:1210	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	6	46	theme	-modified	1036:1044	arg1	proteins					1046:1053	O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	997:1053	O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	997:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	4	47	theme	downstream	666:675	arg1	exploitation					687:698	their downstream potential exploitation	660:698	their downstream potential exploitation	660:698	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	8	48	with	treatment	1347:1355	arg1	5SGlcNHex					1390:1398	5SGlcNHex	1390:1398	5SGlcNHex	1390:1398	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	8	48	with	treatment	1347:1355	arg1	inhibitor					1379:1387	the OGT inhibitor	1371:1387	the OGT inhibitor	1371:1387	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	2	49	from	neurons	361:367	arg1	release					331:337	release	331:337	release of fibrils from dying neurons	331:367	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	2	50	theme	extracellular	378:390	arg1	environment					392:402	the extracellular environment	374:402	the extracellular environment	374:402	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	0	51	theme	cellular	64:71	arg1	internalization					73:87	cellular internalization	64:87	cellular internalization of α-synuclein preformed fibrils	64:120	Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
32365408	1	52	from	forms	235:239	arg1	brain					213:217	the brain	209:217	the brain from aggregated forms of α-synuclein (α-syn)	209:262	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	8	53	theme	PFFs	1440:1443	arg1	uptake					1424:1429	uptake	1424:1429	uptake of α-syn PFFs	1424:1443	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	8	54	theme	proteins	1484:1491	arg1	O-GlcNAcylation					1465:1479	O-GlcNAcylation	1465:1479	O-GlcNAcylation of proteins driving these effects	1465:1513	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	7	55	theme	multiple	1275:1282	arg1	neurons					1328:1334	mouse primary cortical neurons	1305:1334	mouse primary cortical neurons	1305:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	7	55	theme	multiple	1275:1282	arg1	lines					1289:1293	multiple cell lines	1275:1293	multiple cell lines including mouse primary cortical neurons	1275:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	10	56	theme	prion-like	1738:1747	arg1	neuropathologies					1749:1764	prion-like neuropathologies	1738:1764	prion-like neuropathologies	1738:1764	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	9	57	theme	well-characterized	1600:1617	arg1	pathways					1631:1638	well-characterized endocytotic pathways	1600:1638	well-characterized endocytotic pathways	1600:1638	Notably, this effect is mediated through an unknown mechanism that does not involve well-characterized endocytotic pathways.
32365408	7	58	theme	cell	1284:1287	arg1	neurons					1328:1334	mouse primary cortical neurons	1305:1334	mouse primary cortical neurons	1305:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	7	58	theme	cell	1284:1287	arg1	lines					1289:1293	multiple cell lines	1275:1293	multiple cell lines including mouse primary cortical neurons	1275:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	10	59	theme	OGA	1793:1795	arg1	inhibitors					1797:1806	OGA inhibitors	1793:1806	OGA inhibitors	1793:1806	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	9	60	theme	endocytotic	1619:1629	arg1	pathways					1631:1638	well-characterized endocytotic pathways	1600:1638	well-characterized endocytotic pathways	1600:1638	Notably, this effect is mediated through an unknown mechanism that does not involve well-characterized endocytotic pathways.
32365408	7	61	from	reductions	1142:1151	arg1	uptake					1160:1165	the uptake	1156:1165	the uptake of α-syn fibrils caused by inhibition of OGA	1156:1210	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	5	62	theme	cellular	897:904	arg1	uptake					906:911	the cellular uptake	893:911	the cellular uptake of α-syn fibrils	893:928	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	10	63	theme	inhibitors	1797:1806	arg1	exploration					1778:1788	exploration	1778:1788	exploration of OGA inhibitors	1778:1806	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	10	63	theme	inhibitors	1797:1806	arg1	approach					1841:1848	a potential disease-modifying approach	1811:1848	a potential disease-modifying approach to treat PD	1811:1860	These data suggest one mechanism by which OGA inhibitors might exert their protective effects in prion-like neuropathologies and support exploration of OGA inhibitors as a potential disease-modifying approach to treat PD.
32365408	2	64	dep	transferred	298:308	arg1	followed					405:412	followed	405:412	followed by their subsequent uptake by neighboring cells	405:460	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	7	65	theme	cortical	1319:1326	arg1	neurons					1328:1334	mouse primary cortical neurons	1305:1334	mouse primary cortical neurons	1305:1334	These reductions in the uptake of α-syn fibrils caused by inhibition of OGA are both concentration- and time-dependent and are observed in multiple cell lines including mouse primary cortical neurons.
32365408	1	66	theme	aggregated	224:233	arg1	forms					235:239	aggregated forms	224:239	aggregated forms of α-synuclein (α-syn)	224:262	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	4	67	theme	fibrils	628:634	arg1	internalization					598:612	the internalization	594:612	the internalization of such α-syn fibrils	594:634	Identifying new pathways that hinder the internalization of such α-syn fibrils is of high interest for their downstream potential exploitation as a way to create disease-modifying therapeutics for PD.
32365408	8	68	theme	uptake	1424:1429	arg1	level					1415:1419	the level	1411:1419	the level of uptake of α-syn PFFs	1411:1443	Moreover, treatment of cells with the OGT inhibitor, 5SGlcNHex, increases the level of uptake of α-syn PFFs, further supporting O-GlcNAcylation of proteins driving these effects.
32365408	5	69	theme	pharmacological	807:821	arg1	Thiamet-G					777:785	Thiamet-G	777:785	Thiamet-G	777:785	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	5	69	theme	pharmacological	807:821	arg1	agent					823:827	a highly selective pharmacological agent	788:827	a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA)	788:883	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	1	70	theme	disease	164:170	arg1	bodies					185:190	Lewy bodies	180:190	Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn)	180:262	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	1	70	theme	disease	164:170	arg1	hallmark					140:147	The pathological hallmark	123:147	The pathological hallmark of Parkinson's disease (PD)	123:175	The pathological hallmark of Parkinson's disease (PD) is Lewy bodies that form within the brain from aggregated forms of α-synuclein (α-syn).
32365408	5	71	theme	glycoside	847:855	arg1	OGA					880:882	OGA	880:882	OGA	880:882	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	5	71	theme	glycoside	847:855	arg1	O-GlcNAcase					867:877	the glycoside hydrolase O-GlcNAcase	843:877	the glycoside hydrolase O-GlcNAcase (OGA)	843:883	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	6	72	theme	N-acetylglucosamine	1006:1024	arg1	proteins					1046:1053	O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	997:1053	O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	997:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	2	73	theme	neighboring	444:454	arg1	cells					456:460	neighboring cells	444:460	neighboring cells	444:460	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	5	74	theme	selective	797:805	arg1	Thiamet-G					777:785	Thiamet-G	777:785	Thiamet-G	777:785	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	5	74	theme	selective	797:805	arg1	agent					823:827	a highly selective pharmacological agent	788:827	a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA)	788:883	Here, we show that Thiamet-G, a highly selective pharmacological agent that inhibits the glycoside hydrolase O-GlcNAcase (OGA), blunts the cellular uptake of α-syn fibrils.
32365408	2	75	theme	fibrils	342:348	arg1	release					331:337	release	331:337	release of fibrils from dying neurons	331:367	These toxic α-syn aggregates are transferred from cell to cell by release of fibrils from dying neurons into the extracellular environment, followed by their subsequent uptake by neighboring cells.
32365408	6	76	theme	O-linked	997:1004	arg1	N-acetylglucosamine					1006:1024	O-linked N-acetylglucosamine	997:1024	O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins	997:1053	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
32365408	6	76	theme	O-linked	997:1004	arg1	O-GlcNAc					1027:1034	O-GlcNAc	1027:1034	O-GlcNAc	1027:1034	This effect correlates with increased nucleocytoplasmic levels of O-linked N-acetylglucosamine (O-GlcNAc)-modified proteins, and genetic knockdown of OGA expression closely phenocopies both these effects.
34138941	2	0	theme	adult	539:543	arg1	islets					553:558	adult porcine islets	539:558	adult porcine islets	539:558	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	4	1	theme	anti-carbohydrate	776:792	arg1	responses					803:811	The elicited anti-carbohydrate antibody responses	763:811	The elicited anti-carbohydrate antibody responses	763:811	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	4	1	theme	anti-carbohydrate	776:792	arg1	IgM					832:834	IgM	832:834	IgM	832:834	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	8	2	theme	gene	1590:1593	arg1	editing					1595:1601	gene editing	1590:1601	gene editing	1590:1601	These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.
34138941	5	3	theme	linear	975:980	arg1	scale					982:986	a linear scale	973:986	a linear scale	973:986	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	1	4	theme	anti-carbohydrate	172:188	arg1	response					199:206	the anti-carbohydrate antibody response	168:206	the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs	168:270	Understanding the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs is critical to advancing xenotransplantation toward clinical application.
34138941	0	5	theme	adult	90:94	arg1	xenotransplantation					110:128	adult porcine islet xenotransplantation	90:128	adult porcine islet xenotransplantation in cynomolgus macaques	90:151	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	5	6	from	Patterns	875:882	arg1	pre-serum					994:1002	pre-serum	994:1002	pre-serum	994:1002	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	7	7	dep	structures	1254:1263	arg1	glycans					1301:1307	N-linked glycans	1292:1307	N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1292:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	7	7	dep	structures	1254:1263	arg1	Galβ1-4GlcNAcβ1-3Galβ1					1265:1286	Galβ1-4GlcNAcβ1-3Galβ1	1265:1286	Galβ1-4GlcNAcβ1-3Galβ1	1265:1286	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	6	8	theme	X	1187:1187	arg1	antigen					1189:1195	Lexis X antigen	1181:1195	Lexis X antigen	1181:1195	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	3	9	theme	antigen	596:602	arg1	microarray					604:613	a carbohydrate antigen microarray	581:613	a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications	581:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	6	10	theme	individual	1211:1220	arg1	monkeys					1222:1228	individual monkeys	1211:1228	individual monkeys	1211:1228	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	7	11	theme	N-linked	1292:1299	arg1	glycans					1301:1307	N-linked glycans	1292:1307	N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1292:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	5	12	dep	responses	905:913	arg1	units					954:958	log2 base units	944:958	log2 base units; 2.8-fold on a linear scale	944:986	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	5	12	dep	responses	905:913	arg1	difference					932:941	greater than 1.5 difference	915:941	elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens	887:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	7	13	link	N-linked	1292:1299	arg1	glycans					1301:1307	N-linked glycans	1292:1307	N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1292:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	5	14	theme	base	949:952	arg1	units					954:958	log2 base units	944:958	log2 base units; 2.8-fold on a linear scale	944:986	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	0	15	theme	islet	104:108	arg1	xenotransplantation					110:128	adult porcine islet xenotransplantation	90:128	adult porcine islet xenotransplantation in cynomolgus macaques	90:151	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	7	16	theme	carbohydrate	1241:1252	arg1	structures					1254:1263	The novel carbohydrate structures	1231:1263	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1231:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	7	16	theme	carbohydrate	1241:1252	arg1	targets					1377:1383	common targets	1370:1383	common targets of elicited IgM antibodies	1370:1410	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	5	17	theme	antibody	896:903	arg1	responses					905:913	elicited antibody responses	887:913	elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens	887:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	1	18	theme	antibody	190:197	arg1	response					199:206	the anti-carbohydrate antibody response	168:206	the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs	168:270	Understanding the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs is critical to advancing xenotransplantation toward clinical application.
34138941	0	19	theme	porcine	96:102	arg1	xenotransplantation					110:128	adult porcine islet xenotransplantation	90:128	adult porcine islet xenotransplantation in cynomolgus macaques	90:151	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	5	20	from	pre-serum	994:1002	arg1	responses					905:913	elicited antibody responses	887:913	elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens	887:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	5	20	from	pre-serum	994:1002	arg1	Patterns					875:882	Patterns	875:882	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens	875:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	3	21	theme	carbohydrate	583:594	arg1	microarray					604:613	a carbohydrate antigen microarray	581:613	a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications	581:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	2	22	theme	relative	414:421	arg1	concentrations					423:436	relative concentrations	414:436	relative concentrations in five cynomolgus monkeys	414:463	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	0	23	theme	antigen	13:19	arg1	analysis					32:39	Carbohydrate antigen microarray analysis	0:39	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.	0:152	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	8	24	theme	possible	1569:1576	arg1	targets					1578:1584	possible targets	1569:1584	possible targets for gene editing	1569:1601	These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.
34138941	6	25	from	Increases	1105:1113	arg1	response					1140:1147	the elicited antibody response	1118:1147	the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen	1118:1195	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	0	26	theme	antibodies	62:71	arg1	analysis					32:39	Carbohydrate antigen microarray analysis	0:39	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.	0:152	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	5	27	theme	post-serum	1007:1016	arg1	sampling					1018:1025	post-serum sampling	1007:1025	post-serum sampling specific for carbohydrate antigens	1007:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	0	28	theme	Carbohydrate	0:11	arg1	analysis					32:39	Carbohydrate antigen microarray analysis	0:39	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.	0:152	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	4	29	from	IgG	848:850	arg1	monkeys					866:872	4 out of 5 monkeys	855:872	4 out of 5 monkeys	855:872	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	6	30	located	found	1202:1206	arg2	Increases					1105:1113	Increases	1105:1113	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen	1105:1195	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	6	30	located	found	1202:1206	arg1	monkeys					1222:1228	individual monkeys	1211:1228	individual monkeys	1211:1228	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	4	31	theme	antibody	794:801	arg1	responses					803:811	The elicited anti-carbohydrate antibody responses	763:811	The elicited anti-carbohydrate antibody responses	763:811	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	4	31	theme	antibody	794:801	arg1	IgM					832:834	IgM	832:834	IgM	832:834	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	7	32	theme	novel	1235:1239	arg1	structures					1254:1263	The novel carbohydrate structures	1231:1263	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1231:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	7	32	theme	novel	1235:1239	arg1	targets					1377:1383	common targets	1370:1383	common targets of elicited IgM antibodies	1370:1410	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	5	33	theme	responses	905:913	arg1	Patterns					875:882	Patterns	875:882	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens	875:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	5	34	theme	specific	1027:1034	arg1	sampling					1018:1025	post-serum sampling	1007:1025	post-serum sampling specific for carbohydrate antigens	1007:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	8	35	theme	carbohydrate	1463:1474	arg1	epitopes					1476:1483	the carbohydrate epitopes	1459:1483	the carbohydrate epitopes	1459:1483	These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.
34138941	0	36	theme	microarray	21:30	arg1	analysis					32:39	Carbohydrate antigen microarray analysis	0:39	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.	0:152	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	2	37	theme	IgM	375:377	arg1	specificities					396:408	IgM and IgG antibody specificities	375:408	IgM and IgG antibody specificities	375:408	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	3	38	with	antigens	726:733	arg1	modifications					748:760	various modifications	740:760	various modifications	740:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	2	39	theme	cynomolgus	446:455	arg1	monkeys					457:463	five cynomolgus monkeys	441:463	five cynomolgus monkeys	441:463	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	0	40	theme	serum	44:48	arg1	IgG					50:52	serum IgG	44:52	serum IgG	44:52	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	1	41	theme	clinical	324:331	arg1	application					333:343	clinical application	324:343	clinical application	324:343	Understanding the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs is critical to advancing xenotransplantation toward clinical application.
34138941	7	42	theme	antibodies	1401:1410	arg1	structures					1254:1263	The novel carbohydrate structures	1231:1263	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1231:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	7	42	theme	antibodies	1401:1410	arg1	targets					1377:1383	common targets	1370:1383	common targets of elicited IgM antibodies	1370:1410	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	8	43	theme	important	1435:1443	arg1	insights					1445:1452	important insights	1435:1452	important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing	1435:1601	These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.
34138941	1	44	theme	porcine	237:243	arg1	cells					245:249	porcine cells	237:249	porcine cells	237:249	Understanding the anti-carbohydrate antibody response toward epitopes expressed on porcine cells, tissues, and organs is critical to advancing xenotransplantation toward clinical application.
34138941	2	45	theme	intraportal	504:514	arg1	xenotransplantation					516:534	intraportal xenotransplantation	504:534	intraportal xenotransplantation of adult porcine islets	504:558	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	0	46	theme	cynomolgus	133:142	arg1	macaques					144:151	cynomolgus macaques	133:151	cynomolgus macaques	133:151	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	3	47	theme	non-α-Gal	703:711	arg1	antigens					726:733	historically reported α-Gal and non-α-Gal carbohydrate antigens	671:733	historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications	671:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	8	48	theme	islet	1532:1536	arg1	xenotransplantation					1538:1556	pig-to-monkey islet xenotransplantation	1518:1556	pig-to-monkey islet xenotransplantation	1518:1556	These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.
34138941	5	49	theme	log2	944:947	arg1	units					954:958	log2 base units	944:958	log2 base units; 2.8-fold on a linear scale	944:986	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	5	50	theme	elicited	887:894	arg1	responses					905:913	elicited antibody responses	887:913	elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens	887:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	0	51	theme	IgM	58:60	arg1	antibodies					62:71	IgM antibodies	58:71	IgM antibodies	58:71	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	7	52	with	glycans	1301:1307	arg1	structure					1355:1363	Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1314:1363	Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1314:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	2	53	from	specificities	396:408	arg1	monkeys					457:463	five cynomolgus monkeys	441:463	five cynomolgus monkeys	441:463	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	7	54	theme	elicited	1388:1395	arg1	antibodies					1401:1410	elicited IgM antibodies	1388:1410	elicited IgM antibodies	1388:1410	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	0	55	theme	IgG	50:52	arg1	analysis					32:39	Carbohydrate antigen microarray analysis	0:39	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.	0:152	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
34138941	3	56	theme	carbohydrate	713:724	arg1	antigens					726:733	historically reported α-Gal and non-α-Gal carbohydrate antigens	671:733	historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications	671:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	2	57	from	concentrations	423:436	arg1	monkeys					457:463	five cynomolgus monkeys	441:463	five cynomolgus monkeys	441:463	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	7	58	theme	IgM	1397:1399	arg1	antibodies					1401:1410	elicited IgM antibodies	1388:1410	elicited IgM antibodies	1388:1410	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	7	59	theme	common	1370:1375	arg1	structures					1254:1263	The novel carbohydrate structures	1231:1263	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1231:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	7	59	theme	common	1370:1375	arg1	targets					1377:1383	common targets	1370:1383	common targets of elicited IgM antibodies	1370:1410	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	3	60	theme	α-Gal	693:697	arg1	antigens					726:733	historically reported α-Gal and non-α-Gal carbohydrate antigens	671:733	historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications	671:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	8	61	theme	pig-to-monkey	1518:1530	arg1	xenotransplantation					1538:1556	pig-to-monkey islet xenotransplantation	1518:1556	pig-to-monkey islet xenotransplantation	1518:1556	These results provide important insights into the carbohydrate epitopes that elicit antibodies following pig-to-monkey islet xenotransplantation and reveal possible targets for gene editing.
34138941	6	62	theme	antibody	1131:1138	arg1	response					1140:1147	the elicited antibody response	1118:1147	the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen	1118:1195	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	3	63	theme	various	740:746	arg1	modifications					748:760	various modifications	740:760	various modifications	740:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	5	64	theme	carbohydrate	1040:1051	arg1	antigens					1053:1060	carbohydrate antigens	1040:1060	carbohydrate antigens	1040:1060	Patterns of elicited antibody responses greater than 1.5 difference (log2 base units; 2.8-fold on a linear scale) from pre-serum to post-serum sampling specific for carbohydrate antigens were heterogeneous and recipient-specific.
34138941	4	65	theme	elicited	767:774	arg1	responses					803:811	The elicited anti-carbohydrate antibody responses	763:811	The elicited anti-carbohydrate antibody responses	763:811	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	4	65	theme	elicited	767:774	arg1	IgM					832:834	IgM	832:834	IgM	832:834	The elicited anti-carbohydrate antibody responses were predominantly IgM compared to IgG in 4 out of 5 monkeys.
34138941	6	66	theme	elicited	1122:1129	arg1	response					1140:1147	the elicited antibody response	1118:1147	the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen	1118:1195	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	2	67	theme	islets	553:558	arg1	xenotransplantation					516:534	intraportal xenotransplantation	504:534	intraportal xenotransplantation of adult porcine islets	504:558	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	6	68	theme	Lexis	1181:1185	arg1	antigen					1189:1195	Lexis X antigen	1181:1195	Lexis X antigen	1181:1195	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	3	69	used	utilized	572:579	arg2	study					566:570	This study	561:570	This study	561:570	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	2	70	theme	antibody	387:394	arg1	specificities					396:408	IgM and IgG antibody specificities	375:408	IgM and IgG antibody specificities	375:408	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	6	71	theme	GM2	1164:1166	arg1	antigens					1168:1175	GM2 antigens	1164:1175	GM2 antigens	1164:1175	Increases in the elicited antibody response to α-Gal, Sda, GM2 antigens, or Lexis X antigen were found in individual monkeys.
34138941	2	72	theme	porcine	545:551	arg1	islets					553:558	adult porcine islets	539:558	adult porcine islets	539:558	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	7	73	with	Galβ1-4GlcNAcβ1-3Galβ1	1265:1286	arg1	structure					1355:1363	Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1314:1363	Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1314:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	3	74	theme	reported	684:691	arg1	antigens					726:733	historically reported α-Gal and non-α-Gal carbohydrate antigens	671:733	historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications	671:760	This study utilized a carbohydrate antigen microarray that comprised more than 400 glycoconjugates, including historically reported α-Gal and non-α-Gal carbohydrate antigens with various modifications.
34138941	2	75	theme	IgG	383:385	arg1	specificities					396:408	IgM and IgG antibody specificities	375:408	IgM and IgG antibody specificities	375:408	In this study, we determined IgM and IgG antibody specificities and relative concentrations in five cynomolgus monkeys at baseline and at intervals following intraportal xenotransplantation of adult porcine islets.
34138941	7	76	theme	Manβ1-4GlcNAcβ	1340:1353	arg1	structure					1355:1363	Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1314:1363	Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure	1314:1363	The novel carbohydrate structures Galβ1-4GlcNAcβ1-3Galβ1 and N-linked glycans with Manα1-6(GlcNAcβ1-2Manα1-3)Manβ1-4GlcNAcβ structure were common targets of elicited IgM antibodies.
34138941	0	77	from	xenotransplantation	110:128	arg1	macaques					144:151	cynomolgus macaques	133:151	cynomolgus macaques	133:151	Carbohydrate antigen microarray analysis of serum IgG and IgM antibodies before and after adult porcine islet xenotransplantation in cynomolgus macaques.
33446867	0	0	theme	profiling	106:114	arg1	spectrometry					121:132	activity correlation profiling mass spectrometry	85:132	activity correlation profiling mass spectrometry	85:132	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	2	1	gly	glycosylation	328:340	arg2	lumen					359:363	the ER lumen	352:363	the ER lumen	352:363	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	7	2	theme	quaternary	1498:1507	arg1	structure					1509:1517	quaternary structure	1498:1517	quaternary structure	1498:1517	Our results instead strongly suggest that M5-DLO scramblase activity is due to a protein, or protein complex, whose activity is regulated at the level of quaternary structure.
33446867	0	3	theme	correlation	94:104	arg1	spectrometry					121:132	activity correlation profiling mass spectrometry	85:132	activity correlation profiling mass spectrometry	85:132	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	5	4	from	activity	832:839	arg1	proteoliposomes					844:858	proteoliposomes	844:858	proteoliposomes reconstituted with a crude mixture of ER membrane proteins	844:917	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	1	5	gly	glycosylation	190:202	arg1	proteins					207:214	proteins	207:214	proteins	207:214	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	1	5	gly	glycosylation	190:202	arg1	ER					246:247	ER	246:247	ER	246:247	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	1	5	gly	glycosylation	190:202	arg1	reticulum					235:243	the endoplasmic reticulum	219:243	the endoplasmic reticulum (ER)	219:248	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	6	6	theme	gene	1197:1200	arg1	disruption					1202:1211	gene disruption	1197:1211	gene disruption	1197:1211	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	1	7	theme	-linked	182:188	arg1	glycosylation					190:202	asparagine (N)-linked glycosylation	168:202	asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER)	168:248	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	4	8	theme	membrane	617:624	arg1	protein					626:632	The membrane protein	613:632	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane	613:710	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane has not been identified, despite its importance for N-glycosylation.
33446867	4	8	theme	membrane	617:624	arg1	scramblase					642:651	M5-DLO scramblase	635:651	M5-DLO scramblase	635:651	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane has not been identified, despite its importance for N-glycosylation.
33446867	5	9	dep	spectrometry-based	940:957	arg1	profiling					981:989	activity correlation profiling	960:989	activity correlation profiling	960:989	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	1	10	theme	glycolipid	268:277	arg1	Glc3Man9GlcNAc2-PP-dolichol					279:305	the glycolipid Glc3Man9GlcNAc2-PP-dolichol	264:305	the glycolipid Glc3Man9GlcNAc2-PP-dolichol	264:305	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	0	11	theme	mass	116:119	arg1	spectrometry					121:132	activity correlation profiling mass spectrometry	85:132	activity correlation profiling mass spectrometry	85:132	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	3	12	theme	Glycolipid	525:534	arg1	assembly					536:543	Glycolipid assembly	525:543	Glycolipid assembly	525:543	Glycolipid assembly is completed only after M5-DLO is translocated to the luminal side.
33446867	6	13	theme	Trypanosoma	1228:1238	arg1	brucei					1240:1245	the protist Trypanosoma brucei	1216:1245	the protist Trypanosoma brucei	1216:1245	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	5	14	theme	ER	898:899	arg1	proteins					910:917	ER membrane proteins	898:917	ER membrane proteins	898:917	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	4	15	theme	M5-DLO	668:673	arg1	translocation					675:687	M5-DLO translocation	668:687	M5-DLO translocation across the ER membrane	668:710	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane has not been identified, despite its importance for N-glycosylation.
33446867	5	16	theme	yeast	1042:1046	arg1	cerevisiae					1062:1071	the yeast Saccharomyces cerevisiae	1038:1071	the yeast Saccharomyces cerevisiae	1038:1071	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	2	17	theme	lipid	438:442	arg1	Man5GlcNAc2-PP-dolichol					457:479	the lipid intermediate Man5GlcNAc2-PP-dolichol	434:479	the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER	434:522	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	2	17	theme	lipid	438:442	arg1	M5-DLO					482:487	M5-DLO	482:487	M5-DLO	482:487	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	5	18	theme	activity	960:967	arg1	profiling					981:989	activity correlation profiling	960:989	activity correlation profiling	960:989	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	2	19	theme	ER	521:522	arg1	side					509:512	the cytoplasmic side	493:512	the cytoplasmic side of the ER	493:522	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	5	20	theme	Saccharomyces	1048:1060	arg1	cerevisiae					1062:1071	the yeast Saccharomyces cerevisiae	1038:1071	the yeast Saccharomyces cerevisiae	1038:1071	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	4	21	theme	ER	700:701	arg1	membrane					703:710	the ER membrane	696:710	the ER membrane	696:710	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane has not been identified, despite its importance for N-glycosylation.
33446867	2	22	theme	cytoplasmic	497:507	arg1	side					509:512	the cytoplasmic side	493:512	the cytoplasmic side of the ER	493:522	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	5	23	theme	scramblase	821:830	arg1	activity					832:839	scramblase activity	821:839	scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins	821:917	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	6	24	theme	reconstitution-based	1165:1184	arg1	assays					1186:1191	reconstitution-based assays	1165:1191	reconstitution-based assays	1165:1191	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	25	from	disruption	1202:1211	arg1	brucei					1240:1245	the protist Trypanosoma brucei	1216:1245	the protist Trypanosoma brucei	1216:1245	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	1	26	theme	proteins	207:214	arg1	glycosylation					190:202	asparagine (N)-linked glycosylation	168:202	asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER)	168:248	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	2	27	theme	synthesis	415:423	arg1	steps					378:382	the initial steps	366:382	the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis	366:423	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	0	28	theme	eukaryotic	18:27	arg1	scramblase					61:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	0	29	link	dolichol-linked	29:43	arg1	scramblase					61:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	3	30	theme	luminal	599:605	arg1	side					607:610	the luminal side	595:610	the luminal side	595:610	Glycolipid assembly is completed only after M5-DLO is translocated to the luminal side.
33446867	6	31	theme	scramblase	1138:1147	arg1	proteins					1126:1133	six polytopic ER membrane proteins	1100:1133	six polytopic ER membrane proteins	1100:1133	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	31	theme	scramblase	1138:1147	arg1	candidates					1149:1158	scramblase candidates	1138:1158	scramblase candidates	1138:1158	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	1	32	link	-linked	182:188	arg1	glycosylation					190:202	asparagine (N)-linked glycosylation	168:202	asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER)	168:248	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	2	33	theme	initial	370:376	arg1	steps					378:382	the initial steps	366:382	the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis	366:423	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	1	34	theme	endoplasmic	223:233	arg1	ER					246:247	ER	246:247	ER	246:247	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	1	34	theme	endoplasmic	223:233	arg1	reticulum					235:243	the endoplasmic reticulum	219:243	the endoplasmic reticulum (ER)	219:248	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	0	35	theme	oligosaccharide	45:59	arg1	scramblase					61:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	7	36	theme	M5-DLO	1386:1391	arg1	activity					1404:1411	M5-DLO scramblase activity	1386:1411	M5-DLO scramblase activity	1386:1411	Our results instead strongly suggest that M5-DLO scramblase activity is due to a protein, or protein complex, whose activity is regulated at the level of quaternary structure.
33446867	7	37	theme	scramblase	1393:1402	arg1	activity					1404:1411	M5-DLO scramblase activity	1386:1411	M5-DLO scramblase activity	1386:1411	Our results instead strongly suggest that M5-DLO scramblase activity is due to a protein, or protein complex, whose activity is regulated at the level of quaternary structure.
33446867	5	38	theme	membrane	901:908	arg1	proteins					910:917	ER membrane proteins	898:917	ER membrane proteins	898:917	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	0	39	theme	dolichol-linked	29:43	arg1	scramblase					61:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	the eukaryotic dolichol-linked oligosaccharide scramblase	14:70	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	6	40	theme	Data	1074:1077	arg1	curation					1079:1086	Data curation	1074:1086	Data curation	1074:1086	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	5	41	theme	crude	881:885	arg1	mixture					887:893	a crude mixture	879:893	a crude mixture of ER membrane proteins	879:917	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	2	42	theme	intermediate	444:455	arg1	Man5GlcNAc2-PP-dolichol					457:479	the lipid intermediate Man5GlcNAc2-PP-dolichol	434:479	the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER	434:522	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	2	42	theme	intermediate	444:455	arg1	M5-DLO					482:487	M5-DLO	482:487	M5-DLO	482:487	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	6	43	theme	membrane	1117:1124	arg1	proteins					1126:1133	six polytopic ER membrane proteins	1100:1133	six polytopic ER membrane proteins	1100:1133	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	43	theme	membrane	1117:1124	arg1	candidates					1149:1158	scramblase candidates	1138:1158	scramblase candidates	1138:1158	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	44	theme	M5-DLO	1316:1321	arg1	activity					1334:1341	M5-DLO scramblase activity	1316:1341	M5-DLO scramblase activity	1316:1341	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	5	45	theme	correlation	969:979	arg1	profiling					981:989	activity correlation profiling	960:989	activity correlation profiling	960:989	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	0	46	theme	scramblase	61:70	arg1	Complexity					0:9	Complexity	0:9	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase	0:70	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	6	47	theme	protist	1220:1226	arg1	brucei					1240:1245	the protist Trypanosoma brucei	1216:1245	the protist Trypanosoma brucei	1216:1245	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	48	theme	scramblase	1323:1332	arg1	activity					1334:1341	M5-DLO scramblase activity	1316:1341	M5-DLO scramblase activity	1316:1341	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	5	49	theme	scramblase	1013:1022	arg1	candidates					1024:1033	scramblase candidates	1013:1033	scramblase candidates in the yeast Saccharomyces cerevisiae	1013:1071	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	6	50	theme	ER	1114:1115	arg1	proteins					1126:1133	six polytopic ER membrane proteins	1100:1133	six polytopic ER membrane proteins	1100:1133	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	50	theme	ER	1114:1115	arg1	candidates					1149:1158	scramblase candidates	1138:1158	scramblase candidates	1138:1158	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	7	51	theme	structure	1509:1517	arg1	level					1489:1493	the level	1485:1493	the level of quaternary structure	1485:1517	Our results instead strongly suggest that M5-DLO scramblase activity is due to a protein, or protein complex, whose activity is regulated at the level of quaternary structure.
33446867	2	52	from	Man5GlcNAc2-PP-dolichol	457:479	arg1	side					509:512	the cytoplasmic side	493:512	the cytoplasmic side of the ER	493:522	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	2	53	theme	ER	356:357	arg1	lumen					359:363	the ER lumen	352:363	the ER lumen	352:363	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	6	54	theme	polytopic	1104:1112	arg1	proteins					1126:1133	six polytopic ER membrane proteins	1100:1133	six polytopic ER membrane proteins	1100:1133	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	54	theme	polytopic	1104:1112	arg1	candidates					1149:1158	scramblase candidates	1138:1158	scramblase candidates	1138:1158	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	0	55	theme	activity	85:92	arg1	spectrometry					121:132	activity correlation profiling mass spectrometry	85:132	activity correlation profiling mass spectrometry	85:132	Complexity of the eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling mass spectrometry.
33446867	5	56	theme	proteins	910:917	arg1	mixture					887:893	a crude mixture	879:893	a crude mixture of ER membrane proteins	879:917	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	6	57	theme	proteins	1290:1297	arg1	none					1276:1279	none	1276:1279	none of these proteins	1276:1297	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	6	58	from	assays	1186:1191	arg1	brucei					1240:1245	the protist Trypanosoma brucei	1216:1245	the protist Trypanosoma brucei	1216:1245	Data curation prioritized six polytopic ER membrane proteins as scramblase candidates, but reconstitution-based assays and gene disruption in the protist Trypanosoma brucei revealed, unexpectedly, that none of these proteins is necessary for M5-DLO scramblase activity.
33446867	2	59	theme	Glc3Man9GlcNAc2-PP-dolichol	387:413	arg1	synthesis					415:423	Glc3Man9GlcNAc2-PP-dolichol synthesis	387:423	Glc3Man9GlcNAc2-PP-dolichol synthesis	387:423	Remarkably, whereas glycosylation occurs in the ER lumen, the initial steps of Glc3Man9GlcNAc2-PP-dolichol synthesis generate the lipid intermediate Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side of the ER.
33446867	5	60	from	candidates	1024:1033	arg1	cerevisiae					1062:1071	the yeast Saccharomyces cerevisiae	1038:1071	the yeast Saccharomyces cerevisiae	1038:1071	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33446867	4	61	theme	M5-DLO	635:640	arg1	protein					626:632	The membrane protein	613:632	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane	613:710	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane has not been identified, despite its importance for N-glycosylation.
33446867	4	61	theme	M5-DLO	635:640	arg1	scramblase					642:651	M5-DLO scramblase	635:651	M5-DLO scramblase	635:651	The membrane protein (M5-DLO scramblase) that mediates M5-DLO translocation across the ER membrane has not been identified, despite its importance for N-glycosylation.
33446867	7	62	theme	protein	1437:1443	arg1	complex					1445:1451	protein complex	1437:1451	protein complex	1437:1451	Our results instead strongly suggest that M5-DLO scramblase activity is due to a protein, or protein complex, whose activity is regulated at the level of quaternary structure.
33446867	1	63	from	glycosylation	190:202	arg1	ER					246:247	ER	246:247	ER	246:247	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	1	63	from	glycosylation	190:202	arg1	reticulum					235:243	the endoplasmic reticulum	219:243	the endoplasmic reticulum (ER)	219:248	The oligosaccharide required for asparagine (N)-linked glycosylation of proteins in the endoplasmic reticulum (ER) is donated by the glycolipid Glc3Man9GlcNAc2-PP-dolichol.
33446867	5	64	theme	spectrometry-based	940:957	arg1	approach					992:999	a mass spectrometry-based 'activity correlation profiling' approach	933:999	a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae	933:1071	Building on our ability to recapitulate scramblase activity in proteoliposomes reconstituted with a crude mixture of ER membrane proteins, we developed a mass spectrometry-based 'activity correlation profiling' approach to identify scramblase candidates in the yeast Saccharomyces cerevisiae.
33075613	13	0	theme	activity	1870:1877	arg1	recapitulation					1840:1853	recapitulation	1840:1853	recapitulation of mechanistic activity supported in zebrafish	1840:1900	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	11	1	theme	alkylating	1659:1668	arg1	activity					1670:1677	alkylating activity	1659:1677	alkylating activity of novel compounds	1659:1696	As such, the chorion may play an advantageous role in studies to determine alkylating activity of novel compounds.
33075613	6	2	theme	chorionic	863:871	arg1	interference					873:884	the chorionic interference	859:884	the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching	859:1023	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	11	3	theme	compounds	1688:1696	arg1	activity					1670:1677	alkylating activity	1659:1677	alkylating activity of novel compounds	1659:1696	As such, the chorion may play an advantageous role in studies to determine alkylating activity of novel compounds.
33075613	4	4	theme	N-linked	633:640	arg1	glycoproteins					642:654	N-linked glycoproteins	633:654	N-linked glycoproteins	633:654	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	12	5	theme	cisplatin	1776:1784	arg1	exposure					1786:1793	cisplatin exposure	1776:1793	cisplatin exposure	1776:1793	Furthermore, the expression of zebrafish hatching enzyme was not affected by cisplatin exposure.
33075613	7	6	theme	increased	1053:1061	arg1	exposure					1063:1070	increased exposure	1053:1070	increased exposure of cisplatin due to dechorionation	1053:1105	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	6	7	theme	cisplatin	939:947	arg1	interference					873:884	the chorionic interference	859:884	the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching	859:1023	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	4	8	link	N-linked	633:640	arg1	glycoproteins					642:654	N-linked glycoproteins	633:654	N-linked glycoproteins	633:654	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	8	9	theme	Red	1291:1293	arg1	staining					1295:1302	Alizarian Red staining	1281:1302	Alizarian Red staining	1281:1302	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	3	10	theme	throughput	564:573	arg1	capabilities					575:586	high throughput capabilities	559:586	high throughput capabilities	559:586	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	1	11	theme	transparent	205:215	arg1	development					217:227	their rapid, external, and transparent development	178:227	their rapid, external, and transparent development	178:227	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	6	12	theme	chemotherapeutic	921:936	arg1	cisplatin					939:947	a well-characterized alkylating chemotherapeutic, cisplatin	889:947	cisplatin	939:947	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	14	13	from	design	2047:2052	arg1	discovery					2062:2070	drug discovery	2057:2070	drug discovery	2057:2070	Experimental design in drug discovery should consider preliminary studies without dechorionation in order to determine dose impediment or off-target adducting.
33075613	12	14	theme	enzyme	1749:1754	arg1	expression					1716:1725	the expression	1712:1725	the expression of zebrafish hatching enzyme	1712:1754	Furthermore, the expression of zebrafish hatching enzyme was not affected by cisplatin exposure.
33075613	6	15	theme	well-characterized	891:908	arg1	cisplatin					939:947	a well-characterized alkylating chemotherapeutic, cisplatin	889:947	cisplatin	939:947	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	8	16	theme	dechorionated	1323:1335	arg1	groups					1369:1374	dechorionated and non-dechorionated treatment groups	1323:1374	dechorionated and non-dechorionated treatment groups	1323:1374	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	0	17	theme	chorionic	64:72	arg1	degradation					74:84	chorionic degradation	64:84	chorionic degradation	64:84	Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.
33075613	1	18	theme	model	156:160	arg1	popularity					140:149	popularity	140:149	popularity	140:149	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	1	18	theme	model	156:160	arg1	organism					162:169	a model organism	154:169	a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans	154:303	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	0	19	from	activity	21:28	arg1	zebrafish					33:41	zebrafish	33:41	zebrafish	33:41	Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.
33075613	4	20	theme	polypeptides	666:677	arg1	matrix					623:628	a matrix	621:628	a matrix of N-linked glycoproteins and other polypeptides called the chorion	621:696	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	5	21	theme	developing	742:751	arg1	embryo					753:758	the developing embryo	738:758	the developing embryo	738:758	This acelluar barrier is protective of the developing embryo, and thus new approaches for assessment have involved their removal.
33075613	8	22	from	observable	1309:1318	arg1	groups					1369:1374	dechorionated and non-dechorionated treatment groups	1323:1374	dechorionated and non-dechorionated treatment groups	1323:1374	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	1	23	theme	due	171:173	arg1	popularity					140:149	popularity	140:149	popularity	140:149	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	1	23	theme	due	171:173	arg1	organism					162:169	a model organism	154:169	a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans	154:303	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	12	24	theme	zebrafish	1730:1738	arg1	enzyme					1749:1754	zebrafish hatching enzyme	1730:1754	zebrafish hatching enzyme	1730:1754	Furthermore, the expression of zebrafish hatching enzyme was not affected by cisplatin exposure.
33075613	13	25	theme	higher	1957:1962	arg1	vertebrates					1964:1974	higher vertebrates	1957:1974	higher vertebrates	1957:1974	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	5	26	theme	acelluar	704:711	arg1	barrier					713:719	This acelluar barrier	699:719	This acelluar barrier	699:719	This acelluar barrier is protective of the developing embryo, and thus new approaches for assessment have involved their removal.
33075613	2	27	contain	had	339:341	arg1	discovery					325:333	drug discovery	320:333	drug discovery	320:333	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	2	27	contain	had	339:341	arg2	success					348:354	high success	343:354	high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity	343:445	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	2	28	theme	zebrafish	381:389	arg1	implementation					363:376	the implementation	359:376	the implementation of zebrafish	359:389	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	10	29	dep	cisplatin	1518:1526	arg1	crosslinking					1539:1550	crosslinking	1539:1550	crosslinking which reinforces the structure	1539:1581	This may be may be due to cisplatin covalently crosslinking which reinforces the structure.
33075613	13	30	theme	off-target	1923:1932	arg1	toxicities					1934:1943	highly relevant off-target toxicities	1907:1943	highly relevant off-target toxicities observed in higher vertebrates	1907:1974	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	0	31	theme	Cisplatin	0:8	arg1	activity					21:28	Cisplatin alkylating activity	0:28	Cisplatin alkylating activity in zebrafish	0:41	Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.
33075613	2	32	theme	target	406:411	arg1	discovery					413:421	target discovery	406:421	target discovery	406:421	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	7	33	theme	retained	1155:1162	arg1	confinement					1164:1174	retained confinement	1155:1174	retained confinement	1155:1174	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	1	34	theme	vertebrate	276:285	arg1	models					287:292	higher vertebrate models	269:292	higher vertebrate models	269:292	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	14	35	theme	dose	2153:2156	arg1	impediment					2158:2167	dose impediment	2153:2167	dose impediment	2153:2167	Experimental design in drug discovery should consider preliminary studies without dechorionation in order to determine dose impediment or off-target adducting.
33075613	14	36	theme	Experimental	2034:2045	arg1	design					2047:2052	Experimental design	2034:2052	Experimental design in drug discovery	2034:2070	Experimental design in drug discovery should consider preliminary studies without dechorionation in order to determine dose impediment or off-target adducting.
33075613	6	37	theme	delayed	1008:1014	arg1	hatching					1016:1023	delayed hatching	1008:1023	delayed hatching	1008:1023	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	3	38	theme	major	459:463	arg1	dependence					504:513	a dependence	502:513	a dependence on waterborne exposure in order to maintain high throughput capabilities	502:586	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	3	38	theme	major	459:463	arg1	limitation					465:474	a major limitation	457:474	a major limitation of the zebrafish model	457:497	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	7	39	theme	morphological	1121:1133	arg1	endpoints					1135:1143	morphological endpoints	1121:1143	morphological endpoints	1121:1143	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	9	40	theme	cisplatin-treated	1393:1409	arg1	embryos					1411:1417	cisplatin-treated embryos	1393:1417	cisplatin-treated embryos	1393:1417	The chorions of cisplatin-treated embryos showed resistance to degradation unless treated with a pronase solution.
33075613	13	41	located	observed	1945:1952	arg2	toxicities					1934:1943	highly relevant off-target toxicities	1907:1943	highly relevant off-target toxicities observed in higher vertebrates	1907:1974	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	13	41	located	observed	1945:1952	arg1	vertebrates					1964:1974	higher vertebrates	1957:1974	higher vertebrates	1957:1974	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	2	42	theme	drug	320:323	arg1	discovery					325:333	drug discovery	320:333	drug discovery	320:333	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	3	43	theme	zebrafish	483:491	arg1	model					493:497	the zebrafish model	479:497	the zebrafish model	479:497	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	1	44	theme	high	230:233	arg1	fecundity					235:243	high fecundity	230:243	high fecundity	230:243	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	1	45	with	development	217:227	arg1	humans					298:303	humans	298:303	humans	298:303	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	1	45	with	development	217:227	arg1	models					287:292	higher vertebrate models	269:292	higher vertebrate models	269:292	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	4	46	theme	Dose	589:592	arg1	delivery					594:601	Dose delivery	589:601	Dose delivery	589:601	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	13	47	theme	mechanistic	1858:1868	arg1	activity					1870:1877	mechanistic activity	1858:1877	mechanistic activity supported in zebrafish	1858:1900	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	11	48	theme	novel	1682:1686	arg1	compounds					1688:1696	novel compounds	1682:1696	novel compounds	1682:1696	As such, the chorion may play an advantageous role in studies to determine alkylating activity of novel compounds.
33075613	2	49	theme	high	343:346	arg1	success					348:354	high success	343:354	high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity	343:445	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	1	50	theme	gene	250:253	arg1	homology					255:262	gene homology	250:262	gene homology with higher vertebrate models and humans	250:303	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	8	51	theme	non-dechorionated	1341:1357	arg1	groups					1369:1374	dechorionated and non-dechorionated treatment groups	1323:1374	dechorionated and non-dechorionated treatment groups	1323:1374	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	7	52	theme	cisplatin	1075:1083	arg1	exposure					1063:1070	increased exposure	1053:1070	increased exposure of cisplatin due to dechorionation	1053:1105	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	8	53	theme	osteogenesis	1252:1263	arg1	inhibition					1238:1247	inhibition	1238:1247	inhibition	1238:1247	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	9	54	theme	pronase	1474:1480	arg1	solution					1482:1489	a pronase solution	1472:1489	a pronase solution	1472:1489	The chorions of cisplatin-treated embryos showed resistance to degradation unless treated with a pronase solution.
33075613	1	55	theme	rapid	184:188	arg1	development					217:227	their rapid, external, and transparent development	178:227	their rapid, external, and transparent development	178:227	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	3	56	theme	waterborne	518:527	arg1	exposure					529:536	waterborne exposure	518:536	waterborne exposure	518:536	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	1	57	theme	external	191:198	arg1	development					217:227	their rapid, external, and transparent development	178:227	their rapid, external, and transparent development	178:227	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	3	58	theme	high	559:562	arg1	capabilities					575:586	high throughput capabilities	559:586	high throughput capabilities	559:586	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	8	59	theme	Alizarian	1281:1289	arg1	staining					1295:1302	Alizarian Red staining	1281:1302	Alizarian Red staining	1281:1302	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	4	60	gly	glycoproteins	642:654	arg1	glycoproteins					642:654	N-linked glycoproteins	633:654	N-linked glycoproteins	633:654	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	6	61	theme	alkylating	910:919	arg1	cisplatin					939:947	a well-characterized alkylating chemotherapeutic, cisplatin	889:947	cisplatin	939:947	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	2	62	from	success	348:354	arg1	studies					394:400	studies	394:400	studies for target discovery, efficacy, and toxicity	394:445	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	2	62	from	success	348:354	arg1	implementation					363:376	the implementation	359:376	the implementation of zebrafish	359:389	Specifically, drug discovery has had high success in the implementation of zebrafish in studies for target discovery, efficacy, and toxicity.
33075613	12	63	theme	hatching	1740:1747	arg1	enzyme					1749:1754	zebrafish hatching enzyme	1730:1754	zebrafish hatching enzyme	1730:1754	Furthermore, the expression of zebrafish hatching enzyme was not affected by cisplatin exposure.
33075613	6	64	theme	zebrafish	988:996	arg1	chorion					977:983	the chorion	973:983	the chorion of zebrafish	973:996	In these studies, we explored the chorionic interference of a well-characterized alkylating chemotherapeutic, cisplatin, known to accumulate in the chorion of zebrafish and cause delayed hatching.
33075613	4	65	theme	glycoproteins	642:654	arg1	matrix					623:628	a matrix	621:628	a matrix of N-linked glycoproteins and other polypeptides called the chorion	621:696	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	7	66	theme	yolk	1206:1209	arg1	utilization					1211:1221	yolk utilization	1206:1221	yolk utilization	1206:1221	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	4	67	theme	other	660:664	arg1	polypeptides					666:677	other polypeptides	660:677	other polypeptides	660:677	Dose delivery can be impeded by a matrix of N-linked glycoproteins and other polypeptides called the chorion.
33075613	3	68	from	dependence	504:513	arg1	exposure					529:536	waterborne exposure	518:536	waterborne exposure	518:536	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	0	69	theme	osteogenesis	104:115	arg1	inhibition					90:99	inhibition	90:99	inhibition of osteogenesis	90:115	Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.
33075613	0	69	theme	osteogenesis	104:115	arg1	resistance					50:59	resistance	50:59	resistance to chorionic degradation	50:84	Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.
33075613	8	70	theme	treatment	1359:1367	arg1	groups					1369:1374	dechorionated and non-dechorionated treatment groups	1323:1374	dechorionated and non-dechorionated treatment groups	1323:1374	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	7	71	theme	total	1184:1188	arg1	length					1195:1200	total body length	1184:1200	total body length	1184:1200	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	14	72	theme	preliminary	2088:2098	arg1	studies					2100:2106	preliminary studies	2088:2106	preliminary studies	2088:2106	Experimental design in drug discovery should consider preliminary studies without dechorionation in order to determine dose impediment or off-target adducting.
33075613	13	73	theme	relevant	1914:1921	arg1	toxicities					1934:1943	highly relevant off-target toxicities	1907:1943	highly relevant off-target toxicities observed in higher vertebrates	1907:1974	These studies demonstrate that not only was recapitulation of mechanistic activity supported in zebrafish, but highly relevant off-target toxicities observed in higher vertebrates were identified in zebrafish, regardless of chorionation.
33075613	5	74	theme	new	770:772	arg1	approaches					774:783	thus new approaches	765:783	thus new approaches for assessment	765:798	This acelluar barrier is protective of the developing embryo, and thus new approaches for assessment have involved their removal.
33075613	14	75	theme	off-target	2172:2181	arg1	adducting					2183:2191	off-target adducting	2172:2191	off-target adducting	2172:2191	Experimental design in drug discovery should consider preliminary studies without dechorionation in order to determine dose impediment or off-target adducting.
33075613	1	76	theme	higher	269:274	arg1	models					287:292	higher vertebrate models	269:292	higher vertebrate models	269:292	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	14	77	theme	drug	2057:2060	arg1	discovery					2062:2070	drug discovery	2057:2070	drug discovery	2057:2070	Experimental design in drug discovery should consider preliminary studies without dechorionation in order to determine dose impediment or off-target adducting.
33075613	5	78	theme	embryo	753:758	arg1	protective					724:733	protective	724:733	protective	724:733	This acelluar barrier is protective of the developing embryo, and thus new approaches for assessment have involved their removal.
33075613	11	79	theme	advantageous	1617:1628	arg1	role					1630:1633	an advantageous role	1614:1633	an advantageous role	1614:1633	As such, the chorion may play an advantageous role in studies to determine alkylating activity of novel compounds.
33075613	7	80	theme	body	1190:1193	arg1	length					1195:1200	total body length	1184:1200	total body length	1184:1200	Our results indicated that increased exposure of cisplatin due to dechorionation did not alter morphological endpoints, although retained confinement reduced total body length and yolk utilization.
33075613	1	81	with	homology	255:262	arg1	humans					298:303	humans	298:303	humans	298:303	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	1	81	with	homology	255:262	arg1	models					287:292	higher vertebrate models	269:292	higher vertebrate models	269:292	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	9	82	theme	embryos	1411:1417	arg1	chorions					1381:1388	The chorions	1377:1388	The chorions of cisplatin-treated embryos	1377:1417	The chorions of cisplatin-treated embryos showed resistance to degradation unless treated with a pronase solution.
33075613	3	83	theme	model	493:497	arg1	dependence					504:513	a dependence	502:513	a dependence on waterborne exposure in order to maintain high throughput capabilities	502:586	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	3	83	theme	model	493:497	arg1	limitation					465:474	a major limitation	457:474	a major limitation of the zebrafish model	457:497	However, a major limitation of the zebrafish model is a dependence on waterborne exposure in order to maintain high throughput capabilities.
33075613	8	84	from	groups	1369:1374	arg1	observable					1309:1318	observable	1309:1318	observable	1309:1318	Additionally, inhibition of osteogenesis visualized with Alizarian Red staining, was observable in dechorionated and non-dechorionated treatment groups.
33075613	1	85	with	fecundity	235:243	arg1	humans					298:303	humans	298:303	humans	298:303	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	1	85	with	fecundity	235:243	arg1	models					287:292	higher vertebrate models	269:292	higher vertebrate models	269:292	Zebrafish have gained popularity as a model organism due to their rapid, external, and transparent development, high fecundity, and gene homology with higher vertebrate models and humans.
33075613	0	86	theme	alkylating	10:19	arg1	activity					21:28	Cisplatin alkylating activity	0:28	Cisplatin alkylating activity in zebrafish	0:41	Cisplatin alkylating activity in zebrafish causes resistance to chorionic degradation and inhibition of osteogenesis.
32699849	0	0	theme	SARS-CoV-2	41:50	arg1	interactomics					24:36	Comparative multiplexed interactomics	0:36	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins	0:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	6	1	theme	common	1111:1116	arg1	interactions					1118:1129	common interactions	1111:1129	common interactions	1111:1129	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	11	2	from	strains	2024:2030	arg1	OC43					2009:2012	OC43	2009:2012	OC43 from SARS strains	2009:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	11	2	from	strains	2024:2030	arg1	pathogenesis					1993:2004	the divergent pathogenesis	1979:2004	the divergent pathogenesis of OC43 from SARS strains	1979:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	4	3	theme	protein-protein	587:601	arg1	interactions					603:614	the virus-host protein-protein interactions	572:614	the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication	572:697	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	2	4	contain	has	429:431	arg2	virulence					445:453	distinctive virulence	433:453	distinctive virulence	433:453	Despite high sequence similarity between SARS-CoV-1 and -2, each strain has distinctive virulence.
32699849	2	4	contain	has	429:431	arg1	strain					422:427	each strain	417:427	each strain	417:427	Despite high sequence similarity between SARS-CoV-1 and -2, each strain has distinctive virulence.
32699849	10	5	theme	host	1775:1778	arg1	homeostasis					1807:1817	calcium homeostasis	1799:1817	calcium homeostasis	1799:1817	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	10	5	theme	host	1775:1778	arg1	processes					1780:1788	host processes	1775:1788	host processes	1775:1788	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	9	6	theme	Common	1443:1448	arg1	interactors					1455:1465	Common nsp4 interactors	1443:1465	Common nsp4 interactors	1443:1465	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	12	7	theme	multiple	2104:2111	arg1	proteins					2118:2125	multiple bait proteins	2104:2125	multiple bait proteins	2104:2125	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	4	8	theme	virus	681:685	arg1	replication					687:697	virus replication	681:697	virus replication	681:697	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	10	9	theme	organelle	1829:1837	arg1	sites					1847:1851	these organelle contact sites	1823:1851	these organelle contact sites	1823:1851	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	1	10	theme	global	207:212	arg1	health					214:219	global health	207:219	global health	207:219	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	5	11	theme	mass	714:717	arg1	proteomics					748:757	tandem mass tag-multiplexed quantitative proteomics	707:757	tandem mass tag-multiplexed quantitative proteomics	707:757	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	11	12	theme	infection	1921:1929	arg1	cycle					1931:1935	the infection cycle	1917:1935	the infection cycle	1917:1935	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	8	13	theme	nsp4	1307:1310	arg1	interactors					1312:1322	nsp4 interactors	1307:1322	nsp4 interactors	1307:1322	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	8	13	theme	nsp4	1307:1310	arg1	complexes					1375:1383	E3 ubiquitin ligase complexes	1355:1383	E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1355:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	5	14	theme	quantitative	735:746	arg1	proteomics					748:757	tandem mass tag-multiplexed quantitative proteomics	707:757	tandem mass tag-multiplexed quantitative proteomics	707:757	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	7	15	theme	nsp2	1188:1191	arg1	interactors					1193:1203	common nsp2 interactors	1181:1203	common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis	1181:1286	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	9	16	theme	protein	1519:1525	arg1	UPR					1537:1539	UPR	1537:1539	UPR	1537:1539	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	9	16	theme	protein	1519:1525	arg1	response					1527:1534	unfolded protein response	1510:1534	unfolded protein response (UPR)	1510:1540	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	8	17	theme	unique	1324:1329	arg1	interactors					1312:1322	nsp4 interactors	1307:1322	nsp4 interactors	1307:1322	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	8	17	theme	unique	1324:1329	arg1	complexes					1375:1383	E3 ubiquitin ligase complexes	1355:1383	E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1355:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	11	18	theme	host	1949:1952	arg1	factors					1954:1960	host factors	1949:1960	host factors that may mediate the divergent pathogenesis of OC43 from SARS strains	1949:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	1	19	theme	Human	156:160	arg1	coronaviruses					162:174	Human coronaviruses	156:174	Human coronaviruses (hCoV)	156:181	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	1	19	theme	Human	156:160	arg1	hCoV					177:180	hCoV	177:180	hCoV	177:180	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	12	20	theme	proteins	2118:2125	arg1	comparisons					2089:2099	rapid and robust comparisons	2072:2099	rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins	2072:2176	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	9	21	dep	associated	1542:1551	arg1	UPR					1537:1539	UPR	1537:1539	UPR	1537:1539	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	9	21	dep	associated	1542:1551	arg1	response					1527:1534	unfolded protein response	1510:1534	unfolded protein response (UPR)	1510:1540	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	6	22	theme	binding	1041:1047	arg1	partners					1049:1056	both unique and shared host cell protein binding partners	1000:1056	both unique and shared host cell protein binding partners	1000:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	0	23	theme	non-structural	79:92	arg1	proteins					94:101	homologous coronavirus non-structural proteins	56:101	homologous coronavirus non-structural proteins	56:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	5	24	theme	endemic	908:914	arg1	strain					916:921	an endemic strain	905:921	an endemic strain associated with the common cold	905:953	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	6	25	theme	cell	1028:1031	arg1	partners					1049:1056	both unique and shared host cell protein binding partners	1000:1056	both unique and shared host cell protein binding partners	1000:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	7	26	theme	Ca	1244:1245	arg1	signaling					1250:1258	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	6	27	theme	shared	1016:1021	arg1	partners					1049:1056	both unique and shared host cell protein binding partners	1000:1056	both unique and shared host cell protein binding partners	1000:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	8	28	theme	ubiquitin	1358:1366	arg1	ligase					1368:1373	E3 ubiquitin ligase	1355:1373	E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1355:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	9	29	theme	innate	1578:1583	arg1	factors					1602:1608	anti-viral innate immune signaling factors	1567:1608	anti-viral innate immune signaling factors	1567:1608	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	6	30	theme	unique	1005:1010	arg1	partners					1049:1056	both unique and shared host cell protein binding partners	1000:1056	both unique and shared host cell protein binding partners	1000:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	10	31	theme	ER	1714:1715	arg1	membranes					1717:1725	mitochondrial-associated ER membranes	1689:1725	mitochondrial-associated ER membranes	1689:1725	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	7	32	theme	reticulum	1229:1237	arg1	signaling					1250:1258	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	9	33	theme	signaling	1592:1600	arg1	factors					1602:1608	anti-viral innate immune signaling factors	1567:1608	anti-viral innate immune signaling factors	1567:1608	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	0	34	theme	proteins	94:101	arg1	interactomics					24:36	Comparative multiplexed interactomics	0:36	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins	0:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	8	35	theme	SARS-CoV-1	1389:1398	arg1	factors					1419:1425	SARS-CoV-1 and ER homeostasis factors	1389:1425	SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1389:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	0	36	theme	Comparative	0:10	arg1	interactomics					24:36	Comparative multiplexed interactomics	0:36	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins	0:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	2	37	theme	distinctive	433:443	arg1	virulence					445:453	distinctive virulence	433:453	distinctive virulence	433:453	Despite high sequence similarity between SARS-CoV-1 and -2, each strain has distinctive virulence.
32699849	8	38	theme	ER	1404:1405	arg1	homeostasis					1407:1417	ER homeostasis	1404:1417	ER homeostasis	1404:1417	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	10	39	theme	new	1740:1742	arg1	role					1755:1758	a new functional role	1738:1758	a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites	1738:1851	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	11	40	theme	SARS	2019:2022	arg1	strains					2024:2030	SARS strains	2019:2030	SARS strains	2019:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	13	41	theme	anti-viral	2284:2293	arg1	therapeutics					2295:2306	host-directed anti-viral therapeutics	2270:2306	host-directed anti-viral therapeutics	2270:2306	Furthermore, the identified common interactions may present new targets for exploration by host-directed anti-viral therapeutics.
32699849	5	42	theme	nsp2	815:818	arg1	interactomes					799:810	the interactomes	795:810	contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	786:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	7	43	theme	common	1181:1186	arg1	interactors					1193:1203	common nsp2 interactors	1181:1203	common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis	1181:1286	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	3	44	theme	molecular	492:500	arg1	mechanisms					502:511	the basic molecular mechanisms	482:511	the basic molecular mechanisms mediating changes in virulence	482:542	A better understanding of the basic molecular mechanisms mediating changes in virulence is needed.
32699849	5	45	theme	nsp4	824:827	arg1	interactomes					799:810	the interactomes	795:810	contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	786:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	1	46	theme	recent	310:315	arg1	pandemic					326:333	the most recent COVID-19 pandemic	301:333	the most recent COVID-19 pandemic caused by SARS-CoV-2	301:354	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	6	47	theme	related	1152:1158	arg1	strains					1160:1166	related strains	1152:1166	related strains	1152:1166	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	3	48	theme	better	458:463	arg1	understanding					465:477	A better understanding	456:477	A better understanding of the basic molecular mechanisms mediating changes in virulence	456:542	A better understanding of the basic molecular mechanisms mediating changes in virulence is needed.
32699849	2	49	theme	sequence	370:377	arg1	similarity					379:388	high sequence similarity	365:388	high sequence similarity between SARS-CoV-1 and -2	365:414	Despite high sequence similarity between SARS-CoV-1 and -2, each strain has distinctive virulence.
32699849	13	50	theme	common	2207:2212	arg1	interactions					2214:2225	the identified common interactions	2192:2225	the identified common interactions	2192:2225	Furthermore, the identified common interactions may present new targets for exploration by host-directed anti-viral therapeutics.
32699849	12	51	theme	mass	2037:2040	arg1	workflow					2055:2062	Our mass spectrometry workflow	2033:2062	Our mass spectrometry workflow	2033:2062	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	6	52	theme	interactions	1118:1129	arg1	enrichment					1097:1106	the enrichment	1093:1106	the enrichment of common interactions across homologs from related strains	1093:1166	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	4	53	theme	non-structural	628:641	arg1	nsps					653:656	nsps	653:656	nsps	653:656	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	4	53	theme	non-structural	628:641	arg1	proteins					643:650	two hCoV non-structural proteins	619:650	two hCoV non-structural proteins (nsps) that are critical for virus replication	619:697	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	1	54	theme	SARS	254:257	arg1	outbreak					259:266	the SARS outbreak	250:266	the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2	250:354	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	5	55	dep	strains	856:862	arg1	SARS-CoV-2					877:886	SARS-CoV-2	877:886	SARS-CoV-2	877:886	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	55	dep	strains	856:862	arg1	hCoV-OC43					893:901	hCoV-OC43	893:901	hCoV-OC43	893:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	55	dep	strains	856:862	arg1	SARS-CoV-1					865:874	SARS-CoV-1	865:874	SARS-CoV-1	865:874	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	55	dep	strains	856:862	arg1	strains					856:862	three betacoronavirus strains	834:862	three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	834:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	7	56	theme	mitochondria	1264:1275	arg1	biogenesis					1277:1286	mitochondria biogenesis	1264:1286	mitochondria biogenesis	1264:1286	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	4	57	theme	virus-host	576:585	arg1	interactions					603:614	the virus-host protein-protein interactions	572:614	the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication	572:697	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	10	58	theme	nsp2	1616:1619	arg1	interactors					1630:1640	Both nsp2 and nsp4 interactors	1611:1640	Both nsp2 and nsp4 interactors	1611:1640	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	3	59	from	changes	523:529	arg1	virulence					534:542	virulence	534:542	virulence	534:542	A better understanding of the basic molecular mechanisms mediating changes in virulence is needed.
32699849	9	60	theme	nsp4	1450:1453	arg1	interactors					1455:1465	Common nsp4 interactors	1443:1465	Common nsp4 interactors	1443:1465	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	11	61	from	pathogenesis	1993:2004	arg1	strains					2024:2030	SARS strains	2019:2030	SARS strains	2019:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	11	62	theme	hCoV	1895:1898	arg1	proteins					1900:1907	these hCoV proteins	1889:1907	these hCoV proteins	1889:1907	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	10	63	theme	calcium	1799:1805	arg1	homeostasis					1807:1817	calcium homeostasis	1799:1817	calcium homeostasis	1799:1817	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	12	64	theme	viral	2163:2167	arg1	proteins					2169:2176	additional viral proteins	2152:2176	additional viral proteins	2152:2176	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	0	65	theme	homologous	56:65	arg1	proteins					94:101	homologous coronavirus non-structural proteins	56:101	homologous coronavirus non-structural proteins	56:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	13	66	theme	new	2239:2241	arg1	targets					2243:2249	new targets	2239:2249	new targets for exploration by host-directed anti-viral therapeutics	2239:2306	Furthermore, the identified common interactions may present new targets for exploration by host-directed anti-viral therapeutics.
32699849	10	67	located	localized	1676:1684	arg2	proteins					1667:1674	proteins	1667:1674	proteins localized at mitochondrial-associated ER membranes	1667:1725	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	10	67	located	localized	1676:1684	arg1	membranes					1717:1725	mitochondrial-associated ER membranes	1689:1725	mitochondrial-associated ER membranes	1689:1725	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	10	68	theme	contact	1839:1845	arg1	sites					1847:1851	these organelle contact sites	1823:1851	these organelle contact sites	1823:1851	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	9	69	theme	-linked	1477:1483	arg1	machinery					1499:1507	N -linked glycosylation machinery	1475:1507	N -linked glycosylation machinery	1475:1507	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	12	70	theme	additional	2152:2161	arg1	proteins					2169:2176	additional viral proteins	2152:2176	additional viral proteins	2152:2176	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	10	71	theme	nsp4	1625:1628	arg1	interactors					1630:1640	Both nsp2 and nsp4 interactors	1611:1640	Both nsp2 and nsp4 interactors	1611:1640	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	5	72	theme	tandem	707:712	arg1	proteomics					748:757	tandem mass tag-multiplexed quantitative proteomics	707:757	tandem mass tag-multiplexed quantitative proteomics	707:757	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	73	theme	tag-multiplexed	719:733	arg1	proteomics					748:757	tandem mass tag-multiplexed quantitative proteomics	707:757	tandem mass tag-multiplexed quantitative proteomics	707:757	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	9	74	theme	glycosylation	1485:1497	arg1	machinery					1499:1507	N -linked glycosylation machinery	1475:1507	N -linked glycosylation machinery	1475:1507	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	9	75	theme	unfolded	1510:1517	arg1	UPR					1537:1539	UPR	1537:1539	UPR	1537:1539	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	9	75	theme	unfolded	1510:1517	arg1	response					1527:1534	unfolded protein response	1510:1534	unfolded protein response (UPR)	1510:1540	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	5	76	dep	contrast	786:793	arg1	interactomes					799:810	the interactomes	795:810	contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	786:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	77	from	interactomes	799:810	arg1	SARS-CoV-2					877:886	SARS-CoV-2	877:886	SARS-CoV-2	877:886	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	77	from	interactomes	799:810	arg1	hCoV-OC43					893:901	hCoV-OC43	893:901	hCoV-OC43	893:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	77	from	interactomes	799:810	arg1	SARS-CoV-1					865:874	SARS-CoV-1	865:874	SARS-CoV-1	865:874	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	77	from	interactomes	799:810	arg1	strains					856:862	three betacoronavirus strains	834:862	three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	834:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	11	78	theme	OC43	2009:2012	arg1	pathogenesis					1993:2004	the divergent pathogenesis	1979:2004	the divergent pathogenesis of OC43 from SARS strains	1979:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	5	79	theme	common	943:948	arg1	cold					950:953	the common cold	939:953	the common cold	939:953	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	6	80	theme	partners	1049:1056	arg1	ability					1066:1072	the ability	1062:1072	the ability to further compare the enrichment of common interactions across homologs from related strains	1062:1166	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	6	80	theme	partners	1049:1056	arg1	identification					982:995	the identification	978:995	the identification of both unique and shared host cell protein binding partners	978:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	11	81	dep	role	1884:1887	arg1	play					1909:1912	play	1909:1912	play in the infection cycle	1909:1935	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	12	82	theme	bait	2113:2116	arg1	proteins					2118:2125	multiple bait proteins	2104:2125	multiple bait proteins	2104:2125	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	7	83	theme	2+	1247:1248	arg1	signaling					1250:1258	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	9	84	theme	associated	1542:1551	arg1	proteins					1553:1560	unfolded protein response (UPR) associated proteins	1510:1560	unfolded protein response (UPR) associated proteins	1510:1560	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	6	85	theme	protein	1033:1039	arg1	partners					1049:1056	both unique and shared host cell protein binding partners	1000:1056	both unique and shared host cell protein binding partners	1000:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	12	86	theme	rapid	2072:2076	arg1	comparisons					2089:2099	rapid and robust comparisons	2072:2099	rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins	2072:2176	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	0	87	theme	unique	114:119	arg1	dependencies					142:153	unique and shared host-cell dependencies	114:153	unique and shared host-cell dependencies	114:153	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	6	88	theme	host	1023:1026	arg1	partners					1049:1056	both unique and shared host cell protein binding partners	1000:1056	both unique and shared host cell protein binding partners	1000:1056	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	12	89	theme	robust	2082:2087	arg1	comparisons					2089:2099	rapid and robust comparisons	2072:2099	rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins	2072:2176	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	0	90	theme	shared	125:130	arg1	dependencies					142:153	unique and shared host-cell dependencies	114:153	unique and shared host-cell dependencies	114:153	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	9	91	theme	anti-viral	1567:1576	arg1	factors					1602:1608	anti-viral innate immune signaling factors	1567:1608	anti-viral innate immune signaling factors	1567:1608	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	8	92	theme	E3	1355:1356	arg1	ligase					1368:1373	E3 ubiquitin ligase	1355:1373	E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1355:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	10	93	theme	functional	1744:1753	arg1	role					1755:1758	a new functional role	1738:1758	a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites	1738:1851	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	7	94	theme	endoplasmic	1217:1227	arg1	ER					1240:1241	ER	1240:1241	ER	1240:1241	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	7	94	theme	endoplasmic	1217:1227	arg1	reticulum					1229:1237	endoplasmic reticulum	1217:1237	endoplasmic reticulum (ER) Ca 2+ signaling	1217:1258	We identify common nsp2 interactors involved in endoplasmic reticulum (ER) Ca 2+ signaling and mitochondria biogenesis.
32699849	5	95	from	strains	856:862	arg1	nsp4					824:827	nsp4	824:827	nsp4	824:827	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	95	from	strains	856:862	arg1	nsp2					815:818	nsp2	815:818	nsp2	815:818	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	95	from	strains	856:862	arg1	interactomes					799:810	the interactomes	795:810	contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	786:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	9	96	link	-linked	1477:1483	arg1	machinery					1499:1507	N -linked glycosylation machinery	1475:1507	N -linked glycosylation machinery	1475:1507	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	9	97	theme	immune	1585:1590	arg1	factors					1602:1608	anti-viral innate immune signaling factors	1567:1608	anti-viral innate immune signaling factors	1567:1608	Common nsp4 interactors include N -linked glycosylation machinery, unfolded protein response (UPR) associated proteins, and anti-viral innate immune signaling factors.
32699849	8	98	theme	ligase	1368:1373	arg1	complexes					1375:1383	E3 ubiquitin ligase complexes	1355:1383	E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1355:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	10	99	theme	mitochondrial-associated	1689:1712	arg1	membranes					1717:1725	mitochondrial-associated ER membranes	1689:1725	mitochondrial-associated ER membranes	1689:1725	Both nsp2 and nsp4 interactors are strongly enriched in proteins localized at mitochondrial-associated ER membranes suggesting a new functional role for modulating host processes, such as calcium homeostasis, at these organelle contact sites.
32699849	0	100	theme	multiplexed	12:22	arg1	interactomics					24:36	Comparative multiplexed interactomics	0:36	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins	0:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	5	101	theme	betacoronavirus	840:854	arg1	SARS-CoV-2					877:886	SARS-CoV-2	877:886	SARS-CoV-2	877:886	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	101	theme	betacoronavirus	840:854	arg1	hCoV-OC43					893:901	hCoV-OC43	893:901	hCoV-OC43	893:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	101	theme	betacoronavirus	840:854	arg1	SARS-CoV-1					865:874	SARS-CoV-1	865:874	SARS-CoV-1	865:874	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	5	101	theme	betacoronavirus	840:854	arg1	strains					856:862	three betacoronavirus strains	834:862	three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43	834:901	We use tandem mass tag-multiplexed quantitative proteomics to sensitively compare and contrast the interactomes of nsp2 and nsp4 from three betacoronavirus strains: SARS-CoV-1, SARS-CoV-2, and hCoV-OC43 - an endemic strain associated with the common cold.
32699849	13	102	theme	host-directed	2270:2282	arg1	therapeutics					2295:2306	host-directed anti-viral therapeutics	2270:2306	host-directed anti-viral therapeutics	2270:2306	Furthermore, the identified common interactions may present new targets for exploration by host-directed anti-viral therapeutics.
32699849	8	103	theme	homeostasis	1407:1417	arg1	factors					1419:1425	SARS-CoV-1 and ER homeostasis factors	1389:1425	SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2	1389:1440	We also identifiy nsp4 interactors unique to each strain, such as E3 ubiquitin ligase complexes for SARS-CoV-1 and ER homeostasis factors for SARS-CoV-2.
32699849	0	104	theme	host-cell	132:140	arg1	dependencies					142:153	unique and shared host-cell dependencies	114:153	unique and shared host-cell dependencies	114:153	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	0	105	theme	coronavirus	67:77	arg1	proteins					94:101	homologous coronavirus non-structural proteins	56:101	homologous coronavirus non-structural proteins	56:101	Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies.
32699849	1	106	from	outbreak	259:266	arg1	evident					237:243	evident	237:243	evident	237:243	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	1	106	from	outbreak	259:266	arg1	2002					271:274	2002	271:274	2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2	271:354	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	6	107	from	strains	1160:1166	arg1	homologs					1138:1145	homologs	1138:1145	homologs from related strains	1138:1166	This approach enables the identification of both unique and shared host cell protein binding partners and the ability to further compare the enrichment of common interactions across homologs from related strains.
32699849	3	108	theme	mechanisms	502:511	arg1	understanding					465:477	A better understanding	456:477	A better understanding of the basic molecular mechanisms mediating changes in virulence	456:542	A better understanding of the basic molecular mechanisms mediating changes in virulence is needed.
32699849	1	109	theme	COVID-19	317:324	arg1	pandemic					326:333	the most recent COVID-19 pandemic	301:333	the most recent COVID-19 pandemic caused by SARS-CoV-2	301:354	Human coronaviruses (hCoV) have become a threat to global health and society, as evident from the SARS outbreak in 2002 caused by SARS-CoV-1 and the most recent COVID-19 pandemic caused by SARS-CoV-2.
32699849	11	110	theme	divergent	1983:1991	arg1	pathogenesis					1993:2004	the divergent pathogenesis	1979:2004	the divergent pathogenesis of OC43 from SARS strains	1979:2030	Our results shed light on the role these hCoV proteins play in the infection cycle, as well as host factors that may mediate the divergent pathogenesis of OC43 from SARS strains.
32699849	4	111	theme	hCoV	623:626	arg1	nsps					653:656	nsps	653:656	nsps	653:656	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	4	111	theme	hCoV	623:626	arg1	proteins					643:650	two hCoV non-structural proteins	619:650	two hCoV non-structural proteins (nsps) that are critical for virus replication	619:697	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	3	112	theme	basic	486:490	arg1	mechanisms					502:511	the basic molecular mechanisms	482:511	the basic molecular mechanisms mediating changes in virulence	482:542	A better understanding of the basic molecular mechanisms mediating changes in virulence is needed.
32699849	13	113	theme	identified	2196:2205	arg1	interactions					2214:2225	the identified common interactions	2192:2225	the identified common interactions	2192:2225	Furthermore, the identified common interactions may present new targets for exploration by host-directed anti-viral therapeutics.
32699849	12	114	theme	spectrometry	2042:2053	arg1	workflow					2055:2062	Our mass spectrometry workflow	2033:2062	Our mass spectrometry workflow	2033:2062	Our mass spectrometry workflow enables rapid and robust comparisons of multiple bait proteins, which can be applied to additional viral proteins.
32699849	4	115	theme	proteins	643:650	arg1	interactions					603:614	the virus-host protein-protein interactions	572:614	the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication	572:697	Here, we profile the virus-host protein-protein interactions of two hCoV non-structural proteins (nsps) that are critical for virus replication.
32699849	2	116	theme	high	365:368	arg1	similarity					379:388	high sequence similarity	365:388	high sequence similarity between SARS-CoV-1 and -2	365:414	Despite high sequence similarity between SARS-CoV-1 and -2, each strain has distinctive virulence.
32203219	7	0	theme	colony	1087:1092	arg1	formation					1094:1102	colony formation	1087:1102	colony formation	1087:1102	Talniflumate, GCNT3 inhibitor, reduced colony formation and migration in T3M4 and CD18 cells.
32203219	1	1	theme	glycosyltransferases	241:260	arg1	screening					219:227	a global systematic screening	199:227	a global systematic screening of specific glycosyltransferases (glycoTs) in its progression	199:289	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	0	2	theme	cancer	83:88	arg1	pathogenesis					90:101	pancreatic cancer pathogenesis	72:101	pancreatic cancer pathogenesis	72:101	Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.
32203219	6	3	from	migration	992:1000	arg1	line					1042:1045	CD18 cell line	1032:1045	CD18 cell line	1032:1045	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	1	4	theme	pancreatic	171:180	arg1	PC					190:191	PC	190:191	PC	190:191	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	1	4	theme	pancreatic	171:180	arg1	cancer					182:187	pancreatic cancer	171:187	pancreatic cancer (PC)	171:192	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	10	5	theme	GCNT3	1536:1540	arg1	role					1528:1531	the role	1524:1531	the role of GCNT3 in PC	1524:1546	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	6	6	from	EMT	1003:1005	arg1	line					1042:1045	CD18 cell line	1032:1045	CD18 cell line	1032:1045	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	2	7	dep	approach	351:358	arg1	using					360:364	using	360:364	using TCGA-based RNA-Seq analysis	360:392	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	9	8	theme	MUC5AC	1330:1335	arg1	downregulation					1312:1325	downregulation	1312:1325	downregulation of MUC5AC, MUC1, MUC5B including many other proteins	1312:1378	For GCNT3, proteomics revealed downregulation of MUC5AC, MUC1, MUC5B including many other proteins.
32203219	4	9	dep	in	659:660	arg1	vitro					662:666	vitro	662:666	vitro	662:666	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	7	10	theme	GCNT3	1062:1066	arg1	Talniflumate					1048:1059	Talniflumate	1048:1059	Talniflumate	1048:1059	Talniflumate, GCNT3 inhibitor, reduced colony formation and migration in T3M4 and CD18 cells.
32203219	7	10	theme	GCNT3	1062:1066	arg1	inhibitor					1068:1076	GCNT3 inhibitor	1062:1076	GCNT3 inhibitor	1062:1076	Talniflumate, GCNT3 inhibitor, reduced colony formation and migration in T3M4 and CD18 cells.
32203219	8	11	theme	cycle	1244:1248	arg1	genes					1250:1254	cell cycle genes	1239:1254	cell cycle genes	1239:1254	Moreover, we found that loss of GCNT3 suppresses PC progression and metastasis by downregulating cell cycle genes and β-catenin/MUC4 axis.
32203219	4	12	theme	GCNT3	761:765	arg1	expression					767:776	GCNT3 expression	761:776	GCNT3 expression	761:776	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	8	13	theme	PC	1191:1192	arg1	progression					1194:1204	PC progression	1191:1204	PC progression	1191:1204	Moreover, we found that loss of GCNT3 suppresses PC progression and metastasis by downregulating cell cycle genes and β-catenin/MUC4 axis.
32203219	9	14	theme	other	1365:1369	arg1	proteins					1371:1378	many other proteins	1360:1378	many other proteins	1360:1378	For GCNT3, proteomics revealed downregulation of MUC5AC, MUC1, MUC5B including many other proteins.
32203219	10	15	theme	O-	1441:1442	arg1	glycoTs					1457:1463	O- and N-linked glycoTs	1441:1463	O- and N-linked glycoTs	1441:1463	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	2	16	theme	multi-step	395:404	arg1	validation					406:415	multi-step validation	395:415	multi-step validation using RT-qPCR	395:429	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	16	theme	multi-step	395:404	arg1	approach					351:358	a rigorous top-down approach	331:358	a rigorous top-down approach using TCGA-based RNA-Seq analysis	331:392	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	10	17	theme	critical	1424:1431	arg1	role					1433:1436	a critical role	1422:1436	a critical role of O- and N-linked glycoTs in PC progression	1422:1481	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	1	18	from	role	146:149	arg1	PC					190:191	PC	190:191	PC	190:191	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	1	18	from	role	146:149	arg1	cancer					182:187	pancreatic cancer	171:187	pancreatic cancer (PC)	171:192	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	3	19	theme	PC	554:555	arg1	pathogenesis					557:568	PC pathogenesis	554:568	PC pathogenesis	554:568	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	10	20	link	N-linked	1448:1455	arg1	glycoTs					1457:1463	O- and N-linked glycoTs	1441:1463	O- and N-linked glycoTs	1441:1463	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	6	21	theme	cell	1037:1040	arg1	line					1042:1045	CD18 cell line	1032:1045	CD18 cell line	1032:1045	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	0	22	theme	Global	0:5	arg1	analysis					7:14	Global analysis	0:14	Global analysis of human glycosyltransferases	0:44	Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.
32203219	6	23	theme	B3GNT3	933:938	arg1	effects					922:928	the effects	918:928	the effects of B3GNT3, FUT3, GCNT3 and MGAT3	918:961	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	4	24	from	decreases	731:739	arg1	FUT3					752:755	FUT3	752:755	FUT3	752:755	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	4	24	from	decreases	731:739	arg1	expression					767:776	GCNT3 expression	761:776	GCNT3 expression	761:776	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	4	24	from	decreases	731:739	arg1	B3GNT3					744:749	B3GNT3	744:749	B3GNT3	744:749	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	1	25	theme	BACKGROUND	104:113	arg1	reports					123:129	BACKGROUND Several reports	104:129	BACKGROUND Several reports	104:129	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	6	26	theme	CD18	1032:1035	arg1	line					1042:1045	CD18 cell line	1032:1045	CD18 cell line	1032:1045	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	0	27	theme	human	19:23	arg1	glycosyltransferases					25:44	human glycosyltransferases	19:44	human glycosyltransferases	19:44	Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.
32203219	6	28	theme	MGAT3	957:961	arg1	effects					922:928	the effects	918:928	the effects of B3GNT3, FUT3, GCNT3 and MGAT3	918:961	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	10	29	theme	glycoTs	1457:1463	arg1	role					1433:1436	a critical role	1422:1436	a critical role of O- and N-linked glycoTs in PC progression	1422:1481	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	6	30	from	markers	1021:1027	arg1	line					1042:1045	CD18 cell line	1032:1045	CD18 cell line	1032:1045	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	1	31	theme	Several	115:121	arg1	reports					123:129	BACKGROUND Several reports	104:129	BACKGROUND Several reports	104:129	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	3	32	theme	unique	488:493	arg1	FUT3					522:525	FUT3	522:525	FUT3	522:525	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	32	theme	unique	488:493	arg1	FUT6					528:531	FUT6	528:531	FUT6	528:531	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	32	theme	unique	488:493	arg1	B3GNT3					504:509	B3GNT3	504:509	B3GNT3	504:509	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	32	theme	unique	488:493	arg1	B4GALNT3					512:519	B4GALNT3	512:519	B4GALNT3	512:519	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	32	theme	unique	488:493	arg1	GCNT3					534:538	GCNT3	534:538	GCNT3	534:538	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	32	theme	unique	488:493	arg1	MGAT3					544:548	MGAT3	544:548	MGAT3	544:548	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	32	theme	unique	488:493	arg1	glycoTs					495:501	six unique glycoTs	484:501	six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3)	484:549	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	7	33	theme	CD18	1130:1133	arg1	cells					1135:1139	T3M4 and CD18 cells	1121:1139	T3M4 and CD18 cells	1121:1139	Talniflumate, GCNT3 inhibitor, reduced colony formation and migration in T3M4 and CD18 cells.
32203219	10	34	theme	N-linked	1448:1455	arg1	glycoTs					1457:1463	O- and N-linked glycoTs	1441:1463	O- and N-linked glycoTs	1441:1463	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	10	35	from	role	1433:1436	arg1	progression					1471:1481	PC progression	1468:1481	PC progression	1468:1481	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	6	36	theme	GCNT3	947:951	arg1	effects					922:928	the effects	918:928	the effects of B3GNT3, FUT3, GCNT3 and MGAT3	918:961	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	6	37	theme	cell	1016:1019	arg1	markers					1021:1027	stem cell markers	1011:1027	stem cell markers	1011:1027	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	4	38	theme	metastatic	648:657	arg1	models					668:673	Serial metastatic in vitro models	641:673	Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house,	641:719	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	0	39	theme	glycosyltransferases	25:44	arg1	analysis					7:14	Global analysis	0:14	Global analysis of human glycosyltransferases	0:44	Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.
32203219	7	40	theme	T3M4	1121:1124	arg1	cells					1135:1139	T3M4 and CD18 cells	1121:1139	T3M4 and CD18 cells	1121:1139	Talniflumate, GCNT3 inhibitor, reduced colony formation and migration in T3M4 and CD18 cells.
32203219	8	41	theme	cell	1239:1242	arg1	genes					1250:1254	cell cycle genes	1239:1254	cell cycle genes	1239:1254	Moreover, we found that loss of GCNT3 suppresses PC progression and metastasis by downregulating cell cycle genes and β-catenin/MUC4 axis.
32203219	1	42	theme	global	201:206	arg1	screening					219:227	a global systematic screening	199:227	a global systematic screening of specific glycosyltransferases (glycoTs) in its progression	199:289	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	8	43	theme	GCNT3	1174:1178	arg1	loss					1166:1169	loss	1166:1169	loss of GCNT3	1166:1178	Moreover, we found that loss of GCNT3 suppresses PC progression and metastasis by downregulating cell cycle genes and β-catenin/MUC4 axis.
32203219	6	44	theme	FUT3	941:944	arg1	effects					922:928	the effects	918:928	the effects of B3GNT3, FUT3, GCNT3 and MGAT3	918:961	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	6	45	theme	stem	1011:1014	arg1	markers					1021:1027	stem cell markers	1011:1027	stem cell markers	1011:1027	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	4	46	dep	RESULTS	633:639	arg1	exhibited					721:729	exhibited	721:729	exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential	721:811	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	2	47	theme	top-down	342:349	arg1	validation					406:415	multi-step validation	395:415	multi-step validation using RT-qPCR	395:429	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	47	theme	top-down	342:349	arg1	immunohistochemistry					448:467	immunohistochemistry	448:467	immunohistochemistry	448:467	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	47	theme	top-down	342:349	arg1	approach					351:358	a rigorous top-down approach	331:358	a rigorous top-down approach using TCGA-based RNA-Seq analysis	331:392	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	47	theme	top-down	342:349	arg1	immunoblots					432:442	immunoblots	432:442	immunoblots	432:442	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	0	48	theme	novel	54:58	arg1	targets					60:66	novel targets	54:66	novel targets for pancreatic cancer pathogenesis	54:101	Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.
32203219	6	49	from	proliferation	977:989	arg1	line					1042:1045	CD18 cell line	1032:1045	CD18 cell line	1032:1045	Furthermore, the effects of B3GNT3, FUT3, GCNT3 and MGAT3 were shown on proliferation, migration, EMT and stem cell markers in CD18 cell line.
32203219	10	50	from	role	1528:1531	arg1	PC					1545:1546	PC	1545:1546	PC	1545:1546	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	1	51	theme	glycosylation	154:166	arg1	role					146:149	the role	142:149	the role of glycosylation in pancreatic cancer (PC)	142:192	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	2	52	theme	rigorous	333:340	arg1	validation					406:415	multi-step validation	395:415	multi-step validation using RT-qPCR	395:429	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	52	theme	rigorous	333:340	arg1	immunohistochemistry					448:467	immunohistochemistry	448:467	immunohistochemistry	448:467	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	52	theme	rigorous	333:340	arg1	approach					351:358	a rigorous top-down approach	331:358	a rigorous top-down approach using TCGA-based RNA-Seq analysis	331:392	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	2	52	theme	rigorous	333:340	arg1	immunoblots					432:442	immunoblots	432:442	immunoblots	432:442	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	3	53	dep	glycoTs	495:501	arg1	FUT3					522:525	FUT3	522:525	FUT3	522:525	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	53	dep	glycoTs	495:501	arg1	FUT6					528:531	FUT6	528:531	FUT6	528:531	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	53	dep	glycoTs	495:501	arg1	B3GNT3					504:509	B3GNT3	504:509	B3GNT3	504:509	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	53	dep	glycoTs	495:501	arg1	B4GALNT3					512:519	B4GALNT3	512:519	B4GALNT3	512:519	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	53	dep	glycoTs	495:501	arg1	GCNT3					534:538	GCNT3	534:538	GCNT3	534:538	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	53	dep	glycoTs	495:501	arg1	MGAT3					544:548	MGAT3	544:548	MGAT3	544:548	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	3	53	dep	glycoTs	495:501	arg1	glycoTs					495:501	six unique glycoTs	484:501	six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3)	484:549	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	10	54	theme	PC	1468:1469	arg1	progression					1471:1481	PC progression	1468:1481	PC progression	1468:1481	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	3	55	theme	KD	621:622	arg1	systems					624:630	CRISPR/Cas9-based KD systems	603:630	CRISPR/Cas9-based KD systems	603:630	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	5	56	from	significance	855:866	arg1	PC					901:902	PC	901:902	PC	901:902	Immunohistochemistry identified clinical significance for GCNT3, B4GALNT3 and MGAT3 in PC.
32203219	8	57	theme	β-catenin/MUC4	1260:1273	arg1	axis					1275:1278	β-catenin/MUC4 axis	1260:1278	β-catenin/MUC4 axis	1260:1278	Moreover, we found that loss of GCNT3 suppresses PC progression and metastasis by downregulating cell cycle genes and β-catenin/MUC4 axis.
32203219	1	58	theme	systematic	208:217	arg1	screening					219:227	a global systematic screening	199:227	a global systematic screening of specific glycosyltransferases (glycoTs) in its progression	199:289	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	1	59	from	screening	219:227	arg1	progression					279:289	its progression	275:289	its progression	275:289	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	2	60	dep	METHODS	308:314	arg1	demonstrate					319:329	demonstrate	319:329	demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry	319:467	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	10	61	dep	CONCLUSIONS	1381:1391	arg1	delineate					1487:1495	delineate	1487:1495	delineate the mechanism encompassing the role of GCNT3 in PC	1487:1546	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	10	61	dep	CONCLUSIONS	1381:1391	arg1	demonstrate					1410:1420	demonstrate	1410:1420	demonstrate a critical role of O- and N-linked glycoTs in PC progression	1410:1481	CONCLUSIONS Collectively, we demonstrate a critical role of O- and N-linked glycoTs in PC progression and delineate the mechanism encompassing the role of GCNT3 in PC.
32203219	0	62	theme	pancreatic	72:81	arg1	pathogenesis					90:101	pancreatic cancer pathogenesis	72:101	pancreatic cancer pathogenesis	72:101	Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis.
32203219	4	63	theme	Serial	641:646	arg1	models					668:673	Serial metastatic in vitro models	641:673	Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house,	641:719	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	4	64	theme	metastatic	792:801	arg1	potential					803:811	metastatic potential	792:811	metastatic potential	792:811	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	5	65	theme	clinical	846:853	arg1	significance					855:866	clinical significance	846:866	clinical significance for GCNT3, B4GALNT3 and MGAT3 in PC	846:902	Immunohistochemistry identified clinical significance for GCNT3, B4GALNT3 and MGAT3 in PC.
32203219	2	66	theme	RNA-Seq	377:383	arg1	analysis					385:392	TCGA-based RNA-Seq analysis	366:392	TCGA-based RNA-Seq analysis	366:392	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	4	67	theme	in	659:660	arg1	models					668:673	Serial metastatic in vitro models	641:673	Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house,	641:719	RESULTS Serial metastatic in vitro models using T3M4 and HPAF/CD18, generated in house, exhibited decreases in B3GNT3, FUT3 and GCNT3 expression on increasing metastatic potential.
32203219	3	68	theme	CRISPR/Cas9-based	603:619	arg1	systems					624:630	CRISPR/Cas9-based KD systems	603:630	CRISPR/Cas9-based KD systems	603:630	We identified six unique glycoTs (B3GNT3, B4GALNT3, FUT3, FUT6, GCNT3 and MGAT3) in PC pathogenesis and studied their function using CRISPR/Cas9-based KD systems.
32203219	2	69	theme	TCGA-based	366:375	arg1	analysis					385:392	TCGA-based RNA-Seq analysis	366:392	TCGA-based RNA-Seq analysis	366:392	METHODS We demonstrate a rigorous top-down approach using TCGA-based RNA-Seq analysis, multi-step validation using RT-qPCR, immunoblots and immunohistochemistry.
32203219	9	70	theme	many	1360:1363	arg1	proteins					1371:1378	many other proteins	1360:1378	many other proteins	1360:1378	For GCNT3, proteomics revealed downregulation of MUC5AC, MUC1, MUC5B including many other proteins.
32203219	1	71	theme	specific	232:239	arg1	glycoTs					263:269	glycoTs	263:269	glycoTs	263:269	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
32203219	1	71	theme	specific	232:239	arg1	glycosyltransferases					241:260	specific glycosyltransferases	232:260	specific glycosyltransferases (glycoTs)	232:270	BACKGROUND Several reports have shown the role of glycosylation in pancreatic cancer (PC), but a global systematic screening of specific glycosyltransferases (glycoTs) in its progression remains unknown.
33595123	16	0	theme	glycosylation	2105:2117	arg1	level					2077:2081	The high level	2068:2081	The high level of invertase N-linked glycosylation of invertase	2068:2130	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	16	1	theme	N-linked	2096:2103	arg1	glycosylation					2105:2117	invertase N-linked glycosylation	2086:2117	invertase N-linked glycosylation	2086:2117	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	10	2	theme	PRACTICAL	1269:1277	arg1	enzymes					1319:1325	hydrolytic enzymes	1308:1325	hydrolytic enzymes employed in several industrial sectors	1308:1364	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	10	2	theme	PRACTICAL	1269:1277	arg1	APPLICATIONS					1279:1290	PRACTICAL APPLICATIONS	1269:1290	PRACTICAL APPLICATIONS: Invertases	1269:1302	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	14	3	theme	sucrose	1897:1903	arg1	quantification					1879:1892	the quantification	1875:1892	the quantification of sucrose in food and beverage	1875:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	3	4	from	50°C	495:498	arg1	stability					444:452	stability	444:452	stability in alkaline pH and thermal activation at 50°C	444:498	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	3	4	from	50°C	495:498	arg1	pH					466:467	alkaline pH	457:467	alkaline pH	457:467	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	3	4	from	50°C	495:498	arg1	activation					481:490	thermal activation	473:490	thermal activation at 50°C	473:498	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	14	5	from	pH	1801:1802	arg1	stability					1779:1787	The stability	1775:1787	The stability at alkaline pH	1775:1802	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	8	6	theme	glycosidic	924:933	arg1	bonds					935:939	glycosidic bonds	924:939	glycosidic bonds	924:939	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	2	7	theme	chromatographic	272:286	arg1	processes					288:296	two chromatographic processes	268:296	two chromatographic processes	268:296	The enzyme was purified 4.5 times after two chromatographic processes, and it presented a relative molecular mass of 89.2 kDa.
33595123	1	8	theme	growth	185:190	arg1	medium					192:197	a growth medium	183:197	a growth medium supplemented by apple peels	183:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	13	9	theme	increased	1649:1657	arg1	activity					1670:1677	increased hydrolytic activity	1649:1677	its increased hydrolytic activity	1645:1677	Due to its increased hydrolytic activity, the hydrolysis process of the sucrose may employ invertase for the production of invert sugar.
33595123	14	10	theme	alkaline	1792:1799	arg1	pH					1801:1802	alkaline pH	1792:1802	alkaline pH	1792:1802	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	5	11	theme	enzymatic	650:658	arg1	activity					660:667	enzymatic activity	650:667	enzymatic activity	650:667	Also, DTT showed to protect enzymatic activity.
33595123	15	12	theme	sugars	2060:2065	arg1	extraction					2034:2043	the extraction	2030:2043	the extraction of fermentable sugars	2030:2065	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	16	13	theme	high	2072:2075	arg1	level					2077:2081	The high level	2068:2081	The high level of invertase N-linked glycosylation of invertase	2068:2130	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	11	14	from	interest	1463:1470	arg1	microorganisms					1475:1488	microorganisms	1475:1488	microorganisms producing this enzyme	1475:1510	Given their great importance for the economy and several industrial sectors, there is a growing interest in microorganisms producing this enzyme.
33595123	9	15	theme	C.	1147:1148	arg1	PA3S12MM					1161:1168	the C. echinulata PA3S12MM	1143:1168	the C. echinulata PA3S12MM	1143:1168	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	1	16	theme	great	151:155	arg1	fungus					139:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	1	16	theme	great	151:155	arg1	producer					157:164	a great producer	149:164	a great producer of invertases in a growth medium supplemented by apple peels	149:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	12	17	theme	food	1623:1626	arg1	industry					1628:1635	the food industry	1619:1635	the food industry	1619:1635	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	0	18	theme	enzyme	92:97	arg1	characterization					58:73	Biochemical characterization	46:73	Biochemical characterization of a promiscuous enzyme	46:97	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	14	19	from	food	1908:1911	arg1	quantification					1879:1892	the quantification	1875:1892	the quantification of sucrose in food and beverage	1875:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	11	20	theme	several	1416:1422	arg1	sectors					1435:1441	several industrial sectors	1416:1441	several industrial sectors	1416:1441	Given their great importance for the economy and several industrial sectors, there is a growing interest in microorganisms producing this enzyme.
33595123	9	21	theme	industrial	1186:1195	arg1	application					1197:1207	a broad industrial application	1178:1207	a broad industrial application	1178:1207	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	1	22	from	producer	157:164	arg1	medium					192:197	a growth medium	183:197	a growth medium supplemented by apple peels	183:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	16	23	theme	enzyme	2144:2149	arg1	stability					2159:2167	this enzyme thermal stability	2139:2167	this enzyme thermal stability	2139:2167	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	14	24	from	quantification	1879:1892	arg1	food					1908:1911	food	1908:1911	food	1908:1911	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	14	24	from	quantification	1879:1892	arg1	beverage					1917:1924	beverage	1917:1924	beverage	1917:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	10	25	theme	industrial	1347:1356	arg1	sectors					1358:1364	several industrial sectors	1339:1364	several industrial sectors	1339:1364	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	13	26	theme	sugar	1768:1772	arg1	production					1747:1756	the production	1743:1756	the production of invert sugar	1743:1772	Due to its increased hydrolytic activity, the hydrolysis process of the sucrose may employ invertase for the production of invert sugar.
33595123	0	27	theme	Cunninghamella	0:13	arg1	invertase					35:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	8	28	theme	polygalacturonic	977:992	arg1	α1 → 4					969:974	α1 → 4	969:974	α1 → 4	969:974	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	28	theme	polygalacturonic	977:992	arg1	acid					994:997	polygalacturonic acid	977:997	polygalacturonic acid	977:997	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	14	29	from	sucrose	1897:1903	arg1	food					1908:1911	food	1908:1911	food	1908:1911	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	14	29	from	sucrose	1897:1903	arg1	beverage					1917:1924	beverage	1917:1924	beverage	1917:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	1	30	theme	Cunninghamella	104:117	arg1	fungus					139:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	1	30	theme	Cunninghamella	104:117	arg1	producer					157:164	a great producer	149:164	a great producer of invertases in a growth medium supplemented by apple peels	149:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	3	31	theme	maximum	377:383	arg1	activity					385:392	maximum activity	377:392	maximum activity	377:392	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	6	32	theme	sucrose	723:729	arg1	hydrolysis					731:740	the sucrose hydrolysis	719:740	the sucrose hydrolysis	719:740	The apparent values for Km , Vmáx , and Kcat for the sucrose hydrolysis were, respectively, 173.8 mmol/L, 908.7 mmol/L min-1 , and 1,388.79 s-1 .
33595123	16	33	theme	high	2172:2175	arg1	temperatures					2177:2188	high temperatures	2172:2188	high temperatures	2172:2188	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	0	34	theme	PA3S12MM	26:33	arg1	invertase					35:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	1	35	theme	PA3S12MM	130:137	arg1	fungus					139:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	1	35	theme	PA3S12MM	130:137	arg1	producer					157:164	a great producer	149:164	a great producer of invertases in a growth medium supplemented by apple peels	149:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	12	36	theme	biochemical	1533:1543	arg1	properties					1545:1554	the biochemical properties	1529:1554	the biochemical properties of invertase in C. echinulata PA3S12MM	1529:1593	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	15	37	dep	hydrolysis	1980:1989	arg1	the					1968:1970	the	1968:1970	the	1968:1970	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	0	38	dep	characterization	58:73	arg1	invertase					35:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	16	39	link	N-linked	2096:2103	arg1	glycosylation					2105:2117	invertase N-linked glycosylation	2086:2117	invertase N-linked glycosylation	2086:2117	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	2	40	theme	89.2 kDa	345:352	arg1	mass					337:340	a relative molecular mass	316:340	a relative molecular mass of 89.2 kDa	316:352	The enzyme was purified 4.5 times after two chromatographic processes, and it presented a relative molecular mass of 89.2 kDa.
33595123	15	41	theme	by-products	2014:2024	arg1	saccharification					1994:2009	saccharification	1994:2009	saccharification	1994:2009	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	15	41	theme	by-products	2014:2024	arg1	hydrolysis					1980:1989	biomass hydrolysis	1972:1989	biomass hydrolysis	1972:1989	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	14	42	theme	electrodes	1860:1869	arg1	development					1835:1845	the development	1831:1845	the development of enzymatic electrodes for the quantification of sucrose in food and beverage	1831:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	3	43	theme	alkaline	457:464	arg1	pH					466:467	alkaline pH	457:467	alkaline pH	457:467	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	10	44	dep	APPLICATIONS	1279:1290	arg1	Invertases					1293:1302	Invertases	1293:1302	Invertases	1293:1302	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	9	45	theme	food	1254:1257	arg1	industry					1259:1266	the food industry	1250:1266	the food industry	1250:1266	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	3	46	dep	presenting	433:442	arg1	addition					421:428	addition	421:428	addition	421:428	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	16	47	theme	invertase	2086:2094	arg1	glycosylation					2105:2117	invertase N-linked glycosylation	2086:2117	invertase N-linked glycosylation	2086:2117	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	16	48	theme	industrial	2324:2333	arg1	processes					2335:2343	industrial processes	2324:2343	industrial processes	2324:2343	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	8	49	theme	different	905:913	arg1	α1 ↔ 1					1033:1038	α1 ↔ 1	1033:1038	α1 ↔ 1	1033:1038	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	49	theme	different	905:913	arg1	types					915:919	different types	905:919	different types	905:919	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	49	theme	different	905:913	arg1	α1 → 4					969:974	α1 → 4	969:974	α1 → 4	969:974	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	49	theme	different	905:913	arg1	α1 ↔ 2β					950:956	α1 ↔ 2β	950:956	α1 ↔ 2β	950:956	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	13	50	theme	sucrose	1710:1716	arg1	process					1695:1701	the hydrolysis process	1680:1701	the hydrolysis process of the sucrose	1680:1716	Due to its increased hydrolytic activity, the hydrolysis process of the sucrose may employ invertase for the production of invert sugar.
33595123	16	51	dep	resistance	2206:2215	arg1	addition					2194:2201	addition	2194:2201	addition	2194:2201	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	4	52	theme	Mn2+	553:556	arg1	presence					541:548	the presence	537:548	the presence of Mn2+ and dithiothreitol (DTT)	537:581	The enzymatic activity increased in the presence of Mn2+ and dithiothreitol (DTT), while Cu2+ and Z2+ ions inhibited it.
33595123	16	53	theme	invertase	2122:2130	arg1	level					2077:2081	The high level	2068:2081	The high level of invertase N-linked glycosylation of invertase	2068:2130	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	8	54	theme	bonds	935:939	arg1	α1 ↔ 1					1033:1038	α1 ↔ 1	1033:1038	α1 ↔ 1	1033:1038	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	54	theme	bonds	935:939	arg1	types					915:919	different types	905:919	different types	905:919	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	54	theme	bonds	935:939	arg1	α1 → 4					969:974	α1 → 4	969:974	α1 → 4	969:974	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	8	54	theme	bonds	935:939	arg1	α1 ↔ 2β					950:956	α1 ↔ 2β	950:956	α1 ↔ 2β	950:956	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	12	55	from	invertase	1559:1567	arg1	PA3S12MM					1586:1593	PA3S12MM	1586:1593	PA3S12MM	1586:1593	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	4	56	theme	dithiothreitol	562:575	arg1	presence					541:548	the presence	537:548	the presence of Mn2+ and dithiothreitol (DTT)	537:581	The enzymatic activity increased in the presence of Mn2+ and dithiothreitol (DTT), while Cu2+ and Z2+ ions inhibited it.
33595123	13	57	theme	hydrolysis	1684:1693	arg1	process					1695:1701	the hydrolysis process	1680:1701	the hydrolysis process of the sucrose	1680:1716	Due to its increased hydrolytic activity, the hydrolysis process of the sucrose may employ invertase for the production of invert sugar.
33595123	11	58	theme	industrial	1424:1433	arg1	sectors					1435:1441	several industrial sectors	1416:1441	several industrial sectors	1416:1441	Given their great importance for the economy and several industrial sectors, there is a growing interest in microorganisms producing this enzyme.
33595123	12	59	from	properties	1545:1554	arg1	PA3S12MM					1586:1593	PA3S12MM	1586:1593	PA3S12MM	1586:1593	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	11	60	theme	growing	1455:1461	arg1	interest					1463:1470	a growing interest	1453:1470	a growing interest in microorganisms producing this enzyme	1453:1510	Given their great importance for the economy and several industrial sectors, there is a growing interest in microorganisms producing this enzyme.
33595123	2	61	theme	relative	318:325	arg1	mass					337:340	a relative molecular mass	316:340	a relative molecular mass of 89.2 kDa	316:352	The enzyme was purified 4.5 times after two chromatographic processes, and it presented a relative molecular mass of 89.2 kDa.
33595123	13	62	theme	hydrolytic	1659:1668	arg1	activity					1670:1677	increased hydrolytic activity	1649:1677	its increased hydrolytic activity	1645:1677	Due to its increased hydrolytic activity, the hydrolysis process of the sucrose may employ invertase for the production of invert sugar.
33595123	4	63	dep	Cu2+	590:593	arg1	ions					603:606	ions	603:606	ions	603:606	The enzymatic activity increased in the presence of Mn2+ and dithiothreitol (DTT), while Cu2+ and Z2+ ions inhibited it.
33595123	15	64	theme	fermentable	2048:2058	arg1	sugars					2060:2065	fermentable sugars	2048:2065	fermentable sugars	2048:2065	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	9	65	theme	biochemical	1110:1120	arg1	properties					1122:1131	the biochemical properties	1106:1131	the biochemical properties showed by the C. echinulata PA3S12MM	1106:1168	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	12	66	from	applications	1603:1614	arg1	industry					1628:1635	the food industry	1619:1635	the food industry	1619:1635	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	11	67	theme	great	1379:1383	arg1	importance					1385:1394	their great importance	1373:1394	their great importance for the economy and several industrial sectors	1373:1441	Given their great importance for the economy and several industrial sectors, there is a growing interest in microorganisms producing this enzyme.
33595123	16	68	theme	enzyme	2314:2319	arg1	application					2294:2304	the application	2290:2304	the application of this enzyme in industrial processes	2290:2343	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	12	69	from	PA3S12MM	1586:1593	arg1	properties					1545:1554	the biochemical properties	1529:1554	the biochemical properties of invertase in C. echinulata PA3S12MM	1529:1593	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	0	70	theme	promiscuous	80:90	arg1	enzyme					92:97	a promiscuous enzyme	78:97	a promiscuous enzyme	78:97	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	9	71	theme	echinulata	1150:1159	arg1	PA3S12MM					1161:1168	the C. echinulata PA3S12MM	1143:1168	the C. echinulata PA3S12MM	1143:1168	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	14	72	from	application	1816:1826	arg1	development					1835:1845	the development	1831:1845	the development of enzymatic electrodes for the quantification of sucrose in food and beverage	1831:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	16	73	from	application	2294:2304	arg1	processes					2335:2343	industrial processes	2324:2343	industrial processes	2324:2343	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	1	74	theme	invertases	169:178	arg1	fungus					139:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	1	74	theme	invertases	169:178	arg1	producer					157:164	a great producer	149:164	a great producer of invertases in a growth medium supplemented by apple peels	149:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	16	75	theme	proteases	2239:2247	arg1	action					2229:2234	the action	2225:2234	the action	2225:2234	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	16	75	theme	proteases	2239:2247	arg1	characteristics					2270:2284	desirable characteristics	2260:2284	desirable characteristics	2260:2284	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	9	76	theme	broad	1180:1184	arg1	application					1197:1207	a broad industrial application	1178:1207	a broad industrial application	1178:1207	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	14	77	from	beverage	1917:1924	arg1	quantification					1879:1892	the quantification	1875:1892	the quantification of sucrose in food and beverage	1875:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	10	78	theme	hydrolytic	1308:1317	arg1	enzymes					1319:1325	hydrolytic enzymes	1308:1325	hydrolytic enzymes employed in several industrial sectors	1308:1364	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	10	78	theme	hydrolytic	1308:1317	arg1	APPLICATIONS					1279:1290	PRACTICAL APPLICATIONS	1269:1290	PRACTICAL APPLICATIONS: Invertases	1269:1302	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	16	79	theme	thermal	2151:2157	arg1	stability					2159:2167	this enzyme thermal stability	2139:2167	this enzyme thermal stability	2139:2167	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	1	80	theme	apple	215:219	arg1	peels					221:225	apple peels	215:225	apple peels	215:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	12	81	theme	properties	1545:1554	arg1	analysis					1517:1524	The analysis	1513:1524	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM	1513:1593	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	13	82	theme	invert	1761:1766	arg1	sugar					1768:1772	invert sugar	1761:1772	invert sugar	1761:1772	Due to its increased hydrolytic activity, the hydrolysis process of the sucrose may employ invertase for the production of invert sugar.
33595123	0	83	theme	echinulata	15:24	arg1	invertase					35:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase	0:43	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	15	84	theme	multifunctional	1931:1945	arg1	activity					1947:1954	The multifunctional activity	1927:1954	The multifunctional activity	1927:1954	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	12	85	theme	invertase	1559:1567	arg1	properties					1545:1554	the biochemical properties	1529:1554	the biochemical properties of invertase in C. echinulata PA3S12MM	1529:1593	The analysis of the biochemical properties of invertase in C. echinulata PA3S12MM suggest applications in the food industry.
33595123	10	86	theme	several	1339:1345	arg1	sectors					1358:1364	several industrial sectors	1339:1364	several industrial sectors	1339:1364	PRACTICAL APPLICATIONS: Invertases are hydrolytic enzymes employed in several industrial sectors.
33595123	11	87	dep	economy	1404:1410	arg1	the					1400:1402	the	1400:1402	the	1400:1402	Given their great importance for the economy and several industrial sectors, there is a growing interest in microorganisms producing this enzyme.
33595123	16	88	from	temperatures	2177:2188	arg1	grants					2132:2137	grants	2132:2137	grants	2132:2137	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	1	89	theme	echinulata	119:128	arg1	fungus					139:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus	100:144	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	1	89	theme	echinulata	119:128	arg1	producer					157:164	a great producer	149:164	a great producer of invertases in a growth medium supplemented by apple peels	149:225	The Cunninghamella echinulata PA3S12MM fungus is a great producer of invertases in a growth medium supplemented by apple peels.
33595123	0	90	theme	Biochemical	46:56	arg1	characterization					58:73	Biochemical characterization	46:73	Biochemical characterization of a promiscuous enzyme	46:97	Cunninghamella echinulata PA3S12MM invertase: Biochemical characterization of a promiscuous enzyme.
33595123	9	91	theme	biomass	1225:1231	arg1	hydrolysis					1233:1242	the biomass hydrolysis	1221:1242	the biomass hydrolysis	1221:1242	Thus, the biochemical properties showed by the C. echinulata PA3S12MM suggest a broad industrial application, such as in the biomass hydrolysis or in the food industry.
33595123	4	92	theme	enzymatic	505:513	arg1	activity					515:522	The enzymatic activity	501:522	The enzymatic activity	501:522	The enzymatic activity increased in the presence of Mn2+ and dithiothreitol (DTT), while Cu2+ and Z2+ ions inhibited it.
33595123	14	93	theme	enzymatic	1850:1858	arg1	electrodes					1860:1869	enzymatic electrodes	1850:1869	enzymatic electrodes for the quantification of sucrose in food and beverage	1850:1924	The stability at alkaline pH suggests an application in the development of enzymatic electrodes for the quantification of sucrose in food and beverage.
33595123	3	94	theme	6	403:403	arg1	pH					397:398	pH	397:398	pH of 6	397:403	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	3	95	from	stability	444:452	arg1	50°C					495:498	50°C	495:498	50°C	495:498	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	3	95	from	stability	444:452	arg1	pH					466:467	alkaline pH	457:467	alkaline pH	457:467	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	3	95	from	stability	444:452	arg1	activation					481:490	thermal activation	473:490	thermal activation at 50°C	473:498	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	3	96	theme	thermal	473:479	arg1	activation					481:490	thermal activation	473:490	thermal activation at 50°C	473:498	The invertase reached maximum activity at pH of 6 and at 60°C, in addition to presenting stability in alkaline pH and thermal activation at 50°C.
33595123	16	97	theme	desirable	2260:2268	arg1	action					2229:2234	the action	2225:2234	the action	2225:2234	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	16	97	theme	desirable	2260:2268	arg1	characteristics					2270:2284	desirable characteristics	2260:2284	desirable characteristics	2260:2284	The high level of invertase N-linked glycosylation of invertase grants this enzyme thermal stability at high temperatures, in addition to resistance against the action of proteases, which are desirable characteristics for the application of this enzyme in industrial processes.
33595123	2	98	theme	molecular	327:335	arg1	mass					337:340	a relative molecular mass	316:340	a relative molecular mass of 89.2 kDa	316:352	The enzyme was purified 4.5 times after two chromatographic processes, and it presented a relative molecular mass of 89.2 kDa.
33595123	15	99	theme	biomass	1972:1978	arg1	hydrolysis					1980:1989	biomass hydrolysis	1972:1989	biomass hydrolysis	1972:1989	The multifunctional activity may work in the biomass hydrolysis or saccharification of by-products for the extraction of fermentable sugars.
33595123	8	100	theme	hydrolytic	880:889	arg1	activity					891:898	hydrolytic activity	880:898	hydrolytic activity	880:898	The invertase presented hydrolytic activity over different types of glycosidic bonds, such as α1 ↔ 2β (sucrose), α1 → 4 (polygalacturonic acid), α1 → 4 and α1 → 2 (pectin), and α1 ↔ 1 (trehalose), indicating that the enzyme is multifunctional.
33595123	6	101	theme	apparent	674:681	arg1	values					683:688	The apparent values	670:688	The apparent values for Km , Vmáx , and Kcat for the sucrose hydrolysis	670:740	The apparent values for Km , Vmáx , and Kcat for the sucrose hydrolysis were, respectively, 173.8 mmol/L, 908.7 mmol/L min-1 , and 1,388.79 s-1 .
33595123	6	101	theme	apparent	674:681	arg1	173.8 mmol/L					762:773	173.8 mmol/L	762:773	173.8 mmol/L	762:773	The apparent values for Km , Vmáx , and Kcat for the sucrose hydrolysis were, respectively, 173.8 mmol/L, 908.7 mmol/L min-1 , and 1,388.79 s-1 .
33595123	7	102	theme	carbohydrate	820:831	arg1	content					833:839	The carbohydrate content	816:839	The carbohydrate content	816:839	The carbohydrate content was of 83.13%.
33403394	7	0	theme	K-562	1245:1249	arg1	cell					1251:1254	low I antigen expressing K-562 cell	1220:1254	low I antigen expressing K-562 cell	1220:1254	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	0	1	link	N-linked	97:104	arg1	glycosylation					106:118	its N-linked glycosylation	93:118	its N-linked glycosylation	93:118	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	5	2	theme	NK-92MI	1063:1069	arg1	cytotoxicity					1071:1082	NK-92MI cytotoxicity	1063:1082	NK-92MI cytotoxicity	1063:1082	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	1	3	theme	malignant	263:271	arg1	cells					273:277	malignant cells	263:277	malignant cells	263:277	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	2	4	theme	I	370:370	arg1	antigen					372:378	the blood group branched I antigen	345:378	the blood group branched I antigen on the leukemia cell surface	345:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	7	5	theme	antigen	1226:1232	arg1	cell					1251:1254	low I antigen expressing K-562 cell	1220:1254	low I antigen expressing K-562 cell	1220:1254	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	4	6	theme	receptor	860:867	arg1	Fas					869:871	death receptor Fas	854:871	death receptor Fas	854:871	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	4	7	theme	different	795:803	arg1	receptors					833:841	different leukemia cell surface death receptors	795:841	different leukemia cell surface death receptors	795:841	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	0	8	theme	N-linked	97:104	arg1	glycosylation					106:118	its N-linked glycosylation	93:118	its N-linked glycosylation	93:118	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	3	9	theme	NK-92MI	753:759	arg1	targeting					761:769	therapeutic NK-92MI targeting	741:769	therapeutic NK-92MI targeting	741:769	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	4	10	theme	Raji	905:908	arg1	cells					920:924	both Raji and TF-1a cells	900:924	cells	920:924	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	7	11	theme	I	1270:1270	arg1	presence					1280:1287	I antigen presence	1270:1287	I antigen presence	1270:1287	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	6	12	theme	I	1117:1117	arg1	levels					1138:1143	the surface I antigen expression levels	1105:1143	the surface I antigen expression levels	1105:1143	Last, we found that the surface I antigen expression levels enable leukemia cells to respond differently against NK-92MI targeting.
33403394	5	13	theme	extracellular	948:960	arg1	sites					972:976	two Fas extracellular N-linkage sites	940:976	two Fas extracellular N-linkage sites (118 and 136) for glycosylation	940:1008	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	0	14	theme	overall	124:130	arg1	expression					132:141	overall expression	124:141	overall expression	124:141	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	7	15	theme	leukemia	1305:1312	arg1	susceptibility					1319:1332	leukemia cell susceptibility	1305:1332	leukemia cell susceptibility against NK-92MI targeting	1305:1358	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	1	16	from	immunosurveillance	299:316	arg1	escape					282:287	escape	282:287	escape from host immunosurveillance	282:316	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	4	17	theme	cell	814:817	arg1	receptors					833:841	different leukemia cell surface death receptors	795:841	different leukemia cell surface death receptors	795:841	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	2	18	theme	cell	396:399	arg1	surface					401:407	the leukemia cell surface	383:407	the leukemia cell surface	383:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	8	19	theme	other	1368:1372	arg1	cells					1409:1413	other high I antigen expressing leukemia cells	1368:1413	other high I antigen expressing leukemia cells	1368:1413	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	7	20	theme	I	1224:1224	arg1	cell					1251:1254	low I antigen expressing K-562 cell	1220:1254	low I antigen expressing K-562 cell	1220:1254	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	8	21	theme	antigen	1381:1387	arg1	cells					1409:1413	other high I antigen expressing leukemia cells	1368:1413	other high I antigen expressing leukemia cells	1368:1413	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	2	22	from	antigen	372:378	arg1	surface					401:407	the leukemia cell surface	383:407	the leukemia cell surface	383:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	2	23	theme	killer	462:467	arg1	cytotoxicity					488:499	natural killer (NK) cell-mediated cytotoxicity	454:499	natural killer (NK) cell-mediated cytotoxicity	454:499	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	6	24	theme	surface	1109:1115	arg1	levels					1138:1143	the surface I antigen expression levels	1105:1143	the surface I antigen expression levels	1105:1143	Last, we found that the surface I antigen expression levels enable leukemia cells to respond differently against NK-92MI targeting.
33403394	7	25	theme	low	1220:1222	arg1	cell					1251:1254	low I antigen expressing K-562 cell	1220:1254	low I antigen expressing K-562 cell	1220:1254	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	0	26	theme	I	9:9	arg1	antigen					11:17	Branched I antigen	0:17	Branched I antigen	0:17	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	3	27	theme	therapeutic	741:751	arg1	targeting					761:769	therapeutic NK-92MI targeting	741:769	therapeutic NK-92MI targeting	741:769	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	5	28	theme	N-linkage	962:970	arg1	sites					972:976	two Fas extracellular N-linkage sites	940:976	two Fas extracellular N-linkage sites (118 and 136) for glycosylation	940:1008	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	3	29	from	formation	650:658	arg1	cells					672:676	leukemia cells	663:676	leukemia cells	663:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	1	30	theme	important	192:200	arg1	glycosylation					157:169	Cell surface glycosylation	144:169	Cell surface glycosylation	144:169	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	1	30	theme	important	192:200	arg1	process					215:221	an important modification process	189:221	an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance	189:316	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	0	31	theme	Branched	0:7	arg1	antigen					11:17	Branched I antigen	0:17	Branched I antigen	0:17	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	4	32	theme	highest	877:883	arg1	expressions					885:895	highest expressions	877:895	highest expressions	877:895	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	3	33	theme	major	595:599	arg1	type					623:626	the major glycosylation linkage type	591:626	the major glycosylation linkage type for branched I glycan formation on leukemia cells	591:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	3	33	theme	major	595:599	arg1	N-linkage					578:586	N-linkage	578:586	N-linkage	578:586	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	2	34	theme	leukemia	387:394	arg1	surface					401:407	the leukemia cell surface	383:407	the leukemia cell surface	383:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	2	35	theme	natural	454:460	arg1	killer					462:467	natural killer	454:467	natural killer (NK) cell-mediated cytotoxicity	454:499	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	2	35	theme	natural	454:460	arg1	NK					470:471	NK	470:471	NK	470:471	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	1	36	theme	host	294:297	arg1	immunosurveillance					299:316	host immunosurveillance	294:316	host immunosurveillance	294:316	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	4	37	theme	death	854:858	arg1	Fas					869:871	death receptor Fas	854:871	death receptor Fas	854:871	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	8	38	theme	similar	1416:1422	arg1	reduction					1424:1432	similar reduction	1416:1432	similar reduction in I antigen expression	1416:1456	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	7	39	theme	NK-92MI	1342:1348	arg1	targeting					1350:1358	NK-92MI targeting	1342:1358	NK-92MI targeting	1342:1358	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	8	40	theme	leukemia	1400:1407	arg1	cells					1409:1413	other high I antigen expressing leukemia cells	1368:1413	other high I antigen expressing leukemia cells	1368:1413	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	5	41	theme	Fas	944:946	arg1	sites					972:976	two Fas extracellular N-linkage sites	940:976	two Fas extracellular N-linkage sites (118 and 136) for glycosylation	940:1008	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	8	42	theme	expressing	1389:1398	arg1	cells					1409:1413	other high I antigen expressing leukemia cells	1368:1413	other high I antigen expressing leukemia cells	1368:1413	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	5	43	dep	sites	972:976	arg1	136					987:989	136	987:989	136	987:989	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	5	43	dep	sites	972:976	arg1	118					979:981	118	979:981	118	979:981	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	2	44	theme	cell	426:429	arg1	susceptibility					431:444	the cell susceptibility	422:444	the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity	422:499	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	6	45	theme	leukemia	1152:1159	arg1	cells					1161:1165	leukemia cells	1152:1165	leukemia cells	1152:1165	Last, we found that the surface I antigen expression levels enable leukemia cells to respond differently against NK-92MI targeting.
33403394	7	46	theme	antigen	1272:1278	arg1	presence					1280:1287	I antigen presence	1270:1287	I antigen presence	1270:1287	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	5	47	theme	Fas-mediated	1033:1044	arg1	apoptosis					1046:1054	Fas-mediated apoptosis	1033:1054	Fas-mediated apoptosis	1033:1054	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	1	48	theme	modification	202:213	arg1	glycosylation					157:169	Cell surface glycosylation	144:169	Cell surface glycosylation	144:169	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	1	48	theme	modification	202:213	arg1	process					215:221	an important modification process	189:221	an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance	189:316	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	4	49	dep	showed	847:852	arg1	had					873:875	had	873:875	showed death receptor Fas had highest expressions in both Raji and TF-1a cells	847:924	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	0	50	theme	cell	29:32	arg1	susceptibility					34:47	cell susceptibility	29:47	cell susceptibility	29:47	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	2	51	theme	cell-mediated	474:486	arg1	cytotoxicity					488:499	natural killer (NK) cell-mediated cytotoxicity	454:499	natural killer (NK) cell-mediated cytotoxicity	454:499	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	5	52	theme	apoptosis	1046:1054	arg1	activation					1019:1028	activation	1019:1028	activation of Fas-mediated apoptosis during NK-92MI cytotoxicity	1019:1082	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	0	53	theme	natural	57:63	arg1	killer					65:70	natural killer	57:70	natural killer cytotoxicity	57:83	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	8	54	theme	I	1379:1379	arg1	cells					1409:1413	other high I antigen expressing leukemia cells	1368:1413	other high I antigen expressing leukemia cells	1368:1413	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	2	55	theme	target-NK	521:529	arg1	interaction					531:541	target-NK interaction	521:541	target-NK interaction	521:541	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	3	56	theme	glycosylation	601:613	arg1	type					623:626	the major glycosylation linkage type	591:626	the major glycosylation linkage type for branched I glycan formation on leukemia cells	591:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	3	56	theme	glycosylation	601:613	arg1	N-linkage					578:586	N-linkage	578:586	N-linkage	578:586	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	2	57	theme	branched	361:368	arg1	antigen					372:378	the blood group branched I antigen	345:378	the blood group branched I antigen on the leukemia cell surface	345:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	8	58	theme	antigen	1439:1445	arg1	expression					1447:1456	I antigen expression	1437:1456	I antigen expression	1437:1456	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	4	59	theme	TF-1a	914:918	arg1	cells					920:924	both Raji and TF-1a cells	900:924	cells	920:924	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	3	60	theme	leukemia	663:670	arg1	cells					672:676	leukemia cells	663:676	leukemia cells	663:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	3	61	theme	linkage	615:621	arg1	type					623:626	the major glycosylation linkage type	591:626	the major glycosylation linkage type for branched I glycan formation on leukemia cells	591:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	3	61	theme	linkage	615:621	arg1	N-linkage					578:586	N-linkage	578:586	N-linkage	578:586	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	2	62	theme	group	355:359	arg1	antigen					372:378	the blood group branched I antigen	345:378	the blood group branched I antigen on the leukemia cell surface	345:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	8	63	theme	cell	1473:1476	arg1	susceptibility					1478:1491	cell susceptibility	1473:1491	cell susceptibility	1473:1491	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	7	64	theme	presence	1280:1287	arg1	reduction					1257:1265	reduction	1257:1265	reduction of I antigen presence	1257:1287	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	4	65	theme	death	827:831	arg1	receptors					833:841	different leukemia cell surface death receptors	795:841	different leukemia cell surface death receptors	795:841	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	3	66	theme	glycan	643:648	arg1	formation					650:658	branched I glycan formation	632:658	branched I glycan formation on leukemia cells	632:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	5	67	from	Mutations	927:935	arg1	sites					972:976	two Fas extracellular N-linkage sites	940:976	two Fas extracellular N-linkage sites (118 and 136) for glycosylation	940:1008	Mutations on two Fas extracellular N-linkage sites (118 and 136) for glycosylation impaired activation of Fas-mediated apoptosis during NK-92MI cytotoxicity.
33403394	1	68	theme	Cell	144:147	arg1	process					215:221	an important modification process	189:221	an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance	189:316	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	1	68	theme	Cell	144:147	arg1	glycosylation					157:169	Cell surface glycosylation	144:169	Cell surface glycosylation	144:169	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	4	69	theme	leukemia	805:812	arg1	receptors					833:841	different leukemia cell surface death receptors	795:841	different leukemia cell surface death receptors	795:841	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	7	70	theme	cell	1314:1317	arg1	susceptibility					1319:1332	leukemia cell susceptibility	1305:1332	leukemia cell susceptibility against NK-92MI targeting	1305:1358	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33403394	4	71	theme	surface	819:825	arg1	receptors					833:841	different leukemia cell surface death receptors	795:841	different leukemia cell surface death receptors	795:841	Secondly, by examining different leukemia cell surface death receptors, we showed death receptor Fas had highest expressions in both Raji and TF-1a cells.
33403394	1	72	theme	surface	149:155	arg1	process					215:221	an important modification process	189:221	an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance	189:316	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	1	72	theme	surface	149:155	arg1	glycosylation					157:169	Cell surface glycosylation	144:169	Cell surface glycosylation	144:169	Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance.
33403394	8	73	theme	high	1374:1377	arg1	cells					1409:1413	other high I antigen expressing leukemia cells	1368:1413	other high I antigen expressing leukemia cells	1368:1413	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	2	74	theme	blood	349:353	arg1	antigen					372:378	the blood group branched I antigen	345:378	the blood group branched I antigen on the leukemia cell surface	345:407	We previously showed that the blood group branched I antigen on the leukemia cell surface can regulate the cell susceptibility against natural killer (NK) cell-mediated cytotoxicity through interfering target-NK interaction.
33403394	3	75	theme	branched	632:639	arg1	formation					650:658	branched I glycan formation	632:658	branched I glycan formation on leukemia cells	632:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	6	76	theme	NK-92MI	1198:1204	arg1	targeting					1206:1214	NK-92MI targeting	1198:1214	NK-92MI targeting	1198:1214	Last, we found that the surface I antigen expression levels enable leukemia cells to respond differently against NK-92MI targeting.
33403394	6	77	theme	expression	1127:1136	arg1	levels					1138:1143	the surface I antigen expression levels	1105:1143	the surface I antigen expression levels	1105:1143	Last, we found that the surface I antigen expression levels enable leukemia cells to respond differently against NK-92MI targeting.
33403394	8	78	from	reduction	1424:1432	arg1	expression					1447:1456	I antigen expression	1437:1456	I antigen expression	1437:1456	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	0	79	theme	killer	65:70	arg1	cytotoxicity					72:83	natural killer cytotoxicity	57:83	natural killer cytotoxicity	57:83	Branched I antigen regulated cell susceptibility against natural killer cytotoxicity through its N-linked glycosylation and overall expression.
33403394	3	80	theme	cell	716:719	arg1	sensitivity					721:731	cell sensitivity	716:731	cell sensitivity against therapeutic NK-92MI targeting	716:769	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	3	81	theme	I	641:641	arg1	formation					650:658	branched I glycan formation	632:658	branched I glycan formation on leukemia cells	632:676	In this work, we first identified N-linkage as the major glycosylation linkage type for branched I glycan formation on leukemia cells, and this linkage was responsible for cell sensitivity against therapeutic NK-92MI targeting.
33403394	6	82	theme	antigen	1119:1125	arg1	levels					1138:1143	the surface I antigen expression levels	1105:1143	the surface I antigen expression levels	1105:1143	Last, we found that the surface I antigen expression levels enable leukemia cells to respond differently against NK-92MI targeting.
33403394	8	83	theme	I	1437:1437	arg1	expression					1447:1456	I antigen expression	1437:1456	I antigen expression	1437:1456	But in other high I antigen expressing leukemia cells, similar reduction in I antigen expression did not affect cell susceptibility.
33403394	7	84	theme	expressing	1234:1243	arg1	cell					1251:1254	low I antigen expressing K-562 cell	1220:1254	low I antigen expressing K-562 cell	1220:1254	In low I antigen expressing K-562 cell, reduction of I antigen presence greatly reduced leukemia cell susceptibility against NK-92MI targeting.
33161144	6	0	dep	account	1138:1144	arg1	CSPR					1180:1183	CSPR	1180:1183	CSPR	1180:1183	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	6	0	dep	account	1138:1144	arg1	rate					1174:1177	the cell specific perfusion rate	1146:1177	account the cell specific perfusion rate (CSPR)	1138:1184	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	11	1	theme	given	1918:1922	arg1	profile					1938:1944	a given glycosylation profile	1916:1944	a given glycosylation profile	1916:1944	The present data were applied to the GReBA to design a feeding regime targeting a given glycosylation profile.
33161144	12	2	theme	feeding	2145:2151	arg1	regime					2153:2158	the feeding regime	2141:2158	the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile	2141:2228	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	6	3	theme	specific	1155:1162	arg1	CSPR					1180:1183	CSPR	1180:1183	CSPR	1180:1183	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	6	3	theme	specific	1155:1162	arg1	rate					1174:1177	the cell specific perfusion rate	1146:1177	account the cell specific perfusion rate (CSPR)	1138:1184	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	4	4	with	one	634:636	arg1	rate					662:665	the highest uptake rate	643:665	the highest uptake rate	643:665	However, in case of feeding of more than one carbon source simultaneously, the cells give priority to the one with the highest uptake rate, which limits the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose.
33161144	7	5	theme	sugar	1312:1316	arg1	feeding					1318:1324	sugar feeding	1312:1324	sugar feeding	1312:1324	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	9	6	theme	higher	1531:1536	arg1	proportions					1538:1548	higher proportions	1531:1548	higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way	1531:1665	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	2	7	theme	different	282:290	arg1	sources					299:305	different carbon sources	282:305	different carbon sources	282:305	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	7	theme	different	282:290	arg1	mannose					325:331	mannose	325:331	mannose	325:331	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	7	theme	different	282:290	arg1	galactose					337:345	galactose	337:345	galactose	337:345	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	7	theme	different	282:290	arg1	glucose					316:322	glucose	316:322	glucose	316:322	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	4	8	theme	carbon	573:578	arg1	source					580:585	more than one carbon source	559:585	more than one carbon source	559:585	However, in case of feeding of more than one carbon source simultaneously, the cells give priority to the one with the highest uptake rate, which limits the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose.
33161144	0	9	theme	novel	103:107	arg1	feed					118:121	a novel targeted feed	101:121	a novel targeted feed	101:121	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	0	9	theme	novel	103:107	arg1	TAFE					124:127	TAFE	124:127	TAFE	124:127	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	1	10	theme	quality	181:187	arg1	attribute					189:197	an important quality attribute	168:197	an important quality attribute of therapeutic glycoproteins	168:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	10	theme	quality	181:187	arg1	pattern					157:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	12	11	used	used	2126:2129	arg2	model					2113:2117	the GReBA model	2103:2117	the GReBA model	2103:2117	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	9	12	theme	sugars	1565:1570	arg1	proportions					1538:1548	higher proportions	1531:1548	higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way	1531:1665	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	7	13	theme	hamster	1245:1251	arg1	mannose					1360:1366	mannose	1360:1366	mannose	1360:1366	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	13	theme	hamster	1245:1251	arg1	cells					1265:1269	Chinese hamster ovary (CHO) cells	1237:1269	Chinese hamster ovary (CHO) cells	1237:1269	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	13	theme	hamster	1245:1251	arg1	galactose					1346:1354	galactose	1346:1354	galactose	1346:1354	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	13	theme	hamster	1245:1251	arg1	glucose					1337:1343	glucose	1337:1343	glucose	1337:1343	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	10	14	theme	fed	1816:1818	arg1	sources					1827:1833	the fed carbon sources	1812:1833	the fed carbon sources	1812:1833	In previous work, a mathematical model named Glycan Residues Balance Analysis (GReBA) was developed to model the glycosylation profile based on the fed carbon sources.
33161144	11	15	theme	feeding	1891:1897	arg1	regime					1899:1904	a feeding regime	1889:1904	a feeding regime targeting a given glycosylation profile	1889:1944	The present data were applied to the GReBA to design a feeding regime targeting a given glycosylation profile.
33161144	0	16	from	cultures	51:58	arg1	Control					0:6	Control	0:6	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model	0:86	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	9	17	theme	lower	1584:1588	arg1	rates					1600:1604	lower transport rates	1584:1604	lower transport rates	1584:1604	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	7	18	theme	perfusion	1215:1223	arg1	cultures					1225:1232	perfusion cultures	1215:1232	perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose	1215:1366	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	6	19	dep	rate	1093:1096	arg1	taking					1126:1131	taking	1126:1131	taking into account the cell specific perfusion rate (CSPR)	1126:1184	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	6	19	dep	rate	1093:1096	arg1	decided					1098:1104	decided	1098:1104	decided by the operator	1098:1120	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	4	20	theme	uptake	655:660	arg1	rate					662:665	the highest uptake rate	643:665	the highest uptake rate	643:665	However, in case of feeding of more than one carbon source simultaneously, the cells give priority to the one with the highest uptake rate, which limits the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose.
33161144	6	21	theme	specific	1072:1079	arg1	rate					1093:1096	a target cell specific consumption rate	1058:1096	a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR)	1058:1184	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	5	22	theme	new	792:794	arg1	strategy					804:811	a new feeding strategy	790:811	a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation	790:942	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	2	23	gly	glycosylation	375:387	arg1	glycoproteins					400:412	glycoproteins	400:412	glycoproteins	400:412	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	0	24	theme	GReBA	63:67	arg1	model					82:86	GReBA mathematical model	63:86	GReBA mathematical model	63:86	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	1	25	gly	glycoproteins	214:226	arg1	glycoproteins					214:226	therapeutic glycoproteins	202:226	therapeutic glycoproteins	202:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	26	theme	N-linked	134:141	arg1	attribute					189:197	an important quality attribute	168:197	an important quality attribute of therapeutic glycoproteins	168:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	26	theme	N-linked	134:141	arg1	pattern					157:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	0	27	from	Control	0:6	arg1	cultures					51:58	CHO cell perfusion cultures	32:58	CHO cell perfusion cultures	32:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	12	28	theme	leave-one-out	2032:2044	arg1	LOOCV					2064:2068	LOOCV	2064:2068	LOOCV	2064:2068	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	12	28	theme	leave-one-out	2032:2044	arg1	cross-validation					2046:2061	leave-one-out cross-validation	2032:2061	leave-one-out cross-validation (LOOCV)	2032:2069	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	2	29	theme	mammalian	417:425	arg1	culture					432:438	mammalian cell culture	417:438	mammalian cell culture	417:438	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	30	theme	glycoproteins	400:412	arg1	profile					389:395	the glycosylation profile	371:395	the glycosylation profile of glycoproteins in mammalian cell culture	371:438	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	12	31	theme	glycosylation	2208:2220	arg1	profile					2222:2228	a desired glycosylation profile	2198:2228	a desired glycosylation profile	2198:2228	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	0	32	theme	IgG	11:13	arg1	glycosylation					15:27	IgG glycosylation	11:27	IgG glycosylation in CHO cell perfusion cultures	11:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	8	33	theme	different	1397:1405	arg1	profiles					1414:1421	different glycan profiles	1397:1421	different glycan profiles	1397:1421	Applying the TAFE strategy, different glycan profiles were obtained using the different feeding regimes.
33161144	5	34	theme	fed	903:905	arg1	sugars					907:912	fed sugars	903:912	fed sugars influencing the glycosylation	903:942	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	3	35	theme	sugar	455:459	arg1	feeding					461:467	the sugar feeding	451:467	the sugar feeding	451:467	Acting on the sugar feeding is thus an attractive strategy to tune the glycan pattern.
33161144	0	36	theme	cell	36:39	arg1	cultures					51:58	CHO cell perfusion cultures	32:58	CHO cell perfusion cultures	32:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	0	37	gly	glycosylation	15:27	arg1	cultures					51:58	CHO cell perfusion cultures	32:58	CHO cell perfusion cultures	32:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	10	38	theme	Glycan	1713:1718	arg1	Residues					1720:1727	Glycan Residues	1713:1727	Glycan Residues	1713:1727	In previous work, a mathematical model named Glycan Residues Balance Analysis (GReBA) was developed to model the glycosylation profile based on the fed carbon sources.
33161144	3	39	from	Acting	441:446	arg1	feeding					461:467	the sugar feeding	451:467	the sugar feeding	451:467	Acting on the sugar feeding is thus an attractive strategy to tune the glycan pattern.
33161144	1	40	theme	therapeutic	202:212	arg1	glycoproteins					214:226	therapeutic glycoproteins	202:226	therapeutic glycoproteins	202:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	2	41	gly	glycoproteins	400:412	arg1	glycoproteins					400:412	glycoproteins	400:412	glycoproteins	400:412	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	42	from	profile	389:395	arg1	culture					432:438	mammalian cell culture	417:438	mammalian cell culture	417:438	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	8	43	theme	feeding	1457:1463	arg1	regimes					1465:1471	the different feeding regimes	1443:1471	the different feeding regimes	1443:1471	Applying the TAFE strategy, different glycan profiles were obtained using the different feeding regimes.
33161144	6	44	theme	perfusion	1164:1172	arg1	CSPR					1180:1183	CSPR	1180:1183	CSPR	1180:1183	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	6	44	theme	perfusion	1164:1172	arg1	rate					1174:1177	the cell specific perfusion rate	1146:1177	account the cell specific perfusion rate (CSPR)	1138:1184	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	9	45	contain	have	1579:1582	arg1	sugars					1565:1570	non-glucose sugars	1553:1570	non-glucose sugars	1553:1570	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	9	45	contain	have	1579:1582	arg2	rates					1600:1604	lower transport rates	1584:1604	lower transport rates	1584:1604	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	7	46	theme	feeding	1318:1324	arg1	regimes					1301:1307	ten different regimes	1287:1307	ten different regimes of sugar feeding	1287:1324	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	11	47	theme	glycosylation	1924:1936	arg1	profile					1938:1944	a given glycosylation profile	1916:1944	a given glycosylation profile	1916:1944	The present data were applied to the GReBA to design a feeding regime targeting a given glycosylation profile.
33161144	1	48	theme	glycosylation	143:155	arg1	attribute					189:197	an important quality attribute	168:197	an important quality attribute of therapeutic glycoproteins	168:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	48	theme	glycosylation	143:155	arg1	pattern					157:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	7	49	theme	different	1291:1299	arg1	regimes					1301:1307	ten different regimes	1287:1307	ten different regimes of sugar feeding	1287:1324	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	6	50	dep	forced	1020:1025	arg1	such					996:999	such	996:999	such	996:999	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	2	51	theme	carbon	292:297	arg1	sources					299:305	different carbon sources	282:305	different carbon sources	282:305	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	51	theme	carbon	292:297	arg1	mannose					325:331	mannose	325:331	mannose	325:331	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	51	theme	carbon	292:297	arg1	galactose					337:345	galactose	337:345	galactose	337:345	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	2	51	theme	carbon	292:297	arg1	glucose					316:322	glucose	316:322	glucose	316:322	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	7	52	theme	cells	1265:1269	arg1	cultures					1225:1232	perfusion cultures	1215:1232	perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose	1215:1366	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	10	53	theme	glycosylation	1781:1793	arg1	profile					1795:1801	the glycosylation profile	1777:1801	the glycosylation profile based on the fed carbon sources	1777:1833	In previous work, a mathematical model named Glycan Residues Balance Analysis (GReBA) was developed to model the glycosylation profile based on the fed carbon sources.
33161144	0	54	theme	targeted	109:116	arg1	feed					118:121	a novel targeted feed	101:121	a novel targeted feed	101:121	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	0	54	theme	targeted	109:116	arg1	TAFE					124:127	TAFE	124:127	TAFE	124:127	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	3	55	theme	glycan	512:517	arg1	pattern					519:525	the glycan pattern	508:525	the glycan pattern	508:525	Acting on the sugar feeding is thus an attractive strategy to tune the glycan pattern.
33161144	1	56	theme	important	171:179	arg1	attribute					189:197	an important quality attribute	168:197	an important quality attribute of therapeutic glycoproteins	168:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	56	theme	important	171:179	arg1	pattern					157:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	9	57	theme	non-glucose	1553:1563	arg1	sugars					1565:1570	non-glucose sugars	1553:1570	non-glucose sugars	1553:1570	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	7	58	theme	CHO	1260:1262	arg1	mannose					1360:1366	mannose	1360:1366	mannose	1360:1366	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	58	theme	CHO	1260:1262	arg1	cells					1265:1269	Chinese hamster ovary (CHO) cells	1237:1269	Chinese hamster ovary (CHO) cells	1237:1269	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	58	theme	CHO	1260:1262	arg1	galactose					1346:1354	galactose	1346:1354	galactose	1346:1354	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	58	theme	CHO	1260:1262	arg1	glucose					1337:1343	glucose	1337:1343	glucose	1337:1343	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	59	theme	ovary	1253:1257	arg1	mannose					1360:1366	mannose	1360:1366	mannose	1360:1366	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	59	theme	ovary	1253:1257	arg1	cells					1265:1269	Chinese hamster ovary (CHO) cells	1237:1269	Chinese hamster ovary (CHO) cells	1237:1269	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	59	theme	ovary	1253:1257	arg1	galactose					1346:1354	galactose	1346:1354	galactose	1346:1354	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	59	theme	ovary	1253:1257	arg1	glucose					1337:1343	glucose	1337:1343	glucose	1337:1343	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	4	60	theme	source	580:585	arg1	feeding					548:554	feeding	548:554	feeding of more than one carbon source	548:585	However, in case of feeding of more than one carbon source simultaneously, the cells give priority to the one with the highest uptake rate, which limits the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose.
33161144	12	61	theme	GReBA	2107:2111	arg1	model					2113:2117	the GReBA model	2103:2117	the GReBA model	2103:2117	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	7	62	theme	Chinese	1237:1243	arg1	mannose					1360:1366	mannose	1360:1366	mannose	1360:1366	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	62	theme	Chinese	1237:1243	arg1	cells					1265:1269	Chinese hamster ovary (CHO) cells	1237:1269	Chinese hamster ovary (CHO) cells	1237:1269	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	62	theme	Chinese	1237:1243	arg1	galactose					1346:1354	galactose	1346:1354	galactose	1346:1354	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	7	62	theme	Chinese	1237:1243	arg1	glucose					1337:1343	glucose	1337:1343	glucose	1337:1343	This strategy is applied in perfusion cultures of Chinese hamster ovary (CHO) cells, illustrated by ten different regimes of sugar feeding, including glucose, galactose and mannose.
33161144	10	63	theme	previous	1671:1678	arg1	work					1680:1683	previous work	1671:1683	previous work	1671:1683	In previous work, a mathematical model named Glycan Residues Balance Analysis (GReBA) was developed to model the glycosylation profile based on the fed carbon sources.
33161144	11	64	theme	present	1840:1846	arg1	data					1848:1851	The present data	1836:1851	The present data	1836:1851	The present data were applied to the GReBA to design a feeding regime targeting a given glycosylation profile.
33161144	9	65	theme	transport	1590:1598	arg1	rates					1600:1604	lower transport rates	1584:1604	lower transport rates	1584:1604	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	6	66	theme	consumption	1081:1091	arg1	rate					1093:1096	a target cell specific consumption rate	1058:1096	a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR)	1058:1184	The strategy consists in setting the sugar feeding such that the cells are forced to consume these substrates at a target cell specific consumption rate decided by the operator and taking into account the cell specific perfusion rate (CSPR).
33161144	4	67	theme	highest	647:653	arg1	rate					662:665	the highest uptake rate	643:665	the highest uptake rate	643:665	However, in case of feeding of more than one carbon source simultaneously, the cells give priority to the one with the highest uptake rate, which limits the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose.
33161144	0	68	from	glycosylation	15:27	arg1	cultures					51:58	CHO cell perfusion cultures	32:58	CHO cell perfusion cultures	32:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	12	69	theme	perfusion	2165:2173	arg1	culture					2180:2186	a perfusion cell culture	2163:2186	a perfusion cell culture	2163:2186	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	10	70	theme	carbon	1820:1825	arg1	sources					1827:1833	the fed carbon sources	1812:1833	the fed carbon sources	1812:1833	In previous work, a mathematical model named Glycan Residues Balance Analysis (GReBA) was developed to model the glycosylation profile based on the fed carbon sources.
33161144	0	71	theme	mathematical	69:80	arg1	model					82:86	GReBA mathematical model	63:86	GReBA mathematical model	63:86	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	5	72	theme	feeding	796:802	arg1	strategy					804:811	a new feeding strategy	790:811	a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation	790:942	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	5	73	theme	perfusion	853:861	arg1	culture					863:869	perfusion culture	853:869	perfusion culture	853:869	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	9	74	theme	latter	1639:1644	arg1	presence					1622:1629	presence	1622:1629	presence of this latter	1622:1644	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	8	75	theme	TAFE	1382:1385	arg1	strategy					1387:1394	the TAFE strategy	1378:1394	the TAFE strategy	1378:1394	Applying the TAFE strategy, different glycan profiles were obtained using the different feeding regimes.
33161144	12	76	theme	cross-validation	2046:2061	arg1	multi-round					2017:2027	a multi-round	2015:2027	a multi-round of leave-one-out cross-validation (LOOCV)	2015:2069	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	5	77	dep	strategy	804:811	arg1	named					814:818	named	814:818	named 'TAFE' for targeted feeding	814:846	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	0	78	theme	glycosylation	15:27	arg1	Control					0:6	Control	0:6	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model	0:86	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	5	79	theme	targeted	831:838	arg1	feeding					840:846	targeted feeding	831:846	targeted feeding	831:846	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	9	80	theme	controlled	1652:1661	arg1	way					1663:1665	a controlled way	1650:1665	a controlled way	1650:1665	Furthermore, we successfully forced the cells to consume higher proportions of non-glucose sugars, which have lower transport rates than glucose in presence of this latter, in a controlled way.
33161144	8	81	theme	glycan	1407:1412	arg1	profiles					1414:1421	different glycan profiles	1397:1421	different glycan profiles	1397:1421	Applying the TAFE strategy, different glycan profiles were obtained using the different feeding regimes.
33161144	1	82	link	N-linked	134:141	arg1	attribute					189:197	an important quality attribute	168:197	an important quality attribute of therapeutic glycoproteins	168:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	82	link	N-linked	134:141	arg1	pattern					157:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	10	83	theme	mathematical	1688:1699	arg1	model					1701:1705	a mathematical model	1686:1705	a mathematical model named Glycan Residues Balance Analysis (GReBA)	1686:1752	In previous work, a mathematical model named Glycan Residues Balance Analysis (GReBA) was developed to model the glycosylation profile based on the fed carbon sources.
33161144	2	84	theme	glycosylation	375:387	arg1	profile					389:395	the glycosylation profile	371:395	the glycosylation profile of glycoproteins in mammalian cell culture	371:438	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	0	85	theme	CHO	32:34	arg1	cultures					51:58	CHO cell perfusion cultures	32:58	CHO cell perfusion cultures	32:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	0	86	theme	perfusion	41:49	arg1	cultures					51:58	CHO cell perfusion cultures	32:58	CHO cell perfusion cultures	32:58	Control of IgG glycosylation in CHO cell perfusion cultures by GReBA mathematical model supported by a novel targeted feed, TAFE.
33161144	5	87	theme	sugars	907:912	arg1	concentrations					885:898	the concentrations	881:898	the concentrations of fed sugars influencing the glycosylation	881:942	We present here a new feeding strategy (named 'TAFE' for targeted feeding) for perfusion culture to adjust the concentrations of fed sugars influencing the glycosylation.
33161144	2	88	theme	cell	427:430	arg1	culture					432:438	mammalian cell culture	417:438	mammalian cell culture	417:438	It has been reported by our group and by others that different carbon sources, such as glucose, mannose and galactose, can differently impact the glycosylation profile of glycoproteins in mammalian cell culture.
33161144	12	89	theme	desired	2200:2206	arg1	profile					2222:2228	a desired glycosylation profile	2198:2228	a desired glycosylation profile	2198:2228	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	12	90	theme	model	1966:1970	arg1	ability					1951:1957	The ability	1947:1957	The ability of the model to achieve this objective	1947:1996	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	8	91	theme	different	1447:1455	arg1	regimes					1465:1471	the different feeding regimes	1443:1471	the different feeding regimes	1443:1471	Applying the TAFE strategy, different glycan profiles were obtained using the different feeding regimes.
33161144	4	92	theme	tuning	699:704	arg1	usage					685:689	the usage	681:689	the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose	681:771	However, in case of feeding of more than one carbon source simultaneously, the cells give priority to the one with the highest uptake rate, which limits the usage of this tuning, e.g. the cells favor consuming glucose in comparison to galactose.
33161144	1	93	theme	glycoproteins	214:226	arg1	attribute					189:197	an important quality attribute	168:197	an important quality attribute of therapeutic glycoproteins	168:226	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	1	93	theme	glycoproteins	214:226	arg1	pattern					157:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern	130:163	The N-linked glycosylation pattern is an important quality attribute of therapeutic glycoproteins.
33161144	12	94	theme	culture	2180:2186	arg1	regime					2153:2158	the feeding regime	2141:2158	the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile	2141:2228	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	12	95	theme	cell	2175:2178	arg1	culture					2180:2186	a perfusion cell culture	2163:2186	a perfusion cell culture	2163:2186	The ability of the model to achieve this objective was confirmed by a multi-round of leave-one-out cross-validation (LOOCV), leading to the conclusion that the GReBA model can be used to design the feeding regime of a perfusion cell culture to obtain a desired glycosylation profile.
33161144	3	96	theme	attractive	480:489	arg1	strategy					491:498	an attractive strategy	477:498	an attractive strategy to tune the glycan pattern	477:525	Acting on the sugar feeding is thus an attractive strategy to tune the glycan pattern.
33161144	3	96	theme	attractive	480:489	arg1	Acting					441:446	Acting	441:446	Acting on the sugar feeding	441:467	Acting on the sugar feeding is thus an attractive strategy to tune the glycan pattern.
32356523	0	0	theme	lectin	89:94	arg1	ERGIC-53					96:103	the intracellular lectin ERGIC-53	71:103	the intracellular lectin ERGIC-53 involved in glycoprotein transport	71:138	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	1	1	theme	ER-Golgi	180:187	arg1	protein					214:220	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53	141:223	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53)	141:234	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	1	theme	ER-Golgi	180:187	arg1	ERGIC-53					226:233	ERGIC-53	226:233	ERGIC-53	226:233	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	2	theme	factor	281:286	arg1	protein					299:305	the soluble EF-hand multiple coagulation factor deficiency protein 2	240:307	the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2)	240:315	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	2	theme	factor	281:286	arg1	MCFD2					310:314	MCFD2	310:314	MCFD2	310:314	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	0	3	theme	intracellular	75:87	arg1	ERGIC-53					96:103	the intracellular lectin ERGIC-53	71:103	the intracellular lectin ERGIC-53 involved in glycoprotein transport	71:138	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	1	4	theme	cargo	352:356	arg1	complex					324:330	a complex	322:330	a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus	322:463	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	4	theme	cargo	352:356	arg1	receptor					358:365	a cargo receptor	350:365	a cargo receptor	350:365	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	4	theme	cargo	352:356	arg1	glycoproteins					388:400	trafficking various glycoproteins	368:400	trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus	368:463	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	2	5	theme	glycoproteins	675:687	arg1	segments					657:664	polypeptide segments	645:664	polypeptide segments of cargo glycoproteins	645:687	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	1	6	theme	intermediate	189:200	arg1	protein					214:220	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53	141:223	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53)	141:234	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	6	theme	intermediate	189:200	arg1	ERGIC-53					226:233	ERGIC-53	226:233	ERGIC-53	226:233	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	7	theme	deficiency	288:297	arg1	protein					299:305	the soluble EF-hand multiple coagulation factor deficiency protein 2	240:307	the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2)	240:315	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	7	theme	deficiency	288:297	arg1	MCFD2					310:314	MCFD2	310:314	MCFD2	310:314	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	6	8	theme	significant	1163:1173	arg1	plasticity					1190:1199	significant conformational plasticity	1163:1199	significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands	1163:1272	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	2	9	theme	cargo	599:603	arg1	glycoproteins					605:617	cargo glycoproteins	599:617	cargo glycoproteins	599:617	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	1	10	theme	Golgi	449:453	arg1	apparatus					455:463	the Golgi apparatus	445:463	the Golgi apparatus	445:463	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	5	11	theme	other	1030:1034	arg1	forms					1044:1048	three other crystal forms	1024:1048	three other crystal forms	1024:1048	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	2	12	from	glycans	588:594	arg1	glycoproteins					605:617	cargo glycoproteins	599:617	cargo glycoproteins	599:617	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	3	13	theme	ERGIC-53CRD	712:722	arg1	structures					698:707	Crystal structures	690:707	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides	690:773	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides have revealed protein-protein and protein-sugar binding modes.
32356523	6	14	theme	ligands	1266:1272	arg1	accommodation					1229:1241	its accommodation	1225:1241	its accommodation of various polypeptide ligands	1225:1272	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	5	15	theme	crystal	1036:1042	arg1	forms					1044:1048	three other crystal forms	1024:1048	three other crystal forms	1024:1048	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	0	16	theme	glycoprotein	117:128	arg1	transport					130:138	glycoprotein transport	117:138	glycoprotein transport	117:138	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	1	17	theme	trafficking	368:378	arg1	receptor					358:365	a cargo receptor	350:365	a cargo receptor	350:365	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	17	theme	trafficking	368:378	arg1	glycoproteins					388:400	trafficking various glycoproteins	368:400	trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus	368:463	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	2	18	theme	polypeptide	645:655	arg1	segments					657:664	polypeptide segments	645:664	polypeptide segments of cargo glycoproteins	645:687	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	6	19	theme	polypeptide	1254:1264	arg1	ligands					1266:1272	various polypeptide ligands	1246:1272	various polypeptide ligands	1246:1272	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	1	20	theme	compartment	202:212	arg1	protein					214:220	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53	141:223	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53)	141:234	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	20	theme	compartment	202:212	arg1	ERGIC-53					226:233	ERGIC-53	226:233	ERGIC-53	226:233	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	21	theme	various	380:386	arg1	receptor					358:365	a cargo receptor	350:365	a cargo receptor	350:365	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	21	theme	various	380:386	arg1	glycoproteins					388:400	trafficking various glycoproteins	368:400	trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus	368:463	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	6	22	theme	structures	1071:1080	arg1	Comparison					1051:1060	Comparison	1051:1060	Comparison of these structures with those previously reported	1051:1111	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	6	23	theme	various	1246:1252	arg1	ligands					1266:1272	various polypeptide ligands	1246:1272	various polypeptide ligands	1246:1272	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	3	24	theme	mannosyl	749:756	arg1	oligosaccharides					758:773	mannosyl oligosaccharides	749:773	mannosyl oligosaccharides	749:773	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides have revealed protein-protein and protein-sugar binding modes.
32356523	5	25	theme	1.60 Å	931:936	arg1	structure					957:965	a 1.60 Å resolution crystal structure	929:965	a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex	929:998	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	0	26	theme	Crystallographic	0:15	arg1	snapshots					17:25	Crystallographic snapshots	0:25	Crystallographic snapshots of the EF-hand protein MCFD2	0:54	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	5	27	theme	resolution	938:947	arg1	structure					957:965	a 1.60 Å resolution crystal structure	929:965	a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex	929:998	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	3	28	theme	protein-sugar	809:821	arg1	modes					831:835	protein-protein and protein-sugar binding modes	789:835	protein-protein and protein-sugar binding modes	789:835	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides have revealed protein-protein and protein-sugar binding modes.
32356523	2	29	gly	glycoproteins	605:617	arg1	glycoproteins					605:617	cargo glycoproteins	599:617	cargo glycoproteins	599:617	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	0	30	gly	glycoprotein	117:128	arg1	glycoprotein					117:128	glycoprotein transport	117:138	glycoprotein transport	117:138	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	1	31	gly	glycoproteins	388:400	arg1	receptor					358:365	a cargo receptor	350:365	a cargo receptor	350:365	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	31	gly	glycoproteins	388:400	arg1	glycoproteins					388:400	trafficking various glycoproteins	368:400	trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus	368:463	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	5	32	theme	crystal	949:955	arg1	structure					957:965	a 1.60 Å resolution crystal structure	929:965	a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex	929:998	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	0	33	theme	protein	42:48	arg1	MCFD2					50:54	the EF-hand protein MCFD2	30:54	the EF-hand protein MCFD2	30:54	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	3	34	theme	protein-protein	789:803	arg1	modes					831:835	protein-protein and protein-sugar binding modes	789:835	protein-protein and protein-sugar binding modes	789:835	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides have revealed protein-protein and protein-sugar binding modes.
32356523	2	35	link	N-linked	579:586	arg1	glycans					588:594	N-linked glycans	579:594	N-linked glycans on cargo glycoproteins	579:617	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	0	36	theme	EF-hand	34:40	arg1	MCFD2					50:54	the EF-hand protein MCFD2	30:54	the EF-hand protein MCFD2	30:54	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	2	37	gly	glycoproteins	675:687	arg1	glycoproteins					675:687	cargo glycoproteins	669:687	cargo glycoproteins	669:687	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	1	38	theme	endoplasmic	414:424	arg1	ER					437:438	ER	437:438	ER	437:438	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	38	theme	endoplasmic	414:424	arg1	reticulum					426:434	the endoplasmic reticulum	410:434	the endoplasmic reticulum (ER)	410:439	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	2	39	theme	ERGIC-53	541:548	arg1	CRD					533:535	CRD	533:535	CRD	533:535	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	2	39	theme	ERGIC-53	541:548	arg1	ERGIC-53					541:548	ERGIC-53	541:548	ERGIC-53 (ERGIC-53CRD)	541:562	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	2	39	theme	ERGIC-53	541:548	arg1	domain					525:530	the carbohydrate-recognition domain	496:530	the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD)	496:562	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	2	40	dep	interacts	564:572	arg1	whereas					620:626	whereas	620:626	whereas	620:626	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	6	41	theme	conformational	1175:1188	arg1	plasticity					1190:1199	significant conformational plasticity	1163:1199	significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands	1163:1272	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	5	42	theme	ERGIC-53CRD-MCFD2	974:990	arg1	complex					992:998	the ERGIC-53CRD-MCFD2 complex	970:998	the ERGIC-53CRD-MCFD2 complex	970:998	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	0	43	theme	MCFD2	50:54	arg1	snapshots					17:25	Crystallographic snapshots	0:25	Crystallographic snapshots of the EF-hand protein MCFD2	0:54	Crystallographic snapshots of the EF-hand protein MCFD2 complexed with the intracellular lectin ERGIC-53 involved in glycoprotein transport.
32356523	3	44	theme	binding	823:829	arg1	modes					831:835	protein-protein and protein-sugar binding modes	789:835	protein-protein and protein-sugar binding modes	789:835	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides have revealed protein-protein and protein-sugar binding modes.
32356523	2	45	theme	N-linked	579:586	arg1	glycans					588:594	N-linked glycans	579:594	N-linked glycans on cargo glycoproteins	579:617	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	4	46	theme	MCFD2	892:896	arg1	mechanism					879:887	the polypeptide-recognition mechanism	851:887	the polypeptide-recognition mechanism of MCFD2	851:896	In contrast, the polypeptide-recognition mechanism of MCFD2 remains largely unknown.
32356523	5	47	theme	complex	992:998	arg1	structure					957:965	a 1.60 Å resolution crystal structure	929:965	a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex	929:998	Here, a 1.60 Å resolution crystal structure of the ERGIC-53CRD-MCFD2 complex is reported, along with three other crystal forms.
32356523	2	48	theme	cargo	669:673	arg1	glycoproteins					675:687	cargo glycoproteins	669:687	cargo glycoproteins	669:687	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	1	49	theme	soluble	244:250	arg1	protein					299:305	the soluble EF-hand multiple coagulation factor deficiency protein 2	240:307	the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2)	240:315	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	49	theme	soluble	244:250	arg1	MCFD2					310:314	MCFD2	310:314	MCFD2	310:314	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	6	50	with	Comparison	1051:1060	arg1	those					1087:1091	those	1087:1091	those	1087:1091	Comparison of these structures with those previously reported reveal that MCFD2, but not ERGIC-53-CRD, exhibits significant conformational plasticity that may be relevant to its accommodation of various polypeptide ligands.
32356523	1	51	theme	transmembrane	145:157	arg1	protein					214:220	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53	141:223	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53)	141:234	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	51	theme	transmembrane	145:157	arg1	ERGIC-53					226:233	ERGIC-53	226:233	ERGIC-53	226:233	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	52	theme	EF-hand	252:258	arg1	protein					299:305	the soluble EF-hand multiple coagulation factor deficiency protein 2	240:307	the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2)	240:315	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	52	theme	EF-hand	252:258	arg1	MCFD2					310:314	MCFD2	310:314	MCFD2	310:314	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	3	53	theme	Crystal	690:696	arg1	structures					698:707	Crystal structures	690:707	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides	690:773	Crystal structures of ERGIC-53CRD complexed with MCFD2 and mannosyl oligosaccharides have revealed protein-protein and protein-sugar binding modes.
32356523	4	54	theme	polypeptide-recognition	855:877	arg1	mechanism					879:887	the polypeptide-recognition mechanism	851:887	the polypeptide-recognition mechanism of MCFD2	851:896	In contrast, the polypeptide-recognition mechanism of MCFD2 remains largely unknown.
32356523	1	55	theme	intracellular	159:171	arg1	protein					214:220	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53	141:223	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53)	141:234	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	55	theme	intracellular	159:171	arg1	ERGIC-53					226:233	ERGIC-53	226:233	ERGIC-53	226:233	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	56	theme	multiple	260:267	arg1	protein					299:305	the soluble EF-hand multiple coagulation factor deficiency protein 2	240:307	the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2)	240:315	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	56	theme	multiple	260:267	arg1	MCFD2					310:314	MCFD2	310:314	MCFD2	310:314	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	2	57	theme	carbohydrate-recognition	500:523	arg1	CRD					533:535	CRD	533:535	CRD	533:535	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	2	57	theme	carbohydrate-recognition	500:523	arg1	ERGIC-53					541:548	ERGIC-53	541:548	ERGIC-53 (ERGIC-53CRD)	541:562	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	2	57	theme	carbohydrate-recognition	500:523	arg1	domain					525:530	the carbohydrate-recognition domain	496:530	the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD)	496:562	It has been demonstrated that the carbohydrate-recognition domain (CRD) of ERGIC-53 (ERGIC-53CRD) interacts with N-linked glycans on cargo glycoproteins, whereas MCFD2 recognizes polypeptide segments of cargo glycoproteins.
32356523	1	58	theme	lectin	173:178	arg1	protein					214:220	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53	141:223	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53)	141:234	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	58	theme	lectin	173:178	arg1	ERGIC-53					226:233	ERGIC-53	226:233	ERGIC-53	226:233	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	59	theme	coagulation	269:279	arg1	protein					299:305	the soluble EF-hand multiple coagulation factor deficiency protein 2	240:307	the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2)	240:315	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
32356523	1	59	theme	coagulation	269:279	arg1	MCFD2					310:314	MCFD2	310:314	MCFD2	310:314	The transmembrane intracellular lectin ER-Golgi intermediate compartment protein 53 (ERGIC-53) and the soluble EF-hand multiple coagulation factor deficiency protein 2 (MCFD2) form a complex that functions as a cargo receptor, trafficking various glycoproteins between the endoplasmic reticulum (ER) and the Golgi apparatus.
35495330	2	0	theme	site	597:600	arg1	fold					563:566	an intact fold	553:566	an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM	553:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	0	theme	site	597:600	arg1	CV-N					477:480	domain-swapped and dimeric CV-N	450:480	domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds	450:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	5	1	dep	residues	1250:1257	arg1	glutamine					1259:1267	glutamine	1259:1267	glutamine	1259:1267	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	5	1	dep	residues	1250:1257	arg1	acid					1292:1295	glutamic acid	1283:1295	glutamic acid	1283:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	5	1	dep	residues	1250:1257	arg1	residues					1250:1257	residues glutamine, glycine, and glutamic acid	1250:1295	residues glutamine, glycine, and glutamic acid	1250:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	5	1	dep	residues	1250:1257	arg1	glycine					1270:1276	glycine	1270:1276	glycine	1270:1276	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	2	2	theme	high-affinity	575:587	arg1	site					597:600	the high-affinity binding site	571:600	the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM	571:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	5	3	from	mannosylated-derivative	1196:1218	arg1	sequence					1238:1245	the HA peptide sequence	1223:1245	the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1223:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	4	4	theme	ion-pairing	1024:1034	arg1	substitution					1046:1057	one ion-pairing C58E-C73R substitution	1020:1057	one ion-pairing C58E-C73R substitution at K D = 275 nM	1020:1073	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	5	5	theme	triazole	1144:1151	arg1	linkage					1165:1171	a triazole bioisostere linkage	1142:1171	a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1142:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	2	6	theme	dissociation	620:631	arg1	constant					633:640	an equilibrium dissociation constant	605:640	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	3	7	theme	glutamic	705:712	arg1	acid					714:717	ion-pairing amino-acids glutamic acid	681:717	ion-pairing amino-acids glutamic acid	681:717	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	6	8	theme	HA	1483:1484	arg1	domain					1491:1496	the HA head domain	1479:1496	the HA head domain	1479:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	9	theme	immunodeficiency	204:219	arg1	HIV					228:230	HIV	228:230	HIV	228:230	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	1	9	theme	immunodeficiency	204:219	arg1	virus					221:225	human immunodeficiency virus	198:225	human immunodeficiency virus (HIV)	198:231	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	4	10	theme	=	1066:1066	arg1	nM					1072:1073	K D = 275 nM	1062:1073	K D = 275 nM	1062:1073	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	4	11	from	nM	1072:1073	arg1	substitution					1046:1057	one ion-pairing C58E-C73R substitution	1020:1057	one ion-pairing C58E-C73R substitution at K D = 275 nM	1020:1073	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	2	12	theme	Cys-Cys	535:541	arg1	bonds					543:547	three Cys-Cys bonds	529:547	three Cys-Cys bonds	529:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	3	13	gly	dimannosylated	833:846	arg1	binding					856:862	dimannosylated peptide binding	833:862	dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide)	833:966	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	3	14	theme	protein	776:782	arg1	design					784:789	in silico structure-based protein design	750:789	in silico structure-based protein design	750:789	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	1	15	theme	Ebola	374:378	arg1	glycoprotein					380:391	Ebola glycoprotein	374:391	Ebola glycoprotein	374:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	4	16	theme	C58E-C73R	1099:1107	arg1	substitutions					1109:1121	two C58E-C73R substitutions	1095:1121	two C58E-C73R substitutions	1095:1121	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	6	17	with	peptides	1329:1336	arg1	cysteine					1354:1361	N-terminal cysteine	1343:1361	N-terminal cysteine	1343:1361	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	3	18	theme	low-affinity	867:878	arg1	sites					888:892	low-affinity binding sites	867:892	low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide)	867:966	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	2	19	theme	intact	556:561	arg1	fold					563:566	an intact fold	553:566	an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM	553:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	5	20	theme	HA	1227:1228	arg1	sequence					1238:1245	the HA peptide sequence	1223:1245	the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1223:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	1	21	gly	glycoproteins	297:309	arg1	glycoproteins					297:309	various glycoproteins	289:309	various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein	289:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	6	22	theme	dimannosylated	1314:1327	arg1	peptides					1329:1336	mono- and dimannosylated peptides	1304:1336	mono- and dimannosylated peptides with N-terminal cysteine	1304:1361	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	23	theme	viruses	324:330	arg1	glycoproteins					297:309	various glycoproteins	289:309	various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein	289:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	3	24	theme	K	895:895	arg1	D					897:897	K D	895:897	K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide	895:965	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	5	25	theme	respective	1185:1194	arg1	mannosylated-derivative					1196:1218	the respective mannosylated-derivative	1181:1218	the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1181:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	3	26	theme	dimannosylated	833:846	arg1	binding					856:862	dimannosylated peptide binding	833:862	dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide)	833:966	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	0	27	theme	binding	102:108	arg1	sites					110:114	complementary binding sites	88:114	complementary binding sites	88:114	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	6	28	with	interactions	1389:1400	arg1	peptides					1410:1417	HA peptides	1407:1417	HA peptides	1407:1417	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	29	theme	neutralizing	168:179	arg1	activity					181:188	broad neutralizing activity	162:188	broad neutralizing activity against human immunodeficiency virus (HIV)	162:231	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	1	30	theme	influenza	341:349	arg1	hemagglutinin					351:363	influenza hemagglutinin	341:363	influenza hemagglutinin (HA)	341:368	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	1	30	theme	influenza	341:349	arg1	HA					366:367	HA	366:367	HA	366:367	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	2	31	theme	constant	633:640	arg1	D					644:644	an equilibrium dissociation constant K D	605:644	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	3	32	dep	sites	888:892	arg1	D					897:897	K D	895:897	K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide	895:965	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	2	33	theme	domain-swapped	450:463	arg1	CV-N					477:480	domain-swapped and dimeric CV-N	450:480	domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds	450:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	34	from	CV-N	477:480	arg1	D					644:644	an equilibrium dissociation constant K D	605:644	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	5	35	theme	glutamic	1283:1290	arg1	acid					1292:1295	glutamic acid	1283:1295	glutamic acid	1283:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	5	35	theme	glutamic	1283:1290	arg1	residues					1250:1257	residues glutamine, glycine, and glutamic acid	1250:1295	residues glutamine, glycine, and glutamic acid	1250:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	0	36	theme	Mannosylated	0:11	arg1	peptides					27:34	Mannosylated hemagglutinin peptides	0:34	Mannosylated hemagglutinin peptides	0:34	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	1	37	theme	Manα	267:270	arg1	units					272:276	Manα(1→2)Manα units	258:276	Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein	258:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	6	38	from	site	1471:1474	arg1	domain					1491:1496	the HA head domain	1479:1496	the HA head domain	1479:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	5	39	theme	residues	1250:1257	arg1	sequence					1238:1245	the HA peptide sequence	1223:1245	the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1223:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	2	40	theme	dimannosylated	417:430	arg1	peptides					435:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	6	41	theme	site-specific	1375:1387	arg1	interactions					1389:1400	site-specific interactions	1375:1400	site-specific interactions with HA peptides	1375:1417	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	42	theme	various	289:295	arg1	glycoproteins					297:309	various glycoproteins	289:309	various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein	289:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	2	43	theme	dimeric	469:475	arg1	CV-N					477:480	domain-swapped and dimeric CV-N	450:480	domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds	450:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	3	44	theme	Cys-Cys	656:662	arg1	mutagenesis					664:674	Cys-Cys mutagenesis	656:674	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine	656:730	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	6	45	theme	N-linked	1448:1455	arg1	site					1471:1474	a naturally found N-linked glycosylation site	1430:1474	a naturally found N-linked glycosylation site on the HA head domain	1430:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	5	46	theme	bioisostere	1153:1163	arg1	linkage					1165:1171	a triazole bioisostere linkage	1142:1171	a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1142:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	4	47	theme	D	1064:1064	arg1	nM					1072:1073	K D = 275 nM	1062:1073	K D = 275 nM	1062:1073	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	6	48	theme	N-terminal	1343:1352	arg1	cysteine					1354:1361	N-terminal cysteine	1343:1361	N-terminal cysteine	1343:1361	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	3	49	theme	amino-acids	693:703	arg1	acid					714:717	ion-pairing amino-acids glutamic acid	681:717	ion-pairing amino-acids glutamic acid	681:717	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	1	50	theme	Manα	258:261	arg1	units					272:276	Manα(1→2)Manα units	258:276	Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein	258:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	2	51	theme	binding	589:595	arg1	site					597:600	the high-affinity binding site	571:600	the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM	571:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	4	52	theme	C58E-C73R	1036:1044	arg1	substitution					1046:1057	one ion-pairing C58E-C73R substitution	1020:1057	one ion-pairing C58E-C73R substitution at K D = 275 nM	1020:1073	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	2	53	with	fold	563:566	arg1	bonds					543:547	three Cys-Cys bonds	529:547	three Cys-Cys bonds	529:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	53	with	fold	563:566	arg1	disulfide-bonds					499:513	four disulfide-bonds	494:513	four disulfide-bonds (Cys-Cys)	494:523	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	53	with	fold	563:566	arg1	Cys-Cys					516:522	Cys-Cys	516:522	Cys-Cys	516:522	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	4	54	theme	K	1080:1080	arg1	D					1082:1082	K D	1080:1082	K D	1080:1082	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	2	55	from	fold	563:566	arg1	D					644:644	an equilibrium dissociation constant K D	605:644	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	56	theme	equilibrium	608:618	arg1	constant					633:640	an equilibrium dissociation constant	605:640	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	6	57	theme	mono-	1304:1308	arg1	peptides					1329:1336	mono- and dimannosylated peptides	1304:1336	mono- and dimannosylated peptides with N-terminal cysteine	1304:1361	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	6	58	theme	head	1486:1489	arg1	domain					1491:1496	the HA head domain	1479:1496	the HA head domain	1479:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	59	theme	human	198:202	arg1	HIV					228:230	HIV	228:230	HIV	228:230	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	1	59	theme	human	198:202	arg1	virus					221:225	human immunodeficiency virus	198:225	human immunodeficiency virus (HIV)	198:231	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	3	60	gly	dimannosylated	944:957	arg1	peptide					959:965	dimannosylated peptide	944:965	dimannosylated peptide	944:965	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	3	61	theme	in	750:751	arg1	design					784:789	in silico structure-based protein design	750:789	in silico structure-based protein design	750:789	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	6	62	link	N-linked	1448:1455	arg1	site					1471:1474	a naturally found N-linked glycosylation site	1430:1474	a naturally found N-linked glycosylation site on the HA head domain	1430:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	3	63	theme	structure-based	760:774	arg1	design					784:789	in silico structure-based protein design	750:789	in silico structure-based protein design	750:789	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	3	64	theme	binding	880:886	arg1	sites					888:892	low-affinity binding sites	867:892	low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide)	867:966	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	2	65	from	D	644:644	arg1	fold					563:566	an intact fold	553:566	an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM	553:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	65	from	D	644:644	arg1	site					597:600	the high-affinity binding site	571:600	the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM	571:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	65	from	D	644:644	arg1	CV-N					477:480	domain-swapped and dimeric CV-N	450:480	domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds	450:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	5	66	theme	peptide	1230:1236	arg1	sequence					1238:1245	the HA peptide sequence	1223:1245	the HA peptide sequence of residues glutamine, glycine, and glutamic acid	1223:1295	We were utilizing a triazole bioisostere linkage to form the respective mannosylated-derivative on the HA peptide sequence of residues glutamine, glycine, and glutamic acid.
35495330	0	67	theme	complementary	88:100	arg1	sites					110:114	complementary binding sites	88:114	complementary binding sites	88:114	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	2	68	with	CV-N	477:480	arg1	bonds					543:547	three Cys-Cys bonds	529:547	three Cys-Cys bonds	529:547	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	68	with	CV-N	477:480	arg1	disulfide-bonds					499:513	four disulfide-bonds	494:513	four disulfide-bonds (Cys-Cys)	494:523	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	68	with	CV-N	477:480	arg1	Cys-Cys					516:522	Cys-Cys	516:522	Cys-Cys	516:522	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	1	69	theme	broad	162:166	arg1	activity					181:188	broad neutralizing activity	162:188	broad neutralizing activity against human immunodeficiency virus (HIV)	162:231	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	2	70	gly	dimannosylated	417:430	arg1	peptides					435:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	3	71	theme	peptide	848:854	arg1	binding					856:862	dimannosylated peptide binding	833:862	dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide)	833:966	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	3	72	dep	in	750:751	arg1	silico					753:758	silico	753:758	silico	753:758	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	0	73	from	disulfide-bonds	69:83	arg1	sites					110:114	complementary binding sites	88:114	complementary binding sites	88:114	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	2	74	theme	K	642:642	arg1	D					644:644	an equilibrium dissociation constant K D	605:644	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	6	75	gly	glycosylation	1457:1469	arg2	site					1471:1474	a naturally found N-linked glycosylation site	1430:1474	a naturally found N-linked glycosylation site on the HA head domain	1430:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	6	76	theme	found	1442:1446	arg1	site					1471:1474	a naturally found N-linked glycosylation site	1430:1474	a naturally found N-linked glycosylation site on the HA head domain	1430:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	0	77	theme	hemagglutinin	13:25	arg1	peptides					27:34	Mannosylated hemagglutinin peptides	0:34	Mannosylated hemagglutinin peptides	0:34	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	2	78	theme	μM	652:653	arg1	D					644:644	an equilibrium dissociation constant K D	605:644	an equilibrium dissociation constant K D of 10 μM	605:653	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	3	79	dep	D	897:897	arg1	≈					899:899	≈	899:899	≈ 11 μM for one C58-C73 bond	899:926	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	3	79	dep	D	897:897	arg1	binding					933:939	binding	933:939	binding to dimannosylated peptide	933:965	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	2	80	theme	HA	432:433	arg1	peptides					435:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	2	81	theme	synthesized	405:415	arg1	peptides					435:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides	394:442	Chemically synthesized dimannosylated HA peptides bound domain-swapped and dimeric CV-N with either four disulfide-bonds (Cys-Cys), or three Cys-Cys bonds and an intact fold of the high-affinity binding site at an equilibrium dissociation constant K D of 10 μM.
35495330	0	82	theme	independent	54:64	arg1	cyanovirin-N					41:52	cyanovirin-N	41:52	cyanovirin-N independent of disulfide-bonds in complementary binding sites	41:114	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	3	83	theme	C58-C73	915:921	arg1	bond					923:926	one C58-C73 bond	911:926	one C58-C73 bond	911:926	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	0	84	theme	disulfide-bonds	69:83	arg1	independent					54:64	independent	54:64	independent	54:64	Mannosylated hemagglutinin peptides bind cyanovirin-N independent of disulfide-bonds in complementary binding sites.
35495330	3	85	theme	dimannosylated	944:957	arg1	peptide					959:965	dimannosylated peptide	944:965	dimannosylated peptide	944:965	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	6	86	theme	glycosylation	1457:1469	arg1	site					1471:1474	a naturally found N-linked glycosylation site	1430:1474	a naturally found N-linked glycosylation site on the HA head domain	1430:1496	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	87	theme	enveloped	314:322	arg1	hemagglutinin					351:363	influenza hemagglutinin	341:363	influenza hemagglutinin (HA)	341:368	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	1	87	theme	enveloped	314:322	arg1	viruses					324:330	enveloped viruses	314:330	enveloped viruses	314:330	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	1	87	theme	enveloped	314:322	arg1	glycoprotein					380:391	Ebola glycoprotein	374:391	Ebola glycoprotein	374:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	6	88	gly	dimannosylated	1314:1327	arg1	peptides					1329:1336	mono- and dimannosylated peptides	1304:1336	mono- and dimannosylated peptides with N-terminal cysteine	1304:1361	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	1	89	gly	glycoprotein	380:391	arg1	glycoprotein					380:391	Ebola glycoprotein	374:391	Ebola glycoprotein	374:391	Cyanovirin-N (CV-N) has been shown to reveal broad neutralizing activity against human immunodeficiency virus (HIV) and to specifically bind Manα(1→2)Manα units exposed on various glycoproteins of enveloped viruses, such as influenza hemagglutinin (HA) and Ebola glycoprotein.
35495330	4	90	theme	K	1062:1062	arg1	nM					1072:1073	K D = 275 nM	1062:1073	K D = 275 nM	1062:1073	In comparison, binding to HA was achieved based on one ion-pairing C58E-C73R substitution at K D = 275 nM, and K D = 5 μM for two C58E-C73R substitutions.
35495330	3	91	theme	ion-pairing	681:691	arg1	acid					714:717	ion-pairing amino-acids glutamic acid	681:717	ion-pairing amino-acids glutamic acid	681:717	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	6	92	theme	HA	1407:1408	arg1	peptides					1410:1417	HA peptides	1407:1417	HA peptides	1407:1417	Thus, mono- and dimannosylated peptides with N-terminal cysteine facilitated site-specific interactions with HA peptides, mimicking a naturally found N-linked glycosylation site on the HA head domain.
35495330	3	93	with	mutagenesis	664:674	arg1	acid					714:717	ion-pairing amino-acids glutamic acid	681:717	ion-pairing amino-acids glutamic acid	681:717	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
35495330	3	93	with	mutagenesis	664:674	arg1	arginine					723:730	arginine	723:730	arginine	723:730	Cys-Cys mutagenesis with ion-pairing amino-acids glutamic acid and arginine was calculated by in silico structure-based protein design and allowed for recognizing dimannose and dimannosylated peptide binding to low-affinity binding sites (K D ≈ 11 μM for one C58-C73 bond, and binding to dimannosylated peptide).
32149134	8	0	theme	CD147	854:858	arg1	level					845:849	the level	841:849	the level of CD147	841:858	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	9	1	theme	reduced	1171:1177	arg1	proliferation					1184:1196	reduced cell proliferation	1171:1196	reduced cell proliferation	1171:1196	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	6	2	theme	proteins	642:649	arg1	expression					628:637	the expression	624:637	the expression of proteins in BC cells	624:661	Western blotting was performed to detect the expression of proteins in BC cells.
32149134	2	3	from	transmembrane	270:282	arg1	tumors					308:313	tumors	308:313	tumors	308:313	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	2	4	link	N-linked	222:229	arg1	CD147					210:214	Mature CD147	203:214	Mature CD147	203:214	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	2	4	link	N-linked	222:229	arg1	protein					244:250	an N-linked glycosylated protein	219:250	an N-linked glycosylated protein	219:250	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	9	5	theme	cell	1179:1182	arg1	proliferation					1184:1196	reduced cell proliferation	1171:1196	reduced cell proliferation	1171:1196	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	9	6	theme	Ki-67	1060:1064	arg1	expression					1066:1075	increased Ki-67 expression	1050:1075	increased Ki-67 expression	1050:1075	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	1	7	theme	type	124:127	arg1	glycoprotein					145:156	a type I transmembrane glycoprotein	122:156	a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily	122:200	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	1	7	theme	type	124:127	arg1	PURPOSE					85:91	PURPOSE CD147	85:97	PURPOSE CD147	85:97	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	12	8	theme	unfavorable	1611:1621	arg1	GSDMD					1574:1578	GSDMD	1574:1578	GSDMD	1574:1578	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	12	8	theme	unfavorable	1611:1621	arg1	marker					1634:1639	an unfavorable prognostic marker	1608:1639	an unfavorable prognostic marker	1608:1639	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	8	9	dep	RESULTS	736:742	arg1	correlated					864:873	correlated	864:873	was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen	860:960	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	8	9	dep	RESULTS	736:742	arg1	increased					786:794	increased	786:794	was significantly increased in BC when compared to healthy controls	768:834	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	11	10	theme	BC	1317:1318	arg1	patients					1320:1327	BC patients	1317:1327	BC patients with overexpression of CD147	1317:1356	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
32149134	8	11	theme	cell	935:938	arg1	antigen					954:960	a cell proliferation antigen	933:960	a cell proliferation antigen	933:960	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	8	11	theme	cell	935:938	arg1	Ki-67					917:921	Ki-67	917:921	Ki-67	917:921	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	2	12	from	forms	299:303	arg1	tumors					308:313	tumors	308:313	tumors	308:313	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	9	13	theme	increased	1050:1058	arg1	expression					1066:1075	increased Ki-67 expression	1050:1075	increased Ki-67 expression	1050:1075	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	8	14	theme	CD147	762:766	arg1	expression					748:757	The expression	744:757	The expression of CD147	744:766	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	4	15	with	controls	481:488	arg1	BC					463:464	BC	463:464	BC	463:464	METHODS The study included 159 patients with BC and 68 healthy controls.
32149134	1	16	gly	glycoprotein	145:156	arg1	glycoprotein					145:156	a type I transmembrane glycoprotein	122:156	a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily	122:200	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	1	16	gly	glycoprotein	145:156	arg1	PURPOSE					85:91	PURPOSE CD147	85:97	PURPOSE CD147	85:97	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	10	17	theme	peptide	1285:1291	arg1	effect					1269:1274	the inhibitory effect	1254:1274	the inhibitory effect of CD147 peptide on tumor proliferation	1254:1314	Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation.
32149134	9	18	theme	cells	998:1002	arg1	treatment					982:990	CD147 treatment	976:990	CD147 treatment of BC cells	976:1002	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	0	19	from	Proliferation	42:54	arg1	Cancer					67:72	Bladder Cancer	59:72	Bladder Cancer	59:72	CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD.
32149134	8	20	theme	tumor	880:884	arg1	proliferation					886:898	tumor proliferation	880:898	tumor proliferation characterized by Ki-67, which is a cell proliferation antigen	880:960	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	11	21	theme	CD147	1352:1356	arg1	overexpression					1334:1347	overexpression	1334:1347	overexpression of CD147	1334:1356	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
32149134	1	22	theme	I	129:129	arg1	glycoprotein					145:156	a type I transmembrane glycoprotein	122:156	a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily	122:200	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	1	22	theme	I	129:129	arg1	PURPOSE					85:91	PURPOSE CD147	85:97	PURPOSE CD147	85:97	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	12	23	theme	CD147	1523:1527	arg1	expression					1509:1518	high expression	1504:1518	high expression of CD147	1504:1527	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	0	24	theme	Tumor	36:40	arg1	Proliferation					42:54	Tumor Proliferation	36:54	Tumor Proliferation in Bladder Cancer	36:72	CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD.
32149134	5	25	theme	CD147	509:513	arg1	expression					495:504	The expression	491:504	The expression of CD147 and gasdermin D (GSDMD)	491:537	The expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC).
32149134	0	26	theme	CD147	0:4	arg1	Expression					6:15	CD147 Expression	0:15	CD147 Expression	0:15	CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD.
32149134	9	27	theme	CD147	976:980	arg1	treatment					982:990	CD147 treatment	976:990	CD147 treatment of BC cells	976:1002	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	1	28	theme	transmembrane	131:143	arg1	glycoprotein					145:156	a type I transmembrane glycoprotein	122:156	a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily	122:200	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	1	28	theme	transmembrane	131:143	arg1	PURPOSE					85:91	PURPOSE CD147	85:97	PURPOSE CD147	85:97	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	2	29	gly	glycosylated	231:242	arg1	CD147					210:214	Mature CD147	203:214	Mature CD147	203:214	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	2	29	gly	glycosylated	231:242	arg1	protein					244:250	an N-linked glycosylated protein	219:250	an N-linked glycosylated protein	219:250	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	9	30	with	blockade	1090:1097	arg1	peptide					1104:1110	peptide	1104:1110	peptide	1104:1110	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	2	31	theme	soluble	291:297	arg1	forms					299:303	as soluble forms	288:303	as soluble forms	288:303	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	3	32	theme	cell	350:353	arg1	proliferation					355:367	cell proliferation	350:367	cell proliferation of bladder cancer (BC)	350:390	However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.
32149134	12	33	theme	tumor	1544:1548	arg1	proliferation					1550:1562	tumor proliferation	1544:1562	tumor proliferation	1544:1562	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	5	34	theme	gasdermin	519:527	arg1	GSDMD					532:536	GSDMD	532:536	GSDMD	532:536	The expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC).
32149134	5	34	theme	gasdermin	519:527	arg1	D					529:529	gasdermin D	519:529	gasdermin D (GSDMD)	519:537	The expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC).
32149134	2	35	theme	as	288:289	arg1	forms					299:303	as soluble forms	288:303	as soluble forms	288:303	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	12	36	dep	CONCLUSION	1463:1472	arg1	suggested					1489:1497	suggested	1489:1497	suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker	1489:1639	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	7	37	theme	IHC	725:727	arg1	score					729:733	the IHC score	721:733	the IHC score	721:733	The relationship between CD147 and GSDMD was analyzed by the IHC score.
32149134	5	38	theme	D	529:529	arg1	expression					495:504	The expression	491:504	The expression of CD147 and gasdermin D (GSDMD)	491:537	The expression of CD147 and gasdermin D (GSDMD) was analyzed by immunohistochemistry (IHC).
32149134	9	39	theme	BC	995:996	arg1	cells					998:1002	BC cells	995:1002	BC cells	995:1002	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	3	40	theme	CD147	341:345	arg1	function					329:336	the function	325:336	the function of CD147 in cell proliferation of bladder cancer (BC)	325:390	However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.
32149134	11	41	theme	survival	1448:1455	arg1	rate					1457:1460	overall survival rate	1440:1460	overall survival rate	1440:1460	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
32149134	10	42	theme	tumor	1296:1300	arg1	proliferation					1302:1314	tumor proliferation	1296:1314	tumor proliferation	1296:1314	Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation.
32149134	8	43	theme	healthy	819:825	arg1	controls					827:834	healthy controls	819:834	healthy controls	819:834	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	3	44	theme	bladder	372:378	arg1	BC					388:389	BC	388:389	BC	388:389	However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.
32149134	3	44	theme	bladder	372:378	arg1	cancer					380:385	bladder cancer	372:385	bladder cancer (BC)	372:390	However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.
32149134	4	45	dep	METHODS	418:424	arg1	included					436:443	included	436:443	included 159 patients with BC and 68 healthy controls	436:488	METHODS The study included 159 patients with BC and 68 healthy controls.
32149134	11	46	with	correlation	1365:1375	arg1	GSDMD					1382:1386	GSDMD	1382:1386	GSDMD	1382:1386	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
32149134	1	47	theme	immunoglobulin	175:188	arg1	superfamily					190:200	immunoglobulin superfamily	175:200	immunoglobulin superfamily	175:200	PURPOSE CD147, also known as BSG, is a type I transmembrane glycoprotein that belonged to immunoglobulin superfamily.
32149134	3	48	theme	cancer	380:385	arg1	proliferation					355:367	cell proliferation	350:367	cell proliferation of bladder cancer (BC)	350:390	However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.
32149134	12	49	theme	high	1504:1507	arg1	expression					1509:1518	high expression	1504:1518	high expression of CD147	1504:1527	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	10	50	from	effect	1269:1274	arg1	proliferation					1302:1314	tumor proliferation	1296:1314	tumor proliferation	1296:1314	Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation.
32149134	11	51	with	patients	1320:1327	arg1	overexpression					1334:1347	overexpression	1334:1347	overexpression of CD147	1334:1356	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
32149134	3	52	from	function	329:336	arg1	proliferation					355:367	cell proliferation	350:367	cell proliferation of bladder cancer (BC)	350:390	However, the function of CD147 in cell proliferation of bladder cancer (BC) remains to be elucidated.
32149134	2	53	theme	Mature	203:208	arg1	CD147					210:214	Mature CD147	203:214	Mature CD147	203:214	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	2	53	theme	Mature	203:208	arg1	protein					244:250	an N-linked glycosylated protein	219:250	an N-linked glycosylated protein	219:250	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	9	54	theme	GSDMD	1140:1144	arg1	expression					1146:1155	GSDMD expression	1140:1155	GSDMD expression	1140:1155	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	8	55	theme	proliferation	940:952	arg1	antigen					954:960	a cell proliferation antigen	933:960	a cell proliferation antigen	933:960	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	8	55	theme	proliferation	940:952	arg1	Ki-67					917:921	Ki-67	917:921	Ki-67	917:921	RESULTS The expression of CD147 was significantly increased in BC when compared to healthy controls, and the level of CD147 was correlated with tumor proliferation characterized by Ki-67, which is a cell proliferation antigen.
32149134	10	56	theme	GSDMD	1230:1234	arg1	overexpression					1212:1225	overexpression	1212:1225	overexpression of GSDMD	1212:1234	Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation.
32149134	2	57	dep	transmembrane	270:282	arg1	the					266:268	the	266:268	the	266:268	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	6	58	theme	Western	583:589	arg1	blotting					591:598	Western blotting	583:598	Western blotting	583:598	Western blotting was performed to detect the expression of proteins in BC cells.
32149134	4	59	theme	healthy	473:479	arg1	controls					481:488	68 healthy controls	470:488	68 healthy controls	470:488	METHODS The study included 159 patients with BC and 68 healthy controls.
32149134	9	60	theme	CD147	1084:1088	arg1	blockade					1090:1097	CD147 blockade	1084:1097	CD147 blockade with peptide in BC	1084:1116	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	9	61	theme	GSDMD	1032:1036	arg1	expression					1018:1027	the expression	1014:1027	the expression of GSDMD	1014:1036	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	4	62	with	patients	449:456	arg1	BC					463:464	BC	463:464	BC	463:464	METHODS The study included 159 patients with BC and 68 healthy controls.
32149134	11	63	theme	poorer	1419:1424	arg1	prognosis					1426:1434	poorer prognosis	1419:1434	poorer prognosis	1419:1434	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
32149134	6	64	from	expression	628:637	arg1	cells					657:661	BC cells	654:661	BC cells	654:661	Western blotting was performed to detect the expression of proteins in BC cells.
32149134	2	65	theme	glycosylated	231:242	arg1	CD147					210:214	Mature CD147	203:214	Mature CD147	203:214	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	2	65	theme	glycosylated	231:242	arg1	protein					244:250	an N-linked glycosylated protein	219:250	an N-linked glycosylated protein	219:250	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	9	66	from	blockade	1090:1097	arg1	BC					1115:1116	BC	1115:1116	BC	1115:1116	In addition, CD147 treatment of BC cells increased the expression of GSDMD, leading to increased Ki-67 expression, while CD147 blockade with peptide in BC significantly reduced GSDMD expression, resulting in reduced cell proliferation.
32149134	2	67	theme	N-linked	222:229	arg1	CD147					210:214	Mature CD147	203:214	Mature CD147	203:214	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	2	67	theme	N-linked	222:229	arg1	protein					244:250	an N-linked glycosylated protein	219:250	an N-linked glycosylated protein	219:250	Mature CD147 is an N-linked glycosylated protein and exists on the transmembrane and as soluble forms in tumors.
32149134	6	68	theme	BC	654:655	arg1	cells					657:661	BC cells	654:661	BC cells	654:661	Western blotting was performed to detect the expression of proteins in BC cells.
32149134	12	69	theme	prognostic	1623:1632	arg1	GSDMD					1574:1578	GSDMD	1574:1578	GSDMD	1574:1578	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	12	69	theme	prognostic	1623:1632	arg1	marker					1634:1639	an unfavorable prognostic marker	1608:1639	an unfavorable prognostic marker	1608:1639	CONCLUSION These findings suggested that high expression of CD147 contributed to tumor proliferation in BC via GSDMD, which might in turn act as an unfavorable prognostic marker.
32149134	10	70	theme	CD147	1279:1283	arg1	peptide					1285:1291	CD147 peptide	1279:1291	CD147 peptide	1279:1291	Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation.
32149134	0	71	theme	Bladder	59:65	arg1	Cancer					67:72	Bladder Cancer	59:72	Bladder Cancer	59:72	CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD.
32149134	10	72	theme	inhibitory	1258:1267	arg1	effect					1269:1274	the inhibitory effect	1254:1274	the inhibitory effect of CD147 peptide on tumor proliferation	1254:1314	Furthermore, overexpression of GSDMD markedly overcame the inhibitory effect of CD147 peptide on tumor proliferation.
32149134	11	73	theme	overall	1440:1446	arg1	rate					1457:1460	overall survival rate	1440:1460	overall survival rate	1440:1460	BC patients with overexpression of CD147 showed correlation with GSDMD and demonstrated significantly poorer prognosis and overall survival rate.
34960798	8	0	dep	subtypes	1543:1550	arg1	subtypes					1543:1550	subtypes A5 and A17	1543:1561	subtypes A5 and A17	1543:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	0	dep	subtypes	1543:1550	arg1	A17					1559:1561	A17	1559:1561	A17	1559:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	0	dep	subtypes	1543:1550	arg1	A5					1552:1553	A5	1552:1553	A5	1552:1553	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	1	theme	CA	1417:1418	arg1	protein					1420:1426	CA protein	1417:1426	CA protein	1417:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	10	2	link	N-linked	1722:1729	arg1	PNGS					1752:1755	PNGS	1752:1755	PNGS	1752:1755	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	2	link	N-linked	1722:1729	arg1	sites					1745:1749	potential N-linked glycosylation sites	1712:1749	potential N-linked glycosylation sites (PNGS)	1712:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	9	3	theme	SU5	1685:1687	arg1	epitope					1689:1695	the SU5 epitope	1681:1695	the SU5 epitope	1681:1695	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	12	4	theme	subtype	2126:2132	arg1	A17					2134:2136	subtype A17	2126:2136	subtype A17	2126:2136	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	10	5	theme	glycosylation	1731:1743	arg1	PNGS					1752:1755	PNGS	1752:1755	PNGS	1752:1755	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	5	theme	glycosylation	1731:1743	arg1	sites					1745:1749	potential N-linked glycosylation sites	1712:1749	potential N-linked glycosylation sites (PNGS)	1712:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	0	6	theme	global	319:324	arg1	infection					326:334	global infection	319:334	global infection in sheep and goats	319:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	7	7	theme	putative	1254:1261	arg1	events					1277:1282	three putative recombination events	1248:1282	three putative recombination events	1248:1282	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	11	8	theme	TATA	1917:1920	arg1	box					1922:1924	the TATA box	1913:1924	the TATA box	1913:1924	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	12	9	theme	nt	2225:2226	arg1	deletion					2228:2235	a 11 nt deletion	2220:2235	a 11 nt deletion	2220:2235	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	9	10	from	variation	1668:1676	arg1	epitope					1689:1695	the SU5 epitope	1681:1695	the SU5 epitope	1681:1695	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	2	11	theme	flocks	682:687	arg1	numbers					659:665	larger numbers	652:665	larger numbers of animals and flocks	652:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	10	12	theme	potential	1712:1720	arg1	PNGS					1752:1755	PNGS	1752:1755	PNGS	1752:1755	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	12	theme	potential	1712:1720	arg1	sites					1745:1749	potential N-linked glycosylation sites	1712:1749	potential N-linked glycosylation sites (PNGS)	1712:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	0	13	dep	Subtypes	202:209	arg1	group					269:273	a group	267:273	a group of highly divergent viruses responsible for global infection in sheep and goats	267:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	13	dep	Subtypes	202:209	arg1	viruses					295:301	highly divergent viruses	278:301	highly divergent viruses responsible for global infection in sheep and goats	278:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	13	dep	Subtypes	202:209	arg1	A.					224:225	A.	224:225	A.	224:225	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	2	14	theme	present	550:556	arg1	work					558:561	The present work	546:561	The present work	546:561	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	1	15	from	region	538:543	arg1	flocks					515:520	the few flocks	507:520	the few flocks from Małopolska region	507:543	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	2	16	theme	animals	670:676	arg1	numbers					659:665	larger numbers	652:665	larger numbers of animals and flocks	652:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	2	17	from	flocks	635:640	arg1	analysis					608:615	the analysis	604:615	the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks	604:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	0	18	theme	Subtypes	202:209	arg1	Existence					185:193	the Existence	181:193	the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats	181:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	8	19	theme	unique	1510:1515	arg1	mutations					1517:1525	unique mutations	1510:1525	unique mutations in sequences of subtypes A5 and A17	1510:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	14	20	theme	mixed	2496:2500	arg1	flocks					2502:2507	mixed flocks	2496:2507	mixed flocks	2496:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	12	21	theme	TATA	2194:2197	arg1	box					2199:2201	TATA box	2194:2201	TATA box	2194:2201	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	14	22	theme	goats	2487:2491	arg1	evidence					2449:2456	strong and multiple evidence	2429:2456	strong and multiple evidence of dually infected sheep and goats in mixed flocks	2429:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	2	23	theme	different	694:702	arg1	part					704:707	different part	694:707	different part of Poland	694:717	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	8	24	from	sequences	1377:1385	arg1	protein					1420:1426	CA protein	1417:1426	CA protein	1417:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	1	25	theme	previous	361:368	arg1	study					370:374	a previous study	359:374	a previous study	359:374	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	3	26	dep	subtypes	793:800	arg1	A12					810:812	A12	810:812	A12	810:812	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	3	26	dep	subtypes	793:800	arg1	A17					819:821	A17	819:821	A17	819:821	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	3	26	dep	subtypes	793:800	arg1	A5					806:807	A5	806:807	A5	806:807	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	3	26	dep	subtypes	793:800	arg1	B2					802:803	B2	802:803	B2	802:803	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	3	26	dep	subtypes	793:800	arg1	subtypes					793:800	the subtypes B2, A5, A12, and A17	789:821	the subtypes B2, A5, A12, and A17	789:821	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	12	27	theme	substitution	2149:2160	arg1	T					2162:2162	unique substitution T	2142:2162	unique substitution T	2142:2162	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	11	28	theme	LTR	1858:1860	arg1	sequences					1862:1870	LTR sequences	1858:1870	LTR sequences	1858:1870	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	14	29	theme	sheep	2477:2481	arg1	evidence					2449:2456	strong and multiple evidence	2429:2456	strong and multiple evidence of dually infected sheep and goats in mixed flocks	2429:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	2	30	theme	mixed	629:633	arg1	flocks					635:640	mixed flocks	629:640	mixed flocks including larger numbers of animals and flocks	629:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	2	30	theme	mixed	629:633	arg1	numbers					659:665	larger numbers	652:665	larger numbers of animals and flocks	652:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	8	31	from	protein	1420:1426	arg1	sequences					1377:1385	Amino acid (aa) sequences	1361:1385	Amino acid (aa) sequences of immunodominant epitopes in CA protein	1361:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	10	32	gly	glycosylation	1731:1743	arg2	sites					1745:1749	potential N-linked glycosylation sites	1712:1749	potential N-linked glycosylation sites (PNGS)	1712:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	32	gly	glycosylation	1731:1743	arg2	PNGS					1752:1755	PNGS	1752:1755	PNGS	1752:1755	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	3	33	theme	Polish	759:764	arg1	SRLVs					766:770	Polish SRLVs	759:770	Polish SRLVs	759:770	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	12	34	theme	other	2272:2276	arg1	sequences					2278:2286	other sequences	2272:2286	other sequences from Poland	2272:2298	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	10	35	dep	6	1775:1775	arg1	to					1772:1773	to	1772:1773	to	1772:1773	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	2	36	theme	SRLVs	620:624	arg1	analysis					608:615	the analysis	604:615	the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks	604:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	1	37	theme	Małopolska	527:536	arg1	region					538:543	Małopolska region	527:543	Małopolska region	527:543	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	0	38	theme	divergent	285:293	arg1	viruses					295:301	highly divergent viruses	278:301	highly divergent viruses responsible for global infection in sheep and goats	278:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	3	39	theme	sequences	748:756	arg1	basis					727:731	the basis	723:731	the basis of gag and env sequences	723:756	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	11	40	theme	sequences	1862:1870	arg1	analysis					1846:1853	The analysis	1842:1853	The analysis of LTR sequences	1842:1870	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	0	41	theme	Mixed	68:72	arg1	Flocks					74:79	Polish Mixed Flocks	61:79	Polish Mixed Flocks	61:79	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	42	theme	responsible	303:313	arg1	viruses					295:301	highly divergent viruses	278:301	highly divergent viruses responsible for global infection in sheep and goats	278:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	5	43	located	found	1074:1078	arg2	A23					1052:1054	A23	1052:1054	A23	1052:1054	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	43	located	found	1074:1078	arg1	sheep					1088:1092	sheep	1088:1092	sheep	1088:1092	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	43	located	found	1074:1078	arg1	goats					1098:1102	goats	1098:1102	goats	1098:1102	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	43	located	found	1074:1078	arg2	A12					1047:1049	A12	1047:1049	A12	1047:1049	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	43	located	found	1074:1078	arg2	subtypes					1038:1045	subtypes A12, A23, and B2	1038:1062	subtypes A12, A23, and B2	1038:1062	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	43	located	found	1074:1078	arg2	B2					1061:1062	B2	1061:1062	B2	1061:1062	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	13	44	theme	population	2348:2357	arg1	picture					2331:2337	a complex picture	2321:2337	a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B	2321:2415	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	10	45	located	located	1810:1816	arg2	located					1810:1816	located	1810:1816	located	1810:1816	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	45	located	located	1810:1816	arg2	number					1702:1707	The number	1698:1707	The number of potential N-linked glycosylation sites (PNGS)	1698:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	45	located	located	1810:1816	arg1	positions					1831:1839	different positions	1821:1839	different positions	1821:1839	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	2	46	theme	earlier	582:588	arg1	findings					590:597	earlier findings	582:597	earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks	582:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	10	47	from	positions	1831:1839	arg1	number					1702:1707	The number	1698:1707	The number of potential N-linked glycosylation sites (PNGS)	1698:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	47	from	positions	1831:1839	arg1	located					1810:1816	located	1810:1816	located	1810:1816	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	0	48	theme	ruminant	233:240	arg1	SRLVs					256:260	SRLVs	256:260	SRLVs	256:260	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	48	theme	ruminant	233:240	arg1	lentiviruses					242:253	Small ruminant lentiviruses	227:253	A. Small ruminant lentiviruses (SRLVs)	224:261	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	49	theme	Species	108:114	arg1	Infection					135:143	Dual Infection	130:143	Dual Infection	130:143	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	49	theme	Species	108:114	arg1	Event					162:166	a Recombination Event	146:166	a Recombination Event	146:166	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	49	theme	Species	108:114	arg1	Transmission					116:127	Cross Species Transmission	102:127	Cross Species Transmission	102:127	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	11	50	theme	polyadenylation	1946:1960	arg1	A					1975:1975	poly A	1970:1975	poly A	1970:1975	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	11	50	theme	polyadenylation	1946:1960	arg1	signal					1962:1967	polyadenylation signal	1946:1967	polyadenylation signal (poly A)	1946:1976	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	14	51	theme	strong	2429:2434	arg1	evidence					2449:2456	strong and multiple evidence	2429:2456	strong and multiple evidence of dually infected sheep and goats in mixed flocks	2429:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	12	52	contain	have	2215:2218	arg1	sequences					2103:2111	all sequences	2099:2111	all sequences belonging to subtype A17	2099:2136	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	12	52	contain	have	2215:2218	arg2	deletion					2228:2235	a 11 nt deletion	2220:2235	a 11 nt deletion	2220:2235	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	0	53	theme	Molecular	0:8	arg1	Characterization					10:25	Molecular Characterization	0:25	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks	0:79	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	9	54	theme	aa	1577:1578	arg1	sequences					1580:1588	aa sequences	1577:1588	aa sequences of surface glycoprotein	1577:1612	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	12	55	contain	had	2138:2140	arg2	T					2162:2162	unique substitution T	2142:2162	unique substitution T	2142:2162	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	12	55	contain	had	2138:2140	arg1	sequences					2103:2111	all sequences	2099:2111	all sequences belonging to subtype A17	2099:2136	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	12	56	theme	box	2199:2201	arg1	position					2182:2189	the fifth position	2172:2189	the fifth position of TATA box	2172:2201	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	4	57	theme	subtypes	860:867	arg1	existence					841:849	the existence	837:849	the existence of a new subtypes, tentatively designed as A23 and A24,	837:905	Furthermore, the existence of a new subtypes, tentatively designed as A23 and A24, were described for the first time.
34960798	10	58	theme	different	1821:1829	arg1	positions					1831:1839	different positions	1821:1839	different positions	1821:1839	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	0	59	theme	Ruminant	36:43	arg1	Lentiviruses					45:56	Small Ruminant Lentiviruses	30:56	Small Ruminant Lentiviruses	30:56	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	9	60	theme	surface	1593:1599	arg1	glycoprotein					1601:1612	surface glycoprotein	1593:1612	surface glycoprotein	1593:1612	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	7	61	theme	SRLVs	1319:1323	arg1	sequences					1325:1333	gag and env SRLVs sequences	1307:1333	gag and env SRLVs sequences derived from three sheep	1307:1358	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	9	62	theme	glycoprotein	1601:1612	arg1	sequences					1580:1588	aa sequences	1577:1588	aa sequences of surface glycoprotein	1577:1612	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	8	63	theme	acid	1367:1370	arg1	sequences					1377:1385	Amino acid (aa) sequences	1361:1385	Amino acid (aa) sequences of immunodominant epitopes in CA protein	1361:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	13	64	theme	group	2403:2407	arg1	A					2409:2409	group A	2403:2409	group A	2403:2409	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	9	65	theme	higher	1624:1629	arg1	variability					1631:1641	higher variability	1624:1641	higher variability	1624:1641	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	5	66	dep	Subtypes	942:949	arg1	A5					951:952	A5	951:952	A5	951:952	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	66	dep	Subtypes	942:949	arg1	Subtypes					942:949	Subtypes A5 and A17	942:960	Subtypes A5 and A17	942:960	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	66	dep	Subtypes	942:949	arg1	A17					958:960	A17	958:960	A17	958:960	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	10	67	from	located	1810:1816	arg1	positions					1831:1839	different positions	1821:1839	different positions	1821:1839	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	8	68	theme	immunodominant	1390:1403	arg1	epitopes					1405:1412	immunodominant epitopes	1390:1412	immunodominant epitopes in CA protein	1390:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	13	69	theme	SRLVs	2342:2346	arg1	population					2348:2357	SRLVs population	2342:2357	SRLVs population	2342:2357	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	8	70	theme	Homology	1460:1467	arg1	Region					1469:1474	Major Homology Region	1454:1474	Major Homology Region (MHR)	1454:1480	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	70	theme	Homology	1460:1467	arg1	MHR					1477:1479	MHR	1477:1479	MHR	1477:1479	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	7	71	theme	recombination	1263:1275	arg1	events					1277:1282	three putative recombination events	1248:1282	three putative recombination events	1248:1282	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	0	72	dep	A.	224:225	arg1	SRLVs					256:260	SRLVs	256:260	SRLVs	256:260	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	72	dep	A.	224:225	arg1	lentiviruses					242:253	Small ruminant lentiviruses	227:253	A. Small ruminant lentiviruses (SRLVs)	224:261	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	11	73	theme	considerable	2006:2017	arg1	alteration					2019:2028	considerable alteration	2006:2028	considerable alteration	2006:2028	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	10	74	theme	N-linked	1722:1729	arg1	PNGS					1752:1755	PNGS	1752:1755	PNGS	1752:1755	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	74	theme	N-linked	1722:1729	arg1	sites					1745:1749	potential N-linked glycosylation sites	1712:1749	potential N-linked glycosylation sites (PNGS)	1712:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	0	75	theme	New	198:200	arg1	Subtypes					202:209	New Subtypes	198:209	New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats	198:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	1	76	theme	mixed	413:417	arg1	flocks					419:424	mixed flocks	413:424	mixed flocks	413:424	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	6	77	with	Co-infection	1105:1116	arg1	strains					1123:1129	strains	1123:1129	strains belonging to different subtypes	1123:1161	Co-infection with strains belonging to different subtypes was evidenced in three sheep and two goats originating from two flocks.
34960798	2	78	from	SRLVs	620:624	arg1	flocks					635:640	mixed flocks	629:640	mixed flocks including larger numbers of animals and flocks	629:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	2	78	from	SRLVs	620:624	arg1	numbers					659:665	larger numbers	652:665	larger numbers of animals and flocks	652:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	1	79	located	found	404:408	arg2	strains					396:402	SRLV strains	391:402	SRLV strains found in mixed flocks in Poland	391:434	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	1	79	located	found	404:408	arg1	Poland					429:434	Poland	429:434	Poland	429:434	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	1	79	located	found	404:408	arg1	flocks					419:424	mixed flocks	413:424	mixed flocks	413:424	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	8	80	theme	more	1486:1489	arg1	alteration					1491:1500	more alteration	1486:1500	more alteration showing unique mutations in sequences of subtypes A5 and A17	1486:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	12	81	from	Poland	2293:2298	arg1	sequences					2278:2286	other sequences	2272:2286	other sequences from Poland	2272:2298	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	2	82	theme	Poland	712:717	arg1	part					704:707	different part	694:707	different part of Poland	694:717	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	0	83	theme	Dual	130:133	arg1	Infection					135:143	Dual Infection	130:143	Dual Infection	130:143	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	83	theme	Dual	130:133	arg1	Transmission					116:127	Cross Species Transmission	102:127	Cross Species Transmission	102:127	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	14	84	from	flocks	2502:2507	arg1	evidence					2449:2456	strong and multiple evidence	2429:2456	strong and multiple evidence of dually infected sheep and goats in mixed flocks	2429:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	13	85	theme	ovine	2364:2368	arg1	strains					2382:2388	ovine and caprine strains	2364:2388	strains	2382:2388	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	11	86	theme	AP-1	2046:2049	arg1	sites					2051:2055	AP-1 sites	2046:2055	AP-1 sites	2046:2055	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	10	87	theme	sites	1745:1749	arg1	number					1702:1707	The number	1698:1707	The number of potential N-linked glycosylation sites (PNGS)	1698:1756	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	10	87	theme	sites	1745:1749	arg1	located					1810:1816	located	1810:1816	located	1810:1816	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	13	88	theme	caprine	2374:2380	arg1	strains					2382:2388	ovine and caprine strains	2364:2388	strains	2382:2388	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	5	89	dep	subtypes	1038:1045	arg1	B2					1061:1062	B2	1061:1062	B2	1061:1062	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	89	dep	subtypes	1038:1045	arg1	A12					1047:1049	A12	1047:1049	A12	1047:1049	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	89	dep	subtypes	1038:1045	arg1	subtypes					1038:1045	subtypes A12, A23, and B2	1038:1062	subtypes A12, A23, and B2	1038:1062	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	89	dep	subtypes	1038:1045	arg1	A23					1052:1054	A23	1052:1054	A23	1052:1054	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	0	90	theme	Recombination	148:160	arg1	Event					162:166	a Recombination Event	146:166	a Recombination Event	146:166	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	90	theme	Recombination	148:160	arg1	Transmission					116:127	Cross Species Transmission	102:127	Cross Species Transmission	102:127	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	11	91	located	observed	2034:2041	arg2	alteration					2019:2028	considerable alteration	2006:2028	considerable alteration	2006:2028	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	11	91	located	observed	2034:2041	arg1	sites					2051:2055	AP-1 sites	2046:2055	AP-1 sites	2046:2055	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	8	92	from	epitopes	1405:1412	arg1	protein					1420:1426	CA protein	1417:1426	CA protein	1417:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	14	93	theme	infected	2468:2475	arg1	sheep					2477:2481	dually infected sheep	2461:2481	dually infected sheep	2461:2481	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	8	94	theme	subtypes	1543:1550	arg1	sequences					1530:1538	sequences	1530:1538	sequences of subtypes A5 and A17	1530:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	5	95	located	found	972:976	arg2	A17					958:960	A17	958:960	A17	958:960	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	95	located	found	972:976	arg1	goats					981:985	goats	981:985	goats	981:985	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	95	located	found	972:976	arg2	Subtypes					942:949	Subtypes A5 and A17	942:960	Subtypes A5 and A17	942:960	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	95	located	found	972:976	arg2	A5					951:952	A5	951:952	A5	951:952	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	10	96	theme	respective	1780:1789	arg1	sequences					1791:1799	respective sequences	1780:1799	respective sequences	1780:1799	The number of potential N-linked glycosylation sites (PNGS) ranged from 3 to 6 in respective sequences and were located in different positions.
34960798	1	97	theme	SRLV	391:394	arg1	strains					396:402	SRLV strains	391:402	SRLV strains found in mixed flocks in Poland	391:434	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	13	98	with	picture	2331:2337	arg1	strains					2382:2388	ovine and caprine strains	2364:2388	strains	2382:2388	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	14	99	theme	multiple	2440:2447	arg1	evidence					2449:2456	strong and multiple evidence	2429:2456	strong and multiple evidence of dually infected sheep and goats in mixed flocks	2429:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	2	100	theme	larger	652:657	arg1	numbers					659:665	larger numbers	652:665	larger numbers of animals and flocks	652:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	2	101	with	findings	590:597	arg1	analysis					608:615	the analysis	604:615	the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks	604:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	0	102	theme	viruses	295:301	arg1	group					269:273	a group	267:273	a group of highly divergent viruses responsible for global infection in sheep and goats	267:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	102	theme	viruses	295:301	arg1	viruses					295:301	highly divergent viruses	278:301	highly divergent viruses responsible for global infection in sheep and goats	278:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	102	theme	viruses	295:301	arg1	A.					224:225	A.	224:225	A.	224:225	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	11	103	theme	poly	1970:1973	arg1	A					1975:1975	poly A	1970:1975	poly A	1970:1975	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	11	103	theme	poly	1970:1973	arg1	signal					1962:1967	polyadenylation signal	1946:1967	polyadenylation signal (poly A)	1946:1976	The analysis of LTR sequences revealed that sequences corresponding to the TATA box, AP-4, AML-vis, and polyadenylation signal (poly A) were quite conserved, while considerable alteration was observed in AP-1 sites.
34960798	0	104	from	Characterization	10:25	arg1	Flocks					74:79	Polish Mixed Flocks	61:79	Polish Mixed Flocks	61:79	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	2	105	from	analysis	608:615	arg1	flocks					635:640	mixed flocks	629:640	mixed flocks including larger numbers of animals and flocks	629:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	2	105	from	analysis	608:615	arg1	numbers					659:665	larger numbers	652:665	larger numbers of animals and flocks	652:687	The present work aimed at extending earlier findings with the analysis of SRLVs in mixed flocks including larger numbers of animals and flocks from different part of Poland.
34960798	3	106	theme	env	744:746	arg1	sequences					748:756	gag and env sequences	736:756	gag and env sequences	736:756	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	0	107	theme	Cross	102:106	arg1	Infection					135:143	Dual Infection	130:143	Dual Infection	130:143	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	107	theme	Cross	102:106	arg1	Event					162:166	a Recombination Event	146:166	a Recombination Event	146:166	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	107	theme	Cross	102:106	arg1	Transmission					116:127	Cross Species Transmission	102:127	Cross Species Transmission	102:127	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	3	108	theme	gag	736:738	arg1	sequences					748:756	gag and env sequences	736:756	gag and env sequences	736:756	On the basis of gag and env sequences, Polish SRLVs were assigned to the subtypes B2, A5, A12, and A17.
34960798	6	109	theme	different	1144:1152	arg1	subtypes					1154:1161	different subtypes	1144:1161	different subtypes	1144:1161	Co-infection with strains belonging to different subtypes was evidenced in three sheep and two goats originating from two flocks.
34960798	0	110	theme	Small	227:231	arg1	SRLVs					256:260	SRLVs	256:260	SRLVs	256:260	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	110	theme	Small	227:231	arg1	lentiviruses					242:253	Small ruminant lentiviruses	227:253	A. Small ruminant lentiviruses (SRLVs)	224:261	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	5	111	located	detected	1009:1016	arg1	sheep					1026:1030	sheep	1026:1030	sheep	1026:1030	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	5	111	located	detected	1009:1016	arg2	A24					996:998	subtype A24	988:998	subtype A24	988:998	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	0	112	theme	Transmission	116:127	arg1	Evidence					90:97	Evidence	90:97	Evidence of Cross Species Transmission, Dual Infection, a Recombination Event,	90:167	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	8	113	contain	had	1482:1484	arg1	Region					1469:1474	Major Homology Region	1454:1474	Major Homology Region (MHR)	1454:1480	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	113	contain	had	1482:1484	arg2	alteration					1491:1500	more alteration	1486:1500	more alteration showing unique mutations in sequences of subtypes A5 and A17	1486:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	113	contain	had	1482:1484	arg1	MHR					1477:1479	MHR	1477:1479	MHR	1477:1479	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	1	114	dep	subtype	448:454	arg1	A13					456:458	A13	456:458	A13	456:458	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	1	114	dep	subtype	448:454	arg1	A18					464:466	A18	464:466	A18	464:466	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	12	115	theme	fifth	2176:2180	arg1	position					2182:2189	the fifth position	2172:2189	the fifth position of TATA box	2172:2201	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	0	116	theme	Small	30:34	arg1	Lentiviruses					45:56	Small Ruminant Lentiviruses	30:56	Small Ruminant Lentiviruses	30:56	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	9	117	gly	glycoprotein	1601:1612	arg1	glycoprotein					1601:1612	surface glycoprotein	1593:1612	surface glycoprotein	1593:1612	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	8	118	theme	Amino	1361:1365	arg1	aa					1373:1374	aa	1373:1374	aa	1373:1374	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	118	theme	Amino	1361:1365	arg1	acid					1367:1370	Amino acid	1361:1370	Amino acid (aa) sequences of immunodominant epitopes in CA protein	1361:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	1	119	theme	few	511:513	arg1	flocks					515:520	the few flocks	507:520	the few flocks from Małopolska region	507:543	In a previous study we showed that SRLV strains found in mixed flocks in Poland belonged to subtype A13 and A18, but this study was restricted only to the few flocks from Małopolska region.
34960798	7	120	attach	derived	1335:1341	arg2	sequences					1325:1333	gag and env SRLVs sequences	1307:1333	gag and env SRLVs sequences derived from three sheep	1307:1358	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	7	120	attach	derived	1335:1341	arg1	sheep					1354:1358	three sheep	1348:1358	three sheep	1348:1358	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	0	121	theme	Lentiviruses	45:56	arg1	Characterization					10:25	Molecular Characterization	0:25	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks	0:79	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	9	122	theme	type-specific	1654:1666	arg1	variation					1668:1676	type-specific variation	1654:1676	type-specific variation in the SU5 epitope	1654:1695	In contrast, aa sequences of surface glycoprotein exhibited higher variability confirming type-specific variation in the SU5 epitope.
34960798	4	123	theme	new	856:858	arg1	subtypes					860:867	a new subtypes	854:867	a new subtypes	854:867	Furthermore, the existence of a new subtypes, tentatively designed as A23 and A24, were described for the first time.
34960798	0	124	from	infection	326:334	arg1	goats					349:353	goats	349:353	goats	349:353	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	0	124	from	infection	326:334	arg1	sheep					339:343	sheep	339:343	sheep	339:343	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	14	125	from	sheep	2477:2481	arg1	flocks					2502:2507	mixed flocks	2496:2507	mixed flocks	2496:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	13	126	theme	complex	2323:2329	arg1	picture					2331:2337	a complex picture	2321:2337	a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B	2321:2415	These data revealed a complex picture of SRLVs population with ovine and caprine strains belonging to group A and B.
34960798	0	127	theme	Polish	61:66	arg1	Flocks					74:79	Polish Mixed Flocks	61:79	Polish Mixed Flocks	61:79	Molecular Characterization of Small Ruminant Lentiviruses in Polish Mixed Flocks Supports Evidence of Cross Species Transmission, Dual Infection, a Recombination Event, and Reveals the Existence of New Subtypes within Group A. Small ruminant lentiviruses (SRLVs) are a group of highly divergent viruses responsible for global infection in sheep and goats.
34960798	14	128	from	goats	2487:2491	arg1	flocks					2502:2507	mixed flocks	2496:2507	mixed flocks	2496:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	5	129	theme	subtype	988:994	arg1	A24					996:998	subtype A24	988:998	subtype A24	988:998	Subtypes A5 and A17 were only found in goats, subtype A24 has been detected only in sheep while subtypes A12, A23, and B2 have been found in both sheep and goats.
34960798	7	130	theme	env	1315:1317	arg1	sequences					1325:1333	gag and env SRLVs sequences	1307:1333	gag and env SRLVs sequences derived from three sheep	1307:1358	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	12	131	theme	R	2244:2244	arg1	region					2246:2251	the R region	2240:2251	the R region which was noted in other sequences from Poland	2240:2298	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34960798	8	132	from	mutations	1517:1525	arg1	sequences					1530:1538	sequences	1530:1538	sequences of subtypes A5 and A17	1530:1561	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	14	133	from	evidence	2449:2456	arg1	flocks					2502:2507	mixed flocks	2496:2507	mixed flocks	2496:2507	We present strong and multiple evidence of dually infected sheep and goats in mixed flocks and present evidence that these viruses can recombine in vivo.
34960798	8	134	theme	Major	1454:1458	arg1	Region					1469:1474	Major Homology Region	1454:1474	Major Homology Region (MHR)	1454:1480	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	8	134	theme	Major	1454:1458	arg1	MHR					1477:1479	MHR	1477:1479	MHR	1477:1479	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	7	135	theme	gag	1307:1309	arg1	sequences					1325:1333	gag and env SRLVs sequences	1307:1333	gag and env SRLVs sequences derived from three sheep	1307:1358	Furthermore, three putative recombination events were identified within gag and env SRLVs sequences derived from three sheep.
34960798	4	136	theme	first	930:934	arg1	time					936:939	the first time	926:939	the first time	926:939	Furthermore, the existence of a new subtypes, tentatively designed as A23 and A24, were described for the first time.
34960798	8	137	theme	epitopes	1405:1412	arg1	sequences					1377:1385	Amino acid (aa) sequences	1361:1385	Amino acid (aa) sequences of immunodominant epitopes in CA protein	1361:1426	Amino acid (aa) sequences of immunodominant epitopes in CA protein were well conserved while Major Homology Region (MHR) had more alteration showing unique mutations in sequences of subtypes A5 and A17.
34960798	12	138	theme	unique	2142:2147	arg1	T					2162:2162	unique substitution T	2142:2162	unique substitution T	2142:2162	Interestingly, our results revealed that all sequences belonging to subtype A17 had unique substitution T to A in the fifth position of TATA box and did not have a 11 nt deletion in the R region which was noted in other sequences from Poland.
34952005	7	0	theme	cholesteryl	1580:1590	arg1	hemisuccinate					1592:1604	the cholesterol analog cholesteryl hemisuccinate	1557:1604	the cholesterol analog cholesteryl hemisuccinate	1557:1604	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	6	1	theme	Sf9	1137:1139	arg1	membranes					1153:1161	Sf9 insect cell membranes	1137:1161	Sf9 insect cell membranes	1137:1161	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	1	2	theme	glycogenolysis	268:281	arg1	pathways					283:290	the gluconeogenesis and glycogenolysis pathways	244:290	the gluconeogenesis and glycogenolysis pathways	244:290	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	7	3	theme	cholesterol	1561:1571	arg1	hemisuccinate					1592:1604	the cholesterol analog cholesteryl hemisuccinate	1557:1604	the cholesterol analog cholesteryl hemisuccinate	1557:1604	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	8	4	link	N-linked	1651:1658	arg1	glycosylation					1660:1672	N-linked glycosylation	1651:1672	N-linked glycosylation	1651:1672	In contrast, the N96A variant, which blocks N-linked glycosylation, reduced thermostability.
34952005	1	5	theme	catalytic	115:123	arg1	subunit					125:131	Glucose-6-phosphatase catalytic subunit 1	93:133	Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	93:141	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	1	5	theme	catalytic	115:123	arg1	G6PC1					136:140	G6PC1	136:140	G6PC1	136:140	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	3	6	theme	phosphohydrolase	599:614	arg1	activity					616:623	phosphohydrolase activity	599:623	phosphohydrolase activity	599:623	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	4	7	theme	functional	888:897	arg1	form					899:902	a functional form	886:902	a functional form	886:902	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	6	8	theme	specific	1316:1323	arg1	activity					1325:1332	the highest specific activity	1304:1332	the highest specific activity reported to date	1304:1349	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	9	9	theme	necessary	1791:1799	arg1	groundwork					1801:1810	the necessary groundwork	1787:1810	the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1	1787:1881	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	3	10	theme	clinical	634:641	arg1	basis					643:647	the clinical basis	630:647	the clinical basis of glycogen storage disease type 1a	630:683	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	9	11	from	groundwork	1801:1810	arg1	disorders					1917:1925	complex metabolic disorders	1899:1925	complex metabolic disorders	1899:1925	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	2	12	from	glucose-6-phosphate	405:423	arg1	production					389:398	glucose production	381:398	glucose production from glucose-6-phosphate (G6P)	381:429	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	2	13	theme	transport	319:327	arg1	proteins					329:336	accessory transport proteins	309:336	accessory transport proteins	309:336	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	9	14	theme	detailed	1818:1825	arg1	analysis					1827:1834	a detailed analysis	1816:1834	a detailed analysis of the mechanistic structural biology of G6PC1	1816:1881	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	3	15	theme	storage	661:667	arg1	1a					682:683	glycogen storage disease type 1a	652:683	glycogen storage disease type 1a	652:683	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	1	16	theme	terminal	227:234	arg1	step					236:239	the terminal step	223:239	the terminal step of the gluconeogenesis and glycogenolysis pathways	223:290	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	7	17	theme	structural	1435:1444	arg1	stability					1446:1454	the catalytic and structural stability	1417:1454	the catalytic and structural stability of mG6PC1	1417:1464	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	4	18	theme	structure	761:769	arg1	view					747:750	a comprehensive view	731:750	a comprehensive view of G6PC1 structure and mechanism	731:783	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	5	19	theme	biophysical	941:951	arg1	tools					969:973	biophysical and biochemical tools	941:973	biophysical and biochemical tools	941:973	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	9	20	theme	mechanistic	1843:1853	arg1	biology					1866:1872	the mechanistic structural biology	1839:1872	the mechanistic structural biology of G6PC1	1839:1881	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	6	21	theme	intact	1264:1269	arg1	microsomes					1279:1288	intact hepatic microsomes	1264:1288	intact hepatic microsomes	1264:1288	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	7	22	theme	catalytic	1421:1429	arg1	stability					1446:1454	the catalytic and structural stability	1417:1454	the catalytic and structural stability of mG6PC1	1417:1464	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	4	23	theme	mechanism	775:783	arg1	view					747:750	a comprehensive view	731:750	a comprehensive view of G6PC1 structure and mechanism	731:783	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	7	24	theme	enhanced	1495:1502	arg1	thermostability					1504:1518	the enhanced thermostability	1491:1518	the enhanced thermostability conferred by phosphatidylcholine	1491:1551	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	5	25	theme	biochemical	957:967	arg1	tools					969:973	biophysical and biochemical tools	941:973	biophysical and biochemical tools	941:973	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	9	26	theme	biology	1866:1872	arg1	analysis					1827:1834	a detailed analysis	1816:1834	a detailed analysis of the mechanistic structural biology of G6PC1	1816:1881	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	4	27	theme	comprehensive	733:745	arg1	view					747:750	a comprehensive view	731:750	a comprehensive view of G6PC1 structure and mechanism	731:783	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	0	28	theme	subunit	82:88	arg1	properties					27:36	Biophysical and functional properties	0:36	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1	0:90	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1.
34952005	3	29	theme	type	677:680	arg1	1a					682:683	glycogen storage disease type 1a	652:683	glycogen storage disease type 1a	652:683	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	9	30	theme	G6PC1	1877:1881	arg1	biology					1866:1872	the mechanistic structural biology	1839:1872	the mechanistic structural biology of G6PC1	1839:1881	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	8	31	theme	N-linked	1651:1658	arg1	glycosylation					1660:1672	N-linked glycosylation	1651:1672	N-linked glycosylation	1651:1672	In contrast, the N96A variant, which blocks N-linked glycosylation, reduced thermostability.
34952005	1	32	theme	hepatic	168:174	arg1	production					184:193	hepatic glucose production	168:193	hepatic glucose production during fasting	168:208	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	4	33	theme	expression	820:829	arg1	strategies					848:857	expression and purification strategies	820:857	expression and purification strategies that isolate the enzyme in a functional form	820:902	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	1	34	theme	Glucose-6-phosphatase	93:113	arg1	subunit					125:131	Glucose-6-phosphatase catalytic subunit 1	93:133	Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	93:141	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	1	34	theme	Glucose-6-phosphatase	93:113	arg1	G6PC1					136:140	G6PC1	136:140	G6PC1	136:140	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	9	35	theme	metabolic	1907:1915	arg1	disorders					1917:1925	complex metabolic disorders	1899:1925	complex metabolic disorders	1899:1925	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	8	36	theme	N96A	1624:1627	arg1	variant					1629:1635	the N96A variant	1620:1635	the N96A variant	1620:1635	In contrast, the N96A variant, which blocks N-linked glycosylation, reduced thermostability.
34952005	0	37	theme	Biophysical	0:10	arg1	properties					27:36	Biophysical and functional properties	0:36	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1	0:90	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1.
34952005	0	38	theme	functional	16:25	arg1	properties					27:36	Biophysical and functional properties	0:36	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1	0:90	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1.
34952005	2	39	theme	glucose	448:454	arg1	homeostasis					456:466	blood glucose homeostasis	442:466	blood glucose homeostasis	442:466	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	5	40	theme	maltose	1066:1072	arg1	micelles					1108:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	3	41	theme	expression	537:546	arg1	dysregulation					509:521	dysregulation	509:521	dysregulation of G6PC1 gene expression	509:546	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	0	42	theme	glucose-6-phosphatase	50:70	arg1	subunit					82:88	purified glucose-6-phosphatase catalytic subunit 1	41:90	purified glucose-6-phosphatase catalytic subunit 1	41:90	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1.
34952005	5	43	theme	glycol	1084:1089	arg1	micelles					1108:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	4	44	theme	purification	835:846	arg1	strategies					848:857	expression and purification strategies	820:857	expression and purification strategies that isolate the enzyme in a functional form	820:902	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	3	45	theme	G6PC1	526:530	arg1	expression					537:546	G6PC1 gene expression	526:546	G6PC1 gene expression	526:546	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	5	46	theme	G6PC1	1038:1042	arg1	attributes					1003:1012	the in vitro attributes	990:1012	the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles	990:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	7	47	theme	analog	1573:1578	arg1	hemisuccinate					1592:1604	the cholesterol analog cholesteryl hemisuccinate	1557:1604	the cholesterol analog cholesteryl hemisuccinate	1557:1604	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	6	48	theme	insect	1141:1146	arg1	membranes					1153:1161	Sf9 insect cell membranes	1137:1161	Sf9 insect cell membranes	1137:1161	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	2	49	theme	accessory	309:317	arg1	proteins					329:336	accessory transport proteins	309:336	accessory transport proteins	309:336	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	1	50	theme	pathways	283:290	arg1	step					236:239	the terminal step	223:239	the terminal step of the gluconeogenesis and glycogenolysis pathways	223:290	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	6	51	theme	functional	1219:1228	arg1	properties					1230:1239	functional properties	1219:1239	functional properties observed previously in intact hepatic microsomes	1219:1288	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	2	52	theme	glucose	381:387	arg1	production					389:398	glucose production	381:398	glucose production from glucose-6-phosphate (G6P)	381:429	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	1	53	theme	glucose	176:182	arg1	production					184:193	hepatic glucose production	168:193	hepatic glucose production during fasting	168:208	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	6	54	theme	highest	1308:1314	arg1	activity					1325:1332	the highest specific activity	1304:1332	the highest specific activity reported to date	1304:1349	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	6	55	theme	mouse	1181:1185	arg1	mG6PC1					1197:1202	mG6PC1	1197:1202	mG6PC1	1197:1202	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	6	55	theme	mouse	1181:1185	arg1	ortholog					1187:1194	the glycosylated mouse ortholog	1164:1194	the glycosylated mouse ortholog (mG6PC1)	1164:1203	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	3	56	theme	glycogen	652:659	arg1	1a					682:683	glycogen storage disease type 1a	652:683	glycogen storage disease type 1a	652:683	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	7	57	theme	mG6PC1	1459:1464	arg1	stability					1446:1454	the catalytic and structural stability	1417:1454	the catalytic and structural stability of mG6PC1	1417:1464	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	3	58	with	Consistent	469:478	arg1	function					499:506	its metabolic function	485:506	its metabolic function	485:506	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	6	59	theme	hepatic	1271:1277	arg1	microsomes					1279:1288	intact hepatic microsomes	1264:1288	intact hepatic microsomes	1264:1288	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	4	60	theme	G6PC1	755:759	arg1	structure					761:769	G6PC1 structure	755:769	G6PC1 structure	755:769	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	5	61	theme	LMNG	1092:1095	arg1	micelles					1108:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	3	62	theme	1a	682:683	arg1	basis					643:647	the clinical basis	630:647	the clinical basis of glycogen storage disease type 1a	630:683	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	2	63	with	concert	296:302	arg1	proteins					329:336	accessory transport proteins	309:336	accessory transport proteins	309:336	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	9	64	theme	structural	1855:1864	arg1	biology					1866:1872	the mechanistic structural biology	1839:1872	the mechanistic structural biology of G6PC1	1839:1881	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	5	65	theme	detergent	1098:1106	arg1	micelles					1108:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	3	66	theme	disease	669:675	arg1	1a					682:683	glycogen storage disease type 1a	652:683	glycogen storage disease type 1a	652:683	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	1	67	theme	critical	151:158	arg1	role					160:163	a critical role	149:163	a critical role	149:163	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34952005	5	68	theme	in vitro	994:1001	arg1	attributes					1003:1012	the in vitro attributes	990:1012	the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles	990:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	2	69	theme	membrane-integrated	344:362	arg1	enzyme					364:369	this membrane-integrated enzyme	339:369	this membrane-integrated enzyme	339:369	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	9	70	from	obstacles	1756:1764	arg1	field					1773:1777	the field	1769:1777	the field	1769:1777	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	7	71	theme	direct	1390:1395	arg1	correlation					1397:1407	a direct correlation	1388:1407	a direct correlation	1388:1407	Additionally, our results establish a direct correlation between the catalytic and structural stability of mG6PC1, which is underscored by the enhanced thermostability conferred by phosphatidylcholine and the cholesterol analog cholesteryl hemisuccinate.
34952005	9	72	theme	complex	1899:1905	arg1	disorders					1917:1925	complex metabolic disorders	1899:1925	complex metabolic disorders	1899:1925	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	6	73	gly	glycosylated	1168:1179	arg1	mG6PC1					1197:1202	mG6PC1	1197:1202	mG6PC1	1197:1202	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	6	73	gly	glycosylated	1168:1179	arg1	ortholog					1187:1194	the glycosylated mouse ortholog	1164:1194	the glycosylated mouse ortholog (mG6PC1)	1164:1203	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	3	74	theme	metabolic	489:497	arg1	function					499:506	its metabolic function	485:506	its metabolic function	485:506	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	5	75	theme	tools	969:973	arg1	suite					932:936	a suite	930:936	a suite of biophysical and biochemical tools to fingerprint	930:988	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	6	76	located	observed	1241:1248	arg2	properties					1230:1239	functional properties	1219:1239	functional properties observed previously in intact hepatic microsomes	1219:1288	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	6	76	located	observed	1241:1248	arg1	microsomes					1279:1288	intact hepatic microsomes	1264:1288	intact hepatic microsomes	1264:1288	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	0	77	theme	purified	41:48	arg1	subunit					82:88	purified glucose-6-phosphatase catalytic subunit 1	41:90	purified glucose-6-phosphatase catalytic subunit 1	41:90	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1.
34952005	5	78	theme	lauryl	1059:1064	arg1	micelles					1108:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	2	79	theme	blood	442:446	arg1	homeostasis					456:466	blood glucose homeostasis	442:466	blood glucose homeostasis	442:466	In concert with accessory transport proteins, this membrane-integrated enzyme catalyzes glucose production from glucose-6-phosphate (G6P) to support blood glucose homeostasis.
34952005	0	80	theme	catalytic	72:80	arg1	subunit					82:88	purified glucose-6-phosphatase catalytic subunit 1	41:90	purified glucose-6-phosphatase catalytic subunit 1	41:90	Biophysical and functional properties of purified glucose-6-phosphatase catalytic subunit 1.
34952005	9	81	from	role	1891:1894	arg1	disorders					1917:1925	complex metabolic disorders	1899:1925	complex metabolic disorders	1899:1925	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	5	82	theme	neopentyl	1074:1082	arg1	micelles					1108:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	lauryl maltose neopentyl glycol (LMNG) detergent micelles	1059:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	6	83	theme	glycosylated	1168:1179	arg1	mG6PC1					1197:1202	mG6PC1	1197:1202	mG6PC1	1197:1202	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	6	83	theme	glycosylated	1168:1179	arg1	ortholog					1187:1194	the glycosylated mouse ortholog	1164:1194	the glycosylated mouse ortholog (mG6PC1)	1164:1203	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	5	84	theme	active	1031:1036	arg1	G6PC1					1038:1042	catalytically active G6PC1	1017:1042	catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles	1017:1115	In this report, we apply a suite of biophysical and biochemical tools to fingerprint the in vitro attributes of catalytically active G6PC1 solubilized in lauryl maltose neopentyl glycol (LMNG) detergent micelles.
34952005	3	85	theme	gene	532:535	arg1	expression					537:546	G6PC1 gene expression	526:546	G6PC1 gene expression	526:546	Consistent with its metabolic function, dysregulation of G6PC1 gene expression contributes to diabetes, and mutations that impair phosphohydrolase activity form the clinical basis of glycogen storage disease type 1a.
34952005	9	86	theme	long-standing	1742:1754	arg1	obstacles					1756:1764	long-standing obstacles	1742:1764	long-standing obstacles in the field	1742:1777	The methodologies described here overcome long-standing obstacles in the field and lay the necessary groundwork for a detailed analysis of the mechanistic structural biology of G6PC1 and its role in complex metabolic disorders.
34952005	6	87	theme	cell	1148:1151	arg1	membranes					1153:1161	Sf9 insect cell membranes	1137:1161	Sf9 insect cell membranes	1137:1161	When purified from Sf9 insect cell membranes, the glycosylated mouse ortholog (mG6PC1) recapitulated functional properties observed previously in intact hepatic microsomes and displayed the highest specific activity reported to date.
34952005	4	88	theme	strategies	848:857	arg1	absence					809:815	the absence	805:815	the absence of expression and purification strategies that isolate the enzyme in a functional form	805:902	Despite its relevance to health and disease, a comprehensive view of G6PC1 structure and mechanism has been limited by the absence of expression and purification strategies that isolate the enzyme in a functional form.
34952005	1	89	theme	gluconeogenesis	248:262	arg1	pathways					283:290	the gluconeogenesis and glycogenolysis pathways	244:290	the gluconeogenesis and glycogenolysis pathways	244:290	Glucose-6-phosphatase catalytic subunit 1 (G6PC1) plays a critical role in hepatic glucose production during fasting by mediating the terminal step of the gluconeogenesis and glycogenolysis pathways.
34778211	11	0	from	decrease	1770:1777	arg1	content					1795:1801	fucosylation content	1782:1801	fucosylation content	1782:1801	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	6	1	theme	CHO	1067:1069	arg1	cells					1071:1075	wild-type (WT) CHO cells	1052:1075	wild-type (WT) CHO cells	1052:1075	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	2	2	theme	antibody	320:327	arg1	region					332:337	antibody Fc region	320:337	antibody Fc region	320:337	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	7	3	theme	mass	1244:1247	arg1	LC-MS					1263:1267	LC-MS	1263:1267	LC-MS	1263:1267	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	7	3	theme	mass	1244:1247	arg1	spectrometry					1249:1260	high-resolution liquid chromatography mass spectrometry	1206:1260	high-resolution liquid chromatography mass spectrometry (LC-MS)	1206:1268	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	1	4	theme	α-1,6	251:255	arg1	linkage					257:263	an α-1,6 linkage	248:263	an α-1,6 linkage in the mammalian cells	248:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	12	5	theme	enzymes	1968:1974	arg1	Meantime					1922:1929	Meantime	1922:1929	Meantime	1922:1929	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	12	5	theme	enzymes	1968:1974	arg1	total					1934:1938	a total	1932:1938	a total of 51 glycosylation-related enzymes	1932:1974	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	11	6	theme	core-fucosylated	1842:1857	arg1	glycans					1859:1865	core-fucosylated glycans	1842:1865	core-fucosylated glycans	1842:1865	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	12	7	theme	FUT8KO	2070:2075	arg1	cells					2077:2081	the FUT8KO cells	2066:2081	the FUT8KO cells	2066:2081	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	3	8	theme	production	505:514	arg1	platform					516:523	the predominant production platform	489:523	the predominant production platform in biopharmaceutical manufacturing	489:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	3	8	theme	production	505:514	arg1	cells					479:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	1	9	theme	key	162:164	arg1	α1,6-fucosyltransferase					108:130	The α1,6-fucosyltransferase	104:130	The α1,6-fucosyltransferase (encoded by FUT8 gene)	104:153	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	1	9	theme	key	162:164	arg1	fucose					186:191	the key enzyme transferring fucose	158:191	the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells	158:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	10	10	theme	CHO	1744:1746	arg1	cells					1748:1752	wild-type CHO cells	1734:1752	wild-type CHO cells	1734:1752	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	1	11	theme	transferring	173:184	arg1	α1,6-fucosyltransferase					108:130	The α1,6-fucosyltransferase	104:130	The α1,6-fucosyltransferase (encoded by FUT8 gene)	104:153	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	1	11	theme	transferring	173:184	arg1	fucose					186:191	the key enzyme transferring fucose	158:191	the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells	158:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	6	12	theme	FUT8	948:951	arg1	line					972:975	a FUT8 knock-out CHO cell line	946:975	a FUT8 knock-out CHO cell line	946:975	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	4	13	theme	CHO	614:616	arg1	line					623:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	4	14	gly	non-fucosylated	682:696	arg1	antibodies					698:707	completely non-fucosylated antibodies	671:707	completely non-fucosylated antibodies	671:707	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	4	15	theme	line	623:626	arg1	generation					576:585	the generation	572:585	the generation of FUT8 knock-out (FUT8KO) CHO cell line	572:626	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	4	15	theme	line	623:626	arg1	favorable					631:639	favorable	631:639	favorable	631:639	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	11	16	theme	fucosylation	1782:1793	arg1	content					1795:1801	fucosylation content	1782:1801	fucosylation content	1782:1801	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	5	17	theme	regulation	849:858	arg1	rules					860:864	regulation rules	849:864	regulation rules	849:864	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	0	18	from	Roles	68:72	arg1	Glycosylation					89:101	the Glycosylation	85:101	the Glycosylation	85:101	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	4	19	theme	non-fucosylated	682:696	arg1	antibodies					698:707	completely non-fucosylated antibodies	671:707	completely non-fucosylated antibodies	671:707	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	11	20	theme	gene	1907:1910	arg1	effect					1892:1897	an effect	1889:1897	an effect of FUT8 gene knockout	1889:1919	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	6	21	theme	CHO	922:924	arg1	cells					926:930	CHO cells	922:930	CHO cells	922:930	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	7	22	theme	hydrophilic	1113:1123	arg1	chromatography					1125:1138	hydrophilic chromatography	1113:1138	hydrophilic chromatography	1113:1138	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	8	23	theme	N-linked	1295:1302	arg1	IGPs					1347:1350	IGPs	1347:1350	IGPs	1347:1350	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	8	23	theme	N-linked	1295:1302	arg1	glycopeptides					1332:1344	7,127 unique N-linked glycosite-containing intact glycopeptides	1282:1344	7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs)	1282:1351	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	1	24	from	residue	217:223	arg1	N-glycan					231:238	an N-glycan	228:238	an N-glycan through an α-1,6 linkage in the mammalian cells	228:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	6	25	theme	large-scale	993:1003	arg1	glycoproteomics					1005:1019	a large-scale glycoproteomics	991:1019	a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells	991:1075	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	8	26	theme	intact	1325:1330	arg1	IGPs					1347:1350	IGPs	1347:1350	IGPs	1347:1350	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	8	26	theme	intact	1325:1330	arg1	glycopeptides					1332:1344	7,127 unique N-linked glycosite-containing intact glycopeptides	1282:1344	7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs)	1282:1351	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	7	27	theme	chromatography	1229:1242	arg1	LC-MS					1263:1267	LC-MS	1263:1267	LC-MS	1263:1267	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	7	27	theme	chromatography	1229:1242	arg1	spectrometry					1249:1260	high-resolution liquid chromatography mass spectrometry	1206:1260	high-resolution liquid chromatography mass spectrometry (LC-MS)	1206:1268	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	13	28	theme	FUT8	2221:2224	arg1	knock-out					2208:2216	the knock-out	2204:2216	the knock-out of FUT8	2204:2224	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	0	29	theme	FUT8	77:80	arg1	Roles					68:72	Roles	68:72	Roles of FUT8 in the Glycosylation	68:101	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	9	30	theme	identified	1505:1514	arg1	glycosites					1516:1525	928 identified glycosites	1501:1525	928 identified glycosites	1501:1525	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	2	31	from	presence	293:300	arg1	region					332:337	antibody Fc region	320:337	antibody Fc region	320:337	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	13	32	gly	core-fucosylation	2250:2266	arg1	proteins					2271:2278	proteins	2271:2278	proteins	2271:2278	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	6	33	theme	CHO	963:965	arg1	line					972:975	a FUT8 knock-out CHO cell line	946:975	a FUT8 knock-out CHO cell line	946:975	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	10	34	theme	types	1654:1658	arg1	abundance					1618:1626	The relative abundance	1605:1626	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex)	1605:1694	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	5	35	theme	monoclonal	734:743	arg1	antibodies					745:754	monoclonal antibodies	734:754	monoclonal antibodies as well as host cell glycoprotein impurities	734:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	8	36	gly	glycopeptides	1332:1344	arg2	IGPs					1347:1350	IGPs	1347:1350	IGPs	1347:1350	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	8	36	gly	glycopeptides	1332:1344	arg2	glycopeptides					1332:1344	7,127 unique N-linked glycosite-containing intact glycopeptides	1282:1344	7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs)	1282:1351	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	0	37	theme	CHO	50:52	arg1	Cells					54:58	FUT8 Knock-Out CHO Cells	35:58	FUT8 Knock-Out CHO Cells	35:58	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	11	38	gly	core-fucosylated	1842:1857	arg1	glycans					1859:1865	core-fucosylated glycans	1842:1865	core-fucosylated glycans	1842:1865	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	11	39	located	observed	1807:1814	arg2	decrease					1770:1777	a decrease	1768:1777	a decrease in fucosylation content	1768:1801	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	11	39	located	observed	1807:1814	arg1	cells					1826:1830	FUT8KO cells	1819:1830	FUT8KO cells	1819:1830	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	5	40	theme	antibodies	745:754	arg1	characterization					714:729	The characterization	710:729	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities	710:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	6	41	dep	wild-type	1052:1060	arg1	WT					1063:1064	WT	1063:1064	WT	1063:1064	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	2	42	theme	antibody-dependent	351:368	arg1	ADCC					393:396	ADCC	393:396	ADCC	393:396	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	2	42	theme	antibody-dependent	351:368	arg1	cytotoxicity					379:390	antibody-dependent cellular cytotoxicity	351:390	antibody-dependent cellular cytotoxicity (ADCC)	351:397	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	0	43	theme	Glycoproteomic	0:13	arg1	Characterization					15:30	Glycoproteomic Characterization	0:30	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells	0:58	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	2	44	theme	antibody	410:417	arg1	efficiency					431:440	antibody therapeutic efficiency	410:440	antibody therapeutic efficiency	410:440	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	9	45	gly	glycosites	1516:1525	arg2	glycosites					1516:1525	928 identified glycosites	1501:1525	928 identified glycosites	1501:1525	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	5	46	theme	quality	818:824	arg1	purposes					834:841	quality control purposes	818:841	quality control purposes under regulation rules	818:864	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	10	47	theme	N-glycan	1645:1652	arg1	hybrid					1675:1680	hybrid	1675:1680	hybrid	1675:1680	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	10	47	theme	N-glycan	1645:1652	arg1	complex					1687:1693	complex	1687:1693	complex	1687:1693	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	10	47	theme	N-glycan	1645:1652	arg1	high-mannose					1661:1672	high-mannose	1661:1672	high-mannose	1661:1672	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	10	47	theme	N-glycan	1645:1652	arg1	types					1654:1658	all the three N-glycan types	1631:1658	all the three N-glycan types (high-mannose, hybrid, and complex)	1631:1694	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	0	48	theme	Knock-Out	40:48	arg1	Cells					54:58	FUT8 Knock-Out CHO Cells	35:58	FUT8 Knock-Out CHO Cells	35:58	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	8	49	gly	glycosites	1358:1367	arg2	glycosites					1358:1367	928 glycosites	1354:1367	928 glycosites	1354:1367	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	5	50	theme	cell	772:775	arg1	impurities					790:799	host cell glycoprotein impurities	767:799	monoclonal antibodies as well as host cell glycoprotein impurities	734:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	12	51	theme	glycosylation-related	1946:1966	arg1	enzymes					1968:1974	51 glycosylation-related enzymes	1943:1974	51 glycosylation-related enzymes	1943:1974	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	5	52	theme	impurities	790:799	arg1	characterization					714:729	The characterization	710:729	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities	710:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	13	53	theme	glycoproteomic	2167:2180	arg1	results					2182:2188	These glycoproteomic results	2161:2188	These glycoproteomic results	2161:2188	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	9	54	theme	CHO	1594:1596	arg1	cells					1598:1602	wild-type CHO cells	1584:1602	wild-type CHO cells	1584:1602	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	2	55	theme	core	305:308	arg1	fucose					310:315	core fucose	305:315	core fucose	305:315	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	8	56	gly	glycoproteins	1378:1390	arg1	glycoproteins					1378:1390	442 glycoproteins	1374:1390	442 glycoproteins	1374:1390	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	4	57	theme	FUT8	590:593	arg1	line					623:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	8	58	theme	CHO	1427:1429	arg1	cells					1431:1435	WT CHO cells	1424:1435	WT CHO cells	1424:1435	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	13	59	theme	glycosylation	2303:2315	arg1	processes					2327:2335	other glycosylation synthesis processes	2297:2335	other glycosylation synthesis processes	2297:2335	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	8	60	link	N-linked	1295:1302	arg1	IGPs					1347:1350	IGPs	1347:1350	IGPs	1347:1350	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	8	60	link	N-linked	1295:1302	arg1	glycopeptides					1332:1344	7,127 unique N-linked glycosite-containing intact glycopeptides	1282:1344	7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs)	1282:1351	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	13	61	theme	relative	2353:2360	arg1	abundance					2362:2370	the relative abundance	2349:2370	the relative abundance of protein glycosylation	2349:2395	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	2	62	theme	Fc	329:330	arg1	region					332:337	antibody Fc region	320:337	antibody Fc region	320:337	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	6	63	from	role	885:888	arg1	glycosylation					905:917	the glycosylation	901:917	the glycosylation of CHO cells	901:930	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	13	64	theme	protein	2375:2381	arg1	glycosylation					2383:2395	protein glycosylation	2375:2395	protein glycosylation	2375:2395	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	6	65	theme	FUT8	893:896	arg1	role					885:888	the role	881:888	the role of FUT8 in the glycosylation of CHO cells	881:930	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	9	66	from	%	1496:1496	arg1	glycosites					1516:1525	928 identified glycosites	1501:1525	928 identified glycosites	1501:1525	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	9	66	from	%	1496:1496	arg1	glycoproteins					1473:1485	442 identified glycoproteins	1458:1485	442 identified glycoproteins	1458:1485	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	3	67	theme	predominant	493:503	arg1	platform					516:523	the predominant production platform	489:523	the predominant production platform in biopharmaceutical manufacturing	489:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	3	67	theme	predominant	493:503	arg1	cells					479:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	13	68	theme	synthesis	2317:2325	arg1	processes					2327:2335	other glycosylation synthesis processes	2297:2335	other glycosylation synthesis processes	2297:2335	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	13	69	theme	other	2297:2301	arg1	processes					2327:2335	other glycosylation synthesis processes	2297:2335	other glycosylation synthesis processes	2297:2335	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	0	70	theme	Cells	54:58	arg1	Characterization					15:30	Glycoproteomic Characterization	0:30	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells	0:58	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	7	71	theme	high-resolution	1206:1220	arg1	LC-MS					1263:1267	LC-MS	1263:1267	LC-MS	1263:1267	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	7	71	theme	high-resolution	1206:1220	arg1	spectrometry					1249:1260	high-resolution liquid chromatography mass spectrometry	1206:1260	high-resolution liquid chromatography mass spectrometry (LC-MS)	1206:1268	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	1	72	from	linkage	257:263	arg1	cells					282:286	the mammalian cells	268:286	the mammalian cells	268:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	1	73	theme	enzyme	166:171	arg1	α1,6-fucosyltransferase					108:130	The α1,6-fucosyltransferase	104:130	The α1,6-fucosyltransferase (encoded by FUT8 gene)	104:153	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	1	73	theme	enzyme	166:171	arg1	fucose					186:191	the key enzyme transferring fucose	158:191	the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells	158:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	6	74	theme	knock-out	953:961	arg1	line					972:975	a FUT8 knock-out CHO cell line	946:975	a FUT8 knock-out CHO cell line	946:975	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	13	75	theme	glycosylation	2383:2395	arg1	abundance					2362:2370	the relative abundance	2349:2370	the relative abundance of protein glycosylation	2349:2395	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	3	76	theme	biopharmaceutical	528:544	arg1	manufacturing					546:558	biopharmaceutical manufacturing	528:558	biopharmaceutical manufacturing	528:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	5	77	theme	control	826:832	arg1	purposes					834:841	quality control purposes	818:841	quality control purposes under regulation rules	818:864	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	12	78	theme	cell	2010:2013	arg1	types					2015:2019	these two cell types	2000:2019	these two cell types	2000:2019	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	10	79	theme	relative	1609:1616	arg1	abundance					1618:1626	The relative abundance	1605:1626	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex)	1605:1694	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	2	80	theme	fucose	310:315	arg1	presence					293:300	The presence	289:300	The presence of core fucose on antibody Fc region	289:337	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	11	81	theme	knockout	1912:1919	arg1	gene					1907:1910	FUT8 gene knockout	1902:1919	FUT8 gene knockout	1902:1919	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	4	82	theme	cell	618:621	arg1	line					623:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	2	83	attach	presence	293:300	arg1	region					332:337	antibody Fc region	320:337	antibody Fc region	320:337	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	2	83	attach	presence	293:300	arg2	fucose					310:315	core fucose	305:315	core fucose	305:315	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	11	84	theme	FUT8	1902:1905	arg1	gene					1907:1910	FUT8 gene knockout	1902:1919	FUT8 gene knockout	1902:1919	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	9	85	theme	identified	1462:1471	arg1	glycoproteins					1473:1485	442 identified glycoproteins	1458:1485	442 identified glycoproteins	1458:1485	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	6	86	theme	cells	926:930	arg1	glycosylation					905:917	the glycosylation	901:917	the glycosylation of CHO cells	901:930	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	10	87	theme	wild-type	1734:1742	arg1	cells					1748:1752	wild-type CHO cells	1734:1752	wild-type CHO cells	1734:1752	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	8	88	theme	unique	1288:1293	arg1	IGPs					1347:1350	IGPs	1347:1350	IGPs	1347:1350	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	8	88	theme	unique	1288:1293	arg1	glycopeptides					1332:1344	7,127 unique N-linked glycosite-containing intact glycopeptides	1282:1344	7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs)	1282:1351	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	3	89	theme	hamster	459:465	arg1	platform					516:523	the predominant production platform	489:523	the predominant production platform in biopharmaceutical manufacturing	489:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	3	89	theme	hamster	459:465	arg1	cells					479:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	7	90	theme	liquid	1222:1227	arg1	LC-MS					1263:1267	LC-MS	1263:1267	LC-MS	1263:1267	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	7	90	theme	liquid	1222:1227	arg1	spectrometry					1249:1260	high-resolution liquid chromatography mass spectrometry	1206:1260	high-resolution liquid chromatography mass spectrometry (LC-MS)	1206:1268	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	13	91	theme	proteins	2271:2278	arg1	core-fucosylation					2250:2266	the core-fucosylation	2246:2266	the core-fucosylation of proteins	2246:2278	These glycoproteomic results revealed that the knock-out of FUT8 not only influenced the core-fucosylation of proteins but also altered other glycosylation synthesis processes and changed the relative abundance of protein glycosylation.
34778211	1	92	theme	FUT8	144:147	arg1	gene					149:152	FUT8 gene	144:152	FUT8 gene	144:152	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	9	93	gly	glycoproteins	1473:1485	arg1	glycoproteins					1473:1485	442 identified glycoproteins	1458:1485	442 identified glycoproteins	1458:1485	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	1	94	theme	GlcNAc	210:215	arg1	residue					217:223	the innermost GlcNAc residue	196:223	the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells	196:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	6	95	gly	glycosylation	905:917	arg1	cells					926:930	CHO cells	922:930	CHO cells	922:930	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	8	96	theme	glycopeptides	1332:1344	arg1	total					1273:1277	A total	1271:1277	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins	1271:1390	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	3	97	from	platform	516:523	arg1	manufacturing					546:558	biopharmaceutical manufacturing	528:558	biopharmaceutical manufacturing	528:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	6	98	theme	cell	967:970	arg1	line					972:975	a FUT8 knock-out CHO cell line	946:975	a FUT8 knock-out CHO cell line	946:975	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	2	99	theme	cellular	370:377	arg1	ADCC					393:396	ADCC	393:396	ADCC	393:396	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	2	99	theme	cellular	370:377	arg1	cytotoxicity					379:390	antibody-dependent cellular cytotoxicity	351:390	antibody-dependent cellular cytotoxicity (ADCC)	351:397	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	6	100	theme	wild-type	1052:1060	arg1	cells					1071:1075	wild-type (WT) CHO cells	1052:1075	wild-type (WT) CHO cells	1052:1075	To understand the role of FUT8 in the glycosylation of CHO cells, we generated a FUT8 knock-out CHO cell line and performed a large-scale glycoproteomics to characterize the FUT8KO and wild-type (WT) CHO cells.
34778211	2	101	theme	therapeutic	419:429	arg1	efficiency					431:440	antibody therapeutic efficiency	410:440	antibody therapeutic efficiency	410:440	The presence of core fucose on antibody Fc region can inhibit antibody-dependent cellular cytotoxicity (ADCC) and reduce antibody therapeutic efficiency in vivo.
34778211	8	102	theme	glycosites	1358:1367	arg1	total					1273:1277	A total	1271:1277	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins	1271:1390	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	0	103	theme	FUT8	35:38	arg1	Cells					54:58	FUT8 Knock-Out CHO Cells	35:58	FUT8 Knock-Out CHO Cells	35:58	Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation.
34778211	9	104	theme	FUT8KO	1561:1566	arg1	CHO					1568:1570	the FUT8KO CHO	1557:1570	the FUT8KO CHO	1557:1570	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	3	105	theme	Chinese	451:457	arg1	platform					516:523	the predominant production platform	489:523	the predominant production platform in biopharmaceutical manufacturing	489:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	3	105	theme	Chinese	451:457	arg1	cells					479:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	5	106	theme	host	767:770	arg1	impurities					790:799	host cell glycoprotein impurities	767:799	monoclonal antibodies as well as host cell glycoprotein impurities	734:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	1	107	theme	mammalian	272:280	arg1	cells					282:286	the mammalian cells	268:286	the mammalian cells	268:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	7	108	gly	glycopeptides	1082:1094	arg2	glycopeptides					1082:1094	The glycopeptides	1078:1094	The glycopeptides	1078:1094	The glycopeptides were enriched by hydrophilic chromatography and fractionated 25 fractions by bRPLC followed by analysis using high-resolution liquid chromatography mass spectrometry (LC-MS).
34778211	11	109	theme	FUT8KO	1819:1824	arg1	cells					1826:1830	FUT8KO cells	1819:1830	FUT8KO cells	1819:1830	Furthermore, a decrease in fucosylation content was observed in FUT8KO cells, in which core-fucosylated glycans almost disappeared as an effect of FUT8 gene knockout.
34778211	8	110	theme	glycoproteins	1378:1390	arg1	total					1273:1277	A total	1271:1277	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins	1271:1390	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	5	111	theme	glycoprotein	777:788	arg1	impurities					790:799	host cell glycoprotein impurities	767:799	monoclonal antibodies as well as host cell glycoprotein impurities	734:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	9	112	theme	wild-type	1584:1592	arg1	cells					1598:1602	wild-type CHO cells	1584:1602	wild-type CHO cells	1584:1602	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	10	113	dep	types	1654:1658	arg1	hybrid					1675:1680	hybrid	1675:1680	hybrid	1675:1680	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	10	113	dep	types	1654:1658	arg1	complex					1687:1693	complex	1687:1693	complex	1687:1693	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	10	113	dep	types	1654:1658	arg1	high-mannose					1661:1672	high-mannose	1661:1672	high-mannose	1661:1672	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	10	113	dep	types	1654:1658	arg1	types					1654:1658	all the three N-glycan types	1631:1658	all the three N-glycan types (high-mannose, hybrid, and complex)	1631:1694	The relative abundance of all the three N-glycan types (high-mannose, hybrid, and complex) was determined in FUT8KO comparing to wild-type CHO cells.
34778211	3	114	theme	CHO	474:476	arg1	platform					516:523	the predominant production platform	489:523	the predominant production platform in biopharmaceutical manufacturing	489:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	3	114	theme	CHO	474:476	arg1	cells					479:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	5	115	gly	glycoprotein	777:788	arg1	glycoprotein					777:788	host cell glycoprotein impurities	767:799	monoclonal antibodies as well as host cell glycoprotein impurities	734:799	The characterization of monoclonal antibodies as well as host cell glycoprotein impurities are required for quality control purposes under regulation rules.
34778211	8	116	dep	N-linked	1295:1302	arg1	glycosite-containing					1304:1323	glycosite-containing	1304:1323	glycosite-containing	1304:1323	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
34778211	9	117	from	%	1453:1453	arg1	glycosites					1516:1525	928 identified glycosites	1501:1525	928 identified glycosites	1501:1525	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	9	117	from	%	1453:1453	arg1	glycoproteins					1473:1485	442 identified glycoproteins	1458:1485	442 identified glycoproteins	1458:1485	Moreover, 28.62% in 442 identified glycoproteins and 26.69% in 928 identified glycosites were significantly changed in the FUT8KO CHO compared to wild-type CHO cells.
34778211	4	118	theme	knock-out	595:603	arg1	line					623:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	3	119	theme	ovary	467:471	arg1	platform					516:523	the predominant production platform	489:523	the predominant production platform in biopharmaceutical manufacturing	489:558	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	3	119	theme	ovary	467:471	arg1	cells					479:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells	451:483	Chinese hamster ovary (CHO) cells are the predominant production platform in biopharmaceutical manufacturing.
34778211	1	120	theme	innermost	200:208	arg1	residue					217:223	the innermost GlcNAc residue	196:223	the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells	196:286	The α1,6-fucosyltransferase (encoded by FUT8 gene) is the key enzyme transferring fucose to the innermost GlcNAc residue on an N-glycan through an α-1,6 linkage in the mammalian cells.
34778211	4	121	theme	FUT8KO	606:611	arg1	line					623:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	FUT8 knock-out (FUT8KO) CHO cell line	590:626	Therefore, the generation of FUT8 knock-out (FUT8KO) CHO cell line is favorable and can be applied to produce completely non-fucosylated antibodies.
34778211	12	122	theme	them	2031:2034	arg1	16					2025:2026	16	2025:2026	16	2025:2026	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	12	122	theme	them	2031:2034	arg1	them					2031:2034	them	2031:2034	them	2031:2034	Meantime, a total of 51 glycosylation-related enzymes were also quantified in these two cell types and 16 of them were significantly altered in the FUT8KO cells, in which sialyltransferases and glucosyltransferases were sharply decreased.
34778211	8	123	theme	WT	1424:1425	arg1	cells					1431:1435	WT CHO cells	1424:1435	WT CHO cells	1424:1435	A total of 7,127 unique N-linked glycosite-containing intact glycopeptides (IGPs), 928 glycosites, and 442 glycoproteins were identified from FUT8KO and WT CHO cells.
33552045	4	0	theme	cell	579:582	arg1	responses					584:592	T cell responses	577:592	T cell responses to glycosylated epitopes (glyco-epitopes)	577:634	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	7	1	theme	derived	1122:1128	arg1	peptides					1130:1137	HIV derived peptides	1118:1137	HIV derived peptides	1118:1137	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	2	2	theme	antigen	358:364	arg1	presentation					366:377	antigen presentation	358:377	antigen presentation	358:377	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	6	3	with	segments	938:945	arg1	epitopes					977:984	potentially glycosylable epitopes	952:984	potentially glycosylable epitopes	952:984	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	7	4	theme	cell	1098:1101	arg1	recognition					1103:1113	T cell recognition	1096:1113	T cell recognition of HIV derived peptides	1096:1137	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	10	5	theme	cell	1746:1749	arg1	immunity					1751:1758	host T cell immunity	1739:1758	host T cell immunity against viral infections	1739:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	1	6	theme	self	184:187	arg1	epitopes					209:216	self and non-self T cell epitopes	184:216	self and non-self T cell epitopes presented by HLA molecules	184:243	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	8	7	theme	T	1256:1256	arg1	cells					1258:1262	T cells	1256:1262	T cells from HIV infected individuals	1256:1292	Nonetheless, in some cases, addition of simple glycosylation moieties produced neo-epitopes that were recognized by T cells from HIV infected individuals.
33552045	4	8	from	infections	649:658	arg1	literature					667:676	the literature	663:676	the literature	663:676	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	1	9	theme	non-self	193:200	arg1	epitopes					209:216	self and non-self T cell epitopes	184:216	self and non-self T cell epitopes presented by HLA molecules	184:243	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	8	10	theme	glycosylation	1187:1199	arg1	moieties					1201:1208	simple glycosylation moieties	1180:1208	simple glycosylation moieties	1180:1208	Nonetheless, in some cases, addition of simple glycosylation moieties produced neo-epitopes that were recognized by T cells from HIV infected individuals.
33552045	7	11	dep	derived	1122:1128	arg1	HIV					1118:1120	HIV	1118:1120	HIV	1118:1120	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	2	12	theme	N-linked	290:297	arg1	glycosylation					299:311	N-linked glycosylation	290:311	N-linked glycosylation	290:311	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	1	13	theme	cell	204:207	arg1	epitopes					209:216	self and non-self T cell epitopes	184:216	self and non-self T cell epitopes presented by HLA molecules	184:243	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	6	14	theme	protein	930:936	arg1	segments					938:945	in silico viral protein segments	914:945	in silico viral protein segments with potentially glycosylable epitopes	914:984	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	8	15	theme	infected	1273:1280	arg1	individuals					1282:1292	HIV infected individuals	1269:1292	HIV infected individuals	1269:1292	Nonetheless, in some cases, addition of simple glycosylation moieties produced neo-epitopes that were recognized by T cells from HIV infected individuals.
33552045	10	16	theme	glycosylated	1629:1640	arg1	epitopes					1642:1649	glycosylated epitopes	1629:1649	glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections	1629:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	7	17	theme	added	1050:1054	arg1	moieties					1070:1077	Ex vivo synthetically added glycosylation moieties	1028:1077	Ex vivo synthetically added glycosylation moieties	1028:1077	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	5	18	theme	ex	834:835	arg1	studies					849:855	in silico and ex vivo immune studies	820:855	in silico and ex vivo immune studies	820:855	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	5	19	from	role	742:745	arg1	infection					797:805	HIV infection	793:805	HIV infection	793:805	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	9	20	theme	specific	1518:1525	arg1	immunity					1534:1541	glyco-epitope specific T cell immunity	1504:1541	glyco-epitope specific T cell immunity	1504:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	9	21	theme	cell	1529:1532	arg1	immunity					1534:1541	glyco-epitope specific T cell immunity	1504:1541	glyco-epitope specific T cell immunity	1504:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	5	22	theme	specific	764:771	arg1	responses					780:788	glyco-epitope specific T cell responses	750:788	glyco-epitope specific T cell responses	750:788	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	4	23	gly	glycosylated	597:608	arg1	epitopes					610:617	glycosylated epitopes	597:617	glycosylated epitopes (glyco-epitopes)	597:634	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	4	23	gly	glycosylated	597:608	arg1	glyco-epitopes					620:633	glyco-epitopes	620:633	glyco-epitopes	620:633	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	5	24	theme	HIV	885:887	arg1	infection					889:897	chronic HIV infection	877:897	chronic HIV infection	877:897	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	5	25	with	individuals	860:870	arg1	infection					889:897	chronic HIV infection	877:897	chronic HIV infection	877:897	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	6	26	theme	glycosylable	964:975	arg1	epitopes					977:984	potentially glycosylable epitopes	952:984	potentially glycosylable epitopes	952:984	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	10	27	gly	glycosylation	1695:1707	arg1	proteins					1718:1725	viral proteins	1712:1725	viral proteins	1712:1725	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	0	28	theme	HIV-Specific	38:49	arg1	Immunity					58:65	the HIV-Specific T Cell Immunity	34:65	the HIV-Specific T Cell Immunity	34:65	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
33552045	5	29	theme	responses	780:788	arg1	role					742:745	the role	738:745	the role of glyco-epitope specific T cell responses in HIV infection	738:805	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	0	30	theme	Glycosylation	13:25	arg1	Impact					27:32	Antigen Glycosylation Impact	5:32	Antigen Glycosylation Impact	5:32	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
33552045	10	31	theme	T	1744:1744	arg1	immunity					1751:1758	host T cell immunity	1739:1758	host T cell immunity against viral infections	1739:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	1	32	theme	post-translational	94:111	arg1	modifications					121:133	post-translational protein modifications	94:133	post-translational protein modifications	94:133	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	1	32	theme	post-translational	94:111	arg1	glycosylation					146:158	glycosylation	146:158	glycosylation	146:158	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	3	33	theme	viral	461:465	arg1	proteins					467:474	viral proteins	461:474	viral proteins	461:474	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	5	34	theme	cell	775:778	arg1	responses					780:788	glyco-epitope specific T cell responses	750:788	glyco-epitope specific T cell responses	750:788	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	10	35	theme	proteins	1718:1725	arg1	glycosylation					1695:1707	glycosylation	1695:1707	glycosylation of viral proteins	1695:1725	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	0	36	theme	T	51:51	arg1	Immunity					58:65	the HIV-Specific T Cell Immunity	34:65	the HIV-Specific T Cell Immunity	34:65	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
33552045	3	37	theme	epitopes	490:497	arg1	glycosylation					444:456	glycosylation	444:456	glycosylation of viral proteins and processed epitopes	444:497	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	4	38	theme	glycosylated	597:608	arg1	epitopes					610:617	glycosylated epitopes	597:617	glycosylated epitopes (glyco-epitopes)	597:634	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	4	38	theme	glycosylated	597:608	arg1	glyco-epitopes					620:633	glyco-epitopes	620:633	glyco-epitopes	620:633	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	7	39	link	derived	1122:1128	arg1	peptides					1130:1137	HIV derived peptides	1118:1137	HIV derived peptides	1118:1137	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	5	40	dep	in	820:821	arg1	silico					823:828	silico	823:828	silico	823:828	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	2	41	theme	T	383:383	arg1	recognition					390:400	T cell recognition	383:400	T cell recognition	383:400	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	5	42	theme	immune	842:847	arg1	studies					849:855	in silico and ex vivo immune studies	820:855	in silico and ex vivo immune studies	820:855	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	9	43	theme	technology	1401:1410	arg1	limitations					1373:1383	limitations	1373:1383	limitations of the employed technology	1373:1410	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	0	44	theme	Cell	53:56	arg1	Immunity					58:65	the HIV-Specific T Cell Immunity	34:65	the HIV-Specific T Cell Immunity	34:65	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
33552045	10	45	from	research	1597:1604	arg1	cells					1611:1615	T cells	1609:1615	T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections	1609:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	0	46	dep	Does	0:3	arg1	Immunity					58:65	the HIV-Specific T Cell Immunity	34:65	the HIV-Specific T Cell Immunity	34:65	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
33552045	3	47	theme	T	517:517	arg1	response					524:531	the T cell response	513:531	the T cell response to HIV	513:538	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	9	48	theme	new	1417:1419	arg1	methodologies					1421:1433	new methodologies	1417:1433	new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity	1417:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	5	49	dep	conducted	810:818	arg1	explore					730:736	explore	730:736	To explore the role of glyco-epitope specific T cell responses in HIV infection	727:805	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	4	50	theme	T	577:577	arg1	responses					584:592	T cell responses	577:592	T cell responses to glycosylated epitopes (glyco-epitopes)	577:634	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	10	51	theme	viral	1768:1772	arg1	infections					1774:1783	viral infections	1768:1783	viral infections	1768:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	9	52	theme	immunity	1534:1541	arg1	assessment					1490:1499	a more accurate assessment	1474:1499	a more accurate assessment of glyco-epitope specific T cell immunity	1474:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	7	53	dep	Ex	1028:1029	arg1	vivo					1031:1034	vivo	1031:1034	vivo	1031:1034	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	7	54	theme	T	1096:1096	arg1	recognition					1103:1113	T cell recognition	1096:1113	T cell recognition of HIV derived peptides	1096:1137	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	10	55	theme	T	1609:1609	arg1	cells					1611:1615	T cells	1609:1615	T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections	1609:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	7	56	theme	glycosylation	1056:1068	arg1	moieties					1070:1077	Ex vivo synthetically added glycosylation moieties	1028:1077	Ex vivo synthetically added glycosylation moieties	1028:1077	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	1	57	theme	T	202:202	arg1	epitopes					209:216	self and non-self T cell epitopes	184:216	self and non-self T cell epitopes presented by HLA molecules	184:243	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	8	58	theme	simple	1180:1185	arg1	moieties					1201:1208	simple glycosylation moieties	1180:1208	simple glycosylation moieties	1180:1208	Nonetheless, in some cases, addition of simple glycosylation moieties produced neo-epitopes that were recognized by T cells from HIV infected individuals.
33552045	6	59	dep	in	914:915	arg1	silico					917:922	silico	917:922	silico	917:922	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	1	60	theme	epitopes	209:216	arg1	recognition					169:179	recognition	169:179	recognition of self and non-self T cell epitopes presented by HLA molecules	169:243	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	8	61	theme	moieties	1201:1208	arg1	addition					1168:1175	addition	1168:1175	addition of simple glycosylation moieties	1168:1208	Nonetheless, in some cases, addition of simple glycosylation moieties produced neo-epitopes that were recognized by T cells from HIV infected individuals.
33552045	6	62	theme	viral	924:928	arg1	segments					938:945	in silico viral protein segments	914:945	in silico viral protein segments with potentially glycosylable epitopes	914:984	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	4	63	theme	viral	643:647	arg1	infections					649:658	viral infections	643:658	viral infections in the literature	643:676	Although there is some evidence for T cell responses to glycosylated epitopes (glyco-epitopes) during viral infections in the literature, this aspect has been largely neglected for HIV.
33552045	2	64	link	N-linked	290:297	arg1	glycosylation					299:311	N-linked glycosylation	290:311	N-linked glycosylation	290:311	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	7	65	theme	Ex	1028:1029	arg1	moieties					1070:1077	Ex vivo synthetically added glycosylation moieties	1028:1077	Ex vivo synthetically added glycosylation moieties	1028:1077	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	1	66	theme	protein	113:119	arg1	modifications					121:133	post-translational protein modifications	94:133	post-translational protein modifications	94:133	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	1	66	theme	protein	113:119	arg1	glycosylation					146:158	glycosylation	146:158	glycosylation	146:158	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	10	67	theme	host	1739:1742	arg1	immunity					1751:1758	host T cell immunity	1739:1758	host T cell immunity against viral infections	1739:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	6	68	theme	in	914:915	arg1	segments					938:945	in silico viral protein segments	914:945	in silico viral protein segments with potentially glycosylable epitopes	914:984	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	9	69	theme	glyco-epitope	1504:1516	arg1	immunity					1534:1541	glyco-epitope specific T cell immunity	1504:1541	glyco-epitope specific T cell immunity	1504:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	6	70	theme	T	1019:1019	arg1	cells					1021:1025	T cells	1019:1025	T cells	1019:1025	We found that in silico viral protein segments with potentially glycosylable epitopes were less frequently targeted by T cells.
33552045	5	71	theme	in	820:821	arg1	studies					849:855	in silico and ex vivo immune studies	820:855	in silico and ex vivo immune studies	820:855	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	9	72	theme	T	1527:1527	arg1	immunity					1534:1541	glyco-epitope specific T cell immunity	1504:1541	glyco-epitope specific T cell immunity	1504:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	10	73	theme	future	1590:1595	arg1	research					1597:1604	future research	1590:1604	future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections	1590:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	5	74	theme	glyco-epitope	750:762	arg1	responses					780:788	glyco-epitope specific T cell responses	750:788	glyco-epitope specific T cell responses	750:788	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	5	75	theme	chronic	877:883	arg1	infection					889:897	chronic HIV infection	877:897	chronic HIV infection	877:897	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	10	76	gly	glycosylated	1629:1640	arg1	epitopes					1642:1649	glycosylated epitopes	1629:1649	glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections	1629:1783	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	3	77	gly	glycosylation	444:456	arg1	cell					519:522	the T cell response	513:531	the T cell response to HIV	513:538	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	3	77	gly	glycosylation	444:456	arg1	epitopes					490:497	processed epitopes	480:497	processed epitopes	480:497	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	3	77	gly	glycosylation	444:456	arg1	T					517:517	the T cell response	513:531	the T cell response to HIV	513:538	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	3	77	gly	glycosylation	444:456	arg1	proteins					467:474	viral proteins	461:474	viral proteins	461:474	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	9	78	contain	have	1444:1447	arg1	methodologies					1421:1433	new methodologies	1417:1433	new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity	1417:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	9	78	contain	have	1444:1447	arg2	potential					1453:1461	the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity	1449:1541	the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity	1449:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	8	79	from	individuals	1282:1292	arg1	cells					1258:1262	T cells	1256:1262	T cells from HIV infected individuals	1256:1292	Nonetheless, in some cases, addition of simple glycosylation moieties produced neo-epitopes that were recognized by T cells from HIV infected individuals.
33552045	1	80	theme	HLA	231:233	arg1	molecules					235:243	HLA molecules	231:243	HLA molecules	231:243	It is largely unknown how post-translational protein modifications, including glycosylation, impacts recognition of self and non-self T cell epitopes presented by HLA molecules.
33552045	0	81	theme	Antigen	5:11	arg1	Impact					27:32	Antigen Glycosylation Impact	5:32	Antigen Glycosylation Impact	5:32	Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
33552045	9	82	theme	potential	1318:1326	arg1	importance					1328:1337	the potential importance	1314:1337	the potential importance of these observations	1314:1359	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	2	83	theme	cell	385:388	arg1	recognition					390:400	T cell recognition	383:400	T cell recognition	383:400	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	2	84	from	Data	246:249	arg1	literature					258:267	the literature	254:267	the literature	254:267	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	3	85	theme	processed	480:488	arg1	epitopes					490:497	processed epitopes	480:497	processed epitopes	480:497	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	5	86	theme	T	773:773	arg1	responses					780:788	glyco-epitope specific T cell responses	750:788	glyco-epitope specific T cell responses	750:788	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	9	87	theme	observations	1348:1359	arg1	importance					1328:1337	the potential importance	1314:1337	the potential importance of these observations	1314:1359	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	3	88	theme	proteins	467:474	arg1	glycosylation					444:456	glycosylation	444:456	glycosylation of viral proteins and processed epitopes	444:497	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	7	89	theme	peptides	1130:1137	arg1	recognition					1103:1113	T cell recognition	1096:1113	T cell recognition of HIV derived peptides	1096:1137	Ex vivo synthetically added glycosylation moieties generally masked T cell recognition of HIV derived peptides.
33552045	3	90	theme	cell	519:522	arg1	response					524:531	the T cell response	513:531	the T cell response to HIV	513:538	In this perspective, we hypothesize that glycosylation of viral proteins and processed epitopes contribute to the T cell response to HIV.
33552045	10	91	theme	viral	1712:1716	arg1	proteins					1718:1725	viral proteins	1712:1725	viral proteins	1712:1725	Overall, this perspective is aimed to support future research on T cells recognizing glycosylated epitopes in order to expand our understanding on how glycosylation of viral proteins could alter host T cell immunity against viral infections.
33552045	5	92	dep	ex	834:835	arg1	vivo					837:840	vivo	837:840	vivo	837:840	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
33552045	2	93	theme	epitope	325:331	arg1	processing					333:342	epitope processing	325:342	epitope processing	325:342	Data in the literature indicate that O- and N-linked glycosylation can survive epitope processing and influence antigen presentation and T cell recognition.
33552045	9	94	theme	employed	1392:1399	arg1	technology					1401:1410	the employed technology	1388:1410	the employed technology	1388:1410	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	9	95	theme	accurate	1481:1488	arg1	assessment					1490:1499	a more accurate assessment	1474:1499	a more accurate assessment of glyco-epitope specific T cell immunity	1474:1541	Herein, we discuss the potential importance of these observations and compare limitations of the employed technology with new methodologies that may have the potential to provide a more accurate assessment of glyco-epitope specific T cell immunity.
33552045	5	96	theme	HIV	793:795	arg1	infection					797:805	HIV infection	793:805	HIV infection	793:805	To explore the role of glyco-epitope specific T cell responses in HIV infection we conducted in silico and ex vivo immune studies in individuals with chronic HIV infection.
32538734	15	0	from	O-GlcNAcylation	1976:1990	arg1	patients					2009:2016	HSCC patients	2004:2016	HSCC patients	2004:2016	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	1	1	theme	intracellular	305:317	arg1	signaling					319:327	intracellular signaling	305:327	intracellular signaling	305:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	2	2	from	migration	395:403	arg1	cancers					456:462	various cancers	448:462	various cancers	448:462	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	15	3	from	Nrf2	1996:1999	arg1	patients					2009:2016	HSCC patients	2004:2016	HSCC patients	2004:2016	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	13	4	theme	Nrf2	1686:1689	arg1	overexpression					1668:1681	overexpression	1668:1681	overexpression of Nrf2	1668:1689	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	6	5	theme	western	965:971	arg1	analysis					978:985	western blot analysis	965:985	western blot analysis	965:985	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	8	6	theme	Cell	1059:1062	arg1	proliferation					1064:1076	Cell proliferation	1059:1076	Cell proliferation	1059:1076	Cell proliferation was detected by CCK8, colony-forming analysis, and cell cycle assays.
32538734	6	7	theme	protein	854:860	arg1	levels					862:867	The protein levels	850:867	The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues	850:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	2	8	theme	Elevated	330:337	arg1	O-GlcNAcylation					339:353	Elevated O-GlcNAcylation	330:353	Elevated O-GlcNAcylation	330:353	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	1	9	theme	protein	217:223	arg1	modification					243:254	a significant protein posttranslational modification	203:254	a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	203:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	9	theme	protein	217:223	arg1	O-GlcNAcylation					184:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	2	10	from	transduction	432:443	arg1	cancers					456:462	various cancers	448:462	various cancers	448:462	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	5	11	from	O-GlcNAcylation	799:813	arg1	patients					832:839	HSCC patients	827:839	HSCC patients	827:839	Here, we provide a molecular rationale between O-GlcNAcylation and Nrf2 in HSCC patients.
32538734	2	12	theme	cell	370:373	arg1	proliferation					375:387	cell proliferation	370:387	cell proliferation	370:387	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	2	13	theme	various	448:454	arg1	cancers					456:462	various cancers	448:462	various cancers	448:462	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	6	14	from	Nrf2	892:895	arg1	tissues					905:911	HSCC tissues	900:911	HSCC tissues	900:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	5	15	theme	molecular	771:779	arg1	rationale					781:789	a molecular rationale	769:789	a molecular rationale between O-GlcNAcylation and Nrf2 in HSCC patients	769:839	Here, we provide a molecular rationale between O-GlcNAcylation and Nrf2 in HSCC patients.
32538734	1	16	theme	O-linked	261:268	arg1	GlcNAc					293:298	GlcNAc	293:298	GlcNAc	293:298	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	16	theme	O-linked	261:268	arg1	β-N-acetylglucosamine					270:290	O-linked β-N-acetylglucosamine	261:290	O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	261:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	13	17	dep	inhibited	1576:1584	arg1	whereas					1660:1666	whereas	1660:1666	whereas	1660:1666	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	15	18	dep	CONCLUSION	1916:1925	arg1	provide					1936:1942	provide	1936:1942	provide	1936:1942	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	13	19	theme	cell	1644:1647	arg1	apoptosis					1649:1657	cell apoptosis	1644:1657	cell apoptosis	1644:1657	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	5	20	from	Nrf2	819:822	arg1	patients					832:839	HSCC patients	827:839	HSCC patients	827:839	Here, we provide a molecular rationale between O-GlcNAcylation and Nrf2 in HSCC patients.
32538734	12	21	theme	protein	1411:1417	arg1	level					1419:1423	the protein level	1407:1423	the protein level of Nrf2	1407:1431	In addition, the protein level of Nrf2 was found to positively correlate with the expression of O-GlcNAcylation both in vivo and in vitro.
32538734	0	22	theme	Cell	82:85	arg1	Carcinoma					87:95	Hypopharyngeal Squamous Cell Carcinoma	58:95	Hypopharyngeal Squamous Cell Carcinoma	58:95	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	14	23	theme	O-GlcNAcylation	1751:1765	arg1	upregulation					1735:1746	the upregulation	1731:1746	the upregulation of O-GlcNAcylation	1731:1765	Mechanismly, the upregulation of O-GlcNAcylation promoted the phosphorylation of Akt, leading to the stabilization of Nrf2; this could be attenuated by inhibition of the PI3K/Akt signaling pathway.
32538734	2	24	from	proliferation	375:387	arg1	cancers					456:462	various cancers	448:462	various cancers	448:462	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	11	25	theme	tumor	1356:1360	arg1	size					1362:1365	tumor size	1356:1365	tumor size	1356:1365	RESULTS O-GlcNAcylation was obviously up-regulated in HSCC tissues, which correlated with tumor size and lymph node metastasis.
32538734	9	26	theme	Cell	1148:1151	arg1	migration					1153:1161	Cell migration	1148:1161	Cell migration	1148:1161	Cell migration and invasion ability was evaluated by transwell assays.
32538734	7	27	theme	HSCC	1020:1023	arg1	cells					1025:1029	O-GlcNAcylation knockdown HSCC cells	994:1029	O-GlcNAcylation knockdown HSCC cells	994:1029	Then, O-GlcNAcylation knockdown HSCC cells were applied in this study.
32538734	6	28	from	levels	862:867	arg1	tissues					905:911	HSCC tissues	900:911	HSCC tissues	900:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	11	29	theme	node	1377:1380	arg1	metastasis					1382:1391	lymph node metastasis	1371:1391	lymph node metastasis	1371:1391	RESULTS O-GlcNAcylation was obviously up-regulated in HSCC tissues, which correlated with tumor size and lymph node metastasis.
32538734	12	30	theme	O-GlcNAcylation	1490:1504	arg1	expression					1476:1485	the expression	1472:1485	the expression of O-GlcNAcylation	1472:1504	In addition, the protein level of Nrf2 was found to positively correlate with the expression of O-GlcNAcylation both in vivo and in vitro.
32538734	13	31	theme	cell	1591:1594	arg1	growth					1596:1601	HSCC cell growth	1586:1601	HSCC cell growth	1586:1601	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	0	32	theme	Elevated	0:7	arg1	O-GlcNAcylation					9:23	Elevated O-GlcNAcylation	0:23	Elevated O-GlcNAcylation	0:23	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	14	33	theme	pathway	1907:1913	arg1	inhibition					1870:1879	inhibition	1870:1879	inhibition of the PI3K/Akt signaling pathway	1870:1913	Mechanismly, the upregulation of O-GlcNAcylation promoted the phosphorylation of Akt, leading to the stabilization of Nrf2; this could be attenuated by inhibition of the PI3K/Akt signaling pathway.
32538734	8	34	theme	cycle	1134:1138	arg1	assays					1140:1145	cell cycle assays	1129:1145	cell cycle assays	1129:1145	Cell proliferation was detected by CCK8, colony-forming analysis, and cell cycle assays.
32538734	7	35	theme	O-GlcNAcylation	994:1008	arg1	cells					1025:1029	O-GlcNAcylation knockdown HSCC cells	994:1029	O-GlcNAcylation knockdown HSCC cells	994:1029	Then, O-GlcNAcylation knockdown HSCC cells were applied in this study.
32538734	6	36	from	O-GlcNAcylation	872:886	arg1	tissues					905:911	HSCC tissues	900:911	HSCC tissues	900:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	4	37	theme	erythroid-2-related	625:643	arg1	factor					645:650	Nuclear factor erythroid-2-related factor 2	610:652	Nuclear factor erythroid-2-related factor 2 (Nrf2)	610:659	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	37	theme	erythroid-2-related	625:643	arg1	Nrf2					655:658	Nrf2	655:658	Nrf2	655:658	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	37	theme	erythroid-2-related	625:643	arg1	factor					689:694	a master transcriptional factor	664:694	a master transcriptional factor that has been found to be aberrantly activated in HSCC	664:749	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	11	38	theme	HSCC	1320:1323	arg1	tissues					1325:1331	HSCC tissues	1320:1331	HSCC tissues	1320:1331	RESULTS O-GlcNAcylation was obviously up-regulated in HSCC tissues, which correlated with tumor size and lymph node metastasis.
32538734	3	39	theme	Hypopharyngeal	537:550	arg1	HSCC					577:580	HSCC	577:580	HSCC	577:580	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	39	theme	Hypopharyngeal	537:550	arg1	Carcinoma					566:574	Hypopharyngeal Squamous Cell Carcinoma	537:574	Hypopharyngeal Squamous Cell Carcinoma (HSCC)	537:581	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	14	40	theme	PI3K/Akt	1888:1895	arg1	pathway					1907:1913	the PI3K/Akt signaling pathway	1884:1913	the PI3K/Akt signaling pathway	1884:1913	Mechanismly, the upregulation of O-GlcNAcylation promoted the phosphorylation of Akt, leading to the stabilization of Nrf2; this could be attenuated by inhibition of the PI3K/Akt signaling pathway.
32538734	6	41	theme	immunohistochemistry	930:949	arg1	technique					951:959	immunohistochemistry technique	930:959	immunohistochemistry technique	930:959	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	3	42	theme	expression	478:487	arg1	level					489:493	expression level	478:493	expression level	478:493	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	43	theme	O-GlcNAcylation	518:532	arg1	role					510:513	functional role	499:513	functional role	499:513	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	43	theme	O-GlcNAcylation	518:532	arg1	level					489:493	expression level	478:493	expression level	478:493	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	13	44	theme	O-GlcNAcylation	1546:1560	arg1	Knockdown					1533:1541	Knockdown	1533:1541	Knockdown of O-GlcNAcylation	1533:1560	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	1	45	with	modification	243:254	arg1	GlcNAc					293:298	GlcNAc	293:298	GlcNAc	293:298	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	45	with	modification	243:254	arg1	β-N-acetylglucosamine					270:290	O-linked β-N-acetylglucosamine	261:290	O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	261:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	9	46	theme	transwell	1201:1209	arg1	assays					1211:1216	transwell assays	1201:1216	transwell assays	1201:1216	Cell migration and invasion ability was evaluated by transwell assays.
32538734	0	47	theme	Hypopharyngeal	58:71	arg1	Carcinoma					87:95	Hypopharyngeal Squamous Cell Carcinoma	58:95	Hypopharyngeal Squamous Cell Carcinoma	58:95	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	4	48	theme	Nuclear	610:616	arg1	factor					645:650	Nuclear factor erythroid-2-related factor 2	610:652	Nuclear factor erythroid-2-related factor 2 (Nrf2)	610:659	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	48	theme	Nuclear	610:616	arg1	Nrf2					655:658	Nrf2	655:658	Nrf2	655:658	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	48	theme	Nuclear	610:616	arg1	factor					689:694	a master transcriptional factor	664:694	a master transcriptional factor that has been found to be aberrantly activated in HSCC	664:749	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	3	49	theme	Cell	561:564	arg1	HSCC					577:580	HSCC	577:580	HSCC	577:580	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	49	theme	Cell	561:564	arg1	Carcinoma					566:574	Hypopharyngeal Squamous Cell Carcinoma	537:574	Hypopharyngeal Squamous Cell Carcinoma (HSCC)	537:581	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	4	50	theme	master	666:671	arg1	factor					645:650	Nuclear factor erythroid-2-related factor 2	610:652	Nuclear factor erythroid-2-related factor 2 (Nrf2)	610:659	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	50	theme	master	666:671	arg1	factor					689:694	a master transcriptional factor	664:694	a master transcriptional factor that has been found to be aberrantly activated in HSCC	664:749	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	10	51	theme	TUNEL	1250:1254	arg1	analysis					1256:1263	TUNEL analysis	1250:1263	TUNEL analysis	1250:1263	Cell apoptosis was measured by TUNEL analysis.
32538734	2	52	theme	signal	425:430	arg1	transduction					432:443	signal transduction	425:443	signal transduction	425:443	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	14	53	theme	Nrf2	1836:1839	arg1	stabilization					1819:1831	the stabilization	1815:1831	the stabilization of Nrf2	1815:1839	Mechanismly, the upregulation of O-GlcNAcylation promoted the phosphorylation of Akt, leading to the stabilization of Nrf2; this could be attenuated by inhibition of the PI3K/Akt signaling pathway.
32538734	6	54	theme	O-GlcNAcylation	872:886	arg1	levels					862:867	The protein levels	850:867	The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues	850:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	6	55	theme	blot	973:976	arg1	analysis					978:985	western blot analysis	965:985	western blot analysis	965:985	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	2	56	from	apoptosis	411:419	arg1	cancers					456:462	various cancers	448:462	various cancers	448:462	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	6	57	dep	METHODS	842:848	arg1	detected					918:925	detected	918:925	were detected by immunohistochemistry technique and western blot analysis	913:985	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	15	58	theme	HSCC	2004:2007	arg1	patients					2009:2016	HSCC patients	2004:2016	HSCC patients	2004:2016	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	2	59	theme	cell	390:393	arg1	migration					395:403	cell migration	390:403	cell migration	390:403	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	1	60	theme	significant	205:215	arg1	modification					243:254	a significant protein posttranslational modification	203:254	a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	203:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	60	theme	significant	205:215	arg1	O-GlcNAcylation					184:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	11	61	theme	lymph	1371:1375	arg1	metastasis					1382:1391	lymph node metastasis	1371:1391	lymph node metastasis	1371:1391	RESULTS O-GlcNAcylation was obviously up-regulated in HSCC tissues, which correlated with tumor size and lymph node metastasis.
32538734	0	62	theme	PI3K/Akt	143:150	arg1	Pathway					152:158	the PI3K/Akt Pathway	139:158	the PI3K/Akt Pathway	139:158	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	1	63	theme	posttranslational	225:241	arg1	modification					243:254	a significant protein posttranslational modification	203:254	a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	203:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	63	theme	posttranslational	225:241	arg1	O-GlcNAcylation					184:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	6	64	from	tissues	905:911	arg1	levels					862:867	The protein levels	850:867	The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues	850:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	14	65	theme	Akt	1799:1801	arg1	phosphorylation					1780:1794	the phosphorylation	1776:1794	the phosphorylation of Akt	1776:1801	Mechanismly, the upregulation of O-GlcNAcylation promoted the phosphorylation of Akt, leading to the stabilization of Nrf2; this could be attenuated by inhibition of the PI3K/Akt signaling pathway.
32538734	12	66	theme	Nrf2	1428:1431	arg1	level					1419:1423	the protein level	1407:1423	the protein level of Nrf2	1407:1431	In addition, the protein level of Nrf2 was found to positively correlate with the expression of O-GlcNAcylation both in vivo and in vitro.
32538734	15	67	theme	therapeutic	2043:2053	arg1	targets					2055:2061	valuable therapeutic targets	2034:2061	valuable therapeutic targets for the disease	2034:2077	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	0	68	theme	Carcinoma	87:95	arg1	Phenotypes					44:53	Malignant Phenotypes	34:53	Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma	34:95	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	13	69	theme	cell	1615:1618	arg1	migration					1620:1628	cell migration	1615:1628	cell migration	1615:1628	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	1	70	theme	BACKGROUND	161:170	arg1	modification					243:254	a significant protein posttranslational modification	203:254	a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	203:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	70	theme	BACKGROUND	161:170	arg1	O-GlcNAcylation					184:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	11	71	gly	O-GlcNAcylation	1274:1288	arg1	tissues					1325:1331	HSCC tissues	1320:1331	HSCC tissues	1320:1331	RESULTS O-GlcNAcylation was obviously up-regulated in HSCC tissues, which correlated with tumor size and lymph node metastasis.
32538734	5	72	theme	HSCC	827:830	arg1	patients					832:839	HSCC patients	827:839	HSCC patients	827:839	Here, we provide a molecular rationale between O-GlcNAcylation and Nrf2 in HSCC patients.
32538734	8	73	theme	colony-forming	1100:1113	arg1	analysis					1115:1122	colony-forming analysis	1100:1122	colony-forming analysis	1100:1122	Cell proliferation was detected by CCK8, colony-forming analysis, and cell cycle assays.
32538734	1	74	theme	PURPOSE	176:182	arg1	modification					243:254	a significant protein posttranslational modification	203:254	a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	203:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	74	theme	PURPOSE	176:182	arg1	O-GlcNAcylation					184:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation	161:198	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	75	link	O-linked	261:268	arg1	GlcNAc					293:298	GlcNAc	293:298	GlcNAc	293:298	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	1	75	link	O-linked	261:268	arg1	β-N-acetylglucosamine					270:290	O-linked β-N-acetylglucosamine	261:290	O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling	261:327	BACKGROUND AND PURPOSE O-GlcNAcylation is a significant protein posttranslational modification with O-linked β-N-acetylglucosamine (GlcNAc) for intracellular signaling.
32538734	12	76	located	found	1437:1441	arg1	addition					1397:1404	addition	1397:1404	addition	1397:1404	In addition, the protein level of Nrf2 was found to positively correlate with the expression of O-GlcNAcylation both in vivo and in vitro.
32538734	12	76	located	found	1437:1441	arg2	level					1419:1423	the protein level	1407:1423	the protein level of Nrf2	1407:1431	In addition, the protein level of Nrf2 was found to positively correlate with the expression of O-GlcNAcylation both in vivo and in vitro.
32538734	3	77	from	level	489:493	arg1	HSCC					577:580	HSCC	577:580	HSCC	577:580	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	77	from	level	489:493	arg1	Carcinoma					566:574	Hypopharyngeal Squamous Cell Carcinoma	537:574	Hypopharyngeal Squamous Cell Carcinoma (HSCC)	537:581	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	8	78	theme	cell	1129:1132	arg1	assays					1140:1145	cell cycle assays	1129:1145	cell cycle assays	1129:1145	Cell proliferation was detected by CCK8, colony-forming analysis, and cell cycle assays.
32538734	15	79	theme	valuable	2034:2041	arg1	targets					2055:2061	valuable therapeutic targets	2034:2061	valuable therapeutic targets for the disease	2034:2077	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	13	80	theme	HSCC	1586:1589	arg1	growth					1596:1601	HSCC cell growth	1586:1601	HSCC cell growth	1586:1601	Knockdown of O-GlcNAcylation significantly inhibited HSCC cell growth, suppressed cell migration, and promoted cell apoptosis, whereas overexpression of Nrf2 reversed these phenotypes.
32538734	3	81	dep	level	489:493	arg1	the					474:476	the	474:476	the	474:476	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	9	82	theme	invasion	1167:1174	arg1	ability					1176:1182	invasion ability	1167:1182	invasion ability	1167:1182	Cell migration and invasion ability was evaluated by transwell assays.
32538734	3	83	theme	functional	499:508	arg1	role					510:513	functional role	499:513	functional role	499:513	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	0	84	theme	Malignant	34:42	arg1	Phenotypes					44:53	Malignant Phenotypes	34:53	Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma	34:95	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	14	85	theme	signaling	1897:1905	arg1	pathway					1907:1913	the PI3K/Akt signaling pathway	1884:1913	the PI3K/Akt signaling pathway	1884:1913	Mechanismly, the upregulation of O-GlcNAcylation promoted the phosphorylation of Akt, leading to the stabilization of Nrf2; this could be attenuated by inhibition of the PI3K/Akt signaling pathway.
32538734	7	86	theme	knockdown	1010:1018	arg1	cells					1025:1029	O-GlcNAcylation knockdown HSCC cells	994:1029	O-GlcNAcylation knockdown HSCC cells	994:1029	Then, O-GlcNAcylation knockdown HSCC cells were applied in this study.
32538734	11	87	theme	RESULTS	1266:1272	arg1	O-GlcNAcylation					1274:1288	RESULTS O-GlcNAcylation	1266:1288	RESULTS O-GlcNAcylation	1266:1288	RESULTS O-GlcNAcylation was obviously up-regulated in HSCC tissues, which correlated with tumor size and lymph node metastasis.
32538734	3	88	theme	Squamous	552:559	arg1	HSCC					577:580	HSCC	577:580	HSCC	577:580	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	88	theme	Squamous	552:559	arg1	Carcinoma					566:574	Hypopharyngeal Squamous Cell Carcinoma	537:574	Hypopharyngeal Squamous Cell Carcinoma (HSCC)	537:581	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	0	89	theme	Squamous	73:80	arg1	Carcinoma					87:95	Hypopharyngeal Squamous Cell Carcinoma	58:95	Hypopharyngeal Squamous Cell Carcinoma	58:95	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	0	90	theme	Pathway	152:158	arg1	Regulation					125:134	Regulation	125:134	Regulation of the PI3K/Akt Pathway	125:158	Elevated O-GlcNAcylation Promotes Malignant Phenotypes of Hypopharyngeal Squamous Cell Carcinoma by Stabilizing Nrf2 through Regulation of the PI3K/Akt Pathway.
32538734	4	91	theme	factor	618:623	arg1	factor					645:650	Nuclear factor erythroid-2-related factor 2	610:652	Nuclear factor erythroid-2-related factor 2 (Nrf2)	610:659	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	91	theme	factor	618:623	arg1	Nrf2					655:658	Nrf2	655:658	Nrf2	655:658	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	91	theme	factor	618:623	arg1	factor					689:694	a master transcriptional factor	664:694	a master transcriptional factor that has been found to be aberrantly activated in HSCC	664:749	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	2	92	theme	cell	406:409	arg1	apoptosis					411:419	cell apoptosis	406:419	cell apoptosis	406:419	Elevated O-GlcNAcylation contributes to cell proliferation, cell migration, cell apoptosis and signal transduction in various cancers.
32538734	10	93	theme	Cell	1219:1222	arg1	apoptosis					1224:1232	Cell apoptosis	1219:1232	Cell apoptosis	1219:1232	Cell apoptosis was measured by TUNEL analysis.
32538734	6	94	theme	HSCC	900:903	arg1	tissues					905:911	HSCC tissues	900:911	HSCC tissues	900:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	4	95	theme	transcriptional	673:687	arg1	factor					645:650	Nuclear factor erythroid-2-related factor 2	610:652	Nuclear factor erythroid-2-related factor 2 (Nrf2)	610:659	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	4	95	theme	transcriptional	673:687	arg1	factor					689:694	a master transcriptional factor	664:694	a master transcriptional factor that has been found to be aberrantly activated in HSCC	664:749	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a master transcriptional factor that has been found to be aberrantly activated in HSCC.
32538734	6	96	theme	Nrf2	892:895	arg1	levels					862:867	The protein levels	850:867	The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues	850:911	METHODS The protein levels of O-GlcNAcylation and Nrf2 in HSCC tissues were detected by immunohistochemistry technique and western blot analysis.
32538734	15	97	theme	molecular	1946:1954	arg1	association					1956:1966	a molecular association	1944:1966	a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients	1944:2016	CONCLUSION Here, we provide a molecular association between O-GlcNAcylation and Nrf2 in HSCC patients, thus providing valuable therapeutic targets for the disease.
32538734	3	98	from	role	510:513	arg1	HSCC					577:580	HSCC	577:580	HSCC	577:580	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
32538734	3	98	from	role	510:513	arg1	Carcinoma					566:574	Hypopharyngeal Squamous Cell Carcinoma	537:574	Hypopharyngeal Squamous Cell Carcinoma (HSCC)	537:581	However, the expression level and functional role of O-GlcNAcylation in Hypopharyngeal Squamous Cell Carcinoma (HSCC) is not clearly elucidated.
34691043	9	0	theme	glycan	1246:1251	arg1	engineering					1253:1263	glycan engineering	1246:1263	glycan engineering	1246:1263	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	9	0	theme	glycan	1246:1251	arg1	stabilization					1278:1290	cysteine stabilization	1269:1290	cysteine stabilization	1269:1290	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	9	0	theme	glycan	1246:1251	arg1	strategies					1300:1309	two strategies	1296:1309	two strategies that can be used together to alter immunodominance patterns to HA	1296:1375	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	10	1	theme	rational	1399:1406	arg1	approaches					1425:1434	rational immunogen design approaches	1399:1434	rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines	1399:1528	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	10	2	theme	next-generation	1495:1509	arg1	vaccines					1521:1528	next-generation influenza vaccines	1495:1528	next-generation influenza vaccines	1495:1528	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	6	3	theme	dominant	794:801	arg1	epitope					786:792	an otherwise subdominant epitope	761:792	an otherwise subdominant epitope dominant in the murine model	761:821	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	7	4	gly	hyperglycosylated	877:893	arg1	trimer					898:903	the hyperglycosylated HA trimer	873:903	the hyperglycosylated HA trimer	873:903	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	7	5	theme	hyperglycosylated	877:893	arg1	trimer					898:903	the hyperglycosylated HA trimer	873:903	the hyperglycosylated HA trimer	873:903	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	3	6	gly	glycosylation	427:439	arg2	sites					441:445	predicted N-linked glycosylation sites	408:445	predicted N-linked glycosylation sites	408:445	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	7	7	theme	focus	990:994	arg1	responses					996:1004	focus responses	990:1004	focus responses to the HA receptor binding site (RBS)	990:1042	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	7	8	theme	HA	895:896	arg1	trimer					898:903	the hyperglycosylated HA trimer	873:903	the hyperglycosylated HA trimer	873:903	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	4	9	theme	HA	605:606	arg1	"					618:618	HA "breathing"	605:618	HA "breathing" on the virion surface	605:640	This epitope is occluded on the native HA trimer but is likely exposed during HA "breathing" on the virion surface.
34691043	8	10	theme	cysteine	1138:1145	arg1	stabilization					1147:1159	cysteine stabilization	1138:1159	cysteine stabilization	1138:1159	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	7	11	theme	interface	968:976	arg1	epitope					978:984	the interface epitope	964:984	the interface epitope	964:984	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	2	12	from	introduction	349:360	arg1	1968					365:368	1968	365:368	1968	365:368	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	1	13	theme	host	199:202	arg1	responses					220:228	host adaptive immune responses	199:228	host adaptive immune responses	199:228	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	2	14	dep	particular	264:273	arg1	subtype					282:288	the H3 subtype	275:288	particular the H3 subtype	264:288	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	10	15	theme	design	1418:1423	arg1	approaches					1425:1434	rational immunogen design approaches	1399:1434	rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines	1399:1528	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	7	16	theme	HA	1013:1014	arg1	RBS					1039:1041	RBS	1039:1041	RBS	1039:1041	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	7	16	theme	HA	1013:1014	arg1	site					1033:1036	the HA receptor binding site	1009:1036	the HA receptor binding site (RBS)	1009:1042	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	7	17	theme	cysteine	847:854	arg1	stabilization					856:868	cysteine stabilization	847:868	cysteine stabilization of the hyperglycosylated HA trimer	847:903	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	1	18	theme	adaptive	204:211	arg1	responses					220:228	host adaptive immune responses	199:228	host adaptive immune responses	199:228	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	9	19	used	used	1323:1326	arg2	engineering					1253:1263	glycan engineering	1246:1263	glycan engineering	1246:1263	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	9	19	used	used	1323:1326	arg2	strategies					1300:1309	two strategies	1296:1309	two strategies that can be used together to alter immunodominance patterns to HA	1296:1375	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	9	19	used	used	1323:1326	arg2	stabilization					1278:1290	cysteine stabilization	1269:1290	cysteine stabilization	1269:1290	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	8	20	theme	responses	1069:1077	arg1	analysis					1051:1058	analysis	1051:1058	analysis of serum responses from immunized mice	1051:1097	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	10	21	theme	immunogen	1408:1416	arg1	approaches					1425:1434	rational immunogen design approaches	1399:1434	rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines	1399:1528	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	1	22	theme	Influenza	107:115	arg1	virus					117:121	Influenza virus	107:121	Influenza virus	107:121	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	1	23	theme	immune	213:218	arg1	responses					220:228	host adaptive immune responses	199:228	host adaptive immune responses	199:228	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	3	24	theme	predicted	408:416	arg1	sites					441:445	predicted N-linked glycosylation sites	408:445	predicted N-linked glycosylation sites	408:445	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	8	25	theme	serum	1063:1067	arg1	responses					1069:1077	serum responses	1063:1077	serum responses from immunized mice	1063:1097	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	1	26	from	patterns	144:151	arg1	glycoproteins					176:188	its surface exposed glycoproteins	156:188	its surface exposed glycoproteins	156:188	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	2	27	theme	surface	317:323	arg1	glycosylation					325:337	its overall surface glycosylation	305:337	its overall surface glycosylation	305:337	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	4	28	theme	HA	566:567	arg1	trimer					569:574	the native HA trimer	555:574	the native HA trimer	555:574	This epitope is occluded on the native HA trimer but is likely exposed during HA "breathing" on the virion surface.
34691043	8	29	theme	immunized	1084:1092	arg1	mice					1094:1097	immunized mice	1084:1097	immunized mice	1084:1097	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	3	30	from	interface	516:524	arg1	epitope					498:504	a conserved epitope	486:504	a conserved epitope at the HA interface	486:524	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	2	31	theme	overall	309:315	arg1	glycosylation					325:337	its overall surface glycosylation	305:337	its overall surface glycosylation	305:337	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	10	32	theme	immune	1455:1460	arg1	responses					1462:1470	immune responses	1455:1470	immune responses	1455:1470	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	3	33	theme	conserved	488:496	arg1	epitope					498:504	a conserved epitope	486:504	a conserved epitope at the HA interface	486:524	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	6	34	theme	engineering	735:745	arg1	strategy					747:754	This glycan engineering strategy	723:754	This glycan engineering strategy	723:754	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	5	35	theme	ADCC-mediated	698:710	arg1	mechanism					712:720	an ADCC-mediated mechanism	695:720	an ADCC-mediated mechanism	695:720	Antibodies directed to this site are protective via an ADCC-mediated mechanism.
34691043	1	36	theme	glycosylation	130:142	arg1	patterns					144:151	glycosylation patterns	130:151	glycosylation patterns on its surface exposed glycoproteins	130:188	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	10	37	theme	influenza	1511:1519	arg1	vaccines					1521:1528	next-generation influenza vaccines	1495:1528	next-generation influenza vaccines	1495:1528	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	0	38	theme	Immunogens	45:54	arg1	Immunogenicity					13:26	the Immunogenicity	9:26	the Immunogenicity of Hemagglutinin Immunogens	9:54	Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization.
34691043	6	39	from	dominant	794:801	arg1	model					817:821	the murine model	806:821	the murine model	806:821	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	3	40	link	N-linked	418:425	arg1	sites					441:445	predicted N-linked glycosylation sites	408:445	predicted N-linked glycosylation sites	408:445	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	0	41	theme	Hemagglutinin	31:43	arg1	Immunogens					45:54	Hemagglutinin Immunogens	31:54	Hemagglutinin Immunogens	31:54	Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization.
34691043	9	42	theme	immunodominance	1346:1360	arg1	patterns					1362:1369	immunodominance patterns	1346:1369	immunodominance patterns to HA	1346:1375	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	6	43	theme	subdominant	774:784	arg1	epitope					786:792	an otherwise subdominant epitope	761:792	an otherwise subdominant epitope dominant in the murine model	761:821	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	3	44	theme	N-linked	418:425	arg1	sites					441:445	predicted N-linked glycosylation sites	408:445	predicted N-linked glycosylation sites	408:445	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	1	45	gly	glycoproteins	176:188	arg1	glycoproteins					176:188	its surface exposed glycoproteins	156:188	its surface exposed glycoproteins	156:188	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	4	46	from	"	618:618	arg1	surface					634:640	the virion surface	623:640	the virion surface	623:640	This epitope is occluded on the native HA trimer but is likely exposed during HA "breathing" on the virion surface.
34691043	6	47	theme	otherwise	764:772	arg1	epitope					786:792	an otherwise subdominant epitope	761:792	an otherwise subdominant epitope dominant in the murine model	761:821	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	3	48	theme	HA	513:514	arg1	interface					516:524	the HA interface	509:524	the HA interface	509:524	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	3	49	theme	glycosylation	427:439	arg1	sites					441:445	predicted N-linked glycosylation sites	408:445	predicted N-linked glycosylation sites	408:445	We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface.
34691043	4	50	theme	native	559:564	arg1	trimer					569:574	the native HA trimer	555:574	the native HA trimer	555:574	This epitope is occluded on the native HA trimer but is likely exposed during HA "breathing" on the virion surface.
34691043	9	51	theme	cysteine	1269:1276	arg1	engineering					1253:1263	glycan engineering	1246:1263	glycan engineering	1246:1263	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	9	51	theme	cysteine	1269:1276	arg1	stabilization					1278:1290	cysteine stabilization	1269:1290	cysteine stabilization	1269:1290	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	9	51	theme	cysteine	1269:1276	arg1	strategies					1300:1309	two strategies	1296:1309	two strategies that can be used together to alter immunodominance patterns to HA	1296:1375	Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA.
34691043	6	52	from	model	817:821	arg1	dominant					794:801	dominant	794:801	dominant	794:801	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	7	53	theme	receptor	1016:1023	arg1	RBS					1039:1041	RBS	1039:1041	RBS	1039:1041	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	7	53	theme	receptor	1016:1023	arg1	site					1033:1036	the HA receptor binding site	1009:1036	the HA receptor binding site (RBS)	1009:1042	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	8	54	from	analysis	1051:1058	arg1	mice					1094:1097	immunized mice	1084:1097	immunized mice	1084:1097	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	2	55	theme	viral	235:239	arg1	HA					256:257	HA	256:257	HA	256:257	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	2	55	theme	viral	235:239	arg1	hemagglutinin					241:253	The viral hemagglutinin	231:253	The viral hemagglutinin (HA)	231:258	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	2	56	theme	H3	279:280	arg1	subtype					282:288	the H3 subtype	275:288	particular the H3 subtype	264:288	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	7	57	theme	binding	1025:1031	arg1	RBS					1039:1041	RBS	1039:1041	RBS	1039:1041	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	7	57	theme	binding	1025:1031	arg1	site					1033:1036	the HA receptor binding site	1009:1036	the HA receptor binding site (RBS)	1009:1042	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34691043	1	58	dep	exposed	168:174	arg1	surface					160:166	surface	160:166	surface	160:166	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	4	59	theme	breathing	609:617	arg1	"					618:618	HA "breathing"	605:618	HA "breathing" on the virion surface	605:640	This epitope is occluded on the native HA trimer but is likely exposed during HA "breathing" on the virion surface.
34691043	10	60	theme	vaccines	1521:1528	arg1	development					1480:1490	the development	1476:1490	the development of next-generation influenza vaccines	1476:1528	These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines.
34691043	6	61	theme	murine	810:815	arg1	model					817:821	the murine model	806:821	the murine model	806:821	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	8	62	from	mice	1094:1097	arg1	analysis					1051:1058	analysis	1051:1058	analysis of serum responses from immunized mice	1051:1097	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	8	62	from	mice	1094:1097	arg1	responses					1069:1077	serum responses	1063:1077	serum responses from immunized mice	1063:1097	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	0	63	theme	Disulfide	82:90	arg1	Stabilization					92:104	Disulfide Stabilization	82:104	Disulfide Stabilization	82:104	Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization.
34691043	4	64	theme	virion	627:632	arg1	surface					634:640	the virion surface	623:640	the virion surface	623:640	This epitope is occluded on the native HA trimer but is likely exposed during HA "breathing" on the virion surface.
34691043	1	65	theme	exposed	168:174	arg1	glycoproteins					176:188	its surface exposed glycoproteins	156:188	its surface exposed glycoproteins	156:188	Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses.
34691043	8	66	theme	interface	1221:1229	arg1	epitope					1231:1237	the interface epitope	1217:1237	the interface epitope	1217:1237	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	2	67	gly	glycosylation	325:337	arg1	particular					264:273	particular	264:273	particular	264:273	The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968.
34691043	8	68	from	reduction	1186:1194	arg1	immunogenicity					1199:1212	immunogenicity	1199:1212	immunogenicity of the interface epitope	1199:1237	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	8	69	theme	overall	1178:1184	arg1	reduction					1186:1194	an overall reduction	1175:1194	an overall reduction in immunogenicity of the interface epitope	1175:1237	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	6	70	theme	glycan	728:733	arg1	strategy					747:754	This glycan engineering strategy	723:754	This glycan engineering strategy	723:754	This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model.
34691043	8	71	theme	epitope	1231:1237	arg1	immunogenicity					1199:1212	immunogenicity	1199:1212	immunogenicity of the interface epitope	1199:1237	While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope.
34691043	7	72	theme	trimer	898:903	arg1	stabilization					856:868	cysteine stabilization	847:868	cysteine stabilization of the hyperglycosylated HA trimer	847:903	Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS).
34012659	10	0	dep	RESULTS	1027:1033	arg1	observed					1044:1051	observed	1044:1051	observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1044:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	2	1	from	factor	365:370	arg1	types					383:387	several types	375:387	several types of cancer	375:397	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	4	2	theme	tumorous	512:519	arg1	tissues					549:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	10	3	theme	HBV-infected	1084:1095	arg1	HCC					1097:1099	HBV-infected HCC	1084:1099	HBV-infected HCC	1084:1099	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	4	4	theme	adjacent	525:532	arg1	tissues					549:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	6	5	theme	wound	704:708	arg1	healing					710:716	wound healing	704:716	wound healing	704:716	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	6	5	theme	wound	704:708	arg1	CCK8					687:690	CCK8	687:690	CCK8	687:690	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	11	6	theme	BST-2	1471:1475	arg1	form					1463:1466	more non-N-glycosylated form	1439:1466	more non-N-glycosylated form of BST-2	1439:1475	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	12	7	gly	non-N-glycosylated	1519:1536	arg1	mutant					1552:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	1	8	theme	B	182:182	arg1	virus					184:188	hepatitis B virus	172:188	hepatitis B virus (HBV) infection	172:204	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	1	8	theme	B	182:182	arg1	HBV					191:193	HBV	191:193	HBV	191:193	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	13	9	theme	N65/92A	1709:1715	arg1	mutant					1717:1722	N65/92A mutant	1709:1722	N65/92A mutant	1709:1722	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	2	10	theme	cell	283:286	arg1	BST-2					299:303	BST-2	299:303	BST-2	299:303	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	10	theme	cell	283:286	arg1	antigen					288:294	stromal cell antigen 2	275:296	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	15	11	theme	HCC	2079:2081	arg1	tumorigenesis					2083:2095	HCC tumorigenesis	2079:2095	HCC tumorigenesis	2079:2095	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	1	12	dep	BACKGROUND	87:96	arg1	associated					156:165	associated	156:165	associated	156:165	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	13	13	theme	NF-κB/anti-apoptotic	1796:1815	arg1	factors					1817:1823	NF-κB/anti-apoptotic factors	1796:1823	NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1775:1831	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	10	14	from	expression	1070:1079	arg1	HCC					1097:1099	HBV-infected HCC	1084:1099	HBV-infected HCC	1084:1099	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	12	15	theme	lines	1621:1625	arg1	characteristics					1588:1602	the tumor characteristics	1578:1602	the tumor characteristics of hepatoma cell lines	1578:1625	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	10	16	theme	paired	1112:1117	arg1	tissues					1128:1134	their paired adjacent tissues	1106:1134	their paired adjacent tissues	1106:1134	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	5	17	theme	HEK293T	604:610	arg1	lines					617:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines were adopted in this study.
34012659	13	18	theme	stronger	1728:1735	arg1	ability					1737:1743	stronger ability	1728:1743	stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1728:1831	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	13	19	contain	has	1724:1726	arg2	ability					1737:1743	stronger ability	1728:1743	stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1728:1831	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	13	19	contain	has	1724:1726	arg1	mutant					1717:1722	N65/92A mutant	1709:1722	N65/92A mutant	1709:1722	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	11	20	theme	sequential	1383:1392	arg1	removal					1394:1400	sequential removal	1383:1400	sequential removal of mannose residues	1383:1420	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	0	21	theme	HCC	68:70	arg1	tumorigenesis					72:84	HBV-associated HCC tumorigenesis	53:84	HBV-associated HCC tumorigenesis	53:84	Increased BST-2 expression by HBV infection promotes HBV-associated HCC tumorigenesis.
34012659	4	22	dep	METHODS	485:491	arg1	collected					562:570	collected	562:570	were collected	557:570	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	7	23	theme	Western	869:875	arg1	blot					877:880	Western blot	869:880	Western blot	869:880	NF-κB activation was determined by luciferase assay and Western blot.
34012659	10	24	theme	HBV-uninfected	1140:1153	arg1	tissues					1159:1165	HBV-uninfected HCC tissues	1140:1165	HBV-uninfected HCC tissues	1140:1165	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	11	25	link	N-linked	1363:1370	arg1	glycans					1372:1378	N-linked glycans	1363:1378	N-linked glycans	1363:1378	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	8	26	theme	Western	918:924	arg1	blot					926:929	Western blot	918:929	Western blot	918:929	Protein expression was detected by Western blot, ELISA, or qPCR.
34012659	12	27	theme	hepatoma	1607:1614	arg1	lines					1621:1625	hepatoma cell lines	1607:1625	hepatoma cell lines	1607:1625	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	12	28	theme	mouse	1669:1673	arg1	xenografts					1675:1684	mouse xenografts	1669:1684	mouse xenografts	1669:1684	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	11	29	theme	residues	1413:1420	arg1	removal					1394:1400	sequential removal	1383:1400	sequential removal of mannose residues	1383:1420	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	15	30	theme	HBV-associated	1980:1993	arg1	HCC					1995:1997	HBV-associated HCC	1980:1997	HBV-associated HCC	1980:1997	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	2	31	theme	cancer	392:397	arg1	types					383:387	several types	375:387	several types of cancer	375:397	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	0	32	theme	Increased	0:8	arg1	expression					16:25	Increased BST-2 expression	0:25	Increased BST-2 expression by HBV infection	0:42	Increased BST-2 expression by HBV infection promotes HBV-associated HCC tumorigenesis.
34012659	7	33	theme	NF-κB	813:817	arg1	activation					819:828	NF-κB activation	813:828	NF-κB activation	813:828	NF-κB activation was determined by luciferase assay and Western blot.
34012659	12	34	theme	N65/92A	1544:1550	arg1	mutant					1552:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	2	35	gly	N-glycoprotein	310:323	arg1	N-glycoprotein					310:323	an N-glycoprotein	307:323	an N-glycoprotein	307:323	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	35	gly	N-glycoprotein	310:323	arg1	marrow					268:273	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	11	36	theme	glycans	1372:1378	arg1	trimming					1351:1358	trimming	1351:1358	trimming of N-linked glycans by sequential removal of mannose residues	1351:1420	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	6	37	theme	in	757:758	arg1	tumorigenesis					765:777	in vivo tumorigenesis	757:777	in vivo tumorigenesis	757:777	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	1	38	theme	hepatocellular	114:127	arg1	HCC					140:142	HCC	140:142	HCC	140:142	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	1	38	theme	hepatocellular	114:127	arg1	carcinoma					129:137	hepatocellular carcinoma	114:137	hepatocellular carcinoma (HCC)	114:143	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	10	39	theme	aberrant	1186:1193	arg1	BST-2					1214:1218	aberrant non-N-glycosylated BST-2	1186:1218	aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1186:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	2	40	theme	oncogenic	355:363	arg1	factor					365:370	an oncogenic factor	352:370	an oncogenic factor in several types of cancer	352:397	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	40	theme	oncogenic	355:363	arg1	marrow					268:273	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	0	41	theme	HBV	30:32	arg1	infection					34:42	HBV infection	30:42	HBV infection	30:42	Increased BST-2 expression by HBV infection promotes HBV-associated HCC tumorigenesis.
34012659	14	42	theme	HCC	1893:1895	arg1	tumorigenesis					1876:1888	BST-2-mediated tumorigenesis	1861:1888	BST-2-mediated tumorigenesis of HCC	1861:1895	NF-κB inhibitor attenuated BST-2-mediated tumorigenesis of HCC.
34012659	10	43	theme	HBV-infected	1223:1234	arg1	tumors					1240:1245	HBV-infected HCC tumors	1223:1245	HBV-infected HCC tumors	1223:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	10	44	theme	BST-2	1064:1068	arg1	expression					1070:1079	the higher BST-2 expression	1053:1079	the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1053:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	6	45	theme	formation	726:734	arg1	assays					736:741	colony formation assays	719:741	colony formation assays	719:741	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	6	45	theme	formation	726:734	arg1	CCK8					687:690	CCK8	687:690	CCK8	687:690	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	15	46	theme	novel	2018:2022	arg1	relationship					2024:2035	the novel relationship	2014:2035	the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro	2014:2104	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	4	47	theme	nontumor	534:541	arg1	tissues					549:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	11	48	theme	degradation-enhancing	1282:1302	arg1	protein					1323:1329	degradation-enhancing α-mannosidase-like protein 3	1282:1331	degradation-enhancing α-mannosidase-like protein 3 (EDEM3)	1282:1339	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	11	48	theme	degradation-enhancing	1282:1302	arg1	EDEM3					1334:1338	EDEM3	1334:1338	EDEM3	1334:1338	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	3	49	theme	HCC	450:452	arg1	tumorigenesis					454:466	HCC tumorigenesis	450:466	HCC tumorigenesis	450:466	However, whether BST-2 plays an important role in HCC tumorigenesis remains unknown.
34012659	14	50	theme	NF-κB	1834:1838	arg1	inhibitor					1840:1848	NF-κB inhibitor	1834:1848	NF-κB inhibitor	1834:1848	NF-κB inhibitor attenuated BST-2-mediated tumorigenesis of HCC.
34012659	4	51	theme	tissues	549:555	arg1	total					495:499	A total	493:499	A total of 182 HCC tumorous and adjacent nontumor liver tissues	493:555	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	11	52	theme	increased	1269:1277	arg1	ER					1279:1280	the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2	1265:1475	the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2	1265:1475	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	5	53	theme	Huh7	580:583	arg1	lines					617:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines were adopted in this study.
34012659	1	54	theme	HCC	230:232	arg1	mechanism					217:225	the mechanism	213:225	the mechanism of HCC induced by HBV	213:247	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	1	54	theme	HCC	230:232	arg1	debatable					252:260	debatable	252:260	debatable	252:260	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	6	55	theme	mouse	795:799	arg1	xenografts					801:810	mouse xenografts	795:810	mouse xenografts	795:810	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	4	56	theme	HCC	508:510	arg1	tissues					549:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	5	57	theme	L02	586:588	arg1	lines					617:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines were adopted in this study.
34012659	11	58	theme	non-N-glycosylated	1444:1461	arg1	form					1463:1466	more non-N-glycosylated form	1439:1466	more non-N-glycosylated form of BST-2	1439:1475	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	2	59	theme	Bone	263:266	arg1	N-glycoprotein					310:323	an N-glycoprotein	307:323	an N-glycoprotein	307:323	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	59	theme	Bone	263:266	arg1	factor					365:370	an oncogenic factor	352:370	an oncogenic factor in several types of cancer	352:397	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	59	theme	Bone	263:266	arg1	marrow					268:273	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	8	60	theme	Protein	883:889	arg1	expression					891:900	Protein expression	883:900	Protein expression	883:900	Protein expression was detected by Western blot, ELISA, or qPCR.
34012659	13	61	theme	NF-κB/ERK1/2	1775:1786	arg1	pathway					1825:1831	NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1775:1831	NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1775:1831	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	1	62	theme	hepatitis	172:180	arg1	virus					184:188	hepatitis B virus	172:188	hepatitis B virus (HBV) infection	172:204	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	1	62	theme	hepatitis	172:180	arg1	HBV					191:193	HBV	191:193	HBV	191:193	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	5	63	theme	HepG2	573:577	arg1	lines					617:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines were adopted in this study.
34012659	1	64	theme	virus	184:188	arg1	infection					196:204	hepatitis B virus (HBV) infection	172:204	hepatitis B virus (HBV) infection	172:204	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	12	65	theme	BST-2	1509:1513	arg1	mutant					1552:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	13	66	theme	factors	1817:1823	arg1	pathway					1825:1831	NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1775:1831	NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway	1775:1831	Mechanically, N65/92A mutant has stronger ability to promote HCC than BST-2 via NF-κB/ERK1/2 but not NF-κB/anti-apoptotic factors pathway.
34012659	5	67	theme	cell	612:615	arg1	lines					617:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines were adopted in this study.
34012659	2	68	theme	stromal	275:281	arg1	BST-2					299:303	BST-2	299:303	BST-2	299:303	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	68	theme	stromal	275:281	arg1	antigen					288:294	stromal cell antigen 2	275:296	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	12	69	theme	non-N-glycosylated	1519:1536	arg1	mutant					1552:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	11	70	dep	ER	1279:1280	arg1	result					1429:1434	result	1429:1434	might result in more non-N-glycosylated form of BST-2	1423:1475	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	9	71	used	used	972:975	arg2	Immunoprecipitation					948:966	Immunoprecipitation	948:966	Immunoprecipitation	948:966	Immunoprecipitation was used to confirm the interaction between BST-2 and Syk.
34012659	15	72	theme	BST-2	2059:2063	arg1	N-glycosylation					2040:2054	N-glycosylation	2040:2054	N-glycosylation of BST-2	2040:2063	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	10	73	gly	non-N-glycosylated	1195:1212	arg1	BST-2					1214:1218	aberrant non-N-glycosylated BST-2	1186:1218	aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1186:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	15	74	dep	CONCLUSIONS	1898:1908	arg1	illuminate					1923:1932	illuminate	1923:1932	illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC	1923:1997	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	15	74	dep	CONCLUSIONS	1898:1908	arg1	highlight					2004:2012	highlight	2004:2012	highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro	2004:2104	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	5	75	theme	HepAD38	591:597	arg1	lines					617:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines	573:621	HepG2, Huh7, L02, HepAD38, and HEK293T cell lines were adopted in this study.
34012659	1	76	theme	carcinoma	129:137	arg1	majority					102:109	The majority	98:109	The majority of hepatocellular carcinoma (HCC)	98:143	BACKGROUND The majority of hepatocellular carcinoma (HCC) is closely associated with hepatitis B virus (HBV) infection, while the mechanism of HCC induced by HBV is debatable.
34012659	2	77	dep	marrow	268:273	arg1	BST-2					299:303	BST-2	299:303	BST-2	299:303	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	2	77	dep	marrow	268:273	arg1	antigen					288:294	stromal cell antigen 2	275:296	Bone marrow stromal cell antigen 2 (BST-2)	263:304	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	10	78	theme	adjacent	1119:1126	arg1	tissues					1128:1134	their paired adjacent tissues	1106:1134	their paired adjacent tissues	1106:1134	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	12	79	theme	cell	1616:1619	arg1	lines					1621:1625	hepatoma cell lines	1607:1625	hepatoma cell lines	1607:1625	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	6	80	theme	Tumor	651:655	arg1	proliferation					657:669	Tumor proliferation	651:669	Tumor proliferation	651:669	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	10	81	from	BST-2	1214:1218	arg1	tumors					1240:1245	HBV-infected HCC tumors	1223:1245	HBV-infected HCC tumors	1223:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	10	82	theme	HCC	1155:1157	arg1	tissues					1159:1165	HBV-uninfected HCC tissues	1140:1165	HBV-uninfected HCC tissues	1140:1165	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	12	83	theme	tumor	1582:1586	arg1	characteristics					1588:1602	the tumor characteristics	1578:1602	the tumor characteristics of hepatoma cell lines	1578:1625	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	11	84	theme	mannose	1405:1411	arg1	residues					1413:1420	mannose residues	1405:1420	mannose residues	1405:1420	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	11	85	gly	non-N-glycosylated	1444:1461	arg1	BST-2					1471:1475	BST-2	1471:1475	BST-2	1471:1475	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	11	85	gly	non-N-glycosylated	1444:1461	arg1	form					1463:1466	more non-N-glycosylated form	1439:1466	more non-N-glycosylated form of BST-2	1439:1475	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	10	86	dep	tissues	1128:1134	arg1	BST-2					1214:1218	aberrant non-N-glycosylated BST-2	1186:1218	aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1186:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	15	87	theme	HCC	1995:1997	arg1	oncogene					1968:1975	an oncogene	1965:1975	an oncogene of HBV-associated HCC	1965:1997	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	7	88	theme	luciferase	848:857	arg1	assay					859:863	luciferase assay	848:863	luciferase assay	848:863	NF-κB activation was determined by luciferase assay and Western blot.
34012659	0	89	theme	BST-2	10:14	arg1	expression					16:25	Increased BST-2 expression	0:25	Increased BST-2 expression by HBV infection	0:42	Increased BST-2 expression by HBV infection promotes HBV-associated HCC tumorigenesis.
34012659	11	90	theme	N-linked	1363:1370	arg1	glycans					1372:1378	N-linked glycans	1363:1378	N-linked glycans	1363:1378	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	15	91	theme	BST-2	1956:1960	arg1	function					1944:1951	the novel function	1934:1951	the novel function of BST-2 as an oncogene of HBV-associated HCC	1934:1997	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	12	92	theme	BST-2	1538:1542	arg1	mutant					1552:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	BST-2 and non-N-glycosylated BST-2 N65/92A mutant	1509:1557	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	2	93	theme	several	375:381	arg1	types					383:387	several types	375:387	several types of cancer	375:397	Bone marrow stromal cell antigen 2 (BST-2), an N-glycoprotein, has been characterized as an oncogenic factor in several types of cancer.
34012659	10	94	theme	non-N-glycosylated	1195:1212	arg1	BST-2					1214:1218	aberrant non-N-glycosylated BST-2	1186:1218	aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1186:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	15	95	theme	N-glycosylation	2040:2054	arg1	relationship					2024:2035	the novel relationship	2014:2035	the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro	2014:2104	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	15	96	gly	N-glycosylation	2040:2054	arg1	BST-2					2059:2063	BST-2	2059:2063	BST-2	2059:2063	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	15	97	theme	novel	1938:1942	arg1	function					1944:1951	the novel function	1934:1951	the novel function of BST-2 as an oncogene of HBV-associated HCC	1934:1997	CONCLUSIONS Our findings illuminate the novel function of BST-2 as an oncogene of HBV-associated HCC, and highlight the novel relationship of N-glycosylation of BST-2 in regulating HCC tumorigenesis in vitro.
34012659	0	98	theme	HBV-associated	53:66	arg1	tumorigenesis					72:84	HBV-associated HCC tumorigenesis	53:84	HBV-associated HCC tumorigenesis	53:84	Increased BST-2 expression by HBV infection promotes HBV-associated HCC tumorigenesis.
34012659	6	99	dep	in	757:758	arg1	vivo					760:763	vivo	760:763	vivo	760:763	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	10	100	theme	HCC	1236:1238	arg1	tumors					1240:1245	HBV-infected HCC tumors	1223:1245	HBV-infected HCC tumors	1223:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	3	101	theme	important	432:440	arg1	role					442:445	an important role	429:445	an important role	429:445	However, whether BST-2 plays an important role in HCC tumorigenesis remains unknown.
34012659	14	102	theme	BST-2-mediated	1861:1874	arg1	tumorigenesis					1876:1888	BST-2-mediated tumorigenesis	1861:1888	BST-2-mediated tumorigenesis of HCC	1861:1895	NF-κB inhibitor attenuated BST-2-mediated tumorigenesis of HCC.
34012659	4	103	theme	liver	543:547	arg1	tissues					549:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	182 HCC tumorous and adjacent nontumor liver tissues	504:555	METHODS A total of 182 HCC tumorous and adjacent nontumor liver tissues were collected.
34012659	10	104	theme	higher	1057:1062	arg1	expression					1070:1079	the higher BST-2 expression	1053:1079	the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors	1053:1245	RESULTS Here, we observed the higher BST-2 expression in HBV-infected HCC than their paired adjacent tissues and HBV-uninfected HCC tissues, particularly more aberrant non-N-glycosylated BST-2 in HBV-infected HCC tumors.
34012659	6	105	theme	colony	719:724	arg1	assays					736:741	colony formation assays	719:741	colony formation assays	719:741	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	6	105	theme	colony	719:724	arg1	CCK8					687:690	CCK8	687:690	CCK8	687:690	Tumor proliferation was detected by CCK8, transwell, wound healing, colony formation assays in vitro, and in vivo tumorigenesis was measured by mouse xenografts.
34012659	12	106	theme	xenografts	1675:1684	arg1	growth					1659:1664	the growth	1655:1664	the growth of mouse xenografts	1655:1684	Moreover, we demonstrated that BST-2 and non-N-glycosylated BST-2 N65/92A mutant, not only enhanced the tumor characteristics of hepatoma cell lines in vitro, but also enhanced the growth of mouse xenografts in vivo.
34012659	11	107	theme	α-mannosidase-like	1304:1321	arg1	protein					1323:1329	degradation-enhancing α-mannosidase-like protein 3	1282:1331	degradation-enhancing α-mannosidase-like protein 3 (EDEM3)	1282:1339	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
34012659	11	107	theme	α-mannosidase-like	1304:1321	arg1	EDEM3					1334:1338	EDEM3	1334:1338	EDEM3	1334:1338	We also observed the increased ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3), which is trimming of N-linked glycans by sequential removal of mannose residues, might result in more non-N-glycosylated form of BST-2.
33358569	5	0	theme	exogenous	831:839	arg1	addition					841:848	exogenous addition	831:848	exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3),	831:936	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	10	1	with	interactions	1730:1741	arg1	glycans					1797:1803	specific phagocyte cell-surface glycans	1765:1803	specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity	1765:1926	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	6	2	theme	motility-dependent	1146:1163	arg1	interactions					1165:1176	motility-dependent interactions	1146:1176	motility-dependent interactions with cell-surface polyanions	1146:1205	Thus, we hypothesized that the engagement of P. aeruginosa by phagocytic cells is mediated by motility-dependent interactions with cell-surface polyanions.
33358569	4	3	theme	mechanistic	637:647	arg1	bases					649:653	the mechanistic bases	633:653	the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria	633:781	However, the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria are poorly understood.
33358569	9	4	with	interactions	1576:1587	arg1	glycans					1598:1604	the glycans	1594:1604	the glycans	1594:1604	Importantly, the bacterial interactions with the glycans were motility-dependent and could be recapitulated with purified, immobilized glycans.
33358569	5	5	theme	non-motile	965:974	arg1	strains					976:982	non-motile strains	965:982	non-motile strains of P. aeruginosa	965:999	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	7	6	link	N-linked	1251:1258	arg1	glycans					1260:1266	endogenous polyanionic N-linked glycans	1228:1266	endogenous polyanionic N-linked glycans	1228:1266	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	2	7	theme	innate	341:346	arg1	responses					355:363	impaired innate immune responses	332:363	impaired innate immune responses	332:363	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	2	7	theme	innate	341:346	arg1	those					376:380	those	376:380	those	376:380	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	8	8	theme	-mediated	1465:1473	arg1	intoxication					1484:1495	bacterial type 3 secretion system (T3SS)-mediated cellular intoxication	1425:1495	bacterial type 3 secretion system (T3SS)-mediated cellular intoxication	1425:1495	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	10	9	theme	innate	1833:1838	arg1	responses					1847:1855	relevant host innate immune responses	1819:1855	relevant host innate immune responses	1819:1855	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	3	10	theme	Previous	419:426	arg1	studies					428:434	Previous studies	419:434	Previous studies	419:434	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	5	11	with	engagement	951:960	arg1	phagocytes					1006:1015	phagocytes	1006:1015	phagocytes leading to uptake of the bacteria	1006:1049	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	7	12	theme	human	1334:1338	arg1	cells					1350:1354	human monocytic cells	1334:1354	human monocytic cells	1334:1354	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	2	13	theme	impaired	332:339	arg1	responses					355:363	impaired innate immune responses	332:363	impaired innate immune responses	332:363	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	2	13	theme	impaired	332:339	arg1	those					376:380	those	376:380	those	376:380	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	10	14	theme	immune	1840:1845	arg1	responses					1847:1855	relevant host innate immune responses	1819:1855	relevant host innate immune responses	1819:1855	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	5	15	theme	aeruginosa	990:999	arg1	strains					976:982	non-motile strains	965:982	non-motile strains of P. aeruginosa	965:999	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	16	theme	recent	808:813	arg1	insight					815:821	A recent insight	806:821	A recent insight	806:821	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	17	theme	strains	976:982	arg1	engagement					951:960	the engagement	947:960	the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria	947:1049	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	3	18	dep	downregulation	456:469	arg1	the					452:454	the	452:454	the	452:454	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	3	19	theme	phagocytic	589:598	arg1	uptake					600:605	phagocytic uptake	589:605	phagocytic uptake of the bacteria	589:621	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	3	20	theme	bacterial	484:492	arg1	motility					504:511	bacterial flagellar motility	484:511	bacterial flagellar motility	484:511	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	5	21	theme	charged	866:872	arg1	-triphosphate					916:928	phosphatidylinositol-(3,4,5)-triphosphate	888:928	phosphatidylinositol-(3,4,5)-triphosphate (PIP3)	888:935	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	21	theme	charged	866:872	arg1	phospholipid					874:885	a negatively charged phospholipid	853:885	a negatively charged phospholipid	853:885	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	3	22	with	interactions	539:550	arg1	cells					568:572	phagocytic cells	557:572	phagocytic cells that result in phagocytic uptake of the bacteria	557:621	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	4	23	theme	motility-dependent	659:676	arg1	interactions					678:689	motility-dependent interactions	659:689	motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria	659:781	However, the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria are poorly understood.
33358569	3	24	theme	flagellar	494:502	arg1	motility					504:511	bacterial flagellar motility	484:511	bacterial flagellar motility	484:511	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	5	25	theme	phospholipid	874:885	arg1	addition					841:848	exogenous addition	831:848	exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3),	831:936	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	6	26	with	interactions	1165:1176	arg1	polyanions					1196:1205	cell-surface polyanions	1183:1205	cell-surface polyanions	1183:1205	Thus, we hypothesized that the engagement of P. aeruginosa by phagocytic cells is mediated by motility-dependent interactions with cell-surface polyanions.
33358569	9	27	dep	purified	1662:1669	arg1	immobilized					1672:1682	immobilized	1672:1682	immobilized	1672:1682	Importantly, the bacterial interactions with the glycans were motility-dependent and could be recapitulated with purified, immobilized glycans.
33358569	10	28	theme	novel	1724:1728	arg1	interactions					1730:1741	novel interactions	1724:1741	novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity	1724:1926	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	10	29	theme	relevant	1819:1826	arg1	responses					1847:1855	relevant host innate immune responses	1819:1855	relevant host innate immune responses	1819:1855	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	6	30	theme	phagocytic	1114:1123	arg1	cells					1125:1129	phagocytic cells	1114:1129	phagocytic cells	1114:1129	Thus, we hypothesized that the engagement of P. aeruginosa by phagocytic cells is mediated by motility-dependent interactions with cell-surface polyanions.
33358569	0	31	theme	glycans	31:37	arg1	Identification					0:13	Identification	0:13	Identification of cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes.	0:138	Identification of cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes.
33358569	2	32	contain	have	327:330	arg2	those					376:380	those	376:380	those	376:380	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	2	32	contain	have	327:330	arg2	responses					355:363	impaired innate immune responses	332:363	impaired innate immune responses	332:363	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	2	32	contain	have	327:330	arg1	individuals					304:314	susceptible individuals	292:314	susceptible individuals	292:314	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	8	33	theme	P.	1397:1398	arg1	phagocytosis					1411:1422	P. aeruginosa phagocytosis	1397:1422	P. aeruginosa phagocytosis	1397:1422	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	3	34	theme	bacteria	614:621	arg1	uptake					600:605	phagocytic uptake	589:605	phagocytic uptake of the bacteria	589:621	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	1	35	theme	Gram-negative	220:232	arg1	pathogen					269:276	an opportunistic pathogen	252:276	an opportunistic pathogen	252:276	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	1	35	theme	Gram-negative	220:232	arg1	bacterium					234:242	a Gram-negative bacterium	218:242	a Gram-negative bacterium that is an opportunistic pathogen	218:276	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	1	35	theme	Gram-negative	220:232	arg1	aeruginosa					206:215	Pseudomonas aeruginosa	194:215	Pseudomonas aeruginosa	194:215	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	0	36	theme	cell-surface	18:29	arg1	glycans					31:37	cell-surface glycans	18:37	cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes	18:137	Identification of cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes.
33358569	9	37	theme	bacterial	1566:1574	arg1	motility-dependent					1611:1628	motility-dependent	1611:1628	motility-dependent	1611:1628	Importantly, the bacterial interactions with the glycans were motility-dependent and could be recapitulated with purified, immobilized glycans.
33358569	9	37	theme	bacterial	1566:1574	arg1	interactions					1576:1587	the bacterial interactions	1562:1587	the bacterial interactions with the glycans	1562:1604	Importantly, the bacterial interactions with the glycans were motility-dependent and could be recapitulated with purified, immobilized glycans.
33358569	9	38	theme	purified	1662:1669	arg1	glycans					1684:1690	purified, immobilized glycans	1662:1690	purified, immobilized glycans	1662:1690	Importantly, the bacterial interactions with the glycans were motility-dependent and could be recapitulated with purified, immobilized glycans.
33358569	8	39	theme	cells	1542:1546	arg1	intoxication					1484:1495	bacterial type 3 secretion system (T3SS)-mediated cellular intoxication	1425:1495	bacterial type 3 secretion system (T3SS)-mediated cellular intoxication	1425:1495	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	39	theme	cells	1542:1546	arg1	response					1511:1518	the IL-1β response	1501:1518	the IL-1β response of host innate immune cells	1501:1546	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	39	theme	cells	1542:1546	arg1	phagocytosis					1411:1422	P. aeruginosa phagocytosis	1397:1422	P. aeruginosa phagocytosis	1397:1422	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	2	40	theme	immune	348:353	arg1	responses					355:363	impaired innate immune responses	332:363	impaired innate immune responses	332:363	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	2	40	theme	immune	348:353	arg1	those					376:380	those	376:380	those	376:380	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	6	41	theme	aeruginosa	1100:1109	arg1	engagement					1083:1092	the engagement	1079:1092	the engagement of P. aeruginosa by phagocytic cells	1079:1129	Thus, we hypothesized that the engagement of P. aeruginosa by phagocytic cells is mediated by motility-dependent interactions with cell-surface polyanions.
33358569	3	42	theme	phagocytic	557:566	arg1	cells					568:572	phagocytic cells	557:572	phagocytic cells that result in phagocytic uptake of the bacteria	557:621	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	4	43	theme	cell	722:725	arg1	surfaces					727:734	host cell surfaces	717:734	host cell surfaces	717:734	However, the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria are poorly understood.
33358569	10	44	theme	aeruginosa	1749:1758	arg1	interactions					1730:1741	novel interactions	1724:1741	novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity	1724:1926	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	3	45	theme	motility	504:511	arg1	downregulation					456:469	downregulation	456:469	downregulation	456:469	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	3	45	theme	motility	504:511	arg1	loss					475:478	loss	475:478	loss	475:478	Previous studies identified that the downregulation, or loss, of bacterial flagellar motility enables bacteria to evade interactions with phagocytic cells that result in phagocytic uptake of the bacteria.
33358569	7	46	theme	endogenous	1228:1237	arg1	glycans					1260:1266	endogenous polyanionic N-linked glycans	1228:1266	endogenous polyanionic N-linked glycans	1228:1266	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	4	47	theme	bacteria	774:781	arg1	uptake					760:765	phagocytic uptake	749:765	phagocytic uptake of the bacteria	749:781	However, the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria are poorly understood.
33358569	5	48	theme	phosphatidylinositol-	888:908	arg1	-triphosphate					916:928	phosphatidylinositol-(3,4,5)-triphosphate	888:928	phosphatidylinositol-(3,4,5)-triphosphate (PIP3)	888:935	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	48	theme	phosphatidylinositol-	888:908	arg1	phospholipid					874:885	a negatively charged phospholipid	853:885	a negatively charged phospholipid	853:885	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	48	theme	phosphatidylinositol-	888:908	arg1	PIP3					931:934	PIP3	931:934	PIP3	931:934	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	4	49	theme	host	717:720	arg1	surfaces					727:734	host cell surfaces	717:734	host cell surfaces	717:734	However, the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria are poorly understood.
33358569	8	50	theme	secretion	1442:1450	arg1	system					1452:1457	bacterial type 3 secretion system	1425:1457	bacterial type 3 secretion system (T3SS)	1425:1464	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	50	theme	secretion	1442:1450	arg1	T3SS					1460:1463	T3SS	1460:1463	T3SS	1460:1463	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	51	theme	IL-1β	1505:1509	arg1	response					1511:1518	the IL-1β response	1501:1518	the IL-1β response of host innate immune cells	1501:1546	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	1	52	theme	Phagocytic	140:149	arg1	cells					151:155	Phagocytic cells	140:155	Phagocytic cells	140:155	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	0	53	theme	motility-dependent	52:69	arg1	binding					71:77	binding	71:77	binding	71:77	Identification of cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes.
33358569	8	54	theme	bacterial	1425:1433	arg1	system					1452:1457	bacterial type 3 secretion system	1425:1457	bacterial type 3 secretion system (T3SS)	1425:1464	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	54	theme	bacterial	1425:1433	arg1	T3SS					1460:1463	T3SS	1460:1463	T3SS	1460:1463	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	55	theme	host	1523:1526	arg1	cells					1542:1546	host innate immune cells	1523:1546	host innate immune cells	1523:1546	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	7	56	theme	bacterial	1296:1304	arg1	binding					1306:1312	bacterial binding	1296:1312	bacterial binding of P. aeruginosa by human monocytic cells	1296:1354	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	2	57	theme	cystic	387:392	arg1	fibrosis					394:401	cystic fibrosis	387:401	cystic fibrosis	387:401	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	8	58	theme	immune	1535:1540	arg1	cells					1542:1546	host innate immune cells	1523:1546	host innate immune cells	1523:1546	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	7	59	theme	polyanionic	1239:1249	arg1	glycans					1260:1266	endogenous polyanionic N-linked glycans	1228:1266	endogenous polyanionic N-linked glycans	1228:1266	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	10	60	theme	host	1828:1831	arg1	responses					1847:1855	relevant host innate immune responses	1819:1855	relevant host innate immune responses	1819:1855	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	6	61	theme	cell-surface	1183:1194	arg1	polyanions					1196:1205	cell-surface polyanions	1183:1205	cell-surface polyanions	1183:1205	Thus, we hypothesized that the engagement of P. aeruginosa by phagocytic cells is mediated by motility-dependent interactions with cell-surface polyanions.
33358569	8	62	theme	specific	1363:1370	arg1	interactions					1372:1383	These specific interactions	1357:1383	These specific interactions	1357:1383	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	5	63	theme	bacteria	1042:1049	arg1	uptake					1028:1033	uptake	1028:1033	uptake of the bacteria	1028:1049	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	8	64	dep	P.	1397:1398	arg1	aeruginosa					1400:1409	aeruginosa	1400:1409	aeruginosa	1400:1409	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	2	65	theme	susceptible	292:302	arg1	individuals					304:314	susceptible individuals	292:314	susceptible individuals	292:314	Accordingly, susceptible individuals frequently have impaired innate immune responses, including those with cystic fibrosis or neutropenia.
33358569	10	66	theme	cell-surface	1784:1795	arg1	glycans					1797:1803	specific phagocyte cell-surface glycans	1765:1803	specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity	1765:1926	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	4	67	theme	phagocytic	749:758	arg1	uptake					760:765	phagocytic uptake	749:765	phagocytic uptake of the bacteria	749:781	However, the mechanistic bases for motility-dependent interactions between P. aeruginosa and host cell surfaces that lead to phagocytic uptake of the bacteria are poorly understood.
33358569	8	68	theme	type	1435:1438	arg1	system					1452:1457	bacterial type 3 secretion system	1425:1457	bacterial type 3 secretion system (T3SS)	1425:1464	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	68	theme	type	1435:1438	arg1	T3SS					1460:1463	T3SS	1460:1463	T3SS	1460:1463	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	1	69	theme	opportunistic	255:267	arg1	pathogen					269:276	an opportunistic pathogen	252:276	an opportunistic pathogen	252:276	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	1	69	theme	opportunistic	255:267	arg1	bacterium					234:242	a Gram-negative bacterium	218:242	a Gram-negative bacterium that is an opportunistic pathogen	218:276	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	1	69	theme	opportunistic	255:267	arg1	aeruginosa					206:215	Pseudomonas aeruginosa	194:215	Pseudomonas aeruginosa	194:215	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	8	70	theme	cellular	1475:1482	arg1	intoxication					1484:1495	bacterial type 3 secretion system (T3SS)-mediated cellular intoxication	1425:1495	bacterial type 3 secretion system (T3SS)-mediated cellular intoxication	1425:1495	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	8	71	theme	innate	1528:1533	arg1	cells					1542:1546	host innate immune cells	1523:1546	host innate immune cells	1523:1546	These specific interactions resulted in P. aeruginosa phagocytosis, bacterial type 3 secretion system (T3SS)-mediated cellular intoxication and the IL-1β response of host innate immune cells.
33358569	5	72	theme	3,4,5	910:914	arg1	-triphosphate					916:928	phosphatidylinositol-(3,4,5)-triphosphate	888:928	phosphatidylinositol-(3,4,5)-triphosphate (PIP3)	888:935	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	72	theme	3,4,5	910:914	arg1	phospholipid					874:885	a negatively charged phospholipid	853:885	a negatively charged phospholipid	853:885	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	5	72	theme	3,4,5	910:914	arg1	PIP3					931:934	PIP3	931:934	PIP3	931:934	A recent insight is that exogenous addition of a negatively charged phospholipid, phosphatidylinositol-(3,4,5)-triphosphate (PIP3), promotes the engagement of non-motile strains of P. aeruginosa with phagocytes leading to uptake of the bacteria.
33358569	7	73	theme	monocytic	1340:1348	arg1	cells					1350:1354	human monocytic cells	1334:1354	human monocytic cells	1334:1354	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	10	74	theme	specific	1765:1772	arg1	glycans					1797:1803	specific phagocyte cell-surface glycans	1765:1803	specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity	1765:1926	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	10	75	theme	phagocyte	1774:1782	arg1	glycans					1797:1803	specific phagocyte cell-surface glycans	1765:1803	specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity	1765:1926	Therefore, this work describes novel interactions of P. aeruginosa with specific phagocyte cell-surface glycans that modulate relevant host innate immune responses to the bacteria, including phagocytosis, inflammation and cytotoxicity.
33358569	7	76	theme	aeruginosa	1320:1329	arg1	binding					1306:1312	bacterial binding	1296:1312	bacterial binding of P. aeruginosa by human monocytic cells	1296:1354	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	7	77	theme	heparan	1272:1278	arg1	sulfate					1280:1286	heparan sulfate	1272:1286	heparan sulfate	1272:1286	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	7	78	theme	N-linked	1251:1258	arg1	glycans					1260:1266	endogenous polyanionic N-linked glycans	1228:1266	endogenous polyanionic N-linked glycans	1228:1266	Here we report that endogenous polyanionic N-linked glycans and heparan sulfate mediate bacterial binding of P. aeruginosa by human monocytic cells.
33358569	1	79	theme	host	173:176	arg1	defense					178:184	host defense	173:184	host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen	173:276	Phagocytic cells are critical to host defense against Pseudomonas aeruginosa, a Gram-negative bacterium that is an opportunistic pathogen.
33358569	0	80	theme	aeruginosa	114:123	arg1	internalization					83:97	internalization	83:97	internalization	83:97	Identification of cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes.
33358569	0	80	theme	aeruginosa	114:123	arg1	binding					71:77	binding	71:77	binding	71:77	Identification of cell-surface glycans that mediate motility-dependent binding and internalization of Pseudomonas aeruginosa by phagocytes.
33119615	10	0	theme	mutant	1883:1888	arg1	line					1911:1914	mutant RAGE expressing cell line	1883:1914	mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1883:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	6	1	theme	SHSY5Y	1164:1169	arg1	line					1176:1179	SHSY5Y cell line	1164:1179	SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations	1164:1320	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	7	2	theme	binding	1333:1339	arg1	method					1350:1355	Saturated binding kinetics method	1323:1355	Saturated binding kinetics method	1323:1355	Saturated binding kinetics method was adopted to determine the Kd values for Aβ42 binding to RAGE.
33119615	10	3	theme	IL6	1876:1878	arg1	expression					1853:1862	enhanced expression	1844:1862	enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1844:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	5	4	from	pocket	921:926	arg1	variants					961:968	mutant G82S glycosylated RAGE variants	931:968	mutant G82S glycosylated RAGE variants	931:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	9	5	theme	higher	1702:1707	arg1	affinity					1709:1716	higher affinity	1702:1716	higher affinity compared to WT	1702:1731	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	4	6	theme	global	769:774	arg1	changes					787:793	the global structural changes	765:793	the global structural changes	765:793	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	10	7	theme	expressing	1895:1904	arg1	line					1911:1914	mutant RAGE expressing cell line	1883:1914	mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1883:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	3	8	dep	linked	549:554	arg1	N					547:547	N	547:547	N	547:547	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	10	9	theme	mechanistic	1930:1940	arg1	view					1942:1945	a mechanistic view	1928:1945	a mechanistic view for the G82S RAGE association with AD	1928:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	6	10	theme	RAGE	1219:1222	arg1	variant					1224:1230	mutated RAGE variant	1211:1230	mutated RAGE variant	1211:1230	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	1	11	theme	Alzheimers	201:210	arg1	AD					220:221	AD	220:221	AD	220:221	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	1	11	theme	Alzheimers	201:210	arg1	disease					212:218	Alzheimers disease	201:218	Alzheimers disease(AD)	201:222	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	6	12	theme	in	1123:1124	arg1	study					1140:1144	an in vitro binding study	1120:1144	an in vitro binding study	1120:1144	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	3	13	theme	linked	549:554	arg1	glycosylation					556:568	N linked glycosylation	547:568	N linked glycosylation at residue N81	547:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	10	14	theme	G82S	1955:1958	arg1	association					1965:1975	the G82S RAGE association	1951:1975	the G82S RAGE association with AD	1951:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	6	15	theme	recombinant	1192:1202	arg1	WT					1204:1205	recombinant WT	1192:1205	recombinant WT	1192:1205	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	1	16	theme	end	135:137	arg1	products					139:146	advanced glycation end products	116:146	advanced glycation end products (RAGE)	116:153	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	1	16	theme	end	135:137	arg1	RAGE					149:152	RAGE	149:152	RAGE	149:152	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	6	17	theme	above	1105:1109	arg1	concept					1111:1117	the above concept	1101:1117	the above concept	1101:1117	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	10	18	theme	pathway	1819:1825	arg1	activation					1788:1797	activation	1788:1797	activation of the inflammatory pathway	1788:1825	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	8	19	dep	152nM	1505:1509	arg1	to					1502:1503	to	1502:1503	to	1502:1503	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	4	20	theme	dynamics	645:652	arg1	simulations					659:669	molecular dynamics (MD) simulations	635:669	molecular dynamics (MD) simulations	635:669	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	10	21	theme	enhanced	1844:1851	arg1	expression					1853:1862	enhanced expression	1844:1862	enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1844:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	0	22	theme	disease	84:90	arg1	pathology					92:100	Alzheimer's disease pathology	72:100	Alzheimer's disease pathology	72:100	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
33119615	8	23	dep	%	1494:1494	arg1	R2-0.92					1512:1518	R2-0.92	1512:1518	95% CI-52 to 152nM; R2-0.92	1492:1518	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	10	24	from	alteration	1738:1747	arg1	affinity					1760:1767	binding affinity	1752:1767	binding affinity	1752:1767	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	4	25	theme	wild	697:700	arg1	WT					708:709	WT	708:709	WT	708:709	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	4	25	theme	wild	697:700	arg1	type					702:705	the wild type	693:705	the wild type (WT)	693:710	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	5	26	theme	MD	880:881	arg1	trajectory					883:892	the MD trajectory	876:892	the MD trajectory	876:892	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	0	27	from	relevant	60:67	arg1	pathology					92:100	Alzheimer's disease pathology	72:100	Alzheimer's disease pathology	72:100	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
33119615	9	28	theme	<100nM	1595:1600	arg1	value					1586:1590	The Kd value	1579:1590	The Kd value of <100nM observed for both variants	1579:1627	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	8	29	dep	CI	1539:1540	arg1	to					1546:1547	to	1546:1547	to	1546:1547	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	8	29	dep	CI	1539:1540	arg1	R2-0.93					1555:1561	R2-0.93	1555:1561	R2-0.93	1555:1561	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	0	30	theme	G82S	0:3	arg1	polymorphism					10:21	G82S RAGE polymorphism	0:21	G82S RAGE polymorphism	0:21	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
33119615	5	31	theme	RAGE	1076:1079	arg1	affinity					1064:1071	the affinity	1060:1071	the affinity of RAGE for Aβ	1060:1086	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	5	32	theme	pocket	857:862	arg1	analysis					864:871	Binding pocket analysis	849:871	Binding pocket analysis of the MD trajectory	849:892	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	4	33	with	efficiency	819:828	arg1	peptide					840:846	Aβ42 peptide	835:846	Aβ42 peptide	835:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	1	34	theme	advanced	116:123	arg1	products					139:146	advanced glycation end products	116:146	advanced glycation end products (RAGE)	116:153	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	1	34	theme	advanced	116:123	arg1	RAGE					149:152	RAGE	149:152	RAGE	149:152	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	8	35	theme	Aβ42-	1439:1443	arg1	WT					1445:1446	Aβ42- WT	1439:1446	Aβ42- WT	1439:1446	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	3	36	theme	previous	423:430	arg1	study					442:446	Our previous in silico study	419:446	Our previous in silico study	419:446	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	0	37	theme	amyloid-RAGE	34:45	arg1	interactions					47:58	amyloid-RAGE interactions	34:58	amyloid-RAGE interactions relevant in Alzheimer's disease pathology	34:100	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
33119615	6	38	theme	different	1297:1305	arg1	concentrations					1307:1320	different concentrations	1297:1320	different concentrations	1297:1320	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	5	39	theme	G82S	938:941	arg1	variants					961:968	mutant G82S glycosylated RAGE variants	931:968	mutant G82S glycosylated RAGE variants	931:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	4	40	theme	RAGE	748:751	arg1	structures					734:743	the wild type (WT) and G82S glycosylated structures	693:743	the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide	693:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	3	41	theme	higher	460:465	arg1	affinity					475:482	a higher binding affinity	458:482	a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81	458:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	0	42	theme	relevant	60:67	arg1	interactions					47:58	amyloid-RAGE interactions	34:58	amyloid-RAGE interactions relevant in Alzheimer's disease pathology	34:100	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
33119615	1	43	theme	inflammatory	283:294	arg1	response					296:303	inflammatory response	283:303	inflammatory response	283:303	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	5	44	theme	RAGE	956:959	arg1	variants					961:968	mutant G82S glycosylated RAGE variants	931:968	mutant G82S glycosylated RAGE variants	931:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	8	45	theme	RAGE	1464:1467	arg1	binding					1469:1475	Aβ42-mutant RAGE binding	1452:1475	Aβ42-mutant RAGE binding	1452:1475	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	2	46	theme	G82S	306:309	arg1	polymorphism					316:327	G82S RAGE polymorphism	306:327	G82S RAGE polymorphism	306:327	G82S RAGE polymorphism is associated with AD but the molecular mechanism for this association is not understood.
33119615	5	47	theme	cavity/binding	906:919	arg1	pocket					921:926	cavity/binding pocket	906:926	cavity/binding pocket in mutant G82S glycosylated RAGE variants	906:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	4	48	theme	G82S	716:719	arg1	structures					734:743	the wild type (WT) and G82S glycosylated structures	693:743	the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide	693:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	3	49	theme	mutated	488:494	arg1	RAGE					501:504	mutated G82S RAGE	488:504	mutated G82S RAGE	488:504	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	7	50	theme	Kd	1386:1387	arg1	values					1389:1394	the Kd values	1382:1394	the Kd values for Aβ42 binding to RAGE	1382:1419	Saturated binding kinetics method was adopted to determine the Kd values for Aβ42 binding to RAGE.
33119615	10	51	theme	RAGE	1890:1893	arg1	line					1911:1914	mutant RAGE expressing cell line	1883:1914	mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1883:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	6	52	theme	cell	1171:1174	arg1	line					1176:1179	SHSY5Y cell line	1164:1179	SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations	1164:1320	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	4	53	theme	structural	776:785	arg1	changes					787:793	the global structural changes	765:793	the global structural changes	765:793	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	9	54	theme	mutant	1686:1691	arg1	RAGE					1693:1696	mutant RAGE	1686:1696	mutant RAGE	1686:1696	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	9	55	contain	has	1698:1700	arg2	affinity					1709:1716	higher affinity	1702:1716	higher affinity compared to WT	1702:1731	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	9	55	contain	has	1698:1700	arg1	RAGE					1693:1696	mutant RAGE	1686:1696	mutant RAGE	1686:1696	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	8	56	theme	%	1537:1537	arg1	CI					1539:1540	95% CI -29 to 64nM	1535:1552	95% CI -29 to 64nM	1535:1552	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	8	56	theme	%	1537:1537	arg1	nM					1531:1532	45±20 nM	1525:1532	45±20 nM (95% CI -29 to 64nM; R2-0.93)	1525:1562	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	4	57	used	used	676:679	arg2	simulations					659:669	molecular dynamics (MD) simulations	635:669	molecular dynamics (MD) simulations	635:669	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	7	58	theme	kinetics	1341:1348	arg1	method					1350:1355	Saturated binding kinetics method	1323:1355	Saturated binding kinetics method	1323:1355	Saturated binding kinetics method was adopted to determine the Kd values for Aβ42 binding to RAGE.
33119615	7	59	theme	Saturated	1323:1331	arg1	method					1350:1355	Saturated binding kinetics method	1323:1355	Saturated binding kinetics method	1323:1355	Saturated binding kinetics method was adopted to determine the Kd values for Aβ42 binding to RAGE.
33119615	10	60	theme	cell	1906:1909	arg1	line					1911:1914	mutant RAGE expressing cell line	1883:1914	mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1883:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	6	61	theme	Fluor	1261:1265	arg1	Aβ42					1275:1278	HiLyte Fluor labeled Aβ42	1254:1278	HiLyte Fluor labeled Aβ42	1254:1278	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	6	62	theme	binding	1132:1138	arg1	study					1140:1144	an in vitro binding study	1120:1144	an in vitro binding study	1120:1144	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	3	63	gly	glycosylation	556:568	arg2	residue					573:579	residue N81	573:583	residue N81	573:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	3	63	gly	glycosylation	556:568	arg1	residue					573:579	residue N81	573:583	residue N81	573:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	10	64	theme	binding	1752:1758	arg1	affinity					1760:1767	binding affinity	1752:1767	binding affinity	1752:1767	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	0	65	from	pathology	92:100	arg1	relevant					60:67	relevant	60:67	relevant	60:67	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
33119615	2	66	theme	RAGE	311:314	arg1	polymorphism					316:327	G82S RAGE polymorphism	306:327	G82S RAGE polymorphism	306:327	G82S RAGE polymorphism is associated with AD but the molecular mechanism for this association is not understood.
33119615	6	67	theme	mutated	1211:1217	arg1	variant					1224:1230	mutated RAGE variant	1211:1230	mutated RAGE variant	1211:1230	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	1	68	theme	disease	212:218	arg1	pathophysiology					182:196	the pathophysiology	178:196	the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response	178:303	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	10	69	theme	RAGE	1960:1963	arg1	association					1965:1975	the G82S RAGE association	1951:1975	the G82S RAGE association with AD	1951:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	5	70	theme	external	1004:1011	arg1	ligands					1013:1019	external ligands	1004:1019	external ligands	1004:1019	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	1	71	theme	glycation	125:133	arg1	products					139:146	advanced glycation end products	116:146	advanced glycation end products (RAGE)	116:153	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	1	71	theme	glycation	125:133	arg1	RAGE					149:152	RAGE	149:152	RAGE	149:152	Receptor for advanced glycation end products (RAGE) has been implicated in the pathophysiology of Alzheimers disease(AD) due to its ability to bind amyloid-beta (Aβ42) and mediate inflammatory response.
33119615	4	72	theme	binding	811:817	arg1	efficiency					819:828	the binding efficiency	807:828	the binding efficiency with Aβ42 peptide	807:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	10	73	theme	inflammatory	1806:1817	arg1	pathway					1819:1825	the inflammatory pathway	1802:1825	the inflammatory pathway	1802:1825	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	10	74	theme	TNFα	1867:1870	arg1	expression					1853:1862	enhanced expression	1844:1862	enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1844:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	4	75	theme	present	621:627	arg1	study					629:633	the present study	617:633	the present study	617:633	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	6	76	theme	labeled	1267:1273	arg1	Aβ42					1275:1278	HiLyte Fluor labeled Aβ42	1254:1278	HiLyte Fluor labeled Aβ42	1254:1278	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	4	77	theme	molecular	635:643	arg1	MD					655:656	MD	655:656	MD	655:656	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	4	77	theme	molecular	635:643	arg1	dynamics					645:652	molecular dynamics	635:652	molecular dynamics (MD) simulations	635:669	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	6	78	theme	HiLyte	1254:1259	arg1	Aβ42					1275:1278	HiLyte Fluor labeled Aβ42	1254:1278	HiLyte Fluor labeled Aβ42	1254:1278	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	3	79	dep	in	432:433	arg1	silico					435:440	silico	435:440	silico	435:440	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	9	80	theme	Kd	1583:1584	arg1	value					1586:1590	The Kd value	1579:1590	The Kd value of <100nM observed for both variants	1579:1627	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	10	81	from	expression	1853:1862	arg1	line					1911:1914	mutant RAGE expressing cell line	1883:1914	mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD	1883:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	8	82	dep	nM	1488:1489	arg1	%					1494:1494	95% CI-52 to 152nM	1492:1509	95% CI-52 to 152nM; R2-0.92	1492:1518	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	5	83	theme	trajectory	883:892	arg1	analysis					864:871	Binding pocket analysis	849:871	Binding pocket analysis of the MD trajectory	849:892	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	8	84	theme	Kd	1426:1427	arg1	nM					1488:1489	92±40 nM	1482:1489	92±40 nM (95% CI-52 to 152nM; R2-0.92)	1482:1519	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	8	84	theme	Kd	1426:1427	arg1	value					1429:1433	The Kd value	1422:1433	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding	1422:1475	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	4	85	theme	type	702:705	arg1	structures					734:743	the wild type (WT) and G82S glycosylated structures	693:743	the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide	693:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	3	86	from	residue	573:579	arg1	changes					536:542	changes	536:542	changes in N linked glycosylation at residue N81	536:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	3	86	from	residue	573:579	arg1	glycosylation					556:568	N linked glycosylation	547:568	N linked glycosylation at residue N81	547:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	2	87	theme	molecular	359:367	arg1	mechanism					369:377	the molecular mechanism	355:377	the molecular mechanism for this association	355:398	G82S RAGE polymorphism is associated with AD but the molecular mechanism for this association is not understood.
33119615	4	88	gly	glycosylated	721:732	arg1	structures					734:743	the wild type (WT) and G82S glycosylated structures	693:743	the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide	693:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	5	89	theme	WT	1033:1034	arg1	RAGE					1036:1039	WT RAGE	1033:1039	WT RAGE	1033:1039	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	5	90	theme	Binding	849:855	arg1	analysis					864:871	Binding pocket analysis	849:871	Binding pocket analysis of the MD trajectory	849:892	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	3	91	from	changes	536:542	arg1	residue					573:579	residue N81	573:583	residue N81	573:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	3	91	from	changes	536:542	arg1	glycosylation					556:568	N linked glycosylation	547:568	N linked glycosylation at residue N81	547:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	5	92	gly	glycosylated	943:954	arg1	variants					961:968	mutant G82S glycosylated RAGE variants	931:968	mutant G82S glycosylated RAGE variants	931:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	10	93	with	association	1965:1975	arg1	AD					1982:1983	AD	1982:1983	AD	1982:1983	The alteration in binding affinity is responsible for activation of the inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association with AD.
33119615	4	94	dep	structures	734:743	arg1	find					802:805	find	802:805	to find the binding efficiency with Aβ42 peptide	799:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	4	94	dep	structures	734:743	arg1	identify					756:763	identify	756:763	to identify the global structural changes	753:793	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	5	95	theme	mutant	931:936	arg1	variants					961:968	mutant G82S glycosylated RAGE variants	931:968	mutant G82S glycosylated RAGE variants	931:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	8	96	theme	Aβ42-mutant	1452:1462	arg1	binding					1469:1475	Aβ42-mutant RAGE binding	1452:1475	Aβ42-mutant RAGE binding	1452:1475	The Kd value for Aβ42- WT and Aβ42-mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R2-0.92) and 45±20 nM (95% CI -29 to 64nM; R2-0.93), respectively.
33119615	4	97	theme	glycosylated	721:732	arg1	structures					734:743	the wild type (WT) and G82S glycosylated structures	693:743	the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide	693:846	To confirm this hypothesis, in the present study molecular dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated structures of RAGE to identify the global structural changes and to find the binding efficiency with Aβ42 peptide.
33119615	3	98	theme	in	432:433	arg1	study					442:446	Our previous in silico study	419:446	Our previous in silico study	419:446	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	5	99	theme	glycosylated	943:954	arg1	variants					961:968	mutant G82S glycosylated RAGE variants	931:968	mutant G82S glycosylated RAGE variants	931:968	Binding pocket analysis of the MD trajectory showed that cavity/binding pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ.
33119615	3	100	link	linked	549:554	arg1	glycosylation					556:568	N linked glycosylation	547:568	N linked glycosylation at residue N81	547:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	3	101	theme	binding	467:473	arg1	affinity					475:482	a higher binding affinity	458:482	a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81	458:583	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	9	102	theme	high-affinity	1650:1662	arg1	receptor					1664:1671	a high-affinity receptor	1648:1671	a high-affinity receptor for Aβ42	1648:1680	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	9	102	theme	high-affinity	1650:1662	arg1	RAGE					1640:1643	RAGE	1640:1643	RAGE	1640:1643	The Kd value of <100nM observed for both variants implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity compared to WT.
33119615	3	103	theme	G82S	496:499	arg1	RAGE					501:504	mutated G82S RAGE	488:504	mutated G82S RAGE	488:504	Our previous in silico study indicated a higher binding affinity for mutated G82S RAGE, which could be caused due to changes in N linked glycosylation at residue N81.
33119615	6	104	dep	in	1123:1124	arg1	vitro					1126:1130	vitro	1126:1130	vitro	1126:1130	To validate the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 was incubated at different concentrations.
33119615	7	105	theme	Aβ42	1400:1403	arg1	binding					1405:1411	Aβ42 binding	1400:1411	Aβ42 binding to RAGE	1400:1419	Saturated binding kinetics method was adopted to determine the Kd values for Aβ42 binding to RAGE.
33119615	0	106	theme	RAGE	5:8	arg1	polymorphism					10:21	G82S RAGE polymorphism	0:21	G82S RAGE polymorphism	0:21	G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer's disease pathology.
34399822	4	0	theme	potential	634:642	arg1	mechanisms					644:653	the potential mechanisms	630:653	the potential mechanisms	630:653	However, the potential mechanisms are not fully understood.
34399822	5	1	theme	necroptosis	713:723	arg1	role					705:708	the crucial role	693:708	the crucial role of necroptosis in the pathogenesis of IBD	693:750	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	12	2	theme	colonic	1809:1815	arg1	responses					1830:1838	colonic inflammatory responses	1809:1838	colonic inflammatory responses	1809:1838	WMW obviously alleviated colonic inflammatory responses with reduced macrophages, neutrophils infiltration and local IL-1β, IL-6, TNF-α and IFN-γ levels.
34399822	10	3	theme	OGA	1620:1622	arg1	activities					1624:1633	OGT and OGA activities	1612:1633	OGT and OGA activities	1612:1633	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	7	4	theme	cytokines	1154:1162	arg1	levels					1164:1169	local cytokines levels	1148:1169	local cytokines levels	1148:1169	Colonic inflammation was examined by inflammatory cells infiltration and local cytokines levels.
34399822	10	5	theme	O-GlcNAc	1447:1454	arg1	transferase					1456:1466	O-GlcNAc transferase	1447:1466	O-GlcNAc transferase (OGT)	1447:1472	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	5	theme	O-GlcNAc	1447:1454	arg1	enzymes					1419:1425	the key enzymes	1411:1425	the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA)	1411:1494	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	5	theme	O-GlcNAc	1447:1454	arg1	OGT					1469:1471	OGT	1469:1471	OGT	1469:1471	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	3	6	theme	mouse	606:610	arg1	colitis					612:618	mouse colitis	606:618	mouse colitis	606:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	10	7	dep	enzymes	1419:1425	arg1	transferase					1456:1466	O-GlcNAc transferase	1447:1466	O-GlcNAc transferase (OGT)	1447:1472	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	7	dep	enzymes	1419:1425	arg1	enzymes					1419:1425	the key enzymes	1411:1425	the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA)	1411:1494	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	7	dep	enzymes	1419:1425	arg1	OGA					1491:1493	OGA	1491:1493	OGA	1491:1493	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	7	dep	enzymes	1419:1425	arg1	OGT					1469:1471	OGT	1469:1471	OGT	1469:1471	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	7	dep	enzymes	1419:1425	arg1	O-GlcNAcase					1478:1488	O-GlcNAcase	1478:1488	O-GlcNAcase (OGA)	1478:1494	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	16	8	theme	TNBS-induced	2503:2514	arg1	colitis					2516:2522	TNBS-induced colitis	2503:2522	TNBS-induced colitis in mice	2503:2530	CONCLUSION Our work demonstrated that WMW can alleviate TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	11	9	dep	RESULTS	1636:1642	arg1	showed					1656:1661	showed	1656:1661	showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis	1656:1781	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	10	10	theme	OGT	1612:1614	arg1	activities					1624:1633	OGT and OGA activities	1612:1633	OGT and OGA activities	1612:1633	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	9	11	theme	C	1243:1243	arg1	experiments					1267:1277	C O-immunoprecipitation experiments	1243:1277	C O-immunoprecipitation experiments	1243:1277	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	1	12	theme	essential	215:223	arg1	role					225:228	an essential role	212:228	an essential role	212:228	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	5	13	from	role	705:708	arg1	pathogenesis					732:743	the pathogenesis	728:743	the pathogenesis of IBD	728:750	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	7	14	theme	cells	1125:1129	arg1	infiltration					1131:1142	inflammatory cells infiltration	1112:1142	inflammatory cells infiltration	1112:1142	Colonic inflammation was examined by inflammatory cells infiltration and local cytokines levels.
34399822	2	15	theme	signal	361:366	arg1	kinase					415:420	necroptotic signal molecule receptor-interacting serine-threonine kinase 3	349:422	necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	349:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	15	theme	signal	361:366	arg1	RIPK3					425:429	RIPK3	425:429	RIPK3	425:429	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	6	16	theme	disease	1013:1019	arg1	DAI					1037:1039	DAI	1037:1039	DAI	1037:1039	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	16	theme	disease	1013:1019	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	16	theme	disease	1013:1019	arg1	index					1030:1034	disease activity index	1013:1034	disease activity index (DAI)	1013:1040	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	14	17	theme	RIPK3	2221:2225	arg1	binding					2210:2216	the binding	2206:2216	the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis	2206:2278	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	5	18	theme	related	884:890	arg1	mechanisms					892:901	its related mechanisms	880:901	its related mechanisms	880:901	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	14	19	dep	enhanced	2099:2106	arg1	inhibiting					2195:2204	inhibiting	2195:2204	inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis	2195:2278	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	14	19	dep	enhanced	2099:2106	arg1	increasing					2158:2167	increasing	2158:2167	increasing RIPK3 O-GlcNAcylation	2158:2189	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	1	20	theme	inflammatory	253:264	arg1	IBD					281:283	IBD	281:283	IBD	281:283	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	1	20	theme	inflammatory	253:264	arg1	disease					272:278	inflammatory bowel disease	253:278	inflammatory bowel disease (IBD)	253:284	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	6	21	dep	mice	995:998	arg1	DAI					1037:1039	DAI	1037:1039	DAI	1037:1039	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	21	dep	mice	995:998	arg1	length					1067:1072	colon length	1061:1072	colon length	1061:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	21	dep	mice	995:998	arg1	weight					1005:1010	body weight	1000:1010	body weight	1000:1010	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	21	dep	mice	995:998	arg1	rate					1052:1055	survival rate	1043:1055	survival rate	1043:1055	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	21	dep	mice	995:998	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	21	dep	mice	995:998	arg1	index					1030:1034	disease activity index	1013:1034	disease activity index (DAI)	1013:1040	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	7	22	theme	Colonic	1075:1081	arg1	inflammation					1083:1094	Colonic inflammation	1075:1094	Colonic inflammation	1075:1094	Colonic inflammation was examined by inflammatory cells infiltration and local cytokines levels.
34399822	9	23	theme	elevated	1308:1315	arg1	O-GlcNAcylation					1317:1331	elevated O-GlcNAcylation	1308:1331	elevated O-GlcNAcylation	1308:1331	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	1	24	theme	BACKGROUND	146:155	arg1	evidence					170:177	BACKGROUND Accumulating evidence	146:177	BACKGROUND Accumulating evidence	146:177	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	3	25	theme	traditional	522:532	arg1	Wu-Mei-Wan					557:566	traditional Chinese herbal formula Wu-Mei-Wan	522:566	traditional Chinese herbal formula Wu-Mei-Wan (WMW)	522:572	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	25	theme	traditional	522:532	arg1	prescription					590:601	an effective prescription	577:601	an effective prescription in mouse colitis	577:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	25	theme	traditional	522:532	arg1	WMW					569:571	WMW	569:571	WMW	569:571	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	13	26	theme	O-GlcNAcylation	1978:1992	arg1	level					1994:1998	colonic O-GlcNAcylation level	1970:1998	colonic O-GlcNAcylation level	1970:1998	It was found that WMW increased colonic O-GlcNAcylation level and inhibited the activation of RIPK1, RIPK3 and MLKL.
34399822	9	27	theme	necroptotic	1345:1355	arg1	transduction					1364:1375	necroptotic signal transduction	1345:1375	necroptotic signal transduction	1345:1375	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	3	28	from	prescription	590:601	arg1	colitis					612:618	mouse colitis	606:618	mouse colitis	606:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	14	29	theme	RIPK3	2169:2173	arg1	O-GlcNAcylation					2175:2189	RIPK3 O-GlcNAcylation	2169:2189	RIPK3 O-GlcNAcylation	2169:2189	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	13	30	theme	RIPK1	2032:2036	arg1	activation					2018:2027	the activation	2014:2027	the activation of RIPK1, RIPK3 and MLKL	2014:2052	It was found that WMW increased colonic O-GlcNAcylation level and inhibited the activation of RIPK1, RIPK3 and MLKL.
34399822	2	31	link	O-linked	291:298	arg1	O-GlcNAcylation					329:343	O-GlcNAcylation	329:343	O-GlcNAcylation	329:343	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	31	link	O-linked	291:298	arg1	β-N-acetylglucosaminylation					300:326	The O-linked β-N-acetylglucosaminylation	287:326	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	287:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	14	32	theme	further	2061:2067	arg1	experiments					2069:2079	further experiments	2061:2079	further experiments	2061:2079	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	0	33	from	colitis	62:68	arg1	mice					73:76	mice	73:76	mice	73:76	Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	10	34	theme	docking	1524:1530	arg1	analysis					1532:1539	molecular docking analysis	1514:1539	molecular docking analysis	1514:1539	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	0	35	theme	RIPK3	123:127	arg1	O-GlcNAcylation					129:143	RIPK3 O-GlcNAcylation	123:143	RIPK3 O-GlcNAcylation	123:143	Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	0	36	theme	Traditional	0:10	arg1	Wu-Mei-Wan					27:36	Traditional herbal formula Wu-Mei-Wan	0:36	Traditional herbal formula Wu-Mei-Wan	0:36	Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	11	37	dep	improved	1686:1693	arg1	decreased					1745:1753	decreased	1745:1753	decreased DAI in TNBS-induced colitis	1745:1781	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	14	38	theme	suppressed	2125:2134	arg1	activity					2140:2147	suppressed OGA activity	2125:2147	suppressed OGA activity	2125:2147	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	2	39	theme	gut	477:479	arg1	inflammation					481:492	gut inflammation	477:492	gut inflammation	477:492	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	0	40	theme	formula	19:25	arg1	Wu-Mei-Wan					27:36	Traditional herbal formula Wu-Mei-Wan	0:36	Traditional herbal formula Wu-Mei-Wan	0:36	Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	5	41	theme	WMW	834:836	arg1	effect					824:829	the anti-colitis effect	807:829	the anti-colitis effect of WMW	807:836	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	15	42	theme	docking	2295:2301	arg1	analysis					2303:2310	docking analysis	2295:2310	docking analysis	2295:2310	Additionally, docking analysis demonstrated that hesperidin, coptisine and ginsenoside Rb1 may exert a major role in the regulation on OGT and OGA activities by WMW.
34399822	6	43	theme	colon	1061:1065	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	43	theme	colon	1061:1065	arg1	length					1067:1072	colon length	1061:1072	colon length	1061:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	10	44	used	used	1545:1548	arg2	analysis					1532:1539	molecular docking analysis	1514:1539	molecular docking analysis	1514:1539	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	6	45	dep	METHODS	904:910	arg1	effects					927:933	The protective effects	912:933	METHODS The protective effects of WMW on colitis	904:951	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	16	46	theme	RIPK3	2577:2581	arg1	O-GlcNAcylation					2583:2597	RIPK3 O-GlcNAcylation	2577:2597	RIPK3 O-GlcNAcylation	2577:2597	CONCLUSION Our work demonstrated that WMW can alleviate TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	10	47	theme	effective	1563:1571	arg1	compounds					1581:1589	effective natural compounds	1563:1589	effective natural compounds	1563:1589	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	2	48	theme	serine-threonine	398:413	arg1	kinase					415:420	necroptotic signal molecule receptor-interacting serine-threonine kinase 3	349:422	necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	349:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	48	theme	serine-threonine	398:413	arg1	RIPK3					425:429	RIPK3	425:429	RIPK3	425:429	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	1	49	theme	bowel	266:270	arg1	IBD					281:283	IBD	281:283	IBD	281:283	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	1	49	theme	bowel	266:270	arg1	disease					272:278	inflammatory bowel disease	253:278	inflammatory bowel disease (IBD)	253:284	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	9	50	used	used	1284:1287	arg2	experiments					1267:1277	C O-immunoprecipitation experiments	1243:1277	C O-immunoprecipitation experiments	1243:1277	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	12	51	theme	macrophages	1853:1863	arg1	infiltration					1878:1889	reduced macrophages, neutrophils infiltration	1845:1889	reduced macrophages, neutrophils infiltration	1845:1889	WMW obviously alleviated colonic inflammatory responses with reduced macrophages, neutrophils infiltration and local IL-1β, IL-6, TNF-α and IFN-γ levels.
34399822	10	52	theme	key	1415:1417	arg1	transferase					1456:1466	O-GlcNAc transferase	1447:1466	O-GlcNAc transferase (OGT)	1447:1472	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	52	theme	key	1415:1417	arg1	enzymes					1419:1425	the key enzymes	1411:1425	the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA)	1411:1494	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	52	theme	key	1415:1417	arg1	O-GlcNAcase					1478:1488	O-GlcNAcase	1478:1488	O-GlcNAcase (OGA)	1478:1494	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	15	53	theme	ginsenoside	2356:2366	arg1	Rb1					2368:2370	ginsenoside Rb1	2356:2370	ginsenoside Rb1	2356:2370	Additionally, docking analysis demonstrated that hesperidin, coptisine and ginsenoside Rb1 may exert a major role in the regulation on OGT and OGA activities by WMW.
34399822	7	54	theme	inflammatory	1112:1123	arg1	infiltration					1131:1142	inflammatory cells infiltration	1112:1142	inflammatory cells infiltration	1112:1142	Colonic inflammation was examined by inflammatory cells infiltration and local cytokines levels.
34399822	12	55	theme	inflammatory	1817:1828	arg1	responses					1830:1838	colonic inflammatory responses	1809:1838	colonic inflammatory responses	1809:1838	WMW obviously alleviated colonic inflammatory responses with reduced macrophages, neutrophils infiltration and local IL-1β, IL-6, TNF-α and IFN-γ levels.
34399822	7	56	theme	local	1148:1152	arg1	levels					1164:1169	local cytokines levels	1148:1169	local cytokines levels	1148:1169	Colonic inflammation was examined by inflammatory cells infiltration and local cytokines levels.
34399822	3	57	theme	effective	580:588	arg1	Wu-Mei-Wan					557:566	traditional Chinese herbal formula Wu-Mei-Wan	522:566	traditional Chinese herbal formula Wu-Mei-Wan (WMW)	522:572	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	57	theme	effective	580:588	arg1	prescription					590:601	an effective prescription	577:601	an effective prescription in mouse colitis	577:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	6	58	theme	WMW	938:940	arg1	effects					927:933	The protective effects	912:933	METHODS The protective effects of WMW on colitis	904:951	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	14	59	theme	MLKL	2231:2234	arg1	binding					2210:2216	the binding	2206:2216	the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis	2206:2278	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	11	60	theme	survival	1713:1720	arg1	rate					1722:1725	survival rate	1713:1725	survival rate	1713:1725	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	11	60	theme	survival	1713:1720	arg1	mice					1695:1698	mice body weight, survival rate and colon length	1695:1742	mice body weight, survival rate and colon length	1695:1742	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	5	61	theme	crucial	697:703	arg1	role					705:708	the crucial role	693:708	the crucial role of necroptosis in the pathogenesis of IBD	693:750	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	9	62	theme	O-immunoprecipitation	1245:1265	arg1	experiments					1267:1277	C O-immunoprecipitation experiments	1243:1277	C O-immunoprecipitation experiments	1243:1277	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	2	63	theme	molecule	368:375	arg1	kinase					415:420	necroptotic signal molecule receptor-interacting serine-threonine kinase 3	349:422	necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	349:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	63	theme	molecule	368:375	arg1	RIPK3					425:429	RIPK3	425:429	RIPK3	425:429	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	8	64	theme	necroptosis	1210:1220	arg1	levels					1200:1205	the levels	1196:1205	the levels of necroptosis and O-GlcNAcylation	1196:1240	After then, we measured the levels of necroptosis and O-GlcNAcylation.
34399822	6	65	theme	activity	1021:1028	arg1	DAI					1037:1039	DAI	1037:1039	DAI	1037:1039	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	65	theme	activity	1021:1028	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	65	theme	activity	1021:1028	arg1	index					1030:1034	disease activity index	1013:1034	disease activity index (DAI)	1013:1040	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	66	from	effects	927:933	arg1	colitis					945:951	colitis	945:951	colitis	945:951	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	2	67	theme	necroptotic	349:359	arg1	kinase					415:420	necroptotic signal molecule receptor-interacting serine-threonine kinase 3	349:422	necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	349:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	67	theme	necroptotic	349:359	arg1	RIPK3					425:429	RIPK3	425:429	RIPK3	425:429	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	8	68	theme	O-GlcNAcylation	1226:1240	arg1	levels					1200:1205	the levels	1196:1205	the levels of necroptosis and O-GlcNAcylation	1196:1240	After then, we measured the levels of necroptosis and O-GlcNAcylation.
34399822	15	69	theme	OGA	2424:2426	arg1	activities					2428:2437	OGT and OGA activities	2416:2437	OGT and OGA activities	2416:2437	Additionally, docking analysis demonstrated that hesperidin, coptisine and ginsenoside Rb1 may exert a major role in the regulation on OGT and OGA activities by WMW.
34399822	6	70	theme	body	1000:1003	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	70	theme	body	1000:1003	arg1	weight					1005:1010	body weight	1000:1010	body weight	1000:1010	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	15	71	theme	OGT	2416:2418	arg1	activities					2428:2437	OGT and OGA activities	2416:2437	OGT and OGA activities	2416:2437	Additionally, docking analysis demonstrated that hesperidin, coptisine and ginsenoside Rb1 may exert a major role in the regulation on OGT and OGA activities by WMW.
34399822	6	72	theme	colitis	987:993	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	72	theme	colitis	987:993	arg1	index					1030:1034	disease activity index	1013:1034	disease activity index (DAI)	1013:1040	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	72	theme	colitis	987:993	arg1	rate					1052:1055	survival rate	1043:1055	survival rate	1043:1055	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	72	theme	colitis	987:993	arg1	length					1067:1072	colon length	1061:1072	colon length	1061:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	72	theme	colitis	987:993	arg1	weight					1005:1010	body weight	1000:1010	body weight	1000:1010	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	5	73	theme	IBD	748:750	arg1	pathogenesis					732:743	the pathogenesis	728:743	the pathogenesis of IBD	728:750	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	2	74	theme	O-linked	291:298	arg1	O-GlcNAcylation					329:343	O-GlcNAcylation	329:343	O-GlcNAcylation	329:343	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	74	theme	O-linked	291:298	arg1	β-N-acetylglucosaminylation					300:326	The O-linked β-N-acetylglucosaminylation	287:326	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	287:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	16	75	dep	CONCLUSION	2447:2456	arg1	demonstrated					2467:2478	demonstrated	2467:2478	demonstrated that WMW can alleviate TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation	2467:2597	CONCLUSION Our work demonstrated that WMW can alleviate TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	1	76	theme	Accumulating	157:168	arg1	evidence					170:177	BACKGROUND Accumulating evidence	146:177	BACKGROUND Accumulating evidence	146:177	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	13	77	theme	colonic	1970:1976	arg1	level					1994:1998	colonic O-GlcNAcylation level	1970:1998	colonic O-GlcNAcylation level	1970:1998	It was found that WMW increased colonic O-GlcNAcylation level and inhibited the activation of RIPK1, RIPK3 and MLKL.
34399822	3	78	theme	herbal	542:547	arg1	Wu-Mei-Wan					557:566	traditional Chinese herbal formula Wu-Mei-Wan	522:566	traditional Chinese herbal formula Wu-Mei-Wan (WMW)	522:572	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	78	theme	herbal	542:547	arg1	prescription					590:601	an effective prescription	577:601	an effective prescription in mouse colitis	577:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	78	theme	herbal	542:547	arg1	WMW					569:571	WMW	569:571	WMW	569:571	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	6	79	theme	survival	1043:1050	arg1	mice					995:998	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	colitis mice body weight, disease activity index (DAI), survival rate and colon length	987:1072	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	6	79	theme	survival	1043:1050	arg1	rate					1052:1055	survival rate	1043:1055	survival rate	1043:1055	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	5	80	theme	anti-colitis	811:822	arg1	effect					824:829	the anti-colitis effect	807:829	the anti-colitis effect of WMW	807:836	Considering the crucial role of necroptosis in the pathogenesis of IBD, therefore, this study was designed to explain whether the anti-colitis effect of WMW is mediated by modulating necroptosis and its related mechanisms.
34399822	9	81	theme	signal	1357:1362	arg1	transduction					1364:1375	necroptotic signal transduction	1345:1375	necroptotic signal transduction	1345:1375	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	15	82	from	regulation	2402:2411	arg1	activities					2428:2437	OGT and OGA activities	2416:2437	OGT and OGA activities	2416:2437	Additionally, docking analysis demonstrated that hesperidin, coptisine and ginsenoside Rb1 may exert a major role in the regulation on OGT and OGA activities by WMW.
34399822	2	83	theme	receptor-interacting	377:396	arg1	kinase					415:420	necroptotic signal molecule receptor-interacting serine-threonine kinase 3	349:422	necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	349:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	83	theme	receptor-interacting	377:396	arg1	RIPK3					425:429	RIPK3	425:429	RIPK3	425:429	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	10	84	theme	molecular	1514:1522	arg1	analysis					1532:1539	molecular docking analysis	1514:1539	molecular docking analysis	1514:1539	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	15	85	theme	major	2384:2388	arg1	role					2390:2393	a major role	2382:2393	a major role	2382:2393	Additionally, docking analysis demonstrated that hesperidin, coptisine and ginsenoside Rb1 may exert a major role in the regulation on OGT and OGA activities by WMW.
34399822	3	86	theme	recent	499:504	arg1	study					506:510	Our recent study	495:510	Our recent study	495:510	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	0	87	theme	herbal	12:17	arg1	Wu-Mei-Wan					27:36	Traditional herbal formula Wu-Mei-Wan	0:36	Traditional herbal formula Wu-Mei-Wan	0:36	Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	9	88	theme	WMW	1397:1399	arg1	treatment					1384:1392	the treatment	1380:1392	the treatment of WMW	1380:1399	C O-immunoprecipitation experiments were used to address whether elevated O-GlcNAcylation can inhibit necroptotic signal transduction in the treatment of WMW.
34399822	14	89	theme	OGA	2136:2138	arg1	activity					2140:2147	suppressed OGA activity	2125:2147	suppressed OGA activity	2125:2147	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	11	90	dep	mice	1695:1698	arg1	weight					1705:1710	body weight	1700:1710	body weight	1700:1710	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	11	90	dep	mice	1695:1698	arg1	rate					1722:1725	survival rate	1713:1725	survival rate	1713:1725	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	11	90	dep	mice	1695:1698	arg1	length					1737:1742	colon length	1731:1742	colon length	1731:1742	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	11	90	dep	mice	1695:1698	arg1	mice					1695:1698	mice body weight, survival rate and colon length	1695:1742	mice body weight, survival rate and colon length	1695:1742	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	12	91	theme	IFN-γ	1924:1928	arg1	levels					1930:1935	IFN-γ levels	1924:1935	IFN-γ levels	1924:1935	WMW obviously alleviated colonic inflammatory responses with reduced macrophages, neutrophils infiltration and local IL-1β, IL-6, TNF-α and IFN-γ levels.
34399822	10	92	from	enzymes	1419:1425	arg1	O-GlcNAcylation					1430:1444	O-GlcNAcylation	1430:1444	O-GlcNAcylation	1430:1444	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	3	93	theme	Chinese	534:540	arg1	Wu-Mei-Wan					557:566	traditional Chinese herbal formula Wu-Mei-Wan	522:566	traditional Chinese herbal formula Wu-Mei-Wan (WMW)	522:572	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	93	theme	Chinese	534:540	arg1	prescription					590:601	an effective prescription	577:601	an effective prescription in mouse colitis	577:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	93	theme	Chinese	534:540	arg1	WMW					569:571	WMW	569:571	WMW	569:571	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	0	94	theme	TNBS-induced	49:60	arg1	colitis					62:68	TNBS-induced colitis	49:68	TNBS-induced colitis in mice	49:76	Traditional herbal formula Wu-Mei-Wan alleviates TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	6	95	theme	protective	916:925	arg1	effects					927:933	The protective effects	912:933	METHODS The protective effects of WMW on colitis	904:951	METHODS The protective effects of WMW on colitis have been determined by detecting colitis mice body weight, disease activity index (DAI), survival rate and colon length.
34399822	14	96	theme	OGT	2108:2110	arg1	activity					2112:2119	OGT activity	2108:2119	OGT activity	2108:2119	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	11	97	theme	colon	1731:1735	arg1	length					1737:1742	colon length	1731:1742	colon length	1731:1742	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	11	97	theme	colon	1731:1735	arg1	mice					1695:1698	mice body weight, survival rate and colon length	1695:1742	mice body weight, survival rate and colon length	1695:1742	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	2	98	theme	protective	456:465	arg1	effect					467:472	a protective effect	454:472	a protective effect	454:472	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	16	99	from	colitis	2516:2522	arg1	mice					2527:2530	mice	2527:2530	mice	2527:2530	CONCLUSION Our work demonstrated that WMW can alleviate TNBS-induced colitis in mice by inhibiting necroptosis through increasing RIPK3 O-GlcNAcylation.
34399822	10	100	from	regulation	1598:1607	arg1	activities					1624:1633	OGT and OGA activities	1612:1633	OGT and OGA activities	1612:1633	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	10	101	theme	natural	1573:1579	arg1	compounds					1581:1589	effective natural compounds	1563:1589	effective natural compounds	1563:1589	Finally, the key enzymes in O-GlcNAcylation: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) were examined and molecular docking analysis was used to determine effective natural compounds in the regulation on OGT and OGA activities.
34399822	11	102	theme	TNBS-induced	1762:1773	arg1	colitis					1775:1781	TNBS-induced colitis	1762:1781	TNBS-induced colitis	1762:1781	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	2	103	theme	kinase	415:420	arg1	O-GlcNAcylation					329:343	O-GlcNAcylation	329:343	O-GlcNAcylation	329:343	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	2	103	theme	kinase	415:420	arg1	β-N-acetylglucosaminylation					300:326	The O-linked β-N-acetylglucosaminylation	287:326	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3)	287:430	The O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) of necroptotic signal molecule receptor-interacting serine-threonine kinase 3 (RIPK3) was reported to exert a protective effect in gut inflammation.
34399822	12	104	theme	local	1895:1899	arg1	IL-1β					1901:1905	local IL-1β	1895:1905	local IL-1β	1895:1905	WMW obviously alleviated colonic inflammatory responses with reduced macrophages, neutrophils infiltration and local IL-1β, IL-6, TNF-α and IFN-γ levels.
34399822	13	105	theme	RIPK3	2039:2043	arg1	activation					2018:2027	the activation	2014:2027	the activation of RIPK1, RIPK3 and MLKL	2014:2052	It was found that WMW increased colonic O-GlcNAcylation level and inhibited the activation of RIPK1, RIPK3 and MLKL.
34399822	3	106	theme	formula	549:555	arg1	Wu-Mei-Wan					557:566	traditional Chinese herbal formula Wu-Mei-Wan	522:566	traditional Chinese herbal formula Wu-Mei-Wan (WMW)	522:572	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	106	theme	formula	549:555	arg1	prescription					590:601	an effective prescription	577:601	an effective prescription in mouse colitis	577:618	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	3	106	theme	formula	549:555	arg1	WMW					569:571	WMW	569:571	WMW	569:571	Our recent study suggested traditional Chinese herbal formula Wu-Mei-Wan (WMW) as an effective prescription in mouse colitis.
34399822	1	107	theme	disease	272:278	arg1	pathogenesis					237:248	the pathogenesis	233:248	the pathogenesis of inflammatory bowel disease (IBD)	233:284	BACKGROUND Accumulating evidence indicated that necroptosis plays an essential role in the pathogenesis of inflammatory bowel disease (IBD).
34399822	12	108	theme	reduced	1845:1851	arg1	infiltration					1878:1889	reduced macrophages, neutrophils infiltration	1845:1889	reduced macrophages, neutrophils infiltration	1845:1889	WMW obviously alleviated colonic inflammatory responses with reduced macrophages, neutrophils infiltration and local IL-1β, IL-6, TNF-α and IFN-γ levels.
34399822	14	109	theme	necroptosis	2268:2278	arg1	inhibition					2254:2263	the inhibition	2250:2263	the inhibition of necroptosis	2250:2278	Then, further experiments revealed that WMW enhanced OGT activity and suppressed OGA activity, thereby increasing RIPK3 O-GlcNAcylation and inhibiting the binding of RIPK3 and MLKL, which led to the inhibition of necroptosis.
34399822	11	110	theme	body	1700:1703	arg1	weight					1705:1710	body weight	1700:1710	body weight	1700:1710	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	11	110	theme	body	1700:1703	arg1	mice					1695:1698	mice body weight, survival rate and colon length	1695:1742	mice body weight, survival rate and colon length	1695:1742	RESULTS Our results showed that WMW significantly improved mice body weight, survival rate and colon length, decreased DAI in TNBS-induced colitis.
34399822	13	111	theme	MLKL	2049:2052	arg1	activation					2018:2027	the activation	2014:2027	the activation of RIPK1, RIPK3 and MLKL	2014:2052	It was found that WMW increased colonic O-GlcNAcylation level and inhibited the activation of RIPK1, RIPK3 and MLKL.
33515675	4	0	theme	PDAC	521:524	arg1	progression					526:536	PDAC progression	521:536	PDAC progression	521:536	We hypothesized that they could mediate PDAC progression by influencing NOTCH1 O-GlcNAcylation.
33515675	10	1	theme	NOTCH1	1410:1415	arg1	O-GlcNAcylation					1391:1405	the O-GlcNAcylation	1387:1405	the O-GlcNAcylation of NOTCH1	1387:1415	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	10	2	theme	cancer	1576:1581	arg1	cells					1583:1587	pancreatic cancer cells	1565:1587	pancreatic cancer cells	1565:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	6	3	theme	cell	667:670	arg1	lines					672:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	10	4	theme	P21	1558:1560	arg1	transcription					1526:1538	the transcription	1522:1538	the transcription of E-cadherin and P21 in pancreatic cancer cells	1522:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	6	5	theme	cancer	660:665	arg1	lines					672:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	2	6	link	O-linked	267:274	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	6	link	O-linked	267:274	arg1	EOGT					296:299	EOGT	296:299	EOGT	296:299	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	6	link	O-linked	267:274	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	0	7	theme	pancreatic	96:105	arg1	cancer					107:112	pancreatic cancer	96:112	pancreatic cancer	96:112	SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
33515675	10	8	theme	intracellular	1479:1491	arg1	NICD					1501:1504	NICD	1501:1504	NICD	1501:1504	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	10	8	theme	intracellular	1479:1491	arg1	domain					1493:1498	the Notch intracellular domain	1469:1498	the Notch intracellular domain (NICD)	1469:1505	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	1	9	from	progression	167:177	arg1	important					134:142	important	134:142	important	134:142	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	2	10	from	participant	316:326	arg1	NOTCH1					345:350	glycosylating NOTCH1	331:350	glycosylating NOTCH1	331:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	6	11	dep	in	714:715	arg1	vitro					717:721	vitro	717:721	vitro	717:721	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	6	12	used	used	705:708	arg2	models					693:698	nude mouse models	682:698	nude mouse models	682:698	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	6	12	used	used	705:708	arg2	lines					672:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	9	13	dep	In	1061:1062	arg1	vivo					1064:1067	vivo	1064:1067	vivo	1064:1067	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	1	14	from	development	151:161	arg1	important					134:142	important	134:142	important	134:142	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	6	15	theme	in	727:728	arg1	experiments					735:745	in vitro and in vivo experiments	714:745	in vitro and in vivo experiments	714:745	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	0	16	theme	cancer	107:112	arg1	development					81:91	the development	77:91	the development of pancreatic cancer	77:112	SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
33515675	1	17	from	important	134:142	arg1	development					151:161	development	151:161	development	151:161	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	1	17	from	important	134:142	arg1	progression					167:177	progression	167:177	progression	167:177	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	7	18	theme	protein	766:772	arg1	expression					774:783	The protein expression	762:783	The protein expression of EOGT and SHCBP1	762:802	Respectively, The protein expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients.
33515675	7	19	theme	PDAC	870:873	arg1	patients					875:882	PDAC patients	870:882	PDAC patients	870:882	Respectively, The protein expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients.
33515675	1	20	theme	pancreatic	182:191	arg1	PDAC					216:219	PDAC	216:219	PDAC	216:219	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	1	20	theme	pancreatic	182:191	arg1	adenocarcinoma					200:213	pancreatic ductal adenocarcinoma	182:213	pancreatic ductal adenocarcinoma (PDAC)	182:220	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	3	21	theme	PDAC	410:413	arg1	patients					415:422	30 advanced PDAC patients	398:422	30 advanced PDAC patients	398:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	3	22	from	patients	415:422	arg1	specimens					383:391	specimens	383:391	specimens from 30 advanced PDAC patients	383:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	3	22	from	patients	415:422	arg1	sequencing					369:378	High-throughput sequencing	353:378	High-throughput sequencing of specimens from 30 advanced PDAC patients	353:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	9	23	theme	xenograft	1252:1260	arg1	growth					1262:1267	xenograft growth	1252:1267	xenograft growth	1252:1267	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	8	24	theme	cancer	937:942	arg1	proliferation					949:961	pancreatic cancer cell proliferation	926:961	pancreatic cancer cell proliferation	926:961	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	8	25	theme	SHCBP1	895:900	arg1	overexpression					902:915	SHCBP1 overexpression	895:915	SHCBP1 overexpression	895:915	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	1	26	theme	ductal	193:198	arg1	PDAC					216:219	PDAC	216:219	PDAC	216:219	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	1	26	theme	ductal	193:198	arg1	adenocarcinoma					200:213	pancreatic ductal adenocarcinoma	182:213	pancreatic ductal adenocarcinoma (PDAC)	182:220	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	8	27	theme	down	1003:1006	arg1	SHCBP1					1008:1013	knocking down SHCBP1	994:1013	knocking down SHCBP1	994:1013	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	6	28	theme	in	714:715	arg1	experiments					735:745	in vitro and in vivo experiments	714:745	in vitro and in vivo experiments	714:745	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	1	29	theme	adenocarcinoma	200:213	arg1	development					151:161	development	151:161	development	151:161	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	1	29	theme	adenocarcinoma	200:213	arg1	progression					167:177	progression	167:177	progression	167:177	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	10	30	theme	Notch	1473:1477	arg1	NICD					1501:1504	NICD	1501:1504	NICD	1501:1504	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	10	30	theme	Notch	1473:1477	arg1	domain					1493:1498	the Notch intracellular domain	1469:1498	the Notch intracellular domain (NICD)	1469:1505	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	6	31	dep	in	727:728	arg1	vivo					730:733	vivo	730:733	vivo	730:733	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	2	32	theme	key	312:314	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	32	theme	key	312:314	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	10	33	dep	enhance	1379:1385	arg1	inhibiting					1511:1520	inhibiting	1511:1520	inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells	1511:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	10	33	dep	enhance	1379:1385	arg1	promoting					1431:1439	promoting	1431:1439	promoting the nuclear localization of the Notch intracellular domain (NICD)	1431:1505	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	3	34	theme	advanced	401:408	arg1	patients					415:422	30 advanced PDAC patients	398:422	30 advanced PDAC patients	398:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	9	35	theme	In	1061:1062	arg1	data					1069:1072	In vivo data	1061:1072	In vivo data	1061:1072	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	3	36	from	sequencing	369:378	arg1	patients					415:422	30 advanced PDAC patients	398:422	30 advanced PDAC patients	398:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	1	37	dep	development	151:161	arg1	the					147:149	the	147:149	the	147:149	O-GlcNAcylation is important in the development and progression of pancreatic ductal adenocarcinoma (PDAC).
33515675	8	38	theme	cell	944:947	arg1	proliferation					949:961	pancreatic cancer cell proliferation	926:961	pancreatic cancer cell proliferation	926:961	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	8	39	theme	pancreatic	926:935	arg1	proliferation					949:961	pancreatic cancer cell proliferation	926:961	pancreatic cancer cell proliferation	926:961	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	9	40	theme	xenograft	1117:1125	arg1	growth					1127:1132	xenograft growth	1117:1132	xenograft growth	1117:1132	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	9	41	theme	SHCBP1	1086:1091	arg1	overexpression					1093:1106	SHCBP1 overexpression	1086:1106	SHCBP1 overexpression	1086:1106	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	2	42	theme	domain-specific	251:265	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	42	theme	domain-specific	251:265	arg1	EOGT					296:299	EOGT	296:299	EOGT	296:299	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	42	theme	domain-specific	251:265	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	7	43	theme	worse	851:855	arg1	prognosis					857:865	worse prognosis	851:865	worse prognosis in PDAC patients	851:882	Respectively, The protein expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients.
33515675	3	44	theme	prognosis	470:478	arg1	SHCBP1					435:440	SHCBP1	435:440	SHCBP1	435:440	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	3	44	theme	prognosis	470:478	arg1	factors					454:460	factors	454:460	factors of poor prognosis	454:478	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	3	44	theme	prognosis	470:478	arg1	EOGT					446:449	EOGT	446:449	EOGT	446:449	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	7	45	theme	SHCBP1	797:802	arg1	expression					774:783	The protein expression	762:783	The protein expression of EOGT and SHCBP1	762:802	Respectively, The protein expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients.
33515675	9	46	dep	down	1203:1206	arg1	either					1208:1213	either	1208:1213	either	1208:1213	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	9	47	theme	lung	1138:1141	arg1	metastasis					1143:1152	lung metastasis	1138:1152	lung metastasis	1138:1152	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	2	48	theme	EGF	247:249	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	48	theme	EGF	247:249	arg1	EOGT					296:299	EOGT	296:299	EOGT	296:299	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	48	theme	EGF	247:249	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	10	49	from	transcription	1526:1538	arg1	cells					1583:1587	pancreatic cancer cells	1565:1587	pancreatic cancer cells	1565:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	0	50	theme	NOTCH1	57:62	arg1	O-GlcNAcylation					38:52	O-GlcNAcylation	38:52	O-GlcNAcylation of NOTCH1	38:62	SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer.
33515675	3	51	theme	specimens	383:391	arg1	sequencing					369:378	High-throughput sequencing	353:378	High-throughput sequencing of specimens from 30 advanced PDAC patients	353:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	9	52	theme	SHCBP1	1223:1228	arg1	expression					1230:1239	knocking down either EOGT or SHCBP1 expression	1194:1239	expression	1230:1239	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	2	53	theme	glycosyltransferase	227:245	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	53	theme	glycosyltransferase	227:245	arg1	EOGT					296:299	EOGT	296:299	EOGT	296:299	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	53	theme	glycosyltransferase	227:245	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	5	54	theme	186	583:585	arg1	specimens					599:607	186 PDAC tissue specimens	583:607	186 PDAC tissue specimens	583:607	Thus, 186 PDAC tissue specimens were immunostained for EOGT and SHCBP1.
33515675	10	55	theme	E-cadherin	1543:1552	arg1	transcription					1526:1538	the transcription	1522:1538	the transcription of E-cadherin and P21 in pancreatic cancer cells	1522:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	7	56	theme	EOGT	788:791	arg1	expression					774:783	The protein expression	762:783	The protein expression of EOGT and SHCBP1	762:802	Respectively, The protein expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients.
33515675	5	57	theme	PDAC	587:590	arg1	specimens					599:607	186 PDAC tissue specimens	583:607	186 PDAC tissue specimens	583:607	Thus, 186 PDAC tissue specimens were immunostained for EOGT and SHCBP1.
33515675	9	58	theme	prolonged	1288:1296	arg1	survival					1298:1305	prolonged survival	1288:1305	prolonged survival	1288:1305	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	8	59	theme	malignant	1040:1048	arg1	processes					1050:1058	these malignant processes	1034:1058	these malignant processes	1034:1058	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	2	60	gly	glycosylating	331:343	arg0	NOTCH1					345:350	glycosylating NOTCH1	331:350	glycosylating NOTCH1	331:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	10	61	theme	domain	1493:1498	arg1	localization					1453:1464	the nuclear localization	1441:1464	the nuclear localization of the Notch intracellular domain (NICD)	1441:1505	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	5	62	theme	tissue	592:597	arg1	specimens					599:607	186 PDAC tissue specimens	583:607	186 PDAC tissue specimens	583:607	Thus, 186 PDAC tissue specimens were immunostained for EOGT and SHCBP1.
33515675	6	63	theme	mouse	687:691	arg1	models					693:698	nude mouse models	682:698	nude mouse models	682:698	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	10	64	theme	pancreatic	1565:1574	arg1	cells					1583:1587	pancreatic cancer cells	1565:1587	pancreatic cancer cells	1565:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	7	65	from	prognosis	857:865	arg1	patients					875:882	PDAC patients	870:882	PDAC patients	870:882	Respectively, The protein expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients.
33515675	2	66	theme	glycosylating	331:343	arg1	NOTCH1					345:350	glycosylating NOTCH1	331:350	glycosylating NOTCH1	331:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	6	67	theme	nude	682:685	arg1	models					693:698	nude mouse models	682:698	nude mouse models	682:698	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	10	68	theme	molecular	1333:1341	arg1	mechanisms					1343:1352	the molecular mechanisms	1329:1352	the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells	1329:1587	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	6	69	theme	Pancreatic	649:658	arg1	lines					672:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines	649:676	Pancreatic cancer cell lines and nude mouse models were used for in vitro and in vivo experiments.
33515675	2	70	theme	GlcNAc	276:281	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	70	theme	GlcNAc	276:281	arg1	EOGT					296:299	EOGT	296:299	EOGT	296:299	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	70	theme	GlcNAc	276:281	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	9	71	theme	knocking	1194:1201	arg1	down					1203:1206	knocking down either EOGT or SHCBP1 expression	1194:1239	down	1203:1206	In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice, whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival.
33515675	10	72	theme	nuclear	1445:1451	arg1	localization					1453:1464	the nuclear localization	1441:1464	the nuclear localization of the Notch intracellular domain (NICD)	1441:1505	We further clarified the molecular mechanisms by which EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, Subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.
33515675	3	73	theme	poor	465:468	arg1	prognosis					470:478	poor prognosis	465:478	poor prognosis	465:478	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	3	74	theme	High-throughput	353:367	arg1	sequencing					369:378	High-throughput sequencing	353:378	High-throughput sequencing of specimens from 30 advanced PDAC patients	353:422	High-throughput sequencing of specimens from 30 advanced PDAC patients identified SHCBP1 and EOGT as factors of poor prognosis.
33515675	2	75	theme	O-linked	267:274	arg1	participant					316:326	a key participant	310:326	a key participant in glycosylating NOTCH1	310:350	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	75	theme	O-linked	267:274	arg1	EOGT					296:299	EOGT	296:299	EOGT	296:299	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	2	75	theme	O-linked	267:274	arg1	transferase					283:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase	223:293	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT)	223:300	The glycosyltransferase EGF domain-specific O-linked GlcNAc transferase (EOGT) acts as a key participant in glycosylating NOTCH1.
33515675	8	76	theme	knocking	994:1001	arg1	SHCBP1					1008:1013	knocking down SHCBP1	994:1013	knocking down SHCBP1	994:1013	In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation, migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes.
33515675	4	77	theme	NOTCH1	553:558	arg1	O-GlcNAcylation					560:574	NOTCH1 O-GlcNAcylation	553:574	NOTCH1 O-GlcNAcylation	553:574	We hypothesized that they could mediate PDAC progression by influencing NOTCH1 O-GlcNAcylation.
33199824	1	0	theme	hydroxyl	180:187	arg1	threonine					208:216	threonine	208:216	threonine	208:216	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	0	theme	hydroxyl	180:187	arg1	serine					198:203	serine	198:203	serine	198:203	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	0	theme	hydroxyl	180:187	arg1	group					189:193	the hydroxyl group	176:193	the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins	176:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	5	1	dep	cancer	701:706	arg1	EMT					708:710	EMT	708:710	EMT	708:710	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	6	2	theme	O-GlcNAc	810:817	arg1	levels					819:824	cellular O-GlcNAc levels	801:824	cellular O-GlcNAc levels in human lung cancer cells	801:851	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	10	3	theme	luciferase	1258:1267	arg1	result					1172:1177	a result	1170:1177	a result	1170:1177	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	3	theme	luciferase	1258:1267	arg1	activity					1246:1253	the reporter activity	1233:1253	the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE)	1233:1316	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	4	4	theme	major	582:586	arg1	component					533:541	a component	531:541	a component of the SMAD transcriptional complex	531:577	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	4	4	theme	major	582:586	arg1	regulator					588:596	a major regulator	580:596	a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β)	580:666	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	5	5	theme	metastasis	716:725	arg1	promoter					689:696	a powerful promoter	678:696	a powerful promoter of cancer EMT and metastasis	678:725	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	5	5	theme	metastasis	716:725	arg1	TGF-β					669:673	TGF-β	669:673	TGF-β	669:673	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	8	6	theme	impeded	988:994	arg1	interactions					996:1007	impeded interactions	988:1007	impeded interactions between SMAD4 and GSK-3β which promote proteasomal degradation of SMAD4	988:1079	The mechanism behind this interaction was that O-GlcNAc impeded interactions between SMAD4 and GSK-3β which promote proteasomal degradation of SMAD4.
33199824	6	7	theme	cellular	801:808	arg1	levels					819:824	cellular O-GlcNAc levels	801:824	cellular O-GlcNAc levels in human lung cancer cells	801:851	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	2	8	theme	sugar	312:316	arg1	motif					318:322	this single sugar motif	300:322	this single sugar motif	300:322	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	1	9	theme	O-linked	81:88	arg1	β-N-acetylglucosamine					90:110	O-linked β-N-acetylglucosamine	81:110	O-linked β-N-acetylglucosamine (O-GlcNAc)	81:121	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	9	theme	O-linked	81:88	arg1	modification					147:158	a post-translational modification	126:158	a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins	126:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	9	theme	O-linked	81:88	arg1	O-GlcNAc					113:120	O-GlcNAc	113:120	O-GlcNAc	113:120	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	2	10	theme	single	305:310	arg1	motif					318:322	this single sugar motif	300:322	this single sugar motif	300:322	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	11	11	theme	signaling	1398:1406	arg1	pathway					1408:1414	the TGF-β/SMAD signaling pathway	1383:1414	the TGF-β/SMAD signaling pathway	1383:1414	This study's findings imply that cellular O-GlcNAc may regulate the TGF-β/SMAD signaling pathway by stabilizing SMAD4.
33199824	1	12	theme	post-translational	128:145	arg1	β-N-acetylglucosamine					90:110	O-linked β-N-acetylglucosamine	81:110	O-linked β-N-acetylglucosamine (O-GlcNAc)	81:121	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	12	theme	post-translational	128:145	arg1	modification					147:158	a post-translational modification	126:158	a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins	126:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	10	13	theme	binding	1296:1302	arg1	SBE					1313:1315	SBE	1313:1315	SBE	1313:1315	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	13	theme	binding	1296:1302	arg1	element					1304:1310	the TGF-β-responsive SMAD binding element	1270:1310	the TGF-β-responsive SMAD binding element (SBE)	1270:1316	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	13	theme	binding	1296:1302	arg1	luciferase					1258:1267	luciferase	1258:1267	luciferase	1258:1267	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	1	14	link	O-linked	81:88	arg1	β-N-acetylglucosamine					90:110	O-linked β-N-acetylglucosamine	81:110	O-linked β-N-acetylglucosamine (O-GlcNAc)	81:121	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	14	link	O-linked	81:88	arg1	modification					147:158	a post-translational modification	126:158	a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins	126:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	14	link	O-linked	81:88	arg1	O-GlcNAc					113:120	O-GlcNAc	113:120	O-GlcNAc	113:120	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	8	15	theme	proteasomal	1048:1058	arg1	degradation					1060:1070	proteasomal degradation	1048:1070	proteasomal degradation of SMAD4	1048:1079	The mechanism behind this interaction was that O-GlcNAc impeded interactions between SMAD4 and GSK-3β which promote proteasomal degradation of SMAD4.
33199824	7	16	theme	proteins	922:929	arg1	half-life					903:911	the prolonged half-life	889:911	the prolonged half-life of SMAD4 proteins	889:929	This observation was made based on the prolonged half-life of SMAD4 proteins.
33199824	10	17	theme	SMAD	1291:1294	arg1	SBE					1313:1315	SBE	1313:1315	SBE	1313:1315	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	17	theme	SMAD	1291:1294	arg1	element					1304:1310	the TGF-β-responsive SMAD binding element	1270:1310	the TGF-β-responsive SMAD binding element (SBE)	1270:1316	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	17	theme	SMAD	1291:1294	arg1	luciferase					1258:1267	luciferase	1258:1267	luciferase	1258:1267	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	1	18	theme	serine	198:203	arg1	threonine					208:216	threonine	208:216	threonine	208:216	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	18	theme	serine	198:203	arg1	serine					198:203	serine	198:203	serine	198:203	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	18	theme	serine	198:203	arg1	group					189:193	the hydroxyl group	176:193	the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins	176:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	8	19	theme	SMAD4	1075:1079	arg1	degradation					1060:1070	proteasomal degradation	1048:1070	proteasomal degradation of SMAD4	1048:1079	The mechanism behind this interaction was that O-GlcNAc impeded interactions between SMAD4 and GSK-3β which promote proteasomal degradation of SMAD4.
33199824	6	20	theme	proteins	771:778	arg1	proteins					771:778	SMAD4 proteins	765:778	SMAD4 proteins	765:778	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	6	20	theme	proteins	771:778	arg1	amount					755:760	the amount	751:760	the amount of SMAD4 proteins	751:778	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	2	21	theme	biological	342:351	arg1	events					353:358	various biological events	334:358	various biological events	334:358	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	10	22	theme	TGF-β-responsive	1274:1289	arg1	SBE					1313:1315	SBE	1313:1315	SBE	1313:1315	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	22	theme	TGF-β-responsive	1274:1289	arg1	element					1304:1310	the TGF-β-responsive SMAD binding element	1270:1310	the TGF-β-responsive SMAD binding element (SBE)	1270:1316	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	22	theme	TGF-β-responsive	1274:1289	arg1	luciferase					1258:1267	luciferase	1258:1267	luciferase	1258:1267	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	4	23	theme	complex	571:577	arg1	SMAD4					522:526	SMAD4	522:526	SMAD4	522:526	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	4	23	theme	complex	571:577	arg1	component					533:541	a component	531:541	a component of the SMAD transcriptional complex	531:577	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	4	23	theme	complex	571:577	arg1	regulator					588:596	a major regulator	580:596	a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β)	580:666	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	6	24	theme	SMAD4	765:769	arg1	proteins					771:778	SMAD4 proteins	765:778	SMAD4 proteins	765:778	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	2	25	theme	various	334:340	arg1	events					353:358	various biological events	334:358	various biological events	334:358	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	9	26	theme	O-GlcNAc	1095:1102	arg1	modification					1104:1115	O-GlcNAc modification	1095:1115	O-GlcNAc modification on SMAD4 Thr63	1095:1130	In addition, O-GlcNAc modification on SMAD4 Thr63 was responsible for stabilization.
33199824	1	27	theme	threonine	208:216	arg1	threonine					208:216	threonine	208:216	threonine	208:216	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	27	theme	threonine	208:216	arg1	serine					198:203	serine	198:203	serine	198:203	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	27	theme	threonine	208:216	arg1	group					189:193	the hydroxyl group	176:193	the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins	176:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	4	28	theme	transcriptional	555:569	arg1	complex					571:577	the SMAD transcriptional complex	546:577	the SMAD transcriptional complex	546:577	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	7	29	theme	SMAD4	916:920	arg1	proteins					922:929	SMAD4 proteins	916:929	SMAD4 proteins	916:929	This observation was made based on the prolonged half-life of SMAD4 proteins.
33199824	4	30	theme	growth	644:649	arg1	factor-β					651:658	the transforming growth factor-β	627:658	the transforming growth factor-β (TGF-β)	627:666	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	4	30	theme	growth	644:649	arg1	TGF-β					661:665	TGF-β	661:665	TGF-β	661:665	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	5	31	theme	cancer	701:706	arg1	promoter					689:696	a powerful promoter	678:696	a powerful promoter of cancer EMT and metastasis	678:725	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	5	31	theme	cancer	701:706	arg1	TGF-β					669:673	TGF-β	669:673	TGF-β	669:673	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	2	32	theme	motif	318:322	arg1	presence					288:295	the presence	284:295	the presence of this single sugar motif	284:322	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	4	33	theme	transforming	631:642	arg1	factor-β					651:658	the transforming growth factor-β	627:658	the transforming growth factor-β (TGF-β)	627:666	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	4	33	theme	transforming	631:642	arg1	TGF-β					661:665	TGF-β	661:665	TGF-β	661:665	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	0	34	theme	GSK-3β-mediated	40:54	arg1	degradation					68:78	GSK-3β-mediated proteasomal degradation	40:78	GSK-3β-mediated proteasomal degradation	40:78	O-GlcNAc stabilizes SMAD4 by inhibiting GSK-3β-mediated proteasomal degradation.
33199824	1	35	theme	nucleocytoplasmic	230:246	arg1	proteins					248:255	nucleocytoplasmic proteins	230:255	nucleocytoplasmic proteins	230:255	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	6	36	from	levels	819:824	arg1	cells					847:851	human lung cancer cells	829:851	human lung cancer cells	829:851	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	10	37	from	defects	1180:1186	arg1	SMAD4					1210:1214	SMAD4 Thr63	1210:1220	SMAD4 Thr63	1210:1220	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	37	from	defects	1180:1186	arg1	O-GlcNAcylation					1191:1205	O-GlcNAcylation	1191:1205	O-GlcNAcylation on SMAD4 Thr63	1191:1220	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	1	38	theme	proteins	248:255	arg1	threonine					208:216	threonine	208:216	threonine	208:216	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	1	38	theme	proteins	248:255	arg1	serine					198:203	serine	198:203	serine	198:203	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	11	39	theme	cellular	1352:1359	arg1	O-GlcNAc					1361:1368	cellular O-GlcNAc	1352:1368	cellular O-GlcNAc	1352:1368	This study's findings imply that cellular O-GlcNAc may regulate the TGF-β/SMAD signaling pathway by stabilizing SMAD4.
33199824	9	40	from	modification	1104:1115	arg1	SMAD4					1120:1124	SMAD4 Thr63	1120:1130	SMAD4 Thr63	1120:1130	In addition, O-GlcNAc modification on SMAD4 Thr63 was responsible for stabilization.
33199824	6	41	theme	cancer	840:845	arg1	cells					847:851	human lung cancer cells	829:851	human lung cancer cells	829:851	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	3	42	theme	O-GlcNAc-modified	495:511	arg1	protein					513:519	a novel O-GlcNAc-modified protein	487:519	a novel O-GlcNAc-modified protein	487:519	This study identified SMAD4 as a novel O-GlcNAc-modified protein.
33199824	3	42	theme	O-GlcNAc-modified	495:511	arg1	SMAD4					478:482	SMAD4	478:482	SMAD4	478:482	This study identified SMAD4 as a novel O-GlcNAc-modified protein.
33199824	0	43	theme	proteasomal	56:66	arg1	degradation					68:78	GSK-3β-mediated proteasomal degradation	40:78	GSK-3β-mediated proteasomal degradation	40:78	O-GlcNAc stabilizes SMAD4 by inhibiting GSK-3β-mediated proteasomal degradation.
33199824	4	44	theme	SMAD	550:553	arg1	complex					571:577	the SMAD transcriptional complex	546:577	the SMAD transcriptional complex	546:577	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	10	45	from	O-GlcNAcylation	1191:1205	arg1	SMAD4					1210:1214	SMAD4 Thr63	1210:1220	SMAD4 Thr63	1210:1220	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	6	46	theme	lung	835:838	arg1	cells					847:851	human lung cancer cells	829:851	human lung cancer cells	829:851	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	1	47	dep	serine	198:203	arg1	residues					218:225	residues	218:225	residues	218:225	O-linked β-N-acetylglucosamine (O-GlcNAc) is a post-translational modification which occurs on the hydroxyl group of serine or threonine residues of nucleocytoplasmic proteins.
33199824	7	48	theme	prolonged	893:901	arg1	half-life					903:911	the prolonged half-life	889:911	the prolonged half-life of SMAD4 proteins	889:929	This observation was made based on the prolonged half-life of SMAD4 proteins.
33199824	5	49	theme	powerful	680:687	arg1	promoter					689:696	a powerful promoter	678:696	a powerful promoter of cancer EMT and metastasis	678:725	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	5	49	theme	powerful	680:687	arg1	TGF-β					669:673	TGF-β	669:673	TGF-β	669:673	TGF-β is a powerful promoter of cancer EMT and metastasis.
33199824	6	50	theme	human	829:833	arg1	cells					847:851	human lung cancer cells	829:851	human lung cancer cells	829:851	This study showed that the amount of SMAD4 proteins changes according to cellular O-GlcNAc levels in human lung cancer cells.
33199824	9	51	from	addition	1085:1092	arg1	responsible					1136:1146	responsible	1136:1146	responsible	1136:1146	In addition, O-GlcNAc modification on SMAD4 Thr63 was responsible for stabilization.
33199824	10	52	theme	reporter	1237:1244	arg1	result					1172:1177	a result	1170:1177	a result	1170:1177	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	10	52	theme	reporter	1237:1244	arg1	activity					1246:1253	the reporter activity	1233:1253	the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE)	1233:1316	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	4	53	theme	pathway	615:621	arg1	component					533:541	a component	531:541	a component of the SMAD transcriptional complex	531:577	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	4	53	theme	pathway	615:621	arg1	regulator					588:596	a major regulator	580:596	a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β)	580:666	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	10	54	from	SMAD4	1210:1214	arg1	defects					1180:1186	defects	1180:1186	defects in O-GlcNAcylation on SMAD4 Thr63	1180:1220	As a result, defects in O-GlcNAcylation on SMAD4 Thr63 attenuated the reporter activity of luciferase, the TGF-β-responsive SMAD binding element (SBE).
33199824	3	55	theme	novel	489:493	arg1	protein					513:519	a novel O-GlcNAc-modified protein	487:519	a novel O-GlcNAc-modified protein	487:519	This study identified SMAD4 as a novel O-GlcNAc-modified protein.
33199824	3	55	theme	novel	489:493	arg1	SMAD4					478:482	SMAD4	478:482	SMAD4	478:482	This study identified SMAD4 as a novel O-GlcNAc-modified protein.
33199824	8	56	dep	mechanism	936:944	arg1	behind					946:951	behind	946:951	behind this interaction	946:968	The mechanism behind this interaction was that O-GlcNAc impeded interactions between SMAD4 and GSK-3β which promote proteasomal degradation of SMAD4.
33199824	4	57	theme	signaling	605:613	arg1	pathway					615:621	the signaling pathway	601:621	the signaling pathway	601:621	SMAD4 is a component of the SMAD transcriptional complex, a major regulator of the signaling pathway for the transforming growth factor-β (TGF-β).
33199824	9	58	from	responsible	1136:1146	arg1	addition					1085:1092	addition	1085:1092	addition	1085:1092	In addition, O-GlcNAc modification on SMAD4 Thr63 was responsible for stabilization.
33199824	2	59	theme	proteins	391:398	arg1	fate					376:379	the fate	372:379	the fate of target proteins, such as their function, localization, and degradation	372:453	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	11	60	theme	TGF-β/SMAD	1387:1396	arg1	pathway					1408:1414	the TGF-β/SMAD signaling pathway	1383:1414	the TGF-β/SMAD signaling pathway	1383:1414	This study's findings imply that cellular O-GlcNAc may regulate the TGF-β/SMAD signaling pathway by stabilizing SMAD4.
33199824	2	61	theme	target	384:389	arg1	localization					425:436	localization	425:436	localization	425:436	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	2	61	theme	target	384:389	arg1	degradation					443:453	degradation	443:453	degradation	443:453	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	2	61	theme	target	384:389	arg1	function					415:422	their function	409:422	their function	409:422	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
33199824	2	61	theme	target	384:389	arg1	proteins					391:398	target proteins	384:398	target proteins	384:398	It has been reported that the presence of this single sugar motif regulates various biological events by altering the fate of target proteins, such as their function, localization, and degradation.
32343970	0	0	theme	pregnant	78:85	arg1	rats					87:90	virgin but not pregnant rats	63:90	virgin but not pregnant rats	63:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	6	1	theme	glucosamine	810:820	arg1	treatment					822:830	glucosamine treatment	810:830	glucosamine treatment	810:830	In NP rats, glucosamine treatment increased O-GlcNAc expression in UAs accompanied by decreased endothelium-dependent relaxation, which was abolished by L-NAME.
32343970	6	2	theme	O-GlcNAc	842:849	arg1	expression					851:860	O-GlcNAc expression	842:860	O-GlcNAc expression	842:860	In NP rats, glucosamine treatment increased O-GlcNAc expression in UAs accompanied by decreased endothelium-dependent relaxation, which was abolished by L-NAME.
32343970	1	3	theme	endothelial	244:254	arg1	dysfunction					256:266	endothelial dysfunction	244:266	endothelial dysfunction	244:266	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	12	4	theme	hormonal	1739:1746	arg1	alterations					1748:1758	hormonal alterations	1739:1758	hormonal alterations	1739:1758	We speculate that during pregnancy, hormonal alterations play a protective role in preventing O-GlcNAcylation-induced endothelial dysfunction in the UAs.
32343970	9	5	theme	P	1252:1252	arg1	rats					1254:1257	P rats	1252:1257	P rats treated with glucosamine	1252:1282	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	7	6	theme	NP	1077:1078	arg1	rats					1080:1083	NP rats	1077:1083	NP rats	1077:1083	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	5	7	dep	presence	719:726	arg1	the					715:717	the	715:717	the	715:717	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	11	8	from	dependent	1664:1672	arg1	part					1658:1661	part	1658:1661	part	1658:1661	The underlying mechanism is, at least in part, dependent on Akt/GSK3β/OGT modulation.
32343970	5	9	from	nitroprusside	761:773	arg1	absence					731:737	absence	731:737	absence	731:737	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	5	9	from	nitroprusside	761:773	arg1	presence					719:726	presence	719:726	presence	719:726	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	10	10	theme	endothelial	1581:1591	arg1	dysfunction					1593:1603	endothelial dysfunction	1581:1603	endothelial dysfunction in NP rats	1581:1614	Sodium nitroprusside-induced relaxation was not changed in all groups, indicating that glucosamine treatment led to endothelial dysfunction in NP rats.
32343970	3	11	theme	uterine	480:486	arg1	dysfunction					495:505	uterine artery dysfunction	480:505	uterine artery dysfunction	480:505	We hypothesized that glucosamine treatment increases O-GlcNAc, leading to uterine artery dysfunction and this effect is prevented by pregnancy.
32343970	8	12	theme	increased	1138:1146	arg1	activation					1188:1197	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	9	13	theme	OGT	1434:1436	arg1	expression					1438:1447	total Akt and OGT expression	1420:1447	total Akt and OGT expression	1420:1447	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	9	14	from	O-GlcNAc	1304:1311	arg1	UAs					1316:1318	UAs	1316:1318	UAs	1316:1318	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	12	15	theme	O-GlcNAcylation-induced	1797:1819	arg1	dysfunction					1833:1843	O-GlcNAcylation-induced endothelial dysfunction	1797:1843	O-GlcNAcylation-induced endothelial dysfunction in the UAs	1797:1854	We speculate that during pregnancy, hormonal alterations play a protective role in preventing O-GlcNAcylation-induced endothelial dysfunction in the UAs.
32343970	8	16	theme	kinase	1166:1171	arg1	GSK3β					1181:1185	GSK3β	1181:1185	GSK3β	1181:1185	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	8	16	theme	kinase	1166:1171	arg1	beta					1175:1178	glycogen synthase kinase 3 beta	1148:1178	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	3	17	theme	glucosamine	427:437	arg1	treatment					439:447	glucosamine treatment	427:447	glucosamine treatment	427:447	We hypothesized that glucosamine treatment increases O-GlcNAc, leading to uterine artery dysfunction and this effect is prevented by pregnancy.
32343970	11	18	from	part	1658:1661	arg1	dependent					1664:1672	dependent	1664:1672	dependent	1664:1672	The underlying mechanism is, at least in part, dependent on Akt/GSK3β/OGT modulation.
32343970	11	18	from	part	1658:1661	arg1	mechanism					1632:1640	The underlying mechanism	1617:1640	The underlying mechanism	1617:1640	The underlying mechanism is, at least in part, dependent on Akt/GSK3β/OGT modulation.
32343970	11	19	theme	underlying	1621:1630	arg1	mechanism					1632:1640	The underlying mechanism	1617:1640	The underlying mechanism	1617:1640	The underlying mechanism is, at least in part, dependent on Akt/GSK3β/OGT modulation.
32343970	11	19	theme	underlying	1621:1630	arg1	dependent					1664:1672	dependent	1664:1672	dependent	1664:1672	The underlying mechanism is, at least in part, dependent on Akt/GSK3β/OGT modulation.
32343970	4	20	theme	non-pregnant	567:578	arg1	rats					592:595	Pregnant (P) and non-pregnant (NP) Wistar rats	550:595	Pregnant (P) and non-pregnant (NP) Wistar rats	550:595	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	2	21	theme	augmented	277:285	arg1	O-GlcNAc					287:294	augmented O-GlcNAc	277:294	augmented O-GlcNAc	277:294	Whether augmented O-GlcNAc impacts the uterine artery (UA) function and how it affects the UA during pregnancy remains to be elucidated.
32343970	8	22	theme	synthase	1157:1164	arg1	kinase					1166:1171	glycogen synthase kinase 3	1148:1173	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	4	23	dep	Pregnant	550:557	arg1	P					560:560	P	560:560	P	560:560	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	10	24	theme	nitroprusside-induced	1472:1492	arg1	relaxation					1494:1503	Sodium nitroprusside-induced relaxation	1465:1503	Sodium nitroprusside-induced relaxation	1465:1503	Sodium nitroprusside-induced relaxation was not changed in all groups, indicating that glucosamine treatment led to endothelial dysfunction in NP rats.
32343970	9	25	theme	GSK3β	1401:1405	arg1	activity					1407:1414	eNOS and GSK3β activity	1392:1414	eNOS and GSK3β activity	1392:1414	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	5	26	theme	sodium	754:759	arg1	nitroprusside					761:773	sodium nitroprusside	754:773	sodium nitroprusside	754:773	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	8	27	theme	O-GlcNAc-transferase	1203:1222	arg1	expression					1230:1239	O-GlcNAc-transferase (OGT) expression	1203:1239	O-GlcNAc-transferase (OGT) expression in the UA	1203:1249	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	10	28	theme	glucosamine	1552:1562	arg1	treatment					1564:1572	glucosamine treatment	1552:1572	glucosamine treatment	1552:1572	Sodium nitroprusside-induced relaxation was not changed in all groups, indicating that glucosamine treatment led to endothelial dysfunction in NP rats.
32343970	4	29	theme	Pregnant	550:557	arg1	rats					592:595	Pregnant (P) and non-pregnant (NP) Wistar rats	550:595	Pregnant (P) and non-pregnant (NP) Wistar rats	550:595	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	0	30	theme	GSK3β	105:109	arg1	role					97:100	The role	93:100	The role of GSK3β	93:109	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	9	31	theme	eNOS	1392:1395	arg1	activity					1407:1414	eNOS and GSK3β activity	1392:1414	eNOS and GSK3β activity	1392:1414	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	2	32	theme	artery	316:321	arg1	function					328:335	the uterine artery (UA) function	304:335	the uterine artery (UA) function	304:335	Whether augmented O-GlcNAc impacts the uterine artery (UA) function and how it affects the UA during pregnancy remains to be elucidated.
32343970	1	33	theme	several	179:185	arg1	pathologies					187:197	several pathologies	179:197	several pathologies	179:197	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	0	34	theme	endothelial	17:27	arg1	function					29:36	endothelial function	17:36	endothelial function in uterine arteries from virgin but not pregnant rats	17:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	5	35	from	acetylcholine	697:709	arg1	absence					731:737	absence	731:737	absence	731:737	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	5	35	from	acetylcholine	697:709	arg1	presence					719:726	presence	719:726	presence	719:726	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	2	36	theme	uterine	308:314	arg1	artery					316:321	the uterine artery	304:321	the uterine artery (UA) function	304:335	Whether augmented O-GlcNAc impacts the uterine artery (UA) function and how it affects the UA during pregnancy remains to be elucidated.
32343970	2	36	theme	uterine	308:314	arg1	UA					324:325	UA	324:325	UA	324:325	Whether augmented O-GlcNAc impacts the uterine artery (UA) function and how it affects the UA during pregnancy remains to be elucidated.
32343970	8	37	from	expression	1230:1239	arg1	UA					1248:1249	the UA	1244:1249	the UA	1244:1249	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	9	38	theme	total	1420:1424	arg1	Akt					1426:1428	total Akt	1420:1428	total Akt	1420:1428	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	0	39	theme	uterine	41:47	arg1	arteries					49:56	uterine arteries	41:56	uterine arteries from virgin but not pregnant rats	41:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	7	40	theme	total	1013:1017	arg1	expression					1023:1032	total Akt expression	1013:1032	total Akt expression	1013:1032	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	10	41	from	dysfunction	1593:1603	arg1	rats					1611:1614	NP rats	1608:1614	NP rats	1608:1614	Sodium nitroprusside-induced relaxation was not changed in all groups, indicating that glucosamine treatment led to endothelial dysfunction in NP rats.
32343970	10	42	theme	NP	1608:1609	arg1	rats					1611:1614	NP rats	1608:1614	NP rats	1608:1614	Sodium nitroprusside-induced relaxation was not changed in all groups, indicating that glucosamine treatment led to endothelial dysfunction in NP rats.
32343970	9	43	theme	Akt	1426:1428	arg1	expression					1438:1447	total Akt and OGT expression	1420:1447	total Akt and OGT expression	1420:1447	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	8	44	theme	beta	1175:1178	arg1	activation					1188:1197	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	7	45	theme	Akt	1019:1021	arg1	expression					1023:1032	total Akt expression	1013:1032	total Akt expression	1013:1032	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	4	46	dep	non-pregnant	567:578	arg1	NP					581:582	NP	581:582	NP	581:582	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	9	47	theme	decreased	1294:1302	arg1	O-GlcNAc					1304:1311	decreased O-GlcNAc	1294:1311	decreased O-GlcNAc in UAs	1294:1318	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	7	48	theme	synthase	984:991	arg1	activity					1000:1007	Endothelial nitric oxide synthase (eNOS) activity	959:1007	Endothelial nitric oxide synthase (eNOS) activity	959:1007	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	5	49	theme	L-NAME	742:747	arg1	absence					731:737	absence	731:737	absence	731:737	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	5	49	theme	L-NAME	742:747	arg1	presence					719:726	presence	719:726	presence	719:726	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	6	50	theme	endothelium-dependent	894:914	arg1	relaxation					916:925	decreased endothelium-dependent relaxation	884:925	decreased endothelium-dependent relaxation	884:925	In NP rats, glucosamine treatment increased O-GlcNAc expression in UAs accompanied by decreased endothelium-dependent relaxation, which was abolished by L-NAME.
32343970	12	51	theme	endothelial	1821:1831	arg1	dysfunction					1833:1843	O-GlcNAcylation-induced endothelial dysfunction	1797:1843	O-GlcNAcylation-induced endothelial dysfunction in the UAs	1797:1854	We speculate that during pregnancy, hormonal alterations play a protective role in preventing O-GlcNAcylation-induced endothelial dysfunction in the UAs.
32343970	1	52	located	observed	167:174	arg2	O-GlcNAc					154:161	O-GlcNAc	154:161	O-GlcNAc	154:161	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	1	52	located	observed	167:174	arg1	pathologies					187:197	several pathologies	179:197	several pathologies	179:197	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	1	52	located	observed	167:174	arg2	β-N-acetylglucosamine					131:151	Increased O-Linked β-N-acetylglucosamine	112:151	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc)	112:162	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	12	53	theme	protective	1767:1776	arg1	role					1778:1781	a protective role	1765:1781	a protective role	1765:1781	We speculate that during pregnancy, hormonal alterations play a protective role in preventing O-GlcNAcylation-induced endothelial dysfunction in the UAs.
32343970	3	54	theme	artery	488:493	arg1	dysfunction					495:505	uterine artery dysfunction	480:505	uterine artery dysfunction	480:505	We hypothesized that glucosamine treatment increases O-GlcNAc, leading to uterine artery dysfunction and this effect is prevented by pregnancy.
32343970	6	55	theme	decreased	884:892	arg1	relaxation					916:925	decreased endothelium-dependent relaxation	884:925	decreased endothelium-dependent relaxation	884:925	In NP rats, glucosamine treatment increased O-GlcNAc expression in UAs accompanied by decreased endothelium-dependent relaxation, which was abolished by L-NAME.
32343970	5	56	theme	Concentration	658:670	arg1	response-curves					672:686	Concentration response-curves	658:686	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside	658:773	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	5	56	theme	Concentration	658:670	arg1	CRC					689:691	CRC	689:691	CRC	689:691	Concentration response-curves (CRC) to acetylcholine (in the presence or absence of L-NAME) and sodium nitroprusside were performed in UAs.
32343970	4	57	dep	treated	602:608	arg1	300 mg/kg					628:636	300 mg/kg	628:636	300 mg/kg	628:636	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	7	58	theme	nitric	971:976	arg1	eNOS					994:997	eNOS	994:997	eNOS	994:997	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	7	58	theme	nitric	971:976	arg1	synthase					984:991	Endothelial nitric oxide synthase	959:991	Endothelial nitric oxide synthase (eNOS) activity	959:1007	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	6	59	theme	NP	801:802	arg1	rats					804:807	NP rats	801:807	NP rats	801:807	In NP rats, glucosamine treatment increased O-GlcNAc expression in UAs accompanied by decreased endothelium-dependent relaxation, which was abolished by L-NAME.
32343970	11	60	theme	Akt/GSK3β/OGT	1677:1689	arg1	modulation					1691:1700	Akt/GSK3β/OGT modulation	1677:1700	Akt/GSK3β/OGT modulation	1677:1700	The underlying mechanism is, at least in part, dependent on Akt/GSK3β/OGT modulation.
32343970	7	61	theme	oxide	978:982	arg1	eNOS					994:997	eNOS	994:997	eNOS	994:997	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	7	61	theme	oxide	978:982	arg1	synthase					984:991	Endothelial nitric oxide synthase	959:991	Endothelial nitric oxide synthase (eNOS) activity	959:1007	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	4	62	theme	Wistar	585:590	arg1	rats					592:595	Pregnant (P) and non-pregnant (NP) Wistar rats	550:595	Pregnant (P) and non-pregnant (NP) Wistar rats	550:595	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	8	63	from	activation	1188:1197	arg1	UA					1248:1249	the UA	1244:1249	the UA	1244:1249	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	8	64	theme	glycogen	1148:1155	arg1	kinase					1166:1171	glycogen synthase kinase 3	1148:1173	increased glycogen synthase kinase 3 beta (GSK3β) activation	1138:1197	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	1	65	theme	Increased	112:120	arg1	β-N-acetylglucosamine					131:151	Increased O-Linked β-N-acetylglucosamine	112:151	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc)	112:162	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	1	65	theme	Increased	112:120	arg1	O-GlcNAc					154:161	O-GlcNAc	154:161	O-GlcNAc	154:161	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	1	66	theme	O-GlcNAcylation	215:229	arg1	levels					231:236	unbalanced O-GlcNAcylation levels	204:236	unbalanced O-GlcNAcylation levels	204:236	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	8	67	theme	NP	1095:1096	arg1	rats					1098:1101	NP rats	1095:1101	NP rats treated with glucosamine	1095:1126	Further, NP rats treated with glucosamine displayed increased glycogen synthase kinase 3 beta (GSK3β) activation and O-GlcNAc-transferase (OGT) expression in the UA.
32343970	0	68	from	rats	87:90	arg1	function					29:36	endothelial function	17:36	endothelial function in uterine arteries from virgin but not pregnant rats	17:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	0	68	from	rats	87:90	arg1	arteries					49:56	uterine arteries	41:56	uterine arteries from virgin but not pregnant rats	41:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	0	69	dep	impairs	9:15	arg1	role					97:100	The role	93:100	The role of GSK3β	93:109	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	7	70	theme	Endothelial	959:969	arg1	eNOS					994:997	eNOS	994:997	eNOS	994:997	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	7	70	theme	Endothelial	959:969	arg1	synthase					984:991	Endothelial nitric oxide synthase	959:991	Endothelial nitric oxide synthase (eNOS) activity	959:1007	Endothelial nitric oxide synthase (eNOS) activity and total Akt expression were decreased by glucosamine-treatment in NP rats.
32343970	1	71	theme	O-Linked	122:129	arg1	β-N-acetylglucosamine					131:151	Increased O-Linked β-N-acetylglucosamine	112:151	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc)	112:162	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	1	71	theme	O-Linked	122:129	arg1	O-GlcNAc					154:161	O-GlcNAc	154:161	O-GlcNAc	154:161	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	9	72	theme	improved	1346:1353	arg1	relaxation					1355:1364	improved relaxation	1346:1364	improved relaxation to acetylcholine	1346:1381	P rats treated with glucosamine displayed decreased O-GlcNAc in UAs and it was accompanied by improved relaxation to acetylcholine, whereas eNOS and GSK3β activity and total Akt and OGT expression were unchanged.
32343970	0	73	theme	virgin	63:68	arg1	rats					87:90	virgin but not pregnant rats	63:90	virgin but not pregnant rats	63:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	0	74	from	function	29:36	arg1	arteries					49:56	uterine arteries	41:56	uterine arteries from virgin but not pregnant rats	41:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	0	74	from	function	29:36	arg1	rats					87:90	virgin but not pregnant rats	63:90	virgin but not pregnant rats	63:90	O-GlcNAc impairs endothelial function in uterine arteries from virgin but not pregnant rats: The role of GSK3β.
32343970	4	75	dep	300 mg/kg	628:636	arg1	i.p.					639:642	i.p.	639:642	i.p.	639:642	Pregnant (P) and non-pregnant (NP) Wistar rats were treated with glucosamine (300 mg/kg; i.p.) for 21 days.
32343970	1	76	theme	unbalanced	204:213	arg1	levels					231:236	unbalanced O-GlcNAcylation levels	204:236	unbalanced O-GlcNAcylation levels	204:236	Increased O-Linked β-N-acetylglucosamine (O-GlcNAc) is observed in several pathologies, and unbalanced O-GlcNAcylation levels favor endothelial dysfunction.
32343970	12	77	from	dysfunction	1833:1843	arg1	UAs					1852:1854	the UAs	1848:1854	the UAs	1848:1854	We speculate that during pregnancy, hormonal alterations play a protective role in preventing O-GlcNAcylation-induced endothelial dysfunction in the UAs.
33750106	6	0	theme	key	1513:1515	arg1	residue					1528:1534	a key kynurenine residue	1511:1534	a key kynurenine residue from the canonical amino acid tryptophan	1511:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	5	1	theme	Gram-positive	1247:1259	arg1	infections					1271:1280	Gram-positive bacterial infections	1247:1280	Gram-positive bacterial infections	1247:1280	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	2	dep	products	1349:1356	arg1	daptomycin					1358:1367	daptomycin	1358:1367	daptomycin	1358:1367	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	2	dep	products	1349:1356	arg1	F					1379:1379	glycocin F	1370:1379	glycocin F	1370:1379	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	2	dep	products	1349:1356	arg1	alamethicin					1386:1396	alamethicin	1386:1396	alamethicin	1386:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	2	dep	products	1349:1356	arg1	products					1349:1356	the natural products daptomycin, glycocin F, and alamethicin	1337:1396	the natural products daptomycin, glycocin F, and alamethicin	1337:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	8	3	theme	key	2245:2247	arg1	AHMOD					2296:2300	AHMOD	2296:2300	AHMOD	2296:2300	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	3	theme	key	2245:2247	arg1	acid					2290:2293	a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid	2243:2293	a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD)	2243:2301	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	6	4	theme	kynurenine	1517:1526	arg1	residue					1528:1534	a key kynurenine residue	1511:1534	a key kynurenine residue from the canonical amino acid tryptophan	1511:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	9	5	theme	N-terminal	2494:2503	arg1	tails					2511:2515	the N-terminal lipid tails	2490:2515	the N-terminal lipid tails	2490:2515	In both cases, optimization of the N-terminal lipid tails led to the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.
33750106	7	6	from	O-linked	1806:1813	arg1	infections					1852:1861	its native form.For mycobacterial infections	1818:1861	its native form.For mycobacterial infections	1818:1861	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	5	7	with	antibiotics	1211:1221	arg1	potential					1228:1236	potential	1228:1236	potential	1228:1236	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	2	8	theme	treatment	294:302	arg1	modalities					304:313	treatment modalities	294:313	treatment modalities	294:313	To combat this problem, it is imperative that new antibiotics and treatment modalities be developed, especially those toward which bacteria are less capable of developing resistance.
33750106	1	9	theme	medical	188:194	arg1	threat					209:214	an alarming medical and economic threat	176:214	an alarming medical and economic threat to society	176:225	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	7	10	theme	thioacetal	1724:1733	arg1	linkage					1735:1741	a non-native thioacetal linkage	1711:1741	a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1711:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	5	11	dep	synthesis	1307:1315	arg1	the					1303:1305	the	1303:1305	the	1303:1305	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	1	12	theme	multidrug	81:89	arg1	bacteria					101:108	multidrug resistant bacteria	81:108	multidrug resistant bacteria	81:108	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	5	13	theme	product	1094:1100	arg1	antibiotics					1102:1112	peptide-based natural product antibiotics	1072:1112	peptide-based natural product antibiotics	1072:1112	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	1	14	theme	economic	200:207	arg1	threat					209:214	an alarming medical and economic threat	176:214	an alarming medical and economic threat to society	176:225	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	4	15	theme	immune	645:650	arg1	responses					652:660	host immune responses	640:660	host immune responses	640:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	8	16	theme	callyaerin	1993:2002	arg1	A					2004:2004	callyaerin A	1993:2004	callyaerin A	1993:2004	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	4	17	contain	have	581:584	arg2	modulation					626:635	favorable modulation	616:635	favorable modulation of host immune responses	616:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	4	17	contain	have	581:584	arg2	benefits					597:604	additional benefits	586:604	additional benefits including favorable modulation of host immune responses	586:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	4	17	contain	have	581:584	arg1	They					571:574	They	571:574	They	571:574	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	4	18	theme	resistant	734:742	arg1	biofilms					754:761	notoriously treatment resistant bacterial biofilms	712:761	notoriously treatment resistant bacterial biofilms	712:761	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	5	19	theme	range	1063:1067	arg1	development					1046:1056	development	1046:1056	development	1046:1056	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	19	theme	range	1063:1067	arg1	synthesis					1032:1040	total synthesis	1026:1040	total synthesis	1026:1040	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	9	20	theme	analogues	2546:2554	arg1	identification					2528:2541	the identification	2524:2541	the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa	2524:2626	In both cases, optimization of the N-terminal lipid tails led to the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.
33750106	1	21	theme	resistant	91:99	arg1	bacteria					101:108	multidrug resistant bacteria	81:108	multidrug resistant bacteria	81:108	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	5	22	theme	peptide-based	1072:1084	arg1	antibiotics					1102:1112	peptide-based natural product antibiotics	1072:1112	peptide-based natural product antibiotics	1072:1112	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	9	23	theme	potent	2561:2566	arg1	activity					2568:2575	potent activity	2561:2575	potent activity toward Escherichia coli and Pseudomonas aeruginosa	2561:2626	In both cases, optimization of the N-terminal lipid tails led to the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.
33750106	5	24	theme	products	1349:1356	arg1	optimization					1321:1332	optimization	1321:1332	optimization	1321:1332	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	24	theme	products	1349:1356	arg1	synthesis					1307:1315	synthesis	1307:1315	synthesis	1307:1315	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	0	25	theme	Antibiotics	56:66	arg1	Synthesis					11:19	Synthesis	11:19	Synthesis	11:19	Discovery, Synthesis, and Optimization of Peptide-Based Antibiotics.
33750106	0	25	theme	Antibiotics	56:66	arg1	Optimization					26:37	Optimization	26:37	Optimization	26:37	Discovery, Synthesis, and Optimization of Peptide-Based Antibiotics.
33750106	0	25	theme	Antibiotics	56:66	arg1	Discovery					0:8	Discovery	0:8	Discovery	0:8	Discovery, Synthesis, and Optimization of Peptide-Based Antibiotics.
33750106	3	26	dep	modes	554:558	arg1	response					529:536	response	529:536	response	529:536	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	7	27	theme	potent	1647:1652	arg1	compound					1659:1666	a potent lead compound	1645:1666	a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1645:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	6	28	theme	reported	1418:1425	arg1	synthesis					1427:1435	the reported synthesis	1414:1435	the reported synthesis of daptomycin	1414:1449	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	1	29	theme	bacteria	101:108	arg1	rise					73:76	The rise	69:76	The rise of multidrug resistant bacteria	69:108	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	5	30	from	range	844:848	arg1	products					828:835	peptide-based natural products	806:835	peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	806:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	30	from	range	844:848	arg1	wealth					796:801	a wealth	794:801	a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	794:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	31	theme	F	1623:1623	arg1	analogues					1625:1633	glycocin F analogues	1614:1633	glycocin F analogues	1614:1633	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	8	32	theme	Z	2055:2055	arg1	motif					2080:2084	a (Z)-2,3-diaminoacrylamide motif	2052:2084	a (Z)-2,3-diaminoacrylamide motif	2052:2084	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	33	theme	chemistry	1140:1148	arg1	approaches					1150:1159	the medicinal chemistry approaches	1126:1159	the medicinal chemistry approaches	1126:1159	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	3	34	theme	natural	419:425	arg1	products					427:434	Peptide natural products	411:434	Peptide natural products	411:434	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	8	35	theme	-2,3-diaminoacrylamide	2057:2078	arg1	motif					2080:2084	a (Z)-2,3-diaminoacrylamide motif	2052:2084	a (Z)-2,3-diaminoacrylamide motif	2052:2084	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	36	theme	antibiotics	1211:1221	arg1	context					1200:1206	the context	1196:1206	the context of antibiotics with potential	1196:1236	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	37	contain	bears	1705:1709	arg2	linkage					1735:1741	a non-native thioacetal linkage	1711:1741	a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1711:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	37	contain	bears	1705:1709	arg1	compound					1659:1666	a potent lead compound	1645:1666	a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1645:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	6	38	theme	on-resin	1477:1484	arg1	ozonolysis					1486:1495	on-resin ozonolysis	1477:1495	on-resin ozonolysis	1477:1495	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	8	39	theme	Gram-negative	2387:2399	arg1	C					2456:2456	paenipeptin C	2444:2456	paenipeptin C	2444:2456	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	39	theme	Gram-negative	2387:2399	arg1	infections					2411:2420	Gram-negative bacterial infections	2387:2420	Gram-negative bacterial infections	2387:2420	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	39	theme	Gram-negative	2387:2399	arg1	battacin					2431:2438	battacin	2431:2438	battacin	2431:2438	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	40	theme	infections.This	968:982	arg1	Account					984:990	clinically relevant infections.This Account	948:990	clinically relevant infections.This Account	948:990	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	3	41	theme	promising	445:453	arg1	candidates					455:464	promising candidates	445:464	promising candidates	445:464	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	5	42	theme	peptide-based	806:818	arg1	products					828:835	peptide-based natural products	806:835	peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	806:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	43	theme	A	1973:1973	arg1	optimization					1902:1913	optimization	1902:1913	optimization	1902:1913	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	43	theme	A	1973:1973	arg1	synthesis					1888:1896	the synthesis	1884:1896	the synthesis	1884:1896	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	44	theme	callyaerin	1931:1940	arg1	A					1942:1942	callyaerin A	1931:1942	callyaerin A	1931:1942	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	8	45	theme	A	2184:2184	arg1	synthesis					2159:2167	the synthesis	2155:2167	the synthesis of trichoderin A	2155:2184	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	46	theme	products	828:835	arg1	wealth					796:801	a wealth	794:801	a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	794:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	47	theme	teixobactin	1918:1928	arg1	optimization					1902:1913	optimization	1902:1913	optimization	1902:1913	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	47	theme	teixobactin	1918:1928	arg1	synthesis					1888:1896	the synthesis	1884:1896	the synthesis	1884:1896	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	4	48	contain	possess	672:678	arg1	They					571:574	They	571:574	They	571:574	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	4	48	contain	possess	672:678	arg2	activity					695:702	broad-spectrum activity	680:702	broad-spectrum activity against notoriously treatment resistant bacterial biofilms	680:761	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	8	49	theme	antimicrobial	2090:2102	arg1	activity					2104:2111	antimicrobial activity	2090:2111	antimicrobial activity against Mycobacterium tuberculosis	2090:2146	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	6	50	theme	canonical	1545:1553	arg1	tryptophan					1566:1575	the canonical amino acid tryptophan	1541:1575	the canonical amino acid tryptophan	1541:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	7	51	theme	lassomycin	1945:1954	arg1	optimization					1902:1913	optimization	1902:1913	optimization	1902:1913	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	51	theme	lassomycin	1945:1954	arg1	synthesis					1888:1896	the synthesis	1884:1896	the synthesis	1884:1896	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	4	52	theme	additional	586:595	arg1	benefits					597:604	additional benefits	586:604	additional benefits including favorable modulation of host immune responses	586:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	4	52	theme	additional	586:595	arg1	modulation					626:635	favorable modulation	616:635	favorable modulation of host immune responses	616:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	8	53	dep	covers	2332:2337	arg1	highlighted					2022:2032	highlighted	2022:2032	highlighted	2022:2032	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	0	54	theme	Peptide-Based	42:54	arg1	Antibiotics					56:66	Peptide-Based Antibiotics	42:66	Peptide-Based Antibiotics	42:66	Discovery, Synthesis, and Optimization of Peptide-Based Antibiotics.
33750106	8	55	theme	paenipeptin	2444:2454	arg1	C					2456:2456	paenipeptin C	2444:2456	paenipeptin C	2444:2456	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	55	theme	paenipeptin	2444:2454	arg1	infections					2411:2420	Gram-negative bacterial infections	2387:2420	Gram-negative bacterial infections	2387:2420	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	56	theme	R	2217:2217	arg1	-stereoconfiguration					2219:2238	(R)-stereoconfiguration	2216:2238	(R)-stereoconfiguration	2216:2238	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	57	dep	antibiotics	1102:1112	arg1	approaches					1150:1159	the medicinal chemistry approaches	1126:1159	the medicinal chemistry approaches	1126:1159	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	58	from	advances	1010:1017	arg1	development					1046:1056	development	1046:1056	development	1046:1056	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	58	from	advances	1010:1017	arg1	synthesis					1032:1040	total synthesis	1026:1040	total synthesis	1026:1040	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	8	59	theme	-stereoconfiguration	2219:2238	arg1	importance					2202:2211	the importance	2198:2211	the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD)	2198:2301	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	7	60	dep	infections	1852:1861	arg1	covers					1877:1882	covers	1877:1882	covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1877:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	2	61	theme	new	274:276	arg1	antibiotics					278:288	new antibiotics	274:288	new antibiotics	274:288	To combat this problem, it is imperative that new antibiotics and treatment modalities be developed, especially those toward which bacteria are less capable of developing resistance.
33750106	5	62	theme	bacterial	1261:1269	arg1	infections					1271:1280	Gram-positive bacterial infections	1247:1280	Gram-positive bacterial infections	1247:1280	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	8	63	from	importance	2202:2211	arg1	AHMOD					2296:2300	AHMOD	2296:2300	AHMOD	2296:2300	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	63	from	importance	2202:2211	arg1	acid					2290:2293	a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid	2243:2293	a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD)	2243:2301	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	64	theme	2-amino-6-hydroxy-4-methyl-8-oxodecanoic	2249:2288	arg1	AHMOD					2296:2300	AHMOD	2296:2300	AHMOD	2296:2300	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	64	theme	2-amino-6-hydroxy-4-methyl-8-oxodecanoic	2249:2288	arg1	acid					2290:2293	a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid	2243:2293	a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD)	2243:2301	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	4	65	theme	responses	652:660	arg1	modulation					626:635	favorable modulation	616:635	favorable modulation of host immune responses	616:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	9	66	theme	lipid	2505:2509	arg1	tails					2511:2515	the N-terminal lipid tails	2490:2515	the N-terminal lipid tails	2490:2515	In both cases, optimization of the N-terminal lipid tails led to the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.
33750106	1	67	theme	alarming	179:186	arg1	threat					209:214	an alarming medical and economic threat	176:214	an alarming medical and economic threat to society	176:225	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	7	68	theme	non-native	1713:1722	arg1	linkage					1735:1741	a non-native thioacetal linkage	1711:1741	a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1711:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	69	theme	form.For	1829:1836	arg1	infections					1852:1861	its native form.For mycobacterial infections	1818:1861	its native form.For mycobacterial infections	1818:1861	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	3	70	theme	unique	547:552	arg1	modes					554:558	their unique modes	541:558	their unique modes of action	541:568	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	5	71	theme	sources	853:859	arg1	fungi					885:889	fungi	885:889	fungi	885:889	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	71	theme	sources	853:859	arg1	bacteria					872:879	bacteria	872:879	bacteria	872:879	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	71	theme	sources	853:859	arg1	range					844:848	a range	842:848	a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	842:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	3	72	theme	action	563:568	arg1	modes					554:558	their unique modes	541:558	their unique modes of action	541:568	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	5	73	dep	synthesis	1032:1040	arg1	the					1022:1024	the	1022:1024	the	1022:1024	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	8	74	theme	A	2004:2004	arg1	synthesis					1980:1988	The synthesis	1976:1988	The synthesis of callyaerin A	1976:2004	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	75	theme	antibiotics	1102:1112	arg1	range					1063:1067	a range	1061:1067	a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections	1061:1280	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	6	76	theme	acid	1561:1564	arg1	tryptophan					1566:1575	the canonical amino acid tryptophan	1541:1575	the canonical amino acid tryptophan	1541:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	4	77	theme	host	640:643	arg1	responses					652:660	host immune responses	640:660	host immune responses	640:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	5	78	theme	details	1118:1124	arg1	range					1063:1067	a range	1061:1067	a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections	1061:1280	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	79	theme	mycobacterial	1838:1850	arg1	infections					1852:1861	its native form.For mycobacterial infections	1818:1861	its native form.For mycobacterial infections	1818:1861	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	5	80	from	wealth	796:801	arg1	fungi					885:889	fungi	885:889	fungi	885:889	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	80	from	wealth	796:801	arg1	bacteria					872:879	bacteria	872:879	bacteria	872:879	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	80	from	wealth	796:801	arg1	range					844:848	a range	842:848	a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	842:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	81	theme	native	1822:1827	arg1	infections					1852:1861	its native form.For mycobacterial infections	1818:1861	its native form.For mycobacterial infections	1818:1861	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	82	theme	lead	1654:1657	arg1	compound					1659:1666	a potent lead compound	1645:1666	a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A	1645:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	8	83	theme	lipopeptide	2339:2349	arg1	antibiotics					2351:2361	lipopeptide antibiotics	2339:2361	lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C	2339:2456	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	4	84	theme	bacterial	744:752	arg1	biofilms					754:761	notoriously treatment resistant bacterial biofilms	712:761	notoriously treatment resistant bacterial biofilms	712:761	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	5	85	theme	natural	1341:1347	arg1	daptomycin					1358:1367	daptomycin	1358:1367	daptomycin	1358:1367	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	85	theme	natural	1341:1347	arg1	F					1379:1379	glycocin F	1370:1379	glycocin F	1370:1379	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	85	theme	natural	1341:1347	arg1	alamethicin					1386:1396	alamethicin	1386:1396	alamethicin	1386:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	85	theme	natural	1341:1347	arg1	products					1349:1356	the natural products daptomycin, glycocin F, and alamethicin	1337:1396	the natural products daptomycin, glycocin F, and alamethicin	1337:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	6	86	theme	daptomycin	1440:1449	arg1	synthesis					1427:1435	the reported synthesis	1414:1435	the reported synthesis of daptomycin	1414:1449	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	5	87	theme	natural	1086:1092	arg1	antibiotics					1102:1112	peptide-based natural product antibiotics	1072:1112	peptide-based natural product antibiotics	1072:1112	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	4	88	theme	broad-spectrum	680:693	arg1	activity					695:702	broad-spectrum activity	680:702	broad-spectrum activity against notoriously treatment resistant bacterial biofilms	680:761	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
33750106	1	89	theme	antibiotics	154:164	arg1	supply					144:149	our supply	140:149	our supply of antibiotics	140:164	The rise of multidrug resistant bacteria has significantly compromised our supply of antibiotics and poses an alarming medical and economic threat to society.
33750106	9	90	theme	tails	2511:2515	arg1	optimization					2474:2485	optimization	2474:2485	optimization of the N-terminal lipid tails	2474:2515	In both cases, optimization of the N-terminal lipid tails led to the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.
33750106	7	91	theme	glycocin	1614:1621	arg1	analogues					1625:1633	glycocin F analogues	1614:1633	glycocin F analogues	1614:1633	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	9	92	with	analogues	2546:2554	arg1	activity					2568:2575	potent activity	2561:2575	potent activity toward Escherichia coli and Pseudomonas aeruginosa	2561:2626	In both cases, optimization of the N-terminal lipid tails led to the identification of analogues with potent activity toward Escherichia coli and Pseudomonas aeruginosa.
33750106	5	93	theme	medicinal	1130:1138	arg1	chemistry					1140:1148	the medicinal chemistry	1126:1148	the medicinal chemistry approaches	1126:1159	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	94	theme	recent	1003:1008	arg1	advances					1010:1017	recent advances	1003:1017	recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections	1003:1280	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	8	95	theme	motif	2080:2084	arg1	importance					2038:2047	the importance	2034:2047	the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis	2034:2146	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	6	96	from	tryptophan	1566:1575	arg1	residue					1528:1534	a key kynurenine residue	1511:1534	a key kynurenine residue from the canonical amino acid tryptophan	1511:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	7	97	attach	O-linked	1806:1813	arg3	infections					1852:1861	its native form.For mycobacterial infections	1818:1861	its native form.For mycobacterial infections	1818:1861	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	6	98	theme	ozonolysis	1486:1495	arg1	utility					1466:1472	the utility	1462:1472	the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan	1462:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	5	99	theme	relevant	959:966	arg1	Account					984:990	clinically relevant infections.This Account	948:990	clinically relevant infections.This Account	948:990	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	100	theme	N-acetyl-d-glucosamine	1748:1769	arg1	sugar					1780:1784	a N-acetyl-d-glucosamine (GlcNAc) sugar	1746:1784	a N-acetyl-d-glucosamine (GlcNAc) sugar	1746:1784	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	8	101	theme	trichoderin	2172:2182	arg1	A					2184:2184	trichoderin A	2172:2184	trichoderin A	2172:2184	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	5	102	theme	glycocin	1370:1377	arg1	F					1379:1379	glycocin F	1370:1379	glycocin F	1370:1379	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	5	102	theme	glycocin	1370:1377	arg1	products					1349:1356	the natural products daptomycin, glycocin F, and alamethicin	1337:1396	the natural products daptomycin, glycocin F, and alamethicin	1337:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	7	103	theme	trichoderin	1961:1971	arg1	A					1973:1973	trichoderin A	1961:1973	trichoderin A	1961:1973	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	3	104	theme	Peptide	411:417	arg1	products					427:434	Peptide natural products	411:434	Peptide natural products	411:434	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	5	105	theme	natural	820:826	arg1	products					828:835	peptide-based natural products	806:835	peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin	806:1396	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	8	106	theme	bacterial	2401:2409	arg1	C					2456:2456	paenipeptin C	2444:2456	paenipeptin C	2444:2456	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	106	theme	bacterial	2401:2409	arg1	infections					2411:2420	Gram-negative bacterial infections	2387:2420	Gram-negative bacterial infections	2387:2420	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	8	106	theme	bacterial	2401:2409	arg1	battacin					2431:2438	battacin	2431:2438	battacin	2431:2438	The synthesis of callyaerin A, in particular, highlighted the importance of a (Z)-2,3-diaminoacrylamide motif for antimicrobial activity against Mycobacterium tuberculosis, while the synthesis of trichoderin A highlighted the importance of (R)-stereoconfiguration in a key 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (AHMOD) residue.Lastly, this Account covers lipopeptide antibiotics bearing activity toward Gram-negative bacterial infections, namely, battacin and paenipeptin C.
33750106	7	107	theme	A	1942:1942	arg1	optimization					1902:1913	optimization	1902:1913	optimization	1902:1913	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	7	107	theme	A	1942:1942	arg1	synthesis					1888:1896	the synthesis	1884:1896	the synthesis	1884:1896	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	3	108	theme	bacterial	487:495	arg1	resistance					497:506	bacterial resistance	487:506	bacterial resistance	487:506	Peptide natural products stand as promising candidates to meet this need as bacterial resistance is typically slow in response to their unique modes of action.
33750106	6	109	theme	amino	1555:1559	arg1	tryptophan					1566:1575	the canonical amino acid tryptophan	1541:1575	the canonical amino acid tryptophan	1541:1575	In particular, the reported synthesis of daptomycin highlights the utility of on-resin ozonolysis for accessing a key kynurenine residue from the canonical amino acid tryptophan.
33750106	7	110	from	infections	1852:1861	arg1	O-linked					1806:1813	O-linked	1806:1813	O-linked	1806:1813	Furthermore, the investigation into glycocin F analogues uncovered a potent lead compound against Lactobacillus plantarum that bears a non-native thioacetal linkage to a N-acetyl-d-glucosamine (GlcNAc) sugar, which is otherwise O-linked in its native form.For mycobacterial infections, this Account covers the synthesis and optimization of teixobactin, callyaerin A, lassomycin, and trichoderin A.
33750106	5	111	theme	total	1026:1030	arg1	synthesis					1032:1040	total synthesis	1026:1040	total synthesis	1026:1040	Moreover, nature has provided a wealth of peptide-based natural products from a range of sources, including bacteria and fungi, which can be hijacked in order to combat more dangerous clinically relevant infections.This Account highlights recent advances in the total synthesis and development of a range of peptide-based natural product antibiotics and details the medicinal chemistry approaches used to optimize their activity.In the context of antibiotics with potential to treat Gram-positive bacterial infections, this Account covers the synthesis and optimization of the natural products daptomycin, glycocin F, and alamethicin.
33750106	4	112	theme	favorable	616:624	arg1	modulation					626:635	favorable modulation	616:635	favorable modulation of host immune responses	616:660	They also have additional benefits including favorable modulation of host immune responses and often possess broad-spectrum activity against notoriously treatment resistant bacterial biofilms.
34391182	4	0	theme	OGT	928:930	arg1	expression					932:941	OGT expression	928:941	OGT expression	928:941	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	5	1	from	effects	1032:1038	arg1	cells					1078:1082	NSCLC cells	1072:1082	NSCLC cells	1072:1082	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	6	2	theme	chemical	1270:1277	arg1	inhibitors					1279:1288	the specific chemical inhibitors	1257:1288	the specific chemical inhibitors	1257:1288	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	3	3	theme	inflammatory	598:609	arg1	IL-6/STAT3					687:696	IL-6/STAT3	687:696	IL-6/STAT3	687:696	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	3	theme	inflammatory	598:609	arg1	Transducer					642:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	6	4	theme	phosphorylated	1338:1351	arg1	STAT3					1353:1357	phosphorylated STAT3	1338:1357	phosphorylated STAT3 in NSCLC samples	1338:1374	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	10	5	theme	NSCLC	1853:1857	arg1	cells					1859:1863	IL-6 treated NSCLC cells	1840:1863	IL-6 treated NSCLC cells	1840:1863	OGT interacted with and mediated O-GlcNacylation of STAT3, which promoted STAT3 Y705 phosphorylation in IL-6 treated NSCLC cells.
34391182	12	6	theme	phosphorylated	2081:2094	arg1	STAT3					2096:2100	phosphorylated STAT3	2081:2100	phosphorylated STAT3	2081:2100	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	3	7	theme	healing	797:803	arg1	assay					805:809	Scratch wound healing assay	783:809	Scratch wound healing assay	783:809	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	6	8	theme	OGT	1330:1332	arg1	STAT3					1353:1357	phosphorylated STAT3	1338:1357	phosphorylated STAT3 in NSCLC samples	1338:1374	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	6	8	theme	OGT	1330:1332	arg1	distribution					1314:1325	distribution	1314:1325	distribution	1314:1325	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	6	8	theme	OGT	1330:1332	arg1	expression					1299:1308	expression	1299:1308	expression	1299:1308	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	3	9	theme	Transducer	642:651	arg1	A549					743:746	the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549	594:746	the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549	594:746	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	1	10	theme	key	200:202	arg1	transferase					155:165	BACKGROUND O-linked β-N-acetylglucosamine transferase	113:165	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT)	113:193	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	10	theme	key	200:202	arg1	enzyme					204:209	a key enzyme	198:209	a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis	198:335	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	3	11	theme	Scratch	783:789	arg1	assay					805:809	Scratch wound healing assay	783:809	Scratch wound healing assay	783:809	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	12	theme	Interleukin	621:631	arg1	IL-6/STAT3					687:696	IL-6/STAT3	687:696	IL-6/STAT3	687:696	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	12	theme	Interleukin	621:631	arg1	Transducer					642:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	7	13	dep	migration	1456:1464	arg1	the					1452:1454	the	1452:1454	the	1452:1454	RESULTS IL-6/STAT3 promoted the migration and invasion of NSCLC cells.
34391182	12	14	theme	NSCLC	2062:2066	arg1	tissues					2068:2074	human NSCLC tissues	2056:2074	human NSCLC tissues	2056:2074	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	4	15	theme	NSCLCs	1003:1008	arg1	cells					1010:1014	NSCLCs cells	1003:1014	NSCLCs cells	1003:1014	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	0	16	from	signaling	87:95	arg1	cells					106:110	NSCLC cells	100:110	NSCLC cells	100:110	OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells.
34391182	7	17	theme	cells	1488:1492	arg1	invasion					1470:1477	invasion	1470:1477	invasion	1470:1477	RESULTS IL-6/STAT3 promoted the migration and invasion of NSCLC cells.
34391182	7	17	theme	cells	1488:1492	arg1	migration					1456:1464	migration	1456:1464	migration	1456:1464	RESULTS IL-6/STAT3 promoted the migration and invasion of NSCLC cells.
34391182	11	18	theme	IL-6	1943:1946	arg1	stimulation					1948:1958	IL-6 stimulation	1943:1958	IL-6 stimulation	1943:1958	OGT expression was positively regulated by NF-κB p65 signaling pathway after IL-6 stimulation, instead of STAT3 signaling.
34391182	5	19	theme	Immunofluorescence	1136:1153	arg1	staining					1155:1162	Immunofluorescence staining	1136:1162	Immunofluorescence staining	1136:1162	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	3	20	theme	transcription	670:682	arg1	IL-6/STAT3					687:696	IL-6/STAT3	687:696	IL-6/STAT3	687:696	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	20	theme	transcription	670:682	arg1	activator					657:665	activator	657:665	activator	657:665	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	20	theme	transcription	670:682	arg1	Transducer					642:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	1	21	theme	O-GlcNAc	226:233	arg1	modification					235:246	O-GlcNAc modification	226:246	O-GlcNAc modification	226:246	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	4	22	theme	protein	953:959	arg1	O-GlcNacylation					961:975	whole protein O-GlcNacylation	947:975	whole protein O-GlcNacylation	947:975	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	6	23	theme	immunohistochemical	1394:1412	arg1	analysis					1414:1421	immunohistochemical analysis	1394:1421	immunohistochemical analysis	1394:1421	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	5	24	theme	Western	1105:1111	arg1	blot					1113:1116	Western blot	1105:1116	Western blot	1105:1116	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	3	25	theme	activator	657:665	arg1	A549					743:746	the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549	594:746	the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549	594:746	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	1	26	theme	β-N-acetylglucosamine	133:153	arg1	transferase					155:165	BACKGROUND O-linked β-N-acetylglucosamine transferase	113:165	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT)	113:193	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	26	theme	β-N-acetylglucosamine	133:153	arg1	transferase					177:187	O-GlcNAc transferase	168:187	O-GlcNAc transferase	168:187	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	26	theme	β-N-acetylglucosamine	133:153	arg1	enzyme					204:209	a key enzyme	198:209	a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis	198:335	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	9	27	from	expression	1686:1695	arg1	cells					1729:1733	A549 cells	1724:1733	A549 cells	1724:1733	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	6	28	from	expression	1299:1308	arg1	samples					1368:1374	NSCLC samples	1362:1374	NSCLC samples	1362:1374	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	12	29	from	expression	2042:2051	arg1	tissues					2068:2074	human NSCLC tissues	2056:2074	human NSCLC tissues	2056:2074	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	2	30	theme	further	553:559	arg1	elucidation					561:571	further elucidation	553:571	further elucidation	553:571	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	6	31	from	distribution	1314:1325	arg1	samples					1368:1374	NSCLC samples	1362:1374	NSCLC samples	1362:1374	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	3	32	theme	Immunofluorescence	826:843	arg1	staining					845:852	Immunofluorescence staining	826:852	Immunofluorescence staining	826:852	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	13	33	theme	OGT	2180:2182	arg1	O-GlcNacylation					2194:2208	OGT regulated O-GlcNacylation	2180:2208	OGT regulated O-GlcNacylation	2180:2208	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	9	34	theme	IL-6	1640:1643	arg1	N-cadherin					1665:1674	the IL-6 induced EMT marker (N-cadherin and Slug) expression	1636:1695	N-cadherin	1665:1674	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	9	35	from	N-cadherin	1665:1674	arg1	cells					1729:1733	A549 cells	1724:1733	A549 cells	1724:1733	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	3	36	theme	cytoplasmic	871:881	arg1	experiment					894:903	Nuclear and cytoplasmic extraction experiment	859:903	Nuclear and cytoplasmic extraction experiment	859:903	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	9	37	theme	EMT	1653:1655	arg1	N-cadherin					1665:1674	the IL-6 induced EMT marker (N-cadherin and Slug) expression	1636:1695	N-cadherin	1665:1674	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	1	38	theme	BACKGROUND	113:122	arg1	transferase					155:165	BACKGROUND O-linked β-N-acetylglucosamine transferase	113:165	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT)	113:193	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	38	theme	BACKGROUND	113:122	arg1	transferase					177:187	O-GlcNAc transferase	168:187	O-GlcNAc transferase	168:187	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	38	theme	BACKGROUND	113:122	arg1	enzyme					204:209	a key enzyme	198:209	a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis	198:335	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	3	39	theme	Nuclear	859:865	arg1	experiment					894:903	Nuclear and cytoplasmic extraction experiment	859:903	Nuclear and cytoplasmic extraction experiment	859:903	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	0	40	theme	NSCLC	100:104	arg1	cells					106:110	NSCLC cells	100:110	NSCLC cells	100:110	OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells.
34391182	13	41	theme	above	2154:2158	arg1	results					2160:2166	The above results	2150:2166	The above results	2150:2166	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	13	42	dep	CONCLUSION	2139:2148	arg1	showed					2168:2173	showed	2168:2173	showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer	2168:2290	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	2	43	theme	lung	436:439	arg1	cancer					441:446	lung cancer	436:446	lung cancer	436:446	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	12	44	theme	phosphorylated	1997:2010	arg1	STAT3					2012:2016	phosphorylated STAT3	1997:2016	phosphorylated STAT3	1997:2016	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	0	45	theme	OGT	0:2	arg1	O-GlcNacylation					14:28	OGT regulated O-GlcNacylation	0:28	OGT regulated O-GlcNacylation	0:28	OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells.
34391182	9	46	from	invasion	1712:1719	arg1	cells					1729:1733	A549 cells	1724:1733	A549 cells	1724:1733	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	7	47	theme	RESULTS	1424:1430	arg1	IL-6/STAT3					1432:1441	RESULTS IL-6/STAT3	1424:1441	RESULTS IL-6/STAT3	1424:1441	RESULTS IL-6/STAT3 promoted the migration and invasion of NSCLC cells.
34391182	3	48	from	activator	657:665	arg1	cells					737:741	Non-small cell lung cancer (NSCLC) cells	702:741	Non-small cell lung cancer (NSCLC) cells	702:741	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	2	49	theme	underlying	453:462	arg1	mechanisms					474:483	the underlying molecular mechanisms	449:483	the underlying molecular mechanisms	449:483	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	5	50	theme	biological	1021:1030	arg1	effects					1032:1038	The biological effects	1017:1038	The biological effects	1017:1038	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	9	51	from	migration	1698:1706	arg1	cells					1729:1733	A549 cells	1724:1733	A549 cells	1724:1733	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	2	52	theme	inflammatory	514:525	arg1	microenvironment					527:542	the tumor inflammatory microenvironment	504:542	the tumor inflammatory microenvironment	504:542	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	3	53	theme	lung	717:720	arg1	NSCLC					730:734	NSCLC	730:734	NSCLC	730:734	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	53	theme	lung	717:720	arg1	cancer					722:727	Non-small cell lung cancer	702:727	Non-small cell lung cancer (NSCLC) cells	702:741	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	54	from	Transducer	642:651	arg1	cells					737:741	Non-small cell lung cancer (NSCLC) cells	702:741	Non-small cell lung cancer (NSCLC) cells	702:741	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	1	55	theme	tumorigenesis	323:335	arg1	regulation					309:318	the regulation	305:318	the regulation of tumorigenesis	305:335	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	3	56	theme	Non-small	702:710	arg1	NSCLC					730:734	NSCLC	730:734	NSCLC	730:734	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	56	theme	Non-small	702:710	arg1	cancer					722:727	Non-small cell lung cancer	702:727	Non-small cell lung cancer (NSCLC) cells	702:741	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	8	57	theme	OGT	1521:1523	arg1	expression					1525:1534	OGT expression	1521:1534	OGT expression	1521:1534	IL-6 stimulation elevated OGT expression and the total protein O-GlcNacylation in A549 cells.
34391182	10	58	theme	Y705	1816:1819	arg1	phosphorylation					1821:1835	STAT3 Y705 phosphorylation	1810:1835	STAT3 Y705 phosphorylation	1810:1835	OGT interacted with and mediated O-GlcNacylation of STAT3, which promoted STAT3 Y705 phosphorylation in IL-6 treated NSCLC cells.
34391182	1	59	link	O-linked	124:131	arg1	transferase					155:165	BACKGROUND O-linked β-N-acetylglucosamine transferase	113:165	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT)	113:193	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	59	link	O-linked	124:131	arg1	transferase					177:187	O-GlcNAc transferase	168:187	O-GlcNAc transferase	168:187	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	59	link	O-linked	124:131	arg1	enzyme					204:209	a key enzyme	198:209	a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis	198:335	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	5	60	theme	OGT	1065:1067	arg1	effects					1032:1038	The biological effects	1017:1038	The biological effects	1017:1038	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	5	60	theme	OGT	1065:1067	arg1	mechanism					1052:1060	related mechanism	1044:1060	related mechanism	1044:1060	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	6	61	theme	up-stream	1193:1201	arg1	mechanism					1203:1211	The up-stream mechanism	1189:1211	The up-stream mechanism of OGT expression	1189:1229	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	10	62	theme	STAT3	1810:1814	arg1	phosphorylation					1821:1835	STAT3 Y705 phosphorylation	1810:1835	STAT3 Y705 phosphorylation	1810:1835	OGT interacted with and mediated O-GlcNacylation of STAT3, which promoted STAT3 Y705 phosphorylation in IL-6 treated NSCLC cells.
34391182	8	63	theme	total	1544:1548	arg1	O-GlcNacylation					1558:1572	the total protein O-GlcNacylation	1540:1572	the total protein O-GlcNacylation	1540:1572	IL-6 stimulation elevated OGT expression and the total protein O-GlcNacylation in A549 cells.
34391182	10	64	theme	treated	1845:1851	arg1	cells					1859:1863	IL-6 treated NSCLC cells	1840:1863	IL-6 treated NSCLC cells	1840:1863	OGT interacted with and mediated O-GlcNacylation of STAT3, which promoted STAT3 Y705 phosphorylation in IL-6 treated NSCLC cells.
34391182	5	65	theme	NSCLC	1072:1076	arg1	cells					1078:1082	NSCLC cells	1072:1082	NSCLC cells	1072:1082	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	2	66	theme	epithelial-mesenchymal	393:414	arg1	EMT					428:430	EMT	428:430	EMT	428:430	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	2	66	theme	epithelial-mesenchymal	393:414	arg1	transition					416:425	epithelial-mesenchymal transition	393:425	epithelial-mesenchymal transition (EMT) of lung cancer	393:446	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	5	67	from	mechanism	1052:1060	arg1	cells					1078:1082	NSCLC cells	1072:1082	NSCLC cells	1072:1082	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	13	68	theme	lung	2280:2283	arg1	cancer					2285:2290	lung cancer	2280:2290	lung cancer	2280:2290	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	13	69	from	signaling	2267:2275	arg1	cancer					2285:2290	lung cancer	2280:2290	lung cancer	2280:2290	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	3	70	theme	A549	743:746	arg1	role					586:589	The role	582:589	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549	574:746	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	6	71	theme	NSCLC	1362:1366	arg1	samples					1368:1374	NSCLC samples	1362:1374	NSCLC samples	1362:1374	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	6	72	from	STAT3	1353:1357	arg1	samples					1368:1374	NSCLC samples	1362:1374	NSCLC samples	1362:1374	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	3	73	theme	6/Signal	633:640	arg1	IL-6/STAT3					687:696	IL-6/STAT3	687:696	IL-6/STAT3	687:696	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	73	theme	6/Signal	633:640	arg1	Transducer					642:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	6	74	theme	specific	1261:1268	arg1	inhibitors					1279:1288	the specific chemical inhibitors	1257:1288	the specific chemical inhibitors	1257:1288	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	3	75	theme	Transwell	766:774	arg1	assay					776:780	Transwell assay	766:780	Transwell assay	766:780	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	11	76	theme	p65	1915:1917	arg1	pathway					1929:1935	NF-κB p65 signaling pathway	1909:1935	NF-κB p65 signaling pathway	1909:1935	OGT expression was positively regulated by NF-κB p65 signaling pathway after IL-6 stimulation, instead of STAT3 signaling.
34391182	2	77	theme	previous	347:354	arg1	research					356:363	previous research	347:363	previous research	347:363	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	4	78	theme	Western	906:912	arg1	blot					914:917	Western blot	906:917	Western blot	906:917	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	11	79	theme	signaling	1919:1927	arg1	pathway					1929:1935	NF-κB p65 signaling pathway	1909:1935	NF-κB p65 signaling pathway	1909:1935	OGT expression was positively regulated by NF-κB p65 signaling pathway after IL-6 stimulation, instead of STAT3 signaling.
34391182	3	80	theme	signaling	611:619	arg1	IL-6/STAT3					687:696	IL-6/STAT3	687:696	IL-6/STAT3	687:696	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	80	theme	signaling	611:619	arg1	Transducer					642:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	the inflammatory signaling Interleukin 6/Signal Transducer	594:651	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	4	81	theme	IL-6	983:986	arg1	stimulation					988:998	IL-6 stimulation	983:998	IL-6 stimulation in NSCLCs cells	983:1014	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	6	82	theme	expression	1220:1229	arg1	mechanism					1203:1211	The up-stream mechanism	1189:1211	The up-stream mechanism of OGT expression	1189:1229	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	3	83	theme	wound	791:795	arg1	assay					805:809	Scratch wound healing assay	783:809	Scratch wound healing assay	783:809	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	13	84	theme	IL-6/STAT3	2256:2265	arg1	signaling					2267:2275	IL-6/STAT3 signaling	2256:2275	IL-6/STAT3 signaling in lung cancer	2256:2290	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	9	85	theme	Silencing	1589:1597	arg1	OGT					1599:1601	Silencing OGT	1589:1601	Silencing OGT by shRNA	1589:1610	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	12	86	theme	human	2056:2060	arg1	tissues					2068:2074	human NSCLC tissues	2056:2074	human NSCLC tissues	2056:2074	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	8	87	theme	A549	1577:1580	arg1	cells					1582:1586	A549 cells	1577:1586	A549 cells	1577:1586	IL-6 stimulation elevated OGT expression and the total protein O-GlcNacylation in A549 cells.
34391182	1	88	theme	O-linked	124:131	arg1	transferase					155:165	BACKGROUND O-linked β-N-acetylglucosamine transferase	113:165	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT)	113:193	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	88	theme	O-linked	124:131	arg1	transferase					177:187	O-GlcNAc transferase	168:187	O-GlcNAc transferase	168:187	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	88	theme	O-linked	124:131	arg1	enzyme					204:209	a key enzyme	198:209	a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis	198:335	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	4	89	theme	whole	947:951	arg1	O-GlcNacylation					961:975	whole protein O-GlcNacylation	947:975	whole protein O-GlcNacylation	947:975	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	7	90	theme	NSCLC	1482:1486	arg1	cells					1488:1492	NSCLC cells	1482:1492	NSCLC cells	1482:1492	RESULTS IL-6/STAT3 promoted the migration and invasion of NSCLC cells.
34391182	3	91	theme	Western	812:818	arg1	blot					820:823	Western blot	812:823	Western blot	812:823	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	12	92	contain	had	2018:2020	arg2	expression					2042:2051	an obviously higher expression	2022:2051	an obviously higher expression in human NSCLC tissues	2022:2074	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	12	92	contain	had	2018:2020	arg1	OGT					1989:1991	OGT	1989:1991	OGT	1989:1991	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	12	92	contain	had	2018:2020	arg1	STAT3					2012:2016	phosphorylated STAT3	1997:2016	phosphorylated STAT3	1997:2016	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	11	93	theme	OGT	1866:1868	arg1	expression					1870:1879	OGT expression	1866:1879	OGT expression	1866:1879	OGT expression was positively regulated by NF-κB p65 signaling pathway after IL-6 stimulation, instead of STAT3 signaling.
34391182	0	94	theme	IL-6/STAT3	76:85	arg1	signaling					87:95	IL-6/STAT3 signaling	76:95	IL-6/STAT3 signaling in NSCLC cells	76:110	OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells.
34391182	5	95	theme	Transwell	1119:1127	arg1	assay					1129:1133	Transwell assay	1119:1133	Transwell assay	1119:1133	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	1	96	theme	O-GlcNAc	168:175	arg1	transferase					155:165	BACKGROUND O-linked β-N-acetylglucosamine transferase	113:165	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT)	113:193	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	1	96	theme	O-GlcNAc	168:175	arg1	transferase					177:187	O-GlcNAc transferase	168:187	O-GlcNAc transferase	168:187	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	6	97	dep	expression	1299:1308	arg1	the					1295:1297	the	1295:1297	the	1295:1297	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	13	98	theme	regulated	2184:2192	arg1	O-GlcNacylation					2194:2208	OGT regulated O-GlcNacylation	2180:2208	OGT regulated O-GlcNacylation	2180:2208	CONCLUSION The above results showed that OGT regulated O-GlcNacylation promoted migration and invasion by activating IL-6/STAT3 signaling in lung cancer.
34391182	12	99	theme	higher	2035:2040	arg1	expression					2042:2051	an obviously higher expression	2022:2051	an obviously higher expression in human NSCLC tissues	2022:2074	OGT and phosphorylated STAT3 had an obviously higher expression in human NSCLC tissues, and phosphorylated STAT3 was mainly expressed in the nucleus.
34391182	9	100	theme	induced	1645:1651	arg1	N-cadherin					1665:1674	the IL-6 induced EMT marker (N-cadherin and Slug) expression	1636:1695	N-cadherin	1665:1674	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	3	101	theme	extraction	883:892	arg1	experiment					894:903	Nuclear and cytoplasmic extraction experiment	859:903	Nuclear and cytoplasmic extraction experiment	859:903	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	9	102	theme	marker	1657:1662	arg1	N-cadherin					1665:1674	the IL-6 induced EMT marker (N-cadherin and Slug) expression	1636:1695	N-cadherin	1665:1674	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	5	103	theme	related	1044:1050	arg1	mechanism					1052:1060	related mechanism	1044:1060	related mechanism	1044:1060	The biological effects and related mechanism of OGT in NSCLC cells were investigated by Western blot, Transwell assay, Immunofluorescence staining and Immunoprecipitation.
34391182	0	104	theme	regulated	4:12	arg1	O-GlcNacylation					14:28	OGT regulated O-GlcNacylation	0:28	OGT regulated O-GlcNacylation	0:28	OGT regulated O-GlcNacylation promotes migration and invasion by activating IL-6/STAT3 signaling in NSCLC cells.
34391182	11	105	theme	NF-κB	1909:1913	arg1	pathway					1929:1935	NF-κB p65 signaling pathway	1909:1935	NF-κB p65 signaling pathway	1909:1935	OGT expression was positively regulated by NF-κB p65 signaling pathway after IL-6 stimulation, instead of STAT3 signaling.
34391182	9	106	theme	Slug	1680:1683	arg1	expression					1686:1695	the IL-6 induced EMT marker (N-cadherin and Slug) expression	1636:1695	expression	1686:1695	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	8	107	theme	protein	1550:1556	arg1	O-GlcNacylation					1558:1572	the total protein O-GlcNacylation	1540:1572	the total protein O-GlcNacylation	1540:1572	IL-6 stimulation elevated OGT expression and the total protein O-GlcNacylation in A549 cells.
34391182	3	108	dep	METHODS	574:580	arg1	role					586:589	The role	582:589	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549	574:746	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	2	109	theme	molecular	464:472	arg1	mechanisms					474:483	the underlying molecular mechanisms	449:483	the underlying molecular mechanisms	449:483	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	3	110	theme	cell	712:715	arg1	NSCLC					730:734	NSCLC	730:734	NSCLC	730:734	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	3	110	theme	cell	712:715	arg1	cancer					722:727	Non-small cell lung cancer	702:727	Non-small cell lung cancer (NSCLC) cells	702:741	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34391182	1	111	dep	transferase	177:187	arg1	OGT					190:192	OGT	190:192	OGT	190:192	BACKGROUND O-linked β-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT) is a key enzyme that regulates O-GlcNAc modification, which is significantly up-regulated and participates in the regulation of tumorigenesis.
34391182	10	112	theme	STAT3	1788:1792	arg1	O-GlcNacylation					1769:1783	O-GlcNacylation	1769:1783	O-GlcNacylation	1769:1783	OGT interacted with and mediated O-GlcNacylation of STAT3, which promoted STAT3 Y705 phosphorylation in IL-6 treated NSCLC cells.
34391182	2	113	theme	tumor	508:512	arg1	microenvironment					527:542	the tumor inflammatory microenvironment	504:542	the tumor inflammatory microenvironment	504:542	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	8	114	theme	IL-6	1495:1498	arg1	stimulation					1500:1510	IL-6 stimulation	1495:1510	IL-6 stimulation	1495:1510	IL-6 stimulation elevated OGT expression and the total protein O-GlcNacylation in A549 cells.
34391182	2	115	theme	cancer	441:446	arg1	EMT					428:430	EMT	428:430	EMT	428:430	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	2	115	theme	cancer	441:446	arg1	transition					416:425	epithelial-mesenchymal transition	393:425	epithelial-mesenchymal transition (EMT) of lung cancer	393:446	Although previous research indicated that OGT promotes epithelial-mesenchymal transition (EMT) of lung cancer, the underlying molecular mechanisms, especially within the tumor inflammatory microenvironment, require further elucidation.
34391182	6	116	theme	OGT	1216:1218	arg1	expression					1220:1229	OGT expression	1216:1229	OGT expression	1216:1229	The up-stream mechanism of OGT expression was explored by employing the specific chemical inhibitors, and the expression and distribution of OGT and phosphorylated STAT3 in NSCLC samples were confirmed by immunohistochemical analysis.
34391182	4	117	from	stimulation	988:998	arg1	cells					1010:1014	NSCLCs cells	1003:1014	NSCLCs cells	1003:1014	Western blot detected OGT expression and whole protein O-GlcNacylation after IL-6 stimulation in NSCLCs cells.
34391182	11	118	theme	STAT3	1972:1976	arg1	signaling					1978:1986	STAT3 signaling	1972:1986	STAT3 signaling	1972:1986	OGT expression was positively regulated by NF-κB p65 signaling pathway after IL-6 stimulation, instead of STAT3 signaling.
34391182	9	119	theme	A549	1724:1727	arg1	cells					1729:1733	A549 cells	1724:1733	A549 cells	1724:1733	Silencing OGT by shRNA significantly inhibited the IL-6 induced EMT marker (N-cadherin and Slug) expression, migration and invasion in A549 cells.
34391182	3	120	theme	cancer	722:727	arg1	cells					737:741	Non-small cell lung cancer (NSCLC) cells	702:741	Non-small cell lung cancer (NSCLC) cells	702:741	METHODS The role of the inflammatory signaling Interleukin 6/Signal Transducer and activator of transcription 3 (IL-6/STAT3) in Non-small cell lung cancer (NSCLC) cells A549 were confirmed by Transwell assay, Scratch wound healing assay, Western blot, Immunofluorescence staining, and Nuclear and cytoplasmic extraction experiment.
34186233	1	0	theme	β-N-acetylglucosamine	288:308	arg1	moiety					319:324	a single β-N-acetylglucosamine (GlcNAc) moiety	279:324	a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively	279:421	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	8	1	theme	efficient	1244:1252	arg1	compounds					1221:1229	the synthesized compounds	1205:1229	the synthesized compounds	1205:1229	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	8	1	theme	efficient	1244:1252	arg1	inhibitors					1266:1275	efficient competitive inhibitors	1244:1275	efficient competitive inhibitors of hOGA with Ki-s	1244:1293	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	1	2	theme	GlcNAc	311:316	arg1	moiety					319:324	a single β-N-acetylglucosamine (GlcNAc) moiety	279:324	a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively	279:421	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	3	3	theme	O-GlcNAc	601:608	arg1	levels					591:596	aberrantly low levels	576:596	aberrantly low levels of O-GlcNAc	576:608	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	1	4	theme	O-GlcNAc	232:239	arg1	hydrolase					241:249	O-GlcNAc hydrolase	232:249	O-GlcNAc hydrolase (OGA)	232:255	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	4	theme	O-GlcNAc	232:239	arg1	OGA					252:254	OGA	252:254	OGA	252:254	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	8	5	theme	hOGA	1280:1283	arg1	compounds					1221:1229	the synthesized compounds	1205:1229	the synthesized compounds	1205:1229	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	8	5	theme	hOGA	1280:1283	arg1	inhibitors					1266:1275	efficient competitive inhibitors	1244:1275	efficient competitive inhibitors of hOGA with Ki-s	1244:1293	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	6	6	theme	strain	958:963	arg1	selection					965:973	strain selection	958:973	strain selection	958:973	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	8	7	theme	selectivity	1335:1345	arg1	range					1302:1306	the range	1298:1306	the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases	1298:1389	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	6	8	theme	full	1044:1047	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	4	9	theme	potent	684:689	arg1	inhibitors					695:704	potent OGA inhibitors	684:704	potent OGA inhibitors	684:704	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones, have been identified.
34186233	6	10	theme	active	1033:1038	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	2	11	theme	perturbed	428:436	arg1	homeostasis					438:448	The perturbed homeostasis	424:448	The perturbed homeostasis of O-GlcNAc cycling	424:468	The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions.
34186233	8	12	theme	lysosomal	1363:1371	arg1	β-hexosaminidases					1373:1389	lysosomal β-hexosaminidases	1363:1389	lysosomal β-hexosaminidases	1363:1389	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	10	13	theme	structure	1764:1772	arg1	OGA					1807:1809	future structure based inhibitor design targeting OGA	1757:1809	future structure based inhibitor design targeting OGA	1757:1809	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	7	14	theme	environmental	1130:1142	arg1	factors					1144:1150	environmental factors	1130:1150	environmental factors affecting hOGA stability	1130:1175	Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability.
34186233	5	15	theme	%	896:896	arg1	yields					906:911	15-55% overall yields	891:911	15-55% overall yields	891:911	Eight inhibitors were designed and synthesized in five steps starting from d-glucosamine and with 15-55% overall yields.
34186233	6	16	theme	stable	1025:1030	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	7	17	theme	hOGA	1116:1119	arg1	kinetics					1104:1111	Thermal denaturation kinetics	1083:1111	Thermal denaturation kinetics of hOGA	1083:1119	Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability.
34186233	9	18	theme	analogue	1618:1625	arg1	6g					1698:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g	1602:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM)	1602:1712	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	18	theme	analogue	1618:1625	arg1	Ki = 36 nM					1702:1711	Ki = 36 nM	1702:1711	Ki = 36 nM	1702:1711	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	1	19	theme	O-linked	179:186	arg1	OGT					223:225	OGT	223:225	OGT	223:225	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	19	theme	O-linked	179:186	arg1	transferase					210:220	O-linked β-N-acetylglucosamine transferase	179:220	O-linked β-N-acetylglucosamine transferase (OGT)	179:226	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	4	20	theme	semicarbazones	755:768	arg1	inhibitors					695:704	potent OGA inhibitors	684:704	potent OGA inhibitors	684:704	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones, have been identified.
34186233	1	21	theme	nucleocytosolic	366:380	arg1	proteins					400:407	nucleocytosolic and mitochondrial proteins	366:407	nucleocytosolic and mitochondrial proteins	366:407	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	22	theme	mitochondrial	386:398	arg1	proteins					400:407	nucleocytosolic and mitochondrial proteins	366:407	nucleocytosolic and mitochondrial proteins	366:407	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	9	23	theme	2-naphthyl	1672:1681	arg1	6g					1698:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g	1602:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM)	1602:1712	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	23	theme	2-naphthyl	1672:1681	arg1	Ki = 36 nM					1702:1711	Ki = 36 nM	1702:1711	Ki = 36 nM	1702:1711	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	24	theme	-semicarbazone	1683:1696	arg1	6g					1698:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g	1602:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM)	1602:1712	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	24	theme	-semicarbazone	1683:1696	arg1	Ki = 36 nM					1702:1711	Ki = 36 nM	1702:1711	Ki = 36 nM	1702:1711	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	6	25	theme	human	1056:1060	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	2	26	theme	O-GlcNAc	453:460	arg1	cycling					462:468	O-GlcNAc cycling	453:468	O-GlcNAc cycling	453:468	The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions.
34186233	1	27	theme	β-N-acetylglucosamine	188:208	arg1	OGT					223:225	OGT	223:225	OGT	223:225	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	27	theme	β-N-acetylglucosamine	188:208	arg1	transferase					210:220	O-linked β-N-acetylglucosamine transferase	179:220	O-linked β-N-acetylglucosamine transferase (OGT)	179:226	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	10	28	theme	design	1790:1795	arg1	OGA					1807:1809	future structure based inhibitor design targeting OGA	1757:1809	future structure based inhibitor design targeting OGA	1757:1809	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	0	29	theme	Nanomolar	0:8	arg1	inhibition					10:19	Nanomolar inhibition	0:19	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives	0:103	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
34186233	9	30	theme	protein-ligand	1430:1443	arg1	refinements					1445:1455	Prime protein-ligand refinements	1424:1455	Prime protein-ligand refinements	1424:1455	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	1	31	theme	dynamic	127:133	arg1	O-GlcNAcylation					106:120	O-GlcNAcylation	106:120	O-GlcNAcylation	106:120	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	31	theme	dynamic	127:133	arg1	modification					154:165	a dynamic post-translational modification	125:165	a dynamic post-translational modification	125:165	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	6	32	with	protocol	944:951	arg1	isolation					979:987	isolation	979:987	isolation	979:987	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	6	32	with	protocol	944:951	arg1	selection					965:973	strain selection	958:973	strain selection	958:973	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	2	33	theme	several	481:487	arg1	conditions					502:511	several pathological conditions	481:511	several pathological conditions	481:511	The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions.
34186233	5	34	theme	overall	898:904	arg1	yields					906:911	15-55% overall yields	891:911	15-55% overall yields	891:911	Eight inhibitors were designed and synthesized in five steps starting from d-glucosamine and with 15-55% overall yields.
34186233	0	35	theme	OGA	30:32	arg1	inhibition					10:19	Nanomolar inhibition	0:19	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives	0:103	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
34186233	6	36	theme	expression	933:942	arg1	protocol					944:951	A heterologous OGA expression protocol	914:951	A heterologous OGA expression protocol with strain selection and isolation	914:987	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	1	37	link	O-linked	179:186	arg1	OGT					223:225	OGT	223:225	OGT	223:225	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	37	link	O-linked	179:186	arg1	transferase					210:220	O-linked β-N-acetylglucosamine transferase	179:220	O-linked β-N-acetylglucosamine transferase (OGT)	179:226	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	0	38	theme	2-acetamido-2-deoxy-d-glucono-1,5-lactone	37:77	arg1	derivatives					93:103	2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives	37:103	2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives	37:103	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
34186233	9	39	theme	QM/MM-PBSA	1482:1491	arg1	calculations					1513:1524	QM/MM-PBSA binding free energy calculations	1482:1524	QM/MM-PBSA binding free energy calculations	1482:1524	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	8	40	theme	kinetics	1183:1190	arg1	experiments					1192:1202	kinetics experiments	1183:1202	kinetics experiments	1183:1202	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	8	41	from	inhibitors	1266:1275	arg1	range					1302:1306	the range	1298:1306	the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases	1298:1389	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	3	42	theme	therapeutic	539:549	arg1	target					551:556	a promising therapeutic target	527:556	a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease	527:666	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	3	42	theme	therapeutic	539:549	arg1	OGA					520:522	Human OGA	514:522	Human OGA	514:522	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	9	43	theme	free	1501:1504	arg1	calculations					1513:1524	QM/MM-PBSA binding free energy calculations	1482:1524	QM/MM-PBSA binding free energy calculations	1482:1524	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	3	44	theme	low	587:589	arg1	levels					591:596	aberrantly low levels	576:596	aberrantly low levels of O-GlcNAc	576:608	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	8	45	theme	synthesized	1209:1219	arg1	compounds					1221:1229	the synthesized compounds	1205:1229	the synthesized compounds	1205:1229	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	8	45	theme	synthesized	1209:1219	arg1	inhibitors					1266:1275	efficient competitive inhibitors	1244:1275	efficient competitive inhibitors of hOGA with Ki-s	1244:1293	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	4	46	theme	new	671:673	arg1	class					675:679	A new class	669:679	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones,	669:769	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones, have been identified.
34186233	1	47	from	residues	354:361	arg1	moiety					319:324	a single β-N-acetylglucosamine (GlcNAc) moiety	279:324	a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively	279:421	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	48	theme	single	281:286	arg1	moiety					319:324	a single β-N-acetylglucosamine (GlcNAc) moiety	279:324	a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively	279:421	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	9	49	theme	observed	1561:1568	arg1	potencies					1570:1578	the observed potencies	1557:1578	the observed potencies	1557:1578	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	8	50	theme	competitive	1254:1264	arg1	compounds					1221:1229	the synthesized compounds	1205:1229	the synthesized compounds	1205:1229	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	8	50	theme	competitive	1254:1264	arg1	inhibitors					1266:1275	efficient competitive inhibitors	1244:1275	efficient competitive inhibitors of hOGA with Ki-s	1244:1293	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	8	51	theme	∼30-250 nM	1311:1320	arg1	range					1302:1306	the range	1298:1306	the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases	1298:1389	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	7	52	theme	hOGA	1162:1165	arg1	stability					1167:1175	hOGA stability	1162:1175	hOGA stability	1162:1175	Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability.
34186233	3	53	from	target	551:556	arg1	diseases					561:568	diseases	561:568	diseases	561:568	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	3	53	from	target	551:556	arg1	tauopathy					635:643	tauopathy	635:643	tauopathy in Alzheimer's disease	635:666	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	9	54	theme	In	1392:1393	arg1	studies					1402:1408	In silico studies	1392:1408	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations	1392:1524	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	6	55	theme	length	1049:1054	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	6	56	theme	heterologous	916:927	arg1	protocol					944:951	A heterologous OGA expression protocol	914:951	A heterologous OGA expression protocol with strain selection and isolation	914:987	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	8	57	theme	moderate	1326:1333	arg1	selectivity					1335:1345	moderate selectivity	1326:1345	moderate selectivity	1326:1345	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	10	58	theme	based	1774:1778	arg1	OGA					1807:1809	future structure based inhibitor design targeting OGA	1757:1809	future structure based inhibitor design targeting OGA	1757:1809	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	4	59	theme	OGA	691:693	arg1	inhibitors					695:704	potent OGA inhibitors	684:704	potent OGA inhibitors	684:704	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones, have been identified.
34186233	10	60	theme	future	1757:1762	arg1	OGA					1807:1809	future structure based inhibitor design targeting OGA	1757:1809	future structure based inhibitor design targeting OGA	1757:1809	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	7	61	theme	Thermal	1083:1089	arg1	kinetics					1104:1111	Thermal denaturation kinetics	1083:1111	Thermal denaturation kinetics of hOGA	1083:1119	Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability.
34186233	8	62	with	hOGA	1280:1283	arg1	Ki-s					1290:1293	Ki-s	1290:1293	Ki-s	1290:1293	From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with Ki-s in the range of ∼30-250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases.
34186233	7	63	theme	denaturation	1091:1102	arg1	kinetics					1104:1111	Thermal denaturation kinetics	1083:1111	Thermal denaturation kinetics of hOGA	1083:1119	Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability.
34186233	9	64	theme	potent	1611:1616	arg1	6g					1698:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g	1602:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM)	1602:1712	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	64	theme	potent	1611:1616	arg1	Ki = 36 nM					1702:1711	Ki = 36 nM	1702:1711	Ki = 36 nM	1702:1711	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	65	theme	2-acetamido-2-deoxy-d-glucono-1,5-lactone	1627:1667	arg1	6g					1698:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g	1602:1699	the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM)	1602:1712	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	65	theme	2-acetamido-2-deoxy-d-glucono-1,5-lactone	1627:1667	arg1	Ki = 36 nM					1702:1711	Ki = 36 nM	1702:1711	Ki = 36 nM	1702:1711	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	6	66	theme	hOGA	1067:1070	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	1	67	theme	proteins	400:407	arg1	proteins					400:407	nucleocytosolic and mitochondrial proteins	366:407	nucleocytosolic and mitochondrial proteins	366:407	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	67	theme	proteins	400:407	arg1	residues					354:361	serine/threonine residues	337:361	serine/threonine residues	337:361	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	6	68	theme	OGA	1062:1064	arg1	isomorph					1073:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	stable, active and full length human OGA (hOGA) isomorph	1025:1080	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	9	69	theme	6g	1698:1699	arg1	design					1592:1597	design	1592:1597	design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM)	1592:1712	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	3	70	theme	Human	514:518	arg1	target					551:556	a promising therapeutic target	527:556	a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease	527:666	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	3	70	theme	Human	514:518	arg1	OGA					520:522	Human OGA	514:522	Human OGA	514:522	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	9	71	theme	Prime	1424:1428	arg1	refinements					1445:1455	Prime protein-ligand refinements	1424:1455	Prime protein-ligand refinements	1424:1455	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	72	dep	In	1392:1393	arg1	silico					1395:1400	silico	1395:1400	silico	1395:1400	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	10	73	theme	inhibitor	1780:1788	arg1	OGA					1807:1809	future structure based inhibitor design targeting OGA	1757:1809	future structure based inhibitor design targeting OGA	1757:1809	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	0	74	theme	human	24:28	arg1	OGA					30:32	human OGA	24:32	human OGA	24:32	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
34186233	5	75	theme	15-55	891:895	arg1	%					896:896	%	896:896	%	896:896	Eight inhibitors were designed and synthesized in five steps starting from d-glucosamine and with 15-55% overall yields.
34186233	1	76	theme	post-translational	135:152	arg1	O-GlcNAcylation					106:120	O-GlcNAcylation	106:120	O-GlcNAcylation	106:120	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	76	theme	post-translational	135:152	arg1	modification					154:165	a dynamic post-translational modification	125:165	a dynamic post-translational modification	125:165	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	2	77	theme	pathological	489:500	arg1	conditions					502:511	several pathological conditions	481:511	several pathological conditions	481:511	The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions.
34186233	3	78	theme	promising	529:537	arg1	target					551:556	a promising therapeutic target	527:556	a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease	527:666	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	3	78	theme	promising	529:537	arg1	OGA					520:522	Human OGA	514:522	Human OGA	514:522	Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease.
34186233	9	79	theme	QM/MM	1458:1462	arg1	optimizations					1464:1476	QM/MM optimizations	1458:1476	QM/MM optimizations	1458:1476	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	4	80	theme	inhibitors	695:704	arg1	class					675:679	A new class	669:679	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones,	669:769	A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-d-glucono-1,5-lactone (thio)semicarbazones, have been identified.
34186233	2	81	theme	cycling	462:468	arg1	homeostasis					438:448	The perturbed homeostasis	424:448	The perturbed homeostasis of O-GlcNAc cycling	424:468	The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions.
34186233	0	82	theme	semicarbazone	79:91	arg1	derivatives					93:103	2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives	37:103	2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives	37:103	Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
34186233	1	83	theme	serine/threonine	337:352	arg1	proteins					400:407	nucleocytosolic and mitochondrial proteins	366:407	nucleocytosolic and mitochondrial proteins	366:407	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	1	83	theme	serine/threonine	337:352	arg1	residues					354:361	serine/threonine residues	337:361	serine/threonine residues	337:361	O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked β-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single β-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively.
34186233	6	84	theme	OGA	929:931	arg1	protocol					944:951	A heterologous OGA expression protocol	914:951	A heterologous OGA expression protocol with strain selection and isolation	914:987	A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph.
34186233	10	85	contain	has	1737:1739	arg1	protocol					1719:1726	The protocol	1715:1726	The protocol employed	1715:1735	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	10	85	contain	has	1737:1739	arg2	applications					1741:1752	applications	1741:1752	applications	1741:1752	The protocol employed has applications in future structure based inhibitor design targeting OGA.
34186233	9	86	theme	binding	1493:1499	arg1	calculations					1513:1524	QM/MM-PBSA binding free energy calculations	1482:1524	QM/MM-PBSA binding free energy calculations	1482:1524	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	9	87	theme	energy	1506:1511	arg1	calculations					1513:1524	QM/MM-PBSA binding free energy calculations	1482:1524	QM/MM-PBSA binding free energy calculations	1482:1524	In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-d-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (Ki = 36 nM).
34186233	10	88	theme	targeting	1797:1805	arg1	OGA					1807:1809	future structure based inhibitor design targeting OGA	1757:1809	future structure based inhibitor design targeting OGA	1757:1809	The protocol employed has applications in future structure based inhibitor design targeting OGA.
33316265	11	0	theme	vascular	1569:1576	arg1	proteins					1596:1603	vascular O-GlcNAc-modified proteins	1569:1603	vascular O-GlcNAc-modified proteins	1569:1603	Our data showed that pregnancy decreased the content of vascular O-GlcNAc-modified proteins.
33316265	2	1	theme	O-GlcNAc	305:312	arg1	levels					314:319	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	9	2	theme	removal	1375:1381	arg1	effects					1352:1358	the effects	1348:1358	the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats	1348:1441	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	6	3	theme	rats	1111:1114	arg1	arteries					1090:1097	arteries	1090:1097	arteries of P-Wistar rats	1090:1114	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	11	4	theme	O-GlcNAc-modified	1578:1594	arg1	proteins					1596:1603	vascular O-GlcNAc-modified proteins	1569:1603	vascular O-GlcNAc-modified proteins	1569:1603	Our data showed that pregnancy decreased the content of vascular O-GlcNAc-modified proteins.
33316265	2	5	theme	MAIN	292:295	arg1	METHODS					297:303	MAIN METHODS	292:303	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	9	6	theme	L-NAME	1387:1392	arg1	effects					1352:1358	the effects	1348:1358	the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats	1348:1441	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	12	7	theme	eNOS	1681:1684	arg1	modification					1665:1676	decreased O-GlcNAc modification	1646:1676	decreased O-GlcNAc modification	1646:1676	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	12	7	theme	eNOS	1681:1684	arg1	SIGNIFICANCE					1606:1617	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification	1606:1676	SIGNIFICANCE	1606:1617	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	12	8	mod	modification	1665:1676	arg1	eNOS					1681:1684	eNOS	1681:1684	eNOS	1681:1684	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	12	8	mod	modification	1665:1676	arg3	O-GlcNAc					1656:1663	decreased O-GlcNAc modification	1646:1676	decreased O-GlcNAc modification	1646:1676	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	1	9	theme	proteins	201:208	arg1	O-GlcNAc					188:195	O-GlcNAc	188:195	O-GlcNAc	188:195	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	1	9	theme	proteins	201:208	arg1	N-acetylglucosamine					167:185	O-linked N-acetylglucosamine	158:185	O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries	158:229	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	12	10	theme	eNOS	1693:1696	arg1	activity					1698:1705	eNOS activity	1693:1705	eNOS activity	1693:1705	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	10	11	theme	P-SHR	1506:1510	arg1	arteries					1494:1501	arteries	1494:1501	arteries of P-SHR	1494:1510	However, PugNAc did not alter reactivity to PE in arteries of P-SHR.
33316265	1	12	theme	systemic	213:220	arg1	arteries					222:229	systemic arteries	213:229	systemic arteries	213:229	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	2	13	theme	rats	527:530	arg1	aorta					410:414	aorta	410:414	aorta (conductance vessel)	410:435	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	13	theme	rats	527:530	arg1	vessel					429:434	conductance vessel	417:434	conductance vessel	417:434	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	13	theme	rats	527:530	arg1	arteries					452:459	mesenteric arteries	441:459	mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR)	441:572	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	13	theme	rats	527:530	arg1	vessels					473:479	resistance vessels	462:479	resistance vessels	462:479	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	1	14	dep	normotensive	256:267	arg1	rats					286:289	rats	286:289	rats	286:289	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	3	15	theme	O-GlcNAc-modified	584:600	arg1	expression					661:670	O-GlcNAc transferase (OGT) expression	634:670	O-GlcNAc transferase (OGT) expression	634:670	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	3	15	theme	O-GlcNAc-modified	584:600	arg1	O-GlcNAcase					612:622	O-GlcNAcase	612:622	O-GlcNAcase (OGA)	612:628	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	3	15	theme	O-GlcNAc-modified	584:600	arg1	proteins					602:609	Vascular O-GlcNAc-modified proteins	575:609	Vascular O-GlcNAc-modified proteins	575:609	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	9	16	theme	P-Wistar	1429:1436	arg1	rats					1438:1441	P-Wistar rats	1429:1441	P-Wistar rats	1429:1441	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	12	17	theme	O-GlcNAc	1656:1663	arg1	modification					1665:1676	decreased O-GlcNAc modification	1646:1676	decreased O-GlcNAc modification	1646:1676	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	2	18	theme	rats	563:566	arg1	aorta					410:414	aorta	410:414	aorta (conductance vessel)	410:435	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	18	theme	rats	563:566	arg1	vessel					429:434	conductance vessel	417:434	conductance vessel	417:434	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	18	theme	rats	563:566	arg1	arteries					452:459	mesenteric arteries	441:459	mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR)	441:572	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	18	theme	rats	563:566	arg1	vessels					473:479	resistance vessels	462:479	resistance vessels	462:479	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	1	19	from	pregnancy	243:251	arg1	hypertensive					273:284	hypertensive	273:284	hypertensive	273:284	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	1	19	from	pregnancy	243:251	arg1	normotensive					256:267	normotensive	256:267	normotensive	256:267	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	6	20	theme	vascular	973:980	arg1	proteins					1000:1007	vascular O-GlcNAc-modified proteins	973:1007	vascular O-GlcNAc-modified proteins	973:1007	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	1	21	dep	AIM	121:123	arg1	determined					128:137	determined	128:137	determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats	128:289	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	0	22	theme	normotensive	71:82	arg1	rats					115:118	normotensive and spontaneously hypertensive rats	71:118	normotensive and spontaneously hypertensive rats	71:118	Pregnancy decreases O-GlcNAc-modified proteins in systemic arteries of normotensive and spontaneously hypertensive rats.
33316265	2	23	theme	mesenteric	441:450	arg1	arteries					452:459	mesenteric arteries	441:459	mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR)	441:572	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	23	theme	mesenteric	441:450	arg1	vessels					473:479	resistance vessels	462:479	resistance vessels	462:479	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	1	24	theme	O-linked	158:165	arg1	O-GlcNAc					188:195	O-GlcNAc	188:195	O-GlcNAc	188:195	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	1	24	theme	O-linked	158:165	arg1	N-acetylglucosamine					167:185	O-linked N-acetylglucosamine	158:185	O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries	158:229	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	12	25	theme	OGA	1629:1631	arg1	activity					1633:1640	Increased OGA activity	1619:1640	Increased OGA activity	1619:1640	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	13	26	theme	decreased	1825:1833	arg1	activity					1839:1846	decreased OGT activity	1825:1846	decreased OGT activity	1825:1846	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	1	27	from	N-acetylglucosamine	167:185	arg1	arteries					222:229	systemic arteries	213:229	systemic arteries	213:229	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	6	28	dep	FINDINGS	949:956	arg1	lower					1013:1017	lower	1013:1017	lower	1013:1017	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	6	28	dep	FINDINGS	949:956	arg1	higher					1080:1085	higher	1080:1085	higher	1080:1085	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	6	28	dep	FINDINGS	949:956	arg1	content					962:968	The content	958:968	The content of vascular O-GlcNAc-modified proteins	958:1007	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	0	29	theme	rats	115:118	arg1	arteries					59:66	systemic arteries	50:66	systemic arteries of normotensive and spontaneously hypertensive rats	50:118	Pregnancy decreases O-GlcNAc-modified proteins in systemic arteries of normotensive and spontaneously hypertensive rats.
33316265	13	30	theme	O-GlcNAc-modified	1793:1809	arg1	proteins					1811:1818	O-GlcNAc-modified proteins	1793:1818	O-GlcNAc-modified proteins	1793:1818	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	6	31	theme	OGA	1028:1030	arg1	expression					1032:1041	OGA expression	1028:1041	OGA expression	1028:1041	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	2	32	theme	resistance	462:471	arg1	arteries					452:459	mesenteric arteries	441:459	mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR)	441:572	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	32	theme	resistance	462:471	arg1	vessels					473:479	resistance vessels	462:479	resistance vessels	462:479	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	33	mod	modification	334:345	arg1	eNOS					385:388	eNOS	385:388	eNOS	385:388	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	33	mod	modification	334:345	arg1	synthase					375:382	endothelial nitric oxide synthase	350:382	endothelial nitric oxide synthase (eNOS)	350:389	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	33	mod	modification	334:345	arg3	O-GlcNAc					325:332	O-GlcNAc modification	325:345	O-GlcNAc modification	325:345	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	5	34	theme	L-NAME	909:914	arg1	presence					897:904	the presence	893:904	the presence of L-NAME (NOS inhibitor, 100 μmol/L)	893:942	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	0	35	theme	O-GlcNAc-modified	20:36	arg1	proteins					38:45	O-GlcNAc-modified proteins	20:45	O-GlcNAc-modified proteins	20:45	Pregnancy decreases O-GlcNAc-modified proteins in systemic arteries of normotensive and spontaneously hypertensive rats.
33316265	2	36	dep	pregnant	507:514	arg1	P					517:517	P	517:517	P	517:517	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	5	37	theme	NOS	917:919	arg1	100 μmol/L					932:941	100 μmol/L	932:941	100 μmol/L	932:941	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	5	37	theme	NOS	917:919	arg1	inhibitor					921:929	NOS inhibitor	917:929	NOS inhibitor	917:929	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	2	38	theme	non-pregnant	485:496	arg1	rats					527:530	non-pregnant (NP) and pregnant (P) Wistar rats	485:530	non-pregnant (NP) and pregnant (P) Wistar rats	485:530	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	3	39	theme	O-GlcNAc	634:641	arg1	OGT					656:658	OGT	656:658	OGT	656:658	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	3	39	theme	O-GlcNAc	634:641	arg1	transferase					643:653	O-GlcNAc transferase	634:653	O-GlcNAc transferase (OGT) expression	634:670	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	5	40	dep	PugNAc	855:860	arg1	100 μmol/L					878:887	100 μmol/L	878:887	100 μmol/L	878:887	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	5	40	dep	PugNAc	855:860	arg1	inhibitor					867:875	OGA inhibitor	863:875	OGA inhibitor	863:875	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	13	41	from	content	1782:1788	arg1	P-SHR					1740:1744	P-SHR	1740:1744	P-SHR	1740:1744	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	6	42	theme	proteins	1000:1007	arg1	lower					1013:1017	lower	1013:1017	lower	1013:1017	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	6	42	theme	proteins	1000:1007	arg1	content					962:968	The content	958:968	The content of vascular O-GlcNAc-modified proteins	958:1007	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	2	43	theme	synthase	375:382	arg1	levels					314:319	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	43	theme	synthase	375:382	arg1	modification					334:345	O-GlcNAc modification	325:345	O-GlcNAc modification	325:345	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	44	theme	nitric	362:367	arg1	eNOS					385:388	eNOS	385:388	eNOS	385:388	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	44	theme	nitric	362:367	arg1	synthase					375:382	endothelial nitric oxide synthase	350:382	endothelial nitric oxide synthase (eNOS)	350:389	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	1	45	theme	late	238:241	arg1	pregnancy					243:251	late pregnancy	238:251	late pregnancy in normotensive and hypertensive rats	238:289	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	7	46	theme	P-Wistar	1203:1210	arg1	rats					1212:1215	P-Wistar rats	1203:1215	P-Wistar rats treated with PugNAc compared to vehicle	1203:1255	Reactivity to PE increased in arteries of P-Wistar rats treated with PugNAc compared to vehicle.
33316265	13	47	theme	OGA	1755:1757	arg1	activity					1759:1766	altered OGA activity	1747:1766	altered OGA activity	1747:1766	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	3	48	theme	OGA	677:679	arg1	activity					681:688	OGA activity	677:688	OGA activity	677:688	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	9	49	theme	endothelium	1363:1373	arg1	removal					1375:1381	endothelium removal	1363:1381	endothelium removal	1363:1381	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	12	50	theme	P-Wistar	1722:1729	arg1	rats					1731:1734	P-Wistar rats	1722:1734	P-Wistar rats	1722:1734	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	2	51	theme	METHODS	297:303	arg1	levels					314:319	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels	292:319	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	6	52	theme	P-Wistar	1102:1109	arg1	rats					1111:1114	P-Wistar rats	1102:1114	P-Wistar rats	1102:1114	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	11	53	theme	proteins	1596:1603	arg1	content					1558:1564	the content	1554:1564	the content of vascular O-GlcNAc-modified proteins	1554:1603	Our data showed that pregnancy decreased the content of vascular O-GlcNAc-modified proteins.
33316265	2	54	theme	O-GlcNAc	325:332	arg1	modification					334:345	O-GlcNAc modification	325:345	O-GlcNAc modification	325:345	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	3	55	theme	Vascular	575:582	arg1	expression					661:670	O-GlcNAc transferase (OGT) expression	634:670	O-GlcNAc transferase (OGT) expression	634:670	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	3	55	theme	Vascular	575:582	arg1	O-GlcNAcase					612:622	O-GlcNAcase	612:622	O-GlcNAcase (OGA)	612:628	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	3	55	theme	Vascular	575:582	arg1	proteins					602:609	Vascular O-GlcNAc-modified proteins	575:609	Vascular O-GlcNAc-modified proteins	575:609	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	2	56	theme	Wistar	520:525	arg1	rats					527:530	non-pregnant (NP) and pregnant (P) Wistar rats	485:530	non-pregnant (NP) and pregnant (P) Wistar rats	485:530	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	6	57	theme	NP-groups	1150:1158	arg1	arteries					1138:1145	arteries	1138:1145	arteries of NP-groups	1138:1158	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	9	58	theme	rats	1438:1441	arg1	arteries					1417:1424	arteries	1417:1424	arteries of P-Wistar rats	1417:1441	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	12	59	theme	decreased	1646:1654	arg1	modification					1665:1676	decreased O-GlcNAc modification	1646:1676	decreased O-GlcNAc modification	1646:1676	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	6	60	theme	O-GlcNAc-modified	982:998	arg1	proteins					1000:1007	vascular O-GlcNAc-modified proteins	973:1007	vascular O-GlcNAc-modified proteins	973:1007	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	2	61	theme	hypertensive	550:561	arg1	rats					563:566	spontaneously hypertensive rats	536:566	spontaneously hypertensive rats (SHR)	536:572	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	61	theme	hypertensive	550:561	arg1	SHR					569:571	SHR	569:571	SHR	569:571	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	13	62	theme	potential	1856:1864	arg1	mechanism					1866:1874	a potential mechanism	1854:1874	a potential mechanism to reduce glycosylation	1854:1898	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	5	63	theme	OGA	863:865	arg1	100 μmol/L					878:887	100 μmol/L	878:887	100 μmol/L	878:887	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	5	63	theme	OGA	863:865	arg1	inhibitor					867:875	OGA inhibitor	863:875	OGA inhibitor	863:875	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	0	64	theme	hypertensive	102:113	arg1	rats					115:118	normotensive and spontaneously hypertensive rats	71:118	normotensive and spontaneously hypertensive rats	71:118	Pregnancy decreases O-GlcNAc-modified proteins in systemic arteries of normotensive and spontaneously hypertensive rats.
33316265	12	65	theme	Increased	1619:1627	arg1	activity					1633:1640	Increased OGA activity	1619:1640	Increased OGA activity	1619:1640	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	5	66	dep	L-NAME	909:914	arg1	100 μmol/L					932:941	100 μmol/L	932:941	100 μmol/L	932:941	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	5	66	dep	L-NAME	909:914	arg1	inhibitor					921:929	NOS inhibitor	917:929	NOS inhibitor	917:929	Arteries were treated with vehicle or PugNAc (OGA inhibitor, 100 μmol/L) in the presence of L-NAME (NOS inhibitor, 100 μmol/L).
33316265	13	67	theme	OGT	1835:1837	arg1	activity					1839:1846	decreased OGT activity	1825:1846	decreased OGT activity	1825:1846	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	2	68	dep	non-pregnant	485:496	arg1	NP					499:500	NP	499:500	NP	499:500	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	6	69	theme	KEY	945:947	arg1	FINDINGS					949:956	KEY FINDINGS	945:956	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.	945:1159	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	8	70	theme	eNOS	1277:1280	arg1	O-GlcNAcylation					1258:1272	O-GlcNAcylation	1258:1272	O-GlcNAcylation of eNOS	1258:1280	O-GlcNAcylation of eNOS decreased in P-SHR compared to NP-SHR.
33316265	2	71	theme	pregnant	507:514	arg1	rats					527:530	non-pregnant (NP) and pregnant (P) Wistar rats	485:530	non-pregnant (NP) and pregnant (P) Wistar rats	485:530	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	13	72	theme	proteins	1811:1818	arg1	content					1782:1788	the content	1778:1788	the content of O-GlcNAc-modified proteins	1778:1818	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	4	73	theme	Concentration-response	705:726	arg1	curves					750:755	Concentration-response to phenylephrine (PE) curves	705:755	Concentration-response to phenylephrine (PE) curves	705:755	Concentration-response to phenylephrine (PE) curves were constructed for arteries with and without endothelium.
33316265	9	74	from	reactivity	1397:1406	arg1	arteries					1417:1424	arteries	1417:1424	arteries of P-Wistar rats	1417:1441	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	0	75	theme	systemic	50:57	arg1	arteries					59:66	systemic arteries	50:66	systemic arteries of normotensive and spontaneously hypertensive rats	50:118	Pregnancy decreases O-GlcNAc-modified proteins in systemic arteries of normotensive and spontaneously hypertensive rats.
33316265	9	76	from	effects	1352:1358	arg1	reactivity					1397:1406	reactivity	1397:1406	reactivity to PE in arteries of P-Wistar rats	1397:1441	PugNAc partially inhibited the effects of endothelium removal and L-NAME on reactivity to PE in arteries of P-Wistar rats.
33316265	1	77	link	O-linked	158:165	arg1	O-GlcNAc					188:195	O-GlcNAc	188:195	O-GlcNAc	188:195	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	1	77	link	O-linked	158:165	arg1	N-acetylglucosamine					167:185	O-linked N-acetylglucosamine	158:185	O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries	158:229	AIM We determined the role played by O-linked N-acetylglucosamine (O-GlcNAc) of proteins in systemic arteries during late pregnancy in normotensive and hypertensive rats.
33316265	2	78	theme	conductance	417:427	arg1	aorta					410:414	aorta	410:414	aorta (conductance vessel)	410:435	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	78	theme	conductance	417:427	arg1	vessel					429:434	conductance vessel	417:434	conductance vessel	417:434	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	10	79	from	reactivity	1474:1483	arg1	arteries					1494:1501	arteries	1494:1501	arteries of P-SHR	1494:1510	However, PugNAc did not alter reactivity to PE in arteries of P-SHR.
33316265	7	80	theme	rats	1212:1215	arg1	arteries					1191:1198	arteries	1191:1198	arteries of P-Wistar rats treated with PugNAc compared to vehicle	1191:1255	Reactivity to PE increased in arteries of P-Wistar rats treated with PugNAc compared to vehicle.
33316265	13	81	dep	content	1782:1788	arg1	lower					1772:1776	lower	1772:1776	lower	1772:1776	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33316265	2	82	theme	oxide	369:373	arg1	eNOS					385:388	eNOS	385:388	eNOS	385:388	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	82	theme	oxide	369:373	arg1	synthase					375:382	endothelial nitric oxide synthase	350:382	endothelial nitric oxide synthase (eNOS)	350:389	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	6	83	theme	OGA	1063:1065	arg1	activity					1067:1074	OGA activity	1063:1074	OGA activity	1063:1074	KEY FINDINGS The content of vascular O-GlcNAc-modified proteins was lower, OGT and OGA expression did not change, and OGA activity was higher in arteries of P-Wistar rats and P-SHR compared to arteries of NP-groups.
33316265	3	84	theme	transferase	643:653	arg1	expression					661:670	O-GlcNAc transferase (OGT) expression	634:670	O-GlcNAc transferase (OGT) expression	634:670	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	3	84	theme	transferase	643:653	arg1	proteins					602:609	Vascular O-GlcNAc-modified proteins	575:609	Vascular O-GlcNAc-modified proteins	575:609	Vascular O-GlcNAc-modified proteins, O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT) expression, and OGA activity were analyzed.
33316265	12	85	dep	SIGNIFICANCE	1606:1617	arg1	activity					1633:1640	Increased OGA activity	1619:1640	Increased OGA activity	1619:1640	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	2	86	theme	endothelial	350:360	arg1	eNOS					385:388	eNOS	385:388	eNOS	385:388	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	2	86	theme	endothelial	350:360	arg1	synthase					375:382	endothelial nitric oxide synthase	350:382	endothelial nitric oxide synthase (eNOS)	350:389	MAIN METHODS O-GlcNAc levels and O-GlcNAc modification of endothelial nitric oxide synthase (eNOS) were determined in aorta (conductance vessel) and mesenteric arteries (resistance vessels) of non-pregnant (NP) and pregnant (P) Wistar rats and spontaneously hypertensive rats (SHR).
33316265	12	87	theme	rats	1731:1734	arg1	arteries					1710:1717	arteries	1710:1717	arteries of P-Wistar rats	1710:1734	SIGNIFICANCE Increased OGA activity and decreased O-GlcNAc modification of eNOS boosts eNOS activity in arteries of P-Wistar rats.
33316265	13	88	theme	altered	1747:1753	arg1	activity					1759:1766	altered OGA activity	1747:1766	altered OGA activity	1747:1766	In P-SHR, altered OGA activity may lower the content of O-GlcNAc-modified proteins, but decreased OGT activity seems a potential mechanism to reduce glycosylation.
33310751	8	0	theme	same	1149:1152	arg1	domain					1174:1179	the same conserved catalytic domain	1145:1179	the same conserved catalytic domain	1145:1179	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	12	1	theme	intestinal	1878:1887	arg1	physiology					1889:1898	intestinal physiology	1878:1898	intestinal physiology	1878:1898	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	6	2	dep	in	776:777	arg1	vitro					779:783	vitro	779:783	vitro	779:783	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	4	3	theme	OGAs	623:626	arg1	structure					573:581	structure	573:581	structure	573:581	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	4	3	theme	OGAs	623:626	arg1	distribution					597:608	taxonomic distribution	587:608	taxonomic distribution	587:608	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	10	4	theme	In	1405:1406	arg1	studies					1414:1420	In vitro studies	1405:1420	In vitro studies	1405:1420	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	10	5	dep	In	1405:1406	arg1	vitro					1408:1412	vitro	1408:1412	vitro	1408:1412	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	8	6	theme	catalytic	1164:1172	arg1	domain					1174:1179	the same conserved catalytic domain	1145:1179	the same conserved catalytic domain	1145:1179	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	6	7	theme	inflammatory	931:942	arg1	response					944:951	inflammatory response	931:951	inflammatory response in the gut	931:962	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	11	8	dep	In	1600:1601	arg1	vivo					1603:1606	vivo	1603:1606	vivo	1603:1606	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	4	9	theme	OGTs	632:635	arg1	structure					573:581	structure	573:581	structure	573:581	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	4	9	theme	OGTs	632:635	arg1	distribution					597:608	taxonomic distribution	587:608	taxonomic distribution	587:608	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	5	10	theme	genes	697:701	arg1	abundance					703:711	the OGA genes abundance	689:711	the OGA genes abundance in health samples and different diseases	689:752	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	1	11	theme	important	265:273	arg1	N-acetylglucosaminylation					150:174	OBJECTIVE O-linked N-acetylglucosaminylation	131:174	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation)	131:192	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	11	theme	important	265:273	arg1	modification					294:305	an important post-translational modification	262:305	an important post-translational modification of eukaryotic proteins	262:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	10	12	theme	NF-κB	1582:1586	arg1	signalling					1588:1597	NF-κB signalling	1582:1597	NF-κB signalling	1582:1597	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	11	13	theme	induced	1695:1701	arg1	inflammation					1711:1722	chemically induced colonic inflammation	1684:1722	chemically induced colonic inflammation	1684:1722	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	5	14	theme	metagenomic	657:667	arg1	analysis					669:676	metagenomic analysis	657:676	metagenomic analysis	657:676	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	9	15	theme	pooled	1198:1203	arg1	analysis					1205:1212	A pooled analysis	1196:1212	A pooled analysis on 1999 metagenomic samples encompassed six diseases	1196:1265	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	6	16	theme	host	907:910	arg1	cells					912:916	host cells	907:916	host cells	907:916	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	12	17	theme	unrecognised	1812:1823	arg1	activity					1835:1842	a previously unrecognised enzymatic activity	1799:1842	a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology	1799:1898	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	7	18	from	enriched	1009:1016	arg1	divisions					1071:1079	the major bacterial divisions	1051:1079	the major bacterial divisions in the human gut	1051:1096	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	7	18	from	enriched	1009:1016	arg1	Firmicutes					1039:1048	Firmicutes	1039:1048	Firmicutes	1039:1048	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	7	18	from	enriched	1009:1016	arg1	Bacteroidetes					1021:1033	Bacteroidetes	1021:1033	Bacteroidetes	1021:1033	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	6	19	from	proteins	895:902	arg1	cells					912:916	host cells	907:916	host cells	907:916	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	5	20	theme	different	735:743	arg1	diseases					745:752	different diseases	735:752	different diseases	735:752	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	9	21	theme	metagenomic	1222:1232	arg1	samples					1234:1240	1999 metagenomic samples	1217:1240	1999 metagenomic samples encompassed six diseases	1217:1265	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	12	22	from	strategy	1956:1963	arg1	inflammation					1976:1987	colonic inflammation	1968:1987	colonic inflammation	1968:1987	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	7	23	from	Bacteroidetes	1021:1033	arg1	enriched					1009:1016	enriched	1009:1016	enriched	1009:1016	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	7	24	from	divisions	1071:1079	arg1	gut					1094:1096	the human gut	1084:1096	the human gut	1084:1096	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	1	25	theme	O-GlcNAc	231:238	arg1	OGT					253:255	OGT	253:255	OGT	253:255	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	25	theme	O-GlcNAc	231:238	arg1	transferase					240:250	O-GlcNAc transferase	231:250	O-GlcNAc transferase (OGT)	231:256	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	11	26	link	bacteria-derived	1638:1653	arg1	OGAs					1655:1658	gut bacteria-derived OGAs	1634:1658	gut bacteria-derived OGAs	1634:1658	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	7	27	theme	major	1055:1059	arg1	divisions					1071:1079	the major bacterial divisions	1051:1079	the major bacterial divisions in the human gut	1051:1096	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	7	27	theme	major	1055:1059	arg1	Bacteroidetes					1021:1033	Bacteroidetes	1021:1033	Bacteroidetes	1021:1033	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	1	28	theme	OBJECTIVE	131:139	arg1	O-GlcNAcylation					177:191	O-GlcNAcylation	177:191	O-GlcNAcylation	177:191	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	28	theme	OBJECTIVE	131:139	arg1	N-acetylglucosaminylation					150:174	OBJECTIVE O-linked N-acetylglucosaminylation	131:174	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation)	131:192	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	28	theme	OBJECTIVE	131:139	arg1	modification					294:305	an important post-translational modification	262:305	an important post-translational modification of eukaryotic proteins	262:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	9	29	theme	OGA	1291:1293	arg1	genes					1295:1299	bacterial OGA genes	1281:1299	bacterial OGA genes	1281:1299	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	1	30	theme	gut	372:374	arg1	inflammation					376:387	gut inflammation	372:387	gut inflammation	372:387	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	10	31	theme	host	1492:1495	arg1	cells					1497:1501	host cells	1492:1501	host cells	1492:1501	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	8	32	with	enzymes	1132:1138	arg1	domain					1174:1179	the same conserved catalytic domain	1145:1179	the same conserved catalytic domain	1145:1179	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	9	33	theme	human	1327:1331	arg1	gut					1333:1335	healthy human gut	1319:1335	healthy human gut	1319:1335	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	0	34	theme	Bacterial	0:8	arg1	abundance					28:36	Bacterial O-GlcNAcase genes abundance	0:36	Bacterial O-GlcNAcase genes abundance	0:36	Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
33310751	1	35	theme	post-translational	275:292	arg1	N-acetylglucosaminylation					150:174	OBJECTIVE O-linked N-acetylglucosaminylation	131:174	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation)	131:192	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	35	theme	post-translational	275:292	arg1	modification					294:305	an important post-translational modification	262:305	an important post-translational modification of eukaryotic proteins	262:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	10	36	theme	O-GlcNAcylated	1514:1527	arg1	subunit					1539:1545	O-GlcNAcylated NF-κB-p65 subunit	1514:1545	O-GlcNAcylated NF-κB-p65 subunit	1514:1545	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	0	37	theme	genes	22:26	arg1	abundance					28:36	Bacterial O-GlcNAcase genes abundance	0:36	Bacterial O-GlcNAcase genes abundance	0:36	Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
33310751	1	38	theme	proteins	321:328	arg1	N-acetylglucosaminylation					150:174	OBJECTIVE O-linked N-acetylglucosaminylation	131:174	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation)	131:192	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	38	theme	proteins	321:328	arg1	modification					294:305	an important post-translational modification	262:305	an important post-translational modification of eukaryotic proteins	262:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	12	39	theme	colonic	1968:1974	arg1	inflammation					1976:1987	colonic inflammation	1968:1987	colonic inflammation	1968:1987	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	6	40	theme	O-GlcNAcylated	880:893	arg1	proteins					895:902	O-GlcNAcylated proteins	880:902	O-GlcNAcylated proteins in host cells	880:916	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	1	41	link	O-linked	141:148	arg1	O-GlcNAcylation					177:191	O-GlcNAcylation	177:191	O-GlcNAcylation	177:191	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	41	link	O-linked	141:148	arg1	N-acetylglucosaminylation					150:174	OBJECTIVE O-linked N-acetylglucosaminylation	131:174	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation)	131:192	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	41	link	O-linked	141:148	arg1	modification					294:305	an important post-translational modification	262:305	an important post-translational modification of eukaryotic proteins	262:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	11	42	theme	O-GlcNAcylated	1744:1757	arg1	proteins					1759:1766	hydrolysing O-GlcNAcylated proteins	1732:1766	hydrolysing O-GlcNAcylated proteins	1732:1766	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	3	43	theme	enzymes	519:525	arg1	abundance					487:495	abundance	487:495	abundance	487:495	However, the characteristics, abundance and function of these enzymes are unknown.
33310751	3	43	theme	enzymes	519:525	arg1	characteristics					470:484	the characteristics	466:484	the characteristics	466:484	However, the characteristics, abundance and function of these enzymes are unknown.
33310751	3	43	theme	enzymes	519:525	arg1	unknown					531:537	unknown	531:537	unknown	531:537	However, the characteristics, abundance and function of these enzymes are unknown.
33310751	3	43	theme	enzymes	519:525	arg1	function					501:508	function	501:508	function	501:508	However, the characteristics, abundance and function of these enzymes are unknown.
33310751	0	44	theme	ulcerative	51:60	arg1	patients					70:77	ulcerative colitis patients	51:77	ulcerative colitis patients	51:77	Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
33310751	8	45	theme	bacterial	1104:1112	arg1	OGAs					1114:1117	Most bacterial OGAs	1099:1117	Most bacterial OGAs	1099:1117	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	8	45	theme	bacterial	1104:1112	arg1	enzymes					1132:1138	secreted enzymes	1123:1138	secreted enzymes with the same conserved catalytic domain as human OGAs	1123:1193	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	6	46	theme	in	776:777	arg1	experiments					797:807	in vitro and in vivo experiments	776:807	in vitro and in vivo experiments	776:807	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	9	47	theme	ulcerative	1385:1394	arg1	colitis					1396:1402	ulcerative colitis	1385:1402	ulcerative colitis	1385:1402	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	12	48	theme	promising	1934:1942	arg1	strategy					1956:1963	a promising therapeutic strategy	1932:1963	a promising therapeutic strategy in colonic inflammation	1932:1987	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	12	48	theme	promising	1934:1942	arg1	OGAs					1924:1927	bacterial OGAs	1914:1927	bacterial OGAs	1914:1927	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	6	49	theme	bacterial	852:860	arg1	OGAs					862:865	bacterial OGAs	852:865	bacterial OGAs	852:865	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	6	50	from	response	944:951	arg1	gut					960:962	the gut	956:962	the gut	956:962	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	2	51	theme	Gut	390:392	arg1	microbiota					394:403	Gut microbiota	390:403	Gut microbiota	390:403	Gut microbiota encode various enzymes involved in O-GlcNAcylation.
33310751	2	51	theme	Gut	390:392	arg1	enzymes					420:426	various enzymes	412:426	various enzymes involved in O-GlcNAcylation	412:454	Gut microbiota encode various enzymes involved in O-GlcNAcylation.
33310751	5	52	from	abundance	703:711	arg1	samples					723:729	health samples	716:729	health samples	716:729	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	5	52	from	abundance	703:711	arg1	diseases					745:752	different diseases	735:752	different diseases	735:752	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	11	53	theme	bacteria-derived	1638:1653	arg1	OGAs					1655:1658	gut bacteria-derived OGAs	1634:1658	gut bacteria-derived OGAs	1634:1658	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	6	54	dep	in	789:790	arg1	vivo					792:795	vivo	792:795	vivo	792:795	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	4	55	theme	bacterial	613:621	arg1	OGAs					623:626	bacterial OGAs	613:626	bacterial OGAs	613:626	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	5	56	theme	OGA	693:695	arg1	abundance					703:711	the OGA genes abundance	689:711	the OGA genes abundance in health samples and different diseases	689:752	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	8	57	theme	conserved	1154:1162	arg1	domain					1174:1179	the same conserved catalytic domain	1145:1179	the same conserved catalytic domain	1145:1179	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	12	58	theme	gut	1853:1855	arg1	microbiota					1857:1866	gut microbiota	1853:1866	gut microbiota	1853:1866	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	11	59	theme	colonic	1703:1709	arg1	inflammation					1711:1722	chemically induced colonic inflammation	1684:1722	chemically induced colonic inflammation	1684:1722	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	7	60	theme	human	1088:1092	arg1	gut					1094:1096	the human gut	1084:1096	the human gut	1084:1096	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	11	61	theme	In	1600:1601	arg1	studies					1608:1614	In vivo studies	1600:1614	In vivo studies	1600:1614	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	8	62	theme	human	1184:1188	arg1	OGAs					1190:1193	human OGAs	1184:1193	human OGAs	1184:1193	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	12	63	theme	enzymatic	1825:1833	arg1	activity					1835:1842	a previously unrecognised enzymatic activity	1799:1842	a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology	1799:1898	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	6	64	dep	effects	826:832	arg1	the					822:824	the	822:824	the	822:824	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	12	65	dep	CONCLUSION	1769:1778	arg1	highlight					1904:1912	highlight	1904:1912	highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation	1904:1987	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	12	65	dep	CONCLUSION	1769:1778	arg1	reveal					1792:1797	reveal	1792:1797	reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology	1792:1898	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	7	66	theme	bacterial	1061:1069	arg1	divisions					1071:1079	the major bacterial divisions	1051:1079	the major bacterial divisions in the human gut	1051:1096	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	7	66	theme	bacterial	1061:1069	arg1	Bacteroidetes					1021:1033	Bacteroidetes	1021:1033	Bacteroidetes	1021:1033	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	10	67	from	proteins	1480:1487	arg1	cells					1497:1501	host cells	1492:1501	host cells	1492:1501	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	12	68	theme	therapeutic	1944:1954	arg1	strategy					1956:1963	a promising therapeutic strategy	1932:1963	a promising therapeutic strategy in colonic inflammation	1932:1987	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	12	68	theme	therapeutic	1944:1954	arg1	OGAs					1924:1927	bacterial OGAs	1914:1927	bacterial OGAs	1914:1927	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	5	69	theme	health	716:721	arg1	samples					723:729	health samples	716:729	health samples	716:729	Then, we performed metagenomic analysis to explore the OGA genes abundance in health samples and different diseases.
33310751	4	70	dep	structure	573:581	arg1	the					569:571	the	569:571	the	569:571	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	1	71	theme	O-linked	141:148	arg1	O-GlcNAcylation					177:191	O-GlcNAcylation	177:191	O-GlcNAcylation	177:191	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	71	theme	O-linked	141:148	arg1	N-acetylglucosaminylation					150:174	OBJECTIVE O-linked N-acetylglucosaminylation	131:174	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation)	131:192	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	1	71	theme	O-linked	141:148	arg1	modification					294:305	an important post-translational modification	262:305	an important post-translational modification of eukaryotic proteins	262:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	0	72	from	colitis	114:120	arg1	mice					125:128	mice	125:128	mice	125:128	Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
33310751	9	73	from	analysis	1205:1212	arg1	samples					1234:1240	1999 metagenomic samples	1217:1240	1999 metagenomic samples encompassed six diseases	1217:1265	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	9	74	theme	bacterial	1281:1289	arg1	genes					1295:1299	bacterial OGA genes	1281:1299	bacterial OGA genes	1281:1299	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	7	75	dep	RESULTS	965:971	arg1	found					976:980	found	976:980	found OGAs, instead of OGTs,	976:1003	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	1	76	theme	essential	343:351	arg1	role					353:356	an essential role	340:356	an essential role	340:356	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	10	77	theme	bacterial	1434:1442	arg1	OGAs					1444:1447	bacterial OGAs	1434:1447	bacterial OGAs	1434:1447	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	9	78	theme	healthy	1319:1325	arg1	gut					1333:1335	healthy human gut	1319:1335	healthy human gut	1319:1335	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	2	79	theme	various	412:418	arg1	microbiota					394:403	Gut microbiota	390:403	Gut microbiota	390:403	Gut microbiota encode various enzymes involved in O-GlcNAcylation.
33310751	2	79	theme	various	412:418	arg1	enzymes					420:426	various enzymes	412:426	various enzymes involved in O-GlcNAcylation	412:454	Gut microbiota encode various enzymes involved in O-GlcNAcylation.
33310751	0	80	theme	O-GlcNAcase	10:20	arg1	abundance					28:36	Bacterial O-GlcNAcase genes abundance	0:36	Bacterial O-GlcNAcase genes abundance	0:36	Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
33310751	4	81	theme	taxonomic	587:595	arg1	distribution					597:608	taxonomic distribution	587:608	taxonomic distribution	587:608	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	10	82	theme	O-GlcNAcylated	1465:1478	arg1	proteins					1480:1487	O-GlcNAcylated proteins	1465:1487	O-GlcNAcylated proteins	1465:1487	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	10	82	theme	O-GlcNAcylated	1465:1478	arg1	subunit					1539:1545	O-GlcNAcylated NF-κB-p65 subunit	1514:1545	O-GlcNAcylated NF-κB-p65 subunit	1514:1545	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	9	83	theme	high	1342:1345	arg1	abundance					1347:1355	high abundance	1342:1355	high abundance	1342:1355	A pooled analysis on 1999 metagenomic samples encompassed six diseases revealed that bacterial OGA genes were conserved in healthy human gut with high abundance, and reduced exclusively in ulcerative colitis.
33310751	1	84	theme	eukaryotic	310:319	arg1	proteins					321:328	eukaryotic proteins	310:328	eukaryotic proteins	310:328	OBJECTIVE O-linked N-acetylglucosaminylation (O-GlcNAcylation), controlled by O-GlcNAcase (OGA) and O-GlcNAc transferase (OGT), is an important post-translational modification of eukaryotic proteins and plays an essential role in regulating gut inflammation.
33310751	8	85	theme	Most	1099:1102	arg1	OGAs					1114:1117	Most bacterial OGAs	1099:1117	Most bacterial OGAs	1099:1117	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	8	85	theme	Most	1099:1102	arg1	enzymes					1132:1138	secreted enzymes	1123:1138	secreted enzymes with the same conserved catalytic domain as human OGAs	1123:1193	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	11	86	theme	hydrolysing	1732:1742	arg1	proteins					1759:1766	hydrolysing O-GlcNAcylated proteins	1732:1766	hydrolysing O-GlcNAcylated proteins	1732:1766	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
33310751	6	87	theme	in	789:790	arg1	experiments					797:807	in vitro and in vivo experiments	776:807	in vitro and in vivo experiments	776:807	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	0	88	theme	colitis	62:68	arg1	patients					70:77	ulcerative colitis patients	51:77	ulcerative colitis patients	51:77	Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice.
33310751	4	89	dep	DESIGN	540:545	arg1	investigated					556:567	investigated	556:567	investigated the structure and taxonomic distribution of bacterial OGAs and OGTs	556:635	DESIGN We first investigated the structure and taxonomic distribution of bacterial OGAs and OGTs.
33310751	8	90	theme	secreted	1123:1130	arg1	OGAs					1114:1117	Most bacterial OGAs	1099:1117	Most bacterial OGAs	1099:1117	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	8	90	theme	secreted	1123:1130	arg1	enzymes					1132:1138	secreted enzymes	1123:1138	secreted enzymes with the same conserved catalytic domain as human OGAs	1123:1193	Most bacterial OGAs are secreted enzymes with the same conserved catalytic domain as human OGAs.
33310751	6	91	theme	OGAs	862:865	arg1	effects					826:832	effects	826:832	effects	826:832	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	6	91	theme	OGAs	862:865	arg1	mechanisms					838:847	mechanisms	838:847	mechanisms	838:847	Finally, we employed in vitro and in vivo experiments to determine the effects and mechanisms of bacterial OGAs to hydrolyse O-GlcNAcylated proteins in host cells and suppress inflammatory response in the gut.
33310751	12	92	theme	bacterial	1914:1922	arg1	strategy					1956:1963	a promising therapeutic strategy	1932:1963	a promising therapeutic strategy in colonic inflammation	1932:1987	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	12	92	theme	bacterial	1914:1922	arg1	OGAs					1924:1927	bacterial OGAs	1914:1927	bacterial OGAs	1914:1927	CONCLUSION Our results reveal a previously unrecognised enzymatic activity by which gut microbiota influence intestinal physiology and highlight bacterial OGAs as a promising therapeutic strategy in colonic inflammation.
33310751	7	93	from	Firmicutes	1039:1048	arg1	enriched					1009:1016	enriched	1009:1016	enriched	1009:1016	RESULTS We found OGAs, instead of OGTs, are enriched in Bacteroidetes and Firmicutes, the major bacterial divisions in the human gut.
33310751	10	94	theme	NF-κB-p65	1529:1537	arg1	subunit					1539:1545	O-GlcNAcylated NF-κB-p65 subunit	1514:1545	O-GlcNAcylated NF-κB-p65 subunit	1514:1545	In vitro studies showed that bacterial OGAs could hydrolyse O-GlcNAcylated proteins in host cells, including O-GlcNAcylated NF-κB-p65 subunit, which is important for activating NF-κB signalling.
33310751	11	95	theme	gut	1634:1636	arg1	OGAs					1655:1658	gut bacteria-derived OGAs	1634:1658	gut bacteria-derived OGAs	1634:1658	In vivo studies demonstrated that gut bacteria-derived OGAs could protect mice from chemically induced colonic inflammation through hydrolysing O-GlcNAcylated proteins.
32820167	1	0	theme	bioactive	151:159	arg1	peptides					161:168	bioactive peptides	151:168	bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure	151:277	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	4	1	theme	proprotein	560:569	arg1	processing					571:580	proprotein processing	560:580	proprotein processing	560:580	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	0	2	theme	biological	71:80	arg1	roles					82:86	diverse biological roles	63:86	diverse biological roles	63:86	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	0	3	from	atlas	3:7	arg1	hormones					46:53	peptide hormones	38:53	peptide hormones	38:53	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	0	4	link	O-linked	12:19	arg1	glycosylation					21:33	O-linked glycosylation	12:33	O-linked glycosylation	12:33	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	2	5	theme	extensive	340:348	arg1	map					350:352	an extensive map	337:352	an extensive map of O-glycans on peptide hormones	337:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	4	6	theme	identified	486:495	arg1	O-glycosites					497:508	the identified O-glycosites	482:508	the identified O-glycosites	482:508	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	1	7	theme	blood	264:268	arg1	pressure					270:277	blood pressure	264:277	blood pressure	264:277	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	5	8	theme	neuropeptide	733:744	arg1	Y					746:746	neuropeptide Y	733:746	neuropeptide Y	733:746	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	6	9	theme	peptide	928:934	arg1	hormones					936:943	peptide hormones	928:943	peptide hormones	928:943	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	5	10	theme	positioned	669:678	arg1	O-glycans					659:667	O-glycans	659:667	O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families	659:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	6	11	theme	biomolecules	997:1008	arg1	class					988:992	this large class	977:992	this large class of biomolecules	977:1008	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	5	12	theme	Y	746:746	arg1	families					761:768	the neuropeptide Y and glucagon families	729:768	the neuropeptide Y and glucagon families	729:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	3	13	contain	carry	457:461	arg1	third					412:416	third	412:416	third	412:416	We find that almost one third of the 279 classified peptide hormones carry O-glycans.
32820167	3	13	contain	carry	457:461	arg2	O-glycans					463:471	O-glycans	463:471	O-glycans	463:471	We find that almost one third of the 279 classified peptide hormones carry O-glycans.
32820167	6	14	from	importance	880:889	arg1	biology					917:923	the biology	913:923	the biology of peptide hormones	913:943	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	1	15	theme	physiological	184:196	arg1	processes					198:206	physiological processes	184:206	physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure	184:277	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	2	16	from	map	350:352	arg1	hormones					378:385	peptide hormones	370:385	peptide hormones	370:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	5	17	theme	peptide	835:841	arg1	half-lives					843:852	peptide half-lives	835:852	peptide half-lives	835:852	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	6	18	theme	drug	1110:1113	arg1	designs					1115:1121	drug designs	1110:1121	drug designs	1110:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	4	19	from	roles	551:555	arg1	processing					571:580	proprotein processing	560:580	proprotein processing	560:580	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	4	19	from	roles	551:555	arg1	interaction					592:602	receptor interaction	583:602	receptor interaction	583:602	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	4	19	from	roles	551:555	arg1	biostability					625:636	biostability	625:636	biostability	625:636	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	4	19	from	roles	551:555	arg1	biodistribution					605:619	biodistribution	605:619	biodistribution	605:619	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	5	20	theme	receptor	779:786	arg1	properties					799:808	receptor activation properties	779:808	receptor activation properties	779:808	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	5	21	theme	glucagon	752:759	arg1	families					761:768	the neuropeptide Y and glucagon families	729:768	the neuropeptide Y and glucagon families	729:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	2	22	theme	discovery	307:315	arg1	strategy					317:324	a focused discovery strategy	297:324	a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones	297:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	4	23	gly	O-glycosites	497:508	arg2	O-glycosites					497:508	the identified O-glycosites	482:508	the identified O-glycosites	482:508	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	2	24	theme	peptide	370:376	arg1	hormones					378:385	peptide hormones	370:385	peptide hormones	370:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	4	25	theme	O-glycosites	497:508	arg1	Many					474:477	Many	474:477	Many	474:477	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	4	25	theme	O-glycosites	497:508	arg1	O-glycosites					497:508	the identified O-glycosites	482:508	the identified O-glycosites	482:508	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	2	26	from	O-glycans	357:365	arg1	hormones					378:385	peptide hormones	370:385	peptide hormones	370:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	1	27	theme	Peptide	89:95	arg1	hormones					97:104	Peptide hormones	89:104	Peptide hormones	89:104	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	0	28	theme	O-linked	12:19	arg1	glycosylation					21:33	O-linked glycosylation	12:33	O-linked glycosylation	12:33	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	6	29	gly	O-glycosites	961:972	arg2	O-glycosites					961:972	O-glycosites	961:972	O-glycosites	961:972	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	3	30	theme	peptide	440:446	arg1	hormones					448:455	the 279 classified peptide hormones	421:455	the 279 classified peptide hormones	421:455	We find that almost one third of the 279 classified peptide hormones carry O-glycans.
32820167	2	31	theme	focused	299:305	arg1	strategy					317:324	a focused discovery strategy	297:324	a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones	297:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	6	32	theme	large	982:986	arg1	class					988:992	this large class	977:992	this large class of biomolecules	977:1008	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	1	33	theme	peptides	161:168	arg1	class					142:146	a large class	134:146	a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure	134:277	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	3	34	theme	hormones	448:455	arg1	third					412:416	third	412:416	third	412:416	We find that almost one third of the 279 classified peptide hormones carry O-glycans.
32820167	5	35	theme	activation	788:797	arg1	properties					799:808	receptor activation properties	779:808	receptor activation properties	779:808	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	5	36	theme	members	718:724	arg1	motifs					708:713	the receptor binding motifs	687:713	the receptor binding motifs of members of the neuropeptide Y and glucagon families	687:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	6	37	theme	O-glycosylation	894:908	arg1	importance					880:889	the importance	876:889	the importance of O-glycosylation in the biology of peptide hormones	876:943	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	0	38	theme	glycosylation	21:33	arg1	atlas					3:7	An atlas	0:7	An atlas of O-linked glycosylation on peptide hormones	0:53	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	1	39	theme	blood	222:226	arg1	glucose					228:234	blood glucose	222:234	blood glucose	222:234	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	6	40	theme	O-glycosites	961:972	arg1	platform					1032:1039	a discovery platform	1020:1039	a discovery platform for an important class of molecules with potential opportunities for drug designs	1020:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	6	40	theme	O-glycosites	961:972	arg1	map					954:956	our map	950:956	our map of O-glycosites in this large class of biomolecules	950:1008	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	6	41	theme	important	1048:1056	arg1	class					1058:1062	an important class	1045:1062	an important class of molecules with potential opportunities for drug designs	1045:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	0	42	theme	peptide	38:44	arg1	hormones					46:53	peptide hormones	38:53	peptide hormones	38:53	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	6	43	from	map	954:956	arg1	class					988:992	this large class	977:992	this large class of biomolecules	977:1008	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	5	44	theme	receptor	691:698	arg1	motifs					708:713	the receptor binding motifs	687:713	the receptor binding motifs of members of the neuropeptide Y and glucagon families	687:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	2	45	from	hormones	378:385	arg1	map					350:352	an extensive map	337:352	an extensive map of O-glycans on peptide hormones	337:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	6	46	theme	potential	1082:1090	arg1	opportunities					1092:1104	potential opportunities	1082:1104	potential opportunities for drug designs	1082:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	5	47	theme	binding	700:706	arg1	motifs					708:713	the receptor binding motifs	687:713	the receptor binding motifs of members of the neuropeptide Y and glucagon families	687:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	6	48	with	molecules	1067:1075	arg1	opportunities					1092:1104	potential opportunities	1082:1104	potential opportunities for drug designs	1082:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	1	49	theme	large	136:140	arg1	class					142:146	a large class	134:146	a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure	134:277	Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure.
32820167	4	50	theme	receptor	583:590	arg1	interaction					592:602	receptor interaction	583:602	receptor interaction	583:602	Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability.
32820167	0	51	theme	diverse	63:69	arg1	roles					82:86	diverse biological roles	63:86	diverse biological roles	63:86	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles.
32820167	3	52	theme	classified	429:438	arg1	hormones					448:455	the 279 classified peptide hormones	421:455	the 279 classified peptide hormones	421:455	We find that almost one third of the 279 classified peptide hormones carry O-glycans.
32820167	6	53	theme	molecules	1067:1075	arg1	class					1058:1062	an important class	1045:1062	an important class of molecules with potential opportunities for drug designs	1045:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	2	54	theme	O-glycans	357:365	arg1	map					350:352	an extensive map	337:352	an extensive map of O-glycans on peptide hormones	337:385	Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones.
32820167	6	55	theme	hormones	936:943	arg1	biology					917:923	the biology	913:923	the biology of peptide hormones	913:943	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	5	56	theme	families	761:768	arg1	members					718:724	members	718:724	members of the neuropeptide Y and glucagon families	718:768	We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives.
32820167	6	57	theme	discovery	1022:1030	arg1	platform					1032:1039	a discovery platform	1020:1039	a discovery platform for an important class of molecules with potential opportunities for drug designs	1020:1121	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
32820167	6	57	theme	discovery	1022:1030	arg1	map					954:956	our map	950:956	our map of O-glycosites in this large class of biomolecules	950:1008	Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.
33608275	0	0	theme	transcriptome	71:83	arg1	detection					31:39	simultaneous detection	18:39	simultaneous detection of glycans, epitopes, and the transcriptome in single cells	18:99	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.
33608275	1	1	theme	precise	152:158	arg1	mapping					160:166	the precise mapping	148:166	the precise mapping of transcriptional and phenotypic features of cellular differentiation states	148:244	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	0	2	theme	single	88:93	arg1	cells					95:99	single cells	88:99	single cells	88:99	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.
33608275	1	3	theme	simultaneous	269:280	arg1	integration					282:292	simultaneous integration	269:292	simultaneous integration of critical posttranslational modification data	269:340	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	3	4	theme	glycoproteome	578:590	arg1	analysis					592:599	Integrated SUGAR-seq and glycoproteome analysis	553:599	Integrated SUGAR-seq and glycoproteome analysis	553:599	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	2	5	theme	single-cell	534:544	arg1	level					546:550	the single-cell level	530:550	the single-cell level	530:550	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	6	link	N-linked	457:464	arg1	glycosylation					466:478	N-linked glycosylation	457:478	N-linked glycosylation	457:478	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	3	7	theme	Integrated	553:562	arg1	analysis					592:599	Integrated SUGAR-seq and glycoproteome analysis	553:599	Integrated SUGAR-seq and glycoproteome analysis	553:599	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	3	8	theme	SUGAR-seq	564:572	arg1	analysis					592:599	Integrated SUGAR-seq and glycoproteome analysis	553:599	Integrated SUGAR-seq and glycoproteome analysis	553:599	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	1	9	theme	transcriptional	171:185	arg1	features					202:209	transcriptional and phenotypic features	171:209	features	202:209	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	2	10	theme	glycosylation	466:478	arg1	analysis					445:452	analysis	445:452	analysis	445:452	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	10	theme	glycosylation	466:478	arg1	detection					431:439	detection	431:439	detection	431:439	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	3	11	theme	tumor-infiltrating	612:629	arg1	cells					633:637	tumor-infiltrating T cells	612:637	tumor-infiltrating T cells	612:637	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	2	12	theme	N-linked	457:464	arg1	glycosylation					466:478	N-linked glycosylation	457:478	N-linked glycosylation	457:478	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	13	from	level	546:550	arg1	analysis					445:452	analysis	445:452	analysis	445:452	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	13	from	level	546:550	arg1	detection					431:439	detection	431:439	detection	431:439	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	3	14	theme	T	631:631	arg1	cells					633:637	tumor-infiltrating T cells	612:637	tumor-infiltrating T cells	612:637	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	1	15	theme	phenotypic	191:200	arg1	features					202:209	transcriptional and phenotypic features	171:209	features	202:209	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	1	16	theme	critical	297:304	arg1	modification					324:335	critical posttranslational modification	297:335	critical posttranslational modification data	297:340	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	1	17	theme	features	202:209	arg1	mapping					160:166	the precise mapping	148:166	the precise mapping of transcriptional and phenotypic features of cellular differentiation states	148:244	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	0	18	theme	simultaneous	18:29	arg1	detection					31:39	simultaneous detection	18:39	simultaneous detection of glycans, epitopes, and the transcriptome in single cells	18:99	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.
33608275	1	19	theme	posttranslational	306:322	arg1	modification					324:335	critical posttranslational modification	297:335	critical posttranslational modification data	297:340	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	2	20	theme	extracellular	481:493	arg1	epitopes					495:502	extracellular epitopes	481:502	extracellular epitopes	481:502	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	0	21	theme	glycans	44:50	arg1	detection					31:39	simultaneous detection	18:39	simultaneous detection of glycans, epitopes, and the transcriptome in single cells	18:99	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.
33608275	1	22	theme	modification	324:335	arg1	data					337:340	critical posttranslational modification data	297:340	critical posttranslational modification data	297:340	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	3	23	theme	functional	710:719	arg1	state					721:725	their epigenetic and functional state	689:725	their epigenetic and functional state	689:725	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	3	24	theme	unique	644:649	arg1	properties					666:675	unique surface glycan properties	644:675	unique surface glycan properties that report their epigenetic and functional state	644:725	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	1	25	theme	cellular	214:221	arg1	states					239:244	cellular differentiation states	214:244	cellular differentiation states	214:244	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	2	26	theme	epitopes	495:502	arg1	analysis					445:452	analysis	445:452	analysis	445:452	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	26	theme	epitopes	495:502	arg1	detection					431:439	detection	431:439	detection	431:439	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	1	27	theme	data	337:340	arg1	integration					282:292	simultaneous integration	269:292	simultaneous integration of critical posttranslational modification data	269:340	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	3	28	theme	surface	651:657	arg1	properties					666:675	unique surface glycan properties	644:675	unique surface glycan properties that report their epigenetic and functional state	644:725	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	1	29	theme	differentiation	223:237	arg1	states					239:244	cellular differentiation states	214:244	cellular differentiation states	214:244	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	0	30	theme	epitopes	53:60	arg1	detection					31:39	simultaneous detection	18:39	simultaneous detection of glycans, epitopes, and the transcriptome in single cells	18:99	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.
33608275	3	31	theme	epigenetic	695:704	arg1	state					721:725	their epigenetic and functional state	689:725	their epigenetic and functional state	689:725	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	1	32	theme	Multimodal	102:111	arg1	sequencing					129:138	Multimodal single-cell RNA sequencing	102:138	Multimodal single-cell RNA sequencing	102:138	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	1	33	theme	single-cell	113:123	arg1	sequencing					129:138	Multimodal single-cell RNA sequencing	102:138	Multimodal single-cell RNA sequencing	102:138	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	1	34	theme	RNA	125:127	arg1	sequencing					129:138	Multimodal single-cell RNA sequencing	102:138	Multimodal single-cell RNA sequencing	102:138	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	1	35	theme	states	239:244	arg1	features					202:209	transcriptional and phenotypic features	171:209	features	202:209	Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular differentiation states but does not allow for simultaneous integration of critical posttranslational modification data.
33608275	2	36	theme	SUrface-protein	361:375	arg1	Glycan					377:382	SUrface-protein Glycan	361:382	SUrface-protein Glycan	361:382	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	36	theme	SUrface-protein	361:375	arg1	method					411:416	a method	409:416	a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level	409:550	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	36	theme	SUrface-protein	361:375	arg1	SUGAR-seq					397:405	SUGAR-seq	397:405	SUGAR-seq	397:405	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	3	37	theme	glycan	659:664	arg1	properties					666:675	unique surface glycan properties	644:675	unique surface glycan properties that report their epigenetic and functional state	644:725	Integrated SUGAR-seq and glycoproteome analysis identified tumor-infiltrating T cells with unique surface glycan properties that report their epigenetic and functional state.
33608275	2	38	theme	transcriptome	513:525	arg1	analysis					445:452	analysis	445:452	analysis	445:452	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	2	38	theme	transcriptome	513:525	arg1	detection					431:439	detection	431:439	detection	431:439	Here, we describe SUrface-protein Glycan And RNA-seq (SUGAR-seq), a method that enables detection and analysis of N-linked glycosylation, extracellular epitopes, and the transcriptome at the single-cell level.
33608275	0	39	from	detection	31:39	arg1	cells					95:99	single cells	88:99	single cells	88:99	SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells.
33176830	7	0	theme	first	1275:1279	arg1	study					1281:1285	the first study	1271:1285	the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel	1271:1379	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	7	0	theme	first	1275:1279	arg1	It					1260:1261	It	1260:1261	It	1260:1261	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	4	1	theme	conformation	665:676	arg1	N-X-C					678:682	the conformation N-X-C	661:682	the conformation N-X-C based on site directed mutagenesis	661:717	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	5	2	theme	electrophysiological	743:762	arg1	recordings					764:773	electrophysiological recordings	743:773	electrophysiological recordings	743:773	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	6	3	theme	non-canonical	1178:1190	arg1	motifs					1192:1197	non-canonical motifs	1178:1197	non-canonical motifs	1178:1197	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	3	4	dep	expression	536:545	arg1	the					532:534	the	532:534	the	532:534	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	5	5	theme	recordings	764:773	arg1	assays					801:806	surface biotinylation assays	779:806	surface biotinylation assays	779:806	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	5	theme	recordings	764:773	arg1	combination					728:738	a combination	726:738	a combination of electrophysiological recordings	726:773	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	6	theme	plasma	966:971	arg1	membrane					973:980	the plasma membrane	962:980	the plasma membrane	962:980	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	3	7	theme	several	434:440	arg1	residues					453:460	several asparagine residues	434:460	several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels	434:577	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	6	8	gly	N-glycosylation	1134:1148	arg1	Cav3.2					1153:1158	Cav3.2	1153:1158	Cav3.2	1153:1158	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	6	8	gly	N-glycosylation	1134:1148	arg2	motifs					1192:1197	non-canonical motifs	1178:1197	non-canonical motifs	1178:1197	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	6	9	from	expression	1210:1219	arg1	membrane					1250:1257	the plasma membrane	1239:1257	the plasma membrane	1239:1257	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	7	10	theme	non-canonical	1326:1338	arg1	motifs					1356:1361	non-canonical N-glycosylation motifs	1326:1361	non-canonical N-glycosylation motifs	1326:1361	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	7	11	theme	functional	1301:1310	arg1	importance					1312:1321	the functional importance	1297:1321	the functional importance of non-canonical N-glycosylation motifs in an ion channel	1297:1379	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	3	12	theme	glycosylation	405:417	arg1	importance					369:378	the importance	365:378	the importance of asparagine (N)-linked glycosylation	365:417	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	6	13	theme	channel	1228:1234	arg1	expression					1210:1219	expression	1210:1219	expression of the channel in the plasma membrane	1210:1257	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	5	14	theme	human	938:942	arg1	channel					951:957	the human Cav3.2 channel	934:957	the human Cav3.2 channel	934:957	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	3	15	theme	consensus	483:491	arg1	sequence					493:500	the canonical consensus sequence N-X-S/T	469:508	the canonical consensus sequence N-X-S/T	469:508	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	5	16	theme	Cav3.2	944:949	arg1	channel					951:957	the human Cav3.2 channel	934:957	the human Cav3.2 channel	934:957	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	6	17	theme	non-canonical	1044:1056	arg1	motifs					1058:1063	non-canonical motifs	1044:1063	non-canonical motifs	1044:1063	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	7	18	theme	motifs	1356:1361	arg1	importance					1312:1321	the functional importance	1297:1321	the functional importance of non-canonical N-glycosylation motifs in an ion channel	1297:1379	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	1	19	theme	Low-voltage-activated	114:134	arg1	contributors					174:185	important contributors	164:185	important contributors to nervous system function	164:212	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	1	19	theme	Low-voltage-activated	114:134	arg1	channels					151:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	5	20	theme	channel	951:957	arg1	expression					920:929	the expression	916:929	the expression of the human Cav3.2 channel in the plasma membrane	916:980	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	0	21	theme	Functional	0:9	arg1	identification					11:24	Functional identification	0:24	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.	0:112	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	4	22	theme	N-glycosylation	635:649	arg1	motifs					651:656	non-canonical N-glycosylation motifs	621:656	non-canonical N-glycosylation motifs	621:656	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	7	23	from	importance	1312:1321	arg1	channel					1373:1379	an ion channel	1366:1379	an ion channel	1366:1379	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	1	24	theme	T-type	136:141	arg1	contributors					174:185	important contributors	164:185	important contributors to nervous system function	164:212	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	1	24	theme	T-type	136:141	arg1	channels					151:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	3	25	theme	asparagine	442:451	arg1	residues					453:460	several asparagine residues	434:460	several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels	434:577	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	4	26	theme	non-canonical	621:633	arg1	motifs					651:656	non-canonical N-glycosylation motifs	621:656	non-canonical N-glycosylation motifs	621:656	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	5	27	dep	motifs	864:869	arg1	motifs					864:869	the motifs NVC and NPC	860:881	the motifs NVC and NPC	860:881	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	27	dep	motifs	864:869	arg1	NPC					879:881	NPC	879:881	NPC	879:881	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	27	dep	motifs	864:869	arg1	NVC					871:873	NVC	871:873	NVC	871:873	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	7	28	theme	N-glycosylation	1340:1354	arg1	motifs					1356:1361	non-canonical N-glycosylation motifs	1326:1361	non-canonical N-glycosylation motifs	1326:1361	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	1	29	theme	calcium	143:149	arg1	contributors					174:185	important contributors	164:185	important contributors to nervous system function	164:212	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	1	29	theme	calcium	143:149	arg1	channels					151:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	6	30	theme	Cav3.2	1153:1158	arg1	N-glycosylation					1134:1148	N-glycosylation	1134:1148	N-glycosylation of Cav3.2	1134:1158	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	3	31	theme	-linked	397:403	arg1	glycosylation					405:417	asparagine (N)-linked glycosylation	383:417	asparagine (N)-linked glycosylation	383:417	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	7	32	gly	N-glycosylation	1340:1354	arg2	motifs					1356:1361	non-canonical N-glycosylation motifs	1326:1361	non-canonical N-glycosylation motifs	1326:1361	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	3	33	link	-linked	397:403	arg1	glycosylation					405:417	asparagine (N)-linked glycosylation	383:417	asparagine (N)-linked glycosylation	383:417	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	6	34	theme	plasma	1243:1248	arg1	membrane					1250:1257	the plasma membrane	1239:1257	the plasma membrane	1239:1257	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	0	35	theme	N-glycosylation	53:67	arg1	sites					69:73	potential non-canonical N-glycosylation sites	29:73	potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels	29:111	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	4	36	theme	motifs	651:656	arg1	role					613:616	the functional role	598:616	the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis	598:717	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	3	37	theme	Previous	332:339	arg1	studies					341:347	Previous studies	332:347	Previous studies	332:347	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	5	38	from	located	849:855	arg1	motifs					864:869	the motifs NVC and NPC	860:881	the motifs NVC and NPC	860:881	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	38	from	located	849:855	arg1	NPC					879:881	NPC	879:881	NPC	879:881	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	38	from	located	849:855	arg1	NVC					871:873	NVC	871:873	NVC	871:873	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	0	39	theme	non-canonical	39:51	arg1	sites					69:73	potential non-canonical N-glycosylation sites	29:73	potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels	29:111	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	4	40	theme	functional	602:611	arg1	role					613:616	the functional role	598:616	the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis	598:717	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	4	41	from	role	613:616	arg1	N-X-C					678:682	the conformation N-X-C	661:682	the conformation N-X-C based on site directed mutagenesis	661:717	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	0	42	theme	potential	29:37	arg1	sites					69:73	potential non-canonical N-glycosylation sites	29:73	potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels	29:111	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	5	43	theme	located	849:855	arg1	N1780					843:847	N1780	843:847	N1780	843:847	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	43	theme	located	849:855	arg1	N345					834:837	N345	834:837	N345	834:837	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	43	theme	located	849:855	arg1	asparagines					822:832	asparagines N345 and N1780	822:847	asparagines N345 and N1780 located in the motifs NVC and NPC	822:881	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	3	44	theme	canonical	473:481	arg1	sequence					493:500	the canonical consensus sequence N-X-S/T	469:508	the canonical consensus sequence N-X-S/T	469:508	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	5	45	dep	asparagines	822:832	arg1	N1780					843:847	N1780	843:847	N1780	843:847	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	45	dep	asparagines	822:832	arg1	N345					834:837	N345	834:837	N345	834:837	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	45	dep	asparagines	822:832	arg1	asparagines					822:832	asparagines N345 and N1780	822:847	asparagines N345 and N1780 located in the motifs NVC and NPC	822:881	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	46	theme	surface	779:785	arg1	assays					801:806	surface biotinylation assays	779:806	surface biotinylation assays	779:806	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	2	47	theme	Post-translational	215:232	arg1	modification					234:245	Post-translational modification	215:245	Post-translational modification of these channels	215:263	Post-translational modification of these channels has emerged as an important mechanism to control channel activity.
33176830	2	48	theme	important	283:291	arg1	mechanism					293:301	an important mechanism	280:301	an important mechanism to control channel activity	280:329	Post-translational modification of these channels has emerged as an important mechanism to control channel activity.
33176830	4	49	gly	N-glycosylation	635:649	arg2	motifs					651:656	non-canonical N-glycosylation motifs	621:656	non-canonical N-glycosylation motifs	621:656	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	3	50	theme	channels	570:577	arg1	expression					536:545	expression	536:545	expression	536:545	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	3	50	theme	channels	570:577	arg1	function					551:558	function	551:558	function	551:558	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	0	51	theme	sites	69:73	arg1	identification					11:24	Functional identification	0:24	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.	0:112	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	6	52	theme	asparagine	1017:1026	arg1	residues					1028:1035	these newly identified asparagine residues	994:1035	these newly identified asparagine residues within non-canonical motifs	994:1063	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	5	53	theme	biotinylation	787:799	arg1	assays					801:806	surface biotinylation assays	779:806	surface biotinylation assays	779:806	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	5	54	from	motifs	864:869	arg1	located					849:855	located	849:855	located	849:855	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	7	55	theme	ion	1369:1371	arg1	channel					1373:1379	an ion channel	1366:1379	an ion channel	1366:1379	It is also the first study to report the functional importance of non-canonical N-glycosylation motifs in an ion channel.
33176830	1	56	theme	important	164:172	arg1	contributors					174:185	important contributors	164:185	important contributors to nervous system function	164:212	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	1	56	theme	important	164:172	arg1	channels					151:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels	114:158	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	6	57	theme	identified	1006:1015	arg1	residues					1028:1035	these newly identified asparagine residues	994:1035	these newly identified asparagine residues within non-canonical motifs	994:1063	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	5	58	from	expression	920:929	arg1	membrane					973:980	the plasma membrane	962:980	the plasma membrane	962:980	Using a combination of electrophysiological recordings and surface biotinylation assays, we show that asparagines N345 and N1780 located in the motifs NVC and NPC, respectively, are essential for the expression of the human Cav3.2 channel in the plasma membrane.
33176830	4	59	theme	site	693:696	arg1	mutagenesis					707:717	site directed mutagenesis	693:717	site directed mutagenesis	693:717	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
33176830	0	60	gly	N-glycosylation	53:67	arg2	sites					69:73	potential non-canonical N-glycosylation sites	29:73	potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels	29:111	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	3	61	theme	Cav3.2	563:568	arg1	channels					570:577	Cav3.2 channels	563:577	Cav3.2 channels	563:577	Previous studies have documented the importance of asparagine (N)-linked glycosylation and identified several asparagine residues within the canonical consensus sequence N-X-S/T that is essential for the expression and function of Cav3.2 channels.
33176830	0	62	theme	calcium	96:102	arg1	channels					104:111	Cav3.2 T-type calcium channels	82:111	Cav3.2 T-type calcium channels	82:111	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	2	63	theme	channels	256:263	arg1	modification					234:245	Post-translational modification	215:245	Post-translational modification of these channels	215:263	Post-translational modification of these channels has emerged as an important mechanism to control channel activity.
33176830	2	64	theme	channel	314:320	arg1	activity					322:329	channel activity	314:329	channel activity	314:329	Post-translational modification of these channels has emerged as an important mechanism to control channel activity.
33176830	1	65	theme	nervous	190:196	arg1	function					205:212	nervous system function	190:212	nervous system function	190:212	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	0	66	theme	Cav3.2 T-type	82:94	arg1	channels					104:111	Cav3.2 T-type calcium channels	82:111	Cav3.2 T-type calcium channels	82:111	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2 T-type calcium channels.
33176830	6	67	theme	canonical	1101:1109	arg1	sites					1111:1115	canonical sites	1101:1115	canonical sites	1101:1115	Therefore, these newly identified asparagine residues within non-canonical motifs add to those previously reported in canonical sites and suggest that N-glycosylation of Cav3.2 may also occur at non-canonical motifs to control expression of the channel in the plasma membrane.
33176830	1	68	theme	system	198:203	arg1	function					205:212	nervous system function	190:212	nervous system function	190:212	Low-voltage-activated T-type calcium channels are important contributors to nervous system function.
33176830	4	69	theme	directed	698:705	arg1	mutagenesis					707:717	site directed mutagenesis	693:717	site directed mutagenesis	693:717	Here, we explored the functional role of non-canonical N-glycosylation motifs in the conformation N-X-C based on site directed mutagenesis.
32694201	5	0	theme	receptor-binding	657:672	arg1	domains					674:680	three receptor-binding domains	651:680	three receptor-binding domains clamped down by a segment adjacent to the fusion peptide	651:737	The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide.
32694201	6	1	theme	immune	863:868	arg1	responses					870:878	host immune responses	858:878	host immune responses	858:878	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	7	2	theme	vaccines	1005:1012	arg1	development					990:1000	the development	986:1000	the development of vaccines and therapeutics	986:1029	These findings advance our understanding of SARS-CoV-2 entry and may guide the development of vaccines and therapeutics.
32694201	5	3	contain	has	647:649	arg2	domains					674:680	three receptor-binding domains	651:680	three receptor-binding domains clamped down by a segment adjacent to the fusion peptide	651:737	The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide.
32694201	5	3	contain	has	647:649	arg1	trimer					640:645	The prefusion trimer	626:645	The prefusion trimer	626:645	The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide.
32694201	1	4	theme	Intervention	60:71	arg1	strategies					73:82	Intervention strategies	60:82	Intervention strategies	60:82	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	6	5	link	N-linked	795:802	arg1	glycans					804:810	N-linked glycans	795:810	N-linked glycans	795:810	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	6	6	theme	protective	833:842	arg1	roles					844:848	possible protective roles	824:848	possible protective roles	824:848	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	3	7	theme	postfusion	477:486	arg1	conformations					514:526	its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations	433:526	its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations	433:526	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	3	8	theme	cryo-electron	327:339	arg1	microscopy					341:350	cryo-electron microscopy	327:350	two cryo-electron microscopy structures derived from a preparation of the full-length S protein	323:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	5	9	theme	prefusion	630:638	arg1	trimer					640:645	The prefusion trimer	626:645	The prefusion trimer	626:645	The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide.
32694201	6	10	theme	possible	824:831	arg1	roles					844:848	possible protective roles	824:848	possible protective roles	824:848	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	2	11	theme	cell	269:272	arg1	membranes					274:282	target cell membranes	262:282	target cell membranes	262:282	The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection.
32694201	3	12	theme	microscopy	341:350	arg1	structures					352:361	two cryo-electron microscopy structures	323:361	two cryo-electron microscopy structures derived from a preparation of the full-length S protein	323:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	2	13	theme	target	262:267	arg1	membranes					274:282	target cell membranes	262:282	target cell membranes	262:282	The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection.
32694201	3	14	theme	prefusion	437:445	arg1	conformations					514:526	its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations	433:526	its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations	433:526	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	0	15	theme	conformational	9:22	arg1	states					24:29	Distinct conformational states	0:29	Distinct conformational states of SARS-CoV-2	0:43	Distinct conformational states of SARS-CoV-2 spike protein.
32694201	0	16	theme	Distinct	0:7	arg1	states					24:29	Distinct conformational states	0:29	Distinct conformational states of SARS-CoV-2	0:43	Distinct conformational states of SARS-CoV-2 spike protein.
32694201	6	17	theme	host	858:861	arg1	responses					870:878	host immune responses	858:878	host immune responses	858:878	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	6	18	theme	N-linked	795:802	arg1	glycans					804:810	N-linked glycans	795:810	N-linked glycans	795:810	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	4	19	theme	postfusion	577:586	arg1	state					588:592	the postfusion state	573:592	the postfusion state	573:592	The spontaneous transition to the postfusion state is independent of target cells.
32694201	3	20	theme	S	409:409	arg1	protein					411:417	the full-length S protein	393:417	the full-length S protein	393:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	3	21	theme	3.0-angstrom	489:500	arg1	postfusion					477:486	postfusion	477:486	postfusion (3.0-angstrom resolution)	477:512	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	3	21	theme	3.0-angstrom	489:500	arg1	resolution					502:511	3.0-angstrom resolution	489:511	3.0-angstrom resolution	489:511	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	5	22	theme	fusion	724:729	arg1	peptide					731:737	the fusion peptide	720:737	the fusion peptide	720:737	The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide.
32694201	3	23	theme	protein	411:417	arg1	preparation					378:388	a preparation	376:388	a preparation of the full-length S protein	376:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	0	24	theme	SARS-CoV-2	34:43	arg1	states					24:29	Distinct conformational states	0:29	Distinct conformational states of SARS-CoV-2	0:43	Distinct conformational states of SARS-CoV-2 spike protein.
32694201	6	25	theme	external	890:897	arg1	conditions					899:908	harsh external conditions	884:908	harsh external conditions	884:908	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	3	26	theme	2.9-angstrom	448:459	arg1	prefusion					437:445	its prefusion	433:445	its prefusion (2.9-angstrom resolution)	433:471	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	3	26	theme	2.9-angstrom	448:459	arg1	resolution					461:470	2.9-angstrom resolution	448:470	2.9-angstrom resolution	448:470	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	6	27	theme	harsh	884:888	arg1	conditions					899:908	harsh external conditions	884:908	harsh external conditions	884:908	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	1	28	theme	severe	119:124	arg1	pandemic					180:187	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	3	29	theme	full-length	397:407	arg1	protein					411:417	the full-length S protein	393:417	the full-length S protein	393:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	4	30	theme	spontaneous	547:557	arg1	independent					597:607	independent	597:607	independent	597:607	The spontaneous transition to the postfusion state is independent of target cells.
32694201	4	30	theme	spontaneous	547:557	arg1	transition					559:568	The spontaneous transition	543:568	The spontaneous transition to the postfusion state	543:592	The spontaneous transition to the postfusion state is independent of target cells.
32694201	2	31	theme	S	216:216	arg1	protein					219:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection.
32694201	1	32	theme	acute	126:130	arg1	coronavirus					153:163	acute respiratory syndrome coronavirus 2	126:165	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	1	32	theme	acute	126:130	arg1	SARS-CoV-2					168:177	SARS-CoV-2	168:177	SARS-CoV-2	168:177	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	7	33	theme	SARS-CoV-2	955:964	arg1	entry					966:970	SARS-CoV-2 entry	955:970	SARS-CoV-2 entry	955:970	These findings advance our understanding of SARS-CoV-2 entry and may guide the development of vaccines and therapeutics.
32694201	2	34	theme	spike	209:213	arg1	protein					219:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection.
32694201	1	35	theme	respiratory	132:142	arg1	coronavirus					153:163	acute respiratory syndrome coronavirus 2	126:165	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	1	35	theme	respiratory	132:142	arg1	SARS-CoV-2					168:177	SARS-CoV-2	168:177	SARS-CoV-2	168:177	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	7	36	theme	entry	966:970	arg1	understanding					938:950	our understanding	934:950	our understanding of SARS-CoV-2 entry	934:970	These findings advance our understanding of SARS-CoV-2 entry and may guide the development of vaccines and therapeutics.
32694201	4	37	theme	cells	619:623	arg1	independent					597:607	independent	597:607	independent	597:607	The spontaneous transition to the postfusion state is independent of target cells.
32694201	4	37	theme	cells	619:623	arg1	transition					559:568	The spontaneous transition	543:568	The spontaneous transition to the postfusion state	543:592	The spontaneous transition to the postfusion state is independent of target cells.
32694201	5	38	theme	adjacent	708:715	arg1	segment					700:706	a segment	698:706	a segment adjacent to the fusion peptide	698:737	The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide.
32694201	2	39	theme	viral	203:207	arg1	protein					219:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection.
32694201	1	40	theme	syndrome	144:151	arg1	coronavirus					153:163	acute respiratory syndrome coronavirus 2	126:165	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	1	40	theme	syndrome	144:151	arg1	SARS-CoV-2					168:177	SARS-CoV-2	168:177	SARS-CoV-2	168:177	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	4	41	theme	target	612:617	arg1	cells					619:623	target cells	612:623	target cells	612:623	The spontaneous transition to the postfusion state is independent of target cells.
32694201	2	42	theme	trimeric	194:201	arg1	protein					219:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein	190:225	The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection.
32694201	6	43	theme	postfusion	744:753	arg1	structure					755:763	The postfusion structure	740:763	The postfusion structure	740:763	The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions.
32694201	1	44	theme	coronavirus	153:163	arg1	pandemic					180:187	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	115:187	Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
32694201	3	45	attach	derived	363:369	arg1	preparation					378:388	a preparation	376:388	a preparation of the full-length S protein	376:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	3	45	attach	derived	363:369	arg2	structures					352:361	two cryo-electron microscopy structures	323:361	two cryo-electron microscopy structures derived from a preparation of the full-length S protein	323:417	Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively.
32694201	7	46	theme	therapeutics	1018:1029	arg1	development					990:1000	the development	986:1000	the development of vaccines and therapeutics	986:1029	These findings advance our understanding of SARS-CoV-2 entry and may guide the development of vaccines and therapeutics.
32409323	7	0	theme	mice	1107:1110	arg1	samples					1112:1118	aged mice samples	1102:1118	aged mice samples	1102:1118	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	6	1	theme	transcriptional	798:812	arg1	SMAD2/3					821:827	its regulatory transcriptional factor SMAD2/3	783:827	its regulatory transcriptional factor SMAD2/3	783:827	The FBXO6 interacting partner MMP14 and its regulatory transcriptional factor SMAD2/3 were identified and validated in different pathological models as well as SMAD2-/- mice.
32409323	8	2	from	FBXO6	1164:1168	arg1	cartilage					1173:1181	cartilage	1173:1181	cartilage	1173:1181	Global knockout or conditional knockout of FBXO6 in cartilage promoted experimental OA process.
32409323	7	3	theme	STR/ort	1082:1088	arg1	samples					1090:1096	spontaneous OA STR/ort samples	1067:1096	spontaneous OA STR/ort samples	1067:1096	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	10	4	theme	factor	1440:1445	arg1	pathway					1475:1481	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	6	5	theme	pathological	872:883	arg1	models					885:890	different pathological models	862:890	different pathological models as well as SMAD2-/- mice	862:915	The FBXO6 interacting partner MMP14 and its regulatory transcriptional factor SMAD2/3 were identified and validated in different pathological models as well as SMAD2-/- mice.
32409323	7	6	theme	spontaneous	1067:1077	arg1	samples					1090:1096	spontaneous OA STR/ort samples	1067:1096	spontaneous OA STR/ort samples	1067:1096	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	10	7	theme	transforming	1420:1431	arg1	TGFβ					1450:1453	TGFβ	1450:1453	TGFβ	1450:1453	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	10	7	theme	transforming	1420:1431	arg1	factor					1440:1445	transforming growth factor β	1420:1447	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	11	8	theme	OA	1555:1556	arg1	development					1558:1568	post-injury OA development	1543:1568	post-injury OA development	1543:1568	Therefore, the overexpression of FBXO6 protected mice from post-injury OA development.
32409323	4	9	theme	mouse	615:619	arg1	models					624:629	human and multiple mouse OA models	596:629	human and multiple mouse OA models	596:629	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	1	10	theme	mannose	197:203	arg1	glycoproteins					214:226	high mannose N-linked glycoproteins	192:226	high mannose N-linked glycoproteins	192:226	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	8	11	theme	OA	1205:1206	arg1	process					1208:1214	experimental OA process	1192:1214	experimental OA process	1192:1214	Global knockout or conditional knockout of FBXO6 in cartilage promoted experimental OA process.
32409323	4	12	theme	models	624:629	arg1	cartilage					583:591	the cartilage	579:591	the cartilage of human and multiple mouse OA models	579:629	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	5	13	theme	global	694:699	arg1	mice					737:740	transgenic Col2a1-CreER mice	713:740	transgenic Col2a1-CreER mice	713:740	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	5	13	theme	global	694:699	arg1	mice					707:710	global FBXO6 mice	694:710	global FBXO6 mice	694:710	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	9	14	theme	mechanism	1231:1239	arg1	study					1241:1245	The molecular mechanism study	1217:1245	The molecular mechanism study	1217:1245	The molecular mechanism study revealed that FBXO6 decreased MMP14 by ubiquitination and degradation, leading to inhibited proteolytic activation of MMP13.
32409323	13	15	theme	OA	1813:1814	arg1	strategy					1828:1835	a promising OA therapeutic strategy	1801:1835	a promising OA therapeutic strategy	1801:1835	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	12	16	theme	MMP13	1626:1630	arg1	activation					1632:1641	MMP13 activation	1626:1641	MMP13 activation	1626:1641	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway suppressed MMP13 activation by upregulating of FBXO6 transcription and consequently promoting MMP14 proteasomal degradation.
32409323	7	17	theme	human	982:986	arg1	samples					991:997	human OA samples	982:997	human OA samples	982:997	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	1	18	theme	ubiquitin	147:155	arg1	ligases					160:166	the ubiquitin E3 ligases	143:166	the ubiquitin E3 ligases	143:166	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	0	19	theme	FBXO6-mediated	73:86	arg1	ubiquitination					94:107	FBXO6-mediated MMP14 ubiquitination	73:107	FBXO6-mediated MMP14 ubiquitination	73:107	TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.
32409323	4	20	dep	METHODS	531:537	arg1	examined					567:574	examined	567:574	was examined in the cartilage of human and multiple mouse OA models	563:629	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	1	21	theme	ligases	160:166	arg1	FBXO6					121:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	1	21	theme	ligases	160:166	arg1	component					130:138	a component	128:138	a component of the ubiquitin E3 ligases	128:166	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	1	22	link	N-linked	205:212	arg1	glycoproteins					214:226	high mannose N-linked glycoproteins	192:226	high mannose N-linked glycoproteins	192:226	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	11	23	theme	FBXO6	1517:1521	arg1	overexpression					1499:1512	the overexpression	1495:1512	the overexpression of FBXO6	1495:1521	Therefore, the overexpression of FBXO6 protected mice from post-injury OA development.
32409323	7	24	theme	FBXO6	944:948	arg1	expression					930:939	The expression	926:939	The expression of FBXO6	926:948	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	12	25	theme	proteasomal	1715:1725	arg1	degradation					1727:1737	MMP14 proteasomal degradation	1709:1737	MMP14 proteasomal degradation	1709:1737	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway suppressed MMP13 activation by upregulating of FBXO6 transcription and consequently promoting MMP14 proteasomal degradation.
32409323	5	26	theme	transgenic	713:722	arg1	mice					737:740	transgenic Col2a1-CreER mice	713:740	transgenic Col2a1-CreER mice	713:740	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	5	26	theme	transgenic	713:722	arg1	mice					707:710	global FBXO6 mice	694:710	global FBXO6 mice	694:710	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	10	27	theme	signalling	1464:1473	arg1	pathway					1475:1481	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	0	28	theme	MMP14	88:92	arg1	ubiquitination					94:107	FBXO6-mediated MMP14 ubiquitination	73:107	FBXO6-mediated MMP14 ubiquitination	73:107	TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.
32409323	2	29	theme	important	378:386	arg1	roles					388:392	important roles	378:392	important roles	378:392	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	9	30	theme	inhibited	1329:1337	arg1	activation					1351:1360	inhibited proteolytic activation	1329:1360	inhibited proteolytic activation of MMP13	1329:1369	The molecular mechanism study revealed that FBXO6 decreased MMP14 by ubiquitination and degradation, leading to inhibited proteolytic activation of MMP13.
32409323	10	31	theme	FBXO6	1387:1391	arg1	expression					1393:1402	FBXO6 expression	1387:1402	FBXO6 expression	1387:1402	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	2	32	theme	osteoarthritis	416:429	arg1	development					401:411	the development	397:411	the development of osteoarthritis (OA)	397:434	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	0	33	theme	cartilage	16:24	arg1	degradation					47:57	cartilage extracellular matrix degradation	16:57	cartilage extracellular matrix degradation	16:57	TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.
32409323	13	34	from	Inducement	1740:1749	arg1	cartilage					1777:1785	OA cartilage	1774:1785	OA cartilage	1774:1785	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	6	35	theme	different	862:870	arg1	models					885:890	different pathological models	862:890	different pathological models as well as SMAD2-/- mice	862:915	The FBXO6 interacting partner MMP14 and its regulatory transcriptional factor SMAD2/3 were identified and validated in different pathological models as well as SMAD2-/- mice.
32409323	0	36	theme	matrix	40:45	arg1	degradation					47:57	cartilage extracellular matrix degradation	16:57	cartilage extracellular matrix degradation	16:57	TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.
32409323	5	37	from	role	636:639	arg1	degeneration					663:674	cartilage degeneration	653:674	cartilage degeneration	653:674	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	9	38	theme	MMP13	1365:1369	arg1	activation					1351:1360	inhibited proteolytic activation	1329:1360	inhibited proteolytic activation of MMP13	1329:1369	The molecular mechanism study revealed that FBXO6 decreased MMP14 by ubiquitination and degradation, leading to inhibited proteolytic activation of MMP13.
32409323	13	39	theme	FBXO6	1754:1758	arg1	expression					1760:1769	FBXO6 expression	1754:1769	FBXO6 expression	1754:1769	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	4	40	theme	human	596:600	arg1	models					624:629	human and multiple mouse OA models	596:629	human and multiple mouse OA models	596:629	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	7	41	theme	aged	1102:1105	arg1	samples					1112:1118	aged mice samples	1102:1118	aged mice samples	1102:1118	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	1	42	theme	ligase	249:254	arg1	subunits					256:263	ubiquitin ligase subunits	239:263	ubiquitin ligase subunits	239:263	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	1	42	theme	ligase	249:254	arg1	FBXO6					121:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	6	43	theme	SMAD2-/-	903:910	arg1	mice					912:915	SMAD2-/- mice	903:915	different pathological models as well as SMAD2-/- mice	862:915	The FBXO6 interacting partner MMP14 and its regulatory transcriptional factor SMAD2/3 were identified and validated in different pathological models as well as SMAD2-/- mice.
32409323	6	44	theme	regulatory	787:796	arg1	SMAD2/3					821:827	its regulatory transcriptional factor SMAD2/3	783:827	its regulatory transcriptional factor SMAD2/3	783:827	The FBXO6 interacting partner MMP14 and its regulatory transcriptional factor SMAD2/3 were identified and validated in different pathological models as well as SMAD2-/- mice.
32409323	2	45	theme	secretory	287:295	arg1	pathway					297:303	the secretory pathway	283:303	the secretory pathway	283:303	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	7	46	theme	OA	1079:1080	arg1	samples					1090:1096	spontaneous OA STR/ort samples	1067:1096	spontaneous OA STR/ort samples	1067:1096	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	11	47	theme	post-injury	1543:1553	arg1	development					1558:1568	post-injury OA development	1543:1568	post-injury OA development	1543:1568	Therefore, the overexpression of FBXO6 protected mice from post-injury OA development.
32409323	13	48	theme	therapeutic	1816:1826	arg1	strategy					1828:1835	a promising OA therapeutic strategy	1801:1835	a promising OA therapeutic strategy	1801:1835	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	1	49	gly	glycoproteins	214:226	arg1	glycoproteins					214:226	high mannose N-linked glycoproteins	192:226	high mannose N-linked glycoproteins	192:226	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	10	50	theme	growth	1433:1438	arg1	TGFβ					1450:1453	TGFβ	1450:1453	TGFβ	1450:1453	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	10	50	theme	growth	1433:1438	arg1	factor					1440:1445	transforming growth factor β	1420:1447	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	8	51	theme	FBXO6	1164:1168	arg1	knockout					1128:1135	knockout	1128:1135	knockout	1128:1135	Global knockout or conditional knockout of FBXO6 in cartilage promoted experimental OA process.
32409323	7	52	theme	OA	1055:1056	arg1	samples					1058:1064	anterior cruciate ligament transaction (ACLT) -induced OA samples	1000:1064	anterior cruciate ligament transaction (ACLT) -induced OA samples	1000:1064	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	10	53	theme	-SMAD2/3	1455:1462	arg1	pathway					1475:1481	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway	1420:1481	Interestingly, FBXO6 expression is regulated by transforming growth factor β (TGFβ)-SMAD2/3 signalling pathway.
32409323	1	54	theme	high	192:195	arg1	glycoproteins					214:226	high mannose N-linked glycoproteins	192:226	high mannose N-linked glycoproteins	192:226	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	12	55	theme	FBXO6	1662:1666	arg1	transcription					1668:1680	FBXO6 transcription	1662:1680	FBXO6 transcription	1662:1680	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway suppressed MMP13 activation by upregulating of FBXO6 transcription and consequently promoting MMP14 proteasomal degradation.
32409323	4	56	theme	multiple	606:613	arg1	models					624:629	human and multiple mouse OA models	596:629	human and multiple mouse OA models	596:629	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	9	57	theme	molecular	1221:1229	arg1	mechanism					1231:1239	The molecular mechanism	1217:1239	The molecular mechanism study	1217:1245	The molecular mechanism study revealed that FBXO6 decreased MMP14 by ubiquitination and degradation, leading to inhibited proteolytic activation of MMP13.
32409323	1	58	theme	N-linked	205:212	arg1	glycoproteins					214:226	high mannose N-linked glycoproteins	192:226	high mannose N-linked glycoproteins	192:226	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	8	59	theme	experimental	1192:1203	arg1	process					1208:1214	experimental OA process	1192:1214	experimental OA process	1192:1214	Global knockout or conditional knockout of FBXO6 in cartilage promoted experimental OA process.
32409323	4	60	theme	OA	621:622	arg1	models					624:629	human and multiple mouse OA models	596:629	human and multiple mouse OA models	596:629	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	13	61	theme	promising	1803:1811	arg1	strategy					1828:1835	a promising OA therapeutic strategy	1801:1835	a promising OA therapeutic strategy	1801:1835	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	5	62	theme	FBXO6	644:648	arg1	role					636:639	The role	632:639	The role of FBXO6 in cartilage degeneration	632:674	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	5	63	theme	cartilage	653:661	arg1	degeneration					663:674	cartilage degeneration	653:674	cartilage degeneration	653:674	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	2	64	theme	Most	266:269	arg1	proteins					271:278	Most proteins	266:278	Most proteins	266:278	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	2	64	theme	Most	266:269	arg1	metalloproteinases					321:338	matrix metalloproteinases	314:338	matrix metalloproteinases	314:338	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	2	65	from	proteins	271:278	arg1	pathway					297:303	the secretory pathway	283:303	the secretory pathway	283:303	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	12	66	theme	CONCLUSIONS	1571:1581	arg1	pathway					1607:1613	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway	1571:1613	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway	1571:1613	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway suppressed MMP13 activation by upregulating of FBXO6 transcription and consequently promoting MMP14 proteasomal degradation.
32409323	5	67	theme	Col2a1-CreER	724:735	arg1	mice					737:740	transgenic Col2a1-CreER mice	713:740	transgenic Col2a1-CreER mice	713:740	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	5	67	theme	Col2a1-CreER	724:735	arg1	mice					707:710	global FBXO6 mice	694:710	global FBXO6 mice	694:710	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	7	68	theme	OA	988:989	arg1	samples					991:997	human OA samples	982:997	human OA samples	982:997	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	1	69	theme	E3	157:158	arg1	ligases					160:166	the ubiquitin E3 ligases	143:166	the ubiquitin E3 ligases	143:166	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	12	70	theme	signalling	1596:1605	arg1	pathway					1607:1613	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway	1571:1613	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway	1571:1613	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway suppressed MMP13 activation by upregulating of FBXO6 transcription and consequently promoting MMP14 proteasomal degradation.
32409323	7	71	dep	RESULTS	918:924	arg1	decreased					950:958	decreased	950:958	decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples	950:1118	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	13	72	theme	OA	1774:1775	arg1	cartilage					1777:1785	OA cartilage	1774:1785	OA cartilage	1774:1785	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	5	73	theme	FBXO6	701:705	arg1	mice					737:740	transgenic Col2a1-CreER mice	713:740	transgenic Col2a1-CreER mice	713:740	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	5	73	theme	FBXO6	701:705	arg1	mice					707:710	global FBXO6 mice	694:710	global FBXO6 mice	694:710	The role of FBXO6 in cartilage degeneration was analysed with global FBXO6 mice, transgenic Col2a1-CreER mice.
32409323	3	74	theme	regulatory	467:476	arg1	effects					478:484	regulatory effects	467:484	regulatory effects	467:484	However, whether FBXO6 exerts regulatory effects on the pathogenesis of OA remains undefined.
32409323	12	75	theme	MMP14	1709:1713	arg1	degradation					1727:1737	MMP14 proteasomal degradation	1709:1737	MMP14 proteasomal degradation	1709:1737	CONCLUSIONS TGFβ-SMAD2/3 signalling pathway suppressed MMP13 activation by upregulating of FBXO6 transcription and consequently promoting MMP14 proteasomal degradation.
32409323	1	76	theme	OBJECTIVES	110:119	arg1	FBXO6					121:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	1	76	theme	OBJECTIVES	110:119	arg1	component					130:138	a component	128:138	a component of the ubiquitin E3 ligases	128:166	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	1	76	theme	OBJECTIVES	110:119	arg1	subunits					256:263	ubiquitin ligase subunits	239:263	ubiquitin ligase subunits	239:263	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	13	77	theme	expression	1760:1769	arg1	Inducement					1740:1749	Inducement	1740:1749	Inducement of FBXO6 expression in OA cartilage	1740:1785	Inducement of FBXO6 expression in OA cartilage might provide a promising OA therapeutic strategy.
32409323	0	78	theme	extracellular	26:38	arg1	degradation					47:57	cartilage extracellular matrix degradation	16:57	cartilage extracellular matrix degradation	16:57	TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.
32409323	9	79	theme	proteolytic	1339:1349	arg1	activation					1351:1360	inhibited proteolytic activation	1329:1360	inhibited proteolytic activation of MMP13	1329:1369	The molecular mechanism study revealed that FBXO6 decreased MMP14 by ubiquitination and degradation, leading to inhibited proteolytic activation of MMP13.
32409323	4	80	theme	FBXO6	557:561	arg1	expression					543:552	The expression	539:552	The expression of FBXO6	539:561	METHODS The expression of FBXO6 was examined in the cartilage of human and multiple mouse OA models.
32409323	7	81	theme	-induced	1046:1053	arg1	samples					1058:1064	anterior cruciate ligament transaction (ACLT) -induced OA samples	1000:1064	anterior cruciate ligament transaction (ACLT) -induced OA samples	1000:1064	RESULTS The expression of FBXO6 decreased in the cartilage from human OA samples, anterior cruciate ligament transaction (ACLT) -induced OA samples, spontaneous OA STR/ort samples and aged mice samples.
32409323	2	82	theme	matrix	314:319	arg1	metalloproteinases					321:338	matrix metalloproteinases	314:338	matrix metalloproteinases	314:338	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	6	83	theme	factor	814:819	arg1	SMAD2/3					821:827	its regulatory transcriptional factor SMAD2/3	783:827	its regulatory transcriptional factor SMAD2/3	783:827	The FBXO6 interacting partner MMP14 and its regulatory transcriptional factor SMAD2/3 were identified and validated in different pathological models as well as SMAD2-/- mice.
32409323	3	84	theme	OA	509:510	arg1	pathogenesis					493:504	the pathogenesis	489:504	the pathogenesis of OA	489:510	However, whether FBXO6 exerts regulatory effects on the pathogenesis of OA remains undefined.
32409323	2	85	mod	modified	345:352	arg1	proteins					271:278	Most proteins	266:278	Most proteins	266:278	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	2	85	mod	modified	345:352	arg1	metalloproteinases					321:338	matrix metalloproteinases	314:338	matrix metalloproteinases	314:338	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	2	85	mod	modified	345:352	arg3	N-glycans					359:367	N-glycans	359:367	N-glycans	359:367	Most proteins in the secretory pathway, such as matrix metalloproteinases, are modified with N-glycans and play important roles in the development of osteoarthritis (OA).
32409323	1	86	theme	ubiquitin	239:247	arg1	subunits					256:263	ubiquitin ligase subunits	239:263	ubiquitin ligase subunits	239:263	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
32409323	1	86	theme	ubiquitin	239:247	arg1	FBXO6					121:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6	110:125	OBJECTIVES FBXO6, a component of the ubiquitin E3 ligases, has been shown to bind high mannose N-linked glycoproteins and act as ubiquitin ligase subunits.
34831340	9	0	contain	had	1194:1196	arg1	sibling					1186:1192	Neither sibling	1178:1192	Neither sibling	1178:1192	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	9	0	contain	had	1194:1196	arg2	obesity					1206:1212	truncal obesity	1198:1212	truncal obesity	1198:1212	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	7	1	theme	early-onset	1047:1057	arg1	encephalopathy					1069:1082	early-onset epileptic encephalopathy	1047:1082	early-onset epileptic encephalopathy	1047:1082	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	4	2	theme	plasma	679:684	arg1	proteins					686:693	total plasma proteins	673:693	total plasma proteins	673:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	6	3	theme	MAN1B1	929:934	arg1	activity					917:924	The enzymatic activity	903:924	The enzymatic activity of MAN1B1	903:934	The enzymatic activity of MAN1B1 was compromised in patient-derived lymphocytes.
34831340	4	4	gly	sialylated	631:640	arg1	glycans					651:657	sialylated N-linked glycans	631:657	sialylated N-linked glycans released from total plasma proteins	631:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	7	5	theme	unique	1015:1020	arg1	encephalopathy					1069:1082	early-onset epileptic encephalopathy	1047:1082	early-onset epileptic encephalopathy	1047:1082	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	7	5	theme	unique	1015:1020	arg1	infarction					1097:1106	cerebral infarction	1088:1106	cerebral infarction	1088:1106	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	7	5	theme	unique	1015:1020	arg1	manifestations					1022:1035	unique manifestations	1015:1035	unique manifestations including early-onset epileptic encephalopathy and cerebral infarction	1015:1106	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	4	6	theme	total	673:677	arg1	proteins					686:693	total plasma proteins	673:693	total plasma proteins	673:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	8	7	theme	coagulation	1126:1136	arg1	abnormalities					1138:1150	coagulation abnormalities	1126:1150	coagulation abnormalities	1126:1150	They also showed coagulation abnormalities and hypertransaminasemia.
34831340	1	8	theme	Congenital	61:70	arg1	disorders					72:80	Congenital disorders	61:80	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation,	61:169	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	4	9	theme	sialylated	631:640	arg1	glycans					651:657	sialylated N-linked glycans	631:657	sialylated N-linked glycans released from total plasma proteins	631:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	1	10	theme	various	245:251	arg1	manifestations					262:275	various clinical manifestations	245:275	various clinical manifestations	245:275	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	4	11	theme	I	734:734	arg1	activity					736:743	the α1,2-mannosidase I activity	713:743	the α1,2-mannosidase I activity of the lymphocyte microsome fraction	713:780	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	4	12	attach	released	659:666	arg2	glycans					651:657	sialylated N-linked glycans	631:657	sialylated N-linked glycans released from total plasma proteins	631:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	4	12	attach	released	659:666	arg1	proteins					686:693	total plasma proteins	673:693	total plasma proteins	673:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	3	13	theme	MAN1B1	530:535	arg1	variant					519:525	a novel pathogenic variant	500:525	a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents	500:596	Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents.
34831340	1	14	theme	clinical	253:260	arg1	manifestations					262:275	various clinical manifestations	245:275	various clinical manifestations	245:275	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	1	15	from	defects	145:151	arg1	glycosylation					156:168	glycosylation	156:168	glycosylation	156:168	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	3	16	theme	pathogenic	508:517	arg1	variant					519:525	a novel pathogenic variant	500:525	a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents	500:596	Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents.
34831340	6	17	link	patient-derived	955:969	arg1	lymphocytes					971:981	patient-derived lymphocytes	955:981	patient-derived lymphocytes	955:981	The enzymatic activity of MAN1B1 was compromised in patient-derived lymphocytes.
34831340	2	18	theme	transferrin	381:391	arg1	spectrometry					359:370	mass spectrometry	354:370	mass spectrometry	354:370	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	1	19	theme	glycosylation	85:97	arg1	disorders					72:80	Congenital disorders	61:80	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation,	61:169	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	2	20	theme	serum	375:379	arg1	transferrin					381:391	serum transferrin	375:391	serum transferrin	375:391	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	5	21	theme	monosialoglycans	803:818	arg1	accumulation					787:798	The accumulation	783:798	The accumulation of monosialoglycans	783:818	The accumulation of monosialoglycans was observed in MAN1B1-deficient patients, indicating N-glycan-processing defects.
34831340	6	22	theme	enzymatic	907:915	arg1	activity					917:924	The enzymatic activity	903:924	The enzymatic activity of MAN1B1	903:934	The enzymatic activity of MAN1B1 was compromised in patient-derived lymphocytes.
34831340	7	23	theme	present	988:994	arg1	patients					996:1003	The present patients	984:1003	The present patients	984:1003	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	2	24	theme	dysmorphic	300:309	arg1	features					311:318	dysmorphic features	300:318	dysmorphic features	300:318	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	9	25	theme	truncal	1198:1204	arg1	obesity					1206:1212	truncal obesity	1198:1212	truncal obesity	1198:1212	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	4	26	theme	glycans	651:657	arg1	analysis					619:626	a HPLC analysis	612:626	a HPLC analysis of sialylated N-linked glycans released from total plasma proteins	612:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	1	27	theme	manifestations	262:275	arg1	frequency					199:207	a high frequency	192:207	a high frequency of intellectual disability (ID) and various clinical manifestations	192:275	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	5	28	theme	N-glycan-processing	874:892	arg1	defects					894:900	N-glycan-processing defects	874:900	N-glycan-processing defects	874:900	The accumulation of monosialoglycans was observed in MAN1B1-deficient patients, indicating N-glycan-processing defects.
34831340	4	29	theme	α1,2-mannosidase	717:732	arg1	activity					736:743	the α1,2-mannosidase I activity	713:743	the α1,2-mannosidase I activity of the lymphocyte microsome fraction	713:780	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	4	30	theme	N-linked	642:649	arg1	glycans					651:657	sialylated N-linked glycans	631:657	sialylated N-linked glycans released from total plasma proteins	631:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	2	31	theme	type	415:418	arg1	pattern					422:428	a CDG type 2 pattern	409:428	a CDG type 2 pattern	409:428	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	9	32	theme	features	1250:1257	arg1	one					1224:1226	one	1224:1226	one	1224:1226	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	9	32	theme	features	1250:1257	arg1	features					1250:1257	the characteristic features	1231:1257	the characteristic features of MAN1B1-CDG	1231:1271	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	5	33	located	observed	824:831	arg1	patients					853:860	MAN1B1-deficient patients	836:860	MAN1B1-deficient patients	836:860	The accumulation of monosialoglycans was observed in MAN1B1-deficient patients, indicating N-glycan-processing defects.
34831340	5	33	located	observed	824:831	arg2	accumulation					787:798	The accumulation	783:798	The accumulation of monosialoglycans	783:818	The accumulation of monosialoglycans was observed in MAN1B1-deficient patients, indicating N-glycan-processing defects.
34831340	5	34	theme	MAN1B1-deficient	836:851	arg1	patients					853:860	MAN1B1-deficient patients	836:860	MAN1B1-deficient patients	836:860	The accumulation of monosialoglycans was observed in MAN1B1-deficient patients, indicating N-glycan-processing defects.
34831340	2	35	theme	CDG	411:413	arg1	pattern					422:428	a CDG type 2 pattern	409:428	a CDG type 2 pattern	409:428	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	4	36	theme	fraction	773:780	arg1	activity					736:743	the α1,2-mannosidase I activity	713:743	the α1,2-mannosidase I activity of the lymphocyte microsome fraction	713:780	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	7	37	theme	cerebral	1088:1095	arg1	infarction					1097:1106	cerebral infarction	1088:1106	cerebral infarction	1088:1106	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	1	38	theme	high	194:197	arg1	frequency					199:207	a high frequency	192:207	a high frequency of intellectual disability (ID) and various clinical manifestations	192:275	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	0	39	theme	Biochemical	39:49	arg1	Profiles					51:58	Novel Biochemical Profiles	33:58	Novel Biochemical Profiles	33:58	Siblings with MAN1B1-CDG Showing Novel Biochemical Profiles.
34831340	9	40	theme	characteristic	1235:1248	arg1	features					1250:1257	the characteristic features	1231:1257	the characteristic features of MAN1B1-CDG	1231:1271	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	0	41	theme	Novel	33:37	arg1	Profiles					51:58	Novel Biochemical Profiles	33:58	Novel Biochemical Profiles	33:58	Siblings with MAN1B1-CDG Showing Novel Biochemical Profiles.
34831340	4	42	link	N-linked	642:649	arg1	glycans					651:657	sialylated N-linked glycans	631:657	sialylated N-linked glycans released from total plasma proteins	631:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	3	43	theme	Whole-exome	431:441	arg1	sequencing					443:452	Whole-exome sequencing	431:452	Whole-exome sequencing	431:452	Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents.
34831340	1	44	theme	inherited	106:114	arg1	diseases					126:133	inherited metabolic diseases	106:133	inherited metabolic diseases caused by defects in glycosylation	106:168	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	1	44	theme	inherited	106:114	arg1	glycosylation					85:97	glycosylation	85:97	glycosylation (CDG)	85:103	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	1	45	theme	metabolic	116:124	arg1	diseases					126:133	inherited metabolic diseases	106:133	inherited metabolic diseases caused by defects in glycosylation	106:168	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	1	45	theme	metabolic	116:124	arg1	glycosylation					85:97	glycosylation	85:97	glycosylation (CDG)	85:103	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	0	46	with	Siblings	0:7	arg1	MAN1B1-CDG					14:23	MAN1B1-CDG	14:23	MAN1B1-CDG	14:23	Siblings with MAN1B1-CDG Showing Novel Biochemical Profiles.
34831340	1	47	theme	intellectual	212:223	arg1	ID					237:238	ID	237:238	ID	237:238	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	1	47	theme	intellectual	212:223	arg1	disability					225:234	intellectual disability	212:234	intellectual disability (ID)	212:239	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	4	48	theme	microsome	763:771	arg1	fraction					773:780	the lymphocyte microsome fraction	748:780	the lymphocyte microsome fraction	748:780	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	4	49	theme	lymphocyte	752:761	arg1	fraction					773:780	the lymphocyte microsome fraction	748:780	the lymphocyte microsome fraction	748:780	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	7	50	theme	epileptic	1059:1067	arg1	encephalopathy					1069:1082	early-onset epileptic encephalopathy	1047:1082	early-onset epileptic encephalopathy	1047:1082	The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction.
34831340	1	51	theme	disability	225:234	arg1	frequency					199:207	a high frequency	192:207	a high frequency of intellectual disability (ID) and various clinical manifestations	192:275	Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations.
34831340	4	52	theme	HPLC	614:617	arg1	analysis					619:626	a HPLC analysis	612:626	a HPLC analysis of sialylated N-linked glycans released from total plasma proteins	612:693	We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction.
34831340	3	53	theme	healthy	582:588	arg1	parents					590:596	their healthy parents	576:596	their healthy parents	576:596	Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents.
34831340	2	54	theme	mass	354:357	arg1	spectrometry					359:370	mass spectrometry	354:370	mass spectrometry	354:370	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	2	55	with	siblings	282:289	arg1	ID					296:297	ID	296:297	ID	296:297	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	2	55	with	siblings	282:289	arg1	features					311:318	dysmorphic features	300:318	dysmorphic features	300:318	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	2	55	with	siblings	282:289	arg1	epilepsy					325:332	epilepsy	325:332	epilepsy	325:332	Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern.
34831340	6	56	theme	patient-derived	955:969	arg1	lymphocytes					971:981	patient-derived lymphocytes	955:981	patient-derived lymphocytes	955:981	The enzymatic activity of MAN1B1 was compromised in patient-derived lymphocytes.
34831340	9	57	theme	MAN1B1-CDG	1262:1271	arg1	features					1250:1257	the characteristic features	1231:1257	the characteristic features of MAN1B1-CDG	1231:1271	Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
34831340	3	58	theme	novel	502:506	arg1	variant					519:525	a novel pathogenic variant	500:525	a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents	500:596	Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents.
34712242	0	0	theme	Fc	80:81	arg1	Preferences					93:103	Similar IgG Fc Glycoform Preferences	68:103	Similar IgG Fc Glycoform Preferences	68:103	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	4	1	from	testing	859:865	arg1	macaques					913:920	rhesus macaques	906:920	rhesus macaques	906:920	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	0	2	theme	IgG	76:78	arg1	Preferences					93:103	Similar IgG Fc Glycoform Preferences	68:103	Similar IgG Fc Glycoform Preferences	68:103	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	3	3	from	reduction	487:495	arg1	content					524:530	the overall core fucose content	500:530	the overall core fucose content	500:530	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	5	4	theme	glycovariants	954:966	arg1	panel					931:935	a panel	929:935	a panel of 16 human IgG1 glycovariants	929:966	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	1	5	theme	effector	249:256	arg1	functions					258:266	effector functions	249:266	effector functions	249:266	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	1	6	from	glycan	299:304	arg1	region					316:321	the Fc region	309:321	the Fc region	309:321	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	4	7	from	use	760:762	arg1	species					816:822	sialylated glycan species	798:822	sialylated glycan species	798:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	5	8	theme	human	943:947	arg1	glycovariants					954:966	16 human IgG1 glycovariants	940:966	16 human IgG1 glycovariants	940:966	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	0	9	theme	Glycoform	83:91	arg1	Preferences					93:103	Similar IgG Fc Glycoform Preferences	68:103	Similar IgG Fc Glycoform Preferences	68:103	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	5	10	theme	IgG1	949:952	arg1	glycovariants					954:966	16 human IgG1 glycovariants	940:966	16 human IgG1 glycovariants	940:966	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	0	11	theme	Human	108:112	arg1	Receptors					114:122	Human Receptors	108:122	Human Receptors	108:122	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	3	12	theme	core	512:515	arg1	content					524:530	the overall core fucose content	500:530	the overall core fucose content	500:530	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	4	13	theme	Fc	673:674	arg1	glycan					676:681	the Fc glycan	669:681	the Fc glycan	669:681	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	1	14	theme	primate	164:170	arg1	molecules					233:241	molecules	233:241	molecules whose effector functions depend on a conserved N-linked glycan in the Fc region	233:321	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	1	14	theme	primate	164:170	arg1	model					172:176	a common non-human primate model	145:176	a common non-human primate model used in the evaluation of human monoclonal antibodies	145:230	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	1	14	theme	primate	164:170	arg1	macaques					132:139	Rhesus macaques	125:139	Rhesus macaques	125:139	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	3	15	theme	fucose	517:522	arg1	content					524:530	the overall core fucose content	500:530	the overall core fucose content	500:530	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	4	16	gly	sialylated	798:807	arg1	species					816:822	sialylated glycan species	798:822	sialylated glycan species	798:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	17	theme	uncertainty	840:850	arg1	degree					830:835	a degree	828:835	a degree of uncertainty	828:850	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	2	18	theme	efforts	374:380	arg1	carbohydrate					329:340	This carbohydrate	324:340	This carbohydrate	324:340	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	2	18	theme	efforts	374:380	arg1	target					347:352	a target	345:352	a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors	345:469	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	0	19	theme	Biophysical	0:10	arg1	Evaluation					12:21	Biophysical Evaluation	0:21	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors	0:58	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	4	20	from	frequency	728:736	arg1	species					816:822	sialylated glycan species	798:822	sialylated glycan species	798:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	2	21	theme	glycoengineering	357:372	arg1	efforts					374:380	glycoengineering efforts	357:380	glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors	357:469	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	4	22	theme	glycoforms	741:750	arg1	use					760:762	the use	756:762	the use of an alternate monosaccharide in sialylated glycan species	756:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	22	theme	glycoforms	741:750	arg1	frequency					728:736	the frequency	724:736	the frequency of glycoforms	724:750	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	23	theme	glycan	809:814	arg1	species					816:822	sialylated glycan species	798:822	sialylated glycan species	798:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	24	from	monosaccharide	780:793	arg1	species					816:822	sialylated glycan species	798:822	sialylated glycan species	798:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	1	25	theme	conserved	280:288	arg1	glycan					299:304	a conserved N-linked glycan	278:304	a conserved N-linked glycan in the Fc region	278:321	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	4	26	theme	rhesus	906:911	arg1	macaques					913:920	rhesus macaques	906:920	rhesus macaques	906:920	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	5	27	theme	plasmon	1050:1056	arg1	resonance					1058:1066	surface plasmon resonance	1042:1066	surface plasmon resonance	1042:1066	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	3	28	theme	such	539:542	arg1	strategy					544:551	one such strategy	535:551	one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity	535:644	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	3	28	theme	such	539:542	arg1	reduction					487:495	a reduction	485:495	a reduction in the overall core fucose content	485:530	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	2	29	theme	effector	409:416	arg1	function					418:425	antibody effector function	400:425	antibody effector function	400:425	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	0	30	theme	Fc	41:42	arg1	Receptors					50:58	Rhesus Macaque Fc Gamma Receptors	26:58	Rhesus Macaque Fc Gamma Receptors	26:58	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	1	31	theme	N-linked	290:297	arg1	glycan					299:304	a conserved N-linked glycan	278:304	a conserved N-linked glycan in the Fc region	278:321	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	3	32	theme	antibody-mediated	571:587	arg1	cytotoxicity					598:609	antibody-mediated cellular cytotoxicity	571:609	antibody-mediated cellular cytotoxicity	571:609	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	6	33	theme	glycoengineering	1168:1183	arg1	effects					1148:1154	the effects	1144:1154	the effects of antibody glycoengineering	1144:1183	Our results suggest that macaques are a tractable species in which to test the effects of antibody glycoengineering.
34712242	2	34	theme	antibody	400:407	arg1	function					418:425	antibody effector function	400:425	antibody effector function	400:425	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	0	35	theme	Macaque	33:39	arg1	Receptors					50:58	Rhesus Macaque Fc Gamma Receptors	26:58	Rhesus Macaque Fc Gamma Receptors	26:58	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	2	36	theme	receptors	461:469	arg1	affinity					445:452	the affinity	441:452	the affinity of Fcγ receptors	441:469	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	3	37	theme	cellular	589:596	arg1	cytotoxicity					598:609	antibody-mediated cellular cytotoxicity	571:609	antibody-mediated cellular cytotoxicity	571:609	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	1	38	theme	human	204:208	arg1	antibodies					221:230	human monoclonal antibodies	204:230	human monoclonal antibodies	204:230	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	0	39	theme	Receptors	50:58	arg1	Evaluation					12:21	Biophysical Evaluation	0:21	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors	0:58	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	4	40	theme	human	886:890	arg1	antibodies					892:901	glycoengineered human antibodies	870:901	glycoengineered human antibodies	870:901	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	5	41	theme	FcγRs	1007:1011	arg1	affinities					985:994	the affinities	981:994	the affinities of macaque FcγRs for differing glycoforms	981:1036	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	4	42	from	species	816:822	arg1	use					760:762	the use	756:762	the use of an alternate monosaccharide in sialylated glycan species	756:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	42	from	species	816:822	arg1	frequency					728:736	the frequency	724:736	the frequency of glycoforms	724:750	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	0	43	theme	Gamma	44:48	arg1	Receptors					50:58	Rhesus Macaque Fc Gamma Receptors	26:58	Rhesus Macaque Fc Gamma Receptors	26:58	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	4	44	theme	glycoengineered	870:884	arg1	antibodies					892:901	glycoengineered human antibodies	870:901	glycoengineered human antibodies	870:901	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	5	45	theme	differing	1017:1025	arg1	glycoforms					1027:1036	differing glycoforms	1017:1036	differing glycoforms	1017:1036	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	6	46	theme	tractable	1109:1117	arg1	macaques					1094:1101	macaques	1094:1101	macaques	1094:1101	Our results suggest that macaques are a tractable species in which to test the effects of antibody glycoengineering.
34712242	6	46	theme	tractable	1109:1117	arg1	species					1119:1125	a tractable species	1107:1125	a tractable species in which to test the effects of antibody glycoengineering	1107:1183	Our results suggest that macaques are a tractable species in which to test the effects of antibody glycoengineering.
34712242	1	47	theme	Fc	313:314	arg1	region					316:321	the Fc region	309:321	the Fc region	309:321	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	5	48	theme	macaque	999:1005	arg1	FcγRs					1007:1011	macaque FcγRs	999:1011	macaque FcγRs	999:1011	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	4	49	theme	alternate	770:778	arg1	monosaccharide					780:793	an alternate monosaccharide	767:793	an alternate monosaccharide in sialylated glycan species	767:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	50	theme	sialylated	798:807	arg1	species					816:822	sialylated glycan species	798:822	sialylated glycan species	798:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	1	51	theme	Rhesus	125:130	arg1	macaques					132:139	Rhesus macaques	125:139	Rhesus macaques	125:139	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	1	51	theme	Rhesus	125:130	arg1	model					172:176	a common non-human primate model	145:176	a common non-human primate model used in the evaluation of human monoclonal antibodies	145:230	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	4	52	from	differences	709:719	arg1	use					760:762	the use	756:762	the use of an alternate monosaccharide in sialylated glycan species	756:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	52	from	differences	709:719	arg1	frequency					728:736	the frequency	724:736	the frequency of glycoforms	724:750	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	1	53	theme	monoclonal	210:219	arg1	antibodies					221:230	human monoclonal antibodies	204:230	human monoclonal antibodies	204:230	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	4	54	theme	antibodies	892:901	arg1	testing					859:865	the testing	855:865	the testing of glycoengineered human antibodies in rhesus macaques	855:920	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	3	55	theme	Fc-FcγRIIIa	625:635	arg1	affinity					637:644	Fc-FcγRIIIa affinity	625:644	Fc-FcγRIIIa affinity	625:644	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34712242	4	56	theme	glycan	676:681	arg1	position					657:664	the position	653:664	the position of the Fc glycan	653:681	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	1	57	theme	antibodies	221:230	arg1	evaluation					190:199	the evaluation	186:199	the evaluation of human monoclonal antibodies	186:230	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	0	58	theme	Similar	68:74	arg1	Preferences					93:103	Similar IgG Fc Glycoform Preferences	68:103	Similar IgG Fc Glycoform Preferences	68:103	Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors.
34712242	5	59	theme	surface	1042:1048	arg1	resonance					1058:1066	surface plasmon resonance	1042:1066	surface plasmon resonance	1042:1066	Using a panel of 16 human IgG1 glycovariants, we measured the affinities of macaque FcγRs for differing glycoforms via surface plasmon resonance.
34712242	1	60	link	N-linked	290:297	arg1	glycan					299:304	a conserved N-linked glycan	278:304	a conserved N-linked glycan in the Fc region	278:321	Rhesus macaques are a common non-human primate model used in the evaluation of human monoclonal antibodies, molecules whose effector functions depend on a conserved N-linked glycan in the Fc region.
34712242	2	61	theme	Fcγ	457:459	arg1	receptors					461:469	Fcγ receptors	457:469	Fcγ receptors	457:469	This carbohydrate is a target of glycoengineering efforts aimed at altering antibody effector function by modulating the affinity of Fcγ receptors.
34712242	4	62	theme	monosaccharide	780:793	arg1	use					760:762	the use	756:762	the use of an alternate monosaccharide in sialylated glycan species	756:822	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	4	62	theme	monosaccharide	780:793	arg1	frequency					728:736	the frequency	724:736	the frequency of glycoforms	724:750	While the position of the Fc glycan is conserved in macaques, differences in the frequency of glycoforms and the use of an alternate monosaccharide in sialylated glycan species add a degree of uncertainty to the testing of glycoengineered human antibodies in rhesus macaques.
34712242	6	63	theme	antibody	1159:1166	arg1	glycoengineering					1168:1183	antibody glycoengineering	1159:1183	antibody glycoengineering	1159:1183	Our results suggest that macaques are a tractable species in which to test the effects of antibody glycoengineering.
34712242	3	64	theme	overall	504:510	arg1	content					524:530	the overall core fucose content	500:530	the overall core fucose content	500:530	For example, a reduction in the overall core fucose content is one such strategy that can increase antibody-mediated cellular cytotoxicity by increasing Fc-FcγRIIIa affinity.
34696719	12	0	theme	gene	1894:1897	arg1	traits					1906:1911	SeXTH gene family traits	1888:1911	SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1888:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	0	theme	gene	1894:1897	arg1	regulators					1950:1959	potential stress resistance regulators	1922:1959	potential stress resistance regulators in S. europaea	1922:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	9	1	theme	different	1533:1541	arg1	stresses					1543:1550	different stresses	1533:1550	different stresses	1533:1550	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	5	2	theme	Transcriptome	678:690	arg1	system					719:724	PacBio Iso-Seq system	704:724	PacBio Iso-Seq system	704:724	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	5	2	theme	Transcriptome	678:690	arg1	sequencing					692:701	RESULTS Transcriptome sequencing	670:701	RESULTS Transcriptome sequencing (PacBio Iso-Seq system)	670:725	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	4	3	theme	real-time	610:618	arg1	RT-qPCR					660:666	RT-qPCR	660:666	RT-qPCR	660:666	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	4	3	theme	real-time	610:618	arg1	reaction					650:657	real-time quantitative polymerase chain reaction	610:657	real-time quantitative polymerase chain reaction (RT-qPCR)	610:667	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	10	4	from	stress	1748:1753	arg1	roots					1769:1773	roots	1769:1773	roots	1769:1773	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	10	4	from	stress	1748:1753	arg1	shoots					1758:1763	shoots	1758:1763	shoots	1758:1763	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	4	5	used	used	551:554	arg2	data					541:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	10	6	from	shoots	1758:1763	arg1	48 h					1732:1735	48 h	1732:1735	48 h of drought stress in shoots and roots	1732:1773	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	0	7	theme	drought	169:175	arg1	stress					177:182	salinity and drought stress	156:182	stress	177:182	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	8	8	theme	DE	1236:1237	arg1	domain					1257:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	10	9	from	roots	1769:1773	arg1	48 h					1732:1735	48 h	1732:1735	48 h of drought stress in shoots and roots	1732:1773	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	8	10	theme	I/L/F/V	1239:1245	arg1	domain					1257:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	2	11	theme	xyloglucan	310:319	arg1	endotransglycosylase/hydrolase					321:350	xyloglucan endotransglycosylase/hydrolase	310:350	xyloglucan endotransglycosylase/hydrolase (XTH)	310:356	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	2	11	theme	xyloglucan	310:319	arg1	XTH					353:355	XTH	353:355	XTH	353:355	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	8	12	theme	DF	1247:1248	arg1	domain					1257:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	7	13	theme	potential	1046:1054	arg1	proteins					1062:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	12	14	from	regulators	1950:1959	arg1	europaea					1967:1974	S. europaea	1964:1974	S. europaea	1964:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	8	15	theme	motif	1212:1216	arg1	Prediction					1184:1193	Prediction	1184:1193	Prediction of the conserved motif	1184:1216	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	16	theme	T	1366:1366	arg1	G					1378:1378	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	12	17	theme	stress	1932:1937	arg1	traits					1906:1911	SeXTH gene family traits	1888:1911	SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1888:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	17	theme	stress	1932:1937	arg1	regulators					1950:1959	potential stress resistance regulators	1922:1959	potential stress resistance regulators in S. europaea	1922:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	5	18	theme	Iso-Seq	711:717	arg1	system					719:724	PacBio Iso-Seq system	704:724	PacBio Iso-Seq system	704:724	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	5	18	theme	Iso-Seq	711:717	arg1	sequencing					692:701	RESULTS Transcriptome sequencing	670:701	RESULTS Transcriptome sequencing (PacBio Iso-Seq system)	670:725	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	11	19	theme	drought	1832:1838	arg1	stress					1840:1845	salt and drought stress	1823:1845	salt and drought stress	1823:1845	This indicates their function in adaptation to salt and drought stress.
34696719	8	20	theme	EFLG	1252:1255	arg1	domain					1257:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	the DE(I/L/F/V)DF(I)EFLG domain	1232:1262	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	1	21	theme	BACKGROUND	185:194	arg1	europaea					207:214	BACKGROUND Salicornia europaea	185:214	BACKGROUND Salicornia europaea	185:214	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	1	21	theme	BACKGROUND	185:194	arg1	halophyte					221:229	a halophyte	219:229	a halophyte that has a very pronounced salt tolerance	219:271	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	4	22	theme	Iso-Seq	510:516	arg1	data					541:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	8	23	theme	S.	1285:1286	arg1	proteins					1297:1304	the S. europaea proteins	1281:1304	the S. europaea proteins	1281:1304	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	0	24	theme	family	117:122	arg1	characterization					19:34	Transcriptome-wide characterization	0:34	Transcriptome-wide characterization	0:34	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	0	24	theme	family	117:122	arg1	analysis					51:58	functional analysis	40:58	functional analysis	40:58	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	6	25	theme	transcription	970:982	arg1	TFs					993:995	TFs	993:995	TFs	993:995	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	6	25	theme	transcription	970:982	arg1	factors					984:990	6398 possible transcription factors	956:990	6398 possible transcription factors (TFs)	956:996	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	8	26	theme	catalytic	1406:1414	arg1	residues					1416:1423	the catalytic residues	1402:1423	the catalytic residues	1402:1423	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	0	27	theme	Salicornia	127:136	arg1	europaea					138:145	Salicornia europaea L.	127:148	Salicornia europaea L.	127:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	9	28	theme	discrete	1452:1459	arg1	patterns					1472:1479	discrete expression patterns	1452:1479	discrete expression patterns in different tissues, at different times, and under different stresses	1452:1550	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	9	29	from	times	1516:1520	arg1	patterns					1472:1479	discrete expression patterns	1452:1479	discrete expression patterns in different tissues, at different times, and under different stresses	1452:1550	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	12	30	theme	present	1863:1869	arg1	study					1871:1875	The present study	1859:1875	The present study	1859:1875	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	0	31	theme	XTH	107:109	arg1	family					117:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family	63:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L.	63:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	2	32	theme	abiotic	405:411	arg1	stress					413:418	abiotic stress	405:418	abiotic stress	405:418	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	0	33	theme	Transcriptome-wide	0:17	arg1	characterization					19:34	Transcriptome-wide characterization	0:34	Transcriptome-wide characterization	0:34	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	11	34	theme	salt	1823:1826	arg1	stress					1840:1845	salt and drought stress	1823:1845	salt and drought stress	1823:1845	This indicates their function in adaptation to salt and drought stress.
34696719	8	35	theme	N-linked	1322:1329	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	35	theme	N-linked	1322:1329	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	5	36	theme	2112 bp	852:858	arg1	length					842:847	an average length	831:847	an average length of 2112 bp	831:858	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	9	37	theme	different	1484:1492	arg1	tissues					1494:1500	different tissues	1484:1500	different tissues	1484:1500	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	12	38	dep	CONCLUSION	1848:1857	arg1	discovered					1877:1886	discovered	1877:1886	discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1877:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	38	dep	CONCLUSION	1848:1857	arg1	provides					1986:1993	provides	1986:1993	provides a basis for future functional diversity research	1986:2042	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	8	39	theme	domain	1345:1350	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	39	theme	domain	1345:1350	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	3	40	theme	gene	461:464	arg1	family					466:471	the XTH gene family	453:471	the XTH gene family	453:471	However, no systematic study of the XTH gene family in S. europaea is well known.
34696719	6	41	theme	unigenes	879:886	arg1	total					863:867	A total	861:867	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs)	861:996	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	6	41	theme	unigenes	879:886	arg1	unigenes					879:886	24,869 unigenes	872:886	24,869 unigenes	872:886	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	6	41	theme	unigenes	879:886	arg1	%					896:896	with 98%	889:896	with 98%	889:896	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	4	42	theme	sequence	532:539	arg1	data					541:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	2	43	theme	important	367:375	arg1	wall					284:287	a cell wall	277:287	a cell wall manipulating enzyme	277:307	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	2	43	theme	important	367:375	arg1	role					377:380	an important role	364:380	an important role	364:380	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	0	44	theme	Xyloglucan	63:72	arg1	family					117:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family	63:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L.	63:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	7	45	theme	S.	1090:1091	arg1	europaea					1093:1100	S. europaea	1090:1100	S. europaea	1090:1100	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	1	46	contain	has	236:238	arg2	tolerance					263:271	a very pronounced salt tolerance	240:271	a very pronounced salt tolerance	240:271	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	1	46	contain	has	236:238	arg1	europaea					207:214	BACKGROUND Salicornia europaea	185:214	BACKGROUND Salicornia europaea	185:214	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	1	46	contain	has	236:238	arg1	halophyte					221:229	a halophyte	219:229	a halophyte that has a very pronounced salt tolerance	219:271	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	12	47	theme	diversity	2025:2033	arg1	research					2035:2042	future functional diversity research	2007:2042	future functional diversity research	2007:2042	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	10	48	theme	SeXTH	1576:1580	arg1	genes					1582:1586	27 and 15 SeXTH genes	1566:1586	27 and 15 SeXTH genes	1566:1586	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	4	49	theme	quantitative	620:631	arg1	RT-qPCR					660:666	RT-qPCR	660:666	RT-qPCR	660:666	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	4	49	theme	quantitative	620:631	arg1	reaction					650:657	real-time quantitative polymerase chain reaction	610:657	real-time quantitative polymerase chain reaction (RT-qPCR)	610:667	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	12	50	theme	functional	2014:2023	arg1	research					2035:2042	future functional diversity research	2007:2042	future functional diversity research	2007:2042	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	10	51	theme	salt	1620:1623	arg1	stress					1625:1630	salt stress	1620:1630	salt stress	1620:1630	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	1	52	theme	salt	258:261	arg1	tolerance					263:271	a very pronounced salt tolerance	240:271	a very pronounced salt tolerance	240:271	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	7	53	theme	group	1123:1127	arg1	I/II					1129:1132	group I/II	1123:1132	group I/II	1123:1132	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	7	54	theme	genetic	1163:1169	arg1	relatedness					1171:1181	their genetic relatedness	1157:1181	their genetic relatedness	1157:1181	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	4	55	theme	chain	644:648	arg1	RT-qPCR					660:666	RT-qPCR	660:666	RT-qPCR	660:666	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	4	55	theme	chain	644:648	arg1	reaction					650:657	real-time quantitative polymerase chain reaction	610:657	real-time quantitative polymerase chain reaction (RT-qPCR)	610:667	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	5	56	theme	29,520	796:801	arg1	isoforms					803:810	29,520 isoforms	796:810	29,520 isoforms	796:810	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	5	57	theme	RESULTS	670:676	arg1	system					719:724	PacBio Iso-Seq system	704:724	PacBio Iso-Seq system	704:724	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	5	57	theme	RESULTS	670:676	arg1	sequencing					692:701	RESULTS Transcriptome sequencing	670:701	RESULTS Transcriptome sequencing (PacBio Iso-Seq system)	670:725	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	12	58	theme	SeXTH	1888:1892	arg1	traits					1906:1911	SeXTH gene family traits	1888:1911	SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1888:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	58	theme	SeXTH	1888:1892	arg1	regulators					1950:1959	potential stress resistance regulators	1922:1959	potential stress resistance regulators in S. europaea	1922:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	4	59	theme	expression	584:593	arg1	analysis					595:602	bioinformatics and gene expression analysis	560:602	analysis	595:602	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	10	60	from	48 h	1732:1735	arg1	roots					1769:1773	roots	1769:1773	roots	1769:1773	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	10	60	from	48 h	1732:1735	arg1	shoots					1758:1763	shoots	1758:1763	shoots	1758:1763	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	1	61	theme	Salicornia	196:205	arg1	europaea					207:214	BACKGROUND Salicornia europaea	185:214	BACKGROUND Salicornia europaea	185:214	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	1	61	theme	Salicornia	196:205	arg1	halophyte					221:229	a halophyte	219:229	a halophyte that has a very pronounced salt tolerance	219:271	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	6	62	theme	possible	961:968	arg1	TFs					993:995	TFs	993:995	TFs	993:995	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	6	62	theme	possible	961:968	arg1	factors					984:990	6398 possible transcription factors	956:990	6398 possible transcription factors (TFs)	956:996	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	11	63	from	function	1797:1804	arg1	adaptation					1809:1818	adaptation	1809:1818	adaptation to salt and drought stress	1809:1845	This indicates their function in adaptation to salt and drought stress.
34696719	7	64	theme	SeXTH	1056:1060	arg1	proteins					1062:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	9	65	theme	different	1506:1514	arg1	times					1516:1520	different times	1506:1520	different times	1506:1520	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	7	66	theme	non-redundant	1032:1044	arg1	proteins					1062:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	8	67	link	N-linked	1322:1329	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	67	link	N-linked	1322:1329	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	5	68	theme	PacBio	704:709	arg1	system					719:724	PacBio Iso-Seq system	704:724	PacBio Iso-Seq system	704:724	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	5	68	theme	PacBio	704:709	arg1	sequencing					692:701	RESULTS Transcriptome sequencing	670:701	RESULTS Transcriptome sequencing (PacBio Iso-Seq system)	670:725	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	8	69	theme	conserved	1202:1210	arg1	motif					1212:1216	the conserved motif	1198:1216	the conserved motif	1198:1216	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	10	70	theme	drought	1740:1746	arg1	stress					1748:1753	drought stress	1740:1753	drought stress in shoots and roots	1740:1773	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	12	71	theme	potential	1922:1930	arg1	traits					1906:1911	SeXTH gene family traits	1888:1911	SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1888:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	71	theme	potential	1922:1930	arg1	regulators					1950:1959	potential stress resistance regulators	1922:1959	potential stress resistance regulators in S. europaea	1922:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	7	72	theme	Thirty-five	1015:1025	arg1	proteins					1062:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins	1015:1069	Thirty-five (35) non-redundant potential SeXTH proteins were identified in S. europaea and categorized into group I/II and group III based on their genetic relatedness.
34696719	2	73	theme	cell	279:282	arg1	wall					284:287	a cell wall	277:287	a cell wall manipulating enzyme	277:307	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	2	73	theme	cell	279:282	arg1	role					377:380	an important role	364:380	an important role	364:380	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34696719	9	74	theme	SeXTH	1430:1434	arg1	genes					1436:1440	All SeXTH genes	1426:1440	All SeXTH genes	1426:1440	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	12	75	theme	resistance	1939:1948	arg1	traits					1906:1911	SeXTH gene family traits	1888:1911	SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1888:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	75	theme	resistance	1939:1948	arg1	regulators					1950:1959	potential stress resistance regulators	1922:1959	potential stress resistance regulators in S. europaea	1922:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	5	76	theme	Iso-Seq	787:793	arg1	control					776:782	quality control	768:782	quality control of Iso-Seq	768:793	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	10	77	theme	SeXTH	1683:1687	arg1	genes					1689:1693	34 SeXTH genes	1680:1693	34 SeXTH genes	1680:1693	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	12	78	theme	S.	1964:1965	arg1	europaea					1967:1974	S. europaea	1964:1974	S. europaea	1964:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	9	79	from	patterns	1472:1479	arg1	tissues					1494:1500	different tissues	1484:1500	different tissues	1484:1500	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	4	80	theme	PacBio	503:508	arg1	data					541:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	12	81	theme	family	1899:1904	arg1	traits					1906:1911	SeXTH gene family traits	1888:1911	SeXTH gene family traits that are potential stress resistance regulators in S. europaea	1888:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	12	81	theme	family	1899:1904	arg1	regulators					1950:1959	potential stress resistance regulators	1922:1959	potential stress resistance regulators in S. europaea	1922:1974	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	5	82	theme	quality	768:774	arg1	control					776:782	quality control	768:782	quality control of Iso-Seq	768:793	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	0	83	theme	gene	112:115	arg1	family					117:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family	63:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L.	63:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	4	84	theme	transcriptome	518:530	arg1	data					541:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data	503:544	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	0	85	dep	europaea	138:145	arg1	L.					147:148	Salicornia europaea L.	127:148	Salicornia europaea L.	127:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	0	86	theme	europaea	138:145	arg1	family					117:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family	63:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L.	63:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	8	87	theme	europaea	1288:1295	arg1	proteins					1297:1304	the S. europaea proteins	1281:1304	the S. europaea proteins	1281:1304	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	3	88	theme	XTH	457:459	arg1	family					466:471	the XTH gene family	453:471	the XTH gene family	453:471	However, no systematic study of the XTH gene family in S. europaea is well known.
34696719	5	89	theme	average	834:840	arg1	length					842:847	an average length	831:847	an average length of 2112 bp	831:858	RESULTS Transcriptome sequencing (PacBio Iso-Seq system) generated 16,465,671 sub-reads and after quality control of Iso-Seq, 29,520 isoforms were obtained with an average length of 2112 bp.
34696719	9	90	theme	expression	1461:1470	arg1	patterns					1472:1479	discrete expression patterns	1452:1479	discrete expression patterns in different tissues, at different times, and under different stresses	1452:1550	All SeXTH genes exhibited discrete expression patterns in different tissues, at different times, and under different stresses.
34696719	4	91	theme	bioinformatics	560:573	arg1	analysis					595:602	bioinformatics and gene expression analysis	560:602	analysis	595:602	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	0	92	theme	functional	40:49	arg1	analysis					51:58	functional analysis	40:58	functional analysis	40:58	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	4	93	theme	gene	579:582	arg1	analysis					595:602	bioinformatics and gene expression analysis	560:602	analysis	595:602	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	8	94	theme	potential	1312:1320	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	94	theme	potential	1312:1320	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	3	95	theme	S.	476:477	arg1	europaea					479:486	S. europaea	476:486	S. europaea	476:486	However, no systematic study of the XTH gene family in S. europaea is well known.
34696719	3	96	theme	systematic	433:442	arg1	study					444:448	no systematic study	430:448	no systematic study of the XTH gene family in S. europaea	430:486	However, no systematic study of the XTH gene family in S. europaea is well known.
34696719	8	97	theme	glycosylation	1331:1343	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	97	theme	glycosylation	1331:1343	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	3	98	theme	family	466:471	arg1	study					444:448	no systematic study	430:448	no systematic study of the XTH gene family in S. europaea	430:486	However, no systematic study of the XTH gene family in S. europaea is well known.
34696719	0	99	theme	endo-transglycosylase/hydrolase	74:104	arg1	family					117:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family	63:122	Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L.	63:148	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	6	100	theme	24,869	872:877	arg1	unigenes					879:886	24,869 unigenes	872:886	24,869 unigenes	872:886	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	0	101	theme	salinity	156:163	arg1	stress					177:182	salinity and drought stress	156:182	stress	177:182	Transcriptome-wide characterization and functional analysis of Xyloglucan endo-transglycosylase/hydrolase (XTH) gene family of Salicornia europaea L. under salinity and drought stress.
34696719	6	102	theme	coding	927:932	arg1	CDSs					945:948	CDSs	945:948	CDSs	945:948	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	6	102	theme	coding	927:932	arg1	sequences					934:942	coding sequences	927:942	coding sequences (CDSs)	927:949	A total of 24,869 unigenes, with 98% of which were obtained using coding sequences (CDSs), and 6398 possible transcription factors (TFs) were identified.
34696719	10	103	theme	stress	1748:1753	arg1	48 h					1732:1735	48 h	1732:1735	48 h of drought stress in shoots and roots	1732:1773	For example, 27 and 15 SeXTH genes were positively expressed under salt stress in shoots and roots at 200 mM NaCl in 24 h, and 34 SeXTH genes were also positively regulated under 48 h of drought stress in shoots and roots.
34696719	8	104	theme	N	1352:1352	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	104	theme	N	1352:1352	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	12	105	theme	future	2007:2012	arg1	research					2035:2042	future functional diversity research	2007:2042	future functional diversity research	2007:2042	CONCLUSION The present study discovered SeXTH gene family traits that are potential stress resistance regulators in S. europaea, and this provides a basis for future functional diversity research.
34696719	4	106	theme	polymerase	633:642	arg1	RT-qPCR					660:666	RT-qPCR	660:666	RT-qPCR	660:666	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	4	106	theme	polymerase	633:642	arg1	reaction					650:657	real-time quantitative polymerase chain reaction	610:657	real-time quantitative polymerase chain reaction (RT-qPCR)	610:667	PacBio Iso-Seq transcriptome sequence data were used for bioinformatics and gene expression analysis using real-time quantitative polymerase chain reaction (RT-qPCR).
34696719	8	107	theme	T	1354:1354	arg1	R/L/T/I					1358:1364	R/L/T/I	1358:1364	R/L/T/I	1358:1364	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	107	theme	T	1354:1354	arg1	V					1356:1356	a potential N-linked glycosylation domain N(T)V	1310:1356	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	3	108	from	study	444:448	arg1	europaea					479:486	S. europaea	476:486	S. europaea	476:486	However, no systematic study of the XTH gene family in S. europaea is well known.
34696719	1	109	theme	pronounced	247:256	arg1	tolerance					263:271	a very pronounced salt tolerance	240:271	a very pronounced salt tolerance	240:271	BACKGROUND Salicornia europaea is a halophyte that has a very pronounced salt tolerance.
34696719	8	110	theme	V	1356:1356	arg1	T					1366:1366	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T	1310:1366	a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G	1310:1378	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	8	110	theme	V	1356:1356	arg1	S/K/R/F/P					1368:1376	S/K/R/F/P	1368:1376	S/K/R/F/P	1368:1376	Prediction of the conserved motif revealed that the DE(I/L/F/V)DF(I)EFLG domain was conserved in the S. europaea proteins and a potential N-linked glycosylation domain N(T)V(R/L/T/I)T(S/K/R/F/P)G was also located near the catalytic residues.
34696719	2	111	theme	plant	385:389	arg1	resistance					391:400	plant resistance	385:400	plant resistance to abiotic stress	385:418	As a cell wall manipulating enzyme, xyloglucan endotransglycosylase/hydrolase (XTH) plays an important role in plant resistance to abiotic stress.
34633871	1	0	theme	volcanii	170:177	arg1	synthase					249:256	the only archaeal dolichol phosphate (DolP)-mannose synthase	197:256	the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation	197:296	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	1	0	theme	volcanii	170:177	arg1	AglD					179:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	8	1	theme	truncated	1112:1120	arg1	versions					1122:1129	this or other truncated versions	1098:1129	this or other truncated versions of AglD	1098:1137	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	12	2	from	AglD	1484:1487	arg1	coordination					1502:1513	coordination	1502:1513	coordination with AglR	1502:1523	Accordingly, the possibility that AglD, possibly in coordination with AglR, translocates DolP-mannose across the plasma membrane is discussed.
34633871	8	3	link	N-linked	1237:1244	arg1	pentasaccharide					1246:1260	the N-linked pentasaccharide	1233:1260	the N-linked pentasaccharide normally decorating Hfx	1233:1284	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	12	4	theme	plasma	1563:1568	arg1	membrane					1570:1577	the plasma membrane	1559:1577	the plasma membrane	1559:1577	Accordingly, the possibility that AglD, possibly in coordination with AglR, translocates DolP-mannose across the plasma membrane is discussed.
34633871	3	5	theme	AglD	528:531	arg1	domains					543:549	the PF0058 and AglD catalytic domains	513:549	domains	543:549	In this report, similarities between the PF0058 and AglD catalytic domains were revealed.
34633871	6	6	theme	volcanii	809:816	arg1	strains					818:824	volcanii strains	809:824	volcanii strains expressing truncated versions of AglD	809:862	volcanii strains expressing truncated versions of AglD was generated.
34633871	8	7	theme	AglD	1134:1137	arg1	versions					1122:1129	this or other truncated versions	1098:1129	this or other truncated versions of AglD	1098:1137	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	12	8	with	coordination	1502:1513	arg1	AglR					1520:1523	AglR	1520:1523	AglR	1520:1523	Accordingly, the possibility that AglD, possibly in coordination with AglR, translocates DolP-mannose across the plasma membrane is discussed.
34633871	7	9	theme	Mass	879:882	arg1	spectrometry					884:895	Mass spectrometry	879:895	Mass spectrometry	879:895	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	4	10	theme	other	655:659	arg1	synthases					674:682	other DolP-mannose synthases	655:682	other DolP-mannose synthases	655:682	At the same time, AglD includes a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases.
34633871	0	11	theme	Subsequent	109:118	arg1	Processing					120:129	Subsequent Processing	109:129	Subsequent Processing	109:129	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	0	12	dep	Assembly	96:103	arg1	the					92:94	the	92:94	the	92:94	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	8	13	theme	N-linked	1237:1244	arg1	pentasaccharide					1246:1260	the N-linked pentasaccharide	1233:1260	the N-linked pentasaccharide normally decorating Hfx	1233:1284	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	3	14	theme	catalytic	533:541	arg1	domains					543:549	the PF0058 and AglD catalytic domains	513:549	domains	543:549	In this report, similarities between the PF0058 and AglD catalytic domains were revealed.
34633871	11	15	theme	charging	1422:1429	arg1	DolP					1431:1434	charging DolP	1422:1434	charging DolP with mannose	1422:1447	volcanii N-glycosylation beyond charging DolP with mannose.
34633871	0	16	theme	Distinct	0:7	arg1	Regions					9:15	Distinct Regions	0:15	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	0:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	8	17	theme	pentasaccharide	1246:1260	arg1	precursor					1220:1228	the protein-bound tetrasaccharide precursor	1186:1228	the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx	1186:1284	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	8	18	theme	tetrasaccharide	1204:1218	arg1	precursor					1220:1228	the protein-bound tetrasaccharide precursor	1186:1228	the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx	1186:1284	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	2	19	theme	DolP-mannose	384:395	arg1	furiosus					349:356	Pyrococcus furiosus PF0058	338:363	Pyrococcus furiosus PF0058	338:363	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	2	19	theme	DolP-mannose	384:395	arg1	synthase					397:404	the only archaeal DolP-mannose synthase	366:404	the only archaeal DolP-mannose synthase for which structural information is presently available	366:460	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	8	20	theme	protein-bound	1190:1202	arg1	precursor					1220:1228	the protein-bound tetrasaccharide precursor	1186:1228	the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx	1186:1284	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	7	21	theme	catalytic	944:952	arg1	domain					954:959	the catalytic domain	940:959	the catalytic domain	940:959	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	1	22	theme	archaeal	206:213	arg1	synthase					249:256	the only archaeal dolichol phosphate (DolP)-mannose synthase	197:256	the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation	197:296	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	1	22	theme	archaeal	206:213	arg1	AglD					179:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	7	23	dep	nine	988:991	arg1	to					985:986	to	985:986	to	985:986	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	1	24	theme	dolichol	215:222	arg1	synthase					249:256	the only archaeal dolichol phosphate (DolP)-mannose synthase	197:256	the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation	197:296	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	1	24	theme	dolichol	215:222	arg1	AglD					179:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	0	25	theme	volcanii	34:41	arg1	AglD					79:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	4	26	theme	same	573:576	arg1	time					578:581	the same time	569:581	the same time	569:581	At the same time, AglD includes a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases.
34633871	0	27	theme	Mannose	151:157	arg1	Assembly					96:103	Assembly	96:103	Assembly	96:103	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	0	27	theme	Mannose	151:157	arg1	Processing					120:129	Subsequent Processing	109:129	Subsequent Processing	109:129	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	9	28	gly	glycoproteins	1296:1308	arg1	glycoproteins					1296:1308	volcanii glycoproteins	1287:1308	volcanii glycoproteins	1287:1308	volcanii glycoproteins.
34633871	5	29	theme	AglD	729:732	arg1	functions					734:742	AglD functions	729:742	AglD functions	729:742	To determine whether this extension affords AglD functions in addition to generating mannose-charged DolP, a series of Hfx.
34633871	4	30	theme	DolP-mannose	661:672	arg1	synthases					674:682	other DolP-mannose synthases	655:682	other DolP-mannose synthases	655:682	At the same time, AglD includes a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases.
34633871	1	31	theme	phosphate	224:232	arg1	synthase					249:256	the only archaeal dolichol phosphate (DolP)-mannose synthase	197:256	the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation	197:296	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	1	31	theme	phosphate	224:232	arg1	AglD					179:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	0	32	theme	Haloferax	24:32	arg1	volcanii					34:41	Haloferax volcanii	24:41	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	0	33	theme	Lipid-Linked	138:149	arg1	Mannose					151:157	the Lipid-Linked Mannose	134:157	the Lipid-Linked Mannose	134:157	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	4	34	theme	longer	625:630	arg1	domain					614:619	a transmembrane domain	598:619	a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases	598:682	At the same time, AglD includes a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases.
34633871	2	35	theme	structural	416:425	arg1	information					427:437	structural information	416:437	structural information	416:437	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	0	36	theme	Phosphate-Mannose	52:68	arg1	AglD					79:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	5	37	theme	Hfx	804:806	arg1	series					794:799	a series	792:799	a series of Hfx	792:806	To determine whether this extension affords AglD functions in addition to generating mannose-charged DolP, a series of Hfx.
34633871	5	38	theme	mannose-charged	770:784	arg1	DolP					786:789	mannose-charged DolP	770:789	mannose-charged DolP	770:789	To determine whether this extension affords AglD functions in addition to generating mannose-charged DolP, a series of Hfx.
34633871	10	39	theme	additional	1363:1372	arg1	aspects					1374:1380	additional aspects	1363:1380	additional aspects of Hfx	1363:1387	These results thus point to AglD as contributing to additional aspects of Hfx.
34633871	0	40	theme	Dolichol	43:50	arg1	AglD					79:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	8	41	theme	other	1106:1110	arg1	versions					1122:1129	this or other truncated versions	1098:1129	this or other truncated versions of AglD	1098:1137	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
34633871	6	42	theme	AglD	859:862	arg1	versions					847:854	truncated versions	837:854	truncated versions of AglD	837:862	volcanii strains expressing truncated versions of AglD was generated.
34633871	7	43	theme	membrane-spanning	1003:1019	arg1	domains					1021:1027	the six to nine predicted membrane-spanning domains	977:1027	the six to nine predicted membrane-spanning domains	977:1027	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	7	44	theme	AglD	924:927	arg1	version					913:919	a version	911:919	a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains	911:1027	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	11	45	with	DolP	1431:1434	arg1	mannose					1441:1447	mannose	1441:1447	mannose	1441:1447	volcanii N-glycosylation beyond charging DolP with mannose.
34633871	7	46	theme	mannose	1043:1049	arg1	addition					1051:1058	mannose addition	1043:1058	mannose addition to DolP	1043:1066	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	7	47	theme	domains	1021:1027	arg1	two					970:972	two	970:972	two	970:972	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	7	47	theme	domains	1021:1027	arg1	domains					1021:1027	the six to nine predicted membrane-spanning domains	977:1027	the six to nine predicted membrane-spanning domains	977:1027	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	2	48	theme	Pyrococcus	338:347	arg1	furiosus					349:356	Pyrococcus furiosus PF0058	338:363	Pyrococcus furiosus PF0058	338:363	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	2	48	theme	Pyrococcus	338:347	arg1	synthase					397:404	the only archaeal DolP-mannose synthase	366:404	the only archaeal DolP-mannose synthase for which structural information is presently available	366:460	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	1	49	theme	DolP	235:238	arg1	synthase					249:256	the only archaeal dolichol phosphate (DolP)-mannose synthase	197:256	the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation	197:296	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	1	49	theme	DolP	235:238	arg1	AglD					179:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	9	50	theme	volcanii	1287:1294	arg1	glycoproteins					1296:1308	volcanii glycoproteins	1287:1308	volcanii glycoproteins	1287:1308	volcanii glycoproteins.
34633871	1	51	theme	Haloferax	160:168	arg1	volcanii					170:177	Haloferax volcanii	160:177	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	4	52	theme	transmembrane	600:612	arg1	domain					614:619	a transmembrane domain	598:619	a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases	598:682	At the same time, AglD includes a transmembrane domain far longer than that of PF0058 or other DolP-mannose synthases.
34633871	0	53	theme	AglD	79:82	arg1	Regions					9:15	Distinct Regions	0:15	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	0:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	6	54	theme	truncated	837:845	arg1	versions					847:854	truncated versions	837:854	truncated versions of AglD	837:862	volcanii strains expressing truncated versions of AglD was generated.
34633871	7	55	theme	predicted	993:1001	arg1	domains					1021:1027	the six to nine predicted membrane-spanning domains	977:1027	the six to nine predicted membrane-spanning domains	977:1027	Mass spectrometry revealed that a version of AglD comprising the catalytic domain and only two of the six to nine predicted membrane-spanning domains could mediate mannose addition to DolP.
34633871	2	56	theme	archaeal	375:382	arg1	furiosus					349:356	Pyrococcus furiosus PF0058	338:363	Pyrococcus furiosus PF0058	338:363	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	2	56	theme	archaeal	375:382	arg1	synthase					397:404	the only archaeal DolP-mannose synthase	366:404	the only archaeal DolP-mannose synthase for which structural information is presently available	366:460	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	1	57	theme	-mannose	240:247	arg1	synthase					249:256	the only archaeal dolichol phosphate (DolP)-mannose synthase	197:256	the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation	197:296	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	1	57	theme	-mannose	240:247	arg1	AglD					179:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD	160:182	Haloferax volcanii AglD is currently the only archaeal dolichol phosphate (DolP)-mannose synthase shown to participate in N-glycosylation.
34633871	0	58	theme	Synthase	70:77	arg1	AglD					79:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD	20:82	Distinct Regions of the Haloferax volcanii Dolichol Phosphate-Mannose Synthase AglD Mediate the Assembly and Subsequent Processing of the Lipid-Linked Mannose.
34633871	5	59	dep	generating	759:768	arg1	addition					747:754	addition	747:754	addition	747:754	To determine whether this extension affords AglD functions in addition to generating mannose-charged DolP, a series of Hfx.
34633871	10	60	theme	Hfx	1385:1387	arg1	aspects					1374:1380	additional aspects	1363:1380	additional aspects of Hfx	1363:1387	These results thus point to AglD as contributing to additional aspects of Hfx.
34633871	2	61	theme	only	370:373	arg1	furiosus					349:356	Pyrococcus furiosus PF0058	338:363	Pyrococcus furiosus PF0058	338:363	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	2	61	theme	only	370:373	arg1	synthase					397:404	the only archaeal DolP-mannose synthase	366:404	the only archaeal DolP-mannose synthase for which structural information is presently available	366:460	However, the relation between AglD and Pyrococcus furiosus PF0058, the only archaeal DolP-mannose synthase for which structural information is presently available, was unclear.
34633871	8	62	theme	this	1098:1101	arg1	versions					1122:1129	this or other truncated versions	1098:1129	this or other truncated versions of AglD	1098:1137	However, in cells expressing this or other truncated versions of AglD, mannose was not transferred from the lipid to the protein-bound tetrasaccharide precursor of the N-linked pentasaccharide normally decorating Hfx.
33946304	0	0	theme	Respiratory	84:94	arg1	Coronavirus					105:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus	55:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	6	1	theme	Celgosivir	1246:1255	arg1	activity					1209:1216	the low-micromolar activity	1190:1216	the low-micromolar activity of the investigational drug Celgosivir	1190:1255	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	4	2	theme	viruses	820:826	arg1	release					798:804	release	798:804	release of infectious viruses	798:826	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	4	2	theme	viruses	820:826	arg1	decrease					767:774	a marked decrease	758:774	a marked decrease of viral proteins	758:792	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	5	3	theme	viral	1056:1060	arg1	protein					1068:1074	the viral Spike protein	1052:1074	the viral Spike protein	1052:1074	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	0	4	theme	Acute	78:82	arg1	Coronavirus					105:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus	55:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	4	5	theme	infectious	809:818	arg1	viruses					820:826	infectious viruses	809:826	infectious viruses	809:826	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	1	6	theme	new	181:183	arg1	disease					197:203	the new coronavirus disease 2019	177:208	the new coronavirus disease 2019 (COVID-19)	177:219	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	1	6	theme	new	181:183	arg1	COVID-19					211:218	COVID-19	211:218	COVID-19	211:218	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	0	7	theme	Coronavirus	105:115	arg1	SARS-CoV-2					117:126	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	1	8	theme	few	337:339	arg1	options					351:357	very few treatment options	332:357	very few treatment options	332:357	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	5	9	theme	endoplasmic	997:1007	arg1	reticulum					1009:1017	the endoplasmic reticulum	993:1017	the endoplasmic reticulum	993:1017	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	0	10	theme	Syndrome	96:103	arg1	Coronavirus					105:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus	55:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	1	11	theme	treatment	341:349	arg1	options					351:357	very few treatment options	332:357	very few treatment options	332:357	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	5	12	theme	early	925:929	arg1	stages					931:936	the early stages	921:936	the early stages of glycoprotein N-linked oligosaccharide processing	921:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	1	13	theme	Severe	260:265	arg1	Syndrome					285:292	the Severe Acute Respiratory Syndrome	256:292	the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic	256:326	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	5	14	theme	Spike	1062:1066	arg1	protein					1068:1074	the viral Spike protein	1052:1074	the viral Spike protein	1052:1074	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	2	15	theme	viruses	602:608	arg1	variety					581:587	a variety	579:587	a variety of enveloped viruses	579:608	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	15	theme	viruses	602:608	arg1	viruses					602:608	enveloped viruses	592:608	enveloped viruses	592:608	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	1	16	theme	coronavirus	185:195	arg1	disease					197:203	the new coronavirus disease 2019	177:208	the new coronavirus disease 2019 (COVID-19)	177:219	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	1	16	theme	coronavirus	185:195	arg1	COVID-19					211:218	COVID-19	211:218	COVID-19	211:218	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	5	17	theme	protein	1068:1074	arg1	decrease					1040:1047	a marked decrease	1031:1047	a marked decrease of the viral Spike protein	1031:1074	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	2	18	theme	enveloped	592:600	arg1	viruses					602:608	enveloped viruses	592:608	enveloped viruses	592:608	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	4	19	theme	post-entry	728:737	arg1	level					739:743	the post-entry level	724:743	the post-entry level	724:743	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	2	20	theme	iminosugar	378:387	arg1	Miglustat					389:397	The iminosugar Miglustat	374:397	The iminosugar Miglustat	374:397	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	20	theme	iminosugar	378:387	arg1	active					564:569	active	564:569	active	564:569	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	20	theme	iminosugar	378:387	arg1	drug					423:426	a well-characterized drug	402:426	a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C	402:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	21	theme	diseases	479:486	arg1	treatment					436:444	the treatment	432:444	the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C	432:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	6	22	theme	drug	1241:1244	arg1	Celgosivir					1246:1255	the investigational drug Celgosivir	1221:1255	the investigational drug Celgosivir	1221:1255	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	6	23	theme	glycosylation	1120:1132	arg1	inhibitors					1134:1143	protein glycosylation inhibitors	1112:1143	protein glycosylation inhibitors	1112:1143	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	1	24	theme	Acute	267:271	arg1	Syndrome					285:292	the Severe Acute Respiratory Syndrome	256:292	the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic	256:326	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	6	25	theme	investigational	1225:1239	arg1	Celgosivir					1246:1255	the investigational drug Celgosivir	1221:1255	the investigational drug Celgosivir	1221:1255	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	6	26	theme	protein	1112:1118	arg1	inhibitors					1134:1143	protein glycosylation inhibitors	1112:1143	protein glycosylation inhibitors	1112:1143	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	7	27	theme	approach	1302:1309	arg1	role					1289:1292	a relevant role	1278:1292	a relevant role of this approach for the treatment of COVID-19	1278:1339	These data point to a relevant role of this approach for the treatment of COVID-19.
33946304	0	28	theme	Glycosylation	22:34	arg1	Inhibitors					0:9	Inhibitors	0:9	Inhibitors of Protein Glycosylation	0:34	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	1	29	theme	Respiratory	273:283	arg1	Syndrome					285:292	the Severe Acute Respiratory Syndrome	256:292	the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic	256:326	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	6	30	theme	low-micromolar	1194:1207	arg1	activity					1209:1216	the low-micromolar activity	1190:1216	the low-micromolar activity of the investigational drug Celgosivir	1190:1255	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	0	31	theme	Protein	14:20	arg1	Glycosylation					22:34	Protein Glycosylation	14:34	Protein Glycosylation	14:34	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	1	32	theme	Syndrome	285:292	arg1	course					246:251	the course	242:251	the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic	242:326	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	5	33	theme	marked	1033:1038	arg1	decrease					1040:1047	a marked decrease	1031:1047	a marked decrease of the viral Spike protein	1031:1074	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	2	34	theme	well-characterized	404:421	arg1	Miglustat					389:397	The iminosugar Miglustat	374:397	The iminosugar Miglustat	374:397	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	34	theme	well-characterized	404:421	arg1	active					564:569	active	564:569	active	564:569	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	34	theme	well-characterized	404:421	arg1	drug					423:426	a well-characterized drug	402:426	a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C	402:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	35	theme	storage	471:477	arg1	diseases					479:486	rare genetic lysosome storage diseases	449:486	rare genetic lysosome storage diseases	449:486	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	35	theme	storage	471:477	arg1	C					527:527	Niemann-Pick type C	509:527	Niemann-Pick type C	509:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	35	theme	storage	471:477	arg1	Gaucher					497:503	Gaucher	497:503	Gaucher	497:503	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	5	36	theme	processing	979:988	arg1	stages					931:936	the early stages	921:936	the early stages of glycoprotein N-linked oligosaccharide processing	921:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	2	37	theme	lysosome	462:469	arg1	diseases					479:486	rare genetic lysosome storage diseases	449:486	rare genetic lysosome storage diseases	449:486	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	37	theme	lysosome	462:469	arg1	C					527:527	Niemann-Pick type C	509:527	Niemann-Pick type C	509:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	37	theme	lysosome	462:469	arg1	Gaucher					497:503	Gaucher	497:503	Gaucher	497:503	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	5	38	gly	glycoprotein	941:952	arg1	glycoprotein					941:952	glycoprotein N-linked oligosaccharide processing	941:988	glycoprotein N-linked oligosaccharide processing	941:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	4	39	theme	marked	760:765	arg1	decrease					767:774	a marked decrease	758:774	a marked decrease of viral proteins	758:792	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	7	40	theme	relevant	1280:1287	arg1	role					1289:1292	a relevant role	1278:1292	a relevant role of this approach for the treatment of COVID-19	1278:1339	These data point to a relevant role of this approach for the treatment of COVID-19.
33946304	2	41	theme	genetic	454:460	arg1	diseases					479:486	rare genetic lysosome storage diseases	449:486	rare genetic lysosome storage diseases	449:486	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	41	theme	genetic	454:460	arg1	C					527:527	Niemann-Pick type C	509:527	Niemann-Pick type C	509:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	41	theme	genetic	454:460	arg1	Gaucher					497:503	Gaucher	497:503	Gaucher	497:503	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	42	theme	type	522:525	arg1	C					527:527	Niemann-Pick type C	509:527	Niemann-Pick type C	509:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	4	43	theme	viral	779:783	arg1	proteins					785:792	viral proteins	779:792	viral proteins	779:792	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	5	44	theme	inhibitory	858:867	arg1	activity					869:876	the inhibitory activity	854:876	the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum	854:1017	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	2	45	theme	rare	449:452	arg1	diseases					479:486	rare genetic lysosome storage diseases	449:486	rare genetic lysosome storage diseases	449:486	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	45	theme	rare	449:452	arg1	C					527:527	Niemann-Pick type C	509:527	Niemann-Pick type C	509:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	2	45	theme	rare	449:452	arg1	Gaucher					497:503	Gaucher	497:503	Gaucher	497:503	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33946304	4	46	theme	proteins	785:792	arg1	release					798:804	release	798:804	release of infectious viruses	798:826	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	4	46	theme	proteins	785:792	arg1	decrease					767:774	a marked decrease	758:774	a marked decrease of viral proteins	758:792	The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious viruses.
33946304	1	47	theme	pandemic	319:326	arg1	Syndrome					285:292	the Severe Acute Respiratory Syndrome	256:292	the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic	256:326	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	7	48	theme	COVID-19	1332:1339	arg1	treatment					1319:1327	the treatment	1315:1327	the treatment of COVID-19	1315:1339	These data point to a relevant role of this approach for the treatment of COVID-19.
33946304	5	49	theme	glycoprotein	941:952	arg1	processing					979:988	glycoprotein N-linked oligosaccharide processing	941:988	glycoprotein N-linked oligosaccharide processing	941:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	1	50	theme	available	152:160	arg1	drugs					162:166	clinically available drugs	141:166	clinically available drugs	141:166	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	1	51	theme	urgent	227:232	arg1	need					234:237	an urgent need	224:237	an urgent need	224:237	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	1	52	from	need	234:237	arg1	course					246:251	the course	242:251	the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic	242:326	Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
33946304	3	53	theme	Miglustat	627:635	arg1	activity					615:622	The activity	611:622	The activity of Miglustat	611:635	The activity of Miglustat is here demonstrated in the micromolar range for SARS-CoV-2 in vitro.
33946304	5	54	theme	N-linked	954:961	arg1	processing					979:988	glycoprotein N-linked oligosaccharide processing	941:988	glycoprotein N-linked oligosaccharide processing	941:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	6	55	theme	antiviral	1089:1097	arg1	potential					1099:1107	the antiviral potential	1085:1107	the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2	1085:1162	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	0	56	theme	Severe	71:76	arg1	Coronavirus					105:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus	55:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	5	57	theme	oligosaccharide	963:977	arg1	processing					979:988	glycoprotein N-linked oligosaccharide processing	941:988	glycoprotein N-linked oligosaccharide processing	941:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	6	58	theme	inhibitors	1134:1143	arg1	potential					1099:1107	the antiviral potential	1085:1107	the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2	1085:1162	Indeed, the antiviral potential of protein glycosylation inhibitors against SARS-CoV-2 is further highlighted by the low-micromolar activity of the investigational drug Celgosivir.
33946304	0	59	theme	Coronavirus	59:69	arg1	Coronavirus					105:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus	55:115	the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2	55:126	Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
33946304	3	60	theme	micromolar	665:674	arg1	range					676:680	the micromolar range	661:680	the micromolar range for SARS-CoV-2	661:695	The activity of Miglustat is here demonstrated in the micromolar range for SARS-CoV-2 in vitro.
33946304	5	61	link	N-linked	954:961	arg1	processing					979:988	glycoprotein N-linked oligosaccharide processing	941:988	glycoprotein N-linked oligosaccharide processing	941:988	The mechanism resides in the inhibitory activity toward α-glucosidases that are involved in the early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein.
33946304	2	62	theme	Niemann-Pick	509:520	arg1	C					527:527	Niemann-Pick type C	509:527	Niemann-Pick type C	509:527	The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases, such as Gaucher and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses.
33886677	6	0	theme	intracellular	1088:1100	arg1	triphosphate					1112:1123	intracellular adenosine triphosphate	1088:1123	intracellular adenosine triphosphate	1088:1123	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	10	1	theme	antibodies	1811:1820	arg1	control					1789:1795	improved production and quality control	1757:1795	improved production and quality control of monoclonal antibodies	1757:1820	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	10	2	theme	derivatives	1731:1741	arg1	optimization					1695:1706	Further structural optimization	1676:1706	Further structural optimization of 2,5-dimethylpyrrole derivatives	1676:1741	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	9	3	theme	structure-activity	1454:1471	arg1	relationship					1473:1484	the structure-activity relationship	1450:1484	the structure-activity relationship study	1450:1490	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	2	4	theme	hamster	312:318	arg1	cells					326:330	recombinant Chinese hamster ovary cells	292:330	recombinant Chinese hamster ovary cells	292:330	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	4	theme	hamster	312:318	arg1	host					352:355	a host	350:355	a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	350:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	5	from	host	352:355	arg1	production					380:389	monoclonal antibody production	360:389	monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	360:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	0	6	theme	hamster	124:130	arg1	ovary					132:136	Chinese hamster ovary	116:136	a Chinese hamster ovary cell culture	114:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	2	7	theme	recombinant	292:302	arg1	cells					326:330	recombinant Chinese hamster ovary cells	292:330	recombinant Chinese hamster ovary cells	292:330	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	7	theme	recombinant	292:302	arg1	host					352:355	a host	350:355	a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	350:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	1	8	theme	antibody	203:210	arg1	production					212:221	monoclonal antibody production	192:221	monoclonal antibody production	192:221	There is a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction.
33886677	7	9	from	galactosylation	1210:1224	arg1	antibody					1242:1249	a monoclonal antibody	1229:1249	a monoclonal antibody	1229:1249	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	7	9	from	galactosylation	1210:1224	arg1	attribute					1280:1288	a critical quality attribute	1261:1288	a critical quality attribute of therapeutic monoclonal antibodies	1261:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	8	10	used	used	1366:1369	arg2	compound					1343:1350	the compound	1339:1350	the compound	1339:1350	Therefore, the compound might also be used to control the level of the galactosylation for the N-linked glycans.
33886677	0	11	theme	cell	138:141	arg1	culture					143:149	a Chinese hamster ovary cell culture	114:149	a Chinese hamster ovary cell culture	114:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	6	12	theme	triphosphate	1112:1123	arg1	triphosphate					1112:1123	intracellular adenosine triphosphate	1088:1123	intracellular adenosine triphosphate	1088:1123	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	6	12	theme	triphosphate	1112:1123	arg1	rate					1065:1068	cell-specific glucose uptake rate	1036:1068	cell-specific glucose uptake rate	1036:1068	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	6	12	theme	triphosphate	1112:1123	arg1	amount					1078:1083	the amount	1074:1083	the amount of intracellular adenosine triphosphate	1074:1123	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	10	13	theme	Further	1676:1682	arg1	optimization					1695:1706	Further structural optimization	1676:1706	Further structural optimization of 2,5-dimethylpyrrole derivatives	1676:1741	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	4	14	theme	chemical	690:697	arg1	compounds					699:707	new chemical compounds	686:707	new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells	686:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	3	15	theme	antibody	602:609	arg1	production					611:620	monoclonal antibody production	591:620	monoclonal antibody production in mammalian cell cultures	591:647	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	2	16	with	proteins	451:458	arg1	glycans					471:477	ideal glycans	465:477	ideal glycans	465:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	9	17	theme	partial	1549:1555	arg1	2,5-dimethylpyrrole					1506:1524	2,5-dimethylpyrrole	1506:1524	2,5-dimethylpyrrole	1506:1524	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	9	17	theme	partial	1549:1555	arg1	structure					1557:1565	the most effective partial structure	1530:1565	the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production	1530:1673	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	0	18	from	production	100:109	arg1	culture					143:149	a Chinese hamster ovary cell culture	114:149	a Chinese hamster ovary cell culture	114:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	6	19	theme	cell	1005:1008	arg1	growth					1010:1015	cell growth	1005:1015	cell growth	1005:1015	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	0	20	theme	monoclonal	80:89	arg1	production					100:109	monoclonal antibody production	80:109	monoclonal antibody production in a Chinese hamster ovary cell culture	80:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	4	21	theme	antibody	740:747	arg1	production					749:758	cell-specific antibody production	726:758	cell-specific antibody production in recombinant Chinese hamster ovary cells	726:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	5	22	theme	monoclonal	949:958	arg1	production					969:978	monoclonal antibody production	949:978	monoclonal antibody production	949:978	Out of the 23,227 chemicals screened in this study, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide was found to increase monoclonal antibody production.
33886677	2	23	theme	due	391:393	arg1	production					380:389	monoclonal antibody production	360:389	monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	360:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	24	theme	antibody	371:378	arg1	production					380:389	monoclonal antibody production	360:389	monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	360:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	25	used	used	342:345	arg2	cells					326:330	recombinant Chinese hamster ovary cells	292:330	recombinant Chinese hamster ovary cells	292:330	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	25	used	used	342:345	arg2	host					352:355	a host	350:355	a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	350:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	6	26	theme	cell-specific	1036:1048	arg1	rate					1065:1068	cell-specific glucose uptake rate	1036:1068	cell-specific glucose uptake rate	1036:1068	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	2	27	theme	high	410:413	arg1	productivity					415:426	high productivity	410:426	high productivity	410:426	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	0	28	theme	2,5-Dimethyl-1H-pyrrol-1-yl	3:29	arg1	2,5-dioxopyrrolidin-1-yl					35:58	2,5-dioxopyrrolidin-1-yl	35:58	2,5-dioxopyrrolidin-1-yl	35:58	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	0	28	theme	2,5-Dimethyl-1H-pyrrol-1-yl	3:29	arg1	-N-					31:33	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-	0:33	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	0:69	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	6	29	theme	glucose	1050:1056	arg1	rate					1065:1068	cell-specific glucose uptake rate	1036:1068	cell-specific glucose uptake rate	1036:1068	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	2	30	theme	ideal	465:469	arg1	glycans					471:477	ideal glycans	465:477	ideal glycans	465:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	3	31	theme	cell	635:638	arg1	cultures					640:647	mammalian cell cultures	625:647	mammalian cell cultures	625:647	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	10	32	theme	improved	1757:1764	arg1	control					1789:1795	improved production and quality control	1757:1795	improved production and quality control of monoclonal antibodies	1757:1820	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	0	33	theme	-N-	31:33	arg1	benzamide					61:69	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	0:69	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	0:69	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	9	34	theme	antibody	1655:1662	arg1	production					1664:1673	monoclonal antibody production	1644:1673	monoclonal antibody production	1644:1673	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	8	35	theme	N-linked	1423:1430	arg1	glycans					1432:1438	the N-linked glycans	1419:1438	the N-linked glycans	1419:1438	Therefore, the compound might also be used to control the level of the galactosylation for the N-linked glycans.
33886677	10	36	theme	monoclonal	1800:1809	arg1	antibodies					1811:1820	monoclonal antibodies	1800:1820	monoclonal antibodies	1800:1820	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	7	37	theme	monoclonal	1305:1314	arg1	antibodies					1316:1325	therapeutic monoclonal antibodies	1293:1325	therapeutic monoclonal antibodies	1293:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	4	38	theme	Chinese	775:781	arg1	cells					797:801	recombinant Chinese hamster ovary cells	763:801	recombinant Chinese hamster ovary cells	763:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	1	39	theme	medication	227:236	arg1	supply					238:243	medication supply	227:243	medication supply	227:243	There is a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction.
33886677	4	40	theme	ovary	791:795	arg1	cells					797:801	recombinant Chinese hamster ovary cells	763:801	recombinant Chinese hamster ovary cells	763:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	6	41	theme	adenosine	1102:1110	arg1	triphosphate					1112:1123	intracellular adenosine triphosphate	1088:1123	intracellular adenosine triphosphate	1088:1123	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	7	42	theme	monoclonal	1231:1240	arg1	antibody					1242:1249	a monoclonal antibody	1229:1249	a monoclonal antibody	1229:1249	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	7	42	theme	monoclonal	1231:1240	arg1	attribute					1280:1288	a critical quality attribute	1261:1288	a critical quality attribute of therapeutic monoclonal antibodies	1261:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	1	43	theme	cost	257:260	arg1	reduction					262:270	medical cost reduction	249:270	medical cost reduction	249:270	There is a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction.
33886677	3	44	from	production	611:620	arg1	cultures					640:647	mammalian cell cultures	625:647	mammalian cell cultures	625:647	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	3	45	theme	lithium	528:534	arg1	chloride					536:543	lithium chloride	528:543	lithium chloride	528:543	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	2	46	theme	ovary	320:324	arg1	cells					326:330	recombinant Chinese hamster ovary cells	292:330	recombinant Chinese hamster ovary cells	292:330	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	46	theme	ovary	320:324	arg1	host					352:355	a host	350:355	a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	350:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	9	47	from	structure	1557:1565	arg1	production					1664:1673	monoclonal antibody production	1644:1673	monoclonal antibody production	1644:1673	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	3	48	theme	Chemical	480:487	arg1	chloride					536:543	lithium chloride	528:543	lithium chloride	528:543	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	3	48	theme	Chemical	480:487	arg1	sulfoxide					517:525	dimethyl sulfoxide	508:525	dimethyl sulfoxide	508:525	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	3	48	theme	Chemical	480:487	arg1	compounds					489:497	Chemical compounds	480:497	Chemical compounds	480:497	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	3	48	theme	Chemical	480:487	arg1	acid					558:561	butyric acid	550:561	butyric acid	550:561	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	1	49	theme	continuous	163:172	arg1	demand					174:179	a continuous demand	161:179	a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction	161:270	There is a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction.
33886677	3	50	theme	butyric	550:556	arg1	acid					558:561	butyric acid	550:561	butyric acid	550:561	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	9	51	theme	relationship	1473:1484	arg1	study					1486:1490	the structure-activity relationship study	1450:1490	the structure-activity relationship study	1450:1490	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	0	52	theme	ovary	132:136	arg1	culture					143:149	a Chinese hamster ovary cell culture	114:149	a Chinese hamster ovary cell culture	114:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	2	53	theme	Chinese	304:310	arg1	cells					326:330	recombinant Chinese hamster ovary cells	292:330	recombinant Chinese hamster ovary cells	292:330	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	2	53	theme	Chinese	304:310	arg1	host					352:355	a host	350:355	a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	350:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	1	54	theme	monoclonal	192:201	arg1	production					212:221	monoclonal antibody production	192:221	monoclonal antibody production	192:221	There is a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction.
33886677	6	55	theme	antibody	1143:1150	arg1	production					1152:1161	monoclonal antibody production	1132:1161	monoclonal antibody production	1132:1161	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	10	56	theme	structural	1684:1693	arg1	optimization					1695:1706	Further structural optimization	1676:1706	Further structural optimization of 2,5-dimethylpyrrole derivatives	1676:1741	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	10	57	theme	2,5-dimethylpyrrole	1711:1729	arg1	derivatives					1731:1741	2,5-dimethylpyrrole derivatives	1711:1741	2,5-dimethylpyrrole derivatives	1711:1741	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	5	58	theme	-N-	887:889	arg1	benzamide					917:925	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	856:925	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	856:925	Out of the 23,227 chemicals screened in this study, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide was found to increase monoclonal antibody production.
33886677	7	59	theme	quality	1272:1278	arg1	antibody					1242:1249	a monoclonal antibody	1229:1249	a monoclonal antibody	1229:1249	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	7	59	theme	quality	1272:1278	arg1	attribute					1280:1288	a critical quality attribute	1261:1288	a critical quality attribute of therapeutic monoclonal antibodies	1261:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	3	60	theme	monoclonal	591:600	arg1	production					611:620	monoclonal antibody production	591:620	monoclonal antibody production in mammalian cell cultures	591:647	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	9	61	theme	effective	1539:1547	arg1	2,5-dimethylpyrrole					1506:1524	2,5-dimethylpyrrole	1506:1524	2,5-dimethylpyrrole	1506:1524	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	9	61	theme	effective	1539:1547	arg1	structure					1557:1565	the most effective partial structure	1530:1565	the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production	1530:1673	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	8	62	link	N-linked	1423:1430	arg1	glycans					1432:1438	the N-linked glycans	1419:1438	the N-linked glycans	1419:1438	Therefore, the compound might also be used to control the level of the galactosylation for the N-linked glycans.
33886677	4	63	theme	new	686:688	arg1	compounds					699:707	new chemical compounds	686:707	new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells	686:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	0	64	theme	antibody	91:98	arg1	production					100:109	monoclonal antibody production	80:109	monoclonal antibody production in a Chinese hamster ovary cell culture	80:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	5	65	theme	2,5-dimethyl-1H-pyrrol-1-yl	859:885	arg1	2,5-dioxopyrrolidin-1-yl					891:914	2,5-dioxopyrrolidin-1-yl	891:914	2,5-dioxopyrrolidin-1-yl	891:914	Out of the 23,227 chemicals screened in this study, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide was found to increase monoclonal antibody production.
33886677	5	65	theme	2,5-dimethyl-1H-pyrrol-1-yl	859:885	arg1	-N-					887:889	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-	856:889	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	856:925	Out of the 23,227 chemicals screened in this study, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide was found to increase monoclonal antibody production.
33886677	4	66	from	production	749:758	arg1	cells					797:801	recombinant Chinese hamster ovary cells	763:801	recombinant Chinese hamster ovary cells	763:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	9	67	theme	2,5-dimethyl-1H-pyrrol-1-yl	1573:1599	arg1	benzamide					1631:1639	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	1570:1639	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	1570:1639	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	4	68	theme	cell-specific	726:738	arg1	production					749:758	cell-specific antibody production	726:758	cell-specific antibody production in recombinant Chinese hamster ovary cells	726:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	0	69	theme	Chinese	116:122	arg1	ovary					132:136	Chinese hamster ovary	116:136	a Chinese hamster ovary cell culture	114:149	4-(2,5-Dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide improves monoclonal antibody production in a Chinese hamster ovary cell culture.
33886677	9	70	theme	-N-	1601:1603	arg1	benzamide					1631:1639	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	1570:1639	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	1570:1639	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	9	71	theme	2,5-dioxopyrrolidin-1-yl	1605:1628	arg1	benzamide					1631:1639	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	1570:1639	4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide	1570:1639	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	2	72	theme	monoclonal	360:369	arg1	antibody					371:378	monoclonal antibody	360:378	monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans	360:477	For over 20 years, recombinant Chinese hamster ovary cells have been used as a host in monoclonal antibody production due to robustness, high productivity and ability to produce proteins with ideal glycans.
33886677	9	73	theme	benzamide	1631:1639	arg1	2,5-dimethylpyrrole					1506:1524	2,5-dimethylpyrrole	1506:1524	2,5-dimethylpyrrole	1506:1524	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	9	73	theme	benzamide	1631:1639	arg1	structure					1557:1565	the most effective partial structure	1530:1565	the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production	1530:1673	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	6	74	theme	uptake	1058:1063	arg1	rate					1065:1068	cell-specific glucose uptake rate	1036:1068	cell-specific glucose uptake rate	1036:1068	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	5	75	theme	antibody	960:967	arg1	production					969:978	monoclonal antibody production	949:978	monoclonal antibody production	949:978	Out of the 23,227 chemicals screened in this study, 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide was found to increase monoclonal antibody production.
33886677	3	76	theme	mammalian	625:633	arg1	cultures					640:647	mammalian cell cultures	625:647	mammalian cell cultures	625:647	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	10	77	theme	production	1766:1775	arg1	control					1789:1795	improved production and quality control	1757:1795	improved production and quality control of monoclonal antibodies	1757:1820	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	9	78	theme	monoclonal	1644:1653	arg1	production					1664:1673	monoclonal antibody production	1644:1673	monoclonal antibody production	1644:1673	Further, the structure-activity relationship study revealed that 2,5-dimethylpyrrole was the most effective partial structure of 4-(2,5-dimethyl-1H-pyrrol-1-yl)-N-(2,5-dioxopyrrolidin-1-yl) benzamide on monoclonal antibody production.
33886677	7	79	theme	antibodies	1316:1325	arg1	antibody					1242:1249	a monoclonal antibody	1229:1249	a monoclonal antibody	1229:1249	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	7	79	theme	antibodies	1316:1325	arg1	attribute					1280:1288	a critical quality attribute	1261:1288	a critical quality attribute of therapeutic monoclonal antibodies	1261:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	8	80	theme	galactosylation	1399:1413	arg1	level					1386:1390	the level	1382:1390	the level of the galactosylation for the N-linked glycans	1382:1438	Therefore, the compound might also be used to control the level of the galactosylation for the N-linked glycans.
33886677	7	81	theme	therapeutic	1293:1303	arg1	antibodies					1316:1325	therapeutic monoclonal antibodies	1293:1325	therapeutic monoclonal antibodies	1293:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	6	82	theme	monoclonal	1132:1141	arg1	production					1152:1161	monoclonal antibody production	1132:1161	monoclonal antibody production	1132:1161	The compound suppressed cell growth and increased both cell-specific glucose uptake rate and the amount of intracellular adenosine triphosphate during monoclonal antibody production.
33886677	4	83	theme	recombinant	763:773	arg1	cells					797:801	recombinant Chinese hamster ovary cells	763:801	recombinant Chinese hamster ovary cells	763:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	10	84	theme	quality	1781:1787	arg1	control					1789:1795	improved production and quality control	1757:1795	improved production and quality control of monoclonal antibodies	1757:1820	Further structural optimization of 2,5-dimethylpyrrole derivatives could lead to improved production and quality control of monoclonal antibodies.
33886677	7	85	theme	critical	1263:1270	arg1	antibody					1242:1249	a monoclonal antibody	1229:1249	a monoclonal antibody	1229:1249	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	7	85	theme	critical	1263:1270	arg1	attribute					1280:1288	a critical quality attribute	1261:1288	a critical quality attribute of therapeutic monoclonal antibodies	1261:1325	In addition, the compound also suppressed the galactosylation on a monoclonal antibody, which is a critical quality attribute of therapeutic monoclonal antibodies.
33886677	4	86	theme	hamster	783:789	arg1	cells					797:801	recombinant Chinese hamster ovary cells	763:801	recombinant Chinese hamster ovary cells	763:801	In this study, we aimed to discover new chemical compounds that can improve cell-specific antibody production in recombinant Chinese hamster ovary cells.
33886677	3	87	theme	dimethyl	508:515	arg1	sulfoxide					517:525	dimethyl sulfoxide	508:525	dimethyl sulfoxide	508:525	Chemical compounds, such as dimethyl sulfoxide, lithium chloride, and butyric acid, have been shown to improve monoclonal antibody production in mammalian cell cultures.
33886677	1	88	theme	medical	249:255	arg1	reduction					262:270	medical cost reduction	249:270	medical cost reduction	249:270	There is a continuous demand to improve monoclonal antibody production for medication supply and medical cost reduction.
34749984	8	0	theme	exonic	1402:1407	arg1	biomarkers					1436:1445	biomarkers	1436:1445	biomarkers for the early diagnosis of pediatric dental caries in Arabs	1436:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	8	0	theme	exonic	1402:1407	arg1	variants					1409:1416	The significant functional exonic variants	1375:1416	The significant functional exonic variants identified	1375:1427	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	3	1	with	genetics	501:508	arg1	8.75 ± 4.16					552:562	8.75 ± 4.16	552:562	8.75 ± 4.16	552:562	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	1	with	genetics	501:508	arg1	index					545:549	high dmft index	535:549	high dmft index	535:549	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	6	2	theme	genes	1073:1077	arg1	analysis					1049:1056	Functional enrichment analysis	1027:1056	Functional enrichment analysis of significant genes	1027:1077	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	4	3	theme	Pediatric	676:684	arg1	caries					686:691	Pediatric caries	676:691	Pediatric caries	676:691	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	7	4	theme	high	1280:1283	arg1	disorder					1328:1335	a disorder	1326:1335	a disorder of multigene-environment interaction	1326:1372	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	7	4	theme	high	1280:1283	arg1	prevalence					1285:1294	the high prevalence	1276:1294	the high prevalence	1276:1294	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	5	5	theme	tooth	909:913	arg1	p = 0.0404					932:941	p = 0.0404	932:941	p = 0.0404	932:941	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	5	5	theme	tooth	909:913	arg1	habits					924:929	Irregular tooth brushing habits	899:929	Irregular tooth brushing habits (p = 0.0404)	899:942	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	2	6	theme	Decayed	351:357	arg1	Teeth					380:384	Decayed, Missing, and Filled Teeth	351:384	Decayed, Missing, and Filled Teeth	351:384	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	2	6	theme	Decayed	351:357	arg1	DMFT					345:348	high DMFT	340:348	high DMFT (Decayed, Missing, and Filled Teeth)	340:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	8	7	theme	early	1455:1459	arg1	diagnosis					1461:1469	the early diagnosis	1451:1469	the early diagnosis of pediatric dental caries in Arabs	1451:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	8	8	theme	significant	1379:1389	arg1	biomarkers					1436:1445	biomarkers	1436:1445	biomarkers for the early diagnosis of pediatric dental caries in Arabs	1436:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	8	8	theme	significant	1379:1389	arg1	variants					1409:1416	The significant functional exonic variants	1375:1416	The significant functional exonic variants identified	1375:1427	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	3	9	with	subjects	581:588	arg1	n = 111					614:620	n = 111	614:620	n = 111	614:620	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	9	with	subjects	581:588	arg1	dentition					603:611	primary dentition	595:611	primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	595:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	2	10	theme	dental	300:305	arg1	caries					307:312	dental caries	300:312	dental caries	300:312	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	4	11	theme	nucleotide	733:742	arg1	SNP					759:761	SNP	759:761	SNP	759:761	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	4	11	theme	nucleotide	733:742	arg1	polymorphisms					744:756	single nucleotide polymorphisms	726:756	single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	726:862	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	2	12	with	children	326:333	arg1	DMFT					345:348	high DMFT	340:348	high DMFT (Decayed, Missing, and Filled Teeth)	340:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	2	12	with	children	326:333	arg1	Teeth					380:384	Decayed, Missing, and Filled Teeth	351:384	Decayed, Missing, and Filled Teeth	351:384	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	4	13	theme	single	726:731	arg1	SNP					759:761	SNP	759:761	SNP	759:761	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	4	13	theme	single	726:731	arg1	polymorphisms					744:756	single nucleotide polymorphisms	726:756	single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	726:862	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	4	14	theme	Bonferroni	876:885	arg1	correction					887:896	Bonferroni correction	876:896	Bonferroni correction	876:896	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	7	15	theme	CONCLUSION	1195:1204	arg1	predispositions					1214:1228	CONCLUSION Genetic predispositions	1195:1228	CONCLUSION Genetic predispositions	1195:1228	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	4	16	dep	RESULTS	668:674	arg1	associated					710:719	associated	710:719	associated	710:719	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	8	17	from	caries	1491:1496	arg1	Arabs					1501:1505	Arabs	1501:1505	Arabs	1501:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	3	18	theme	Arab-ancestry	567:579	arg1	subjects					581:588	Arab-ancestry subjects	567:588	Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	567:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	6	19	theme	chloride	1116:1123	arg1	channel					1125:1131	calcium-activated chloride channel	1098:1131	calcium-activated chloride channel	1098:1131	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	3	20	theme	putative	428:435	arg1	n = 243,345					465:475	n = 243,345	465:475	n = 243,345	465:475	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	20	theme	putative	428:435	arg1	exonic-variants					448:462	putative functional exonic-variants	428:462	putative functional exonic-variants (n = 243,345)	428:476	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	5	21	theme	brushing	915:922	arg1	p = 0.0404					932:941	p = 0.0404	932:941	p = 0.0404	932:941	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	5	21	theme	brushing	915:922	arg1	habits					924:929	Irregular tooth brushing habits	899:929	Irregular tooth brushing habits (p = 0.0404)	899:942	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	3	22	dep	DESIGN	388:393	arg1	analysed					419:426	analysed	419:426	analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	419:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	4	23	from	polymorphisms	744:756	arg1	genes					858:862	the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	767:862	the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	767:862	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	2	24	theme	genetic	273:279	arg1	predispositions					281:295	identity genetic predispositions	264:295	identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth)	264:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	3	25	theme	functional	437:446	arg1	n = 243,345					465:475	n = 243,345	465:475	n = 243,345	465:475	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	25	theme	functional	437:446	arg1	exonic-variants					448:462	putative functional exonic-variants	428:462	putative functional exonic-variants (n = 243,345)	428:476	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	7	26	theme	multigene-environment	1340:1360	arg1	interaction					1362:1372	multigene-environment interaction	1340:1372	multigene-environment interaction	1340:1372	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	1	27	theme	Pediatric	92:100	arg1	caries					109:114	Pediatric dental caries	92:114	BACKGROUND Pediatric dental caries	81:114	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	2	28	theme	Filled	373:378	arg1	Teeth					380:384	Decayed, Missing, and Filled Teeth	351:384	Decayed, Missing, and Filled Teeth	351:384	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	2	28	theme	Filled	373:378	arg1	DMFT					345:348	high DMFT	340:348	high DMFT (Decayed, Missing, and Filled Teeth)	340:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	0	29	theme	Exome	0:4	arg1	array					6:10	Exome array	0:10	Exome array	0:10	Exome array identifies functional exonic biomarkers for pediatric dental caries.
34749984	7	30	theme	Genetic	1206:1212	arg1	predispositions					1214:1228	CONCLUSION Genetic predispositions	1195:1228	CONCLUSION Genetic predispositions	1195:1228	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	1	31	theme	dental	102:107	arg1	caries					109:114	Pediatric dental caries	92:114	BACKGROUND Pediatric dental caries	81:114	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	1	32	theme	possible	182:189	arg1	genes					191:195	possible genes	182:195	possible genes	182:195	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	0	33	theme	functional	23:32	arg1	biomarkers					41:50	functional exonic biomarkers	23:50	functional exonic biomarkers for pediatric dental caries	23:78	Exome array identifies functional exonic biomarkers for pediatric dental caries.
34749984	8	34	theme	dental	1484:1489	arg1	caries					1491:1496	pediatric dental caries	1474:1496	pediatric dental caries in Arabs	1474:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	5	35	theme	dental	958:963	arg1	p = 0.0050					973:982	p = 0.0050	973:982	p = 0.0050	973:982	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	5	35	theme	dental	958:963	arg1	visits					965:970	irregular dental visits	948:970	irregular dental visits (p = 0.0050)	948:983	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	8	36	theme	pediatric	1474:1482	arg1	caries					1491:1496	pediatric dental caries	1474:1496	pediatric dental caries in Arabs	1474:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	2	37	theme	Saudi	320:324	arg1	children					326:333	Saudi children	320:333	Saudi children with high DMFT (Decayed, Missing, and Filled Teeth)	320:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	5	38	theme	irregular	948:956	arg1	p = 0.0050					973:982	p = 0.0050	973:982	p = 0.0050	973:982	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	5	38	theme	irregular	948:956	arg1	visits					965:970	irregular dental visits	948:970	irregular dental visits (p = 0.0050)	948:983	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	2	39	theme	caries	307:312	arg1	predispositions					281:295	identity genetic predispositions	264:295	identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth)	264:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	8	40	from	Arabs	1501:1505	arg1	diagnosis					1461:1469	the early diagnosis	1451:1469	the early diagnosis of pediatric dental caries in Arabs	1451:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	3	41	dep	n = 111	614:620	arg1	dmft>5					633:638	dmft>5	633:638	dmft>5	633:638	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	41	dep	n = 111	614:620	arg1	controls					647:654	35 controls	644:654	35 controls	644:654	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	41	dep	n = 111	614:620	arg1	cases					626:630	76 cases	623:630	76 cases	623:630	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	41	dep	n = 111	614:620	arg1	dmft = 0					657:664	dmft = 0	657:664	dmft = 0	657:664	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	6	42	theme	aureus	1149:1154	arg1	infection					1156:1164	Staphylococcus aureus infection	1134:1164	Staphylococcus aureus infection	1134:1164	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	3	43	theme	molecular	491:499	arg1	genetics					501:508	the molecular genetics	487:508	the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	487:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	6	44	theme	significant	1061:1071	arg1	genes					1073:1077	significant genes	1061:1077	significant genes	1061:1077	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	3	45	theme	primary	595:601	arg1	n = 111					614:620	n = 111	614:620	n = 111	614:620	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	45	theme	primary	595:601	arg1	dentition					603:611	primary dentition	595:611	primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	595:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	7	46	theme	interaction	1362:1372	arg1	prevalence					1285:1294	the high prevalence	1276:1294	the high prevalence	1276:1294	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	7	46	theme	interaction	1362:1372	arg1	disorder					1328:1335	a disorder	1326:1335	a disorder of multigene-environment interaction	1326:1372	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	1	47	theme	molecular	201:209	arg1	mechanisms					211:220	molecular mechanisms	201:220	molecular mechanisms	201:220	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	0	48	theme	exonic	34:39	arg1	biomarkers					41:50	functional exonic biomarkers	23:50	functional exonic biomarkers for pediatric dental caries	23:78	Exome array identifies functional exonic biomarkers for pediatric dental caries.
34749984	3	49	theme	case-control	400:411	arg1	study					413:417	This case-control study	395:417	This case-control study	395:417	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	6	50	link	N-linked	1171:1178	arg1	glycosylation					1180:1192	N-linked glycosylation	1171:1192	N-linked glycosylation	1171:1192	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	6	51	theme	Functional	1027:1036	arg1	analysis					1049:1056	Functional enrichment analysis	1027:1056	Functional enrichment analysis of significant genes	1027:1077	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	7	52	theme	caries	1309:1314	arg1	disorder					1328:1335	a disorder	1326:1335	a disorder of multigene-environment interaction	1326:1372	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	7	52	theme	caries	1309:1314	arg1	prevalence					1285:1294	the high prevalence	1276:1294	the high prevalence	1276:1294	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34749984	0	53	theme	pediatric	56:64	arg1	caries					73:78	pediatric dental caries	56:78	pediatric dental caries	56:78	Exome array identifies functional exonic biomarkers for pediatric dental caries.
34749984	8	54	theme	caries	1491:1496	arg1	diagnosis					1461:1469	the early diagnosis	1451:1469	the early diagnosis of pediatric dental caries in Arabs	1451:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	6	55	theme	Staphylococcus	1134:1147	arg1	infection					1156:1164	Staphylococcus aureus infection	1134:1164	Staphylococcus aureus infection	1134:1164	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	6	56	theme	N-linked	1171:1178	arg1	glycosylation					1180:1192	N-linked glycosylation	1171:1192	N-linked glycosylation	1171:1192	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	4	57	theme	CFH-rs1065489G	818:831	arg1	genes					858:862	the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	767:862	the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	767:862	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	1	58	dep	BACKGROUND	81:90	arg1	caries					109:114	Pediatric dental caries	92:114	BACKGROUND Pediatric dental caries	81:114	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	8	59	theme	functional	1391:1400	arg1	biomarkers					1436:1445	biomarkers	1436:1445	biomarkers for the early diagnosis of pediatric dental caries in Arabs	1436:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	8	59	theme	functional	1391:1400	arg1	variants					1409:1416	The significant functional exonic variants	1375:1416	The significant functional exonic variants identified	1375:1427	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	4	60	theme	GRIN2B-rs4764039C	771:787	arg1	genes					858:862	the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	767:862	the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes	767:862	RESULTS Pediatric caries is significantly associated with single nucleotide polymorphisms (SNP) in the GRIN2B-rs4764039C (p-value = 2.03 × 10-08) and CFH-rs1065489G (p-value = 8.26 × 10-08) genes, even after Bonferroni correction.
34749984	2	61	theme	identity	264:271	arg1	predispositions					281:295	identity genetic predispositions	264:295	identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth)	264:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	6	62	theme	enrichment	1038:1047	arg1	analysis					1049:1056	Functional enrichment analysis	1027:1056	Functional enrichment analysis of significant genes	1027:1077	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	1	63	theme	Arab	132:135	arg1	children					137:144	Arab children	132:144	Arab children	132:144	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	3	64	from	8.75 ± 4.16	552:562	arg1	subjects					581:588	Arab-ancestry subjects	567:588	Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	567:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	65	theme	high	535:538	arg1	8.75 ± 4.16					552:562	8.75 ± 4.16	552:562	8.75 ± 4.16	552:562	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	65	theme	high	535:538	arg1	index					545:549	high dmft index	535:549	high dmft index	535:549	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	66	theme	dmft	540:543	arg1	8.75 ± 4.16					552:562	8.75 ± 4.16	552:562	8.75 ± 4.16	552:562	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	66	theme	dmft	540:543	arg1	index					545:549	high dmft index	535:549	high dmft index	535:549	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	3	67	theme	caries	523:528	arg1	genetics					501:508	the molecular genetics	487:508	the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0)	487:665	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	2	68	theme	high	340:343	arg1	DMFT					345:348	high DMFT	340:348	high DMFT (Decayed, Missing, and Filled Teeth)	340:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	2	68	theme	high	340:343	arg1	Teeth					380:384	Decayed, Missing, and Filled Teeth	351:384	Decayed, Missing, and Filled Teeth	351:384	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	5	69	theme	Irregular	899:907	arg1	p = 0.0404					932:941	p = 0.0404	932:941	p = 0.0404	932:941	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	5	69	theme	Irregular	899:907	arg1	habits					924:929	Irregular tooth brushing habits	899:929	Irregular tooth brushing habits (p = 0.0404)	899:942	Irregular tooth brushing habits (p = 0.0404) and irregular dental visits (p = 0.0050) are significantly associated with caries.
34749984	8	70	from	diagnosis	1461:1469	arg1	Arabs					1501:1505	Arabs	1501:1505	Arabs	1501:1505	The significant functional exonic variants identified can be biomarkers for the early diagnosis of pediatric dental caries in Arabs.
34749984	3	71	theme	pediatric	513:521	arg1	caries					523:528	pediatric caries	513:528	pediatric caries	513:528	DESIGN This case-control study analysed putative functional exonic-variants (n = 243,345) to study the molecular genetics of pediatric caries with high dmft index, 8.75 ± 4.16 on Arab-ancestry subjects with primary dentition (n = 111; 76 cases, dmft>5 and 35 controls, dmft = 0).
34749984	6	72	theme	calcium-activated	1098:1114	arg1	channel					1125:1131	calcium-activated chloride channel	1098:1131	calcium-activated chloride channel	1098:1131	Functional enrichment analysis of significant genes is associated with calcium-activated chloride channel, Staphylococcus aureus infection, and N-linked glycosylation.
34749984	1	73	theme	caries	237:242	arg1	development					244:254	caries development	237:254	caries development	237:254	BACKGROUND Pediatric dental caries is common among Arab children, however we are still searching for possible genes and molecular mechanisms that influence caries development.
34749984	0	74	theme	dental	66:71	arg1	caries					73:78	pediatric dental caries	56:78	pediatric dental caries	56:78	Exome array identifies functional exonic biomarkers for pediatric dental caries.
34749984	2	75	theme	Missing	360:366	arg1	Teeth					380:384	Decayed, Missing, and Filled Teeth	351:384	Decayed, Missing, and Filled Teeth	351:384	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	2	75	theme	Missing	360:366	arg1	DMFT					345:348	high DMFT	340:348	high DMFT (Decayed, Missing, and Filled Teeth)	340:385	AIM To identity genetic predispositions of dental caries among Saudi children with high DMFT (Decayed, Missing, and Filled Teeth).
34749984	7	76	theme	pediatric	1299:1307	arg1	caries					1309:1314	pediatric caries	1299:1314	pediatric caries	1299:1314	CONCLUSION Genetic predispositions are found to be significantly associated with the high prevalence of pediatric caries, which is a disorder of multigene-environment interaction.
34017182	0	0	theme	Mouse	94:98	arg1	Brains					100:105	Mouse Brains	94:105	Mouse Brains	94:105	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains.
34017182	7	1	theme	molecular	1397:1405	arg1	mechanisms					1407:1416	molecular mechanisms	1397:1416	molecular mechanisms	1397:1416	We believed that some of these changes would highlight pathways and molecular mechanisms that could link obesity to brain impairment.
34017182	7	2	attach	link	1429:1432	arg2	pathways					1384:1391	pathways	1384:1391	pathways	1384:1391	We believed that some of these changes would highlight pathways and molecular mechanisms that could link obesity to brain impairment.
34017182	7	2	attach	link	1429:1432	arg1	impairment					1451:1460	brain impairment	1445:1460	brain impairment	1445:1460	We believed that some of these changes would highlight pathways and molecular mechanisms that could link obesity to brain impairment.
34017182	7	2	attach	link	1429:1432	arg2	mechanisms					1407:1416	molecular mechanisms	1397:1416	molecular mechanisms	1397:1416	We believed that some of these changes would highlight pathways and molecular mechanisms that could link obesity to brain impairment.
34017182	3	3	theme	glycogen-synthase	690:706	arg1	kinase-3β					708:716	glycogen-synthase kinase-3β	690:716	glycogen-synthase kinase-3β	690:716	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	13	4	theme	new	2194:2196	arg1	perspectives					2198:2209	new perspectives	2194:2209	new perspectives on the connection between diet-induced obesity and brain impairment	2194:2277	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	10	5	from	metabolism	1845:1854	arg1	mice					1902:1905	obese mice	1896:1905	obese mice	1896:1905	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	5	6	theme	post-translational	1096:1113	arg1	proteins					1124:1131	post-translational modified proteins	1096:1131	post-translational modified proteins (phosphorylated and N-linked glycosylated)	1096:1174	Moreover, post-translational modified proteins (phosphorylated and N-linked glycosylated) were studied.
34017182	10	7	theme	mitochondria	1880:1891	arg1	metabolism					1845:1854	a reduced metabolism	1835:1854	a reduced metabolism	1835:1854	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	10	7	theme	mitochondria	1880:1891	arg1	activity					1868:1875	a lower activity	1860:1875	a lower activity of mitochondria in obese mice	1860:1905	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	2	8	theme	neurodegeneration	299:315	arg1	hallmarks					286:294	The hallmarks	282:294	The hallmarks of neurodegeneration	282:315	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	8	9	theme	mice	1647:1650	arg1	brains					1631:1636	brains	1631:1636	brains of obese mice	1631:1650	The results showed in this study suggest that, together with cytoskeletal proteins, mitochondria and metabolic proteins are changing their post-translational status in brains of obese mice.
34017182	6	10	theme	study	1205:1209	arg1	aim					1194:1196	The aim	1190:1196	The aim of the study	1190:1209	The aim of the study was to identify proteins present in the brain that are changing their expression based on the diet given to the mice.
34017182	8	11	theme	metabolic	1564:1572	arg1	proteins					1574:1581	metabolic proteins	1564:1581	metabolic proteins	1564:1581	The results showed in this study suggest that, together with cytoskeletal proteins, mitochondria and metabolic proteins are changing their post-translational status in brains of obese mice.
34017182	6	12	theme	present	1236:1242	arg1	proteins					1227:1234	proteins	1227:1234	proteins present in the brain that are changing their expression based on the diet given to the mice	1227:1326	The aim of the study was to identify proteins present in the brain that are changing their expression based on the diet given to the mice.
34017182	6	13	attach	present	1236:1242	arg2	proteins					1227:1234	proteins	1227:1234	proteins present in the brain that are changing their expression based on the diet given to the mice	1227:1326	The aim of the study was to identify proteins present in the brain that are changing their expression based on the diet given to the mice.
34017182	6	13	attach	present	1236:1242	arg1	brain					1251:1255	the brain	1247:1255	the brain	1247:1255	The aim of the study was to identify proteins present in the brain that are changing their expression based on the diet given to the mice.
34017182	3	14	theme	several	553:559	arg1	studies					561:567	several studies	553:567	several studies	553:567	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	2	15	theme	proteasome	343:352	arg1	impairment					354:363	proteasome impairment	343:363	proteasome impairment	343:363	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	3	16	from	impairment	761:770	arg1	brain					806:810	the AD patient's brain	789:810	the AD patient's brain	789:810	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	13	17	theme	diet-induced	2237:2248	arg1	obesity					2250:2256	diet-induced obesity	2237:2256	diet-induced obesity	2237:2256	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	8	18	from	status	1621:1626	arg1	brains					1631:1636	brains	1631:1636	brains of obese mice	1631:1650	The results showed in this study suggest that, together with cytoskeletal proteins, mitochondria and metabolic proteins are changing their post-translational status in brains of obese mice.
34017182	12	19	theme	well-studied	2052:2063	arg1	correlation					2065:2075	the well-studied correlation	2048:2075	the well-studied correlation between obesity and brain damage	2048:2108	These results might shed light on the well-studied correlation between obesity and brain damage.
34017182	3	20	from	increase	662:669	arg1	protein					678:684	tau protein	674:684	tau protein	674:684	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	20	from	increase	662:669	arg1	kinase-3β					708:716	glycogen-synthase kinase-3β	690:716	glycogen-synthase kinase-3β	690:716	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	21	theme	healthy	730:736	arg1	controls					738:745	healthy controls	730:745	healthy controls	730:745	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	6	22	from	present	1236:1242	arg1	brain					1251:1255	the brain	1247:1255	the brain	1247:1255	The aim of the study was to identify proteins present in the brain that are changing their expression based on the diet given to the mice.
34017182	2	23	theme	aggregates	429:438	arg1	accumulation					396:407	accumulation	396:407	accumulation of abnormal protein aggregates	396:438	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	2	23	theme	aggregates	429:438	arg1	stress					335:340	oxidative stress	325:340	oxidative stress	325:340	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	2	23	theme	aggregates	429:438	arg1	impairment					354:363	proteasome impairment	343:363	proteasome impairment	343:363	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	2	23	theme	aggregates	429:438	arg1	dysfunction					380:390	mitochondrial dysfunction	366:390	mitochondrial dysfunction	366:390	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	2	23	theme	aggregates	429:438	arg1	alterations					461:471	metabolic alterations	451:471	metabolic alterations	451:471	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	10	24	from	activity	1868:1875	arg1	mice					1902:1905	obese mice	1896:1905	obese mice	1896:1905	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	5	25	dep	proteins	1124:1131	arg1	phosphorylated					1134:1147	phosphorylated	1134:1147	phosphorylated	1134:1147	Moreover, post-translational modified proteins (phosphorylated and N-linked glycosylated) were studied.
34017182	5	25	dep	proteins	1124:1131	arg1	glycosylated					1162:1173	glycosylated	1162:1173	glycosylated	1162:1173	Moreover, post-translational modified proteins (phosphorylated and N-linked glycosylated) were studied.
34017182	9	26	theme	metabolic	1688:1696	arg1	pathways					1698:1705	metabolic pathways	1688:1705	metabolic pathways	1688:1705	Specifically, proteins involved in metabolic pathways and in mitochondrial functions are mainly downregulated in mice fed with obesogenic diets compared to SD.
34017182	2	27	theme	protein	421:427	arg1	aggregates					429:438	abnormal protein aggregates	412:438	abnormal protein aggregates	412:438	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	0	28	theme	Obesogenic	0:9	arg1	Diets					11:15	Obesogenic Diets	0:15	Obesogenic Diets	0:15	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains.
34017182	3	29	theme	metabolism	775:784	arg1	impairment					761:770	an impairment	758:770	an impairment of metabolism in the AD patient's brain	758:810	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	4	30	theme	present	851:857	arg1	study					859:863	the present study	847:863	the present study	847:863	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	13	31	from	perspectives	2198:2209	arg1	connection					2218:2227	the connection	2214:2227	the connection between diet-induced obesity and brain impairment	2214:2277	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	5	32	dep	glycosylated	1162:1173	arg1	N-linked					1153:1160	N-linked	1153:1160	N-linked	1153:1160	Moreover, post-translational modified proteins (phosphorylated and N-linked glycosylated) were studied.
34017182	4	33	theme	mass	1052:1055	arg1	approach					1076:1083	a quantitative mass spectrometry-based approach	1037:1083	a quantitative mass spectrometry-based approach	1037:1083	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	2	34	theme	abnormal	412:419	arg1	aggregates					429:438	abnormal protein aggregates	412:438	abnormal protein aggregates	412:438	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	9	35	theme	obesogenic	1780:1789	arg1	diets					1791:1795	obesogenic diets	1780:1795	obesogenic diets compared to SD	1780:1810	Specifically, proteins involved in metabolic pathways and in mitochondrial functions are mainly downregulated in mice fed with obesogenic diets compared to SD.
34017182	13	36	theme	previous	2160:2167	arg1	findings					2169:2176	previous findings	2160:2176	previous findings	2160:2176	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	2	37	theme	oxidative	325:333	arg1	stress					335:340	oxidative stress	325:340	oxidative stress	325:340	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	4	38	theme	quantitative	1039:1050	arg1	approach					1076:1083	a quantitative mass spectrometry-based approach	1037:1083	a quantitative mass spectrometry-based approach	1037:1083	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	1	39	theme	diseases	193:200	arg1	variety					182:188	a variety	180:188	a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration	180:279	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	1	39	theme	diseases	193:200	arg1	diseases					193:200	diseases	193:200	diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration	193:279	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	4	40	theme	obesogenic	911:920	arg1	diets					922:926	2 obesogenic diets	909:926	2 obesogenic diets	909:926	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	40	theme	obesogenic	911:920	arg1	diet					938:941	high-fat diet	929:941	high-fat diet (HFD)	929:947	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	40	theme	obesogenic	911:920	arg1	diet					968:971	high-glycaemic diet	953:971	high-glycaemic diet (HGD)	953:977	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	11	41	theme	brain	1988:1992	arg1	impairment					1994:2003	brain impairment	1988:2003	brain impairment	1988:2003	Some of these proteins, such as PGM1 and MCT1 have been shown to be involved in brain impairment as well.
34017182	10	42	theme	reduced	1837:1843	arg1	metabolism					1845:1854	a reduced metabolism	1835:1854	a reduced metabolism	1835:1854	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	3	43	theme	receptor	646:653	arg1	example					480:486	an example	477:486	an example	477:486	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	43	theme	receptor	646:653	arg1	increase					662:669	an increase	659:669	an increase in tau protein and glycogen-synthase kinase-3β	659:716	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	43	theme	receptor	646:653	arg1	reduction					583:591	reduction	583:591	reduction of insulin, insulin-like growth factor 1 and insulin receptor	583:653	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	2	44	theme	metabolic	451:459	arg1	alterations					461:471	metabolic alterations	451:471	metabolic alterations	451:471	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	8	45	theme	cytoskeletal	1524:1535	arg1	proteins					1537:1544	cytoskeletal proteins	1524:1544	cytoskeletal proteins	1524:1544	The results showed in this study suggest that, together with cytoskeletal proteins, mitochondria and metabolic proteins are changing their post-translational status in brains of obese mice.
34017182	4	46	theme	high-fat	929:936	arg1	HFD					944:946	HFD	944:946	HFD	944:946	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	46	theme	high-fat	929:936	arg1	diets					922:926	2 obesogenic diets	909:926	2 obesogenic diets	909:926	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	46	theme	high-fat	929:936	arg1	diet					938:941	high-fat diet	929:941	high-fat diet (HFD)	929:947	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	3	47	theme	insulin-like	605:616	arg1	factor					625:630	insulin-like growth factor 1	605:632	insulin-like growth factor 1	605:632	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	4	48	theme	spectrometry-based	1057:1074	arg1	approach					1076:1083	a quantitative mass spectrometry-based approach	1037:1083	a quantitative mass spectrometry-based approach	1037:1083	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	13	49	theme	brain	2262:2266	arg1	impairment					2268:2277	brain impairment	2262:2277	brain impairment	2262:2277	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	5	50	theme	modified	1115:1122	arg1	proteins					1124:1131	post-translational modified proteins	1096:1131	post-translational modified proteins (phosphorylated and N-linked glycosylated)	1096:1174	Moreover, post-translational modified proteins (phosphorylated and N-linked glycosylated) were studied.
34017182	8	51	theme	obese	1641:1645	arg1	mice					1647:1650	obese mice	1641:1650	obese mice	1641:1650	The results showed in this study suggest that, together with cytoskeletal proteins, mitochondria and metabolic proteins are changing their post-translational status in brains of obese mice.
34017182	0	52	from	Modifications	77:89	arg1	Brains					100:105	Mouse Brains	94:105	Mouse Brains	94:105	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains.
34017182	3	53	theme	growth	618:623	arg1	factor					625:630	insulin-like growth factor 1	605:632	insulin-like growth factor 1	605:632	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	1	54	theme	metabolic	215:223	arg1	disease					244:250	metabolic and cardiovascular disease	215:250	metabolic and cardiovascular disease	215:250	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	1	54	theme	metabolic	215:223	arg1	cancer					253:258	cancer	253:258	cancer	253:258	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	13	55	with	agreement	2145:2153	arg1	aim					2182:2184	aim	2182:2184	aim	2182:2184	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	13	55	with	agreement	2145:2153	arg1	findings					2169:2176	previous findings	2160:2176	previous findings	2160:2176	The results presented here are in agreement with previous findings and aim to open new perspectives on the connection between diet-induced obesity and brain impairment.
34017182	9	56	theme	mitochondrial	1714:1726	arg1	functions					1728:1736	mitochondrial functions	1714:1736	mitochondrial functions	1714:1736	Specifically, proteins involved in metabolic pathways and in mitochondrial functions are mainly downregulated in mice fed with obesogenic diets compared to SD.
34017182	3	57	theme	insulin	596:602	arg1	example					480:486	an example	477:486	an example	477:486	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	57	theme	insulin	596:602	arg1	increase					662:669	an increase	659:669	an increase in tau protein and glycogen-synthase kinase-3β	659:716	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	57	theme	insulin	596:602	arg1	reduction					583:591	reduction	583:591	reduction of insulin, insulin-like growth factor 1 and insulin receptor	583:653	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	10	58	theme	obese	1896:1900	arg1	mice					1902:1905	obese mice	1896:1905	obese mice	1896:1905	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	2	59	theme	mitochondrial	366:378	arg1	dysfunction					380:390	mitochondrial dysfunction	366:390	mitochondrial dysfunction	366:390	The hallmarks of neurodegeneration include oxidative stress, proteasome impairment, mitochondrial dysfunction and accumulation of abnormal protein aggregates as well as metabolic alterations.
34017182	10	60	theme	lower	1862:1866	arg1	activity					1868:1875	a lower activity	1860:1875	a lower activity of mitochondria in obese mice	1860:1905	These changes suggest a reduced metabolism and a lower activity of mitochondria in obese mice.
34017182	4	61	theme	mice	891:894	arg1	brains					881:886	brains	881:886	brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach	881:1083	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	62	theme	evidence	834:841	arg1	lines					825:829	these lines	819:829	these lines of evidence	819:841	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	1	63	theme	major	130:134	arg1	threat					150:155	a major global health threat	128:155	a major global health threat	128:155	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	3	64	theme	AD	793:794	arg1	patient					796:802	the AD patient's	789:804	the AD patient's brain	789:810	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	5	65	gly	glycosylated	1162:1173	arg1	proteins					1124:1131	post-translational modified proteins	1096:1131	post-translational modified proteins (phosphorylated and N-linked glycosylated)	1096:1174	Moreover, post-translational modified proteins (phosphorylated and N-linked glycosylated) were studied.
34017182	1	66	theme	global	136:141	arg1	threat					150:155	a major global health threat	128:155	a major global health threat	128:155	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	8	67	theme	post-translational	1602:1619	arg1	status					1621:1626	their post-translational status	1596:1626	their post-translational status in brains of obese mice	1596:1650	The results showed in this study suggest that, together with cytoskeletal proteins, mitochondria and metabolic proteins are changing their post-translational status in brains of obese mice.
34017182	7	68	theme	brain	1445:1449	arg1	impairment					1451:1460	brain impairment	1445:1460	brain impairment	1445:1460	We believed that some of these changes would highlight pathways and molecular mechanisms that could link obesity to brain impairment.
34017182	3	69	theme	insulin	638:644	arg1	receptor					646:653	insulin receptor	638:653	insulin receptor	638:653	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	1	70	theme	health	143:148	arg1	threat					150:155	a major global health threat	128:155	a major global health threat	128:155	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	3	71	from	reduction	583:591	arg1	protein					678:684	tau protein	674:684	tau protein	674:684	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	71	from	reduction	583:591	arg1	kinase-3β					708:716	glycogen-synthase kinase-3β	690:716	glycogen-synthase kinase-3β	690:716	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	1	72	theme	cardiovascular	229:242	arg1	disease					244:250	metabolic and cardiovascular disease	215:250	metabolic and cardiovascular disease	215:250	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	1	72	theme	cardiovascular	229:242	arg1	cancer					253:258	cancer	253:258	cancer	253:258	Obesity constitutes a major global health threat and is associated with a variety of diseases ranging from metabolic and cardiovascular disease, cancer to neurodegeneration.
34017182	4	73	theme	high-glycaemic	953:966	arg1	diets					922:926	2 obesogenic diets	909:926	2 obesogenic diets	909:926	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	73	theme	high-glycaemic	953:966	arg1	HGD					974:976	HGD	974:976	HGD	974:976	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	73	theme	high-glycaemic	953:966	arg1	diet					968:971	high-glycaemic diet	953:971	high-glycaemic diet (HGD)	953:977	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	3	74	theme	tau	674:676	arg1	protein					678:684	tau protein	674:684	tau protein	674:684	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	75	theme	factor	625:630	arg1	example					480:486	an example	477:486	an example	477:486	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	75	theme	factor	625:630	arg1	increase					662:669	an increase	659:669	an increase in tau protein and glycogen-synthase kinase-3β	659:716	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	75	theme	factor	625:630	arg1	reduction					583:591	reduction	583:591	reduction of insulin, insulin-like growth factor 1 and insulin receptor	583:653	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	76	theme	post-mortem	492:502	arg1	brain					504:508	post-mortem brain	492:508	post-mortem brain of patients with Alzheimer's disease (AD)	492:550	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	3	77	theme	patients	513:520	arg1	brain					504:508	post-mortem brain	492:508	post-mortem brain of patients with Alzheimer's disease (AD)	492:550	As an example, in post-mortem brain of patients with Alzheimer's disease (AD), several studies have reported reduction of insulin, insulin-like growth factor 1 and insulin receptor and an increase in tau protein and glycogen-synthase kinase-3β compared to healthy controls suggesting an impairment of metabolism in the AD patient's brain.
34017182	6	78	from	brain	1251:1255	arg1	present					1236:1242	present	1236:1242	present	1236:1242	The aim of the study was to identify proteins present in the brain that are changing their expression based on the diet given to the mice.
34017182	0	79	theme	Post-Translational	58:75	arg1	Modifications					77:89	Post-Translational Modifications	58:89	Post-Translational Modifications in Mouse Brains	58:105	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains.
34017182	0	80	from	Alterations	23:33	arg1	Proteins					38:45	Proteins	38:45	Proteins	38:45	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains.
34017182	0	80	from	Alterations	23:33	arg1	Theirs					51:56	Theirs	51:56	Theirs	51:56	Obesogenic Diets Cause Alterations on Proteins and Theirs Post-Translational Modifications in Mouse Brains.
34017182	12	81	theme	brain	2097:2101	arg1	damage					2103:2108	brain damage	2097:2108	brain damage	2097:2108	These results might shed light on the well-studied correlation between obesity and brain damage.
34017182	4	82	theme	standard	1008:1015	arg1	diet					1017:1020	a standard diet	1006:1020	a standard diet (SD) employing a quantitative mass spectrometry-based approach	1006:1083	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
34017182	4	82	theme	standard	1008:1015	arg1	SD					1023:1024	SD	1023:1024	SD	1023:1024	Given these lines of evidence, in the present study we investigated brains of mice treated with 2 obesogenic diets, high-fat diet (HFD) and high-glycaemic diet (HGD), compared to mice fed with a standard diet (SD) employing a quantitative mass spectrometry-based approach.
32898162	0	0	theme	prion	89:93	arg1	conversion					103:112	bank vole prion protein conversion	79:112	bank vole prion protein conversion	79:112	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	7	1	theme	C-terminal	1149:1158	arg1	linchpin					1182:1189	a linchpin	1180:1189	a linchpin for bank vole and mouse prion conversion	1180:1230	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	1	theme	C-terminal	1149:1158	arg1	domain					1160:1165	a C-terminal domain	1147:1165	a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion	1147:1230	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	1	2	theme	neurodegenerative	164:180	arg1	diseases					182:189	fatal neurodegenerative diseases	158:189	fatal neurodegenerative diseases in humans and other mammals	158:217	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	4	3	theme	templating	561:570	arg1	ability					572:578	its templating ability	557:578	its templating ability	557:578	Thus, its templating ability is not dependent on sequence homology with the substrate.
32898162	0	4	theme	vole	84:87	arg1	conversion					103:112	bank vole prion protein conversion	79:112	bank vole prion protein conversion	79:112	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	6	5	theme	residues	879:886	arg1	sufficient					951:960	sufficient	951:960	sufficient	951:960	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	5	theme	residues	879:886	arg1	absence					909:915	the absence	905:915	the absence of the second N-linked glycan	905:945	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	5	theme	residues	879:886	arg1	presence					842:849	the presence	838:849	the presence of the bank vole amino acid residues E227 and S230	838:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	6	theme	native	1043:1048	arg1	strains					1067:1073	several native infectious prion strains	1035:1073	several native infectious prion strains	1035:1073	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	7	theme	infectious	1050:1059	arg1	strains					1067:1073	several native infectious prion strains	1035:1073	several native infectious prion strains	1035:1073	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	8	theme	acid	874:877	arg1	residues					879:886	the bank vole amino acid residues	854:886	the bank vole amino acid residues E227 and S230	854:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	8	theme	acid	874:877	arg1	S230					897:900	S230	897:900	S230	897:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	8	theme	acid	874:877	arg1	E227					888:891	E227	888:891	E227	888:891	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	1	9	from	diseases	182:189	arg1	humans					194:199	humans	194:199	humans	194:199	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	1	9	from	diseases	182:189	arg1	mammals					211:217	other mammals	205:217	other mammals	205:217	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	0	10	theme	protein	95:101	arg1	conversion					103:112	bank vole prion protein conversion	79:112	bank vole prion protein conversion	79:112	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	6	11	theme	amino	868:872	arg1	residues					879:886	the bank vole amino acid residues	854:886	the bank vole amino acid residues E227 and S230	854:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	11	theme	amino	868:872	arg1	S230					897:900	S230	897:900	S230	897:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	11	theme	amino	868:872	arg1	E227					888:891	E227	888:891	E227	888:891	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	5	12	theme	present	645:651	arg1	study					653:657	the present study	641:657	the present study	641:657	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	3	13	theme	bank	501:504	arg1	vole					506:509	bank vole	501:509	bank vole but not mouse PrPC substrates	501:539	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	6	14	dep	residues	879:886	arg1	residues					879:886	the bank vole amino acid residues	854:886	the bank vole amino acid residues E227 and S230	854:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	14	dep	residues	879:886	arg1	S230					897:900	S230	897:900	S230	897:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	14	dep	residues	879:886	arg1	E227					888:891	E227	888:891	E227	888:891	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	15	theme	glycan	940:945	arg1	sufficient					951:960	sufficient	951:960	sufficient	951:960	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	15	theme	glycan	940:945	arg1	absence					909:915	the absence	905:915	the absence of the second N-linked glycan	905:945	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	15	theme	glycan	940:945	arg1	presence					842:849	the presence	838:849	the presence of the bank vole amino acid residues E227 and S230	838:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	16	theme	vole	863:866	arg1	residues					879:886	the bank vole amino acid residues	854:886	the bank vole amino acid residues E227 and S230	854:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	16	theme	vole	863:866	arg1	S230					897:900	S230	897:900	S230	897:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	16	theme	vole	863:866	arg1	E227					888:891	E227	888:891	E227	888:891	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	5	17	theme	protein-only	781:792	arg1	recPrPSc					794:801	Mo protein-only recPrPSc	778:801	Mo protein-only recPrPSc	778:801	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	3	18	theme	mouse	519:523	arg1	substrates					530:539	mouse PrPC substrates	519:539	bank vole but not mouse PrPC substrates	501:539	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	19	theme	protein-only	444:455	arg1	recPrPSc					457:464	mouse protein-only recPrPSc	438:464	mouse protein-only recPrPSc	438:464	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	19	theme	protein-only	444:455	arg1	conformer					427:435	a recombinant mouse PrPSc conformer	401:435	a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)	401:465	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	5	20	theme	Mo	778:779	arg1	recPrPSc					794:801	Mo protein-only recPrPSc	778:801	Mo protein-only recPrPSc	778:801	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	6	21	theme	bank	858:861	arg1	residues					879:886	the bank vole amino acid residues	854:886	the bank vole amino acid residues E227 and S230	854:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	21	theme	bank	858:861	arg1	S230					897:900	S230	897:900	S230	897:900	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	6	21	theme	bank	858:861	arg1	E227					888:891	E227	888:891	E227	888:891	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	3	22	theme	PrPSc	421:425	arg1	tool					479:482	a unique tool	470:482	a unique tool that can convert bank vole but not mouse PrPC substrates in vitro	470:548	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	22	theme	PrPSc	421:425	arg1	recPrPSc					457:464	mouse protein-only recPrPSc	438:464	mouse protein-only recPrPSc	438:464	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	22	theme	PrPSc	421:425	arg1	conformer					427:435	a recombinant mouse PrPSc conformer	401:435	a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)	401:465	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	2	23	theme	PrPSc	301:305	arg1	self-templating					257:271	the self-templating	253:271	the self-templating of the pathogenic conformer PrPSc	253:305	Prion propagation occurs through the self-templating of the pathogenic conformer PrPSc, onto the cell-expressed conformer, PrPC.
32898162	5	24	used	used	663:666	arg2	we					660:661	we	660:661	we	660:661	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	7	25	theme	domain	1160:1165	arg1	residues					1092:1099	residues 227 and 230	1092:1111	residues	1092:1099	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	25	theme	domain	1160:1165	arg1	230					1109:1111	230	1109:1111	230	1109:1111	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	25	theme	domain	1160:1165	arg1	part					1139:1142	part	1139:1142	part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion	1139:1230	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	25	theme	domain	1160:1165	arg1	glycan					1128:1133	the second glycan	1117:1133	the second glycan	1117:1133	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	6	26	theme	several	1035:1041	arg1	strains					1067:1073	several native infectious prion strains	1035:1073	several native infectious prion strains	1035:1073	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	7	27	theme	second	1121:1126	arg1	residues					1092:1099	residues 227 and 230	1092:1111	residues	1092:1099	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	27	theme	second	1121:1126	arg1	230					1109:1111	230	1109:1111	230	1109:1111	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	27	theme	second	1121:1126	arg1	part					1139:1142	part	1139:1142	part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion	1139:1230	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	7	27	theme	second	1121:1126	arg1	glycan					1128:1133	the second glycan	1117:1133	the second glycan	1117:1133	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	6	28	theme	N-linked	931:938	arg1	glycan					940:945	the second N-linked glycan	920:945	the second N-linked glycan	920:945	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	3	29	theme	mouse	438:442	arg1	recPrPSc					457:464	mouse protein-only recPrPSc	438:464	mouse protein-only recPrPSc	438:464	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	29	theme	mouse	438:442	arg1	conformer					427:435	a recombinant mouse PrPSc conformer	401:435	a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)	401:465	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	0	30	theme	homology-independent	20:39	arg1	domain					50:55	a homology-independent linchpin domain	18:55	a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion	18:112	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	6	31	theme	second	924:929	arg1	glycan					940:945	the second N-linked glycan	920:945	the second N-linked glycan	920:945	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	5	32	theme	chimeric	668:675	arg1	substrates					698:707	chimeric bank vole/mouse PrPC substrates	668:707	chimeric bank vole/mouse PrPC substrates	668:707	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	6	33	theme	Mo	1006:1007	arg1	recPrPSc					1022:1029	Mo protein-only recPrPSc	1006:1029	Mo protein-only recPrPSc	1006:1029	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	5	34	theme	bank	677:680	arg1	substrates					698:707	chimeric bank vole/mouse PrPC substrates	668:707	chimeric bank vole/mouse PrPC substrates	668:707	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	2	35	theme	cell-expressed	317:330	arg1	conformer					332:340	the cell-expressed conformer	313:340	the cell-expressed conformer	313:340	Prion propagation occurs through the self-templating of the pathogenic conformer PrPSc, onto the cell-expressed conformer, PrPC.
32898162	2	35	theme	cell-expressed	317:330	arg1	PrPC					343:346	PrPC	343:346	PrPC	343:346	Prion propagation occurs through the self-templating of the pathogenic conformer PrPSc, onto the cell-expressed conformer, PrPC.
32898162	3	36	theme	unique	472:477	arg1	tool					479:482	a unique tool	470:482	a unique tool that can convert bank vole but not mouse PrPC substrates in vitro	470:548	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	36	theme	unique	472:477	arg1	conformer					427:435	a recombinant mouse PrPSc conformer	401:435	a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)	401:465	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	0	37	theme	domain	50:55	arg1	Identification					0:13	Identification	0:13	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.	0:113	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	7	38	theme	mouse	1209:1213	arg1	conversion					1221:1230	mouse prion conversion	1209:1230	mouse prion conversion	1209:1230	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	5	39	theme	vole/mouse	682:691	arg1	substrates					698:707	chimeric bank vole/mouse PrPC substrates	668:707	chimeric bank vole/mouse PrPC substrates	668:707	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	1	40	theme	other	205:209	arg1	mammals					211:217	other mammals	205:217	other mammals	205:217	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	7	41	theme	prion	1215:1219	arg1	conversion					1221:1230	mouse prion conversion	1209:1230	mouse prion conversion	1209:1230	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	0	42	theme	linchpin	41:48	arg1	domain					50:55	a homology-independent linchpin domain	18:55	a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion	18:112	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	5	43	theme	PrPC	693:696	arg1	substrates					698:707	chimeric bank vole/mouse PrPC substrates	668:707	chimeric bank vole/mouse PrPC substrates	668:707	In the present study, we used chimeric bank vole/mouse PrPC substrates to systematically determine the domain that allows for conversion by Mo protein-only recPrPSc.
32898162	6	44	theme	PrPC	971:974	arg1	substrates					976:985	PrPC substrates	971:985	PrPC substrates	971:985	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	3	45	theme	recombinant	403:413	arg1	tool					479:482	a unique tool	470:482	a unique tool that can convert bank vole but not mouse PrPC substrates in vitro	470:548	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	45	theme	recombinant	403:413	arg1	recPrPSc					457:464	mouse protein-only recPrPSc	438:464	mouse protein-only recPrPSc	438:464	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	45	theme	recombinant	403:413	arg1	conformer					427:435	a recombinant mouse PrPSc conformer	401:435	a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)	401:465	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	6	46	link	N-linked	931:938	arg1	glycan					940:945	the second N-linked glycan	920:945	the second N-linked glycan	920:945	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	3	47	theme	mouse	415:419	arg1	tool					479:482	a unique tool	470:482	a unique tool that can convert bank vole but not mouse PrPC substrates in vitro	470:548	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	47	theme	mouse	415:419	arg1	recPrPSc					457:464	mouse protein-only recPrPSc	438:464	mouse protein-only recPrPSc	438:464	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	3	47	theme	mouse	415:419	arg1	conformer					427:435	a recombinant mouse PrPSc conformer	401:435	a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc)	401:465	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	6	48	theme	protein-only	1009:1020	arg1	recPrPSc					1022:1029	Mo protein-only recPrPSc	1006:1029	Mo protein-only recPrPSc	1006:1029	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	1	49	theme	unorthodox	126:135	arg1	pathogens					137:145	unorthodox pathogens	126:145	unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals	126:217	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	1	49	theme	unorthodox	126:135	arg1	Prions					115:120	Prions	115:120	Prions	115:120	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	2	50	theme	Prion	220:224	arg1	propagation					226:236	Prion propagation	220:236	Prion propagation	220:236	Prion propagation occurs through the self-templating of the pathogenic conformer PrPSc, onto the cell-expressed conformer, PrPC.
32898162	2	51	theme	conformer	291:299	arg1	PrPSc					301:305	the pathogenic conformer PrPSc	276:305	the pathogenic conformer PrPSc	276:305	Prion propagation occurs through the self-templating of the pathogenic conformer PrPSc, onto the cell-expressed conformer, PrPC.
32898162	7	52	theme	bank	1195:1198	arg1	vole					1200:1203	bank vole	1195:1203	bank vole	1195:1203	We propose that residues 227 and 230 and the second glycan are part of a C-terminal domain that acts as a linchpin for bank vole and mouse prion conversion.
32898162	3	53	theme	PrPC	525:528	arg1	substrates					530:539	mouse PrPC substrates	519:539	bank vole but not mouse PrPC substrates	501:539	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32898162	2	54	theme	pathogenic	280:289	arg1	PrPSc					301:305	the pathogenic conformer PrPSc	276:305	the pathogenic conformer PrPSc	276:305	Prion propagation occurs through the self-templating of the pathogenic conformer PrPSc, onto the cell-expressed conformer, PrPC.
32898162	6	55	theme	prion	1061:1065	arg1	strains					1067:1073	several native infectious prion strains	1035:1073	several native infectious prion strains	1035:1073	Our results show that that either the presence of the bank vole amino acid residues E227 and S230 or the absence of the second N-linked glycan are sufficient to allow PrPC substrates to be converted by Mo protein-only recPrPSc and several native infectious prion strains.
32898162	0	56	theme	bank	79:82	arg1	conversion					103:112	bank vole prion protein conversion	79:112	bank vole prion protein conversion	79:112	Identification of a homology-independent linchpin domain controlling mouse and bank vole prion protein conversion.
32898162	4	57	with	homology	609:616	arg1	substrate					627:635	the substrate	623:635	the substrate	623:635	Thus, its templating ability is not dependent on sequence homology with the substrate.
32898162	4	58	theme	sequence	600:607	arg1	homology					609:616	sequence homology	600:616	sequence homology with the substrate	600:635	Thus, its templating ability is not dependent on sequence homology with the substrate.
32898162	1	59	theme	fatal	158:162	arg1	diseases					182:189	fatal neurodegenerative diseases	158:189	fatal neurodegenerative diseases in humans and other mammals	158:217	Prions are unorthodox pathogens that cause fatal neurodegenerative diseases in humans and other mammals.
32898162	3	60	theme	PrPC	381:384	arg1	conversion					367:376	the conversion	363:376	the conversion of PrPC to PrPSc	363:393	Here we study the conversion of PrPC to PrPSc using a recombinant mouse PrPSc conformer (mouse protein-only recPrPSc) as a unique tool that can convert bank vole but not mouse PrPC substrates in vitro.
32860273	3	0	theme	quaternary	732:741	arg1	structure					743:751	the tertiary and quaternary structure	715:751	the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components	715:819	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	3	1	from	resolution	767:776	arg1	structure					743:751	the tertiary and quaternary structure	715:751	the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components	715:819	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	2	2	theme	overall	498:504	arg1	structure					506:514	the overall structure	494:514	the overall structure of IRBP	494:522	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	1	3	theme	neural	362:367	arg1	retina					369:374	neural retina	362:374	neural retina	362:374	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	4	from	transport	340:348	arg1	homeostasis					277:287	photoreceptor homeostasis	263:287	photoreceptor homeostasis	263:287	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	5	theme	photoreceptor	263:275	arg1	homeostasis					277:287	photoreceptor homeostasis	263:287	photoreceptor homeostasis	263:287	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	3	6	theme	cryo-electron	679:691	arg1	microscopy					693:702	cryo-electron microscopy	679:702	cryo-electron microscopy	679:702	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	4	7	theme	carbohydrate	915:926	arg1	modifications					947:959	N-linked carbohydrate post-translational modifications	906:959	N-linked carbohydrate post-translational modifications	906:959	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	4	8	dep	structure	879:887	arg1	the					875:877	the	875:877	the	875:877	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	5	9	theme	IRBP	1011:1014	arg1	structure					998:1006	the structure	994:1006	the structure of IRBP	994:1014	This work provides insight into the structure of IRBP, displaying an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins.
32860273	0	10	theme	monoclonal	97:106	arg1	antibody					108:115	a monoclonal antibody	95:115	a monoclonal antibody	95:115	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.
32860273	3	11	theme	tertiary	719:726	arg1	structure					743:751	the tertiary and quaternary structure	715:751	the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components	715:819	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	4	12	theme	N-linked	906:913	arg1	modifications					947:959	N-linked carbohydrate post-translational modifications	906:959	N-linked carbohydrate post-translational modifications	906:959	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	3	13	from	structure	599:607	arg1	complex					634:640	complex	634:640	complex with a monoclonal antibody (mAb5)	634:674	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	1	14	theme	retinal	380:386	arg1	epithelium					396:405	retinal pigment epithelium	380:405	retinal pigment epithelium	380:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	6	15	theme	first	1147:1151	arg1	step					1153:1156	the first step	1143:1156	the first step in elucidation of the function of this enigmatic protein	1143:1213	This work is the first step in elucidation of the function of this enigmatic protein.
32860273	6	15	theme	first	1147:1151	arg1	work					1135:1138	This work	1130:1138	This work	1130:1138	This work is the first step in elucidation of the function of this enigmatic protein.
32860273	1	16	theme	expressed	181:189	arg1	protein					191:197	a highly expressed protein	172:197	a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium	172:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	16	theme	expressed	181:189	arg1	protein					154:160	Interphotoreceptor retinoid-binding protein	118:160	Interphotoreceptor retinoid-binding protein (IRBP)	118:167	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	17	theme	pigment	388:394	arg1	epithelium					396:405	retinal pigment epithelium	380:405	retinal pigment epithelium	380:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	4	18	link	N-linked	906:913	arg1	modifications					947:959	N-linked carbohydrate post-translational modifications	906:959	N-linked carbohydrate post-translational modifications	906:959	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	0	19	theme	particle	7:14	arg1	cryo-EM					16:22	Single particle cryo-EM	0:22	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.	0:116	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.
32860273	5	20	theme	three-dimensional	1051:1067	arg1	architecture					1069:1080	an elongated, flexible three-dimensional architecture	1028:1080	an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins	1028:1127	This work provides insight into the structure of IRBP, displaying an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins.
32860273	4	21	theme	post-translational	928:945	arg1	modifications					947:959	N-linked carbohydrate post-translational modifications	906:959	N-linked carbohydrate post-translational modifications	906:959	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	0	22	theme	Single	0:5	arg1	cryo-EM					16:22	Single particle cryo-EM	0:22	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.	0:116	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.
32860273	3	23	with	complex	634:640	arg1	mAb5					670:673	mAb5	670:673	mAb5	670:673	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	3	23	with	complex	634:640	arg1	antibody					660:667	a monoclonal antibody	647:667	a monoclonal antibody (mAb5)	647:674	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	2	24	theme	IRBP	464:467	arg1	decades					473:479	decades	473:479	decades of research	473:491	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	2	24	theme	IRBP	464:467	arg1	fragments					451:459	fragments	451:459	fragments of IRBP	451:467	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	1	25	dep	retina	369:374	arg1	the					358:360	the	358:360	the	358:360	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	5	26	theme	other	1097:1101	arg1	proteins					1120:1127	other retinoid-binding proteins	1097:1127	other retinoid-binding proteins	1097:1127	This work provides insight into the structure of IRBP, displaying an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins.
32860273	6	27	theme	protein	1207:1213	arg1	function					1180:1187	the function	1176:1187	the function of this enigmatic protein	1176:1213	This work is the first step in elucidation of the function of this enigmatic protein.
32860273	1	28	theme	rod	211:213	arg1	photoreceptors					224:237	rod and cone photoreceptors	211:237	rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium	211:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	29	theme	retinoid	300:307	arg1	acid					335:338	retinoid and polyunsaturated fatty acid	300:338	acid	335:338	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	30	theme	Interphotoreceptor	118:135	arg1	IRBP					163:166	IRBP	163:166	IRBP	163:166	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	30	theme	Interphotoreceptor	118:135	arg1	protein					154:160	Interphotoreceptor retinoid-binding protein	118:160	Interphotoreceptor retinoid-binding protein (IRBP)	118:167	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	30	theme	Interphotoreceptor	118:135	arg1	protein					191:197	a highly expressed protein	172:197	a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium	172:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	2	31	theme	research	484:491	arg1	decades					473:479	decades	473:479	decades of research	473:491	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	2	31	theme	research	484:491	arg1	fragments					451:459	fragments	451:459	fragments of IRBP	451:467	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	0	32	theme	complex	31:37	arg1	cryo-EM					16:22	Single particle cryo-EM	0:22	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.	0:116	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.
32860273	3	33	theme	monoclonal	649:658	arg1	mAb5					670:673	mAb5	670:673	mAb5	670:673	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	3	33	theme	monoclonal	649:658	arg1	antibody					660:667	a monoclonal antibody	647:667	a monoclonal antibody (mAb5)	647:674	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	4	34	theme	mass	836:839	arg1	spectrometry					841:852	mass spectrometry	836:852	Complementary mass spectrometry experiments	822:864	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	1	35	theme	cone	219:222	arg1	photoreceptors					224:237	rod and cone photoreceptors	211:237	rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium	211:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	2	36	theme	crystal	420:426	arg1	structures					428:437	two crystal structures	416:437	two crystal structures reported on fragments of IRBP and decades of research	416:491	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	1	37	theme	polyunsaturated	313:327	arg1	acid					335:338	retinoid and polyunsaturated fatty acid	300:338	acid	335:338	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	2	38	theme	visual	548:553	arg1	cycle					555:559	the visual cycle	544:559	the visual cycle	544:559	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	4	39	theme	Complementary	822:834	arg1	experiments					854:864	Complementary mass spectrometry experiments	822:864	Complementary mass spectrometry experiments	822:864	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	0	40	theme	interphotoreceptor	47:64	arg1	protein					83:89	interphotoreceptor retinoid-binding protein	47:89	interphotoreceptor retinoid-binding protein	47:89	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.
32860273	1	41	theme	fatty	329:333	arg1	acid					335:338	retinoid and polyunsaturated fatty acid	300:338	acid	335:338	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	4	42	theme	modifications	947:959	arg1	structure					879:887	structure	879:887	structure	879:887	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	4	42	theme	modifications	947:959	arg1	locations					893:901	locations	893:901	locations	893:901	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	3	43	theme	sufficient	756:765	arg1	resolution					767:776	sufficient resolution	756:776	sufficient resolution	756:776	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	1	44	contain	has	244:246	arg2	transport					340:348	retinoid and polyunsaturated fatty acid transport	300:348	major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport	248:348	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	44	contain	has	244:246	arg2	roles					254:258	major roles	248:258	major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport	248:348	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	44	contain	has	244:246	arg1	photoreceptors					224:237	rod and cone photoreceptors	211:237	rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium	211:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	45	theme	retinoid-binding	137:152	arg1	IRBP					163:166	IRBP	163:166	IRBP	163:166	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	45	theme	retinoid-binding	137:152	arg1	protein					154:160	Interphotoreceptor retinoid-binding protein	118:160	Interphotoreceptor retinoid-binding protein (IRBP)	118:167	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	45	theme	retinoid-binding	137:152	arg1	protein					191:197	a highly expressed protein	172:197	a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium	172:405	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	46	theme	acid	335:338	arg1	transport					340:348	retinoid and polyunsaturated fatty acid transport	300:348	major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport	248:348	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	1	47	from	roles	254:258	arg1	homeostasis					277:287	photoreceptor homeostasis	263:287	photoreceptor homeostasis	263:287	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	5	48	theme	retinoid-binding	1103:1118	arg1	proteins					1120:1127	other retinoid-binding proteins	1097:1127	other retinoid-binding proteins	1097:1127	This work provides insight into the structure of IRBP, displaying an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins.
32860273	4	49	theme	spectrometry	841:852	arg1	experiments					854:864	Complementary mass spectrometry experiments	822:864	Complementary mass spectrometry experiments	822:864	Complementary mass spectrometry experiments revealed the structure and locations of N-linked carbohydrate post-translational modifications.
32860273	5	50	dep	elongated	1031:1039	arg1	flexible					1042:1049	flexible	1042:1049	flexible	1042:1049	This work provides insight into the structure of IRBP, displaying an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins.
32860273	3	51	theme	IRBP	626:629	arg1	structure					599:607	the structure	595:607	the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5)	595:674	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	6	52	theme	function	1180:1187	arg1	elucidation					1161:1171	elucidation	1161:1171	elucidation of the function of this enigmatic protein	1161:1213	This work is the first step in elucidation of the function of this enigmatic protein.
32860273	5	53	theme	elongated	1031:1039	arg1	architecture					1069:1080	an elongated, flexible three-dimensional architecture	1028:1080	an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins	1028:1127	This work provides insight into the structure of IRBP, displaying an elongated, flexible three-dimensional architecture not seen among other retinoid-binding proteins.
32860273	2	54	theme	IRBP	519:522	arg1	function					528:535	function	528:535	function within the visual cycle	528:559	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	2	54	theme	IRBP	519:522	arg1	structure					506:514	the overall structure	494:514	the overall structure of IRBP	494:522	Despite two crystal structures reported on fragments of IRBP and decades of research, the overall structure of IRBP and function within the visual cycle remain unsolved.
32860273	3	55	theme	native	612:617	arg1	IRBP					626:629	native bovine IRBP	612:629	native bovine IRBP	612:629	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	6	56	from	step	1153:1156	arg1	elucidation					1161:1171	elucidation	1161:1171	elucidation of the function of this enigmatic protein	1161:1213	This work is the first step in elucidation of the function of this enigmatic protein.
32860273	1	57	theme	major	248:252	arg1	roles					254:258	major roles	248:258	major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport	248:348	Interphotoreceptor retinoid-binding protein (IRBP) is a highly expressed protein secreted by rod and cone photoreceptors that has major roles in photoreceptor homeostasis as well as retinoid and polyunsaturated fatty acid transport between the neural retina and retinal pigment epithelium.
32860273	0	58	theme	retinoid-binding	66:81	arg1	protein					83:89	interphotoreceptor retinoid-binding protein	47:89	interphotoreceptor retinoid-binding protein	47:89	Single particle cryo-EM of the complex between interphotoreceptor retinoid-binding protein and a monoclonal antibody.
32860273	6	59	theme	enigmatic	1197:1205	arg1	protein					1207:1213	this enigmatic protein	1192:1213	this enigmatic protein	1192:1213	This work is the first step in elucidation of the function of this enigmatic protein.
32860273	3	60	theme	bovine	619:624	arg1	IRBP					626:629	native bovine IRBP	612:629	native bovine IRBP	612:629	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32860273	3	61	theme	complex	802:808	arg1	components					810:819	the complex components	798:819	the complex components	798:819	Here, we studied the structure of native bovine IRBP in complex with a monoclonal antibody (mAb5) by cryo-electron microscopy, revealing the tertiary and quaternary structure at sufficient resolution to clearly identify the complex components.
32485989	4	0	theme	same	477:480	arg1	venom					482:486	the same venom	473:486	the same venom	473:486	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	7	1	theme	lupus	1064:1068	arg1	testing					1084:1090	lupus anticoagulant testing	1064:1090	lupus anticoagulant testing	1064:1090	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	1	2	theme	venom	147:151	arg1	protease					160:167	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	1	3	theme	ammodytes	230:238	arg1	Vipera					223:228	Vipera ammodytes ammodytes	223:248	Vipera ammodytes ammodytes	223:248	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	1	3	theme	ammodytes	230:238	arg1	viper					216:220	the nose-horned viper	200:220	the nose-horned viper (Vipera ammodytes ammodytes)	200:249	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	2	4	link	N-linked	314:321	arg1	carbohydrates					323:335	five kDa N-linked carbohydrates	305:335	five kDa N-linked carbohydrates	305:335	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	7	5	theme	anticoagulant	1070:1082	arg1	testing					1084:1090	lupus anticoagulant testing	1064:1090	lupus anticoagulant testing	1064:1090	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	6	6	theme	blood	784:788	arg1	factors					802:808	these two blood coagulation factors	774:808	these two blood coagulation factors	774:808	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	1	7	theme	serine	153:158	arg1	protease					160:167	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	0	8	theme	Factor	90:95	arg1	V					97:97	Factor V	90:97	Factor V	90:97	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	4	9	from	venom	482:486	arg1	VaaSP-6					460:466	VaaSP-6	460:466	VaaSP-6 from the same venom	460:486	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	7	10	theme	serine	934:939	arg1	protease					941:948	a serine protease	932:948	a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis	932:1142	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	7	11	with	protease	941:948	arg1	activity					967:974	such a dual activity	955:974	such a dual activity	955:974	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	2	12	gly	glycoprotein	264:275	arg1	glycoprotein					264:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	6	13	theme	prothrombinase	859:872	arg1	complex					874:880	the prothrombinase complex	855:880	the prothrombinase complex	855:880	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	14	dep	factors	660:666	arg1	factors					660:666	blood coagulation factors	642:666	blood coagulation factors X and V	642:674	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	14	dep	factors	660:666	arg1	V					674:674	V	674:674	V	674:674	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	14	dep	factors	660:666	arg1	X					668:668	X	668:668	X	668:668	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	2	15	theme	kDa	260:262	arg1	glycoprotein					264:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	7	16	theme	analysis	1135:1142	arg1	reliability					1116:1126	greater reliability	1108:1126	greater reliability of the analysis	1108:1142	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	2	17	theme	34	257:258	arg1	glycoprotein					264:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	4	18	from	venom	512:516	arg1	nikobin					495:501	nikobin	495:501	nikobin	495:501	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	0	19	dep	Coagulation	78:88	arg1	Blood					72:76	a Dual, Blood Coagulation Factor V and X-Activating Activity	64:123	Blood	72:76	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	0	19	dep	Coagulation	78:88	arg1	V					97:97	Factor V	90:97	Factor V	90:97	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	0	19	dep	Coagulation	78:88	arg1	Activity					116:123	X-Activating Activity	103:123	X-Activating Activity	103:123	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	0	20	theme	Procoagulant	4:15	arg1	Venom					23:27	The Procoagulant Snake Venom	0:27	The Procoagulant Snake Venom Serine Protease	0:43	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	7	21	theme	diluted	1031:1037	arg1	venom					1055:1059	diluted Russell's viper venom	1031:1059	diluted Russell's viper venom	1031:1059	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	7	22	theme	first	915:919	arg1	example					921:927	the first example	911:927	the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis	911:1142	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	4	23	theme	Vipera	521:526	arg1	nikolskii					528:536	Vipera nikolskii	521:536	Vipera nikolskii	521:536	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	6	24	theme	factors	660:666	arg1	proteolysis					627:637	The specific proteolysis	614:637	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX	614:686	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	8	25	theme	serpin	1209:1214	arg1	inhibition					1216:1225	serpin inhibition	1209:1225	serpin inhibition	1209:1225	As a blood-coagulation-promoting substance that is resistant to serpin inhibition, VaaSP-VX is also interesting from the therapeutic point of view for treating patients suffering from hemophilia.
32485989	0	26	theme	Venom	23:27	arg1	Protease					36:43	The Procoagulant Snake Venom Serine Protease	0:43	The Procoagulant Snake Venom Serine Protease	0:43	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	8	27	from	point	1278:1282	arg1	interesting					1245:1255	interesting	1245:1255	interesting	1245:1255	As a blood-coagulation-promoting substance that is resistant to serpin inhibition, VaaSP-VX is also interesting from the therapeutic point of view for treating patients suffering from hemophilia.
32485989	6	28	theme	coagulation	648:658	arg1	factors					660:666	blood coagulation factors	642:666	blood coagulation factors X and V	642:674	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	28	theme	coagulation	648:658	arg1	V					674:674	V	674:674	V	674:674	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	28	theme	coagulation	648:658	arg1	X					668:668	X	668:668	X	668:668	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	0	29	theme	Snake	17:21	arg1	Venom					23:27	The Procoagulant Snake Venom	0:27	The Procoagulant Snake Venom Serine Protease	0:43	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	0	30	theme	X-Activating	103:114	arg1	Activity					116:123	X-Activating Activity	103:123	X-Activating Activity	103:123	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	8	31	theme	view	1287:1290	arg1	point					1278:1282	the therapeutic point	1262:1282	the therapeutic point of view	1262:1290	As a blood-coagulation-promoting substance that is resistant to serpin inhibition, VaaSP-VX is also interesting from the therapeutic point of view for treating patients suffering from hemophilia.
32485989	6	32	theme	blood	642:646	arg1	factors					660:666	blood coagulation factors	642:666	blood coagulation factors X and V	642:674	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	32	theme	blood	642:646	arg1	V					674:674	V	674:674	V	674:674	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	6	32	theme	blood	642:646	arg1	X					668:668	X	668:668	X	668:668	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	3	33	theme	chymotrypsin-like	384:400	arg1	protease					409:416	a chymotrypsin-like serine protease	382:416	a chymotrypsin-like serine protease	382:416	Amino acid sequencing showed VaaSP-VX to be a chymotrypsin-like serine protease.
32485989	4	34	theme	nikolskii	528:536	arg1	venom					512:516	the venom	508:516	the venom of Vipera nikolskii	508:536	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	7	35	theme	suitable	1001:1008	arg1	candidate					1010:1018	a highly suitable candidate	992:1018	a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis	992:1142	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	1	36	dep	Vipera	223:228	arg1	ammodytes					240:248	Vipera ammodytes ammodytes	223:248	Vipera ammodytes ammodytes	223:248	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	0	37	theme	Serine	29:34	arg1	Protease					36:43	The Procoagulant Snake Venom Serine Protease	0:43	The Procoagulant Snake Venom Serine Protease	0:43	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	3	38	theme	serine	402:407	arg1	protease					409:416	a chymotrypsin-like serine protease	382:416	a chymotrypsin-like serine protease	382:416	Amino acid sequencing showed VaaSP-VX to be a chymotrypsin-like serine protease.
32485989	4	39	contain	have	556:559	arg1	neither					539:545	neither	539:545	neither	539:545	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	4	39	contain	have	556:559	arg2	functions					567:575	known functions	561:575	known functions	561:575	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	3	40	theme	Amino	338:342	arg1	sequencing					349:358	Amino acid sequencing	338:358	Amino acid sequencing	338:358	Amino acid sequencing showed VaaSP-VX to be a chymotrypsin-like serine protease.
32485989	8	41	theme	blood-coagulation-promoting	1150:1176	arg1	substance					1178:1186	a blood-coagulation-promoting substance	1148:1186	a blood-coagulation-promoting substance that is resistant to serpin inhibition	1148:1225	As a blood-coagulation-promoting substance that is resistant to serpin inhibition, VaaSP-VX is also interesting from the therapeutic point of view for treating patients suffering from hemophilia.
32485989	8	41	theme	blood-coagulation-promoting	1150:1176	arg1	resistant					1196:1204	resistant	1196:1204	resistant	1196:1204	As a blood-coagulation-promoting substance that is resistant to serpin inhibition, VaaSP-VX is also interesting from the therapeutic point of view for treating patients suffering from hemophilia.
32485989	1	42	attach	isolated	173:180	arg2	protease					160:167	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	1	42	attach	isolated	173:180	arg1	venom					191:195	the venom	187:195	the venom of the nose-horned viper (Vipera ammodytes ammodytes)	187:249	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	2	43	theme	N-linked	314:321	arg1	carbohydrates					323:335	five kDa N-linked carbohydrates	305:335	five kDa N-linked carbohydrates	305:335	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	4	44	theme	known	561:565	arg1	functions					567:575	known functions	561:575	known functions	561:575	Structurally, it is highly homologous to VaaSP-6 from the same venom and to nikobin from the venom of Vipera nikolskii, neither of which have known functions.
32485989	7	45	theme	viper	1049:1053	arg1	venom					1055:1059	diluted Russell's viper venom	1031:1059	diluted Russell's viper venom	1031:1059	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	7	46	theme	dual	962:965	arg1	activity					967:974	such a dual activity	955:974	such a dual activity	955:974	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	2	47	theme	kDa	310:312	arg1	carbohydrates					323:335	five kDa N-linked carbohydrates	305:335	five kDa N-linked carbohydrates	305:335	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	7	48	theme	greater	1108:1114	arg1	reliability					1116:1126	greater reliability	1108:1126	greater reliability of the analysis	1108:1142	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	6	49	theme	blood-coagulation-inducing	706:731	arg1	effect					733:738	its blood-coagulation-inducing effect	702:738	its blood-coagulation-inducing effect	702:738	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	8	50	theme	therapeutic	1266:1276	arg1	point					1278:1282	the therapeutic point	1262:1282	the therapeutic point of view	1262:1290	As a blood-coagulation-promoting substance that is resistant to serpin inhibition, VaaSP-VX is also interesting from the therapeutic point of view for treating patients suffering from hemophilia.
32485989	6	51	theme	specific	618:625	arg1	proteolysis					627:637	The specific proteolysis	614:637	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX	614:686	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	1	52	theme	nose-horned	204:214	arg1	Vipera					223:228	Vipera ammodytes ammodytes	223:248	Vipera ammodytes ammodytes	223:248	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	1	52	theme	nose-horned	204:214	arg1	viper					216:220	the nose-horned viper	200:220	the nose-horned viper (Vipera ammodytes ammodytes)	200:249	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	1	53	theme	viper	216:220	arg1	venom					191:195	the venom	187:195	the venom of the nose-horned viper (Vipera ammodytes ammodytes)	187:249	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	0	54	theme	Dual	66:69	arg1	Coagulation					78:88	a Dual, Blood Coagulation Factor V and X-Activating Activity	64:123	Coagulation	78:88	The Procoagulant Snake Venom Serine Protease Potentially Having a Dual, Blood Coagulation Factor V and X-Activating Activity.
32485989	6	55	theme	coagulation	790:800	arg1	factors					802:808	these two blood coagulation factors	774:808	these two blood coagulation factors	774:808	The specific proteolysis of blood coagulation factors X and V by VaaSP-VX suggests that its blood-coagulation-inducing effect is due to its ability to activate these two blood coagulation factors, which following activation, combine to form the prothrombinase complex.
32485989	1	56	theme	procoagulant	128:139	arg1	venom					147:151	procoagulant snake venom	128:151	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	2	57	contain	possesses	295:303	arg1	glycoprotein					264:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein	252:275	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	2	57	contain	possesses	295:303	arg2	carbohydrates					323:335	five kDa N-linked carbohydrates	305:335	five kDa N-linked carbohydrates	305:335	This 34 kDa glycoprotein, termed VaaSP-VX, possesses five kDa N-linked carbohydrates.
32485989	7	58	theme	protease	941:948	arg1	example					921:927	the first example	911:927	the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis	911:1142	VaaSP-VX may thus represent the first example of a serine protease with such a dual activity, which makes it a highly suitable candidate to replace diluted Russell's viper venom in lupus anticoagulant testing, thus achieving greater reliability of the analysis.
32485989	1	59	theme	snake	141:145	arg1	venom					147:151	procoagulant snake venom	128:151	A procoagulant snake venom serine protease	126:167	A procoagulant snake venom serine protease was isolated from the venom of the nose-horned viper (Vipera ammodytes ammodytes).
32485989	3	60	theme	acid	344:347	arg1	sequencing					349:358	Amino acid sequencing	338:358	Amino acid sequencing	338:358	Amino acid sequencing showed VaaSP-VX to be a chymotrypsin-like serine protease.
32555531	2	0	theme	SOC	539:541	arg1	product					518:524	the putative gene product	500:524	the putative gene product of AM fungi, SOC, and soil aggregates	500:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	0	theme	SOC	539:541	arg1	dynamics					389:396	the temporal and spatial dynamics	364:396	the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	364:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	1	theme	fungi	532:536	arg1	product					518:524	the putative gene product	500:524	the putative gene product of AM fungi, SOC, and soil aggregates	500:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	1	theme	fungi	532:536	arg1	dynamics					389:396	the temporal and spatial dynamics	364:396	the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	364:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	6	2	theme	total	1059:1063	arg1	SOC					1074:1076	SOC	1074:1076	SOC	1074:1076	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	6	2	theme	total	1059:1063	arg1	highest					1087:1093	highest	1087:1093	highest	1087:1093	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	6	2	theme	total	1059:1063	arg1	GRSP					1065:1068	The total GRSP	1055:1068	The total GRSP	1055:1068	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	1	3	from	function	282:289	arg1	sequestration					326:338	soil carbon sequestration	314:338	soil carbon sequestration	314:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	8	4	theme	total	1522:1526	arg1	N					1528:1528	total N	1522:1528	total N	1522:1528	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	6	5	from	layer	1115:1119	arg1	2013					1128:1131	May 2013 and November 2012	1124:1149	2013	1128:1131	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	6	5	from	layer	1115:1119	arg1	November					1137:1144	November	1137:1144	November	1137:1144	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	2	6	theme	aggregates	553:562	arg1	product					518:524	the putative gene product	500:524	the putative gene product of AM fungi, SOC, and soil aggregates	500:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	6	theme	aggregates	553:562	arg1	dynamics					389:396	the temporal and spatial dynamics	364:396	the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	364:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	7	link	N-linked	474:481	arg1	protein					433:439	glomalin-related soil protein	411:439	glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	411:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	7	link	N-linked	474:481	arg1	glycoprotein					483:494	a N-linked glycoprotein	472:494	a N-linked glycoprotein	472:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	1	8	theme	mycorrhizal	183:193	arg1	fungi					200:204	arbuscular mycorrhizal (AM) fungi	172:204	arbuscular mycorrhizal (AM) fungi	172:204	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	7	9	theme	total	1279:1283	arg1	GRSP					1285:1288	total GRSP	1279:1288	total GRSP	1279:1288	Correlation coefficient analysis revealed that AM colonization and spore density were positively correlated with total GRSP.
32555531	2	10	theme	China	677:681	arg1	areas					653:657	coastal saline areas	638:657	coastal saline areas of North Jiangsu, China	638:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	3	11	theme	Soil	684:687	arg1	samples					689:695	Soil samples	684:695	Soil samples	684:695	Soil samples were collected from a depth of up to 30 cm in two plantation regions from August 2012 to May 2013.
32555531	6	12	theme	0-10 cm	1102:1108	arg1	layer					1115:1119	the 0-10 cm soil layer	1098:1119	the 0-10 cm soil layer in May 2013 and November 2012	1098:1149	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	8	13	theme	pH.	1535:1537	arg1	SOC					1539:1541	pH. SOC	1535:1541	pH. SOC	1535:1541	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	1	14	theme	AM	196:197	arg1	fungi					200:204	arbuscular mycorrhizal (AM) fungi	172:204	arbuscular mycorrhizal (AM) fungi	172:204	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	3	15	from	August	771:776	arg1	regions					758:764	two plantation regions	743:764	two plantation regions from August 2012 to May 2013	743:793	Soil samples were collected from a depth of up to 30 cm in two plantation regions from August 2012 to May 2013.
32555531	5	16	theme	farm	964:967	arg1	layer					948:952	the 10-20 cm soil layer	930:952	the 10-20 cm soil layer of Jinhai farm in August 2012	930:982	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	4	17	theme	symbiotic	840:848	arg1	relationship					850:861	a strong symbiotic relationship	831:861	a strong symbiotic relationship to AM fungi	831:873	Results showed K. virginica formed a strong symbiotic relationship to AM fungi.
32555531	8	18	theme	significant	1833:1843	arg1	correlation					1845:1855	no significant correlation	1830:1855	no significant correlation between soil aggregates and AM colonization	1830:1899	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	9	19	theme	vital	1942:1946	arg1	source					1948:1953	a vital source	1940:1953	a vital source of saline soil C pool	1940:1975	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	9	19	theme	vital	1942:1946	arg1	GRSP					1932:1935	total GRSP	1926:1935	total GRSP	1926:1935	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	1	20	from	sequestration	326:338	arg1	analysis					266:273	analysis	266:273	analysis of the function of coastal wetlands in soil carbon sequestration	266:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	21	theme	coastal	210:216	arg1	SOC					246:248	SOC	246:248	SOC	246:248	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	21	theme	coastal	210:216	arg1	carbon					238:243	coastal saline soil organic carbon	210:243	coastal saline soil organic carbon (SOC)	210:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	7	22	theme	spore	1233:1237	arg1	density					1239:1245	spore density	1233:1245	spore density	1233:1245	Correlation coefficient analysis revealed that AM colonization and spore density were positively correlated with total GRSP.
32555531	2	23	theme	saline	646:651	arg1	areas					653:657	coastal saline areas	638:657	coastal saline areas of North Jiangsu, China	638:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	5	24	theme	soil	943:946	arg1	layer					948:952	the 10-20 cm soil layer	930:952	the 10-20 cm soil layer of Jinhai farm in August 2012	930:982	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	8	25	theme	spore	1574:1578	arg1	density					1580:1586	spore density	1574:1586	spore density	1574:1586	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	26	theme	gene	513:516	arg1	product					518:524	the putative gene product	500:524	the putative gene product of AM fungi, SOC, and soil aggregates	500:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	3	27	theme	up	728:729	arg1	depth					719:723	a depth	717:723	a depth of up to 30 cm	717:738	Soil samples were collected from a depth of up to 30 cm in two plantation regions from August 2012 to May 2013.
32555531	8	28	theme	large	1358:1362	arg1	>3 mm					1381:1385	>3 mm	1381:1385	>3 mm	1381:1385	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	28	theme	large	1358:1362	arg1	macroaggregates					1364:1378	large macroaggregates	1358:1378	large macroaggregates (>3 mm)	1358:1386	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	9	29	theme	pool	1972:1975	arg1	source					1948:1953	a vital source	1940:1953	a vital source of saline soil C pool	1940:1975	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	9	29	theme	pool	1972:1975	arg1	GRSP					1932:1935	total GRSP	1926:1935	total GRSP	1926:1935	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	9	29	theme	pool	1972:1975	arg1	indicator					2005:2013	an important biological indicator	1981:2013	an important biological indicator for evaluating coastal saline SOC pool and soil fertility	1981:2071	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	0	30	theme	organic	66:72	arg1	carbon					74:79	soil organic carbon	61:79	soil organic carbon	61:79	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	1	31	theme	wetlands	302:309	arg1	function					282:289	the function	278:289	the function of coastal wetlands in soil carbon sequestration	278:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	9	32	theme	soil	1965:1968	arg1	pool					1972:1975	saline soil C pool	1958:1975	saline soil C pool	1958:1975	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	2	33	theme	putative	504:511	arg1	product					518:524	the putative gene product	500:524	the putative gene product of AM fungi, SOC, and soil aggregates	500:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	5	34	from	layer	948:952	arg1	August					972:977	August	972:977	August	972:977	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	1	35	theme	soil	314:317	arg1	sequestration					326:338	soil carbon sequestration	314:338	soil carbon sequestration	314:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	8	36	theme	small	1612:1616	arg1	macroaggregates					1618:1632	small macroaggregates	1612:1632	small macroaggregates (2-0.25 mm)	1612:1644	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	36	theme	small	1612:1616	arg1	2-0.25 mm					1635:1643	2-0.25 mm	1635:1643	2-0.25 mm	1635:1643	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	37	gly	glycoprotein	483:494	arg1	protein					433:439	glomalin-related soil protein	411:439	glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	411:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	37	gly	glycoprotein	483:494	arg1	glycoprotein					483:494	a N-linked glycoprotein	472:494	a N-linked glycoprotein	472:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	9	38	theme	biological	1994:2003	arg1	indicator					2005:2013	an important biological indicator	1981:2013	an important biological indicator for evaluating coastal saline SOC pool and soil fertility	1981:2071	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	0	39	theme	saline	92:97	arg1	soil					99:102	coastal saline soil	84:102	coastal saline soil of China	84:111	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	5	40	theme	AM	876:877	arg1	colonization					879:890	AM colonization	876:890	AM colonization	876:890	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	40	theme	AM	876:877	arg1	density					902:908	spore density	896:908	spore density	896:908	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	40	theme	AM	876:877	arg1	highest					919:925	highest	919:925	highest	919:925	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	8	41	theme	statistical	1758:1768	arg1	it					1746:1747	it	1746:1747	it	1746:1747	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	41	theme	statistical	1758:1768	arg1	artifact					1770:1777	a statistical artifact	1756:1777	a statistical artifact	1756:1777	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	42	theme	total	1394:1398	arg1	P					1400:1400	total P	1394:1400	total P	1394:1400	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	43	theme	rhizosphere	618:628	arg1	soil					630:633	halophyte Kosteletzkya virginica rhizosphere soil	585:633	halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China	585:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	9	44	theme	coastal	2030:2036	arg1	pool					2049:2052	coastal saline SOC pool	2030:2052	coastal saline SOC pool	2030:2052	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	0	45	theme	Spatio-temporal	0:14	arg1	dynamics					16:23	Spatio-temporal dynamics	0:23	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.	0:112	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	8	46	theme	alkaline	1647:1654	arg1	N					1656:1656	alkaline N	1647:1656	alkaline N	1647:1656	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	9	47	theme	saline	2038:2043	arg1	pool					2049:2052	coastal saline SOC pool	2030:2052	coastal saline SOC pool	2030:2052	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	7	48	theme	coefficient	1178:1188	arg1	analysis					1190:1197	Correlation coefficient analysis	1166:1197	Correlation coefficient analysis	1166:1197	Correlation coefficient analysis revealed that AM colonization and spore density were positively correlated with total GRSP.
32555531	2	49	theme	AM	401:402	arg1	fungi					404:408	AM fungi	401:408	AM fungi	401:408	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	49	theme	AM	401:402	arg1	protein					433:439	glomalin-related soil protein	411:439	glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	411:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	50	theme	Kosteletzkya	595:606	arg1	soil					630:633	halophyte Kosteletzkya virginica rhizosphere soil	585:633	halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China	585:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	9	51	theme	SOC	2045:2047	arg1	pool					2049:2052	coastal saline SOC pool	2030:2052	coastal saline SOC pool	2030:2052	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	0	52	theme	mycorrhizal	39:49	arg1	fungi					51:55	arbuscular mycorrhizal fungi	28:55	arbuscular mycorrhizal fungi	28:55	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	5	53	theme	roots	1029:1033	arg1	presence					1000:1007	the presence	996:1007	the presence of numerous fibrous roots in this soil layer	996:1052	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	8	54	theme	interesting	1792:1802	arg1	phenomenon					1804:1813	an interesting phenomenon	1789:1813	an interesting phenomenon	1789:1813	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	55	theme	N-linked	474:481	arg1	protein					433:439	glomalin-related soil protein	411:439	glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	411:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	55	theme	N-linked	474:481	arg1	glycoprotein					483:494	a N-linked glycoprotein	472:494	a N-linked glycoprotein	472:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	56	theme	soil	428:431	arg1	fungi					404:408	AM fungi	401:408	AM fungi	401:408	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	56	theme	soil	428:431	arg1	GRSP					442:445	GRSP	442:445	GRSP	442:445	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	56	theme	soil	428:431	arg1	protein					433:439	glomalin-related soil protein	411:439	glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	411:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	56	theme	soil	428:431	arg1	glycoprotein					483:494	a N-linked glycoprotein	472:494	a N-linked glycoprotein	472:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	5	57	theme	10-20 cm	934:941	arg1	layer					948:952	the 10-20 cm soil layer	930:952	the 10-20 cm soil layer of Jinhai farm in August 2012	930:982	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	58	attach	presence	1000:1007	arg2	roots					1029:1033	numerous fibrous roots	1012:1033	numerous fibrous roots	1012:1033	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	58	attach	presence	1000:1007	arg1	layer					1048:1052	this soil layer	1038:1052	this soil layer	1038:1052	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	8	59	theme	microbial	1421:1429	arg1	SMBC					1447:1450	SMBC	1447:1450	SMBC	1447:1450	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	59	theme	microbial	1421:1429	arg1	carbon					1439:1444	soil microbial biomass carbon	1416:1444	soil microbial biomass carbon (SMBC)	1416:1451	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	1	60	theme	saline	218:223	arg1	SOC					246:248	SOC	246:248	SOC	246:248	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	60	theme	saline	218:223	arg1	carbon					238:243	coastal saline soil organic carbon	210:243	coastal saline soil organic carbon (SOC)	210:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	9	61	theme	soil	2058:2061	arg1	fertility					2063:2071	soil fertility	2058:2071	soil fertility	2058:2071	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	8	62	theme	total	1302:1306	arg1	Meanwhile					1291:1299	Meanwhile	1291:1299	Meanwhile	1291:1299	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	62	theme	total	1302:1306	arg1	GRSP					1308:1311	total GRSP	1302:1311	total GRSP	1302:1311	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	1	63	theme	organic	230:236	arg1	SOC					246:248	SOC	246:248	SOC	246:248	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	63	theme	organic	230:236	arg1	carbon					238:243	coastal saline soil organic carbon	210:243	coastal saline soil organic carbon (SOC)	210:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	5	64	from	presence	1000:1007	arg1	layer					1048:1052	this soil layer	1038:1052	this soil layer	1038:1052	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	4	65	dep	showed	804:809	arg1	formed					824:829	formed	824:829	showed K. virginica formed a strong symbiotic relationship to AM fungi	804:873	Results showed K. virginica formed a strong symbiotic relationship to AM fungi.
32555531	9	66	theme	spore	2099:2103	arg1	density					2105:2111	spore density	2099:2111	spore density	2099:2111	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	8	67	theme	soil	1513:1516	arg1	EC					1518:1519	soil EC	1513:1519	soil EC	1513:1519	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	68	theme	AM	529:530	arg1	fungi					532:536	AM fungi	529:536	AM fungi	529:536	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	6	69	theme	May	1124:1126	arg1	2013					1128:1131	May 2013 and November 2012	1124:1149	2013	1128:1131	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	1	70	from	analysis	266:273	arg1	sequestration					326:338	soil carbon sequestration	314:338	soil carbon sequestration	314:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	71	theme	arbuscular	172:181	arg1	fungi					200:204	arbuscular mycorrhizal (AM) fungi	172:204	arbuscular mycorrhizal (AM) fungi	172:204	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	2	72	theme	soil	548:551	arg1	aggregates					553:562	soil aggregates	548:562	soil aggregates	548:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	6	73	theme	soil	1110:1113	arg1	layer					1115:1119	the 0-10 cm soil layer	1098:1119	the 0-10 cm soil layer in May 2013 and November 2012	1098:1149	The total GRSP and SOC were the highest in the 0-10 cm soil layer in May 2013 and November 2012, respectively.
32555531	9	74	theme	total	1926:1930	arg1	source					1948:1953	a vital source	1940:1953	a vital source of saline soil C pool	1940:1975	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	9	74	theme	total	1926:1930	arg1	GRSP					1932:1935	total GRSP	1926:1935	total GRSP	1926:1935	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	5	75	theme	numerous	1012:1019	arg1	roots					1029:1033	numerous fibrous roots	1012:1033	numerous fibrous roots	1012:1033	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	8	76	theme	AM	1885:1886	arg1	colonization					1888:1899	AM colonization	1885:1899	AM colonization	1885:1899	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	4	77	theme	strong	833:838	arg1	relationship					850:861	a strong symbiotic relationship	831:861	a strong symbiotic relationship to AM fungi	831:873	Results showed K. virginica formed a strong symbiotic relationship to AM fungi.
32555531	2	78	theme	areas	653:657	arg1	soil					630:633	halophyte Kosteletzkya virginica rhizosphere soil	585:633	halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China	585:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	1	79	theme	coastal	294:300	arg1	wetlands					302:309	coastal wetlands	294:309	coastal wetlands	294:309	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	5	80	theme	fibrous	1021:1027	arg1	roots					1029:1033	numerous fibrous roots	1012:1033	numerous fibrous roots	1012:1033	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	2	81	theme	coastal	638:644	arg1	areas					653:657	coastal saline areas	638:657	coastal saline areas of North Jiangsu, China	638:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	9	82	theme	saline	1958:1963	arg1	pool					1972:1975	saline soil C pool	1958:1975	saline soil C pool	1958:1975	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	1	83	theme	comprehensive	116:128	arg1	crucial					254:260	crucial	254:260	crucial	254:260	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	83	theme	comprehensive	116:128	arg1	understanding					130:142	A comprehensive understanding	114:142	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC)	114:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	4	84	theme	K.	811:812	arg1	virginica					814:822	K. virginica	811:822	K. virginica	811:822	Results showed K. virginica formed a strong symbiotic relationship to AM fungi.
32555531	9	85	theme	C	1970:1970	arg1	pool					1972:1975	saline soil C pool	1958:1975	saline soil C pool	1958:1975	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	0	86	theme	carbon	74:79	arg1	dynamics					16:23	Spatio-temporal dynamics	0:23	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.	0:112	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	5	87	theme	Jinhai	957:962	arg1	farm					964:967	Jinhai farm	957:967	Jinhai farm in August 2012	957:982	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	7	88	theme	AM	1213:1214	arg1	colonization					1216:1227	AM colonization	1213:1227	AM colonization	1213:1227	Correlation coefficient analysis revealed that AM colonization and spore density were positively correlated with total GRSP.
32555531	0	89	theme	coastal	84:90	arg1	soil					99:102	coastal saline soil	84:102	coastal saline soil of China	84:111	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	8	90	theme	large	1589:1593	arg1	macroaggregates					1595:1609	large macroaggregates	1589:1609	large macroaggregates	1589:1609	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	1	91	theme	relationship	151:162	arg1	crucial					254:260	crucial	254:260	crucial	254:260	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	91	theme	relationship	151:162	arg1	understanding					130:142	A comprehensive understanding	114:142	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC)	114:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	0	92	from	dynamics	16:23	arg1	soil					99:102	coastal saline soil	84:102	coastal saline soil of China	84:111	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	2	93	theme	halophyte	585:593	arg1	soil					630:633	halophyte Kosteletzkya virginica rhizosphere soil	585:633	halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China	585:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	3	94	theme	plantation	747:756	arg1	regions					758:764	two plantation regions	743:764	two plantation regions from August 2012 to May 2013	743:793	Soil samples were collected from a depth of up to 30 cm in two plantation regions from August 2012 to May 2013.
32555531	5	95	from	August	972:977	arg1	layer					948:952	the 10-20 cm soil layer	930:952	the 10-20 cm soil layer of Jinhai farm in August 2012	930:982	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	1	96	theme	carbon	319:324	arg1	sequestration					326:338	soil carbon sequestration	314:338	soil carbon sequestration	314:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	3	97	theme	May	786:788	arg1	2013					790:793	May 2013	786:793	May 2013	786:793	Soil samples were collected from a depth of up to 30 cm in two plantation regions from August 2012 to May 2013.
32555531	0	98	theme	China	107:111	arg1	soil					99:102	coastal saline soil	84:102	coastal saline soil of China	84:111	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	9	99	theme	important	1984:1992	arg1	indicator					2005:2013	an important biological indicator	1981:2013	an important biological indicator for evaluating coastal saline SOC pool and soil fertility	1981:2071	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	4	100	theme	AM	866:867	arg1	fungi					869:873	AM fungi	866:873	AM fungi	866:873	Results showed K. virginica formed a strong symbiotic relationship to AM fungi.
32555531	5	101	from	farm	964:967	arg1	August					972:977	August	972:977	August	972:977	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	7	102	theme	Correlation	1166:1176	arg1	analysis					1190:1197	Correlation coefficient analysis	1166:1197	Correlation coefficient analysis	1166:1197	Correlation coefficient analysis revealed that AM colonization and spore density were positively correlated with total GRSP.
32555531	2	103	theme	fungi	404:408	arg1	product					518:524	the putative gene product	500:524	the putative gene product of AM fungi, SOC, and soil aggregates	500:562	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	103	theme	fungi	404:408	arg1	dynamics					389:396	the temporal and spatial dynamics	364:396	the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	364:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	8	104	theme	Olsen	1403:1407	arg1	P					1409:1409	Olsen P	1403:1409	Olsen P	1403:1409	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	105	theme	virginica	608:616	arg1	soil					630:633	halophyte Kosteletzkya virginica rhizosphere soil	585:633	halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China	585:681	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	106	theme	field	346:350	arg1	experiment					352:361	a field experiment	344:361	a field experiment	344:361	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	0	107	theme	arbuscular	28:37	arg1	fungi					51:55	arbuscular mycorrhizal fungi	28:55	arbuscular mycorrhizal fungi	28:55	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	8	108	theme	soil	1865:1868	arg1	aggregates					1870:1879	soil aggregates	1865:1879	soil aggregates	1865:1879	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	109	theme	spatial	381:387	arg1	dynamics					389:396	the temporal and spatial dynamics	364:396	the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	364:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	0	110	theme	fungi	51:55	arg1	dynamics					16:23	Spatio-temporal dynamics	0:23	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.	0:112	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	8	111	theme	soil	1416:1419	arg1	SMBC					1447:1450	SMBC	1447:1450	SMBC	1447:1450	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	111	theme	soil	1416:1419	arg1	carbon					1439:1444	soil microbial biomass carbon	1416:1444	soil microbial biomass carbon (SMBC)	1416:1451	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	2	112	theme	temporal	368:375	arg1	dynamics					389:396	the temporal and spatial dynamics	364:396	the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	364:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	0	113	theme	soil	61:64	arg1	carbon					74:79	soil organic carbon	61:79	soil organic carbon	61:79	Spatio-temporal dynamics of arbuscular mycorrhizal fungi and soil organic carbon in coastal saline soil of China.
32555531	1	114	theme	function	282:289	arg1	analysis					266:273	analysis	266:273	analysis of the function of coastal wetlands in soil carbon sequestration	266:338	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	2	115	theme	glomalin-related	411:426	arg1	fungi					404:408	AM fungi	401:408	AM fungi	401:408	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	115	theme	glomalin-related	411:426	arg1	GRSP					442:445	GRSP	442:445	GRSP	442:445	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	115	theme	glomalin-related	411:426	arg1	protein					433:439	glomalin-related soil protein	411:439	glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein	411:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	2	115	theme	glomalin-related	411:426	arg1	glycoprotein					483:494	a N-linked glycoprotein	472:494	a N-linked glycoprotein	472:494	In a field experiment, the temporal and spatial dynamics of AM fungi, glomalin-related soil protein (GRSP) - which is described as a N-linked glycoprotein and the putative gene product of AM fungi, SOC, and soil aggregates were investigated in halophyte Kosteletzkya virginica rhizosphere soil of coastal saline areas of North Jiangsu, China.
32555531	8	116	theme	biomass	1431:1437	arg1	SMBC					1447:1450	SMBC	1447:1450	SMBC	1447:1450	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	8	116	theme	biomass	1431:1437	arg1	carbon					1439:1444	soil microbial biomass carbon	1416:1444	soil microbial biomass carbon (SMBC)	1416:1451	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	5	117	theme	soil	1043:1046	arg1	layer					1048:1052	this soil layer	1038:1052	this soil layer	1038:1052	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	118	theme	spore	896:900	arg1	colonization					879:890	AM colonization	876:890	AM colonization	876:890	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	118	theme	spore	896:900	arg1	density					902:908	spore density	896:908	spore density	896:908	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	5	118	theme	spore	896:900	arg1	highest					919:925	highest	919:925	highest	919:925	AM colonization and spore density were the highest in the 10-20 cm soil layer of Jinhai farm in August 2012, because of the presence of numerous fibrous roots in this soil layer.
32555531	8	119	theme	spore	1904:1908	arg1	density					1910:1916	spore density	1904:1916	spore density	1904:1916	Meanwhile, total GRSP was significantly positively correlated with large macroaggregates (>3 mm), SOC, total P, Olsen P, and soil microbial biomass carbon (SMBC), but negatively correlated with microaggregates (<0.25 mm), soil EC, total N, and pH. SOC was positively correlated with spore density, large macroaggregates, small macroaggregates (2-0.25 mm), alkaline N, and SMBC and negatively correlated with microaggregates, EC, pH, and total K. Although it may be a statistical artifact, we found an interesting phenomenon that there was no significant correlation between soil aggregates and AM colonization or spore density.
32555531	9	120	theme	AM	2080:2081	arg1	colonization					2083:2094	AM colonization	2080:2094	AM colonization	2080:2094	Hence, total GRSP is a vital source of saline soil C pool and an important biological indicator for evaluating coastal saline SOC pool and soil fertility, while AM colonization or spore density may not be.
32555531	1	121	theme	soil	225:228	arg1	SOC					246:248	SOC	246:248	SOC	246:248	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	121	theme	soil	225:228	arg1	carbon					238:243	coastal saline soil organic carbon	210:243	coastal saline soil organic carbon (SOC)	210:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	122	theme	carbon	238:243	arg1	crucial					254:260	crucial	254:260	crucial	254:260	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
32555531	1	122	theme	carbon	238:243	arg1	understanding					130:142	A comprehensive understanding	114:142	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC)	114:249	A comprehensive understanding of the relationship between arbuscular mycorrhizal (AM) fungi and coastal saline soil organic carbon (SOC) is crucial for analysis of the function of coastal wetlands in soil carbon sequestration.
31644407	10	0	theme	expected	1455:1462	arg1	values					1483:1488	expected genotype frequency values	1455:1488	expected genotype frequency values	1455:1488	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	3	1	theme	accurate	534:541	arg1	connection					553:562	the accurate causative connection	530:562	the accurate causative connection between glycosylation and disease	530:596	However, relatively little is known about regulatory factors of this procedure and about the accurate causative connection between glycosylation and disease.
31644407	1	2	theme	specific	249:256	arg1	manner					258:263	a specific manner	247:263	a specific manner	247:263	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	4	3	theme	study	632:636	arg1	aim					613:615	The aim	609:615	The aim of the present study	609:636	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	13	4	theme	N-linked	2034:2041	arg1	oligosaccharides					2043:2058	biantennary N-linked oligosaccharides	2022:2058	biantennary N-linked oligosaccharides	2022:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	2	5	theme	variable	279:286	arg1	modifications					321:333	These highly variable and versatile post-translational modifications	266:333	These highly variable and versatile post-translational modifications	266:333	These highly variable and versatile post-translational modifications finetune protein functions by influencing sorting, folding, enzyme activity and subcellular localization.
31644407	9	6	theme	OpenArray	1282:1290	arg1	approach					1292:1299	The TaqMan OpenArray approach	1271:1299	The TaqMan OpenArray approach	1271:1299	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	9	7	dep	%	1369:1369	arg1	%					1386:1386	99.6%	1382:1386	99.6%	1382:1386	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	1	8	gly	glycosylation	203:215	arg1	proteins					235:242	plasma proteins	228:242	plasma proteins	228:242	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	10	9	theme	frequency	1473:1481	arg1	values					1483:1488	expected genotype frequency values	1455:1488	expected genotype frequency values	1455:1488	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	4	10	from	polymorphisms	691:703	arg1	genes					715:719	genes	715:719	genes encoding glycosyltransferases and glycosidases	715:766	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	11	11	from	UTR	1688:1690	arg1	localized					1668:1676	localized	1668:1676	localized	1668:1676	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	4	12	theme	single	673:678	arg1	SNPs					706:709	SNPs	706:709	SNPs	706:709	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	4	12	theme	single	673:678	arg1	polymorphisms					691:703	certain single nucleotide polymorphisms	665:703	certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases	665:766	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	2	13	theme	versatile	292:300	arg1	modifications					321:333	These highly variable and versatile post-translational modifications	266:333	These highly variable and versatile post-translational modifications	266:333	These highly variable and versatile post-translational modifications finetune protein functions by influencing sorting, folding, enzyme activity and subcellular localization.
31644407	6	14	theme	putative	1017:1024	arg1	functions					1037:1045	putative biological functions	1017:1045	putative biological functions (missense or regulatory variants)	1017:1079	Polymorphisms with putative biological functions (missense or regulatory variants) were recruited.
31644407	7	15	theme	TaqMan	1122:1127	arg1	platform					1139:1146	a TaqMan OpenArray platform	1120:1146	a TaqMan OpenArray platform	1120:1146	SNPs were genotyped by a TaqMan OpenArray platform.
31644407	9	16	theme	genotype	1332:1339	arg1	data					1341:1344	accurate and reliable genotype data	1310:1344	accurate and reliable genotype data	1310:1344	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	1	17	theme	human	120:124	arg1	diseases					139:146	human inflammatory diseases	120:146	human inflammatory diseases	120:146	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	13	18	theme	beta	1974:1977	arg1	linkage					1983:1989	beta 1-6 linkage	1974:1989	beta 1-6 linkage	1974:1989	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	9	19	theme	call	1354:1357	arg1	%					1369:1369	global call rate: 94.9%	1347:1369	global call rate: 94.9%	1347:1369	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	9	19	theme	call	1354:1357	arg1	accuracy					1372:1379	accuracy	1372:1379	accuracy	1372:1379	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	5	20	theme	association	976:986	arg1	analysis					988:995	the association analysis	972:995	the association analysis	972:995	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	6	21	dep	functions	1037:1045	arg1	missense					1048:1055	missense	1048:1055	missense	1048:1055	Polymorphisms with putative biological functions (missense or regulatory variants) were recruited.
31644407	6	21	dep	functions	1037:1045	arg1	variants					1071:1078	regulatory variants	1060:1078	regulatory variants	1060:1078	Polymorphisms with putative biological functions (missense or regulatory variants) were recruited.
31644407	1	22	from	alterations	184:194	arg1	pattern					217:223	the glycosylation pattern	199:223	the glycosylation pattern of plasma proteins	199:242	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	1	23	theme	tumors	152:157	arg1	number					110:115	A number	108:115	A number of human inflammatory diseases and tumors	108:157	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	9	24	dep	provided	1301:1308	arg1	%					1369:1369	global call rate: 94.9%	1347:1369	global call rate: 94.9%	1347:1369	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	9	24	dep	provided	1301:1308	arg1	accuracy					1372:1379	accuracy	1372:1379	accuracy	1372:1379	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	0	25	theme	Lung	84:87	arg1	Cancer					89:94	Lung Cancer	84:94	Lung Cancer	84:94	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	6	26	theme	regulatory	1060:1069	arg1	variants					1071:1078	regulatory variants	1060:1078	regulatory variants	1060:1078	Polymorphisms with putative biological functions (missense or regulatory variants) were recruited.
31644407	4	27	theme	obstructive	819:829	arg1	COPD					850:853	COPD	850:853	COPD	850:853	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	4	27	theme	obstructive	819:829	arg1	disease					841:847	chronic obstructive pulmonary disease	811:847	chronic obstructive pulmonary disease (COPD)	811:854	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	1	28	theme	diseases	139:146	arg1	number					110:115	A number	108:115	A number of human inflammatory diseases and tumors	108:157	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	10	29	theme	sample	1542:1547	arg1	group					1549:1553	the healthy control sample group	1522:1553	the healthy control sample group	1522:1553	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	2	30	theme	subcellular	415:425	arg1	localization					427:438	subcellular localization	415:438	subcellular localization	415:438	These highly variable and versatile post-translational modifications finetune protein functions by influencing sorting, folding, enzyme activity and subcellular localization.
31644407	4	31	dep	OBJECTIVE	599:607	arg1	was					638:640	was	638:640	was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma	638:878	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	10	32	theme	healthy	1526:1532	arg1	group					1549:1553	the healthy control sample group	1522:1553	the healthy control sample group	1522:1553	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	4	33	theme	elevated	793:800	arg1	risk					802:805	elevated risk	793:805	elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma	793:878	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	13	34	theme	alpha-linked	1998:2009	arg1	mannose					2011:2017	the alpha-linked mannose	1994:2017	the alpha-linked mannose of biantennary N-linked oligosaccharides	1994:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	0	35	theme	High	0:3	arg1	SNP-analysis					26:37	High Throughput Multiplex SNP-analysis	0:37	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer	0:94	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	13	36	theme	oligosaccharides	2043:2058	arg1	mannose					2011:2017	the alpha-linked mannose	1994:2017	the alpha-linked mannose of biantennary N-linked oligosaccharides	1994:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	0	37	theme	Multiplex	16:24	arg1	SNP-analysis					26:37	High Throughput Multiplex SNP-analysis	0:37	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer	0:94	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	8	38	theme	single	1151:1156	arg1	method					1179:1184	A single base extension-based method	1149:1184	A single base extension-based method in combination with capillary gel electrophoresis	1149:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	10	39	theme	reliable	1585:1592	arg1	sampling					1594:1601	reliable sampling	1585:1601	reliable sampling	1585:1601	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	5	40	dep	SNPs	903:906	arg1	localized					908:916	localized	908:916	localized	908:916	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	0	41	theme	Obstructive	50:60	arg1	Disease					72:78	Chronic Obstructive Pulmonary Disease	42:78	Chronic Obstructive Pulmonary Disease	42:78	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	8	42	theme	extension-based	1163:1177	arg1	method					1179:1184	A single base extension-based method	1149:1184	A single base extension-based method in combination with capillary gel electrophoresis	1149:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	11	43	theme	polymorphism	1655:1666	arg1	frequencies					1626:1636	Allele frequencies	1619:1636	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene	1619:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	13	44	link	alpha-linked	1998:2009	arg1	mannose					2011:2017	the alpha-linked mannose	1994:2017	the alpha-linked mannose of biantennary N-linked oligosaccharides	1994:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	11	45	theme	localized	1668:1676	arg1	polymorphism					1655:1666	the rs3944508 polymorphism	1641:1666	the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene	1641:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	12	46	theme	lung	1852:1855	arg1	cancer					1857:1862	lung cancer	1852:1862	lung cancer	1852:1862	CONCLUSION Our results suggest that the rs34944508 SNP might modulate the risk for lung cancer by influencing the expression of MGAT5.
31644407	3	47	theme	causative	543:551	arg1	connection					553:562	the accurate causative connection	530:562	the accurate causative connection between glycosylation and disease	530:596	However, relatively little is known about regulatory factors of this procedure and about the accurate causative connection between glycosylation and disease.
31644407	1	48	theme	proteins	235:242	arg1	pattern					217:223	the glycosylation pattern	199:223	the glycosylation pattern of plasma proteins	199:242	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	12	49	dep	CONCLUSION	1769:1778	arg1	suggest					1792:1798	suggest	1792:1798	suggest that the rs34944508 SNP might modulate the risk for lung cancer by influencing the expression of MGAT5	1792:1901	CONCLUSION Our results suggest that the rs34944508 SNP might modulate the risk for lung cancer by influencing the expression of MGAT5.
31644407	8	50	with	combination	1189:1199	arg1	electrophoresis					1220:1234	capillary gel electrophoresis	1206:1234	capillary gel electrophoresis	1206:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	11	51	theme	gene	1705:1708	arg1	UTR					1688:1690	the 3' UTR	1681:1690	the 3' UTR of the MGAT5 gene	1681:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	13	52	link	N-linked	2034:2041	arg1	oligosaccharides					2043:2058	biantennary N-linked oligosaccharides	2022:2058	biantennary N-linked oligosaccharides	2022:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	8	53	theme	gel	1216:1218	arg1	electrophoresis					1220:1234	capillary gel electrophoresis	1206:1234	capillary gel electrophoresis	1206:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	5	54	dep	METHODS	881:887	arg1	total					891:895	A total	889:895	METHODS A total of 32 SNPs localized in genes related to N-glycosylation	881:952	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	13	55	theme	biantennary	2022:2032	arg1	oligosaccharides					2043:2058	biantennary N-linked oligosaccharides	2022:2058	biantennary N-linked oligosaccharides	2022:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	4	56	theme	present	624:630	arg1	study					632:636	the present study	620:636	the present study	620:636	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	9	57	theme	TaqMan	1275:1280	arg1	approach					1292:1299	The TaqMan OpenArray approach	1271:1299	The TaqMan OpenArray approach	1271:1299	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	5	58	theme	SNPs	903:906	arg1	total					891:895	A total	889:895	METHODS A total of 32 SNPs localized in genes related to N-glycosylation	881:952	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	12	59	theme	MGAT5	1897:1901	arg1	expression					1883:1892	the expression	1879:1892	the expression of MGAT5	1879:1901	CONCLUSION Our results suggest that the rs34944508 SNP might modulate the risk for lung cancer by influencing the expression of MGAT5.
31644407	8	60	used	used	1240:1243	arg2	method					1179:1184	A single base extension-based method	1149:1184	A single base extension-based method in combination with capillary gel electrophoresis	1149:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	11	61	theme	Allele	1619:1624	arg1	frequencies					1626:1636	Allele frequencies	1619:1636	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene	1619:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	7	62	theme	OpenArray	1129:1137	arg1	platform					1139:1146	a TaqMan OpenArray platform	1120:1146	a TaqMan OpenArray platform	1120:1146	SNPs were genotyped by a TaqMan OpenArray platform.
31644407	10	63	theme	genotype	1464:1471	arg1	values					1483:1488	expected genotype frequency values	1455:1488	expected genotype frequency values	1455:1488	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	2	64	theme	post-translational	302:319	arg1	modifications					321:333	These highly variable and versatile post-translational modifications	266:333	These highly variable and versatile post-translational modifications	266:333	These highly variable and versatile post-translational modifications finetune protein functions by influencing sorting, folding, enzyme activity and subcellular localization.
31644407	6	65	theme	biological	1026:1035	arg1	functions					1037:1045	putative biological functions	1017:1045	putative biological functions (missense or regulatory variants)	1017:1079	Polymorphisms with putative biological functions (missense or regulatory variants) were recruited.
31644407	6	66	with	Polymorphisms	998:1010	arg1	functions					1037:1045	putative biological functions	1017:1045	putative biological functions (missense or regulatory variants)	1017:1079	Polymorphisms with putative biological functions (missense or regulatory variants) were recruited.
31644407	4	67	theme	certain	665:671	arg1	SNPs					706:709	SNPs	706:709	SNPs	706:709	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	4	67	theme	certain	665:671	arg1	polymorphisms					691:703	certain single nucleotide polymorphisms	665:703	certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases	665:766	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	9	68	theme	reliable	1323:1330	arg1	data					1341:1344	accurate and reliable genotype data	1310:1344	accurate and reliable genotype data	1310:1344	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	1	69	theme	glycosylation	203:215	arg1	pattern					217:223	the glycosylation pattern	199:223	the glycosylation pattern of plasma proteins	199:242	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	4	70	theme	nucleotide	680:689	arg1	SNPs					706:709	SNPs	706:709	SNPs	706:709	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	4	70	theme	nucleotide	680:689	arg1	polymorphisms					691:703	certain single nucleotide polymorphisms	665:703	certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases	665:766	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	9	71	theme	accurate	1310:1317	arg1	data					1341:1344	accurate and reliable genotype data	1310:1344	accurate and reliable genotype data	1310:1344	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	9	72	theme	global	1347:1352	arg1	%					1369:1369	global call rate: 94.9%	1347:1369	global call rate: 94.9%	1347:1369	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	9	72	theme	global	1347:1352	arg1	accuracy					1372:1379	accuracy	1372:1379	accuracy	1372:1379	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	1	73	theme	inflammatory	126:137	arg1	diseases					139:146	human inflammatory diseases	120:146	human inflammatory diseases	120:146	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	13	74	theme	1-6	1979:1981	arg1	linkage					1983:1989	beta 1-6 linkage	1974:1989	beta 1-6 linkage	1974:1989	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	9	75	theme	rate	1359:1362	arg1	%					1369:1369	global call rate: 94.9%	1347:1369	global call rate: 94.9%	1347:1369	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	9	75	theme	rate	1359:1362	arg1	accuracy					1372:1379	accuracy	1372:1379	accuracy	1372:1379	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	5	76	from	genes	921:925	arg1	localized					908:916	localized	908:916	localized	908:916	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	5	77	theme	related	927:933	arg1	genes					921:925	genes	921:925	genes related to N-glycosylation	921:952	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	9	78	dep	RESULTS	1263:1269	arg1	provided					1301:1308	provided	1301:1308	provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%)	1301:1387	RESULTS The TaqMan OpenArray approach provided accurate and reliable genotype data (global call rate: 94.9%, accuracy: 99.6%).
31644407	0	79	from	SNP-analysis	26:37	arg1	Disease					72:78	Chronic Obstructive Pulmonary Disease	42:78	Chronic Obstructive Pulmonary Disease	42:78	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	0	79	from	SNP-analysis	26:37	arg1	Cancer					89:94	Lung Cancer	84:94	Lung Cancer	84:94	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	13	80	theme	N-acetylglucosamine	1942:1960	arg1	addition					1930:1937	the addition	1926:1937	the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides	1926:2058	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	5	81	from	localized	908:916	arg1	genes					921:925	genes	921:925	genes related to N-glycosylation	921:952	METHODS A total of 32 SNPs localized in genes related to N-glycosylation were selected for the association analysis.
31644407	1	82	dep	BACKGROUND	97:106	arg1	shown					169:173	shown	169:173	have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner	159:263	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	8	83	from	method	1179:1184	arg1	combination					1189:1199	combination	1189:1199	combination with capillary gel electrophoresis	1189:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	10	84	theme	Hardy-Weinberg	1491:1504	arg1	the					1438:1440	the	1438:1440	the	1438:1440	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	10	84	theme	Hardy-Weinberg	1491:1504	arg1	equilibrium					1506:1516	Hardy-Weinberg equilibrium	1491:1516	Hardy-Weinberg equilibrium	1491:1516	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	4	85	theme	chronic	811:817	arg1	COPD					850:853	COPD	850:853	COPD	850:853	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	4	85	theme	chronic	811:817	arg1	disease					841:847	chronic obstructive pulmonary disease	811:847	chronic obstructive pulmonary disease (COPD)	811:854	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	3	86	theme	procedure	510:518	arg1	factors					494:500	regulatory factors	483:500	regulatory factors of this procedure	483:518	However, relatively little is known about regulatory factors of this procedure and about the accurate causative connection between glycosylation and disease.
31644407	10	87	theme	control	1534:1540	arg1	group					1549:1553	the healthy control sample group	1522:1553	the healthy control sample group	1522:1553	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	4	88	theme	pulmonary	831:839	arg1	COPD					850:853	COPD	850:853	COPD	850:853	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	4	88	theme	pulmonary	831:839	arg1	disease					841:847	chronic obstructive pulmonary disease	811:847	chronic obstructive pulmonary disease (COPD)	811:854	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	0	89	theme	Throughput	5:14	arg1	SNP-analysis					26:37	High Throughput Multiplex SNP-analysis	0:37	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer	0:94	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	13	90	theme	malignancies	2127:2138	arg1	characteristic					2100:2113	the characteristic	2096:2113	the characteristic of invasive malignancies	2096:2138	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	13	90	theme	malignancies	2127:2138	arg1	branching					2078:2086	branching	2078:2086	branching that is the characteristic of invasive malignancies	2078:2138	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	10	91	located	detected	1421:1428	arg1	group					1549:1553	the healthy control sample group	1522:1553	the healthy control sample group	1522:1553	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	10	91	located	detected	1421:1428	arg2	discrepancy					1405:1415	No significant discrepancy	1390:1415	No significant discrepancy	1390:1415	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	2	92	theme	enzyme	395:400	arg1	activity					402:409	enzyme activity	395:409	enzyme activity	395:409	These highly variable and versatile post-translational modifications finetune protein functions by influencing sorting, folding, enzyme activity and subcellular localization.
31644407	0	93	theme	Chronic	42:48	arg1	Disease					72:78	Chronic Obstructive Pulmonary Disease	42:78	Chronic Obstructive Pulmonary Disease	42:78	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	8	94	theme	base	1158:1161	arg1	method					1179:1184	A single base extension-based method	1149:1184	A single base extension-based method in combination with capillary gel electrophoresis	1149:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	11	95	from	localized	1668:1676	arg1	UTR					1688:1690	the 3' UTR	1681:1690	the 3' UTR of the MGAT5 gene	1681:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	11	96	theme	sample	1745:1750	arg1	groups					1752:1757	the sample groups	1741:1757	the sample groups compared	1741:1766	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	4	97	theme	lung	860:863	arg1	adenocarcinoma					865:878	lung adenocarcinoma	860:878	lung adenocarcinoma	860:878	OBJECTIVE The aim of the present study was to investigate whether certain single nucleotide polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma.
31644407	10	98	theme	significant	1393:1403	arg1	discrepancy					1405:1415	No significant discrepancy	1390:1415	No significant discrepancy	1390:1415	No significant discrepancy was detected between the obtained and expected genotype frequency values (Hardy-Weinberg equilibrium) in the healthy control sample group in case of any SNP confirming reliable sampling and genotyping.
31644407	3	99	theme	regulatory	483:492	arg1	factors					494:500	regulatory factors	483:500	regulatory factors of this procedure	483:518	However, relatively little is known about regulatory factors of this procedure and about the accurate causative connection between glycosylation and disease.
31644407	0	100	theme	Pulmonary	62:70	arg1	Disease					72:78	Chronic Obstructive Pulmonary Disease	42:78	Chronic Obstructive Pulmonary Disease	42:78	High Throughput Multiplex SNP-analysis in Chronic Obstructive Pulmonary Disease and Lung Cancer.
31644407	13	101	theme	invasive	2118:2125	arg1	malignancies					2127:2138	invasive malignancies	2118:2138	invasive malignancies	2118:2138	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	11	102	theme	rs3944508	1645:1653	arg1	polymorphism					1655:1666	the rs3944508 polymorphism	1641:1666	the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene	1641:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
31644407	13	103	from	addition	1930:1937	arg1	linkage					1983:1989	beta 1-6 linkage	1974:1989	beta 1-6 linkage	1974:1989	This enzyme catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides, thus, increasing branching that is the characteristic of invasive malignancies.
31644407	2	104	theme	protein	344:350	arg1	functions					352:360	protein functions	344:360	protein functions	344:360	These highly variable and versatile post-translational modifications finetune protein functions by influencing sorting, folding, enzyme activity and subcellular localization.
31644407	1	105	theme	plasma	228:233	arg1	proteins					235:242	plasma proteins	228:242	plasma proteins	228:242	BACKGROUND A number of human inflammatory diseases and tumors have been shown to cause alterations in the glycosylation pattern of plasma proteins in a specific manner.
31644407	8	106	theme	capillary	1206:1214	arg1	electrophoresis					1220:1234	capillary gel electrophoresis	1206:1234	capillary gel electrophoresis	1206:1234	A single base extension-based method in combination with capillary gel electrophoresis was used for verification.
31644407	11	107	theme	MGAT5	1699:1703	arg1	gene					1705:1708	the MGAT5 gene	1695:1708	the MGAT5 gene	1695:1708	Allele frequencies of the rs3944508 polymorphism localized in the 3' UTR of the MGAT5 gene significantly differed between the sample groups compared.
34695439	9	0	from	effect	1374:1379	arg1	context					1426:1432	the context	1422:1432	the context of AMD	1422:1439	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	4	1	theme	B3GLCT	615:620	arg1	role					607:610	the role	603:610	the role of B3GLCT in AMD	603:627	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	2	2	theme	type	375:378	arg1	TSR					391:393	TSR	391:393	TSR	391:393	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	2	theme	type	375:378	arg1	repeats					382:388	thrombospondin type I repeats	360:388	thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	360:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	1	3	theme	B3GLCT	259:264	arg1	locus					267:271	the β1-3 glucosyltransferase (B3GLCT) locus	229:271	the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies	229:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	7	4	attach	present	1099:1105	arg2	C-mannosylation					1070:1084	C-mannosylation	1070:1084	C-mannosylation	1070:1084	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	7	4	attach	present	1099:1105	arg1	TSP1					1113:1116	WT TSP1	1110:1116	WT TSP1	1110:1116	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	4	5	theme	proteins	688:695	arg1	secretion					675:683	secretion	675:683	secretion	675:683	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	5	theme	proteins	688:695	arg1	glycosylation					657:669	glycosylation	657:669	glycosylation	657:669	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	6	gly	glycosylation	657:669	arg1	proteins					688:695	proteins	688:695	proteins from retinal pigment epithelium (RPE) cells	688:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	7	theme	retinal	702:708	arg1	RPE					730:732	RPE	730:732	RPE	730:732	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	7	theme	retinal	702:708	arg1	epithelium					718:727	retinal pigment epithelium	702:727	retinal pigment epithelium (RPE) cells	702:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	8	from	secretion	675:683	arg1	cells					735:739	retinal pigment epithelium (RPE) cells	702:739	retinal pigment epithelium (RPE) cells	702:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	6	9	theme	glucose-β1,3-fucose	972:990	arg1	product					992:998	the glucose-β1,3-fucose product	968:998	the glucose-β1,3-fucose product of B3GLCT	968:1008	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	9	10	from	context	1426:1432	arg1	effect					1374:1379	the effect	1370:1379	the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins	1370:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	0	11	theme	epithelial	116:125	arg1	cells					127:131	retinal pigment epithelial cells	100:131	retinal pigment epithelial cells	100:131	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	4	12	from	glycosylation	657:669	arg1	cells					735:739	retinal pigment epithelium (RPE) cells	702:739	retinal pigment epithelium (RPE) cells	702:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	1	13	theme	protective	198:207	arg1	variants					217:224	protective genetic variants	198:224	protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies	198:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	6	14	attach	presence	956:963	arg2	product					992:998	the glucose-β1,3-fucose product	968:998	the glucose-β1,3-fucose product of B3GLCT	968:1008	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	14	attach	presence	956:963	arg1	TSP1					1013:1016	TSP1	1013:1016	TSP1 in wildtype (WT) cells	1013:1039	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	14	attach	presence	956:963	arg1	cells					1063:1067	KO cells	1060:1067	KO cells	1060:1067	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	5	15	theme	thrombospondin	830:843	arg1	glycosylation					799:811	glycosylation	799:811	glycosylation	799:811	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	5	15	theme	thrombospondin	830:843	arg1	secretion					817:825	secretion	817:825	secretion	817:825	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	5	16	dep	knockout	762:769	arg1	KO					772:773	KO	772:773	KO	772:773	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	9	17	theme	AMD	1437:1439	arg1	context					1426:1432	the context	1422:1432	the context of AMD	1422:1439	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	3	18	theme	B3GLCT-mediated	481:495	arg1	modification					497:508	B3GLCT-mediated modification	481:508	B3GLCT-mediated modification	481:508	B3GLCT-mediated modification is required for proper secretion of TSR-containing proteins.
34695439	4	19	theme	epithelium	718:727	arg1	cells					735:739	retinal pigment epithelium (RPE) cells	702:739	retinal pigment epithelium (RPE) cells	702:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	7	20	dep	domains	1139:1145	arg1	1					1147:1147	1	1147:1147	1	1147:1147	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	7	20	dep	domains	1139:1145	arg1	3					1153:1153	3	1153:1153	3	1153:1153	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	8	21	theme	TNFα	1267:1270	arg1	treatment					1272:1280	TNFα treatment	1267:1280	TNFα treatment	1267:1280	Secretion of TSP1 was not affected by the absence of B3GLCT, even not when TSP1 was upregulated by TNFα treatment or when TSP1 was overexpressed in HEK293T cells.
34695439	5	22	theme	relevant	903:910	arg1	processes					886:894	cellular processes	877:894	cellular processes highly relevant to AMD	877:917	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	7	23	located	present	1099:1105	arg2	C-mannosylation					1070:1084	C-mannosylation	1070:1084	C-mannosylation	1070:1084	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	7	23	located	present	1099:1105	arg1	TSP1					1113:1116	WT TSP1	1110:1116	WT TSP1	1110:1116	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	1	24	theme	Age-related	134:144	arg1	degeneration					154:165	Age-related macular degeneration	134:165	Age-related macular degeneration (AMD)	134:171	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	1	24	theme	Age-related	134:144	arg1	AMD					168:170	AMD	168:170	AMD	168:170	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	7	25	theme	KO	1158:1159	arg1	cells					1161:1165	KO cells	1158:1165	KO cells	1158:1165	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	9	26	theme	TSP1	1481:1484	arg1	effects					1489:1495	effects	1489:1495	effects on other TSR proteins	1489:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	9	26	theme	TSP1	1481:1484	arg1	loss					1473:1476	functional loss	1462:1476	functional loss of TSP1	1462:1484	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	6	27	theme	KO	1060:1061	arg1	cells					1063:1067	KO cells	1060:1067	KO cells	1060:1067	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	2	28	theme	glycosylation	459:471	arg1	motifs					473:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	6	29	from	TSP1	1013:1016	arg1	cells					1035:1039	wildtype (WT) cells	1021:1039	wildtype (WT) cells	1021:1039	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	0	30	theme	TSP1	64:67	arg1	glycosylation					47:59	glycosylation	47:59	glycosylation of TSP1	47:67	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	2	31	theme	C-linked	442:449	arg1	mannose					451:457	C-linked mannose	442:457	C-linked mannose	442:457	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	8	32	theme	HEK293T	1316:1322	arg1	cells					1324:1328	HEK293T cells	1316:1328	HEK293T cells	1316:1328	Secretion of TSP1 was not affected by the absence of B3GLCT, even not when TSP1 was upregulated by TNFα treatment or when TSP1 was overexpressed in HEK293T cells.
34695439	2	33	theme	fucose	431:436	arg1	motifs					473:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	1	34	theme	association	293:303	arg1	studies					305:311	genome-wide association studies	281:311	genome-wide association studies	281:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	2	35	with	proteins	346:353	arg1	TSR					391:393	TSR	391:393	TSR	391:393	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	35	with	proteins	346:353	arg1	repeats					382:388	thrombospondin type I repeats	360:388	thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	360:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	9	36	theme	other	1500:1504	arg1	proteins					1510:1517	other TSR proteins	1500:1517	other TSR proteins	1500:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	1	37	theme	macular	146:152	arg1	degeneration					154:165	Age-related macular degeneration	134:165	Age-related macular degeneration (AMD)	134:171	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	1	37	theme	macular	146:152	arg1	AMD					168:170	AMD	168:170	AMD	168:170	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	2	38	theme	glucose	418:424	arg1	fucose					431:436	O-linked glucose β1-3 fucose	409:436	O-linked glucose β1-3 fucose	409:436	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	0	39	theme	B3GLCT	27:32	arg1	gene					34:37	the AMD-associated B3GLCT gene	8:37	the AMD-associated B3GLCT gene	8:37	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	7	40	theme	TSR	1135:1137	arg1	domains					1139:1145	TSR domains 1 and 3	1135:1153	TSR domains 1 and 3	1135:1153	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	9	41	from	defects	1411:1417	arg1	context					1426:1432	the context	1422:1432	the context of AMD	1422:1439	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	2	42	theme	thrombospondin	360:373	arg1	type					375:378	thrombospondin type I	360:380	thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	360:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	6	43	from	presence	956:963	arg1	TSP1					1013:1016	TSP1	1013:1016	TSP1 in wildtype (WT) cells	1013:1039	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	43	from	presence	956:963	arg1	cells					1063:1067	KO cells	1060:1067	KO cells	1060:1067	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	2	44	link	O-linked	409:416	arg1	fucose					431:436	O-linked glucose β1-3 fucose	409:436	O-linked glucose β1-3 fucose	409:436	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	45	theme	proteins	346:353	arg1	modification					330:341	modification	330:341	modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	330:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	46	gly	glycosylation	459:471	arg2	motifs					473:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	47	theme	O-linked	409:416	arg1	fucose					431:436	O-linked glucose β1-3 fucose	409:436	O-linked glucose β1-3 fucose	409:436	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	3	48	theme	TSR-containing	546:559	arg1	proteins					561:568	TSR-containing proteins	546:568	TSR-containing proteins	546:568	B3GLCT-mediated modification is required for proper secretion of TSR-containing proteins.
34695439	9	49	theme	Future	1331:1336	arg1	research					1338:1345	Future research	1331:1345	Future research	1331:1345	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	6	50	theme	Glycopeptide	920:931	arg1	analysis					933:940	Glycopeptide analysis	920:940	Glycopeptide analysis	920:940	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	0	51	gly	glycosylation	47:59	arg1	TSP1					64:67	TSP1	64:67	TSP1	64:67	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	7	52	theme	WT	1110:1111	arg1	TSP1					1113:1116	WT TSP1	1110:1116	WT TSP1	1110:1116	C-mannosylation was variably present on WT TSP1 and increased on TSR domains 1 and 3 in KO cells.
34695439	6	53	from	absence	1049:1055	arg1	TSP1					1013:1016	TSP1	1013:1016	TSP1 in wildtype (WT) cells	1013:1039	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	53	from	absence	1049:1055	arg1	cells					1063:1067	KO cells	1060:1067	KO cells	1060:1067	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	54	theme	product	992:998	arg1	presence					956:963	the presence	952:963	the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells	952:1039	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	54	theme	product	992:998	arg1	absence					1049:1055	its absence	1045:1055	its absence in KO cells	1045:1067	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	9	55	theme	observed	1388:1395	arg1	defects					1411:1417	the observed glycosylation defects	1384:1417	the observed glycosylation defects	1384:1417	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	1	56	theme	genetic	209:215	arg1	variants					217:224	protective genetic variants	198:224	protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies	198:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	8	57	theme	B3GLCT	1221:1226	arg1	absence					1210:1216	the absence	1206:1216	the absence of B3GLCT	1206:1226	Secretion of TSP1 was not affected by the absence of B3GLCT, even not when TSP1 was upregulated by TNFα treatment or when TSP1 was overexpressed in HEK293T cells.
34695439	2	58	contain	contain	401:407	arg1	TSR					391:393	TSR	391:393	TSR	391:393	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	58	contain	contain	401:407	arg1	repeats					382:388	thrombospondin type I repeats	360:388	thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	360:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	2	58	contain	contain	401:407	arg2	motifs					473:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	1	59	from	variants	217:224	arg1	locus					267:271	the β1-3 glucosyltransferase (B3GLCT) locus	229:271	the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies	229:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	8	60	theme	TSP1	1181:1184	arg1	Secretion					1168:1176	Secretion	1168:1176	Secretion of TSP1	1168:1184	Secretion of TSP1 was not affected by the absence of B3GLCT, even not when TSP1 was upregulated by TNFα treatment or when TSP1 was overexpressed in HEK293T cells.
34695439	4	61	from	effect	647:652	arg1	secretion					675:683	secretion	675:683	secretion	675:683	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	61	from	effect	647:652	arg1	glycosylation					657:669	glycosylation	657:669	glycosylation	657:669	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	5	62	theme	cellular	877:884	arg1	processes					886:894	cellular processes	877:894	cellular processes highly relevant to AMD	877:917	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	9	63	from	effects	1489:1495	arg1	proteins					1510:1517	other TSR proteins	1500:1517	other TSR proteins	1500:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	6	64	theme	wildtype	1021:1028	arg1	cells					1035:1039	wildtype (WT) cells	1021:1039	wildtype (WT) cells	1021:1039	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	4	65	theme	pigment	710:716	arg1	RPE					730:732	RPE	730:732	RPE	730:732	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	65	theme	pigment	710:716	arg1	epithelium					718:727	retinal pigment epithelium	702:727	retinal pigment epithelium (RPE) cells	702:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	5	66	theme	RPE	776:778	arg1	cells					780:784	B3GLCT knockout (KO) RPE cells	755:784	B3GLCT knockout (KO) RPE cells	755:784	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	2	67	link	C-linked	442:449	arg1	mannose					451:457	C-linked mannose	442:457	C-linked mannose	442:457	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	9	68	theme	functional	1462:1471	arg1	loss					1473:1476	functional loss	1462:1476	functional loss of TSP1	1462:1484	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	9	69	from	loss	1473:1476	arg1	proteins					1510:1517	other TSR proteins	1500:1517	other TSR proteins	1500:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	6	70	theme	B3GLCT	1003:1008	arg1	product					992:998	the glucose-β1,3-fucose product	968:998	the glucose-β1,3-fucose product of B3GLCT	968:1008	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	6	71	dep	wildtype	1021:1028	arg1	WT					1031:1032	WT	1031:1032	WT	1031:1032	Glycopeptide analysis confirmed the presence of the glucose-β1,3-fucose product of B3GLCT on TSP1 in wildtype (WT) cells and its absence in KO cells.
34695439	0	72	theme	pigment	108:114	arg1	cells					127:131	retinal pigment epithelial cells	100:131	retinal pigment epithelial cells	100:131	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	9	73	theme	glycosylation	1397:1409	arg1	defects					1411:1417	the observed glycosylation defects	1384:1417	the observed glycosylation defects	1384:1417	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	5	74	theme	knockout	762:769	arg1	cells					780:784	B3GLCT knockout (KO) RPE cells	755:784	B3GLCT knockout (KO) RPE cells	755:784	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	4	75	from	role	607:610	arg1	AMD					625:627	AMD	625:627	AMD	625:627	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	2	76	theme	mannose	451:457	arg1	motifs					473:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs	409:478	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	0	77	theme	AMD-associated	12:25	arg1	gene					34:37	the AMD-associated B3GLCT gene	8:37	the AMD-associated B3GLCT gene	8:37	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	1	78	theme	genome-wide	281:291	arg1	studies					305:311	genome-wide association studies	281:311	genome-wide association studies	281:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	2	79	theme	β1-3	426:429	arg1	fucose					431:436	O-linked glucose β1-3 fucose	409:436	O-linked glucose β1-3 fucose	409:436	B3GLCT mediates modification of proteins with thrombospondin type I repeats (TSR) that contain O-linked glucose β1-3 fucose and C-linked mannose glycosylation motifs.
34695439	0	80	theme	gene	34:37	arg1	Loss					0:3	Loss	0:3	Loss of the AMD-associated B3GLCT gene	0:37	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	9	81	theme	defects	1411:1417	arg1	effect					1374:1379	the effect	1370:1379	the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins	1370:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	9	82	theme	TSR	1506:1508	arg1	proteins					1510:1517	other TSR proteins	1500:1517	other TSR proteins	1500:1517	Future research is needed to elucidate the effect of the observed glycosylation defects in the context of AMD, which might involve functional loss of TSP1 or effects on other TSR proteins.
34695439	1	83	theme	β1-3	233:236	arg1	locus					267:271	the β1-3 glucosyltransferase (B3GLCT) locus	229:271	the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies	229:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34695439	0	84	theme	retinal	100:106	arg1	cells					127:131	retinal pigment epithelial cells	100:131	retinal pigment epithelial cells	100:131	Loss of the AMD-associated B3GLCT gene affects glycosylation of TSP1 without impairing secretion in retinal pigment epithelial cells.
34695439	3	85	theme	proper	526:531	arg1	secretion					533:541	proper secretion	526:541	proper secretion of TSR-containing proteins	526:568	B3GLCT-mediated modification is required for proper secretion of TSR-containing proteins.
34695439	4	86	from	cells	735:739	arg1	proteins					688:695	proteins	688:695	proteins from retinal pigment epithelium (RPE) cells	688:739	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	86	from	cells	735:739	arg1	secretion					675:683	secretion	675:683	secretion	675:683	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	4	86	from	cells	735:739	arg1	glycosylation					657:669	glycosylation	657:669	glycosylation	657:669	We aimed to start understanding the role of B3GLCT in AMD by evaluating its effect on glycosylation and secretion of proteins from retinal pigment epithelium (RPE) cells.
34695439	5	87	gly	glycosylation	799:811	arg1	protein					857:863	a protein	855:863	a protein involved in cellular processes highly relevant to AMD	855:917	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	5	87	gly	glycosylation	799:811	arg1	thrombospondin					830:843	thrombospondin 1	830:845	thrombospondin 1 (TSP1)	830:852	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	5	87	gly	glycosylation	799:811	arg1	TSP1					848:851	TSP1	848:851	TSP1	848:851	We generated B3GLCT knockout (KO) RPE cells and analyzed glycosylation and secretion of thrombospondin 1 (TSP1), a protein involved in cellular processes highly relevant to AMD.
34695439	3	88	theme	proteins	561:568	arg1	secretion					533:541	proper secretion	526:541	proper secretion of TSR-containing proteins	526:568	B3GLCT-mediated modification is required for proper secretion of TSR-containing proteins.
34695439	1	89	theme	glucosyltransferase	238:256	arg1	locus					267:271	the β1-3 glucosyltransferase (B3GLCT) locus	229:271	the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies	229:311	Age-related macular degeneration (AMD) has been associated with protective genetic variants in the β1-3 glucosyltransferase (B3GLCT) locus through genome-wide association studies.
34325731	4	0	theme	lung	883:886	arg1	tissues					888:894	control lung tissues	875:894	control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq)	875:969	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	7	1	from	patients	1398:1405	arg1	different					1548:1556	different	1548:1556	different	1548:1556	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	0	2	theme	FOXF1	157:161	arg1	locus					163:167	the FOXF1 locus	153:167	the FOXF1 locus	153:167	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	3	3	theme	therapeutic	681:691	arg1	targets					693:699	potential therapeutic targets	671:699	potential therapeutic targets for ACD/MPV	671:711	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	13	4	theme	DNA	2241:2243	arg1	analyses					2257:2264	DNA methylation analyses	2241:2264	DNA methylation analyses of patients without a genomic FOXF1 variant	2241:2308	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	9	5	theme	hypermethylated	1722:1736	arg1	region					1738:1743	a large hypermethylated region	1714:1743	a large hypermethylated region overlapping the first FOXF1 exon	1714:1776	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	4	6	theme	methylation	851:861	arg1	patterns					863:870	methylation patterns	851:870	methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq)	851:969	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	7	7	theme	methylation	1481:1491	arg1	patterns					1493:1500	DNA methylation patterns	1477:1500	DNA methylation patterns in this FOXF1 enhancer	1477:1523	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	3	8	theme	FOXF1	526:530	arg1	haploinsufficiency					532:549	FOXF1 haploinsufficiency	526:549	FOXF1 haploinsufficiency	526:549	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	1	9	theme	Alveolar	181:188	arg1	dysplasia					200:208	BACKGROUND Alveolar capillary dysplasia	170:208	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV)	170:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	9	theme	Alveolar	181:188	arg1	disorder					300:307	a lethal congenital lung disorder	275:307	a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	275:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	9	10	theme	first	1761:1765	arg1	exon					1773:1776	the first FOXF1 exon	1757:1776	the first FOXF1 exon	1757:1776	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	6	11	theme	signalling	1286:1295	arg1	pathways					1297:1304	developmental signalling pathways	1272:1304	developmental signalling pathways	1272:1304	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	3	12	theme	ACD/MPV	568:574	arg1	haploinsufficiency					532:549	FOXF1 haploinsufficiency	526:549	FOXF1 haploinsufficiency	526:549	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	3	12	theme	ACD/MPV	568:574	arg1	cause					559:563	the cause	555:563	the cause of ACD/MPV in patients without a genomic FOXF1 variant	555:618	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	9	13	theme	large	1716:1720	arg1	region					1738:1743	a large hypermethylated region	1714:1743	a large hypermethylated region overlapping the first FOXF1 exon	1714:1776	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	4	14	theme	DNA	946:948	arg1	MeD-seq					962:968	MeD-seq	962:968	MeD-seq	962:968	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	4	14	theme	DNA	946:948	arg1	sequencing					950:959	DNA sequencing	946:959	DNA sequencing (MeD-seq)	946:969	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	7	15	theme	FOXF1	1461:1465	arg1	enhancer					1467:1474	the 60 kb FOXF1 enhancer	1451:1474	the 60 kb FOXF1 enhancer	1451:1474	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	6	16	theme	developmental	1272:1284	arg1	pathways					1297:1304	developmental signalling pathways	1272:1304	developmental signalling pathways	1272:1304	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	12	17	theme	FOXF1	2205:2209	arg1	region					2218:2223	the FOXF1 coding region	2201:2223	the FOXF1 coding region	2201:2223	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	1	18	from	alterations	359:369	arg1	gene					384:387	the FOXF1 gene	374:387	the FOXF1 gene	374:387	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	18	from	alterations	359:369	arg1	enhancer					402:409	its 60 kb enhancer	392:409	its 60 kb enhancer	392:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	13	19	theme	abnormal	2323:2330	arg1	hypermethylation					2332:2347	abnormal hypermethylation	2323:2347	abnormal hypermethylation of exon 1	2323:2357	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	11	20	theme	60 kb	2053:2057	arg1	enhancer					2065:2072	the 60 kb FOXF1 enhancer	2049:2072	the 60 kb FOXF1 enhancer	2049:2072	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	7	21	theme	large	1414:1418	arg1	deletion					1429:1436	a large maternal deletion	1412:1436	a large maternal deletion encompassing the 60 kb FOXF1 enhancer	1412:1474	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	12	22	theme	heterozygous	2175:2186	arg1	mutations					2188:2196	heterozygous mutations	2175:2196	heterozygous mutations in the FOXF1 coding region	2175:2223	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	3	23	from	cause	559:563	arg1	patients					579:586	patients	579:586	patients without a genomic FOXF1 variant	579:618	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	7	24	with	patients	1398:1405	arg1	deletion					1429:1436	a large maternal deletion	1412:1436	a large maternal deletion encompassing the 60 kb FOXF1 enhancer	1412:1474	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	11	25	theme	FOXF1	2059:2063	arg1	enhancer					2065:2072	the 60 kb FOXF1 enhancer	2049:2072	the 60 kb FOXF1 enhancer	2049:2072	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	9	26	located	found	1782:1786	arg1	patients					1810:1817	the ACD/MPV patients	1798:1817	the ACD/MPV patients without a known pathogenic FOXF1 variation	1798:1860	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	9	26	located	found	1782:1786	arg2	region					1738:1743	a large hypermethylated region	1714:1743	a large hypermethylated region overlapping the first FOXF1 exon	1714:1776	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	9	26	located	found	1782:1786	arg1	one					1791:1793	one	1791:1793	one	1791:1793	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	9	27	theme	patients	1810:1817	arg1	patients					1810:1817	the ACD/MPV patients	1798:1817	the ACD/MPV patients without a known pathogenic FOXF1 variation	1798:1860	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	9	27	theme	patients	1810:1817	arg1	one					1791:1793	one	1791:1793	one	1791:1793	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	6	28	theme	upregulated	1223:1233	arg1	genes					1235:1239	The potentially upregulated genes	1207:1239	The potentially upregulated genes	1207:1239	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	6	29	dep	enriched	1260:1267	arg1	whereas					1307:1313	whereas	1307:1313	whereas	1307:1313	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	0	30	theme	dysplasia	59:67	arg1	tissue					74:79	alveolar capillary dysplasia lung tissue	40:79	alveolar capillary dysplasia lung tissue	40:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	3	31	theme	FOXF1	606:610	arg1	variant					612:618	a genomic FOXF1 variant	596:618	a genomic FOXF1 variant	596:618	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	9	32	theme	ACD/MPV	1802:1808	arg1	patients					1810:1817	the ACD/MPV patients	1798:1817	the ACD/MPV patients without a known pathogenic FOXF1 variation	1798:1860	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	12	33	theme	FOXF1	2140:2144	arg1	haploinsufficiency					2146:2163	FOXF1 haploinsufficiency	2140:2163	FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region	2140:2223	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	0	34	theme	tissue	74:79	arg1	analysis					28:35	Genome wide DNA methylation analysis	0:35	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue	0:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	1	35	theme	heterozygous	338:349	arg1	alterations					359:369	heterozygous genomic alterations	338:369	heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	338:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	9	36	theme	pathogenic	1835:1844	arg1	FOXF1					1846:1850	a known pathogenic FOXF1	1827:1850	a known pathogenic FOXF1 variation	1827:1860	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	2	37	from	alteration	436:445	arg1	locus					460:464	the FOXF1 locus	450:464	the FOXF1 locus	450:464	Cases without a genomic alteration in the FOXF1 locus have been described as well.
34325731	0	38	theme	aberrant	89:96	arg1	methylation					98:108	aberrant methylation	89:108	aberrant methylation of genes involved in development including the FOXF1 locus	89:167	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	1	39	theme	alterations	359:369	arg1	variety					327:333	a variety	325:333	a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	325:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	39	theme	alterations	359:369	arg1	alterations					359:369	heterozygous genomic alterations	338:369	heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	338:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	5	40	theme	ACD/MPV	986:992	arg1	samples					1006:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	4	41	theme	wide	782:785	arg1	patterns					799:806	genome wide methylation patterns	775:806	genome wide methylation patterns of ACD/MPV lung tissues	775:830	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	11	42	theme	DNA	1973:1975	arg1	analyses					1989:1996	DNA methylation analyses	1973:1996	DNA methylation analyses in the FOXF1 locus	1973:2015	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	5	43	theme	regions	1143:1149	arg1	wide					1165:1168	319 differentially methylated regions (DMRs) genome wide	1113:1168	319 differentially methylated regions (DMRs) genome wide	1113:1168	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	5	44	theme	tissue	999:1004	arg1	samples					1006:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	0	45	theme	Genome	0:5	arg1	analysis					28:35	Genome wide DNA methylation analysis	0:35	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue	0:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	5	46	theme	coding	1193:1198	arg1	genes					1200:1204	115 protein coding genes	1181:1204	115 protein coding genes	1181:1204	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	2	47	theme	genomic	428:434	arg1	alteration					436:445	a genomic alteration	426:445	a genomic alteration in the FOXF1 locus	426:464	Cases without a genomic alteration in the FOXF1 locus have been described as well.
34325731	4	48	theme	DNA	758:760	arg1	methylation					762:772	aberrant DNA methylation	749:772	aberrant DNA methylation	749:772	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	0	49	theme	DNA	12:14	arg1	analysis					28:35	Genome wide DNA methylation analysis	0:35	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue	0:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	1	50	theme	congenital	284:293	arg1	dysplasia					200:208	BACKGROUND Alveolar capillary dysplasia	170:208	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV)	170:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	50	theme	congenital	284:293	arg1	disorder					300:307	a lethal congenital lung disorder	275:307	a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	275:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	5	51	theme	RESULTS	972:978	arg1	samples					1006:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	4	52	theme	tissues	824:830	arg1	patterns					799:806	genome wide methylation patterns	775:806	genome wide methylation patterns of ACD/MPV lung tissues	775:830	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	13	53	theme	genomic	2288:2294	arg1	variant					2302:2308	a genomic FOXF1 variant	2286:2308	a genomic FOXF1 variant	2286:2308	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	8	54	located	detected	1622:1629	arg1	enhancer					1650:1657	the 60 kb FOXF1 enhancer	1634:1657	the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation	1634:1703	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	8	54	located	detected	1622:1629	arg2	regions					1609:1615	two hypermethylated regions	1589:1615	two hypermethylated regions	1589:1615	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	2	55	theme	FOXF1	454:458	arg1	locus					460:464	the FOXF1 locus	450:464	the FOXF1 locus	450:464	Cases without a genomic alteration in the FOXF1 locus have been described as well.
34325731	8	56	theme	FOXF1	1644:1648	arg1	enhancer					1650:1657	the 60 kb FOXF1 enhancer	1634:1657	the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation	1634:1703	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	10	57	theme	wide	1915:1918	arg1	data					1932:1935	genome wide methylation data	1908:1935	genome wide methylation data	1908:1935	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	0	58	theme	alveolar	40:47	arg1	tissue					74:79	alveolar capillary dysplasia lung tissue	40:79	alveolar capillary dysplasia lung tissue	40:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	5	59	theme	115	1181:1183	arg1	genes					1200:1204	115 protein coding genes	1181:1204	115 protein coding genes	1181:1204	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	10	60	theme	first	1886:1890	arg1	study					1892:1896	the first study	1882:1896	the first study providing genome wide methylation data on lung tissue of ACD/MPV patients	1882:1970	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	10	60	theme	first	1886:1890	arg1	CONCLUSION					1863:1872	CONCLUSION	1863:1872	CONCLUSION This	1863:1877	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	3	61	theme	potential	671:679	arg1	targets					693:699	potential therapeutic targets	671:699	potential therapeutic targets for ACD/MPV	671:711	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	10	62	theme	lung	1940:1943	arg1	tissue					1945:1950	lung tissue	1940:1950	lung tissue of ACD/MPV patients	1940:1970	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	4	63	theme	ACD/MPV	811:817	arg1	tissues					824:830	ACD/MPV lung tissues	811:830	ACD/MPV lung tissues	811:830	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	1	64	theme	pulmonary	246:254	arg1	ACD/MPV					263:269	ACD/MPV	263:269	ACD/MPV	263:269	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	64	theme	pulmonary	246:254	arg1	veins					256:260	the pulmonary veins	242:260	the pulmonary veins (ACD/MPV)	242:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	65	from	variety	327:333	arg1	gene					384:387	the FOXF1 gene	374:387	the FOXF1 gene	374:387	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	65	from	variety	327:333	arg1	enhancer					402:409	its 60 kb enhancer	392:409	its 60 kb enhancer	392:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	12	66	from	enhancer	2111:2118	arg1	Hypermethylation					2075:2090	Hypermethylation	2075:2090	Hypermethylation at the 60 kb FOXF1 enhancer	2075:2118	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	5	67	theme	control	1024:1030	arg1	samples					1032:1038	three control samples	1018:1038	three control samples	1018:1038	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	8	68	theme	FOXF1	1684:1688	arg1	mutation					1696:1703	a FOXF1 point mutation	1682:1703	a FOXF1 point mutation	1682:1703	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	12	69	theme	FOXF1	2105:2109	arg1	enhancer					2111:2118	the 60 kb FOXF1 enhancer	2095:2118	the 60 kb FOXF1 enhancer	2095:2118	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	4	70	theme	control	875:881	arg1	tissues					888:894	control lung tissues	875:894	control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq)	875:969	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	6	71	link	O-linked	1371:1378	arg1	glycosylation					1380:1392	O-linked glycosylation	1371:1392	O-linked glycosylation	1371:1392	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	10	72	theme	patients	1963:1970	arg1	tissue					1945:1950	lung tissue	1940:1950	lung tissue of ACD/MPV patients	1940:1970	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	6	73	theme	downregulated	1327:1339	arg1	genes					1341:1345	potentially downregulated genes	1315:1345	potentially downregulated genes	1315:1345	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	13	74	theme	methylation	2245:2255	arg1	analyses					2257:2264	DNA methylation analyses	2241:2264	DNA methylation analyses of patients without a genomic FOXF1 variant	2241:2308	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	4	75	theme	tissues	888:894	arg1	patterns					863:870	methylation patterns	851:870	methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq)	851:969	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	11	76	theme	enhancer	2065:2072	arg1	imprinting					2035:2044	maternal imprinting	2026:2044	maternal imprinting of the 60 kb FOXF1 enhancer	2026:2072	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	1	77	theme	BACKGROUND	170:179	arg1	dysplasia					200:208	BACKGROUND Alveolar capillary dysplasia	170:208	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV)	170:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	77	theme	BACKGROUND	170:179	arg1	disorder					300:307	a lethal congenital lung disorder	275:307	a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	275:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	7	78	theme	FOXF1	1510:1514	arg1	enhancer					1516:1523	this FOXF1 enhancer	1505:1523	this FOXF1 enhancer	1505:1523	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	12	79	theme	coding	2211:2216	arg1	region					2218:2223	the FOXF1 coding region	2201:2223	the FOXF1 coding region	2201:2223	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	1	80	theme	capillary	190:198	arg1	dysplasia					200:208	BACKGROUND Alveolar capillary dysplasia	170:208	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV)	170:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	80	theme	capillary	190:198	arg1	disorder					300:307	a lethal congenital lung disorder	275:307	a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	275:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	5	81	theme	genome	1158:1163	arg1	wide					1165:1168	319 differentially methylated regions (DMRs) genome wide	1113:1168	319 differentially methylated regions (DMRs) genome wide	1113:1168	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	9	82	theme	FOXF1	1767:1771	arg1	exon					1773:1776	the first FOXF1 exon	1757:1776	the first FOXF1 exon	1757:1776	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	7	83	theme	DNA	1477:1479	arg1	patterns					1493:1500	DNA methylation patterns	1477:1500	DNA methylation patterns in this FOXF1 enhancer	1477:1523	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	10	84	dep	CONCLUSION	1863:1872	arg1	This					1874:1877	This	1874:1877	This	1874:1877	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	11	85	theme	maternal	2026:2033	arg1	imprinting					2035:2044	maternal imprinting	2026:2044	maternal imprinting of the 60 kb FOXF1 enhancer	2026:2072	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	7	86	from	different	1548:1556	arg1	patients					1398:1405	patients	1398:1405	patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer	1398:1474	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	7	87	theme	60 kb	1455:1459	arg1	enhancer					1467:1474	the 60 kb FOXF1 enhancer	1451:1474	the 60 kb FOXF1 enhancer	1451:1474	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	11	88	from	analyses	1989:1996	arg1	locus					2011:2015	the FOXF1 locus	2001:2015	the FOXF1 locus	2001:2015	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	6	89	theme	O-linked	1371:1378	arg1	glycosylation					1380:1392	O-linked glycosylation	1371:1392	O-linked glycosylation	1371:1392	The potentially upregulated genes were significantly enriched in developmental signalling pathways, whereas potentially downregulated genes were mainly enriched in O-linked glycosylation.
34325731	1	90	theme	60 kb	396:400	arg1	enhancer					402:409	its 60 kb enhancer	392:409	its 60 kb enhancer	392:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	5	91	theme	wide	1165:1168	arg1	identification					1095:1108	identification	1095:1108	identification of 319 differentially methylated regions (DMRs) genome wide	1095:1168	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	5	92	theme	mutual	1065:1070	arg1	comparison					1072:1081	their mutual comparison	1059:1081	their mutual comparison	1059:1081	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	10	93	theme	genome	1908:1913	arg1	data					1932:1935	genome wide methylation data	1908:1935	genome wide methylation data	1908:1935	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	4	94	theme	developed	915:923	arg1	technique					925:933	the recently developed technique	902:933	the recently developed technique Methylated DNA sequencing (MeD-seq)	902:969	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	7	95	theme	maternal	1420:1427	arg1	deletion					1429:1436	a large maternal deletion	1412:1436	a large maternal deletion encompassing the 60 kb FOXF1 enhancer	1412:1474	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	0	96	theme	lung	69:72	arg1	tissue					74:79	alveolar capillary dysplasia lung tissue	40:79	alveolar capillary dysplasia lung tissue	40:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	3	97	theme	genomic	598:604	arg1	variant					612:618	a genomic FOXF1 variant	596:618	a genomic FOXF1 variant	596:618	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	13	98	theme	exon	2352:2355	arg1	hypermethylation					2332:2347	abnormal hypermethylation	2323:2347	abnormal hypermethylation of exon 1	2323:2357	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	1	99	from	enhancer	402:409	arg1	variety					327:333	a variety	325:333	a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	325:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	99	from	enhancer	402:409	arg1	alterations					359:369	heterozygous genomic alterations	338:369	heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	338:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	7	100	from	patterns	1493:1500	arg1	enhancer					1516:1523	this FOXF1 enhancer	1505:1523	this FOXF1 enhancer	1505:1523	In patients with a large maternal deletion encompassing the 60 kb FOXF1 enhancer, DNA methylation patterns in this FOXF1 enhancer were not significantly different compared to controls.
34325731	9	101	theme	known	1829:1833	arg1	FOXF1					1846:1850	a known pathogenic FOXF1	1827:1850	a known pathogenic FOXF1 variation	1827:1860	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	3	102	from	haploinsufficiency	532:549	arg1	patients					579:586	patients	579:586	patients without a genomic FOXF1 variant	579:618	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	1	103	theme	genomic	351:357	arg1	alterations					359:369	heterozygous genomic alterations	338:369	heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	338:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	9	104	theme	FOXF1	1846:1850	arg1	variation					1852:1860	a known pathogenic FOXF1 variation	1827:1860	a known pathogenic FOXF1 variation	1827:1860	Lastly, a large hypermethylated region overlapping the first FOXF1 exon was found in one of the ACD/MPV patients without a known pathogenic FOXF1 variation.
34325731	8	105	theme	hypermethylated	1593:1607	arg1	regions					1609:1615	two hypermethylated regions	1589:1615	two hypermethylated regions	1589:1615	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	4	106	theme	methylation	762:772	arg1	contribution					733:744	the contribution	729:744	the contribution of aberrant DNA methylation	729:772	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	0	107	theme	genes	113:117	arg1	methylation					98:108	aberrant methylation	89:108	aberrant methylation of genes involved in development including the FOXF1 locus	89:167	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	5	108	theme	methylated	1132:1141	arg1	regions					1143:1149	319 differentially methylated regions	1113:1149	319 differentially methylated regions (DMRs) genome wide	1113:1168	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	5	108	theme	methylated	1132:1141	arg1	DMRs					1152:1155	DMRs	1152:1155	DMRs	1152:1155	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	5	109	theme	lung	994:997	arg1	samples					1006:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples	972:1012	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	4	110	theme	genome	775:780	arg1	patterns					799:806	genome wide methylation patterns	775:806	genome wide methylation patterns of ACD/MPV lung tissues	775:830	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	1	111	from	gene	384:387	arg1	variety					327:333	a variety	325:333	a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	325:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	111	from	gene	384:387	arg1	alterations					359:369	heterozygous genomic alterations	338:369	heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	338:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	0	112	theme	wide	7:10	arg1	analysis					28:35	Genome wide DNA methylation analysis	0:35	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue	0:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	1	113	theme	FOXF1	378:382	arg1	gene					384:387	the FOXF1 gene	374:387	the FOXF1 gene	374:387	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	0	114	theme	methylation	16:26	arg1	analysis					28:35	Genome wide DNA methylation analysis	0:35	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue	0:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	1	115	theme	lethal	277:282	arg1	dysplasia					200:208	BACKGROUND Alveolar capillary dysplasia	170:208	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV)	170:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	115	theme	lethal	277:282	arg1	disorder					300:307	a lethal congenital lung disorder	275:307	a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	275:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	12	116	from	mutations	2188:2196	arg1	region					2218:2223	the FOXF1 coding region	2201:2223	the FOXF1 coding region	2201:2223	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	8	117	theme	60 kb	1638:1642	arg1	enhancer					1650:1657	the 60 kb FOXF1 enhancer	1634:1657	the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation	1634:1703	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	4	118	theme	aberrant	749:756	arg1	methylation					762:772	aberrant DNA methylation	749:772	aberrant DNA methylation	749:772	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	11	119	theme	FOXF1	2005:2009	arg1	locus					2011:2015	the FOXF1 locus	2001:2015	the FOXF1 locus	2001:2015	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	1	120	theme	lung	295:298	arg1	dysplasia					200:208	BACKGROUND Alveolar capillary dysplasia	170:208	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV)	170:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	1	120	theme	lung	295:298	arg1	disorder					300:307	a lethal congenital lung disorder	275:307	a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer	275:409	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
34325731	10	121	theme	methylation	1920:1930	arg1	data					1932:1935	genome wide methylation data	1908:1935	genome wide methylation data	1908:1935	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	4	122	theme	lung	819:822	arg1	tissues					824:830	ACD/MPV lung tissues	811:830	ACD/MPV lung tissues	811:830	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	0	123	theme	capillary	49:57	arg1	tissue					74:79	alveolar capillary dysplasia lung tissue	40:79	alveolar capillary dysplasia lung tissue	40:79	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus.
34325731	13	124	theme	FOXF1	2296:2300	arg1	variant					2302:2308	a genomic FOXF1 variant	2286:2308	a genomic FOXF1 variant	2286:2308	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	8	125	theme	patients	1662:1669	arg1	enhancer					1650:1657	the 60 kb FOXF1 enhancer	1634:1657	the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation	1634:1703	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	10	126	theme	ACD/MPV	1955:1961	arg1	patients					1963:1970	ACD/MPV patients	1955:1970	ACD/MPV patients	1955:1970	CONCLUSION This is the first study providing genome wide methylation data on lung tissue of ACD/MPV patients.
34325731	13	127	from	ACD/MPV	2385:2391	arg1	patients					2396:2403	patients	2396:2403	patients	2396:2403	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	5	128	theme	protein	1185:1191	arg1	genes					1200:1204	115 protein coding genes	1181:1204	115 protein coding genes	1181:1204	RESULTS Eight ACD/MPV lung tissue samples and three control samples were sequenced and their mutual comparison resulted in identification of 319 differentially methylated regions (DMRs) genome wide, involving 115 protein coding genes.
34325731	4	129	theme	methylation	787:797	arg1	patterns					799:806	genome wide methylation patterns	775:806	genome wide methylation patterns of ACD/MPV lung tissues	775:830	To investigate the contribution of aberrant DNA methylation, genome wide methylation patterns of ACD/MPV lung tissues were compared with methylation patterns of control lung tissues using the recently developed technique Methylated DNA sequencing (MeD-seq).
34325731	13	130	theme	patients	2269:2276	arg1	analyses					2257:2264	DNA methylation analyses	2241:2264	DNA methylation analyses of patients without a genomic FOXF1 variant	2241:2308	Interestingly, DNA methylation analyses of patients without a genomic FOXF1 variant suggest that abnormal hypermethylation of exon 1 might play a role in some ACD/MPV in patients.
34325731	12	131	theme	60 kb	2099:2103	arg1	enhancer					2111:2118	the 60 kb FOXF1 enhancer	2095:2118	the 60 kb FOXF1 enhancer	2095:2118	Hypermethylation at the 60 kb FOXF1 enhancer might contribute to FOXF1 haploinsufficiency caused by heterozygous mutations in the FOXF1 coding region.
34325731	11	132	theme	methylation	1977:1987	arg1	analyses					1989:1996	DNA methylation analyses	1973:1996	DNA methylation analyses in the FOXF1 locus	1973:2015	DNA methylation analyses in the FOXF1 locus excludes maternal imprinting of the 60 kb FOXF1 enhancer.
34325731	8	133	theme	point	1690:1694	arg1	mutation					1696:1703	a FOXF1 point mutation	1682:1703	a FOXF1 point mutation	1682:1703	However, two hypermethylated regions were detected in the 60 kb FOXF1 enhancer of patients harbouring a FOXF1 point mutation.
34325731	3	134	theme	responsible	510:520	arg1	mechanisms					499:508	The mechanisms	495:508	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant	495:618	The mechanisms responsible for FOXF1 haploinsufficiency and the cause of ACD/MPV in patients without a genomic FOXF1 variant are poorly understood, complicating the search for potential therapeutic targets for ACD/MPV.
34325731	1	135	theme	veins	256:260	arg1	misalignment					226:237	misalignment	226:237	misalignment of the pulmonary veins (ACD/MPV)	226:270	BACKGROUND Alveolar capillary dysplasia with or without misalignment of the pulmonary veins (ACD/MPV) is a lethal congenital lung disorder associated with a variety of heterozygous genomic alterations in the FOXF1 gene or its 60 kb enhancer.
33686291	1	0	link	O-linked	86:93	arg1	N-acetylglucosamine					95:113	O-linked N-acetylglucosamine	86:113	O-linked N-acetylglucosamine (O-GlcNAc)	86:124	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	0	link	O-linked	86:93	arg1	modification					173:184	an essential and dynamic post-translational modification	129:184	an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins	129:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	0	link	O-linked	86:93	arg1	O-GlcNAc					116:123	O-GlcNAc	116:123	O-GlcNAc	116:123	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	0	1	from	deglycosylation	15:29	arg1	cells					41:45	living cells	34:45	living cells	34:45	Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase.
33686291	1	2	theme	post-translational	154:171	arg1	N-acetylglucosamine					95:113	O-linked N-acetylglucosamine	86:113	O-linked N-acetylglucosamine (O-GlcNAc)	86:124	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	2	theme	post-translational	154:171	arg1	modification					173:184	an essential and dynamic post-translational modification	129:184	an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins	129:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	5	3	theme	split	761:765	arg1	OGA					767:769	the nanobody-fused split OGA	742:769	the nanobody-fused split OGA using four nanobodies against five target proteins	742:820	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	4	4	theme	reduced	574:580	arg1	activity					605:612	reduced inherent deglycosidase activity	574:612	reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody	574:706	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	4	5	theme	systematic	509:518	arg1	optimization					529:540	systematic cellular optimization	509:540	systematic cellular optimization	509:540	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	3	6	from	cells	496:500	arg1	deglycosylation					457:471	selective deglycosylation	447:471	selective deglycosylation of a target protein in cells	447:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	7	theme	split	397:401	arg1	eraser					436:441	an O-GlcNAc eraser	424:441	an O-GlcNAc eraser for selective deglycosylation of a target protein in cells	424:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	7	theme	split	397:401	arg1	OGA					416:418	OGA	416:418	OGA	416:418	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	7	theme	split	397:401	arg1	O-GlcNAcase					403:413	a nanobody-fused split O-GlcNAcase	380:413	a nanobody-fused split O-GlcNAcase (OGA)	380:419	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	4	8	with	OGA	565:567	arg1	activity					605:612	reduced inherent deglycosidase activity	574:612	reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody	574:706	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	4	9	theme	deglycosidase	591:603	arg1	activity					605:612	reduced inherent deglycosidase activity	574:612	reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody	574:706	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	6	10	theme	functional	989:998	arg1	evaluation					1000:1009	functional evaluation	989:1009	functional evaluation	989:1009	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	3	11	theme	target	478:483	arg1	protein					485:491	a target protein	476:491	a target protein in cells	476:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	5	12	theme	nanobody-fused	746:759	arg1	OGA					767:769	the nanobody-fused split OGA	742:769	the nanobody-fused split OGA using four nanobodies against five target proteins	742:820	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	6	13	from	proteins	1093:1100	arg1	removal					1057:1063	the selective removal	1043:1063	the selective removal of O-GlcNAc from individual proteins directly in cells	1043:1118	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	6	13	from	proteins	1093:1100	arg1	cells					1114:1118	cells	1114:1118	cells	1114:1118	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	2	14	theme	target	295:300	arg1	protein					302:308	a single target protein	286:308	a single target protein	286:308	Interrogating the role of O-GlcNAc on a single target protein is crucial, yet challenging to perform in cells.
33686291	3	15	theme	O-GlcNAc	427:434	arg1	eraser					436:441	an O-GlcNAc eraser	424:441	an O-GlcNAc eraser for selective deglycosylation of a target protein in cells	424:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	15	theme	O-GlcNAc	427:434	arg1	O-GlcNAcase					403:413	a nanobody-fused split O-GlcNAcase	380:413	a nanobody-fused split O-GlcNAcase (OGA)	380:419	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	4	16	theme	inherent	582:589	arg1	activity					605:612	reduced inherent deglycosidase activity	574:612	reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody	574:706	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	2	17	theme	single	288:293	arg1	protein					302:308	a single target protein	286:308	a single target protein	286:308	Interrogating the role of O-GlcNAc on a single target protein is crucial, yet challenging to perform in cells.
33686291	2	18	from	role	266:269	arg1	protein					302:308	a single target protein	286:308	a single target protein	286:308	Interrogating the role of O-GlcNAc on a single target protein is crucial, yet challenging to perform in cells.
33686291	4	19	theme	target	665:670	arg1	protein					672:678	the desired target protein	653:678	the desired target protein	653:678	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	3	20	theme	nanobody-fused	382:395	arg1	eraser					436:441	an O-GlcNAc eraser	424:441	an O-GlcNAc eraser for selective deglycosylation of a target protein in cells	424:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	20	theme	nanobody-fused	382:395	arg1	OGA					416:418	OGA	416:418	OGA	416:418	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	20	theme	nanobody-fused	382:395	arg1	O-GlcNAcase					403:413	a nanobody-fused split O-GlcNAcase	380:413	a nanobody-fused split O-GlcNAcase (OGA)	380:419	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	6	21	theme	new	968:970	arg1	strategy					972:979	a new strategy	966:979	a new strategy for the functional evaluation and engineering of O-GlcNAc	966:1037	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	5	22	theme	OGA	767:769	arg1	generality					728:737	the generality	724:737	the generality of the nanobody-fused split OGA using four nanobodies against five target proteins	724:820	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	1	23	theme	O-linked	86:93	arg1	N-acetylglucosamine					95:113	O-linked N-acetylglucosamine	86:113	O-linked N-acetylglucosamine (O-GlcNAc)	86:124	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	23	theme	O-linked	86:93	arg1	modification					173:184	an essential and dynamic post-translational modification	129:184	an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins	129:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	23	theme	O-linked	86:93	arg1	O-GlcNAc					116:123	O-GlcNAc	116:123	O-GlcNAc	116:123	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	6	24	theme	individual	1082:1091	arg1	proteins					1093:1100	individual proteins	1082:1100	individual proteins directly in cells	1082:1118	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	0	25	theme	Target	0:5	arg1	protein					7:13	Target protein	0:13	Target protein	0:13	Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase.
33686291	3	26	from	protein	485:491	arg1	cells					496:500	cells	496:500	cells	496:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	6	27	theme	O-GlcNAc	1068:1075	arg1	removal					1057:1063	the selective removal	1043:1063	the selective removal of O-GlcNAc from individual proteins directly in cells	1043:1118	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	5	28	dep	factors	894:900	arg1	c-Jun					902:906	c-Jun	902:906	c-Jun	902:906	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	28	dep	factors	894:900	arg1	factors					894:900	the transcription factors c-Jun and c-Fos	876:916	the transcription factors c-Jun and c-Fos	876:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	28	dep	factors	894:900	arg1	c-Fos					912:916	c-Fos	912:916	c-Fos	912:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	4	29	theme	split	559:563	arg1	OGA					565:567	a split OGA	557:567	a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody	557:706	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	4	30	theme	desired	657:663	arg1	protein					672:678	the desired target protein	653:678	the desired target protein	653:678	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	1	31	theme	nucleocytoplasmic	220:236	arg1	proteins					238:245	nucleocytoplasmic proteins	220:245	nucleocytoplasmic proteins	220:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	0	32	theme	living	34:39	arg1	cells					41:45	living cells	34:45	living cells	34:45	Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase.
33686291	3	33	gly	deglycosylation	457:471	arg1	protein					485:491	a target protein	476:491	a target protein in cells	476:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	3	34	theme	selective	447:455	arg1	deglycosylation					457:471	selective deglycosylation	447:471	selective deglycosylation of a target protein in cells	447:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	5	35	theme	target	806:811	arg1	proteins					813:820	five target proteins	801:820	five target proteins	801:820	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	4	36	theme	cellular	520:527	arg1	optimization					529:540	systematic cellular optimization	509:540	systematic cellular optimization	509:540	After systematic cellular optimization, we identified a split OGA with reduced inherent deglycosidase activity that selectively removed O-GlcNAc from the desired target protein when directed by a nanobody.
33686291	6	37	theme	selective	1047:1055	arg1	removal					1057:1063	the selective removal	1043:1063	the selective removal of O-GlcNAc from individual proteins directly in cells	1043:1118	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	0	38	gly	deglycosylation	15:29	arg1	cells					41:45	living cells	34:45	living cells	34:45	Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase.
33686291	5	39	from	impact	854:859	arg1	c-Jun					902:906	c-Jun	902:906	c-Jun	902:906	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	39	from	impact	854:859	arg1	factors					894:900	the transcription factors c-Jun and c-Fos	876:916	the transcription factors c-Jun and c-Fos	876:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	39	from	impact	854:859	arg1	c-Fos					912:916	c-Fos	912:916	c-Fos	912:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	3	40	theme	protein	485:491	arg1	deglycosylation					457:471	selective deglycosylation	447:471	selective deglycosylation of a target protein in cells	447:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	6	41	dep	evaluation	1000:1009	arg1	the					985:987	the	985:987	the	985:987	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	3	42	from	deglycosylation	457:471	arg1	cells					496:500	cells	496:500	cells	496:500	Herein, we developed a nanobody-fused split O-GlcNAcase (OGA) as an O-GlcNAc eraser for selective deglycosylation of a target protein in cells.
33686291	6	43	theme	O-GlcNAc	941:948	arg1	eraser					950:955	The nanobody-directed O-GlcNAc eraser	919:955	The nanobody-directed O-GlcNAc eraser	919:955	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	1	44	theme	essential	132:140	arg1	N-acetylglucosamine					95:113	O-linked N-acetylglucosamine	86:113	O-linked N-acetylglucosamine (O-GlcNAc)	86:124	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	44	theme	essential	132:140	arg1	modification					173:184	an essential and dynamic post-translational modification	129:184	an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins	129:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	0	45	theme	split	67:71	arg1	O-GlcNAcase					73:83	a nanobody-fused split O-GlcNAcase	50:83	a nanobody-fused split O-GlcNAcase	50:83	Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase.
33686291	1	46	theme	proteins	238:245	arg1	thousands					207:215	thousands	207:215	thousands of nucleocytoplasmic proteins	207:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	2	47	theme	O-GlcNAc	274:281	arg1	role					266:269	the role	262:269	the role of O-GlcNAc on a single target protein	262:308	Interrogating the role of O-GlcNAc on a single target protein is crucial, yet challenging to perform in cells.
33686291	5	48	theme	transcription	880:892	arg1	c-Jun					902:906	c-Jun	902:906	c-Jun	902:906	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	48	theme	transcription	880:892	arg1	factors					894:900	the transcription factors c-Jun and c-Fos	876:916	the transcription factors c-Jun and c-Fos	876:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	48	theme	transcription	880:892	arg1	c-Fos					912:916	c-Fos	912:916	c-Fos	912:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	5	49	theme	O-GlcNAc	864:871	arg1	impact					854:859	the impact	850:859	the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos	850:916	We demonstrate the generality of the nanobody-fused split OGA using four nanobodies against five target proteins and use the system to study the impact of O-GlcNAc on the transcription factors c-Jun and c-Fos.
33686291	6	50	theme	O-GlcNAc	1030:1037	arg1	engineering					1015:1025	engineering	1015:1025	engineering	1015:1025	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	6	50	theme	O-GlcNAc	1030:1037	arg1	evaluation					1000:1009	functional evaluation	989:1009	functional evaluation	989:1009	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	0	51	theme	nanobody-fused	52:65	arg1	O-GlcNAcase					73:83	a nanobody-fused split O-GlcNAcase	50:83	a nanobody-fused split O-GlcNAcase	50:83	Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase.
33686291	6	52	theme	nanobody-directed	923:939	arg1	eraser					950:955	The nanobody-directed O-GlcNAc eraser	919:955	The nanobody-directed O-GlcNAc eraser	919:955	The nanobody-directed O-GlcNAc eraser provides a new strategy for the functional evaluation and engineering of O-GlcNAc via the selective removal of O-GlcNAc from individual proteins directly in cells.
33686291	1	53	theme	dynamic	146:152	arg1	N-acetylglucosamine					95:113	O-linked N-acetylglucosamine	86:113	O-linked N-acetylglucosamine (O-GlcNAc)	86:124	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
33686291	1	53	theme	dynamic	146:152	arg1	modification					173:184	an essential and dynamic post-translational modification	129:184	an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins	129:245	O-linked N-acetylglucosamine (O-GlcNAc) is an essential and dynamic post-translational modification that is presented on thousands of nucleocytoplasmic proteins.
32796070	0	0	theme	HIV-1	76:80	arg1	Particles					82:90	HIV-1 Particles	76:90	HIV-1 Particles	76:90	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.
32796070	7	1	theme	virus	1114:1118	arg1	capture					1120:1126	antibody-dependent virus capture	1095:1126	antibody-dependent virus capture	1095:1126	Moreover, the effect of SERINC5 on antibody-dependent virus capture was abrogated by Nef expression.
32796070	6	2	theme	SERINC5-resistant	1029:1045	arg1	protein					1051:1057	the SERINC5-resistant Env protein	1025:1057	the SERINC5-resistant Env protein	1025:1057	In contrast, SERINC5 did not alter the capture of HIV-1 particles bearing the SERINC5-resistant Env protein.
32796070	2	3	theme	antiviral	364:372	arg1	effect					374:379	the antiviral effect	360:379	the antiviral effect of SERINC5	360:390	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	4	4	from	effects	613:619	arg1	conformation					639:650	Env conformation	635:650	Env conformation	635:650	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	8	5	theme	physical	1278:1285	arg1	masking					1287:1293	physical masking	1278:1293	physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism	1278:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	4	6	theme	Env	635:637	arg1	conformation					639:650	Env conformation	635:650	Env conformation	635:650	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	10	7	theme	antiviral	1752:1760	arg1	strategies					1762:1771	new antiviral strategies	1748:1771	new antiviral strategies targeting Env	1748:1785	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	8	8	theme	novel	1412:1416	arg1	mechanism					1440:1448	a novel and poorly understood mechanism	1410:1448	a novel and poorly understood mechanism	1410:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	10	9	from	effects	1662:1668	arg1	conformation					1707:1718	the HIV-1 glycoprotein conformation	1684:1718	the HIV-1 glycoprotein conformation	1684:1718	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	8	10	theme	host	1350:1353	arg1	protein					1360:1366	a host cell protein	1348:1366	a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism	1348:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	8	10	theme	host	1350:1353	arg1	SERINC5					1337:1343	epitopes.IMPORTANCE SERINC5	1317:1343	epitopes.IMPORTANCE SERINC5	1317:1343	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	3	11	theme	Env	581:583	arg1	conformation					585:596	Env conformation	581:596	Env conformation	581:596	While the precise mechanism by which SERINC5 inhibits HIV-1 infectivity is unclear, previous studies have suggested that SERINC5 affects Env conformation.
32796070	0	12	from	Conformation	51:62	arg1	Particles					82:90	HIV-1 Particles	76:90	HIV-1 Particles	76:90	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.
32796070	7	13	theme	antibody-dependent	1095:1112	arg1	capture					1120:1126	antibody-dependent virus capture	1095:1126	antibody-dependent virus capture	1095:1126	Moreover, the effect of SERINC5 on antibody-dependent virus capture was abrogated by Nef expression.
32796070	4	14	theme	immobilized	701:711	arg1	antibodies					737:746	immobilized Env-specific monoclonal antibodies	701:746	immobilized Env-specific monoclonal antibodies	701:746	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	8	15	theme	specific	1298:1305	arg1	Env					1313:1315	specific HIV-1 Env	1298:1315	specific HIV-1 Env	1298:1315	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	4	16	theme	monoclonal	726:735	arg1	antibodies					737:746	immobilized Env-specific monoclonal antibodies	701:746	immobilized Env-specific monoclonal antibodies	701:746	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	2	17	theme	accessory	421:429	arg1	protein					431:437	the viral accessory protein	411:437	the viral accessory protein Nef	411:441	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	9	18	theme	proteins	1543:1550	arg1	conformation					1513:1524	the conformation	1509:1524	the conformation of the HIV-1 Env proteins	1509:1550	Here, we provide evidence that the SERINC5 protein alters the conformation of the HIV-1 Env proteins and that this action is correlated with SERINC5's ability to inhibit HIV-1 infectivity.
32796070	1	19	theme	budding	173:179	arg1	particles					187:195	budding HIV-1 particles	173:195	budding HIV-1 particles	173:195	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	7	20	theme	SERINC5	1084:1090	arg1	effect					1074:1079	the effect	1070:1079	the effect of SERINC5 on antibody-dependent virus capture	1070:1126	Moreover, the effect of SERINC5 on antibody-dependent virus capture was abrogated by Nef expression.
32796070	6	21	theme	HIV-1	1001:1005	arg1	particles					1007:1015	HIV-1 particles	1001:1015	HIV-1 particles bearing the SERINC5-resistant Env protein	1001:1057	In contrast, SERINC5 did not alter the capture of HIV-1 particles bearing the SERINC5-resistant Env protein.
32796070	1	22	theme	HIV-1	181:185	arg1	particles					187:195	budding HIV-1 particles	173:195	budding HIV-1 particles	173:195	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	5	23	theme	SERINC5-susceptible	823:841	arg1	Env					843:845	a SERINC5-susceptible Env	821:845	a SERINC5-susceptible Env	821:845	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	5	24	link	N-linked	934:941	arg1	glycan					943:948	an N-linked glycan	931:948	an N-linked glycan	931:948	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	2	25	theme	Env	332:334	arg1	gp120					349:353	the viral Env glycoprotein gp120	322:353	the viral Env glycoprotein gp120	322:353	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	10	26	gly	glycoprotein	1694:1705	arg1	glycoprotein					1694:1705	the HIV-1 glycoprotein conformation	1684:1718	the HIV-1 glycoprotein conformation	1684:1718	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	8	27	theme	gp120	1254:1258	arg1	conformation					1238:1249	the conformation	1234:1249	the conformation of gp120	1234:1258	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	2	28	theme	viral	326:330	arg1	gp120					349:353	the viral Env glycoprotein gp120	322:353	the viral Env glycoprotein gp120	322:353	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	2	29	theme	SERINC5	384:390	arg1	effect					374:379	the antiviral effect	360:379	the antiviral effect of SERINC5	360:390	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	7	30	from	effect	1074:1079	arg1	capture					1120:1126	antibody-dependent virus capture	1095:1126	antibody-dependent virus capture	1095:1126	Moreover, the effect of SERINC5 on antibody-dependent virus capture was abrogated by Nef expression.
32796070	9	31	theme	HIV-1	1621:1625	arg1	infectivity					1627:1637	HIV-1 infectivity	1621:1637	HIV-1 infectivity	1621:1637	Here, we provide evidence that the SERINC5 protein alters the conformation of the HIV-1 Env proteins and that this action is correlated with SERINC5's ability to inhibit HIV-1 infectivity.
32796070	2	32	theme	protein	431:437	arg1	Nef					439:441	the viral accessory protein Nef	411:441	the viral accessory protein Nef	411:441	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	0	33	theme	HIV-1	17:21	arg1	Infectivity					23:33	HIV-1 Infectivity	17:33	HIV-1 Infectivity	17:33	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.
32796070	5	34	theme	N-linked	934:941	arg1	glycan					943:948	an N-linked glycan	931:948	an N-linked glycan	931:948	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	10	35	theme	new	1748:1750	arg1	strategies					1762:1771	new antiviral strategies	1748:1771	new antiviral strategies targeting Env	1748:1785	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	1	36	theme	HIV-1	209:213	arg1	infectivity					215:225	HIV-1 infectivity	209:225	HIV-1 infectivity	209:225	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	5	37	theme	HIV-1	797:801	arg1	particles					803:811	HIV-1 particles	797:811	HIV-1 particles bearing a SERINC5-susceptible Env	797:845	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	4	38	theme	Env-specific	713:724	arg1	antibodies					737:746	immobilized Env-specific monoclonal antibodies	701:746	immobilized Env-specific monoclonal antibodies	701:746	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	9	39	theme	SERINC5	1486:1492	arg1	protein					1494:1500	the SERINC5 protein	1482:1500	the SERINC5 protein	1482:1500	Here, we provide evidence that the SERINC5 protein alters the conformation of the HIV-1 Env proteins and that this action is correlated with SERINC5's ability to inhibit HIV-1 infectivity.
32796070	3	40	theme	precise	454:460	arg1	mechanism					462:470	the precise mechanism	450:470	the precise mechanism by which SERINC5 inhibits HIV-1 infectivity	450:514	While the precise mechanism by which SERINC5 inhibits HIV-1 infectivity is unclear, previous studies have suggested that SERINC5 affects Env conformation.
32796070	3	40	theme	precise	454:460	arg1	unclear					519:525	unclear	519:525	unclear	519:525	While the precise mechanism by which SERINC5 inhibits HIV-1 infectivity is unclear, previous studies have suggested that SERINC5 affects Env conformation.
32796070	8	41	theme	HIV-1	1401:1405	arg1	infectivity					1386:1396	the infectivity	1382:1396	the infectivity of HIV-1	1382:1405	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	5	42	theme	soluble	891:897	arg1	sCD4					904:907	sCD4	904:907	sCD4	904:907	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	5	42	theme	soluble	891:897	arg1	CD4					899:901	a soluble CD4	889:901	a soluble CD4 (sCD4)	889:908	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	2	43	theme	viral	415:419	arg1	protein					431:437	the viral accessory protein	411:437	the viral accessory protein Nef	411:441	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	5	44	theme	particles	803:811	arg1	binding					786:792	the binding	782:792	the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan	782:948	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	7	45	theme	Nef	1145:1147	arg1	expression					1149:1158	Nef expression	1145:1158	Nef expression	1145:1158	Moreover, the effect of SERINC5 on antibody-dependent virus capture was abrogated by Nef expression.
32796070	8	46	theme	Env	1313:1315	arg1	masking					1287:1293	physical masking	1278:1293	physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism	1278:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	5	47	theme	V3	880:881	arg1	loop					883:886	the V3 loop	876:886	the V3 loop	876:886	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	10	48	theme	SERINC5	1673:1679	arg1	effects					1662:1668	the specific effects	1649:1668	the specific effects of SERINC5 on the HIV-1 glycoprotein conformation	1649:1718	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	8	49	theme	HIV-1	1204:1208	arg1	infectivity					1210:1220	HIV-1 infectivity	1204:1220	HIV-1 infectivity	1204:1220	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	10	50	theme	glycoprotein	1694:1705	arg1	conformation					1707:1718	the HIV-1 glycoprotein conformation	1684:1718	the HIV-1 glycoprotein conformation	1684:1718	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	3	51	theme	HIV-1	498:502	arg1	infectivity					504:514	HIV-1 infectivity	498:514	HIV-1 infectivity	498:514	While the precise mechanism by which SERINC5 inhibits HIV-1 infectivity is unclear, previous studies have suggested that SERINC5 affects Env conformation.
32796070	9	52	theme	HIV-1	1533:1537	arg1	proteins					1543:1550	the HIV-1 Env proteins	1529:1550	the HIV-1 Env proteins	1529:1550	Here, we provide evidence that the SERINC5 protein alters the conformation of the HIV-1 Env proteins and that this action is correlated with SERINC5's ability to inhibit HIV-1 infectivity.
32796070	1	53	theme	10-transmembrane-domain	106:128	arg1	protein					139:145	a 10-transmembrane-domain cellular protein	104:145	a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion	104:257	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	1	53	theme	10-transmembrane-domain	106:128	arg1	SERINC5					93:99	SERINC5	93:99	SERINC5	93:99	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	8	54	dep	masking	1287:1293	arg1	protein					1360:1366	a host cell protein	1348:1366	a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism	1348:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	8	54	dep	masking	1287:1293	arg1	SERINC5					1337:1343	epitopes.IMPORTANCE SERINC5	1317:1343	epitopes.IMPORTANCE SERINC5	1317:1343	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	2	55	gly	glycoprotein	336:347	arg1	glycoprotein					336:347	the viral Env glycoprotein gp120	322:353	the viral Env glycoprotein gp120	322:353	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	4	56	theme	HIV-1	682:686	arg1	particles					688:696	HIV-1 particles	682:696	HIV-1 particles	682:696	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	1	57	theme	cellular	130:137	arg1	protein					139:145	a 10-transmembrane-domain cellular protein	104:145	a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion	104:257	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	1	57	theme	cellular	130:137	arg1	SERINC5					93:99	SERINC5	93:99	SERINC5	93:99	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	6	58	theme	particles	1007:1015	arg1	capture					990:996	the capture	986:996	the capture of HIV-1 particles bearing the SERINC5-resistant Env protein	986:1057	In contrast, SERINC5 did not alter the capture of HIV-1 particles bearing the SERINC5-resistant Env protein.
32796070	8	59	theme	cell	1355:1358	arg1	protein					1360:1366	a host cell protein	1348:1366	a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism	1348:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	8	59	theme	cell	1355:1358	arg1	SERINC5					1337:1343	epitopes.IMPORTANCE SERINC5	1317:1343	epitopes.IMPORTANCE SERINC5	1317:1343	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	5	60	theme	-induced	909:916	arg1	epitope					918:924	a soluble CD4 (sCD4)-induced epitope	889:924	a soluble CD4 (sCD4)-induced epitope	889:924	We observed that SERINC5 reduced the binding of HIV-1 particles bearing a SERINC5-susceptible Env to antibodies that recognize the V3 loop, a soluble CD4 (sCD4)-induced epitope, and an N-linked glycan.
32796070	8	61	theme	epitopes.IMPORTANCE	1317:1335	arg1	protein					1360:1366	a host cell protein	1348:1366	a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism	1348:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	8	61	theme	epitopes.IMPORTANCE	1317:1335	arg1	SERINC5					1337:1343	epitopes.IMPORTANCE SERINC5	1317:1343	epitopes.IMPORTANCE SERINC5	1317:1343	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	10	62	theme	specific	1653:1660	arg1	effects					1662:1668	the specific effects	1649:1668	the specific effects of SERINC5 on the HIV-1 glycoprotein conformation	1649:1718	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	2	63	theme	glycoprotein	336:347	arg1	gp120					349:353	the viral Env glycoprotein gp120	322:353	the viral Env glycoprotein gp120	322:353	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	2	64	from	sequences	309:317	arg1	gp120					349:353	the viral Env glycoprotein gp120	322:353	the viral Env glycoprotein gp120	322:353	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	1	65	theme	virus-cell	241:250	arg1	fusion					252:257	virus-cell fusion	241:257	virus-cell fusion	241:257	SERINC5 is a 10-transmembrane-domain cellular protein that is incorporated into budding HIV-1 particles and reduces HIV-1 infectivity by inhibiting virus-cell fusion.
32796070	0	66	theme	gp120	67:71	arg1	Conformation					51:62	the Conformation	47:62	the Conformation of gp120 on HIV-1 Particles	47:90	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.
32796070	10	67	theme	HIV-1	1688:1692	arg1	conformation					1707:1718	the HIV-1 glycoprotein conformation	1684:1718	the HIV-1 glycoprotein conformation	1684:1718	Defining the specific effects of SERINC5 on the HIV-1 glycoprotein conformation may be useful for designing new antiviral strategies targeting Env.
32796070	8	68	theme	understood	1429:1438	arg1	mechanism					1440:1448	a novel and poorly understood mechanism	1410:1448	a novel and poorly understood mechanism	1410:1448	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	6	69	theme	Env	1047:1049	arg1	protein					1051:1057	the SERINC5-resistant Env protein	1025:1057	the SERINC5-resistant Env protein	1025:1057	In contrast, SERINC5 did not alter the capture of HIV-1 particles bearing the SERINC5-resistant Env protein.
32796070	4	70	theme	particles	688:696	arg1	binding					671:677	the binding	667:677	the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies	667:746	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32796070	8	71	theme	HIV-1	1307:1311	arg1	Env					1313:1315	specific HIV-1 Env	1298:1315	specific HIV-1 Env	1298:1315	Our results indicate that SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on virions and/or physical masking of specific HIV-1 Env epitopes.IMPORTANCE SERINC5 is a host cell protein that inhibits the infectivity of HIV-1 by a novel and poorly understood mechanism.
32796070	9	72	theme	Env	1539:1541	arg1	proteins					1543:1550	the HIV-1 Env proteins	1529:1550	the HIV-1 Env proteins	1529:1550	Here, we provide evidence that the SERINC5 protein alters the conformation of the HIV-1 Env proteins and that this action is correlated with SERINC5's ability to inhibit HIV-1 infectivity.
32796070	2	73	theme	HIV-1	260:264	arg1	susceptibility					266:279	HIV-1 susceptibility	260:279	HIV-1 susceptibility to SERINC5	260:290	HIV-1 susceptibility to SERINC5 is determined by sequences in the viral Env glycoprotein gp120, and the antiviral effect of SERINC5 is counteracted by the viral accessory protein Nef.
32796070	3	74	theme	previous	528:535	arg1	studies					537:543	previous studies	528:543	previous studies	528:543	While the precise mechanism by which SERINC5 inhibits HIV-1 infectivity is unclear, previous studies have suggested that SERINC5 affects Env conformation.
32796070	4	75	theme	SERINC5	624:630	arg1	effects					613:619	the effects	609:619	the effects of SERINC5 on Env conformation	609:650	To define the effects of SERINC5 on Env conformation, we quantified the binding of HIV-1 particles to immobilized Env-specific monoclonal antibodies.
32709309	7	0	theme	amide	1421:1425	arg1	column					1427:1432	an amide column	1418:1432	an amide column	1418:1432	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	1	1	gly	glycoproteins	204:216	arg1	glycoproteins					204:216	glycoproteins	204:216	glycoproteins using high-performance liquid chromatography (HPLC)	204:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	2	2	theme	excess	401:406	arg1	reagents					417:424	excess labeling reagents	401:424	excess labeling reagents	401:424	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	4	3	theme	online	621:626	arg1	procedure					643:651	an online sample cleanup procedure	618:651	an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	618:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	6	4	theme	AP-labeled	1022:1031	arg1	glycans					1033:1039	The AP-labeled glycans	1018:1039	The AP-labeled glycans	1018:1039	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	5	5	theme	mm	979:980	arg1	i.d.					982:985	4.6 mm i.d.	975:985	4.6 mm i.d.	975:985	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	5	5	theme	mm	979:980	arg1	cm					990:991	1 cm long	988:996	1 cm long	988:996	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	6	6	theme	ODS	1060:1062	arg1	column					1064:1069	an ODS column	1057:1069	an ODS column (4.6 mm i.d., 1 cm long)	1057:1094	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	7	7	theme	ODS	1276:1278	arg1	column					1280:1285	the ODS column	1272:1285	the ODS column	1272:1285	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	8	8	link	N-linked	1530:1537	arg1	glycans					1539:1545	N-linked glycans	1530:1545	N-linked glycans released from several glycoprotein samples	1530:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	4	9	theme	cation	790:795	arg1	SCX					813:815	SCX	813:815	SCX	813:815	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	4	9	theme	cation	790:795	arg1	resin					806:810	strong cation exchange resin	783:810	a strong cation exchange resin (SCX)	781:816	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	6	10	from	contaminants	1136:1147	arg1	separate					1107:1114	separate	1107:1114	separate	1107:1114	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	4	11	theme	cleanup	635:641	arg1	procedure					643:651	an online sample cleanup procedure	618:651	an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	618:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	0	12	theme	hydrophilic	91:101	arg1	interaction					103:113	hydrophilic interaction	91:113	hydrophilic interaction	91:113	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	6	13	theme	long	1090:1093	arg1	i.d.					1079:1082	4.6 mm i.d.	1072:1082	4.6 mm i.d.	1072:1082	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	6	13	theme	long	1090:1093	arg1	cm					1087:1088	1 cm long	1085:1093	1 cm long	1085:1093	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	4	14	theme	strong	783:788	arg1	SCX					813:815	SCX	813:815	SCX	813:815	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	4	14	theme	strong	783:788	arg1	resin					806:810	strong cation exchange resin	783:810	a strong cation exchange resin (SCX)	781:816	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	8	15	theme	glycoprotein	1569:1580	arg1	samples					1582:1588	several glycoprotein samples	1561:1588	several glycoprotein samples	1561:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	1	16	theme	glycans	182:188	arg1	analysis					170:177	Quantitative analysis	157:177	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC)	157:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	1	17	theme	Quantitative	157:168	arg1	analysis					170:177	Quantitative analysis	157:177	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC)	157:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	0	18	theme	reversed-phase	119:132	arg1	chromatography					141:154	reversed-phase liquid chromatography	119:154	reversed-phase liquid chromatography	119:154	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	7	19	theme	analysis	1225:1232	arg1	column					1234:1239	an analysis column	1222:1239	an analysis column	1222:1239	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	5	20	theme	4.6	975:977	arg1	mm					979:980	mm	979:980	mm	979:980	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	4	21	theme	-labeled	694:701	arg1	glycans					703:709	2-aminopyridine (AP)-labeled glycans	674:709	2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	674:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	4	22	theme	sample	628:633	arg1	procedure					643:651	an online sample cleanup procedure	618:651	an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	618:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	1	23	attach	released	190:197	arg2	glycans					182:188	glycans	182:188	glycans released from glycoproteins using high-performance liquid chromatography (HPLC)	182:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	1	23	attach	released	190:197	arg1	glycoproteins					204:216	glycoproteins	204:216	glycoproteins using high-performance liquid chromatography (HPLC)	204:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	4	24	theme	silica	847:852	arg1	gel					854:856	ODS silica gel	843:856	ODS silica gel	843:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	3	25	theme	quantitative	576:587	arg1	analysis					589:596	quantitative analysis	576:596	quantitative analysis	576:596	Furthermore, these methods, including solvent extraction and solid phase extraction (SPE), often impair quantitative analysis.
32709309	2	26	theme	reaction	435:442	arg1	mixture					444:450	the reaction mixture	431:450	the reaction mixture	431:450	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	7	27	theme	hydrophilic	1350:1360	arg1	HILIC					1397:1401	HILIC	1397:1401	HILIC	1397:1401	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	27	theme	hydrophilic	1350:1360	arg1	chromatography					1381:1394	hydrophilic interaction liquid chromatography	1350:1394	hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column	1350:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	4	28	dep	columns	756:762	arg1	other					826:830	other	826:830	other	826:830	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	4	28	dep	columns	756:762	arg1	one					765:767	one	765:767	one	765:767	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	1	29	theme	high-performance	224:239	arg1	chromatography					248:261	high-performance liquid chromatography	224:261	high-performance liquid chromatography (HPLC)	224:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	1	29	theme	high-performance	224:239	arg1	HPLC					264:267	HPLC	264:267	HPLC	264:267	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	8	30	gly	glycoprotein	1569:1580	arg1	glycoprotein					1569:1580	several glycoprotein samples	1561:1588	several glycoprotein samples	1561:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	8	31	attach	released	1547:1554	arg1	samples					1582:1588	several glycoprotein samples	1561:1588	several glycoprotein samples	1561:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	8	31	attach	released	1547:1554	arg2	glycans					1539:1545	N-linked glycans	1530:1545	N-linked glycans released from several glycoprotein samples	1530:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	1	32	theme	liquid	241:246	arg1	chromatography					248:261	high-performance liquid chromatography	224:261	high-performance liquid chromatography (HPLC)	224:268	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	1	32	theme	liquid	241:246	arg1	HPLC					264:267	HPLC	264:267	HPLC	264:267	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	0	33	theme	2-aminopyridine	12:26	arg1	Analysis					0:7	Analysis	0:7	Analysis of 2-aminopyridine	0:26	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	0	34	theme	liquid	134:139	arg1	chromatography					141:154	reversed-phase liquid chromatography	119:154	reversed-phase liquid chromatography	119:154	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	5	35	theme	SCX	963:965	arg1	column					967:972	an SCX column	960:972	an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C	960:1015	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	4	36	theme	six-port/two-way	719:734	arg1	valve					736:740	a six-port/two-way valve	717:740	a six-port/two-way valve	717:740	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	7	37	from	separation	1404:1413	arg1	column					1477:1482	a C30 column	1471:1482	a C30 column	1471:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	37	from	separation	1404:1413	arg1	column					1427:1432	an amide column	1418:1432	an amide column	1418:1432	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	37	from	separation	1404:1413	arg1	separation					1457:1466	reversed-phase mode separation	1437:1466	reversed-phase mode separation	1437:1466	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	5	38	theme	excess	931:936	arg1	AP					938:939	excess AP	931:939	excess AP	931:939	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	7	39	theme	chromatography	1381:1394	arg1	separation					1404:1413	hydrophilic interaction liquid chromatography (HILIC) separation	1350:1413	hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column	1350:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	40	theme	C30	1473:1475	arg1	column					1477:1482	a C30 column	1471:1482	a C30 column	1471:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	5	41	theme	long	993:996	arg1	i.d.					982:985	4.6 mm i.d.	975:985	4.6 mm i.d.	975:985	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	5	41	theme	long	993:996	arg1	cm					990:991	1 cm long	988:996	1 cm long	988:996	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	4	42	theme	glycans	703:709	arg1	analysis					662:669	HPLC analysis	657:669	HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	657:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	7	43	theme	liquid	1374:1379	arg1	HILIC					1397:1401	HILIC	1397:1401	HILIC	1397:1401	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	43	theme	liquid	1374:1379	arg1	chromatography					1381:1394	hydrophilic interaction liquid chromatography	1350:1394	hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column	1350:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	44	theme	AP-labeled	1242:1251	arg1	glycans					1253:1259	AP-labeled glycans	1242:1259	AP-labeled glycans trapped in the ODS column	1242:1285	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	8	45	used	used	1514:1517	arg2	method					1490:1495	This method	1485:1495	This method	1485:1495	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	3	46	theme	solvent	510:516	arg1	extraction					518:527	solvent extraction	510:527	solvent extraction	510:527	Furthermore, these methods, including solvent extraction and solid phase extraction (SPE), often impair quantitative analysis.
32709309	0	47	theme	online	57:62	arg1	extraction					76:85	dual-mode online solid phase extraction	47:85	dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography	47:154	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	5	48	theme	injection	896:904	arg1	port					906:909	an injection port	893:909	an injection port	893:909	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	7	49	theme	valve	1166:1170	arg1	position					1172:1179	the valve position	1162:1179	the valve position after 2 min to connect the ODS column to an analysis column	1162:1239	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	4	50	theme	ODS	843:845	arg1	gel					854:856	ODS silica gel	843:856	ODS silica gel	843:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	6	51	theme	mm	1076:1077	arg1	i.d.					1079:1082	4.6 mm i.d.	1072:1082	4.6 mm i.d.	1072:1082	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	6	51	theme	mm	1076:1077	arg1	cm					1087:1088	1 cm long	1085:1093	1 cm long	1085:1093	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	4	52	theme	small	750:754	arg1	columns					756:762	two small columns	746:762	two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	746:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	0	53	theme	dual-mode	47:55	arg1	extraction					76:85	dual-mode online solid phase extraction	47:85	dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography	47:154	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	7	54	theme	reversed-phase	1437:1450	arg1	separation					1457:1466	reversed-phase mode separation	1437:1466	reversed-phase mode separation	1437:1466	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	6	55	dep	column	1064:1069	arg1	i.d.					1079:1082	4.6 mm i.d.	1072:1082	4.6 mm i.d.	1072:1082	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	6	55	dep	column	1064:1069	arg1	cm					1087:1088	1 cm long	1085:1093	1 cm long	1085:1093	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	2	56	theme	large	384:388	arg1	amounts					390:396	large amounts	384:396	large amounts of excess labeling reagents	384:424	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	2	56	theme	large	384:388	arg1	reagents					417:424	excess labeling reagents	401:424	excess labeling reagents	401:424	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	7	57	theme	mode	1452:1455	arg1	separation					1457:1466	reversed-phase mode separation	1437:1466	reversed-phase mode separation	1437:1466	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	3	58	theme	solid	533:537	arg1	extraction					545:554	solid phase extraction	533:554	solid phase extraction (SPE)	533:560	Furthermore, these methods, including solvent extraction and solid phase extraction (SPE), often impair quantitative analysis.
32709309	3	58	theme	solid	533:537	arg1	SPE					557:559	SPE	557:559	SPE	557:559	Furthermore, these methods, including solvent extraction and solid phase extraction (SPE), often impair quantitative analysis.
32709309	6	59	theme	4.6	1072:1074	arg1	mm					1076:1077	mm	1076:1077	mm	1076:1077	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	7	60	theme	acetonitrile-containing	1307:1329	arg1	eluent					1331:1336	an acetonitrile-containing eluent	1304:1336	an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column	1304:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	4	61	theme	exchange	797:804	arg1	SCX					813:815	SCX	813:815	SCX	813:815	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	4	61	theme	exchange	797:804	arg1	resin					806:810	strong cation exchange resin	783:810	a strong cation exchange resin (SCX)	781:816	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	7	62	theme	ODS	1208:1210	arg1	column					1212:1217	the ODS column	1204:1217	the ODS column	1204:1217	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	63	theme	interaction	1362:1372	arg1	HILIC					1397:1401	HILIC	1397:1401	HILIC	1397:1401	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	7	63	theme	interaction	1362:1372	arg1	chromatography					1381:1394	hydrophilic interaction liquid chromatography	1350:1394	hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column	1350:1482	By changing the valve position after 2 min to connect the ODS column to an analysis column, AP-labeled glycans trapped in the ODS column were eluted with an acetonitrile-containing eluent followed by hydrophilic interaction liquid chromatography (HILIC) separation on an amide column or reversed-phase mode separation on a C30 column.
32709309	3	64	theme	phase	539:543	arg1	extraction					545:554	solid phase extraction	533:554	solid phase extraction (SPE)	533:560	Furthermore, these methods, including solvent extraction and solid phase extraction (SPE), often impair quantitative analysis.
32709309	3	64	theme	phase	539:543	arg1	SPE					557:559	SPE	557:559	SPE	557:559	Furthermore, these methods, including solvent extraction and solid phase extraction (SPE), often impair quantitative analysis.
32709309	5	65	dep	column	967:972	arg1	i.d.					982:985	4.6 mm i.d.	975:985	4.6 mm i.d.	975:985	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	5	65	dep	column	967:972	arg1	cm					990:991	1 cm long	988:996	1 cm long	988:996	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	0	66	theme	phase	70:74	arg1	extraction					76:85	dual-mode online solid phase extraction	47:85	dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography	47:154	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	5	67	theme	AP-labeled	859:868	arg1	glycans					870:876	AP-labeled glycans	859:876	AP-labeled glycans delivered from an injection port	859:909	AP-labeled glycans delivered from an injection port were separated from excess AP by passing through an SCX column (4.6 mm i.d., 1 cm long) regulated to 40°C.
32709309	6	68	theme	inorganic	1126:1134	arg1	contaminants					1136:1147	inorganic contaminants	1126:1147	inorganic contaminants	1126:1147	The AP-labeled glycans were trapped on an ODS column (4.6 mm i.d., 1 cm long) to further separate them from inorganic contaminants.
32709309	4	69	theme	2-aminopyridine	674:688	arg1	glycans					703:709	2-aminopyridine (AP)-labeled glycans	674:709	2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	674:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	2	70	theme	reagents	417:424	arg1	amounts					390:396	large amounts	384:396	large amounts of excess labeling reagents	384:424	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	2	70	theme	reagents	417:424	arg1	reagents					417:424	excess labeling reagents	401:424	excess labeling reagents	401:424	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	1	71	theme	fluorescent	279:289	arg1	labeling					295:302	fluorescent tag labeling	279:302	fluorescent tag labeling	279:302	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32709309	0	72	theme	solid	64:68	arg1	extraction					76:85	dual-mode online solid phase extraction	47:85	dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography	47:154	Analysis of 2-aminopyridine labeled glycans by dual-mode online solid phase extraction for hydrophilic interaction and reversed-phase liquid chromatography.
32709309	8	73	theme	N-linked	1530:1537	arg1	glycans					1539:1545	N-linked glycans	1530:1545	N-linked glycans released from several glycoprotein samples	1530:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	4	74	theme	HPLC	657:660	arg1	analysis					662:669	HPLC analysis	657:669	HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel	657:856	Here, we developed an online sample cleanup procedure for HPLC analysis of 2-aminopyridine (AP)-labeled glycans using a six-port/two-way valve and two small columns: one packed with a strong cation exchange resin (SCX) and the other comprising ODS silica gel.
32709309	2	75	theme	labeling	408:415	arg1	reagents					417:424	excess labeling reagents	401:424	excess labeling reagents	401:424	However, the methods required to remove large amounts of excess labeling reagents from the reaction mixture are time-consuming.
32709309	8	76	theme	several	1561:1567	arg1	samples					1582:1588	several glycoprotein samples	1561:1588	several glycoprotein samples	1561:1588	This method was successfully used to analyze N-linked glycans released from several glycoprotein samples.
32709309	1	77	theme	tag	291:293	arg1	labeling					295:302	fluorescent tag labeling	279:302	fluorescent tag labeling	279:302	Quantitative analysis of glycans released from glycoproteins using high-performance liquid chromatography (HPLC) requires fluorescent tag labeling to enhance sensitivity and selectivity.
32545589	4	0	theme	Limulus	782:788	arg1	polyphemus					790:799	Limulus polyphemus	782:799	Limulus polyphemus	782:799	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	6	1	theme	expression	1020:1029	arg1	level					1031:1035	the mRNA expression level	1011:1035	the mRNA expression level of this receptor	1011:1052	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	6	1	theme	expression	1020:1029	arg1	higher					1072:1077	higher	1072:1077	higher	1072:1077	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	3	2	theme	glycosylation	629:641	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	3	theme	HdhGnRH-R	490:498	arg1	gene					500:503	HdhGnRH-R gene	490:503	HdhGnRH-R gene	490:503	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	11	4	theme	evolution	1808:1816	arg1	studies					1791:1797	further studies	1783:1797	further studies of GPCRs evolution	1783:1816	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	3	5	theme	phosphorylation	655:669	arg1	sites					671:675	phosphorylation sites	655:675	phosphorylation sites	655:675	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	5	theme	phosphorylation	655:669	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	5	theme	phosphorylation	655:669	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	10	6	theme	discus	1679:1684	arg1	hannai					1686:1691	H. discus hannai	1676:1691	H. discus hannai	1676:1691	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	1	7	theme	full-length	168:178	arg1	sequence					185:192	A full-length cDNA sequence	166:192	A full-length cDNA sequence encoding a GnRH receptor	166:217	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	6	8	theme	pleuropedal	1086:1096	arg1	ganglion					1098:1105	the pleuropedal ganglion	1082:1105	the pleuropedal ganglion	1082:1105	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	9	9	theme	pleuropedal	1504:1514	arg1	ganglion					1516:1523	pleuropedal ganglion	1504:1523	pleuropedal ganglion	1504:1523	In situ hybridization revealed that HdhGnRH-R mRNA was expressed in neurosecretory cells of pleuropedal ganglion.
32545589	7	10	theme	gene	1182:1185	arg1	activities					1163:1172	Transcriptional activities	1147:1172	Transcriptional activities of this gene in gonadal tissues	1147:1204	Transcriptional activities of this gene in gonadal tissues were significantly higher in the ripening stage.
32545589	8	11	theme	effective	1366:1374	arg1	temperature					1389:1399	higher effective accumulative temperature	1359:1399	higher effective accumulative temperature (1000 °C)	1359:1409	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	8	11	theme	effective	1366:1374	arg1	°C					1407:1408	1000 °C	1402:1408	1000 °C	1402:1408	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	3	12	theme	receptors	549:557	arg1	sites					671:675	phosphorylation sites	655:675	phosphorylation sites	655:675	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	12	theme	receptors	549:557	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	12	theme	receptors	549:557	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	12	theme	receptors	549:557	arg1	features					519:526	key features	515:526	key features	515:526	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	12	theme	receptors	549:557	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	12	theme	receptors	549:557	arg1	domains					602:608	seven membrane spanning domains	578:608	seven membrane spanning domains	578:608	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	4	13	theme	Mizuhopecten	806:817	arg1	sequences					840:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	10	14	theme	HdhGnRH-R	1551:1559	arg1	gene					1561:1564	HdhGnRH-R gene	1551:1564	HdhGnRH-R gene synthesized in the neural ganglia	1551:1598	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	11	15	theme	discus	1735:1740	arg1	hannai					1742:1747	H. discus hannai	1732:1747	H. discus hannai	1732:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	0	16	theme	Haliotis	142:149	arg1	hannai					158:163	Haliotis discus hannai	142:163	Haliotis discus hannai	142:163	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	16	theme	Haliotis	142:149	arg1	Receptor					104:111	a Gonadotropin-Releasing Hormone Receptor	71:111	a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone	71:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	5	17	theme	O.	965:966	arg1	GnRH-R					936:941	GnRH-R II	936:944	GnRH-R II of O. vulgaris and O. bimaculoides	936:979	Phylogenetic analysis indicated that HdhGnRH-R gene was clustered with GnRH-R II of O. vulgaris and O. bimaculoides.
32545589	11	18	theme	method	1867:1872	arg1	development					1840:1850	the development	1836:1850	the development of aquaculture method of this abalone species	1836:1896	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	4	19	theme	GnRH-R	830:835	arg1	sequences					840:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	0	20	from	Receptor	104:111	arg1	Abalone					133:139	Pacific Abalone	125:139	Pacific Abalone	125:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	6	21	theme	other	1124:1128	arg1	tissue					1139:1144	any other examined tissue	1120:1144	any other examined tissue	1120:1144	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	7	22	theme	ripening	1239:1246	arg1	stage					1248:1252	the ripening stage	1235:1252	the ripening stage	1235:1252	Transcriptional activities of this gene in gonadal tissues were significantly higher in the ripening stage.
32545589	11	23	theme	species	1890:1896	arg1	development					1840:1850	the development	1836:1850	the development of aquaculture method of this abalone species	1836:1896	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	9	24	theme	HdhGnRH-R	1448:1456	arg1	mRNA					1458:1461	HdhGnRH-R mRNA	1448:1461	HdhGnRH-R mRNA	1448:1461	In situ hybridization revealed that HdhGnRH-R mRNA was expressed in neurosecretory cells of pleuropedal ganglion.
32545589	11	25	theme	first	1706:1710	arg1	This					1694:1697	This	1694:1697	This	1694:1697	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	11	25	theme	first	1706:1710	arg1	report					1712:1717	the first report	1702:1717	the first report of GnRH-R in H. discus hannai	1702:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	0	26	theme	Gonadotropin-Releasing	73:94	arg1	GnRH-R					114:119	GnRH-R	114:119	GnRH-R	114:119	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	26	theme	Gonadotropin-Releasing	73:94	arg1	hannai					158:163	Haliotis discus hannai	142:163	Haliotis discus hannai	142:163	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	26	theme	Gonadotropin-Releasing	73:94	arg1	Receptor					104:111	a Gonadotropin-Releasing Hormone Receptor	71:111	a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone	71:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	27	theme	Receptor	104:111	arg1	Characterization					26:41	Characterization	26:41	Characterization	26:41	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	27	theme	Receptor	104:111	arg1	Identification					10:23	Molecular Identification	0:23	Molecular Identification	0:23	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	27	theme	Receptor	104:111	arg1	Analysis					59:66	Expression Analysis	48:66	Expression Analysis	48:66	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	5	28	theme	HdhGnRH-R	902:910	arg1	gene					912:915	HdhGnRH-R gene	902:915	HdhGnRH-R gene	902:915	Phylogenetic analysis indicated that HdhGnRH-R gene was clustered with GnRH-R II of O. vulgaris and O. bimaculoides.
32545589	9	29	dep	In	1412:1413	arg1	situ					1415:1418	situ	1415:1418	situ	1415:1418	In situ hybridization revealed that HdhGnRH-R mRNA was expressed in neurosecretory cells of pleuropedal ganglion.
32545589	2	30	theme	amino	375:379	arg1	residues					386:393	460 amino acid residues	371:393	460 amino acid residues	371:393	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	10	31	theme	neural	1585:1590	arg1	ganglia					1592:1598	the neural ganglia	1581:1598	the neural ganglia	1581:1598	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	0	32	theme	Molecular	0:8	arg1	Identification					10:23	Molecular Identification	0:23	Molecular Identification	0:23	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	1	33	theme	Pacific	267:273	arg1	abalone					275:281	the Pacific abalone	263:281	the Pacific abalone	263:281	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	5	34	theme	Phylogenetic	865:876	arg1	analysis					878:885	Phylogenetic analysis	865:885	Phylogenetic analysis	865:885	Phylogenetic analysis indicated that HdhGnRH-R gene was clustered with GnRH-R II of O. vulgaris and O. bimaculoides.
32545589	2	35	theme	molecular	403:411	arg1	mass					413:416	a molecular mass	401:416	a molecular mass of 52.22 kDa	401:429	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	8	36	theme	pleuropedal	1316:1326	arg1	ganglion					1328:1335	pleuropedal ganglion	1316:1335	pleuropedal ganglion	1316:1335	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	3	37	theme	spanning	593:600	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	37	theme	spanning	593:600	arg1	domains					602:608	seven membrane spanning domains	578:608	seven membrane spanning domains	578:608	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	37	theme	spanning	593:600	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	2	38	theme	residues	386:393	arg1	protein					360:366	a protein	358:366	a protein of 460 amino acid residues	358:393	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	1	39	theme	discus	293:298	arg1	hannai					300:305	Haliotis discus hannai	284:305	Haliotis discus hannai	284:305	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	1	39	theme	discus	293:298	arg1	ganglion					251:258	the pleuropedal ganglion	235:258	the pleuropedal ganglion of the Pacific abalone	235:281	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	2	40	with	1499-bp	331:337	arg1	mass					413:416	a molecular mass	401:416	a molecular mass of 52.22 kDa	401:429	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	40	with	1499-bp	331:337	arg1	pI					457:458	pI	457:458	pI	457:458	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	40	with	1499-bp	331:337	arg1	point					450:454	an isoelectric point	435:454	an isoelectric point (pI) of 9.57	435:467	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	5	41	theme	O.	949:950	arg1	GnRH-R					936:941	GnRH-R II	936:944	GnRH-R II of O. vulgaris and O. bimaculoides	936:979	Phylogenetic analysis indicated that HdhGnRH-R gene was clustered with GnRH-R II of O. vulgaris and O. bimaculoides.
32545589	2	42	theme	kDa	427:429	arg1	mass					413:416	a molecular mass	401:416	a molecular mass of 52.22 kDa	401:429	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	42	theme	kDa	427:429	arg1	pI					457:458	pI	457:458	pI	457:458	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	42	theme	kDa	427:429	arg1	point					450:454	an isoelectric point	435:454	an isoelectric point (pI) of 9.57	435:467	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	4	43	theme	sequence	739:746	arg1	identities					748:757	sequence identities	739:757	sequence identities	739:757	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	10	44	theme	maturation	1644:1653	arg1	control					1625:1631	the control	1621:1631	the control of gonadal maturation and gametogenesis of H. discus hannai	1621:1691	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	0	45	theme	Expression	48:57	arg1	Analysis					59:66	Expression Analysis	48:66	Expression Analysis	48:66	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	3	46	gly	glycosylation	629:641	arg2	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	47	theme	N-linked	620:627	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	11	48	theme	further	1783:1789	arg1	studies					1791:1797	further studies	1783:1797	further studies of GPCRs evolution	1783:1816	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	0	49	from	Abalone	133:139	arg1	Characterization					26:41	Characterization	26:41	Characterization	26:41	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	49	from	Abalone	133:139	arg1	Identification					10:23	Molecular Identification	0:23	Molecular Identification	0:23	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	49	from	Abalone	133:139	arg1	Analysis					59:66	Expression Analysis	48:66	Expression Analysis	48:66	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	8	50	theme	higher	1359:1364	arg1	temperature					1389:1399	higher effective accumulative temperature	1359:1399	higher effective accumulative temperature (1000 °C)	1359:1409	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	8	50	theme	higher	1359:1364	arg1	°C					1407:1408	1000 °C	1402:1408	1000 °C	1402:1408	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	10	51	theme	H.	1676:1677	arg1	hannai					1686:1691	H. discus hannai	1676:1691	H. discus hannai	1676:1691	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	7	52	theme	gonadal	1190:1196	arg1	tissues					1198:1204	gonadal tissues	1190:1204	gonadal tissues	1190:1204	Transcriptional activities of this gene in gonadal tissues were significantly higher in the ripening stage.
32545589	10	53	theme	gametogenesis	1659:1671	arg1	control					1625:1631	the control	1621:1631	the control of gonadal maturation and gametogenesis of H. discus hannai	1621:1691	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	1	54	theme	pleuropedal	239:249	arg1	ganglion					251:258	the pleuropedal ganglion	235:258	the pleuropedal ganglion of the Pacific abalone	235:281	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	1	54	theme	pleuropedal	239:249	arg1	hannai					300:305	Haliotis discus hannai	284:305	Haliotis discus hannai	284:305	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	11	55	from	hannai	1742:1747	arg1	This					1694:1697	This	1694:1697	This	1694:1697	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	11	55	from	hannai	1742:1747	arg1	report					1712:1717	the first report	1702:1717	the first report of GnRH-R in H. discus hannai	1702:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	6	56	theme	mRNA	1015:1018	arg1	level					1031:1035	the mRNA expression level	1011:1035	the mRNA expression level of this receptor	1011:1052	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	6	56	theme	mRNA	1015:1018	arg1	higher					1072:1077	higher	1072:1077	higher	1072:1077	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	2	57	from	1499-bp	331:337	arg1	length					342:347	length	342:347	length encoding a protein of 460 amino acid residues	342:393	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	3	58	theme	serine	680:685	arg1	sites					671:675	phosphorylation sites	655:675	phosphorylation sites	655:675	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	58	theme	serine	680:685	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	58	theme	serine	680:685	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	58	theme	serine	680:685	arg1	domains					602:608	seven membrane spanning domains	578:608	seven membrane spanning domains	578:608	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	58	theme	serine	680:685	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	10	59	theme	hannai	1686:1691	arg1	gametogenesis					1659:1671	gametogenesis	1659:1671	gametogenesis	1659:1671	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	10	59	theme	hannai	1686:1691	arg1	maturation					1644:1653	gonadal maturation	1636:1653	gonadal maturation	1636:1653	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	11	60	from	GnRH-R	1722:1727	arg1	hannai					1742:1747	H. discus hannai	1732:1747	H. discus hannai	1732:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	2	61	from	length	342:347	arg1	1499-bp					331:337	1499-bp	331:337	1499-bp	331:337	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	61	from	length	342:347	arg1	sequence					319:326	The cloned sequence	308:326	The cloned sequence	308:326	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	7	62	theme	Transcriptional	1147:1161	arg1	activities					1163:1172	Transcriptional activities	1147:1172	Transcriptional activities of this gene in gonadal tissues	1147:1204	Transcriptional activities of this gene in gonadal tissues were significantly higher in the ripening stage.
32545589	3	63	theme	key	515:517	arg1	sites					671:675	phosphorylation sites	655:675	phosphorylation sites	655:675	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	63	theme	key	515:517	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	63	theme	key	515:517	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	63	theme	key	515:517	arg1	features					519:526	key features	515:526	key features	515:526	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	63	theme	key	515:517	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	63	theme	key	515:517	arg1	domains					602:608	seven membrane spanning domains	578:608	seven membrane spanning domains	578:608	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	1	64	theme	cDNA	180:183	arg1	sequence					185:192	A full-length cDNA sequence	166:192	A full-length cDNA sequence encoding a GnRH receptor	166:217	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	4	65	theme	Octopus	764:770	arg1	vulgaris					772:779	Octopus vulgaris	764:779	Octopus vulgaris	764:779	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	5	66	dep	O.	949:950	arg1	vulgaris					952:959	O. vulgaris	949:959	O. vulgaris	949:959	Phylogenetic analysis indicated that HdhGnRH-R gene was clustered with GnRH-R II of O. vulgaris and O. bimaculoides.
32545589	5	66	dep	O.	949:950	arg1	bimaculoides					968:979	bimaculoides	968:979	bimaculoides	968:979	Phylogenetic analysis indicated that HdhGnRH-R gene was clustered with GnRH-R II of O. vulgaris and O. bimaculoides.
32545589	11	67	theme	H.	1732:1733	arg1	hannai					1742:1747	H. discus hannai	1732:1747	H. discus hannai	1732:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	0	68	theme	Pacific	125:131	arg1	Abalone					133:139	Pacific Abalone	125:139	Pacific Abalone	125:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	3	69	theme	gene	500:503	arg1	architecture					474:485	The architecture	470:485	The architecture of HdhGnRH-R gene	470:503	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	4	70	theme	II	837:838	arg1	sequences					840:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	8	71	theme	accumulative	1376:1387	arg1	temperature					1389:1399	higher effective accumulative temperature	1359:1399	higher effective accumulative temperature (1000 °C)	1359:1409	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	8	71	theme	accumulative	1376:1387	arg1	°C					1407:1408	1000 °C	1402:1408	1000 °C	1402:1408	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	3	72	theme	threonine	691:699	arg1	sites					671:675	phosphorylation sites	655:675	phosphorylation sites	655:675	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	72	theme	threonine	691:699	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	72	theme	threonine	691:699	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	72	theme	threonine	691:699	arg1	domains					602:608	seven membrane spanning domains	578:608	seven membrane spanning domains	578:608	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	72	theme	threonine	691:699	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	73	theme	protein-coupled	533:547	arg1	GPCRs					560:564	GPCRs	560:564	GPCRs	560:564	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	73	theme	protein-coupled	533:547	arg1	receptors					549:557	G protein-coupled receptors	531:557	G protein-coupled receptors (GPCRs)	531:565	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	1	74	theme	GnRH	205:208	arg1	receptor					210:217	a GnRH receptor	203:217	a GnRH receptor	203:217	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	11	75	from	report	1712:1717	arg1	hannai					1742:1747	H. discus hannai	1732:1747	H. discus hannai	1732:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	0	76	theme	discus	151:156	arg1	hannai					158:163	Haliotis discus hannai	142:163	Haliotis discus hannai	142:163	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	76	theme	discus	151:156	arg1	Receptor					104:111	a Gonadotropin-Releasing Hormone Receptor	71:111	a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone	71:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	11	77	theme	aquaculture	1855:1865	arg1	method					1867:1872	aquaculture method	1855:1872	aquaculture method	1855:1872	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	9	78	theme	In	1412:1413	arg1	hybridization					1420:1432	In situ hybridization	1412:1432	In situ hybridization	1412:1432	In situ hybridization revealed that HdhGnRH-R mRNA was expressed in neurosecretory cells of pleuropedal ganglion.
32545589	4	79	theme	yessoensis	819:828	arg1	sequences					840:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	Mizuhopecten yessoensis GnRH-R II sequences	806:848	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	7	80	from	activities	1163:1172	arg1	tissues					1198:1204	gonadal tissues	1190:1204	gonadal tissues	1190:1204	Transcriptional activities of this gene in gonadal tissues were significantly higher in the ripening stage.
32545589	6	81	theme	examined	1130:1137	arg1	tissue					1139:1144	any other examined tissue	1120:1144	any other examined tissue	1120:1144	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	11	82	theme	abalone	1882:1888	arg1	species					1890:1896	this abalone species	1877:1896	this abalone species	1877:1896	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	4	83	dep	%	723:723	arg1	identities					748:757	sequence identities	739:757	sequence identities	739:757	It shared 63%, 52%, and 30% sequence identities with Octopus vulgaris, Limulus polyphemus, and Mizuhopecten yessoensis GnRH-R II sequences, respectively.
32545589	0	84	from	Characterization	26:41	arg1	Abalone					133:139	Pacific Abalone	125:139	Pacific Abalone	125:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	85	theme	Hormone	96:102	arg1	GnRH-R					114:119	GnRH-R	114:119	GnRH-R	114:119	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	85	theme	Hormone	96:102	arg1	hannai					158:163	Haliotis discus hannai	142:163	Haliotis discus hannai	142:163	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	0	85	theme	Hormone	96:102	arg1	Receptor					104:111	a Gonadotropin-Releasing Hormone Receptor	71:111	a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone	71:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	2	86	theme	isoelectric	438:448	arg1	pI					457:458	pI	457:458	pI	457:458	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	86	theme	isoelectric	438:448	arg1	point					450:454	an isoelectric point	435:454	an isoelectric point (pI) of 9.57	435:467	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	0	87	from	Identification	10:23	arg1	Abalone					133:139	Pacific Abalone	125:139	Pacific Abalone	125:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	8	88	theme	mRNA	1259:1262	arg1	higher					1306:1311	higher	1306:1311	higher	1306:1311	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	8	88	theme	mRNA	1259:1262	arg1	expression					1264:1273	The mRNA expression	1255:1273	The mRNA expression of this gene	1255:1286	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	2	89	theme	9.57	464:467	arg1	mass					413:416	a molecular mass	401:416	a molecular mass of 52.22 kDa	401:429	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	89	theme	9.57	464:467	arg1	pI					457:458	pI	457:458	pI	457:458	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	89	theme	9.57	464:467	arg1	point					450:454	an isoelectric point	435:454	an isoelectric point (pI) of 9.57	435:467	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	0	90	from	Analysis	59:66	arg1	Abalone					133:139	Pacific Abalone	125:139	Pacific Abalone	125:139	Molecular Identification, Characterization, and Expression Analysis of a Gonadotropin-Releasing Hormone Receptor (GnRH-R) in Pacific Abalone, Haliotis discus hannai.
32545589	9	91	theme	neurosecretory	1480:1493	arg1	cells					1495:1499	neurosecretory cells	1480:1499	neurosecretory cells of pleuropedal ganglion	1480:1523	In situ hybridization revealed that HdhGnRH-R mRNA was expressed in neurosecretory cells of pleuropedal ganglion.
32545589	8	92	theme	gene	1283:1286	arg1	higher					1306:1311	higher	1306:1311	higher	1306:1311	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	8	92	theme	gene	1283:1286	arg1	expression					1264:1273	The mRNA expression	1255:1273	The mRNA expression of this gene	1255:1286	The mRNA expression of this gene was significantly higher in pleuropedal ganglion, testis, and ovary at higher effective accumulative temperature (1000 °C).
32545589	11	93	theme	GnRH-R	1722:1727	arg1	This					1694:1697	This	1694:1697	This	1694:1697	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	11	93	theme	GnRH-R	1722:1727	arg1	report					1712:1717	the first report	1702:1717	the first report of GnRH-R in H. discus hannai	1702:1747	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32545589	1	94	theme	abalone	275:281	arg1	ganglion					251:258	the pleuropedal ganglion	235:258	the pleuropedal ganglion of the Pacific abalone	235:281	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	1	94	theme	abalone	275:281	arg1	hannai					300:305	Haliotis discus hannai	284:305	Haliotis discus hannai	284:305	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	9	95	theme	ganglion	1516:1523	arg1	cells					1495:1499	neurosecretory cells	1480:1499	neurosecretory cells of pleuropedal ganglion	1480:1523	In situ hybridization revealed that HdhGnRH-R mRNA was expressed in neurosecretory cells of pleuropedal ganglion.
32545589	6	96	theme	qPCR	982:985	arg1	assay					987:991	qPCR assay	982:991	qPCR assay	982:991	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	3	97	theme	membrane	584:591	arg1	threonine					691:699	threonine	691:699	threonine	691:699	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	97	theme	membrane	584:591	arg1	domains					602:608	seven membrane spanning domains	578:608	seven membrane spanning domains	578:608	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	3	97	theme	membrane	584:591	arg1	serine					680:685	serine	680:685	serine	680:685	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	1	98	theme	Haliotis	284:291	arg1	hannai					300:305	Haliotis discus hannai	284:305	Haliotis discus hannai	284:305	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	1	98	theme	Haliotis	284:291	arg1	ganglion					251:258	the pleuropedal ganglion	235:258	the pleuropedal ganglion of the Pacific abalone	235:281	A full-length cDNA sequence encoding a GnRH receptor was cloned from the pleuropedal ganglion of the Pacific abalone, Haliotis discus hannai.
32545589	2	99	theme	acid	381:384	arg1	residues					386:393	460 amino acid residues	371:393	460 amino acid residues	371:393	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	3	100	theme	putative	611:618	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	10	101	theme	gonadal	1636:1642	arg1	maturation					1644:1653	gonadal maturation	1636:1653	gonadal maturation	1636:1653	Our results suggest that HdhGnRH-R gene synthesized in the neural ganglia might be involved in the control of gonadal maturation and gametogenesis of H. discus hannai.
32545589	3	102	dep	serine	680:685	arg1	residues					701:708	residues	701:708	residues	701:708	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	6	103	theme	receptor	1045:1052	arg1	level					1031:1035	the mRNA expression level	1011:1035	the mRNA expression level of this receptor	1011:1052	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	6	103	theme	receptor	1045:1052	arg1	higher					1072:1077	higher	1072:1077	higher	1072:1077	qPCR assay demonstrated that the mRNA expression level of this receptor was significantly higher in the pleuropedal ganglion than that in any other examined tissue.
32545589	2	104	theme	cloned	312:317	arg1	1499-bp					331:337	1499-bp	331:337	1499-bp	331:337	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	2	104	theme	cloned	312:317	arg1	sequence					319:326	The cloned sequence	308:326	The cloned sequence	308:326	The cloned sequence is 1499-bp in length encoding a protein of 460 amino acid residues, with a molecular mass of 52.22 kDa and an isoelectric point (pI) of 9.57.
32545589	3	105	link	N-linked	620:627	arg1	motifs					643:648	putative N-linked glycosylation motifs	611:648	putative N-linked glycosylation motifs	611:648	The architecture of HdhGnRH-R gene exhibited key features of G protein-coupled receptors (GPCRs), including seven membrane spanning domains, putative N-linked glycosylation motifs, and phosphorylation sites of serine and threonine residues.
32545589	11	106	theme	GPCRs	1802:1806	arg1	evolution					1808:1816	GPCRs evolution	1802:1816	GPCRs evolution	1802:1816	This is the first report of GnRH-R in H. discus hannai and the results may contribute to further studies of GPCRs evolution or may useful for the development of aquaculture method of this abalone species.
32340215	6	0	theme	ataxia	1045:1050	arg1	diagnosis					1010:1018	the diagnosis	1006:1018	the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia	1006:1074	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	1	1	theme	encoding	145:152	arg1	MAG					186:188	MAG	186:188	MAG	186:188	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	1	theme	encoding	145:152	arg1	glycoprotein					172:183	encoding myelin-associated glycoprotein	145:183	encoding myelin-associated glycoprotein (MAG)	145:189	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	1	theme	encoding	145:152	arg1	MAG					140:142	MAG	140:142	MAG	140:142	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	2	theme	hereditary	239:248	arg1	HSP					270:272	HSP	270:272	HSP	270:272	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	2	theme	hereditary	239:248	arg1	paraplegia					258:267	hereditary spastic paraplegia	239:267	hereditary spastic paraplegia (HSP)	239:273	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	0	3	theme	Molecular	68:76	arg1	Basis					78:82	Molecular Basis	68:82	Molecular Basis	68:82	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	1	4	gly	glycoprotein	172:183	arg1	MAG					186:188	MAG	186:188	MAG	186:188	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	4	gly	glycoprotein	172:183	arg1	glycoprotein					172:183	encoding myelin-associated glycoprotein	145:183	encoding myelin-associated glycoprotein (MAG)	145:189	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	4	gly	glycoprotein	172:183	arg1	MAG					140:142	MAG	140:142	MAG	140:142	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	5	theme	myelin-associated	154:170	arg1	MAG					186:188	MAG	186:188	MAG	186:188	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	5	theme	myelin-associated	154:170	arg1	glycoprotein					172:183	encoding myelin-associated glycoprotein	145:183	encoding myelin-associated glycoprotein (MAG)	145:189	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	5	theme	myelin-associated	154:170	arg1	MAG					140:142	MAG	140:142	MAG	140:142	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	6	theme	spastic	250:256	arg1	HSP					270:272	HSP	270:272	HSP	270:272	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	6	theme	spastic	250:256	arg1	paraplegia					258:267	hereditary spastic paraplegia	239:267	hereditary spastic paraplegia (HSP)	239:273	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	0	7	theme	Expanded	88:95	arg1	Phenotype					106:114	Expanded Clinical Phenotype	88:114	Expanded Clinical Phenotype	88:114	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	3	8	theme	autosomal	507:515	arg1	ataxia					538:543	early-onset autosomal recessive cerebellar ataxia	495:543	early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	495:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	1	9	theme	paraplegia	258:267	arg1	forms					230:234	complicated forms	218:234	complicated forms of hereditary spastic paraplegia (HSP)	218:273	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	5	10	link	N-linked	830:837	arg1	glycosylation					839:851	N-linked glycosylation	830:851	N-linked glycosylation	830:851	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	5	10	link	N-linked	830:837	arg1	processing					818:827	post-translational processing	799:827	post-translational processing (N-linked glycosylation)	799:852	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	3	11	theme	recessive	517:525	arg1	ataxia					538:543	early-onset autosomal recessive cerebellar ataxia	495:543	early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	495:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	4	12	theme	cellular	668:675	arg1	studies					677:683	cellular studies	668:683	cellular studies	668:683	We used homozygosity mapping and exome sequencing to identify the MAG variant, and cellular studies to confirm its detrimental effect.
32340215	5	13	theme	N-linked	830:837	arg1	glycosylation					839:851	N-linked glycosylation	830:851	N-linked glycosylation	830:851	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	5	13	theme	N-linked	830:837	arg1	processing					818:827	post-translational processing	799:827	post-translational processing (N-linked glycosylation)	799:852	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	3	14	theme	homozygous	409:418	arg1	variant					429:435	a novel homozygous missense variant	401:435	a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	401:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	0	15	theme	Clinical	97:104	arg1	Phenotype					106:114	Expanded Clinical Phenotype	88:114	Expanded Clinical Phenotype	88:114	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	1	16	from	variants	128:135	arg1	glycoprotein					172:183	encoding myelin-associated glycoprotein	145:183	encoding myelin-associated glycoprotein (MAG)	145:189	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	1	16	from	variants	128:135	arg1	MAG					140:142	MAG	140:142	MAG	140:142	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	3	17	theme	early-onset	495:505	arg1	ataxia					538:543	early-onset autosomal recessive cerebellar ataxia	495:543	early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	495:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	3	18	theme	missense	420:427	arg1	variant					429:435	a novel homozygous missense variant	401:435	a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	401:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	0	19	theme	MAG	6:8	arg1	Variant					10:16	Novel MAG Variant	0:16	Novel MAG Variant	0:16	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	5	20	theme	function	929:936	arg1	loss					913:916	a loss	911:916	a loss of protein function	911:936	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	0	21	theme	Novel	0:4	arg1	Variant					10:16	Novel MAG Variant	0:16	Novel MAG Variant	0:16	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	6	22	theme	MAG	969:971	arg1	variants					973:980	MAG variants	969:980	MAG variants	969:980	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	2	23	theme	glycoprotein	285:296	arg1	MAG					276:278	MAG	276:278	MAG	276:278	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	2	23	theme	glycoprotein	285:296	arg1	member					298:303	a glycoprotein member	283:303	a glycoprotein member	283:303	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	3	24	theme	novel	403:407	arg1	variant					429:435	a novel homozygous missense variant	401:435	a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	401:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	5	25	theme	post-translational	799:816	arg1	glycosylation					839:851	N-linked glycosylation	830:851	N-linked glycosylation	830:851	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	5	25	theme	post-translational	799:816	arg1	processing					818:827	post-translational processing	799:827	post-translational processing (N-linked glycosylation)	799:852	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	3	26	with	variant	429:435	arg1	ataxia					538:543	early-onset autosomal recessive cerebellar ataxia	495:543	early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	495:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	3	27	theme	cerebellar	527:536	arg1	ataxia					538:543	early-onset autosomal recessive cerebellar ataxia	495:543	early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia	495:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	4	28	theme	exome	618:622	arg1	sequencing					624:633	exome sequencing	618:633	exome sequencing	618:633	We used homozygosity mapping and exome sequencing to identify the MAG variant, and cellular studies to confirm its detrimental effect.
32340215	0	29	dep	Apraxia	59:65	arg1	Basis					78:82	Molecular Basis	68:82	Molecular Basis	68:82	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	0	29	dep	Apraxia	59:65	arg1	Phenotype					106:114	Expanded Clinical Phenotype	88:114	Expanded Clinical Phenotype	88:114	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	3	30	theme	Portuguese	472:481	arg1	family					483:488	a Portuguese family	470:488	a Portuguese family	470:488	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	2	31	theme	immunoglobulin	312:325	arg1	superfamily					327:337	the immunoglobulin superfamily	308:337	the immunoglobulin superfamily	308:337	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	3	32	with	ataxia	538:543	arg1	apraxia					576:582	oculomotor apraxia	565:582	oculomotor apraxia	565:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	3	32	with	ataxia	538:543	arg1	neuropathy					550:559	neuropathy	550:559	neuropathy	550:559	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	4	33	theme	MAG	651:653	arg1	variant					655:661	the MAG variant	647:661	the MAG variant	647:661	We used homozygosity mapping and exome sequencing to identify the MAG variant, and cellular studies to confirm its detrimental effect.
32340215	6	34	theme	cerebellar	1034:1043	arg1	ataxia					1045:1050	hereditary cerebellar ataxia	1023:1050	hereditary cerebellar ataxia with oculomotor apraxia	1023:1074	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	0	35	theme	Cerebellar	25:34	arg1	Ataxia					36:41	Cerebellar Ataxia	25:41	Cerebellar Ataxia	25:41	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	4	36	used	used	588:591	arg2	We					585:586	We	585:586	We	585:586	We used homozygosity mapping and exome sequencing to identify the MAG variant, and cellular studies to confirm its detrimental effect.
32340215	3	37	from	variant	429:435	arg1	MAG					440:442	MAG	440:442	MAG	440:442	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	3	37	from	variant	429:435	arg1	family					483:488	a Portuguese family	470:488	a Portuguese family	470:488	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	6	38	theme	hereditary	1023:1032	arg1	ataxia					1045:1050	hereditary cerebellar ataxia	1023:1050	hereditary cerebellar ataxia with oculomotor apraxia	1023:1074	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	0	39	theme	Oculomotor	48:57	arg1	Apraxia					59:65	Oculomotor Apraxia	48:65	Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype	48:114	Novel MAG Variant Causes Cerebellar Ataxia with Oculomotor Apraxia: Molecular Basis and Expanded Clinical Phenotype.
32340215	5	40	theme	MAG	886:888	arg1	glycosylation					839:851	N-linked glycosylation	830:851	N-linked glycosylation	830:851	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	5	40	theme	MAG	886:888	arg1	localization					870:881	subcellular localization	858:881	subcellular localization	858:881	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	5	40	theme	MAG	886:888	arg1	processing					818:827	post-translational processing	799:827	post-translational processing (N-linked glycosylation)	799:852	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	2	41	theme	superfamily	327:337	arg1	MAG					276:278	MAG	276:278	MAG	276:278	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	2	41	theme	superfamily	327:337	arg1	member					298:303	a glycoprotein member	283:303	a glycoprotein member	283:303	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	5	42	dep	processing	818:827	arg1	the					795:797	the	795:797	the	795:797	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	6	43	theme	oculomotor	1057:1066	arg1	apraxia					1068:1074	oculomotor apraxia	1057:1074	oculomotor apraxia	1057:1074	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	3	44	theme	oculomotor	565:574	arg1	apraxia					576:582	oculomotor apraxia	565:582	oculomotor apraxia	565:582	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	1	45	theme	Homozygous	117:126	arg1	variants					128:135	Homozygous variants	117:135	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG),	117:190	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	3	46	dep	variant	429:435	arg1	c.124T>C					445:452	c.124T>C	445:452	c.124T>C; p.Cys42Arg	445:464	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	4	47	theme	detrimental	700:710	arg1	effect					712:717	its detrimental effect	696:717	its detrimental effect	696:717	We used homozygosity mapping and exome sequencing to identify the MAG variant, and cellular studies to confirm its detrimental effect.
32340215	3	48	dep	c.124T>C	445:452	arg1	p.Cys42Arg					455:464	p.Cys42Arg	455:464	c.124T>C; p.Cys42Arg	445:464	In this study, we identified a novel homozygous missense variant in MAG (c.124T>C; p.Cys42Arg) in a Portuguese family with early-onset autosomal recessive cerebellar ataxia with neuropathy and oculomotor apraxia.
32340215	5	49	theme	protein	921:927	arg1	function					929:936	protein function	921:936	protein function	921:936	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	1	50	theme	complicated	218:228	arg1	forms					230:234	complicated forms	218:234	complicated forms of hereditary spastic paraplegia (HSP)	218:273	Homozygous variants in MAG, encoding myelin-associated glycoprotein (MAG), have been associated with complicated forms of hereditary spastic paraplegia (HSP).
32340215	2	51	gly	glycoprotein	285:296	arg1	glycoprotein					285:296	a glycoprotein member	283:303	a glycoprotein member	283:303	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	6	52	with	ataxia	1045:1050	arg1	apraxia					1068:1074	oculomotor apraxia	1057:1074	oculomotor apraxia	1057:1074	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	2	53	theme	myelination	353:363	arg1	cells					365:369	myelination cells	353:369	myelination cells	353:369	MAG is a glycoprotein member of the immunoglobulin superfamily, expressed by myelination cells.
32340215	5	54	theme	subcellular	858:868	arg1	localization					870:881	subcellular localization	858:881	subcellular localization	858:881	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	5	55	theme	protein	765:771	arg1	stability					773:781	protein stability	765:781	protein stability	765:781	Our results showed that this variant reduces protein stability and impairs the post-translational processing (N-linked glycosylation) and subcellular localization of MAG, thereby associating a loss of protein function with the phenotype.
32340215	6	56	theme	spastic	1092:1098	arg1	paraplegia					1100:1109	spastic paraplegia	1092:1109	spastic paraplegia	1092:1109	Therefore, MAG variants should be considered in the diagnosis of hereditary cerebellar ataxia with oculomotor apraxia, in addition to spastic paraplegia.
32340215	4	57	theme	homozygosity	593:604	arg1	mapping					606:612	homozygosity mapping	593:612	homozygosity mapping	593:612	We used homozygosity mapping and exome sequencing to identify the MAG variant, and cellular studies to confirm its detrimental effect.
34853076	6	0	theme	human	907:911	arg1	C5a					913:915	recombinant human C5a	895:915	recombinant human C5a to purified plasma-derived human C5a	895:952	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	9	1	theme	functional/cytokine	1656:1674	arg1	assays					1676:1681	functional/cytokine assays	1656:1681	functional/cytokine assays conducted in human primary immune cells	1656:1721	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	3	2	contain	contains	348:355	arg2	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	3	2	contain	contains	348:355	arg1	C5a					344:346	Native C5a	337:346	Native C5a	337:346	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	7	3	theme	C5aR2-mediated	1123:1136	arg1	signaling					1143:1151	C5aR2-mediated cell signaling	1123:1151	C5aR2-mediated cell signaling	1123:1151	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	3	4	theme	studies	484:490	arg1	majority					462:469	the vast majority	453:469	the vast majority of published studies examining C5a	453:504	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	2	5	theme	proinflammatory	158:172	arg1	actions					195:201	potent proinflammatory and immunomodulatory actions	151:201	potent proinflammatory and immunomodulatory actions	151:201	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	3	6	link	N-linked	365:372	arg1	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	9	7	theme	human	1696:1700	arg1	cells					1717:1721	human primary immune cells	1696:1721	human primary immune cells	1696:1721	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	9	8	with	paired	1782:1787	arg1	inhibitors					1800:1809	C5aR1 inhibitors	1794:1809	C5aR1 inhibitors	1794:1809	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	9	8	with	paired	1782:1787	arg1	C5a					1839:1841	purified/synthetic human C5a	1814:1841	purified/synthetic human C5a	1814:1841	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	7	9	link	monocyte-derived	1214:1229	arg1	macrophages					1231:1241	primary human monocyte-derived macrophages	1200:1241	primary human monocyte-derived macrophages	1200:1241	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	6	10	theme	current	864:870	arg1	study					872:876	the current study	860:876	the current study	860:876	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	9	11	theme	immune	1710:1715	arg1	cells					1717:1721	human primary immune cells	1696:1721	human primary immune cells	1696:1721	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	8	12	theme	C5a	1287:1289	arg1	sources					1264:1270	Multiple commercial sources	1244:1270	Multiple commercial sources	1244:1270	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	7	13	theme	similar	1080:1086	arg1	potencies					1088:1096	similar potencies	1080:1096	similar potencies	1080:1096	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	2	14	theme	cells	330:334	arg1	signaling					284:292	multiple signaling and functional activities	275:318	signaling	284:292	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	2	14	theme	cells	330:334	arg1	activities					309:318	multiple signaling and functional activities	275:318	activities	309:318	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	7	15	theme	C5a	1066:1068	arg1	versions					1054:1061	both versions	1049:1061	both versions of C5a	1049:1068	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	3	16	theme	recombinant	553:563	arg1	C5a					565:567	Escherichia coli-generated recombinant C5a	526:567	Escherichia coli-generated recombinant C5a	526:567	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	2	17	theme	functional	298:307	arg1	activities					309:318	multiple signaling and functional activities	275:318	activities	309:318	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	8	18	theme	commercial	1253:1262	arg1	sources					1264:1270	Multiple commercial sources	1244:1270	Multiple commercial sources	1244:1270	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	6	19	theme	plasma-derived	929:942	arg1	C5a					950:952	purified plasma-derived human C5a	920:952	purified plasma-derived human C5a	920:952	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	4	20	theme	"	704:704	arg1	form					706:709	a plasma-purified "native" form	679:709	a plasma-purified "native" form of C5a	679:716	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	4	20	theme	"	704:704	arg1	available					739:747	available	739:747	available	739:747	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	1	21	theme	complement	117:126	arg1	activation					128:137	complement activation	117:137	complement activation	117:137	The anaphylatoxin C5a is core effector of complement activation.
34853076	9	22	theme	human	1762:1766	arg1	C5a					1768:1770	recombinant human C5a	1750:1770	recombinant human C5a	1750:1770	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	8	23	theme	NF-κB	1488:1492	arg1	signaling					1494:1502	NF-κB signaling	1488:1502	NF-κB signaling	1488:1502	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	8	24	theme	synthetic	1325:1333	arg1	version					1339:1345	a synthetic C5a version	1323:1345	a synthetic C5a version	1323:1345	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	6	25	theme	primary	1014:1020	arg1	macrophages					1022:1032	human primary macrophages	1008:1032	human primary macrophages	1008:1032	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	6	26	link	plasma-derived	929:942	arg1	C5a					950:952	purified plasma-derived human C5a	920:952	purified plasma-derived human C5a	920:952	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	3	27	theme	Native	337:342	arg1	C5a					344:346	Native C5a	337:346	Native C5a	337:346	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	5	28	theme	different	754:762	arg1	size					764:767	different size	754:767	different size	754:767	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	6	29	theme	functional	983:992	arg1	activities					994:1003	the signaling and functional activities	965:1003	activities	994:1003	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	3	30	theme	glycosylation	374:386	arg1	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	8	31	theme	monocyte-derived	1362:1377	arg1	macrophages					1379:1389	human monocyte-derived macrophages	1356:1389	human monocyte-derived macrophages	1356:1389	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	7	32	theme	monocyte-derived	1214:1229	arg1	macrophages					1231:1241	primary human monocyte-derived macrophages	1200:1241	primary human monocyte-derived macrophages	1200:1241	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	3	33	theme	Escherichia	526:536	arg1	C5a					565:567	Escherichia coli-generated recombinant C5a	526:567	Escherichia coli-generated recombinant C5a	526:567	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	6	34	theme	signaling	969:977	arg1	activities					994:1003	the signaling and functional activities	965:1003	activities	994:1003	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	3	35	theme	large	359:363	arg1	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	7	36	theme	primary	1200:1206	arg1	macrophages					1231:1241	primary human monocyte-derived macrophages	1200:1241	primary human monocyte-derived macrophages	1200:1241	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	1	37	theme	anaphylatoxin	79:91	arg1	C5a					93:95	The anaphylatoxin C5a	75:95	The anaphylatoxin C5a	75:95	The anaphylatoxin C5a is core effector of complement activation.
34853076	1	37	theme	anaphylatoxin	79:91	arg1	effector					105:112	core effector	100:112	core effector of complement activation	100:137	The anaphylatoxin C5a is core effector of complement activation.
34853076	9	38	theme	human	1833:1837	arg1	C5a					1839:1841	purified/synthetic human C5a	1814:1841	purified/synthetic human C5a	1814:1841	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	3	39	from	suppliers	622:630	arg1	available					587:595	available	587:595	available	587:595	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	0	40	theme	Unexpected	0:9	arg1	Activities					22:31	Unexpected Off-Target Activities	0:31	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages	0:72	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages.
34853076	5	41	theme	versions	804:811	arg1	glycosylation					773:785	glycosylation	773:785	glycosylation	773:785	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	5	41	theme	versions	804:811	arg1	size					764:767	different size	754:767	different size	754:767	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	3	42	gly	glycosylation	374:386	arg2	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	3	42	gly	glycosylation	374:386	arg2	Asn64					396:400	Asn64	396:400	Asn64	396:400	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	9	43	theme	sole	1605:1608	arg1	use					1610:1612	the sole use	1601:1612	the sole use of recombinant human C5a	1601:1637	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	9	44	theme	relevant	1854:1861	arg1	findings					1863:1870	relevant findings	1854:1870	relevant findings	1854:1870	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	3	45	theme	m.w.	439:442	arg1	%					430:430	up to 25%	422:430	up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers	422:630	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	3	45	theme	m.w.	439:442	arg1	m.w.					439:442	its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers	435:630	its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers	435:630	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	0	46	theme	Recombinant	37:47	arg1	C5a					49:51	Recombinant C5a	37:51	Recombinant C5a in Human Macrophages	37:72	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages.
34853076	8	47	theme	receptor-independent	1426:1445	arg1	manner					1447:1452	a C5a receptor-independent manner	1420:1452	a C5a receptor-independent manner	1420:1452	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	9	48	theme	human	1629:1633	arg1	C5a					1635:1637	recombinant human C5a	1617:1637	recombinant human C5a	1617:1637	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	3	49	theme	numerous	602:609	arg1	suppliers					622:630	numerous commercial suppliers	602:630	numerous commercial suppliers	602:630	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	2	50	theme	multiple	275:282	arg1	signaling					284:292	multiple signaling and functional activities	275:318	signaling	284:292	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	7	51	theme	cell	1138:1141	arg1	signaling					1143:1151	C5aR2-mediated cell signaling	1123:1151	C5aR2-mediated cell signaling	1123:1151	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	3	52	theme	published	474:482	arg1	studies					484:490	published studies	474:490	published studies examining C5a	474:504	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	6	53	theme	recombinant	895:905	arg1	C5a					913:915	recombinant human C5a	895:915	recombinant human C5a to purified plasma-derived human C5a	895:952	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	2	54	theme	potent	151:156	arg1	actions					195:201	potent proinflammatory and immunomodulatory actions	151:201	potent proinflammatory and immunomodulatory actions	151:201	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	7	55	theme	distinct	1167:1174	arg1	responses					1187:1195	distinct functional responses	1167:1195	distinct functional responses	1167:1195	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	9	56	theme	primary	1702:1708	arg1	cells					1717:1721	human primary immune cells	1696:1721	human primary immune cells	1696:1721	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	8	57	theme	recombinant	1275:1285	arg1	C5a					1287:1289	recombinant C5a	1275:1289	recombinant C5a	1275:1289	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	2	58	theme	immune	323:328	arg1	cells					330:334	immune cells	323:334	immune cells	323:334	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	8	59	link	monocyte-derived	1362:1377	arg1	macrophages					1379:1389	human monocyte-derived macrophages	1356:1389	human monocyte-derived macrophages	1356:1389	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	5	60	theme	functional	824:833	arg1	implications					835:846	functional implications	824:846	functional implications	824:846	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	6	61	theme	human	944:948	arg1	C5a					950:952	purified plasma-derived human C5a	920:952	purified plasma-derived human C5a	920:952	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	9	62	theme	C5aR1	1794:1798	arg1	inhibitors					1800:1809	C5aR1 inhibitors	1794:1809	C5aR1 inhibitors	1794:1809	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	8	63	theme	Multiple	1244:1251	arg1	sources					1264:1270	Multiple commercial sources	1244:1270	Multiple commercial sources	1244:1270	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	6	64	theme	purified	920:927	arg1	C5a					950:952	purified plasma-derived human C5a	920:952	purified plasma-derived human C5a	920:952	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	9	65	theme	recombinant	1750:1760	arg1	C5a					1768:1770	recombinant human C5a	1750:1770	recombinant human C5a	1750:1770	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	4	66	theme	native	698:703	arg1	form					706:709	a plasma-purified "native" form	679:709	a plasma-purified "native" form of C5a	679:716	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	4	66	theme	native	698:703	arg1	available					739:747	available	739:747	available	739:747	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	3	67	dep	m.w.	439:442	arg1	performed					510:518	performed	510:518	are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers	506:630	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	3	68	theme	commercial	611:620	arg1	suppliers					622:630	numerous commercial suppliers	602:630	numerous commercial suppliers	602:630	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	1	69	theme	activation	128:137	arg1	C5a					93:95	The anaphylatoxin C5a	75:95	The anaphylatoxin C5a	75:95	The anaphylatoxin C5a is core effector of complement activation.
34853076	1	69	theme	activation	128:137	arg1	effector					105:112	core effector	100:112	core effector of complement activation	100:137	The anaphylatoxin C5a is core effector of complement activation.
34853076	3	70	theme	coli-generated	538:551	arg1	C5a					565:567	Escherichia coli-generated recombinant C5a	526:567	Escherichia coli-generated recombinant C5a	526:567	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	6	71	theme	macrophages	1022:1032	arg1	activities					994:1003	the signaling and functional activities	965:1003	activities	994:1003	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	6	72	theme	human	1008:1012	arg1	macrophages					1022:1032	human primary macrophages	1008:1032	human primary macrophages	1008:1032	Therefore, the current study aimed to compare recombinant human C5a to purified plasma-derived human C5a in driving the signaling and functional activities of human primary macrophages.
34853076	8	73	theme	C5a	1335:1337	arg1	version					1339:1345	a synthetic C5a version	1323:1345	a synthetic C5a version	1323:1345	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	8	74	theme	endotoxin	1530:1538	arg1	contamination					1540:1552	endotoxin contamination	1530:1552	endotoxin contamination	1530:1552	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	4	75	theme	plasma-purified	681:695	arg1	form					706:709	a plasma-purified "native" form	679:709	a plasma-purified "native" form of C5a	679:716	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	4	75	theme	plasma-purified	681:695	arg1	available					739:747	available	739:747	available	739:747	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	7	76	theme	human	1208:1212	arg1	macrophages					1231:1241	primary human monocyte-derived macrophages	1200:1241	primary human monocyte-derived macrophages	1200:1241	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
34853076	8	77	theme	human	1356:1360	arg1	macrophages					1379:1389	human monocyte-derived macrophages	1356:1389	human monocyte-derived macrophages	1356:1389	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	3	78	from	Asn64	396:400	arg1	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	3	79	theme	N-linked	365:372	arg1	site					388:391	a large N-linked glycosylation site	357:391	a large N-linked glycosylation site	357:391	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	0	80	from	C5a	49:51	arg1	Macrophages					62:72	Human Macrophages	56:72	Human Macrophages	56:72	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages.
34853076	0	81	theme	Off-Target	11:20	arg1	Activities					22:31	Unexpected Off-Target Activities	0:31	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages	0:72	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages.
34853076	5	82	contain	have	819:822	arg1	glycosylation					773:785	glycosylation	773:785	glycosylation	773:785	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	5	82	contain	have	819:822	arg1	size					764:767	different size	754:767	different size	754:767	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	5	82	contain	have	819:822	arg2	implications					835:846	functional implications	824:846	functional implications	824:846	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	4	83	theme	C5a	714:716	arg1	form					706:709	a plasma-purified "native" form	679:709	a plasma-purified "native" form of C5a	679:716	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	4	83	theme	C5a	714:716	arg1	available					739:747	available	739:747	available	739:747	However, a plasma-purified "native" form of C5a is also commercially available.
34853076	5	84	theme	C5a	800:802	arg1	versions					804:811	these two C5a versions	790:811	these two C5a versions	790:811	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	1	85	theme	core	100:103	arg1	C5a					93:95	The anaphylatoxin C5a	75:95	The anaphylatoxin C5a	75:95	The anaphylatoxin C5a is core effector of complement activation.
34853076	1	85	theme	core	100:103	arg1	effector					105:112	core effector	100:112	core effector of complement activation	100:137	The anaphylatoxin C5a is core effector of complement activation.
34853076	3	86	dep	25	428:429	arg1	to					425:426	to	425:426	to	425:426	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	2	87	theme	immunomodulatory	178:193	arg1	actions					195:201	potent proinflammatory and immunomodulatory actions	151:201	potent proinflammatory and immunomodulatory actions	151:201	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	9	88	theme	purified/synthetic	1814:1831	arg1	C5a					1839:1841	purified/synthetic human C5a	1814:1841	purified/synthetic human C5a	1814:1841	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	0	89	theme	Human	56:60	arg1	Macrophages					62:72	Human Macrophages	56:72	Human Macrophages	56:72	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages.
34853076	9	90	theme	recombinant	1617:1627	arg1	C5a					1635:1637	recombinant human C5a	1617:1637	recombinant human C5a	1617:1637	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	2	91	theme	C5a	232:234	arg1	C5aR1					247:251	C5aR1	247:251	C5aR1	247:251	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	2	91	theme	C5a	232:234	arg1	receptors					236:244	its C5a receptors	228:244	its C5a receptors	228:244	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	2	91	theme	C5a	232:234	arg1	C5aR2					257:261	C5aR2	257:261	C5aR2	257:261	C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells.
34853076	8	92	theme	C5a	1422:1424	arg1	manner					1447:1452	a C5a receptor-independent manner	1420:1452	a C5a receptor-independent manner	1420:1452	Multiple commercial sources of recombinant C5a, but not the plasma-purified or a synthetic C5a version, induced human monocyte-derived macrophages to produce IL-6 and IL-10 in a C5a receptor-independent manner, which was driven through Syk and NF-κB signaling and apparently not due to endotoxin contamination.
34853076	9	93	theme	C5a	1635:1637	arg1	use					1610:1612	the sole use	1601:1612	the sole use of recombinant human C5a	1601:1637	Our results, therefore, offer caution against the sole use of recombinant human C5a, particularly in functional/cytokine assays conducted in human primary immune cells, and suggest studies using recombinant human C5a should be paired with C5aR1 inhibitors or purified/synthetic human C5a to confirm relevant findings.
34853076	3	94	theme	glycosylation	648:660	arg1	moiety					662:667	this glycosylation moiety	643:667	this glycosylation moiety	643:667	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	3	95	theme	vast	457:460	arg1	majority					462:469	the vast majority	453:469	the vast majority of published studies examining C5a	453:504	Native C5a contains a large N-linked glycosylation site at Asn64, which accounts for up to 25% of its m.w. To date, the vast majority of published studies examining C5a are performed using Escherichia coli-generated recombinant C5a, which is readily available from numerous commercial suppliers, but lacks this glycosylation moiety.
34853076	5	96	gly	glycosylation	773:785	arg1	versions					804:811	these two C5a versions	790:811	these two C5a versions	790:811	The different size and glycosylation of these two C5a versions could have functional implications.
34853076	7	97	theme	functional	1176:1185	arg1	responses					1187:1195	distinct functional responses	1167:1195	distinct functional responses	1167:1195	We found that both versions of C5a displayed similar potencies at triggering C5aR1- and C5aR2-mediated cell signaling, but elicited distinct functional responses in primary human monocyte-derived macrophages.
32273875	9	0	theme	closer	1720:1725	arg1	models					1697:1702	preclinical models	1685:1702	preclinical models of hemophilia A closer to humans	1685:1735	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	3	1	with	interaction	516:526	arg1	receptors					566:574	mannose-sensitive receptors	548:574	mannose-sensitive receptors on antigen-presenting cells	548:602	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	8	2	from	dissimilarities	1553:1567	arg1	pathways					1492:1499	the endocytic pathways	1478:1499	the endocytic pathways	1478:1499	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	7	3	theme	VIII-deficient	1420:1433	arg1	mice					1435:1438	factor VIII-deficient mice	1413:1438	factor VIII-deficient mice	1413:1438	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	6	4	theme	VIII	1239:1242	arg1	endocytosis					1244:1254	factor VIII endocytosis	1232:1254	factor VIII endocytosis	1232:1254	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	4	5	theme	tail	890:893	arg1	clip					895:898	tail clip	890:898	tail clip	890:898	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	4	6	theme	factor	689:694	arg1	mice					711:714	factor VIII-deficient mice	689:714	factor VIII-deficient mice	689:714	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	7	7	with	agreement	1327:1335	arg1	this					1342:1345	this	1342:1345	this	1342:1345	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	6	8	theme	mouse	1292:1296	arg1	cells					1317:1321	mouse antigen-presenting cells	1292:1321	mouse antigen-presenting cells	1292:1321	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	4	9	from	experiments	674:684	arg1	mice					711:714	factor VIII-deficient mice	689:714	factor VIII-deficient mice	689:714	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	1	10	theme	major	193:197	arg1	development					120:130	The development	116:130	The development of an immune response against therapeutic factor VIII	116:184	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	1	10	theme	major	193:197	arg1	complication					199:210	the major complication	189:210	the major complication in hemophilia A patients	189:235	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	9	11	theme	exact	1764:1768	arg1	role					1770:1773	the exact role	1760:1773	the exact role of mannose-ending glycans in factor VIII immunogenicity	1760:1829	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	4	12	theme	Gene	660:663	arg1	experiments					674:684	Gene transfer experiments	660:684	Gene transfer experiments in factor VIII-deficient mice	660:714	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	4	13	contain	have	771:774	arg1	N239Q					731:735	N239Q	731:735	N239Q	731:735	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	4	13	contain	have	771:774	arg2	activities					793:802	similar specific activities	776:802	similar specific activities	776:802	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	4	13	contain	have	771:774	arg1	N2118Q					744:749	N2118Q	744:749	N2118Q	744:749	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	5	14	theme	cells	1117:1121	arg1	activation					1081:1090	the activation	1077:1090	the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells	1077:1163	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	3	15	theme	antigen-presenting	579:596	arg1	cells					598:602	antigen-presenting cells	579:602	antigen-presenting cells	579:602	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	5	16	theme	human	1126:1130	arg1	cells					1159:1163	human monocyte-derived dendritic cells	1126:1163	human monocyte-derived dendritic cells	1126:1163	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	2	17	theme	Oligomannose	238:249	arg1	carbohydrates					251:263	Oligomannose carbohydrates	238:263	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII	238:299	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	1	18	theme	A	226:226	arg1	patients					228:235	hemophilia A patients	215:235	hemophilia A patients	215:235	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	5	19	attach	removal	990:996	arg3	N2118					1036:1040	N2118	1036:1040	N2118	1036:1040	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	5	19	attach	removal	990:996	arg2	site					1028:1031	the N-linked glycosylation site	1001:1031	the N-linked glycosylation site	1001:1031	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	9	20	theme	glycans	1793:1799	arg1	role					1770:1773	the exact role	1760:1773	the exact role of mannose-ending glycans in factor VIII immunogenicity	1760:1829	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	6	21	theme	T	1281:1281	arg1	cells					1283:1287	CD4+ T cells	1276:1287	CD4+ T cells	1276:1287	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	4	22	theme	factor	751:756	arg1	mutants					763:769	factor VIII mutants	751:769	factor VIII mutants	751:769	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	1	23	from	complication	199:210	arg1	patients					228:235	hemophilia A patients	215:235	hemophilia A patients	215:235	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	5	24	theme	chains	968:973	arg1	Production					901:910	Production	901:910	Production of the corresponding recombinant FVIII mutants or light chains	901:973	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	9	25	theme	factor	1804:1809	arg1	immunogenicity					1816:1829	factor VIII immunogenicity	1804:1829	factor VIII immunogenicity	1804:1829	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	8	26	theme	cell	1535:1538	arg1	subsets					1540:1546	dendritic cell subsets	1525:1546	dendritic cell subsets	1525:1546	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	5	27	theme	CD4+	1110:1113	arg1	cells					1117:1121	FVIII-specific CD4+ T cells	1095:1121	FVIII-specific CD4+ T cells	1095:1121	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	1	28	theme	immune	138:143	arg1	response					145:152	an immune response	135:152	an immune response against therapeutic factor VIII	135:184	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	7	29	theme	VIII	1390:1393	arg1	immunogenicity					1395:1408	factor VIII immunogenicity	1383:1408	factor VIII immunogenicity in factor VIII-deficient mice	1383:1438	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	3	30	theme	factor	632:637	arg1	VIII					639:642	factor VIII	632:642	factor VIII immunogenicity	632:657	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	5	31	theme	FVIII	945:949	arg1	mutants					951:957	the corresponding recombinant FVIII mutants	915:957	the corresponding recombinant FVIII mutants	915:957	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	0	32	theme	Human	76:80	arg1	Cells					109:113	Human Monocyte-Derived Dendritic Cells	76:113	Human Monocyte-Derived Dendritic Cells	76:113	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	1	33	theme	factor	174:179	arg1	VIII					181:184	therapeutic factor VIII	162:184	therapeutic factor VIII	162:184	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	8	34	theme	tissue	1572:1577	arg1	distribution					1579:1590	tissue distribution	1572:1590	tissue distribution	1572:1590	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	3	35	from	receptors	566:574	arg1	cells					598:602	antigen-presenting cells	579:602	antigen-presenting cells	579:602	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	0	36	theme	Dendritic	99:107	arg1	Cells					109:113	Human Monocyte-Derived Dendritic Cells	76:113	Human Monocyte-Derived Dendritic Cells	76:113	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	5	37	theme	dendritic	1149:1157	arg1	cells					1159:1163	human monocyte-derived dendritic cells	1126:1163	human monocyte-derived dendritic cells	1126:1163	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	6	38	theme	factor	1232:1237	arg1	VIII					1239:1242	factor VIII	1232:1242	factor VIII endocytosis	1232:1254	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	4	39	dep	N239Q	731:735	arg1	mutants					763:769	factor VIII mutants	751:769	factor VIII mutants	751:769	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	9	40	from	role	1770:1773	arg1	immunogenicity					1816:1829	factor VIII immunogenicity	1804:1829	factor VIII immunogenicity	1804:1829	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	4	41	theme	non-mutated	819:829	arg1	VIII					838:841	non-mutated factor VIII	819:841	non-mutated factor VIII	819:841	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	2	42	from	carbohydrates	251:263	arg1	VIII					296:299	factor VIII	289:299	factor VIII	289:299	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	7	43	theme	factor	1383:1388	arg1	immunogenicity					1395:1408	factor VIII immunogenicity	1383:1408	factor VIII immunogenicity in factor VIII-deficient mice	1383:1438	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	2	44	theme	T	458:458	arg1	lymphocytes					460:470	CD4+ T lymphocytes	453:470	CD4+ T lymphocytes	453:470	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	4	45	theme	similar	776:782	arg1	activities					793:802	similar specific activities	776:802	similar specific activities	776:802	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	2	46	from	N239	268:271	arg1	carbohydrates					251:263	Oligomannose carbohydrates	238:263	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII	238:299	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	8	47	theme	receptors	1618:1626	arg1	function					1596:1603	function	1596:1603	function	1596:1603	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	8	47	theme	receptors	1618:1626	arg1	distribution					1579:1590	tissue distribution	1572:1590	tissue distribution	1572:1590	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	0	48	theme	Mannose-Ending	11:24	arg1	Glycan					26:31	Mannose-Ending Glycan	11:31	Mannose-Ending Glycan	11:31	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	3	49	theme	VIII	538:541	arg1	interaction					516:526	the interaction	512:526	the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells	512:602	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	5	50	theme	N-linked	1005:1012	arg1	site					1028:1031	the N-linked glycosylation site	1001:1031	the N-linked glycosylation site	1001:1031	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	2	51	from	N2118	280:284	arg1	carbohydrates					251:263	Oligomannose carbohydrates	238:263	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII	238:299	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	1	52	theme	response	145:152	arg1	development					120:130	The development	116:130	The development of an immune response against therapeutic factor VIII	116:184	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	1	52	theme	response	145:152	arg1	complication					199:210	the major complication	189:210	the major complication in hemophilia A patients	189:235	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	2	53	dep	VIII	416:419	arg1	presentation					437:448	presentation	437:448	presentation to CD4+ T lymphocytes	437:470	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	2	53	dep	VIII	416:419	arg1	endocytosis					421:431	endocytosis	421:431	endocytosis	421:431	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	6	54	from	N2118	1212:1216	arg1	removal					1175:1181	removal	1175:1181	removal of mannose-ending glycans at N2118	1175:1216	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	9	55	theme	preclinical	1685:1695	arg1	models					1697:1702	preclinical models	1685:1702	preclinical models of hemophilia A closer to humans	1685:1735	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	8	56	theme	endocytic	1482:1490	arg1	pathways					1492:1499	the endocytic pathways	1478:1499	the endocytic pathways	1478:1499	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	2	57	theme	mannose	337:343	arg1	receptor					345:352	the macrophage mannose receptor	322:352	the macrophage mannose receptor expressed on human dendritic cells	322:387	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	6	58	attach	removal	1175:1181	arg2	glycans					1201:1207	mannose-ending glycans	1186:1207	mannose-ending glycans	1186:1207	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	6	58	attach	removal	1175:1181	arg3	N2118					1212:1216	N2118	1212:1216	N2118	1212:1216	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	4	59	theme	N239Q/N2118Q	844:855	arg1	mutant					857:862	N239Q/N2118Q mutant	844:862	N239Q/N2118Q mutant	844:862	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	5	60	link	N-linked	1005:1012	arg1	site					1028:1031	the N-linked glycosylation site	1001:1031	the N-linked glycosylation site	1001:1031	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	9	61	theme	A	1718:1718	arg1	models					1697:1702	preclinical models	1685:1702	preclinical models of hemophilia A closer to humans	1685:1735	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	8	62	from	CD206	1636:1640	arg1	species					1650:1656	both species	1645:1656	both species	1645:1656	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	2	63	theme	human	367:371	arg1	cells					383:387	human dendritic cells	367:387	human dendritic cells	367:387	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	5	64	from	N2118	1036:1040	arg1	removal					990:996	removal	990:996	removal of the N-linked glycosylation site at N2118	990:1040	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	0	65	attach	Removal	0:6	arg2	Glycan					26:31	Mannose-Ending Glycan	11:31	Mannose-Ending Glycan	11:31	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	0	65	attach	Removal	0:6	arg3	Asn2118					36:42	Asn2118	36:42	Asn2118	36:42	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	3	66	theme	mannose-sensitive	548:564	arg1	receptors					566:574	mannose-sensitive receptors	548:574	mannose-sensitive receptors on antigen-presenting cells	548:602	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	5	67	theme	mutants	951:957	arg1	Production					901:910	Production	901:910	Production of the corresponding recombinant FVIII mutants or light chains	901:973	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	2	68	theme	factor	289:294	arg1	VIII					296:299	factor VIII	289:299	factor VIII	289:299	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	8	69	from	differences	1463:1473	arg1	pathways					1492:1499	the endocytic pathways	1478:1499	the endocytic pathways	1478:1499	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	6	70	theme	antigen-presenting	1298:1315	arg1	cells					1317:1321	mouse antigen-presenting cells	1292:1321	mouse antigen-presenting cells	1292:1321	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	4	71	theme	VIII-deficient	696:709	arg1	mice					711:714	factor VIII-deficient mice	689:714	factor VIII-deficient mice	689:714	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	6	72	theme	glycans	1201:1207	arg1	removal					1175:1181	removal	1175:1181	removal of mannose-ending glycans at N2118	1175:1216	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	5	73	theme	corresponding	919:931	arg1	mutants					951:957	the corresponding recombinant FVIII mutants	915:957	the corresponding recombinant FVIII mutants	915:957	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	1	74	theme	hemophilia	215:224	arg1	patients					228:235	hemophilia A patients	215:235	hemophilia A patients	215:235	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	9	75	theme	mannose-ending	1778:1791	arg1	glycans					1793:1799	mannose-ending glycans	1778:1799	mannose-ending glycans	1778:1799	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	8	76	theme	dendritic	1525:1533	arg1	subsets					1540:1546	dendritic cell subsets	1525:1546	dendritic cell subsets	1525:1546	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	4	77	theme	transfer	665:672	arg1	experiments					674:684	Gene transfer experiments	660:684	Gene transfer experiments in factor VIII-deficient mice	660:714	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	5	78	theme	monocyte-derived	1132:1147	arg1	cells					1159:1163	human monocyte-derived dendritic cells	1126:1163	human monocyte-derived dendritic cells	1126:1163	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	5	79	theme	light	962:966	arg1	chains					968:973	light chains	962:973	light chains	962:973	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	6	80	theme	CD4+	1276:1279	arg1	cells					1283:1287	CD4+ T cells	1276:1287	CD4+ T cells	1276:1287	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	5	81	theme	FVIII-specific	1095:1108	arg1	cells					1117:1121	FVIII-specific CD4+ T cells	1095:1121	FVIII-specific CD4+ T cells	1095:1121	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	3	82	theme	VIII	639:642	arg1	immunogenicity					644:657	factor VIII immunogenicity	632:657	factor VIII immunogenicity	632:657	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
32273875	9	83	theme	VIII	1811:1814	arg1	immunogenicity					1816:1829	factor VIII immunogenicity	1804:1829	factor VIII immunogenicity	1804:1829	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	7	84	theme	factor	1413:1418	arg1	mice					1435:1438	factor VIII-deficient mice	1413:1438	factor VIII-deficient mice	1413:1438	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	4	85	theme	VIII	758:761	arg1	mutants					763:769	factor VIII mutants	751:769	factor VIII mutants	751:769	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	5	86	theme	T	1115:1115	arg1	cells					1117:1121	FVIII-specific CD4+ T cells	1095:1121	FVIII-specific CD4+ T cells	1095:1121	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	5	87	theme	recombinant	933:943	arg1	mutants					951:957	the corresponding recombinant FVIII mutants	915:957	the corresponding recombinant FVIII mutants	915:957	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	5	88	gly	glycosylation	1014:1026	arg2	site					1028:1031	the N-linked glycosylation site	1001:1031	the N-linked glycosylation site	1001:1031	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	0	89	theme	Monocyte-Derived	82:97	arg1	Cells					109:113	Human Monocyte-Derived Dendritic Cells	76:113	Human Monocyte-Derived Dendritic Cells	76:113	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	1	90	theme	therapeutic	162:172	arg1	VIII					181:184	therapeutic factor VIII	162:184	therapeutic factor VIII	162:184	The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients.
32273875	5	91	link	monocyte-derived	1132:1147	arg1	cells					1159:1163	human monocyte-derived dendritic cells	1126:1163	human monocyte-derived dendritic cells	1126:1163	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	5	92	theme	glycosylation	1014:1026	arg1	site					1028:1031	the N-linked glycosylation site	1001:1031	the N-linked glycosylation site	1001:1031	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	5	93	theme	site	1028:1031	arg1	removal					990:996	removal	990:996	removal of the N-linked glycosylation site at N2118	990:1040	Production of the corresponding recombinant FVIII mutants or light chains indicated that removal of the N-linked glycosylation site at N2118 is sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human monocyte-derived dendritic cells.
32273875	7	94	from	immunogenicity	1395:1408	arg1	mice					1435:1438	factor VIII-deficient mice	1413:1438	factor VIII-deficient mice	1413:1438	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	0	95	from	Asn2118	36:42	arg1	Removal					0:6	Removal	0:6	Removal of Mannose-Ending Glycan at Asn2118	0:42	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	2	96	theme	CD4+	453:456	arg1	lymphocytes					460:470	CD4+ T lymphocytes	453:470	CD4+ T lymphocytes	453:470	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	0	97	theme	Glycan	26:31	arg1	Removal					0:6	Removal	0:6	Removal of Mannose-Ending Glycan at Asn2118	0:42	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	7	98	theme	N2118Q	1352:1357	arg1	mutation					1359:1366	the N2118Q mutation	1348:1366	the N2118Q mutation	1348:1366	In agreement with this, the N2118Q mutation did not reduce factor VIII immunogenicity in factor VIII-deficient mice.
32273875	4	99	theme	specific	784:791	arg1	activities					793:802	similar specific activities	776:802	similar specific activities	776:802	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	9	100	theme	Further	1659:1665	arg1	investigations					1667:1680	Further investigations	1659:1680	Further investigations in preclinical models of hemophilia A closer to humans	1659:1735	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	9	101	from	investigations	1667:1680	arg1	models					1697:1702	preclinical models	1685:1702	preclinical models of hemophilia A closer to humans	1685:1735	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	2	102	theme	factor	409:414	arg1	VIII					416:419	factor VIII endocytosis and presentation to CD4+ T lymphocytes	409:470	factor VIII endocytosis and presentation to CD4+ T lymphocytes	409:470	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	0	103	theme	FVIII	54:58	arg1	Presentation					60:71	FVIII Presentation	54:71	FVIII Presentation	54:71	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells.
32273875	8	104	theme	endocytic	1608:1616	arg1	receptors					1618:1626	endocytic receptors	1608:1626	endocytic receptors such as CD206 in both species	1608:1656	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	8	104	theme	endocytic	1608:1616	arg1	CD206					1636:1640	CD206	1636:1640	CD206 in both species	1636:1656	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	6	105	theme	mannose-ending	1186:1199	arg1	glycans					1201:1207	mannose-ending glycans	1186:1207	mannose-ending glycans	1186:1207	However, removal of mannose-ending glycans at N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse antigen-presenting cells.
32273875	2	106	theme	dendritic	373:381	arg1	cells					383:387	human dendritic cells	367:387	human dendritic cells	367:387	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	4	107	theme	blood	874:878	arg1	loss					880:883	blood loss	874:883	blood loss upon tail clip	874:898	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	8	108	dep	human	1509:1513	arg1	subsets					1540:1546	dendritic cell subsets	1525:1546	dendritic cell subsets	1525:1546	Our results highlight differences in the endocytic pathways between human and mouse dendritic cell subsets, and dissimilarities in tissue distribution and function of endocytic receptors such as CD206 in both species.
32273875	4	109	theme	factor	831:836	arg1	VIII					838:841	non-mutated factor VIII	819:841	non-mutated factor VIII	819:841	Gene transfer experiments in factor VIII-deficient mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected blood loss upon tail clip.
32273875	2	110	theme	macrophage	326:335	arg1	receptor					345:352	the macrophage mannose receptor	322:352	the macrophage mannose receptor expressed on human dendritic cells	322:387	Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to CD4+ T lymphocytes.
32273875	9	111	theme	hemophilia	1707:1716	arg1	A					1718:1718	hemophilia A	1707:1718	hemophilia A	1707:1718	Further investigations in preclinical models of hemophilia A closer to humans are needed to decipher the exact role of mannose-ending glycans in factor VIII immunogenicity.
32273875	3	112	theme	factor	531:536	arg1	VIII					538:541	factor VIII	531:541	factor VIII	531:541	Here, we investigated whether altering the interaction of factor VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy to reduce factor VIII immunogenicity.
34674311	9	0	theme	histological	1706:1717	arg1	changes					1719:1725	histological changes	1706:1725	histological changes indicative of ACM	1706:1743	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	6	1	theme	age-dependent	1125:1137	arg1	decline					1139:1145	age-dependent decline	1125:1145	age-dependent decline	1125:1145	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	3	2	theme	pluripotent	488:498	arg1	iPSCs					512:516	iPSCs	512:516	iPSCs	512:516	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	3	2	theme	pluripotent	488:498	arg1	cells					505:509	induced pluripotent stem cells	480:509	induced pluripotent stem cells (iPSCs)	480:517	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	9	3	theme	indicative	1727:1736	arg1	changes					1719:1725	histological changes	1706:1725	histological changes indicative of ACM	1706:1743	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	2	4	theme	molecular	290:298	arg1	mechanism					300:308	the molecular mechanism	286:308	the molecular mechanism of ACM caused by the TMEM43 variant	286:344	However, the molecular mechanism of ACM caused by the TMEM43 variant has not yet been fully elucidated.
34674311	9	5	theme	transcriptomic	1472:1485	arg1	analysis					1487:1494	our comprehensive transcriptomic analysis	1454:1494	our comprehensive transcriptomic analysis	1454:1494	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	9	6	theme	ACM	1741:1743	arg1	indicative					1727:1736	indicative	1727:1736	indicative	1727:1736	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	4	7	theme	KI	628:629	arg1	rats					631:634	The Tmem43-S358L KI rats	611:634	The Tmem43-S358L KI rats	611:634	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	10	8	theme	TMEM43S358L	1815:1825	arg1	accumulation					1799:1810	the aberrant accumulation	1786:1810	the aberrant accumulation of TMEM43S358L	1786:1825	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	1	9	theme	heart	200:204	arg1	disease					206:212	a fully penetrant heart disease	182:212	a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia	182:274	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	1	9	theme	heart	200:204	arg1	cardiomyopathy					133:146	Arrhythmogenic cardiomyopathy	118:146	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L	118:177	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	6	10	theme	TMEM43S358L	981:991	arg1	glycosylation					993:1005	TMEM43S358L glycosylation	981:1005	TMEM43S358L glycosylation	981:1005	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	5	11	with	TMEM43	803:808	arg1	TMEM43S358L					836:846	TMEM43S358L	836:846	TMEM43S358L	836:846	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	11	with	TMEM43	803:808	arg1	variant					827:833	the p.S358L variant	815:833	the p.S358L variant (TMEM43S358L )	815:848	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	3	12	theme	p.S358L	571:577	arg1	variant					579:585	TMEM43 p.S358L variant	564:585	TMEM43 p.S358L variant from a family with ACM	564:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	9	13	theme	gene	1542:1545	arg1	patterns					1558:1565	gene expression patterns	1542:1565	gene expression patterns	1542:1565	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	10	14	theme	TMEM43	1871:1876	arg1	variant					1886:1892	TMEM43 p.S358L variant	1871:1892	TMEM43 p.S358L variant	1871:1892	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	5	15	gly	glycosylation	887:899	arg1	cardiomyocytes					916:929	KI rat cardiomyocytes	909:929	KI rat cardiomyocytes	909:929	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	15	gly	glycosylation	887:899	arg1	cardiomyocytes					965:978	patient-specific iPSC-derived cardiomyocytes	935:978	patient-specific iPSC-derived cardiomyocytes	935:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	1	16	theme	Arrhythmogenic	118:131	arg1	ACM					149:151	ACM	149:151	ACM	149:151	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	1	16	theme	Arrhythmogenic	118:131	arg1	disease					206:212	a fully penetrant heart disease	182:212	a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia	182:274	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	1	16	theme	Arrhythmogenic	118:131	arg1	cardiomyopathy					133:146	Arrhythmogenic cardiomyopathy	118:146	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L	118:177	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	10	17	theme	transmural	1911:1920	arg1	expression					1927:1936	the transmural gene expression	1907:1936	the transmural gene expression within the myocardium	1907:1958	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	5	18	theme	rat	912:914	arg1	cardiomyocytes					916:929	KI rat cardiomyocytes	909:929	KI rat cardiomyocytes	909:929	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	6	19	theme	endoplasmic	1050:1060	arg1	ER					1073:1074	ER	1073:1074	ER	1073:1074	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	6	19	theme	endoplasmic	1050:1060	arg1	reticulum					1062:1070	endoplasmic reticulum	1050:1070	enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function	1041:1164	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	0	20	theme	gene	68:71	arg1	expression					73:82	perturbed transmural gene expression	47:82	perturbed transmural gene expression in arrhythmogenic cardiomyopathy	47:115	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	4	21	theme	fibrotic	673:680	arg1	replacement					693:703	fibrotic myocardial replacement	673:703	fibrotic myocardial replacement	673:703	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	3	22	with	family	594:599	arg1	ACM					606:608	ACM	606:608	ACM	606:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	4	23	theme	human	751:755	arg1	phenotype					761:769	the human ACM phenotype	747:769	the human ACM phenotype	747:769	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	7	24	theme	membrane	1249:1256	arg1	topology					1258:1265	the altered membrane topology	1237:1265	the altered membrane topology of TMEM43	1237:1275	Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34674311	9	25	theme	wild	1618:1621	arg1	type					1623:1626	the wild type	1614:1626	the wild type myocardium	1614:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	6	26	theme	pharmacological	1094:1108	arg1	stimulation					1110:1120	pharmacological stimulation	1094:1120	pharmacological stimulation	1094:1120	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	3	27	from	family	594:599	arg1	identification					546:559	the identification	542:559	the identification of TMEM43 p.S358L variant from a family with ACM	542:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	3	27	from	family	594:599	arg1	variant					579:585	TMEM43 p.S358L variant	564:585	TMEM43 p.S358L variant from a family with ACM	564:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	3	28	theme	knock-in	409:416	arg1	rats					423:426	knock-in (KI) rats	409:426	knock-in (KI) rats harboring a Tmem43 p.S358L mutation	409:462	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	0	29	theme	Aberrant	0:7	arg1	accumulation					9:20	Aberrant accumulation	0:20	Aberrant accumulation of TMEM43	0:30	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	5	30	theme	four-transmembrane	776:793	arg1	TMEM43					803:808	The four-transmembrane protein TMEM43	772:808	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L )	772:848	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	31	theme	p.S358L	819:825	arg1	TMEM43S358L					836:846	TMEM43S358L	836:846	TMEM43S358L	836:846	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	31	theme	p.S358L	819:825	arg1	variant					827:833	the p.S358L variant	815:833	the p.S358L variant (TMEM43S358L )	815:848	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	32	theme	iPSC-derived	952:963	arg1	cardiomyocytes					965:978	patient-specific iPSC-derived cardiomyocytes	935:978	patient-specific iPSC-derived cardiomyocytes	935:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	7	33	theme	specific	1185:1192	arg1	glycosylation					1194:1206	the specific glycosylation	1181:1206	the specific glycosylation of TMEM43S358L	1181:1221	Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34674311	5	34	theme	protein	795:801	arg1	TMEM43					803:808	The four-transmembrane protein TMEM43	772:808	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L )	772:848	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	9	35	theme	KI	1672:1673	arg1	myocardium					1675:1684	the KI myocardium	1668:1684	the KI myocardium prior to exhibiting histological changes indicative of ACM	1668:1743	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	6	36	theme	function	1157:1164	arg1	decline					1139:1145	age-dependent decline	1125:1145	age-dependent decline	1125:1145	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	6	36	theme	function	1157:1164	arg1	stimulation					1110:1120	pharmacological stimulation	1094:1120	pharmacological stimulation	1094:1120	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	3	37	theme	p.S358L	447:453	arg1	mutation					455:462	a Tmem43 p.S358L mutation	438:462	a Tmem43 p.S358L mutation	438:462	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	1	38	theme	impaired	230:237	arg1	function					247:254	impaired cardiac function	230:254	impaired cardiac function	230:254	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	9	39	theme	prior	1686:1690	arg1	myocardium					1675:1684	the KI myocardium	1668:1684	the KI myocardium prior to exhibiting histological changes indicative of ACM	1668:1743	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	3	40	theme	stem	500:503	arg1	iPSCs					512:516	iPSCs	512:516	iPSCs	512:516	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	3	40	theme	stem	500:503	arg1	cells					505:509	induced pluripotent stem cells	480:509	induced pluripotent stem cells (iPSCs)	480:517	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	5	41	link	iPSC-derived	952:963	arg1	cardiomyocytes					965:978	patient-specific iPSC-derived cardiomyocytes	935:978	patient-specific iPSC-derived cardiomyocytes	935:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	3	42	theme	induced	480:486	arg1	iPSCs					512:516	iPSCs	512:516	iPSCs	512:516	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	3	42	theme	induced	480:486	arg1	cells					505:509	induced pluripotent stem cells	480:509	induced pluripotent stem cells (iPSCs)	480:517	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	1	43	theme	fatal	259:263	arg1	arrhythmia					265:274	fatal arrhythmia	259:274	fatal arrhythmia	259:274	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	5	44	mod	modified	866:873	arg3	glycosylation					887:899	N-linked glycosylation	878:899	N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes	878:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	44	mod	modified	866:873	arg1	TMEM43					803:808	The four-transmembrane protein TMEM43	772:808	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L )	772:848	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	9	45	theme	comprehensive	1458:1470	arg1	analysis					1487:1494	our comprehensive transcriptomic analysis	1454:1494	our comprehensive transcriptomic analysis	1454:1494	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	9	46	theme	outer	1589:1593	arg1	layers					1595:1600	the inner and outer layers	1575:1600	the inner and outer layers observed in the wild type myocardium	1575:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	0	47	theme	perturbed	47:55	arg1	expression					73:82	perturbed transmural gene expression	47:82	perturbed transmural gene expression in arrhythmogenic cardiomyopathy	47:115	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	4	48	theme	Tmem43-S358L	615:626	arg1	rats					631:634	The Tmem43-S358L KI rats	611:634	The Tmem43-S358L KI rats	611:634	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	1	49	theme	penetrant	190:198	arg1	disease					206:212	a fully penetrant heart disease	182:212	a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia	182:274	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	1	49	theme	penetrant	190:198	arg1	cardiomyopathy					133:146	Arrhythmogenic cardiomyopathy	118:146	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L	118:177	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	2	50	theme	ACM	313:315	arg1	mechanism					300:308	the molecular mechanism	286:308	the molecular mechanism of ACM caused by the TMEM43 variant	286:344	However, the molecular mechanism of ACM caused by the TMEM43 variant has not yet been fully elucidated.
34674311	9	51	theme	regional	1518:1525	arg1	differences					1527:1537	the regional differences	1514:1537	the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium	1514:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	3	52	theme	TMEM43	564:569	arg1	variant					579:585	TMEM43 p.S358L variant	564:585	TMEM43 p.S358L variant from a family with ACM	564:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	0	53	from	expression	73:82	arg1	cardiomyopathy					102:115	arrhythmogenic cardiomyopathy	87:115	arrhythmogenic cardiomyopathy	87:115	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	10	54	theme	p.S358L	1878:1884	arg1	variant					1886:1892	TMEM43 p.S358L variant	1871:1892	TMEM43 p.S358L variant	1871:1892	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	9	55	theme	expression	1547:1556	arg1	patterns					1558:1565	gene expression patterns	1542:1565	gene expression patterns	1542:1565	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	4	56	theme	myocardial	682:691	arg1	replacement					693:703	fibrotic myocardial replacement	673:703	fibrotic myocardial replacement	673:703	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	10	57	theme	gene	1922:1925	arg1	expression					1927:1936	the transmural gene expression	1907:1936	the transmural gene expression within the myocardium	1907:1958	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	5	58	theme	KI	909:910	arg1	cardiomyocytes					916:929	KI rat cardiomyocytes	909:929	KI rat cardiomyocytes	909:929	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	10	59	theme	ACM	1857:1859	arg1	pathogenesis					1841:1852	the pathogenesis	1837:1852	the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium	1837:1958	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	6	60	theme	reticulum	1062:1070	arg1	stress					1077:1082	enhanced endoplasmic reticulum (ER) stress	1041:1082	enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function	1041:1164	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	8	61	theme	nuclear	1374:1380	arg1	envelope					1382:1389	the nuclear envelope	1370:1389	the nuclear envelope of cardiomyocytes with the increase in glycosylation	1370:1442	Moreover, unlike TMEM43WT , which is mainly localized to the ER, TMEM43S358L accumulated at the nuclear envelope of cardiomyocytes with the increase in glycosylation.
34674311	8	62	with	envelope	1382:1389	arg1	increase					1418:1425	the increase	1414:1425	the increase in glycosylation	1414:1442	Moreover, unlike TMEM43WT , which is mainly localized to the ER, TMEM43S358L accumulated at the nuclear envelope of cardiomyocytes with the increase in glycosylation.
34674311	7	63	theme	TMEM43	1270:1275	arg1	topology					1258:1265	the altered membrane topology	1237:1265	the altered membrane topology of TMEM43	1237:1275	Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34674311	3	64	theme	variant	579:585	arg1	identification					546:559	the identification	542:559	the identification of TMEM43 p.S358L variant from a family with ACM	542:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	9	65	theme	inner	1579:1583	arg1	layers					1595:1600	the inner and outer layers	1575:1600	the inner and outer layers observed in the wild type myocardium	1575:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	6	66	theme	enhanced	1041:1048	arg1	stress					1077:1082	enhanced endoplasmic reticulum (ER) stress	1041:1082	enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function	1041:1164	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	9	67	located	observed	1602:1609	arg2	layers					1595:1600	the inner and outer layers	1575:1600	the inner and outer layers observed in the wild type myocardium	1575:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	9	67	located	observed	1602:1609	arg1	myocardium					1628:1637	the wild type myocardium	1614:1637	the wild type myocardium	1614:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	4	68	theme	ventricular	646:656	arg1	arrhythmia					658:667	ventricular arrhythmia	646:667	ventricular arrhythmia	646:667	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	0	69	theme	arrhythmogenic	87:100	arg1	cardiomyopathy					102:115	arrhythmogenic cardiomyopathy	87:115	arrhythmogenic cardiomyopathy	87:115	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	5	70	theme	N-linked	878:885	arg1	glycosylation					887:899	N-linked glycosylation	878:899	N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes	878:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	7	71	theme	altered	1241:1247	arg1	topology					1258:1265	the altered membrane topology	1237:1265	the altered membrane topology of TMEM43	1237:1275	Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34674311	5	72	from	glycosylation	887:899	arg1	cardiomyocytes					916:929	KI rat cardiomyocytes	909:929	KI rat cardiomyocytes	909:929	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	72	from	glycosylation	887:899	arg1	cardiomyocytes					965:978	patient-specific iPSC-derived cardiomyocytes	935:978	patient-specific iPSC-derived cardiomyocytes	935:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	4	73	theme	ACM	757:759	arg1	phenotype					761:769	the human ACM phenotype	747:769	the human ACM phenotype	747:769	The Tmem43-S358L KI rats exhibited ventricular arrhythmia and fibrotic myocardial replacement in the subepicardium, which recapitulated the human ACM phenotype.
34674311	7	74	theme	TMEM43S358L	1211:1221	arg1	glycosylation					1194:1206	the specific glycosylation	1181:1206	the specific glycosylation of TMEM43S358L	1181:1221	Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34674311	9	75	theme	type	1623:1626	arg1	myocardium					1628:1637	the wild type myocardium	1614:1637	the wild type myocardium	1614:1637	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	8	76	theme	cardiomyocytes	1394:1407	arg1	envelope					1382:1389	the nuclear envelope	1370:1389	the nuclear envelope of cardiomyocytes with the increase in glycosylation	1370:1442	Moreover, unlike TMEM43WT , which is mainly localized to the ER, TMEM43S358L accumulated at the nuclear envelope of cardiomyocytes with the increase in glycosylation.
34674311	3	77	from	identification	546:559	arg1	family					594:599	a family	592:599	a family with ACM	592:608	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	0	78	theme	TMEM43	25:30	arg1	accumulation					9:20	Aberrant accumulation	0:20	Aberrant accumulation of TMEM43	0:30	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	5	79	link	N-linked	878:885	arg1	glycosylation					887:899	N-linked glycosylation	878:899	N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes	878:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	5	80	theme	patient-specific	935:950	arg1	cardiomyocytes					965:978	patient-specific iPSC-derived cardiomyocytes	935:978	patient-specific iPSC-derived cardiomyocytes	935:978	The four-transmembrane protein TMEM43 with the p.S358L variant (TMEM43S358L ) was found to be modified by N-linked glycosylation in both KI rat cardiomyocytes and patient-specific iPSC-derived cardiomyocytes.
34674311	6	81	theme	stress	1077:1082	arg1	conditions					1027:1036	the conditions	1023:1036	the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function	1023:1164	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	3	82	theme	Tmem43	440:445	arg1	mutation					455:462	a Tmem43 p.S358L mutation	438:462	a Tmem43 p.S358L mutation	438:462	In this study, we generated knock-in (KI) rats harboring a Tmem43 p.S358L mutation and established induced pluripotent stem cells (iPSCs) from patients based on the identification of TMEM43 p.S358L variant from a family with ACM.
34674311	0	83	theme	transmural	57:66	arg1	expression					73:82	perturbed transmural gene expression	47:82	perturbed transmural gene expression in arrhythmogenic cardiomyopathy	47:115	Aberrant accumulation of TMEM43 accompanied by perturbed transmural gene expression in arrhythmogenic cardiomyopathy.
34674311	9	84	from	differences	1527:1537	arg1	patterns					1558:1565	gene expression patterns	1542:1565	gene expression patterns	1542:1565	Finally, our comprehensive transcriptomic analysis demonstrated that the regional differences in gene expression patterns between the inner and outer layers observed in the wild type myocardium were partially diminished in the KI myocardium prior to exhibiting histological changes indicative of ACM.
34674311	6	85	theme	ER	1154:1155	arg1	function					1157:1164	the ER function	1150:1164	the ER function	1150:1164	TMEM43S358L glycosylation increased under the conditions of enhanced endoplasmic reticulum (ER) stress caused by pharmacological stimulation or age-dependent decline of the ER function.
34674311	1	86	theme	cardiac	239:245	arg1	function					247:254	impaired cardiac function	230:254	impaired cardiac function	230:254	Arrhythmogenic cardiomyopathy (ACM) caused by TMEM43 p.S358L is a fully penetrant heart disease that results in impaired cardiac function or fatal arrhythmia.
34674311	10	87	theme	aberrant	1790:1797	arg1	accumulation					1799:1810	the aberrant accumulation	1786:1810	the aberrant accumulation of TMEM43S358L	1786:1825	Altogether, these findings suggest that the aberrant accumulation of TMEM43S358L underlies the pathogenesis of ACM caused by TMEM43 p.S358L variant by affecting the transmural gene expression within the myocardium.
34674311	7	88	gly	glycosylation	1194:1206	arg1	TMEM43S358L					1211:1221	TMEM43S358L	1211:1221	TMEM43S358L	1211:1221	Intriguingly, the specific glycosylation of TMEM43S358L resulted from the altered membrane topology of TMEM43.
34674311	8	89	from	increase	1418:1425	arg1	glycosylation					1430:1442	glycosylation	1430:1442	glycosylation	1430:1442	Moreover, unlike TMEM43WT , which is mainly localized to the ER, TMEM43S358L accumulated at the nuclear envelope of cardiomyocytes with the increase in glycosylation.
34201818	4	0	theme	antibiotic-resistant	499:518	arg1	strains					520:526	antibiotic-resistant strains	499:526	antibiotic-resistant strains	499:526	The bacterium is the deadliest pathogen known to humans and antibiotic-resistant strains are appearing naturally.
34201818	1	1	theme	health	186:191	arg1	worldwide					201:209	a nosocomial health problem worldwide	173:209	a nosocomial health problem worldwide	173:209	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
34201818	6	2	theme	novel	635:639	arg1	compounds					641:649	novel compounds	635:649	novel compounds based on metallacarborane cage	635:680	In the current work, novel compounds based on metallacarborane cage were studied on strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica.
34201818	10	3	theme	novel	1395:1399	arg1	drugs					1415:1419	novel anti-Yersinia drugs	1395:1419	novel anti-Yersinia drugs	1395:1419	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	1	4	theme	problem	193:199	arg1	worldwide					201:209	a nosocomial health problem worldwide	173:209	a nosocomial health problem worldwide	173:209	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
34201818	7	5	theme	μM	894:895	arg1	values					829:834	IC50 values	824:834	IC50 values below 10 µM against Y. enterocolitica	824:872	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	7	5	theme	μM	894:895	arg1	values					878:883	values	878:883	values of 20-50 μM	878:895	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	9	6	from	division	1316:1323	arg1	enterocolitica					1331:1344	Y. enterocolitica	1328:1344	Y. enterocolitica	1328:1344	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	8	7	theme	drug	1015:1018	arg1	resistance					1020:1029	drug resistance	1015:1029	drug resistance	1015:1029	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	8	7	theme	drug	1015:1018	arg1	first					1036:1040	first	1036:1040	first	1036:1040	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	8	8	link	N-linked	1084:1091	arg1	metallacarboranes					1093:1109	N-linked metallacarboranes	1084:1109	N-linked metallacarboranes	1084:1109	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	9	9	theme	strains	1213:1219	arg1	analysis					1178:1185	SEM analysis	1174:1185	SEM analysis of the compound-resistant strains	1174:1219	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	8	10	theme	compound-resistant	945:962	arg1	enterocolitica					967:980	compound-resistant Y. enterocolitica	945:980	compound-resistant Y. enterocolitica	945:980	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	10	11	from	resistance	1500:1509	arg1	bacteria					1514:1521	bacteria	1514:1521	bacteria	1514:1521	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	7	12	contain	had	820:822	arg1	compounds					810:818	The representative compounds	791:818	The representative compounds	791:818	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	7	12	contain	had	820:822	arg2	values					829:834	IC50 values	824:834	IC50 values below 10 µM against Y. enterocolitica	824:872	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	7	12	contain	had	820:822	arg2	values					878:883	values	878:883	values of 20-50 μM	878:895	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	6	13	theme	aeruginosa	721:730	arg1	strains					698:704	strains	698:704	strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica	698:788	In the current work, novel compounds based on metallacarborane cage were studied on strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica.
34201818	8	14	theme	N-linked	1084:1091	arg1	metallacarboranes					1093:1109	N-linked metallacarboranes	1084:1109	N-linked metallacarboranes	1084:1109	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	9	15	theme	bacteriostatic	1267:1280	arg1	effect					1282:1287	a predominantly bacteriostatic effect	1251:1287	a predominantly bacteriostatic effect	1251:1287	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	2	16	theme	many	300:303	arg1	antibiotics					305:315	many antibiotics	300:315	many antibiotics	300:315	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	6	17	theme	current	621:627	arg1	work					629:632	the current work	617:632	the current work	617:632	In the current work, novel compounds based on metallacarborane cage were studied on strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica.
34201818	10	18	theme	starting	1372:1379	arg1	point					1381:1385	a starting point	1370:1385	a starting point towards novel anti-Yersinia drugs	1370:1419	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	10	18	theme	starting	1372:1379	arg1	compounds					1351:1359	The compounds	1347:1359	The compounds	1347:1359	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	10	19	theme	drug	1495:1498	arg1	resistance					1500:1509	any future drug resistance	1484:1509	any future drug resistance in bacteria	1484:1521	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	2	20	theme	commercial	334:343	arg1	vaccine					345:351	no commercial vaccine	331:351	no commercial vaccine against it	331:362	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	0	21	theme	Metallacarborane	0:15	arg1	Derivatives					17:27	Metallacarborane Derivatives	0:27	Metallacarborane Derivatives	0:27	Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica.
34201818	10	22	theme	future	1488:1493	arg1	resistance					1500:1509	any future drug resistance	1484:1509	any future drug resistance in bacteria	1484:1521	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	7	23	theme	Y.	856:857	arg1	enterocolitica					859:872	Y. enterocolitica	856:872	Y. enterocolitica	856:872	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	3	24	theme	zoonotic	386:393	arg1	pestis					374:379	Yersinia pestis	365:379	Yersinia pestis	365:379	Yersinia pestis is a zoonotic pathogen that is on the Select Agents list.
34201818	3	24	theme	zoonotic	386:393	arg1	pathogen					395:402	a zoonotic pathogen	384:402	a zoonotic pathogen that is on the Select Agents list	384:436	Yersinia pestis is a zoonotic pathogen that is on the Select Agents list.
34201818	8	25	theme	cellular	1128:1135	arg1	mechanisms					1137:1146	cellular mechanisms	1128:1146	cellular mechanisms of resistance generation	1128:1171	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	1	26	theme	opportunistic	128:140	arg1	pathogen					148:155	an opportunistic human pathogen	125:155	an opportunistic human pathogen that has become a nosocomial health problem worldwide	125:209	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
34201818	1	26	theme	opportunistic	128:140	arg1	aeruginosa					111:120	Pseudomonas aeruginosa	99:120	Pseudomonas aeruginosa	99:120	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
34201818	2	27	contain	has	225:227	arg2	removal					243:249	multiple drug removal	229:249	multiple drug removal	229:249	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	2	27	contain	has	225:227	arg1	pathogen					216:223	The pathogen	212:223	The pathogen	212:223	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	2	27	contain	has	225:227	arg2	systems					275:281	virulence secretion systems	255:281	virulence secretion systems	255:281	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	10	28	theme	anti-Yersinia	1401:1413	arg1	drugs					1415:1419	novel anti-Yersinia drugs	1395:1419	novel anti-Yersinia drugs	1395:1419	The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.
34201818	7	29	theme	IC50	824:827	arg1	values					829:834	IC50 values	824:834	IC50 values below 10 µM against Y. enterocolitica	824:872	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	9	30	theme	bacterial	1301:1309	arg1	division					1316:1323	bacterial cell division	1301:1323	bacterial cell division in Y. enterocolitica	1301:1344	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	1	31	theme	human	142:146	arg1	pathogen					148:155	an opportunistic human pathogen	125:155	an opportunistic human pathogen that has become a nosocomial health problem worldwide	125:209	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
34201818	1	31	theme	human	142:146	arg1	aeruginosa					111:120	Pseudomonas aeruginosa	99:120	Pseudomonas aeruginosa	99:120	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
34201818	8	32	theme	Artificial	920:929	arg1	generation					931:940	Artificial generation	920:940	Artificial generation of compound-resistant Y. enterocolitica	920:980	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	3	33	theme	Select	419:424	arg1	list					433:436	the Select Agents list	415:436	the Select Agents list	415:436	Yersinia pestis is a zoonotic pathogen that is on the Select Agents list.
34201818	9	34	theme	cell	1311:1314	arg1	division					1316:1323	bacterial cell division	1301:1323	bacterial cell division in Y. enterocolitica	1301:1344	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	9	35	theme	SEM	1174:1176	arg1	analysis					1178:1185	SEM analysis	1174:1185	SEM analysis of the compound-resistant strains	1174:1219	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	3	36	theme	Agents	426:431	arg1	list					433:436	the Select Agents list	415:436	the Select Agents list	415:436	Yersinia pestis is a zoonotic pathogen that is on the Select Agents list.
34201818	2	37	theme	secretion	265:273	arg1	systems					275:281	virulence secretion systems	255:281	virulence secretion systems	255:281	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	8	38	theme	Y.	964:965	arg1	enterocolitica					967:980	compound-resistant Y. enterocolitica	945:980	compound-resistant Y. enterocolitica	945:980	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	0	39	theme	Yersinia	74:81	arg1	enterocolitica					83:96	Yersinia enterocolitica	74:96	Yersinia enterocolitica	74:96	Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica.
34201818	8	40	theme	generation	1162:1171	arg1	mechanisms					1137:1146	cellular mechanisms	1128:1146	cellular mechanisms of resistance generation	1128:1171	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	4	41	theme	deadliest	460:468	arg1	bacterium					443:451	The bacterium	439:451	The bacterium	439:451	The bacterium is the deadliest pathogen known to humans and antibiotic-resistant strains are appearing naturally.
34201818	4	41	theme	deadliest	460:468	arg1	pathogen					470:477	the deadliest pathogen	456:477	the deadliest pathogen known to humans	456:493	The bacterium is the deadliest pathogen known to humans and antibiotic-resistant strains are appearing naturally.
34201818	2	42	theme	virulence	255:263	arg1	systems					275:281	virulence secretion systems	255:281	virulence secretion systems	255:281	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	5	43	theme	commercial	565:574	arg1	vaccine					576:582	no commercial vaccine	562:582	no commercial vaccine against the pathogen	562:603	There is no commercial vaccine against the pathogen, either.
34201818	8	44	theme	resistance	1151:1160	arg1	generation					1162:1171	resistance generation	1151:1171	resistance generation	1151:1171	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	9	45	theme	Y.	1328:1329	arg1	enterocolitica					1331:1344	Y. enterocolitica	1328:1344	Y. enterocolitica	1328:1344	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	7	46	theme	representative	795:808	arg1	compounds					810:818	The representative compounds	791:818	The representative compounds	791:818	The representative compounds had IC50 values below 10 µM against Y. enterocolitica and values of 20-50 μM against P. aeruginosa.
34201818	2	47	theme	drug	238:241	arg1	removal					243:249	multiple drug removal	229:249	multiple drug removal	229:249	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	8	48	theme	enterocolitica	967:980	arg1	generation					931:940	Artificial generation	920:940	Artificial generation of compound-resistant Y. enterocolitica	920:980	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	6	49	theme	metallacarborane	660:675	arg1	cage					677:680	metallacarborane cage	660:680	metallacarborane cage	660:680	In the current work, novel compounds based on metallacarborane cage were studied on strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica.
34201818	9	50	theme	compound-resistant	1194:1211	arg1	strains					1213:1219	the compound-resistant strains	1190:1219	the compound-resistant strains	1190:1219	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	2	51	theme	multiple	229:236	arg1	removal					243:249	multiple drug removal	229:249	multiple drug removal	229:249	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	8	52	theme	common	994:999	arg1	mechanism					1001:1009	a common mechanism	992:1009	a common mechanism for drug resistance, the first reported in the literature,	992:1068	Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation.
34201818	2	53	dep	has	225:227	arg1	resistant					287:295	resistant	287:295	resistant	287:295	The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it.
34201818	6	54	theme	pestis	747:752	arg1	strains					698:704	strains	698:704	strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica	698:788	In the current work, novel compounds based on metallacarborane cage were studied on strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica.
34201818	9	55	contain	had	1247:1249	arg1	compounds					1237:1245	the compounds	1233:1245	the compounds	1233:1245	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	9	55	contain	had	1247:1249	arg2	effect					1282:1287	a predominantly bacteriostatic effect	1251:1287	a predominantly bacteriostatic effect	1251:1287	SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica.
34201818	1	56	theme	nosocomial	175:184	arg1	worldwide					201:209	a nosocomial health problem worldwide	173:209	a nosocomial health problem worldwide	173:209	Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide.
32760395	7	0	theme	DC	1506:1507	arg1	expansion					1493:1501	expansion	1493:1501	expansion of DC	1493:1507	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	9	1	theme	placental	2172:2180	arg1	glycocode					2182:2190	the placental glycocode	2168:2190	the placental glycocode	2168:2190	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	2	2	theme	balanced	322:329	arg1	interactions					342:353	balanced DC-NK cell interactions	322:353	balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions	322:439	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	8	3	theme	galectin-1	1880:1889	arg1	expression					1891:1900	galectin-1 expression	1880:1900	galectin-1 expression	1880:1900	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	6	4	theme	N-linked	1162:1169	arg1	glycosylation					1171:1183	N-linked glycosylation	1162:1183	N-linked glycosylation	1162:1183	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	0	5	theme	Altered	0:6	arg1	Glycosylation					8:20	Altered Glycosylation	0:20	Altered Glycosylation	0:20	Altered Glycosylation Contributes to Placental Dysfunction Upon Early Disruption of the NK Cell-DC Dynamics.
32760395	6	6	theme	O-	1155:1156	arg1	increases					1142:1150	significant increases	1130:1150	significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1130:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	9	7	theme	placentation	1940:1951	arg1	sites					1966:1970	pre- and post- placentation implantation sites	1925:1970	pre- and post- placentation implantation sites	1925:1970	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	6	8	theme	pre-placental	1242:1254	arg1	period					1256:1261	the pre-placental period	1238:1261	the pre-placental period	1238:1261	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	2	9	theme	placental	280:288	arg1	development					300:310	Proper placental and fetal development	273:310	Proper placental and fetal development	273:310	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	1	10	theme	killer	163:168	arg1	cells					175:179	natural killer (NK) cells]	155:180	natural killer (NK) cells]	155:180	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	6	11	theme	increased	1340:1348	arg1	expression					1350:1359	increased expression	1340:1359	increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1340:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	12	theme	O-glycans	1326:1334	arg1	downregulation					1276:1289	downregulation	1276:1289	downregulation of core 1 and poly-LacNAc extended O-glycans	1276:1334	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	12	theme	O-glycans	1326:1334	arg1	expression					1350:1359	increased expression	1340:1359	increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1340:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	8	13	theme	spatiotemporal	1757:1770	arg1	variation					1772:1780	this spatiotemporal variation	1752:1780	this spatiotemporal variation in the glycosylation pattern of the implantation site	1752:1834	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	7	14	from	changes	1662:1668	arg1	pattern					1691:1697	the glycosylation pattern	1673:1697	the glycosylation pattern during the post-placentation period	1673:1733	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	4	15	theme	health	713:718	arg1	determinants					684:695	essential determinants	674:695	essential determinants of reproductive health	674:718	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	4	15	theme	health	713:718	arg1	Glycans					662:668	Glycans	662:668	Glycans	662:668	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	6	16	theme	poly-LacNAc	1305:1315	arg1	O-glycans					1326:1334	core 1 and poly-LacNAc extended O-glycans	1294:1334	O-glycans	1326:1334	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	5	17	theme	cell-DC	1030:1036	arg1	dynamics					1038:1045	the NK cell-DC dynamics	1023:1045	the NK cell-DC dynamics during early pregnancy	1023:1068	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	6	18	theme	decidual	1208:1215	arg1	zone					1226:1229	the decidual vascular zone	1204:1229	the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1204:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	19	link	N-linked	1162:1169	arg1	glycosylation					1171:1183	N-linked glycosylation	1162:1183	N-linked glycosylation	1162:1183	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	3	20	theme	fetal	607:611	arg1	development					613:623	placental and fetal development	593:623	placental and fetal development leading to fetal growth restriction	593:659	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	8	21	theme	glycosylation	1789:1801	arg1	pattern					1803:1809	the glycosylation pattern	1785:1809	the glycosylation pattern of the implantation site	1785:1834	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	7	22	theme	branched	1594:1601	arg1	expression					1612:1621	branched N-glycan expression	1594:1621	branched N-glycan expression	1594:1621	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	4	23	theme	essential	674:682	arg1	determinants					684:695	essential determinants	674:695	essential determinants of reproductive health	674:718	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	4	23	theme	essential	674:682	arg1	Glycans					662:668	Glycans	662:668	Glycans	662:668	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	6	24	theme	placental	1404:1412	arg1	cells					1420:1424	placental giant cells	1404:1424	placental giant cells	1404:1424	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	3	25	theme	placental	593:601	arg1	development					613:623	placental and fetal development	593:623	placental and fetal development leading to fetal growth restriction	593:659	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	9	26	theme	cell-DC	2031:2037	arg1	dynamics					2039:2046	the NK cell-DC dynamics	2024:2046	the NK cell-DC dynamics	2024:2046	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	8	27	theme	implantation	1818:1829	arg1	site					1831:1834	the implantation site	1814:1834	the implantation site	1814:1834	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	7	28	theme	mucin-type	1568:1577	arg1	O-glycans					1579:1587	mucin-type O-glycans	1568:1587	mucin-type O-glycans	1568:1587	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	0	29	theme	Cell-DC	91:97	arg1	Dynamics					99:106	the NK Cell-DC Dynamics	84:106	the NK Cell-DC Dynamics	84:106	Altered Glycosylation Contributes to Placental Dysfunction Upon Early Disruption of the NK Cell-DC Dynamics.
32760395	2	30	theme	immune	366:371	arg1	cell					373:376	immune cell homing, maternal vascular expansion, and trophoblast functions	366:439	cell	373:376	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	6	31	theme	zone	1468:1471	arg1	spongiotrophoblasts					1430:1448	spongiotrophoblasts	1430:1448	spongiotrophoblasts	1430:1448	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	31	theme	zone	1468:1471	arg1	cells					1420:1424	placental giant cells	1404:1424	placental giant cells	1404:1424	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	1	32	theme	mammalian	252:260	arg1	pregnancy					262:270	successful mammalian pregnancy	241:270	successful mammalian pregnancy	241:270	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	6	33	dep	cells	1420:1424	arg1	the					1400:1402	the	1400:1402	the	1400:1402	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	7	34	theme	antigen	1541:1547	arg1	increase					1526:1533	a milder increase	1517:1533	a milder increase of Tn antigen (truncated form of mucin-type O-glycans)	1517:1588	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	7	34	theme	antigen	1541:1547	arg1	expression					1612:1621	branched N-glycan expression	1594:1621	branched N-glycan expression	1594:1621	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	1	35	theme	Immune	109:114	arg1	cells					116:120	Immune cells	109:120	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells]	109:180	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	1	35	theme	Immune	109:114	arg1	players					195:201	critical players	186:201	critical players	186:201	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	8	36	from	changes	1869:1875	arg1	expression					1891:1900	galectin-1 expression	1880:1900	galectin-1 expression	1880:1900	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	3	37	theme	fetal	636:640	arg1	restriction					649:659	fetal growth restriction	636:659	fetal growth restriction	636:659	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	3	38	from	impact	583:588	arg1	development					613:623	placental and fetal development	593:623	placental and fetal development leading to fetal growth restriction	593:659	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	2	39	theme	maternal	386:393	arg1	expansion					404:412	maternal vascular expansion	386:412	maternal vascular expansion	386:412	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	0	40	theme	Placental	37:45	arg1	Dysfunction					47:57	Placental Dysfunction	37:57	Placental Dysfunction	37:57	Altered Glycosylation Contributes to Placental Dysfunction Upon Early Disruption of the NK Cell-DC Dynamics.
32760395	3	41	theme	in	469:470	arg1	disruption					477:486	in vivo disruption	469:486	in vivo disruption of the uterine NK cell-DC balance	469:520	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	7	42	theme	milder	1519:1524	arg1	increase					1526:1533	a milder increase	1517:1533	a milder increase of Tn antigen (truncated form of mucin-type O-glycans)	1517:1588	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	5	43	theme	NK	1027:1028	arg1	dynamics					1038:1045	the NK cell-DC dynamics	1023:1045	the NK cell-DC dynamics during early pregnancy	1023:1068	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	3	44	theme	cell-DC	506:512	arg1	balance					514:520	the uterine NK cell-DC balance	491:520	the uterine NK cell-DC balance	491:520	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	6	45	theme	cells	1104:1108	arg1	depletion					1088:1096	depletion	1088:1096	depletion of NK cells	1088:1108	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	1	46	theme	critical	186:193	arg1	cells					116:120	Immune cells	109:120	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells]	109:180	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	1	46	theme	critical	186:193	arg1	players					195:201	critical players	186:201	critical players	186:201	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	6	47	theme	core	1294:1297	arg1	downregulation					1276:1289	downregulation	1276:1289	downregulation of core 1 and poly-LacNAc extended O-glycans	1276:1334	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	47	theme	core	1294:1297	arg1	expression					1350:1359	increased expression	1340:1359	increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1340:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	2	48	theme	DC-NK	331:335	arg1	interactions					342:353	balanced DC-NK cell interactions	322:353	balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions	322:439	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	4	49	theme	developmental	838:850	arg1	state					869:873	its developmental and pathological state	834:873	its developmental and pathological state	834:873	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	3	50	theme	balance	514:520	arg1	disruption					477:486	in vivo disruption	469:486	in vivo disruption of the uterine NK cell-DC balance	469:520	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	1	51	theme	pre-placentation	214:229	arg1	stage					231:235	the pre-placentation stage	210:235	the pre-placentation stage for successful mammalian pregnancy	210:270	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	7	52	theme	other	1481:1485	arg1	hand					1487:1490	the other hand	1477:1490	the other hand	1477:1490	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	4	53	theme	pathological	856:867	arg1	state					869:873	its developmental and pathological state	834:873	its developmental and pathological state	834:873	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	6	54	theme	glycosylation	1171:1183	arg1	increases					1142:1150	significant increases	1130:1150	significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1130:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	9	55	theme	pre-	1925:1928	arg1	sites					1966:1970	pre- and post- placentation implantation sites	1925:1970	pre- and post- placentation implantation sites	1925:1970	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	9	56	contain	have	1972:1975	arg1	sites					1966:1970	pre- and post- placentation implantation sites	1925:1970	pre- and post- placentation implantation sites	1925:1970	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	9	56	contain	have	1972:1975	arg2	glycopattern					1992:2003	a differential glycopattern	1977:2003	a differential glycopattern	1977:2003	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	3	57	theme	NK	503:504	arg1	balance					514:520	the uterine NK cell-DC balance	491:520	the uterine NK cell-DC balance	491:520	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	1	58	theme	natural	155:161	arg1	NK					171:172	NK	171:172	NK	171:172	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	1	58	theme	natural	155:161	arg1	killer					163:168	natural killer	155:168	natural killer (NK) cells]	155:180	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	4	59	theme	cell	820:823	arg1	type					825:828	the cell type	816:828	the cell type	816:828	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	9	60	theme	post-	1934:1938	arg1	sites					1966:1970	pre- and post- placentation implantation sites	1925:1970	pre- and post- placentation implantation sites	1925:1970	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	8	61	from	variation	1772:1780	arg1	pattern					1803:1809	the glycosylation pattern	1785:1809	the glycosylation pattern of the implantation site	1785:1834	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	3	62	theme	decidualization	542:556	arg1	process					558:564	the decidualization process	538:564	the decidualization process	538:564	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	4	63	dep	placenta	783:790	arg1	e.g.					777:780	e.g.	777:780	e.g.	777:780	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	9	64	theme	implantation	1953:1964	arg1	sites					1966:1970	pre- and post- placentation implantation sites	1925:1970	pre- and post- placentation implantation sites	1925:1970	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	2	65	theme	Proper	273:278	arg1	development					300:310	Proper placental and fetal development	273:310	Proper placental and fetal development	273:310	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	7	66	theme	vascular	1630:1637	arg1	zone					1639:1642	the vascular zone	1626:1642	the vascular zone	1626:1642	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	6	67	theme	significant	1130:1140	arg1	increases					1142:1150	significant increases	1130:1150	significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1130:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	3	68	theme	subsequent	572:581	arg1	impact					583:588	subsequent impact	572:588	subsequent impact on placental and fetal development leading to fetal growth restriction	572:659	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	9	69	theme	differential	1979:1990	arg1	glycopattern					1992:2003	a differential glycopattern	1977:2003	a differential glycopattern	1977:2003	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	6	70	theme	extended	1317:1324	arg1	O-glycans					1326:1334	core 1 and poly-LacNAc extended O-glycans	1294:1334	O-glycans	1326:1334	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	7	71	theme	N-glycan	1603:1610	arg1	expression					1612:1621	branched N-glycan expression	1594:1621	branched N-glycan expression	1594:1621	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	6	72	theme	vascular	1217:1224	arg1	zone					1226:1229	the decidual vascular zone	1204:1229	the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1204:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	4	73	theme	reproductive	700:711	arg1	health					713:718	reproductive health	700:718	reproductive health	700:718	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	5	74	theme	dynamics	1038:1045	arg1	disruption					1009:1018	disruption	1009:1018	disruption of the NK cell-DC dynamics during early pregnancy	1009:1068	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	1	75	theme	g.	126:127	arg1	cells					140:144	g., dendritic cells	126:144	cells	140:144	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	1	75	theme	g.	126:127	arg1	DC					147:148	DC	147:148	DC	147:148	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	6	76	theme	giant	1414:1418	arg1	cells					1420:1424	placental giant cells	1404:1424	placental giant cells	1404:1424	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	5	77	theme	early	1054:1058	arg1	pregnancy					1060:1068	early pregnancy	1054:1068	early pregnancy	1054:1068	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	1	78	theme	dendritic	130:138	arg1	cells					140:144	g., dendritic cells	126:144	cells	140:144	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	1	78	theme	dendritic	130:138	arg1	DC					147:148	DC	147:148	DC	147:148	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	7	79	theme	O-glycans	1579:1587	arg1	form					1560:1563	truncated form	1550:1563	truncated form of mucin-type O-glycans	1550:1587	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	9	80	theme	NK	2028:2029	arg1	dynamics					2039:2046	the NK cell-DC dynamics	2024:2046	the NK cell-DC dynamics	2024:2046	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	6	81	theme	N-glycans	1373:1381	arg1	downregulation					1276:1289	downregulation	1276:1289	downregulation of core 1 and poly-LacNAc extended O-glycans	1276:1334	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	81	theme	N-glycans	1373:1381	arg1	expression					1350:1359	increased expression	1340:1359	increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1340:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	0	82	theme	NK	88:89	arg1	Dynamics					99:106	the NK Cell-DC Dynamics	84:106	the NK Cell-DC Dynamics	84:106	Altered Glycosylation Contributes to Placental Dysfunction Upon Early Disruption of the NK Cell-DC Dynamics.
32760395	9	83	theme	dynamics	2039:2046	arg1	disruption					2010:2019	disruption	2010:2019	disruption of the NK cell-DC dynamics	2010:2046	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	0	84	theme	Dynamics	99:106	arg1	Disruption					70:79	Early Disruption	64:79	Early Disruption of the NK Cell-DC Dynamics	64:106	Altered Glycosylation Contributes to Placental Dysfunction Upon Early Disruption of the NK Cell-DC Dynamics.
32760395	7	85	theme	post-placentation	1710:1726	arg1	period					1728:1733	the post-placentation period	1706:1733	the post-placentation period	1706:1733	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	7	86	theme	truncated	1550:1558	arg1	form					1560:1563	truncated form	1550:1563	truncated form of mucin-type O-glycans	1550:1587	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	8	87	gly	glycosylation	1789:1801	arg1	site					1831:1834	the implantation site	1814:1834	the implantation site	1814:1834	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	4	88	theme	particular	753:762	arg1	compartment					764:774	a particular compartment	751:774	a particular compartment (e.g., placenta)	751:791	Glycans are essential determinants of reproductive health and the glycocode expressed in a particular compartment (e.g., placenta) is highly dependent on the cell type and its developmental and pathological state.
32760395	9	89	from	imbalance	2072:2080	arg1	gestation					2091:2099	gestation	2091:2099	gestation	2091:2099	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	6	90	theme	branched	1364:1371	arg1	N-glycans					1373:1381	branched N-glycans	1364:1381	branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1364:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	8	91	theme	site	1831:1834	arg1	pattern					1803:1809	the glycosylation pattern	1785:1809	the glycosylation pattern of the implantation site	1785:1834	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	3	92	dep	in	469:470	arg1	vivo					472:475	vivo	472:475	vivo	472:475	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	9	93	theme	immune	2065:2070	arg1	imbalance					2072:2080	immune imbalance	2065:2080	immune imbalance early in gestation	2065:2099	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	5	94	theme	maternal	910:917	arg1	glycovariation					933:946	the maternal and placental glycovariation	906:946	the maternal and placental glycovariation	906:946	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	7	95	theme	glycosylation	1677:1689	arg1	pattern					1691:1697	the glycosylation pattern	1673:1697	the glycosylation pattern during the post-placentation period	1673:1733	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	2	96	theme	trophoblast	419:429	arg1	functions					431:439	trophoblast functions	419:439	trophoblast functions	419:439	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	6	97	from	increases	1142:1150	arg1	zone					1226:1229	the decidual vascular zone	1204:1229	the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone	1204:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	6	98	theme	junctional	1457:1466	arg1	zone					1468:1471	the junctional zone	1453:1471	the junctional zone	1453:1471	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	1	99	theme	successful	241:250	arg1	pregnancy					262:270	successful mammalian pregnancy	241:270	successful mammalian pregnancy	241:270	Immune cells [e. g., dendritic cells (DC) and natural killer (NK) cells] are critical players during the pre-placentation stage for successful mammalian pregnancy.
32760395	8	100	theme	corresponding	1855:1867	arg1	changes					1869:1875	corresponding changes	1855:1875	corresponding changes in galectin-1 expression	1855:1900	In both groups, this spatiotemporal variation in the glycosylation pattern of the implantation site was accompanied by corresponding changes in galectin-1 expression.
32760395	5	101	theme	placental	923:931	arg1	glycovariation					933:946	the maternal and placental glycovariation	906:946	the maternal and placental glycovariation	906:946	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	5	102	theme	pre-	959:962	arg1	period					986:991	the pre- and post-placentation period	955:991	the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy	955:1068	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	2	103	theme	vascular	395:402	arg1	expansion					404:412	maternal vascular expansion	386:412	maternal vascular expansion	386:412	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	7	104	theme	modest	1655:1660	arg1	changes					1662:1668	only modest changes	1650:1668	only modest changes in the glycosylation pattern during the post-placentation period	1650:1733	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	9	105	theme	placentation	2109:2120	arg1	development					2132:2142	placentation and fetal development	2109:2142	placentation and fetal development	2109:2142	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	7	106	dep	antigen	1541:1547	arg1	form					1560:1563	truncated form	1550:1563	truncated form of mucin-type O-glycans	1550:1587	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	0	107	theme	Early	64:68	arg1	Disruption					70:79	Early Disruption	64:79	Early Disruption of the NK Cell-DC Dynamics	64:106	Altered Glycosylation Contributes to Placental Dysfunction Upon Early Disruption of the NK Cell-DC Dynamics.
32760395	7	108	theme	Tn	1538:1539	arg1	antigen					1541:1547	Tn antigen	1538:1547	Tn antigen (truncated form of mucin-type O-glycans)	1538:1588	On the other hand, expansion of DC induced a milder increase of Tn antigen (truncated form of mucin-type O-glycans) and branched N-glycan expression in the vascular zone, with only modest changes in the glycosylation pattern during the post-placentation period.
32760395	2	109	theme	cell	337:340	arg1	interactions					342:353	balanced DC-NK cell interactions	322:353	balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions	322:439	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	9	110	theme	fetal	2126:2130	arg1	development					2132:2142	placentation and fetal development	2109:2142	placentation and fetal development	2109:2142	Our results show that pre- and post- placentation implantation sites have a differential glycopattern upon disruption of the NK cell-DC dynamics, suggesting that immune imbalance early in gestation impacts placentation and fetal development by directly influencing the placental glycocode.
32760395	5	111	theme	post-placentation	968:984	arg1	period					986:991	the pre- and post-placentation period	955:991	the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy	955:1068	Here, we aimed to investigate the maternal and placental glycovariation during the pre- and post-placentation period associated with disruption of the NK cell-DC dynamics during early pregnancy.
32760395	3	112	theme	growth	642:647	arg1	restriction					649:659	fetal growth restriction	636:659	fetal growth restriction	636:659	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32760395	2	113	theme	fetal	294:298	arg1	development					300:310	Proper placental and fetal development	273:310	Proper placental and fetal development	273:310	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	6	114	theme	NK	1101:1102	arg1	cells					1104:1108	NK cells	1101:1108	NK cells	1101:1108	We observed that depletion of NK cells was associated with significant increases of O- and N-linked glycosylation and sialylation in the decidual vascular zone during the pre-placental period, followed by downregulation of core 1 and poly-LacNAc extended O-glycans and increased expression of branched N-glycans affecting mainly the placental giant cells and spongiotrophoblasts of the junctional zone.
32760395	2	115	dep	cell	373:376	arg1	homing					378:383	homing	378:383	homing	378:383	Proper placental and fetal development relies on balanced DC-NK cell interactions regulating immune cell homing, maternal vascular expansion, and trophoblast functions.
32760395	3	116	theme	uterine	495:501	arg1	balance					514:520	the uterine NK cell-DC balance	491:520	the uterine NK cell-DC balance	491:520	Previously, we showed that in vivo disruption of the uterine NK cell-DC balance interferes with the decidualization process, with subsequent impact on placental and fetal development leading to fetal growth restriction.
32710576	8	0	theme	hemagglutinin	1037:1049	arg1	constructs					1069:1078	different hemagglutinin and neuraminidase constructs	1027:1078	different hemagglutinin and neuraminidase constructs	1027:1078	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	8	1	theme	HAs	1158:1160	arg1	array					1139:1143	a wide array	1132:1143	a wide array of different HAs, NAs and their mutants	1132:1183	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	8	2	theme	different	1027:1035	arg1	constructs					1069:1078	different hemagglutinin and neuraminidase constructs	1027:1078	different hemagglutinin and neuraminidase constructs	1027:1078	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	8	3	theme	NAs	1163:1165	arg1	array					1139:1143	a wide array	1132:1143	a wide array of different HAs, NAs and their mutants	1132:1183	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	0	4	from	Drivers	0:6	arg1	cells					105:109	mammalian cells	95:109	mammalian cells	95:109	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	8	5	theme	neuraminidase	1055:1067	arg1	constructs					1069:1078	different hemagglutinin and neuraminidase constructs	1027:1078	different hemagglutinin and neuraminidase constructs	1027:1078	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	6	6	theme	sfGFP	839:843	arg1	fusions					845:851	sfGFP fusions	839:851	sfGFP fusions	839:851	Here we report that using codon-optimized genes and sfGFP fusions, the expression yield of HA can be significantly improved.
32710576	0	7	theme	mammalian	95:103	arg1	cells					105:109	mammalian cells	95:109	mammalian cells	95:109	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	4	8	theme	glycosylation	638:650	arg1	presence					617:624	the presence	613:624	the presence of N-linked glycosylation and disulfide bond formation	613:679	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	5	9	theme	mammalian-cell	690:703	arg1	expression					705:714	mammalian-cell expression	690:714	mammalian-cell expression	690:714	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	2	10	theme	Receptor	284:291	arg1	binding					293:299	Receptor binding	284:299	Receptor binding	284:299	Receptor binding and sialic acid cleavage by recombinant proteins correlate satisfactorily compared to whole viruses.
32710576	1	11	theme	biological	261:270	arg1	properties					272:281	biological properties	261:281	biological properties	261:281	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	4	12	dep	expressed	573:581	arg1	cell					568:571	cell	568:571	cell	568:571	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	3	13	theme	laboratory	469:478	arg1	hosts					480:484	different laboratory hosts	459:484	different laboratory hosts	459:484	Expression of HA and NA can be achieved in a plethora of different laboratory hosts.
32710576	5	14	theme	important	771:779	arg1	yield					759:763	an increased expression yield	735:763	an increased expression yield	735:763	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	5	14	theme	important	771:779	arg1	goal					781:784	an important goal	768:784	an important goal	768:784	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	3	15	theme	NA	423:424	arg1	Expression					402:411	Expression	402:411	Expression of HA and NA	402:424	Expression of HA and NA can be achieved in a plethora of different laboratory hosts.
32710576	6	16	theme	codon-optimized	813:827	arg1	genes					829:833	codon-optimized genes	813:833	codon-optimized genes	813:833	Here we report that using codon-optimized genes and sfGFP fusions, the expression yield of HA can be significantly improved.
32710576	4	17	theme	formation	671:679	arg1	presence					617:624	the presence	613:624	the presence of N-linked glycosylation and disulfide bond formation	613:679	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	8	18	theme	mutants	1177:1183	arg1	array					1139:1143	a wide array	1132:1143	a wide array of different HAs, NAs and their mutants	1132:1183	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	1	19	theme	tetrameric	183:192	arg1	NAs					210:212	NAs	210:212	NAs	210:212	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	1	19	theme	tetrameric	183:192	arg1	neuraminidases					194:207	tetrameric neuraminidases	183:207	tetrameric neuraminidases (NAs)	183:213	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	8	20	theme	valuable	1108:1115	arg1	tools					1117:1121	valuable tools	1108:1121	valuable tools	1108:1121	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	2	21	theme	acid	312:315	arg1	cleavage					317:324	sialic acid cleavage	305:324	sialic acid cleavage by recombinant proteins	305:348	Receptor binding and sialic acid cleavage by recombinant proteins correlate satisfactorily compared to whole viruses.
32710576	0	22	theme	soluble	23:29	arg1	hemagglutinin					49:61	recombinant soluble influenza A virus hemagglutinin	11:61	recombinant soluble influenza A virus hemagglutinin	11:61	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	4	23	theme	mammalian	558:566	arg1	proteins					583:590	insect and mammalian cell expressed proteins	547:590	insect and mammalian cell expressed proteins	547:590	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	2	24	theme	sialic	305:310	arg1	cleavage					317:324	sialic acid cleavage	305:324	sialic acid cleavage by recombinant proteins	305:348	Receptor binding and sialic acid cleavage by recombinant proteins correlate satisfactorily compared to whole viruses.
32710576	3	25	theme	different	459:467	arg1	hosts					480:484	different laboratory hosts	459:484	different laboratory hosts	459:484	Expression of HA and NA can be achieved in a plethora of different laboratory hosts.
32710576	0	26	theme	recombinant	11:21	arg1	hemagglutinin					49:61	recombinant soluble influenza A virus hemagglutinin	11:61	recombinant soluble influenza A virus hemagglutinin	11:61	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	4	27	link	N-linked	629:636	arg1	glycosylation					638:650	N-linked glycosylation	629:650	N-linked glycosylation	629:650	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	1	28	theme	Recombinant	112:122	arg1	virus					153:157	Recombinant soluble trimeric influenza A virus	112:157	Recombinant soluble trimeric influenza A virus hemagglutinins (HA)	112:177	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	1	29	theme	virus	153:157	arg1	hemagglutinins					159:172	Recombinant soluble trimeric influenza A virus hemagglutinins	112:172	Recombinant soluble trimeric influenza A virus hemagglutinins (HA)	112:177	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	1	29	theme	virus	153:157	arg1	HA					175:176	HA	175:176	HA	175:176	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	0	30	theme	A	41:41	arg1	hemagglutinin					49:61	recombinant soluble influenza A virus hemagglutinin	11:61	recombinant soluble influenza A virus hemagglutinin	11:61	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	4	31	theme	expressed	573:581	arg1	proteins					583:590	insect and mammalian cell expressed proteins	547:590	insect and mammalian cell expressed proteins	547:590	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	5	32	theme	increased	738:746	arg1	yield					759:763	an increased expression yield	735:763	an increased expression yield	735:763	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	5	32	theme	increased	738:746	arg1	goal					781:784	an important goal	768:784	an important goal	768:784	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	0	33	dep	hemagglutinin	49:61	arg1	expression					81:90	expression	81:90	expression	81:90	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	4	34	theme	bond	666:669	arg1	formation					671:679	disulfide bond formation	656:679	disulfide bond formation	656:679	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	0	35	theme	influenza	31:39	arg1	hemagglutinin					49:61	recombinant soluble influenza A virus hemagglutinin	11:61	recombinant soluble influenza A virus hemagglutinin	11:61	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	5	36	theme	expression	748:757	arg1	yield					759:763	an increased expression yield	735:763	an increased expression yield	735:763	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	5	36	theme	expression	748:757	arg1	goal					781:784	an important goal	768:784	an important goal	768:784	Because mammalian-cell expression is widely applied, an increased expression yield is an important goal.
32710576	6	37	theme	HA	878:879	arg1	yield					869:873	the expression yield	854:873	the expression yield of HA	854:879	Here we report that using codon-optimized genes and sfGFP fusions, the expression yield of HA can be significantly improved.
32710576	4	38	theme	disulfide	656:664	arg1	formation					671:679	disulfide bond formation	656:679	disulfide bond formation	656:679	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	0	39	theme	hemagglutinin	49:61	arg1	Drivers					0:6	Drivers	0:6	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.	0:110	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	8	40	theme	wide	1134:1137	arg1	array					1139:1143	a wide array	1132:1143	a wide array of different HAs, NAs and their mutants	1132:1183	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	1	41	theme	soluble	124:130	arg1	virus					153:157	Recombinant soluble trimeric influenza A virus	112:157	Recombinant soluble trimeric influenza A virus hemagglutinins (HA)	112:177	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	0	42	theme	virus	43:47	arg1	hemagglutinin					49:61	recombinant soluble influenza A virus hemagglutinin	11:61	recombinant soluble influenza A virus hemagglutinin	11:61	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	3	43	theme	hosts	480:484	arg1	plethora					447:454	a plethora	445:454	a plethora of different laboratory hosts	445:484	Expression of HA and NA can be achieved in a plethora of different laboratory hosts.
32710576	8	44	theme	constructs	1069:1078	arg1	suite					1018:1022	a suite	1016:1022	a suite of different hemagglutinin and neuraminidase constructs	1016:1078	In this study, a suite of different hemagglutinin and neuraminidase constructs are described, which can be valuable tools to study a wide array of different HAs, NAs and their mutants.
32710576	1	45	theme	trimeric	132:139	arg1	virus					153:157	Recombinant soluble trimeric influenza A virus	112:157	Recombinant soluble trimeric influenza A virus hemagglutinins (HA)	112:177	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	4	46	theme	insect	547:552	arg1	proteins					583:590	insect and mammalian cell expressed proteins	547:590	insect and mammalian cell expressed proteins	547:590	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	6	47	theme	expression	858:867	arg1	yield					869:873	the expression yield	854:873	the expression yield of HA	854:879	Here we report that using codon-optimized genes and sfGFP fusions, the expression yield of HA can be significantly improved.
32710576	7	48	theme	NA	997:998	arg1	N-terminus					983:992	the N-terminus	979:992	the N-terminus of NA	979:998	sfGFP also significantly increased expression yields when fused to the N-terminus of NA.
32710576	1	49	theme	influenza	141:149	arg1	virus					153:157	Recombinant soluble trimeric influenza A virus	112:157	Recombinant soluble trimeric influenza A virus hemagglutinins (HA)	112:177	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	7	50	theme	expression	947:956	arg1	yields					958:963	expression yields	947:963	expression yields	947:963	sfGFP also significantly increased expression yields when fused to the N-terminus of NA.
32710576	4	51	theme	interaction	518:528	arg1	studies					530:536	receptor interaction studies	509:536	receptor interaction studies	509:536	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	1	52	theme	A	151:151	arg1	virus					153:157	Recombinant soluble trimeric influenza A virus	112:157	Recombinant soluble trimeric influenza A virus hemagglutinins (HA)	112:177	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
32710576	2	53	theme	recombinant	329:339	arg1	proteins					341:348	recombinant proteins	329:348	recombinant proteins	329:348	Receptor binding and sialic acid cleavage by recombinant proteins correlate satisfactorily compared to whole viruses.
32710576	0	54	theme	neuraminidase	67:79	arg1	Drivers					0:6	Drivers	0:6	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.	0:110	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells.
32710576	2	55	theme	whole	387:391	arg1	viruses					393:399	whole viruses	387:399	whole viruses	387:399	Receptor binding and sialic acid cleavage by recombinant proteins correlate satisfactorily compared to whole viruses.
32710576	4	56	theme	N-linked	629:636	arg1	glycosylation					638:650	N-linked glycosylation	629:650	N-linked glycosylation	629:650	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	3	57	theme	HA	416:417	arg1	Expression					402:411	Expression	402:411	Expression of HA and NA	402:424	Expression of HA and NA can be achieved in a plethora of different laboratory hosts.
32710576	4	58	theme	receptor	509:516	arg1	studies					530:536	receptor interaction studies	509:536	receptor interaction studies	509:536	For immunological and receptor interaction studies however, insect and mammalian cell expressed proteins are preferred due to the presence of N-linked glycosylation and disulfide bond formation.
32710576	1	59	theme	excellent	233:241	arg1	tools					243:247	excellent tools	233:247	excellent tools to decipher biological properties	233:281	Recombinant soluble trimeric influenza A virus hemagglutinins (HA) and tetrameric neuraminidases (NAs) have proven to be excellent tools to decipher biological properties.
33562410	7	0	theme	potential	1140:1148	arg1	roles					1150:1154	potential roles	1140:1154	potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC	1140:1207	These results imply potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC.
33562410	6	1	theme	LFNG	1064:1067	arg1	expression					1036:1045	low expression	1032:1045	low expression of both EOGT and LFNG	1032:1067	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	2	2	theme	Notch	353:357	arg1	signaling					359:367	Notch signaling	353:367	Notch signaling	353:367	However, dysregulation of Notch signaling by post-translational modification of Notch receptors remains poorly understood.
33562410	1	3	theme	downstream	156:165	arg1	genes					174:178	their downstream target genes	150:178	their downstream target genes	150:178	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	4	4	from	PDAC	811:814	arg1	subset					776:781	a subset	774:781	a subset of Notch signaling genes in PDAC	774:814	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	5	theme	Notch	786:790	arg1	genes					802:806	Notch signaling genes	786:806	Notch signaling genes in PDAC	786:814	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	6	theme	growth	649:654	arg1	EGF					664:666	EGF	664:666	EGF	664:666	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	6	theme	growth	649:654	arg1	factor					656:661	epidermal growth factor	639:661	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT)	639:719	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	0	7	theme	Pancreatic	90:99	arg1	Cancers					101:107	Pancreatic Cancers	90:107	Pancreatic Cancers	90:107	Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers.
33562410	5	8	theme	activation	951:960	arg1	inhibition					931:940	the inhibition	927:940	the inhibition of Notch activation	927:960	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	4	9	theme	genes	802:806	arg1	subset					776:781	a subset	774:781	a subset of Notch signaling genes in PDAC	774:814	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	10	theme	epidermal	639:647	arg1	EGF					664:666	EGF	664:666	EGF	664:666	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	10	theme	epidermal	639:647	arg1	factor					656:661	epidermal growth factor	639:661	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT)	639:719	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	0	11	from	Roles	59:63	arg1	Cancers					101:107	Pancreatic Cancers	90:107	Pancreatic Cancers	90:107	Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers.
33562410	4	12	theme	domain-specific	669:683	arg1	N-acetylglucosamine					694:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine	639:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT)	639:719	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	12	theme	domain-specific	669:683	arg1	EOGT					715:718	EOGT	715:718	EOGT	715:718	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	3	13	theme	signaling	565:573	arg1	pathway					575:581	the ligand-dependent Notch signaling pathway	538:581	the ligand-dependent Notch signaling pathway	538:581	Here, we analyzed the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway.
33562410	5	14	theme	cells	905:909	arg1	migration					885:893	migration	885:893	migration	885:893	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	5	14	theme	cells	905:909	arg1	proliferation					867:879	proliferation	867:879	proliferation	867:879	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	1	15	theme	target	167:172	arg1	genes					174:178	their downstream target genes	150:178	their downstream target genes	150:178	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	6	16	theme	basal	1013:1017	arg1	subtype					1019:1025	the basal subtype	1009:1025	the basal subtype	1009:1025	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	5	17	dep	EOGT	829:832	arg1	expression					842:851	expression	842:851	expression	842:851	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	3	18	theme	pathway	575:581	arg1	regulation					524:533	the regulation	520:533	the regulation of the ligand-dependent Notch signaling pathway	520:581	Here, we analyzed the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway.
33562410	6	19	theme	PDAC	1105:1108	arg1	patients					1110:1117	PDAC patients	1105:1117	PDAC patients	1105:1117	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	5	20	theme	Panc-1	898:903	arg1	cells					905:909	Panc-1 cells	898:909	Panc-1 cells	898:909	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	6	21	from	survival	1093:1100	arg1	patients					1110:1117	PDAC patients	1105:1117	PDAC patients	1105:1117	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	6	22	theme	overall	1085:1091	arg1	survival					1093:1100	better overall survival	1078:1100	better overall survival in PDAC patients	1078:1117	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	4	23	theme	Lunatic	725:731	arg1	LFNG					741:744	LFNG	741:744	LFNG	741:744	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	23	theme	Lunatic	725:731	arg1	fringe					733:738	Lunatic fringe	725:738	Lunatic fringe (LFNG)	725:745	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	5	24	theme	LFNG	837:840	arg1	lack					821:824	The lack	817:824	The lack of EOGT or LFNG expression	817:851	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	1	25	theme	Notch	262:266	arg1	signaling					268:276	Notch signaling	262:276	Notch signaling	262:276	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	4	26	from	genes	802:806	arg1	PDAC					811:814	PDAC	811:814	PDAC	811:814	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	2	27	theme	post-translational	372:389	arg1	modification					391:402	post-translational modification	372:402	post-translational modification of Notch receptors	372:421	However, dysregulation of Notch signaling by post-translational modification of Notch receptors remains poorly understood.
33562410	7	28	theme	Notch	1185:1189	arg1	signaling					1191:1199	EOGT- and LFNG-dependent Notch signaling	1160:1199	EOGT- and LFNG-dependent Notch signaling	1160:1199	These results imply potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC.
33562410	1	29	theme	signaling	268:276	arg1	role					254:257	a role	252:257	a role of Notch signaling in pancreatic tumor development and progression	252:324	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	1	30	from	role	254:257	arg1	development					298:308	pancreatic tumor development	281:308	pancreatic tumor development	281:308	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	1	30	from	role	254:257	arg1	progression					314:324	progression	314:324	progression	314:324	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	4	31	from	subset	776:781	arg1	PDAC					811:814	PDAC	811:814	PDAC	811:814	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	32	theme	signaling	792:800	arg1	genes					802:806	Notch signaling genes	786:806	Notch signaling genes in PDAC	786:814	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	3	33	theme	Notch-modifying	472:486	arg1	glycosyltransferase					488:506	the Notch-modifying glycosyltransferase	468:506	the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway	468:581	Here, we analyzed the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway.
33562410	0	34	theme	Functional	19:28	arg1	Analyses					30:37	Functional Analyses	19:37	Functional Analyses	19:37	Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers.
33562410	6	35	theme	EOGT	963:966	arg1	expression					968:977	EOGT expression	963:977	EOGT expression	963:977	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	1	36	theme	Notch	110:114	arg1	receptors					126:134	Notch signaling receptors	110:134	Notch signaling receptors	110:134	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	1	37	theme	pancreatic	200:209	arg1	PDAC					234:237	PDAC	234:237	PDAC	234:237	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	1	37	theme	pancreatic	200:209	arg1	adenocarcinoma					218:231	pancreatic ductal adenocarcinoma	200:231	pancreatic ductal adenocarcinoma (PDAC)	200:238	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	0	38	theme	Potential	49:57	arg1	Roles					59:63	Potential Roles	49:63	Potential Roles for EOGT and L-fringe in Pancreatic Cancers	49:107	Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers.
33562410	1	39	theme	pancreatic	281:290	arg1	development					298:308	pancreatic tumor development	281:308	pancreatic tumor development	281:308	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	6	40	theme	better	1078:1083	arg1	survival					1093:1100	better overall survival	1078:1100	better overall survival in PDAC patients	1078:1117	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	1	41	theme	ductal	211:216	arg1	PDAC					234:237	PDAC	234:237	PDAC	234:237	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	1	41	theme	ductal	211:216	arg1	adenocarcinoma					218:231	pancreatic ductal adenocarcinoma	200:231	pancreatic ductal adenocarcinoma (PDAC)	200:238	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	2	42	theme	Notch	407:411	arg1	receptors					413:421	Notch receptors	407:421	Notch receptors	407:421	However, dysregulation of Notch signaling by post-translational modification of Notch receptors remains poorly understood.
33562410	1	43	theme	tumor	292:296	arg1	development					298:308	pancreatic tumor development	281:308	pancreatic tumor development	281:308	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	7	44	theme	LFNG-dependent	1170:1183	arg1	signaling					1191:1199	EOGT- and LFNG-dependent Notch signaling	1160:1199	EOGT- and LFNG-dependent Notch signaling	1160:1199	These results imply potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC.
33562410	2	45	theme	receptors	413:421	arg1	modification					391:402	post-translational modification	372:402	post-translational modification of Notch receptors	372:421	However, dysregulation of Notch signaling by post-translational modification of Notch receptors remains poorly understood.
33562410	6	46	theme	EOGT	1055:1058	arg1	expression					1036:1045	low expression	1032:1045	low expression of both EOGT and LFNG	1032:1067	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
33562410	1	47	theme	signaling	116:124	arg1	receptors					126:134	Notch signaling receptors	110:134	Notch signaling receptors	110:134	Notch signaling receptors, ligands, and their downstream target genes are dysregulated in pancreatic ductal adenocarcinoma (PDAC), suggesting a role of Notch signaling in pancreatic tumor development and progression.
33562410	5	48	theme	EOGT	829:832	arg1	lack					821:824	The lack	817:824	The lack of EOGT or LFNG expression	817:851	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	4	49	theme	Bioinformatic	584:596	arg1	analysis					598:605	Bioinformatic analysis	584:605	Bioinformatic analysis	584:605	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	7	50	from	roles	1150:1154	arg1	PDAC					1204:1207	PDAC	1204:1207	PDAC	1204:1207	These results imply potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC.
33562410	7	51	theme	EOGT-	1160:1164	arg1	signaling					1191:1199	EOGT- and LFNG-dependent Notch signaling	1160:1199	EOGT- and LFNG-dependent Notch signaling	1160:1199	These results imply potential roles for EOGT- and LFNG-dependent Notch signaling in PDAC.
33562410	4	52	theme	fringe	733:738	arg1	expression					625:634	the expression	621:634	the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG)	621:745	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	5	53	theme	Notch	945:949	arg1	activation					951:960	Notch activation	945:960	Notch activation	945:960	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	3	54	theme	Notch	559:563	arg1	pathway					575:581	the ligand-dependent Notch signaling pathway	538:581	the ligand-dependent Notch signaling pathway	538:581	Here, we analyzed the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway.
33562410	4	55	theme	factor	656:661	arg1	N-acetylglucosamine					694:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine	639:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT)	639:719	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	55	theme	factor	656:661	arg1	EOGT					715:718	EOGT	715:718	EOGT	715:718	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	56	theme	N-acetylglucosamine	694:712	arg1	expression					625:634	the expression	621:634	the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG)	621:745	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	57	link	O-linked	685:692	arg1	N-acetylglucosamine					694:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine	639:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT)	639:719	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	57	link	O-linked	685:692	arg1	EOGT					715:718	EOGT	715:718	EOGT	715:718	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	58	theme	O-linked	685:692	arg1	N-acetylglucosamine					694:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine	639:712	epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT)	639:719	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	4	58	theme	O-linked	685:692	arg1	EOGT					715:718	EOGT	715:718	EOGT	715:718	Bioinformatic analysis revealed that the expression of epidermal growth factor (EGF) domain-specific O-linked N-acetylglucosamine (EOGT) and Lunatic fringe (LFNG) positively correlates with a subset of Notch signaling genes in PDAC.
33562410	3	59	theme	ligand-dependent	542:557	arg1	pathway					575:581	the ligand-dependent Notch signaling pathway	538:581	the ligand-dependent Notch signaling pathway	538:581	Here, we analyzed the Notch-modifying glycosyltransferase involved in the regulation of the ligand-dependent Notch signaling pathway.
33562410	5	60	dep	proliferation	867:879	arg1	the					863:865	the	863:865	the	863:865	The lack of EOGT or LFNG expression inhibited the proliferation and migration of Panc-1 cells, as observed by the inhibition of Notch activation.
33562410	2	61	theme	signaling	359:367	arg1	dysregulation					336:348	dysregulation	336:348	dysregulation of Notch signaling by post-translational modification of Notch receptors	336:421	However, dysregulation of Notch signaling by post-translational modification of Notch receptors remains poorly understood.
33562410	6	62	theme	low	1032:1034	arg1	expression					1036:1045	low expression	1032:1045	low expression of both EOGT and LFNG	1032:1067	EOGT expression is significantly increased in the basal subtype, and low expression of both EOGT and LFNG predicts better overall survival in PDAC patients.
32508185	2	0	with	patients	401:408	arg1	T2DM					415:418	T2DM	415:418	T2DM	415:418	We sought to elucidate the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM.
32508185	6	1	theme	normal	881:886	arg1	conditions					896:905	normal glucose conditions	881:905	normal glucose conditions (24 hours at 5 mmol/L)	881:928	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	2	2	from	involvement	334:344	arg1	dysfunction					386:396	endothelial dysfunction	374:396	endothelial dysfunction in patients with T2DM	374:418	We sought to elucidate the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM.
32508185	4	3	theme	O-GlcNAc	598:605	arg1	levels					607:612	Endothelial O-GlcNAc levels	586:612	Endothelial O-GlcNAc levels	586:612	Endothelial O-GlcNAc levels were 1.8-ford higher in T2DM patients than in nondiabetic controls (P=0.003).
32508185	6	4	from	patients	861:868	arg1	cells					850:854	endothelial cells	838:854	endothelial cells from patients with T2DM	838:878	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	3	5	theme	patients	525:532	arg1	vein					517:520	a forearm vein	507:520	a forearm vein of patients with T2DM (n=18)	507:549	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	4	6	theme	nondiabetic	660:670	arg1	P=0.003					682:688	P=0.003	682:688	P=0.003	682:688	Endothelial O-GlcNAc levels were 1.8-ford higher in T2DM patients than in nondiabetic controls (P=0.003).
32508185	4	6	theme	nondiabetic	660:670	arg1	controls					672:679	nondiabetic controls	660:679	nondiabetic controls (P=0.003)	660:689	Endothelial O-GlcNAc levels were 1.8-ford higher in T2DM patients than in nondiabetic controls (P=0.003).
32508185	8	7	dep	dynamic	1451:1457	arg1	glucose-induced					1460:1474	glucose-induced	1460:1474	glucose-induced	1460:1474	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	0	8	theme	Human	86:90	arg1	Mellitus					101:108	Human Diabetes Mellitus	86:108	Human Diabetes Mellitus	86:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	3	9	from	vein	517:520	arg1	biopsy					495:500	J-wire biopsy	488:500	J-wire biopsy from a forearm vein of patients with T2DM (n=18)	488:549	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	1	10	theme	glucose	224:230	arg1	levels					232:237	high glucose levels	219:237	high glucose levels in type 2 diabetes mellitus (T2DM)	219:272	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	2	11	from	dysfunction	386:396	arg1	patients					401:408	patients	401:408	patients with T2DM	401:418	We sought to elucidate the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM.
32508185	4	12	theme	T2DM	638:641	arg1	patients					643:650	T2DM patients	638:650	T2DM patients	638:650	Endothelial O-GlcNAc levels were 1.8-ford higher in T2DM patients than in nondiabetic controls (P=0.003).
32508185	8	13	from	patients	1561:1568	arg1	activation					1524:1533	endothelial nitric oxide synthase activation	1490:1533	endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1490:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	8	13	from	patients	1561:1568	arg1	cells					1550:1554	endothelial cells	1538:1554	endothelial cells from patients with T2DM	1538:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	5	14	theme	O-GlcNAc	711:718	arg1	levels					720:725	Higher endothelial O-GlcNAc levels	692:725	Higher endothelial O-GlcNAc levels	692:725	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	8	15	from	cells	1550:1554	arg1	impairment					1476:1485	the dynamic, glucose-induced impairment	1447:1485	the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1447:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	8	16	theme	endothelial	1490:1500	arg1	synthase					1515:1522	endothelial nitric oxide synthase	1490:1522	endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1490:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	6	17	dep	lowered	930:936	arg1	whereas					1033:1039	whereas	1033:1039	whereas	1033:1039	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	1	18	from	levels	232:237	arg1	T2DM					268:271	T2DM	268:271	T2DM	268:271	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	18	from	levels	232:237	arg1	mellitus					258:265	type 2 diabetes mellitus	242:265	type 2 diabetes mellitus (T2DM)	242:272	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	8	19	theme	oxide	1509:1513	arg1	synthase					1515:1522	endothelial nitric oxide synthase	1490:1522	endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1490:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	5	20	theme	Higher	692:697	arg1	levels					720:725	Higher endothelial O-GlcNAc levels	692:725	Higher endothelial O-GlcNAc levels	692:725	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	6	21	theme	oxide	1017:1021	arg1	synthase					1023:1030	endothelial nitric oxide synthase	998:1030	endothelial nitric oxide synthase	998:1030	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	8	22	theme	activation	1524:1533	arg1	impairment					1476:1485	the dynamic, glucose-induced impairment	1447:1485	the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1447:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	7	23	theme	phosphorylation	1319:1333	arg1	improvement					1253:1263	the improvement	1249:1263	the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation	1249:1333	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	6	24	theme	endothelial	998:1008	arg1	synthase					1023:1030	endothelial nitric oxide synthase	998:1030	endothelial nitric oxide synthase	998:1030	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	8	25	theme	endothelial	1538:1548	arg1	cells					1550:1554	endothelial cells	1538:1554	endothelial cells from patients with T2DM	1538:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	0	26	theme	Diabetes	92:99	arg1	Mellitus					101:108	Human Diabetes Mellitus	86:108	Human Diabetes Mellitus	86:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	9	27	theme	O-GlcNAc	1581:1588	arg1	target					1630:1635	a treatment target	1618:1635	a treatment target for vascular dysfunction in T2DM	1618:1668	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	9	27	theme	O-GlcNAc	1581:1588	arg1	modification					1598:1609	O-GlcNAc protein modification	1581:1609	O-GlcNAc protein modification	1581:1609	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	5	28	theme	serum	743:747	arg1	level					771:775	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	3	29	dep	Methods	421:427	arg1	cells					470:474	Freshly isolated endothelial cells	441:474	Freshly isolated endothelial cells	441:474	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	8	30	with	patients	1561:1568	arg1	T2DM					1575:1578	T2DM	1575:1578	T2DM	1575:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	5	31	theme	blood	757:761	arg1	level					771:775	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	7	32	theme	O-GlcNAc	1221:1228	arg1	levels					1230:1235	O-GlcNAc levels	1221:1235	O-GlcNAc levels	1221:1235	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	3	33	theme	isolated	449:456	arg1	cells					470:474	Freshly isolated endothelial cells	441:474	Freshly isolated endothelial cells	441:474	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	1	34	theme	cellular	288:295	arg1	function					297:304	cellular function	288:304	cellular function	288:304	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	35	theme	Background	111:120	arg1	modification					148:159	Background Posttranslational protein modification	111:159	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc)	111:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	0	36	theme	Glucose-Induced	25:39	arg1	Alterations					41:51	Glucose-Induced Alterations	25:51	Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus	25:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	1	37	theme	protein	140:146	arg1	modification					148:159	Background Posttranslational protein modification	111:159	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc)	111:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	6	38	theme	high	1041:1044	arg1	30 mmol/L					1066:1074	30 mmol/L	1066:1074	30 mmol/L	1066:1074	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	6	38	theme	high	1041:1044	arg1	conditions					1054:1063	high glucose conditions	1041:1063	high glucose conditions (30 mmol/L)	1041:1075	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	1	39	attach	linked	209:214	arg2	modification					148:159	Background Posttranslational protein modification	111:159	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc)	111:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	39	attach	linked	209:214	arg1	levels					232:237	high glucose levels	219:237	high glucose levels in type 2 diabetes mellitus (T2DM)	219:272	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	8	40	theme	O-GlcNAc	1422:1429	arg1	modification					1431:1442	O-GlcNAc modification	1422:1442	O-GlcNAc modification	1422:1442	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	7	41	theme	endothelial	1151:1161	arg1	cells					1163:1167	endothelial cells	1151:1167	endothelial cells	1151:1167	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	6	42	theme	endothelial	838:848	arg1	cells					850:854	endothelial cells	838:854	endothelial cells from patients with T2DM	838:878	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	7	43	theme	synthase	1310:1317	arg1	phosphorylation					1319:1333	insulin-mediated endothelial nitric oxide synthase phosphorylation	1268:1333	insulin-mediated endothelial nitric oxide synthase phosphorylation	1268:1333	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	1	44	link	O-linked	166:173	arg1	O-GlcNAc					196:203	O-GlcNAc	196:203	O-GlcNAc	196:203	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	44	link	O-linked	166:173	arg1	N-acetylglucosamine					175:193	O-linked N-acetylglucosamine	166:193	O-linked N-acetylglucosamine (O-GlcNAc)	166:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	2	45	theme	modification	358:369	arg1	involvement					334:344	the involvement	330:344	the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM	330:418	We sought to elucidate the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM.
32508185	0	46	theme	Cell	68:71	arg1	Phenotype					73:81	Endothelial Cell Phenotype	56:81	Endothelial Cell Phenotype in Human Diabetes Mellitus	56:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	6	47	theme	insulin	1122:1128	arg1	action					1130:1135	insulin action	1122:1135	insulin action	1122:1135	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	8	48	theme	dynamic	1451:1457	arg1	impairment					1476:1485	the dynamic, glucose-induced impairment	1447:1485	the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1447:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	6	49	dep	conditions	896:905	arg1	24 hours					908:915	24 hours	908:915	24 hours at 5 mmol/L	908:927	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	1	50	theme	diabetes	249:256	arg1	T2DM					268:271	T2DM	268:271	T2DM	268:271	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	50	theme	diabetes	249:256	arg1	mellitus					258:265	type 2 diabetes mellitus	242:265	type 2 diabetes mellitus (T2DM)	242:272	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	7	51	theme	insulin-mediated	1268:1283	arg1	synthase					1310:1317	insulin-mediated endothelial nitric oxide synthase	1268:1317	insulin-mediated endothelial nitric oxide synthase phosphorylation	1268:1333	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	6	52	theme	O-GlcNAc	1093:1100	arg1	levels					1102:1107	both O-GlcNAc levels	1088:1107	both O-GlcNAc levels	1088:1107	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	6	53	with	patients	861:868	arg1	T2DM					875:878	T2DM	875:878	T2DM	875:878	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	3	54	with	patients	525:532	arg1	n=18					545:548	n=18	545:548	n=18	545:548	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	3	54	with	patients	525:532	arg1	T2DM					539:542	T2DM	539:542	T2DM (n=18)	539:549	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	2	55	theme	endothelial	374:384	arg1	dysfunction					386:396	endothelial dysfunction	374:396	endothelial dysfunction in patients with T2DM	374:418	We sought to elucidate the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM.
32508185	6	56	theme	glucose	888:894	arg1	conditions					896:905	normal glucose conditions	881:905	normal glucose conditions (24 hours at 5 mmol/L)	881:928	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	5	57	dep	r=0.418	816:822	arg1	P=0.042					825:831	P=0.042	825:831	P=0.042	825:831	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	7	58	with	Treatment	1138:1146	arg1	inhibitor					1200:1208	an O-GlcNAcase inhibitor	1185:1208	an O-GlcNAcase inhibitor	1185:1208	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	7	58	with	Treatment	1138:1146	arg1	G					1182:1182	Thiamet G	1174:1182	Thiamet G	1174:1182	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	4	59	theme	Endothelial	586:596	arg1	levels					607:612	Endothelial O-GlcNAc levels	586:612	Endothelial O-GlcNAc levels	586:612	Endothelial O-GlcNAc levels were 1.8-ford higher in T2DM patients than in nondiabetic controls (P=0.003).
32508185	8	60	from	impairment	1476:1485	arg1	cells					1550:1554	endothelial cells	1538:1554	endothelial cells from patients with T2DM	1538:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	1	61	theme	high	219:222	arg1	levels					232:237	high glucose levels	219:237	high glucose levels in type 2 diabetes mellitus (T2DM)	219:272	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	5	62	theme	endothelial	699:709	arg1	levels					720:725	Higher endothelial O-GlcNAc levels	692:725	Higher endothelial O-GlcNAc levels	692:725	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	6	63	theme	O-GlcNAc	938:945	arg1	levels					947:952	O-GlcNAc levels	938:952	O-GlcNAc levels	938:952	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	9	64	theme	treatment	1620:1628	arg1	target					1630:1635	a treatment target	1618:1635	a treatment target for vascular dysfunction in T2DM	1618:1668	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	9	64	theme	treatment	1620:1628	arg1	modification					1598:1609	O-GlcNAc protein modification	1581:1609	O-GlcNAc protein modification	1581:1609	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	7	65	theme	nitric	1297:1302	arg1	synthase					1310:1317	insulin-mediated endothelial nitric oxide synthase	1268:1317	insulin-mediated endothelial nitric oxide synthase phosphorylation	1268:1333	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	1	66	theme	type	242:245	arg1	T2DM					268:271	T2DM	268:271	T2DM	268:271	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	66	theme	type	242:245	arg1	mellitus					258:265	type 2 diabetes mellitus	242:265	type 2 diabetes mellitus (T2DM)	242:272	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	5	67	dep	level	771:775	arg1	P=0.024					787:793	P=0.024	787:793	P=0.024	787:793	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	5	67	dep	level	771:775	arg1	r=0.433					778:784	r=0.433	778:784	r=0.433	778:784	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	8	68	theme	nitric	1502:1507	arg1	synthase					1515:1522	endothelial nitric oxide synthase	1490:1522	endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1490:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	8	69	theme	synthase	1515:1522	arg1	activation					1524:1533	endothelial nitric oxide synthase activation	1490:1533	endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1490:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	1	70	theme	O-linked	166:173	arg1	O-GlcNAc					196:203	O-GlcNAc	196:203	O-GlcNAc	196:203	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	70	theme	O-linked	166:173	arg1	N-acetylglucosamine					175:193	O-linked N-acetylglucosamine	166:193	O-linked N-acetylglucosamine (O-GlcNAc)	166:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	6	71	theme	synthase	1023:1030	arg1	activation					984:993	insulin-mediated activation	967:993	insulin-mediated activation of endothelial nitric oxide synthase	967:1030	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	5	72	theme	glucose	763:769	arg1	level					771:775	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	6	73	theme	nitric	1010:1015	arg1	synthase					1023:1030	endothelial nitric oxide synthase	998:1030	endothelial nitric oxide synthase	998:1030	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	0	74	from	Alterations	41:51	arg1	Phenotype					73:81	Endothelial Cell Phenotype	56:81	Endothelial Cell Phenotype in Human Diabetes Mellitus	56:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	8	75	from	activation	1524:1533	arg1	patients					1561:1568	patients	1561:1568	patients with T2DM	1561:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	8	75	from	activation	1524:1533	arg1	cells					1550:1554	endothelial cells	1538:1554	endothelial cells from patients with T2DM	1538:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
32508185	7	76	theme	O-GlcNAcase	1188:1198	arg1	inhibitor					1200:1208	an O-GlcNAcase inhibitor	1185:1208	an O-GlcNAcase inhibitor	1185:1208	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	7	76	theme	O-GlcNAcase	1188:1198	arg1	G					1182:1182	Thiamet G	1174:1182	Thiamet G	1174:1182	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	9	77	theme	protein	1590:1596	arg1	target					1630:1635	a treatment target	1618:1635	a treatment target for vascular dysfunction in T2DM	1618:1668	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	9	77	theme	protein	1590:1596	arg1	modification					1598:1609	O-GlcNAc protein modification	1581:1609	O-GlcNAc protein modification	1581:1609	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	6	78	theme	insulin-mediated	967:982	arg1	activation					984:993	insulin-mediated activation	967:993	insulin-mediated activation of endothelial nitric oxide synthase	967:1030	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	0	79	from	Phenotype	73:81	arg1	Mellitus					101:108	Human Diabetes Mellitus	86:108	Human Diabetes Mellitus	86:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	5	80	theme	fasting	749:755	arg1	level					771:775	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	serum fasting blood glucose level (r=0.433, P=0.024)	743:794	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	5	81	theme	hemoglobin	800:809	arg1	A1c					811:813	hemoglobin A1c	800:813	hemoglobin A1c (r=0.418, P=0.042)	800:832	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	5	81	theme	hemoglobin	800:809	arg1	r=0.418					816:822	r=0.418	816:822	r=0.418	816:822	Higher endothelial O-GlcNAc levels correlated with serum fasting blood glucose level (r=0.433, P=0.024) and hemoglobin A1c (r=0.418, P=0.042).
32508185	1	82	with	modification	148:159	arg1	O-GlcNAc					196:203	O-GlcNAc	196:203	O-GlcNAc	196:203	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	1	82	with	modification	148:159	arg1	N-acetylglucosamine					175:193	O-linked N-acetylglucosamine	166:193	O-linked N-acetylglucosamine (O-GlcNAc)	166:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	7	83	theme	glucose	1338:1344	arg1	normalization					1346:1358	glucose normalization	1338:1358	glucose normalization	1338:1358	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	3	84	theme	endothelial	458:468	arg1	cells					470:474	Freshly isolated endothelial cells	441:474	Freshly isolated endothelial cells	441:474	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	7	85	theme	cells	1163:1167	arg1	Treatment					1138:1146	Treatment	1138:1146	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor,	1138:1209	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	1	86	theme	Posttranslational	122:138	arg1	modification					148:159	Background Posttranslational protein modification	111:159	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc)	111:204	Background Posttranslational protein modification with O-linked N-acetylglucosamine (O-GlcNAc) is linked to high glucose levels in type 2 diabetes mellitus (T2DM) and may alter cellular function.
32508185	6	87	theme	glucose	1046:1052	arg1	30 mmol/L					1066:1074	30 mmol/L	1066:1074	30 mmol/L	1066:1074	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	6	87	theme	glucose	1046:1052	arg1	conditions					1054:1063	high glucose conditions	1041:1063	high glucose conditions (30 mmol/L)	1041:1075	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	0	88	theme	Endothelial	56:66	arg1	Phenotype					73:81	Endothelial Cell Phenotype	56:81	Endothelial Cell Phenotype in Human Diabetes Mellitus	56:108	O-GlcNAcylation Mediates Glucose-Induced Alterations in Endothelial Cell Phenotype in Human Diabetes Mellitus.
32508185	9	89	theme	vascular	1641:1648	arg1	dysfunction					1650:1660	vascular dysfunction	1641:1660	vascular dysfunction in T2DM	1641:1668	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	9	90	from	dysfunction	1650:1660	arg1	T2DM					1665:1668	T2DM	1665:1668	T2DM	1665:1668	O-GlcNAc protein modification may be a treatment target for vascular dysfunction in T2DM.
32508185	7	91	theme	oxide	1304:1308	arg1	synthase					1310:1317	insulin-mediated endothelial nitric oxide synthase	1268:1317	insulin-mediated endothelial nitric oxide synthase phosphorylation	1268:1333	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	3	92	theme	J-wire	488:493	arg1	biopsy					495:500	J-wire biopsy	488:500	J-wire biopsy from a forearm vein of patients with T2DM (n=18)	488:549	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	7	93	theme	endothelial	1285:1295	arg1	synthase					1310:1317	insulin-mediated endothelial nitric oxide synthase	1268:1317	insulin-mediated endothelial nitric oxide synthase phosphorylation	1268:1333	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	2	94	theme	O-GlcNAc	349:356	arg1	modification					358:369	O-GlcNAc modification	349:369	O-GlcNAc modification	349:369	We sought to elucidate the involvement of O-GlcNAc modification in endothelial dysfunction in patients with T2DM.
32508185	6	95	from	5 mmol/L	920:927	arg1	24 hours					908:915	24 hours	908:915	24 hours at 5 mmol/L	908:927	In endothelial cells from patients with T2DM, normal glucose conditions (24 hours at 5 mmol/L) lowered O-GlcNAc levels and restored insulin-mediated activation of endothelial nitric oxide synthase, whereas high glucose conditions (30 mmol/L) maintained both O-GlcNAc levels and impaired insulin action.
32508185	3	96	theme	forearm	509:515	arg1	vein					517:520	a forearm vein	507:520	a forearm vein of patients with T2DM (n=18)	507:549	Methods and Results Freshly isolated endothelial cells obtained by J-wire biopsy from a forearm vein of patients with T2DM (n=18) was compared with controls (n=10).
32508185	7	97	theme	Thiamet	1174:1180	arg1	inhibitor					1200:1208	an O-GlcNAcase inhibitor	1185:1208	an O-GlcNAcase inhibitor	1185:1208	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	7	97	theme	Thiamet	1174:1180	arg1	G					1182:1182	Thiamet G	1174:1182	Thiamet G	1174:1182	Treatment of endothelial cells with Thiamet G, an O-GlcNAcase inhibitor, increased O-GlcNAc levels and blunted the improvement of insulin-mediated endothelial nitric oxide synthase phosphorylation by glucose normalization.
32508185	8	98	from	role	1413:1416	arg1	impairment					1476:1485	the dynamic, glucose-induced impairment	1447:1485	the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM	1447:1578	Conclusions Taken together, our findings indicate a role for O-GlcNAc modification in the dynamic, glucose-induced impairment of endothelial nitric oxide synthase activation in endothelial cells from patients with T2DM.
34650217	7	0	theme	TWIST1	1062:1067	arg1	expression					1069:1078	TWIST1 expression	1062:1078	TWIST1 expression	1062:1078	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	7	1	theme	c-Myc	1151:1155	arg1	acetylation					1157:1167	c-Myc acetylation	1151:1167	c-Myc acetylation	1151:1167	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	3	2	theme	HCC	560:562	arg1	metastasis					564:573	HCC metastasis	560:573	HCC metastasis	560:573	However, whether PCK1 deficiency and hyper O-GlcNAcylation can induce HCC metastasis is largely unknown.
34650217	7	3	theme	epithelial-mesenchymal	1185:1206	arg1	transition					1208:1217	epithelial-mesenchymal transition	1185:1217	epithelial-mesenchymal transition (EMT)	1185:1223	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	7	3	theme	epithelial-mesenchymal	1185:1206	arg1	EMT					1220:1222	EMT	1220:1222	EMT	1220:1222	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	9	4	theme	post-translational	1554:1571	arg1	modification					1573:1584	post-translational modification	1554:1584	post-translational modification (PTM)	1554:1590	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	9	4	theme	post-translational	1554:1571	arg1	PTM					1587:1589	PTM	1587:1589	PTM	1587:1589	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	9	4	theme	post-translational	1554:1571	arg1	enzyme					1546:1551	metabolic enzyme	1536:1551	metabolic enzyme	1536:1551	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	2	5	theme	hepatic	323:329	arg1	gluconeogenesis					331:345	hepatic gluconeogenesis	323:345	hepatic gluconeogenesis	323:345	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	9	6	theme	metabolic	1536:1544	arg1	modification					1573:1584	post-translational modification	1554:1584	post-translational modification (PTM)	1554:1590	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	9	6	theme	metabolic	1536:1544	arg1	enzyme					1546:1551	metabolic enzyme	1536:1551	metabolic enzyme	1536:1551	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	5	7	theme	MYST	772:775	arg1	family					777:782	the MYST family	768:782	the MYST family of histone acetyltransferases (HAT)	768:818	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	9	8	theme	PCK1	1407:1410	arg1	depletion					1412:1420	PCK1 depletion	1407:1420	PCK1 depletion	1407:1420	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	5	9	theme	lysine	720:725	arg1	acetyltransferase					727:743	lysine acetyltransferase 5	720:745	lysine acetyltransferase 5 (KAT5)	720:752	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	5	9	theme	lysine	720:725	arg1	KAT5					748:751	KAT5	748:751	KAT5	748:751	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	3	10	theme	hyper	527:531	arg1	O-GlcNAcylation					533:547	hyper O-GlcNAcylation	527:547	hyper O-GlcNAcylation	527:547	However, whether PCK1 deficiency and hyper O-GlcNAcylation can induce HCC metastasis is largely unknown.
34650217	8	11	theme	targeting	1246:1254	arg1	O-GlcNAcylation					1269:1283	targeting HBP-mediated O-GlcNAcylation	1246:1283	targeting HBP-mediated O-GlcNAcylation of KAT5	1246:1291	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	6	12	theme	KAT5	935:938	arg1	ubiquitination					940:953	KAT5 ubiquitination	935:953	KAT5 ubiquitination	935:953	Mechanistically, PCK1 depletion suppressed KAT5 ubiquitination by increasing its O-GlcNAcylation, thereby stabilizing KAT5.
34650217	5	13	theme	knockout	867:874	arg1	cells					885:889	PCK1 knockout hepatoma cells	862:889	PCK1 knockout hepatoma cells	862:889	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	1	14	theme	Aberrant	85:92	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	14	theme	Aberrant	85:92	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	14	theme	Aberrant	85:92	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	15	theme	hepatocellular	205:218	arg1	HCC					231:233	HCC	231:233	HCC	231:233	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	15	theme	hepatocellular	205:218	arg1	carcinoma					220:228	hepatocellular carcinoma	205:228	hepatocellular carcinoma (HCC)	205:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	8	16	theme	lung	1302:1305	arg1	metastasis					1307:1316	lung metastasis	1302:1316	lung metastasis of HCC	1302:1323	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	1	17	theme	glucose	94:100	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	17	theme	glucose	94:100	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	17	theme	glucose	94:100	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	18	theme	carcinoma	220:228	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	18	theme	carcinoma	220:228	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	18	theme	carcinoma	220:228	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	8	19	theme	Pck1-deletion	1343:1355	arg1	mice					1357:1360	hepatospecific Pck1-deletion mice	1328:1360	hepatospecific Pck1-deletion mice	1328:1360	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	0	20	theme	O-GlcNAc	0:7	arg1	modified-TIP60/KAT5					9:27	O-GlcNAc modified-TIP60/KAT5	0:27	O-GlcNAc modified-TIP60/KAT5	0:27	O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.
34650217	4	21	theme	gain-	601:605	arg1	studies					628:634	gain- and loss-of-function studies	601:634	gain- and loss-of-function studies	601:634	Here, gain- and loss-of-function studies demonstrate that PCK1 suppresses HCC metastasis in vitro and in vivo.
34650217	8	22	theme	hepatospecific	1328:1341	arg1	mice					1357:1360	hepatospecific Pck1-deletion mice	1328:1360	hepatospecific Pck1-deletion mice	1328:1360	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	8	23	theme	KAT5	1288:1291	arg1	O-GlcNAcylation					1269:1283	targeting HBP-mediated O-GlcNAcylation	1246:1283	targeting HBP-mediated O-GlcNAcylation of KAT5	1246:1291	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	9	24	theme	KAT5	1451:1454	arg1	O-GlcNAcylation					1432:1446	O-GlcNAcylation	1432:1446	O-GlcNAcylation of KAT5	1432:1454	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	7	25	theme	KAT5	1016:1019	arg1	O-GlcNAcylation					1021:1035	KAT5 O-GlcNAcylation	1016:1035	KAT5 O-GlcNAcylation	1016:1035	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	2	26	theme	gluconeogenesis	331:345	arg1	enzyme					313:318	the major rate-limiting enzyme	289:318	the major rate-limiting enzyme of hepatic gluconeogenesis	289:345	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	26	theme	gluconeogenesis	331:345	arg1	carboxykinase					265:277	phosphoenolpyruvate carboxykinase 1	245:279	phosphoenolpyruvate carboxykinase 1 (PCK1)	245:286	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	3	27	theme	PCK1	507:510	arg1	deficiency					512:521	PCK1 deficiency	507:521	PCK1 deficiency	507:521	However, whether PCK1 deficiency and hyper O-GlcNAcylation can induce HCC metastasis is largely unknown.
34650217	5	28	mod	modified	831:838	arg1	acetyltransferase					727:743	lysine acetyltransferase 5	720:745	lysine acetyltransferase 5 (KAT5)	720:752	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	5	28	mod	modified	831:838	arg1	KAT5					748:751	KAT5	748:751	KAT5	748:751	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	5	28	mod	modified	831:838	arg3	O-GlcNAcylation					843:857	O-GlcNAcylation	843:857	O-GlcNAcylation	843:857	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	4	29	theme	loss-of-function	611:626	arg1	studies					628:634	gain- and loss-of-function studies	601:634	gain- and loss-of-function studies	601:634	Here, gain- and loss-of-function studies demonstrate that PCK1 suppresses HCC metastasis in vitro and in vivo.
34650217	2	30	theme	rate-limiting	299:311	arg1	enzyme					313:318	the major rate-limiting enzyme	289:318	the major rate-limiting enzyme of hepatic gluconeogenesis	289:345	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	30	theme	rate-limiting	299:311	arg1	carboxykinase					265:277	phosphoenolpyruvate carboxykinase 1	245:279	phosphoenolpyruvate carboxykinase 1 (PCK1)	245:286	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	6	31	theme	PCK1	909:912	arg1	depletion					914:922	PCK1 depletion	909:922	PCK1 depletion	909:922	Mechanistically, PCK1 depletion suppressed KAT5 ubiquitination by increasing its O-GlcNAcylation, thereby stabilizing KAT5.
34650217	1	32	theme	O-linked	126:133	arg1	O-GlcNAcylation					171:185	O-GlcNAcylation	171:185	O-GlcNAcylation	171:185	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	32	theme	O-linked	126:133	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	32	theme	O-linked	126:133	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	32	theme	O-linked	126:133	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	2	33	theme	cell	459:462	arg1	growth					464:469	cell growth	459:469	cell growth	459:469	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	0	34	theme	PCK1	45:48	arg1	metastasis					73:82	PCK1 deficiency-induced HCC metastasis	45:82	PCK1 deficiency-induced HCC metastasis	45:82	O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.
34650217	7	35	theme	MMP14	1130:1134	arg1	expression					1136:1145	MMP9 and MMP14 expression	1121:1145	MMP9 and MMP14 expression	1121:1145	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	5	36	theme	hepatoma	876:883	arg1	cells					885:889	PCK1 knockout hepatoma cells	862:889	PCK1 knockout hepatoma cells	862:889	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	8	37	theme	HCC	1321:1323	arg1	metastasis					1307:1316	lung metastasis	1302:1316	lung metastasis of HCC	1302:1323	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	9	38	theme	epigenetic	1597:1606	arg1	regulation					1608:1617	epigenetic regulation	1597:1617	epigenetic regulation	1597:1617	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	0	39	theme	HCC	69:71	arg1	metastasis					73:82	PCK1 deficiency-induced HCC metastasis	45:82	PCK1 deficiency-induced HCC metastasis	45:82	O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.
34650217	9	40	theme	TWIST1	1480:1485	arg1	expression					1487:1496	TWIST1 expression	1480:1496	TWIST1 expression	1480:1496	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	7	41	theme	MMP9	1121:1124	arg1	expression					1136:1145	MMP9 and MMP14 expression	1121:1145	MMP9 and MMP14 expression	1121:1145	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	5	42	theme	acetyltransferases	795:812	arg1	family					777:782	the MYST family	768:782	the MYST family of histone acetyltransferases (HAT)	768:818	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	2	43	theme	carboxykinase	265:277	arg1	Loss					237:240	Loss	237:240	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis,	237:346	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	44	from	O-GlcNAcylation	413:427	arg1	cell					441:444	hepatoma cell	432:444	hepatoma cell	432:444	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	1	45	theme	β-N-acetylglucosamine	135:155	arg1	O-GlcNAcylation					171:185	O-GlcNAcylation	171:185	O-GlcNAcylation	171:185	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	45	theme	β-N-acetylglucosamine	135:155	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	45	theme	β-N-acetylglucosamine	135:155	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	45	theme	β-N-acetylglucosamine	135:155	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	0	46	theme	deficiency-induced	50:67	arg1	metastasis					73:82	PCK1 deficiency-induced HCC metastasis	45:82	PCK1 deficiency-induced HCC metastasis	45:82	O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.
34650217	2	47	theme	phosphoenolpyruvate	245:263	arg1	enzyme					313:318	the major rate-limiting enzyme	289:318	the major rate-limiting enzyme of hepatic gluconeogenesis	289:345	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	47	theme	phosphoenolpyruvate	245:263	arg1	carboxykinase					265:277	phosphoenolpyruvate carboxykinase 1	245:279	phosphoenolpyruvate carboxykinase 1 (PCK1)	245:286	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	47	theme	phosphoenolpyruvate	245:263	arg1	PCK1					282:285	PCK1	282:285	PCK1	282:285	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	7	48	theme	histone	1084:1090	arg1	acetylation					1095:1105	histone H4 acetylation	1084:1105	histone H4 acetylation	1084:1105	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	7	49	theme	H4	1092:1093	arg1	acetylation					1095:1105	histone H4 acetylation	1084:1105	histone H4 acetylation	1084:1105	KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC.
34650217	2	50	theme	biosynthetic	369:380	arg1	pathway					382:388	hexosamine biosynthetic pathway	358:388	hexosamine biosynthetic pathway (HBP)	358:394	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	50	theme	biosynthetic	369:380	arg1	HBP					391:393	HBP	391:393	HBP	391:393	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	1	51	theme	elevated	117:124	arg1	O-GlcNAcylation					171:185	O-GlcNAcylation	171:185	O-GlcNAcylation	171:185	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	51	theme	elevated	117:124	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	51	theme	elevated	117:124	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	51	theme	elevated	117:124	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	4	52	theme	HCC	669:671	arg1	metastasis					673:682	HCC metastasis	669:682	HCC metastasis	669:682	Here, gain- and loss-of-function studies demonstrate that PCK1 suppresses HCC metastasis in vitro and in vivo.
34650217	2	53	theme	major	293:297	arg1	enzyme					313:318	the major rate-limiting enzyme	289:318	the major rate-limiting enzyme of hepatic gluconeogenesis	289:345	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	53	theme	major	293:297	arg1	carboxykinase					265:277	phosphoenolpyruvate carboxykinase 1	245:279	phosphoenolpyruvate carboxykinase 1 (PCK1)	245:286	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	8	54	theme	HBP-mediated	1256:1267	arg1	O-GlcNAcylation					1269:1283	targeting HBP-mediated O-GlcNAcylation	1246:1283	targeting HBP-mediated O-GlcNAcylation of KAT5	1246:1291	In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice.
34650217	2	55	theme	hexosamine	358:367	arg1	pathway					382:388	hexosamine biosynthetic pathway	358:388	hexosamine biosynthetic pathway (HBP)	358:394	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	55	theme	hexosamine	358:367	arg1	HBP					391:393	HBP	391:393	HBP	391:393	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	9	56	theme	HCC	1511:1513	arg1	metastasis					1515:1524	HCC metastasis	1511:1524	HCC metastasis	1511:1524	Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.
34650217	5	57	theme	histone	787:793	arg1	acetyltransferases					795:812	histone acetyltransferases	787:812	histone acetyltransferases (HAT)	787:818	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	5	57	theme	histone	787:793	arg1	HAT					815:817	HAT	815:817	HAT	815:817	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	5	58	theme	PCK1	862:865	arg1	cells					885:889	PCK1 knockout hepatoma cells	862:889	PCK1 knockout hepatoma cells	862:889	Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
34650217	2	59	theme	protein	405:411	arg1	O-GlcNAcylation					413:427	hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation	358:427	hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell	358:444	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	2	60	theme	hepatoma	432:439	arg1	cell					441:444	hepatoma cell	432:444	hepatoma cell	432:444	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
34650217	1	61	link	O-linked	126:133	arg1	O-GlcNAcylation					171:185	O-GlcNAcylation	171:185	O-GlcNAcylation	171:185	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	61	link	O-linked	126:133	arg1	hallmarks					192:200	hallmarks	192:200	hallmarks of hepatocellular carcinoma (HCC)	192:234	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	61	link	O-linked	126:133	arg1	modification					157:168	elevated O-linked β-N-acetylglucosamine modification	117:168	elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation)	117:186	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	1	61	link	O-linked	126:133	arg1	metabolism					102:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism	85:111	Aberrant glucose metabolism and elevated O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC).
34650217	2	62	theme	-mediated	395:403	arg1	O-GlcNAcylation					413:427	hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation	358:427	hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell	358:444	Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation.
32791164	10	0	theme	malignant	1563:1571	arg1	tumors					1579:1584	malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats	1563:1698	malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats	1563:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	1	dep	aliases	1615:1621	arg1	GP340					1623:1627	GP340	1623:1627	GP340	1623:1627	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	1	dep	aliases	1615:1621	arg1	aliases					1615:1621	the aliases GP340 and SALSA	1611:1637	the aliases GP340 and SALSA	1611:1637	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	1	dep	aliases	1615:1621	arg1	SALSA					1633:1637	SALSA	1633:1637	SALSA	1633:1637	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	1	2	theme	sialic	254:259	arg1	ligands					277:283	sialic acid-containing ligands	254:283	sialic acid-containing ligands	254:283	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	4	3	theme	human	865:869	arg1	airways					871:877	human airways	865:877	human airways	865:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	3	4	from	ligands	639:645	arg1	ducts					672:676	ducts	672:676	ducts	672:676	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	3	4	from	ligands	639:645	arg1	glands					661:666	submucosal glands	650:666	submucosal glands	650:666	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	10	5	with	glycoprotein	1649:1660	arg1	repeats					1692:1698	multiple O-glycosylation repeats	1667:1698	multiple O-glycosylation repeats	1667:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	3	6	theme	airway	710:715	arg1	layer					723:727	the airway mucus layer	706:727	the airway mucus layer	706:727	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	11	7	link	O-linked	1856:1863	arg1	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	7	link	O-linked	1856:1863	arg1	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	8	from	ligand	1785:1790	arg1	layer					1818:1822	the human airway mucus layer	1795:1822	the human airway mucus layer	1795:1822	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	9	9	theme	kDa	1460:1462	arg1	weight					1431:1436	a molecular weight	1419:1436	a molecular weight of approximately 1000 kDa	1419:1462	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	13	10	from	ligand	2065:2070	arg1	airways					2094:2100	human airways	2088:2100	human airways	2088:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	11	11	theme	airway	1805:1810	arg1	layer					1818:1822	the human airway mucus layer	1795:1822	the human airway mucus layer	1795:1822	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	0	12	theme	cell	103:106	arg1	Siglec-8					134:141	the eosinophil and mast cell immunoinhibitory receptor Siglec-8	79:141	Siglec-8	134:141	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	6	13	theme	Siglec-8	1069:1076	arg1	ligands					1078:1084	Siglec-8 ligands	1069:1084	Siglec-8 ligands	1069:1084	Proteins were resolved by gel electrophoresis and blotted, and Siglec-8 ligands detected.
32791164	5	14	from	clinic	998:1003	arg1	lavage					968:973	presurgical nasal lavage	950:973	presurgical nasal lavage of patients at a sinus clinic	950:1003	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	9	15	theme	patient	1481:1487	arg1	samples					1502:1508	all patient nasal lavage samples	1477:1508	all patient nasal lavage samples	1477:1508	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	2	16	theme	submucosal	535:544	arg1	glands					546:551	submucosal glands	535:551	submucosal glands	535:551	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	8	17	theme	Siglec-8	1291:1298	arg1	binding					1300:1306	Siglec-8 binding	1291:1306	Siglec-8 binding	1291:1306	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	0	18	theme	receptor	125:132	arg1	Siglec-8					134:141	the eosinophil and mast cell immunoinhibitory receptor Siglec-8	79:141	Siglec-8	134:141	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	10	19	gly	glycoprotein	1649:1660	arg1	1					1586:1586	1	1586:1586	1	1586:1586	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	19	gly	glycoprotein	1649:1660	arg1	glycoprotein					1649:1660	a large glycoprotein	1641:1660	a large glycoprotein with multiple O-glycosylation repeats	1641:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	1	20	theme	eosinophils	218:228	arg1	surface					201:207	the surface	197:207	the surface of human eosinophils and mast cells	197:243	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	3	21	theme	tissue	751:756	arg1	preparation					758:768	tissue preparation	751:768	tissue preparation	751:768	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	5	22	theme	airway	900:905	arg1	layer					913:917	upper airway mucus layer	894:917	Human upper airway mucus layer proteins	888:926	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	11	23	gly	sialylated	1865:1874	arg1	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	23	gly	sialylated	1865:1874	arg1	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	8	24	theme	human	1320:1324	arg1	ligand					1333:1338	purified human airway ligand	1311:1338	purified human airway ligand	1311:1338	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	10	25	dep	tumors	1579:1584	arg1	DMBT1					1589:1593	DMBT1	1589:1593	DMBT1	1589:1593	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	25	dep	tumors	1579:1584	arg1	1					1586:1586	1	1586:1586	1	1586:1586	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	25	dep	tumors	1579:1584	arg1	glycoprotein					1649:1660	a large glycoprotein	1641:1660	a large glycoprotein with multiple O-glycosylation repeats	1641:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	5	26	theme	layer	913:917	arg1	proteins					919:926	Human upper airway mucus layer proteins	888:926	Human upper airway mucus layer proteins	888:926	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	7	27	theme	electrophoretic	1225:1239	arg1	colocalization					1259:1272	electrophoretic and histochemical colocalization	1225:1272	electrophoretic and histochemical colocalization	1225:1272	Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization.
32791164	2	28	theme	upper	488:492	arg1	airways					494:500	upper airways	488:500	upper airways	488:500	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	0	29	theme	ligand	68:73	arg1	identification					11:24	identification	11:24	identification	11:24	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	0	29	theme	ligand	68:73	arg1	characterization					31:46	characterization	31:46	characterization	31:46	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	0	29	theme	ligand	68:73	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	1	30	theme	immunoinhibitory	159:174	arg1	Siglec-8					185:192	The immunoinhibitory receptor Siglec-8	155:192	The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells	155:243	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	1	31	theme	mast	355:358	arg1	degranulation					365:377	mast cell degranulation	355:377	mast cell degranulation	355:377	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	5	32	theme	nasal	962:966	arg1	lavage					968:973	presurgical nasal lavage	950:973	presurgical nasal lavage of patients at a sinus clinic	950:1003	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	12	33	contain	has	1956:1958	arg1	DMBT1S8					1948:1954	DMBT1S8	1948:1954	DMBT1S8	1948:1954	Quantitative inhibition revealed that DMBT1S8 has picomolar affinity for Siglec-8.
32791164	12	33	contain	has	1956:1958	arg2	affinity					1970:1977	picomolar affinity	1960:1977	picomolar affinity for Siglec-8	1960:1990	Quantitative inhibition revealed that DMBT1S8 has picomolar affinity for Siglec-8.
32791164	8	34	theme	glycan	1372:1377	arg1	binding					1379:1385	glycan binding	1372:1385	glycan binding	1372:1385	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	10	35	theme	large	1643:1647	arg1	1					1586:1586	1	1586:1586	1	1586:1586	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	10	35	theme	large	1643:1647	arg1	glycoprotein					1649:1660	a large glycoprotein	1641:1660	a large glycoprotein with multiple O-glycosylation repeats	1641:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	7	36	theme	mass	1189:1192	arg1	spectrometry					1194:1205	proteomic mass spectrometry	1179:1205	proteomic mass spectrometry	1179:1205	Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization.
32791164	4	37	from	ligand	836:841	arg1	layer					856:860	the mucus layer	846:860	the mucus layer of human airways	846:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	2	38	theme	human	455:459	arg1	trachea					461:467	postmortem human trachea	444:467	postmortem human trachea	444:467	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	0	39	theme	airway	61:66	arg1	ligand					68:73	the human airway ligand	51:73	the human airway ligand	51:73	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	5	40	dep	METHODS	880:886	arg1	recovered					933:941	recovered	933:941	were recovered during presurgical nasal lavage of patients at a sinus clinic	928:1003	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	12	41	theme	Quantitative	1910:1921	arg1	inhibition					1923:1932	Quantitative inhibition	1910:1932	Quantitative inhibition	1910:1932	Quantitative inhibition revealed that DMBT1S8 has picomolar affinity for Siglec-8.
32791164	10	42	theme	O-glycosylation	1676:1690	arg1	repeats					1692:1698	multiple O-glycosylation repeats	1667:1698	multiple O-glycosylation repeats	1667:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	1	43	theme	local	292:296	arg1	milieu					298:303	the local milieu	288:303	the local milieu	288:303	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	6	44	theme	gel	1032:1034	arg1	electrophoresis					1036:1050	gel electrophoresis	1032:1050	gel electrophoresis	1032:1050	Proteins were resolved by gel electrophoresis and blotted, and Siglec-8 ligands detected.
32791164	3	45	theme	submucosal	650:659	arg1	glands					661:666	submucosal glands	650:666	submucosal glands	650:666	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	2	46	theme	Siglec-8	413:420	arg1	ligands					422:428	Siglec-8 ligands	413:428	Siglec-8 ligands	413:428	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	7	47	theme	affinity	1140:1147	arg1	chromatography					1149:1162	affinity chromatography	1140:1162	affinity chromatography	1140:1162	Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization.
32791164	0	48	theme	human	55:59	arg1	ligand					68:73	the human airway ligand	51:73	the human airway ligand	51:73	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	4	49	theme	Siglec-8	815:822	arg1	ligand					836:841	the major Siglec-8 sialoglycan ligand	805:841	the major Siglec-8 sialoglycan ligand on the mucus layer of human airways	805:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	11	50	theme	sialylated	1865:1874	arg1	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	50	theme	sialylated	1865:1874	arg1	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	51	contain	carrying	1847:1854	arg2	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	51	contain	carrying	1847:1854	arg2	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	51	contain	carrying	1847:1854	arg1	DMBT1					1841:1845	DMBT1	1841:1845	DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8)	1841:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	52	theme	enzyme	1743:1748	arg1	treatments					1750:1759	enzyme treatments	1743:1759	enzyme treatments	1743:1759	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	13	53	theme	major	2046:2050	arg1	ligand					2065:2070	the major high-avidity ligand	2042:2070	the major high-avidity ligand for Siglec-8 on human airways	2042:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	53	theme	major	2046:2050	arg1	isoform					2021:2027	A distinct DMBT1 isoform	2004:2027	A distinct DMBT1 isoform	2004:2027	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	1	54	theme	cells	239:243	arg1	surface					201:207	the surface	197:207	the surface of human eosinophils and mast cells	197:243	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	5	55	theme	sinus	992:996	arg1	clinic					998:1003	a sinus clinic	990:1003	a sinus clinic	990:1003	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	10	56	theme	brain	1573:1577	arg1	tumors					1579:1584	malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats	1563:1698	malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats	1563:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	11	57	theme	sulfate	1884:1890	arg1	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	57	theme	sulfate	1884:1890	arg1	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	4	58	theme	mucus	850:854	arg1	layer					856:860	the mucus layer	846:860	the mucus layer of human airways	846:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	7	59	theme	histochemical	1245:1257	arg1	colocalization					1259:1272	electrophoretic and histochemical colocalization	1225:1272	electrophoretic and histochemical colocalization	1225:1272	Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization.
32791164	1	60	theme	acid-containing	261:275	arg1	ligands					277:283	sialic acid-containing ligands	254:283	sialic acid-containing ligands	254:283	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	9	61	located	found	1468:1472	arg1	samples					1502:1508	all patient nasal lavage samples	1477:1508	all patient nasal lavage samples	1477:1508	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	9	61	located	found	1468:1472	arg2	RESULTS					1388:1394	RESULTS	1388:1394	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa	1388:1462	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	10	62	dep	known	1602:1606	arg1	also					1597:1600	also	1597:1600	also	1597:1600	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	13	63	theme	distinct	2006:2013	arg1	DMBT1S8					2030:2036	DMBT1S8	2030:2036	DMBT1S8	2030:2036	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	63	theme	distinct	2006:2013	arg1	isoform					2021:2027	A distinct DMBT1 isoform	2004:2027	A distinct DMBT1 isoform	2004:2027	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	63	theme	distinct	2006:2013	arg1	ligand					2065:2070	the major high-avidity ligand	2042:2070	the major high-avidity ligand for Siglec-8 on human airways	2042:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	1	64	theme	receptor	176:183	arg1	Siglec-8					185:192	The immunoinhibitory receptor Siglec-8	155:192	The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells	155:243	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	4	65	theme	sialoglycan	824:834	arg1	ligand					836:841	the major Siglec-8 sialoglycan ligand	805:841	the major Siglec-8 sialoglycan ligand on the mucus layer of human airways	805:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	3	66	theme	mucus	717:721	arg1	layer					723:727	the airway mucus layer	706:727	the airway mucus layer	706:727	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	2	67	located	found	435:439	arg1	glands					546:551	submucosal glands	535:551	submucosal glands	535:551	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	2	67	located	found	435:439	arg1	compartments					507:518	2 compartments	505:518	2 compartments	505:518	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	2	67	located	found	435:439	arg2	ligands					422:428	Siglec-8 ligands	413:428	Siglec-8 ligands	413:428	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	2	67	located	found	435:439	arg1	trachea					461:467	postmortem human trachea	444:467	postmortem human trachea	444:467	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	2	67	located	found	435:439	arg1	cartilage					521:529	cartilage	521:529	cartilage	521:529	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	0	68	theme	immunoinhibitory	108:123	arg1	Siglec-8					134:141	the eosinophil and mast cell immunoinhibitory receptor Siglec-8	79:141	Siglec-8	134:141	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	5	69	theme	Human	888:892	arg1	proteins					919:926	Human upper airway mucus layer proteins	888:926	Human upper airway mucus layer proteins	888:926	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	11	70	theme	mucus	1812:1816	arg1	layer					1818:1822	the human airway mucus layer	1795:1822	the human airway mucus layer	1795:1822	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	9	71	theme	nasal	1489:1493	arg1	samples					1502:1508	all patient nasal lavage samples	1477:1508	all patient nasal lavage samples	1477:1508	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	12	72	theme	picomolar	1960:1968	arg1	affinity					1970:1977	picomolar affinity	1960:1977	picomolar affinity for Siglec-8	1960:1990	Quantitative inhibition revealed that DMBT1S8 has picomolar affinity for Siglec-8.
32791164	11	73	theme	DMBT1	1841:1845	arg1	isoform					1830:1836	an isoform	1827:1836	an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8)	1827:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	73	theme	DMBT1	1841:1845	arg1	ligand					1785:1790	Siglec-8 ligand	1776:1790	Siglec-8 ligand on the human airway mucus layer	1776:1822	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	1	74	theme	inflammation	399:410	arg1	inhibition					341:350	inhibition	341:350	inhibition of mast cell degranulation	341:377	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	1	74	theme	inflammation	399:410	arg1	apoptosis					330:338	eosinophil apoptosis	319:338	eosinophil apoptosis	319:338	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	1	74	theme	inflammation	399:410	arg1	suppression					384:394	suppression	384:394	suppression of inflammation	384:410	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	5	75	theme	upper	894:898	arg1	layer					913:917	upper airway mucus layer	894:917	Human upper airway mucus layer proteins	888:926	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	4	76	theme	airways	871:877	arg1	layer					856:860	the mucus layer	846:860	the mucus layer of human airways	846:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	8	77	theme	binding	1300:1306	arg1	affinity					1279:1286	The affinity	1275:1286	The affinity of Siglec-8 binding to purified human airway ligand	1275:1338	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	10	78	dep	1	1586:1586	arg1	known					1602:1606	known	1602:1606	known by the aliases GP340 and SALSA	1602:1637	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	5	79	theme	mucus	907:911	arg1	layer					913:917	upper airway mucus layer	894:917	Human upper airway mucus layer proteins	888:926	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	8	80	theme	purified	1311:1318	arg1	ligand					1333:1338	purified human airway ligand	1311:1338	purified human airway ligand	1311:1338	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	11	81	theme	Siglec-8	1776:1783	arg1	isoform					1830:1836	an isoform	1827:1836	an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8)	1827:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	81	theme	Siglec-8	1776:1783	arg1	ligand					1785:1790	Siglec-8 ligand	1776:1790	Siglec-8 ligand on the human airway mucus layer	1776:1822	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	10	82	dep	revealed	1543:1550	arg1	deleted					1552:1558	deleted	1552:1558	revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats	1543:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	4	83	dep	OBJECTIVE	771:779	arg1	was					789:791	was	789:791	was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways	789:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	13	84	dep	CONCLUSION	1993:2002	arg1	ligand					2065:2070	the major high-avidity ligand	2042:2070	the major high-avidity ligand for Siglec-8 on human airways	2042:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	84	dep	CONCLUSION	1993:2002	arg1	isoform					2021:2027	A distinct DMBT1 isoform	2004:2027	A distinct DMBT1 isoform	2004:2027	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	8	85	theme	airway	1326:1331	arg1	ligand					1333:1338	purified human airway ligand	1311:1338	purified human airway ligand	1311:1338	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	13	86	theme	human	2088:2092	arg1	airways					2094:2100	human airways	2088:2100	human airways	2088:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	1	87	from	Siglec-8	185:192	arg1	surface					201:207	the surface	197:207	the surface of human eosinophils and mast cells	197:243	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	13	88	theme	high-avidity	2052:2063	arg1	ligand					2065:2070	the major high-avidity ligand	2042:2070	the major high-avidity ligand for Siglec-8 on human airways	2042:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	88	theme	high-avidity	2052:2063	arg1	isoform					2021:2027	A distinct DMBT1 isoform	2004:2027	A distinct DMBT1 isoform	2004:2027	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	11	89	theme	human	1799:1803	arg1	layer					1818:1822	the human airway mucus layer	1795:1822	the human airway mucus layer	1795:1822	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	5	90	theme	presurgical	950:960	arg1	lavage					968:973	presurgical nasal lavage	950:973	presurgical nasal lavage of patients at a sinus clinic	950:1003	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	9	91	dep	RESULTS	1388:1394	arg1	Siglec-8-ligand					1398:1412	A Siglec-8-ligand	1396:1412	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa	1388:1462	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	0	92	theme	mast	98:101	arg1	Siglec-8					134:141	the eosinophil and mast cell immunoinhibitory receptor Siglec-8	79:141	Siglec-8	134:141	Isolation, identification, and characterization of the human airway ligand for the eosinophil and mast cell immunoinhibitory receptor Siglec-8.
32791164	1	93	theme	cell	360:363	arg1	degranulation					365:377	mast cell degranulation	355:377	mast cell degranulation	355:377	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	7	94	theme	proteomic	1179:1187	arg1	spectrometry					1194:1205	proteomic mass spectrometry	1179:1205	proteomic mass spectrometry	1179:1205	Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization.
32791164	2	95	theme	postmortem	444:453	arg1	trachea					461:467	postmortem human trachea	444:467	postmortem human trachea	444:467	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	8	96	theme	binding	1379:1385	arg1	inhibition					1358:1367	inhibition	1358:1367	inhibition of glycan binding	1358:1385	The affinity of Siglec-8 binding to purified human airway ligand was determined by inhibition of glycan binding.
32791164	2	97	from	epithelium	597:606	arg1	absent					581:586	absent	581:586	absent	581:586	Siglec-8 ligands were found on postmortem human trachea and bronchi and on upper airways in 2 compartments, cartilage and submucosal glands, but they were surprisingly absent from the epithelium.
32791164	1	98	dep	BACKGROUND	144:153	arg1	binds					245:249	binds	245:249	binds	245:249	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	10	99	theme	multiple	1667:1674	arg1	repeats					1692:1698	multiple O-glycosylation repeats	1667:1698	multiple O-glycosylation repeats	1667:1698	Purification and identification revealed deleted in malignant brain tumors 1 (DMBT1) (also known by the aliases GP340 and SALSA), a large glycoprotein with multiple O-glycosylation repeats.
32791164	1	100	theme	human	212:216	arg1	eosinophils					218:228	human eosinophils	212:228	human eosinophils	212:228	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	3	101	theme	Siglec-8	630:637	arg1	ligands					639:645	Siglec-8 ligands	630:645	Siglec-8 ligands in submucosal glands and ducts	630:676	We hypothesized that Siglec-8 ligands in submucosal glands and ducts are normally transported to the airway mucus layer, which is lost during tissue preparation.
32791164	7	102	theme	size	1121:1124	arg1	exclusion					1126:1134	size exclusion	1121:1134	size exclusion	1121:1134	Ligands were purified by size exclusion and affinity chromatography, identified by proteomic mass spectrometry, and validated by electrophoretic and histochemical colocalization.
32791164	1	103	theme	degranulation	365:377	arg1	inhibition					341:350	inhibition	341:350	inhibition of mast cell degranulation	341:377	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	1	103	theme	degranulation	365:377	arg1	apoptosis					330:338	eosinophil apoptosis	319:338	eosinophil apoptosis	319:338	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	1	103	theme	degranulation	365:377	arg1	suppression					384:394	suppression	384:394	suppression of inflammation	384:410	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	4	104	theme	major	809:813	arg1	ligand					836:841	the major Siglec-8 sialoglycan ligand	805:841	the major Siglec-8 sialoglycan ligand on the mucus layer of human airways	805:877	OBJECTIVE Our aim was to identify the major Siglec-8 sialoglycan ligand on the mucus layer of human airways.
32791164	11	105	theme	keratan	1876:1882	arg1	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	105	theme	keratan	1876:1882	arg1	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	1	106	theme	eosinophil	319:328	arg1	apoptosis					330:338	eosinophil apoptosis	319:338	eosinophil apoptosis	319:338	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	5	107	theme	patients	978:985	arg1	lavage					968:973	presurgical nasal lavage	950:973	presurgical nasal lavage of patients at a sinus clinic	950:1003	METHODS Human upper airway mucus layer proteins were recovered during presurgical nasal lavage of patients at a sinus clinic.
32791164	13	108	theme	DMBT1	2015:2019	arg1	DMBT1S8					2030:2036	DMBT1S8	2030:2036	DMBT1S8	2030:2036	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	108	theme	DMBT1	2015:2019	arg1	isoform					2021:2027	A distinct DMBT1 isoform	2004:2027	A distinct DMBT1 isoform	2004:2027	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	13	108	theme	DMBT1	2015:2019	arg1	ligand					2065:2070	the major high-avidity ligand	2042:2070	the major high-avidity ligand for Siglec-8 on human airways	2042:2100	CONCLUSION A distinct DMBT1 isoform, DMBT1S8, is the major high-avidity ligand for Siglec-8 on human airways.
32791164	11	109	theme	O-linked	1856:1863	arg1	chains					1892:1897	O-linked sialylated keratan sulfate chains	1856:1897	O-linked sialylated keratan sulfate chains (DMBT1S8)	1856:1907	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	11	109	theme	O-linked	1856:1863	arg1	DMBT1S8					1900:1906	DMBT1S8	1900:1906	DMBT1S8	1900:1906	Immunoblotting, immunohistochemistry, and enzyme treatments confirmed that Siglec-8 ligand on the human airway mucus layer is an isoform of DMBT1 carrying O-linked sialylated keratan sulfate chains (DMBT1S8).
32791164	1	110	theme	mast	234:237	arg1	cells					239:243	mast cells	234:243	mast cells	234:243	BACKGROUND The immunoinhibitory receptor Siglec-8 on the surface of human eosinophils and mast cells binds to sialic acid-containing ligands in the local milieu, resulting in eosinophil apoptosis, inhibition of mast cell degranulation, and suppression of inflammation.
32791164	9	111	theme	lavage	1495:1500	arg1	samples					1502:1508	all patient nasal lavage samples	1477:1508	all patient nasal lavage samples	1477:1508	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	9	112	with	Siglec-8-ligand	1398:1412	arg1	weight					1431:1436	a molecular weight	1419:1436	a molecular weight of approximately 1000 kDa	1419:1462	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32791164	9	113	theme	molecular	1421:1429	arg1	weight					1431:1436	a molecular weight	1419:1436	a molecular weight of approximately 1000 kDa	1419:1462	RESULTS A Siglec-8-ligand with a molecular weight of approximately 1000 kDa was found in all patient nasal lavage samples.
32081641	10	0	theme	expression	1353:1362	arg1	levels					1364:1369	the expression levels	1349:1369	the expression levels of NALP3 and NALP6	1349:1388	In addition, pretreatment with benzyl-α-GalNAc up-regulated the expression levels of NALP3 and NALP6.
32081641	2	1	from	role	226:229	arg1	AIH					306:308	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	11	2	theme	T	1490:1490	arg1	cells					1492:1496	T cells	1490:1496	T cells	1490:1496	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	8	3	theme	transaminase	1103:1114	arg1	levels					1116:1121	the serum transaminase levels	1093:1121	the serum transaminase levels	1093:1121	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	8	4	from	necrosis	1157:1164	arg1	livers					1169:1174	livers	1169:1174	livers of Con A administrated mice	1169:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	2	5	theme	autoimmune	284:293	arg1	AIH					306:308	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	1	6	theme	cell	205:208	arg1	activation					210:219	immune cell activation	198:219	immune cell activation	198:219	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	8	7	from	infiltration	1140:1151	arg1	livers					1169:1174	livers	1169:1174	livers of Con A administrated mice	1169:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	12	8	theme	A-induced	1723:1731	arg1	AIH					1733:1735	Con A-induced AIH	1719:1735	Con A-induced AIH	1719:1735	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	8	9	theme	A	1183:1183	arg1	mice					1199:1202	Con A administrated mice	1179:1202	Con A administrated mice	1179:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	11	10	dep	especially	1558:1567	arg1	that					1569:1572	that	1569:1572	that	1569:1572	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	8	11	theme	mice	1199:1202	arg1	livers					1169:1174	livers	1169:1174	livers of Con A administrated mice	1169:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	4	12	theme	mg/kg	612:616	arg1	doses					595:599	doses	595:599	doses of 1 and 5 mg/kg, respectively	595:630	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	7	13	theme	NALP3	990:994	arg1	well					1034:1037	well	1034:1037	well	1034:1037	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	7	13	theme	NALP3	990:994	arg1	levels					943:948	The expression levels	928:948	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver	928:1014	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	7	14	theme	expression	932:941	arg1	well					1034:1037	well	1034:1037	well	1034:1037	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	7	14	theme	expression	932:941	arg1	levels					943:948	The expression levels	928:948	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver	928:1014	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	11	15	theme	cells	1455:1459	arg1	apoptosis					1435:1443	apoptosis	1435:1443	apoptosis of thymus cells	1435:1459	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	7	16	theme	neutrophilic	953:964	arg1	NALP3					990:994	neutrophilic alkaline phosphatase-3 (NALP3)	953:995	neutrophilic alkaline phosphatase-3 (NALP3)	953:995	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	12	17	theme	Con	1719:1721	arg1	AIH					1733:1735	Con A-induced AIH	1719:1735	Con A-induced AIH	1719:1735	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	2	18	gly	O-glycosylation	234:248	arg1	hepatitis					295:303	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	2	19	theme	Con	269:271	arg1	A					273:273	Con A	269:273	Con A	269:273	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	1	20	theme	immunological	168:180	arg1	recognition					182:192	immunological recognition	168:192	immunological recognition	168:192	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	12	21	theme	present	1657:1663	arg1	research					1665:1672	The present research	1653:1672	The present research	1653:1672	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	0	22	theme	Concanavalin	84:95	arg1	injury					113:118	Concanavalin A-induced liver injury	84:118	Concanavalin A-induced liver injury	84:118	Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury.
32081641	12	23	theme	proliferation	1883:1895	arg1	levels					1839:1844	the levels	1835:1844	the levels of cytokines, as well as influencing proliferation of T cells	1835:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	5	24	theme	score	827:831	arg1	injury					839:844	score liver injury	827:844	score liver injury	827:844	Before and after administration of Con A for 6 and 12 h, mice were sacrificed and their plasma and livers were collected to score liver injury.
32081641	6	25	theme	cytometry	908:916	arg1	analysis					918:925	flow cytometry analysis	903:925	flow cytometry analysis	903:925	Peripheral blood, spleen, and thymus were collected for flow cytometry analysis.
32081641	0	26	theme	liver	107:111	arg1	injury					113:118	Concanavalin A-induced liver injury	84:118	Concanavalin A-induced liver injury	84:118	Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury.
32081641	9	27	theme	cytokines	1241:1249	arg1	levels					1209:1214	The levels	1205:1214	The levels of some pro-inflammation cytokines	1205:1249	The levels of some pro-inflammation cytokines also increased in administrated mice.
32081641	12	28	theme	T	1900:1900	arg1	cells					1902:1906	T cells	1900:1906	T cells	1900:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	3	29	theme	METHODS	348:354	arg1	Mice					356:359	METHODS Mice	348:359	METHODS Mice	348:359	METHODS Mice were intravenously injected with Con A (10 mg/kg) to establish an AIH mouse model.
32081641	3	30	theme	Con	394:396	arg1	A					398:398	Con A	394:398	Con A (10 mg/kg)	394:409	METHODS Mice were intravenously injected with Con A (10 mg/kg) to establish an AIH mouse model.
32081641	3	30	theme	Con	394:396	arg1	mg/kg					404:408	10 mg/kg	401:408	10 mg/kg	401:408	METHODS Mice were intravenously injected with Con A (10 mg/kg) to establish an AIH mouse model.
32081641	4	31	theme	saline	695:700	arg1	volume					685:690	the same volume	676:690	the same volume of saline	676:700	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	9	32	theme	administrated	1269:1281	arg1	mice					1283:1286	administrated mice	1269:1286	administrated mice	1269:1286	The levels of some pro-inflammation cytokines also increased in administrated mice.
32081641	0	33	theme	O-linked-glycosylation	14:35	arg1	Deficiency					0:9	Deficiency	0:9	Deficiency of O-linked-glycosylation	0:35	Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury.
32081641	12	34	theme	levels	1839:1844	arg1	regulation					1821:1830	regulation	1821:1830	regulation of the levels of cytokines, as well as influencing proliferation of T cells	1821:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	1	35	theme	OBJECTIVE	121:129	arg1	glycosylation					139:151	OBJECTIVE Protein glycosylation	121:151	OBJECTIVE Protein glycosylation	121:151	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	3	36	theme	mouse	431:435	arg1	model					437:441	an AIH mouse model	424:441	an AIH mouse model	424:441	METHODS Mice were intravenously injected with Con A (10 mg/kg) to establish an AIH mouse model.
32081641	5	37	theme	A	742:742	arg1	administration					720:733	administration	720:733	administration of Con A for 6 and 12 h	720:757	Before and after administration of Con A for 6 and 12 h, mice were sacrificed and their plasma and livers were collected to score liver injury.
32081641	12	38	theme	cytokines	1849:1857	arg1	levels					1839:1844	the levels	1835:1844	the levels of cytokines, as well as influencing proliferation of T cells	1835:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	4	39	theme	A	486:486	arg1	administration					464:477	administration	464:477	administration of Con A	464:486	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	11	40	theme	mice	1552:1555	arg1	spleen					1522:1527	spleen	1522:1527	spleen	1522:1527	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	11	40	theme	mice	1552:1555	arg1	blood					1512:1516	peripheral blood	1501:1516	peripheral blood	1501:1516	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	0	41	theme	T	61:61	arg1	cells					63:67	T cells	61:67	T cells	61:67	Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury.
32081641	1	42	theme	Protein	131:137	arg1	glycosylation					139:151	OBJECTIVE Protein glycosylation	121:151	OBJECTIVE Protein glycosylation	121:151	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	4	43	theme	experimental	489:500	arg1	mice					502:505	experimental mice	489:505	experimental mice	489:505	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	11	44	theme	A	1536:1536	arg1	mice					1552:1555	Con A administrated mice	1532:1555	Con A administrated mice	1532:1555	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	2	45	theme	present	333:339	arg1	study					341:345	the present study	329:345	the present study	329:345	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	12	46	theme	inhibitor	1774:1782	arg1	role					1746:1749	the role	1742:1749	the role of the O-glycosylation inhibitor as the aggravation	1742:1801	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	12	46	theme	inhibitor	1774:1782	arg1	related					1810:1816	related	1810:1816	related	1810:1816	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	6	47	theme	Peripheral	847:856	arg1	blood					858:862	Peripheral blood	847:862	Peripheral blood	847:862	Peripheral blood, spleen, and thymus were collected for flow cytometry analysis.
32081641	4	48	theme	O-glycosylation	548:562	arg1	benzyl-α-GalNAc					575:589	benzyl-α-GalNAc	575:589	benzyl-α-GalNAc	575:589	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	4	48	theme	O-glycosylation	548:562	arg1	inhibitor					564:572	O-glycosylation inhibitor	548:572	O-glycosylation inhibitor (benzyl-α-GalNAc)	548:590	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	11	49	theme	physiological	1590:1602	arg1	progression					1604:1614	the physiological progression	1586:1614	the physiological progression of CD4+CD25-CD69+ subset	1586:1639	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	11	50	theme	peripheral	1501:1510	arg1	blood					1512:1516	peripheral blood	1501:1516	peripheral blood	1501:1516	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	11	51	theme	cells	1492:1496	arg1	activation					1476:1485	activation	1476:1485	activation of T cells	1476:1496	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	2	52	theme	hepatitis	295:303	arg1	AIH					306:308	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	2	53	dep	-induced	275:282	arg1	A					266:266	Concanavalin A	253:266	Concanavalin A	253:266	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	2	53	dep	-induced	275:282	arg1	A					273:273	Con A	269:273	Con A	269:273	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	1	54	theme	immune	198:203	arg1	activation					210:219	immune cell activation	198:219	immune cell activation	198:219	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	8	55	theme	serum	1097:1101	arg1	levels					1116:1121	the serum transaminase levels	1093:1121	the serum transaminase levels	1093:1121	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	11	56	theme	subset	1634:1639	arg1	progression					1604:1614	the physiological progression	1586:1614	the physiological progression of CD4+CD25-CD69+ subset	1586:1639	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	7	57	theme	NALP6	1001:1005	arg1	well					1034:1037	well	1034:1037	well	1034:1037	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	7	57	theme	NALP6	1001:1005	arg1	levels					943:948	The expression levels	928:948	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver	928:1014	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	10	58	theme	NALP3	1374:1378	arg1	levels					1364:1369	the expression levels	1349:1369	the expression levels of NALP3 and NALP6	1349:1388	In addition, pretreatment with benzyl-α-GalNAc up-regulated the expression levels of NALP3 and NALP6.
32081641	8	59	theme	Con	1179:1181	arg1	A					1183:1183	Con A	1179:1183	Con A administrated mice	1179:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	1	60	gly	glycosylation	139:151	arg1	activation					210:219	immune cell activation	198:219	immune cell activation	198:219	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	1	60	gly	glycosylation	139:151	arg1	recognition					182:192	immunological recognition	168:192	immunological recognition	168:192	OBJECTIVE Protein glycosylation is involved in immunological recognition and immune cell activation.
32081641	8	61	theme	administrated	1185:1197	arg1	mice					1199:1202	Con A administrated mice	1179:1202	Con A administrated mice	1179:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	7	62	from	levels	943:948	arg1	liver					1010:1014	liver	1010:1014	liver	1010:1014	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	7	63	theme	alkaline	966:973	arg1	NALP3					990:994	neutrophilic alkaline phosphatase-3 (NALP3)	953:995	neutrophilic alkaline phosphatase-3 (NALP3)	953:995	The expression levels of neutrophilic alkaline phosphatase-3 (NALP3) and NALP6 in liver were evaluated as well.
32081641	2	64	theme	Concanavalin	253:264	arg1	A					266:266	Concanavalin A	253:266	Concanavalin A	253:266	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	5	65	theme	liver	833:837	arg1	injury					839:844	score liver injury	827:844	score liver injury	827:844	Before and after administration of Con A for 6 and 12 h, mice were sacrificed and their plasma and livers were collected to score liver injury.
32081641	10	66	with	pretreatment	1302:1313	arg1	benzyl-α-GalNAc					1320:1334	benzyl-α-GalNAc	1320:1334	benzyl-α-GalNAc	1320:1334	In addition, pretreatment with benzyl-α-GalNAc up-regulated the expression levels of NALP3 and NALP6.
32081641	11	67	theme	thymus	1448:1453	arg1	cells					1455:1459	thymus cells	1448:1459	thymus cells	1448:1459	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	2	68	theme	-induced	275:282	arg1	AIH					306:308	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	253:309	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	4	69	theme	same	680:683	arg1	volume					685:690	the same volume	676:690	the same volume of saline	676:700	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	11	70	theme	apoptosis	1435:1443	arg1	levels					1425:1430	the levels	1421:1430	the levels of apoptosis of thymus cells	1421:1459	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	4	71	theme	control	639:645	arg1	mice					647:650	control mice	639:650	control mice	639:650	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	0	72	theme	A-induced	97:105	arg1	injury					113:118	Concanavalin A-induced liver injury	84:118	Concanavalin A-induced liver injury	84:118	Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury.
32081641	4	73	theme	Con	482:484	arg1	A					486:486	Con A	482:486	Con A	482:486	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	9	74	theme	pro-inflammation	1224:1239	arg1	cytokines					1241:1249	some pro-inflammation cytokines	1219:1249	some pro-inflammation cytokines	1219:1249	The levels of some pro-inflammation cytokines also increased in administrated mice.
32081641	12	75	theme	cells	1902:1906	arg1	cytokines					1849:1857	cytokines	1849:1857	cytokines	1849:1857	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	12	75	theme	cells	1902:1906	arg1	proliferation					1883:1895	influencing proliferation	1871:1895	influencing proliferation of T cells	1871:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	6	76	theme	flow	903:906	arg1	analysis					918:925	flow cytometry analysis	903:925	flow cytometry analysis	903:925	Peripheral blood, spleen, and thymus were collected for flow cytometry analysis.
32081641	10	77	theme	NALP6	1384:1388	arg1	levels					1364:1369	the expression levels	1349:1369	the expression levels of NALP3 and NALP6	1349:1388	In addition, pretreatment with benzyl-α-GalNAc up-regulated the expression levels of NALP3 and NALP6.
32081641	8	78	with	Pre-treatment	1048:1060	arg1	benzyl-α-GalNAc					1067:1081	benzyl-α-GalNAc	1067:1081	benzyl-α-GalNAc	1067:1081	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	4	79	theme	1	604:604	arg1	doses					595:599	doses	595:599	doses of 1 and 5 mg/kg, respectively	595:630	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	4	80	theme	prior	455:459	arg1	h					453:453	24 h	450:453	24 h prior to administration of Con A	450:486	Here, 24 h prior to administration of Con A, experimental mice were intragastrically administrated with O-glycosylation inhibitor (benzyl-α-GalNAc) at doses of 1 and 5 mg/kg, respectively, while control mice were administrated with the same volume of saline.
32081641	3	81	theme	AIH	427:429	arg1	model					437:441	an AIH mouse model	424:441	an AIH mouse model	424:441	METHODS Mice were intravenously injected with Con A (10 mg/kg) to establish an AIH mouse model.
32081641	12	82	theme	influencing	1871:1881	arg1	proliferation					1883:1895	influencing proliferation	1871:1895	influencing proliferation of T cells	1871:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	8	83	dep	RESULTS	1040:1046	arg1	induced					1127:1133	induced	1127:1133	induced more infiltration and necrosis in livers of Con A administrated mice	1127:1202	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	8	83	dep	RESULTS	1040:1046	arg1	increased					1083:1091	increased	1083:1091	increased the serum transaminase levels	1083:1121	RESULTS Pre-treatment with benzyl-α-GalNAc increased the serum transaminase levels and induced more infiltration and necrosis in livers of Con A administrated mice.
32081641	5	84	theme	Con	738:740	arg1	A					742:742	Con A	738:742	Con A	738:742	Before and after administration of Con A for 6 and 12 h, mice were sacrificed and their plasma and livers were collected to score liver injury.
32081641	11	85	theme	administrated	1538:1550	arg1	mice					1552:1555	Con A administrated mice	1532:1555	Con A administrated mice	1532:1555	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	0	86	theme	cells	63:67	arg1	activation					47:56	activation	47:56	activation of T cells	47:67	Deficiency of O-linked-glycosylation regulates activation of T cells and aggravates Concanavalin A-induced liver injury.
32081641	2	87	theme	O-glycosylation	234:248	arg1	role					226:229	The role	222:229	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH)	222:309	The role of O-glycosylation in Concanavalin A (Con A)-induced autoimmune hepatitis (AIH) was elucidated in the present study.
32081641	11	88	theme	Con	1532:1534	arg1	A					1536:1536	Con A	1532:1536	Con A administrated mice	1532:1555	And benzyl-α-GalNAc inhibited the levels of apoptosis of thymus cells and influenced activation of T cells in peripheral blood and spleen of Con A administrated mice, especially that accelerated the physiological progression of CD4+CD25-CD69+ subset.
32081641	12	89	dep	CONCLUSION	1642:1651	arg1	demonstrated					1674:1685	demonstrated	1674:1685	demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells	1674:1906	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
32081641	12	90	theme	O-glycosylation	1758:1772	arg1	inhibitor					1774:1782	the O-glycosylation inhibitor	1754:1782	the O-glycosylation inhibitor	1754:1782	CONCLUSION The present research demonstrated that benzyl-α-GalNAc aggravated Con A-induced AIH, and the role of the O-glycosylation inhibitor as the aggravation may be related to regulation of the levels of cytokines, as well as influencing proliferation of T cells.
34199200	1	0	with	interactions	258:269	arg1	glycan					298:303	the rapidly modifying glycan shield	276:310	the rapidly modifying glycan shield of influenza A.	276:326	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	8	1	theme	CVN2	1757:1760	arg1	binding					1762:1768	CVN2 binding	1757:1768	CVN2 binding	1757:1768	They can also induce high-affinity binding in antiviral CV-N to HA at two sites, and CVN2 binding is achieved at low-affinity binding sites.
34199200	1	2	theme	modifying	288:296	arg1	glycan					298:303	the rapidly modifying glycan shield	276:310	the rapidly modifying glycan shield of influenza A.	276:326	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	2	3	theme	immunodeficiency	619:634	arg1	virus					636:640	human immunodeficiency virus	613:640	human immunodeficiency virus (HIV) gp120	613:652	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	2	3	theme	immunodeficiency	619:634	arg1	HIV					643:645	HIV	643:645	HIV	643:645	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	3	4	theme	sites	988:992	arg1	number					953:958	the number	949:958	the number of (high-) affinity binding sites	949:992	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	1	5	theme	receptor	479:486	arg1	site					496:499	the host receptor binding site	470:499	the host receptor binding site	470:499	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	1	6	theme	shield	305:310	arg1	glycan					298:303	the rapidly modifying glycan shield	276:310	the rapidly modifying glycan shield of influenza A.	276:326	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	3	7	theme	affinity	971:978	arg1	sites					988:992	(high-) affinity binding sites	963:992	(high-) affinity binding sites	963:992	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	2	8	theme	binding	740:746	arg1	response					748:755	the binding response	736:755	the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR)	736:820	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	0	9	theme	Binding	76:82	arg1	Site					84:87	the Low-Affinity Carbohydrate Binding Site	46:87	the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability	46:131	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	8	10	theme	binding	1798:1804	arg1	sites					1806:1810	low-affinity binding sites	1785:1810	low-affinity binding sites	1785:1810	They can also induce high-affinity binding in antiviral CV-N to HA at two sites, and CVN2 binding is achieved at low-affinity binding sites.
34199200	6	11	theme	binding	1450:1456	arg1	scheme					1458:1463	the bivalent binding scheme	1437:1463	the bivalent binding scheme in SPR	1437:1470	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	7	12	theme	membrane-anchored	1577:1593	arg1	regions					1598:1604	the membrane-anchored HA regions	1573:1604	the membrane-anchored HA regions	1573:1604	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	2	13	theme	trimer-folded	764:776	arg1	gp140					778:782	the trimer-folded gp140	760:782	the trimer-folded gp140 using surface plasmon resonance (SPR)	760:820	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	8	14	from	binding	1707:1713	arg1	CV-N					1728:1731	antiviral CV-N	1718:1731	antiviral CV-N	1718:1731	They can also induce high-affinity binding in antiviral CV-N to HA at two sites, and CVN2 binding is achieved at low-affinity binding sites.
34199200	7	15	theme	affinity	1550:1557	arg1	maturation					1559:1568	affinity maturation	1550:1568	affinity maturation in the membrane-anchored HA regions	1550:1604	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	1	16	dep	interactions	258:269	arg1	bind					366:369	bind	366:369	bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site	366:499	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	6	17	theme	envelope	1259:1266	arg1	proteins					1274:1281	All three envelope spike proteins	1249:1281	All three envelope spike proteins	1249:1281	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	1	18	theme	Glycan-targeting	134:149	arg1	antibodies					151:160	Glycan-targeting antibodies	134:160	Glycan-targeting antibodies	134:160	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	2	19	theme	GP	686:687	arg1	1,2					689:691	Ebola (GP)1,2	679:691	Ebola (GP)1,2	679:691	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	1	20	theme	epitopes	458:465	arg1	location					446:453	the location	442:453	the location of epitopes	442:465	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	3	21	theme	Binding-site	823:834	arg1	variants					845:852	Binding-site knockout variants	823:852	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2)	823:898	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	2	22	theme	binding	712:718	arg1	affinities					720:729	their binding affinities	706:729	their binding affinities	706:729	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	0	23	theme	Carbohydrate	63:74	arg1	Site					84:87	the Low-Affinity Carbohydrate Binding Site	46:87	the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability	46:131	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	8	24	theme	antiviral	1718:1726	arg1	CV-N					1728:1731	antiviral CV-N	1718:1731	antiviral CV-N	1718:1731	They can also induce high-affinity binding in antiviral CV-N to HA at two sites, and CVN2 binding is achieved at low-affinity binding sites.
34199200	2	25	gly	glycoproteins	582:594	arg1	glycoproteins					582:594	surface-expressed glycoproteins	564:594	surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2	564:691	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	2	25	gly	glycoproteins	582:594	arg1	those					604:608	those	604:608	those	604:608	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	3	26	theme	dimeric	871:877	arg1	CVN2					894:897	CVN2	894:897	CVN2	894:897	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	3	26	theme	dimeric	871:877	arg1	molecule					884:891	an engineered dimeric CV-N molecule	857:891	an engineered dimeric CV-N molecule (CVN2)	857:898	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	7	27	theme	protein	1509:1515	arg1	patterns					1517:1524	invariant structural protein patterns	1488:1524	invariant structural protein patterns	1488:1524	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	1	28	theme	A.	325:326	arg1	glycan					298:303	the rapidly modifying glycan shield	276:310	the rapidly modifying glycan shield of influenza A.	276:326	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	1	29	theme	same	378:381	arg1	order					383:387	the same order	374:387	the same order	374:387	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	7	30	theme	shield	1629:1634	arg1	glycan					1622:1627	the glycan	1618:1627	the glycan shield on the membrane-distal HA top part	1618:1669	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	7	31	theme	invariant	1488:1496	arg1	patterns					1517:1524	invariant structural protein patterns	1488:1524	invariant structural protein patterns	1488:1524	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	4	32	link	N-linked	1049:1056	arg1	glycans					1058:1064	N-linked glycans	1049:1064	N-linked glycans upon binding with two low-affinity carbohydrate binding sites	1049:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	0	33	theme	Direct	97:102	arg1	Ability					125:131	Direct Virus Neutralization Ability	97:131	Direct Virus Neutralization Ability	97:131	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	6	34	from	scheme	1458:1463	arg1	SPR					1468:1470	SPR	1468:1470	SPR	1468:1470	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	2	35	theme	cyanovirin-N	541:552	arg1	binding					530:536	the binding	526:536	the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2	526:691	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	7	36	theme	HA	1659:1660	arg1	part					1666:1669	the membrane-distal HA top part	1639:1669	the membrane-distal HA top part	1639:1669	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	0	37	theme	Neutralization	110:123	arg1	Ability					125:131	Direct Virus Neutralization Ability	97:131	Direct Virus Neutralization Ability	97:131	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	3	38	theme	molecule	884:891	arg1	variants					845:852	Binding-site knockout variants	823:852	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2)	823:898	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	4	39	theme	Binding	995:1001	arg1	curves					1003:1008	Binding curves	995:1008	Binding curves	995:1008	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	2	40	theme	Ebola	679:683	arg1	1,2					689:691	Ebola (GP)1,2	679:691	Ebola (GP)1,2	679:691	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	6	41	theme	Ebola	1379:1383	arg1	GP1,2					1385:1389	Ebola GP1,2	1379:1389	Ebola GP1,2	1379:1389	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	3	42	theme	binding	911:917	arg1	affinity					919:926	a binding affinity	909:926	a binding affinity that correlated with the number of (high-) affinity binding sites	909:992	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	0	43	theme	Viral	19:23	arg1	Proteins					34:41	Viral Envelope Proteins	19:41	Viral Envelope Proteins	19:41	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	5	44	theme	domain-swapped	1168:1181	arg1	CVN2					1183:1186	a domain-swapped CVN2	1166:1186	a domain-swapped CVN2	1166:1186	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	7	45	theme	HA	1595:1596	arg1	regions					1598:1604	the membrane-anchored HA regions	1573:1604	the membrane-anchored HA regions	1573:1604	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	4	46	theme	carbohydrate	1101:1112	arg1	sites					1122:1126	two low-affinity carbohydrate binding sites	1084:1126	two low-affinity carbohydrate binding sites	1084:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	3	47	theme	knockout	836:843	arg1	variants					845:852	Binding-site knockout variants	823:852	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2)	823:898	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	1	48	theme	neutralizing	336:347	arg1	agents					359:364	Broadly neutralizing antiviral agents	328:364	Broadly neutralizing antiviral agents	328:364	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	1	49	with	avidity	239:245	arg1	glycan					298:303	the rapidly modifying glycan shield	276:310	the rapidly modifying glycan shield of influenza A.	276:326	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	6	50	theme	neutralizing	1341:1352	arg1	2G12					1354:1357	HIV neutralizing 2G12	1337:1357	HIV neutralizing 2G12	1337:1357	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	5	51	theme	active	1147:1152	arg1	assembly					1154:1161	This biologically active assembly	1129:1161	This biologically active assembly of a domain-swapped CVN2	1129:1186	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	1	52	with	stoichiometry	224:236	arg1	glycan					298:303	the rapidly modifying glycan shield	276:310	the rapidly modifying glycan shield of influenza A.	276:326	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	4	53	theme	N-linked	1049:1056	arg1	glycans					1058:1064	N-linked glycans	1049:1064	N-linked glycans upon binding with two low-affinity carbohydrate binding sites	1049:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	7	54	theme	membrane-distal	1643:1657	arg1	part					1666:1669	the membrane-distal HA top part	1639:1669	the membrane-distal HA top part	1639:1669	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	4	55	with	binding	1071:1077	arg1	sites					1122:1126	two low-affinity carbohydrate binding sites	1084:1126	two low-affinity carbohydrate binding sites	1084:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	2	56	theme	surface	790:796	arg1	SPR					817:819	SPR	817:819	SPR	817:819	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	2	56	theme	surface	790:796	arg1	resonance					806:814	surface plasmon resonance	790:814	surface plasmon resonance (SPR)	790:820	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	3	57	dep	sites	988:992	arg1	high-					964:968	high-	964:968	high-	964:968	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	2	58	theme	virus	636:640	arg1	gp120					648:652	human immunodeficiency virus (HIV) gp120	613:652	human immunodeficiency virus (HIV) gp120	613:652	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	3	59	theme	binding	980:986	arg1	sites					988:992	(high-) affinity binding sites	963:992	(high-) affinity binding sites	963:992	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	1	60	theme	host	474:477	arg1	site					496:499	the host receptor binding site	470:499	the host receptor binding site	470:499	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	5	61	theme	monomeric	1192:1200	arg1	CV-N					1202:1205	monomeric CV-N	1192:1205	monomeric CV-N	1192:1205	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	2	62	theme	human	613:617	arg1	virus					636:640	human immunodeficiency virus	613:640	human immunodeficiency virus (HIV) gp120	613:652	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	2	62	theme	human	613:617	arg1	HIV					643:645	HIV	643:645	HIV	643:645	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	4	63	theme	binding	1114:1120	arg1	sites					1122:1126	two low-affinity carbohydrate binding sites	1084:1126	two low-affinity carbohydrate binding sites	1084:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	8	64	theme	low-affinity	1785:1796	arg1	sites					1806:1810	low-affinity binding sites	1785:1810	low-affinity binding sites	1785:1810	They can also induce high-affinity binding in antiviral CV-N to HA at two sites, and CVN2 binding is achieved at low-affinity binding sites.
34199200	1	65	theme	binding	488:494	arg1	site					496:499	the host receptor binding site	470:499	the host receptor binding site	470:499	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	6	66	theme	bivalent	1441:1448	arg1	scheme					1458:1463	the bivalent binding scheme	1437:1463	the bivalent binding scheme in SPR	1437:1470	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	2	67	theme	surface-expressed	564:580	arg1	glycoproteins					582:594	surface-expressed glycoproteins	564:594	surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2	564:691	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	2	67	theme	surface-expressed	564:580	arg1	those					604:608	those	604:608	those	604:608	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	4	68	theme	low-affinity	1088:1099	arg1	sites					1122:1126	two low-affinity carbohydrate binding sites	1084:1126	two low-affinity carbohydrate binding sites	1084:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	6	69	theme	spike	1268:1272	arg1	proteins					1274:1281	All three envelope spike proteins	1249:1281	All three envelope spike proteins	1249:1281	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	6	70	dep	recognized	1288:1297	arg1	whereas					1318:1324	whereas	1318:1324	whereas	1318:1324	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	5	71	theme	nM	1245:1246	arg1	KD					1235:1236	a maximum KD	1225:1236	a maximum KD of 2.7 nM	1225:1246	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	6	72	theme	HIV	1337:1339	arg1	2G12					1354:1357	HIV neutralizing 2G12	1337:1357	HIV neutralizing 2G12	1337:1357	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	8	73	theme	high-affinity	1693:1705	arg1	binding					1707:1713	high-affinity binding	1693:1713	high-affinity binding in antiviral CV-N to HA	1693:1737	They can also induce high-affinity binding in antiviral CV-N to HA at two sites, and CVN2 binding is achieved at low-affinity binding sites.
34199200	7	74	theme	top	1662:1664	arg1	part					1666:1669	the membrane-distal HA top part	1639:1669	the membrane-distal HA top part	1639:1669	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	7	75	theme	structural	1498:1507	arg1	patterns					1517:1524	invariant structural protein patterns	1488:1524	invariant structural protein patterns	1488:1524	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	3	76	theme	CV-N	879:882	arg1	CVN2					894:897	CVN2	894:897	CVN2	894:897	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	3	76	theme	CV-N	879:882	arg1	molecule					884:891	an engineered dimeric CV-N molecule	857:891	an engineered dimeric CV-N molecule (CVN2)	857:898	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	5	77	theme	maximum	1227:1233	arg1	KD					1235:1236	a maximum KD	1225:1236	a maximum KD of 2.7 nM	1225:1246	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	0	78	theme	Virus	104:108	arg1	Ability					125:131	Direct Virus Neutralization Ability	97:131	Direct Virus Neutralization Ability	97:131	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	3	79	theme	engineered	860:869	arg1	CVN2					894:897	CVN2	894:897	CVN2	894:897	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	3	79	theme	engineered	860:869	arg1	molecule					884:891	an engineered dimeric CV-N molecule	857:891	an engineered dimeric CV-N molecule (CVN2)	857:898	Binding-site knockout variants of an engineered dimeric CV-N molecule (CVN2) revealed a binding affinity that correlated with the number of (high-) affinity binding sites.
34199200	6	80	theme	nanomolar	1304:1312	arg1	KD					1314:1315	a nanomolar KD	1302:1315	a nanomolar KD	1302:1315	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	4	81	with	interaction	1032:1042	arg1	glycans					1058:1064	N-linked glycans	1049:1064	N-linked glycans upon binding with two low-affinity carbohydrate binding sites	1049:1126	Binding curves were specific for the interaction with N-linked glycans upon binding with two low-affinity carbohydrate binding sites.
34199200	1	82	theme	enveloped	410:418	arg1	viruses					420:426	enveloped viruses	410:426	enveloped viruses	410:426	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	7	83	from	maturation	1559:1568	arg1	regions					1598:1604	the membrane-anchored HA regions	1573:1604	the membrane-anchored HA regions	1573:1604	In conclusion, invariant structural protein patterns provide a substrate for affinity maturation in the membrane-anchored HA regions, as well as the glycan shield on the membrane-distal HA top part.
34199200	0	84	theme	Envelope	25:32	arg1	Proteins					34:41	Viral Envelope Proteins	19:41	Viral Envelope Proteins	19:41	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	6	85	theme	targeting	1362:1370	arg1	HA					1372:1373	targeting HA	1362:1373	targeting HA	1362:1373	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	5	86	theme	CVN2	1183:1186	arg1	CV-N					1202:1205	monomeric CV-N	1192:1205	monomeric CV-N	1192:1205	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	5	86	theme	CVN2	1183:1186	arg1	assembly					1154:1161	This biologically active assembly	1129:1161	This biologically active assembly of a domain-swapped CVN2	1129:1186	This biologically active assembly of a domain-swapped CVN2, or monomeric CV-N, bound to HA with a maximum KD of 2.7 nM.
34199200	6	87	theme	µM	1411:1412	arg1	range					1414:1418	the µM range	1407:1418	the µM range	1407:1418	All three envelope spike proteins were recognized at a nanomolar KD, whereas binding to HIV neutralizing 2G12 by targeting HA and Ebola GP1,2 was measured in the µM range and specific for the bivalent binding scheme in SPR.
34199200	0	88	theme	Low-Affinity	50:61	arg1	Site					84:87	the Low-Affinity Carbohydrate Binding Site	46:87	the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability	46:131	Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
34199200	1	89	theme	antiviral	349:357	arg1	agents					359:364	Broadly neutralizing antiviral agents	328:364	Broadly neutralizing antiviral agents	328:364	Glycan-targeting antibodies and pseudo-antibodies have been extensively studied for their stoichiometry, avidity, and their interactions with the rapidly modifying glycan shield of influenza A. Broadly neutralizing antiviral agents bind in the same order when they neutralize enveloped viruses regardless of the location of epitopes to the host receptor binding site.
34199200	2	90	theme	plasmon	798:804	arg1	SPR					817:819	SPR	817:819	SPR	817:819	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
34199200	2	90	theme	plasmon	798:804	arg1	resonance					806:814	surface plasmon resonance	790:814	surface plasmon resonance (SPR)	790:820	Herein, we investigated the binding of cyanovirin-N (CV-N) to surface-expressed glycoproteins such as those of human immunodeficiency virus (HIV) gp120, hemagglutinin (HA), and Ebola (GP)1,2 and compared their binding affinities with the binding response to the trimer-folded gp140 using surface plasmon resonance (SPR).
33608773	0	0	theme	liver	90:94	arg1	fibrogenesis					96:107	liver fibrogenesis	90:107	liver fibrogenesis	90:107	Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.
33608773	4	1	theme	FUT8	734:737	arg1	level					744:748	FUT8 mRNA level	734:748	FUT8 mRNA level	734:748	Herein, we reported FUT8 mRNA level was increased in patients with liver fibrosis from GEO database and positively correlated with fibrosis progression.
33608773	8	2	theme	feedback	1435:1442	arg1	loop					1444:1447	a negative feedback loop	1424:1447	a negative feedback loop	1424:1447	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	4	3	theme	fibrosis	845:852	arg1	progression					854:864	fibrosis progression	845:864	fibrosis progression	845:864	Herein, we reported FUT8 mRNA level was increased in patients with liver fibrosis from GEO database and positively correlated with fibrosis progression.
33608773	5	4	theme	core	891:894	arg1	fucosylation					896:907	the core fucosylation	887:907	the core fucosylation	887:907	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	8	5	theme	liver	1501:1505	arg1	fibrosis					1507:1514	liver fibrosis	1501:1514	liver fibrosis	1501:1514	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	2	6	link	N-linked	395:402	arg1	oligosaccharides					404:419	N-linked oligosaccharides	395:419	N-linked oligosaccharides	395:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	5	7	theme	fibrosis	955:962	arg1	model					964:968	TAA-induced mouse liver fibrosis model	931:968	TAA-induced mouse liver fibrosis model	931:968	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	5	8	theme	liver	949:953	arg1	model					964:968	TAA-induced mouse liver fibrosis model	931:968	TAA-induced mouse liver fibrosis model	931:968	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	4	9	with	patients	767:774	arg1	fibrosis					787:794	liver fibrosis	781:794	liver fibrosis	781:794	Herein, we reported FUT8 mRNA level was increased in patients with liver fibrosis from GEO database and positively correlated with fibrosis progression.
33608773	6	10	theme	core	1129:1132	arg1	fucosylation					1134:1145	total core fucosylation	1123:1145	total core fucosylation	1123:1145	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	4	11	theme	mRNA	739:742	arg1	level					744:748	FUT8 mRNA level	734:748	FUT8 mRNA level	734:748	Herein, we reported FUT8 mRNA level was increased in patients with liver fibrosis from GEO database and positively correlated with fibrosis progression.
33608773	8	12	theme	potential	1462:1470	arg1	strategy					1488:1495	potential new therapeutic strategy	1462:1495	potential new therapeutic strategy for liver fibrosis	1462:1514	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	1	13	theme	chronic	174:180	arg1	injury					188:193	chronic liver injury	174:193	chronic liver injury	174:193	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	3	14	theme	liver	698:702	arg1	fibrosis					704:711	liver fibrosis	698:711	liver fibrosis	698:711	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	7	15	from	trans-differentiation	1236:1256	arg1	HSCs					1310:1313	HSCs	1310:1313	HSCs	1310:1313	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	6	16	theme	fucosylation	1134:1145	arg1	expression					1100:1109	the expression	1096:1109	the expression of FUT8 and total core fucosylation levels in HSCs	1096:1160	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	6	17	theme	pro-fibrogenic	1057:1070	arg1	cytokine					1072:1079	the most pro-fibrogenic cytokine	1048:1079	the most pro-fibrogenic cytokine	1048:1079	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	1	18	theme	liver	182:186	arg1	injury					188:193	chronic liver injury	174:193	chronic liver injury	174:193	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	2	19	theme	cell	474:477	arg1	differentiation					479:493	cell differentiation	474:493	cell differentiation	474:493	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	20	theme	Core	288:291	arg1	fucosylation					293:304	Core fucosylation	288:304	Core fucosylation catalyzed by FUT8	288:322	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	8	21	theme	new	1472:1474	arg1	strategy					1488:1495	potential new therapeutic strategy	1462:1495	potential new therapeutic strategy for liver fibrosis	1462:1514	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	7	22	from	migration	1259:1267	arg1	HSCs					1310:1313	HSCs	1310:1313	HSCs	1310:1313	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	5	23	theme	TAA-induced	931:941	arg1	model					964:968	TAA-induced mouse liver fibrosis model	931:968	TAA-induced mouse liver fibrosis model	931:968	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	2	24	theme	fucosyl	345:351	arg1	moiety					353:358	the fucosyl moiety	341:358	the fucosyl moiety	341:358	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	25	theme	oligosaccharides	404:419	arg1	residue					384:390	the innermost GlcNAc residue	363:390	the innermost GlcNAc residue of N-linked oligosaccharides	363:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	25	theme	oligosaccharides	404:419	arg1	oligosaccharides					404:419	N-linked oligosaccharides	395:419	N-linked oligosaccharides	395:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	8	26	theme	negative	1426:1433	arg1	loop					1444:1447	a negative feedback loop	1424:1447	a negative feedback loop	1424:1447	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	8	27	theme	TGF-β1-induced	1391:1404	arg1	activation					1410:1419	TGF-β1-induced HSC activation	1391:1419	TGF-β1-induced HSC activation	1391:1419	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	1	28	theme	Liver	110:114	arg1	response					155:162	a continuous wound healing response	128:162	a continuous wound healing response caused by chronic liver injury	128:193	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	28	theme	Liver	110:114	arg1	fibrosis					116:123	Liver fibrosis	110:123	Liver fibrosis	110:123	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	0	29	theme	FUT8	17:20	arg1	Up-regulation					0:12	Up-regulation	0:12	Up-regulation of FUT8	0:20	Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.
33608773	1	30	theme	main	269:272	arg1	event					274:278	the main event	265:278	the main event for it	265:285	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	30	theme	main	269:272	arg1	activation					204:213	the activation	200:213	the activation of hepatic stellate cells (HSCs)	200:246	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	5	31	gly	fucosylation	896:907	arg1	model					964:968	TAA-induced mouse liver fibrosis model	931:968	TAA-induced mouse liver fibrosis model	931:968	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	8	32	theme	FUT8	1377:1380	arg1	up-regulation					1360:1372	the up-regulation	1356:1372	the up-regulation of FUT8	1356:1380	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	3	33	theme	core	544:547	arg1	fucosylation					549:560	Aberrant core fucosylation	535:560	Aberrant core fucosylation	535:560	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	6	34	theme	total	1123:1127	arg1	fucosylation					1134:1145	total core fucosylation	1123:1145	total core fucosylation	1123:1145	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	2	35	theme	biological	445:454	arg1	transduction					521:532	signaling transduction	511:532	signaling transduction	511:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	35	theme	biological	445:454	arg1	processes					456:464	many biological processes	440:464	many biological processes such as cell differentiation, migration, and signaling transduction	440:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	35	theme	biological	445:454	arg1	migration					496:504	migration	496:504	migration	496:504	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	35	theme	biological	445:454	arg1	differentiation					479:493	cell differentiation	474:493	cell differentiation	474:493	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	36	theme	signaling	511:519	arg1	transduction					521:532	signaling transduction	511:532	signaling transduction	511:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	7	37	theme	pro-fibrogenic	1273:1286	arg1	pathways					1298:1305	pro-fibrogenic signaling pathways	1273:1305	pro-fibrogenic signaling pathways in HSCs	1273:1313	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	5	38	theme	FUT8	867:870	arg1	expression					872:881	FUT8 expression	867:881	FUT8 expression	867:881	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	2	39	theme	GlcNAc	377:382	arg1	residue					384:390	the innermost GlcNAc residue	363:390	the innermost GlcNAc residue of N-linked oligosaccharides	363:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	39	theme	GlcNAc	377:382	arg1	oligosaccharides					404:419	N-linked oligosaccharides	395:419	N-linked oligosaccharides	395:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	0	40	theme	TGF-β1-induced	31:44	arg1	activation					46:55	TGF-β1-induced activation	31:55	TGF-β1-induced activation of hepatic stellate cells	31:81	Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.
33608773	2	41	theme	many	440:443	arg1	transduction					521:532	signaling transduction	511:532	signaling transduction	511:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	41	theme	many	440:443	arg1	processes					456:464	many biological processes	440:464	many biological processes such as cell differentiation, migration, and signaling transduction	440:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	41	theme	many	440:443	arg1	migration					496:504	migration	496:504	migration	496:504	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	41	theme	many	440:443	arg1	differentiation					479:493	cell differentiation	474:493	cell differentiation	474:493	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	5	42	theme	fibrous	1006:1012	arg1	septum					1014:1019	the fibrous septum	1002:1019	the fibrous septum of mouse liver	1002:1034	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	2	43	theme	innermost	367:375	arg1	residue					384:390	the innermost GlcNAc residue	363:390	the innermost GlcNAc residue of N-linked oligosaccharides	363:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	43	theme	innermost	367:375	arg1	oligosaccharides					404:419	N-linked oligosaccharides	395:419	N-linked oligosaccharides	395:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	0	44	theme	hepatic	60:66	arg1	cells					77:81	hepatic stellate cells	60:81	hepatic stellate cells	60:81	Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.
33608773	7	45	theme	FUT8	1198:1201	arg1	up-regulation					1181:1193	up-regulation	1181:1193	up-regulation of FUT8 in turn	1181:1209	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	8	46	theme	HSC	1406:1408	arg1	activation					1410:1419	TGF-β1-induced HSC activation	1391:1419	TGF-β1-induced HSC activation	1391:1419	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	5	47	theme	mouse	943:947	arg1	model					964:968	TAA-induced mouse liver fibrosis model	931:968	TAA-induced mouse liver fibrosis model	931:968	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	5	48	theme	mouse	1024:1028	arg1	liver					1030:1034	mouse liver	1024:1034	mouse liver	1024:1034	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	4	49	theme	GEO	801:803	arg1	database					805:812	GEO database	801:812	GEO database	801:812	Herein, we reported FUT8 mRNA level was increased in patients with liver fibrosis from GEO database and positively correlated with fibrosis progression.
33608773	7	50	from	pathways	1298:1305	arg1	HSCs					1310:1313	HSCs	1310:1313	HSCs	1310:1313	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	3	51	theme	diseases	594:601	arg1	tumors					637:642	tumors	637:642	tumors	637:642	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	3	51	theme	diseases	594:601	arg1	diseases					594:601	diseases	594:601	diseases including cardiovascular disease, tumors and neuroinflammation	594:664	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	3	51	theme	diseases	594:601	arg1	disease					628:634	cardiovascular disease	613:634	cardiovascular disease	613:634	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	3	51	theme	diseases	594:601	arg1	variety					583:589	a variety	581:589	a variety of diseases including cardiovascular disease, tumors and neuroinflammation	581:664	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	3	51	theme	diseases	594:601	arg1	neuroinflammation					648:664	neuroinflammation	648:664	neuroinflammation	648:664	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	2	52	gly	fucosylation	293:304	arg1	transduction					521:532	signaling transduction	511:532	signaling transduction	511:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	52	gly	fucosylation	293:304	arg1	processes					456:464	many biological processes	440:464	many biological processes such as cell differentiation, migration, and signaling transduction	440:532	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	52	gly	fucosylation	293:304	arg1	migration					496:504	migration	496:504	migration	496:504	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	2	52	gly	fucosylation	293:304	arg1	differentiation					479:493	cell differentiation	474:493	cell differentiation	474:493	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	5	53	theme	liver	1030:1034	arg1	septum					1014:1019	the fibrous septum	1002:1019	the fibrous septum of mouse liver	1002:1034	FUT8 expression and the core fucosylation were also elevated in TAA-induced mouse liver fibrosis model, and were mainly distributed in the fibrous septum of mouse liver.
33608773	6	54	from	expression	1100:1109	arg1	HSCs					1157:1160	HSCs	1157:1160	HSCs	1157:1160	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	1	55	theme	continuous	130:139	arg1	response					155:162	a continuous wound healing response	128:162	a continuous wound healing response caused by chronic liver injury	128:193	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	55	theme	continuous	130:139	arg1	fibrosis					116:123	Liver fibrosis	110:123	Liver fibrosis	110:123	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	3	56	theme	Aberrant	535:542	arg1	fucosylation					549:560	Aberrant core fucosylation	535:560	Aberrant core fucosylation	535:560	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	1	57	theme	hepatic	218:224	arg1	cells					235:239	hepatic stellate cells	218:239	hepatic stellate cells (HSCs)	218:246	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	57	theme	hepatic	218:224	arg1	HSCs					242:245	HSCs	242:245	HSCs	242:245	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	8	58	theme	therapeutic	1476:1486	arg1	strategy					1488:1495	potential new therapeutic strategy	1462:1495	potential new therapeutic strategy for liver fibrosis	1462:1514	In conclusion, our results suggest that the up-regulation of FUT8 inhibits TGF-β1-induced HSC activation in a negative feedback loop, and provide potential new therapeutic strategy for liver fibrosis by targeting FUT8.
33608773	3	59	theme	cardiovascular	613:626	arg1	disease					628:634	cardiovascular disease	613:634	cardiovascular disease	613:634	Aberrant core fucosylation is associated with a variety of diseases including cardiovascular disease, tumors and neuroinflammation, but much less is understood in liver fibrosis.
33608773	1	60	theme	wound	141:145	arg1	response					155:162	a continuous wound healing response	128:162	a continuous wound healing response caused by chronic liver injury	128:193	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	60	theme	wound	141:145	arg1	fibrosis					116:123	Liver fibrosis	110:123	Liver fibrosis	110:123	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	61	theme	stellate	226:233	arg1	cells					235:239	hepatic stellate cells	218:239	hepatic stellate cells (HSCs)	218:246	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	61	theme	stellate	226:233	arg1	HSCs					242:245	HSCs	242:245	HSCs	242:245	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	0	62	theme	cells	77:81	arg1	activation					46:55	TGF-β1-induced activation	31:55	TGF-β1-induced activation of hepatic stellate cells	31:81	Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.
33608773	7	63	theme	signaling	1288:1296	arg1	pathways					1298:1305	pro-fibrogenic signaling pathways	1273:1305	pro-fibrogenic signaling pathways in HSCs	1273:1313	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	4	64	theme	liver	781:785	arg1	fibrosis					787:794	liver fibrosis	781:794	liver fibrosis	781:794	Herein, we reported FUT8 mRNA level was increased in patients with liver fibrosis from GEO database and positively correlated with fibrosis progression.
33608773	1	65	theme	healing	147:153	arg1	response					155:162	a continuous wound healing response	128:162	a continuous wound healing response caused by chronic liver injury	128:193	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	65	theme	healing	147:153	arg1	fibrosis					116:123	Liver fibrosis	110:123	Liver fibrosis	110:123	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	6	66	dep	FUT8	1114:1117	arg1	levels					1147:1152	levels	1147:1152	levels	1147:1152	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	1	67	theme	cells	235:239	arg1	event					274:278	the main event	265:278	the main event for it	265:285	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	1	67	theme	cells	235:239	arg1	activation					204:213	the activation	200:213	the activation of hepatic stellate cells (HSCs)	200:246	Liver fibrosis is a continuous wound healing response caused by chronic liver injury, and the activation of hepatic stellate cells (HSCs) is considered as the main event for it.
33608773	0	68	theme	stellate	68:75	arg1	cells					77:81	hepatic stellate cells	60:81	hepatic stellate cells	60:81	Up-regulation of FUT8 inhibits TGF-β1-induced activation of hepatic stellate cells during liver fibrogenesis.
33608773	6	69	theme	FUT8	1114:1117	arg1	expression					1100:1109	the expression	1096:1109	the expression of FUT8 and total core fucosylation levels in HSCs	1096:1160	TGF-β1, as the most pro-fibrogenic cytokine, could promote the expression of FUT8 and total core fucosylation levels in HSCs in vitro.
33608773	2	70	theme	N-linked	395:402	arg1	oligosaccharides					404:419	N-linked oligosaccharides	395:419	N-linked oligosaccharides	395:419	Core fucosylation catalyzed by FUT8 refers to adding the fucosyl moiety to the innermost GlcNAc residue of N-linked oligosaccharides and is involved in many biological processes such as cell differentiation, migration, and signaling transduction.
33608773	7	71	theme	TGF-β1-induced	1221:1234	arg1	trans-differentiation					1236:1256	TGF-β1-induced trans-differentiation	1221:1256	TGF-β1-induced trans-differentiation	1221:1256	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
33608773	7	72	from	up-regulation	1181:1193	arg1	turn					1206:1209	turn	1206:1209	turn	1206:1209	However, up-regulation of FUT8 in turn inhibited TGF-β1-induced trans-differentiation, migration and pro-fibrogenic signaling pathways in HSCs.
32608236	7	0	theme	Salla	1155:1159	arg1	disease					1161:1167	Salla disease	1155:1167	Salla disease	1155:1167	Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease.
32608236	6	1	theme	In	898:899	arg1	studies					929:935	In vitro and molecular docking studies	898:935	In vitro and molecular docking studies	898:935	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	4	2	theme	hydrophobic	681:691	arg1	chain					698:702	a hydrophobic side chain	679:702	a hydrophobic side chain	679:702	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	2	3	theme	acids	333:337	arg1	incorporation					299:311	metabolic incorporation	289:311	metabolic incorporation of exogenous sialic acids	289:337	It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans.
32608236	2	4	theme	sialic	326:331	arg1	acids					333:337	exogenous sialic acids	316:337	exogenous sialic acids	316:337	It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans.
32608236	1	5	theme	Salla	225:229	arg1	leukodystrophy					257:270	a rare inherited leukodystrophy	240:270	a rare inherited leukodystrophy	240:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	5	theme	Salla	225:229	arg1	disease					231:237	Salla disease	225:237	Salla disease	225:237	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	6	6	theme	cytosol-facing	1033:1046	arg1	conformation					1048:1059	a cytosol-facing conformation	1031:1059	a cytosol-facing conformation	1031:1059	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	8	7	theme	pharmacological	1294:1308	arg1	chaperones					1310:1319	pharmacological chaperones	1294:1319	pharmacological chaperones for Salla disease	1294:1337	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	4	8	theme	acid	584:587	arg1	backbone					589:596	an amino acid backbone	575:596	an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain	575:702	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	0	9	theme	Ligands	78:84	arg1	Class					69:73	a New Class	63:73	a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin	63:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	0	9	theme	Ligands	78:84	arg1	Substituents					47:58	Aromatic or Heteroaromatic Substituents	20:58	Aromatic or Heteroaromatic Substituents	20:58	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	6	10	theme	molecular	911:919	arg1	studies					929:935	In vitro and molecular docking studies	898:935	In vitro and molecular docking studies	898:935	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	3	11	theme	virtual	472:478	arg1	screening					480:488	virtual screening	472:488	virtual screening	472:488	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	3	12	theme	sialin	454:459	arg1	ligands					461:467	human sialin ligands	448:467	human sialin ligands	448:467	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	0	13	theme	Lysosomal	94:102	arg1	Transporter					116:126	the Lysosomal Sialic Acid Transporter Sialin	90:133	the Lysosomal Sialic Acid Transporter Sialin	90:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	3	14	theme	ligands	461:467	arg1	class					439:443	a novel class	431:443	a novel class of human sialin ligands	431:467	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	6	15	from	site	1023:1026	arg1	conformation					1048:1059	a cytosol-facing conformation	1031:1059	a cytosol-facing conformation	1031:1059	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	6	16	theme	Neu5Ac	1016:1021	arg1	site					1023:1026	the Neu5Ac site	1012:1026	the Neu5Ac site in a cytosol-facing conformation	1012:1059	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	2	17	theme	N-glycolylneuraminic	374:393	arg1	acid					395:398	N-glycolylneuraminic acid	374:398	N-glycolylneuraminic acid in humans	374:408	It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans.
32608236	4	18	theme	amino	578:582	arg1	backbone					589:596	an amino acid backbone	575:596	an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain	575:702	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	7	19	theme	trafficking	1096:1106	arg1	defect					1108:1113	the trafficking defect	1092:1113	the trafficking defect of the pathogenic mutant (R39C) causing Salla disease	1092:1167	Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease.
32608236	5	20	dep	400-fold	859:866	arg1	lower					868:872	lower	868:872	lower	868:872	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	4	21	theme	aromatic	635:642	arg1	carboxylate					610:620	a free carboxylate	603:620	a free carboxylate	603:620	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	21	theme	aromatic	635:642	arg1	substituent					662:672	an N-linked aromatic or heteroaromatic substituent	623:672	an N-linked aromatic or heteroaromatic substituent	623:672	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	7	22	theme	pathogenic	1122:1131	arg1	R39C					1141:1144	R39C	1141:1144	R39C	1141:1144	Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease.
32608236	7	22	theme	pathogenic	1122:1131	arg1	mutant					1133:1138	the pathogenic mutant	1118:1138	the pathogenic mutant (R39C) causing Salla disease	1118:1167	Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease.
32608236	3	23	theme	structure-activity	494:511	arg1	relationship					513:524	structure-activity relationship	494:524	structure-activity relationship	494:524	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	1	24	theme	SLC17A5	159:165	arg1	gene					167:170	the SLC17A5 gene	155:170	the SLC17A5 gene	155:170	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	0	25	theme	Amino	0:4	arg1	Acids					6:10	Amino Acids	0:10	Amino Acids	0:10	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	3	26	dep	screening	480:488	arg1	studies					526:532	studies	526:532	studies	526:532	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	4	27	theme	heteroaromatic	647:660	arg1	carboxylate					610:620	a free carboxylate	603:620	a free carboxylate	603:620	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	27	theme	heteroaromatic	647:660	arg1	substituent					662:672	an N-linked aromatic or heteroaromatic substituent	623:672	an N-linked aromatic or heteroaromatic substituent	623:672	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	0	28	theme	Aromatic	20:27	arg1	Class					69:73	a New Class	63:73	a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin	63:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	0	28	theme	Aromatic	20:27	arg1	Substituents					47:58	Aromatic or Heteroaromatic Substituents	20:58	Aromatic or Heteroaromatic Substituents	20:58	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	1	29	theme	rare	242:245	arg1	leukodystrophy					257:270	a rare inherited leukodystrophy	240:270	a rare inherited leukodystrophy	240:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	29	theme	rare	242:245	arg1	disease					231:237	Salla disease	225:237	Salla disease	225:237	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	0	30	theme	Acid	111:114	arg1	Transporter					116:126	the Lysosomal Sialic Acid Transporter Sialin	90:133	the Lysosomal Sialic Acid Transporter Sialin	90:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	8	31	theme	Salla	1325:1329	arg1	disease					1331:1337	Salla disease	1325:1337	Salla disease	1325:1337	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	1	32	theme	inherited	247:255	arg1	leukodystrophy					257:270	a rare inherited leukodystrophy	240:270	a rare inherited leukodystrophy	240:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	32	theme	inherited	247:255	arg1	disease					231:237	Salla disease	225:237	Salla disease	225:237	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	0	33	theme	Sialic	104:109	arg1	Transporter					116:126	the Lysosomal Sialic Acid Transporter Sialin	90:133	the Lysosomal Sialic Acid Transporter Sialin	90:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	6	34	theme	selective	981:989	arg1	binding					1001:1007	selective inhibitor binding	981:1007	selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation	981:1059	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	8	35	theme	inhibitors	1202:1211	arg1	class					1179:1183	This new class	1170:1183	This new class of cell-permeant inhibitors	1170:1211	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	0	36	theme	Heteroaromatic	32:45	arg1	Class					69:73	a New Class	63:73	a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin	63:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	0	36	theme	Heteroaromatic	32:45	arg1	Substituents					47:58	Aromatic or Heteroaromatic Substituents	20:58	Aromatic or Heteroaromatic Substituents	20:58	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	5	37	theme	400-fold	859:866	arg1	μM					847:848	2.5 μM	843:848	2.5 μM	843:848	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	5	37	theme	400-fold	859:866	arg1	value					853:857	a value	851:857	a value 400-fold lower than the KM for Neu5Ac	851:895	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	6	38	theme	inhibitor	991:999	arg1	binding					1001:1007	selective inhibitor binding	981:1007	selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation	981:1059	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	4	39	theme	N-linked	626:633	arg1	carboxylate					610:620	a free carboxylate	603:620	a free carboxylate	603:620	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	39	theme	N-linked	626:633	arg1	substituent					662:672	an N-linked aromatic or heteroaromatic substituent	623:672	an N-linked aromatic or heteroaromatic substituent	623:672	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	8	40	theme	new	1175:1177	arg1	class					1179:1183	This new class	1170:1183	This new class of cell-permeant inhibitors	1170:1211	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	5	41	theme	potent	714:719	arg1	compound					721:728	The most potent compound	705:728	The most potent compound	705:728	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	5	41	theme	potent	714:719	arg1	45					731:732	45	731:732	45	731:732	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	6	42	theme	non-competitive	952:966	arg1	character					968:976	the non-competitive character	948:976	the non-competitive character	948:976	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	5	43	theme	non-competitive	808:822	arg1	manner					824:829	a non-competitive manner	806:829	a non-competitive manner	806:829	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	1	44	theme	lysosomal	178:186	arg1	transporter					200:210	a lysosomal sialic acid transporter	176:210	a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy	176:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	44	theme	lysosomal	178:186	arg1	Sialin					136:141	Sialin	136:141	Sialin	136:141	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	5	45	theme	N-acetylneuraminic	758:775	arg1	acid					777:780	N-acetylneuraminic acid 1	758:782	N-acetylneuraminic acid 1 (Neu5Ac) transport	758:801	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	5	45	theme	N-acetylneuraminic	758:775	arg1	Neu5Ac					785:790	Neu5Ac	785:790	Neu5Ac	785:790	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	5	46	theme	acid	777:780	arg1	transport					793:801	N-acetylneuraminic acid 1 (Neu5Ac) transport	758:801	N-acetylneuraminic acid 1 (Neu5Ac) transport	758:801	The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac.
32608236	4	47	theme	ligand	539:544	arg1	scaffold					546:553	The ligand scaffold	535:553	The ligand scaffold	535:553	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	2	48	theme	exogenous	316:324	arg1	acids					333:337	exogenous sialic acids	316:337	exogenous sialic acids	316:337	It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans.
32608236	1	49	from	disease	231:237	arg1	defective					212:220	defective	212:220	defective	212:220	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	50	from	defective	212:220	arg1	leukodystrophy					257:270	a rare inherited leukodystrophy	240:270	a rare inherited leukodystrophy	240:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	50	from	defective	212:220	arg1	disease					231:237	Salla disease	225:237	Salla disease	225:237	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	6	51	dep	In	898:899	arg1	vitro					901:905	vitro	901:905	vitro	901:905	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	4	52	with	backbone	589:596	arg1	chain					698:702	a hydrophobic side chain	679:702	a hydrophobic side chain	679:702	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	52	with	backbone	589:596	arg1	carboxylate					610:620	a free carboxylate	603:620	a free carboxylate	603:620	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	52	with	backbone	589:596	arg1	substituent					662:672	an N-linked aromatic or heteroaromatic substituent	623:672	an N-linked aromatic or heteroaromatic substituent	623:672	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	53	theme	side	693:696	arg1	chain					698:702	a hydrophobic side chain	679:702	a hydrophobic side chain	679:702	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	54	link	N-linked	626:633	arg1	carboxylate					610:620	a free carboxylate	603:620	a free carboxylate	603:620	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	54	link	N-linked	626:633	arg1	substituent					662:672	an N-linked aromatic or heteroaromatic substituent	623:672	an N-linked aromatic or heteroaromatic substituent	623:672	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	8	55	theme	cell-permeant	1188:1200	arg1	inhibitors					1202:1211	cell-permeant inhibitors	1188:1211	cell-permeant inhibitors	1188:1211	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	3	56	theme	human	448:452	arg1	ligands					461:467	human sialin ligands	448:467	human sialin ligands	448:467	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	1	57	theme	sialic	188:193	arg1	transporter					200:210	a lysosomal sialic acid transporter	176:210	a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy	176:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	57	theme	sialic	188:193	arg1	Sialin					136:141	Sialin	136:141	Sialin	136:141	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	2	58	theme	metabolic	289:297	arg1	incorporation					299:311	metabolic incorporation	289:311	metabolic incorporation of exogenous sialic acids	289:337	It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans.
32608236	1	59	theme	acid	195:198	arg1	transporter					200:210	a lysosomal sialic acid transporter	176:210	a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy	176:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	59	theme	acid	195:198	arg1	Sialin					136:141	Sialin	136:141	Sialin	136:141	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	0	60	theme	New	65:67	arg1	Class					69:73	a New Class	63:73	a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin	63:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	0	60	theme	New	65:67	arg1	Substituents					47:58	Aromatic or Heteroaromatic Substituents	20:58	Aromatic or Heteroaromatic Substituents	20:58	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	3	61	theme	novel	433:437	arg1	class					439:443	a novel class	431:443	a novel class of human sialin ligands	431:467	Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies.
32608236	2	62	from	acid	395:398	arg1	humans					403:408	humans	403:408	humans	403:408	It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans.
32608236	8	63	theme	sialin	1270:1275	arg1	roles					1261:1265	the physiological roles	1243:1265	the physiological roles of sialin	1243:1275	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	8	64	theme	physiological	1247:1259	arg1	roles					1261:1265	the physiological roles	1243:1265	the physiological roles of sialin	1243:1275	This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.
32608236	4	65	theme	free	605:608	arg1	carboxylate					610:620	a free carboxylate	603:620	a free carboxylate	603:620	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	4	65	theme	free	605:608	arg1	substituent					662:672	an N-linked aromatic or heteroaromatic substituent	623:672	an N-linked aromatic or heteroaromatic substituent	623:672	The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain.
32608236	6	66	theme	docking	921:927	arg1	studies					929:935	In vitro and molecular docking studies	898:935	In vitro and molecular docking studies	898:935	In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation.
32608236	0	67	dep	Transporter	116:126	arg1	Sialin					128:133	Sialin	128:133	the Lysosomal Sialic Acid Transporter Sialin	90:133	Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
32608236	7	68	theme	mutant	1133:1138	arg1	defect					1108:1113	the trafficking defect	1092:1113	the trafficking defect of the pathogenic mutant (R39C) causing Salla disease	1092:1167	Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease.
32608236	1	69	theme	defective	212:220	arg1	transporter					200:210	a lysosomal sialic acid transporter	176:210	a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy	176:270	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32608236	1	69	theme	defective	212:220	arg1	Sialin					136:141	Sialin	136:141	Sialin	136:141	Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy.
32393818	0	0	theme	form	82:85	arg1	bispecifics					87:97	form bispecifics	82:97	form bispecifics	82:97	Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.
32393818	6	1	with	cells	1082:1086	arg1	HLA/peptide					1100:1110	target HLA/peptide	1093:1110	target HLA/peptide on their surfaces	1093:1128	These TCR/CD3 bispecifics can redirect T cells to kill tumor cells with target HLA/peptide on their surfaces in vitro.
32393818	3	2	theme	variable	661:668	arg1	mutation					677:684	variable domain mutation	661:684	variable domain mutation	661:684	The stabilizing mutations rescue the expression of TCRs destabilized through variable domain mutation.
32393818	2	3	theme	molecular	303:311	arg1	modeling					313:320	molecular modeling	303:320	molecular modeling	303:320	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	4	theme	Cα/Cβ	423:427	arg1	temperature					408:418	the unfolding temperature	394:418	the unfolding temperature of Cα/Cβ by 20 °C	394:436	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	3	5	theme	stabilizing	588:598	arg1	mutations					600:608	The stabilizing mutations	584:608	The stabilizing mutations	584:608	The stabilizing mutations rescue the expression of TCRs destabilized through variable domain mutation.
32393818	2	6	theme	poor	558:561	arg1	stability					573:581	poor intrinsic stability	558:581	poor intrinsic stability	558:581	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	6	7	theme	target	1093:1098	arg1	HLA/peptide					1100:1110	target HLA/peptide	1093:1110	target HLA/peptide on their surfaces	1093:1128	These TCR/CD3 bispecifics can redirect T cells to kill tumor cells with target HLA/peptide on their surfaces in vitro.
32393818	5	8	theme	molecules	952:960	arg1	assembly					916:923	assembly	916:923	assembly	916:923	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	5	8	theme	molecules	952:960	arg1	expression					901:910	expression	901:910	expression	901:910	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	1	9	used	used	143:146	arg2	TCRs					130:133	TCRs	130:133	TCRs	130:133	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	1	9	used	used	143:146	arg2	receptors					119:127	Recombinant T cell receptors	100:127	Recombinant T cell receptors (TCRs)	100:134	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	3	10	theme	TCRs	635:638	arg1	expression					621:630	the expression	617:630	the expression of TCRs destabilized through variable domain mutation	617:684	The stabilizing mutations rescue the expression of TCRs destabilized through variable domain mutation.
32393818	2	11	theme	TCRs	548:551	arg1	assembly					522:529	assembly	522:529	assembly	522:529	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	11	theme	TCRs	548:551	arg1	stability					535:543	stability	535:543	stability	535:543	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	5	12	theme	well-behaved	928:939	arg1	molecules					952:960	well-behaved bispecific molecules	928:960	well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR	928:1018	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	5	13	theme	bispecific	941:950	arg1	molecules					952:960	well-behaved bispecific molecules	928:960	well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR	928:1018	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	6	14	theme	T	1060:1060	arg1	cells					1062:1066	T cells	1060:1066	T cells	1060:1066	These TCR/CD3 bispecifics can redirect T cells to kill tumor cells with target HLA/peptide on their surfaces in vitro.
32393818	4	15	link	N-linked	827:834	arg1	enzymes					850:856	N-linked glycosylation enzymes	827:856	N-linked glycosylation enzymes	827:856	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	4	16	theme	improved	691:698	arg1	stability					700:708	improved stability	691:708	improved stability	691:708	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	2	17	dep	assembly	522:529	arg1	the					518:520	the	518:520	the	518:520	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	18	dep	3-	491:492	arg1	to					494:495	to	494:495	to	494:495	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	5	19	theme	antibody-like	887:899	arg1	expression					901:910	expression	901:910	expression	901:910	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	1	20	theme	naïve	160:164	arg1	cells					168:172	naïve T cells	160:172	naïve T cells	160:172	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	0	21	theme	Computational	0:12	arg1	stabilization					14:26	Computational stabilization	0:26	Computational stabilization of T cell receptors	0:46	Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.
32393818	3	22	theme	domain	670:675	arg1	mutation					677:684	variable domain mutation	661:684	variable domain mutation	661:684	The stabilizing mutations rescue the expression of TCRs destabilized through variable domain mutation.
32393818	4	23	theme	conformational	773:786	arg1	stabilization					788:800	conformational stabilization	773:800	conformational stabilization that restricts access to N-linked glycosylation enzymes	773:856	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	1	24	theme	T	166:166	arg1	cells					168:172	naïve T cells	160:172	naïve T cells	160:172	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	0	25	theme	T	31:31	arg1	receptors					38:46	T cell receptors	31:46	T cell receptors	31:46	Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.
32393818	2	26	theme	α/β	479:481	arg1	TCRs					483:486	four separate α/β TCRs	465:486	four separate α/β TCRs	465:486	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	27	theme	intrinsic	563:571	arg1	stability					573:581	poor intrinsic stability	558:581	poor intrinsic stability	558:581	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	1	28	theme	Recombinant	100:110	arg1	TCRs					130:133	TCRs	130:133	TCRs	130:133	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	1	28	theme	Recombinant	100:110	arg1	receptors					119:127	Recombinant T cell receptors	100:127	Recombinant T cell receptors (TCRs)	100:134	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	6	29	theme	TCR/CD3	1027:1033	arg1	bispecifics					1035:1045	These TCR/CD3 bispecifics	1021:1045	These TCR/CD3 bispecifics	1021:1045	These TCR/CD3 bispecifics can redirect T cells to kill tumor cells with target HLA/peptide on their surfaces in vitro.
32393818	2	30	theme	separate	470:477	arg1	TCRs					483:486	four separate α/β TCRs	465:486	four separate α/β TCRs	465:486	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	1	31	theme	T	112:112	arg1	TCRs					130:133	TCRs	130:133	TCRs	130:133	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	1	31	theme	T	112:112	arg1	receptors					119:127	Recombinant T cell receptors	100:127	Recombinant T cell receptors (TCRs)	100:134	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	6	32	theme	tumor	1076:1080	arg1	cells					1082:1086	tumor cells	1076:1086	tumor cells with target HLA/peptide on their surfaces	1076:1128	These TCR/CD3 bispecifics can redirect T cells to kill tumor cells with target HLA/peptide on their surfaces in vitro.
32393818	0	33	theme	receptors	38:46	arg1	stabilization					14:26	Computational stabilization	0:26	Computational stabilization of T cell receptors	0:46	Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.
32393818	1	34	theme	low	253:255	arg1	stability					257:265	low stability	253:265	low stability	253:265	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	2	35	theme	constant	355:362	arg1	Cα/Cβ					373:377	Cα/Cβ	373:377	Cα/Cβ	373:377	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	35	theme	constant	355:362	arg1	domains					364:370	the TCR constant domains	347:370	the TCR constant domains (Cα/Cβ)	347:378	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	0	36	theme	cell	33:36	arg1	receptors					38:46	T cell receptors	31:46	T cell receptors	31:46	Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.
32393818	4	37	theme	TCRs	729:732	arg1	folding					714:720	folding	714:720	folding	714:720	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	4	37	theme	TCRs	729:732	arg1	stability					700:708	improved stability	691:708	improved stability	691:708	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	2	38	from	mutations	334:342	arg1	Cα/Cβ					373:377	Cα/Cβ	373:377	Cα/Cβ	373:377	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	38	from	mutations	334:342	arg1	domains					364:370	the TCR constant domains	347:370	the TCR constant domains (Cα/Cβ)	347:378	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	2	39	theme	unfolding	398:406	arg1	temperature					408:418	the unfolding temperature	394:418	the unfolding temperature of Cα/Cβ by 20 °C	394:436	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	4	40	theme	glycosylation	836:848	arg1	enzymes					850:856	N-linked glycosylation enzymes	827:856	N-linked glycosylation enzymes	827:856	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	1	41	theme	cell	114:117	arg1	TCRs					130:133	TCRs	130:133	TCRs	130:133	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	1	41	theme	cell	114:117	arg1	receptors					119:127	Recombinant T cell receptors	100:127	Recombinant T cell receptors (TCRs)	100:134	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	1	42	theme	uneven	271:276	arg1	expression					278:287	uneven expression	271:287	uneven expression	271:287	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	4	43	theme	N-linked	827:834	arg1	enzymes					850:856	N-linked glycosylation enzymes	827:856	N-linked glycosylation enzymes	827:856	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	5	44	theme	stabilized	1005:1014	arg1	TCR					1016:1018	the stabilized TCR	1001:1018	the stabilized TCR	1001:1018	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	6	45	from	HLA/peptide	1100:1110	arg1	surfaces					1121:1128	their surfaces	1115:1128	their surfaces	1115:1128	These TCR/CD3 bispecifics can redirect T cells to kill tumor cells with target HLA/peptide on their surfaces in vitro.
32393818	5	46	theme	Cα/Cβ	863:867	arg1	mutations					869:877	The Cα/Cβ mutations	859:877	The Cα/Cβ mutations	859:877	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32393818	1	47	theme	infected	195:202	arg1	cells					217:221	virally infected or cancerous cells	187:221	virally infected or cancerous cells	187:221	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	2	48	theme	TCRs	483:486	arg1	expression					451:460	the expression	447:460	the expression of four separate α/β TCRs by 3- to 10-fold	447:503	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	0	49	with	pairing	55:61	arg1	antibodies					68:77	antibodies	68:77	antibodies to form bispecifics	68:97	Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.
32393818	2	50	with	TCRs	548:551	arg1	stability					573:581	poor intrinsic stability	558:581	poor intrinsic stability	558:581	Here, we use molecular modeling to identify mutations in the TCR constant domains (Cα/Cβ) that increase the unfolding temperature of Cα/Cβ by 20 °C, improve the expression of four separate α/β TCRs by 3- to 10-fold, and improve the assembly and stability of TCRs with poor intrinsic stability.
32393818	4	51	dep	stability	700:708	arg1	The					687:689	The	687:689	The	687:689	The improved stability and folding of the TCRs reduces glycosylation, perhaps through conformational stabilization that restricts access to N-linked glycosylation enzymes.
32393818	1	52	theme	cancerous	207:215	arg1	cells					217:221	virally infected or cancerous cells	187:221	virally infected or cancerous cells	187:221	Recombinant T cell receptors (TCRs) can be used to redirect naïve T cells to eliminate virally infected or cancerous cells; however, they are plagued by low stability and uneven expression.
32393818	5	53	theme	anti-CD3	978:985	arg1	antibody					987:994	an anti-CD3 antibody	975:994	an anti-CD3 antibody	975:994	The Cα/Cβ mutations enables antibody-like expression and assembly of well-behaved bispecific molecules that combine an anti-CD3 antibody with the stabilized TCR.
32187935	16	0	gly	glycosylation	1916:1928	arg2	sites					1930:1934	glycosylation sites	1916:1934	glycosylation sites	1916:1934	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	13	1	theme	G	1523:1523	arg1	protein					1525:1531	the G protein	1519:1531	the G protein	1519:1531	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	8	2	dep	subgroups	864:872	arg1	subgroups					864:872	The two distinct subgroups	847:872	The two distinct subgroups (HRSV-A and HRSV-B)	847:892	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	8	2	dep	subgroups	864:872	arg1	HRSV-B					886:891	HRSV-B	886:891	HRSV-B	886:891	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	8	2	dep	subgroups	864:872	arg1	HRSV-A					875:880	HRSV-A	875:880	HRSV-A	875:880	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	9	3	theme	prevalence	1002:1011	arg1	rate					1013:1016	The HRSV prevalence rate	993:1016	The HRSV prevalence rate	993:1016	The HRSV prevalence rate decreased with age.
32187935	2	4	theme	Nasopharyngeal	278:291	arg1	specimens					299:307	Nasopharyngeal swabs specimens	278:307	Nasopharyngeal swabs specimens	278:307	Methods: Nasopharyngeal swabs specimens were collected from 0-6 year old children hospitalized with acute respiratory infection, then HRSV was tested and genotyped by RT-PCR.
32187935	7	5	theme	HRSV-positive	751:763	arg1	%					777:777	17.06%	772:777	17.06%	772:777	Among the 209 HRSV-positive cases (17.06%), 117 cases (55.98%) were HRSV-A and 92 cases (44.02%) were HRSV-B.
32187935	7	5	theme	HRSV-positive	751:763	arg1	cases					765:769	the 209 HRSV-positive cases	743:769	the 209 HRSV-positive cases (17.06%)	743:778	Among the 209 HRSV-positive cases (17.06%), 117 cases (55.98%) were HRSV-A and 92 cases (44.02%) were HRSV-B.
32187935	13	6	theme	amino	1562:1566	arg1	condon					1554:1559	stop condon	1549:1559	stop condon	1549:1559	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	13	6	theme	amino	1562:1566	arg1	substitutions					1573:1585	amino acid substitutions	1562:1585	amino acid substitutions	1562:1585	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	5	7	theme	specimens	622:630	arg1	total					592:596	A total	590:596	A total of 1 225 nasopharyngeal specimens	590:630	Results: A total of 1 225 nasopharyngeal specimens were collected, including 783 males and 442 females.
32187935	1	8	theme	epidemiological	179:193	arg1	characteristics					195:209	epidemiological characteristics	179:209	epidemiological characteristics	179:209	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	1	9	from	characteristics	195:209	arg1	Guangzhou					258:266	Guangzhou	258:266	Guangzhou	258:266	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	13	10	theme	protein	1525:1531	arg1	HVR2					1511:1514	The HVR2	1507:1514	The HVR2 of the G protein	1507:1531	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	12	11	theme	G	1366:1366	arg1	protein					1368:1374	the G protein	1362:1374	the G protein	1362:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	0	12	from	children	86:93	arg1	Guangzhou					98:106	Guangzhou	98:106	Guangzhou	98:106	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	16	13	theme	greater	1828:1834	arg1	diversification					1836:1850	A greater diversification	1826:1850	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites	1826:1934	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	1	14	theme	respiratory	220:230	arg1	HRSV					249:252	HRSV	249:252	HRSV	249:252	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	1	14	theme	respiratory	220:230	arg1	virus					242:246	human respiratory syncytial virus	214:246	human respiratory syncytial virus (HRSV)	214:253	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	12	15	theme	region	1345:1350	arg1	analysis					1308:1315	Phylogenetic tree analysis	1290:1315	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein	1290:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	4	16	gly	glycosylation	560:572	arg2	sites					574:578	the potential N-linked glycosylation sites	537:578	the potential N-linked glycosylation sites	537:578	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	0	17	from	2013	113:116	arg1	[Epidemiology					0:12	[Epidemiology	0:12	[Epidemiology	0:12	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	0	17	from	2013	113:116	arg1	biology					28:34	molecular biology	18:34	molecular biology	18:34	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	0	17	from	2013	113:116	arg1	virus					61:65	respiratory syncytial virus	39:65	respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017]	39:125	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	11	18	theme	co-infection	1261:1272	arg1	rate					1274:1277	the co-infection rate	1257:1277	the co-infection rate of 15.31%	1257:1287	There were 32 HRSV positive cases co-infected with at least one respiratory virus, with the co-infection rate of 15.31%.
32187935	16	19	theme	protein	1967:1973	arg1	polymorphism					1949:1960	the polymorphism	1945:1960	the polymorphism of G protein	1945:1973	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	12	20	theme	second	1324:1329	arg1	HVR2					1353:1356	HVR2	1353:1356	HVR2	1353:1356	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	12	20	theme	second	1324:1329	arg1	region					1345:1350	the second hypervariable region	1320:1350	the second hypervariable region (HVR2) of the G protein	1320:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	4	21	theme	NetNGlyc	497:504	arg1	server					510:515	NetNGlyc 1.0 server	497:515	NetNGlyc 1.0 server	497:515	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	11	22	theme	%	1287:1287	arg1	rate					1274:1277	the co-infection rate	1257:1277	the co-infection rate of 15.31%	1257:1287	There were 32 HRSV positive cases co-infected with at least one respiratory virus, with the co-infection rate of 15.31%.
32187935	0	23	from	[Epidemiology	0:12	arg1	2013					113:116	2013	113:116	2013	113:116	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	10	24	theme	cases	1162:1166	arg1	cases					1162:1166	the total positive cases	1143:1166	the total positive cases	1143:1166	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	10	24	theme	cases	1162:1166	arg1	%					1138:1138	93.78%	1133:1138	93.78% of the total positive cases	1133:1166	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	13	25	theme	glycosylation	1588:1600	arg1	condon					1554:1559	stop condon	1549:1559	stop condon	1549:1559	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	13	25	theme	glycosylation	1588:1600	arg1	sites					1602:1606	glycosylation sites	1588:1606	glycosylation sites	1588:1606	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	12	26	theme	ON1	1413:1415	arg1	genotypes					1438:1446	ON1 (n=62) and NA1 (n=2) genotypes	1413:1446	ON1 (n=62) and NA1 (n=2) genotypes	1413:1446	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	12	27	theme	tree	1303:1306	arg1	analysis					1308:1315	Phylogenetic tree analysis	1290:1315	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein	1290:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	11	28	theme	positive	1188:1195	arg1	cases					1197:1201	32 HRSV positive cases	1180:1201	32 HRSV positive cases co-infected with at least one respiratory virus	1180:1249	There were 32 HRSV positive cases co-infected with at least one respiratory virus, with the co-infection rate of 15.31%.
32187935	16	29	theme	protective	1983:1992	arg1	antigen					1994:2000	main protective antigen	1978:2000	main protective antigen	1978:2000	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	14	30	from	population	1667:1676	arg1	Guangzhou					1699:1707	Guangzhou	1699:1707	Guangzhou	1699:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	15	31	theme	primary	1737:1743	arg1	genetype					1745:1752	a primary genetype	1735:1752	a primary genetype of the HRSV-A subgroup	1735:1775	ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup.
32187935	10	32	theme	old	1090:1092	arg1	years					1084:1088	2 years old	1082:1092	2 years old	1082:1092	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	4	33	theme	potential	541:549	arg1	sites					574:578	the potential N-linked glycosylation sites	537:578	the potential N-linked glycosylation sites	537:578	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	0	34	theme	molecular	18:26	arg1	biology					28:34	molecular biology	18:34	molecular biology	18:34	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	14	35	theme	risk	1662:1665	arg1	Children					1621:1628	Children	1621:1628	Children under 2 years old	1621:1646	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	35	theme	risk	1662:1665	arg1	Conclusion					1609:1618	Conclusion	1609:1618	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.	1609:1708	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	35	theme	risk	1662:1665	arg1	population					1667:1676	the high risk population	1653:1676	the high risk population of HRSV infection in Guangzhou	1653:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	4	36	theme	glycosylation	560:572	arg1	sites					574:578	the potential N-linked glycosylation sites	537:578	the potential N-linked glycosylation sites	537:578	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	16	37	theme	main	1978:1981	arg1	antigen					1994:2000	main protective antigen	1978:2000	main protective antigen	1978:2000	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	8	38	theme	dominant	913:920	arg1	role					922:925	dominant role	913:925	dominant role	913:925	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	0	39	theme	syncytial	51:59	arg1	virus					61:65	respiratory syncytial virus	39:65	respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017]	39:125	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	16	40	theme	sites	1930:1934	arg1	deletion					1890:1897	deletion	1890:1897	deletion	1890:1897	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	16	40	theme	sites	1930:1934	arg1	substitutions					1866:1878	amino acid substitutions	1855:1878	amino acid substitutions	1855:1878	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	16	40	theme	sites	1930:1934	arg1	insertion					1903:1911	insertion	1903:1911	insertion	1903:1911	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	14	41	theme	old	1644:1646	arg1	years					1638:1642	2 years old	1636:1646	2 years old	1636:1646	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	3	42	theme	MEGA	478:481	arg1	software					487:494	MEGA 6.0 software	478:494	MEGA 6.0 software	478:494	Phylogenetic tree was bulit using MEGA 6.0 software.
32187935	1	43	theme	syncytial	232:240	arg1	HRSV					249:252	HRSV	249:252	HRSV	249:252	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	1	43	theme	syncytial	232:240	arg1	virus					242:246	human respiratory syncytial virus	214:246	human respiratory syncytial virus (HRSV)	214:253	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	8	44	theme	HRSV	936:939	arg1	infection					941:949	HRSV infection	936:949	HRSV infection	936:949	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	16	45	theme	substitutions	1866:1878	arg1	diversification					1836:1850	A greater diversification	1826:1850	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites	1826:1934	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	2	46	theme	respiratory	375:385	arg1	infection					387:395	acute respiratory infection	369:395	acute respiratory infection	369:395	Methods: Nasopharyngeal swabs specimens were collected from 0-6 year old children hospitalized with acute respiratory infection, then HRSV was tested and genotyped by RT-PCR.
32187935	15	47	theme	HRSV-A	1761:1766	arg1	subgroup					1768:1775	the HRSV-A subgroup	1757:1775	the HRSV-A subgroup	1757:1775	ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup.
32187935	16	48	theme	deletion	1890:1897	arg1	diversification					1836:1850	A greater diversification	1826:1850	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites	1826:1934	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	4	49	link	N-linked	551:558	arg1	sites					574:578	the potential N-linked glycosylation sites	537:578	the potential N-linked glycosylation sites	537:578	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	12	50	theme	BA	1487:1488	arg1	n=53					1500:1503	n=53	1500:1503	n=53	1500:1503	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	12	50	theme	BA	1487:1488	arg1	genotype					1490:1497	BA genotype	1487:1497	BA genotype (n=53)	1487:1504	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	11	51	theme	HRSV	1183:1186	arg1	cases					1197:1201	32 HRSV positive cases	1180:1201	32 HRSV positive cases co-infected with at least one respiratory virus	1180:1249	There were 32 HRSV positive cases co-infected with at least one respiratory virus, with the co-infection rate of 15.31%.
32187935	9	52	theme	HRSV	997:1000	arg1	rate					1013:1016	The HRSV prevalence rate	993:1016	The HRSV prevalence rate	993:1016	The HRSV prevalence rate decreased with age.
32187935	2	53	theme	swabs	293:297	arg1	specimens					299:307	Nasopharyngeal swabs specimens	278:307	Nasopharyngeal swabs specimens	278:307	Methods: Nasopharyngeal swabs specimens were collected from 0-6 year old children hospitalized with acute respiratory infection, then HRSV was tested and genotyped by RT-PCR.
32187935	6	54	dep	age	711:713	arg1	P					704:704	P(75)	704:708	P(75)	704:708	The median (P(25), P(75)) age was 8 (3, 24) months.
32187935	6	54	dep	age	711:713	arg1	P					697:697	P(25)	697:701	P(25)	697:701	The median (P(25), P(75)) age was 8 (3, 24) months.
32187935	5	55	theme	nasopharyngeal	607:620	arg1	specimens					622:630	1 225 nasopharyngeal specimens	601:630	1 225 nasopharyngeal specimens	601:630	Results: A total of 1 225 nasopharyngeal specimens were collected, including 783 males and 442 females.
32187935	10	56	theme	positive	1153:1160	arg1	cases					1162:1166	the total positive cases	1143:1166	the total positive cases	1143:1166	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	1	57	theme	genetic	157:163	arg1	variation					165:173	genetic variation	157:173	genetic variation	157:173	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	12	58	theme	HRSV-B	1458:1463	arg1	specimens					1465:1473	all HRSV-B specimens	1454:1473	all HRSV-B specimens	1454:1473	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	4	59	used	used	521:524	arg2	server					510:515	NetNGlyc 1.0 server	497:515	NetNGlyc 1.0 server	497:515	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	12	60	theme	protein	1368:1374	arg1	HVR2					1353:1356	HVR2	1353:1356	HVR2	1353:1356	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	12	60	theme	protein	1368:1374	arg1	region					1345:1350	the second hypervariable region	1320:1350	the second hypervariable region (HVR2) of the G protein	1320:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	15	61	theme	HRSV-B	1809:1814	arg1	subgroup					1816:1823	the HRSV-B subgroup	1805:1823	the HRSV-B subgroup	1805:1823	ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup.
32187935	16	62	theme	amino	1855:1859	arg1	substitutions					1866:1878	amino acid substitutions	1855:1878	amino acid substitutions	1855:1878	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	10	63	theme	HRSV-positive	1042:1054	arg1	rate					1056:1059	The HRSV-positive rate	1038:1059	The HRSV-positive rate among children under 2 years old	1038:1092	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	10	63	theme	HRSV-positive	1042:1054	arg1	%					1103:1103	18.83%	1098:1103	18.83% (196 cases)	1098:1115	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	0	64	theme	hospitalized	73:84	arg1	children					86:93	hospitalized children	73:93	hospitalized children in Guangzhou	73:106	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	12	65	theme	hypervariable	1331:1343	arg1	HVR2					1353:1356	HVR2	1353:1356	HVR2	1353:1356	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	12	65	theme	hypervariable	1331:1343	arg1	region					1345:1350	the second hypervariable region	1320:1350	the second hypervariable region (HVR2) of the G protein	1320:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	0	66	from	biology	28:34	arg1	2013					113:116	2013	113:116	2013	113:116	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	13	67	theme	acid	1568:1571	arg1	condon					1554:1559	stop condon	1549:1559	stop condon	1549:1559	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	13	67	theme	acid	1568:1571	arg1	substitutions					1573:1585	amino acid substitutions	1562:1585	amino acid substitutions	1562:1585	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	16	68	dep	deletion	1890:1897	arg1	some					1885:1888	some	1885:1888	some	1885:1888	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	8	69	theme	distinct	855:862	arg1	subgroups					864:872	The two distinct subgroups	847:872	The two distinct subgroups (HRSV-A and HRSV-B)	847:892	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	8	69	theme	distinct	855:862	arg1	HRSV-B					886:891	HRSV-B	886:891	HRSV-B	886:891	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	8	69	theme	distinct	855:862	arg1	HRSV-A					875:880	HRSV-A	875:880	HRSV-A	875:880	The two distinct subgroups (HRSV-A and HRSV-B) alternately played dominant role to cause HRSV infection and exchange almost once every two years.
32187935	1	70	from	variation	165:173	arg1	Guangzhou					258:266	Guangzhou	258:266	Guangzhou	258:266	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	12	71	theme	Phylogenetic	1290:1301	arg1	analysis					1308:1315	Phylogenetic tree analysis	1290:1315	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein	1290:1374	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	14	72	from	infection	1686:1694	arg1	Guangzhou					1699:1707	Guangzhou	1699:1707	Guangzhou	1699:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	12	73	theme	NA1	1428:1430	arg1	genotypes					1438:1446	ON1 (n=62) and NA1 (n=2) genotypes	1413:1446	ON1 (n=62) and NA1 (n=2) genotypes	1413:1446	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	13	74	theme	stop	1549:1552	arg1	condon					1554:1559	stop condon	1549:1559	stop condon	1549:1559	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	13	74	theme	stop	1549:1552	arg1	substitutions					1573:1585	amino acid substitutions	1562:1585	amino acid substitutions	1562:1585	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	13	74	theme	stop	1549:1552	arg1	sites					1602:1606	glycosylation sites	1588:1606	glycosylation sites	1588:1606	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	16	75	theme	glycosylation	1916:1928	arg1	sites					1930:1934	glycosylation sites	1916:1934	glycosylation sites	1916:1934	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	14	76	from	Guangzhou	1699:1707	arg1	Children					1621:1628	Children	1621:1628	Children under 2 years old	1621:1646	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	76	from	Guangzhou	1699:1707	arg1	Conclusion					1609:1618	Conclusion	1609:1618	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.	1609:1708	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	76	from	Guangzhou	1699:1707	arg1	population					1667:1676	the high risk population	1653:1676	the high risk population of HRSV infection in Guangzhou	1653:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	6	77	theme	median	689:694	arg1	age					711:713	The median (P(25), P(75)) age	685:713	The median (P(25), P(75)) age	685:713	The median (P(25), P(75)) age was 8 (3, 24) months.
32187935	6	77	theme	median	689:694	arg1	months					729:734	8 (3, 24) months	719:734	months	729:734	The median (P(25), P(75)) age was 8 (3, 24) months.
32187935	3	78	theme	Phylogenetic	444:455	arg1	tree					457:460	Phylogenetic tree	444:460	Phylogenetic tree	444:460	Phylogenetic tree was bulit using MEGA 6.0 software.
32187935	13	79	gly	glycosylation	1588:1600	arg2	condon					1554:1559	stop condon	1549:1559	stop condon	1549:1559	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	13	79	gly	glycosylation	1588:1600	arg2	sites					1602:1606	glycosylation sites	1588:1606	glycosylation sites	1588:1606	The HVR2 of the G protein varied in using stop condon, amino acid substitutions, glycosylation sites.
32187935	14	80	theme	HRSV	1681:1684	arg1	infection					1686:1694	HRSV infection	1681:1694	HRSV infection in Guangzhou	1681:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	4	81	theme	N-linked	551:558	arg1	sites					574:578	the potential N-linked glycosylation sites	537:578	the potential N-linked glycosylation sites	537:578	NetNGlyc 1.0 server was used to predict the potential N-linked glycosylation sites.
32187935	11	82	theme	respiratory	1233:1243	arg1	virus					1245:1249	at least one respiratory virus	1220:1249	at least one respiratory virus	1220:1249	There were 32 HRSV positive cases co-infected with at least one respiratory virus, with the co-infection rate of 15.31%.
32187935	15	83	theme	ON1	1710:1712	arg1	genotype					1714:1721	ON1 genotype	1710:1721	ON1 genotype	1710:1721	ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup.
32187935	16	84	theme	G	1965:1965	arg1	protein					1967:1973	G protein	1965:1973	G protein	1965:1973	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	0	85	theme	respiratory	39:49	arg1	virus					61:65	respiratory syncytial virus	39:65	respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017]	39:125	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	1	86	theme	human	214:218	arg1	HRSV					249:252	HRSV	249:252	HRSV	249:252	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	1	86	theme	human	214:218	arg1	virus					242:246	human respiratory syncytial virus	214:246	human respiratory syncytial virus (HRSV)	214:253	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	14	87	theme	high	1657:1660	arg1	Children					1621:1628	Children	1621:1628	Children under 2 years old	1621:1646	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	87	theme	high	1657:1660	arg1	Conclusion					1609:1618	Conclusion	1609:1618	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.	1609:1708	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	87	theme	high	1657:1660	arg1	population					1667:1676	the high risk population	1653:1676	the high risk population of HRSV infection in Guangzhou	1653:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	12	88	theme	HRSV-A	1391:1396	arg1	specimens					1398:1406	the HRSV-A specimens	1387:1406	the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes	1387:1446	Phylogenetic tree analysis of the second hypervariable region (HVR2) of the G protein classified the HRSV-A specimens into ON1 (n=62) and NA1 (n=2) genotypes while all HRSV-B specimens belonged to BA genotype (n=53).
32187935	0	89	theme	virus	61:65	arg1	[Epidemiology					0:12	[Epidemiology	0:12	[Epidemiology	0:12	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	0	89	theme	virus	61:65	arg1	biology					28:34	molecular biology	18:34	molecular biology	18:34	[Epidemiology and molecular biology of respiratory syncytial virus among hospitalized children in Guangzhou from 2013 to 2017].
32187935	15	90	theme	BA	1783:1784	arg1	genotype					1786:1793	BA genotype	1783:1793	BA genotype	1783:1793	ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup.
32187935	1	91	dep	variation	165:173	arg1	the					153:155	the	153:155	the	153:155	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	2	92	theme	old	338:340	arg1	children					342:349	0-6 year old children	329:349	0-6 year old children hospitalized with acute respiratory infection	329:395	Methods: Nasopharyngeal swabs specimens were collected from 0-6 year old children hospitalized with acute respiratory infection, then HRSV was tested and genotyped by RT-PCR.
32187935	15	93	theme	subgroup	1768:1775	arg1	genetype					1745:1752	a primary genetype	1735:1752	a primary genetype of the HRSV-A subgroup	1735:1775	ON1 genotype turned into a primary genetype of the HRSV-A subgroup while BA genotype dominated the HRSV-B subgroup.
32187935	14	94	theme	infection	1686:1694	arg1	Children					1621:1628	Children	1621:1628	Children under 2 years old	1621:1646	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	94	theme	infection	1686:1694	arg1	Conclusion					1609:1618	Conclusion	1609:1618	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.	1609:1708	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	14	94	theme	infection	1686:1694	arg1	population					1667:1676	the high risk population	1653:1676	the high risk population of HRSV infection in Guangzhou	1653:1707	Conclusion: Children under 2 years old were the high risk population of HRSV infection in Guangzhou.
32187935	10	95	theme	total	1147:1151	arg1	cases					1162:1166	the total positive cases	1143:1166	the total positive cases	1143:1166	The HRSV-positive rate among children under 2 years old was 18.83% (196 cases), accounting for 93.78% of the total positive cases.
32187935	1	96	theme	virus	242:246	arg1	variation					165:173	genetic variation	157:173	genetic variation	157:173	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	1	96	theme	virus	242:246	arg1	characteristics					195:209	epidemiological characteristics	179:209	epidemiological characteristics	179:209	Objective: To understand the genetic variation and epidemiological characteristics of human respiratory syncytial virus (HRSV) in Guangzhou.
32187935	16	97	theme	acid	1861:1864	arg1	substitutions					1866:1878	amino acid substitutions	1855:1878	amino acid substitutions	1855:1878	A greater diversification of amino acid substitutions, and some deletion and insertion of glycosylation sites embodied the polymorphism of G protein as main protective antigen.
32187935	2	98	theme	acute	369:373	arg1	infection					387:395	acute respiratory infection	369:395	acute respiratory infection	369:395	Methods: Nasopharyngeal swabs specimens were collected from 0-6 year old children hospitalized with acute respiratory infection, then HRSV was tested and genotyped by RT-PCR.
33592173	6	0	theme	MIC19	1027:1031	arg1	import					1055:1060	MIC19 mitochondrial protein import	1027:1060	MIC19 mitochondrial protein import	1027:1060	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	0	1	theme	cristae	95:101	arg1	formation					103:111	cristae formation	95:111	cristae formation	95:111	A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation.
33592173	6	2	theme	protein	1047:1053	arg1	import					1055:1060	MIC19 mitochondrial protein import	1027:1060	MIC19 mitochondrial protein import	1027:1060	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	5	3	theme	Phosphorylated	747:760	arg1	OGT					762:764	Phosphorylated OGT	747:764	Phosphorylated OGT	747:764	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	7	4	theme	PERK-OGT-TOM70	1112:1125	arg1	axis					1127:1130	a cold-stress inter-organelle PERK-OGT-TOM70 axis	1082:1130	a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation	1082:1232	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	4	5	theme	β-adrenergic	639:650	arg1	stimulation					652:662	β-adrenergic stimulation	639:662	β-adrenergic stimulation	639:662	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	3	6	theme	reconstitution	416:429	arg1	experiments					431:441	in vivo and in vitro reconstitution experiments	395:441	in vivo and in vitro reconstitution experiments	395:441	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	6	7	theme	mitochondrial	1033:1045	arg1	import					1055:1060	MIC19 mitochondrial protein import	1027:1060	MIC19 mitochondrial protein import	1027:1060	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	3	8	theme	critical	585:592	arg1	import					566:571	TOM70-assisted mitochondrial import	537:571	TOM70-assisted mitochondrial import of MIC19	537:580	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	8	theme	critical	585:592	arg1	subunit					594:600	a critical subunit	583:600	a critical subunit of the MICOS complex	583:621	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	2	9	theme	regulatory	346:355	arg1	mechanisms					357:366	upstream regulatory mechanisms	337:366	upstream regulatory mechanisms	337:366	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	1	10	contain	contains	193:200	arg1	organization					175:186	a spatial mitochondrial organization	151:186	a spatial mitochondrial organization that contains functional respiratory complexes	151:233	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	1	10	contain	contains	193:200	arg2	complexes					225:233	functional respiratory complexes	202:233	functional respiratory complexes	202:233	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	3	11	theme	complex	615:621	arg1	import					566:571	TOM70-assisted mitochondrial import	537:571	TOM70-assisted mitochondrial import of MIC19	537:580	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	11	theme	complex	615:621	arg1	subunit					594:600	a critical subunit	583:600	a critical subunit of the MICOS complex	583:621	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	6	12	theme	OGT	921:923	arg1	O-GlcNAcylates					925:938	PERK-activated OGT O-GlcNAcylates	906:938	PERK-activated OGT O-GlcNAcylates	906:938	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	2	13	theme	upstream	337:344	arg1	mechanisms					357:366	upstream regulatory mechanisms	337:366	upstream regulatory mechanisms	337:366	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	8	14	theme	stress	1324:1329	arg1	conditions					1331:1340	stress conditions	1324:1340	stress conditions	1324:1340	These studies have significant implications in cellular bioenergetics and adaptations to stress conditions.
33592173	6	15	theme	PERK-activated	906:919	arg1	O-GlcNAcylates					925:938	PERK-activated OGT O-GlcNAcylates	906:938	PERK-activated OGT O-GlcNAcylates	906:938	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	5	16	gly	glycosylates	766:777	arg1	TOM70					779:783	TOM70	779:783	TOM70	779:783	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	1	17	theme	functional	202:211	arg1	complexes					225:233	functional respiratory complexes	202:233	functional respiratory complexes	202:233	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	3	18	theme	in vitro	407:414	arg1	experiments					431:441	in vivo and in vitro reconstitution experiments	395:441	in vivo and in vitro reconstitution experiments	395:441	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	5	19	dep	glycosylates	766:777	arg1	promoting					848:856	promoting	848:856	promoting cristae formation and respiration	848:890	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	5	19	dep	glycosylates	766:777	arg1	enhancing					795:803	enhancing	795:803	enhancing MIC19 protein import into mitochondria	795:842	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	1	20	theme	respiratory	213:223	arg1	complexes					225:233	functional respiratory complexes	202:233	functional respiratory complexes	202:233	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	0	21	theme	cold-stress-inducible	2:22	arg1	axis					33:36	A cold-stress-inducible PERK/OGT axis	0:36	A cold-stress-inducible PERK/OGT axis	0:36	A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation.
33592173	3	22	theme	kinase	484:489	arg1	PERK					491:494	the endoplasmic reticulum (ER) kinase PERK	453:494	the endoplasmic reticulum (ER) kinase PERK	453:494	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	23	theme	endoplasmic	457:467	arg1	ER					480:481	ER	480:481	ER	480:481	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	23	theme	endoplasmic	457:467	arg1	reticulum					469:477	endoplasmic reticulum	457:477	the endoplasmic reticulum (ER) kinase PERK	453:494	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	4	24	theme	Cold	624:627	arg1	stress					629:634	Cold stress	624:634	Cold stress	624:634	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	6	25	theme	TOM70	985:989	arg1	phosphorylation					997:1011	TOM70 Ser94 phosphorylation	985:1011	TOM70 Ser94 phosphorylation	985:1011	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	7	26	theme	cold-stress	1084:1094	arg1	axis					1127:1130	a cold-stress inter-organelle PERK-OGT-TOM70 axis	1082:1130	a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation	1082:1232	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	7	27	theme	inter-organelle	1096:1110	arg1	axis					1127:1130	a cold-stress inter-organelle PERK-OGT-TOM70 axis	1082:1130	a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation	1082:1232	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	0	28	theme	PERK/OGT	24:31	arg1	axis					33:36	A cold-stress-inducible PERK/OGT axis	0:36	A cold-stress-inducible PERK/OGT axis	0:36	A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation.
33592173	5	29	theme	MIC19	805:809	arg1	import					819:824	MIC19 protein import	805:824	MIC19 protein import into mitochondria	805:842	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	6	30	theme	Ser94	991:995	arg1	phosphorylation					997:1011	TOM70 Ser94 phosphorylation	985:1011	TOM70 Ser94 phosphorylation	985:1011	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	3	31	theme	TOM70-assisted	537:550	arg1	import					566:571	TOM70-assisted mitochondrial import	537:571	TOM70-assisted mitochondrial import of MIC19	537:580	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	31	theme	TOM70-assisted	537:550	arg1	subunit					594:600	a critical subunit	583:600	a critical subunit of the MICOS complex	583:621	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	0	32	theme	TOM70-assisted	47:60	arg1	import					84:89	TOM70-assisted mitochondrial protein import	47:89	TOM70-assisted mitochondrial protein import	47:89	A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation.
33592173	5	33	theme	protein	811:817	arg1	import					819:824	MIC19 protein import	805:824	MIC19 protein import into mitochondria	805:842	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	4	34	link	O-linked	699:706	arg1	OGT					741:743	OGT	741:743	OGT	741:743	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	4	34	link	O-linked	699:706	arg1	transferase					728:738	O-linked N-acetylglucosamine transferase	699:738	O-linked N-acetylglucosamine transferase (OGT)	699:744	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	2	35	theme	complex	288:294	arg1	subunits					296:303	MICOS complex subunits	282:303	MICOS complex subunits	282:303	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	2	36	theme	MICOS	282:286	arg1	subunits					296:303	MICOS complex subunits	282:303	MICOS complex subunits	282:303	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	7	37	theme	protein	1186:1192	arg1	import					1194:1199	mitochondrial protein import	1172:1199	mitochondrial protein import	1172:1199	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	0	38	theme	protein	76:82	arg1	import					84:89	TOM70-assisted mitochondrial protein import	47:89	TOM70-assisted mitochondrial protein import	47:89	A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation.
33592173	7	39	theme	cristae	1216:1222	arg1	formation					1224:1232	subsequent cristae formation	1205:1232	subsequent cristae formation	1205:1232	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	3	40	theme	in vivo	395:401	arg1	experiments					431:441	in vivo and in vitro reconstitution experiments	395:441	in vivo and in vitro reconstitution experiments	395:441	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	1	41	theme	cristae	134:140	arg1	architecture					118:129	The architecture	114:129	The architecture of cristae	114:140	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	0	42	theme	mitochondrial	62:74	arg1	import					84:89	TOM70-assisted mitochondrial protein import	47:89	TOM70-assisted mitochondrial protein import	47:89	A cold-stress-inducible PERK/OGT axis controls TOM70-assisted mitochondrial protein import and cristae formation.
33592173	3	43	theme	MIC19	576:580	arg1	import					566:571	TOM70-assisted mitochondrial import	537:571	TOM70-assisted mitochondrial import of MIC19	537:580	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	43	theme	MIC19	576:580	arg1	subunit					594:600	a critical subunit	583:600	a critical subunit of the MICOS complex	583:621	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	8	44	theme	cellular	1282:1289	arg1	bioenergetics					1291:1303	cellular bioenergetics	1282:1303	cellular bioenergetics	1282:1303	These studies have significant implications in cellular bioenergetics and adaptations to stress conditions.
33592173	7	45	theme	mitochondrial	1172:1184	arg1	import					1194:1199	mitochondrial protein import	1172:1199	mitochondrial protein import	1172:1199	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	3	46	theme	mitochondrial	552:564	arg1	import					566:571	TOM70-assisted mitochondrial import	537:571	TOM70-assisted mitochondrial import of MIC19	537:580	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	46	theme	mitochondrial	552:564	arg1	subunit					594:600	a critical subunit	583:600	a critical subunit of the MICOS complex	583:621	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	8	47	theme	significant	1254:1264	arg1	implications					1266:1277	significant implications	1254:1277	significant implications	1254:1277	These studies have significant implications in cellular bioenergetics and adaptations to stress conditions.
33592173	7	48	theme	subsequent	1205:1214	arg1	formation					1224:1232	subsequent cristae formation	1205:1232	subsequent cristae formation	1205:1232	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	2	49	theme	protein	244:250	arg1	OPA1					273:276	OPA1	273:276	OPA1	273:276	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	2	49	theme	protein	244:250	arg1	components					252:261	Several protein components	236:261	Several protein components including OPA1 and MICOS complex subunits	236:303	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	2	49	theme	protein	244:250	arg1	subunits					296:303	MICOS complex subunits	282:303	MICOS complex subunits	282:303	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	2	50	theme	cristae	314:320	arg1	structure					322:330	cristae structure	314:330	cristae structure	314:330	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	7	51	theme	cell	1147:1150	arg1	respiration					1152:1162	cell respiration	1147:1162	cell respiration	1147:1162	We have identified a cold-stress inter-organelle PERK-OGT-TOM70 axis that increases cell respiration through mitochondrial protein import and subsequent cristae formation.
33592173	1	52	theme	spatial	153:159	arg1	organization					175:186	a spatial mitochondrial organization	151:186	a spatial mitochondrial organization that contains functional respiratory complexes	151:233	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	8	53	contain	have	1249:1252	arg1	studies					1241:1247	These studies	1235:1247	These studies	1235:1247	These studies have significant implications in cellular bioenergetics and adaptations to stress conditions.
33592173	8	53	contain	have	1249:1252	arg2	implications					1266:1277	significant implications	1254:1277	significant implications	1254:1277	These studies have significant implications in cellular bioenergetics and adaptations to stress conditions.
33592173	5	54	theme	cristae	858:864	arg1	formation					866:874	cristae formation	858:874	cristae formation	858:874	Phosphorylated OGT glycosylates TOM70 on Ser94, enhancing MIC19 protein import into mitochondria and promoting cristae formation and respiration.
33592173	2	55	theme	Several	236:242	arg1	OPA1					273:276	OPA1	273:276	OPA1	273:276	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	2	55	theme	Several	236:242	arg1	components					252:261	Several protein components	236:261	Several protein components including OPA1 and MICOS complex subunits	236:303	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	2	55	theme	Several	236:242	arg1	subunits					296:303	MICOS complex subunits	282:303	MICOS complex subunits	282:303	Several protein components including OPA1 and MICOS complex subunits organize cristae structure, but upstream regulatory mechanisms are largely unknown.
33592173	6	56	theme	CK2α	955:958	arg1	activity					960:967	CK2α activity	955:967	CK2α activity	955:967	In addition, PERK-activated OGT O-GlcNAcylates and attenuates CK2α activity, which mediates TOM70 Ser94 phosphorylation and decreases MIC19 mitochondrial protein import.
33592173	1	57	theme	mitochondrial	161:173	arg1	organization					175:186	a spatial mitochondrial organization	151:186	a spatial mitochondrial organization that contains functional respiratory complexes	151:233	The architecture of cristae provides a spatial mitochondrial organization that contains functional respiratory complexes.
33592173	3	58	theme	cristae	505:511	arg1	formation					513:521	cristae formation	505:521	cristae formation	505:521	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	4	59	theme	N-acetylglucosamine	708:726	arg1	OGT					741:743	OGT	741:743	OGT	741:743	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	4	59	theme	N-acetylglucosamine	708:726	arg1	transferase					728:738	O-linked N-acetylglucosamine transferase	699:738	O-linked N-acetylglucosamine transferase (OGT)	699:744	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	3	60	theme	reticulum	469:477	arg1	PERK					491:494	the endoplasmic reticulum (ER) kinase PERK	453:494	the endoplasmic reticulum (ER) kinase PERK	453:494	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	3	61	theme	MICOS	609:613	arg1	complex					615:621	the MICOS complex	605:621	the MICOS complex	605:621	Here, in vivo and in vitro reconstitution experiments show that the endoplasmic reticulum (ER) kinase PERK promotes cristae formation by increasing TOM70-assisted mitochondrial import of MIC19, a critical subunit of the MICOS complex.
33592173	4	62	theme	O-linked	699:706	arg1	OGT					741:743	OGT	741:743	OGT	741:743	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
33592173	4	62	theme	O-linked	699:706	arg1	transferase					728:738	O-linked N-acetylglucosamine transferase	699:738	O-linked N-acetylglucosamine transferase (OGT)	699:744	Cold stress or β-adrenergic stimulation activates PERK that phosphorylates O-linked N-acetylglucosamine transferase (OGT).
32848054	6	0	from	changes	954:960	arg1	pathway					985:991	the STAT3 signaling pathway	965:991	the STAT3 signaling pathway	965:991	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	2	1	theme	differentiated	327:340	arg1	astrocytes					342:351	differentiated astrocytes	327:351	differentiated astrocytes	327:351	However, a coextensive model has been proposed in which division-coupled conversion of NSCs into differentiated astrocytes restrict the stem cell pool with age.
32848054	5	2	from	loss	724:727	arg1	mice					761:764	young mice	755:764	young mice	755:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	3	3	theme	glial	529:533	arg1	switch					540:545	a glial fate switch	527:545	a glial fate switch	527:545	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	4	4	theme	increased	650:658	arg1	gliogenesis					660:670	increased gliogenesis	650:670	increased gliogenesis	650:670	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	7	5	theme	mutagenesis	1157:1167	arg1	approach					1169:1176	an in vitro site-directed mutagenesis approach	1131:1176	an in vitro site-directed mutagenesis approach	1131:1176	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	2	6	theme	coextensive	241:251	arg1	model					253:257	a coextensive model	239:257	a coextensive model	239:257	However, a coextensive model has been proposed in which division-coupled conversion of NSCs into differentiated astrocytes restrict the stem cell pool with age.
32848054	1	7	from	hippocampus	217:227	arg1	determinant					156:166	a major determinant	148:166	a major determinant of age-related regenerative decline in the adult hippocampus	148:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	7	from	hippocampus	217:227	arg1	quiescence					134:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	4	8	from	neurogenesis	633:644	arg1	hippocampus					686:696	the mature hippocampus	675:696	the mature hippocampus	675:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	6	9	theme	glial	1007:1011	arg1	differentiation					1013:1027	glial differentiation	1007:1027	glial differentiation	1007:1027	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	7	10	dep	identify	1182:1189	arg1	using					1040:1044	using	1040:1044	using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus	1040:1114	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	5	11	from	O-GlcNAcylation	736:750	arg1	mice					761:764	young mice	755:764	young mice	755:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	1	12	theme	age-related	171:181	arg1	decline					196:202	age-related regenerative decline	171:202	age-related regenerative decline in the adult hippocampus	171:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	6	13	theme	indicative	993:1002	arg1	changes					954:960	changes	954:960	changes in the STAT3 signaling pathway indicative of glial differentiation	954:1027	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	7	14	theme	spectrometry	1069:1080	arg1	analysis					1082:1089	O-GlcNAc-specific mass spectrometry analysis	1046:1089	O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus	1046:1114	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	1	15	theme	decline	196:202	arg1	determinant					156:166	a major determinant	148:166	a major determinant of age-related regenerative decline in the adult hippocampus	148:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	15	theme	decline	196:202	arg1	quiescence					134:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	6	16	theme	signaling	975:983	arg1	pathway					985:991	the STAT3 signaling pathway	965:991	the STAT3 signaling pathway	965:991	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	8	17	theme	key	1342:1344	arg1	regulator					1356:1364	a key molecular regulator	1340:1364	a key molecular regulator of regenerative decline underlying an age-related NSC fate switch	1340:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	8	17	theme	key	1342:1344	arg1	modification					1313:1324	the posttranslational modification	1291:1324	the posttranslational modification	1291:1324	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	7	18	theme	hippocampus	1104:1114	arg1	analysis					1082:1089	O-GlcNAc-specific mass spectrometry analysis	1046:1089	O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus	1046:1114	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	19	theme	O-GlcNAc-specific	1046:1062	arg1	analysis					1082:1089	O-GlcNAc-specific mass spectrometry analysis	1046:1089	O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus	1046:1114	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	1	20	theme	neural	111:116	arg1	NSC					129:131	NSC	129:131	NSC	129:131	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	20	theme	neural	111:116	arg1	cell					123:126	neural stem cell	111:126	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	21	theme	cell	123:126	arg1	determinant					156:166	a major determinant	148:166	a major determinant of age-related regenerative decline in the adult hippocampus	148:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	21	theme	cell	123:126	arg1	quiescence					134:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	8	22	theme	regenerative	1369:1380	arg1	decline					1382:1388	regenerative decline	1369:1388	regenerative decline underlying an age-related NSC fate switch	1369:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	0	23	theme	fate	63:66	arg1	switch					68:73	a glial fate switch	55:73	a glial fate switch	55:73	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	8	24	theme	age-related	1404:1414	arg1	switch					1425:1430	an age-related NSC fate switch	1401:1430	an age-related NSC fate switch	1401:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	5	25	theme	NSC	732:734	arg1	O-GlcNAcylation					736:750	NSC O-GlcNAcylation	732:750	NSC O-GlcNAcylation in young mice	732:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	7	26	from	Threonine	1217:1225	arg1	loss					1191:1194	loss	1191:1194	loss of STAT3 O-GlcNAc at Threonine 717	1191:1229	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	26	from	Threonine	1217:1225	arg1	O-GlcNAc					1205:1212	STAT3 O-GlcNAc	1199:1212	STAT3 O-GlcNAc at Threonine 717	1199:1229	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	26	from	Threonine	1217:1225	arg1	driver					1236:1241	a driver	1234:1241	a driver of astrocyte differentiation	1234:1270	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	8	27	theme	fate	1420:1423	arg1	switch					1425:1430	an age-related NSC fate switch	1401:1430	an age-related NSC fate switch	1401:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	3	28	theme	age-related	411:421	arg1	loss					423:426	age-related loss	411:426	age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs	411:516	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	7	29	theme	STAT3	1199:1203	arg1	O-GlcNAc					1205:1212	STAT3 O-GlcNAc	1199:1212	STAT3 O-GlcNAc at Threonine 717	1199:1229	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	0	30	theme	glial	57:61	arg1	switch					68:73	a glial fate switch	55:73	a glial fate switch	55:73	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	2	31	theme	cell	371:374	arg1	pool					376:379	the stem cell pool	362:379	the stem cell pool	362:379	However, a coextensive model has been proposed in which division-coupled conversion of NSCs into differentiated astrocytes restrict the stem cell pool with age.
32848054	0	32	theme	Age-related	0:10	arg1	loss					12:15	Age-related loss	0:15	Age-related loss of neural stem cell O-GlcNAc	0:44	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	3	33	theme	posttranslational	435:451	arg1	β-N-acetylglucosamine					476:496	O-linked β-N-acetylglucosamine	467:496	O-linked β-N-acetylglucosamine (O-GlcNAc)	467:507	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	3	33	theme	posttranslational	435:451	arg1	modification					453:464	the posttranslational modification	431:464	the posttranslational modification	431:464	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	5	34	theme	associated	837:846	arg1	function					858:865	associated cognitive function	837:865	associated cognitive function	837:865	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	6	35	theme	NSCs	900:903	arg1	RNA-sequencing					874:887	RNA-sequencing	874:887	RNA-sequencing of primary NSCs following decreased O-GlcNAcylation	874:939	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	4	36	theme	mature	679:684	arg1	hippocampus					686:696	the mature hippocampus	675:696	the mature hippocampus	675:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	0	37	theme	stem	27:30	arg1	O-GlcNAc					37:44	neural stem cell O-GlcNAc	20:44	neural stem cell O-GlcNAc	20:44	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	7	38	theme	O-GlcNAc	1205:1212	arg1	loss					1191:1194	loss	1191:1194	loss of STAT3 O-GlcNAc at Threonine 717	1191:1229	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	38	theme	O-GlcNAc	1205:1212	arg1	driver					1236:1241	a driver	1234:1241	a driver of astrocyte differentiation	1234:1270	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	0	39	theme	O-GlcNAc	37:44	arg1	loss					12:15	Age-related loss	0:15	Age-related loss of neural stem cell O-GlcNAc	0:44	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	4	40	with	coincident	607:616	arg1	neurogenesis					633:644	decreased neurogenesis	623:644	decreased neurogenesis	623:644	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	4	40	with	coincident	607:616	arg1	gliogenesis					660:670	increased gliogenesis	650:670	increased gliogenesis	650:670	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	1	41	theme	adult	211:215	arg1	hippocampus					217:227	the adult hippocampus	207:227	the adult hippocampus	207:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	4	42	theme	O-GlcNAc	591:598	arg1	levels					600:605	NSC O-GlcNAc levels	587:605	NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus	587:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	3	43	from	loss	423:426	arg1	NSCs					513:516	NSCs	513:516	NSCs	513:516	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	4	44	theme	age-dependent	561:573	arg1	decrease					575:582	an age-dependent decrease	558:582	an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus	558:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	7	45	theme	site-directed	1143:1155	arg1	approach					1169:1176	an in vitro site-directed mutagenesis approach	1131:1176	an in vitro site-directed mutagenesis approach	1131:1176	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	4	46	from	gliogenesis	660:670	arg1	hippocampus					686:696	the mature hippocampus	675:696	the mature hippocampus	675:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	6	47	theme	decreased	915:923	arg1	O-GlcNAcylation					925:939	decreased O-GlcNAcylation	915:939	decreased O-GlcNAcylation	915:939	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	7	48	theme	in	1134:1135	arg1	approach					1169:1176	an in vitro site-directed mutagenesis approach	1131:1176	an in vitro site-directed mutagenesis approach	1131:1176	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	2	49	theme	division-coupled	286:301	arg1	conversion					303:312	division-coupled conversion	286:312	division-coupled conversion of NSCs into differentiated astrocytes	286:351	However, a coextensive model has been proposed in which division-coupled conversion of NSCs into differentiated astrocytes restrict the stem cell pool with age.
32848054	1	50	theme	major	150:154	arg1	determinant					156:166	a major determinant	148:166	a major determinant of age-related regenerative decline in the adult hippocampus	148:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	50	theme	major	150:154	arg1	quiescence					134:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	6	51	theme	differentiation	1013:1027	arg1	indicative					993:1002	indicative	993:1002	indicative	993:1002	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	8	52	theme	posttranslational	1295:1311	arg1	regulator					1356:1364	a key molecular regulator	1340:1364	a key molecular regulator of regenerative decline underlying an age-related NSC fate switch	1340:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	8	52	theme	posttranslational	1295:1311	arg1	O-GlcNAc					1327:1334	O-GlcNAc	1327:1334	O-GlcNAc	1327:1334	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	8	52	theme	posttranslational	1295:1311	arg1	modification					1313:1324	the posttranslational modification	1291:1324	the posttranslational modification	1291:1324	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	3	53	theme	fate	535:538	arg1	switch					540:545	a glial fate switch	527:545	a glial fate switch	527:545	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	5	54	theme	cognitive	848:856	arg1	function					858:865	associated cognitive function	837:865	associated cognitive function	837:865	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	4	55	theme	coincident	607:616	arg1	levels					600:605	NSC O-GlcNAc levels	587:605	NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus	587:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	7	56	dep	in	1134:1135	arg1	vitro					1137:1141	vitro	1137:1141	vitro	1137:1141	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	5	57	theme	age-related	712:722	arg1	loss					724:727	an age-related loss	709:727	an age-related loss of NSC O-GlcNAcylation in young mice	709:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	1	58	theme	regenerative	183:194	arg1	decline					196:202	age-related regenerative decline	171:202	age-related regenerative decline in the adult hippocampus	171:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	4	59	theme	decreased	623:631	arg1	neurogenesis					633:644	decreased neurogenesis	623:644	decreased neurogenesis	623:644	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	4	60	from	decrease	575:582	arg1	levels					600:605	NSC O-GlcNAc levels	587:605	NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus	587:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	7	61	theme	aging	1098:1102	arg1	hippocampus					1104:1114	the aging hippocampus	1094:1114	the aging hippocampus	1094:1114	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	1	62	from	decline	196:202	arg1	hippocampus					217:227	the adult hippocampus	207:227	the adult hippocampus	207:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	63	theme	Increased	101:109	arg1	determinant					156:166	a major determinant	148:166	a major determinant of age-related regenerative decline in the adult hippocampus	148:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	63	theme	Increased	101:109	arg1	quiescence					134:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	6	64	theme	STAT3	969:973	arg1	pathway					985:991	the STAT3 signaling pathway	965:991	the STAT3 signaling pathway	965:991	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	3	65	link	O-linked	467:474	arg1	β-N-acetylglucosamine					476:496	O-linked β-N-acetylglucosamine	467:496	O-linked β-N-acetylglucosamine (O-GlcNAc)	467:507	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	3	65	link	O-linked	467:474	arg1	O-GlcNAc					499:506	O-GlcNAc	499:506	O-GlcNAc	499:506	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	3	65	link	O-linked	467:474	arg1	modification					453:464	the posttranslational modification	431:464	the posttranslational modification	431:464	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	7	66	theme	mass	1064:1067	arg1	analysis					1082:1089	O-GlcNAc-specific mass spectrometry analysis	1046:1089	O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus	1046:1114	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	1	67	theme	stem	118:121	arg1	NSC					129:131	NSC	129:131	NSC	129:131	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	1	67	theme	stem	118:121	arg1	cell					123:126	neural stem cell	111:126	Increased neural stem cell (NSC) quiescence	101:143	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	8	68	theme	molecular	1346:1354	arg1	regulator					1356:1364	a key molecular regulator	1340:1364	a key molecular regulator of regenerative decline underlying an age-related NSC fate switch	1340:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	8	68	theme	molecular	1346:1354	arg1	modification					1313:1324	the posttranslational modification	1291:1324	the posttranslational modification	1291:1324	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	5	69	theme	young	755:759	arg1	mice					761:764	young mice	755:764	young mice	755:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	5	70	from	mice	761:764	arg1	loss					724:727	an age-related loss	709:727	an age-related loss of NSC O-GlcNAcylation in young mice	709:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	1	71	from	determinant	156:166	arg1	hippocampus					217:227	the adult hippocampus	207:227	the adult hippocampus	207:227	Increased neural stem cell (NSC) quiescence is a major determinant of age-related regenerative decline in the adult hippocampus.
32848054	7	72	from	loss	1191:1194	arg1	Threonine					1217:1225	Threonine 717	1217:1229	Threonine 717	1217:1229	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	73	theme	astrocyte	1246:1254	arg1	differentiation					1256:1270	astrocyte differentiation	1246:1270	astrocyte differentiation	1246:1270	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	74	theme	differentiation	1256:1270	arg1	loss					1191:1194	loss	1191:1194	loss of STAT3 O-GlcNAc at Threonine 717	1191:1229	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	7	74	theme	differentiation	1256:1270	arg1	driver					1236:1241	a driver	1234:1241	a driver of astrocyte differentiation	1234:1270	Moreover, using O-GlcNAc-specific mass spectrometry analysis of the aging hippocampus, together with an in vitro site-directed mutagenesis approach, we identify loss of STAT3 O-GlcNAc at Threonine 717 as a driver of astrocyte differentiation.
32848054	8	75	theme	decline	1382:1388	arg1	regulator					1356:1364	a key molecular regulator	1340:1364	a key molecular regulator of regenerative decline underlying an age-related NSC fate switch	1340:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	8	75	theme	decline	1382:1388	arg1	modification					1313:1324	the posttranslational modification	1291:1324	the posttranslational modification	1291:1324	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	0	76	theme	STAT3	83:87	arg1	activation					89:98	STAT3 activation	83:98	STAT3 activation	83:98	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	5	77	theme	O-GlcNAcylation	736:750	arg1	loss					724:727	an age-related loss	709:727	an age-related loss of NSC O-GlcNAcylation in young mice	709:764	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	8	78	theme	NSC	1416:1418	arg1	switch					1425:1430	an age-related NSC fate switch	1401:1430	an age-related NSC fate switch	1401:1430	Our data identify the posttranslational modification, O-GlcNAc, as a key molecular regulator of regenerative decline underlying an age-related NSC fate switch.
32848054	2	79	theme	stem	366:369	arg1	pool					376:379	the stem cell pool	362:379	the stem cell pool	362:379	However, a coextensive model has been proposed in which division-coupled conversion of NSCs into differentiated astrocytes restrict the stem cell pool with age.
32848054	0	80	theme	neural	20:25	arg1	O-GlcNAc					37:44	neural stem cell O-GlcNAc	20:44	neural stem cell O-GlcNAc	20:44	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	3	81	theme	modification	453:464	arg1	loss					423:426	age-related loss	411:426	age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs	411:516	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	0	82	theme	cell	32:35	arg1	O-GlcNAc					37:44	neural stem cell O-GlcNAc	20:44	neural stem cell O-GlcNAc	20:44	Age-related loss of neural stem cell O-GlcNAc promotes a glial fate switch through STAT3 activation.
32848054	6	83	theme	primary	892:898	arg1	NSCs					900:903	primary NSCs	892:903	primary NSCs	892:903	Using RNA-sequencing of primary NSCs following decreased O-GlcNAcylation, we detected changes in the STAT3 signaling pathway indicative of glial differentiation.
32848054	5	84	theme	astrocyte	798:806	arg1	differentiation					808:822	astrocyte differentiation	798:822	astrocyte differentiation	798:822	Mimicking an age-related loss of NSC O-GlcNAcylation in young mice reduces neurogenesis, increases astrocyte differentiation, and impairs associated cognitive function.
32848054	2	85	theme	NSCs	317:320	arg1	conversion					303:312	division-coupled conversion	286:312	division-coupled conversion of NSCs into differentiated astrocytes	286:351	However, a coextensive model has been proposed in which division-coupled conversion of NSCs into differentiated astrocytes restrict the stem cell pool with age.
32848054	4	86	theme	NSC	587:589	arg1	levels					600:605	NSC O-GlcNAc levels	587:605	NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus	587:696	We detect an age-dependent decrease in NSC O-GlcNAc levels coincident with decreased neurogenesis and increased gliogenesis in the mature hippocampus.
32848054	3	87	theme	O-linked	467:474	arg1	β-N-acetylglucosamine					476:496	O-linked β-N-acetylglucosamine	467:496	O-linked β-N-acetylglucosamine (O-GlcNAc)	467:507	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	3	87	theme	O-linked	467:474	arg1	O-GlcNAc					499:506	O-GlcNAc	499:506	O-GlcNAc	499:506	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
32848054	3	87	theme	O-linked	467:474	arg1	modification					453:464	the posttranslational modification	431:464	the posttranslational modification	431:464	Here we report that age-related loss of the posttranslational modification, O-linked β-N-acetylglucosamine (O-GlcNAc), in NSCs promotes a glial fate switch.
35309180	5	0	theme	independent	591:601	arg1	lineage					603:609	an independent lineage	588:609	an independent lineage without an obvious sister group within the Trebouxiophyceae	588:669	The alga turned out to belong to an independent lineage without an obvious sister group within the Trebouxiophyceae.
35309180	16	1	theme	subsequent	1769:1778	arg1	exposure					1787:1794	a subsequent stress exposure	1767:1794	a subsequent stress exposure	1767:1794	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	11	2	theme	mg	1177:1178	arg1	day-1					1184:1188	24 mg L-1 day-1	1174:1188	24 mg L-1 day-1	1174:1188	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	10	3	dep	day-1	1130:1134	arg1	mg					1123:1124	mg	1123:1124	mg	1123:1124	The biomass yield reached up to 53.5 mg L-1 day-1.
35309180	1	4	theme	unsaturated	139:149	arg1	acids					157:161	unsaturated fatty acids	139:161	unsaturated fatty acids	139:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	9	5	dep	pH-regulated	927:938	arg1	episodic					941:948	episodic	941:948	episodic	941:948	Growth was optimized by pH-regulated, episodic CO2 supplement during the logarithmic growth-phase, and half of the biomass was thereafter exposed to nitrogen and phosphate depletion.
35309180	4	6	theme	rDNA	474:477	arg1	analyses					458:465	Phylogenetic analyses	445:465	Phylogenetic analyses of 18S rDNA and rbcL markers	445:494	Phylogenetic analyses of 18S rDNA and rbcL markers placed the strain into the Trebouxiophyceae (Chlorophyta).
35309180	16	7	theme	curvula	1653:1659	arg1	advantage					1637:1645	The advantage	1633:1645	The advantage of T. curvula	1633:1659	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	16	7	theme	curvula	1653:1659	arg1	robustness					1668:1677	its robustness	1664:1677	its robustness	1664:1677	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	1	8	dep	Iceland	107:113	arg1	exhibits					115:122	exhibits	115:122	exhibits high levels of unsaturated fatty acids	115:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	11	9	theme	Fatty	1137:1141	arg1	FA					1149:1150	FA	1149:1150	FA	1149:1150	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	11	9	theme	Fatty	1137:1141	arg1	acid					1143:1146	Fatty acid	1137:1146	Fatty acid (FA) production	1137:1162	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	12	10	theme	log	1251:1253	arg1	phase					1255:1259	the log phase	1247:1259	the log phase	1247:1259	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	12	11	theme	mass	1287:1290	arg1	%					1278:1278	approximately 45%	1262:1278	approximately 45% of dry mass	1262:1290	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	12	11	theme	mass	1287:1290	arg1	mass					1287:1290	dry mass	1283:1290	dry mass	1283:1290	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	9	12	theme	biomass	1018:1024	arg1	half					1006:1009	half	1006:1009	half of the biomass	1006:1024	Growth was optimized by pH-regulated, episodic CO2 supplement during the logarithmic growth-phase, and half of the biomass was thereafter exposed to nitrogen and phosphate depletion.
35309180	12	13	theme	dry	1283:1285	arg1	mass					1287:1290	dry mass	1283:1290	dry mass	1283:1290	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	12	14	theme	eicosapentaenoic	1315:1330	arg1	acid					1332:1335	eicosapentaenoic acid	1315:1335	eicosapentaenoic acid	1315:1335	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	6	15	theme	new	748:750	arg1	curvula					784:790	curvula	784:790	curvula	784:790	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	6	15	theme	new	748:750	arg1	genus					752:756	a new genus	746:756	a new genus	746:756	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	6	15	theme	new	748:750	arg1	strain					722:727	the strain	718:727	the strain	718:727	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	1	16	theme	fatty	151:155	arg1	acids					157:161	unsaturated fatty acids	139:161	unsaturated fatty acids	139:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	3	17	dep	curved	368:373	arg1	crescent					376:383	crescent	376:383	crescent	376:383	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	1	18	from	Iceland	107:113	arg1	microalga					92:100	a semi-terrestrial microalga	73:100	a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids	73:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	1	18	from	Iceland	107:113	arg1	nov					35:37	nov	35:37	nov	35:37	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	2	19	theme	SAG	230:232	arg1	strain					222:227	the strain	218:227	the strain (SAG 2627)	218:238	A terrestrial green alga was isolated at Iceland, and the strain (SAG 2627) was described for its morphology and phylogenetic position and tested for biotechnological capabilities.
35309180	2	19	theme	SAG	230:232	arg1	2627					234:237	SAG 2627	230:237	SAG 2627	230:237	A terrestrial green alga was isolated at Iceland, and the strain (SAG 2627) was described for its morphology and phylogenetic position and tested for biotechnological capabilities.
35309180	1	20	theme	acids	157:161	arg1	levels					129:134	high levels	124:134	high levels of unsaturated fatty acids	124:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	4	21	theme	Phylogenetic	445:456	arg1	analyses					458:465	Phylogenetic analyses	445:465	Phylogenetic analyses of 18S rDNA and rbcL markers	445:494	Phylogenetic analyses of 18S rDNA and rbcL markers placed the strain into the Trebouxiophyceae (Chlorophyta).
35309180	15	22	theme	new	1550:1552	arg1	microalgae					1554:1563	new microalgae	1550:1563	new microalgae	1550:1563	The study demonstrated that new microalgae can be found at Iceland, potentially suitable for applied purposes.
35309180	11	23	theme	acid	1143:1146	arg1	production					1153:1162	Fatty acid (FA) production	1137:1162	Fatty acid (FA) production	1137:1162	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	11	24	theme	L-1	1180:1182	arg1	day-1					1184:1188	24 mg L-1 day-1	1174:1188	24 mg L-1 day-1	1174:1188	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	16	25	theme	log	1749:1751	arg1	phase					1753:1757	log phase	1749:1757	log phase	1749:1757	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	10	26	theme	biomass	1090:1096	arg1	yield					1098:1102	The biomass yield	1086:1102	The biomass yield	1086:1102	The biomass yield reached up to 53.5 mg L-1 day-1.
35309180	8	27	theme	column	834:839	arg1	reactors					841:848	column reactors	834:848	column reactors	834:848	Biomass was generated in column reactors and subsequently screened for promising metabolites.
35309180	9	28	theme	pH-regulated	927:938	arg1	supplement					954:963	pH-regulated, episodic CO2 supplement	927:963	pH-regulated, episodic CO2 supplement	927:963	Growth was optimized by pH-regulated, episodic CO2 supplement during the logarithmic growth-phase, and half of the biomass was thereafter exposed to nitrogen and phosphate depletion.
35309180	16	29	theme	significant	1688:1698	arg1	lipids					1711:1716	lipids	1711:1716	lipids	1711:1716	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	16	29	theme	significant	1688:1698	arg1	amounts					1700:1706	significant amounts	1688:1706	significant amounts of lipids	1688:1716	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	3	30	contain	had	351:353	arg2	shape					385:389	a distinctly curved, crescent shape	355:389	a distinctly curved, crescent shape	355:389	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	3	30	contain	had	351:353	arg1	Cells					345:349	Cells	345:349	Cells	345:349	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	16	31	theme	stress	1780:1785	arg1	exposure					1787:1794	a subsequent stress exposure	1767:1794	a subsequent stress exposure	1767:1794	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	3	32	theme	single	416:421	arg1	chloroplast					432:442	a single parietal chloroplast	414:442	a single parietal chloroplast	414:442	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	14	33	link	N-linked	1439:1446	arg1	glycans					1448:1454	The N-linked glycans	1435:1454	The N-linked glycans of glycoproteins	1435:1471	The N-linked glycans of glycoproteins were assessed to reveal chemotaxonomic patterns.
35309180	1	34	theme	semi-terrestrial	75:90	arg1	microalga					92:100	a semi-terrestrial microalga	73:100	a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids	73:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	1	34	theme	semi-terrestrial	75:90	arg1	nov					35:37	nov	35:37	nov	35:37	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	14	35	theme	chemotaxonomic	1497:1510	arg1	patterns					1512:1519	chemotaxonomic patterns	1497:1519	chemotaxonomic patterns	1497:1519	The N-linked glycans of glycoproteins were assessed to reveal chemotaxonomic patterns.
35309180	3	36	theme	parietal	423:430	arg1	chloroplast					432:442	a single parietal chloroplast	414:442	a single parietal chloroplast	414:442	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	11	37	dep	83	1200:1201	arg1	to					1197:1198	to	1197:1198	to	1197:1198	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	6	38	dep	curvula	784:790	arg1	sp					800:801	et sp	797:801	Thorsmoerkia curvula gen. et sp	771:801	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	15	39	located	found	1572:1576	arg1	Iceland					1581:1587	Iceland	1581:1587	Iceland	1581:1587	The study demonstrated that new microalgae can be found at Iceland, potentially suitable for applied purposes.
35309180	15	39	located	found	1572:1576	arg2	microalgae					1554:1563	new microalgae	1550:1563	new microalgae	1550:1563	The study demonstrated that new microalgae can be found at Iceland, potentially suitable for applied purposes.
35309180	13	40	dep	2.94	1374:1377	arg1	to					1371:1372	to	1371:1372	to	1371:1372	Carotenoid production reached up to 2.94 mg L-1 day-1 but it was halted during the stress phase.
35309180	9	41	theme	phosphate	1065:1073	arg1	depletion					1075:1083	phosphate depletion	1065:1083	phosphate depletion	1065:1083	Growth was optimized by pH-regulated, episodic CO2 supplement during the logarithmic growth-phase, and half of the biomass was thereafter exposed to nitrogen and phosphate depletion.
35309180	3	42	theme	conical	396:402	arg1	poles					404:408	conical poles	396:408	conical poles	396:408	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	4	43	theme	markers	488:494	arg1	analyses					458:465	Phylogenetic analyses	445:465	Phylogenetic analyses of 18S rDNA and rbcL markers	445:494	Phylogenetic analyses of 18S rDNA and rbcL markers placed the strain into the Trebouxiophyceae (Chlorophyta).
35309180	9	44	theme	CO2	950:952	arg1	supplement					954:963	pH-regulated, episodic CO2 supplement	927:963	pH-regulated, episodic CO2 supplement	927:963	Growth was optimized by pH-regulated, episodic CO2 supplement during the logarithmic growth-phase, and half of the biomass was thereafter exposed to nitrogen and phosphate depletion.
35309180	14	45	gly	glycoproteins	1459:1471	arg1	glycoproteins					1459:1471	glycoproteins	1459:1471	glycoproteins	1459:1471	The N-linked glycans of glycoproteins were assessed to reveal chemotaxonomic patterns.
35309180	11	46	theme	FAs	1211:1213	arg1	%					1202:1202	up to 83%	1194:1202	up to 83% of all FAs	1194:1213	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	11	46	theme	FAs	1211:1213	arg1	FAs					1211:1213	all FAs	1207:1213	all FAs	1207:1213	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	14	47	theme	glycoproteins	1459:1471	arg1	glycans					1448:1454	The N-linked glycans	1435:1454	The N-linked glycans of glycoproteins	1435:1471	The N-linked glycans of glycoproteins were assessed to reveal chemotaxonomic patterns.
35309180	13	48	dep	day-1	1386:1390	arg1	mg					1379:1380	mg	1379:1380	mg	1379:1380	Carotenoid production reached up to 2.94 mg L-1 day-1 but it was halted during the stress phase.
35309180	16	49	theme	lipids	1711:1716	arg1	lipids					1711:1716	lipids	1711:1716	lipids	1711:1716	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	16	49	theme	lipids	1711:1716	arg1	amounts					1700:1706	significant amounts	1688:1706	significant amounts of lipids	1688:1716	The advantage of T. curvula is its robustness and that significant amounts of lipids are already accumulated during log phase, making a subsequent stress exposure dispensable.
35309180	4	50	theme	rbcL	483:486	arg1	markers					488:494	rbcL markers	483:494	rbcL markers	483:494	Phylogenetic analyses of 18S rDNA and rbcL markers placed the strain into the Trebouxiophyceae (Chlorophyta).
35309180	5	51	theme	obvious	622:628	arg1	group					637:641	an obvious sister group	619:641	an obvious sister group within the Trebouxiophyceae	619:669	The alga turned out to belong to an independent lineage without an obvious sister group within the Trebouxiophyceae.
35309180	6	52	theme	et	797:798	arg1	sp					800:801	et sp	797:801	Thorsmoerkia curvula gen. et sp	771:801	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	13	53	theme	Carotenoid	1338:1347	arg1	production					1349:1358	Carotenoid production	1338:1358	Carotenoid production	1338:1358	Carotenoid production reached up to 2.94 mg L-1 day-1 but it was halted during the stress phase.
35309180	3	54	theme	curved	368:373	arg1	shape					385:389	a distinctly curved, crescent shape	355:389	a distinctly curved, crescent shape	355:389	Cells had a distinctly curved, crescent shape with conical poles and a single parietal chloroplast.
35309180	5	55	theme	sister	630:635	arg1	group					637:641	an obvious sister group	619:641	an obvious sister group within the Trebouxiophyceae	619:669	The alga turned out to belong to an independent lineage without an obvious sister group within the Trebouxiophyceae.
35309180	10	56	dep	mg	1123:1124	arg1	53.5					1118:1121	53.5	1118:1121	53.5	1118:1121	The biomass yield reached up to 53.5 mg L-1 day-1.
35309180	8	57	theme	promising	880:888	arg1	metabolites					890:900	promising metabolites	880:900	promising metabolites	880:900	Biomass was generated in column reactors and subsequently screened for promising metabolites.
35309180	15	58	theme	applied	1615:1621	arg1	purposes					1623:1630	applied purposes	1615:1630	applied purposes	1615:1630	The study demonstrated that new microalgae can be found at Iceland, potentially suitable for applied purposes.
35309180	13	59	theme	stress	1421:1426	arg1	phase					1428:1432	the stress phase	1417:1432	the stress phase	1417:1432	Carotenoid production reached up to 2.94 mg L-1 day-1 but it was halted during the stress phase.
35309180	10	60	dep	53.5	1118:1121	arg1	to					1115:1116	to	1115:1116	to	1115:1116	The biomass yield reached up to 53.5 mg L-1 day-1.
35309180	13	61	theme	L-1	1382:1384	arg1	day-1					1386:1390	up to 2.94 mg L-1 day-1	1368:1390	up to 2.94 mg L-1 day-1	1368:1390	Carotenoid production reached up to 2.94 mg L-1 day-1 but it was halted during the stress phase.
35309180	13	62	dep	mg	1379:1380	arg1	2.94					1374:1377	2.94	1374:1377	2.94	1374:1377	Carotenoid production reached up to 2.94 mg L-1 day-1 but it was halted during the stress phase.
35309180	2	63	theme	phylogenetic	277:288	arg1	position					290:297	phylogenetic position	277:297	phylogenetic position	277:297	A terrestrial green alga was isolated at Iceland, and the strain (SAG 2627) was described for its morphology and phylogenetic position and tested for biotechnological capabilities.
35309180	9	64	theme	logarithmic	976:986	arg1	growth-phase					988:999	the logarithmic growth-phase	972:999	the logarithmic growth-phase	972:999	Growth was optimized by pH-regulated, episodic CO2 supplement during the logarithmic growth-phase, and half of the biomass was thereafter exposed to nitrogen and phosphate depletion.
35309180	12	65	theme	phase	1255:1259	arg1	end					1240:1242	the end	1236:1242	the end of the log phase	1236:1259	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	11	66	theme	24	1174:1175	arg1	mg					1177:1178	mg	1177:1178	mg	1177:1178	Fatty acid (FA) production peaked at 24 mg L-1 day-1 and up to 83% of all FAs were unsaturated.
35309180	2	67	theme	green	178:182	arg1	alga					184:187	A terrestrial green alga	164:187	A terrestrial green alga	164:187	A terrestrial green alga was isolated at Iceland, and the strain (SAG 2627) was described for its morphology and phylogenetic position and tested for biotechnological capabilities.
35309180	6	68	theme	phylogenetic	699:710	arg1	data					712:715	morphological and phylogenetic data	681:715	morphological and phylogenetic data	681:715	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	1	69	dep	Trebouxiophyceae	41:56	arg1	Chlorophyta					59:69	Chlorophyta	59:69	Chlorophyta	59:69	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	10	70	theme	L-1	1126:1128	arg1	day-1					1130:1134	up to 53.5 mg L-1 day-1	1112:1134	up to 53.5 mg L-1 day-1	1112:1134	The biomass yield reached up to 53.5 mg L-1 day-1.
35309180	2	71	theme	terrestrial	166:176	arg1	alga					184:187	A terrestrial green alga	164:187	A terrestrial green alga	164:187	A terrestrial green alga was isolated at Iceland, and the strain (SAG 2627) was described for its morphology and phylogenetic position and tested for biotechnological capabilities.
35309180	0	72	dep	curvula	13:19	arg1	et					26:27	Thorsmoerkia curvula gen. et	0:27	Thorsmoerkia curvula gen. et spec	0:32	Thorsmoerkia curvula gen. et spec.
35309180	1	73	theme	high	124:127	arg1	levels					129:134	high levels	124:134	high levels of unsaturated fatty acids	124:161	nov. (Trebouxiophyceae, Chlorophyta), a semi-terrestrial microalga from Iceland exhibits high levels of unsaturated fatty acids.
35309180	12	74	from	end	1240:1242	arg1	lipids					1297:1302	lipids	1297:1302	lipids	1297:1302	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	12	74	from	end	1240:1242	arg1	acid					1332:1335	eicosapentaenoic acid	1315:1335	eicosapentaenoic acid	1315:1335	At the end of the log phase, approximately 45% of dry mass were lipids, including eicosapentaenoic acid.
35309180	4	75	theme	18S	470:472	arg1	rDNA					474:477	18S rDNA	470:477	18S rDNA	470:477	Phylogenetic analyses of 18S rDNA and rbcL markers placed the strain into the Trebouxiophyceae (Chlorophyta).
35309180	14	76	theme	N-linked	1439:1446	arg1	glycans					1448:1454	The N-linked glycans	1435:1454	The N-linked glycans of glycoproteins	1435:1471	The N-linked glycans of glycoproteins were assessed to reveal chemotaxonomic patterns.
35309180	6	77	theme	morphological	681:693	arg1	data					712:715	morphological and phylogenetic data	681:715	morphological and phylogenetic data	681:715	Based on morphological and phylogenetic data, the strain was described as a new genus and species, Thorsmoerkia curvula gen. et sp.
35309180	2	78	theme	biotechnological	314:329	arg1	capabilities					331:342	biotechnological capabilities	314:342	biotechnological capabilities	314:342	A terrestrial green alga was isolated at Iceland, and the strain (SAG 2627) was described for its morphology and phylogenetic position and tested for biotechnological capabilities.
34804021	2	0	theme	tissues	474:480	arg1	types					465:469	53 types	462:469	53 types of tissues (GTEx v7)	462:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	3	1	theme	gene	661:664	arg1	associations					666:677	55 gene associations	658:677	55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues	658:783	We identified 55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues.
34804021	6	2	theme	systolic	1329:1336	arg1	pressure					1344:1351	systolic blood pressure	1329:1351	systolic blood pressure	1329:1351	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	2	theme	systolic	1329:1336	arg1	height					1304:1309	height	1304:1309	height	1304:1309	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	2	3	theme	trait	400:404	arg1	eQTL					412:415	eQTL	412:415	eQTL	412:415	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	2	3	theme	trait	400:404	arg1	loci					406:409	quantitative trait loci	387:409	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	0	4	from	Enrichment	13:22	arg1	Tissues					72:78	Specific Tissues	63:78	Specific Tissues	63:78	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.
34804021	2	5	theme	genes	566:570	arg1	expression					552:561	the specific expression	539:561	the specific expression of genes (LDSC-SEG)	539:581	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	7	6	theme	target	1566:1571	arg1	genes					1573:1577	their target genes	1560:1577	their target genes	1560:1577	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	4	7	theme	candidate	883:891	arg1	predisposition					901:914	candidate genetic predisposition	883:914	candidate genetic predisposition affecting IgG N-glycosylation traits	883:951	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	5	8	theme	several	993:999	arg1	modification					1146:1157	subsequent modification	1135:1157	subsequent modification	1135:1157	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	8	theme	several	993:999	arg1	biosynthesis					1091:1102	N-glycan biosynthesis	1082:1102	N-glycan biosynthesis	1082:1102	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	8	theme	several	993:999	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	8	theme	several	993:999	arg1	pathways					1029:1036	several IgG N-glycosylation-related pathways	993:1036	several IgG N-glycosylation-related pathways	993:1036	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	8	theme	several	993:999	arg1	transport					1108:1116	transport	1108:1116	transport	1108:1116	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	4	9	theme	coassociated	851:862	arg1	scenarios					800:808	Three working scenarios	786:808	Three working scenarios	786:808	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	2	10	theme	association	618:628	arg1	TWAS					637:640	TWAS	637:640	TWAS	637:640	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	2	10	theme	association	618:628	arg1	study					630:634	a transcriptome-wide association study	597:634	a transcriptome-wide association study (TWAS)	597:641	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	6	11	theme	most	1211:1214	arg1	variants					1224:1231	most genetic variants	1211:1231	most genetic variants underlying TWAS hits	1211:1252	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	7	12	theme	loci	1551:1554	arg1	atlas					1523:1527	an atlas	1520:1527	an atlas of genetic regulatory loci and their target genes within functionally relevant tissues	1520:1614	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	4	13	theme	IgG	926:928	arg1	traits					946:951	IgG N-glycosylation traits	926:951	IgG N-glycosylation traits	926:951	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	3	14	theme	predicted	685:693	arg1	levels					695:700	levels	695:700	levels	695:700	We identified 55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues.
34804021	3	15	from	N-glycosylation	755:769	arg1	tissues					777:783	14 tissues	774:783	14 tissues	774:783	We identified 55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues.
34804021	2	16	theme	transcriptome-wide	599:616	arg1	association					618:628	a transcriptome-wide association	597:628	a transcriptome-wide association study (TWAS)	597:641	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	5	17	theme	subsequent	1135:1144	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	17	theme	subsequent	1135:1144	arg1	modification					1146:1157	subsequent modification	1135:1157	subsequent modification	1135:1157	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	17	theme	subsequent	1135:1144	arg1	pathways					1029:1036	several IgG N-glycosylation-related pathways	993:1036	several IgG N-glycosylation-related pathways	993:1036	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	7	18	theme	diseases	1694:1701	arg1	mechanisms					1644:1653	the mechanisms	1640:1653	the mechanisms of IgG N-glycosylation and its related diseases	1640:1701	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	7	19	theme	related	1686:1692	arg1	diseases					1694:1701	its related diseases	1682:1701	its related diseases	1682:1701	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	2	20	from	expression	448:457	arg1	data					418:421	large-scale expression quantitative trait loci (eQTL) data	364:421	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	2	20	from	expression	448:457	arg1	data					305:308	data	305:308	data from GWAS summary statistics for 8,090 Europeans	305:357	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	6	21	theme	health	1287:1292	arg1	disease					1425:1431	inflammatory bowel disease	1406:1431	inflammatory bowel disease	1406:1431	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	21	theme	health	1287:1292	arg1	erythematosus					1391:1403	systemic lupus erythematosus	1376:1403	systemic lupus erythematosus	1376:1403	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	21	theme	health	1287:1292	arg1	measures					1294:1301	health measures	1287:1301	health measures (height, waist-hip ratio, systolic blood pressure)	1287:1352	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	21	theme	health	1287:1292	arg1	disease					1450:1456	Parkinson's disease	1438:1456	Parkinson's disease	1438:1456	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	2	22	from	statistics	328:337	arg1	data					418:421	large-scale expression quantitative trait loci (eQTL) data	364:421	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	2	22	from	statistics	328:337	arg1	data					305:308	data	305:308	data from GWAS summary statistics for 8,090 Europeans	305:357	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	1	23	theme	Genome-wide	81:91	arg1	GWAS					114:117	GWAS	114:117	GWAS	114:117	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	1	23	theme	Genome-wide	81:91	arg1	studies					105:111	Genome-wide association studies	81:111	Genome-wide association studies (GWAS)	81:118	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	1	24	theme	immunoglobulin	173:186	arg1	IgG					191:193	IgG	191:193	IgG	191:193	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	1	24	theme	immunoglobulin	173:186	arg1	G					188:188	immunoglobulin G	173:188	immunoglobulin G (IgG) N-glycosylation	173:210	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	2	25	theme	types	465:469	arg1	expression					448:457	the genotype-tissue expression	428:457	the genotype-tissue expression of 53 types of tissues (GTEx v7)	428:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	1	26	theme	association	93:103	arg1	GWAS					114:117	GWAS	114:117	GWAS	114:117	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	1	26	theme	association	93:103	arg1	studies					105:111	Genome-wide association studies	81:111	Genome-wide association studies (GWAS)	81:118	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	1	27	theme	G	188:188	arg1	N-glycosylation					196:210	immunoglobulin G (IgG) N-glycosylation	173:210	immunoglobulin G (IgG) N-glycosylation	173:210	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	2	28	theme	genotype-tissue	432:446	arg1	expression					448:457	the genotype-tissue expression	428:457	the genotype-tissue expression of 53 types of tissues (GTEx v7)	428:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	6	29	theme	systemic	1376:1383	arg1	erythematosus					1391:1403	systemic lupus erythematosus	1376:1403	systemic lupus erythematosus	1376:1403	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	1	30	from	genes	233:237	arg1	tissues					271:277	relevant tissues	262:277	relevant tissues	262:277	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	2	31	theme	expression	376:385	arg1	data					418:421	large-scale expression quantitative trait loci (eQTL) data	364:421	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	0	32	theme	Heritability	0:11	arg1	Enrichment					13:22	Heritability Enrichment	0:22	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.	0:79	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.
34804021	1	33	theme	relevant	262:269	arg1	tissues					271:277	relevant tissues	262:277	relevant tissues	262:277	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	4	34	theme	tissue-specific	817:831	arg1	scenarios					800:808	Three working scenarios	786:808	Three working scenarios	786:808	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	7	35	from	studies	1629:1635	arg1	mechanisms					1644:1653	the mechanisms	1640:1653	the mechanisms of IgG N-glycosylation and its related diseases	1640:1701	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	7	36	theme	N-glycosylation	1662:1676	arg1	mechanisms					1644:1653	the mechanisms	1640:1653	the mechanisms of IgG N-glycosylation and its related diseases	1640:1701	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	2	37	theme	large-scale	364:374	arg1	data					418:421	large-scale expression quantitative trait loci (eQTL) data	364:421	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	0	38	theme	Immunoglobulin	27:40	arg1	N-Glycosylation					44:58	Immunoglobulin G N-Glycosylation	27:58	Immunoglobulin G N-Glycosylation	27:58	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.
34804021	2	39	theme	disequilibrium	514:527	arg1	score					529:533	a linkage disequilibrium score	504:533	a linkage disequilibrium score for the specific expression of genes (LDSC-SEG)	504:581	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	4	40	theme	pleiotropic	834:844	arg1	scenarios					800:808	Three working scenarios	786:808	Three working scenarios	786:808	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	2	41	theme	linkage	506:512	arg1	score					529:533	a linkage disequilibrium score	504:533	a linkage disequilibrium score for the specific expression of genes (LDSC-SEG)	504:581	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	5	42	theme	N-glycan	1082:1089	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	42	theme	N-glycan	1082:1089	arg1	biosynthesis					1091:1102	N-glycan biosynthesis	1082:1102	N-glycan biosynthesis	1082:1102	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	42	theme	N-glycan	1082:1089	arg1	pathways					1029:1036	several IgG N-glycosylation-related pathways	993:1036	several IgG N-glycosylation-related pathways	993:1036	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	6	43	theme	phenome-wide	1168:1179	arg1	studies					1193:1199	phenome-wide association studies	1168:1199	phenome-wide association studies (PheWAS)	1168:1208	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	43	theme	phenome-wide	1168:1179	arg1	PheWAS					1202:1207	PheWAS	1202:1207	PheWAS	1202:1207	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	0	44	theme	N-Glycosylation	44:58	arg1	Enrichment					13:22	Heritability Enrichment	0:22	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.	0:79	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.
34804021	3	45	theme	expression	705:714	arg1	levels					695:700	levels	695:700	levels	695:700	We identified 55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues.
34804021	7	46	theme	genetic	1532:1538	arg1	loci					1551:1554	genetic regulatory loci	1532:1554	genetic regulatory loci	1532:1554	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	7	47	theme	further	1621:1627	arg1	studies					1629:1635	further studies	1621:1635	further studies on the mechanisms of IgG N-glycosylation and its related diseases	1621:1701	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	4	48	theme	working	792:798	arg1	scenarios					800:808	Three working scenarios	786:808	Three working scenarios	786:808	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	5	49	link	N-linked	1058:1065	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	0	50	theme	G	42:42	arg1	N-Glycosylation					44:58	Immunoglobulin G N-Glycosylation	27:58	Immunoglobulin G N-Glycosylation	27:58	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.
34804021	3	51	theme	IgG	751:753	arg1	N-glycosylation					755:769	IgG N-glycosylation	751:769	IgG N-glycosylation in 14 tissues	751:783	We identified 55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues.
34804021	6	52	theme	blood	1338:1342	arg1	pressure					1344:1351	systolic blood pressure	1329:1351	systolic blood pressure	1329:1351	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	52	theme	blood	1338:1342	arg1	height					1304:1309	height	1304:1309	height	1304:1309	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	7	53	theme	genes	1573:1577	arg1	atlas					1523:1527	an atlas	1520:1527	an atlas of genetic regulatory loci and their target genes within functionally relevant tissues	1520:1614	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	2	54	theme	loci	406:409	arg1	data					418:421	large-scale expression quantitative trait loci (eQTL) data	364:421	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	0	55	theme	Specific	63:70	arg1	Tissues					72:78	Specific Tissues	63:78	Specific Tissues	63:78	Heritability Enrichment of Immunoglobulin G N-Glycosylation in Specific Tissues.
34804021	4	56	theme	N-glycosylation	930:944	arg1	traits					946:951	IgG N-glycosylation traits	926:951	IgG N-glycosylation traits	926:951	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	2	57	theme	specific	543:550	arg1	expression					552:561	the specific expression	539:561	the specific expression of genes (LDSC-SEG)	539:581	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	7	58	theme	relevant	1599:1606	arg1	tissues					1608:1614	functionally relevant tissues	1586:1614	functionally relevant tissues	1586:1614	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	6	59	theme	inflammatory	1406:1417	arg1	disease					1425:1431	inflammatory bowel disease	1406:1431	inflammatory bowel disease	1406:1431	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	1	60	from	abundance	249:257	arg1	tissues					271:277	relevant tissues	262:277	relevant tissues	262:277	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	5	61	theme	asparagine	1047:1056	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	7	62	theme	regulatory	1540:1549	arg1	loci					1551:1554	genetic regulatory loci	1532:1554	genetic regulatory loci	1532:1554	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	6	63	theme	lupus	1385:1389	arg1	erythematosus					1391:1403	systemic lupus erythematosus	1376:1403	systemic lupus erythematosus	1376:1403	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	5	64	theme	N-linked	1058:1065	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	6	65	theme	TWAS	1244:1247	arg1	hits					1249:1252	TWAS hits	1244:1252	TWAS hits	1244:1252	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	2	66	theme	summary	320:326	arg1	statistics					328:337	GWAS summary statistics	315:337	GWAS summary statistics for 8,090 Europeans	315:357	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	6	67	theme	association	1181:1191	arg1	studies					1193:1199	phenome-wide association studies	1168:1199	phenome-wide association studies (PheWAS)	1168:1208	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	67	theme	association	1181:1191	arg1	PheWAS					1202:1207	PheWAS	1202:1207	PheWAS	1202:1207	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	68	theme	waist-hip	1312:1320	arg1	height					1304:1309	height	1304:1309	height	1304:1309	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	68	theme	waist-hip	1312:1320	arg1	ratio					1322:1326	waist-hip ratio	1312:1326	waist-hip ratio	1312:1326	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	5	69	theme	pathway	967:973	arg1	enrichment					975:984	pathway enrichment	967:984	pathway enrichment	967:984	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	7	70	theme	IgG	1658:1660	arg1	N-glycosylation					1662:1676	IgG N-glycosylation	1658:1676	IgG N-glycosylation	1658:1676	Our study provides an atlas of genetic regulatory loci and their target genes within functionally relevant tissues, for further studies on the mechanisms of IgG N-glycosylation and its related diseases.
34804021	2	71	theme	GWAS	315:318	arg1	statistics					328:337	GWAS summary statistics	315:337	GWAS summary statistics for 8,090 Europeans	315:357	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	6	72	theme	IgG	1480:1482	arg1	N-glycosylation					1484:1498	IgG N-glycosylation	1480:1498	IgG N-glycosylation	1480:1498	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	73	theme	genetic	1216:1222	arg1	variants					1224:1231	most genetic variants	1211:1231	most genetic variants underlying TWAS hits	1211:1252	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	2	74	theme	GTEx	483:486	arg1	tissues					474:480	tissues	474:480	tissues (GTEx v7)	474:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	2	74	theme	GTEx	483:486	arg1	v7					488:489	GTEx v7	483:489	GTEx v7	483:489	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	4	75	theme	genetic	893:899	arg1	predisposition					901:914	candidate genetic predisposition	883:914	candidate genetic predisposition affecting IgG N-glycosylation traits	883:951	Three working scenarios, i.e., tissue-specific, pleiotropic, and coassociated, were observed for candidate genetic predisposition affecting IgG N-glycosylation traits.
34804021	5	76	theme	IgG	1001:1003	arg1	modification					1146:1157	subsequent modification	1135:1157	subsequent modification	1135:1157	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	76	theme	IgG	1001:1003	arg1	biosynthesis					1091:1102	N-glycan biosynthesis	1082:1102	N-glycan biosynthesis	1082:1102	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	76	theme	IgG	1001:1003	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	76	theme	IgG	1001:1003	arg1	pathways					1029:1036	several IgG N-glycosylation-related pathways	993:1036	several IgG N-glycosylation-related pathways	993:1036	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	76	theme	IgG	1001:1003	arg1	transport					1108:1116	transport	1108:1116	transport	1108:1116	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	1	77	theme	genetic	144:150	arg1	loci					152:155	60 genetic loci	141:155	60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation	141:210	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	2	78	theme	quantitative	387:398	arg1	eQTL					412:415	eQTL	412:415	eQTL	412:415	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	2	78	theme	quantitative	387:398	arg1	loci					406:409	quantitative trait loci	387:409	large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7)	364:490	Leveraging data from GWAS summary statistics for 8,090 Europeans, and large-scale expression quantitative trait loci (eQTL) data from the genotype-tissue expression of 53 types of tissues (GTEx v7), we derived a linkage disequilibrium score for the specific expression of genes (LDSC-SEG) and conducted a transcriptome-wide association study (TWAS).
34804021	1	79	theme	causal	226:231	arg1	uncertain					283:291	uncertain	283:291	uncertain	283:291	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	1	79	theme	causal	226:231	arg1	genes					233:237	the causal genes	222:237	the causal genes	222:237	Genome-wide association studies (GWAS) have identified over 60 genetic loci associated with immunoglobulin G (IgG) N-glycosylation; however, the causal genes and their abundance in relevant tissues are uncertain.
34804021	6	80	theme	bowel	1419:1423	arg1	disease					1425:1431	inflammatory bowel disease	1406:1431	inflammatory bowel disease	1406:1431	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	3	81	gly	N-glycosylation	755:769	arg1	tissues					777:783	14 tissues	774:783	14 tissues	774:783	We identified 55 gene associations whose predicted levels of expression were significantly associated with IgG N-glycosylation in 14 tissues.
34804021	5	82	theme	N-glycosylation-related	1005:1027	arg1	modification					1146:1157	subsequent modification	1135:1157	subsequent modification	1135:1157	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	82	theme	N-glycosylation-related	1005:1027	arg1	biosynthesis					1091:1102	N-glycan biosynthesis	1082:1102	N-glycan biosynthesis	1082:1102	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	82	theme	N-glycosylation-related	1005:1027	arg1	glycosylation					1067:1079	asparagine N-linked glycosylation	1047:1079	asparagine N-linked glycosylation	1047:1079	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	82	theme	N-glycosylation-related	1005:1027	arg1	pathways					1029:1036	several IgG N-glycosylation-related pathways	993:1036	several IgG N-glycosylation-related pathways	993:1036	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	5	82	theme	N-glycosylation-related	1005:1027	arg1	transport					1108:1116	transport	1108:1116	transport	1108:1116	Furthermore, pathway enrichment showed several IgG N-glycosylation-related pathways, such as asparagine N-linked glycosylation, N-glycan biosynthesis and transport to the Golgi and subsequent modification.
34804021	6	83	dep	measures	1294:1301	arg1	pressure					1344:1351	systolic blood pressure	1329:1351	systolic blood pressure	1329:1351	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	83	dep	measures	1294:1301	arg1	height					1304:1309	height	1304:1309	height	1304:1309	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34804021	6	83	dep	measures	1294:1301	arg1	ratio					1322:1326	waist-hip ratio	1312:1326	waist-hip ratio	1312:1326	Through phenome-wide association studies (PheWAS), most genetic variants underlying TWAS hits were found to be correlated with health measures (height, waist-hip ratio, systolic blood pressure) and diseases, such as systemic lupus erythematosus, inflammatory bowel disease, and Parkinson's disease, which are related to IgG N-glycosylation.
34276694	7	0	theme	pro-proliferative	1511:1527	arg1	effects					1529:1535	the direct pro-proliferative effects	1500:1535	the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells	1500:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	3	1	from	leukemia	683:690	arg1	enriched					644:651	enriched	644:651	enriched	644:651	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	1	from	leukemia	683:690	arg1	signaling					538:546	the signaling	534:546	the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs)	534:638	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	11	2	from	differences	2243:2253	arg1	biology					2263:2269	IL-7 biology	2258:2269	IL-7 biology	2258:2269	With the latter finding we discovered differences in IL-7 biology between the human and mouse species.
34276694	8	3	theme	neutrophil	1706:1715	arg1	elastase					1717:1724	neutrophil elastase	1706:1724	neutrophil elastase	1706:1724	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	3	theme	neutrophil	1706:1715	arg1	proteases					1696:1704	the neutrophil serine proteases	1674:1704	the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases	1674:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	10	4	theme	protease-sensitive	2136:2153	arg1	loop					2155:2158	the protease-sensitive loop	2132:2158	the protease-sensitive loop	2132:2158	Finally, we showed that mouse IL-7 does not contain the protease-sensitive loop and, consequently, was not cleaved by MMP-9.
34276694	3	5	from	enriched	644:651	arg1	T-ALL					693:697	T-ALL	693:697	T-ALL	693:697	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	5	from	enriched	644:651	arg1	leukemia					683:690	T cell acute lymphoblastic leukemia	656:690	T cell acute lymphoblastic leukemia (T-ALL)	656:698	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	8	6	theme	proteases	1771:1779	arg1	proteinase					1727:1736	proteinase 3	1727:1738	proteinase 3	1727:1738	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	6	theme	proteases	1771:1779	arg1	combinations					1744:1755	combinations	1744:1755	combinations of neutrophil proteases	1744:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	6	theme	proteases	1771:1779	arg1	elastase					1717:1724	neutrophil elastase	1706:1724	neutrophil elastase	1706:1724	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	6	theme	proteases	1771:1779	arg1	proteases					1696:1704	the neutrophil serine proteases	1674:1704	the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases	1674:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	3	7	theme	IL-7R	524:528	arg1	enriched					644:651	enriched	644:651	enriched	644:651	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	7	theme	IL-7R	524:528	arg1	alterations					505:515	Gain-of-function alterations	488:515	Gain-of-function alterations of the IL-7R	488:528	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	7	theme	IL-7R	524:528	arg1	signaling					538:546	the signaling	534:546	the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs)	534:638	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	6	8	dep	α-helices	1313:1321	arg1	D					1329:1329	D	1329:1329	D	1329:1329	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	6	8	dep	α-helices	1313:1321	arg1	C					1323:1323	C	1323:1323	C	1323:1323	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	6	8	dep	α-helices	1313:1321	arg1	α-helices					1313:1321	the α-helices C and D	1309:1329	the α-helices C and D	1309:1329	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	7	9	theme	IL-7	1438:1441	arg1	cleavage					1426:1433	the proteolytic cleavage	1410:1433	the proteolytic cleavage of IL-7	1410:1441	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	3	10	theme	autocrine	704:712	arg1	production					714:723	autocrine production	704:723	autocrine production of IL-7 by T-ALL cells	704:746	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	11	theme	Janus	556:560	arg1	kinases					562:568	Janus kinases	556:568	Janus kinases (JAKs)	556:575	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	11	theme	Janus	556:560	arg1	JAKs					571:574	JAKs	571:574	JAKs	571:574	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	1	12	theme	cell	184:187	arg1	Interleukin					158:168	Interleukin 7	158:170	Interleukin 7 (IL-7)	158:177	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	1	12	theme	cell	184:187	arg1	factor					196:201	a cell growth factor	182:201	a cell growth factor with a central role in normal T cell development, survival and differentiation	182:280	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	3	13	theme	signal	581:586	arg1	transducers					588:598	signal transducers	581:598	signal transducers	581:598	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	10	14	dep	contain	2124:2130	arg1	cleaved					2187:2193	cleaved	2187:2193	was not cleaved by MMP-9	2179:2202	Finally, we showed that mouse IL-7 does not contain the protease-sensitive loop and, consequently, was not cleaved by MMP-9.
34276694	8	15	theme	neutrophil	1760:1769	arg1	proteases					1771:1779	neutrophil proteases	1760:1779	neutrophil proteases	1760:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	4	16	theme	due	946:948	arg1	metalloproteinase-9					917:935	matrix metalloproteinase-9	910:935	matrix metalloproteinase-9 (MMP-9)	910:943	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	4	16	theme	due	946:948	arg1	MMP-9					938:942	MMP-9	938:942	MMP-9	938:942	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	6	17	theme	human	1270:1274	arg1	IL-7					1276:1279	human IL-7	1270:1279	human IL-7	1270:1279	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	9	18	theme	redox	2016:2020	arg1	state					2022:2026	physiological redox state	2002:2026	physiological redox state	2002:2026	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	9	19	theme	posttranslational	1832:1848	arg1	modifications					1850:1862	two posttranslational modifications	1828:1862	two posttranslational modifications	1828:1862	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	4	20	theme	matrix	910:915	arg1	metalloproteinase-9					917:935	matrix metalloproteinase-9	910:935	matrix metalloproteinase-9 (MMP-9)	910:943	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	4	20	theme	matrix	910:915	arg1	MMP-9					938:942	MMP-9	938:942	MMP-9	938:942	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	8	21	dep	proteases	1696:1704	arg1	proteinase					1727:1736	proteinase 3	1727:1738	proteinase 3	1727:1738	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	21	dep	proteases	1696:1704	arg1	combinations					1744:1755	combinations	1744:1755	combinations of neutrophil proteases	1744:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	21	dep	proteases	1696:1704	arg1	elastase					1717:1724	neutrophil elastase	1706:1724	neutrophil elastase	1706:1724	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	21	dep	proteases	1696:1704	arg1	proteases					1696:1704	the neutrophil serine proteases	1674:1704	the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases	1674:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	7	22	theme	blood	1612:1616	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	9	23	theme	IL-7	2038:2041	arg1	conformations					2043:2055	the IL-7 conformations	2034:2055	the IL-7 conformations	2034:2055	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	9	23	theme	IL-7	2038:2041	arg1	proteoforms					2067:2077	active proteoforms	2060:2077	active proteoforms	2060:2077	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	3	24	theme	initiation	790:799	arg1	phenotypes					767:776	the phenotypes	763:776	the phenotypes of leukemic initiation and oncogenic spreading	763:823	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	7	25	theme	human	1595:1599	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	4	26	theme	regulated	986:994	arg1	production					996:1005	its regulated production	982:1005	its regulated production by other cell types	982:1025	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	7	27	theme	primary	1582:1588	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	11	28	theme	IL-7	2258:2261	arg1	biology					2263:2269	IL-7 biology	2258:2269	IL-7 biology	2258:2269	With the latter finding we discovered differences in IL-7 biology between the human and mouse species.
34276694	9	29	theme	IL-7	1874:1877	arg1	bioavailability					1879:1893	IL-7 bioavailability	1874:1893	IL-7 bioavailability in the human species	1874:1914	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	4	30	theme	neutrophil	953:962	arg1	degranulation					964:976	neutrophil degranulation	953:976	neutrophil degranulation	953:976	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	3	31	theme	oncogenic	805:813	arg1	spreading					815:823	oncogenic spreading	805:823	oncogenic spreading	805:823	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	0	32	theme	Neutrophil	106:115	arg1	Metalloproteinases					117:134	Neutrophil Metalloproteinases	106:134	Neutrophil Metalloproteinases	106:134	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	5	33	theme	many	1106:1109	arg1	cytokines					1111:1119	many cytokines	1106:1119	many cytokines	1106:1119	Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases.
34276694	9	34	theme	disulfide	1807:1815	arg1	bonding					1817:1823	disulfide bonding	1807:1823	disulfide bonding	1807:1823	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	11	35	theme	latter	2214:2219	arg1	finding					2221:2227	the latter finding	2210:2227	the latter finding	2210:2227	With the latter finding we discovered differences in IL-7 biology between the human and mouse species.
34276694	2	36	theme	increased	378:386	arg1	activity					398:405	increased signaling activity	378:405	increased signaling activity	378:405	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	0	37	theme	Internal	0:7	arg1	Bonding					19:25	Internal Disulfide Bonding	0:25	Internal Disulfide Bonding	0:25	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	5	38	theme	several	1179:1185	arg1	proteases					1212:1220	several other neutrophil-derived proteases	1179:1220	several other neutrophil-derived proteases	1179:1220	Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases.
34276694	2	39	theme	chronic	441:447	arg1	inflammation					449:460	chronic inflammation	441:460	chronic inflammation	441:460	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	5	40	theme	neutrophil-derived	1193:1210	arg1	proteases					1212:1220	several other neutrophil-derived proteases	1179:1220	several other neutrophil-derived proteases	1179:1220	Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases.
34276694	7	41	theme	cell	1556:1559	arg1	HPB-ALL					1567:1573	HPB-ALL	1567:1573	HPB-ALL	1567:1573	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	7	41	theme	cell	1556:1559	arg1	line					1561:1564	T-ALL cell line	1550:1564	a T-ALL cell line (HPB-ALL)	1548:1574	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	4	42	theme	cell	1016:1019	arg1	types					1021:1025	other cell types	1010:1025	other cell types	1010:1025	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	3	43	theme	T	656:656	arg1	T-ALL					693:697	T-ALL	693:697	T-ALL	693:697	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	43	theme	T	656:656	arg1	leukemia					683:690	T cell acute lymphoblastic leukemia	656:690	T cell acute lymphoblastic leukemia (T-ALL)	656:698	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	4	44	theme	other	1010:1014	arg1	types					1021:1025	other cell types	1010:1025	other cell types	1010:1025	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	11	45	dep	human	2283:2287	arg1	the					2279:2281	the	2279:2281	the	2279:2281	With the latter finding we discovered differences in IL-7 biology between the human and mouse species.
34276694	11	45	dep	human	2283:2287	arg1	species					2299:2305	species	2299:2305	species	2299:2305	With the latter finding we discovered differences in IL-7 biology between the human and mouse species.
34276694	4	46	theme	Several	826:832	arg1	pathologies					850:860	Several IL-7-associated pathologies	826:860	Several IL-7-associated pathologies	826:860	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	2	47	theme	signaling	326:334	arg1	lack					287:290	The lack	283:290	The lack of IL-7-IL-7 receptor(R)-mediated signaling	283:334	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	0	48	theme	Interleukin-7	48:60	arg1	Bonding					19:25	Internal Disulfide Bonding	0:25	Internal Disulfide Bonding	0:25	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	0	48	theme	Interleukin-7	48:60	arg1	Glycosylation					31:43	Glycosylation	31:43	Glycosylation of Interleukin-7	31:60	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	1	49	with	factor	196:201	arg1	role					218:221	a central role	208:221	a central role in normal T cell development, survival and differentiation	208:280	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	7	50	theme	IL-7	1540:1543	arg1	effects					1529:1535	the direct pro-proliferative effects	1500:1535	the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells	1500:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	3	51	theme	Gain-of-function	488:503	arg1	alterations					505:515	Gain-of-function alterations	488:515	Gain-of-function alterations of the IL-7R	488:528	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	5	52	link	neutrophil-derived	1193:1210	arg1	proteases					1212:1220	several other neutrophil-derived proteases	1179:1220	several other neutrophil-derived proteases	1179:1220	Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases.
34276694	3	53	theme	acute	663:667	arg1	T-ALL					693:697	T-ALL	693:697	T-ALL	693:697	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	53	theme	acute	663:667	arg1	leukemia					683:690	T cell acute lymphoblastic leukemia	656:690	T cell acute lymphoblastic leukemia (T-ALL)	656:698	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	1	54	theme	T	233:233	arg1	development					240:250	normal T cell development	226:250	normal T cell development	226:250	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	7	55	theme	direct	1504:1509	arg1	effects					1529:1535	the direct pro-proliferative effects	1500:1535	the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells	1500:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	3	56	theme	leukemic	781:788	arg1	initiation					790:799	leukemic initiation	781:799	leukemic initiation	781:799	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	2	57	theme	lymphoid	348:355	arg1	development					357:367	lymphoid development	348:367	lymphoid development	348:367	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	8	58	theme	neutrophil	1678:1687	arg1	proteinase					1727:1736	proteinase 3	1727:1738	proteinase 3	1727:1738	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	58	theme	neutrophil	1678:1687	arg1	elastase					1717:1724	neutrophil elastase	1706:1724	neutrophil elastase	1706:1724	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	58	theme	neutrophil	1678:1687	arg1	proteases					1696:1704	the neutrophil serine proteases	1674:1704	the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases	1674:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	4	59	theme	increased	888:896	arg1	presence					898:905	increased presence	888:905	increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types	888:1025	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	8	60	theme	comparable	1639:1648	arg1	effect					1650:1655	A comparable effect	1637:1655	A comparable effect	1637:1655	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	3	61	theme	IL-7	728:731	arg1	production					714:723	autocrine production	704:723	autocrine production of IL-7 by T-ALL cells	704:746	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	6	62	theme	exposed	1288:1294	arg1	loop					1296:1299	the exposed loop	1284:1299	the exposed loop between the α-helices C and D	1284:1329	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	7	63	theme	IL-7Rα	1461:1466	arg1	binding					1468:1474	IL-7Rα binding	1461:1474	IL-7Rα binding	1461:1474	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	4	64	theme	IL-7-associated	834:848	arg1	pathologies					850:860	Several IL-7-associated pathologies	826:860	Several IL-7-associated pathologies	826:860	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	9	65	theme	internal	1969:1976	arg1	cysteine					1978:1985	internal cysteine	1969:1985	internal cysteine bridging under physiological redox state	1969:2026	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	1	66	theme	growth	189:194	arg1	Interleukin					158:168	Interleukin 7	158:170	Interleukin 7 (IL-7)	158:177	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	1	66	theme	growth	189:194	arg1	factor					196:201	a cell growth factor	182:201	a cell growth factor with a central role in normal T cell development, survival and differentiation	182:280	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	7	67	theme	proteolytic	1414:1424	arg1	cleavage					1426:1433	the proteolytic cleavage	1410:1433	the proteolytic cleavage of IL-7	1410:1441	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	9	68	theme	physiological	2002:2014	arg1	state					2022:2026	physiological redox state	2002:2026	physiological redox state	2002:2026	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	3	69	theme	T-ALL	736:740	arg1	cells					742:746	T-ALL cells	736:746	T-ALL cells	736:746	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	1	70	theme	central	210:216	arg1	role					218:221	a central role	208:221	a central role in normal T cell development, survival and differentiation	208:280	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	7	71	theme	mononuclear	1618:1628	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	1	72	from	role	218:221	arg1	differentiation					266:280	differentiation	266:280	differentiation	266:280	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	1	72	from	role	218:221	arg1	survival					253:260	survival	253:260	survival	253:260	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	1	72	from	role	218:221	arg1	development					240:250	normal T cell development	226:250	normal T cell development	226:250	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	7	73	theme	peripheral	1601:1610	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	9	74	dep	glycosylation	1789:1801	arg1	influence					1864:1872	influence	1864:1872	influence IL-7 bioavailability in the human species	1864:1914	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	7	75	theme	CD8+	1590:1593	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	4	76	theme	metalloproteinase-9	917:935	arg1	presence					898:905	increased presence	888:905	increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types	888:1025	Several IL-7-associated pathologies are also characterized by increased presence of matrix metalloproteinase-9 (MMP-9), due to neutrophil degranulation and its regulated production by other cell types.
34276694	0	77	theme	Proteolytic	78:88	arg1	Inactivation					90:101	Proteolytic Inactivation	78:101	Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases	78:155	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	3	78	theme	transcription	618:630	arg1	kinases					562:568	Janus kinases	556:568	Janus kinases (JAKs)	556:575	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	78	theme	transcription	618:630	arg1	activators					604:613	activators	604:613	activators	604:613	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	78	theme	transcription	618:630	arg1	transducers					588:598	signal transducers	581:598	signal transducers	581:598	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	78	theme	transcription	618:630	arg1	JAKs					571:574	JAKs	571:574	JAKs	571:574	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	9	79	theme	active	2060:2065	arg1	conformations					2043:2055	the IL-7 conformations	2034:2055	the IL-7 conformations	2034:2055	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	9	79	theme	active	2060:2065	arg1	proteoforms					2067:2077	active proteoforms	2060:2077	active proteoforms	2060:2077	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	6	80	theme	IL-7	1367:1370	arg1	glycosylation					1381:1393	IL-7 N-linked glycosylation	1367:1393	IL-7 N-linked glycosylation	1367:1393	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	10	81	theme	mouse	2104:2108	arg1	IL-7					2110:2113	mouse IL-7	2104:2113	mouse IL-7	2104:2113	Finally, we showed that mouse IL-7 does not contain the protease-sensitive loop and, consequently, was not cleaved by MMP-9.
34276694	6	82	theme	N-linked	1372:1379	arg1	glycosylation					1381:1393	IL-7 N-linked glycosylation	1367:1393	IL-7 N-linked glycosylation	1367:1393	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	3	83	theme	spreading	815:823	arg1	phenotypes					767:776	the phenotypes	763:776	the phenotypes of leukemic initiation and oncogenic spreading	763:823	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	0	84	theme	Serine	140:145	arg1	Proteases					147:155	Serine Proteases	140:155	Serine Proteases	140:155	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	5	85	theme	cytokines	1111:1119	arg1	activity					1094:1101	the activity	1090:1101	the activity of many cytokines	1090:1119	Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases.
34276694	2	86	theme	signaling	388:396	arg1	activity					398:405	increased signaling activity	378:405	increased signaling activity	378:405	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	0	87	theme	Disulfide	9:17	arg1	Bonding					19:25	Internal Disulfide Bonding	0:25	Internal Disulfide Bonding	0:25	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	2	88	theme	inflammation	449:460	arg1	development					426:436	the development	422:436	the development of chronic inflammation, cancer and autoimmunity	422:485	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	6	89	link	N-linked	1372:1379	arg1	glycosylation					1381:1393	IL-7 N-linked glycosylation	1367:1393	IL-7 N-linked glycosylation	1367:1393	We demonstrated that MMP-9 efficiently cleaved human IL-7 in the exposed loop between the α-helices C and D and that this process is delayed by IL-7 N-linked glycosylation.
34276694	5	90	theme	other	1187:1191	arg1	proteases					1212:1220	several other neutrophil-derived proteases	1179:1220	several other neutrophil-derived proteases	1179:1220	Since proteases secreted by neutrophils are known to modulate the activity of many cytokines, we investigated the interactions between IL-7, MMP-9 and several other neutrophil-derived proteases.
34276694	9	91	dep	protects	1931:1938	arg1	whereas					1961:1967	whereas	1961:1967	whereas	1961:1967	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	9	91	dep	protects	1931:1938	arg1	glycosylation					1789:1801	glycosylation	1789:1801	glycosylation	1789:1801	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	9	91	dep	protects	1931:1938	arg1	bonding					1817:1823	disulfide bonding	1807:1823	disulfide bonding	1807:1823	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	2	92	dep	-mediated	316:324	arg1	receptor					305:312	IL-7-IL-7 receptor	295:312	IL-7-IL-7 receptor	295:312	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	2	93	theme	autoimmunity	474:485	arg1	development					426:436	the development	422:436	the development of chronic inflammation, cancer and autoimmunity	422:485	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	10	94	contain	contain	2124:2130	arg2	loop					2155:2158	the protease-sensitive loop	2132:2158	the protease-sensitive loop	2132:2158	Finally, we showed that mouse IL-7 does not contain the protease-sensitive loop and, consequently, was not cleaved by MMP-9.
34276694	10	94	contain	contain	2124:2130	arg1	IL-7					2110:2113	mouse IL-7	2104:2113	mouse IL-7	2104:2113	Finally, we showed that mouse IL-7 does not contain the protease-sensitive loop and, consequently, was not cleaved by MMP-9.
34276694	7	95	theme	T-ALL	1550:1554	arg1	HPB-ALL					1567:1573	HPB-ALL	1567:1573	HPB-ALL	1567:1573	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	7	95	theme	T-ALL	1550:1554	arg1	line					1561:1564	T-ALL cell line	1550:1564	a T-ALL cell line (HPB-ALL)	1548:1574	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	2	96	theme	cancer	463:468	arg1	development					426:436	the development	422:436	the development of chronic inflammation, cancer and autoimmunity	422:485	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	9	97	from	bioavailability	1879:1893	arg1	species					1908:1914	the human species	1898:1914	the human species	1898:1914	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	3	98	theme	lymphoblastic	669:681	arg1	T-ALL					693:697	T-ALL	693:697	T-ALL	693:697	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	98	theme	lymphoblastic	669:681	arg1	leukemia					683:690	T cell acute lymphoblastic leukemia	656:690	T cell acute lymphoblastic leukemia (T-ALL)	656:698	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	2	99	theme	-mediated	316:324	arg1	signaling					326:334	IL-7-IL-7 receptor(R)-mediated signaling	295:334	IL-7-IL-7 receptor(R)-mediated signaling	295:334	The lack of IL-7-IL-7 receptor(R)-mediated signaling compromises lymphoid development, whereas increased signaling activity contributes to the development of chronic inflammation, cancer and autoimmunity.
34276694	0	100	gly	Glycosylation	31:43	arg1	Interleukin-7					48:60	Interleukin-7	48:60	Interleukin-7	48:60	Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases.
34276694	9	101	theme	human	1902:1906	arg1	species					1908:1914	the human species	1898:1914	the human species	1898:1914	Hence, glycosylation and disulfide bonding as two posttranslational modifications influence IL-7 bioavailability in the human species: glycosylation protects against proteolysis, whereas internal cysteine bridging under physiological redox state keeps the IL-7 conformations as active proteoforms.
34276694	3	102	theme	cell	658:661	arg1	T-ALL					693:697	T-ALL	693:697	T-ALL	693:697	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	3	102	theme	cell	658:661	arg1	leukemia					683:690	T cell acute lymphoblastic leukemia	656:690	T cell acute lymphoblastic leukemia (T-ALL)	656:698	Gain-of-function alterations of the IL-7R and the signaling through Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) are enriched in T cell acute lymphoblastic leukemia (T-ALL) and autocrine production of IL-7 by T-ALL cells is involved in the phenotypes of leukemic initiation and oncogenic spreading.
34276694	1	103	theme	normal	226:231	arg1	development					240:250	normal T cell development	226:250	normal T cell development	226:250	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
34276694	7	104	from	effects	1529:1535	arg1	cells					1630:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	primary CD8+ human peripheral blood mononuclear cells	1582:1634	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	7	104	from	effects	1529:1535	arg1	HPB-ALL					1567:1573	HPB-ALL	1567:1573	HPB-ALL	1567:1573	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	7	104	from	effects	1529:1535	arg1	line					1561:1564	T-ALL cell line	1550:1564	a T-ALL cell line (HPB-ALL)	1548:1574	Functionally, the proteolytic cleavage of IL-7 did not influence IL-7Rα binding and internalization nor the direct pro-proliferative effects of IL-7 on a T-ALL cell line (HPB-ALL) or in primary CD8+ human peripheral blood mononuclear cells.
34276694	8	105	theme	serine	1689:1694	arg1	proteinase					1727:1736	proteinase 3	1727:1738	proteinase 3	1727:1738	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	105	theme	serine	1689:1694	arg1	elastase					1717:1724	neutrophil elastase	1706:1724	neutrophil elastase	1706:1724	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	8	105	theme	serine	1689:1694	arg1	proteases					1696:1704	the neutrophil serine proteases	1674:1704	the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases	1674:1779	A comparable effect was observed for the neutrophil serine proteases neutrophil elastase, proteinase 3 and combinations of neutrophil proteases.
34276694	1	106	theme	cell	235:238	arg1	development					240:250	normal T cell development	226:250	normal T cell development	226:250	Interleukin 7 (IL-7) is a cell growth factor with a central role in normal T cell development, survival and differentiation.
33033255	7	0	theme	binding	1190:1196	arg1	affinities					1198:1207	high binding affinities	1185:1207	high binding affinities	1185:1207	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	4	1	with	interaction	671:681	arg1	ICOS-L					688:693	ICOS-L	688:693	ICOS-L	688:693	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	7	2	theme	receptor-ligand	1086:1100	arg1	interactions					1115:1126	receptor-ligand binding core interactions	1086:1126	receptor-ligand binding core interactions	1086:1126	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	5	3	theme	N110	845:848	arg1	glycan					859:864	the ICOS N110 N-linked glycan	836:864	the ICOS N110 N-linked glycan	836:864	Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding.
33033255	1	4	theme	activated	244:252	arg1	cells					256:260	activated T cells	244:260	activated T cells	244:260	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	8	5	contain	have	1317:1320	arg1	results					1214:1220	Our results	1210:1220	Our results	1210:1220	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	8	5	contain	have	1317:1320	arg2	implications					1329:1340	direct implications	1322:1340	direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors	1322:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	7	6	theme	binding	1102:1108	arg1	interactions					1115:1126	receptor-ligand binding core interactions	1086:1126	receptor-ligand binding core interactions	1086:1126	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	4	7	from	orientation	729:739	arg1	comparison					744:753	comparison	744:753	comparison to other family members	744:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	5	8	theme	N-linked	850:857	arg1	glycan					859:864	the ICOS N110 N-linked glycan	836:864	the ICOS N110 N-linked glycan	836:864	Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding.
33033255	1	9	theme	T	254:254	arg1	cells					256:260	activated T cells	244:260	activated T cells	244:260	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	7	10	dep	contacting	1144:1153	arg1	addition					1132:1139	addition	1132:1139	addition	1132:1139	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	6	11	from	evaluation	1012:1021	arg1	immunotherapy					1026:1038	immunotherapy	1026:1038	immunotherapy	1026:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	3	12	theme	ICOS/ICOS-L	516:526	arg1	complex					535:541	the ICOS/ICOS-L immune complex	512:541	the ICOS/ICOS-L immune complex	512:541	Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution.
33033255	4	13	theme	central	566:572	arg1	motif					581:585	A central FDPPPF motif	564:585	A central FDPPPF motif	564:585	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	4	13	theme	central	566:572	arg1	responsible					632:642	responsible	632:642	responsible	632:642	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	0	14	theme	therapeutic	96:106	arg1	antibodies					108:117	therapeutic antibodies	96:117	therapeutic antibodies	96:117	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	4	15	theme	distinct	703:710	arg1	orientation					729:739	a distinct receptor binding orientation	701:739	a distinct receptor binding orientation in comparison to other family members	701:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	3	16	theme	immune	528:533	arg1	complex					535:541	the ICOS/ICOS-L immune complex	512:541	the ICOS/ICOS-L immune complex	512:541	Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution.
33033255	5	17	theme	ICOS-L	882:887	arg1	binding					889:895	ICOS-L binding	882:895	ICOS-L binding	882:895	Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding.
33033255	2	18	theme	pathway	321:327	arg1	Dysregulation					299:311	Dysregulation	299:311	Dysregulation of this pathway	299:327	Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade.
33033255	7	19	theme	antibody	1053:1060	arg1	paratopes					1062:1070	antibody paratopes	1053:1070	antibody paratopes	1053:1070	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	8	20	theme	molecular	1234:1242	arg1	interactions					1244:1255	key molecular interactions	1230:1255	key molecular interactions of an immune complex central to human adaptive immunity	1230:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	5	21	theme	binding	811:817	arg1	data					819:822	our structure and binding data	793:822	data	819:822	Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding.
33033255	6	22	from	structures	929:938	arg1	complex					962:968	complex	962:968	complex with monoclonal antibodies under clinical evaluation in immunotherapy	962:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	8	23	theme	central	1278:1284	arg1	complex					1270:1276	an immune complex	1260:1276	an immune complex central to human adaptive immunity	1260:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	4	24	theme	binding	721:727	arg1	orientation					729:739	a distinct receptor binding orientation	701:739	a distinct receptor binding orientation in comparison to other family members	701:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	4	25	with	responsible	632:642	arg1	orientation					729:739	a distinct receptor binding orientation	701:739	a distinct receptor binding orientation in comparison to other family members	701:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	8	26	theme	key	1230:1232	arg1	interactions					1244:1255	key molecular interactions	1230:1255	key molecular interactions of an immune complex central to human adaptive immunity	1230:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	1	27	theme	CD28/B7	174:180	arg1	superfamily					182:192	the CD28/B7 superfamily	170:192	the CD28/B7 superfamily	170:192	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	0	28	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of the ICOS/ICOS-L immune complex	0:60	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	6	29	theme	crystal	921:927	arg1	structures					929:938	crystal structures	921:938	crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy	921:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	3	30	theme	Å	550:550	arg1	resolution					552:561	3.3 Å resolution	546:561	3.3 Å resolution	546:561	Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution.
33033255	3	31	from	resolution	552:561	arg1	interactions					496:507	the molecular interactions	482:507	the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution	482:561	Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution.
33033255	2	32	theme	autoimmune	352:361	arg1	diseases					363:370	autoimmune diseases	352:370	autoimmune diseases	352:370	Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade.
33033255	2	33	theme	clinical	407:414	arg1	investigation					416:428	clinical investigation	407:428	clinical investigation	407:428	Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade.
33033255	8	34	theme	immune	1409:1414	arg1	receptors					1427:1435	immune checkpoint receptors	1409:1435	immune checkpoint receptors	1409:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	3	35	theme	complex	535:541	arg1	interactions					496:507	the molecular interactions	482:507	the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution	482:561	Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution.
33033255	8	36	theme	adaptive	1295:1302	arg1	immunity					1304:1311	human adaptive immunity	1289:1311	human adaptive immunity	1289:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	6	37	theme	clinical	1003:1010	arg1	evaluation					1012:1021	clinical evaluation	1003:1021	clinical evaluation in immunotherapy	1003:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	8	38	theme	ongoing	1350:1356	arg1	development					1358:1368	the ongoing development	1346:1368	the ongoing development of therapeutic interventions targeting immune checkpoint receptors	1346:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	5	39	link	N-linked	850:857	arg1	glycan					859:864	the ICOS N110 N-linked glycan	836:864	the ICOS N110 N-linked glycan	836:864	Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding.
33033255	0	40	theme	immune	47:52	arg1	complex					54:60	the ICOS/ICOS-L immune complex	31:60	the ICOS/ICOS-L immune complex	31:60	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	8	41	theme	complex	1270:1276	arg1	interactions					1244:1255	key molecular interactions	1230:1255	key molecular interactions of an immune complex central to human adaptive immunity	1230:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	7	42	theme	peripheral	1155:1164	arg1	residues					1166:1173	peripheral residues	1155:1173	peripheral residues	1155:1173	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	1	43	theme	superfamily	182:192	arg1	co-stimulator					134:146	The inducible co-stimulator	120:146	The inducible co-stimulator (ICOS)	120:153	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	1	43	theme	superfamily	182:192	arg1	member					160:165	a member	158:165	a member of the CD28/B7 superfamily	158:192	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	7	44	theme	core	1110:1113	arg1	interactions					1115:1126	receptor-ligand binding core interactions	1086:1126	receptor-ligand binding core interactions	1086:1126	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	2	45	theme	checkpoint	443:452	arg1	blockade					454:461	an immune checkpoint blockade	433:461	an immune checkpoint blockade	433:461	Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade.
33033255	0	46	theme	ICOS/ICOS-L	35:45	arg1	complex					54:60	the ICOS/ICOS-L immune complex	31:60	the ICOS/ICOS-L immune complex	31:60	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	6	47	theme	ICOS	943:946	arg1	structures					929:938	crystal structures	921:938	crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy	921:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	4	48	theme	family	764:769	arg1	members					771:777	other family members	758:777	other family members	758:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	4	49	theme	CC	611:612	arg1	loop					615:618	the CC' loop	607:618	the CC' loop of ICOS	607:626	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	2	50	theme	immune	436:441	arg1	blockade					454:461	an immune checkpoint blockade	433:461	an immune checkpoint blockade	433:461	Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade.
33033255	8	51	theme	checkpoint	1416:1425	arg1	receptors					1427:1435	immune checkpoint receptors	1409:1435	immune checkpoint receptors	1409:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	1	52	theme	inducible	124:132	arg1	ICOS					149:152	ICOS	149:152	ICOS	149:152	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	1	52	theme	inducible	124:132	arg1	co-stimulator					134:146	The inducible co-stimulator	120:146	The inducible co-stimulator (ICOS)	120:153	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	1	52	theme	inducible	124:132	arg1	member					160:165	a member	158:165	a member of the CD28/B7 superfamily	158:192	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	0	53	theme	complex	54:60	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of the ICOS/ICOS-L immune complex	0:60	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	6	54	with	complex	962:968	arg1	antibodies					986:995	monoclonal antibodies	975:995	monoclonal antibodies under clinical evaluation in immunotherapy	975:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	7	55	theme	high	1185:1188	arg1	affinities					1198:1207	high binding affinities	1185:1207	high binding affinities	1185:1207	Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities.
33033255	4	56	theme	ICOS	623:626	arg1	loop					615:618	the CC' loop	607:618	the CC' loop of ICOS	607:626	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	8	57	theme	immune	1263:1268	arg1	complex					1270:1276	an immune complex	1260:1276	an immune complex central to human adaptive immunity	1260:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	8	58	theme	interventions	1385:1397	arg1	development					1358:1368	the ongoing development	1346:1368	the ongoing development of therapeutic interventions targeting immune checkpoint receptors	1346:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	8	59	theme	human	1289:1293	arg1	immunity					1304:1311	human adaptive immunity	1289:1311	human adaptive immunity	1289:1311	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	8	60	theme	therapeutic	1373:1383	arg1	interventions					1385:1397	therapeutic interventions	1373:1397	therapeutic interventions targeting immune checkpoint receptors	1373:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	1	61	theme	positive	210:217	arg1	signal					234:239	a positive co-stimulatory signal	208:239	a positive co-stimulatory signal	208:239	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	4	62	theme	receptor	712:719	arg1	orientation					729:739	a distinct receptor binding orientation	701:739	a distinct receptor binding orientation in comparison to other family members	701:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	4	63	theme	interaction	671:681	arg1	specificity					652:662	the specificity	648:662	the specificity of the interaction with ICOS-L	648:693	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	8	64	theme	direct	1322:1327	arg1	implications					1329:1340	direct implications	1322:1340	direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors	1322:1435	Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.
33033255	1	65	theme	co-stimulatory	219:232	arg1	signal					234:239	a positive co-stimulatory signal	208:239	a positive co-stimulatory signal	208:239	The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L).
33033255	0	66	theme	molecular	75:83	arg1	mimicry					85:91	high molecular mimicry	70:91	high molecular mimicry by therapeutic antibodies	70:117	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	6	67	theme	monoclonal	975:984	arg1	antibodies					986:995	monoclonal antibodies	975:995	monoclonal antibodies under clinical evaluation in immunotherapy	975:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
33033255	4	68	theme	other	758:762	arg1	members					771:777	other family members	758:777	other family members	758:777	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	3	69	theme	molecular	486:494	arg1	interactions					496:507	the molecular interactions	482:507	the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution	482:561	Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution.
33033255	0	70	theme	high	70:73	arg1	mimicry					85:91	high molecular mimicry	70:91	high molecular mimicry by therapeutic antibodies	70:117	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
33033255	4	71	theme	FDPPPF	574:579	arg1	motif					581:585	A central FDPPPF motif	564:585	A central FDPPPF motif	564:585	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	4	71	theme	FDPPPF	574:579	arg1	responsible					632:642	responsible	632:642	responsible	632:642	A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members.
33033255	5	72	theme	ICOS	840:843	arg1	glycan					859:864	the ICOS N110 N-linked glycan	836:864	the ICOS N110 N-linked glycan	836:864	Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding.
33033255	6	73	theme	ICOS-L	952:957	arg1	structures					929:938	crystal structures	921:938	crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy	921:1038	In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy.
32995354	8	0	theme	human	1647:1651	arg1	p <					1668:1670	p < 0.005	1668:1676	p < 0.005	1668:1676	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	0	theme	human	1647:1651	arg1	in vivo					1659:1665	human liver in vivo	1647:1665	human liver in vivo (p < 0.005)	1647:1677	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	2	1	theme	cells	357:361	arg1	approaches					230:239	The two leading approaches	214:239	The two leading approaches	214:239	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	1	theme	cells	357:361	arg1	cells					282:286	transiently transfected human HEK293 cells	245:286	transiently transfected human HEK293 cells	245:286	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	1	theme	cells	357:361	arg1	infection					309:317	live baculovirus infection	292:317	live baculovirus infection	292:317	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	7	2	contain	have	1399:1402	arg2	PTMs					1414:1417	their own PTMs	1404:1417	their own PTMs	1404:1417	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	7	2	contain	have	1399:1402	arg2	glycans					1463:1469	potentially immunogenic N-linked glycans	1430:1469	potentially immunogenic N-linked glycans	1430:1469	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	7	2	contain	have	1399:1402	arg1	impurities					1355:1364	host cell protein impurities	1337:1364	host cell protein impurities	1337:1364	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	6	3	theme	rAAV	1208:1211	arg1	genomes					1213:1219	(2) rAAV genomes	1204:1219	(2) rAAV genomes	1204:1219	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	5	4	dep	differences	609:619	arg1	in vitro					912:919	in vitro	912:919	in vitro	912:919	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	4	dep	differences	609:619	arg1	differences					609:619	differences	609:619	differences with multiple analytical approaches	609:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	4	dep	differences	609:619	arg1	in vivo					925:931	in vivo	925:931	in vivo	925:931	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	2	5	theme	live	292:295	arg1	infection					309:317	live baculovirus infection	292:317	live baculovirus infection	292:317	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	7	6	theme	N-linked	1454:1461	arg1	glycans					1463:1469	potentially immunogenic N-linked glycans	1430:1469	potentially immunogenic N-linked glycans	1430:1469	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	1	7	theme	adeno-associated	183:198	arg1	virus					200:204	recombinant adeno-associated virus	171:204	recombinant adeno-associated virus (rAAV)	171:211	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	1	7	theme	adeno-associated	183:198	arg1	rAAV					207:210	rAAV	207:210	rAAV	207:210	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	1	8	used	used	145:148	arg2	approaches					130:139	Different approaches	120:139	Different approaches	120:139	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	3	9	from	differences	376:386	arg1	performance					398:408	vector performance	391:408	vector performance	391:408	Unexplained differences in vector performance have been seen clinically and preclinically.
32995354	8	10	from	tissues	1605:1611	arg1	potent					1502:1507	potent	1502:1507	potent	1502:1507	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	2	11	theme	Spodoptera	322:331	arg1	Sf9					345:347	Sf9	345:347	Sf9	345:347	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	11	theme	Spodoptera	322:331	arg1	frugiperda					333:342	Spodoptera frugiperda	322:342	Spodoptera frugiperda (Sf9) insect cells	322:361	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	5	12	with	profiling	861:869	arg1	approaches					646:655	multiple analytical approaches	626:655	multiple analytical approaches	626:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	6	13	theme	major	1010:1014	arg1	discoveries					1016:1026	two major discoveries	1006:1026	two major discoveries	1006:1026	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	7	14	theme	own	1410:1412	arg1	glycans					1463:1469	potentially immunogenic N-linked glycans	1430:1469	potentially immunogenic N-linked glycans	1430:1469	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	7	14	theme	own	1410:1412	arg1	PTMs					1414:1417	their own PTMs	1404:1417	their own PTMs	1404:1417	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	5	15	theme	denaturation	770:781	arg1	assays					783:788	denaturation assays	770:788	denaturation assays	770:788	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	15	theme	denaturation	770:781	arg1	spectrometry					686:697	mass spectrometry	681:697	mass spectrometry	681:697	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	9	16	theme	rAAV	1733:1736	arg1	durability					1801:1810	expression durability	1790:1810	expression durability	1790:1810	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	16	theme	rAAV	1733:1736	arg1	trafficking					1756:1766	trafficking	1756:1766	trafficking	1756:1766	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	16	theme	rAAV	1733:1736	arg1	kinetics					1780:1787	expression kinetics	1769:1787	expression kinetics	1769:1787	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	16	theme	rAAV	1733:1736	arg1	binding					1747:1753	rAAV receptor binding	1733:1753	rAAV receptor binding	1733:1753	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	16	theme	rAAV	1733:1736	arg1	immunogenicity					1820:1833	vector immunogenicity	1813:1833	vector immunogenicity	1813:1833	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	6	17	dep	made	1001:1004	arg1	1					1030:1030	1	1030:1030	1	1030:1030	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	5	18	theme	electron	744:751	arg1	cryo-EM					722:728	cryo-EM	722:728	cryo-EM (transmission electron cryomicroscopy)	722:767	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	18	theme	electron	744:751	arg1	cryomicroscopy					753:766	transmission electron cryomicroscopy	731:766	transmission electron cryomicroscopy	731:766	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	2	19	theme	human	269:273	arg1	approaches					230:239	The two leading approaches	214:239	The two leading approaches	214:239	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	19	theme	human	269:273	arg1	cells					282:286	transiently transfected human HEK293 cells	245:286	transiently transfected human HEK293 cells	245:286	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	8	20	dep	types	1554:1558	arg1	in vitro					1560:1567	in vitro	1560:1567	various cell types in vitro (p < 0.05-0.0001)	1541:1585	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	20	dep	types	1554:1558	arg1	0.05-0.0001					1574:1584	p < 0.05-0.0001	1570:1584	p < 0.05-0.0001	1570:1584	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	5	21	theme	liver	957:961	arg1	mice					963:966	humanized liver mice	947:966	humanized liver mice	947:966	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	9	22	theme	expression	1769:1778	arg1	kinetics					1780:1787	expression kinetics	1769:1787	expression kinetics	1769:1787	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	22	theme	expression	1769:1778	arg1	binding					1747:1753	rAAV receptor binding	1733:1753	rAAV receptor binding	1733:1753	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	8	23	theme	various	1541:1547	arg1	types					1554:1558	various cell types in vitro (p < 0.05-0.0001)	1541:1585	various cell types in vitro (p < 0.05-0.0001)	1541:1585	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	5	24	theme	packaged	828:835	arg1	genomes					837:843	packaged genomes	828:843	packaged genomes	828:843	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	25	theme	analytical	635:644	arg1	approaches					646:655	multiple analytical approaches	626:655	multiple analytical approaches	626:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	6	26	theme	rAAV	1033:1036	arg1	capsids					1038:1044	rAAV capsids	1033:1044	rAAV capsids	1033:1044	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	3	27	theme	Unexplained	364:374	arg1	differences					376:386	Unexplained differences	364:386	Unexplained differences in vector performance	364:408	Unexplained differences in vector performance have been seen clinically and preclinically.
32995354	4	28	theme	host	536:539	arg1	species					546:552	only the host cell species	527:552	only the host cell species	527:552	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	6	29	contain	have	1046:1049	arg2	phosphorylation					1130:1144	phosphorylation	1130:1144	phosphorylation	1130:1144	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	29	contain	have	1046:1049	arg1	capsids					1038:1044	rAAV capsids	1033:1044	rAAV capsids	1033:1044	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	29	contain	have	1046:1049	arg2	methylation					1151:1161	methylation	1151:1161	methylation	1151:1161	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	29	contain	have	1046:1049	arg2	glycosylation					1102:1114	glycosylation	1102:1114	glycosylation	1102:1114	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	29	contain	have	1046:1049	arg2	acetylation					1117:1127	acetylation	1117:1127	acetylation	1117:1127	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	29	contain	have	1046:1049	arg2	modifications					1070:1082	post-translational modifications	1051:1082	post-translational modifications (PTMs)	1051:1089	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	29	contain	have	1046:1049	arg2	PTMs					1085:1088	PTMs	1085:1088	PTMs	1085:1088	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	4	30	theme	comparative	487:497	arg1	analysis					510:517	a controlled comparative production analysis	474:517	a controlled comparative production analysis varying only the host cell species but maintaining all other parameters	474:589	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	5	31	dep	focusing	712:719	arg1	isoelectric					700:710	isoelectric	700:710	isoelectric	700:710	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	32	theme	epigenomic	803:812	arg1	sequencing					814:823	genomic and epigenomic sequencing	791:823	genomic and epigenomic sequencing of packaged genomes	791:843	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	32	theme	epigenomic	803:812	arg1	spectrometry					686:697	mass spectrometry	681:697	mass spectrometry	681:697	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	8	33	from	types	1554:1558	arg1	potent					1502:1507	potent	1502:1507	potent	1502:1507	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	7	34	theme	protein	1347:1353	arg1	impurities					1355:1364	host cell protein impurities	1337:1364	host cell protein impurities	1337:1364	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	4	35	theme	other	574:578	arg1	parameters					580:589	all other parameters	570:589	all other parameters	570:589	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	5	36	theme	functional	876:885	arg1	assessments					900:910	functional transduction assessments	876:910	functional transduction assessments	876:910	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	7	37	theme	host	1337:1340	arg1	impurities					1355:1364	host cell protein impurities	1337:1364	host cell protein impurities	1337:1364	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	8	38	theme	various	1591:1597	arg1	tissues					1605:1611	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	0	39	theme	Production	25:34	arg1	Platforms					36:44	Standard Production Platforms	16:44	Methods Matter: Standard Production Platforms for Recombinant AAV	0:64	Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
32995354	9	40	theme	cost	1847:1850	arg1	considerations					1852:1865	cost considerations	1847:1865	cost considerations	1847:1865	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	2	41	theme	insect	350:355	arg1	cells					357:361	Spodoptera frugiperda (Sf9) insect cells	322:361	Spodoptera frugiperda (Sf9) insect cells	322:361	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	5	42	theme	cytokine	852:859	arg1	profiling					861:869	human cytokine profiling	846:869	human cytokine profiling	846:869	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	8	43	theme	Human-produced	1472:1485	arg1	rAAVs					1487:1491	Human-produced rAAVs	1472:1491	Human-produced rAAVs	1472:1491	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	5	44	theme	human	846:850	arg1	profiling					861:869	human cytokine profiling	846:869	human cytokine profiling	846:869	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	0	45	dep	Methods	0:6	arg1	Matter					8:13	Matter	8:13	Methods Matter: Standard Production Platforms for Recombinant AAV	0:64	Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
32995354	2	46	theme	baculovirus	297:307	arg1	infection					309:317	live baculovirus infection	292:317	live baculovirus infection	292:317	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	8	47	theme	liver	1653:1657	arg1	p <					1668:1670	p < 0.005	1668:1676	p < 0.005	1668:1676	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	47	theme	liver	1653:1657	arg1	in vivo					1659:1665	human liver in vivo	1647:1665	human liver in vivo (p < 0.005)	1647:1677	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	1	48	theme	recombinant	171:181	arg1	virus					200:204	recombinant adeno-associated virus	171:204	recombinant adeno-associated virus (rAAV)	171:211	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	1	48	theme	recombinant	171:181	arg1	rAAV					207:210	rAAV	207:210	rAAV	207:210	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	5	49	theme	mass	681:684	arg1	sequencing					814:823	genomic and epigenomic sequencing	791:823	genomic and epigenomic sequencing of packaged genomes	791:843	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	49	theme	mass	681:684	arg1	cryo-EM					722:728	cryo-EM	722:728	cryo-EM (transmission electron cryomicroscopy)	722:767	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	49	theme	mass	681:684	arg1	spectrometry					686:697	mass spectrometry	681:697	mass spectrometry	681:697	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	49	theme	mass	681:684	arg1	focusing					712:719	focusing	712:719	focusing	712:719	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	49	theme	mass	681:684	arg1	assays					783:788	denaturation assays	770:788	denaturation assays	770:788	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	2	50	theme	frugiperda	333:342	arg1	cells					357:361	Spodoptera frugiperda (Sf9) insect cells	322:361	Spodoptera frugiperda (Sf9) insect cells	322:361	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	1	51	theme	virus	200:204	arg1	production					157:166	the production	153:166	the production of recombinant adeno-associated virus (rAAV)	153:211	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	7	52	theme	immunogenic	1442:1452	arg1	glycans					1463:1469	potentially immunogenic N-linked glycans	1430:1469	potentially immunogenic N-linked glycans	1430:1469	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	5	53	theme	transduction	887:898	arg1	assessments					900:910	functional transduction assessments	876:910	functional transduction assessments	876:910	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	9	54	theme	clinical	1707:1714	arg1	implications					1716:1727	clinical implications	1707:1727	clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity	1707:1833	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	4	55	theme	controlled	476:485	arg1	analysis					510:517	a controlled comparative production analysis	474:517	a controlled comparative production analysis varying only the host cell species but maintaining all other parameters	474:589	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	7	56	link	N-linked	1454:1461	arg1	glycans					1463:1469	potentially immunogenic N-linked glycans	1430:1469	potentially immunogenic N-linked glycans	1430:1469	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	8	57	from	in vivo	1659:1665	arg1	potent					1502:1507	potent	1502:1507	potent	1502:1507	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	58	dep	tissues	1605:1611	arg1	in vivo					1613:1619	in vivo	1613:1619	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	58	dep	tissues	1605:1611	arg1	0.03-0.0001					1626:1636	p < 0.03-0.0001	1622:1636	p < 0.03-0.0001	1622:1636	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	2	59	theme	leading	222:228	arg1	approaches					230:239	The two leading approaches	214:239	The two leading approaches	214:239	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	59	theme	leading	222:228	arg1	cells					282:286	transiently transfected human HEK293 cells	245:286	transiently transfected human HEK293 cells	245:286	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	1	60	theme	Different	120:128	arg1	approaches					130:139	Different approaches	120:139	Different approaches	120:139	Different approaches are used in the production of recombinant adeno-associated virus (rAAV).
32995354	9	61	theme	receptor	1738:1745	arg1	durability					1801:1810	expression durability	1790:1810	expression durability	1790:1810	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	61	theme	receptor	1738:1745	arg1	trafficking					1756:1766	trafficking	1756:1766	trafficking	1756:1766	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	61	theme	receptor	1738:1745	arg1	kinetics					1780:1787	expression kinetics	1769:1787	expression kinetics	1769:1787	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	61	theme	receptor	1738:1745	arg1	binding					1747:1753	rAAV receptor binding	1733:1753	rAAV receptor binding	1733:1753	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	61	theme	receptor	1738:1745	arg1	immunogenicity					1820:1833	vector immunogenicity	1813:1833	vector immunogenicity	1813:1833	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	8	62	theme	baculovirus-Sf9	1514:1528	arg1	vectors					1530:1536	baculovirus-Sf9 vectors	1514:1536	baculovirus-Sf9 vectors	1514:1536	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	6	63	dep	genomes	1213:1219	arg1	2					1205:1205	2	1205:1205	2	1205:1205	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	5	64	theme	transmission	731:742	arg1	cryo-EM					722:728	cryo-EM	722:728	cryo-EM (transmission electron cryomicroscopy)	722:767	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	64	theme	transmission	731:742	arg1	cryomicroscopy					753:766	transmission electron cryomicroscopy	731:766	transmission electron cryomicroscopy	731:766	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	2	65	theme	HEK293	275:280	arg1	approaches					230:239	The two leading approaches	214:239	The two leading approaches	214:239	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	65	theme	HEK293	275:280	arg1	cells					282:286	transiently transfected human HEK293 cells	245:286	transiently transfected human HEK293 cells	245:286	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	8	66	from	potent	1502:1507	arg1	types					1554:1558	various cell types in vitro (p < 0.05-0.0001)	1541:1585	various cell types in vitro (p < 0.05-0.0001)	1541:1585	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	66	from	potent	1502:1507	arg1	p <					1668:1670	p < 0.005	1668:1676	p < 0.005	1668:1676	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	66	from	potent	1502:1507	arg1	tissues					1605:1611	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	8	66	from	potent	1502:1507	arg1	in vivo					1659:1665	human liver in vivo	1647:1665	human liver in vivo (p < 0.005)	1647:1677	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	2	67	theme	transfected	257:267	arg1	approaches					230:239	The two leading approaches	214:239	The two leading approaches	214:239	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	2	67	theme	transfected	257:267	arg1	cells					282:286	transiently transfected human HEK293 cells	245:286	transiently transfected human HEK293 cells	245:286	The two leading approaches are transiently transfected human HEK293 cells and live baculovirus infection of Spodoptera frugiperda (Sf9) insect cells.
32995354	5	68	theme	humanized	947:955	arg1	mice					963:966	humanized liver mice	947:966	humanized liver mice	947:966	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	6	69	theme	post-translational	1051:1068	arg1	PTMs					1085:1088	PTMs	1085:1088	PTMs	1085:1088	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	69	theme	post-translational	1051:1068	arg1	phosphorylation					1130:1144	phosphorylation	1130:1144	phosphorylation	1130:1144	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	69	theme	post-translational	1051:1068	arg1	methylation					1151:1161	methylation	1151:1161	methylation	1151:1161	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	69	theme	post-translational	1051:1068	arg1	modifications					1070:1082	post-translational modifications	1051:1082	post-translational modifications (PTMs)	1051:1089	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	69	theme	post-translational	1051:1068	arg1	glycosylation					1102:1114	glycosylation	1102:1114	glycosylation	1102:1114	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	6	69	theme	post-translational	1051:1068	arg1	acetylation					1117:1127	acetylation	1117:1127	acetylation	1117:1127	Using these approaches, we have made two major discoveries: (1) rAAV capsids have post-translational modifications (PTMs), including glycosylation, acetylation, phosphorylation, and methylation, and these differ between platforms; and (2) rAAV genomes are methylated during production, and these are also differentially deposited between platforms.
32995354	8	70	theme	cell	1549:1552	arg1	types					1554:1558	various cell types in vitro (p < 0.05-0.0001)	1541:1585	various cell types in vitro (p < 0.05-0.0001)	1541:1585	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	4	71	theme	cell	541:544	arg1	species					546:552	only the host cell species	527:552	only the host cell species	527:552	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	0	72	theme	Distinct	102:109	arg1	Vectors					111:117	Chemically and Functionally Distinct Vectors	74:117	Chemically and Functionally Distinct Vectors	74:117	Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
32995354	9	73	theme	expression	1790:1799	arg1	binding					1747:1753	rAAV receptor binding	1733:1753	rAAV receptor binding	1733:1753	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	73	theme	expression	1790:1799	arg1	durability					1801:1810	expression durability	1790:1810	expression durability	1790:1810	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	4	74	theme	production	499:508	arg1	analysis					510:517	a controlled comparative production analysis	474:517	a controlled comparative production analysis varying only the host cell species but maintaining all other parameters	474:589	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	5	75	theme	genomic	791:797	arg1	sequencing					814:823	genomic and epigenomic sequencing	791:823	genomic and epigenomic sequencing of packaged genomes	791:843	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	75	theme	genomic	791:797	arg1	spectrometry					686:697	mass spectrometry	681:697	mass spectrometry	681:697	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	76	theme	proteomic	658:666	arg1	profiling					668:676	proteomic profiling	658:676	proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes	658:843	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	77	with	differences	609:619	arg1	approaches					646:655	multiple analytical approaches	626:655	multiple analytical approaches	626:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	7	78	theme	cell	1342:1345	arg1	impurities					1355:1364	host cell protein impurities	1337:1364	host cell protein impurities	1337:1364	Our data show that host cell protein impurities differ between platforms and can have their own PTMs, including potentially immunogenic N-linked glycans.
32995354	0	79	theme	Standard	16:23	arg1	Platforms					36:44	Standard Production Platforms	16:44	Methods Matter: Standard Production Platforms for Recombinant AAV	0:64	Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
32995354	4	80	dep	analysis	510:517	arg1	maintaining					558:568	maintaining	558:568	maintaining all other parameters	558:589	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	4	80	dep	analysis	510:517	arg1	varying					519:525	varying	519:525	varying only the host cell species	519:552	Thus, we performed a controlled comparative production analysis varying only the host cell species but maintaining all other parameters.
32995354	5	81	theme	multiple	626:633	arg1	approaches					646:655	multiple analytical approaches	626:655	multiple analytical approaches	626:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	3	82	theme	vector	391:396	arg1	performance					398:408	vector performance	391:408	vector performance	391:408	Unexplained differences in vector performance have been seen clinically and preclinically.
32995354	8	83	theme	mouse	1599:1603	arg1	tissues					1605:1611	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	various mouse tissues in vivo (p < 0.03-0.0001)	1591:1637	Human-produced rAAVs are more potent than baculovirus-Sf9 vectors in various cell types in vitro (p < 0.05-0.0001), in various mouse tissues in vivo (p < 0.03-0.0001), and in human liver in vivo (p < 0.005).
32995354	5	84	theme	genomes	837:843	arg1	sequencing					814:823	genomic and epigenomic sequencing	791:823	genomic and epigenomic sequencing of packaged genomes	791:843	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	84	theme	genomes	837:843	arg1	spectrometry					686:697	mass spectrometry	681:697	mass spectrometry	681:697	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	5	85	with	assessments	900:910	arg1	approaches					646:655	multiple analytical approaches	626:655	multiple analytical approaches	626:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	0	86	theme	Recombinant	50:60	arg1	AAV					62:64	Recombinant AAV	50:64	Recombinant AAV	50:64	Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
32995354	5	87	with	profiling	668:676	arg1	approaches					646:655	multiple analytical approaches	626:655	multiple analytical approaches	626:655	We characterized differences with multiple analytical approaches: proteomic profiling by mass spectrometry, isoelectric focusing, cryo-EM (transmission electron cryomicroscopy), denaturation assays, genomic and epigenomic sequencing of packaged genomes, human cytokine profiling, and functional transduction assessments in vitro and in vivo, including in humanized liver mice.
32995354	9	88	contain	have	1702:1705	arg2	considerations					1852:1865	cost considerations	1847:1865	cost considerations	1847:1865	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	88	contain	have	1702:1705	arg1	differences					1686:1696	These differences	1680:1696	These differences	1680:1696	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	88	contain	have	1702:1705	arg2	implications					1716:1727	clinical implications	1707:1727	clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity	1707:1833	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	0	89	dep	Matter	8:13	arg1	Platforms					36:44	Standard Production Platforms	16:44	Methods Matter: Standard Production Platforms for Recombinant AAV	0:64	Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors.
32995354	9	90	theme	vector	1813:1818	arg1	binding					1747:1753	rAAV receptor binding	1733:1753	rAAV receptor binding	1733:1753	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32995354	9	90	theme	vector	1813:1818	arg1	immunogenicity					1820:1833	vector immunogenicity	1813:1833	vector immunogenicity	1813:1833	These differences may have clinical implications for rAAV receptor binding, trafficking, expression kinetics, expression durability, vector immunogenicity, as well as cost considerations.
32169063	6	0	theme	Monoclonal	877:886	arg1	strains					897:903	Monoclonal CHO cell strains	877:903	Monoclonal CHO cell strains stably and efficiently expressing the IFNs	877:946	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	2	1	theme	clinical	330:337	arg1	application					339:349	its clinical application	326:349	its clinical application	326:349	However, because the half-life of IFN is short, its clinical application is limited.
32169063	1	2	theme	antitumor	237:245	arg1	effects					269:275	antiviral, antitumor, and immunomodulatory effects	226:275	antiviral, antitumor, and immunomodulatory effects	226:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	11	3	theme	extended	1575:1582	arg1	half-life					1584:1592	an extended half-life	1572:1592	an extended half-life	1572:1592	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	4	4	theme	bunit	662:666	arg1	CTP					616:618	CTP	616:618	CTP	616:618	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	4	theme	bunit	662:666	arg1	peptide					607:613	the carboxyl-terminal peptide	585:613	the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences	585:703	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	7	5	theme	sieve	1178:1182	arg1	chromatography					1184:1197	molecular sieve chromatography	1168:1197	molecular sieve chromatography	1168:1197	The proteins were purified with affinity chromatography and molecular sieve chromatography.
32169063	11	6	theme	potential	1609:1617	arg1	applications					1619:1630	potential applications	1609:1630	potential applications	1609:1630	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	4	7	dep	bunit	662:666	arg1	sequences					695:703	sequences	695:703	sequences	695:703	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	3	8	theme	research	475:482	arg1	focus					462:466	the focus	458:466	the focus of IFN research	458:482	Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.
32169063	1	9	theme	immunomodulatory	252:267	arg1	effects					269:275	antiviral, antitumor, and immunomodulatory effects	226:275	antiviral, antitumor, and immunomodulatory effects	226:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	4	10	theme	glycosylation	681:693	arg1	CTP					616:618	CTP	616:618	CTP	616:618	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	10	theme	glycosylation	681:693	arg1	peptide					607:613	the carboxyl-terminal peptide	585:613	the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences	585:703	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	3	11	dep	yield	378:382	arg1	the					374:376	the	374:376	the	374:376	Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.
32169063	8	12	theme	antiproliferative	1247:1263	arg1	activities					1265:1274	antiviral and antiproliferative activities	1233:1274	antiviral and antiproliferative activities	1233:1274	IFN-1CTPON and IFN-2CTPON showed antiviral and antiproliferative activities in vitro.
32169063	4	13	theme	human	628:632	arg1	gonadotropin					644:655	human chorionic gonadotropin	628:655	the human chorionic gonadotropin β su bunit	624:666	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	7	14	theme	molecular	1168:1176	arg1	chromatography					1184:1197	molecular sieve chromatography	1168:1197	molecular sieve chromatography	1168:1197	The proteins were purified with affinity chromatography and molecular sieve chromatography.
32169063	5	15	theme	rhIFN-α2b	865:873	arg1	N-terminus					851:860	N-terminus	851:860	N-terminus	851:860	They were designated IFN-1CTPON (fused at the C-terminus of rhIFN-α2b) and IFN-2CTPON (fused at both the C-terminus and N-terminus of rhIFN-α2b).
32169063	5	15	theme	rhIFN-α2b	865:873	arg1	C-terminus					836:845	C-terminus	836:845	C-terminus	836:845	They were designated IFN-1CTPON (fused at the C-terminus of rhIFN-α2b) and IFN-2CTPON (fused at both the C-terminus and N-terminus of rhIFN-α2b).
32169063	3	16	theme	biological	388:397	arg1	activity					399:406	biological activity	388:406	biological activity	388:406	Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.
32169063	10	17	theme	CHO	1441:1443	arg1	strains					1450:1456	CONCLUSIONS CHO cell strains	1429:1456	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b	1429:1496	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b were screened.
32169063	4	18	link	N-linked	672:679	arg1	glycosylation					681:693	N-linked glycosylation	672:693	N-linked glycosylation	672:693	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	1	19	theme	cytokines	160:168	arg1	cytokines					160:168	cytokines	160:168	cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects	160:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	1	19	theme	cytokines	160:168	arg1	group					151:155	a group	149:155	a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects	149:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	7	20	theme	affinity	1140:1147	arg1	chromatography					1149:1162	affinity chromatography	1140:1162	affinity chromatography	1140:1162	The proteins were purified with affinity chromatography and molecular sieve chromatography.
32169063	9	21	theme	IFN-2CTPON	1327:1336	arg1	half-life					1299:1307	the half-life	1295:1307	the half-life of IFN-1CTPON and IFN-2CTPON in vivo	1295:1344	Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.
32169063	9	21	theme	IFN-2CTPON	1327:1336	arg1	longer					1375:1380	longer	1375:1380	longer	1375:1380	Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.
32169063	10	22	theme	CONCLUSIONS	1429:1439	arg1	strains					1450:1456	CONCLUSIONS CHO cell strains	1429:1456	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b	1429:1496	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b were screened.
32169063	1	23	theme	type	100:103	arg1	family					130:135	The type I human interferon (IFN) family	96:135	The type I human interferon (IFN) family	96:135	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	9	24	theme	IFN-1CTPON	1312:1321	arg1	half-life					1299:1307	the half-life	1295:1307	the half-life of IFN-1CTPON and IFN-2CTPON in vivo	1295:1344	Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.
32169063	9	24	theme	IFN-1CTPON	1312:1321	arg1	longer					1375:1380	longer	1375:1380	longer	1375:1380	Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.
32169063	4	25	theme	gonadotropin	644:655	arg1	bunit					662:666	the human chorionic gonadotropin β su bunit	624:666	the human chorionic gonadotropin β su bunit	624:666	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	10	26	theme	cell	1445:1448	arg1	strains					1450:1456	CONCLUSIONS CHO cell strains	1429:1456	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b	1429:1496	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b were screened.
32169063	6	27	theme	cell	892:895	arg1	strains					897:903	Monoclonal CHO cell strains	877:903	Monoclonal CHO cell strains stably and efficiently expressing the IFNs	877:946	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	1	28	theme	I	105:105	arg1	family					130:135	The type I human interferon (IFN) family	96:135	The type I human interferon (IFN) family	96:135	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	3	29	theme	IFN	411:413	arg1	yield					378:382	yield	378:382	yield	378:382	Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.
32169063	3	29	theme	IFN	411:413	arg1	activity					399:406	biological activity	388:406	biological activity	388:406	Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.
32169063	5	30	theme	rhIFN-α2b	791:799	arg1	C-terminus					777:786	the C-terminus	773:786	the C-terminus of rhIFN-α2b	773:799	They were designated IFN-1CTPON (fused at the C-terminus of rhIFN-α2b) and IFN-2CTPON (fused at both the C-terminus and N-terminus of rhIFN-α2b).
32169063	4	31	theme	IFN-α2b	533:539	arg1	proteins					553:560	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	32	dep	RESULTS	485:491	arg1	designed					567:574	designed	567:574	were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b	562:728	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	1	33	theme	human	107:111	arg1	family					130:135	The type I human interferon (IFN) family	96:135	The type I human interferon (IFN) family	96:135	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	10	34	theme	long-acting	1476:1486	arg1	rhIFN-α2b					1488:1496	long-acting rhIFN-α2b	1476:1496	long-acting rhIFN-α2b	1476:1496	CONCLUSIONS CHO cell strains stably expressing long-acting rhIFN-α2b were screened.
32169063	6	35	theme	highest	1008:1014	arg1	levels					1027:1032	the highest expression levels	1004:1032	the highest expression levels	1004:1032	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	6	35	theme	highest	1008:1014	arg1	1468 mg/l					1039:1047	1468 mg/l	1039:1047	1468 mg/l	1039:1047	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	0	36	theme	biological	16:25	arg1	activity					27:34	biological activity	16:34	biological activity	16:34	Development and biological activity of long-acting recombinant human interferon-α2b.
32169063	11	37	contain	has	1544:1546	arg2	activity					1559:1566	biological activity	1548:1566	biological activity	1548:1566	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	11	37	contain	has	1544:1546	arg2	half-life					1584:1592	an extended half-life	1572:1592	an extended half-life	1572:1592	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	11	37	contain	has	1544:1546	arg1	protein					1536:1542	The purified IFN-CTPON protein	1513:1542	The purified IFN-CTPON protein	1513:1542	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	1	38	theme	interferon	113:122	arg1	family					130:135	The type I human interferon (IFN) family	96:135	The type I human interferon (IFN) family	96:135	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	0	39	theme	long-acting	39:49	arg1	interferon-α2b					69:82	long-acting recombinant human interferon-α2b	39:82	long-acting recombinant human interferon-α2b	39:82	Development and biological activity of long-acting recombinant human interferon-α2b.
32169063	3	40	theme	IFN	471:473	arg1	research					475:482	IFN research	471:482	IFN research	471:482	Increasing the yield and biological activity of IFN while extending its half-life is currently the focus of IFN research.
32169063	4	41	theme	chorionic	634:642	arg1	gonadotropin					644:655	human chorionic gonadotropin	628:655	the human chorionic gonadotropin β su bunit	624:666	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	1	42	theme	biological	193:202	arg1	effects					269:275	antiviral, antitumor, and immunomodulatory effects	226:275	antiviral, antitumor, and immunomodulatory effects	226:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	1	42	theme	biological	193:202	arg1	activities					204:213	biological activities	193:213	biological activities	193:213	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	8	43	theme	antiviral	1233:1241	arg1	activities					1265:1274	antiviral and antiproliferative activities	1233:1274	antiviral and antiproliferative activities	1233:1274	IFN-1CTPON and IFN-2CTPON showed antiviral and antiproliferative activities in vitro.
32169063	4	44	attach	linked	710:715	arg2	peptide					607:613	the carboxyl-terminal peptide	585:613	the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences	585:703	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	44	attach	linked	710:715	arg1	rhIFN-α2b					720:728	rhIFN-α2b	720:728	rhIFN-α2b	720:728	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	44	attach	linked	710:715	arg3	which					579:583	which	579:583	which	579:583	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	44	attach	linked	710:715	arg2	CTP					616:618	CTP	616:618	CTP	616:618	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	45	theme	N-linked	672:679	arg1	glycosylation					681:693	N-linked glycosylation	672:693	N-linked glycosylation	672:693	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	5	46	dep	C-terminus	836:845	arg1	the					832:834	the	832:834	the	832:834	They were designated IFN-1CTPON (fused at the C-terminus of rhIFN-α2b) and IFN-2CTPON (fused at both the C-terminus and N-terminus of rhIFN-α2b).
32169063	1	47	theme	activities	204:213	arg1	multiplicity					177:188	a multiplicity	175:188	a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects	175:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	0	48	theme	human	63:67	arg1	interferon-α2b					69:82	long-acting recombinant human interferon-α2b	39:82	long-acting recombinant human interferon-α2b	39:82	Development and biological activity of long-acting recombinant human interferon-α2b.
32169063	4	49	theme	novel	497:501	arg1	proteins					553:560	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	50	theme	long-acting	503:513	arg1	rhIFN-α2b					542:550	rhIFN-α2b	542:550	rhIFN-α2b	542:550	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	50	theme	long-acting	503:513	arg1	IFN-α2b					533:539	long-acting recombinant human IFN-α2b	503:539	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	1	51	dep	BACKGROUND	85:94	arg1	consists					137:144	consists	137:144	consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects	137:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	0	52	theme	recombinant	51:61	arg1	interferon-α2b					69:82	long-acting recombinant human interferon-α2b	39:82	long-acting recombinant human interferon-α2b	39:82	Development and biological activity of long-acting recombinant human interferon-α2b.
32169063	4	53	theme	human	527:531	arg1	rhIFN-α2b					542:550	rhIFN-α2b	542:550	rhIFN-α2b	542:550	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	53	theme	human	527:531	arg1	IFN-α2b					533:539	long-acting recombinant human IFN-α2b	503:539	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	1	54	theme	IFN	125:127	arg1	family					130:135	The type I human interferon (IFN) family	96:135	The type I human interferon (IFN) family	96:135	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	11	55	theme	purified	1517:1524	arg1	protein					1536:1542	The purified IFN-CTPON protein	1513:1542	The purified IFN-CTPON protein	1513:1542	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	4	56	theme	recombinant	515:525	arg1	rhIFN-α2b					542:550	rhIFN-α2b	542:550	rhIFN-α2b	542:550	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	56	theme	recombinant	515:525	arg1	IFN-α2b					533:539	long-acting recombinant human IFN-α2b	503:539	Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins	493:560	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	11	57	theme	IFN-CTPON	1526:1534	arg1	protein					1536:1542	The purified IFN-CTPON protein	1513:1542	The purified IFN-CTPON protein	1513:1542	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	1	58	with	cytokines	160:168	arg1	multiplicity					177:188	a multiplicity	175:188	a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects	175:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	6	59	theme	expression	1016:1025	arg1	levels					1027:1032	the highest expression levels	1004:1032	the highest expression levels	1004:1032	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	6	59	theme	expression	1016:1025	arg1	1468 mg/l					1039:1047	1468 mg/l	1039:1047	1468 mg/l	1039:1047	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	2	60	theme	IFN	312:314	arg1	short					319:323	short	319:323	short	319:323	However, because the half-life of IFN is short, its clinical application is limited.
32169063	2	60	theme	IFN	312:314	arg1	half-life					299:307	the half-life	295:307	the half-life of IFN	295:314	However, because the half-life of IFN is short, its clinical application is limited.
32169063	4	61	theme	su	659:660	arg1	bunit					662:666	the human chorionic gonadotropin β su bunit	624:666	the human chorionic gonadotropin β su bunit	624:666	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	1	62	theme	antiviral	226:234	arg1	effects					269:275	antiviral, antitumor, and immunomodulatory effects	226:275	antiviral, antitumor, and immunomodulatory effects	226:275	BACKGROUND The type I human interferon (IFN) family consists of a group of cytokines with a multiplicity of biological activities, including antiviral, antitumor, and immunomodulatory effects.
32169063	0	63	theme	interferon-α2b	69:82	arg1	Development					0:10	Development	0:10	Development	0:10	Development and biological activity of long-acting recombinant human interferon-α2b.
32169063	0	63	theme	interferon-α2b	69:82	arg1	activity					27:34	biological activity	16:34	biological activity	16:34	Development and biological activity of long-acting recombinant human interferon-α2b.
32169063	6	64	theme	CHO	888:890	arg1	strains					897:903	Monoclonal CHO cell strains	877:903	Monoclonal CHO cell strains stably and efficiently expressing the IFNs	877:946	Monoclonal CHO cell strains stably and efficiently expressing the IFNs were successfully selected with methotrexate (MTX), and the highest expression levels were 1468 mg/l and 1196 mg/l for IFN-1CTPON and IFN-2CTPON, respectively.
32169063	9	65	theme	available	1408:1416	arg1	rhIFN-α2b					1418:1426	commercially available rhIFN-α2b	1395:1426	commercially available rhIFN-α2b	1395:1426	Notably, the half-life of IFN-1CTPON and IFN-2CTPON in vivo were three-fold and two-fold longer than that of commercially available rhIFN-α2b.
32169063	4	66	theme	β	657:657	arg1	bunit					662:666	the human chorionic gonadotropin β su bunit	624:666	the human chorionic gonadotropin β su bunit	624:666	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	11	67	theme	biological	1548:1557	arg1	activity					1559:1566	biological activity	1548:1566	biological activity	1548:1566	The purified IFN-CTPON protein has biological activity and an extended half-life, and therefore potential applications.
32169063	4	68	theme	carboxyl-terminal	589:605	arg1	CTP					616:618	CTP	616:618	CTP	616:618	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
32169063	4	68	theme	carboxyl-terminal	589:605	arg1	peptide					607:613	the carboxyl-terminal peptide	585:613	the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences	585:703	RESULTS Two novel long-acting recombinant human IFN-α2b (rhIFN-α2b) proteins were designed in which the carboxyl-terminal peptide (CTP) of the human chorionic gonadotropin β su bunit and N-linked glycosylation sequences were linked to rhIFN-α2b.
31901900	1	0	theme	death	161:165	arg1	PD-L1					177:181	PD-L1	177:181	PD-L1	177:181	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	1	0	theme	death	161:165	arg1	ligand-1					167:174	programmed death ligand-1	150:174	programmed death ligand-1 (PD-L1)	150:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	7	1	theme	RSV	1451:1453	arg1	mechanism					1438:1446	This unforeseen immunomodulating mechanism	1405:1446	This unforeseen immunomodulating mechanism of RSV	1405:1453	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	3	2	theme	endoplasmic	753:763	arg1	reticulum					765:773	the endoplasmic reticulum	749:773	the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1	749:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	6	3	theme	cancer	1360:1365	arg1	cells					1367:1371	cancer cells	1360:1371	cancer cells	1360:1371	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	1	4	dep	strategies	99:108	arg1	block					113:117	block	113:117	to block the immune evasion activity of programmed death ligand-1 (PD-L1)	110:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	4	5	theme	compound	1006:1013	arg1	BMS-202					1015:1021	the small compound BMS-202	996:1021	the small compound BMS-202 that binds to and induces dimerization of PD-L1	996:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	3	6	theme	reticulum	765:773	arg1	retention					775:783	the endoplasmic reticulum retention	749:783	the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1	749:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	6	7	theme	real-time	1249:1257	arg1	xCELLigence					1274:1284	xCELLigence	1274:1284	xCELLigence	1274:1284	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	6	7	theme	real-time	1249:1257	arg1	analysis					1264:1271	Impedance-based real-time cell analysis	1233:1271	Impedance-based real-time cell analysis (xCELLigence)	1233:1285	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	3	8	theme	direct	599:604	arg1	inhibitor					606:614	a direct inhibitor	597:614	a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1	597:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	4	9	theme	small	1000:1004	arg1	BMS-202					1015:1021	the small compound BMS-202	996:1021	the small compound BMS-202 that binds to and induces dimerization of PD-L1	996:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	6	10	theme	Impedance-based	1233:1247	arg1	xCELLigence					1274:1284	xCELLigence	1274:1284	xCELLigence	1274:1284	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	6	10	theme	Impedance-based	1233:1247	arg1	analysis					1264:1271	Impedance-based real-time cell analysis	1233:1271	Impedance-based real-time cell analysis (xCELLigence)	1233:1285	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	2	11	theme	differential	368:379	arg1	capacity					381:388	its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern	364:451	its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern	364:451	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	7	12	theme	T-cell	1498:1503	arg1	function					1505:1512	T-cell function	1498:1512	T-cell function	1498:1512	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	7	13	theme	natural	1570:1576	arg1	polyphenols					1578:1588	natural polyphenols	1570:1588	natural polyphenols	1570:1588	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	7	14	theme	immunomodulating	1421:1436	arg1	mechanism					1438:1446	This unforeseen immunomodulating mechanism	1405:1446	This unforeseen immunomodulating mechanism of RSV	1405:1453	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	2	15	theme	PD-L1	413:417	arg1	pattern					445:451	a distinct PD-L1 electrophoretic migration pattern	402:451	a distinct PD-L1 electrophoretic migration pattern	402:451	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	4	16	theme	BMS-202	1015:1021	arg1	space					987:991	the target space	976:991	the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1	976:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	7	17	theme	immunologic	1542:1552	arg1	checkpoint					1554:1563	the PD-1/PD-L1 immunologic checkpoint	1527:1563	the PD-1/PD-L1 immunologic checkpoint	1527:1563	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	4	18	theme	PD-L1	904:908	arg1	surface					893:899	the inner surface	883:899	the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1	883:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	2	19	theme	drugs	295:299	arg1	effects					239:245	the PD-L1-targeted effects	220:245	the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs	220:299	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	2	20	theme	distinct	404:411	arg1	pattern					445:451	a distinct PD-L1 electrophoretic migration pattern	402:451	a distinct PD-L1 electrophoretic migration pattern	402:451	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	3	21	theme	mannose-rich	790:801	arg1	form					828:831	a mannose-rich, abnormally glycosylated form	788:831	a mannose-rich, abnormally glycosylated form of PD-L1	788:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	1	22	theme	New	95:97	arg1	strategies					99:108	New strategies	95:108	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1)	95:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	6	23	theme	T-lymphocyte	1309:1320	arg1	activity					1322:1329	cytotoxic T-lymphocyte activity	1299:1329	cytotoxic T-lymphocyte activity	1299:1329	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	2	24	theme	polyphenol	326:335	arg1	RSV					350:352	RSV	350:352	RSV	350:352	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	2	24	theme	polyphenol	326:335	arg1	resveratrol					337:347	the dietary polyphenol resveratrol	314:347	the dietary polyphenol resveratrol (RSV)	314:353	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	7	25	theme	PD-1/PD-L1	1531:1540	arg1	checkpoint					1554:1563	the PD-1/PD-L1 immunologic checkpoint	1527:1563	the PD-1/PD-L1 immunologic checkpoint	1527:1563	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	3	26	theme	biochemical	460:470	arg1	assays					472:477	biochemical assays	460:477	biochemical assays	460:477	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	27	theme	PD-L1	836:840	arg1	form					828:831	a mannose-rich, abnormally glycosylated form	788:831	a mannose-rich, abnormally glycosylated form of PD-L1	788:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	5	28	theme	RSV	1087:1089	arg1	ability					1076:1082	The ability	1072:1082	The ability of RSV to directly target PD-L1	1072:1114	The ability of RSV to directly target PD-L1 interferes with its stability and trafficking, ultimately impeding its targeting to the cancer cell plasma membrane.
31901900	2	29	theme	dietary	318:324	arg1	RSV					350:352	RSV	350:352	RSV	350:352	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	2	29	theme	dietary	318:324	arg1	resveratrol					337:347	the dietary polyphenol resveratrol	314:347	the dietary polyphenol resveratrol (RSV)	314:353	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	6	30	theme	cytotoxic	1299:1307	arg1	T-lymphocyte					1309:1320	cytotoxic T-lymphocyte	1299:1320	cytotoxic T-lymphocyte activity	1299:1329	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	3	31	theme	dynamics	513:520	arg1	simulations					522:532	computer-aided docking/molecular dynamics simulations	480:532	computer-aided docking/molecular dynamics simulations	480:532	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	32	link	N-linked	694:701	arg1	decoration					710:719	N-linked glycan decoration	694:719	N-linked glycan decoration of PD-L1	694:728	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	4	33	theme	target	980:985	arg1	space					987:991	the target space	976:991	the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1	976:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	1	34	theme	ligand-1	167:174	arg1	activity					138:145	the immune evasion activity	119:145	the immune evasion activity of programmed death ligand-1 (PD-L1)	119:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	3	35	theme	form	828:831	arg1	retention					775:783	the endoplasmic reticulum retention	749:783	the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1	749:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	36	theme	PD-L1	724:728	arg1	decoration					710:719	N-linked glycan decoration	694:719	N-linked glycan decoration of PD-L1	694:728	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	4	37	theme	inner	887:891	arg1	surface					893:899	the inner surface	883:899	the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1	883:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	6	38	theme	cell	1259:1262	arg1	xCELLigence					1274:1284	xCELLigence	1274:1284	xCELLigence	1274:1284	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	6	38	theme	cell	1259:1262	arg1	analysis					1264:1271	Impedance-based real-time cell analysis	1233:1271	Impedance-based real-time cell analysis (xCELLigence)	1233:1285	Impedance-based real-time cell analysis (xCELLigence) showed that cytotoxic T-lymphocyte activity was notably exacerbated when cancer cells were previously exposed to RSV.
31901900	2	39	theme	migration	435:443	arg1	pattern					445:451	a distinct PD-L1 electrophoretic migration pattern	402:451	a distinct PD-L1 electrophoretic migration pattern	402:451	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	3	40	theme	N-linked	694:701	arg1	decoration					710:719	N-linked glycan decoration	694:719	N-linked glycan decoration of PD-L1	694:728	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	41	theme	glycan	703:708	arg1	decoration					710:719	N-linked glycan decoration	694:719	N-linked glycan decoration of PD-L1	694:728	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	2	42	theme	PD-L1-targeted	224:237	arg1	effects					239:245	the PD-L1-targeted effects	220:245	the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs	220:299	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	2	43	theme	electrophoretic	419:433	arg1	pattern					445:451	a distinct PD-L1 electrophoretic migration pattern	402:451	a distinct PD-L1 electrophoretic migration pattern	402:451	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	3	44	dep	mannose-rich	790:801	arg1	glycosylated					815:826	glycosylated	815:826	glycosylated	815:826	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	45	theme	glyco-PD-L1-processing	619:640	arg1	α-glucosidase/α-mannosidase					651:677	α-glucosidase/α-mannosidase	651:677	α-glucosidase/α-mannosidase	651:677	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	45	theme	glyco-PD-L1-processing	619:640	arg1	enzymes					642:648	glyco-PD-L1-processing enzymes	619:648	glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1	619:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	46	theme	fluorescence	539:550	arg1	microscopy					552:561	fluorescence microscopy	539:561	fluorescence microscopy	539:561	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	4	47	theme	PD-L1	1065:1069	arg1	dimerization					1049:1060	dimerization	1049:1060	dimerization of PD-L1	1049:1069	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	5	48	theme	cell	1211:1214	arg1	membrane					1223:1230	the cancer cell plasma membrane	1200:1230	the cancer cell plasma membrane	1200:1230	The ability of RSV to directly target PD-L1 interferes with its stability and trafficking, ultimately impeding its targeting to the cancer cell plasma membrane.
31901900	3	49	theme	enzymes	642:648	arg1	inhibitor					606:614	a direct inhibitor	597:614	a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1	597:840	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	7	50	theme	unforeseen	1410:1419	arg1	mechanism					1438:1446	This unforeseen immunomodulating mechanism	1405:1446	This unforeseen immunomodulating mechanism of RSV	1405:1453	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	1	51	theme	immune	123:128	arg1	activity					138:145	the immune evasion activity	119:145	the immune evasion activity of programmed death ligand-1 (PD-L1)	119:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	5	52	theme	plasma	1216:1221	arg1	membrane					1223:1230	the cancer cell plasma membrane	1200:1230	the cancer cell plasma membrane	1200:1230	The ability of RSV to directly target PD-L1 interferes with its stability and trafficking, ultimately impeding its targeting to the cancer cell plasma membrane.
31901900	2	53	theme	metabolism-targeting	274:293	arg1	drugs					295:299	mechanistically diverse metabolism-targeting drugs	250:299	mechanistically diverse metabolism-targeting drugs	250:299	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	1	54	theme	evasion	130:136	arg1	activity					138:145	the immune evasion activity	119:145	the immune evasion activity of programmed death ligand-1 (PD-L1)	119:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	2	55	theme	diverse	266:272	arg1	drugs					295:299	mechanistically diverse metabolism-targeting drugs	250:299	mechanistically diverse metabolism-targeting drugs	250:299	When exploring the PD-L1-targeted effects of mechanistically diverse metabolism-targeting drugs, exposure to the dietary polyphenol resveratrol (RSV) revealed its differential capacity to generate a distinct PD-L1 electrophoretic migration pattern.
31901900	7	56	theme	new	1472:1474	arg1	approaches					1476:1485	new approaches	1472:1485	new approaches	1472:1485	This unforeseen immunomodulating mechanism of RSV might illuminate new approaches to restore T-cell function by targeting the PD-1/PD-L1 immunologic checkpoint with natural polyphenols.
31901900	0	57	theme	T-cell	78:83	arg1	immunity					85:92	antitumor T-cell immunity	68:92	antitumor T-cell immunity	68:92	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
31901900	3	58	theme	docking/molecular	495:511	arg1	simulations					522:532	computer-aided docking/molecular dynamics simulations	480:532	computer-aided docking/molecular dynamics simulations	480:532	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	3	59	theme	computer-aided	480:493	arg1	simulations					522:532	computer-aided docking/molecular dynamics simulations	480:532	computer-aided docking/molecular dynamics simulations	480:532	Using biochemical assays, computer-aided docking/molecular dynamics simulations, and fluorescence microscopy, we found that RSV can operate as a direct inhibitor of glyco-PD-L1-processing enzymes (α-glucosidase/α-mannosidase) that modulate N-linked glycan decoration of PD-L1, thereby promoting the endoplasmic reticulum retention of a mannose-rich, abnormally glycosylated form of PD-L1.
31901900	4	60	with	interaction	926:936	arg1	PD-1					943:946	PD-1	943:946	PD-1	943:946	RSV was also predicted to interact with the inner surface of PD-L1 involved in the interaction with PD-1, almost perfectly occupying the target space of the small compound BMS-202 that binds to and induces dimerization of PD-L1.
31901900	0	61	theme	antitumor	68:76	arg1	immunity					85:92	antitumor T-cell immunity	68:92	antitumor T-cell immunity	68:92	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
31901900	0	62	theme	PD-L1	20:24	arg1	glycosylation					26:38	PD-L1 glycosylation	20:38	PD-L1 glycosylation	20:38	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
31901900	1	63	theme	programmed	150:159	arg1	PD-L1					177:181	PD-L1	177:181	PD-L1	177:181	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	1	63	theme	programmed	150:159	arg1	ligand-1					167:174	programmed death ligand-1	150:174	programmed death ligand-1 (PD-L1)	150:182	New strategies to block the immune evasion activity of programmed death ligand-1 (PD-L1) are urgently needed.
31901900	5	64	theme	cancer	1204:1209	arg1	membrane					1223:1230	the cancer cell plasma membrane	1200:1230	the cancer cell plasma membrane	1200:1230	The ability of RSV to directly target PD-L1 interferes with its stability and trafficking, ultimately impeding its targeting to the cancer cell plasma membrane.
34567092	4	0	theme	non-functional	908:921	arg1	splicing					935:942	non-functional alternative splicing	908:942	non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9)	908:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	6	1	from	America	1295:1301	arg1	report					1254:1259	the first report	1244:1259	the first report of an ALG1-CDG patient from Latin America	1244:1301	This is the first report of an ALG1-CDG patient from Latin America.
34567092	6	1	from	America	1295:1301	arg1	This					1236:1239	This	1236:1239	This	1236:1239	This is the first report of an ALG1-CDG patient from Latin America.
34567092	6	1	from	America	1295:1301	arg1	patient					1276:1282	an ALG1-CDG patient	1264:1282	an ALG1-CDG patient from Latin America	1264:1301	This is the first report of an ALG1-CDG patient from Latin America.
34567092	6	2	theme	first	1248:1252	arg1	report					1254:1259	the first report	1244:1259	the first report of an ALG1-CDG patient from Latin America	1244:1301	This is the first report of an ALG1-CDG patient from Latin America.
34567092	6	2	theme	first	1248:1252	arg1	This					1236:1239	This	1236:1239	This	1236:1239	This is the first report of an ALG1-CDG patient from Latin America.
34567092	3	3	dep	c.[208	652:657	arg1	T					685:685	1312C > T	677:685	1312C > T	677:685	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	4	4	theme	benign	974:979	arg1	variant					981:987	the benign variant	970:987	the benign variant	970:987	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	5	5	theme	tetrasaccharide	1129:1143	arg1	marker					1145:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker	1085:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1085:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	0	6	theme	Complex	84:90	arg1	Allele					92:97	a Novel Pathogenic Complex Allele	65:97	a Novel Pathogenic Complex Allele	65:97	ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele.
34567092	3	7	theme	>	683:683	arg1	T					685:685	1312C > T	677:685	1312C > T	677:685	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	1	8	theme	multi-systemic	155:168	arg1	syndrome					170:177	a multi-systemic syndrome	153:177	a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile	153:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	5	9	theme	marker	1145:1150	arg1	serum					1076:1080	the patient's serum	1062:1080	the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1062:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	1	10	with	patient	140:146	arg1	syndrome					170:177	a multi-systemic syndrome	153:177	a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile	153:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	4	11	theme	pathogenic	794:803	arg1	variant					805:811	a known ALG1 pathogenic variant	781:811	a known ALG1 pathogenic variant (c.1312C > T)	781:825	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	11	theme	pathogenic	794:803	arg1	T					824:824	c.1312C > T	814:824	c.1312C > T	814:824	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	12	dep	variant	874:880	arg1	c.208					883:887	c.208	883:887	c.208	883:887	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	12	dep	variant	874:880	arg1	T					897:897	25G > T	891:897	25G > T	891:897	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	13	with	conjunction	953:963	arg1	variant					981:987	the benign variant	970:987	the benign variant	970:987	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	14	contain	carried	844:850	arg2	variant					874:880	a new uncharacterized variant	852:880	a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9)	852:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	14	contain	carried	844:850	arg1	other					838:842	other	838:842	other	838:842	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	15	theme	>	895:895	arg1	T					897:897	25G > T	891:897	25G > T	891:897	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	16	contain	carried	711:717	arg2	19dup					755:759	19dup	755:759	19dup	755:759	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	16	contain	carried	711:717	arg2	16_208					746:751	16_208	746:751	16_208	746:751	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	16	contain	carried	711:717	arg1	alleles					703:709	both alleles	698:709	both alleles	698:709	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	16	contain	carried	711:717	arg2	variant					730:736	the benign variant c.208 + 16_208	719:751	variant	730:736	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	3	17	theme	complex	549:555	arg1	NM_019109.5					570:580	NM_019109.5	570:580	NM_019109.5	570:580	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	17	theme	complex	549:555	arg1	alleles					557:563	The identified complex alleles	534:563	The identified complex alleles	534:563	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	c.[208					652:657	c.[208	652:657	c.[208	652:657	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	c.[208					589:594	c.[208	589:594	c.[208	589:594	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	16_208					661:666	16_208	661:666	16_208	661:666	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	NM_019109.5					633:643	NM_019109.5	633:643	NM_019109.5	633:643	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	ALG1					645:648	ALG1	645:648	ALG1	645:648	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	16_208					598:603	16_208	598:603	16_208	598:603	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	19dup					670:674	19dup	670:674	19dup	670:674	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	18	dep	NM_019109.5	570:580	arg1	19dup					607:611	19dup	607:611	19dup	607:611	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	2	19	theme	dolichol-pyrophosphate-GlcNAc2Man5	436:469	arg1	formation					419:427	the formation	415:427	the formation of the dolichol-pyrophosphate-GlcNAc2Man5	415:469	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	2	19	theme	dolichol-pyrophosphate-GlcNAc2Man5	436:469	arg1	intermediate					494:505	a lipid-linked glycan intermediate	472:505	a lipid-linked glycan intermediate during N-glycan synthesis	472:531	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	4	20	theme	25G	891:893	arg1	T					897:897	25G > T	891:897	25G > T	891:897	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	2	21	theme	complex	289:295	arg1	alleles					297:303	complex alleles	289:303	complex alleles	289:303	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	4	22	theme	>	822:822	arg1	variant					805:811	a known ALG1 pathogenic variant	781:811	a known ALG1 pathogenic variant (c.1312C > T)	781:825	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	22	theme	>	822:822	arg1	T					824:824	c.1312C > T	814:824	c.1312C > T	814:824	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	23	theme	benign	723:728	arg1	variant					730:736	the benign variant c.208 + 16_208	719:751	variant	730:736	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	1	24	theme	neurological	189:200	arg1	involvement					202:212	neurological involvement	189:212	neurological involvement	189:212	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	2	25	theme	N-glycan	514:521	arg1	synthesis					523:531	N-glycan synthesis	514:531	N-glycan synthesis	514:531	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	4	26	theme	c.1312C	814:820	arg1	variant					805:811	a known ALG1 pathogenic variant	781:811	a known ALG1 pathogenic variant (c.1312C > T)	781:825	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	26	theme	c.1312C	814:820	arg1	T					824:824	c.1312C > T	814:824	c.1312C > T	814:824	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	2	27	theme	encoding	318:325	arg1	ALG1					308:311	ALG1	308:311	ALG1	308:311	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	2	27	theme	encoding	318:325	arg1	gene					327:330	the encoding gene	314:330	the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis	314:531	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	0	28	theme	Non-functional	19:32	arg1	Splicing					46:53	Non-functional Alternative Splicing	19:53	Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele	19:97	ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele.
34567092	5	29	theme	pathognomonic	1089:1101	arg1	marker					1145:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker	1085:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1085:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	4	30	theme	uncharacterized	858:872	arg1	variant					874:880	a new uncharacterized variant	852:880	a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9)	852:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	2	31	theme	glycan	487:492	arg1	intermediate					494:505	a lipid-linked glycan intermediate	472:505	a lipid-linked glycan intermediate during N-glycan synthesis	472:531	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	2	31	theme	glycan	487:492	arg1	formation					419:427	the formation	415:427	the formation of the dolichol-pyrophosphate-GlcNAc2Man5	415:469	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	3	32	theme	25G	620:622	arg1	T					626:626	25G > T	620:626	25G > T	620:626	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	5	33	theme	N-linked	1103:1110	arg1	marker					1145:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker	1085:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1085:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	4	34	theme	new	854:856	arg1	variant					874:880	a new uncharacterized variant	852:880	a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9)	852:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	3	35	dep	c.[208	589:594	arg1	208					614:616	208	614:616	208	614:616	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	35	dep	c.[208	589:594	arg1	T					626:626	25G > T	620:626	25G > T	620:626	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	2	36	theme	lipid-linked	474:485	arg1	intermediate					494:505	a lipid-linked glycan intermediate	472:505	a lipid-linked glycan intermediate during N-glycan synthesis	472:531	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	2	36	theme	lipid-linked	474:485	arg1	formation					419:427	the formation	415:427	the formation of the dolichol-pyrophosphate-GlcNAc2Man5	415:469	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	5	37	theme	mannose-deprived	1112:1127	arg1	marker					1145:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker	1085:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1085:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	4	38	theme	known	783:787	arg1	variant					805:811	a known ALG1 pathogenic variant	781:811	a known ALG1 pathogenic variant (c.1312C > T)	781:825	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	38	theme	known	783:787	arg1	T					824:824	c.1312C > T	814:824	c.1312C > T	814:824	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	6	39	theme	patient	1276:1282	arg1	report					1254:1259	the first report	1244:1259	the first report of an ALG1-CDG patient from Latin America	1244:1301	This is the first report of an ALG1-CDG patient from Latin America.
34567092	6	39	theme	patient	1276:1282	arg1	This					1236:1239	This	1236:1239	This	1236:1239	This is the first report of an ALG1-CDG patient from Latin America.
34567092	1	40	theme	type	220:223	arg1	profile					245:251	a type I serum transferrin profile	218:251	a type I serum transferrin profile	218:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	0	41	theme	Alternative	34:44	arg1	Splicing					46:53	Non-functional Alternative Splicing	19:53	Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele	19:97	ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele.
34567092	4	42	contain	carried	773:779	arg1	allele					766:771	one allele	762:771	one allele	762:771	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	42	contain	carried	773:779	arg2	variant					805:811	a known ALG1 pathogenic variant	781:811	a known ALG1 pathogenic variant (c.1312C > T)	781:825	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	42	contain	carried	773:779	arg2	T					824:824	c.1312C > T	814:824	c.1312C > T	814:824	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	6	43	from	report	1254:1259	arg1	America					1295:1301	America	1295:1301	America	1295:1301	This is the first report of an ALG1-CDG patient from Latin America.
34567092	6	44	theme	ALG1-CDG	1267:1274	arg1	patient					1276:1282	an ALG1-CDG patient	1264:1282	an ALG1-CDG patient from Latin America	1264:1301	This is the first report of an ALG1-CDG patient from Latin America.
34567092	3	45	theme	>	624:624	arg1	T					626:626	25G > T	620:626	25G > T	620:626	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	5	46	from	presence	1050:1057	arg1	serum					1076:1080	the patient's serum	1062:1080	the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1062:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	4	47	theme	ALG1	789:792	arg1	variant					805:811	a known ALG1 pathogenic variant	781:811	a known ALG1 pathogenic variant (c.1312C > T)	781:825	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	47	theme	ALG1	789:792	arg1	T					824:824	c.1312C > T	814:824	c.1312C > T	814:824	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	2	48	theme	chitobiosyldiphosphodolichol	340:367	arg1	beta-mannosyltransferase					369:392	the chitobiosyldiphosphodolichol beta-mannosyltransferase	336:392	the chitobiosyldiphosphodolichol beta-mannosyltransferase	336:392	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	4	49	theme	pathogenic	1002:1011	arg1	p.N70S_S71ins9					1029:1042	p.N70S_S71ins9	1029:1042	p.N70S_S71ins9	1029:1042	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	49	theme	pathogenic	1002:1011	arg1	effect					1021:1026	the pathogenic protein effect	998:1026	the pathogenic protein effect (p.N70S_S71ins9)	998:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	3	50	theme	1312C	677:681	arg1	T					685:685	1312C > T	677:685	1312C > T	677:685	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	4	51	theme	alternative	923:933	arg1	splicing					935:942	non-functional alternative splicing	908:942	non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9)	908:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	1	52	theme	Mexican	124:130	arg1	patient					140:146	a Mexican mestizo patient	122:146	a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile	122:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	1	53	theme	serum	227:231	arg1	profile					245:251	a type I serum transferrin profile	218:251	a type I serum transferrin profile	218:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	5	54	link	N-linked	1103:1110	arg1	marker					1145:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker	1085:1150	the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc)	1085:1200	The presence in the patient's serum of the pathognomonic N-linked mannose-deprived tetrasaccharide marker for ALG1-CDG (Neu5Acα2,6Galβ1,4-GlcNAcβ1,4GlcNAc) further supported this diagnosis.
34567092	1	55	theme	mestizo	132:138	arg1	patient					140:146	a Mexican mestizo patient	122:146	a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile	122:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	1	56	theme	transferrin	233:243	arg1	profile					245:251	a type I serum transferrin profile	218:251	a type I serum transferrin profile	218:251	This study reports on a Mexican mestizo patient with a multi-systemic syndrome including neurological involvement and a type I serum transferrin profile.
34567092	0	57	theme	Pathogenic	73:82	arg1	Allele					92:97	a Novel Pathogenic Complex Allele	65:97	a Novel Pathogenic Complex Allele	65:97	ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele.
34567092	2	58	link	lipid-linked	474:485	arg1	intermediate					494:505	a lipid-linked glycan intermediate	472:505	a lipid-linked glycan intermediate during N-glycan synthesis	472:531	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	2	58	link	lipid-linked	474:485	arg1	formation					419:427	the formation	415:427	the formation of the dolichol-pyrophosphate-GlcNAc2Man5	415:469	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	2	59	theme	exome	263:267	arg1	sequencing					269:278	Clinical exome sequencing	254:278	Clinical exome sequencing	254:278	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
34567092	3	60	theme	identified	538:547	arg1	NM_019109.5					570:580	NM_019109.5	570:580	NM_019109.5	570:580	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	3	60	theme	identified	538:547	arg1	alleles					557:563	The identified complex alleles	534:563	The identified complex alleles	534:563	The identified complex alleles were NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 208 + 25G > T] and NM_019109.5(ALG1): c.[208 + 16_208 + 19dup; 1312C > T].
34567092	4	61	theme	protein	1013:1019	arg1	p.N70S_S71ins9					1029:1042	p.N70S_S71ins9	1029:1042	p.N70S_S71ins9	1029:1042	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	4	61	theme	protein	1013:1019	arg1	effect					1021:1026	the pathogenic protein effect	998:1026	the pathogenic protein effect (p.N70S_S71ins9)	998:1043	Although both alleles carried the benign variant c.208 + 16_208 + 19dup, one allele carried a known ALG1 pathogenic variant (c.1312C > T), while the other carried a new uncharacterized variant (c.208 + 25G > T) causing non-functional alternative splicing that, in conjunction with the benign variant, defines the pathogenic protein effect (p.N70S_S71ins9).
34567092	0	62	theme	Novel	67:71	arg1	Allele					92:97	a Novel Pathogenic Complex Allele	65:97	a Novel Pathogenic Complex Allele	65:97	ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele.
34567092	2	63	theme	Clinical	254:261	arg1	sequencing					269:278	Clinical exome sequencing	254:278	Clinical exome sequencing	254:278	Clinical exome sequencing revealed complex alleles in ALG1, the encoding gene for the chitobiosyldiphosphodolichol beta-mannosyltransferase that participates in the formation of the dolichol-pyrophosphate-GlcNAc2Man5, a lipid-linked glycan intermediate during N-glycan synthesis.
31851120	4	0	theme	humanized	564:572	arg1	METHODS					530:536	METHODS	530:536	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene)	530:670	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	0	theme	humanized	564:572	arg1	SP-B-T					585:590	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	SP-B-T	585:590	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	7	1	theme	surfactants	1070:1080	arg1	tension					1059:1065	Surface tension	1051:1065	Surface tension of surfactants	1051:1080	Surface tension of surfactants was determined with constrained drop surfactometry.
31851120	8	2	from	cells	1315:1319	arg1	numbers					1277:1283	reduced numbers	1269:1283	reduced numbers of lamellar bodies in type II cells	1269:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	2	from	cells	1315:1319	arg1	inflammation					1204:1215	inflammation	1204:1215	inflammation	1204:1215	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	2	from	cells	1315:1319	arg1	mortality					1221:1229	mortality	1221:1229	mortality	1221:1229	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	2	from	cells	1315:1319	arg1	bioluminescence					1168:1182	higher bioluminescence	1161:1182	higher bioluminescence	1161:1182	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	2	from	cells	1315:1319	arg1	CFUs					1188:1191	CFUs	1188:1191	CFUs	1188:1191	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	2	from	cells	1315:1319	arg1	score					1243:1247	the higher score	1232:1247	the higher score of lung injury	1232:1262	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	1	3	theme	surface	247:253	arg1	tension					255:261	lowering alveolar surface tension	229:261	lowering alveolar surface tension	229:261	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	10	4	theme	multiple	1485:1492	arg1	cytokines					1494:1502	multiple cytokines	1485:1502	multiple cytokines	1485:1502	Levels of multiple cytokines in the lung of infected SP-B-C were higher than those of SP-B-T and WT (P < 0.01).
31851120	9	5	theme	Minimum	1360:1366	arg1	tension					1376:1382	Minimum surface tension	1360:1382	Minimum surface tension	1360:1382	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	8	6	from	CFUs	1188:1191	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	4	7	theme	T	638:638	arg1	allele					640:645	either hSP-B C or T allele	620:645	allele	640:645	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	2	8	link	N-linked	346:353	arg1	glycosylation					355:367	the N-linked glycosylation	342:367	the N-linked glycosylation	342:367	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	12	9	theme	inflammatory	1874:1885	arg1	signaling					1887:1895	inflammatory signaling	1874:1895	inflammatory signaling	1874:1895	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	8	10	from	bioluminescence	1168:1182	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	11	11	theme	NLRP3	1674:1678	arg1	activation					1693:1702	NLRP3 inflammasome activation	1674:1702	NLRP3 inflammasome activation	1674:1702	Furthermore, compared with SP-B-T or WT, SP-B-C exhibited lower SP-B, higher NF-κB and NLRP3 inflammasome activation, and higher activated caspase-3.
31851120	8	12	theme	higher	1161:1166	arg1	bioluminescence					1168:1182	higher bioluminescence	1161:1182	higher bioluminescence	1161:1182	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	1	13	theme	critical	194:201	arg1	roles					203:207	critical roles	194:207	critical roles	194:207	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	12	14	theme	cell	1858:1861	arg1	death					1863:1867	cell death	1858:1867	cell death	1858:1867	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	7	15	theme	drop	1114:1117	arg1	surfactometry					1119:1131	constrained drop surfactometry	1102:1131	constrained drop surfactometry	1102:1131	Surface tension of surfactants was determined with constrained drop surfactometry.
31851120	8	16	from	mortality	1221:1229	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	17	theme	lung	1252:1255	arg1	injury					1257:1262	lung injury	1252:1262	lung injury	1252:1262	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	10	18	theme	infected	1519:1526	arg1	SP-B-C					1528:1533	infected SP-B-C	1519:1533	infected SP-B-C	1519:1533	Levels of multiple cytokines in the lung of infected SP-B-C were higher than those of SP-B-T and WT (P < 0.01).
31851120	11	19	dep	lower	1645:1649	arg1	SP-B					1651:1654	SP-B	1651:1654	SP-B	1651:1654	Furthermore, compared with SP-B-T or WT, SP-B-C exhibited lower SP-B, higher NF-κB and NLRP3 inflammasome activation, and higher activated caspase-3.
31851120	11	19	dep	lower	1645:1649	arg1	higher					1657:1662	higher	1657:1662	higher	1657:1662	Furthermore, compared with SP-B-T or WT, SP-B-C exhibited lower SP-B, higher NF-κB and NLRP3 inflammasome activation, and higher activated caspase-3.
31851120	8	20	from	inflammation	1204:1215	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	1	21	theme	Surfactant	134:143	arg1	SP-B					156:159	SP-B	156:159	SP-B	156:159	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	1	21	theme	Surfactant	134:143	arg1	B					153:153	Surfactant protein B	134:153	Surfactant protein B (SP-B)	134:160	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	5	22	dep	in	912:913	arg1	vivo					915:918	vivo	915:918	vivo	915:918	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	5	23	dep	postinfection	895:907	arg1	h					893:893	h	893:893	h	893:893	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	8	24	from	score	1243:1247	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	4	25	dep	50 μL	707:711	arg1	Xen5					779:782	Pseudomonas aeruginosa Xen5	756:782	50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5	707:782	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	26	theme	SP-B	661:664	arg1	gene					666:669	mouse SP-B gene	655:669	mouse SP-B gene	655:669	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	27	dep	Wild-type	538:546	arg1	WT					549:550	WT	549:550	WT	549:550	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	5	28	theme	dynamic	849:855	arg1	growths					857:863	Bacterial dynamic growths	839:863	Bacterial dynamic growths	839:863	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	8	29	dep	RESULTS	1134:1140	arg1	showed					1154:1159	showed	1154:1159	showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05)	1154:1357	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	5	30	dep	48	890:891	arg1	to					887:888	to	887:888	to	887:888	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	12	31	theme	surface	1826:1832	arg1	activity					1834:1841	the surface activity	1822:1841	the surface activity of surfactant, cell death, and inflammatory signaling in sepsis	1822:1905	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	9	32	theme	>	1460:1460	arg1	WT					1471:1472	SP-B-C > SP-B-T > WT	1453:1472	SP-B-C > SP-B-T > WT	1453:1472	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	6	33	theme	cellular	948:955	arg1	changes					972:978	Histopathological, cellular, and molecular changes	929:978	Histopathological, cellular, and molecular changes of lung tissues	929:994	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	8	34	theme	bodies	1297:1302	arg1	numbers					1277:1283	reduced numbers	1269:1283	reduced numbers of lamellar bodies in type II cells	1269:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	34	theme	bodies	1297:1302	arg1	inflammation					1204:1215	inflammation	1204:1215	inflammation	1204:1215	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	34	theme	bodies	1297:1302	arg1	mortality					1221:1229	mortality	1221:1229	mortality	1221:1229	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	34	theme	bodies	1297:1302	arg1	bioluminescence					1168:1182	higher bioluminescence	1161:1182	higher bioluminescence	1161:1182	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	34	theme	bodies	1297:1302	arg1	CFUs					1188:1191	CFUs	1188:1191	CFUs	1188:1191	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	34	theme	bodies	1297:1302	arg1	score					1243:1247	the higher score	1232:1247	the higher score of lung injury	1232:1262	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	11	35	theme	lower	1645:1649	arg1	NF-κB					1664:1668	lower SP-B, higher NF-κB	1645:1668	lower SP-B, higher NF-κB	1645:1668	Furthermore, compared with SP-B-T or WT, SP-B-C exhibited lower SP-B, higher NF-κB and NLRP3 inflammasome activation, and higher activated caspase-3.
31851120	0	36	theme	Pseudomonas	85:95	arg1	Sepsis					126:131	Pseudomonas Aeruginosa Pneumonia-Induced Sepsis	85:131	Pseudomonas Aeruginosa Pneumonia-Induced Sepsis	85:131	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	4	37	dep	FVB/NJ	553:558	arg1	expressing					609:618	expressing	609:618	expressing either hSP-B C or T allele without mouse SP-B gene	609:669	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	9	38	theme	>	1469:1469	arg1	WT					1471:1472	SP-B-C > SP-B-T > WT	1453:1472	SP-B-C > SP-B-T > WT	1453:1472	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	6	39	theme	Histopathological	929:945	arg1	changes					972:978	Histopathological, cellular, and molecular changes	929:978	Histopathological, cellular, and molecular changes of lung tissues	929:994	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	8	40	theme	type	1307:1310	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	0	41	theme	Pneumonia-Induced	108:124	arg1	Sepsis					126:131	Pseudomonas Aeruginosa Pneumonia-Induced Sepsis	85:131	Pseudomonas Aeruginosa Pneumonia-Induced Sepsis	85:131	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	0	42	dep	Pseudomonas	85:95	arg1	Aeruginosa					97:106	Aeruginosa	97:106	Aeruginosa	97:106	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	0	43	theme	Regulatory	0:9	arg1	Roles					11:15	Regulatory Roles	0:15	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.	0:132	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	6	44	theme	lavage	1016:1021	arg1	fluid					1023:1027	bronchoalveolar lavage fluid	1000:1027	bronchoalveolar lavage fluid (BALF)	1000:1034	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	6	44	theme	lavage	1016:1021	arg1	BALF					1030:1033	BALF	1030:1033	BALF	1030:1033	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	4	45	theme	units	736:740	arg1	50 μL					707:711	50 μL	707:711	50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5	707:782	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	45	theme	units	736:740	arg1	/mouse					748:753	4 × 10 colony-forming units [CFUs]/mouse	714:753	4 × 10 colony-forming units [CFUs]/mouse	714:753	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	12	46	theme	hSP-B	1749:1753	arg1	variants					1755:1762	CONCLUSIONS hSP-B variants	1737:1762	CONCLUSIONS hSP-B variants	1737:1762	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	8	47	theme	reduced	1269:1275	arg1	numbers					1277:1283	reduced numbers	1269:1283	reduced numbers of lamellar bodies in type II cells	1269:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	9	48	dep	increased	1384:1392	arg1	P < 0.01					1425:1432	P < 0.01	1425:1432	P < 0.01	1425:1432	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	2	49	theme	SP-B	396:399	arg1	function					401:408	SP-B function	396:408	SP-B function	396:408	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	7	50	theme	constrained	1102:1112	arg1	surfactometry					1119:1131	constrained drop surfactometry	1102:1131	constrained drop surfactometry	1102:1131	Surface tension of surfactants was determined with constrained drop surfactometry.
31851120	0	51	theme	Surfactant	26:35	arg1	Variants					47:54	Human Surfactant Protein B Variants	20:54	Human Surfactant Protein B Variants	20:54	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	12	52	from	activity	1834:1841	arg1	sepsis					1900:1905	sepsis	1900:1905	sepsis	1900:1905	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	6	53	theme	lung	983:986	arg1	tissues					988:994	lung tissues	983:994	lung tissues	983:994	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	3	54	theme	variants	477:484	arg1	roles					454:458	the regulatory roles	439:458	the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis	439:527	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	4	55	dep	h	820:820	arg1	infection					828:836	infection	828:836	infection	828:836	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	3	56	theme	hSP-B	463:467	arg1	variants					477:484	hSP-B genetic variants	463:484	hSP-B genetic variants	463:484	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	1	57	theme	host	212:215	arg1	defense					217:223	host defense	212:223	host defense	212:223	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	2	58	theme	N-linked	346:353	arg1	glycosylation					355:367	the N-linked glycosylation	342:367	the N-linked glycosylation	342:367	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	3	59	theme	lung	489:492	arg1	injury					494:499	lung injury	489:499	lung injury in pneumonia-induced sepsis	489:527	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	1	60	theme	alveolar	238:245	arg1	tension					255:261	lowering alveolar surface tension	229:261	lowering alveolar surface tension	229:261	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	10	61	theme	cytokines	1494:1502	arg1	Levels					1475:1480	Levels	1475:1480	Levels of multiple cytokines in the lung of infected SP-B-C	1475:1533	Levels of multiple cytokines in the lung of infected SP-B-C were higher than those of SP-B-T and WT (P < 0.01).
31851120	7	62	theme	Surface	1051:1057	arg1	tension					1059:1065	Surface tension	1051:1065	Surface tension of surfactants	1051:1080	Surface tension of surfactants was determined with constrained drop surfactometry.
31851120	3	63	from	injury	494:499	arg1	sepsis					522:527	pneumonia-induced sepsis	504:527	pneumonia-induced sepsis	504:527	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	4	64	theme	transgenic	574:583	arg1	METHODS					530:536	METHODS	530:536	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene)	530:670	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	64	theme	transgenic	574:583	arg1	SP-B-T					585:590	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	SP-B-T	585:590	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	2	65	theme	single-nucleotide	266:282	arg1	polymorphism					284:295	A single-nucleotide polymorphism	264:295	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B)	264:333	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	2	65	theme	single-nucleotide	266:282	arg1	hSP-B					328:332	hSP-B	328:332	hSP-B	328:332	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	2	65	theme	single-nucleotide	266:282	arg1	SNP					298:300	SNP rs1130866	298:310	SNP rs1130866	298:310	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	9	66	theme	surface	1368:1374	arg1	tension					1376:1382	Minimum surface tension	1360:1382	Minimum surface tension	1360:1382	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	0	67	theme	B	45:45	arg1	Variants					47:54	Human Surfactant Protein B Variants	20:54	Human Surfactant Protein B Variants	20:54	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	8	68	theme	increased	1194:1202	arg1	inflammation					1204:1215	inflammation	1204:1215	inflammation	1204:1215	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	69	theme	SP-B-C	1142:1147	arg1	mice					1149:1152	SP-B-C mice	1142:1152	SP-B-C mice	1142:1152	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	11	70	theme	inflammasome	1680:1691	arg1	activation					1693:1702	NLRP3 inflammasome activation	1674:1702	NLRP3 inflammasome activation	1674:1702	Furthermore, compared with SP-B-T or WT, SP-B-C exhibited lower SP-B, higher NF-κB and NLRP3 inflammasome activation, and higher activated caspase-3.
31851120	12	71	theme	signaling	1887:1895	arg1	activity					1834:1841	the surface activity	1822:1841	the surface activity of surfactant, cell death, and inflammatory signaling in sepsis	1822:1905	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	8	72	theme	higher	1236:1241	arg1	score					1243:1247	the higher score	1232:1247	the higher score of lung injury	1232:1262	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	10	73	theme	SP-B-C	1528:1533	arg1	lung					1511:1514	the lung	1507:1514	the lung of infected SP-B-C	1507:1533	Levels of multiple cytokines in the lung of infected SP-B-C were higher than those of SP-B-T and WT (P < 0.01).
31851120	12	74	theme	death	1863:1867	arg1	activity					1834:1841	the surface activity	1822:1841	the surface activity of surfactant, cell death, and inflammatory signaling in sepsis	1822:1905	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	1	75	theme	protein	145:151	arg1	SP-B					156:159	SP-B	156:159	SP-B	156:159	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	1	75	theme	protein	145:151	arg1	B					153:153	Surfactant protein B	134:153	Surfactant protein B (SP-B)	134:160	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
31851120	9	76	theme	SP-B-T	1462:1467	arg1	WT					1471:1472	SP-B-C > SP-B-T > WT	1453:1472	SP-B-C > SP-B-T > WT	1453:1472	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	8	77	theme	injury	1257:1262	arg1	numbers					1277:1283	reduced numbers	1269:1283	reduced numbers of lamellar bodies in type II cells	1269:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	77	theme	injury	1257:1262	arg1	inflammation					1204:1215	inflammation	1204:1215	inflammation	1204:1215	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	77	theme	injury	1257:1262	arg1	mortality					1221:1229	mortality	1221:1229	mortality	1221:1229	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	77	theme	injury	1257:1262	arg1	bioluminescence					1168:1182	higher bioluminescence	1161:1182	higher bioluminescence	1161:1182	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	77	theme	injury	1257:1262	arg1	CFUs					1188:1191	CFUs	1188:1191	CFUs	1188:1191	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	8	77	theme	injury	1257:1262	arg1	score					1243:1247	the higher score	1232:1247	the higher score of lung injury	1232:1262	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	2	78	theme	SP-B	322:325	arg1	polymorphism					284:295	A single-nucleotide polymorphism	264:295	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B)	264:333	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	2	78	theme	SP-B	322:325	arg1	hSP-B					328:332	hSP-B	328:332	hSP-B	328:332	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	2	78	theme	SP-B	322:325	arg1	SNP					298:300	SNP rs1130866	298:310	SNP rs1130866	298:310	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	0	79	theme	Genetic	59:65	arg1	Susceptibility					67:80	Genetic Susceptibility	59:80	Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis	59:131	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	5	80	theme	Bacterial	839:847	arg1	growths					857:863	Bacterial dynamic growths	839:863	Bacterial dynamic growths	839:863	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	6	81	theme	molecular	962:970	arg1	changes					972:978	Histopathological, cellular, and molecular changes	929:978	Histopathological, cellular, and molecular changes of lung tissues	929:994	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	4	82	theme	mouse	655:659	arg1	gene					666:669	mouse SP-B gene	655:669	mouse SP-B gene	655:669	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	83	dep	METHODS	530:536	arg1	METHODS					530:536	METHODS	530:536	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene)	530:670	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	83	dep	METHODS	530:536	arg1	SP-B-T					585:590	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	SP-B-T	585:590	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	83	dep	METHODS	530:536	arg1	mice					603:606	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	mice	603:606	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	83	dep	METHODS	530:536	arg1	FVB/NJ					553:558	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	FVB/NJ	553:558	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	9	84	theme	SP-B-C	1453:1458	arg1	WT					1471:1472	SP-B-C > SP-B-T > WT	1453:1472	SP-B-C > SP-B-T > WT	1453:1472	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	0	85	from	Roles	11:15	arg1	Susceptibility					67:80	Genetic Susceptibility	59:80	Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis	59:131	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	5	86	dep	h	893:893	arg1	48					890:891	48	890:891	48	890:891	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	12	87	theme	surfactant	1846:1855	arg1	activity					1834:1841	the surface activity	1822:1841	the surface activity of surfactant, cell death, and inflammatory signaling in sepsis	1822:1905	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	5	88	theme	in	912:913	arg1	imaging					920:926	in vivo imaging	912:926	in vivo imaging	912:926	Bacterial dynamic growths were monitored from 0 to 48 h postinfection by in vivo imaging.
31851120	8	89	theme	lamellar	1288:1295	arg1	bodies					1297:1302	lamellar bodies	1288:1302	lamellar bodies in type II cells	1288:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	4	90	theme	[CFUs	742:746	arg1	50 μL					707:711	50 μL	707:711	50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5	707:782	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	90	theme	[CFUs	742:746	arg1	/mouse					748:753	4 × 10 colony-forming units [CFUs]/mouse	714:753	4 × 10 colony-forming units [CFUs]/mouse	714:753	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	2	91	theme	human	316:320	arg1	SP-B					322:325	human SP-B	316:325	human SP-B	316:325	A single-nucleotide polymorphism (SNP rs1130866) of human SP-B (hSP-B) alters the N-linked glycosylation, thus presumably affecting SP-B function.
31851120	9	92	theme	infected	1410:1417	arg1	mice					1419:1422	infected mice	1410:1422	infected mice	1410:1422	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	9	93	theme	WT	1471:1472	arg1	order					1444:1448	the order	1440:1448	the order of SP-B-C > SP-B-T > WT	1440:1472	Minimum surface tension increased dramatically in infected mice (P < 0.01) with the order of SP-B-C > SP-B-T > WT.
31851120	8	94	from	numbers	1277:1283	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	0	95	theme	Human	20:24	arg1	Variants					47:54	Human Surfactant Protein B Variants	20:54	Human Surfactant Protein B Variants	20:54	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	6	96	theme	bronchoalveolar	1000:1014	arg1	fluid					1023:1027	bronchoalveolar lavage fluid	1000:1027	bronchoalveolar lavage fluid (BALF)	1000:1034	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	6	96	theme	bronchoalveolar	1000:1014	arg1	BALF					1030:1033	BALF	1030:1033	BALF	1030:1033	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	4	97	theme	4 × 10 colony-forming	714:734	arg1	units					736:740	4 × 10 colony-forming units	714:740	4 × 10 colony-forming units [CFUs]/mouse	714:753	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	0	98	theme	Protein	37:43	arg1	Variants					47:54	Human Surfactant Protein B Variants	20:54	Human Surfactant Protein B Variants	20:54	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	6	99	theme	tissues	988:994	arg1	fluid					1023:1027	bronchoalveolar lavage fluid	1000:1027	bronchoalveolar lavage fluid (BALF)	1000:1034	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	6	99	theme	tissues	988:994	arg1	changes					972:978	Histopathological, cellular, and molecular changes	929:978	Histopathological, cellular, and molecular changes of lung tissues	929:994	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	6	99	theme	tissues	988:994	arg1	BALF					1030:1033	BALF	1030:1033	BALF	1030:1033	Histopathological, cellular, and molecular changes of lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed.
31851120	3	100	theme	regulatory	443:452	arg1	roles					454:458	the regulatory roles	439:458	the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis	439:527	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	0	101	theme	Variants	47:54	arg1	Roles					11:15	Regulatory Roles	0:15	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.	0:132	Regulatory Roles of Human Surfactant Protein B Variants on Genetic Susceptibility to Pseudomonas Aeruginosa Pneumonia-Induced Sepsis.
31851120	4	102	theme	Wild-type	538:546	arg1	METHODS					530:536	METHODS	530:536	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene)	530:670	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	4	102	theme	Wild-type	538:546	arg1	FVB/NJ					553:558	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	FVB/NJ	553:558	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	3	103	from	roles	454:458	arg1	injury					494:499	lung injury	489:499	lung injury in pneumonia-induced sepsis	489:527	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	12	104	theme	CONCLUSIONS	1737:1747	arg1	variants					1755:1762	CONCLUSIONS hSP-B variants	1737:1762	CONCLUSIONS hSP-B variants	1737:1762	CONCLUSIONS hSP-B variants differentially regulate susceptibility through modulating the surface activity of surfactant, cell death, and inflammatory signaling in sepsis.
31851120	10	105	from	Levels	1475:1480	arg1	lung					1511:1514	the lung	1507:1514	the lung of infected SP-B-C	1507:1533	Levels of multiple cytokines in the lung of infected SP-B-C were higher than those of SP-B-T and WT (P < 0.01).
31851120	4	106	theme	SP-B-C	596:601	arg1	mice					603:606	Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice	538:606	mice	603:606	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	3	107	theme	genetic	469:475	arg1	variants					477:484	hSP-B genetic variants	463:484	hSP-B genetic variants	463:484	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	8	108	from	bodies	1297:1302	arg1	cells					1315:1319	type II cells	1307:1319	type II cells	1307:1319	RESULTS SP-B-C mice showed higher bioluminescence and CFUs, increased inflammation and mortality, the higher score of lung injury, and reduced numbers of lamellar bodies in type II cells compared with SP-B-T or WT (P < 0.05).
31851120	4	109	theme	hSP-B	627:631	arg1	C					633:633	either hSP-B C or T allele	620:645	C	633:633	METHODS Wild-type (WT) FVB/NJ and humanized transgenic SP-B-T and SP-B-C mice (expressing either hSP-B C or T allele without mouse SP-B gene) were infected intratracheally with 50 μL (4 × 10 colony-forming units [CFUs]/mouse) Pseudomonas aeruginosa Xen5 or saline, and then killed 24 or 48 h after infection.
31851120	3	110	theme	pneumonia-induced	504:520	arg1	sepsis					522:527	pneumonia-induced sepsis	504:527	pneumonia-induced sepsis	504:527	This study has investigated the regulatory roles of hSP-B genetic variants on lung injury in pneumonia-induced sepsis.
31851120	1	111	theme	lowering	229:236	arg1	tension					255:261	lowering alveolar surface tension	229:261	lowering alveolar surface tension	229:261	Surfactant protein B (SP-B) is essential for life and plays critical roles in host defense and lowering alveolar surface tension.
34662212	14	0	theme	lower	2307:2311	arg1	Δp					2313:2314	a lower Δp	2305:2314	a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it	2305:2460	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	8	1	theme	intestinal	1471:1480	arg1	colonization					1482:1493	intestinal colonization	1471:1493	intestinal colonization	1471:1493	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	10	2	theme	ΔtonB4	1736:1741	arg1	mutants					1755:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants did not significantly affect intestinal colonization.
34662212	6	3	theme	single	1175:1180	arg1	mutants					1182:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	14	4	theme	energy	2659:2664	arg1	harvesting					2645:2654	the harvesting	2641:2654	the harvesting of energy	2641:2664	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	4	5	dep	-ferrichrome	923:934	arg1	III					919:921	III	919:921	III	919:921	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	11	6	theme	ΔtonB3	1847:1852	arg1	strain					1861:1866	the ΔtonB3 mutant strain	1843:1866	the ΔtonB3 mutant strain	1843:1866	Moreover, the survival of the ΔtonB3 mutant strain was completely eradicated in a rat model of intra-abdominal infection.
34662212	14	7	theme	fermentation	2274:2285	arg1	metabolism					2287:2296	anaerobic fermentation metabolism	2264:2296	anaerobic fermentation metabolism	2264:2296	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	8	from	state	2377:2381	arg1	contrast					2411:2418	its periplasmic space-in contrast	2386:2418	its periplasmic space-in contrast to an oxidative environment	2386:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	6	9	theme	ΔtonB5	1156:1161	arg1	mutants					1182:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	1	10	theme	opportunistic	180:192	arg1	638R					293:296	Bacteroides fragilis strain 638R	265:296	Bacteroides fragilis strain 638R	265:296	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	10	theme	opportunistic	180:192	arg1	pathogen					205:212	The opportunistic, anaerobic pathogen	176:212	pathogen	205:212	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	9	11	theme	intestinal	1531:1540	arg1	defect					1549:1554	This intestinal growth defect	1526:1554	This intestinal growth defect	1526:1554	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	13	12	theme	tonB1	2050:2054	arg1	organization					2034:2045	The genetic organization	2022:2045	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs	2022:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	11	13	theme	infection	1928:1936	arg1	model					1903:1907	a rat model	1897:1907	a rat model of intra-abdominal infection	1897:1936	Moreover, the survival of the ΔtonB3 mutant strain was completely eradicated in a rat model of intra-abdominal infection.
34662212	6	14	theme	ΔtonB4	1148:1153	arg1	mutants					1182:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	0	15	from	Survival	96:103	arg1	Colonization					132:143	Experimental Intestinal Colonization	108:143	Experimental Intestinal Colonization	108:143	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	0	15	from	Survival	96:103	arg1	Infection					165:173	Intra-Abdominal Infection	149:173	Intra-Abdominal Infection	149:173	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	1	16	theme	anaerobic	195:203	arg1	638R					293:296	Bacteroides fragilis strain 638R	265:296	Bacteroides fragilis strain 638R	265:296	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	16	theme	anaerobic	195:203	arg1	pathogen					205:212	The opportunistic, anaerobic pathogen	176:212	pathogen	205:212	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	2	17	theme	TonB	520:523	arg1	domain					536:541	the TonB C-terminal domain	516:541	the TonB C-terminal domain	516:541	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	7	18	theme	functional	1253:1262	arg1	compensation					1264:1275	no functional compensation	1250:1275	no functional compensation for the lack of TonB3	1250:1297	This indicates that there was no functional compensation for the lack of TonB3, and it demonstrates that TonB3, alone, drives the TBDTs involved in the transport of essential nutrients.
34662212	3	19	theme	nutrient	699:706	arg1	acquisition					708:718	nutrient acquisition	699:718	nutrient acquisition in B. fragilis	699:733	However, TonB's role in activating nearly one hundred TBDTs for nutrient acquisition in B. fragilis during intestinal colonization and extraintestinal infection has not been established.
34662212	11	20	theme	strain	1861:1866	arg1	survival					1831:1838	the survival	1827:1838	the survival of the ΔtonB3 mutant strain	1827:1866	Moreover, the survival of the ΔtonB3 mutant strain was completely eradicated in a rat model of intra-abdominal infection.
34662212	3	21	theme	intestinal	742:751	arg1	colonization					753:764	intestinal colonization	742:764	intestinal colonization	742:764	However, TonB's role in activating nearly one hundred TBDTs for nutrient acquisition in B. fragilis during intestinal colonization and extraintestinal infection has not been established.
34662212	0	22	theme	Intestinal	121:130	arg1	Colonization					132:143	Experimental Intestinal Colonization	108:143	Experimental Intestinal Colonization	108:143	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	14	23	theme	oxidative	2426:2434	arg1	environment					2436:2446	an oxidative environment	2423:2446	an oxidative environment	2423:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	11	24	theme	intra-abdominal	1912:1926	arg1	infection					1928:1936	intra-abdominal infection	1912:1936	intra-abdominal infection	1912:1936	Moreover, the survival of the ΔtonB3 mutant strain was completely eradicated in a rat model of intra-abdominal infection.
34662212	0	25	from	fragilis	50:57	arg1	Analysis					0:7	Analysis	0:7	Analysis of Six tonB Gene Homologs in Bacteroides fragilis	0:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	1	26	theme	ExbDs	393:397	arg1	orthologs					399:407	five ExbDs orthologs	388:407	five ExbDs orthologs	388:407	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	26	theme	ExbDs	393:397	arg1	ExbD1-5					410:416	ExbD1-5	410:416	ExbD1-5	410:416	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	13	27	theme	tonB6	2082:2086	arg1	orthologs					2093:2101	tonB6 gene orthologs	2082:2101	tonB6 gene orthologs	2082:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	9	28	theme	ΔtonB6	1583:1588	arg1	strain					1604:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	2	29	from	force	500:504	arg1	energy					470:475	energy	470:475	energy from the proton motive force (Δp)	470:509	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	13	30	theme	orthologs	2093:2101	arg1	organization					2034:2045	The genetic organization	2022:2045	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs	2022:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	14	31	theme	space-in	2402:2409	arg1	contrast					2411:2418	its periplasmic space-in contrast	2386:2418	its periplasmic space-in contrast to an oxidative environment	2386:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	9	32	theme	mutant	1597:1602	arg1	strain					1604:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	8	33	contain	had	1424:1426	arg1	mutant					1417:1422	The ΔtonB3 mutant	1406:1422	The ΔtonB3 mutant	1406:1422	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	8	33	contain	had	1424:1426	arg2	defect					1444:1449	a severe growth defect	1428:1449	a severe growth defect	1428:1449	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	4	34	link	N-linked	963:970	arg1	starch					937:942	starch	937:942	starch	937:942	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	34	link	N-linked	963:970	arg1	glycans					972:978	N-linked glycans	963:978	N-linked glycans	963:978	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	34	link	N-linked	963:970	arg1	heme					897:900	heme	897:900	heme	897:900	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	34	link	N-linked	963:970	arg1	mucin-glycans					945:957	mucin-glycans	945:957	mucin-glycans	945:957	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	34	link	N-linked	963:970	arg1	B12					911:913	vitamin B12	903:913	vitamin B12	903:913	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	34	link	N-linked	963:970	arg1	substrate					995:1003	a substrate	993:1003	a substrate for growth	993:1014	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	34	link	N-linked	963:970	arg1	-ferrichrome					923:934	Fe(III)-ferrichrome	916:934	Fe(III)-ferrichrome	916:934	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	2	35	theme	C-terminal	525:534	arg1	domain					536:541	the TonB C-terminal domain	516:541	the TonB C-terminal domain	516:541	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	13	36	theme	genetic	2026:2032	arg1	organization					2034:2045	The genetic organization	2022:2045	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs	2022:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	4	37	theme	vitamin	903:909	arg1	starch					937:942	starch	937:942	starch	937:942	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	37	theme	vitamin	903:909	arg1	glycans					972:978	N-linked glycans	963:978	N-linked glycans	963:978	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	37	theme	vitamin	903:909	arg1	heme					897:900	heme	897:900	heme	897:900	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	37	theme	vitamin	903:909	arg1	mucin-glycans					945:957	mucin-glycans	945:957	mucin-glycans	945:957	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	37	theme	vitamin	903:909	arg1	B12					911:913	vitamin B12	903:913	vitamin B12	903:913	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	37	theme	vitamin	903:909	arg1	substrate					995:1003	a substrate	993:1003	a substrate for growth	993:1014	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	37	theme	vitamin	903:909	arg1	-ferrichrome					923:934	Fe(III)-ferrichrome	916:934	Fe(III)-ferrichrome	916:934	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	0	38	from	Analysis	0:7	arg1	fragilis					50:57	Bacteroides fragilis	38:57	Bacteroides fragilis	38:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	14	39	theme	reduced	2363:2369	arg1	state					2377:2381	a reduced redox state	2361:2381	a reduced redox state in its periplasmic space-in contrast to an oxidative environment	2361:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	2	40	theme	membrane	429:436	arg1	complex					453:459	The inner membrane TonB/ExbB/ExbD complex	419:459	The inner membrane TonB/ExbB/ExbD complex	419:459	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	2	41	theme	motive	493:498	arg1	Δp					507:508	Δp	507:508	Δp	507:508	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	2	41	theme	motive	493:498	arg1	force					500:504	the proton motive force	482:504	the proton motive force (Δp)	482:509	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	1	42	theme	strain	286:291	arg1	638R					293:296	Bacteroides fragilis strain 638R	265:296	Bacteroides fragilis strain 638R	265:296	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	42	theme	strain	286:291	arg1	pathogen					205:212	The opportunistic, anaerobic pathogen	176:212	pathogen	205:212	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	4	43	theme	N-linked	963:970	arg1	starch					937:942	starch	937:942	starch	937:942	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	43	theme	N-linked	963:970	arg1	glycans					972:978	N-linked glycans	963:978	N-linked glycans	963:978	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	43	theme	N-linked	963:970	arg1	heme					897:900	heme	897:900	heme	897:900	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	43	theme	N-linked	963:970	arg1	mucin-glycans					945:957	mucin-glycans	945:957	mucin-glycans	945:957	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	43	theme	N-linked	963:970	arg1	B12					911:913	vitamin B12	903:913	vitamin B12	903:913	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	43	theme	N-linked	963:970	arg1	substrate					995:1003	a substrate	993:1003	a substrate for growth	993:1014	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	43	theme	N-linked	963:970	arg1	-ferrichrome					923:934	Fe(III)-ferrichrome	916:934	Fe(III)-ferrichrome	916:934	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	13	44	theme	tonB2	2057:2061	arg1	organization					2034:2045	The genetic organization	2022:2045	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs	2022:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	7	45	theme	nutrients	1395:1403	arg1	transport					1372:1380	the transport	1368:1380	the transport of essential nutrients	1368:1403	This indicates that there was no functional compensation for the lack of TonB3, and it demonstrates that TonB3, alone, drives the TBDTs involved in the transport of essential nutrients.
34662212	9	46	theme	intestinal	1668:1677	arg1	tract					1679:1683	the mouse intestinal tract	1658:1683	the mouse intestinal tract	1658:1683	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	0	47	theme	Gene	21:24	arg1	Homologs					26:33	Six tonB Gene Homologs	12:33	Six tonB Gene Homologs in Bacteroides fragilis	12:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	5	48	theme	mutant	1064:1069	arg1	complementation					1034:1048	Genetic complementation	1026:1048	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene	1026:1089	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene restored growth on these substrates.
34662212	14	49	theme	orthologs	2527:2535	arg1	system					2502:2507	the diverse system	2490:2507	the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis	2490:2558	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	2	50	theme	proton	486:491	arg1	Δp					507:508	Δp	507:508	Δp	507:508	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	2	50	theme	proton	486:491	arg1	force					500:504	the proton motive force	482:504	the proton motive force (Δp)	482:509	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	14	51	contain	has	2357:2359	arg1	respiration					2329:2339	aerobic respiration	2321:2339	aerobic respiration	2321:2339	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	51	contain	has	2357:2359	arg1	fragilis					2348:2355	B. fragilis	2345:2355	B. fragilis	2345:2355	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	51	contain	has	2357:2359	arg2	state					2377:2381	a reduced redox state	2361:2381	a reduced redox state in its periplasmic space-in contrast to an oxidative environment	2361:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	1	52	theme	TonB	322:325	arg1	proteins					327:334	six predicted TonB proteins	308:334	six predicted TonB proteins	308:334	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	13	53	theme	physiological	2202:2214	arg1	relevance					2216:2224	the physiological relevance	2198:2224	the physiological relevance of this	2198:2232	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	8	54	theme	growth	1437:1442	arg1	defect					1444:1449	a severe growth defect	1428:1449	a severe growth defect	1428:1449	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	14	55	theme	aerobic	2321:2327	arg1	respiration					2329:2339	aerobic respiration	2321:2339	aerobic respiration	2321:2339	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	13	56	theme	outer	2169:2173	arg1	proteins					2184:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	14	57	theme	diverse	2494:2500	arg1	system					2502:2507	the diverse system	2490:2507	the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis	2490:2558	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	58	contain	have	2560:2563	arg1	system					2502:2507	the diverse system	2490:2507	the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis	2490:2558	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	58	contain	have	2560:2563	arg2	sensitivity					2578:2588	an increased sensitivity	2565:2588	an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions	2565:2691	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	8	59	theme	parent	1511:1516	arg1	strain					1518:1523	the parent strain	1507:1523	the parent strain	1507:1523	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	1	60	theme	large	241:245	arg1	tract					258:262	the human large intestinal tract	231:262	the human large intestinal tract	231:262	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	8	61	theme	mouse	1456:1460	arg1	model					1462:1466	a mouse model	1454:1466	a mouse model of intestinal colonization	1454:1493	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	1	62	theme	tract	258:262	arg1	commensal					218:226	commensal	218:226	commensal	218:226	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	62	theme	tract	258:262	arg1	638R					293:296	Bacteroides fragilis strain 638R	265:296	Bacteroides fragilis strain 638R	265:296	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	62	theme	tract	258:262	arg1	pathogen					205:212	The opportunistic, anaerobic pathogen	176:212	pathogen	205:212	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	2	63	theme	membrane	589:596	arg1	TBDTs					627:631	TBDTs	627:631	TBDTs	627:631	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	2	63	theme	membrane	589:596	arg1	transporters					613:624	outer membrane TonB-dependent transporters	583:624	outer membrane TonB-dependent transporters (TBDTs)	583:632	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	6	64	theme	ΔtonB6	1168:1173	arg1	mutants					1182:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	1	65	contain	contains	299:306	arg2	proteins					327:334	six predicted TonB proteins	308:334	six predicted TonB proteins	308:334	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	65	contain	contains	299:306	arg1	commensal					218:226	commensal	218:226	commensal	218:226	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	65	contain	contains	299:306	arg1	638R					293:296	Bacteroides fragilis strain 638R	265:296	Bacteroides fragilis strain 638R	265:296	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	65	contain	contains	299:306	arg1	pathogen					205:212	The opportunistic, anaerobic pathogen	176:212	pathogen	205:212	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	66	theme	Bacteroides	265:275	arg1	638R					293:296	Bacteroides fragilis strain 638R	265:296	Bacteroides fragilis strain 638R	265:296	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	66	theme	Bacteroides	265:275	arg1	pathogen					205:212	The opportunistic, anaerobic pathogen	176:212	pathogen	205:212	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	8	67	theme	colonization	1482:1493	arg1	model					1462:1466	a mouse model	1454:1466	a mouse model of intestinal colonization	1454:1493	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	14	68	theme	anaerobic	2264:2272	arg1	metabolism					2287:2296	anaerobic fermentation metabolism	2264:2296	anaerobic fermentation metabolism	2264:2296	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	2	69	theme	TonB-dependent	598:611	arg1	TBDTs					627:631	TBDTs	627:631	TBDTs	627:631	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	2	69	theme	TonB-dependent	598:611	arg1	transporters					613:624	outer membrane TonB-dependent transporters	583:624	outer membrane TonB-dependent transporters (TBDTs)	583:632	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	10	70	theme	ΔtonB5	1748:1753	arg1	mutants					1755:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants did not significantly affect intestinal colonization.
34662212	13	71	theme	periplasmic	2141:2151	arg1	proteins					2184:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	2	72	theme	outer	583:587	arg1	TBDTs					627:631	TBDTs	627:631	TBDTs	627:631	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	2	72	theme	outer	583:587	arg1	transporters					613:624	outer membrane TonB-dependent transporters	583:624	outer membrane TonB-dependent transporters (TBDTs)	583:632	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	7	73	theme	TonB3	1293:1297	arg1	lack					1285:1288	the lack	1281:1288	the lack of TonB3	1281:1297	This indicates that there was no functional compensation for the lack of TonB3, and it demonstrates that TonB3, alone, drives the TBDTs involved in the transport of essential nutrients.
34662212	10	74	theme	intestinal	1792:1801	arg1	colonization					1803:1814	intestinal colonization	1792:1814	intestinal colonization	1792:1814	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants did not significantly affect intestinal colonization.
34662212	0	75	theme	Experimental	108:119	arg1	Colonization					132:143	Experimental Intestinal Colonization	108:143	Experimental Intestinal Colonization	108:143	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	11	76	theme	mutant	1854:1859	arg1	strain					1861:1866	the ΔtonB3 mutant strain	1843:1866	the ΔtonB3 mutant strain	1843:1866	Moreover, the survival of the ΔtonB3 mutant strain was completely eradicated in a rat model of intra-abdominal infection.
34662212	11	77	theme	rat	1899:1901	arg1	model					1903:1907	a rat model	1897:1907	a rat model of intra-abdominal infection	1897:1936	Moreover, the survival of the ΔtonB3 mutant strain was completely eradicated in a rat model of intra-abdominal infection.
34662212	9	78	theme	growth	1542:1547	arg1	defect					1549:1554	This intestinal growth defect	1526:1554	This intestinal growth defect	1526:1554	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	6	79	theme	ΔtonB2	1140:1145	arg1	mutants					1182:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	0	80	theme	Intra-Abdominal	149:163	arg1	Infection					165:173	Intra-Abdominal Infection	149:173	Intra-Abdominal Infection	149:173	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	9	81	theme	ΔtonB3	1576:1581	arg1	strain					1604:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	1	82	dep	Bacteroides	265:275	arg1	fragilis					277:284	fragilis	277:284	fragilis	277:284	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	6	83	theme	ΔtonB1	1132:1137	arg1	mutants					1182:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants	1128:1188	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	14	84	theme	anaerobic	2672:2680	arg1	conditions					2682:2691	anaerobic conditions	2672:2691	anaerobic conditions	2672:2691	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	13	85	theme	gene	2088:2091	arg1	orthologs					2093:2101	tonB6 gene orthologs	2082:2101	tonB6 gene orthologs	2082:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	9	86	theme	double	1590:1595	arg1	strain					1604:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	the ΔtonB3 ΔtonB6 double mutant strain	1572:1609	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	13	87	theme	tonB4	2064:2068	arg1	organization					2034:2045	The genetic organization	2022:2045	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs	2022:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	14	88	theme	periplasmic	2390:2400	arg1	contrast					2411:2418	its periplasmic space-in contrast	2386:2418	its periplasmic space-in contrast to an oxidative environment	2386:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	4	89	theme	Fe	916:917	arg1	starch					937:942	starch	937:942	starch	937:942	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	89	theme	Fe	916:917	arg1	glycans					972:978	N-linked glycans	963:978	N-linked glycans	963:978	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	89	theme	Fe	916:917	arg1	heme					897:900	heme	897:900	heme	897:900	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	89	theme	Fe	916:917	arg1	mucin-glycans					945:957	mucin-glycans	945:957	mucin-glycans	945:957	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	89	theme	Fe	916:917	arg1	B12					911:913	vitamin B12	903:913	vitamin B12	903:913	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	89	theme	Fe	916:917	arg1	substrate					995:1003	a substrate	993:1003	a substrate for growth	993:1014	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	89	theme	Fe	916:917	arg1	-ferrichrome					923:934	Fe(III)-ferrichrome	916:934	Fe(III)-ferrichrome	916:934	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	3	90	theme	extraintestinal	770:784	arg1	infection					786:794	extraintestinal infection	770:794	extraintestinal infection	770:794	However, TonB's role in activating nearly one hundred TBDTs for nutrient acquisition in B. fragilis during intestinal colonization and extraintestinal infection has not been established.
34662212	13	91	theme	tonB5	2071:2075	arg1	organization					2034:2045	The genetic organization	2022:2045	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs	2022:2101	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	4	92	theme	ΔtonB3	878:883	arg1	mutant					885:890	the ΔtonB3 mutant	874:890	the ΔtonB3 mutant	874:890	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	5	93	with	complementation	1034:1048	arg1	gene					1086:1089	the tonB3 gene	1076:1089	the tonB3 gene	1076:1089	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene restored growth on these substrates.
34662212	5	94	theme	ΔtonB3	1057:1062	arg1	mutant					1064:1069	the ΔtonB3 mutant	1053:1069	the ΔtonB3 mutant	1053:1069	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene restored growth on these substrates.
34662212	14	95	theme	relative	2598:2605	arg1	PMF					2593:2595	PMF	2593:2595	PMF (relative to aerobic bacteria)	2593:2626	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	96	theme	redox	2371:2375	arg1	state					2377:2381	a reduced redox state	2361:2381	a reduced redox state in its periplasmic space-in contrast to an oxidative environment	2361:2446	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	1	97	theme	ExbBs	358:362	arg1	ExbB1-4					375:381	ExbB1-4	375:381	ExbB1-4	375:381	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	1	97	theme	ExbBs	358:362	arg1	orthologs					364:372	four ExbBs orthologs	353:372	four ExbBs orthologs	353:372	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	14	98	theme	increased	2568:2576	arg1	sensitivity					2578:2588	an increased sensitivity	2565:2588	an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions	2565:2691	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	0	99	from	Homologs	26:33	arg1	fragilis					50:57	Bacteroides fragilis	38:57	Bacteroides fragilis	38:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	3	100	from	acquisition	708:718	arg1	fragilis					726:733	B. fragilis	723:733	B. fragilis	723:733	However, TonB's role in activating nearly one hundred TBDTs for nutrient acquisition in B. fragilis during intestinal colonization and extraintestinal infection has not been established.
34662212	5	101	theme	Genetic	1026:1032	arg1	complementation					1034:1048	Genetic complementation	1026:1048	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene	1026:1089	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene restored growth on these substrates.
34662212	4	102	used	used	985:988	arg2	substrate					995:1003	a substrate	993:1003	a substrate for growth	993:1014	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	102	used	used	985:988	arg2	B12					911:913	vitamin B12	903:913	vitamin B12	903:913	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	102	used	used	985:988	arg2	heme					897:900	heme	897:900	heme	897:900	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	102	used	used	985:988	arg2	-ferrichrome					923:934	Fe(III)-ferrichrome	916:934	Fe(III)-ferrichrome	916:934	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	102	used	used	985:988	arg2	starch					937:942	starch	937:942	starch	937:942	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	102	used	used	985:988	arg2	glycans					972:978	N-linked glycans	963:978	N-linked glycans	963:978	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	4	102	used	used	985:988	arg2	mucin-glycans					945:957	mucin-glycans	945:957	mucin-glycans	945:957	In this study, we show that growth was abolished in the ΔtonB3 mutant when heme, vitamin B12, Fe(III)-ferrichrome, starch, mucin-glycans, or N-linked glycans were used as a substrate for growth in vitro.
34662212	2	103	theme	inner	423:427	arg1	complex					453:459	The inner membrane TonB/ExbB/ExbD complex	419:459	The inner membrane TonB/ExbB/ExbD complex	419:459	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	8	104	theme	ΔtonB3	1410:1415	arg1	mutant					1417:1422	The ΔtonB3 mutant	1406:1422	The ΔtonB3 mutant	1406:1422	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	0	105	theme	tonB	16:19	arg1	Homologs					26:33	Six tonB Gene Homologs	12:33	Six tonB Gene Homologs in Bacteroides fragilis	12:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	13	106	theme	this	2229:2232	arg1	relevance					2216:2224	the physiological relevance	2198:2224	the physiological relevance of this	2198:2232	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	9	107	theme	mouse	1662:1666	arg1	tract					1679:1683	the mouse intestinal tract	1658:1683	the mouse intestinal tract	1658:1683	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	0	108	theme	Homologs	26:33	arg1	Analysis					0:7	Analysis	0:7	Analysis of Six tonB Gene Homologs in Bacteroides fragilis	0:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	8	109	theme	severe	1430:1435	arg1	defect					1444:1449	a severe growth defect	1428:1449	a severe growth defect	1428:1449	The ΔtonB3 mutant had a severe growth defect in a mouse model of intestinal colonization compared to the parent strain.
34662212	0	110	theme	Bacteroides	38:48	arg1	fragilis					50:57	Bacteroides fragilis	38:57	Bacteroides fragilis	38:57	Analysis of Six tonB Gene Homologs in Bacteroides fragilis Revealed That tonB3 is Essential for Survival in Experimental Intestinal Colonization and Intra-Abdominal Infection.
34662212	1	111	theme	predicted	312:320	arg1	proteins					327:334	six predicted TonB proteins	308:334	six predicted TonB proteins	308:334	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	7	112	theme	essential	1385:1393	arg1	nutrients					1395:1403	essential nutrients	1385:1403	essential nutrients	1385:1403	This indicates that there was no functional compensation for the lack of TonB3, and it demonstrates that TonB3, alone, drives the TBDTs involved in the transport of essential nutrients.
34662212	14	113	dep	Δp	2313:2314	arg1	has					2357:2359	has	2357:2359	has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it	2357:2460	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	14	114	theme	TonB/ExbB/ExbD	2512:2525	arg1	orthologs					2527:2535	TonB/ExbB/ExbD orthologs	2512:2535	TonB/ExbB/ExbD orthologs	2512:2535	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	2	115	theme	TonB/ExbB/ExbD	438:451	arg1	complex					453:459	The inner membrane TonB/ExbB/ExbD complex	419:459	The inner membrane TonB/ExbB/ExbD complex	419:459	The inner membrane TonB/ExbB/ExbD complex harvests energy from the proton motive force (Δp), and the TonB C-terminal domain interacts with and transduces energy to outer membrane TonB-dependent transporters (TBDTs).
34662212	10	116	theme	ΔtonB2	1728:1733	arg1	mutants					1755:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants did not significantly affect intestinal colonization.
34662212	5	117	theme	tonB3	1080:1084	arg1	gene					1086:1089	the tonB3 gene	1076:1089	the tonB3 gene	1076:1089	Genetic complementation of the ΔtonB3 mutant with the tonB3 gene restored growth on these substrates.
34662212	13	118	theme	nonreceptor	2157:2167	arg1	proteins					2184:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	14	119	theme	aerobic	2610:2616	arg1	bacteria					2618:2625	aerobic bacteria	2610:2625	aerobic bacteria	2610:2625	Because anaerobic fermentation metabolism yields a lower Δp than aerobic respiration and B. fragilis has a reduced redox state in its periplasmic space-in contrast to an oxidative environment in aerobes-it remains to be determined if the diverse system of TonB/ExbB/ExbD orthologs encoded by B. fragilis have an increased sensitivity to PMF (relative to aerobic bacteria) to allow for the harvesting of energy under anaerobic conditions.
34662212	9	120	theme	parent	1701:1706	arg1	strain					1708:1713	the parent strain	1697:1713	the parent strain	1697:1713	This intestinal growth defect was enhanced in the ΔtonB3 ΔtonB6 double mutant strain, which completely lost its ability to colonize the mouse intestinal tract compared to the parent strain.
34662212	6	121	theme	growth	1205:1210	arg1	defect					1212:1217	a growth defect	1203:1217	a growth defect	1203:1217	The ΔtonB1, ΔtonB2, ΔtonB4, ΔtonB5, and ΔtonB6 single mutants did not show a growth defect.
34662212	10	122	theme	ΔtonB1	1720:1725	arg1	mutants					1755:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants	1716:1761	The ΔtonB1, ΔtonB2, ΔtonB4, and ΔtonB5 mutants did not significantly affect intestinal colonization.
34662212	1	123	theme	human	235:239	arg1	tract					258:262	the human large intestinal tract	231:262	the human large intestinal tract	231:262	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
34662212	13	124	theme	membrane	2175:2182	arg1	proteins					2184:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	periplasmic and nonreceptor outer membrane proteins	2141:2191	The genetic organization of tonB1, tonB2, tonB4, tonB5, and tonB6 gene orthologs indicates that they may interact with periplasmic and nonreceptor outer membrane proteins, but the physiological relevance of this has not been defined.
34662212	1	125	theme	intestinal	247:256	arg1	tract					258:262	the human large intestinal tract	231:262	the human large intestinal tract	231:262	The opportunistic, anaerobic pathogen and commensal of the human large intestinal tract, Bacteroides fragilis strain 638R, contains six predicted TonB proteins, termed TonB1-6, four ExbBs orthologs, ExbB1-4, and five ExbDs orthologs, ExbD1-5.
33977716	0	0	theme	ANdG-	128:132	arg1	Duplexes					158:165	ANdG- and APdG-Containing DNA Duplexes	128:165	ANdG- and APdG-Containing DNA Duplexes	128:165	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	9	1	theme	DNA	2281:2283	arg1	structure					2235:2243	structure	2235:2243	structure	2235:2243	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	9	1	theme	DNA	2281:2283	arg1	outcomes					2260:2267	biological outcomes	2249:2267	biological outcomes	2249:2267	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	0	2	theme	APdG-Containing	138:152	arg1	Duplexes					158:165	ANdG- and APdG-Containing DNA Duplexes	128:165	ANdG- and APdG-Containing DNA Duplexes	128:165	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	5	3	theme	aryl	1354:1357	arg1	size					1366:1369	aryl moiety size	1354:1369	aryl moiety size	1354:1369	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	4	4	theme	nearest	1014:1020	arg1	G1G2					1008:1011	G1G2	1008:1011	G1G2	1008:1011	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	4	theme	nearest	1014:1020	arg1	neighbors					1022:1030	nearest neighbors	1014:1030	nearest neighbors	1014:1030	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	2	5	link	AA-derived	324:333	arg1	adducts					335:341	AA-derived adducts	324:341	AA-derived adducts	324:341	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	0	6	theme	Duplexes	158:165	arg1	Study					119:123	A Molecular Dynamics Case Study	93:123	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	3	7	contain	containing	628:637	arg2	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	7	contain	containing	628:637	arg2	ANdG					702:705	ANdG	702:705	ANdG	702:705	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	7	contain	containing	628:637	arg1	DNA					624:626	DNA	624:626	DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation)	624:913	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	7	contain	containing	628:637	arg2	G3					802:803	G3	802:803	G3	802:803	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	7	contain	containing	628:637	arg2	-aniline					692:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline	639:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG)	639:706	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	7	contain	containing	628:637	arg2	G2					795:796	G2	795:796	G2	795:796	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	4	8	theme	sites	1001:1005	arg1	orientations					1136:1147	anti/syn lesion glycosidic orientations	1109:1147	anti/syn lesion glycosidic orientations	1109:1147	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	8	theme	sites	1001:1005	arg1	combination					978:988	each combination	973:988	each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides))	973:1103	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	0	9	theme	Amines	85:90	arg1	Toxicity					64:71	the Toxicity	60:71	the Toxicity of Aromatic Amines	60:90	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	3	10	theme	four-ringed	725:735	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	2	11	theme	DNA	532:534	arg1	duplexes					536:543	monoadducted and diadducted DNA duplexes	504:543	monoadducted and diadducted DNA duplexes	504:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	6	12	theme	promutagenic	1610:1621	arg1	conformation					1623:1634	a promutagenic conformation	1608:1634	a promutagenic conformation regardless of adduct size	1608:1660	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	0	13	theme	Dynamics	105:112	arg1	Study					119:123	A Molecular Dynamics Case Study	93:123	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	5	14	theme	other	1158:1162	arg1	adducts					1179:1185	other N-linked C8-dG adducts	1158:1185	other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity	1158:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	4	15	dep	sites	1001:1005	arg1	neighbors					1022:1030	nearest neighbors	1014:1030	nearest neighbors	1014:1030	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	15	dep	sites	1001:1005	arg1	nucleotides					1091:1101	two intervening nucleotides	1075:1101	two intervening nucleotides	1075:1101	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	15	dep	sites	1001:1005	arg1	sites					1001:1005	damaged sites	993:1005	damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides))	993:1103	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	15	dep	sites	1001:1005	arg1	G1G3					1069:1072	G1G3	1069:1072	G1G3	1069:1072	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	15	dep	sites	1001:1005	arg1	G1G2					1008:1011	G1G2	1008:1011	G1G2	1008:1011	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	15	dep	sites	1001:1005	arg1	G2G3					1034:1037	G2G3	1034:1037	G2G3	1034:1037	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	15	dep	sites	1001:1005	arg1	neighbors					1053:1061	next-nearest neighbors	1040:1061	next-nearest neighbors	1040:1061	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	6	16	theme	damaged	1582:1588	arg1	sites					1590:1594	next-nearest damaged sites	1569:1594	next-nearest damaged sites	1569:1594	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	2	17	theme	monoadducted	382:393	arg1	DNA					396:398	(monoadducted) DNA	381:398	(monoadducted) DNA containing a single lesion	381:425	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	5	18	theme	C8-dG	1173:1177	arg1	adducts					1179:1185	other N-linked C8-dG adducts	1158:1185	other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity	1158:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	3	19	theme	dynamics	570:577	arg1	simulations					584:594	molecular dynamics (MD) simulations	560:594	molecular dynamics (MD) simulations	560:594	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	6	20	theme	adduct	1461:1466	arg1	addition					1440:1447	the addition	1436:1447	the addition of a second adduct depending on lesion separation	1436:1497	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	2	21	theme	present	432:438	arg1	work					440:443	the present work	428:443	the present work	428:443	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	4	22	theme	next-nearest	1040:1051	arg1	G2G3					1034:1037	G2G3	1034:1037	G2G3	1034:1037	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	22	theme	next-nearest	1040:1051	arg1	neighbors					1053:1061	next-nearest neighbors	1040:1061	next-nearest neighbors	1040:1061	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	0	23	theme	Position	48:55	arg1	Impact					0:5	Impact	0:5	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	6	24	theme	next-nearest	1569:1580	arg1	sites					1590:1594	next-nearest damaged sites	1569:1594	next-nearest damaged sites	1569:1594	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	7	25	theme	corresponding	1750:1762	arg1	system					1777:1782	the corresponding monoadducted system	1746:1782	the corresponding monoadducted system	1746:1782	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	0	26	from	Impact	0:5	arg1	Toxicity					64:71	the Toxicity	60:71	the Toxicity of Aromatic Amines	60:90	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	9	27	theme	spatial	2166:2172	arg1	separation					2174:2183	their spatial separation	2160:2183	their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA	2160:2283	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	7	28	theme	monoadducted	1883:1894	arg1	DNA					1896:1898	monoadducted DNA	1883:1898	monoadducted DNA	1883:1898	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	3	29	theme	deletion	815:822	arg1	5'-G1G2CG3CC					833:844	5'-G1G2CG3CC	833:844	5'-G1G2CG3CC	833:844	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	29	theme	deletion	815:822	arg1	hotspot					824:830	the AA deletion hotspot	808:830	the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation)	808:913	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	2	30	theme	first	458:462	arg1	comparison					473:482	the first in-depth comparison	454:482	the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes	454:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	8	31	theme	monoadducted	1932:1943	arg1	DNA					1945:1947	monoadducted DNA	1932:1947	monoadducted DNA	1932:1947	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	6	32	theme	adduct	1650:1655	arg1	size					1657:1660	adduct size	1650:1660	adduct size	1650:1660	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	9	33	theme	growing	2192:2198	arg1	list					2200:2203	the growing list	2188:2203	the growing list of factors that determine the structure and biological outcomes of adducted DNA	2188:2283	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	6	34	dep	conformation	1552:1563	arg1	a					1537:1537	a	1537:1537	a	1537:1537	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	4	35	theme	intervening	1079:1089	arg1	nucleotides					1091:1101	two intervening nucleotides	1075:1101	two intervening nucleotides	1075:1101	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	35	theme	intervening	1079:1089	arg1	G1G3					1069:1072	G1G3	1069:1072	G1G3	1069:1072	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	0	36	theme	DNA	10:12	arg1	Size					21:24	DNA Adduct Size	10:24	DNA Adduct Size	10:24	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	1	37	theme	DNA	235:237	arg1	adducts					239:245	carcinogenic DNA adducts	222:245	carcinogenic DNA adducts	222:245	Human exposure to aromatic amines (AAs) can result in carcinogenic DNA adducts.
33977716	7	38	theme	diadducted	1846:1855	arg1	DNA					1857:1859	diadducted DNA	1846:1859	diadducted DNA	1846:1859	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	5	39	theme	dependence	1207:1216	arg1	heterogeneity					1233:1245	sequence dependence conformational heterogeneity	1198:1245	sequence dependence conformational heterogeneity	1198:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	0	40	theme	Size	21:24	arg1	Impact					0:5	Impact	0:5	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	2	41	theme	single	413:418	arg1	lesion					420:425	a single lesion	411:425	a single lesion	411:425	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	0	42	theme	Number	27:32	arg1	Impact					0:5	Impact	0:5	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	7	43	theme	monoadducted	1764:1775	arg1	system					1777:1782	the corresponding monoadducted system	1746:1782	the corresponding monoadducted system	1746:1782	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	8	44	theme	second	2041:2046	arg1	event					2057:2061	a second damaging event	2039:2061	a second damaging event	2039:2061	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	4	45	theme	lesion	1118:1123	arg1	orientations					1136:1147	anti/syn lesion glycosidic orientations	1109:1147	anti/syn lesion glycosidic orientations	1109:1147	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	5	46	theme	conformational	1293:1306	arg1	homogeneity					1308:1318	helical conformational homogeneity	1285:1318	helical conformational homogeneity that is exclusively controlled by aryl moiety size	1285:1369	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	6	47	theme	damaged	1395:1401	arg1	conformation					1407:1418	the preferred damaged DNA conformation	1381:1418	the preferred damaged DNA conformation	1381:1418	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	7	48	theme	differential	1797:1808	arg1	outcomes					1833:1840	differential replication and repair outcomes	1797:1840	differential replication and repair outcomes for diadducted DNA	1797:1859	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	4	49	theme	damaged	993:999	arg1	G1G2					1008:1011	G1G2	1008:1011	G1G2	1008:1011	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	49	theme	damaged	993:999	arg1	sites					1001:1005	damaged sites	993:1005	damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides))	993:1103	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	49	theme	damaged	993:999	arg1	G2G3					1034:1037	G2G3	1034:1037	G2G3	1034:1037	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	4	49	theme	damaged	993:999	arg1	G1G3					1069:1072	G1G3	1069:1072	G1G3	1069:1072	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	2	50	theme	AA-derived	324:333	arg1	adducts					335:341	AA-derived adducts	324:341	AA-derived adducts	324:341	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	0	51	dep	Impact	0:5	arg1	Study					119:123	A Molecular Dynamics Case Study	93:123	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	3	52	theme	glycosidic	866:875	arg1	orientation					877:887	the anti or syn glycosidic orientation	850:887	orientation	877:887	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	53	theme	N-	670:671	arg1	ANdG					702:705	ANdG	702:705	ANdG	702:705	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	53	theme	N-	670:671	arg1	-aniline					692:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline	639:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG)	639:706	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	5	54	theme	APdG	1265:1268	arg1	lesion					1270:1275	a single ANdG or APdG lesion	1248:1275	lesion	1270:1275	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	9	55	theme	adducted	2272:2279	arg1	DNA					2281:2283	adducted DNA	2272:2283	adducted DNA	2272:2283	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	3	56	theme	nonmutagenic	643:654	arg1	ANdG					702:705	ANdG	702:705	ANdG	702:705	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	56	theme	nonmutagenic	643:654	arg1	-aniline					692:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline	639:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG)	639:706	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	0	57	theme	DNA	154:156	arg1	Duplexes					158:165	ANdG- and APdG-Containing DNA Duplexes	128:165	ANdG- and APdG-Containing DNA Duplexes	128:165	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	2	58	theme	duplexes	536:543	arg1	structure					491:499	the structure	487:499	the structure of monoadducted and diadducted DNA duplexes	487:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	3	59	theme	duplex	894:899	arg1	conformation					901:912	B/S duplex conformation	890:912	B/S duplex conformation	890:912	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	59	theme	duplex	894:899	arg1	anti					854:857	anti	854:857	anti	854:857	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	8	60	theme	relative	2092:2099	arg1	position					2101:2108	relative position	2092:2108	relative position	2092:2108	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	2	61	contain	containing	400:409	arg1	DNA					396:398	(monoadducted) DNA	381:398	(monoadducted) DNA containing a single lesion	381:425	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	2	61	contain	containing	400:409	arg2	lesion					420:425	a single lesion	411:425	a single lesion	411:425	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	9	62	dep	structure	2235:2243	arg1	the					2231:2233	the	2231:2233	the	2231:2233	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	3	63	theme	deoxyguanosin-8-yl	673:690	arg1	ANdG					702:705	ANdG	702:705	ANdG	702:705	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	63	theme	deoxyguanosin-8-yl	673:690	arg1	-aniline					692:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline	639:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG)	639:706	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	2	64	theme	previous	262:269	arg1	work					271:274	previous work	262:274	previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion	262:425	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	3	65	from	G1	791:792	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	65	from	G1	791:792	arg1	G2					795:796	G2	795:796	G2	795:796	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	65	from	G1	791:792	arg1	G3					802:803	G3	802:803	G3	802:803	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	65	from	G1	791:792	arg1	ANdG					702:705	ANdG	702:705	ANdG	702:705	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	65	from	G1	791:792	arg1	-aniline					692:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline	639:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG)	639:706	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	2	66	theme	structure	491:499	arg1	comparison					473:482	the first in-depth comparison	454:482	the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes	454:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	0	67	theme	Molecular	95:103	arg1	Study					119:123	A Molecular Dynamics Case Study	93:123	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	1	68	theme	Human	168:172	arg1	exposure					174:181	Human exposure	168:181	Human exposure to aromatic amines (AAs)	168:206	Human exposure to aromatic amines (AAs) can result in carcinogenic DNA adducts.
33977716	5	69	theme	moiety	1359:1364	arg1	size					1366:1369	aryl moiety size	1354:1369	aryl moiety size	1354:1369	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	3	70	theme	N-	737:738	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	0	71	theme	Case	114:117	arg1	Study					119:123	A Molecular Dynamics Case Study	93:123	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.	0:166	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	2	72	theme	diadducted	521:530	arg1	duplexes					536:543	monoadducted and diadducted DNA duplexes	504:543	monoadducted and diadducted DNA duplexes	504:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	5	73	link	N-linked	1164:1171	arg1	adducts					1179:1185	other N-linked C8-dG adducts	1158:1185	other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity	1158:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	3	74	theme	mutagenic	715:723	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	6	75	theme	lesion	1481:1486	arg1	separation					1488:1497	lesion separation	1481:1497	lesion separation	1481:1497	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	7	76	theme	diadducted	1676:1685	arg1	result					1668:1673	a result	1666:1673	a result	1666:1673	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	7	76	theme	diadducted	1676:1685	arg1	DNA					1687:1689	diadducted DNA	1676:1689	diadducted DNA	1676:1689	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	2	77	theme	monoadducted	504:515	arg1	duplexes					536:543	monoadducted and diadducted DNA duplexes	504:543	monoadducted and diadducted DNA duplexes	504:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	5	78	theme	N-linked	1164:1171	arg1	adducts					1179:1185	other N-linked C8-dG adducts	1158:1185	other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity	1158:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	3	79	theme	-1-aminopyrene	759:772	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	0	80	theme	Relative	39:46	arg1	Position					48:55	Relative Position	39:55	Relative Position	39:55	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	3	81	theme	molecular	560:568	arg1	dynamics					570:577	molecular dynamics	560:577	molecular dynamics (MD) simulations	560:594	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	81	theme	molecular	560:568	arg1	MD					580:581	MD	580:581	MD	580:581	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	82	from	hotspot	824:830	arg1	orientation					877:887	the anti or syn glycosidic orientation	850:887	orientation	877:887	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	82	from	hotspot	824:830	arg1	anti					854:857	anti	854:857	anti	854:857	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	82	from	hotspot	824:830	arg1	conformation					901:912	B/S duplex conformation	890:912	B/S duplex conformation	890:912	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	83	theme	deoxyguanosin-8-yl	740:757	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	6	84	theme	second	1454:1459	arg1	adduct					1461:1466	a second adduct	1452:1466	a second adduct depending on lesion separation	1452:1497	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	2	85	theme	in-depth	464:471	arg1	comparison					473:482	the first in-depth comparison	454:482	the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes	454:543	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	4	86	theme	anti/syn	1109:1116	arg1	orientations					1136:1147	anti/syn lesion glycosidic orientations	1109:1147	anti/syn lesion glycosidic orientations	1109:1147	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	5	87	theme	conformational	1218:1231	arg1	heterogeneity					1233:1245	sequence dependence conformational heterogeneity	1198:1245	sequence dependence conformational heterogeneity	1198:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	3	88	theme	APdG	775:778	arg1	lesion					781:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion	711:786	the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1	711:792	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	0	89	theme	Aromatic	76:83	arg1	Amines					85:90	Aromatic Amines	76:90	Aromatic Amines	76:90	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	6	90	theme	nonmutagenic	1539:1550	arg1	conformation					1552:1563	nonmutagenic conformation	1539:1563	nonmutagenic conformation	1539:1563	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	8	91	theme	DNA	1945:1947	arg1	toxicity					1920:1927	the toxicity	1916:1927	the toxicity of monoadducted DNA	1916:1947	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	3	92	theme	AA	812:813	arg1	5'-G1G2CG3CC					833:844	5'-G1G2CG3CC	833:844	5'-G1G2CG3CC	833:844	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	92	theme	AA	812:813	arg1	hotspot					824:830	the AA deletion hotspot	808:830	the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation)	808:913	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	2	93	theme	adducts	335:341	arg1	mutagenicity					308:319	the mutagenicity	304:319	the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion	304:425	To complement previous work geared toward understanding the mutagenicity of AA-derived adducts, which has almost exclusively studied (monoadducted) DNA containing a single lesion, the present work provides the first in-depth comparison of the structure of monoadducted and diadducted DNA duplexes.
33977716	0	94	theme	Adduct	14:19	arg1	Size					21:24	DNA Adduct Size	10:24	DNA Adduct Size	10:24	Impact of DNA Adduct Size, Number, and Relative Position on the Toxicity of Aromatic Amines: A Molecular Dynamics Case Study of ANdG- and APdG-Containing DNA Duplexes.
33977716	1	95	theme	carcinogenic	222:233	arg1	adducts					239:245	carcinogenic DNA adducts	222:245	carcinogenic DNA adducts	222:245	Human exposure to aromatic amines (AAs) can result in carcinogenic DNA adducts.
33977716	6	96	theme	neighboring	1505:1515	arg1	lesions					1517:1523	neighboring lesions	1505:1523	neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size	1505:1660	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	4	97	theme	diadducted	930:939	arg1	strands					941:947	diadducted strands	930:947	diadducted strands	930:947	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	5	98	theme	sequence	1198:1205	arg1	heterogeneity					1233:1245	sequence dependence conformational heterogeneity	1198:1245	sequence dependence conformational heterogeneity	1198:1245	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	9	99	theme	factors	2208:2214	arg1	list					2200:2203	the growing list	2188:2203	the growing list of factors that determine the structure and biological outcomes of adducted DNA	2188:2283	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	8	100	theme	lesion	1983:1988	arg1	size					1990:1993	lesion size	1983:1993	lesion size	1983:1993	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	7	101	theme	repair	1826:1831	arg1	outcomes					1833:1840	differential replication and repair outcomes	1797:1840	differential replication and repair outcomes for diadducted DNA	1797:1859	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	7	102	theme	replication	1810:1820	arg1	outcomes					1833:1840	differential replication and repair outcomes	1797:1840	differential replication and repair outcomes for diadducted DNA	1797:1859	As a result, diadducted DNA is found to adopt conformations that are unfavored for the corresponding monoadducted system, pointing to differential replication and repair outcomes for diadducted DNA compared to those for monoadducted DNA.
33977716	3	103	theme	syn	862:864	arg1	orientation					877:887	the anti or syn glycosidic orientation	850:887	orientation	877:887	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	8	104	theme	damaging	2048:2055	arg1	event					2057:2061	a second damaging event	2039:2061	a second damaging event	2039:2061	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	4	105	theme	glycosidic	1125:1134	arg1	orientations					1136:1147	anti/syn lesion glycosidic orientations	1109:1147	anti/syn lesion glycosidic orientations	1109:1147	Subsequently, diadducted strands were assessed that span each combination of damaged sites (G1G2 (nearest neighbors), G2G3 (next-nearest neighbors), and G1G3 (two intervening nucleotides)) and anti/syn lesion glycosidic orientations.
33977716	5	106	theme	helical	1285:1291	arg1	homogeneity					1308:1318	helical conformational homogeneity	1285:1318	helical conformational homogeneity that is exclusively controlled by aryl moiety size	1285:1369	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	6	107	theme	DNA	1403:1405	arg1	conformation					1407:1418	the preferred damaged DNA conformation	1381:1418	the preferred damaged DNA conformation	1381:1418	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	9	108	theme	lesions	2148:2154	arg1	number					2138:2143	the number	2134:2143	the number of lesions	2134:2154	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	9	108	theme	lesions	2148:2154	arg1	separation					2174:2183	their spatial separation	2160:2183	their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA	2160:2283	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	5	109	theme	single	1250:1255	arg1	ANdG					1257:1260	a single ANdG or APdG lesion	1248:1275	ANdG	1257:1260	Despite other N-linked C8-dG adducts exhibiting sequence dependence conformational heterogeneity, a single ANdG or APdG lesion induces helical conformational homogeneity that is exclusively controlled by aryl moiety size.
33977716	9	110	theme	biological	2249:2258	arg1	outcomes					2260:2267	biological outcomes	2249:2267	biological outcomes	2249:2267	Overall, our work adds the number of lesions and their spatial separation to the growing list of factors that determine the structure and biological outcomes of adducted DNA.
33977716	6	111	theme	preferred	1385:1393	arg1	conformation					1407:1418	the preferred damaged DNA conformation	1381:1418	the preferred damaged DNA conformation	1381:1418	However, the preferred damaged DNA conformation can change upon the addition of a second adduct depending on lesion separation, with neighboring lesions stabilizing a nonmutagenic conformation and next-nearest damaged sites stabilizing a promutagenic conformation regardless of adduct size.
33977716	1	112	theme	aromatic	186:193	arg1	amines					195:200	aromatic amines	186:200	aromatic amines (AAs)	186:206	Human exposure to aromatic amines (AAs) can result in carcinogenic DNA adducts.
33977716	1	112	theme	aromatic	186:193	arg1	AAs					203:205	AAs	203:205	AAs	203:205	Human exposure to aromatic amines (AAs) can result in carcinogenic DNA adducts.
33977716	3	113	theme	B/S	890:892	arg1	conformation					901:912	B/S duplex conformation	890:912	B/S duplex conformation	890:912	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	113	theme	B/S	890:892	arg1	anti					854:857	anti	854:857	anti	854:857	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	8	114	theme	lesion	2076:2081	arg1	size					2083:2086	lesion size	2076:2086	lesion size	2076:2086	Thus, although the toxicity of monoadducted DNA is most significantly dictated by lesion size, the toxicity can increase or decrease upon a second damaging event depending on lesion size and relative position.
33977716	3	115	theme	single-ringed	656:668	arg1	ANdG					702:705	ANdG	702:705	ANdG	702:705	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33977716	3	115	theme	single-ringed	656:668	arg1	-aniline					692:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline	639:699	the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG)	639:706	Specifically, molecular dynamics (MD) simulations were initially performed on DNA containing the nonmutagenic single-ringed N-(deoxyguanosin-8-yl)-aniline (ANdG) or the mutagenic four-ringed N-(deoxyguanosin-8-yl)-1-aminopyrene (APdG) lesion at G1, G2, or G3 in the AA deletion hotspot (5'-G1G2CG3CC) in the anti or syn glycosidic orientation (B/S duplex conformation).
33904933	8	0	theme	unfavorable	1644:1654	arg1	behavior					1674:1681	unfavorable colorectal cancer behavior	1644:1681	unfavorable colorectal cancer behavior	1644:1681	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	7	1	theme	ionization	1307:1316	arg1	spectrometry					1338:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	2	2	theme	gland	356:360	arg1	cells					362:366	noncancerous gland cells	343:366	noncancerous gland cells	343:366	In this study, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells.
33904933	6	3	theme	colorectal	1242:1251	arg1	P = 0.0418					1261:1270	P = 0.0418	1261:1270	P = 0.0418	1261:1270	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	3	theme	colorectal	1242:1251	arg1	cancer					1253:1258	colorectal cancer	1242:1258	colorectal cancer (P = 0.0418)	1242:1271	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	4	with	patients	1133:1140	arg1	P = 0.0196					1166:1175	P = 0.0196	1166:1175	P = 0.0196	1166:1175	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	4	with	patients	1133:1140	arg1	cancer					1158:1163	colorectal cancer	1147:1163	colorectal cancer (P = 0.0196)	1147:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	5	theme	patients	1228:1235	arg1	association					1084:1094	significantly higher association	1063:1094	significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1063:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	5	theme	patients	1228:1235	arg1	rate					1220:1223	unfavorable progression-free survival rate	1182:1223	unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418)	1182:1271	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	4	6	theme	butyrate-induced	676:691	arg1	cells					714:718	sodium butyrate-induced differentiated HT-29 cells	669:718	sodium butyrate-induced differentiated HT-29 cells	669:718	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	2	7	theme	monoclonal	255:264	arg1	antibody					266:273	a monoclonal antibody	253:273	a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells	253:366	In this study, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells.
33904933	6	8	theme	12G5A	928:932	arg1	%					988:988	more than 50%	976:988	more than 50% of colon cancer cells intensively stained with 12G5A antibody	976:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	8	theme	12G5A	928:932	arg1	cells					1006:1010	colon cancer cells	993:1010	colon cancer cells intensively stained with 12G5A antibody	993:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	8	theme	12G5A	928:932	arg1	immunoreactivity					934:949	high 12G5A immunoreactivity	923:949	high 12G5A immunoreactivity	923:949	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	4	9	theme	HT-29	708:712	arg1	cells					714:718	sodium butyrate-induced differentiated HT-29 cells	669:718	sodium butyrate-induced differentiated HT-29 cells	669:718	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	2	10	theme	colorectal	307:316	arg1	cells					325:329	colorectal cancer cells	307:329	colorectal cancer cells relative to noncancerous gland cells	307:366	In this study, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells.
33904933	1	11	theme	molecular	191:199	arg1	therapy					208:214	molecular target therapy	191:214	molecular target therapy	191:214	Cancer-associated antigens are not only a good marker for monitoring cancer progression but are also useful for molecular target therapy.
33904933	6	12	theme	cells	1006:1010	arg1	%					988:988	more than 50%	976:988	more than 50% of colon cancer cells intensively stained with 12G5A antibody	976:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	12	theme	cells	1006:1010	arg1	cells					1006:1010	colon cancer cells	993:1010	colon cancer cells intensively stained with 12G5A antibody	993:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	12	theme	cells	1006:1010	arg1	immunoreactivity					934:949	high 12G5A immunoreactivity	923:949	high 12G5A immunoreactivity	923:949	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	13	theme	progression-free	1194:1209	arg1	rate					1220:1223	unfavorable progression-free survival rate	1182:1223	unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418)	1182:1271	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	11	14	theme	colorectal	1906:1915	arg1	behavior					1924:1931	unfavorable colorectal cancer behavior	1894:1931	unfavorable colorectal cancer behavior	1894:1931	• 12G5A immunoreactivity was related to unfavorable colorectal cancer behavior.
33904933	5	15	theme	12G5A	759:763	arg1	immunoreactivity					765:780	12G5A immunoreactivity	759:780	12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees	759:848	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	5	16	theme	noncancerous	888:899	arg1	cells					907:911	noncancerous gland cells	888:911	noncancerous gland cells	888:911	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	6	17	theme	colon	993:997	arg1	cells					1006:1010	colon cancer cells	993:1010	colon cancer cells intensively stained with 12G5A antibody	993:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	18	theme	overall	1108:1114	arg1	rate					1125:1128	a poor overall survival rate	1101:1128	a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1101:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	8	19	theme	cancer-associated	1557:1573	arg1	epitope					1589:1595	a cancer-associated glycosylation epitope	1555:1595	a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior	1555:1681	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	7	20	theme	glycosylated	1467:1478	arg1	epitope					1480:1486	the glycosylated epitope	1463:1486	the glycosylated epitope on annexin A2 protein	1463:1508	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	11	21	theme	unfavorable	1894:1904	arg1	behavior					1924:1931	unfavorable colorectal cancer behavior	1894:1931	unfavorable colorectal cancer behavior	1894:1931	• 12G5A immunoreactivity was related to unfavorable colorectal cancer behavior.
33904933	8	22	theme	annexin	1600:1606	arg1	A2					1608:1609	annexin A2	1600:1609	annexin A2	1600:1609	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	7	23	theme	desorption	1296:1305	arg1	spectrometry					1338:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	1	24	dep	are	106:108	arg1	only					114:117	only	114:117	only	114:117	Cancer-associated antigens are not only a good marker for monitoring cancer progression but are also useful for molecular target therapy.
33904933	7	25	theme	Matrix-assisted	1274:1288	arg1	spectrometry					1338:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	6	26	theme	12G5A	1037:1041	arg1	antibody					1043:1050	12G5A antibody	1037:1050	12G5A antibody	1037:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	11	27	theme	cancer	1917:1922	arg1	behavior					1924:1931	unfavorable colorectal cancer behavior	1894:1931	unfavorable colorectal cancer behavior	1894:1931	• 12G5A immunoreactivity was related to unfavorable colorectal cancer behavior.
33904933	5	28	theme	cancer	798:803	arg1	specimens					812:820	all 73 colon cancer tissue specimens	785:820	all 73 colon cancer tissue specimens examined at various degrees	785:848	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	9	29	theme	KEY	1684:1686	arg1	antibody					1716:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	0	30	from	antigen	48:54	arg1	protein					70:76	annexin A2 protein	59:76	annexin A2 protein	59:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	5	31	theme	tissue	805:810	arg1	specimens					812:820	all 73 colon cancer tissue specimens	785:820	all 73 colon cancer tissue specimens examined at various degrees	785:848	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	10	32	theme	12G5A	1778:1782	arg1	antibody					1784:1791	• 12G5A antibody	1776:1791	• 12G5A antibody	1776:1791	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	0	33	theme	Human	0:4	arg1	antigen					48:54	Human colorectal cancer-associated carbohydrate antigen	0:54	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein	0:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	7	34	theme	tunicamycin	1410:1420	arg1	treatment					1422:1430	tunicamycin treatment	1410:1430	tunicamycin treatment	1410:1430	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	8	35	theme	cancer	1667:1672	arg1	behavior					1674:1681	unfavorable colorectal cancer behavior	1644:1681	unfavorable colorectal cancer behavior	1644:1681	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	0	36	theme	cancer-associated	17:33	arg1	antigen					48:54	Human colorectal cancer-associated carbohydrate antigen	0:54	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein	0:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	6	37	theme	high	923:926	arg1	%					988:988	more than 50%	976:988	more than 50% of colon cancer cells intensively stained with 12G5A antibody	976:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	37	theme	high	923:926	arg1	cells					1006:1010	colon cancer cells	993:1010	colon cancer cells intensively stained with 12G5A antibody	993:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	37	theme	high	923:926	arg1	immunoreactivity					934:949	high 12G5A immunoreactivity	923:949	high 12G5A immunoreactivity	923:949	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	9	38	theme	12G5A	1699:1703	arg1	antibody					1716:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	3	39	theme	cancer	419:424	arg1	lysates					431:437	HT-29 colorectal cancer cell lysates	402:437	HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells	402:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	10	40	theme	N-linked	1808:1815	arg1	epitope					1831:1837	the N-linked glycosylation epitope	1804:1837	the N-linked glycosylation epitope on annexin A2	1804:1851	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	7	41	theme	enzymatic	1379:1387	arg1	deglycosylation					1389:1403	enzymatic deglycosylation	1379:1403	enzymatic deglycosylation	1379:1403	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	3	42	theme	HT-29	402:406	arg1	lysates					431:437	HT-29 colorectal cancer cell lysates	402:437	HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells	402:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	2	43	theme	noncancerous	343:354	arg1	cells					362:366	noncancerous gland cells	343:366	noncancerous gland cells	343:366	In this study, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells.
33904933	0	44	theme	annexin	59:65	arg1	protein					70:76	annexin A2 protein	59:76	annexin A2 protein	59:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	2	45	theme	relative	331:338	arg1	cells					325:329	colorectal cancer cells	307:329	colorectal cancer cells relative to noncancerous gland cells	307:366	In this study, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells.
33904933	9	46	theme	cancer-associated	1749:1765	arg1	epitope					1767:1773	a colorectal cancer-associated epitope	1736:1773	a colorectal cancer-associated epitope	1736:1773	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	7	47	theme	si-RNA	1352:1357	arg1	analysis					1369:1376	si-RNA silencing analysis	1352:1376	si-RNA silencing analysis	1352:1376	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	4	48	theme	HT-29	630:634	arg1	cells					649:653	HT-29 colon cancer cells	630:653	HT-29 colon cancer cells	630:653	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	11	49	theme	12G5A	1856:1860	arg1	immunoreactivity					1862:1877	• 12G5A immunoreactivity	1854:1877	• 12G5A immunoreactivity	1854:1877	• 12G5A immunoreactivity was related to unfavorable colorectal cancer behavior.
33904933	10	50	from	epitope	1831:1837	arg1	A2					1850:1851	annexin A2	1842:1851	annexin A2	1842:1851	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	6	51	theme	colorectal	1147:1156	arg1	P = 0.0196					1166:1175	P = 0.0196	1166:1175	P = 0.0196	1166:1175	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	51	theme	colorectal	1147:1156	arg1	cancer					1158:1163	colorectal cancer	1147:1163	colorectal cancer (P = 0.0196)	1147:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	4	52	theme	cancer	642:647	arg1	cells					649:653	HT-29 colon cancer cells	630:653	HT-29 colon cancer cells	630:653	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	5	53	from	immunoreactivity	765:780	arg1	specimens					812:820	all 73 colon cancer tissue specimens	785:820	all 73 colon cancer tissue specimens examined at various degrees	785:848	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	6	54	theme	patients	1133:1140	arg1	rate					1125:1128	a poor overall survival rate	1101:1128	a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1101:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	3	55	theme	differentiated	515:528	arg1	cells					536:540	sodium butyrate-induced enterocytically differentiated HT-29 cells	475:540	sodium butyrate-induced enterocytically differentiated HT-29 cells	475:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	2	56	theme	cancer	318:323	arg1	cells					325:329	colorectal cancer cells	307:329	colorectal cancer cells relative to noncancerous gland cells	307:366	In this study, we aimed to generate a monoclonal antibody that preferentially reacts with colorectal cancer cells relative to noncancerous gland cells.
33904933	6	57	with	patients	1228:1235	arg1	P = 0.0418					1261:1270	P = 0.0418	1261:1270	P = 0.0418	1261:1270	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	57	with	patients	1228:1235	arg1	cancer					1253:1258	colorectal cancer	1242:1258	colorectal cancer (P = 0.0418)	1242:1271	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	58	theme	survival	1211:1218	arg1	rate					1220:1223	unfavorable progression-free survival rate	1182:1223	unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418)	1182:1271	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	4	59	theme	differentiated	693:706	arg1	cells					714:718	sodium butyrate-induced differentiated HT-29 cells	669:718	sodium butyrate-induced differentiated HT-29 cells	669:718	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	1	60	theme	target	201:206	arg1	therapy					208:214	molecular target therapy	191:214	molecular target therapy	191:214	Cancer-associated antigens are not only a good marker for monitoring cancer progression but are also useful for molecular target therapy.
33904933	6	61	theme	cancer	999:1004	arg1	cells					1006:1010	colon cancer cells	993:1010	colon cancer cells intensively stained with 12G5A antibody	993:1050	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	6	62	theme	unfavorable	1182:1192	arg1	rate					1220:1223	unfavorable progression-free survival rate	1182:1223	unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418)	1182:1271	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	5	63	theme	gland	901:905	arg1	cells					907:911	noncancerous gland cells	888:911	noncancerous gland cells	888:911	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	8	64	theme	glycosylation	1575:1587	arg1	epitope					1589:1595	a cancer-associated glycosylation epitope	1555:1595	a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior	1555:1681	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	7	65	theme	annexin	1491:1497	arg1	protein					1502:1508	annexin A2 protein	1491:1508	annexin A2 protein	1491:1508	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	1	66	theme	good	121:124	arg1	marker					126:131	a good marker	119:131	a good marker for monitoring cancer progression	119:165	Cancer-associated antigens are not only a good marker for monitoring cancer progression but are also useful for molecular target therapy.
33904933	7	67	gly	glycosylated	1467:1478	arg1	epitope					1480:1486	the glycosylated epitope	1463:1486	the glycosylated epitope on annexin A2 protein	1463:1508	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	6	68	with	rate	1220:1223	arg1	rate					1125:1128	a poor overall survival rate	1101:1128	a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1101:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	5	69	theme	Immunohistochemical	721:739	arg1	staining					741:748	Immunohistochemical staining	721:748	Immunohistochemical staining	721:748	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	7	70	theme	A2	1499:1500	arg1	protein					1502:1508	annexin A2 protein	1491:1508	annexin A2 protein	1491:1508	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	6	71	theme	higher	1077:1082	arg1	association					1084:1094	significantly higher association	1063:1094	significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1063:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	3	72	theme	butyrate-induced	482:497	arg1	cells					536:540	sodium butyrate-induced enterocytically differentiated HT-29 cells	475:540	sodium butyrate-induced enterocytically differentiated HT-29 cells	475:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	7	73	theme	laser	1290:1294	arg1	spectrometry					1338:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	1	74	theme	cancer	148:153	arg1	progression					155:165	cancer progression	148:165	cancer progression	148:165	Cancer-associated antigens are not only a good marker for monitoring cancer progression but are also useful for molecular target therapy.
33904933	10	75	theme	annexin	1842:1848	arg1	A2					1850:1851	annexin A2	1842:1851	annexin A2	1842:1851	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	5	76	theme	colon	792:796	arg1	specimens					812:820	all 73 colon cancer tissue specimens	785:820	all 73 colon cancer tissue specimens examined at various degrees	785:848	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	1	77	theme	Cancer-associated	79:95	arg1	antigens					97:104	Cancer-associated antigens	79:104	Cancer-associated antigens	79:104	Cancer-associated antigens are not only a good marker for monitoring cancer progression but are also useful for molecular target therapy.
33904933	8	78	theme	colorectal	1656:1665	arg1	behavior					1674:1681	unfavorable colorectal cancer behavior	1644:1681	unfavorable colorectal cancer behavior	1644:1681	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	0	79	theme	colorectal	6:15	arg1	antigen					48:54	Human colorectal cancer-associated carbohydrate antigen	0:54	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein	0:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	9	80	theme	MESSAGE	1688:1694	arg1	antibody					1716:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	6	81	theme	survival	1116:1123	arg1	rate					1125:1128	a poor overall survival rate	1101:1128	a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1101:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	10	82	theme	•	1776:1776	arg1	antibody					1784:1791	• 12G5A antibody	1776:1791	• 12G5A antibody	1776:1791	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	0	83	theme	carbohydrate	35:46	arg1	antigen					48:54	Human colorectal cancer-associated carbohydrate antigen	0:54	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein	0:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	9	84	theme	•	1697:1697	arg1	antibody					1716:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	7	85	from	epitope	1480:1486	arg1	protein					1502:1508	annexin A2 protein	1491:1508	annexin A2 protein	1491:1508	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	6	86	theme	poor	1103:1106	arg1	rate					1125:1128	a poor overall survival rate	1101:1128	a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1101:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	10	87	theme	glycosylation	1817:1829	arg1	epitope					1831:1837	the N-linked glycosylation epitope	1804:1837	the N-linked glycosylation epitope on annexin A2	1804:1851	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	5	88	theme	various	834:840	arg1	degrees					842:848	various degrees	834:848	various degrees	834:848	Immunohistochemical staining revealed 12G5A immunoreactivity in all 73 colon cancer tissue specimens examined at various degrees, but little or no immunoreactivity in noncancerous gland cells.
33904933	9	89	theme	monoclonal	1705:1714	arg1	antibody					1716:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody	1684:1723	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	3	90	theme	cell	426:429	arg1	lysates					431:437	HT-29 colorectal cancer cell lysates	402:437	HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells	402:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	8	91	from	epitope	1589:1595	arg1	A2					1608:1609	annexin A2	1600:1609	annexin A2	1600:1609	Our findings indicate that 12G5A identified a cancer-associated glycosylation epitope on annexin A2, whose expression was related to unfavorable colorectal cancer behavior.
33904933	0	92	theme	A2	67:68	arg1	protein					70:76	annexin A2 protein	59:76	annexin A2 protein	59:76	Human colorectal cancer-associated carbohydrate antigen on annexin A2 protein.
33904933	7	93	theme	silencing	1359:1367	arg1	analysis					1369:1376	si-RNA silencing analysis	1352:1376	si-RNA silencing analysis	1352:1376	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33904933	3	94	theme	colorectal	408:417	arg1	lysates					431:437	HT-29 colorectal cancer cell lysates	402:437	HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells	402:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	4	95	theme	monoclonal	572:581	arg1	antibody					583:590	a monoclonal antibody	570:590	a monoclonal antibody	570:590	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	10	96	link	N-linked	1808:1815	arg1	epitope					1831:1837	the N-linked glycosylation epitope	1804:1837	the N-linked glycosylation epitope on annexin A2	1804:1851	• 12G5A antibody recognized the N-linked glycosylation epitope on annexin A2.
33904933	3	97	theme	HT-29	530:534	arg1	cells					536:540	sodium butyrate-induced enterocytically differentiated HT-29 cells	475:540	sodium butyrate-induced enterocytically differentiated HT-29 cells	475:540	We prepared antigens composed of HT-29 colorectal cancer cell lysates that were adsorbed by antibodies to sodium butyrate-induced enterocytically differentiated HT-29 cells.
33904933	6	98	with	association	1084:1094	arg1	rate					1125:1128	a poor overall survival rate	1101:1128	a poor overall survival rate of patients with colorectal cancer (P = 0.0196)	1101:1176	Notably, high 12G5A immunoreactivity, which was determined as more than 50% of colon cancer cells intensively stained with 12G5A antibody, exhibited significantly higher association with a poor overall survival rate of patients with colorectal cancer (P = 0.0196) and unfavorable progression-free survival rate of patients with colorectal cancer (P = 0.0418).
33904933	9	99	theme	colorectal	1738:1747	arg1	epitope					1767:1773	a colorectal cancer-associated epitope	1736:1773	a colorectal cancer-associated epitope	1736:1773	KEY MESSAGE: • 12G5A monoclonal antibody recognized a colorectal cancer-associated epitope.
33904933	4	100	theme	colon	636:640	arg1	cells					649:653	HT-29 colon cancer cells	630:653	HT-29 colon cancer cells	630:653	Subsequently, we generated a monoclonal antibody, designated 12G5A, which reacted with HT-29 colon cancer cells, but not with sodium butyrate-induced differentiated HT-29 cells.
33904933	11	101	theme	•	1854:1854	arg1	immunoreactivity					1862:1877	• 12G5A immunoreactivity	1854:1877	• 12G5A immunoreactivity	1854:1877	• 12G5A immunoreactivity was related to unfavorable colorectal cancer behavior.
33904933	7	102	theme	mass	1333:1336	arg1	spectrometry					1338:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry	1274:1349	Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, si-RNA silencing analysis, enzymatic deglycosylation, and tunicamycin treatment revealed that 12G5A recognized the glycosylated epitope on annexin A2 protein.
33542268	6	0	link	N-linked	1379:1386	arg1	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	0	link	N-linked	1379:1386	arg1	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	7	1	theme	C-terminal	1652:1661	arg1	variant					1663:1669	another C-terminal variant	1644:1669	another C-terminal variant	1644:1669	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	1	theme	C-terminal	1652:1661	arg1	Y397H					1672:1676	Y397H	1672:1676	Y397H (42.0 ± 10.1% of WT F3 levels)	1672:1707	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	2	from	defect	1634:1639	arg1	variant					1663:1669	another C-terminal variant	1644:1669	another C-terminal variant	1644:1669	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	2	from	defect	1634:1639	arg1	Y397H					1672:1676	Y397H	1672:1676	Y397H (42.0 ± 10.1% of WT F3 levels)	1672:1707	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	1	3	theme	primary	249:255	arg1	glaucoma					268:275	primary open angle glaucoma	249:275	primary open angle glaucoma	249:275	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	4	theme	angle	262:266	arg1	glaucoma					268:275	primary open angle glaucoma	249:275	primary open angle glaucoma	249:275	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	7	5	theme	secretion	1624:1632	arg1	defect					1634:1639	a previously undiscovered secretion defect	1598:1639	a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels)	1598:1707	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	6	6	theme	N-linked	1379:1386	arg1	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	6	theme	N-linked	1379:1386	arg1	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	4	7	theme	secretion	839:847	arg1	defect					849:854	a significant secretion defect	825:854	a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels)	825:896	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	9	8	theme	identified	1959:1968	arg1	mutations					1989:1997	previously identified disease-associated mutations	1948:1997	previously identified disease-associated mutations (e.g., R140W)	1948:2011	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	9	8	theme	identified	1959:1968	arg1	R140W					2006:2010	R140W	2006:2010	R140W	2006:2010	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	6	9	theme	sole	1362:1365	arg1	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	9	theme	sole	1362:1365	arg1	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	7	10	theme	secretion	1501:1509	arg1	defects					1511:1517	secretion defects	1501:1517	secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively)	1501:1577	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	4	11	theme	F3	887:888	arg1	levels					890:895	wild-type (WT) F3 levels	872:895	wild-type (WT) F3 levels	872:895	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	8	12	theme	glycan	1715:1720	arg1	removal					1722:1728	glycan removal	1715:1728	glycan removal	1715:1728	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	2	13	theme	cultured	526:533	arg1	cells					535:539	cultured cells	526:539	cultured cells	526:539	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	5	14	theme	conserved	1018:1026	arg1	L451					1037:1040	L451	1037:1040	L451	1037:1040	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	14	theme	conserved	1018:1026	arg1	residue					1028:1034	this conserved residue	1013:1034	this conserved residue (L451)	1013:1041	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	3	15	theme	clinically-identified	586:606	arg1	mutations					611:619	fifteen other clinically-identified F3 mutations	572:619	fifteen other clinically-identified F3 mutations	572:619	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	4	16	theme	wild-type	872:880	arg1	levels					890:895	wild-type (WT) F3 levels	872:895	wild-type (WT) F3 levels	872:895	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	5	17	from	importance	1165:1174	arg1	residue					1224:1230	this residue	1219:1230	this residue	1219:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	9	18	from	WT	2040:2041	arg1	indistinguishable					2017:2033	indistinguishable	2017:2033	indistinguishable	2017:2033	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	6	19	gly	glycosylation	1388:1400	arg2	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	19	gly	glycosylation	1388:1400	arg2	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	20	theme	clinically-identified	1426:1446	arg1	mutants					1451:1457	select clinically-identified F3 mutants	1419:1457	select clinically-identified F3 mutants	1419:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	1	21	theme	extracellular	136:148	arg1	fibulin-3					166:174	fibulin-3	166:174	fibulin-3 (F3)	166:179	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	21	theme	extracellular	136:148	arg1	protein					157:163	the secreted extracellular matrix protein	123:163	the secreted extracellular matrix protein	123:163	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	8	22	theme	relative	1749:1756	arg1	secretion					1758:1766	the relative secretion	1745:1766	the relative secretion of the N-terminal mutants tested	1745:1799	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	1	23	theme	matrix	150:155	arg1	fibulin-3					166:174	fibulin-3	166:174	fibulin-3 (F3)	166:179	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	23	theme	matrix	150:155	arg1	protein					157:163	the secreted extracellular matrix protein	123:163	the secreted extracellular matrix protein	123:163	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	4	24	theme	intracellular	930:942	arg1	levels					944:949	intracellular levels	930:949	intracellular levels	930:949	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	1	25	theme	rare	328:331	arg1	dystrophy					341:349	a rare macular dystrophy	326:349	a rare macular dystrophy	326:349	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	25	theme	rare	328:331	arg1	Leventinese					361:371	Malattia Leventinese	352:371	Malattia Leventinese (ML)	352:376	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	7	26	theme	levels	1557:1562	arg1	levels					1557:1562	WT F3 levels	1551:1562	WT F3 levels	1551:1562	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	26	theme	levels	1557:1562	arg1	%					1530:1530	19.8 ± 3.0%	1520:1530	19.8 ± 3.0%	1520:1530	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	26	theme	levels	1557:1562	arg1	%					1546:1546	12.4 ± 1.2%	1536:1546	12.4 ± 1.2% of WT F3 levels	1536:1562	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	0	27	from	mutations	33:41	arg1	fibulin-3					46:54	fibulin-3	46:54	fibulin-3	46:54	Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization.
33542268	8	28	theme	N-terminal	1775:1784	arg1	mutants					1786:1792	the N-terminal mutants	1771:1792	the N-terminal mutants tested	1771:1799	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	7	29	theme	WT	1551:1552	arg1	levels					1557:1562	WT F3 levels	1551:1562	WT F3 levels	1551:1562	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	9	30	dep	R345W	1901:1905	arg1	variants					1917:1924	variants	1917:1924	variants	1917:1924	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	9	30	dep	R345W	1901:1905	arg1	the					1897:1899	the	1897:1899	the	1897:1899	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	1	31	theme	Malattia	352:359	arg1	dystrophy					341:349	a rare macular dystrophy	326:349	a rare macular dystrophy	326:349	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	31	theme	Malattia	352:359	arg1	Leventinese					361:371	Malattia Leventinese	352:371	Malattia Leventinese (ML)	352:376	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	31	theme	Malattia	352:359	arg1	ML					374:375	ML	374:375	ML	374:375	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	2	32	theme	steady	503:508	arg1	levels					516:521	intracellular steady state levels	489:521	higher intracellular steady state levels in cultured cells	482:539	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	2	33	theme	R345W	383:387	arg1	mutation					392:399	The R345W F3 mutation	379:399	The R345W F3 mutation that causes ML	379:414	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	4	34	theme	levels	975:980	arg1	levels					975:980	WT F3 levels	969:980	WT F3 levels	969:980	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	4	34	theme	levels	975:980	arg1	%					964:964	226.8 ± 25.4%	952:964	226.8 ± 25.4% of WT F3 levels	952:980	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	0	35	theme	Clinically-identified	0:20	arg1	mutations					33:41	Clinically-identified C-terminal mutations	0:41	Clinically-identified C-terminal mutations in fibulin-3	0:54	Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization.
33542268	5	36	dep	charged	1060:1066	arg1	Arg					1076:1078	Arg	1076:1078	Arg	1076:1078	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	36	dep	charged	1060:1066	arg1	Asp					1069:1071	Asp	1069:1071	Asp	1069:1071	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	6	37	theme	inherent	1254:1261	arg1	instability					1266:1276	potential inherent F3 instability	1244:1276	potential inherent F3 instability not easily observed under typical culture conditions	1244:1329	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	1	38	theme	cuticular	280:288	arg1	degeneration					310:321	cuticular age-related macular degeneration	280:321	cuticular age-related macular degeneration	280:321	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	5	39	from	residue	1224:1230	arg1	importance					1165:1174	the importance	1161:1174	the importance of small side chains (Leu, Ala, or Gly) at this residue	1161:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	39	from	residue	1224:1230	arg1	Gly					1211:1213	Gly	1211:1213	Gly	1211:1213	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	39	from	residue	1224:1230	arg1	Leu					1198:1200	Leu	1198:1200	Leu	1198:1200	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	39	from	residue	1224:1230	arg1	Ala					1203:1205	Ala	1203:1205	Ala	1203:1205	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	39	from	residue	1224:1230	arg1	chains					1190:1195	small side chains	1179:1195	small side chains (Leu, Ala, or Gly) at this residue	1179:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	9	40	theme	uniqueness	1851:1860	arg1	similarities					1876:1887	the uniqueness and molecular similarities	1847:1887	similarities	1876:1887	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	5	41	theme	side	1185:1188	arg1	Ala					1203:1205	Ala	1203:1205	Ala	1203:1205	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	41	theme	side	1185:1188	arg1	Gly					1211:1213	Gly	1211:1213	Gly	1211:1213	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	41	theme	side	1185:1188	arg1	Leu					1198:1200	Leu	1198:1200	Leu	1198:1200	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	41	theme	side	1185:1188	arg1	chains					1190:1195	small side chains	1179:1195	small side chains (Leu, Ala, or Gly) at this residue	1179:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	1	42	theme	macular	302:308	arg1	degeneration					310:321	cuticular age-related macular degeneration	280:321	cuticular age-related macular degeneration	280:321	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	4	43	theme	WT	969:970	arg1	levels					975:980	WT F3 levels	969:980	WT F3 levels	969:980	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	3	44	theme	similar	633:639	arg1	levels					641:646	similar levels	633:646	similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity	633:746	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	4	45	dep	defect	849:854	arg1	levels					890:895	wild-type (WT) F3 levels	872:895	wild-type (WT) F3 levels	872:895	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	4	45	dep	defect	849:854	arg1	%					867:867	69.5 ± 2.4%	857:867	69.5 ± 2.4% of wild-type (WT) F3 levels	857:895	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	7	46	theme	levels	1701:1706	arg1	levels					1701:1706	WT F3 levels	1695:1706	WT F3 levels	1695:1706	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	46	theme	levels	1701:1706	arg1	%					1690:1690	42.0 ± 10.1%	1679:1690	42.0 ± 10.1% of WT F3 levels	1679:1706	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	5	47	dep	chains	1190:1195	arg1	Ala					1203:1205	Ala	1203:1205	Ala	1203:1205	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	47	dep	chains	1190:1195	arg1	Gly					1211:1213	Gly	1211:1213	Gly	1211:1213	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	47	dep	chains	1190:1195	arg1	Leu					1198:1200	Leu	1198:1200	Leu	1198:1200	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	47	dep	chains	1190:1195	arg1	chains					1190:1195	small side chains	1179:1195	small side chains (Leu, Ala, or Gly) at this residue	1179:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	3	48	theme	defects	676:682	arg1	levels					641:646	similar levels	633:646	similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity	633:746	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	4	49	theme	single	784:789	arg1	L451F					803:807	L451F	803:807	L451F	803:807	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	4	49	theme	single	784:789	arg1	variant					794:800	only a single F3 variant	777:800	only a single F3 variant	777:800	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	9	50	theme	alternative	2114:2124	arg1	mechanism					2126:2134	an alternative mechanism	2111:2134	an alternative mechanism	2111:2134	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	7	51	theme	WT	1695:1696	arg1	levels					1701:1706	WT F3 levels	1695:1706	WT F3 levels	1695:1706	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	2	52	theme	F3	389:390	arg1	mutation					392:399	The R345W F3 mutation	379:399	The R345W F3 mutation that causes ML	379:414	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	7	53	dep	R345W	1485:1489	arg1	defects					1511:1517	secretion defects	1501:1517	secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively)	1501:1577	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	6	54	theme	culture	1312:1318	arg1	conditions					1320:1329	typical culture conditions	1304:1329	typical culture conditions	1304:1329	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	1	55	theme	diseases	227:234	arg1	number					210:215	a number	208:215	a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML)	208:376	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	8	56	theme	mutants	1786:1792	arg1	secretion					1758:1766	the relative secretion	1745:1766	the relative secretion of the N-terminal mutants tested	1745:1799	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	4	57	from	increase	918:925	arg1	levels					944:949	intracellular levels	930:949	intracellular levels	930:949	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	8	58	dep	D49A	1802:1805	arg1	I220F					1815:1819	I220F	1815:1819	I220F	1815:1819	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	8	58	dep	D49A	1802:1805	arg1	R140W					1808:1812	R140W	1808:1812	R140W	1808:1812	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	9	59	theme	molecular	1866:1874	arg1	similarities					1876:1887	the uniqueness and molecular similarities	1847:1887	similarities	1876:1887	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	1	60	theme	open	257:260	arg1	glaucoma					268:275	primary open angle glaucoma	249:275	primary open angle glaucoma	249:275	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	9	61	dep	R140W	2006:2010	arg1	e.g.					2000:2003	e.g.	2000:2003	e.g.	2000:2003	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	7	62	theme	undiscovered	1611:1622	arg1	defect					1634:1639	a previously undiscovered secretion defect	1598:1639	a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels)	1598:1707	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	63	dep	Y397H	1672:1676	arg1	levels					1701:1706	WT F3 levels	1695:1706	WT F3 levels	1695:1706	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	63	dep	Y397H	1672:1676	arg1	%					1690:1690	42.0 ± 10.1%	1679:1690	42.0 ± 10.1% of WT F3 levels	1679:1706	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	3	64	theme	potential	724:732	arg1	pathogenicity					734:746	their potential pathogenicity	718:746	their potential pathogenicity	718:746	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	6	65	theme	glycosylation	1388:1400	arg1	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	65	theme	glycosylation	1388:1400	arg1	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	5	66	theme	bulky	1084:1088	arg1	residue					1106:1112	a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue	1058:1112	residue	1106:1112	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	6	67	theme	stabilizing	1367:1377	arg1	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	67	theme	stabilizing	1367:1377	arg1	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	4	68	theme	significant	827:837	arg1	defect					849:854	a significant secretion defect	825:854	a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels)	825:896	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	9	69	theme	disease-associated	1970:1987	arg1	mutations					1989:1997	previously identified disease-associated mutations	1948:1997	previously identified disease-associated mutations (e.g., R140W)	1948:2011	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	9	69	theme	disease-associated	1970:1987	arg1	R140W					2006:2010	R140W	2006:2010	R140W	2006:2010	These results highlight the uniqueness and molecular similarities between the R345W and L451F variants and also suggest that previously identified disease-associated mutations (e.g., R140W) are indistinguishable from WT with respect to secretion, hinting that they may lead to disease by an alternative mechanism.
33542268	4	70	dep	increase	918:925	arg1	levels					975:980	WT F3 levels	969:980	WT F3 levels	969:980	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	4	70	dep	increase	918:925	arg1	%					964:964	226.8 ± 25.4%	952:964	226.8 ± 25.4% of WT F3 levels	952:980	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	5	71	dep	residue	1106:1112	arg1	Trp					1096:1098	Trp	1096:1098	Trp	1096:1098	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	71	dep	residue	1106:1112	arg1	Pro					1091:1093	Pro	1091:1093	Pro	1091:1093	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	71	dep	residue	1106:1112	arg1	Tyr					1101:1103	Tyr	1101:1103	Tyr	1101:1103	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	3	72	theme	other	580:584	arg1	mutations					611:619	fifteen other clinically-identified F3 mutations	572:619	fifteen other clinically-identified F3 mutations	572:619	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	4	73	theme	levels	890:895	arg1	levels					890:895	wild-type (WT) F3 levels	872:895	wild-type (WT) F3 levels	872:895	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	4	73	theme	levels	890:895	arg1	%					867:867	69.5 ± 2.4%	857:867	69.5 ± 2.4% of wild-type (WT) F3 levels	857:895	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	2	74	from	higher	482:487	arg1	accumulation					466:477	accumulation	466:477	accumulation at higher intracellular steady state levels in cultured cells	466:539	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	2	74	from	higher	482:487	arg1	misfolding					428:437	F3 misfolding	425:437	F3 misfolding	425:437	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	2	74	from	higher	482:487	arg1	secretion					452:460	inefficient secretion	440:460	inefficient secretion	440:460	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	6	75	theme	F3	1448:1449	arg1	mutants					1451:1457	select clinically-identified F3 mutants	1419:1457	select clinically-identified F3 mutants	1419:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	1	76	theme	secreted	127:134	arg1	fibulin-3					166:174	fibulin-3	166:174	fibulin-3 (F3)	166:179	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	76	theme	secreted	127:134	arg1	protein					157:163	the secreted extracellular matrix protein	123:163	the secreted extracellular matrix protein	123:163	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	5	77	theme	follow-up	989:997	arg1	studies					999:1005	follow-up studies	989:1005	follow-up studies	989:1005	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	6	78	theme	select	1419:1424	arg1	mutants					1451:1457	select clinically-identified F3 mutants	1419:1457	select clinically-identified F3 mutants	1419:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	79	from	mutants	1451:1457	arg1	N249					1408:1411	N249	1408:1411	N249	1408:1411	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	6	79	from	mutants	1451:1457	arg1	site					1402:1405	the sole stabilizing N-linked glycosylation site	1358:1405	the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants	1358:1457	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	7	80	dep	defects	1511:1517	arg1	levels					1557:1562	WT F3 levels	1551:1562	WT F3 levels	1551:1562	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	80	dep	defects	1511:1517	arg1	%					1530:1530	19.8 ± 3.0%	1520:1530	19.8 ± 3.0%	1520:1530	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	7	80	dep	defects	1511:1517	arg1	%					1546:1546	12.4 ± 1.2%	1536:1546	12.4 ± 1.2% of WT F3 levels	1536:1562	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	3	81	theme	F3	608:609	arg1	mutations					611:619	fifteen other clinically-identified F3 mutations	572:619	fifteen other clinically-identified F3 mutations	572:619	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	5	82	theme	F3	1115:1116	arg1	secretion					1118:1126	F3 secretion	1115:1126	F3 secretion	1115:1126	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	4	83	dep	wild-type	872:880	arg1	WT					883:884	WT	883:884	WT	883:884	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	1	84	theme	macular	333:339	arg1	dystrophy					341:349	a rare macular dystrophy	326:349	a rare macular dystrophy	326:349	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	84	theme	macular	333:339	arg1	Leventinese					361:371	Malattia Leventinese	352:371	Malattia Leventinese (ML)	352:376	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	4	85	from	defect	849:854	arg1	levels					944:949	intracellular levels	930:949	intracellular levels	930:949	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	7	86	theme	F3	1554:1555	arg1	levels					1557:1562	WT F3 levels	1551:1562	WT F3 levels	1551:1562	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	2	87	theme	state	510:514	arg1	levels					516:521	intracellular steady state levels	489:521	higher intracellular steady state levels in cultured cells	482:539	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	5	88	theme	chains	1190:1195	arg1	importance					1165:1174	the importance	1161:1174	the importance of small side chains (Leu, Ala, or Gly) at this residue	1161:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	2	89	theme	intracellular	489:501	arg1	levels					516:521	intracellular steady state levels	489:521	higher intracellular steady state levels in cultured cells	482:539	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	0	90	theme	C-terminal	22:31	arg1	mutations					33:41	Clinically-identified C-terminal mutations	0:41	Clinically-identified C-terminal mutations in fibulin-3	0:54	Clinically-identified C-terminal mutations in fibulin-3 are prone to misfolding and destabilization.
33542268	1	91	theme	Distinct	101:108	arg1	mutations					110:118	Distinct mutations	101:118	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3),	101:180	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	4	92	theme	F3	972:973	arg1	levels					975:980	WT F3 levels	969:980	WT F3 levels	969:980	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	6	93	theme	F3	1263:1264	arg1	instability					1266:1276	potential inherent F3 instability	1244:1276	potential inherent F3 instability not easily observed under typical culture conditions	1244:1329	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	8	94	dep	change	1738:1743	arg1	D49A					1802:1805	D49A	1802:1805	D49A	1802:1805	Yet, glycan removal did not change the relative secretion of the N-terminal mutants tested (D49A, R140W, I220F).
33542268	5	95	theme	small	1179:1183	arg1	Ala					1203:1205	Ala	1203:1205	Ala	1203:1205	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	95	theme	small	1179:1183	arg1	Gly					1211:1213	Gly	1211:1213	Gly	1211:1213	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	95	theme	small	1179:1183	arg1	Leu					1198:1200	Leu	1198:1200	Leu	1198:1200	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	5	95	theme	small	1179:1183	arg1	chains					1190:1195	small side chains	1179:1195	small side chains (Leu, Ala, or Gly) at this residue	1179:1230	Upon follow-up studies, when this conserved residue (L451) was mutated to a charged (Asp or Arg) or bulky (Pro, Trp, Tyr) residue, F3 secretion was also compromised, indicating the importance of small side chains (Leu, Ala, or Gly) at this residue.
33542268	6	96	theme	potential	1244:1252	arg1	instability					1266:1276	potential inherent F3 instability	1244:1276	potential inherent F3 instability not easily observed under typical culture conditions	1244:1329	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
33542268	1	97	theme	age-related	290:300	arg1	degeneration					310:321	cuticular age-related macular degeneration	280:321	cuticular age-related macular degeneration	280:321	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	98	from	mutations	110:118	arg1	fibulin-3					166:174	fibulin-3	166:174	fibulin-3 (F3)	166:179	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	1	98	from	mutations	110:118	arg1	protein					157:163	the secreted extracellular matrix protein	123:163	the secreted extracellular matrix protein	123:163	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	2	99	theme	inefficient	440:450	arg1	secretion					452:460	inefficient secretion	440:460	inefficient secretion	440:460	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	4	100	theme	corresponding	904:916	arg1	increase					918:925	a corresponding increase	902:925	a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels)	902:981	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	7	101	theme	F3	1698:1699	arg1	levels					1701:1706	WT F3 levels	1695:1706	WT F3 levels	1695:1706	This removal exacerbated R345W and L451F secretion defects (19.8 ± 3.0% and 12.4 ± 1.2% of WT F3 levels, respectively), but also revealed a previously undiscovered secretion defect in another C-terminal variant, Y397H (42.0 ± 10.1% of WT F3 levels).
33542268	3	102	theme	secretion	666:674	arg1	defects					676:682	misfolding and secretion defects	651:682	misfolding and secretion defects	651:682	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	2	103	dep	higher	482:487	arg1	levels					516:521	intracellular steady state levels	489:521	higher intracellular steady state levels in cultured cells	482:539	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	3	104	theme	misfolding	651:660	arg1	defects					676:682	misfolding and secretion defects	651:682	misfolding and secretion defects	651:682	Herein, we determined whether fifteen other clinically-identified F3 mutations also led to similar levels of misfolding and secretion defects, which might provide insight into their potential pathogenicity.
33542268	1	105	theme	ocular	220:225	arg1	diseases					227:234	ocular diseases	220:234	ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML)	220:376	Distinct mutations in the secreted extracellular matrix protein, fibulin-3 (F3), have been associated with a number of ocular diseases ranging from primary open angle glaucoma to cuticular age-related macular degeneration to a rare macular dystrophy, Malattia Leventinese (ML).
33542268	4	106	theme	F3	791:792	arg1	L451F					803:807	L451F	803:807	L451F	803:807	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	4	106	theme	F3	791:792	arg1	variant					794:800	only a single F3 variant	777:800	only a single F3 variant	777:800	Surprisingly, we found that only a single F3 variant, L451F, presented with a significant secretion defect (69.5 ± 2.4% of wild-type (WT) F3 levels) and a corresponding increase in intracellular levels (226.8 ± 25.4% of WT F3 levels).
33542268	2	107	theme	F3	425:426	arg1	misfolding					428:437	F3 misfolding	425:437	F3 misfolding	425:437	The R345W F3 mutation that causes ML leads to F3 misfolding, inefficient secretion and accumulation at higher intracellular steady state levels in cultured cells.
33542268	6	108	theme	typical	1304:1310	arg1	conditions					1320:1329	typical culture conditions	1304:1329	typical culture conditions	1304:1329	To uncover potential inherent F3 instability not easily observed under typical culture conditions, we genetically eliminated the sole stabilizing N-linked glycosylation site (N249) from select clinically-identified F3 mutants.
34029329	9	0	theme	distinct	1438:1445	arg1	profiles					1464:1471	distinct country specific profiles	1438:1471	distinct country specific profiles	1438:1471	Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles.
34029329	4	1	theme	length	637:642	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	3	2	theme	epitope	593:599	arg1	specificities					601:613	distinct epitope specificities	584:613	distinct epitope specificities	584:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	9	3	theme	specific	1455:1462	arg1	profiles					1464:1471	distinct country specific profiles	1438:1471	distinct country specific profiles	1438:1471	Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles.
34029329	8	4	theme	loop	1235:1238	arg1	lengths					1240:1246	Variable loop lengths	1226:1246	Variable loop lengths	1226:1246	Variable loop lengths and charges within Indian and African clusters were also found to be distinct from each other, specifically for V1, V2 and V4 loops.
34029329	5	5	theme	phylogenetic	826:837	arg1	association					839:849	their phylogenetic association	820:849	their phylogenetic association	820:849	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	5	theme	phylogenetic	826:837	arg1	prevalence					878:887	prevalence	878:887	prevalence of potential N-linked glycosylation sites (pNLGS)	878:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	5	theme	phylogenetic	826:837	arg1	lengths					866:872	variable loop lengths	852:872	variable loop lengths	852:872	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	2	6	theme	subtype	300:306	arg1	C					308:308	HIV-1 subtype C	294:308	HIV-1 subtype C	294:308	HIV-1 subtype C is responsible for majority of global HIV-1 infections.
34029329	5	7	theme	sites	925:929	arg1	association					839:849	their phylogenetic association	820:849	their phylogenetic association	820:849	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	7	theme	sites	925:929	arg1	prevalence					878:887	prevalence	878:887	prevalence of potential N-linked glycosylation sites (pNLGS)	878:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	7	theme	sites	925:929	arg1	lengths					866:872	variable loop lengths	852:872	variable loop lengths	852:872	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	11	8	theme	disparate	1805:1813	arg1	sensitivity					1831:1841	the disparate region-specific sensitivity	1801:1841	the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs	1801:1881	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	4	9	from	countries	683:691	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	4	9	from	countries	683:691	arg1	total					618:622	A total	616:622	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries	616:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	6	10	theme	machine	1000:1006	arg1	algorithm					1017:1025	a machine learning algorithm	998:1025	a machine learning algorithm 'bNAb-ReP'	998:1036	Responses of these sequences to bnAbs were predicted with a machine learning algorithm 'bNAb-ReP' and compared with those reported in the CATNAP database.
34029329	0	11	from	impact	70:75	arg1	sensitivity					110:120	broadly neutralizing antibody sensitivity	80:120	broadly neutralizing antibody sensitivity	80:120	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	11	12	theme	circulating	1846:1856	arg1	C					1872:1872	circulating HIV-1 subtype C	1846:1872	circulating HIV-1 subtype C	1846:1872	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	7	13	theme	C	1103:1103	arg1	sequences					1105:1113	Subtype C sequences	1095:1113	Subtype C sequences from Asian countries including India	1095:1150	Subtype C sequences from Asian countries including India differed phylogenetically when compared with that from African countries.
34029329	5	14	theme	N-linked	902:909	arg1	sites					925:929	potential N-linked glycosylation sites	892:929	potential N-linked glycosylation sites (pNLGS)	892:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	14	theme	N-linked	902:909	arg1	pNLGS					932:936	pNLGS	932:936	pNLGS	932:936	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	1	15	theme	Evolving	123:130	arg1	diversity					132:140	Evolving diversity	123:140	Evolving diversity in globally circulating HIV-1 subtypes	123:179	Evolving diversity in globally circulating HIV-1 subtypes presents a formidable challenge in defining and developing neutralizing antibodies for prevention and treatment.
34029329	11	16	theme	C	1759:1759	arg1	sequences					1767:1775	global intra-subtype C gp120 sequences	1738:1775	global intra-subtype C gp120 sequences	1738:1775	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	10	17	located	observed	1523:1530	arg2	p<0.001					1506:1512	p<0.001***	1506:1515	p<0.001***	1506:1515	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	17	located	observed	1523:1530	arg2	differences					1493:1503	Highly significant differences	1474:1503	Highly significant differences (p<0.001***)	1474:1516	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	17	located	observed	1523:1530	arg1	prevalence					1535:1544	prevalence	1535:1544	prevalence of four pNLGS (N130, N295, N392 and N448)	1535:1586	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	11	18	theme	global	1738:1743	arg1	sequences					1767:1775	global intra-subtype C gp120 sequences	1738:1775	global intra-subtype C gp120 sequences	1738:1775	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	1	19	theme	circulating	154:164	arg1	subtypes					172:179	globally circulating HIV-1 subtypes	145:179	globally circulating HIV-1 subtypes	145:179	Evolving diversity in globally circulating HIV-1 subtypes presents a formidable challenge in defining and developing neutralizing antibodies for prevention and treatment.
34029329	10	20	theme	significant	1481:1491	arg1	p<0.001					1506:1512	p<0.001***	1506:1515	p<0.001***	1506:1515	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	20	theme	significant	1481:1491	arg1	differences					1493:1503	Highly significant differences	1474:1503	Highly significant differences (p<0.001***)	1474:1516	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	4	21	theme	HIV	744:746	arg1	www.hiv.lanl.gov					758:773	www.hiv.lanl.gov	758:773	www.hiv.lanl.gov	758:773	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	4	21	theme	HIV	744:746	arg1	database					748:755	Los Alamos National Laboratory HIV database	713:755	Los Alamos National Laboratory HIV database (www.hiv.lanl.gov)	713:774	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	5	22	link	N-linked	902:909	arg1	sites					925:929	potential N-linked glycosylation sites	892:929	potential N-linked glycosylation sites (pNLGS)	892:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	22	link	N-linked	902:909	arg1	pNLGS					932:936	pNLGS	932:936	pNLGS	932:936	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	6	23	theme	bNAb-ReP	1028:1035	arg1	algorithm					1017:1025	a machine learning algorithm	998:1025	a machine learning algorithm 'bNAb-ReP'	998:1036	Responses of these sequences to bnAbs were predicted with a machine learning algorithm 'bNAb-ReP' and compared with those reported in the CATNAP database.
34029329	0	24	from	diversity	42:50	arg1	sensitivity					110:120	broadly neutralizing antibody sensitivity	80:120	broadly neutralizing antibody sensitivity	80:120	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	5	25	theme	acid	787:790	arg1	sequences					792:800	The amino acid sequences	777:800	The amino acid sequences	777:800	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	1	26	from	diversity	132:140	arg1	subtypes					172:179	globally circulating HIV-1 subtypes	145:179	globally circulating HIV-1 subtypes	145:179	Evolving diversity in globally circulating HIV-1 subtypes presents a formidable challenge in defining and developing neutralizing antibodies for prevention and treatment.
34029329	11	27	theme	subtype	1864:1870	arg1	C					1872:1872	circulating HIV-1 subtype C	1846:1872	circulating HIV-1 subtype C	1846:1872	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	10	28	theme	disease	1632:1638	arg1	burden					1640:1645	most disease burden	1627:1645	most disease burden associated with subtype C	1627:1671	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	0	29	theme	Geospatial	0:9	arg1	diversity					42:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	7	30	from	countries	1126:1134	arg1	sequences					1105:1113	Subtype C sequences	1095:1113	Subtype C sequences from Asian countries including India	1095:1150	Subtype C sequences from Asian countries including India differed phylogenetically when compared with that from African countries.
34029329	3	31	theme	C	500:500	arg1	sequences					508:516	region-specific HIV-1 subtype C gp120 sequences	470:516	region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities	470:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	0	32	theme	subtype	17:23	arg1	diversity					42:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	4	33	theme	National	724:731	arg1	www.hiv.lanl.gov					758:773	www.hiv.lanl.gov	758:773	www.hiv.lanl.gov	758:773	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	4	33	theme	National	724:731	arg1	database					748:755	Los Alamos National Laboratory HIV database	713:755	Los Alamos National Laboratory HIV database (www.hiv.lanl.gov)	713:774	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	3	34	theme	HIV-1	486:490	arg1	sequences					508:516	region-specific HIV-1 subtype C gp120 sequences	470:516	region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities	470:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	10	35	theme	subtype	1663:1669	arg1	C					1671:1671	subtype C	1663:1671	subtype C	1663:1671	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	7	36	theme	African	1207:1213	arg1	countries					1215:1223	African countries	1207:1223	African countries	1207:1223	Subtype C sequences from Asian countries including India differed phylogenetically when compared with that from African countries.
34029329	0	37	theme	gp120	27:31	arg1	diversity					42:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	10	38	theme	pNLGS	1554:1558	arg1	prevalence					1535:1544	prevalence	1535:1544	prevalence of four pNLGS (N130, N295, N392 and N448)	1535:1586	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	8	39	dep	V1	1360:1361	arg1	loops					1374:1378	loops	1374:1378	loops	1374:1378	Variable loop lengths and charges within Indian and African clusters were also found to be distinct from each other, specifically for V1, V2 and V4 loops.
34029329	2	40	theme	infections	354:363	arg1	majority					329:336	majority	329:336	majority of global HIV-1 infections	329:363	HIV-1 subtype C is responsible for majority of global HIV-1 infections.
34029329	1	41	theme	neutralizing	240:251	arg1	antibodies					253:262	neutralizing antibodies	240:262	neutralizing antibodies	240:262	Evolving diversity in globally circulating HIV-1 subtypes presents a formidable challenge in defining and developing neutralizing antibodies for prevention and treatment.
34029329	4	42	theme	HIV-1	644:648	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	3	43	theme	subtype	492:498	arg1	sequences					508:516	region-specific HIV-1 subtype C gp120 sequences	470:516	region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities	470:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	9	44	theme	pNLG	1417:1420	arg1	sites					1422:1426	the 25 pNLG sites	1410:1426	the 25 pNLG sites	1410:1426	Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles.
34029329	0	45	theme	HIV-1	11:15	arg1	diversity					42:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	3	46	theme	neutralization	540:553	arg1	outcomes					555:562	virus neutralization outcomes	534:562	virus neutralization outcomes to key bnAbs having distinct epitope specificities	534:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	6	47	theme	sequences	959:967	arg1	Responses					940:948	Responses	940:948	Responses of these sequences to bnAbs	940:976	Responses of these sequences to bnAbs were predicted with a machine learning algorithm 'bNAb-ReP' and compared with those reported in the CATNAP database.
34029329	5	48	gly	glycosylation	911:923	arg2	pNLGS					932:936	pNLGS	932:936	pNLGS	932:936	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	48	gly	glycosylation	911:923	arg2	sites					925:929	potential N-linked glycosylation sites	892:929	potential N-linked glycosylation sites (pNLGS)	892:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	3	49	theme	distinct	584:591	arg1	specificities					601:613	distinct epitope specificities	584:613	distinct epitope specificities	584:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	9	50	theme	country	1447:1453	arg1	profiles					1464:1471	distinct country specific profiles	1438:1471	distinct country specific profiles	1438:1471	Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles.
34029329	11	51	theme	C	1872:1872	arg1	sensitivity					1831:1841	the disparate region-specific sensitivity	1801:1841	the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs	1801:1881	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	4	52	theme	full	632:635	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	5	53	theme	glycosylation	911:923	arg1	sites					925:929	potential N-linked glycosylation sites	892:929	potential N-linked glycosylation sites (pNLGS)	892:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	53	theme	glycosylation	911:923	arg1	pNLGS					932:936	pNLGS	932:936	pNLGS	932:936	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	8	54	theme	Variable	1226:1233	arg1	lengths					1240:1246	Variable loop lengths	1226:1246	Variable loop lengths	1226:1246	Variable loop lengths and charges within Indian and African clusters were also found to be distinct from each other, specifically for V1, V2 and V4 loops.
34029329	7	55	theme	Asian	1120:1124	arg1	India					1146:1150	India	1146:1150	India	1146:1150	Subtype C sequences from Asian countries including India differed phylogenetically when compared with that from African countries.
34029329	7	55	theme	Asian	1120:1124	arg1	countries					1126:1134	Asian countries	1120:1134	Asian countries including India	1120:1150	Subtype C sequences from Asian countries including India differed phylogenetically when compared with that from African countries.
34029329	2	56	theme	global	341:346	arg1	infections					354:363	global HIV-1 infections	341:363	global HIV-1 infections	341:363	HIV-1 subtype C is responsible for majority of global HIV-1 infections.
34029329	1	57	theme	formidable	192:201	arg1	challenge					203:211	a formidable challenge	190:211	a formidable challenge	190:211	Evolving diversity in globally circulating HIV-1 subtypes presents a formidable challenge in defining and developing neutralizing antibodies for prevention and treatment.
34029329	11	58	theme	region-specific	1815:1829	arg1	sensitivity					1831:1841	the disparate region-specific sensitivity	1801:1841	the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs	1801:1881	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	6	59	theme	learning	1008:1015	arg1	algorithm					1017:1025	a machine learning algorithm	998:1025	a machine learning algorithm 'bNAb-ReP'	998:1036	Responses of these sequences to bnAbs were predicted with a machine learning algorithm 'bNAb-ReP' and compared with those reported in the CATNAP database.
34029329	4	60	theme	sequence	666:673	arg1	total					618:622	A total	616:622	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries	616:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	7	61	theme	Subtype	1095:1101	arg1	sequences					1105:1113	Subtype C sequences	1095:1113	Subtype C sequences from Asian countries including India	1095:1150	Subtype C sequences from Asian countries including India differed phylogenetically when compared with that from African countries.
34029329	5	62	theme	potential	892:900	arg1	sites					925:929	potential N-linked glycosylation sites	892:929	potential N-linked glycosylation sites (pNLGS)	892:937	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	62	theme	potential	892:900	arg1	pNLGS					932:936	pNLGS	932:936	pNLGS	932:936	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	8	63	theme	Indian	1267:1272	arg1	clusters					1286:1293	Indian and African clusters	1267:1293	Indian and African clusters	1267:1293	Variable loop lengths and charges within Indian and African clusters were also found to be distinct from each other, specifically for V1, V2 and V4 loops.
34029329	11	64	theme	HIV-1	1858:1862	arg1	C					1872:1872	circulating HIV-1 subtype C	1846:1872	circulating HIV-1 subtype C	1846:1872	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	8	65	theme	African	1278:1284	arg1	clusters					1286:1293	Indian and African clusters	1267:1293	Indian and African clusters	1267:1293	Variable loop lengths and charges within Indian and African clusters were also found to be distinct from each other, specifically for V1, V2 and V4 loops.
34029329	2	66	theme	HIV-1	294:298	arg1	C					308:308	HIV-1 subtype C	294:308	HIV-1 subtype C	294:308	HIV-1 subtype C is responsible for majority of global HIV-1 infections.
34029329	11	67	theme	gp120	1761:1765	arg1	sequences					1767:1775	global intra-subtype C gp120 sequences	1738:1775	global intra-subtype C gp120 sequences	1738:1775	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	0	68	theme	predicted	60:68	arg1	impact					70:75	its predicted impact	56:75	its predicted impact on broadly neutralizing antibody sensitivity	56:120	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	11	69	theme	intra-subtype	1745:1757	arg1	sequences					1767:1775	global intra-subtype C gp120 sequences	1738:1775	global intra-subtype C gp120 sequences	1738:1775	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	10	70	dep	pNLGS	1554:1558	arg1	N392					1573:1576	N392	1573:1576	N392	1573:1576	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	70	dep	pNLGS	1554:1558	arg1	N295					1567:1570	N295	1567:1570	N295	1567:1570	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	70	dep	pNLGS	1554:1558	arg1	pNLGS					1554:1558	four pNLGS	1549:1558	four pNLGS (N130, N295, N392 and N448)	1549:1586	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	70	dep	pNLGS	1554:1558	arg1	N130					1561:1564	N130	1561:1564	N130	1561:1564	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	10	70	dep	pNLGS	1554:1558	arg1	N448					1582:1585	N448	1582:1585	N448	1582:1585	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	9	71	from	each	1402:1405	arg1	analyses					1390:1397	Pairwise analyses	1381:1397	Pairwise analyses at each of the 25 pNLG sites	1381:1426	Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles.
34029329	1	72	theme	HIV-1	166:170	arg1	subtypes					172:179	globally circulating HIV-1 subtypes	145:179	globally circulating HIV-1 subtypes	145:179	Evolving diversity in globally circulating HIV-1 subtypes presents a formidable challenge in defining and developing neutralizing antibodies for prevention and treatment.
34029329	4	73	theme	Laboratory	733:742	arg1	www.hiv.lanl.gov					758:773	www.hiv.lanl.gov	758:773	www.hiv.lanl.gov	758:773	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	4	73	theme	Laboratory	733:742	arg1	database					748:755	Los Alamos National Laboratory HIV database	713:755	Los Alamos National Laboratory HIV database (www.hiv.lanl.gov)	713:774	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	0	74	theme	neutralizing	88:99	arg1	sensitivity					110:120	broadly neutralizing antibody sensitivity	80:120	broadly neutralizing antibody sensitivity	80:120	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	2	75	theme	HIV-1	348:352	arg1	infections					354:363	global HIV-1 infections	341:363	global HIV-1 infections	341:363	HIV-1 subtype C is responsible for majority of global HIV-1 infections.
34029329	5	76	theme	amino	781:785	arg1	sequences					792:800	The amino acid sequences	777:800	The amino acid sequences	777:800	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	3	77	theme	present	373:379	arg1	study					381:385	the present study	369:385	the present study	369:385	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	3	78	theme	region-specific	470:484	arg1	sequences					508:516	region-specific HIV-1 subtype C gp120 sequences	470:516	region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities	470:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	4	79	from	total	618:622	arg1	countries					683:691	37 countries	680:691	37 countries	680:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	3	80	from	diversity	404:412	arg1	attributes					440:449	attributes	440:449	attributes	440:449	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	3	80	from	diversity	404:412	arg1	signatures					425:434	genetic signatures	417:434	genetic signatures	417:434	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	11	81	theme	evolving	1713:1720	arg1	clusters					1722:1729	distinctly evolving clusters	1702:1729	distinctly evolving clusters within global intra-subtype C gp120 sequences	1702:1775	Our findings highlight that distinctly evolving clusters within global intra-subtype C gp120 sequences are likely to influence the disparate region-specific sensitivity of circulating HIV-1 subtype C to bnAbs.
34029329	10	82	theme	most	1627:1630	arg1	burden					1640:1645	most disease burden	1627:1645	most disease burden associated with subtype C	1627:1671	Highly significant differences (p<0.001***) were observed in prevalence of four pNLGS (N130, N295, N392 and N448) between South Africa and India, having most disease burden associated with subtype C.
34029329	0	83	theme	C	25:25	arg1	diversity					42:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	5	84	theme	loop	861:864	arg1	association					839:849	their phylogenetic association	820:849	their phylogenetic association	820:849	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	84	theme	loop	861:864	arg1	lengths					866:872	variable loop lengths	852:872	variable loop lengths	852:872	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	3	85	theme	gp120	502:506	arg1	sequences					508:516	region-specific HIV-1 subtype C gp120 sequences	470:516	region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities	470:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	0	86	theme	sequence	33:40	arg1	diversity					42:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity	0:50	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	9	87	theme	Pairwise	1381:1388	arg1	analyses					1390:1397	Pairwise analyses	1381:1397	Pairwise analyses at each of the 25 pNLG sites	1381:1426	Pairwise analyses at each of the 25 pNLG sites indicated distinct country specific profiles.
34029329	6	88	theme	CATNAP	1078:1083	arg1	database					1085:1092	the CATNAP database	1074:1092	the CATNAP database	1074:1092	Responses of these sequences to bnAbs were predicted with a machine learning algorithm 'bNAb-ReP' and compared with those reported in the CATNAP database.
34029329	3	89	contain	having	577:582	arg1	bnAbs					571:575	key bnAbs	567:575	key bnAbs having distinct epitope specificities	567:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	3	89	contain	having	577:582	arg2	specificities					601:613	distinct epitope specificities	584:613	distinct epitope specificities	584:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	0	90	theme	antibody	101:108	arg1	sensitivity					110:120	broadly neutralizing antibody sensitivity	80:120	broadly neutralizing antibody sensitivity	80:120	Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity.
34029329	3	91	theme	genetic	417:423	arg1	signatures					425:434	genetic signatures	417:434	genetic signatures	417:434	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	3	92	theme	virus	534:538	arg1	outcomes					555:562	virus neutralization outcomes	534:562	virus neutralization outcomes to key bnAbs having distinct epitope specificities	534:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	4	93	theme	subtype	650:656	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	3	94	theme	key	567:569	arg1	bnAbs					571:575	key bnAbs	567:575	key bnAbs having distinct epitope specificities	567:613	In the present study, we examined the diversity in genetic signatures and attributes that differentiate region-specific HIV-1 subtype C gp120 sequences associated with virus neutralization outcomes to key bnAbs having distinct epitope specificities.
34029329	4	95	theme	gp120	660:664	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	4	96	theme	C	658:658	arg1	sequence					666:673	1814 full length HIV-1 subtype C gp120 sequence	627:673	1814 full length HIV-1 subtype C gp120 sequence from 37 countries	627:691	A total of 1814 full length HIV-1 subtype C gp120 sequence from 37 countries were retrieved from Los Alamos National Laboratory HIV database (www.hiv.lanl.gov).
34029329	5	97	theme	variable	852:859	arg1	association					839:849	their phylogenetic association	820:849	their phylogenetic association	820:849	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34029329	5	97	theme	variable	852:859	arg1	lengths					866:872	variable loop lengths	852:872	variable loop lengths	852:872	The amino acid sequences were assessed for their phylogenetic association, variable loop lengths and prevalence of potential N-linked glycosylation sites (pNLGS).
34407556	7	0	theme	shorter	1365:1371	arg1	HL					1378:1379	25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL	1285:1379	25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL	1285:1379	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	10	1	theme	frequent	1859:1866	arg1	genotypes					1874:1882	frequent ASGR2 genotypes	1859:1882	frequent ASGR2 genotypes	1859:1882	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	1	2	from	variation	318:326	arg1	HA					384:385	HA	384:385	HA	384:385	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	1	2	from	variation	318:326	arg1	A					381:381	hemophilia A	370:381	hemophilia A (HA)	370:386	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	7	3	dep	13.5 hours	1382:1391	arg1	p = 0.016					1405:1413	p = 0.016	1405:1413	p = 0.016	1405:1413	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	4	4	theme	reverse	790:796	arg1	reaction					829:836	white blood cell reverse transcription-polymerase chain reaction	773:836	white blood cell reverse transcription-polymerase chain reaction	773:836	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	4	5	theme	PK	634:635	arg1	parameters					637:646	PK parameters	634:646	PK parameters	634:646	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	4	6	theme	chain	823:827	arg1	reaction					829:836	white blood cell reverse transcription-polymerase chain reaction	773:836	white blood cell reverse transcription-polymerase chain reaction	773:836	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	3	7	theme	HA	557:558	arg1	patients					560:567	Thirty-two HA patients	546:567	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.	538:632	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	7	8	dep	shorter	1289:1295	arg1	time					1312:1315	mean residence time	1297:1315	mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038)	1297:1355	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	9	9	theme	linear	1544:1549	arg1	models					1562:1567	different linear regression models	1534:1567	different linear regression models	1534:1567	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	7	10	theme	mean	1297:1300	arg1	time					1312:1315	mean residence time	1297:1315	mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038)	1297:1355	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	11	dep	3.60 hours	1179:1188	arg1	p = 0.006					1227:1235	p = 0.006	1227:1235	p = 0.006	1227:1235	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	11	dep	3.60 hours	1179:1188	arg1	1.44-5.76					1216:1224	1.44-5.76	1216:1224	1.44-5.76	1216:1224	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	11	dep	3.60 hours	1179:1188	arg1	%					1193:1193	95%	1191:1193	95% confidence interval	1191:1213	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	0	12	dep	affinity	195:202	arg1	FVIII					217:221	FVIII	217:221	FVIII	217:221	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	0	12	dep	affinity	195:202	arg1	VIII					211:214	factor VIII	204:214	high affinity factor VIII (FVIII)	190:222	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	0	13	theme	asialoglycoprotein	143:160	arg1	ASGPR					172:176	ASGPR	172:176	ASGPR	172:176	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	0	13	theme	asialoglycoprotein	143:160	arg1	receptor					162:169	The asialoglycoprotein receptor	139:169	The asialoglycoprotein receptor (ASGPR)	139:177	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	4	14	dep	recombinant	757:767	arg1	approaches					838:847	approaches	838:847	approaches	838:847	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	0	15	from	Pharmacokinetics	66:81	arg1	BACKGROUND					128:137	Hemophilia A. BACKGROUND	114:137	Hemophilia A. BACKGROUND	114:137	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	10	16	theme	antigen	1934:1940	arg1	levels					1942:1947	ABO and VWF antigen levels	1922:1947	levels	1942:1947	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	10	17	contain	has	1956:1958	arg2	implications					1970:1981	potential implications	1960:1981	potential implications for genetically tailored substitutive treatment in HA	1960:2035	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	10	17	contain	has	1956:1958	arg1	levels					1942:1947	ABO and VWF antigen levels	1922:1947	levels	1942:1947	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	4	18	theme	untranslated	687:698	arg1	region					700:705	ASGR2 5' untranslated region	678:705	ASGR2 5' untranslated region (5'UTR) polymorphisms	678:727	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	4	18	theme	untranslated	687:698	arg1	UTR					710:712	5'UTR	708:712	5'UTR	708:712	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	5	19	theme	frequent	894:901	arg1	haplotype					917:925	a frequent and conserved haplotype	892:925	a frequent and conserved haplotype (HT1) in a regulatory region	892:954	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	5	19	theme	frequent	894:901	arg1	HT1					928:930	HT1	928:930	HT1	928:930	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	9	20	theme	ASGR2	1594:1598	arg1	genotypes					1600:1608	the ASGR2 genotypes	1590:1608	the ASGR2 genotypes	1590:1608	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	10	21	from	treatment	2021:2029	arg1	HA					2034:2035	HA	2034:2035	HA	2034:2035	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	1	22	theme	FVIII	339:343	arg1	PK					363:364	PK	363:364	PK	363:364	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	1	22	theme	FVIII	339:343	arg1	pharmacokinetics					345:360	infused FVIII pharmacokinetics	331:360	infused FVIII pharmacokinetics (PK)	331:365	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	7	23	theme	c.-95TT	1116:1122	arg1	n = 9					1137:1141	n = 9	1137:1141	n = 9	1137:1141	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	23	theme	c.-95TT	1116:1122	arg1	homozygotes					1124:1134	the c.-95TT homozygotes	1112:1134	the c.-95TT homozygotes (n = 9)	1112:1142	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	3	24	dep	METHODS	538:544	arg1	patients					560:567	Thirty-two HA patients	546:567	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.	538:632	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	3	24	dep	METHODS	538:544	arg1	underwent					591:599	underwent	591:599	underwent 66 single-dose FVIII PK studies	591:631	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	6	25	theme	HT1	961:963	arg1	homozygotes					965:975	The HT1 homozygotes	957:975	The HT1 homozygotes	957:975	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	10	26	theme	CONCLUSION	1804:1813	arg1	distribution					1829:1840	CONCLUSION Infused FVIII distribution	1804:1840	CONCLUSION Infused FVIII distribution	1804:1840	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	0	27	theme	Factor	86:91	arg1	Concentrates					98:109	Factor VIII Concentrates	86:109	Factor VIII Concentrates	86:109	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	2	28	from	variability	429:439	arg1	outcomes					453:460	FVIII PK outcomes	444:460	FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit	444:535	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	0	29	theme	Concentrates	98:109	arg1	Pharmacokinetics					66:81	Pharmacokinetics	66:81	Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND	66:137	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	0	30	theme	Hemophilia	114:123	arg1	BACKGROUND					128:137	Hemophilia A. BACKGROUND	114:137	Hemophilia A. BACKGROUND	114:137	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	1	31	theme	hemophilia	370:379	arg1	HA					384:385	HA	384:385	HA	384:385	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	1	31	theme	hemophilia	370:379	arg1	A					381:381	hemophilia A	370:381	hemophilia A (HA)	370:386	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	6	32	theme	mRNA	1028:1031	arg1	transcripts					1033:1043	alternatively spliced mRNA transcripts	1006:1043	alternatively spliced mRNA transcripts	1006:1043	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	2	33	from	outcomes	453:460	arg1	relation					465:472	relation	465:472	relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit	465:535	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	9	34	theme	variability	1791:1801	arg1	%					1746:1746	15 to 18%	1738:1746	15 to 18% (Beta HL)	1738:1756	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	34	theme	variability	1791:1801	arg1	MRT					1732:1734	MRT	1732:1734	MRT	1732:1734	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	34	theme	variability	1791:1801	arg1	%					1765:1765	22%	1763:1765	22% (Alpha HL) of parameter variability	1763:1801	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	34	theme	variability	1791:1801	arg1	variability					1791:1801	parameter variability	1781:1801	parameter variability	1781:1801	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	34	theme	variability	1791:1801	arg1	HL					1754:1755	Beta HL	1749:1755	Beta HL	1749:1755	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	34	theme	variability	1791:1801	arg1	%					1729:1729	14%	1727:1729	14% (MRT)	1727:1735	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	34	theme	variability	1791:1801	arg1	HL					1774:1775	Alpha HL	1768:1775	Alpha HL	1768:1775	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	5	35	theme	conserved	907:915	arg1	haplotype					917:925	a frequent and conserved haplotype	892:925	a frequent and conserved haplotype (HT1) in a regulatory region	892:954	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	5	35	theme	conserved	907:915	arg1	HT1					928:930	HT1	928:930	HT1	928:930	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	9	36	theme	von	1669:1671	arg1	VWF					1692:1694	VWF	1692:1694	VWF	1692:1694	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	36	theme	von	1669:1671	arg1	factor					1684:1689	von Willebrand factor	1669:1689	von Willebrand factor (VWF) antigen levels	1669:1710	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	10	37	theme	substitutive	2008:2019	arg1	treatment					2021:2029	genetically tailored substitutive treatment	1987:2029	genetically tailored substitutive treatment in HA	1987:2035	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	0	38	theme	Receptor	23:30	arg1	Gene					46:49	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	9	39	theme	factor	1684:1689	arg1	levels					1705:1710	von Willebrand factor (VWF) antigen levels	1669:1710	von Willebrand factor (VWF) antigen levels	1669:1710	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	0	40	theme	Subunit	38:44	arg1	Gene					46:49	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	1	41	theme	inter-individual	301:316	arg1	variation					318:326	the wide inter-individual variation	292:326	the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA)	292:386	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	0	42	gly	Asialoglycoprotein	4:21	arg1	Asialoglycoprotein					4:21	The Asialoglycoprotein Receptor	0:30	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	2	43	theme	PK	450:451	arg1	outcomes					453:460	FVIII PK outcomes	444:460	FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit	444:535	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	3	44	theme	FVIII	616:620	arg1	studies					625:631	66 single-dose FVIII PK studies	601:631	66 single-dose FVIII PK studies	601:631	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	4	45	theme	blood	779:783	arg1	cell					785:788	white blood cell	773:788	white blood cell reverse transcription-polymerase chain reaction	773:836	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	7	46	theme	ASGR2	1095:1099	arg1	genotypes					1101:1109	the other ASGR2 genotypes	1085:1109	the other ASGR2 genotypes	1085:1109	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	9	47	theme	antigen	1697:1703	arg1	levels					1705:1710	von Willebrand factor (VWF) antigen levels	1669:1710	von Willebrand factor (VWF) antigen levels	1669:1710	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	7	48	theme	Beta	1373:1376	arg1	HL					1378:1379	25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL	1285:1379	25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL	1285:1379	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	10	49	theme	FVIII	1823:1827	arg1	distribution					1829:1840	CONCLUSION Infused FVIII distribution	1804:1840	CONCLUSION Infused FVIII distribution	1804:1840	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	8	50	theme	full-length	1507:1517	arg1	FVIII					1519:1523	full-length FVIII	1507:1523	full-length FVIII only	1507:1528	These differences were confirmed in patients (n = 27) undergoing PK studies (n = 54) with full-length FVIII only.
34407556	6	51	theme	ASGPR2	1054:1059	arg1	isoforms					1061:1068	ASGPR2 isoforms	1054:1068	ASGPR2 isoforms	1054:1068	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	10	52	theme	ASGR2	1868:1872	arg1	genotypes					1874:1882	frequent ASGR2 genotypes	1859:1882	frequent ASGR2 genotypes	1859:1882	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	0	53	theme	high	190:193	arg1	affinity					195:202	high affinity factor VIII (FVIII)	190:222	high affinity factor VIII (FVIII)	190:222	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	8	54	theme	PK	1482:1483	arg1	studies					1485:1491	PK studies	1482:1491	PK studies	1482:1491	These differences were confirmed in patients (n = 27) undergoing PK studies (n = 54) with full-length FVIII only.
34407556	0	55	theme	factor	204:209	arg1	FVIII					217:221	FVIII	217:221	FVIII	217:221	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	0	55	theme	factor	204:209	arg1	VIII					211:214	factor VIII	204:214	high affinity factor VIII (FVIII)	190:222	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	7	56	dep	showed	1278:1283	arg1	13.5 hours					1382:1391	13.5 hours	1382:1391	13.5 hours	1382:1391	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	57	theme	15.0-22.0	1335:1343	arg1	p = 0.038					1346:1354	p = 0.038	1346:1354	p = 0.038	1346:1354	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	57	theme	15.0-22.0	1335:1343	arg1	MRT					1318:1320	MRT	1318:1320	MRT	1318:1320	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	4	58	theme	cell	785:788	arg1	reaction					829:836	white blood cell reverse transcription-polymerase chain reaction	773:836	white blood cell reverse transcription-polymerase chain reaction	773:836	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	7	59	theme	longer	1162:1167	arg1	HL					1175:1176	threefold longer Alpha HL	1152:1176	threefold longer Alpha HL	1152:1176	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	3	60	theme	Thirty-two	546:555	arg1	patients					560:567	Thirty-two HA patients	546:567	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.	538:632	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	0	61	link	N-linked	236:243	arg1	oligosaccharides					245:260	its N-linked oligosaccharides	232:260	its N-linked oligosaccharides	232:260	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	4	62	theme	transcription-polymerase	798:821	arg1	reaction					829:836	white blood cell reverse transcription-polymerase chain reaction	773:836	white blood cell reverse transcription-polymerase chain reaction	773:836	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	10	63	theme	ABO	1922:1924	arg1	levels					1942:1947	ABO and VWF antigen levels	1922:1947	levels	1942:1947	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	10	64	theme	tailored	1999:2006	arg1	treatment					2021:2029	genetically tailored substitutive treatment	1987:2029	genetically tailored substitutive treatment in HA	1987:2035	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	2	65	theme	ASGPR2	522:527	arg1	subunit					529:535	the ASGPR2 subunit	518:535	the ASGPR2 subunit	518:535	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	7	66	theme	residence	1302:1310	arg1	time					1312:1315	mean residence time	1297:1315	mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038)	1297:1355	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	9	67	theme	different	1534:1542	arg1	models					1562:1567	different linear regression models	1534:1567	different linear regression models	1534:1567	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	68	theme	genotypes	1600:1608	arg1	contribution					1574:1585	the contribution	1570:1585	the contribution of the ASGR2 genotypes	1570:1608	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	2	69	from	variation	485:493	arg1	ASGR2					502:506	the ASGR2	498:506	the ASGR2	498:506	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	7	70	theme	shorter	1289:1295	arg1	HL					1378:1379	25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL	1285:1379	25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL	1285:1379	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	9	71	theme	Beta	1749:1752	arg1	variability					1791:1801	parameter variability	1781:1801	parameter variability	1781:1801	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	71	theme	Beta	1749:1752	arg1	%					1746:1746	15 to 18%	1738:1746	15 to 18% (Beta HL)	1738:1756	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	71	theme	Beta	1749:1752	arg1	HL					1754:1755	Beta HL	1749:1755	Beta HL	1749:1755	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	7	72	dep	MRT	1318:1320	arg1	18.5 hours					1323:1332	18.5 hours	1323:1332	18.5 hours	1323:1332	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	10	73	theme	VWF	1930:1932	arg1	levels					1942:1947	ABO and VWF antigen levels	1922:1947	levels	1942:1947	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	4	74	theme	ASGR2	678:682	arg1	region					700:705	ASGR2 5' untranslated region	678:705	ASGR2 5' untranslated region (5'UTR) polymorphisms	678:727	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	4	74	theme	ASGR2	678:682	arg1	UTR					710:712	5'UTR	708:712	5'UTR	708:712	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	8	75	with	patients	1453:1460	arg1	FVIII					1519:1523	full-length FVIII	1507:1523	full-length FVIII only	1507:1528	These differences were confirmed in patients (n = 27) undergoing PK studies (n = 54) with full-length FVIII only.
34407556	0	76	gly	asialoglycoprotein	143:160	arg1	asialoglycoprotein					143:160	The asialoglycoprotein receptor	139:169	The asialoglycoprotein receptor (ASGPR)	139:177	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	10	77	theme	potential	1960:1968	arg1	implications					1970:1981	potential implications	1960:1981	potential implications for genetically tailored substitutive treatment in HA	1960:2035	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	7	78	theme	Alpha	1169:1173	arg1	HL					1175:1176	threefold longer Alpha HL	1152:1176	threefold longer Alpha HL	1152:1176	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	3	79	theme	C	580:580	arg1	≤2 IU/dL					582:589	C ≤2 IU/dL	580:589	C ≤2 IU/dL	580:589	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	2	80	theme	genetic	477:483	arg1	variation					485:493	genetic variation	477:493	genetic variation in the ASGR2, encoding the ASGPR2 subunit	477:535	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	0	81	theme	VIII	93:96	arg1	Concentrates					98:109	Factor VIII Concentrates	86:109	Factor VIII Concentrates	86:109	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	1	82	theme	pharmacokinetics	345:360	arg1	variation					318:326	the wide inter-individual variation	292:326	the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA)	292:386	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	9	83	dep	18	1744:1745	arg1	to					1741:1742	to	1741:1742	to	1741:1742	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	7	84	dep	time	1312:1315	arg1	p = 0.038					1346:1354	p = 0.038	1346:1354	p = 0.038	1346:1354	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	84	dep	time	1312:1315	arg1	MRT					1318:1320	MRT	1318:1320	MRT	1318:1320	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	9	85	theme	regression	1551:1560	arg1	models					1562:1567	different linear regression models	1534:1567	different linear regression models	1534:1567	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	86	theme	Alpha	1768:1772	arg1	variability					1791:1801	parameter variability	1781:1801	parameter variability	1781:1801	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	86	theme	Alpha	1768:1772	arg1	%					1765:1765	22%	1763:1765	22% (Alpha HL) of parameter variability	1763:1801	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	86	theme	Alpha	1768:1772	arg1	HL					1774:1775	Alpha HL	1768:1775	Alpha HL	1768:1775	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	3	87	with	patients	560:567	arg1	FVIII					574:578	FVIII	574:578	FVIII	574:578	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	0	88	theme	A.	125:126	arg1	BACKGROUND					128:137	Hemophilia A. BACKGROUND	114:137	Hemophilia A. BACKGROUND	114:137	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	0	89	theme	N-linked	236:243	arg1	oligosaccharides					245:260	its N-linked oligosaccharides	232:260	its N-linked oligosaccharides	232:260	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	6	90	theme	transcripts	1033:1043	arg1	amounts					995:1001	the amounts	991:1001	the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms	991:1068	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	6	90	theme	transcripts	1033:1043	arg1	isoforms					1061:1068	ASGPR2 isoforms	1054:1068	ASGPR2 isoforms	1054:1068	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	6	90	theme	transcripts	1033:1043	arg1	transcripts					1033:1043	alternatively spliced mRNA transcripts	1006:1043	alternatively spliced mRNA transcripts	1006:1043	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	9	91	theme	ABO	1651:1653	arg1	genotypes					1655:1663	ABO genotypes	1651:1663	ABO genotypes	1651:1663	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	92	theme	parameter	1781:1789	arg1	variability					1791:1801	parameter variability	1781:1801	parameter variability	1781:1801	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	0	93	theme	Asialoglycoprotein	4:21	arg1	Receptor					23:30	The Asialoglycoprotein Receptor	0:30	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	6	94	theme	spliced	1020:1026	arg1	transcripts					1033:1043	alternatively spliced mRNA transcripts	1006:1043	alternatively spliced mRNA transcripts	1006:1043	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	4	95	theme	region	700:705	arg1	polymorphisms					715:727	ASGR2 5' untranslated region (5'UTR) polymorphisms	678:727	ASGR2 5' untranslated region (5'UTR) polymorphisms	678:727	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	0	96	theme	Minor	32:36	arg1	Gene					46:49	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene	0:49	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. BACKGROUND The asialoglycoprotein receptor (ASGPR) binds with high affinity factor VIII (FVIII) through its N-linked oligosaccharides.
34407556	9	97	theme	Willebrand	1673:1682	arg1	VWF					1692:1694	VWF	1692:1694	VWF	1692:1694	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	9	97	theme	Willebrand	1673:1682	arg1	factor					1684:1689	von Willebrand factor	1669:1689	von Willebrand factor (VWF) antigen levels	1669:1710	In different linear regression models, the contribution of the ASGR2 genotypes remained significant after adjustment by ABO genotypes and von Willebrand factor (VWF) antigen levels, and explained 14% (MRT), 15 to 18% (Beta HL), and 22% (Alpha HL) of parameter variability.
34407556	3	98	theme	PK	622:623	arg1	studies					625:631	66 single-dose FVIII PK studies	601:631	66 single-dose FVIII PK studies	601:631	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	1	99	theme	wide	296:299	arg1	variation					318:326	the wide inter-individual variation	292:326	the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA)	292:386	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	10	100	theme	Infused	1815:1821	arg1	distribution					1829:1840	CONCLUSION Infused FVIII distribution	1804:1840	CONCLUSION Infused FVIII distribution	1804:1840	CONCLUSION Infused FVIII distribution was modulated by frequent ASGR2 genotypes, independently from and together with ABO and VWF antigen levels, which has potential implications for genetically tailored substitutive treatment in HA.
34407556	3	101	theme	single-dose	604:614	arg1	studies					625:631	66 single-dose FVIII PK studies	601:631	66 single-dose FVIII PK studies	601:631	METHODS Thirty-two HA patients with FVIII:C ≤2 IU/dL underwent 66 single-dose FVIII PK studies.
34407556	5	102	dep	RESULTS	850:856	arg1	UTR					864:866	The 5'UTR	858:866	RESULTS The 5'UTR polymorphisms	850:880	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	5	102	dep	RESULTS	850:856	arg1	polymorphisms					868:880	polymorphisms	868:880	RESULTS The 5'UTR polymorphisms	850:880	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	7	103	theme	other	1089:1093	arg1	genotypes					1101:1109	the other ASGR2 genotypes	1085:1109	the other ASGR2 genotypes	1085:1109	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	104	theme	interval	1206:1213	arg1	%					1193:1193	95%	1191:1193	95% confidence interval	1191:1213	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	2	105	theme	FVIII	444:448	arg1	outcomes					453:460	FVIII PK outcomes	444:460	FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit	444:535	OBJECTIVE To investigate the variability in FVIII PK outcomes in relation to genetic variation in the ASGR2, encoding the ASGPR2 subunit.
34407556	4	106	theme	white	773:777	arg1	cell					785:788	white blood cell	773:788	white blood cell reverse transcription-polymerase chain reaction	773:836	PK parameters were evaluated in relation to ASGR2 5' untranslated region (5'UTR) polymorphisms, which were investigated by recombinant and white blood cell reverse transcription-polymerase chain reaction approaches.
34407556	5	107	from	haplotype	917:925	arg1	region					949:954	a regulatory region	936:954	a regulatory region	936:954	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	1	108	theme	infused	331:337	arg1	PK					363:364	PK	363:364	PK	363:364	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	1	108	theme	infused	331:337	arg1	pharmacokinetics					345:360	infused FVIII pharmacokinetics	331:360	infused FVIII pharmacokinetics (PK)	331:365	However, its contribution to the wide inter-individual variation of infused FVIII pharmacokinetics (PK) in hemophilia A (HA) is unknown.
34407556	5	109	theme	regulatory	938:947	arg1	region					949:954	a regulatory region	936:954	a regulatory region	936:954	RESULTS The 5'UTR polymorphisms determine a frequent and conserved haplotype (HT1) in a regulatory region.
34407556	7	110	dep	showed	1145:1150	arg1	3.60 hours					1179:1188	3.60 hours	1179:1188	3.60 hours	1179:1188	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	6	111	theme	isoforms	1061:1068	arg1	amounts					995:1001	the amounts	991:1001	the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms	991:1068	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	6	111	theme	isoforms	1061:1068	arg1	isoforms					1061:1068	ASGPR2 isoforms	1054:1068	ASGPR2 isoforms	1054:1068	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	6	111	theme	isoforms	1061:1068	arg1	transcripts					1033:1043	alternatively spliced mRNA transcripts	1006:1043	alternatively spliced mRNA transcripts	1006:1043	The HT1 homozygotes may differ in the amounts of alternatively spliced mRNA transcripts and thus ASGPR2 isoforms.
34407556	7	112	theme	c.-95TC	1247:1253	arg1	n = 17					1270:1275	n = 17	1270:1275	n = 17	1270:1275	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
34407556	7	112	theme	c.-95TC	1247:1253	arg1	heterozygotes					1255:1267	the c.-95TC heterozygotes	1243:1267	the c.-95TC heterozygotes (n = 17)	1243:1276	Compared with the other ASGR2 genotypes, the c.-95TT homozygotes (n = 9), showed threefold longer Alpha HL (3.60 hours, 95% confidence interval: 1.44-5.76, p = 0.006), and the c.-95TC heterozygotes (n = 17) showed 25% shorter mean residence time (MRT; 18.5 hours, 15.0-22.0, p = 0.038) and 32% shorter Beta HL (13.5 hours, 10.9-16.0, p = 0.016).
31986066	4	0	theme	residues	928:935	arg1	importance					895:904	the importance	891:904	the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R	891:983	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	8	1	theme	vitamin	1511:1517	arg1	D3					1519:1520	active vitamin D3	1504:1520	active vitamin D3	1504:1520	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	8	2	theme	key	1563:1565	arg1	factor					1567:1572	a major key factor	1555:1572	a major key factor for osteoclastogenesis	1555:1595	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	8	2	theme	key	1563:1565	arg1	RANKL					1548:1552	RANKL	1548:1552	RANKL	1548:1552	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	10	3	theme	genetic	2149:2155	arg1	disorders					2157:2165	genetic disorders	2149:2165	genetic disorders	2149:2165	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	10	3	theme	genetic	2149:2155	arg1	PFE					2178:2180	PFE	2178:2180	PFE	2178:2180	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	7	4	link	iPSC-derived	1430:1441	arg1	cells					1443:1447	control iPSC-derived cells	1422:1447	control iPSC-derived cells	1422:1447	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	7	5	theme	BGLAP	1299:1303	arg1	expression					1269:1278	The mRNA expression	1260:1278	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R	1260:1370	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	9	6	theme	P132L	1777:1781	arg1	PTH1R					1791:1795	P132L variant PTH1R	1777:1795	P132L variant PTH1R	1777:1795	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	7	7	theme	genes	1347:1351	arg1	expression					1269:1278	The mRNA expression	1260:1278	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R	1260:1370	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	10	8	theme	PFE-associated	1975:1988	arg1	alteration					1998:2007	PFE-associated genetic alteration	1975:2007	PFE-associated genetic alteration	1975:2007	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	4	9	theme	impaired	799:806	arg1	accumulation					813:824	severely impaired cAMP accumulation	790:824	severely impaired cAMP accumulation	790:824	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	5	10	from	mutation	1146:1153	arg1	lines					1089:1093	the induced pluripotent stem cell (iPSC) lines	1048:1093	the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation	1048:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	10	11	theme	causative	2013:2021	arg1	impairment					2034:2043	causative functional impairment	2013:2043	causative functional impairment	2013:2043	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	3	12	contain	had	551:553	arg1	variants					524:531	Two particular variants	509:531	Two particular variants	509:531	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	3	12	contain	had	551:553	arg2	reduction					562:570	severe reduction	555:570	severe reduction in a level of N-linked glycosylation	555:607	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	3	12	contain	had	551:553	arg1	P132L					544:548	P132L	544:548	P132L	544:548	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	3	12	contain	had	551:553	arg1	P119L					534:538	P119L	534:538	P119L	534:538	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	1	13	theme	primary	182:188	arg1	failure					190:196	primary failure	182:196	primary failure of eruption (PFE)	182:214	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	2	14	theme	vector-mediated	471:485	arg1	modification					495:506	a lentiviral vector-mediated genetic modification	458:506	a lentiviral vector-mediated genetic modification	458:506	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
31986066	7	15	theme	mRNA	1264:1267	arg1	expression					1269:1278	The mRNA expression	1260:1278	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R	1260:1370	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	1	16	theme	parathyroid	106:116	arg1	PTH1R					138:142	PTH1R	138:142	PTH1R	138:142	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	1	16	theme	parathyroid	106:116	arg1	receptor					128:135	parathyroid hormone 1 receptor	106:135	the parathyroid hormone 1 receptor (PTH1R) gene	102:148	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	10	17	theme	PTH1R	2048:2052	arg1	alteration					1998:2007	PFE-associated genetic alteration	1975:2007	PFE-associated genetic alteration	1975:2007	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	10	17	theme	PTH1R	2048:2052	arg1	impairment					2034:2043	causative functional impairment	2013:2043	causative functional impairment	2013:2043	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	5	18	from	patient	1102:1108	arg1	lines					1089:1093	the induced pluripotent stem cell (iPSC) lines	1048:1093	the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation	1048:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	7	19	theme	protein	1487:1493	arg1	presence					1456:1463	the presence	1452:1463	the presence of bone morphogenetic protein 2	1452:1495	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	9	20	theme	heterozygous	1838:1849	arg1	mutation					1862:1869	heterozygous PTH1R gene mutation	1838:1869	heterozygous PTH1R gene mutation	1838:1869	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	10	21	from	elucidation	2118:2128	arg1	disorders					2157:2165	genetic disorders	2149:2165	genetic disorders	2149:2165	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	10	21	from	elucidation	2118:2128	arg1	PFE					2178:2180	PFE	2178:2180	PFE	2178:2180	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	7	22	theme	bone	1468:1471	arg1	protein					1487:1493	bone morphogenetic protein 2	1468:1495	bone morphogenetic protein 2	1468:1495	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	9	23	theme	gene	1857:1860	arg1	mutation					1862:1869	heterozygous PTH1R gene mutation	1838:1869	heterozygous PTH1R gene mutation	1838:1869	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	0	24	theme	Eruption	66:73	arg1	Failure					55:61	Primary Failure	47:61	Primary Failure of Eruption	47:73	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption.
31986066	10	25	theme	modeling	2098:2105	arg1	utility					2068:2074	a utility	2066:2074	a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE	2066:2180	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	10	25	theme	modeling	2098:2105	arg1	link					1962:1965	a link	1960:1965	a link between PFE-associated genetic alteration and causative functional impairment of PTH1R	1960:2052	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	5	26	theme	P132L	1140:1144	arg1	mutation					1146:1153	the heterozygous P132L mutation	1123:1153	the heterozygous P132L mutation	1123:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	9	27	theme	PTH-dependent	1883:1895	arg1	response					1897:1904	PTH-dependent response	1883:1904	PTH-dependent response in osteoblasts	1883:1919	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	4	28	from	decrease	733:740	arg1	affinity					749:756	the affinity	745:756	the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R	745:983	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	0	29	theme	Functional	0:9	arg1	Analysis					11:18	Functional Analysis	0:18	Functional Analysis of PTH1R Variants	0:36	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption.
31986066	5	30	theme	pluripotent	1060:1070	arg1	iPSC					1083:1086	iPSC	1083:1086	iPSC	1083:1086	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	5	30	theme	pluripotent	1060:1070	arg1	cell					1077:1080	pluripotent stem cell	1060:1080	the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation	1048:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	1	31	theme	many	85:88	arg1	variants					90:97	many variants	85:97	many variants of the parathyroid hormone 1 receptor (PTH1R) gene	85:148	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	4	32	theme	PTH1R	979:983	arg1	proper					957:962	proper	957:962	proper	957:962	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	4	33	theme	acid	923:926	arg1	residues					928:935	these 2 amino acid residues	909:935	these 2 amino acid residues	909:935	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	10	34	theme	future	2111:2116	arg1	elucidation					2118:2128	future elucidation	2111:2128	future elucidation of pathogenesis in genetic disorders, including PFE	2111:2180	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	5	35	theme	cell	1077:1080	arg1	lines					1089:1093	the induced pluripotent stem cell (iPSC) lines	1048:1093	the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation	1048:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	7	36	theme	control	1422:1428	arg1	cells					1443:1447	control iPSC-derived cells	1422:1447	control iPSC-derived cells	1422:1447	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	0	37	theme	Variants	29:36	arg1	Analysis					11:18	Functional Analysis	0:18	Functional Analysis of PTH1R Variants	0:36	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption.
31986066	9	38	with	consistent	1798:1807	arg1	idea					1818:1821	the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts	1814:1919	the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts	1814:1919	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	2	39	theme	functional	297:306	arg1	analyses					308:315	functional analyses	297:315	functional analyses of PTH1R variants reported in PFE	297:349	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
31986066	9	40	theme	RANKL	1731:1735	arg1	expression					1742:1751	RANKL mRNA expression	1731:1751	RANKL mRNA expression	1731:1751	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	10	41	theme	genetic	1990:1996	arg1	alteration					1998:2007	PFE-associated genetic alteration	1975:2007	PFE-associated genetic alteration	1975:2007	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	2	42	theme	variants	326:333	arg1	analyses					308:315	functional analyses	297:315	functional analyses of PTH1R variants reported in PFE	297:349	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
31986066	1	43	theme	eruption	201:208	arg1	failure					190:196	primary failure	182:196	primary failure of eruption (PFE)	182:214	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	9	44	theme	expression	1742:1751	arg1	induction					1718:1726	no induction	1715:1726	no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R	1715:1795	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	3	45	theme	glycosylation	595:607	arg1	level					577:581	a level	575:581	a level of N-linked glycosylation	575:607	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	5	46	with	patient	1102:1108	arg1	PFE					1115:1117	PFE	1115:1117	PFE	1115:1117	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	7	47	theme	that	1358:1361	arg1	expression					1269:1278	The mRNA expression	1260:1278	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R	1260:1370	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	8	48	theme	active	1504:1509	arg1	D3					1519:1520	active vitamin D3	1504:1520	active vitamin D3	1504:1520	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	8	49	theme	major	1557:1561	arg1	factor					1567:1572	a major key factor	1555:1572	a major key factor for osteoclastogenesis	1555:1595	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	8	49	theme	major	1557:1561	arg1	RANKL					1548:1552	RANKL	1548:1552	RANKL	1548:1552	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	4	50	from	stimulation	831:841	arg1	cells					846:850	cells	846:850	cells expressing these mutants	846:875	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	2	51	theme	genetic	487:493	arg1	modification					495:506	a lentiviral vector-mediated genetic modification	458:506	a lentiviral vector-mediated genetic modification	458:506	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
31986066	7	52	theme	osteoblastic	1310:1321	arg1	genes					1347:1351	the osteoblastic differentiation-related genes	1306:1351	the osteoblastic differentiation-related genes	1306:1351	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	3	53	theme	wild-type	628:636	arg1	PTH1R					638:642	wild-type PTH1R	628:642	wild-type PTH1R	628:642	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	1	54	theme	gene	145:148	arg1	variants					90:97	many variants	85:97	many variants of the parathyroid hormone 1 receptor (PTH1R) gene	85:148	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	7	55	theme	differentiation-related	1323:1345	arg1	genes					1347:1351	the osteoblastic differentiation-related genes	1306:1351	the osteoblastic differentiation-related genes	1306:1351	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	4	56	theme	marked	726:731	arg1	decrease					733:740	marked decrease	726:740	marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R	726:983	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	9	57	theme	variant	1783:1789	arg1	PTH1R					1791:1795	P132L variant PTH1R	1777:1795	P132L variant PTH1R	1777:1795	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	2	58	theme	HeLa	442:445	arg1	cells					447:451	HeLa cells	442:451	HeLa cells	442:451	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
31986066	7	59	theme	SP7	1290:1292	arg1	expression					1269:1278	The mRNA expression	1260:1278	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R	1260:1370	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	3	60	link	N-linked	586:593	arg1	glycosylation					595:607	N-linked glycosylation	586:607	N-linked glycosylation	586:607	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	8	61	theme	osteoblastic	1609:1620	arg1	cells					1622:1626	osteoblastic cells	1609:1626	osteoblastic cells derived from control and PFE-iPSCs	1609:1661	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	4	62	theme	cAMP	808:811	arg1	accumulation					813:824	severely impaired cAMP accumulation	790:824	severely impaired cAMP accumulation	790:824	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	7	63	theme	RUNX2	1283:1287	arg1	expression					1269:1278	The mRNA expression	1260:1278	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R	1260:1370	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	3	64	theme	modest	672:677	arg1	alteration					679:688	modest alteration	672:688	modest alteration	672:688	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	2	65	theme	lentiviral	460:469	arg1	modification					495:506	a lentiviral vector-mediated genetic modification	458:506	a lentiviral vector-mediated genetic modification	458:506	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
31986066	6	66	theme	osteoblastic-lineage	1181:1200	arg1	cells					1202:1206	osteoblastic-lineage cells	1181:1206	osteoblastic-lineage cells	1181:1206	When differentiated into osteoblastic-lineage cells, PFE-iPSCs showed no abnormality in mineralization.
31986066	1	67	theme	hormone	118:124	arg1	PTH1R					138:142	PTH1R	138:142	PTH1R	138:142	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	1	67	theme	hormone	118:124	arg1	receptor					128:135	parathyroid hormone 1 receptor	106:135	the parathyroid hormone 1 receptor (PTH1R) gene	102:148	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	9	68	from	induction	1718:1726	arg1	cells					1760:1764	the cells	1756:1764	the cells expressing P132L variant PTH1R	1756:1795	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	7	69	theme	morphogenetic	1473:1485	arg1	protein					1487:1493	bone morphogenetic protein 2	1468:1495	bone morphogenetic protein 2	1468:1495	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	4	70	contain	having	697:702	arg1	PTH1R					691:695	PTH1R	691:695	PTH1R having P119L or P132L	691:717	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	4	70	contain	having	697:702	arg2	P132L					713:717	P132L	713:717	P132L	713:717	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	4	70	contain	having	697:702	arg2	P119L					704:708	P119L	704:708	P119L	704:708	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	3	71	theme	particular	513:522	arg1	variants					524:531	Two particular variants	509:531	Two particular variants	509:531	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	3	71	theme	particular	513:522	arg1	P132L					544:548	P132L	544:548	P132L	544:548	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	3	71	theme	particular	513:522	arg1	P119L					534:538	P119L	534:538	P119L	534:538	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	1	72	theme	receptor	128:135	arg1	gene					145:148	the parathyroid hormone 1 receptor (PTH1R) gene	102:148	the parathyroid hormone 1 receptor (PTH1R) gene	102:148	Although many variants of the parathyroid hormone 1 receptor (PTH1R) gene are known to be associated with primary failure of eruption (PFE), the mechanisms underlying the link remains poorly understood.
31986066	9	73	theme	PTH1R	1851:1855	arg1	mutation					1862:1869	heterozygous PTH1R gene mutation	1838:1869	heterozygous PTH1R gene mutation	1838:1869	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	5	74	theme	PTH1R	1016:1020	arg1	functions					1022:1030	PTH1R functions	1016:1030	PTH1R functions	1016:1030	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	9	75	theme	mutation	1862:1869	arg1	type					1830:1833	a type	1828:1833	a type of heterozygous PTH1R gene mutation	1828:1869	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	5	76	theme	heterozygous	1127:1138	arg1	mutation					1146:1153	the heterozygous P132L mutation	1123:1153	the heterozygous P132L mutation	1123:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	10	77	theme	disease	2090:2096	arg1	modeling					2098:2105	iPSC-based disease modeling	2079:2105	iPSC-based disease modeling	2079:2105	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	10	78	theme	functional	2023:2032	arg1	impairment					2034:2043	causative functional impairment	2013:2043	causative functional impairment	2013:2043	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	9	79	theme	sharp	1667:1671	arg1	contrast					1673:1680	sharp contrast	1667:1680	sharp contrast	1667:1680	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	10	80	theme	pathogenesis	2133:2144	arg1	elucidation					2118:2128	future elucidation	2111:2128	future elucidation of pathogenesis in genetic disorders, including PFE	2111:2180	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	8	81	attach	derived	1628:1634	arg2	cells					1622:1626	osteoblastic cells	1609:1626	osteoblastic cells derived from control and PFE-iPSCs	1609:1661	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	8	81	attach	derived	1628:1634	arg1	control					1641:1647	control	1641:1647	control	1641:1647	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	8	81	attach	derived	1628:1634	arg1	PFE-iPSCs					1653:1661	PFE-iPSCs	1653:1661	PFE-iPSCs	1653:1661	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	0	82	theme	PTH1R	23:27	arg1	Variants					29:36	PTH1R Variants	23:36	PTH1R Variants	23:36	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption.
31986066	5	83	theme	stem	1072:1075	arg1	iPSC					1083:1086	iPSC	1083:1086	iPSC	1083:1086	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	5	83	theme	stem	1072:1075	arg1	cell					1077:1080	pluripotent stem cell	1060:1080	the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation	1048:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	10	84	theme	iPSC-based	2079:2088	arg1	modeling					2098:2105	iPSC-based disease modeling	2079:2105	iPSC-based disease modeling	2079:2105	Collectively, this study demonstrates a link between PFE-associated genetic alteration and causative functional impairment of PTH1R, as well as a utility of iPSC-based disease modeling for future elucidation of pathogenesis in genetic disorders, including PFE.
31986066	4	85	theme	amino	917:921	arg1	residues					928:935	these 2 amino acid residues	909:935	these 2 amino acid residues	909:935	PTH1R having P119L or P132L showed marked decrease in the affinity to PTH1-34, which likely led to severely impaired cAMP accumulation upon stimulation in cells expressing these mutants, highlighting the importance of these 2 amino acid residues for ligand-mediated proper functioning of PTH1R.
31986066	7	86	theme	iPSC-derived	1430:1441	arg1	cells					1443:1447	control iPSC-derived cells	1422:1447	control iPSC-derived cells	1422:1447	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	9	87	theme	mRNA	1737:1740	arg1	expression					1742:1751	RANKL mRNA expression	1731:1751	RANKL mRNA expression	1731:1751	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	0	88	theme	Primary	47:53	arg1	Failure					55:61	Primary Failure	47:61	Primary Failure of Eruption	47:73	Functional Analysis of PTH1R Variants Found in Primary Failure of Eruption.
31986066	5	89	with	mutation	1146:1153	arg1	PFE					1115:1117	PFE	1115:1117	PFE	1115:1117	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	5	90	theme	induced	1052:1058	arg1	lines					1089:1093	the induced pluripotent stem cell (iPSC) lines	1048:1093	the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation	1048:1153	To further gain insights into PTH1R functions, we established the induced pluripotent stem cell (iPSC) lines from a patient with PFE and the heterozygous P132L mutation.
31986066	7	91	theme	PFE-iPSC-derived	1395:1410	arg1	cells					1412:1416	PFE-iPSC-derived cells	1395:1416	PFE-iPSC-derived cells	1395:1416	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	9	92	from	response	1897:1904	arg1	osteoblasts					1909:1919	osteoblasts	1909:1919	osteoblasts	1909:1919	In sharp contrast, exposure to PTH1-34 resulted in no induction of RANKL mRNA expression in the cells expressing P132L variant PTH1R, consistent with the idea that a type of heterozygous PTH1R gene mutation would spoil PTH-dependent response in osteoblasts.
31986066	3	93	theme	severe	555:560	arg1	reduction					562:570	severe reduction	555:570	severe reduction in a level of N-linked glycosylation	555:607	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	8	94	theme	RANKL	1548:1552	arg1	expression					1534:1543	the expression	1530:1543	the expression of RANKL, a major key factor for osteoclastogenesis,	1530:1596	Also, active vitamin D3 induced the expression of RANKL, a major key factor for osteoclastogenesis, equally in osteoblastic cells derived from control and PFE-iPSCs.
31986066	7	95	link	PFE-iPSC-derived	1395:1410	arg1	cells					1412:1416	PFE-iPSC-derived cells	1395:1416	PFE-iPSC-derived cells	1395:1416	The mRNA expression of RUNX2, SP7, and BGLAP, the osteoblastic differentiation-related genes, and that of PTH1R were augmented in both PFE-iPSC-derived cells and control iPSC-derived cells in the presence of bone morphogenetic protein 2.
31986066	3	96	from	reduction	562:570	arg1	level					577:581	a level	575:581	a level of N-linked glycosylation	575:607	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	3	97	theme	N-linked	586:593	arg1	glycosylation					595:607	N-linked glycosylation	586:607	N-linked glycosylation	586:607	Two particular variants, P119L and P132L, had severe reduction in a level of N-linked glycosylation when compared with wild-type PTH1R, whereas the other 2 showed modest alteration.
31986066	2	98	theme	PTH1R	320:324	arg1	variants					326:333	PTH1R variants	320:333	PTH1R variants reported in PFE	320:349	We here performed functional analyses of PTH1R variants reported in PFE patients-namely, 356C>T (P119L), 395C>T (P132L), 439C>T (R147C), and 1148G>A (R383Q)-using HeLa cells with a lentiviral vector-mediated genetic modification.
34452239	3	0	theme	greater	887:893	arg1	levels					895:900	greater levels	887:900	greater levels of brain penetration	887:921	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	4	1	theme	Ang	955:957	arg1	peptide					965:971	the native Ang (1-7) peptide	944:971	the native Ang (1-7) peptide	944:971	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	9	2	theme	residual	1971:1978	arg1	content					1986:1992	low residual water content	1967:1992	low residual water content in the solid-state	1967:2011	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	0	3	theme	Dried	161:165	arg1	Angiotensin					167:177	Advanced Spray Dried and Co-Spray Dried Angiotensin	127:177	Angiotensin	167:177	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	1	4	theme	essential	396:404	arg1	Angiotensin					327:337	The peptide hormone Angiotensin	307:337	The peptide hormone Angiotensin (1-7)	307:343	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	4	theme	essential	396:404	arg1	component					406:414	an essential component	393:414	an essential component of the renin-angiotensin system (RAS)	393:452	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	5	5	theme	phase	1092:1096	arg1	SPPS					1117:1120	SPPS	1117:1120	SPPS	1117:1120	Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5.
34452239	5	5	theme	phase	1092:1096	arg1	synthesis					1106:1114	Solid phase peptide synthesis	1086:1114	Solid phase peptide synthesis (SPPS)	1086:1121	Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5.
34452239	4	6	theme	1-7	960:962	arg1	peptide					965:971	the native Ang (1-7) peptide	944:971	the native Ang (1-7) peptide	944:971	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	2	7	theme	therapeutic	637:647	arg1	approach					649:656	a novel therapeutic approach	629:656	a novel therapeutic approach for the treatment of many diseases	629:691	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	8	8	theme	amorphous	1807:1815	arg1	formation					1830:1838	the amorphous glassy state formation	1803:1838	the amorphous glassy state formation with Tgs that are compatible with use in vivo	1803:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	3	9	theme	penetration	911:921	arg1	levels					895:900	greater levels	887:900	greater levels of brain penetration	887:921	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	9	theme	penetration	911:921	arg1	stability					865:873	enhanced stability	856:873	enhanced stability in vivo	856:881	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	1	10	theme	renin-angiotensin	423:439	arg1	system					441:446	the renin-angiotensin system	419:446	the renin-angiotensin system (RAS)	419:452	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	10	theme	renin-angiotensin	423:439	arg1	RAS					449:451	RAS	449:451	RAS	449:451	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	2	11	theme	biological	574:583	arg1	activities					585:594	various biological activities	566:594	various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases	566:691	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	0	12	theme	Cell	66:69	arg1	Culture					71:77	In Vitro 2D/3D Human Cell Culture	45:77	In Vitro 2D/3D Human Cell Culture	45:77	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	2	13	theme	many	679:682	arg1	diseases					684:691	many diseases	679:691	many diseases	679:691	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	8	14	theme	distinct	1755:1762	arg1	Tg					1783:1784	Tg	1783:1784	Tg	1783:1784	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	8	14	theme	distinct	1755:1762	arg1	transitions					1770:1780	distinct glass transitions	1755:1780	distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo	1755:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	11	15	theme	brain	2228:2232	arg1	cells					2234:2238	different human respiratory and brain cells	2196:2238	cells	2234:2238	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	6	16	theme	raw	1213:1215	arg1	1-7					1222:1224	1-7	1222:1224	1-7	1222:1224	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	16	theme	raw	1213:1215	arg1	Ang					1217:1219	raw Ang	1213:1219	raw Ang (1-7)	1213:1225	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	17	theme	lipophilicity	1196:1208	arg1	PNA5					1235:1238	raw PNA5	1231:1238	raw PNA5	1231:1238	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	17	theme	lipophilicity	1196:1208	arg1	Measurements					1165:1176	Measurements	1165:1176	Measurements of solubility and lipophilicity of raw Ang (1-7)	1165:1225	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	0	18	theme	Dry	286:288	arg1	Inhalers					297:304	Dry Powder Inhalers	286:304	Dry Powder Inhalers	286:304	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	2	19	theme	receptor	535:542	arg1	Activation					516:525	Activation	516:525	Activation of this receptor in the CNS	516:553	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	3	20	link	O-linked	706:713	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	20	link	O-linked	706:713	arg1	-amide					768:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide	729:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5)	729:780	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	20	link	O-linked	706:713	arg1	revision					797:804	a biousian revision	786:804	a biousian revision of the native peptide hormone Ang (1-7)	786:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	21	theme	related	698:704	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	21	theme	related	698:704	arg1	-amide					768:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide	729:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5)	729:780	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	21	theme	related	698:704	arg1	revision					797:804	a biousian revision	786:804	a biousian revision of the native peptide hormone Ang (1-7)	786:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	6	22	theme	solubility	1181:1190	arg1	PNA5					1235:1238	raw PNA5	1231:1238	raw PNA5	1231:1238	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	22	theme	solubility	1181:1190	arg1	Measurements					1165:1176	Measurements	1165:1176	Measurements of solubility and lipophilicity of raw Ang (1-7)	1165:1225	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	8	23	theme	co-SD	1691:1695	arg1	powders					1697:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	8	24	with	formation	1830:1838	arg1	Tgs					1845:1847	Tgs	1845:1847	Tgs that are compatible with use in vivo	1845:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	3	25	theme	O-β-D-Glc	758:766	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	25	theme	O-β-D-Glc	758:766	arg1	PNA5					776:779	PNA5	776:779	PNA5	776:779	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	25	theme	O-β-D-Glc	758:766	arg1	-amide					768:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide	729:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5)	729:780	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	7	26	with	powders	1564:1570	arg1	trehalose					1638:1646	trehalose	1638:1646	trehalose	1638:1646	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	26	with	powders	1564:1570	arg1	sugar					1602:1606	the non-reducing sugar	1585:1606	the non-reducing sugar	1585:1606	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	26	with	powders	1564:1570	arg1	excipient					1627:1635	pharmaceutical excipient	1612:1635	pharmaceutical excipient	1612:1635	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	4	27	theme	targeted	1030:1037	arg1	delivery					1051:1058	targeted respiratory delivery	1030:1058	targeted respiratory delivery	1030:1058	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	3	28	theme	Asp-Arg-Val-Tyr-Ile-His-Ser-	729:756	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	28	theme	Asp-Arg-Val-Tyr-Ile-His-Ser-	729:756	arg1	PNA5					776:779	PNA5	776:779	PNA5	776:779	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	28	theme	Asp-Arg-Val-Tyr-Ile-His-Ser-	729:756	arg1	-amide					768:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide	729:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5)	729:780	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	0	29	theme	Human	60:64	arg1	Culture					71:77	In Vitro 2D/3D Human Cell Culture	45:77	In Vitro 2D/3D Human Cell Culture	45:77	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	8	30	theme	peptide	1660:1666	arg1	powders					1697:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	3	31	gly	glycopeptide	715:726	arg2	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	31	gly	glycopeptide	715:726	arg2	revision					797:804	a biousian revision	786:804	a biousian revision of the native peptide hormone Ang (1-7)	786:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	31	gly	glycopeptide	715:726	arg2	-amide					768:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide	729:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5)	729:780	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	6	32	theme	raw	1231:1233	arg1	PNA5					1235:1238	raw PNA5	1231:1238	raw PNA5	1231:1238	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	8	33	theme	glycopeptide	1669:1680	arg1	powders					1697:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	2	34	theme	Ang	610:612	arg1	axis					624:627	the Ang (1-7)/MAS axis	606:627	the Ang (1-7)/MAS axis	606:627	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	8	35	with	consistent	1787:1796	arg1	formation					1830:1838	the amorphous glassy state formation	1803:1838	the amorphous glassy state formation with Tgs that are compatible with use in vivo	1803:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	10	36	theme	human	2062:2066	arg1	device					2072:2077	a human DPI device	2060:2077	a human DPI device	2060:2077	Excellent aerosol dispersion performance with a human DPI device was demonstrated.
34452239	8	37	theme	SD	1683:1684	arg1	powders					1697:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders	1649:1703	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	7	38	theme	co-spray-dried	1549:1562	arg1	co-SD					1573:1577	co-SD	1573:1577	co-SD	1573:1577	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	38	theme	co-spray-dried	1549:1562	arg1	powders					1564:1570	co-spray-dried powders	1549:1570	co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose	1549:1646	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	8	39	theme	state	1824:1828	arg1	formation					1830:1838	the amorphous glassy state formation	1803:1838	the amorphous glassy state formation with Tgs that are compatible with use in vivo	1803:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	10	40	theme	DPI	2068:2070	arg1	device					2072:2077	a human DPI device	2060:2077	a human DPI device	2060:2077	Excellent aerosol dispersion performance with a human DPI device was demonstrated.
34452239	1	41	theme	receptor	496:503	arg1	agonist					477:483	an agonist	474:483	an agonist of the Mas receptor	474:503	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	41	theme	receptor	496:503	arg1	Angiotensin					327:337	The peptide hormone Angiotensin	307:337	The peptide hormone Angiotensin (1-7)	307:343	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	41	theme	receptor	496:503	arg1	component					406:414	an essential component	393:414	an essential component of the renin-angiotensin system (RAS)	393:452	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	0	42	theme	Targeted	253:260	arg1	Delivery					274:281	Targeted Respiratory Delivery	253:281	Targeted Respiratory Delivery	253:281	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	3	43	theme	peptide	820:826	arg1	1-7					841:843	the native peptide hormone Ang (1-7)	809:844	the native peptide hormone Ang (1-7)	809:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	2	44	theme	/MAS	619:622	arg1	axis					624:627	the Ang (1-7)/MAS axis	606:627	the Ang (1-7)/MAS axis	606:627	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	4	45	theme	native	948:953	arg1	peptide					965:971	the native Ang (1-7) peptide	944:971	the native Ang (1-7) peptide	944:971	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	0	46	theme	Physicochemical	11:25	arg1	Characterization					27:42	Physicochemical Characterization	11:42	Physicochemical Characterization	11:42	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	3	47	theme	1-7	841:843	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	47	theme	1-7	841:843	arg1	revision					797:804	a biousian revision	786:804	a biousian revision of the native peptide hormone Ang (1-7)	786:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	9	48	theme	small	1923:1927	arg1	sizes					1929:1933	small sizes	1923:1933	small sizes in the nanometer size range	1923:1961	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	10	49	with	performance	2043:2053	arg1	device					2072:2077	a human DPI device	2060:2077	a human DPI device	2060:2077	Excellent aerosol dispersion performance with a human DPI device was demonstrated.
34452239	8	50	theme	consistent	1787:1796	arg1	Tg					1783:1784	Tg	1783:1784	Tg	1783:1784	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	8	50	theme	consistent	1787:1796	arg1	transitions					1770:1780	distinct glass transitions	1755:1780	distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo	1755:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	7	51	theme	spray	1411:1415	arg1	drying					1417:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	8	52	theme	glassy	1817:1822	arg1	formation					1830:1838	the amorphous glassy state formation	1803:1838	the amorphous glassy state formation with Tgs that are compatible with use in vivo	1803:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	1	53	theme	peptide	311:317	arg1	hormone					319:325	peptide hormone	311:325	The peptide hormone Angiotensin (1-7)	307:343	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	7	54	theme	organic	1394:1400	arg1	drying					1417:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	3	55	theme	enhanced	856:863	arg1	stability					865:873	enhanced stability	856:873	enhanced stability in vivo	856:881	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	8	56	with	compatible	1858:1867	arg1	use					1874:1876	use	1874:1876	use in vivo	1874:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	0	57	with	Synthesis	0:8	arg1	Trehalose					207:215	Trehalose	207:215	Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers	207:304	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	11	58	theme	cell	2112:2115	arg1	assays					2127:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	0	59	theme	2D/3D	54:58	arg1	Culture					71:77	In Vitro 2D/3D Human Cell Culture	45:77	In Vitro 2D/3D Human Cell Culture	45:77	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	9	60	theme	low	1967:1969	arg1	content					1986:1992	low residual water content	1967:1992	low residual water content in the solid-state	1967:2011	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	0	61	theme	Angiotensin	167:177	arg1	Peptide					185:191	Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide	127:191	Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide	127:191	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	5	62	theme	Solid	1086:1090	arg1	SPPS					1117:1120	SPPS	1117:1120	SPPS	1117:1120	Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5.
34452239	5	62	theme	Solid	1086:1090	arg1	synthesis					1106:1114	Solid phase peptide synthesis	1086:1114	Solid phase peptide synthesis (SPPS)	1086:1121	Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5.
34452239	7	63	gly	glycopeptide	1524:1535	arg2	glycopeptide					1524:1535	the glycopeptide	1520:1535	the glycopeptide	1520:1535	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	8	64	theme	glass	1764:1768	arg1	Tg					1783:1784	Tg	1783:1784	Tg	1783:1784	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	8	64	theme	glass	1764:1768	arg1	transitions					1770:1780	distinct glass transitions	1755:1780	distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo	1755:1884	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	2	65	from	Activation	516:525	arg1	CNS					551:553	the CNS	547:553	the CNS	547:553	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	9	66	theme	water	1980:1984	arg1	content					1986:1992	low residual water content	1967:1992	low residual water content in the solid-state	1967:2011	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	0	67	with	Culture	71:77	arg1	Trehalose					207:215	Trehalose	207:215	Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers	207:304	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	8	68	theme	native	1653:1658	arg1	peptide					1660:1666	The native peptide	1649:1666	The native peptide	1649:1666	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	5	69	theme	peptide	1098:1104	arg1	SPPS					1117:1120	SPPS	1117:1120	SPPS	1117:1120	Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5.
34452239	5	69	theme	peptide	1098:1104	arg1	synthesis					1106:1114	Solid phase peptide synthesis	1086:1114	Solid phase peptide synthesis (SPPS)	1086:1121	Solid phase peptide synthesis (SPPS) successfully produced Ang (1-7) and PNA5.
34452239	3	70	theme	brain	905:909	arg1	penetration					911:921	brain penetration	905:921	brain penetration	905:921	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	11	71	theme	viability	2117:2125	arg1	assays					2127:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	0	72	theme	Peptide	185:191	arg1	Culture					71:77	In Vitro 2D/3D Human Cell Culture	45:77	In Vitro 2D/3D Human Cell Culture	45:77	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	72	theme	Peptide	185:191	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis	0:8	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	72	theme	Peptide	185:191	arg1	Characterization					27:42	Physicochemical Characterization	11:42	Physicochemical Characterization	11:42	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	72	theme	Peptide	185:191	arg1	Performance					112:122	In Vitro Aerosol Dispersion Performance	84:122	In Vitro Aerosol Dispersion Performance	84:122	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	4	73	theme	inhalable	1063:1071	arg1	them					1021:1024	them	1021:1024	them	1021:1024	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	4	73	theme	inhalable	1063:1071	arg1	powders					1077:1083	inhalable dry powders	1063:1083	inhalable dry powders	1063:1083	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	2	74	theme	diseases	684:691	arg1	treatment					666:674	the treatment	662:674	the treatment of many diseases	662:691	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	0	75	theme	PNA5	197:200	arg1	Culture					71:77	In Vitro 2D/3D Human Cell Culture	45:77	In Vitro 2D/3D Human Cell Culture	45:77	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	75	theme	PNA5	197:200	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis	0:8	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	75	theme	PNA5	197:200	arg1	Characterization					27:42	Physicochemical Characterization	11:42	Physicochemical Characterization	11:42	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	75	theme	PNA5	197:200	arg1	Performance					112:122	In Vitro Aerosol Dispersion Performance	84:122	In Vitro Aerosol Dispersion Performance	84:122	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	1	76	theme	system	441:446	arg1	agonist					477:483	an agonist	474:483	an agonist of the Mas receptor	474:503	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	76	theme	system	441:446	arg1	Angiotensin					327:337	The peptide hormone Angiotensin	307:337	The peptide hormone Angiotensin (1-7)	307:343	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	76	theme	system	441:446	arg1	component					406:414	an essential component	393:414	an essential component of the renin-angiotensin system (RAS)	393:452	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	7	77	theme	peptide	1508:1514	arg1	powders					1564:1570	co-spray-dried powders	1549:1570	co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose	1549:1646	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	77	theme	peptide	1508:1514	arg1	SD					1492:1493	SD	1492:1493	SD	1492:1493	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	77	theme	peptide	1508:1514	arg1	co-SD					1573:1577	co-SD	1573:1577	co-SD	1573:1577	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	77	theme	peptide	1508:1514	arg1	powders					1483:1489	spray-dried powders	1471:1489	spray-dried powders (SD)	1471:1494	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	2	78	theme	various	566:572	arg1	activities					585:594	various biological activities	566:594	various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases	566:691	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	7	79	theme	pharmaceutical	1612:1625	arg1	excipient					1627:1635	pharmaceutical excipient	1612:1635	pharmaceutical excipient	1612:1635	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	10	80	theme	aerosol	2024:2030	arg1	performance					2043:2053	Excellent aerosol dispersion performance	2014:2053	Excellent aerosol dispersion performance with a human DPI device	2014:2077	Excellent aerosol dispersion performance with a human DPI device was demonstrated.
34452239	6	81	theme	Ang	1217:1219	arg1	solubility					1181:1190	solubility	1181:1190	solubility	1181:1190	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	81	theme	Ang	1217:1219	arg1	lipophilicity					1196:1208	lipophilicity	1196:1208	lipophilicity	1196:1208	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	4	82	theme	dry	1073:1075	arg1	them					1021:1024	them	1021:1024	them	1021:1024	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	4	82	theme	dry	1073:1075	arg1	powders					1077:1083	inhalable dry powders	1063:1083	inhalable dry powders	1063:1083	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	9	83	from	sizes	1929:1933	arg1	range					1957:1961	the nanometer size range	1938:1961	the nanometer size range	1938:1961	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	9	83	from	sizes	1929:1933	arg1	solid-state					2001:2011	the solid-state	1997:2011	the solid-state	1997:2011	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	0	84	theme	Dried	142:146	arg1	Peptide					185:191	Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide	127:191	Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide	127:191	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	4	85	gly	glycopeptide	981:992	arg2	glycopeptide					981:992	the glycopeptide	977:992	the glycopeptide	977:992	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	4	85	gly	glycopeptide	981:992	arg2	PNA5					995:998	PNA5	995:998	PNA5	995:998	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	9	86	theme	nanometer	1942:1950	arg1	range					1957:1961	the nanometer size range	1938:1961	the nanometer size range	1938:1961	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	2	87	theme	novel	631:635	arg1	approach					649:656	a novel therapeutic approach	629:656	a novel therapeutic approach for the treatment of many diseases	629:691	Activation of this receptor in the CNS stimulates various biological activities that make the Ang (1-7)/MAS axis a novel therapeutic approach for the treatment of many diseases.
34452239	3	88	theme	O-linked	706:713	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	88	theme	O-linked	706:713	arg1	-amide					768:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide	729:773	Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5)	729:780	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	88	theme	O-linked	706:713	arg1	revision					797:804	a biousian revision	786:804	a biousian revision of the native peptide hormone Ang (1-7)	786:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	0	89	theme	Co-Spray	152:159	arg1	Angiotensin					167:177	Advanced Spray Dried and Co-Spray Dried Angiotensin	127:177	Angiotensin	167:177	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	90	theme	Powder	290:295	arg1	Inhalers					297:304	Dry Powder Inhalers	286:304	Dry Powder Inhalers	286:304	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	3	91	theme	biousian	788:795	arg1	glycopeptide					715:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide	694:726	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	3	91	theme	biousian	788:795	arg1	revision					797:804	a biousian revision	786:804	a biousian revision of the native peptide hormone Ang (1-7)	786:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	7	92	theme	spray-dried	1471:1481	arg1	SD					1492:1493	SD	1492:1493	SD	1492:1493	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	92	theme	spray-dried	1471:1481	arg1	powders					1483:1489	spray-dried powders	1471:1489	spray-dried powders (SD)	1471:1494	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	4	93	theme	respiratory	1039:1049	arg1	delivery					1051:1058	targeted respiratory delivery	1030:1058	targeted respiratory delivery	1030:1058	We have synthesized the native Ang (1-7) peptide and the glycopeptide, PNA5, and have formulated them for targeted respiratory delivery as inhalable dry powders.
34452239	0	94	with	Performance	112:122	arg1	Trehalose					207:215	Trehalose	207:215	Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers	207:304	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	6	95	theme	experimental	1246:1257	arg1	approaches					1277:1286	experimental and computational approaches	1246:1286	experimental and computational approaches	1246:1286	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	7	96	theme	non-reducing	1589:1600	arg1	trehalose					1638:1646	trehalose	1638:1646	trehalose	1638:1646	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	96	theme	non-reducing	1589:1600	arg1	sugar					1602:1606	the non-reducing sugar	1585:1606	the non-reducing sugar	1585:1606	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	97	with	powders	1483:1489	arg1	trehalose					1638:1646	trehalose	1638:1646	trehalose	1638:1646	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	97	with	powders	1483:1489	arg1	sugar					1602:1606	the non-reducing sugar	1585:1606	the non-reducing sugar	1585:1606	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	97	with	powders	1483:1489	arg1	excipient					1627:1635	pharmaceutical excipient	1612:1635	pharmaceutical excipient	1612:1635	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	3	98	theme	native	813:818	arg1	1-7					841:843	the native peptide hormone Ang (1-7)	809:844	the native peptide hormone Ang (1-7)	809:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	0	99	theme	Dispersion	101:110	arg1	Performance					112:122	In Vitro Aerosol Dispersion Performance	84:122	In Vitro Aerosol Dispersion Performance	84:122	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	0	100	theme	In	84:85	arg1	Performance					112:122	In Vitro Aerosol Dispersion Performance	84:122	In Vitro Aerosol Dispersion Performance	84:122	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	6	101	gly	glycopeptide	1324:1335	arg2	glycopeptide					1324:1335	glycopeptide	1324:1335	glycopeptide	1324:1335	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	11	102	theme	human	2106:2110	arg1	assays					2127:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	11	103	theme	different	2196:2204	arg1	respiratory					2212:2222	different human respiratory and brain cells	2196:2238	respiratory	2212:2222	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	1	104	theme	Mas	492:494	arg1	receptor					496:503	the Mas receptor	488:503	the Mas receptor	488:503	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	0	105	theme	Aerosol	93:99	arg1	Performance					112:122	In Vitro Aerosol Dispersion Performance	84:122	In Vitro Aerosol Dispersion Performance	84:122	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	3	106	theme	Ang	836:838	arg1	1-7					841:843	the native peptide hormone Ang (1-7)	809:844	the native peptide hormone Ang (1-7)	809:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	0	107	dep	In	84:85	arg1	Vitro					87:91	Vitro	87:91	Vitro	87:91	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	11	108	theme	In	2097:2098	arg1	assays					2127:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays	2097:2132	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	3	109	theme	hormone	828:834	arg1	1-7					841:843	the native peptide hormone Ang (1-7)	809:844	the native peptide hormone Ang (1-7)	809:844	The related O-linked glycopeptide, Asp-Arg-Val-Tyr-Ile-His-Ser-(O-β-D-Glc)-amide (PNA5), is a biousian revision of the native peptide hormone Ang (1-7) and shows enhanced stability in vivo and greater levels of brain penetration.
34452239	8	110	gly	glycopeptide	1669:1680	arg2	glycopeptide					1669:1680	glycopeptide	1669:1680	glycopeptide	1669:1680	The native peptide, glycopeptide, SD, and co-SD powders were comprehensively characterized, and exhibited distinct glass transitions (Tg) consistent with the amorphous glassy state formation with Tgs that are compatible with use in vivo.
34452239	9	111	theme	homogeneous	1891:1901	arg1	particles					1903:1911	The homogeneous particles	1887:1911	The homogeneous particles	1887:1911	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	9	112	from	content	1986:1992	arg1	range					1957:1961	the nanometer size range	1938:1961	the nanometer size range	1938:1961	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	9	112	from	content	1986:1992	arg1	solid-state					2001:2011	the solid-state	1997:2011	the solid-state	1997:2011	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	0	113	theme	Respiratory	262:272	arg1	Delivery					274:281	Targeted Respiratory Delivery	253:281	Targeted Respiratory Delivery	253:281	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	7	114	used	used	1428:1431	arg2	drying					1417:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	0	115	theme	In	45:46	arg1	Culture					71:77	In Vitro 2D/3D Human Cell Culture	45:77	In Vitro 2D/3D Human Cell Culture	45:77	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	7	116	theme	glycopeptide	1524:1535	arg1	powders					1564:1570	co-spray-dried powders	1549:1570	co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose	1549:1646	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	116	theme	glycopeptide	1524:1535	arg1	SD					1492:1493	SD	1492:1493	SD	1492:1493	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	116	theme	glycopeptide	1524:1535	arg1	co-SD					1573:1577	co-SD	1573:1577	co-SD	1573:1577	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	7	116	theme	glycopeptide	1524:1535	arg1	powders					1483:1489	spray-dried powders	1471:1489	spray-dried powders (SD)	1471:1494	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	10	117	theme	Excellent	2014:2022	arg1	performance					2043:2053	Excellent aerosol dispersion performance	2014:2053	Excellent aerosol dispersion performance with a human DPI device	2014:2077	Excellent aerosol dispersion performance with a human DPI device was demonstrated.
34452239	0	118	with	Characterization	27:42	arg1	Trehalose					207:215	Trehalose	207:215	Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers	207:304	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	6	119	theme	computational	1263:1275	arg1	approaches					1277:1286	experimental and computational approaches	1246:1286	experimental and computational approaches	1246:1286	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	0	120	dep	In	45:46	arg1	Vitro					48:52	Vitro	48:52	Vitro	48:52	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1-7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers.
34452239	11	121	dep	In	2097:2098	arg1	vitro					2100:2104	vitro	2100:2104	vitro	2100:2104	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	1	122	theme	hormone	319:325	arg1	1-7					340:342	1-7	340:342	1-7	340:342	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	122	theme	hormone	319:325	arg1	Ang					346:348	Ang (1-7)	346:354	Ang (1-7)	346:354	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	122	theme	hormone	319:325	arg1	Angiotensin					327:337	The peptide hormone Angiotensin	307:337	The peptide hormone Angiotensin (1-7)	307:343	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	122	theme	hormone	319:325	arg1	Asp-Arg-Val-Tyr-Ile-His-Pro					360:386	(Asp-Arg-Val-Tyr-Ile-His-Pro)	359:387	(Asp-Arg-Val-Tyr-Ile-His-Pro)	359:387	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	1	122	theme	hormone	319:325	arg1	component					406:414	an essential component	393:414	an essential component of the renin-angiotensin system (RAS)	393:452	The peptide hormone Angiotensin (1-7), Ang (1-7) or (Asp-Arg-Val-Tyr-Ile-His-Pro), is an essential component of the renin-angiotensin system (RAS) peripherally and is an agonist of the Mas receptor centrally.
34452239	6	123	contain	have	1337:1340	arg1	glycopeptide					1324:1335	glycopeptide	1324:1335	glycopeptide	1324:1335	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	123	contain	have	1337:1340	arg1	amphipathic					1372:1382	amphipathic	1372:1382	amphipathic	1372:1382	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	123	contain	have	1337:1340	arg2	solubility					1353:1362	high-water solubility	1342:1362	high-water solubility	1342:1362	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	6	123	contain	have	1337:1340	arg1	peptide					1312:1318	the peptide	1308:1318	the peptide	1308:1318	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
34452239	7	124	theme	solution	1402:1409	arg1	drying					1417:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	9	125	theme	size	1952:1955	arg1	range					1957:1961	the nanometer size range	1938:1961	the nanometer size range	1938:1961	The homogeneous particles displayed small sizes in the nanometer size range and low residual water content in the solid-state.
34452239	10	126	theme	dispersion	2032:2041	arg1	performance					2043:2053	Excellent aerosol dispersion performance	2014:2053	Excellent aerosol dispersion performance with a human DPI device	2014:2077	Excellent aerosol dispersion performance with a human DPI device was demonstrated.
34452239	7	127	theme	Advanced	1385:1392	arg1	drying					1417:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying	1385:1422	Advanced organic solution spray drying was used to engineer the particles and produce spray-dried powders (SD) of both the peptide and the glycopeptide, as well as co-spray-dried powders (co-SD) with the non-reducing sugar and pharmaceutical excipient, trehalose.
34452239	11	128	theme	human	2206:2210	arg1	respiratory					2212:2222	different human respiratory and brain cells	2196:2238	respiratory	2212:2222	In vitro human cell viability assays showed that Ang (1-7) and PNA5 are biocompatible and safe for different human respiratory and brain cells.
34452239	6	129	theme	high-water	1342:1351	arg1	solubility					1353:1362	high-water solubility	1342:1362	high-water solubility	1342:1362	Measurements of solubility and lipophilicity of raw Ang (1-7) and raw PNA5 using experimental and computational approaches confirmed that both the peptide and glycopeptide have high-water solubility and are amphipathic.
33657401	4	0	theme	lipogenic	758:766	arg1	pre-mRNAs					768:776	lipogenic pre-mRNAs	758:776	lipogenic pre-mRNAs	758:776	Consequently, O-GlcNAcylated SRPK2 was imported into the nucleus, where it phosphorylated serine/arginine-rich proteins and promoted splicing of lipogenic pre-mRNAs.
33657401	6	1	theme	posttranscriptional	968:986	arg1	regulation					988:997	posttranscriptional regulation	968:997	posttranscriptional regulation of de novo lipogenesis	968:1020	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	1	2	link	O-linked	90:97	arg1	O-GlcNAc					123:130	O-GlcNAc	123:130	O-GlcNAc	123:130	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	2	link	O-linked	90:97	arg1	glucosamine					110:120	O-linked β-N-acetyl glucosamine	90:120	O-linked β-N-acetyl glucosamine (O-GlcNAc)	90:131	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	6	3	theme	importin	1054:1061	arg1	α					1063:1063	importin α	1054:1063	importin α	1054:1063	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	6	3	theme	importin	1054:1061	arg1	"					1077:1077	a "reader"	1068:1077	a "reader" of an O-GlcNAcylated NLS	1068:1102	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	5	4	theme	protein	798:804	arg1	import					814:819	protein nuclear import	798:819	protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α	798:887	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	5	4	theme	protein	798:804	arg1	mechanism					908:916	a general mechanism	898:916	a general mechanism in cells	898:925	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	6	5	theme	O-GlcNAc	956:963	arg1	role					948:951	a role	946:951	a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis	946:1020	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	3	6	theme	SRPK2	592:596	arg1	binding					581:587	binding	581:587	binding of SRPK2 to importin α	581:610	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	2	7	theme	posttranslational	315:331	arg1	modification					333:344	posttranslational modification	315:344	posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc	315:405	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	4	8	theme	O-GlcNAcylated	627:640	arg1	SRPK2					642:646	O-GlcNAcylated SRPK2	627:646	O-GlcNAcylated SRPK2	627:646	Consequently, O-GlcNAcylated SRPK2 was imported into the nucleus, where it phosphorylated serine/arginine-rich proteins and promoted splicing of lipogenic pre-mRNAs.
33657401	5	9	theme	nuclear	806:812	arg1	import					814:819	protein nuclear import	798:819	protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α	798:887	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	5	9	theme	nuclear	806:812	arg1	mechanism					908:916	a general mechanism	898:916	a general mechanism in cells	898:925	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	6	10	theme	O-GlcNAcylated	1085:1098	arg1	NLS					1100:1102	an O-GlcNAcylated NLS	1082:1102	an O-GlcNAcylated NLS	1082:1102	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	1	11	theme	O-linked	90:97	arg1	O-GlcNAc					123:130	O-GlcNAc	123:130	O-GlcNAc	123:130	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	11	theme	O-linked	90:97	arg1	glucosamine					110:120	O-linked β-N-acetyl glucosamine	90:120	O-linked β-N-acetyl glucosamine (O-GlcNAc)	90:131	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	3	12	theme	O-GlcNAc	484:491	arg1	transferase					493:503	O-GlcNAc transferase	484:503	O-GlcNAc transferase	484:503	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	5	13	theme	cargo	861:865	arg1	protein					867:873	cargo protein	861:873	cargo protein	861:873	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	1	14	theme	β-N-acetyl	99:108	arg1	O-GlcNAc					123:130	O-GlcNAc	123:130	O-GlcNAc	123:130	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	14	theme	β-N-acetyl	99:108	arg1	glucosamine					110:120	O-linked β-N-acetyl glucosamine	90:120	O-linked β-N-acetyl glucosamine (O-GlcNAc)	90:131	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	15	theme	posttranslational	196:212	arg1	modification					214:225	this posttranslational modification	191:225	this posttranslational modification	191:225	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	2	16	theme	kinase	378:383	arg1	modification					333:344	posttranslational modification	315:344	posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc	315:405	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	0	17	theme	Posttranscriptional	0:18	arg1	regulation					20:29	Posttranscriptional regulation	0:29	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.	0:88	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.
33657401	6	18	from	role	948:951	arg1	regulation					988:997	posttranscriptional regulation	968:997	posttranscriptional regulation of de novo lipogenesis	968:1020	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	3	19	from	signal	552:557	arg1	O-GlcNAcylated					505:518	O-GlcNAcylated	505:518	O-GlcNAcylated	505:518	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	2	20	theme	protein	370:376	arg1	SRPK2					388:392	SRPK2	388:392	SRPK2	388:392	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	2	20	theme	protein	370:376	arg1	kinase					378:383	serine/arginine-rich protein kinase 2	349:385	serine/arginine-rich protein kinase 2 (SRPK2)	349:393	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	0	21	theme	de	34:35	arg1	lipogenesis					42:52	de novo lipogenesis	34:52	de novo lipogenesis	34:52	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.
33657401	2	22	theme	serine/arginine-rich	349:368	arg1	SRPK2					388:392	SRPK2	388:392	SRPK2	388:392	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	2	22	theme	serine/arginine-rich	349:368	arg1	kinase					378:383	serine/arginine-rich protein kinase 2	349:385	serine/arginine-rich protein kinase 2 (SRPK2)	349:393	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	5	23	theme	general	900:906	arg1	import					814:819	protein nuclear import	798:819	protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α	798:887	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	5	23	theme	general	900:906	arg1	mechanism					908:916	a general mechanism	898:916	a general mechanism in cells	898:925	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	2	24	dep	de	417:418	arg1	novo					420:423	novo	420:423	novo	420:423	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	3	25	theme	importin	601:608	arg1	α					610:610	importin α	601:610	importin α	601:610	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	1	26	theme	molecular	238:246	arg1	changes					266:272	molecular and physiological changes	238:272	molecular and physiological changes that affect cell fate	238:294	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	0	27	theme	lipogenesis	42:52	arg1	regulation					20:29	Posttranscriptional regulation	0:29	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.	0:88	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.
33657401	6	28	dep	de	1002:1003	arg1	novo					1005:1008	novo	1005:1008	novo	1005:1008	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	4	29	theme	serine/arginine-rich	703:722	arg1	proteins					724:731	serine/arginine-rich proteins	703:731	serine/arginine-rich proteins	703:731	Consequently, O-GlcNAcylated SRPK2 was imported into the nucleus, where it phosphorylated serine/arginine-rich proteins and promoted splicing of lipogenic pre-mRNAs.
33657401	5	30	theme	protein	867:873	arg1	binding					850:856	O-GlcNAcylation-dependent binding	824:856	O-GlcNAcylation-dependent binding of cargo protein to importin α	824:887	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	1	31	theme	physiological	252:264	arg1	changes					266:272	molecular and physiological changes	238:272	molecular and physiological changes that affect cell fate	238:294	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	0	32	theme	glucose-induced	57:71	arg1	O-GlcNAcylation					73:87	glucose-induced O-GlcNAcylation	57:87	glucose-induced O-GlcNAcylation	57:87	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.
33657401	6	33	theme	lipogenesis	1010:1020	arg1	regulation					988:997	posttranscriptional regulation	968:997	posttranscriptional regulation of de novo lipogenesis	968:1020	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	5	34	theme	importin	878:885	arg1	α					887:887	importin α	878:887	importin α	878:887	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	4	35	theme	pre-mRNAs	768:776	arg1	splicing					746:753	splicing	746:753	splicing of lipogenic pre-mRNAs	746:776	Consequently, O-GlcNAcylated SRPK2 was imported into the nucleus, where it phosphorylated serine/arginine-rich proteins and promoted splicing of lipogenic pre-mRNAs.
33657401	6	36	theme	de	1002:1003	arg1	lipogenesis					1010:1020	de novo lipogenesis	1002:1020	de novo lipogenesis	1002:1020	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	0	37	dep	de	34:35	arg1	novo					37:40	novo	37:40	novo	37:40	Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation.
33657401	5	38	from	mechanism	908:916	arg1	cells					921:925	cells	921:925	cells	921:925	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	3	39	theme	nuclear	531:537	arg1	signal					552:557	a nuclear localization signal	529:557	a nuclear localization signal (NLS)	529:563	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	3	39	theme	nuclear	531:537	arg1	NLS					560:562	NLS	560:562	NLS	560:562	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	3	40	theme	localization	539:550	arg1	signal					552:557	a nuclear localization signal	529:557	a nuclear localization signal (NLS)	529:563	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	3	40	theme	localization	539:550	arg1	NLS					560:562	NLS	560:562	NLS	560:562	We found that O-GlcNAc transferase O-GlcNAcylated SRPK2 at a nuclear localization signal (NLS), which triggers binding of SRPK2 to importin α.
33657401	6	41	theme	reader	1071:1076	arg1	α					1063:1063	importin α	1054:1063	importin α	1054:1063	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	6	41	theme	reader	1071:1076	arg1	"					1077:1077	a "reader"	1068:1077	a "reader" of an O-GlcNAcylated NLS	1068:1102	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	2	42	theme	pre-mRNA	451:458	arg1	splicing					460:467	pre-mRNA splicing	451:467	pre-mRNA splicing	451:467	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	6	43	theme	NLS	1100:1102	arg1	α					1063:1063	importin α	1054:1063	importin α	1054:1063	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	6	43	theme	NLS	1100:1102	arg1	"					1077:1077	a "reader"	1068:1077	a "reader" of an O-GlcNAcylated NLS	1068:1102	This work reveals a role of O-GlcNAc in posttranscriptional regulation of de novo lipogenesis, and our findings indicate that importin α is a "reader" of an O-GlcNAcylated NLS.
33657401	2	44	theme	de	417:418	arg1	lipogenesis					425:435	de novo lipogenesis	417:435	de novo lipogenesis	417:435	Here we show that posttranslational modification of serine/arginine-rich protein kinase 2 (SRPK2) by O-GlcNAc regulates de novo lipogenesis by regulating pre-mRNA splicing.
33657401	5	45	theme	O-GlcNAcylation-dependent	824:848	arg1	binding					850:856	O-GlcNAcylation-dependent binding	824:856	O-GlcNAcylation-dependent binding of cargo protein to importin α	824:887	We determined that protein nuclear import by O-GlcNAcylation-dependent binding of cargo protein to importin α might be a general mechanism in cells.
33657401	1	46	attach	attached	136:143	arg1	proteins					148:155	proteins	148:155	proteins	148:155	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	46	attach	attached	136:143	arg2	glucosamine					110:120	O-linked β-N-acetyl glucosamine	90:120	O-linked β-N-acetyl glucosamine (O-GlcNAc)	90:131	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	46	attach	attached	136:143	arg2	O-GlcNAc					123:130	O-GlcNAc	123:130	O-GlcNAc	123:130	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	47	theme	glucose-replete	163:177	arg1	conditions					179:188	glucose-replete conditions	163:188	glucose-replete conditions	163:188	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33657401	1	48	theme	cell	286:289	arg1	fate					291:294	cell fate	286:294	cell fate	286:294	O-linked β-N-acetyl glucosamine (O-GlcNAc) is attached to proteins under glucose-replete conditions; this posttranslational modification results in molecular and physiological changes that affect cell fate.
33078708	7	0	from	selection	1175:1183	arg1	tract					1241:1245	the female reproductive tract	1217:1245	the female reproductive tract	1217:1245	These findings provide molecular insight into sperm selection for successful fertilization in the female reproductive tract.
33078708	1	1	theme	ejaculated	136:145	arg1	sperm					147:151	ejaculated sperm	136:151	ejaculated sperm	136:151	Out of millions of ejaculated sperm, a few reach the fertilization site in mammals.
33078708	0	2	theme	molecular	60:68	arg1	signatures					70:79	molecular signatures	60:79	molecular signatures of fertilizing spermatozoa in mice	60:114	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	7	3	theme	molecular	1146:1154	arg1	insight					1156:1162	molecular insight	1146:1162	molecular insight into sperm selection for successful fertilization in the female reproductive tract	1146:1245	These findings provide molecular insight into sperm selection for successful fertilization in the female reproductive tract.
33078708	1	4	theme	sperm	147:151	arg1	millions					124:131	millions	124:131	millions of ejaculated sperm	124:151	Out of millions of ejaculated sperm, a few reach the fertilization site in mammals.
33078708	2	5	theme	calcium	274:280	arg1	complexes					290:298	multi-subunit CatSper calcium channel complexes	252:298	multi-subunit CatSper calcium channel complexes	252:298	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	3	6	theme	processing	565:574	arg1	cascades					614:621	capacitation-induced processing dependent on Ca2+ and phosphorylation cascades	544:621	capacitation-induced processing dependent on Ca2+ and phosphorylation cascades	544:621	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	5	7	theme	3D	765:766	arg1	imaging					786:792	3D in situ molecular imaging	765:792	3D in situ molecular imaging	765:792	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	3	8	gly	glycosylated	511:522	arg1	CatSper1					487:494	CatSper1	487:494	CatSper1	487:494	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	3	8	gly	glycosylated	511:522	arg1	protein					524:530	an O-linked glycosylated protein	499:530	an O-linked glycosylated protein	499:530	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	2	9	from	migration	323:331	arg1	tract					347:351	the female tract	336:351	the female tract	336:351	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	2	10	theme	CatSper	266:272	arg1	complexes					290:298	multi-subunit CatSper calcium channel complexes	252:298	multi-subunit CatSper calcium channel complexes	252:298	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	5	11	theme	in	768:769	arg1	imaging					786:792	3D in situ molecular imaging	765:792	3D in situ molecular imaging	765:792	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	4	12	theme	tyrosine	668:675	arg1	pY					694:695	pY	694:695	pY	694:695	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	4	12	theme	tyrosine	668:675	arg1	phosphorylation					677:691	protein tyrosine phosphorylation	660:691	protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo	660:756	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	2	13	theme	multi-subunit	252:264	arg1	complexes					290:298	multi-subunit CatSper calcium channel complexes	252:298	multi-subunit CatSper calcium channel complexes	252:298	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	3	14	theme	biochemical	426:436	arg1	studies					458:464	biochemical and pharmacological studies	426:464	biochemical and pharmacological studies	426:464	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	5	15	theme	sperm	831:835	arg1	imaging					786:792	3D in situ molecular imaging	765:792	3D in situ molecular imaging	765:792	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	5	15	theme	sperm	831:835	arg1	detection					818:826	ANN-based automatic detection	798:826	ANN-based automatic detection	798:826	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	7	16	theme	sperm	1169:1173	arg1	selection					1175:1183	sperm selection	1169:1183	sperm selection for successful fertilization in the female reproductive tract	1169:1245	These findings provide molecular insight into sperm selection for successful fertilization in the female reproductive tract.
33078708	7	17	theme	female	1221:1226	arg1	tract					1241:1245	the female reproductive tract	1217:1245	the female reproductive tract	1217:1245	These findings provide molecular insight into sperm selection for successful fertilization in the female reproductive tract.
33078708	4	18	from	development	698:708	arg1	cells					719:723	sperm cells	713:723	sperm cells capacitated in vitro and in vivo	713:756	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	2	19	theme	CatSper-dependent	366:382	arg1	mechanisms					384:393	CatSper-dependent mechanisms	366:393	CatSper-dependent mechanisms	366:393	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	0	20	theme	in	3:4	arg1	imaging					11:17	3D in situ imaging	0:17	3D in situ imaging of the female reproductive tract	0:50	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	5	21	theme	ANN-based	798:806	arg1	detection					818:826	ANN-based automatic detection	798:826	ANN-based automatic detection	798:826	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	4	22	theme	sperm	713:717	arg1	cells					719:723	sperm cells	713:723	sperm cells capacitated in vitro and in vivo	713:756	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	0	23	theme	3D	0:1	arg1	imaging					11:17	3D in situ imaging	0:17	3D in situ imaging of the female reproductive tract	0:50	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	6	24	theme	mouse	1017:1021	arg1	spermatozoa					1023:1033	fertilizing mouse spermatozoa	1005:1033	fertilizing mouse spermatozoa	1005:1033	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	6	25	theme	pY	1096:1097	arg1	lack					1088:1091	lack	1088:1091	lack of pY	1088:1097	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	6	25	theme	pY	1096:1097	arg1	channel					1079:1085	intact CatSper channel	1064:1085	intact CatSper channel	1064:1085	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	6	26	theme	fertilizing	1005:1015	arg1	spermatozoa					1023:1033	fertilizing mouse spermatozoa	1005:1033	fertilizing mouse spermatozoa	1005:1033	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	3	27	theme	dependent	576:584	arg1	cascades					614:621	capacitation-induced processing dependent on Ca2+ and phosphorylation cascades	544:621	capacitation-induced processing dependent on Ca2+ and phosphorylation cascades	544:621	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	4	28	theme	phosphorylation	677:691	arg1	development					698:708	protein tyrosine phosphorylation (pY) development	660:708	protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo	660:756	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	5	29	theme	cleared	859:865	arg1	tract					874:878	the cleared female tract	855:878	the cleared female tract	855:878	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	3	30	link	O-linked	502:509	arg1	CatSper1					487:494	CatSper1	487:494	CatSper1	487:494	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	3	30	link	O-linked	502:509	arg1	protein					524:530	an O-linked glycosylated protein	499:530	an O-linked glycosylated protein	499:530	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	2	31	theme	channel	282:288	arg1	complexes					290:298	multi-subunit CatSper calcium channel complexes	252:298	multi-subunit CatSper calcium channel complexes	252:298	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	1	32	theme	fertilization	170:182	arg1	site					184:187	the fertilization site	166:187	the fertilization site in mammals	166:198	Out of millions of ejaculated sperm, a few reach the fertilization site in mammals.
33078708	5	33	theme	automatic	808:816	arg1	detection					818:826	ANN-based automatic detection	798:826	ANN-based automatic detection	798:826	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	5	34	theme	intact	955:960	arg1	signals					971:977	the intact CatSper1 signals	951:977	the intact CatSper1 signals	951:977	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	3	35	theme	pharmacological	442:456	arg1	studies					458:464	biochemical and pharmacological studies	426:464	biochemical and pharmacological studies	426:464	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	2	36	theme	Ca2+	211:214	arg1	nanodomains					226:236	Flagellar Ca2+ signaling nanodomains	201:236	Flagellar Ca2+ signaling nanodomains	201:236	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	2	37	theme	sperm	398:402	arg1	selection					404:412	sperm selection	398:412	sperm selection	398:412	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	7	38	theme	successful	1189:1198	arg1	fertilization					1200:1212	successful fertilization	1189:1212	successful fertilization	1189:1212	These findings provide molecular insight into sperm selection for successful fertilization in the female reproductive tract.
33078708	2	39	theme	Flagellar	201:209	arg1	nanodomains					226:236	Flagellar Ca2+ signaling nanodomains	201:236	Flagellar Ca2+ signaling nanodomains	201:236	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	1	40	from	site	184:187	arg1	mammals					192:198	mammals	192:198	mammals	192:198	Out of millions of ejaculated sperm, a few reach the fertilization site in mammals.
33078708	0	41	theme	reproductive	33:44	arg1	tract					46:50	the female reproductive tract	22:50	the female reproductive tract	22:50	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	5	42	dep	in	768:769	arg1	situ					771:774	situ	771:774	situ	771:774	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	0	43	theme	female	26:31	arg1	tract					46:50	the female reproductive tract	22:50	the female reproductive tract	22:50	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	4	44	theme	CatSper1	624:631	arg1	processing					633:642	CatSper1 processing	624:642	CatSper1 processing	624:642	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	3	45	theme	O-linked	502:509	arg1	CatSper1					487:494	CatSper1	487:494	CatSper1	487:494	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	3	45	theme	O-linked	502:509	arg1	protein					524:530	an O-linked glycosylated protein	499:530	an O-linked glycosylated protein	499:530	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	2	46	theme	sperm	317:321	arg1	migration					323:331	sperm migration	317:331	sperm migration in the female tract	317:351	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	5	47	theme	CatSper1	962:969	arg1	signals					971:977	the intact CatSper1 signals	951:977	the intact CatSper1 signals	951:977	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	6	48	theme	CatSper	1071:1077	arg1	lack					1088:1091	lack	1088:1091	lack of pY	1088:1097	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	6	48	theme	CatSper	1071:1077	arg1	channel					1079:1085	intact CatSper channel	1064:1085	intact CatSper channel	1064:1085	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	3	49	theme	capacitation-induced	544:563	arg1	cascades					614:621	capacitation-induced processing dependent on Ca2+ and phosphorylation cascades	544:621	capacitation-induced processing dependent on Ca2+ and phosphorylation cascades	544:621	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	5	50	contain	possess	943:949	arg2	signals					971:977	the intact CatSper1 signals	951:977	the intact CatSper1 signals	951:977	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	5	50	contain	possess	943:949	arg1	spermatozoa					901:911	spermatozoa	901:911	spermatozoa past the utero-tubal junction	901:941	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	5	51	theme	utero-tubal	922:932	arg1	junction					934:941	the utero-tubal junction	918:941	the utero-tubal junction	918:941	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	6	52	theme	intact	1064:1069	arg1	lack					1088:1091	lack	1088:1091	lack of pY	1088:1097	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	6	52	theme	intact	1064:1069	arg1	channel					1079:1085	intact CatSper channel	1064:1085	intact CatSper channel	1064:1085	Together, we reveal that fertilizing mouse spermatozoa in situ are characterized by intact CatSper channel, lack of pY, and reacted acrosomes.
33078708	5	53	theme	molecular	776:784	arg1	imaging					786:792	3D in situ molecular imaging	765:792	3D in situ molecular imaging	765:792	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	0	54	dep	in	3:4	arg1	situ					6:9	situ	6:9	situ	6:9	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	5	55	theme	female	867:872	arg1	tract					874:878	the cleared female tract	855:878	the cleared female tract	855:878	Using 3D in situ molecular imaging and ANN-based automatic detection of sperm distributed along the cleared female tract, we demonstrate that spermatozoa past the utero-tubal junction possess the intact CatSper1 signals.
33078708	3	56	theme	glycosylated	511:522	arg1	CatSper1					487:494	CatSper1	487:494	CatSper1	487:494	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	3	56	theme	glycosylated	511:522	arg1	protein					524:530	an O-linked glycosylated protein	499:530	an O-linked glycosylated protein	499:530	Here using biochemical and pharmacological studies, we demonstrate that CatSper1 is an O-linked glycosylated protein, undergoing capacitation-induced processing dependent on Ca2+ and phosphorylation cascades.
33078708	4	57	theme	protein	660:666	arg1	pY					694:695	pY	694:695	pY	694:695	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	4	57	theme	protein	660:666	arg1	phosphorylation					677:691	protein tyrosine phosphorylation	660:691	protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo	660:756	CatSper1 processing correlates with protein tyrosine phosphorylation (pY) development in sperm cells capacitated in vitro and in vivo.
33078708	0	58	theme	tract	46:50	arg1	imaging					11:17	3D in situ imaging	0:17	3D in situ imaging of the female reproductive tract	0:50	3D in situ imaging of the female reproductive tract reveals molecular signatures of fertilizing spermatozoa in mice.
33078708	7	59	theme	reproductive	1228:1239	arg1	tract					1241:1245	the female reproductive tract	1217:1245	the female reproductive tract	1217:1245	These findings provide molecular insight into sperm selection for successful fertilization in the female reproductive tract.
33078708	2	60	theme	signaling	216:224	arg1	nanodomains					226:236	Flagellar Ca2+ signaling nanodomains	201:236	Flagellar Ca2+ signaling nanodomains	201:236	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
33078708	2	61	theme	female	340:345	arg1	tract					347:351	the female tract	336:351	the female tract	336:351	Flagellar Ca2+ signaling nanodomains, organized by multi-subunit CatSper calcium channel complexes, are pivotal for sperm migration in the female tract, implicating CatSper-dependent mechanisms in sperm selection.
32691273	10	0	theme	signal	1519:1524	arg1	transduction					1526:1537	the insulin signal transduction	1507:1537	the insulin signal transduction	1507:1537	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	7	1	theme	state	1070:1074	arg1	impact					1047:1052	the impact	1043:1052	the impact of the cellular state of insulin sensibility on this hypothesis	1043:1116	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	3	2	theme	small	499:503	arg1	sensor					589:594	a nutrient sensor	578:594	a nutrient sensor	578:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	2	theme	small	499:503	arg1	branch					505:510	a small branch	497:510	a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor	497:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	2	theme	small	499:503	arg1	pathway					480:486	The hexosamine biosynthesis pathway	452:486	The hexosamine biosynthesis pathway (HBP)	452:492	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	13	3	theme	only	1961:1964	arg1	gene					1942:1945	the OGT gene	1934:1945	the OGT gene	1934:1945	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	13	3	theme	only	1961:1964	arg1	gene					1966:1969	the only gene	1957:1969	the only gene	1957:1969	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	10	4	theme	protein	1549:1555	arg1	response					1557:1564	unfolded protein response	1540:1564	unfolded protein response	1540:1564	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	13	5	theme	OGT	1938:1940	arg1	gene					1942:1945	the OGT gene	1934:1945	the OGT gene	1934:1945	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	13	5	theme	OGT	1938:1940	arg1	gene					1966:1969	the only gene	1957:1969	the only gene	1957:1969	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	14	6	theme	insulin	2218:2224	arg1	signaling					2235:2243	insulin receptor signaling	2218:2243	insulin receptor signaling	2218:2243	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	8	7	theme	insulin-sensitive	1135:1151	arg1	preadipocytes					1153:1165	insulin-sensitive preadipocytes	1135:1165	insulin-sensitive preadipocytes	1135:1165	So, we employed insulin-sensitive preadipocytes and insulin-resistant adipocytes to answer these questions.
32691273	6	8	theme	positive	919:926	arg1	control					937:943	a positive internal control	917:943	a positive internal control	917:943	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	6	8	theme	positive	919:926	arg1	stressor					991:998	a widely-used endoplasmic reticulum stressor	955:998	a widely-used endoplasmic reticulum stressor	955:998	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	6	8	theme	positive	919:926	arg1	cells					891:895	cells	891:895	cells	891:895	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	7	9	theme	in	1013:1014	arg1	models					1022:1027	two in vitro models	1009:1027	two in vitro models	1009:1027	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	13	10	theme	stimulated	2119:2128	arg1	modification					2139:2150	the externally stimulated O-GlcNAc modification	2104:2150	the externally stimulated O-GlcNAc modification conditions	2104:2161	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	7	11	used	used	1004:1007	arg2	We					1001:1002	We	1001:1002	We	1001:1002	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	10	12	from	role	1451:1454	arg1	response					1557:1564	unfolded protein response	1540:1564	unfolded protein response	1540:1564	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	10	12	from	role	1451:1454	arg1	HBP					1571:1573	HBP	1571:1573	HBP	1571:1573	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	10	12	from	role	1451:1454	arg1	transduction					1526:1537	the insulin signal transduction	1507:1537	the insulin signal transduction	1507:1537	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	4	13	theme	signal	697:702	arg1	transduction					704:715	the insulin signal transduction	685:715	the insulin signal transduction	685:715	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	14	14	theme	insulin	2339:2345	arg1	resistance					2347:2356	insulin resistance	2339:2356	insulin resistance	2339:2356	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	6	15	theme	endoplasmic	969:979	arg1	reticulum					981:989	a widely-used endoplasmic reticulum	955:989	a widely-used endoplasmic reticulum stressor	955:998	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	2	16	theme	nuclear	421:427	arg1	proteins					442:449	the nuclear and cellular proteins	417:449	the nuclear and cellular proteins	417:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	4	17	theme	O-GlcNAc	651:658	arg1	stimulus					673:680	external O-GlcNAc modification stimulus	642:680	external O-GlcNAc modification stimulus	642:680	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	15	18	theme	reticulum	2457:2465	arg1	stress					2467:2472	endoplasmic reticulum stress	2445:2472	endoplasmic reticulum stress	2445:2472	Therefore, it can be a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress.
32691273	15	19	dep	potential	2382:2390	arg1	therapeutic					2392:2402	therapeutic	2392:2402	therapeutic	2392:2402	Therefore, it can be a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress.
32691273	4	20	theme	stimulus	673:680	arg1	impact					632:637	the impact	628:637	the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells	628:767	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	13	21	theme	proteins	1890:1897	arg1	O-GlcNAcylation					1861:1875	reduced O-GlcNAcylation	1853:1875	reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule,	1853:2016	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	0	22	theme	reticulum	72:80	arg1	stress					82:87	endoplasmic reticulum stress	60:87	endoplasmic reticulum stress	60:87	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	13	23	theme	reticulum	2066:2074	arg1	stress					2076:2081	endoplasmic reticulum stress	2054:2081	endoplasmic reticulum stress	2054:2081	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	4	24	from	HBP	749:751	arg1	cells					763:767	3T3-L1 cells	756:767	3T3-L1 cells	756:767	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	1	25	theme	post-translational	152:169	arg1	modification					179:190	a post-translational protein modification	150:190	a post-translational protein modification that regulates cell signaling and involves in several pathological conditions	150:268	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	1	25	theme	post-translational	152:169	arg1	N-acetyl-glucosamine					115:134	O-linked N-acetyl-glucosamine	106:134	O-linked N-acetyl-glucosamine (O-GlcNAc)	106:145	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	0	26	from	Role	0:3	arg1	stress					82:87	endoplasmic reticulum stress	60:87	endoplasmic reticulum stress	60:87	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	0	26	from	Role	0:3	arg1	resistance					45:54	insulin resistance	37:54	insulin resistance	37:54	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	10	27	theme	above-mentioned	1407:1421	arg1	compounds					1423:1431	the above-mentioned compounds	1403:1431	the above-mentioned compounds	1403:1431	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	14	28	theme	total	2308:2312	arg1	proteins					2314:2321	total proteins	2308:2321	total proteins	2308:2321	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	9	29	theme	insulin-resistant	1271:1287	arg1	model					1302:1306	the insulin-resistant preadipocyte model	1267:1306	the insulin-resistant preadipocyte model	1267:1306	Secondly, the OGT-silencing achieved in the insulin-resistant preadipocyte model by using the short-hairpin RNA (shRNA) interference method.
32691273	2	30	theme	threonine	395:403	arg1	proteins					442:449	the nuclear and cellular proteins	417:449	the nuclear and cellular proteins	417:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	2	30	theme	threonine	395:403	arg1	residues					405:412	the serine or threonine residues	381:412	residues	405:412	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	13	31	theme	insulin	2031:2037	arg1	resistance					2039:2048	insulin resistance	2031:2048	insulin resistance	2031:2048	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	2	32	theme	serine	385:390	arg1	proteins					442:449	the nuclear and cellular proteins	417:449	the nuclear and cellular proteins	417:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	2	32	theme	serine	385:390	arg1	residues					405:412	the serine or threonine residues	381:412	residues	405:412	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	2	33	theme	cellular	433:440	arg1	proteins					442:449	the nuclear and cellular proteins	417:449	the nuclear and cellular proteins	417:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	2	34	theme	O-GlcNAc	271:278	arg1	OGT					293:295	OGT	293:295	OGT	293:295	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	2	34	theme	O-GlcNAc	271:278	arg1	transferase					280:290	O-GlcNAc transferase	271:290	O-GlcNAc transferase (OGT)	271:296	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	10	35	theme	protein	1483:1489	arg1	modification					1491:1502	the diminished O-GlcNAc protein modification	1459:1502	the diminished O-GlcNAc protein modification	1459:1502	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	4	36	theme	protein	727:733	arg1	response					735:742	unfolded protein response	718:742	unfolded protein response	718:742	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	3	37	theme	biosynthesis	467:478	arg1	branch					505:510	a small branch	497:510	a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor	497:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	37	theme	biosynthesis	467:478	arg1	HBP					489:491	HBP	489:491	HBP	489:491	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	37	theme	biosynthesis	467:478	arg1	pathway					480:486	The hexosamine biosynthesis pathway	452:486	The hexosamine biosynthesis pathway (HBP)	452:492	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	9	38	theme	short-hairpin	1321:1333	arg1	shRNA					1340:1344	shRNA	1340:1344	shRNA	1340:1344	Secondly, the OGT-silencing achieved in the insulin-resistant preadipocyte model by using the short-hairpin RNA (shRNA) interference method.
32691273	9	38	theme	short-hairpin	1321:1333	arg1	RNA					1335:1337	short-hairpin RNA	1321:1337	the short-hairpin RNA (shRNA) interference method	1317:1365	Secondly, the OGT-silencing achieved in the insulin-resistant preadipocyte model by using the short-hairpin RNA (shRNA) interference method.
32691273	7	39	from	impact	1047:1052	arg1	hypothesis					1107:1116	this hypothesis	1102:1116	this hypothesis	1102:1116	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	10	40	theme	diminished	1463:1472	arg1	modification					1491:1502	the diminished O-GlcNAc protein modification	1459:1502	the diminished O-GlcNAc protein modification	1459:1502	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	11	41	theme	endoplasmic	1696:1706	arg1	stress					1718:1723	endoplasmic reticulum stress	1696:1723	endoplasmic reticulum stress	1696:1723	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
32691273	14	42	theme	unfolded	2249:2256	arg1	response					2266:2273	unfolded protein response	2249:2273	unfolded protein response	2249:2273	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	0	43	theme	modification	21:32	arg1	Role					0:3	Role	0:3	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.	0:104	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	10	44	theme	insulin	1511:1517	arg1	transduction					1526:1537	the insulin signal transduction	1507:1537	the insulin signal transduction	1507:1537	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	13	45	theme	O-GlcNAc	1999:2006	arg1	molecule					2008:2015	the O-GlcNAc molecule	1995:2015	the O-GlcNAc molecule	1995:2015	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	7	46	theme	insulin	1079:1085	arg1	sensibility					1087:1097	insulin sensibility	1079:1097	insulin sensibility	1079:1097	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	12	47	theme	sensitivity	1830:1840	arg1	state					1813:1817	the cellular state	1800:1817	the cellular state of insulin sensitivity	1800:1840	Furthermore, we identified that the degree of this correlation depends on the cellular state of insulin sensitivity.
32691273	12	48	theme	insulin	1822:1828	arg1	sensitivity					1830:1840	insulin sensitivity	1822:1840	insulin sensitivity	1822:1840	Furthermore, we identified that the degree of this correlation depends on the cellular state of insulin sensitivity.
32691273	1	49	link	O-linked	106:113	arg1	O-GlcNAc					137:144	O-GlcNAc	137:144	O-GlcNAc	137:144	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	1	49	link	O-linked	106:113	arg1	N-acetyl-glucosamine					115:134	O-linked N-acetyl-glucosamine	106:134	O-linked N-acetyl-glucosamine (O-GlcNAc)	106:145	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	1	49	link	O-linked	106:113	arg1	modification					179:190	a post-translational protein modification	150:190	a post-translational protein modification that regulates cell signaling and involves in several pathological conditions	150:268	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	4	50	theme	3T3-L1	756:761	arg1	cells					763:767	3T3-L1 cells	756:767	3T3-L1 cells	756:767	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	10	51	theme	unfolded	1540:1547	arg1	response					1557:1564	unfolded protein response	1540:1564	unfolded protein response	1540:1564	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	1	52	theme	pathological	246:257	arg1	conditions					259:268	several pathological conditions	238:268	several pathological conditions	238:268	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	14	53	theme	receptor	2226:2233	arg1	signaling					2235:2243	insulin receptor signaling	2218:2243	insulin receptor signaling	2218:2243	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	7	54	theme	cellular	1061:1068	arg1	state					1070:1074	the cellular state	1057:1074	the cellular state of insulin sensibility	1057:1097	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	11	55	theme	elevated	1590:1597	arg1	O-GlcNAcylation					1599:1613	elevated O-GlcNAcylation	1590:1613	elevated O-GlcNAcylation of the total proteins	1590:1635	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
32691273	2	56	theme	GlcNAc	359:364	arg1	molecules					366:374	the GlcNAc molecules	355:374	the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins	355:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	13	57	theme	modification	2139:2150	arg1	conditions					2152:2161	the externally stimulated O-GlcNAc modification conditions	2104:2161	the externally stimulated O-GlcNAc modification conditions	2104:2161	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	15	58	theme	endoplasmic	2445:2455	arg1	stress					2467:2472	endoplasmic reticulum stress	2445:2472	endoplasmic reticulum stress	2445:2472	Therefore, it can be a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress.
32691273	14	59	dep	resistance	2347:2356	arg1	response					2327:2334	response	2327:2334	response	2327:2334	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	11	60	theme	total	1622:1626	arg1	proteins					1628:1635	the total proteins	1618:1635	the total proteins	1618:1635	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
32691273	3	61	theme	glycolysis	515:524	arg1	sensor					589:594	a nutrient sensor	578:594	a nutrient sensor	578:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	61	theme	glycolysis	515:524	arg1	branch					505:510	a small branch	497:510	a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor	497:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	61	theme	glycolysis	515:524	arg1	pathway					480:486	The hexosamine biosynthesis pathway	452:486	The hexosamine biosynthesis pathway (HBP)	452:492	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	4	62	from	impact	632:637	arg1	transduction					704:715	the insulin signal transduction	685:715	the insulin signal transduction	685:715	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	4	62	from	impact	632:637	arg1	response					735:742	unfolded protein response	718:742	unfolded protein response	718:742	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	4	62	from	impact	632:637	arg1	HBP					749:751	HBP	749:751	HBP in 3T3-L1 cells	749:767	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	1	63	theme	protein	171:177	arg1	modification					179:190	a post-translational protein modification	150:190	a post-translational protein modification that regulates cell signaling and involves in several pathological conditions	150:268	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	1	63	theme	protein	171:177	arg1	N-acetyl-glucosamine					115:134	O-linked N-acetyl-glucosamine	106:134	O-linked N-acetyl-glucosamine (O-GlcNAc)	106:145	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	0	64	theme	insulin	37:43	arg1	resistance					45:54	insulin resistance	37:54	insulin resistance	37:54	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	11	65	theme	definite	1649:1656	arg1	correlation					1658:1668	a definite correlation	1647:1668	a definite correlation	1647:1668	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
32691273	13	66	theme	gene	1942:1945	arg1	silencing					1921:1929	the shRNA-mediated silencing	1902:1929	the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule,	1902:2016	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	15	67	theme	insulin	2422:2428	arg1	resistance					2430:2439	insulin resistance	2422:2439	insulin resistance	2422:2439	Therefore, it can be a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress.
32691273	6	68	theme	internal	928:935	arg1	control					937:943	a positive internal control	917:943	a positive internal control	917:943	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	6	68	theme	internal	928:935	arg1	stressor					991:998	a widely-used endoplasmic reticulum stressor	955:998	a widely-used endoplasmic reticulum stressor	955:998	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	6	68	theme	internal	928:935	arg1	cells					891:895	cells	891:895	cells	891:895	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	1	69	theme	cell	207:210	arg1	signaling					212:220	cell signaling	207:220	cell signaling	207:220	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	0	70	from	stress	82:87	arg1	cells					99:103	3T3-L1 cells	92:103	3T3-L1 cells	92:103	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	5	71	theme	proteins	864:871	arg1	O-GlcNAcylation					839:853	the O-GlcNAcylation	835:853	the O-GlcNAcylation of total proteins	835:871	First, we treated cells with glucosamine and PUGNAc to stimulate the O-GlcNAcylation of total proteins.
32691273	15	72	theme	potential	2382:2390	arg1	it					2370:2371	it	2370:2371	it	2370:2371	Therefore, it can be a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress.
32691273	15	72	theme	potential	2382:2390	arg1	target					2404:2409	a potential therapeutic target	2380:2409	a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress	2380:2472	Therefore, it can be a potential therapeutic target to prevent insulin resistance and endoplasmic reticulum stress.
32691273	13	73	theme	O-GlcNAc	2130:2137	arg1	modification					2139:2150	the externally stimulated O-GlcNAc modification	2104:2150	the externally stimulated O-GlcNAc modification conditions	2104:2161	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	1	74	theme	O-linked	106:113	arg1	O-GlcNAc					137:144	O-GlcNAc	137:144	O-GlcNAc	137:144	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	1	74	theme	O-linked	106:113	arg1	N-acetyl-glucosamine					115:134	O-linked N-acetyl-glucosamine	106:134	O-linked N-acetyl-glucosamine (O-GlcNAc)	106:145	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	1	74	theme	O-linked	106:113	arg1	modification					179:190	a post-translational protein modification	150:190	a post-translational protein modification that regulates cell signaling and involves in several pathological conditions	150:268	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	8	75	theme	insulin-resistant	1171:1187	arg1	adipocytes					1189:1198	insulin-resistant adipocytes	1171:1198	insulin-resistant adipocytes	1171:1198	So, we employed insulin-sensitive preadipocytes and insulin-resistant adipocytes to answer these questions.
32691273	13	76	theme	shRNA-mediated	1906:1919	arg1	silencing					1921:1929	the shRNA-mediated silencing	1902:1929	the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule,	1902:2016	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	6	77	theme	reticulum	981:989	arg1	stressor					991:998	a widely-used endoplasmic reticulum stressor	955:998	a widely-used endoplasmic reticulum stressor	955:998	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	6	77	theme	reticulum	981:989	arg1	control					937:943	a positive internal control	917:943	a positive internal control	917:943	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	6	77	theme	reticulum	981:989	arg1	cells					891:895	cells	891:895	cells	891:895	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	4	78	theme	insulin	689:695	arg1	transduction					704:715	the insulin signal transduction	685:715	the insulin signal transduction	685:715	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	0	79	theme	endoplasmic	60:70	arg1	stress					82:87	endoplasmic reticulum stress	60:87	endoplasmic reticulum stress	60:87	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	3	80	theme	nutrient	580:587	arg1	sensor					589:594	a nutrient sensor	578:594	a nutrient sensor	578:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	80	theme	nutrient	580:587	arg1	branch					505:510	a small branch	497:510	a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor	497:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	6	81	theme	widely-used	957:967	arg1	reticulum					981:989	a widely-used endoplasmic reticulum	955:989	a widely-used endoplasmic reticulum stressor	955:998	Also, we treated cells with tunicamycin as a positive internal control, which is a widely-used endoplasmic reticulum stressor.
32691273	4	82	theme	external	642:649	arg1	stimulus					673:680	external O-GlcNAc modification stimulus	642:680	external O-GlcNAc modification stimulus	642:680	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	13	83	theme	total	1884:1888	arg1	proteins					1890:1897	the total proteins	1880:1897	the total proteins	1880:1897	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	13	84	theme	endoplasmic	2054:2064	arg1	stress					2076:2081	endoplasmic reticulum stress	2054:2081	endoplasmic reticulum stress	2054:2081	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	5	85	theme	total	858:862	arg1	proteins					864:871	total proteins	858:871	total proteins	858:871	First, we treated cells with glucosamine and PUGNAc to stimulate the O-GlcNAcylation of total proteins.
32691273	4	86	theme	modification	660:671	arg1	stimulus					673:680	external O-GlcNAc modification stimulus	642:680	external O-GlcNAc modification stimulus	642:680	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	14	87	theme	proteins	2314:2321	arg1	levels					2298:2303	O-GlcNAc levels	2289:2303	O-GlcNAc levels of total proteins	2289:2321	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	0	88	theme	3T3-L1	92:97	arg1	cells					99:103	3T3-L1 cells	92:103	3T3-L1 cells	92:103	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	13	89	theme	stress	2076:2081	arg1	phenotype					2083:2091	the insulin resistance and endoplasmic reticulum stress phenotype	2027:2091	the insulin resistance and endoplasmic reticulum stress phenotype	2027:2091	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	0	90	from	resistance	45:54	arg1	cells					99:103	3T3-L1 cells	92:103	3T3-L1 cells	92:103	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	13	91	theme	reduced	1853:1859	arg1	O-GlcNAcylation					1861:1875	reduced O-GlcNAcylation	1853:1875	reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule,	1853:2016	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	9	92	theme	preadipocyte	1289:1300	arg1	model					1302:1306	the insulin-resistant preadipocyte model	1267:1306	the insulin-resistant preadipocyte model	1267:1306	Secondly, the OGT-silencing achieved in the insulin-resistant preadipocyte model by using the short-hairpin RNA (shRNA) interference method.
32691273	4	93	from	response	735:742	arg1	cells					763:767	3T3-L1 cells	756:767	3T3-L1 cells	756:767	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	14	94	theme	O-GlcNAc	2289:2296	arg1	levels					2298:2303	O-GlcNAc levels	2289:2303	O-GlcNAc levels of total proteins	2289:2321	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	13	95	theme	resistance	2039:2048	arg1	phenotype					2083:2091	the insulin resistance and endoplasmic reticulum stress phenotype	2027:2091	the insulin resistance and endoplasmic reticulum stress phenotype	2027:2091	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	2	96	theme	proteins	442:449	arg1	proteins					442:449	the nuclear and cellular proteins	417:449	the nuclear and cellular proteins	417:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	2	96	theme	proteins	442:449	arg1	residues					405:412	the serine or threonine residues	381:412	residues	405:412	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	0	97	theme	O-GlcNAc	12:19	arg1	modification					21:32	the O-GlcNAc modification	8:32	the O-GlcNAc modification	8:32	Role of the O-GlcNAc modification on insulin resistance and endoplasmic reticulum stress in 3T3-L1 cells.
32691273	4	98	from	transduction	704:715	arg1	cells					763:767	3T3-L1 cells	756:767	3T3-L1 cells	756:767	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	12	99	theme	correlation	1777:1787	arg1	degree					1762:1767	the degree	1758:1767	the degree of this correlation	1758:1787	Furthermore, we identified that the degree of this correlation depends on the cellular state of insulin sensitivity.
32691273	10	100	theme	O-GlcNAc	1474:1481	arg1	modification					1491:1502	the diminished O-GlcNAc protein modification	1459:1502	the diminished O-GlcNAc protein modification	1459:1502	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	4	101	theme	unfolded	718:725	arg1	response					735:742	unfolded protein response	718:742	unfolded protein response	718:742	In this study, we investigated the impact of external O-GlcNAc modification stimulus on the insulin signal transduction, unfolded protein response, and HBP in 3T3-L1 cells.
32691273	14	102	theme	protein	2258:2264	arg1	response					2266:2273	unfolded protein response	2249:2273	unfolded protein response	2249:2273	In conclusion, our results suggest that OGT regulates insulin receptor signaling and unfolded protein response by modulating O-GlcNAc levels of total proteins, in response to insulin resistance.
32691273	7	103	theme	sensibility	1087:1097	arg1	state					1070:1074	the cellular state	1057:1074	the cellular state of insulin sensibility	1057:1097	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	9	104	theme	RNA	1335:1337	arg1	method					1360:1365	the short-hairpin RNA (shRNA) interference method	1317:1365	the short-hairpin RNA (shRNA) interference method	1317:1365	Secondly, the OGT-silencing achieved in the insulin-resistant preadipocyte model by using the short-hairpin RNA (shRNA) interference method.
32691273	11	105	theme	insulin	1673:1679	arg1	resistance					1681:1690	insulin resistance	1673:1690	insulin resistance	1673:1690	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
32691273	3	106	theme	hexosamine	456:465	arg1	branch					505:510	a small branch	497:510	a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor	497:594	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	106	theme	hexosamine	456:465	arg1	HBP					489:491	HBP	489:491	HBP	489:491	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	3	106	theme	hexosamine	456:465	arg1	pathway					480:486	The hexosamine biosynthesis pathway	452:486	The hexosamine biosynthesis pathway (HBP)	452:492	The hexosamine biosynthesis pathway (HBP) is a small branch of glycolysis that provides a substrate for the OGT and serves as a nutrient sensor.
32691273	12	107	theme	cellular	1804:1811	arg1	state					1813:1817	the cellular state	1800:1817	the cellular state of insulin sensitivity	1800:1840	Furthermore, we identified that the degree of this correlation depends on the cellular state of insulin sensitivity.
32691273	9	108	theme	interference	1347:1358	arg1	method					1360:1365	the short-hairpin RNA (shRNA) interference method	1317:1365	the short-hairpin RNA (shRNA) interference method	1317:1365	Secondly, the OGT-silencing achieved in the insulin-resistant preadipocyte model by using the short-hairpin RNA (shRNA) interference method.
32691273	13	109	with	proteins	1981:1988	arg1	molecule					2008:2015	the O-GlcNAc molecule	1995:2015	the O-GlcNAc molecule	1995:2015	Moreover, reduced O-GlcNAcylation of the total proteins by the shRNA-mediated silencing of the OGT gene, which is the only gene to modify proteins with the O-GlcNAc molecule, reversed the insulin resistance and endoplasmic reticulum stress phenotype, even with the externally stimulated O-GlcNAc modification conditions.
32691273	10	110	theme	modification	1491:1502	arg1	role					1451:1454	the role	1447:1454	the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP	1447:1573	Thereafter, the cells treated with the above-mentioned compounds to understand the role of the diminished O-GlcNAc protein modification on the insulin signal transduction, unfolded protein response, and HBP.
32691273	11	111	theme	reticulum	1708:1716	arg1	stress					1718:1723	endoplasmic reticulum stress	1696:1723	endoplasmic reticulum stress	1696:1723	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
32691273	1	112	theme	several	238:244	arg1	conditions					259:268	several pathological conditions	238:268	several pathological conditions	238:268	O-linked N-acetyl-glucosamine (O-GlcNAc) is a post-translational protein modification that regulates cell signaling and involves in several pathological conditions.
32691273	2	113	from	residues	405:412	arg1	molecules					366:374	the GlcNAc molecules	355:374	the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins	355:449	O-GlcNAc transferase (OGT) catalyzes the attachment, while O-GlcNAcase (OGA) splits the GlcNAc molecules from the serine or threonine residues of the nuclear and cellular proteins.
32691273	7	114	dep	in	1013:1014	arg1	vitro					1016:1020	vitro	1016:1020	vitro	1016:1020	We used two in vitro models to understand the impact of the cellular state of insulin sensibility on this hypothesis.
32691273	11	115	theme	proteins	1628:1635	arg1	O-GlcNAcylation					1599:1613	elevated O-GlcNAcylation	1590:1613	elevated O-GlcNAcylation of the total proteins	1590:1635	We found that elevated O-GlcNAcylation of the total proteins displayed a definite correlation in insulin resistance and endoplasmic reticulum stress.
34053187	8	0	from	abnormalities	1212:1224	arg1	distribution					1242:1253	VWF multimer distribution	1229:1253	VWF multimer distribution	1229:1253	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	10	1	gly	sialylation	1487:1497	arg1	COVID-19					1522:1529	severe COVID-19	1515:1529	severe COVID-19	1515:1529	We observed that both N- and O-linked sialylation were altered in severe COVID-19.
34053187	2	2	theme	ThrombSpondin	350:362	arg1	type					370:373	ThrombSpondin Motif type 1	350:375	ThrombSpondin Motif type 1 motif	350:381	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	8	3	theme	VWF	1191:1193	arg1	ratio					1205:1209	VWF:ADAMTS-13 ratio	1191:1209	VWF:ADAMTS-13 ratio	1191:1209	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	11	4	theme	ADAMTS-13	1566:1574	arg1	interleukin-6					1587:1599	interleukin-6	1587:1599	interleukin-6	1587:1599	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	4	theme	ADAMTS-13	1566:1574	arg1	factor					1633:1638	platelet factor 4	1624:1640	platelet factor 4	1624:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	4	theme	ADAMTS-13	1566:1574	arg1	inhibitors					1576:1585	the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1562:1640	the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1562:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	4	theme	ADAMTS-13	1566:1574	arg1	thrombospondin-1					1602:1617	thrombospondin-1	1602:1617	thrombospondin-1	1602:1617	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	3	5	theme	severe	553:558	arg1	infection					614:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection	553:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis	553:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	8	6	theme	ADAMTS-13	1195:1203	arg1	ratio					1205:1209	VWF:ADAMTS-13 ratio	1191:1209	VWF:ADAMTS-13 ratio	1191:1209	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	13	7	theme	Further	1886:1892	arg1	studies					1894:1900	Further studies	1886:1900	Further studies	1886:1900	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	7	8	theme	median	1140:1145	arg1	68.2 IU/dl					1147:1156	median 68.2 IU/dl	1140:1156	median 68.2 IU/dl	1140:1156	Conversely, plasma ADAMTS-13 activity was significantly reduced (median 68.2 IU/dl).
34053187	5	9	theme	known	878:882	arg1	inhibitors					884:893	known inhibitors	878:893	known inhibitors thereof	878:901	Plasma VWF antigen, multimer distribution, ADAMTS-13 activity, and known inhibitors thereof were assessed.
34053187	12	10	theme	VWF	1814:1816	arg1	levels					1818:1823	plasma VWF levels	1807:1823	plasma VWF levels	1807:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	6	11	theme	severe	1004:1009	arg1	COVID-19					1011:1018	severe COVID-19	1004:1018	severe COVID-19	1004:1018	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	13	12	from	thrombosis	2049:2058	arg1	useful					2019:2024	useful	2019:2024	useful	2019:2024	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	3	13	theme	respiratory	566:576	arg1	infection					614:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection	553:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis	553:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	5	14	theme	ADAMTS-13	854:862	arg1	activity					864:871	ADAMTS-13 activity	854:871	ADAMTS-13 activity	854:871	Plasma VWF antigen, multimer distribution, ADAMTS-13 activity, and known inhibitors thereof were assessed.
34053187	8	15	theme	multimer	1233:1240	arg1	distribution					1242:1253	VWF multimer distribution	1229:1253	VWF multimer distribution	1229:1253	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	7	16	dep	reduced	1131:1137	arg1	68.2 IU/dl					1147:1156	median 68.2 IU/dl	1140:1156	median 68.2 IU/dl	1140:1156	Conversely, plasma ADAMTS-13 activity was significantly reduced (median 68.2 IU/dl).
34053187	7	17	theme	ADAMTS-13	1094:1102	arg1	activity					1104:1111	plasma ADAMTS-13 activity	1087:1111	plasma ADAMTS-13 activity	1087:1111	Conversely, plasma ADAMTS-13 activity was significantly reduced (median 68.2 IU/dl).
34053187	5	18	theme	multimer	831:838	arg1	distribution					840:851	multimer distribution	831:851	multimer distribution	831:851	Plasma VWF antigen, multimer distribution, ADAMTS-13 activity, and known inhibitors thereof were assessed.
34053187	12	19	from	increases	1794:1802	arg1	levels					1818:1823	plasma VWF levels	1807:1823	plasma VWF levels	1807:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	12	19	from	increases	1794:1802	arg1	function					1876:1883	ADAMTS-13 function	1866:1883	ADAMTS-13 function	1866:1883	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	8	20	theme	high	1313:1316	arg1	multimers					1339:1347	high molecular weight VWF multimers	1313:1347	high molecular weight VWF multimers	1313:1347	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	6	21	theme	VWF	957:959	arg1	activity					978:985	markedly increased VWF collagen-binding activity	938:985	markedly increased VWF collagen-binding activity in patients with severe COVID-19	938:1018	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	8	22	theme	weight	1328:1333	arg1	multimers					1339:1347	high molecular weight VWF multimers	1313:1347	high molecular weight VWF multimers	1313:1347	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	13	23	from	useful	2019:2024	arg1	angiopathy					2064:2073	angiopathy	2064:2073	angiopathy	2064:2073	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	13	23	from	useful	2019:2024	arg1	thrombosis					2049:2058	COVID-microvascular thrombosis	2029:2058	COVID-microvascular thrombosis	2029:2058	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	3	24	theme	microvascular	653:665	arg1	thrombosis					667:676	the observed microvascular thrombosis	640:676	the observed microvascular thrombosis	640:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	8	25	from	reductions	1299:1308	arg1	multimers					1339:1347	high molecular weight VWF multimers	1313:1347	high molecular weight VWF multimers	1313:1347	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	1	26	theme	plasma	144:149	arg1	VWF					174:176	VWF	174:176	VWF	174:176	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	1	26	theme	plasma	144:149	arg1	factor					166:171	plasma von Willebrand factor	144:171	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	12	27	theme	plasma	1807:1812	arg1	levels					1818:1823	plasma VWF levels	1807:1823	plasma VWF levels	1807:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	4	28	theme	Beaumont	756:763	arg1	ICU					795:797	ICU	795:797	ICU	795:797	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	28	theme	Beaumont	756:763	arg1	Unit					789:792	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	10	29	link	O-linked	1478:1485	arg1	sialylation					1487:1497	O-linked sialylation	1478:1497	O-linked sialylation	1478:1497	We observed that both N- and O-linked sialylation were altered in severe COVID-19.
34053187	1	30	theme	Willebrand	155:164	arg1	VWF					174:176	VWF	174:176	VWF	174:176	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	1	30	theme	Willebrand	155:164	arg1	factor					166:171	plasma von Willebrand factor	144:171	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	12	31	theme	profound	1756:1763	arg1	increases					1794:1802	profound quantitative and qualitative increases	1756:1802	profound quantitative and qualitative increases in plasma VWF levels	1756:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	6	32	theme	median	1042:1047	arg1	509.1					1049:1053	median 509.1	1042:1053	median 509.1	1042:1053	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	6	33	dep	controls	1032:1039	arg1	509.1					1049:1053	median 509.1	1042:1053	median 509.1	1042:1053	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	6	33	dep	controls	1032:1039	arg1	94.3 IU/dl					1062:1071	94.3 IU/dl	1062:1071	94.3 IU/dl	1062:1071	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	2	34	theme	VWF	276:278	arg1	function					264:271	function	264:271	function	264:271	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	2	34	theme	VWF	276:278	arg1	size					255:258	multimeric size	244:258	multimeric size	244:258	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	13	35	from	angiopathy	2064:2073	arg1	useful					2019:2024	useful	2019:2024	useful	2019:2024	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	10	36	theme	severe	1515:1520	arg1	COVID-19					1522:1529	severe COVID-19	1515:1529	severe COVID-19	1515:1529	We observed that both N- and O-linked sialylation were altered in severe COVID-19.
34053187	12	37	from	down-regulation	1847:1861	arg1	levels					1818:1823	plasma VWF levels	1807:1823	plasma VWF levels	1807:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	12	37	from	down-regulation	1847:1861	arg1	function					1876:1883	ADAMTS-13 function	1866:1883	ADAMTS-13 function	1866:1883	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	4	38	theme	Intensive	774:782	arg1	ICU					795:797	ICU	795:797	ICU	795:797	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	38	theme	Intensive	774:782	arg1	Unit					789:792	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	13	39	theme	ADAMTS-13-VWF	1977:1989	arg1	dysfunction					2000:2010	correct ADAMTS-13-VWF multimer dysfunction	1969:2010	correct ADAMTS-13-VWF multimer dysfunction	1969:2010	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	0	40	theme	ADAMTS13	0:7	arg1	regulation					9:18	ADAMTS13 regulation	0:18	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.	0:67	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
34053187	1	41	theme	fulminant	96:104	arg1	activation					123:132	fulminant endothelial cell activation	96:132	fulminant endothelial cell activation	96:132	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	2	42	theme	--mediated	405:414	arg1	proteolysis					416:426	member 13 (ADAMTS-13)--mediated proteolysis	384:426	member 13 (ADAMTS-13)--mediated proteolysis	384:426	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	2	42	theme	--mediated	405:414	arg1	Disintegrin					313:323	A Disintegrin	311:323	A Disintegrin	311:323	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	9	43	theme	VWF	1381:1383	arg1	susceptibility					1385:1398	VWF susceptibility	1381:1398	VWF susceptibility to proteolysis	1381:1413	Terminal sialylation regulates VWF susceptibility to proteolysis by ADAMTS-13 and other proteases.
34053187	8	44	from	increase	1179:1186	arg1	ratio					1205:1209	VWF:ADAMTS-13 ratio	1191:1209	VWF:ADAMTS-13 ratio	1191:1209	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	1	45	theme	cell	118:121	arg1	activation					123:132	fulminant endothelial cell activation	96:132	fulminant endothelial cell activation	96:132	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	13	46	theme	therapeutic	1940:1950	arg1	interventions					1952:1964	therapeutic interventions	1940:1964	therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction	1940:2010	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	0	47	theme	multimer	27:34	arg1	distribution					36:47	VWF multimer distribution	23:47	VWF multimer distribution	23:47	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
34053187	4	48	dep	PATIENTS	679:686	arg1	Patients					700:707	Patients	700:707	Patients	700:707	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	49	with	METHODS	692:698	arg1	n = 23					724:729	n = 23	724:729	n = 23	724:729	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	49	with	METHODS	692:698	arg1	COVID-19					714:721	COVID-19	714:721	COVID-19 (n = 23)	714:730	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	5	50	theme	VWF	818:820	arg1	antigen					822:828	Plasma VWF antigen	811:828	Plasma VWF antigen	811:828	Plasma VWF antigen, multimer distribution, ADAMTS-13 activity, and known inhibitors thereof were assessed.
34053187	4	51	with	PATIENTS	679:686	arg1	n = 23					724:729	n = 23	724:729	n = 23	724:729	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	51	with	PATIENTS	679:686	arg1	COVID-19					714:721	COVID-19	714:721	COVID-19 (n = 23)	714:730	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	3	52	theme	distribution	521:532	arg1	regulation					494:503	ADAMTS-13 regulation	484:503	ADAMTS-13 regulation of VWF multimer distribution	484:532	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	5	53	theme	Plasma	811:816	arg1	antigen					822:828	Plasma VWF antigen	811:828	Plasma VWF antigen	811:828	Plasma VWF antigen, multimer distribution, ADAMTS-13 activity, and known inhibitors thereof were assessed.
34053187	6	54	theme	increased	947:955	arg1	activity					978:985	markedly increased VWF collagen-binding activity	938:985	markedly increased VWF collagen-binding activity in patients with severe COVID-19	938:1018	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	1	55	with	patients	216:223	arg1	COVID-19					230:237	COVID-19	230:237	COVID-19	230:237	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	8	56	with	patients	1270:1277	arg1	COVID-19					1284:1291	COVID-19	1284:1291	COVID-19	1284:1291	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	2	57	theme	Motif	364:368	arg1	type					370:373	ThrombSpondin Motif type 1	350:375	ThrombSpondin Motif type 1 motif	350:381	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	12	58	theme	multifactorial	1832:1845	arg1	down-regulation					1847:1861	a multifactorial down-regulation	1830:1861	a multifactorial down-regulation in ADAMTS-13 function	1830:1883	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	8	59	with	common	1260:1265	arg1	reductions					1299:1308	reductions	1299:1308	reductions in high molecular weight VWF multimers	1299:1347	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	6	60	with	patients	990:997	arg1	COVID-19					1011:1018	severe COVID-19	1004:1018	severe COVID-19	1004:1018	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	12	61	dep	CONCLUSIONS	1671:1681	arg1	support					1698:1704	support	1698:1704	support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function	1698:1883	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	11	62	theme	inhibitors	1576:1585	arg1	levels					1552:1557	plasma levels	1545:1557	plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1545:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	63	theme	platelet	1624:1631	arg1	factor					1633:1638	platelet factor 4	1624:1640	platelet factor 4	1624:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	63	theme	platelet	1624:1631	arg1	inhibitors					1576:1585	the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1562:1640	the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1562:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	3	64	theme	syndrome-coronavirus-2	578:599	arg1	infection					614:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection	553:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis	553:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	1	65	theme	antigen	179:185	arg1	levels					187:192	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	2	66	dep	size	255:258	arg1	The					240:242	The	240:242	The	240:242	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	3	67	theme	acute	560:564	arg1	infection					614:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection	553:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis	553:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	3	68	theme	VWF	508:510	arg1	distribution					521:532	VWF multimer distribution	508:532	VWF multimer distribution	508:532	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	7	69	theme	plasma	1087:1092	arg1	activity					1104:1111	plasma ADAMTS-13 activity	1087:1111	plasma ADAMTS-13 activity	1087:1111	Conversely, plasma ADAMTS-13 activity was significantly reduced (median 68.2 IU/dl).
34053187	1	70	with	Consistent	80:89	arg1	activation					123:132	fulminant endothelial cell activation	96:132	fulminant endothelial cell activation	96:132	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	3	71	theme	SARS-CoV-2	602:611	arg1	infection					614:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection	553:622	severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis	553:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	8	72	from	patients	1270:1277	arg1	common					1260:1265	common	1260:1265	common	1260:1265	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	6	73	theme	collagen-binding	961:976	arg1	activity					978:985	markedly increased VWF collagen-binding activity	938:985	markedly increased VWF collagen-binding activity in patients with severe COVID-19	938:1018	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	3	74	theme	observed	644:651	arg1	thrombosis					667:676	the observed microvascular thrombosis	640:676	the observed microvascular thrombosis	640:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	8	75	from	common	1260:1265	arg1	patients					1270:1277	patients	1270:1277	patients with COVID-19	1270:1291	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	1	76	theme	elevated	135:142	arg1	levels					187:192	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	12	77	theme	qualitative	1782:1792	arg1	increases					1794:1802	profound quantitative and qualitative increases	1756:1802	profound quantitative and qualitative increases in plasma VWF levels	1756:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	8	78	theme	molecular	1318:1326	arg1	multimers					1339:1347	high molecular weight VWF multimers	1313:1347	high molecular weight VWF multimers	1313:1347	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	13	79	theme	COVID-microvascular	2029:2047	arg1	thrombosis					2049:2058	COVID-microvascular thrombosis	2029:2058	COVID-microvascular thrombosis	2029:2058	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	2	80	theme	multimeric	244:253	arg1	size					255:258	multimeric size	244:258	multimeric size	244:258	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	1	81	theme	von	151:153	arg1	VWF					174:176	VWF	174:176	VWF	174:176	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	1	81	theme	von	151:153	arg1	factor					166:171	plasma von Willebrand factor	144:171	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	8	82	theme	VWF	1335:1337	arg1	multimers					1339:1347	high molecular weight VWF multimers	1313:1347	high molecular weight VWF multimers	1313:1347	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	13	83	theme	multimer	1991:1998	arg1	dysfunction					2000:2010	correct ADAMTS-13-VWF multimer dysfunction	1969:2010	correct ADAMTS-13-VWF multimer dysfunction	1969:2010	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	1	84	theme	factor	166:171	arg1	levels					187:192	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	elevated plasma von Willebrand factor (VWF) antigen levels	135:192	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	0	85	from	regulation	9:18	arg1	COVID-19					59:66	severe COVID-19	52:66	severe COVID-19	52:66	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
34053187	10	86	theme	O-linked	1478:1485	arg1	sialylation					1487:1497	O-linked sialylation	1478:1497	O-linked sialylation	1478:1497	We observed that both N- and O-linked sialylation were altered in severe COVID-19.
34053187	11	87	theme	plasma	1545:1550	arg1	levels					1552:1557	plasma levels	1545:1557	plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1545:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	12	88	theme	quantitative	1765:1776	arg1	increases					1794:1802	profound quantitative and qualitative increases	1756:1802	profound quantitative and qualitative increases in plasma VWF levels	1756:1823	CONCLUSIONS These findings support the hypothesis that SARS-CoV-2 is associated with profound quantitative and qualitative increases in plasma VWF levels, and a multifactorial down-regulation in ADAMTS-13 function.
34053187	13	89	theme	correct	1969:1975	arg1	dysfunction					2000:2010	correct ADAMTS-13-VWF multimer dysfunction	1969:2010	correct ADAMTS-13-VWF multimer dysfunction	1969:2010	Further studies will be required to determine whether therapeutic interventions to correct ADAMTS-13-VWF multimer dysfunction may be useful in COVID-microvascular thrombosis and angiopathy.
34053187	2	90	theme	member	384:389	arg1	proteolysis					416:426	member 13 (ADAMTS-13)--mediated proteolysis	384:426	member 13 (ADAMTS-13)--mediated proteolysis	384:426	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	2	90	theme	member	384:389	arg1	Disintegrin					313:323	A Disintegrin	311:323	A Disintegrin	311:323	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	9	91	theme	Terminal	1350:1357	arg1	sialylation					1359:1369	Terminal sialylation	1350:1369	Terminal sialylation	1350:1369	Terminal sialylation regulates VWF susceptibility to proteolysis by ADAMTS-13 and other proteases.
34053187	4	92	theme	Hospital	765:772	arg1	ICU					795:797	ICU	795:797	ICU	795:797	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	92	theme	Hospital	765:772	arg1	Unit					789:792	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	0	93	theme	VWF	23:25	arg1	distribution					36:47	VWF multimer distribution	23:47	VWF multimer distribution	23:47	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
34053187	1	94	theme	endothelial	106:116	arg1	activation					123:132	fulminant endothelial cell activation	96:132	fulminant endothelial cell activation	96:132	BACKGROUND Consistent with fulminant endothelial cell activation, elevated plasma von Willebrand factor (VWF) antigen levels have been reported in patients with COVID-19.
34053187	4	95	theme	Care	784:787	arg1	ICU					795:797	ICU	795:797	ICU	795:797	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	4	95	theme	Care	784:787	arg1	Unit					789:792	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	the Beaumont Hospital Intensive Care Unit (ICU)	752:798	PATIENTS AND METHODS Patients with COVID-19 (n = 23) were recruited from the Beaumont Hospital Intensive Care Unit (ICU) in Dublin.
34053187	0	96	theme	distribution	36:47	arg1	regulation					9:18	ADAMTS13 regulation	0:18	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.	0:67	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
34053187	2	97	with	Disintegrin	313:323	arg1	motif					377:381	ThrombSpondin Motif type 1 motif	350:381	ThrombSpondin Motif type 1 motif	350:381	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	8	98	theme	VWF	1229:1231	arg1	distribution					1242:1253	VWF multimer distribution	1229:1253	VWF multimer distribution	1229:1253	In keeping with an increase in VWF:ADAMTS-13 ratio, abnormalities in VWF multimer distribution were common in patients with COVID-19, with reductions in high molecular weight VWF multimers.
34053187	0	99	theme	severe	52:57	arg1	COVID-19					59:66	severe COVID-19	52:66	severe COVID-19	52:66	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.
34053187	2	100	with	Metalloprotease	329:343	arg1	motif					377:381	ThrombSpondin Motif type 1 motif	350:381	ThrombSpondin Motif type 1 motif	350:381	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
34053187	3	101	dep	OBJECTIVES	429:438	arg1	investigated					451:462	investigated	451:462	investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis	451:676	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	3	102	theme	multimer	512:519	arg1	distribution					521:532	VWF multimer distribution	508:532	VWF multimer distribution	508:532	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	11	103	dep	inhibitors	1576:1585	arg1	interleukin-6					1587:1599	interleukin-6	1587:1599	interleukin-6	1587:1599	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	103	dep	inhibitors	1576:1585	arg1	factor					1633:1638	platelet factor 4	1624:1640	platelet factor 4	1624:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	103	dep	inhibitors	1576:1585	arg1	inhibitors					1576:1585	the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1562:1640	the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4	1562:1640	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	11	103	dep	inhibitors	1576:1585	arg1	thrombospondin-1					1602:1617	thrombospondin-1	1602:1617	thrombospondin-1	1602:1617	Furthermore, plasma levels of the ADAMTS-13 inhibitors interleukin-6, thrombospondin-1, and platelet factor 4 were significantly elevated.
34053187	6	104	from	activity	978:985	arg1	patients					990:997	patients	990:997	patients with severe COVID-19	990:1018	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	3	105	theme	ADAMTS-13	484:492	arg1	regulation					494:503	ADAMTS-13 regulation	484:503	ADAMTS-13 regulation of VWF multimer distribution	484:532	OBJECTIVES This study investigated the hypothesis that ADAMTS-13 regulation of VWF multimer distribution may be impaired in severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection contributing to the observed microvascular thrombosis.
34053187	9	106	theme	other	1432:1436	arg1	proteases					1438:1446	other proteases	1432:1446	other proteases	1432:1446	Terminal sialylation regulates VWF susceptibility to proteolysis by ADAMTS-13 and other proteases.
34053187	6	107	dep	RESULTS	918:924	arg1	observed					929:936	observed	929:936	observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl)	929:1072	RESULTS We observed markedly increased VWF collagen-binding activity in patients with severe COVID-19 compared to controls (median 509.1 versus 94.3 IU/dl).
34053187	2	108	theme	type	370:373	arg1	motif					377:381	ThrombSpondin Motif type 1 motif	350:381	ThrombSpondin Motif type 1 motif	350:381	The multimeric size and function of VWF are normally regulated through A Disintegrin And Metalloprotease with ThrombSpondin Motif type 1 motif, member 13 (ADAMTS-13)--mediated proteolysis.
32783937	4	0	theme	transcription	720:732	arg1	factor					734:739	the lineage-specifying transcription factor	697:739	the lineage-specifying transcription factor Neurogenin 3	697:752	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	1	1	theme	wide	148:151	arg1	range					153:157	a wide range	146:157	a wide range of metabolic processes	146:180	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	3	2	from	modification	502:513	arg1	proteins					532:539	intracellular proteins	518:539	intracellular proteins	518:539	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	4	3	theme	factor	734:739	arg1	expression					683:692	expression	683:692	expression of the lineage-specifying transcription factor Neurogenin 3	683:752	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	4	3	theme	factor	734:739	arg1	differentiation					772:786	L cell differentiation	765:786	L cell differentiation	765:786	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	3	4	from	β-N-acetylglucosamine	553:573	arg1	cells					611:615	intestinal epithelial cells	589:615	intestinal epithelial cells	589:615	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	0	5	theme	Enteroendocrine	93:107	arg1	Cells					111:115	Enteroendocrine L Cells	93:115	Enteroendocrine L Cells	93:115	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	5	6	theme	improved	1063:1070	arg1	control					1081:1087	improved glycemic control	1063:1087	improved glycemic control	1063:1087	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	4	7	theme	enteroendocrine	793:807	arg1	progenitors					809:819	enteroendocrine progenitors	793:819	enteroendocrine progenitors	793:819	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	5	8	theme	microbial	984:992	arg1	compositions					994:1005	gut microbial compositions	980:1005	gut microbial compositions	980:1005	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	1	9	theme	obesity	249:255	arg1	pathogenesis					233:244	the pathogenesis	229:244	the pathogenesis of obesity and diabetes	229:268	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	3	10	link	O-linked	544:551	arg1	β-N-acetylglucosamine					553:573	O-linked β-N-acetylglucosamine	544:573	O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells	544:615	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	3	10	link	O-linked	544:551	arg1	O-GlcNAc					576:583	O-GlcNAc	576:583	O-GlcNAc	576:583	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	4	11	dep	factor	734:739	arg1	Neurogenin					741:750	Neurogenin 3	741:752	the lineage-specifying transcription factor Neurogenin 3	697:752	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	0	12	theme	Cells	111:115	arg1	Differentiation					74:88	the Differentiation	70:88	the Differentiation of Enteroendocrine L Cells	70:115	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	0	13	attach	Links	30:34	arg1	Differentiation					74:88	the Differentiation	70:88	the Differentiation of Enteroendocrine L Cells	70:115	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	0	13	attach	Links	30:34	arg2	Modification					17:28	Protein O-GlcNAc Modification	0:28	Protein O-GlcNAc Modification	0:28	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	6	14	theme	cell	1168:1171	arg1	development					1173:1183	L cell development	1166:1183	L cell development	1166:1183	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	5	15	theme	increased	907:915	arg1	secretion					917:925	increased secretion	907:925	increased secretion of glucagon-like peptide 1 (GLP-1)	907:960	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	2	16	theme	cells	377:381	arg1	development					360:370	the development	356:370	the development of L cells	356:381	However, it is incompletely understood how luminal signals are integrated to control the development of L cells.
32783937	0	17	theme	L	109:109	arg1	Cells					111:115	Enteroendocrine L Cells	93:115	Enteroendocrine L Cells	93:115	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	5	18	theme	OGT	856:858	arg1	ablation					844:851	Intestinal epithelial ablation	822:851	Intestinal epithelial ablation of OGT in mice	822:866	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	3	19	theme	O-linked	544:551	arg1	β-N-acetylglucosamine					553:573	O-linked β-N-acetylglucosamine	544:573	O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells	544:615	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	3	19	theme	O-linked	544:551	arg1	O-GlcNAc					576:583	O-GlcNAc	576:583	O-GlcNAc	576:583	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	1	20	theme	metabolic	162:170	arg1	processes					172:180	metabolic processes	162:180	metabolic processes	162:180	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	0	21	theme	O-GlcNAc	8:15	arg1	Modification					17:28	Protein O-GlcNAc Modification	0:28	Protein O-GlcNAc Modification	0:28	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	6	22	theme	O-GlcNAc	1133:1140	arg1	signaling					1142:1150	intestinal epithelial O-GlcNAc signaling	1111:1150	intestinal epithelial O-GlcNAc signaling	1111:1150	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	6	22	theme	O-GlcNAc	1133:1140	arg1	brake					1157:1161	a brake	1155:1161	a brake on L cell development and function in response to nutritional and microbial cues	1155:1242	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	4	23	theme	L	765:765	arg1	differentiation					772:786	L cell differentiation	765:786	L cell differentiation	765:786	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	6	24	theme	intestinal	1111:1120	arg1	signaling					1142:1150	intestinal epithelial O-GlcNAc signaling	1111:1150	intestinal epithelial O-GlcNAc signaling	1111:1150	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	6	24	theme	intestinal	1111:1120	arg1	brake					1157:1161	a brake	1155:1161	a brake on L cell development and function in response to nutritional and microbial cues	1155:1242	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	1	25	theme	processes	172:180	arg1	range					153:157	a wide range	146:157	a wide range of metabolic processes	146:180	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	0	26	theme	Protein	0:6	arg1	Modification					17:28	Protein O-GlcNAc Modification	0:28	Protein O-GlcNAc Modification	0:28	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	1	27	theme	diabetes	261:268	arg1	pathogenesis					233:244	the pathogenesis	229:244	the pathogenesis of obesity and diabetes	229:268	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	3	28	theme	intestinal	589:598	arg1	cells					611:615	intestinal epithelial cells	589:615	intestinal epithelial cells	589:615	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	3	29	theme	food	402:405	arg1	availability					407:418	food availability	402:418	food availability	402:418	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	4	30	theme	FOXO1	622:626	arg1	O-GlcNAcylation					628:642	FOXO1 O-GlcNAcylation	622:642	FOXO1 O-GlcNAcylation	622:642	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	6	31	theme	epithelial	1122:1131	arg1	signaling					1142:1150	intestinal epithelial O-GlcNAc signaling	1111:1150	intestinal epithelial O-GlcNAc signaling	1111:1150	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	6	31	theme	epithelial	1122:1131	arg1	brake					1157:1161	a brake	1155:1161	a brake on L cell development and function in response to nutritional and microbial cues	1155:1242	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	5	32	theme	peptide	944:950	arg1	hyperplasia					891:901	L cell hyperplasia	884:901	L cell hyperplasia	884:901	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	5	32	theme	peptide	944:950	arg1	secretion					917:925	increased secretion	907:925	increased secretion of glucagon-like peptide 1 (GLP-1)	907:960	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	5	33	theme	gut	980:982	arg1	compositions					994:1005	gut microbial compositions	980:1005	gut microbial compositions	980:1005	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	3	34	theme	short-chain	448:458	arg1	acids					466:470	gut microbiota-produced short-chain fatty acids	424:470	gut microbiota-produced short-chain fatty acids	424:470	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	6	35	theme	nutritional	1213:1223	arg1	cues					1239:1242	nutritional and microbial cues	1213:1242	nutritional and microbial cues	1213:1242	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	4	36	theme	cell	767:770	arg1	differentiation					772:786	L cell differentiation	765:786	L cell differentiation	765:786	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	1	37	theme	L-cell	187:192	arg1	dysfunction					194:204	L-cell dysfunction	187:204	L-cell dysfunction	187:204	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	5	38	theme	Intestinal	822:831	arg1	ablation					844:851	Intestinal epithelial ablation	822:851	Intestinal epithelial ablation of OGT in mice	822:866	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	3	39	theme	posttranslational	484:500	arg1	modification					502:513	the posttranslational modification	480:513	the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells	480:615	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	5	40	theme	L	884:884	arg1	hyperplasia					891:901	L cell hyperplasia	884:901	L cell hyperplasia	884:901	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	3	41	theme	gut	424:426	arg1	acids					466:470	gut microbiota-produced short-chain fatty acids	424:470	gut microbiota-produced short-chain fatty acids	424:470	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	0	42	theme	Dietary	36:42	arg1	Cues					62:65	Dietary and Gut Microbial Cues	36:65	Dietary and Gut Microbial Cues	36:65	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	5	43	theme	epithelial	833:842	arg1	ablation					844:851	Intestinal epithelial ablation	822:851	Intestinal epithelial ablation of OGT in mice	822:866	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	3	44	theme	microbiota-produced	428:446	arg1	acids					466:470	gut microbiota-produced short-chain fatty acids	424:470	gut microbiota-produced short-chain fatty acids	424:470	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	0	45	theme	Microbial	52:60	arg1	Cues					62:65	Dietary and Gut Microbial Cues	36:65	Dietary and Gut Microbial Cues	36:65	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	3	46	theme	epithelial	600:609	arg1	cells					611:615	intestinal epithelial cells	589:615	intestinal epithelial cells	589:615	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	6	47	theme	L	1166:1166	arg1	development					1173:1183	L cell development	1166:1183	L cell development	1166:1183	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	3	48	theme	fatty	460:464	arg1	acids					466:470	gut microbiota-produced short-chain fatty acids	424:470	gut microbiota-produced short-chain fatty acids	424:470	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	0	49	theme	Gut	48:50	arg1	Cues					62:65	Dietary and Gut Microbial Cues	36:65	Dietary and Gut Microbial Cues	36:65	Protein O-GlcNAc Modification Links Dietary and Gut Microbial Cues to the Differentiation of Enteroendocrine L Cells.
32783937	5	50	theme	glycemic	1072:1079	arg1	control					1081:1087	improved glycemic control	1063:1087	improved glycemic control	1063:1087	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	1	51	theme	Intestinal	118:127	arg1	cells					131:135	Intestinal L cells	118:135	Intestinal L cells	118:135	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	1	52	theme	L	129:129	arg1	cells					131:135	Intestinal L cells	118:135	Intestinal L cells	118:135	Intestinal L cells regulate a wide range of metabolic processes, and L-cell dysfunction has been implicated in the pathogenesis of obesity and diabetes.
32783937	6	53	theme	microbial	1229:1237	arg1	cues					1239:1242	nutritional and microbial cues	1213:1242	nutritional and microbial cues	1213:1242	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	5	54	theme	glucagon-like	930:942	arg1	peptide					944:950	glucagon-like peptide 1	930:952	glucagon-like peptide 1 (GLP-1)	930:960	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	5	54	theme	glucagon-like	930:942	arg1	GLP-1					955:959	GLP-1	955:959	GLP-1	955:959	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	2	55	theme	luminal	314:320	arg1	signals					322:328	luminal signals	314:328	luminal signals	314:328	However, it is incompletely understood how luminal signals are integrated to control the development of L cells.
32783937	5	56	theme	cell	886:889	arg1	hyperplasia					891:901	L cell hyperplasia	884:901	L cell hyperplasia	884:901	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	5	57	theme	decreased	1037:1045	arg1	gain					1054:1057	decreased weight gain	1037:1057	decreased weight gain	1037:1057	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	3	58	theme	intracellular	518:530	arg1	proteins					532:539	intracellular proteins	518:539	intracellular proteins	518:539	Here we show that food availability and gut microbiota-produced short-chain fatty acids control the posttranslational modification on intracellular proteins by O-linked β-N-acetylglucosamine (O-GlcNAc) in intestinal epithelial cells.
32783937	2	59	theme	L	375:375	arg1	cells					377:381	L cells	375:381	L cells	375:381	However, it is incompletely understood how luminal signals are integrated to control the development of L cells.
32783937	4	60	theme	O-GlcNAc	645:652	arg1	OGT					667:669	OGT	667:669	OGT	667:669	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	4	60	theme	O-GlcNAc	645:652	arg1	transferase					654:664	O-GlcNAc transferase	645:664	O-GlcNAc transferase (OGT)	645:670	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32783937	5	61	from	ablation	844:851	arg1	mice					863:866	mice	863:866	mice	863:866	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	5	62	theme	weight	1047:1052	arg1	gain					1054:1057	decreased weight gain	1037:1057	decreased weight gain	1037:1057	Intestinal epithelial ablation of OGT in mice not only causes L cell hyperplasia and increased secretion of glucagon-like peptide 1 (GLP-1) but also disrupts gut microbial compositions, which notably contributes to decreased weight gain and improved glycemic control.
32783937	6	63	from	brake	1157:1161	arg1	response					1201:1208	response	1201:1208	response to nutritional and microbial cues	1201:1242	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	6	63	from	brake	1157:1161	arg1	function					1189:1196	function	1189:1196	function	1189:1196	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	6	63	from	brake	1157:1161	arg1	development					1173:1183	L cell development	1166:1183	L cell development	1166:1183	Our results identify intestinal epithelial O-GlcNAc signaling as a brake on L cell development and function in response to nutritional and microbial cues.
32783937	4	64	theme	lineage-specifying	701:718	arg1	factor					734:739	the lineage-specifying transcription factor	697:739	the lineage-specifying transcription factor Neurogenin 3	697:752	Via FOXO1 O-GlcNAcylation, O-GlcNAc transferase (OGT) suppresses expression of the lineage-specifying transcription factor Neurogenin 3 and, thus, L cell differentiation from enteroendocrine progenitors.
32738016	6	0	theme	family	953:958	arg1	ST8SIA3					910:916	Knocking down ST8SIA3	896:916	Knocking down ST8SIA3	896:916	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	6	0	theme	family	953:958	arg1	member					921:926	a member	919:926	a member of the sialyltransferase family	919:958	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	8	1	theme	HBV	1409:1411	arg1	cycle					1418:1422	the HBV life cycle	1405:1422	the HBV life cycle	1405:1422	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	8	2	theme	HBsAg	1290:1294	arg1	secretion					1308:1316	HBsAg and HBV DNA secretion	1290:1316	secretion	1308:1316	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	5	3	theme	them	851:854	arg1	them					851:854	them	851:854	them	851:854	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	5	3	theme	them	851:854	arg1	two					844:846	two	844:846	two	844:846	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	1	4	theme	proteolytic	220:230	arg1	entry					197:201	entry	197:201	entry into host cells	197:217	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	4	theme	proteolytic	220:230	arg1	processing					232:241	proteolytic processing	220:241	proteolytic processing	220:241	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	4	theme	proteolytic	220:230	arg1	functions					178:186	crucial functions	170:186	crucial functions	170:186	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	0	5	theme	B	105:105	arg1	virus					107:111	hepatitis B virus	95:111	hepatitis B virus	95:111	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	8	6	theme	glycosylation	1366:1378	arg1	pathway					1380:1386	the host glycosylation pathway	1357:1386	the host glycosylation pathway	1357:1386	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	8	6	theme	glycosylation	1366:1378	arg1	important					1391:1399	important	1391:1399	important	1391:1399	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	8	7	theme	HBV	1300:1302	arg1	secretion					1308:1316	HBsAg and HBV DNA secretion	1290:1316	secretion	1308:1316	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	5	8	theme	siRNA	870:874	arg1	effects					887:893	siRNA off-target effects	870:893	siRNA off-target effects	870:893	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	4	9	theme	hepatitis	635:643	arg1	HBsAg					664:668	HBsAg	664:668	HBsAg	664:668	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	4	9	theme	hepatitis	635:643	arg1	antigen					655:661	hepatitis B surface antigen	635:661	hepatitis B surface antigen (HBsAg)	635:669	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	0	10	theme	hepatitis	95:103	arg1	virus					107:111	hepatitis B virus	95:111	hepatitis B virus	95:111	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	4	11	theme	DNA	679:681	arg1	secretion					683:691	HBV DNA secretion	675:691	HBV DNA secretion	675:691	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	2	12	theme	candidate	306:314	arg1	molecules					316:324	candidate molecules	306:324	candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway	306:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	8	13	theme	down	1241:1244	arg1	ST8SIA3					1250:1256	ST8SIA3	1250:1256	ST8SIA3	1250:1256	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	4	14	theme	surface	647:653	arg1	HBsAg					664:668	HBsAg	664:668	HBsAg	664:668	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	4	14	theme	surface	647:653	arg1	antigen					655:661	hepatitis B surface antigen	635:661	hepatitis B surface antigen (HBsAg)	635:669	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	2	15	theme	agents	365:370	arg1	development					334:344	the development	330:344	the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway	330:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	8	16	theme	novel	1479:1483	arg1	agents					1494:1499	novel anti-HBV agents	1479:1499	novel anti-HBV agents	1479:1499	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	5	17	theme	HBsAg	778:782	arg1	secretion					799:807	HBsAg and/or HBV DNA secretion	778:807	secretion	799:807	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	3	18	theme	HepG2.2.15.7	466:477	arg1	cells					479:483	METHODS HepG2.2.15.7 cells	458:483	METHODS HepG2.2.15.7 cells that consistently produce HBV	458:513	METHODS HepG2.2.15.7 cells that consistently produce HBV were employed for our in vitro study.
32738016	2	19	theme	antiviral	355:363	arg1	agents					365:370	novel antiviral agents	349:370	novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway	349:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	7	20	theme	Knocking	1017:1024	arg1	GALNT7					1031:1036	Knocking down GALNT7	1017:1036	Knocking down GALNT7	1017:1036	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	7	21	theme	HBV	1178:1180	arg1	levels					1186:1191	HBV DNA levels	1178:1191	HBV DNA levels	1178:1191	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	2	22	theme	study	284:288	arg1	aim					272:274	The aim	268:274	The aim of this study	268:288	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	6	23	theme	DNA	1002:1004	arg1	secretion					1006:1014	HBV DNA secretion	998:1014	HBV DNA secretion	998:1014	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	2	24	theme	novel	349:353	arg1	agents					365:370	novel antiviral agents	349:370	novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway	349:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	0	25	theme	Screening	0:8	arg1	siRNAs					10:15	Screening siRNAs	0:15	Screening siRNAs against host glycosylation pathways	0:51	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	1	26	theme	protein	247:253	arg1	entry					197:201	entry	197:201	entry into host cells	197:217	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	26	theme	protein	247:253	arg1	trafficking					255:265	protein trafficking	247:265	protein trafficking	247:265	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	26	theme	protein	247:253	arg1	functions					178:186	crucial functions	170:186	crucial functions	170:186	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	7	27	theme	down	1026:1029	arg1	GALNT7					1031:1036	Knocking down GALNT7	1017:1036	Knocking down GALNT7	1017:1036	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	5	28	theme	off-target	876:885	arg1	effects					887:893	siRNA off-target effects	870:893	siRNA off-target effects	870:893	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	1	29	theme	crucial	170:176	arg1	entry					197:201	entry	197:201	entry into host cells	197:217	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	29	theme	crucial	170:176	arg1	processing					232:241	proteolytic processing	220:241	proteolytic processing	220:241	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	29	theme	crucial	170:176	arg1	trafficking					255:265	protein trafficking	247:265	protein trafficking	247:265	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	29	theme	crucial	170:176	arg1	functions					178:186	crucial functions	170:186	crucial functions	170:186	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	0	30	theme	host	25:28	arg1	pathways					44:51	host glycosylation pathways	25:51	host glycosylation pathways	25:51	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	8	31	theme	anti-HBV	1485:1492	arg1	agents					1494:1499	novel anti-HBV agents	1479:1499	novel anti-HBV agents	1479:1499	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	5	32	dep	RESULTS	727:733	arg1	identified					738:747	identified	738:747	identified four glycogenes that reduced HBsAg and/or HBV DNA secretion	738:807	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	3	33	theme	in	537:538	arg1	study					546:550	our in vitro study	533:550	our in vitro study	533:550	METHODS HepG2.2.15.7 cells that consistently produce HBV were employed for our in vitro study.
32738016	4	34	theme	different	606:614	arg1	glycogenes					621:630	88 different host glycogenes	603:630	88 different host glycogenes	603:630	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	2	35	theme	siRNA	393:397	arg1	system					409:414	an siRNA screening system	390:414	an siRNA screening system targeting the host glycosylation pathway	390:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	6	36	theme	down	905:908	arg1	ST8SIA3					910:916	Knocking down ST8SIA3	896:916	Knocking down ST8SIA3	896:916	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	6	36	theme	down	905:908	arg1	member					921:926	a member	919:926	a member of the sialyltransferase family	919:958	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	4	37	theme	siRNA	703:707	arg1	system					719:724	the siRNA screening system	699:724	the siRNA screening system	699:724	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	8	38	theme	HepG2.2.15.7	1321:1332	arg1	cells					1334:1338	HepG2.2.15.7 cells	1321:1338	HepG2.2.15.7 cells	1321:1338	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	6	39	theme	Knocking	896:903	arg1	ST8SIA3					910:916	Knocking down ST8SIA3	896:916	Knocking down ST8SIA3	896:916	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	6	39	theme	Knocking	896:903	arg1	member					921:926	a member	919:926	a member of the sialyltransferase family	919:958	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	8	40	theme	knocking	1232:1239	arg1	ST8SIA3					1250:1256	ST8SIA3	1250:1256	ST8SIA3	1250:1256	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	4	41	theme	B	645:645	arg1	HBsAg					664:668	HBsAg	664:668	HBsAg	664:668	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	4	41	theme	B	645:645	arg1	antigen					655:661	hepatitis B surface antigen	635:661	hepatitis B surface antigen (HBsAg)	635:669	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	5	42	theme	observed	823:830	arg1	due					863:865	due	863:865	due	863:865	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	5	42	theme	observed	823:830	arg1	results					832:838	the observed results	819:838	the observed results for two of them	819:854	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	2	43	theme	glycosylation	435:447	arg1	pathway					449:455	the host glycosylation pathway	426:455	the host glycosylation pathway	426:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	0	44	theme	glycosylation	30:42	arg1	pathways					44:51	host glycosylation pathways	25:51	host glycosylation pathways	25:51	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	8	45	theme	life	1413:1416	arg1	cycle					1418:1422	the HBV life cycle	1405:1422	the HBV life cycle	1405:1422	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	2	46	theme	screening	399:407	arg1	system					409:414	an siRNA screening system	390:414	an siRNA screening system targeting the host glycosylation pathway	390:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	4	47	theme	host	616:619	arg1	glycogenes					621:630	88 different host glycogenes	603:630	88 different host glycogenes	603:630	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	2	48	theme	host	430:433	arg1	pathway					449:455	the host glycosylation pathway	426:455	the host glycosylation pathway	426:455	The aim of this study was to identify candidate molecules for the development of novel antiviral agents against HBV using an siRNA screening system targeting the host glycosylation pathway.
32738016	4	49	from	effects	573:579	arg1	HBsAg					664:668	HBsAg	664:668	HBsAg	664:668	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	4	49	from	effects	573:579	arg1	antigen					655:661	hepatitis B surface antigen	635:661	hepatitis B surface antigen (HBsAg)	635:669	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	4	49	from	effects	573:579	arg1	secretion					683:691	HBV DNA secretion	675:691	HBV DNA secretion	675:691	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	7	50	link	O-linked	1089:1096	arg1	glycosylation					1098:1110	O-linked glycosylation	1089:1110	O-linked glycosylation	1089:1110	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	7	51	theme	DNA	1182:1184	arg1	levels					1186:1191	HBV DNA levels	1178:1191	HBV DNA levels	1178:1191	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	8	52	theme	host	1361:1364	arg1	pathway					1380:1386	the host glycosylation pathway	1357:1386	the host glycosylation pathway	1357:1386	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	8	52	theme	host	1361:1364	arg1	important					1391:1399	important	1391:1399	important	1391:1399	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	1	53	theme	AIM	114:116	arg1	HBV					137:139	HBV	137:139	HBV	137:139	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	53	theme	AIM	114:116	arg1	virus					130:134	AIM Hepatitis B virus	114:134	AIM Hepatitis B virus (HBV)	114:140	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	7	54	theme	O-linked	1089:1096	arg1	glycosylation					1098:1110	O-linked glycosylation	1089:1110	O-linked glycosylation	1089:1110	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	1	55	theme	Hepatitis	118:126	arg1	HBV					137:139	HBV	137:139	HBV	137:139	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	55	theme	Hepatitis	118:126	arg1	virus					130:134	AIM Hepatitis B virus	114:134	AIM Hepatitis B virus (HBV)	114:140	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	4	56	theme	HBV	675:677	arg1	secretion					683:691	HBV DNA secretion	675:691	HBV DNA secretion	675:691	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	8	57	theme	agents	1494:1499	arg1	development					1464:1474	the development	1460:1474	the development of novel anti-HBV agents	1460:1499	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	7	58	gly	glycosylation	1098:1110	arg1	apparatus					1125:1133	the Golgi apparatus	1115:1133	the Golgi apparatus	1115:1133	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	1	59	theme	B	128:128	arg1	HBV					137:139	HBV	137:139	HBV	137:139	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	1	59	theme	B	128:128	arg1	virus					130:134	AIM Hepatitis B virus	114:134	AIM Hepatitis B virus (HBV)	114:140	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	4	60	theme	screening	709:717	arg1	system					719:724	the siRNA screening system	699:724	the siRNA screening system	699:724	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	4	61	theme	siRNAs	584:589	arg1	effects					573:579	the effects	569:579	the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion	569:691	We investigated the effects of siRNAs that target 88 different host glycogenes on hepatitis B surface antigen (HBsAg) and HBV DNA secretion using the siRNA screening system.
32738016	8	62	theme	DNA	1304:1306	arg1	secretion					1308:1316	HBsAg and HBV DNA secretion	1290:1316	secretion	1308:1316	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	8	63	dep	ST8SIA3	1250:1256	arg1	glycogenes					1269:1278	glycogenes	1269:1278	glycogenes	1269:1278	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	8	63	dep	ST8SIA3	1250:1256	arg1	the					1246:1248	the	1246:1248	the	1246:1248	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	6	64	theme	HBV	998:1000	arg1	secretion					1006:1014	HBV DNA secretion	998:1014	HBV DNA secretion	998:1014	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
32738016	3	65	theme	METHODS	458:464	arg1	cells					479:483	METHODS HepG2.2.15.7 cells	458:483	METHODS HepG2.2.15.7 cells that consistently produce HBV	458:513	METHODS HepG2.2.15.7 cells that consistently produce HBV were employed for our in vitro study.
32738016	8	66	dep	CONCLUSIONS	1194:1204	arg1	showed					1220:1225	showed	1220:1225	showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents	1220:1499	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	0	67	theme	antiviral	70:78	arg1	agents					80:85	novel antiviral agents	64:85	novel antiviral agents	64:85	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	5	68	theme	DNA	795:797	arg1	secretion					799:807	HBsAg and/or HBV DNA secretion	778:807	secretion	799:807	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	3	69	dep	in	537:538	arg1	vitro					540:544	vitro	540:544	vitro	540:544	METHODS HepG2.2.15.7 cells that consistently produce HBV were employed for our in vitro study.
32738016	1	70	theme	host	208:211	arg1	cells					213:217	host cells	208:217	host cells	208:217	AIM Hepatitis B virus (HBV) relies on glycosylation for crucial functions, such as entry into host cells, proteolytic processing and protein trafficking.
32738016	0	71	theme	novel	64:68	arg1	agents					80:85	novel antiviral agents	64:85	novel antiviral agents	64:85	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus.
32738016	8	72	theme	potential	1439:1447	arg1	target					1449:1454	a potential target	1437:1454	a potential target for the development of novel anti-HBV agents	1437:1499	CONCLUSIONS These results showed that knocking down the ST8SIA3 and GALNT7 glycogenes inhibited HBsAg and HBV DNA secretion in HepG2.2.15.7 cells, indicating that the host glycosylation pathway is important for the HBV life cycle and could be a potential target for the development of novel anti-HBV agents.
32738016	5	73	theme	HBV	791:793	arg1	secretion					799:807	HBsAg and/or HBV DNA secretion	778:807	secretion	799:807	RESULTS We identified four glycogenes that reduced HBsAg and/or HBV DNA secretion; however, the observed results for two of them may be due to siRNA off-target effects.
32738016	7	74	theme	Golgi	1119:1123	arg1	apparatus					1125:1133	the Golgi apparatus	1115:1133	the Golgi apparatus	1115:1133	Knocking down GALNT7, which transfers N-acetylgalactosamine to initiate O-linked glycosylation in the Golgi apparatus, also significantly reduced both HBsAg and HBV DNA levels.
32738016	6	75	theme	sialyltransferase	935:951	arg1	family					953:958	the sialyltransferase family	931:958	the sialyltransferase family	931:958	Knocking down ST8SIA3, a member of the sialyltransferase family, significantly reduced both HBsAg and HBV DNA secretion.
31941975	5	0	theme	test	846:849	arg1	sets					851:854	Training and test sets	833:854	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	833:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	0	theme	test	846:849	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	6	1	theme	%	1126:1126	arg1	accuracy					1102:1109	an accuracy	1099:1109	an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets	1099:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	2	2	theme	structural	295:304	arg1	stability					306:314	structural stability	295:314	structural stability	295:314	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	4	3	theme	spectrometry	708:719	arg1	network					785:791	the deep neural network	769:791	the deep neural network (DNN)	769:797	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	3	theme	spectrometry	708:719	arg1	machine					818:824	support vector machine	803:824	support vector machine (SVM)	803:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	3	theme	spectrometry	708:719	arg1	algorithms					750:759	tandem mass spectrometry (MS/MS) and machine learning algorithms	696:759	tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM)	696:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	1	4	theme	cell	179:182	arg1	recognition					184:194	cell recognition	179:194	cell recognition	179:194	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	6	5	theme	greater	1192:1198	arg1	values					1185:1190	manual characterization and area under the curve values	1136:1190	manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets	1136:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	10	6	dep	distinguish	1835:1845	arg1	MS/MS					1826:1830	MS/MS	1826:1830	MS/MS	1826:1830	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	6	7	theme	decoy	1271:1275	arg1	datasets					1277:1284	target and decoy datasets	1260:1284	datasets	1277:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	10	8	theme	machine	1780:1786	arg1	methods					1797:1803	the machine learning methods	1776:1803	the machine learning methods	1776:1803	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	5	9	theme	spectra	879:885	arg1	sets					851:854	Training and test sets	833:854	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	833:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	9	theme	spectra	879:885	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	9	10	from	mono-	1697:1701	arg1	dominant					1681:1688	dominant	1681:1688	dominant	1681:1688	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	8	11	theme	82N-glycopeptides	1389:1405	arg1	total					1380:1384	A total	1378:1384	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins,	1378:1493	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	8	11	theme	82N-glycopeptides	1389:1405	arg1	type					1532:1535	the same type	1523:1535	the same type in both the DNN and SVM	1523:1559	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	4	12	theme	tandem	696:701	arg1	spectrometry					708:719	tandem mass spectrometry	696:719	tandem mass spectrometry (MS/MS)	696:727	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	12	theme	tandem	696:701	arg1	MS/MS					722:726	MS/MS	722:726	MS/MS	722:726	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	5	13	gly	N-glycopeptides	890:904	arg1	gamma					930:934	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	gamma	930:934	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	13	gly	N-glycopeptides	890:904	arg1	standards					966:974	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	standards	966:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	13	gly	N-glycopeptides	890:904	arg2	N-glycopeptides					890:904	N-glycopeptides	890:904	N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	890:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	2	14	link	N-linked	332:339	arg1	glycoproteins					341:353	N-linked glycoproteins	332:353	N-linked glycoproteins	332:353	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	9	15	theme	N-glycoproteins	1737:1751	arg1	mono-					1697:1701	mono-	1697:1701	mono-	1697:1701	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	6	16	theme	probability	1236:1246	arg1	scores					1248:1253	probability scores	1236:1253	probability scores from target and decoy datasets	1236:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	5	17	theme	alpha	940:944	arg1	standards					966:974	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	standards	966:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	9	18	theme	human	1756:1760	arg1	plasma					1762:1767	human plasma	1756:1767	human plasma	1756:1767	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	0	19	theme	N-Glycoproteins	59:73	arg1	Core					28:31	Core	28:31	Core	28:31	Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.
31941975	0	19	theme	N-Glycoproteins	59:73	arg1	Fucosylation					43:54	Outer Fucosylation	37:54	Outer Fucosylation	37:54	Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.
31941975	5	20	theme	N-glycopeptides	890:904	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	4	21	theme	learning	741:748	arg1	network					785:791	the deep neural network	769:791	the deep neural network (DNN)	769:797	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	21	theme	learning	741:748	arg1	machine					818:824	support vector machine	803:824	support vector machine (SVM)	803:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	21	theme	learning	741:748	arg1	algorithms					750:759	tandem mass spectrometry (MS/MS) and machine learning algorithms	696:759	tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM)	696:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	0	22	theme	Mass	81:84	arg1	Spectrometry					86:97	Mass Spectrometry	81:97	Mass Spectrometry	81:97	Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.
31941975	4	23	gly	N-glycopeptides	637:651	arg2	N-glycopeptides					637:651	N-glycopeptides	637:651	N-glycopeptides	637:651	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	9	24	from	N-glycopeptides	1636:1650	arg1	dominant					1599:1606	dominant	1599:1606	dominant	1599:1606	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	9	25	from	bi-antennary	1704:1715	arg1	dominant					1681:1688	dominant	1681:1688	dominant	1681:1688	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	4	26	theme	support	803:809	arg1	SVM					827:829	SVM	827:829	SVM	827:829	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	26	theme	support	803:809	arg1	machine					818:824	support vector machine	803:824	support vector machine (SVM)	803:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	3	27	theme	structural	471:480	arg1	classification					482:495	structural classification	471:495	structural classification of fucosylated N-glycoproteins such as core or outer isoforms	471:557	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	1	28	gly	glycosylation	108:120	arg1	recognition					184:194	cell recognition	179:194	cell recognition	179:194	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	28	gly	glycosylation	108:120	arg1	differentiation					205:219	differentiation	205:219	differentiation	205:219	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	28	gly	glycosylation	108:120	arg1	progresses					160:169	biological progresses	149:169	biological progresses such as cell recognition, growth, differentiation, and apoptosis	149:234	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	28	gly	glycosylation	108:120	arg1	apoptosis					226:234	apoptosis	226:234	apoptosis	226:234	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	28	gly	glycosylation	108:120	arg1	growth					197:202	growth	197:202	growth	197:202	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	3	29	theme	protein	408:414	arg1	fucosylation					416:427	protein fucosylation	408:427	protein fucosylation by fucosyltransferases	408:450	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	4	30	theme	neural	778:783	arg1	network					785:791	the deep neural network	769:791	the deep neural network (DNN)	769:797	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	30	theme	neural	778:783	arg1	DNN					794:796	DNN	794:796	DNN	794:796	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	0	31	theme	Machine	0:6	arg1	Learning					8:15	Machine Learning	0:15	Machine Learning	0:15	Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.
31941975	7	32	gly	N-glycoproteins	1343:1357	arg1	N-glycoproteins					1343:1357	fucosylated N-glycoproteins	1331:1357	fucosylated N-glycoproteins	1331:1357	Finally, this model was applied to classify fucosylated N-glycoproteins from human plasma.
31941975	1	33	theme	Protein	100:106	arg1	glycosylation					108:120	Protein glycosylation	100:120	Protein glycosylation	100:120	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	3	34	theme	studies	397:403	arg1	studies					397:403	biological and clinical studies	373:403	biological and clinical studies of protein fucosylation by fucosyltransferases	373:450	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	3	34	theme	studies	397:403	arg1	many					365:368	many	365:368	many	365:368	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	3	35	theme	N-glycoproteins	512:526	arg1	classification					482:495	structural classification	471:495	structural classification of fucosylated N-glycoproteins such as core or outer isoforms	471:557	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	7	36	theme	fucosylated	1331:1341	arg1	N-glycoproteins					1343:1357	fucosylated N-glycoproteins	1331:1357	fucosylated N-glycoproteins	1331:1357	Finally, this model was applied to classify fucosylated N-glycoproteins from human plasma.
31941975	8	37	gly	82N-glycopeptides	1389:1405	arg2	82N-glycopeptides					1389:1405	82N-glycopeptides	1389:1405	82N-glycopeptides	1389:1405	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	6	38	theme	best-performing	1073:1087	arg1	model					1089:1093	The best-performing model	1069:1093	The best-performing model	1069:1093	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	3	39	gly	fucosylated	500:510	arg1	N-glycoproteins					512:526	fucosylated N-glycoproteins	500:526	fucosylated N-glycoproteins	500:526	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	8	40	from	type	1532:1535	arg1	SVM					1557:1559	SVM	1557:1559	SVM	1557:1559	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	8	40	from	type	1532:1535	arg1	DNN					1549:1551	DNN	1549:1551	DNN	1549:1551	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	9	41	theme	tri-	1611:1614	arg1	N-glycopeptides					1636:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	6	42	theme	area	1164:1167	arg1	values					1185:1190	manual characterization and area under the curve values	1136:1190	manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets	1136:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	2	43	gly	glycoproteins	341:353	arg1	glycoproteins					341:353	N-linked glycoproteins	332:353	N-linked glycoproteins	332:353	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	8	44	attach	derived	1464:1470	arg2	types					1458:1462	4 dual-fucosylation types	1438:1462	4 dual-fucosylation types derived from 54 glycoproteins	1438:1492	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	8	44	attach	derived	1464:1470	arg1	glycoproteins					1480:1492	54 glycoproteins	1477:1492	54 glycoproteins	1477:1492	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	5	45	theme	types	1029:1033	arg1	classification					994:1007	classification	994:1007	classification of the fucosylation types	994:1033	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	6	46	theme	characterization	1143:1158	arg1	values					1185:1190	manual characterization and area under the curve values	1136:1190	manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets	1136:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	4	47	theme	N-glycopeptides	637:651	arg1	classification					619:632	the classification	615:632	the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM)	615:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	10	48	theme	fucosylated	1877:1887	arg1	N-glycopeptides					1889:1903	fucosylated N-glycopeptides	1877:1903	fucosylated N-glycopeptides	1877:1903	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	8	49	theme	dual-fucosylation	1440:1456	arg1	types					1458:1462	4 dual-fucosylation types	1438:1462	4 dual-fucosylation types derived from 54 glycoproteins	1438:1492	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	5	50	from	standards	966:974	arg1	N-glycopeptides					890:904	N-glycopeptides	890:904	N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	890:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	50	from	standards	966:974	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	51	theme	supervised	1041:1050	arg1	models					1061:1066	supervised learning models	1041:1066	supervised learning models	1041:1066	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	6	52	from	datasets	1277:1284	arg1	scores					1248:1253	probability scores	1236:1253	probability scores from target and decoy datasets	1236:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	9	53	theme	core	1659:1662	arg1	fucosylation					1664:1675	core fucosylation	1659:1675	core fucosylation	1659:1675	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	10	54	theme	learning	1788:1795	arg1	methods					1797:1803	the machine learning methods	1776:1803	the machine learning methods	1776:1803	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	9	55	gly	N-glycopeptides	1636:1650	arg2	N-glycopeptides					1636:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	4	56	gly	outer-fucosylated	666:682	arg1	types					684:688	outer-fucosylated types	666:688	outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM)	666:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	10	57	gly	fucosylated	1877:1887	arg1	N-glycopeptides					1889:1903	fucosylated N-glycopeptides	1877:1903	fucosylated N-glycopeptides	1877:1903	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	4	58	theme	mass	703:706	arg1	spectrometry					708:719	tandem mass spectrometry	696:719	tandem mass spectrometry (MS/MS)	696:727	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	58	theme	mass	703:706	arg1	MS/MS					722:726	MS/MS	722:726	MS/MS	722:726	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	2	59	theme	N-linked	332:339	arg1	glycoproteins					341:353	N-linked glycoproteins	332:353	N-linked glycoproteins	332:353	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	5	60	theme	MS/MS	873:877	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	2	61	gly	glycoproteins	253:265	arg1	glycoproteins					253:265	Fucosylation of glycoproteins	237:265	Fucosylation of glycoproteins	237:265	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	8	62	gly	glycoproteins	1480:1492	arg1	glycoproteins					1480:1492	54 glycoproteins	1477:1492	54 glycoproteins	1477:1492	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	9	63	from	dominant	1681:1688	arg1	bi-antennary					1704:1715	bi-antennary	1704:1715	bi-antennary	1704:1715	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	9	63	from	dominant	1681:1688	arg1	types					1728:1732	hybrid types	1721:1732	hybrid types	1721:1732	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	9	63	from	dominant	1681:1688	arg1	mono-					1697:1701	mono-	1697:1701	mono-	1697:1701	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	4	64	theme	outer-fucosylated	666:682	arg1	types					684:688	outer-fucosylated types	666:688	outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM)	666:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	2	65	theme	Fucosylation of	237:251	arg1	glycoproteins					253:265	Fucosylation of glycoproteins	237:265	Fucosylation of glycoproteins	237:265	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	9	66	gly	N-glycoproteins	1737:1751	arg1	N-glycoproteins					1737:1751	N-glycoproteins	1737:1751	N-glycoproteins in human plasma	1737:1767	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	9	67	theme	hybrid	1721:1726	arg1	types					1728:1732	hybrid types	1721:1732	hybrid types	1721:1732	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	6	68	theme	target	1260:1265	arg1	datasets					1277:1284	target and decoy datasets	1260:1284	datasets	1277:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	5	69	theme	immunoglobulin	915:928	arg1	gamma					930:934	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	gamma	930:934	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	2	70	theme	important	276:284	arg1	role					286:289	an important role	273:289	an important role	273:289	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	9	71	from	N-glycoproteins	1737:1751	arg1	plasma					1762:1767	human plasma	1756:1767	human plasma	1756:1767	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	8	72	dep	DNN	1549:1551	arg1	the					1545:1547	the	1545:1547	the	1545:1547	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	5	73	from	spectra	879:885	arg1	gamma					930:934	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	gamma	930:934	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	73	from	spectra	879:885	arg1	standards					966:974	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	standards	966:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	9	74	from	types	1728:1732	arg1	dominant					1681:1688	dominant	1681:1688	dominant	1681:1688	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	5	75	gly	1-acid-glycoprotein	946:964	arg1	1-acid-glycoprotein					946:964	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	1-acid-glycoprotein	946:964	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	7	76	gly	fucosylated	1331:1341	arg1	N-glycoproteins					1343:1357	fucosylated N-glycoproteins	1331:1357	fucosylated N-glycoproteins	1331:1357	Finally, this model was applied to classify fucosylated N-glycoproteins from human plasma.
31941975	8	77	theme	same	1527:1530	arg1	total					1380:1384	A total	1378:1384	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins,	1378:1493	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	8	77	theme	same	1527:1530	arg1	type					1532:1535	the same type	1523:1535	the same type in both the DNN and SVM	1523:1559	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	4	78	theme	machine	733:739	arg1	learning					741:748	machine learning	733:748	machine learning	733:748	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	9	79	theme	tetra-antennary	1620:1634	arg1	N-glycopeptides					1636:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	3	80	theme	clinical	388:395	arg1	studies					397:403	biological and clinical studies	373:403	biological and clinical studies of protein fucosylation by fucosyltransferases	373:450	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	8	81	with	82N-glycopeptides	1389:1405	arg1	types					1458:1462	4 dual-fucosylation types	1438:1462	4 dual-fucosylation types derived from 54 glycoproteins	1438:1492	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	8	81	with	82N-glycopeptides	1389:1405	arg1	outer-					1426:1431	24 outer-	1423:1431	24 outer-	1423:1431	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	8	81	with	82N-glycopeptides	1389:1405	arg1	core-					1416:1420	54 core-	1413:1420	54 core-	1413:1420	A total of 82N-glycopeptides, with 54 core-, 24 outer-, and 4 dual-fucosylation types derived from 54 glycoproteins, were commonly classified as the same type in both the DNN and SVM.
31941975	7	82	theme	human	1364:1368	arg1	plasma					1370:1375	human plasma	1364:1375	human plasma	1364:1375	Finally, this model was applied to classify fucosylated N-glycoproteins from human plasma.
31941975	3	83	theme	biological	373:382	arg1	studies					397:403	biological and clinical studies	373:403	biological and clinical studies of protein fucosylation by fucosyltransferases	373:450	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	6	84	contain	had	1095:1097	arg1	model					1089:1093	The best-performing model	1069:1093	The best-performing model	1069:1093	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	6	84	contain	had	1095:1097	arg2	accuracy					1102:1109	an accuracy	1099:1109	an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets	1099:1284	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	5	85	theme	1-acid-glycoprotein	946:964	arg1	standards					966:974	the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	911:974	standards	966:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	3	86	theme	fucosylation	416:427	arg1	studies					397:403	biological and clinical studies	373:403	biological and clinical studies of protein fucosylation by fucosyltransferases	373:450	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	4	87	theme	deep	773:776	arg1	network					785:791	the deep neural network	769:791	the deep neural network (DNN)	769:797	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	87	theme	deep	773:776	arg1	DNN					794:796	DNN	794:796	DNN	794:796	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	5	88	theme	Training	833:840	arg1	sets					851:854	Training and test sets	833:854	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	833:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	88	theme	Training	833:840	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	89	from	gamma	930:934	arg1	N-glycopeptides					890:904	N-glycopeptides	890:904	N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	890:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	5	89	from	gamma	930:934	arg1	spectra					879:885	more than 800 MS/MS spectra	859:885	more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards	859:974	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	9	90	theme	outer	1576:1580	arg1	fucosylation					1582:1593	outer fucosylation	1576:1593	outer fucosylation	1576:1593	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	4	91	theme	first	604:608	arg1	time					610:613	the first time	600:613	the first time	600:613	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	0	92	theme	Outer	37:41	arg1	Fucosylation					43:54	Outer Fucosylation	37:54	Outer Fucosylation	37:54	Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.
31941975	5	93	theme	learning	1052:1059	arg1	models					1061:1066	supervised learning models	1041:1066	supervised learning models	1041:1066	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	9	94	from	dominant	1599:1606	arg1	N-glycopeptides					1636:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	tri- and tetra-antennary N-glycopeptides	1611:1650	Specifically, outer fucosylation was dominant in tri- and tetra-antennary N-glycopeptides, while core fucosylation was dominant in the mono-, bi-antennary and hybrid types of N-glycoproteins in human plasma.
31941975	10	95	theme	different	1855:1863	arg1	isoforms					1865:1872	different isoforms	1855:1872	different isoforms of fucosylated N-glycopeptides	1855:1903	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	3	96	gly	N-glycoproteins	512:526	arg1	N-glycoproteins					512:526	fucosylated N-glycoproteins	500:526	fucosylated N-glycoproteins	500:526	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	3	97	theme	fucosylated	500:510	arg1	N-glycoproteins					512:526	fucosylated N-glycoproteins	500:526	fucosylated N-glycoproteins	500:526	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	1	98	theme	biological	149:158	arg1	recognition					184:194	cell recognition	179:194	cell recognition	179:194	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	98	theme	biological	149:158	arg1	differentiation					205:219	differentiation	205:219	differentiation	205:219	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	98	theme	biological	149:158	arg1	progresses					160:169	biological progresses	149:169	biological progresses such as cell recognition, growth, differentiation, and apoptosis	149:234	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	98	theme	biological	149:158	arg1	apoptosis					226:234	apoptosis	226:234	apoptosis	226:234	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	1	98	theme	biological	149:158	arg1	growth					197:202	growth	197:202	growth	197:202	Protein glycosylation is known to be involved in biological progresses such as cell recognition, growth, differentiation, and apoptosis.
31941975	3	99	theme	outer	544:548	arg1	isoforms					550:557	outer isoforms	544:557	outer isoforms	544:557	Although many of biological and clinical studies of protein fucosylation by fucosyltransferases has been reported, structural classification of fucosylated N-glycoproteins such as core or outer isoforms remains a challenge.
31941975	5	100	theme	fucosylation	1016:1027	arg1	types					1029:1033	the fucosylation types	1012:1033	the fucosylation types	1012:1033	Training and test sets of more than 800 MS/MS spectra of N-glycopeptides from the immunoglobulin gamma and alpha 1-acid-glycoprotein standards were selected for classification of the fucosylation types using supervised learning models.
31941975	10	101	theme	N-glycopeptides	1889:1903	arg1	isoforms					1865:1872	different isoforms	1855:1872	different isoforms of fucosylated N-glycopeptides	1855:1903	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
31941975	4	102	theme	vector	811:816	arg1	SVM					827:829	SVM	827:829	SVM	827:829	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	4	102	theme	vector	811:816	arg1	machine					818:824	support vector machine	803:824	support vector machine (SVM)	803:830	Here, we report for the first time the classification of N-glycopeptides as core- and outer-fucosylated types using tandem mass spectrometry (MS/MS) and machine learning algorithms such as the deep neural network (DNN) and support vector machine (SVM).
31941975	2	103	theme	glycoproteins	341:353	arg1	function					320:327	function	320:327	function	320:327	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	2	103	theme	glycoproteins	341:353	arg1	stability					306:314	structural stability	295:314	structural stability	295:314	Fucosylation of glycoproteins plays an important role for structural stability and function of N-linked glycoproteins.
31941975	0	104	gly	Fucosylation	43:54	arg1	N-Glycoproteins					59:73	N-Glycoproteins	59:73	N-Glycoproteins Using Mass Spectrometry	59:97	Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.
31941975	6	105	theme	manual	1136:1141	arg1	characterization					1143:1158	manual characterization	1136:1158	manual characterization	1136:1158	The best-performing model had an accuracy of more than 99% against manual characterization and area under the curve values greater than 0.99, which were calculated by probability scores from target and decoy datasets.
31941975	10	106	gly	N-glycopeptides	1889:1903	arg2	N-glycopeptides					1889:1903	fucosylated N-glycopeptides	1877:1903	fucosylated N-glycopeptides	1877:1903	Thus, the machine learning methods can be combined with MS/MS to distinguish between different isoforms of fucosylated N-glycopeptides.
34878920	11	0	theme	protein	1644:1650	arg1	processing					1652:1661	Env protein processing	1640:1661	Env protein processing	1640:1661	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	4	1	theme	protein	737:743	arg1	detection					712:720	the detection	708:720	the detection of p27 and Env protein in the supernatant and gp37 in the cell culture	708:791	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	1	2	theme	J	150:150	arg1	ALV-J					174:178	ALV-J	174:178	ALV-J	174:178	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	2	theme	J	150:150	arg1	virus					167:171	the subgroup J avian leukosis virus	137:171	the subgroup J avian leukosis virus (ALV-J)	137:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	12	3	theme	ALV-J	1854:1858	arg1	control					1843:1849	the control	1839:1849	the control of ALV-J	1839:1858	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	1	4	theme	leukosis	158:165	arg1	ALV-J					174:178	ALV-J	174:178	ALV-J	174:178	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	4	theme	leukosis	158:165	arg1	virus					167:171	the subgroup J avian leukosis virus	137:171	the subgroup J avian leukosis virus (ALV-J)	137:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	3	5	theme	Env-receptor	498:509	arg1	binding					511:517	Env-receptor binding	498:517	Env-receptor binding	498:517	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	12	6	theme	different	1730:1738	arg1	aspects					1740:1746	different aspects	1730:1746	different aspects	1730:1746	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	1	7	gly	glycoprotein	115:126	arg1	Env					129:131	Env	129:131	Env	129:131	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	7	gly	glycoprotein	115:126	arg1	glycoprotein					115:126	envelope glycoprotein	106:126	envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J)	106:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	9	8	from	important	1399:1407	arg1	binding					1421:1427	receptor binding	1412:1427	receptor binding	1412:1427	Notably, viruses isolated recently seem to lose their 6th and 11th NGS, which proved to be important in receptor binding.
34878920	4	9	theme	cell	780:783	arg1	culture					785:791	the cell culture	776:791	the cell culture	776:791	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	6	10	from	tumors	1064:1069	arg1	chickens					1074:1081	chickens	1074:1081	chickens	1074:1081	IMPORTANCE ALV-J is a retrovirus that can cause multiple types of tumors in chickens.
34878920	3	11	theme	blocking	524:531	arg1	assay					533:537	a blocking assay	522:537	a blocking assay of the viral entrance	522:559	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	1	12	theme	envelope	106:113	arg1	Env					129:131	Env	129:131	Env	129:131	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	12	theme	envelope	106:113	arg1	glycoprotein					115:126	envelope glycoprotein	106:126	envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J)	106:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	6	13	theme	multiple	1046:1053	arg1	types					1055:1059	multiple types	1046:1059	multiple types of tumors in chickens	1046:1081	IMPORTANCE ALV-J is a retrovirus that can cause multiple types of tumors in chickens.
34878920	6	14	from	chickens	1074:1081	arg1	types					1055:1059	multiple types	1046:1059	multiple types of tumors in chickens	1046:1081	IMPORTANCE ALV-J is a retrovirus that can cause multiple types of tumors in chickens.
34878920	9	15	theme	6th	1362:1364	arg1	NGS					1375:1377	their 6th and 11th NGS	1356:1377	their 6th and 11th NGS	1356:1377	Notably, viruses isolated recently seem to lose their 6th and 11th NGS, which proved to be important in receptor binding.
34878920	12	16	theme	antiviral	1817:1825	arg1	targets					1827:1833	antiviral targets	1817:1833	antiviral targets for the control of ALV-J	1817:1858	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	5	17	theme	anti-ALV-J	975:984	arg1	strategies					986:995	anti-ALV-J strategies	975:995	anti-ALV-J strategies	975:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	9	18	theme	11th	1370:1373	arg1	NGS					1375:1377	their 6th and 11th NGS	1356:1377	their 6th and 11th NGS	1356:1377	Notably, viruses isolated recently seem to lose their 6th and 11th NGS, which proved to be important in receptor binding.
34878920	2	19	theme	virus	417:421	arg1	replication					423:433	virus replication	417:433	virus replication	417:433	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	1	20	dep	integrity	218:226	arg1	the					207:209	the	207:209	the	207:209	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	4	21	theme	protein	649:655	arg1	processing					657:666	Env protein processing	645:666	Env protein processing	645:666	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	6	22	from	types	1055:1059	arg1	chickens					1074:1081	chickens	1074:1081	chickens	1074:1081	IMPORTANCE ALV-J is a retrovirus that can cause multiple types of tumors in chickens.
34878920	7	23	gly	glycosylated	1126:1137	arg1	protein					1148:1154	the heavily glycosylated envelope protein	1114:1154	the heavily glycosylated envelope protein	1114:1154	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	7	23	gly	glycosylated	1126:1137	arg1	crucial					1170:1176	crucial	1170:1176	crucial	1170:1176	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	0	24	from	Sites	43:47	arg1	Glycosylation					0:12	Glycosylation	0:12	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193	0:58	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	2	25	theme	glycosylation	313:325	arg1	NGSs					334:337	NGSs	334:337	NGSs	334:337	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	25	theme	glycosylation	313:325	arg1	sites					327:331	the 13 predicted N-linked glycosylation sites	287:331	the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6	287:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	0	26	theme	Virus	78:82	arg1	Infection					84:92	the Virus Infection	74:92	the Virus Infection	74:92	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	5	27	theme	ALV	956:958	arg1	cycle					965:969	the ALV life cycle	952:969	the ALV life cycle	952:969	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	2	28	theme	Tibetan	351:357	arg1	TBC-J6					374:379	Tibetan chicken strain TBC-J6	351:379	Tibetan chicken strain TBC-J6	351:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	8	29	theme	Env	1215:1217	arg1	function					1227:1234	Env protein function	1215:1234	Env protein function	1215:1234	Glycosylation plays a major role in Env protein function, including protein processing, receptor attachment, and immune evasion.
34878920	2	30	theme	predicted	294:302	arg1	NGSs					334:337	NGSs	334:337	NGSs	334:337	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	30	theme	predicted	294:302	arg1	sites					327:331	the 13 predicted N-linked glycosylation sites	287:331	the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6	287:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	1	31	theme	virion	211:216	arg1	integrity					218:226	virion integrity	211:226	virion integrity	211:226	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	5	32	theme	systematic	809:818	arg1	research					820:827	systematic research	809:827	systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies	809:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	3	33	from	N193	484:487	arg1	mutation					472:479	a mutation	470:479	a mutation at N193	470:487	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	0	34	theme	ALV-J	17:21	arg1	Protein					32:38	ALV-J Envelope Protein	17:38	ALV-J Envelope Protein	17:38	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	3	35	theme	viral	546:550	arg1	entrance					552:559	the viral entrance	542:559	the viral entrance	542:559	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	10	36	theme	8th	1462:1464	arg1	NGS					1473:1475	the 1st (N17) and 8th (N193) NGS	1444:1475	the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6	1444:1504	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	0	37	theme	Protein	32:38	arg1	Glycosylation					0:12	Glycosylation	0:12	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193	0:58	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	4	38	dep	supernatant	752:762	arg1	the					748:750	the	748:750	the	748:750	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	7	39	theme	envelope	1139:1146	arg1	protein					1148:1154	the heavily glycosylated envelope protein	1114:1154	the heavily glycosylated envelope protein	1114:1154	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	7	39	theme	envelope	1139:1146	arg1	crucial					1170:1176	crucial	1170:1176	crucial	1170:1176	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	2	40	theme	strain	367:372	arg1	TBC-J6					374:379	Tibetan chicken strain TBC-J6	351:379	Tibetan chicken strain TBC-J6	351:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	41	link	N-linked	304:311	arg1	NGSs					334:337	NGSs	334:337	NGSs	334:337	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	41	link	N-linked	304:311	arg1	sites					327:331	the 13 predicted N-linked glycosylation sites	287:331	the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6	287:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	10	42	theme	gp85	1480:1483	arg1	NGS					1473:1475	the 1st (N17) and 8th (N193) NGS	1444:1475	the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6	1444:1504	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	8	43	theme	receptor	1267:1274	arg1	attachment					1276:1285	receptor attachment	1267:1285	receptor attachment	1267:1285	Glycosylation plays a major role in Env protein function, including protein processing, receptor attachment, and immune evasion.
34878920	5	44	theme	NGSs	870:873	arg1	function					858:865	the biological function	843:865	the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies	843:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	11	45	gly	Deglycosylation	1553:1567	arg1	N193					1572:1575	N193	1572:1575	N193	1572:1575	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	11	45	gly	Deglycosylation	1553:1567	arg2	N193					1572:1575	N193	1572:1575	N193	1572:1575	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	10	46	theme	TBC-J6	1499:1504	arg1	gp85					1480:1483	gp85	1480:1483	gp85 of the strain TBC-J6	1480:1504	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	9	47	theme	receptor	1412:1419	arg1	binding					1421:1427	receptor binding	1412:1427	receptor binding	1412:1427	Notably, viruses isolated recently seem to lose their 6th and 11th NGS, which proved to be important in receptor binding.
34878920	7	48	theme	viral	1098:1102	arg1	proteins					1104:1111	all the viral proteins	1090:1111	all the viral proteins	1090:1111	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	11	49	theme	Env	1640:1642	arg1	processing					1652:1661	Env protein processing	1640:1661	Env protein processing	1640:1661	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	5	50	from	function	858:865	arg1	ALV-J					878:882	ALV-J gp85	878:887	ALV-J gp85	878:887	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	1	51	theme	essential	189:197	arg1	role					199:202	an essential role	186:202	an essential role	186:202	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	11	52	from	N193	1572:1575	arg1	Deglycosylation					1553:1567	Deglycosylation	1553:1567	Deglycosylation at N193	1553:1575	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	3	53	theme	Further	436:442	arg1	research					444:451	Further research	436:451	Further research	436:451	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	4	54	theme	p27	725:727	arg1	detection					712:720	the detection	708:720	the detection of p27 and Env protein in the supernatant and gp37 in the cell culture	708:791	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	10	55	theme	virus	1546:1550	arg1	titer					1532:1536	the titer	1528:1536	the titer of this virus	1528:1550	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	1	56	theme	subgroup	141:148	arg1	ALV-J					174:178	ALV-J	174:178	ALV-J	174:178	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	56	theme	subgroup	141:148	arg1	virus					167:171	the subgroup J avian leukosis virus	137:171	the subgroup J avian leukosis virus (ALV-J)	137:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	4	57	theme	Env	733:735	arg1	protein					737:743	Env protein	733:743	Env protein	733:743	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	1	58	theme	avian	152:156	arg1	ALV-J					174:178	ALV-J	174:178	ALV-J	174:178	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	58	theme	avian	152:156	arg1	virus					167:171	the subgroup J avian leukosis virus	137:171	the subgroup J avian leukosis virus (ALV-J)	137:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	0	59	from	Pivotal	63:69	arg1	Infection					84:92	the Virus Infection	74:92	the Virus Infection	74:92	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	1	60	theme	virus	167:171	arg1	Env					129:131	Env	129:131	Env	129:131	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	60	theme	virus	167:171	arg1	glycoprotein					115:126	envelope glycoprotein	106:126	envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J)	106:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	0	61	from	193	56:58	arg1	Glycosylation					0:12	Glycosylation	0:12	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193	0:58	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	5	62	theme	gp85	944:947	arg1	role					936:939	the role	932:939	the role of gp85 in the ALV life cycle and anti-ALV-J strategies	932:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	4	63	from	detection	712:720	arg1	gp37					768:771	gp37	768:771	gp37	768:771	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	4	63	from	detection	712:720	arg1	supernatant					752:762	supernatant	752:762	supernatant	752:762	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	0	64	from	Infection	84:92	arg1	Pivotal					63:69	Pivotal	63:69	Pivotal	63:69	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	6	65	theme	tumors	1064:1069	arg1	types					1055:1059	multiple types	1046:1059	multiple types of tumors in chickens	1046:1081	IMPORTANCE ALV-J is a retrovirus that can cause multiple types of tumors in chickens.
34878920	11	66	theme	Env-receptor	1586:1597	arg1	binding					1599:1605	Env-receptor binding	1586:1605	Env-receptor binding	1586:1605	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	5	67	theme	valuable	910:917	arg1	insight					919:925	valuable insight	910:925	valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies	910:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	4	68	theme	virion	678:683	arg1	incorporation					685:697	later virion incorporation	672:697	later virion incorporation	672:697	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	4	69	from	gp37	768:771	arg1	culture					785:791	the cell culture	776:791	the cell culture	776:791	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	12	70	from	function	1701:1708	arg1	ALV-J					1721:1725	ALV-J	1721:1725	ALV-J	1721:1725	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	12	70	from	function	1701:1708	arg1	aspects					1740:1746	different aspects	1730:1746	different aspects	1730:1746	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	12	71	theme	ALV-J	1799:1803	arg1	cycle					1790:1794	the life cycle	1781:1794	the life cycle of ALV-J	1781:1803	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	4	72	from	supernatant	752:762	arg1	culture					785:791	the cell culture	776:791	the cell culture	776:791	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	8	73	theme	immune	1292:1297	arg1	evasion					1299:1305	immune evasion	1292:1305	immune evasion	1292:1305	Glycosylation plays a major role in Env protein function, including protein processing, receptor attachment, and immune evasion.
34878920	10	74	dep	1st	1448:1450	arg1	N17					1453:1455	N17	1453:1455	N17	1453:1455	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	10	74	dep	1st	1448:1450	arg1	N193					1467:1470	N193	1467:1470	N193	1467:1470	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	12	75	theme	NGSs	1713:1716	arg1	function					1701:1708	the function	1697:1708	the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J	1697:1858	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	4	76	theme	Env	645:647	arg1	processing					657:666	Env protein processing	645:666	Env protein processing	645:666	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	5	77	theme	biological	847:856	arg1	function					858:865	the biological function	843:865	the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies	843:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	2	78	gly	glycosylation	313:325	arg2	13					291:292	13	291:292	13	291:292	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	78	gly	glycosylation	313:325	arg2	NGSs					334:337	NGSs	334:337	NGSs	334:337	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	78	gly	glycosylation	313:325	arg2	sites					327:331	the 13 predicted N-linked glycosylation sites	287:331	the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6	287:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	8	79	theme	major	1201:1205	arg1	role					1207:1210	a major role	1199:1210	a major role	1199:1210	Glycosylation plays a major role in Env protein function, including protein processing, receptor attachment, and immune evasion.
34878920	2	80	theme	N-linked	304:311	arg1	NGSs					334:337	NGSs	334:337	NGSs	334:337	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	2	80	theme	N-linked	304:311	arg1	sites					327:331	the 13 predicted N-linked glycosylation sites	287:331	the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6	287:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	5	81	theme	life	960:963	arg1	cycle					965:969	the ALV life cycle	952:969	the ALV life cycle	952:969	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	11	82	from	N17	1625:1627	arg1	mutation					1613:1620	mutation	1613:1620	mutation at N17	1613:1627	Deglycosylation at N193 weakened Env-receptor binding while mutation at N17 influenced Env protein processing.
34878920	10	83	theme	1st	1448:1450	arg1	NGS					1473:1475	the 1st (N17) and 8th (N193) NGS	1444:1475	the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6	1444:1504	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34878920	0	84	theme	Envelope	23:30	arg1	Protein					32:38	ALV-J Envelope Protein	17:38	ALV-J Envelope Protein	17:38	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	1	85	from	Glycans	95:101	arg1	Env					129:131	Env	129:131	Env	129:131	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	1	85	from	Glycans	95:101	arg1	glycoprotein					115:126	envelope glycoprotein	106:126	envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J)	106:179	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	8	86	theme	protein	1219:1225	arg1	function					1227:1234	Env protein function	1215:1234	Env protein function	1215:1234	Glycosylation plays a major role in Env protein function, including protein processing, receptor attachment, and immune evasion.
34878920	1	87	theme	infection	232:240	arg1	process					242:248	infection process	232:248	infection process	232:248	Glycans on envelope glycoprotein (Env) of the subgroup J avian leukosis virus (ALV-J) play an essential role in the virion integrity and infection process.
34878920	0	88	gly	Glycosylation	0:12	arg2	Sites					43:47	Sites 17 and 193	43:58	Sites	43:47	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	0	88	gly	Glycosylation	0:12	arg2	193					56:58	193	56:58	193	56:58	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	0	88	gly	Glycosylation	0:12	arg1	Protein					32:38	ALV-J Envelope Protein	17:38	ALV-J Envelope Protein	17:38	Glycosylation of ALV-J Envelope Protein at Sites 17 and 193 Is Pivotal in the Virus Infection.
34878920	9	89	from	binding	1421:1427	arg1	important					1399:1407	important	1399:1407	important	1399:1407	Notably, viruses isolated recently seem to lose their 6th and 11th NGS, which proved to be important in receptor binding.
34878920	7	90	theme	glycosylated	1126:1137	arg1	protein					1148:1154	the heavily glycosylated envelope protein	1114:1154	the heavily glycosylated envelope protein	1114:1154	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	7	90	theme	glycosylated	1126:1137	arg1	crucial					1170:1176	crucial	1170:1176	crucial	1170:1176	Among all the viral proteins, the heavily glycosylated envelope protein is especially crucial.
34878920	2	91	theme	TBC-J6	374:379	arg1	gp85					343:346	gp85	343:346	gp85 of Tibetan chicken strain TBC-J6	343:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	5	92	from	role	936:939	arg1	cycle					965:969	the ALV life cycle	952:969	the ALV life cycle	952:969	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	5	92	from	role	936:939	arg1	strategies					986:995	anti-ALV-J strategies	975:995	anti-ALV-J strategies	975:995	This report is systematic research on clarifying the biological function of NGSs on ALV-J gp85, which would provide valuable insight into the role of gp85 in the ALV life cycle and anti-ALV-J strategies.
34878920	2	93	theme	chicken	359:365	arg1	TBC-J6					374:379	Tibetan chicken strain TBC-J6	351:379	Tibetan chicken strain TBC-J6	351:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	8	94	theme	protein	1247:1253	arg1	processing					1255:1264	protein processing	1247:1264	protein processing	1247:1264	Glycosylation plays a major role in Env protein function, including protein processing, receptor attachment, and immune evasion.
34878920	3	95	theme	entrance	552:559	arg1	assay					533:537	a blocking assay	522:537	a blocking assay of the viral entrance	522:559	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	3	95	theme	entrance	552:559	arg1	coimmunoprecipitation					562:582	coimmunoprecipitation	562:582	coimmunoprecipitation	562:582	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	3	95	theme	entrance	552:559	arg1	ELISA					589:593	ELISA	589:593	ELISA	589:593	Further research illustrated that a mutation at N193 weakened Env-receptor binding in a blocking assay of the viral entrance, coimmunoprecipitation, and ELISA.
34878920	4	96	theme	later	672:676	arg1	incorporation					685:697	later virion incorporation	672:697	later virion incorporation	672:697	Our studies also showed that N17 was involved in Env protein processing and later virion incorporation based on the detection of p27 and Env protein in the supernatant and gp37 in the cell culture.
34878920	12	97	theme	life	1785:1788	arg1	cycle					1790:1794	the life cycle	1781:1794	the life cycle of ALV-J	1781:1803	This study systemically analyzed the function of NGSs in ALV-J in different aspects, which may help us to understand the life cycle of ALV-J and provide antiviral targets for the control of ALV-J.
34878920	2	98	from	sites	327:331	arg1	gp85					343:346	gp85	343:346	gp85 of Tibetan chicken strain TBC-J6	343:379	In this study, we found that, among the 13 predicted N-linked glycosylation sites (NGSs) in gp85 of Tibetan chicken strain TBC-J6, N17, and N193/N191 are pivotal for virus replication.
34878920	10	99	theme	strain	1492:1497	arg1	TBC-J6					1499:1504	the strain TBC-J6	1488:1504	the strain TBC-J6	1488:1504	In our study, the 1st (N17) and 8th (N193) NGS of gp85 of the strain TBC-J6 can largely influence the titer of this virus.
34184536	6	0	theme	human	1188:1192	arg1	platelets					1194:1202	human platelets	1188:1202	human platelets	1188:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	6	1	from	lines	1178:1182	arg1	measurements					1113:1124	Precision measurements	1103:1124	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets	1103:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	7	2	theme	model	1340:1344	arg1	simulations					1297:1307	Monte Carlo simulations	1285:1307	Monte Carlo simulations of a geometric microtubule-IgG model	1285:1344	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	4	3	theme	point	913:917	arg1	accumulation					919:930	point accumulation	913:930	point accumulation in nanoscale topography	913:954	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	4	theme	G	737:737	arg1	antibodies					745:754	several immunoglobulin G (IgG) antibodies	714:754	several immunoglobulin G (IgG) antibodies from different animal species	714:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	10	5	theme	primary	1899:1905	arg1	conjugates					1911:1920	well-characterized primary IgG conjugates	1880:1920	well-characterized primary IgG conjugates	1880:1920	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	5	6	link	N-linked	1085:1092	arg1	glycans					1094:1100	N-linked glycans	1085:1100	N-linked glycans	1085:1100	Glutamine labeling was restricted to two sites per IgG and saturable by exploiting microbial transglutaminase after removal of N-linked glycans.
34184536	4	7	theme	IgG	740:742	arg1	antibodies					745:754	several immunoglobulin G (IgG) antibodies	714:754	several immunoglobulin G (IgG) antibodies from different animal species	714:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	9	8	theme	unphysiological	1774:1788	arg1	conformations					1790:1802	unphysiological conformations	1774:1802	unphysiological conformations of DNA-labeled IgGs	1774:1822	DNA-PAINT surprisingly yielded larger linkage errors than STORM, indicating unphysiological conformations of DNA-labeled IgGs.
34184536	2	9	theme	primary	326:332	arg1	cells					334:338	primary cells	326:338	primary cells	326:338	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	8	10	theme	restricted	1548:1557	arg1	orientation					1567:1577	the restricted binding orientation	1544:1577	the restricted binding orientation of the primary antibody's Fab fragment	1544:1616	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	4	11	theme	several	714:720	arg1	antibodies					745:754	several immunoglobulin G (IgG) antibodies	714:754	several immunoglobulin G (IgG) antibodies from different animal species	714:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	10	12	theme	precise	1946:1952	arg1	measurements					1958:1969	precise SRM measurements	1946:1969	precise SRM measurements in arbitrary fixed samples	1946:1996	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	7	13	theme	microtubule-IgG	1324:1338	arg1	model					1340:1344	a geometric microtubule-IgG model	1312:1344	a geometric microtubule-IgG model	1312:1344	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	10	14	theme	arbitrary	1974:1982	arg1	samples					1990:1996	arbitrary fixed samples	1974:1996	arbitrary fixed samples	1974:1996	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	8	15	theme	Fab	1605:1607	arg1	fragment					1609:1616	the primary antibody's Fab fragment	1582:1616	the primary antibody's Fab fragment	1582:1616	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	4	16	theme	different	761:769	arg1	species					778:784	different animal species	761:784	different animal species	761:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	1	17	dep	situ</i>	158:165	arg1	proteins					143:150	proteins	143:150	proteins <i>in situ</i> by super-resolution microscopy (SRM)	143:202	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	1	17	dep	situ</i>	158:165	arg1	<i>in					152:156	<i>in	152:156	<i>in	152:156	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	5	18	theme	microbial	1041:1049	arg1	transglutaminase					1051:1066	microbial transglutaminase	1041:1066	microbial transglutaminase	1041:1066	Glutamine labeling was restricted to two sites per IgG and saturable by exploiting microbial transglutaminase after removal of N-linked glycans.
34184536	8	19	theme	Fc	1462:1463	arg1	segments					1465:1472	Fab and Fc segments	1454:1472	Fab and Fc segments	1454:1472	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	3	20	theme	site-specific	485:497	arg1	labeling					518:525	site-specific and stoichiometric labeling	485:525	site-specific and stoichiometric labeling of primary antibodies	485:547	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	7	21	theme	Monte	1285:1289	arg1	simulations					1297:1307	Monte Carlo simulations	1285:1307	Monte Carlo simulations of a geometric microtubule-IgG model	1285:1344	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	6	22	theme	cell	1173:1176	arg1	lines					1178:1182	cell lines	1173:1182	cell lines	1173:1182	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	0	23	theme	Site-Specifically-Labeled	0:24	arg1	Antibodies					26:35	Site-Specifically-Labeled Antibodies	0:35	Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy	0:67	Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal <i>In Situ</i> Linkage Errors.
34184536	1	24	theme	spatial	119:125	arg1	localization					127:138	The precise spatial localization	107:138	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM)	107:202	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	6	25	theme	dimensions	1159:1168	arg1	measurements					1113:1124	Precision measurements	1103:1124	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets	1103:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	6	26	theme	labeling	1144:1151	arg1	dimensions					1159:1168	3D microtubule labeling shell dimensions	1129:1168	3D microtubule labeling shell dimensions in cell lines and human platelets	1129:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	3	27	theme	linkage	461:467	arg1	errors					469:474	relatively large linkage errors	444:474	relatively large linkage errors	444:474	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	4	28	theme	two-step	619:626	arg1	protocol					628:635	a simple two-step protocol	610:635	a simple two-step protocol	610:635	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	3	29	theme	stoichiometric	503:516	arg1	labeling					518:525	site-specific and stoichiometric labeling	485:525	site-specific and stoichiometric labeling of primary antibodies	485:547	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	6	30	theme	3D	1129:1130	arg1	dimensions					1159:1168	3D microtubule labeling shell dimensions	1129:1168	3D microtubule labeling shell dimensions in cell lines and human platelets	1129:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	0	31	theme	Linkage	91:97	arg1	Errors					99:104	<i>In Situ</i> Linkage Errors	76:104	<i>In Situ</i> Linkage Errors	76:104	Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal <i>In Situ</i> Linkage Errors.
34184536	8	32	theme	secondary	1518:1526	arg1	antibody					1528:1535	the secondary antibody	1514:1535	the secondary antibody	1514:1535	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	10	33	theme	cost-effective	1841:1854	arg1	protocol					1856:1863	our cost-effective protocol	1837:1863	our cost-effective protocol for generating well-characterized primary IgG conjugates	1837:1920	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	0	34	theme	<i>In	76:80	arg1	Errors					99:104	<i>In Situ</i> Linkage Errors	76:104	<i>In Situ</i> Linkage Errors	76:104	Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal <i>In Situ</i> Linkage Errors.
34184536	9	35	theme	linkage	1736:1742	arg1	errors					1744:1749	larger linkage errors	1729:1749	larger linkage errors	1729:1749	DNA-PAINT surprisingly yielded larger linkage errors than STORM, indicating unphysiological conformations of DNA-labeled IgGs.
34184536	4	36	theme	stochastic	852:861	arg1	microscopy					886:895	stochastic optical reconstruction microscopy	852:895	stochastic optical reconstruction microscopy	852:895	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	36	theme	stochastic	852:861	arg1	STORM					845:849	3D STORM	842:849	3D STORM (stochastic optical reconstruction microscopy)	842:896	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	3	37	theme	antibodies	538:547	arg1	labeling					518:525	site-specific and stoichiometric labeling	485:525	site-specific and stoichiometric labeling of primary antibodies	485:547	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	4	38	theme	reconstruction	871:884	arg1	microscopy					886:895	stochastic optical reconstruction microscopy	852:895	stochastic optical reconstruction microscopy	852:895	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	38	theme	reconstruction	871:884	arg1	STORM					845:849	3D STORM	842:849	3D STORM (stochastic optical reconstruction microscopy)	842:896	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	10	39	theme	well-characterized	1880:1897	arg1	conjugates					1911:1920	well-characterized primary IgG conjugates	1880:1920	well-characterized primary IgG conjugates	1880:1920	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	5	40	theme	glycans	1094:1100	arg1	removal					1074:1080	removal	1074:1080	removal of N-linked glycans	1074:1100	Glutamine labeling was restricted to two sites per IgG and saturable by exploiting microbial transglutaminase after removal of N-linked glycans.
34184536	7	41	theme	quantitative	1354:1365	arg1	agreement					1367:1375	quantitative agreement	1354:1375	quantitative agreement with STORM results	1354:1394	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	6	42	from	platelets	1194:1202	arg1	measurements					1113:1124	Precision measurements	1103:1124	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets	1103:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	4	43	theme	nanoscale	935:943	arg1	topography					945:954	nanoscale topography	935:954	nanoscale topography	935:954	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	2	44	from	patients	356:363	arg1	challenge					313:321	a challenge	311:321	a challenge in primary cells or tissues from patients that cannot be easily genetically modified	311:406	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	2	44	from	patients	356:363	arg1	cells					334:338	primary cells	326:338	primary cells	326:338	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	2	44	from	patients	356:363	arg1	tissues					343:349	tissues	343:349	tissues	343:349	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	6	45	from	dimensions	1159:1168	arg1	platelets					1194:1202	human platelets	1188:1202	human platelets	1188:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	6	45	from	dimensions	1159:1168	arg1	lines					1178:1182	cell lines	1173:1182	cell lines	1173:1182	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	7	46	with	agreement	1367:1375	arg1	results					1388:1394	STORM results	1382:1394	STORM results	1382:1394	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	10	47	theme	IgG	1907:1909	arg1	conjugates					1911:1920	well-characterized primary IgG conjugates	1880:1920	well-characterized primary IgG conjugates	1880:1920	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	9	48	theme	IgGs	1819:1822	arg1	conformations					1790:1802	unphysiological conformations	1774:1802	unphysiological conformations of DNA-labeled IgGs	1774:1822	DNA-PAINT surprisingly yielded larger linkage errors than STORM, indicating unphysiological conformations of DNA-labeled IgGs.
34184536	4	49	theme	immunoglobulin	722:735	arg1	antibodies					745:754	several immunoglobulin G (IgG) antibodies	714:754	several immunoglobulin G (IgG) antibodies from different animal species	714:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	6	50	theme	secondary	1248:1256	arg1	antibodies					1258:1267	primary and secondary antibodies	1236:1267	primary and secondary antibodies	1236:1267	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	10	51	theme	easy	1932:1935	arg1	route					1937:1941	an easy route	1929:1941	an easy route to precise SRM measurements in arbitrary fixed samples	1929:1996	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	4	52	dep	DNA-PAINT	902:910	arg1	accumulation					919:930	point accumulation	913:930	point accumulation in nanoscale topography	913:954	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	8	53	theme	binding	1559:1565	arg1	orientation					1567:1577	the restricted binding orientation	1544:1577	the restricted binding orientation of the primary antibody's Fab fragment	1544:1616	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	6	54	theme	primary	1236:1242	arg1	antibodies					1258:1267	primary and secondary antibodies	1236:1267	primary and secondary antibodies	1236:1267	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	1	55	theme	super-resolution	170:185	arg1	microscopy					187:196	super-resolution microscopy	170:196	super-resolution microscopy (SRM)	170:202	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	1	55	theme	super-resolution	170:185	arg1	SRM					199:201	SRM	199:201	SRM	199:201	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	1	56	theme	targeted	218:225	arg1	labeling					227:234	their targeted labeling	212:234	their targeted labeling	212:234	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	10	57	theme	SRM	1954:1956	arg1	measurements					1958:1969	precise SRM measurements	1946:1969	precise SRM measurements in arbitrary fixed samples	1946:1996	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	1	58	theme	proteins	143:150	arg1	localization					127:138	The precise spatial localization	107:138	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM)	107:202	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	8	59	theme	primary	1586:1592	arg1	antibody					1594:1601	the primary antibody	1582:1601	the primary antibody's Fab fragment	1582:1616	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	4	60	theme	animal	771:776	arg1	species					778:784	different animal species	761:784	different animal species	761:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	61	dep	fluorophores	683:694	arg1	handles					703:709	handles	703:709	handles to several immunoglobulin G (IgG) antibodies from different animal species	703:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	8	62	theme	Fab	1454:1456	arg1	segments					1465:1472	Fab and Fc segments	1454:1472	Fab and Fc segments	1454:1472	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	7	63	theme	geometric	1314:1322	arg1	model					1340:1344	a geometric microtubule-IgG model	1312:1344	a geometric microtubule-IgG model	1312:1344	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	10	64	theme	fixed	1984:1988	arg1	samples					1990:1996	arbitrary fixed samples	1974:1996	arbitrary fixed samples	1974:1996	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	5	65	theme	Glutamine	958:966	arg1	labeling					968:975	Glutamine labeling	958:975	Glutamine labeling	958:975	Glutamine labeling was restricted to two sites per IgG and saturable by exploiting microbial transglutaminase after removal of N-linked glycans.
34184536	2	66	from	challenge	313:321	arg1	cells					334:338	primary cells	326:338	primary cells	326:338	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	2	66	from	challenge	313:321	arg1	patients					356:363	patients	356:363	patients	356:363	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	2	66	from	challenge	313:321	arg1	tissues					343:349	tissues	343:349	tissues	343:349	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	6	67	theme	Precision	1103:1111	arg1	measurements					1113:1124	Precision measurements	1103:1124	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets	1103:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	9	68	theme	DNA-labeled	1807:1817	arg1	IgGs					1819:1822	DNA-labeled IgGs	1807:1822	DNA-labeled IgGs	1807:1822	DNA-PAINT surprisingly yielded larger linkage errors than STORM, indicating unphysiological conformations of DNA-labeled IgGs.
34184536	8	69	theme	flexible	1431:1438	arg1	hinge					1440:1444	the flexible hinge	1427:1444	the flexible hinge between Fab and Fc segments	1427:1472	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	7	70	theme	Carlo	1291:1295	arg1	simulations					1297:1307	Monte Carlo simulations	1285:1307	Monte Carlo simulations of a geometric microtubule-IgG model	1285:1344	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	6	71	from	measurements	1113:1124	arg1	platelets					1194:1202	human platelets	1188:1202	human platelets	1188:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	6	71	from	measurements	1113:1124	arg1	lines					1178:1182	cell lines	1173:1182	cell lines	1173:1182	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	4	72	theme	conjugates	827:836	arg1	performance					806:816	the performance	802:816	the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography)	802:955	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	73	from	accumulation	919:930	arg1	topography					945:954	nanoscale topography	935:954	nanoscale topography	935:954	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	8	74	theme	systematic	1644:1653	arg1	offset					1655:1660	the systematic offset	1640:1660	the systematic offset between the reporter and α-tubulin	1640:1695	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	4	75	theme	3D	842:843	arg1	microscopy					886:895	stochastic optical reconstruction microscopy	852:895	stochastic optical reconstruction microscopy	852:895	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	75	theme	3D	842:843	arg1	STORM					845:849	3D STORM	842:849	3D STORM (stochastic optical reconstruction microscopy)	842:896	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	1	76	theme	precise	111:117	arg1	localization					127:138	The precise spatial localization	107:138	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM)	107:202	The precise spatial localization of proteins <i>in situ</i> by super-resolution microscopy (SRM) demands their targeted labeling.
34184536	10	77	from	measurements	1958:1969	arg1	samples					1990:1996	arbitrary fixed samples	1974:1996	arbitrary fixed samples	1974:1996	In summary, our cost-effective protocol for generating well-characterized primary IgG conjugates offers an easy route to precise SRM measurements in arbitrary fixed samples.
34184536	4	78	theme	simple	612:617	arg1	protocol					628:635	a simple two-step protocol	610:635	a simple two-step protocol	610:635	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	3	79	dep	introduces	433:442	arg1	whereas					477:483	whereas	477:483	whereas	477:483	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	0	80	theme	Super-Resolution	41:56	arg1	Microscopy					58:67	Super-Resolution Microscopy	41:67	Super-Resolution Microscopy	41:67	Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal <i>In Situ</i> Linkage Errors.
34184536	6	81	theme	shell	1153:1157	arg1	dimensions					1159:1168	3D microtubule labeling shell dimensions	1129:1168	3D microtubule labeling shell dimensions in cell lines and human platelets	1129:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	3	82	theme	Indirect	409:416	arg1	immunolabeling					418:431	Indirect immunolabeling	409:431	Indirect immunolabeling	409:431	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	6	83	from	antibodies	1258:1267	arg1	errors					1224:1229	linkage errors	1216:1229	linkage errors from primary and secondary antibodies	1216:1267	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	3	84	theme	primary	530:536	arg1	antibodies					538:547	primary antibodies	530:547	primary antibodies	530:547	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	6	85	theme	microtubule	1132:1142	arg1	dimensions					1159:1168	3D microtubule labeling shell dimensions	1129:1168	3D microtubule labeling shell dimensions in cell lines and human platelets	1129:1202	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	0	86	theme	Situ</i>	82:89	arg1	Errors					99:104	<i>In Situ</i> Linkage Errors	76:104	<i>In Situ</i> Linkage Errors	76:104	Site-Specifically-Labeled Antibodies for Super-Resolution Microscopy Reveal <i>In Situ</i> Linkage Errors.
34184536	9	87	theme	larger	1729:1734	arg1	errors					1744:1749	larger linkage errors	1729:1749	larger linkage errors	1729:1749	DNA-PAINT surprisingly yielded larger linkage errors than STORM, indicating unphysiological conformations of DNA-labeled IgGs.
34184536	7	88	theme	STORM	1382:1386	arg1	results					1388:1394	STORM results	1382:1394	STORM results	1382:1394	Monte Carlo simulations of a geometric microtubule-IgG model were in quantitative agreement with STORM results.
34184536	3	89	theme	large	455:459	arg1	errors					469:474	relatively large linkage errors	444:474	relatively large linkage errors	444:474	Indirect immunolabeling introduces relatively large linkage errors, whereas site-specific and stoichiometric labeling of primary antibodies relies on elaborate chemistries.
34184536	2	90	theme	reporter	249:256	arg1	molecules					258:266	reporter molecules	249:266	reporter molecules	249:266	Positioning reporter molecules as close as possible to the target remains a challenge in primary cells or tissues from patients that cannot be easily genetically modified.
34184536	6	91	theme	linkage	1216:1222	arg1	errors					1224:1229	linkage errors	1216:1229	linkage errors from primary and secondary antibodies	1216:1267	Precision measurements of 3D microtubule labeling shell dimensions in cell lines and human platelets showed that linkage errors from primary and secondary antibodies did not add up.
34184536	8	92	theme	antibody	1528:1535	arg1	direction					1501:1509	the direction	1497:1509	the direction of the secondary antibody	1497:1535	The simulations revealed that the flexible hinge between Fab and Fc segments effectively randomized the direction of the secondary antibody, while the restricted binding orientation of the primary antibody's Fab fragment accounted for most of the systematic offset between the reporter and α-tubulin.
34184536	4	93	from	species	778:784	arg1	antibodies					745:754	several immunoglobulin G (IgG) antibodies	714:754	several immunoglobulin G (IgG) antibodies from different animal species	714:784	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	5	94	theme	N-linked	1085:1092	arg1	glycans					1094:1100	N-linked glycans	1085:1100	N-linked glycans	1085:1100	Glutamine labeling was restricted to two sites per IgG and saturable by exploiting microbial transglutaminase after removal of N-linked glycans.
34184536	4	95	theme	optical	863:869	arg1	microscopy					886:895	stochastic optical reconstruction microscopy	852:895	stochastic optical reconstruction microscopy	852:895	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
34184536	4	95	theme	optical	863:869	arg1	STORM					845:849	3D STORM	842:849	3D STORM (stochastic optical reconstruction microscopy)	842:896	In this study, we developed a simple two-step protocol to site-specifically attach reporters such as fluorophores or DNA handles to several immunoglobulin G (IgG) antibodies from different animal species and benchmarked the performance of these conjugates for 3D STORM (stochastic optical reconstruction microscopy) and DNA-PAINT (point accumulation in nanoscale topography).
33499100	0	0	theme	Thyroid	85:91	arg1	Cancer					93:98	Anaplastic Thyroid Cancer	74:98	Anaplastic Thyroid Cancer	74:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	3	1	from	ATCs	416:419	arg1	restoration					337:347	TM-induced restoration	326:347	TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs	326:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	8	2	theme	marked	1012:1017	arg1	inhibition					1032:1041	marked tumor growth inhibition	1012:1041	marked tumor growth inhibition	1012:1041	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	6	3	theme	cell	713:716	arg1	lines					718:722	both cell lines	708:722	both cell lines	708:722	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	1	4	theme	radioiodine	165:175	arg1	therapy					177:183	radioiodine therapy	165:183	radioiodine therapy for anaplastic thyroid cancers (ATCs)	165:221	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	0	5	theme	Anaplastic	74:83	arg1	Cancer					93:98	Anaplastic Thyroid Cancer	74:98	Anaplastic Thyroid Cancer	74:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	9	6	theme	radioiodine	1286:1296	arg1	therapy					1298:1304	effective radioiodine therapy	1276:1304	effective radioiodine therapy	1276:1304	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	5	7	theme	protein	643:649	arg1	expression					651:660	the protein expression	639:660	the protein expression of NIS	639:667	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	6	8	theme	CAL62	789:793	arg1	cells					795:799	CAL62 cells	789:799	CAL62 cells	789:799	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	8	9	from	reduction	972:980	arg1	ability					1000:1006	colony-forming ability	985:1006	colony-forming ability	985:1006	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	7	10	theme	protein	846:852	arg1	downregulation					806:819	The downregulation	802:819	The downregulation of glucose transporter 1 protein	802:852	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	4	11	theme	cell	462:465	arg1	CAL62					495:499	CAL62	495:499	CAL62	495:499	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	11	theme	cell	462:465	arg1	lines					467:471	TM-treated ATC cell lines	447:471	TM-treated ATC cell lines	447:471	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	11	theme	cell	462:465	arg1	BHT101					484:489	BHT101	484:489	BHT101	484:489	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	3	12	theme	responsiveness	352:365	arg1	restoration					337:347	TM-induced restoration	326:347	TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs	326:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	8	13	theme	growth	1025:1030	arg1	inhibition					1032:1041	marked tumor growth inhibition	1012:1041	marked tumor growth inhibition	1012:1041	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	4	14	theme	125I	422:425	arg1	uptake					427:432	125I uptake	422:432	125I uptake	422:432	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	3	15	theme	refractory	405:414	arg1	ATCs					416:419	radioiodine refractory ATCs	393:419	radioiodine refractory ATCs	393:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	8	16	theme	tumor	1019:1023	arg1	inhibition					1032:1041	marked tumor growth inhibition	1012:1041	marked tumor growth inhibition	1012:1041	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	1	17	from	difficulties	149:160	arg1	therapy					177:183	radioiodine therapy	165:183	radioiodine therapy for anaplastic thyroid cancers (ATCs)	165:221	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	5	18	theme	mRNA	594:597	arg1	expression					599:608	the mRNA expression	590:608	the mRNA expression of iodide-handling genes	590:633	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	2	19	link	N-linked	245:252	arg1	inhibitor					268:276	an N-linked glycosylation inhibitor	242:276	an N-linked glycosylation inhibitor	242:276	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	2	19	link	N-linked	245:252	arg1	Tunicamycin					224:234	Tunicamycin	224:234	Tunicamycin (TM)	224:239	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	7	20	theme	transporter	832:842	arg1	protein					846:852	glucose transporter 1 protein	824:852	glucose transporter 1 protein	824:852	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	7	21	theme	glucose	824:830	arg1	protein					846:852	glucose transporter 1 protein	824:852	glucose transporter 1 protein	824:852	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	6	22	located	observed	777:784	arg1	cells					795:799	CAL62 cells	789:799	CAL62 cells	789:799	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	6	22	located	observed	777:784	arg2	phosphorylation					752:766	AKT (protein kinase B) phosphorylation	729:766	AKT (protein kinase B) phosphorylation	729:766	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	0	23	from	Agent	41:45	arg1	Therapy					62:68	Radioiodine Therapy	50:68	Radioiodine Therapy for Anaplastic Thyroid Cancer	50:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	5	24	theme	iodide-handling	613:627	arg1	genes					629:633	iodide-handling genes	613:633	iodide-handling genes	613:633	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	9	25	theme	expression	1219:1228	arg1	restoration					1183:1193	the restoration	1179:1193	the restoration of iodide-handling gene expression and radioiodine avidity	1179:1252	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	1	26	theme	anaplastic	189:198	arg1	ATCs					217:220	ATCs	217:220	ATCs	217:220	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	1	26	theme	anaplastic	189:198	arg1	cancers					208:214	anaplastic thyroid cancers	189:214	anaplastic thyroid cancers (ATCs)	189:221	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	7	27	theme	18F-fluorodeoxyglucose	921:942	arg1	uptake					950:955	18F-fluorodeoxyglucose (FDG) uptake	921:955	18F-fluorodeoxyglucose (FDG) uptake	921:955	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	5	28	theme	genes	629:633	arg1	expression					651:660	the protein expression	639:660	the protein expression of NIS	639:667	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	5	28	theme	genes	629:633	arg1	expression					599:608	the mRNA expression	590:608	the mRNA expression of iodide-handling genes	590:633	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	6	29	theme	pERK1/2	681:687	arg1	phosphorylation					689:703	pERK1/2 phosphorylation	681:703	pERK1/2 phosphorylation	681:703	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	1	30	theme	thyroid	200:206	arg1	ATCs					217:220	ATCs	217:220	ATCs	217:220	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	1	30	theme	thyroid	200:206	arg1	cancers					208:214	anaplastic thyroid cancers	189:214	anaplastic thyroid cancers (ATCs)	189:221	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	3	31	theme	radioiodine	393:403	arg1	ATCs					416:419	radioiodine refractory ATCs	393:419	radioiodine refractory ATCs	393:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	4	32	theme	symporter	548:556	arg1	inhibitor					564:572	a sodium-iodide symporter (NIS) inhibitor	532:572	a sodium-iodide symporter (NIS) inhibitor	532:572	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	32	theme	symporter	548:556	arg1	KClO4					525:529	KClO4	525:529	KClO4	525:529	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	9	33	theme	gene	1214:1217	arg1	expression					1219:1228	iodide-handling gene expression	1198:1228	iodide-handling gene expression	1198:1228	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	3	34	theme	radioiodine	370:380	arg1	therapy					382:388	radioiodine therapy	370:388	radioiodine therapy	370:388	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	4	35	theme	sodium-iodide	534:546	arg1	symporter					548:556	sodium-iodide symporter	534:556	a sodium-iodide symporter (NIS) inhibitor	532:572	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	35	theme	sodium-iodide	534:546	arg1	NIS					559:561	NIS	559:561	NIS	559:561	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	8	36	theme	combination	1064:1074	arg1	group					1076:1080	the combination group	1060:1080	the combination group	1060:1080	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	7	37	theme	significant	896:906	arg1	reduction					908:916	a significant reduction	894:916	a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake	894:955	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	7	38	theme	FDG	945:947	arg1	uptake					950:955	18F-fluorodeoxyglucose (FDG) uptake	921:955	18F-fluorodeoxyglucose (FDG) uptake	921:955	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	3	39	from	restoration	337:347	arg1	ATCs					416:419	radioiodine refractory ATCs	393:419	radioiodine refractory ATCs	393:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	2	40	theme	anticancer	285:294	arg1	drug					296:299	an anticancer drug	282:299	an anticancer drug	282:299	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	2	40	theme	anticancer	285:294	arg1	Tunicamycin					224:234	Tunicamycin	224:234	Tunicamycin (TM)	224:239	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	9	41	from	function	1118:1125	arg1	ATC					1161:1163	ATC	1161:1163	ATC	1161:1163	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	9	42	contain	possess	1102:1108	arg2	function					1118:1125	a novel function	1110:1125	a novel function as a redifferentiation inducer in ATC	1110:1163	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	9	42	contain	possess	1102:1108	arg1	TM					1083:1084	TM	1083:1084	TM	1083:1084	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	4	43	theme	ATC	458:460	arg1	CAL62					495:499	CAL62	495:499	CAL62	495:499	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	43	theme	ATC	458:460	arg1	lines					467:471	TM-treated ATC cell lines	447:471	TM-treated ATC cell lines	447:471	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	43	theme	ATC	458:460	arg1	BHT101					484:489	BHT101	484:489	BHT101	484:489	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	9	44	theme	effective	1276:1284	arg1	therapy					1298:1304	effective radioiodine therapy	1276:1304	effective radioiodine therapy	1276:1304	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	8	45	located	observed	1048:1055	arg1	group					1076:1080	the combination group	1060:1080	the combination group	1060:1080	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	8	45	located	observed	1048:1055	arg2	reduction					972:980	A significant reduction	958:980	A significant reduction in colony-forming ability	958:1006	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	8	45	located	observed	1048:1055	arg2	inhibition					1032:1041	marked tumor growth inhibition	1012:1041	marked tumor growth inhibition	1012:1041	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	0	46	theme	Redifferentiation	23:39	arg1	Agent					41:45	a Novel Redifferentiation Agent	15:45	a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer	15:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	8	47	theme	significant	960:970	arg1	reduction					972:980	A significant reduction	958:980	A significant reduction in colony-forming ability	958:1006	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	3	48	from	responsiveness	352:365	arg1	ATCs					416:419	radioiodine refractory ATCs	393:419	radioiodine refractory ATCs	393:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	0	49	theme	Novel	17:21	arg1	Agent					41:45	a Novel Redifferentiation Agent	15:45	a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer	15:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	6	50	theme	kinase	742:747	arg1	B					749:749	protein kinase B	734:749	protein kinase B	734:749	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	6	50	theme	kinase	742:747	arg1	AKT					729:731	AKT	729:731	AKT (protein kinase B) phosphorylation	729:766	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	8	51	from	inhibition	1032:1041	arg1	ability					1000:1006	colony-forming ability	985:1006	colony-forming ability	985:1006	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	0	52	theme	Radioiodine	50:60	arg1	Therapy					62:68	Radioiodine Therapy	50:68	Radioiodine Therapy for Anaplastic Thyroid Cancer	50:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	5	53	theme	NIS	665:667	arg1	expression					651:660	the protein expression	639:660	the protein expression of NIS	639:667	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	5	53	theme	NIS	665:667	arg1	expression					599:608	the mRNA expression	590:608	the mRNA expression of iodide-handling genes	590:633	TM upregulated the mRNA expression of iodide-handling genes and the protein expression of NIS.
33499100	6	54	theme	protein	734:740	arg1	B					749:749	protein kinase B	734:749	protein kinase B	734:749	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	6	54	theme	protein	734:740	arg1	AKT					729:731	AKT	729:731	AKT (protein kinase B) phosphorylation	729:766	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	9	55	theme	radioiodine	1234:1244	arg1	avidity					1246:1252	radioiodine avidity	1234:1252	radioiodine avidity	1234:1252	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	9	56	theme	novel	1112:1116	arg1	function					1118:1125	a novel function	1110:1125	a novel function as a redifferentiation inducer in ATC	1110:1163	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	1	57	theme	thyroid-related	118:132	arg1	genes					134:138	thyroid-related genes	118:138	thyroid-related genes	118:138	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	8	58	theme	colony-forming	985:998	arg1	ability					1000:1006	colony-forming ability	985:1006	colony-forming ability	985:1006	A significant reduction in colony-forming ability and marked tumor growth inhibition were observed in the combination group.
33499100	9	59	theme	avidity	1246:1252	arg1	restoration					1183:1193	the restoration	1179:1193	the restoration of iodide-handling gene expression and radioiodine avidity	1179:1252	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	2	60	theme	glycosylation	254:266	arg1	inhibitor					268:276	an N-linked glycosylation inhibitor	242:276	an N-linked glycosylation inhibitor	242:276	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	2	60	theme	glycosylation	254:266	arg1	Tunicamycin					224:234	Tunicamycin	224:234	Tunicamycin (TM)	224:239	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	6	61	theme	AKT	729:731	arg1	phosphorylation					752:766	AKT (protein kinase B) phosphorylation	729:766	AKT (protein kinase B) phosphorylation	729:766	TM blocked pERK1/2 phosphorylation in both cell lines, but AKT (protein kinase B) phosphorylation was only observed in CAL62 cells.
33499100	1	62	theme	genes	134:138	arg1	silencing					105:113	The silencing	101:113	The silencing of thyroid-related genes	101:138	The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs).
33499100	4	63	theme	TM-treated	447:456	arg1	CAL62					495:499	CAL62	495:499	CAL62	495:499	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	63	theme	TM-treated	447:456	arg1	lines					467:471	TM-treated ATC cell lines	447:471	TM-treated ATC cell lines	447:471	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	4	63	theme	TM-treated	447:456	arg1	BHT101					484:489	BHT101	484:489	BHT101	484:489	125I uptake increased in TM-treated ATC cell lines, including BHT101 and CAL62, which was inhibited by KClO4, a sodium-iodide symporter (NIS) inhibitor.
33499100	2	64	theme	N-linked	245:252	arg1	inhibitor					268:276	an N-linked glycosylation inhibitor	242:276	an N-linked glycosylation inhibitor	242:276	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	2	64	theme	N-linked	245:252	arg1	Tunicamycin					224:234	Tunicamycin	224:234	Tunicamycin (TM)	224:239	Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug.
33499100	7	65	theme	TM-treated	871:880	arg1	cells					882:886	TM-treated cells	871:886	TM-treated cells	871:886	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	7	66	from	reduction	908:916	arg1	uptake					950:955	18F-fluorodeoxyglucose (FDG) uptake	921:955	18F-fluorodeoxyglucose (FDG) uptake	921:955	The downregulation of glucose transporter 1 protein was confirmed in TM-treated cells, with a significant reduction in 18F-fluorodeoxyglucose (FDG) uptake.
33499100	9	67	theme	iodide-handling	1198:1212	arg1	expression					1219:1228	iodide-handling gene expression	1198:1228	iodide-handling gene expression	1198:1228	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
33499100	3	68	theme	TM-induced	326:335	arg1	restoration					337:347	TM-induced restoration	326:347	TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs	326:419	Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiodine refractory ATCs.
33499100	0	69	dep	Tunicamycin	0:10	arg1	Agent					41:45	a Novel Redifferentiation Agent	15:45	a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer	15:98	Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer.
33499100	9	70	theme	redifferentiation	1132:1148	arg1	inducer					1150:1156	a redifferentiation inducer	1130:1156	a redifferentiation inducer	1130:1156	TM was revealed to possess a novel function as a redifferentiation inducer in ATC as it induces the restoration of iodide-handling gene expression and radioiodine avidity, thereby facilitating effective radioiodine therapy.
32422350	0	0	theme	deglycosylation	72:86	arg1	disorder					60:67	NGLY1-congenital disorder	43:67	NGLY1-congenital disorder of deglycosylation	43:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	0	1	from	failure	12:18	arg1	patient					30:36	a male patient	23:36	a male patient with NGLY1-congenital disorder of deglycosylation	23:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	9	2	theme	first	1104:1108	arg1	report					1110:1115	the first report	1100:1115	the first report of a reversible ALF among patients with NGLY1-CDDG	1100:1166	This is the first report of a reversible ALF among patients with NGLY1-CDDG.
32422350	9	2	theme	first	1104:1108	arg1	This					1092:1095	This	1092:1095	This	1092:1095	This is the first report of a reversible ALF among patients with NGLY1-CDDG.
32422350	5	3	theme	NGLY1	688:692	arg1	gene					694:697	the NGLY1 gene	684:697	the NGLY1 gene	684:697	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	4	4	theme	failure	578:584	arg1	episode					555:561	a severe episode	546:561	a severe episode of acute liver failure (ALF)	546:590	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	5	5	dep	c.1891del	712:720	arg1	p.					723:724	c.1891del, p.	712:724	p.	723:724	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	4	6	theme	male	519:522	arg1	patient					524:530	a five-year-old male patient	503:530	a five-year-old male patient who presented a severe episode of acute liver failure (ALF)	503:590	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	10	7	theme	NGLY1	1337:1341	arg1	function					1348:1355	impaired NGLY1 gene function	1328:1355	impaired NGLY1 gene function	1328:1355	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	1	8	theme	NGLY1	237:241	arg1	gene					243:246	the NGLY1 gene	233:246	the NGLY1 gene	233:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	4	9	theme	five-year-old	505:517	arg1	patient					524:530	a five-year-old male patient	503:530	a five-year-old male patient who presented a severe episode of acute liver failure (ALF)	503:590	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	10	10	theme	impaired	1328:1335	arg1	function					1348:1355	impaired NGLY1 gene function	1328:1355	impaired NGLY1 gene function	1328:1355	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	10	11	theme	chain	1297:1301	arg1	damage					1303:1308	mitochondrial respiratory chain damage	1271:1308	mitochondrial respiratory chain damage	1271:1308	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	5	12	theme	Gln631Serfs	726:736	arg1	*					737:737	Gln631Serfs*7	726:738	Gln631Serfs*7	726:738	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	12	theme	Gln631Serfs	726:736	arg1	c.1891del					712:720	c.1891del	712:720	c.1891del	712:720	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	6	13	theme	frequent	829:836	arg1	infections					854:863	the most frequent viral hepatitis infections	820:863	the most frequent viral hepatitis infections	820:863	Serology for the most frequent viral hepatitis infections, autoimmune panel, and investigations for metabolic or toxic causes were also normal or negative.
32422350	10	14	theme	mitochondrial	1271:1283	arg1	damage					1303:1308	mitochondrial respiratory chain damage	1271:1308	mitochondrial respiratory chain damage	1271:1308	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	5	15	theme	Exome	593:597	arg1	sequencing					599:608	Exome sequencing	593:608	Exome sequencing	593:608	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	16	from	c.1891del	712:720	arg1	exon					744:747	exon 12 and NM_018297.3	744:766	exon	744:747	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	16	from	c.1891del	712:720	arg1	NM_018297.3					756:766	NM_018297.3	756:766	NM_018297.3	756:766	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	9	17	theme	reversible	1122:1131	arg1	ALF					1133:1135	a reversible ALF	1120:1135	a reversible ALF among patients with NGLY1-CDDG	1120:1166	This is the first report of a reversible ALF among patients with NGLY1-CDDG.
32422350	5	18	dep	heterozygous	630:641	arg1	pathogenic					661:670	pathogenic	661:670	pathogenic	661:670	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	11	19	from	prognosis	1418:1426	arg1	patients					1438:1445	patients	1438:1445	patients with NGLY1-CDDG	1438:1461	Further reports are required in order to know the long-term prognosis of ALF in patients with NGLY1-CDDG.
32422350	6	20	theme	toxic	920:924	arg1	causes					926:931	metabolic or toxic causes	907:931	metabolic or toxic causes	907:931	Serology for the most frequent viral hepatitis infections, autoimmune panel, and investigations for metabolic or toxic causes were also normal or negative.
32422350	5	21	dep	c.531dup	768:775	arg1	p.					778:779	c.531dup, p.	768:779	p.	778:779	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	9	22	theme	ALF	1133:1135	arg1	report					1110:1115	the first report	1100:1115	the first report of a reversible ALF among patients with NGLY1-CDDG	1100:1166	This is the first report of a reversible ALF among patients with NGLY1-CDDG.
32422350	9	22	theme	ALF	1133:1135	arg1	This					1092:1095	This	1092:1095	This	1092:1095	This is the first report of a reversible ALF among patients with NGLY1-CDDG.
32422350	2	23	theme	Transient	249:257	arg1	dysfunction					296:306	the typical hepatic dysfunction	276:306	the typical hepatic dysfunction described in these patients	276:334	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	2	23	theme	Transient	249:257	arg1	transaminitis					259:271	Transient transaminitis	249:271	Transient transaminitis	249:271	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	3	24	theme	intrahepatic	434:445	arg1	inclusions					459:468	intrahepatic cytoplasmic inclusions	434:468	intrahepatic cytoplasmic inclusions	434:468	Microscopically, intrahepatic cytoplasmic inclusions and fibrosis are seen.
32422350	0	25	theme	liver	6:10	arg1	failure					12:18	Acute liver failure	0:18	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation	0:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	5	26	theme	heterozygous	630:641	arg1	variants					672:679	compound heterozygous pathogenic/likely pathogenic variants	621:679	compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9)	621:794	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	0	27	theme	Acute	0:4	arg1	failure					12:18	Acute liver failure	0:18	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation	0:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	9	28	with	patients	1143:1150	arg1	NGLY1-CDDG					1157:1166	NGLY1-CDDG	1157:1166	NGLY1-CDDG	1157:1166	This is the first report of a reversible ALF among patients with NGLY1-CDDG.
32422350	10	29	theme	function	1348:1355	arg1	context					1317:1323	the context	1313:1323	the context of impaired NGLY1 gene function	1313:1355	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	1	30	theme	Congenital	89:98	arg1	disorder					191:198	a very rare autosomal recessive disorder	159:198	a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene	159:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	30	theme	Congenital	89:98	arg1	disorder					100:107	Congenital disorder	89:107	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273)	89:154	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	10	31	theme	liver	1253:1257	arg1	disease					1259:1265	liver disease	1253:1265	liver disease	1253:1265	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	1	32	theme	rare	166:169	arg1	disorder					100:107	Congenital disorder	89:107	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273)	89:154	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	32	theme	rare	166:169	arg1	disorder					191:198	a very rare autosomal recessive disorder	159:198	a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene	159:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	11	33	with	patients	1438:1445	arg1	NGLY1-CDDG					1452:1461	NGLY1-CDDG	1452:1461	NGLY1-CDDG	1452:1461	Further reports are required in order to know the long-term prognosis of ALF in patients with NGLY1-CDDG.
32422350	4	34	theme	severe	548:553	arg1	episode					555:561	a severe episode	546:561	a severe episode of acute liver failure (ALF)	546:590	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	8	35	theme	function	1019:1026	arg1	tests					1028:1032	Liver function tests	1013:1032	Liver function tests	1013:1032	Liver function tests and elastography remains normal after a 2-year follow-up.
32422350	10	36	theme	gene	1343:1346	arg1	function					1348:1355	impaired NGLY1 gene function	1328:1355	impaired NGLY1 gene function	1328:1355	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	2	37	theme	hepatic	288:294	arg1	dysfunction					296:306	the typical hepatic dysfunction	276:306	the typical hepatic dysfunction described in these patients	276:334	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	2	37	theme	hepatic	288:294	arg1	transaminitis					259:271	Transient transaminitis	249:271	Transient transaminitis	249:271	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	1	38	dep	disorder	100:107	arg1	MIM					144:146	MIM 615273	144:153	MIM 615273	144:153	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	38	dep	disorder	100:107	arg1	CDDG					138:141	CDDG	138:141	CDDG	138:141	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	39	theme	autosomal	171:179	arg1	disorder					100:107	Congenital disorder	89:107	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273)	89:154	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	39	theme	autosomal	171:179	arg1	disorder					191:198	a very rare autosomal recessive disorder	159:198	a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene	159:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	5	40	theme	Asn178Glnfs	781:791	arg1	*					792:792	Asn178Glnfs*9	781:793	Asn178Glnfs*9	781:793	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	40	theme	Asn178Glnfs	781:791	arg1	c.531dup					768:775	c.531dup	768:775	c.531dup	768:775	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	4	41	theme	acute	566:570	arg1	ALF					587:589	ALF	587:589	ALF	587:589	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	4	41	theme	acute	566:570	arg1	failure					578:584	acute liver failure	566:584	acute liver failure (ALF)	566:590	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	8	42	theme	Liver	1013:1017	arg1	tests					1028:1032	Liver function tests	1013:1032	Liver function tests	1013:1032	Liver function tests and elastography remains normal after a 2-year follow-up.
32422350	2	43	theme	typical	280:286	arg1	dysfunction					296:306	the typical hepatic dysfunction	276:306	the typical hepatic dysfunction described in these patients	276:334	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	2	43	theme	typical	280:286	arg1	transaminitis					259:271	Transient transaminitis	249:271	Transient transaminitis	249:271	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	1	44	theme	recessive	181:189	arg1	disorder					100:107	Congenital disorder	89:107	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273)	89:154	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	44	theme	recessive	181:189	arg1	disorder					191:198	a very rare autosomal recessive disorder	159:198	a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene	159:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	0	45	theme	male	25:28	arg1	patient					30:36	a male patient	23:36	a male patient with NGLY1-congenital disorder of deglycosylation	23:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	10	46	theme	direct	1229:1234	arg1	relation					1236:1243	a direct relation	1227:1243	a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function	1227:1355	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	3	47	theme	cytoplasmic	447:457	arg1	inclusions					459:468	intrahepatic cytoplasmic inclusions	434:468	intrahepatic cytoplasmic inclusions	434:468	Microscopically, intrahepatic cytoplasmic inclusions and fibrosis are seen.
32422350	4	48	theme	liver	572:576	arg1	ALF					587:589	ALF	587:589	ALF	587:589	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	4	48	theme	liver	572:576	arg1	failure					578:584	acute liver failure	566:584	acute liver failure (ALF)	566:590	We report a five-year-old male patient who presented a severe episode of acute liver failure (ALF).
32422350	10	49	theme	respiratory	1285:1295	arg1	damage					1303:1308	mitochondrial respiratory chain damage	1271:1308	mitochondrial respiratory chain damage	1271:1308	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	6	50	theme	autoimmune	866:875	arg1	panel					877:881	autoimmune panel	866:881	autoimmune panel	866:881	Serology for the most frequent viral hepatitis infections, autoimmune panel, and investigations for metabolic or toxic causes were also normal or negative.
32422350	1	51	from	variants	221:228	arg1	gene					243:246	the NGLY1 gene	233:246	the NGLY1 gene	233:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	6	52	theme	metabolic	907:915	arg1	causes					926:931	metabolic or toxic causes	907:931	metabolic or toxic causes	907:931	Serology for the most frequent viral hepatitis infections, autoimmune panel, and investigations for metabolic or toxic causes were also normal or negative.
32422350	7	53	theme	Hepatic	963:969	arg1	disease					971:977	Hepatic disease	963:977	Hepatic disease	963:977	Hepatic disease resolved favorably after 46 days.
32422350	1	54	theme	N-linked	112:119	arg1	deglycosylation					121:135	N-linked deglycosylation	112:135	N-linked deglycosylation	112:135	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	6	55	theme	viral	838:842	arg1	infections					854:863	the most frequent viral hepatitis infections	820:863	the most frequent viral hepatitis infections	820:863	Serology for the most frequent viral hepatitis infections, autoimmune panel, and investigations for metabolic or toxic causes were also normal or negative.
32422350	6	56	theme	hepatitis	844:852	arg1	infections					854:863	the most frequent viral hepatitis infections	820:863	the most frequent viral hepatitis infections	820:863	Serology for the most frequent viral hepatitis infections, autoimmune panel, and investigations for metabolic or toxic causes were also normal or negative.
32422350	1	57	theme	deglycosylation	121:135	arg1	disorder					191:198	a very rare autosomal recessive disorder	159:198	a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene	159:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	1	57	theme	deglycosylation	121:135	arg1	disorder					100:107	Congenital disorder	89:107	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273)	89:154	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	5	58	from	variants	672:679	arg1	gene					694:697	the NGLY1 gene	684:697	the NGLY1 gene	684:697	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	1	59	link	N-linked	112:119	arg1	deglycosylation					121:135	N-linked deglycosylation	112:135	N-linked deglycosylation	112:135	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	10	60	from	relation	1236:1243	arg1	context					1317:1323	the context	1313:1323	the context of impaired NGLY1 gene function	1313:1355	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	11	61	theme	ALF	1431:1433	arg1	prognosis					1418:1426	the long-term prognosis	1404:1426	the long-term prognosis of ALF in patients with NGLY1-CDDG	1404:1461	Further reports are required in order to know the long-term prognosis of ALF in patients with NGLY1-CDDG.
32422350	11	62	theme	long-term	1408:1416	arg1	prognosis					1418:1426	the long-term prognosis	1404:1426	the long-term prognosis of ALF in patients with NGLY1-CDDG	1404:1461	Further reports are required in order to know the long-term prognosis of ALF in patients with NGLY1-CDDG.
32422350	1	63	theme	pathogenic	210:219	arg1	variants					221:228	pathogenic variants	210:228	pathogenic variants in the NGLY1 gene	210:246	Congenital disorder of N-linked deglycosylation (CDDG, MIM 615273) is a very rare autosomal recessive disorder caused by pathogenic variants in the NGLY1 gene.
32422350	8	64	theme	2-year	1074:1079	arg1	follow-up					1081:1089	a 2-year follow-up	1072:1089	a 2-year follow-up	1072:1089	Liver function tests and elastography remains normal after a 2-year follow-up.
32422350	10	65	theme	definitive	1182:1191	arg1	cause					1193:1197	its definitive cause	1178:1197	its definitive cause	1178:1197	Although its definitive cause remains unknown, we suggest a direct relation between liver disease and mitochondrial respiratory chain damage in the context of impaired NGLY1 gene function.
32422350	0	66	with	patient	30:36	arg1	disorder					60:67	NGLY1-congenital disorder	43:67	NGLY1-congenital disorder of deglycosylation	43:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	2	67	theme	neonatal	355:362	arg1	jaundice					364:371	neonatal jaundice	355:371	neonatal jaundice	355:371	Transient transaminitis is the typical hepatic dysfunction described in these patients, but also included neonatal jaundice, hepatomegaly, splenomegaly, and steatosis.
32422350	0	68	theme	NGLY1-congenital	43:58	arg1	disorder					60:67	NGLY1-congenital disorder	43:67	NGLY1-congenital disorder of deglycosylation	43:86	Acute liver failure in a male patient with NGLY1-congenital disorder of deglycosylation.
32422350	5	69	dep	variants	672:679	arg1	*					737:737	Gln631Serfs*7	726:738	Gln631Serfs*7	726:738	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	69	dep	variants	672:679	arg1	c.1891del					712:720	c.1891del	712:720	c.1891del	712:720	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	69	dep	variants	672:679	arg1	*					792:792	Asn178Glnfs*9	781:793	Asn178Glnfs*9	781:793	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	69	dep	variants	672:679	arg1	NM_018297.3					700:710	NM_018297.3	700:710	NM_018297.3	700:710	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	5	69	dep	variants	672:679	arg1	c.531dup					768:775	c.531dup	768:775	c.531dup	768:775	Exome sequencing identified compound heterozygous pathogenic/likely pathogenic variants in the NGLY1 gene: NM_018297.3:c.1891del, p.(Gln631Serfs*7) in exon 12 and NM_018297.3:c.531dup, p.(Asn178Glnfs*9) in exon 4.
32422350	11	70	theme	Further	1358:1364	arg1	reports					1366:1372	Further reports	1358:1372	Further reports	1358:1372	Further reports are required in order to know the long-term prognosis of ALF in patients with NGLY1-CDDG.
34362956	0	0	theme	low	67:69	arg1	patients					92:99	low polygenic risk score patients	67:99	low polygenic risk score patients	67:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	4	1	theme	T1D	590:592	arg1	cases					594:598	3302 T1D cases	585:598	3302 T1D cases	585:598	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	1	2	from	loci	253:256	arg1	cases					267:271	these cases	261:271	these cases	261:271	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	5	3	theme	T1D	715:717	arg1	PRS					719:721	low T1D PRS	711:721	low T1D PRS	711:721	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	6	4	theme	low	963:965	arg1	T1D					971:973	low PRS T1D	963:973	low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08)	963:1018	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	1	5	theme	T1D	194:196	arg1	cases					198:202	T1D cases	194:202	T1D cases with low T1D PRS	194:219	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	2	6	theme	T1D	405:407	arg1	effects					305:311	genetic effects	297:311	genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D	297:407	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	8	7	theme	long	1369:1372	arg1	lncRNA					1410:1415	lncRNA	1410:1415	lncRNA	1410:1415	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	8	7	theme	long	1369:1372	arg1	RNAs					1404:1407	long intergenic non-protein coding RNAs	1369:1407	long intergenic non-protein coding RNAs (lncRNA)	1369:1416	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	8	8	link	N-linked	1442:1449	arg1	glycosylation					1451:1463	N-linked glycosylation	1442:1463	N-linked glycosylation	1442:1463	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	6	9	from	significance	990:1001	arg1	T1D					971:973	low PRS T1D	963:973	low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08)	963:1018	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	5	10	theme	low	784:786	arg1	PRS					792:794	low T1D PRS	784:794	low T1D PRS	784:794	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	6	11	theme	genetic	850:856	arg1	loci					858:861	Thirteen novel genetic loci	835:861	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91)	835:916	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	5	12	theme	association	811:821	arg1	test					829:832	genome-wide association (GWA) test	799:832	genome-wide association (GWA) test	799:832	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	0	13	theme	risk	81:84	arg1	patients					92:99	low polygenic risk score patients	67:99	low polygenic risk score patients	67:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	6	14	theme	established	1038:1048	arg1	loci					1054:1057	4 established T1D loci	1036:1057	4 established T1D loci	1036:1057	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	5	15	with	Cases	700:704	arg1	PRS					719:721	low T1D PRS	711:721	low T1D PRS	711:721	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	0	16	theme	polygenic	71:79	arg1	patients					92:99	low polygenic risk score patients	67:99	low polygenic risk score patients	67:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	7	17	theme	previous	1327:1334	arg1	studies					1340:1346	previous GWA studies	1327:1346	previous GWA studies	1327:1346	For the 13 novel loci, 9 regions have been reported of association with obesity related traits by previous GWA studies.
34362956	5	18	with	controls	770:777	arg1	PRS					792:794	low T1D PRS	784:794	low T1D PRS	784:794	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	1	19	theme	low	209:211	arg1	PRS					217:219	low T1D PRS	209:219	low T1D PRS	209:219	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	4	20	theme	T1D	671:673	arg1	cases					675:679	3297 T1D cases	666:679	3297 T1D cases	666:679	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	0	21	theme	score	86:90	arg1	patients					92:99	low polygenic risk score patients	67:99	low polygenic risk score patients	67:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	6	22	theme	genome-wide	978:988	arg1	P ≤ 5.0 × E-08					1004:1017	P ≤ 5.0 × E-08	1004:1017	P ≤ 5.0 × E-08	1004:1017	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	22	theme	genome-wide	978:988	arg1	significance					990:1001	genome-wide significance	978:1001	genome-wide significance (P ≤ 5.0 × E-08)	978:1018	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	4	23	theme	3297	666:669	arg1	cases					675:679	3297 T1D cases	666:679	3297 T1D cases	666:679	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	1	24	theme	autoimmune	138:147	arg1	T1D					166:168	T1D	166:168	T1D	166:168	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	1	24	theme	autoimmune	138:147	arg1	diabetes					156:163	autoimmune type 1 diabetes (T1D)	138:169	autoimmune type 1 diabetes (T1D)	138:169	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	2	25	theme	non-mainstream	370:383	arg1	effects					305:311	genetic effects	297:311	genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D	297:407	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	6	26	theme	novel	844:848	arg1	loci					858:861	Thirteen novel genetic loci	835:861	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91)	835:916	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	4	27	theme	independent	627:637	arg1	cohort					646:651	the independent second cohort	623:651	the independent second cohort	623:651	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	1	28	theme	type	149:152	arg1	T1D					166:168	T1D	166:168	T1D	166:168	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	1	28	theme	type	149:152	arg1	diabetes					156:163	autoimmune type 1 diabetes (T1D)	138:169	autoimmune type 1 diabetes (T1D)	138:169	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	1	29	theme	T1D	213:215	arg1	PRS					217:219	low T1D PRS	209:219	low T1D PRS	209:219	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	6	30	theme	previous	1083:1090	arg1	study					1092:1096	our previous study	1079:1096	our previous study	1079:1096	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	31	theme	high	868:871	arg1	quality					884:890	high imputation quality	868:890	high imputation quality (Quality Score r2 > 0.91)	868:916	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	31	theme	high	868:871	arg1	Score					901:905	Quality Score r2 > 0.91	893:915	Quality Score r2 > 0.91	893:915	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	3	32	dep	PRS	502:504	arg1	PRS					502:504	the PRS modeling and testing	498:525	the PRS modeling and testing	498:525	Two cohorts for the PRS modeling and testing respectively were included.
34362956	3	32	dep	PRS	502:504	arg1	testing					519:525	testing	519:525	testing	519:525	Two cohorts for the PRS modeling and testing respectively were included.
34362956	3	32	dep	PRS	502:504	arg1	modeling					506:513	modeling	506:513	modeling	506:513	Two cohorts for the PRS modeling and testing respectively were included.
34362956	0	33	theme	type	29:32	arg1	diabetes					36:43	non-autoimmune type 1 diabetes	14:43	non-autoimmune type 1 diabetes	14:43	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	5	34	theme	genome-wide	799:809	arg1	test					829:832	genome-wide association (GWA) test	799:832	genome-wide association (GWA) test	799:832	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	5	35	theme	GWA	824:826	arg1	test					829:832	genome-wide association (GWA) test	799:832	genome-wide association (GWA) test	799:832	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	2	36	theme	previous	440:447	arg1	studies					449:455	the previous studies	436:455	the previous studies on T1D cases in general	436:479	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	0	37	theme	non-autoimmune	14:27	arg1	diabetes					36:43	non-autoimmune type 1 diabetes	14:43	non-autoimmune type 1 diabetes	14:43	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	2	38	theme	T1D	460:462	arg1	cases					464:468	T1D cases	460:468	T1D cases in general	460:479	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	7	39	theme	GWA	1336:1338	arg1	studies					1340:1346	previous GWA studies	1327:1346	previous GWA studies	1327:1346	For the 13 novel loci, 9 regions have been reported of association with obesity related traits by previous GWA studies.
34362956	4	40	theme	second	639:644	arg1	cohort					646:651	the independent second cohort	623:651	the independent second cohort	623:651	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	2	41	theme	rare	344:347	arg1	variants					357:364	relatively rare genetic variants	333:364	relatively rare genetic variants	333:364	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	8	42	theme	non-protein	1385:1395	arg1	lncRNA					1410:1415	lncRNA	1410:1415	lncRNA	1410:1415	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	8	42	theme	non-protein	1385:1395	arg1	RNAs					1404:1407	long intergenic non-protein coding RNAs	1369:1407	long intergenic non-protein coding RNAs (lncRNA)	1369:1416	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	7	43	with	association	1284:1294	arg1	traits					1317:1322	obesity related traits	1301:1322	obesity related traits	1301:1322	For the 13 novel loci, 9 regions have been reported of association with obesity related traits by previous GWA studies.
34362956	6	44	theme	potential	1112:1120	arg1	loci					1128:1131	9 potential novel loci	1110:1131	9 potential novel loci	1110:1131	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	8	45	theme	N-linked	1442:1449	arg1	glycosylation					1451:1463	N-linked glycosylation	1442:1463	N-linked glycosylation	1442:1463	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	2	46	theme	non-autoimmune	389:402	arg1	T1D					405:407	non-mainstream (or non-autoimmune) T1D	370:407	T1D	405:407	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	8	47	theme	intergenic	1374:1383	arg1	lncRNA					1410:1415	lncRNA	1410:1415	lncRNA	1410:1415	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	8	47	theme	intergenic	1374:1383	arg1	RNAs					1404:1407	long intergenic non-protein coding RNAs	1369:1407	long intergenic non-protein coding RNAs (lncRNA)	1369:1416	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	6	48	theme	rare	1148:1151	arg1	SNVs					1153:1156	rare SNVs	1148:1156	rare SNVs	1148:1156	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	0	49	from	loci	59:62	arg1	patients					92:99	low polygenic risk score patients	67:99	low polygenic risk score patients	67:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	6	50	theme	novel	1122:1126	arg1	loci					1128:1131	9 potential novel loci	1110:1131	9 potential novel loci	1110:1131	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	7	51	theme	obesity	1301:1307	arg1	traits					1317:1322	obesity related traits	1301:1322	obesity related traits	1301:1322	For the 13 novel loci, 9 regions have been reported of association with obesity related traits by previous GWA studies.
34362956	1	52	theme	susceptibility	238:251	arg1	loci					253:256	susceptibility loci	238:256	susceptibility loci in these cases	238:271	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	6	53	theme	imputation	1183:1192	arg1	quality					1194:1200	relatively low imputation quality	1168:1200	relatively low imputation quality (Quality Score r2 < 0.90)	1168:1226	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	53	theme	imputation	1183:1192	arg1	Score					1211:1215	Quality Score r2 < 0.90	1203:1225	Quality Score r2 < 0.90	1203:1225	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	54	theme	Quality	1203:1209	arg1	quality					1194:1200	relatively low imputation quality	1168:1200	relatively low imputation quality (Quality Score r2 < 0.90)	1168:1226	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	54	theme	Quality	1203:1209	arg1	Score					1211:1215	Quality Score r2 < 0.90	1203:1225	Quality Score r2 < 0.90	1203:1225	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	5	55	theme	T1D	788:790	arg1	PRS					792:794	low T1D PRS	784:794	low T1D PRS	784:794	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	8	56	theme	coding	1397:1402	arg1	lncRNA					1410:1415	lncRNA	1410:1415	lncRNA	1410:1415	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	8	56	theme	coding	1397:1402	arg1	RNAs					1404:1407	long intergenic non-protein coding RNAs	1369:1407	long intergenic non-protein coding RNAs (lncRNA)	1369:1416	Three loci encoding long intergenic non-protein coding RNAs (lncRNA), and 2 loci involved in N-linked glycosylation are also highlighted in this study.
34362956	7	57	theme	related	1309:1315	arg1	traits					1317:1322	obesity related traits	1301:1322	obesity related traits	1301:1322	For the 13 novel loci, 9 regions have been reported of association with obesity related traits by previous GWA studies.
34362956	6	58	theme	reported	1062:1069	arg1	loci					1071:1074	3 reported loci	1060:1074	3 reported loci by our previous study	1060:1096	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	59	theme	T1D	1050:1052	arg1	loci					1054:1057	4 established T1D loci	1036:1057	4 established T1D loci	1036:1057	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	60	with	loci	858:861	arg1	quality					884:890	high imputation quality	868:890	high imputation quality (Quality Score r2 > 0.91)	868:916	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	60	with	loci	858:861	arg1	Score					901:905	Quality Score r2 > 0.91	893:915	Quality Score r2 > 0.91	893:915	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	0	61	with	Insights	0:7	arg1	loci					59:62	13 novel loci	50:62	13 novel loci in low polygenic risk score patients	50:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	1	62	theme	polygenic	107:115	arg1	PRS					129:131	PRS	129:131	PRS	129:131	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	1	62	theme	polygenic	107:115	arg1	score					122:126	polygenic risk score	107:126	polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D)	107:169	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	6	63	theme	Quality	893:899	arg1	quality					884:890	high imputation quality	868:890	high imputation quality (Quality Score r2 > 0.91)	868:916	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	63	theme	Quality	893:899	arg1	Score					901:905	Quality Score r2 > 0.91	893:915	Quality Score r2 > 0.91	893:915	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	1	64	with	cases	198:202	arg1	PRS					217:219	low T1D PRS	209:219	low T1D PRS	209:219	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	7	65	theme	novel	1240:1244	arg1	loci					1246:1249	the 13 novel loci	1233:1249	the 13 novel loci	1233:1249	For the 13 novel loci, 9 regions have been reported of association with obesity related traits by previous GWA studies.
34362956	1	66	theme	risk	117:120	arg1	PRS					129:131	PRS	129:131	PRS	129:131	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	1	66	theme	risk	117:120	arg1	score					122:126	polygenic risk score	107:126	polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D)	107:169	With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases.
34362956	6	67	theme	low	1179:1181	arg1	quality					1194:1200	relatively low imputation quality	1168:1200	relatively low imputation quality (Quality Score r2 < 0.90)	1168:1226	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	67	theme	low	1179:1181	arg1	Score					1211:1215	Quality Score r2 < 0.90	1203:1225	Quality Score r2 < 0.90	1203:1225	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	2	68	from	studies	449:455	arg1	cases					464:468	T1D cases	460:468	T1D cases in general	460:479	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	6	69	theme	PRS	967:969	arg1	T1D					971:973	low PRS T1D	963:973	low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08)	963:1018	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	2	70	theme	genetic	349:355	arg1	variants					357:364	relatively rare genetic variants	333:364	relatively rare genetic variants	333:364	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	2	71	theme	genetic	297:303	arg1	effects					305:311	genetic effects	297:311	genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D	297:407	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	4	72	theme	first	559:563	arg1	cohort					565:570	The first cohort	555:570	The first cohort	555:570	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	2	73	from	cases	464:468	arg1	general					473:479	general	473:479	general	473:479	Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general.
34362956	0	74	theme	novel	53:57	arg1	loci					59:62	13 novel loci	50:62	13 novel loci in low polygenic risk score patients	50:99	Insights into non-autoimmune type 1 diabetes with 13 novel loci in low polygenic risk score patients.
34362956	5	75	theme	low	711:713	arg1	PRS					719:721	low T1D PRS	711:721	low T1D PRS	711:721	Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test.
34362956	4	76	theme	3302	585:588	arg1	cases					594:598	3302 T1D cases	585:598	3302 T1D cases	585:598	The first cohort consisted of 3302 T1D cases and 6181 controls, and the independent second cohort consisted of 3297 T1D cases and 6169 controls.
34362956	6	77	theme	imputation	873:882	arg1	quality					884:890	high imputation quality	868:890	high imputation quality (Quality Score r2 > 0.91)	868:916	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
34362956	6	77	theme	imputation	873:882	arg1	Score					901:905	Quality Score r2 > 0.91	893:915	Quality Score r2 > 0.91	893:915	Thirteen novel genetic loci with high imputation quality (Quality Score r2 > 0.91) were identified of SNPs/SNVs associated with low PRS T1D at genome-wide significance (P ≤ 5.0 × E-08), in addition to 4 established T1D loci, 3 reported loci by our previous study, as well as 9 potential novel loci represented by rare SNVs, but with relatively low imputation quality (Quality Score r2 < 0.90).
33952641	10	0	theme	population	1493:1502	arg1	population					1493:1502	the world's population	1481:1502	the world's population before the age of 5	1481:1522	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	10	0	theme	population	1493:1502	arg1	%					1476:1476	essentially 100%	1461:1476	essentially 100% of the world's population before the age of 5	1461:1522	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	14	1	theme	impaired	2034:2041	arg1	activation					2043:2052	impaired activation	2034:2052	impaired activation in response to T cell receptor stimulation	2034:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	4	2	gly	glycoproteins	525:537	arg1	glycoproteins					525:537	glycoproteins	525:537	glycoproteins that are differentially expressed on the surface of HHV6A-infected cells	525:610	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	2	3	theme	glycoproteins	340:352	arg1	strategy					274:281	One common host-evasion strategy	250:281	One common host-evasion strategy	250:281	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	2	3	theme	glycoproteins	340:352	arg1	downregulation					290:303	the downregulation	286:303	the downregulation of host-encoded, surface-expressed glycoproteins	286:352	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	12	4	theme	virus-infected	1765:1778	arg1	cells					1780:1784	virus-infected cells	1765:1784	virus-infected cells	1765:1784	Host immune cells rely on the presence of surface-expressed proteins to identify and target virus-infected cells.
33952641	11	5	dep	pervasive	1634:1642	arg1	the					1625:1627	the	1625:1627	the	1625:1627	As such, these viruses are among the most pervasive and stealthy of all viruses.
33952641	14	6	theme	CD45	1990:1993	arg1	reduction					1977:1985	a reduction	1975:1985	a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation	1975:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	10	7	theme	Human	1425:1429	arg1	herpesviruses-6					1431:1445	IMPORTANCE Human herpesviruses-6	1414:1445	IMPORTANCE Human herpesviruses-6	1414:1445	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	13	8	theme	T	1877:1877	arg1	cells					1879:1883	T cells	1877:1883	T cells	1877:1883	Here, we investigated the changes that occur to proteins expressed on the cell surface of T cells after infection with human herpesvirus-6A.
33952641	5	9	theme	T	877:877	arg1	cells					879:883	T cells	877:883	T cells infected with HHV6A	877:903	We found that the protein tyrosine phosphatase CD45 is downregulated in T cells infected with HHV6A.
33952641	10	10	from	latent	1540:1545	arg1	host					1570:1573	their host	1564:1573	their host throughout life	1564:1589	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	4	11	gly	glycoproteins	659:671	arg1	glycoproteins					659:671	N-linked glycoproteins	650:671	N-linked glycoproteins present on the surface of T cells infected with HHV6A	650:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	12	12	theme	immune	1678:1683	arg1	cells					1685:1689	Host immune cells	1673:1689	Host immune cells	1673:1689	Host immune cells rely on the presence of surface-expressed proteins to identify and target virus-infected cells.
33952641	2	13	theme	common	254:259	arg1	strategy					274:281	One common host-evasion strategy	250:281	One common host-evasion strategy	250:281	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	2	13	theme	common	254:259	arg1	downregulation					290:303	the downregulation	286:303	the downregulation of host-encoded, surface-expressed glycoproteins	286:352	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	2	14	dep	host-encoded	308:319	arg1	surface-expressed					322:338	surface-expressed	322:338	surface-expressed	322:338	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	1	15	theme	host	224:227	arg1	responses					239:247	host antiviral responses	224:247	host antiviral responses	224:247	Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong infection within their host, requiring these viruses to evade host antiviral responses.
33952641	7	16	dep	essential	1001:1009	arg1	necessary					1070:1078	necessary	1070:1078	necessary	1070:1078	CD45 is essential for signaling through the T cell receptor and, as such, is necessary for developing a fully functional immune response.
33952641	14	17	from	surface	2002:2008	arg1	response					2057:2064	response	2057:2064	response to T cell receptor stimulation	2057:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	14	18	theme	T	2022:2022	arg1	cells					2024:2028	infected T cells	2013:2028	infected T cells	2013:2028	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	3	19	theme	TCR/CD3	482:488	arg1	complex					490:496	the TCR/CD3 complex	478:496	the TCR/CD3 complex	478:496	Roseoloviruses have been shown to evade the host immune response by downregulating NK-activating ligands, class I MHC, and the TCR/CD3 complex.
33952641	1	20	theme	antiviral	229:237	arg1	responses					239:247	host antiviral responses	224:247	host antiviral responses	224:247	Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong infection within their host, requiring these viruses to evade host antiviral responses.
33952641	14	21	theme	infected	2013:2020	arg1	cells					2024:2028	infected T cells	2013:2028	infected T cells	2013:2028	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	8	22	theme	murine	1217:1222	arg1	cytomegalovirus					1224:1238	murine cytomegalovirus	1217:1238	murine cytomegalovirus (MCMV)	1217:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	22	theme	murine	1217:1222	arg1	betaherpesviruses					1166:1182	the closely related betaherpesviruses	1146:1182	the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV)	1146:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	22	theme	murine	1217:1222	arg1	MCMV					1241:1244	MCMV	1241:1244	MCMV	1241:1244	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	4	23	theme	present	759:765	arg1	proteins					750:757	proteins	750:757	proteins present on the surface of uninfected T cells	750:802	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	5	24	theme	phosphatase	840:850	arg1	CD45					852:855	the protein tyrosine phosphatase CD45	819:855	the protein tyrosine phosphatase CD45	819:855	We found that the protein tyrosine phosphatase CD45 is downregulated in T cells infected with HHV6A.
33952641	4	25	theme	N-linked	650:657	arg1	glycoproteins					659:671	N-linked glycoproteins	650:671	N-linked glycoproteins present on the surface of T cells infected with HHV6A	650:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	8	26	theme	human	1184:1188	arg1	betaherpesviruses					1166:1182	the closely related betaherpesviruses	1146:1182	the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV)	1146:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	26	theme	human	1184:1188	arg1	HCMV					1207:1210	HCMV	1207:1210	HCMV	1207:1210	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	26	theme	human	1184:1188	arg1	cytomegalovirus					1190:1204	human cytomegalovirus	1184:1204	human cytomegalovirus (HCMV)	1184:1211	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	10	27	from	host	1570:1573	arg1	latent					1540:1545	latent	1540:1545	latent	1540:1545	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	0	28	theme	Tyrosine	44:51	arg1	CD45					72:75	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45).
33952641	14	29	theme	cells	2024:2028	arg1	activation					2043:2052	impaired activation	2034:2052	impaired activation in response to T cell receptor stimulation	2034:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	14	29	theme	cells	2024:2028	arg1	surface					2002:2008	the surface	1998:2008	the surface of infected T cells	1998:2028	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	1	30	dep	roseoloviruses	107:120	arg1	-6B					130:132	-6B	130:132	-6B	130:132	Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong infection within their host, requiring these viruses to evade host antiviral responses.
33952641	1	30	dep	roseoloviruses	107:120	arg1	-7					139:140	-7	139:140	-7	139:140	Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong infection within their host, requiring these viruses to evade host antiviral responses.
33952641	1	30	dep	roseoloviruses	107:120	arg1	HHV6A					123:127	HHV6A	123:127	HHV6A	123:127	Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong infection within their host, requiring these viruses to evade host antiviral responses.
33952641	1	30	dep	roseoloviruses	107:120	arg1	roseoloviruses					107:120	the roseoloviruses	103:120	the roseoloviruses (HHV6A, -6B, and -7)	103:141	Like all herpesviruses, the roseoloviruses (HHV6A, -6B, and -7) establish lifelong infection within their host, requiring these viruses to evade host antiviral responses.
33952641	3	31	theme	NK-activating	438:450	arg1	ligands					452:458	NK-activating ligands	438:458	NK-activating ligands	438:458	Roseoloviruses have been shown to evade the host immune response by downregulating NK-activating ligands, class I MHC, and the TCR/CD3 complex.
33952641	10	32	theme	5	1522:1522	arg1	age					1515:1517	the age	1511:1517	the age of 5	1511:1522	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	13	33	theme	cell	1861:1864	arg1	surface					1866:1872	the cell surface	1857:1872	the cell surface of T cells	1857:1883	Here, we investigated the changes that occur to proteins expressed on the cell surface of T cells after infection with human herpesvirus-6A.
33952641	4	34	theme	present	673:679	arg1	glycoproteins					659:671	N-linked glycoproteins	650:671	N-linked glycoproteins present on the surface of T cells infected with HHV6A	650:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	14	35	theme	receptor	2076:2083	arg1	stimulation					2085:2095	T cell receptor stimulation	2069:2095	T cell receptor stimulation	2069:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	10	36	theme	IMPORTANCE	1414:1423	arg1	herpesviruses-6					1431:1445	IMPORTANCE Human herpesviruses-6	1414:1445	IMPORTANCE Human herpesviruses-6	1414:1445	IMPORTANCE Human herpesviruses-6 and -7 infect essentially 100% of the world's population before the age of 5 and then remain latent or persistent in their host throughout life.
33952641	5	37	theme	protein	823:829	arg1	CD45					852:855	the protein tyrosine phosphatase CD45	819:855	the protein tyrosine phosphatase CD45	819:855	We found that the protein tyrosine phosphatase CD45 is downregulated in T cells infected with HHV6A.
33952641	4	38	theme	glycoproteins	659:671	arg1	capture					639:645	cell surface capture	626:645	cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A	626:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	7	39	theme	functional	1103:1112	arg1	response					1121:1128	a fully functional immune response	1095:1128	a fully functional immune response	1095:1128	CD45 is essential for signaling through the T cell receptor and, as such, is necessary for developing a fully functional immune response.
33952641	12	40	theme	Host	1673:1676	arg1	cells					1685:1689	Host immune cells	1673:1689	Host immune cells	1673:1689	Host immune cells rely on the presence of surface-expressed proteins to identify and target virus-infected cells.
33952641	7	41	theme	T	1037:1037	arg1	receptor					1044:1051	the T cell receptor	1033:1051	the T cell receptor	1033:1051	CD45 is essential for signaling through the T cell receptor and, as such, is necessary for developing a fully functional immune response.
33952641	14	42	from	activation	2043:2052	arg1	response					2057:2064	response	2057:2064	response to T cell receptor stimulation	2057:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	3	43	theme	class	461:465	arg1	MHC					469:471	class I MHC	461:471	class I MHC	461:471	Roseoloviruses have been shown to evade the host immune response by downregulating NK-activating ligands, class I MHC, and the TCR/CD3 complex.
33952641	7	44	theme	immune	1114:1119	arg1	response					1121:1128	a fully functional immune response	1095:1128	a fully functional immune response	1095:1128	CD45 is essential for signaling through the T cell receptor and, as such, is necessary for developing a fully functional immune response.
33952641	7	45	theme	cell	1039:1042	arg1	receptor					1044:1051	the T cell receptor	1033:1051	the T cell receptor	1033:1051	CD45 is essential for signaling through the T cell receptor and, as such, is necessary for developing a fully functional immune response.
33952641	2	46	theme	host-evasion	261:272	arg1	strategy					274:281	One common host-evasion strategy	250:281	One common host-evasion strategy	250:281	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	2	46	theme	host-evasion	261:272	arg1	downregulation					290:303	the downregulation	286:303	the downregulation of host-encoded, surface-expressed glycoproteins	286:352	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	3	47	theme	I	467:467	arg1	MHC					469:471	class I MHC	461:471	class I MHC	461:471	Roseoloviruses have been shown to evade the host immune response by downregulating NK-activating ligands, class I MHC, and the TCR/CD3 complex.
33952641	3	48	theme	host	399:402	arg1	response					411:418	the host immune response	395:418	the host immune response	395:418	Roseoloviruses have been shown to evade the host immune response by downregulating NK-activating ligands, class I MHC, and the TCR/CD3 complex.
33952641	4	49	attach	present	759:765	arg1	surface					774:780	the surface	770:780	the surface of uninfected T cells	770:802	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	4	49	attach	present	759:765	arg2	proteins					750:757	proteins	750:757	proteins present on the surface of uninfected T cells	750:802	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	8	50	dep	betaherpesviruses	1166:1182	arg1	cytomegalovirus					1224:1238	murine cytomegalovirus	1217:1238	murine cytomegalovirus (MCMV)	1217:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	50	dep	betaherpesviruses	1166:1182	arg1	MCMV					1241:1244	MCMV	1241:1244	MCMV	1241:1244	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	50	dep	betaherpesviruses	1166:1182	arg1	HCMV					1207:1210	HCMV	1207:1210	HCMV	1207:1210	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	50	dep	betaherpesviruses	1166:1182	arg1	betaherpesviruses					1166:1182	the closely related betaherpesviruses	1146:1182	the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV)	1146:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	50	dep	betaherpesviruses	1166:1182	arg1	cytomegalovirus					1190:1204	human cytomegalovirus	1184:1204	human cytomegalovirus (HCMV)	1184:1211	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	14	51	from	reduction	1977:1985	arg1	activation					2043:2052	impaired activation	2034:2052	impaired activation in response to T cell receptor stimulation	2034:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	14	51	from	reduction	1977:1985	arg1	surface					2002:2008	the surface	1998:2008	the surface of infected T cells	1998:2028	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	4	52	theme	T	796:796	arg1	cells					798:802	uninfected T cells	785:802	uninfected T cells	785:802	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	13	53	theme	human	1906:1910	arg1	herpesvirus-6A					1912:1925	human herpesvirus-6A	1906:1925	human herpesvirus-6A	1906:1925	Here, we investigated the changes that occur to proteins expressed on the cell surface of T cells after infection with human herpesvirus-6A.
33952641	0	54	theme	Protein	36:42	arg1	CD45					72:75	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45).
33952641	14	55	theme	cell	2071:2074	arg1	stimulation					2085:2095	T cell receptor stimulation	2069:2095	T cell receptor stimulation	2069:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	2	56	gly	glycoproteins	340:352	arg1	glycoproteins					340:352	host-encoded, surface-expressed glycoproteins	308:352	host-encoded, surface-expressed glycoproteins	308:352	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	4	57	theme	uninfected	785:794	arg1	cells					798:802	uninfected T cells	785:802	uninfected T cells	785:802	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	13	58	with	infection	1891:1899	arg1	herpesvirus-6A					1912:1925	human herpesvirus-6A	1906:1925	human herpesvirus-6A	1906:1925	Here, we investigated the changes that occur to proteins expressed on the cell surface of T cells after infection with human herpesvirus-6A.
33952641	4	59	theme	surface	631:637	arg1	capture					639:645	cell surface capture	626:645	cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A	626:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	0	60	theme	PTPRC	65:69	arg1	CD45					72:75	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45).
33952641	9	61	theme	CD45	1396:1399	arg1	transcripts					1401:1411	CD45 transcripts	1396:1411	CD45 transcripts	1396:1411	While HCMV and MCMV target CD45 signaling and trafficking, HHV6A acts to downregulate CD45 transcripts.
33952641	8	62	theme	related	1158:1164	arg1	betaherpesviruses					1166:1182	the closely related betaherpesviruses	1146:1182	the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV)	1146:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	62	theme	related	1158:1164	arg1	cytomegalovirus					1224:1238	murine cytomegalovirus	1217:1238	murine cytomegalovirus (MCMV)	1217:1245	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	8	62	theme	related	1158:1164	arg1	cytomegalovirus					1190:1204	human cytomegalovirus	1184:1204	human cytomegalovirus (HCMV)	1184:1211	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	4	63	attach	present	673:679	arg1	surface					688:694	the surface	684:694	the surface of T cells infected with HHV6A	684:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	4	63	attach	present	673:679	arg2	glycoproteins					659:671	N-linked glycoproteins	650:671	N-linked glycoproteins present on the surface of T cells infected with HHV6A	650:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	4	64	link	N-linked	650:657	arg1	glycoproteins					659:671	N-linked glycoproteins	650:671	N-linked glycoproteins present on the surface of T cells infected with HHV6A	650:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	12	65	theme	proteins	1733:1740	arg1	presence					1703:1710	the presence	1699:1710	the presence of surface-expressed proteins	1699:1740	Host immune cells rely on the presence of surface-expressed proteins to identify and target virus-infected cells.
33952641	4	66	theme	cells	701:705	arg1	surface					688:694	the surface	684:694	the surface of T cells infected with HHV6A	684:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	0	67	theme	Phosphatase	53:63	arg1	CD45					72:75	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	the Protein Tyrosine Phosphatase PTPRC (CD45)	32:76	The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45).
33952641	9	68	theme	MCMV	1325:1328	arg1	CD45					1337:1340	MCMV target CD45	1325:1340	MCMV target CD45 signaling	1325:1350	While HCMV and MCMV target CD45 signaling and trafficking, HHV6A acts to downregulate CD45 transcripts.
33952641	4	69	theme	cells	798:802	arg1	surface					774:780	the surface	770:780	the surface of uninfected T cells	770:802	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	2	70	theme	host-encoded	308:319	arg1	glycoproteins					340:352	host-encoded, surface-expressed glycoproteins	308:352	host-encoded, surface-expressed glycoproteins	308:352	One common host-evasion strategy is the downregulation of host-encoded, surface-expressed glycoproteins.
33952641	9	71	theme	target	1330:1335	arg1	CD45					1337:1340	MCMV target CD45	1325:1340	MCMV target CD45 signaling	1325:1350	While HCMV and MCMV target CD45 signaling and trafficking, HHV6A acts to downregulate CD45 transcripts.
33952641	13	72	theme	cells	1879:1883	arg1	surface					1866:1872	the cell surface	1857:1872	the cell surface of T cells	1857:1883	Here, we investigated the changes that occur to proteins expressed on the cell surface of T cells after infection with human herpesvirus-6A.
33952641	14	73	theme	T	2069:2069	arg1	stimulation					2085:2095	T cell receptor stimulation	2069:2095	T cell receptor stimulation	2069:2095	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	4	74	theme	cells	606:610	arg1	surface					580:586	the surface	576:586	the surface of HHV6A-infected cells	576:610	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	14	75	theme	HHV-6A	1947:1952	arg1	infection					1954:1962	HHV-6A infection	1947:1962	HHV-6A infection	1947:1962	We discovered that HHV-6A infection results in a reduction of CD45 on the surface of infected T cells and impaired activation in response to T cell receptor stimulation.
33952641	4	76	theme	HHV6A-infected	591:604	arg1	cells					606:610	HHV6A-infected cells	591:610	HHV6A-infected cells	591:610	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	4	77	theme	cell	626:629	arg1	capture					639:645	cell surface capture	626:645	cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A	626:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33952641	8	78	theme	unique	1276:1281	arg1	mechanisms					1283:1292	unique mechanisms	1276:1292	unique mechanisms	1276:1292	Interestingly, the closely related betaherpesviruses human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV) have also separately evolved unique mechanisms to target CD45.
33952641	5	79	theme	tyrosine	831:838	arg1	CD45					852:855	the protein tyrosine phosphatase CD45	819:855	the protein tyrosine phosphatase CD45	819:855	We found that the protein tyrosine phosphatase CD45 is downregulated in T cells infected with HHV6A.
33952641	3	80	theme	immune	404:409	arg1	response					411:418	the host immune response	395:418	the host immune response	395:418	Roseoloviruses have been shown to evade the host immune response by downregulating NK-activating ligands, class I MHC, and the TCR/CD3 complex.
33952641	11	81	theme	viruses	1664:1670	arg1	pervasive					1634:1642	pervasive	1634:1642	pervasive	1634:1642	As such, these viruses are among the most pervasive and stealthy of all viruses.
33952641	12	82	theme	surface-expressed	1715:1731	arg1	proteins					1733:1740	surface-expressed proteins	1715:1740	surface-expressed proteins	1715:1740	Host immune cells rely on the presence of surface-expressed proteins to identify and target virus-infected cells.
33952641	9	83	theme	CD45	1337:1340	arg1	signaling					1342:1350	MCMV target CD45 signaling	1325:1350	MCMV target CD45 signaling	1325:1350	While HCMV and MCMV target CD45 signaling and trafficking, HHV6A acts to downregulate CD45 transcripts.
33952641	4	84	theme	T	699:699	arg1	cells					701:705	T cells	699:705	T cells infected with HHV6A	699:725	To more globally identify glycoproteins that are differentially expressed on the surface of HHV6A-infected cells, we performed cell surface capture of N-linked glycoproteins present on the surface of T cells infected with HHV6A, and compared these to proteins present on the surface of uninfected T cells.
33493676	2	0	attach	present	363:369	arg1	form					378:381	the form	374:381	the form of five N-linked complex glycans	374:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	2	0	attach	present	363:369	arg2	carbohydrates					340:352	45% carbohydrates	336:352	45% carbohydrates that are present in the form of five N-linked complex glycans	336:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	6	1	theme	antibodies	1050:1059	arg1	isolation					1028:1036	isolation	1028:1036	isolation of AGP with antibodies and affinity chromatography	1028:1087	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	6	2	theme	bloodplasma	1145:1155	arg1	5 μl					1137:1140	5 μl	1137:1140	5 μl of bloodplasma in a 96-well format	1137:1175	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	10	3	theme	lower	1945:1949	arg1	sialylation					1951:1961	lower sialylation	1945:1961	lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site	1945:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	7	4	theme	AGP	1200:1202	arg1	glycopeptides					1204:1216	AGP glycopeptides	1200:1216	AGP glycopeptides	1200:1216	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	10	5	from	branching	1896:1904	arg1	site					1936:1939	AGP's second glycosylation site	1909:1939	AGP's second glycosylation site	1909:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	10	5	from	branching	1896:1904	arg1	site					2023:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	11	6	theme	N-glycan	2131:2138	arg1	profile					2140:2146	site-specific AGP N-glycan profile	2113:2146	site-specific AGP N-glycan profile	2113:2146	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	0	7	theme	High-Throughput	0:14	arg1	Analysis					50:57	High-Throughput and Site-Specific N-Glycosylation Analysis	0:57	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein	0:92	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	1	8	theme	acute	186:190	arg1	glycoprotein					198:209	an acute phase glycoprotein	183:209	an acute phase glycoprotein	183:209	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	8	theme	acute	186:190	arg1	glycoprotein					161:172	Alpha-1-acid glycoprotein	148:172	Alpha-1-acid glycoprotein (AGP)	148:178	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	11	9	theme	site-specific	2113:2125	arg1	profile					2140:2146	site-specific AGP N-glycan profile	2113:2146	site-specific AGP N-glycan profile	2113:2146	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	10	10	gly	glycosylation	1922:1934	arg2	site					1936:1939	AGP's second glycosylation site	1909:1939	AGP's second glycosylation site	1909:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	4	11	gly	glycosylation	608:620	arg1	cohorts					651:657	small cohorts	645:657	small cohorts	645:657	However, AGP glycosylation was mainly analyzed in small cohorts and without detailed site-specific glycan information.
33493676	5	12	theme	large	859:863	arg1	cohorts					865:871	large cohorts	859:871	large cohorts	859:871	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	9	13	theme	critical	1704:1711	arg1	illness					1713:1719	critical illness	1704:1719	critical illness (59 cases and 49 controls)	1704:1746	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	5	14	theme	AGP	831:833	arg1	analysis					819:826	a high-throughput and site-specific N-glycosylation LC-MS analysis	761:826	a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	761:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	5	15	theme	LC-MS	813:817	arg1	analysis					819:826	a high-throughput and site-specific N-glycosylation LC-MS analysis	761:826	a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	761:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	11	16	theme	prospective	2075:2085	arg1	cohort					2087:2092	a larger prospective cohort	2066:2092	a larger prospective cohort	2066:2092	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	4	17	theme	site-specific	680:692	arg1	information					701:711	detailed site-specific glycan information	671:711	detailed site-specific glycan information	671:711	However, AGP glycosylation was mainly analyzed in small cohorts and without detailed site-specific glycan information.
33493676	10	18	theme	glycosylation	2009:2021	arg1	site					2023:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	5	19	theme	disease	898:904	arg1	biomarkers					906:915	novel disease biomarkers	892:915	novel disease biomarkers	892:915	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	5	20	theme	novel	892:896	arg1	biomarkers					906:915	novel disease biomarkers	892:915	novel disease biomarkers	892:915	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	0	21	theme	Glycoprotein	81:92	arg1	Analysis					50:57	High-Throughput and Site-Specific N-Glycosylation Analysis	0:57	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein	0:92	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	3	22	theme	prognostic	573:582	arg1	potential					584:592	a great diagnostic and prognostic potential	550:592	a great diagnostic and prognostic potential	550:592	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	2	23	located	present	363:369	arg1	form					378:381	the form	374:381	the form of five N-linked complex glycans	374:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	2	23	located	present	363:369	arg2	carbohydrates					340:352	45% carbohydrates	336:352	45% carbohydrates that are present in the form of five N-linked complex glycans	336:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	11	24	theme	larger	2068:2073	arg1	cohort					2087:2092	a larger prospective cohort	2066:2092	a larger prospective cohort	2066:2092	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	9	25	dep	illness	1713:1719	arg1	cases					1725:1729	59 cases	1722:1729	59 cases	1722:1729	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	9	25	dep	illness	1713:1719	arg1	controls					1738:1745	49 controls	1735:1745	49 controls	1735:1745	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	10	26	from	sialylation	1951:1961	arg1	site					1936:1939	AGP's second glycosylation site	1909:1939	AGP's second glycosylation site	1909:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	10	26	from	sialylation	1951:1961	arg1	site					2023:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	8	27	theme	time	1518:1521	arg1	points					1523:1528	three time points	1512:1528	three time points	1512:1528	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	9	28	from	method	1626:1631	arg1	population					1638:1647	a population	1636:1647	a population	1636:1647	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	9	29	theme	increased	1782:1790	arg1	risk					1792:1795	a significantly increased risk	1766:1795	a significantly increased risk of developing type 2 diabetes	1766:1825	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	8	30	from	stable	1463:1468	arg1	individuals					1481:1491	healthy individuals	1473:1491	healthy individuals (14 individuals in three time points)	1473:1529	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	0	31	theme	New	123:125	arg1	Discovery					137:145	New Biomarker Discovery	123:145	New Biomarker Discovery	123:145	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	7	32	theme	chromatography-electrospray	1345:1371	arg1	ionization-MS					1373:1385	reversed-phase-liquid chromatography-electrospray ionization-MS	1323:1385	reversed-phase-liquid chromatography-electrospray ionization-MS	1323:1385	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	5	33	theme	N-glycosylation	797:811	arg1	analysis					819:826	a high-throughput and site-specific N-glycosylation LC-MS analysis	761:826	a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	761:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	1	34	theme	biological	275:284	arg1	role					286:289	role	286:289	role	286:289	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	9	35	theme	type	1811:1814	arg1	diabetes					1818:1825	type 2 diabetes	1811:1825	type 2 diabetes	1811:1825	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	2	36	theme	glycans	408:414	arg1	form					378:381	the form	374:381	the form of five N-linked complex glycans	374:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	0	37	theme	Site-Specific	20:32	arg1	Analysis					50:57	High-Throughput and Site-Specific N-Glycosylation Analysis	0:57	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein	0:92	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	5	38	gly	N-glycosylation	797:811	arg1	AGP					831:833	AGP	831:833	AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	831:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	2	39	theme	N-linked	391:398	arg1	glycans					408:414	five N-linked complex glycans	386:414	five N-linked complex glycans	386:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	7	40	theme	solid-phase	1284:1294	arg1	extraction					1296:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	10	41	theme	higher	1843:1848	arg1	risk					1850:1853	higher risk	1843:1853	higher risk of diabetes	1843:1865	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	3	42	theme	different	469:477	arg1	diseases					479:486	many different diseases	464:486	many different diseases	464:486	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	0	43	theme	Human	62:66	arg1	Glycoprotein					81:92	Human Alpha-1-Acid Glycoprotein	62:92	Human Alpha-1-Acid Glycoprotein	62:92	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	7	44	theme	interaction	1251:1261	arg1	extraction					1296:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	8	45	theme	diagnostic	1577:1586	arg1	potential					1588:1596	its diagnostic potential	1573:1596	its diagnostic potential	1573:1596	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	10	46	theme	N-glycan	1887:1894	arg1	branching					1896:1904	increased N-glycan branching	1877:1904	increased N-glycan branching on AGP's second glycosylation site	1877:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	8	47	theme	AGP	1439:1441	arg1	profile					1452:1458	AGP N-glycan profile	1439:1458	AGP N-glycan profile	1439:1458	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	5	48	theme	role	959:962	arg1	understanding					936:948	better understanding	929:948	better understanding of AGP's role and function in health and disease	929:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	6	49	theme	chromatography	1074:1087	arg1	isolation					1028:1036	isolation	1028:1036	isolation of AGP with antibodies and affinity chromatography	1028:1087	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	0	50	theme	Alpha-1-Acid	68:79	arg1	Glycoprotein					81:92	Human Alpha-1-Acid Glycoprotein	62:92	Human Alpha-1-Acid Glycoprotein	62:92	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	5	51	theme	function	968:975	arg1	understanding					936:948	better understanding	929:948	better understanding of AGP's role and function in health and disease	929:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	5	52	theme	cost-effective	735:748	arg1	method					750:755	a cost-effective method	733:755	a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	733:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	6	53	theme	AGP with	1041:1048	arg1	antibodies					1050:1059	AGP with antibodies	1041:1059	AGP with antibodies	1041:1059	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	3	54	contain	has	546:548	arg2	potential					584:592	a great diagnostic and prognostic potential	550:592	a great diagnostic and prognostic potential	550:592	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	3	54	contain	has	546:548	arg1	it					543:544	it	543:544	it	543:544	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	1	55	gly	glycoprotein	198:209	arg1	glycoprotein					198:209	an acute phase glycoprotein	183:209	an acute phase glycoprotein	183:209	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	55	gly	glycoprotein	198:209	arg1	glycoprotein					161:172	Alpha-1-acid glycoprotein	148:172	Alpha-1-acid glycoprotein (AGP)	148:178	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	5	56	from	understanding	936:948	arg1	health					980:985	health	980:985	health	980:985	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	5	56	from	understanding	936:948	arg1	disease					991:997	disease	991:997	disease	991:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	2	57	theme	%	338:338	arg1	carbohydrates					340:352	45% carbohydrates	336:352	45% carbohydrates that are present in the form of five N-linked complex glycans	336:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	5	58	from	function	968:975	arg1	health					980:985	health	980:985	health	980:985	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	5	58	from	function	968:975	arg1	disease					991:997	disease	991:997	disease	991:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	9	59	theme	registered	1676:1685	arg1	hyperglycemia					1687:1699	registered hyperglycemia	1676:1699	registered hyperglycemia in critical illness (59 cases and 49 controls)	1676:1746	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	10	60	theme	glycosylation	1922:1934	arg1	site					1936:1939	AGP's second glycosylation site	1909:1939	AGP's second glycosylation site	1909:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	5	61	from	role	959:962	arg1	health					980:985	health	980:985	health	980:985	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	5	61	from	role	959:962	arg1	disease					991:997	disease	991:997	disease	991:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	1	62	theme	phase	192:196	arg1	glycoprotein					198:209	an acute phase glycoprotein	183:209	an acute phase glycoprotein	183:209	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	62	theme	phase	192:196	arg1	glycoprotein					161:172	Alpha-1-acid glycoprotein	148:172	Alpha-1-acid glycoprotein (AGP)	148:178	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	9	63	from	hyperglycemia	1687:1699	arg1	illness					1713:1719	critical illness	1704:1719	critical illness (59 cases and 49 controls)	1704:1746	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
33493676	11	64	theme	AGP	2127:2129	arg1	profile					2140:2146	site-specific AGP N-glycan profile	2113:2146	site-specific AGP N-glycan profile	2113:2146	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	2	65	from	present	363:369	arg1	form					378:381	the form	374:381	the form of five N-linked complex glycans	374:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	6	66	theme	acid	1113:1116	arg1	precipitation					1118:1130	acid precipitation	1113:1130	acid precipitation from 5 μl of bloodplasma in a 96-well format	1113:1175	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	10	67	theme	N-glycans	1966:1974	arg1	sialylation					1951:1961	lower sialylation	1945:1961	lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site	1945:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	10	67	theme	N-glycans	1966:1974	arg1	branching					1896:1904	increased N-glycan branching	1877:1904	increased N-glycan branching on AGP's second glycosylation site	1877:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	5	68	from	disease	991:997	arg1	understanding					936:948	better understanding	929:948	better understanding of AGP's role and function in health and disease	929:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	1	69	gly	glycoprotein	161:172	arg1	AGP					175:177	AGP	175:177	AGP	175:177	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	69	gly	glycoprotein	161:172	arg1	glycoprotein					161:172	Alpha-1-acid glycoprotein	148:172	Alpha-1-acid glycoprotein (AGP)	148:178	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	69	gly	glycoprotein	161:172	arg1	glycoprotein					198:209	an acute phase glycoprotein	183:209	an acute phase glycoprotein	183:209	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	3	70	theme	great	552:556	arg1	potential					584:592	a great diagnostic and prognostic potential	550:592	a great diagnostic and prognostic potential	550:592	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	5	71	from	health	980:985	arg1	understanding					936:948	better understanding	929:948	better understanding of AGP's role and function in health and disease	929:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	8	72	theme	healthy	1473:1479	arg1	individuals					1481:1491	healthy individuals	1473:1491	healthy individuals (14 individuals in three time points)	1473:1529	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	4	73	theme	AGP	604:606	arg1	glycosylation					608:620	AGP glycosylation	604:620	AGP glycosylation	604:620	However, AGP glycosylation was mainly analyzed in small cohorts and without detailed site-specific glycan information.
33493676	4	74	theme	detailed	671:678	arg1	information					701:711	detailed site-specific glycan information	671:711	detailed site-specific glycan information	671:711	However, AGP glycosylation was mainly analyzed in small cohorts and without detailed site-specific glycan information.
33493676	1	75	theme	Alpha-1-acid	148:159	arg1	AGP					175:177	AGP	175:177	AGP	175:177	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	75	theme	Alpha-1-acid	148:159	arg1	glycoprotein					161:172	Alpha-1-acid glycoprotein	148:172	Alpha-1-acid glycoprotein (AGP)	148:178	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	1	75	theme	Alpha-1-acid	148:159	arg1	glycoprotein					198:209	an acute phase glycoprotein	183:209	an acute phase glycoprotein	183:209	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	2	76	from	form	378:381	arg1	present					363:369	present	363:369	present	363:369	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	6	77	theme	96-well	1162:1168	arg1	format					1170:1175	a 96-well format	1160:1175	a 96-well format	1160:1175	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	4	78	theme	glycan	694:699	arg1	information					701:711	detailed site-specific glycan information	671:711	detailed site-specific glycan information	671:711	However, AGP glycosylation was mainly analyzed in small cohorts and without detailed site-specific glycan information.
33493676	10	79	theme	fourth	2002:2007	arg1	site					2023:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	1	80	from	glycoprotein	198:209	arg1	blood					214:218	blood	214:218	blood	214:218	Alpha-1-acid glycoprotein (AGP) is an acute phase glycoprotein in blood, which is primarily synthetized in the liver and whose biological role is not completely understood.
33493676	11	81	theme	diabetes	2209:2216	arg1	risk					2194:2197	risk	2194:2197	risk of type 2 diabetes	2194:2216	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	4	82	theme	small	645:649	arg1	cohorts					651:657	small cohorts	645:657	small cohorts	645:657	However, AGP glycosylation was mainly analyzed in small cohorts and without detailed site-specific glycan information.
33493676	0	83	theme	Great	103:107	arg1	Potential					109:117	a Great Potential	101:117	a Great Potential for New Biomarker Discovery	101:145	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	11	84	theme	type	2202:2205	arg1	diabetes					2209:2216	type 2 diabetes	2202:2216	type 2 diabetes	2202:2216	Although this should be confirmed on a larger prospective cohort, it indicates that site-specific AGP N-glycan profile could help distinguish individuals who are at risk of type 2 diabetes.
33493676	8	85	from	individuals	1497:1507	arg1	points					1523:1528	three time points	1512:1528	three time points	1512:1528	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	10	86	gly	glycosylation	2009:2021	arg2	site					2023:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	5	87	theme	better	929:934	arg1	understanding					936:948	better understanding	929:948	better understanding of AGP's role and function in health and disease	929:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	6	88	from	5 μl	1137:1140	arg1	format					1170:1175	a 96-well format	1160:1175	a 96-well format	1160:1175	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	6	88	from	5 μl	1137:1140	arg1	precipitation					1118:1130	acid precipitation	1113:1130	acid precipitation from 5 μl of bloodplasma in a 96-well format	1113:1175	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	0	89	theme	Biomarker	127:135	arg1	Discovery					137:145	New Biomarker Discovery	123:145	New Biomarker Discovery	123:145	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	7	90	theme	reversed-phase-liquid	1323:1343	arg1	ionization-MS					1373:1385	reversed-phase-liquid chromatography-electrospray ionization-MS	1323:1385	reversed-phase-liquid chromatography-electrospray ionization-MS	1323:1385	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	8	91	used	used	1391:1394	arg2	We					1388:1389	We	1388:1389	We	1388:1389	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	5	92	theme	site-specific	783:795	arg1	analysis					819:826	a high-throughput and site-specific N-glycosylation LC-MS analysis	761:826	a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	761:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	3	93	theme	AGP	417:419	arg1	N-glycosylation					421:435	AGP N-glycosylation	417:435	AGP N-glycosylation	417:435	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	0	94	theme	N-Glycosylation	34:48	arg1	Analysis					50:57	High-Throughput and Site-Specific N-Glycosylation Analysis	0:57	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein	0:92	High-Throughput and Site-Specific N-Glycosylation Analysis of Human Alpha-1-Acid Glycoprotein Offers a Great Potential for New Biomarker Discovery.
33493676	10	95	gly	sialylation	1951:1961	arg1	N-glycans					1966:1974	N-glycans	1966:1974	N-glycans	1966:1974	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	10	95	gly	sialylation	1951:1961	arg1	site					1936:1939	AGP's second glycosylation site	1909:1939	AGP's second glycosylation site	1909:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	10	95	gly	sialylation	1951:1961	arg1	site					2023:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	AGP's third and AGP1's fourth glycosylation site	1979:2026	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	10	96	theme	diabetes	1858:1865	arg1	risk					1850:1853	higher risk	1843:1853	higher risk of diabetes	1843:1865	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	2	97	theme	complex	400:406	arg1	glycans					408:414	five N-linked complex glycans	386:414	five N-linked complex glycans	386:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	8	98	dep	individuals	1481:1491	arg1	individuals					1497:1507	14 individuals	1494:1507	14 individuals in three time points	1494:1528	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	7	99	gly	glycopeptides	1204:1216	arg2	glycopeptides					1204:1216	AGP glycopeptides	1200:1216	AGP glycopeptides	1200:1216	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	7	100	theme	chromatography-based	1263:1282	arg1	extraction					1296:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	8	101	from	individuals	1481:1491	arg1	stable					1463:1468	stable	1463:1468	stable	1463:1468	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	5	102	theme	high-throughput	763:777	arg1	analysis					819:826	a high-throughput and site-specific N-glycosylation LC-MS analysis	761:826	a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease	761:997	Here, we developed a cost-effective method for a high-throughput and site-specific N-glycosylation LC-MS analysis of AGP which can be applied on large cohorts, aid in search for novel disease biomarkers, and enable better understanding of AGP's role and function in health and disease.
33493676	7	103	theme	hydrophilic	1239:1249	arg1	extraction					1296:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	a hydrophilic interaction chromatography-based solid-phase extraction	1237:1305	After trypsinization, AGP glycopeptides are purified using a hydrophilic interaction chromatography-based solid-phase extraction and analyzed by reversed-phase-liquid chromatography-electrospray ionization-MS.
33493676	8	104	theme	potential	1588:1596	arg1	evaluation					1559:1568	evaluation	1559:1568	evaluation of its diagnostic potential	1559:1596	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	2	105	link	N-linked	391:398	arg1	glycans					408:414	five N-linked complex glycans	386:414	five N-linked complex glycans	386:414	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	8	106	theme	first	1423:1427	arg1	time					1429:1432	the first time	1419:1432	the first time	1419:1432	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	2	107	theme	45	336:337	arg1	%					338:338	%	338:338	%	338:338	It consists of 45% carbohydrates that are present in the form of five N-linked complex glycans.
33493676	3	108	theme	diagnostic	558:567	arg1	potential					584:592	a great diagnostic and prognostic potential	550:592	a great diagnostic and prognostic potential	550:592	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	10	109	theme	increased	1877:1885	arg1	branching					1896:1904	increased N-glycan branching	1877:1904	increased N-glycan branching on AGP's second glycosylation site	1877:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	3	110	gly	N-glycosylation	421:435	arg1	diseases					479:486	many different diseases	464:486	many different diseases	464:486	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	3	111	theme	many	464:467	arg1	diseases					479:486	many different diseases	464:486	many different diseases	464:486	AGP N-glycosylation was shown to be changed in many different diseases, and some changes appear to be disease-specific; thus, it has a great diagnostic and prognostic potential.
33493676	10	112	from	risk	1850:1853	arg1	Individuals					1828:1838	Individuals	1828:1838	Individuals at higher risk of diabetes	1828:1865	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	6	113	theme	affinity	1065:1072	arg1	chromatography					1074:1087	affinity chromatography	1065:1087	affinity chromatography	1065:1087	The method does not require isolation of AGP with antibodies and affinity chromatography, but AGP is enriched by acid precipitation from 5 μl of bloodplasma in a 96-well format.
33493676	10	114	theme	second	1915:1920	arg1	site					1936:1939	AGP's second glycosylation site	1909:1939	AGP's second glycosylation site	1909:1939	Individuals at higher risk of diabetes presented increased N-glycan branching on AGP's second glycosylation site and lower sialylation of N-glycans on AGP's third and AGP1's fourth glycosylation site.
33493676	8	115	theme	N-glycan	1443:1450	arg1	profile					1452:1458	AGP N-glycan profile	1439:1458	AGP N-glycan profile	1439:1458	We used our method to show for the first time that AGP N-glycan profile is stable in healthy individuals (14 individuals in three time points), which is a requirement for evaluation of its diagnostic potential.
33493676	9	116	with	individuals	1659:1669	arg1	hyperglycemia					1687:1699	registered hyperglycemia	1676:1699	registered hyperglycemia in critical illness (59 cases and 49 controls)	1676:1746	Furthermore, we tested our method on a population including individuals with registered hyperglycemia in critical illness (59 cases and 49 controls), which represents a significantly increased risk of developing type 2 diabetes.
32864552	5	0	theme	mouse	654:658	arg1	protein					663:669	mouse TF protein	654:669	mouse TF protein	654:669	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	11	1	theme	TF	1414:1415	arg1	antibodies					1417:1426	Two anti-human TF antibodies	1399:1426	Two anti-human TF antibodies that are claimed to cross	1399:1452	Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF.
32864552	8	2	theme	mouse	1131:1135	arg1	TF					1137:1138	mouse TF	1131:1138	mouse TF	1131:1138	More variability was observed in detecting mouse TF.
32864552	6	3	theme	TF	886:887	arg1	size					878:881	the size	874:881	the size of TF based on western blotting	874:913	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
32864552	1	4	used	used	156:159	arg2	blotting					144:151	BACKGROUND Western blotting	125:151	BACKGROUND Western blotting	125:151	BACKGROUND Western blotting is used to measure protein expression in cells and tissues.
32864552	5	5	theme	protein	663:669	arg1	RESULTS					636:642	RESULTS	636:642	RESULTS Human and mouse TF protein detected by western blotting	636:698	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	9	6	theme	TF	1156:1157	arg1	antibodies					1159:1168	Two anti-mouse TF antibodies	1141:1168	Two anti-mouse TF antibodies	1141:1168	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	9	7	located	observed	1233:1240	arg2	signal					1222:1227	no signal	1219:1227	no signal	1219:1227	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	9	7	located	observed	1233:1240	arg1	line					1264:1267	a TF knockout cell line	1245:1267	a TF knockout cell line	1245:1267	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	7	8	theme	line	1071:1074	arg1	PaCa-2					1080:1085	a TF-negative cell line MIA PaCa-2	1052:1085	a TF-negative cell line MIA PaCa-2	1052:1085	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	10	9	theme	TF-positive	1359:1369	arg1	mouse					1353:1357	the mouse TF-positive	1349:1369	the mouse TF-positive	1349:1369	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	13	10	dep	CONCLUSION	1638:1647	arg1	recommend					1652:1660	recommend	1652:1660	recommend that all commercial antibodies should be validated to ensure that they detect TF	1652:1741	CONCLUSION We recommend that all commercial antibodies should be validated to ensure that they detect TF.
32864552	5	11	theme	Human	644:648	arg1	RESULTS					636:642	RESULTS	636:642	RESULTS Human and mouse TF protein detected by western blotting	636:698	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	6	12	theme	molecular	768:776	arg1	weight					778:783	The apparent molecular weight	755:783	The apparent molecular weight of TF	755:789	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
32864552	0	13	theme	western	107:113	arg1	blotting					115:122	western blotting	107:122	western blotting	107:122	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	12	14	theme	DISCUSSION	1539:1548	arg1	results					1554:1560	DISCUSSION Our results	1539:1560	DISCUSSION Our results	1539:1560	DISCUSSION Our results indicate that there is a range in quality of commercial anti-TF antibodies.
32864552	9	15	theme	cell	1205:1208	arg1	line					1210:1213	a TF-positive cell line	1191:1213	a TF-positive cell line	1191:1213	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	7	16	theme	TF-positive	988:998	arg1	line					1005:1008	a TF-positive cell line HPAF-II	986:1016	a TF-positive cell line HPAF-II	986:1016	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	13	17	theme	commercial	1671:1680	arg1	antibodies					1682:1691	all commercial antibodies	1667:1691	all commercial antibodies	1667:1691	CONCLUSION We recommend that all commercial antibodies should be validated to ensure that they detect TF.
32864552	7	18	theme	MIA	1076:1078	arg1	PaCa-2					1080:1085	a TF-negative cell line MIA PaCa-2	1052:1085	a TF-negative cell line MIA PaCa-2	1052:1085	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	1	19	theme	BACKGROUND	125:134	arg1	blotting					144:151	BACKGROUND Western blotting	125:151	BACKGROUND Western blotting	125:151	BACKGROUND Western blotting is used to measure protein expression in cells and tissues.
32864552	2	20	theme	resulting	243:251	arg1	data					253:256	resulting data	243:256	resulting data	243:256	Appropriate interpretation of resulting data is contingent upon antibody validation.
32864552	7	21	theme	TF	957:958	arg1	antibodies					960:969	four commercial anti-human TF antibodies	930:969	four commercial anti-human TF antibodies	930:969	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	3	22	theme	commercial	329:338	arg1	antibodies					385:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	4	23	theme	cell	501:504	arg1	lines					506:510	human pancreatic cancer cell lines	477:510	human pancreatic cancer cell lines expressing different levels of TF	477:544	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	0	24	theme	human	74:78	arg1	factor					97:102	human and mouse tissue factor	74:102	human and mouse tissue factor	74:102	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	7	25	theme	commercial	935:944	arg1	antibodies					960:969	four commercial anti-human TF antibodies	930:969	four commercial anti-human TF antibodies	930:969	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	12	26	theme	anti-TF	1618:1624	arg1	antibodies					1626:1635	commercial anti-TF antibodies	1607:1635	commercial anti-TF antibodies	1607:1635	DISCUSSION Our results indicate that there is a range in quality of commercial anti-TF antibodies.
32864552	10	27	theme	nonspecific	1321:1331	arg1	protein					1333:1339	a nonspecific protein	1319:1339	a nonspecific protein	1319:1339	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	0	28	theme	mouse	84:88	arg1	factor					97:102	human and mouse tissue factor	74:102	human and mouse tissue factor	74:102	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	9	29	theme	knockout	1250:1257	arg1	line					1264:1267	a TF knockout cell line	1245:1267	a TF knockout cell line	1245:1267	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	3	30	theme	tissue	366:371	arg1	factor					373:378	tissue factor	366:378	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	3	30	theme	tissue	366:371	arg1	TF					381:382	TF	381:382	TF	381:382	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	4	31	theme	pancreatic	483:492	arg1	lines					506:510	human pancreatic cancer cell lines	477:510	human pancreatic cancer cell lines expressing different levels of TF	477:544	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	7	32	located	observed	1040:1047	arg1	PaCa-2					1080:1085	a TF-negative cell line MIA PaCa-2	1052:1085	a TF-negative cell line MIA PaCa-2	1052:1085	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	7	32	located	observed	1040:1047	arg2	signal					1029:1034	no signal	1026:1034	no signal	1026:1034	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	0	33	theme	different	14:22	arg1	antibodies					35:44	different commercial antibodies	14:44	different commercial antibodies for their ability	14:62	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	4	34	theme	pancreatic	558:567	arg1	line					581:584	a mouse pancreatic cancer cell line	550:584	a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative	550:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	0	35	theme	antibodies	35:44	arg1	Evaluation					0:9	Evaluation	0:9	Evaluation of different commercial antibodies for their ability	0:62	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	11	36	theme	mouse	1529:1533	arg1	TF					1535:1536	mouse TF	1529:1536	mouse TF	1529:1536	Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF.
32864552	4	37	theme	TF	543:544	arg1	levels					533:538	different levels	523:538	different levels of TF	523:544	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	11	38	theme	mouse	1465:1469	arg1	TF					1471:1472	mouse TF	1465:1472	mouse TF	1465:1472	Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF.
32864552	10	39	dep	both	1344:1347	arg1	mouse					1353:1357	the mouse TF-positive	1349:1369	the mouse TF-positive	1349:1369	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	4	40	used	used	472:475	arg2	We					469:470	We	469:470	We	469:470	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	6	41	theme	western	898:904	arg1	blotting					906:913	western blotting	898:913	western blotting	898:913	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
32864552	4	42	theme	matched	607:613	arg1	derivative					624:633	a matched knockout derivative	605:633	a matched knockout derivative	605:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	10	43	theme	anti-mouse	1287:1296	arg1	antibody					1301:1308	a third anti-mouse TF antibody	1279:1308	a third anti-mouse TF antibody	1279:1308	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	5	44	from	levels	716:721	arg1	lines					748:752	these cell lines	737:752	these cell lines	737:752	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	4	45	theme	cell	576:579	arg1	line					581:584	a mouse pancreatic cancer cell line	550:584	a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative	550:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	3	46	dep	OBJECTIVES	298:307	arg1	assessed					312:319	assessed	312:319	assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting	312:445	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	5	47	theme	TF	660:661	arg1	protein					663:669	mouse TF protein	654:669	mouse TF protein	654:669	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	9	48	theme	anti-mouse	1145:1154	arg1	antibodies					1159:1168	Two anti-mouse TF antibodies	1141:1168	Two anti-mouse TF antibodies	1141:1168	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	12	49	from	range	1587:1591	arg1	quality					1596:1602	quality	1596:1602	quality of commercial anti-TF antibodies	1596:1635	DISCUSSION Our results indicate that there is a range in quality of commercial anti-TF antibodies.
32864552	7	50	theme	cell	1066:1069	arg1	PaCa-2					1080:1085	a TF-negative cell line MIA PaCa-2	1052:1085	a TF-negative cell line MIA PaCa-2	1052:1085	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	6	51	theme	TF	788:789	arg1	weight					778:783	The apparent molecular weight	755:783	The apparent molecular weight of TF	755:789	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
32864552	2	52	theme	antibody	277:284	arg1	validation					286:295	antibody validation	277:295	antibody validation	277:295	Appropriate interpretation of resulting data is contingent upon antibody validation.
32864552	9	53	theme	mouse	1179:1183	arg1	TF					1185:1186	mouse TF	1179:1186	mouse TF	1179:1186	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	1	54	theme	protein	172:178	arg1	expression					180:189	protein expression	172:189	protein expression in cells and tissues	172:210	BACKGROUND Western blotting is used to measure protein expression in cells and tissues.
32864552	7	55	theme	TF-negative	1054:1064	arg1	PaCa-2					1080:1085	a TF-negative cell line MIA PaCa-2	1052:1085	a TF-negative cell line MIA PaCa-2	1052:1085	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	7	56	from	TF	980:981	arg1	line					1005:1008	a TF-positive cell line HPAF-II	986:1016	a TF-positive cell line HPAF-II	986:1016	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	6	57	theme	apparent	759:766	arg1	weight					778:783	The apparent molecular weight	755:783	The apparent molecular weight of TF	755:789	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
32864552	9	58	theme	TF-positive	1193:1203	arg1	line					1210:1213	a TF-positive cell line	1191:1213	a TF-positive cell line	1191:1213	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	5	59	theme	TF	726:727	arg1	mRNA					729:732	TF mRNA	726:732	TF mRNA	726:732	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	2	60	theme	Appropriate	213:223	arg1	interpretation					225:238	Appropriate interpretation	213:238	Appropriate interpretation of resulting data	213:256	Appropriate interpretation of resulting data is contingent upon antibody validation.
32864552	7	61	theme	cell	1000:1003	arg1	line					1005:1008	a TF-positive cell line HPAF-II	986:1016	a TF-positive cell line HPAF-II	986:1016	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	3	62	theme	several	321:327	arg1	antibodies					385:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	11	63	theme	nonspecific	1494:1504	arg1	band					1506:1509	a nonspecific band	1492:1509	a nonspecific band	1492:1509	Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF.
32864552	5	64	theme	western	683:689	arg1	blotting					691:698	western blotting	683:698	western blotting	683:698	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	4	65	with	TF	597:598	arg1	derivative					624:633	a matched knockout derivative	605:633	a matched knockout derivative	605:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	12	66	theme	antibodies	1626:1635	arg1	quality					1596:1602	quality	1596:1602	quality of commercial anti-TF antibodies	1596:1635	DISCUSSION Our results indicate that there is a range in quality of commercial anti-TF antibodies.
32864552	5	67	theme	cell	743:746	arg1	lines					748:752	these cell lines	737:752	these cell lines	737:752	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	2	68	theme	data	253:256	arg1	interpretation					225:238	Appropriate interpretation	213:238	Appropriate interpretation of resulting data	213:256	Appropriate interpretation of resulting data is contingent upon antibody validation.
32864552	1	69	from	expression	180:189	arg1	cells					194:198	cells	194:198	cells	194:198	BACKGROUND Western blotting is used to measure protein expression in cells and tissues.
32864552	1	69	from	expression	180:189	arg1	tissues					204:210	tissues	204:210	tissues	204:210	BACKGROUND Western blotting is used to measure protein expression in cells and tissues.
32864552	1	70	theme	Western	136:142	arg1	blotting					144:151	BACKGROUND Western blotting	125:151	BACKGROUND Western blotting	125:151	BACKGROUND Western blotting is used to measure protein expression in cells and tissues.
32864552	3	71	theme	anti-mouse	355:364	arg1	antibodies					385:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	5	72	theme	mRNA	729:732	arg1	levels					716:721	levels	716:721	levels of TF mRNA in these cell lines	716:752	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	3	73	theme	anti-human	340:349	arg1	antibodies					385:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	4	74	theme	different	523:531	arg1	levels					533:538	different levels	523:538	different levels of TF	523:544	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	10	75	theme	cell	1387:1390	arg1	lines					1392:1396	both the mouse TF-positive and TF-negative cell lines	1344:1396	both the mouse TF-positive and TF-negative cell lines	1344:1396	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	0	76	theme	tissue	90:95	arg1	factor					97:102	human and mouse tissue factor	74:102	human and mouse tissue factor	74:102	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	9	77	theme	TF	1247:1248	arg1	line					1264:1267	a TF knockout cell line	1245:1267	a TF knockout cell line	1245:1267	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	7	78	theme	anti-human	946:955	arg1	antibodies					960:969	four commercial anti-human TF antibodies	930:969	four commercial anti-human TF antibodies	930:969	We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2.
32864552	12	79	theme	commercial	1607:1616	arg1	antibodies					1626:1635	commercial anti-TF antibodies	1607:1635	commercial anti-TF antibodies	1607:1635	DISCUSSION Our results indicate that there is a range in quality of commercial anti-TF antibodies.
32864552	4	80	theme	human	477:481	arg1	lines					506:510	human pancreatic cancer cell lines	477:510	human pancreatic cancer cell lines expressing different levels of TF	477:544	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	9	81	theme	cell	1259:1262	arg1	line					1264:1267	a TF knockout cell line	1245:1267	a TF knockout cell line	1245:1267	Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line.
32864552	3	82	theme	factor	373:378	arg1	antibodies					385:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	several commercial anti-human and anti-mouse tissue factor (TF) antibodies	321:394	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	4	83	theme	cancer	494:499	arg1	lines					506:510	human pancreatic cancer cell lines	477:510	human pancreatic cancer cell lines expressing different levels of TF	477:544	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	4	84	theme	mouse	552:556	arg1	line					581:584	a mouse pancreatic cancer cell line	550:584	a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative	550:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	11	85	dep	react	1454:1458	arg1	either					1474:1479	either	1474:1479	either	1474:1479	Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF.
32864552	11	86	theme	anti-human	1403:1412	arg1	antibodies					1417:1426	Two anti-human TF antibodies	1399:1426	Two anti-human TF antibodies that are claimed to cross	1399:1452	Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF.
32864552	3	87	theme	western	430:436	arg1	blotting					438:445	western blotting	430:445	western blotting	430:445	OBJECTIVES We assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting.
32864552	0	88	theme	commercial	24:33	arg1	antibodies					35:44	different commercial antibodies	14:44	different commercial antibodies for their ability	14:62	Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
32864552	4	89	theme	cancer	569:574	arg1	line					581:584	a mouse pancreatic cancer cell line	550:584	a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative	550:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	4	90	dep	used	472:475	arg1	METHODS					461:467	METHODS	461:467	METHODS	461:467	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	4	90	dep	used	472:475	arg1	MATERIAL					448:455	MATERIAL	448:455	MATERIAL	448:455	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	5	91	dep	Human	644:648	arg1	detected					671:678	detected	671:678	detected by western blotting	671:698	RESULTS Human and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines.
32864552	10	92	theme	third	1281:1285	arg1	antibody					1301:1308	a third anti-mouse TF antibody	1279:1308	a third anti-mouse TF antibody	1279:1308	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	10	93	dep	lines	1392:1396	arg1	TF-negative					1375:1385	TF-negative	1375:1385	TF-negative	1375:1385	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	10	93	dep	lines	1392:1396	arg1	both					1344:1347	both	1344:1347	both	1344:1347	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	8	94	theme	More	1088:1091	arg1	variability					1093:1103	More variability	1088:1103	More variability	1088:1103	More variability was observed in detecting mouse TF.
32864552	6	95	theme	N-linked	807:814	arg1	glycosylation					816:828	N-linked glycosylation	807:828	N-linked glycosylation	807:828	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
32864552	4	96	theme	knockout	615:622	arg1	derivative					624:633	a matched knockout derivative	605:633	a matched knockout derivative	605:633	MATERIAL AND METHODS We used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
32864552	10	97	theme	TF	1298:1299	arg1	antibody					1301:1308	a third anti-mouse TF antibody	1279:1308	a third anti-mouse TF antibody	1279:1308	However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines.
32864552	6	98	link	N-linked	807:814	arg1	glycosylation					816:828	N-linked glycosylation	807:828	N-linked glycosylation	807:828	The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting.
33287410	0	0	theme	High-Throughput	83:97	arg1	Profiling					108:116	Automated High-Throughput N-Glycan Profiling	73:116	Automated High-Throughput N-Glycan Profiling	73:116	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	5	1	theme	resolution	914:923	arg1	separation					925:934	high resolution separation	909:934	high resolution separation of N-linked glycans released from the serum glycoproteins	909:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	2	theme	automated	771:779	arg1	platform					807:814	our automated, high-throughput analysis platform	767:814	platform	807:814	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	3	theme	liquid	870:875	arg1	UPLC					893:896	UPLC	893:896	UPLC	893:896	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	3	theme	liquid	870:875	arg1	chromatography					877:890	ultra-performance liquid chromatography	852:890	ultra-performance liquid chromatography (UPLC)	852:897	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	4	theme	bisecting	1126:1134	arg1	glycans					1136:1142	bisecting glycans	1126:1142	bisecting glycans (A2B, A2(6)BG1)	1126:1158	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	4	5	theme	glycosylation	583:595	arg1	patterns					597:604	differential glycosylation patterns	570:604	differential glycosylation patterns	570:604	The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa.
33287410	0	6	theme	Automated	73:81	arg1	Profiling					108:116	Automated High-Throughput N-Glycan Profiling	73:116	Automated High-Throughput N-Glycan Profiling	73:116	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	2	7	theme	aggressive	338:347	arg1	form					349:352	the more invasive aggressive form	320:352	the more invasive aggressive form	320:352	This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood.
33287410	2	8	from	PCa	313:315	arg1	transition					277:286	the transition	273:286	the transition from clinically indolent PCa to the more invasive aggressive form	273:352	This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood.
33287410	4	9	theme	differential	570:581	arg1	patterns					597:604	differential glycosylation patterns	570:604	differential glycosylation patterns	570:604	The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa.
33287410	5	10	gly	glycoproteins	980:992	arg1	glycoproteins					980:992	the serum glycoproteins	970:992	the serum glycoproteins	970:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	0	11	from	Glycosylation	0:12	arg1	Cancer					63:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	5	12	theme	Whole	675:679	arg1	profiling					696:704	Whole serum N-glycan profiling	675:704	Whole serum N-glycan profiling	675:704	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	13	from	decreases	1196:1204	arg1	glycans					1254:1260	triantennary trigalactosylated trisialylated glycans	1209:1260	triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3)	1209:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	13	from	decreases	1196:1204	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	13	from	decreases	1196:1204	arg1	hybrid					1020:1025	hybrid	1020:1025	hybrid	1020:1025	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	13	from	decreases	1196:1204	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	13	from	decreases	1196:1204	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	13	from	decreases	1196:1204	arg1	oligomannose					1028:1039	oligomannose	1028:1039	oligomannose	1028:1039	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	13	from	decreases	1196:1204	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	0	14	theme	N-Glycan	99:106	arg1	Profiling					108:116	Automated High-Throughput N-Glycan Profiling	73:116	Automated High-Throughput N-Glycan Profiling	73:116	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	5	15	theme	serum	681:685	arg1	profiling					696:704	Whole serum N-glycan profiling	675:704	Whole serum N-glycan profiling	675:704	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	7	16	theme	disease	1433:1439	arg1	pathogenesis					1441:1452	the disease pathogenesis	1429:1452	the disease pathogenesis	1429:1452	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	6	17	theme	biantennary	1046:1056	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	17	theme	biantennary	1046:1056	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	17	theme	biantennary	1046:1056	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	17	theme	biantennary	1046:1056	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	7	18	theme	potential	1467:1475	arg1	biomarkers					1477:1486	potential biomarkers	1467:1486	potential biomarkers	1467:1486	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	5	19	theme	glycans	948:954	arg1	separation					925:934	high resolution separation	909:934	high resolution separation of N-linked glycans released from the serum glycoproteins	909:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	4	20	theme	significant	642:652	arg1	PCa					670:672	indolent, significant, and aggressive PCa	632:672	indolent, significant, and aggressive PCa	632:672	The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa.
33287410	1	21	dep	diagnosis	123:131	arg1	The					119:121	The	119:121	The	119:121	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	5	22	theme	analysis	798:805	arg1	platform					807:814	our automated, high-throughput analysis platform	767:814	platform	807:814	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	23	dep	fucose	1284:1289	arg1	FA3G3S3					1303:1309	FA3G3S3	1303:1309	FA3G3S3	1303:1309	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	23	dep	fucose	1284:1289	arg1	A3G3S3					1292:1297	A3G3S3	1292:1297	A3G3S3	1292:1297	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	5	24	theme	N-linked	939:946	arg1	glycans					948:954	N-linked glycans	939:954	N-linked glycans released from the serum glycoproteins	939:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	25	theme	aggressive	1371:1380	arg1	disease					1382:1388	significant and aggressive disease	1355:1388	significant and aggressive disease	1355:1388	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	5	26	theme	serum	974:978	arg1	glycoproteins					980:992	the serum glycoproteins	970:992	the serum glycoproteins	970:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	27	from	indolent	1338:1345	arg1	progression					1321:1331	PCa progression	1317:1331	PCa progression from indolent through significant and aggressive disease	1317:1388	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	3	28	theme	glycan	417:422	arg1	patterns					435:442	glycan expression patterns	417:442	glycan expression patterns	417:442	It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis.
33287410	7	29	dep	biomarkers	1477:1486	arg1	need					1538:1541	need	1538:1541	need further confirmation studies	1538:1570	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	6	30	theme	trisialylated	1240:1252	arg1	glycans					1254:1260	triantennary trigalactosylated trisialylated glycans	1209:1260	triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3)	1209:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	2	31	theme	indolent	304:311	arg1	PCa					313:315	clinically indolent PCa	293:315	clinically indolent PCa	293:315	This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood.
33287410	3	32	theme	expression	424:433	arg1	patterns					435:442	glycan expression patterns	417:442	glycan expression patterns	417:442	It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis.
33287410	6	33	from	increases	1007:1015	arg1	glycans					1254:1260	triantennary trigalactosylated trisialylated glycans	1209:1260	triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3)	1209:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	33	from	increases	1007:1015	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	33	from	increases	1007:1015	arg1	hybrid					1020:1025	hybrid	1020:1025	hybrid	1020:1025	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	33	from	increases	1007:1015	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	33	from	increases	1007:1015	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	33	from	increases	1007:1015	arg1	oligomannose					1028:1039	oligomannose	1028:1039	oligomannose	1028:1039	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	33	from	increases	1007:1015	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	1	34	theme	health-care	183:193	arg1	treatment					137:145	treatment	137:145	treatment	137:145	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	34	theme	health-care	183:193	arg1	diagnosis					123:131	diagnosis	123:131	diagnosis	123:131	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	34	theme	health-care	183:193	arg1	worldwide					203:211	a major health-care concern worldwide	175:211	a major health-care concern worldwide	175:211	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	0	35	theme	Indolent	17:24	arg1	Cancer					63:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	5	36	link	N-linked	939:946	arg1	glycans					948:954	N-linked glycans	939:954	N-linked glycans released from the serum glycoproteins	939:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	7	37	theme	further	1543:1549	arg1	studies					1564:1570	further confirmation studies	1543:1570	further confirmation studies	1543:1570	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	3	38	theme	tumorigenesis	511:523	arg1	onset					502:506	the onset	498:506	the onset of tumorigenesis	498:523	It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis.
33287410	1	39	theme	concern	195:201	arg1	treatment					137:145	treatment	137:145	treatment	137:145	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	39	theme	concern	195:201	arg1	diagnosis					123:131	diagnosis	123:131	diagnosis	123:131	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	39	theme	concern	195:201	arg1	worldwide					203:211	a major health-care concern worldwide	175:211	a major health-care concern worldwide	175:211	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	5	40	theme	high-throughput	782:796	arg1	platform					807:814	our automated, high-throughput analysis platform	767:814	platform	807:814	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	41	theme	A2	1150:1151	arg1	BG1					1155:1157	A2(6)BG1	1150:1157	A2(6)BG1	1150:1157	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	41	theme	A2	1150:1151	arg1	A2B					1145:1147	A2B	1145:1147	A2B	1145:1147	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	42	theme	PCa	1317:1319	arg1	progression					1321:1331	PCa progression	1317:1331	PCa progression from indolent through significant and aggressive disease	1317:1388	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	7	43	theme	confirmation	1551:1562	arg1	studies					1564:1570	further confirmation studies	1543:1570	further confirmation studies	1543:1570	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	6	44	theme	trigalactosylated	1222:1238	arg1	glycans					1254:1260	triantennary trigalactosylated trisialylated glycans	1209:1260	triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3)	1209:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	1	45	theme	major	177:181	arg1	treatment					137:145	treatment	137:145	treatment	137:145	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	45	theme	major	177:181	arg1	diagnosis					123:131	diagnosis	123:131	diagnosis	123:131	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	45	theme	major	177:181	arg1	worldwide					203:211	a major health-care concern worldwide	175:211	a major health-care concern worldwide	175:211	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	4	46	theme	aggressive	659:668	arg1	PCa					670:672	indolent, significant, and aggressive PCa	632:672	indolent, significant, and aggressive PCa	632:672	The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa.
33287410	0	47	theme	Significant	27:37	arg1	Cancer					63:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	5	48	theme	prostate	729:736	arg1	patients					745:752	117 prostate cancer patients	725:752	117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins	725:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	6	49	theme	triantennary	1209:1220	arg1	glycans					1254:1260	triantennary trigalactosylated trisialylated glycans	1209:1260	triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3)	1209:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	0	50	theme	Prostate	54:61	arg1	Cancer					63:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	5	51	theme	cancer	738:743	arg1	patients					745:752	117 prostate cancer patients	725:752	117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins	725:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	52	theme	N-glycan	687:694	arg1	profiling					696:704	Whole serum N-glycan profiling	675:704	Whole serum N-glycan profiling	675:704	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	7	53	dep	us	1410:1411	arg1	insight					1416:1422	an insight	1413:1422	us an insight into the disease pathogenesis	1410:1452	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	6	54	dep	glycans	1090:1096	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	54	dep	glycans	1090:1096	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	54	dep	glycans	1090:1096	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	54	dep	glycans	1090:1096	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	2	55	theme	invasive	329:336	arg1	form					349:352	the more invasive aggressive form	320:352	the more invasive aggressive form	320:352	This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood.
33287410	0	56	theme	Aggressive	43:52	arg1	Cancer					63:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Indolent, Significant and Aggressive Prostate Cancer	17:68	Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput N-Glycan Profiling.
33287410	4	57	theme	study	542:546	arg1	aim					530:532	The aim	526:532	The aim of this study	526:546	The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa.
33287410	6	58	dep	glycans	1136:1142	arg1	BG1					1155:1157	A2(6)BG1	1150:1157	A2(6)BG1	1150:1157	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	58	dep	glycans	1136:1142	arg1	A2B					1145:1147	A2B	1145:1147	A2B	1145:1147	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	59	theme	core	1279:1282	arg1	fucose					1284:1289	core fucose	1279:1289	core fucose (A3G3S3 and FA3G3S3)	1279:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	2	60	theme	distinct	254:261	arg1	forms					263:267	many distinct forms	249:267	many distinct forms	249:267	This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood.
33287410	6	61	gly	trisialylated	1240:1252	arg1	glycans					1254:1260	triantennary trigalactosylated trisialylated glycans	1209:1260	triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3)	1209:1310	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	5	62	theme	high	909:912	arg1	separation					925:934	high resolution separation	909:934	high resolution separation of N-linked glycans released from the serum glycoproteins	909:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	7	63	theme	PCa	1507:1509	arg1	progression					1511:1521	the PCa progression	1503:1521	the PCa progression	1503:1521	These changes give us an insight into the disease pathogenesis and identify potential biomarkers for monitoring the PCa progression, however these need further confirmation studies.
33287410	2	64	theme	many	249:252	arg1	forms					263:267	many distinct forms	249:267	many distinct forms	249:267	This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood.
33287410	6	65	gly	monosialylated	1075:1088	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	65	gly	monosialylated	1075:1088	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	65	gly	monosialylated	1075:1088	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	65	gly	monosialylated	1075:1088	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	66	theme	significant	1355:1365	arg1	disease					1382:1388	significant and aggressive disease	1355:1388	significant and aggressive disease	1355:1388	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	67	theme	monosialylated	1075:1088	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	67	theme	monosialylated	1075:1088	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	67	theme	monosialylated	1075:1088	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	67	theme	monosialylated	1075:1088	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	3	68	theme	cellular	460:467	arg1	modifications					469:481	the cellular modifications	456:481	the cellular modifications that accompany the onset of tumorigenesis	456:523	It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis.
33287410	1	69	theme	prostate	150:157	arg1	cancer					159:164	prostate cancer	150:164	prostate cancer (PCa)	150:170	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	69	theme	prostate	150:157	arg1	PCa					167:169	PCa	167:169	PCa	167:169	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	6	70	theme	monoantennary	1164:1176	arg1	A1					1187:1188	A1	1187:1188	A1	1187:1188	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	70	theme	monoantennary	1164:1176	arg1	glycans					1178:1184	monoantennary glycans	1164:1184	monoantennary glycans (A1)	1164:1189	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	71	theme	digalactosylated	1058:1073	arg1	M8					1109:1110	M8	1109:1110	M8	1109:1110	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	71	theme	digalactosylated	1058:1073	arg1	A2G2S1					1117:1122	A2G2S1	1117:1122	A2G2S1	1117:1122	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	71	theme	digalactosylated	1058:1073	arg1	M5A1G1S1					1099:1106	M5A1G1S1	1099:1106	M5A1G1S1	1099:1106	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	6	71	theme	digalactosylated	1058:1073	arg1	glycans					1090:1096	biantennary digalactosylated monosialylated glycans	1046:1096	biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1)	1046:1123	We observed increases in hybrid, oligomannose, and biantennary digalactosylated monosialylated glycans (M5A1G1S1, M8, and A2G2S1), bisecting glycans (A2B, A2(6)BG1) and monoantennary glycans (A1), and decreases in triantennary trigalactosylated trisialylated glycans with and without core fucose (A3G3S3 and FA3G3S3) with PCa progression from indolent through significant and aggressive disease.
33287410	5	72	attach	released	956:963	arg2	glycans					948:954	N-linked glycans	939:954	N-linked glycans released from the serum glycoproteins	939:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	72	attach	released	956:963	arg1	glycoproteins					980:992	the serum glycoproteins	970:992	the serum glycoproteins	970:992	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	73	theme	ultra-performance	852:868	arg1	UPLC					893:896	UPLC	893:896	UPLC	893:896	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	5	73	theme	ultra-performance	852:868	arg1	chromatography					877:890	ultra-performance liquid chromatography	852:890	ultra-performance liquid chromatography (UPLC)	852:897	Whole serum N-glycan profiling was carried out on 117 prostate cancer patients' serum using our automated, high-throughput analysis platform for glycan-profiling which utilizes ultra-performance liquid chromatography (UPLC) to obtain high resolution separation of N-linked glycans released from the serum glycoproteins.
33287410	1	74	theme	cancer	159:164	arg1	treatment					137:145	treatment	137:145	treatment	137:145	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	74	theme	cancer	159:164	arg1	diagnosis					123:131	diagnosis	123:131	diagnosis	123:131	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	1	74	theme	cancer	159:164	arg1	worldwide					203:211	a major health-care concern worldwide	175:211	a major health-care concern worldwide	175:211	The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide.
33287410	4	75	theme	indolent	632:639	arg1	PCa					670:672	indolent, significant, and aggressive PCa	632:672	indolent, significant, and aggressive PCa	632:672	The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa.
36189205	2	0	with	design	307:312	arg1	activities					405:414	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	4	1	theme	N-glycan	837:844	arg1	structures					846:855	different N-glycan structures	827:855	different N-glycan structures	827:855	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	4	2	with	FcγRIIIa	813:820	arg1	structures					846:855	different N-glycan structures	827:855	different N-glycan structures	827:855	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	3	3	theme	natural	632:638	arg1	heterogeneity					640:652	the natural heterogeneity	628:652	the natural heterogeneity in N-glycosylation	628:671	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	4	4	theme	different	827:835	arg1	structures					846:855	different N-glycan structures	827:855	different N-glycan structures	827:855	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	1	5	theme	important	124:132	arg1	roles					134:138	important roles	124:138	important roles	124:138	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	5	6	theme	allotypes	1006:1014	arg1	variants					971:978	FcγRIIIa variants	962:978	FcγRIIIa variants of both the 158F and 158V allotypes	962:1014	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	0	7	from	Role	0:3	arg1	interaction					36:46	FcγRIIIa interaction	27:46	FcγRIIIa interaction with IgG	27:55	Role of N-Glycosylation in FcγRIIIa interaction with IgG.
36189205	6	8	theme	highest	1141:1147	arg1	affinity					1157:1164	the highest binding affinity	1137:1164	the highest binding affinity	1137:1164	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	4	9	with	IgG1	804:807	arg1	structures					846:855	different N-glycan structures	827:855	different N-glycan structures	827:855	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	6	10	contain	has	1133:1135	arg2	affinity					1157:1164	the highest binding affinity	1137:1164	the highest binding affinity	1137:1164	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	10	contain	has	1133:1135	arg1	IgG1					1128:1131	afucosylated IgG1	1115:1131	afucosylated IgG1	1115:1131	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	4	11	theme	genetic	715:721	arg1	engineering					723:733	comprehensive genetic engineering	701:733	comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines	701:791	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	4	12	from	engineering	723:733	arg1	lines					787:791	mammalian cell lines	772:791	mammalian cell lines	772:791	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	2	13	theme	IgG	233:235	arg1	interaction					218:228	interaction	218:228	interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	218:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	1	14	dep	Immunoglobulins	58:72	arg1	G					74:74	G	74:74	G (IgG)	74:80	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	1	14	dep	Immunoglobulins	58:72	arg1	IgG					77:79	IgG	77:79	IgG	77:79	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	4	15	theme	binding	928:934	arg1	interactions					936:947	FcγRIIIa binding interactions	919:947	FcγRIIIa binding interactions	919:947	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	5	16	theme	binding	1073:1079	arg1	affinity					1081:1088	binding affinity	1073:1088	binding affinity	1073:1088	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	6	17	gly	afucosylated	1115:1126	arg1	IgG1					1128:1131	afucosylated IgG1	1115:1131	afucosylated IgG1	1115:1131	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	18	theme	binding	1149:1155	arg1	affinity					1157:1164	the highest binding affinity	1137:1164	the highest binding affinity	1137:1164	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	2	19	from	N-glycan	176:183	arg1	region					195:200	the Fc region	188:200	the Fc region of IgG1	188:208	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	20	theme	therapeutics	326:337	arg1	design					307:312	the design	303:312	the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	303:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	3	21	with	interaction	549:559	arg1	N-glycans					596:604	distinct N-glycans	587:604	distinct N-glycans	587:604	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	3	22	gly	N-glycosylation	450:464	arg1	receptor					489:496	receptor interactions	489:509	receptor interactions with IgG	489:518	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	3	22	gly	N-glycosylation	450:464	arg1	FcγRIII					473:479	the FcγRIII	469:479	the FcγRIII	469:479	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	2	23	theme	antibody	317:324	arg1	therapeutics					326:337	antibody therapeutics	317:337	antibody therapeutics	317:337	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	5	24	theme	158F	992:995	arg1	variants					971:978	FcγRIIIa variants	962:978	FcγRIIIa variants of both the 158F and 158V allotypes	962:1014	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	2	25	theme	resulting	256:264	arg1	functions					275:283	the resulting effector functions	252:283	the resulting effector functions	252:283	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	4	26	theme	N-glycosylation	742:756	arg1	capacities					758:767	the N-glycosylation capacities	738:767	the N-glycosylation capacities	738:767	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	3	27	theme	detailed	525:532	arg1	studies					534:540	detailed studies	525:540	detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans	525:604	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	1	28	theme	immune	147:152	arg1	system					154:159	our immune system	143:159	our immune system	143:159	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	2	29	theme	cytotoxicity	385:396	arg1	activities					405:414	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	6	30	theme	glycan	1194:1199	arg1	structure					1201:1209	a glycan structure	1192:1209	a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa	1192:1322	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	30	theme	glycan	1194:1199	arg1	FcγRIIIa					1182:1189	oligomannose FcγRIIIa	1169:1189	oligomannose FcγRIIIa	1169:1189	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	4	31	theme	comprehensive	701:713	arg1	engineering					723:733	comprehensive genetic engineering	701:733	comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines	701:791	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	2	32	theme	antibody-dependent	361:378	arg1	ADCC					399:402	ADCC	399:402	ADCC	399:402	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	32	theme	antibody-dependent	361:378	arg1	cytotoxicity					385:396	antibody-dependent cell cytotoxicity	361:396	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	33	theme	cell	380:383	arg1	ADCC					399:402	ADCC	399:402	ADCC	399:402	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	33	theme	cell	380:383	arg1	cytotoxicity					385:396	antibody-dependent cell cytotoxicity	361:396	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	5	34	theme	key	1037:1039	arg1	features					1050:1057	the key N-glycan features	1033:1057	the key N-glycan features that affected binding affinity	1033:1088	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	6	35	theme	afucosylated	1115:1126	arg1	IgG1					1128:1131	afucosylated IgG1	1115:1131	afucosylated IgG1	1115:1131	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	2	36	theme	improved	352:359	arg1	activities					405:414	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	greatly improved antibody-dependent cell cytotoxicity (ADCC) activities	344:414	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	6	37	theme	expressed	1305:1313	arg1	FcγRIIIa					1315:1322	recombinantly expressed FcγRIIIa	1291:1322	recombinantly expressed FcγRIIIa	1291:1322	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	5	38	theme	N-glycan	1041:1048	arg1	features					1050:1057	the key N-glycan features	1033:1057	the key N-glycan features that affected binding affinity	1033:1088	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	2	39	theme	Fc	192:193	arg1	region					195:200	the Fc region	188:200	the Fc region of IgG1	188:208	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	5	40	dep	158F	992:995	arg1	the					988:990	the	988:990	the	988:990	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	0	41	theme	FcγRIIIa	27:34	arg1	interaction					36:46	FcγRIIIa interaction	27:46	FcγRIIIa interaction with IgG	27:55	Role of N-Glycosylation in FcγRIIIa interaction with IgG.
36189205	3	42	from	heterogeneity	640:652	arg1	N-glycosylation					657:671	N-glycosylation	657:671	N-glycosylation	657:671	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	3	43	theme	FcγRIIIa	573:580	arg1	interaction					549:559	the interaction	545:559	the interaction of IgG1 and FcγRIIIa with distinct N-glycans	545:604	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	3	44	theme	interaction	549:559	arg1	studies					534:540	detailed studies	525:540	detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans	525:604	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	4	45	theme	FcγRIIIa	919:926	arg1	interactions					936:947	FcγRIIIa binding interactions	919:947	FcγRIIIa binding interactions	919:947	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	3	46	with	interactions	498:509	arg1	IgG					516:518	IgG	516:518	IgG	516:518	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	6	47	located	found	1220:1224	arg2	structure					1201:1209	a glycan structure	1192:1209	a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa	1192:1322	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	47	located	found	1220:1224	arg1	FcγRIIIa					1239:1246	FcγRIIIa	1239:1246	FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa	1239:1322	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	47	located	found	1220:1224	arg1	Asn162					1229:1234	Asn162	1229:1234	Asn162	1229:1234	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	47	located	found	1220:1224	arg2	FcγRIIIa					1182:1189	oligomannose FcγRIIIa	1169:1189	oligomannose FcγRIIIa	1169:1189	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	3	48	theme	distinct	587:594	arg1	N-glycans					596:604	distinct N-glycans	587:604	distinct N-glycans	587:604	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	1	49	theme	Fc	92:93	arg1	receptors					101:109	their Fc gamma receptors	86:109	their Fc gamma receptors (FcγRs)	86:117	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	1	49	theme	Fc	92:93	arg1	FcγRs					112:116	FcγRs	112:116	FcγRs	112:116	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	4	50	theme	N-glycosylation	895:909	arg1	role					887:890	the role	883:890	the role of N-glycosylation in IgG1	883:917	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	2	51	theme	conserved	166:174	arg1	N-glycan					176:183	The conserved N-glycan	162:183	The conserved N-glycan in the Fc region of IgG1	162:208	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	5	52	theme	158V	1001:1004	arg1	allotypes					1006:1014	158V allotypes	1001:1014	158V allotypes	1001:1014	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	1	53	theme	gamma	95:99	arg1	receptors					101:109	their Fc gamma receptors	86:109	their Fc gamma receptors (FcγRs)	86:117	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	1	53	theme	gamma	95:99	arg1	FcγRs					112:116	FcγRs	112:116	FcγRs	112:116	Immunoglobulins G (IgG) and their Fc gamma receptors (FcγRs) play important roles in our immune system.
36189205	3	54	theme	IgG1	564:567	arg1	interaction					549:559	the interaction	545:559	the interaction of IgG1 and FcγRIIIa with distinct N-glycans	545:604	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	6	55	theme	NK	1261:1262	arg1	cells					1264:1268	NK cells	1261:1268	NK cells but not monocytes or recombinantly expressed FcγRIIIa	1261:1322	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	5	56	theme	FcγRIIIa	962:969	arg1	variants					971:978	FcγRIIIa variants	962:978	FcγRIIIa variants of both the 158F and 158V allotypes	962:1014	We included FcγRIIIa variants of both the 158F and 158V allotypes and investigated the key N-glycan features that affected binding affinity.
36189205	4	57	theme	capacities	758:767	arg1	engineering					723:733	comprehensive genetic engineering	701:733	comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines	701:791	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	4	58	theme	cell	782:785	arg1	lines					787:791	mammalian cell lines	772:791	mammalian cell lines	772:791	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	3	59	theme	receptor	489:496	arg1	interactions					498:509	receptor interactions	489:509	receptor interactions with IgG	489:518	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	2	60	theme	IgG1	205:208	arg1	region					195:200	the Fc region	188:200	the Fc region of IgG1	188:208	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	61	theme	effector	266:273	arg1	functions					275:283	the resulting effector functions	252:283	the resulting effector functions	252:283	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	62	with	interaction	218:228	arg1	functions					275:283	the resulting effector functions	252:283	the resulting effector functions	252:283	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	2	62	with	interaction	218:228	arg1	FcγRs					242:246	FcγRs	242:246	FcγRs	242:246	The conserved N-glycan in the Fc region of IgG1 impacts interaction of IgG with FcγRs and the resulting effector functions, which has led to the design of antibody therapeutics with greatly improved antibody-dependent cell cytotoxicity (ADCC) activities.
36189205	4	63	from	role	887:890	arg1	IgG1					914:917	IgG1	914:917	IgG1	914:917	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	4	64	theme	mammalian	772:780	arg1	lines					787:791	mammalian cell lines	772:791	mammalian cell lines	772:791	In this study, we employed comprehensive genetic engineering of the N-glycosylation capacities in mammalian cell lines to express IgG1 and FcγRIIIa with different N-glycan structures to more generally explore the role of N-glycosylation in IgG1:FcγRIIIa binding interactions.
36189205	0	65	theme	N-Glycosylation	8:22	arg1	Role					0:3	Role	0:3	Role of N-Glycosylation in FcγRIIIa interaction with IgG.	0:56	Role of N-Glycosylation in FcγRIIIa interaction with IgG.
36189205	0	66	with	interaction	36:46	arg1	IgG					53:55	IgG	53:55	IgG	53:55	Role of N-Glycosylation in FcγRIIIa interaction with IgG.
36189205	3	67	theme	FcγRIII	473:479	arg1	N-glycosylation					450:464	N-glycosylation	450:464	N-glycosylation of the FcγRIII	450:479	Studies have suggested that also N-glycosylation of the FcγRIII affects receptor interactions with IgG, but detailed studies of the interaction of IgG1 and FcγRIIIa with distinct N-glycans have been hindered by the natural heterogeneity in N-glycosylation.
36189205	6	68	theme	oligomannose	1169:1180	arg1	structure					1201:1209	a glycan structure	1192:1209	a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa	1192:1322	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
36189205	6	68	theme	oligomannose	1169:1180	arg1	FcγRIIIa					1182:1189	oligomannose FcγRIIIa	1169:1189	oligomannose FcγRIIIa	1169:1189	Our study confirms that afucosylated IgG1 has the highest binding affinity to oligomannose FcγRIIIa, a glycan structure commonly found on Asn162 on FcγRIIIa expressed by NK cells but not monocytes or recombinantly expressed FcγRIIIa.
35447118	0	0	theme	non-small-cell	98:111	arg1	cells					125:129	small-cell and non-small-cell lung cancer cells	83:129	small-cell and non-small-cell lung cancer cells	83:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	7	1	theme	cancer	1329:1334	arg1	sEVs					1336:1339	lung cancer sEVs	1324:1339	lung cancer sEVs	1324:1339	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	1	2	theme	proteins	185:192	arg1	N-glycosylation					165:179	N-glycosylation	165:179	N-glycosylation	165:179	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	2	theme	proteins	185:192	arg1	glycosylation					150:162	Asparagine-linked glycosylation	132:162	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome	132:216	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	5	3	theme	NSCLC-sEVs	949:958	arg1	N-glycoproteomics					914:930	lectin-assisted N-glycoproteomics	898:930	lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs	898:958	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	1	4	theme	cancer	285:290	arg1	detection					292:300	cancer detection	285:300	cancer detection	285:300	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	0	5	theme	cancer	118:123	arg1	cells					125:129	small-cell and non-small-cell lung cancer cells	83:129	small-cell and non-small-cell lung cancer cells	83:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	0	6	from	Identification	0:13	arg1	vesicles					69:76	extracellular vesicles	55:76	extracellular vesicles from small-cell and non-small-cell lung cancer cells	55:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	4	7	theme	NSCLC-associated	849:864	arg1	fucosylation					871:882	NSCLC-associated core fucosylation	849:882	NSCLC-associated core fucosylation	849:882	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	2	8	theme	extracellular	323:335	arg1	sEVs					347:350	sEVs	347:350	sEVs	347:350	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	2	8	theme	extracellular	323:335	arg1	vesicles					337:344	Small extracellular vesicles	317:344	Small extracellular vesicles (sEVs)	317:351	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	5	9	theme	types	1037:1041	arg1	sEVs					1012:1015	sEVs	1012:1015	sEVs of both cancer cell types	1012:1041	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	0	10	theme	lung	113:116	arg1	cells					125:129	small-cell and non-small-cell lung cancer cells	83:129	small-cell and non-small-cell lung cancer cells	83:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	0	11	from	vesicles	69:76	arg1	Identification					0:13	Identification	0:13	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.	0:130	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	3	12	theme	carcinoma	584:592	arg1	cells					643:647	small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	568:647	small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	568:647	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	2	13	theme	Small	317:321	arg1	sEVs					347:350	sEVs	347:350	sEVs	347:350	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	2	13	theme	Small	317:321	arg1	vesicles					337:344	Small extracellular vesicles	317:344	Small extracellular vesicles (sEVs)	317:351	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	6	14	theme	immunopurified	1173:1186	arg1	α6					1197:1198	the immunopurified integrin α6	1169:1198	the immunopurified integrin α6 from NSCLC-sEVs	1169:1214	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	4	15	theme	structural	729:738	arg1	units					740:744	structural units	729:744	structural units also found in the brain N-glycome	729:778	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	4	16	gly	fucosylation	871:882	arg1	N-glycans					834:842	typical lung-type N-glycans	816:842	typical lung-type N-glycans with NSCLC-associated core fucosylation	816:882	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	2	17	theme	cancer	480:485	arg1	characteristics					487:501	known cancer characteristics	474:501	known cancer characteristics	474:501	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	4	18	theme	core	866:869	arg1	fucosylation					871:882	NSCLC-associated core fucosylation	849:882	NSCLC-associated core fucosylation	849:882	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	7	19	theme	cancers	1387:1393	arg1	histology					1369:1377	the histology	1365:1377	the histology of lung cancers	1365:1393	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	3	20	gly	N-glycosylation	530:544	arg1	sEVs					549:552	sEVs	549:552	sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	549:647	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	1	21	theme	cancer	201:206	arg1	secretome					208:216	the cancer secretome	197:216	the cancer secretome	197:216	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	2	22	theme	known	474:478	arg1	characteristics					487:501	known cancer characteristics	474:501	known cancer characteristics	474:501	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	0	23	from	patterns	43:50	arg1	vesicles					69:76	extracellular vesicles	55:76	extracellular vesicles from small-cell and non-small-cell lung cancer cells	55:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	7	24	theme	protein	1297:1303	arg1	N-glycosylation					1305:1319	protein N-glycosylation	1297:1319	protein N-glycosylation in lung cancer sEVs	1297:1339	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	7	25	gly	N-glycosylation	1305:1319	arg1	sEVs					1336:1339	lung cancer sEVs	1324:1339	lung cancer sEVs	1324:1339	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	5	26	theme	lectin-assisted	898:912	arg1	N-glycoproteomics					914:930	lectin-assisted N-glycoproteomics	898:930	lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs	898:958	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	5	27	theme	cancer	1025:1030	arg1	types					1037:1041	both cancer cell types	1020:1041	both cancer cell types	1020:1041	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	7	28	from	N-glycosylation	1305:1319	arg1	sEVs					1336:1339	lung cancer sEVs	1324:1339	lung cancer sEVs	1324:1339	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	6	29	theme	NSCLC-type	1227:1236	arg1	N-glycans					1238:1246	NSCLC-type N-glycans	1227:1246	NSCLC-type N-glycans	1227:1246	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	4	30	theme	SCLC-sEVs	681:689	arg1	N-glycans					668:676	the N-glycans	664:676	the N-glycans of SCLC-sEVs	664:689	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	0	31	theme	N-glycosylation	27:41	arg1	patterns					43:50	distinct N-glycosylation patterns	18:50	distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells	18:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	1	32	gly	glycosylation	150:162	arg1	secretome					208:216	the cancer secretome	197:216	the cancer secretome	197:216	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	32	gly	glycosylation	150:162	arg1	proteins					185:192	proteins	185:192	proteins	185:192	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	33	from	glycosylation	150:162	arg1	secretome					208:216	the cancer secretome	197:216	the cancer secretome	197:216	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	4	34	theme	brain	764:768	arg1	N-glycome					770:778	the brain N-glycome	760:778	the brain N-glycome	760:778	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	6	35	from	NSCLC-sEVs	1205:1214	arg1	α6					1197:1198	the immunopurified integrin α6	1169:1198	the immunopurified integrin α6 from NSCLC-sEVs	1169:1214	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	6	35	from	NSCLC-sEVs	1205:1214	arg1	N-glycomics					1154:1164	N-glycomics	1154:1164	N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs	1154:1214	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	7	36	theme	lung	1382:1385	arg1	cancers					1387:1393	lung cancers	1382:1393	lung cancers	1382:1393	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	0	37	theme	distinct	18:25	arg1	patterns					43:50	distinct N-glycosylation patterns	18:50	distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells	18:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	7	38	theme	lung	1324:1327	arg1	sEVs					1336:1339	lung cancer sEVs	1324:1339	lung cancer sEVs	1324:1339	Thus, we conclude that protein N-glycosylation in lung cancer sEVs may potentially reflect the histology of lung cancers.
35447118	5	39	theme	integrin	1074:1081	arg1	heterodimer					1088:1098	the epithelium-specific integrin α6β4 heterodimer	1050:1098	the epithelium-specific integrin α6β4 heterodimer	1050:1098	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	3	40	theme	sEVs	549:552	arg1	N-glycosylation					530:544	the N-glycosylation	526:544	the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	526:647	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	6	41	theme	α6	1197:1198	arg1	N-glycomics					1154:1164	N-glycomics	1154:1164	N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs	1154:1214	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	4	42	with	N-glycans	834:842	arg1	fucosylation					871:882	NSCLC-associated core fucosylation	849:882	NSCLC-associated core fucosylation	849:882	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	3	43	theme	carcinoma	625:633	arg1	cells					643:647	small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	568:647	small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	568:647	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	1	44	theme	increasing	235:244	arg1	biomarker					271:279	a potential biomarker	259:279	a potential biomarker for cancer detection and diagnosis	259:314	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	44	theme	increasing	235:244	arg1	attention					246:254	increasing attention	235:254	increasing attention	235:254	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	0	45	theme	patterns	43:50	arg1	Identification					0:13	Identification	0:13	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.	0:130	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	4	46	located	found	751:755	arg2	units					740:744	structural units	729:744	structural units also found in the brain N-glycome	729:778	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	4	46	located	found	751:755	arg1	N-glycome					770:778	the brain N-glycome	760:778	the brain N-glycome	760:778	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	4	47	theme	lung-type	824:832	arg1	N-glycans					834:842	typical lung-type N-glycans	816:842	typical lung-type N-glycans with NSCLC-associated core fucosylation	816:882	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	3	48	attach	released	554:561	arg2	sEVs					549:552	sEVs	549:552	sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	549:647	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	48	attach	released	554:561	arg1	cells					643:647	small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	568:647	small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells	568:647	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	49	theme	non-small-cell	605:618	arg1	carcinoma					625:633	non-small-cell lung carcinoma	605:633	non-small-cell lung carcinoma (NSCLC)	605:641	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	49	theme	non-small-cell	605:618	arg1	NSCLC					636:640	NSCLC	636:640	NSCLC	636:640	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	1	50	theme	Asparagine-linked	132:148	arg1	N-glycosylation					165:179	N-glycosylation	165:179	N-glycosylation	165:179	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	50	theme	Asparagine-linked	132:148	arg1	glycosylation					150:162	Asparagine-linked glycosylation	132:162	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome	132:216	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	0	51	theme	extracellular	55:67	arg1	vesicles					69:76	extracellular vesicles	55:76	extracellular vesicles from small-cell and non-small-cell lung cancer cells	55:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	6	52	theme	integrin	1256:1263	arg1	subunit					1265:1271	this integrin subunit	1251:1271	this integrin subunit	1251:1271	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	5	53	theme	α6β4	1083:1086	arg1	heterodimer					1088:1098	the epithelium-specific integrin α6β4 heterodimer	1050:1098	the epithelium-specific integrin α6β4 heterodimer	1050:1098	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	3	54	theme	lung	620:623	arg1	carcinoma					625:633	non-small-cell lung carcinoma	605:633	non-small-cell lung carcinoma (NSCLC)	605:641	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	54	theme	lung	620:623	arg1	NSCLC					636:640	NSCLC	636:640	NSCLC	636:640	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	2	55	theme	large	366:370	arg1	part					372:375	a large part	364:375	a large part of the cancer secretome	364:399	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	1	56	link	Asparagine-linked	132:148	arg1	N-glycosylation					165:179	N-glycosylation	165:179	N-glycosylation	165:179	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	56	link	Asparagine-linked	132:148	arg1	glycosylation					150:162	Asparagine-linked glycosylation	132:162	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome	132:216	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	0	57	from	cells	125:129	arg1	vesicles					69:76	extracellular vesicles	55:76	extracellular vesicles from small-cell and non-small-cell lung cancer cells	55:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	5	58	theme	cell	1032:1035	arg1	types					1037:1041	both cancer cell types	1020:1041	both cancer cell types	1020:1041	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	5	59	theme	epithelium-specific	1054:1072	arg1	heterodimer					1088:1098	the epithelium-specific integrin α6β4 heterodimer	1050:1098	the epithelium-specific integrin α6β4 heterodimer	1050:1098	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	5	60	theme	integrin	974:981	arg1	αV					983:984	integrin αV	974:984	integrin αV	974:984	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	3	61	theme	small-cell	568:577	arg1	SCLC					595:598	SCLC	595:598	SCLC	595:598	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	61	theme	small-cell	568:577	arg1	carcinoma					584:592	small-cell lung carcinoma	568:592	small-cell lung carcinoma (SCLC)	568:599	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	62	theme	lung	579:582	arg1	SCLC					595:598	SCLC	595:598	SCLC	595:598	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	3	62	theme	lung	579:582	arg1	carcinoma					584:592	small-cell lung carcinoma	568:592	small-cell lung carcinoma (SCLC)	568:599	Here, we investigated the N-glycosylation of sEVs released from small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC) cells.
35447118	6	63	from	N-glycomics	1154:1164	arg1	NSCLC-sEVs					1205:1214	NSCLC-sEVs	1205:1214	NSCLC-sEVs	1205:1214	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	4	64	theme	units	740:744	arg1	presence					717:724	the presence	713:724	the presence of structural units also found in the brain N-glycome	713:778	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	6	65	theme	integrin	1188:1195	arg1	α6					1197:1198	the immunopurified integrin α6	1169:1198	the immunopurified integrin α6 from NSCLC-sEVs	1169:1214	Importantly, N-glycomics of the immunopurified integrin α6 from NSCLC-sEVs identified NSCLC-type N-glycans on this integrin subunit.
35447118	0	66	theme	small-cell	83:92	arg1	cells					125:129	small-cell and non-small-cell lung cancer cells	83:129	small-cell and non-small-cell lung cancer cells	83:129	Identification of distinct N-glycosylation patterns on extracellular vesicles from small-cell and non-small-cell lung cancer cells.
35447118	5	67	theme	SCLC-sEVs	935:943	arg1	N-glycoproteomics					914:930	lectin-assisted N-glycoproteomics	898:930	lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs	898:958	In addition, lectin-assisted N-glycoproteomics of SCLC-sEVs and NSCLC-sEVs revealed that integrin αV was commonly expressed in sEVs of both cancer cell types, while the epithelium-specific integrin α6β4 heterodimer was selectively expressed in NSCLC-sEVs.
35447118	4	68	theme	typical	816:822	arg1	N-glycans					834:842	typical lung-type N-glycans	816:842	typical lung-type N-glycans with NSCLC-associated core fucosylation	816:882	We found that the N-glycans of SCLC-sEVs were characterized by the presence of structural units also found in the brain N-glycome, while NSCLC-sEVs were dominated by typical lung-type N-glycans with NSCLC-associated core fucosylation.
35447118	2	69	theme	secretome	391:399	arg1	part					372:375	a large part	364:375	a large part of the cancer secretome	364:399	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	1	70	theme	potential	261:269	arg1	biomarker					271:279	a potential biomarker	259:279	a potential biomarker for cancer detection and diagnosis	259:314	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	1	70	theme	potential	261:269	arg1	attention					246:254	increasing attention	235:254	increasing attention	235:254	Asparagine-linked glycosylation (N-glycosylation) of proteins in the cancer secretome has been gaining increasing attention as a potential biomarker for cancer detection and diagnosis.
35447118	2	71	theme	N-glycosylation	442:456	arg1	status					458:463	their N-glycosylation status	436:463	their N-glycosylation status	436:463	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
35447118	2	72	theme	cancer	384:389	arg1	secretome					391:399	the cancer secretome	380:399	the cancer secretome	380:399	Small extracellular vesicles (sEVs) constitute a large part of the cancer secretome, yet little is known about whether their N-glycosylation status reflects known cancer characteristics.
36124803	4	0	theme	glycoprotein	687:698	arg1	UniProt					659:665	UniProt	659:665	UniProt	659:665	We show how to enhance site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database.
36124803	4	0	theme	glycoprotein	687:698	arg1	database					700:707	our glycoprotein database	683:707	our glycoprotein database	683:707	We show how to enhance site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database.
36124803	3	1	theme	protein	564:570	arg1	glycosylation					572:584	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	2	theme	Coronavirus	531:541	arg1	glycosylation					572:584	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	2	3	theme	structural	272:281	arg1	procedure					292:300	the structural matching procedure	268:300	the structural matching procedure	268:300	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	4	4	theme	site	610:613	arg1	annotation					615:624	site annotation	610:624	site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database	610:707	We show how to enhance site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database.
36124803	3	5	theme	Respiratory	510:520	arg1	Coronavirus					531:541	Severe Acute Respiratory Syndrome Coronavirus 2	497:543	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	5	theme	Respiratory	510:520	arg1	SARS-CoV-2					546:555	SARS-CoV-2	546:555	SARS-CoV-2	546:555	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	6	theme	Syndrome	522:529	arg1	Coronavirus					531:541	Severe Acute Respiratory Syndrome Coronavirus 2	497:543	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	6	theme	Syndrome	522:529	arg1	SARS-CoV-2					546:555	SARS-CoV-2	546:555	SARS-CoV-2	546:555	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	2	7	theme	actual	365:370	arg1	implementation					372:385	the actual implementation	361:385	the actual implementation of a glycan structure search	361:414	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	1	8	theme	tree-based	74:83	arg1	ontology					85:92	a tree-based ontology	72:92	a tree-based ontology to represent glycan structures with the aim of searching these structures with a glyco-driven syntax	72:193	MOTIVATION We have previously designed and implemented a tree-based ontology to represent glycan structures with the aim of searching these structures with a glyco-driven syntax.
36124803	3	9	theme	spike	558:562	arg1	glycosylation					572:584	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	1	10	theme	glyco-driven	175:186	arg1	syntax					188:193	a glyco-driven syntax	173:193	a glyco-driven syntax	173:193	MOTIVATION We have previously designed and implemented a tree-based ontology to represent glycan structures with the aim of searching these structures with a glyco-driven syntax.
36124803	2	11	theme	structure	399:407	arg1	search					409:414	a glycan structure search	390:414	a glycan structure search	390:414	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	2	12	theme	search	409:414	arg1	implementation					372:385	the actual implementation	361:385	the actual implementation of a glycan structure search	361:414	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	2	13	theme	procedure	292:300	arg1	knowledge-base					236:249	the GlySTreeM knowledge-base	222:249	the GlySTreeM knowledge-base	222:249	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	2	13	theme	procedure	292:300	arg1	linchpin					256:263	a linchpin	254:263	a linchpin of the structural matching procedure	254:300	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	2	14	theme	glycan	392:397	arg1	structure					399:407	a glycan structure	390:407	a glycan structure search	390:414	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	4	15	theme	federated	631:639	arg1	queries					641:647	federated queries	631:647	federated queries involving UniProt and GlyConnect, our glycoprotein database	631:707	We show how to enhance site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database.
36124803	2	16	theme	GlySTreeM	226:234	arg1	knowledge-base					236:249	the GlySTreeM knowledge-base	222:249	the GlySTreeM knowledge-base	222:249	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	2	16	theme	GlySTreeM	226:234	arg1	linchpin					256:263	a linchpin	254:263	a linchpin of the structural matching procedure	254:300	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	1	17	dep	MOTIVATION	17:26	arg1	implemented					60:70	implemented	60:70	implemented	60:70	MOTIVATION We have previously designed and implemented a tree-based ontology to represent glycan structures with the aim of searching these structures with a glyco-driven syntax.
36124803	1	17	dep	MOTIVATION	17:26	arg1	designed					47:54	designed	47:54	designed	47:54	MOTIVATION We have previously designed and implemented a tree-based ontology to represent glycan structures with the aim of searching these structures with a glyco-driven syntax.
36124803	3	18	dep	RESULTS	417:423	arg1	illustrated					458:468	illustrated	458:468	illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	458:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	18	dep	RESULTS	417:423	arg1	described					444:452	described	444:452	described	444:452	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	1	19	theme	glycan	107:112	arg1	structures					114:123	glycan structures	107:123	glycan structures	107:123	MOTIVATION We have previously designed and implemented a tree-based ontology to represent glycan structures with the aim of searching these structures with a glyco-driven syntax.
36124803	5	20	dep	//glyconnect.expasy.org/glycoql/	748:779	arg1	IMPLEMENTATION					727:740	IMPLEMENTATION	727:740	IMPLEMENTATION	727:740	AVAILABILITY AND IMPLEMENTATION https://glyconnect.expasy.org/glycoql/.
36124803	5	20	dep	//glyconnect.expasy.org/glycoql/	748:779	arg1	AVAILABILITY					710:721	AVAILABILITY	710:721	AVAILABILITY	710:721	AVAILABILITY AND IMPLEMENTATION https://glyconnect.expasy.org/glycoql/.
36124803	2	21	theme	query	325:329	arg1	language					331:338	a query language	323:338	a query language	323:338	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	4	22	gly	glycoprotein	687:698	arg1	glycoprotein					687:698	our glycoprotein database	683:707	our glycoprotein database	683:707	We show how to enhance site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database.
36124803	4	23	with	annotation	615:624	arg1	queries					641:647	federated queries	631:647	federated queries involving UniProt and GlyConnect, our glycoprotein database	631:707	We show how to enhance site annotation with federated queries involving UniProt and GlyConnect, our glycoprotein database.
36124803	2	24	theme	matching	283:290	arg1	procedure					292:300	the structural matching procedure	268:300	the structural matching procedure	268:300	This resulted in creating the GlySTreeM knowledge-base as a linchpin of the structural matching procedure and we now introduce a query language, called GlycoQL, for the actual implementation of a glycan structure search.
36124803	5	25	dep	AVAILABILITY	710:721	arg1	https					742:746	https	742:746	https	742:746	AVAILABILITY AND IMPLEMENTATION https://glyconnect.expasy.org/glycoql/.
36124803	3	26	theme	Severe	497:502	arg1	Coronavirus					531:541	Severe Acute Respiratory Syndrome Coronavirus 2	497:543	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	26	theme	Severe	497:502	arg1	SARS-CoV-2					546:555	SARS-CoV-2	546:555	SARS-CoV-2	546:555	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	27	theme	Acute	504:508	arg1	Coronavirus					531:541	Severe Acute Respiratory Syndrome Coronavirus 2	497:543	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation	497:584	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
36124803	3	27	theme	Acute	504:508	arg1	SARS-CoV-2					546:555	SARS-CoV-2	546:555	SARS-CoV-2	546:555	RESULTS The methodology is described and illustrated with a use-case focused on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein glycosylation.
35092134	6	0	theme	dominant	934:941	arg1	type					970:973	the complex type	958:973	the complex type	958:973	The results indicated that most sites were fully glycosylated and that the dominant population was the complex type.
35092134	6	0	theme	dominant	934:941	arg1	population					943:952	the dominant population	930:952	the dominant population	930:952	The results indicated that most sites were fully glycosylated and that the dominant population was the complex type.
35092134	4	1	theme	cancer	657:662	arg1	cells					664:668	H1975 and EBC-1 lung cancer cells	636:668	H1975 and EBC-1 lung cancer cells	636:668	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	3	2	theme	HGF-induced	461:471	arg1	signaling					477:485	HGF-induced MET signaling	461:485	HGF-induced MET signaling	461:485	We report herein that these N-glycans regulate the proteolytic processing of MET and HGF-induced MET signaling, and that this regulation is site specific.
35092134	10	3	theme	surface	1463:1469	arg1	expression					1471:1480	cell surface expression	1458:1480	cell surface expression	1458:1480	Processing, cell surface expression, and signaling were significantly suppressed in the case of the all-N-glycan-deletion mutant.
35092134	5	4	theme	recombinant	721:731	arg1	domain					747:752	the recombinant extracellular domain	717:752	the recombinant extracellular domain of human MET	717:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	5	4	theme	recombinant	721:731	arg1	MET					763:765	human MET	757:765	human MET	757:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	6	5	theme	most	886:889	arg1	sites					891:895	most sites	886:895	most sites	886:895	The results indicated that most sites were fully glycosylated and that the dominant population was the complex type.
35092134	3	6	theme	MET	473:475	arg1	signaling					477:485	HGF-induced MET signaling	461:485	HGF-induced MET signaling	461:485	We report herein that these N-glycans regulate the proteolytic processing of MET and HGF-induced MET signaling, and that this regulation is site specific.
35092134	7	7	theme	CHO	1079:1081	arg1	cells					1083:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	7	8	theme	MET	1156:1158	arg1	mutants					1145:1151	N-glycan-deletion mutants	1127:1151	N-glycan-deletion mutants of MET	1127:1158	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	7	9	theme	knockout	1063:1070	arg1	cells					1083:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	10	10	theme	all-N-glycan-deletion	1546:1566	arg1	mutant					1568:1573	the all-N-glycan-deletion mutant	1542:1573	the all-N-glycan-deletion mutant	1542:1573	Processing, cell surface expression, and signaling were significantly suppressed in the case of the all-N-glycan-deletion mutant.
35092134	6	11	theme	complex	962:968	arg1	type					970:973	the complex type	958:973	the complex type	958:973	The results indicated that most sites were fully glycosylated and that the dominant population was the complex type.
35092134	6	11	theme	complex	962:968	arg1	population					943:952	the dominant population	930:952	the dominant population	930:952	The results indicated that most sites were fully glycosylated and that the dominant population was the complex type.
35092134	4	12	theme	CHO-K1	691:696	arg1	cells					698:702	CHO-K1 cells	691:702	CHO-K1 cells	691:702	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	11	13	theme	MET	1623:1625	arg1	N-glycans					1610:1618	N-glycans	1610:1618	N-glycans of MET	1610:1625	The overall findings suggest that N-glycans of MET affect the status and the function of the receptor in a site-specific manner.
35092134	7	14	theme	Flp-In	1072:1077	arg1	cells					1083:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	11	15	theme	receptor	1669:1676	arg1	status					1638:1643	the status	1634:1643	the status	1634:1643	The overall findings suggest that N-glycans of MET affect the status and the function of the receptor in a site-specific manner.
35092134	11	15	theme	receptor	1669:1676	arg1	function					1653:1660	the function	1649:1660	the function	1649:1660	The overall findings suggest that N-glycans of MET affect the status and the function of the receptor in a site-specific manner.
35092134	2	16	theme	site-specific	311:323	arg1	roles					325:329	the site-specific roles	307:329	the site-specific roles of these N-glycans	307:348	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	1	17	theme	non-small	226:234	arg1	cancer					246:251	non-small cell lung cancer	226:251	non-small cell lung cancer	226:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	7	18	theme	mutants	1145:1151	arg1	series					1117:1122	a series	1115:1122	a series of N-glycan-deletion mutants of MET	1115:1158	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	7	19	theme	endogenous	1048:1057	arg1	cells					1083:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	5	20	theme	N-glycan	800:807	arg1	structures					809:818	the site-specific N-glycan structures	782:818	the site-specific N-glycan structures	782:818	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	1	21	theme	tyrosine	156:163	arg1	inhibitors					172:181	tyrosine kinase inhibitors	156:181	tyrosine kinase inhibitors	156:181	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	21	theme	tyrosine	156:163	arg1	drugs					188:192	key drugs	184:192	key drugs that are used in the therapy of non-small cell lung cancer	184:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	4	22	theme	MET	629:631	arg1	trafficking					603:613	trafficking	603:613	trafficking	603:613	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	4	22	theme	MET	629:631	arg1	processing					588:597	processing	588:597	processing	588:597	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	4	23	theme	N-glycosylation	545:559	arg1	Inhibitors					531:540	Inhibitors	531:540	Inhibitors of N-glycosylation	531:559	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	7	24	theme	MET	1059:1061	arg1	cells					1083:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	endogenous MET knockout Flp-In CHO cells	1048:1087	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	9	25	theme	HGF	1431:1433	arg1	signaling					1435:1443	HGF signaling	1431:1443	HGF signaling	1431:1443	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	4	26	theme	endogenous	618:627	arg1	MET					629:631	endogenous MET	618:631	endogenous MET	618:631	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	5	27	theme	MET	763:765	arg1	domain					747:752	the recombinant extracellular domain	717:752	the recombinant extracellular domain of human MET	717:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	5	27	theme	MET	763:765	arg1	MET					763:765	human MET	757:765	human MET	757:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	9	28	theme	SEMA	1298:1301	arg1	MET					1313:1315	MET	1313:1315	MET	1313:1315	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	9	28	theme	SEMA	1298:1301	arg1	domain					1303:1308	the SEMA domain	1294:1308	the SEMA domain of MET	1294:1315	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	2	29	theme	potential	270:278	arg1	sites					296:300	11 potential N-glycosylation sites	267:300	11 potential N-glycosylation sites	267:300	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	2	30	theme	N-glycans	340:348	arg1	roles					325:329	the site-specific roles	307:329	the site-specific roles of these N-glycans	307:348	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	7	31	theme	N-glycan-deletion	1127:1143	arg1	mutants					1145:1151	N-glycan-deletion mutants	1127:1151	N-glycan-deletion mutants of MET	1127:1158	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	1	32	theme	cell	236:239	arg1	cancer					246:251	non-small cell lung cancer	226:251	non-small cell lung cancer	226:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	4	33	theme	exogenous	674:682	arg1	MET					684:686	exogenous MET	674:686	exogenous MET in CHO-K1 cells	674:702	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	1	34	theme	hepatocyte	82:91	arg1	HGF					108:110	HGF	108:110	HGF	108:110	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	34	theme	hepatocyte	82:91	arg1	factor					100:105	the hepatocyte growth factor	78:105	the hepatocyte growth factor (HGF)	78:111	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	11	35	theme	overall	1580:1586	arg1	findings					1588:1595	The overall findings	1576:1595	The overall findings	1576:1595	The overall findings suggest that N-glycans of MET affect the status and the function of the receptor in a site-specific manner.
35092134	1	36	theme	kinase	165:170	arg1	inhibitors					172:181	tyrosine kinase inhibitors	156:181	tyrosine kinase inhibitors	156:181	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	36	theme	kinase	165:170	arg1	drugs					188:192	key drugs	184:192	key drugs that are used in the therapy of non-small cell lung cancer	184:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	37	theme	lung	241:244	arg1	cancer					246:251	non-small cell lung cancer	226:251	non-small cell lung cancer	226:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	7	38	theme	MET	1031:1033	arg1	N-glycans					1018:1026	N-glycans	1018:1026	N-glycans of MET	1018:1033	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	6	39	gly	glycosylated	908:919	arg1	sites					891:895	most sites	886:895	most sites	886:895	The results indicated that most sites were fully glycosylated and that the dominant population was the complex type.
35092134	1	40	theme	growth	93:98	arg1	HGF					108:110	HGF	108:110	HGF	108:110	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	40	theme	growth	93:98	arg1	factor					100:105	the hepatocyte growth factor	78:105	the hepatocyte growth factor (HGF)	78:111	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	4	41	from	trafficking	603:613	arg1	cells					664:668	H1975 and EBC-1 lung cancer cells	636:668	H1975 and EBC-1 lung cancer cells	636:668	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	4	41	from	trafficking	603:613	arg1	MET					684:686	exogenous MET	674:686	exogenous MET in CHO-K1 cells	674:702	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	5	42	theme	site-specific	786:798	arg1	structures					809:818	the site-specific N-glycan structures	782:818	the site-specific N-glycan structures	782:818	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	1	43	theme	cancer	246:251	arg1	therapy					215:221	the therapy	211:221	the therapy of non-small cell lung cancer	211:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	4	44	theme	lung	652:655	arg1	cells					664:668	H1975 and EBC-1 lung cancer cells	636:668	H1975 and EBC-1 lung cancer cells	636:668	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	3	45	theme	proteolytic	427:437	arg1	processing					439:448	the proteolytic processing	423:448	the proteolytic processing of MET and HGF-induced MET signaling	423:485	We report herein that these N-glycans regulate the proteolytic processing of MET and HGF-induced MET signaling, and that this regulation is site specific.
35092134	5	46	theme	extracellular	733:745	arg1	domain					747:752	the recombinant extracellular domain	717:752	the recombinant extracellular domain of human MET	717:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	5	46	theme	extracellular	733:745	arg1	MET					763:765	human MET	757:765	human MET	757:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	4	47	theme	H1975	636:640	arg1	cells					664:668	H1975 and EBC-1 lung cancer cells	636:668	H1975 and EBC-1 lung cancer cells	636:668	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	7	48	theme	N-glycans	1018:1026	arg1	deletion					1006:1013	the deletion	1002:1013	the deletion of N-glycans of MET	1002:1033	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	9	49	theme	domain	1404:1409	arg1	N-glycans					1360:1368	the N-glycans	1356:1368	the N-glycans of the region other than the SEMA domain	1356:1409	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	9	50	dep	other	1384:1388	arg1	than					1390:1393	than	1390:1393	than	1390:1393	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	4	51	from	processing	588:597	arg1	cells					664:668	H1975 and EBC-1 lung cancer cells	636:668	H1975 and EBC-1 lung cancer cells	636:668	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	4	51	from	processing	588:597	arg1	MET					684:686	exogenous MET	674:686	exogenous MET in CHO-K1 cells	674:702	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	1	52	theme	key	184:186	arg1	inhibitors					172:181	tyrosine kinase inhibitors	156:181	tyrosine kinase inhibitors	156:181	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	52	theme	key	184:186	arg1	drugs					188:192	key drugs	184:192	key drugs that are used in the therapy of non-small cell lung cancer	184:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	4	53	theme	EBC-1	646:650	arg1	cells					664:668	H1975 and EBC-1 lung cancer cells	636:668	H1975 and EBC-1 lung cancer cells	636:668	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	9	54	theme	domain	1303:1308	arg1	N-glycans					1281:1289	the N-glycans	1277:1289	the N-glycans of the SEMA domain of MET	1277:1315	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	5	55	theme	mass	840:843	arg1	spectrometry					845:856	mass spectrometry	840:856	mass spectrometry	840:856	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	10	56	theme	mutant	1568:1573	arg1	case					1534:1537	the case	1530:1537	the case of the all-N-glycan-deletion mutant	1530:1573	Processing, cell surface expression, and signaling were significantly suppressed in the case of the all-N-glycan-deletion mutant.
35092134	2	57	contain	contains	258:265	arg2	sites					296:300	11 potential N-glycosylation sites	267:300	11 potential N-glycosylation sites	267:300	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	2	57	contain	contains	258:265	arg1	MET					254:256	MET	254:256	MET	254:256	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	7	58	theme	deletion	1006:1013	arg1	effects					991:997	the effects	987:997	the effects of the deletion of N-glycans of MET	987:1033	To examine the effects of the deletion of N-glycans of MET, we prepared endogenous MET knockout Flp-In CHO cells and transfected them with a series of N-glycan-deletion mutants of MET.
35092134	3	59	theme	MET	453:455	arg1	processing					439:448	the proteolytic processing	423:448	the proteolytic processing of MET and HGF-induced MET signaling	423:485	We report herein that these N-glycans regulate the proteolytic processing of MET and HGF-induced MET signaling, and that this regulation is site specific.
35092134	5	60	theme	human	757:761	arg1	MET					763:765	human MET	757:765	human MET	757:765	We purified the recombinant extracellular domain of human MET and determined the site-specific N-glycan structures and occupancy using mass spectrometry.
35092134	9	61	theme	MET	1313:1315	arg1	MET					1313:1315	MET	1313:1315	MET	1313:1315	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	9	61	theme	MET	1313:1315	arg1	domain					1303:1308	the SEMA domain	1294:1308	the SEMA domain of MET	1294:1315	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	10	62	theme	cell	1458:1461	arg1	expression					1471:1480	cell surface expression	1458:1480	cell surface expression	1458:1480	Processing, cell surface expression, and signaling were significantly suppressed in the case of the all-N-glycan-deletion mutant.
35092134	4	63	dep	processing	588:597	arg1	the					584:586	the	584:586	the	584:586	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	9	64	theme	SEMA	1399:1402	arg1	domain					1404:1409	the SEMA domain	1395:1409	the region other than the SEMA domain	1373:1409	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	8	65	theme	MET	1239:1241	arg1	processing					1225:1234	the processing	1221:1234	the processing of MET	1221:1241	The results showed that several N-glycans are implicated in the processing of MET.
35092134	4	66	from	MET	684:686	arg1	cells					698:702	CHO-K1 cells	691:702	CHO-K1 cells	691:702	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	2	67	gly	N-glycosylation	280:294	arg2	11					267:268	11	267:268	11	267:268	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	2	67	gly	N-glycosylation	280:294	arg2	sites					296:300	11 potential N-glycosylation sites	267:300	11 potential N-glycosylation sites	267:300	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	1	68	used	used	203:206	arg2	drugs					188:192	key drugs	184:192	key drugs that are used in the therapy of non-small cell lung cancer	184:251	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	1	68	used	used	203:206	arg2	inhibitors					172:181	tyrosine kinase inhibitors	156:181	tyrosine kinase inhibitors	156:181	MET, the receptor for the hepatocyte growth factor (HGF), is strongly associated with resistance to tyrosine kinase inhibitors, key drugs that are used in the therapy of non-small cell lung cancer.
35092134	9	69	theme	region	1377:1382	arg1	N-glycans					1360:1368	the N-glycans	1356:1368	the N-glycans of the region other than the SEMA domain	1356:1409	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	0	70	dep	MET	26:28	arg1	processing					30:39	processing	30:39	processing	30:39	N-glycosylation regulates MET processing and signaling.
35092134	2	71	theme	N-glycosylation	280:294	arg1	sites					296:300	11 potential N-glycosylation sites	267:300	11 potential N-glycosylation sites	267:300	MET contains 11 potential N-glycosylation sites, but the site-specific roles of these N-glycans have not been elucidated.
35092134	9	72	theme	HGF	1337:1339	arg1	signaling					1341:1349	HGF signaling	1337:1349	HGF signaling	1337:1349	The findings also suggested that the N-glycans of the SEMA domain of MET positively regulate HGF signaling, and the N-glycans of the region other than the SEMA domain negatively regulate HGF signaling.
35092134	3	73	theme	signaling	477:485	arg1	processing					439:448	the proteolytic processing	423:448	the proteolytic processing of MET and HGF-induced MET signaling	423:485	We report herein that these N-glycans regulate the proteolytic processing of MET and HGF-induced MET signaling, and that this regulation is site specific.
35092134	4	74	from	cells	664:668	arg1	cells					698:702	CHO-K1 cells	691:702	CHO-K1 cells	691:702	Inhibitors of N-glycosylation were found to suppress the processing and trafficking of endogenous MET in H1975 and EBC-1 lung cancer cells and exogenous MET in CHO-K1 cells.
35092134	8	75	theme	several	1185:1191	arg1	N-glycans					1193:1201	several N-glycans	1185:1201	several N-glycans	1185:1201	The results showed that several N-glycans are implicated in the processing of MET.
35092134	11	76	theme	site-specific	1683:1695	arg1	manner					1697:1702	a site-specific manner	1681:1702	a site-specific manner	1681:1702	The overall findings suggest that N-glycans of MET affect the status and the function of the receptor in a site-specific manner.
36036581	0	0	with	Characterization	46:61	arg1	StrucGP					92:98	StrucGP	92:98	StrucGP	92:98	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	3	1	theme	sequencing	518:527	arg1	algorithm					529:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	1	theme	sequencing	518:527	arg1	StrucGP					540:546	StrucGP	540:546	StrucGP	540:546	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	1	2	theme	COVID-19	143:150	arg1	infection					165:173	COVID-19 (SARS-CoV-2) infection	143:173	COVID-19 (SARS-CoV-2) infection	143:173	The spike (S) protein plays a key role in COVID-19 (SARS-CoV-2) infection and host-cell entry.
36036581	4	3	theme	uncommon	623:630	arg1	structures					646:655	many uncommon glycosylation structures	618:655	many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures	618:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	3	theme	uncommon	623:630	arg1	structures					758:767	bisected core structures	744:767	bisected core structures	744:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	3	theme	uncommon	623:630	arg1	residues					730:737	Mannose 6-phosphate (M6P) residues	704:737	Mannose 6-phosphate (M6P) residues	704:737	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	3	theme	uncommon	623:630	arg1	structures					674:683	LacdiNAc structures	665:683	LacdiNAc structures	665:683	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	3	theme	uncommon	623:630	arg1	structures					692:701	Lewis structures	686:701	Lewis structures	686:701	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	2	4	theme	many	287:290	arg1	motifs					313:318	many important structural motifs	287:318	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	1	5	theme	S	112:112	arg1	protein					115:121	The spike (S) protein	101:121	The spike (S) protein	101:121	The spike (S) protein plays a key role in COVID-19 (SARS-CoV-2) infection and host-cell entry.
36036581	5	6	theme	virus	959:963	arg1	spike					965:969	the COVID-19 virus spike	946:969	the COVID-19 virus spike	946:969	These data further support the glycosylation structural-functional investigations of the COVID-19 virus spike.
36036581	4	7	from	protomer	851:858	arg1	total					800:804	a total	798:804	a total of 20 glycosites in the S protein trimer and protomer	798:858	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	8	dep	trimer	840:845	arg1	the					826:828	the	826:828	the	826:828	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	5	9	theme	glycosylation	892:904	arg1	investigations					928:941	the glycosylation structural-functional investigations	888:941	the glycosylation structural-functional investigations of the COVID-19 virus spike	888:969	These data further support the glycosylation structural-functional investigations of the COVID-19 virus spike.
36036581	4	10	theme	previous	600:607	arg1	studies					609:615	previous studies	600:615	previous studies	600:615	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	11	theme	6-phosphate	712:722	arg1	residues					730:737	Mannose 6-phosphate (M6P) residues	704:737	Mannose 6-phosphate (M6P) residues	704:737	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	12	dep	N-glycans	575:583	arg1	addition					552:559	addition	552:559	addition	552:559	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	12	dep	N-glycans	575:583	arg1	detected					588:595	detected	588:595	detected in previous studies	588:615	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	3	13	theme	developed	460:468	arg1	algorithm					529:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	13	theme	developed	460:468	arg1	StrucGP					540:546	StrucGP	540:546	StrucGP	540:546	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	14	theme	S	403:403	arg1	protein					405:411	the S protein	399:411	the S protein	399:411	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	4	15	from	trimer	840:845	arg1	total					800:804	a total	798:804	a total of 20 glycosites in the S protein trimer and protomer	798:858	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	3	16	gly	N-glycosylation	380:394	arg1	level					432:436	a site-specific level	416:436	a site-specific level	416:436	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	16	gly	N-glycosylation	380:394	arg1	protein					405:411	the S protein	399:411	the S protein	399:411	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	1	17	theme	SARS-CoV-2	153:162	arg1	infection					165:173	COVID-19 (SARS-CoV-2) infection	143:173	COVID-19 (SARS-CoV-2) infection	143:173	The spike (S) protein plays a key role in COVID-19 (SARS-CoV-2) infection and host-cell entry.
36036581	4	18	gly	glycosites	812:821	arg2	glycosites					812:821	20 glycosites	809:821	20 glycosites in the S protein trimer and protomer	809:858	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	5	19	theme	structural-functional	906:926	arg1	investigations					928:941	the glycosylation structural-functional investigations	888:941	the glycosylation structural-functional investigations of the COVID-19 virus spike	888:969	These data further support the glycosylation structural-functional investigations of the COVID-19 virus spike.
36036581	4	20	theme	bisected	744:751	arg1	structures					758:767	bisected core structures	744:767	bisected core structures	744:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	21	theme	common	568:573	arg1	N-glycans					575:583	the common N-glycans	564:583	the common N-glycans as detected in previous studies	564:615	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	1	22	theme	spike	105:109	arg1	protein					115:121	The spike (S) protein	101:121	The spike (S) protein	101:121	The spike (S) protein plays a key role in COVID-19 (SARS-CoV-2) infection and host-cell entry.
36036581	3	23	theme	site-specific	418:430	arg1	level					432:436	a site-specific level	416:436	a site-specific level	416:436	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	0	24	theme	N-Glycosylation	30:44	arg1	Characterization					46:61	Site-Specific N-Glycosylation Characterization	16:61	Site-Specific N-Glycosylation Characterization	16:61	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	2	25	theme	structural	302:311	arg1	motifs					313:318	many important structural motifs	287:318	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	0	26	theme	Site-Specific	16:28	arg1	Characterization					46:61	Site-Specific N-Glycosylation Characterization	16:61	Site-Specific N-Glycosylation Characterization	16:61	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	5	27	theme	spike	965:969	arg1	investigations					928:941	the glycosylation structural-functional investigations	888:941	the glycosylation structural-functional investigations of the COVID-19 virus spike	888:969	These data further support the glycosylation structural-functional investigations of the COVID-19 virus spike.
36036581	2	28	theme	important	292:300	arg1	motifs					313:318	many important structural motifs	287:318	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	1	29	theme	host-cell	179:187	arg1	entry					189:193	host-cell entry	179:193	host-cell entry	179:193	The spike (S) protein plays a key role in COVID-19 (SARS-CoV-2) infection and host-cell entry.
36036581	3	30	theme	protein	405:411	arg1	N-glycosylation					380:394	structural-clear N-glycosylation	363:394	structural-clear N-glycosylation of the S protein	363:411	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	31	theme	N-glycoproteomics	500:516	arg1	algorithm					529:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	31	theme	N-glycoproteomics	500:516	arg1	StrucGP					540:546	StrucGP	540:546	StrucGP	540:546	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	4	32	theme	Lewis	686:690	arg1	structures					692:701	Lewis structures	686:701	Lewis structures	686:701	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	33	theme	LacdiNAc	665:672	arg1	structures					674:683	LacdiNAc structures	665:683	LacdiNAc structures	665:683	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	34	theme	Mannose	704:710	arg1	residues					730:737	Mannose 6-phosphate (M6P) residues	704:737	Mannose 6-phosphate (M6P) residues	704:737	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	35	theme	glycosites	812:821	arg1	total					800:804	a total	798:804	a total of 20 glycosites in the S protein trimer and protomer	798:858	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	0	36	theme	Virus	75:79	arg1	Spike					81:85	COVID-19 Virus Spike	66:85	COVID-19 Virus Spike	66:85	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	4	37	theme	S	830:830	arg1	trimer					840:845	S protein trimer	830:845	S protein trimer	830:845	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	3	38	theme	site-specific	486:498	arg1	algorithm					529:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	38	theme	site-specific	486:498	arg1	StrucGP					540:546	StrucGP	540:546	StrucGP	540:546	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	0	39	theme	COVID-19	66:73	arg1	Spike					81:85	COVID-19 Virus Spike	66:85	COVID-19 Virus Spike	66:85	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	4	40	theme	protein	832:838	arg1	trimer					840:845	S protein trimer	830:845	S protein trimer	830:845	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	2	41	theme	Previous	196:203	arg1	studies					205:211	Previous studies	196:211	Previous studies	196:211	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	2	42	theme	protein	329:335	arg1	motifs					313:318	many important structural motifs	287:318	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	2	42	theme	protein	329:335	arg1	compositions					263:274	site-specific glycan compositions	242:274	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	0	43	with	Structural-	0:10	arg1	StrucGP					92:98	StrucGP	92:98	StrucGP	92:98	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	2	44	theme	S	327:327	arg1	protein					329:335	the S protein	323:335	the S protein	323:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	4	45	theme	many	618:621	arg1	structures					646:655	many uncommon glycosylation structures	618:655	many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures	618:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	45	theme	many	618:621	arg1	structures					758:767	bisected core structures	744:767	bisected core structures	744:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	45	theme	many	618:621	arg1	residues					730:737	Mannose 6-phosphate (M6P) residues	704:737	Mannose 6-phosphate (M6P) residues	704:737	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	45	theme	many	618:621	arg1	structures					674:683	LacdiNAc structures	665:683	LacdiNAc structures	665:683	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	45	theme	many	618:621	arg1	structures					692:701	Lewis structures	686:701	Lewis structures	686:701	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	46	from	glycosites	812:821	arg1	protomer					851:858	protomer	851:858	protomer	851:858	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	46	from	glycosites	812:821	arg1	trimer					840:845	S protein trimer	830:845	S protein trimer	830:845	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	2	47	theme	glycan	256:261	arg1	compositions					263:274	site-specific glycan compositions	242:274	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	4	48	theme	core	753:756	arg1	structures					758:767	bisected core structures	744:767	bisected core structures	744:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	5	49	theme	COVID-19	950:957	arg1	spike					965:969	the COVID-19 virus spike	946:969	the COVID-19 virus spike	946:969	These data further support the glycosylation structural-functional investigations of the COVID-19 virus spike.
36036581	3	50	theme	structural-	470:480	arg1	algorithm					529:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm	447:537	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	3	50	theme	structural-	470:480	arg1	StrucGP					540:546	StrucGP	540:546	StrucGP	540:546	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	2	51	theme	site-specific	242:254	arg1	compositions					263:274	site-specific glycan compositions	242:274	site-specific glycan compositions as well as many important structural motifs of the S protein	242:335	Previous studies have systematically analyzed site-specific glycan compositions as well as many important structural motifs of the S protein.
36036581	1	52	theme	key	131:133	arg1	role					135:138	a key role	129:138	a key role	129:138	The spike (S) protein plays a key role in COVID-19 (SARS-CoV-2) infection and host-cell entry.
36036581	4	53	theme	glycosylation	632:644	arg1	structures					646:655	many uncommon glycosylation structures	618:655	many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures	618:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	53	theme	glycosylation	632:644	arg1	structures					758:767	bisected core structures	744:767	bisected core structures	744:767	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	53	theme	glycosylation	632:644	arg1	residues					730:737	Mannose 6-phosphate (M6P) residues	704:737	Mannose 6-phosphate (M6P) residues	704:737	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	53	theme	glycosylation	632:644	arg1	structures					674:683	LacdiNAc structures	665:683	LacdiNAc structures	665:683	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	53	theme	glycosylation	632:644	arg1	structures					692:701	Lewis structures	686:701	Lewis structures	686:701	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	0	54	theme	Spike	81:85	arg1	Structural-					0:10	Structural-	0:10	Structural-	0:10	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	0	54	theme	Spike	81:85	arg1	Characterization					46:61	Site-Specific N-Glycosylation Characterization	16:61	Site-Specific N-Glycosylation Characterization	16:61	Structural- and Site-Specific N-Glycosylation Characterization of COVID-19 Virus Spike with StrucGP.
36036581	3	55	theme	structural-clear	363:378	arg1	N-glycosylation					380:394	structural-clear N-glycosylation	363:394	structural-clear N-glycosylation of the S protein	363:411	Here, we further provide structural-clear N-glycosylation of the S protein at a site-specific level by using our recently developed structural- and site-specific N-glycoproteomics sequencing algorithm, StrucGP.
36036581	4	56	from	total	800:804	arg1	protomer					851:858	protomer	851:858	protomer	851:858	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	56	from	total	800:804	arg1	trimer					840:845	S protein trimer	830:845	S protein trimer	830:845	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
36036581	4	57	theme	M6P	725:727	arg1	residues					730:737	Mannose 6-phosphate (M6P) residues	704:737	Mannose 6-phosphate (M6P) residues	704:737	In addition to the common N-glycans as detected in previous studies, many uncommon glycosylation structures such as LacdiNAc structures, Lewis structures, Mannose 6-phosphate (M6P) residues, and bisected core structures were unambiguously mapped at a total of 20 glycosites in the S protein trimer and protomer.
33082260	4	0	theme	Cryptosporidium	997:1011	arg1	parvum					1013:1018	Cryptosporidium parvum	997:1018	Cryptosporidium parvum	997:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	8	1	theme	resistances	1753:1763	arg1	ability					1813:1819	the parasite's ability	1798:1819	the parasite's ability to manipulate host cells and evade immune systems	1798:1869	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	8	1	theme	resistances	1753:1763	arg1	emergence					1740:1748	the emergence	1736:1748	the emergence of resistances against available therapies	1736:1791	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	8	1	theme	resistances	1753:1763	arg1	absence					1713:1719	The absence	1709:1719	The absence of treatments	1709:1733	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	3	2	theme	GNA1	781:784	arg1	requirement					766:776	the requirement	762:776	the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites	762:912	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	7	3	theme	drug	1596:1599	arg1	target					1601:1606	a drug target	1594:1606	a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy	1594:1706	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	4	4	theme	ortholog	983:990	arg1	structure					961:969	the 1.95 Å resolution structure	939:969	the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries	939:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	4	theme	ortholog	983:990	arg1	surrogate					1113:1121	a surrogate	1111:1121	a surrogate for P. falciparum GNA1	1111:1144	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	8	5	theme	available	1773:1781	arg1	therapies					1783:1791	available therapies	1773:1791	available therapies	1773:1791	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	3	6	theme	pool	810:813	arg1	generation					794:803	the generation	790:803	the generation of a pool of UDP-GlcNAc	790:827	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	6	7	theme	apicomplexan	1377:1388	arg1	enzymes					1395:1401	apicomplexan GNA1 enzymes	1377:1401	apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites	1377:1494	The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway.
33082260	8	8	theme	host	1835:1838	arg1	cells					1840:1844	host cells	1835:1844	host cells	1835:1844	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	5	9	theme	site-specific	1310:1322	arg1	mutants					1324:1330	site-specific mutants	1310:1330	site-specific mutants	1310:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	7	10	from	burden	1672:1677	arg1	economy					1700:1706	economy	1700:1706	economy	1700:1706	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	7	10	from	burden	1672:1677	arg1	health					1689:1694	global health	1682:1694	global health	1682:1694	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	4	11	theme	1.95 Å	943:948	arg1	structure					961:969	the 1.95 Å resolution structure	939:969	the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries	939:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	11	theme	1.95 Å	943:948	arg1	surrogate					1113:1121	a surrogate	1111:1121	a surrogate for P. falciparum GNA1	1111:1144	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	12	from	cause	1065:1069	arg1	countries					1097:1105	developing countries	1086:1105	developing countries	1086:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	7	13	theme	apicomplexan	1573:1584	arg1	GNA1					1586:1589	apicomplexan GNA1	1573:1589	apicomplexan GNA1	1573:1589	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	8	14	theme	immune	1856:1861	arg1	systems					1863:1869	immune systems	1856:1869	immune systems	1856:1869	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	1	15	theme	hexosamine	221:230	arg1	pathway					245:251	the hexosamine biosynthetic pathway	217:251	the hexosamine biosynthetic pathway	217:251	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	2	16	theme	independent	617:627	arg1	origin					642:647	an independent evolutionary origin	614:647	an independent evolutionary origin	614:647	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	10	17	from	structure	2330:2338	arg1	parasite					2383:2390	the apicomplexan parasite	2366:2390	the apicomplexan parasite C. parvum	2366:2400	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	3	18	theme	UDP-GlcNAc	818:827	arg1	pool					810:813	a pool	808:813	a pool of UDP-GlcNAc	808:827	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	1	19	theme	pathway	245:251	arg1	product					206:212	the main product	197:212	the main product of the hexosamine biosynthetic pathway	197:251	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	1	19	theme	pathway	245:251	arg1	UDP-N-acetylglucosamine					159:181	UDP-N-acetylglucosamine	159:181	UDP-N-acetylglucosamine (UDP-GlcNAc)	159:194	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	3	20	theme	intraerythrocytic	856:872	arg1	parasites					904:912	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	2	21	contain	have	447:450	arg2	pathway					465:471	a hexosamine pathway	452:471	a hexosamine pathway comparable to other eukaryotic organisms	452:512	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	21	contain	have	447:450	arg1	parasites					437:445	Apicomplexan parasites	424:445	Apicomplexan parasites	424:445	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	22	theme	eukaryotic	493:502	arg1	organisms					504:512	other eukaryotic organisms	487:512	other eukaryotic organisms	487:512	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	8	23	theme	urgent	1885:1890	arg1	need					1892:1895	the urgent need	1881:1895	the urgent need to characterize new drug targets to treat infections caused by these parasites	1881:1974	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	2	24	theme	significant	653:663	arg1	differences					665:675	significant differences	653:675	significant differences from nonapicomplexan GNA1s	653:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	11	25	theme	malaria	2566:2572	arg1	parasite					2574:2581	the malaria parasite	2562:2581	the malaria parasite	2562:2581	These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
33082260	10	26	dep	parasite	2383:2390	arg1	parvum					2395:2400	C. parvum	2392:2400	the apicomplexan parasite C. parvum	2366:2400	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	3	27	theme	parasites	904:912	arg1	development					841:851	the development	837:851	the development of intraerythrocytic asexual Plasmodium falciparum parasites	837:912	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	3	28	theme	conditional	714:724	arg1	engineering					734:744	conditional genetic engineering	714:744	conditional genetic engineering	714:744	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	8	29	theme	new	1913:1915	arg1	targets					1922:1928	new drug targets	1913:1928	new drug targets	1913:1928	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	4	30	theme	diarrhea	1074:1081	arg1	cause					1065:1069	a leading cause	1055:1069	a leading cause of diarrhea in developing countries	1055:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	30	theme	diarrhea	1074:1081	arg1	parasite					1037:1044	an apicomplexan parasite	1021:1044	an apicomplexan parasite which is a leading cause of diarrhea in developing countries	1021:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	30	theme	diarrhea	1074:1081	arg1	ortholog					983:990	the GNA1 ortholog	974:990	the GNA1 ortholog from Cryptosporidium parvum	974:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	10	31	from	parasite	2383:2390	arg1	structure					2330:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	10	31	from	parasite	2383:2390	arg1	ortholog					2352:2359	the GNA1 ortholog	2343:2359	the GNA1 ortholog from the apicomplexan parasite C. parvum	2343:2400	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	3	32	theme	Plasmodium	882:891	arg1	falciparum					893:902	Plasmodium falciparum	882:902	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	0	33	theme	Amino	99:103	arg1	Metabolism					111:120	Amino Sugar Metabolism	99:120	Amino Sugar Metabolism	99:120	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	5	34	theme	specific	1206:1213	arg1	residues					1215:1222	specific residues	1206:1222	specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants	1206:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	2	35	theme	other	487:491	arg1	organisms					504:512	other eukaryotic organisms	487:512	other eukaryotic organisms	487:512	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	36	theme	glucosamine-phosphate	541:561	arg1	step					600:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step	537:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s	537:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	10	37	theme	crystal	2322:2328	arg1	structure					2330:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	9	38	theme	parasite	2272:2279	arg1	death					2259:2263	the death	2255:2263	the death of the parasite	2255:2279	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	5	39	theme	relevant	1224:1231	arg1	residues					1215:1222	specific residues	1206:1222	specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants	1206:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	1	40	theme	main	201:204	arg1	product					206:212	the main product	197:212	the main product of the hexosamine biosynthetic pathway	197:251	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	1	40	theme	main	201:204	arg1	UDP-N-acetylglucosamine					159:181	UDP-N-acetylglucosamine	159:181	UDP-N-acetylglucosamine (UDP-GlcNAc)	159:194	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	2	41	theme	step	600:603	arg1	exception					524:532	the exception	520:532	the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s	520:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	9	42	theme	blood	2159:2163	arg1	development					2171:2181	P. falciparum asexual blood stage development	2137:2181	P. falciparum asexual blood stage development	2137:2181	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	0	43	theme	Asexual	126:132	arg1	Development					146:156	Asexual Blood Stage Development	126:156	Asexual Blood Stage Development	126:156	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	4	44	from	structure	961:969	arg1	parvum					1013:1018	Cryptosporidium parvum	997:1018	Cryptosporidium parvum	997:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	10	45	theme	GNA1	2347:2350	arg1	ortholog					2352:2359	the GNA1 ortholog	2343:2359	the GNA1 ortholog from the apicomplexan parasite C. parvum	2343:2400	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	2	46	contain	has	610:612	arg2	differences					665:675	significant differences	653:675	significant differences from nonapicomplexan GNA1s	653:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	46	contain	has	610:612	arg2	origin					642:647	an independent evolutionary origin	614:647	an independent evolutionary origin	614:647	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	46	contain	has	610:612	arg1	step					600:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step	537:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s	537:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	0	47	theme	Stage	140:144	arg1	Development					146:156	Asexual Blood Stage Development	126:156	Asexual Blood Stage Development	126:156	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	11	48	theme	specific	2534:2541	arg1	inhibitors					2543:2552	specific inhibitors	2534:2552	specific inhibitors against the malaria parasite	2534:2581	These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
33082260	1	49	link	O-linked	406:413	arg1	glycans					415:421	O-linked glycans	406:421	O-linked glycans	406:421	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	0	50	theme	Plasmodium	0:9	arg1	falciparum					11:20	Plasmodium falciparum	0:20	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	1	51	theme	sugar	314:318	arg1	moiety					320:325	its sugar moiety	310:325	its sugar moiety	310:325	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	4	52	theme	falciparum	1130:1139	arg1	GNA1					1141:1144	P. falciparum GNA1	1127:1144	P. falciparum GNA1	1127:1144	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	10	53	theme	apicomplexan	2370:2381	arg1	parasite					2383:2390	the apicomplexan parasite	2366:2390	the apicomplexan parasite C. parvum	2366:2400	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	0	54	theme	Apicomplexan-Specific	22:42	arg1	N-Acetyltransferase					68:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	7	55	dep	target	1601:1606	arg1	cause					1658:1662	cause	1658:1662	cause a major burden on global health and economy	1658:1706	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	5	56	theme	GNA1	1237:1240	arg1	activity					1252:1259	GNA1 enzymatic activity	1237:1259	GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants	1237:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	6	57	theme	hexosamine	1514:1523	arg1	pathway					1525:1531	the hexosamine pathway	1510:1531	the hexosamine pathway	1510:1531	The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway.
33082260	9	58	theme	gene	2214:2217	arg1	disruption					2196:2205	the disruption	2192:2205	the disruption of the gene encoding this enzyme	2192:2238	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	5	59	theme	mutants	1324:1330	arg1	creation					1298:1305	the creation	1294:1305	the creation of site-specific mutants	1294:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	7	60	theme	malaria.IMPORTANCE	1616:1633	arg1	parasites					1648:1656	malaria.IMPORTANCE Apicomplexan parasites	1616:1656	malaria.IMPORTANCE Apicomplexan parasites	1616:1656	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	8	61	theme	treatments	1724:1733	arg1	ability					1813:1819	the parasite's ability	1798:1819	the parasite's ability to manipulate host cells and evade immune systems	1798:1869	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	8	61	theme	treatments	1724:1733	arg1	emergence					1740:1748	the emergence	1736:1748	the emergence of resistances against available therapies	1736:1791	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	8	61	theme	treatments	1724:1733	arg1	absence					1713:1719	The absence	1709:1719	The absence of treatments	1709:1733	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	2	62	theme	hexosamine	454:463	arg1	pathway					465:471	a hexosamine pathway	452:471	a hexosamine pathway comparable to other eukaryotic organisms	452:512	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	4	63	from	diarrhea	1074:1081	arg1	countries					1097:1105	developing countries	1086:1105	developing countries	1086:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	10	64	theme	human	2469:2473	arg1	GNA1					2475:2478	human GNA1	2469:2478	human GNA1	2469:2478	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	1	65	theme	glycosylphosphatidylinositol	348:375	arg1	glycolipids					383:393	glycosylphosphatidylinositol (GPI) glycolipids	348:393	glycosylphosphatidylinositol (GPI) glycolipids	348:393	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	4	66	theme	developing	1086:1095	arg1	countries					1097:1105	developing countries	1086:1105	developing countries	1086:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	1	67	theme	protozoan	284:292	arg1	parasites					294:302	protozoan parasites	284:302	protozoan parasites	284:302	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	2	68	theme	nonapicomplexan	682:696	arg1	GNA1s					698:702	nonapicomplexan GNA1s	682:702	nonapicomplexan GNA1s	682:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	10	69	from	GNA1	2475:2478	arg1	differences					2452:2462	significant differences	2440:2462	significant differences from human GNA1	2440:2478	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	6	70	theme	GNA1	1390:1393	arg1	enzymes					1395:1401	apicomplexan GNA1 enzymes	1377:1401	apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites	1377:1494	The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway.
33082260	7	71	theme	GNA1	1586:1589	arg1	potential					1560:1568	the potential	1556:1568	the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy	1556:1706	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	4	72	theme	GNA1	978:981	arg1	cause					1065:1069	a leading cause	1055:1069	a leading cause of diarrhea in developing countries	1055:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	72	theme	GNA1	978:981	arg1	parasite					1037:1044	an apicomplexan parasite	1021:1044	an apicomplexan parasite which is a leading cause of diarrhea in developing countries	1021:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	72	theme	GNA1	978:981	arg1	ortholog					983:990	the GNA1 ortholog	974:990	the GNA1 ortholog from Cryptosporidium parvum	974:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	9	73	theme	life	2290:2293	arg1	cycle					2295:2299	a life cycle	2288:2299	a life cycle	2288:2299	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	6	74	theme	distinct	1356:1363	arg1	features					1365:1372	distinct features	1356:1372	distinct features	1356:1372	The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway.
33082260	4	75	theme	resolution	950:959	arg1	structure					961:969	the 1.95 Å resolution structure	939:969	the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries	939:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	75	theme	resolution	950:959	arg1	surrogate					1113:1121	a surrogate	1111:1121	a surrogate for P. falciparum GNA1	1111:1144	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	6	76	theme	selective	1451:1459	arg1	inhibitors					1461:1470	selective inhibitors	1451:1470	selective inhibitors against these parasites	1451:1494	The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway.
33082260	1	77	theme	biosynthetic	232:243	arg1	pathway					245:251	the hexosamine biosynthetic pathway	217:251	the hexosamine biosynthetic pathway	217:251	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	9	78	theme	UDP-N-acetylglucosamine	2082:2104	arg1	biosynthesis					2066:2077	the biosynthesis	2062:2077	the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc)	2062:2117	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	9	79	dep	P.	2137:2138	arg1	falciparum					2140:2149	falciparum	2140:2149	falciparum	2140:2149	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	10	80	theme	significant	2440:2450	arg1	differences					2452:2462	significant differences	2440:2462	significant differences from human GNA1	2440:2478	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	10	81	theme	high-resolution	2306:2320	arg1	structure					2330:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	3	82	theme	asexual	874:880	arg1	parasites					904:912	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	1	83	from	metabolite	270:279	arg1	parasites					294:302	protozoan parasites	284:302	protozoan parasites	284:302	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	5	84	theme	crystal	1176:1182	arg1	analysis					1160:1167	The in-depth analysis	1147:1167	The in-depth analysis of the crystal	1147:1182	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	4	85	theme	apicomplexan	1024:1035	arg1	cause					1065:1069	a leading cause	1055:1069	a leading cause of diarrhea in developing countries	1055:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	85	theme	apicomplexan	1024:1035	arg1	parasite					1037:1044	an apicomplexan parasite	1021:1044	an apicomplexan parasite which is a leading cause of diarrhea in developing countries	1021:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	85	theme	apicomplexan	1024:1035	arg1	ortholog					983:990	the GNA1 ortholog	974:990	the GNA1 ortholog from Cryptosporidium parvum	974:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	11	86	theme	inhibitors	2543:2552	arg1	design					2524:2529	the design	2520:2529	the design of specific inhibitors against the malaria parasite	2520:2581	These divergences can be exploited for the design of specific inhibitors against the malaria parasite.
33082260	4	87	from	parvum	1013:1018	arg1	cause					1065:1069	a leading cause	1055:1069	a leading cause of diarrhea in developing countries	1055:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	87	from	parvum	1013:1018	arg1	structure					961:969	the 1.95 Å resolution structure	939:969	the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries	939:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	87	from	parvum	1013:1018	arg1	parasite					1037:1044	an apicomplexan parasite	1021:1044	an apicomplexan parasite which is a leading cause of diarrhea in developing countries	1021:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	87	from	parvum	1013:1018	arg1	surrogate					1113:1121	a surrogate	1111:1121	a surrogate for P. falciparum GNA1	1111:1144	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	87	from	parvum	1013:1018	arg1	ortholog					983:990	the GNA1 ortholog	974:990	the GNA1 ortholog from Cryptosporidium parvum	974:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	2	88	theme	evolutionary	629:640	arg1	origin					642:647	an independent evolutionary origin	614:647	an independent evolutionary origin	614:647	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	0	89	theme	Sugar	105:109	arg1	Metabolism					111:120	Amino Sugar Metabolism	99:120	Amino Sugar Metabolism	99:120	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	5	90	theme	in-depth	1151:1158	arg1	analysis					1160:1167	The in-depth analysis	1147:1167	The in-depth analysis of the crystal	1147:1182	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	2	91	theme	N-acetyltransferase	563:581	arg1	step					600:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step	537:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s	537:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	9	92	theme	P.	2137:2138	arg1	development					2171:2181	P. falciparum asexual blood stage development	2137:2181	P. falciparum asexual blood stage development	2137:2181	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	4	93	theme	leading	1057:1063	arg1	cause					1065:1069	a leading cause	1055:1069	a leading cause of diarrhea in developing countries	1055:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	93	theme	leading	1057:1063	arg1	parasite					1037:1044	an apicomplexan parasite	1021:1044	an apicomplexan parasite which is a leading cause of diarrhea in developing countries	1021:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	93	theme	leading	1057:1063	arg1	ortholog					983:990	the GNA1 ortholog	974:990	the GNA1 ortholog from Cryptosporidium parvum	974:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	3	94	theme	falciparum	893:902	arg1	parasites					904:912	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	intraerythrocytic asexual Plasmodium falciparum parasites	856:912	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	5	95	theme	residues	1215:1222	arg1	presence					1194:1201	the presence	1190:1201	the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants	1190:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	8	96	theme	drug	1917:1920	arg1	targets					1922:1928	new drug targets	1913:1928	new drug targets	1913:1928	The absence of treatments, the emergence of resistances against available therapies, and the parasite's ability to manipulate host cells and evade immune systems highlight the urgent need to characterize new drug targets to treat infections caused by these parasites.
33082260	9	97	theme	asexual	2151:2157	arg1	development					2171:2181	P. falciparum asexual blood stage development	2137:2181	P. falciparum asexual blood stage development	2137:2181	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	0	98	theme	Blood	134:138	arg1	Development					146:156	Asexual Blood Stage Development	126:156	Asexual Blood Stage Development	126:156	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	10	99	theme	ortholog	2352:2359	arg1	structure					2330:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure	2302:2338	The high-resolution crystal structure of the GNA1 ortholog from the apicomplexan parasite C. parvum, used here as a surrogate, highlights significant differences from human GNA1.
33082260	7	100	theme	global	1682:1687	arg1	health					1689:1694	global health	1682:1694	global health	1682:1694	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	2	101	theme	enzymatic	590:598	arg1	step					600:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step	537:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s	537:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	9	102	theme	stage	2165:2169	arg1	development					2171:2181	P. falciparum asexual blood stage development	2137:2181	P. falciparum asexual blood stage development	2137:2181	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	1	103	theme	O-linked	406:413	arg1	glycans					415:421	O-linked glycans	406:421	O-linked glycans	406:421	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	2	104	theme	GNA1	584:587	arg1	step					600:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step	537:603	the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s	537:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	0	105	theme	falciparum	11:20	arg1	N-Acetyltransferase					68:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	2	106	theme	Apicomplexan	424:435	arg1	parasites					437:445	Apicomplexan parasites	424:445	Apicomplexan parasites	424:445	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	0	107	theme	Glucosamine-6-Phosphate	44:66	arg1	N-Acetyltransferase					68:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase	0:86	Plasmodium falciparum Apicomplexan-Specific Glucosamine-6-Phosphate N-Acetyltransferase Is Key for Amino Sugar Metabolism and Asexual Blood Stage Development.
33082260	4	108	theme	P.	1127:1128	arg1	GNA1					1141:1144	P. falciparum GNA1	1127:1144	P. falciparum GNA1	1127:1144	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	2	109	from	GNA1s	698:702	arg1	origin					642:647	an independent evolutionary origin	614:647	an independent evolutionary origin	614:647	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	109	from	GNA1s	698:702	arg1	differences					665:675	significant differences	653:675	significant differences from nonapicomplexan GNA1s	653:702	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	2	110	theme	comparable	473:482	arg1	pathway					465:471	a hexosamine pathway	452:471	a hexosamine pathway comparable to other eukaryotic organisms	452:512	Apicomplexan parasites have a hexosamine pathway comparable to other eukaryotic organisms, with the exception of the glucosamine-phosphate N-acetyltransferase (GNA1) enzymatic step that has an independent evolutionary origin and significant differences from nonapicomplexan GNA1s.
33082260	3	111	theme	genetic	726:732	arg1	engineering					734:744	conditional genetic engineering	714:744	conditional genetic engineering	714:744	By using conditional genetic engineering, we demonstrate the requirement of GNA1 for the generation of a pool of UDP-GlcNAc and for the development of intraerythrocytic asexual Plasmodium falciparum parasites.
33082260	6	112	theme	inhibitors	1461:1470	arg1	generation					1437:1446	the generation	1433:1446	the generation of selective inhibitors against these parasites	1433:1494	The experiments reveal distinct features in apicomplexan GNA1 enzymes that could be exploitable for the generation of selective inhibitors against these parasites, by targeting the hexosamine pathway.
33082260	5	113	theme	enzymatic	1242:1250	arg1	activity					1252:1259	GNA1 enzymatic activity	1237:1259	GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants	1237:1330	The in-depth analysis of the crystal shows the presence of specific residues relevant for GNA1 enzymatic activity that are further investigated by the creation of site-specific mutants.
33082260	7	114	theme	major	1666:1670	arg1	burden					1672:1677	a major burden	1664:1677	a major burden on global health and economy	1664:1706	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	4	115	from	countries	1097:1105	arg1	cause					1065:1069	a leading cause	1055:1069	a leading cause of diarrhea in developing countries	1055:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	115	from	countries	1097:1105	arg1	parasite					1037:1044	an apicomplexan parasite	1021:1044	an apicomplexan parasite which is a leading cause of diarrhea in developing countries	1021:1105	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	4	115	from	countries	1097:1105	arg1	ortholog					983:990	the GNA1 ortholog	974:990	the GNA1 ortholog from Cryptosporidium parvum	974:1018	Furthermore, we present the 1.95 Å resolution structure of the GNA1 ortholog from Cryptosporidium parvum, an apicomplexan parasite which is a leading cause of diarrhea in developing countries, as a surrogate for P. falciparum GNA1.
33082260	1	116	theme	important	260:268	arg1	metabolite					270:279	an important metabolite	257:279	an important metabolite in protozoan parasites	257:302	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	1	116	theme	important	260:268	arg1	UDP-N-acetylglucosamine					159:181	UDP-N-acetylglucosamine	159:181	UDP-N-acetylglucosamine (UDP-GlcNAc)	159:194	UDP-N-acetylglucosamine (UDP-GlcNAc), the main product of the hexosamine biosynthetic pathway, is an important metabolite in protozoan parasites since its sugar moiety is incorporated into glycosylphosphatidylinositol (GPI) glycolipids and N- and O-linked glycans.
33082260	7	117	theme	Apicomplexan	1635:1646	arg1	parasites					1648:1656	malaria.IMPORTANCE Apicomplexan parasites	1616:1656	malaria.IMPORTANCE Apicomplexan parasites	1616:1656	This work underscores the potential of apicomplexan GNA1 as a drug target against malaria.IMPORTANCE Apicomplexan parasites cause a major burden on global health and economy.
33082260	9	118	theme	glucosamine-6-phosphate	1997:2019	arg1	GNA1					2042:2045	GNA1	2042:2045	GNA1	2042:2045	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
33082260	9	118	theme	glucosamine-6-phosphate	1997:2019	arg1	N-acetyltransferase					2021:2039	glucosamine-6-phosphate N-acetyltransferase	1997:2039	glucosamine-6-phosphate N-acetyltransferase (GNA1)	1997:2046	We demonstrate that glucosamine-6-phosphate N-acetyltransferase (GNA1), required for the biosynthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), is essential for P. falciparum asexual blood stage development and that the disruption of the gene encoding this enzyme quickly causes the death of the parasite within a life cycle.
34911982	8	0	theme	immune	1463:1468	arg1	responses					1470:1478	immune responses	1463:1478	immune responses occurring in the spleen	1463:1502	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	6	1	theme	IgG	1000:1002	arg1	LC-MS					1063:1067	LC-MS	1063:1067	LC-MS	1063:1067	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	6	1	theme	IgG	1000:1002	arg1	spectrometry					1049:1060	IgG subclass-specific liquid chromatography-mass spectrometry	1000:1060	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation	1000:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	1	2	theme	immune	117:122	arg1	populations					129:139	immune cell populations	117:139	immune cell populations	117:139	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	6	3	theme	spleen	955:960	arg1	role					943:946	the role	939:946	the role of the spleen in IgG-Fc glycosylation	939:984	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	10	4	theme	B	1822:1822	arg1	cells					1824:1828	B cells	1822:1828	B cells	1822:1828	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	5	5	gly	afucosylated	821:832	arg1	responses					838:846	afucosylated IgG responses	821:846	afucosylated IgG responses	821:846	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	1	6	theme	cell	124:127	arg1	populations					129:139	immune cell populations	117:139	immune cell populations	117:139	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	3	7	theme	crystallizable	598:611	arg1	region					618:623	the fragment crystallizable (Fc) region	585:623	the fragment crystallizable (Fc) region	585:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	8	attach	present	554:560	arg2	fucose					547:552	fucose	547:552	fucose	547:552	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	8	attach	present	554:560	arg2	amount					537:542	the reduced amount	525:542	the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region	525:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	8	attach	present	554:560	arg1	glycans					574:580	N-linked glycans	565:580	N-linked glycans of the fragment crystallizable (Fc) region	565:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	1	9	theme	antigen-specific	217:232	arg1	responses					241:249	antigen-specific immune responses	217:249	antigen-specific immune responses	217:249	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	6	10	theme	individuals	1120:1130	arg1	cohort					1110:1115	a large cohort	1102:1115	a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis	1102:1189	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	9	11	theme	ITP	1640:1642	arg1	patients					1644:1651	ITP patients	1640:1651	ITP patients	1640:1651	Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls.
34911982	7	12	theme	IgG-Fc	1192:1197	arg1	fucosylation					1199:1210	IgG-Fc fucosylation	1192:1210	IgG-Fc fucosylation	1192:1210	IgG-Fc fucosylation was consistently increased after splenectomy, while no effects for IgG-Fc galactosylation and sialylation were observed.
34911982	1	13	theme	immune	234:239	arg1	responses					241:249	antigen-specific immune responses	217:249	antigen-specific immune responses	217:249	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	0	14	from	IgG	48:50	arg1	humans					55:60	humans	55:60	humans	55:60	A functional spleen contributes to afucosylated IgG in humans.
34911982	5	15	theme	preferential	799:810	arg1	site					812:815	a preferential site	797:815	a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis	797:923	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	5	15	theme	preferential	799:810	arg1	spleen					746:751	a spleen	744:751	a spleen	744:751	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	3	16	theme	immunizations	441:453	arg1	types					432:436	both types	427:436	both types of immunizations	427:453	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	10	17	theme	unrecognized	1718:1729	arg1	role					1731:1734	a yet unrecognized role	1712:1734	a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells	1712:1828	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	6	18	theme	chromatography-mass	1029:1047	arg1	LC-MS					1063:1067	LC-MS	1063:1067	LC-MS	1063:1067	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	6	18	theme	chromatography-mass	1029:1047	arg1	spectrometry					1049:1060	IgG subclass-specific liquid chromatography-mass spectrometry	1000:1060	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation	1000:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	1	19	theme	populations	129:139	arg1	organ					77:81	a lymphoid organ	66:81	a lymphoid organ	66:81	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	1	19	theme	populations	129:139	arg1	range					108:112	a wide range	101:112	a wide range	101:112	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	6	20	theme	glycosylation	1085:1097	arg1	analysis					1070:1077	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis	1000:1077	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation	1000:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	6	21	theme	splenectomized	1132:1145	arg1	individuals					1120:1130	individuals	1120:1130	individuals splenectomized due to trauma, due to ITP, or spherocytosis	1120:1189	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	8	22	theme	fucosylation	1368:1379	arg1	level					1381:1385	IgG2/3-Fc fucosylation level	1358:1385	IgG2/3-Fc fucosylation level	1358:1385	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	2	23	theme	immune	355:360	arg1	responses					362:370	adaptive immune responses	346:370	adaptive immune responses to enveloped viral infections and alloantigens	346:417	In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens.
34911982	0	24	theme	functional	2:11	arg1	spleen					13:18	A functional spleen	0:18	A functional spleen	0:18	A functional spleen contributes to afucosylated IgG in humans.
34911982	1	25	theme	lymphoid	68:75	arg1	organ					77:81	a lymphoid organ	66:81	a lymphoid organ	66:81	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	1	25	theme	lymphoid	68:75	arg1	range					108:112	a wide range	101:112	a wide range	101:112	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	2	26	theme	adaptive	346:353	arg1	responses					362:370	adaptive immune responses	346:370	adaptive immune responses to enveloped viral infections and alloantigens	346:417	In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens.
34911982	4	27	theme	immune	685:690	arg1	functions					701:709	immune effector functions	685:709	immune effector functions	685:709	These glycans are essential for mediating the induction of immune effector functions.
34911982	2	28	theme	splenic	271:277	arg1	microenvironment					279:294	the splenic microenvironment	267:294	the splenic microenvironment	267:294	In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens.
34911982	3	29	theme	region	618:623	arg1	glycans					574:580	N-linked glycans	565:580	N-linked glycans of the fragment crystallizable (Fc) region	565:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	4	30	theme	functions	701:709	arg1	induction					672:680	the induction	668:680	the induction of immune effector functions	668:709	These glycans are essential for mediating the induction of immune effector functions.
34911982	5	31	theme	thrombocytopenia	889:904	arg1	pathogenesis					912:923	immune thrombocytopenia (ITP) pathogenesis	882:923	immune thrombocytopenia (ITP) pathogenesis	882:923	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	3	32	theme	reduced	529:535	arg1	amount					537:542	the reduced amount	525:542	the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region	525:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	32	theme	reduced	529:535	arg1	fucose					547:552	fucose	547:552	fucose	547:552	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	6	33	theme	spectrometry	1049:1060	arg1	analysis					1070:1077	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis	1000:1077	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation	1000:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	6	34	theme	subclass-specific	1004:1020	arg1	LC-MS					1063:1067	LC-MS	1063:1067	LC-MS	1063:1067	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	6	34	theme	subclass-specific	1004:1020	arg1	spectrometry					1049:1060	IgG subclass-specific liquid chromatography-mass spectrometry	1000:1060	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation	1000:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	3	35	theme	fucose	547:552	arg1	amount					537:542	the reduced amount	525:542	the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region	525:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	35	theme	fucose	547:552	arg1	fucose					547:552	fucose	547:552	fucose	547:552	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	8	36	gly	afucosylated	1542:1553	arg1	responses					1559:1567	afucosylated IgG responses	1542:1567	afucosylated IgG responses	1542:1567	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	6	37	theme	large	1104:1108	arg1	cohort					1110:1115	a large cohort	1102:1115	a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis	1102:1189	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	2	38	theme	viral	385:389	arg1	infections					391:400	enveloped viral infections	375:400	enveloped viral infections	375:400	In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens.
34911982	0	39	theme	afucosylated	35:46	arg1	IgG					48:50	afucosylated IgG	35:50	afucosylated IgG in humans	35:60	A functional spleen contributes to afucosylated IgG in humans.
34911982	10	40	theme	spleen	1743:1748	arg1	role					1731:1734	a yet unrecognized role	1712:1734	a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells	1712:1828	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	9	41	theme	healthy	1665:1671	arg1	controls					1673:1680	healthy controls	1665:1680	healthy controls	1665:1680	Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls.
34911982	2	42	theme	enveloped	375:383	arg1	infections					391:400	enveloped viral infections	375:400	enveloped viral infections	375:400	In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens.
34911982	3	43	theme	N-linked	565:572	arg1	glycans					574:580	N-linked glycans	565:580	N-linked glycans of the fragment crystallizable (Fc) region	565:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	6	44	theme	liquid	1022:1027	arg1	LC-MS					1063:1067	LC-MS	1063:1067	LC-MS	1063:1067	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	6	44	theme	liquid	1022:1027	arg1	spectrometry					1049:1060	IgG subclass-specific liquid chromatography-mass spectrometry	1000:1060	IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation	1000:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	1	45	theme	blood-borne	164:174	arg1	antigens					176:183	blood-borne antigens	164:183	blood-borne antigens	164:183	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	5	46	theme	afucosylated	821:832	arg1	responses					838:846	afucosylated IgG responses	821:846	afucosylated IgG responses	821:846	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	5	47	theme	IgG	834:836	arg1	responses					838:846	afucosylated IgG responses	821:846	afucosylated IgG responses	821:846	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	9	48	theme	total	1597:1601	arg1	fucosylation					1610:1621	total IgG-Fc fucosylation	1597:1621	total IgG-Fc fucosylation	1597:1621	Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls.
34911982	8	49	theme	first	1435:1439	arg1	time					1441:1444	the first time	1431:1444	the first time	1431:1444	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	8	50	theme	IgG2/3-Fc	1358:1366	arg1	level					1381:1385	IgG2/3-Fc fucosylation level	1358:1385	IgG2/3-Fc fucosylation level	1358:1385	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	9	51	theme	IgG-Fc	1603:1608	arg1	fucosylation					1610:1621	total IgG-Fc fucosylation	1597:1621	total IgG-Fc fucosylation	1597:1621	Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls.
34911982	10	52	theme	afucosylated	1792:1803	arg1	responses					1809:1817	afucosylated IgG responses	1792:1817	afucosylated IgG responses	1792:1817	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	3	53	link	N-linked	565:572	arg1	glycans					574:580	N-linked glycans	565:580	N-linked glycans of the fragment crystallizable (Fc) region	565:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	8	54	theme	IgG	1555:1557	arg1	responses					1559:1567	afucosylated IgG responses	1542:1567	afucosylated IgG responses	1542:1567	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	3	55	theme	Fc	614:615	arg1	region					618:623	the fragment crystallizable (Fc) region	585:623	the fragment crystallizable (Fc) region	585:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	56	theme	present	554:560	arg1	amount					537:542	the reduced amount	525:542	the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region	525:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	56	theme	present	554:560	arg1	fucose					547:552	fucose	547:552	fucose	547:552	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	3	57	theme	immunoglobulins	473:487	arg1	IgGs					492:495	antigen-specific immunoglobulins G (IgGs)	456:496	antigen-specific immunoglobulins G (IgGs)	456:496	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	5	58	theme	humoral	766:772	arg1	responses					774:782	humoral responses	766:782	humoral responses	766:782	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	10	59	gly	afucosylated	1792:1803	arg1	responses					1809:1817	afucosylated IgG responses	1792:1817	afucosylated IgG responses	1792:1817	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	6	60	from	role	943:946	arg1	glycosylation					972:984	IgG-Fc glycosylation	965:984	IgG-Fc glycosylation	965:984	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	3	61	theme	G	489:489	arg1	IgGs					492:495	antigen-specific immunoglobulins G (IgGs)	456:496	antigen-specific immunoglobulins G (IgGs)	456:496	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	10	62	theme	IgG	1805:1807	arg1	responses					1809:1817	afucosylated IgG responses	1792:1817	afucosylated IgG responses	1792:1817	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	10	63	theme	responses	1809:1817	arg1	maintenance					1777:1787	maintenance	1777:1787	maintenance	1777:1787	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	10	63	theme	responses	1809:1817	arg1	induction					1764:1772	induction	1764:1772	induction	1764:1772	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	3	64	theme	fragment	589:596	arg1	region					618:623	the fragment crystallizable (Fc) region	585:623	the fragment crystallizable (Fc) region	585:623	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	4	65	theme	effector	692:699	arg1	functions					701:709	immune effector functions	685:709	immune effector functions	685:709	These glycans are essential for mediating the induction of immune effector functions.
34911982	6	66	theme	Fc	1082:1083	arg1	glycosylation					1085:1097	Fc glycosylation	1082:1097	Fc glycosylation	1082:1097	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	0	67	gly	afucosylated	35:46	arg1	IgG					48:50	afucosylated IgG	35:50	afucosylated IgG in humans	35:60	A functional spleen contributes to afucosylated IgG in humans.
34911982	1	68	theme	wide	103:106	arg1	organ					77:81	a lymphoid organ	66:81	a lymphoid organ	66:81	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	1	68	theme	wide	103:106	arg1	range					108:112	a wide range	101:112	a wide range	101:112	As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses.
34911982	7	69	theme	IgG-Fc	1279:1284	arg1	galactosylation					1286:1300	IgG-Fc galactosylation	1279:1300	IgG-Fc galactosylation	1279:1300	IgG-Fc fucosylation was consistently increased after splenectomy, while no effects for IgG-Fc galactosylation and sialylation were observed.
34911982	5	70	theme	immune	882:887	arg1	ITP					907:909	ITP	907:909	ITP	907:909	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	5	70	theme	immune	882:887	arg1	thrombocytopenia					889:904	immune thrombocytopenia	882:904	immune thrombocytopenia (ITP) pathogenesis	882:923	Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis.
34911982	8	71	from	increase	1336:1343	arg1	level					1381:1385	IgG2/3-Fc fucosylation level	1358:1385	IgG2/3-Fc fucosylation level	1358:1385	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	8	71	from	increase	1336:1343	arg1	IgG1-					1348:1352	IgG1-	1348:1352	IgG1-	1348:1352	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
34911982	6	72	theme	due	1162:1164	arg1	trauma					1154:1159	trauma	1154:1159	trauma	1154:1159	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	10	73	dep	induction	1764:1772	arg1	the					1760:1762	the	1760:1762	the	1760:1762	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	3	74	theme	antigen-specific	456:471	arg1	IgGs					492:495	antigen-specific immunoglobulins G (IgGs)	456:496	antigen-specific immunoglobulins G (IgGs)	456:496	During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region.
34911982	6	75	theme	IgG-Fc	965:970	arg1	glycosylation					972:984	IgG-Fc glycosylation	965:984	IgG-Fc glycosylation	965:984	To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis.
34911982	10	76	from	role	1731:1734	arg1	maintenance					1777:1787	maintenance	1777:1787	maintenance	1777:1787	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	10	76	from	role	1731:1734	arg1	induction					1764:1772	induction	1764:1772	induction	1764:1772	Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.
34911982	9	77	theme	fucosylation	1610:1621	arg1	level					1588:1592	the level	1584:1592	the level of total IgG-Fc fucosylation	1584:1621	Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls.
34911982	2	78	theme	prominent	328:336	arg1	role					338:341	a prominent role	326:341	a prominent role	326:341	In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens.
34911982	8	79	theme	afucosylated	1542:1553	arg1	responses					1559:1567	afucosylated IgG responses	1542:1567	afucosylated IgG responses	1542:1567	An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses.
33051095	7	0	theme	donor	1531:1535	arg1	levels					1537:1542	healthy donor levels	1523:1542	healthy donor levels in CD8+ T and NK cells	1523:1565	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	10	1	theme	XMEN	1923:1926	arg1	T					1933:1933	MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells	1891:1946	T	1933:1933	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	0	2	theme	neoplasia	180:188	arg1	disease					190:196	neoplasia disease	180:196	neoplasia disease	180:196	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	1	3	link	N-linked	291:298	arg1	glycosylation					300:312	N-linked glycosylation	291:312	N-linked glycosylation	291:312	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	4	4	theme	Experimental	876:887	arg1	transfer					889:896	Experimental transfer	876:896	Experimental transfer of donor EBV-specific cytotoxic T cells	876:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	7	5	theme	patient	1459:1465	arg1	lymphocytes					1467:1477	XMEN patient lymphocytes	1454:1477	XMEN patient lymphocytes	1454:1477	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	3	6	theme	XMEN	699:702	arg1	disease					704:710	XMEN disease	699:710	XMEN disease	699:710	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	10	7	theme	NK	1939:1940	arg1	cells					1942:1946	MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells	1891:1946	cells	1942:1946	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	6	8	theme	mRNA	1276:1279	arg1	EP					1298:1299	EP	1298:1299	EP	1298:1299	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	6	8	theme	mRNA	1276:1279	arg1	electroporation					1281:1295	MAGT1 mRNA electroporation	1270:1295	MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application	1270:1375	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	2	9	dep	recognition	588:598	arg1	the					584:586	the	584:586	the	584:586	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	7	10	theme	MAGT1	1485:1489	arg1	electroporation					1496:1510	MAGT1 mRNA electroporation	1485:1510	MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP	1485:1586	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	9	11	theme	NK	1684:1685	arg1	cells					1687:1691	XMEN NK cells	1679:1691	XMEN NK cells	1679:1691	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	3	12	theme	increased	728:736	arg1	susceptibility					738:751	increased susceptibility	728:751	increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available	728:873	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	10	13	theme	receptor	1776:1783	arg1	expression					1785:1794	The restored NKG2D receptor expression	1757:1794	The restored NKG2D receptor expression	1757:1794	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	1	14	theme	BACKGROUND	199:208	arg1	deficiency					229:238	BACKGROUND AIM X-linked MAGT1 deficiency	199:238	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	199:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	4	15	theme	T	930:930	arg1	cells					932:936	donor EBV-specific cytotoxic T cells	901:936	donor EBV-specific cytotoxic T cells	901:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	6	16	theme	lymphocytes	1236:1246	arg1	efficiency					1200:1209	efficiency	1200:1209	efficiency	1200:1209	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	6	16	theme	lymphocytes	1236:1246	arg1	feasibility					1184:1194	feasibility	1184:1194	feasibility	1184:1194	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	7	17	theme	NKG2D	1417:1421	arg1	expression					1423:1432	NKG2D expression	1417:1432	NKG2D expression	1417:1432	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	10	18	theme	short	1962:1966	arg1	therapy					1973:1979	potential short term therapy	1952:1979	potential short term therapy for XMEN patients without the risks of alloimmunization	1952:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	1	19	theme	MAGT1	392:396	arg1	gene					399:402	the magnesium transporter 1 (MAGT1) gene	363:402	the magnesium transporter 1 (MAGT1) gene	363:402	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	10	20	theme	restored	1761:1768	arg1	expression					1785:1794	The restored NKG2D receptor expression	1757:1794	The restored NKG2D receptor expression	1757:1794	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	1	21	theme	X-linked	214:221	arg1	deficiency					229:238	BACKGROUND AIM X-linked MAGT1 deficiency	199:238	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	199:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	2	22	theme	NK	552:553	arg1	cells					555:559	CD8+ T and NK cells	541:559	cells	555:559	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	0	23	theme	Epstein-Barr	147:158	arg1	virus					160:164	Epstein-Barr virus	147:164	Epstein-Barr virus infection	147:174	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	4	24	theme	EBV-specific	907:918	arg1	cells					932:936	donor EBV-specific cytotoxic T cells	901:936	donor EBV-specific cytotoxic T cells	901:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	6	25	theme	autologous	1225:1234	arg1	lymphocytes					1236:1246	correcting autologous lymphocytes	1214:1246	correcting autologous lymphocytes from XMEN patients	1214:1265	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	3	26	theme	cell	792:795	arg1	malignancies					797:808	EBV-associated B cell malignancies	775:808	EBV-associated B cell malignancies	775:808	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	5	27	theme	viral	1053:1057	arg1	infections					1059:1068	viral infections	1053:1068	viral infections	1053:1068	An approach for cell therapy to address viral infections and associated complications that avoids the risks of alloimmunity is needed.
33051095	3	28	theme	specific	824:831	arg1	options					843:849	no specific treatment options	821:849	no specific treatment options	821:849	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	2	29	theme	proteins	502:509	arg1	expression					477:486	expression	477:486	expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function	477:682	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	0	30	from	therapy	87:93	arg1	immunodeficiency					107:122	X-linked immunodeficiency	98:122	X-linked immunodeficiency	98:122	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	3	31	theme	EBV-associated	775:788	arg1	malignancies					797:808	EBV-associated B cell malignancies	775:808	EBV-associated B cell malignancies	775:808	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	5	32	theme	alloimmunity	1124:1135	arg1	risks					1115:1119	the risks	1111:1119	the risks of alloimmunity	1111:1135	An approach for cell therapy to address viral infections and associated complications that avoids the risks of alloimmunity is needed.
33051095	10	33	theme	alloimmunization	2020:2035	arg1	risks					2011:2015	the risks	2007:2015	the risks of alloimmunization	2007:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	9	34	theme	cytotoxic	1701:1709	arg1	activity					1711:1718	cytotoxic activity	1701:1718	cytotoxic activity	1701:1718	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	2	35	theme	key	491:493	arg1	receptor					529:536	the NKG2D receptor	519:536	the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells	519:650	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	2	35	theme	key	491:493	arg1	proteins					502:509	key immune proteins	491:509	key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function	491:682	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	9	36	theme	NK	1742:1743	arg1	cell					1745:1748	healthy donor NK cell	1728:1748	healthy donor NK cell level	1728:1754	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	6	37	from	efficiency	1200:1209	arg1	patients					1258:1265	XMEN patients	1253:1265	XMEN patients	1253:1265	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	0	38	theme	potential	72:80	arg1	therapy					87:93	potential cell therapy	72:93	potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease	72:196	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	2	39	theme	NKG2D	523:527	arg1	receptor					529:536	the NKG2D receptor	519:536	the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells	519:650	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	2	39	theme	NKG2D	523:527	arg1	biomarker					655:663	a biomarker	653:663	a biomarker for MAGT1 function	653:682	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	6	40	theme	correcting	1214:1223	arg1	lymphocytes					1236:1246	correcting autologous lymphocytes	1214:1246	correcting autologous lymphocytes from XMEN patients	1214:1265	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	1	41	theme	magnesium	367:375	arg1	gene					399:402	the magnesium transporter 1 (MAGT1) gene	363:402	the magnesium transporter 1 (MAGT1) gene	363:402	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	6	42	theme	clinical	1356:1363	arg1	application					1365:1375	clinical application	1356:1375	clinical application	1356:1375	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	2	43	theme	glycosylation	441:453	arg1	defect					455:460	a glycosylation defect	439:460	a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function	439:682	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	9	44	theme	cell	1745:1748	arg1	level					1750:1754	healthy donor NK cell level	1728:1754	healthy donor NK cell level	1728:1754	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	3	45	contain	have	723:726	arg2	susceptibility					738:751	increased susceptibility	728:751	increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available	728:873	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	3	45	contain	have	723:726	arg1	Patients					685:692	Patients	685:692	Patients with XMEN disease	685:710	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	6	46	from	feasibility	1184:1194	arg1	patients					1258:1265	XMEN patients	1253:1265	XMEN patients	1253:1265	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	0	47	theme	MAGT1	0:4	arg1	messenger					6:14	MAGT1 messenger	0:14	MAGT1 messenger	0:14	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	1	48	theme	defect	314:319	arg1	disease					329:335	defect' (XMEN) disease	314:335	defect' (XMEN) disease	314:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	2	49	theme	cells	646:650	arg1	recognition					588:598	recognition	588:598	recognition	588:598	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	2	49	theme	cells	646:650	arg1	killing					604:610	killing	604:610	killing	604:610	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	2	50	theme	function	419:426	arg1	Loss					405:408	Loss	405:408	Loss of MAGT1 function	405:426	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	1	51	with	deficiency	229:238	arg1	susceptibility					255:268	increased susceptibility	245:268	increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	245:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	10	52	theme	feasible	1862:1869	arg1	infusions					1878:1886	feasible repeat infusions	1862:1886	feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization	1862:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	0	53	theme	T	41:41	arg1	cells					62:66	autologous T and natural killer cells	30:66	autologous T and natural killer cells	30:66	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	1	54	from	mutations	350:358	arg1	gene					399:402	the magnesium transporter 1 (MAGT1) gene	363:402	the magnesium transporter 1 (MAGT1) gene	363:402	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	7	55	theme	CD8+	1547:1550	arg1	cells					1561:1565	CD8+ T and NK cells	1547:1565	CD8+ T and NK cells	1547:1565	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	10	56	theme	MAGT1	1891:1895	arg1	T					1933:1933	MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells	1891:1946	T	1933:1933	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	2	57	from	receptor	529:536	arg1	T					546:546	CD8+ T and NK cells	541:559	T	546:546	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	2	57	from	receptor	529:536	arg1	cells					555:559	CD8+ T and NK cells	541:559	cells	555:559	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	7	58	theme	healthy	1523:1529	arg1	levels					1537:1542	healthy donor levels	1523:1542	healthy donor levels in CD8+ T and NK cells	1523:1565	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	10	59	theme	CD8+	1928:1931	arg1	T					1933:1933	MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells	1891:1946	T	1933:1933	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	10	60	theme	autologous	1912:1921	arg1	T					1933:1933	MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells	1891:1946	T	1933:1933	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	1	61	theme	N-linked	291:298	arg1	glycosylation					300:312	N-linked glycosylation	291:312	N-linked glycosylation	291:312	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	7	62	theme	mRNA	1491:1494	arg1	electroporation					1496:1510	MAGT1 mRNA electroporation	1485:1510	MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP	1485:1586	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	10	63	theme	cells	1942:1946	arg1	infusions					1878:1886	feasible repeat infusions	1862:1886	feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization	1862:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	0	64	theme	natural	47:53	arg1	killer					55:60	natural killer	47:60	natural killer	47:60	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	9	65	theme	XMEN	1679:1682	arg1	cells					1687:1691	XMEN NK cells	1679:1691	XMEN NK cells	1679:1691	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	7	66	theme	XMEN	1454:1457	arg1	lymphocytes					1467:1477	XMEN patient lymphocytes	1454:1477	XMEN patient lymphocytes	1454:1477	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	6	67	theme	MAGT1	1270:1274	arg1	EP					1298:1299	EP	1298:1299	EP	1298:1299	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	6	67	theme	MAGT1	1270:1274	arg1	electroporation					1281:1295	MAGT1 mRNA electroporation	1270:1295	MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application	1270:1375	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	9	68	theme	cells	1687:1691	arg1	mRNA-correction					1660:1674	mRNA-correction	1660:1674	mRNA-correction of XMEN NK cells	1660:1691	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	10	69	theme	term	1968:1971	arg1	therapy					1973:1979	potential short term therapy	1952:1979	potential short term therapy for XMEN patients without the risks of alloimmunization	1952:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	0	70	theme	magnesium	129:137	arg1	defect					139:144	magnesium defect	129:144	magnesium defect	129:144	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	0	71	with	therapy	87:93	arg1	defect					139:144	magnesium defect	129:144	magnesium defect	129:144	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	0	71	with	therapy	87:93	arg1	infection					166:174	Epstein-Barr virus infection	147:174	Epstein-Barr virus infection	147:174	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	0	71	with	therapy	87:93	arg1	disease					190:196	neoplasia disease	180:196	neoplasia disease	180:196	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	10	72	theme	NKG2D	1770:1774	arg1	expression					1785:1794	The restored NKG2D receptor expression	1757:1794	The restored NKG2D receptor expression	1757:1794	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	1	73	theme	AIM	210:212	arg1	deficiency					229:238	BACKGROUND AIM X-linked MAGT1 deficiency	199:238	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	199:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	2	74	theme	CD8+	541:544	arg1	T					546:546	CD8+ T and NK cells	541:559	T	546:546	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	7	75	theme	expression	1423:1432	arg1	Restoration					1402:1412	RESULTS AND CONCLUSIONS Restoration	1378:1412	RESULTS AND CONCLUSIONS Restoration of NKG2D expression	1378:1432	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	10	76	theme	potential	1952:1960	arg1	therapy					1973:1979	potential short term therapy	1952:1979	potential short term therapy for XMEN patients without the risks of alloimmunization	1952:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	5	77	theme	associated	1074:1083	arg1	complications					1085:1097	associated complications	1074:1097	associated complications	1074:1097	An approach for cell therapy to address viral infections and associated complications that avoids the risks of alloimmunity is needed.
33051095	1	78	theme	MAGT1	223:227	arg1	deficiency					229:238	BACKGROUND AIM X-linked MAGT1 deficiency	199:238	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	199:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	4	79	theme	cells	932:936	arg1	transfer					889:896	Experimental transfer	876:896	Experimental transfer of donor EBV-specific cytotoxic T cells	876:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	6	80	theme	XMEN	1253:1256	arg1	patients					1258:1265	XMEN patients	1253:1265	XMEN patients	1253:1265	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	0	81	theme	virus	160:164	arg1	infection					166:174	Epstein-Barr virus infection	147:174	Epstein-Barr virus infection	147:174	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	9	82	theme	healthy	1728:1734	arg1	cell					1745:1748	healthy donor NK cell	1728:1748	healthy donor NK cell level	1728:1754	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	7	83	theme	CONCLUSIONS	1390:1400	arg1	Restoration					1402:1412	RESULTS AND CONCLUSIONS Restoration	1378:1412	RESULTS AND CONCLUSIONS Restoration of NKG2D expression	1378:1432	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	2	84	theme	MAGT1	669:673	arg1	function					675:682	MAGT1 function	669:682	MAGT1 function	669:682	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	3	85	theme	EBV	756:758	arg1	infections					760:769	EBV infections	756:769	EBV infections	756:769	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	6	86	theme	genomic	1314:1320	arg1	integration					1322:1332	genomic integration	1314:1332	genomic integration	1314:1332	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	4	87	theme	donor	901:905	arg1	cells					932:936	donor EBV-specific cytotoxic T cells	901:936	donor EBV-specific cytotoxic T cells	901:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	1	88	dep	EBV-infection	273:285	arg1	disease					329:335	defect' (XMEN) disease	314:335	defect' (XMEN) disease	314:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	7	89	theme	RESULTS	1378:1384	arg1	Restoration					1402:1412	RESULTS AND CONCLUSIONS Restoration	1378:1412	RESULTS AND CONCLUSIONS Restoration of NKG2D expression	1378:1432	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	6	90	from	patients	1258:1265	arg1	efficiency					1200:1209	efficiency	1200:1209	efficiency	1200:1209	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	6	90	from	patients	1258:1265	arg1	feasibility					1184:1194	feasibility	1184:1194	feasibility	1184:1194	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	6	90	from	patients	1258:1265	arg1	lymphocytes					1236:1246	correcting autologous lymphocytes	1214:1246	correcting autologous lymphocytes from XMEN patients	1214:1265	METHODS Here the authors assess the feasibility and efficiency of correcting autologous lymphocytes from XMEN patients by MAGT1 mRNA electroporation (EP) that avoids genomic integration and can be scaled for clinical application.
33051095	3	91	theme	treatment	833:841	arg1	options					843:849	no specific treatment options	821:849	no specific treatment options	821:849	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	2	92	theme	immune	495:500	arg1	receptor					529:536	the NKG2D receptor	519:536	the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells	519:650	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	2	92	theme	immune	495:500	arg1	proteins					502:509	key immune proteins	491:509	key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function	491:682	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	3	93	theme	B	790:790	arg1	malignancies					797:808	EBV-associated B cell malignancies	775:808	EBV-associated B cell malignancies	775:808	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	0	94	theme	cell	82:85	arg1	therapy					87:93	potential cell therapy	72:93	potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease	72:196	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	9	95	theme	donor	1736:1740	arg1	cell					1745:1748	healthy donor NK cell	1728:1748	healthy donor NK cell level	1728:1754	Functionally, mRNA-correction of XMEN NK cells rescued cytotoxic activity also to healthy donor NK cell level.
33051095	4	96	theme	cytotoxic	920:928	arg1	cells					932:936	donor EBV-specific cytotoxic T cells	901:936	donor EBV-specific cytotoxic T cells	901:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	2	97	theme	transformed	634:644	arg1	cells					646:650	virus-infected and transformed cells	615:650	virus-infected and transformed cells	615:650	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	1	98	link	X-linked	214:221	arg1	deficiency					229:238	BACKGROUND AIM X-linked MAGT1 deficiency	199:238	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	199:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	2	99	theme	virus-infected	615:628	arg1	cells					646:650	virus-infected and transformed cells	615:650	virus-infected and transformed cells	615:650	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	1	100	theme	transporter	377:387	arg1	gene					399:402	the magnesium transporter 1 (MAGT1) gene	363:402	the magnesium transporter 1 (MAGT1) gene	363:402	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	0	101	theme	autologous	30:39	arg1	cells					62:66	autologous T and natural killer cells	30:66	autologous T and natural killer cells	30:66	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	10	102	theme	repeat	1871:1876	arg1	infusions					1878:1886	feasible repeat infusions	1862:1886	feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization	1862:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	2	103	theme	MAGT1	413:417	arg1	function					419:426	MAGT1 function	413:426	MAGT1 function	413:426	Loss of MAGT1 function results in a glycosylation defect that abrogates expression of key immune proteins such as the NKG2D receptor on CD8+ T and NK cells, which is critical for the recognition and killing of virus-infected and transformed cells, a biomarker for MAGT1 function.
33051095	4	104	theme	alloimmune	991:1000	arg1	responses					1002:1010	alloimmune responses	991:1010	alloimmune responses	991:1010	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	8	105	theme	NKG2D	1589:1593	arg1	expression					1595:1604	NKG2D expression	1589:1604	NKG2D expression	1589:1604	NKG2D expression persisted at ∼50% for 2 weeks after EP.
33051095	0	106	theme	X-linked	98:105	arg1	immunodeficiency					107:122	X-linked immunodeficiency	98:122	X-linked immunodeficiency	98:122	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	0	107	theme	killer	55:60	arg1	cells					62:66	autologous T and natural killer cells	30:66	autologous T and natural killer cells	30:66	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	7	108	theme	NK	1558:1559	arg1	cells					1561:1565	CD8+ T and NK cells	1547:1565	CD8+ T and NK cells	1547:1565	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	5	109	theme	cell	1029:1032	arg1	therapy					1034:1040	cell therapy	1029:1040	cell therapy	1029:1040	An approach for cell therapy to address viral infections and associated complications that avoids the risks of alloimmunity is needed.
33051095	4	110	contain	carries	960:966	arg1	transfer					889:896	Experimental transfer	876:896	Experimental transfer of donor EBV-specific cytotoxic T cells	876:936	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	4	110	contain	carries	960:966	arg2	risks					972:976	the risks	968:976	the risks of eliciting alloimmune responses	968:1010	Experimental transfer of donor EBV-specific cytotoxic T cells may be beneficial but carries the risks of eliciting alloimmune responses.
33051095	10	111	theme	mRNA-corrected	1897:1910	arg1	T					1933:1933	MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells	1891:1946	T	1933:1933	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
33051095	3	112	with	Patients	685:692	arg1	disease					704:710	XMEN disease	699:710	XMEN disease	699:710	Patients with XMEN disease frequently have increased susceptibility to EBV infections and EBV-associated B cell malignancies, for which no specific treatment options are currently available.
33051095	7	113	theme	T	1552:1552	arg1	cells					1561:1565	CD8+ T and NK cells	1547:1565	CD8+ T and NK cells	1547:1565	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	1	114	theme	increased	245:253	arg1	susceptibility					255:268	increased susceptibility	245:268	increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease	245:335	BACKGROUND AIM X-linked MAGT1 deficiency with increased susceptibility to EBV-infection and N-linked glycosylation defect' (XMEN) disease is caused by mutations in the magnesium transporter 1 (MAGT1) gene.
33051095	7	115	from	levels	1537:1542	arg1	cells					1561:1565	CD8+ T and NK cells	1547:1565	CD8+ T and NK cells	1547:1565	RESULTS AND CONCLUSIONS Restoration of NKG2D expression was demonstrated in XMEN patient lymphocytes after MAGT1 mRNA electroporation that reach healthy donor levels in CD8+ T and NK cells at 1-2 days after EP.
33051095	0	116	link	X-linked	98:105	arg1	immunodeficiency					107:122	X-linked immunodeficiency	98:122	X-linked immunodeficiency	98:122	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease.
33051095	10	117	theme	T	1933:1933	arg1	infusions					1878:1886	feasible repeat infusions	1862:1886	feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization	1862:2035	The restored NKG2D receptor expression and function were unaffected by cryopreservation, which will make feasible repeat infusions of MAGT1 mRNA-corrected autologous XMEN CD8+ T and NK cells for potential short term therapy for XMEN patients without the risks of alloimmunization.
32592613	4	0	theme	A549	799:802	arg1	cells					822:826	A549 human lung cancer cells	799:826	A549 human lung cancer cells	799:826	Blocking the interaction between HA and CD44 reduced viability of A549 human lung cancer cells.
32592613	2	1	theme	factor-binding	348:361	arg1	IGFBP-3					374:380	IGFBP-3	374:380	IGFBP-3	374:380	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	1	theme	factor-binding	348:361	arg1	protein-3					363:371	insulin-like growth factor-binding protein-3	328:371	insulin-like growth factor-binding protein-3 (IGFBP-3)	328:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	3	2	theme	full-length	632:642	arg1	protein					652:658	the full-length IGFBP-3 protein	628:658	the full-length IGFBP-3 protein	628:658	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	8	3	theme	N-linked	1392:1399	arg1	oligosaccharides					1401:1416	N-linked oligosaccharides	1392:1416	N-linked oligosaccharides	1392:1416	Removing N-linked oligosaccharides from CD44 increased its ability to compete with IGFBP-3 for binding HA, while reduction of CD44 rendered the protein relatively ineffective at blocking IGFBP-3-HA interactions.
32592613	2	4	theme	growth	341:346	arg1	IGFBP-3					374:380	IGFBP-3	374:380	IGFBP-3	374:380	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	4	theme	growth	341:346	arg1	protein-3					363:371	insulin-like growth factor-binding protein-3	328:371	insulin-like growth factor-binding protein-3 (IGFBP-3)	328:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	6	5	theme	IGFBP-3	1019:1025	arg1	peptide					1027:1033	the IGFBP-3 peptide	1015:1033	the IGFBP-3 peptide	1015:1033	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	3	6	theme	IGFBP-3	644:650	arg1	protein					652:658	the full-length IGFBP-3 protein	628:658	the full-length IGFBP-3 protein	628:658	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	4	7	theme	lung	810:813	arg1	cells					822:826	A549 human lung cancer cells	799:826	A549 human lung cancer cells	799:826	Blocking the interaction between HA and CD44 reduced viability of A549 human lung cancer cells.
32592613	1	8	theme	IGF/IGF-IR	230:239	arg1	interactions					241:252	IGF/IGF-IR interactions	230:252	IGF/IGF-IR interactions	230:252	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	7	9	theme	IGFBP-3	1115:1121	arg1	Binding					1104:1110	Binding	1104:1110	Binding of IGFBP-3 to either HA or HN	1104:1140	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	4	10	theme	human	804:808	arg1	cells					822:826	A549 human lung cancer cells	799:826	A549 human lung cancer cells	799:826	Blocking the interaction between HA and CD44 reduced viability of A549 human lung cancer cells.
32592613	8	11	theme	ineffective	1546:1556	arg1	protein					1527:1533	the protein	1523:1533	the protein relatively ineffective	1523:1556	Removing N-linked oligosaccharides from CD44 increased its ability to compete with IGFBP-3 for binding HA, while reduction of CD44 rendered the protein relatively ineffective at blocking IGFBP-3-HA interactions.
32592613	5	12	theme	IGFBP-3-HA	878:887	arg1	interactions					889:900	IGFBP-3-HA interactions	878:900	IGFBP-3-HA interactions	878:900	In this study, we set out to better characterize IGFBP-3-HA interactions.
32592613	2	13	theme	C-terminal	307:316	arg1	protein-3					363:371	insulin-like growth factor-binding protein-3	328:371	insulin-like growth factor-binding protein-3 (IGFBP-3)	328:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	13	theme	C-terminal	307:316	arg1	domain					318:323	The C-terminal domain	303:323	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3)	303:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	7	14	theme	full-length	1362:1372	arg1	protein					1374:1380	the full-length protein	1358:1380	the full-length protein	1358:1380	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	15	theme	18-amino	1225:1232	arg1	sequence					1247:1254	the basic 18-amino acid residue sequence	1215:1254	the basic 18-amino acid residue sequence of IGFBP-3	1215:1265	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	16	with	interaction	1290:1300	arg1	HN					1314:1315	HN	1314:1315	HN	1314:1315	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	16	with	interaction	1290:1300	arg1	reduction					1345:1353	reduction	1345:1353	reduction of the full-length protein	1345:1380	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	16	with	interaction	1290:1300	arg1	HA					1320:1321	HA	1320:1321	HA	1320:1321	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	1	17	theme	abundant	82:89	arg1	IGFBP					91:95	the most abundant IGFBP	73:95	the most abundant IGFBP	73:95	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	17	theme	abundant	82:89	arg1	IGFBP-3					64:70	IGFBP-3	64:70	IGFBP-3	64:70	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	6	18	theme	interaction	995:1005	arg1	identity					952:959	amino acid identity	941:959	amino acid identity	941:959	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	18	theme	interaction	995:1005	arg1	determinants					975:986	important determinants	965:986	important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects	965:1101	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	18	theme	interaction	995:1005	arg1	stereochemistry					921:935	stereochemistry	921:935	stereochemistry	921:935	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	2	19	theme	capable	432:438	arg1	motif					426:430	an 18-basic amino acid motif	403:430	an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA)	403:497	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	0	20	theme	Biochemical	0:10	arg1	determinants					12:23	Biochemical determinants	0:23	Biochemical determinants of the IGFBP-3-hyaluronan interaction.	0:62	Biochemical determinants of the IGFBP-3-hyaluronan interaction.
32592613	3	21	theme	HA	698:699	arg1	CD44					711:714	CD44	711:714	CD44	711:714	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	3	21	theme	HA	698:699	arg1	receptor					701:708	the HA receptor	694:708	the HA receptor	694:708	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	1	22	from	carrier	110:116	arg1	circulation					165:175	the circulation	161:175	the circulation	161:175	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	3	23	theme	18-amino	530:537	arg1	peptide					552:558	the 18-amino acid IGFBP-3 peptide	526:558	the 18-amino acid IGFBP-3 peptide	526:558	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	3	23	theme	18-amino	530:537	arg1	capable					563:569	capable	563:569	capable	563:569	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	7	24	theme	basic	1219:1223	arg1	sequence					1247:1254	the basic 18-amino acid residue sequence	1215:1254	the basic 18-amino acid residue sequence of IGFBP-3	1215:1265	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	2	25	theme	acid	421:424	arg1	motif					426:430	an 18-basic amino acid motif	403:430	an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA)	403:497	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	7	26	dep	unaffected	1146:1155	arg1	suggesting					1199:1208	suggesting	1199:1208	suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein	1199:1380	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	2	27	theme	18-basic	406:413	arg1	motif					426:430	an 18-basic amino acid motif	403:430	an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA)	403:497	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	28	theme	amino	415:419	arg1	motif					426:430	an 18-basic amino acid motif	403:430	an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA)	403:497	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	1	29	theme	main	105:108	arg1	carrier					110:116	the main carrier	101:116	the main carrier	101:116	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	29	theme	main	105:108	arg1	IGFBP-3					64:70	IGFBP-3	64:70	IGFBP-3	64:70	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	6	30	theme	important	965:973	arg1	identity					952:959	amino acid identity	941:959	amino acid identity	941:959	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	30	theme	important	965:973	arg1	determinants					975:986	important determinants	965:986	important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects	965:1101	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	30	theme	important	965:973	arg1	stereochemistry					921:935	stereochemistry	921:935	stereochemistry	921:935	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	0	31	theme	interaction	51:61	arg1	determinants					12:23	Biochemical determinants	0:23	Biochemical determinants of the IGFBP-3-hyaluronan interaction.	0:62	Biochemical determinants of the IGFBP-3-hyaluronan interaction.
32592613	9	32	theme	disulfide	1637:1645	arg1	formation					1652:1660	disulfide bond formation	1637:1660	disulfide bond formation	1637:1660	We conclude that both deglycosylation and disulfide bond formation are important for CD44 to compete with IGFBP-3 for binding HA.
32592613	7	33	theme	IGFBP-3	1190:1196	arg1	reduction					1177:1185	reduction	1177:1185	reduction of IGFBP-3	1177:1196	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	33	theme	IGFBP-3	1190:1196	arg1	glycosylation					1160:1172	glycosylation	1160:1172	glycosylation	1160:1172	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	0	34	theme	IGFBP-3-hyaluronan	32:49	arg1	interaction					51:61	the IGFBP-3-hyaluronan interaction	28:61	the IGFBP-3-hyaluronan interaction	28:61	Biochemical determinants of the IGFBP-3-hyaluronan interaction.
32592613	1	35	theme	antiproliferative	276:292	arg1	effects					294:300	antiproliferative effects	276:300	antiproliferative effects	276:300	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	9	36	theme	bond	1647:1650	arg1	formation					1652:1660	disulfide bond formation	1637:1660	disulfide bond formation	1637:1660	We conclude that both deglycosylation and disulfide bond formation are important for CD44 to compete with IGFBP-3 for binding HA.
32592613	7	37	theme	protein	1374:1380	arg1	HN					1314:1315	HN	1314:1315	HN	1314:1315	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	37	theme	protein	1374:1380	arg1	reduction					1345:1353	reduction	1345:1353	reduction of the full-length protein	1345:1380	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	7	37	theme	protein	1374:1380	arg1	HA					1320:1321	HA	1320:1321	HA	1320:1321	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	4	38	theme	cells	822:826	arg1	viability					786:794	viability	786:794	viability of A549 human lung cancer cells	786:826	Blocking the interaction between HA and CD44 reduced viability of A549 human lung cancer cells.
32592613	3	39	theme	acid	539:542	arg1	peptide					552:558	the 18-amino acid IGFBP-3 peptide	526:558	the 18-amino acid IGFBP-3 peptide	526:558	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	3	39	theme	acid	539:542	arg1	capable					563:569	capable	563:569	capable	563:569	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	2	40	theme	insulin-like	328:339	arg1	IGFBP-3					374:380	IGFBP-3	374:380	IGFBP-3	374:380	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	40	theme	insulin-like	328:339	arg1	protein-3					363:371	insulin-like growth factor-binding protein-3	328:371	insulin-like growth factor-binding protein-3 (IGFBP-3)	328:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	6	41	theme	cytotoxic	1085:1093	arg1	effects					1095:1101	its cytotoxic effects	1081:1101	its cytotoxic effects	1081:1101	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	4	42	theme	cancer	815:820	arg1	cells					822:826	A549 human lung cancer cells	799:826	A549 human lung cancer cells	799:826	Blocking the interaction between HA and CD44 reduced viability of A549 human lung cancer cells.
32592613	3	43	theme	IGFBP-3	544:550	arg1	peptide					552:558	the 18-amino acid IGFBP-3 peptide	526:558	the 18-amino acid IGFBP-3 peptide	526:558	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	3	43	theme	IGFBP-3	544:550	arg1	capable					563:569	capable	563:569	capable	563:569	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	8	44	theme	CD44	1509:1512	arg1	reduction					1496:1504	reduction	1496:1504	reduction of CD44	1496:1512	Removing N-linked oligosaccharides from CD44 increased its ability to compete with IGFBP-3 for binding HA, while reduction of CD44 rendered the protein relatively ineffective at blocking IGFBP-3-HA interactions.
32592613	8	45	theme	IGFBP-3-HA	1570:1579	arg1	interactions					1581:1592	IGFBP-3-HA interactions	1570:1592	IGFBP-3-HA interactions	1570:1592	Removing N-linked oligosaccharides from CD44 increased its ability to compete with IGFBP-3 for binding HA, while reduction of CD44 rendered the protein relatively ineffective at blocking IGFBP-3-HA interactions.
32592613	2	46	contain	contain	395:401	arg1	protein-3					363:371	insulin-like growth factor-binding protein-3	328:371	insulin-like growth factor-binding protein-3 (IGFBP-3)	328:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	46	contain	contain	395:401	arg1	domain					318:323	The C-terminal domain	303:323	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3)	303:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	46	contain	contain	395:401	arg2	motif					426:430	an 18-basic amino acid motif	403:430	an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA)	403:497	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	6	47	theme	amino	941:945	arg1	identity					952:959	amino acid identity	941:959	amino acid identity	941:959	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	47	theme	amino	941:945	arg1	determinants					975:986	important determinants	965:986	important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects	965:1101	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	47	theme	amino	941:945	arg1	stereochemistry					921:935	stereochemistry	921:935	stereochemistry	921:935	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	1	48	theme	insulin-like	121:132	arg1	factor					141:146	insulin-like growth factor I	121:148	insulin-like growth factor I (IGF-I)	121:156	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	48	theme	insulin-like	121:132	arg1	IGF-I					151:155	IGF-I	151:155	IGF-I	151:155	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	6	49	theme	acid	947:950	arg1	identity					952:959	amino acid identity	941:959	amino acid identity	941:959	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	49	theme	acid	947:950	arg1	determinants					975:986	important determinants	965:986	important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects	965:1101	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	6	49	theme	acid	947:950	arg1	stereochemistry					921:935	stereochemistry	921:935	stereochemistry	921:935	We show that both stereochemistry and amino acid identity are important determinants of the interaction between the IGFBP-3 peptide and HA and for the peptide's ability to exert its cytotoxic effects.
32592613	7	50	gly	glycosylation	1160:1172	arg1	IGFBP-3					1190:1196	IGFBP-3	1190:1196	IGFBP-3	1190:1196	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	3	51	theme	comparable	603:612	arg1	affinities					614:623	comparable affinities	603:623	comparable affinities to the full-length IGFBP-3 protein	603:658	We previously showed that the 18-amino acid IGFBP-3 peptide is capable of binding either HA or HN with comparable affinities to the full-length IGFBP-3 protein and that IGFBP-3 can compete with the HA receptor, CD44, for binding HA.
32592613	7	52	theme	IGFBP-3	1259:1265	arg1	sequence					1247:1254	the basic 18-amino acid residue sequence	1215:1254	the basic 18-amino acid residue sequence of IGFBP-3	1215:1265	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	1	53	theme	growth	134:139	arg1	factor					141:146	insulin-like growth factor I	121:148	insulin-like growth factor I (IGF-I)	121:156	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	53	theme	growth	134:139	arg1	IGF-I					151:155	IGF-I	151:155	IGF-I	151:155	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	54	from	IGFBP	91:95	arg1	circulation					165:175	the circulation	161:175	the circulation	161:175	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	55	theme	high	198:201	arg1	affinity					203:210	high affinity	198:210	high affinity	198:210	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	7	56	theme	residue	1239:1245	arg1	sequence					1247:1254	the basic 18-amino acid residue sequence	1215:1254	the basic 18-amino acid residue sequence of IGFBP-3	1215:1265	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	8	57	link	N-linked	1392:1399	arg1	oligosaccharides					1401:1416	N-linked oligosaccharides	1392:1416	N-linked oligosaccharides	1392:1416	Removing N-linked oligosaccharides from CD44 increased its ability to compete with IGFBP-3 for binding HA, while reduction of CD44 rendered the protein relatively ineffective at blocking IGFBP-3-HA interactions.
32592613	1	58	theme	factor	141:146	arg1	carrier					110:116	the main carrier	101:116	the main carrier	101:116	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	58	theme	factor	141:146	arg1	IGFBP					91:95	the most abundant IGFBP	73:95	the most abundant IGFBP	73:95	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	1	58	theme	factor	141:146	arg1	IGFBP-3					64:70	IGFBP-3	64:70	IGFBP-3	64:70	IGFBP-3, the most abundant IGFBP and the main carrier of insulin-like growth factor I (IGF-I) in the circulation, can bind IGF-1 with high affinity, which attenuates IGF/IGF-IR interactions, thereby resulting in antiproliferative effects.
32592613	7	59	theme	acid	1234:1237	arg1	sequence					1247:1254	the basic 18-amino acid residue sequence	1215:1254	the basic 18-amino acid residue sequence of IGFBP-3	1215:1265	Binding of IGFBP-3 to either HA or HN was unaffected by glycosylation or reduction of IGFBP-3, suggesting that the basic 18-amino acid residue sequence of IGFBP-3 remains accessible for interaction with either HN or HA upon glycosylation or reduction of the full-length protein.
32592613	2	60	theme	protein-3	363:371	arg1	protein-3					363:371	insulin-like growth factor-binding protein-3	328:371	insulin-like growth factor-binding protein-3 (IGFBP-3)	328:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
32592613	2	60	theme	protein-3	363:371	arg1	domain					318:323	The C-terminal domain	303:323	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3)	303:381	The C-terminal domain of insulin-like growth factor-binding protein-3 (IGFBP-3) is known to contain an 18-basic amino acid motif capable of interacting with either humanin (HN) or hyaluronan (HA).
31981002	4	0	theme	glycosylation	824:836	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	0	theme	glycosylation	824:836	arg1	sites					838:842	two N-linked glycosylation sites	811:842	two N-linked glycosylation sites	811:842	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	0	1	theme	IRE1	149:152	arg1	role					141:144	its role	137:144	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.	0:217	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	7	2	theme	Megalobrama	1618:1628	arg1	amblycephala					1630:1641	Megalobrama amblycephala	1618:1641	Megalobrama amblycephala	1618:1641	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	6	3	theme	enzyme	1199:1204	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	1	4	theme	full-length	256:266	arg1	cDNA					268:271	the full-length cDNA	252:271	the full-length cDNA of IRE1 from fish Megalobrama amblycephala	252:314	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	3	5	theme	reading	518:524	arg1	frame					526:530	an open reading frame	510:530	an open reading frame of 3096 bp encoding 1031 amino acids	510:567	The cDNA obtained covered 3665 bp with an open reading frame of 3096 bp encoding 1031 amino acids.
31981002	4	6	gly	glycosylation	824:836	arg2	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	6	gly	glycosylation	824:836	arg2	sites					838:842	two N-linked glycosylation sites	811:842	two N-linked glycosylation sites	811:842	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	6	gly	glycosylation	824:836	arg2	two					811:813	two	811:813	two	811:813	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	7	theme	lipopolysaccharide	1087:1104	arg1	challenge					1112:1120	lipopolysaccharide (LPS) challenge	1087:1120	lipopolysaccharide (LPS) challenge	1087:1120	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	3	8	theme	amino	557:561	arg1	acids					563:567	1031 amino acids	552:567	1031 amino acids	552:567	The cDNA obtained covered 3665 bp with an open reading frame of 3096 bp encoding 1031 amino acids.
31981002	6	9	theme	interleukin-6	1362:1374	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	10	dep	upregulated	1482:1492	arg1	tested					1508:1513	tested	1508:1513	tested in the intestine except C/EBP homologous protein	1508:1562	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	5	11	dep	brain	957:961	arg1	the					953:955	the	953:955	the	953:955	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	4	12	link	N-linked	815:822	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	12	link	N-linked	815:822	arg1	sites					838:842	two N-linked glycosylation sites	811:842	two N-linked glycosylation sites	811:842	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	13	theme	binding	1230:1236	arg1	protein					1238:1244	spliced X-box binding protein 1	1216:1246	spliced X-box binding protein 1 (XBP1s)	1216:1254	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	13	theme	binding	1230:1236	arg1	XBP1s					1249:1253	XBP1s	1249:1253	XBP1s	1249:1253	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	14	theme	B	1311:1311	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	4	15	theme	several	849:855	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	15	theme	several	849:855	arg1	sites					873:877	several phosphorylation sites	849:877	several phosphorylation sites	849:877	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	16	theme	protein	1160:1166	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	17	theme	spliced	1216:1222	arg1	protein					1238:1244	spliced X-box binding protein 1	1216:1246	spliced X-box binding protein 1 (XBP1s)	1216:1254	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	17	theme	spliced	1216:1222	arg1	XBP1s					1249:1253	XBP1s	1249:1253	XBP1s	1249:1253	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	5	18	theme	low	994:996	arg1	levels					1009:1014	relatively low expression levels	983:1014	relatively low expression levels	983:1014	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	4	19	theme	signal	700:705	arg1	loop					805:808	one activation loop	790:808	one activation loop	790:808	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	19	theme	signal	700:705	arg1	domain					728:733	one luminal domain	716:733	one luminal domain	716:733	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	19	theme	signal	700:705	arg1	domain					782:787	one RNase domain	772:787	one RNase domain	772:787	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	19	theme	signal	700:705	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	19	theme	signal	700:705	arg1	sites					873:877	several phosphorylation sites	849:877	several phosphorylation sites	849:877	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	19	theme	signal	700:705	arg1	sites					838:842	two N-linked glycosylation sites	811:842	two N-linked glycosylation sites	811:842	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	19	theme	signal	700:705	arg1	domain					764:769	one serine/threonine kinase domain	736:769	one serine/threonine kinase domain	736:769	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	5	20	theme	IRE1	892:895	arg1	expression					897:906	The highest IRE1 expression	880:906	The highest IRE1 expression	880:906	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	21	located	detected	1021:1028	arg1	skin					1064:1067	skin	1064:1067	skin	1064:1067	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	21	located	detected	1021:1028	arg1	intestine					1044:1052	intestine	1044:1052	intestine	1044:1052	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	21	located	detected	1021:1028	arg1	heart					1074:1078	heart	1074:1078	heart	1074:1078	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	21	located	detected	1021:1028	arg1	adipose					1055:1061	adipose	1055:1061	adipose	1055:1061	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	21	located	detected	1021:1028	arg2	levels					1009:1014	relatively low expression levels	983:1014	relatively low expression levels	983:1014	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	21	located	detected	1021:1028	arg1	liver					1037:1041	liver	1037:1041	liver	1037:1041	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	22	dep	observed	912:919	arg1	whereas					975:981	whereas	975:981	whereas	975:981	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	22	dep	observed	912:919	arg1	followed					941:948	followed	941:948	followed by the brain and spleen	941:972	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	8	23	theme	vital	1849:1853	arg1	role					1855:1858	a vital role	1847:1858	a vital role	1847:1858	Its expression in three tissues was induced remarkably by the LPS challenge, which indicated that IRE1 played a vital role in LPS-induced inflammation on fish.
31981002	6	24	theme	homologous	1263:1272	arg1	protein					1274:1280	C/EBP homologous protein	1257:1280	C/EBP homologous protein (CHOP)	1257:1287	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	24	theme	homologous	1263:1272	arg1	CHOP					1283:1286	CHOP	1283:1286	CHOP	1283:1286	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	2	25	dep	RT-PCR	443:448	arg1	approaches					459:468	approaches	459:468	approaches	459:468	A full-length cDNA coding IRE1 was cloned from blunt snout bream by RT-PCR and RACE approaches.
31981002	5	26	theme	trunk	928:932	arg1	kidney					934:939	the trunk kidney	924:939	the trunk kidney	924:939	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	6	27	theme	homologous	1545:1554	arg1	protein					1556:1562	C/EBP homologous protein	1539:1562	C/EBP homologous protein	1539:1562	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	4	28	theme	serine/threonine	740:755	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	28	theme	serine/threonine	740:755	arg1	domain					764:769	one serine/threonine kinase domain	736:769	one serine/threonine kinase domain	736:769	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	0	29	theme	snout	97:101	arg1	amblycephala					122:133	amblycephala	122:133	amblycephala	122:133	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	0	29	theme	snout	97:101	arg1	bream					103:107	blunt snout bream	91:107	blunt snout bream (Megalobrama amblycephala)	91:134	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	1	30	from	role	336:339	arg1	response					365:372	the pro-inflammatory response	344:372	the pro-inflammatory response	344:372	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	0	31	from	pattern	42:48	arg1	amblycephala					122:133	amblycephala	122:133	amblycephala	122:133	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	0	31	from	pattern	42:48	arg1	bream					103:107	blunt snout bream	91:107	blunt snout bream (Megalobrama amblycephala)	91:134	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	2	32	theme	full-length	377:387	arg1	cDNA					389:392	A full-length cDNA	375:392	A full-length cDNA coding IRE1	375:404	A full-length cDNA coding IRE1 was cloned from blunt snout bream by RT-PCR and RACE approaches.
31981002	0	33	theme	Molecular	0:8	arg1	characterization					10:25	Molecular characterization	0:25	Molecular characterization	0:25	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	2	34	dep	bream	434:438	arg1	blunt					422:426	blunt	422:426	blunt	422:426	A full-length cDNA coding IRE1 was cloned from blunt snout bream by RT-PCR and RACE approaches.
31981002	6	35	theme	sampling	1445:1452	arg1	points					1459:1464	different sampling time points	1435:1464	different sampling time points	1435:1464	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	2	36	theme	snout	428:432	arg1	bream					434:438	blunt snout bream	422:438	blunt snout bream	422:438	A full-length cDNA coding IRE1 was cloned from blunt snout bream by RT-PCR and RACE approaches.
31981002	4	37	theme	luminal	720:726	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	37	theme	luminal	720:726	arg1	domain					728:733	one luminal domain	716:733	one luminal domain	716:733	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	38	theme	kappa	1305:1309	arg1	B					1311:1311	nuclear factor kappa B	1290:1311	nuclear factor kappa B (NF-κB)	1290:1319	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	38	theme	kappa	1305:1309	arg1	NF-κB					1314:1318	NF-κB	1314:1318	NF-κB	1314:1318	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	1	39	theme	IRE1	276:279	arg1	cDNA					268:271	the full-length cDNA	252:271	the full-length cDNA of IRE1 from fish Megalobrama amblycephala	252:314	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	6	40	theme	nuclear	1290:1296	arg1	B					1311:1311	nuclear factor kappa B	1290:1311	nuclear factor kappa B (NF-κB)	1290:1319	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	40	theme	nuclear	1290:1296	arg1	NF-κB					1314:1318	NF-κB	1314:1318	NF-κB	1314:1318	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	1	41	theme	fish	286:289	arg1	amblycephala					303:314	fish Megalobrama amblycephala	286:314	fish Megalobrama amblycephala	286:314	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	0	42	theme	inositol-requiring	53:70	arg1	IRE1					82:85	IRE1	82:85	IRE1	82:85	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	0	42	theme	inositol-requiring	53:70	arg1	enzyme					72:77	inositol-requiring enzyme 1	53:79	inositol-requiring enzyme 1 (IRE1)	53:86	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	7	43	theme	bony	1718:1721	arg1	species					1728:1734	several bony fish species	1710:1734	several bony fish species	1710:1734	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	5	44	dep	liver	1037:1041	arg1	the					1033:1035	the	1033:1035	the	1033:1035	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	6	45	theme	factor	1337:1342	arg1	alpha					1344:1348	tumor necrosis factor alpha	1322:1348	tumor necrosis factor alpha (TNFα)	1322:1355	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	45	theme	factor	1337:1342	arg1	TNFα					1351:1354	TNFα	1351:1354	TNFα	1351:1354	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	7	46	theme	amblycephala	1630:1641	arg1	gene					1610:1613	the IRE1 gene	1601:1613	the IRE1 gene of Megalobrama amblycephala	1601:1641	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	8	47	from	expression	1741:1750	arg1	tissues					1761:1767	three tissues	1755:1767	three tissues	1755:1767	Its expression in three tissues was induced remarkably by the LPS challenge, which indicated that IRE1 played a vital role in LPS-induced inflammation on fish.
31981002	1	48	from	amblycephala	303:314	arg1	cDNA					268:271	the full-length cDNA	252:271	the full-length cDNA of IRE1 from fish Megalobrama amblycephala	252:314	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	6	49	theme	tumor	1322:1326	arg1	alpha					1344:1348	tumor necrosis factor alpha	1322:1348	tumor necrosis factor alpha (TNFα)	1322:1355	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	49	theme	tumor	1322:1326	arg1	TNFα					1351:1354	TNFα	1351:1354	TNFα	1351:1354	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	4	50	theme	N-linked	815:822	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	50	theme	N-linked	815:822	arg1	sites					838:842	two N-linked glycosylation sites	811:842	two N-linked glycosylation sites	811:842	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	0	51	theme	inflammatory	166:177	arg1	response					179:186	inflammatory response	166:186	inflammatory response induced by lipopolysaccharide	166:216	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	7	52	theme	IRE1	1605:1608	arg1	gene					1610:1613	the IRE1 gene	1601:1613	the IRE1 gene of Megalobrama amblycephala	1601:1641	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	4	53	theme	Sequence	570:577	arg1	alignment					579:587	Sequence alignment	570:587	Sequence alignment	570:587	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	54	theme	inositol-requiring	1180:1197	arg1	enzyme					1199:1204	inositol-requiring enzyme 1	1180:1206	inositol-requiring enzyme 1 (IRE1)	1180:1213	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	54	theme	inositol-requiring	1180:1197	arg1	IRE1					1209:1212	IRE1	1209:1212	IRE1	1209:1212	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	3	55	theme	open	513:516	arg1	frame					526:530	an open reading frame	510:530	an open reading frame of 3096 bp encoding 1031 amino acids	510:567	The cDNA obtained covered 3665 bp with an open reading frame of 3096 bp encoding 1031 amino acids.
31981002	4	56	theme	activation	794:803	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	56	theme	activation	794:803	arg1	loop					805:808	one activation loop	790:808	one activation loop	790:808	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	57	theme	conservation	641:652	arg1	degree					631:636	a high degree	624:636	a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites	624:877	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	3	58	theme	3096 bp	535:541	arg1	frame					526:530	an open reading frame	510:530	an open reading frame of 3096 bp encoding 1031 amino acids	510:567	The cDNA obtained covered 3665 bp with an open reading frame of 3096 bp encoding 1031 amino acids.
31981002	6	59	theme	protein	1238:1244	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	60	from	points	1459:1464	arg1	brain					1426:1430	brain	1426:1430	brain	1426:1430	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	60	from	points	1459:1464	arg1	spleen					1415:1420	the spleen	1411:1420	the spleen	1411:1420	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	61	theme	X-box	1224:1228	arg1	protein					1238:1244	spliced X-box binding protein 1	1216:1246	spliced X-box binding protein 1 (XBP1s)	1216:1254	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	61	theme	X-box	1224:1228	arg1	XBP1s					1249:1253	XBP1s	1249:1253	XBP1s	1249:1253	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	62	theme	glucose-regulated	1142:1158	arg1	protein					1160:1166	glucose-regulated protein 78 (GRP78)	1142:1177	glucose-regulated protein 78 (GRP78)	1142:1177	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	5	63	theme	expression	998:1007	arg1	levels					1009:1014	relatively low expression levels	983:1014	relatively low expression levels	983:1014	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	64	theme	highest	884:890	arg1	expression					897:906	The highest IRE1 expression	880:906	The highest IRE1 expression	880:906	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	6	65	dep	increased	1387:1395	arg1	all					1383:1385	all	1383:1385	all	1383:1385	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	4	66	theme	phosphorylation	857:871	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	66	theme	phosphorylation	857:871	arg1	sites					873:877	several phosphorylation sites	849:877	several phosphorylation sites	849:877	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	8	67	theme	LPS	1799:1801	arg1	challenge					1803:1811	the LPS challenge	1795:1811	the LPS challenge	1795:1811	Its expression in three tissues was induced remarkably by the LPS challenge, which indicated that IRE1 played a vital role in LPS-induced inflammation on fish.
31981002	4	68	theme	high	626:629	arg1	degree					631:636	a high degree	624:636	a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites	624:877	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	69	theme	protein	1274:1280	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	0	70	from	characterization	10:25	arg1	amblycephala					122:133	amblycephala	122:133	amblycephala	122:133	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	0	70	from	characterization	10:25	arg1	bream					103:107	blunt snout bream	91:107	blunt snout bream (Megalobrama amblycephala)	91:134	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	4	71	theme	various	669:675	arg1	species					677:683	various species	669:683	various species	669:683	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	72	theme	C/EBP	1257:1261	arg1	protein					1274:1280	C/EBP homologous protein	1257:1280	C/EBP homologous protein (CHOP)	1257:1287	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	72	theme	C/EBP	1257:1261	arg1	CHOP					1283:1286	CHOP	1283:1286	CHOP	1283:1286	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	0	73	dep	bream	103:107	arg1	blunt					91:95	blunt	91:95	blunt	91:95	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	1	74	theme	pro-inflammatory	348:363	arg1	response					365:372	the pro-inflammatory response	344:372	the pro-inflammatory response	344:372	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	6	75	theme	C/EBP	1539:1543	arg1	protein					1556:1562	C/EBP homologous protein	1539:1562	C/EBP homologous protein	1539:1562	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	76	theme	time	1454:1457	arg1	points					1459:1464	different sampling time points	1435:1464	different sampling time points	1435:1464	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	8	77	from	inflammation	1875:1886	arg1	fish					1891:1894	fish	1891:1894	fish	1891:1894	Its expression in three tissues was induced remarkably by the LPS challenge, which indicated that IRE1 played a vital role in LPS-induced inflammation on fish.
31981002	0	78	theme	expression	31:40	arg1	pattern					42:48	expression pattern	31:48	expression pattern	31:48	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	6	79	theme	different	1435:1443	arg1	points					1459:1464	different sampling time points	1435:1464	different sampling time points	1435:1464	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	80	theme	factor	1298:1303	arg1	B					1311:1311	nuclear factor kappa B	1290:1311	nuclear factor kappa B (NF-κB)	1290:1319	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	80	theme	factor	1298:1303	arg1	NF-κB					1314:1318	NF-κB	1314:1318	NF-κB	1314:1318	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	7	81	theme	fish	1723:1726	arg1	species					1728:1734	several bony fish species	1710:1734	several bony fish species	1710:1734	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	4	82	theme	RNase	776:780	arg1	domain					782:787	one RNase domain	772:787	one RNase domain	772:787	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	82	theme	RNase	776:780	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	0	83	theme	enzyme	72:77	arg1	characterization					10:25	Molecular characterization	0:25	Molecular characterization	0:25	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	0	83	theme	enzyme	72:77	arg1	pattern					42:48	expression pattern	31:48	expression pattern	31:48	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	1	84	theme	Megalobrama	291:301	arg1	amblycephala					303:314	fish Megalobrama amblycephala	286:314	fish Megalobrama amblycephala	286:314	This study aimed to characterize the full-length cDNA of IRE1 from fish Megalobrama amblycephala and investigate its role in the pro-inflammatory response.
31981002	7	85	theme	several	1710:1716	arg1	species					1728:1734	several bony fish species	1710:1734	several bony fish species	1710:1734	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	8	86	theme	LPS-induced	1863:1873	arg1	inflammation					1875:1886	LPS-induced inflammation	1863:1886	LPS-induced inflammation on fish	1863:1894	Its expression in three tissues was induced remarkably by the LPS challenge, which indicated that IRE1 played a vital role in LPS-induced inflammation on fish.
31981002	7	87	theme	other	1682:1686	arg1	species					1728:1734	several bony fish species	1710:1734	several bony fish species	1710:1734	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	7	87	theme	other	1682:1686	arg1	vertebrates					1688:1698	other vertebrates	1682:1698	other vertebrates including several bony fish species	1682:1734	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	5	88	located	observed	912:919	arg2	expression					897:906	The highest IRE1 expression	880:906	The highest IRE1 expression	880:906	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	5	88	located	observed	912:919	arg1	kidney					934:939	the trunk kidney	924:939	the trunk kidney	924:939	The highest IRE1 expression was observed in the trunk kidney followed by the brain and spleen, whereas relatively low expression levels were detected in the liver, intestine, adipose, skin, and heart.
31981002	4	89	theme	phylogenetic	593:604	arg1	analysis					606:613	phylogenetic analysis	593:613	phylogenetic analysis	593:613	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	90	theme	kinase	757:762	arg1	peptide					707:713	one signal peptide	696:713	one signal peptide	696:713	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	4	90	theme	kinase	757:762	arg1	domain					764:769	one serine/threonine kinase domain	736:769	one serine/threonine kinase domain	736:769	Sequence alignment and phylogenetic analysis revealed a high degree of conservation (74-92%) among various species, retaining one signal peptide, one luminal domain, one serine/threonine kinase domain, one RNase domain, one activation loop, two N-linked glycosylation sites, and several phosphorylation sites.
31981002	6	91	theme	alpha	1344:1348	arg1	expressions					1127:1137	the expressions	1123:1137	the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6)	1123:1381	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	0	92	dep	characterization	10:25	arg1	role					141:144	its role	137:144	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.	0:217	Molecular characterization and expression pattern of inositol-requiring enzyme 1 (IRE1) in blunt snout bream (Megalobrama amblycephala): its role of IRE1 involved in inflammatory response induced by lipopolysaccharide.
31981002	7	93	theme	high	1652:1655	arg1	similarity					1657:1666	a high similarity	1650:1666	a high similarity	1650:1666	Overall, the results indicated that the IRE1 gene of Megalobrama amblycephala shared a high similarity compared with other vertebrates including several bony fish species.
31981002	6	94	theme	necrosis	1328:1335	arg1	alpha					1344:1348	tumor necrosis factor alpha	1322:1348	tumor necrosis factor alpha (TNFα)	1322:1355	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
31981002	6	94	theme	necrosis	1328:1335	arg1	TNFα					1351:1354	TNFα	1351:1354	TNFα	1351:1354	After lipopolysaccharide (LPS) challenge, the expressions of glucose-regulated protein 78 (GRP78), inositol-requiring enzyme 1 (IRE1), spliced X-box binding protein 1 (XBP1s), C/EBP homologous protein (CHOP), nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) all increased remarkably in the spleen and brain at different sampling time points, while LPS also upregulated all the genes tested in the intestine except C/EBP homologous protein.
32357974	9	0	theme	bound	1712:1716	arg1	asparagine					1718:1727	HLA-I bound asparagine	1706:1727	HLA-I bound asparagine deamidated peptides	1706:1747	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	7	1	theme	Chemical	1314:1321	arg1	inhibition					1323:1332	Chemical inhibition	1314:1332	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins,	1314:1476	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	10	2	gly	glycoprotein	2061:2072	arg1	glycoprotein					2061:2072	glycoprotein antigens	2061:2081	glycoprotein antigens	2061:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	1	3	theme	surveilling	275:285	arg1	cells					289:293	surveilling T cells	275:293	surveilling T cells	275:293	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	9	4	theme	deamidated	1729:1738	arg1	peptides					1740:1747	HLA-I bound asparagine deamidated peptides	1706:1747	HLA-I bound asparagine deamidated peptides	1706:1747	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	2	5	theme	immunopeptidomics	305:321	arg1	studies					323:329	immunopeptidomics studies	305:329	immunopeptidomics studies	305:329	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	8	6	contain	containing	1626:1635	arg1	peptides					1613:1620	peptides	1613:1620	peptides not containing a consensus NX(S/T) motif	1613:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	8	6	contain	containing	1626:1635	arg2	motif					1657:1661	a consensus NX(S/T) motif	1637:1661	a consensus NX(S/T) motif	1637:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	10	7	theme	therapeutic	2028:2038	arg1	targets					2040:2046	novel T cell therapeutic targets	2015:2046	novel T cell therapeutic targets derived from glycoprotein antigens	2015:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	1	8	theme	HLA	202:204	arg1	molecules					206:214	cell surface HLA molecules	189:214	cell surface HLA molecules	189:214	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	7	9	theme	peptides	1546:1553	arg1	subset					1515:1520	this subset	1510:1520	this subset of deamidated HLA-bound peptides	1510:1553	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	2	10	from	lines	392:396	arg1	analyses					427:434	in-depth analyses	418:434	in-depth analyses of the proportion	418:452	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	10	from	lines	392:396	arg1	thousands					350:358	thousands	350:358	thousands of HLA-bound peptides from cell lines and tissue samples	350:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	10	from	lines	392:396	arg1	peptides					373:380	HLA-bound peptides	363:380	HLA-bound peptides from cell lines and tissue samples	363:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	10	from	lines	392:396	arg1	nature					458:463	nature	458:463	nature of peptides bearing one or more PTMs	458:500	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	9	11	gly	deglycosylation	1819:1833	arg1	proteins					1790:1797	formerly glycosylated proteins	1768:1797	formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway	1768:1890	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	5	12	theme	N-linked	930:937	arg1	abundant					978:985	abundant	978:985	abundant	978:985	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	5	12	theme	N-linked	930:937	arg1	motif					953:957	the N-linked glycosylation motif NX(S/T)	926:965	the N-linked glycosylation motif NX(S/T)	926:965	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	9	13	theme	glycosylated	1777:1788	arg1	proteins					1790:1797	formerly glycosylated proteins	1768:1797	formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway	1768:1890	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	10	14	theme	glycoprotein	2061:2072	arg1	antigens					2074:2081	glycoprotein antigens	2061:2081	glycoprotein antigens	2061:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	3	15	theme	spectrometry-detected	630:650	arg1	PTMs					652:655	mass spectrometry-detected PTMs	625:655	mass spectrometry-detected PTMs	625:655	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	6	16	theme	HLA-ligand	1291:1300	arg1	precursors					1302:1311	HLA-ligand precursors	1291:1311	HLA-ligand precursors	1291:1311	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	1	17	theme	modified	162:169	arg1	peptides					177:184	post-translationally modified (PTM) peptides	141:184	post-translationally modified (PTM) peptides	141:184	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	1	17	theme	modified	162:169	arg1	PTM					172:174	PTM	172:174	PTM	172:174	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	10	18	theme	deamidation	1932:1942	arg1	models					1955:1960	deamidation prediction models	1932:1960	deamidation prediction models for HLA-peptide repertoires	1932:1988	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	9	19	theme	ER-associated	1843:1855	arg1	degradation					1865:1875	ER-associated protein degradation	1843:1875	the ER-associated protein degradation (ERAD) pathway	1839:1890	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	9	19	theme	ER-associated	1843:1855	arg1	ERAD					1878:1881	ERAD	1878:1881	ERAD	1878:1881	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	1	20	theme	peptides	177:184	arg1	presentation					125:136	The presentation	121:136	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules	121:214	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	9	21	theme	degradation	1865:1875	arg1	pathway					1884:1890	the ER-associated protein degradation (ERAD) pathway	1839:1890	the ER-associated protein degradation (ERAD) pathway	1839:1890	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	4	22	theme	asparagine	740:749	arg1	deamidation					751:761	asparagine deamidation	740:761	asparagine deamidation	740:761	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	0	23	theme	Deglycosylated	94:107	arg1	Precursors					109:118	Deglycosylated Precursors	94:118	Deglycosylated Precursors	94:118	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.
32357974	1	24	theme	cell	189:192	arg1	molecules					206:214	cell surface HLA molecules	189:214	cell surface HLA molecules	189:214	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	8	25	theme	PNGase	1592:1597	arg1	inhibition					1599:1608	PNGase inhibition	1592:1608	PNGase inhibition	1592:1608	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	7	26	dep	Peptide	1337:1343	arg1	N-Glycanase					1345:1355	N-Glycanase	1345:1355	N-Glycanase (PNGase)	1345:1364	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	7	26	dep	Peptide	1337:1343	arg1	PNGase					1358:1363	PNGase	1358:1363	PNGase	1358:1363	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	7	27	theme	deamidated	1525:1534	arg1	peptides					1546:1553	deamidated HLA-bound peptides	1525:1553	deamidated HLA-bound peptides	1525:1553	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	10	28	attach	derived	2048:2054	arg1	antigens					2074:2081	glycoprotein antigens	2061:2081	glycoprotein antigens	2061:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	10	28	attach	derived	2048:2054	arg2	targets					2040:2046	novel T cell therapeutic targets	2015:2046	novel T cell therapeutic targets derived from glycoprotein antigens	2015:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	5	29	link	N-linked	930:937	arg1	abundant					978:985	abundant	978:985	abundant	978:985	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	5	29	link	N-linked	930:937	arg1	motif					953:957	the N-linked glycosylation motif NX(S/T)	926:965	the N-linked glycosylation motif NX(S/T)	926:965	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	2	30	theme	in-depth	418:425	arg1	analyses					427:434	in-depth analyses	418:434	in-depth analyses of the proportion	418:452	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	0	31	theme	Immunopeptidomic	0:15	arg1	Analysis					17:24	Immunopeptidomic Analysis	0:24	Immunopeptidomic Analysis	0:24	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.
32357974	4	32	dep	arise	767:771	arg1	reaction					815:822	enzymatic reaction	805:822	enzymatic reaction	805:822	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	4	32	dep	arise	767:771	arg1	either					773:778	either	773:778	either	773:778	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	10	33	theme	HLA-peptide	1966:1976	arg1	repertoires					1978:1988	HLA-peptide repertoires	1966:1988	HLA-peptide repertoires	1966:1988	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	2	34	theme	peptides	468:475	arg1	analyses					427:434	in-depth analyses	418:434	in-depth analyses of the proportion	418:452	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	34	theme	peptides	468:475	arg1	thousands					350:358	thousands	350:358	thousands of HLA-bound peptides from cell lines and tissue samples	350:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	34	theme	peptides	468:475	arg1	nature					458:463	nature	458:463	nature of peptides bearing one or more PTMs	458:500	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	4	35	theme	enzymatic	805:813	arg1	reaction					815:822	enzymatic reaction	805:822	enzymatic reaction	805:822	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	8	36	from	impact	1582:1587	arg1	peptides					1613:1620	peptides	1613:1620	peptides not containing a consensus NX(S/T) motif	1613:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	5	37	theme	HLA-bound	1016:1024	arg1	peptides					1026:1033	asparagine-deamidated HLA-bound peptides	994:1033	asparagine-deamidated HLA-bound peptides	994:1033	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	7	38	from	glycoproteins	1463:1475	arg1	removal					1407:1413	the removal	1403:1413	the removal of glycans from misfolded and retrotranslocated glycoproteins	1403:1475	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	6	39	theme	epitopes	1109:1116	arg1	handful					1080:1086	a handful	1078:1086	a handful of deamidated T cell epitopes	1078:1116	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	8	40	theme	NX	1649:1650	arg1	motif					1657:1661	a consensus NX(S/T) motif	1637:1661	a consensus NX(S/T) motif	1637:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	3	41	theme	glutamine	695:703	arg1	deamidation					666:676	deamidation	666:676	deamidation of asparagine or glutamine	666:703	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	2	42	theme	proportion	443:452	arg1	analyses					427:434	in-depth analyses	418:434	in-depth analyses of the proportion	418:452	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	42	theme	proportion	443:452	arg1	thousands					350:358	thousands	350:358	thousands of HLA-bound peptides from cell lines and tissue samples	350:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	42	theme	proportion	443:452	arg1	nature					458:463	nature	458:463	nature of peptides bearing one or more PTMs	458:500	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	0	43	theme	Deamidated	39:48	arg1	Peptides					60:67	Deamidated HLA-bound Peptides	39:67	Deamidated HLA-bound Peptides	39:67	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.
32357974	6	44	theme	T	1102:1102	arg1	epitopes					1109:1116	deamidated T cell epitopes	1091:1116	deamidated T cell epitopes	1091:1116	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	8	45	theme	S/T	1652:1654	arg1	motif					1657:1661	a consensus NX(S/T) motif	1637:1661	a consensus NX(S/T) motif	1637:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	3	46	theme	asparagine	681:690	arg1	deamidation					666:676	deamidation	666:676	deamidation of asparagine or glutamine	666:703	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	6	47	from	transport	1168:1176	arg1	ER					1228:1229	the ER	1224:1229	the ER	1224:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	2	48	theme	cell	387:390	arg1	lines					392:396	cell lines	387:396	cell lines	387:396	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	49	theme	peptides	373:380	arg1	analyses					427:434	in-depth analyses	418:434	in-depth analyses of the proportion	418:452	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	49	theme	peptides	373:380	arg1	thousands					350:358	thousands	350:358	thousands of HLA-bound peptides from cell lines and tissue samples	350:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	49	theme	peptides	373:380	arg1	nature					458:463	nature	458:463	nature of peptides bearing one or more PTMs	458:500	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	3	50	theme	HLA-bound	545:553	arg1	peptides					555:562	HLA-bound peptides	545:562	HLA-bound peptides from a variety of allotypes	545:590	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	9	51	theme	HLA-I	1706:1710	arg1	asparagine					1718:1727	HLA-I bound asparagine	1706:1727	HLA-I bound asparagine deamidated peptides	1706:1747	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	2	52	from	nature	458:463	arg1	lines					392:396	cell lines	387:396	cell lines	387:396	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	52	from	nature	458:463	arg1	samples					409:415	tissue samples	402:415	tissue samples	402:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	7	53	theme	Peptide	1337:1343	arg1	inhibition					1323:1332	Chemical inhibition	1314:1332	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins,	1314:1476	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	10	54	theme	novel	2015:2019	arg1	targets					2040:2046	novel T cell therapeutic targets	2015:2046	novel T cell therapeutic targets derived from glycoprotein antigens	2015:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	9	55	theme	asparagine	1718:1727	arg1	peptides					1740:1747	HLA-I bound asparagine deamidated peptides	1706:1747	HLA-I bound asparagine deamidated peptides	1706:1747	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	1	56	theme	T	287:287	arg1	cells					289:293	surveilling T cells	275:293	surveilling T cells	275:293	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	9	57	theme	peptides	1740:1747	arg1	proportion					1692:1701	a large proportion	1684:1701	a large proportion of HLA-I bound asparagine deamidated peptides	1684:1747	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	6	58	theme	subsequent	1241:1250	arg1	degradation					1252:1262	their subsequent degradation	1235:1262	their subsequent degradation within the cytosol to form HLA-ligand precursors	1235:1311	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	10	59	theme	targets	2040:2046	arg1	design					2005:2010	the design	2001:2010	the design of novel T cell therapeutic targets derived from glycoprotein antigens	2001:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	9	60	gly	glycosylated	1777:1788	arg1	proteins					1790:1797	formerly glycosylated proteins	1768:1797	formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway	1768:1890	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	1	61	theme	surface	194:200	arg1	molecules					206:214	cell surface HLA molecules	189:214	cell surface HLA molecules	189:214	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	7	62	theme	HLA-bound	1536:1544	arg1	peptides					1546:1553	deamidated HLA-bound peptides	1525:1553	deamidated HLA-bound peptides	1525:1553	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	7	63	theme	subset	1515:1520	arg1	presentation					1494:1505	presentation	1494:1505	presentation of this subset of deamidated HLA-bound peptides	1494:1553	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	10	64	theme	cell	2023:2026	arg1	targets					2040:2046	novel T cell therapeutic targets	2015:2046	novel T cell therapeutic targets derived from glycoprotein antigens	2015:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	2	65	from	samples	409:415	arg1	analyses					427:434	in-depth analyses	418:434	in-depth analyses of the proportion	418:452	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	65	from	samples	409:415	arg1	thousands					350:358	thousands	350:358	thousands of HLA-bound peptides from cell lines and tissue samples	350:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	65	from	samples	409:415	arg1	peptides					373:380	HLA-bound peptides	363:380	HLA-bound peptides from cell lines and tissue samples	363:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	65	from	samples	409:415	arg1	nature					458:463	nature	458:463	nature of peptides bearing one or more PTMs	458:500	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	3	66	theme	allotypes	582:590	arg1	variety					571:577	a variety	569:577	a variety of allotypes	569:590	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	3	66	theme	allotypes	582:590	arg1	allotypes					582:590	allotypes	582:590	allotypes	582:590	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	6	67	theme	polypeptides	1206:1217	arg1	transport					1168:1176	the retrograde transport	1153:1176	the retrograde transport of nascently N-glycosylated polypeptides from the ER	1153:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	6	67	theme	polypeptides	1206:1217	arg1	degradation					1252:1262	their subsequent degradation	1235:1262	their subsequent degradation within the cytosol to form HLA-ligand precursors	1235:1311	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	3	68	theme	mass	625:628	arg1	PTMs					652:655	mass spectrometry-detected PTMs	625:655	mass spectrometry-detected PTMs	625:655	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	7	69	gly	glycoproteins	1463:1475	arg1	glycoproteins					1463:1475	misfolded and retrotranslocated glycoproteins	1431:1475	misfolded and retrotranslocated glycoproteins	1431:1475	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	5	70	gly	glycosylation	939:951	arg2	abundant					978:985	abundant	978:985	abundant	978:985	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	5	70	gly	glycosylation	939:951	arg2	motif					953:957	the N-linked glycosylation motif NX(S/T)	926:965	the N-linked glycosylation motif NX(S/T)	926:965	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	7	71	theme	retrotranslocated	1445:1461	arg1	glycoproteins					1463:1475	misfolded and retrotranslocated glycoproteins	1431:1475	misfolded and retrotranslocated glycoproteins	1431:1475	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	10	72	theme	prediction	1944:1953	arg1	models					1955:1960	deamidation prediction models	1932:1960	deamidation prediction models for HLA-peptide repertoires	1932:1988	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	6	73	theme	deamidated	1091:1100	arg1	epitopes					1109:1116	deamidated T cell epitopes	1091:1116	deamidated T cell epitopes	1091:1116	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	7	74	theme	misfolded	1431:1439	arg1	glycoproteins					1463:1475	misfolded and retrotranslocated glycoproteins	1431:1475	misfolded and retrotranslocated glycoproteins	1431:1475	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	3	75	theme	PTMs	652:655	arg1	distribution					609:620	the distribution	605:620	the distribution of mass spectrometry-detected PTMs	605:655	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	5	76	theme	glycosylation	939:951	arg1	abundant					978:985	abundant	978:985	abundant	978:985	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	5	76	theme	glycosylation	939:951	arg1	motif					953:957	the N-linked glycosylation motif NX(S/T)	926:965	the N-linked glycosylation motif NX(S/T)	926:965	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	9	77	theme	protein	1857:1863	arg1	degradation					1865:1875	ER-associated protein degradation	1843:1875	the ER-associated protein degradation (ERAD) pathway	1839:1890	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	9	77	theme	protein	1857:1863	arg1	ERAD					1878:1881	ERAD	1878:1881	ERAD	1878:1881	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	7	78	theme	glycans	1418:1424	arg1	removal					1407:1413	the removal	1403:1413	the removal of glycans from misfolded and retrotranslocated glycoproteins	1403:1475	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	8	79	theme	inhibition	1599:1608	arg1	impact					1582:1587	no impact	1579:1587	no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif	1579:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	3	80	from	variety	571:577	arg1	peptides					555:562	HLA-bound peptides	545:562	HLA-bound peptides from a variety of allotypes	545:590	Here we have analyzed HLA-bound peptides from a variety of allotypes and assessed the distribution of mass spectrometry-detected PTMs, finding deamidation of asparagine or glutamine to be highly prevalent.
32357974	2	81	from	thousands	350:358	arg1	lines					392:396	cell lines	387:396	cell lines	387:396	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	81	from	thousands	350:358	arg1	samples					409:415	tissue samples	402:415	tissue samples	402:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	0	82	gly	Deglycosylated	94:107	arg1	Precursors					109:118	Deglycosylated Precursors	94:118	Deglycosylated Precursors	94:118	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.
32357974	6	83	theme	global	1137:1142	arg1	role					1144:1147	a more global role	1130:1147	a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors	1130:1311	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	6	84	gly	N-glycosylated	1191:1204	arg1	polypeptides					1206:1217	nascently N-glycosylated polypeptides	1181:1217	nascently N-glycosylated polypeptides from the ER	1181:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	6	85	from	degradation	1252:1262	arg1	ER					1228:1229	the ER	1224:1229	the ER	1224:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	4	86	dep	either	773:778	arg1	spontaneously					780:792	spontaneously	780:792	spontaneously	780:792	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	7	87	theme	responsible	1387:1397	arg1	endoglycosidase					1371:1385	the endoglycosidase	1367:1385	the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins	1367:1475	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	7	87	theme	responsible	1387:1397	arg1	Peptide					1337:1343	Peptide	1337:1343	Peptide	1337:1343	Chemical inhibition of Peptide:N-Glycanase (PNGase), the endoglycosidase responsible for the removal of glycans from misfolded and retrotranslocated glycoproteins, greatly reduced presentation of this subset of deamidated HLA-bound peptides.
32357974	8	88	theme	consensus	1639:1647	arg1	motif					1657:1661	a consensus NX(S/T) motif	1637:1661	a consensus NX(S/T) motif	1637:1661	Importantly, there was no impact of PNGase inhibition on peptides not containing a consensus NX(S/T) motif.
32357974	5	89	theme	asparagine-deamidated	994:1014	arg1	peptides					1026:1033	asparagine-deamidated HLA-bound peptides	994:1033	asparagine-deamidated HLA-bound peptides	994:1033	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	1	90	contain	has	216:218	arg2	potential					224:232	the potential to increase the diversity of targets for surveilling T cells	220:293	the potential to increase the diversity of targets for surveilling T cells	220:293	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	1	90	contain	has	216:218	arg1	presentation					125:136	The presentation	121:136	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules	121:214	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32357974	5	91	dep	motif	953:957	arg1	NX					959:960	NX	959:960	the N-linked glycosylation motif NX(S/T)	926:965	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	5	91	dep	motif	953:957	arg1	S/T					962:964	S/T	962:964	S/T	962:964	Notably, we found that the N-linked glycosylation motif NX(S/T) was highly abundant across asparagine-deamidated HLA-bound peptides.
32357974	6	92	from	ER	1228:1229	arg1	polypeptides					1206:1217	nascently N-glycosylated polypeptides	1181:1217	nascently N-glycosylated polypeptides from the ER	1181:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	6	92	from	ER	1228:1229	arg1	transport					1168:1176	the retrograde transport	1153:1176	the retrograde transport of nascently N-glycosylated polypeptides from the ER	1153:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	6	92	from	ER	1228:1229	arg1	degradation					1252:1262	their subsequent degradation	1235:1262	their subsequent degradation within the cytosol to form HLA-ligand precursors	1235:1311	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	0	93	theme	HLA-bound	50:58	arg1	Peptides					60:67	Deamidated HLA-bound Peptides	39:67	Deamidated HLA-bound Peptides	39:67	Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.
32357974	6	94	theme	cell	1104:1107	arg1	epitopes					1109:1116	deamidated T cell epitopes	1091:1116	deamidated T cell epitopes	1091:1116	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	6	95	theme	N-glycosylated	1191:1204	arg1	polypeptides					1206:1217	nascently N-glycosylated polypeptides	1181:1217	nascently N-glycosylated polypeptides from the ER	1181:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	4	96	theme	modified	884:891	arg1	residues					893:900	the modified residues	880:900	the modified residues	880:900	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	9	97	theme	large	1686:1690	arg1	proportion					1692:1701	a large proportion	1684:1701	a large proportion of HLA-I bound asparagine deamidated peptides	1684:1747	This indicates that a large proportion of HLA-I bound asparagine deamidated peptides are generated from formerly glycosylated proteins that have undergone deglycosylation via the ER-associated protein degradation (ERAD) pathway.
32357974	2	98	from	analyses	427:434	arg1	lines					392:396	cell lines	387:396	cell lines	387:396	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	2	98	from	analyses	427:434	arg1	samples					409:415	tissue samples	402:415	tissue samples	402:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	4	99	theme	allele-specific	837:851	arg1	motifs					864:869	allele-specific and global motifs	837:869	allele-specific and global motifs flanking the modified residues	837:900	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	2	100	theme	HLA-bound	363:371	arg1	peptides					373:380	HLA-bound peptides	363:380	HLA-bound peptides from cell lines and tissue samples	363:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	6	101	theme	retrograde	1157:1166	arg1	transport					1168:1176	the retrograde transport	1153:1176	the retrograde transport of nascently N-glycosylated polypeptides from the ER	1153:1229	This finding, demonstrated previously for a handful of deamidated T cell epitopes, implicates a more global role for the retrograde transport of nascently N-glycosylated polypeptides from the ER and their subsequent degradation within the cytosol to form HLA-ligand precursors.
32357974	10	102	theme	T	2021:2021	arg1	targets					2040:2046	novel T cell therapeutic targets	2015:2046	novel T cell therapeutic targets derived from glycoprotein antigens	2015:2081	The information herein will help train deamidation prediction models for HLA-peptide repertoires and aid in the design of novel T cell therapeutic targets derived from glycoprotein antigens.
32357974	4	103	theme	global	857:862	arg1	motifs					864:869	allele-specific and global motifs	837:869	allele-specific and global motifs flanking the modified residues	837:900	Given that asparagine deamidation may arise either spontaneously or through enzymatic reaction, we assessed allele-specific and global motifs flanking the modified residues.
32357974	2	104	theme	tissue	402:407	arg1	samples					409:415	tissue samples	402:415	tissue samples	402:415	Although immunopeptidomics studies routinely identify thousands of HLA-bound peptides from cell lines and tissue samples, in-depth analyses of the proportion and nature of peptides bearing one or more PTMs remains challenging.
32357974	1	105	theme	targets	263:269	arg1	diversity					250:258	the diversity	246:258	the diversity of targets for surveilling T cells	246:293	The presentation of post-translationally modified (PTM) peptides by cell surface HLA molecules has the potential to increase the diversity of targets for surveilling T cells.
32341520	8	0	theme	tumor	1177:1181	arg1	progression					1183:1193	morphological tumor progression	1163:1193	morphological tumor progression	1163:1193	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	6	1	theme	N-glycan	806:813	arg1	profiles					815:822	the N-glycan profiles	802:822	the N-glycan profiles	802:822	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	2	2	theme	pathognomonic	251:263	arg1	FUS-DDIT3					265:273	a pathognomonic FUS-DDIT3	249:273	a pathognomonic FUS-DDIT3	249:273	MLS is characterized by a pathognomonic FUS-DDIT3, or rarely EWSR1-DDIT3, gene fusion.
32341520	8	3	theme	tumor	1209:1213	arg1	grade					1228:1232	increased tumor histological grade	1199:1232	increased tumor histological grade	1199:1232	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	5	4	theme	laser	595:599	arg1	spectrometry					628:639	matrix-assisted laser desorption/ionization mass spectrometry	579:639	matrix-assisted laser desorption/ionization mass spectrometry imaging	579:647	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	9	5	theme	high	1239:1242	arg1	abundance					1244:1252	The high abundance	1235:1252	The high abundance of tri-antennary N-glycan species	1235:1286	The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival.
32341520	6	6	theme	type	884:887	arg1	glycans					889:895	high-mannose type glycans	871:895	high-mannose type glycans	871:895	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	5	7	theme	mass	623:626	arg1	spectrometry					628:639	matrix-assisted laser desorption/ionization mass spectrometry	579:639	matrix-assisted laser desorption/ionization mass spectrometry imaging	579:647	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	1	8	theme	liposarcoma	176:186	arg1	liposarcoma					121:131	Myxoid liposarcoma	114:131	Myxoid liposarcoma (MLS)	114:137	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	8	theme	liposarcoma	176:186	arg1	subtype					165:171	the second most common subtype	142:171	the second most common subtype of liposarcoma	142:186	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	7	9	from	glycans	1014:1020	arg1	increase					955:962	an increase	952:962	an increase of the average number of mannoses on high-mannose glycans	952:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	5	10	theme	glycans	697:703	arg1	distribution					672:683	the spatial distribution	660:683	the spatial distribution of N-linked glycans on an MLS microarray	660:724	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	9	11	theme	N-glycan	1271:1278	arg1	species					1280:1286	tri-antennary N-glycan species	1257:1286	tri-antennary N-glycan species	1257:1286	The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival.
32341520	1	12	theme	~6	204:205	arg1	%					206:206	~6%	204:206	~6% of all sarcomas	204:222	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	12	theme	~6	204:205	arg1	sarcomas					215:222	all sarcomas	211:222	all sarcomas	211:222	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	5	13	theme	spatial	664:670	arg1	distribution					672:683	the spatial distribution	660:683	the spatial distribution of N-linked glycans on an MLS microarray	660:724	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	9	14	theme	poor	1313:1316	arg1	survival					1335:1342	poor disease-specific survival	1313:1342	poor disease-specific survival	1313:1342	The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival.
32341520	0	15	theme	N-glycan	78:85	arg1	spectrometry					92:103	N-glycan mass spectrometry	78:103	N-glycan mass spectrometry imaging	78:111	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	7	16	theme	average	971:977	arg1	number					979:984	the average number	967:984	the average number of mannoses on high-mannose glycans	967:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	8	17	theme	complex-type	1063:1074	arg1	glycans					1076:1082	complex-type glycans	1063:1082	complex-type glycans	1063:1082	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	10	18	with	line	1475:1478	arg1	role					1495:1498	a general role	1485:1498	a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression	1485:1586	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	3	19	theme	round	346:350	arg1	areas					357:361	≥5% hypercellular round cell areas	328:361	≥5% hypercellular round cell areas	328:361	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	10	20	theme	high-mannose	1503:1514	arg1	glycans					1516:1522	high-mannose glycans	1503:1522	high-mannose glycans	1503:1522	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	0	21	theme	Molecular	0:8	arg1	signatures					10:19	Molecular signatures	0:19	Molecular signatures of tumor progression in myxoid liposarcoma	0:62	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	3	22	theme	%	330:330	arg1	areas					357:361	≥5% hypercellular round cell areas	328:361	≥5% hypercellular round cell areas	328:361	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	6	23	theme	high-mannose	871:882	arg1	glycans					889:895	high-mannose type glycans	871:895	high-mannose type glycans	871:895	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	1	24	theme	Myxoid	114:119	arg1	MLS					134:136	MLS	134:136	MLS	134:136	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	24	theme	Myxoid	114:119	arg1	liposarcoma					121:131	Myxoid liposarcoma	114:131	Myxoid liposarcoma (MLS)	114:137	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	24	theme	Myxoid	114:119	arg1	subtype					165:171	the second most common subtype	142:171	the second most common subtype of liposarcoma	142:186	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	10	25	theme	complex-type	1545:1556	arg1	glycans					1558:1564	higher-antennary complex-type glycans	1528:1564	higher-antennary complex-type glycans	1528:1564	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	0	26	theme	progression	30:40	arg1	signatures					10:19	Molecular signatures	0:19	Molecular signatures of tumor progression in myxoid liposarcoma	0:62	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	5	27	theme	tumor	769:773	arg1	progression					775:785	tumor progression	769:785	tumor progression	769:785	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	3	28	theme	areas	357:361	arg1	presence					316:323	The presence	312:323	The presence of ≥5% hypercellular round cell areas	312:361	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	4	29	theme	areas	477:481	arg1	unknown					549:555	unknown	549:555	unknown	549:555	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	4	29	theme	areas	477:481	arg1	significance					461:472	The prognostic significance	446:472	The prognostic significance of areas with moderately increased cellularity (intermediate)	446:534	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	0	30	theme	myxoid	45:50	arg1	liposarcoma					52:62	myxoid liposarcoma	45:62	myxoid liposarcoma	45:62	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	6	31	theme	increased	838:846	arg1	abundances					857:866	increased relative abundances	838:866	increased relative abundances of high-mannose type glycans	838:895	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	10	32	theme	colorectal	1390:1399	arg1	cancer					1401:1406	colorectal cancer	1390:1406	colorectal cancer	1390:1406	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	2	33	theme	gene	299:302	arg1	fusion					304:309	gene fusion	299:309	gene fusion	299:309	MLS is characterized by a pathognomonic FUS-DDIT3, or rarely EWSR1-DDIT3, gene fusion.
32341520	5	34	from	distribution	672:683	arg1	microarray					715:724	an MLS microarray	708:724	an MLS microarray	708:724	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	8	35	theme	N-glycans	1135:1143	arg1	increase					1098:1105	an increase	1095:1105	an increase of tri- and tetra-antennary N-glycans	1095:1143	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	10	36	theme	ovarian	1424:1430	arg1	cancer					1432:1437	ovarian cancer	1424:1437	ovarian cancer	1424:1437	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	5	37	theme	molecular	747:755	arg1	markers					757:763	molecular markers	747:763	molecular markers for tumor progression	747:785	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	5	38	theme	spectrometry	628:639	arg1	imaging					641:647	matrix-assisted laser desorption/ionization mass spectrometry imaging	579:647	matrix-assisted laser desorption/ionization mass spectrometry imaging	579:647	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	5	39	link	N-linked	688:695	arg1	glycans					697:703	N-linked glycans	688:703	N-linked glycans	688:703	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	8	40	theme	morphological	1163:1175	arg1	progression					1183:1193	morphological tumor progression	1163:1193	morphological tumor progression	1163:1193	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	6	41	theme	tumor	918:922	arg1	progression					924:934	tumor progression	918:934	tumor progression	918:934	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	5	42	theme	matrix-assisted	579:593	arg1	spectrometry					628:639	matrix-assisted laser desorption/ionization mass spectrometry	579:639	matrix-assisted laser desorption/ionization mass spectrometry imaging	579:647	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	1	43	theme	common	158:163	arg1	liposarcoma					121:131	Myxoid liposarcoma	114:131	Myxoid liposarcoma (MLS)	114:137	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	43	theme	common	158:163	arg1	subtype					165:171	the second most common subtype	142:171	the second most common subtype of liposarcoma	142:186	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	8	44	theme	increased	1199:1207	arg1	grade					1228:1232	increased tumor histological grade	1199:1232	increased tumor histological grade	1199:1232	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	6	45	theme	glycans	889:895	arg1	abundances					857:866	increased relative abundances	838:866	increased relative abundances of high-mannose type glycans	838:895	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	5	46	theme	desorption/ionization	601:621	arg1	spectrometry					628:639	matrix-assisted laser desorption/ionization mass spectrometry	579:639	matrix-assisted laser desorption/ionization mass spectrometry imaging	579:647	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	8	47	theme	histological	1215:1226	arg1	grade					1228:1232	increased tumor histological grade	1199:1232	increased tumor histological grade	1199:1232	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	5	48	theme	N-linked	688:695	arg1	glycans					697:703	N-linked glycans	688:703	N-linked glycans	688:703	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	9	49	theme	tri-antennary	1257:1269	arg1	species					1280:1286	tri-antennary N-glycan species	1257:1286	tri-antennary N-glycan species	1257:1286	The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival.
32341520	10	50	from	role	1495:1498	arg1	progression					1576:1586	cancer progression	1569:1586	cancer progression	1569:1586	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	9	51	theme	species	1280:1286	arg1	abundance					1244:1252	The high abundance	1235:1252	The high abundance of tri-antennary N-glycan species	1235:1286	The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival.
32341520	7	52	from	increase	955:962	arg1	glycans					1014:1020	high-mannose glycans	1001:1020	high-mannose glycans	1001:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	9	53	theme	disease-specific	1318:1333	arg1	survival					1335:1342	poor disease-specific survival	1313:1342	poor disease-specific survival	1313:1342	The high abundance of tri-antennary N-glycan species was also associated with poor disease-specific survival.
32341520	7	54	theme	high-mannose	1001:1012	arg1	glycans					1014:1020	high-mannose glycans	1001:1020	high-mannose glycans	1001:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	4	55	theme	prognostic	450:459	arg1	unknown					549:555	unknown	549:555	unknown	549:555	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	4	55	theme	prognostic	450:459	arg1	significance					461:472	The prognostic significance	446:472	The prognostic significance of areas with moderately increased cellularity (intermediate)	446:534	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	10	56	from	observations	1374:1385	arg1	cholangiocarcinoma					1444:1461	cholangiocarcinoma	1444:1461	cholangiocarcinoma	1444:1461	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	10	56	from	observations	1374:1385	arg1	cancer					1401:1406	colorectal cancer	1390:1406	colorectal cancer	1390:1406	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	10	56	from	observations	1374:1385	arg1	cancer					1416:1421	breast cancer	1409:1421	breast cancer	1409:1421	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	10	56	from	observations	1374:1385	arg1	cancer					1432:1437	ovarian cancer	1424:1437	ovarian cancer	1424:1437	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	0	57	theme	mass	87:90	arg1	spectrometry					92:103	N-glycan mass spectrometry	78:103	N-glycan mass spectrometry imaging	78:111	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	8	58	theme	overall	1045:1051	arg1	levels					1053:1058	overall levels	1045:1058	overall levels of complex-type glycans	1045:1082	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	7	59	theme	mannoses	989:996	arg1	number					979:984	the average number	967:984	the average number of mannoses on high-mannose glycans	967:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	1	60	theme	second	146:151	arg1	liposarcoma					121:131	Myxoid liposarcoma	114:131	Myxoid liposarcoma (MLS)	114:137	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	60	theme	second	146:151	arg1	subtype					165:171	the second most common subtype	142:171	the second most common subtype of liposarcoma	142:186	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	0	61	from	signatures	10:19	arg1	liposarcoma					52:62	myxoid liposarcoma	45:62	myxoid liposarcoma	45:62	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	10	62	theme	general	1487:1493	arg1	role					1495:1498	a general role	1485:1498	a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression	1485:1586	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	7	63	from	number	979:984	arg1	glycans					1014:1020	high-mannose glycans	1001:1020	high-mannose glycans	1001:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	5	64	theme	MLS	711:713	arg1	microarray					715:724	an MLS microarray	708:724	an MLS microarray	708:724	Here we have applied matrix-assisted laser desorption/ionization mass spectrometry imaging to analyze the spatial distribution of N-linked glycans on an MLS microarray in order to identify molecular markers for tumor progression.
32341520	7	65	theme	number	979:984	arg1	increase					955:962	an increase	952:962	an increase of the average number of mannoses on high-mannose glycans	952:1020	Concomitantly, an increase of the average number of mannoses on high-mannose glycans was observed.
32341520	3	66	theme	≥5	328:329	arg1	%					330:330	%	330:330	%	330:330	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	8	67	theme	glycans	1076:1082	arg1	levels					1053:1058	overall levels	1045:1058	overall levels of complex-type glycans	1045:1082	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	10	68	theme	glycans	1516:1522	arg1	role					1495:1498	a general role	1485:1498	a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression	1485:1586	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	3	69	theme	cell	352:355	arg1	areas					357:361	≥5% hypercellular round cell areas	328:361	≥5% hypercellular round cell areas	328:361	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	3	70	theme	worse	384:388	arg1	prognosis					390:398	a worse prognosis	382:398	a worse prognosis for the patient	382:414	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	0	71	theme	tumor	24:28	arg1	progression					30:40	tumor progression	24:40	tumor progression	24:40	Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.
32341520	3	72	theme	hypercellular	332:344	arg1	areas					357:361	≥5% hypercellular round cell areas	328:361	≥5% hypercellular round cell areas	328:361	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	10	73	theme	glycans	1558:1564	arg1	role					1495:1498	a general role	1485:1498	a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression	1485:1586	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	10	74	theme	recent	1367:1372	arg1	observations					1374:1385	recent observations	1367:1385	recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma	1367:1461	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	8	75	theme	tri-	1110:1113	arg1	N-glycans					1135:1143	tri- and tetra-antennary N-glycans	1110:1143	tri- and tetra-antennary N-glycans	1110:1143	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	10	76	theme	higher-antennary	1528:1543	arg1	glycans					1558:1564	higher-antennary complex-type glycans	1528:1564	higher-antennary complex-type glycans	1528:1564	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	10	77	theme	breast	1409:1414	arg1	cancer					1416:1421	breast cancer	1409:1421	breast cancer	1409:1421	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	8	78	theme	tetra-antennary	1119:1133	arg1	N-glycans					1135:1143	tri- and tetra-antennary N-glycans	1110:1143	tri- and tetra-antennary N-glycans	1110:1143	Although overall levels of complex-type glycans decreased, an increase of tri- and tetra-antennary N-glycans was observed with morphological tumor progression and increased tumor histological grade.
32341520	6	79	theme	relative	848:855	arg1	abundances					857:866	increased relative abundances	838:866	increased relative abundances of high-mannose type glycans	838:895	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	4	80	theme	increased	499:507	arg1	intermediate					522:533	intermediate	522:533	intermediate	522:533	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	4	80	theme	increased	499:507	arg1	cellularity					509:519	moderately increased cellularity	488:519	moderately increased cellularity (intermediate)	488:534	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	4	81	with	significance	461:472	arg1	intermediate					522:533	intermediate	522:533	intermediate	522:533	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	4	81	with	significance	461:472	arg1	cellularity					509:519	moderately increased cellularity	488:519	moderately increased cellularity (intermediate)	488:534	The prognostic significance of areas with moderately increased cellularity (intermediate) is currently unknown.
32341520	10	82	theme	cancer	1569:1574	arg1	progression					1576:1586	cancer progression	1569:1586	cancer progression	1569:1586	These findings mirror recent observations in colorectal cancer, breast cancer, ovarian cancer, and cholangiocarcinoma, and are in line with a general role of high-mannose glycans and higher-antennary complex-type glycans in cancer progression.
32341520	3	83	theme	high	434:437	arg1	grade					439:443	high grade	434:443	high grade	434:443	The presence of ≥5% hypercellular round cell areas is associated with a worse prognosis for the patient and is considered high grade.
32341520	6	84	theme	profiles	815:822	arg1	Comparison					788:797	Comparison	788:797	Comparison of the N-glycan profiles	788:822	Comparison of the N-glycan profiles revealed that increased relative abundances of high-mannose type glycans were associated with tumor progression.
32341520	1	85	theme	sarcomas	215:222	arg1	%					206:206	~6%	204:206	~6% of all sarcomas	204:222	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
32341520	1	85	theme	sarcomas	215:222	arg1	sarcomas					215:222	all sarcomas	211:222	all sarcomas	211:222	Myxoid liposarcoma (MLS) is the second most common subtype of liposarcoma, accounting for ~6% of all sarcomas.
33897873	12	0	theme	curative	2073:2080	arg1	surgery					2082:2088	curative surgery	2073:2088	curative surgery	2073:2088	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	6	1	theme	critical	1265:1272	arg1	factors					1257:1263	potential factors	1247:1263	potential factors critical for the ferroptosis sensitivity of LUAD cells	1247:1318	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	3	2	theme	biosynthesis	507:518	arg1	HBP					529:531	HBP	529:531	HBP	529:531	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	2	theme	biosynthesis	507:518	arg1	pathway					520:526	the hexosamine biosynthesis pathway	492:526	the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation)	492:600	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	13	3	theme	glutamate	2197:2205	arg1	inhibition					2228:2237	endogenous glutamate following system XC- inhibition	2186:2237	endogenous glutamate following system XC- inhibition	2186:2237	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	12	4	from	patients	2050:2057	arg1	data					2040:2043	data	2040:2043	data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues	2040:2154	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	18	5	with	LUADs	2744:2748	arg1	expression					2767:2776	high ADCY10 expression	2755:2776	high ADCY10 expression	2755:2776	Advanced-stage LUADs with high ADCY10 expression are sensitive to ferroptosis.
33897873	3	6	theme	cyclase	745:751	arg1	activation					769:778	adenylyl cyclase (ADCY)-mediated activation	736:778	adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA)	736:804	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	6	7	theme	potential	1247:1255	arg1	factors					1257:1263	potential factors	1247:1263	potential factors critical for the ferroptosis sensitivity of LUAD cells	1247:1318	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	3	8	theme	O-linked	544:551	arg1	O-GlcNAcylation					585:599	O-GlcNAcylation	585:599	O-GlcNAcylation	585:599	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	8	theme	O-linked	544:551	arg1	beta-N-acetylglucosaminylation					553:582	-dependent O-linked beta-N-acetylglucosaminylation	533:582	the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation)	492:600	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	13	9	theme	system	2217:2222	arg1	inhibition					2228:2237	endogenous glutamate following system XC- inhibition	2186:2237	endogenous glutamate following system XC- inhibition	2186:2237	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	16	10	theme	downstream	2522:2531	arg1	target					2533:2538	a key downstream target	2516:2538	a key downstream target	2516:2538	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	16	10	theme	downstream	2522:2531	arg1	effects					2560:2566	the effects	2556:2566	the effects of glutamate on the PKA-dependent suppression of GFPT1	2556:2621	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	16	10	theme	downstream	2522:2531	arg1	ADCY10					2501:2506	ADCY10	2501:2506	ADCY10	2501:2506	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	10	11	theme	reporter	1673:1680	arg1	assay					1682:1686	a luciferase reporter assay	1660:1686	a luciferase reporter assay	1660:1686	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	21	12	theme	LUAD	3372:3375	arg1	patients					3377:3384	LUAD patients	3372:3384	LUAD patients with later-stage and/or therapy-resistant tumors	3372:3433	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	13	13	theme	endogenous	2186:2195	arg1	inhibition					2228:2237	endogenous glutamate following system XC- inhibition	2186:2237	endogenous glutamate following system XC- inhibition	2186:2237	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	19	14	theme	therapy	2843:2849	arg1	resistance					2851:2860	acquired therapy resistance	2834:2860	acquired therapy resistance	2834:2860	Moreover, LUAD cells with acquired therapy resistance are also prone to higher ADCY10 expression and are more likely to respond to ferroptosis.
33897873	4	15	theme	ferroptosis	868:878	arg1	sensitivity					880:890	ferroptosis sensitivity	868:890	ferroptosis sensitivity	868:890	However, whether accumulated endogenous glutamate determines ferroptosis sensitivity by influencing the ADCY/PKA/HBP/YAP axis in LUAD cells is not understood.
33897873	10	16	theme	Transcriptional	1613:1627	arg1	regulation					1629:1638	Transcriptional regulation	1613:1638	Transcriptional regulation	1613:1638	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	3	17	theme	-mediated	759:767	arg1	activation					769:778	adenylyl cyclase (ADCY)-mediated activation	736:778	adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA)	736:804	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	14	18	theme	GFPT1	2413:2417	arg1	impairment					2399:2408	impairment	2399:2408	impairment of GFPT1	2399:2417	YAP O-GlcNAcylation and expression cannot be sustained in LUAD cells upon impairment of GFPT1.
33897873	11	19	theme	cell	1818:1821	arg1	transplantation					1823:1837	limiting dilution cell transplantation	1800:1837	limiting dilution cell transplantation	1800:1837	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	5	20	theme	malondialdehyde	1064:1078	arg1	generation					1010:1019	the generation	1006:1019	the generation	1006:1019	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	20	theme	malondialdehyde	1064:1078	arg1	viability					980:988	Cell viability	975:988	Cell viability	975:988	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	20	theme	malondialdehyde	1064:1078	arg1	death					996:1000	cell death	991:1000	cell death	991:1000	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	10	21	theme	mobility	1747:1754	arg1	EMSA					1769:1772	EMSA	1769:1772	EMSA	1769:1772	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	10	21	theme	mobility	1747:1754	arg1	assay					1762:1766	electrophoretic mobility shift assay	1731:1766	electrophoretic mobility shift assay (EMSA)	1731:1773	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	12	22	theme	drug	1979:1982	arg1	efficacy					1984:1991	drug efficacy	1979:1991	drug efficacy	1979:1991	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	20	23	theme	iron	2998:3001	arg1	increase					3003:3010	secondary labile iron increase	2981:3010	secondary labile iron increase	2981:3010	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	10	24	theme	luciferase	1662:1671	arg1	assay					1682:1686	a luciferase reporter assay	1660:1686	a luciferase reporter assay	1660:1686	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	3	25	theme	kinase	791:796	arg1	PKA					801:803	PKA	801:803	PKA	801:803	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	25	theme	kinase	791:796	arg1	A					798:798	protein kinase A	783:798	protein kinase A (PKA)	783:804	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	6	26	theme	LUAD	1309:1312	arg1	cells					1314:1318	LUAD cells	1309:1318	LUAD cells	1309:1318	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	3	27	theme	protein	783:789	arg1	PKA					801:803	PKA	801:803	PKA	801:803	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	27	theme	protein	783:789	arg1	A					798:798	protein kinase A	783:798	protein kinase A (PKA)	783:804	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	8	28	theme	Co-immunoprecipitation	1422:1443	arg1	assays					1453:1458	Co-immunoprecipitation (co-IP) assays	1422:1458	Co-immunoprecipitation (co-IP) assays	1422:1458	Co-immunoprecipitation (co-IP) assays were performed to identify protein-protein interactions and posttranslational modifications.
33897873	7	29	theme	quantitative	1345:1356	arg1	RT-PCR					1358:1363	quantitative RT-PCR	1345:1363	quantitative RT-PCR (qPCR)	1345:1370	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	7	29	theme	quantitative	1345:1356	arg1	qPCR					1366:1369	qPCR	1366:1369	qPCR	1366:1369	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	11	30	link	cell-derived	1859:1870	arg1	CDX					1883:1885	CDX	1883:1885	CDX	1883:1885	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	11	30	link	cell-derived	1859:1870	arg1	xenograft					1872:1880	cell-derived xenograft	1859:1880	cell-derived xenograft (CDX)	1859:1886	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	12	31	theme	primary	2125:2131	arg1	cells					2138:2142	patient-derived primary LUAD cells	2109:2142	patient-derived primary LUAD cells	2109:2142	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	21	32	theme	ferroptosis	3241:3251	arg1	sensitivity					3253:3263	ferroptosis sensitivity	3241:3263	ferroptosis sensitivity following the inhibition of system XC- in LUAD cells	3241:3316	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	14	33	gly	O-GlcNAcylation	2329:2343	arg1	cells					2388:2392	LUAD cells	2383:2392	LUAD cells	2383:2392	YAP O-GlcNAcylation and expression cannot be sustained in LUAD cells upon impairment of GFPT1.
33897873	4	34	theme	LUAD	936:939	arg1	cells					941:945	LUAD cells	936:945	LUAD cells	936:945	However, whether accumulated endogenous glutamate determines ferroptosis sensitivity by influencing the ADCY/PKA/HBP/YAP axis in LUAD cells is not understood.
33897873	6	35	theme	mass	1205:1208	arg1	TMTs					1216:1219	TMTs	1216:1219	TMTs	1216:1219	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	6	35	theme	mass	1205:1208	arg1	tags					1210:1213	Tandem mass tags	1198:1213	Tandem mass tags (TMTs)	1198:1220	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	4	36	from	axis	928:931	arg1	cells					941:945	LUAD cells	936:945	LUAD cells	936:945	However, whether accumulated endogenous glutamate determines ferroptosis sensitivity by influencing the ADCY/PKA/HBP/YAP axis in LUAD cells is not understood.
33897873	1	37	theme	identified	149:158	arg1	form					160:163	a newly identified form	141:163	a newly identified form of regulated cell death	141:187	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	1	37	theme	identified	149:158	arg1	Ferroptosis					128:138	Ferroptosis	128:138	Ferroptosis	128:138	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	20	38	theme	secondary	2981:2989	arg1	increase					3003:3010	secondary labile iron increase	2981:3010	secondary labile iron increase	2981:3010	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	17	39	theme	ADCY10	2697:2702	arg1	effects					2686:2692	the protumorigenic and proferroptotic effects	2648:2692	the protumorigenic and proferroptotic effects of ADCY10	2648:2702	We also discovered that the protumorigenic and proferroptotic effects of ADCY10 are mediated separately.
33897873	14	40	theme	LUAD	2383:2386	arg1	cells					2388:2392	LUAD cells	2383:2392	LUAD cells	2383:2392	YAP O-GlcNAcylation and expression cannot be sustained in LUAD cells upon impairment of GFPT1.
33897873	13	41	theme	LUAD	2313:2316	arg1	cells					2318:2322	LUAD cells	2313:2322	LUAD cells	2313:2322	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	11	42	theme	limiting	1800:1807	arg1	transplantation					1823:1837	limiting dilution cell transplantation	1800:1837	limiting dilution cell transplantation	1800:1837	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	0	43	theme	lung	96:99	arg1	adenocarcinoma					101:114	lung adenocarcinoma	96:114	lung adenocarcinoma	96:114	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
33897873	1	44	theme	cell	178:181	arg1	death					183:187	regulated cell death	168:187	regulated cell death	168:187	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	20	45	theme	varying	2963:2969	arg1	degree					2971:2976	a varying degree	2961:2976	a varying degree of secondary labile iron increase	2961:3010	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	9	46	theme	appropriate	1595:1605	arg1	kits					1607:1610	the appropriate kits	1591:1610	the appropriate kits	1591:1610	Metabolite levels were measured using the appropriate kits.
33897873	12	47	theme	clinical	1961:1968	arg1	outcome					1970:1976	clinical outcome	1961:1976	clinical outcome	1961:1976	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	9	48	theme	Metabolite	1553:1562	arg1	levels					1564:1569	Metabolite levels	1553:1569	Metabolite levels	1553:1569	Metabolite levels were measured using the appropriate kits.
33897873	19	49	theme	higher	2880:2885	arg1	expression					2894:2903	higher ADCY10 expression	2880:2903	higher ADCY10 expression	2880:2903	Moreover, LUAD cells with acquired therapy resistance are also prone to higher ADCY10 expression and are more likely to respond to ferroptosis.
33897873	18	50	theme	Advanced-stage	2729:2742	arg1	LUADs					2744:2748	Advanced-stage LUADs	2729:2748	Advanced-stage LUADs with high ADCY10 expression	2729:2776	Advanced-stage LUADs with high ADCY10 expression are sensitive to ferroptosis.
33897873	8	51	theme	posttranslational	1520:1536	arg1	modifications					1538:1550	posttranslational modifications	1520:1550	posttranslational modifications	1520:1550	Co-immunoprecipitation (co-IP) assays were performed to identify protein-protein interactions and posttranslational modifications.
33897873	14	52	theme	YAP	2325:2327	arg1	O-GlcNAcylation					2329:2343	YAP O-GlcNAcylation	2325:2343	YAP O-GlcNAcylation	2325:2343	YAP O-GlcNAcylation and expression cannot be sustained in LUAD cells upon impairment of GFPT1.
33897873	11	53	theme	mouse	1924:1928	arg1	models					1930:1935	patient-derived xenograft (PDX) mouse models	1892:1935	patient-derived xenograft (PDX) mouse models	1892:1935	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	0	54	theme	Endogenous	0:9	arg1	glutamate					11:19	Endogenous glutamate	0:19	Endogenous glutamate	0:19	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
33897873	1	55	theme	impaired	288:295	arg1	uptake					297:302	the impaired uptake	284:302	the impaired uptake of cystine	284:313	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	20	56	theme	YAP-stimulated	3048:3061	arg1	compensation					3079:3090	YAP-stimulated transcriptional compensation	3048:3090	YAP-stimulated transcriptional compensation for ferritin	3048:3103	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	18	57	theme	ADCY10	2760:2765	arg1	expression					2767:2776	high ADCY10 expression	2755:2776	high ADCY10 expression	2755:2776	Advanced-stage LUADs with high ADCY10 expression are sensitive to ferroptosis.
33897873	5	58	theme	Cell	975:978	arg1	viability					980:988	Cell viability	975:988	Cell viability	975:988	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	19	59	theme	acquired	2834:2841	arg1	resistance					2851:2860	acquired therapy resistance	2834:2860	acquired therapy resistance	2834:2860	Moreover, LUAD cells with acquired therapy resistance are also prone to higher ADCY10 expression and are more likely to respond to ferroptosis.
33897873	16	60	theme	glutamate	2571:2579	arg1	target					2533:2538	a key downstream target	2516:2538	a key downstream target	2516:2538	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	16	60	theme	glutamate	2571:2579	arg1	effects					2560:2566	the effects	2556:2566	the effects of glutamate on the PKA-dependent suppression of GFPT1	2556:2621	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	16	60	theme	glutamate	2571:2579	arg1	ADCY10					2501:2506	ADCY10	2501:2506	ADCY10	2501:2506	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	5	61	theme	reactive	1030:1037	arg1	ROS					1055:1057	ROS	1055:1057	ROS	1055:1057	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	61	theme	reactive	1030:1037	arg1	species					1046:1052	lipid reactive oxygen species	1024:1052	lipid reactive oxygen species (ROS)	1024:1058	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	3	62	theme	rate-limiting	664:676	arg1	enzyme					678:683	the rate-limiting enzyme	660:683	the rate-limiting enzyme of the HBP	660:694	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	62	theme	rate-limiting	664:676	arg1	transaminase					638:649	glutamine-fructose-6-phosphate transaminase	607:649	glutamine-fructose-6-phosphate transaminase (GFPT1)	607:657	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	4	63	theme	accumulated	824:834	arg1	glutamate					847:855	accumulated endogenous glutamate	824:855	accumulated endogenous glutamate	824:855	However, whether accumulated endogenous glutamate determines ferroptosis sensitivity by influencing the ADCY/PKA/HBP/YAP axis in LUAD cells is not understood.
33897873	10	64	theme	electrophoretic	1731:1745	arg1	EMSA					1769:1772	EMSA	1769:1772	EMSA	1769:1772	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	10	64	theme	electrophoretic	1731:1745	arg1	assay					1762:1766	electrophoretic mobility shift assay	1731:1766	electrophoretic mobility shift assay (EMSA)	1731:1773	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	0	65	theme	ADCY10-dependent	60:75	arg1	suppression					81:91	ADCY10-dependent YAP suppression	60:91	ADCY10-dependent YAP suppression in lung adenocarcinoma	60:114	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
33897873	5	66	theme	ferroptosis	1146:1156	arg1	induction					1133:1141	the induction	1129:1141	the induction of ferroptosis following the inhibition of system XC-	1129:1195	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	67	theme	species	1046:1052	arg1	generation					1010:1019	the generation	1006:1019	the generation	1006:1019	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	67	theme	species	1046:1052	arg1	viability					980:988	Cell viability	975:988	Cell viability	975:988	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	67	theme	species	1046:1052	arg1	death					996:1000	cell death	991:1000	cell death	991:1000	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	20	68	theme	later	3108:3112	arg1	stages					3114:3119	later stages	3108:3119	later stages	3108:3119	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	11	69	theme	xenograft	1908:1916	arg1	models					1930:1935	patient-derived xenograft (PDX) mouse models	1892:1935	patient-derived xenograft (PDX) mouse models	1892:1935	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	13	70	theme	XC-	2224:2226	arg1	inhibition					2228:2237	endogenous glutamate following system XC- inhibition	2186:2237	endogenous glutamate following system XC- inhibition	2186:2237	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	19	71	theme	LUAD	2818:2821	arg1	cells					2823:2827	LUAD cells	2818:2827	LUAD cells with acquired therapy resistance	2818:2860	Moreover, LUAD cells with acquired therapy resistance are also prone to higher ADCY10 expression and are more likely to respond to ferroptosis.
33897873	3	72	theme	HBP	692:694	arg1	enzyme					678:683	the rate-limiting enzyme	660:683	the rate-limiting enzyme of the HBP	660:694	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	72	theme	HBP	692:694	arg1	transaminase					638:649	glutamine-fructose-6-phosphate transaminase	607:649	glutamine-fructose-6-phosphate transaminase (GFPT1)	607:657	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	21	73	with	patients	3377:3384	arg1	tumors					3428:3433	later-stage and/or therapy-resistant tumors	3391:3433	later-stage and/or therapy-resistant tumors	3391:3433	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	11	74	theme	PDX	1919:1921	arg1	models					1930:1935	patient-derived xenograft (PDX) mouse models	1892:1935	patient-derived xenograft (PDX) mouse models	1892:1935	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	1	75	theme	antiporter	251:260	arg1	XC-					269:271	cystine-glutamate antiporter system XC-	233:271	cystine-glutamate antiporter system XC-	233:271	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	21	76	theme	later-stage	3391:3401	arg1	tumors					3428:3433	later-stage and/or therapy-resistant tumors	3391:3433	later-stage and/or therapy-resistant tumors	3391:3433	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	2	77	theme	endogenous	367:376	arg1	glutamate					378:386	endogenous glutamate	367:386	endogenous glutamate	367:386	However, the outcome following the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD) has not yet been determined.
33897873	15	78	theme	pathway-like	2432:2443	arg1	phosphorylation					2445:2459	Hippo pathway-like phosphorylation	2426:2459	Hippo pathway-like phosphorylation	2426:2459	Thus, Hippo pathway-like phosphorylation and ubiquitination of YAP are enhanced.
33897873	1	79	theme	XC-	269:271	arg1	inhibition					219:228	the inhibition	215:228	the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine	215:313	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	16	80	theme	key	2518:2520	arg1	target					2533:2538	a key downstream target	2516:2538	a key downstream target	2516:2538	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	16	80	theme	key	2518:2520	arg1	effects					2560:2566	the effects	2556:2566	the effects of glutamate on the PKA-dependent suppression of GFPT1	2556:2621	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	16	80	theme	key	2518:2520	arg1	ADCY10					2501:2506	ADCY10	2501:2506	ADCY10	2501:2506	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	21	81	theme	good	3356:3359	arg1	treatment					3341:3349	ferroptosis-based treatment	3323:3349	ferroptosis-based treatment	3323:3349	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	21	81	theme	good	3356:3359	arg1	Conclusions					3191:3201	Conclusions	3191:3201	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.	3191:3434	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	21	81	theme	good	3356:3359	arg1	choice					3361:3366	a good choice	3354:3366	a good choice for LUAD patients with later-stage and/or therapy-resistant tumors	3354:3433	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	3	82	theme	-dependent	533:542	arg1	O-GlcNAcylation					585:599	O-GlcNAcylation	585:599	O-GlcNAcylation	585:599	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	82	theme	-dependent	533:542	arg1	beta-N-acetylglucosaminylation					553:582	-dependent O-linked beta-N-acetylglucosaminylation	533:582	the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation)	492:600	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	13	83	theme	following	2207:2215	arg1	inhibition					2228:2237	endogenous glutamate following system XC- inhibition	2186:2237	endogenous glutamate following system XC- inhibition	2186:2237	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	2	84	from	accumulation	351:362	arg1	LUAD					412:415	LUAD	412:415	LUAD	412:415	However, the outcome following the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD) has not yet been determined.
33897873	2	84	from	accumulation	351:362	arg1	adenocarcinoma					396:409	lung adenocarcinoma	391:409	lung adenocarcinoma (LUAD)	391:416	However, the outcome following the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD) has not yet been determined.
33897873	7	85	theme	mRNA	1405:1408	arg1	expression					1410:1419	protein and mRNA expression	1393:1419	protein and mRNA expression	1393:1419	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	21	86	theme	ferroptosis-based	3323:3339	arg1	treatment					3341:3349	ferroptosis-based treatment	3323:3349	ferroptosis-based treatment	3323:3349	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	21	86	theme	ferroptosis-based	3323:3339	arg1	Conclusions					3191:3201	Conclusions	3191:3201	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.	3191:3434	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	21	86	theme	ferroptosis-based	3323:3339	arg1	choice					3361:3366	a good choice	3354:3366	a good choice for LUAD patients with later-stage and/or therapy-resistant tumors	3354:3433	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	1	87	theme	death	183:187	arg1	form					160:163	a newly identified form	141:163	a newly identified form of regulated cell death	141:187	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	1	87	theme	death	183:187	arg1	Ferroptosis					128:138	Ferroptosis	128:138	Ferroptosis	128:138	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	4	88	theme	endogenous	836:845	arg1	glutamate					847:855	accumulated endogenous glutamate	824:855	accumulated endogenous glutamate	824:855	However, whether accumulated endogenous glutamate determines ferroptosis sensitivity by influencing the ADCY/PKA/HBP/YAP axis in LUAD cells is not understood.
33897873	7	89	theme	protein	1393:1399	arg1	expression					1410:1419	protein and mRNA expression	1393:1419	protein and mRNA expression	1393:1419	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	0	90	from	suppression	81:91	arg1	adenocarcinoma					101:114	lung adenocarcinoma	96:114	lung adenocarcinoma	96:114	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
33897873	3	91	theme	adenylyl	736:743	arg1	ADCY					754:757	ADCY	754:757	ADCY	754:757	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	91	theme	adenylyl	736:743	arg1	cyclase					745:751	adenylyl cyclase	736:751	adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA)	736:804	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	12	92	theme	ADCY10	1997:2002	arg1	expression					2004:2013	ADCY10 expression	1997:2013	ADCY10 expression	1997:2013	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	20	93	theme	LUAD	3179:3182	arg1	cells					3184:3188	LUAD cells	3179:3188	LUAD cells	3179:3188	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	3	94	theme	hexosamine	496:505	arg1	HBP					529:531	HBP	529:531	HBP	529:531	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	94	theme	hexosamine	496:505	arg1	pathway					520:526	the hexosamine biosynthesis pathway	492:526	the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation)	492:600	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	6	95	theme	cells	1314:1318	arg1	sensitivity					1294:1304	the ferroptosis sensitivity	1278:1304	the ferroptosis sensitivity of LUAD cells	1278:1318	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	3	96	theme	glutamine-fructose-6-phosphate	607:636	arg1	enzyme					678:683	the rate-limiting enzyme	660:683	the rate-limiting enzyme of the HBP	660:694	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	96	theme	glutamine-fructose-6-phosphate	607:636	arg1	GFPT1					652:656	GFPT1	652:656	GFPT1	652:656	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	96	theme	glutamine-fructose-6-phosphate	607:636	arg1	transaminase					638:649	glutamine-fructose-6-phosphate transaminase	607:649	glutamine-fructose-6-phosphate transaminase (GFPT1)	607:657	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	20	97	theme	ferroptosis	3142:3152	arg1	sensitivity					3154:3164	ferroptosis sensitivity	3142:3164	ferroptosis sensitivity	3142:3164	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	20	98	theme	labile	2991:2996	arg1	increase					3003:3010	secondary labile iron increase	2981:3010	secondary labile iron increase	2981:3010	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	17	99	theme	protumorigenic	2652:2665	arg1	effects					2686:2692	the protumorigenic and proferroptotic effects	2648:2692	the protumorigenic and proferroptotic effects of ADCY10	2648:2702	We also discovered that the protumorigenic and proferroptotic effects of ADCY10 are mediated separately.
33897873	7	100	used	used	1377:1380	arg2	Immunoblotting					1321:1334	Immunoblotting	1321:1334	Immunoblotting (IB)	1321:1339	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	7	100	used	used	1377:1380	arg2	qPCR					1366:1369	qPCR	1366:1369	qPCR	1366:1369	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	7	100	used	used	1377:1380	arg2	RT-PCR					1358:1363	quantitative RT-PCR	1345:1363	quantitative RT-PCR (qPCR)	1345:1370	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	7	100	used	used	1377:1380	arg2	IB					1337:1338	IB	1337:1338	IB	1337:1338	Immunoblotting (IB) and quantitative RT-PCR (qPCR) were used to analyze protein and mRNA expression.
33897873	3	101	theme	A	798:798	arg1	activation					769:778	adenylyl cyclase (ADCY)-mediated activation	736:778	adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA)	736:804	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	15	102	theme	Hippo	2426:2430	arg1	phosphorylation					2445:2459	Hippo pathway-like phosphorylation	2426:2459	Hippo pathway-like phosphorylation	2426:2459	Thus, Hippo pathway-like phosphorylation and ubiquitination of YAP are enhanced.
33897873	19	103	theme	ADCY10	2887:2892	arg1	expression					2894:2903	higher ADCY10 expression	2880:2903	higher ADCY10 expression	2880:2903	Moreover, LUAD cells with acquired therapy resistance are also prone to higher ADCY10 expression and are more likely to respond to ferroptosis.
33897873	4	104	theme	ADCY/PKA/HBP/YAP	911:926	arg1	axis					928:931	the ADCY/PKA/HBP/YAP axis	907:931	the ADCY/PKA/HBP/YAP axis in LUAD cells	907:945	However, whether accumulated endogenous glutamate determines ferroptosis sensitivity by influencing the ADCY/PKA/HBP/YAP axis in LUAD cells is not understood.
33897873	20	105	theme	increase	3003:3010	arg1	degree					2971:2976	a varying degree	2961:2976	a varying degree of secondary labile iron increase	2961:3010	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	17	106	theme	proferroptotic	2671:2684	arg1	effects					2686:2692	the protumorigenic and proferroptotic effects	2648:2692	the protumorigenic and proferroptotic effects of ADCY10	2648:2702	We also discovered that the protumorigenic and proferroptotic effects of ADCY10 are mediated separately.
33897873	12	107	theme	patient-derived	2109:2123	arg1	cells					2138:2142	patient-derived primary LUAD cells	2109:2142	patient-derived primary LUAD cells	2109:2142	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	11	108	theme	cell-derived	1859:1870	arg1	CDX					1883:1885	CDX	1883:1885	CDX	1883:1885	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	11	108	theme	cell-derived	1859:1870	arg1	xenograft					1872:1880	cell-derived xenograft	1859:1880	cell-derived xenograft (CDX)	1859:1886	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	6	109	theme	ferroptosis	1282:1292	arg1	sensitivity					1294:1304	the ferroptosis sensitivity	1278:1304	the ferroptosis sensitivity of LUAD cells	1278:1318	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	16	110	theme	GFPT1	2617:2621	arg1	suppression					2602:2612	the PKA-dependent suppression	2584:2612	the PKA-dependent suppression of GFPT1	2584:2621	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	11	111	link	patient-derived	1892:1906	arg1	models					1930:1935	patient-derived xenograft (PDX) mouse models	1892:1935	patient-derived xenograft (PDX) mouse models	1892:1935	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	6	112	theme	Tandem	1198:1203	arg1	TMTs					1216:1219	TMTs	1216:1219	TMTs	1216:1219	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	6	112	theme	Tandem	1198:1203	arg1	tags					1210:1213	Tandem mass tags	1198:1213	Tandem mass tags (TMTs)	1198:1220	Tandem mass tags (TMTs) were employed to explore potential factors critical for the ferroptosis sensitivity of LUAD cells.
33897873	12	113	theme	LUAD	2133:2136	arg1	cells					2138:2142	patient-derived primary LUAD cells	2109:2142	patient-derived primary LUAD cells	2109:2142	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	11	114	theme	Drug	1776:1779	arg1	administration					1781:1794	Drug administration	1776:1794	Drug administration	1776:1794	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	21	115	theme	Endogenous	3204:3213	arg1	glutamate					3215:3223	Endogenous glutamate	3204:3223	Endogenous glutamate	3204:3223	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	16	116	from	effects	2560:2566	arg1	suppression					2602:2612	the PKA-dependent suppression	2584:2612	the PKA-dependent suppression of GFPT1	2584:2621	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	1	117	theme	regulated	168:176	arg1	death					183:187	regulated cell death	168:187	regulated cell death	168:187	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	21	118	from	inhibition	3279:3288	arg1	cells					3312:3316	LUAD cells	3307:3316	LUAD cells	3307:3316	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	8	119	theme	protein-protein	1487:1501	arg1	interactions					1503:1514	protein-protein interactions	1487:1514	protein-protein interactions	1487:1514	Co-immunoprecipitation (co-IP) assays were performed to identify protein-protein interactions and posttranslational modifications.
33897873	11	120	theme	dilution	1809:1816	arg1	transplantation					1823:1837	limiting dilution cell transplantation	1800:1837	limiting dilution cell transplantation	1800:1837	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	15	121	theme	YAP	2483:2485	arg1	ubiquitination					2465:2478	ubiquitination	2465:2478	ubiquitination	2465:2478	Thus, Hippo pathway-like phosphorylation and ubiquitination of YAP are enhanced.
33897873	15	121	theme	YAP	2483:2485	arg1	phosphorylation					2445:2459	Hippo pathway-like phosphorylation	2426:2459	Hippo pathway-like phosphorylation	2426:2459	Thus, Hippo pathway-like phosphorylation and ubiquitination of YAP are enhanced.
33897873	5	122	theme	cell	991:994	arg1	death					996:1000	cell death	991:1000	cell death	991:1000	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	3	123	link	O-linked	544:551	arg1	O-GlcNAcylation					585:599	O-GlcNAcylation	585:599	O-GlcNAcylation	585:599	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	123	link	O-linked	544:551	arg1	beta-N-acetylglucosaminylation					553:582	-dependent O-linked beta-N-acetylglucosaminylation	533:582	the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation)	492:600	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	21	124	theme	therapy-resistant	3410:3426	arg1	tumors					3428:3433	later-stage and/or therapy-resistant tumors	3391:3433	later-stage and/or therapy-resistant tumors	3391:3433	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	13	125	theme	inhibition	2228:2237	arg1	accumulation					2170:2181	The accumulation	2166:2181	The accumulation of endogenous glutamate following system XC- inhibition	2166:2237	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	3	126	theme	Yes-associated	447:460	arg1	YAP					471:473	YAP	471:473	YAP	471:473	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	126	theme	Yes-associated	447:460	arg1	protein					462:468	Yes-associated protein	447:468	Yes-associated protein (YAP)	447:474	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	20	127	theme	transcriptional	3063:3077	arg1	compensation					3079:3090	YAP-stimulated transcriptional compensation	3048:3090	YAP-stimulated transcriptional compensation for ferritin	3048:3103	Finally, a varying degree of secondary labile iron increase is caused by the failure to sustain YAP-stimulated transcriptional compensation for ferritin at later stages further explains why ferroptosis sensitivity varies among LUAD cells.
33897873	2	128	theme	lung	391:394	arg1	LUAD					412:415	LUAD	412:415	LUAD	412:415	However, the outcome following the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD) has not yet been determined.
33897873	2	128	theme	lung	391:394	arg1	adenocarcinoma					396:409	lung adenocarcinoma	391:409	lung adenocarcinoma (LUAD)	391:416	However, the outcome following the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD) has not yet been determined.
33897873	0	129	theme	ferroptosis	32:42	arg1	sensitivity					44:54	ferroptosis sensitivity	32:54	ferroptosis sensitivity	32:54	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
33897873	1	130	theme	uptake	297:302	arg1	inhibition					219:228	the inhibition	215:228	the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine	215:313	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	3	131	dep	pathway	520:526	arg1	O-GlcNAcylation					585:599	O-GlcNAcylation	585:599	O-GlcNAcylation	585:599	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	3	131	dep	pathway	520:526	arg1	beta-N-acetylglucosaminylation					553:582	-dependent O-linked beta-N-acetylglucosaminylation	533:582	the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation)	492:600	Yes-associated protein (YAP) is sustained by the hexosamine biosynthesis pathway (HBP)-dependent O-linked beta-N-acetylglucosaminylation (O-GlcNAcylation), and glutamine-fructose-6-phosphate transaminase (GFPT1), the rate-limiting enzyme of the HBP, can be phosphorylated and inhibited by adenylyl cyclase (ADCY)-mediated activation of protein kinase A (PKA).
33897873	18	132	theme	high	2755:2758	arg1	expression					2767:2776	high ADCY10 expression	2755:2776	high ADCY10 expression	2755:2776	Advanced-stage LUADs with high ADCY10 expression are sensitive to ferroptosis.
33897873	21	133	theme	LUAD	3307:3310	arg1	cells					3312:3316	LUAD cells	3307:3316	LUAD cells	3307:3316	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	5	134	theme	system	1186:1191	arg1	inhibition					1172:1181	the inhibition	1168:1181	the inhibition of system XC-	1168:1195	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	1	135	theme	cystine	307:313	arg1	uptake					297:302	the impaired uptake	284:302	the impaired uptake of cystine	284:313	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	5	136	theme	lipid	1024:1028	arg1	ROS					1055:1057	ROS	1055:1057	ROS	1055:1057	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	136	theme	lipid	1024:1028	arg1	species					1046:1052	lipid reactive oxygen species	1024:1052	lipid reactive oxygen species (ROS)	1024:1058	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	10	137	theme	chromatin	1689:1697	arg1	immunoprecipitation					1699:1717	chromatin immunoprecipitation	1689:1717	chromatin immunoprecipitation (ChIP)	1689:1724	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	10	137	theme	chromatin	1689:1697	arg1	ChIP					1720:1723	ChIP	1720:1723	ChIP	1720:1723	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	0	138	theme	YAP	77:79	arg1	suppression					81:91	ADCY10-dependent YAP suppression	60:91	ADCY10-dependent YAP suppression in lung adenocarcinoma	60:114	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
33897873	19	139	with	cells	2823:2827	arg1	resistance					2851:2860	acquired therapy resistance	2834:2860	acquired therapy resistance	2834:2860	Moreover, LUAD cells with acquired therapy resistance are also prone to higher ADCY10 expression and are more likely to respond to ferroptosis.
33897873	12	140	link	patient-derived	2109:2123	arg1	cells					2138:2142	patient-derived primary LUAD cells	2109:2142	patient-derived primary LUAD cells	2109:2142	The associations among clinical outcome, drug efficacy and ADCY10 expression were determined based on data from patients who underwent curative surgery and evaluated with patient-derived primary LUAD cells and tissues.
33897873	5	141	theme	oxygen	1039:1044	arg1	ROS					1055:1057	ROS	1055:1057	ROS	1055:1057	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	5	141	theme	oxygen	1039:1044	arg1	species					1046:1052	lipid reactive oxygen species	1024:1052	lipid reactive oxygen species (ROS)	1024:1058	Methods: Cell viability, cell death and the generation of lipid reactive oxygen species (ROS) and malondialdehyde (MDA) were measured to evaluate the responses to the induction of ferroptosis following the inhibition of system XC-.
33897873	11	142	theme	patient-derived	1892:1906	arg1	models					1930:1935	patient-derived xenograft (PDX) mouse models	1892:1935	patient-derived xenograft (PDX) mouse models	1892:1935	Drug administration and limiting dilution cell transplantation were performed with cell-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models.
33897873	13	143	theme	ferroptosis	2267:2277	arg1	sensitivity					2279:2289	ferroptosis sensitivity	2267:2289	ferroptosis sensitivity	2267:2289	Results: The accumulation of endogenous glutamate following system XC- inhibition has been shown to determine ferroptosis sensitivity by suppressing YAP in LUAD cells.
33897873	1	144	theme	cystine-glutamate	233:249	arg1	XC-					269:271	cystine-glutamate antiporter system XC-	233:271	cystine-glutamate antiporter system XC-	233:271	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
33897873	16	145	theme	PKA-dependent	2588:2600	arg1	suppression					2602:2612	the PKA-dependent suppression	2584:2612	the PKA-dependent suppression of GFPT1	2584:2621	ADCY10 acts as a key downstream target and diversifies the effects of glutamate on the PKA-dependent suppression of GFPT1.
33897873	10	146	theme	shift	1756:1760	arg1	EMSA					1769:1772	EMSA	1769:1772	EMSA	1769:1772	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	10	146	theme	shift	1756:1760	arg1	assay					1762:1766	electrophoretic mobility shift assay	1731:1766	electrophoretic mobility shift assay (EMSA)	1731:1773	Transcriptional regulation was evaluated using a luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA).
33897873	21	147	theme	system	3293:3298	arg1	inhibition					3279:3288	the inhibition	3275:3288	the inhibition of system XC- in LUAD cells	3275:3316	Conclusions: Endogenous glutamate is critical for ferroptosis sensitivity following the inhibition of system XC- in LUAD cells, and ferroptosis-based treatment is a good choice for LUAD patients with later-stage and/or therapy-resistant tumors.
33897873	2	148	theme	glutamate	378:386	arg1	accumulation					351:362	the accumulation	347:362	the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD)	347:416	However, the outcome following the accumulation of endogenous glutamate in lung adenocarcinoma (LUAD) has not yet been determined.
33897873	1	149	theme	system	262:267	arg1	XC-					269:271	cystine-glutamate antiporter system XC-	233:271	cystine-glutamate antiporter system XC-	233:271	Rationale: Ferroptosis, a newly identified form of regulated cell death, can be induced following the inhibition of cystine-glutamate antiporter system XC- because of the impaired uptake of cystine.
34636989	0	0	theme	X-box-binding	38:50	arg1	protein					52:58	X-box-binding protein 1	38:60	X-box-binding protein 1 (XBP1)	38:67	Genome-wide mRNA profiling identifies X-box-binding protein 1 (XBP1) as an IRE1 and PUMA repressor.
34636989	0	0	theme	X-box-binding	38:50	arg1	XBP1					63:66	XBP1	63:66	XBP1	63:66	Genome-wide mRNA profiling identifies X-box-binding protein 1 (XBP1) as an IRE1 and PUMA repressor.
34636989	0	0	theme	X-box-binding	38:50	arg1	IRE1					75:78	an IRE1	72:78	an IRE1	72:78	Genome-wide mRNA profiling identifies X-box-binding protein 1 (XBP1) as an IRE1 and PUMA repressor.
34636989	6	1	theme	XBP1s-induced	1017:1029	arg1	line					1036:1039	the XBP1s-induced cell line	1013:1039	the XBP1s-induced cell line	1013:1039	We then compared those results to the XBP1s-induced cell line without pharmacological ER stress induction.
34636989	8	2	theme	PUMA	1575:1578	arg1	expression					1588:1597	reduced PUMA protein expression	1567:1597	reduced PUMA protein expression	1567:1597	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	9	3	theme	further	1609:1615	arg1	studies					1617:1623	further studies	1609:1623	further studies	1609:1623	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	3	4	theme	XBP1	475:478	arg1	mRNA					480:483	XBP1 mRNA	475:483	XBP1 mRNA	475:483	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	0	5	theme	Genome-wide	0:10	arg1	profiling					17:25	Genome-wide mRNA profiling	0:25	Genome-wide mRNA profiling	0:25	Genome-wide mRNA profiling identifies X-box-binding protein 1 (XBP1) as an IRE1 and PUMA repressor.
34636989	1	6	theme	unfolded	155:162	arg1	UPR					182:184	UPR	182:184	UPR	182:184	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	6	theme	unfolded	155:162	arg1	response					172:179	the unfolded protein response	151:179	the unfolded protein response (UPR)	151:185	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	6	theme	unfolded	155:162	arg1	important					232:240	important	232:240	important	232:240	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	6	theme	unfolded	155:162	arg1	pathway					216:222	a multifunctional signaling pathway	188:222	a multifunctional signaling pathway that is important for cell survival	188:258	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	3	7	theme	spliced	500:506	arg1	XBP1s					519:523	XBP1s	519:523	XBP1s	519:523	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	3	7	theme	spliced	500:506	arg1	mRNA					513:516	spliced XBP1 mRNA	500:516	spliced XBP1 mRNA (XBP1s)	500:524	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	4	8	theme	XBP1	541:544	arg1	targets					562:568	XBP1 transcriptional targets	541:568	XBP1 transcriptional targets	541:568	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	5	9	theme	transcription	752:764	arg1	factor					766:771	this transcription factor	747:771	this transcription factor	747:771	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	9	10	theme	underlying	1654:1663	arg1	mechanisms					1675:1684	the underlying molecular mechanisms	1650:1684	the underlying molecular mechanisms involved in the relationship between these genes with XBP1	1650:1743	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	8	11	theme	stress	1377:1382	arg1	conditions					1384:1393	ER stress conditions	1374:1393	ER stress conditions	1374:1393	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	4	12	used	utilized	574:581	arg2	we					571:572	we	571:572	we	571:572	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	7	13	theme	mRNA	1290:1293	arg1	expression					1295:1304	IRE1 mRNA expression	1285:1304	IRE1 mRNA expression during the UPR	1285:1319	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	1	14	theme	misfolded	116:124	arg1	proteins					126:133	misfolded proteins	116:133	misfolded proteins	116:133	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	8	15	theme	ER-stressed	1421:1431	arg1	cells					1433:1437	ER-stressed cells	1421:1437	ER-stressed cells	1421:1437	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	4	16	theme	human	602:606	arg1	line					613:616	an XBP1s-inducible human cell line	583:616	an XBP1s-inducible human cell line	583:616	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	5	17	theme	N-linked	829:836	arg1	inhibitor					852:860	an N-linked glycosylation inhibitor	826:860	an N-linked glycosylation inhibitor (tunicamycin)	826:874	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	17	theme	N-linked	829:836	arg1	tunicamycin					863:873	tunicamycin	863:873	tunicamycin	863:873	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	8	18	theme	elevating	1448:1456	arg1	expression					1463:1472	elevating XBP1 expression	1448:1472	elevating XBP1 expression during ER stress using an inducible cell line	1448:1518	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	7	19	theme	motifs	1170:1175	arg1	analysis					1145:1152	bioinformatic analysis	1131:1152	bioinformatic analysis of XBP1-binding motifs	1131:1175	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	0	20	theme	PUMA	84:87	arg1	repressor					89:97	PUMA repressor	84:97	PUMA repressor	84:97	Genome-wide mRNA profiling identifies X-box-binding protein 1 (XBP1) as an IRE1 and PUMA repressor.
34636989	5	21	theme	sarco/endoplasmic	915:931	arg1	reticulum					933:941	the sarco/endoplasmic reticulum	911:941	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	8	22	theme	ER	1481:1482	arg1	stress					1484:1489	ER stress	1481:1489	ER stress using an inducible cell line	1481:1518	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	2	23	theme	inositol-requiring	333:350	arg1	protein					352:358	inositol-requiring protein 1	333:360	inositol-requiring protein 1 (IRE1)	333:367	The UPR is regulated by three ER transmembrane sensors, one of which is inositol-requiring protein 1 (IRE1).
34636989	2	23	theme	inositol-requiring	333:350	arg1	IRE1					363:366	IRE1	363:366	IRE1	363:366	The UPR is regulated by three ER transmembrane sensors, one of which is inositol-requiring protein 1 (IRE1).
34636989	5	24	theme	specific	725:732	arg1	silencing					734:742	specific silencing	725:742	specific silencing of this transcription factor	725:771	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	1	25	theme	cell	246:249	arg1	survival					251:258	cell survival	246:258	cell survival	246:258	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	7	26	theme	proapoptotic	1262:1273	arg1	PUMA					1254:1257	PUMA	1254:1257	PUMA (a proapoptotic gene)	1254:1279	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	7	26	theme	proapoptotic	1262:1273	arg1	gene					1275:1278	a proapoptotic gene	1260:1278	a proapoptotic gene	1260:1278	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	3	27	theme	X-box-binding	409:421	arg1	XBP1					434:437	XBP1	434:437	XBP1	434:437	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	3	27	theme	X-box-binding	409:421	arg1	factor					401:406	a transcription factor	385:406	a transcription factor	385:406	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	3	27	theme	X-box-binding	409:421	arg1	protein					423:429	X-box-binding protein 1	409:431	X-box-binding protein 1 (XBP1)	409:438	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	5	28	link	N-linked	829:836	arg1	inhibitor					852:860	an N-linked glycosylation inhibitor	826:860	an N-linked glycosylation inhibitor (tunicamycin)	826:874	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	28	link	N-linked	829:836	arg1	tunicamycin					863:873	tunicamycin	863:873	tunicamycin	863:873	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	29	theme	non-competitive	882:896	arg1	inhibitor					898:906	a non-competitive inhibitor	880:906	a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	880:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	1	30	theme	proteins	126:133	arg1	Accumulation					100:111	Accumulation	100:111	Accumulation of misfolded proteins in ER	100:139	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	9	31	theme	repressive	1777:1786	arg1	role					1788:1791	a novel repressive role	1769:1791	a novel repressive role of XBP1 during the UPR	1769:1814	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	8	32	theme	inducible	1500:1508	arg1	line					1515:1518	an inducible cell line	1497:1518	an inducible cell line	1497:1518	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	7	33	theme	bioinformatic	1131:1143	arg1	analysis					1145:1152	bioinformatic analysis	1131:1152	bioinformatic analysis of XBP1-binding motifs	1131:1175	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	5	34	theme	identified	688:697	arg1	genes					714:718	the identified XBP1-dependent genes	684:718	the identified XBP1-dependent genes	684:718	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	7	35	theme	next-generation	1092:1106	arg1	sequencing					1108:1117	next-generation sequencing	1092:1117	next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs	1092:1175	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	2	36	theme	sensors	308:314	arg1	one					317:319	one	317:319	one	317:319	The UPR is regulated by three ER transmembrane sensors, one of which is inositol-requiring protein 1 (IRE1).
34636989	2	36	theme	sensors	308:314	arg1	sensors					308:314	three ER transmembrane sensors	285:314	three ER transmembrane sensors	285:314	The UPR is regulated by three ER transmembrane sensors, one of which is inositol-requiring protein 1 (IRE1).
34636989	5	37	theme	thapsigargin	964:975	arg1	inhibitor					852:860	an N-linked glycosylation inhibitor	826:860	an N-linked glycosylation inhibitor (tunicamycin)	826:874	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	37	theme	thapsigargin	964:975	arg1	inhibitor					898:906	a non-competitive inhibitor	880:906	a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	880:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	37	theme	thapsigargin	964:975	arg1	tunicamycin					863:873	tunicamycin	863:873	tunicamycin	863:873	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	6	38	theme	ER	1065:1066	arg1	induction					1075:1083	pharmacological ER stress induction	1049:1083	pharmacological ER stress induction	1049:1083	We then compared those results to the XBP1s-induced cell line without pharmacological ER stress induction.
34636989	2	39	theme	ER	291:292	arg1	sensors					308:314	three ER transmembrane sensors	285:314	three ER transmembrane sensors	285:314	The UPR is regulated by three ER transmembrane sensors, one of which is inositol-requiring protein 1 (IRE1).
34636989	5	40	theme	Ca2+	943:946	arg1	thapsigargin					964:975	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	8	41	theme	clear	1538:1542	arg1	effect					1556:1561	a clear prosurvival effect	1536:1561	a clear prosurvival effect	1536:1561	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	8	42	theme	ER	1374:1375	arg1	conditions					1384:1393	ER stress conditions	1374:1393	ER stress conditions	1374:1393	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	5	43	theme	ER	796:797	arg1	induction					806:814	pharmacological ER stress induction	780:814	pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	780:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	1	44	theme	signaling	206:214	arg1	pathway					216:222	a multifunctional signaling pathway	188:222	a multifunctional signaling pathway that is important for cell survival	188:258	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	44	theme	signaling	206:214	arg1	important					232:240	important	232:240	important	232:240	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	44	theme	signaling	206:214	arg1	response					172:179	the unfolded protein response	151:179	the unfolded protein response (UPR)	151:185	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	6	45	theme	cell	1031:1034	arg1	line					1036:1039	the XBP1s-induced cell line	1013:1039	the XBP1s-induced cell line	1013:1039	We then compared those results to the XBP1s-induced cell line without pharmacological ER stress induction.
34636989	7	46	theme	regulatory	1197:1206	arg1	network					1208:1214	an XBP1 regulatory network	1189:1214	an XBP1 regulatory network	1189:1214	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	8	47	theme	reduced	1567:1573	arg1	expression					1588:1597	reduced PUMA protein expression	1567:1597	reduced PUMA protein expression	1567:1597	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	8	48	theme	protein	1580:1586	arg1	expression					1588:1597	reduced PUMA protein expression	1567:1597	reduced PUMA protein expression	1567:1597	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	3	49	theme	26-base	455:461	arg1	intron					463:468	a 26-base intron	453:468	a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s)	453:524	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	5	50	theme	stress	799:804	arg1	induction					806:814	pharmacological ER stress induction	780:814	pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	780:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	51	theme	pharmacological	780:794	arg1	induction					806:814	pharmacological ER stress induction	780:814	pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	780:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	1	52	theme	protein	164:170	arg1	UPR					182:184	UPR	182:184	UPR	182:184	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	52	theme	protein	164:170	arg1	response					172:179	the unfolded protein response	151:179	the unfolded protein response (UPR)	151:185	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	52	theme	protein	164:170	arg1	important					232:240	important	232:240	important	232:240	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	52	theme	protein	164:170	arg1	pathway					216:222	a multifunctional signaling pathway	188:222	a multifunctional signaling pathway that is important for cell survival	188:258	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	5	53	theme	factor	766:771	arg1	silencing					734:742	specific silencing	725:742	specific silencing of this transcription factor	725:771	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	9	54	theme	molecular	1665:1673	arg1	mechanisms					1675:1684	the underlying molecular mechanisms	1650:1684	the underlying molecular mechanisms involved in the relationship between these genes with XBP1	1650:1743	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	8	55	theme	cell	1407:1410	arg1	death					1412:1416	cell death	1407:1416	cell death	1407:1416	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	4	56	theme	transcriptional	546:560	arg1	targets					562:568	XBP1 transcriptional targets	541:568	XBP1 transcriptional targets	541:568	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	3	57	theme	XBP1	508:511	arg1	XBP1s					519:523	XBP1s	519:523	XBP1s	519:523	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	3	57	theme	XBP1	508:511	arg1	mRNA					513:516	spliced XBP1 mRNA	500:516	spliced XBP1 mRNA (XBP1s)	500:524	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	5	58	theme	glycosylation	838:850	arg1	inhibitor					852:860	an N-linked glycosylation inhibitor	826:860	an N-linked glycosylation inhibitor (tunicamycin)	826:874	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	58	theme	glycosylation	838:850	arg1	tunicamycin					863:873	tunicamycin	863:873	tunicamycin	863:873	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	3	59	from	mRNA	480:483	arg1	intron					463:468	a 26-base intron	453:468	a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s)	453:524	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	4	60	theme	XBP1	627:630	arg1	expression					632:641	XBP1 expression	627:641	XBP1 expression	627:641	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	9	61	with	relationship	1702:1713	arg1	XBP1					1740:1743	XBP1	1740:1743	XBP1	1740:1743	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	8	62	dep	impairing	1343:1351	arg1	accelerates					1395:1405	accelerates	1395:1405	accelerates	1395:1405	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	7	63	theme	IRE1	1285:1288	arg1	expression					1295:1304	IRE1 mRNA expression	1285:1304	IRE1 mRNA expression during the UPR	1285:1319	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	4	64	theme	XBP1s-inducible	586:600	arg1	line					613:616	an XBP1s-inducible human cell line	583:616	an XBP1s-inducible human cell line	583:616	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	8	65	theme	XBP1	1458:1461	arg1	expression					1463:1472	elevating XBP1 expression	1448:1472	elevating XBP1 expression during ER stress using an inducible cell line	1448:1518	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	4	66	theme	cell	608:611	arg1	line					613:616	an XBP1s-inducible human cell line	583:616	an XBP1s-inducible human cell line	583:616	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	7	67	theme	XBP1-binding	1157:1168	arg1	motifs					1170:1175	XBP1-binding motifs	1157:1175	XBP1-binding motifs	1157:1175	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	3	68	theme	transcription	387:399	arg1	factor					401:406	a transcription factor	385:406	a transcription factor	385:406	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	3	68	theme	transcription	387:399	arg1	protein					423:429	X-box-binding protein 1	409:431	X-box-binding protein 1 (XBP1)	409:438	IRE1 activates a transcription factor, X-box-binding protein 1 (XBP1), by removing a 26-base intron from XBP1 mRNA that generates spliced XBP1 mRNA (XBP1s).
34636989	0	69	theme	mRNA	12:15	arg1	profiling					17:25	Genome-wide mRNA profiling	0:25	Genome-wide mRNA profiling	0:25	Genome-wide mRNA profiling identifies X-box-binding protein 1 (XBP1) as an IRE1 and PUMA repressor.
34636989	1	70	from	Accumulation	100:111	arg1	ER					138:139	ER	138:139	ER	138:139	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	7	71	theme	PUMA	1254:1257	arg1	XBP1					1231:1234	XBP1	1231:1234	XBP1	1231:1234	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	7	71	theme	PUMA	1254:1257	arg1	repressor					1241:1249	a repressor	1239:1249	a repressor of PUMA (a proapoptotic gene)	1239:1279	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	7	71	theme	PUMA	1254:1257	arg1	expression					1295:1304	IRE1 mRNA expression	1285:1304	IRE1 mRNA expression during the UPR	1285:1319	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
34636989	9	72	theme	novel	1771:1775	arg1	role					1788:1791	a novel repressive role	1769:1791	a novel repressive role of XBP1 during the UPR	1769:1814	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	8	73	theme	cell	1510:1513	arg1	line					1515:1518	an inducible cell line	1497:1518	an inducible cell line	1497:1518	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	4	74	theme	controlled	648:657	arg1	manner					659:664	a controlled manner	646:664	a controlled manner	646:664	To search for XBP1 transcriptional targets, we utilized an XBP1s-inducible human cell line to limit XBP1 expression in a controlled manner.
34636989	5	75	theme	SERCA	956:960	arg1	thapsigargin					964:975	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	76	theme	XBP1-dependent	699:712	arg1	genes					714:718	the identified XBP1-dependent genes	684:718	the identified XBP1-dependent genes	684:718	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	6	77	theme	stress	1068:1073	arg1	induction					1075:1083	pharmacological ER stress induction	1049:1083	pharmacological ER stress induction	1049:1083	We then compared those results to the XBP1s-induced cell line without pharmacological ER stress induction.
34636989	9	78	theme	XBP1	1796:1799	arg1	role					1788:1791	a novel repressive role	1769:1791	a novel repressive role of XBP1 during the UPR	1769:1814	Although further studies will be required to test the underlying molecular mechanisms involved in the relationship between these genes with XBP1, these studies identify a novel repressive role of XBP1 during the UPR.
34636989	5	79	with	induction	806:814	arg1	inhibitor					852:860	an N-linked glycosylation inhibitor	826:860	an N-linked glycosylation inhibitor (tunicamycin)	826:874	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	79	with	induction	806:814	arg1	inhibitor					898:906	a non-competitive inhibitor	880:906	a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	880:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	5	79	with	induction	806:814	arg1	tunicamycin					863:873	tunicamycin	863:873	tunicamycin	863:873	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	2	80	theme	transmembrane	294:306	arg1	sensors					308:314	three ER transmembrane sensors	285:314	three ER transmembrane sensors	285:314	The UPR is regulated by three ER transmembrane sensors, one of which is inositol-requiring protein 1 (IRE1).
34636989	5	81	theme	reticulum	933:941	arg1	thapsigargin					964:975	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	6	82	theme	pharmacological	1049:1063	arg1	induction					1075:1083	pharmacological ER stress induction	1049:1083	pharmacological ER stress induction	1049:1083	We then compared those results to the XBP1s-induced cell line without pharmacological ER stress induction.
34636989	8	83	theme	prosurvival	1544:1554	arg1	effect					1556:1561	a clear prosurvival effect	1536:1561	a clear prosurvival effect	1536:1561	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	8	84	theme	IRE1	1353:1356	arg1	activity					1358:1365	IRE1 activity	1353:1365	IRE1 activity	1353:1365	Our results indicate impairing IRE1 activity during ER stress conditions accelerates cell death in ER-stressed cells, whereas elevating XBP1 expression during ER stress using an inducible cell line correlated with a clear prosurvival effect and reduced PUMA protein expression.
34636989	1	85	theme	multifunctional	190:204	arg1	pathway					216:222	a multifunctional signaling pathway	188:222	a multifunctional signaling pathway that is important for cell survival	188:258	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	85	theme	multifunctional	190:204	arg1	important					232:240	important	232:240	important	232:240	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	1	85	theme	multifunctional	190:204	arg1	response					172:179	the unfolded protein response	151:179	the unfolded protein response (UPR)	151:185	Accumulation of misfolded proteins in ER activates the unfolded protein response (UPR), a multifunctional signaling pathway that is important for cell survival.
34636989	5	86	theme	ATPase	948:953	arg1	thapsigargin					964:975	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin)	911:976	We also verified the identified XBP1-dependent genes with specific silencing of this transcription factor during pharmacological ER stress induction with both an N-linked glycosylation inhibitor (tunicamycin) and a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) (thapsigargin).
34636989	7	87	theme	XBP1	1192:1195	arg1	network					1208:1214	an XBP1 regulatory network	1189:1214	an XBP1 regulatory network	1189:1214	Using next-generation sequencing followed by bioinformatic analysis of XBP1-binding motifs, we defined an XBP1 regulatory network and identified XBP1 as a repressor of PUMA (a proapoptotic gene) and IRE1 mRNA expression during the UPR.
33583770	9	0	theme	functional	1919:1928	arg1	role					1930:1933	an early functional role	1910:1933	an early functional role of galectin-1 in the myogenic program	1910:1971	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	8	1	theme	galectin-1	1789:1798	arg1	upregulation					1773:1784	the upregulation	1769:1784	the upregulation of galectin-1 (LGALS1)	1769:1807	Myogenesis was also associated with the regulation of several lectins, most notably the upregulation of galectin-1 (LGALS1).
33583770	3	2	theme	lectins	755:761	arg1	understanding					694:706	our molecular understanding	680:706	our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved	680:770	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	3	3	theme	diseases	569:576	arg1	development					537:547	the development	533:547	the development of several muscular diseases	533:576	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	3	4	theme	muscle	656:661	arg1	development					663:673	muscle development	656:673	muscle development	656:673	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	6	5	theme	glycoepitopes	1361:1373	arg1	role					1347:1350	a functional role	1334:1350	a functional role of these glycoepitopes in myogenesis	1334:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	3	6	theme	lectin-mediated	612:626	arg1	functions					628:636	essential glycan- and lectin-mediated functions	590:636	essential glycan- and lectin-mediated functions	590:636	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	1	7	theme	organisms	270:278	arg1	development					241:251	the development	237:251	the development of multicellular organisms	237:278	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	2	8	with	regulation	434:443	arg1	lectins					418:424	specific glycan-binding lectins	394:424	specific glycan-binding lectins	394:424	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	7	9	theme	multiple	1533:1540	arg1	approaches					1556:1565	multiple fragmentation approaches	1533:1565	multiple fragmentation approaches	1533:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	3	10	theme	glycan-	600:606	arg1	functions					628:636	essential glycan- and lectin-mediated functions	590:636	essential glycan- and lectin-mediated functions	590:636	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	1	11	theme	covalent	177:184	arg1	addition					186:193	the covalent addition	173:193	the covalent addition of glycans that play an important role in the development of multicellular organisms	173:278	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	9	12	theme	myogenic	1956:1963	arg1	program					1965:1971	the myogenic program	1952:1971	the myogenic program	1952:1971	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	10	13	from	changes	1995:2001	arg1	N-glycosylation					2006:2020	N-glycosylation	2006:2020	N-glycosylation	2006:2020	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	10	13	from	changes	1995:2001	arg1	upregulation					2030:2041	the upregulation	2026:2041	the upregulation of galectin-1 during postnatal skeletal muscle development	2026:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	6	14	theme	functional	1336:1345	arg1	role					1347:1350	a functional role	1334:1350	a functional role of these glycoepitopes in myogenesis	1334:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	10	15	theme	skeletal	2074:2081	arg1	development					2090:2100	postnatal skeletal muscle development	2064:2100	postnatal skeletal muscle development	2064:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	6	16	theme	released	1092:1099	arg1	glycans					1110:1116	released N-linked glycans	1092:1116	released N-linked glycans	1092:1116	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	12	17	theme	healthy	2427:2433	arg1	development					2442:2452	healthy muscle development	2427:2452	healthy muscle development	2427:2452	Our data form a valuable resource to further understand the glycobiology of myogenesis and will aid the development of intervention strategies to promote healthy muscle development or regeneration.
33583770	11	18	dep	viruses	2186:2192	arg1	overexpress					2197:2207	overexpress	2197:2207	to overexpress galectin-1 in the musculature	2194:2237	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	3	19	theme	Aberrant	477:484	arg1	glycosylation					494:506	Aberrant protein glycosylation	477:506	Aberrant protein glycosylation	477:506	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	7	20	theme	regulated	1610:1618	arg1	glycans					1620:1626	these regulated glycans	1604:1626	these regulated glycans including several integrins and growth factor receptors	1604:1682	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	20	theme	regulated	1610:1618	arg1	integrins					1646:1654	several integrins	1638:1654	several integrins	1638:1654	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	20	theme	regulated	1610:1618	arg1	receptors					1674:1682	growth factor receptors	1660:1682	growth factor receptors	1660:1682	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	12	21	theme	intervention	2392:2403	arg1	strategies					2405:2414	intervention strategies	2392:2414	intervention strategies	2392:2414	Our data form a valuable resource to further understand the glycobiology of myogenesis and will aid the development of intervention strategies to promote healthy muscle development or regeneration.
33583770	4	22	from	myogenesis	906:915	arg1	culture					925:931	cell culture	920:931	cell culture	920:931	Here, we quantified dynamic remodeling of the membrane-associated proteome during a time-course of myogenesis in cell culture.
33583770	9	23	from	role	1930:1933	arg1	program					1965:1971	the myogenic program	1952:1971	the myogenic program	1952:1971	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	1	24	theme	secreted	139:146	arg1	proteins					148:155	Many cell surface and secreted proteins	117:155	proteins	148:155	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	8	25	theme	several	1739:1745	arg1	lectins					1747:1753	several lectins	1739:1753	several lectins	1739:1753	Myogenesis was also associated with the regulation of several lectins, most notably the upregulation of galectin-1 (LGALS1).
33583770	7	26	theme	glycopeptides	1514:1526	arg1	labeling					1480:1487	multiplexed stable isotope labeling	1453:1487	multiplexed stable isotope labeling	1453:1487	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	26	theme	glycopeptides	1514:1526	arg1	analysis					1493:1500	analysis	1493:1500	analysis of enriched glycopeptides with multiple fragmentation approaches	1493:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	27	theme	glycoproteomic	1424:1437	arg1	analysis					1439:1446	dynamic quantitative glycoproteomic analysis	1403:1446	dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches	1403:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	10	28	gly	N-glycosylation	2006:2020	arg1	galectin-1					2046:2055	galectin-1	2046:2055	galectin-1	2046:2055	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	3	29	theme	molecular	684:692	arg1	understanding					694:706	our molecular understanding	680:706	our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved	680:770	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	7	30	theme	dynamic	1403:1409	arg1	analysis					1439:1446	dynamic quantitative glycoproteomic analysis	1403:1446	dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches	1403:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	31	gly	glycopeptides	1514:1526	arg2	glycopeptides					1514:1526	enriched glycopeptides	1505:1526	enriched glycopeptides with multiple fragmentation approaches	1505:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	5	32	theme	important	994:1002	arg1	lectins					1004:1010	several important lectins	986:1010	several important lectins	986:1010	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	2	33	theme	glycan	287:292	arg1	modifications					294:306	These glycan modifications	281:306	These glycan modifications	281:306	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	11	34	with	Treatment	2125:2133	arg1	viruses					2186:2192	recombinant adeno-associated viruses	2157:2192	recombinant adeno-associated viruses to overexpress galectin-1 in the musculature	2157:2237	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	6	35	theme	glycans	1110:1116	arg1	quantification					1074:1087	Glycomics-based quantification	1058:1087	Glycomics-based quantification of released N-linked glycans	1058:1116	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	11	36	theme	muscle	2260:2265	arg1	mass					2267:2270	enhanced muscle mass	2251:2270	enhanced muscle mass	2251:2270	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	4	37	theme	membrane-associated	853:871	arg1	proteome					873:880	the membrane-associated proteome	849:880	the membrane-associated proteome	849:880	Here, we quantified dynamic remodeling of the membrane-associated proteome during a time-course of myogenesis in cell culture.
33583770	6	38	from	role	1347:1350	arg1	myogenesis					1378:1387	myogenesis	1378:1387	myogenesis	1378:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	3	39	theme	protein	486:492	arg1	glycosylation					494:506	Aberrant protein glycosylation	477:506	Aberrant protein glycosylation	477:506	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	9	40	theme	CRISPR/Cas9-mediated	1810:1829	arg1	deletion					1831:1838	CRISPR/Cas9-mediated deletion	1810:1838	CRISPR/Cas9-mediated deletion of Lgals1	1810:1848	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	6	41	theme	responsible	1226:1236	arg1	glycosyltransferases					1188:1207	glycosyltransferases	1188:1207	glycosyltransferases	1188:1207	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	0	42	from	Role	40:43	arg1	Myogenesis					82:91	Myogenesis	82:91	Myogenesis	82:91	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development.
33583770	0	42	from	Role	40:43	arg1	Muscle					97:102	Muscle	97:102	Muscle	97:102	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development.
33583770	0	43	theme	Integrated	0:9	arg1	Glycoproteomics					11:25	Integrated Glycoproteomics	0:25	Integrated Glycoproteomics	0:25	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development.
33583770	8	44	dep	lectins	1747:1753	arg1	upregulation					1773:1784	the upregulation	1769:1784	the upregulation of galectin-1 (LGALS1)	1769:1807	Myogenesis was also associated with the regulation of several lectins, most notably the upregulation of galectin-1 (LGALS1).
33583770	0	45	dep	Myogenesis	82:91	arg1	Development					104:114	Development	104:114	Development	104:114	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development.
33583770	7	46	theme	fragmentation	1542:1554	arg1	approaches					1556:1565	multiple fragmentation approaches	1533:1565	multiple fragmentation approaches	1533:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	4	47	theme	dynamic	827:833	arg1	remodeling					835:844	dynamic remodeling	827:844	dynamic remodeling of the membrane-associated proteome	827:880	Here, we quantified dynamic remodeling of the membrane-associated proteome during a time-course of myogenesis in cell culture.
33583770	2	48	theme	signaling	466:474	arg1	interactions					376:387	interactions	376:387	interactions with specific glycan-binding lectins	376:424	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	2	48	theme	signaling	466:474	arg1	regulation					434:443	the regulation	430:443	the regulation of receptor-mediated signaling	430:474	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	1	49	theme	Many	117:120	arg1	surface					127:133	Many cell surface and secreted proteins	117:155	surface	127:133	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	1	50	mod	modified	161:168	arg3	addition					186:193	the covalent addition	173:193	the covalent addition of glycans that play an important role in the development of multicellular organisms	173:278	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	1	50	mod	modified	161:168	arg1	surface					127:133	Many cell surface and secreted proteins	117:155	surface	127:133	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	1	50	mod	modified	161:168	arg1	proteins					148:155	Many cell surface and secreted proteins	117:155	proteins	148:155	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	0	51	theme	Galectin-1	68:77	arg1	Role					40:43	a Role	38:43	a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development	38:114	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development.
33583770	4	52	theme	myogenesis	906:915	arg1	time-course					891:901	time-course	891:901	time-course	891:901	Here, we quantified dynamic remodeling of the membrane-associated proteome during a time-course of myogenesis in cell culture.
33583770	7	53	theme	enriched	1505:1512	arg1	glycopeptides					1514:1526	enriched glycopeptides	1505:1526	enriched glycopeptides with multiple fragmentation approaches	1505:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	3	54	theme	precise	715:721	arg1	glycans					723:729	the precise glycans	711:729	the precise glycans	711:729	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	4	55	theme	cell	920:923	arg1	culture					925:931	cell culture	920:931	cell culture	920:931	Here, we quantified dynamic remodeling of the membrane-associated proteome during a time-course of myogenesis in cell culture.
33583770	10	56	theme	similar	1987:1993	arg1	changes					1995:2001	similar changes	1987:2001	similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development	1987:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	0	57	theme	N-Glycosylation	48:62	arg1	Role					40:43	a Role	38:43	a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development	38:114	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development.
33583770	1	58	theme	cell	122:125	arg1	surface					127:133	Many cell surface and secreted proteins	117:155	surface	127:133	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	2	59	with	interactions	376:387	arg1	lectins					418:424	specific glycan-binding lectins	394:424	specific glycan-binding lectins	394:424	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	11	60	theme	enhanced	2251:2258	arg1	mass					2267:2270	enhanced muscle mass	2251:2270	enhanced muscle mass	2251:2270	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	6	61	theme	digalactose-to-sialic	1289:1309	arg1	switch					1316:1321	a previously unknown digalactose-to-sialic acid switch	1268:1321	a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis	1268:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	11	62	theme	adeno-associated	2169:2184	arg1	viruses					2186:2192	recombinant adeno-associated viruses	2157:2192	recombinant adeno-associated viruses to overexpress galectin-1 in the musculature	2157:2237	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	11	63	theme	new-born	2138:2145	arg1	mice					2147:2150	new-born mice	2138:2150	new-born mice	2138:2150	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	1	64	theme	important	219:227	arg1	role					229:232	an important role	216:232	an important role	216:232	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	3	65	theme	enzymes	742:748	arg1	understanding					694:706	our molecular understanding	680:706	our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved	680:770	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	2	66	theme	specific	394:401	arg1	lectins					418:424	specific glycan-binding lectins	394:424	specific glycan-binding lectins	394:424	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	9	67	theme	early	1913:1917	arg1	role					1930:1933	an early functional role	1910:1933	an early functional role of galectin-1 in the myogenic program	1910:1971	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	7	68	theme	stable	1465:1470	arg1	labeling					1480:1487	multiplexed stable isotope labeling	1453:1487	multiplexed stable isotope labeling	1453:1487	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	69	with	analysis	1439:1446	arg1	labeling					1480:1487	multiplexed stable isotope labeling	1453:1487	multiplexed stable isotope labeling	1453:1487	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	69	with	analysis	1439:1446	arg1	analysis					1493:1500	analysis	1493:1500	analysis of enriched glycopeptides with multiple fragmentation approaches	1493:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	3	70	theme	muscular	560:567	arg1	diseases					569:576	several muscular diseases	552:576	several muscular diseases	552:576	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	12	71	theme	myogenesis	2349:2358	arg1	glycobiology					2333:2344	the glycobiology	2329:2344	the glycobiology of myogenesis	2329:2358	Our data form a valuable resource to further understand the glycobiology of myogenesis and will aid the development of intervention strategies to promote healthy muscle development or regeneration.
33583770	10	72	theme	galectin-1	2046:2055	arg1	N-glycosylation					2006:2020	N-glycosylation	2006:2020	N-glycosylation	2006:2020	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	10	72	theme	galectin-1	2046:2055	arg1	upregulation					2030:2041	the upregulation	2026:2041	the upregulation of galectin-1 during postnatal skeletal muscle development	2026:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	1	73	theme	multicellular	256:268	arg1	organisms					270:278	multicellular organisms	256:278	multicellular organisms	256:278	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	7	74	theme	growth	1660:1665	arg1	receptors					1674:1682	growth factor receptors	1660:1682	growth factor receptors	1660:1682	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	9	75	theme	galectin-1	1938:1947	arg1	role					1930:1933	an early functional role	1910:1933	an early functional role of galectin-1 in the myogenic program	1910:1971	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	3	76	theme	essential	590:598	arg1	functions					628:636	essential glycan- and lectin-mediated functions	590:636	essential glycan- and lectin-mediated functions	590:636	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	5	77	theme	wide-spread	946:956	arg1	changes					958:964	wide-spread changes	946:964	wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis	946:1055	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	10	78	theme	muscle	2083:2088	arg1	development					2090:2100	postnatal skeletal muscle development	2064:2100	postnatal skeletal muscle development	2064:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	6	79	theme	N-linked	1101:1108	arg1	glycans					1110:1116	released N-linked glycans	1092:1116	released N-linked glycans	1092:1116	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	7	80	theme	factor	1667:1672	arg1	receptors					1674:1682	growth factor receptors	1660:1682	growth factor receptors	1660:1682	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	10	81	theme	postnatal	2064:2072	arg1	development					2090:2100	postnatal skeletal muscle development	2064:2100	postnatal skeletal muscle development	2064:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	1	82	theme	glycans	198:204	arg1	addition					186:193	the covalent addition	173:193	the covalent addition of glycans that play an important role in the development of multicellular organisms	173:278	Many cell surface and secreted proteins are modified by the covalent addition of glycans that play an important role in the development of multicellular organisms.
33583770	7	83	gly	glycoproteins	1578:1590	arg1	glycoproteins					1578:1590	glycoproteins	1578:1590	glycoproteins modified by these regulated glycans including several integrins and growth factor receptors	1578:1682	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	2	84	theme	extracellular	351:363	arg1	matrix					365:370	the extracellular matrix	347:370	the extracellular matrix	347:370	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	7	85	with	glycopeptides	1514:1526	arg1	approaches					1556:1565	multiple fragmentation approaches	1533:1565	multiple fragmentation approaches	1533:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	6	86	theme	Glycomics-based	1058:1072	arg1	quantification					1074:1087	Glycomics-based quantification	1058:1087	Glycomics-based quantification of released N-linked glycans	1058:1116	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	7	87	theme	several	1638:1644	arg1	integrins					1646:1654	several integrins	1638:1654	several integrins	1638:1654	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	12	88	theme	muscle	2435:2440	arg1	development					2442:2452	healthy muscle development	2427:2452	healthy muscle development	2427:2452	Our data form a valuable resource to further understand the glycobiology of myogenesis and will aid the development of intervention strategies to promote healthy muscle development or regeneration.
33583770	6	89	link	N-linked	1101:1108	arg1	glycans					1110:1116	released N-linked glycans	1092:1116	released N-linked glycans	1092:1116	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	5	90	theme	lectins	1004:1010	arg1	abundance					973:981	the abundance	969:981	the abundance of several important lectins and enzymes facilitating glycan biosynthesis	969:1055	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	6	91	with	consistent	1154:1163	arg1	regulation					1174:1183	the regulation	1170:1183	the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis	1170:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	5	92	theme	enzymes	1016:1022	arg1	abundance					973:981	the abundance	969:981	the abundance of several important lectins and enzymes facilitating glycan biosynthesis	969:1055	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	8	93	theme	lectins	1747:1753	arg1	regulation					1725:1734	the regulation	1721:1734	the regulation of several lectins, most notably the upregulation of galectin-1 (LGALS1)	1721:1807	Myogenesis was also associated with the regulation of several lectins, most notably the upregulation of galectin-1 (LGALS1).
33583770	12	94	theme	strategies	2405:2414	arg1	development					2377:2387	the development	2373:2387	the development of intervention strategies	2373:2414	Our data form a valuable resource to further understand the glycobiology of myogenesis and will aid the development of intervention strategies to promote healthy muscle development or regeneration.
33583770	7	95	theme	isotope	1472:1478	arg1	labeling					1480:1487	multiplexed stable isotope labeling	1453:1487	multiplexed stable isotope labeling	1453:1487	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	7	96	theme	quantitative	1411:1422	arg1	analysis					1439:1446	dynamic quantitative glycoproteomic analysis	1403:1446	dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches	1403:1565	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33583770	6	97	theme	glycome	1146:1152	arg1	remodeling					1128:1137	remodeling	1128:1137	remodeling of the glycome	1128:1152	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	12	98	theme	valuable	2289:2296	arg1	resource					2298:2305	a valuable resource	2287:2305	a valuable resource to further understand the glycobiology of myogenesis	2287:2358	Our data form a valuable resource to further understand the glycobiology of myogenesis and will aid the development of intervention strategies to promote healthy muscle development or regeneration.
33583770	5	99	from	changes	958:964	arg1	abundance					973:981	the abundance	969:981	the abundance of several important lectins and enzymes facilitating glycan biosynthesis	969:1055	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	5	100	theme	several	986:992	arg1	lectins					1004:1010	several important lectins	986:1010	several important lectins	986:1010	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	5	101	theme	glycan	1037:1042	arg1	biosynthesis					1044:1055	glycan biosynthesis	1037:1055	glycan biosynthesis	1037:1055	We observed wide-spread changes in the abundance of several important lectins and enzymes facilitating glycan biosynthesis.
33583770	6	102	theme	glycosidases	1213:1224	arg1	regulation					1174:1183	the regulation	1170:1183	the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis	1170:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	2	103	theme	glycan-binding	403:416	arg1	lectins					418:424	specific glycan-binding lectins	394:424	specific glycan-binding lectins	394:424	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	9	104	theme	Lgals1	1843:1848	arg1	deletion					1831:1838	CRISPR/Cas9-mediated deletion	1810:1838	CRISPR/Cas9-mediated deletion of Lgals1	1810:1848	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	6	105	theme	glycosyltransferases	1188:1207	arg1	regulation					1174:1183	the regulation	1170:1183	the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis	1170:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	3	106	theme	glycans	723:729	arg1	understanding					694:706	our molecular understanding	680:706	our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved	680:770	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	2	107	theme	receptor-mediated	448:464	arg1	signaling					466:474	receptor-mediated signaling	448:474	receptor-mediated signaling	448:474	These glycan modifications enable communication between cells and the extracellular matrix via interactions with specific glycan-binding lectins and the regulation of receptor-mediated signaling.
33583770	10	108	located	observed	2107:2114	arg2	changes					1995:2001	similar changes	1987:2001	similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development	1987:2100	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	10	108	located	observed	2107:2114	arg1	mice					2119:2122	mice	2119:2122	mice	2119:2122	Importantly, similar changes in N-glycosylation and the upregulation of galectin-1 during postnatal skeletal muscle development were observed in mice.
33583770	9	109	theme	myotube	1880:1886	arg1	formation					1888:1896	myotube formation	1880:1896	myotube formation	1880:1896	CRISPR/Cas9-mediated deletion of Lgals1 inhibited differentiation and myotube formation, suggesting an early functional role of galectin-1 in the myogenic program.
33583770	6	110	theme	acid	1311:1314	arg1	switch					1316:1321	a previously unknown digalactose-to-sialic acid switch	1268:1321	a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis	1268:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	3	111	theme	several	552:558	arg1	diseases					569:576	several muscular diseases	552:576	several muscular diseases	552:576	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	11	112	theme	recombinant	2157:2167	arg1	viruses					2186:2192	recombinant adeno-associated viruses	2157:2192	recombinant adeno-associated viruses to overexpress galectin-1 in the musculature	2157:2237	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	6	113	theme	unknown	1281:1287	arg1	switch					1316:1321	a previously unknown digalactose-to-sialic acid switch	1268:1321	a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis	1268:1387	Glycomics-based quantification of released N-linked glycans confirmed remodeling of the glycome consistent with the regulation of glycosyltransferases and glycosidases responsible for their formation including a previously unknown digalactose-to-sialic acid switch supporting a functional role of these glycoepitopes in myogenesis.
33583770	3	114	theme	catalytic	732:740	arg1	enzymes					742:748	catalytic enzymes	732:748	catalytic enzymes	732:748	Aberrant protein glycosylation has been associated with the development of several muscular diseases, suggesting essential glycan- and lectin-mediated functions in myogenesis and muscle development, but our molecular understanding of the precise glycans, catalytic enzymes, and lectins involved remains only partially understood.
33583770	4	115	theme	proteome	873:880	arg1	remodeling					835:844	dynamic remodeling	827:844	dynamic remodeling of the membrane-associated proteome	827:880	Here, we quantified dynamic remodeling of the membrane-associated proteome during a time-course of myogenesis in cell culture.
33583770	11	116	theme	mice	2147:2150	arg1	Treatment					2125:2133	Treatment	2125:2133	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature	2125:2237	Treatment of new-born mice with recombinant adeno-associated viruses to overexpress galectin-1 in the musculature resulted in enhanced muscle mass.
33583770	7	117	theme	multiplexed	1453:1463	arg1	labeling					1480:1487	multiplexed stable isotope labeling	1453:1487	multiplexed stable isotope labeling	1453:1487	Furthermore, dynamic quantitative glycoproteomic analysis with multiplexed stable isotope labeling and analysis of enriched glycopeptides with multiple fragmentation approaches identified glycoproteins modified by these regulated glycans including several integrins and growth factor receptors.
33362243	5	0	theme	viral	651:655	arg1	HA					672:673	HA	672:673	HA	672:673	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	5	0	theme	viral	651:655	arg1	hemagglutinin					657:669	viral hemagglutinin	651:669	the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes	647:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	7	1	theme	better	1068:1073	arg1	efficacy					1086:1093	much better protective efficacy	1063:1093	much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA	1063:1184	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	6	2	theme	NLG	765:767	arg1	modifications					769:781	2 NLG modifications	763:781	2 NLG modifications	763:781	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	8	3	theme	lower	1397:1401	arg1	tracts					1415:1420	the upper and lower respiratory tracts	1383:1420	the upper and lower respiratory tracts	1383:1420	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	10	4	theme	influenza	1737:1745	arg1	vaccines					1747:1754	avian influenza vaccines	1731:1754	avian influenza vaccines	1731:1754	These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
33362243	6	5	with	viruses	910:916	arg1	change					926:931	no change	923:931	no change in the viral antigenicity	923:957	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	9	6	theme	HA	1487:1488	arg1	modification					1494:1505	the HA NLG modification	1483:1505	the HA NLG modification	1483:1505	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	6	7	theme	cell	830:833	arg1	culture					835:841	cell culture	830:841	cell culture	830:841	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	7	8	theme	NLG	1039:1041	arg1	additions					1043:1051	2 HA NLG additions	1034:1051	2 HA NLG additions	1034:1051	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	10	9	theme	strong	1677:1682	arg1	potential					1684:1692	the strong potential	1673:1692	the strong potential of HA NLG modifications in designing avian influenza vaccines	1673:1754	These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
33362243	0	10	theme	influenza	76:84	arg1	virus					86:90	H7N9 influenza virus	71:90	H7N9 influenza virus	71:90	Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
33362243	2	11	theme	human	302:306	arg1	infection					308:316	human infection	302:316	human infection with an almost 40% case-fatality rate	302:354	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	10	12	theme	avian	1731:1735	arg1	vaccines					1747:1754	avian influenza vaccines	1731:1754	avian influenza vaccines	1731:1754	These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
33362243	9	13	theme	NLG	1490:1492	arg1	modification					1494:1505	the HA NLG modification	1483:1505	the HA NLG modification	1483:1505	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	10	14	theme	NLG	1700:1702	arg1	modifications					1704:1716	HA NLG modifications	1697:1716	HA NLG modifications	1697:1716	These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
33362243	8	15	from	replication	1368:1378	arg1	tracts					1415:1420	the upper and lower respiratory tracts	1383:1420	the upper and lower respiratory tracts	1383:1420	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	6	16	theme	vaccine	902:908	arg1	viruses					910:916	other vaccine viruses	896:916	other vaccine viruses with no change in the viral antigenicity	896:957	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	8	17	theme	upper	1387:1391	arg1	tracts					1415:1420	the upper and lower respiratory tracts	1383:1420	the upper and lower respiratory tracts	1383:1420	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	2	18	theme	H7N9	235:238	arg1	virus					240:244	the low pathogenic avian influenza H7N9 virus	200:244	the low pathogenic avian influenza H7N9 virus	200:244	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	5	19	theme	H7N9	539:542	arg1	vaccine					550:556	an efficacious H7N9 human vaccine	524:556	an efficacious H7N9 human vaccine	524:556	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	6	20	dep	did	892:894	arg1	than					887:890	than	887:890	than	887:890	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	5	21	theme	hemagglutinin	657:669	arg1	protein					676:682	the viral hemagglutinin (HA) protein	647:682	the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes	647:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	2	22	theme	avian	219:223	arg1	virus					240:244	the low pathogenic avian influenza H7N9 virus	200:244	the low pathogenic avian influenza H7N9 virus	200:244	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	1	23	theme	severe	131:136	arg1	threats					145:151	severe health threats	131:151	severe health threats to humans	131:161	Zoonotic avian influenza viruses pose severe health threats to humans.
33362243	7	24	with	candidate	1153:1161	arg1	HA					1183:1184	wild-type (WT) HA	1168:1184	wild-type (WT) HA	1168:1184	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	7	25	theme	inactivated	978:988	arg1	formulation					998:1008	an inactivated vaccine formulation	975:1008	an inactivated vaccine formulation	975:1008	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	2	26	theme	February	256:263	arg1	2013					265:268	February 2013	256:268	February 2013	256:268	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	8	27	theme	ferret	1235:1240	arg1	model					1242:1246	a ferret model	1233:1246	a ferret model	1233:1246	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	5	28	theme	NLG	724:726	arg1	changes					728:734	H7 HA NLG changes	718:734	H7 HA NLG changes	718:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	5	29	from	patterns	603:610	arg1	protein					676:682	the viral hemagglutinin (HA) protein	647:682	the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes	647:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	7	30	from	efficacy	1086:1093	arg1	mice					1129:1132	mice	1129:1132	mice than did a vaccine candidate with wild-type (WT) HA	1129:1184	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	7	31	theme	vaccine	1145:1151	arg1	candidate					1153:1161	a vaccine candidate	1143:1161	a vaccine candidate with wild-type (WT) HA	1143:1184	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	9	32	theme	study	1476:1480	arg1	mode					1461:1464	a mode	1459:1464	a mode of action study	1459:1480	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	4	33	theme	strains	460:466	arg1	emergence					429:437	the emergence	425:437	the emergence of highly pathogenic strains	425:466	However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics.
33362243	8	34	theme	vaccine	1265:1271	arg1	viruses					1273:1279	the 2 NLG-added vaccine viruses	1249:1279	the 2 NLG-added vaccine viruses	1249:1279	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	5	35	theme	H7	718:719	arg1	changes					728:734	H7 HA NLG changes	718:734	H7 HA NLG changes	718:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	3	36	theme	poultry	372:378	arg1	Vaccination					357:367	Vaccination	357:367	Vaccination of poultry	357:378	Vaccination of poultry appears to reduce human infections.
33362243	5	37	theme	HA	721:722	arg1	changes					728:734	H7 HA NLG changes	718:734	H7 HA NLG changes	718:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	5	38	theme	vaccine	571:577	arg1	viruses					579:585	vaccine viruses	571:585	vaccine viruses	571:585	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	1	39	theme	avian	102:106	arg1	viruses					118:124	Zoonotic avian influenza viruses	93:124	Zoonotic avian influenza viruses	93:124	Zoonotic avian influenza viruses pose severe health threats to humans.
33362243	8	40	theme	hemagglutination-inhibiting	1294:1320	arg1	antibodies					1322:1331	hemagglutination-inhibiting antibodies	1294:1331	hemagglutination-inhibiting antibodies	1294:1331	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	6	41	theme	growth	814:819	arg1	rates					821:825	higher growth rates	807:825	higher growth rates	807:825	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	3	42	theme	human	398:402	arg1	infections					404:413	human infections	398:413	human infections	398:413	Vaccination of poultry appears to reduce human infections.
33362243	0	43	theme	H7N9	71:74	arg1	virus					86:90	H7N9 influenza virus	71:90	H7N9 influenza virus	71:90	Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
33362243	7	44	dep	wild-type	1168:1176	arg1	WT					1179:1180	WT	1179:1180	WT	1179:1180	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	7	45	theme	lethal	1103:1108	arg1	challenge					1116:1124	lethal viral challenge	1103:1124	lethal viral challenge	1103:1124	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	7	46	with	virus	1023:1027	arg1	additions					1043:1051	2 HA NLG additions	1034:1051	2 HA NLG additions	1034:1051	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	2	47	theme	several	167:173	arg1	subtypes					181:188	several viral subtypes	167:188	several viral subtypes reported	167:197	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	4	48	theme	H7N9	497:500	arg1	pandemics					502:510	H7N9 pandemics	497:510	H7N9 pandemics	497:510	However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics.
33362243	9	49	theme	protein	1531:1537	arg1	contents					1539:1546	HA protein contents	1528:1546	HA protein contents incorporated into viral particles	1528:1580	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	2	50	theme	low	204:206	arg1	virus					240:244	the low pathogenic avian influenza H7N9 virus	200:244	the low pathogenic avian influenza H7N9 virus	200:244	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	7	51	theme	viral	1198:1202	arg1	replication					1204:1214	viral replication	1198:1214	viral replication	1198:1214	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	6	52	theme	cross-reactive	861:874	arg1	antibodies					876:885	more cross-reactive antibodies	856:885	more cross-reactive antibodies	856:885	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	9	53	theme	viral	1566:1570	arg1	particles					1572:1580	viral particles	1566:1580	viral particles	1566:1580	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	2	54	theme	case-fatality	337:349	arg1	rate					351:354	an almost 40% case-fatality rate	323:354	an almost 40% case-fatality rate	323:354	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	8	55	theme	WT	1440:1441	arg1	vaccines					1446:1453	the WT HA vaccines	1436:1453	the WT HA vaccines	1436:1453	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	10	56	theme	HA	1697:1698	arg1	modifications					1704:1716	HA NLG modifications	1697:1716	HA NLG modifications	1697:1716	These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
33362243	7	57	theme	HA	1036:1037	arg1	additions					1043:1051	2 HA NLG additions	1034:1051	2 HA NLG additions	1034:1051	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	5	58	theme	glycosylation	624:636	arg1	patterns					603:610	the patterns	599:610	the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes	599:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	2	59	theme	infection	308:316	arg1	cases					293:297	more than 1,500 cases	277:297	more than 1,500 cases of human infection with an almost 40% case-fatality rate	277:354	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	7	60	theme	vaccine	1015:1021	arg1	virus					1023:1027	the vaccine virus	1011:1027	the vaccine virus with 2 HA NLG additions	1011:1051	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	10	61	theme	modifications	1704:1716	arg1	potential					1684:1692	the strong potential	1673:1692	the strong potential of HA NLG modifications in designing avian influenza vaccines	1673:1754	These results suggest the strong potential of HA NLG modifications in designing avian influenza vaccines.
33362243	9	62	theme	vaccine	1633:1639	arg1	efficacy					1641:1648	vaccine efficacy	1633:1648	vaccine efficacy	1633:1648	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	6	63	theme	other	896:900	arg1	viruses					910:916	other vaccine viruses	896:916	other vaccine viruses with no change in the viral antigenicity	896:957	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	4	64	theme	pathogenic	449:458	arg1	strains					460:466	highly pathogenic strains	442:466	highly pathogenic strains	442:466	However, the emergence of highly pathogenic strains has increased concerns about H7N9 pandemics.
33362243	7	65	theme	vaccine	990:996	arg1	formulation					998:1008	an inactivated vaccine formulation	975:1008	an inactivated vaccine formulation	975:1008	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	2	66	theme	influenza	225:233	arg1	virus					240:244	the low pathogenic avian influenza H7N9 virus	200:244	the low pathogenic avian influenza H7N9 virus	200:244	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	5	67	theme	human	544:548	arg1	vaccine					550:556	an efficacious H7N9 human vaccine	524:556	an efficacious H7N9 human vaccine	524:556	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	7	68	theme	viral	1110:1114	arg1	challenge					1116:1124	lethal viral challenge	1103:1124	lethal viral challenge	1103:1124	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	1	69	theme	health	138:143	arg1	threats					145:151	severe health threats	131:151	severe health threats to humans	131:161	Zoonotic avian influenza viruses pose severe health threats to humans.
33362243	7	70	theme	wild-type	1168:1176	arg1	HA					1183:1184	wild-type (WT) HA	1168:1184	wild-type (WT) HA	1168:1184	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	8	71	theme	HA	1443:1444	arg1	vaccines					1446:1453	the WT HA vaccines	1436:1453	the WT HA vaccines	1436:1453	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	5	72	theme	changes	728:734	arg1	patterns					706:713	evolutionary patterns	693:713	evolutionary patterns of H7 HA NLG changes	693:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	5	73	theme	efficacious	527:537	arg1	vaccine					550:556	an efficacious H7N9 human vaccine	524:556	an efficacious H7N9 human vaccine	524:556	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	6	74	theme	viral	940:944	arg1	antigenicity					946:957	the viral antigenicity	936:957	the viral antigenicity	936:957	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	5	75	theme	evolutionary	693:704	arg1	patterns					706:713	evolutionary patterns	693:713	evolutionary patterns of H7 HA NLG changes	693:734	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	9	76	theme	action	1469:1474	arg1	study					1476:1480	action study	1469:1480	action study	1469:1480	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	2	77	with	infection	308:316	arg1	rate					351:354	an almost 40% case-fatality rate	323:354	an almost 40% case-fatality rate	323:354	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	7	78	dep	mice	1129:1132	arg1	did					1139:1141	did	1139:1141	did	1139:1141	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	2	79	dep	%	335:335	arg1	40					333:334	40	333:334	40	333:334	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	6	80	from	change	926:931	arg1	antigenicity					946:957	the viral antigenicity	936:957	the viral antigenicity	936:957	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	2	81	dep	rate	351:354	arg1	%					335:335	%	335:335	%	335:335	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	5	82	theme	N-linked	615:622	arg1	glycosylation					624:636	N-linked glycosylation	615:636	N-linked glycosylation (NLG)	615:642	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	5	82	theme	N-linked	615:622	arg1	NLG					639:641	NLG	639:641	NLG	639:641	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	1	83	theme	Zoonotic	93:100	arg1	viruses					118:124	Zoonotic avian influenza viruses	93:124	Zoonotic avian influenza viruses	93:124	Zoonotic avian influenza viruses pose severe health threats to humans.
33362243	5	84	link	N-linked	615:622	arg1	glycosylation					624:636	N-linked glycosylation	615:636	N-linked glycosylation (NLG)	615:642	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	5	84	link	N-linked	615:622	arg1	NLG					639:641	NLG	639:641	NLG	639:641	To develop an efficacious H7N9 human vaccine, we designed vaccine viruses by changing the patterns of N-linked glycosylation (NLG) on the viral hemagglutinin (HA) protein based on evolutionary patterns of H7 HA NLG changes.
33362243	0	85	theme	efficacious	27:37	arg1	vaccine					55:61	an efficacious and immunogenic vaccine	24:61	an efficacious and immunogenic vaccine against H7N9 influenza virus	24:90	Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
33362243	1	86	theme	influenza	108:116	arg1	viruses					118:124	Zoonotic avian influenza viruses	93:124	Zoonotic avian influenza viruses	93:124	Zoonotic avian influenza viruses pose severe health threats to humans.
33362243	0	87	theme	immunogenic	43:53	arg1	vaccine					55:61	an efficacious and immunogenic vaccine	24:61	an efficacious and immunogenic vaccine against H7N9 influenza virus	24:90	Glycosylation generates an efficacious and immunogenic vaccine against H7N9 influenza virus.
33362243	6	88	theme	higher	807:812	arg1	rates					821:825	higher growth rates	807:825	higher growth rates	807:825	Notably, a virus in which 2 NLG modifications were added to HA showed higher growth rates in cell culture and elicited more cross-reactive antibodies than did other vaccine viruses with no change in the viral antigenicity.
33362243	2	89	theme	viral	175:179	arg1	subtypes					181:188	several viral subtypes	167:188	several viral subtypes reported	167:197	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	7	90	theme	protective	1075:1084	arg1	efficacy					1086:1093	much better protective efficacy	1063:1093	much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA	1063:1184	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	9	91	theme	HA	1528:1529	arg1	contents					1539:1546	HA protein contents	1528:1546	HA protein contents incorporated into viral particles	1528:1580	In a mode of action study, the HA NLG modification appeared to increase HA protein contents incorporated into viral particles, which would be successfully translated to improve vaccine efficacy.
33362243	7	92	dep	did	1139:1141	arg1	than					1134:1137	than	1134:1137	than	1134:1137	Developed into an inactivated vaccine formulation, the vaccine virus with 2 HA NLG additions exhibited much better protective efficacy against lethal viral challenge in mice than did a vaccine candidate with wild-type (WT) HA by reducing viral replication in the lungs.
33362243	2	93	theme	pathogenic	208:217	arg1	virus					240:244	the low pathogenic avian influenza H7N9 virus	200:244	the low pathogenic avian influenza H7N9 virus	200:244	Of several viral subtypes reported, the low pathogenic avian influenza H7N9 virus has since February 2013 caused more than 1,500 cases of human infection with an almost 40% case-fatality rate.
33362243	8	94	theme	respiratory	1403:1413	arg1	tracts					1415:1420	the upper and lower respiratory tracts	1383:1420	the upper and lower respiratory tracts	1383:1420	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	8	95	theme	NLG-added	1255:1263	arg1	viruses					1273:1279	the 2 NLG-added vaccine viruses	1249:1279	the 2 NLG-added vaccine viruses	1249:1279	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33362243	8	96	theme	viral	1362:1366	arg1	replication					1368:1378	viral replication	1362:1378	viral replication in the upper and lower respiratory tracts	1362:1420	In a ferret model, the 2 NLG-added vaccine viruses also induced hemagglutination-inhibiting antibodies and significantly suppressed viral replication in the upper and lower respiratory tracts compared with the WT HA vaccines.
33343565	3	0	theme	removal	629:635	arg1	N-terminus					614:623	the IgG N-terminus	606:623	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	6	1	theme	antibody	1374:1381	arg1	titers					1383:1388	up to 150-fold higher antibody titers	1352:1388	up to 150-fold higher antibody titers than ZE3 antigen alone	1352:1411	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	3	2	theme	light	648:652	arg1	chain					654:658	the IgG light chain	640:658	the IgG light chain	640:658	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	3	theme	Complement	518:527	arg1	C1q					537:539	Complement protein C1q	518:539	Complement protein C1q binding of the IgG fusions	518:566	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	4	theme	plant-specific	864:877	arg1	xylose					891:896	plant-specific β1,2-linked xylose	864:896	plant-specific β1,2-linked xylose	864:896	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	5	link	N-linked	921:928	arg1	glycans					930:936	α1,3-linked fucose N-linked glycans	902:936	α1,3-linked fucose N-linked glycans	902:936	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	6	theme	regions	667:673	arg1	removal					629:635	removal	629:635	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	7	dep	addition	679:686	arg1	3					676:676	3	676:676	3	676:676	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	1	8	theme	IgG	196:198	arg1	domain					203:208	the IgG Fc domain	192:208	the IgG Fc domain	192:208	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	3	9	theme	C1q	537:539	arg1	binding					541:547	Complement protein C1q binding	518:547	Complement protein C1q binding of the IgG fusions	518:566	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	10	theme	addition	679:686	arg1	N-terminus					614:623	the IgG N-terminus	606:623	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	11	theme	IgG	725:727	arg1	Fc					729:730	the IgG Fc	721:730	the IgG Fc	721:730	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	0	12	theme	Plant-Made	41:50	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	1	13	theme	IgG	307:309	arg1	fusions					311:317	IgG fusions	307:317	IgG fusions	307:317	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	0	14	theme	Expressing	9:18	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	4	15	theme	fusions	1014:1020	arg1	solubility					977:986	solubility	977:986	solubility	977:986	We also characterized the expression, solubility, and stability of the IgG fusions.
33343565	4	15	theme	fusions	1014:1020	arg1	stability					993:1001	stability	993:1001	stability	993:1001	We also characterized the expression, solubility, and stability of the IgG fusions.
33343565	4	15	theme	fusions	1014:1020	arg1	expression					965:974	expression	965:974	expression	965:974	We also characterized the expression, solubility, and stability of the IgG fusions.
33343565	0	16	theme	Fusion	56:61	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	5	17	theme	high	1133:1136	arg1	stability					1138:1146	high stability	1133:1146	high stability	1133:1146	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	3	18	theme	hexamer-inducing	691:706	arg1	mutations					708:716	hexamer-inducing mutations	691:716	hexamer-inducing mutations in the IgG Fc	691:730	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	19	theme	α1,3-linked fucose	902:919	arg1	glycans					930:936	α1,3-linked fucose N-linked glycans	902:936	α1,3-linked fucose N-linked glycans	902:936	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	7	20	theme	other	1489:1493	arg1	vaccines					1495:1502	other vaccines	1489:1502	other vaccines	1489:1502	We anticipate these findings will be broadly applicable to the creation of other vaccines and antibody-based therapeutics.
33343565	5	21	theme	g	1186:1186	arg1	weight					1199:1204	g leaf fresh weight	1186:1204	g leaf fresh weight	1186:1204	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	2	22	theme	key	366:368	arg1	properties					370:379	the key properties	362:379	the key properties of seven different plant-made human IgG1 fusion vaccine candidates	362:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	0	23	theme	Antigen	89:95	arg1	Immunogenicity					97:110	Antigen Immunogenicity	89:110	Antigen Immunogenicity in Mice	89:118	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	3	24	theme	epitope	758:764	arg1	tag					766:768	a self-binding epitope tag	743:768	a self-binding epitope tag	743:768	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	2	25	theme	fusion	422:427	arg1	candidates					437:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	5	26	theme	fresh	1193:1197	arg1	weight					1199:1204	g leaf fresh weight	1186:1204	g leaf fresh weight	1186:1204	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	1	27	theme	fewer	250:254	arg1	studies					256:262	fewer studies	250:262	fewer studies	250:262	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	2	28	theme	human	411:415	arg1	candidates					437:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	5	29	theme	mg	1168:1169	arg1	fusion					1175:1180	1.5 mg IgG fusion	1164:1180	1.5 mg IgG fusion	1164:1180	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	2	30	theme	different	390:398	arg1	candidates					437:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	6	31	theme	Zika-specific	1256:1268	arg1	antibodies					1270:1279	Zika-specific antibodies	1256:1279	Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant	1256:1340	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	5	32	theme	immune	1037:1042	arg1	formation					1052:1060	immune complex formation	1037:1060	immune complex formation	1037:1060	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	7	33	theme	vaccines	1495:1502	arg1	creation					1477:1484	the creation	1473:1484	the creation of other vaccines and antibody-based therapeutics	1473:1534	We anticipate these findings will be broadly applicable to the creation of other vaccines and antibody-based therapeutics.
33343565	3	34	theme	recombinant	780:790	arg1	RIC					810:812	RIC	810:812	RIC	810:812	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	34	theme	recombinant	780:790	arg1	complexes					799:807	recombinant immune complexes	780:807	recombinant immune complexes (RIC)	780:813	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	2	35	theme	Zika	454:457	arg1	domain					481:486	Zika virus (ZIKV) envelope domain III	454:490	Zika virus (ZIKV) envelope domain III (ZE3)	454:496	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	35	theme	Zika	454:457	arg1	ZE3					493:495	ZE3	493:495	ZE3	493:495	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	35	theme	Zika	454:457	arg1	antigen					509:515	a model antigen	501:515	a model antigen	501:515	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	0	36	theme	Soluble	21:27	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	2	37	theme	candidates	437:446	arg1	properties					370:379	the key properties	362:379	the key properties of seven different plant-made human IgG1 fusion vaccine candidates	362:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	6	38	theme	IgG	1220:1222	arg1	fusions					1224:1230	the IgG fusions	1216:1230	the IgG fusions	1216:1230	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	3	39	dep	removal	629:635	arg1	2					626:626	2	626:626	2	626:626	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	40	theme	IgG	556:558	arg1	fusions					560:566	the IgG fusions	552:566	the IgG fusions	552:566	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	41	from	addition	679:686	arg1	Fc					729:730	the IgG Fc	721:730	the IgG Fc	721:730	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	5	42	theme	immunogenic	1074:1084	arg1	candidate					1094:1102	a potently immunogenic vaccine candidate	1063:1102	a potently immunogenic vaccine candidate with improved solubility and high stability	1063:1146	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	3	43	theme	antigen	588:594	arg1	fusion					596:601	1) antigen fusion	585:601	1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	585:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	0	44	theme	Stable	34:39	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	3	45	theme	IgG	610:612	arg1	N-terminus					614:623	the IgG N-terminus	606:623	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	6	46	dep	150-fold	1358:1365	arg1	to					1355:1356	to	1355:1356	to	1355:1356	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	6	46	dep	150-fold	1358:1365	arg1	higher					1367:1372	higher	1367:1372	higher	1367:1372	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	3	47	theme	β1,2-linked	879:889	arg1	xylose					891:896	plant-specific β1,2-linked xylose	864:896	plant-specific β1,2-linked xylose	864:896	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	48	from	Fc	729:730	arg1	addition					679:686	addition	679:686	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	49	theme	chain	654:658	arg1	removal					629:635	removal	629:635	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	1	50	theme	interest	180:187	arg1	protein					169:175	a protein	167:175	a protein of interest	167:187	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	3	51	theme	IgG	644:646	arg1	chain					654:658	the IgG light chain	640:658	the IgG light chain	640:658	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	52	theme	protein	529:535	arg1	C1q					537:539	Complement protein C1q	518:539	Complement protein C1q binding of the IgG fusions	518:566	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	0	53	from	Immunogenicity	97:110	arg1	Mice					115:118	Mice	115:118	Mice	115:118	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	3	54	theme	Fab	663:665	arg1	regions					667:673	Fab regions	663:673	Fab regions	663:673	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	55	theme	fusions	560:566	arg1	binding					541:547	Complement protein C1q binding	518:547	Complement protein C1q binding of the IgG fusions	518:566	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	2	56	theme	model	503:507	arg1	antigen					509:515	a model antigen	501:515	a model antigen	501:515	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	56	theme	model	503:507	arg1	domain					481:486	Zika virus (ZIKV) envelope domain III	454:490	Zika virus (ZIKV) envelope domain III (ZE3)	454:496	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	4	57	theme	IgG	1010:1012	arg1	fusions					1014:1020	the IgG fusions	1006:1020	the IgG fusions	1006:1020	We also characterized the expression, solubility, and stability of the IgG fusions.
33343565	0	58	theme	IgG	52:54	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	2	59	theme	ZIKV	466:469	arg1	domain					481:486	Zika virus (ZIKV) envelope domain III	454:490	Zika virus (ZIKV) envelope domain III (ZE3)	454:496	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	59	theme	ZIKV	466:469	arg1	ZE3					493:495	ZE3	493:495	ZE3	493:495	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	59	theme	ZIKV	466:469	arg1	antigen					509:515	a model antigen	501:515	a model antigen	501:515	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	1	60	theme	Fc	200:201	arg1	domain					203:208	the IgG Fc domain	192:208	the IgG Fc domain	192:208	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	5	61	theme	improved	1109:1116	arg1	solubility					1118:1127	improved solubility	1109:1127	improved solubility	1109:1127	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	0	62	theme	Vaccine	63:69	arg1	Strategy					71:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy	0:78	A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.
33343565	1	63	theme	fusions	311:317	arg1	potential					294:302	the vaccine potential	282:302	the vaccine potential of IgG fusions	282:317	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	3	64	theme	N-linked	921:928	arg1	glycans					930:936	α1,3-linked fucose N-linked glycans	902:936	α1,3-linked fucose N-linked glycans	902:936	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	6	65	theme	ZE3	1395:1397	arg1	antigen					1399:1405	ZE3 antigen	1395:1405	ZE3 antigen alone	1395:1411	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	3	66	theme	self-binding	745:756	arg1	tag					766:768	a self-binding epitope tag	743:768	a self-binding epitope tag	743:768	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	2	67	theme	virus	459:463	arg1	domain					481:486	Zika virus (ZIKV) envelope domain III	454:490	Zika virus (ZIKV) envelope domain III (ZE3)	454:496	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	67	theme	virus	459:463	arg1	ZE3					493:495	ZE3	493:495	ZE3	493:495	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	67	theme	virus	459:463	arg1	antigen					509:515	a model antigen	501:515	a model antigen	501:515	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	3	68	theme	mutations	708:716	arg1	addition					679:686	addition	679:686	the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4)	606:734	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	6	69	dep	titers	1383:1388	arg1	150-fold					1358:1365	150-fold	1358:1365	150-fold	1358:1365	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	2	70	theme	envelope	472:479	arg1	domain					481:486	Zika virus (ZIKV) envelope domain III	454:490	Zika virus (ZIKV) envelope domain III (ZE3)	454:496	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	70	theme	envelope	472:479	arg1	ZE3					493:495	ZE3	493:495	ZE3	493:495	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	2	70	theme	envelope	472:479	arg1	antigen					509:515	a model antigen	501:515	a model antigen	501:515	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	5	71	theme	leaf	1188:1191	arg1	weight					1199:1204	g leaf fresh weight	1186:1204	g leaf fresh weight	1186:1204	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	3	72	dep	adding	736:741	arg1	producing					822:830	producing	822:830	producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans	822:936	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	2	73	theme	IgG1	417:420	arg1	candidates					437:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	5	74	theme	1.5	1164:1166	arg1	mg					1168:1169	mg	1168:1169	mg	1168:1169	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	6	75	theme	antibodies	1270:1279	arg1	titers					1246:1251	high titers	1241:1251	high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant	1241:1340	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	7	76	theme	antibody-based	1508:1521	arg1	therapeutics					1523:1534	antibody-based therapeutics	1508:1534	antibody-based therapeutics	1508:1534	We anticipate these findings will be broadly applicable to the creation of other vaccines and antibody-based therapeutics.
33343565	2	77	theme	plant-made	400:409	arg1	candidates					437:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	3	78	from	mutations	708:716	arg1	Fc					729:730	the IgG Fc	721:730	the IgG Fc	721:730	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	5	79	theme	IgG	1171:1173	arg1	fusion					1175:1180	1.5 mg IgG fusion	1164:1180	1.5 mg IgG fusion	1164:1180	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	5	80	theme	complex	1044:1050	arg1	formation					1052:1060	immune complex formation	1037:1060	immune complex formation	1037:1060	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	3	81	theme	immune	792:797	arg1	RIC					810:812	RIC	810:812	RIC	810:812	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	81	theme	immune	792:797	arg1	complexes					799:807	recombinant immune complexes	780:807	recombinant immune complexes (RIC)	780:813	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	6	82	theme	high	1241:1244	arg1	titers					1246:1251	high titers	1241:1251	high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant	1241:1340	In mice, the IgG fusions elicited high titers of Zika-specific antibodies which neutralized ZIKV using only two doses without adjuvant, reaching up to 150-fold higher antibody titers than ZE3 antigen alone.
33343565	1	83	theme	vaccine	286:292	arg1	potential					294:302	the vaccine potential	282:302	the vaccine potential of IgG fusions	282:317	Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions.
33343565	2	84	theme	vaccine	429:435	arg1	candidates					437:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	seven different plant-made human IgG1 fusion vaccine candidates	384:446	In this study, we systematically compared the key properties of seven different plant-made human IgG1 fusion vaccine candidates using Zika virus (ZIKV) envelope domain III (ZE3) as a model antigen.
33343565	7	85	theme	therapeutics	1523:1534	arg1	creation					1477:1484	the creation	1473:1484	the creation of other vaccines and antibody-based therapeutics	1473:1534	We anticipate these findings will be broadly applicable to the creation of other vaccines and antibody-based therapeutics.
33343565	5	86	with	candidate	1094:1102	arg1	solubility					1118:1127	improved solubility	1109:1127	improved solubility	1109:1127	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	5	86	with	candidate	1094:1102	arg1	stability					1138:1146	high stability	1133:1146	high stability	1133:1146	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	5	87	theme	vaccine	1086:1092	arg1	candidate					1094:1102	a potently immunogenic vaccine candidate	1063:1102	a potently immunogenic vaccine candidate with improved solubility and high stability	1063:1146	By optimizing immune complex formation, a potently immunogenic vaccine candidate with improved solubility and high stability was produced at 1.5 mg IgG fusion per g leaf fresh weight.
33343565	3	88	theme	IgG	832:834	arg1	fusions					836:842	IgG fusions	832:842	IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans	832:936	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	89	from	fusions	836:842	arg1	plants					847:852	plants	847:852	plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans	847:936	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
33343565	3	90	link	β1,2-linked	879:889	arg1	xylose					891:896	plant-specific β1,2-linked xylose	864:896	plant-specific β1,2-linked xylose	864:896	Complement protein C1q binding of the IgG fusions was enhanced by: 1) antigen fusion to the IgG N-terminus; 2) removal of the IgG light chain or Fab regions; 3) addition of hexamer-inducing mutations in the IgG Fc; 4) adding a self-binding epitope tag to create recombinant immune complexes (RIC); or 5) producing IgG fusions in plants that lack plant-specific β1,2-linked xylose and α1,3-linked fucose N-linked glycans.
35211008	12	0	theme	Decreased	2147:2155	arg1	N-glycosylation					2157:2171	Decreased N-glycosylation	2147:2171	Decreased N-glycosylation of β1 adrenergic receptors	2147:2198	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	9	1	theme	calcium	1678:1684	arg1	transient					1686:1694	calcium transient	1678:1694	calcium transient	1678:1694	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	6	2	theme	potential	1115:1123	arg1	mechanism					1125:1133	the potential mechanism	1111:1133	the potential mechanism of stachytine hydrochloride (12 mg/kg/day)	1111:1176	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	14	3	theme	α-1,3-mannosyl-glycoprotein	2613:2639	arg1	MGAT4a					2680:2685	MGAT4a	2680:2685	MGAT4a	2680:2685	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	14	3	theme	α-1,3-mannosyl-glycoprotein	2613:2639	arg1	A					2677:2677	α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A	2613:2677	α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a)	2613:2686	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	2	4	theme	even	389:392	arg1	failure					400:406	even heart failure	389:406	even heart failure	389:406	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	14	5	theme	adrenergic	2734:2743	arg1	receptors					2745:2753	β1 adrenergic receptors	2731:2753	β1 adrenergic receptors	2731:2753	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	2	6	theme	cardiovascular	306:319	arg1	events					321:326	various cardiovascular events	298:326	various cardiovascular events	298:326	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	13	7	theme	Stachytine	2306:2315	arg1	hydrochloride					2317:2329	Stachytine hydrochloride	2306:2329	Stachytine hydrochloride	2306:2329	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	0	8	gly	N-Glycosylation	130:144	arg1	β1AR					149:152	β1AR	149:152	β1AR	149:152	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	6	9	theme	receptor	1199:1206	arg1	pathway					1215:1221	the β1 adrenergic receptor signal pathway	1181:1221	the β1 adrenergic receptor signal pathway in the heart	1181:1234	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	12	10	theme	myocardial	2258:2267	arg1	excitation					2269:2278	myocardial excitation	2258:2278	myocardial excitation	2258:2278	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	11	11	theme	mice	2100:2103	arg1	heart					2091:2095	the heart	2087:2095	the heart of mice with isoproterenol-induced heart failure	2087:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	14	12	theme	N-glycosylation	2706:2720	arg1	level					2722:2726	the N-glycosylation level	2702:2726	the N-glycosylation level on β1 adrenergic receptors	2702:2753	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	6	13	theme	β1	1185:1186	arg1	pathway					1215:1221	the β1 adrenergic receptor signal pathway	1181:1221	the β1 adrenergic receptor signal pathway in the heart	1181:1234	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	4	14	theme	cardioprotective	708:723	arg1	effect					725:730	a good cardioprotective effect	701:730	a good cardioprotective effect	701:730	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	4	15	contain	has	790:792	arg1	hydrochloride					776:788	stachytine hydrochloride	765:788	stachytine hydrochloride	765:788	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	4	15	contain	has	790:792	arg2	effect					797:802	an effect	794:802	an effect on the β1 adrenergic receptor signal pathway	794:847	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	1	16	theme	major	205:209	arg1	problem					225:231	a major public health problem	203:231	a major public health problem that seriously threatens human health	203:269	Background: Cardiovascular diseases have become a major public health problem that seriously threatens human health.
35211008	10	17	theme	chronic	1860:1866	arg1	activation					1891:1900	chronic β1 adrenergic receptor activation	1860:1900	chronic β1 adrenergic receptor activation	1860:1900	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	9	18	dep	N-glycosylation	1661:1675	arg1	function					1725:1732	function	1725:1732	function	1725:1732	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	3	19	theme	Chinese	586:592	arg1	ingredient					540:549	the main active ingredient	524:549	the main active ingredient	524:549	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	19	theme	Chinese	586:592	arg1	hydrochloride					507:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	19	theme	Chinese	586:592	arg1	medicine					594:601	a traditional Chinese medicine	572:601	a traditional Chinese medicine used to treat gynecological diseases	572:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	5	20	theme	study	870:874	arg1	purpose					854:860	The purpose	850:860	The purpose of this study	850:874	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	0	21	theme	β1AR	149:152	arg1	N-Glycosylation					130:144	N-Glycosylation	130:144	N-Glycosylation of β1AR	130:152	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	10	22	theme	adrenergic	1871:1880	arg1	activation					1891:1900	chronic β1 adrenergic receptor activation	1860:1900	chronic β1 adrenergic receptor activation	1860:1900	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	0	23	from	α-1,6-Fucosylation	108:125	arg1	N-Glycosylation					130:144	N-Glycosylation	130:144	N-Glycosylation of β1AR	130:152	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	5	24	theme	adrenergic	939:948	arg1	pathway					966:972	the β1 adrenergic receptor signal pathway	932:972	the β1 adrenergic receptor signal pathway	932:972	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	7	25	from	changes	1246:1252	arg1	morphology					1265:1274	cardiac morphology	1257:1274	cardiac morphology	1257:1274	Evaluate changes in cardiac morphology and function by echocardiography, cardiac hemodynamics, and histological methods, and detect molecular changes by Western blot and immunofluorescence.
35211008	7	26	theme	Western	1390:1396	arg1	blot					1398:1401	Western blot	1390:1401	Western blot	1390:1401	Evaluate changes in cardiac morphology and function by echocardiography, cardiac hemodynamics, and histological methods, and detect molecular changes by Western blot and immunofluorescence.
35211008	14	27	theme	sugar	2553:2557	arg1	chain					2559:2563	the N-terminal sugar chain	2538:2563	the N-terminal sugar chain	2538:2563	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	2	28	theme	cumulative	276:285	arg1	effects					287:293	The cumulative effects	272:293	The cumulative effects of various cardiovascular events	272:326	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	5	29	from	effect	894:899	arg1	pathway					966:972	the β1 adrenergic receptor signal pathway	932:972	the β1 adrenergic receptor signal pathway	932:972	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	5	30	theme	signal	959:964	arg1	pathway					966:972	the β1 adrenergic receptor signal pathway	932:972	the β1 adrenergic receptor signal pathway	932:972	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	7	31	theme	cardiac	1257:1263	arg1	morphology					1265:1274	cardiac morphology	1257:1274	cardiac morphology	1257:1274	Evaluate changes in cardiac morphology and function by echocardiography, cardiac hemodynamics, and histological methods, and detect molecular changes by Western blot and immunofluorescence.
35211008	5	32	theme	hydrochloride	915:927	arg1	effect					894:899	the effect	890:899	the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway	890:972	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	6	33	theme	isoproterenol	1023:1035	arg1	infusion					1011:1018	a continuous infusion	998:1018	a continuous infusion of isoproterenol (40 mg/kg/day)	998:1050	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	12	34	theme	adrenergic	2179:2188	arg1	receptors					2190:2198	β1 adrenergic receptors	2176:2198	β1 adrenergic receptors	2176:2198	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	14	35	theme	α-1,6-fucosylation	2516:2533	arg1	synthesis					2503:2511	the synthesis	2499:2511	the synthesis of α-1,6-fucosylation on the N-terminal sugar chain	2499:2563	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	12	36	gly	N-glycosylation	2157:2171	arg1	receptors					2190:2198	β1 adrenergic receptors	2176:2198	β1 adrenergic receptors	2176:2198	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	11	37	theme	isoproterenol-induced	2110:2130	arg1	failure					2138:2144	isoproterenol-induced heart failure	2110:2144	isoproterenol-induced heart failure	2110:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	8	38	theme	10-2	1551:1554	arg1	F					1548:1548	PNGase F	1541:1548	PNGase F (10-2 units/ml)	1541:1564	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	8	38	theme	10-2	1551:1554	arg1	units/ml					1556:1563	10-2 units/ml	1551:1563	10-2 units/ml	1551:1563	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	14	39	from	level	2722:2726	arg1	receptors					2745:2753	β1 adrenergic receptors	2731:2753	β1 adrenergic receptors	2731:2753	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	4	40	theme	β1	811:812	arg1	pathway					841:847	the β1 adrenergic receptor signal pathway	807:847	the β1 adrenergic receptor signal pathway	807:847	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	2	41	theme	adrenergic	420:429	arg1	pathway					447:453	the β1 adrenergic receptor signal pathway	413:453	the β1 adrenergic receptor signal pathway	413:453	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	7	42	theme	molecular	1369:1377	arg1	changes					1379:1385	molecular changes	1369:1385	molecular changes	1369:1385	Evaluate changes in cardiac morphology and function by echocardiography, cardiac hemodynamics, and histological methods, and detect molecular changes by Western blot and immunofluorescence.
35211008	0	43	from	Function	42:49	arg1	Mice					54:57	Mice	54:57	Mice with ISO-Induced Heart Failure	54:88	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	14	44	theme	stachytine	2465:2474	arg1	hydrochloride					2476:2488	stachytine hydrochloride	2465:2488	stachytine hydrochloride	2465:2488	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	11	45	theme	continuous	1974:1983	arg1	stimulation					1999:2009	continuous isoproterenol stimulation	1974:2009	continuous isoproterenol stimulation	1974:2009	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	0	46	theme	Stachytine	0:9	arg1	Hydrochloride					11:23	Stachytine Hydrochloride	0:23	Stachytine Hydrochloride	0:23	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	2	47	theme	important	464:472	arg1	role					474:477	an important role	461:477	an important role	461:477	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	10	48	theme	cardiac	1797:1803	arg1	remodeling					1805:1814	cardiac remodeling	1797:1814	cardiac remodeling	1797:1814	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	8	49	theme	cultured	1441:1448	arg1	myocytes					1490:1497	primary cultured adult mouse or neonatal rat ventricular myocytes	1433:1497	primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol)	1433:1604	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	2	50	theme	signal	440:445	arg1	pathway					447:453	the β1 adrenergic receptor signal pathway	413:453	the β1 adrenergic receptor signal pathway	413:453	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	11	51	with	mice	2100:2103	arg1	failure					2138:2144	isoproterenol-induced heart failure	2110:2144	isoproterenol-induced heart failure	2110:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	13	52	theme	cardiac	2375:2381	arg1	glycoproteins					2392:2404	isoproterenol-induced cardiac N-linked glycoproteins	2353:2404	isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation	2353:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	11	53	gly	N-glycosylation	2060:2074	arg1	β1AR					2079:2082	β1AR	2079:2082	β1AR	2079:2082	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	11	53	gly	N-glycosylation	2060:2074	arg1	heart					2091:2095	the heart	2087:2095	the heart of mice with isoproterenol-induced heart failure	2087:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	0	54	theme	ISO-Induced	64:74	arg1	Failure					82:88	ISO-Induced Heart Failure	64:88	ISO-Induced Heart Failure	64:88	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	8	55	theme	mouse	1456:1460	arg1	myocytes					1490:1497	primary cultured adult mouse or neonatal rat ventricular myocytes	1433:1497	primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol)	1433:1604	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	14	56	theme	pathway	2788:2794	arg1	activation					2796:2805	cAMP/PKA signal pathway activation	2772:2805	cAMP/PKA signal pathway activation	2772:2805	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	8	57	theme	neonatal	1465:1472	arg1	rat					1474:1476	neonatal rat	1465:1476	neonatal rat	1465:1476	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	13	58	link	N-linked	2383:2390	arg1	glycoproteins					2392:2404	isoproterenol-induced cardiac N-linked glycoproteins	2353:2404	isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation	2353:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	2	59	theme	heart	365:369	arg1	insufficiency					371:383	chronic heart insufficiency	357:383	chronic heart insufficiency	357:383	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	14	60	theme	cAMP/PKA	2772:2779	arg1	activation					2796:2805	cAMP/PKA signal pathway activation	2772:2805	cAMP/PKA signal pathway activation	2772:2805	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	6	61	theme	stachytine	1138:1147	arg1	hydrochloride					1149:1161	stachytine hydrochloride	1138:1161	stachytine hydrochloride (12 mg/kg/day)	1138:1176	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	6	61	theme	stachytine	1138:1147	arg1	12 mg/kg/day					1164:1175	12 mg/kg/day	1164:1175	12 mg/kg/day	1164:1175	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	8	62	theme	time	1619:1622	arg1	points					1624:1629	different time points	1609:1629	different time points	1609:1629	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	11	63	theme	adrenergic	1937:1946	arg1	receptors					1948:1956	β1 adrenergic receptors	1934:1956	β1 adrenergic receptors	1934:1956	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	11	64	theme	stachytine	2018:2027	arg1	hydrochloride					2029:2041	stachytine hydrochloride	2018:2041	stachytine hydrochloride	2018:2041	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	8	65	theme	ventricular	1478:1488	arg1	myocytes					1490:1497	primary cultured adult mouse or neonatal rat ventricular myocytes	1433:1497	primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol)	1433:1604	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	0	66	with	Mice	54:57	arg1	Failure					82:88	ISO-Induced Heart Failure	64:88	ISO-Induced Heart Failure	64:88	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	1	67	theme	human	258:262	arg1	health					264:269	human health	258:269	human health	258:269	Background: Cardiovascular diseases have become a major public health problem that seriously threatens human health.
35211008	14	68	from	synthesis	2503:2511	arg1	chain					2559:2563	the N-terminal sugar chain	2538:2563	the N-terminal sugar chain	2538:2563	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	14	69	theme	4-β-N-acetylglucosaminyltransferase	2641:2675	arg1	MGAT4a					2680:2685	MGAT4a	2680:2685	MGAT4a	2680:2685	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	14	69	theme	4-β-N-acetylglucosaminyltransferase	2641:2675	arg1	A					2677:2677	α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A	2613:2677	α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a)	2613:2686	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	2	70	theme	heart	394:398	arg1	failure					400:406	even heart failure	389:406	even heart failure	389:406	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	13	71	with	glycoproteins	2392:2404	arg1	α-1,6-fucosylation					2411:2428	α-1,6-fucosylation	2411:2428	α-1,6-fucosylation	2411:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	9	72	gly	α-1,6-fucosylation	1639:1656	arg1	relaxation					1714:1723	relaxation	1714:1723	relaxation	1714:1723	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	9	72	gly	α-1,6-fucosylation	1639:1656	arg1	contraction					1697:1707	contraction	1697:1707	contraction	1697:1707	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	9	72	gly	α-1,6-fucosylation	1639:1656	arg1	N-glycosylation					1661:1675	N-glycosylation	1661:1675	N-glycosylation	1661:1675	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	9	72	gly	α-1,6-fucosylation	1639:1656	arg1	transient					1686:1694	calcium transient	1678:1694	calcium transient	1678:1694	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	1	73	theme	health	218:223	arg1	problem					225:231	a major public health problem	203:231	a major public health problem that seriously threatens human health	203:269	Background: Cardiovascular diseases have become a major public health problem that seriously threatens human health.
35211008	2	74	theme	events	321:326	arg1	effects					287:293	The cumulative effects	272:293	The cumulative effects of various cardiovascular events	272:326	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	14	75	theme	β1	2731:2732	arg1	receptors					2745:2753	β1 adrenergic receptors	2731:2753	β1 adrenergic receptors	2731:2753	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	6	76	theme	signal	1208:1213	arg1	pathway					1215:1221	the β1 adrenergic receptor signal pathway	1181:1221	the β1 adrenergic receptor signal pathway in the heart	1181:1234	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	2	77	theme	various	298:304	arg1	events					321:326	various cardiovascular events	298:326	various cardiovascular events	298:326	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	6	78	theme	adrenergic	1188:1197	arg1	pathway					1215:1221	the β1 adrenergic receptor signal pathway	1181:1221	the β1 adrenergic receptor signal pathway in the heart	1181:1234	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	4	79	theme	good	703:706	arg1	effect					725:730	a good cardioprotective effect	701:730	a good cardioprotective effect	701:730	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	3	80	theme	traditional	574:584	arg1	ingredient					540:549	the main active ingredient	524:549	the main active ingredient	524:549	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	80	theme	traditional	574:584	arg1	hydrochloride					507:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	80	theme	traditional	574:584	arg1	medicine					594:601	a traditional Chinese medicine	572:601	a traditional Chinese medicine used to treat gynecological diseases	572:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	1	81	theme	public	211:216	arg1	problem					225:231	a major public health problem	203:231	a major public health problem that seriously threatens human health	203:269	Background: Cardiovascular diseases have become a major public health problem that seriously threatens human health.
35211008	9	82	theme	related	1738:1744	arg1	signals					1746:1752	α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals	1639:1752	α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals	1639:1752	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	11	83	from	N-glycosylation	2060:2074	arg1	heart					2091:2095	the heart	2087:2095	the heart of mice with isoproterenol-induced heart failure	2087:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	12	84	theme	cAMP/PKA	2222:2229	arg1	pathway					2238:2244	the cAMP/PKA signal pathway	2218:2244	the cAMP/PKA signal pathway	2218:2244	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	3	85	theme	active	533:538	arg1	ingredient					540:549	the main active ingredient	524:549	the main active ingredient	524:549	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	85	theme	active	533:538	arg1	hydrochloride					507:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	85	theme	active	533:538	arg1	medicine					594:601	a traditional Chinese medicine	572:601	a traditional Chinese medicine used to treat gynecological diseases	572:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	11	86	theme	β1	1934:1935	arg1	receptors					1948:1956	β1 adrenergic receptors	1934:1956	β1 adrenergic receptors	1934:1956	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	3	87	theme	gynecological	617:629	arg1	diseases					631:638	gynecological diseases	617:638	gynecological diseases	617:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	4	88	theme	stachytine	672:681	arg1	hydrochloride					683:695	stachytine hydrochloride	672:695	stachytine hydrochloride	672:695	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	10	89	theme	β1	1868:1869	arg1	activation					1891:1900	chronic β1 adrenergic receptor activation	1860:1900	chronic β1 adrenergic receptor activation	1860:1900	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	5	90	theme	β1	936:937	arg1	pathway					966:972	the β1 adrenergic receptor signal pathway	932:972	the β1 adrenergic receptor signal pathway	932:972	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	10	91	theme	Stachytine	1764:1773	arg1	hydrochloride					1775:1787	Stachytine hydrochloride	1764:1787	Stachytine hydrochloride	1764:1787	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	14	92	theme	signal	2781:2786	arg1	activation					2796:2805	cAMP/PKA signal pathway activation	2772:2805	cAMP/PKA signal pathway activation	2772:2805	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	12	93	theme	receptors	2190:2198	arg1	N-glycosylation					2157:2171	Decreased N-glycosylation	2147:2171	Decreased N-glycosylation of β1 adrenergic receptors	2147:2198	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	4	94	theme	receptor	825:832	arg1	pathway					841:847	the β1 adrenergic receptor signal pathway	807:847	the β1 adrenergic receptor signal pathway	807:847	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	5	95	theme	receptor	950:957	arg1	pathway					966:972	the β1 adrenergic receptor signal pathway	932:972	the β1 adrenergic receptor signal pathway	932:972	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	10	96	theme	hemodynamic	1830:1840	arg1	parameters					1842:1851	hemodynamic parameters	1830:1851	hemodynamic parameters	1830:1851	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	11	97	gly	N-glycosylation	1915:1929	arg1	receptors					1948:1956	β1 adrenergic receptors	1934:1956	β1 adrenergic receptors	1934:1956	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	14	98	theme	N-terminal	2542:2551	arg1	chain					2559:2563	the N-terminal sugar chain	2538:2563	the N-terminal sugar chain	2538:2563	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	0	99	theme	Heart	76:80	arg1	Failure					82:88	ISO-Induced Heart Failure	64:88	ISO-Induced Heart Failure	64:88	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	11	100	theme	β1AR	2079:2082	arg1	N-glycosylation					2060:2074	the N-glycosylation	2056:2074	the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure	2056:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	12	101	theme	signal	2231:2236	arg1	pathway					2238:2244	the cAMP/PKA signal pathway	2218:2244	the cAMP/PKA signal pathway	2218:2244	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	5	102	theme	stachytine	904:913	arg1	hydrochloride					915:927	stachytine hydrochloride	904:927	stachytine hydrochloride	904:927	The purpose of this study is to explore the effect of stachytine hydrochloride on the β1 adrenergic receptor signal pathway.
35211008	11	103	theme	heart	2132:2136	arg1	failure					2138:2144	isoproterenol-induced heart failure	2110:2144	isoproterenol-induced heart failure	2110:2144	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	8	104	theme	PNGase	1541:1546	arg1	F					1548:1548	PNGase F	1541:1548	PNGase F (10-2 units/ml)	1541:1564	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	8	104	theme	PNGase	1541:1546	arg1	units/ml					1556:1563	10-2 units/ml	1551:1563	10-2 units/ml	1551:1563	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	11	105	theme	receptors	1948:1956	arg1	N-glycosylation					1915:1929	The N-glycosylation	1911:1929	The N-glycosylation of β1 adrenergic receptors	1911:1956	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	1	106	theme	Cardiovascular	167:180	arg1	diseases					182:189	Cardiovascular diseases	167:189	Cardiovascular diseases	167:189	Background: Cardiovascular diseases have become a major public health problem that seriously threatens human health.
35211008	12	107	theme	β1	2176:2177	arg1	receptors					2190:2198	β1 adrenergic receptors	2176:2198	β1 adrenergic receptors	2176:2198	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	12	108	theme	contraction	2284:2294	arg1	coupling					2296:2303	contraction coupling	2284:2303	contraction coupling	2284:2303	Decreased N-glycosylation of β1 adrenergic receptors will downregulate the cAMP/PKA signal pathway and inhibit myocardial excitation and contraction coupling.
35211008	6	109	theme	continuous	1000:1009	arg1	infusion					1011:1018	a continuous infusion	998:1018	a continuous infusion of isoproterenol (40 mg/kg/day)	998:1050	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	13	110	gly	α-1,6-fucosylation	2411:2428	arg1	glycoproteins					2392:2404	isoproterenol-induced cardiac N-linked glycoproteins	2353:2404	isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation	2353:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	4	111	from	effect	797:802	arg1	pathway					841:847	the β1 adrenergic receptor signal pathway	807:847	the β1 adrenergic receptor signal pathway	807:847	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	6	112	from	pathway	1215:1221	arg1	heart					1230:1234	the heart	1226:1234	the heart	1226:1234	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	2	113	theme	β1	417:418	arg1	pathway					447:453	the β1 adrenergic receptor signal pathway	413:453	the β1 adrenergic receptor signal pathway	413:453	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	6	114	theme	ventricular	1081:1091	arg1	myocytes					1093:1100	ventricular myocytes	1081:1100	ventricular myocytes	1081:1100	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	8	115	theme	stachytine	1571:1580	arg1	hydrochloride					1582:1594	stachytine hydrochloride	1571:1594	stachytine hydrochloride (10 μMol)	1571:1604	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	8	115	theme	stachytine	1571:1580	arg1	10 μMol					1597:1603	10 μMol	1597:1603	10 μMol	1597:1603	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	4	116	theme	stachytine	765:774	arg1	hydrochloride					776:788	stachytine hydrochloride	765:788	stachytine hydrochloride	765:788	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	11	117	theme	isoproterenol	1985:1997	arg1	stimulation					1999:2009	continuous isoproterenol stimulation	1974:2009	continuous isoproterenol stimulation	1974:2009	The N-glycosylation of β1 adrenergic receptors decreased after continuous isoproterenol stimulation, while stachytine hydrochloride can increase the N-glycosylation of β1AR in the heart of mice with isoproterenol-induced heart failure.
35211008	0	118	theme	Cardiac	34:40	arg1	Function					42:49	Cardiac Function	34:49	Cardiac Function in Mice with ISO-Induced Heart Failure	34:88	Stachytine Hydrochloride Improves Cardiac Function in Mice with ISO-Induced Heart Failure by Inhibiting the α-1,6-Fucosylation on N-Glycosylation of β1AR.
35211008	10	119	theme	receptor	1882:1889	arg1	activation					1891:1900	chronic β1 adrenergic receptor activation	1860:1900	chronic β1 adrenergic receptor activation	1860:1900	Results: Stachytine hydrochloride reduces cardiac remodeling and modulates hemodynamic parameters during chronic β1 adrenergic receptor activation in vivo.
35211008	7	120	theme	histological	1336:1347	arg1	methods					1349:1355	histological methods	1336:1355	histological methods	1336:1355	Evaluate changes in cardiac morphology and function by echocardiography, cardiac hemodynamics, and histological methods, and detect molecular changes by Western blot and immunofluorescence.
35211008	13	121	gly	glycoproteins	2392:2404	arg1	glycoproteins					2392:2404	isoproterenol-induced cardiac N-linked glycoproteins	2353:2404	isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation	2353:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	3	122	theme	Stachytine	496:505	arg1	ingredient					540:549	the main active ingredient	524:549	the main active ingredient	524:549	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	122	theme	Stachytine	496:505	arg1	hydrochloride					507:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	122	theme	Stachytine	496:505	arg1	medicine					594:601	a traditional Chinese medicine	572:601	a traditional Chinese medicine used to treat gynecological diseases	572:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	8	123	theme	primary	1433:1439	arg1	myocytes					1490:1497	primary cultured adult mouse or neonatal rat ventricular myocytes	1433:1497	primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol)	1433:1604	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	2	124	theme	receptor	431:438	arg1	pathway					447:453	the β1 adrenergic receptor signal pathway	413:453	the β1 adrenergic receptor signal pathway	413:453	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	13	125	theme	N-linked	2383:2390	arg1	glycoproteins					2392:2404	isoproterenol-induced cardiac N-linked glycoproteins	2353:2404	isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation	2353:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
35211008	7	126	theme	cardiac	1310:1316	arg1	hemodynamics					1318:1329	cardiac hemodynamics	1310:1329	cardiac hemodynamics	1310:1329	Evaluate changes in cardiac morphology and function by echocardiography, cardiac hemodynamics, and histological methods, and detect molecular changes by Western blot and immunofluorescence.
35211008	8	127	theme	different	1609:1617	arg1	points					1624:1629	different time points	1609:1629	different time points	1609:1629	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	8	128	theme	adult	1450:1454	arg1	mouse					1456:1460	adult mouse	1450:1460	adult mouse	1450:1460	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	3	129	theme	main	528:531	arg1	ingredient					540:549	the main active ingredient	524:549	the main active ingredient	524:549	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	129	theme	main	528:531	arg1	hydrochloride					507:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	129	theme	main	528:531	arg1	medicine					594:601	a traditional Chinese medicine	572:601	a traditional Chinese medicine used to treat gynecological diseases	572:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	4	130	theme	signal	834:839	arg1	pathway					841:847	the β1 adrenergic receptor signal pathway	807:847	the β1 adrenergic receptor signal pathway	807:847	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	14	131	gly	α-1,3-mannosyl-glycoprotein	2613:2639	arg1	α-1,3-mannosyl-glycoprotein					2613:2639	α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A	2613:2677	α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a)	2613:2686	Conclusion: Our results show that stachytine hydrochloride inhibits the synthesis of α-1,6-fucosylation on the N-terminal sugar chain by reducing α-1,6-fucosyltransferase (FUT8) and α-1,3-mannosyl-glycoprotein 4-β-N-acetylglucosaminyltransferase A (MGAT4a), upregulating the N-glycosylation level on β1 adrenergic receptors, and maintaining cAMP/PKA signal pathway activation.
35211008	9	132	theme	α-1,6-fucosylation	1639:1656	arg1	signals					1746:1752	α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals	1639:1752	α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals	1639:1752	Detect α-1,6-fucosylation on N-glycosylation, calcium transient, contraction, and relaxation function and related signals.
35211008	6	133	theme	hydrochloride	1149:1161	arg1	mechanism					1125:1133	the potential mechanism	1111:1133	the potential mechanism of stachytine hydrochloride (12 mg/kg/day)	1111:1176	Method: In this study, a continuous infusion of isoproterenol (40 mg/kg/day) was administered to mice and ventricular myocytes explored the potential mechanism of stachytine hydrochloride (12 mg/kg/day) on the β1 adrenergic receptor signal pathway in the heart.
35211008	4	134	theme	Modern	641:646	arg1	studies					648:654	Modern studies	641:654	Modern studies	641:654	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	4	135	contain	has	697:699	arg2	effect					725:730	a good cardioprotective effect	701:730	a good cardioprotective effect	701:730	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	4	135	contain	has	697:699	arg1	hydrochloride					683:695	stachytine hydrochloride	672:695	stachytine hydrochloride	672:695	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	4	136	theme	adrenergic	814:823	arg1	pathway					841:847	the β1 adrenergic receptor signal pathway	807:847	the β1 adrenergic receptor signal pathway	807:847	Modern studies have found that stachytine hydrochloride has a good cardioprotective effect, but it is still unclear whether stachytine hydrochloride has an effect on the β1 adrenergic receptor signal pathway.
35211008	2	137	theme	chronic	357:363	arg1	insufficiency					371:383	chronic heart insufficiency	357:383	chronic heart insufficiency	357:383	The cumulative effects of various cardiovascular events will eventually develop into chronic heart insufficiency and even heart failure, and the β1 adrenergic receptor signal pathway plays an important role in this process.
35211008	8	138	theme	rat	1474:1476	arg1	myocytes					1490:1497	primary cultured adult mouse or neonatal rat ventricular myocytes	1433:1497	primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol)	1433:1604	Treat primary cultured adult mouse or neonatal rat ventricular myocytes with or without isoproterenol (0.1 μMol), PNGase F (10-2 units/ml), and stachytine hydrochloride (10 μMol) at different time points.
35211008	3	139	theme	Yimucao	554:560	arg1	ingredient					540:549	the main active ingredient	524:549	the main active ingredient	524:549	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	139	theme	Yimucao	554:560	arg1	hydrochloride					507:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride	496:519	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	3	139	theme	Yimucao	554:560	arg1	medicine					594:601	a traditional Chinese medicine	572:601	a traditional Chinese medicine used to treat gynecological diseases	572:638	Stachytine hydrochloride is the main active ingredient of Yimucao, which is a traditional Chinese medicine used to treat gynecological diseases.
35211008	13	140	theme	isoproterenol-induced	2353:2373	arg1	glycoproteins					2392:2404	isoproterenol-induced cardiac N-linked glycoproteins	2353:2404	isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation	2353:2428	Stachytine hydrochloride significantly reduced isoproterenol-induced cardiac N-linked glycoproteins with α-1,6-fucosylation.
31996426	8	0	from	aggregation	1142:1152	arg1	surface					1182:1188	the cell surface	1173:1188	the cell surface of RK13 cells	1173:1202	eBD2 and -3 also caused the aggregation of EHV1 virions on the cell surface of RK13 cells.
31996426	12	1	theme	herpesvirus	1696:1706	arg1	infection					1726:1734	herpesvirus respiratory tract infection	1696:1734	herpesvirus respiratory tract infection	1696:1734	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	16	2	theme	cell	2590:2593	arg1	invasion					2595:2602	further host cell invasion	2577:2602	further host cell invasion	2577:2602	Infected cells synthesized eBD2 and -3, promoting further host cell invasion by EHV1.
31996426	15	3	with	preincubation	2475:2487	arg1	-2					2515:2516	-2	2515:2516	-2	2515:2516	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	15	3	with	preincubation	2475:2487	arg1	-3					2523:2524	-3	2523:2524	-3	2523:2524	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	15	3	with	preincubation	2475:2487	arg1	eBD1					2509:2512	eBD1	2509:2512	eBD1	2509:2512	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	6	4	theme	-3	807:808	arg1	action					788:793	the marked antimicrobial action	763:793	the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens	763:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	12	5	theme	novel	1653:1657	arg1	mechanisms					1659:1668	These novel mechanisms	1647:1668	These novel mechanisms	1647:1668	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	6	6	theme	eBD2	798:801	arg1	action					788:793	the marked antimicrobial action	763:793	the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens	763:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	13	7	used	used	1939:1942	arg2	We					1936:1937	We	1936:1937	We	1936:1937	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	18	8	theme	host-pathogen	2891:2903	arg1	coevolution					2905:2915	host-pathogen coevolution	2891:2915	host-pathogen coevolution	2891:2915	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	8	9	theme	RK13	1193:1196	arg1	cells					1198:1202	RK13 cells	1193:1202	RK13 cells	1193:1202	eBD2 and -3 also caused the aggregation of EHV1 virions on the cell surface of RK13 cells.
31996426	10	10	theme	virus-infected	1489:1502	arg1	EREC					1504:1507	influenza virus-infected EREC	1479:1507	influenza virus-infected EREC	1479:1507	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	6	11	theme	marked	767:772	arg1	action					788:793	the marked antimicrobial action	763:793	the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens	763:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	12	12	theme	model	1921:1925	arg1	systems					1927:1933	host-specific model systems	1907:1933	host-specific model systems	1907:1933	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	6	13	theme	protein	946:952	arg1	action					902:907	the action	898:907	the action of the viral glycoprotein M envelope protein	898:952	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	13	14	theme	key	2046:2048	arg1	event					2050:2054	this key event	2041:2054	this key event	2041:2054	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	8	15	theme	virions	1162:1168	arg1	aggregation					1142:1152	the aggregation	1138:1152	the aggregation of EHV1 virions on the cell surface of RK13 cells	1138:1202	eBD2 and -3 also caused the aggregation of EHV1 virions on the cell surface of RK13 cells.
31996426	6	16	theme	M	935:935	arg1	protein					946:952	the viral glycoprotein M envelope protein	912:952	the viral glycoprotein M envelope protein	912:952	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	7	17	theme	rabbit	1039:1044	arg1	cells					1060:1064	rabbit kidney (RK13) cells	1039:1064	rabbit kidney (RK13) cells	1039:1064	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	7	18	link	N-linked	1096:1103	arg1	glycans					1105:1111	viral N-linked glycans	1090:1111	viral N-linked glycans	1090:1111	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	6	19	theme	viral	916:920	arg1	protein					946:952	the viral glycoprotein M envelope protein	912:952	the viral glycoprotein M envelope protein	912:952	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	15	20	theme	virion	2380:2385	arg1	binding					2387:2393	virion binding	2380:2393	virion binding to	2380:2396	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	18	21	theme	host	2806:2809	arg1	colonization					2811:2822	host colonization	2806:2822	host colonization	2806:2822	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	7	22	theme	EHV1	971:974	arg1	virions					976:982	EHV1 virions	971:982	EHV1 virions	971:982	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	17	23	theme	well-known	2671:2680	arg1	dissemination					2687:2699	well-known EHV1 dissemination and latency vessels	2671:2719	dissemination	2687:2699	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	17	23	theme	well-known	2671:2680	arg1	which					2661:2665	which	2661:2665	which	2661:2665	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	3	24	theme	suitable	335:342	arg1	systems					362:368	suitable respiratory model systems	335:368	suitable respiratory model systems	335:368	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	16	25	theme	Infected	2527:2534	arg1	cells					2536:2540	Infected cells	2527:2540	Infected cells	2527:2540	Infected cells synthesized eBD2 and -3, promoting further host cell invasion by EHV1.
31996426	14	26	theme	glycoprotein	2247:2258	arg1	action					2237:2242	the action	2233:2242	the action of glycoprotein	2233:2258	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	11	27	theme	infection	1625:1633	arg1	reservoirs					1635:1644	latent infection reservoirs	1618:1644	latent infection reservoirs	1618:1644	In addition, these eBDs attracted leukocytes, which are essential for EHV1 dissemination and which serve as latent infection reservoirs.
31996426	11	27	theme	infection	1625:1633	arg1	which					1603:1607	which	1603:1607	which	1603:1607	In addition, these eBDs attracted leukocytes, which are essential for EHV1 dissemination and which serve as latent infection reservoirs.
31996426	0	28	theme	Tract	79:83	arg1	Infection					85:93	Respiratory Tract Infection	67:93	Respiratory Tract Infection	67:93	An Alphaherpesvirus Exploits Antimicrobial β-Defensins To Initiate Respiratory Tract Infection.
31996426	9	29	theme	primary	1221:1227	arg1	EREC					1266:1269	EREC	1266:1269	EREC	1266:1269	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	9	29	theme	primary	1221:1227	arg1	cells					1259:1263	primary equine respiratory epithelial cells	1221:1263	primary equine respiratory epithelial cells (EREC)	1221:1270	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	1	30	theme	pathogens	170:178	arg1	myriad					150:155	the myriad	146:155	the myriad of microbial pathogens entering the airways with each breath	146:216	β-Defensins protect the respiratory tract against the myriad of microbial pathogens entering the airways with each breath.
31996426	17	31	theme	EHV1	2682:2685	arg1	dissemination					2687:2699	well-known EHV1 dissemination and latency vessels	2671:2719	dissemination	2687:2699	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	17	31	theme	EHV1	2682:2685	arg1	which					2661:2665	which	2661:2665	which	2661:2665	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	9	32	theme	respiratory	1236:1246	arg1	EREC					1266:1269	EREC	1266:1269	EREC	1266:1269	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	9	32	theme	respiratory	1236:1246	arg1	cells					1259:1263	primary equine respiratory epithelial cells	1221:1263	primary equine respiratory epithelial cells (EREC)	1221:1270	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	14	33	dep	resisted	2160:2167	arg1	M.					2260:2261	M.	2260:2261	M.	2260:2261	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	4	34	theme	herpesvirus	543:553	arg1	EHV1					563:566	EHV1	563:566	EHV1	563:566	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	4	34	theme	herpesvirus	543:553	arg1	alphaherpesvirus					518:533	a central alphaherpesvirus	508:533	a central alphaherpesvirus	508:533	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	4	34	theme	herpesvirus	543:553	arg1	type					555:558	equine herpesvirus type 1	536:560	equine herpesvirus type 1 (EHV1)	536:567	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	14	35	theme	particle	2301:2308	arg1	aggregation					2310:2320	EHV1 particle aggregation and infection	2296:2334	aggregation	2310:2320	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	9	36	theme	cells	1259:1263	arg1	Pretreatment					1205:1216	Pretreatment	1205:1216	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3	1205:1292	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	15	37	theme	epithelial	2438:2447	arg1	cells					2449:2453	respiratory epithelial cells	2426:2453	respiratory epithelial cells	2426:2453	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	3	38	theme	model	356:360	arg1	systems					362:368	suitable respiratory model systems	335:368	suitable respiratory model systems	335:368	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	5	39	theme	upper	730:734	arg1	tract					748:752	the upper respiratory tract	726:752	the upper respiratory tract	726:752	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	18	40	theme	defenses	2754:2761	arg1	exploitation					2726:2737	The exploitation	2722:2737	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization	2722:2822	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	4	41	theme	central	510:516	arg1	alphaherpesvirus					518:533	a central alphaherpesvirus	508:533	a central alphaherpesvirus	508:533	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	4	41	theme	central	510:516	arg1	type					555:558	equine herpesvirus type 1	536:560	equine herpesvirus type 1 (EHV1)	536:567	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	17	42	dep	recruited	2639:2647	arg1	dissemination					2687:2699	well-known EHV1 dissemination and latency vessels	2671:2719	dissemination	2687:2699	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	17	42	dep	recruited	2639:2647	arg1	vessels					2713:2719	well-known EHV1 dissemination and latency vessels	2671:2719	vessels	2713:2719	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	17	42	dep	recruited	2639:2647	arg1	which					2661:2665	which	2661:2665	which	2661:2665	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	3	43	theme	mucosal	447:453	arg1	β-defensins					455:465	the abundant mucosal β-defensins	434:465	the abundant mucosal β-defensins	434:465	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	12	44	theme	hosts	1838:1842	arg1	infection					1821:1829	infection	1821:1829	infection of new hosts	1821:1842	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	15	45	theme	subsequent	2402:2411	arg1	infection					2413:2421	subsequent infection	2402:2421	subsequent infection of respiratory epithelial cells	2402:2453	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	6	46	theme	EHV1	854:857	arg1	virions					859:865	EHV1 virions	854:865	EHV1 virions	854:865	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	14	47	theme	equine	2190:2195	arg1	eBD2					2216:2219	eBD2	2216:2219	eBD2	2216:2219	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	47	theme	equine	2190:2195	arg1	eBDs					2210:2213	eBDs	2210:2213	eBDs	2210:2213	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	47	theme	equine	2190:2195	arg1	β-defensins					2197:2207	potent antimicrobial equine β-defensins	2169:2207	potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3	2169:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	47	theme	equine	2190:2195	arg1	eBD3					2225:2228	eBD3	2225:2228	eBD3	2225:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	5	48	dep	β-defensins	657:667	arg1	-2					682:683	-2	682:683	-2	682:683	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	5	48	dep	β-defensins	657:667	arg1	-3					690:691	-3	690:691	-3	690:691	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	5	48	dep	β-defensins	657:667	arg1	eBD1					676:679	eBD1	676:679	eBD1	676:679	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	10	49	theme	eBD2	1432:1435	arg1	production					1418:1427	an increased production	1405:1427	an increased production of eBD2 and -3	1405:1442	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	11	50	theme	EHV1	1580:1583	arg1	dissemination					1585:1597	EHV1 dissemination	1580:1597	EHV1 dissemination	1580:1597	In addition, these eBDs attracted leukocytes, which are essential for EHV1 dissemination and which serve as latent infection reservoirs.
31996426	13	51	theme	alphaherpesvirus	1948:1963	arg1	type					1984:1987	the alphaherpesvirus equine herpesvirus type 1	1944:1989	the alphaherpesvirus equine herpesvirus type 1 (EHV1)	1944:1996	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	13	51	theme	alphaherpesvirus	1948:1963	arg1	EHV1					1992:1995	EHV1	1992:1995	EHV1	1992:1995	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	7	52	theme	N-linked	1096:1103	arg1	glycans					1105:1111	viral N-linked glycans	1090:1111	viral N-linked glycans	1090:1111	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	18	53	theme	host	2742:2745	arg1	defenses					2754:2761	host innate defenses	2742:2761	host innate defenses	2742:2761	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	11	54	theme	latent	1618:1623	arg1	reservoirs					1635:1644	latent infection reservoirs	1618:1644	latent infection reservoirs	1618:1644	In addition, these eBDs attracted leukocytes, which are essential for EHV1 dissemination and which serve as latent infection reservoirs.
31996426	11	54	theme	latent	1618:1623	arg1	which					1603:1607	which	1603:1607	which	1603:1607	In addition, these eBDs attracted leukocytes, which are essential for EHV1 dissemination and which serve as latent infection reservoirs.
31996426	13	55	theme	herpesvirus	1972:1982	arg1	type					1984:1987	the alphaherpesvirus equine herpesvirus type 1	1944:1989	the alphaherpesvirus equine herpesvirus type 1 (EHV1)	1944:1996	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	13	55	theme	herpesvirus	1972:1982	arg1	EHV1					1992:1995	EHV1	1992:1995	EHV1	1992:1995	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	6	56	theme	many	818:821	arg1	pathogens					843:851	many bacterial and viral pathogens	818:851	many bacterial and viral pathogens	818:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	14	57	theme	antimicrobial	2176:2188	arg1	eBD2					2216:2219	eBD2	2216:2219	eBD2	2216:2219	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	57	theme	antimicrobial	2176:2188	arg1	eBDs					2210:2213	eBDs	2210:2213	eBDs	2210:2213	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	57	theme	antimicrobial	2176:2188	arg1	β-defensins					2197:2207	potent antimicrobial equine β-defensins	2169:2207	potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3	2169:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	57	theme	antimicrobial	2176:2188	arg1	eBD3					2225:2228	eBD3	2225:2228	eBD3	2225:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	58	theme	rabbit	2339:2344	arg1	cells					2360:2364	rabbit kidney (RK13) cells	2339:2364	rabbit kidney (RK13) cells	2339:2364	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	9	59	theme	EHV1	1316:1319	arg1	binding					1328:1334	increased EHV1 virion binding	1306:1334	increased EHV1 virion binding to and infection of these cells	1306:1366	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	0	60	theme	Respiratory	67:77	arg1	Infection					85:93	Respiratory Tract Infection	67:93	Respiratory Tract Infection	67:93	An Alphaherpesvirus Exploits Antimicrobial β-Defensins To Initiate Respiratory Tract Infection.
31996426	12	61	theme	respiratory	1708:1718	arg1	infection					1726:1734	herpesvirus respiratory tract infection	1696:1734	herpesvirus respiratory tract infection	1696:1734	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	4	62	theme	viral	632:636	arg1	spread					638:643	viral spread	632:643	viral spread	632:643	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	10	63	theme	-3	1441:1442	arg1	production					1418:1427	an increased production	1405:1427	an increased production of eBD2 and -3	1405:1442	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	13	64	theme	alphaherpesvirus	2067:2082	arg1	pathogenesis					2084:2095	general alphaherpesvirus pathogenesis	2059:2095	general alphaherpesvirus pathogenesis	2059:2095	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	5	65	theme	equine	650:655	arg1	eBDs					670:673	eBDs	670:673	eBDs	670:673	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	5	65	theme	equine	650:655	arg1	β-defensins					657:667	The equine β-defensins	646:667	The equine β-defensins (eBDs) eBD1, -2, and -3	646:691	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	16	66	theme	host	2585:2588	arg1	invasion					2595:2602	further host cell invasion	2577:2602	further host cell invasion	2577:2602	Infected cells synthesized eBD2 and -3, promoting further host cell invasion by EHV1.
31996426	6	67	gly	glycoprotein	922:933	arg1	glycoprotein					922:933	the viral glycoprotein M envelope protein	912:952	the viral glycoprotein M envelope protein	912:952	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	2	68	theme	entry	298:302	arg1	environment					253:263	this potentially hostile environment	228:263	this potentially hostile environment	228:263	However, this potentially hostile environment is known to serve as a portal of entry for herpesviruses.
31996426	2	68	theme	entry	298:302	arg1	portal					288:293	a portal	286:293	a portal of entry for herpesviruses	286:320	However, this potentially hostile environment is known to serve as a portal of entry for herpesviruses.
31996426	12	69	theme	systems	1927:1933	arg1	lack					1899:1902	a lack	1897:1902	a lack of host-specific model systems	1897:1933	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	12	70	theme	new	1678:1680	arg1	insights					1682:1689	new insights	1678:1689	new insights into herpesvirus respiratory tract infection	1678:1734	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	14	71	dep	β-defensins	2197:2207	arg1	eBD2					2216:2219	eBD2	2216:2219	eBD2	2216:2219	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	71	dep	β-defensins	2197:2207	arg1	β-defensins					2197:2207	potent antimicrobial equine β-defensins	2169:2207	potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3	2169:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	71	dep	β-defensins	2197:2207	arg1	eBD3					2225:2228	eBD3	2225:2228	eBD3	2225:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	7	72	theme	cells	1060:1064	arg1	infection					1026:1034	the subsequent infection	1011:1034	the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans	1011:1111	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	14	73	theme	EHV1	2296:2299	arg1	aggregation					2310:2320	EHV1 particle aggregation and infection	2296:2334	aggregation	2310:2320	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	74	theme	several	2113:2119	arg1	viruses					2133:2139	several respiratory viruses	2113:2139	several respiratory viruses	2113:2139	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	8	75	theme	cell	1177:1180	arg1	surface					1182:1188	the cell surface	1173:1188	the cell surface of RK13 cells	1173:1202	eBD2 and -3 also caused the aggregation of EHV1 virions on the cell surface of RK13 cells.
31996426	14	76	theme	respiratory	2121:2131	arg1	viruses					2133:2139	several respiratory viruses	2113:2139	several respiratory viruses	2113:2139	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	7	77	theme	RK13	1054:1057	arg1	cells					1060:1064	rabbit kidney (RK13) cells	1039:1064	rabbit kidney (RK13) cells	1039:1064	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	6	78	theme	antimicrobial	774:786	arg1	action					788:793	the marked antimicrobial action	763:793	the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens	763:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	9	79	theme	cells	1362:1366	arg1	infection					1343:1351	and infection	1339:1351	infection	1343:1351	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	13	80	theme	equine	2002:2007	arg1	tissues					2021:2027	equine respiratory tissues	2002:2027	equine respiratory tissues	2002:2027	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	10	81	theme	influenza	1479:1487	arg1	EREC					1504:1507	influenza virus-infected EREC	1479:1507	influenza virus-infected EREC	1479:1507	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	7	82	theme	kidney	1046:1051	arg1	cells					1060:1064	rabbit kidney (RK13) cells	1039:1064	rabbit kidney (RK13) cells	1039:1064	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	12	83	theme	host-specific	1907:1919	arg1	systems					1927:1933	host-specific model systems	1907:1933	host-specific model systems	1907:1933	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	6	84	theme	envelope	937:944	arg1	protein					946:952	the viral glycoprotein M envelope protein	912:952	the viral glycoprotein M envelope protein	912:952	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	14	85	theme	RK13	2354:2357	arg1	cells					2360:2364	rabbit kidney (RK13) cells	2339:2364	rabbit kidney (RK13) cells	2339:2364	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	8	86	theme	cells	1198:1202	arg1	surface					1182:1188	the cell surface	1173:1188	the cell surface of RK13 cells	1173:1202	eBD2 and -3 also caused the aggregation of EHV1 virions on the cell surface of RK13 cells.
31996426	18	87	theme	early	2791:2795	arg1	phase					2797:2801	the early phase	2787:2801	the early phase of host colonization	2787:2822	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	8	88	theme	EHV1	1157:1160	arg1	virions					1162:1168	EHV1 virions	1157:1168	EHV1 virions	1157:1168	eBD2 and -3 also caused the aggregation of EHV1 virions on the cell surface of RK13 cells.
31996426	6	89	theme	glycoprotein	922:933	arg1	protein					946:952	the viral glycoprotein M envelope protein	912:952	the viral glycoprotein M envelope protein	912:952	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	7	90	theme	subsequent	1015:1024	arg1	infection					1026:1034	the subsequent infection	1011:1034	the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans	1011:1111	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	13	91	theme	general	2059:2065	arg1	pathogenesis					2084:2095	general alphaherpesvirus pathogenesis	2059:2095	general alphaherpesvirus pathogenesis	2059:2095	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	2	92	theme	hostile	245:251	arg1	environment					253:263	this potentially hostile environment	228:263	this potentially hostile environment	228:263	However, this potentially hostile environment is known to serve as a portal of entry for herpesviruses.
31996426	2	92	theme	hostile	245:251	arg1	portal					288:293	a portal	286:293	a portal of entry for herpesviruses	286:320	However, this potentially hostile environment is known to serve as a portal of entry for herpesviruses.
31996426	1	93	with	airways	193:199	arg1	breath					211:216	each breath	206:216	each breath	206:216	β-Defensins protect the respiratory tract against the myriad of microbial pathogens entering the airways with each breath.
31996426	13	94	theme	respiratory	2009:2019	arg1	tissues					2021:2027	equine respiratory tissues	2002:2027	equine respiratory tissues	2002:2027	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	18	95	theme	colonization	2811:2822	arg1	phase					2797:2801	the early phase	2787:2801	the early phase of host colonization	2787:2822	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	7	96	with	Pretreatment	955:966	arg1	eBD2					989:992	eBD2	989:992	eBD2	989:992	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	7	96	with	Pretreatment	955:966	arg1	-3					998:999	-3	998:999	-3	998:999	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	5	97	theme	respiratory	736:746	arg1	tract					748:752	the upper respiratory tract	726:752	the upper respiratory tract	726:752	The equine β-defensins (eBDs) eBD1, -2, and -3 were produced and secreted along the upper respiratory tract.
31996426	7	98	theme	virions	976:982	arg1	Pretreatment					955:966	Pretreatment	955:966	Pretreatment of EHV1 virions with eBD2 and -3	955:999	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	1	99	theme	microbial	160:168	arg1	pathogens					170:178	microbial pathogens	160:178	microbial pathogens entering the airways with each breath	160:216	β-Defensins protect the respiratory tract against the myriad of microbial pathogens entering the airways with each breath.
31996426	3	100	theme	respiratory	344:354	arg1	systems					362:368	suitable respiratory model systems	335:368	suitable respiratory model systems	335:368	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	4	101	theme	equine	536:541	arg1	EHV1					563:566	EHV1	563:566	EHV1	563:566	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	4	101	theme	equine	536:541	arg1	alphaherpesvirus					518:533	a central alphaherpesvirus	508:533	a central alphaherpesvirus	508:533	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	4	101	theme	equine	536:541	arg1	type					555:558	equine herpesvirus type 1	536:560	equine herpesvirus type 1 (EHV1)	536:567	We demonstrate how a central alphaherpesvirus, equine herpesvirus type 1 (EHV1), actually exploits β-defensins to invade its host and initiate viral spread.
31996426	9	102	theme	equine	1229:1234	arg1	EREC					1266:1269	EREC	1266:1269	EREC	1266:1269	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	9	102	theme	equine	1229:1234	arg1	cells					1259:1263	primary equine respiratory epithelial cells	1221:1263	primary equine respiratory epithelial cells (EREC)	1221:1270	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	12	103	theme	respiratory	1856:1866	arg1	tract					1868:1872	the respiratory tract	1852:1872	the respiratory tract	1852:1872	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	9	104	theme	epithelial	1248:1257	arg1	EREC					1266:1269	EREC	1266:1269	EREC	1266:1269	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	9	104	theme	epithelial	1248:1257	arg1	cells					1259:1263	primary equine respiratory epithelial cells	1221:1263	primary equine respiratory epithelial cells (EREC)	1221:1270	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	14	105	gly	glycoprotein	2247:2258	arg1	glycoprotein					2247:2258	glycoprotein	2247:2258	glycoprotein	2247:2258	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	17	106	theme	latency	2705:2711	arg1	vessels					2713:2719	well-known EHV1 dissemination and latency vessels	2671:2719	vessels	2713:2719	Finally, eBD1, -2, and -3 recruited leukocytes, which are well-known EHV1 dissemination and latency vessels.
31996426	9	107	with	Pretreatment	1205:1216	arg1	-2					1283:1284	-2	1283:1284	-2	1283:1284	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	9	107	with	Pretreatment	1205:1216	arg1	-3					1291:1292	-3	1291:1292	-3	1291:1292	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	9	107	with	Pretreatment	1205:1216	arg1	eBD1					1277:1280	eBD1	1277:1280	eBD1	1277:1280	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	12	108	theme	new	1834:1836	arg1	hosts					1838:1842	new hosts	1834:1842	new hosts	1834:1842	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	15	109	theme	cells	2449:2453	arg1	binding					2387:2393	virion binding	2380:2393	virion binding to	2380:2396	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	15	109	theme	cells	2449:2453	arg1	infection					2413:2421	subsequent infection	2402:2421	subsequent infection of respiratory epithelial cells	2402:2453	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	3	110	theme	systems	362:368	arg1	lack					327:330	The lack	323:330	The lack of suitable respiratory model systems	323:368	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	18	111	theme	specialized	2846:2856	arg1	strategies					2858:2867	highly specialized strategies	2839:2867	highly specialized strategies	2839:2867	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	3	112	theme	host	474:477	arg1	invasion					479:486	host invasion	474:486	host invasion	474:486	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	18	113	theme	innate	2747:2752	arg1	defenses					2754:2761	host innate defenses	2742:2761	host innate defenses	2742:2761	The exploitation of host innate defenses by herpesviruses during the early phase of host colonization indicates that highly specialized strategies have developed during host-pathogen coevolution.
31996426	15	114	theme	respiratory	2426:2436	arg1	cells					2449:2453	respiratory epithelial cells	2426:2453	respiratory epithelial cells	2426:2453	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	3	115	theme	herpesvirus	405:415	arg1	virions					417:423	herpesvirus virions	405:423	herpesvirus virions	405:423	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	10	116	theme	EHV1-infected	1369:1381	arg1	EREC					1383:1386	EHV1-infected EREC	1369:1386	EHV1-infected EREC	1369:1386	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	12	117	dep	pathogenesis.IMPORTANCE	1740:1762	arg1	circumvent					1782:1791	circumvent	1782:1791	circumvent mucosal defenses to promote infection of new hosts through the respiratory tract	1782:1872	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	0	118	theme	Antimicrobial	29:41	arg1	β-Defensins					43:53	Antimicrobial β-Defensins	29:53	Antimicrobial β-Defensins	29:53	An Alphaherpesvirus Exploits Antimicrobial β-Defensins To Initiate Respiratory Tract Infection.
31996426	1	119	theme	respiratory	120:130	arg1	tract					132:136	the respiratory tract	116:136	the respiratory tract	116:136	β-Defensins protect the respiratory tract against the myriad of microbial pathogens entering the airways with each breath.
31996426	14	120	dep	viruses	2133:2139	arg1	contrast					2101:2108	contrast	2101:2108	contrast	2101:2108	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	3	121	theme	abundant	438:445	arg1	β-defensins					455:465	the abundant mucosal β-defensins	434:465	the abundant mucosal β-defensins	434:465	The lack of suitable respiratory model systems has precluded understanding of how herpesvirus virions overcome the abundant mucosal β-defensins during host invasion.
31996426	14	122	theme	cells	2360:2364	arg1	infection					2326:2334	EHV1 particle aggregation and infection	2296:2334	infection	2326:2334	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	122	theme	cells	2360:2364	arg1	aggregation					2310:2320	EHV1 particle aggregation and infection	2296:2334	aggregation	2310:2320	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	7	123	theme	viral	1090:1094	arg1	glycans					1105:1111	viral N-linked glycans	1090:1111	viral N-linked glycans	1090:1111	Pretreatment of EHV1 virions with eBD2 and -3 increased the subsequent infection of rabbit kidney (RK13) cells, which was dependent on viral N-linked glycans.
31996426	10	124	from	EREC	1383:1386	arg1	turn					1392:1395	turn	1392:1395	turn	1392:1395	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	6	125	theme	viral	837:841	arg1	pathogens					843:851	many bacterial and viral pathogens	818:851	many bacterial and viral pathogens	818:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	12	126	theme	tract	1720:1724	arg1	infection					1726:1734	herpesvirus respiratory tract infection	1696:1734	herpesvirus respiratory tract infection	1696:1734	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	13	127	theme	equine	1965:1970	arg1	type					1984:1987	the alphaherpesvirus equine herpesvirus type 1	1944:1989	the alphaherpesvirus equine herpesvirus type 1 (EHV1)	1944:1996	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	13	127	theme	equine	1965:1970	arg1	EHV1					1992:1995	EHV1	1992:1995	EHV1	1992:1995	We used the alphaherpesvirus equine herpesvirus type 1 (EHV1) and equine respiratory tissues to decipher this key event in general alphaherpesvirus pathogenesis.
31996426	12	128	theme	mucosal	1793:1799	arg1	defenses					1801:1808	mucosal defenses	1793:1808	mucosal defenses	1793:1808	These novel mechanisms provide new insights into herpesvirus respiratory tract infection and pathogenesis.IMPORTANCE How herpesviruses circumvent mucosal defenses to promote infection of new hosts through the respiratory tract remains unknown due to a lack of host-specific model systems.
31996426	6	129	theme	bacterial	823:831	arg1	pathogens					843:851	many bacterial and viral pathogens	818:851	many bacterial and viral pathogens	818:851	Despite the marked antimicrobial action of eBD2 and -3 against many bacterial and viral pathogens, EHV1 virions were resistant to eBDs through the action of the viral glycoprotein M envelope protein.
31996426	10	130	theme	increased	1408:1416	arg1	production					1418:1427	an increased production	1405:1427	an increased production of eBD2 and -3	1405:1442	EHV1-infected EREC, in turn, showed an increased production of eBD2 and -3 compared to that seen in mock- and influenza virus-infected EREC.
31996426	14	131	theme	kidney	2346:2351	arg1	cells					2360:2364	rabbit kidney (RK13) cells	2339:2364	rabbit kidney (RK13) cells	2339:2364	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	15	132	theme	cells	2498:2502	arg1	preincubation					2475:2487	preincubation	2475:2487	preincubation of these cells with eBD1, -2, and -3	2475:2524	In addition, virion binding to and subsequent infection of respiratory epithelial cells were increased upon preincubation of these cells with eBD1, -2, and -3.
31996426	9	133	theme	increased	1306:1314	arg1	binding					1328:1334	increased EHV1 virion binding	1306:1334	increased EHV1 virion binding to and infection of these cells	1306:1366	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
31996426	16	134	theme	further	2577:2583	arg1	invasion					2595:2602	further host cell invasion	2577:2602	further host cell invasion	2577:2602	Infected cells synthesized eBD2 and -3, promoting further host cell invasion by EHV1.
31996426	14	135	theme	potent	2169:2174	arg1	eBD2					2216:2219	eBD2	2216:2219	eBD2	2216:2219	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	135	theme	potent	2169:2174	arg1	eBDs					2210:2213	eBDs	2210:2213	eBDs	2210:2213	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	135	theme	potent	2169:2174	arg1	β-defensins					2197:2207	potent antimicrobial equine β-defensins	2169:2207	potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3	2169:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	14	135	theme	potent	2169:2174	arg1	eBD3					2225:2228	eBD3	2225:2228	eBD3	2225:2228	In contrast to several respiratory viruses and bacteria, EHV1 resisted potent antimicrobial equine β-defensins (eBDs) eBD2 and eBD3 by the action of glycoprotein M. Instead, eBD2 and -3 facilitated EHV1 particle aggregation and infection of rabbit kidney (RK13) cells.
31996426	9	136	theme	virion	1321:1326	arg1	binding					1328:1334	increased EHV1 virion binding	1306:1334	increased EHV1 virion binding to and infection of these cells	1306:1366	Pretreatment of primary equine respiratory epithelial cells (EREC) with eBD1, -2, and -3 resulted in increased EHV1 virion binding to and infection of these cells.
34685658	7	0	theme	inducing	1531:1538	arg1	Tet1					1540:1543	the DNA demethylation inducing Tet1	1509:1543	the DNA demethylation inducing Tet1	1509:1543	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	1	1	theme	methylation	230:240	arg1	5-azacytidine					252:264	the DNA methylation inhibitor 5-azacytidine	222:264	the DNA methylation inhibitor 5-azacytidine	222:264	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	7	2	theme	DNA	1513:1515	arg1	Tet1					1540:1543	the DNA demethylation inducing Tet1	1509:1543	the DNA demethylation inducing Tet1	1509:1543	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	4	3	theme	weak	1051:1054	arg1	signals					1078:1084	weak in situ hybridization signals	1051:1084	weak in situ hybridization signals	1051:1084	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	1	4	theme	5-azacytidine	252:264	arg1	effects					211:217	the effects	207:217	the effects of the DNA methylation inhibitor 5-azacytidine	207:264	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	1	4	theme	5-azacytidine	252:264	arg1	pattern					147:153	the gene expression pattern	127:153	the gene expression pattern of selected enzymes involved in DNA methylation	127:201	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	3	5	theme	strong	685:690	arg1	expression					717:726	very strong but gradually decreasing expression	680:726	very strong but gradually decreasing expression of Tet1	680:734	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	5	6	theme	early	1222:1226	arg1	stages					1228:1233	the early stages	1218:1233	the early stages of chondrogenesis	1218:1251	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	1	7	theme	selected	158:165	arg1	enzymes					167:173	selected enzymes	158:173	selected enzymes involved in DNA methylation	158:201	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	3	8	theme	Tet1	731:734	arg1	expression					717:726	very strong but gradually decreasing expression	680:726	very strong but gradually decreasing expression of Tet1	680:734	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	7	9	theme	formation	1693:1701	arg1	phases					1664:1669	different phases	1654:1669	different phases of in vitro cartilage formation	1654:1701	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	3	10	dep	in	768:769	arg1	vitro					771:775	vitro	771:775	vitro	771:775	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	1	11	theme	DNA	187:189	arg1	methylation					191:201	DNA methylation	187:201	DNA methylation	187:201	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	3	12	from	hybridization	907:919	arg1	sections					931:938	frozen sections	924:938	frozen sections of 15-day-old mouse embryos	924:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	2	13	link	O-linked	523:530	arg1	transferase					552:562	O-linked N-acetylglucosamine transferase	523:562	O-linked N-acetylglucosamine transferase	523:562	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	13	link	O-linked	523:530	arg1	Ogt					518:520	Ogt	518:520	Ogt (O-linked N-acetylglucosamine transferase)	518:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	6	14	theme	quantitative	1342:1353	arg1	PCR					1376:1378	quantitative methylation-specific PCR	1342:1378	quantitative methylation-specific PCR	1342:1378	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	2	15	theme	N-acetylglucosamine	532:550	arg1	transferase					552:562	O-linked N-acetylglucosamine transferase	523:562	O-linked N-acetylglucosamine transferase	523:562	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	15	theme	N-acetylglucosamine	532:550	arg1	Ogt					518:520	Ogt	518:520	Ogt (O-linked N-acetylglucosamine transferase)	518:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	3	16	dep	in	899:900	arg1	situ					902:905	situ	902:905	situ	902:905	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	3	17	theme	cartilaginous	836:848	arg1	skeleton					860:867	the cartilaginous embryonic skeleton	832:867	the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos	832:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	7	18	theme	different	1654:1662	arg1	phases					1664:1669	different phases	1654:1669	different phases of in vitro cartilage formation	1654:1701	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	3	19	theme	cartilage	777:785	arg1	differentiation					787:801	in vitro cartilage differentiation	768:801	in vitro cartilage differentiation	768:801	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	6	20	theme	differentiated	1309:1322	arg1	chondrocytes					1324:1335	differentiated chondrocytes	1309:1335	differentiated chondrocytes	1309:1335	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	4	21	theme	Dnmt3a	969:974	arg1	expressions					984:994	Dnmt3a and Ogt expressions	969:994	Dnmt3a and Ogt expressions	969:994	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	3	22	theme	in	768:769	arg1	differentiation					787:801	in vitro cartilage differentiation	768:801	in vitro cartilage differentiation	768:801	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	6	23	theme	key	1423:1425	arg1	genes					1447:1451	key chondrogenic marker genes	1423:1451	key chondrogenic marker genes	1423:1451	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	7	24	dep	in	1674:1675	arg1	vitro					1677:1681	vitro	1677:1681	vitro	1677:1681	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	1	25	theme	gene	131:134	arg1	pattern					147:153	the gene expression pattern	127:153	the gene expression pattern of selected enzymes involved in DNA methylation	127:201	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	3	26	theme	specific	875:882	arg1	probes					888:893	specific RNA probes	875:893	specific RNA probes	875:893	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	4	27	theme	Ogt	980:982	arg1	expressions					984:994	Dnmt3a and Ogt expressions	969:994	Dnmt3a and Ogt expressions	969:994	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	3	28	theme	strong	814:819	arg1	signals					821:827	strong signals	814:827	strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos	814:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	5	29	theme	cartilage-specific	1139:1156	arg1	expression					1163:1172	cartilage-specific gene expression	1139:1172	cartilage-specific gene expression	1139:1172	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	4	30	dep	in	1056:1057	arg1	situ					1059:1062	situ	1059:1062	situ	1059:1062	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	7	31	theme	DNA	1611:1613	arg1	methylation					1615:1625	DNA methylation	1611:1625	DNA methylation	1611:1625	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	0	32	from	Analysis	0:7	arg1	Models					103:108	Murine Chondrogenic Models	83:108	Murine Chondrogenic Models	83:108	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	6	33	theme	DNA	1396:1398	arg1	pattern					1412:1418	the DNA methylation pattern	1392:1418	the DNA methylation pattern of key chondrogenic marker genes	1392:1451	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	3	34	theme	in	899:900	arg1	hybridization					907:919	in situ hybridization	899:919	in situ hybridization on frozen sections of 15-day-old mouse embryos	899:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	2	35	theme	chondrifying	361:372	arg1	cells					404:408	chondrifying BMP2-overexpressing C3H10T1/2 cells	361:408	chondrifying BMP2-overexpressing C3H10T1/2 cells	361:408	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	0	36	theme	Murine	83:88	arg1	Models					103:108	Murine Chondrogenic Models	83:108	Murine Chondrogenic Models	83:108	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	5	37	theme	methylation	1095:1105	arg1	5-azacytidine					1117:1129	The DNA methylation inhibitor 5-azacytidine	1087:1129	The DNA methylation inhibitor 5-azacytidine	1087:1129	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	2	38	theme	micromass	651:659	arg1	cultures					661:668	murine cell line-based and primary chondrifying micromass cultures	603:668	cultures	661:668	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	3	39	theme	frozen	924:929	arg1	sections					931:938	frozen sections	924:938	frozen sections of 15-day-old mouse embryos	924:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	2	40	theme	relative	415:422	arg1	expressions					424:434	the relative expressions	411:434	the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase)	411:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	41	theme	primary	630:636	arg1	cultures					661:668	murine cell line-based and primary chondrifying micromass cultures	603:668	cultures	661:668	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	0	42	theme	Gene	12:15	arg1	Patterns					28:35	Gene Expression Patterns	12:35	Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt	12:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	2	43	theme	methylcytosine	449:462	arg1	dioxygenase					464:474	tet methylcytosine dioxygenase 1	445:476	tet methylcytosine dioxygenase 1	445:476	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	43	theme	methylcytosine	449:462	arg1	Tet1					439:442	Tet1	439:442	Tet1 (tet methylcytosine dioxygenase 1)	439:477	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	44	theme	C3H10T1/2	394:402	arg1	cells					404:408	chondrifying BMP2-overexpressing C3H10T1/2 cells	361:408	chondrifying BMP2-overexpressing C3H10T1/2 cells	361:408	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	0	45	theme	Patterns	28:35	arg1	Analysis					0:7	Analysis	0:7	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.	0:109	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	1	46	theme	in	286:287	arg1	formation					304:312	in vitro and in vivo cartilage formation	273:312	in vitro and in vivo cartilage formation	273:312	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	3	47	theme	mouse	954:958	arg1	embryos					960:966	15-day-old mouse embryos	943:966	15-day-old mouse embryos	943:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	0	48	theme	Epigenetic	40:49	arg1	Tet1					67:70	Tet1	67:70	Tet1	67:70	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	0	48	theme	Epigenetic	40:49	arg1	Dnmt3a					59:64	Dnmt3a	59:64	Dnmt3a	59:64	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	0	48	theme	Epigenetic	40:49	arg1	Ogt					76:78	Ogt	76:78	Ogt	76:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	0	48	theme	Epigenetic	40:49	arg1	Enzymes					51:57	Epigenetic Enzymes	40:57	Epigenetic Enzymes Dnmt3a, Tet1 and Ogt	40:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	5	49	theme	cartilage	1178:1186	arg1	formation					1188:1196	cartilage formation	1178:1196	cartilage formation	1178:1196	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	4	50	theme	hybridization	1064:1076	arg1	signals					1078:1084	weak in situ hybridization signals	1051:1084	weak in situ hybridization signals	1051:1084	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	2	51	theme	PCR	338:340	arg1	array					342:346	a PCR array	336:346	a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells	336:408	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	6	52	theme	genes	1447:1451	arg1	pattern					1412:1418	the DNA methylation pattern	1392:1418	the DNA methylation pattern of key chondrogenic marker genes	1392:1451	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	7	53	theme	demethylation	1517:1529	arg1	Tet1					1540:1543	the DNA demethylation inducing Tet1	1509:1543	the DNA demethylation inducing Tet1	1509:1543	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	5	54	theme	chondrogenesis	1238:1251	arg1	stages					1228:1233	the early stages	1218:1233	the early stages of chondrogenesis	1218:1251	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	1	55	theme	DNA	226:228	arg1	5-azacytidine					252:264	the DNA methylation inhibitor 5-azacytidine	222:264	the DNA methylation inhibitor 5-azacytidine	222:264	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	4	56	theme	in	1056:1057	arg1	hybridization					1064:1076	in situ hybridization	1056:1076	weak in situ hybridization signals	1051:1084	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	1	57	theme	inhibitor	242:250	arg1	5-azacytidine					252:264	the DNA methylation inhibitor 5-azacytidine	222:264	the DNA methylation inhibitor 5-azacytidine	222:264	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	4	58	with	changes	1021:1027	arg1	RT-qPCR					1034:1040	RT-qPCR	1034:1040	RT-qPCR	1034:1040	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	3	59	theme	decreasing	706:715	arg1	expression					717:726	very strong but gradually decreasing expression	680:726	very strong but gradually decreasing expression of Tet1	680:734	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	6	60	theme	stimulatory	1276:1286	arg1	effect					1288:1293	a stimulatory effect	1274:1293	a stimulatory effect	1274:1293	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	6	61	theme	marker	1440:1445	arg1	genes					1447:1451	key chondrogenic marker genes	1423:1451	key chondrogenic marker genes	1423:1451	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	1	62	theme	cartilage	294:302	arg1	formation					304:312	in vitro and in vivo cartilage formation	273:312	in vitro and in vivo cartilage formation	273:312	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	1	63	theme	enzymes	167:173	arg1	effects					211:217	the effects	207:217	the effects of the DNA methylation inhibitor 5-azacytidine	207:264	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	1	63	theme	enzymes	167:173	arg1	pattern					147:153	the gene expression pattern	127:153	the gene expression pattern of selected enzymes involved in DNA methylation	127:201	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	7	64	theme	cartilage	1683:1691	arg1	formation					1693:1701	in vitro cartilage formation	1674:1701	in vitro cartilage formation	1674:1701	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	7	65	theme	in	1674:1675	arg1	formation					1693:1701	in vitro cartilage formation	1674:1701	in vitro cartilage formation	1674:1701	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	6	66	theme	methylation-specific	1355:1374	arg1	PCR					1376:1378	quantitative methylation-specific PCR	1342:1378	quantitative methylation-specific PCR	1342:1378	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	1	67	dep	in	273:274	arg1	vitro					276:280	vitro	276:280	vitro	276:280	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	2	68	theme	O-linked	523:530	arg1	transferase					552:562	O-linked N-acetylglucosamine transferase	523:562	O-linked N-acetylglucosamine transferase	523:562	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	68	theme	O-linked	523:530	arg1	Ogt					518:520	Ogt	518:520	Ogt (O-linked N-acetylglucosamine transferase)	518:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	3	69	theme	entire	751:756	arg1	course					758:763	the entire course	747:763	the entire course of in vitro cartilage differentiation	747:801	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	3	70	theme	embryonic	850:858	arg1	skeleton					860:867	the cartilaginous embryonic skeleton	832:867	the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos	832:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	7	71	theme	distinct	1634:1641	arg1	effects					1643:1649	distinct effects	1634:1649	distinct effects	1634:1649	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	2	72	theme	Ogt	518:520	arg1	expressions					424:434	the relative expressions	411:434	the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase)	411:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	3	73	theme	differentiation	787:801	arg1	course					758:763	the entire course	747:763	the entire course of in vitro cartilage differentiation	747:801	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	6	74	theme	chondrogenic	1427:1438	arg1	genes					1447:1451	key chondrogenic marker genes	1423:1451	key chondrogenic marker genes	1423:1451	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	7	75	theme	methylation	1615:1625	arg1	inhibition					1597:1606	inhibition	1597:1606	inhibition of DNA methylation	1597:1625	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	1	76	theme	expression	136:145	arg1	pattern					147:153	the gene expression pattern	127:153	the gene expression pattern of selected enzymes involved in DNA methylation	127:201	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	3	77	theme	RNA	884:886	arg1	probes					888:893	specific RNA probes	875:893	specific RNA probes	875:893	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	6	78	theme	methylation	1400:1410	arg1	pattern					1412:1418	the DNA methylation pattern	1392:1418	the DNA methylation pattern of key chondrogenic marker genes	1392:1451	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	5	79	theme	gene	1158:1161	arg1	expression					1163:1172	cartilage-specific gene expression	1139:1172	cartilage-specific gene expression	1139:1172	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	2	80	theme	DNA	488:490	arg1	Dnmt3a					480:485	Dnmt3a	480:485	Dnmt3a (DNA methyltransferase 3)	480:511	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	80	theme	DNA	488:490	arg1	methyltransferase					492:508	DNA methyltransferase 3	488:510	DNA methyltransferase 3	488:510	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	0	81	theme	Chondrogenic	90:101	arg1	Models					103:108	Murine Chondrogenic Models	83:108	Murine Chondrogenic Models	83:108	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	5	82	theme	DNA	1091:1093	arg1	5-azacytidine					1117:1129	The DNA methylation inhibitor 5-azacytidine	1087:1129	The DNA methylation inhibitor 5-azacytidine	1087:1129	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	2	83	theme	Dnmt3a	480:485	arg1	expressions					424:434	the relative expressions	411:434	the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase)	411:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	1	84	dep	in	286:287	arg1	vivo					289:292	vivo	289:292	vivo	289:292	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	5	85	theme	inhibitor	1107:1115	arg1	5-azacytidine					1117:1129	The DNA methylation inhibitor 5-azacytidine	1087:1129	The DNA methylation inhibitor 5-azacytidine	1087:1129	The DNA methylation inhibitor 5-azacytidine reduced cartilage-specific gene expression and cartilage formation when applied during the early stages of chondrogenesis.
34685658	4	86	theme	significant	1009:1019	arg1	changes					1021:1027	significant changes	1009:1027	significant changes with RT-qPCR	1009:1040	Dnmt3a and Ogt expressions did not show significant changes with RT-qPCR and gave weak in situ hybridization signals.
34685658	2	87	theme	chondrifying	638:649	arg1	cultures					661:668	murine cell line-based and primary chondrifying micromass cultures	603:668	cultures	661:668	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	88	theme	array	342:346	arg1	data					328:331	the data	324:331	the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells	324:408	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	0	89	theme	Expression	17:26	arg1	Patterns					28:35	Gene Expression Patterns	12:35	Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt	12:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	1	90	theme	in	273:274	arg1	formation					304:312	in vitro and in vivo cartilage formation	273:312	in vitro and in vivo cartilage formation	273:312	We investigated the gene expression pattern of selected enzymes involved in DNA methylation and the effects of the DNA methylation inhibitor 5-azacytidine during in vitro and in vivo cartilage formation.
34685658	6	91	contain	had	1270:1272	arg1	it					1267:1268	it	1267:1268	it	1267:1268	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	6	91	contain	had	1270:1272	arg2	effect					1288:1293	a stimulatory effect	1274:1293	a stimulatory effect	1274:1293	In contrast, it had a stimulatory effect when added to differentiated chondrocytes, and quantitative methylation-specific PCR proved that the DNA methylation pattern of key chondrogenic marker genes was altered by the treatment.
34685658	0	92	dep	Enzymes	51:57	arg1	Tet1					67:70	Tet1	67:70	Tet1	67:70	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	0	92	dep	Enzymes	51:57	arg1	Dnmt3a					59:64	Dnmt3a	59:64	Dnmt3a	59:64	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	0	92	dep	Enzymes	51:57	arg1	Ogt					76:78	Ogt	76:78	Ogt	76:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	0	92	dep	Enzymes	51:57	arg1	Enzymes					51:57	Epigenetic Enzymes	40:57	Epigenetic Enzymes Dnmt3a, Tet1 and Ogt	40:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	2	93	theme	tet	445:447	arg1	dioxygenase					464:474	tet methylcytosine dioxygenase 1	445:476	tet methylcytosine dioxygenase 1	445:476	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	2	93	theme	tet	445:447	arg1	Tet1					439:442	Tet1	439:442	Tet1 (tet methylcytosine dioxygenase 1)	439:477	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	3	94	from	signals	821:827	arg1	skeleton					860:867	the cartilaginous embryonic skeleton	832:867	the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos	832:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	2	95	theme	BMP2-overexpressing	374:392	arg1	cells					404:408	chondrifying BMP2-overexpressing C3H10T1/2 cells	361:408	chondrifying BMP2-overexpressing C3H10T1/2 cells	361:408	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	0	96	theme	Enzymes	51:57	arg1	Patterns					28:35	Gene Expression Patterns	12:35	Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt	12:78	Analysis of Gene Expression Patterns of Epigenetic Enzymes Dnmt3a, Tet1 and Ogt in Murine Chondrogenic Models.
34685658	3	97	theme	embryos	960:966	arg1	sections					931:938	frozen sections	924:938	frozen sections of 15-day-old mouse embryos	924:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
34685658	2	98	theme	Tet1	439:442	arg1	expressions					424:434	the relative expressions	411:434	the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase)	411:563	Based on the data of a PCR array performed on chondrifying BMP2-overexpressing C3H10T1/2 cells, the relative expressions of Tet1 (tet methylcytosine dioxygenase 1), Dnmt3a (DNA methyltransferase 3), and Ogt (O-linked N-acetylglucosamine transferase) were further examined with RT-qPCR in murine cell line-based and primary chondrifying micromass cultures.
34685658	7	99	theme	significant	1553:1563	arg1	role					1565:1568	a significant role	1551:1568	a significant role	1551:1568	Our results indicate that the DNA demethylation inducing Tet1 plays a significant role during chondrogenesis, and inhibition of DNA methylation exerts distinct effects in different phases of in vitro cartilage formation.
34685658	3	100	theme	15-day-old	943:952	arg1	embryos					960:966	15-day-old mouse embryos	943:966	15-day-old mouse embryos	943:966	We found very strong but gradually decreasing expression of Tet1 throughout the entire course of in vitro cartilage differentiation along with strong signals in the cartilaginous embryonic skeleton using specific RNA probes for in situ hybridization on frozen sections of 15-day-old mouse embryos.
37026711	8	0	theme	structural	1552:1561	arg1	consequences					1563:1574	The structural consequences	1548:1574	The structural consequences of glycosylation on the loop dynamics	1548:1612	The structural consequences of glycosylation on the loop dynamics are further emphasized with larger glycan molecules attached.
37026711	8	1	theme	loop	1600:1603	arg1	dynamics					1605:1612	the loop dynamics	1596:1612	the loop dynamics	1596:1612	The structural consequences of glycosylation on the loop dynamics are further emphasized with larger glycan molecules attached.
37026711	1	2	theme	physiological	136:148	arg1	processes					150:158	various physiological processes	128:158	various physiological processes	128:158	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	1	3	theme	metabolites	239:249	arg1	translocation					180:192	the translocation	176:192	the translocation of amino acids, neurotransmitters, and other metabolites	176:249	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	0	4	from	Effects	4:10	arg1	Transporters					46:57	SLC6 Transporters	41:57	SLC6 Transporters	41:57	The Effects of N-Linked Glycosylation on SLC6 Transporters.
37026711	3	5	link	N-linked	465:472	arg1	mechanism					514:522	a universal regulatory mechanism	491:522	a universal regulatory mechanism among eukaryotes	491:539	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	3	5	link	N-linked	465:472	arg1	glycosylation					474:486	N-linked glycosylation	465:486	N-linked glycosylation	465:486	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	2	6	theme	post-translational	338:355	arg1	modifications					357:369	various post-translational modifications	330:369	various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics	330:456	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	6	7	gly	glycosylation	1251:1263	arg2	site					1265:1268	each glycosylation site	1246:1268	each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter	1246:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	7	8	theme	regions	1539:1545	arg1	dynamics					1475:1482	the dynamics	1471:1482	the dynamics of the glycosylated extracellular loop and surrounding regions	1471:1545	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	3	9	theme	SLC6	598:601	arg1	family					615:620	the SLC6 transporter family	594:620	the SLC6 transporter family	594:620	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	9	10	theme	conformational	1869:1882	arg1	dynamics					1884:1891	conformational dynamics	1869:1891	conformational dynamics associated with substrate transport	1869:1927	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	5	11	dep	dynamics	966:973	arg1	data					991:994	simulation data	980:994	aggregated all-atom molecular dynamics (MD) simulation data	936:994	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	9	12	theme	gating	1748:1753	arg1	helices					1755:1761	the gating helices	1744:1761	the gating helices	1744:1761	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	7	13	theme	loop	1518:1521	arg1	dynamics					1475:1482	the dynamics	1471:1482	the dynamics of the glycosylated extracellular loop and surrounding regions	1471:1545	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	6	14	theme	possible	1200:1207	arg1	combinations					1209:1220	all possible combinations	1196:1220	all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter	1196:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	1	15	theme	Membrane	60:67	arg1	transporters					69:80	Membrane transporters	60:80	Membrane transporters of the solute carrier 6 (SLC6) family	60:118	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	3	16	gly	glycosylation	572:584	arg1	transporter					603:613	the SLC6 transporter family	594:620	the SLC6 transporter family	594:620	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	3	16	gly	glycosylation	572:584	arg1	SLC6					598:601	the SLC6 transporter family	594:620	the SLC6 transporter family	594:620	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	3	17	theme	regulatory	503:512	arg1	mechanism					514:522	a universal regulatory mechanism	491:522	a universal regulatory mechanism among eukaryotes	491:539	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	3	17	theme	regulatory	503:512	arg1	glycosylation					474:486	N-linked glycosylation	465:486	N-linked glycosylation	465:486	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	2	18	theme	membrane	423:430	arg1	trafficking					432:442	membrane trafficking	423:442	membrane trafficking	423:442	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	3	19	theme	consistent	544:553	arg1	mechanism					555:563	a consistent mechanism	542:563	a consistent mechanism of how glycosylation affects the SLC6 transporter family	542:620	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	4	20	theme	membrane	713:720	arg1	trafficking					722:732	membrane trafficking	713:732	membrane trafficking	713:732	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	6	21	dep	larger	1310:1315	arg1	oligo-N-linked					1318:1331	oligo-N-linked	1318:1331	oligo-N-linked	1318:1331	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	7	22	theme	glycosylated	1491:1502	arg1	loop					1518:1521	the glycosylated extracellular loop	1487:1521	the glycosylated extracellular loop	1487:1521	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	8	23	theme	larger	1642:1647	arg1	molecules					1656:1664	larger glycan molecules	1642:1664	larger glycan molecules attached	1642:1673	The structural consequences of glycosylation on the loop dynamics are further emphasized with larger glycan molecules attached.
37026711	5	24	from	impact	1027:1032	arg1	dynamics					1067:1074	SLC6 transporter dynamics	1050:1074	SLC6 transporter dynamics	1050:1074	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	4	25	theme	transporter	687:697	arg1	stability					699:707	transporter stability	687:707	transporter stability	687:707	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	7	26	theme	extracellular	1504:1516	arg1	loop					1518:1521	the glycosylated extracellular loop	1487:1521	the glycosylated extracellular loop	1487:1521	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	9	27	theme	helices	1755:1761	arg1	movement					1732:1739	movement	1732:1739	movement	1732:1739	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	9	27	theme	helices	1755:1761	arg1	stability					1719:1727	ligand stability	1712:1727	ligand stability	1712:1727	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	4	28	theme	transporter	773:783	arg1	dynamics					785:792	transporter dynamics	773:792	transporter dynamics	773:792	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	7	29	gly	glycosylated	1491:1502	arg1	loop					1518:1521	the glycosylated extracellular loop	1487:1521	the glycosylated extracellular loop	1487:1521	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	2	30	theme	protein	392:398	arg1	expression					400:409	protein expression	392:409	protein expression	392:409	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	7	31	gly	glycosylation	1390:1402	arg1	transporter					1438:1448	the transporter structure	1434:1458	the transporter structure	1434:1458	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	6	32	theme	B0AT1	1156:1160	arg1	transporters					1104:1115	four human SLC6 transporters	1088:1115	four human SLC6 transporters	1088:1115	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	32	theme	B0AT1	1156:1160	arg1	transporters					1162:1173	B0AT1 transporters	1156:1173	B0AT1 transporters	1156:1173	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	2	33	from	implications	376:387	arg1	expression					400:409	protein expression	392:409	protein expression	392:409	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	2	33	from	implications	376:387	arg1	dynamics					449:456	dynamics	449:456	dynamics	449:456	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	2	33	from	implications	376:387	arg1	stability					412:420	stability	412:420	stability	412:420	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	2	33	from	implications	376:387	arg1	trafficking					432:442	membrane trafficking	423:442	membrane trafficking	423:442	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	1	34	theme	solute	89:94	arg1	family					113:118	the solute carrier 6 (SLC6) family	85:118	the solute carrier 6 (SLC6) family	85:118	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	9	35	contain	have	1843:1846	arg1	glycosylation					1820:1832	glycosylation	1820:1832	glycosylation	1820:1832	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	9	35	contain	have	1843:1846	arg2	effect					1859:1864	a profound effect	1848:1864	a profound effect	1848:1864	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	6	36	theme	SLC6	1099:1102	arg1	dopamine					1133:1140	dopamine	1133:1140	dopamine	1133:1140	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	36	theme	SLC6	1099:1102	arg1	transporters					1104:1115	four human SLC6 transporters	1088:1115	four human SLC6 transporters	1088:1115	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	36	theme	SLC6	1099:1102	arg1	transporters					1162:1173	B0AT1 transporters	1156:1173	B0AT1 transporters	1156:1173	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	36	theme	SLC6	1099:1102	arg1	serotonin					1122:1130	the serotonin	1118:1130	the serotonin	1118:1130	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	36	theme	SLC6	1099:1102	arg1	glycine					1143:1149	glycine	1143:1149	glycine	1143:1149	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	0	37	theme	N-Linked	15:22	arg1	Glycosylation					24:36	N-Linked Glycosylation	15:36	N-Linked Glycosylation	15:36	The Effects of N-Linked Glycosylation on SLC6 Transporters.
37026711	6	38	attach	attached	1234:1241	arg1	site					1265:1268	each glycosylation site	1246:1268	each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter	1246:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	38	attach	attached	1234:1241	arg2	glycan					1227:1232	a glycan	1225:1232	a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter	1225:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	39	theme	larger	1310:1315	arg1	glycans					1333:1339	larger, oligo-N-linked glycans	1310:1339	larger, oligo-N-linked glycans	1310:1339	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	1	40	theme	carrier	96:102	arg1	family					113:118	the solute carrier 6 (SLC6) family	85:118	the solute carrier 6 (SLC6) family	85:118	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	6	41	theme	human	1093:1097	arg1	dopamine					1133:1140	dopamine	1133:1140	dopamine	1133:1140	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	41	theme	human	1093:1097	arg1	transporters					1104:1115	four human SLC6 transporters	1088:1115	four human SLC6 transporters	1088:1115	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	41	theme	human	1093:1097	arg1	transporters					1162:1173	B0AT1 transporters	1156:1173	B0AT1 transporters	1156:1173	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	41	theme	human	1093:1097	arg1	serotonin					1122:1130	the serotonin	1118:1130	the serotonin	1118:1130	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	6	41	theme	human	1093:1097	arg1	glycine					1143:1149	glycine	1143:1149	glycine	1143:1149	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	2	42	theme	transporters	287:298	arg1	activity					269:276	the activity	265:276	the activity of these transporters	265:298	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	5	43	theme	aggregated	936:945	arg1	MD					976:977	MD	976:977	MD	976:977	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	5	43	theme	aggregated	936:945	arg1	dynamics					966:973	aggregated all-atom molecular dynamics	936:973	aggregated all-atom molecular dynamics (MD) simulation data	936:994	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	1	44	theme	amino	197:201	arg1	acids					203:207	amino acids	197:207	amino acids	197:207	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	9	45	from	differences	1697:1707	arg1	movement					1732:1739	movement	1732:1739	movement	1732:1739	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	9	45	from	differences	1697:1707	arg1	stability					1719:1727	ligand stability	1712:1727	ligand stability	1712:1727	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	5	46	theme	molecular	956:964	arg1	MD					976:977	MD	976:977	MD	976:977	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	5	46	theme	molecular	956:964	arg1	dynamics					966:973	aggregated all-atom molecular dynamics	936:973	aggregated all-atom molecular dynamics (MD) simulation data	936:994	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	5	47	theme	SLC6	1050:1053	arg1	dynamics					1067:1074	SLC6 transporter dynamics	1050:1074	SLC6 transporter dynamics	1050:1074	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	1	48	theme	acids	203:207	arg1	translocation					180:192	the translocation	176:192	the translocation of amino acids, neurotransmitters, and other metabolites	176:249	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	0	49	theme	Glycosylation	24:36	arg1	Effects					4:10	The Effects	0:10	The Effects of N-Linked Glycosylation on SLC6 Transporters	0:57	The Effects of N-Linked Glycosylation on SLC6 Transporters.
37026711	7	50	theme	surrounding	1527:1537	arg1	regions					1539:1545	surrounding regions	1527:1545	surrounding regions	1527:1545	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	7	51	theme	transporter	1438:1448	arg1	structure					1450:1458	the transporter structure	1434:1458	the transporter structure	1434:1458	The simulations reveal that glycosylation does not significantly affect the transporter structure but alters the dynamics of the glycosylated extracellular loop and surrounding regions.
37026711	5	52	theme	transporter	1055:1065	arg1	dynamics					1067:1074	SLC6 transporter dynamics	1050:1074	SLC6 transporter dynamics	1050:1074	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	3	53	theme	N-linked	465:472	arg1	mechanism					514:522	a universal regulatory mechanism	491:522	a universal regulatory mechanism among eukaryotes	491:539	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	3	53	theme	N-linked	465:472	arg1	glycosylation					474:486	N-linked glycosylation	465:486	N-linked glycosylation	465:486	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	9	54	theme	substrate	1909:1917	arg1	transport					1919:1927	substrate transport	1909:1927	substrate transport	1909:1927	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	8	55	theme	glycan	1649:1654	arg1	molecules					1656:1664	larger glycan molecules	1642:1664	larger glycan molecules attached	1642:1673	The structural consequences of glycosylation on the loop dynamics are further emphasized with larger glycan molecules attached.
37026711	3	56	theme	transporter	603:613	arg1	family					615:620	the SLC6 transporter family	594:620	the SLC6 transporter family	594:620	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	2	57	theme	various	330:336	arg1	modifications					357:369	various post-translational modifications	330:369	various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics	330:456	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	0	58	theme	SLC6	41:44	arg1	Transporters					46:57	SLC6 Transporters	41:57	SLC6 Transporters	41:57	The Effects of N-Linked Glycosylation on SLC6 Transporters.
37026711	2	59	with	modifications	357:369	arg1	implications					376:387	implications	376:387	implications on protein expression, stability, membrane trafficking, and dynamics	376:456	In the body, the activity of these transporters is tightly controlled through various post-translational modifications with implications on protein expression, stability, membrane trafficking, and dynamics.
37026711	4	60	theme	SLC6	882:885	arg1	family					887:892	the SLC6 family	878:892	the SLC6 family	878:892	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	9	61	theme	profound	1850:1857	arg1	effect					1859:1864	a profound effect	1848:1864	a profound effect	1848:1864	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	1	62	theme	SLC6	107:110	arg1	family					113:118	the solute carrier 6 (SLC6) family	85:118	the solute carrier 6 (SLC6) family	85:118	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	9	63	theme	ligand	1712:1717	arg1	stability					1719:1727	ligand stability	1712:1727	ligand stability	1712:1727	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	6	64	theme	glycans	1333:1339	arg1	effect					1300:1305	the effect	1296:1305	the effect of larger, oligo-N-linked glycans to each transporter	1296:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	9	65	theme	apparent	1688:1695	arg1	differences					1697:1707	no apparent differences	1685:1707	no apparent differences in ligand stability or movement of the gating helices	1685:1761	However, no apparent differences in ligand stability or movement of the gating helices were observed, and as such, the simulations suggest that glycosylation does not have a profound effect on conformational dynamics associated with substrate transport.
37026711	6	66	theme	glycosylation	1251:1263	arg1	site					1265:1268	each glycosylation site	1246:1268	each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter	1246:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	4	67	theme	glycosylation	756:768	arg1	role					748:751	the role	744:751	the role of glycosylation on transporter dynamics	744:792	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	5	68	theme	simulation	980:989	arg1	data					991:994	simulation data	980:994	aggregated all-atom molecular dynamics (MD) simulation data	936:994	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	1	69	theme	neurotransmitters	210:226	arg1	translocation					180:192	the translocation	176:192	the translocation of amino acids, neurotransmitters, and other metabolites	176:249	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	5	70	theme	all-atom	947:954	arg1	MD					976:977	MD	976:977	MD	976:977	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	5	70	theme	all-atom	947:954	arg1	dynamics					966:973	aggregated all-atom molecular dynamics	936:973	aggregated all-atom molecular dynamics (MD) simulation data	936:994	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	6	71	theme	glycan	1227:1232	arg1	combinations					1209:1220	all possible combinations	1196:1220	all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter	1196:1359	We modeled four human SLC6 transporters, the serotonin, dopamine, glycine, and B0AT1 transporters, by first simulating all possible combinations of a glycan attached to each glycosylation site followed by investigating the effect of larger, oligo-N-linked glycans to each transporter.
37026711	1	72	theme	family	113:118	arg1	transporters					69:80	Membrane transporters	60:80	Membrane transporters of the solute carrier 6 (SLC6) family	60:118	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	4	73	from	role	748:751	arg1	dynamics					785:792	transporter dynamics	773:792	transporter dynamics	773:792	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	5	74	theme	dynamics	966:973	arg1	ms					930:931	1 ms	928:931	1 ms of aggregated all-atom molecular dynamics (MD) simulation data	928:994	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	8	75	theme	glycosylation	1579:1591	arg1	consequences					1563:1574	The structural consequences	1548:1574	The structural consequences of glycosylation on the loop dynamics	1548:1612	The structural consequences of glycosylation on the loop dynamics are further emphasized with larger glycan molecules attached.
37026711	8	76	from	consequences	1563:1574	arg1	dynamics					1605:1612	the loop dynamics	1596:1612	the loop dynamics	1596:1612	The structural consequences of glycosylation on the loop dynamics are further emphasized with larger glycan molecules attached.
37026711	5	77	theme	N-glycans	1037:1045	arg1	impact					1027:1032	the impact	1023:1032	the impact of N-glycans on SLC6 transporter dynamics	1023:1074	In this study, we collected over 1 ms of aggregated all-atom molecular dynamics (MD) simulation data to systematically identify the impact of N-glycans on SLC6 transporter dynamics.
37026711	3	78	theme	universal	493:501	arg1	mechanism					514:522	a universal regulatory mechanism	491:522	a universal regulatory mechanism among eukaryotes	491:539	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	3	78	theme	universal	493:501	arg1	glycosylation					474:486	N-linked glycosylation	465:486	N-linked glycosylation	465:486	While N-linked glycosylation is a universal regulatory mechanism among eukaryotes, a consistent mechanism of how glycosylation affects the SLC6 transporter family remains elusive.
37026711	4	79	theme	individual	847:856	arg1	transporters					858:869	individual transporters	847:869	individual transporters across the SLC6 family	847:892	It is generally believed that glycans influence transporter stability and membrane trafficking; however, the role of glycosylation on transporter dynamics remains disputable, with differing conclusions among individual transporters across the SLC6 family.
37026711	1	80	theme	various	128:134	arg1	processes					150:158	various physiological processes	128:158	various physiological processes	128:158	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
37026711	1	81	theme	other	233:237	arg1	metabolites					239:249	other metabolites	233:249	other metabolites	233:249	Membrane transporters of the solute carrier 6 (SLC6) family mediate various physiological processes by facilitating the translocation of amino acids, neurotransmitters, and other metabolites.
36244450	6	0	theme	site-specific	889:901	arg1	N-					903:904	site-specific N-	889:904	site-specific N-	889:904	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	7	1	theme	MR-Fc	1281:1285	arg1	Treatment					1261:1269	Treatment	1261:1269	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases,	1261:1367	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	7	2	theme	MR	1517:1518	arg1	CTLDs					1520:1524	the MR CTLDs	1513:1524	the MR CTLDs	1513:1524	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	2	3	theme	extracellular	311:323	arg1	domains					325:331	the ten extracellular domains	303:331	the ten extracellular domains of the MR	303:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	3	theme	extracellular	311:323	arg1	MR					340:341	the MR	336:341	the MR	336:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	6	4	theme	microarray	1195:1204	arg1	analysis					1206:1213	glycan microarray analysis	1188:1213	glycan microarray analysis in combination with glycan-modifying enzymes	1188:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	5	5	theme	differential	810:821	arg1	glycosylation					823:835	differential glycosylation	810:835	differential glycosylation	810:835	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	4	6	theme	recombinant	629:639	arg1	version					641:647	a recombinant version	627:647	a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc)	627:708	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	6	7	gly	glycosylation	939:951	arg2	site					953:956	glycosylation site characterization	939:973	glycosylation site characterization	939:973	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	6	7	gly	glycosylation	939:951	arg2	characterization					958:973	glycosylation site characterization	939:973	glycosylation site characterization	939:973	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	1	8	theme	endocytic	158:166	arg1	receptor					118:125	The macrophage mannose receptor	95:125	The macrophage mannose receptor (MR, CD206)	95:137	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	1	8	theme	endocytic	158:166	arg1	receptor					175:182	a transmembrane endocytic lectin receptor	142:182	a transmembrane endocytic lectin receptor	142:182	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	9	9	theme	terminal	1722:1729	arg1	GlcNAc					1744:1749	terminal, nonreducing GlcNAc	1722:1749	terminal, nonreducing GlcNAc in N-glycans	1722:1762	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	6	10	theme	receptor	1162:1169	arg1	functionality					1171:1183	the receptor functionality	1158:1183	the receptor functionality	1158:1183	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	6	11	theme	glycosylation	939:951	arg1	characterization					958:973	glycosylation site characterization	939:973	glycosylation site characterization	939:973	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	5	12	theme	cell	773:776	arg1	lines					778:782	different glycosylation-mutant cell lines	742:782	different glycosylation-mutant cell lines	742:782	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	9	13	theme	tissue-	1802:1808	arg1	manner					1828:1833	a tissue- and cell-specific manner	1800:1833	a tissue- and cell-specific manner	1800:1833	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	7	14	theme	MR	1419:1420	arg1	CTLDs					1422:1426	MR CTLDs	1419:1426	MR CTLDs	1419:1426	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	3	15	theme	glycan	536:541	arg1	binding					543:549	its glycan binding	532:549	its glycan binding	532:549	Previous studies indicated that self-glycosylation of MR regulates its glycan binding.
36244450	1	16	theme	mannose	110:116	arg1	receptor					118:125	The macrophage mannose receptor	95:125	The macrophage mannose receptor (MR, CD206)	95:137	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	1	16	theme	mannose	110:116	arg1	receptor					175:182	a transmembrane endocytic lectin receptor	142:182	a transmembrane endocytic lectin receptor	142:182	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	4	17	theme	human	678:682	arg1	Fc-portion					684:693	human Fc-portion	678:693	human Fc-portion of IgG (MR-Fc)	678:708	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	6	18	theme	O-glycosylation	1022:1036	arg1	sites					1038:1042	several novel O-glycosylation sites	1008:1042	several novel O-glycosylation sites	1008:1042	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	7	19	theme	trans-binding	1393:1405	arg1	GlcNAc					1490:1495	trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc	1393:1495	trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc	1393:1495	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	0	20	theme	glycan	54:59	arg1	binding					61:67	glycan binding	54:67	glycan binding	54:67	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	5	21	theme	glycan-binding	849:862	arg1	properties					864:873	receptor glycan-binding properties	840:873	receptor glycan-binding properties	840:873	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	6	22	theme	several	1008:1014	arg1	sites					1038:1042	several novel O-glycosylation sites	1008:1042	several novel O-glycosylation sites	1008:1042	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	9	23	theme	MR	1785:1786	arg1	activity					1788:1795	MR activity	1785:1795	MR activity	1785:1795	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	4	24	theme	MR	658:659	arg1	CTLD4-7					661:667	mouse MR CTLD4-7	652:667	mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc)	652:708	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	6	25	with	combination	1218:1228	arg1	enzymes					1252:1258	glycan-modifying enzymes	1235:1258	glycan-modifying enzymes	1235:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	6	26	theme	glycan-modifying	1235:1250	arg1	enzymes					1252:1258	glycan-modifying enzymes	1235:1258	glycan-modifying enzymes	1235:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	1	27	dep	receptor	118:125	arg1	MR					128:129	MR	128:129	MR	128:129	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	6	28	dep	confirmed	1076:1084	arg1	guided					1128:1133	guided	1128:1133	guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes	1128:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	0	29	theme	lectin	79:84	arg1	domains					86:92	C-type lectin domains	72:92	C-type lectin domains	72:92	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	6	30	theme	mass	981:984	arg1	spectrometry					986:997	mass spectrometry	981:997	mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes	981:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	2	31	theme	calcium-dependent	439:455	arg1	manner					457:462	a calcium-dependent manner	437:462	a calcium-dependent manner	437:462	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	8	32	theme	N-glycans	1548:1556	arg1	Regalactosylation					1527:1543	Regalactosylation	1527:1543	Regalactosylation of N-glycans	1527:1556	Regalactosylation of N-glycans rescues mannose binding by MR-Fc.
36244450	2	33	theme	lectin	354:359	arg1	domains					325:331	the ten extracellular domains	303:331	the ten extracellular domains of the MR	303:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	33	theme	lectin	354:359	arg1	Eight					294:298	Eight	294:298	Eight	294:298	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	33	theme	lectin	354:359	arg1	CTLDs					370:374	CTLDs	370:374	CTLDs	370:374	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	33	theme	lectin	354:359	arg1	domains					361:367	C-type lectin domains	347:367	C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner	347:462	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	9	34	theme	cell-specific	1814:1826	arg1	manner					1828:1833	a tissue- and cell-specific manner	1800:1833	a tissue- and cell-specific manner	1800:1833	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	8	35	theme	mannose	1566:1572	arg1	binding					1574:1580	mannose binding	1566:1580	mannose binding	1566:1580	Regalactosylation of N-glycans rescues mannose binding by MR-Fc.
36244450	6	36	from	analysis	1206:1213	arg1	combination					1218:1228	combination	1218:1228	combination with glycan-modifying enzymes	1218:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	5	37	theme	glycosylation-mutant	752:771	arg1	lines					778:782	different glycosylation-mutant cell lines	742:782	different glycosylation-mutant cell lines	742:782	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	0	38	theme	mannose	19:25	arg1	CD206					37:41	CD206	37:41	CD206	37:41	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	0	38	theme	mannose	19:25	arg1	receptor					27:34	mannose receptor	19:34	mannose receptor (CD206)	19:42	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	2	39	theme	fucose	415:420	arg1	binding					395:401	the binding	391:401	the binding of mannose, fucose, and GlcNAc	391:432	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	9	40	theme	bacterial	1863:1871	arg1	pathogenesis					1873:1884	bacterial pathogenesis	1863:1884	bacterial pathogenesis	1863:1884	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	7	41	theme	active	1274:1279	arg1	MR-Fc					1281:1285	active MR-Fc	1274:1285	active MR-Fc	1274:1285	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	7	42	theme	CTLDs	1520:1524	arg1	N-glycans					1500:1508	N-glycans	1500:1508	N-glycans of the MR CTLDs	1500:1524	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	9	43	theme	immunomodulatory	1892:1907	arg1	fashion					1909:1915	an immunomodulatory fashion	1889:1915	an immunomodulatory fashion	1889:1915	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	2	44	theme	mannose	406:412	arg1	binding					395:401	the binding	391:401	the binding of mannose, fucose, and GlcNAc	391:432	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	6	45	theme	N-	903:904	arg1	analysis					926:933	site-specific N- and O-glycosylation analysis	889:933	site-specific N- and O-glycosylation analysis	889:933	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	9	46	theme	regulatory	1655:1664	arg1	switch					1666:1671	a regulatory switch	1653:1671	a regulatory switch	1653:1671	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	9	46	theme	regulatory	1655:1664	arg1	glycans					1618:1624	glycans	1618:1624	glycans within the MR CTLDs	1618:1644	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	7	47	from	loss	1385:1388	arg1	N-glycans					1500:1508	N-glycans	1500:1508	N-glycans of the MR CTLDs	1500:1524	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	9	48	dep	terminal	1722:1729	arg1	nonreducing					1732:1742	nonreducing	1732:1742	nonreducing	1732:1742	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	2	49	theme	domains	325:331	arg1	domains					325:331	the ten extracellular domains	303:331	the ten extracellular domains of the MR	303:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	49	theme	domains	325:331	arg1	Eight					294:298	Eight	294:298	Eight	294:298	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	49	theme	domains	325:331	arg1	MR					340:341	the MR	336:341	the MR	336:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	49	theme	domains	325:331	arg1	domains					361:367	C-type lectin domains	347:367	C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner	347:462	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	1	50	theme	endothelial	218:228	arg1	cells					230:234	selected immune and endothelial cells	198:234	cells	230:234	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	7	51	theme	GlcNAc	1490:1495	arg1	loss					1385:1388	the loss	1381:1388	the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs	1381:1524	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	5	52	gly	glycosylation	823:835	arg1	receptor					840:847	receptor glycan-binding properties	840:873	receptor glycan-binding properties	840:873	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	7	53	theme	terminal	1468:1475	arg1	unmasking					1455:1463	unmasking	1455:1463	unmasking of terminal	1455:1475	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	3	54	theme	Previous	465:472	arg1	studies					474:480	Previous studies	465:480	Previous studies	465:480	Previous studies indicated that self-glycosylation of MR regulates its glycan binding.
36244450	5	55	theme	glycosylation	823:835	arg1	influence					797:805	the influence	793:805	the influence of differential glycosylation on receptor glycan-binding properties	793:873	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	6	56	theme	glycan	1188:1193	arg1	analysis					1206:1213	glycan microarray analysis	1188:1213	glycan microarray analysis in combination with glycan-modifying enzymes	1188:1258	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	3	57	theme	MR	519:520	arg1	self-glycosylation					497:514	self-glycosylation	497:514	self-glycosylation of MR	497:520	Previous studies indicated that self-glycosylation of MR regulates its glycan binding.
36244450	1	58	theme	transmembrane	144:156	arg1	receptor					118:125	The macrophage mannose receptor	95:125	The macrophage mannose receptor (MR, CD206)	95:137	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	1	58	theme	transmembrane	144:156	arg1	receptor					175:182	a transmembrane endocytic lectin receptor	142:182	a transmembrane endocytic lectin receptor	142:182	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	1	59	theme	lectin	168:173	arg1	receptor					118:125	The macrophage mannose receptor	95:125	The macrophage mannose receptor (MR, CD206)	95:137	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	1	59	theme	lectin	168:173	arg1	receptor					175:182	a transmembrane endocytic lectin receptor	142:182	a transmembrane endocytic lectin receptor	142:182	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	6	60	theme	site	953:956	arg1	characterization					958:973	glycosylation site characterization	939:973	glycosylation site characterization	939:973	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	1	61	dep	immune	207:212	arg1	selected					198:205	selected	198:205	selected	198:205	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	4	62	theme	structure-function	576:593	arg1	relationship					595:606	this structure-function relationship	571:606	this structure-function relationship	571:606	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	9	63	from	GlcNAc	1744:1749	arg1	N-glycans					1754:1762	N-glycans	1754:1762	N-glycans	1754:1762	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	7	64	theme	non-MR	1431:1436	arg1	glycans					1438:1444	non-MR glycans	1431:1444	non-MR glycans	1431:1444	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	5	65	from	influence	797:805	arg1	properties					864:873	receptor glycan-binding properties	840:873	receptor glycan-binding properties	840:873	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	1	66	theme	macrophage	99:108	arg1	receptor					118:125	The macrophage mannose receptor	95:125	The macrophage mannose receptor (MR, CD206)	95:137	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	1	66	theme	macrophage	99:108	arg1	receptor					175:182	a transmembrane endocytic lectin receptor	142:182	a transmembrane endocytic lectin receptor	142:182	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	6	67	theme	O-glycosylation	910:924	arg1	analysis					926:933	site-specific N- and O-glycosylation analysis	889:933	site-specific N- and O-glycosylation analysis	889:933	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	7	68	theme	CTLDs	1422:1426	arg1	binding					1408:1414	binding	1408:1414	binding of MR CTLDs to non-MR glycans	1408:1444	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	4	69	theme	CTLD4-7	661:667	arg1	version					641:647	a recombinant version	627:647	a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc)	627:708	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	7	70	with	Treatment	1261:1269	arg1	combinations					1292:1303	combinations	1292:1303	combinations of exoglycosidases, including neuraminidase and galactosidases,	1292:1367	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	3	71	gly	self-glycosylation	497:514	arg1	MR					519:520	MR	519:520	MR	519:520	Previous studies indicated that self-glycosylation of MR regulates its glycan binding.
36244450	7	72	dep	trans-binding	1393:1405	arg1	binding					1408:1414	binding	1408:1414	binding of MR CTLDs to non-MR glycans	1408:1444	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	7	72	dep	trans-binding	1393:1405	arg1	due					1448:1450	due	1448:1450	due	1448:1450	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	7	72	dep	trans-binding	1393:1405	arg1	nonreducing					1478:1488	nonreducing	1478:1488	nonreducing	1478:1488	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	5	73	theme	receptor	840:847	arg1	properties					864:873	receptor glycan-binding properties	840:873	receptor glycan-binding properties	840:873	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	6	74	theme	novel	1016:1020	arg1	sites					1038:1042	several novel O-glycosylation sites	1008:1042	several novel O-glycosylation sites	1008:1042	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	2	75	theme	GlcNAc	427:432	arg1	binding					395:401	the binding	391:401	the binding of mannose, fucose, and GlcNAc	391:432	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	0	76	theme	C-type	72:77	arg1	domains					86:92	C-type lectin domains	72:92	C-type lectin domains	72:92	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	1	77	theme	CD206	132:136	arg1	MR					128:129	MR	128:129	MR	128:129	The macrophage mannose receptor (MR, CD206) is a transmembrane endocytic lectin receptor, expressed in selected immune and endothelial cells, and is involved in immunity and maintaining homeostasis.
36244450	4	78	theme	mouse	652:656	arg1	CTLD4-7					661:667	mouse MR CTLD4-7	652:667	mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc)	652:708	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	2	79	theme	C-type	347:352	arg1	domains					325:331	the ten extracellular domains	303:331	the ten extracellular domains of the MR	303:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	79	theme	C-type	347:352	arg1	Eight					294:298	Eight	294:298	Eight	294:298	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	79	theme	C-type	347:352	arg1	CTLDs					370:374	CTLDs	370:374	CTLDs	370:374	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	79	theme	C-type	347:352	arg1	domains					361:367	C-type lectin domains	347:367	C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner	347:462	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	5	80	theme	different	742:750	arg1	lines					778:782	different glycosylation-mutant cell lines	742:782	different glycosylation-mutant cell lines	742:782	The construct was expressed in different glycosylation-mutant cell lines to study the influence of differential glycosylation on receptor glycan-binding properties.
36244450	2	81	theme	MR	340:341	arg1	domains					325:331	the ten extracellular domains	303:331	the ten extracellular domains of the MR	303:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	2	81	theme	MR	340:341	arg1	MR					340:341	the MR	336:341	the MR	336:341	Eight of the ten extracellular domains of the MR are C-type lectin domains (CTLDs) which mediate the binding of mannose, fucose, and GlcNAc in a calcium-dependent manner.
36244450	0	82	theme	receptor	27:34	arg1	N-glycosylation					0:14	N-glycosylation	0:14	N-glycosylation of mannose receptor (CD206)	0:42	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	6	83	theme	mouse	1063:1067	arg1	MR					1069:1070	mouse MR	1063:1070	mouse MR	1063:1070	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
36244450	4	84	theme	IgG	698:700	arg1	Fc-portion					684:693	human Fc-portion	678:693	human Fc-portion of IgG (MR-Fc)	678:708	To further explore this structure-function relationship, we studied herein a recombinant version of mouse MR CTLD4-7 fused to human Fc-portion of IgG (MR-Fc).
36244450	0	85	gly	N-glycosylation	0:14	arg1	CD206					37:41	CD206	37:41	CD206	37:41	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	0	85	gly	N-glycosylation	0:14	arg1	receptor					27:34	mannose receptor	19:34	mannose receptor (CD206)	19:42	N-glycosylation of mannose receptor (CD206) regulates glycan binding by C-type lectin domains.
36244450	9	86	theme	MR	1637:1638	arg1	CTLDs					1640:1644	the MR CTLDs	1633:1644	the MR CTLDs	1633:1644	Our results indicate that glycans within the MR CTLDs act as a regulatory switch by masking and unmasking self-ligands, including terminal, nonreducing GlcNAc in N-glycans, which could control MR activity in a tissue- and cell-specific manner or which potentially affect bacterial pathogenesis in an immunomodulatory fashion.
36244450	7	87	theme	exoglycosidases	1308:1322	arg1	combinations					1292:1303	combinations	1292:1303	combinations of exoglycosidases, including neuraminidase and galactosidases,	1292:1367	Treatment of active MR-Fc with combinations of exoglycosidases, including neuraminidase and galactosidases, resulted in the loss of trans-binding (binding of MR CTLDs to non-MR glycans), due to unmasking of terminal, nonreducing GlcNAc in N-glycans of the MR CTLDs.
36244450	6	88	gly	O-glycosylation	1022:1036	arg2	sites					1038:1042	several novel O-glycosylation sites	1008:1042	several novel O-glycosylation sites	1008:1042	We conducted site-specific N- and O-glycosylation analysis and glycosylation site characterization using mass spectrometry by which several novel O-glycosylation sites were identified in mouse MR and confirmed in human full-length MR. This information guided experiments evaluating the receptor functionality by glycan microarray analysis in combination with glycan-modifying enzymes.
34611864	1	0	theme	bioinformatics	112:125	arg1	resources					127:135	bioinformatics resources	112:135	bioinformatics resources that have been recently released in glycobiology	112:184	The present chapter focuses on the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology.
34611864	3	1	theme	converging	449:458	arg1	efforts					460:466	converging efforts	449:466	converging efforts	449:466	This overview highlights converging efforts toward building a consistent picture of protein glycosylation.
34611864	2	2	from	field	225:229	arg1	analysis					203:210	The comparative analysis	187:210	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology	187:306	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	3	3	theme	glycosylation	516:528	arg1	picture					497:503	a consistent picture	484:503	a consistent picture of protein glycosylation	484:528	This overview highlights converging efforts toward building a consistent picture of protein glycosylation.
34611864	1	4	theme	resources	127:135	arg1	aspects					101:107	the interactive and explorative aspects	69:107	the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology	69:184	The present chapter focuses on the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology.
34611864	2	5	theme	main	295:298	arg1	biology					300:306	main biology	295:306	main biology	295:306	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	0	6	theme	Interactive	3:13	arg1	View					15:18	An Interactive View	0:18	An Interactive View of Glycosylation	0:35	An Interactive View of Glycosylation.
34611864	0	7	theme	Glycosylation	23:35	arg1	View					15:18	An Interactive View	0:18	An Interactive View of Glycosylation	0:35	An Interactive View of Glycosylation.
34611864	1	8	theme	interactive	73:83	arg1	aspects					101:107	the interactive and explorative aspects	69:107	the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology	69:184	The present chapter focuses on the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology.
34611864	2	9	theme	efficient	317:325	arg1	visualization					327:339	efficient visualization	317:339	efficient visualization	317:339	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	2	10	theme	comparative	191:201	arg1	analysis					203:210	The comparative analysis	187:210	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology	187:306	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	2	11	from	analysis	203:210	arg1	field					225:229	a field	223:229	a field where knowledge is scattered, incomplete, and disconnected from main biology	223:306	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	2	12	from	data	215:218	arg1	field					225:229	a field	223:229	a field where knowledge is scattered, incomplete, and disconnected from main biology	223:306	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	3	13	theme	protein	508:514	arg1	glycosylation					516:528	protein glycosylation	508:528	protein glycosylation	508:528	This overview highlights converging efforts toward building a consistent picture of protein glycosylation.
34611864	1	14	theme	present	42:48	arg1	chapter					50:56	The present chapter	38:56	The present chapter	38:56	The present chapter focuses on the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology.
34611864	1	15	theme	explorative	89:99	arg1	aspects					101:107	the interactive and explorative aspects	69:107	the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology	69:184	The present chapter focuses on the interactive and explorative aspects of bioinformatics resources that have been recently released in glycobiology.
34611864	2	16	theme	interactive	359:369	arg1	tools					371:375	interactive tools	359:375	interactive tools that are currently only partially implemented	359:421	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	2	17	theme	data	215:218	arg1	analysis					203:210	The comparative analysis	187:210	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology	187:306	The comparative analysis of data in a field where knowledge is scattered, incomplete, and disconnected from main biology requires efficient visualization, integration, and interactive tools that are currently only partially implemented.
34611864	3	18	theme	consistent	486:495	arg1	picture					497:503	a consistent picture	484:503	a consistent picture of protein glycosylation	484:528	This overview highlights converging efforts toward building a consistent picture of protein glycosylation.
35887202	0	0	theme	Molecular	86:94	arg1	Dynamics					96:103	Molecular Dynamics	86:103	Molecular Dynamics	86:103	O-Glycan-Dependent Interaction between MUC1 Glycopeptide and MY.1E12 Antibody by NMR, Molecular Dynamics and Docking Simulations.
35887202	9	1	used	used	1368:1371	arg2	mode					1339:1342	The VH/VL-shared recognition mode	1310:1342	The VH/VL-shared recognition mode of this antibody	1310:1359	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	1	used	used	1368:1371	arg2	template					1378:1385	a template	1376:1385	a template for the rational design and development of anti-glycopeptide antibodies	1376:1457	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	2	gly	anti-glycopeptide	1430:1446	arg2	anti-glycopeptide					1430:1446	anti-glycopeptide	1430:1446	anti-glycopeptide	1430:1446	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	3	theme	rational	1395:1402	arg1	design					1404:1409	design	1404:1409	design	1404:1409	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	3	4	theme	2-3	512:514	arg1	GalNAc					525:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	4	theme	2-3	512:514	arg1	O-glycan					495:502	an immature O-glycan	483:502	an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	483:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	5	from	O-glycan	495:502	arg1	Thr					547:549	a specific Thr	536:549	a specific Thr	536:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	7	6	gly	O-glycosylated	1094:1107	arg1	Thr					1109:1111	the O-glycosylated Thr	1090:1111	the O-glycosylated Thr	1090:1111	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	8	7	theme	O-glycan	1295:1302	arg1	part					1304:1307	the O-glycan part	1291:1307	the O-glycan part	1291:1307	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	2	8	gly	glycosylation	280:292	arg1	MUC1					256:259	MUC1	256:259	MUC1	256:259	This is based on the fact that MUC1 undergoes aberrant glycosylation upon cancer progression, and anti-MUC1 antibodies differentiate changes in glycan structure.
35887202	7	9	theme	side	1076:1079	arg1	chain					1081:1085	side chain	1076:1085	side chain of the O-glycosylated Thr	1076:1111	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	7	10	theme	Thr	1109:1111	arg1	chain					1081:1085	side chain	1076:1085	side chain of the O-glycosylated Thr	1076:1111	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	7	10	theme	Thr	1109:1111	arg1	flexibility					1036:1046	the flexibility	1032:1046	the flexibility of the peptide backbone	1032:1070	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	2	11	theme	aberrant	271:278	arg1	glycosylation					280:292	aberrant glycosylation	271:292	aberrant glycosylation	271:292	This is based on the fact that MUC1 undergoes aberrant glycosylation upon cancer progression, and anti-MUC1 antibodies differentiate changes in glycan structure.
35887202	9	12	theme	VH/VL-shared	1314:1325	arg1	template					1378:1385	a template	1376:1385	a template for the rational design and development of anti-glycopeptide antibodies	1376:1457	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	12	theme	VH/VL-shared	1314:1325	arg1	mode					1339:1342	The VH/VL-shared recognition mode	1310:1342	The VH/VL-shared recognition mode of this antibody	1310:1359	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	6	13	theme	O-glycosylation	921:935	arg1	site					937:940	the O-glycosylation site	917:940	the O-glycosylation site	917:940	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	8	14	theme	modeled	1140:1146	arg1	Fv					1156:1157	modeled MY.1E12 Fv and MUC1 O-glycopeptide	1140:1181	Fv	1156:1157	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	9	15	theme	anti-glycopeptide	1430:1446	arg1	antibodies					1448:1457	anti-glycopeptide antibodies	1430:1457	anti-glycopeptide antibodies	1430:1457	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	7	16	theme	peptide	1055:1061	arg1	backbone					1063:1070	the peptide backbone	1051:1070	the peptide backbone	1051:1070	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	8	17	theme	MUC1	1245:1248	arg1	portion					1258:1264	the MUC1 peptide portion	1241:1264	the MUC1 peptide portion	1241:1264	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	3	18	with	antibody	420:427	arg1	specificity					445:455	a distinct specificity	434:455	a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	434:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	0	19	theme	Docking	109:115	arg1	Simulations					117:127	Docking Simulations	109:127	Docking Simulations	109:127	O-Glycan-Dependent Interaction between MUC1 Glycopeptide and MY.1E12 Antibody by NMR, Molecular Dynamics and Docking Simulations.
35887202	6	20	theme	MUC1	823:826	arg1	O-glycopeptides					828:842	MUC1 O-glycopeptides	823:842	MUC1 O-glycopeptides	823:842	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	7	21	theme	backbone	1063:1070	arg1	chain					1081:1085	side chain	1076:1085	side chain of the O-glycosylated Thr	1076:1111	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	7	21	theme	backbone	1063:1070	arg1	flexibility					1036:1046	the flexibility	1032:1046	the flexibility of the peptide backbone	1032:1070	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	8	22	gly	O-glycopeptide	1168:1181	arg2	O-glycopeptide					1168:1181	modeled MY.1E12 Fv and MUC1 O-glycopeptide	1140:1181	O-glycopeptide	1168:1181	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	5	23	theme	molecular	754:762	arg1	MD					774:775	MD	774:775	MD	774:775	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	5	23	theme	molecular	754:762	arg1	dynamics					764:771	molecular dynamics	754:771	molecular dynamics (MD)	754:776	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	9	24	dep	design	1404:1409	arg1	the					1391:1393	the	1391:1393	the	1391:1393	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	2	25	from	changes	358:364	arg1	structure					376:384	glycan structure	369:384	glycan structure	369:384	This is based on the fact that MUC1 undergoes aberrant glycosylation upon cancer progression, and anti-MUC1 antibodies differentiate changes in glycan structure.
35887202	0	26	theme	O-Glycan-Dependent	0:17	arg1	Interaction					19:29	O-Glycan-Dependent Interaction	0:29	O-Glycan-Dependent Interaction between MUC1 Glycopeptide and MY.1E12 Antibody by NMR, Molecular Dynamics and Docking Simulations.	0:128	O-Glycan-Dependent Interaction between MUC1 Glycopeptide and MY.1E12 Antibody by NMR, Molecular Dynamics and Docking Simulations.
35887202	3	27	theme	specific	538:545	arg1	Thr					547:549	a specific Thr	536:549	a specific Thr	536:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	0	28	theme	MY.1E12	61:67	arg1	Antibody					69:76	MY.1E12 Antibody	61:76	MY.1E12 Antibody	61:76	O-Glycan-Dependent Interaction between MUC1 Glycopeptide and MY.1E12 Antibody by NMR, Molecular Dynamics and Docking Simulations.
35887202	3	29	theme	distinct	436:443	arg1	specificity					445:455	a distinct specificity	434:455	a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	434:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	0	30	theme	MUC1	39:42	arg1	Glycopeptide					44:55	MUC1 Glycopeptide	39:55	MUC1 Glycopeptide	39:55	O-Glycan-Dependent Interaction between MUC1 Glycopeptide and MY.1E12 Antibody by NMR, Molecular Dynamics and Docking Simulations.
35887202	6	31	link	O-linked	892:899	arg1	glycan					901:906	the O-linked glycan	888:906	the O-linked glycan	888:906	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	8	32	theme	portion	1258:1264	arg1	recognition					1226:1236	the recognition	1222:1236	the recognition of the MUC1 peptide portion	1222:1264	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	2	33	theme	cancer	299:304	arg1	progression					306:316	cancer progression	299:316	cancer progression	299:316	This is based on the fact that MUC1 undergoes aberrant glycosylation upon cancer progression, and anti-MUC1 antibodies differentiate changes in glycan structure.
35887202	1	34	theme	cancer	193:198	arg1	diagnosis					200:208	breast cancer diagnosis	186:208	breast cancer diagnosis	186:208	Anti-mucin1 (MUC1) antibodies have been widely used for breast cancer diagnosis and treatment.
35887202	5	35	theme	study	660:664	arg1	aim					648:650	The aim	644:650	The aim of this study	644:664	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	5	36	theme	MUC1	726:729	arg1	O-glycopeptide					731:744	MUC1 O-glycopeptide	726:744	MUC1 O-glycopeptide	726:744	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	3	37	theme	NeuAcα	505:510	arg1	GalNAc					525:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	37	theme	NeuAcα	505:510	arg1	O-glycan					495:502	an immature O-glycan	483:502	an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	483:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	6	38	theme	NMR	803:805	arg1	titration					807:815	NMR titration	803:815	NMR titration using MUC1 O-glycopeptides	803:842	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	1	39	theme	breast	186:191	arg1	diagnosis					200:208	breast cancer diagnosis	186:208	breast cancer diagnosis	186:208	Anti-mucin1 (MUC1) antibodies have been widely used for breast cancer diagnosis and treatment.
35887202	6	40	theme	O-linked	892:899	arg1	glycan					901:906	the O-linked glycan	888:906	the O-linked glycan	888:906	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	8	41	theme	MUC1	1163:1166	arg1	O-glycopeptide					1168:1181	modeled MY.1E12 Fv and MUC1 O-glycopeptide	1140:1181	O-glycopeptide	1168:1181	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	7	42	theme	MUC1	961:964	arg1	glycopeptide					966:977	MUC1 glycopeptide	961:977	MUC1 glycopeptide	961:977	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	5	43	theme	docking	782:788	arg1	simulations					790:800	docking simulations	782:800	docking simulations	782:800	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	3	44	theme	promising	400:408	arg1	antibody					420:427	a promising anti-MUC1 antibody	398:427	a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	398:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	44	theme	promising	400:408	arg1	MY.1E12					387:393	MY.1E12	387:393	MY.1E12	387:393	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	7	45	gly	glycopeptide	966:977	arg2	glycopeptide					966:977	MUC1 glycopeptide	961:977	MUC1 glycopeptide	961:977	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	6	46	located	located	873:879	arg2	located					873:879	located	873:879	located	873:879	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	6	46	located	located	873:879	arg2	epitope					862:868	the epitope	858:868	the epitope	858:868	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	6	46	located	located	873:879	arg1	glycan					901:906	the O-linked glycan	888:906	the O-linked glycan	888:906	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	7	47	theme	glycopeptide	966:977	arg1	simulations					946:956	MD simulations	943:956	MD simulations of MUC1 glycopeptide	943:977	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	8	48	theme	peptide	1250:1256	arg1	portion					1258:1264	the MUC1 peptide portion	1241:1264	the MUC1 peptide portion	1241:1264	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	3	49	theme	anti-MUC1	410:418	arg1	antibody					420:427	a promising anti-MUC1 antibody	398:427	a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	398:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	49	theme	anti-MUC1	410:418	arg1	MY.1E12					387:393	MY.1E12	387:393	MY.1E12	387:393	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	9	50	theme	recognition	1327:1337	arg1	template					1378:1385	a template	1376:1385	a template for the rational design and development of anti-glycopeptide antibodies	1376:1457	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	50	theme	recognition	1327:1337	arg1	mode					1339:1342	The VH/VL-shared recognition mode	1310:1342	The VH/VL-shared recognition mode of this antibody	1310:1359	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	6	51	gly	O-glycosylation	921:935	arg2	site					937:940	the O-glycosylation site	917:940	the O-glycosylation site	917:940	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	1	52	theme	Anti-mucin1	130:140	arg1	antibodies					149:158	Anti-mucin1 (MUC1) antibodies	130:158	Anti-mucin1 (MUC1) antibodies	130:158	Anti-mucin1 (MUC1) antibodies have been widely used for breast cancer diagnosis and treatment.
35887202	6	53	gly	O-glycopeptides	828:842	arg2	O-glycopeptides					828:842	MUC1 O-glycopeptides	823:842	MUC1 O-glycopeptides	823:842	NMR titration using MUC1 O-glycopeptides suggests that the epitope is located within the O-linked glycan and near the O-glycosylation site.
35887202	7	54	theme	O-glycosylated	1094:1107	arg1	Thr					1109:1111	the O-glycosylated Thr	1090:1111	the O-glycosylated Thr	1090:1111	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	5	55	gly	O-glycopeptide	731:744	arg2	O-glycopeptide					731:744	MUC1 O-glycopeptide	726:744	MUC1 O-glycopeptide	726:744	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	3	56	theme	immature	486:493	arg1	GalNAc					525:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	56	theme	immature	486:493	arg1	O-glycan					495:502	an immature O-glycan	483:502	an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	483:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	4	57	theme	structural	565:574	arg1	basis					576:580	the structural basis	561:580	the structural basis for the interaction between MY.1E12 and MUC1	561:625	However, the structural basis for the interaction between MY.1E12 and MUC1 remains unclear.
35887202	8	58	theme	MY.1E12	1148:1154	arg1	Fv					1156:1157	modeled MY.1E12 Fv and MUC1 O-glycopeptide	1140:1181	Fv	1156:1157	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
35887202	2	59	theme	glycan	369:374	arg1	structure					376:384	glycan structure	369:384	glycan structure	369:384	This is based on the fact that MUC1 undergoes aberrant glycosylation upon cancer progression, and anti-MUC1 antibodies differentiate changes in glycan structure.
35887202	2	60	theme	anti-MUC1	323:331	arg1	antibodies					333:342	anti-MUC1 antibodies	323:342	anti-MUC1 antibodies	323:342	This is based on the fact that MUC1 undergoes aberrant glycosylation upon cancer progression, and anti-MUC1 antibodies differentiate changes in glycan structure.
35887202	5	61	theme	interaction	694:704	arg1	mode					686:689	the mode	682:689	the mode of interaction between MY.1E12 and MUC1 O-glycopeptide	682:744	The aim of this study is to elucidate the mode of interaction between MY.1E12 and MUC1 O-glycopeptide by NMR, molecular dynamics (MD) and docking simulations.
35887202	1	62	used	used	177:180	arg2	antibodies					149:158	Anti-mucin1 (MUC1) antibodies	130:158	Anti-mucin1 (MUC1) antibodies	130:158	Anti-mucin1 (MUC1) antibodies have been widely used for breast cancer diagnosis and treatment.
35887202	7	63	theme	MD	943:944	arg1	simulations					946:956	MD simulations	943:956	MD simulations of MUC1 glycopeptide	943:977	MD simulations of MUC1 glycopeptide showed that the O-glycosylation significantly limits the flexibility of the peptide backbone and side chain of the O-glycosylated Thr.
35887202	9	64	theme	antibodies	1448:1457	arg1	development					1415:1425	development	1415:1425	development	1415:1425	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	64	theme	antibodies	1448:1457	arg1	design					1404:1409	design	1404:1409	design	1404:1409	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	65	theme	antibody	1352:1359	arg1	template					1378:1385	a template	1376:1385	a template for the rational design and development of anti-glycopeptide antibodies	1376:1457	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	9	65	theme	antibody	1352:1359	arg1	mode					1339:1342	The VH/VL-shared recognition mode	1310:1342	The VH/VL-shared recognition mode of this antibody	1310:1359	The VH/VL-shared recognition mode of this antibody may be used as a template for the rational design and development of anti-glycopeptide antibodies.
35887202	3	66	theme	Galβ	516:519	arg1	GalNAc					525:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	NeuAcα(2-3)Galβ(1-3)GalNAc	505:530	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	3	66	theme	Galβ	516:519	arg1	O-glycan					495:502	an immature O-glycan	483:502	an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr	483:549	MY.1E12 is a promising anti-MUC1 antibody with a distinct specificity toward MUC1 modified with an immature O-glycan (NeuAcα(2-3)Galβ(1-3)GalNAc) on a specific Thr.
35887202	8	67	theme	Docking	1114:1120	arg1	simulations					1122:1132	Docking simulations	1114:1132	Docking simulations	1114:1132	Docking simulations using modeled MY.1E12 Fv and MUC1 O-glycopeptide, suggest that VH mainly contributes to the recognition of the MUC1 peptide portion while VL mainly binds to the O-glycan part.
36512245	6	0	theme	glycoside	950:958	arg1	hydrolases					960:969	glycoside hydrolases	950:969	glycoside hydrolases	950:969	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	1	1	theme	sites	131:135	arg1	one					114:116	one	114:116	one	114:116	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	1	theme	sites	131:135	arg1	apparatus					101:109	The Golgi apparatus	91:109	The Golgi apparatus	91:109	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	1	theme	sites	131:135	arg1	glycosylation					158:170	lipid glycosylation	152:170	lipid glycosylation	152:170	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	1	theme	sites	131:135	arg1	sites					131:135	the major sites	121:135	the major sites of protein and lipid glycosylation and processing	121:185	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	1	theme	sites	131:135	arg1	protein					140:146	protein	140:146	protein	140:146	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	3	2	located	localized	347:355	arg2	glycosyltransferases					297:316	Various glycosyltransferases	289:316	Various glycosyltransferases	289:316	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	3	2	located	localized	347:355	arg1	cisterna					365:372	each cisterna	360:372	each cisterna	360:372	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	3	2	located	localized	347:355	arg2	hydrolases					332:341	glycoside hydrolases	322:341	glycoside hydrolases	322:341	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	3	2	located	localized	347:355	arg1	apparatus					387:395	the Golgi apparatus	377:395	the Golgi apparatus	377:395	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	5	3	theme	magnetic	742:749	arg1	resonance					751:759	nuclear magnetic resonance	734:759	nuclear magnetic resonance spectroscopy	734:772	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	1	4	gly	glycosylation	158:170	arg2	protein					140:146	protein	140:146	protein	140:146	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	4	gly	glycosylation	158:170	arg2	sites					131:135	the major sites	121:135	the major sites of protein and lipid glycosylation and processing	121:185	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	4	gly	glycosylation	158:170	arg2	glycosylation					158:170	lipid glycosylation	152:170	lipid glycosylation	152:170	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	5	5	theme	resonance	751:759	arg1	spectroscopy					761:772	nuclear magnetic resonance spectroscopy	734:772	nuclear magnetic resonance spectroscopy	734:772	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	5	6	theme	mass	671:674	arg1	spectrometry					676:687	mass spectrometry	671:687	mass spectrometry	671:687	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	5	7	theme	glycan	600:605	arg1	structure					607:615	glycan structure	600:615	glycan structure	600:615	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	6	8	theme	genes	911:915	arg1	disruption					897:906	disruption	897:906	disruption of genes encoding glycosyltransferases or glycoside hydrolases	897:969	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	8	theme	genes	911:915	arg1	analysis					990:997	glycan structural analysis	972:997	glycan structural analysis using lectins and mass spectrometry	972:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	8	theme	genes	911:915	arg1	visualization					1040:1052	visualization	1040:1052	visualization of glycan metabolic pathways in silico	1040:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	5	9	theme	structure	607:615	arg1	analysis					588:595	the analysis	584:595	the analysis of glycan structure	584:615	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	3	10	theme	large	414:418	arg1	variety					420:426	a large variety	412:426	a large variety of N-glycan structures	412:449	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	3	10	theme	large	414:418	arg1	structures					440:449	N-glycan structures	431:449	N-glycan structures	431:449	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	1	11	theme	protein	140:146	arg1	protein					140:146	protein	140:146	protein	140:146	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	11	theme	protein	140:146	arg1	glycosylation					158:170	lipid glycosylation	152:170	lipid glycosylation	152:170	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	11	theme	protein	140:146	arg1	sites					131:135	the major sites	121:135	the major sites of protein and lipid glycosylation and processing	121:185	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	5	12	theme	specialized	626:636	arg1	instruments					638:648	specialized instruments	626:648	specialized instruments	626:648	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	3	13	theme	Golgi	381:385	arg1	apparatus					387:395	the Golgi apparatus	377:395	the Golgi apparatus	377:395	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	3	14	theme	N-glycan	431:438	arg1	structures					440:449	N-glycan structures	431:449	N-glycan structures	431:449	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	0	15	theme	N-Glycan	7:14	arg1	Analysis					24:31	Simple N-Glycan Profile Analysis	0:31	Simple N-Glycan Profile Analysis	0:31	Simple N-Glycan Profile Analysis Using Lectin Staining, Mass Spectrometry, and GlycoMaple.
36512245	4	16	theme	N-glycans	481:489	arg1	pathways					469:476	The biosynthetic pathways	452:476	The biosynthetic pathways of N-glycans	452:489	The biosynthetic pathways of N-glycans are complicated, which hiders the rational design of glycan metabolic pathways.
36512245	6	17	from	visualization	1040:1052	arg1	silico					1086:1091	silico	1086:1091	silico	1086:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	18	theme	mass	1017:1020	arg1	spectrometry					1022:1033	mass spectrometry	1017:1033	mass spectrometry	1017:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	1	19	theme	lipid	152:156	arg1	glycosylation					158:170	lipid glycosylation	152:170	lipid glycosylation	152:170	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	0	20	theme	Simple	0:5	arg1	Analysis					24:31	Simple N-Glycan Profile Analysis	0:31	Simple N-Glycan Profile Analysis	0:31	Simple N-Glycan Profile Analysis Using Lectin Staining, Mass Spectrometry, and GlycoMaple.
36512245	4	21	theme	metabolic	551:559	arg1	pathways					561:568	glycan metabolic pathways	544:568	glycan metabolic pathways	544:568	The biosynthetic pathways of N-glycans are complicated, which hiders the rational design of glycan metabolic pathways.
36512245	1	22	theme	glycosylation	158:170	arg1	protein					140:146	protein	140:146	protein	140:146	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	22	theme	glycosylation	158:170	arg1	glycosylation					158:170	lipid glycosylation	152:170	lipid glycosylation	152:170	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	22	theme	glycosylation	158:170	arg1	sites					131:135	the major sites	121:135	the major sites of protein and lipid glycosylation and processing	121:185	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	4	23	theme	glycan	544:549	arg1	pathways					561:568	glycan metabolic pathways	544:568	glycan metabolic pathways	544:568	The biosynthetic pathways of N-glycans are complicated, which hiders the rational design of glycan metabolic pathways.
36512245	0	24	theme	Profile	16:22	arg1	Analysis					24:31	Simple N-Glycan Profile Analysis	0:31	Simple N-Glycan Profile Analysis	0:31	Simple N-Glycan Profile Analysis Using Lectin Staining, Mass Spectrometry, and GlycoMaple.
36512245	1	25	theme	Golgi	95:99	arg1	one					114:116	one	114:116	one	114:116	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	25	theme	Golgi	95:99	arg1	apparatus					101:109	The Golgi apparatus	91:109	The Golgi apparatus	91:109	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	25	theme	Golgi	95:99	arg1	sites					131:135	the major sites	121:135	the major sites of protein and lipid glycosylation and processing	121:185	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	0	26	theme	Lectin	39:44	arg1	Staining					46:53	Lectin Staining	39:53	Lectin Staining	39:53	Simple N-Glycan Profile Analysis Using Lectin Staining, Mass Spectrometry, and GlycoMaple.
36512245	4	27	theme	pathways	561:568	arg1	design					534:539	the rational design	521:539	the rational design of glycan metabolic pathways	521:568	The biosynthetic pathways of N-glycans are complicated, which hiders the rational design of glycan metabolic pathways.
36512245	3	28	theme	structures	440:449	arg1	variety					420:426	a large variety	412:426	a large variety of N-glycan structures	412:449	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	3	28	theme	structures	440:449	arg1	structures					440:449	N-glycan structures	431:449	N-glycan structures	431:449	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	4	29	theme	rational	525:532	arg1	design					534:539	the rational design	521:539	the rational design of glycan metabolic pathways	521:568	The biosynthetic pathways of N-glycans are complicated, which hiders the rational design of glycan metabolic pathways.
36512245	5	30	theme	nuclear	734:740	arg1	resonance					751:759	nuclear magnetic resonance	734:759	nuclear magnetic resonance spectroscopy	734:772	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	4	31	theme	biosynthetic	456:467	arg1	pathways					469:476	The biosynthetic pathways	452:476	The biosynthetic pathways of N-glycans	452:489	The biosynthetic pathways of N-glycans are complicated, which hiders the rational design of glycan metabolic pathways.
36512245	2	32	theme	critical	218:225	arg1	roles					227:231	critical roles	218:231	critical roles	218:231	Protein N-glycosylation plays critical roles in protein folding, transport, stability, and activity.
36512245	6	33	theme	structural	979:988	arg1	analysis					990:997	glycan structural analysis	972:997	glycan structural analysis using lectins and mass spectrometry	972:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	34	theme	N-glycan	868:875	arg1	analysis					877:884	N-glycan analysis	868:884	N-glycan analysis	868:884	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	35	from	analysis	990:997	arg1	silico					1086:1091	silico	1086:1091	silico	1086:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	36	theme	glycan	972:977	arg1	analysis					990:997	glycan structural analysis	972:997	glycan structural analysis using lectins and mass spectrometry	972:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	3	37	theme	Various	289:295	arg1	glycosyltransferases					297:316	Various glycosyltransferases	289:316	Various glycosyltransferases	289:316	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	2	38	theme	Protein	188:194	arg1	N-glycosylation					196:210	Protein N-glycosylation	188:210	Protein N-glycosylation	188:210	Protein N-glycosylation plays critical roles in protein folding, transport, stability, and activity.
36512245	5	39	theme	high-performance	690:705	arg1	chromatography					714:727	high-performance liquid chromatography	690:727	high-performance liquid chromatography	690:727	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	6	40	theme	pathways	1074:1081	arg1	disruption					897:906	disruption	897:906	disruption of genes encoding glycosyltransferases or glycoside hydrolases	897:969	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	40	theme	pathways	1074:1081	arg1	analysis					990:997	glycan structural analysis	972:997	glycan structural analysis using lectins and mass spectrometry	972:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	40	theme	pathways	1074:1081	arg1	visualization					1040:1052	visualization	1040:1052	visualization of glycan metabolic pathways in silico	1040:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	5	41	theme	liquid	707:712	arg1	chromatography					714:727	high-performance liquid chromatography	690:727	high-performance liquid chromatography	690:727	In addition, the analysis of glycan structure requires specialized instruments for analyses such as mass spectrometry, high-performance liquid chromatography, and nuclear magnetic resonance spectroscopy, which are not familiar to all laboratories.
36512245	6	42	theme	simple	849:854	arg1	methods					856:862	relatively simple methods	838:862	relatively simple methods	838:862	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	42	theme	simple	849:854	arg1	disruption					897:906	disruption	897:906	disruption of genes encoding glycosyltransferases or glycoside hydrolases	897:969	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	42	theme	simple	849:854	arg1	visualization					1040:1052	visualization	1040:1052	visualization of glycan metabolic pathways in silico	1040:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	42	theme	simple	849:854	arg1	analysis					990:997	glycan structural analysis	972:997	glycan structural analysis using lectins and mass spectrometry	972:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	43	theme	metabolic	1064:1072	arg1	pathways					1074:1081	glycan metabolic pathways	1057:1081	glycan metabolic pathways	1057:1081	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	3	44	theme	glycoside	322:330	arg1	hydrolases					332:341	glycoside hydrolases	322:341	glycoside hydrolases	322:341	Various glycosyltransferases and glycoside hydrolases are localized at each cisterna in the Golgi apparatus and synthesize a large variety of N-glycan structures.
36512245	2	45	theme	protein	236:242	arg1	folding					244:250	protein folding	236:250	protein folding	236:250	Protein N-glycosylation plays critical roles in protein folding, transport, stability, and activity.
36512245	6	46	theme	glycan	1057:1062	arg1	pathways					1074:1081	glycan metabolic pathways	1057:1081	glycan metabolic pathways	1057:1081	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	0	47	theme	Mass	56:59	arg1	Spectrometry					61:72	Mass Spectrometry	56:72	Mass Spectrometry	56:72	Simple N-Glycan Profile Analysis Using Lectin Staining, Mass Spectrometry, and GlycoMaple.
36512245	6	48	theme	hydrolases	960:969	arg1	disruption					897:906	disruption	897:906	disruption of genes encoding glycosyltransferases or glycoside hydrolases	897:969	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	48	theme	hydrolases	960:969	arg1	analysis					990:997	glycan structural analysis	972:997	glycan structural analysis using lectins and mass spectrometry	972:1033	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	6	48	theme	hydrolases	960:969	arg1	visualization					1040:1052	visualization	1040:1052	visualization of glycan metabolic pathways in silico	1040:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
36512245	1	49	theme	major	125:129	arg1	protein					140:146	protein	140:146	protein	140:146	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	49	theme	major	125:129	arg1	glycosylation					158:170	lipid glycosylation	152:170	lipid glycosylation	152:170	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	1	49	theme	major	125:129	arg1	sites					131:135	the major sites	121:135	the major sites of protein and lipid glycosylation and processing	121:185	The Golgi apparatus is one of the major sites of protein and lipid glycosylation and processing.
36512245	6	50	from	disruption	897:906	arg1	silico					1086:1091	silico	1086:1091	silico	1086:1091	Here, we introduce relatively simple methods for N-glycan analysis, including disruption of genes encoding glycosyltransferases or glycoside hydrolases, glycan structural analysis using lectins and mass spectrometry, and visualization of glycan metabolic pathways in silico.
35977913	4	0	theme	analogous	568:576	arg1	N-GlcNAc					558:565	N-GlcNAc	558:565	N-GlcNAc	558:565	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	4	1	theme	homogeneous	635:645	arg1	forms					662:666	various homogeneous N-glycosylated forms	627:666	various homogeneous N-glycosylated forms	627:666	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	2	2	from	sources	180:186	arg1	proteins					158:165	N-glycosylated proteins	143:165	N-glycosylated proteins from natural sources	143:186	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	4	3	theme	tree	583:586	arg1	stump					588:592	a tree stump	581:592	a tree stump	581:592	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	4	4	theme	various	627:633	arg1	forms					662:666	various homogeneous N-glycosylated forms	627:666	various homogeneous N-glycosylated forms	627:666	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	3	5	theme	enzymatic	390:398	arg1	approaches					420:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	To address this issue, various synthetic, enzymatic, and chemoenzymatic approaches have been elegantly designed.
35977913	2	6	theme	therapeutic	322:332	arg1	applications					334:345	therapeutic applications	322:345	therapeutic applications	322:345	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	5	7	theme	concept	725:731	arg1	article					733:739	this concept article	720:739	this concept article	720:739	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	2	8	gly	N-glycosylated	143:156	arg1	proteins					158:165	N-glycosylated proteins	143:165	N-glycosylated proteins from natural sources	143:186	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	4	9	theme	N-glycosylated	647:660	arg1	forms					662:666	various homogeneous N-glycosylated forms	627:666	various homogeneous N-glycosylated forms	627:666	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	3	10	theme	synthetic	379:387	arg1	approaches					420:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	To address this issue, various synthetic, enzymatic, and chemoenzymatic approaches have been elegantly designed.
35977913	2	11	theme	N-glycosylated	143:156	arg1	proteins					158:165	N-glycosylated proteins	143:165	N-glycosylated proteins from natural sources	143:186	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	5	12	theme	analogues	827:835	arg1	generation					790:799	the generation	786:799	the generation of N-GlcNAc and its close analogues on proteins and peptides	786:860	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	2	13	theme	basic	303:307	arg1	research					309:316	corresponding basic research	289:316	corresponding basic research	289:316	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	5	14	theme	scientific	921:930	arg1	community					932:940	the scientific community	917:940	the scientific community	917:940	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	5	15	theme	close	821:825	arg1	analogues					827:835	its close analogues	817:835	its close analogues	817:835	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	0	16	theme	N-Glycan	0:7	arg1	Engineering					9:19	N-Glycan Engineering	0:19	N-Glycan Engineering: Constructing the N-GlcNAc Stump.	0:53	N-Glycan Engineering: Constructing the N-GlcNAc Stump.
35977913	4	17	theme	endoglycosidase-catalyzed	475:499	arg1	method					520:525	the endoglycosidase-catalyzed transglycosylation method	471:525	the endoglycosidase-catalyzed transglycosylation method	471:525	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	4	18	gly	N-glycosylated	647:660	arg1	forms					662:666	various homogeneous N-glycosylated forms	627:666	various homogeneous N-glycosylated forms	627:666	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	4	19	from	N-acetylglucosamine	537:555	arg1	proteins					598:605	proteins	598:605	proteins	598:605	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	5	20	theme	current	880:886	arg1	challenges					888:897	the current challenges	876:897	the current challenges	876:897	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	3	21	theme	chemoenzymatic	405:418	arg1	approaches					420:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	To address this issue, various synthetic, enzymatic, and chemoenzymatic approaches have been elegantly designed.
35977913	5	22	from	generation	790:799	arg1	proteins					840:847	proteins	840:847	proteins	840:847	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	5	22	from	generation	790:799	arg1	peptides					853:860	peptides	853:860	peptides	853:860	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	0	23	theme	N-GlcNAc	39:46	arg1	Stump					48:52	the N-GlcNAc Stump	35:52	the N-GlcNAc Stump	35:52	N-Glycan Engineering: Constructing the N-GlcNAc Stump.
35977913	4	24	dep	N-acetylglucosamine	537:555	arg1	N-GlcNAc					558:565	N-GlcNAc	558:565	N-GlcNAc	558:565	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	4	25	theme	efforts	708:714	arg1	focus					690:694	the focus	686:694	the focus of research efforts	686:714	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	2	26	theme	natural	172:178	arg1	sources					180:186	natural sources	172:186	natural sources	172:186	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	4	27	theme	research	699:706	arg1	efforts					708:714	research efforts	699:714	research efforts	699:714	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	2	28	theme	appended	230:237	arg1	oligosaccharides					239:254	the appended oligosaccharides	226:254	the appended oligosaccharides	226:254	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	4	29	theme	single	530:535	arg1	N-acetylglucosamine					537:555	a single N-acetylglucosamine	528:555	a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins	528:605	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	5	30	dep	challenges	888:897	arg1	facing					945:950	facing	945:950	is facing	942:950	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	2	31	theme	corresponding	289:301	arg1	research					309:316	corresponding basic research	289:316	corresponding basic research	289:316	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	1	32	theme	proteins	124:131	arg1	function					112:119	function	112:119	function	112:119	N-Glycosylation is often essential for the structure and function of proteins.
35977913	1	32	theme	proteins	124:131	arg1	structure					98:106	structure	98:106	structure	98:106	N-Glycosylation is often essential for the structure and function of proteins.
35977913	4	33	theme	transglycosylation	501:518	arg1	method					520:525	the endoglycosidase-catalyzed transglycosylation method	471:525	the endoglycosidase-catalyzed transglycosylation method	471:525	Utilizing the endoglycosidase-catalyzed transglycosylation method, a single N-acetylglucosamine (N-GlcNAc, analogous to a tree stump) on proteins can be converted to various homogeneous N-glycosylated forms, thereby becoming the focus of research efforts.
35977913	5	34	theme	N-GlcNAc	804:811	arg1	generation					790:799	the generation	786:799	the generation of N-GlcNAc and its close analogues on proteins and peptides	786:860	In this concept article, we briefly introduce the methods that allow the generation of N-GlcNAc and its close analogues on proteins and peptides and highlight the current challenges and opportunities the scientific community is facing.
35977913	2	35	theme	considerable	196:207	arg1	heterogeneity					209:221	considerable heterogeneity	196:221	considerable heterogeneity	196:221	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35977913	0	36	dep	Engineering	9:19	arg1	Constructing					22:33	Constructing	22:33	Constructing the N-GlcNAc Stump	22:52	N-Glycan Engineering: Constructing the N-GlcNAc Stump.
35977913	1	37	dep	structure	98:106	arg1	the					94:96	the	94:96	the	94:96	N-Glycosylation is often essential for the structure and function of proteins.
35977913	3	38	theme	various	371:377	arg1	approaches					420:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	various synthetic, enzymatic, and chemoenzymatic approaches	371:429	To address this issue, various synthetic, enzymatic, and chemoenzymatic approaches have been elegantly designed.
35977913	2	39	theme	daunting	266:273	arg1	challenges					275:284	daunting challenges	266:284	daunting challenges	266:284	However, N-glycosylated proteins from natural sources exhibit considerable heterogeneity in the appended oligosaccharides, bringing daunting challenges to corresponding basic research and therapeutic applications.
35304921	12	0	theme	β1	1728:1729	arg1	activity					1740:1747	α5 β1 integrin activity	1725:1747	α5 β1 integrin activity	1725:1747	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	4	1	theme	tetraantennary	513:526	arg1	N-glycans					528:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	11	2	theme	striking	1295:1302	arg1	example					1304:1310	A striking example	1293:1310	A striking example	1293:1310	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	1	3	gly	glycosylated	146:157	arg1	INFORMATION					77:87	BACKGROUND INFORMATION	66:87	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin	66:141	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	6	4	theme	complex	773:779	arg1	N-glycans					781:789	Almost all complex N-glycans	762:789	Almost all complex N-glycans	762:789	Almost all complex N-glycans had fully galactosylated and sialylated antennae.
35304921	2	5	theme	glycan	322:327	arg1	map					329:331	the first comprehensive site-specific glycan map	284:331	the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver	284:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	7	6	theme	Moderate	841:848	arg1	levels					850:855	Moderate levels	841:855	Moderate levels of core fucosylation	841:876	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	15	7	theme	"	2199:2199	arg1	glycoproteins					2201:2213	"native" glycoproteins	2192:2213	"native" glycoproteins	2192:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	12	8	theme	mechanisms	1689:1698	arg1	exploration					1663:1673	the exploration	1659:1673	the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking	1659:1773	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	10	9	theme	α5	1277:1278	arg1	integrin					1283:1290	α5 β1 integrin	1277:1290	α5 β1 integrin	1277:1290	We have used this model for the discussion of how glycosylation might be used in the functional cycle of α5 β1 integrin.
35304921	11	10	theme	glycan-binding	1340:1353	arg1	galectins					1355:1363	glycan-binding galectins	1340:1363	glycan-binding galectins	1340:1363	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	12	11	dep	CONCLUSION	1558:1567	arg1	expect					1572:1577	expect	1572:1577	expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking	1572:1773	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	3	12	from	variations	459:468	arg1	composition					480:490	glycan composition	473:490	glycan composition	473:490	This analysis revealed striking site selective variations in glycan composition.
35304921	14	13	gly	glycosylation	1973:1985	arg2	glycosylation					1973:1985	glycosylation	1973:1985	glycosylation	1973:1985	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	14	13	gly	glycosylation	1973:1985	arg2	sites					1964:1968	the specific sites	1951:1968	notably the specific sites of glycosylation	1943:1985	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	14	13	gly	glycosylation	1973:1985	arg2	glycosylation					1928:1940	its glycosylation	1924:1940	its glycosylation	1924:1940	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	9	14	theme	β1	1120:1121	arg1	integrin					1123:1130	α5 β1 integrin	1117:1130	α5 β1 integrin that was obtained by homology modeling	1117:1169	The extensive glycan information that results from our study was projected onto a map of α5 β1 integrin that was obtained by homology modeling.
35304921	8	15	theme	O-linked	964:971	arg1	HexNAc					973:978	An O-linked HexNAc	961:978	An O-linked HexNAc	961:978	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	4	16	gly	N-glycosylation	596:610	arg2	sites					612:616	most potential N-glycosylation sites	581:616	most potential N-glycosylation sites	581:616	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	9	17	theme	homology	1153:1160	arg1	modeling					1162:1169	homology modeling	1153:1169	homology modeling	1153:1169	The extensive glycan information that results from our study was projected onto a map of α5 β1 integrin that was obtained by homology modeling.
35304921	11	18	theme	lattices	1474:1481	arg1	formation					1461:1469	the formation	1457:1469	the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis	1457:1555	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	4	19	theme	most	581:584	arg1	sites					612:616	most potential N-glycosylation sites	581:616	most potential N-glycosylation sites	581:616	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	3	20	theme	selective	449:457	arg1	variations					459:468	striking site selective variations	435:468	striking site selective variations in glycan composition	435:490	This analysis revealed striking site selective variations in glycan composition.
35304921	15	21	theme	natural	2077:2083	arg1	source					2085:2090	a natural source	2075:2090	a natural source	2075:2090	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	4	22	theme	N-glycosylation	596:610	arg1	sites					612:616	most potential N-glycosylation sites	581:616	most potential N-glycosylation sites	581:616	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	7	23	located	observed	934:941	arg2	levels					887:892	high levels	882:892	high levels of O-acetylation of NeuAc residues	882:927	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	7	23	located	observed	934:941	arg1	sites					954:958	certain sites	946:958	certain sites	946:958	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	7	23	located	observed	934:941	arg2	levels					850:855	Moderate levels	841:855	Moderate levels of core fucosylation	841:876	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	5	24	theme	high	674:677	arg1	mannose					679:685	high mannose or hybrid glycans	674:703	mannose	679:685	A few of these sites were nonglycosylated or contained high mannose or hybrid glycans, indicating that early N-glycan processing was hindered.
35304921	1	25	theme	various	186:192	arg1	activities					194:203	its various activities	182:203	its various activities in ways that mostly remain to be determined	182:247	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	5	26	theme	sites	634:638	arg1	few					621:623	few	621:623	few	621:623	A few of these sites were nonglycosylated or contained high mannose or hybrid glycans, indicating that early N-glycan processing was hindered.
35304921	1	27	theme	surface	110:116	arg1	proteins					118:125	most other cell surface proteins	94:125	most other cell surface proteins	94:125	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	15	28	from	lot	2134:2136	arg1	field					2159:2163	the field	2155:2163	the field about the glycosylation of "native" glycoproteins	2155:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	9	29	theme	integrin	1123:1130	arg1	map					1110:1112	a map	1108:1112	a map of α5 β1 integrin that was obtained by homology modeling	1108:1169	The extensive glycan information that results from our study was projected onto a map of α5 β1 integrin that was obtained by homology modeling.
35304921	14	30	theme	glycosylation	1928:1940	arg1	knowledge					1911:1919	detailed knowledge	1902:1919	detailed knowledge of its glycosylation, notably the specific sites of glycosylation,	1902:1986	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	13	31	theme	SIGNIFICANCE	1776:1787	arg1	Glycosylation					1789:1801	SIGNIFICANCE Glycosylation	1776:1801	SIGNIFICANCE Glycosylation of α5 β1 integrin	1776:1819	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	11	32	theme	glycoproteins	1415:1427	arg1	homeostasis					1400:1410	the molecular homeostasis	1386:1410	the molecular homeostasis of glycoproteins	1386:1427	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	0	33	theme	rat	55:57	arg1	liver					59:63	rat liver	55:63	rat liver	55:63	Site-specific N-glycan profiles of α5 β1 integrin from rat liver.
35304921	7	34	theme	certain	946:952	arg1	sites					954:958	certain sites	946:958	certain sites	946:958	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	1	35	theme	β1	131:132	arg1	integrin					134:141	β1 integrin	131:141	β1 integrin	131:141	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	12	36	theme	study	1624:1628	arg1	data					1604:1607	the glycoproteomics data	1584:1607	the glycoproteomics data of the current study	1584:1628	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	12	36	theme	study	1624:1628	arg1	resource					1646:1653	a resource	1644:1653	a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking	1644:1773	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	10	37	used	used	1180:1183	arg2	We					1172:1173	We	1172:1173	We	1172:1173	We have used this model for the discussion of how glycosylation might be used in the functional cycle of α5 β1 integrin.
35304921	5	38	theme	early	722:726	arg1	processing					737:746	early N-glycan processing	722:746	early N-glycan processing	722:746	A few of these sites were nonglycosylated or contained high mannose or hybrid glycans, indicating that early N-glycan processing was hindered.
35304921	13	39	theme	multiple	1844:1851	arg1	aspects					1853:1859	multiple aspects	1844:1859	multiple aspects of integrin function and structure	1844:1894	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	8	40	theme	EGF-like	996:1003	arg1	domain					1005:1010	an EGF-like domain	993:1010	an EGF-like domain of β1 integrin	993:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	8	40	theme	EGF-like	996:1003	arg1	integrin					1018:1025	β1 integrin	1015:1025	β1 integrin	1015:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	7	41	theme	residues	920:927	arg1	O-acetylation					897:909	O-acetylation	897:909	O-acetylation of NeuAc residues	897:927	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	11	42	from	surface	1441:1447	arg1	involvement					1325:1335	the involvement	1321:1335	the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface	1321:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	11	42	from	surface	1441:1447	arg1	regulation					1372:1381	the regulation	1368:1381	the regulation of the molecular homeostasis of glycoproteins at the cell surface	1368:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	9	43	theme	extensive	1032:1040	arg1	information					1049:1059	The extensive glycan information	1028:1059	The extensive glycan information that results from our study	1028:1087	The extensive glycan information that results from our study was projected onto a map of α5 β1 integrin that was obtained by homology modeling.
35304921	13	44	theme	integrin	1812:1819	arg1	Glycosylation					1789:1801	SIGNIFICANCE Glycosylation	1776:1801	SIGNIFICANCE Glycosylation of α5 β1 integrin	1776:1819	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	1	45	theme	BACKGROUND	66:75	arg1	INFORMATION					77:87	BACKGROUND INFORMATION	66:87	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin	66:141	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	2	46	theme	integrin	342:349	arg1	map					329:331	the first comprehensive site-specific glycan map	284:331	the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver	284:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	0	47	theme	Site-specific	0:12	arg1	profiles					23:30	Site-specific N-glycan profiles	0:30	Site-specific N-glycan profiles of α5	0:36	Site-specific N-glycan profiles of α5 β1 integrin from rat liver.
35304921	8	48	theme	integrin	1018:1025	arg1	domain					1005:1010	an EGF-like domain	993:1010	an EGF-like domain of β1 integrin	993:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	8	48	theme	integrin	1018:1025	arg1	integrin					1018:1025	β1 integrin	1015:1025	β1 integrin	1015:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	4	49	theme	bi	501:502	arg1	N-glycans					528:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	15	50	gly	glycoproteins	2201:2213	arg1	glycoproteins					2201:2213	"native" glycoproteins	2192:2213	"native" glycoproteins	2192:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	11	51	theme	homeostasis	1400:1410	arg1	regulation					1372:1381	the regulation	1368:1381	the regulation of the molecular homeostasis of glycoproteins at the cell surface	1368:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	2	52	theme	natural	376:382	arg1	source					384:389	a natural source	374:389	a natural source	374:389	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	2	52	theme	natural	376:382	arg1	liver					405:409	rat liver	401:409	rat liver	401:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	1	53	theme	other	99:103	arg1	proteins					118:125	most other cell surface proteins	94:125	most other cell surface proteins	94:125	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	4	54	theme	tri	505:507	arg1	N-glycans					528:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	13	55	theme	function	1873:1880	arg1	aspects					1853:1859	multiple aspects	1844:1859	multiple aspects of integrin function and structure	1844:1894	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	0	56	theme	α5	35:36	arg1	profiles					23:30	Site-specific N-glycan profiles	0:30	Site-specific N-glycan profiles of α5	0:36	Site-specific N-glycan profiles of α5 β1 integrin from rat liver.
35304921	2	57	theme	rat	401:403	arg1	source					384:389	a natural source	374:389	a natural source	374:389	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	2	57	theme	rat	401:403	arg1	liver					405:409	rat liver	401:409	rat liver	401:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	11	58	theme	GL-Lect	1537:1543	arg1	hypothesis					1546:1555	the glycolipid-lectin (GL-Lect) hypothesis	1514:1555	the glycolipid-lectin (GL-Lect) hypothesis	1514:1555	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	2	59	theme	site-specific	308:320	arg1	map					329:331	the first comprehensive site-specific glycan map	284:331	the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver	284:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	8	60	link	O-linked	964:971	arg1	HexNAc					973:978	An O-linked HexNAc	961:978	An O-linked HexNAc	961:978	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	11	61	theme	glycolipid-lectin	1518:1534	arg1	hypothesis					1546:1555	the glycolipid-lectin (GL-Lect) hypothesis	1514:1555	the glycolipid-lectin (GL-Lect) hypothesis	1514:1555	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	2	62	theme	first	288:292	arg1	map					329:331	the first comprehensive site-specific glycan map	284:331	the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver	284:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	13	63	gly	Glycosylation	1789:1801	arg1	integrin					1812:1819	α5 β1 integrin	1806:1819	α5 β1 integrin	1806:1819	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	13	63	gly	Glycosylation	1789:1801	arg1	aspects					1853:1859	multiple aspects	1844:1859	multiple aspects of integrin function and structure	1844:1894	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	12	64	theme	α5	1725:1726	arg1	activity					1740:1747	α5 β1 integrin activity	1725:1747	α5 β1 integrin activity	1725:1747	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	10	65	theme	integrin	1283:1290	arg1	cycle					1268:1272	the functional cycle	1253:1272	the functional cycle of α5 β1 integrin	1253:1290	We have used this model for the discussion of how glycosylation might be used in the functional cycle of α5 β1 integrin.
35304921	2	66	theme	α5	336:337	arg1	integrin					342:349	α5 β1 integrin	336:349	α5 β1 integrin that was purified from a natural source, that is, rat liver	336:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	15	67	theme	glycoproteins	2201:2213	arg1	glycosylation					2175:2187	the glycosylation	2171:2187	the glycosylation of "native" glycoproteins	2171:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	1	68	from	activities	194:203	arg1	ways					208:211	ways	208:211	ways that mostly remain to be determined	208:247	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	15	69	theme	β1	2020:2021	arg1	preparation					2032:2042	the α5 β1 integrin preparation	2013:2042	the α5 β1 integrin preparation that was analyzed here	2013:2065	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	12	70	theme	integrin	1731:1738	arg1	activity					1740:1747	α5 β1 integrin activity	1725:1747	α5 β1 integrin activity	1725:1747	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	4	71	theme	various	558:564	arg1	proportions					566:576	various proportions	558:576	various proportions	558:576	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	9	72	theme	α5	1117:1118	arg1	integrin					1123:1130	α5 β1 integrin	1117:1130	α5 β1 integrin that was obtained by homology modeling	1117:1169	The extensive glycan information that results from our study was projected onto a map of α5 β1 integrin that was obtained by homology modeling.
35304921	3	73	theme	site	444:447	arg1	variations					459:468	striking site selective variations	435:468	striking site selective variations in glycan composition	435:490	This analysis revealed striking site selective variations in glycan composition.
35304921	7	74	theme	core	860:863	arg1	fucosylation					865:876	core fucosylation	860:876	core fucosylation	860:876	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	15	75	theme	native	2193:2198	arg1	glycoproteins					2201:2213	"native" glycoproteins	2192:2213	"native" glycoproteins	2192:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	6	76	theme	all	769:771	arg1	N-glycans					781:789	Almost all complex N-glycans	762:789	Almost all complex N-glycans	762:789	Almost all complex N-glycans had fully galactosylated and sialylated antennae.
35304921	8	77	located	found	984:988	arg2	HexNAc					973:978	An O-linked HexNAc	961:978	An O-linked HexNAc	961:978	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	8	77	located	found	984:988	arg1	domain					1005:1010	an EGF-like domain	993:1010	an EGF-like domain of β1 integrin	993:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	8	77	located	found	984:988	arg1	integrin					1018:1025	β1 integrin	1015:1025	β1 integrin	1015:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	3	78	theme	glycan	473:478	arg1	composition					480:490	glycan composition	473:490	glycan composition	473:490	This analysis revealed striking site selective variations in glycan composition.
35304921	13	79	theme	structure	1886:1894	arg1	aspects					1853:1859	multiple aspects	1844:1859	multiple aspects of integrin function and structure	1844:1894	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	4	80	from	sites	612:616	arg1	predominant					543:553	predominant	543:553	predominant	543:553	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	12	81	theme	structural	1678:1687	arg1	mechanisms					1689:1698	structural mechanisms	1678:1698	structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking	1678:1773	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	11	82	theme	endocytic	1486:1494	arg1	pits					1496:1499	endocytic pits	1486:1499	endocytic pits	1486:1499	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	11	83	theme	pits	1496:1499	arg1	formation					1461:1469	the formation	1457:1469	the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis	1457:1555	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	3	84	theme	striking	435:442	arg1	variations					459:468	striking site selective variations	435:468	striking site selective variations in glycan composition	435:490	This analysis revealed striking site selective variations in glycan composition.
35304921	11	85	from	involvement	1325:1335	arg1	surface					1441:1447	the cell surface	1432:1447	the cell surface	1432:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	11	85	from	involvement	1325:1335	arg1	regulation					1372:1381	the regulation	1368:1381	the regulation of the molecular homeostasis of glycoproteins at the cell surface	1368:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	4	86	attach	predominant	543:553	arg1	proportions					566:576	various proportions	558:576	various proportions	558:576	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	4	86	attach	predominant	543:553	arg1	sites					612:616	most potential N-glycosylation sites	581:616	most potential N-glycosylation sites	581:616	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	4	86	attach	predominant	543:553	arg2	N-glycans					528:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans	493:536	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	0	87	from	liver	59:63	arg1	integrin					41:48	integrin	41:48	integrin from rat liver	41:63	Site-specific N-glycan profiles of α5 β1 integrin from rat liver.
35304921	4	88	theme	potential	586:594	arg1	sites					612:616	most potential N-glycosylation sites	581:616	most potential N-glycosylation sites	581:616	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	1	89	theme	cell	105:108	arg1	proteins					118:125	most other cell surface proteins	94:125	most other cell surface proteins	94:125	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	10	90	gly	glycosylation	1222:1234	arg1	cycle					1268:1272	the functional cycle	1253:1272	the functional cycle of α5 β1 integrin	1253:1290	We have used this model for the discussion of how glycosylation might be used in the functional cycle of α5 β1 integrin.
35304921	5	91	gly	nonglycosylated	645:659	arg1	few					621:623	few	621:623	few	621:623	A few of these sites were nonglycosylated or contained high mannose or hybrid glycans, indicating that early N-glycan processing was hindered.
35304921	11	92	gly	glycoproteins	1415:1427	arg1	glycoproteins					1415:1427	glycoproteins	1415:1427	glycoproteins	1415:1427	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	15	93	gly	glycosylation	2175:2187	arg1	glycoproteins					2201:2213	"native" glycoproteins	2192:2213	"native" glycoproteins	2192:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	13	94	theme	integrin	1864:1871	arg1	function					1873:1880	integrin function	1864:1880	integrin function	1864:1880	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	4	95	from	proportions	566:576	arg1	predominant					543:553	predominant	543:553	predominant	543:553	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	12	96	theme	current	1616:1622	arg1	study					1624:1628	the current study	1612:1628	the current study	1612:1628	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	2	97	dep	RESULTS	250:256	arg1	established					272:282	established	272:282	have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver	267:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	11	98	theme	cell	1436:1439	arg1	surface					1441:1447	the cell surface	1432:1447	the cell surface	1432:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	10	99	used	used	1245:1248	arg2	glycosylation					1222:1234	glycosylation	1222:1234	glycosylation	1222:1234	We have used this model for the discussion of how glycosylation might be used in the functional cycle of α5 β1 integrin.
35304921	13	100	theme	α5	1806:1807	arg1	integrin					1812:1819	α5 β1 integrin	1806:1819	α5 β1 integrin	1806:1819	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	5	101	theme	hybrid	690:695	arg1	glycans					697:703	high mannose or hybrid glycans	674:703	glycans	697:703	A few of these sites were nonglycosylated or contained high mannose or hybrid glycans, indicating that early N-glycan processing was hindered.
35304921	8	102	theme	β1	1015:1016	arg1	integrin					1018:1025	β1 integrin	1015:1025	β1 integrin	1015:1025	An O-linked HexNAc was found in an EGF-like domain of β1 integrin.
35304921	14	103	theme	specific	1955:1962	arg1	glycosylation					1973:1985	glycosylation	1973:1985	glycosylation	1973:1985	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	14	103	theme	specific	1955:1962	arg1	sites					1964:1968	the specific sites	1951:1968	notably the specific sites of glycosylation	1943:1985	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	14	103	theme	specific	1955:1962	arg1	glycosylation					1928:1940	its glycosylation	1924:1940	its glycosylation	1924:1940	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	12	104	theme	glycoproteomics	1588:1602	arg1	data					1604:1607	the glycoproteomics data	1584:1607	the glycoproteomics data of the current study	1584:1628	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	12	104	theme	glycoproteomics	1588:1602	arg1	resource					1646:1653	a resource	1644:1653	a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking	1644:1773	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	9	105	theme	glycan	1042:1047	arg1	information					1049:1059	The extensive glycan information	1028:1059	The extensive glycan information that results from our study	1028:1087	The extensive glycan information that results from our study was projected onto a map of α5 β1 integrin that was obtained by homology modeling.
35304921	0	106	theme	N-glycan	14:21	arg1	profiles					23:30	Site-specific N-glycan profiles	0:30	Site-specific N-glycan profiles of α5	0:36	Site-specific N-glycan profiles of α5 β1 integrin from rat liver.
35304921	7	107	theme	NeuAc	914:918	arg1	residues					920:927	NeuAc residues	914:927	NeuAc residues	914:927	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	11	108	theme	molecular	1390:1398	arg1	homeostasis					1400:1410	the molecular homeostasis	1386:1410	the molecular homeostasis of glycoproteins	1386:1427	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	2	109	theme	β1	339:340	arg1	integrin					342:349	α5 β1 integrin	336:349	α5 β1 integrin that was purified from a natural source, that is, rat liver	336:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	7	110	theme	O-acetylation	897:909	arg1	levels					850:855	Moderate levels	841:855	Moderate levels of core fucosylation	841:876	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	7	110	theme	O-acetylation	897:909	arg1	levels					887:892	high levels	882:892	high levels of O-acetylation of NeuAc residues	882:927	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	1	111	theme	most	94:97	arg1	proteins					118:125	most other cell surface proteins	94:125	most other cell surface proteins	94:125	BACKGROUND INFORMATION Like most other cell surface proteins, α5 β1 integrin is glycosylated, which is required for its various activities in ways that mostly remain to be determined.
35304921	5	112	theme	N-glycan	728:735	arg1	processing					737:746	early N-glycan processing	722:746	early N-glycan processing	722:746	A few of these sites were nonglycosylated or contained high mannose or hybrid glycans, indicating that early N-glycan processing was hindered.
35304921	13	113	theme	β1	1809:1810	arg1	integrin					1812:1819	α5 β1 integrin	1806:1819	α5 β1 integrin	1806:1819	SIGNIFICANCE Glycosylation of α5 β1 integrin has been implicated in multiple aspects of integrin function and structure.
35304921	14	114	theme	detailed	1902:1909	arg1	knowledge					1911:1919	detailed knowledge	1902:1919	detailed knowledge of its glycosylation, notably the specific sites of glycosylation,	1902:1986	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	4	115	theme	Complex	493:499	arg1	bi					501:502	Complex bi	493:502	Complex bi	493:502	Complex bi, tri, or tetraantennary N-glycans were predominant at various proportions at most potential N-glycosylation sites.
35304921	10	116	theme	functional	1257:1266	arg1	cycle					1268:1272	the functional cycle	1253:1272	the functional cycle of α5 β1 integrin	1253:1290	We have used this model for the discussion of how glycosylation might be used in the functional cycle of α5 β1 integrin.
35304921	2	117	theme	comprehensive	294:306	arg1	map					329:331	the first comprehensive site-specific glycan map	284:331	the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver	284:409	RESULTS Here, we have established the first comprehensive site-specific glycan map of α5 β1 integrin that was purified from a natural source, that is, rat liver.
35304921	7	118	theme	high	882:885	arg1	levels					887:892	high levels	882:892	high levels of O-acetylation of NeuAc residues	882:927	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	15	119	theme	literature	2141:2150	arg1	literature					2141:2150	literature	2141:2150	literature	2141:2150	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	15	119	theme	literature	2141:2150	arg1	lot					2134:2136	a lot	2132:2136	a lot of literature in the field about the glycosylation of "native" glycoproteins	2132:2213	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	15	120	theme	integrin	2023:2030	arg1	preparation					2032:2042	the α5 β1 integrin preparation	2013:2042	the α5 β1 integrin preparation that was analyzed here	2013:2065	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35304921	12	121	theme	endocytic	1753:1761	arg1	trafficking					1763:1773	endocytic trafficking	1753:1773	endocytic trafficking	1753:1773	CONCLUSION We expect that the glycoproteomics data of the current study will serve as a resource for the exploration of structural mechanisms by which glycans control α5 β1 integrin activity and endocytic trafficking.
35304921	14	122	theme	glycosylation	1973:1985	arg1	glycosylation					1973:1985	glycosylation	1973:1985	glycosylation	1973:1985	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	14	122	theme	glycosylation	1973:1985	arg1	sites					1964:1968	the specific sites	1951:1968	notably the specific sites of glycosylation	1943:1985	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	14	122	theme	glycosylation	1973:1985	arg1	glycosylation					1928:1940	its glycosylation	1924:1940	its glycosylation	1924:1940	Yet, detailed knowledge of its glycosylation, notably the specific sites of glycosylation, is lacking.
35304921	7	123	theme	fucosylation	865:876	arg1	levels					850:855	Moderate levels	841:855	Moderate levels of core fucosylation	841:876	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	7	123	theme	fucosylation	865:876	arg1	levels					887:892	high levels	882:892	high levels of O-acetylation of NeuAc residues	882:927	Moderate levels of core fucosylation and high levels of O-acetylation of NeuAc residues were observed at certain sites.
35304921	11	124	theme	galectins	1355:1363	arg1	involvement					1325:1335	the involvement	1321:1335	the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface	1321:1447	A striking example concerns the involvement of glycan-binding galectins in the regulation of the molecular homeostasis of glycoproteins at the cell surface through the formation of lattices or endocytic pits according to the glycolipid-lectin (GL-Lect) hypothesis.
35304921	15	125	theme	α5	2017:2018	arg1	preparation					2032:2042	the α5 β1 integrin preparation	2013:2042	the α5 β1 integrin preparation that was analyzed here	2013:2065	Furthermore, the α5 β1 integrin preparation that was analyzed here is from a natural source, which is of importance as there is not a lot of literature in the field about the glycosylation of "native" glycoproteins.
35077806	0	0	theme	skin	63:66	arg1	secretions					68:77	anuran skin secretions	56:77	anuran skin secretions	56:77	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	5	1	theme	responsible	784:794	arg1	enzymes					776:782	the enzymes	772:782	the enzymes responsible for glycan synthesis pathways	772:824	Additionally, the enzymes responsible for glycan synthesis pathways were evaluated based on their skin tissue transcriptome.
35077806	3	2	link	protein-linked	462:475	arg1	oligosaccharides					477:492	protein-linked oligosaccharides	462:492	protein-linked oligosaccharides	462:492	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	11	3	theme	amphibians	1666:1675	arg1	secretions					1682:1691	amphibians skin secretions	1666:1691	amphibians skin secretions	1666:1691	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	6	4	theme	N-	930:931	arg1	structures					946:955	various N- and O-glycan structures	922:955	various N- and O-glycan structures commonly found in vertebrate proteins	922:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	0	5	theme	anuran	56:61	arg1	secretions					68:77	anuran skin secretions	56:77	anuran skin secretions	56:77	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	6	6	theme	O-glycan	937:944	arg1	structures					946:955	various N- and O-glycan structures	922:955	various N- and O-glycan structures commonly found in vertebrate proteins	922:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	10	7	theme	linked	1434:1439	arg1	glycoproteins					1441:1453	O- linked glycoproteins	1431:1453	O- linked glycoproteins	1431:1453	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	3	8	theme	homing	531:536	arg1	glycoproteins					547:559	their homing secreted glycoproteins	525:559	their homing secreted glycoproteins	525:559	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	10	9	dep	linked	1434:1439	arg1	O-					1431:1432	O-	1431:1432	O-	1431:1432	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	10	theme	transcriptomic	1479:1492	arg1	data					1494:1497	the transcriptomic data	1475:1497	the transcriptomic data	1475:1497	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	3	11	theme	secreted	538:545	arg1	glycoproteins					547:559	their homing secreted glycoproteins	525:559	their homing secreted glycoproteins	525:559	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	3	12	gly	glycoproteins	547:559	arg1	glycoproteins					547:559	their homing secreted glycoproteins	525:559	their homing secreted glycoproteins	525:559	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	11	13	attach	presence	1634:1641	arg2	oligosaccharides					1646:1661	oligosaccharides	1646:1661	oligosaccharides	1646:1661	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	11	13	attach	presence	1634:1641	arg1	secretions					1682:1691	amphibians skin secretions	1666:1691	amphibians skin secretions	1666:1691	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	10	14	theme	secreted	1415:1422	arg1	N-					1424:1425	secreted N-	1415:1425	secreted N-	1415:1425	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	0	15	from	O-glycosylation	27:41	arg1	look					8:11	A first look	0:11	A first look at the N- and O-glycosylation landscape in anuran skin secretions.	0:78	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	0	15	from	O-glycosylation	27:41	arg1	secretions					68:77	anuran skin secretions	56:77	anuran skin secretions	56:77	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	7	16	theme	amphibians	1064:1073	arg1	secretion					1046:1054	the skin secretion	1037:1054	the skin secretion of both amphibians	1037:1073	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	3	17	theme	numerous	353:360	arg1	studies					362:368	the numerous studies	349:368	the numerous studies aiming at the biochemical characterization of anuran skin secretions	349:437	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	6	18	theme	various	922:928	arg1	structures					946:955	various N- and O-glycan structures	922:955	various N- and O-glycan structures commonly found in vertebrate proteins	922:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	5	19	theme	tissue	861:866	arg1	transcriptome					868:880	their skin tissue transcriptome	850:880	their skin tissue transcriptome	850:880	Additionally, the enzymes responsible for glycan synthesis pathways were evaluated based on their skin tissue transcriptome.
35077806	4	20	theme	O-linked	642:649	arg1	oligosaccharides					651:666	O-linked oligosaccharides	642:666	O-linked oligosaccharides	642:666	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	2	21	theme	biomolecules	270:281	arg1	Glycans					218:224	Glycans	218:224	Glycans	218:224	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	2	21	theme	biomolecules	270:281	arg1	class					261:265	a rapidly evolving and complex class	230:265	a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events	230:338	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	7	22	from	abundant	1025:1032	arg1	secretion					1046:1054	the skin secretion	1037:1054	the skin secretion of both amphibians	1037:1073	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	8	23	theme	glycomic	1215:1222	arg1	analyses					1224:1231	glycomic analyses	1215:1231	glycomic analyses	1215:1231	A good correlation between the structures discovered in glycomic analyses and transcripts encoding enzymes necessary for their synthesis was obtained.
35077806	0	24	from	N-	20:21	arg1	look					8:11	A first look	0:11	A first look at the N- and O-glycosylation landscape in anuran skin secretions.	0:78	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	0	24	from	N-	20:21	arg1	secretions					68:77	anuran skin secretions	56:77	anuran skin secretions	56:77	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	5	25	theme	glycan	800:805	arg1	pathways					817:824	glycan synthesis pathways	800:824	glycan synthesis pathways	800:824	Additionally, the enzymes responsible for glycan synthesis pathways were evaluated based on their skin tissue transcriptome.
35077806	9	26	located	found	1377:1381	arg2	those					1335:1339	those	1335:1339	those	1335:1339	Some transcripts such as those of MAN1A2, FUT8, and ST6GALNAC were found solely in B. raniceps.
35077806	9	26	located	found	1377:1381	arg1	B. raniceps					1393:1403	B. raniceps	1393:1403	B. raniceps	1393:1403	Some transcripts such as those of MAN1A2, FUT8, and ST6GALNAC were found solely in B. raniceps.
35077806	9	26	located	found	1377:1381	arg2	transcripts					1315:1325	Some transcripts	1310:1325	Some transcripts such as those of MAN1A2, FUT8, and ST6GALNAC	1310:1370	Some transcripts such as those of MAN1A2, FUT8, and ST6GALNAC were found solely in B. raniceps.
35077806	7	27	theme	skin	1041:1044	arg1	secretion					1046:1054	the skin secretion	1037:1054	the skin secretion of both amphibians	1037:1073	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	4	28	theme	skin	675:678	arg1	secretion					680:688	the skin secretion	671:688	the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps	671:755	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	0	29	theme	first	2:6	arg1	look					8:11	A first look	0:11	A first look at the N- and O-glycosylation landscape in anuran skin secretions.	0:78	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	4	30	from	diversity	622:630	arg1	secretion					680:688	the skin secretion	671:688	the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps	671:755	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	6	31	located	found	966:970	arg1	proteins					986:993	vertebrate proteins	975:993	vertebrate proteins	975:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	6	31	located	found	966:970	arg2	structures					946:955	various N- and O-glycan structures	922:955	various N- and O-glycan structures commonly found in vertebrate proteins	922:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	2	32	theme	recognition	321:331	arg1	events					333:338	intrinsic and extrinsic recognition events	297:338	intrinsic and extrinsic recognition events	297:338	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	1	33	theme	coinhabiting	163:174	arg1	microorganisms					176:189	coinhabiting microorganisms	163:189	coinhabiting microorganisms	163:189	Amphibians secrete a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators.
35077806	2	34	theme	extrinsic	311:319	arg1	events					333:338	intrinsic and extrinsic recognition events	297:338	intrinsic and extrinsic recognition events	297:338	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	4	35	theme	frogs	712:716	arg1	secretion					680:688	the skin secretion	671:688	the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps	671:755	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	10	36	link	linked	1434:1439	arg1	glycoproteins					1441:1453	O- linked glycoproteins	1431:1453	O- linked glycoproteins	1431:1453	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	37	theme	protease	1530:1537	arg1	proteases					1516:1524	proteases	1516:1524	proteases	1516:1524	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	37	theme	protease	1530:1537	arg1	inhibitors					1539:1548	protease inhibitors	1530:1548	protease inhibitors	1530:1548	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	37	theme	protease	1530:1537	arg1	sources					1563:1569	putative sources	1554:1569	putative sources of the glycans described herein	1554:1601	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	7	38	theme	N-glycan	1104:1111	arg1	structures					1113:1122	hybrid and complex N-glycan structures	1085:1122	hybrid and complex N-glycan structures	1085:1122	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	7	39	theme	Paucimannosidic	996:1010	arg1	glycans					1012:1018	Paucimannosidic glycans	996:1018	Paucimannosidic glycans	996:1018	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	4	40	theme	oligosaccharides	651:666	arg1	diversity					622:630	the diversity	618:630	the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps	618:755	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	3	41	theme	biochemical	384:394	arg1	characterization					396:411	the biochemical characterization	380:411	the biochemical characterization of anuran skin secretions	380:437	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	10	42	theme	glycans	1578:1584	arg1	proteases					1516:1524	proteases	1516:1524	proteases	1516:1524	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	42	theme	glycans	1578:1584	arg1	inhibitors					1539:1548	protease inhibitors	1530:1548	protease inhibitors	1530:1548	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	42	theme	glycans	1578:1584	arg1	sources					1563:1569	putative sources	1554:1569	putative sources of the glycans described herein	1554:1601	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	2	43	theme	intrinsic	297:305	arg1	events					333:338	intrinsic and extrinsic recognition events	297:338	intrinsic and extrinsic recognition events	297:338	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	6	44	theme	structures	946:955	arg1	annotation					908:917	the annotation	904:917	the annotation of various N- and O-glycan structures commonly found in vertebrate proteins	904:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	1	45	theme	macroscopic	195:205	arg1	predators					207:215	macroscopic predators	195:215	macroscopic predators	195:215	Amphibians secrete a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators.
35077806	3	46	theme	secretions	428:437	arg1	characterization					396:411	the biochemical characterization	380:411	the biochemical characterization of anuran skin secretions	380:437	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	11	47	theme	skin	1677:1680	arg1	secretions					1682:1691	amphibians skin secretions	1666:1691	amphibians skin secretions	1666:1691	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	3	48	theme	protein-linked	462:475	arg1	oligosaccharides					477:492	protein-linked oligosaccharides	462:492	protein-linked oligosaccharides	462:492	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	4	49	theme	American	703:710	arg1	frogs					712:716	two South American frogs	693:716	two South American frogs	693:716	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	4	49	theme	American	703:710	arg1	azureus					730:736	Pithecopus azureus	719:736	Pithecopus azureus	719:736	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	4	49	theme	American	703:710	arg1	Boana					742:746	Boana	742:746	Boana	742:746	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	5	50	theme	synthesis	807:815	arg1	pathways					817:824	glycan synthesis pathways	800:824	glycan synthesis pathways	800:824	Additionally, the enzymes responsible for glycan synthesis pathways were evaluated based on their skin tissue transcriptome.
35077806	10	51	gly	glycoproteins	1441:1453	arg1	glycoproteins					1441:1453	O- linked glycoproteins	1431:1453	O- linked glycoproteins	1431:1453	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	3	52	theme	anuran	416:421	arg1	secretions					428:437	anuran skin secretions	416:437	anuran skin secretions	416:437	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	6	53	theme	vertebrate	975:984	arg1	proteins					986:993	vertebrate proteins	975:993	vertebrate proteins	975:993	Our analyses allowed the annotation of various N- and O-glycan structures commonly found in vertebrate proteins.
35077806	8	54	theme	necessary	1266:1274	arg1	enzymes					1258:1264	enzymes	1258:1264	enzymes necessary for their synthesis	1258:1294	A good correlation between the structures discovered in glycomic analyses and transcripts encoding enzymes necessary for their synthesis was obtained.
35077806	10	55	theme	putative	1554:1561	arg1	proteases					1516:1524	proteases	1516:1524	proteases	1516:1524	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	55	theme	putative	1554:1561	arg1	inhibitors					1539:1548	protease inhibitors	1530:1548	protease inhibitors	1530:1548	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	10	55	theme	putative	1554:1561	arg1	sources					1563:1569	putative sources	1554:1569	putative sources of the glycans described herein	1554:1601	Finally, secreted N- and O- linked glycoproteins were predicted from the transcriptomic data, indicating that proteases and protease inhibitors are putative sources of the glycans described herein.
35077806	0	56	dep	N-	20:21	arg1	landscape					43:51	landscape	43:51	landscape	43:51	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	0	56	dep	N-	20:21	arg1	the					16:18	the	16:18	the	16:18	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	4	57	used	used	598:601	arg2	LC-MS/MS					585:592	LC-MS/MS	585:592	LC-MS/MS	585:592	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	7	58	theme	complex	1096:1102	arg1	N-glycan					1104:1111	complex N-glycan	1096:1111	complex N-glycan	1096:1111	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	3	59	theme	skin	423:426	arg1	secretions					428:437	anuran skin secretions	416:437	anuran skin secretions	416:437	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	4	60	theme	present	569:575	arg1	report					577:582	the present report	565:582	the present report	565:582	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	7	61	theme	hybrid	1085:1090	arg1	structures					1113:1122	hybrid and complex N-glycan structures	1085:1122	hybrid and complex N-glycan structures	1085:1122	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	1	62	theme	complex	101:107	arg1	array					109:113	a complex array	99:113	a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators	99:215	Amphibians secrete a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators.
35077806	0	63	gly	O-glycosylation	27:41	arg1	secretions					68:77	anuran skin secretions	56:77	anuran skin secretions	56:77	A first look at the N- and O-glycosylation landscape in anuran skin secretions.
35077806	1	64	with	interactions	145:156	arg1	microorganisms					176:189	coinhabiting microorganisms	163:189	coinhabiting microorganisms	163:189	Amphibians secrete a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators.
35077806	1	64	with	interactions	145:156	arg1	predators					207:215	macroscopic predators	195:215	macroscopic predators	195:215	Amphibians secrete a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators.
35077806	11	65	theme	amphibian	1795:1803	arg1	evolution					1805:1813	amphibian evolution	1795:1813	amphibian evolution	1795:1813	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	3	66	theme	synthesis	501:509	arg1	pathways					511:518	their synthesis pathways	495:518	their synthesis pathways	495:518	Despite the numerous studies aiming at the biochemical characterization of anuran skin secretions, little is known about protein-linked oligosaccharides, their synthesis pathways, and their homing secreted glycoproteins.
35077806	7	67	from	secretion	1046:1054	arg1	abundant					1025:1032	abundant	1025:1032	abundant	1025:1032	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	4	68	link	O-linked	642:649	arg1	oligosaccharides					651:666	O-linked oligosaccharides	642:666	O-linked oligosaccharides	642:666	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35077806	11	69	theme	novel	1766:1770	arg1	perspectives					1772:1783	novel perspectives	1766:1783	novel perspectives involving amphibian evolution and ecology	1766:1825	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	2	70	theme	complex	253:259	arg1	Glycans					218:224	Glycans	218:224	Glycans	218:224	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	2	70	theme	complex	253:259	arg1	class					261:265	a rapidly evolving and complex class	230:265	a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events	230:338	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	8	71	theme	good	1161:1164	arg1	correlation					1166:1176	A good correlation	1159:1176	A good correlation between the structures discovered in glycomic analyses and transcripts encoding enzymes necessary for their synthesis	1159:1294	A good correlation between the structures discovered in glycomic analyses and transcripts encoding enzymes necessary for their synthesis was obtained.
35077806	7	72	located	detected	1129:1136	arg2	structures					1113:1122	hybrid and complex N-glycan structures	1085:1122	hybrid and complex N-glycan structures	1085:1122	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	7	72	located	detected	1129:1136	arg1	B. raniceps					1146:1156	B. raniceps	1146:1156	B. raniceps	1146:1156	Paucimannosidic glycans were abundant in the skin secretion of both amphibians; however, hybrid and complex N-glycan structures were detected only in B. raniceps.
35077806	5	73	theme	skin	856:859	arg1	transcriptome					868:880	their skin tissue transcriptome	850:880	their skin tissue transcriptome	850:880	Additionally, the enzymes responsible for glycan synthesis pathways were evaluated based on their skin tissue transcriptome.
35077806	1	74	theme	molecules	118:126	arg1	array					109:113	a complex array	99:113	a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators	99:215	Amphibians secrete a complex array of molecules that shape their interactions with coinhabiting microorganisms and macroscopic predators.
35077806	11	75	theme	oligosaccharides	1646:1661	arg1	presence					1634:1641	the presence	1630:1641	the presence of oligosaccharides in amphibians skin secretions	1630:1691	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	2	76	theme	evolving	240:247	arg1	Glycans					218:224	Glycans	218:224	Glycans	218:224	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	2	76	theme	evolving	240:247	arg1	class					261:265	a rapidly evolving and complex class	230:265	a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events	230:338	Glycans are a rapidly evolving and complex class of biomolecules implicated in intrinsic and extrinsic recognition events.
35077806	11	77	from	presence	1634:1641	arg1	secretions					1682:1691	amphibians skin secretions	1666:1691	amphibians skin secretions	1666:1691	Overall, our results show the presence of oligosaccharides in amphibians skin secretions and suggest that their diversity is species-specific, paving the way for novel perspectives involving amphibian evolution and ecology.
35077806	4	78	theme	N-	635:636	arg1	diversity					622:630	the diversity	618:630	the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps	618:755	In the present report, LC-MS/MS was used to investigate the diversity of N- and O-linked oligosaccharides in the skin secretion of two South American frogs, Pithecopus azureus and Boana raniceps.
35782731	8	0	theme	dynamical	1246:1254	arg1	properties					1256:1265	HRP protein's structural and dynamical properties	1217:1265	HRP protein's structural and dynamical properties at a molecular level	1217:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	8	1	theme	local	1168:1172	arg1	analysis					1174:1181	a global and local analysis	1155:1181	a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level	1155:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	8	2	theme	HRP	1217:1219	arg1	protein					1221:1227	HRP protein's	1217:1229	HRP protein's	1217:1229	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	1	3	theme	peroxidase	248:257	arg1	structure					153:161	structure	153:161	structure	153:161	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	3	theme	peroxidase	248:257	arg1	dynamics					167:174	dynamics	167:174	dynamics	167:174	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	2	4	theme	tertiary	339:346	arg1	structures					348:357	tertiary structures	339:357	tertiary structures of both proteins	339:374	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	7	5	from	influence	1001:1009	arg1	cofactor					1096:1103	the heme cofactor	1087:1103	the heme cofactor	1087:1103	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	7	5	from	influence	1001:1009	arg1	potential					1055:1063	the electrostatic potential	1037:1063	the electrostatic potential of the protein	1037:1078	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	5	6	theme	peripheral	699:708	arg1	region					710:715	The peripheral region	695:715	The peripheral region	695:715	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	0	7	from	Effect	0:5	arg1	peroxidase					41:50	horseradish peroxidase	29:50	horseradish peroxidase	29:50	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	7	8	theme	electrostatic	1041:1053	arg1	potential					1055:1063	the electrostatic potential	1037:1063	the electrostatic potential of the protein	1037:1078	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	3	9	theme	protein	550:556	arg1	structure					558:566	the protein structure	546:566	the protein structure	546:566	Fluctuations in the protein structure along both proteins are decreased when glycosylation is introduced.
35782731	5	10	with	region	765:770	arg1	effect					813:818	a propagated effect	800:818	a propagated effect of glycans	800:829	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	1	11	dep	structure	153:161	arg1	the					149:151	the	149:151	the	149:151	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	8	12	from	influence	1204:1212	arg1	properties					1256:1265	HRP protein's structural and dynamical properties	1217:1265	HRP protein's structural and dynamical properties at a molecular level	1217:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	2	13	from	absence	422:428	arg1	stable					380:385	stable	380:385	stable	380:385	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	4	14	theme	main	654:657	arg1	regions					659:665	two main regions	650:665	two main regions that are affected the most	650:692	We identified two main regions that are affected the most.
35782731	5	15	theme	glycans	823:829	arg1	effect					813:818	a propagated effect	800:818	a propagated effect of glycans	800:829	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	6	16	from	region	860:865	arg1	glycoprotein					874:885	the glycoprotein	870:885	the glycoprotein	870:885	Since the mentioned central region in the glycoprotein is not surrounded by glycans and is close to the heme, it is easily approachable to the solvent and substrate.
35782731	6	17	theme	central	852:858	arg1	region					860:865	the mentioned central region	838:865	the mentioned central region in the glycoprotein	838:885	Since the mentioned central region in the glycoprotein is not surrounded by glycans and is close to the heme, it is easily approachable to the solvent and substrate.
35782731	8	18	from	properties	1256:1265	arg1	analysis					1174:1181	a global and local analysis	1155:1181	a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level	1155:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	8	19	theme	molecular	1272:1280	arg1	level					1282:1286	a molecular level	1270:1286	a molecular level	1270:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	8	20	theme	global	1157:1162	arg1	analysis					1174:1181	a global and local analysis	1155:1181	a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level	1155:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	6	21	theme	mentioned	842:850	arg1	region					860:865	the mentioned central region	838:865	the mentioned central region in the glycoprotein	838:885	Since the mentioned central region in the glycoprotein is not surrounded by glycans and is close to the heme, it is easily approachable to the solvent and substrate.
35782731	7	22	theme	glycan	1018:1023	arg1	presence					1025:1032	the glycan presence	1014:1032	the glycan presence	1014:1032	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	1	23	theme	horseradish	183:193	arg1	HRP					207:209	HRP	207:209	HRP	207:209	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	23	theme	horseradish	183:193	arg1	peroxidase					195:204	the horseradish peroxidase	179:204	the horseradish peroxidase (HRP)	179:210	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	5	24	theme	active	783:788	arg1	site					790:793	the active site	779:793	the active site	779:793	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	7	25	theme	presence	1025:1032	arg1	influence					1001:1009	An influence	998:1009	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor	998:1103	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	1	26	theme	peroxidase	195:204	arg1	structure					153:161	structure	153:161	structure	153:161	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	26	theme	peroxidase	195:204	arg1	dynamics					167:174	dynamics	167:174	dynamics	167:174	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	7	27	theme	heme	1091:1094	arg1	cofactor					1096:1103	the heme cofactor	1087:1103	the heme cofactor	1087:1103	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	1	28	theme	different	103:111	arg1	types					123:127	different branching types	103:127	different branching types of glycosylation	103:144	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	0	29	theme	N-glycosylation	10:24	arg1	Effect					0:5	Effect	0:5	Effect of N-glycosylation on horseradish peroxidase	0:50	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	1	30	theme	branching	113:121	arg1	types					123:127	different branching types	103:127	different branching types of glycosylation	103:144	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	5	31	theme	propagated	802:811	arg1	effect					813:818	a propagated effect	800:818	a propagated effect of glycans	800:829	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	1	32	theme	all-atom	284:291	arg1	simulations					317:327	all-atom molecular dynamics (MD) simulations	284:327	all-atom molecular dynamics (MD) simulations	284:327	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	2	33	theme	glycans	508:514	arg1	presence					496:503	the presence	492:503	the presence of glycans	492:514	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	2	34	from	differences	442:452	arg1	properties					471:480	the dynamical properties	457:480	the dynamical properties regarding the presence of glycans	457:514	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	2	35	theme	proteins	367:374	arg1	structures					348:357	tertiary structures	339:357	tertiary structures of both proteins	339:374	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	8	36	theme	influence	1204:1212	arg1	analysis					1174:1181	a global and local analysis	1155:1181	a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level	1155:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	0	37	theme	horseradish	29:39	arg1	peroxidase					41:50	horseradish peroxidase	29:50	horseradish peroxidase	29:50	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	1	38	theme	molecular	293:301	arg1	simulations					317:327	all-atom molecular dynamics (MD) simulations	284:327	all-atom molecular dynamics (MD) simulations	284:327	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	2	39	theme	glycans	433:439	arg1	absence					422:428	the absence	418:428	the absence of glycans	418:439	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	8	40	from	analysis	1174:1181	arg1	properties					1256:1265	HRP protein's structural and dynamical properties	1217:1265	HRP protein's structural and dynamical properties at a molecular level	1217:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	8	41	theme	glycosylation	1190:1202	arg1	influence					1204:1212	the glycosylation influence	1186:1212	the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level	1186:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	7	42	theme	protein	1072:1078	arg1	potential					1055:1063	the electrostatic potential	1037:1063	the electrostatic potential of the protein	1037:1078	An influence of the glycan presence on the electrostatic potential of the protein and on the heme cofactor was also observed.
35782731	1	43	theme	dynamics	303:310	arg1	simulations					317:327	all-atom molecular dynamics (MD) simulations	284:327	all-atom molecular dynamics (MD) simulations	284:327	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	0	44	gly	N-glycosylation	10:24	arg1	horseradish					29:39	horseradish peroxidase	29:50	horseradish peroxidase	29:50	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	1	45	theme	types	123:127	arg1	effect					93:98	The effect	89:98	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP)	89:264	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	0	46	theme	structural	52:61	arg1	properties					77:86	structural and dynamical properties	52:86	structural and dynamical properties	52:86	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	8	47	from	level	1282:1286	arg1	properties					1256:1265	HRP protein's structural and dynamical properties	1217:1265	HRP protein's structural and dynamical properties at a molecular level	1217:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	1	48	theme	MD	313:314	arg1	simulations					317:327	all-atom molecular dynamics (MD) simulations	284:327	all-atom molecular dynamics (MD) simulations	284:327	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	5	49	with	glycans	741:747	arg1	effect					813:818	a propagated effect	800:818	a propagated effect of glycans	800:829	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	2	50	from	stable	380:385	arg1	presence					394:401	the presence	390:401	the presence	390:401	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	2	50	from	stable	380:385	arg1	absence					422:428	the absence	418:428	the absence of glycans	418:439	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	1	51	theme	glycosylation	132:144	arg1	types					123:127	different branching types	103:127	different branching types of glycosylation	103:144	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	0	52	dep	properties	77:86	arg1	Effect					0:5	Effect	0:5	Effect of N-glycosylation on horseradish peroxidase	0:50	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	2	53	from	presence	394:401	arg1	stable					380:385	stable	380:385	stable	380:385	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	1	54	from	effect	93:98	arg1	structure					153:161	structure	153:161	structure	153:161	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	54	from	effect	93:98	arg1	dynamics					167:174	dynamics	167:174	dynamics	167:174	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	55	theme	engineered	219:228	arg1	sHRP					260:263	sHRP	260:263	sHRP	260:263	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	55	theme	engineered	219:228	arg1	peroxidase					248:257	an engineered split horseradish peroxidase	216:257	an engineered split horseradish peroxidase (sHRP)	216:264	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	2	56	theme	dynamical	461:469	arg1	properties					471:480	the dynamical properties	457:480	the dynamical properties regarding the presence of glycans	457:514	Although tertiary structures of both proteins are stable in the presence, as well as in the absence of glycans, differences in the dynamical properties regarding the presence of glycans were noticed.
35782731	6	57	gly	glycoprotein	874:885	arg1	glycoprotein					874:885	the glycoprotein	870:885	the glycoprotein	870:885	Since the mentioned central region in the glycoprotein is not surrounded by glycans and is close to the heme, it is easily approachable to the solvent and substrate.
35782731	3	58	from	Fluctuations	530:541	arg1	structure					558:566	the protein structure	546:566	the protein structure	546:566	Fluctuations in the protein structure along both proteins are decreased when glycosylation is introduced.
35782731	1	59	theme	split	230:234	arg1	sHRP					260:263	sHRP	260:263	sHRP	260:263	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	59	theme	split	230:234	arg1	peroxidase					248:257	an engineered split horseradish peroxidase	216:257	an engineered split horseradish peroxidase (sHRP)	216:264	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	0	60	theme	dynamical	67:75	arg1	properties					77:86	structural and dynamical properties	52:86	structural and dynamical properties	52:86	Effect of N-glycosylation on horseradish peroxidase structural and dynamical properties.
35782731	5	61	theme	central	757:763	arg1	region					765:770	the central region	753:770	the central region within the active site with a propagated effect of glycans	753:829	The peripheral region is impacted directly by glycans and the central region within the active site with a propagated effect of glycans.
35782731	8	62	theme	structural	1231:1240	arg1	properties					1256:1265	HRP protein's structural and dynamical properties	1217:1265	HRP protein's structural and dynamical properties at a molecular level	1217:1286	Altogether, this work presents a global and local analysis of the glycosylation influence on HRP protein's structural and dynamical properties at a molecular level.
35782731	1	63	theme	horseradish	236:246	arg1	sHRP					260:263	sHRP	260:263	sHRP	260:263	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35782731	1	63	theme	horseradish	236:246	arg1	peroxidase					248:257	an engineered split horseradish peroxidase	216:257	an engineered split horseradish peroxidase (sHRP)	216:264	The effect of different branching types of glycosylation on the structure and dynamics of the horseradish peroxidase (HRP) and an engineered split horseradish peroxidase (sHRP) was studied using all-atom molecular dynamics (MD) simulations.
35421698	5	0	from	compostions	967:977	arg1	structures					942:951	81 glycan structures	932:951	81 glycan structures from 54 glcan compostions	932:977	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	5	1	theme	structure-diagnostic	896:915	arg1	ions					926:929	structure-diagnostic fragment ions	896:929	structure-diagnostic fragment ions	896:929	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	3	2	gly	N-glycopeptides	511:525	arg1	Arabidopsis					530:540	Arabidopsis	530:540	Arabidopsis	530:540	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	3	2	gly	N-glycopeptides	511:525	arg2	N-glycopeptides					511:525	intact N-glycopeptides	504:525	intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment	504:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	4	3	theme	best	838:841	arg1	knowledge					843:851	our best knowledge	834:851	our best knowledge	834:851	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	6	4	theme	site-	1043:1047	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	4	theme	site-	1043:1047	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	4	5	from	3,713 N-glycosites	709:726	arg1	5,687 N-glycopeptides					682:702	5,687 N-glycopeptides	682:702	5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins	682:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	4	6	gly	3,140 N-glycoproteins	731:751	arg1	3,140 N-glycoproteins					731:751	3,140 N-glycoproteins	731:751	3,140 N-glycoproteins	731:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	0	7	theme	mass-spectrometry-based	112:134	arg1	N-glycoproteomics					136:152	mass-spectrometry-based N-glycoproteomics	112:152	mass-spectrometry-based N-glycoproteomics	112:152	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	1	8	from	bioprocess	191:200	arg1	plant					205:209	plant	205:209	plant	205:209	The N-glycosylation is an important bioprocess in plant.
35421698	2	9	theme	sequence	372:379	arg1	structures					381:390	resolve multiple sequence structures	355:390	resolve multiple sequence structures of a single composition	355:414	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	6	10	theme	functional	1178:1187	arg1	studies					1189:1195	the coming functional studies	1167:1195	the coming functional studies of this widely adopted model organism of plant	1167:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	5	11	theme	glcan	961:965	arg1	compostions					967:977	54 glcan compostions	958:977	54 glcan compostions	958:977	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	2	12	theme	multiple	363:370	arg1	structures					381:390	resolve multiple sequence structures	355:390	resolve multiple sequence structures of a single composition	355:414	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	4	13	theme	most	801:804	arg1	comprohensive					806:818	the currently most comprohensive	787:818	the currently most comprohensive profilling to our best knowledge	787:851	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	2	14	from	N-glycopeptides	276:290	arg1	characterization					245:260	Monosaccharide composition-level characterization	212:260	Monosaccharide composition-level characterization at the intact N-glycopeptides	212:290	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	5	15	theme	glycan	935:940	arg1	structures					942:951	81 glycan structures	932:951	81 glycan structures from 54 glcan compostions	932:977	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	6	16	theme	experimental	1030:1041	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	16	theme	experimental	1030:1041	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	2	17	theme	resolve	355:361	arg1	structures					381:390	resolve multiple sequence structures	355:390	resolve multiple sequence structures of a single composition	355:414	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	0	18	theme	site-	14:18	arg1	characterization					43:58	Comprehensive site- and structure-specific characterization	0:58	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.	0:153	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	0	19	from	characterization	43:58	arg1	Arabidopsis					94:104	model plant Arabidopsis	82:104	model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics	82:152	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	4	20	gly	5,687 N-glycopeptides	682:702	arg1	3,140 N-glycoproteins					731:751	3,140 N-glycoproteins	731:751	3,140 N-glycoproteins	731:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	4	20	gly	5,687 N-glycopeptides	682:702	arg1	3,713 N-glycosites					709:726	3,713 N-glycosites	709:726	3,713 N-glycosites of 3,140 N-glycoproteins	709:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	4	20	gly	5,687 N-glycopeptides	682:702	arg2	5,687 N-glycopeptides					682:702	5,687 N-glycopeptides	682:702	5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins	682:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	2	21	theme	composition	404:414	arg1	structures					381:390	resolve multiple sequence structures	355:390	resolve multiple sequence structures of a single composition	355:414	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	6	22	theme	organism	1226:1233	arg1	studies					1189:1195	the coming functional studies	1167:1195	the coming functional studies of this widely adopted model organism of plant	1167:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	3	23	theme	Arabidopsis	530:540	arg1	N-glycopeptides					511:525	intact N-glycopeptides	504:525	intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment	504:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	0	24	theme	Comprehensive	0:12	arg1	characterization					43:58	Comprehensive site- and structure-specific characterization	0:58	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.	0:153	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	4	25	theme	spectrum-level	657:670	arg1	%					679:679	spectrum-level FDR ≤ 1%	657:679	spectrum-level FDR ≤ 1%	657:679	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	2	26	theme	single	397:402	arg1	composition					404:414	a single composition	395:414	a single composition	395:414	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	0	27	theme	structure-specific	24:41	arg1	characterization					43:58	Comprehensive site- and structure-specific characterization	0:58	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.	0:153	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	4	28	gly	3,713 N-glycosites	709:726	arg1	3,140 N-glycoproteins					731:751	3,140 N-glycoproteins	731:751	3,140 N-glycoproteins	731:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	4	28	gly	3,713 N-glycosites	709:726	arg2	3,140 N-glycoproteins					731:751	3,140 N-glycoproteins	731:751	3,140 N-glycoproteins	731:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	4	28	gly	3,713 N-glycosites	709:726	arg2	3,713 N-glycosites					709:726	3,713 N-glycosites	709:726	3,713 N-glycosites of 3,140 N-glycoproteins	709:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	3	29	theme	comprehensive	453:465	arg1	identification					486:499	a comprehensive structure-specific identification	451:499	a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment	451:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	3	30	with	N-glycopeptides	511:525	arg1	HILIC					552:556	HILIC	552:556	HILIC	552:556	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	3	30	with	N-glycopeptides	511:525	arg1	enrichment					566:575	RAX enrichment	562:575	RAX enrichment	562:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	6	31	theme	structure-specific	1053:1070	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	31	theme	structure-specific	1053:1070	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	3	32	theme	N-glycopeptides	511:525	arg1	pGlyco					602:607	pGlyco	602:607	pGlyco	602:607	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	3	32	theme	N-glycopeptides	511:525	arg1	identification					486:499	a comprehensive structure-specific identification	451:499	a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment	451:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	3	32	theme	N-glycopeptides	511:525	arg1	GPSeeker					589:596	GPSeeker	589:596	GPSeeker	589:596	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	6	33	theme	plant	1238:1242	arg1	organism					1226:1233	this widely adopted model organism	1200:1233	this widely adopted model organism of plant	1200:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	5	34	theme	fragment	917:924	arg1	ions					926:929	structure-diagnostic fragment ions	896:929	structure-diagnostic fragment ions	896:929	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	6	35	theme	valuable	1144:1151	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	35	theme	valuable	1144:1151	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	5	36	theme	experimental	863:874	arg1	support					885:891	the experimental evidence support	859:891	the experimental evidence support of structure-diagnostic fragment ions	859:929	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	2	37	theme	composition-level	227:243	arg1	characterization					245:260	Monosaccharide composition-level characterization	212:260	Monosaccharide composition-level characterization at the intact N-glycopeptides	212:290	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	3	38	theme	RAX	562:564	arg1	enrichment					566:575	RAX enrichment	562:575	RAX enrichment	562:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	5	39	theme	evidence	876:883	arg1	support					885:891	the experimental evidence support	859:891	the experimental evidence support of structure-diagnostic fragment ions	859:929	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	2	40	theme	Monosaccharide	212:225	arg1	characterization					245:260	Monosaccharide composition-level characterization	212:260	Monosaccharide composition-level characterization at the intact N-glycopeptides	212:290	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	0	41	theme	N-glycosylation	63:77	arg1	characterization					43:58	Comprehensive site- and structure-specific characterization	0:58	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.	0:153	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	6	42	theme	comprehensive	1016:1028	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	42	theme	comprehensive	1016:1028	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	3	43	theme	intact	504:509	arg1	N-glycopeptides					511:525	intact N-glycopeptides	504:525	intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment	504:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	6	44	theme	N-glycosylation	1072:1086	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	44	theme	N-glycosylation	1072:1086	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	2	45	gly	N-glycopeptides	276:290	arg2	N-glycopeptides					276:290	the intact N-glycopeptides	265:290	the intact N-glycopeptides	265:290	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	4	46	theme	target-decoy	631:642	arg1	searches					644:651	target-decoy searches	631:651	target-decoy searches	631:651	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	5	47	theme	ions	926:929	arg1	support					885:891	the experimental evidence support	859:891	the experimental evidence support of structure-diagnostic fragment ions	859:929	Wtih the experimental evidence support of structure-diagnostic fragment ions, 81 glycan structures from 54 glcan compostions were unambiguouly distinguished.
35421698	4	48	theme	3,140 N-glycoproteins	731:751	arg1	3,140 N-glycoproteins					731:751	3,140 N-glycoproteins	731:751	3,140 N-glycoproteins	731:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	4	48	theme	3,140 N-glycoproteins	731:751	arg1	3,713 N-glycosites					709:726	3,713 N-glycosites	709:726	3,713 N-glycosites of 3,140 N-glycoproteins	709:751	With target-decoy searches and spectrum-level FDR ≤ 1%, 5,687 N-glycopeptides from 3,713 N-glycosites of 3,140 N-glycoproteins were identified, which represents the currently most comprohensive profilling to our best knowledge.
35421698	3	49	dep	GPSeeker	589:596	arg1	search					618:623	database search	609:623	database search	609:623	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	2	50	theme	intact	269:274	arg1	N-glycopeptides					276:290	the intact N-glycopeptides	265:290	the intact N-glycopeptides	265:290	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	1	51	theme	important	181:189	arg1	N-glycosylation					159:173	The N-glycosylation	155:173	The N-glycosylation	155:173	The N-glycosylation is an important bioprocess in plant.
35421698	1	51	theme	important	181:189	arg1	bioprocess					191:200	an important bioprocess	178:200	an important bioprocess in plant	178:209	The N-glycosylation is an important bioprocess in plant.
35421698	6	52	theme	model	1220:1224	arg1	organism					1226:1233	this widely adopted model organism	1200:1233	this widely adopted model organism of plant	1200:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	0	53	theme	plant	88:92	arg1	Arabidopsis					94:104	model plant Arabidopsis	82:104	model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics	82:152	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	2	54	theme	structure-specific	327:344	arg1	study					346:350	structure-specific study	327:350	structure-specific study to resolve multiple sequence structures of a single composition	327:414	Monosaccharide composition-level characterization at the intact N-glycopeptides has been extensively reported, yet structure-specific study to resolve multiple sequence structures of a single composition is still lacking.
35421698	3	55	theme	database	609:616	arg1	search					618:623	database search	609:623	database search	609:623	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	6	56	theme	adopted	1212:1218	arg1	organism					1226:1233	this widely adopted model organism	1200:1233	this widely adopted model organism of plant	1200:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	0	57	theme	model	82:86	arg1	Arabidopsis					94:104	model plant Arabidopsis	82:104	model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics	82:152	Comprehensive site- and structure-specific characterization of N-glycosylation in model plant Arabidopsis using mass-spectrometry-based N-glycoproteomics.
35421698	6	58	theme	coming	1171:1176	arg1	studies					1189:1195	the coming functional studies	1167:1195	the coming functional studies of this widely adopted model organism of plant	1167:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	3	59	theme	structure-specific	467:484	arg1	identification					486:499	a comprehensive structure-specific identification	451:499	a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment	451:575	Here, we present a comprehensive structure-specific identification of intact N-glycopeptides of Arabidopsis with both HILIC and RAX enrichment, as well as GPSeeker and pGlyco database search.
35421698	6	60	theme	fundamental	1132:1142	arg1	data					1088:1091	The comprehensive experimental site- and structure-specific N-glycosylation data	1012:1091	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study	1012:1114	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
35421698	6	60	theme	fundamental	1132:1142	arg1	reference					1153:1161	a fundamental valuable reference	1130:1161	a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant	1130:1242	The comprehensive experimental site- and structure-specific N-glycosylation data reported in this study will serve as a fundamental valuable reference for the coming functional studies of this widely adopted model organism of plant.
36252735	5	0	theme	Regional	630:637	arg1	variations					639:648	Regional variations	630:648	Regional variations	630:648	Regional variations were also found with regard to the glycan types including high mannose and complex-type structures.
36252735	7	1	theme	compositions	900:911	arg1	representation					875:888	the broader representation	863:888	the broader representation of glycan compositions	863:911	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	5	2	theme	high	708:711	arg1	mannose					713:719	high mannose	708:719	high mannose	708:719	Regional variations were also found with regard to the glycan types including high mannose and complex-type structures.
36252735	3	3	theme	disease	528:534	arg1	progression					501:511	the progression	497:511	the progression of Alzheimer's disease	497:534	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	7	4	from	two	954:956	arg1	90s					967:969	their 90s	961:969	their 90s representing two Alzheimer's disease subjects	961:1015	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	2	5	theme	cell-cell	262:270	arg1	interactions					272:283	cell-cell interactions	262:283	cell-cell interactions that are of fundamental importance to the brain	262:331	The glycans and glycoproteins are involved in cell-cell interactions that are of fundamental importance to the brain.
36252735	7	6	from	two	933:935	arg1	70s					946:948	their 70s	940:948	their 70s	940:948	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	7	theme	cognitive	1077:1085	arg1	impairment					1087:1096	no cognitive impairment	1074:1096	no cognitive impairment	1074:1096	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	9	8	theme	Marked	1185:1190	arg1	differences					1192:1202	Marked differences	1185:1202	Marked differences in the glycomic and glycoproteomic profiles	1185:1246	Marked differences in the glycomic and glycoproteomic profiles were observed between the samples.
36252735	7	9	theme	broader	867:873	arg1	representation					875:888	the broader representation	863:888	the broader representation of glycan compositions	863:911	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	5	10	theme	complex-type	725:736	arg1	structures					738:747	complex-type structures	725:747	complex-type structures	725:747	Regional variations were also found with regard to the glycan types including high mannose and complex-type structures.
36252735	7	11	with	subjects	919:926	arg1	two					954:956	two	954:956	two	954:956	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	11	with	subjects	919:926	arg1	two					933:935	two	933:935	two	933:935	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	11	with	subjects	919:926	arg1	impairment					1087:1096	no cognitive impairment	1074:1096	no cognitive impairment	1074:1096	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	11	with	subjects	919:926	arg1	subject					1044:1050	one hippocampal sclerosis subject	1018:1050	one hippocampal sclerosis subject	1018:1050	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	1	12	from	proteins	118:125	arg1	membrane					139:146	the cell membrane	130:146	the cell membrane of the brain	130:159	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	8	13	theme	brain	1170:1174	arg1	regions					1176:1182	11 brain regions	1167:1182	11 brain regions	1167:1182	The four subjects were all glycomically mapped across 11 brain regions.
36252735	1	14	theme	brain	155:159	arg1	membrane					139:146	the cell membrane	130:146	the cell membrane of the brain	130:159	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	3	15	theme	comprehensive	353:365	arg1	N-glycome					367:375	the comprehensive N-glycome	349:375	the comprehensive N-glycome	349:375	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	2	16	theme	fundamental	297:307	arg1	importance					309:318	fundamental importance	297:318	fundamental importance	297:318	The glycans and glycoproteins are involved in cell-cell interactions that are of fundamental importance to the brain.
36252735	3	17	theme	brain	404:408	arg1	N-glycoproteome					381:395	N-glycoproteome	381:395	N-glycoproteome	381:395	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	3	17	theme	brain	404:408	arg1	N-glycome					367:375	the comprehensive N-glycome	349:375	the comprehensive N-glycome	349:375	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	0	18	theme	Regio-Specific	0:13	arg1	N-Glycome					15:23	Regio-Specific N-Glycome	0:23	Regio-Specific N-Glycome	0:23	Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
36252735	0	19	theme	N-Glycoproteome	29:43	arg1	Map					45:47	N-Glycoproteome Map	29:47	N-Glycoproteome Map	29:47	Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
36252735	9	20	theme	glycomic	1211:1218	arg1	profiles					1239:1246	the glycomic and glycoproteomic profiles	1207:1246	the glycomic and glycoproteomic profiles	1207:1246	Marked differences in the glycomic and glycoproteomic profiles were observed between the samples.
36252735	3	21	theme	brain	443:447	arg1	them					466:469	them	466:469	them	466:469	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	3	21	theme	brain	443:447	arg1	some					458:461	some	458:461	some	458:461	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	3	21	theme	brain	443:447	arg1	regions					449:455	11 functional brain regions	429:455	11 functional brain regions	429:455	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	5	22	theme	glycan	685:690	arg1	types					692:696	the glycan types	681:696	the glycan types including high mannose and complex-type structures	681:747	Regional variations were also found with regard to the glycan types including high mannose and complex-type structures.
36252735	5	22	theme	glycan	685:690	arg1	mannose					713:719	high mannose	708:719	high mannose	708:719	Regional variations were also found with regard to the glycan types including high mannose and complex-type structures.
36252735	5	22	theme	glycan	685:690	arg1	structures					738:747	complex-type structures	725:747	complex-type structures	725:747	Regional variations were also found with regard to the glycan types including high mannose and complex-type structures.
36252735	7	23	with	subject	1061:1067	arg1	two					954:956	two	954:956	two	954:956	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	23	with	subject	1061:1067	arg1	two					933:935	two	933:935	two	933:935	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	23	with	subject	1061:1067	arg1	impairment					1087:1096	no cognitive impairment	1074:1096	no cognitive impairment	1074:1096	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	23	with	subject	1061:1067	arg1	subject					1044:1050	one hippocampal sclerosis subject	1018:1050	one hippocampal sclerosis subject	1018:1050	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	9	24	theme	glycoproteomic	1224:1237	arg1	profiles					1239:1246	the glycomic and glycoproteomic profiles	1207:1246	the glycomic and glycoproteomic profiles	1207:1246	Marked differences in the glycomic and glycoproteomic profiles were observed between the samples.
36252735	3	25	theme	functional	432:441	arg1	them					466:469	them	466:469	them	466:469	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	3	25	theme	functional	432:441	arg1	some					458:461	some	458:461	some	458:461	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	3	25	theme	functional	432:441	arg1	regions					449:455	11 functional brain regions	429:455	11 functional brain regions	429:455	In this study, the comprehensive N-glycome and N-glycoproteome of the brain were determined in 11 functional brain regions, some of them known to be affected with the progression of Alzheimer's disease.
36252735	0	26	theme	Elderly	56:62	arg1	Brain					70:74	the Elderly Human Brain	52:74	the Elderly Human Brain	52:74	Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
36252735	7	27	theme	sclerosis	1034:1042	arg1	two					933:935	two	933:935	two	933:935	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	27	theme	sclerosis	1034:1042	arg1	subject					1044:1050	one hippocampal sclerosis subject	1018:1050	one hippocampal sclerosis subject	1018:1050	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	6	28	theme	Glycoproteomic	750:763	arg1	analysis					765:772	Glycoproteomic analysis	750:772	Glycoproteomic analysis	750:772	Glycoproteomic analysis identified the proteins that differed in glycosylation in the various regions.
36252735	1	29	mod	modified	165:172	arg1	proteins					118:125	The proteins	114:125	The proteins in the cell membrane of the brain	114:159	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	1	29	mod	modified	165:172	arg3	glycans					177:183	glycans	177:183	glycans in highly interactive regions	177:213	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	1	30	from	glycans	177:183	arg1	regions					207:213	highly interactive regions	188:213	highly interactive regions	188:213	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	9	31	from	differences	1192:1202	arg1	profiles					1239:1246	the glycomic and glycoproteomic profiles	1207:1246	the glycomic and glycoproteomic profiles	1207:1246	Marked differences in the glycomic and glycoproteomic profiles were observed between the samples.
36252735	1	32	theme	interactive	195:205	arg1	regions					207:213	highly interactive regions	188:213	highly interactive regions	188:213	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	7	33	theme	hippocampal	1022:1032	arg1	two					933:935	two	933:935	two	933:935	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	7	33	theme	hippocampal	1022:1032	arg1	subject					1044:1050	one hippocampal sclerosis subject	1018:1050	one hippocampal sclerosis subject	1018:1050	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	6	34	theme	various	836:842	arg1	regions					844:850	the various regions	832:850	the various regions	832:850	Glycoproteomic analysis identified the proteins that differed in glycosylation in the various regions.
36252735	1	35	theme	cell	134:137	arg1	membrane					139:146	the cell membrane	130:146	the cell membrane of the brain	130:159	The proteins in the cell membrane of the brain are modified by glycans in highly interactive regions.
36252735	0	36	theme	Brain	70:74	arg1	N-Glycome					15:23	Regio-Specific N-Glycome	0:23	Regio-Specific N-Glycome	0:23	Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
36252735	0	36	theme	Brain	70:74	arg1	Map					45:47	N-Glycoproteome Map	29:47	N-Glycoproteome Map	29:47	Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
36252735	7	37	theme	disease	1000:1006	arg1	subjects					1008:1015	two Alzheimer's disease subjects	984:1015	two Alzheimer's disease subjects	984:1015	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
36252735	0	38	theme	Human	64:68	arg1	Brain					70:74	the Elderly Human Brain	52:74	the Elderly Human Brain	52:74	Regio-Specific N-Glycome and N-Glycoproteome Map of the Elderly Human Brain With and Without Alzheimer's Disease.
36252735	2	39	gly	glycoproteins	232:244	arg1	glycoproteins					232:244	glycoproteins	232:244	glycoproteins	232:244	The glycans and glycoproteins are involved in cell-cell interactions that are of fundamental importance to the brain.
36252735	7	40	theme	glycan	893:898	arg1	compositions					900:911	glycan compositions	893:911	glycan compositions	893:911	To obtain the broader representation of glycan compositions, four subjects with two in their 70s and two in their 90s representing two Alzheimer's disease subjects, one hippocampal sclerosis subject, and one subject with no cognitive impairment were analyzed.
35995381	12	0	theme	protein	1893:1899	arg1	profiles					1853:1860	N-glycosylation profiles	1837:1860	N-glycosylation profiles of human thyroid thyroglobulin protein	1837:1899	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	9	1	theme	human	1467:1471	arg1	protein					1476:1482	human Tg protein	1467:1482	human Tg protein	1467:1482	It is expected that the results obtained from this study will contribute to functional studies to be conducted on human Tg protein.
35995381	12	2	theme	N-glycosylation	1837:1851	arg1	profiles					1853:1860	N-glycosylation profiles	1837:1860	N-glycosylation profiles of human thyroid thyroglobulin protein	1837:1899	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	4	3	theme	sulfated	612:619	arg1	complex					621:627	The sulfated complex and hybrid type N-glycan species	608:660	complex	621:627	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	3	4	theme	glycan	496:501	arg1	contents					503:510	their glycan contents	490:510	their glycan contents	490:510	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	8	5	theme	sulfated	1216:1223	arg1	structures					1235:1244	sulfated glycoform structures	1216:1244	sulfated glycoform structures	1216:1244	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	8	6	theme	glycosylation	1289:1301	arg1	sites					1303:1307	glycosylation sites	1289:1307	glycosylation sites containing complex and hybrid type glycans	1289:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	7	7	theme	other	1148:1152	arg1	regions					1154:1160	other regions	1148:1160	other regions	1148:1160	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	11	8	theme	comprehensive	1618:1630	arg1	essential					1696:1704	essential	1696:1704	essential	1696:1704	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	11	8	theme	comprehensive	1618:1630	arg1	analysis					1632:1639	a comprehensive analysis	1616:1639	a comprehensive analysis of the N-glycosylation sites of human thyroglobulin	1616:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	3	9	theme	glyco-analytical	537:552	arg1	strategies					554:563	high-throughput glyco-analytical strategies	521:563	high-throughput glyco-analytical strategies	521:563	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	3	9	theme	glyco-analytical	537:552	arg1	glycopeptide					576:587	glycopeptide	576:587	glycopeptide	576:587	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	3	9	theme	glyco-analytical	537:552	arg1	levels					600:605	glycan levels	593:605	glycan levels	593:605	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	8	10	gly	glycopeptide	1267:1278	arg2	glycopeptide					1267:1278	the glycopeptide level	1263:1284	the glycopeptide level	1263:1284	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	3	11	theme	glycan	593:598	arg1	levels					600:605	glycan levels	593:605	glycan levels	593:605	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	1	12	theme	essential	194:202	arg1	thyroglobulin					132:144	Human thyroglobulin	126:144	Human thyroglobulin (Tg)	126:149	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	1	12	theme	essential	194:202	arg1	protein					204:210	an essential protein	191:210	an essential protein produced by the human thyroid glands	191:247	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	7	13	theme	type	1128:1131	arg1	glycans					1133:1139	high-mannose type glycans	1115:1139	high-mannose type glycans	1115:1139	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	10	14	dep	SIGNIFICANCE	1496:1507	arg1	modulate					1543:1550	modulate	1543:1550	modulate thyroid hormone synthesis both in vivo and in vitro	1543:1602	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
35995381	8	15	theme	type	1339:1342	arg1	glycans					1344:1350	complex and hybrid type glycans	1320:1350	glycans	1344:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	15	16	theme	determined	2256:2265	arg1	sites					2281:2285	all determined glycosylation sites	2252:2285	all determined glycosylation sites	2252:2285	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	12	17	theme	present	1773:1779	arg1	research					1781:1788	The present research	1769:1788	The present research	1769:1788	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	3	18	gly	glycopeptide	576:587	arg2	glycopeptide					576:587	glycopeptide	576:587	glycopeptide	576:587	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	1	19	gly	glycosylation	167:179	arg2	sites					181:185	many glycosylation sites	162:185	many glycosylation sites	162:185	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	2	20	theme	Tg	265:266	arg1	N-glycans					268:276	human Tg N-glycans	259:276	human Tg N-glycans	259:276	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	5	21	theme	site-specific	955:967	arg1	analysis					983:990	site-specific glycosylation analysis	955:990	site-specific glycosylation analysis	955:990	The human Tg was digested with multiple enzymes by applying both in-gel and in-solution protocols to enhance site-specific glycosylation analysis.
35995381	15	22	contain	containing	2184:2193	arg2	types					2227:2231	bisecting types	2217:2231	bisecting types	2217:2231	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	15	22	contain	containing	2184:2193	arg2	core-fucosylation					2195:2211	core-fucosylation	2195:2211	core-fucosylation	2195:2211	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	15	22	contain	containing	2184:2193	arg1	structures					2173:2182	N-glycan structures	2164:2182	N-glycan structures containing core-fucosylation and bisecting types	2164:2231	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	4	23	theme	human	701:705	arg1	samples					710:716	the human Tg samples	697:716	the human Tg samples	697:716	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	5	24	theme	in-gel	911:916	arg1	protocols					934:942	both in-gel and in-solution protocols	906:942	both in-gel and in-solution protocols	906:942	The human Tg was digested with multiple enzymes by applying both in-gel and in-solution protocols to enhance site-specific glycosylation analysis.
35995381	4	25	theme	samples	710:716	arg1	analysis					685:692	the analysis	681:692	the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS.	681:743	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	13	26	theme	comprehensive	1991:2003	arg1	strategies					2022:2031	comprehensive glyco-analytical strategies	1991:2031	comprehensive glyco-analytical strategies	1991:2031	For instance, as highlighted here, sulfated N-glycan structures were characterized using comprehensive glyco-analytical strategies.
35995381	0	27	theme	Glyco-analytical	97:112	arg1	strategies					114:123	mass spectrometry-based Glyco-analytical strategies	73:123	mass spectrometry-based Glyco-analytical strategies	73:123	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	14	28	from	time	2124:2127	arg1	work					2145:2148	this current work	2132:2148	this current work	2132:2148	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	5	29	theme	in-solution	922:932	arg1	protocols					934:942	both in-gel and in-solution protocols	906:942	both in-gel and in-solution protocols	906:942	The human Tg was digested with multiple enzymes by applying both in-gel and in-solution protocols to enhance site-specific glycosylation analysis.
35995381	10	30	theme	BIOLOGICAL	1485:1494	arg1	SIGNIFICANCE					1496:1507	BIOLOGICAL SIGNIFICANCE	1485:1507	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.	1485:1603	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
35995381	10	31	theme	thyroglobulin	1529:1541	arg1	N-glycans					1510:1518	N-glycans	1510:1518	N-glycans of human thyroglobulin	1510:1541	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
35995381	4	32	gly	fucosylated	767:777	arg1	N-glycans					779:787	all fucosylated N-glycans	763:787	all fucosylated N-glycans	763:787	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	14	33	theme	first	2118:2122	arg1	time					2124:2127	the first time	2114:2127	the first time in this current work	2114:2148	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	2	34	theme	structures	384:393	arg1	distribution					361:372	the site-specific distribution	343:372	the site-specific distribution of glycan structures	343:393	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	0	35	theme	Site-specific	0:12	arg1	analysis					30:37	Site-specific N-glycosylation analysis	0:37	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies	0:123	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	1	36	theme	Human	126:130	arg1	Tg					147:148	Tg	147:148	Tg	147:148	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	1	36	theme	Human	126:130	arg1	thyroglobulin					132:144	Human thyroglobulin	126:144	Human thyroglobulin (Tg)	126:149	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	1	36	theme	Human	126:130	arg1	protein					204:210	an essential protein	191:210	an essential protein produced by the human thyroid glands	191:247	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	4	37	theme	fucosylated	767:777	arg1	N-glycans					779:787	all fucosylated N-glycans	763:787	all fucosylated N-glycans	763:787	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	7	38	contain	contain	1102:1108	arg2	glycans					1133:1139	high-mannose type glycans	1115:1139	high-mannose type glycans	1115:1139	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	7	38	contain	contain	1102:1108	arg1	sites					1096:1100	6 N-glycosylation sites	1078:1100	6 N-glycosylation sites	1078:1100	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	3	39	theme	human	455:459	arg1	sites					480:484	human Tg N-glycosylation sites	455:484	human Tg N-glycosylation sites	455:484	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	5	40	theme	human	850:854	arg1	Tg					856:857	The human Tg	846:857	The human Tg	846:857	The human Tg was digested with multiple enzymes by applying both in-gel and in-solution protocols to enhance site-specific glycosylation analysis.
35995381	3	41	theme	high-throughput	521:535	arg1	strategies					554:563	high-throughput glyco-analytical strategies	521:563	high-throughput glyco-analytical strategies	521:563	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	3	41	theme	high-throughput	521:535	arg1	glycopeptide					576:587	glycopeptide	576:587	glycopeptide	576:587	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	3	41	theme	high-throughput	521:535	arg1	levels					600:605	glycan levels	593:605	glycan levels	593:605	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	10	42	theme	thyroid	1552:1558	arg1	synthesis					1568:1576	thyroid hormone synthesis	1552:1576	thyroid hormone synthesis	1552:1576	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
35995381	4	43	with	analysis	685:692	arg1	HPLC-HILIC-FLD-MS/MS.					723:743	HPLC-HILIC-FLD-MS/MS.	723:743	HPLC-HILIC-FLD-MS/MS.	723:743	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	13	44	theme	sulfated	1937:1944	arg1	structures					1955:1964	sulfated N-glycan structures	1937:1964	sulfated N-glycan structures	1937:1964	For instance, as highlighted here, sulfated N-glycan structures were characterized using comprehensive glyco-analytical strategies.
35995381	11	45	gly	N-glycosylation	1648:1662	arg1	thyroglobulin					1679:1691	human thyroglobulin	1673:1691	human thyroglobulin	1673:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	11	45	gly	N-glycosylation	1648:1662	arg2	thyroglobulin					1679:1691	human thyroglobulin	1673:1691	human thyroglobulin	1673:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	11	45	gly	N-glycosylation	1648:1662	arg2	sites					1664:1668	the N-glycosylation sites	1644:1668	the N-glycosylation sites of human thyroglobulin	1644:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	0	46	theme	human	42:46	arg1	thyroglobulin					56:68	human thyroid thyroglobulin	42:68	human thyroid thyroglobulin	42:68	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	0	47	gly	N-glycosylation	14:28	arg1	thyroglobulin					56:68	human thyroid thyroglobulin	42:68	human thyroid thyroglobulin	42:68	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	11	48	theme	sites	1664:1668	arg1	essential					1696:1704	essential	1696:1704	essential	1696:1704	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	11	48	theme	sites	1664:1668	arg1	analysis					1632:1639	a comprehensive analysis	1616:1639	a comprehensive analysis of the N-glycosylation sites of human thyroglobulin	1616:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	0	49	theme	thyroglobulin	56:68	arg1	analysis					30:37	Site-specific N-glycosylation analysis	0:37	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies	0:123	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	6	50	gly	20 N-glycosylation	1013:1030	arg2	sites					1032:1036	20 N-glycosylation sites	1013:1036	20 N-glycosylation sites	1013:1036	In total, 17 out of 20 N-glycosylation sites were characterized.
35995381	3	51	theme	N-glycosylation	464:478	arg1	sites					480:484	human Tg N-glycosylation sites	455:484	human Tg N-glycosylation sites	455:484	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	1	52	theme	human	228:232	arg1	glands					242:247	the human thyroid glands	224:247	the human thyroid glands	224:247	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	15	53	theme	bisecting	2217:2225	arg1	types					2227:2231	bisecting types	2217:2231	bisecting types	2217:2231	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	12	54	theme	thyroglobulin	1879:1891	arg1	protein					1893:1899	human thyroid thyroglobulin protein	1865:1899	human thyroid thyroglobulin protein	1865:1899	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	1	55	theme	many	162:165	arg1	sites					181:185	many glycosylation sites	162:185	many glycosylation sites	162:185	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	4	56	theme	core	830:833	arg1	structure					835:843	their N-glycan core structure	815:843	their N-glycan core structure	815:843	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	4	57	theme	hybrid	633:638	arg1	species					654:660	The sulfated complex and hybrid type N-glycan species	608:660	species	654:660	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	7	58	theme	complex	1170:1176	arg1	glycans					1194:1200	complex and hybrid type glycans	1170:1200	glycans	1194:1200	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	11	59	theme	human	1673:1677	arg1	thyroglobulin					1679:1691	human thyroglobulin	1673:1691	human thyroglobulin	1673:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	2	60	theme	site-specific	347:359	arg1	distribution					361:372	the site-specific distribution	343:372	the site-specific distribution of glycan structures	343:393	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	15	61	gly	glycosylation	2267:2279	arg2	sites					2281:2285	all determined glycosylation sites	2252:2285	all determined glycosylation sites	2252:2285	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	9	62	theme	Tg	1473:1474	arg1	protein					1476:1482	human Tg protein	1467:1482	human Tg protein	1467:1482	It is expected that the results obtained from this study will contribute to functional studies to be conducted on human Tg protein.
35995381	12	63	theme	human	1865:1869	arg1	protein					1893:1899	human thyroid thyroglobulin protein	1865:1899	human thyroid thyroglobulin protein	1865:1899	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	11	64	theme	function	1742:1749	arg1	understanding					1721:1733	our understanding	1717:1733	our understanding of the function of its N-glycans	1717:1766	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	2	65	theme	critical	283:290	arg1	roles					292:296	critical roles	283:296	critical roles	283:296	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	5	66	theme	multiple	877:884	arg1	enzymes					886:892	multiple enzymes	877:892	multiple enzymes	877:892	The human Tg was digested with multiple enzymes by applying both in-gel and in-solution protocols to enhance site-specific glycosylation analysis.
35995381	7	67	theme	type	1189:1192	arg1	glycans					1194:1200	complex and hybrid type glycans	1170:1200	glycans	1194:1200	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	8	68	contain	containing	1309:1318	arg1	sites					1303:1307	glycosylation sites	1289:1307	glycosylation sites containing complex and hybrid type glycans	1289:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	8	68	contain	containing	1309:1318	arg2	glycans					1344:1350	complex and hybrid type glycans	1320:1350	glycans	1344:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	12	69	gly	N-glycosylation	1837:1851	arg1	protein					1893:1899	human thyroid thyroglobulin protein	1865:1899	human thyroid thyroglobulin protein	1865:1899	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	1	70	contain	has	158:160	arg2	sites					181:185	many glycosylation sites	162:185	many glycosylation sites	162:185	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	1	70	contain	has	158:160	arg1	Tg					147:148	Tg	147:148	Tg	147:148	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	1	70	contain	has	158:160	arg1	thyroglobulin					132:144	Human thyroglobulin	126:144	Human thyroglobulin (Tg)	126:149	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	1	70	contain	has	158:160	arg1	protein					204:210	an essential protein	191:210	an essential protein produced by the human thyroid glands	191:247	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	14	71	theme	N-glycan	2034:2041	arg1	patterns					2043:2050	N-glycan patterns	2034:2050	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122	2034:2093	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	8	72	theme	glycoform	1225:1233	arg1	structures					1235:1244	sulfated glycoform structures	1216:1244	sulfated glycoform structures	1216:1244	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	7	73	theme	high-mannose	1115:1126	arg1	glycans					1133:1139	high-mannose type glycans	1115:1139	high-mannose type glycans	1115:1139	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	2	74	theme	cellular	305:312	arg1	events					314:319	the cellular events	301:319	the cellular events of the Thyroid gland	301:340	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	15	75	theme	glycosylation	2267:2279	arg1	sites					2281:2285	all determined glycosylation sites	2252:2285	all determined glycosylation sites	2252:2285	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	4	76	theme	N-glycan	645:652	arg1	species					654:660	The sulfated complex and hybrid type N-glycan species	608:660	species	654:660	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	8	77	gly	glycosylation	1289:1301	arg2	sites					1303:1307	glycosylation sites	1289:1307	glycosylation sites containing complex and hybrid type glycans	1289:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	14	78	dep	sites	2060:2064	arg1	Asn110					2066:2071	Asn110	2066:2071	Asn110	2066:2071	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	14	78	dep	sites	2060:2064	arg1	sites					2060:2064	the sites Asn110, Asn1869, and Asn2122	2056:2093	the sites Asn110, Asn1869, and Asn2122	2056:2093	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	14	78	dep	sites	2060:2064	arg1	Asn1869					2074:2080	Asn1869	2074:2080	Asn1869	2074:2080	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	14	78	dep	sites	2060:2064	arg1	Asn2122					2087:2093	Asn2122	2087:2093	Asn2122	2087:2093	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	8	79	theme	hybrid	1332:1337	arg1	glycans					1344:1350	complex and hybrid type glycans	1320:1350	glycans	1344:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	7	80	theme	6 N-glycosylation	1078:1094	arg1	sites					1096:1100	6 N-glycosylation sites	1078:1100	6 N-glycosylation sites	1078:1100	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	8	81	theme	glycopeptide	1267:1278	arg1	level					1280:1284	the glycopeptide level	1263:1284	the glycopeptide level	1263:1284	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	7	82	gly	6 N-glycosylation	1078:1094	arg2	sites					1096:1100	6 N-glycosylation sites	1078:1100	6 N-glycosylation sites	1078:1100	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	4	83	contain	carried	789:795	arg2	residue					804:810	fucose residue	797:810	fucose residue	797:810	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	4	83	contain	carried	789:795	arg3	structure					835:843	their N-glycan core structure	815:843	their N-glycan core structure	815:843	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	4	83	contain	carried	789:795	arg1	N-glycans					779:787	all fucosylated N-glycans	763:787	all fucosylated N-glycans	763:787	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	2	84	theme	Thyroid	328:334	arg1	gland					336:340	the Thyroid gland	324:340	the Thyroid gland	324:340	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	0	85	theme	spectrometry-based	78:95	arg1	strategies					114:123	mass spectrometry-based Glyco-analytical strategies	73:123	mass spectrometry-based Glyco-analytical strategies	73:123	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	2	86	theme	human	259:263	arg1	N-glycans					268:276	human Tg N-glycans	259:276	human Tg N-glycans	259:276	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	1	87	theme	glycosylation	167:179	arg1	sites					181:185	many glycosylation sites	162:185	many glycosylation sites	162:185	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	4	88	theme	Tg	707:708	arg1	samples					710:716	the human Tg samples	697:716	the human Tg samples	697:716	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	13	89	theme	glyco-analytical	2005:2020	arg1	strategies					2022:2031	comprehensive glyco-analytical strategies	1991:2031	comprehensive glyco-analytical strategies	1991:2031	For instance, as highlighted here, sulfated N-glycan structures were characterized using comprehensive glyco-analytical strategies.
35995381	15	90	theme	N-glycan	2164:2171	arg1	structures					2173:2182	N-glycan structures	2164:2182	N-glycan structures containing core-fucosylation and bisecting types	2164:2231	In addition, N-glycan structures containing core-fucosylation and bisecting types were confirmed for all determined glycosylation sites.
35995381	6	91	theme	20 N-glycosylation	1013:1030	arg1	sites					1032:1036	20 N-glycosylation sites	1013:1036	20 N-glycosylation sites	1013:1036	In total, 17 out of 20 N-glycosylation sites were characterized.
35995381	13	92	theme	N-glycan	1946:1953	arg1	structures					1955:1964	sulfated N-glycan structures	1937:1964	sulfated N-glycan structures	1937:1964	For instance, as highlighted here, sulfated N-glycan structures were characterized using comprehensive glyco-analytical strategies.
35995381	8	93	theme	complex	1320:1326	arg1	glycans					1344:1350	complex and hybrid type glycans	1320:1350	glycans	1344:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	10	94	theme	human	1523:1527	arg1	thyroglobulin					1529:1541	human thyroglobulin	1523:1541	human thyroglobulin	1523:1541	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
35995381	4	95	theme	fucose	797:802	arg1	residue					804:810	fucose residue	797:810	fucose residue	797:810	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	0	96	theme	N-glycosylation	14:28	arg1	analysis					30:37	Site-specific N-glycosylation analysis	0:37	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies	0:123	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	5	97	theme	glycosylation	969:981	arg1	analysis					983:990	site-specific glycosylation analysis	955:990	site-specific glycosylation analysis	955:990	The human Tg was digested with multiple enzymes by applying both in-gel and in-solution protocols to enhance site-specific glycosylation analysis.
35995381	2	98	theme	glycan	377:382	arg1	structures					384:393	glycan structures	377:393	glycan structures	377:393	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	10	99	theme	hormone	1560:1566	arg1	synthesis					1568:1576	thyroid hormone synthesis	1552:1576	thyroid hormone synthesis	1552:1576	BIOLOGICAL SIGNIFICANCE: N-glycans of human thyroglobulin modulate thyroid hormone synthesis both in vivo and in vitro.
35995381	11	100	theme	N-glycans	1758:1766	arg1	function					1742:1749	the function	1738:1749	the function of its N-glycans	1738:1766	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	3	101	gly	N-glycosylation	464:478	arg2	sites					480:484	human Tg N-glycosylation sites	455:484	human Tg N-glycosylation sites	455:484	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	3	102	theme	Tg	461:462	arg1	sites					480:484	human Tg N-glycosylation sites	455:484	human Tg N-glycosylation sites	455:484	This study aimed to profile human Tg N-glycosylation sites and their glycan contents by using high-throughput glyco-analytical strategies, including glycopeptide and glycan levels.
35995381	0	103	theme	thyroid	48:54	arg1	thyroglobulin					56:68	human thyroid thyroglobulin	42:68	human thyroid thyroglobulin	42:68	Site-specific N-glycosylation analysis of human thyroid thyroglobulin by mass spectrometry-based Glyco-analytical strategies.
35995381	11	104	theme	N-glycosylation	1648:1662	arg1	sites					1664:1668	the N-glycosylation sites	1644:1668	the N-glycosylation sites of human thyroglobulin	1644:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	11	104	theme	N-glycosylation	1648:1662	arg1	thyroglobulin					1679:1691	human thyroglobulin	1673:1691	human thyroglobulin	1673:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	7	105	theme	hybrid	1182:1187	arg1	glycans					1194:1200	complex and hybrid type glycans	1170:1200	glycans	1194:1200	It was noticed that 6 N-glycosylation sites contain only high-mannose type glycans, while other regions include complex and hybrid type glycans.
35995381	8	106	located	detected	1251:1258	arg1	sites					1303:1307	glycosylation sites	1289:1307	glycosylation sites containing complex and hybrid type glycans	1289:1350	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	8	106	located	detected	1251:1258	arg1	addition					1206:1213	addition	1206:1213	addition	1206:1213	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	8	106	located	detected	1251:1258	arg2	structures					1235:1244	sulfated glycoform structures	1216:1244	sulfated glycoform structures	1216:1244	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	8	106	located	detected	1251:1258	arg1	level					1280:1284	the glycopeptide level	1263:1284	the glycopeptide level	1263:1284	In addition, sulfated glycoform structures were detected at the glycopeptide level in glycosylation sites containing complex and hybrid type glycans.
35995381	2	107	theme	gland	336:340	arg1	events					314:319	the cellular events	301:319	the cellular events of the Thyroid gland	301:340	Although human Tg N-glycans play critical roles in the cellular events of the Thyroid gland, the site-specific distribution of glycan structures has not been studied in detail.
35995381	9	108	theme	functional	1429:1438	arg1	studies					1440:1446	functional studies	1429:1446	functional studies	1429:1446	It is expected that the results obtained from this study will contribute to functional studies to be conducted on human Tg protein.
35995381	14	109	theme	current	2137:2143	arg1	work					2145:2148	this current work	2132:2148	this current work	2132:2148	N-glycan patterns for the sites Asn110, Asn1869, and Asn2122 were described for the first time in this current work.
35995381	11	110	theme	thyroglobulin	1679:1691	arg1	sites					1664:1668	the N-glycosylation sites	1644:1668	the N-glycosylation sites of human thyroglobulin	1644:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	11	110	theme	thyroglobulin	1679:1691	arg1	thyroglobulin					1679:1691	human thyroglobulin	1673:1691	human thyroglobulin	1673:1691	Therefore, a comprehensive analysis of the N-glycosylation sites of human thyroglobulin is essential to improve our understanding of the function of its N-glycans.
35995381	1	111	theme	thyroid	234:240	arg1	glands					242:247	the human thyroid glands	224:247	the human thyroid glands	224:247	Human thyroglobulin (Tg), which has many glycosylation sites, is an essential protein produced by the human thyroid glands.
35995381	12	112	theme	thyroid	1871:1877	arg1	protein					1893:1899	human thyroid thyroglobulin protein	1865:1899	human thyroid thyroglobulin protein	1865:1899	The present research significantly expanded the knowledge regarding N-glycosylation profiles of human thyroid thyroglobulin protein.
35995381	4	113	theme	type	640:643	arg1	species					654:660	The sulfated complex and hybrid type N-glycan species	608:660	species	654:660	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
35995381	4	114	theme	N-glycan	821:828	arg1	structure					835:843	their N-glycan core structure	815:843	their N-glycan core structure	815:843	The sulfated complex and hybrid type N-glycan species were determined by the analysis of the human Tg samples with HPLC-HILIC-FLD-MS/MS. It was found that all fucosylated N-glycans carried fucose residue on their N-glycan core structure.
34611874	7	0	theme	UHPLC	1157:1161	arg1	separation					1163:1172	the UHPLC separation	1153:1172	the UHPLC separation of plasma N-glycans	1153:1192	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	1	1	theme	biomarkers	150:159	arg1	serum					122:126	serum	122:126	serum	122:126	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	1	theme	biomarkers	150:159	arg1	plasma					111:116	Human blood plasma	99:116	Human blood plasma	99:116	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	1	theme	biomarkers	150:159	arg1	source					140:145	a source	138:145	a source of biomarkers for the indication and progression of many diseases for a few decades now	138:233	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	7	2	theme	online	1329:1334	arg1	spectrometry					1341:1352	online mass spectrometry	1329:1352	online mass spectrometry for glycan identification	1329:1378	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	3	3	with	home	477:480	arg1	skills					510:515	no specialist clinical skills	487:515	no specialist clinical skills required to obtain good quality samples for pathology lab analysis	487:582	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	5	4	theme	early	859:863	arg1	stage					865:869	an early stage	856:869	an early stage	856:869	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	5	5	theme	increasing	688:697	arg1	interest					699:706	increasing interest	688:706	increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage	688:869	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	6	6	dep	identify	947:954	arg1	need					1080:1083	need	1080:1083	need to be robust	1080:1096	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	4	7	gly	glycosylated	633:644	arg1	Many					585:588	Many	585:588	Many	585:588	Many of the proteins that constitute plasma are glycosylated with both N- and O-type glycans.
34611874	4	7	gly	glycosylated	633:644	arg1	proteins					597:604	the proteins	593:604	the proteins that constitute plasma	593:627	Many of the proteins that constitute plasma are glycosylated with both N- and O-type glycans.
34611874	5	8	from	stage	865:869	arg1	indicative					804:813	indicative	804:813	indicative	804:813	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	2	9	theme	excellent	266:274	arg1	source					276:281	an excellent source material	263:290	an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status	263:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	2	9	theme	excellent	266:274	arg1	plasma					248:253	Human blood plasma	236:253	Human blood plasma	236:253	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	6	10	theme	sufficient	1003:1012	arg1	specificity					1014:1024	sufficient specificity	1003:1024	sufficient specificity	1003:1024	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	3	11	theme	good	536:539	arg1	samples					549:555	good quality samples	536:555	good quality samples	536:555	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	4	12	theme	O-type	663:668	arg1	glycans					670:676	O-type glycans	663:676	O-type glycans	663:676	Many of the proteins that constitute plasma are glycosylated with both N- and O-type glycans.
34611874	5	13	theme	disease	818:824	arg1	indicative					804:813	indicative	804:813	indicative	804:813	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	7	14	theme	analytical	1131:1140	arg1	method					1142:1147	an analytical method	1128:1147	an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification	1128:1378	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	6	15	theme	required	1054:1061	arg1	tools					1074:1078	the required analytical tools	1050:1078	the required analytical tools	1050:1078	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	6	15	theme	required	1054:1061	arg1	robust					1091:1096	robust	1091:1096	robust	1091:1096	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	3	16	theme	specialist	490:499	arg1	skills					510:515	no specialist clinical skills	487:515	no specialist clinical skills required to obtain good quality samples for pathology lab analysis	487:582	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	7	17	theme	stoichiometric	1271:1284	arg1	analysis					1286:1293	stoichiometric analysis	1271:1293	stoichiometric analysis of relative glycan abundance	1271:1322	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	2	18	theme	detectable	367:376	arg1	biomarkers					356:365	biomarkers	356:365	biomarkers detectable for the assessment of health status	356:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	6	19	dep	quality	876:882	arg1	The					872:874	The	872:874	The	872:874	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	3	20	theme	clinical	501:508	arg1	skills					510:515	no specialist clinical skills	487:515	no specialist clinical skills required to obtain good quality samples for pathology lab analysis	487:582	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	2	21	theme	biomarkers	356:365	arg1	multitude					343:351	a multitude	341:351	a multitude of biomarkers detectable for the assessment of health status	341:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	5	22	theme	glycan	779:784	arg1	features					786:793	glycan features	779:793	glycan features	779:793	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	5	23	theme	scientific	715:724	arg1	community					726:734	the scientific community	711:734	the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage	711:869	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	1	24	theme	Human	99:103	arg1	serum					122:126	serum	122:126	serum	122:126	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	24	theme	Human	99:103	arg1	plasma					111:116	Human blood plasma	99:116	Human blood plasma	99:116	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	24	theme	Human	99:103	arg1	source					140:145	a source	138:145	a source of biomarkers for the indication and progression of many diseases for a few decades now	138:233	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	5	25	theme	particular	834:843	arg1	disease					845:851	particular disease	834:851	particular disease	834:851	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	0	26	theme	N-glycan	0:7	arg1	Characterization					9:24	N-glycan Characterization	0:24	N-glycan Characterization by Liquid Chromatography	0:49	N-glycan Characterization by Liquid Chromatography Coupled with Fluorimetry and Mass Spectrometry.
34611874	3	27	from	use	466:468	arg1	home					477:480	the home	473:480	the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis	473:582	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	3	28	theme	quality	541:547	arg1	samples					549:555	good quality samples	536:555	good quality samples	536:555	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	8	29	theme	example	1424:1430	arg1	technique					1432:1440	example technique	1424:1440	example technique	1424:1440	Exoglycosidase digestions were employed as example technique to aid and enable structure identification.
34611874	8	29	theme	example	1424:1430	arg1	digestions					1396:1405	Exoglycosidase digestions	1381:1405	Exoglycosidase digestions	1381:1405	Exoglycosidase digestions were employed as example technique to aid and enable structure identification.
34611874	0	30	theme	Liquid	29:34	arg1	Chromatography					36:49	Liquid Chromatography	29:49	Liquid Chromatography	29:49	N-glycan Characterization by Liquid Chromatography Coupled with Fluorimetry and Mass Spectrometry.
34611874	7	31	theme	glycan	1307:1312	arg1	abundance					1314:1322	relative glycan abundance	1298:1322	relative glycan abundance	1298:1322	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	7	32	theme	mass	1336:1339	arg1	spectrometry					1341:1352	online mass spectrometry	1329:1352	online mass spectrometry for glycan identification	1329:1378	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	2	33	theme	material	283:290	arg1	source					276:281	an excellent source material	263:290	an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status	263:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	2	33	theme	material	283:290	arg1	plasma					248:253	Human blood plasma	236:253	Human blood plasma	236:253	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	4	34	theme	proteins	597:604	arg1	Many					585:588	Many	585:588	Many	585:588	Many of the proteins that constitute plasma are glycosylated with both N- and O-type glycans.
34611874	4	34	theme	proteins	597:604	arg1	proteins					597:604	the proteins	593:604	the proteins that constitute plasma	593:627	Many of the proteins that constitute plasma are glycosylated with both N- and O-type glycans.
34611874	1	35	theme	blood	105:109	arg1	serum					122:126	serum	122:126	serum	122:126	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	35	theme	blood	105:109	arg1	plasma					111:116	Human blood plasma	99:116	Human blood plasma	99:116	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	35	theme	blood	105:109	arg1	source					140:145	a source	138:145	a source of biomarkers for the indication and progression of many diseases for a few decades now	138:233	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	36	theme	many	199:202	arg1	diseases					204:211	many diseases	199:211	many diseases	199:211	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	5	37	theme	potential	748:756	arg1	biomarkers					765:774	potential glycan biomarkers	748:774	potential glycan biomarkers	748:774	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	6	38	theme	data	923:926	arg1	reproducibility					888:902	reproducibility	888:902	reproducibility	888:902	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	6	38	theme	data	923:926	arg1	quality					876:882	quality	876:882	quality	876:882	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	3	39	theme	sampling	421:428	arg1	kits					430:433	Blood sampling kits	415:433	Blood sampling kits	415:433	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	3	40	theme	pathology	561:569	arg1	analysis					575:582	pathology lab analysis	561:582	pathology lab analysis	561:582	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	1	41	theme	diseases	204:211	arg1	progression					184:194	progression	184:194	progression	184:194	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	1	41	theme	diseases	204:211	arg1	indication					169:178	indication	169:178	indication	169:178	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	5	42	theme	glycan	758:763	arg1	biomarkers					765:774	potential glycan biomarkers	748:774	potential glycan biomarkers	748:774	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	6	43	theme	analysis	914:921	arg1	data					923:926	glycan analysis data	907:926	glycan analysis data	907:926	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	3	44	theme	lab	571:573	arg1	analysis					575:582	pathology lab analysis	561:582	pathology lab analysis	561:582	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	6	45	theme	glycan	907:912	arg1	data					923:926	glycan analysis data	907:926	glycan analysis data	907:926	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	5	46	from	interest	699:706	arg1	community					726:734	the scientific community	711:734	the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage	711:869	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	6	47	with	biomarkers	987:996	arg1	specificity					1014:1024	sufficient specificity	1003:1024	sufficient specificity	1003:1024	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	6	47	with	biomarkers	987:996	arg1	sensitivity					1030:1040	sensitivity	1030:1040	sensitivity	1030:1040	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	7	48	theme	terminus	1230:1237	arg1	labeling					1251:1258	both glycan reducing terminus fluorophore labeling	1209:1258	both glycan reducing terminus fluorophore labeling	1209:1258	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	2	49	theme	status	407:412	arg1	assessment					386:395	the assessment	382:395	the assessment of health status	382:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	8	50	theme	Exoglycosidase	1381:1394	arg1	technique					1432:1440	example technique	1424:1440	example technique	1424:1440	Exoglycosidase digestions were employed as example technique to aid and enable structure identification.
34611874	8	50	theme	Exoglycosidase	1381:1394	arg1	digestions					1396:1405	Exoglycosidase digestions	1381:1405	Exoglycosidase digestions	1381:1405	Exoglycosidase digestions were employed as example technique to aid and enable structure identification.
34611874	1	51	dep	indication	169:178	arg1	the					165:167	the	165:167	the	165:167	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	5	52	from	indicative	804:813	arg1	disease					845:851	particular disease	834:851	particular disease	834:851	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	7	53	theme	fluorophore	1239:1249	arg1	labeling					1251:1258	both glycan reducing terminus fluorophore labeling	1209:1258	both glycan reducing terminus fluorophore labeling	1209:1258	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	7	54	theme	abundance	1314:1322	arg1	analysis					1286:1293	stoichiometric analysis	1271:1293	stoichiometric analysis of relative glycan abundance	1271:1322	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	6	55	theme	blood	981:985	arg1	biomarkers					987:996	glycan-based blood biomarkers	968:996	glycan-based blood biomarkers with sufficient specificity and sensitivity	968:1040	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	7	56	theme	glycan	1214:1219	arg1	labeling					1251:1258	both glycan reducing terminus fluorophore labeling	1209:1258	both glycan reducing terminus fluorophore labeling	1209:1258	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	7	57	theme	glycan	1358:1363	arg1	identification					1365:1378	glycan identification	1358:1378	glycan identification	1358:1378	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	2	58	theme	blood	242:246	arg1	source					276:281	an excellent source material	263:290	an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status	263:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	2	58	theme	blood	242:246	arg1	plasma					248:253	Human blood plasma	236:253	Human blood plasma	236:253	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	7	59	theme	reducing	1221:1228	arg1	labeling					1251:1258	both glycan reducing terminus fluorophore labeling	1209:1258	both glycan reducing terminus fluorophore labeling	1209:1258	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	7	60	theme	relative	1298:1305	arg1	abundance					1314:1322	relative glycan abundance	1298:1322	relative glycan abundance	1298:1322	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	1	61	theme	few	219:221	arg1	decades					223:229	a few decades	217:229	a few decades now	217:233	Human blood plasma and serum have been a source of biomarkers for the indication and progression of many diseases for a few decades now.
34611874	0	62	theme	Mass	80:83	arg1	Spectrometry					85:96	Mass Spectrometry	80:96	Mass Spectrometry	80:96	N-glycan Characterization by Liquid Chromatography Coupled with Fluorimetry and Mass Spectrometry.
34611874	8	63	theme	structure	1460:1468	arg1	identification					1470:1483	structure identification	1460:1483	structure identification	1460:1483	Exoglycosidase digestions were employed as example technique to aid and enable structure identification.
34611874	2	64	theme	Human	236:240	arg1	source					276:281	an excellent source material	263:290	an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status	263:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	2	64	theme	Human	236:240	arg1	plasma					248:253	Human blood plasma	236:253	Human blood plasma	236:253	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	5	65	from	disease	845:851	arg1	indicative					804:813	indicative	804:813	indicative	804:813	There is increasing interest in the scientific community to identify potential glycan biomarkers or glycan features that are indicative of disease, and in particular disease at an early stage.
34611874	3	66	theme	Blood	415:419	arg1	kits					430:433	Blood sampling kits	415:433	Blood sampling kits	415:433	Blood sampling kits are increasingly available for use in the home with no specialist clinical skills required to obtain good quality samples for pathology lab analysis.
34611874	6	67	theme	glycan-based	968:979	arg1	biomarkers					987:996	glycan-based blood biomarkers	968:996	glycan-based blood biomarkers with sufficient specificity and sensitivity	968:1040	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	7	68	theme	plasma	1177:1182	arg1	N-glycans					1184:1192	plasma N-glycans	1177:1192	plasma N-glycans	1177:1192	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
34611874	2	69	theme	health	400:405	arg1	status					407:412	health status	400:412	health status	400:412	Human blood plasma is also an excellent source material to enable patients to monitor their health, with a multitude of biomarkers detectable for the assessment of health status.
34611874	6	70	theme	analytical	1063:1072	arg1	tools					1074:1078	the required analytical tools	1050:1078	the required analytical tools	1050:1078	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	6	70	theme	analytical	1063:1072	arg1	robust					1091:1096	robust	1091:1096	robust	1091:1096	The quality and reproducibility of glycan analysis data is key in order to identify and utilise glycan-based blood biomarkers with sufficient specificity and sensitivity; hence, the required analytical tools need to be robust.
34611874	7	71	theme	N-glycans	1184:1192	arg1	separation					1163:1172	the UHPLC separation	1153:1172	the UHPLC separation of plasma N-glycans	1153:1192	In this chapter, we describe an analytical method for the UHPLC separation of plasma N-glycans which utilizes both glycan reducing terminus fluorophore labeling, to ensure stoichiometric analysis of relative glycan abundance, and online mass spectrometry for glycan identification.
36241003	5	0	dep	nine	676:679	arg1	to					673:674	to	673:674	to	673:674	We identified 54 O-glycans, consisting of up to nine monosaccharide residues.
36241003	9	1	theme	skin	1311:1314	arg1	mucins					1316:1321	skin mucins	1311:1321	skin mucins	1311:1321	Rainbow trout mucins from gill and intestine bound A. salmonicida and A. hydrophila more efficiently than skin mucins.
36241003	10	2	theme	bacterial	1396:1404	arg1	adhesion					1406:1413	bacterial adhesion	1396:1413	bacterial adhesion	1396:1413	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	6	3	theme	Skin	706:709	arg1	glycans					711:717	Skin glycans	706:717	Skin glycans	706:717	Skin glycans were most acidic, shortest on average and consisted mainly of NeuAcα2-6GalNAc.
36241003	1	4	theme	mucus	155:159	arg1	surfaces					192:199	the mucus covering internal and external surfaces	151:199	the mucus covering internal and external surfaces of fish	151:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	4	5	theme	mucin	562:566	arg1	O-glycosylation					568:582	distal intestinal mucin O-glycosylation	544:582	distal intestinal mucin O-glycosylation	544:582	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	0	6	theme	epithelial	80:89	arg1	sites					91:95	rainbow trout epithelial sites	66:95	rainbow trout epithelial sites	66:95	Mucin O-glycosylation and pathogen binding ability differ between rainbow trout epithelial sites.
36241003	1	7	theme	covering	161:168	arg1	surfaces					192:199	the mucus covering internal and external surfaces	151:199	the mucus covering internal and external surfaces of fish	151:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	4	8	theme	intestinal	551:560	arg1	O-glycosylation					568:582	distal intestinal mucin O-glycosylation	544:582	distal intestinal mucin O-glycosylation	544:582	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	8	9	theme	average	1124:1130	arg1	size					1132:1135	average size	1124:1135	average size	1124:1135	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	3	10	from	productivity	412:423	arg1	aquaculture					440:450	aquaculture	440:450	aquaculture	440:450	Knowledge on this mucosal defense system can enable alternative treatments to diseases posing a threat to productivity and welfare in aquaculture.
36241003	3	11	theme	alternative	358:368	arg1	treatments					370:379	alternative treatments	358:379	alternative treatments	358:379	Knowledge on this mucosal defense system can enable alternative treatments to diseases posing a threat to productivity and welfare in aquaculture.
36241003	5	12	theme	monosaccharide	681:694	arg1	residues					696:703	up to nine monosaccharide residues	670:703	up to nine monosaccharide residues	670:703	We identified 54 O-glycans, consisting of up to nine monosaccharide residues.
36241003	10	13	theme	small	1376:1380	arg1	glycans					1382:1388	small glycans	1376:1388	small glycans	1376:1388	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	7	14	theme	distal	917:922	arg1	intestine					924:932	distal intestine	917:932	distal intestine	917:932	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	10	15	theme	fish	1422:1425	arg1	surface					1427:1433	the fish surface	1418:1433	the fish surface	1418:1433	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	4	16	theme	teleost	608:614	arg1	O-glycomes					616:625	known teleost O-glycomes	602:625	known teleost O-glycomes	602:625	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	1	17	theme	internal	170:177	arg1	surfaces					192:199	the mucus covering internal and external surfaces	151:199	the mucus covering internal and external surfaces of fish	151:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	10	18	with	mucins	1364:1369	arg1	glycans					1382:1388	small glycans	1376:1388	small glycans	1376:1388	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	8	19	from	trends	1091:1096	arg1	distribution					1110:1121	the core distribution	1101:1121	the core distribution	1101:1121	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	8	19	from	trends	1091:1096	arg1	size					1132:1135	average size	1124:1135	average size	1124:1135	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	8	19	from	trends	1091:1096	arg1	acidity					1149:1155	overall acidity	1141:1155	overall acidity	1141:1155	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	8	20	theme	overall	1141:1147	arg1	acidity					1149:1155	overall acidity	1141:1155	overall acidity	1141:1155	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	4	21	theme	rainbow	479:485	arg1	trout					487:491	the rainbow trout	475:491	the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation	475:582	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	4	21	theme	rainbow	479:485	arg1	mykiss					507:512	Oncorhynchus mykiss	494:512	Oncorhynchus mykiss	494:512	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	3	22	theme	mucosal	324:330	arg1	system					340:345	this mucosal defense system	319:345	this mucosal defense system	319:345	Knowledge on this mucosal defense system can enable alternative treatments to diseases posing a threat to productivity and welfare in aquaculture.
36241003	1	23	theme	external	183:190	arg1	surfaces					192:199	the mucus covering internal and external surfaces	151:199	the mucus covering internal and external surfaces of fish	151:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	0	24	theme	Mucin	0:4	arg1	O-glycosylation					6:20	Mucin O-glycosylation	0:20	Mucin O-glycosylation	0:20	Mucin O-glycosylation and pathogen binding ability differ between rainbow trout epithelial sites.
36241003	4	25	dep	trout	487:491	arg1	O-glycosylation					568:582	distal intestinal mucin O-glycosylation	544:582	distal intestinal mucin O-glycosylation	544:582	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	4	25	dep	trout	487:491	arg1	ceca					535:538	pyloric ceca	527:538	pyloric ceca	527:538	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	4	25	dep	trout	487:491	arg1	gill					515:518	gill	515:518	gill	515:518	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	4	25	dep	trout	487:491	arg1	skin					521:524	skin	521:524	skin	521:524	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	10	26	theme	complex	1447:1453	arg1	glycans					1472:1478	the complex intestinal mucin glycans	1443:1478	the complex intestinal mucin glycans	1443:1478	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	10	27	theme	skin	1359:1362	arg1	mucins					1364:1369	skin mucins	1359:1369	skin mucins with small glycans	1359:1388	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	0	28	theme	pathogen	26:33	arg1	ability					43:49	pathogen binding ability	26:49	pathogen binding ability	26:49	Mucin O-glycosylation and pathogen binding ability differ between rainbow trout epithelial sites.
36241003	4	29	theme	pyloric	527:533	arg1	ceca					535:538	pyloric ceca	527:538	pyloric ceca	527:538	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	8	30	theme	Atlantic	1057:1064	arg1	salmon					1066:1071	Atlantic salmon	1057:1071	Atlantic salmon	1057:1071	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	7	31	theme	pyloric	900:906	arg1	ceca					908:911	pyloric ceca	900:911	pyloric ceca	900:911	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	7	32	theme	core	967:970	arg1	glycans					974:980	core 5 glycans	967:980	core 5 glycans	967:980	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	4	33	theme	distal	544:549	arg1	O-glycosylation					568:582	distal intestinal mucin O-glycosylation	544:582	distal intestinal mucin O-glycosylation	544:582	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	1	34	gly	glycosylated	116:127	arg1	Mucins					98:103	Mucins	98:103	Mucins	98:103	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	1	34	gly	glycosylated	116:127	arg1	proteins					129:136	highly glycosylated proteins	109:136	highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish	109:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	9	35	theme	trout	1213:1217	arg1	mucins					1219:1224	Rainbow trout mucins	1205:1224	Rainbow trout mucins from gill and intestine	1205:1248	Rainbow trout mucins from gill and intestine bound A. salmonicida and A. hydrophila more efficiently than skin mucins.
36241003	1	36	theme	fish	204:207	arg1	surfaces					192:199	the mucus covering internal and external surfaces	151:199	the mucus covering internal and external surfaces of fish	151:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	2	37	theme	quorum	244:249	arg1	sensing					251:257	pathogen quorum sensing	235:257	pathogen quorum sensing	235:257	Mucin O-glycans regulate pathogen quorum sensing, growth, virulence and attachment to the host.
36241003	0	38	theme	binding	35:41	arg1	ability					43:49	pathogen binding ability	26:49	pathogen binding ability	26:49	Mucin O-glycosylation and pathogen binding ability differ between rainbow trout epithelial sites.
36241003	8	39	theme	core	1105:1108	arg1	distribution					1110:1121	the core distribution	1101:1121	the core distribution	1101:1121	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	2	40	theme	pathogen	235:242	arg1	sensing					251:257	pathogen quorum sensing	235:257	pathogen quorum sensing	235:257	Mucin O-glycans regulate pathogen quorum sensing, growth, virulence and attachment to the host.
36241003	9	41	from	intestine	1240:1248	arg1	mucins					1219:1224	Rainbow trout mucins	1205:1224	Rainbow trout mucins from gill and intestine	1205:1248	Rainbow trout mucins from gill and intestine bound A. salmonicida and A. hydrophila more efficiently than skin mucins.
36241003	10	42	theme	epithelial	1528:1537	arg1	surface					1539:1545	the epithelial surface	1524:1545	the epithelial surface	1524:1545	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	0	43	theme	rainbow	66:72	arg1	trout					74:78	rainbow trout	66:78	rainbow trout epithelial sites	66:95	Mucin O-glycosylation and pathogen binding ability differ between rainbow trout epithelial sites.
36241003	7	44	from	gills	815:819	arg1	Glycans					798:804	Glycans	798:804	Glycans from the gills	798:819	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	1	45	theme	glycosylated	116:127	arg1	Mucins					98:103	Mucins	98:103	Mucins	98:103	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	1	45	theme	glycosylated	116:127	arg1	proteins					129:136	highly glycosylated proteins	109:136	highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish	109:207	Mucins are highly glycosylated proteins that make up the mucus covering internal and external surfaces of fish.
36241003	10	46	with	line	1335:1338	arg1	model					1347:1351	a model	1345:1351	a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface	1345:1545	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	8	47	theme	Arctic	1077:1082	arg1	charr					1084:1088	Arctic charr	1077:1088	Arctic charr	1077:1088	When compared to Atlantic salmon and Arctic charr, trends on the core distribution, average size and overall acidity remained similar, although the epitopes varied.
36241003	2	48	theme	Mucin	210:214	arg1	O-glycans					216:224	Mucin O-glycans	210:224	Mucin O-glycans	210:224	Mucin O-glycans regulate pathogen quorum sensing, growth, virulence and attachment to the host.
36241003	9	49	theme	Rainbow	1205:1211	arg1	trout					1213:1217	Rainbow trout	1205:1217	Rainbow trout mucins from gill and intestine	1205:1248	Rainbow trout mucins from gill and intestine bound A. salmonicida and A. hydrophila more efficiently than skin mucins.
36241003	9	50	dep	A.	1275:1276	arg1	hydrophila					1278:1287	A. hydrophila	1275:1287	A. hydrophila	1275:1287	Rainbow trout mucins from gill and intestine bound A. salmonicida and A. hydrophila more efficiently than skin mucins.
36241003	10	51	theme	mucin	1466:1470	arg1	glycans					1472:1478	the complex intestinal mucin glycans	1443:1478	the complex intestinal mucin glycans	1443:1478	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	7	52	with	acidic	831:836	arg1	core					857:860	predominantly core 1 and 2 glycans	843:876	core	857:860	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	7	52	with	acidic	831:836	arg1	glycans					870:876	predominantly core 1 and 2 glycans	843:876	glycans	870:876	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	7	53	theme	glycans	974:980	arg1	number					957:962	an increased number	944:962	an increased number	944:962	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	7	54	from	ceca	908:911	arg1	glycans					887:893	glycans	887:893	glycans from pyloric ceca and distal intestine	887:932	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	10	55	theme	intestinal	1455:1464	arg1	glycans					1472:1478	the complex intestinal mucin glycans	1443:1478	the complex intestinal mucin glycans	1443:1478	This is in line with a model where skin mucins with small glycans limit bacterial adhesion to the fish surface whereas the complex intestinal mucin glycans aid in trapping and removing pathogens from the epithelial surface.
36241003	9	56	from	gill	1231:1234	arg1	mucins					1219:1224	Rainbow trout mucins	1205:1224	Rainbow trout mucins from gill and intestine	1205:1248	Rainbow trout mucins from gill and intestine bound A. salmonicida and A. hydrophila more efficiently than skin mucins.
36241003	0	57	theme	trout	74:78	arg1	sites					91:95	rainbow trout epithelial sites	66:95	rainbow trout epithelial sites	66:95	Mucin O-glycosylation and pathogen binding ability differ between rainbow trout epithelial sites.
36241003	3	58	from	welfare	429:435	arg1	aquaculture					440:450	aquaculture	440:450	aquaculture	440:450	Knowledge on this mucosal defense system can enable alternative treatments to diseases posing a threat to productivity and welfare in aquaculture.
36241003	4	59	theme	known	602:606	arg1	O-glycomes					616:625	known teleost O-glycomes	602:625	known teleost O-glycomes	602:625	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	3	60	theme	defense	332:338	arg1	system					340:345	this mucosal defense system	319:345	this mucosal defense system	319:345	Knowledge on this mucosal defense system can enable alternative treatments to diseases posing a threat to productivity and welfare in aquaculture.
36241003	4	61	theme	Oncorhynchus	494:505	arg1	trout					487:491	the rainbow trout	475:491	the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation	475:582	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	4	61	theme	Oncorhynchus	494:505	arg1	mykiss					507:512	Oncorhynchus mykiss	494:512	Oncorhynchus mykiss	494:512	Here, we characterize the rainbow trout (Oncorhynchus mykiss) gill, skin, pyloric ceca and distal intestinal mucin O-glycosylation and compare it to known teleost O-glycomes.
36241003	7	62	theme	increased	947:955	arg1	number					957:962	an increased number	944:962	an increased number	944:962	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	7	63	from	intestine	924:932	arg1	glycans					887:893	glycans	887:893	glycans from pyloric ceca and distal intestine	887:932	Glycans from the gills were less acidic with predominantly core 1 and 2 glycans, whereas glycans from pyloric ceca and distal intestine expressed an increased number of core 5 glycans, distinctly decorated with NeuAcα2-8NeuAc- like epitopes.
36241003	3	64	from	Knowledge	306:314	arg1	system					340:345	this mucosal defense system	319:345	this mucosal defense system	319:345	Knowledge on this mucosal defense system can enable alternative treatments to diseases posing a threat to productivity and welfare in aquaculture.
35022995	5	0	theme	T/S	731:733	arg1	region					743:748	The T/S cluster region	727:748	The T/S cluster region	727:748	The T/S cluster region is required for transport to the cytoplasmic membrane and cell transformation.
35022995	8	1	theme	I-type	1134:1139	arg1	Gal-GalNAc					1158:1167	Gal-GalNAc	1158:1167	Gal-GalNAc	1158:1167	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	8	1	theme	I-type	1134:1139	arg1	O-glycosylation					1141:1155	Core I-type O-glycosylation	1129:1155	Core I-type O-glycosylation (Gal-GalNAc)	1129:1168	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	4	2	theme	T/S	664:666	arg1	region					676:681	the T/S cluster region	660:681	the T/S cluster region	660:681	Using dynAP mutants, we herein showed that the T/S cluster region is responsible for the anomalous migration.
35022995	4	2	theme	T/S	664:666	arg1	responsible					686:696	responsible	686:696	responsible	686:696	Using dynAP mutants, we herein showed that the T/S cluster region is responsible for the anomalous migration.
35022995	5	3	theme	cluster	735:741	arg1	region					743:748	The T/S cluster region	727:748	The T/S cluster region	727:748	The T/S cluster region is required for transport to the cytoplasmic membrane and cell transformation.
35022995	7	4	theme	full-length	1110:1120	arg1	dynAP					1122:1126	full-length dynAP	1110:1126	full-length dynAP	1110:1126	Asn143 displayed complex-type glycosylation, suggesting that oligosaccharide transferase may recognize the NXT/S sequon in the secretory form, but not clearly in full-length dynAP.
35022995	3	5	dep	expected	560:567	arg1	22.5 kDa					570:577	22.5 kDa	570:577	22.5 kDa	570:577	In SDS-PAGE, dynAP migrates anomalously at ~ 45 kDa, much larger than expected (22.5 kDa) based on the amino acid composition.
35022995	4	6	theme	anomalous	706:714	arg1	migration					716:724	the anomalous migration	702:724	the anomalous migration	702:724	Using dynAP mutants, we herein showed that the T/S cluster region is responsible for the anomalous migration.
35022995	6	7	from	fragment	872:879	arg1	form					908:911	secreted form	899:911	secreted form	899:911	We produced and purified the extracellular fragment (dynAP135-210) in secreted form and analyzed the attached glycans.
35022995	6	8	theme	extracellular	858:870	arg1	dynAP135-210					882:893	dynAP135-210	882:893	dynAP135-210	882:893	We produced and purified the extracellular fragment (dynAP135-210) in secreted form and analyzed the attached glycans.
35022995	6	8	theme	extracellular	858:870	arg1	fragment					872:879	the extracellular fragment	854:879	the extracellular fragment (dynAP135-210) in secreted form	854:911	We produced and purified the extracellular fragment (dynAP135-210) in secreted form and analyzed the attached glycans.
35022995	8	9	theme	spectrometry	1197:1208	arg1	weak					1221:1224	weak	1221:1224	weak	1221:1224	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	8	9	theme	spectrometry	1197:1208	arg1	signal					1210:1215	the mass spectrometry signal	1188:1215	the mass spectrometry signal	1188:1215	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	8	10	theme	mass	1192:1195	arg1	weak					1221:1224	weak	1221:1224	weak	1221:1224	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	8	10	theme	mass	1192:1195	arg1	signal					1210:1215	the mass spectrometry signal	1188:1215	the mass spectrometry signal	1188:1215	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	2	11	theme	C-terminal	386:395	arg1	residues					405:412	residues 173-210	405:420	residues 173-210	405:420	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	11	theme	C-terminal	386:395	arg1	region					397:402	a distal C-terminal region	377:402	a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	377:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	8	12	theme	Core	1129:1132	arg1	Gal-GalNAc					1158:1167	Gal-GalNAc	1158:1167	Gal-GalNAc	1158:1167	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	8	12	theme	Core	1129:1132	arg1	O-glycosylation					1141:1155	Core I-type O-glycosylation	1129:1155	Core I-type O-glycosylation (Gal-GalNAc)	1129:1168	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	7	13	theme	secretory	1075:1083	arg1	form					1085:1088	the secretory form	1071:1088	the secretory form	1071:1088	Asn143 displayed complex-type glycosylation, suggesting that oligosaccharide transferase may recognize the NXT/S sequon in the secretory form, but not clearly in full-length dynAP.
35022995	2	14	gly	O-glycosylated	474:487	arg1	O-glycosylated					474:487	O-glycosylated	474:487	O-glycosylated	474:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	14	gly	O-glycosylated	474:487	arg1	cluster					454:460	a Thr/Ser-rich (T/S) cluster	433:460	a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	433:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	14	gly	O-glycosylated	474:487	arg1	T/S					449:451	T/S	449:451	T/S	449:451	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	15	theme	distal	379:384	arg1	residues					405:412	residues 173-210	405:420	residues 173-210	405:420	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	15	theme	distal	379:384	arg1	region					397:402	a distal C-terminal region	377:402	a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	377:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	16	theme	Thr/Ser-rich	435:446	arg1	O-glycosylated					474:487	O-glycosylated	474:487	O-glycosylated	474:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	16	theme	Thr/Ser-rich	435:446	arg1	cluster					454:460	a Thr/Ser-rich (T/S) cluster	433:460	a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	433:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	16	theme	Thr/Ser-rich	435:446	arg1	T/S					449:451	T/S	449:451	T/S	449:451	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	8	17	from	modifications	1291:1303	arg1	region					1313:1318	this region	1308:1318	this region	1308:1318	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	1	18	theme	human	112:116	arg1	dynAP					147:151	dynAP	147:151	dynAP	147:151	Overexpression of human dynactin-associated protein (dynAP) transforms NIH3T3 cells.
35022995	1	18	theme	human	112:116	arg1	protein					138:144	human dynactin-associated protein	112:144	human dynactin-associated protein (dynAP)	112:152	Overexpression of human dynactin-associated protein (dynAP) transforms NIH3T3 cells.
35022995	2	19	dep	residues	405:412	arg1	173-210					414:420	173-210	414:420	173-210	414:420	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	5	20	theme	cytoplasmic	783:793	arg1	membrane					795:802	the cytoplasmic membrane	779:802	the cytoplasmic membrane	779:802	The T/S cluster region is required for transport to the cytoplasmic membrane and cell transformation.
35022995	6	21	theme	attached	930:937	arg1	glycans					939:945	the attached glycans	926:945	the attached glycans	926:945	We produced and purified the extracellular fragment (dynAP135-210) in secreted form and analyzed the attached glycans.
35022995	2	22	theme	single-pass	190:200	arg1	protein					216:222	a single-pass transmembrane protein	188:222	a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	188:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	22	theme	single-pass	190:200	arg1	DynAP					179:183	DynAP	179:183	DynAP	179:183	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	1	23	theme	dynactin-associated	118:136	arg1	dynAP					147:151	dynAP	147:151	dynAP	147:151	Overexpression of human dynactin-associated protein (dynAP) transforms NIH3T3 cells.
35022995	1	23	theme	dynactin-associated	118:136	arg1	protein					138:144	human dynactin-associated protein	112:144	human dynactin-associated protein (dynAP)	112:152	Overexpression of human dynactin-associated protein (dynAP) transforms NIH3T3 cells.
35022995	0	24	theme	Glycosylation	36:48	arg1	Sites					50:54	Potential Glycosylation Sites	26:54	Potential Glycosylation Sites of Dynactin-Associated Protein	26:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	0	24	theme	Glycosylation	36:48	arg1	Protein					79:85	Dynactin-Associated Protein	59:85	Dynactin-Associated Protein	59:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	7	25	theme	NXT/S	1055:1059	arg1	sequon					1061:1066	the NXT/S sequon	1051:1066	the NXT/S sequon	1051:1066	Asn143 displayed complex-type glycosylation, suggesting that oligosaccharide transferase may recognize the NXT/S sequon in the secretory form, but not clearly in full-length dynAP.
35022995	5	26	theme	cell	808:811	arg1	transformation					813:826	cell transformation	808:826	cell transformation	808:826	The T/S cluster region is required for transport to the cytoplasmic membrane and cell transformation.
35022995	2	27	theme	amino	256:260	arg1	region					248:253	a carboxy-terminal region	229:253	a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	229:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	27	theme	amino	256:260	arg1	acids					262:266	amino acids 135-210	256:274	amino acids 135-210	256:274	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	4	28	theme	dynAP	623:627	arg1	mutants					629:635	dynAP mutants	623:635	dynAP mutants	623:635	Using dynAP mutants, we herein showed that the T/S cluster region is responsible for the anomalous migration.
35022995	0	29	theme	Potential	26:34	arg1	Sites					50:54	Potential Glycosylation Sites	26:54	Potential Glycosylation Sites of Dynactin-Associated Protein	26:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	0	29	theme	Potential	26:34	arg1	Protein					79:85	Dynactin-Associated Protein	59:85	Dynactin-Associated Protein	59:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	8	30	theme	further	1251:1257	arg1	studies					1259:1265	further studies	1251:1265	further studies	1251:1265	Core I-type O-glycosylation (Gal-GalNAc) was observed, but the mass spectrometry signal was weak, clearly indicating that further studies are needed to elucidate modifications in this region.
35022995	7	31	theme	oligosaccharide	1009:1023	arg1	transferase					1025:1035	oligosaccharide transferase	1009:1035	oligosaccharide transferase	1009:1035	Asn143 displayed complex-type glycosylation, suggesting that oligosaccharide transferase may recognize the NXT/S sequon in the secretory form, but not clearly in full-length dynAP.
35022995	1	32	theme	protein	138:144	arg1	Overexpression					94:107	Overexpression	94:107	Overexpression of human dynactin-associated protein (dynAP)	94:152	Overexpression of human dynactin-associated protein (dynAP) transforms NIH3T3 cells.
35022995	0	33	theme	Sites	50:54	arg1	Function					14:21	Function	14:21	Function	14:21	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	0	33	theme	Sites	50:54	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	2	34	contain	possessing	312:321	arg1	cell					307:310	the cell	303:310	the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	303:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	34	contain	possessing	312:321	arg2	residues					405:412	residues 173-210	405:420	residues 173-210	405:420	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	34	contain	possessing	312:321	arg2	region					397:402	a distal C-terminal region	377:402	a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	377:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	34	contain	possessing	312:321	arg2	position					359:366	position 143	359:370	position 143	359:370	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	34	contain	possessing	312:321	arg2	site					353:356	one potential N-glycosylation site	323:356	one potential N-glycosylation site (position 143)	323:371	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	35	theme	carboxy-terminal	231:246	arg1	region					248:253	a carboxy-terminal region	229:253	a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	229:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	35	theme	carboxy-terminal	231:246	arg1	acids					262:266	amino acids 135-210	256:274	amino acids 135-210	256:274	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	4	36	theme	cluster	668:674	arg1	region					676:681	the T/S cluster region	660:681	the T/S cluster region	660:681	Using dynAP mutants, we herein showed that the T/S cluster region is responsible for the anomalous migration.
35022995	4	36	theme	cluster	668:674	arg1	responsible					686:696	responsible	686:696	responsible	686:696	Using dynAP mutants, we herein showed that the T/S cluster region is responsible for the anomalous migration.
35022995	6	37	theme	secreted	899:906	arg1	form					908:911	secreted form	899:911	secreted form	899:911	We produced and purified the extracellular fragment (dynAP135-210) in secreted form and analyzed the attached glycans.
35022995	3	38	theme	amino	593:597	arg1	composition					604:614	the amino acid composition	589:614	the amino acid composition	589:614	In SDS-PAGE, dynAP migrates anomalously at ~ 45 kDa, much larger than expected (22.5 kDa) based on the amino acid composition.
35022995	2	39	theme	N-glycosylation	337:351	arg1	site					353:356	one potential N-glycosylation site	323:356	one potential N-glycosylation site (position 143)	323:371	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	39	theme	N-glycosylation	337:351	arg1	position					359:366	position 143	359:370	position 143	359:370	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	40	gly	N-glycosylation	337:351	arg2	one					323:325	one	323:325	one	323:325	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	40	gly	N-glycosylation	337:351	arg2	position					359:366	position 143	359:370	position 143	359:370	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	40	gly	N-glycosylation	337:351	arg2	site					353:356	one potential N-glycosylation site	323:356	one potential N-glycosylation site (position 143)	323:371	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	3	41	theme	acid	599:602	arg1	composition					604:614	the amino acid composition	589:614	the amino acid composition	589:614	In SDS-PAGE, dynAP migrates anomalously at ~ 45 kDa, much larger than expected (22.5 kDa) based on the amino acid composition.
35022995	7	42	theme	complex-type	965:976	arg1	glycosylation					978:990	complex-type glycosylation	965:990	complex-type glycosylation	965:990	Asn143 displayed complex-type glycosylation, suggesting that oligosaccharide transferase may recognize the NXT/S sequon in the secretory form, but not clearly in full-length dynAP.
35022995	2	43	theme	potential	327:335	arg1	site					353:356	one potential N-glycosylation site	323:356	one potential N-glycosylation site (position 143)	323:371	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	43	theme	potential	327:335	arg1	position					359:366	position 143	359:370	position 143	359:370	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	0	44	theme	Protein	79:85	arg1	Sites					50:54	Potential Glycosylation Sites	26:54	Potential Glycosylation Sites of Dynactin-Associated Protein	26:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	0	44	theme	Protein	79:85	arg1	Protein					79:85	Dynactin-Associated Protein	59:85	Dynactin-Associated Protein	59:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	2	45	theme	transmembrane	202:214	arg1	protein					216:222	a single-pass transmembrane protein	188:222	a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	188:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	45	theme	transmembrane	202:214	arg1	DynAP					179:183	DynAP	179:183	DynAP	179:183	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	46	with	protein	216:222	arg1	region					248:253	a carboxy-terminal region	229:253	a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated	229:487	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	2	46	with	protein	216:222	arg1	acids					262:266	amino acids 135-210	256:274	amino acids 135-210	256:274	DynAP is a single-pass transmembrane protein with a carboxy-terminal region (amino acids 135-210) exposed to the outside of the cell possessing one potential N-glycosylation site (position 143) and a distal C-terminal region (residues 173-210) harboring a Thr/Ser-rich (T/S) cluster that may be O-glycosylated.
35022995	0	47	theme	Dynactin-Associated	59:77	arg1	Protein					79:85	Dynactin-Associated Protein	59:85	Dynactin-Associated Protein	59:85	Structure and Function of Potential Glycosylation Sites of Dynactin-Associated Protein dynAP.
35022995	1	48	theme	NIH3T3	165:170	arg1	cells					172:176	NIH3T3 cells	165:176	NIH3T3 cells	165:176	Overexpression of human dynactin-associated protein (dynAP) transforms NIH3T3 cells.
37156312	1	0	link	O-linked	88:95	arg1	glycosylation					97:109	O-linked glycosylation	88:109	O-linked glycosylation	88:109	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	9	1	theme	independent	1248:1258	arg1	AUC					1280:1282	AUC	1280:1282	AUC: 0.9323	1280:1290	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	9	1	theme	independent	1248:1258	arg1	dataset					1271:1277	independent validation dataset	1248:1277	independent validation dataset (AUC: 0.9323)	1248:1291	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	9	2	theme	proposed	1151:1158	arg1	model					1160:1164	the proposed model	1147:1164	the proposed model	1147:1164	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	9	2	theme	proposed	1151:1158	arg1	O-GlyThr					1174:1181	O-GlyThr	1174:1181	namely O-GlyThr	1167:1181	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	9	3	theme	training	1217:1224	arg1	set					1226:1228	training set	1217:1228	training set (AUC: 0.9308)	1217:1242	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	10	4	theme	independent	1392:1402	arg1	dataset					1409:1415	the independent test dataset	1388:1415	the independent test dataset	1388:1415	Compared with previously published predictors, O-GlyThr achieved the highest ACC of 0.8475 on the independent test dataset.
37156312	10	5	theme	highest	1363:1369	arg1	ACC					1371:1373	the highest ACC	1359:1373	the highest ACC of 0.8475 on the independent test dataset	1359:1415	Compared with previously published predictors, O-GlyThr achieved the highest ACC of 0.8475 on the independent test dataset.
37156312	5	6	theme	prediction	684:693	arg1	model					695:699	a prediction model	682:699	a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens	682:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	12	7	theme	user-friendly	1548:1560	arg1	webserver					1562:1570	a user-friendly webserver	1546:1570	a user-friendly webserver named O-GlyThr (http://cbcb.cdutcm.edu.cn/O-GlyThr/)	1546:1623	Furthermore, a user-friendly webserver named O-GlyThr (http://cbcb.cdutcm.edu.cn/O-GlyThr/) was developed to assist glycobiologists in the research associated with glycosylation structure and function.
37156312	3	8	dep	experiments	493:503	arg1	identify					508:515	identify	508:515	to identify O-glycosites in batches	505:539	Biochemical experiments to identify O-glycosites in batches are technically and economically demanding.
37156312	2	9	theme	sequence	317:324	arg1	features					326:333	nonspecific sequence features	305:333	nonspecific sequence features	305:333	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	7	10	theme	sample	968:973	arg1	sequence					975:982	the sample sequence	964:982	the sample sequence	964:982	Seven feature coding methods were fused to represent the sample sequence.
37156312	2	11	theme	glycan	349:354	arg1	structure					361:369	nonstable glycan core structure	339:369	nonstable glycan core structure	339:369	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	5	12	theme	threonine	756:764	arg1	residues					766:773	the threonine residues	752:773	the threonine residues in Homo sapiens	752:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	6	13	theme	threonine	889:897	arg1	glycosites					899:908	O-linked threonine glycosites	880:908	O-linked threonine glycosites	880:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	2	14	theme	nonspecific	305:315	arg1	features					326:333	nonspecific sequence features	305:333	nonspecific sequence features	305:333	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	6	15	theme	training	799:806	arg1	model					808:812	the training model	795:812	the training model	795:812	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	2	16	theme	core	356:359	arg1	structure					361:369	nonstable glycan core structure	339:369	nonstable glycan core structure	339:369	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	12	17	dep	O-GlyThr	1578:1585	arg1	http					1588:1591	http	1588:1591	http://cbcb.cdutcm.edu.cn/O-GlyThr/	1588:1622	Furthermore, a user-friendly webserver named O-GlyThr (http://cbcb.cdutcm.edu.cn/O-GlyThr/) was developed to assist glycobiologists in the research associated with glycosylation structure and function.
37156312	9	18	dep	AUC	1231:1233	arg1	0.9308					1236:1241	0.9308	1236:1241	0.9308	1236:1241	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	5	19	theme	feature	710:716	arg1	fusion					718:723	feature fusion	710:723	feature fusion for O-glycosites linked to the threonine residues in Homo sapiens	710:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	2	20	theme	computational	458:470	arg1	methods					472:478	experimental or computational methods	442:478	experimental or computational methods	442:478	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	2	21	dep	O-glycosites	402:413	arg1	either					432:437	either	432:437	either	432:437	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	2	22	theme	challenging	420:430	arg1	O-glycosites					402:413	O-glycosites	402:413	O-glycosites more challenging	402:430	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	6	23	with	data	870:873	arg1	glycosites					899:908	O-linked threonine glycosites	880:908	O-linked threonine glycosites	880:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	8	24	theme	classification	1092:1105	arg1	model					1107:1111	the classification model	1088:1111	the classification model	1088:1111	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	4	25	theme	computation-based	611:627	arg1	methods					629:635	computation-based methods	611:635	computation-based methods	611:635	Therefore, development of computation-based methods is greatly warranted.
37156312	9	26	dep	set	1226:1228	arg1	AUC					1231:1233	AUC	1231:1233	AUC: 0.9308	1231:1241	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	10	27	theme	test	1404:1407	arg1	dataset					1409:1415	the independent test dataset	1388:1415	the independent test dataset	1388:1415	Compared with previously published predictors, O-GlyThr achieved the highest ACC of 0.8475 on the independent test dataset.
37156312	1	28	theme	O-linked	88:95	arg1	glycosylation					97:109	O-linked glycosylation	88:109	O-linked glycosylation	88:109	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	9	29	dep	AUC	1280:1282	arg1	0.9323					1285:1290	0.9323	1285:1290	AUC: 0.9323	1280:1290	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	1	30	theme	human	180:184	arg1	proteins					186:193	human proteins	180:193	human proteins modulating various cellular metabolic and signaling pathways	180:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	0	31	link	O-linked	30:37	arg1	glycosites					49:58	human O-linked threonine glycosites	24:58	human O-linked threonine glycosites using multi-feature fusion	24:85	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	2	32	theme	nonstable	339:347	arg1	structure					361:369	nonstable glycan core structure	339:369	nonstable glycan core structure	339:369	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	7	33	theme	coding	925:930	arg1	methods					932:938	Seven feature coding methods	911:938	Seven feature coding methods	911:938	Seven feature coding methods were fused to represent the sample sequence.
37156312	1	34	theme	proteins	186:193	arg1	modifications					157:169	the most complex post-translational modifications	121:169	the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways	121:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	1	34	theme	proteins	186:193	arg1	PTM					172:174	PTM	172:174	PTM	172:174	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	2	35	contain	has	301:303	arg1	O-glycosylation					285:299	the O-glycosylation	281:299	the O-glycosylation	281:299	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	2	35	contain	has	301:303	arg2	features					326:333	nonspecific sequence features	305:333	nonspecific sequence features	305:333	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	2	35	contain	has	301:303	arg2	structure					361:369	nonstable glycan core structure	339:369	nonstable glycan core structure	339:369	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	6	36	theme	human	856:860	arg1	data					870:873	high-quality human protein data	843:873	high-quality human protein data with O-linked threonine glycosites	843:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	9	37	theme	validation	1260:1269	arg1	AUC					1280:1282	AUC	1280:1282	AUC: 0.9323	1280:1290	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	9	37	theme	validation	1260:1269	arg1	dataset					1271:1277	independent validation dataset	1248:1277	independent validation dataset (AUC: 0.9323)	1248:1291	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	6	38	theme	protein	862:868	arg1	data					870:873	high-quality human protein data	843:873	high-quality human protein data with O-linked threonine glycosites	843:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	2	39	gly	O-glycosites	402:413	arg2	O-glycosites					402:413	O-glycosites	402:413	O-glycosites more challenging	402:430	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	7	40	theme	feature	917:923	arg1	methods					932:938	Seven feature coding methods	911:938	Seven feature coding methods	911:938	Seven feature coding methods were fused to represent the sample sequence.
37156312	8	41	theme	different	1002:1010	arg1	algorithms					1012:1021	different algorithms	1002:1021	different algorithms	1002:1021	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	2	42	theme	O-glycosites	402:413	arg1	identification					384:397	identification	384:397	identification of O-glycosites more challenging either by experimental or computational methods	384:478	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	0	43	theme	O-linked	30:37	arg1	glycosites					49:58	human O-linked threonine glycosites	24:58	human O-linked threonine glycosites using multi-feature fusion	24:85	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	3	44	theme	Biochemical	481:491	arg1	experiments					493:503	Biochemical experiments	481:503	Biochemical experiments to identify O-glycosites in batches	481:539	Biochemical experiments to identify O-glycosites in batches are technically and economically demanding.
37156312	5	45	gly	O-glycosites	729:740	arg2	O-glycosites					729:740	O-glycosites	729:740	O-glycosites linked to the threonine residues in Homo sapiens	729:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	0	46	theme	human	24:28	arg1	glycosites					49:58	human O-linked threonine glycosites	24:58	human O-linked threonine glycosites using multi-feature fusion	24:85	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	6	47	gly	glycosites	899:908	arg2	glycosites					899:908	O-linked threonine glycosites	880:908	O-linked threonine glycosites	880:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	11	48	theme	threonine	1513:1521	arg1	residues					1523:1530	threonine residues	1513:1530	threonine residues	1513:1530	These results demonstrated the high competency of our predictor in identifying O-glycosites on threonine residues.
37156312	11	49	from	O-glycosites	1497:1508	arg1	residues					1523:1530	threonine residues	1513:1530	threonine residues	1513:1530	These results demonstrated the high competency of our predictor in identifying O-glycosites on threonine residues.
37156312	10	50	theme	published	1319:1327	arg1	predictors					1329:1338	previously published predictors	1308:1338	previously published predictors	1308:1338	Compared with previously published predictors, O-GlyThr achieved the highest ACC of 0.8475 on the independent test dataset.
37156312	6	51	theme	high-quality	843:854	arg1	data					870:873	high-quality human protein data	843:873	high-quality human protein data with O-linked threonine glycosites	843:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	2	52	theme	experimental	442:453	arg1	methods					472:478	experimental or computational methods	442:478	experimental or computational methods	442:478	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	0	53	theme	glycosites	49:58	arg1	Prediction					10:19	Prediction	10:19	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.	0:86	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	12	54	theme	glycosylation	1697:1709	arg1	structure					1711:1719	glycosylation structure	1697:1719	glycosylation structure	1697:1719	Furthermore, a user-friendly webserver named O-GlyThr (http://cbcb.cdutcm.edu.cn/O-GlyThr/) was developed to assist glycobiologists in the research associated with glycosylation structure and function.
37156312	10	55	theme	0.8475	1378:1383	arg1	ACC					1371:1373	the highest ACC	1359:1373	the highest ACC of 0.8475 on the independent test dataset	1359:1415	Compared with previously published predictors, O-GlyThr achieved the highest ACC of 0.8475 on the independent test dataset.
37156312	11	56	theme	predictor	1472:1480	arg1	competency					1454:1463	the high competency	1445:1463	the high competency of our predictor in identifying O-glycosites on threonine residues	1445:1530	These results demonstrated the high competency of our predictor in identifying O-glycosites on threonine residues.
37156312	3	57	gly	O-glycosites	517:528	arg2	O-glycosites					517:528	O-glycosites	517:528	O-glycosites in batches	517:539	Biochemical experiments to identify O-glycosites in batches are technically and economically demanding.
37156312	3	58	from	O-glycosites	517:528	arg1	batches					533:539	batches	533:539	batches	533:539	Biochemical experiments to identify O-glycosites in batches are technically and economically demanding.
37156312	0	59	theme	threonine	39:47	arg1	glycosites					49:58	human O-linked threonine glycosites	24:58	human O-linked threonine glycosites using multi-feature fusion	24:85	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	4	60	theme	methods	629:635	arg1	development					596:606	development	596:606	development of computation-based methods	596:635	Therefore, development of computation-based methods is greatly warranted.
37156312	2	61	dep	has	301:303	arg1	makes					378:382	makes	378:382	makes identification of O-glycosites more challenging either by experimental or computational methods	378:478	Unlike N-glycosylation, the O-glycosylation has nonspecific sequence features and nonstable glycan core structure, which makes identification of O-glycosites more challenging either by experimental or computational methods.
37156312	10	62	from	ACC	1371:1373	arg1	dataset					1409:1415	the independent test dataset	1388:1415	the independent test dataset	1388:1415	Compared with previously published predictors, O-GlyThr achieved the highest ACC of 0.8475 on the independent test dataset.
37156312	11	63	gly	O-glycosites	1497:1508	arg2	O-glycosites					1497:1508	O-glycosites	1497:1508	O-glycosites on threonine residues	1497:1530	These results demonstrated the high competency of our predictor in identifying O-glycosites on threonine residues.
37156312	8	64	theme	algorithms	1012:1021	arg1	comparison					988:997	comparison	988:997	comparison of different algorithms	988:1021	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	0	65	gly	glycosites	49:58	arg2	glycosites					49:58	human O-linked threonine glycosites	24:58	human O-linked threonine glycosites using multi-feature fusion	24:85	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	5	66	theme	Homo	778:781	arg1	sapiens					783:789	Homo sapiens	778:789	Homo sapiens	778:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	8	67	theme	final	1058:1062	arg1	forest					1031:1036	random forest	1024:1036	random forest	1024:1036	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	8	67	theme	final	1058:1062	arg1	classifier					1064:1073	the final classifier	1054:1073	the final classifier to construct the classification model	1054:1111	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	1	68	theme	most	125:128	arg1	modifications					157:169	the most complex post-translational modifications	121:169	the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways	121:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	1	68	theme	most	125:128	arg1	PTM					172:174	PTM	172:174	PTM	172:174	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	5	69	attach	linked	742:747	arg1	residues					766:773	the threonine residues	752:773	the threonine residues in Homo sapiens	752:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	5	69	attach	linked	742:747	arg2	O-glycosites					729:740	O-glycosites	729:740	O-glycosites linked to the threonine residues in Homo sapiens	729:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	12	70	dep	http	1588:1591	arg1	//cbcb.cdutcm.edu.cn/O-GlyThr/					1593:1622	//cbcb.cdutcm.edu.cn/O-GlyThr/	1593:1622	http://cbcb.cdutcm.edu.cn/O-GlyThr/	1588:1622	Furthermore, a user-friendly webserver named O-GlyThr (http://cbcb.cdutcm.edu.cn/O-GlyThr/) was developed to assist glycobiologists in the research associated with glycosylation structure and function.
37156312	8	71	theme	random	1024:1029	arg1	forest					1031:1036	random forest	1024:1036	random forest	1024:1036	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	8	71	theme	random	1024:1029	arg1	classifier					1064:1073	the final classifier	1054:1073	the final classifier to construct the classification model	1054:1111	By comparison of different algorithms, random forest was selected as the final classifier to construct the classification model.
37156312	11	72	theme	high	1449:1452	arg1	competency					1454:1463	the high competency	1445:1463	the high competency of our predictor in identifying O-glycosites on threonine residues	1445:1530	These results demonstrated the high competency of our predictor in identifying O-glycosites on threonine residues.
37156312	1	73	theme	complex	130:136	arg1	modifications					157:169	the most complex post-translational modifications	121:169	the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways	121:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	1	73	theme	complex	130:136	arg1	PTM					172:174	PTM	172:174	PTM	172:174	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	6	74	theme	O-linked	880:887	arg1	glycosites					899:908	O-linked threonine glycosites	880:908	O-linked threonine glycosites	880:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	1	75	theme	signaling	237:245	arg1	pathways					247:254	signaling pathways	237:254	signaling pathways	237:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	0	76	theme	multi-feature	66:78	arg1	fusion					80:85	multi-feature fusion	66:85	multi-feature fusion	66:85	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	1	77	theme	post-translational	138:155	arg1	modifications					157:169	the most complex post-translational modifications	121:169	the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways	121:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	1	77	theme	post-translational	138:155	arg1	PTM					172:174	PTM	172:174	PTM	172:174	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	9	78	theme	5-fold	1122:1127	arg1	cross-validation					1129:1144	5-fold cross-validation	1122:1144	5-fold cross-validation	1122:1144	Through 5-fold cross-validation, the proposed model, namely O-GlyThr, performed satisfactorily on both training set (AUC: 0.9308) and independent validation dataset (AUC: 0.9323).
37156312	5	79	from	residues	766:773	arg1	sapiens					783:789	Homo sapiens	778:789	Homo sapiens	778:789	This study constructed a prediction model based on feature fusion for O-glycosites linked to the threonine residues in Homo sapiens.
37156312	6	80	link	O-linked	880:887	arg1	glycosites					899:908	O-linked threonine glycosites	880:908	O-linked threonine glycosites	880:908	In the training model, we collected and sorted out high-quality human protein data with O-linked threonine glycosites.
37156312	0	81	dep	O-GlyThr	0:7	arg1	Prediction					10:19	Prediction	10:19	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.	0:86	O-GlyThr: Prediction of human O-linked threonine glycosites using multi-feature fusion.
37156312	1	82	theme	modifications	157:169	arg1	modifications					157:169	the most complex post-translational modifications	121:169	the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways	121:254	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	1	82	theme	modifications	157:169	arg1	PTM					172:174	PTM	172:174	PTM	172:174	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
37156312	1	82	theme	modifications	157:169	arg1	one					114:116	one	114:116	one	114:116	O-linked glycosylation is one of the most complex post-translational modifications (PTM) of human proteins modulating various cellular metabolic and signaling pathways.
36470649	4	0	theme	studies	660:666	arg1	view					641:644	a bird's-eye view	628:644	a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	628:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	6	1	theme	C-glycoside	1149:1159	arg1	analogs					1161:1167	C-glycoside analogs	1149:1167	C-glycoside analogs based on pseudo-GM3	1149:1187	In order to improve access to C-glycoside analogs based on pseudo-GM3, it is still important to streamline the synthesis process.
36470649	3	2	theme	biological	487:496	arg1	potential					498:506	their biological potential	481:506	their biological potential	481:506	However, their biological potential is not yet well understood because only a few pseudo glycans have so far been synthesized.
36470649	5	3	theme	anticipated	994:1004	arg1	successful					1056:1065	successful	1056:1065	successful	1056:1065	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	5	3	theme	anticipated	994:1004	arg1	control					1021:1027	the anticipated conformational control	990:1027	the anticipated conformational control by F-atom introduction	990:1050	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	4	4	theme	C-sialoside	852:862	arg1	bond					864:867	the C-sialoside bond	848:867	the C-sialoside bond	848:867	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	6	5	theme	synthesis	1230:1238	arg1	process					1240:1246	the synthesis process	1226:1246	the synthesis process	1226:1246	In order to improve access to C-glycoside analogs based on pseudo-GM3, it is still important to streamline the synthesis process.
36470649	5	6	theme	CHF-sialoside	947:959	arg1	disaccharides					961:973	the synthesized CHF-sialoside disaccharides	931:973	the synthesized CHF-sialoside disaccharides	931:973	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	5	7	theme	synthesized	935:945	arg1	disaccharides					961:973	the synthesized CHF-sialoside disaccharides	931:973	the synthesized CHF-sialoside disaccharides	931:973	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	1	8	theme	C-glycosidic	253:264	arg1	linkage					266:272	a C-glycosidic linkage	251:272	a C-glycosidic linkage	251:272	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	4	9	theme	analogs	699:705	arg1	creation					675:682	the creation	671:682	the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	671:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	5	10	theme	disaccharides	961:973	arg1	analysis					919:926	Conformational analysis	904:926	Conformational analysis of the synthesized CHF-sialoside disaccharides	904:973	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	4	11	theme	GM3	722:724	arg1	analogs					699:705	C-glycoside analogs	687:705	C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	687:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	4	12	from	view	641:644	arg1	creation					675:682	the creation	671:682	the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	671:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	1	13	theme	pseudo-glycans	124:137	arg1	development					109:119	the development	105:119	the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage	105:272	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	7	14	theme	atom-transfer	1332:1344	arg1	coupling					1354:1361	atom-transfer radical coupling	1332:1361	atom-transfer radical coupling	1332:1361	With this in mind, we designed and developed a direct C-glycosylation method using atom-transfer radical coupling, and employed it in syntheses of pseudo-isomaltose and pseudo-KRN7000.
36470649	1	15	dep	author	63:68	arg1	the					59:61	the	59:61	the	59:61	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	7	16	theme	radical	1346:1352	arg1	coupling					1354:1361	atom-transfer radical coupling	1332:1361	atom-transfer radical coupling	1332:1361	With this in mind, we designed and developed a direct C-glycosylation method using atom-transfer radical coupling, and employed it in syntheses of pseudo-isomaltose and pseudo-KRN7000.
36470649	4	17	theme	stereoselective	819:833	arg1	synthesis					835:843	our stereoselective synthesis	815:843	our stereoselective synthesis of the C-sialoside bond	815:867	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	2	18	theme	cellular	309:316	arg1	hydrolases					328:337	cellular glycoside hydrolases	309:337	cellular glycoside hydrolases	309:337	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	2	19	theme	molecular	374:382	arg1	tools					384:388	useful molecular tools	367:388	useful molecular tools that may maintain the original biological activity for a long period in the cell	367:469	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	4	20	theme	C-glycoside	687:697	arg1	analogs					699:705	C-glycoside analogs	687:705	C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	687:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	2	21	theme	useful	367:372	arg1	tools					384:388	useful molecular tools	367:388	useful molecular tools that may maintain the original biological activity for a long period in the cell	367:469	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	0	22	theme	C-glycoside	30:40	arg1	linkage					42:48	a C-glycoside linkage	28:48	a C-glycoside linkage	28:48	Pseudo-glycoconjugates with a C-glycoside linkage.
36470649	5	23	theme	Conformational	904:917	arg1	analysis					919:926	Conformational analysis	904:926	Conformational analysis of the synthesized CHF-sialoside disaccharides	904:973	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	4	24	theme	ganglioside	710:720	arg1	GM3					722:724	ganglioside GM3	710:724	ganglioside GM3 based on the CHF-sialoside linkage	710:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	2	25	theme	original	412:419	arg1	activity					432:439	the original biological activity	408:439	the original biological activity for a long period in the cell	408:469	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	2	26	theme	biological	421:430	arg1	activity					432:439	the original biological activity	408:439	the original biological activity for a long period in the cell	408:469	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	4	27	theme	recent	653:658	arg1	studies					660:666	our recent studies	649:666	our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	649:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	7	28	theme	pseudo-KRN7000	1418:1431	arg1	syntheses					1383:1391	syntheses	1383:1391	syntheses of pseudo-isomaltose and pseudo-KRN7000	1383:1431	With this in mind, we designed and developed a direct C-glycosylation method using atom-transfer radical coupling, and employed it in syntheses of pseudo-isomaltose and pseudo-KRN7000.
36470649	7	29	theme	C-glycosylation	1303:1317	arg1	method					1319:1324	a direct C-glycosylation method	1294:1324	a direct C-glycosylation method	1294:1324	With this in mind, we designed and developed a direct C-glycosylation method using atom-transfer radical coupling, and employed it in syntheses of pseudo-isomaltose and pseudo-KRN7000.
36470649	1	30	theme	O-glycosidic	178:189	arg1	linkage					191:197	the O-glycosidic linkage	174:197	the O-glycosidic linkage of the natural-type glycan structure	174:234	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	7	31	theme	pseudo-isomaltose	1396:1412	arg1	syntheses					1383:1391	syntheses	1383:1391	syntheses of pseudo-isomaltose and pseudo-KRN7000	1383:1431	With this in mind, we designed and developed a direct C-glycosylation method using atom-transfer radical coupling, and employed it in syntheses of pseudo-isomaltose and pseudo-KRN7000.
36470649	5	32	theme	F-atom	1032:1037	arg1	introduction					1039:1050	F-atom introduction	1032:1050	F-atom introduction	1032:1050	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	1	33	theme	natural-type	206:217	arg1	structure					226:234	the natural-type glycan structure	202:234	the natural-type glycan structure	202:234	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	5	34	theme	biological	1098:1107	arg1	activity					1109:1116	the biological activity	1094:1116	the biological activity	1094:1116	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	3	35	theme	pseudo	554:559	arg1	glycans					561:567	only a few pseudo glycans	543:567	only a few pseudo glycans	543:567	However, their biological potential is not yet well understood because only a few pseudo glycans have so far been synthesized.
36470649	2	36	theme	long	447:450	arg1	period					452:457	a long period	445:457	a long period	445:457	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	4	37	theme	bond	864:867	arg1	synthesis					835:843	our stereoselective synthesis	815:843	our stereoselective synthesis of the C-sialoside bond	815:867	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	4	38	theme	chemical	781:788	arg1	insights					790:797	the chemical insights	777:797	the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond	777:867	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	4	39	theme	bird's-eye	630:639	arg1	view					641:644	a bird's-eye view	628:644	a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	628:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	0	40	with	Pseudo-glycoconjugates	0:21	arg1	linkage					42:48	a C-glycoside linkage	28:48	a C-glycoside linkage	28:48	Pseudo-glycoconjugates with a C-glycoside linkage.
36470649	4	41	from	creation	675:682	arg1	view					641:644	a bird's-eye view	628:644	a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	628:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	1	42	theme	glycan	219:224	arg1	structure					226:234	the natural-type glycan structure	202:234	the natural-type glycan structure	202:234	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	4	43	theme	CHF-sialoside	739:751	arg1	linkage					753:759	the CHF-sialoside linkage	735:759	the CHF-sialoside linkage	735:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36470649	2	44	theme	glycoside	318:326	arg1	hydrolases					328:337	cellular glycoside hydrolases	309:337	cellular glycoside hydrolases	309:337	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	1	45	theme	structure	226:234	arg1	linkage					191:197	the O-glycosidic linkage	174:197	the O-glycosidic linkage of the natural-type glycan structure	174:234	Work by the author and colleagues has been focused on the development of pseudo-glycans (pseudo-glycoconjugates), in which the O-glycosidic linkage of the natural-type glycan structure is replaced by a C-glycosidic linkage.
36470649	5	46	theme	conformational	1006:1019	arg1	successful					1056:1065	successful	1056:1065	successful	1056:1065	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	5	46	theme	conformational	1006:1019	arg1	control					1021:1027	the anticipated conformational control	990:1027	the anticipated conformational control by F-atom introduction	990:1050	Conformational analysis of the synthesized CHF-sialoside disaccharides confirmed that the anticipated conformational control by F-atom introduction was successful, and furthermore, enhanced the biological activity.
36470649	7	47	theme	direct	1296:1301	arg1	method					1319:1324	a direct C-glycosylation method	1294:1324	a direct C-glycosylation method	1294:1324	With this in mind, we designed and developed a direct C-glycosylation method using atom-transfer radical coupling, and employed it in syntheses of pseudo-isomaltose and pseudo-KRN7000.
36470649	2	48	from	activity	432:439	arg1	cell					466:469	the cell	462:469	the cell	462:469	These analogs are not degraded by cellular glycoside hydrolases and are thus expected to be useful molecular tools that may maintain the original biological activity for a long period in the cell.
36470649	4	49	from	studies	660:666	arg1	creation					675:682	the creation	671:682	the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage	671:759	This article aims to provide a bird's-eye view of our recent studies on the creation of C-glycoside analogs of ganglioside GM3 based on the CHF-sialoside linkage, and summarizes the chemical insights acquired during our stereoselective synthesis of the C-sialoside bond, ultimately leading to pseudo-GM3.
36598201	6	0	theme	attenuated	879:888	arg1	replication					890:900	attenuated replication	879:900	attenuated replication in cultured cell lines	879:923	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	3	1	theme	glycans	473:479	arg1	role					465:468	the role	461:468	the role of glycans	461:479	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	15	2	contain	had	2213:2215	arg2	diarrhea					2229:2236	less severe diarrhea	2217:2236	less severe diarrhea	2217:2236	In addition, mice infected with the N-glycosylation-defective virus had less severe diarrhea than mice infected with the wild type.
36598201	15	2	contain	had	2213:2215	arg1	mice					2158:2161	mice	2158:2161	mice infected with the N-glycosylation-defective virus	2158:2211	In addition, mice infected with the N-glycosylation-defective virus had less severe diarrhea than mice infected with the wild type.
36598201	4	3	theme	genetics	555:562	arg1	system					564:569	a reverse genetics system	545:569	a reverse genetics system	545:569	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	8	4	located	observed	1345:1352	arg2	impairments					1324:1334	these impairments	1318:1334	these impairments	1318:1334	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	8	4	located	observed	1345:1352	arg1	cells					1362:1366	HT29 cells	1357:1366	HT29 cells	1357:1366	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	6	5	theme	glycosylation-defective	841:863	arg1	virus					865:869	glycosylation-defective virus	841:869	a recombinant virus that lost both glycosylation sites (glycosylation-defective virus)	785:870	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	9	6	from	cells	1495:1499	arg1	impaired					1455:1462	impaired	1455:1462	impaired	1455:1462	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	17	7	theme	glycosylation-defective	2461:2483	arg1	virus					2485:2489	this glycosylation-defective virus	2456:2489	this glycosylation-defective virus	2456:2489	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	17	7	theme	glycosylation-defective	2461:2483	arg1	candidate					2533:2541	an ideal live attenuated vaccine candidate	2500:2541	an ideal live attenuated vaccine candidate	2500:2541	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	4	8	theme	viral	624:628	arg1	replication					630:640	viral replication	624:640	viral replication	624:640	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	9	9	theme	glycosylation-defective	1412:1434	arg1	virus					1436:1440	glycosylation-defective virus	1412:1440	glycosylation-defective virus	1412:1440	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	13	10	used	used	1968:1971	arg2	we					1965:1966	we	1965:1966	we	1965:1966	Here, we used a reverse genetics approach to examine the role of NSP4 N-glycosylation.
36598201	10	11	theme	In	1574:1575	arg1	experiments					1588:1598	In vivo mouse experiments	1574:1598	In vivo mouse experiments	1574:1598	In vivo mouse experiments also showed that the glycosylation-defective virus was less pathogenic than the wild-type virus.
36598201	10	12	dep	In	1574:1575	arg1	vivo					1577:1580	vivo	1577:1580	vivo	1577:1580	In vivo mouse experiments also showed that the glycosylation-defective virus was less pathogenic than the wild-type virus.
36598201	1	13	theme	high	166:169	arg1	economic					171:178	a high economic and health burden worldwide	164:206	economic	171:178	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	8	14	theme	Ca2+	1248:1251	arg1	elevation					1253:1261	cytosolic Ca2+ elevation	1238:1261	cytosolic Ca2+ elevation	1238:1261	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	11	15	theme	vital	1767:1771	arg1	role					1773:1776	a vital role	1765:1776	a vital role	1765:1776	Taken together, the data suggest that N-glycosylation of NSP4 plays a vital role in viral replication and pathogenicity.
36598201	12	16	theme	128,500	1933:1939	arg1	deaths					1941:1946	deaths	1941:1946	deaths	1941:1946	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	17	17	theme	live	2509:2512	arg1	candidate					2533:2541	an ideal live attenuated vaccine candidate	2500:2541	an ideal live attenuated vaccine candidate	2500:2541	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	17	17	theme	live	2509:2512	arg1	virus					2485:2489	this glycosylation-defective virus	2456:2489	this glycosylation-defective virus	2456:2489	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	4	18	theme	N-glycosylation	601:615	arg1	role					588:591	the role	584:591	the role of NSP4 N-glycosylation during viral replication and pathogenesis	584:657	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	5	19	theme	viruses	691:697	arg1	rate					671:674	The growth rate	660:674	The growth rate of recombinant viruses that lost one glycosylation site	660:730	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	5	19	theme	viruses	691:697	arg1	high					739:742	high	739:742	high	739:742	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	7	20	theme	HT29	999:1002	arg1	cells					1004:1008	MA104 and HT29 cells	989:1008	cells	1004:1008	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	1	21	theme	burden	191:196	arg1	worldwide					198:206	a high economic and health burden worldwide	164:206	worldwide	198:206	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	8	22	theme	NSP4	1207:1210	arg1	mislocalization					1212:1226	NSP4 mislocalization	1207:1226	NSP4 mislocalization	1207:1226	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	6	23	theme	cell	914:917	arg1	lines					919:923	cultured cell lines	905:923	cultured cell lines	905:923	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	10	24	theme	mouse	1582:1586	arg1	experiments					1588:1598	In vivo mouse experiments	1574:1598	In vivo mouse experiments	1574:1598	In vivo mouse experiments also showed that the glycosylation-defective virus was less pathogenic than the wild-type virus.
36598201	7	25	theme	MA104	989:993	arg1	cells					1004:1008	MA104 and HT29 cells	989:1008	cells	1004:1008	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	5	26	theme	growth	664:669	arg1	rate					671:674	The growth rate	660:674	The growth rate of recombinant viruses that lost one glycosylation site	660:730	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	5	26	theme	growth	664:669	arg1	high					739:742	high	739:742	high	739:742	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	7	27	theme	virus	980:984	arg1	replications					940:951	replications	940:951	replications of glycosylation-defective virus in MA104 and HT29 cells	940:1008	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	15	28	theme	severe	2222:2227	arg1	diarrhea					2229:2236	less severe diarrhea	2217:2236	less severe diarrhea	2217:2236	In addition, mice infected with the N-glycosylation-defective virus had less severe diarrhea than mice infected with the wild type.
36598201	9	29	theme	HT29	1467:1470	arg1	cells					1472:1476	HT29 cells	1467:1476	HT29 cells	1467:1476	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	3	30	contain	has	411:413	arg1	protein					354:360	a multifunctional protein	336:360	a multifunctional protein involved in various viral replication processes	336:408	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	3	30	contain	has	411:413	arg2	sites					445:449	two conserved N-glycosylation sites	415:449	two conserved N-glycosylation sites	415:449	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	3	30	contain	has	411:413	arg1	NSP4					330:333	NSP4	330:333	NSP4	330:333	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	13	31	theme	N-glycosylation	2029:2043	arg1	role					2016:2019	the role	2012:2019	the role of NSP4 N-glycosylation	2012:2043	Here, we used a reverse genetics approach to examine the role of NSP4 N-glycosylation.
36598201	0	32	theme	Rotavirus	19:27	arg1	Protein					34:40	Rotavirus NSP4 Protein	19:40	Rotavirus NSP4 Protein	19:40	N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.
36598201	1	33	theme	gastroenteritis	127:141	arg1	cause					118:122	the most common cause	102:122	the most common cause of gastroenteritis in children	102:153	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	1	33	theme	gastroenteritis	127:141	arg1	Rotavirus					86:94	Rotavirus	86:94	Rotavirus (RV)	86:99	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	17	34	theme	propagation	2423:2433	arg1	rate					2435:2438	the high propagation rate	2414:2438	the high propagation rate in MA104 cells	2414:2453	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	16	35	theme	viral	2328:2332	arg1	replication					2334:2344	viral replication	2328:2344	viral replication	2328:2344	These results suggest that N-glycosylation affects viral replication and pathogenesis.
36598201	8	36	from	formation	1283:1291	arg1	cells					1302:1306	MA104 cells	1296:1306	MA104 cells	1296:1306	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	9	37	theme	RV	1518:1519	arg1	mechanism					1533:1541	RV replication mechanism	1518:1541	RV replication mechanism	1518:1541	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	5	38	theme	glycosylation	713:725	arg1	site					727:730	one glycosylation site	709:730	one glycosylation site	709:730	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	11	39	gly	N-glycosylation	1735:1749	arg1	NSP4					1754:1757	NSP4	1754:1757	NSP4	1754:1757	Taken together, the data suggest that N-glycosylation of NSP4 plays a vital role in viral replication and pathogenicity.
36598201	17	40	theme	high	2418:2421	arg1	rate					2435:2438	the high propagation rate	2414:2438	the high propagation rate in MA104 cells	2414:2453	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	14	41	theme	N-glycosylation-defective	2049:2073	arg1	virus					2075:2079	An N-glycosylation-defective virus	2046:2079	An N-glycosylation-defective virus	2046:2079	An N-glycosylation-defective virus showed attenuated and cell-type-dependent replication in vitro.
36598201	5	42	gly	glycosylation	713:725	arg2	site					727:730	one glycosylation site	709:730	one glycosylation site	709:730	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	5	42	gly	glycosylation	713:725	arg2	one					709:711	one	709:711	one	709:711	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	6	43	gly	glycosylation	820:832	arg2	sites					834:838	both glycosylation sites	815:838	both glycosylation sites	815:838	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	7	44	theme	critical	1133:1140	arg1	role					1142:1145	a critical role	1131:1145	a critical role	1131:1145	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	12	45	theme	main	1846:1849	arg1	cause					1851:1855	the main cause	1842:1855	the main cause of gastroenteritis in young children and infants worldwide	1842:1914	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	12	45	theme	main	1846:1849	arg1	Rotavirus					1829:1837	IMPORTANCE Rotavirus	1818:1837	IMPORTANCE Rotavirus	1818:1837	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	6	46	theme	glycosylation	820:832	arg1	sites					834:838	both glycosylation sites	815:838	both glycosylation sites	815:838	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	3	47	theme	viral	382:386	arg1	processes					400:408	various viral replication processes	374:408	various viral replication processes	374:408	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	17	48	from	pathogenicity	2388:2400	arg1	cells					2449:2453	MA104 cells	2443:2453	MA104 cells	2443:2453	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	3	49	theme	conserved	419:427	arg1	sites					445:449	two conserved N-glycosylation sites	415:449	two conserved N-glycosylation sites	415:449	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	0	50	theme	Protein	34:40	arg1	N-Glycosylation					0:14	N-Glycosylation	0:14	N-Glycosylation of Rotavirus NSP4 Protein	0:40	N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.
36598201	3	51	gly	N-glycosylation	429:443	arg2	sites					445:449	two conserved N-glycosylation sites	415:449	two conserved N-glycosylation sites	415:449	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	3	51	gly	N-glycosylation	429:443	arg2	two					415:417	two	415:417	two	415:417	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	17	52	from	rate	2435:2438	arg1	cells					2449:2453	MA104 cells	2443:2453	MA104 cells	2443:2453	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	2	53	theme	viral	311:315	arg1	replication					317:327	viral replication	311:327	viral replication	311:327	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	0	54	theme	Viral	50:54	arg1	Replication					56:66	Viral Replication	50:66	Viral Replication	50:66	N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.
36598201	12	55	theme	IMPORTANCE	1818:1827	arg1	cause					1851:1855	the main cause	1842:1855	the main cause of gastroenteritis in young children and infants worldwide	1842:1914	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	12	55	theme	IMPORTANCE	1818:1827	arg1	Rotavirus					1829:1837	IMPORTANCE Rotavirus	1818:1837	IMPORTANCE Rotavirus	1818:1837	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	17	56	theme	attenuated	2514:2523	arg1	candidate					2533:2541	an ideal live attenuated vaccine candidate	2500:2541	an ideal live attenuated vaccine candidate	2500:2541	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	17	56	theme	attenuated	2514:2523	arg1	virus					2485:2489	this glycosylation-defective virus	2456:2489	this glycosylation-defective virus	2456:2489	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	10	57	theme	wild-type	1680:1688	arg1	virus					1690:1694	the wild-type virus	1676:1694	the wild-type virus	1676:1694	In vivo mouse experiments also showed that the glycosylation-defective virus was less pathogenic than the wild-type virus.
36598201	17	58	theme	reduced	2380:2386	arg1	pathogenicity					2388:2400	the reduced pathogenicity	2376:2400	the reduced pathogenicity in vivo	2376:2408	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	6	59	from	replication	890:900	arg1	lines					919:923	cultured cell lines	905:923	cultured cell lines	905:923	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	13	60	theme	reverse	1975:1981	arg1	approach					1992:1999	a reverse genetics approach	1973:1999	a reverse genetics approach	1973:1999	Here, we used a reverse genetics approach to examine the role of NSP4 N-glycosylation.
36598201	4	61	used	used	507:510	arg2	we					504:505	we	504:505	we	504:505	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	4	62	theme	reverse	547:553	arg1	system					564:569	a reverse genetics system	545:569	a reverse genetics system	545:569	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	2	63	theme	nonstructural	252:264	arg1	proteins					266:273	six nonstructural proteins	248:273	six nonstructural proteins	248:273	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	2	63	theme	nonstructural	252:264	arg1	RV					209:210	RV	209:210	RV	209:210	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	9	64	theme	virus	1436:1440	arg1	assembly					1400:1407	assembly	1400:1407	assembly of glycosylation-defective virus	1400:1440	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	9	65	from	cells	1472:1476	arg1	impaired					1455:1462	impaired	1455:1462	impaired	1455:1462	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	11	66	theme	viral	1781:1785	arg1	replication					1787:1797	viral replication	1781:1797	viral replication	1781:1797	Taken together, the data suggest that N-glycosylation of NSP4 plays a vital role in viral replication and pathogenicity.
36598201	12	67	from	cause	1851:1855	arg1	children					1885:1892	young children	1879:1892	young children	1879:1892	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	12	67	from	cause	1851:1855	arg1	infants					1898:1904	infants	1898:1904	infants	1898:1904	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	17	68	theme	ideal	2503:2507	arg1	candidate					2533:2541	an ideal live attenuated vaccine candidate	2500:2541	an ideal live attenuated vaccine candidate	2500:2541	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	17	68	theme	ideal	2503:2507	arg1	virus					2485:2489	this glycosylation-defective virus	2456:2489	this glycosylation-defective virus	2456:2489	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	8	69	theme	cytosolic	1238:1246	arg1	elevation					1253:1261	cytosolic Ca2+ elevation	1238:1261	cytosolic Ca2+ elevation	1238:1261	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	5	70	theme	recombinant	679:689	arg1	viruses					691:697	recombinant viruses	679:697	recombinant viruses that lost one glycosylation site	679:730	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	1	71	theme	health	184:189	arg1	worldwide					198:206	a high economic and health burden worldwide	164:206	worldwide	198:206	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	8	72	theme	glycosylation-defective	1170:1192	arg1	virus					1194:1198	The glycosylation-defective virus	1166:1198	The glycosylation-defective virus	1166:1198	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	4	73	theme	NSP4	596:599	arg1	N-glycosylation					601:615	NSP4 N-glycosylation	596:615	NSP4 N-glycosylation	596:615	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	8	74	from	delay	1229:1233	arg1	cells					1302:1306	MA104 cells	1296:1306	MA104 cells	1296:1306	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	12	75	theme	deaths	1941:1946	arg1	year					1953:1956	128,500 deaths each year	1933:1956	128,500 deaths each year	1933:1956	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	6	76	theme	cultured	905:912	arg1	lines					919:923	cultured cell lines	905:923	cultured cell lines	905:923	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	8	77	from	mislocalization	1212:1226	arg1	cells					1302:1306	MA104 cells	1296:1306	MA104 cells	1296:1306	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	1	78	theme	common	111:116	arg1	cause					118:122	the most common cause	102:122	the most common cause of gastroenteritis in children	102:153	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	1	78	theme	common	111:116	arg1	Rotavirus					86:94	Rotavirus	86:94	Rotavirus (RV)	86:99	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	8	79	theme	viroplasm	1273:1281	arg1	formation					1283:1291	less viroplasm formation	1268:1291	less viroplasm formation in MA104 cells	1268:1306	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	2	80	theme	structural	224:233	arg1	RV					209:210	RV	209:210	RV	209:210	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	2	80	theme	structural	224:233	arg1	proteins					235:242	six structural proteins	220:242	six structural proteins	220:242	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	2	80	theme	structural	224:233	arg1	NSPs					276:279	NSPs	276:279	NSPs	276:279	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	12	81	theme	worldwide	1906:1914	arg1	children					1885:1892	young children	1879:1892	young children	1879:1892	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	7	82	theme	glycosylation-defective	956:978	arg1	virus					980:984	glycosylation-defective virus	956:984	glycosylation-defective virus	956:984	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	15	83	theme	N-glycosylation-defective	2181:2205	arg1	virus					2207:2211	the N-glycosylation-defective virus	2177:2211	the N-glycosylation-defective virus	2177:2211	In addition, mice infected with the N-glycosylation-defective virus had less severe diarrhea than mice infected with the wild type.
36598201	7	84	from	replications	940:951	arg1	cells					1004:1008	MA104 and HT29 cells	989:1008	cells	1004:1008	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	14	85	theme	cell-type-dependent	2103:2121	arg1	replication					2123:2133	attenuated and cell-type-dependent replication	2088:2133	attenuated and cell-type-dependent replication	2088:2133	An N-glycosylation-defective virus showed attenuated and cell-type-dependent replication in vitro.
36598201	11	86	theme	NSP4	1754:1757	arg1	N-glycosylation					1735:1749	N-glycosylation	1735:1749	N-glycosylation of NSP4	1735:1757	Taken together, the data suggest that N-glycosylation of NSP4 plays a vital role in viral replication and pathogenicity.
36598201	7	87	theme	RV	1150:1151	arg1	replication					1153:1163	RV replication	1150:1163	RV replication	1150:1163	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	12	88	theme	young	1879:1883	arg1	children					1885:1892	young children	1879:1892	young children	1879:1892	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	9	89	theme	replication	1521:1531	arg1	mechanism					1533:1541	RV replication mechanism	1518:1541	RV replication mechanism	1518:1541	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	14	90	theme	attenuated	2088:2097	arg1	replication					2123:2133	attenuated and cell-type-dependent replication	2088:2133	attenuated and cell-type-dependent replication	2088:2133	An N-glycosylation-defective virus showed attenuated and cell-type-dependent replication in vitro.
36598201	10	91	theme	glycosylation-defective	1621:1643	arg1	virus					1645:1649	the glycosylation-defective virus	1617:1649	the glycosylation-defective virus	1617:1649	In vivo mouse experiments also showed that the glycosylation-defective virus was less pathogenic than the wild-type virus.
36598201	10	91	theme	glycosylation-defective	1621:1643	arg1	pathogenic					1660:1669	pathogenic	1660:1669	pathogenic	1660:1669	In vivo mouse experiments also showed that the glycosylation-defective virus was less pathogenic than the wild-type virus.
36598201	5	92	theme	wild-type	759:767	arg1	virus					769:773	the wild-type virus	755:773	the wild-type virus	755:773	The growth rate of recombinant viruses that lost one glycosylation site was as high as that of the wild-type virus.
36598201	13	93	theme	NSP4	2024:2027	arg1	N-glycosylation					2029:2043	NSP4 N-glycosylation	2024:2043	NSP4 N-glycosylation	2024:2043	Here, we used a reverse genetics approach to examine the role of NSP4 N-glycosylation.
36598201	1	94	from	cause	118:122	arg1	children					146:153	children	146:153	children	146:153	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	4	95	theme	recombinant	512:522	arg1	viruses					524:530	recombinant viruses	512:530	recombinant viruses generated by a reverse genetics system	512:569	Here, we used recombinant viruses generated by a reverse genetics system to determine the role of NSP4 N-glycosylation during viral replication and pathogenesis.
36598201	0	96	theme	NSP4	29:32	arg1	Protein					34:40	Rotavirus NSP4 Protein	19:40	Rotavirus NSP4 Protein	19:40	N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.
36598201	3	97	theme	multifunctional	338:352	arg1	protein					354:360	a multifunctional protein	336:360	a multifunctional protein involved in various viral replication processes	336:408	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	3	97	theme	multifunctional	338:352	arg1	NSP4					330:333	NSP4	330:333	NSP4	330:333	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	6	98	dep	virus	799:803	arg1	virus					865:869	glycosylation-defective virus	841:869	a recombinant virus that lost both glycosylation sites (glycosylation-defective virus)	785:870	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	7	99	theme	NSP4	1120:1123	arg1	N-glycosylation					1101:1115	N-glycosylation	1101:1115	N-glycosylation of NSP4	1101:1123	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	12	100	theme	gastroenteritis	1860:1874	arg1	cause					1851:1855	the main cause	1842:1855	the main cause of gastroenteritis in young children and infants worldwide	1842:1914	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	12	100	theme	gastroenteritis	1860:1874	arg1	Rotavirus					1829:1837	IMPORTANCE Rotavirus	1818:1837	IMPORTANCE Rotavirus	1818:1837	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	0	101	gly	N-Glycosylation	0:14	arg1	Protein					34:40	Rotavirus NSP4 Protein	19:40	Rotavirus NSP4 Protein	19:40	N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.
36598201	3	102	theme	replication	388:398	arg1	processes					400:408	various viral replication processes	374:408	various viral replication processes	374:408	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	1	103	contain	carries	156:162	arg2	worldwide					198:206	a high economic and health burden worldwide	164:206	worldwide	198:206	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	1	103	contain	carries	156:162	arg1	Rotavirus					86:94	Rotavirus	86:94	Rotavirus (RV)	86:99	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	1	103	contain	carries	156:162	arg1	cause					118:122	the most common cause	102:122	the most common cause of gastroenteritis in children	102:153	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	1	103	contain	carries	156:162	arg2	economic					171:178	a high economic and health burden worldwide	164:206	economic	171:178	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	1	103	contain	carries	156:162	arg1	RV					97:98	RV	97:98	RV	97:98	Rotavirus (RV), the most common cause of gastroenteritis in children, carries a high economic and health burden worldwide.
36598201	8	104	theme	HT29	1357:1360	arg1	cells					1362:1366	HT29 cells	1357:1366	HT29 cells	1357:1366	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	13	105	theme	genetics	1983:1990	arg1	approach					1992:1999	a reverse genetics approach	1973:1999	a reverse genetics approach	1973:1999	Here, we used a reverse genetics approach to examine the role of NSP4 N-glycosylation.
36598201	3	106	theme	N-glycosylation	429:443	arg1	sites					445:449	two conserved N-glycosylation sites	415:449	two conserved N-glycosylation sites	415:449	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	15	107	theme	wild	2266:2269	arg1	type					2271:2274	the wild type	2262:2274	the wild type	2262:2274	In addition, mice infected with the N-glycosylation-defective virus had less severe diarrhea than mice infected with the wild type.
36598201	3	108	theme	various	374:380	arg1	processes					400:408	various viral replication processes	374:408	various viral replication processes	374:408	NSP4, a multifunctional protein involved in various viral replication processes, has two conserved N-glycosylation sites; however, the role of glycans remains elusive.
36598201	7	109	gly	N-glycosylation	1101:1115	arg1	NSP4					1120:1123	NSP4	1120:1123	NSP4	1120:1123	Specifically, replications of glycosylation-defective virus in MA104 and HT29 cells were 10- and 100,000-fold lower, respectively, than that of the wild-type, suggesting that N-glycosylation of NSP4 plays a critical role in RV replication.
36598201	6	110	theme	recombinant	787:797	arg1	virus					799:803	a recombinant virus	785:803	a recombinant virus that lost both glycosylation sites (glycosylation-defective virus)	785:870	However, a recombinant virus that lost both glycosylation sites (glycosylation-defective virus) showed attenuated replication in cultured cell lines.
36598201	9	111	from	impaired	1455:1462	arg1	cells					1495:1499	MA104 cells	1489:1499	MA104 cells	1489:1499	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	9	111	from	impaired	1455:1462	arg1	cells					1472:1476	HT29 cells	1467:1476	HT29 cells	1467:1476	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36598201	17	112	theme	vaccine	2525:2531	arg1	candidate					2533:2541	an ideal live attenuated vaccine candidate	2500:2541	an ideal live attenuated vaccine candidate	2500:2541	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	17	112	theme	vaccine	2525:2531	arg1	virus					2485:2489	this glycosylation-defective virus	2456:2489	this glycosylation-defective virus	2456:2489	Considering the reduced pathogenicity in vivo and the high propagation rate in MA104 cells, this glycosylation-defective virus could be an ideal live attenuated vaccine candidate.
36598201	2	113	theme	different	292:300	arg1	roles					302:306	different roles	292:306	different roles	292:306	RV encodes six structural proteins and six nonstructural proteins (NSPs) that play different roles in viral replication.
36598201	8	114	theme	elevation	1253:1261	arg1	delay					1229:1233	delay	1229:1233	delay of cytosolic Ca2+ elevation	1229:1261	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	8	114	theme	elevation	1253:1261	arg1	mislocalization					1212:1226	NSP4 mislocalization	1207:1226	NSP4 mislocalization	1207:1226	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	8	114	theme	elevation	1253:1261	arg1	formation					1283:1291	less viroplasm formation	1268:1291	less viroplasm formation in MA104 cells	1268:1306	The glycosylation-defective virus showed NSP4 mislocalization, delay of cytosolic Ca2+ elevation, and less viroplasm formation in MA104 cells; however, these impairments were not observed in HT29 cells.
36598201	12	115	theme	each	1948:1951	arg1	year					1953:1956	128,500 deaths each year	1933:1956	128,500 deaths each year	1933:1956	IMPORTANCE Rotavirus is the main cause of gastroenteritis in young children and infants worldwide, contributing to 128,500 deaths each year.
36598201	9	116	theme	Further	1369:1375	arg1	analysis					1377:1384	Further analysis	1369:1384	Further analysis	1369:1384	Further analysis revealed that assembly of glycosylation-defective virus was severely impaired in HT29 cells but not in MA104 cells, suggesting that RV replication mechanism is highly cell type dependent.
36018613	10	0	dep	cleavage	1099:1106	arg1	is					1076:1077	is	1076:1077	is	1076:1077	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	0	dep	cleavage	1099:1106	arg1	as					1073:1074	as	1073:1074	as	1073:1074	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	1	1	link	N-linked	279:286	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	10	2	theme	furanose	1149:1156	arg1	structures					1174:1183	furanose oxazolinium ion structures	1149:1183	furanose oxazolinium ion structures	1149:1183	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	6	3	theme	structure	505:513	arg1	irrespective					413:424	irrespective	413:424	irrespective	413:424	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	13	4	theme	m/z	1522:1524	arg1	structure					1542:1550	a furanose m/z 204 product ion structure	1511:1550	a furanose m/z 204 product ion structure	1511:1550	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	1	5	theme	glycosylated	288:299	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	6	theme	262	1361:1363	arg1	fragment					1373:1380	the complementary m/z 262 peptide fragment	1339:1380	the complementary m/z 262 peptide fragment	1339:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	12	7	theme	m/z	1357:1359	arg1	fragment					1373:1380	the complementary m/z 262 peptide fragment	1339:1380	the complementary m/z 262 peptide fragment	1339:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	6	8	theme	N-acetylated	485:496	arg1	structure					505:513	the N-acetylated hexose structure	481:513	the N-acetylated hexose structure (GlcNAc or GalNAc)	481:532	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	13	9	theme	product	1530:1536	arg1	structure					1542:1550	a furanose m/z 204 product ion structure	1511:1550	a furanose m/z 204 product ion structure	1511:1550	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	1	10	theme	isomerization	192:204	arg1	reactions					206:214	pyranose to furanose N-acetylated ion isomerization reactions	154:214	pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al	154:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	11	theme	fragment	1373:1380	arg1	spectra					1328:1334	The IR action spectra	1314:1334	The IR action spectra of the complementary m/z 262 peptide fragment	1314:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	12	11	theme	fragment	1373:1380	arg1	mixture					1401:1407	a mixture	1399:1407	a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature	1399:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	1	12	theme	amino	301:305	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	13	theme	IR	1318:1319	arg1	spectra					1328:1334	The IR action spectra	1314:1334	The IR action spectra of the complementary m/z 262 peptide fragment	1314:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	12	13	theme	IR	1318:1319	arg1	mixture					1401:1407	a mixture	1399:1407	a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature	1399:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	11	14	theme	204	1245:1247	arg1	population					1278:1287	the m/z 204, C8H14N1O5+, glycan fragment population	1237:1287	population	1278:1287	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	7	15	theme	present	542:548	arg1	article					550:556	the present article	538:556	the present article	538:556	In the present article, we test the generality of the preceding findings by examining threonyl α-GalNAc-glycosylated peptides.
36018613	8	16	theme	various	712:718	arg1	dissociation					720:731	the various dissociation and isomerization pathways	708:758	dissociation	720:731	We utilize computational chemistry to compare the various dissociation and isomerization pathways accessible with collisional activation.
36018613	12	17	theme	lowest-energy	1416:1428	arg1	structures					1430:1439	the lowest-energy structures	1412:1439	the lowest-energy structures of [ATA+H]+ consistent with the literature	1412:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	9	18	with	glycan	862:867	arg1	spectroscopy					914:925	infrared "action" spectroscopy	896:925	infrared "action" spectroscopy	896:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	10	19	theme	glycosidic	1083:1092	arg1	cleavage					1099:1106	the glycosidic bond cleavage	1079:1106	the glycosidic bond cleavage of the newly formed furanose form	1079:1140	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	1	20	theme	computational	128:140	arg1	evidence					142:149	computational evidence	128:149	computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al	128:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	7	21	theme	threonyl	621:628	arg1	peptides					652:659	threonyl α-GalNAc-glycosylated peptides	621:659	threonyl α-GalNAc-glycosylated peptides	621:659	In the present article, we test the generality of the preceding findings by examining threonyl α-GalNAc-glycosylated peptides.
36018613	10	22	theme	ion	1170:1172	arg1	structures					1174:1183	furanose oxazolinium ion structures	1149:1183	furanose oxazolinium ion structures	1149:1183	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	23	gly	glycopeptide	983:994	arg2	glycopeptide					983:994	the protonated glycopeptide [AT	968:998	the protonated glycopeptide [AT	968:998	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	6	24	theme	linkage	444:450	arg1	stereochemistry					452:466	the glycosidic linkage stereochemistry	429:466	the glycosidic linkage stereochemistry (α or β)	429:475	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	13	25	theme	ion	1577:1579	arg1	population					1581:1590	the ion population	1573:1590	the ion population available for MS3 dissociation and glycopeptide sequence identification	1573:1662	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	7	26	theme	preceding	589:597	arg1	findings					599:606	the preceding findings	585:606	the preceding findings	585:606	In the present article, we test the generality of the preceding findings by examining threonyl α-GalNAc-glycosylated peptides.
36018613	1	27	theme	N-acetylated	175:186	arg1	reactions					206:214	pyranose to furanose N-acetylated ion isomerization reactions	154:214	pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al	154:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	28	theme	consistent	1453:1462	arg1	structures					1430:1439	the lowest-energy structures	1412:1439	the lowest-energy structures of [ATA+H]+ consistent with the literature	1412:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	11	29	theme	action	1218:1223	arg1	spectra					1225:1231	IR action spectra	1215:1231	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population	1215:1287	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	1	30	dep	Guan	327:330	arg1	al					335:336	Guan et al	327:336	Guan et al	327:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	11	31	theme	m/z	1241:1243	arg1	population					1278:1287	the m/z 204, C8H14N1O5+, glycan fragment population	1237:1287	population	1278:1287	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	0	32	theme	Protonated	0:9	arg1	Chemistry					58:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry.
36018613	10	33	theme	bond	1094:1097	arg1	cleavage					1099:1106	the glycosidic bond cleavage	1079:1106	the glycosidic bond cleavage of the newly formed furanose form	1079:1140	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	1	34	gly	glycosylated	288:299	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	1	35	theme	H/D	110:112	arg1	labeling					114:121	H/D labeling	110:121	H/D labeling	110:121	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	9	36	theme	charged	854:860	arg1	glycan					862:867	charged glycan and peptide fragments	854:889	glycan	862:867	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	0	37	theme	Galactose	22:30	arg1	Chemistry					58:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry.
36018613	1	38	theme	model	312:316	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	39	theme	[ATA+H	1444:1449	arg1	structures					1430:1439	the lowest-energy structures	1412:1439	the lowest-energy structures of [ATA+H]+ consistent with the literature	1412:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	0	40	theme	Dissociation	45:56	arg1	Chemistry					58:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry.
36018613	9	41	theme	fragments	881:889	arg1	s					834:834	the structure(s)	820:835	the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy	820:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	13	42	theme	available	1592:1600	arg1	population					1581:1590	the ion population	1573:1590	the ion population available for MS3 dissociation and glycopeptide sequence identification	1573:1662	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	10	43	theme	pyranose	958:965	arg1	Isomerization					928:940	Isomerization	928:940	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+,	928:1012	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	9	44	theme	infrared	896:903	arg1	spectroscopy					914:925	infrared "action" spectroscopy	896:925	infrared "action" spectroscopy	896:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	1	45	theme	bond	250:253	arg1	cleavage					255:262	glycosidic bond cleavage	239:262	glycosidic bond cleavage	239:262	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	46	theme	structures	1430:1439	arg1	spectra					1328:1334	The IR action spectra	1314:1334	The IR action spectra of the complementary m/z 262 peptide fragment	1314:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	12	46	theme	structures	1430:1439	arg1	mixture					1401:1407	a mixture	1399:1407	a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature	1399:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	7	47	gly	α-GalNAc-glycosylated	630:650	arg1	peptides					652:659	threonyl α-GalNAc-glycosylated peptides	621:659	threonyl α-GalNAc-glycosylated peptides	621:659	In the present article, we test the generality of the preceding findings by examining threonyl α-GalNAc-glycosylated peptides.
36018613	9	48	theme	action	906:911	arg1	spectroscopy					914:925	infrared "action" spectroscopy	896:925	infrared "action" spectroscopy	896:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	1	49	dep	occurred	221:228	arg1	Guan					327:330	Guan	327:330	Guan	327:330	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	10	50	theme	furanose	1128:1135	arg1	form					1137:1140	the newly formed furanose form	1111:1140	the newly formed furanose form	1111:1140	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	51	theme	glycopeptide	983:994	arg1	[AT					996:998	the protonated glycopeptide [AT	968:998	the protonated glycopeptide [AT	968:998	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	51	theme	glycopeptide	983:994	arg1	pyranose					958:965	the original pyranose	945:965	the original pyranose	945:965	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	51	theme	glycopeptide	983:994	arg1	GalNAc					1000:1005	GalNAc	1000:1005	GalNAc	1000:1005	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	5	52	dep	Phys.	357:361	arg1	23256-23266					374:384	23256-23266	374:384	23256-23266	374:384	Phys., 2021, 23, 23256-23266).
36018613	13	53	theme	ion	1538:1540	arg1	structure					1542:1550	a furanose m/z 204 product ion structure	1511:1550	a furanose m/z 204 product ion structure	1511:1550	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	10	54	theme	oxazolinium	1158:1168	arg1	structures					1174:1183	furanose oxazolinium ion structures	1149:1183	furanose oxazolinium ion structures	1149:1183	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	13	55	theme	glycopeptide	1627:1638	arg1	identification					1649:1662	glycopeptide sequence identification	1627:1662	glycopeptide sequence identification	1627:1662	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	13	56	theme	furanose	1513:1520	arg1	structure					1542:1550	a furanose m/z 204 product ion structure	1511:1550	a furanose m/z 204 product ion structure	1511:1550	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	1	57	theme	N-linked	279:286	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	58	theme	peptide	1365:1371	arg1	fragment					1373:1380	the complementary m/z 262 peptide fragment	1339:1380	the complementary m/z 262 peptide fragment	1339:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	6	59	dep	structure	505:513	arg1	GalNAc					526:531	GalNAc	526:531	GalNAc	526:531	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	6	59	dep	structure	505:513	arg1	GlcNAc					516:521	GlcNAc	516:521	GlcNAc	516:521	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	6	60	theme	hexose	498:503	arg1	structure					505:513	the N-acetylated hexose structure	481:513	the N-acetylated hexose structure (GlcNAc or GalNAc)	481:532	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	1	61	theme	reactions	206:214	arg1	evidence					142:149	computational evidence	128:149	computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al	128:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	1	61	theme	reactions	206:214	arg1	spectrometric					95:107	mass spectrometric	90:107	mass spectrometric	90:107	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	1	61	theme	reactions	206:214	arg1	labeling					114:121	H/D labeling	110:121	H/D labeling	110:121	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	1	62	theme	ion	188:190	arg1	reactions					206:214	pyranose to furanose N-acetylated ion isomerization reactions	154:214	pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al	154:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	12	63	theme	complementary	1343:1355	arg1	fragment					1373:1380	the complementary m/z 262 peptide fragment	1339:1380	the complementary m/z 262 peptide fragment	1339:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	11	64	theme	fragment	1269:1276	arg1	population					1278:1287	the m/z 204, C8H14N1O5+, glycan fragment population	1237:1287	population	1278:1287	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	8	65	theme	computational	673:685	arg1	chemistry					687:695	computational chemistry	673:695	computational chemistry	673:695	We utilize computational chemistry to compare the various dissociation and isomerization pathways accessible with collisional activation.
36018613	9	66	with	fragments	881:889	arg1	spectroscopy					914:925	infrared "action" spectroscopy	896:925	infrared "action" spectroscopy	896:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	9	67	theme	structure	824:832	arg1	s					834:834	the structure(s)	820:835	the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy	820:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	12	68	theme	action	1321:1326	arg1	spectra					1328:1334	The IR action spectra	1314:1334	The IR action spectra of the complementary m/z 262 peptide fragment	1314:1380	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	12	68	theme	action	1321:1326	arg1	mixture					1401:1407	a mixture	1399:1407	a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature	1399:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	11	69	dep	population	1278:1287	arg1	glycan					1262:1267	the m/z 204, C8H14N1O5+, glycan fragment population	1237:1287	glycan	1262:1267	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	11	69	dep	population	1278:1287	arg1	C8H14N1O5+					1250:1259	the m/z 204, C8H14N1O5+, glycan fragment population	1237:1287	C8H14N1O5+	1250:1259	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	8	70	theme	isomerization	737:749	arg1	pathways					751:758	the various dissociation and isomerization pathways	708:758	pathways	751:758	We utilize computational chemistry to compare the various dissociation and isomerization pathways accessible with collisional activation.
36018613	13	71	gly	glycopeptide	1627:1638	arg2	glycopeptide					1627:1638	glycopeptide sequence identification	1627:1662	glycopeptide sequence identification	1627:1662	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	12	72	with	consistent	1453:1462	arg1	literature					1473:1482	the literature	1469:1482	the literature	1469:1482	The IR action spectra of the complementary m/z 262 peptide fragment were assigned as a mixture of the lowest-energy structures of [ATA+H]+ consistent with the literature.
36018613	8	73	theme	accessible	760:769	arg1	dissociation					720:731	the various dissociation and isomerization pathways	708:758	dissociation	720:731	We utilize computational chemistry to compare the various dissociation and isomerization pathways accessible with collisional activation.
36018613	7	74	theme	α-GalNAc-glycosylated	630:650	arg1	peptides					652:659	threonyl α-GalNAc-glycosylated peptides	621:659	threonyl α-GalNAc-glycosylated peptides	621:659	In the present article, we test the generality of the preceding findings by examining threonyl α-GalNAc-glycosylated peptides.
36018613	1	75	theme	pyranose	154:161	arg1	reactions					206:214	pyranose to furanose N-acetylated ion isomerization reactions	154:214	pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al	154:336	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	8	76	theme	collisional	776:786	arg1	activation					788:797	collisional activation	776:797	collisional activation	776:797	We utilize computational chemistry to compare the various dissociation and isomerization pathways accessible with collisional activation.
36018613	6	77	theme	glycosidic	433:442	arg1	stereochemistry					452:466	the glycosidic linkage stereochemistry	429:466	the glycosidic linkage stereochemistry (α or β)	429:475	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	7	78	theme	findings	599:606	arg1	generality					571:580	the generality	567:580	the generality of the preceding findings	567:606	In the present article, we test the generality of the preceding findings by examining threonyl α-GalNAc-glycosylated peptides.
36018613	1	79	theme	mass	90:93	arg1	spectrometric					95:107	mass spectrometric	90:107	mass spectrometric	90:107	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	13	80	theme	MS3	1606:1608	arg1	dissociation					1610:1621	MS3 dissociation	1606:1621	MS3 dissociation	1606:1621	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	8	81	with	accessible	760:769	arg1	activation					788:797	collisional activation	776:797	collisional activation	776:797	We utilize computational chemistry to compare the various dissociation and isomerization pathways accessible with collisional activation.
36018613	0	82	theme	α-N-Acetyl	11:20	arg1	Chemistry					58:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry.
36018613	10	83	theme	direct	1052:1057	arg1	dissociation					1059:1070	direct dissociation	1052:1070	direct dissociation	1052:1070	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	84	theme	original	949:956	arg1	[AT					996:998	the protonated glycopeptide [AT	968:998	the protonated glycopeptide [AT	968:998	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	84	theme	original	949:956	arg1	pyranose					958:965	the original pyranose	945:965	the original pyranose	945:965	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	85	dep	GalNAc	1000:1005	arg1	A+H					1007:1009	A+H	1007:1009	A+H	1007:1009	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	6	86	dep	stereochemistry	452:466	arg1	α					469:469	α	469:469	α	469:469	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	6	86	dep	stereochemistry	452:466	arg1	β					474:474	β	474:474	β	474:474	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	9	87	theme	resulting	844:852	arg1	glycan					862:867	charged glycan and peptide fragments	854:889	glycan	862:867	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	0	88	theme	Glycopeptide	32:43	arg1	Chemistry					58:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry	0:66	Protonated α-N-Acetyl Galactose Glycopeptide Dissociation Chemistry.
36018613	1	89	theme	acid	307:310	arg1	systems					318:324	N-linked glycosylated amino acid model systems	279:324	N-linked glycosylated amino acid model systems	279:324	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	9	90	theme	glycan	862:867	arg1	s					834:834	the structure(s)	820:835	the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy	820:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	10	91	theme	protonated	972:981	arg1	[AT					996:998	the protonated glycopeptide [AT	968:998	the protonated glycopeptide [AT	968:998	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	91	theme	protonated	972:981	arg1	pyranose					958:965	the original pyranose	945:965	the original pyranose	945:965	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	10	91	theme	protonated	972:981	arg1	GalNAc					1000:1005	GalNAc	1000:1005	GalNAc	1000:1005	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	9	92	theme	peptide	873:879	arg1	fragments					881:889	charged glycan and peptide fragments	854:889	fragments	881:889	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	11	93	theme	IR	1215:1216	arg1	spectra					1225:1231	IR action spectra	1215:1231	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population	1215:1287	IR action spectra for the m/z 204, C8H14N1O5+, glycan fragment population support this prediction.
36018613	6	94	theme	stereochemistry	452:466	arg1	irrespective					413:424	irrespective	413:424	irrespective	413:424	These reactions occurred irrespective of the glycosidic linkage stereochemistry (α or β) and the N-acetylated hexose structure (GlcNAc or GalNAc).
36018613	13	95	theme	sequence	1640:1647	arg1	identification					1649:1662	glycopeptide sequence identification	1627:1662	glycopeptide sequence identification	1627:1662	If general, the change to a furanose m/z 204 product ion structure fundamentally alters the ion population available for MS3 dissociation and glycopeptide sequence identification.
36018613	10	96	theme	form	1137:1140	arg1	cleavage					1099:1106	the glycosidic bond cleavage	1079:1106	the glycosidic bond cleavage of the newly formed furanose form	1079:1140	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
36018613	1	97	theme	glycosidic	239:248	arg1	cleavage					255:262	glycosidic bond cleavage	239:262	glycosidic bond cleavage	239:262	We recently provided mass spectrometric, H/D labeling, and computational evidence of pyranose to furanose N-acetylated ion isomerization reactions that occurred prior to glycosidic bond cleavage in both O- and N-linked glycosylated amino acid model systems (Guan et al.
36018613	9	98	theme	"	912:912	arg1	spectroscopy					914:925	infrared "action" spectroscopy	896:925	infrared "action" spectroscopy	896:925	We then interrogate the structure(s) of the resulting charged glycan and peptide fragments with infrared "action" spectroscopy.
36018613	10	99	theme	formed	1121:1126	arg1	form					1137:1140	the newly formed furanose form	1111:1140	the newly formed furanose form	1111:1140	Isomerization of the original pyranose, the protonated glycopeptide [AT(GalNAc)A+H]+, is predicted to be facile compared to direct dissociation, as is the glycosidic bond cleavage of the newly formed furanose form, i.e., furanose oxazolinium ion structures are predicted to predominate.
34939082	4	0	theme	visual	519:524	arg1	representations					526:540	visual representations	519:540	visual representations of the glycans and glycopeptides from a variety of species	519:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	1	1	theme	key	159:161	arg1	features					163:170	key features	159:170	key features	159:170	A substantial shortcoming of large-scale datasets is often the inability to easily represent and visualize key features.
34939082	5	2	theme	N-linked	796:803	arg1	glycans					805:811	N-linked glycans	796:811	N-linked glycans	796:811	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	4	3	dep	glycans	549:555	arg1	the					545:547	the	545:547	the	545:547	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	4	from	representations	526:540	arg1	variety					582:588	a variety	580:588	a variety of species	580:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	4	from	representations	526:540	arg1	species					593:599	species	593:599	species	593:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	1	5	theme	substantial	54:64	arg1	inability					115:123	the inability	111:123	the inability to easily represent and visualize key features	111:170	A substantial shortcoming of large-scale datasets is often the inability to easily represent and visualize key features.
34939082	1	5	theme	substantial	54:64	arg1	shortcoming					66:76	A substantial shortcoming	52:76	A substantial shortcoming of large-scale datasets	52:100	A substantial shortcoming of large-scale datasets is often the inability to easily represent and visualize key features.
34939082	3	6	theme	graphical	359:367	arg1	representation					369:382	a simple, concise graphical representation	341:382	a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites	341:479	Here, we describe a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites.
34939082	2	7	theme	glycans	296:302	arg1	numbers					267:273	large numbers	261:273	large numbers of glycopeptides and glycans	261:302	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	5	8	located	found	749:753	arg1	case					788:791	the case	784:791	the case of N-linked glycans	784:811	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	8	located	found	749:753	arg1	samples					768:774	different samples	758:774	different samples	758:774	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	8	located	found	749:753	arg2	modifications					735:747	modifications	735:747	modifications found in different samples and, in the case of N-linked glycans	735:811	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	3	9	theme	simple	343:348	arg1	representation					369:382	a simple, concise graphical representation	341:382	a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites	341:479	Here, we describe a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites.
34939082	5	10	from	steps	826:830	arg1	pathway					852:858	the biosynthetic pathway	835:858	the biosynthetic pathway	835:858	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	11	theme	glycans	805:811	arg1	case					788:791	the case	784:791	the case of N-linked glycans	784:811	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	1	12	theme	large-scale	81:91	arg1	datasets					93:100	large-scale datasets	81:100	large-scale datasets	81:100	A substantial shortcoming of large-scale datasets is often the inability to easily represent and visualize key features.
34939082	3	13	theme	specific	466:473	arg1	sites					475:479	specific sites	466:479	specific sites	466:479	Here, we describe a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites.
34939082	0	14	theme	graphical	2:10	arg1	representation					12:25	A graphical representation	0:25	A graphical representation of glycan heterogeneity	0:49	A graphical representation of glycan heterogeneity.
34939082	1	15	theme	datasets	93:100	arg1	inability					115:123	the inability	111:123	the inability to easily represent and visualize key features	111:170	A substantial shortcoming of large-scale datasets is often the inability to easily represent and visualize key features.
34939082	1	15	theme	datasets	93:100	arg1	shortcoming					66:76	A substantial shortcoming	52:76	A substantial shortcoming of large-scale datasets	52:100	A substantial shortcoming of large-scale datasets is often the inability to easily represent and visualize key features.
34939082	3	16	theme	glycan	443:448	arg1	modification					450:461	glycan modification	443:461	glycan modification at specific sites	443:479	Here, we describe a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites.
34939082	5	17	theme	graphical	606:614	arg1	representation					616:629	The graphical representation	602:629	The graphical representation presented	602:639	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	18	link	N-linked	796:803	arg1	glycans					805:811	N-linked glycans	796:811	N-linked glycans	796:811	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	4	19	from	variety	582:588	arg1	glycopeptides					561:573	glycopeptides	561:573	glycopeptides	561:573	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	19	from	variety	582:588	arg1	representations					526:540	visual representations	519:540	visual representations of the glycans and glycopeptides from a variety of species	519:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	19	from	variety	582:588	arg1	glycans					549:555	glycans	549:555	glycans	549:555	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	5	20	theme	modifications	735:747	arg1	differences					720:730	differences	720:730	differences	720:730	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	20	theme	modifications	735:747	arg1	similarities					703:714	similarities	703:714	similarities	703:714	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	20	theme	modifications	735:747	arg1	compositions					674:685	the compositions	670:685	the compositions of all glycans	670:700	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	2	21	from	profile	253:259	arg1	studies					314:320	recent studies	307:320	recent studies	307:320	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	5	22	theme	biosynthetic	839:850	arg1	pathway					852:858	the biosynthetic pathway	835:858	the biosynthetic pathway	835:858	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	4	23	theme	species	593:599	arg1	variety					582:588	a variety	580:588	a variety of species	580:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	23	theme	species	593:599	arg1	species					593:599	species	593:599	species	593:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	2	24	theme	recent	307:312	arg1	studies					314:320	recent studies	307:320	recent studies	307:320	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	0	25	theme	heterogeneity	37:49	arg1	representation					12:25	A graphical representation	0:25	A graphical representation of glycan heterogeneity	0:49	A graphical representation of glycan heterogeneity.
34939082	0	26	theme	glycan	30:35	arg1	heterogeneity					37:49	glycan heterogeneity	30:49	glycan heterogeneity	30:49	A graphical representation of glycan heterogeneity.
34939082	5	27	theme	different	758:766	arg1	samples					768:774	different samples	758:774	different samples	758:774	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	3	28	from	sites	475:479	arg1	modification					450:461	glycan modification	443:461	glycan modification at specific sites	443:479	Here, we describe a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites.
34939082	4	29	theme	glycans	549:555	arg1	representations					526:540	visual representations	519:540	visual representations of the glycans and glycopeptides from a variety of species	519:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	3	30	dep	simple	343:348	arg1	concise					351:357	concise	351:357	concise	351:357	Here, we describe a simple, concise graphical representation intended to capture the microheterogeneity associated with glycan modification at specific sites.
34939082	2	31	theme	technical	232:240	arg1	ability					242:248	the increasing technical ability	217:248	the increasing technical ability	217:248	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	5	32	theme	initial	818:824	arg1	compositions					674:685	the compositions	670:685	the compositions of all glycans	670:700	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	32	theme	initial	818:824	arg1	steps					826:830	the initial steps	814:830	the initial steps in the biosynthetic pathway	814:858	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	2	33	theme	increasing	221:230	arg1	ability					242:248	the increasing technical ability	217:248	the increasing technical ability	217:248	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	5	34	theme	glycans	694:700	arg1	differences					720:730	differences	720:730	differences	720:730	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	34	theme	glycans	694:700	arg1	similarities					703:714	similarities	703:714	similarities	703:714	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	34	theme	glycans	694:700	arg1	compositions					674:685	the compositions	670:685	the compositions of all glycans	670:700	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	5	34	theme	glycans	694:700	arg1	steps					826:830	the initial steps	814:830	the initial steps in the biosynthetic pathway	814:858	The graphical representation presented allows one to easily discern the compositions of all glycans, similarities and differences of modifications found in different samples and, in the case of N-linked glycans, the initial steps in the biosynthetic pathway.
34939082	4	35	theme	glycopeptides	561:573	arg1	representations					526:540	visual representations	519:540	visual representations of the glycans and glycopeptides from a variety of species	519:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	2	36	gly	glycopeptides	278:290	arg2	glycopeptides					278:290	glycopeptides	278:290	glycopeptides	278:290	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	2	37	theme	glycopeptides	278:290	arg1	numbers					267:273	large numbers	261:273	large numbers of glycopeptides and glycans	261:302	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	2	38	theme	large	261:265	arg1	numbers					267:273	large numbers	261:273	large numbers of glycopeptides and glycans	261:302	This problem becomes acute when considering the increasing technical ability to profile large numbers of glycopeptides and glycans in recent studies.
34939082	4	39	gly	glycopeptides	561:573	arg1	variety					582:588	a variety	580:588	a variety of species	580:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	39	gly	glycopeptides	561:573	arg1	species					593:599	species	593:599	species	593:599	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
34939082	4	39	gly	glycopeptides	561:573	arg2	glycopeptides					561:573	glycopeptides	561:573	glycopeptides	561:573	We illustrate this method by showing visual representations of the glycans and glycopeptides from a variety of species.
37382290	6	0	theme	glycan	861:866	arg1	moiety					868:873	the glycan moiety	857:873	the glycan moiety	857:873	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	10	1	theme	glycoproteomics	1844:1858	arg1	analysis					1860:1867	glycoproteomics analysis	1844:1867	glycoproteomics analysis	1844:1867	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent misidentification of structure-specific fragments in glycoproteomics analysis.
37382290	2	2	theme	hurdles	324:330	arg1	hurdles					324:330	the most daunting hurdles	306:330	the most daunting hurdles in the field of glycoproteomics	306:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	2	2	theme	hurdles	324:330	arg1	one					299:301	one	299:301	one	299:301	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	7	3	theme	fragmentation	1158:1170	arg1	specificity					1172:1182	fragmentation specificity	1158:1182	fragmentation specificity	1158:1182	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	3	4	theme	biological	551:560	arg1	systems					562:568	biological systems	551:568	biological systems	551:568	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	11	5	from	quest	1921:1925	arg1	forward					1906:1912	forward	1906:1912	forward	1906:1912	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	2	6	gly	glycopeptide	267:278	arg2	glycopeptide					267:278	isobaric glycopeptide structures	258:289	isobaric glycopeptide structures	258:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	2	7	theme	isobaric	258:265	arg1	structures					280:289	isobaric glycopeptide structures	258:289	isobaric glycopeptide structures	258:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	7	8	theme	N-glycoproteomics	1114:1130	arg1	analysis					1132:1139	N-glycoproteomics analysis	1114:1139	N-glycoproteomics analysis	1114:1139	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	1	9	theme	analysis	172:179	arg1	world					149:153	the intricate world	135:153	the intricate world of glycosylation analysis	135:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37382290	9	10	theme	"	1570:1570	arg1	fragments					1572:1580	"Ghost" fragments	1564:1580	"Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell	1564:1683	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	8	11	theme	reducing	1298:1305	arg1	GlcNAc					1316:1321	the reducing terminal GlcNAc	1294:1321	the reducing terminal GlcNAc	1294:1321	These standards were isotopically labeled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by the oligomannose core moiety and fragments generated from outer antennary structures.
37382290	11	12	theme	glycoproteomics	1958:1972	arg1	measurements					1974:1985	more accurate and reliable glycoproteomics measurements	1931:1985	more accurate and reliable glycoproteomics measurements	1931:1985	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	6	13	theme	specific	978:985	arg1	moieties					994:1001	specific glycan moieties	978:1001	specific glycan moieties	978:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	9	14	theme	single	1597:1602	arg1	rearrangement					1615:1627	glyco unit rearrangement	1604:1627	glyco unit rearrangement	1604:1627	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	8	15	theme	core	1391:1394	arg1	moiety					1396:1401	the oligomannose core moiety	1374:1401	the oligomannose core moiety	1374:1401	These standards were isotopically labeled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by the oligomannose core moiety and fragments generated from outer antennary structures.
37382290	9	16	theme	unit	1610:1613	arg1	rearrangement					1615:1627	glyco unit rearrangement	1604:1627	glyco unit rearrangement	1604:1627	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	5	17	theme	different	778:786	arg1	stabilities					788:798	different stabilities	778:798	different stabilities	778:798	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37382290	6	18	theme	fragments	1038:1046	arg1	specificity					1017:1027	the specificity	1013:1027	the specificity of these fragments	1013:1046	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	4	19	theme	qualitative	701:711	arg1	purposes					713:720	qualitative purposes	701:720	qualitative purposes	701:720	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	1	20	theme	intricate	139:147	arg1	world					149:153	the intricate world	135:153	the intricate world of glycosylation analysis	135:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37382290	8	21	theme	outer	1432:1436	arg1	structures					1448:1457	outer antennary structures	1432:1457	outer antennary structures	1432:1457	These standards were isotopically labeled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by the oligomannose core moiety and fragments generated from outer antennary structures.
37382290	5	22	theme	glycan	745:750	arg1	units					752:756	glycan units	745:756	glycan units	745:756	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37382290	2	23	theme	structures	280:289	arg1	analysis					246:253	the qualitative and quantitative analysis	213:253	the qualitative and quantitative analysis of isobaric glycopeptide structures	213:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	1	24	theme	crucial	113:119	arg1	insights					121:128	crucial insights	113:128	crucial insights into the intricate world of glycosylation analysis	113:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37382290	5	25	theme	CID/HCD	806:812	arg1	conditions					828:837	CID/HCD fragmentation conditions	806:837	CID/HCD fragmentation conditions	806:837	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37382290	9	26	theme	collision	1670:1678	arg1	cell					1680:1683	the collision cell	1666:1683	the collision cell	1666:1683	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	0	27	from	Ions	17:20	arg1	Analysis					69:76	Site-Specific Glycoproteomics Analysis	39:76	Site-Specific Glycoproteomics Analysis	39:76	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	0	27	from	Ions	17:20	arg1	Structure					25:33	Structure	25:33	Structure	25:33	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	0	28	theme	"	6:6	arg1	Ions					17:20	Ghost" Fragment Ions	1:20	Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis	1:76	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	6	29	theme	oxonium	911:917	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	29	theme	oxonium	911:917	arg1	ions					919:922	oxonium ions	911:922	oxonium ions	911:922	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	3	30	theme	complex	406:412	arg1	structures					421:430	these complex glycan structures	400:430	these complex glycan structures	400:430	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	7	31	gly	N-glycopeptide	1223:1236	arg2	N-glycopeptide					1223:1236	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	7	32	theme	N-glycopeptide	1223:1236	arg1	standards					1238:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	5	33	theme	fragmentation	814:826	arg1	conditions					828:837	CID/HCD fragmentation conditions	806:837	CID/HCD fragmentation conditions	806:837	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37382290	0	34	theme	Site-Specific	39:51	arg1	Analysis					69:76	Site-Specific Glycoproteomics Analysis	39:76	Site-Specific Glycoproteomics Analysis	39:76	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	7	35	theme	stable	1200:1205	arg1	standards					1238:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	6	36	theme	molecular	888:896	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	36	theme	molecular	888:896	arg1	signature					964:972	a structure-specific signature	943:972	a structure-specific signature for specific glycan moieties	943:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	36	theme	molecular	888:896	arg1	ions					919:922	oxonium ions	911:922	oxonium ions	911:922	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	10	37	theme	structure-specific	1812:1829	arg1	fragments					1831:1839	structure-specific fragments	1812:1839	structure-specific fragments	1812:1839	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent misidentification of structure-specific fragments in glycoproteomics analysis.
37382290	3	38	theme	glycoproteins	534:546	arg1	role					526:529	the role	522:529	the role of glycoproteins in biological systems	522:568	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	6	39	theme	structure-specific	945:962	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	39	theme	structure-specific	945:962	arg1	signature					964:972	a structure-specific signature	943:972	a structure-specific signature for specific glycan moieties	943:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	4	40	theme	collision	618:626	arg1	CE					636:637	CE	636:637	CE	636:637	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	4	40	theme	collision	618:626	arg1	energy					628:633	collision energy	618:633	collision energy (CE)	618:638	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	9	41	theme	structure	1517:1525	arg1	assignments					1527:1537	false-positive structure assignments	1502:1537	false-positive structure assignments	1502:1537	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	2	42	from	hurdles	324:330	arg1	field					339:343	the field	335:343	the field of glycoproteomics	335:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	4	43	theme	recent	577:582	arg1	publications					584:595	A few recent publications	571:595	A few recent publications	571:595	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	3	44	gly	glycoproteins	534:546	arg1	glycoproteins					534:546	glycoproteins	534:546	glycoproteins	534:546	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	3	45	from	role	526:529	arg1	systems					562:568	biological systems	551:568	biological systems	551:568	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	2	46	theme	glycopeptide	267:278	arg1	structures					280:289	isobaric glycopeptide structures	258:289	isobaric glycopeptide structures	258:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	1	47	theme	glycosylation	158:170	arg1	analysis					172:179	glycosylation analysis	158:179	glycosylation analysis	158:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37382290	4	48	theme	structural	662:671	arg1	elucidation					673:683	structural elucidation	662:683	structural elucidation	662:683	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	11	49	theme	accurate	1936:1943	arg1	measurements					1974:1985	more accurate and reliable glycoproteomics measurements	1931:1985	more accurate and reliable glycoproteomics measurements	1931:1985	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	11	50	from	forward	1906:1912	arg1	quest					1921:1925	the quest	1917:1925	the quest for more accurate and reliable glycoproteomics measurements	1917:1985	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	9	51	theme	core	1640:1643	arg1	fragmentation					1645:1657	mannose core fragmentation	1632:1657	mannose core fragmentation	1632:1657	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	10	52	theme	minimal	1732:1738	arg1	threshold					1750:1758	a minimal intensity threshold	1730:1758	a minimal intensity threshold for these fragments	1730:1778	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent misidentification of structure-specific fragments in glycoproteomics analysis.
37382290	5	53	theme	Different	723:731	arg1	linkages					733:740	Different linkages	723:740	Different linkages of glycan units	723:756	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37382290	2	54	theme	qualitative	217:227	arg1	analysis					246:253	the qualitative and quantitative analysis	213:253	the qualitative and quantitative analysis of isobaric glycopeptide structures	213:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	9	55	theme	fragments	1572:1580	arg1	occurrence					1550:1559	the occurrence	1546:1559	the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell	1546:1683	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	6	56	theme	glycan	987:992	arg1	moieties					994:1001	specific glycan moieties	978:1001	specific glycan moieties	978:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	8	57	theme	terminal	1307:1314	arg1	GlcNAc					1316:1321	the reducing terminal GlcNAc	1294:1321	the reducing terminal GlcNAc	1294:1321	These standards were isotopically labeled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by the oligomannose core moiety and fragments generated from outer antennary structures.
37382290	11	58	theme	reliable	1949:1956	arg1	measurements					1974:1985	more accurate and reliable glycoproteomics measurements	1931:1985	more accurate and reliable glycoproteomics measurements	1931:1985	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	9	59	theme	glyco	1604:1608	arg1	rearrangement					1615:1627	glyco unit rearrangement	1604:1627	glyco unit rearrangement	1604:1627	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	8	60	theme	oligomannose	1378:1389	arg1	moiety					1396:1401	the oligomannose core moiety	1374:1401	the oligomannose core moiety	1374:1401	These standards were isotopically labeled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by the oligomannose core moiety and fragments generated from outer antennary structures.
37382290	11	61	theme	crucial	1893:1899	arg1	step					1901:1904	a crucial step	1891:1904	a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements	1891:1985	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	0	62	theme	Glycoproteomics	53:67	arg1	Analysis					69:76	Site-Specific Glycoproteomics Analysis	39:76	Site-Specific Glycoproteomics Analysis	39:76	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	2	63	theme	quantitative	233:244	arg1	analysis					246:253	the qualitative and quantitative analysis	213:253	the qualitative and quantitative analysis of isobaric glycopeptide structures	213:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	9	64	theme	mannose	1632:1638	arg1	fragmentation					1645:1657	mannose core fragmentation	1632:1657	mannose core fragmentation	1632:1657	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37382290	11	65	theme	forward	1906:1912	arg1	step					1901:1904	a crucial step	1891:1904	a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements	1891:1985	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37382290	5	66	theme	units	752:756	arg1	linkages					733:740	Different linkages	723:740	Different linkages of glycan units	723:756	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37382290	8	67	theme	antennary	1438:1446	arg1	structures					1448:1457	outer antennary structures	1432:1457	outer antennary structures	1432:1457	These standards were isotopically labeled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by the oligomannose core moiety and fragments generated from outer antennary structures.
37382290	3	68	theme	significant	440:450	arg1	challenge					452:460	a significant challenge	438:460	a significant challenge	438:460	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	0	69	theme	Ghost	1:5	arg1	Ions					17:20	Ghost" Fragment Ions	1:20	Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis	1:76	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	1	70	theme	Mass	79:82	arg1	spectrometry					84:95	Mass spectrometry	79:95	Mass spectrometry (MS)	79:100	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37382290	1	70	theme	Mass	79:82	arg1	MS					98:99	MS	98:99	MS	98:99	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37382290	10	71	theme	intensity	1740:1748	arg1	threshold					1750:1758	a minimal intensity threshold	1730:1758	a minimal intensity threshold for these fragments	1730:1778	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent misidentification of structure-specific fragments in glycoproteomics analysis.
37382290	0	72	theme	Fragment	8:15	arg1	Ions					17:20	Ghost" Fragment Ions	1:20	Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis	1:76	"Ghost" Fragment Ions in Structure and Site-Specific Glycoproteomics Analysis.
37382290	4	73	theme	few	573:575	arg1	publications					584:595	A few recent publications	571:595	A few recent publications	571:595	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	7	74	theme	isotope-labeled	1207:1221	arg1	standards					1238:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	3	75	theme	glycan	414:419	arg1	structures					421:430	these complex glycan structures	400:430	these complex glycan structures	400:430	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37382290	7	76	theme	synthetic	1190:1198	arg1	standards					1238:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	synthetic stable isotope-labeled N-glycopeptide standards	1190:1246	Here, we particularly focused on N-glycoproteomics analysis and investigated fragmentation specificity using synthetic stable isotope-labeled N-glycopeptide standards.
37382290	6	77	theme	weight	898:903	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	77	theme	weight	898:903	arg1	signature					964:972	a structure-specific signature	943:972	a structure-specific signature for specific glycan moieties	943:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	77	theme	weight	898:903	arg1	ions					919:922	oxonium ions	911:922	oxonium ions	911:922	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	2	78	theme	immense	194:200	arg1	potential					202:210	its immense potential	190:210	its immense potential	190:210	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	10	79	theme	fragments	1831:1839	arg1	misidentification					1791:1807	misidentification	1791:1807	misidentification of structure-specific fragments	1791:1839	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent misidentification of structure-specific fragments in glycoproteomics analysis.
37382290	6	80	theme	low	884:886	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	80	theme	low	884:886	arg1	signature					964:972	a structure-specific signature	943:972	a structure-specific signature for specific glycan moieties	943:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	6	80	theme	low	884:886	arg1	ions					919:922	oxonium ions	911:922	oxonium ions	911:922	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	2	81	theme	daunting	315:322	arg1	hurdles					324:330	the most daunting hurdles	306:330	the most daunting hurdles in the field of glycoproteomics	306:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	6	82	theme	moiety	868:873	arg1	Fragmentation					840:852	Fragmentation	840:852	Fragmentation of the glycan moiety	840:873	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties; however, the specificity of these fragments has never been examined closely.
37382290	4	83	theme	energy	628:633	arg1	use					611:613	the use	607:613	the use of collision energy (CE) modulation to improve structural elucidation	607:683	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37382290	2	84	theme	glycoproteomics	348:362	arg1	field					339:343	the field	335:343	the field of glycoproteomics	335:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37382290	9	85	theme	false-positive	1502:1515	arg1	assignments					1527:1537	false-positive structure assignments	1502:1537	false-positive structure assignments	1502:1537	Our research identified the potential for false-positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37219590	0	0	from	validation	13:22	arg1	Privateer					60:68	Privateer	60:68	Privateer	60:68	Analysis and validation of overall N-glycan conformation in Privateer.
37219590	1	1	from	oligosaccharides	75:90	arg1	N-glycosylation					95:109	N-glycosylation	95:109	N-glycosylation	95:109	The oligosaccharides in N-glycosylation provide key structural and functional contributions to a glycoprotein.
37219590	4	2	theme	overall	593:599	arg1	conformation					601:612	the overall conformation	589:612	the overall conformation of N-glycans	589:625	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	3	3	theme	atomic	356:361	arg1	structures					363:372	the atomic structures	352:372	the atomic structures of carbohydrates, including N-glycans	352:410	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	4	4	theme	preferences	706:716	arg1	preferences					706:716	glycosidic linkage torsional preferences	677:716	glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	677:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	4	theme	preferences	706:716	arg1	set					670:672	a newly compiled set	653:672	a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	653:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	0	5	from	Analysis	0:7	arg1	Privateer					60:68	Privateer	60:68	Privateer	60:68	Analysis and validation of overall N-glycan conformation in Privateer.
37219590	4	6	theme	models	763:768	arg1	models					763:768	glycoprotein models	750:768	glycoprotein models	750:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	6	theme	models	763:768	arg1	set					743:745	a curated set	733:745	a curated set of glycoprotein models	733:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	7	gly	glycoprotein	750:761	arg1	glycoprotein					750:761	glycoprotein models	750:768	glycoprotein models	750:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	3	8	theme	carbohydrates	377:389	arg1	structures					363:372	the atomic structures	352:372	the atomic structures of carbohydrates, including N-glycans	352:410	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	3	9	theme	Privateer	280:288	arg1	software					290:297	The Privateer software	276:297	The Privateer software	276:297	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	4	10	theme	N-glycans	617:625	arg1	conformation					601:612	the overall conformation	589:612	the overall conformation of N-glycans	589:625	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	11	theme	compiled	661:668	arg1	preferences					706:716	glycosidic linkage torsional preferences	677:716	glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	677:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	11	theme	compiled	661:668	arg1	set					670:672	a newly compiled set	653:672	a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	653:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	12	theme	glycoprotein	750:761	arg1	models					763:768	glycoprotein models	750:768	glycoprotein models	750:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	13	theme	glycosidic	677:686	arg1	preferences					706:716	glycosidic linkage torsional preferences	677:716	glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	677:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	3	14	theme	glycan	463:468	arg1	composition					470:480	glycan composition	463:480	glycan composition	463:480	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	3	15	theme	structural	306:315	arg1	biologists					317:326	structural biologists	306:326	structural biologists	306:326	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	1	16	theme	key	119:121	arg1	contributions					149:161	key structural and functional contributions	119:161	key structural and functional contributions to a glycoprotein	119:179	The oligosaccharides in N-glycosylation provide key structural and functional contributions to a glycoprotein.
37219590	3	17	theme	glycomics	501:509	arg1	data					511:514	glycomics data	501:514	glycomics data	501:514	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	0	18	theme	N-glycan	35:42	arg1	conformation					44:55	overall N-glycan conformation	27:55	overall N-glycan conformation	27:55	Analysis and validation of overall N-glycan conformation in Privateer.
37219590	0	19	theme	overall	27:33	arg1	conformation					44:55	overall N-glycan conformation	27:55	overall N-glycan conformation	27:55	Analysis and validation of overall N-glycan conformation in Privateer.
37219590	4	20	theme	scope	543:547	arg1	broadening					525:534	a broadening	523:534	a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans	523:625	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	1	21	theme	structural	123:132	arg1	contributions					149:161	key structural and functional contributions	119:161	key structural and functional contributions to a glycoprotein	119:179	The oligosaccharides in N-glycosylation provide key structural and functional contributions to a glycoprotein.
37219590	0	22	theme	conformation	44:55	arg1	validation					13:22	validation	13:22	validation	13:22	Analysis and validation of overall N-glycan conformation in Privateer.
37219590	0	22	theme	conformation	44:55	arg1	Analysis					0:7	Analysis	0:7	Analysis	0:7	Analysis and validation of overall N-glycan conformation in Privateer.
37219590	4	23	theme	software	556:563	arg1	scope					543:547	the scope	539:547	the scope of the software to analyse and validate the overall conformation of N-glycans	539:625	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	2	24	theme	overall	239:245	arg1	conformation					247:258	overall conformation	239:258	overall conformation	239:258	These contributions are dependent on the composition and overall conformation of the glycans.
37219590	1	25	theme	functional	138:147	arg1	contributions					149:161	key structural and functional contributions	119:161	key structural and functional contributions to a glycoprotein	119:179	The oligosaccharides in N-glycosylation provide key structural and functional contributions to a glycoprotein.
37219590	1	26	gly	glycoprotein	168:179	arg1	glycoprotein					168:179	a glycoprotein	166:179	a glycoprotein	166:179	The oligosaccharides in N-glycosylation provide key structural and functional contributions to a glycoprotein.
37219590	4	27	theme	curated	735:741	arg1	models					763:768	glycoprotein models	750:768	glycoprotein models	750:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	4	27	theme	curated	735:741	arg1	set					743:745	a curated set	733:745	a curated set of glycoprotein models	733:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	3	28	theme	data	511:514	arg1	use					494:496	the use	490:496	the use of glycomics data	490:514	The Privateer software allows structural biologists to evaluate and improve the atomic structures of carbohydrates, including N-glycans; this software has recently been extended to check glycan composition through the use of glycomics data.
37219590	4	29	theme	torsional	696:704	arg1	preferences					706:716	glycosidic linkage torsional preferences	677:716	glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	677:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	2	30	theme	glycans	267:273	arg1	composition					223:233	composition	223:233	composition	223:233	These contributions are dependent on the composition and overall conformation of the glycans.
37219590	2	30	theme	glycans	267:273	arg1	conformation					247:258	overall conformation	239:258	overall conformation	239:258	These contributions are dependent on the composition and overall conformation of the glycans.
37219590	4	31	theme	linkage	688:694	arg1	preferences					706:716	glycosidic linkage torsional preferences	677:716	glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models	677:768	Here, a broadening of the scope of the software to analyse and validate the overall conformation of N-glycans is presented, focusing on a newly compiled set of glycosidic linkage torsional preferences harvested from a curated set of glycoprotein models.
37219590	2	32	dep	composition	223:233	arg1	the					219:221	the	219:221	the	219:221	These contributions are dependent on the composition and overall conformation of the glycans.
35696078	3	0	from	apparatus	383:391	arg1	systems					406:412	mammalian systems	396:412	mammalian systems	396:412	Glycans are synthesized through a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems.
35696078	7	1	theme	glycosylation	929:941	arg1	pathway					943:949	the glycosylation pathway	925:949	the glycosylation pathway	925:949	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	7	2	from	pathway	943:949	arg1	proteins					982:989	proteins	982:989	proteins	982:989	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	7	3	theme	glycan-related	823:836	arg1	databases					838:846	glycan-related databases	823:846	glycan-related databases	823:846	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	4	4	theme	biological	544:553	arg1	sample					555:560	a biological sample	542:560	a biological sample to ascertain its glycome	542:585	Because there is currently no sequencer for glycans, technologies such as mass spectrometry is used to characterize glycans in a biological sample to ascertain its glycome.
35696078	5	5	theme	high	628:631	arg1	levels					633:638	high levels	628:638	high levels of expertise and equipment	628:665	This is a tedious process that requires high levels of expertise and equipment.
35696078	7	6	theme	databases	838:846	arg1	development					808:818	the development	804:818	the development of glycan-related databases and a glycan repository	804:870	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	3	7	theme	enzymatic	339:347	arg1	reactions					349:357	enzymatic reactions	339:357	enzymatic reactions that occur in the Golgi apparatus in mammalian systems	339:412	Glycans are synthesized through a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems.
35696078	3	8	theme	complex	320:326	arg1	process					328:334	a complex process	318:334	a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems	318:412	Glycans are synthesized through a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems.
35696078	4	9	used	used	510:513	arg2	spectrometry					494:505	mass spectrometry	489:505	mass spectrometry	489:505	Because there is currently no sequencer for glycans, technologies such as mass spectrometry is used to characterize glycans in a biological sample to ascertain its glycome.
35696078	4	9	used	used	510:513	arg2	technologies					468:479	technologies	468:479	technologies such as mass spectrometry	468:505	Because there is currently no sequencer for glycans, technologies such as mass spectrometry is used to characterize glycans in a biological sample to ascertain its glycome.
35696078	1	10	theme	acid	167:170	arg1	residue					172:178	an amino acid residue	158:178	an amino acid residue of a protein	158:191	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	1	10	theme	acid	167:170	arg1	protein					185:191	a protein	183:191	a protein	183:191	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	1	11	theme	amino	161:165	arg1	residue					172:178	an amino acid residue	158:178	an amino acid residue of a protein	158:191	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	1	11	theme	amino	161:165	arg1	protein					185:191	a protein	183:191	a protein	183:191	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	5	12	theme	tedious	598:604	arg1	process					606:612	a tedious process	596:612	a tedious process that requires high levels of expertise and equipment	596:665	This is a tedious process that requires high levels of expertise and equipment.
35696078	5	12	theme	tedious	598:604	arg1	This					588:591	This	588:591	This	588:591	This is a tedious process that requires high levels of expertise and equipment.
35696078	3	13	theme	mammalian	396:404	arg1	systems					406:412	mammalian systems	396:412	mammalian systems	396:412	Glycans are synthesized through a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems.
35696078	4	14	theme	mass	489:492	arg1	spectrometry					494:505	mass spectrometry	489:505	mass spectrometry	489:505	Because there is currently no sequencer for glycans, technologies such as mass spectrometry is used to characterize glycans in a biological sample to ascertain its glycome.
35696078	8	15	theme	Web	1042:1044	arg1	resources					1046:1054	related Web resources	1034:1054	related Web resources	1034:1054	This chapter introduces these methods and related Web resources for understanding glycan function.
35696078	8	16	theme	related	1034:1040	arg1	resources					1046:1054	related Web resources	1034:1054	related Web resources	1034:1054	This chapter introduces these methods and related Web resources for understanding glycan function.
35696078	7	17	from	sites	973:977	arg1	proteins					982:989	proteins	982:989	proteins	982:989	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	3	18	theme	reactions	349:357	arg1	process					328:334	a complex process	318:334	a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems	318:412	Glycans are synthesized through a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems.
35696078	7	19	gly	glycosylation	959:971	arg2	sites					973:977	the glycosylation sites	955:977	the glycosylation sites on proteins	955:989	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	2	20	theme	proteins	276:283	arg1	function					264:271	the function	260:271	the function of proteins	260:283	These glycans are often branched structures and serve to modulate the function of proteins.
35696078	0	21	theme	Glycosylation	13:25	arg1	Functions					0:8	Functions	0:8	Functions of Glycosylation	0:25	Functions of Glycosylation and Related Web Resources for Its Prediction.
35696078	0	21	theme	Glycosylation	13:25	arg1	Resources					43:51	Related Web Resources	31:51	Related Web Resources for Its Prediction	31:70	Functions of Glycosylation and Related Web Resources for Its Prediction.
35696078	0	22	theme	Web	39:41	arg1	Resources					43:51	Related Web Resources	31:51	Related Web Resources for Its Prediction	31:70	Functions of Glycosylation and Related Web Resources for Its Prediction.
35696078	1	23	theme	protein	185:191	arg1	residue					172:178	an amino acid residue	158:178	an amino acid residue of a protein	158:191	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	1	23	theme	protein	185:191	arg1	protein					185:191	a protein	183:191	a protein	183:191	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	0	24	theme	Related	31:37	arg1	Resources					43:51	Related Web Resources	31:51	Related Web Resources for Its Prediction	31:70	Functions of Glycosylation and Related Web Resources for Its Prediction.
35696078	8	25	theme	glycan	1074:1079	arg1	function					1081:1088	glycan function	1074:1088	glycan function	1074:1088	This chapter introduces these methods and related Web resources for understanding glycan function.
35696078	6	26	theme	called	708:713	arg1	enzymes					678:684	the enzymes	674:684	the enzymes that work on glycans	674:705	Thus, the enzymes that work on glycans, called glycogenes or glycoenzymes, have been studied to better understand glycan function.
35696078	6	26	theme	called	708:713	arg1	glycogenes					715:724	glycogenes	715:724	glycogenes	715:724	Thus, the enzymes that work on glycans, called glycogenes or glycoenzymes, have been studied to better understand glycan function.
35696078	1	27	theme	carbohydrate	114:125	arg1	chains					133:138	carbohydrate sugar chains	114:138	carbohydrate sugar chains	114:138	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	3	28	theme	Golgi	377:381	arg1	apparatus					383:391	the Golgi apparatus	373:391	the Golgi apparatus in mammalian systems	373:412	Glycans are synthesized through a complex process of enzymatic reactions that occur in the Golgi apparatus in mammalian systems.
35696078	5	29	theme	expertise	643:651	arg1	levels					633:638	high levels	628:638	high levels of expertise and equipment	628:665	This is a tedious process that requires high levels of expertise and equipment.
35696078	1	30	theme	sugar	127:131	arg1	chains					133:138	carbohydrate sugar chains	114:138	carbohydrate sugar chains	114:138	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	1	31	theme	chains	133:138	arg1	attachment					100:109	the attachment	96:109	the attachment of carbohydrate sugar chains, or glycans	96:150	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
35696078	7	32	theme	bioinformatics	873:886	arg1	approaches					888:897	bioinformatics approaches	873:897	bioinformatics approaches	873:897	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	5	33	theme	equipment	657:665	arg1	levels					633:638	high levels	628:638	high levels of expertise and equipment	628:665	This is a tedious process that requires high levels of expertise and equipment.
35696078	6	34	theme	glycan	782:787	arg1	function					789:796	glycan function	782:796	glycan function	782:796	Thus, the enzymes that work on glycans, called glycogenes or glycoenzymes, have been studied to better understand glycan function.
35696078	7	35	theme	glycosylation	959:971	arg1	sites					973:977	the glycosylation sites	955:977	the glycosylation sites on proteins	955:989	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	7	36	theme	glycan	854:859	arg1	repository					861:870	a glycan repository	852:870	a glycan repository	852:870	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	7	37	theme	repository	861:870	arg1	development					808:818	the development	804:818	the development of glycan-related databases and a glycan repository	804:870	With the development of glycan-related databases and a glycan repository, bioinformatics approaches have attempted to predict the glycosylation pathway and the glycosylation sites on proteins.
35696078	1	38	theme	glycans	144:150	arg1	attachment					100:109	the attachment	96:109	the attachment of carbohydrate sugar chains, or glycans	96:150	Glycosylation involves the attachment of carbohydrate sugar chains, or glycans, onto an amino acid residue of a protein.
37158251	0	0	theme	Lupinus	79:85	arg1	γ-Conglutin					101:111	Lupinus angustifolius γ-Conglutin	79:111	Lupinus angustifolius γ-Conglutin	79:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	7	1	contain	have	1434:1437	arg2	effect					1402:1407	a functional effect	1389:1407	a functional effect that glycosylation might have on γ-conglutin structure integrity	1389:1472	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	7	1	contain	have	1434:1437	arg1	glycosylation					1414:1426	glycosylation	1414:1426	glycosylation	1414:1426	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	1	2	from	protein	166:172	arg1	terms					182:186	terms	182:186	terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials	182:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	3	dep	composition	648:658	arg1	ii					611:612	ii	611:612	ii	611:612	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	4	4	theme	different	851:859	arg1	classes					861:867	different classes	851:867	different classes attached to the Asn98 residue	851:897	The obtained results indicate the presence of glycans belonging to different classes attached to the Asn98 residue.
37158251	3	5	theme	qualitative	619:629	arg1	composition					648:658	the qualitative and quantitative composition	615:658	(ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability	610:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	5	theme	qualitative	619:629	arg1	identification					565:578	the identification	561:578	(i) the identification of the N-glycan-bearing site	557:607	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	0	6	theme	γ-Conglutin	101:111	arg1	Behavior					67:74	the Molecular Behavior	53:74	the Molecular Behavior of Lupinus angustifolius γ-Conglutin	53:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	0	7	from	Characteristics	0:14	arg1	Behavior					67:74	the Molecular Behavior	53:74	the Molecular Behavior of Lupinus angustifolius γ-Conglutin	53:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	6	8	theme	thermal	1175:1181	arg1	stability					1183:1191	γ-conglutin thermal stability	1163:1191	γ-conglutin thermal stability	1163:1191	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	5	9	theme	oligosaccharide	935:949	arg1	detachment					917:926	the detachment	913:926	the detachment of the oligosaccharide	913:949	In addition, the detachment of the oligosaccharide significantly affects secondary structure composition, which disturbs the oligomerization process.
37158251	1	10	theme	broad	239:243	arg1	spectrum					245:252	a broad spectrum	237:252	a broad spectrum of unique health-promoting properties manifested in animal and human trials	237:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	0	11	theme	angustifolius	87:99	arg1	γ-Conglutin					101:111	Lupinus angustifolius γ-Conglutin	79:111	Lupinus angustifolius γ-Conglutin	79:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	6	12	theme	γ-conglutin	1163:1173	arg1	stability					1183:1191	γ-conglutin thermal stability	1163:1191	γ-conglutin thermal stability	1163:1191	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	1	13	theme	spectrum	245:252	arg1	complexity					195:204	the complexity	191:204	the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials	191:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	14	from	effect	713:718	arg1	stability					773:781	structural and thermal stability	750:781	structural and thermal stability	750:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	5	15	theme	secondary	973:981	arg1	composition					993:1003	secondary structure composition	973:1003	secondary structure composition	973:1003	In addition, the detachment of the oligosaccharide significantly affects secondary structure composition, which disturbs the oligomerization process.
37158251	6	16	from	increase	1151:1158	arg1	stability					1183:1191	γ-conglutin thermal stability	1163:1191	γ-conglutin thermal stability	1163:1191	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	1	17	theme	intriguing	155:164	arg1	protein					166:172	an intriguing protein	152:172	an intriguing protein	152:172	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	1	17	theme	intriguing	155:164	arg1	γ-Conglutin					114:124	γ-Conglutin	114:124	γ-Conglutin	114:124	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	6	18	gly	deglycosylated	1214:1227	arg1	form					1239:1242	the deglycosylated monomeric form	1210:1242	the deglycosylated monomeric form	1210:1242	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	0	19	from	Impact	43:48	arg1	Behavior					67:74	the Molecular Behavior	53:74	the Molecular Behavior of Lupinus angustifolius γ-Conglutin	53:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	4	20	theme	obtained	788:795	arg1	results					797:803	The obtained results	784:803	The obtained results	784:803	The obtained results indicate the presence of glycans belonging to different classes attached to the Asn98 residue.
37158251	5	21	theme	structure	983:991	arg1	composition					993:1003	secondary structure composition	973:1003	secondary structure composition	973:1003	In addition, the detachment of the oligosaccharide significantly affects secondary structure composition, which disturbs the oligomerization process.
37158251	7	22	theme	maturation	1347:1356	arg1	complexity					1310:1319	the high complexity	1301:1319	the high complexity of the post-translational maturation	1301:1356	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	7	23	theme	effect	1402:1407	arg1	possibility					1374:1384	the possibility	1370:1384	the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity	1370:1472	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	6	24	theme	monomeric	1229:1237	arg1	form					1239:1242	the deglycosylated monomeric form	1210:1242	the deglycosylated monomeric form	1210:1242	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	2	25	theme	evolutionary	360:371	arg1	cornerstone					373:383	an evolutionary cornerstone	357:383	an evolutionary cornerstone whose physiological significance for the plant has not been determined yet	357:458	Moreover, this protein is an evolutionary cornerstone whose physiological significance for the plant has not been determined yet.
37158251	2	25	theme	evolutionary	360:371	arg1	protein					346:352	this protein	341:352	this protein	341:352	Moreover, this protein is an evolutionary cornerstone whose physiological significance for the plant has not been determined yet.
37158251	3	26	theme	oligosaccharide	723:737	arg1	removal					739:745	oligosaccharide removal	723:745	oligosaccharide removal	723:745	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	4	27	theme	glycans	830:836	arg1	presence					818:825	the presence	814:825	the presence of glycans belonging to different classes attached to the Asn98 residue	814:897	The obtained results indicate the presence of glycans belonging to different classes attached to the Asn98 residue.
37158251	1	28	theme	unique	257:262	arg1	properties					281:290	unique health-promoting properties	257:290	unique health-promoting properties manifested in animal and human trials	257:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	6	29	theme	4.5	1143:1145	arg1	value					1134:1138	a pH value	1129:1138	a pH value of 4.5, an increase in γ-conglutin thermal stability	1129:1191	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	7	30	theme	functional	1391:1400	arg1	effect					1402:1407	a functional effect	1389:1407	a functional effect that glycosylation might have on γ-conglutin structure integrity	1389:1472	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	7	31	theme	high	1305:1308	arg1	complexity					1310:1319	the high complexity	1301:1319	the high complexity of the post-translational maturation	1301:1356	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	0	32	theme	N-Glycosylation	19:33	arg1	Impact					43:48	Its Impact	39:48	Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin	39:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	0	32	theme	N-Glycosylation	19:33	arg1	Characteristics					0:14	Characteristics	0:14	Characteristics of N-Glycosylation	0:33	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	1	33	theme	health-promoting	264:279	arg1	properties					281:290	unique health-promoting properties	257:290	unique health-promoting properties manifested in animal and human trials	257:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	34	theme	γ-conglutin	505:515	arg1	glycosylation					517:529	γ-conglutin glycosylation	505:529	γ-conglutin glycosylation	505:529	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	35	dep	identification	565:578	arg1	i					558:558	i	558:558	i	558:558	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	7	36	theme	complexity	1310:1319	arg1	evidence					1289:1296	evidence	1289:1296	evidence of the high complexity of the post-translational maturation	1289:1356	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	1	37	theme	properties	281:290	arg1	structure					223:231	its molecular structure	209:231	its molecular structure	209:231	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	1	37	theme	properties	281:290	arg1	spectrum					245:252	a broad spectrum	237:252	a broad spectrum of unique health-promoting properties manifested in animal and human trials	237:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	38	theme	quantitative	635:646	arg1	composition					648:658	the qualitative and quantitative composition	615:658	(ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability	610:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	38	theme	quantitative	635:646	arg1	identification					565:578	the identification	561:578	(i) the identification of the N-glycan-bearing site	557:607	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	39	theme	N-glycan-bearing	587:602	arg1	site					604:607	the N-glycan-bearing site	583:607	the N-glycan-bearing site	583:607	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	6	40	theme	structural	1054:1063	arg1	changes					1065:1071	The structural changes	1050:1071	The structural changes	1050:1071	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	6	41	theme	biophysical	1096:1106	arg1	parameters					1108:1117	biophysical parameters	1096:1117	biophysical parameters	1096:1117	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	7	42	theme	post-translational	1328:1345	arg1	maturation					1347:1356	the post-translational maturation	1324:1356	the post-translational maturation	1324:1356	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	3	43	theme	site	604:607	arg1	composition					648:658	the qualitative and quantitative composition	615:658	(ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability	610:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	43	theme	site	604:607	arg1	identification					565:578	the identification	561:578	(i) the identification of the N-glycan-bearing site	557:607	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	1	44	theme	complexity	195:204	arg1	terms					182:186	terms	182:186	terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials	182:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	45	theme	thermal	765:771	arg1	stability					773:781	structural and thermal stability	750:781	structural and thermal stability	750:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	4	46	theme	Asn98	885:889	arg1	residue					891:897	the Asn98 residue	881:897	the Asn98 residue	881:897	The obtained results indicate the presence of glycans belonging to different classes attached to the Asn98 residue.
37158251	3	47	theme	removal	739:745	arg1	effect					713:718	the effect	709:718	(iii) the effect of oligosaccharide removal on structural and thermal stability	703:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	6	48	theme	deglycosylated	1214:1227	arg1	form					1239:1242	the deglycosylated monomeric form	1210:1242	the deglycosylated monomeric form	1210:1242	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	3	49	theme	comprehensive	471:483	arg1	characterization					485:500	a comprehensive characterization	469:500	a comprehensive characterization of γ-conglutin glycosylation	469:529	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	1	50	theme	animal	306:311	arg1	trials					323:328	animal and human trials	306:328	animal and human trials	306:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	51	dep	effect	713:718	arg1	iii					704:706	iii	704:706	iii	704:706	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	52	theme	glycan-building	663:677	arg1	saccharides					679:689	glycan-building saccharides	663:689	glycan-building saccharides	663:689	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	6	53	dep	reflected	1083:1091	arg1	at					1126:1127	at	1126:1127	at	1126:1127	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	6	54	theme	pH	1131:1132	arg1	value					1134:1138	a pH value	1129:1138	a pH value of 4.5, an increase in γ-conglutin thermal stability	1129:1191	The structural changes were also reflected in biophysical parameters, i.e., at a pH value of 4.5, an increase in γ-conglutin thermal stability was observed for the deglycosylated monomeric form.
37158251	3	55	theme	structural	750:759	arg1	stability					773:781	structural and thermal stability	750:781	structural and thermal stability	750:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	56	theme	saccharides	679:689	arg1	composition					648:658	the qualitative and quantitative composition	615:658	(ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability	610:781	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	3	56	theme	saccharides	679:689	arg1	identification					565:578	the identification	561:578	(i) the identification of the N-glycan-bearing site	557:607	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	5	57	theme	oligomerization	1025:1039	arg1	process					1041:1047	the oligomerization process	1021:1047	the oligomerization process	1021:1047	In addition, the detachment of the oligosaccharide significantly affects secondary structure composition, which disturbs the oligomerization process.
37158251	1	58	theme	lupin	129:133	arg1	protein					140:146	a lupin seed protein	127:146	a lupin seed protein	127:146	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	1	58	theme	lupin	129:133	arg1	γ-Conglutin					114:124	γ-Conglutin	114:124	γ-Conglutin	114:124	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	7	59	theme	γ-conglutin	1442:1452	arg1	integrity					1464:1472	γ-conglutin structure integrity	1442:1472	γ-conglutin structure integrity	1442:1472	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	7	60	theme	structure	1454:1462	arg1	integrity					1464:1472	γ-conglutin structure integrity	1442:1472	γ-conglutin structure integrity	1442:1472	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	1	61	theme	seed	135:138	arg1	protein					140:146	a lupin seed protein	127:146	a lupin seed protein	127:146	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	1	61	theme	seed	135:138	arg1	γ-Conglutin					114:124	γ-Conglutin	114:124	γ-Conglutin	114:124	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	4	62	attach	attached	869:876	arg1	residue					891:897	the Asn98 residue	881:897	the Asn98 residue	881:897	The obtained results indicate the presence of glycans belonging to different classes attached to the Asn98 residue.
37158251	4	62	attach	attached	869:876	arg2	classes					861:867	different classes	851:867	different classes attached to the Asn98 residue	851:897	The obtained results indicate the presence of glycans belonging to different classes attached to the Asn98 residue.
37158251	7	63	theme	presented	1263:1271	arg1	results					1273:1279	the presented results	1259:1279	the presented results	1259:1279	Collectively, the presented results provide evidence of the high complexity of the post-translational maturation and suggest the possibility of a functional effect that glycosylation might have on γ-conglutin structure integrity.
37158251	2	64	theme	physiological	391:403	arg1	significance					405:416	physiological significance	391:416	physiological significance for the plant	391:430	Moreover, this protein is an evolutionary cornerstone whose physiological significance for the plant has not been determined yet.
37158251	1	65	dep	terms	182:186	arg1	both					174:177	both	174:177	both	174:177	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	3	66	theme	glycosylation	517:529	arg1	characterization					485:500	a comprehensive characterization	469:500	a comprehensive characterization of γ-conglutin glycosylation	469:529	Herein, a comprehensive characterization of γ-conglutin glycosylation is presented and includes (i) the identification of the N-glycan-bearing site, (ii) the qualitative and quantitative composition of glycan-building saccharides, as well as (iii) the effect of oligosaccharide removal on structural and thermal stability.
37158251	1	67	theme	molecular	213:221	arg1	structure					223:231	its molecular structure	209:231	its molecular structure	209:231	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	0	68	theme	Molecular	57:65	arg1	Behavior					67:74	the Molecular Behavior	53:74	the Molecular Behavior of Lupinus angustifolius γ-Conglutin	53:111	Characteristics of N-Glycosylation and Its Impact on the Molecular Behavior of Lupinus angustifolius γ-Conglutin.
37158251	1	69	theme	human	317:321	arg1	trials					323:328	animal and human trials	306:328	animal and human trials	306:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
37158251	1	70	theme	structure	223:231	arg1	complexity					195:204	the complexity	191:204	the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials	191:328	γ-Conglutin, a lupin seed protein, is an intriguing protein both in terms of the complexity of its molecular structure and a broad spectrum of unique health-promoting properties manifested in animal and human trials.
35053284	11	0	theme	large	1612:1616	arg1	N-glycans					1652:1660	very large, likewise methylated complex-type N-glycans	1607:1660	very large, likewise methylated complex-type N-glycans	1607:1660	Some mosses additionally presented very large, likewise methylated complex-type N-glycans.
35053284	7	1	dep	MMXF	1135:1138	arg1	GnGnXF					1151:1156	GnGnXF	1151:1156	GnGnXF	1151:1156	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	7	1	dep	MMXF	1135:1138	arg1	MGnXF					1141:1145	MGnXF	1141:1145	MGnXF	1141:1145	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	12	2	theme	green	1787:1791	arg1	algae					1793:1797	green algae	1787:1797	green algae	1787:1797	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	1	3	theme	phylogenetic	147:158	arg1	specificities					160:172	phylogenetic specificities	147:172	phylogenetic specificities of various kinds	147:189	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	12	4	theme	first	1668:1672	arg1	finding					1674:1680	This first finding	1663:1680	This first finding of the methylation of N-glycans in land plants	1663:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	4	5	theme	N-glycan	573:580	arg1	structures					582:591	unique and unusual N-glycan structures	554:591	unique and unusual N-glycan structures	554:591	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	5	6	theme	million	756:762	arg1	years					764:768	at least 400 million years	743:768	at least 400 million years of evolution from vascular plants	743:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	5	7	from	years	764:768	arg1	plants					797:802	vascular plants	788:802	vascular plants	788:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	7	8	dep	residues	1125:1132	arg1	MMXF					1135:1138	MMXF	1135:1138	MMXF	1135:1138	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	12	9	theme	phylogenetic	1752:1763	arg1	relation					1765:1772	phylogenetic relation	1752:1772	phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait	1752:1882	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	3	10	theme	A	499:499	arg1	determinants					501:512	Lewis A determinants	493:512	Lewis A determinants	493:512	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	4	11	theme	unusual	565:571	arg1	structures					582:591	unique and unusual N-glycan structures	554:591	unique and unusual N-glycan structures	554:591	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	3	12	theme	land	340:343	arg1	plants					345:350	land plants	340:350	land plants	340:350	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	6	13	theme	several	964:970	arg1	species					977:983	several moss species	964:983	several moss species	964:983	To challenge this view, we analysed the N-glycomes of several moss species using MALDI-TOF/TOF, PGC-MS/MS and GC-MS.
35053284	7	14	theme	Da	1219:1220	arg1	increments					1222:1231	14.02 Da increments	1213:1231	14.02 Da increments	1213:1231	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	3	15	theme	Lewis	493:497	arg1	determinants					501:512	Lewis A determinants	493:512	Lewis A determinants	493:512	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	3	16	theme	angiosperms	327:337	arg1	kinds					307:311	all kinds	303:311	all kinds of gymno- and angiosperms	303:337	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	9	17	contain	had	1442:1444	arg1	others					1435:1440	others	1435:1440	others	1435:1440	In some species, methylated glycans dominated, while others had no methylation at all.
35053284	9	17	contain	had	1442:1444	arg2	methylation					1449:1459	no methylation	1446:1459	no methylation	1446:1459	In some species, methylated glycans dominated, while others had no methylation at all.
35053284	1	18	theme	animal	71:76	arg1	kingdom					78:84	the animal kingdom	67:84	the animal kingdom	67:84	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	5	19	theme	N-glycosylation	846:860	arg1	machinery					862:870	an N-glycosylation machinery	843:870	an N-glycosylation machinery identical to that of vascular plants	843:907	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	4	20	theme	various	663:669	arg1	monosaccharides					607:621	uncommon monosaccharides	598:621	uncommon monosaccharides	598:621	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	20	theme	various	663:669	arg1	kinds					671:675	various kinds	663:675	various kinds of O-methylation	663:692	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	7	21	theme	GlcNAc	1118:1123	arg1	residues					1125:1132	one or two terminal GlcNAc residues	1098:1132	one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively)	1098:1171	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	11	22	theme	complex-type	1639:1650	arg1	N-glycans					1652:1660	very large, likewise methylated complex-type N-glycans	1607:1660	very large, likewise methylated complex-type N-glycans	1607:1660	Some mosses additionally presented very large, likewise methylated complex-type N-glycans.
35053284	3	23	theme	pentasaccharide	394:408	arg1	core					410:413	the common pentasaccharide core	383:413	the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants	383:512	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	4	24	theme	uncommon	598:605	arg1	monosaccharides					607:621	uncommon monosaccharides	598:621	uncommon monosaccharides	598:621	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	24	theme	uncommon	598:605	arg1	plethora					626:633	a plethora	624:633	a plethora of different structures	624:657	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	24	theme	uncommon	598:605	arg1	kinds					671:675	various kinds	663:675	various kinds of O-methylation	663:692	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	1	25	theme	various	177:183	arg1	kinds					185:189	various kinds	177:189	various kinds	177:189	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	5	26	theme	vascular	788:795	arg1	plants					797:802	vascular plants	788:802	vascular plants	788:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	5	27	from	plants	797:802	arg1	evolution					773:781	evolution	773:781	evolution from vascular plants	773:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	5	27	from	plants	797:802	arg1	years					764:768	at least 400 million years	743:768	at least 400 million years of evolution from vascular plants	743:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	7	28	theme	many	1174:1177	arg1	species					1179:1185	many species	1174:1185	many species	1174:1185	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	12	29	theme	land	1717:1720	arg1	plants					1722:1727	land plants	1717:1727	land plants	1717:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	1	30	theme	kinds	185:189	arg1	specificities					160:172	phylogenetic specificities	147:172	phylogenetic specificities of various kinds	147:189	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	0	31	theme	O-methylated	0:11	arg1	N-glycans					13:21	O-methylated N-glycans	0:21	O-methylated N-glycans	0:21	O-methylated N-glycans Distinguish Mosses from Vascular Plants.
35053284	11	32	dep	large	1612:1616	arg1	methylated					1628:1637	methylated	1628:1637	methylated	1628:1637	Some mosses additionally presented very large, likewise methylated complex-type N-glycans.
35053284	12	33	theme	N-glycans	1704:1712	arg1	methylation					1689:1699	the methylation	1685:1699	the methylation of N-glycans in land plants	1685:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	12	34	theme	common	1871:1876	arg1	trait					1878:1882	a common trait	1869:1882	a common trait	1869:1882	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	12	34	theme	common	1871:1876	arg1	O-methylation					1810:1822	the O-methylation	1806:1822	the O-methylation of mannose and many other monosaccharides	1806:1864	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	8	35	theme	methylation	1323:1333	arg1	level					1314:1318	the level	1310:1318	the level of methylation	1310:1333	Throughout all analysed moss N-glycans, the level of methylation differed strongly even within the same family.
35053284	6	36	theme	species	977:983	arg1	N-glycomes					950:959	the N-glycomes	946:959	the N-glycomes of several moss species	946:983	To challenge this view, we analysed the N-glycomes of several moss species using MALDI-TOF/TOF, PGC-MS/MS and GC-MS.
35053284	12	37	theme	monosaccharides	1850:1864	arg1	trait					1878:1882	a common trait	1869:1882	a common trait	1869:1882	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	12	37	theme	monosaccharides	1850:1864	arg1	O-methylation					1810:1822	the O-methylation	1806:1822	the O-methylation of mannose and many other monosaccharides	1806:1864	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	12	38	from	methylation	1689:1699	arg1	plants					1722:1727	land plants	1717:1727	land plants	1717:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	3	39	with	structures	367:376	arg1	core					410:413	the common pentasaccharide core	383:413	the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants	383:512	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	10	40	theme	terminal	1554:1561	arg1	mannose					1563:1569	2,6-O-methylated terminal mannose	1537:1569	2,6-O-methylated terminal mannose	1537:1569	GC-MS revealed the main glycan from Funaria hygrometrica to contain 2,6-O-methylated terminal mannose.
35053284	12	41	theme	other	1844:1848	arg1	monosaccharides					1850:1864	many other monosaccharides	1839:1864	many other monosaccharides	1839:1864	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	8	42	theme	moss	1294:1297	arg1	N-glycans					1299:1307	all analysed moss N-glycans	1281:1307	all analysed moss N-glycans	1281:1307	Throughout all analysed moss N-glycans, the level of methylation differed strongly even within the same family.
35053284	3	43	theme	maybe	458:462	arg1	residues					480:487	maybe terminal GlcNAc residues	458:487	maybe terminal GlcNAc residues	458:487	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	0	44	theme	Vascular	47:54	arg1	Plants					56:61	Vascular Plants	47:61	Vascular Plants	47:61	O-methylated N-glycans Distinguish Mosses from Vascular Plants.
35053284	4	45	theme	unique	554:559	arg1	structures					582:591	unique and unusual N-glycan structures	554:591	unique and unusual N-glycan structures	554:591	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	46	theme	structures	648:657	arg1	monosaccharides					607:621	uncommon monosaccharides	598:621	uncommon monosaccharides	598:621	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	46	theme	structures	648:657	arg1	plethora					626:633	a plethora	624:633	a plethora of different structures	624:657	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	46	theme	structures	648:657	arg1	kinds					671:675	various kinds	663:675	various kinds of O-methylation	663:692	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	7	47	contain	contained	1045:1053	arg1	species					1037:1043	all species	1033:1043	all species	1033:1043	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	7	47	contain	contained	1045:1053	arg2	heptasaccharide					1073:1087	heptasaccharide	1073:1087	heptasaccharide	1073:1087	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	7	47	contain	contained	1045:1053	arg2	residues					1125:1132	one or two terminal GlcNAc residues	1098:1132	one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively)	1098:1171	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	3	48	theme	core	440:443	arg1	α1,3-fucose					445:455	core α1,3-fucose	440:455	core α1,3-fucose	440:455	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	5	49	theme	plants	714:719	arg1	Mosses					695:700	Mosses	695:700	Mosses	695:700	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	5	49	theme	plants	714:719	arg1	group					705:709	a group	703:709	a group of plants that are separated by at least 400 million years of evolution from vascular plants	703:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	5	49	theme	plants	714:719	arg1	plants					714:719	plants	714:719	plants	714:719	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	6	50	theme	moss	972:975	arg1	species					977:983	several moss species	964:983	several moss species	964:983	To challenge this view, we analysed the N-glycomes of several moss species using MALDI-TOF/TOF, PGC-MS/MS and GC-MS.
35053284	4	51	theme	different	638:646	arg1	structures					648:657	different structures	638:657	different structures	638:657	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	5	52	theme	evolution	773:781	arg1	years					764:768	at least 400 million years	743:768	at least 400 million years of evolution from vascular plants	743:802	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	10	53	theme	2,6-O-methylated	1537:1552	arg1	mannose					1563:1569	2,6-O-methylated terminal mannose	1537:1569	2,6-O-methylated terminal mannose	1537:1569	GC-MS revealed the main glycan from Funaria hygrometrica to contain 2,6-O-methylated terminal mannose.
35053284	12	54	theme	mannose	1827:1833	arg1	trait					1878:1882	a common trait	1869:1882	a common trait	1869:1882	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	12	54	theme	mannose	1827:1833	arg1	O-methylation					1810:1822	the O-methylation	1806:1822	the O-methylation of mannose and many other monosaccharides	1806:1864	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	5	55	theme	vascular	893:900	arg1	plants					902:907	vascular plants	893:907	vascular plants	893:907	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	3	56	theme	common	387:392	arg1	core					410:413	the common pentasaccharide core	383:413	the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants	383:512	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	4	57	theme	green	528:532	arg1	algae					534:538	green algae	528:538	green algae	528:538	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	8	58	theme	same	1369:1372	arg1	family					1374:1379	the same family	1365:1379	the same family	1365:1379	Throughout all analysed moss N-glycans, the level of methylation differed strongly even within the same family.
35053284	1	59	theme	N-glycan	109:116	arg1	structures					118:127	N-glycan structures	109:127	N-glycan structures	109:127	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	12	60	theme	many	1839:1842	arg1	monosaccharides					1850:1864	many other monosaccharides	1839:1864	many other monosaccharides	1839:1864	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	2	61	theme	plant	199:203	arg1	kingdom					205:211	the plant kingdom	195:211	the plant kingdom	195:211	In the plant kingdom, however, N-glycosylation appears to be strictly conservative and uniform.
35053284	1	62	theme	structures	118:127	arg1	structures					118:127	N-glycan structures	109:127	N-glycan structures	109:127	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	1	62	theme	structures	118:127	arg1	variety					98:104	a stunning variety	87:104	a stunning variety of N-glycan structures	87:127	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	1	63	theme	stunning	89:96	arg1	structures					118:127	N-glycan structures	109:127	N-glycan structures	109:127	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	1	63	theme	stunning	89:96	arg1	variety					98:104	a stunning variety	87:104	a stunning variety of N-glycan structures	87:127	In the animal kingdom, a stunning variety of N-glycan structures have emerged with phylogenetic specificities of various kinds.
35053284	10	64	from	hygrometrica	1513:1524	arg1	glycan					1493:1498	the main glycan	1484:1498	the main glycan from Funaria hygrometrica to contain 2,6-O-methylated terminal mannose	1484:1569	GC-MS revealed the main glycan from Funaria hygrometrica to contain 2,6-O-methylated terminal mannose.
35053284	12	65	from	plants	1722:1727	arg1	finding					1674:1680	This first finding	1663:1680	This first finding of the methylation of N-glycans in land plants	1663:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	8	66	theme	analysed	1285:1292	arg1	N-glycans					1299:1307	all analysed moss N-glycans	1281:1307	all analysed moss N-glycans	1281:1307	Throughout all analysed moss N-glycans, the level of methylation differed strongly even within the same family.
35053284	3	67	theme	GlcNAc	473:478	arg1	residues					480:487	maybe terminal GlcNAc residues	458:487	maybe terminal GlcNAc residues	458:487	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	3	68	theme	terminal	464:471	arg1	residues					480:487	maybe terminal GlcNAc residues	458:487	maybe terminal GlcNAc residues	458:487	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	3	69	theme	gymno-	316:321	arg1	kinds					307:311	all kinds	303:311	all kinds of gymno- and angiosperms	303:337	From mosses to all kinds of gymno- and angiosperms, land plants mainly express structures with the common pentasaccharide core substituted with xylose, core α1,3-fucose, maybe terminal GlcNAc residues and Lewis A determinants.
35053284	12	70	from	finding	1674:1680	arg1	plants					1722:1727	land plants	1717:1727	land plants	1717:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	12	71	theme	mosses	1777:1782	arg1	relation					1765:1772	phylogenetic relation	1752:1772	phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait	1752:1882	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35053284	5	72	theme	identical	872:880	arg1	machinery					862:870	an N-glycosylation machinery	843:870	an N-glycosylation machinery identical to that of vascular plants	843:907	Mosses, a group of plants that are separated by at least 400 million years of evolution from vascular plants, have hitherto been seen as harbouring an N-glycosylation machinery identical to that of vascular plants.
35053284	9	73	theme	methylated	1399:1408	arg1	glycans					1410:1416	methylated glycans	1399:1416	methylated glycans	1399:1416	In some species, methylated glycans dominated, while others had no methylation at all.
35053284	10	74	theme	main	1488:1491	arg1	glycan					1493:1498	the main glycan	1484:1498	the main glycan from Funaria hygrometrica to contain 2,6-O-methylated terminal mannose	1484:1569	GC-MS revealed the main glycan from Funaria hygrometrica to contain 2,6-O-methylated terminal mannose.
35053284	7	75	theme	terminal	1109:1116	arg1	residues					1125:1132	one or two terminal GlcNAc residues	1098:1132	one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively)	1098:1171	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	4	76	theme	O-methylation	680:692	arg1	monosaccharides					607:621	uncommon monosaccharides	598:621	uncommon monosaccharides	598:621	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	76	theme	O-methylation	680:692	arg1	plethora					626:633	a plethora	624:633	a plethora of different structures	624:657	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	4	76	theme	O-methylation	680:692	arg1	kinds					671:675	various kinds	663:675	various kinds of O-methylation	663:692	In contrast, green algae biosynthesise unique and unusual N-glycan structures with uncommon monosaccharides, a plethora of different structures and various kinds of O-methylation.
35053284	7	77	theme	MS	1197:1198	arg1	signals					1200:1206	MS signals	1197:1206	MS signals	1197:1206	While all species contained the plant-typical heptasaccharide with no, one or two terminal GlcNAc residues (MMXF, MGnXF and GnGnXF, respectively), many species exhibited MS signals with 14.02 Da increments as characteristic for O-methylation.
35053284	12	78	theme	methylation	1689:1699	arg1	finding					1674:1680	This first finding	1663:1680	This first finding of the methylation of N-glycans in land plants	1663:1727	This first finding of the methylation of N-glycans in land plants mirrors the presumable phylogenetic relation of mosses to green algae, where the O-methylation of mannose and many other monosaccharides is a common trait.
35091091	6	0	theme	new	1331:1333	arg1	method					1335:1340	The new method	1327:1340	The new method	1327:1340	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	2	1	theme	search	392:397	arg1	engine					399:404	our MSFragger search engine	378:404	our MSFragger search engine	378:404	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	5	2	theme	glycopeptide	1242:1253	arg1	analyses					1255:1262	complex glycopeptide analyses	1234:1262	complex glycopeptide analyses	1234:1262	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	2	3	from	method	368:373	arg1	engine					399:404	our MSFragger search engine	378:404	our MSFragger search engine	378:404	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	6	4	with	annotation	1552:1561	arg1	control					1615:1621	false discovery rate control	1594:1621	false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1594:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	5	5	theme	complex	1234:1240	arg1	analyses					1255:1262	complex glycopeptide analyses	1234:1262	complex glycopeptide analyses	1234:1262	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	6	6	theme	rate	1610:1613	arg1	control					1615:1621	false discovery rate control	1594:1621	false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1594:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	2	7	theme	glycoproteomics	345:359	arg1	method					368:373	a fast and sensitive glycoproteomics search method	324:373	a fast and sensitive glycoproteomics search method	324:373	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	6	8	theme	false	1594:1598	arg1	rate					1610:1613	false discovery rate	1594:1613	false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1594:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	1	9	theme	resulting	219:227	arg1	spectrometry					234:245	the resulting mass spectrometry	215:245	the resulting mass spectrometry data	215:250	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	3	10	contain	have	662:665	arg1	glycans					654:660	many glycans	649:660	many glycans	649:660	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	3	10	contain	have	662:665	arg2	masses					688:693	similar or identical masses	667:693	similar or identical masses	667:693	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	6	11	theme	modification	1386:1397	arg1	tool					1408:1411	the PTM-Shepherd modification analysis tool	1369:1411	the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface	1369:1501	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	3	12	theme	specific	585:592	arg1	composition					601:611	a specific glycan composition	583:611	a specific glycan composition	583:611	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	6	13	theme	spectra	1581:1587	arg1	annotation					1552:1561	annotation	1552:1561	annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1552:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	1	14	theme	spectrometry	234:245	arg1	data					247:250	the resulting mass spectrometry data	215:250	the resulting mass spectrometry data	215:250	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	4	15	theme	Y-type	953:958	arg1	ions					960:963	observed glycan B-type (oxonium) and Y-type ions	916:963	observed glycan B-type (oxonium) and Y-type ions	916:963	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	6	16	gly	N-glycopeptide	1566:1579	arg2	N-glycopeptide					1566:1579	N-glycopeptide spectra	1566:1587	N-glycopeptide spectra	1566:1587	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	4	17	theme	glycan	925:930	arg1	B-type					932:937	glycan B-type	925:937	glycan B-type (oxonium)	925:947	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	17	theme	glycan	925:930	arg1	oxonium					940:946	oxonium	940:946	oxonium	940:946	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	18	theme	new	722:724	arg1	method					726:731	a new method	720:731	a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates	720:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	1	19	theme	large-scale	146:156	arg1	analyses					158:165	increasingly large-scale analyses	133:165	increasingly large-scale analyses of complex glycopeptide samples	133:197	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	5	20	theme	discovery	1090:1098	arg1	rate					1100:1103	false discovery rate	1084:1103	false discovery rate estimation for the glycan assignment	1084:1140	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	3	21	theme	many	649:652	arg1	glycans					654:660	many glycans	649:660	many glycans	649:660	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	6	22	theme	glycan	1643:1648	arg1	components					1650:1659	both peptide and glycan components	1626:1659	components	1650:1659	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	4	23	theme	monoisotopic	988:999	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	6	24	theme	MSFragger	1439:1447	arg1	search					1455:1460	the MSFragger glyco search	1435:1460	the MSFragger glyco search	1435:1460	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	6	25	theme	peptide	1631:1637	arg1	components					1650:1659	both peptide and glycan components	1626:1659	components	1650:1659	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	4	26	dep	glycopeptides	784:796	arg1	fragmented					798:807	fragmented	798:807	fragmented	798:807	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	5	27	theme	false	1301:1305	arg1	assignments					1314:1324	false glycan assignments	1301:1324	false glycan assignments	1301:1324	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	4	28	from	spectrum	896:903	arg1	information					875:885	information	875:885	information from the spectrum	875:903	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	28	from	spectrum	896:903	arg1	sources					864:870	multiple sources	855:870	multiple sources	855:870	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	28	from	spectrum	896:903	arg1	ions					960:963	observed glycan B-type (oxonium) and Y-type ions	916:963	observed glycan B-type (oxonium) and Y-type ions	916:963	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	28	from	spectrum	896:903	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	29	theme	N-linked	775:782	arg1	glycopeptides					784:796	N-linked glycopeptides	775:796	N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates	775:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	5	30	theme	assignments	1314:1324	arg1	rate					1293:1296	the rate	1289:1296	the rate of false glycan assignments	1289:1324	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	2	31	theme	peptide	457:463	arg1	sequence					465:472	a peptide sequence	455:472	a peptide sequence	455:472	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	6	32	theme	graphical	1478:1486	arg1	interface					1493:1501	the FragPipe graphical user interface	1465:1501	the FragPipe graphical user interface	1465:1501	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	2	33	theme	glycan	503:508	arg1	mass					482:485	the mass	478:485	the mass of the attached glycan	478:508	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	2	33	theme	glycan	503:508	arg1	combination					440:450	a combination	438:450	a combination of a peptide sequence	438:472	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	0	34	theme	FDR	41:43	arg1	Control					45:51	FDR Control	41:51	FDR Control	41:51	Multiattribute Glycan Identification and FDR Control for Glycoproteomics.
35091091	4	35	theme	possible	1042:1049	arg1	candidates					1058:1067	possible glycan candidates	1042:1067	possible glycan candidates	1042:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	36	theme	multiple	855:862	arg1	sources					864:870	multiple sources	855:870	multiple sources	855:870	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	36	theme	multiple	855:862	arg1	ions					960:963	observed glycan B-type (oxonium) and Y-type ions	916:963	observed glycan B-type (oxonium) and Y-type ions	916:963	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	36	theme	multiple	855:862	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	2	37	theme	MSFragger	382:390	arg1	engine					399:404	our MSFragger search engine	378:404	our MSFragger search engine	378:404	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	1	38	theme	high	257:260	arg1	confidence					262:271	high confidence	257:271	high confidence	257:271	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	1	39	theme	glycopeptide	178:189	arg1	samples					191:197	complex glycopeptide samples	170:197	complex glycopeptide samples	170:197	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	4	40	theme	hybrid	827:832	arg1	activation					834:843	hybrid activation	827:843	hybrid activation	827:843	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	3	41	theme	complex	527:533	arg1	patterns					549:556	complex glycosylation patterns	527:556	complex glycosylation patterns	527:556	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	6	42	theme	complete	1516:1523	arg1	pipeline					1539:1546	a complete computational pipeline	1514:1546	a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1514:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	1	43	theme	major	283:287	arg1	bottleneck					289:298	a major bottleneck	281:298	a major bottleneck	281:298	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	2	44	theme	fast	326:329	arg1	method					368:373	a fast and sensitive glycoproteomics search method	324:373	a fast and sensitive glycoproteomics search method	324:373	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	2	45	theme	search	361:366	arg1	method					368:373	a fast and sensitive glycoproteomics search method	324:373	a fast and sensitive glycoproteomics search method	324:373	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	3	46	with	samples	514:520	arg1	patterns					549:556	complex glycosylation patterns	527:556	complex glycosylation patterns	527:556	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	3	47	theme	glycan	594:599	arg1	composition					601:611	a specific glycan composition	583:611	a specific glycan composition	583:611	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	6	48	theme	discovery	1600:1608	arg1	rate					1610:1613	false discovery rate	1594:1613	false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1594:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	3	49	dep	straightforward	620:634	arg1	have					662:665	have	662:665	have similar or identical masses	662:693	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	4	50	theme	information	875:885	arg1	sources					864:870	multiple sources	855:870	multiple sources	855:870	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	50	theme	information	875:885	arg1	ions					960:963	observed glycan B-type (oxonium) and Y-type ions	916:963	observed glycan B-type (oxonium) and Y-type ions	916:963	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	50	theme	information	875:885	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	6	51	theme	analysis	1399:1406	arg1	tool					1408:1411	the PTM-Shepherd modification analysis tool	1369:1411	the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface	1369:1501	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	2	52	theme	sensitive	335:343	arg1	method					368:373	a fast and sensitive glycoproteomics search method	324:373	a fast and sensitive glycoproteomics search method	324:373	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	1	53	theme	mass	229:232	arg1	spectrometry					234:245	the resulting mass spectrometry	215:245	the resulting mass spectrometry data	215:250	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	6	54	theme	PTM-Shepherd	1373:1384	arg1	tool					1408:1411	the PTM-Shepherd modification analysis tool	1369:1411	the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface	1369:1501	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	6	55	theme	N-glycopeptide	1566:1579	arg1	spectra					1581:1587	N-glycopeptide spectra	1566:1587	N-glycopeptide spectra	1566:1587	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	1	56	gly	glycopeptide	178:189	arg2	glycopeptide					178:189	complex glycopeptide samples	170:197	complex glycopeptide samples	170:197	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	5	57	theme	glycan	1124:1129	arg1	assignment					1131:1140	the glycan assignment	1120:1140	the glycan assignment	1120:1140	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	4	58	theme	observed	916:923	arg1	ions					960:963	observed glycan B-type (oxonium) and Y-type ions	916:963	observed glycan B-type (oxonium) and Y-type ions	916:963	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	5	59	theme	false	1084:1088	arg1	rate					1100:1103	false discovery rate	1084:1103	false discovery rate estimation for the glycan assignment	1084:1140	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	6	60	theme	components	1650:1659	arg1	control					1615:1621	false discovery rate control	1594:1621	false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1594:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	4	61	theme	B-type	932:937	arg1	ions					960:963	observed glycan B-type (oxonium) and Y-type ions	916:963	observed glycan B-type (oxonium) and Y-type ions	916:963	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	6	62	theme	glyco	1449:1453	arg1	search					1455:1460	the MSFragger glyco search	1435:1460	the MSFragger glyco search	1435:1460	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	5	63	theme	rate	1100:1103	arg1	estimation					1105:1114	false discovery rate estimation	1084:1114	false discovery rate estimation for the glycan assignment	1084:1140	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	1	64	theme	complex	170:176	arg1	samples					191:197	complex glycopeptide samples	170:197	complex glycopeptide samples	170:197	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	4	65	theme	precursor	978:986	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	66	gly	glycopeptides	784:796	arg2	glycopeptides					784:796	N-linked glycopeptides	775:796	N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates	775:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	1	67	theme	samples	191:197	arg1	analyses					158:165	increasingly large-scale analyses	133:165	increasingly large-scale analyses of complex glycopeptide samples	133:197	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	4	68	theme	selection	1001:1009	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	5	69	theme	glycan	1307:1312	arg1	assignments					1314:1324	false glycan assignments	1301:1324	false glycan assignments	1301:1324	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	6	70	theme	false	1703:1707	arg1	identifications					1709:1723	false identifications	1703:1723	false identifications	1703:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	1	71	theme	improving	82:90	arg1	methods					92:98	Rapidly improving methods	74:98	Rapidly improving methods for glycoproteomics	74:118	Rapidly improving methods for glycoproteomics have enabled increasingly large-scale analyses of complex glycopeptide samples, but annotating the resulting mass spectrometry data with high confidence remains a major bottleneck.
35091091	4	72	theme	mass	969:972	arg1	errors					1011:1016	mass and precursor monoisotopic selection errors	969:1016	errors	1011:1016	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	5	73	gly	glycopeptide	1242:1253	arg2	glycopeptide					1242:1253	complex glycopeptide analyses	1234:1262	complex glycopeptide analyses	1234:1262	Combined with false discovery rate estimation for the glycan assignment, we show that this method is capable of specifically and sensitively identifying glycans in complex glycopeptide analyses and effectively controls the rate of false glycan assignments.
35091091	4	74	theme	glycopeptides	784:796	arg1	composition					760:770	the glycan composition	749:770	the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates	749:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	0	75	theme	Glycan	15:20	arg1	Identification					22:35	Glycan Identification	15:35	Glycan Identification	15:35	Multiattribute Glycan Identification and FDR Control for Glycoproteomics.
35091091	4	76	from	sources	864:870	arg1	spectrum					896:903	the spectrum	892:903	the spectrum	892:903	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	4	77	theme	glycan	1051:1056	arg1	candidates					1058:1067	possible glycan candidates	1042:1067	possible glycan candidates	1042:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	2	78	gly	glycopeptides	421:433	arg2	glycopeptides					421:433	glycopeptides	421:433	glycopeptides	421:433	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	6	79	theme	user	1488:1491	arg1	interface					1493:1501	the FragPipe graphical user interface	1465:1501	the FragPipe graphical user interface	1465:1501	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	2	80	theme	sequence	465:472	arg1	mass					482:485	the mass	478:485	the mass of the attached glycan	478:508	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	2	80	theme	sequence	465:472	arg1	combination					440:450	a combination	438:450	a combination of a peptide sequence	438:472	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	3	81	theme	similar	667:673	arg1	masses					688:693	similar or identical masses	667:693	similar or identical masses	667:693	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	4	82	theme	glycan	753:758	arg1	composition					760:770	the glycan composition	749:770	the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates	749:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	6	83	theme	FragPipe	1469:1476	arg1	interface					1493:1501	the FragPipe graphical user interface	1465:1501	the FragPipe graphical user interface	1465:1501	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
35091091	2	84	theme	attached	494:501	arg1	glycan					503:508	the attached glycan	490:508	the attached glycan	490:508	We recently introduced a fast and sensitive glycoproteomics search method in our MSFragger search engine, which reports glycopeptides as a combination of a peptide sequence and the mass of the attached glycan.
35091091	3	85	theme	glycosylation	535:547	arg1	patterns					549:556	complex glycosylation patterns	527:556	complex glycosylation patterns	527:556	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	4	86	link	N-linked	775:782	arg1	glycopeptides					784:796	N-linked glycopeptides	775:796	N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates	775:1067	Here, we have developed a new method for determining the glycan composition of N-linked glycopeptides fragmented by collisional or hybrid activation that uses multiple sources of information from the spectrum, including observed glycan B-type (oxonium) and Y-type ions and mass and precursor monoisotopic selection errors to discriminate between possible glycan candidates.
35091091	3	87	theme	identical	678:686	arg1	masses					688:693	similar or identical masses	667:693	similar or identical masses	667:693	In samples with complex glycosylation patterns, converting this mass to a specific glycan composition is not straightforward; however, as many glycans have similar or identical masses.
35091091	6	88	theme	computational	1525:1537	arg1	pipeline					1539:1546	a complete computational pipeline	1514:1546	a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications	1514:1723	The new method has been incorporated into the PTM-Shepherd modification analysis tool to work directly with the MSFragger glyco search in the FragPipe graphical user interface, providing a complete computational pipeline for annotation of N-glycopeptide spectra with false discovery rate control of both peptide and glycan components that is both sensitive and robust against false identifications.
36122299	5	0	theme	GlcNAc	700:705	arg1	modifications					707:719	isobaric GalNAc and GlcNAc modifications	680:719	isobaric GalNAc and GlcNAc modifications	680:719	However, it has been difficult to distinguish isobaric GalNAc and GlcNAc modifications by using mass spectrometry only.
36122299	6	1	theme	oxonium	778:784	arg1	ions					786:789	oxonium ions	778:789	oxonium ions of standard O-GlcNAc/O-GalNAc peptides	778:828	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	7	2	theme	comprehensive	976:988	arg1	sets					995:998	comprehensive data sets	976:998	comprehensive data sets	976:998	Then a binary logistic regression model was established by training comprehensive data sets from glycoproteomics studies reported.
36122299	10	3	theme	corresponding	1298:1310	arg1	HexNAcQuest					1323:1333	HexNAcQuest	1323:1333	HexNAcQuest	1323:1333	Based on this model, a corresponding Web server HexNAcQuest has been constructed, which is freely accessible to users.
36122299	10	3	theme	corresponding	1298:1310	arg1	server					1316:1321	a corresponding Web server	1296:1321	a corresponding Web server HexNAcQuest	1296:1333	Based on this model, a corresponding Web server HexNAcQuest has been constructed, which is freely accessible to users.
36122299	4	4	theme	saccharide	561:570	arg1	ions					580:583	abundant saccharide oxonium ions	552:583	abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues	552:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	4	5	theme	glycoproteomic	419:432	arg1	analysis					434:441	typical glycoproteomic analysis	411:441	typical glycoproteomic analysis	411:441	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	4	6	theme	abundant	552:559	arg1	ions					580:583	abundant saccharide oxonium ions	552:583	abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues	552:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	8	7	theme	>87	1150:1152	arg1	%					1153:1153	%	1153:1153	%	1153:1153	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	4	8	theme	typical	411:417	arg1	analysis					434:441	typical glycoproteomic analysis	411:441	typical glycoproteomic analysis	411:441	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	4	9	contain	containing	585:594	arg2	residues					624:631	N-acetylhexosamine (HexNAc) residues	596:631	N-acetylhexosamine (HexNAc) residues	596:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	4	9	contain	containing	585:594	arg1	ions					580:583	abundant saccharide oxonium ions	552:583	abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues	552:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	11	10	theme	HexNAc	1500:1505	arg1	modifications					1507:1519	the isobaric HexNAc modifications	1487:1519	the isobaric HexNAc modifications	1487:1519	The model can also be easily integrated in MS-based glycoproteomics workflows to distinguish the isobaric HexNAc modifications.
36122299	3	11	theme	glycopeptides	373:385	arg1	isomers					350:356	structural isomers	339:356	structural isomers of glycans and glycopeptides	339:385	Despite the great progress, characterization of structural isomers of glycans and glycopeptides remains challenging.
36122299	8	12	theme	data	1100:1103	arg1	sets					1105:1108	independent O-glycoproteomics data sets	1070:1108	independent O-glycoproteomics data sets	1070:1108	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	8	13	theme	independent	1070:1080	arg1	sets					1105:1108	independent O-glycoproteomics data sets	1070:1108	independent O-glycoproteomics data sets	1070:1108	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	9	14	theme	empirical	1183:1191	arg1	observations					1193:1204	empirical observations	1183:1204	empirical observations	1183:1204	In comparison to empirical observations and criteria used previously, our model is accurate and generalized.
36122299	11	15	theme	isobaric	1491:1498	arg1	modifications					1507:1519	the isobaric HexNAc modifications	1487:1519	the isobaric HexNAc modifications	1487:1519	The model can also be easily integrated in MS-based glycoproteomics workflows to distinguish the isobaric HexNAc modifications.
36122299	4	16	theme	dissociation	510:521	arg1	fragmentation					529:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	8	17	theme	O-glycoproteomics	1082:1098	arg1	sets					1105:1108	independent O-glycoproteomics data sets	1070:1108	independent O-glycoproteomics data sets	1070:1108	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	1	18	theme	Protein	58:64	arg1	glycosylation					66:78	Protein glycosylation	58:78	Protein glycosylation	58:78	Protein glycosylation plays crucial roles in the regulation of diverse biological processes.
36122299	3	19	theme	glycans	361:367	arg1	isomers					350:356	structural isomers	339:356	structural isomers of glycans and glycopeptides	339:385	Despite the great progress, characterization of structural isomers of glycans and glycopeptides remains challenging.
36122299	5	20	theme	isobaric	680:687	arg1	modifications					707:719	isobaric GalNAc and GlcNAc modifications	680:719	isobaric GalNAc and GlcNAc modifications	680:719	However, it has been difficult to distinguish isobaric GalNAc and GlcNAc modifications by using mass spectrometry only.
36122299	6	21	theme	fragmentation	866:878	arg1	patterns					880:887	the fragmentation patterns	862:887	the fragmentation patterns of different ions	862:905	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	7	22	theme	logistic	922:929	arg1	model					942:946	Then a binary logistic regression model	908:946	Then a binary logistic regression model	908:946	Then a binary logistic regression model was established by training comprehensive data sets from glycoproteomics studies reported.
36122299	4	23	theme	HCD	524:526	arg1	fragmentation					529:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	5	24	theme	GalNAc	689:694	arg1	modifications					707:719	isobaric GalNAc and GlcNAc modifications	680:719	isobaric GalNAc and GlcNAc modifications	680:719	However, it has been difficult to distinguish isobaric GalNAc and GlcNAc modifications by using mass spectrometry only.
36122299	7	25	theme	regression	931:940	arg1	model					942:946	Then a binary logistic regression model	908:946	Then a binary logistic regression model	908:946	Then a binary logistic regression model was established by training comprehensive data sets from glycoproteomics studies reported.
36122299	4	26	theme	HexNAc	616:621	arg1	residues					624:631	N-acetylhexosamine (HexNAc) residues	596:631	N-acetylhexosamine (HexNAc) residues	596:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	8	27	theme	reliable	1116:1123	arg1	classification					1125:1138	reliable classification	1116:1138	reliable classification achieved (>87% accuracy)	1116:1163	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	1	28	theme	crucial	86:92	arg1	roles					94:98	crucial roles	86:98	crucial roles	86:98	Protein glycosylation plays crucial roles in the regulation of diverse biological processes.
36122299	9	29	from	accurate	1249:1256	arg1	comparison					1169:1178	comparison	1169:1178	comparison to empirical observations and criteria used previously	1169:1233	In comparison to empirical observations and criteria used previously, our model is accurate and generalized.
36122299	3	30	gly	glycopeptides	373:385	arg2	glycopeptides					373:385	glycopeptides	373:385	glycopeptides	373:385	Despite the great progress, characterization of structural isomers of glycans and glycopeptides remains challenging.
36122299	6	31	theme	different	892:900	arg1	ions					902:905	different ions	892:905	different ions	892:905	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	6	32	theme	ions	902:905	arg1	patterns					880:887	the fragmentation patterns	862:887	the fragmentation patterns of different ions	862:905	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	11	33	theme	MS-based	1437:1444	arg1	workflows					1462:1470	MS-based glycoproteomics workflows	1437:1470	MS-based glycoproteomics workflows	1437:1470	The model can also be easily integrated in MS-based glycoproteomics workflows to distinguish the isobaric HexNAc modifications.
36122299	11	34	theme	glycoproteomics	1446:1460	arg1	workflows					1462:1470	MS-based glycoproteomics workflows	1437:1470	MS-based glycoproteomics workflows	1437:1470	The model can also be easily integrated in MS-based glycoproteomics workflows to distinguish the isobaric HexNAc modifications.
36122299	2	35	theme	critical	156:163	arg1	step					165:168	a critical step	154:168	a critical step	154:168	As a critical step, mass spectrometry-based site-specific analysis of protein glycosylation is important to better understand these events.
36122299	2	36	theme	glycosylation	229:241	arg1	analysis					209:216	mass spectrometry-based site-specific analysis	171:216	mass spectrometry-based site-specific analysis of protein glycosylation	171:241	As a critical step, mass spectrometry-based site-specific analysis of protein glycosylation is important to better understand these events.
36122299	8	37	theme	%	1153:1153	arg1	accuracy					1155:1162	>87% accuracy	1150:1162	>87% accuracy	1150:1162	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	8	38	dep	classification	1125:1138	arg1	achieved					1140:1147	achieved	1140:1147	achieved (>87% accuracy)	1140:1163	The model was then tested with independent O-glycoproteomics data sets, with reliable classification achieved (>87% accuracy).
36122299	4	39	theme	oxonium	572:578	arg1	ions					580:583	abundant saccharide oxonium ions	552:583	abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues	552:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	5	40	theme	mass	730:733	arg1	spectrometry					735:746	mass spectrometry	730:746	mass spectrometry only	730:751	However, it has been difficult to distinguish isobaric GalNAc and GlcNAc modifications by using mass spectrometry only.
36122299	4	41	theme	higher-energy	484:496	arg1	fragmentation					529:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	2	42	theme	protein	221:227	arg1	glycosylation					229:241	protein glycosylation	221:241	protein glycosylation	221:241	As a critical step, mass spectrometry-based site-specific analysis of protein glycosylation is important to better understand these events.
36122299	4	43	theme	N-acetylhexosamine	596:613	arg1	residues					624:631	N-acetylhexosamine (HexNAc) residues	596:631	N-acetylhexosamine (HexNAc) residues	596:631	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	7	44	theme	binary	915:920	arg1	model					942:946	Then a binary logistic regression model	908:946	Then a binary logistic regression model	908:946	Then a binary logistic regression model was established by training comprehensive data sets from glycoproteomics studies reported.
36122299	4	45	theme	collision-induced	444:460	arg1	CID					476:478	CID	476:478	CID	476:478	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	4	45	theme	collision-induced	444:460	arg1	dissociation					462:473	collision-induced dissociation	444:473	collision-induced dissociation (CID)	444:479	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	6	46	theme	peptides	821:828	arg1	ions					786:789	oxonium ions	778:789	oxonium ions of standard O-GlcNAc/O-GalNAc peptides	778:828	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	4	47	theme	collisional	498:508	arg1	fragmentation					529:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	higher-energy collisional dissociation (HCD) fragmentation	484:541	In typical glycoproteomic analysis, collision-induced dissociation (CID) or higher-energy collisional dissociation (HCD) fragmentation produces abundant saccharide oxonium ions containing N-acetylhexosamine (HexNAc) residues.
36122299	2	48	theme	site-specific	195:207	arg1	analysis					209:216	mass spectrometry-based site-specific analysis	171:216	mass spectrometry-based site-specific analysis of protein glycosylation	171:241	As a critical step, mass spectrometry-based site-specific analysis of protein glycosylation is important to better understand these events.
36122299	0	49	dep	Tool	15:18	arg1	HexNAcQuest					0:10	HexNAcQuest	0:10	HexNAcQuest	0:10	HexNAcQuest: A Tool to Distinguish O-GlcNAc and O-GalNAc.
36122299	6	50	theme	O-GlcNAc/O-GalNAc	803:819	arg1	peptides					821:828	standard O-GlcNAc/O-GalNAc peptides	794:828	standard O-GlcNAc/O-GalNAc peptides	794:828	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	7	51	theme	glycoproteomics	1005:1019	arg1	studies					1021:1027	glycoproteomics studies	1005:1027	glycoproteomics studies reported	1005:1036	Then a binary logistic regression model was established by training comprehensive data sets from glycoproteomics studies reported.
36122299	3	52	theme	great	303:307	arg1	progress					309:316	the great progress	299:316	the great progress	299:316	Despite the great progress, characterization of structural isomers of glycans and glycopeptides remains challenging.
36122299	2	53	theme	spectrometry-based	176:193	arg1	analysis					209:216	mass spectrometry-based site-specific analysis	171:216	mass spectrometry-based site-specific analysis of protein glycosylation	171:241	As a critical step, mass spectrometry-based site-specific analysis of protein glycosylation is important to better understand these events.
36122299	6	54	theme	standard	794:801	arg1	peptides					821:828	standard O-GlcNAc/O-GalNAc peptides	794:828	standard O-GlcNAc/O-GalNAc peptides	794:828	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	1	55	theme	diverse	121:127	arg1	processes					140:148	diverse biological processes	121:148	diverse biological processes	121:148	Protein glycosylation plays crucial roles in the regulation of diverse biological processes.
36122299	7	56	theme	data	990:993	arg1	sets					995:998	comprehensive data sets	976:998	comprehensive data sets	976:998	Then a binary logistic regression model was established by training comprehensive data sets from glycoproteomics studies reported.
36122299	3	57	theme	structural	339:348	arg1	isomers					350:356	structural isomers	339:356	structural isomers of glycans and glycopeptides	339:385	Despite the great progress, characterization of structural isomers of glycans and glycopeptides remains challenging.
36122299	1	58	theme	biological	129:138	arg1	processes					140:148	diverse biological processes	121:148	diverse biological processes	121:148	Protein glycosylation plays crucial roles in the regulation of diverse biological processes.
36122299	10	59	theme	Web	1312:1314	arg1	HexNAcQuest					1323:1333	HexNAcQuest	1323:1333	HexNAcQuest	1323:1333	Based on this model, a corresponding Web server HexNAcQuest has been constructed, which is freely accessible to users.
36122299	10	59	theme	Web	1312:1314	arg1	server					1316:1321	a corresponding Web server	1296:1321	a corresponding Web server HexNAcQuest	1296:1333	Based on this model, a corresponding Web server HexNAcQuest has been constructed, which is freely accessible to users.
36122299	3	60	theme	isomers	350:356	arg1	characterization					319:334	characterization	319:334	characterization of structural isomers of glycans and glycopeptides	319:385	Despite the great progress, characterization of structural isomers of glycans and glycopeptides remains challenging.
36122299	9	61	from	comparison	1169:1178	arg1	accurate					1249:1256	accurate	1249:1256	accurate	1249:1256	In comparison to empirical observations and criteria used previously, our model is accurate and generalized.
36122299	6	62	theme	ions	786:789	arg1	intensities					763:773	intensities	763:773	intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides	763:828	By using intensities of oxonium ions of standard O-GlcNAc/O-GalNAc peptides, we systematically investigated the fragmentation patterns of different ions.
36122299	1	63	theme	processes	140:148	arg1	regulation					107:116	the regulation	103:116	the regulation of diverse biological processes	103:148	Protein glycosylation plays crucial roles in the regulation of diverse biological processes.
35349291	5	0	theme	search	637:642	arg1	GPSeeker					651:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	5	1	theme	N-glycan	805:812	arg1	moieties					814:821	N-glycan moieties	805:821	N-glycan moieties	805:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	5	2	theme	moieties	814:821	arg1	fragmentation					788:800	selective fragmentation	778:800	selective fragmentation of N-glycan moieties	778:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	4	3	theme	spectrometry	451:462	arg1	characterization					464:479	comprehensive mass spectrometry characterization	432:479	comprehensive mass spectrometry characterization of N-glycosylation of mAbs	432:506	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	6	4	theme	antibody	917:924	arg1	material					936:943	NIST monoclonal antibody reference material 8671	901:948	NIST monoclonal antibody reference material 8671	901:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	4	5	theme	N-glycosylation	484:498	arg1	characterization					464:479	comprehensive mass spectrometry characterization	432:479	comprehensive mass spectrometry characterization of N-glycosylation of mAbs	432:506	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	5	6	theme	structure-diagnostic	738:757	arg1	ions					768:771	structure-diagnostic fragment ions	738:771	structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties	738:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	5	7	theme	N-glycosylation	708:722	arg1	characterization					688:703	structure-specific characterization	669:703	structure-specific characterization of N-glycosylation	669:722	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	5	8	theme	fragment	759:766	arg1	ions					768:771	structure-diagnostic fragment ions	738:771	structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties	738:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	6	9	theme	N-glycoproteomics	863:879	arg1	characterization					881:896	our structure-specific N-glycoproteomics characterization	840:896	our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671	840:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	1	10	theme	great	200:204	arg1	expectation					206:216	great expectation	200:216	great expectation	200:216	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors show great expectation in therapy.
35349291	4	11	theme	biosynthetic	572:583	arg1	rules					585:589	known biosynthetic rules	566:589	known biosynthetic rules	566:589	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	5	12	theme	structure-specific	669:686	arg1	characterization					688:703	structure-specific characterization	669:703	structure-specific characterization of N-glycosylation	669:722	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	6	13	theme	structure-specific	844:861	arg1	characterization					881:896	our structure-specific N-glycoproteomics characterization	840:896	our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671	840:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	0	14	theme	N-Glycoproteomics	19:35	arg1	Characterization					37:52	Structure-Specific N-Glycoproteomics Characterization	0:52	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.	0:105	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	4	15	theme	known	566:570	arg1	rules					585:589	known biosynthetic rules	566:589	known biosynthetic rules	566:589	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	5	16	theme	selective	778:786	arg1	fragmentation					788:800	selective fragmentation	778:800	selective fragmentation of N-glycan moieties	778:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	0	17	theme	Structure-Specific	0:17	arg1	Characterization					37:52	Structure-Specific N-Glycoproteomics Characterization	0:52	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.	0:105	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	4	18	theme	mass	446:449	arg1	characterization					464:479	comprehensive mass spectrometry characterization	432:479	comprehensive mass spectrometry characterization of N-glycosylation of mAbs	432:506	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	6	19	theme	isomers	1016:1022	arg1	pairs					1007:1011	16 pairs	1004:1011	16 pairs of isomers	1004:1022	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	6	20	dep	structures	982:991	arg1	including					994:1002	including	994:1002	including 16 pairs of isomers	994:1022	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	5	21	from	fragmentation	788:800	arg1	ions					768:771	structure-diagnostic fragment ions	738:771	structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties	738:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	4	22	theme	comprehensive	432:444	arg1	characterization					464:479	comprehensive mass spectrometry characterization	432:479	comprehensive mass spectrometry characterization of N-glycosylation of mAbs	432:506	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	1	23	theme	monoclonal	130:139	arg1	mAbs					153:156	mAbs	153:156	mAbs	153:156	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors show great expectation in therapy.
35349291	1	23	theme	monoclonal	130:139	arg1	antibodies					141:150	monoclonal antibodies	130:150	monoclonal antibodies (mAbs) cohering various function effectors	130:193	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors show great expectation in therapy.
35349291	6	24	theme	monoclonal	906:915	arg1	antibody					917:924	NIST monoclonal antibody	901:924	NIST monoclonal antibody reference material 8671	901:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	1	25	theme	antibodies	141:150	arg1	characteristics					111:125	The characteristics	107:125	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors	107:193	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors show great expectation in therapy.
35349291	0	26	theme	Monoclonal	62:71	arg1	Material					92:99	NIST Monoclonal Antibody Reference Material 8671	57:104	NIST Monoclonal Antibody Reference Material 8671	57:104	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	4	27	theme	monosaccharide	513:526	arg1	compositions					528:539	monosaccharide compositions	513:539	monosaccharide compositions	513:539	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	2	28	theme	post-translational	263:280	arg1	modifications					282:294	the common post-translational modifications	252:294	the common post-translational modifications	252:294	Glycosylation, one of the common post-translational modifications, deeply influences cohesion.
35349291	0	29	theme	NIST	57:60	arg1	Material					92:99	NIST Monoclonal Antibody Reference Material 8671	57:104	NIST Monoclonal Antibody Reference Material 8671	57:104	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	2	30	theme	common	256:261	arg1	modifications					282:294	the common post-translational modifications	252:294	the common post-translational modifications	252:294	Glycosylation, one of the common post-translational modifications, deeply influences cohesion.
35349291	5	31	theme	engine	644:649	arg1	GPSeeker					651:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	0	32	theme	Reference	82:90	arg1	Material					92:99	NIST Monoclonal Antibody Reference Material 8671	57:104	NIST Monoclonal Antibody Reference Material 8671	57:104	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	0	33	theme	Antibody	73:80	arg1	Material					92:99	NIST Monoclonal Antibody Reference Material 8671	57:104	NIST Monoclonal Antibody Reference Material 8671	57:104	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	5	34	with	possible	724:731	arg1	ions					768:771	structure-diagnostic fragment ions	738:771	structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties	738:821	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	3	35	theme	monosaccharide	350:363	arg1	composition/sequence					365:384	monosaccharide composition/sequence	350:384	monosaccharide composition/sequence	350:384	It is necessary to grasp monosaccharide composition/sequence and glycan structures in mAbs.
35349291	4	36	theme	mAbs	503:506	arg1	N-glycosylation					484:498	N-glycosylation	484:498	N-glycosylation of mAbs	484:506	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35349291	6	37	theme	material	936:943	arg1	characterization					881:896	our structure-specific N-glycoproteomics characterization	840:896	our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671	840:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	5	38	gly	N-glycopeptide	622:635	arg2	N-glycopeptide					622:635	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	6	39	theme	reference	926:934	arg1	material					936:943	NIST monoclonal antibody reference material 8671	901:948	NIST monoclonal antibody reference material 8671	901:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	6	40	theme	NIST	901:904	arg1	antibody					917:924	NIST monoclonal antibody	901:924	NIST monoclonal antibody reference material 8671	901:948	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	5	41	theme	developed	605:613	arg1	GPSeeker					651:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	6	42	theme	N-glycan	973:980	arg1	structures					982:991	59 N-glycan structures	970:991	59 N-glycan structures (including 16 pairs of isomers)	970:1023	Here, we report our structure-specific N-glycoproteomics characterization of NIST monoclonal antibody reference material 8671 using GPSeeker, and 59 N-glycan structures (including 16 pairs of isomers) are characterized.
35349291	3	43	theme	glycan	390:395	arg1	structures					397:406	glycan structures	390:406	glycan structures	390:406	It is necessary to grasp monosaccharide composition/sequence and glycan structures in mAbs.
35349291	5	44	theme	intact	615:620	arg1	GPSeeker					651:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	1	45	theme	various	168:174	arg1	effectors					185:193	various function effectors	168:193	various function effectors	168:193	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors show great expectation in therapy.
35349291	0	46	theme	Material	92:99	arg1	Characterization					37:52	Structure-Specific N-Glycoproteomics Characterization	0:52	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.	0:105	Structure-Specific N-Glycoproteomics Characterization of NIST Monoclonal Antibody Reference Material 8671.
35349291	2	47	theme	modifications	282:294	arg1	Glycosylation					230:242	Glycosylation	230:242	Glycosylation	230:242	Glycosylation, one of the common post-translational modifications, deeply influences cohesion.
35349291	2	47	theme	modifications	282:294	arg1	modifications					282:294	the common post-translational modifications	252:294	the common post-translational modifications	252:294	Glycosylation, one of the common post-translational modifications, deeply influences cohesion.
35349291	2	47	theme	modifications	282:294	arg1	one					245:247	one	245:247	one	245:247	Glycosylation, one of the common post-translational modifications, deeply influences cohesion.
35349291	5	48	theme	N-glycopeptide	622:635	arg1	GPSeeker					651:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker	592:658	Our recently developed intact N-glycopeptide search engine GPSeeker has made structure-specific characterization of N-glycosylation possible with structure-diagnostic fragment ions from selective fragmentation of N-glycan moieties.
35349291	1	49	theme	function	176:183	arg1	effectors					185:193	various function effectors	168:193	various function effectors	168:193	The characteristics of monoclonal antibodies (mAbs) cohering various function effectors show great expectation in therapy.
35349291	4	50	gly	N-glycosylation	484:498	arg1	mAbs					503:506	mAbs	503:506	mAbs	503:506	There has been comprehensive mass spectrometry characterization of N-glycosylation of mAbs, and monosaccharide compositions are deduced according to known biosynthetic rules.
35848837	4	0	from	linkages	551:558	arg1	bacteria					563:570	bacteria	563:570	bacteria	563:570	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	6	1	link	N-linked	837:844	arg1	system					860:865	the N-linked glycosylation system	833:865	the N-linked glycosylation system in Campylobacter jejuni	833:889	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	4	2	theme	available	609:617	arg1	enzyme					602:607	no enzyme	599:607	no enzyme available to release glycans from bacterial glycoproteins	599:665	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	3	3	theme	common	346:351	arg1	method					353:358	A common method	344:358	A common method for glycan analysis	344:378	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	7	4	theme	protein	1090:1096	arg1	2:1-3:1					1105:1111	2:1-3:1	1105:1111	2:1-3:1	1105:1111	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	7	4	theme	protein	1090:1096	arg1	ratio					1098:1102	protein ratio	1090:1102	protein ratio (2:1-3:1)	1090:1112	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	5	5	theme	free	681:684	arg1	glycans					686:692	free glycans	681:692	free glycans	681:692	In addition, free glycans have also been described in mammalian cells, bacteria, yeast, plants, and fish.
35848837	4	6	theme	glycan-protein	536:549	arg1	different					576:584	different	576:584	different	576:584	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	4	6	theme	glycan-protein	536:549	arg1	linkages					551:558	the glycan-protein linkages	532:558	the glycan-protein linkages in bacteria	532:570	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	7	7	theme	higher	1073:1078	arg1	enzyme					1080:1085	a higher enzyme	1071:1085	a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h)	1071:1151	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	1	8	theme	Protein	78:84	arg1	glycosylation					86:98	Protein glycosylation	78:98	Protein glycosylation	78:98	Protein glycosylation is one of the most common and complex post-translational modifications.
35848837	4	9	theme	release	622:628	arg1	glycans					630:636	release glycans	622:636	release glycans from bacterial glycoproteins	622:665	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	8	10	theme	mass	1288:1291	arg1	spectrometry					1293:1304	mass spectrometry	1288:1304	mass spectrometry	1288:1304	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	8	11	theme	carbon	1238:1243	arg1	cartridges					1245:1254	porous graphitic carbon cartridges	1221:1254	porous graphitic carbon cartridges	1221:1254	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	3	12	theme	glycan	364:369	arg1	analysis					371:378	glycan analysis	364:378	glycan analysis	364:378	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	4	13	gly	glycoproteins	653:665	arg1	glycoproteins					653:665	bacterial glycoproteins	643:665	bacterial glycoproteins	643:665	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	2	14	from	roles	237:241	arg1	functions					321:329	the functions	317:329	the functions of proteins	317:341	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	2	15	theme	Many	172:175	arg1	techniques					177:186	Many techniques	172:186	Many techniques	172:186	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	7	16	from	jejuni	1032:1037	arg1	proteins					1015:1022	total proteins	1009:1022	total proteins from C. jejuni	1009:1037	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	7	17	theme	incubation	1127:1136	arg1	time					1138:1141	a longer incubation time	1118:1141	a longer incubation time (48-72 h)	1118:1151	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	7	17	theme	incubation	1127:1136	arg1	h					1150:1150	48-72 h	1144:1150	48-72 h	1144:1150	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	2	18	from	relationship	259:270	arg1	functions					321:329	the functions	317:329	the functions of proteins	317:341	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	6	19	attach	present	794:800	arg2	we					791:792	we	791:792	we	791:792	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	6	19	attach	present	794:800	arg1	article					782:788	this article	777:788	this article	777:788	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	0	20	theme	Proteolysis-Based	12:28	arg1	Strategy					40:47	Nonspecific Proteolysis-Based Glycomics Strategy	0:47	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins	0:75	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins.
35848837	7	21	theme	Pronase	1056:1062	arg1	E					1064:1064	Pronase E	1056:1064	Pronase E	1056:1064	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	7	22	theme	longer	1120:1125	arg1	time					1138:1141	a longer incubation time	1118:1141	a longer incubation time (48-72 h)	1118:1151	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	7	22	theme	longer	1120:1125	arg1	h					1150:1150	48-72 h	1144:1150	48-72 h	1144:1150	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	6	23	link	-linked	920:926	arg1	glycans					937:943	asparagine (Asn)-linked and free glycans	904:943	asparagine (Asn)-linked and free glycans that are not attached to their target proteins	904:990	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	0	24	theme	Nonspecific	0:10	arg1	Strategy					40:47	Nonspecific Proteolysis-Based Glycomics Strategy	0:47	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins	0:75	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins.
35848837	2	25	theme	proteins	334:341	arg1	functions					321:329	the functions	317:329	the functions of proteins	317:341	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	8	26	theme	free	1183:1186	arg1	glycans					1188:1194	Asn-glycans and free glycans	1167:1194	The resulted Asn-glycans and free glycans	1154:1194	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	3	27	theme	exoglycosidase	393:406	arg1	cleavage					408:415	exoglycosidase cleavage	393:415	exoglycosidase cleavage	393:415	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	6	28	theme	Campylobacter	870:882	arg1	jejuni					884:889	Campylobacter jejuni	870:889	Campylobacter jejuni	870:889	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	1	29	theme	common	119:124	arg1	modifications					157:169	the most common and complex post-translational modifications	110:169	the most common and complex post-translational modifications	110:169	Protein glycosylation is one of the most common and complex post-translational modifications.
35848837	3	30	theme	PNGase	512:517	arg1	F					509:509	Peptide-N-Glycosidase F	487:509	Peptide-N-Glycosidase F (PNGase F)	487:520	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	3	30	theme	PNGase	512:517	arg1	F					519:519	PNGase F	512:519	PNGase F	512:519	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	0	31	theme	Bacterial	53:61	arg1	Glycoproteins					63:75	Bacterial Glycoproteins	53:75	Bacterial Glycoproteins	53:75	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins.
35848837	8	32	theme	porous	1221:1226	arg1	cartridges					1245:1254	porous graphitic carbon cartridges	1221:1254	porous graphitic carbon cartridges	1221:1254	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	3	33	theme	Peptide-N-Glycosidase	487:507	arg1	F					509:509	Peptide-N-Glycosidase F	487:509	Peptide-N-Glycosidase F (PNGase F)	487:520	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	3	33	theme	Peptide-N-Glycosidase	487:507	arg1	F					519:519	PNGase F	512:519	PNGase F	512:519	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	0	34	theme	Glycomics	30:38	arg1	Strategy					40:47	Nonspecific Proteolysis-Based Glycomics Strategy	0:47	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins	0:75	Nonspecific Proteolysis-Based Glycomics Strategy for Bacterial Glycoproteins.
35848837	3	35	link	N-linked	428:435	arg1	glycans					437:443	N-linked glycans	428:443	N-linked glycans	428:443	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	8	36	theme	resulted	1158:1165	arg1	glycans					1188:1194	Asn-glycans and free glycans	1167:1194	The resulted Asn-glycans and free glycans	1154:1194	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	6	37	theme	glycosylation	846:858	arg1	system					860:865	the N-linked glycosylation system	833:865	the N-linked glycosylation system in Campylobacter jejuni	833:889	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	8	38	theme	graphitic	1228:1236	arg1	cartridges					1245:1254	porous graphitic carbon cartridges	1221:1254	porous graphitic carbon cartridges	1221:1254	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	3	39	theme	N-linked	428:435	arg1	glycans					437:443	N-linked glycans	428:443	N-linked glycans	428:443	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	6	40	theme	free	932:935	arg1	glycans					937:943	asparagine (Asn)-linked and free glycans	904:943	asparagine (Asn)-linked and free glycans that are not attached to their target proteins	904:990	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	7	41	theme	C.	1029:1030	arg1	jejuni					1032:1037	C. jejuni	1029:1037	C. jejuni	1029:1037	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	6	42	theme	N-linked	837:844	arg1	system					860:865	the N-linked glycosylation system	833:865	the N-linked glycosylation system in Campylobacter jejuni	833:889	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	2	43	theme	glycans	246:252	arg1	relationship					259:270	the relationship	255:270	the relationship between their structures	255:295	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	2	43	theme	glycans	246:252	arg1	roles					237:241	the specific roles	224:241	the specific roles of glycans	224:252	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	2	43	theme	glycans	246:252	arg1	impact					307:312	their impact	301:312	their impact on the functions of proteins	301:341	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	1	44	theme	complex	130:136	arg1	modifications					157:169	the most common and complex post-translational modifications	110:169	the most common and complex post-translational modifications	110:169	Protein glycosylation is one of the most common and complex post-translational modifications.
35848837	2	45	from	impact	307:312	arg1	functions					321:329	the functions	317:329	the functions of proteins	317:341	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	7	46	theme	total	1009:1013	arg1	proteins					1015:1022	total proteins	1009:1022	total proteins from C. jejuni	1009:1037	In this method, total proteins from C. jejuni were digested by Pronase E with a higher enzyme to protein ratio (2:1-3:1) and a longer incubation time (48-72 h).
35848837	6	47	attach	attached	958:965	arg1	proteins					983:990	their target proteins	970:990	their target proteins	970:990	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	6	47	attach	attached	958:965	arg2	glycans					937:943	asparagine (Asn)-linked and free glycans	904:943	asparagine (Asn)-linked and free glycans that are not attached to their target proteins	904:990	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	1	48	theme	post-translational	138:155	arg1	modifications					157:169	the most common and complex post-translational modifications	110:169	the most common and complex post-translational modifications	110:169	Protein glycosylation is one of the most common and complex post-translational modifications.
35848837	5	49	theme	mammalian	722:730	arg1	cells					732:736	mammalian cells	722:736	mammalian cells	722:736	In addition, free glycans have also been described in mammalian cells, bacteria, yeast, plants, and fish.
35848837	2	50	theme	specific	228:235	arg1	roles					237:241	the specific roles	224:241	the specific roles of glycans	224:252	Many techniques have been developed to characterize the specific roles of glycans, the relationship between their structures and their impact on the functions of proteins.
35848837	3	51	gly	glycopeptides	467:479	arg2	glycopeptides					467:479	glycopeptides	467:479	glycopeptides	467:479	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	1	52	theme	modifications	157:169	arg1	one					103:105	one	103:105	one	103:105	Protein glycosylation is one of the most common and complex post-translational modifications.
35848837	1	52	theme	modifications	157:169	arg1	modifications					157:169	the most common and complex post-translational modifications	110:169	the most common and complex post-translational modifications	110:169	Protein glycosylation is one of the most common and complex post-translational modifications.
35848837	4	53	from	glycoproteins	653:665	arg1	glycans					630:636	release glycans	622:636	release glycans from bacterial glycoproteins	622:665	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35848837	8	54	theme	permethylated	1257:1269	arg1	cartridges					1245:1254	porous graphitic carbon cartridges	1221:1254	porous graphitic carbon cartridges	1221:1254	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	8	55	theme	Asn-glycans	1167:1177	arg1	glycans					1188:1194	Asn-glycans and free glycans	1167:1194	The resulted Asn-glycans and free glycans	1154:1194	The resulted Asn-glycans and free glycans were then purified using porous graphitic carbon cartridges, permethylated, and analyzed by mass spectrometry.
35848837	6	56	theme	target	976:981	arg1	proteins					983:990	their target proteins	970:990	their target proteins	970:990	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	6	57	theme	-linked	920:926	arg1	glycans					937:943	asparagine (Asn)-linked and free glycans	904:943	asparagine (Asn)-linked and free glycans that are not attached to their target proteins	904:990	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	3	58	gly	glycoproteins	450:462	arg1	glycoproteins					450:462	glycoproteins	450:462	glycoproteins	450:462	A common method for glycan analysis is to employ exoglycosidase cleavage to release N-linked glycans from glycoproteins or glycopeptides using Peptide-N-Glycosidase F (PNGase F).
35848837	6	59	from	system	860:865	arg1	jejuni					884:889	Campylobacter jejuni	870:889	Campylobacter jejuni	870:889	In this article, we present a method that can characterize the N-linked glycosylation system in Campylobacter jejuni by detecting asparagine (Asn)-linked and free glycans that are not attached to their target proteins.
35848837	4	60	theme	bacterial	643:651	arg1	glycoproteins					653:665	bacterial glycoproteins	643:665	bacterial glycoproteins	643:665	However, the glycan-protein linkages in bacteria are different and there is no enzyme available to release glycans from bacterial glycoproteins.
35183770	5	0	from	study	1095:1099	arg1	infertility					1148:1158	male infertility	1143:1158	male infertility	1143:1158	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	3	1	theme	other	781:785	arg1	tissues					787:793	other tissues	781:793	other tissues	781:793	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	2	2	theme	human	369:373	arg1	spermatozoa					375:385	human spermatozoa	369:385	human spermatozoa using our recently developed site-specific glycoproteomic approaches	369:454	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	4	3	theme	LacdiNAc	936:943	arg1	structures					945:954	LacdiNAc structures	936:954	LacdiNAc structures	936:954	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	1	4	theme	sperm-egg	259:267	arg1	recognition					269:279	sperm-egg recognition	259:279	sperm-egg recognition	259:279	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	2	5	theme	glycoproteins	514:526	arg1	number					492:497	a number	490:497	a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization	490:644	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	1	6	theme	essential	172:180	arg1	roles					182:186	essential roles	172:186	essential roles	172:186	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	4	7	theme	bisected	907:914	arg1	structures					921:930	bisected core structures	907:930	bisected core structures	907:930	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	3	8	theme	cell	734:737	arg1	surface					739:745	cell surface	734:745	cell surface	734:745	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	5	9	from	knowledge	1012:1020	arg1	spermatozoa					1045:1055	spermatozoa	1045:1055	spermatozoa	1045:1055	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	4	10	theme	core	916:919	arg1	structures					921:930	bisected core structures	907:930	bisected core structures	907:930	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	3	11	dep	extracellular	716:728	arg1	regions					747:753	regions	747:753	regions	747:753	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	12	from	extracellular	716:728	arg1	located					705:711	located	705:711	located	705:711	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	2	13	contain	contain	482:488	arg1	spermatozoa					470:480	spermatozoa	470:480	spermatozoa	470:480	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	2	13	contain	contain	482:488	arg2	number					492:497	a number	490:497	a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization	490:644	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	2	14	theme	site-specific	416:428	arg1	approaches					445:454	our recently developed site-specific glycoproteomic approaches	393:454	our recently developed site-specific glycoproteomic approaches	393:454	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	3	15	located	observed	669:676	arg1	glycoproteins					684:696	14 glycoproteins	681:696	14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues	681:793	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	15	located	observed	669:676	arg2	fucosylation					653:664	Heavy fucosylation	647:664	Heavy fucosylation	647:664	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	16	gly	glycoproteins	684:696	arg1	glycoproteins					684:696	14 glycoproteins	681:696	14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues	681:793	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	17	from	spermatozoa	758:768	arg1	located					705:711	located	705:711	located	705:711	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	2	18	theme	developed	406:414	arg1	approaches					445:454	our recently developed site-specific glycoproteomic approaches	393:454	our recently developed site-specific glycoproteomic approaches	393:454	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	0	19	from	N-Glycosylation	46:60	arg1	Spermatozoa					71:81	Human Spermatozoa	65:81	Human Spermatozoa	65:81	Precision Glycoproteomics Reveals Distinctive N-Glycosylation in Human Spermatozoa.
35183770	3	20	from	tissues	787:793	arg1	located					705:711	located	705:711	located	705:711	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	0	21	theme	Precision	0:8	arg1	Glycoproteomics					10:24	Precision Glycoproteomics	0:24	Precision Glycoproteomics	0:24	Precision Glycoproteomics Reveals Distinctive N-Glycosylation in Human Spermatozoa.
35183770	1	22	theme	special	115:121	arg1	type					128:131	a very special cell type	108:131	a very special cell type in human body	108:145	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	1	23	theme	whole	195:199	arg1	life					201:204	its whole life	191:204	its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization	191:298	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	0	24	theme	Distinctive	34:44	arg1	N-Glycosylation					46:60	Distinctive N-Glycosylation	34:60	Distinctive N-Glycosylation in Human Spermatozoa	34:81	Precision Glycoproteomics Reveals Distinctive N-Glycosylation in Human Spermatozoa.
35183770	5	25	theme	functional	1084:1093	arg1	study					1095:1099	functional study	1084:1099	functional study of glycosylation	1084:1116	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	2	26	gly	glycoproteins	514:526	arg1	glycoproteins					514:526	distinctive glycoproteins	502:526	distinctive glycoproteins	502:526	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	5	27	theme	glycan	1122:1127	arg1	structures					1129:1138	glycan structures	1122:1138	glycan structures in male infertility	1122:1158	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	2	28	theme	distinctive	502:512	arg1	glycoproteins					514:526	distinctive glycoproteins	502:526	distinctive glycoproteins	502:526	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	2	29	theme	comprehensive	336:348	arg1	N-glycoproteome					350:364	the most comprehensive N-glycoproteome	327:364	the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches	327:454	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	2	30	theme	acrosome	575:582	arg1	reaction					584:591	acrosome reaction	575:591	acrosome reaction	575:591	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	1	31	theme	cell	123:126	arg1	type					128:131	a very special cell type	108:131	a very special cell type in human body	108:145	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	4	32	theme	biological	847:856	arg1	process					858:864	the biological process	843:864	the biological process of immune response in spermatozoa	843:898	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	5	33	from	structures	1129:1138	arg1	infertility					1148:1158	male infertility	1143:1158	male infertility	1143:1158	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	2	34	theme	glycoproteomic	430:443	arg1	approaches					445:454	our recently developed site-specific glycoproteomic approaches	393:454	our recently developed site-specific glycoproteomic approaches	393:454	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	3	35	from	surface	739:745	arg1	located					705:711	located	705:711	located	705:711	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	2	36	theme	membrane	610:617	arg1	binding					619:625	oocyte membrane binding	603:625	oocyte membrane binding	603:625	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	5	37	theme	male	1143:1146	arg1	infertility					1148:1158	male infertility	1143:1158	male infertility	1143:1158	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	4	38	theme	immune	869:874	arg1	response					876:883	immune response	869:883	immune response	869:883	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	0	39	theme	Human	65:69	arg1	Spermatozoa					71:81	Human Spermatozoa	65:81	Human Spermatozoa	65:81	Precision Glycoproteomics Reveals Distinctive N-Glycosylation in Human Spermatozoa.
35183770	2	40	theme	oocyte	603:608	arg1	binding					619:625	oocyte membrane binding	603:625	oocyte membrane binding	603:625	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	4	41	theme	response	876:883	arg1	process					858:864	the biological process	843:864	the biological process of immune response in spermatozoa	843:898	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	4	42	from	process	858:864	arg1	spermatozoa					888:898	spermatozoa	888:898	spermatozoa	888:898	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	4	42	from	process	858:864	arg1	enriched					831:838	enriched	831:838	enriched	831:838	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	1	43	theme	human	136:140	arg1	body					142:145	human body	136:145	human body	136:145	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	1	44	from	type	128:131	arg1	body					142:145	human body	136:145	human body	136:145	Spermatozoon represents a very special cell type in human body, and glycosylation plays essential roles in its whole life including spermatogenesis, maturation, capacitation, sperm-egg recognition, and fertilization.
35183770	4	45	theme	Lewis	812:816	arg1	epitopes					818:825	Lewis epitopes	812:825	Lewis epitopes	812:825	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	5	46	theme	glycosylation	1104:1116	arg1	structures					1129:1138	glycan structures	1122:1138	glycan structures in male infertility	1122:1158	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	5	46	theme	glycosylation	1104:1116	arg1	study					1095:1099	functional study	1084:1099	functional study of glycosylation	1084:1116	These data deepen our knowledge about glycosylation in spermatozoa and lay the foundation for functional study of glycosylation and glycan structures in male infertility.
35183770	3	47	gly	fucosylation	653:664	arg1	glycoproteins					684:696	14 glycoproteins	681:696	14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues	681:793	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	48	from	located	705:711	arg1	tissues					787:793	other tissues	781:793	other tissues	781:793	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	48	from	located	705:711	arg1	spermatozoa					758:768	spermatozoa	758:768	spermatozoa	758:768	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	3	49	theme	Heavy	647:651	arg1	fucosylation					653:664	Heavy fucosylation	647:664	Heavy fucosylation	647:664	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
35183770	4	50	from	enriched	831:838	arg1	process					858:864	the biological process	843:864	the biological process of immune response in spermatozoa	843:898	Sialylation and Lewis epitopes are enriched in the biological process of immune response in spermatozoa, while bisected core structures and LacdiNAc structures are highly expressed in acrosome.
35183770	2	51	theme	spermatozoa	375:385	arg1	N-glycoproteome					350:364	the most comprehensive N-glycoproteome	327:364	the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches	327:454	In this study, by mapping the most comprehensive N-glycoproteome of human spermatozoa using our recently developed site-specific glycoproteomic approaches, we show that spermatozoa contain a number of distinctive glycoproteins, which are mainly involved in spermatogenesis, acrosome reaction and sperm:oocyte membrane binding, and fertilization.
35183770	3	52	dep	glycoproteins	684:696	arg1	located					705:711	located	705:711	located	705:711	Heavy fucosylation is observed on 14 glycoproteins mostly located at extracellular and cell surface regions in spermatozoa but not in other tissues.
34985300	12	0	theme	glycosylation	2174:2186	arg1	sites					2188:2192	257 glycosylation sites	2170:2192	257 glycosylation sites in 145 proteins	2170:2208	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	2	1	with	phylum	223:228	arg1	findings					235:242	findings	235:242	findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia	235:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	4	2	theme	based	616:620	arg1	deglycosylation					533:547	partial deglycosylation	525:547	partial deglycosylation with trifluoromethanesulfonic acid	525:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	2	theme	based	616:620	arg1	strategies					646:655	both HILIC and FAIMS based glycopeptide enrichment strategies	595:655	glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins	488:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	10	3	theme	IMPORTANCE	1631:1640	arg1	gingivalis					1656:1665	IMPORTANCE Porphyromonas gingivalis	1631:1665	IMPORTANCE Porphyromonas gingivalis	1631:1665	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	10	3	theme	IMPORTANCE	1631:1640	arg1	pathogen					1678:1685	an oral pathogen	1670:1685	an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers	1670:1842	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	7	4	theme	abundant	1197:1204	arg1	proteins					1206:1213	abundant proteins	1197:1213	abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins	1197:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	7	4	theme	abundant	1197:1204	arg1	proteins					1271:1278	abundant T9SS cargo proteins	1251:1278	abundant T9SS cargo proteins	1251:1278	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	7	4	theme	abundant	1197:1204	arg1	lipoproteins					1289:1300	surface lipoproteins	1281:1300	surface lipoproteins	1281:1300	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	7	4	theme	abundant	1197:1204	arg1	proteins					1331:1338	outer membrane β-barrel proteins	1307:1338	outer membrane β-barrel proteins	1307:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	6	5	theme	Western	855:861	arg1	analyses					868:875	Western blot analyses	855:875	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135	855:941	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	2	6	theme	extensive	340:348	arg1	analysis					366:373	an extensive O-glycoproteome analysis	337:373	an extensive O-glycoproteome analysis in Tannerella forsythia	337:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	7	from	species	324:330	arg1	analysis					366:373	an extensive O-glycoproteome analysis	337:373	an extensive O-glycoproteome analysis in Tannerella forsythia	337:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	7	from	species	324:330	arg1	motif					277:281	the O-glycosylation motif	257:281	the O-glycosylation motif	257:281	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	7	from	species	324:330	arg1	structure					288:296	the structure	284:296	the structure of the O-glycans in a few species	284:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	4	8	theme	enrichment	635:644	arg1	deglycosylation					533:547	partial deglycosylation	525:547	partial deglycosylation with trifluoromethanesulfonic acid	525:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	8	theme	enrichment	635:644	arg1	strategies					646:655	both HILIC and FAIMS based glycopeptide enrichment strategies	595:655	glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins	488:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	12	9	link	O-linked	2062:2069	arg1	glycosylation					2071:2083	O-linked glycosylation	2062:2083	O-linked glycosylation	2062:2083	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	9	10	theme	P.	1501:1502	arg1	system					1531:1536	The P. gingivalis O-glycosylation system	1497:1536	The P. gingivalis O-glycosylation system	1497:1536	The P. gingivalis O-glycosylation system may therefore function to establish the desired physicochemical properties of the periplasm.
34985300	12	11	theme	O-glycans	2144:2152	arg1	structure					2127:2135	the basic structure	2117:2135	the basic structure of the O-glycans	2117:2152	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	5	12	dep	-dHex-Hex-HexA-Hex	829:846	arg1	-dHex-Hex-HexA-Hex					829:846	-dHex-Hex-HexA-Hex	829:846	-dHex-Hex-HexA-Hex	829:846	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	5	12	dep	-dHex-Hex-HexA-Hex	829:846	arg1	sequence					749:756	The sequence	745:756	The sequence of the major O-glycan	745:778	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	5	12	dep	-dHex-Hex-HexA-Hex	829:846	arg1	dHex					848:851	dHex	848:851	dHex	848:851	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	4	13	theme	sites	717:721	arg1	identification					672:685	the identification	668:685	the identification of 257 putative glycosylation sites in 145 glycoproteins	668:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	14	from	sites	717:721	arg1	glycoproteins					730:742	145 glycoproteins	726:742	145 glycoproteins	726:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	9	15	theme	O-glycosylation	1515:1529	arg1	system					1531:1536	The P. gingivalis O-glycosylation system	1497:1536	The P. gingivalis O-glycosylation system	1497:1536	The P. gingivalis O-glycosylation system may therefore function to establish the desired physicochemical properties of the periplasm.
34985300	10	16	theme	severe	1713:1718	arg1	disease					1732:1738	severe periodontal disease	1713:1738	severe periodontal disease	1713:1738	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	7	17	theme	strong	1154:1159	arg1	bias					1161:1164	a strong bias	1152:1164	a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins	1152:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	12	18	theme	basic	2121:2125	arg1	structure					2127:2135	the basic structure	2117:2135	the basic structure of the O-glycans	2117:2152	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	2	19	from	analysis	366:373	arg1	species					324:330	a few species	318:330	a few species	318:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	19	from	analysis	366:373	arg1	forsythia					389:397	Tannerella forsythia	378:397	Tannerella forsythia	378:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	20	gly	O-glycosylation	261:275	arg2	motif					277:281	the O-glycosylation motif	257:281	the O-glycosylation motif	257:281	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	11	21	theme	protein	1919:1925	arg1	function					1927:1934	protein function	1919:1934	protein function	1919:1934	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	2	22	theme	O-glycans	305:313	arg1	analysis					366:373	an extensive O-glycoproteome analysis	337:373	an extensive O-glycoproteome analysis in Tannerella forsythia	337:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	22	theme	O-glycans	305:313	arg1	motif					277:281	the O-glycosylation motif	257:281	the O-glycosylation motif	257:281	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	22	theme	O-glycans	305:313	arg1	structure					288:296	the structure	284:296	the structure of the O-glycans in a few species	284:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	6	23	theme	mass	1014:1017	arg1	analysis					1032:1039	mass spectrometry analysis	1014:1039	mass spectrometry analysis of the truncated O-glycans	1014:1066	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	13	24	dep	exposed	2319:2325	arg1	surface					2311:2317	surface	2311:2317	surface	2311:2317	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	4	25	theme	putative	694:701	arg1	sites					717:721	257 putative glycosylation sites	690:721	257 putative glycosylation sites in 145 glycoproteins	690:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	5	26	theme	O-glycan	771:778	arg1	-dHex-Hex-HexA-Hex					829:846	-dHex-Hex-HexA-Hex	829:846	-dHex-Hex-HexA-Hex	829:846	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	5	26	theme	O-glycan	771:778	arg1	sequence					749:756	The sequence	745:756	The sequence of the major O-glycan	745:778	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	5	26	theme	O-glycan	771:778	arg1	dHex					848:851	dHex	848:851	dHex	848:851	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	7	27	theme	cell	1230:1233	arg1	surface					1235:1241	the cell surface	1226:1241	the cell surface	1226:1241	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	15	28	theme	heterologous	2592:2603	arg1	organisms					2605:2613	heterologous organisms	2592:2613	heterologous organisms	2592:2613	These glycans are likely to have a stabilizing role to the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms.
34985300	6	29	theme	glycan	1001:1006	arg1	biosynthesis					981:992	the biosynthesis	977:992	the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars	977:1134	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	15	30	theme	stabilizing	2479:2489	arg1	role					2491:2494	a stabilizing role	2477:2494	a stabilizing role	2477:2494	These glycans are likely to have a stabilizing role to the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms.
34985300	9	31	theme	desired	1578:1584	arg1	properties					1602:1611	the desired physicochemical properties	1574:1611	the desired physicochemical properties of the periplasm	1574:1628	The P. gingivalis O-glycosylation system may therefore function to establish the desired physicochemical properties of the periplasm.
34985300	2	32	from	structure	288:296	arg1	species					324:330	a few species	318:330	a few species	318:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	32	from	structure	288:296	arg1	forsythia					389:397	Tannerella forsythia	378:397	Tannerella forsythia	378:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	1	33	theme	model	136:140	arg1	organism					142:149	a model organism	134:149	a model organism for the Bacteroidetes phylum	134:178	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	8	34	theme	proteins	1389:1396	arg1	majority					1377:1384	the great majority	1367:1384	the great majority of proteins associated with the inner membrane or periplasm	1367:1444	In contrast, the great majority of proteins associated with the inner membrane or periplasm were glycosylated irrespective of their abundance.
34985300	11	35	theme	reasons	1901:1907	arg1	solubility					1937:1946	solubility	1937:1946	solubility	1937:1946	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	35	theme	reasons	1901:1907	arg1	variety					1890:1896	a variety	1888:1896	a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability	1888:1996	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	35	theme	reasons	1901:1907	arg1	stability					1988:1996	thermodynamic stability	1974:1996	thermodynamic stability	1974:1996	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	35	theme	reasons	1901:1907	arg1	reasons					1901:1907	reasons	1901:1907	reasons including protein function, solubility, protease resistance, and thermodynamic stability	1901:1996	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	35	theme	reasons	1901:1907	arg1	resistance					1958:1967	protease resistance	1949:1967	protease resistance	1949:1967	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	35	theme	reasons	1901:1907	arg1	function					1927:1934	protein function	1919:1934	protein function	1919:1934	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	7	36	theme	surface	1281:1287	arg1	lipoproteins					1289:1300	surface lipoproteins	1281:1300	surface lipoproteins	1281:1300	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	6	37	theme	O-glycans	1058:1066	arg1	analysis					1032:1039	mass spectrometry analysis	1014:1039	mass spectrometry analysis of the truncated O-glycans	1014:1066	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	2	38	gly	O-glycosylation	181:195	arg1	phylum					223:228	this phylum	218:228	this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia	218:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	8	39	theme	inner	1418:1422	arg1	membrane					1424:1431	the inner membrane	1414:1431	the inner membrane	1414:1431	In contrast, the great majority of proteins associated with the inner membrane or periplasm were glycosylated irrespective of their abundance.
34985300	7	40	theme	T9SS	1260:1263	arg1	proteins					1271:1278	abundant T9SS cargo proteins	1251:1278	abundant T9SS cargo proteins	1251:1278	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	15	41	contain	have	2472:2475	arg2	role					2491:2494	a stabilizing role	2477:2494	a stabilizing role	2477:2494	These glycans are likely to have a stabilizing role to the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms.
34985300	15	41	contain	have	2472:2475	arg1	glycans					2450:2456	These glycans	2444:2456	These glycans	2444:2456	These glycans are likely to have a stabilizing role to the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms.
34985300	4	42	theme	glycoproteomics	488:502	arg1	approaches					504:513	glycoproteomics approaches	488:513	glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins	488:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	42	theme	glycoproteomics	488:502	arg1	deglycosylation					533:547	partial deglycosylation	525:547	partial deglycosylation with trifluoromethanesulfonic acid	525:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	1	43	dep	Bacteroidetes	159:171	arg1	phylum					173:178	phylum	173:178	phylum	173:178	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	14	44	theme	glycerol	2401:2408	arg1	phosphate					2410:2418	a glycerol phosphate	2399:2418	a glycerol phosphate with 0-2 acetyl groups	2399:2441	The O-glycans consisted of seven monosaccharides and a glycerol phosphate with 0-2 acetyl groups.
34985300	10	45	theme	rheumatoid	1768:1777	arg1	arthritis					1779:1787	rheumatoid arthritis	1768:1787	rheumatoid arthritis	1768:1787	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	4	46	gly	glycopeptide	622:633	arg2	glycopeptide					622:633	both HILIC and FAIMS based glycopeptide enrichment strategies	595:655	glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins	488:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	1	47	theme	human	110:114	arg1	pathogen					116:123	an important human pathogen	97:123	an important human pathogen	97:123	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	1	47	theme	human	110:114	arg1	gingivalis					83:92	Porphyromonas gingivalis	69:92	Porphyromonas gingivalis	69:92	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	4	48	theme	HILIC	600:604	arg1	deglycosylation					533:547	partial deglycosylation	525:547	partial deglycosylation with trifluoromethanesulfonic acid	525:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	48	theme	HILIC	600:604	arg1	strategies					646:655	both HILIC and FAIMS based glycopeptide enrichment strategies	595:655	glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins	488:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	3	49	theme	P.	455:456	arg1	gingivalis					458:467	P. gingivalis	455:467	P. gingivalis	455:467	However, O-glycosylation has not yet been confirmed in P. gingivalis.
34985300	12	50	from	presence	2050:2057	arg1	organism					2093:2100	this organism	2088:2100	this organism	2088:2100	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	4	51	theme	trifluoromethanesulfonic	554:577	arg1	acid					579:582	trifluoromethanesulfonic acid	554:582	trifluoromethanesulfonic acid	554:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	52	used	used	483:486	arg2	We					470:471	We	470:471	We	470:471	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	6	53	theme	mutants	880:886	arg1	analyses					868:875	Western blot analyses	855:875	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135	855:941	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	15	54	contain	bear	2517:2520	arg1	proteins					2503:2510	the proteins	2499:2510	the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms	2499:2613	These glycans are likely to have a stabilizing role to the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms.
34985300	15	54	contain	bear	2517:2520	arg2	them					2522:2525	them	2522:2525	them	2522:2525	These glycans are likely to have a stabilizing role to the proteins that bear them and must be taken into account when the proteins are produced in heterologous organisms.
34985300	6	55	dep	glycosyltransferases	900:919	arg1	glycosyltransferases					900:919	the glycosyltransferases PGN_1134 and PGN_1135	896:941	the glycosyltransferases PGN_1134 and PGN_1135	896:941	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	6	55	dep	glycosyltransferases	900:919	arg1	PGN_1135					934:941	PGN_1135	934:941	PGN_1135	934:941	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	6	55	dep	glycosyltransferases	900:919	arg1	PGN_1134					921:928	PGN_1134	921:928	PGN_1134	921:928	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	12	56	gly	glycosylation	2174:2186	arg2	sites					2188:2192	257 glycosylation sites	2170:2192	257 glycosylation sites in 145 proteins	2170:2208	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	14	57	with	phosphate	2410:2418	arg1	groups					2436:2441	0-2 acetyl groups	2425:2441	0-2 acetyl groups	2425:2441	The O-glycans consisted of seven monosaccharides and a glycerol phosphate with 0-2 acetyl groups.
34985300	8	58	gly	glycosylated	1451:1462	arg1	majority					1377:1384	the great majority	1367:1384	the great majority of proteins associated with the inner membrane or periplasm	1367:1444	In contrast, the great majority of proteins associated with the inner membrane or periplasm were glycosylated irrespective of their abundance.
34985300	8	58	gly	glycosylated	1451:1462	arg2	majority					1377:1384	the great majority	1367:1384	the great majority of proteins associated with the inner membrane or periplasm	1367:1444	In contrast, the great majority of proteins associated with the inner membrane or periplasm were glycosylated irrespective of their abundance.
34985300	8	58	gly	glycosylated	1451:1462	arg1	contrast					1357:1364	contrast	1357:1364	contrast	1357:1364	In contrast, the great majority of proteins associated with the inner membrane or periplasm were glycosylated irrespective of their abundance.
34985300	11	59	theme	Protein	1845:1851	arg1	glycosylation					1853:1865	Protein glycosylation	1845:1865	Protein glycosylation	1845:1865	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	7	60	theme	β-barrel	1322:1329	arg1	proteins					1331:1338	outer membrane β-barrel proteins	1307:1338	outer membrane β-barrel proteins	1307:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	10	61	theme	Porphyromonas	1642:1654	arg1	gingivalis					1656:1665	IMPORTANCE Porphyromonas gingivalis	1631:1665	IMPORTANCE Porphyromonas gingivalis	1631:1665	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	10	61	theme	Porphyromonas	1642:1654	arg1	pathogen					1678:1685	an oral pathogen	1670:1685	an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers	1670:1842	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	4	62	gly	glycosylation	703:715	arg2	sites					717:721	257 putative glycosylation sites	690:721	257 putative glycosylation sites in 145 glycoproteins	690:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	62	gly	glycosylation	703:715	arg2	257					690:692	257	690:692	257	690:692	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	2	63	theme	O-glycoproteome	350:364	arg1	analysis					366:373	an extensive O-glycoproteome analysis	337:373	an extensive O-glycoproteome analysis in Tannerella forsythia	337:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	12	64	theme	257	2170:2172	arg1	sites					2188:2192	257 glycosylation sites	2170:2192	257 glycosylation sites in 145 proteins	2170:2208	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	7	65	theme	outer	1307:1311	arg1	proteins					1331:1338	outer membrane β-barrel proteins	1307:1338	outer membrane β-barrel proteins	1307:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	4	66	from	glycoproteins	730:742	arg1	identification					672:685	the identification	668:685	the identification of 257 putative glycosylation sites in 145 glycoproteins	668:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	67	theme	glycopeptide	622:633	arg1	deglycosylation					533:547	partial deglycosylation	525:547	partial deglycosylation with trifluoromethanesulfonic acid	525:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	4	67	theme	glycopeptide	622:633	arg1	strategies					646:655	both HILIC and FAIMS based glycopeptide enrichment strategies	595:655	glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins	488:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	10	68	theme	oral	1673:1676	arg1	gingivalis					1656:1665	IMPORTANCE Porphyromonas gingivalis	1631:1665	IMPORTANCE Porphyromonas gingivalis	1631:1665	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	10	68	theme	oral	1673:1676	arg1	pathogen					1678:1685	an oral pathogen	1670:1685	an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers	1670:1842	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	9	69	theme	gingivalis	1504:1513	arg1	system					1531:1536	The P. gingivalis O-glycosylation system	1497:1536	The P. gingivalis O-glycosylation system	1497:1536	The P. gingivalis O-glycosylation system may therefore function to establish the desired physicochemical properties of the periplasm.
34985300	0	70	theme	gingivalis	57:66	arg1	O-Glycoproteome					24:38	the O-Glycoproteome	20:38	the O-Glycoproteome of Porphyromonas gingivalis	20:66	Characterization of the O-Glycoproteome of Porphyromonas gingivalis.
34985300	4	71	theme	glycosylation	703:715	arg1	sites					717:721	257 putative glycosylation sites	690:721	257 putative glycosylation sites in 145 glycoproteins	690:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	10	72	theme	periodontal	1720:1730	arg1	disease					1732:1738	severe periodontal disease	1713:1738	severe periodontal disease	1713:1738	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	2	73	theme	few	320:322	arg1	species					324:330	a few species	318:330	a few species	318:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	6	74	theme	spectrometry	1019:1030	arg1	analysis					1032:1039	mass spectrometry analysis	1014:1039	mass spectrometry analysis of the truncated O-glycans	1014:1066	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	14	75	with	monosaccharides	2379:2393	arg1	groups					2436:2441	0-2 acetyl groups	2425:2441	0-2 acetyl groups	2425:2441	The O-glycans consisted of seven monosaccharides and a glycerol phosphate with 0-2 acetyl groups.
34985300	10	76	theme	certain	1828:1834	arg1	cancers					1836:1842	certain cancers	1828:1842	certain cancers	1828:1842	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	5	77	theme	major	765:769	arg1	O-glycan					771:778	the major O-glycan	761:778	the major O-glycan	761:778	The sequence of the major O-glycan was elucidated to be HexNAc-HexNAc(P-Gro-[Ac]0-2)-dHex-Hex-HexA-Hex(dHex).
34985300	4	78	from	identification	672:685	arg1	glycoproteins					730:742	145 glycoproteins	726:742	145 glycoproteins	726:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	12	79	theme	glycosylation	2071:2083	arg1	presence					2050:2057	the presence	2046:2057	the presence of O-linked glycosylation in this organism	2046:2100	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	12	80	theme	O-linked	2062:2069	arg1	glycosylation					2071:2083	O-linked glycosylation	2062:2083	O-linked glycosylation	2062:2083	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	4	81	gly	glycoproteins	730:742	arg1	glycoproteins					730:742	145 glycoproteins	726:742	145 glycoproteins	726:742	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	11	82	gly	glycosylation	1853:1865	arg1	stability					1988:1996	thermodynamic stability	1974:1996	thermodynamic stability	1974:1996	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	82	gly	glycosylation	1853:1865	arg1	resistance					1958:1967	protease resistance	1949:1967	protease resistance	1949:1967	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	82	gly	glycosylation	1853:1865	arg1	solubility					1937:1946	solubility	1937:1946	solubility	1937:1946	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	82	gly	glycosylation	1853:1865	arg1	reasons					1901:1907	reasons	1901:1907	reasons including protein function, solubility, protease resistance, and thermodynamic stability	1901:1996	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	82	gly	glycosylation	1853:1865	arg1	function					1927:1934	protein function	1919:1934	protein function	1919:1934	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	11	83	theme	protease	1949:1956	arg1	resistance					1958:1967	protease resistance	1949:1967	protease resistance	1949:1967	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	13	84	theme	most	2229:2232	arg1	proteins					2234:2241	most proteins	2229:2241	most proteins exposed to the periplasm	2229:2266	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	9	85	theme	physicochemical	1586:1600	arg1	properties					1602:1611	the desired physicochemical properties	1574:1611	the desired physicochemical properties of the periplasm	1574:1628	The P. gingivalis O-glycosylation system may therefore function to establish the desired physicochemical properties of the periplasm.
34985300	6	86	theme	PGN_1135	1096:1103	arg1	transfer					1105:1112	PGN_1134 and PGN_1135 transfer	1083:1112	transfer	1105:1112	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	13	87	dep	O-glycosylated	2273:2286	arg1	proteins					2327:2334	the abundant surface exposed proteins	2298:2334	the abundant surface exposed proteins	2298:2334	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	13	87	dep	O-glycosylated	2273:2286	arg1	were					2336:2339	were	2336:2339	were not	2336:2343	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	14	88	theme	acetyl	2429:2434	arg1	groups					2436:2441	0-2 acetyl groups	2425:2441	0-2 acetyl groups	2425:2441	The O-glycans consisted of seven monosaccharides and a glycerol phosphate with 0-2 acetyl groups.
34985300	2	89	theme	O-glycosylation	261:275	arg1	motif					277:281	the O-glycosylation motif	257:281	the O-glycosylation motif	257:281	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	6	90	theme	PGN_1134	1083:1090	arg1	transfer					1105:1112	PGN_1134 and PGN_1135 transfer	1083:1112	transfer	1105:1112	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	4	91	theme	partial	525:531	arg1	deglycosylation					533:547	partial deglycosylation	525:547	partial deglycosylation with trifluoromethanesulfonic acid	525:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	8	92	theme	great	1371:1375	arg1	majority					1377:1384	the great majority	1367:1384	the great majority of proteins associated with the inner membrane or periplasm	1367:1444	In contrast, the great majority of proteins associated with the inner membrane or periplasm were glycosylated irrespective of their abundance.
34985300	12	93	from	sites	2188:2192	arg1	proteins					2201:2208	145 proteins	2197:2208	145 proteins	2197:2208	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	9	94	theme	periplasm	1620:1628	arg1	properties					1602:1611	the desired physicochemical properties	1574:1611	the desired physicochemical properties of the periplasm	1574:1628	The P. gingivalis O-glycosylation system may therefore function to establish the desired physicochemical properties of the periplasm.
34985300	2	95	from	O-glycans	305:313	arg1	species					324:330	a few species	318:330	a few species	318:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	6	96	dep	suggested	1068:1076	arg1	sugars					1129:1134	the two HexNAc sugars	1114:1134	the two HexNAc sugars	1114:1134	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	7	97	theme	cargo	1265:1269	arg1	proteins					1271:1278	abundant T9SS cargo proteins	1251:1278	abundant T9SS cargo proteins	1251:1278	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	3	98	gly	O-glycosylation	409:423	arg1	gingivalis					458:467	P. gingivalis	455:467	P. gingivalis	455:467	However, O-glycosylation has not yet been confirmed in P. gingivalis.
34985300	1	99	theme	Porphyromonas	69:81	arg1	pathogen					116:123	an important human pathogen	97:123	an important human pathogen	97:123	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	1	99	theme	Porphyromonas	69:81	arg1	gingivalis					83:92	Porphyromonas gingivalis	69:92	Porphyromonas gingivalis	69:92	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	6	100	theme	truncated	1048:1056	arg1	O-glycans					1058:1066	the truncated O-glycans	1044:1066	the truncated O-glycans	1044:1066	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	14	101	theme	0-2	2425:2427	arg1	groups					2436:2441	0-2 acetyl groups	2425:2441	0-2 acetyl groups	2425:2441	The O-glycans consisted of seven monosaccharides and a glycerol phosphate with 0-2 acetyl groups.
34985300	7	102	theme	abundant	1251:1258	arg1	proteins					1271:1278	abundant T9SS cargo proteins	1251:1278	abundant T9SS cargo proteins	1251:1278	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	12	103	theme	first	2022:2026	arg1	time					2028:2031	the first time	2018:2031	the first time	2018:2031	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	12	104	attach	presence	2050:2057	arg2	glycosylation					2071:2083	O-linked glycosylation	2062:2083	O-linked glycosylation	2062:2083	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	12	104	attach	presence	2050:2057	arg1	organism					2093:2100	this organism	2088:2100	this organism	2088:2100	This study has for the first time demonstrated the presence of O-linked glycosylation in this organism by determining the basic structure of the O-glycans and identifying 257 glycosylation sites in 145 proteins.
34985300	1	105	theme	important	100:108	arg1	pathogen					116:123	an important human pathogen	97:123	an important human pathogen	97:123	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	1	105	theme	important	100:108	arg1	gingivalis					83:92	Porphyromonas gingivalis	69:92	Porphyromonas gingivalis	69:92	Porphyromonas gingivalis is an important human pathogen and also a model organism for the Bacteroidetes phylum.
34985300	6	106	dep	sugars	1129:1134	arg1	transfer					1105:1112	PGN_1134 and PGN_1135 transfer	1083:1112	transfer	1105:1112	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	2	107	theme	Tannerella	378:387	arg1	forsythia					389:397	Tannerella forsythia	378:397	Tannerella forsythia	378:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	0	108	theme	O-Glycoproteome	24:38	arg1	Characterization					0:15	Characterization	0:15	Characterization of the O-Glycoproteome of Porphyromonas gingivalis.	0:67	Characterization of the O-Glycoproteome of Porphyromonas gingivalis.
34985300	6	109	theme	HexNAc	1122:1127	arg1	sugars					1129:1134	the two HexNAc sugars	1114:1134	the two HexNAc sugars	1114:1134	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	10	110	theme	cardiovascular	1800:1813	arg1	disease					1815:1821	cardiovascular disease	1800:1821	cardiovascular disease	1800:1821	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	0	111	theme	Porphyromonas	43:55	arg1	gingivalis					57:66	Porphyromonas gingivalis	43:66	Porphyromonas gingivalis	43:66	Characterization of the O-Glycoproteome of Porphyromonas gingivalis.
34985300	7	112	gly	O-glycosylation	1178:1192	arg1	proteins					1206:1213	abundant proteins	1197:1213	abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins	1197:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	7	112	gly	O-glycosylation	1178:1192	arg1	proteins					1271:1278	abundant T9SS cargo proteins	1251:1278	abundant T9SS cargo proteins	1251:1278	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	7	112	gly	O-glycosylation	1178:1192	arg1	lipoproteins					1289:1300	surface lipoproteins	1281:1300	surface lipoproteins	1281:1300	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	7	112	gly	O-glycosylation	1178:1192	arg1	proteins					1331:1338	outer membrane β-barrel proteins	1307:1338	outer membrane β-barrel proteins	1307:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	2	113	from	motif	277:281	arg1	species					324:330	a few species	318:330	a few species	318:330	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	2	113	from	motif	277:281	arg1	forsythia					389:397	Tannerella forsythia	378:397	Tannerella forsythia	378:397	O-glycosylation has been reported in this phylum with findings that include the O-glycosylation motif, the structure of the O-glycans in a few species, and an extensive O-glycoproteome analysis in Tannerella forsythia.
34985300	7	114	theme	proteins	1206:1213	arg1	O-glycosylation					1178:1192	the O-glycosylation	1174:1192	the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins	1174:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	10	115	dep	pathogen	1678:1685	arg1	associated					1697:1706	associated	1697:1706	primarily associated with severe periodontal disease	1687:1738	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	10	115	dep	pathogen	1678:1685	arg1	associated					1752:1761	associated	1752:1761	further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers	1744:1842	IMPORTANCE Porphyromonas gingivalis is an oral pathogen primarily associated with severe periodontal disease and further associated with rheumatoid arthritis, dementia, cardiovascular disease, and certain cancers.
34985300	4	116	with	deglycosylation	533:547	arg1	acid					579:582	trifluoromethanesulfonic acid	554:582	trifluoromethanesulfonic acid	554:582	We therefore used glycoproteomics approaches including partial deglycosylation with trifluoromethanesulfonic acid as well as both HILIC and FAIMS based glycopeptide enrichment strategies leading to the identification of 257 putative glycosylation sites in 145 glycoproteins.
34985300	13	117	gly	O-glycosylated	2273:2286	arg1	proteins					2234:2241	most proteins	2229:2241	most proteins exposed to the periplasm	2229:2266	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	11	118	theme	thermodynamic	1974:1986	arg1	stability					1988:1996	thermodynamic stability	1974:1996	thermodynamic stability	1974:1996	Protein glycosylation can be important for a variety of reasons including protein function, solubility, protease resistance, and thermodynamic stability.
34985300	13	119	theme	abundant	2302:2309	arg1	proteins					2327:2334	the abundant surface exposed proteins	2298:2334	the abundant surface exposed proteins	2298:2334	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	13	119	theme	abundant	2302:2309	arg1	were					2336:2339	were	2336:2339	were not	2336:2343	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	6	120	theme	blot	863:866	arg1	analyses					868:875	Western blot analyses	855:875	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135	855:941	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	7	121	theme	membrane	1313:1320	arg1	proteins					1331:1338	outer membrane β-barrel proteins	1307:1338	outer membrane β-barrel proteins	1307:1338	Interestingly, a strong bias against the O-glycosylation of abundant proteins exposed to the cell surface such as abundant T9SS cargo proteins, surface lipoproteins, and outer membrane β-barrel proteins was observed.
34985300	6	122	from	involvement	962:972	arg1	biosynthesis					981:992	the biosynthesis	977:992	the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars	977:1134	Western blot analyses of mutants lacking the glycosyltransferases PGN_1134 and PGN_1135 demonstrated their involvement in the biosynthesis of the glycan while mass spectrometry analysis of the truncated O-glycans suggested that PGN_1134 and PGN_1135 transfer the two HexNAc sugars.
34985300	13	123	theme	exposed	2319:2325	arg1	proteins					2327:2334	the abundant surface exposed proteins	2298:2334	the abundant surface exposed proteins	2298:2334	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
34985300	13	123	theme	exposed	2319:2325	arg1	were					2336:2339	were	2336:2339	were not	2336:2343	It was found that most proteins exposed to the periplasm were O-glycosylated; however, the abundant surface exposed proteins were not.
37189353	4	0	from	N-glycosylation	587:601	arg1	fibrillation					644:655	atrial fibrillation	637:655	atrial fibrillation	637:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	4	1	with	patients	697:704	arg1	fibrillation					718:729	atrial fibrillation	711:729	atrial fibrillation	711:729	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	4	2	gly	N-glycosylation	674:688	arg1	patients					697:704	172 patients	693:704	172 patients with atrial fibrillation	693:729	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	5	3	theme	liquid	896:901	arg1	chromatography					903:916	ultra-high-performance liquid chromatography	873:916	ultra-high-performance liquid chromatography	873:916	An analysis was performed using ultra-high-performance liquid chromatography.
37189353	0	4	from	N-Glycosylation	4:18	arg1	Fibrillation					63:74	Atrial Fibrillation	56:74	Atrial Fibrillation	56:74	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	3	5	from	biomarkers	473:482	arg1	those					520:524	those	520:524	those	520:524	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	3	5	from	biomarkers	473:482	arg1	diseases					497:504	different diseases	487:504	different diseases	487:504	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	7	6	theme	plasma	1173:1178	arg1	N-glycans					1180:1188	four plasma N-glycans	1168:1188	four plasma N-glycans	1168:1188	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	6	theme	plasma	1173:1178	arg1	related					1251:1257	related	1251:1257	related	1251:1257	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	6	theme	plasma	1173:1178	arg1	structures					1211:1220	oligomannose structures	1198:1220	oligomannose structures	1198:1220	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	6	theme	plasma	1173:1178	arg1	trait					1236:1240	a derived trait	1226:1240	a derived trait that was related to them	1226:1265	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	4	7	gly	N-glycosylation	587:601	arg1	IgG					630:632	IgG	630:632	IgG in atrial fibrillation	630:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	4	7	gly	N-glycosylation	587:601	arg1	proteins					617:624	the plasma proteins	606:624	the plasma proteins	606:624	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	7	8	theme	derived	1228:1234	arg1	trait					1236:1240	a derived trait	1226:1240	a derived trait that was related to them	1226:1265	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	8	theme	derived	1228:1234	arg1	related					1251:1257	related	1251:1257	related	1251:1257	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	8	theme	derived	1228:1234	arg1	N-glycans					1180:1188	four plasma N-glycans	1168:1188	four plasma N-glycans	1168:1188	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	4	9	theme	atrial	637:642	arg1	fibrillation					644:655	atrial fibrillation	637:655	atrial fibrillation	637:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	6	10	theme	IgG	998:1000	arg1	N-glycans					1002:1010	the plasma N-glycome and six IgG N-glycans	969:1010	N-glycans	1002:1010	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	4	11	from	changes	572:578	arg1	N-glycosylation					587:601	the N-glycosylation	583:601	the N-glycosylation of the plasma proteins and IgG in atrial fibrillation	583:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	9	12	from	patterns	1616:1623	arg1	fibrillation					1635:1646	atrial fibrillation	1628:1646	atrial fibrillation	1628:1646	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	3	13	theme	great	456:460	arg1	promise					462:468	great promise	456:468	great promise	456:468	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	3	13	theme	great	456:460	arg1	biomarkers					473:482	biomarkers	473:482	biomarkers in different diseases, specifically those involving inflammatory changes	473:555	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	7	14	theme	oligomannose	1198:1209	arg1	N-glycans					1180:1188	four plasma N-glycans	1168:1188	four plasma N-glycans	1168:1188	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	14	theme	oligomannose	1198:1209	arg1	structures					1211:1220	oligomannose structures	1198:1220	oligomannose structures	1198:1220	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	4	15	theme	healthy	823:829	arg1	controls					831:838	54 cardiovascularly healthy controls	803:838	54 cardiovascularly healthy controls	803:838	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	6	16	theme	bisecting	1053:1061	arg1	N-acetylglucosamine					1063:1081	bisecting N-acetylglucosamine	1053:1081	bisecting N-acetylglucosamine	1053:1081	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	9	17	theme	first	1573:1577	arg1	study					1579:1583	the first study	1569:1583	the first study looking at the N-glycosylation patterns in atrial fibrillation	1569:1646	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	9	17	theme	first	1573:1577	arg1	This					1561:1564	This	1561:1564	This	1561:1564	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	4	18	from	fibrillation	644:655	arg1	N-glycosylation					587:601	the N-glycosylation	583:601	the N-glycosylation of the plasma proteins and IgG in atrial fibrillation	583:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	2	19	theme	interstitial	361:372	arg1	fibrosis					374:381	interstitial fibrosis	361:381	interstitial fibrosis	361:381	These changes, such as the accumulation of adipose tissue and interstitial fibrosis, are characterized by the presence of inflammation.
37189353	7	20	located	found	1273:1277	arg2	trait					1236:1240	a derived trait	1226:1240	a derived trait that was related to them	1226:1265	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	20	located	found	1273:1277	arg2	related					1251:1257	related	1251:1257	related	1251:1257	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	20	located	found	1273:1277	arg2	N-glycans					1180:1188	four plasma N-glycans	1168:1188	four plasma N-glycans	1168:1188	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	20	located	found	1273:1277	arg1	addition					1158:1165	addition	1158:1165	addition	1158:1165	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	20	located	found	1273:1277	arg2	structures					1211:1220	oligomannose structures	1198:1220	oligomannose structures	1198:1220	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	4	21	theme	cardiovascularly	806:821	arg1	controls					831:838	54 cardiovascularly healthy controls	803:838	54 cardiovascularly healthy controls	803:838	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	7	22	link	derived	1228:1234	arg1	trait					1236:1240	a derived trait	1226:1240	a derived trait that was related to them	1226:1265	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	22	link	derived	1228:1234	arg1	related					1251:1257	related	1251:1257	related	1251:1257	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	7	22	link	derived	1228:1234	arg1	N-glycans					1180:1188	four plasma N-glycans	1168:1188	four plasma N-glycans	1168:1188	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	6	23	theme	N-glycan	945:952	arg1	structure					954:962	one oligomannose N-glycan structure	928:962	one oligomannose N-glycan structure	928:962	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	1	24	with	disease	102:108	arg1	pathophysiology					125:139	a complex pathophysiology	115:139	a complex pathophysiology	115:139	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	1	25	theme	Atrial	77:82	arg1	fibrillation					84:95	Atrial fibrillation	77:95	Atrial fibrillation	77:95	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	1	25	theme	Atrial	77:82	arg1	disease					102:108	a disease	100:108	a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate	100:296	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	2	26	theme	tissue	350:355	arg1	accumulation					326:337	the accumulation	322:337	the accumulation of adipose tissue and interstitial fibrosis	322:381	These changes, such as the accumulation of adipose tissue and interstitial fibrosis, are characterized by the presence of inflammation.
37189353	4	27	theme	patients	697:704	arg1	N-glycosylation					674:688	the N-glycosylation	670:688	the N-glycosylation of 172 patients with atrial fibrillation	670:729	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	4	28	theme	atrial	711:716	arg1	fibrillation					718:729	atrial fibrillation	711:729	atrial fibrillation	711:729	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	4	29	from	IgG	630:632	arg1	fibrillation					644:655	atrial fibrillation	637:655	atrial fibrillation	637:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	2	30	theme	adipose	342:348	arg1	tissue					350:355	adipose tissue	342:355	adipose tissue	342:355	These changes, such as the accumulation of adipose tissue and interstitial fibrosis, are characterized by the presence of inflammation.
37189353	0	31	theme	Total	23:27	arg1	Proteins					36:43	Total Plasma Proteins	23:43	Total Plasma Proteins	23:43	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	7	32	theme	fibrillation	1337:1348	arg1	recurrence					1350:1359	an atrial fibrillation recurrence	1327:1359	an atrial fibrillation recurrence	1327:1359	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	9	33	theme	atrial	1730:1735	arg1	fibrillation					1737:1748	atrial fibrillation	1730:1748	atrial fibrillation	1730:1748	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	3	34	theme	inflammatory	536:547	arg1	changes					549:555	inflammatory changes	536:555	inflammatory changes	536:555	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	4	35	theme	proteins	617:624	arg1	N-glycosylation					587:601	the N-glycosylation	583:601	the N-glycosylation of the plasma proteins and IgG in atrial fibrillation	583:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	6	36	theme	plasma	973:978	arg1	N-glycome					980:988	the plasma N-glycome and six IgG N-glycans	969:1010	N-glycome	980:988	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	9	37	theme	N-glycosylation	1600:1614	arg1	patterns					1616:1623	the N-glycosylation patterns	1596:1623	the N-glycosylation patterns in atrial fibrillation	1596:1646	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	4	38	from	proteins	617:624	arg1	fibrillation					644:655	atrial fibrillation	637:655	atrial fibrillation	637:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	4	39	theme	plasma	610:615	arg1	proteins					617:624	the plasma proteins	606:624	the plasma proteins	606:624	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	0	40	theme	Proteins	36:43	arg1	N-Glycosylation					4:18	The N-Glycosylation	0:18	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.	0:75	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	4	41	theme	IgG	630:632	arg1	N-glycosylation					587:601	the N-glycosylation	583:601	the N-glycosylation of the plasma proteins and IgG in atrial fibrillation	583:655	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	0	42	theme	Plasma	29:34	arg1	Proteins					36:43	Total Plasma Proteins	23:43	Total Plasma Proteins	23:43	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	1	43	theme	susceptible	270:280	arg1	substrate					288:296	a susceptible heart substrate	268:296	a susceptible heart substrate	268:296	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	6	44	from	N-glycome	980:988	arg1	structure					954:962	one oligomannose N-glycan structure	928:962	one oligomannose N-glycan structure	928:962	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	0	45	gly	N-Glycosylation	4:18	arg1	Proteins					36:43	Total Plasma Proteins	23:43	Total Plasma Proteins	23:43	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	0	45	gly	N-Glycosylation	4:18	arg1	IgG					49:51	IgG	49:51	IgG	49:51	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	7	46	from	different	1285:1293	arg1	patients					1302:1309	the patients	1298:1309	the patients who experienced an atrial fibrillation recurrence during the six-month follow-up	1298:1390	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	1	47	theme	aberrant	198:205	arg1	signaling					218:226	aberrant electrical signaling	198:226	aberrant electrical signaling in the heart	198:239	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	0	48	theme	IgG	49:51	arg1	N-Glycosylation					4:18	The N-Glycosylation	0:18	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.	0:75	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	1	49	theme	heart	282:286	arg1	substrate					288:296	a susceptible heart substrate	268:296	a susceptible heart substrate	268:296	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	7	50	theme	six-month	1372:1380	arg1	follow-up					1382:1390	the six-month follow-up	1368:1390	the six-month follow-up	1368:1390	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	6	51	theme	case	1130:1133	arg1	groups					1147:1152	the case and control groups	1126:1152	groups	1147:1152	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	9	52	theme	further	1661:1667	arg1	investigation					1669:1681	further investigation	1661:1681	further investigation into the prospect of glycans as biomarkers for atrial fibrillation	1661:1748	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	2	53	theme	inflammation	421:432	arg1	presence					409:416	the presence	405:416	the presence of inflammation	405:432	These changes, such as the accumulation of adipose tissue and interstitial fibrosis, are characterized by the presence of inflammation.
37189353	1	54	theme	substrate	288:296	arg1	development					253:263	the development	249:263	the development of a susceptible heart substrate	249:296	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	6	55	from	N-glycans	1002:1010	arg1	structure					954:962	one oligomannose N-glycan structure	928:962	one oligomannose N-glycan structure	928:962	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	8	56	theme	CHA2DS2-VASc	1449:1460	arg1	score					1462:1466	the CHA2DS2-VASc score	1445:1466	the CHA2DS2-VASc score	1445:1466	IgG N-glycosylation was extensively associated with the CHA2DS2-VASc score, confirming its previously reported associations with the conditions that make up the score.
37189353	6	57	theme	oligomannose	932:943	arg1	structure					954:962	one oligomannose N-glycan structure	928:962	one oligomannose N-glycan structure	928:962	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	9	58	theme	atrial	1628:1633	arg1	fibrillation					1635:1646	atrial fibrillation	1628:1646	atrial fibrillation	1628:1646	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	8	59	theme	reported	1495:1502	arg1	associations					1504:1515	its previously reported associations	1480:1515	its previously reported associations	1480:1515	IgG N-glycosylation was extensively associated with the CHA2DS2-VASc score, confirming its previously reported associations with the conditions that make up the score.
37189353	4	60	theme	pulmonary	762:770	arg1	procedure					787:795	a pulmonary vein isolation procedure	760:795	a pulmonary vein isolation procedure	760:795	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	7	61	from	patients	1302:1309	arg1	different					1285:1293	different	1285:1293	different	1285:1293	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	6	62	theme	control	1139:1145	arg1	groups					1147:1152	the case and control groups	1126:1152	groups	1147:1152	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	8	63	theme	IgG	1393:1395	arg1	N-glycosylation					1397:1411	IgG N-glycosylation	1393:1411	IgG N-glycosylation	1393:1411	IgG N-glycosylation was extensively associated with the CHA2DS2-VASc score, confirming its previously reported associations with the conditions that make up the score.
37189353	1	64	theme	electrical	207:216	arg1	signaling					218:226	aberrant electrical signaling	198:226	aberrant electrical signaling in the heart	198:239	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	1	65	from	signaling	218:226	arg1	heart					235:239	the heart	231:239	the heart	231:239	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	1	66	theme	complex	117:123	arg1	pathophysiology					125:139	a complex pathophysiology	115:139	a complex pathophysiology	115:139	Atrial fibrillation is a disease with a complex pathophysiology, whose occurrence and persistence are caused not only by aberrant electrical signaling in the heart, but by the development of a susceptible heart substrate.
37189353	0	67	theme	Atrial	56:61	arg1	Fibrillation					63:74	Atrial Fibrillation	56:74	Atrial Fibrillation	56:74	The N-Glycosylation of Total Plasma Proteins and IgG in Atrial Fibrillation.
37189353	2	68	theme	fibrosis	374:381	arg1	accumulation					326:337	the accumulation	322:337	the accumulation of adipose tissue and interstitial fibrosis	322:381	These changes, such as the accumulation of adipose tissue and interstitial fibrosis, are characterized by the presence of inflammation.
37189353	4	69	theme	isolation	777:785	arg1	procedure					787:795	a pulmonary vein isolation procedure	760:795	a pulmonary vein isolation procedure	760:795	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	6	70	theme	N-acetylglucosamine	1063:1081	arg1	presence					1041:1048	the presence	1037:1048	the presence of bisecting N-acetylglucosamine	1037:1081	We found one oligomannose N-glycan structure from the plasma N-glycome and six IgG N-glycans, mainly revolving around the presence of bisecting N-acetylglucosamine, that were significantly different between the case and control groups.
37189353	3	71	theme	different	487:495	arg1	those					520:524	those	520:524	those	520:524	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	3	71	theme	different	487:495	arg1	diseases					497:504	different diseases	487:504	different diseases	487:504	N-glycans have shown great promise as biomarkers in different diseases, specifically those involving inflammatory changes.
37189353	7	72	theme	atrial	1330:1335	arg1	fibrillation					1337:1348	an atrial fibrillation	1327:1348	an atrial fibrillation recurrence	1327:1359	In addition, four plasma N-glycans, mostly oligomannose structures and a derived trait that was related to them, were found to be different in the patients who experienced an atrial fibrillation recurrence during the six-month follow-up.
37189353	9	73	theme	glycans	1704:1710	arg1	prospect					1692:1699	the prospect	1688:1699	the prospect of glycans as biomarkers for atrial fibrillation	1688:1748	This is the first study looking at the N-glycosylation patterns in atrial fibrillation and warrants further investigation into the prospect of glycans as biomarkers for atrial fibrillation.
37189353	4	74	theme	vein	772:775	arg1	procedure					787:795	a pulmonary vein isolation procedure	760:795	a pulmonary vein isolation procedure	760:795	To assess the changes in the N-glycosylation of the plasma proteins and IgG in atrial fibrillation, we analyzed the N-glycosylation of 172 patients with atrial fibrillation, before and six months after a pulmonary vein isolation procedure, with 54 cardiovascularly healthy controls.
37189353	5	75	theme	ultra-high-performance	873:894	arg1	chromatography					903:916	ultra-high-performance liquid chromatography	873:916	ultra-high-performance liquid chromatography	873:916	An analysis was performed using ultra-high-performance liquid chromatography.
36174116	13	0	theme	cardiometabolic	1890:1904	arg1	risk					1906:1909	cardiometabolic risk	1890:1909	cardiometabolic risk beyond classic risk factors, including clinical biomarkers	1890:1968	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	4	1	theme	N-glycan	660:667	arg1	IgG-GPs					676:682	IgG-GPs	676:682	IgG-GPs	676:682	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	4	1	theme	N-glycan	660:667	arg1	peaks					669:673	24 IgG N-glycan peaks	653:673	24 IgG N-glycan peaks (IgG-GPs)	653:683	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	3	2	dep	DESIGN	331:336	arg1	performed					353:361	performed	353:361	performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases])	353:627	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	2	3	theme	cardiovascular	292:305	arg1	CVD					316:318	CVD	316:318	CVD	316:318	We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD).
36174116	2	3	theme	cardiovascular	292:305	arg1	disease					307:313	cardiovascular disease	292:313	cardiovascular disease (CVD)	292:319	We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD).
36174116	10	4	theme	SD	1585:1586	arg1	%					1596:1596	SD 0.80 [95% CI	1585:1599	SD 0.80 [95% CI 0.65-0.98])	1585:1611	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	6	5	theme	independent	1023:1033	arg1	studies					1035:1041	three independent studies	1017:1041	three independent studies	1017:1041	Diabetes risk associations were validated in three independent studies.
36174116	8	6	theme	independent	1305:1315	arg1	studies					1328:1334	independent validation studies	1305:1334	independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64])	1305:1432	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	11	7	theme	1.47	1717:1720	arg1	%					1725:1725	1.47 [95%	1717:1725	1.47 [95% CI 1.20-1.80	1717:1738	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	3	8	theme	CVD	569:571	arg1	infarction					599:608	the CVD subcohort [417 myocardial infarction	565:608	the CVD subcohort [417 myocardial infarction	565:608	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	3	9	theme	stroke	614:619	arg1	cases					621:625	the CVD subcohort [417 myocardial infarction and stroke cases	565:625	the CVD subcohort [417 myocardial infarction and stroke cases	565:625	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	8	10	theme	higher	1264:1269	arg1	risk					1280:1283	a higher diabetes risk	1262:1283	a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64])	1262:1432	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	3	11	theme	RESEARCH	322:329	arg1	DESIGN					331:336	RESEARCH DESIGN	322:336	RESEARCH DESIGN	322:336	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	4	12	theme	ultraperformance	702:717	arg1	chromatography					726:739	ultraperformance liquid chromatography	702:739	ultraperformance liquid chromatography	702:739	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	3	13	theme	infarction	599:608	arg1	cases					621:625	the CVD subcohort [417 myocardial infarction and stroke cases	565:625	the CVD subcohort [417 myocardial infarction and stroke cases	565:625	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	8	14	from	risk	1280:1283	arg1	EPIC-Potsdam					1288:1299	EPIC-Potsdam	1288:1299	EPIC-Potsdam	1288:1299	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	8	14	from	risk	1280:1283	arg1	studies					1328:1334	independent validation studies	1305:1334	independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64])	1305:1432	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	1	15	theme	functional	131:140	arg1	modification					160:171	a functional posttranslational modification	129:171	a functional posttranslational modification of immunoglobulins (Igs)	129:196	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	1	15	theme	functional	131:140	arg1	N-glycosylation					110:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	6	16	theme	risk	981:984	arg1	associations					986:997	Diabetes risk associations	972:997	Diabetes risk associations	972:997	Diabetes risk associations were validated in three independent studies.
36174116	11	17	theme	CVD	1697:1699	arg1	risk					1701:1704	higher CVD risk	1690:1704	higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80])	1690:1740	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	2	18	theme	type	272:275	arg1	diabetes					279:286	incident type 2 diabetes	263:286	incident type 2 diabetes	263:286	We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD).
36174116	1	19	theme	immunoglobulins	176:190	arg1	modification					160:171	a functional posttranslational modification	129:171	a functional posttranslational modification of immunoglobulins (Igs)	129:196	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	1	19	theme	immunoglobulins	176:190	arg1	N-glycosylation					110:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	0	20	theme	Cardiovascular	76:89	arg1	Disease					91:97	Cardiovascular Disease	76:97	Cardiovascular Disease	76:97	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	11	21	dep	%	1725:1725	arg1	CI					1727:1728	CI 1.20-1.80	1727:1738	1.47 [95% CI 1.20-1.80	1717:1738	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	5	22	theme	confounder-adjusted	940:958	arg1	models					964:969	confounder-adjusted Cox models	940:969	confounder-adjusted Cox models	940:969	End point-associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models.
36174116	8	23	theme	total	1341:1345	arg1	cases					1347:1351	843 total cases	1337:1351	843 total cases	1337:1351	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	8	23	theme	total	1341:1345	arg1	non-cases					1366:1374	3,149 total non-cases	1354:1374	3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]	1354:1431	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	3	24	theme	case-cohort	363:373	arg1	studies					375:381	case-cohort studies	363:381	case-cohort studies	363:381	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	7	25	dep	confounders	1073:1083	arg1	correction					1106:1115	correction	1106:1115	correction	1106:1115	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	7	25	dep	confounders	1073:1083	arg1	IgG-GP7					1118:1124	IgG-GP7	1118:1124	IgG-GP7	1118:1124	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	7	25	dep	confounders	1073:1083	arg1	IgG-GP11					1145:1152	IgG-GP11	1145:1152	IgG-GP11	1145:1152	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	7	25	dep	confounders	1073:1083	arg1	confounders					1073:1083	confounders	1073:1083	confounders	1073:1083	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	7	25	dep	confounders	1073:1083	arg1	IgG-GP8					1127:1133	IgG-GP8	1127:1133	IgG-GP8	1127:1133	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	7	25	dep	confounders	1073:1083	arg1	IgG-GP19					1159:1166	IgG-GP19	1159:1166	IgG-GP19	1159:1166	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	7	25	dep	confounders	1073:1083	arg1	IgG-GP9					1136:1142	IgG-GP9	1136:1142	IgG-GP9	1136:1142	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	3	26	theme	Prospective	420:430	arg1	Investigation					432:444	the population-based European Prospective Investigation	390:444	the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort	390:492	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	7	27	dep	diabetes	1196:1203	arg1	risk					1205:1208	risk	1205:1208	type 2 diabetes risk	1189:1208	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	0	28	theme	Immunoglobulin	0:13	arg1	Signatures					33:42	Immunoglobulin G N-Glycosylation Signatures	0:42	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.	0:98	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	12	29	theme	disease	1816:1822	arg1	incidence					1824:1832	cardiometabolic disease incidence	1800:1832	cardiometabolic disease incidence	1800:1832	In addition, several derived traits were associated with cardiometabolic disease incidence.
36174116	1	30	theme	OBJECTIVE	100:108	arg1	modification					160:171	a functional posttranslational modification	129:171	a functional posttranslational modification of immunoglobulins (Igs)	129:196	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	1	30	theme	OBJECTIVE	100:108	arg1	N-glycosylation					110:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	3	31	theme	population-based	394:409	arg1	Investigation					432:444	the population-based European Prospective Investigation	390:444	the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort	390:492	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	4	32	theme	glycosylation	752:764	arg1	traits					766:771	eight glycosylation traits	746:771	eight glycosylation traits	746:771	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	0	33	theme	N-Glycosylation	17:31	arg1	Signatures					33:42	Immunoglobulin G N-Glycosylation Signatures	0:42	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.	0:98	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	12	34	theme	derived	1764:1770	arg1	traits					1772:1777	several derived traits	1756:1777	several derived traits	1756:1777	In addition, several derived traits were associated with cardiometabolic disease incidence.
36174116	0	35	theme	Type	56:59	arg1	Diabetes					63:70	Incident Type 2 Diabetes	47:70	Incident Type 2 Diabetes	47:70	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	2	36	theme	IgG	229:231	arg1	N-glycans					233:241	specific IgG N-glycans	220:241	specific IgG N-glycans	220:241	We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD).
36174116	4	37	theme	structural	795:804	arg1	similarity					806:815	structural similarity	795:815	structural similarity	795:815	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	13	38	theme	clinical	1950:1957	arg1	biomarkers					1959:1968	clinical biomarkers	1950:1968	clinical biomarkers	1950:1968	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	3	39	theme	incident	539:546	arg1	cases					548:552	the type 2 diabetes subcohort [741 incident cases	504:552	the type 2 diabetes subcohort [741 incident cases	504:552	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	4	40	theme	IgG	656:658	arg1	IgG-GPs					676:682	IgG-GPs	676:682	IgG-GPs	676:682	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	4	40	theme	IgG	656:658	arg1	peaks					669:673	24 IgG N-glycan peaks	653:673	24 IgG N-glycan peaks (IgG-GPs)	653:683	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	6	41	theme	Diabetes	972:979	arg1	associations					986:997	Diabetes risk associations	972:997	Diabetes risk associations	972:997	Diabetes risk associations were validated in three independent studies.
36174116	10	42	dep	%	1596:1596	arg1	0.65-0.98					1601:1609	0.65-0.98	1601:1609	0.65-0.98	1601:1609	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	3	43	theme	subcohort	524:532	arg1	cases					548:552	the type 2 diabetes subcohort [741 incident cases	504:552	the type 2 diabetes subcohort [741 incident cases	504:552	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	13	44	dep	Selected	1847:1854	arg1	CONCLUSIONS					1835:1845	CONCLUSIONS	1835:1845	CONCLUSIONS Selected IgG N-glycans	1835:1868	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	13	44	dep	Selected	1847:1854	arg1	N-glycans					1860:1868	N-glycans	1860:1868	N-glycans	1860:1868	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	13	44	dep	Selected	1847:1854	arg1	IgG					1856:1858	IgG	1856:1858	IgG	1856:1858	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	10	45	theme	hazard	1563:1568	arg1	risk					1557:1560	CVD risk	1553:1560	CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98])	1553:1611	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	10	45	theme	hazard	1563:1568	arg1	ratio					1570:1574	hazard ratio [HR	1563:1578	hazard ratio [HR	1563:1578	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	11	46	theme	weighted	1624:1631	arg1	score					1633:1637	a weighted score	1622:1637	a weighted score based on IgG-GP19 and IgG-GP23	1622:1668	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	13	47	theme	classic	1918:1924	arg1	biomarkers					1959:1968	clinical biomarkers	1950:1968	clinical biomarkers	1950:1968	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	13	47	theme	classic	1918:1924	arg1	factors					1931:1937	classic risk factors	1918:1937	classic risk factors	1918:1937	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	5	48	theme	prospective	897:907	arg1	associations					909:920	prospective associations	897:920	prospective associations	897:920	End point-associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models.
36174116	9	49	theme	IgG-GPs	1451:1457	arg1	Associations					1435:1446	Associations	1435:1446	Associations of IgG-GPs with CVD risk	1435:1471	Associations of IgG-GPs with CVD risk differed between men and women.
36174116	8	50	theme	diabetes	1271:1278	arg1	risk					1280:1283	a higher diabetes risk	1262:1283	a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64])	1262:1432	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	10	51	theme	0.80	1588:1591	arg1	%					1596:1596	SD 0.80 [95% CI	1585:1599	SD 0.80 [95% CI 0.65-0.98])	1585:1611	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	3	52	theme	subcohort	573:581	arg1	infarction					599:608	the CVD subcohort [417 myocardial infarction	565:608	the CVD subcohort [417 myocardial infarction	565:608	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	9	53	theme	CVD	1464:1466	arg1	risk					1468:1471	CVD risk	1464:1471	CVD risk	1464:1471	Associations of IgG-GPs with CVD risk differed between men and women.
36174116	4	54	theme	peaks	669:673	arg1	abundances					639:648	Relative abundances	630:648	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs)	630:683	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	4	55	theme	Relative	630:637	arg1	abundances					639:648	Relative abundances	630:648	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs)	630:683	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	2	56	theme	incident	263:270	arg1	diabetes					279:286	incident type 2 diabetes	263:286	incident type 2 diabetes	263:286	We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD).
36174116	5	57	theme	fractional	869:878	arg1	polynomials					880:890	fractional polynomials	869:890	fractional polynomials	869:890	End point-associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models.
36174116	8	58	theme	validation	1317:1326	arg1	studies					1328:1334	independent validation studies	1305:1334	independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64])	1305:1432	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	11	59	dep	risk	1701:1704	arg1	HR					1707:1708	HR	1707:1708	HR	1707:1708	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	3	60	theme	myocardial	588:597	arg1	infarction					599:608	the CVD subcohort [417 myocardial infarction	565:608	the CVD subcohort [417 myocardial infarction	565:608	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	7	61	theme	multiple	1089:1096	arg1	testing					1098:1104	multiple testing	1089:1104	multiple testing	1089:1104	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	5	62	theme	Cox	960:962	arg1	models					964:969	confounder-adjusted Cox models	940:969	confounder-adjusted Cox models	940:969	End point-associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models.
36174116	11	63	dep	HR	1707:1708	arg1	%					1725:1725	1.47 [95%	1717:1725	1.47 [95% CI 1.20-1.80	1717:1738	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	1	64	theme	posttranslational	142:158	arg1	modification					160:171	a functional posttranslational modification	129:171	a functional posttranslational modification of immunoglobulins (Igs)	129:196	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	1	64	theme	posttranslational	142:158	arg1	N-glycosylation					110:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation	100:124	OBJECTIVE N-glycosylation is a functional posttranslational modification of immunoglobulins (Igs).
36174116	4	65	theme	liquid	719:724	arg1	chromatography					726:739	ultraperformance liquid chromatography	702:739	ultraperformance liquid chromatography	702:739	Relative abundances of 24 IgG N-glycan peaks (IgG-GPs) were measured by ultraperformance liquid chromatography, and eight glycosylation traits were derived based on structural similarity.
36174116	0	66	from	Signatures	33:42	arg1	Diabetes					63:70	Incident Type 2 Diabetes	47:70	Incident Type 2 Diabetes	47:70	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	0	66	from	Signatures	33:42	arg1	Disease					91:97	Cardiovascular Disease	76:97	Cardiovascular Disease	76:97	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	11	67	theme	higher	1690:1695	arg1	risk					1701:1704	higher CVD risk	1690:1704	higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80])	1690:1740	In men, a weighted score based on IgG-GP19 and IgG-GP23 was associated with higher CVD risk (HR per SD 1.47 [95% CI 1.20-1.80]).
36174116	8	68	theme	total	1360:1364	arg1	cases					1347:1351	843 total cases	1337:1351	843 total cases	1337:1351	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	8	68	theme	total	1360:1364	arg1	non-cases					1366:1374	3,149 total non-cases	1354:1374	3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]	1354:1431	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	8	69	dep	studies	1328:1334	arg1	cases					1347:1351	843 total cases	1337:1351	843 total cases	1337:1351	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	8	69	dep	studies	1328:1334	arg1	non-cases					1366:1374	3,149 total non-cases	1354:1374	3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]	1354:1431	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	8	70	dep	increase	1400:1407	arg1	%					1417:1417	[95% CI 1.37-1.64	1414:1430	SD increase 1.50 [95% CI 1.37-1.64	1397:1430	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	12	71	theme	cardiometabolic	1800:1814	arg1	incidence					1824:1832	cardiometabolic disease incidence	1800:1832	cardiometabolic disease incidence	1800:1832	In addition, several derived traits were associated with cardiometabolic disease incidence.
36174116	3	72	dep	Cancer	451:456	arg1	cohort					487:492	-Potsdam cohort	478:492	-Potsdam cohort	478:492	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	3	73	theme	-Potsdam	478:485	arg1	cohort					487:492	-Potsdam cohort	478:492	-Potsdam cohort	478:492	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	5	74	theme	End	818:820	arg1	IgG-GPs					839:845	End point-associated IgG-GPs	818:845	End point-associated IgG-GPs	818:845	End point-associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models.
36174116	8	75	theme	SD	1397:1398	arg1	increase					1400:1407	SD increase 1.50	1397:1412	SD increase 1.50 [95% CI 1.37-1.64	1397:1430	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	5	76	theme	point-associated	822:837	arg1	IgG-GPs					839:845	End point-associated IgG-GPs	818:845	End point-associated IgG-GPs	818:845	End point-associated IgG-GPs were preselected with fractional polynomials, and prospective associations were estimated in confounder-adjusted Cox models.
36174116	3	77	theme	European	411:418	arg1	Investigation					432:444	the population-based European Prospective Investigation	390:444	the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort	390:492	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	0	78	theme	Incident	47:54	arg1	Diabetes					63:70	Incident Type 2 Diabetes	47:70	Incident Type 2 Diabetes	47:70	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36174116	8	79	dep	non-cases	1366:1374	arg1	estimate					1384:1391	estimate	1384:1391	estimate per SD increase 1.50 [95% CI 1.37-1.64	1384:1430	A score based on these IgG-GPs was associated with a higher diabetes risk in EPIC-Potsdam and independent validation studies (843 total cases, 3,149 total non-cases, pooled estimate per SD increase 1.50 [95% CI 1.37-1.64]).
36174116	12	80	link	derived	1764:1770	arg1	traits					1772:1777	several derived traits	1756:1777	several derived traits	1756:1777	In addition, several derived traits were associated with cardiometabolic disease incidence.
36174116	3	81	dep	performed	353:361	arg1	2,127					495:499	2,127	495:499	2,127	495:499	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	9	82	with	Associations	1435:1446	arg1	risk					1468:1471	CVD risk	1464:1471	CVD risk	1464:1471	Associations of IgG-GPs with CVD risk differed between men and women.
36174116	7	83	theme	type	1189:1192	arg1	diabetes					1196:1203	type 2 diabetes risk	1189:1208	type 2 diabetes risk	1189:1208	RESULTS After adjustment for confounders and multiple testing correction, IgG-GP7, IgG-GP8, IgG-GP9, IgG-GP11, and IgG-GP19 were associated with type 2 diabetes risk.
36174116	3	84	from	2,127	495:499	arg1	cases					621:625	the CVD subcohort [417 myocardial infarction and stroke cases	565:625	the CVD subcohort [417 myocardial infarction and stroke cases	565:625	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	3	84	from	2,127	495:499	arg1	cases					548:552	the type 2 diabetes subcohort [741 incident cases	504:552	the type 2 diabetes subcohort [741 incident cases	504:552	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	3	85	theme	diabetes	515:522	arg1	cases					548:552	the type 2 diabetes subcohort [741 incident cases	504:552	the type 2 diabetes subcohort [741 incident cases	504:552	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	12	86	theme	several	1756:1762	arg1	traits					1772:1777	several derived traits	1756:1777	several derived traits	1756:1777	In addition, several derived traits were associated with cardiometabolic disease incidence.
36174116	2	87	theme	specific	220:227	arg1	N-glycans					233:241	specific IgG N-glycans	220:241	specific IgG N-glycans	220:241	We hypothesized that specific IgG N-glycans are associated with incident type 2 diabetes and cardiovascular disease (CVD).
36174116	13	88	theme	risk	1926:1929	arg1	biomarkers					1959:1968	clinical biomarkers	1950:1968	clinical biomarkers	1950:1968	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	13	88	theme	risk	1926:1929	arg1	factors					1931:1937	classic risk factors	1918:1937	classic risk factors	1918:1937	CONCLUSIONS Selected IgG N-glycans are associated with cardiometabolic risk beyond classic risk factors, including clinical biomarkers.
36174116	3	89	theme	type	508:511	arg1	cases					548:552	the type 2 diabetes subcohort [741 incident cases	504:552	the type 2 diabetes subcohort [741 incident cases	504:552	RESEARCH DESIGN AND METHODS We performed case-cohort studies within the population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (2,127 in the type 2 diabetes subcohort [741 incident cases]; 2,175 in the CVD subcohort [417 myocardial infarction and stroke cases]).
36174116	10	90	theme	CVD	1553:1555	arg1	risk					1557:1560	CVD risk	1553:1560	CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98])	1553:1611	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	10	90	theme	CVD	1553:1555	arg1	ratio					1570:1574	hazard ratio [HR	1563:1578	hazard ratio [HR	1563:1578	In women, IgG-GP9 was inversely associated with CVD risk (hazard ratio [HR] per SD 0.80 [95% CI 0.65-0.98]).
36174116	0	91	theme	G	15:15	arg1	Signatures					33:42	Immunoglobulin G N-Glycosylation Signatures	0:42	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.	0:98	Immunoglobulin G N-Glycosylation Signatures in Incident Type 2 Diabetes and Cardiovascular Disease.
36999031	6	0	theme	fucosylated	1188:1198	arg1	structures					1232:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	1	dep	0.56	1629:1632	arg1	P<0.001					1654:1660	P<0.001	1654:1660	P<0.001	1654:1660	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	1	dep	0.56	1629:1632	arg1	%					1637:1637	95% CI: 0.45-0.69	1635:1651	95% CI: 0.45-0.69	1635:1651	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	2	theme	monosialylated	1104:1117	arg1	biantennary					1119:1129	digalactosylated monosialylated biantennary	1087:1129	digalactosylated monosialylated biantennary with core	1087:1139	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	1	3	theme	Altered	102:108	arg1	IgG					128:130	IgG	128:130	IgG	128:130	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	3	theme	Altered	102:108	arg1	G					125:125	Introduction Altered Immunoglobulin G	89:125	Introduction Altered Immunoglobulin G (IgG) N-glycosylation	89:147	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	7	4	from	Individuals	1788:1798	arg1	tertile					1815:1821	the highest tertile	1803:1821	the highest tertile of the glycan score	1803:1841	Individuals in the highest tertile of the glycan score own an increased risk (OR: 11.41), compared with those in the lowest.
36999031	6	5	gly	fucosylated	1463:1473	arg1	structures					1492:1501	all fucosylated digalactosylated structures	1459:1501	all fucosylated digalactosylated structures in total neutral IgG glycans	1459:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	11	6	theme	mechanism	2307:2315	arg1	perspective					2281:2291	the perspective	2277:2291	the perspective of biological mechanism	2277:2315	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	4	7	theme	ESCC-related	781:792	arg1	score					801:805	an ESCC-related glycan score	778:805	an ESCC-related glycan score	778:805	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	6	8	dep	IGP75	1415:1419	arg1	incidence					1426:1434	the incidence	1422:1434	the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans	1422:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	9	dep	0.52	1664:1667	arg1	P<0.001					1689:1695	P<0.001	1689:1695	P<0.001	1689:1695	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	9	dep	0.52	1664:1667	arg1	%					1672:1672	95% CI: 0.41-0.65	1670:1686	95% CI: 0.41-0.65	1670:1686	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	7	10	theme	highest	1807:1813	arg1	tertile					1815:1821	the highest tertile	1803:1821	the highest tertile of the glycan score	1803:1841	Individuals in the highest tertile of the glycan score own an increased risk (OR: 11.41), compared with those in the lowest.
36999031	6	11	gly	disialylated	1219:1230	arg1	structures					1232:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	11	12	theme	personalized	2456:2467	arg1	interventions					2469:2481	personalized interventions	2456:2481	personalized interventions of cancer progression	2456:2503	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	6	13	dep	IGP44	1245:1249	arg1	4.03					1559:1562	4.03	1559:1562	4.03	1559:1562	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	13	dep	IGP44	1245:1249	arg1	ratio					1175:1179	the ratio	1171:1179	the ratio	1171:1179	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	13	dep	IGP44	1245:1249	arg1	proportion					1256:1265	the proportion	1252:1265	the proportion of high mannose glycan structures in total neutral IgG glycans	1252:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	13	dep	IGP44	1245:1249	arg1	P<0.001					1764:1770	P<0.001	1764:1770	P<0.001	1764:1770	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	13	dep	IGP44	1245:1249	arg1	%					1747:1747	95% CI: 2.33-3.53	1745:1761	95% CI: 2.33-3.53	1745:1761	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	13	dep	IGP44	1245:1249	arg1	%					1567:1567	95% CI: 3.03-5.36	1565:1581	95% CI: 3.03-5.36	1565:1581	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	10	14	theme	esophageal	2253:2262	arg1	cancer					2264:2269	esophageal cancer	2253:2269	esophageal cancer	2253:2269	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	11	15	theme	IgG	2318:2320	arg1	fucosylation					2322:2333	IgG fucosylation	2318:2333	IgG fucosylation	2318:2333	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	6	16	gly	monosialylated	1104:1117	arg1	biantennary					1119:1129	digalactosylated monosialylated biantennary	1087:1129	digalactosylated monosialylated biantennary with core	1087:1139	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	4	17	from	model	851:855	arg1	population					874:883	the discovery population	860:883	the discovery population	860:883	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	3	18	theme	ESCC	575:578	arg1	precancerosis					589:601	precancerosis	589:601	precancerosis (n=187)	589:609	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	18	theme	ESCC	575:578	arg1	Methods					538:544	Methods	538:544	Methods In total	538:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	18	theme	ESCC	575:578	arg1	n=187					604:608	n=187	604:608	n=187	604:608	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	18	theme	ESCC	575:578	arg1	controls					615:622	controls	615:622	controls (n=195) from the discovery population (n=348) and validation population (n=148)	615:702	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	18	theme	ESCC	575:578	arg1	individuals					560:570	496 individuals	556:570	496 individuals of ESCC (n=114)	556:586	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	18	theme	ESCC	575:578	arg1	n=195					625:629	n=195	625:629	n=195	625:629	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	1	19	from	effect	220:225	arg1	carcinoma					255:263	esophageal squamous cell carcinoma	230:263	esophageal squamous cell carcinoma (ESCC)	230:270	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	19	from	effect	220:225	arg1	ESCC					266:269	ESCC	266:269	ESCC	266:269	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	8	20	theme	95	1952:1953	arg1	%					1954:1954	%	1954:1954	%	1954:1954	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	6	21	theme	structures	1232:1241	arg1	ratio					1175:1179	the ratio	1171:1179	the ratio	1171:1179	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	9	22	theme	average	2034:2040	arg1	AUC					2042:2044	an average AUC	2031:2044	an average AUC of 0.807 (95% CI: 0.758-0.864)	2031:2075	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	6	23	theme	fucosylated	1463:1473	arg1	structures					1492:1501	all fucosylated digalactosylated structures	1459:1501	all fucosylated digalactosylated structures in total neutral IgG glycans	1459:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	4	24	theme	ordinal	834:840	arg1	model					851:855	a stepwise ordinal logistic model	823:855	a stepwise ordinal logistic model in the discovery population	823:883	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	0	25	theme	esophageal	67:76	arg1	carcinoma					78:86	esophageal carcinoma	67:86	esophageal carcinoma	67:86	Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma.
36999031	6	26	from	structures	1290:1299	arg1	glycans					1322:1328	total neutral IgG glycans	1304:1328	total neutral IgG glycans	1304:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	27	theme	bisecting	1439:1447	arg1	GlcNAc					1449:1454	bisecting GlcNAc	1439:1454	bisecting GlcNAc	1439:1454	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	28	theme	glycan	1283:1288	arg1	structures					1290:1299	high mannose glycan structures	1270:1299	high mannose glycan structures in total neutral IgG glycans	1270:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	9	29	theme	%	2058:2058	arg1	CI					2060:2061	95% CI	2056:2061	95% CI: 0.758-0.864	2056:2074	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	6	30	with	biantennary	1119:1129	arg1	core					1136:1139	core	1136:1139	core	1136:1139	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	2	31	theme	targeted	509:516	arg1	prevention					518:527	targeted prevention	509:527	targeted prevention	509:527	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	11	32	theme	cancer	2486:2491	arg1	progression					2493:2503	cancer progression	2486:2503	cancer progression	2486:2503	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	6	33	theme	high	1270:1273	arg1	structures					1290:1299	high mannose glycan structures	1270:1299	high mannose glycan structures in total neutral IgG glycans	1270:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	5	34	theme	score	1018:1022	arg1	performance					992:1002	the performance	988:1002	the performance of the glycan score	988:1022	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	5	35	theme	operating	899:907	arg1	curve					930:934	The receiver operating characteristic (ROC) curve	886:934	The receiver operating characteristic (ROC) curve with the bootstrapping procedure	886:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	10	36	theme	glycan	2148:2153	arg1	score					2155:2159	the proposed glycan score	2135:2159	the proposed glycan score	2135:2159	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	10	36	theme	glycan	2148:2153	arg1	markers					2195:2201	promising predictive markers	2174:2201	promising predictive markers for ESCC	2174:2210	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	6	37	theme	IgG	1520:1522	arg1	glycans					1524:1530	total neutral IgG glycans	1506:1530	total neutral IgG glycans	1506:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	1	38	theme	Introduction	89:100	arg1	IgG					128:130	IgG	128:130	IgG	128:130	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	38	theme	Introduction	89:100	arg1	G					125:125	Introduction Altered Immunoglobulin G	89:125	Introduction Altered Immunoglobulin G (IgG) N-glycosylation	89:147	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	6	39	dep	7.17	1699:1702	arg1	P<0.001					1725:1731	P<0.001	1725:1731	P<0.001	1725:1731	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	39	dep	7.17	1699:1702	arg1	%					1707:1707	95% CI: 4.77-10.79	1705:1722	95% CI: 4.77-10.79	1705:1722	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	3	40	from	population	685:694	arg1	precancerosis					589:601	precancerosis	589:601	precancerosis (n=187)	589:609	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	40	from	population	685:694	arg1	Methods					538:544	Methods	538:544	Methods In total	538:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	40	from	population	685:694	arg1	n=187					604:608	n=187	604:608	n=187	604:608	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	40	from	population	685:694	arg1	controls					615:622	controls	615:622	controls (n=195) from the discovery population (n=348) and validation population (n=148)	615:702	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	40	from	population	685:694	arg1	individuals					560:570	496 individuals	556:570	496 individuals of ESCC (n=114)	556:586	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	40	from	population	685:694	arg1	n=195					625:629	n=195	625:629	n=195	625:629	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	0	41	theme	carcinoma	78:86	arg1	biomarkers					53:62	IgG N-glycosylation biomarkers	33:62	IgG N-glycosylation biomarkers of esophageal carcinoma	33:86	Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma.
36999031	1	42	dep	aging	168:172	arg1	status					202:207	status	202:207	status	202:207	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	10	43	theme	predictive	2184:2193	arg1	score					2155:2159	the proposed glycan score	2135:2159	the proposed glycan score	2135:2159	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	10	43	theme	predictive	2184:2193	arg1	markers					2195:2201	promising predictive markers	2174:2201	promising predictive markers for ESCC	2174:2210	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	6	44	theme	total	1506:1510	arg1	glycans					1524:1530	total neutral IgG glycans	1506:1530	total neutral IgG glycans	1506:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	1	45	theme	Immunoglobulin	110:123	arg1	IgG					128:130	IgG	128:130	IgG	128:130	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	45	theme	Immunoglobulin	110:123	arg1	G					125:125	Introduction Altered Immunoglobulin G	89:125	Introduction Altered Immunoglobulin G (IgG) N-glycosylation	89:147	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	11	46	theme	therapeutic	2432:2442	arg1	targets					2444:2450	potential therapeutic targets	2422:2450	potential therapeutic targets for personalized interventions of cancer progression	2422:2503	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	3	47	from	individuals	560:570	arg1	total					549:553	total	549:553	total	549:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	2	48	theme	N-glycosylation	379:393	arg1	progression					418:428	the carcinogenesis progression	399:428	the carcinogenesis progression of ESCC	399:436	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	2	48	theme	N-glycosylation	379:393	arg1	association					360:370	the association	356:370	the association of IgG N-glycosylation	356:393	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	11	49	theme	progression	2493:2503	arg1	interventions					2469:2481	personalized interventions	2456:2481	personalized interventions of cancer progression	2456:2503	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	4	50	theme	N-glycosylation	737:751	arg1	profile					753:759	IgG N-glycosylation profile	733:759	IgG N-glycosylation profile	733:759	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	0	51	theme	IgG	33:35	arg1	biomarkers					53:62	IgG N-glycosylation biomarkers	33:62	IgG N-glycosylation biomarkers of esophageal carcinoma	33:86	Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma.
36999031	5	52	theme	bootstrapping	945:957	arg1	procedure					959:967	the bootstrapping procedure	941:967	the bootstrapping procedure	941:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	2	53	theme	ESCC	433:436	arg1	progression					418:428	the carcinogenesis progression	399:428	the carcinogenesis progression of ESCC	399:436	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	2	53	theme	ESCC	433:436	arg1	association					360:370	the association	356:370	the association of IgG N-glycosylation	356:393	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	7	54	theme	increased	1850:1858	arg1	risk					1860:1863	an increased risk	1847:1863	an increased risk (OR: 11.41)	1847:1875	Individuals in the highest tertile of the glycan score own an increased risk (OR: 11.41), compared with those in the lowest.
36999031	7	54	theme	increased	1850:1858	arg1	OR					1866:1867	OR: 11.41	1866:1874	OR: 11.41	1866:1874	Individuals in the highest tertile of the glycan score own an increased risk (OR: 11.41), compared with those in the lowest.
36999031	6	55	theme	neutral	1310:1316	arg1	glycans					1322:1328	total neutral IgG glycans	1304:1328	total neutral IgG glycans	1304:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	8	56	theme	multi-class	1925:1935	arg1	0.822					1945:1949	0.822	1945:1949	0.822	1945:1949	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	8	56	theme	multi-class	1925:1935	arg1	AUC					1937:1939	The average multi-class AUC	1913:1939	The average multi-class AUC	1913:1939	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	10	57	theme	early	2233:2237	arg1	prevention					2239:2248	the early prevention	2229:2248	the early prevention of esophageal cancer	2229:2269	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	6	58	from	structures	1373:1382	arg1	glycans					1405:1411	total neutral IgG glycans	1387:1411	total neutral IgG glycans	1387:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	59	theme	total	1387:1391	arg1	glycans					1405:1411	total neutral IgG glycans	1387:1411	total neutral IgG glycans	1387:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	60	from	percentage	1343:1352	arg1	glycans					1405:1411	total neutral IgG glycans	1387:1411	total neutral IgG glycans	1387:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	5	61	with	curve	930:934	arg1	procedure					959:967	the bootstrapping procedure	941:967	the bootstrapping procedure	941:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	7	62	theme	glycan	1830:1835	arg1	score					1837:1841	the glycan score	1826:1841	the glycan score	1826:1841	Individuals in the highest tertile of the glycan score own an increased risk (OR: 11.41), compared with those in the lowest.
36999031	6	63	theme	structures	1373:1382	arg1	percentage					1343:1352	the percentage	1339:1352	the percentage of all fucosylated structures in total neutral IgG glycans	1339:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	1	64	theme	esophageal	230:239	arg1	carcinoma					255:263	esophageal squamous cell carcinoma	230:263	esophageal squamous cell carcinoma (ESCC)	230:270	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	64	theme	esophageal	230:239	arg1	ESCC					266:269	ESCC	266:269	ESCC	266:269	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	9	65	dep	CI	2060:2061	arg1	0.758-0.864					2064:2074	0.758-0.864	2064:2074	0.758-0.864	2064:2074	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	3	66	theme	discovery	641:649	arg1	n=348					663:667	n=348	663:667	n=348	663:667	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	66	theme	discovery	641:649	arg1	population					651:660	the discovery population	637:660	the discovery population (n=348)	637:668	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	6	67	theme	monosyalilated	1200:1213	arg1	structures					1232:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	2	68	theme	first	320:324	arg1	this					308:311	this	308:311	this	308:311	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	2	68	theme	first	320:324	arg1	study					326:330	the first study	316:330	the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC	316:436	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	1	69	theme	cell	250:253	arg1	carcinoma					255:263	esophageal squamous cell carcinoma	230:263	esophageal squamous cell carcinoma (ESCC)	230:270	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	69	theme	cell	250:253	arg1	ESCC					266:269	ESCC	266:269	ESCC	266:269	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	8	70	theme	%	1954:1954	arg1	CI					1956:1957	95% CI	1952:1957	95% CI: 0.786-0.849	1952:1970	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	4	71	theme	glycan	794:799	arg1	score					801:805	an ESCC-related glycan score	778:805	an ESCC-related glycan score	778:805	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	3	72	from	precancerosis	589:601	arg1	total					549:553	total	549:553	total	549:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	6	73	theme	digalactosylated	1087:1102	arg1	biantennary					1119:1129	digalactosylated monosialylated biantennary	1087:1129	digalactosylated monosialylated biantennary with core	1087:1139	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	0	74	theme	biomarkers	53:62	arg1	validation					19:28	validation	19:28	validation	19:28	Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma.
36999031	0	74	theme	biomarkers	53:62	arg1	Identification					0:13	Identification	0:13	Identification	0:13	Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma.
36999031	3	75	from	population	651:660	arg1	precancerosis					589:601	precancerosis	589:601	precancerosis (n=187)	589:609	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	75	from	population	651:660	arg1	Methods					538:544	Methods	538:544	Methods In total	538:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	75	from	population	651:660	arg1	n=187					604:608	n=187	604:608	n=187	604:608	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	75	from	population	651:660	arg1	controls					615:622	controls	615:622	controls (n=195) from the discovery population (n=348) and validation population (n=148)	615:702	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	75	from	population	651:660	arg1	individuals					560:570	496 individuals	556:570	496 individuals of ESCC (n=114)	556:586	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	75	from	population	651:660	arg1	n=195					625:629	n=195	625:629	n=195	625:629	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	11	76	theme	biological	2296:2305	arg1	mechanism					2307:2315	biological mechanism	2296:2315	biological mechanism	2296:2315	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	9	77	theme	validation	2003:2012	arg1	population					2014:2023	the validation population	1999:2023	the validation population	1999:2023	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	4	78	theme	logistic	842:849	arg1	model					851:855	a stepwise ordinal logistic model	823:855	a stepwise ordinal logistic model in the discovery population	823:883	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	10	79	theme	cancer	2264:2269	arg1	prevention					2239:2248	the early prevention	2229:2248	the early prevention of esophageal cancer	2229:2269	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	6	80	dep	GP20	1081:1084	arg1	fucose					1155:1160	antennary fucose	1145:1160	antennary fucose	1145:1160	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	80	dep	GP20	1081:1084	arg1	biantennary					1119:1129	digalactosylated monosialylated biantennary	1087:1129	digalactosylated monosialylated biantennary with core	1087:1139	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	5	81	used	used	973:976	arg2	curve					930:934	The receiver operating characteristic (ROC) curve	886:934	The receiver operating characteristic (ROC) curve with the bootstrapping procedure	886:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	6	82	theme	IgG	1401:1403	arg1	glycans					1405:1411	total neutral IgG glycans	1387:1411	total neutral IgG glycans	1387:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	5	83	theme	glycan	1011:1016	arg1	score					1018:1022	the glycan score	1007:1022	the glycan score	1007:1022	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	10	84	dep	Discussion	2078:2087	arg1	demonstrated					2099:2110	demonstrated	2099:2110	demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer	2099:2269	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	6	85	theme	digalactosylated	1475:1490	arg1	structures					1492:1501	all fucosylated digalactosylated structures	1459:1501	all fucosylated digalactosylated structures in total neutral IgG glycans	1459:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	86	dep	%	1567:1567	arg1	P<0.001					1584:1590	P<0.001	1584:1590	P<0.001	1584:1590	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	87	theme	antennary	1145:1153	arg1	fucose					1155:1160	antennary fucose	1145:1160	antennary fucose	1145:1160	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	3	88	from	Methods	538:544	arg1	total					549:553	total	549:553	total	549:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	6	89	theme	disialylated	1219:1230	arg1	structures					1232:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	90	from	structures	1492:1501	arg1	glycans					1524:1530	total neutral IgG glycans	1506:1530	total neutral IgG glycans	1506:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	91	with	fucose	1155:1160	arg1	core					1136:1139	core	1136:1139	core	1136:1139	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	4	92	theme	stepwise	825:832	arg1	model					851:855	a stepwise ordinal logistic model	823:855	a stepwise ordinal logistic model in the discovery population	823:883	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	6	93	theme	glycan	1542:1547	arg1	score					1549:1553	the glycan score	1538:1553	the glycan score	1538:1553	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	93	theme	glycan	1542:1547	arg1	GP20					1081:1084	GP20	1081:1084	GP20	1081:1084	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	94	theme	total	1304:1308	arg1	glycans					1322:1328	total neutral IgG glycans	1304:1328	total neutral IgG glycans	1304:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	95	from	glycans	1322:1328	arg1	proportion					1256:1265	the proportion	1252:1265	the proportion of high mannose glycan structures in total neutral IgG glycans	1252:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	9	96	theme	0.807	2049:2053	arg1	AUC					2042:2044	an average AUC	2031:2044	an average AUC of 0.807 (95% CI: 0.758-0.864)	2031:2075	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	6	97	theme	GlcNAc	1449:1454	arg1	incidence					1426:1434	the incidence	1422:1434	the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans	1422:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	98	gly	fucosylated	1188:1198	arg1	structures					1232:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	all fucosylated monosyalilated and disialylated structures	1184:1241	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	8	99	dep	CI	1956:1957	arg1	0.786-0.849					1960:1970	0.786-0.849	1960:1970	0.786-0.849	1960:1970	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	6	100	theme	structures	1290:1299	arg1	proportion					1256:1265	the proportion	1252:1265	the proportion of high mannose glycan structures in total neutral IgG glycans	1252:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	101	gly	fucosylated	1361:1371	arg1	structures					1373:1382	all fucosylated structures	1357:1382	all fucosylated structures in total neutral IgG glycans	1357:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	9	102	theme	95	2056:2057	arg1	%					2058:2058	%	2058:2058	%	2058:2058	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	2	103	theme	innovative	449:458	arg1	biomarkers					460:469	innovative biomarkers	449:469	innovative biomarkers	449:469	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	10	104	theme	IgG	2117:2119	arg1	N-glycans					2121:2129	IgG N-glycans	2117:2129	IgG N-glycans	2117:2129	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	6	105	theme	mannose	1275:1281	arg1	structures					1290:1299	high mannose glycan structures	1270:1299	high mannose glycan structures in total neutral IgG glycans	1270:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	5	106	theme	receiver	890:897	arg1	curve					930:934	The receiver operating characteristic (ROC) curve	886:934	The receiver operating characteristic (ROC) curve with the bootstrapping procedure	886:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	6	107	dep	0.69	1594:1597	arg1	%					1602:1602	95% CI: 0.55-0.87	1600:1616	95% CI: 0.55-0.87	1600:1616	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	107	dep	0.69	1594:1597	arg1	P<0.001					1619:1625	P<0.001	1619:1625	P<0.001	1619:1625	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	4	108	theme	discovery	864:872	arg1	population					874:883	the discovery population	860:883	the discovery population	860:883	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	11	109	theme	potential	2422:2430	arg1	targets					2444:2450	potential therapeutic targets	2422:2450	potential therapeutic targets for personalized interventions of cancer progression	2422:2503	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	8	110	dep	0.822	1945:1949	arg1	CI					1956:1957	95% CI	1952:1957	95% CI: 0.786-0.849	1952:1970	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	6	111	from	proportion	1256:1265	arg1	glycans					1322:1328	total neutral IgG glycans	1304:1328	total neutral IgG glycans	1304:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	2	112	theme	ESCC	532:535	arg1	identification					490:503	predictive identification	479:503	predictive identification	479:503	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	2	112	theme	ESCC	532:535	arg1	prevention					518:527	targeted prevention	509:527	targeted prevention	509:527	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	5	113	theme	characteristic	909:922	arg1	curve					930:934	The receiver operating characteristic (ROC) curve	886:934	The receiver operating characteristic (ROC) curve with the bootstrapping procedure	886:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	2	114	theme	predictive	479:488	arg1	identification					490:503	predictive identification	479:503	predictive identification	479:503	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	10	115	theme	proposed	2139:2146	arg1	score					2155:2159	the proposed glycan score	2135:2159	the proposed glycan score	2135:2159	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	10	115	theme	proposed	2139:2146	arg1	markers					2195:2201	promising predictive markers	2174:2201	promising predictive markers for ESCC	2174:2210	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	3	116	theme	validation	674:683	arg1	population					685:694	validation population	674:694	validation population (n=148)	674:702	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	3	116	theme	validation	674:683	arg1	n=148					697:701	n=148	697:701	n=148	697:701	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	6	117	theme	neutral	1512:1518	arg1	glycans					1524:1530	total neutral IgG glycans	1506:1530	total neutral IgG glycans	1506:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	118	from	glycans	1405:1411	arg1	percentage					1343:1352	the percentage	1339:1352	the percentage of all fucosylated structures in total neutral IgG glycans	1339:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	2	119	theme	carcinogenesis	403:416	arg1	progression					418:428	the carcinogenesis progression	399:428	the carcinogenesis progression of ESCC	399:436	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	10	120	theme	promising	2174:2182	arg1	score					2155:2159	the proposed glycan score	2135:2159	the proposed glycan score	2135:2159	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	10	120	theme	promising	2174:2182	arg1	markers					2195:2201	promising predictive markers	2174:2201	promising predictive markers for ESCC	2174:2210	Discussion Our study demonstrated that IgG N-glycans and the proposed glycan score appear to be promising predictive markers for ESCC, contributing to the early prevention of esophageal cancer.
36999031	11	121	theme	carcinogenesis	2374:2387	arg1	progression					2389:2399	the carcinogenesis progression	2370:2399	the carcinogenesis progression of ESCC	2370:2407	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	2	122	dep	identification	490:503	arg1	the					475:477	the	475:477	the	475:477	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	1	123	theme	G	125:125	arg1	N-glycosylation					133:147	Introduction Altered Immunoglobulin G (IgG) N-glycosylation	89:147	Introduction Altered Immunoglobulin G (IgG) N-glycosylation	89:147	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	9	124	dep	0.807	2049:2053	arg1	CI					2060:2061	95% CI	2056:2061	95% CI: 0.758-0.864	2056:2074	Findings are verified in the validation population, with an average AUC of 0.807 (95% CI: 0.758-0.864).
36999031	6	125	from	incidence	1426:1434	arg1	structures					1492:1501	all fucosylated digalactosylated structures	1459:1501	all fucosylated digalactosylated structures in total neutral IgG glycans	1459:1530	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	2	126	theme	IgG	375:377	arg1	N-glycosylation					379:393	IgG N-glycosylation	375:393	IgG N-glycosylation	375:393	As far as we know, this is the first study to explore and validate the association of IgG N-glycosylation and the carcinogenesis progression of ESCC, providing innovative biomarkers for the predictive identification and targeted prevention of ESCC.
36999031	0	127	theme	N-glycosylation	37:51	arg1	biomarkers					53:62	IgG N-glycosylation biomarkers	33:62	IgG N-glycosylation biomarkers of esophageal carcinoma	33:86	Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma.
36999031	4	128	theme	IgG	733:735	arg1	profile					753:759	IgG N-glycosylation profile	733:759	IgG N-glycosylation profile	733:759	IgG N-glycosylation profile was analyzed and an ESCC-related glycan score was composed by a stepwise ordinal logistic model in the discovery population.
36999031	6	129	theme	IgG	1318:1320	arg1	glycans					1322:1328	total neutral IgG glycans	1304:1328	total neutral IgG glycans	1304:1328	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	130	dep	IGP58	1332:1336	arg1	percentage					1343:1352	the percentage	1339:1352	the percentage of all fucosylated structures in total neutral IgG glycans	1339:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	131	dep	Results	1025:1031	arg1	adjusted					1066:1073	adjusted	1066:1073	adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively	1066:1785	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	6	132	theme	neutral	1393:1399	arg1	glycans					1405:1411	total neutral IgG glycans	1387:1411	total neutral IgG glycans	1387:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	8	133	theme	average	1917:1923	arg1	0.822					1945:1949	0.822	1945:1949	0.822	1945:1949	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	8	133	theme	average	1917:1923	arg1	AUC					1937:1939	The average multi-class AUC	1913:1939	The average multi-class AUC	1913:1939	The average multi-class AUC are 0.822 (95% CI: 0.786-0.849).
36999031	5	134	theme	ROC	925:927	arg1	curve					930:934	The receiver operating characteristic (ROC) curve	886:934	The receiver operating characteristic (ROC) curve with the bootstrapping procedure	886:967	The receiver operating characteristic (ROC) curve with the bootstrapping procedure was used to assess the performance of the glycan score.
36999031	6	135	theme	discovery	1040:1048	arg1	population					1050:1059	the discovery population	1036:1059	the discovery population	1036:1059	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	11	136	theme	ESCC	2404:2407	arg1	progression					2389:2399	the carcinogenesis progression	2370:2399	the carcinogenesis progression of ESCC	2370:2407	From the perspective of biological mechanism, IgG fucosylation and mannosylation might involve in the carcinogenesis progression of ESCC, and provide potential therapeutic targets for personalized interventions of cancer progression.
36999031	3	137	from	controls	615:622	arg1	total					549:553	total	549:553	total	549:553	Methods In total, 496 individuals of ESCC (n=114), precancerosis (n=187) and controls (n=195) from the discovery population (n=348) and validation population (n=148) were recruited in the study.
36999031	7	138	theme	score	1837:1841	arg1	tertile					1815:1821	the highest tertile	1803:1821	the highest tertile of the glycan score	1803:1841	Individuals in the highest tertile of the glycan score own an increased risk (OR: 11.41), compared with those in the lowest.
36999031	6	139	theme	fucosylated	1361:1371	arg1	structures					1373:1382	all fucosylated structures	1357:1382	all fucosylated structures in total neutral IgG glycans	1357:1411	Results In the discovery population, the adjusted OR of GP20 (digalactosylated monosialylated biantennary with core and antennary fucose), IGP33 (the ratio of all fucosylated monosyalilated and disialylated structures), IGP44 (the proportion of high mannose glycan structures in total neutral IgG glycans), IGP58 (the percentage of all fucosylated structures in total neutral IgG glycans), IGP75 (the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total neutral IgG glycans), and the glycan score are 4.03 (95% CI: 3.03-5.36, P<0.001), 0.69 (95% CI: 0.55-0.87, P<0.001), 0.56 (95% CI: 0.45-0.69, P<0.001), 0.52 (95% CI: 0.41-0.65, P<0.001), 7.17 (95% CI: 4.77-10.79, P<0.001), and 2.86 (95% CI: 2.33-3.53, P<0.001), respectively.
36999031	1	140	theme	squamous	241:248	arg1	carcinoma					255:263	esophageal squamous cell carcinoma	230:263	esophageal squamous cell carcinoma (ESCC)	230:270	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
36999031	1	140	theme	squamous	241:248	arg1	ESCC					266:269	ESCC	266:269	ESCC	266:269	Introduction Altered Immunoglobulin G (IgG) N-glycosylation is associated with aging, inflammation, and diseases status, while its effect on esophageal squamous cell carcinoma (ESCC) remains unknown.
35481895	0	0	theme	S-layer	86:92	arg1	protein					94:100	the PGF-CTERM sorting domain-containing S-layer protein	46:100	the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri	46:129	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	4	1	from	O-glycosylated	873:886	arg1	contrast					741:748	contrast	741:748	contrast	741:748	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	10	2	from	report	1758:1763	arg1	archaeon					1797:1804	an archaeon	1794:1804	an archaeon from the Order Methanomicrobiales	1794:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	2	from	report	1758:1763	arg1	Methanomicrobiales					1821:1838	the Order Methanomicrobiales	1811:1838	the Order Methanomicrobiales	1811:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	7	3	theme	threonine-rich	1291:1304	arg1	region					1306:1311	the threonine-rich region	1287:1311	the threonine-rich region near the C-terminus with O-glycans composed exclusively of hexoses	1287:1378	The S-layer protein is also extensively modified in the threonine-rich region near the C-terminus with O-glycans composed exclusively of hexoses.
35481895	0	4	theme	domain-containing	68:84	arg1	protein					94:100	the PGF-CTERM sorting domain-containing S-layer protein	46:100	the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri	46:129	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	7	5	with	region	1306:1311	arg1	O-glycans					1338:1346	O-glycans	1338:1346	O-glycans composed exclusively of hexoses	1338:1378	The S-layer protein is also extensively modified in the threonine-rich region near the C-terminus with O-glycans composed exclusively of hexoses.
35481895	8	6	theme	S-layer	1391:1397	arg1	protein					1399:1405	the S-layer protein	1387:1405	the S-layer protein	1387:1405	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	7	theme	expected	1507:1514	arg1	product					1516:1522	the expected product	1503:1522	the expected product of processing by an archaeosortase	1503:1557	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	7	theme	expected	1507:1514	arg1	C-terminus					1491:1500	a truncated and lipidated C-terminus	1465:1500	a truncated and lipidated C-terminus	1465:1500	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	4	8	from	N-	866:867	arg1	contrast					741:748	contrast	741:748	contrast	741:748	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	9	theme	constituent	713:723	arg1	archaellins					725:735	the constituent archaellins	709:735	the constituent archaellins	709:735	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	3	10	theme	mesophilic	537:546	arg1	methanogen					548:557	a mesophilic methanogen	535:557	a mesophilic methanogen from the Order Methanomicrobiales	535:591	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	3	10	theme	mesophilic	537:546	arg1	marisnigri					523:532	Methanoculleus marisnigri	508:532	Methanoculleus marisnigri	508:532	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	8	11	theme	C-terminus	1491:1500	arg1	evidence					1453:1460	no evidence	1450:1460	no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase,	1450:1558	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	4	12	theme	mass	605:608	arg1	MS					624:625	MS	624:625	MS	624:625	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	12	theme	mass	605:608	arg1	spectrometry					610:621	mass spectrometry	605:621	mass spectrometry (MS) analysis of purified archaella	605:657	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	0	13	theme	protein	94:100	arg1	N-					19:20	N-	19:20	N-	19:20	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	0	13	theme	protein	94:100	arg1	glycans					35:41	O-linked glycans	26:41	O-linked glycans	26:41	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	4	14	theme	S-layer	755:761	arg1	protein					763:769	the S-layer protein	751:769	the S-layer protein	751:769	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	14	theme	S-layer	755:761	arg1	N-					866:867	N-	866:867	N-	866:867	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	8	15	contain	has	1407:1409	arg2	site					1444:1447	a predicted PGF-CTERM processing site	1411:1447	a predicted PGF-CTERM processing site	1411:1447	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	15	contain	has	1407:1409	arg1	protein					1399:1405	the S-layer protein	1387:1405	the S-layer protein	1387:1405	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	5	16	theme	MS	930:931	arg1	analysis					933:940	MS analysis	930:940	MS analysis	930:940	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	0	17	theme	marisnigri	120:129	arg1	protein					94:100	the PGF-CTERM sorting domain-containing S-layer protein	46:100	the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri	46:129	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	3	18	theme	O-glycan	472:479	arg1	investigation					444:456	our investigation	440:456	our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales	440:591	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	8	19	theme	PGF-CTERM	1423:1431	arg1	site					1444:1447	a predicted PGF-CTERM processing site	1411:1447	a predicted PGF-CTERM processing site	1411:1447	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	1	20	theme	widespread	178:187	arg1	modification					207:218	a widespread posttranslational modification	176:218	a widespread posttranslational modification in Archaea	176:229	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	1	20	theme	widespread	178:187	arg1	glycosylation					136:148	The glycosylation	132:148	The glycosylation of structural proteins	132:171	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	0	21	theme	Methanoculleus	105:118	arg1	marisnigri					120:129	Methanoculleus marisnigri	105:129	Methanoculleus marisnigri	105:129	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	10	22	theme	first	1752:1756	arg1	This					1740:1743	This	1740:1743	This	1740:1743	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	22	theme	first	1752:1756	arg1	report					1758:1763	the first report	1748:1763	the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales	1748:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	8	23	theme	predicted	1413:1421	arg1	site					1444:1447	a predicted PGF-CTERM processing site	1411:1447	a predicted PGF-CTERM processing site	1411:1447	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	5	24	theme	second	1007:1012	arg1	2-N-acetyl					1025:1034	2-N-acetyl	1025:1034	2-N-acetyl	1025:1034	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	5	24	theme	second	1007:1012	arg1	residue					1014:1020	the second residue	1003:1020	the second residue	1003:1020	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	1	25	theme	posttranslational	189:205	arg1	modification					207:218	a widespread posttranslational modification	176:218	a widespread posttranslational modification in Archaea	176:229	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	1	25	theme	posttranslational	189:205	arg1	glycosylation					136:148	The glycosylation	132:148	The glycosylation of structural proteins	132:171	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	6	26	theme	type	1220:1223	arg1	pilin					1228:1232	a type IV pilin	1218:1232	a type IV pilin	1218:1232	The same trisaccharide was also found N-linked to a type IV pilin.
35481895	3	27	theme	Order	568:572	arg1	Methanomicrobiales					574:591	the Order Methanomicrobiales	564:591	the Order Methanomicrobiales	564:591	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	10	28	theme	N-	1768:1769	arg1	This					1740:1743	This	1740:1743	This	1740:1743	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	28	theme	N-	1768:1769	arg1	report					1758:1763	the first report	1748:1763	the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales	1748:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	5	29	dep	identified	908:917	arg1	α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn					959:995	a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn	943:995	a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide	943:1165	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	4	30	theme	sorting	798:804	arg1	protein					824:830	a PGF-CTERM sorting domain-containing protein	786:830	a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690	786:855	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	0	31	link	O-linked	26:33	arg1	glycans					35:41	O-linked glycans	26:41	O-linked glycans	26:41	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	9	32	theme	tetrasaccharide	1672:1686	arg1	unit					1688:1691	a repeating tetrasaccharide unit	1660:1691	a repeating tetrasaccharide unit of [-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-	1660:1736	Finally, NMR also identified a polysaccharide expressed by M. marisnigri and composed of a repeating tetrasaccharide unit of [-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-].
35481895	8	33	theme	processing	1433:1442	arg1	site					1444:1447	a predicted PGF-CTERM processing site	1411:1447	a predicted PGF-CTERM processing site	1411:1447	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	10	34	theme	Order	1815:1819	arg1	Methanomicrobiales					1821:1838	the Order Methanomicrobiales	1811:1838	the Order Methanomicrobiales	1811:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	5	35	theme	terminal	1119:1126	arg1	residue					1128:1134	the terminal residue	1115:1134	the terminal residue	1115:1134	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	5	35	theme	terminal	1119:1126	arg1	di-N-acetyl-glucosamide					1143:1165	2,3 di-N-acetyl-glucosamide	1139:1165	2,3 di-N-acetyl-glucosamide	1139:1165	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	5	36	theme	trisaccharide	945:957	arg1	α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn					959:995	a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn	943:995	a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide	943:1165	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	6	37	theme	same	1172:1175	arg1	trisaccharide					1177:1189	The same trisaccharide	1168:1189	The same trisaccharide	1168:1189	The same trisaccharide was also found N-linked to a type IV pilin.
35481895	4	38	theme	archaella	649:657	arg1	analysis					628:635	mass spectrometry (MS) analysis	605:635	mass spectrometry (MS) analysis of purified archaella	605:657	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	2	39	theme	archaeal	259:266	arg1	structures					277:286	archaeal N-glycan structures	259:286	archaeal N-glycan structures	259:286	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	3	40	from	Methanomicrobiales	574:591	arg1	methanogen					548:557	a mesophilic methanogen	535:557	a mesophilic methanogen from the Order Methanomicrobiales	535:591	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	3	40	from	Methanomicrobiales	574:591	arg1	marisnigri					523:532	Methanoculleus marisnigri	508:532	Methanoculleus marisnigri	508:532	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	2	41	theme	life	415:418	arg1	life					415:418	life	415:418	life	415:418	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	2	41	theme	life	415:418	arg1	domains					404:410	the other domains	394:410	the other domains of life	394:418	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	0	42	theme	O-linked	26:33	arg1	glycans					35:41	O-linked glycans	26:41	O-linked glycans	26:41	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	1	43	gly	glycosylation	136:148	arg1	proteins					164:171	structural proteins	153:171	structural proteins	153:171	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	4	44	theme	domain-containing	806:822	arg1	protein					824:830	a PGF-CTERM sorting domain-containing protein	786:830	a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690	786:855	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	45	theme	purified	640:647	arg1	archaella					649:657	purified archaella	640:657	purified archaella	640:657	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	5	46	theme	2,3	1139:1141	arg1	residue					1128:1134	the terminal residue	1115:1134	the terminal residue	1115:1134	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	5	46	theme	2,3	1139:1141	arg1	di-N-acetyl-glucosamide					1143:1165	2,3 di-N-acetyl-glucosamide	1139:1165	2,3 di-N-acetyl-glucosamide	1139:1165	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	8	47	theme	truncated	1467:1475	arg1	product					1516:1522	the expected product	1503:1522	the expected product of processing by an archaeosortase	1503:1557	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	47	theme	truncated	1467:1475	arg1	C-terminus					1491:1500	a truncated and lipidated C-terminus	1465:1500	a truncated and lipidated C-terminus	1465:1500	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	2	48	theme	structures	354:363	arg1	greater					378:384	greater	378:384	greater	378:384	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	2	48	theme	structures	354:363	arg1	diversity					341:349	the diversity	337:349	the diversity of structures expressed	337:373	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	3	49	dep	N-	465:466	arg1	modifications					481:493	modifications	481:493	modifications	481:493	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	3	49	dep	N-	465:466	arg1	the					461:463	the	461:463	the	461:463	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	5	50	theme	disaccharide	1068:1079	arg1	β-GlcNAc3NAcAN-4-β-Glc-Asn					1081:1106	a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn	1066:1106	a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn	1066:1106	Two N-glycans were identified by NMR and MS analysis: a trisaccharide α-GlcNAc-4-β-GlcNAc3NGaAN-4-β-Glc-Asn where the second residue is 2-N-acetyl, 3-N-glyceryl-glucosamide and a disaccharide β-GlcNAc3NAcAN-4-β-Glc-Asn, where the terminal residue is 2,3 di-N-acetyl-glucosamide.
35481895	10	51	theme	O-glycosylation	1775:1789	arg1	This					1740:1743	This	1740:1743	This	1740:1743	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	51	theme	O-glycosylation	1775:1789	arg1	report					1758:1763	the first report	1748:1763	the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales	1748:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	52	from	Methanomicrobiales	1821:1838	arg1	This					1740:1743	This	1740:1743	This	1740:1743	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	52	from	Methanomicrobiales	1821:1838	arg1	archaeon					1797:1804	an archaeon	1794:1804	an archaeon from the Order Methanomicrobiales	1794:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	10	52	from	Methanomicrobiales	1821:1838	arg1	report					1758:1763	the first report	1748:1763	the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales	1748:1838	This is the first report of N- and O-glycosylation in an archaeon from the Order Methanomicrobiales.
35481895	4	53	theme	PGF-CTERM	788:796	arg1	protein					824:830	a PGF-CTERM sorting domain-containing protein	786:830	a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690	786:855	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	54	gly	O-glycosylation	690:704	arg1	archaellins					725:735	the constituent archaellins	709:735	the constituent archaellins	709:735	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	8	55	theme	processing	1527:1536	arg1	product					1516:1522	the expected product	1503:1522	the expected product of processing by an archaeosortase	1503:1557	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	55	theme	processing	1527:1536	arg1	C-terminus					1491:1500	a truncated and lipidated C-terminus	1465:1500	a truncated and lipidated C-terminus	1465:1500	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	56	theme	lipidated	1481:1489	arg1	product					1516:1522	the expected product	1503:1522	the expected product of processing by an archaeosortase	1503:1557	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	8	56	theme	lipidated	1481:1489	arg1	C-terminus					1491:1500	a truncated and lipidated C-terminus	1465:1500	a truncated and lipidated C-terminus	1465:1500	While the S-layer protein has a predicted PGF-CTERM processing site, no evidence of a truncated and lipidated C-terminus, the expected product of processing by an archaeosortase, was found.
35481895	9	57	theme	[-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-	1696:1736	arg1	unit					1688:1691	a repeating tetrasaccharide unit	1660:1691	a repeating tetrasaccharide unit of [-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-	1660:1736	Finally, NMR also identified a polysaccharide expressed by M. marisnigri and composed of a repeating tetrasaccharide unit of [-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-].
35481895	3	58	theme	N-	465:466	arg1	investigation					444:456	our investigation	440:456	our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales	440:591	Here, we report on our investigation of the N- and O-glycan modifications expressed by Methanoculleus marisnigri, a mesophilic methanogen from the Order Methanomicrobiales.
35481895	6	59	theme	IV	1225:1226	arg1	pilin					1228:1232	a type IV pilin	1218:1232	a type IV pilin	1218:1232	The same trisaccharide was also found N-linked to a type IV pilin.
35481895	0	60	dep	N-	19:20	arg1	the					15:17	the	15:17	the	15:17	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	1	61	from	modification	207:218	arg1	Archaea					223:229	Archaea	223:229	Archaea	223:229	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	4	62	theme	archaellins	725:735	arg1	O-glycosylation					690:704	O-glycosylation	690:704	O-glycosylation	690:704	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	62	theme	archaellins	725:735	arg1	N-					684:685	N-	684:685	N-	684:685	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	4	63	theme	spectrometry	610:621	arg1	analysis					628:635	mass spectrometry (MS) analysis	605:635	mass spectrometry (MS) analysis of purified archaella	605:657	Unusually, mass spectrometry (MS) analysis of purified archaella revealed no evidence for N- or O-glycosylation of the constituent archaellins, In contrast, the S-layer protein, identified as a PGF-CTERM sorting domain-containing protein encoded by MEMAR_RS02690, is both N- and O-glycosylated.
35481895	0	64	theme	sorting	60:66	arg1	protein					94:100	the PGF-CTERM sorting domain-containing S-layer protein	46:100	the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri	46:129	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	2	65	theme	structures	277:286	arg1	handful					248:254	only a handful	241:254	only a handful of archaeal N-glycan structures	241:286	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	1	66	theme	structural	153:162	arg1	proteins					164:171	structural proteins	153:171	structural proteins	153:171	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	2	67	theme	other	398:402	arg1	life					415:418	life	415:418	life	415:418	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	2	67	theme	other	398:402	arg1	domains					404:410	the other domains	394:410	the other domains of life	394:418	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	0	68	theme	PGF-CTERM	50:58	arg1	protein					94:100	the PGF-CTERM sorting domain-containing S-layer protein	46:100	the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri	46:129	Characterizing the N- and O-linked glycans of the PGF-CTERM sorting domain-containing S-layer protein of Methanoculleus marisnigri.
35481895	7	69	theme	S-layer	1239:1245	arg1	protein					1247:1253	The S-layer protein	1235:1253	The S-layer protein	1235:1253	The S-layer protein is also extensively modified in the threonine-rich region near the C-terminus with O-glycans composed exclusively of hexoses.
35481895	2	70	theme	N-glycan	268:275	arg1	structures					277:286	archaeal N-glycan structures	259:286	archaeal N-glycan structures	259:286	Although only a handful of archaeal N-glycan structures have been determined to date, it is evident that the diversity of structures expressed is greater than in the other domains of life.
35481895	1	71	theme	proteins	164:171	arg1	glycosylation					136:148	The glycosylation	132:148	The glycosylation of structural proteins	132:171	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	1	71	theme	proteins	164:171	arg1	modification					207:218	a widespread posttranslational modification	176:218	a widespread posttranslational modification in Archaea	176:229	The glycosylation of structural proteins is a widespread posttranslational modification in Archaea.
35481895	9	72	theme	repeating	1662:1670	arg1	unit					1688:1691	a repeating tetrasaccharide unit	1660:1691	a repeating tetrasaccharide unit of [-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-	1660:1736	Finally, NMR also identified a polysaccharide expressed by M. marisnigri and composed of a repeating tetrasaccharide unit of [-2-β-Ribf-3-α-Rha2OMe-3-α-Rha - 2-α-Rha-].
36870092	8	0	theme	fragment	1255:1262	arg1	ions					1264:1267	structure-diagnostic fragment ions	1234:1267	structure-diagnostic fragment ions	1234:1267	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	9	1	theme	quantified	1281:1290	arg1	N-glycopeptides					1299:1313	1717 quantified intact N-glycopeptides	1276:1313	1717 quantified intact N-glycopeptides	1276:1313	Among 1717 quantified intact N-glycopeptides, 104 DEGPs were determined (fold change ≥ 1.5 and p value < 0.05).
36870092	6	2	theme	MCF-7	833:837	arg1	CSCs					839:842	ADR-sensitive MCF-7 CSCs	819:842	ADR-sensitive MCF-7 CSCs	819:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	5	3	theme	putative	640:647	arg1	markers					649:655	putative markers	640:655	putative markers	640:655	To the end, it is urgent to figure out the knowledge on cell-surface altered N-glycosylation and putative markers.
36870092	9	4	theme	104	1316:1318	arg1	DEGPs					1320:1324	104 DEGPs	1316:1324	104 DEGPs	1316:1324	Among 1717 quantified intact N-glycopeptides, 104 DEGPs were determined (fold change ≥ 1.5 and p value < 0.05).
36870092	10	5	with	N-glycopeptide	1519:1532	arg1	GlcNAc					1549:1554	bisecting GlcNAc	1539:1554	bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide	1539:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	10	5	with	N-glycopeptide	1519:1532	arg1	N-glycan					1644:1651	β1,6-branching N-glycan	1629:1651	β1,6-branching N-glycan from integrin beta-5	1629:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	6	6	from	N-glycopeptides	697:711	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	6	from	N-glycopeptides	697:711	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	10	7	from	protein	1577:1583	arg1	GlcNAc					1549:1554	bisecting GlcNAc	1539:1554	bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide	1539:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	7	8	gly	N-glycopeptides	935:949	arg2	N-glycopeptides					935:949	The intact N-glycopeptides	924:949	The intact N-glycopeptides	924:949	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	2	9	theme	mesenchymal	232:242	arg1	EMT					256:258	EMT	256:258	EMT	256:258	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	9	theme	mesenchymal	232:242	arg1	driver					281:286	a driver	279:286	a driver of cancer which are responsible for cancer metastasis and drug resistance	279:360	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	9	theme	mesenchymal	232:242	arg1	transition					244:253	epithelial mesenchymal transition	221:253	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	9	theme	mesenchymal	232:242	arg1	responsible					308:318	responsible	308:318	responsible	308:318	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	9	theme	mesenchymal	232:242	arg1	cells					197:201	Cancer stem cells	185:201	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	10	10	from	N-glycopeptide	1609:1622	arg1	GlcNAc					1549:1554	bisecting GlcNAc	1539:1554	bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide	1539:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	5	11	from	knowledge	586:594	arg1	markers					649:655	putative markers	640:655	putative markers	640:655	To the end, it is urgent to figure out the knowledge on cell-surface altered N-glycosylation and putative markers.
36870092	5	11	from	knowledge	586:594	arg1	N-glycosylation					620:634	cell-surface altered N-glycosylation	599:634	cell-surface altered N-glycosylation	599:634	To the end, it is urgent to figure out the knowledge on cell-surface altered N-glycosylation and putative markers.
36870092	6	12	theme	differential	664:675	arg1	N-glycopeptides					697:711	differential cell-surface intact N-glycopeptides	664:711	differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	664:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	7	13	theme	search	1068:1073	arg1	engine					1075:1080	intact N-glycopeptide search engine	1046:1080	intact N-glycopeptide search engine GPSeeker	1046:1089	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	1	14	theme	mortality	155:163	arg1	all					165:167	the highest mortality all	143:167	the highest mortality all over the world	143:182	Breast cancer is responsible for the highest mortality all over the world.
36870092	0	15	theme	cancer	91:96	arg1	cells					103:107	MCF-7/ADR cancer stem cells	81:107	MCF-7/ADR cancer stem cells	81:107	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	7	16	theme	intact	1046:1051	arg1	engine					1075:1080	intact N-glycopeptide search engine	1046:1080	intact N-glycopeptide search engine GPSeeker	1046:1089	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	10	17	from	beta-5	1667:1672	arg1	N-glycan					1644:1651	β1,6-branching N-glycan	1629:1651	β1,6-branching N-glycan from integrin beta-5	1629:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	10	18	theme	intact	1602:1607	arg1	N-glycopeptide					1609:1622	up-regulated intact N-glycopeptide	1589:1622	up-regulated intact N-glycopeptide	1589:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	0	19	theme	cells	103:107	arg1	N-glycosylation					62:76	cell-surface N-glycosylation	49:76	cell-surface N-glycosylation of MCF-7/ADR cancer stem cells	49:107	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	10	20	theme	intact	1512:1517	arg1	N-glycopeptide					1519:1532	down-regulated intact N-glycopeptide	1497:1532	down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5	1497:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	5	21	theme	altered	612:618	arg1	N-glycosylation					620:634	cell-surface altered N-glycosylation	599:634	cell-surface altered N-glycosylation	599:634	To the end, it is urgent to figure out the knowledge on cell-surface altered N-glycosylation and putative markers.
36870092	4	22	theme	glycosylation	490:502	arg1	types					481:485	different types	471:485	different types of glycosylation which are involved in drug resistance	471:540	Additionally, glycosyltransferases regulate different types of glycosylation which are involved in drug resistance.
36870092	10	23	theme	protein-protein	1396:1410	arg1	interaction					1412:1422	protein-protein interaction	1396:1422	protein-protein interaction	1396:1422	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	10	24	gly	N-glycopeptide	1519:1532	arg2	N-glycopeptide					1519:1532	down-regulated intact N-glycopeptide	1497:1532	down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5	1497:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	0	25	theme	Structural	0:9	arg1	characterization					29:44	Structural N-glycoproteomics characterization	0:44	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.	0:108	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	8	26	theme	N-glycan	1149:1156	arg1	structures					1167:1176	N-glycan sequence structures	1149:1176	N-glycan sequence structures among 2764 IDs	1149:1191	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	3	27	theme	Several	363:369	arg1	pathways					381:388	Several signaling pathways	363:388	Several signaling pathways	363:388	Several signaling pathways are associated with drug resistance.
36870092	6	28	theme	ADR-sensitive	819:831	arg1	CSCs					839:842	ADR-sensitive MCF-7 CSCs	819:842	ADR-sensitive MCF-7 CSCs	819:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	10	29	theme	processes	1439:1447	arg1	Annotation					1382:1391	Annotation	1382:1391	Annotation of protein-protein interaction and biological processes among others of DEGPs	1382:1469	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	3	30	theme	drug	410:413	arg1	resistance					415:424	drug resistance	410:424	drug resistance	410:424	Several signaling pathways are associated with drug resistance.
36870092	10	31	theme	integrin	1658:1665	arg1	beta-5					1667:1672	integrin beta-5	1658:1672	integrin beta-5	1658:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	2	32	theme	stem	192:195	arg1	CSCs					204:207	CSCs	204:207	CSCs	204:207	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	32	theme	stem	192:195	arg1	driver					281:286	a driver	279:286	a driver of cancer which are responsible for cancer metastasis and drug resistance	279:360	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	32	theme	stem	192:195	arg1	cells					197:201	Cancer stem cells	185:201	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	32	theme	stem	192:195	arg1	responsible					308:318	responsible	308:318	responsible	308:318	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	32	theme	stem	192:195	arg1	transition					244:253	epithelial mesenchymal transition	221:253	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	6	33	theme	intact	690:695	arg1	N-glycopeptides					697:711	differential cell-surface intact N-glycopeptides	664:711	differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	664:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	0	34	theme	cell-surface	49:60	arg1	N-glycosylation					62:76	cell-surface N-glycosylation	49:76	cell-surface N-glycosylation of MCF-7/ADR cancer stem cells	49:107	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	8	35	theme	2764	1184:1187	arg1	IDs					1189:1191	2764 IDs	1184:1191	2764 IDs	1184:1191	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	6	36	theme	quantitative	892:903	arg1	N-glycoproteomics					905:921	structure-specific quantitative N-glycoproteomics	873:921	structure-specific quantitative N-glycoproteomics	873:921	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	10	37	theme	DEGPs	1465:1469	arg1	Annotation					1382:1391	Annotation	1382:1391	Annotation of protein-protein interaction and biological processes among others of DEGPs	1382:1469	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	10	38	theme	p38-interacting	1561:1575	arg1	protein					1577:1583	p38-interacting protein	1561:1583	p38-interacting protein	1561:1583	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	6	39	theme	stem	779:782	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	39	theme	stem	779:782	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	0	40	gly	N-glycosylation	62:76	arg1	cells					103:107	MCF-7/ADR cancer stem cells	81:107	MCF-7/ADR cancer stem cells	81:107	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	10	41	gly	N-glycopeptide	1609:1622	arg2	N-glycopeptide					1609:1622	up-regulated intact N-glycopeptide	1589:1622	up-regulated intact N-glycopeptide	1589:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	6	42	theme	cancer	759:764	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	42	theme	cancer	759:764	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	7	43	theme	expressed	970:978	arg1	DEGPs					1004:1008	DEGPs	1004:1008	DEGPs	1004:1008	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	7	43	theme	expressed	970:978	arg1	N-glycopeptides					987:1001	differentially expressed intact N-glycopeptides	955:1001	differentially expressed intact N-glycopeptides (DEGPs)	955:1009	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	6	44	theme	michigan	743:750	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	44	theme	michigan	743:750	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	2	45	theme	drug	346:349	arg1	resistance					351:360	drug resistance	346:360	drug resistance	346:360	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	8	46	theme	structure-diagnostic	1234:1253	arg1	ions					1264:1267	structure-diagnostic fragment ions	1234:1267	structure-diagnostic fragment ions	1234:1267	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	6	47	gly	N-glycopeptides	697:711	arg2	N-glycopeptides					697:711	differential cell-surface intact N-glycopeptides	664:711	differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	664:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	9	48	theme	intact	1292:1297	arg1	N-glycopeptides					1299:1313	1717 quantified intact N-glycopeptides	1276:1313	1717 quantified intact N-glycopeptides	1276:1313	Among 1717 quantified intact N-glycopeptides, 104 DEGPs were determined (fold change ≥ 1.5 and p value < 0.05).
36870092	7	49	theme	intact	928:933	arg1	N-glycopeptides					935:949	The intact N-glycopeptides	924:949	The intact N-glycopeptides	924:949	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	10	50	theme	down-regulated	1497:1510	arg1	N-glycopeptide					1519:1532	down-regulated intact N-glycopeptide	1497:1532	down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5	1497:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	6	51	theme	relative	807:814	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	51	theme	relative	807:814	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	10	52	theme	bisecting	1539:1547	arg1	GlcNAc					1549:1554	bisecting GlcNAc	1539:1554	bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide	1539:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	2	53	theme	cancer	291:296	arg1	responsible					308:318	responsible	308:318	responsible	308:318	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	53	theme	cancer	291:296	arg1	driver					281:286	a driver	279:286	a driver of cancer which are responsible for cancer metastasis and drug resistance	279:360	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	53	theme	cancer	291:296	arg1	transition					244:253	epithelial mesenchymal transition	221:253	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	53	theme	cancer	291:296	arg1	cells					197:201	Cancer stem cells	185:201	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	9	54	gly	N-glycopeptides	1299:1313	arg2	N-glycopeptides					1299:1313	1717 quantified intact N-glycopeptides	1276:1313	1717 quantified intact N-glycopeptides	1276:1313	Among 1717 quantified intact N-glycopeptides, 104 DEGPs were determined (fold change ≥ 1.5 and p value < 0.05).
36870092	4	55	theme	different	471:479	arg1	types					481:485	different types	471:485	different types of glycosylation which are involved in drug resistance	471:540	Additionally, glycosyltransferases regulate different types of glycosylation which are involved in drug resistance.
36870092	7	56	gly	N-glycopeptides	987:1001	arg2	N-glycopeptides					987:1001	differentially expressed intact N-glycopeptides	955:1001	differentially expressed intact N-glycopeptides (DEGPs)	955:1009	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	7	56	gly	N-glycopeptides	987:1001	arg2	DEGPs					1004:1008	DEGPs	1004:1008	DEGPs	1004:1008	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	6	57	theme	cell-surface	677:688	arg1	N-glycopeptides					697:711	differential cell-surface intact N-glycopeptides	664:711	differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	664:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	1	58	theme	highest	147:153	arg1	all					165:167	the highest mortality all	143:167	the highest mortality all over the world	143:182	Breast cancer is responsible for the highest mortality all over the world.
36870092	8	59	gly	N-glycopeptides	1113:1127	arg2	N-glycopeptides					1113:1127	4777 intact N-glycopeptides	1101:1127	4777 intact N-glycopeptides	1101:1127	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	0	60	theme	stem	98:101	arg1	cells					103:107	MCF-7/ADR cancer stem cells	81:107	MCF-7/ADR cancer stem cells	81:107	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	7	61	theme	engine	1075:1080	arg1	GPSeeker					1082:1089	intact N-glycopeptide search engine GPSeeker	1046:1089	intact N-glycopeptide search engine GPSeeker	1046:1089	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	4	62	theme	drug	526:529	arg1	resistance					531:540	drug resistance	526:540	drug resistance	526:540	Additionally, glycosyltransferases regulate different types of glycosylation which are involved in drug resistance.
36870092	8	63	theme	intact	1106:1111	arg1	N-glycopeptides					1113:1127	4777 intact N-glycopeptides	1101:1127	4777 intact N-glycopeptides	1101:1127	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	7	64	theme	N-glycopeptide	1053:1066	arg1	engine					1075:1080	intact N-glycopeptide search engine	1046:1080	intact N-glycopeptide search engine GPSeeker	1046:1089	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	9	65	dep	determined	1331:1340	arg1	fold					1343:1346	fold change ≥ 1.5	1343:1359	fold change ≥ 1.5	1343:1359	Among 1717 quantified intact N-glycopeptides, 104 DEGPs were determined (fold change ≥ 1.5 and p value < 0.05).
36870092	9	65	dep	determined	1331:1340	arg1	p					1365:1365	p value < 0.05	1365:1378	p value < 0.05	1365:1378	Among 1717 quantified intact N-glycopeptides, 104 DEGPs were determined (fold change ≥ 1.5 and p value < 0.05).
36870092	10	66	theme	up-regulated	1589:1600	arg1	N-glycopeptide					1609:1622	up-regulated intact N-glycopeptide	1589:1622	up-regulated intact N-glycopeptide	1589:1622	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	5	67	theme	cell-surface	599:610	arg1	N-glycosylation					620:634	cell-surface altered N-glycosylation	599:634	cell-surface altered N-glycosylation	599:634	To the end, it is urgent to figure out the knowledge on cell-surface altered N-glycosylation and putative markers.
36870092	6	68	theme	-resistant	732:741	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	68	theme	-resistant	732:741	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	10	69	theme	interaction	1412:1422	arg1	Annotation					1382:1391	Annotation	1382:1391	Annotation of protein-protein interaction and biological processes among others of DEGPs	1382:1469	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	10	70	theme	β1,6-branching	1629:1642	arg1	N-glycan					1644:1651	β1,6-branching N-glycan	1629:1651	β1,6-branching N-glycan from integrin beta-5	1629:1672	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	0	71	theme	N-glycoproteomics	11:27	arg1	characterization					29:44	Structural N-glycoproteomics characterization	0:44	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.	0:108	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	8	72	theme	sequence	1158:1165	arg1	structures					1167:1176	N-glycan sequence structures	1149:1176	N-glycan sequence structures among 2764 IDs	1149:1191	Totally, 4777 intact N-glycopeptides were identified and N-glycan sequence structures among 2764 IDs were distinguished from their isomers by structure-diagnostic fragment ions.
36870092	1	73	theme	Breast	110:115	arg1	cancer					117:122	Breast cancer	110:122	Breast cancer	110:122	Breast cancer is responsible for the highest mortality all over the world.
36870092	3	74	theme	signaling	371:379	arg1	pathways					381:388	Several signaling pathways	363:388	Several signaling pathways	363:388	Several signaling pathways are associated with drug resistance.
36870092	7	75	gly	N-glycopeptide	1053:1066	arg2	N-glycopeptide					1053:1066	intact N-glycopeptide search engine	1046:1080	intact N-glycopeptide search engine GPSeeker	1046:1089	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	10	76	theme	biological	1428:1437	arg1	processes					1439:1447	biological processes	1428:1447	biological processes	1428:1447	Annotation of protein-protein interaction and biological processes among others of DEGPs were finally carried out; down-regulated intact N-glycopeptide with bisecting GlcNAc from p38-interacting protein and up-regulated intact N-glycopeptide with β1,6-branching N-glycan from integrin beta-5 were found.
36870092	0	77	theme	N-glycosylation	62:76	arg1	characterization					29:44	Structural N-glycoproteomics characterization	0:44	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.	0:108	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	2	78	theme	Cancer	185:190	arg1	CSCs					204:207	CSCs	204:207	CSCs	204:207	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	78	theme	Cancer	185:190	arg1	driver					281:286	a driver	279:286	a driver of cancer which are responsible for cancer metastasis and drug resistance	279:360	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	78	theme	Cancer	185:190	arg1	cells					197:201	Cancer stem cells	185:201	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	78	theme	Cancer	185:190	arg1	responsible					308:318	responsible	308:318	responsible	308:318	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	2	78	theme	Cancer	185:190	arg1	transition					244:253	epithelial mesenchymal transition	221:253	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT)	185:259	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	6	79	theme	MCF-7/ADR	791:799	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	79	theme	MCF-7/ADR	791:799	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	0	80	theme	MCF-7/ADR	81:89	arg1	cells					103:107	MCF-7/ADR cancer stem cells	81:107	MCF-7/ADR cancer stem cells	81:107	Structural N-glycoproteomics characterization of cell-surface N-glycosylation of MCF-7/ADR cancer stem cells.
36870092	6	81	theme	structure-specific	873:890	arg1	N-glycoproteomics					905:921	structure-specific quantitative N-glycoproteomics	873:921	structure-specific quantitative N-glycoproteomics	873:921	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	2	82	theme	cancer	324:329	arg1	metastasis					331:340	cancer metastasis	324:340	cancer metastasis	324:340	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	7	83	theme	intact	980:985	arg1	DEGPs					1004:1008	DEGPs	1004:1008	DEGPs	1004:1008	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	7	83	theme	intact	980:985	arg1	N-glycopeptides					987:1001	differentially expressed intact N-glycopeptides	955:1001	differentially expressed intact N-glycopeptides (DEGPs)	955:1009	The intact N-glycopeptides and differentially expressed intact N-glycopeptides (DEGPs) were determined and quantified via intact N-glycopeptide search engine GPSeeker.
36870092	6	84	theme	foundation-7	766:777	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	84	theme	foundation-7	766:777	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	2	85	dep	along	210:214	arg1	with					216:219	with	216:219	with	216:219	Cancer stem cells (CSCs) along with epithelial mesenchymal transition (EMT) are identified as a driver of cancer which are responsible for cancer metastasis and drug resistance.
36870092	6	86	theme	breast	752:757	arg1	cells					784:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells	716:788	adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs	716:842	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
36870092	6	86	theme	breast	752:757	arg1	CSCs					801:804	MCF-7/ADR CSCs	791:804	MCF-7/ADR CSCs	791:804	Here, differential cell-surface intact N-glycopeptides in adriamycin (ADR)-resistant michigan breast cancer foundation-7 stem cells (MCF-7/ADR CSCs) relative to ADR-sensitive MCF-7 CSCs were analyzed with site- and structure-specific quantitative N-glycoproteomics.
35364496	0	0	theme	guar	90:93	arg1	gum					95:97	guar gum	90:97	guar gum	90:97	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	7	1	theme	better	1224:1229	arg1	performance					1231:1241	a better performance	1222:1241	a better performance	1222:1241	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	2	2	theme	infrared	370:377	arg1	grafting					331:338	grafting	331:338	grafting	331:338	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	2	theme	infrared	370:377	arg1	profile					390:396	infrared absorption profile	370:396	infrared absorption profile	370:396	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	7	3	theme	rheological	1170:1180	arg1	properties					1182:1191	glycinin superior emulsifying and rheological properties	1136:1191	glycinin superior emulsifying and rheological properties	1136:1191	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	0	4	dep	study	114:118	arg1	structure					10:18	Molecular structure	0:18	Molecular structure	0:18	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	0	4	dep	study	114:118	arg1	properties					35:44	functional properties	24:44	functional properties	24:44	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	2	5	theme	protein	341:347	arg1	composition					357:367	protein subunit composition	341:367	protein subunit composition	341:367	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	5	theme	protein	341:347	arg1	grafting					331:338	grafting	331:338	grafting	331:338	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	3	6	theme	low	579:581	arg1	weight					593:598	its relatively low molecular weight	564:598	its relatively low molecular weight	564:598	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	6	7	theme	viscous	955:961	arg1	modulus					963:969	viscous modulus	955:969	viscous modulus	955:969	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	6	8	theme	structure	1058:1066	arg1	appearance					1021:1030	the appearance	1017:1030	the appearance of stable elastic network structure	1017:1066	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	0	9	theme	comparative	102:112	arg1	study					114:118	A comparative study	100:118	A comparative study	100:118	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	2	10	theme	protein	426:432	arg1	structures					444:453	protein secondary structures	426:453	protein secondary structures	426:453	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	3	11	theme	guar	548:551	arg1	gum					553:555	guar gum	548:555	guar gum	548:555	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	1	12	theme	glycinin	170:177	arg1	structure					131:139	Molecular structure	121:139	Molecular structure	121:139	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum using a dry-heating method were comparatively analyzed.
35364496	1	12	theme	glycinin	170:177	arg1	properties					156:165	functional properties	145:165	functional properties	145:165	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum using a dry-heating method were comparatively analyzed.
35364496	6	13	theme	apparent	914:921	arg1	viscosity					923:931	apparent viscosity	914:931	apparent viscosity	914:931	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	5	14	theme	emulsifying	865:875	arg1	activity					877:884	enhanced emulsifying activity	856:884	enhanced emulsifying activity	856:884	Glycinin glycosylated with both polysaccharides exhibited enhanced emulsifying activity and stability.
35364496	5	15	theme	enhanced	856:863	arg1	activity					877:884	enhanced emulsifying activity	856:884	enhanced emulsifying activity	856:884	Glycinin glycosylated with both polysaccharides exhibited enhanced emulsifying activity and stability.
35364496	2	16	theme	grafting	331:338	arg1	changes					403:409	changes	403:409	changes in contents of protein secondary structures	403:453	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	16	theme	grafting	331:338	arg1	degree					321:326	the degree	317:326	the degree of grafting, protein subunit composition, infrared absorption profile,	317:397	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	7	17	theme	glycinin	1136:1143	arg1	properties					1182:1191	glycinin superior emulsifying and rheological properties	1136:1191	glycinin superior emulsifying and rheological properties	1136:1191	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	0	18	theme	Molecular	0:8	arg1	structure					10:18	Molecular structure	0:18	Molecular structure	0:18	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	6	19	theme	network	1050:1056	arg1	structure					1058:1066	stable elastic network structure	1035:1066	stable elastic network structure	1035:1066	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	3	20	theme	molecular	583:591	arg1	weight					593:598	its relatively low molecular weight	564:598	its relatively low molecular weight	564:598	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	0	21	theme	functional	24:33	arg1	properties					35:44	functional properties	24:44	functional properties	24:44	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	6	22	theme	elastic	1042:1048	arg1	structure					1058:1066	stable elastic network structure	1035:1066	stable elastic network structure	1035:1066	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	2	23	theme	secondary	434:442	arg1	structures					444:453	protein secondary structures	426:453	protein secondary structures	426:453	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	24	theme	structures	444:453	arg1	contents					414:421	contents	414:421	contents of protein secondary structures	414:453	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	6	25	theme	stable	1035:1040	arg1	structure					1058:1066	stable elastic network structure	1035:1066	stable elastic network structure	1035:1066	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	5	26	gly	glycosylated	807:818	arg1	Glycinin					798:805	Glycinin	798:805	Glycinin glycosylated with both polysaccharides	798:844	Glycinin glycosylated with both polysaccharides exhibited enhanced emulsifying activity and stability.
35364496	6	27	theme	elastic	934:940	arg1	modulus					942:948	elastic modulus	934:948	elastic modulus	934:948	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	1	28	theme	guar	211:214	arg1	gum					216:218	guar gum	211:218	guar gum	211:218	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum using a dry-heating method were comparatively analyzed.
35364496	7	29	theme	guar	1255:1258	arg1	gum					1260:1262	guar gum	1255:1262	guar gum	1255:1262	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	4	30	theme	glycinin	731:738	arg1	point					722:726	the isoelectric point	706:726	the isoelectric point of glycinin	706:738	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	7	31	theme	superior	1145:1152	arg1	properties					1182:1191	glycinin superior emulsifying and rheological properties	1136:1191	glycinin superior emulsifying and rheological properties	1136:1191	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	4	32	theme	guar	692:695	arg1	gum					697:699	guar gum	692:699	guar gum	692:699	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	7	33	theme	emulsifying	1154:1164	arg1	properties					1182:1191	glycinin superior emulsifying and rheological properties	1136:1191	glycinin superior emulsifying and rheological properties	1136:1191	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	7	34	with	glycosylation	1081:1093	arg1	polysaccharides					1110:1124	these two polysaccharides	1100:1124	these two polysaccharides	1100:1124	In summary, glycosylation with these two polysaccharides conferred glycinin superior emulsifying and rheological properties, and κ-carrageenan exhibited a better performance compared to guar gum.
35364496	3	35	theme	charged	615:621	arg1	characteristics					623:637	negatively charged characteristics	604:637	negatively charged characteristics	604:637	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	4	36	with	glycosylation	764:776	arg1	κ-carrageenan					783:795	κ-carrageenan	783:795	κ-carrageenan	783:795	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	3	37	contain	possess	484:490	arg1	K-carrageenan					456:468	K-carrageenan	456:468	K-carrageenan	456:468	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	3	37	contain	possess	484:490	arg2	susceptibility					502:515	a greater susceptibility	492:515	a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics	492:637	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	0	38	theme	glycinin	49:56	arg1	structure					10:18	Molecular structure	0:18	Molecular structure	0:18	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	0	38	theme	glycinin	49:56	arg1	properties					35:44	functional properties	24:44	functional properties	24:44	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum: A comparative study.
35364496	3	39	theme	greater	494:500	arg1	susceptibility					502:515	a greater susceptibility	492:515	a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics	492:637	K-carrageenan was proven to possess a greater susceptibility to be grafted to glycinin than guar gum due to its relatively low molecular weight and negatively charged characteristics.
35364496	6	40	theme	enhanced	905:912	arg1	viscosity					923:931	apparent viscosity	914:931	apparent viscosity	914:931	The enhanced apparent viscosity, elastic modulus, and viscous modulus also demonstrated that glycosylation promoted the appearance of stable elastic network structure.
35364496	2	41	theme	subunit	349:355	arg1	composition					357:367	protein subunit composition	341:367	protein subunit composition	341:367	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	41	theme	subunit	349:355	arg1	grafting					331:338	grafting	331:338	grafting	331:338	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	42	from	changes	403:409	arg1	contents					414:421	contents	414:421	contents of protein secondary structures	414:453	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	1	43	theme	Molecular	121:129	arg1	structure					131:139	Molecular structure	121:139	Molecular structure	121:139	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum using a dry-heating method were comparatively analyzed.
35364496	4	44	with	solubility	659:668	arg1	gum					697:699	guar gum	692:699	guar gum	692:699	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	1	45	theme	functional	145:154	arg1	properties					156:165	functional properties	145:165	functional properties	145:165	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum using a dry-heating method were comparatively analyzed.
35364496	1	46	theme	dry-heating	228:238	arg1	method					240:245	a dry-heating method	226:245	a dry-heating method	226:245	Molecular structure and functional properties of glycinin conjugated to κ-carrageenan and guar gum using a dry-heating method were comparatively analyzed.
35364496	4	47	theme	solubility	659:668	arg1	better					744:749	better	744:749	better	744:749	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	4	47	theme	solubility	659:668	arg1	improvement					644:654	The improvement	640:654	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin	640:738	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	4	48	theme	isoelectric	710:720	arg1	point					722:726	the isoelectric point	706:726	the isoelectric point of glycinin	706:738	The improvement of solubility by glycosylation with guar gum near the isoelectric point of glycinin was better than that by glycosylation with κ-carrageenan.
35364496	2	49	theme	absorption	379:388	arg1	grafting					331:338	grafting	331:338	grafting	331:338	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	49	theme	absorption	379:388	arg1	profile					390:396	infrared absorption profile	370:396	infrared absorption profile	370:396	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
35364496	2	50	from	degree	321:326	arg1	contents					414:421	contents	414:421	contents of protein secondary structures	414:453	Glycosylation was confirmed by analyzing the degree of grafting, protein subunit composition, infrared absorption profile, and changes in contents of protein secondary structures.
36959210	4	0	gly	glycosylation	667:679	arg1	tissues					647:653	tissues	647:653	tissues with unique glycosylation	647:679	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	4	1	theme	glycan	803:808	arg1	patterns					810:817	specific glycan patterns	794:817	specific glycan patterns	794:817	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	6	2	theme	host	1136:1139	arg1	mechanism					1141:1149	a natural host mechanism	1126:1149	a natural host mechanism	1126:1149	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	6	2	theme	host	1136:1139	arg1	glycans					1115:1121	mucin glycans	1109:1121	mucin glycans	1109:1121	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	5	3	theme	spatial	975:981	arg1	structure					983:991	spatial structure	975:991	spatial structure	975:991	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	4	4	theme	specific	794:801	arg1	patterns					810:817	specific glycan patterns	794:817	specific glycan patterns	794:817	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	6	5	theme	healthy	1202:1208	arg1	communities					1220:1230	healthy microbial communities	1202:1230	healthy microbial communities	1202:1230	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	3	6	theme	diverse	560:566	arg1	microbes					568:575	diverse microbes	560:575	diverse microbes	560:575	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	4	7	theme	glycan	747:752	arg1	libraries					754:762	isolated mucin glycan libraries	732:762	isolated mucin glycan libraries	732:762	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	4	8	theme	mucin	741:745	arg1	libraries					754:762	isolated mucin glycan libraries	732:762	isolated mucin glycan libraries	732:762	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	6	9	theme	natural	1128:1134	arg1	mechanism					1141:1149	a natural host mechanism	1126:1149	a natural host mechanism	1126:1149	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	6	9	theme	natural	1128:1134	arg1	glycans					1115:1121	mucin glycans	1109:1121	mucin glycans	1109:1121	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	1	10	theme	Human	71:75	arg1	composition					88:98	Human microbiome composition	71:98	Human microbiome composition	71:98	Human microbiome composition is closely tied to health, but how the host manages its microbial inhabitants remains unclear.
36959210	4	11	theme	microbial	702:710	arg1	composition					712:722	microbial composition	702:722	microbial composition	702:722	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	2	12	theme	potential	373:381	arg1	function					394:401	potential regulatory function	373:401	potential regulatory function	373:401	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	4	13	from	importance	780:789	arg1	modulation					833:842	microbiome modulation	822:842	microbiome modulation	822:842	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	1	14	theme	microbiome	77:86	arg1	composition					88:98	Human microbiome composition	71:98	Human microbiome composition	71:98	Human microbiome composition is closely tied to health, but how the host manages its microbial inhabitants remains unclear.
36959210	1	15	theme	microbial	156:164	arg1	inhabitants					166:176	its microbial inhabitants	152:176	its microbial inhabitants	152:176	Human microbiome composition is closely tied to health, but how the host manages its microbial inhabitants remains unclear.
36959210	2	16	theme	gel-forming	290:300	arg1	mucins					317:322	mucins	317:322	mucins	317:322	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	16	theme	gel-forming	290:300	arg1	glycoproteins					302:314	gel-forming glycoproteins	290:314	gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function	290:401	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	17	theme	structures	357:366	arg1	hundreds					338:345	hundreds	338:345	hundreds of glycan structures	338:366	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	0	18	theme	Mucin	0:4	arg1	glycans					6:12	Mucin glycans	0:12	Mucin glycans	0:12	Mucin glycans drive oral microbial community composition and function.
36959210	5	19	theme	several	897:903	arg1	ways					905:908	several ways	897:908	several ways	897:908	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	3	20	theme	microbes	568:575	arg1	coexistence					545:555	the coexistence	541:555	the coexistence of diverse microbes	541:575	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	2	21	theme	glycan	350:355	arg1	structures					357:366	glycan structures	350:366	glycan structures	350:366	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	0	22	theme	oral	20:23	arg1	composition					45:55	oral microbial community composition	20:55	oral microbial community composition	20:55	Mucin glycans drive oral microbial community composition and function.
36959210	5	23	theme	metabolic	943:951	arg1	diversity					953:961	metabolic diversity	943:961	metabolic diversity	943:961	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	6	24	theme	microbial	1210:1218	arg1	communities					1220:1230	healthy microbial communities	1202:1230	healthy microbial communities	1202:1230	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	6	25	theme	mucin	1109:1113	arg1	mechanism					1141:1149	a natural host mechanism	1126:1149	a natural host mechanism	1126:1149	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	6	25	theme	mucin	1109:1113	arg1	glycans					1115:1121	mucin glycans	1109:1121	mucin glycans	1109:1121	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	5	26	dep	support	935:941	arg1	limiting					1035:1042	limiting	1035:1042	limiting antagonism between competing taxa	1035:1076	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	5	26	dep	support	935:941	arg1	organizing					964:973	organizing	964:973	organizing spatial structure through reduced aggregation	964:1019	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	3	27	theme	mucin	520:524	arg1	glycans					526:532	mucin glycans	520:532	mucin glycans	520:532	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	5	28	theme	reduced	1001:1007	arg1	aggregation					1009:1019	reduced aggregation	1001:1019	reduced aggregation	1001:1019	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	4	29	from	tissues	647:653	arg1	Mucins					635:640	Mucins	635:640	Mucins from tissues with unique glycosylation	635:679	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	5	30	theme	microbial	872:880	arg1	communities					882:892	microbial communities	872:892	microbial communities in several ways	872:908	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	0	31	theme	community	35:43	arg1	composition					45:55	oral microbial community composition	20:55	oral microbial community composition	20:55	Mucin glycans drive oral microbial community composition and function.
36959210	3	32	theme	tractable	417:425	arg1	system					441:446	a tractable culture-based system	415:446	a tractable culture-based system to study how mucins influence oral microbial communities	415:503	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	4	33	theme	unique	660:665	arg1	glycosylation					667:679	unique glycosylation	660:679	unique glycosylation	660:679	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	0	34	theme	microbial	25:33	arg1	composition					45:55	oral microbial community composition	20:55	oral microbial community composition	20:55	Mucin glycans drive oral microbial community composition and function.
36959210	2	35	theme	understudied	214:225	arg1	environment					255:265	the natural host environment	238:265	the natural host environment	238:265	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	35	theme	understudied	214:225	arg1	factor					228:233	One important, but understudied, factor	195:233	One important, but understudied, factor	195:233	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	5	36	from	communities	882:892	arg1	ways					905:908	several ways	897:908	several ways	897:908	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
36959210	2	37	theme	regulatory	383:392	arg1	function					394:401	potential regulatory function	373:401	potential regulatory function	373:401	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	3	38	theme	culture-based	427:439	arg1	system					441:446	a tractable culture-based system	415:446	a tractable culture-based system to study how mucins influence oral microbial communities	415:503	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	6	39	theme	potential	1155:1163	arg1	intervention					1177:1188	potential therapeutic intervention	1155:1188	potential therapeutic intervention	1155:1188	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	3	40	theme	microbial	483:491	arg1	communities					493:503	oral microbial communities	478:503	oral microbial communities	478:503	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	2	41	contain	contains	281:288	arg2	glycoproteins					302:314	gel-forming glycoproteins	290:314	gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function	290:401	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	41	contain	contains	281:288	arg1	environment					255:265	the natural host environment	238:265	the natural host environment	238:265	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	41	contain	contains	281:288	arg1	factor					228:233	One important, but understudied, factor	195:233	One important, but understudied, factor	195:233	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	41	contain	contains	281:288	arg2	mucins					317:322	mucins	317:322	mucins	317:322	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	42	theme	important	199:207	arg1	environment					255:265	the natural host environment	238:265	the natural host environment	238:265	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	42	theme	important	199:207	arg1	factor					228:233	One important, but understudied, factor	195:233	One important, but understudied, factor	195:233	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	4	43	theme	isolated	732:739	arg1	libraries					754:762	isolated mucin glycan libraries	732:762	isolated mucin glycan libraries	732:762	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	2	44	gly	glycoproteins	302:314	arg1	mucins					317:322	mucins	317:322	mucins	317:322	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	44	gly	glycoproteins	302:314	arg1	glycoproteins					302:314	gel-forming glycoproteins	290:314	gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function	290:401	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	4	45	theme	microbiome	822:831	arg1	modulation					833:842	microbiome modulation	822:842	microbiome modulation	822:842	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	2	46	theme	natural	242:248	arg1	environment					255:265	the natural host environment	238:265	the natural host environment	238:265	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	46	theme	natural	242:248	arg1	factor					228:233	One important, but understudied, factor	195:233	One important, but understudied, factor	195:233	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	3	47	theme	disease-associated	594:611	arg1	shifts					627:632	disease-associated compositional shifts	594:632	disease-associated compositional shifts	594:632	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	6	48	theme	therapeutic	1165:1175	arg1	intervention					1177:1188	potential therapeutic intervention	1155:1188	potential therapeutic intervention	1155:1188	Overall, this work identifies mucin glycans as a natural host mechanism and potential therapeutic intervention to maintain healthy microbial communities.
36959210	2	49	theme	host	250:253	arg1	environment					255:265	the natural host environment	238:265	the natural host environment	238:265	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	2	49	theme	host	250:253	arg1	factor					228:233	One important, but understudied, factor	195:233	One important, but understudied, factor	195:233	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	4	50	with	tissues	647:653	arg1	glycosylation					667:679	unique glycosylation	660:679	unique glycosylation	660:679	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	4	51	theme	patterns	810:817	arg1	importance					780:789	the importance	776:789	the importance of specific glycan patterns in microbiome modulation	776:842	Mucins from tissues with unique glycosylation differentially tuned microbial composition, as did isolated mucin glycan libraries, uncovering the importance of specific glycan patterns in microbiome modulation.
36959210	3	52	theme	oral	478:481	arg1	communities					493:503	oral microbial communities	478:503	oral microbial communities	478:503	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	3	53	theme	compositional	613:625	arg1	shifts					627:632	disease-associated compositional shifts	594:632	disease-associated compositional shifts	594:632	Leveraging a tractable culture-based system to study how mucins influence oral microbial communities, we found that mucin glycans enable the coexistence of diverse microbes, while resisting disease-associated compositional shifts.
36959210	2	54	dep	environment	255:265	arg1	mucus					268:272	mucus	268:272	mucus	268:272	One important, but understudied, factor is the natural host environment: mucus, which contains gel-forming glycoproteins (mucins) that display hundreds of glycan structures with potential regulatory function.
36959210	5	55	theme	competing	1063:1071	arg1	taxa					1073:1076	competing taxa	1063:1076	competing taxa	1063:1076	We found that mucins shape microbial communities in several ways: serving as nutrients to support metabolic diversity, organizing spatial structure through reduced aggregation, and possibly limiting antagonism between competing taxa.
37162352	3	0	gly	O-glycosylation	386:400	arg1	proteins					413:420	S-layer proteins	405:420	S-layer proteins	405:420	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	3	0	gly	O-glycosylation	386:400	arg1	virulence					484:492	certain virulence features	476:501	certain virulence features	476:501	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	3	0	gly	O-glycosylation	386:400	arg1	forsythia					436:444	Tannerella forsythia	425:444	Tannerella forsythia	425:444	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	7	1	theme	glycosylated	966:977	arg1	sites					979:983	The glycosylated sites	962:983	The glycosylated sites	962:983	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	7	1	theme	glycosylated	966:977	arg1	located					1004:1010	located	1004:1010	located	1004:1010	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	3	2	theme	certain	476:482	arg1	features					494:501	certain virulence features	476:501	certain virulence features	476:501	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	4	3	theme	F.	559:560	arg1	johnsoniae					562:571	F. johnsoniae	559:571	F. johnsoniae	559:571	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	13	4	theme	sites	1715:1719	arg1	finding					1686:1692	the finding	1682:1692	the finding of the glycosylation sites	1682:1719	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	8	5	gly	O-glycosylated	1186:1199	arg1	proteins					1108:1115	Six proteins	1104:1115	Six proteins associated with gliding motility or the T9SS	1104:1160	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated.
37162352	3	6	theme	virulence	484:492	arg1	features					494:501	certain virulence features	476:501	certain virulence features	476:501	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	12	7	theme	glycosylated	1526:1537	arg1	domains					1539:1545	The glycosylated domains	1522:1545	The glycosylated domains	1522:1545	The glycosylated domains were mainly localized to the periplasm.
37162352	12	7	theme	glycosylated	1526:1537	arg1	localized					1559:1567	localized	1559:1567	localized	1559:1567	The glycosylated domains were mainly localized to the periplasm.
37162352	3	8	from	O-glycosylation	386:400	arg1	forsythia					436:444	Tannerella forsythia	425:444	Tannerella forsythia	425:444	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	6	9	theme	glycoproteins	803:815	arg1	localization					783:794	Bioinformatic localization	769:794	Bioinformatic localization of the glycoproteins	769:815	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	1	10	theme	Flavobacterium	70:83	arg1	member					113:118	a free-living member	99:118	a free-living member of the Bacteroidota phylum that is found in soil and water	99:177	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	1	10	theme	Flavobacterium	70:83	arg1	johnsoniae					85:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	4	11	gly	O-glycosylation	592:606	arg2	sites					608:612	325 O-glycosylation sites	588:612	325 O-glycosylation sites within 226 glycoproteins	588:637	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	4	11	gly	O-glycosylation	592:606	arg2	325					588:590	325	588:590	325	588:590	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	4	12	theme	johnsoniae	562:571	arg1	O-glycoproteome					540:554	the O-glycoproteome	536:554	the O-glycoproteome of F. johnsoniae	536:571	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	5	13	theme	sequence	716:723	arg1	-Me-HexA-Pent-HexA-Me-HexNAcA					738:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	1	14	located	found	155:159	arg1	water					173:177	water	173:177	water	173:177	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	1	14	located	found	155:159	arg1	soil					164:167	soil	164:167	soil	164:167	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	1	14	located	found	155:159	arg2	member					113:118	a free-living member	99:118	a free-living member of the Bacteroidota phylum that is found in soil and water	99:177	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	1	14	located	found	155:159	arg2	johnsoniae					85:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	7	15	theme	protein	1077:1083	arg1	folding/stability					1085:1101	protein folding/stability	1077:1101	protein folding/stability	1077:1101	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	7	16	from	located	1004:1010	arg1	periplasm					1019:1027	the periplasm	1015:1027	the periplasm	1015:1027	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	2	17	theme	dependent	261:269	arg1	motility					252:259	gliding motility	244:259	gliding motility dependent on the type IX secretion system (T9SS)	244:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	3	18	theme	proteins	413:420	arg1	important					462:470	important	462:470	important	462:470	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	3	18	theme	proteins	413:420	arg1	O-glycosylation					386:400	the O-glycosylation	382:400	the O-glycosylation of S-layer proteins in Tannerella forsythia	382:444	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	5	19	theme	Hex-	725:728	arg1	-Me-HexA-Pent-HexA-Me-HexNAcA					738:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	6	20	theme	outer	883:887	arg1	proteins					898:905	26 outer membrane proteins	880:905	26 outer membrane proteins	880:905	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	9	21	theme	IMPORTANCE	1202:1211	arg1	bacterium					1258:1266	a Gram-negative bacterium	1242:1266	a Gram-negative bacterium that is found in soil and water	1242:1298	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	9	21	theme	IMPORTANCE	1202:1211	arg1	johnsoniae					1228:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	2	22	theme	motility	252:259	arg1	type					236:239	a type	234:239	a type of gliding motility dependent on the type IX secretion system (T9SS)	234:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	7	23	located	located	1004:1010	arg1	periplasm					1019:1027	the periplasm	1015:1027	the periplasm	1015:1027	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	7	23	located	located	1004:1010	arg2	located					1004:1010	located	1004:1010	located	1004:1010	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	7	23	located	located	1004:1010	arg2	sites					979:983	The glycosylated sites	962:983	The glycosylated sites	962:983	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	3	24	theme	Bacteroidota	356:367	arg1	species					369:375	several Bacteroidota species	348:375	several Bacteroidota species	348:375	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	14	25	theme	gliding	1814:1820	arg1	motility					1822:1829	gliding motility	1814:1829	gliding motility	1814:1829	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated, which may impact the structure and function of these components.
37162352	4	26	gly	glycoproteins	625:637	arg1	glycoproteins					625:637	226 glycoproteins	621:637	226 glycoproteins	621:637	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	9	27	theme	Flavobacterium	1213:1226	arg1	bacterium					1258:1266	a Gram-negative bacterium	1242:1266	a Gram-negative bacterium that is found in soil and water	1242:1298	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	9	27	theme	Flavobacterium	1213:1226	arg1	johnsoniae					1228:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	1	28	theme	free-living	101:111	arg1	member					113:118	a free-living member	99:118	a free-living member of the Bacteroidota phylum that is found in soil and water	99:177	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	1	28	theme	free-living	101:111	arg1	johnsoniae					85:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	6	29	theme	membrane	889:896	arg1	proteins					898:905	26 outer membrane proteins	880:905	26 outer membrane proteins	880:905	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	14	30	dep	structure	1904:1912	arg1	the					1900:1902	the	1900:1902	the	1900:1902	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated, which may impact the structure and function of these components.
37162352	13	31	theme	glycosylation	1701:1713	arg1	sites					1715:1719	the glycosylation sites	1697:1719	the glycosylation sites	1697:1719	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	6	32	theme	Bioinformatic	769:781	arg1	localization					783:794	Bioinformatic localization	769:794	Bioinformatic localization of the glycoproteins	769:815	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	2	33	theme	secretion	286:294	arg1	T9SS					304:307	T9SS	304:307	T9SS	304:307	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	2	33	theme	secretion	286:294	arg1	system					296:301	the type IX secretion system	274:301	the type IX secretion system (T9SS)	274:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	14	34	gly	O-glycosylated	1867:1880	arg1	proteins					1789:1796	Six proteins	1785:1796	Six proteins associated with gliding motility or the T9SS	1785:1841	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated, which may impact the structure and function of these components.
37162352	3	35	theme	S-layer	405:411	arg1	proteins					413:420	S-layer proteins	405:420	S-layer proteins	405:420	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	0	36	theme	O-Glycoproteome	24:38	arg1	Characterization					0:15	Characterization	0:15	Characterization of the O-Glycoproteome of Flavobacterium johnsoniae.	0:68	Characterization of the O-Glycoproteome of Flavobacterium johnsoniae.
37162352	2	37	theme	IX	283:284	arg1	T9SS					304:307	T9SS	304:307	T9SS	304:307	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	2	37	theme	IX	283:284	arg1	system					296:301	the type IX secretion system	274:301	the type IX secretion system (T9SS)	274:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	3	38	theme	several	348:354	arg1	species					369:375	several Bacteroidota species	348:375	several Bacteroidota species	348:375	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	7	39	gly	glycosylated	966:977	arg1	sites					979:983	The glycosylated sites	962:983	The glycosylated sites	962:983	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	7	39	gly	glycosylated	966:977	arg1	located					1004:1010	located	1004:1010	located	1004:1010	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	10	40	used	used	1318:1321	arg2	It					1301:1302	It	1301:1302	It	1301:1302	It is frequently used as a model species for studying gliding motility and the T9SS.
37162352	10	40	used	used	1318:1321	arg2	species					1334:1340	a model species	1326:1340	a model species for studying gliding motility and the T9SS	1326:1383	It is frequently used as a model species for studying gliding motility and the T9SS.
37162352	2	41	theme	type	278:281	arg1	T9SS					304:307	T9SS	304:307	T9SS	304:307	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	2	41	theme	type	278:281	arg1	system					296:301	the type IX secretion system	274:301	the type IX secretion system (T9SS)	274:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	11	42	theme	F.	1441:1442	arg1	johnsoniae					1444:1453	F. johnsoniae	1441:1453	F. johnsoniae	1441:1453	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	5	43	with	hexasaccharide	692:705	arg1	-Me-HexA-Pent-HexA-Me-HexNAcA					738:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	0	44	theme	Flavobacterium	43:56	arg1	johnsoniae					58:67	Flavobacterium johnsoniae	43:67	Flavobacterium johnsoniae	43:67	Characterization of the O-Glycoproteome of Flavobacterium johnsoniae.
37162352	13	45	contain	has	1721:1723	arg2	relevance					1725:1733	relevance	1725:1733	relevance for studies involving expression of the proteins	1725:1782	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	13	45	contain	has	1721:1723	arg1	finding					1686:1692	the finding	1682:1692	the finding of the glycosylation sites	1682:1719	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	11	46	gly	glycoproteins	1507:1519	arg1	glycoproteins					1507:1519	226 glycoproteins	1503:1519	226 glycoproteins	1503:1519	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	9	47	theme	Gram-negative	1244:1256	arg1	bacterium					1258:1266	a Gram-negative bacterium	1242:1266	a Gram-negative bacterium that is found in soil and water	1242:1298	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	9	47	theme	Gram-negative	1244:1256	arg1	johnsoniae					1228:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	11	48	theme	johnsoniae	1444:1453	arg1	O-glycoproteome					1422:1436	the O-glycoproteome	1418:1436	the O-glycoproteome of F. johnsoniae	1418:1453	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	3	49	theme	Tannerella	425:434	arg1	forsythia					436:444	Tannerella forsythia	425:444	Tannerella forsythia	425:444	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	3	50	gly	O-Glycosylation	311:325	arg1	species					369:375	several Bacteroidota species	348:375	several Bacteroidota species	348:375	O-Glycosylation has been reported in several Bacteroidota species, and the O-glycosylation of S-layer proteins in Tannerella forsythia was shown to be important for certain virulence features.
37162352	6	51	theme	periplasmic	858:868	arg1	proteins					870:877	60 periplasmic proteins	855:877	60 periplasmic proteins	855:877	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	13	52	theme	proteins	1775:1782	arg1	expression					1757:1766	expression	1757:1766	expression of the proteins	1757:1782	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	13	53	dep	protein	1640:1646	arg1	folding					1648:1654	folding	1648:1654	folding	1648:1654	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	13	53	dep	protein	1640:1646	arg1	stability					1660:1668	stability	1660:1668	stability	1660:1668	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	5	54	theme	major	661:665	arg1	glycan					667:672	the major glycan	657:672	the major glycan	657:672	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	5	55	theme	Me-dHex	730:736	arg1	-Me-HexA-Pent-HexA-Me-HexNAcA					738:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	712:766	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	1	56	theme	Bacteroidota	127:138	arg1	phylum					140:145	the Bacteroidota phylum	123:145	the Bacteroidota phylum	123:145	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	0	57	theme	johnsoniae	58:67	arg1	O-Glycoproteome					24:38	the O-Glycoproteome	20:38	the O-Glycoproteome of Flavobacterium johnsoniae	20:67	Characterization of the O-Glycoproteome of Flavobacterium johnsoniae.
37162352	5	58	theme	glycan	667:672	arg1	structure					644:652	The structure	640:652	The structure of the major glycan	640:672	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	5	58	theme	glycan	667:672	arg1	hexasaccharide					692:705	a hexasaccharide	690:705	a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA	690:766	The structure of the major glycan was found to be a hexasaccharide with the sequence Hex-(Me-dHex)-Me-HexA-Pent-HexA-Me-HexNAcA.
37162352	2	59	theme	model	207:211	arg1	It					180:181	It	180:181	It	180:181	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	2	59	theme	model	207:211	arg1	species					213:219	a model species	205:219	a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS)	205:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	10	60	theme	model	1328:1332	arg1	species					1334:1340	a model species	1326:1340	a model species for studying gliding motility and the T9SS	1326:1383	It is frequently used as a model species for studying gliding motility and the T9SS.
37162352	10	60	theme	model	1328:1332	arg1	It					1301:1302	It	1301:1302	It	1301:1302	It is frequently used as a model species for studying gliding motility and the T9SS.
37162352	1	61	theme	phylum	140:145	arg1	member					113:118	a free-living member	99:118	a free-living member of the Bacteroidota phylum that is found in soil and water	99:177	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	1	61	theme	phylum	140:145	arg1	johnsoniae					85:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae	70:94	Flavobacterium johnsoniae is a free-living member of the Bacteroidota phylum that is found in soil and water.
37162352	6	62	gly	glycoproteins	803:815	arg1	glycoproteins					803:815	the glycoproteins	799:815	the glycoproteins	799:815	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	11	63	gly	O-glycosylation	1474:1488	arg2	325					1470:1472	325	1470:1472	325	1470:1472	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	11	63	gly	O-glycosylation	1474:1488	arg2	sites					1490:1494	325 O-glycosylation sites	1470:1494	325 O-glycosylation sites within 226 glycoproteins	1470:1519	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	12	64	gly	glycosylated	1526:1537	arg1	domains					1539:1545	The glycosylated domains	1522:1545	The glycosylated domains	1522:1545	The glycosylated domains were mainly localized to the periplasm.
37162352	12	64	gly	glycosylated	1526:1537	arg1	localized					1559:1567	localized	1559:1567	localized	1559:1567	The glycosylated domains were mainly localized to the periplasm.
37162352	2	65	theme	gliding	244:250	arg1	motility					252:259	gliding motility	244:259	gliding motility dependent on the type IX secretion system (T9SS)	244:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	13	66	gly	glycosylation	1701:1713	arg2	sites					1715:1719	the glycosylation sites	1697:1719	the glycosylation sites	1697:1719	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	7	67	from	periplasm	1019:1027	arg1	sites					979:983	The glycosylated sites	962:983	The glycosylated sites	962:983	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	7	67	from	periplasm	1019:1027	arg1	located					1004:1010	located	1004:1010	located	1004:1010	The glycosylated sites were predominantly located in the periplasm, where they are postulated to be beneficial for protein folding/stability.
37162352	6	68	theme	membrane	836:843	arg1	proteins					845:852	68 inner membrane proteins	827:852	68 inner membrane proteins	827:852	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	13	69	theme	O-glycosylation	1603:1617	arg1	function					1591:1598	The function	1587:1598	The function of O-glycosylation	1587:1617	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	13	69	theme	O-glycosylation	1603:1617	arg1	related					1629:1635	related	1629:1635	related	1629:1635	The function of O-glycosylation is likely related to protein folding and stability; therefore, the finding of the glycosylation sites has relevance for studies involving expression of the proteins.
37162352	8	70	theme	gliding	1133:1139	arg1	motility					1141:1148	gliding motility	1133:1148	gliding motility	1133:1148	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated.
37162352	6	71	theme	inner	830:834	arg1	proteins					845:852	68 inner membrane proteins	827:852	68 inner membrane proteins	827:852	Bioinformatic localization of the glycoproteins predicted 68 inner membrane proteins, 60 periplasmic proteins, 26 outer membrane proteins, 57 lipoproteins, and 9 proteins secreted by the T9SS.
37162352	11	72	theme	O-glycosylation	1474:1488	arg1	sites					1490:1494	325 O-glycosylation sites	1470:1494	325 O-glycosylation sites within 226 glycoproteins	1470:1519	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
37162352	2	73	used	used	197:200	arg2	species					213:219	a model species	205:219	a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS)	205:308	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	2	73	used	used	197:200	arg2	It					180:181	It	180:181	It	180:181	It is frequently used as a model species for studying a type of gliding motility dependent on the type IX secretion system (T9SS).
37162352	14	74	theme	components	1936:1945	arg1	function					1918:1925	function	1918:1925	function	1918:1925	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated, which may impact the structure and function of these components.
37162352	14	74	theme	components	1936:1945	arg1	structure					1904:1912	structure	1904:1912	structure	1904:1912	Six proteins associated with gliding motility or the T9SS were demonstrated to be O-glycosylated, which may impact the structure and function of these components.
37162352	10	75	theme	gliding	1355:1361	arg1	motility					1363:1370	gliding motility	1355:1370	gliding motility	1355:1370	It is frequently used as a model species for studying gliding motility and the T9SS.
37162352	9	76	located	found	1276:1280	arg2	johnsoniae					1228:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae	1202:1237	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	9	76	located	found	1276:1280	arg2	bacterium					1258:1266	a Gram-negative bacterium	1242:1266	a Gram-negative bacterium that is found in soil and water	1242:1298	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	9	76	located	found	1276:1280	arg1	water					1294:1298	water	1294:1298	water	1294:1298	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	9	76	located	found	1276:1280	arg1	soil					1285:1288	soil	1285:1288	soil	1285:1288	IMPORTANCE Flavobacterium johnsoniae is a Gram-negative bacterium that is found in soil and water.
37162352	4	77	theme	O-glycosylation	592:606	arg1	sites					608:612	325 O-glycosylation sites	588:612	325 O-glycosylation sites within 226 glycoproteins	588:637	In this study, we characterized the O-glycoproteome of F. johnsoniae and identified 325 O-glycosylation sites within 226 glycoproteins.
34939126	5	0	theme	O-deglycosylation	681:697	arg1	toolbox					699:705	an enzymatic O-deglycosylation toolbox	668:705	an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase	668:843	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	8	1	theme	structural	1208:1217	arg1	knowledge					1219:1227	structural knowledge	1208:1227	structural knowledge on fungal O-glycosylation	1208:1253	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	4	2	theme	selective	605:613	arg1	application					615:625	selective application	605:625	selective application of exoglycosidases	605:644	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	5	3	theme	bean	826:829	arg1	α-mannosidase					831:843	the jack bean α-mannosidase	817:843	the jack bean α-mannosidase	817:843	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	5	3	theme	bean	826:829	arg1	novalis					752:758	Neobacillus novalis	740:758	Neobacillus novalis	740:758	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	6	4	theme	I	990:990	arg1	linker					962:967	the O-glycosylated linker	943:967	the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	943:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	8	5	dep	ready-to-use	1270:1281	arg1	enzymatic					1283:1291	enzymatic	1283:1291	enzymatic	1283:1291	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	6	6	theme	linkage	923:929	arg1	analysis					931:938	a full glycosyl linkage analysis	907:938	a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	907:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	4	7	theme	complete	540:547	arg1	removal					549:555	complete removal	540:555	complete removal	540:555	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	6	8	theme	O-deglycosylation	870:886	arg1	extent					850:855	The extent	846:855	The extent of enzymatic O-deglycosylation	846:886	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	4	9	dep	strategy	480:487	arg1	address					492:498	address	492:498	to address these challenges	489:515	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	3	10	theme	nonnative	389:397	arg1	chains					406:411	nonnative glycan chains	389:411	nonnative glycan chains that may not fulfill the requirement for therapeutic proteins	389:473	Moreover, heterologous protein expression can introduce nonnative glycan chains that may not fulfill the requirement for therapeutic proteins.
34939126	6	11	theme	enzymatic	860:868	arg1	O-deglycosylation					870:886	enzymatic O-deglycosylation	860:886	enzymatic O-deglycosylation	860:886	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	2	12	theme	techniques	295:304	arg1	use					284:286	the use	280:286	the use of key techniques such as mass spectrometry	280:330	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	5	13	theme	Amesia	794:799	arg1	atrobrunnea					801:811	Amesia atrobrunnea	794:811	Amesia atrobrunnea	794:811	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	6	14	theme	linker	962:967	arg1	analysis					931:938	a full glycosyl linkage analysis	907:938	a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	907:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	2	15	theme	key	291:293	arg1	techniques					295:304	key techniques	291:304	key techniques	291:304	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	7	16	from	influence	1044:1052	arg1	functionality					1084:1096	TrCel7A functionality	1076:1096	TrCel7A functionality	1076:1096	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	6	17	from	linker	962:967	arg1	TrCel7A					1017:1023	TrCel7A	1017:1023	TrCel7A	1017:1023	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	6	17	from	linker	962:967	arg1	reesei					1009:1014	Trichoderma reesei	997:1014	Trichoderma reesei (TrCel7A)	997:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	4	18	theme	partial	520:526	arg1	trimming					528:535	partial trimming	520:535	partial trimming	520:535	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	1	19	with	variants	158:165	arg1	properties					180:189	desired properties	172:189	desired properties	172:189	Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties.
34939126	8	20	theme	filamentous	1368:1378	arg1	fungi					1380:1384	filamentous fungi	1368:1384	filamentous fungi	1368:1384	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	8	21	theme	fungal	1232:1237	arg1	O-glycosylation					1239:1253	fungal O-glycosylation	1232:1253	fungal O-glycosylation	1232:1253	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	8	22	attach	presents	1259:1266	arg1	glycoproteins					1341:1353	glycoproteins	1341:1353	glycoproteins expressed in filamentous fungi	1341:1384	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	8	22	attach	presents	1259:1266	arg2	study					1194:1198	This study	1189:1198	This study	1189:1198	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	6	23	from	reesei	1009:1014	arg1	linker					962:967	the O-glycosylated linker	943:967	the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	943:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	6	23	from	reesei	1009:1014	arg1	I					990:990	cellobiohydrolase I	972:990	cellobiohydrolase I from Trichoderma reesei (TrCel7A)	972:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	0	24	theme	high-mannose	19:30	arg1	structures					32:41	fungal high-mannose structures	12:41	fungal high-mannose structures	12:41	Analysis of fungal high-mannose structures using CAZymes.
34939126	8	25	gly	glycoproteins	1341:1353	arg1	glycoproteins					1341:1353	glycoproteins	1341:1353	glycoproteins expressed in filamentous fungi	1341:1384	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	1	26	theme	glycosylation	106:118	arg1	patterns					120:127	glycosylation patterns	106:127	glycosylation patterns	106:127	Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties.
34939126	8	27	from	knowledge	1219:1227	arg1	O-glycosylation					1239:1253	fungal O-glycosylation	1232:1253	fungal O-glycosylation	1232:1253	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	3	28	theme	therapeutic	454:464	arg1	proteins					466:473	therapeutic proteins	454:473	therapeutic proteins	454:473	Moreover, heterologous protein expression can introduce nonnative glycan chains that may not fulfill the requirement for therapeutic proteins.
34939126	3	29	theme	glycan	399:404	arg1	chains					406:411	nonnative glycan chains	389:411	nonnative glycan chains that may not fulfill the requirement for therapeutic proteins	389:473	Moreover, heterologous protein expression can introduce nonnative glycan chains that may not fulfill the requirement for therapeutic proteins.
34939126	7	30	gly	deglycosylation	1057:1071	arg1	TrCel7A					1076:1082	TrCel7A functionality	1076:1096	TrCel7A functionality	1076:1096	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	7	31	theme	O-deglycosylated	1154:1169	arg1	forms					1171:1175	native and O-deglycosylated forms	1143:1175	native and O-deglycosylated forms of TrCel7A	1143:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	8	32	theme	O-glycan	1317:1324	arg1	engineering					1326:1336	controlled O-glycan engineering	1306:1336	controlled O-glycan engineering	1306:1336	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	2	33	theme	mass	314:317	arg1	spectrometry					319:330	mass spectrometry	314:330	mass spectrometry	314:330	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	0	34	theme	fungal	12:17	arg1	structures					32:41	fungal high-mannose structures	12:41	fungal high-mannose structures	12:41	Analysis of fungal high-mannose structures using CAZymes.
34939126	7	35	theme	forms	1171:1175	arg1	characterization					1123:1138	kinetic characterization	1115:1138	kinetic characterization of native and O-deglycosylated forms of TrCel7A	1115:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	7	36	theme	TrCel7A	1180:1186	arg1	forms					1171:1175	native and O-deglycosylated forms	1143:1175	native and O-deglycosylated forms of TrCel7A	1143:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	7	37	theme	native	1143:1148	arg1	forms					1171:1175	native and O-deglycosylated forms	1143:1175	native and O-deglycosylated forms of TrCel7A	1143:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	5	38	from	atrobrunnea	801:811	arg1	β-galactofuranosidase					767:787	a GH2 β-galactofuranosidase	761:787	a GH2 β-galactofuranosidase from Amesia atrobrunnea	761:811	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	5	38	from	atrobrunnea	801:811	arg1	α-mannosidase					831:843	the jack bean α-mannosidase	817:843	the jack bean α-mannosidase	817:843	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	5	38	from	atrobrunnea	801:811	arg1	novalis					752:758	Neobacillus novalis	740:758	Neobacillus novalis	740:758	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	5	39	from	novalis	752:758	arg1	toolbox					699:705	an enzymatic O-deglycosylation toolbox	668:705	an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase	668:843	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	0	40	theme	structures	32:41	arg1	Analysis					0:7	Analysis	0:7	Analysis of fungal high-mannose structures	0:41	Analysis of fungal high-mannose structures using CAZymes.
34939126	4	41	theme	glycan	560:565	arg1	chains					567:572	glycan chains	560:572	glycan chains	560:572	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	1	42	gly	glycoprotein	145:156	arg1	glycoprotein					145:156	new glycoprotein variants	141:165	new glycoprotein variants with desired properties	141:189	Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties.
34939126	2	43	theme	common	194:199	arg1	challenge					201:209	A common challenge	192:209	A common challenge	192:209	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	2	43	theme	common	194:199	arg1	heterogeneity					221:233	glycan heterogeneity	214:233	glycan heterogeneity	214:233	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	2	44	theme	protein	253:259	arg1	function					261:268	protein function	253:268	protein function	253:268	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	8	45	theme	ready-to-use	1270:1281	arg1	approach					1293:1300	a ready-to-use enzymatic approach	1268:1300	a ready-to-use enzymatic approach for controlled O-glycan engineering	1268:1336	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	5	46	theme	GH92	712:715	arg1	α-1,2-mannosidase					717:733	a GH92 α-1,2-mannosidase	710:733	a GH92 α-1,2-mannosidase	710:733	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	6	47	theme	glycosyl	914:921	arg1	analysis					931:938	a full glycosyl linkage analysis	907:938	a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	907:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	6	48	theme	O-glycosylated	947:960	arg1	linker					962:967	the O-glycosylated linker	943:967	the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	943:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	5	49	theme	GH2	763:765	arg1	β-galactofuranosidase					767:787	a GH2 β-galactofuranosidase	761:787	a GH2 β-galactofuranosidase from Amesia atrobrunnea	761:811	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	5	49	theme	GH2	763:765	arg1	novalis					752:758	Neobacillus novalis	740:758	Neobacillus novalis	740:758	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	5	50	theme	α-1,2-mannosidase	717:733	arg1	toolbox					699:705	an enzymatic O-deglycosylation toolbox	668:705	an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase	668:843	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34939126	6	51	theme	full	909:912	arg1	analysis					931:938	a full glycosyl linkage analysis	907:938	a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	907:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	7	52	theme	TrCel7A	1076:1082	arg1	functionality					1084:1096	TrCel7A functionality	1076:1096	TrCel7A functionality	1076:1096	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	1	53	theme	new	141:143	arg1	variants					158:165	new glycoprotein variants	141:165	new glycoprotein variants with desired properties	141:189	Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties.
34939126	4	54	theme	chains	567:572	arg1	trimming					528:535	partial trimming	520:535	partial trimming	520:535	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	4	54	theme	chains	567:572	arg1	removal					549:555	complete removal	540:555	complete removal	540:555	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	1	55	theme	glycoprotein	145:156	arg1	variants					158:165	new glycoprotein variants	141:165	new glycoprotein variants with desired properties	141:189	Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties.
34939126	7	56	theme	kinetic	1115:1121	arg1	characterization					1123:1138	kinetic characterization	1115:1138	kinetic characterization of native and O-deglycosylated forms of TrCel7A	1115:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	7	57	theme	deglycosylation	1057:1071	arg1	influence					1044:1052	the influence	1040:1052	the influence of deglycosylation on TrCel7A functionality	1040:1096	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	7	58	gly	O-deglycosylated	1154:1169	arg1	TrCel7A					1180:1186	TrCel7A	1180:1186	TrCel7A	1180:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	7	58	gly	O-deglycosylated	1154:1169	arg1	forms					1171:1175	native and O-deglycosylated forms	1143:1175	native and O-deglycosylated forms of TrCel7A	1143:1186	Furthermore, the influence of deglycosylation on TrCel7A functionality was evaluated by kinetic characterization of native and O-deglycosylated forms of TrCel7A.
34939126	4	59	theme	exoglycosidases	630:644	arg1	application					615:625	selective application	605:625	selective application of exoglycosidases	605:644	One strategy to address these challenges is partial trimming or complete removal of glycan chains, which can be obtained through selective application of exoglycosidases.
34939126	3	60	theme	heterologous	343:354	arg1	expression					364:373	heterologous protein expression	343:373	heterologous protein expression	343:373	Moreover, heterologous protein expression can introduce nonnative glycan chains that may not fulfill the requirement for therapeutic proteins.
34939126	2	61	theme	glycan	214:219	arg1	challenge					201:209	A common challenge	192:209	A common challenge	192:209	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	2	61	theme	glycan	214:219	arg1	heterogeneity					221:233	glycan heterogeneity	214:233	glycan heterogeneity	214:233	A common challenge is glycan heterogeneity, which may affect protein function and limit the use of key techniques such as mass spectrometry.
34939126	6	62	gly	O-glycosylated	947:960	arg1	linker					962:967	the O-glycosylated linker	943:967	the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A)	943:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	6	63	theme	cellobiohydrolase	972:988	arg1	I					990:990	cellobiohydrolase I	972:990	cellobiohydrolase I from Trichoderma reesei (TrCel7A)	972:1024	The extent of enzymatic O-deglycosylation was mapped against a full glycosyl linkage analysis of the O-glycosylated linker of cellobiohydrolase I from Trichoderma reesei (TrCel7A).
34939126	3	64	theme	protein	356:362	arg1	expression					364:373	heterologous protein expression	343:373	heterologous protein expression	343:373	Moreover, heterologous protein expression can introduce nonnative glycan chains that may not fulfill the requirement for therapeutic proteins.
34939126	8	65	theme	controlled	1306:1315	arg1	engineering					1326:1336	controlled O-glycan engineering	1306:1336	controlled O-glycan engineering	1306:1336	This study expands structural knowledge on fungal O-glycosylation and presents a ready-to-use enzymatic approach for controlled O-glycan engineering in glycoproteins expressed in filamentous fungi.
34939126	1	66	theme	desired	172:178	arg1	properties					180:189	desired properties	172:189	desired properties	172:189	Glycoengineering ultimately allows control over glycosylation patterns to generate new glycoprotein variants with desired properties.
34939126	5	67	theme	enzymatic	671:679	arg1	toolbox					699:705	an enzymatic O-deglycosylation toolbox	668:705	an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase	668:843	Here, we demonstrate an enzymatic O-deglycosylation toolbox of a GH92 α-1,2-mannosidase from Neobacillus novalis, a GH2 β-galactofuranosidase from Amesia atrobrunnea and the jack bean α-mannosidase.
34611867	4	0	theme	galactosylated	651:664	arg1	glycoforms					698:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	4	1	theme	agalactosylated	667:681	arg1	glycoforms					698:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	6	2	theme	therapeutic	993:1003	arg1	activities					1005:1014	higher specific therapeutic activities	977:1014	higher specific therapeutic activities	977:1014	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	1	3	from	attribute	134:142	arg1	relation					147:154	relation	147:154	relation to its therapeutic application	147:185	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	6	4	theme	specific	984:991	arg1	activities					1005:1014	higher specific therapeutic activities	977:1014	higher specific therapeutic activities	977:1014	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	2	5	theme	parameters	275:284	arg1	difficult					241:249	difficult	241:249	difficult	241:249	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	2	5	theme	parameters	275:284	arg1	control					192:198	The control	188:198	The control of this profile during biomanufacture	188:236	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	6	6	theme	higher	977:982	arg1	activities					1005:1014	higher specific therapeutic activities	977:1014	higher specific therapeutic activities	977:1014	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	2	7	theme	glycosylation	302:314	arg1	metabolism					316:325	the glycosylation metabolism	298:325	the glycosylation metabolism within the cell	298:341	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	1	8	theme	N-glycosylation	57:71	arg1	profile					73:79	The N-glycosylation profile	53:79	The N-glycosylation profile of a monoclonal antibody (mAb)	53:110	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	8	theme	N-glycosylation	57:71	arg1	attribute					134:142	a critical quality attribute	115:142	a critical quality attribute in relation to its therapeutic application	115:185	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	2	9	theme	multiple	266:273	arg1	parameters					275:284	the multiple parameters	262:284	the multiple parameters that affect the glycosylation metabolism within the cell	262:341	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	3	10	theme	preferred	443:451	arg1	profile					460:466	a preferred glycan profile	441:466	a preferred glycan profile	441:466	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	6	11	theme	glycans	882:888	arg1	modeling					866:873	Chemoenzymatic modeling	851:873	Chemoenzymatic modeling of mAb glycans	851:888	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	5	12	theme	structures	778:787	arg1	assignment					764:773	assignment	764:773	assignment	764:773	Methods for analysis and assignment of structures of the samples following glycoengineering are also described.
34611867	5	12	theme	structures	778:787	arg1	analysis					751:758	analysis	751:758	analysis	751:758	Methods for analysis and assignment of structures of the samples following glycoengineering are also described.
34611867	4	13	theme	preferred	617:625	arg1	glycoforms					627:636	preferred glycoforms	617:636	preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms	617:707	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	6	14	theme	mAb	878:880	arg1	glycans					882:888	mAb glycans	878:888	mAb glycans	878:888	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	0	15	theme	Free	5:8	arg1	Remodeling					10:19	Cell Free Remodeling	0:19	Cell Free Remodeling of Glycosylation of Antibodies	0:50	Cell Free Remodeling of Glycosylation of Antibodies.
34611867	3	16	used	used	425:428	arg2	One					391:393	One	391:393	One	391:393	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	3	16	used	used	425:428	arg2	approaches					402:411	the approaches	398:411	the approaches	398:411	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	0	17	theme	Cell	0:3	arg1	Remodeling					10:19	Cell Free Remodeling	0:19	Cell Free Remodeling of Glycosylation of Antibodies	0:50	Cell Free Remodeling of Glycosylation of Antibodies.
34611867	6	18	theme	mAbs	967:970	arg1	biomanufacturing					947:962	biomanufacturing	947:962	biomanufacturing of mAbs with higher specific therapeutic activities	947:1014	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	4	19	theme	sialylated	687:696	arg1	glycoforms					698:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	1	20	theme	monoclonal	86:95	arg1	mAb					107:109	mAb	107:109	mAb	107:109	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	20	theme	monoclonal	86:95	arg1	antibody					97:104	monoclonal antibody	86:104	a monoclonal antibody (mAb)	84:110	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	3	21	theme	approaches	402:411	arg1	One					391:393	One	391:393	One	391:393	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	3	21	theme	approaches	402:411	arg1	approaches					402:411	the approaches	398:411	the approaches	398:411	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	6	22	with	biomanufacturing	947:962	arg1	activities					1005:1014	higher specific therapeutic activities	977:1014	higher specific therapeutic activities	977:1014	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	1	23	theme	antibody	97:104	arg1	profile					73:79	The N-glycosylation profile	53:79	The N-glycosylation profile of a monoclonal antibody (mAb)	53:110	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	23	theme	antibody	97:104	arg1	attribute					134:142	a critical quality attribute	115:142	a critical quality attribute in relation to its therapeutic application	115:185	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	5	24	theme	samples	796:802	arg1	structures					778:787	structures	778:787	structures of the samples following glycoengineering	778:829	Methods for analysis and assignment of structures of the samples following glycoengineering are also described.
34611867	3	25	theme	single	473:478	arg1	glycoform					480:488	a single glycoform	471:488	a single glycoform	471:488	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	4	26	gly	sialylated	687:696	arg1	glycoforms					698:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	galactosylated, agalactosylated, or sialylated glycoforms	651:707	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	6	27	theme	Chemoenzymatic	851:864	arg1	modeling					866:873	Chemoenzymatic modeling	851:873	Chemoenzymatic modeling of mAb glycans	851:888	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	1	28	theme	therapeutic	163:173	arg1	application					175:185	its therapeutic application	159:185	its therapeutic application	159:185	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	0	29	theme	Glycosylation	24:36	arg1	Remodeling					10:19	Cell Free Remodeling	0:19	Cell Free Remodeling of Glycosylation of Antibodies	0:50	Cell Free Remodeling of Glycosylation of Antibodies.
34611867	4	30	theme	mAb	734:736	arg1	isolation					719:727	isolation	719:727	isolation of a mAb	719:736	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	2	31	theme	profile	208:214	arg1	difficult					241:249	difficult	241:249	difficult	241:249	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	2	31	theme	profile	208:214	arg1	control					192:198	The control	188:198	The control of this profile during biomanufacture	188:236	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	6	32	contain	has	890:892	arg2	potential					898:906	the potential	894:906	the potential for scale-up	894:919	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	6	32	contain	has	890:892	arg1	modeling					866:873	Chemoenzymatic modeling	851:873	Chemoenzymatic modeling of mAb glycans	851:888	Chemoenzymatic modeling of mAb glycans has the potential for scale-up and to be introduced into biomanufacturing of mAbs with higher specific therapeutic activities.
34611867	3	33	theme	glycan	453:458	arg1	profile					460:466	a preferred glycan profile	441:466	a preferred glycan profile	441:466	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	0	34	theme	Antibodies	41:50	arg1	Glycosylation					24:36	Glycosylation	24:36	Glycosylation of Antibodies	24:50	Cell Free Remodeling of Glycosylation of Antibodies.
34611867	3	35	theme	mAb	553:555	arg1	isolation					538:546	the isolation	534:546	the isolation of a mAb	534:555	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	0	36	gly	Glycosylation	24:36	arg1	Antibodies					41:50	Antibodies	41:50	Antibodies	41:50	Cell Free Remodeling of Glycosylation of Antibodies.
34611867	3	37	theme	chemoenzymatic	501:514	arg1	remodeling					516:525	chemoenzymatic remodeling	501:525	chemoenzymatic remodeling	501:525	One of the approaches that can be used to produce a preferred glycan profile or a single glycoform is through chemoenzymatic remodeling during the isolation of a mAb.
34611867	4	38	used	utilized	597:604	arg2	protocols					575:583	protocols	575:583	protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb	575:736	Here we describe protocols that can be utilized to produce preferred glycoforms that include galactosylated, agalactosylated, or sialylated glycoforms following isolation of a mAb.
34611867	1	39	theme	quality	126:132	arg1	profile					73:79	The N-glycosylation profile	53:79	The N-glycosylation profile of a monoclonal antibody (mAb)	53:110	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	39	theme	quality	126:132	arg1	attribute					134:142	a critical quality attribute	115:142	a critical quality attribute in relation to its therapeutic application	115:185	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	40	gly	N-glycosylation	57:71	arg1	mAb					107:109	mAb	107:109	mAb	107:109	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	40	gly	N-glycosylation	57:71	arg1	antibody					97:104	monoclonal antibody	86:104	a monoclonal antibody (mAb)	84:110	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	41	theme	critical	117:124	arg1	profile					73:79	The N-glycosylation profile	53:79	The N-glycosylation profile of a monoclonal antibody (mAb)	53:110	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	1	41	theme	critical	117:124	arg1	attribute					134:142	a critical quality attribute	115:142	a critical quality attribute in relation to its therapeutic application	115:185	The N-glycosylation profile of a monoclonal antibody (mAb) is a critical quality attribute in relation to its therapeutic application.
34611867	2	42	theme	environment	351:361	arg1	difficult					241:249	difficult	241:249	difficult	241:249	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
34611867	2	42	theme	environment	351:361	arg1	control					192:198	The control	188:198	The control of this profile during biomanufacture	188:236	The control of this profile during biomanufacture is difficult because of the multiple parameters that affect the glycosylation metabolism within the cell and the environment in which the cell is grown.
36029899	10	0	theme	sufficient	1520:1529	arg1	N-glycosylation					1531:1545	sufficient N-glycosylation	1520:1545	sufficient N-glycosylation	1520:1545	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER, ADA2 exerts its function and is secreted extracellularly.
36029899	1	1	theme	adenosine	145:153	arg1	levels					135:140	extracellular levels	121:140	extracellular levels of adenosine	121:153	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	5	2	theme	glucosidase	733:743	arg1	inhibitor					745:753	the endoplasmic reticulum (ER) glucosidase inhibitor	702:753	the endoplasmic reticulum (ER) glucosidase inhibitor	702:753	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	8	3	from	inhibitor	1143:1151	arg1	ER					1180:1181	the ER	1176:1181	the ER	1176:1181	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	8	4	theme	editing	1165:1171	arg1	castanospermine					1123:1137	castanospermine	1123:1137	castanospermine	1123:1137	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	8	4	theme	editing	1165:1171	arg1	inhibitor					1143:1151	an inhibitor	1140:1151	an inhibitor of N-glycan editing in the ER	1140:1181	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	0	5	from	role	2:5	arg1	production					59:68	active adenosine deaminase 2 production	30:68	active adenosine deaminase 2 production	30:68	A role for N-glycosylation in active adenosine deaminase 2 production.
36029899	3	6	gly	N-glycosylation	374:388	arg1	structures					421:430	functional structures	410:430	functional structures	410:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	6	7	theme	initial	831:837	arg1	N-glycosylation					839:853	the initial N-glycosylation	827:853	the initial N-glycosylation of ADA2 in the ER	827:871	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	6	8	with	treatment	906:914	arg1	inhibitors					937:946	N-glycosylation inhibitors	921:946	N-glycosylation inhibitors	921:946	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	6	9	theme	N-glycosylation	921:935	arg1	inhibitors					937:946	N-glycosylation inhibitors	921:946	N-glycosylation inhibitors	921:946	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	8	10	theme	rate	1228:1231	arg1	reduction					1198:1206	a reduction	1196:1206	a reduction of the localization rate to the Golgi	1196:1244	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	9	11	theme	active	1424:1429	arg1	enzyme					1436:1441	an active ADA2 enzyme	1421:1441	an active ADA2 enzyme	1421:1441	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	2	12	theme	enzyme	302:307	arg1	production					276:285	the production	272:285	the production of active ADA2 enzyme	272:307	However, the mechanisms regulating the production of active ADA2 enzyme are not fully understood.
36029899	5	13	theme	Subcellular	658:668	arg1	localization					670:681	Subcellular localization	658:681	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor	658:753	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	9	14	gly	N-glycosylation	1338:1352	arg1	enzyme					1436:1441	an active ADA2 enzyme	1421:1441	an active ADA2 enzyme	1421:1441	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	9	14	gly	N-glycosylation	1338:1352	arg1	ER					1382:1383	the ER	1378:1383	the ER	1378:1383	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	7	15	located	observed	1076:1083	arg1	time					1011:1014	this time	1006:1014	this time	1006:1014	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	7	15	located	observed	1076:1083	arg1	cells					1092:1096	the cells	1088:1096	the cells	1088:1096	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	7	15	located	observed	1076:1083	arg2	decreases					1017:1025	decreases	1017:1025	decreases in the ADA2 homodimers and ADA2 aggregation	1017:1069	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	9	16	theme	ADA2	1431:1434	arg1	enzyme					1436:1441	an active ADA2 enzyme	1421:1441	an active ADA2 enzyme	1421:1441	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	6	17	from	N-glycosylation	839:853	arg1	ER					870:871	the ER	866:871	the ER	866:871	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	9	18	theme	proper	1447:1452	arg1	trafficking					1454:1464	proper trafficking	1447:1464	proper trafficking to the extracellular space	1447:1491	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	4	19	theme	inhibitors	646:655	arg1	application					615:625	the application	611:625	the application of N-glycosylation inhibitors	611:655	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	19	theme	inhibitors	646:655	arg1	mutagenesis					595:605	site-directed mutagenesis	581:605	site-directed mutagenesis	581:605	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	20	from	roles	495:499	arg1	secretion					559:567	secretion	559:567	secretion	559:567	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	20	from	roles	495:499	arg1	activity					527:534	activity	527:534	activity	527:534	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	20	from	roles	495:499	arg1	homodimerization					537:552	homodimerization	537:552	homodimerization	537:552	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	21	dep	activity	527:534	arg1	the					523:525	the	523:525	the	523:525	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	0	22	theme	active	30:35	arg1	deaminase					47:55	active adenosine deaminase	30:55	active adenosine deaminase 2 production	30:68	A role for N-glycosylation in active adenosine deaminase 2 production.
36029899	3	23	from	pathway	450:456	arg1	formation					397:405	the formation	393:405	the formation of functional structures	393:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	1	24	theme	BACKGROUND	71:80	arg1	deaminase					92:100	BACKGROUND Adenosine deaminase 2	71:102	BACKGROUND Adenosine deaminase 2 (ADA2)	71:109	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	1	24	theme	BACKGROUND	71:80	arg1	ADA2					105:108	ADA2	105:108	ADA2	105:108	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	6	25	gly	N-glycosylation	839:853	arg1	ADA2					858:861	ADA2	858:861	ADA2	858:861	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	6	25	gly	N-glycosylation	839:853	arg1	ER					870:871	the ER	866:871	the ER	866:871	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	1	26	theme	optimal	163:169	arg1	expression					171:180	the optimal expression	159:180	the optimal expression of ADA2	159:188	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	1	26	theme	optimal	163:169	arg1	essential					193:201	essential	193:201	essential	193:201	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	9	27	theme	initial	1330:1336	arg1	N-glycosylation					1338:1352	initial N-glycosylation	1330:1352	initial N-glycosylation	1330:1352	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	9	27	theme	initial	1330:1336	arg1	essential					1389:1397	essential	1389:1397	essential	1389:1397	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	9	28	from	N-glycosylation	1338:1352	arg1	ER					1382:1383	the ER	1378:1383	the ER	1378:1383	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	4	29	theme	N-glycosylation	630:644	arg1	inhibitors					646:655	N-glycosylation inhibitors	630:655	N-glycosylation inhibitors	630:655	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	1	30	theme	Adenosine	82:90	arg1	deaminase					92:100	BACKGROUND Adenosine deaminase 2	71:102	BACKGROUND Adenosine deaminase 2 (ADA2)	71:109	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	1	30	theme	Adenosine	82:90	arg1	ADA2					105:108	ADA2	105:108	ADA2	105:108	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	10	31	gly	N-glycosylation	1531:1545	arg1	SIGNIFICANCE					1502:1513	GENERAL SIGNIFICANCE	1494:1513	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER	1494:1555	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER, ADA2 exerts its function and is secreted extracellularly.
36029899	7	32	from	decreases	1017:1025	arg1	homodimers					1039:1048	the ADA2 homodimers	1030:1048	the ADA2 homodimers	1030:1048	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	7	32	from	decreases	1017:1025	arg1	aggregation					1059:1069	ADA2 aggregation	1054:1069	ADA2 aggregation	1054:1069	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	10	33	theme	GENERAL	1494:1500	arg1	SIGNIFICANCE					1502:1513	GENERAL SIGNIFICANCE	1494:1513	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER	1494:1555	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER, ADA2 exerts its function and is secreted extracellularly.
36029899	6	34	theme	intracellular	960:972	arg1	activity					979:986	the intracellular ADA2 activity	956:986	the intracellular ADA2 activity	956:986	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	2	35	theme	ADA2	297:300	arg1	enzyme					302:307	active ADA2 enzyme	290:307	active ADA2 enzyme	290:307	However, the mechanisms regulating the production of active ADA2 enzyme are not fully understood.
36029899	9	36	theme	enzyme	1436:1441	arg1	trafficking					1454:1464	proper trafficking	1447:1464	proper trafficking to the extracellular space	1447:1491	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	9	36	theme	enzyme	1436:1441	arg1	production					1407:1416	the production	1403:1416	the production of an active ADA2 enzyme	1403:1441	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	2	37	theme	active	290:295	arg1	enzyme					302:307	active ADA2 enzyme	290:307	active ADA2 enzyme	290:307	However, the mechanisms regulating the production of active ADA2 enzyme are not fully understood.
36029899	1	38	theme	ADA2	185:188	arg1	expression					171:180	the optimal expression	159:180	the optimal expression of ADA2	159:188	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	1	38	theme	ADA2	185:188	arg1	essential					193:201	essential	193:201	essential	193:201	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	9	39	theme	N-glycan	1358:1365	arg1	editing					1367:1373	N-glycan editing	1358:1373	N-glycan editing	1358:1373	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	6	40	theme	site-directed	877:889	arg1	mutagenesis					891:901	site-directed mutagenesis	877:901	site-directed mutagenesis	877:901	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	3	41	theme	secretory	440:448	arg1	pathway					450:456	the secretory pathway	436:456	the secretory pathway of ADA2	436:464	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	3	42	theme	N-glycosylation	374:388	arg1	pathway					450:456	the secretory pathway	436:456	the secretory pathway of ADA2	436:464	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	3	42	theme	N-glycosylation	374:388	arg1	role					366:369	the role	362:369	the role of N-glycosylation in the formation of functional structures	362:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	9	43	dep	CONCLUSIONS	1290:1300	arg1	suggest					1313:1319	suggest	1313:1319	suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space	1313:1491	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	5	44	theme	endoplasmic	706:716	arg1	ER					729:730	ER	729:730	ER	729:730	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	5	44	theme	endoplasmic	706:716	arg1	reticulum					718:726	endoplasmic reticulum	706:726	the endoplasmic reticulum (ER) glucosidase inhibitor	702:753	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	8	45	from	editing	1165:1171	arg1	ER					1180:1181	the ER	1176:1181	the ER	1176:1181	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	10	46	with	SIGNIFICANCE	1502:1513	arg1	N-glycosylation					1531:1545	sufficient N-glycosylation	1520:1545	sufficient N-glycosylation	1520:1545	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER, ADA2 exerts its function and is secreted extracellularly.
36029899	3	47	theme	structures	421:430	arg1	formation					397:405	the formation	393:405	the formation of functional structures	393:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	5	48	theme	fluorescence	783:794	arg1	microscope					796:805	confocal fluorescence microscope	774:805	confocal fluorescence microscope	774:805	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	5	49	theme	reticulum	718:726	arg1	inhibitor					745:753	the endoplasmic reticulum (ER) glucosidase inhibitor	702:753	the endoplasmic reticulum (ER) glucosidase inhibitor	702:753	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	4	50	dep	METHODS	467:473	arg1	investigated					478:489	investigated	478:489	investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors	478:655	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	0	51	theme	deaminase	47:55	arg1	production					59:68	active adenosine deaminase 2 production	30:68	active adenosine deaminase 2 production	30:68	A role for N-glycosylation in active adenosine deaminase 2 production.
36029899	9	52	theme	extracellular	1473:1485	arg1	space					1487:1491	the extracellular space	1469:1491	the extracellular space	1469:1491	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	7	53	theme	ADA2	1054:1057	arg1	aggregation					1059:1069	ADA2 aggregation	1054:1069	ADA2 aggregation	1054:1069	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	3	54	theme	ADA2	461:464	arg1	pathway					450:456	the secretory pathway	436:456	the secretory pathway of ADA2	436:464	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	3	54	theme	ADA2	461:464	arg1	role					366:369	the role	362:369	the role of N-glycosylation in the formation of functional structures	362:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	0	55	theme	adenosine	37:45	arg1	deaminase					47:55	active adenosine deaminase	30:55	active adenosine deaminase 2 production	30:68	A role for N-glycosylation in active adenosine deaminase 2 production.
36029899	6	56	theme	ADA2	974:977	arg1	activity					979:986	the intracellular ADA2 activity	956:986	the intracellular ADA2 activity	956:986	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	9	57	from	editing	1367:1373	arg1	ER					1382:1383	the ER	1378:1383	the ER	1378:1383	CONCLUSIONS These data suggest that the initial N-glycosylation and N-glycan editing in the ER are essential for the production of an active ADA2 enzyme and proper trafficking to the extracellular space.
36029899	8	58	theme	localization	1215:1226	arg1	rate					1228:1231	the localization rate	1211:1231	the localization rate	1211:1231	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	4	59	theme	N-glycosylation	504:518	arg1	roles					495:499	the roles	491:499	the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2	491:575	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	5	60	theme	ADA2	686:689	arg1	localization					670:681	Subcellular localization	658:681	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor	658:753	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	6	61	theme	ADA2	858:861	arg1	N-glycosylation					839:853	the initial N-glycosylation	827:853	the initial N-glycosylation of ADA2 in the ER	827:871	RESULTS Inhibiting the initial N-glycosylation of ADA2 in the ER via site-directed mutagenesis or treatment with N-glycosylation inhibitors reduced the intracellular ADA2 activity and secretion.
36029899	7	62	theme	ADA2	1034:1037	arg1	homodimers					1039:1048	the ADA2 homodimers	1030:1048	the ADA2 homodimers	1030:1048	At this time, decreases in the ADA2 homodimers and ADA2 aggregation were observed in the cells.
36029899	5	63	theme	confocal	774:781	arg1	microscope					796:805	confocal fluorescence microscope	774:805	confocal fluorescence microscope	774:805	Subcellular localization of ADA2 along with the endoplasmic reticulum (ER) glucosidase inhibitor was observed under confocal fluorescence microscope.
36029899	8	64	from	ER	1180:1181	arg1	castanospermine					1123:1137	castanospermine	1123:1137	castanospermine	1123:1137	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	8	64	from	ER	1180:1181	arg1	inhibitor					1143:1151	an inhibitor	1140:1151	an inhibitor of N-glycan editing in the ER	1140:1181	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	1	65	theme	extracellular	121:133	arg1	levels					135:140	extracellular levels	121:140	extracellular levels of adenosine	121:153	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	4	66	theme	ADA2	572:575	arg1	secretion					559:567	secretion	559:567	secretion	559:567	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	66	theme	ADA2	572:575	arg1	activity					527:534	activity	527:534	activity	527:534	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	66	theme	ADA2	572:575	arg1	homodimerization					537:552	homodimerization	537:552	homodimerization	537:552	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	8	67	theme	N-glycan	1156:1163	arg1	editing					1165:1171	N-glycan editing	1156:1171	N-glycan editing in the ER	1156:1181	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	8	68	theme	ADA2	1274:1277	arg1	secretion					1279:1287	the ADA2 secretion	1270:1287	the ADA2 secretion	1270:1287	Treating the cells with castanospermine, an inhibitor of N-glycan editing in the ER, resulted in a reduction of the localization rate to the Golgi and markedly suppressed the ADA2 secretion.
36029899	3	69	theme	functional	410:419	arg1	structures					421:430	functional structures	410:430	functional structures	410:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	1	70	theme	immune	222:227	arg1	system					229:234	the immune system	218:234	the immune system	218:234	BACKGROUND Adenosine deaminase 2 (ADA2) regulates extracellular levels of adenosine and the optimal expression of ADA2 is essential for modulating the immune system.
36029899	3	71	from	role	366:369	arg1	formation					397:405	the formation	393:405	the formation of functional structures	393:430	In this study, we examined the role of N-glycosylation in the formation of functional structures and the secretory pathway of ADA2.
36029899	10	72	from	SIGNIFICANCE	1502:1513	arg1	ER					1554:1555	the ER	1550:1555	the ER	1550:1555	GENERAL SIGNIFICANCE With sufficient N-glycosylation in the ER, ADA2 exerts its function and is secreted extracellularly.
36029899	4	73	gly	N-glycosylation	504:518	arg1	ADA2					572:575	ADA2	572:575	ADA2	572:575	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
36029899	4	74	theme	site-directed	581:593	arg1	mutagenesis					595:605	site-directed mutagenesis	581:605	site-directed mutagenesis	581:605	METHODS We investigated the roles of N-glycosylation in the activity, homodimerization, and secretion of ADA2 via site-directed mutagenesis and the application of N-glycosylation inhibitors.
35416297	8	0	theme	antigen	1473:1479	arg1	presentation					1481:1492	antigen presentation	1473:1492	antigen presentation by DCs	1473:1499	Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation.
35416297	1	1	theme	therapeutic	162:172	arg1	antibodies					174:183	therapeutic antibodies	162:183	therapeutic antibodies	162:183	In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity.
35416297	1	2	theme	antibodies	174:183	arg1	recognition					147:157	immune recognition	140:157	immune recognition of therapeutic antibodies	140:183	In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity.
35416297	11	3	theme	clinical	1832:1839	arg1	immunogenicity					1841:1854	clinical immunogenicity	1832:1854	clinical immunogenicity	1832:1854	Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
35416297	8	4	theme	stronger	1554:1561	arg1	activation					1580:1589	either stronger or weaker T cell activation	1547:1589	either stronger or weaker T cell activation	1547:1589	Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation.
35416297	3	5	theme	structures	591:600	arg1	effects					559:565	effects	559:565	effects of Fc-associated glycan structures on immune cell responses	559:625	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	8	6	theme	T	1573:1573	arg1	activation					1580:1589	either stronger or weaker T cell activation	1547:1589	either stronger or weaker T cell activation	1547:1589	Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation.
35416297	4	7	dep	recognition	770:780	arg1	1					767:767	1	767:767	1	767:767	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	3	8	from	effects	559:565	arg1	responses					617:625	immune cell responses	605:625	immune cell responses	605:625	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	2	9	theme	human	385:389	arg1	glycosylation					391:403	human glycosylation	385:403	human glycosylation	385:403	Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines.
35416297	5	10	dep	in	1016:1017	arg1	vivo					1019:1022	vivo	1019:1022	vivo	1019:1022	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	4	11	theme	dendritic	796:804	arg1	DCs					813:815	DCs	813:815	DCs	813:815	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	4	11	theme	dendritic	796:804	arg1	cells					806:810	dendritic cells	796:810	dendritic cells (DCs)	796:816	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	8	12	theme	weaker	1566:1571	arg1	activation					1580:1589	either stronger or weaker T cell activation	1547:1589	either stronger or weaker T cell activation	1547:1589	Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation.
35416297	10	13	theme	defined	1710:1716	arg1	structures					1725:1734	defined glycan structures	1710:1734	defined glycan structures	1710:1734	Hence, defined glycan structures can modulate immune recognition and alter ADA responses.
35416297	3	14	theme	Fc-associated	570:582	arg1	structures					591:600	Fc-associated glycan structures	570:600	Fc-associated glycan structures	570:600	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	2	15	theme	cell	430:433	arg1	lines					435:439	non-human cell lines	420:439	non-human cell lines	420:439	Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines.
35416297	5	16	dep	in	958:959	arg1	vitro					961:965	vitro	961:965	vitro	961:965	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	2	17	theme	high	299:302	arg1	heterogeneity					304:316	the high heterogeneity	295:316	the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines	295:439	Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines.
35416297	2	18	theme	non-human	420:428	arg1	lines					435:439	non-human cell lines	420:439	non-human cell lines	420:439	Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines.
35416297	0	19	theme	antibody	12:19	arg1	glycosylation					21:33	Therapeutic antibody glycosylation	0:33	Therapeutic antibody glycosylation	0:33	Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity.
35416297	8	20	theme	cell	1575:1578	arg1	activation					1580:1589	either stronger or weaker T cell activation	1547:1589	either stronger or weaker T cell activation	1547:1589	Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation.
35416297	6	21	gly	aglycosylated	1118:1130	arg1	form					1132:1135	its aglycosylated form	1114:1135	its aglycosylated form	1114:1135	We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors.
35416297	0	22	theme	Therapeutic	0:10	arg1	glycosylation					21:33	Therapeutic antibody glycosylation	0:33	Therapeutic antibody glycosylation	0:33	Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity.
35416297	11	23	theme	ADA-associated	1860:1873	arg1	reactions					1915:1923	hypersensitivity reactions	1898:1923	hypersensitivity reactions	1898:1923	Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
35416297	11	23	theme	ADA-associated	1860:1873	arg1	events					1883:1888	ADA-associated adverse events	1860:1888	ADA-associated adverse events	1860:1888	Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
35416297	9	24	theme	antibody	1621:1628	arg1	glycosylation					1630:1642	antibody glycosylation	1621:1642	antibody glycosylation	1621:1642	Finally, we demonstrate that antibody glycosylation impacts anti-drug antibody (ADA) responses to RTX in vivo.
35416297	5	25	theme	human	980:984	arg1	DCs					986:988	human DCs	980:988	human DCs	980:988	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	1	26	theme	defined	195:201	arg1	structures					210:219	defined glycan structures	195:219	defined glycan structures	195:219	In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity.
35416297	6	27	theme	unmodified	1078:1087	arg1	RTX					1089:1091	unmodified RTX	1078:1091	unmodified RTX	1078:1091	We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors.
35416297	3	28	theme	immune	605:610	arg1	responses					617:625	immune cell responses	605:625	immune cell responses	605:625	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	1	29	theme	glycan	203:208	arg1	structures					210:219	defined glycan structures	195:219	defined glycan structures	195:219	In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity.
35416297	6	30	theme	aglycosylated	1118:1130	arg1	form					1132:1135	its aglycosylated form	1114:1135	its aglycosylated form	1114:1135	We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors.
35416297	4	31	theme	antigen	826:832	arg1	processing					843:852	processing	843:852	processing	843:852	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	4	31	theme	antigen	826:832	arg1	routing					834:840	antigen routing	826:840	antigen routing	826:840	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	4	31	theme	antigen	826:832	arg1	presentation					858:869	presentation	858:869	presentation	858:869	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	3	32	theme	cell	612:615	arg1	responses					617:625	immune cell responses	605:625	immune cell responses	605:625	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	7	33	theme	activating	1351:1360	arg1	receptors					1402:1410	activating (by mannosylation) or inhibitory lectin receptors	1351:1410	activating (by mannosylation) or inhibitory lectin receptors	1351:1410	Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation).
35416297	6	34	theme	human	1047:1051	arg1	DCs					1053:1055	human DCs	1047:1055	human DCs	1047:1055	We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors.
35416297	10	35	theme	glycan	1718:1723	arg1	structures					1725:1734	defined glycan structures	1710:1734	defined glycan structures	1710:1734	Hence, defined glycan structures can modulate immune recognition and alter ADA responses.
35416297	4	36	dep	routing	834:840	arg1	2					823:823	2	823:823	2	823:823	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	5	37	theme	different	890:898	arg1	variants					914:921	different glycosylation variants	890:921	different glycosylation variants of the antibody rituximab (RTX)	890:953	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	0	38	theme	antigen	43:49	arg1	recognition					51:61	antigen recognition	43:61	antigen recognition	43:61	Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity.
35416297	3	39	theme	non-human	448:456	arg1	glycosylation					458:470	non-human glycosylation	448:470	non-human glycosylation	448:470	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	9	40	theme	anti-drug	1652:1660	arg1	antibody					1662:1669	anti-drug antibody	1652:1669	anti-drug antibody (ADA) responses to RTX	1652:1692	Finally, we demonstrate that antibody glycosylation impacts anti-drug antibody (ADA) responses to RTX in vivo.
35416297	9	40	theme	anti-drug	1652:1660	arg1	ADA					1672:1674	ADA	1672:1674	ADA	1672:1674	Finally, we demonstrate that antibody glycosylation impacts anti-drug antibody (ADA) responses to RTX in vivo.
35416297	5	41	theme	glycosylation	900:912	arg1	variants					914:921	different glycosylation variants	890:921	different glycosylation variants of the antibody rituximab (RTX)	890:953	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	3	42	theme	hypersensitivity	492:507	arg1	reactions					509:517	hypersensitivity reactions	492:517	hypersensitivity reactions	492:517	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	11	43	theme	hypersensitivity	1898:1913	arg1	reactions					1915:1923	hypersensitivity reactions	1898:1923	hypersensitivity reactions	1898:1923	Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
35416297	11	44	theme	adverse	1875:1881	arg1	reactions					1915:1923	hypersensitivity reactions	1898:1923	hypersensitivity reactions	1898:1923	Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
35416297	11	44	theme	adverse	1875:1881	arg1	events					1883:1888	ADA-associated adverse events	1860:1888	ADA-associated adverse events	1860:1888	Glyco-engineering may help to decrease clinical immunogenicity and ADA-associated adverse events such as hypersensitivity reactions.
35416297	9	45	theme	antibody	1662:1669	arg1	responses					1677:1685	anti-drug antibody (ADA) responses	1652:1685	anti-drug antibody (ADA) responses to RTX	1652:1692	Finally, we demonstrate that antibody glycosylation impacts anti-drug antibody (ADA) responses to RTX in vivo.
35416297	10	46	theme	ADA	1778:1780	arg1	responses					1782:1790	ADA responses	1778:1790	ADA responses	1778:1790	Hence, defined glycan structures can modulate immune recognition and alter ADA responses.
35416297	6	47	theme	glycan-specific	1204:1218	arg1	receptors					1220:1228	glycan-specific receptors	1204:1228	glycan-specific receptors	1204:1228	We found that human DCs bind and internalize unmodified RTX stronger compared to its aglycosylated form suggesting that glycosylation mediates uptake after recognition by glycan-specific receptors.
35416297	5	48	theme	in	958:959	arg1	assays					967:972	in vitro assays	958:972	in vitro assays using human DCs and T cells	958:1000	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	2	49	from	heterogeneity	304:316	arg1	glycosylation					321:333	glycosylation	321:333	glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines	321:439	Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines.
35416297	7	50	dep	activating	1351:1360	arg1	mannosylation					1366:1378	mannosylation	1366:1378	mannosylation	1366:1378	Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation).
35416297	8	51	theme	specific	1509:1516	arg1	glycovariants					1518:1530	specific glycovariants	1509:1530	specific glycovariants	1509:1530	Moreover, glycosylation seems to influence antigen presentation by DCs because specific glycovariants tend to induce either stronger or weaker T cell activation.
35416297	7	52	theme	lectin	1395:1400	arg1	receptors					1402:1410	activating (by mannosylation) or inhibitory lectin receptors	1351:1410	activating (by mannosylation) or inhibitory lectin receptors	1351:1410	Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation).
35416297	5	53	theme	antibody	930:937	arg1	RTX					950:952	RTX	950:952	RTX	950:952	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	5	53	theme	antibody	930:937	arg1	rituximab					939:947	the antibody rituximab	926:947	the antibody rituximab (RTX)	926:953	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	4	54	theme	antigen	672:678	arg1	recognition					680:690	antigen recognition	672:690	antigen recognition	672:690	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	3	55	theme	glycan	584:589	arg1	structures					591:600	Fc-associated glycan structures	570:600	Fc-associated glycan structures	570:600	While non-human glycosylation is thought to cause hypersensitivity reactions and immunogenicity, less is known about effects of Fc-associated glycan structures on immune cell responses.
35416297	5	56	theme	T	994:994	arg1	cells					996:1000	T cells	994:1000	T cells	994:1000	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	1	57	theme	immune	140:145	arg1	recognition					147:157	immune recognition	140:157	immune recognition of therapeutic antibodies	140:183	In this study we show that glycosylation is relevant for immune recognition of therapeutic antibodies, and that defined glycan structures can modulate immunogenicity.
35416297	2	58	dep	Concerns	250:257	arg1	arise					284:288	arise	284:288	arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines	284:439	Concerns regarding immunogenicity arise from the high heterogeneity in glycosylation that is difficult to control and can deviate from human glycosylation if produced in non-human cell lines.
35416297	5	59	theme	in	1016:1017	arg1	studies					1024:1030	in vivo studies	1016:1030	in vivo studies	1016:1030	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	4	60	theme	humoral	709:715	arg1	responses					717:725	humoral responses	709:725	humoral responses to therapeutic antibodies	709:751	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	5	61	theme	rituximab	939:947	arg1	variants					914:921	different glycosylation variants	890:921	different glycosylation variants of the antibody rituximab (RTX)	890:953	Here, we compared different glycosylation variants of the antibody rituximab (RTX) in in vitro assays using human DCs and T cells as well as in in vivo studies.
35416297	4	62	theme	therapeutic	730:740	arg1	antibodies					742:751	therapeutic antibodies	730:751	therapeutic antibodies	730:751	We postulated that glycosylation influences antigen recognition and subsequently humoral responses to therapeutic antibodies by modulating 1) recognition and uptake by dendritic cells (DCs), and 2) antigen routing, processing and presentation.
35416297	7	63	theme	inhibitory	1384:1393	arg1	receptors					1402:1410	activating (by mannosylation) or inhibitory lectin receptors	1351:1410	activating (by mannosylation) or inhibitory lectin receptors	1351:1410	Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation).
35416297	7	64	dep	recognize	1341:1349	arg1	sialylation					1416:1426	sialylation	1416:1426	sialylation	1416:1426	Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation).
35416297	7	65	theme	RTX	1270:1272	arg1	DC-uptake					1257:1265	DC-uptake	1257:1265	DC-uptake of RTX	1257:1272	Furthermore, we show that DC-uptake of RTX increases or decreases if glycosylation is selectively modified to recognize activating (by mannosylation) or inhibitory lectin receptors (by sialylation).
35416297	10	66	theme	immune	1749:1754	arg1	recognition					1756:1766	immune recognition	1749:1766	immune recognition	1749:1766	Hence, defined glycan structures can modulate immune recognition and alter ADA responses.
36719065	0	0	theme	Thermococcus	96:107	arg1	Archaeon					87:94	the Hyperthermophilic Archaeon Thermococcus kodakarensis	65:120	the Hyperthermophilic Archaeon Thermococcus kodakarensis	65:120	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	6	1	from	level	1078:1082	arg1	function					1029:1036	the primitive function	1015:1036	the primitive function of glycan modification at the molecular level	1015:1082	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	5	2	theme	straightforward	732:746	arg1	synthesis					748:756	The straightforward synthesis	728:756	The straightforward synthesis of this glycan	728:771	The straightforward synthesis of this glycan was accomplished via diastereoselective phosphorylation and phosphodiester construction by SN2 coupling.
36719065	2	3	theme	N-glycan	391:398	arg1	synthesis					378:386	chemical synthesis	369:386	chemical synthesis	369:386	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	2	3	theme	N-glycan	391:398	arg1	isolation					328:336	isolation	328:336	isolation	328:336	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	2	3	theme	N-glycan	391:398	arg1	determination					350:362	structural determination	339:362	structural determination	339:362	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	5	4	theme	phosphodiester	833:846	arg1	construction					848:859	phosphodiester construction	833:859	phosphodiester construction	833:859	The straightforward synthesis of this glycan was accomplished via diastereoselective phosphorylation and phosphodiester construction by SN2 coupling.
36719065	4	5	gly	glycosylated	653:664	arg2	myo-inositol					630:641	myo-inositol	630:641	myo-inositol	630:641	In this structure, myo-inositol is highly glycosylated and linked with a disaccharide unit through a phosphodiester.
36719065	4	5	gly	glycosylated	653:664	arg1	myo-inositol					630:641	myo-inositol	630:641	myo-inositol	630:641	In this structure, myo-inositol is highly glycosylated and linked with a disaccharide unit through a phosphodiester.
36719065	4	5	gly	glycosylated	653:664	arg1	structure					619:627	this structure	614:627	this structure	614:627	In this structure, myo-inositol is highly glycosylated and linked with a disaccharide unit through a phosphodiester.
36719065	6	6	theme	organisms	932:940	arg1	divergence					900:909	the early divergence	890:909	the early divergence of hyperthermophilic organisms in evolution	890:953	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	5	7	theme	SN2	864:866	arg1	coupling					868:875	SN2 coupling	864:875	SN2 coupling	864:875	The straightforward synthesis of this glycan was accomplished via diastereoselective phosphorylation and phosphodiester construction by SN2 coupling.
36719065	6	8	theme	hyperthermophilic	914:930	arg1	organisms					932:940	hyperthermophilic organisms	914:940	hyperthermophilic organisms	914:940	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	1	9	theme	abundant	203:210	arg1	modifications					231:243	the most abundant post-translational modifications	194:243	the most abundant post-translational modifications	194:243	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	0	10	theme	Hyperthermophilic	69:85	arg1	Archaeon					87:94	the Hyperthermophilic Archaeon Thermococcus kodakarensis	65:120	the Hyperthermophilic Archaeon Thermococcus kodakarensis	65:120	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	1	11	theme	post-translational	212:229	arg1	modifications					231:243	the most abundant post-translational modifications	194:243	the most abundant post-translational modifications	194:243	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	0	12	theme	Structural	0:9	arg1	Determination					11:23	Structural Determination	0:23	Structural Determination	0:23	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	0	13	dep	Archaeon	87:94	arg1	kodakarensis					109:120	the Hyperthermophilic Archaeon Thermococcus kodakarensis	65:120	the Hyperthermophilic Archaeon Thermococcus kodakarensis	65:120	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	1	14	theme	modifications	231:243	arg1	one					187:189	one	187:189	one	187:189	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	1	14	theme	modifications	231:243	arg1	modifications					231:243	the most abundant post-translational modifications	194:243	the most abundant post-translational modifications	194:243	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	0	15	theme	Chemical	29:36	arg1	Synthesis					38:46	Chemical Synthesis	29:46	Chemical Synthesis	29:46	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	6	16	theme	early	894:898	arg1	divergence					900:909	the early divergence	890:909	the early divergence of hyperthermophilic organisms in evolution	890:953	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	2	17	theme	structural	339:348	arg1	determination					350:362	structural determination	339:362	structural determination	339:362	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	6	18	from	divergence	900:909	arg1	evolution					945:953	evolution	945:953	evolution	945:953	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	5	19	theme	diastereoselective	794:811	arg1	phosphorylation					813:827	diastereoselective phosphorylation	794:827	diastereoselective phosphorylation	794:827	The straightforward synthesis of this glycan was accomplished via diastereoselective phosphorylation and phosphodiester construction by SN2 coupling.
36719065	1	20	theme	protein	141:147	arg1	N-glycosylations					165:180	N-glycosylations	165:180	N-glycosylations	165:180	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	1	20	theme	protein	141:147	arg1	glycosylations					149:162	Asparagine-linked protein glycosylations	123:162	Asparagine-linked protein glycosylations (N-glycosylations)	123:181	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	0	21	from	Archaeon	87:94	arg1	Determination					11:23	Structural Determination	0:23	Structural Determination	0:23	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	0	21	from	Archaeon	87:94	arg1	Synthesis					38:46	Chemical Synthesis	29:46	Chemical Synthesis	29:46	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	6	22	theme	molecular	1068:1076	arg1	level					1078:1082	the molecular level	1064:1082	the molecular level	1064:1082	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	2	23	from	archaeon	427:434	arg1	synthesis					378:386	chemical synthesis	369:386	chemical synthesis	369:386	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	2	23	from	archaeon	427:434	arg1	isolation					328:336	isolation	328:336	isolation	328:336	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	2	23	from	archaeon	427:434	arg1	determination					350:362	structural determination	339:362	structural determination	339:362	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	0	24	theme	N-Glycan	51:58	arg1	Determination					11:23	Structural Determination	0:23	Structural Determination	0:23	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	0	24	theme	N-Glycan	51:58	arg1	Synthesis					38:46	Chemical Synthesis	29:46	Chemical Synthesis	29:46	Structural Determination and Chemical Synthesis of N-Glycan from the Hyperthermophilic Archaeon Thermococcus kodakarensis.
36719065	5	25	theme	glycan	766:771	arg1	synthesis					748:756	The straightforward synthesis	728:756	The straightforward synthesis of this glycan	728:771	The straightforward synthesis of this glycan was accomplished via diastereoselective phosphorylation and phosphodiester construction by SN2 coupling.
36719065	3	26	contain	possesses	494:502	arg1	N-glycan					467:474	The N-glycan	463:474	The N-glycan from the organism	463:492	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	3	26	contain	possesses	494:502	arg2	structure					513:521	a unique structure	504:521	a unique structure	504:521	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	6	27	theme	modification	1048:1059	arg1	function					1029:1036	the primitive function	1015:1036	the primitive function of glycan modification at the molecular level	1015:1082	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	3	28	located	found	566:570	arg1	N-glycans					600:608	previously characterized N-glycans	575:608	previously characterized N-glycans	575:608	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	3	28	located	found	566:570	arg2	structure					513:521	a unique structure	504:521	a unique structure	504:521	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	2	29	theme	chemical	369:376	arg1	synthesis					378:386	chemical synthesis	369:386	chemical synthesis	369:386	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	1	30	theme	Asparagine-linked	123:139	arg1	N-glycosylations					165:180	N-glycosylations	165:180	N-glycosylations	165:180	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	1	30	theme	Asparagine-linked	123:139	arg1	glycosylations					149:162	Asparagine-linked protein glycosylations	123:162	Asparagine-linked protein glycosylations (N-glycosylations)	123:181	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	1	31	theme	various	267:273	arg1	phenomena					286:294	various biological phenomena	267:294	various biological phenomena	267:294	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	3	32	from	organism	485:492	arg1	N-glycan					467:474	The N-glycan	463:474	The N-glycan from the organism	463:492	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	1	33	theme	biological	275:284	arg1	phenomena					286:294	various biological phenomena	267:294	various biological phenomena	267:294	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	1	34	link	Asparagine-linked	123:139	arg1	N-glycosylations					165:180	N-glycosylations	165:180	N-glycosylations	165:180	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	1	34	link	Asparagine-linked	123:139	arg1	glycosylations					149:162	Asparagine-linked protein glycosylations	123:162	Asparagine-linked protein glycosylations (N-glycosylations)	123:181	Asparagine-linked protein glycosylations (N-glycosylations) are one of the most abundant post-translational modifications and are essential for various biological phenomena.
36719065	2	35	theme	hyperthermophilic	409:425	arg1	archaeon					427:434	the hyperthermophilic archaeon	405:434	the hyperthermophilic archaeon	405:434	In this study, we achieved the isolation, structural determination, and chemical synthesis of N-glycan from the hyperthermophilic archaeon Thermococcus kodakarensis.
36719065	3	36	theme	unique	506:511	arg1	structure					513:521	a unique structure	504:521	a unique structure	504:521	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	6	37	theme	primitive	1019:1027	arg1	function					1029:1036	the primitive function	1015:1036	the primitive function of glycan modification at the molecular level	1015:1082	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	6	38	theme	glycan	1041:1046	arg1	modification					1048:1059	glycan modification	1041:1059	glycan modification	1041:1059	Considering the early divergence of hyperthermophilic organisms in evolution, this study can be expected to open the door to approaching the primitive function of glycan modification at the molecular level.
36719065	3	39	theme	characterized	586:598	arg1	N-glycans					600:608	previously characterized N-glycans	575:608	previously characterized N-glycans	575:608	The N-glycan from the organism possesses a unique structure including myo-inositol, which has not been found in previously characterized N-glycans.
36719065	4	40	theme	disaccharide	684:695	arg1	unit					697:700	a disaccharide unit	682:700	a disaccharide unit	682:700	In this structure, myo-inositol is highly glycosylated and linked with a disaccharide unit through a phosphodiester.
35616904	1	0	gly	glycoproteins	91:103	arg1	glycoproteins					91:103	N-Linked glycoproteins	82:103	N-Linked glycoproteins	82:103	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	0	1	from	Interpretation	21:34	arg1	Plasma					74:79	Seminal Plasma	66:79	Seminal Plasma	66:79	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.
35616904	5	2	theme	branch	814:819	arg1	structures					821:830	13 branch structures	811:830	13 branch structures	811:830	These glycans were comprised of four types of core structures and 13 branch structures.
35616904	3	3	theme	interpretation	545:558	arg1	software					560:567	a recently developed glycan structure interpretation software	507:567	a recently developed glycan structure interpretation software	507:567	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	3	3	theme	interpretation	545:558	arg1	StrucGP					570:576	StrucGP	570:576	StrucGP	570:576	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	9	4	from	study	1484:1488	arg1	system					1532:1537	the male reproduction system	1510:1537	the male reproduction system	1510:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	4	5	theme	human	630:634	arg1	plasma					644:649	human seminal plasma	630:649	human seminal plasma	630:649	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	5	6	theme	structures	821:830	arg1	types					782:786	four types	777:786	four types of core structures and 13 branch structures	777:830	These glycans were comprised of four types of core structures and 13 branch structures.
35616904	4	7	gly	N-glycosites	708:719	arg2	N-glycosites					708:719	1019 N-glycosites	703:719	1019 N-glycosites from 620 glycoproteins	703:742	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	8	8	theme	glycan	1302:1307	arg1	structures					1309:1318	more complicated glycan structures	1285:1318	more complicated glycan structures	1285:1318	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	7	9	theme	pathways	1191:1198	arg1	response					1145:1152	the immune response	1134:1152	the immune response of biological processes and reactome pathways	1134:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	8	10	theme	seminal	1323:1329	arg1	plasma					1331:1336	seminal plasma	1323:1336	seminal plasma	1323:1336	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	3	11	theme	precision	364:372	arg1	map					404:406	a precision site-specific N-glycoproteome map	362:406	a precision site-specific N-glycoproteome map of human seminal plasma	362:430	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	8	12	gly	glycoproteins	1380:1392	arg1	glycoproteins					1380:1392	their shared glycoproteins	1367:1392	their shared glycoproteins	1367:1392	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	7	13	theme	biological	1157:1166	arg1	processes					1168:1176	biological processes	1157:1176	biological processes	1157:1176	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	14	dep	fucosylation	966:977	arg1	residues					987:994	fucose residues ≥6	980:997	fucose residues ≥6 per glycan	980:1008	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	4	15	from	glycoproteins	730:742	arg1	structures					688:697	773 N-linked glycan structures	668:697	773 N-linked glycan structures	668:697	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	4	15	from	glycoproteins	730:742	arg1	N-glycosites					708:719	1019 N-glycosites	703:719	1019 N-glycosites from 620 glycoproteins	703:742	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	3	16	theme	site-specific	374:386	arg1	map					404:406	a precision site-specific N-glycoproteome map	362:406	a precision site-specific N-glycoproteome map of human seminal plasma	362:430	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	7	17	theme	processes	1168:1176	arg1	response					1145:1152	the immune response	1134:1152	the immune response of biological processes and reactome pathways	1134:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	6	18	theme	glycoproteins	860:872	arg1	majority					837:844	The majority	833:844	The majority of identified glycoproteins	833:872	The majority of identified glycoproteins functioned in response to stimulus and immunity.
35616904	2	19	theme	glycan	310:315	arg1	structures					317:326	site-specific glycan structures	296:326	site-specific glycan structures	296:326	However, the detailed information on these glycoproteins, particularly site-specific glycan structures, is still limited.
35616904	3	20	theme	developed	518:526	arg1	structure					535:543	a recently developed glycan structure	507:543	a recently developed glycan structure interpretation software	507:567	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	5	21	theme	core	791:794	arg1	structures					796:805	core structures	791:805	core structures	791:805	These glycans were comprised of four types of core structures and 13 branch structures.
35616904	8	22	theme	seminal	1245:1251	arg1	plasma					1253:1258	plasma	1253:1258	plasma	1253:1258	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	6	23	theme	identified	849:858	arg1	glycoproteins					860:872	identified glycoproteins	849:872	identified glycoproteins	849:872	The majority of identified glycoproteins functioned in response to stimulus and immunity.
35616904	1	24	theme	N-Linked	82:89	arg1	glycoproteins					91:103	N-Linked glycoproteins	82:103	N-Linked glycoproteins	82:103	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	1	25	theme	sperm	179:183	arg1	function					185:192	sperm function	179:192	sperm function	179:192	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	4	26	theme	seminal	636:642	arg1	plasma					644:649	human seminal plasma	630:649	human seminal plasma	630:649	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	9	27	theme	present	1401:1407	arg1	data					1409:1412	These present data	1395:1412	These present data	1395:1412	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	8	28	theme	complicated	1290:1300	arg1	structures					1309:1318	more complicated glycan structures	1285:1318	more complicated glycan structures	1285:1318	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	3	29	theme	human	411:415	arg1	plasma					425:430	human seminal plasma	411:430	human seminal plasma	411:430	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	2	30	from	information	247:257	arg1	glycoproteins					268:280	these glycoproteins	262:280	these glycoproteins	262:280	However, the detailed information on these glycoproteins, particularly site-specific glycan structures, is still limited.
35616904	3	31	theme	site-specific	465:477	arg1	approach					494:501	the site-specific glycoproteomic approach	461:501	the site-specific glycoproteomic approach	461:501	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	0	32	theme	Structural	10:19	arg1	Interpretation					21:34	Precision Structural Interpretation	0:34	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.	0:80	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.
35616904	7	33	located	detected	1020:1027	arg1	protein					1102:1108	galectin-3-binding protein	1083:1108	galectin-3-binding protein	1083:1108	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	33	located	detected	1020:1027	arg2	fucosylation					966:977	heavy fucosylation	960:977	heavy fucosylation (fucose residues ≥6 per glycan)	960:1009	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	33	located	detected	1020:1027	arg1	glycoproteins					1047:1059	seminal plasma glycoproteins	1032:1059	seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways	1032:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	33	located	detected	1020:1027	arg1	clusterin					1069:1077	clusterin	1069:1077	clusterin	1069:1077	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	4	34	theme	620	726:728	arg1	glycoproteins					730:742	620 glycoproteins	726:742	620 glycoproteins	726:742	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	0	35	theme	Precision	0:8	arg1	Interpretation					21:34	Precision Structural Interpretation	0:34	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.	0:80	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.
35616904	4	36	theme	unique	595:600	arg1	glycopeptides					602:614	9567 unique glycopeptides	590:614	9567 unique glycopeptides identified in human seminal plasma	590:649	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	7	37	theme	immune	1138:1143	arg1	response					1145:1152	the immune response	1134:1152	the immune response of biological processes and reactome pathways	1134:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	1	38	from	plasma	125:130	arg1	rich					109:112	rich	109:112	rich	109:112	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	2	39	dep	glycoproteins	268:280	arg1	structures					317:326	site-specific glycan structures	296:326	site-specific glycan structures	296:326	However, the detailed information on these glycoproteins, particularly site-specific glycan structures, is still limited.
35616904	3	40	theme	N-glycoproteome	388:402	arg1	map					404:406	a precision site-specific N-glycoproteome map	362:406	a precision site-specific N-glycoproteome map of human seminal plasma	362:430	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	7	41	theme	fucose	980:985	arg1	residues					987:994	fucose residues ≥6	980:997	fucose residues ≥6 per glycan	980:1008	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	8	42	theme	shared	1373:1378	arg1	glycoproteins					1380:1392	their shared glycoproteins	1367:1392	their shared glycoproteins	1367:1392	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	9	43	theme	reproduction	1519:1530	arg1	system					1532:1537	the male reproduction system	1510:1537	the male reproduction system	1510:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	9	44	theme	structural	1458:1467	arg1	study					1484:1488	the in-depth structural and functional study	1445:1488	the in-depth structural and functional study of glycosylation in the male reproduction system	1445:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	1	45	theme	fertilization	202:214	arg1	process					216:222	the fertilization process	198:222	the fertilization process	198:222	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	7	46	theme	plasma	1040:1045	arg1	protein					1102:1108	galectin-3-binding protein	1083:1108	galectin-3-binding protein	1083:1108	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	46	theme	plasma	1040:1045	arg1	glycoproteins					1047:1059	seminal plasma glycoproteins	1032:1059	seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways	1032:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	46	theme	plasma	1040:1045	arg1	clusterin					1069:1077	clusterin	1069:1077	clusterin	1069:1077	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	2	47	theme	site-specific	296:308	arg1	structures					317:326	site-specific glycan structures	296:326	site-specific glycan structures	296:326	However, the detailed information on these glycoproteins, particularly site-specific glycan structures, is still limited.
35616904	1	48	theme	seminal	117:123	arg1	plasma					125:130	seminal plasma	117:130	seminal plasma	117:130	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	9	49	theme	male	1514:1517	arg1	system					1532:1537	the male reproduction system	1510:1537	the male reproduction system	1510:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	4	50	theme	N-linked	672:679	arg1	structures					688:697	773 N-linked glycan structures	668:697	773 N-linked glycan structures	668:697	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	0	51	theme	N-Glycans	53:61	arg1	Interpretation					21:34	Precision Structural Interpretation	0:34	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.	0:80	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.
35616904	4	52	theme	glycopeptides	602:614	arg1	total					581:585	A total	579:585	A total of 9567 unique glycopeptides identified in human seminal plasma	579:649	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	7	53	theme	heavy	960:964	arg1	fucosylation					966:977	heavy fucosylation	960:977	heavy fucosylation (fucose residues ≥6 per glycan)	960:1009	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	3	54	theme	glycoproteomic	479:492	arg1	approach					494:501	the site-specific glycoproteomic approach	461:501	the site-specific glycoproteomic approach	461:501	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	0	55	theme	Site-Specific	39:51	arg1	N-Glycans					53:61	Site-Specific N-Glycans	39:61	Site-Specific N-Glycans	39:61	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.
35616904	8	56	theme	more	1285:1288	arg1	structures					1309:1318	more complicated glycan structures	1285:1318	more complicated glycan structures	1285:1318	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	2	57	theme	detailed	238:245	arg1	information					247:257	the detailed information	234:257	the detailed information on these glycoproteins, particularly site-specific glycan structures,	234:327	However, the detailed information on these glycoproteins, particularly site-specific glycan structures, is still limited.
35616904	9	58	theme	glycosylation	1493:1505	arg1	study					1484:1488	the in-depth structural and functional study	1445:1488	the in-depth structural and functional study of glycosylation in the male reproduction system	1445:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	5	59	theme	structures	796:805	arg1	types					782:786	four types	777:786	four types of core structures and 13 branch structures	777:830	These glycans were comprised of four types of core structures and 13 branch structures.
35616904	0	60	theme	Seminal	66:72	arg1	Plasma					74:79	Seminal Plasma	66:79	Seminal Plasma	66:79	Precision Structural Interpretation of Site-Specific N-Glycans in Seminal Plasma.
35616904	8	61	theme	glycans	1229:1235	arg1	Comparison					1201:1210	Comparison	1201:1210	Comparison of site-specific glycans between seminal plasma and spermatozoa	1201:1274	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35616904	4	62	gly	glycoproteins	730:742	arg1	glycoproteins					730:742	620 glycoproteins	726:742	620 glycoproteins	726:742	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	3	63	theme	glycan	528:533	arg1	structure					535:543	a recently developed glycan structure	507:543	a recently developed glycan structure interpretation software	507:567	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	3	64	theme	plasma	425:430	arg1	map					404:406	a precision site-specific N-glycoproteome map	362:406	a precision site-specific N-glycoproteome map of human seminal plasma	362:430	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	9	65	theme	in-depth	1449:1456	arg1	study					1484:1488	the in-depth structural and functional study	1445:1488	the in-depth structural and functional study of glycosylation in the male reproduction system	1445:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	7	66	theme	reactome	1182:1189	arg1	pathways					1191:1198	reactome pathways	1182:1198	reactome pathways	1182:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	4	67	gly	glycopeptides	602:614	arg2	glycopeptides					602:614	9567 unique glycopeptides	590:614	9567 unique glycopeptides identified in human seminal plasma	590:649	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	3	68	theme	structure	535:543	arg1	software					560:567	a recently developed glycan structure interpretation software	507:567	a recently developed glycan structure interpretation software	507:567	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	3	68	theme	structure	535:543	arg1	StrucGP					570:576	StrucGP	570:576	StrucGP	570:576	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	6	69	gly	glycoproteins	860:872	arg1	glycoproteins					860:872	identified glycoproteins	849:872	identified glycoproteins	849:872	The majority of identified glycoproteins functioned in response to stimulus and immunity.
35616904	7	70	gly	fucosylation	966:977	arg1	protein					1102:1108	galectin-3-binding protein	1083:1108	galectin-3-binding protein	1083:1108	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	70	gly	fucosylation	966:977	arg1	glycoproteins					1047:1059	seminal plasma glycoproteins	1032:1059	seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways	1032:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	70	gly	fucosylation	966:977	arg1	clusterin					1069:1077	clusterin	1069:1077	clusterin	1069:1077	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	71	gly	glycoproteins	1047:1059	arg1	protein					1102:1108	galectin-3-binding protein	1083:1108	galectin-3-binding protein	1083:1108	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	71	gly	glycoproteins	1047:1059	arg1	glycoproteins					1047:1059	seminal plasma glycoproteins	1032:1059	seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways	1032:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	71	gly	glycoproteins	1047:1059	arg1	clusterin					1069:1077	clusterin	1069:1077	clusterin	1069:1077	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	72	theme	galectin-3-binding	1083:1100	arg1	protein					1102:1108	galectin-3-binding protein	1083:1108	galectin-3-binding protein	1083:1108	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	73	theme	seminal	1032:1038	arg1	protein					1102:1108	galectin-3-binding protein	1083:1108	galectin-3-binding protein	1083:1108	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	73	theme	seminal	1032:1038	arg1	glycoproteins					1047:1059	seminal plasma glycoproteins	1032:1059	seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways	1032:1198	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	7	73	theme	seminal	1032:1038	arg1	clusterin					1069:1077	clusterin	1069:1077	clusterin	1069:1077	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	1	74	theme	various	141:147	arg1	roles					159:163	various essential roles	141:163	various essential roles	141:163	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	9	75	theme	functional	1473:1482	arg1	study					1484:1488	the in-depth structural and functional study	1445:1488	the in-depth structural and functional study of glycosylation in the male reproduction system	1445:1537	These present data will be greatly beneficial for the in-depth structural and functional study of glycosylation in the male reproduction system.
35616904	4	76	theme	glycan	681:686	arg1	structures					688:697	773 N-linked glycan structures	668:697	773 N-linked glycan structures	668:697	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	1	77	theme	essential	149:157	arg1	roles					159:163	various essential roles	141:163	various essential roles	141:163	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	1	78	from	rich	109:112	arg1	plasma					125:130	seminal plasma	117:130	seminal plasma	117:130	N-Linked glycoproteins are rich in seminal plasma, playing various essential roles in supporting sperm function and the fertilization process.
35616904	3	79	theme	seminal	417:423	arg1	plasma					425:430	human seminal plasma	411:430	human seminal plasma	411:430	In this study, a precision site-specific N-glycoproteome map of human seminal plasma was established by employing the site-specific glycoproteomic approach and a recently developed glycan structure interpretation software, StrucGP.
35616904	4	80	link	N-linked	672:679	arg1	structures					688:697	773 N-linked glycan structures	668:697	773 N-linked glycan structures	668:697	A total of 9567 unique glycopeptides identified in human seminal plasma were composed of 773 N-linked glycan structures and 1019 N-glycosites from 620 glycoproteins.
35616904	2	81	gly	glycoproteins	268:280	arg1	glycoproteins					268:280	these glycoproteins	262:280	these glycoproteins	262:280	However, the detailed information on these glycoproteins, particularly site-specific glycan structures, is still limited.
35616904	7	82	theme	human	941:945	arg1	spermatozoa					947:957	human spermatozoa	941:957	human spermatozoa	941:957	As we reported in human spermatozoa, heavy fucosylation (fucose residues ≥6 per glycan) was also detected on seminal plasma glycoproteins such as clusterin and galectin-3-binding protein, which were involved in the immune response of biological processes and reactome pathways.
35616904	8	83	theme	site-specific	1215:1227	arg1	glycans					1229:1235	site-specific glycans	1215:1235	site-specific glycans	1215:1235	Comparison of site-specific glycans between seminal plasma and spermatozoa revealed more complicated glycan structures in seminal plasma than in spermatozoa, even on their shared glycoproteins.
35470665	1	0	gly	glycosylation	93:105	arg1	HIV-1					176:180	HIV-1	176:180	HIV-1	176:180	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	0	gly	glycosylation	93:105	arg1	virus-1					167:173	the human immunodeficiency virus-1	140:173	the human immunodeficiency virus-1 (HIV-1)	140:181	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	6	1	theme	analogue	1071:1078	arg1	conjugates					1080:1089	the modified analogue conjugates	1058:1089	the modified analogue conjugates	1058:1089	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	8	2	from	epitopes	1348:1355	arg1	glycoconjugates					1376:1390	the synthesized glycoconjugates	1360:1390	the synthesized glycoconjugates	1360:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	8	3	theme	glycan	1425:1430	arg1	epitopes					1432:1439	native glycan epitopes	1418:1439	native glycan epitopes on gp120	1418:1448	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	2	4	dep	potent	468:473	arg1	neutralizing					483:494	neutralizing	483:494	neutralizing	483:494	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	1	5	theme	end	271:273	arg1	accessibility					210:222	the accessibility	206:222	the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion	206:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	6	theme	Man5GlcNAc2	357:367	arg1	structure					369:377	the Man5GlcNAc2 structure	353:377	the Man5GlcNAc2 structure	353:377	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	7	7	theme	gp120	1180:1184	arg1	antigen					1186:1192	the native gp120 antigen	1169:1192	the native gp120 antigen	1169:1192	However, these antibodies could not bind the native gp120 antigen.
35470665	2	8	theme	HIV-neutralizing	556:571	arg1	activity					573:580	HIV-neutralizing activity	556:580	HIV-neutralizing activity	556:580	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	1	9	dep	glycans	310:316	arg1	up					275:276	up	275:276	up	275:276	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	7	10	theme	native	1173:1178	arg1	antigen					1186:1192	the native gp120 antigen	1169:1192	the native gp120 antigen	1169:1192	However, these antibodies could not bind the native gp120 antigen.
35470665	4	11	theme	analogues	812:820	arg1	synthesis					732:740	the synthesis	728:740	the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues	728:820	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	4	12	theme	S-linked	803:810	arg1	analogues					812:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	4	13	theme	monofluoro-modified	758:776	arg1	analogues					812:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	1	14	theme	high-mannose-type	283:299	arg1	glycans					310:316	high-mannose-type N-linked glycans	283:316	high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion	283:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	6	15	theme	serological	943:953	arg1	assays					955:960	The serological assays	939:960	The serological assays	939:960	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	5	16	theme	glycoconjugates	914:928	arg1	immunogenicity					892:905	the immunogenicity	888:905	the immunogenicity of the glycoconjugates in mice	888:936	We coupled these haptens to carrier protein CRM197 and evaluated the immunogenicity of the glycoconjugates in mice.
35470665	1	17	theme	Dense	87:91	arg1	glycosylation					93:105	Dense glycosylation	87:105	Dense glycosylation	87:105	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	18	theme	envelope	183:190	arg1	protein					192:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein	87:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein	87:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	8	19	theme	tolerance	1238:1246	arg1	mechanism					1248:1256	the immune tolerance mechanism	1227:1256	the immune tolerance mechanism	1227:1256	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	1	20	theme	certain	390:396	arg1	proportion					398:407	a certain proportion	388:407	a certain proportion	388:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	8	21	theme	Man5-related	1293:1304	arg1	structures					1306:1315	Man5-related structures	1293:1315	Man5-related structures	1293:1315	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	1	22	theme	glycosylation	93:105	arg1	protein					192:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein	87:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein	87:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	2	23	theme	Man5GlcNAc2	414:424	arg1	glycan					426:431	The Man5GlcNAc2 glycan	410:431	The Man5GlcNAc2 glycan	410:431	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	5	24	theme	carrier	851:857	arg1	CRM197					867:872	carrier protein CRM197	851:872	carrier protein CRM197	851:872	We coupled these haptens to carrier protein CRM197 and evaluated the immunogenicity of the glycoconjugates in mice.
35470665	4	25	theme	trifluoro-modified	779:796	arg1	analogues					812:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	8	26	theme	glycan	1341:1346	arg1	epitopes					1348:1355	glycan epitopes	1341:1355	glycan epitopes on the synthesized glycoconjugates	1341:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	2	27	theme	potent	468:473	arg1	antibodies					496:505	some potent broadly neutralizing antibodies	463:505	some potent broadly neutralizing antibodies	463:505	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	1	28	theme	N-linked	301:308	arg1	glycans					310:316	high-mannose-type N-linked glycans	283:316	high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion	283:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	29	from	glycans	310:316	arg1	spike					334:338	the envelope spike	321:338	the envelope spike	321:338	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	3	30	theme	potential	611:619	arg1	target					621:626	a potential target	609:626	a potential target for HIV-1 vaccine development	609:656	Therefore, Man5GlcNAc2 is a potential target for HIV-1 vaccine development.
35470665	3	30	theme	potential	611:619	arg1	Man5GlcNAc2					594:604	Man5GlcNAc2	594:604	Man5GlcNAc2	594:604	Therefore, Man5GlcNAc2 is a potential target for HIV-1 vaccine development.
35470665	8	31	theme	epitopes	1348:1355	arg1	distinct					1396:1403	distinct	1396:1403	distinct	1396:1403	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	8	31	theme	epitopes	1348:1355	arg1	conformation					1325:1336	the conformation	1321:1336	the conformation of glycan epitopes on the synthesized glycoconjugates	1321:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	5	32	theme	protein	859:865	arg1	CRM197					867:872	carrier protein CRM197	851:872	carrier protein CRM197	851:872	We coupled these haptens to carrier protein CRM197 and evaluated the immunogenicity of the glycoconjugates in mice.
35470665	8	33	from	glycoconjugates	1376:1390	arg1	distinct					1396:1403	distinct	1396:1403	distinct	1396:1403	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	8	33	from	glycoconjugates	1376:1390	arg1	conformation					1325:1336	the conformation	1321:1336	the conformation of glycan epitopes on the synthesized glycoconjugates	1321:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	1	34	theme	trimeric	115:122	arg1	conformation					124:135	the trimeric conformation	111:135	the trimeric conformation of the human immunodeficiency virus-1 (HIV-1)	111:181	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	8	35	from	that	1410:1413	arg1	distinct					1396:1403	distinct	1396:1403	distinct	1396:1403	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	8	35	from	that	1410:1413	arg1	conformation					1325:1336	the conformation	1321:1336	the conformation of glycan epitopes on the synthesized glycoconjugates	1321:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	0	36	theme	Immunological	14:26	arg1	Evaluation					28:37	Immunological Evaluation	14:37	Immunological Evaluation	14:37	Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates.
35470665	6	37	theme	Man5-specific	1018:1030	arg1	antibodies					1032:1041	Man5-specific antibodies	1018:1041	Man5-specific antibodies	1018:1041	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	1	38	theme	conformation	124:135	arg1	protein					192:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein	87:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein	87:198	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	2	39	theme	antibodies	496:505	arg1	antibodies					496:505	some potent broadly neutralizing antibodies	463:505	some potent broadly neutralizing antibodies	463:505	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	2	39	theme	antibodies	496:505	arg1	sites					454:458	the binding sites	442:458	the binding sites of some potent broadly neutralizing antibodies	442:505	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	2	40	theme	binding	446:452	arg1	antibodies					496:505	some potent broadly neutralizing antibodies	463:505	some potent broadly neutralizing antibodies	463:505	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	2	40	theme	binding	446:452	arg1	sites					454:458	the binding sites	442:458	the binding sites of some potent broadly neutralizing antibodies	442:505	The Man5GlcNAc2 glycan composes the binding sites of some potent broadly neutralizing antibodies, and some lectins that can bind Man5GlcNAc2 show HIV-neutralizing activity.
35470665	0	41	theme	Pentamannose-Based	42:59	arg1	Candidates					75:84	Pentamannose-Based HIV-1 Vaccine Candidates	42:84	Pentamannose-Based HIV-1 Vaccine Candidates	42:84	Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates.
35470665	8	42	theme	native	1418:1423	arg1	epitopes					1432:1439	native glycan epitopes	1418:1439	native glycan epitopes on gp120	1418:1448	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	1	43	with	accessibility	210:222	arg1	glycans					310:316	high-mannose-type N-linked glycans	283:316	high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion	283:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	8	44	theme	synthesized	1364:1374	arg1	glycoconjugates					1376:1390	the synthesized glycoconjugates	1360:1390	the synthesized glycoconjugates	1360:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	3	45	theme	HIV-1	632:636	arg1	development					646:656	HIV-1 vaccine development	632:656	HIV-1 vaccine development	632:656	Therefore, Man5GlcNAc2 is a potential target for HIV-1 vaccine development.
35470665	8	46	from	epitopes	1432:1439	arg1	gp120					1444:1448	gp120	1444:1448	gp120	1444:1448	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	6	47	theme	antibody	1108:1115	arg1	responses					1117:1125	stronger antibody responses	1099:1125	stronger antibody responses	1099:1125	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	1	48	theme	envelope	325:332	arg1	spike					334:338	the envelope spike	321:338	the envelope spike	321:338	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	3	49	theme	vaccine	638:644	arg1	development					646:656	HIV-1 vaccine development	632:656	HIV-1 vaccine development	632:656	Therefore, Man5GlcNAc2 is a potential target for HIV-1 vaccine development.
35470665	5	50	from	immunogenicity	892:905	arg1	mice					933:936	mice	933:936	mice	933:936	We coupled these haptens to carrier protein CRM197 and evaluated the immunogenicity of the glycoconjugates in mice.
35470665	1	51	theme	cellular	232:239	arg1	enzymes					259:265	some cellular glycan processing enzymes	227:265	some cellular glycan processing enzymes	227:265	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	0	52	theme	Vaccine	67:73	arg1	Candidates					75:84	Pentamannose-Based HIV-1 Vaccine Candidates	42:84	Pentamannose-Based HIV-1 Vaccine Candidates	42:84	Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates.
35470665	8	53	theme	immune	1231:1236	arg1	mechanism					1248:1256	the immune tolerance mechanism	1227:1256	the immune tolerance mechanism	1227:1256	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	6	54	theme	stronger	1099:1106	arg1	responses					1117:1125	stronger antibody responses	1099:1125	stronger antibody responses	1099:1125	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	0	55	theme	HIV-1	61:65	arg1	Candidates					75:84	Pentamannose-Based HIV-1 Vaccine Candidates	42:84	Pentamannose-Based HIV-1 Vaccine Candidates	42:84	Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates.
35470665	4	56	link	S-linked	803:810	arg1	analogues					812:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	its monofluoro-modified, trifluoro-modified, and S-linked analogues	754:820	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	8	57	from	conformation	1325:1336	arg1	glycoconjugates					1376:1390	the synthesized glycoconjugates	1360:1390	the synthesized glycoconjugates	1360:1390	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	4	58	theme	Man5	745:748	arg1	synthesis					732:740	the synthesis	728:740	the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues	728:820	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	6	59	theme	Man5	985:988	arg1	conjugates					990:999	the native Man5 conjugates	974:999	the native Man5 conjugates	974:999	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	1	60	theme	human	144:148	arg1	HIV-1					176:180	HIV-1	176:180	HIV-1	176:180	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	60	theme	human	144:148	arg1	virus-1					167:173	the human immunodeficiency virus-1	140:173	the human immunodeficiency virus-1 (HIV-1)	140:181	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	61	theme	glycan	241:246	arg1	enzymes					259:265	some cellular glycan processing enzymes	227:265	some cellular glycan processing enzymes	227:265	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	62	theme	immunodeficiency	150:165	arg1	HIV-1					176:180	HIV-1	176:180	HIV-1	176:180	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	62	theme	immunodeficiency	150:165	arg1	virus-1					167:173	the human immunodeficiency virus-1	140:173	the human immunodeficiency virus-1 (HIV-1)	140:181	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	63	theme	processing	248:257	arg1	enzymes					259:265	some cellular glycan processing enzymes	227:265	some cellular glycan processing enzymes	227:265	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	4	64	theme	convergent	676:685	arg1	strategy					701:708	a highly convergent and effective strategy	667:708	a highly convergent and effective strategy	667:708	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	1	65	theme	virus-1	167:173	arg1	glycosylation					93:105	Dense glycosylation	87:105	Dense glycosylation	87:105	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	1	65	theme	virus-1	167:173	arg1	conformation					124:135	the trimeric conformation	111:135	the trimeric conformation of the human immunodeficiency virus-1 (HIV-1)	111:181	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	4	66	theme	effective	691:699	arg1	strategy					701:708	a highly convergent and effective strategy	667:708	a highly convergent and effective strategy	667:708	Herein, a highly convergent and effective strategy was developed for the synthesis of Man5 and its monofluoro-modified, trifluoro-modified, and S-linked analogues.
35470665	1	67	theme	enzymes	259:265	arg1	accessibility					210:222	the accessibility	206:222	the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion	206:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	0	68	theme	Candidates	75:84	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis	0:8	Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates.
35470665	0	68	theme	Candidates	75:84	arg1	Evaluation					28:37	Immunological Evaluation	14:37	Immunological Evaluation	14:37	Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates.
35470665	6	69	theme	native	978:983	arg1	conjugates					990:999	the native Man5 conjugates	974:999	the native Man5 conjugates	974:999	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35470665	8	70	theme	immune	1273:1278	arg1	responses					1280:1288	the immune responses	1269:1288	the immune responses to Man5-related structures	1269:1315	These results demonstrated that the immune tolerance mechanism suppressed the immune responses to Man5-related structures and the conformation of glycan epitopes on the synthesized glycoconjugates was distinct from that of native glycan epitopes on gp120.
35470665	1	71	link	N-linked	301:308	arg1	glycans					310:316	high-mannose-type N-linked glycans	283:316	high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion	283:407	Dense glycosylation and the trimeric conformation of the human immunodeficiency virus-1 (HIV-1) envelope protein limit the accessibility of some cellular glycan processing enzymes and end up with high-mannose-type N-linked glycans on the envelope spike, among which the Man5GlcNAc2 structure occupies a certain proportion.
35470665	6	72	theme	modified	1062:1069	arg1	conjugates					1080:1089	the modified analogue conjugates	1058:1089	the modified analogue conjugates	1058:1089	The serological assays showed that the native Man5 conjugates failed to induce Man5-specific antibodies in vivo, while the modified analogue conjugates induced stronger antibody responses.
35320529	7	0	gly	N-glycosylation	1124:1138	arg2	sites					1140:1144	five N-glycosylation sites	1119:1144	five N-glycosylation sites	1119:1144	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	0	gly	N-glycosylation	1124:1138	arg2	five					1119:1122	five	1119:1122	five	1119:1122	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	5	1	theme	available	817:825	arg1	material					827:834	available material	817:834	available material from a single donor	817:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	6	2	theme	N-glycan	979:986	arg1	structures					988:997	N-glycan structures	979:997	N-glycan structures on CD16a isolated from primary NK cells of healthy human donors	979:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	7	3	theme	N-glycosylation	1124:1138	arg1	sites					1140:1144	five N-glycosylation sites	1119:1144	five N-glycosylation sites	1119:1144	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	8	4	from	sites	1418:1422	arg1	lymphocytes					1487:1497	circulating primary human lymphocytes	1461:1497	circulating primary human lymphocytes	1461:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	5	theme	circulating	1461:1471	arg1	lymphocytes					1487:1497	circulating primary human lymphocytes	1461:1497	circulating primary human lymphocytes	1461:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	2	6	theme	proteins	313:320	arg1	galectins					323:331	galectins	323:331	galectins	323:331	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	2	6	theme	proteins	313:320	arg1	family					288:293	a family	286:293	a family of glycan-binding proteins	286:320	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	6	7	theme	donors	1056:1061	arg1	cells					1033:1037	primary NK cells	1022:1037	primary NK cells of healthy human donors	1022:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	2	8	theme	lymphocyte	170:179	arg1	receptors					190:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	7	9	theme	cell	1089:1092	arg1	CD16a					1094:1098	NK cell CD16a	1086:1098	NK cell CD16a	1086:1098	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	6	10	from	structures	988:997	arg1	CD16a					1002:1006	CD16a	1002:1006	CD16a isolated from primary NK cells of healthy human donors	1002:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	2	11	theme	glycan-binding	298:311	arg1	proteins					313:320	glycan-binding proteins	298:320	glycan-binding proteins	298:320	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	6	12	theme	human	1050:1054	arg1	donors					1056:1061	healthy human donors	1042:1061	healthy human donors	1042:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	6	13	from	variability	964:974	arg1	CD16a					1002:1006	CD16a	1002:1006	CD16a isolated from primary NK cells of healthy human donors	1002:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	6	13	from	variability	964:974	arg1	structures					988:997	N-glycan structures	979:997	N-glycan structures on CD16a isolated from primary NK cells of healthy human donors	979:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	2	14	theme	human	164:168	arg1	receptors					190:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	5	15	theme	glycan	891:896	arg1	structures					898:907	glycan structures	891:907	glycan structures that can potentially modify a protein	891:945	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	3	16	contain	have	450:453	arg1	galectins					440:448	Several galectins	432:448	Several galectins	432:448	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	3	16	contain	have	450:453	arg2	degree					465:470	a varying degree	455:470	a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide	455:532	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	8	17	theme	specific	1395:1402	arg1	sites					1418:1422	specific glycosylation sites	1395:1422	specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes	1395:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	17	theme	specific	1395:1402	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	4	18	theme	healthy	722:728	arg1	individuals					730:740	healthy individuals	722:740	healthy individuals	722:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	5	19	theme	single	843:848	arg1	donor					850:854	a single donor	841:854	a single donor	841:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	2	20	theme	Most	159:162	arg1	receptors					190:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	4	21	from	receptors	709:717	arg1	individuals					730:740	healthy individuals	722:740	healthy individuals	722:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	3	22	theme	affinity	475:482	arg1	degree					465:470	a varying degree	455:470	a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide	455:532	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	0	23	from	Ligands	32:38	arg1	Glycoproteins					63:75	Lymphocyte Membrane Glycoproteins	43:75	Lymphocyte Membrane Glycoproteins	43:75	Method for Identifying Galectin Ligands on Lymphocyte Membrane Glycoproteins.
35320529	6	24	theme	Donor-dependent	948:962	arg1	variability					964:974	Donor-dependent variability	948:974	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors	948:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	5	25	from	heterogeneity	874:886	arg1	structures					898:907	glycan structures	891:907	glycan structures that can potentially modify a protein	891:945	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	25	from	heterogeneity	874:886	arg1	donor					850:854	a single donor	841:854	a single donor	841:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	3	26	theme	varying	457:463	arg1	degree					465:470	a varying degree	455:470	a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide	455:532	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	7	27	theme	multiple	1225:1232	arg1	ligands					1268:1274	ligands	1268:1274	ligands for endogenous galectins	1268:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	27	theme	multiple	1225:1232	arg1	repeats					1241:1247	multiple LacNAc repeats	1225:1247	multiple LacNAc repeats which can serve as ligands for endogenous galectins	1225:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	6	28	theme	healthy	1042:1048	arg1	donors					1056:1061	healthy human donors	1042:1061	healthy human donors	1042:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	7	29	with	N-glycans	1210:1218	arg1	ligands					1268:1274	ligands	1268:1274	ligands for endogenous galectins	1268:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	29	with	N-glycans	1210:1218	arg1	repeats					1241:1247	multiple LacNAc repeats	1225:1247	multiple LacNAc repeats which can serve as ligands for endogenous galectins	1225:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	8	30	from	lymphocytes	1487:1497	arg1	sites					1418:1422	specific glycosylation sites	1395:1422	specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes	1395:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	30	from	lymphocytes	1487:1497	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	0	31	theme	Galectin	23:30	arg1	Ligands					32:38	Galectin Ligands	23:38	Galectin Ligands on Lymphocyte Membrane Glycoproteins	23:75	Method for Identifying Galectin Ligands on Lymphocyte Membrane Glycoproteins.
35320529	7	32	theme	sites	1167:1171	arg1	sites					1167:1171	the five sites	1158:1171	the five sites	1158:1171	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	32	theme	sites	1167:1171	arg1	two					1151:1153	two	1151:1153	two	1151:1153	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	8	33	theme	endogenous	1427:1436	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	34	theme	receptor	1447:1454	arg1	sites					1418:1422	specific glycosylation sites	1395:1422	specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes	1395:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	34	theme	receptor	1447:1454	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	3	35	theme	N-acetyllactosamine	492:510	arg1	disaccharide					521:532	the N-acetyllactosamine (LacNAc) disaccharide	488:532	the N-acetyllactosamine (LacNAc) disaccharide	488:532	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	7	36	gly	glycosylated	1103:1114	arg1	CD16a					1094:1098	NK cell CD16a	1086:1098	NK cell CD16a	1086:1098	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	36	gly	glycosylated	1103:1114	arg2	sites					1140:1144	five N-glycosylation sites	1119:1144	five N-glycosylation sites	1119:1144	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	3	37	contain	carrying	611:618	arg1	structures					600:609	glycan structures	593:609	glycan structures carrying this motif	593:629	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	3	37	contain	carrying	611:618	arg2	motif					625:629	this motif	620:629	this motif	620:629	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	3	38	theme	glycan	593:598	arg1	structures					600:609	glycan structures	593:609	glycan structures carrying this motif	593:629	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	5	39	theme	compositional	860:872	arg1	heterogeneity					874:886	compositional heterogeneity	860:886	compositional heterogeneity in glycan structures that can potentially modify a protein	860:945	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	40	theme	material	827:834	arg1	abundance					804:812	low abundance	800:812	low abundance of available material from a single donor	800:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	40	theme	material	827:834	arg1	reason					771:776	The main reason	762:776	The main reason for the limitation	762:795	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	40	theme	material	827:834	arg1	heterogeneity					874:886	compositional heterogeneity	860:886	compositional heterogeneity in glycan structures that can potentially modify a protein	860:945	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	2	41	theme	lymphocyte	361:370	arg1	development					372:382	lymphocyte development	361:382	lymphocyte development	361:382	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	5	42	theme	main	766:769	arg1	abundance					804:812	low abundance	800:812	low abundance of available material from a single donor	800:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	42	theme	main	766:769	arg1	reason					771:776	The main reason	762:776	The main reason for the limitation	762:795	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	6	43	theme	NK	1030:1031	arg1	cells					1033:1037	primary NK cells	1022:1037	primary NK cells of healthy human donors	1022:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	4	44	from	composition	666:676	arg1	receptors					709:717	primary lymphocyte membrane receptors	681:717	primary lymphocyte membrane receptors in healthy individuals	681:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	4	45	theme	lymphocyte	689:698	arg1	receptors					709:717	primary lymphocyte membrane receptors	681:717	primary lymphocyte membrane receptors in healthy individuals	681:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	6	46	theme	primary	1022:1028	arg1	cells					1033:1037	primary NK cells	1022:1037	primary NK cells of healthy human donors	1022:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	2	47	mod	modified	204:211	arg3	structures					231:240	diverse glycan structures	216:240	diverse glycan structures	216:240	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	2	47	mod	modified	204:211	arg1	receptors					190:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	2	48	theme	functional	247:256	arg1	studies					258:264	functional studies	247:264	functional studies	247:264	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	7	49	theme	NK	1086:1087	arg1	CD16a					1094:1098	NK cell CD16a	1086:1098	NK cell CD16a	1086:1098	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	4	50	theme	primary	681:687	arg1	receptors					709:717	primary lymphocyte membrane receptors	681:717	primary lymphocyte membrane receptors in healthy individuals	681:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	0	51	theme	Membrane	54:61	arg1	Glycoproteins					63:75	Lymphocyte Membrane Glycoproteins	43:75	Lymphocyte Membrane Glycoproteins	43:75	Method for Identifying Galectin Ligands on Lymphocyte Membrane Glycoproteins.
35320529	8	52	gly	glycosylation	1404:1416	arg2	sites					1418:1422	specific glycosylation sites	1395:1422	specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes	1395:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	52	gly	glycosylation	1404:1416	arg2	lymphocytes					1487:1497	circulating primary human lymphocytes	1461:1497	circulating primary human lymphocytes	1461:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	52	gly	glycosylation	1404:1416	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	52	gly	glycosylation	1404:1416	arg2	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	2	53	theme	membrane	181:188	arg1	receptors					190:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors	159:198	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	5	54	gly	heterogeneity	874:886	arg1	material					827:834	available material	817:834	available material from a single donor	817:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	55	from	donor	850:854	arg1	abundance					804:812	low abundance	800:812	low abundance of available material from a single donor	800:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	55	from	donor	850:854	arg1	material					827:834	available material	817:834	available material from a single donor	817:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	55	from	donor	850:854	arg1	reason					771:776	The main reason	762:776	The main reason for the limitation	762:795	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	55	from	donor	850:854	arg1	heterogeneity					874:886	compositional heterogeneity	860:886	compositional heterogeneity in glycan structures that can potentially modify a protein	860:945	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	1	56	theme	common	111:116	arg1	modifications					144:156	the most common protein posttranslational modifications	102:156	the most common protein posttranslational modifications	102:156	Glycosylation is one of the most common protein posttranslational modifications.
35320529	0	57	theme	Lymphocyte	43:52	arg1	Glycoproteins					63:75	Lymphocyte Membrane Glycoproteins	43:75	Lymphocyte Membrane Glycoproteins	43:75	Method for Identifying Galectin Ligands on Lymphocyte Membrane Glycoproteins.
35320529	6	58	from	CD16a	1002:1006	arg1	variability					964:974	Donor-dependent variability	948:974	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors	948:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	6	59	attach	isolated	1008:1015	arg2	CD16a					1002:1006	CD16a	1002:1006	CD16a isolated from primary NK cells of healthy human donors	1002:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	6	59	attach	isolated	1008:1015	arg1	cells					1033:1037	primary NK cells	1022:1037	primary NK cells of healthy human donors	1022:1061	Donor-dependent variability in N-glycan structures on CD16a isolated from primary NK cells of healthy human donors was recently reported.
35320529	1	60	theme	protein	118:124	arg1	modifications					144:156	the most common protein posttranslational modifications	102:156	the most common protein posttranslational modifications	102:156	Glycosylation is one of the most common protein posttranslational modifications.
35320529	8	61	theme	human	1481:1485	arg1	lymphocytes					1487:1497	circulating primary human lymphocytes	1461:1497	circulating primary human lymphocytes	1461:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	7	62	mod	modified	1177:1184	arg1	sites					1167:1171	the five sites	1158:1171	the five sites	1158:1171	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	62	mod	modified	1177:1184	arg1	two					1151:1153	two	1151:1153	two	1151:1153	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	62	mod	modified	1177:1184	arg3	N-glycans					1210:1218	N-glycans	1210:1218	N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins	1210:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	2	63	theme	glycan	224:229	arg1	structures					231:240	diverse glycan structures	216:240	diverse glycan structures	216:240	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	8	64	theme	glycosylation	1404:1416	arg1	sites					1418:1422	specific glycosylation sites	1395:1422	specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes	1395:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	64	theme	glycosylation	1404:1416	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	8	65	theme	membrane	1438:1445	arg1	receptor					1447:1454	endogenous membrane receptor	1427:1454	endogenous membrane receptor from circulating primary human lymphocytes	1427:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	1	66	theme	posttranslational	126:142	arg1	modifications					144:156	the most common protein posttranslational modifications	102:156	the most common protein posttranslational modifications	102:156	Glycosylation is one of the most common protein posttranslational modifications.
35320529	2	67	theme	diverse	216:222	arg1	structures					231:240	diverse glycan structures	216:240	diverse glycan structures	216:240	Most human lymphocyte membrane receptors are modified by diverse glycan structures, and functional studies have indicated that a family of glycan-binding proteins, galectins, can significantly modulate lymphocyte development and function by interacting with these glycans.
35320529	8	68	theme	primary	1473:1479	arg1	lymphocytes					1487:1497	circulating primary human lymphocytes	1461:1497	circulating primary human lymphocytes	1461:1497	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	1	69	theme	modifications	144:156	arg1	modifications					144:156	the most common protein posttranslational modifications	102:156	the most common protein posttranslational modifications	102:156	Glycosylation is one of the most common protein posttranslational modifications.
35320529	1	69	theme	modifications	144:156	arg1	one					95:97	one	95:97	one	95:97	Glycosylation is one of the most common protein posttranslational modifications.
35320529	8	70	theme	galectin	1375:1382	arg1	ligands					1384:1390	galectin ligands	1375:1390	galectin ligands	1375:1390	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	3	71	theme	LacNAc	513:518	arg1	disaccharide					521:532	the N-acetyllactosamine (LacNAc) disaccharide	488:532	the N-acetyllactosamine (LacNAc) disaccharide	488:532	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	5	72	theme	low	800:802	arg1	abundance					804:812	low abundance	800:812	low abundance of available material from a single donor	800:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	72	theme	low	800:802	arg1	reason					771:776	The main reason	762:776	The main reason for the limitation	762:795	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	73	from	abundance	804:812	arg1	structures					898:907	glycan structures	891:907	glycan structures that can potentially modify a protein	891:945	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	5	73	from	abundance	804:812	arg1	donor					850:854	a single donor	841:854	a single donor	841:854	The main reason for the limitation is low abundance of available material from a single donor and compositional heterogeneity in glycan structures that can potentially modify a protein.
35320529	3	74	mod	modified	581:588	arg1	receptors					564:572	some critical lymphocyte receptors	539:572	some critical lymphocyte receptors	539:572	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	3	74	mod	modified	581:588	arg3	structures					600:609	glycan structures	593:609	glycan structures carrying this motif	593:629	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	3	75	theme	critical	544:551	arg1	receptors					564:572	some critical lymphocyte receptors	539:572	some critical lymphocyte receptors	539:572	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	4	76	theme	membrane	700:707	arg1	receptors					709:717	primary lymphocyte membrane receptors	681:717	primary lymphocyte membrane receptors in healthy individuals	681:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	4	77	theme	glycan	659:664	arg1	composition					666:676	the site-specific glycan composition	641:676	the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals	641:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
35320529	3	78	theme	Several	432:438	arg1	galectins					440:448	Several galectins	432:448	Several galectins	432:448	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	7	79	theme	LacNAc	1234:1239	arg1	ligands					1268:1274	ligands	1268:1274	ligands for endogenous galectins	1268:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	7	79	theme	LacNAc	1234:1239	arg1	repeats					1241:1247	multiple LacNAc repeats	1225:1247	multiple LacNAc repeats which can serve as ligands for endogenous galectins	1225:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	8	80	used	utilized	1354:1361	arg2	protocol					1312:1319	the protocol	1308:1319	the protocol described in this section	1308:1345	Thus, the protocol described in this section can be utilized to identify galectin ligands at specific glycosylation sites of endogenous membrane receptor from circulating primary human lymphocytes.
35320529	3	81	theme	lymphocyte	553:562	arg1	receptors					564:572	some critical lymphocyte receptors	539:572	some critical lymphocyte receptors	539:572	Several galectins have a varying degree of affinity for the N-acetyllactosamine (LacNAc) disaccharide, and some critical lymphocyte receptors can be modified by glycan structures carrying this motif.
35320529	7	82	theme	endogenous	1280:1289	arg1	galectins					1291:1299	endogenous galectins	1280:1299	endogenous galectins	1280:1299	NK cell CD16a is glycosylated at five N-glycosylation sites, and two of the five sites are modified, almost exclusively, by N-glycans with multiple LacNAc repeats which can serve as ligands for endogenous galectins.
35320529	4	83	theme	site-specific	645:657	arg1	composition					666:676	the site-specific glycan composition	641:676	the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals	641:740	However, the site-specific glycan composition on primary lymphocyte membrane receptors in healthy individuals is largely limited.
36769208	8	0	theme	comparable	1296:1305	arg1	events					1289:1294	events	1289:1294	events comparable to those found in some neurodegenerative diseases	1289:1355	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	5	1	theme	HFD	793:795	arg1	diet					787:790	a high-fat diet	776:790	a high-fat diet (HFD group)	776:802	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	1	theme	HFD	793:795	arg1	group					797:801	HFD group	793:801	HFD group	793:801	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	4	2	theme	high-fat	527:534	arg1	diet					536:539	a high-fat diet	525:539	a high-fat diet	525:539	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	8	3	from	composition	1235:1245	arg1	hamsters					1268:1275	high-fat diet-fed hamsters	1250:1275	high-fat diet-fed hamsters	1250:1275	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	1	4	from	fats	148:151	arg1	rich					130:133	rich	130:133	rich	130:133	The consumption of diets rich in saturated fats is known to be associated with higher mortality.
36769208	7	5	theme	forty-nine	1063:1072	arg1	lipids					1074:1079	forty-nine lipids	1063:1079	forty-nine lipids	1063:1079	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	6	6	dep	significant	931:941	arg1	nine					983:986	nine	983:986	nine	983:986	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	6	6	dep	significant	931:941	arg1	one					1021:1023	one	1021:1023	one	1021:1023	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	6	6	dep	significant	931:941	arg1	<					946:946	p < 0.05	944:951	p < 0.05	944:951	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	2	7	theme	Mediterranean	261:273	arg1	diet					275:278	a Mediterranean diet	259:278	a Mediterranean diet	259:278	The adoption of healthy habits, for instance adhering to a Mediterranean diet, has proved to exert a preventive effect towards cardiovascular diseases and dyslipidemia.
36769208	0	8	theme	Dyslipidemic	82:93	arg1	Hamsters					95:102	Dyslipidemic Hamsters	82:102	Dyslipidemic Hamsters	82:102	Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters.
36769208	6	9	theme	MED	996:998	arg1	groups					1009:1014	MED and CTRL groups	996:1014	MED and CTRL groups	996:1014	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	5	10	theme	Mediterranean-like	839:856	arg1	diet					858:861	a Mediterranean-like diet	837:861	a Mediterranean-like diet (MED group)	837:873	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	10	theme	Mediterranean-like	839:856	arg1	group					868:872	MED group	864:872	MED group	864:872	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	7	11	theme	HFD	1102:1104	arg1	groups					1115:1120	HFD and CTRL groups	1102:1120	groups	1115:1120	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	4	12	theme	Golden	596:601	arg1	hamsters					610:617	male Golden Syrian hamsters	591:617	male Golden Syrian hamsters	591:617	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	6	13	theme	CTRL	970:973	arg1	groups					975:980	HFD and CTRL groups	962:980	groups	975:980	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	2	14	theme	adhering	247:254	arg1	instance					238:245	instance	238:245	instance adhering to a Mediterranean diet	238:278	The adoption of healthy habits, for instance adhering to a Mediterranean diet, has proved to exert a preventive effect towards cardiovascular diseases and dyslipidemia.
36769208	4	15	theme	male	591:594	arg1	hamsters					610:617	male Golden Syrian hamsters	591:617	male Golden Syrian hamsters	591:617	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	8	16	theme	neurodegenerative	1330:1346	arg1	diseases					1348:1355	some neurodegenerative diseases	1325:1355	some neurodegenerative diseases	1325:1355	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	7	17	theme	CTRL	1110:1113	arg1	groups					1115:1120	HFD and CTRL groups	1102:1120	groups	1115:1120	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	1	18	from	rich	130:133	arg1	fats					148:151	saturated fats	138:151	saturated fats	138:151	The consumption of diets rich in saturated fats is known to be associated with higher mortality.
36769208	5	19	theme	high-fat	811:818	arg1	diet					820:823	a high-fat diet	809:823	a high-fat diet followed by a Mediterranean-like diet (MED group)	809:873	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	8	20	located	found	1316:1320	arg2	those					1310:1314	those	1310:1314	those	1310:1314	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	8	20	located	found	1316:1320	arg1	diseases					1348:1355	some neurodegenerative diseases	1325:1355	some neurodegenerative diseases	1325:1355	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	0	21	theme	Brain	0:4	arg1	N-Glycosylation					6:20	Brain N-Glycosylation and Lipidomic Profile Changes	0:50	N-Glycosylation	6:20	Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters.
36769208	4	22	theme	diet	673:676	arg1	potential					639:647	the potential	635:647	the potential of a Mediterranean-like diet to reverse this situation	635:702	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	3	23	theme	suboptimal	399:408	arg1	diet					410:413	a suboptimal diet	397:413	a suboptimal diet	397:413	Little is known about how a suboptimal diet can affect brain function, structure, and the mechanisms involved.
36769208	0	24	theme	Lipidomic	26:34	arg1	Changes					44:50	Brain N-Glycosylation and Lipidomic Profile Changes	0:50	Changes	44:50	Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters.
36769208	6	25	theme	HFD	1041:1043	arg1	groups					1045:1050	MED and HFD groups	1033:1050	MED and HFD groups	1033:1050	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	4	26	from	profile	580:586	arg1	hamsters					610:617	male Golden Syrian hamsters	591:617	male Golden Syrian hamsters	591:617	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	4	27	theme	lipid	574:578	arg1	profile					580:586	lipid profile	574:586	lipid profile	574:586	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	5	28	theme	fat	753:755	arg1	diet					757:760	a normal fat diet	744:760	a normal fat diet (CTRL group)	744:773	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	28	theme	fat	753:755	arg1	group					768:772	CTRL group	763:772	CTRL group	763:772	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	29	theme	normal	746:751	arg1	diet					757:760	a normal fat diet	744:760	a normal fat diet (CTRL group)	744:773	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	29	theme	normal	746:751	arg1	group					768:772	CTRL group	763:772	CTRL group	763:772	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	1	30	theme	higher	184:189	arg1	mortality					191:199	higher mortality	184:199	higher mortality	184:199	The consumption of diets rich in saturated fats is known to be associated with higher mortality.
36769208	0	31	from	Diet	74:77	arg1	Hamsters					95:102	Dyslipidemic Hamsters	82:102	Dyslipidemic Hamsters	82:102	Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters.
36769208	2	32	theme	healthy	218:224	arg1	habits					226:231	healthy habits	218:231	healthy habits	218:231	The adoption of healthy habits, for instance adhering to a Mediterranean diet, has proved to exert a preventive effect towards cardiovascular diseases and dyslipidemia.
36769208	4	33	theme	Syrian	603:608	arg1	hamsters					610:617	male Golden Syrian hamsters	591:617	male Golden Syrian hamsters	591:617	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	5	34	theme	CTRL	763:766	arg1	diet					757:760	a normal fat diet	744:760	a normal fat diet (CTRL group)	744:773	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	34	theme	CTRL	763:766	arg1	group					768:772	CTRL group	763:772	CTRL group	763:772	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	0	35	theme	Profile	36:42	arg1	Changes					44:50	Brain N-Glycosylation and Lipidomic Profile Changes	0:50	Changes	44:50	Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters.
36769208	8	36	theme	diet-fed	1259:1266	arg1	hamsters					1268:1275	high-fat diet-fed hamsters	1250:1275	high-fat diet-fed hamsters	1250:1275	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	4	37	from	N-glycan	561:568	arg1	hamsters					610:617	male Golden Syrian hamsters	591:617	male Golden Syrian hamsters	591:617	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	7	38	theme	MED	1175:1177	arg1	groups					1187:1192	MED and HFD groups	1175:1192	MED and HFD groups	1175:1192	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	3	39	theme	brain	426:430	arg1	function					432:439	brain function	426:439	brain function	426:439	Little is known about how a suboptimal diet can affect brain function, structure, and the mechanisms involved.
36769208	8	40	theme	brain	1374:1378	arg1	ageing					1380:1385	brain ageing	1374:1385	brain ageing	1374:1385	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	8	41	theme	high-fat	1250:1257	arg1	hamsters					1268:1275	high-fat diet-fed hamsters	1250:1275	high-fat diet-fed hamsters	1250:1275	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	2	42	theme	preventive	303:312	arg1	effect					314:319	a preventive effect	301:319	a preventive effect	301:319	The adoption of healthy habits, for instance adhering to a Mediterranean diet, has proved to exert a preventive effect towards cardiovascular diseases and dyslipidemia.
36769208	4	43	theme	study	499:503	arg1	aims					486:489	The aims	482:489	The aims of this study	482:503	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	7	44	theme	MED	1137:1139	arg1	groups					1150:1155	MED and CTRL groups	1137:1155	MED and CTRL groups	1137:1155	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	4	45	dep	N-glycan	561:568	arg1	the					551:553	the	551:553	the	551:553	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	1	46	theme	saturated	138:146	arg1	fats					148:151	saturated fats	138:151	saturated fats	138:151	The consumption of diets rich in saturated fats is known to be associated with higher mortality.
36769208	7	47	theme	CTRL	1145:1148	arg1	groups					1150:1155	MED and CTRL groups	1137:1155	MED and CTRL groups	1137:1155	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	8	48	theme	brain	1220:1224	arg1	composition					1235:1245	brain N-glycan composition	1220:1245	brain N-glycan composition in high-fat diet-fed hamsters	1220:1275	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	5	49	theme	MED	864:866	arg1	diet					858:861	a Mediterranean-like diet	837:861	a Mediterranean-like diet (MED group)	837:873	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	49	theme	MED	864:866	arg1	group					868:872	MED group	864:872	MED group	864:872	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	7	50	theme	HFD	1183:1185	arg1	groups					1187:1192	MED and HFD groups	1175:1192	MED and HFD groups	1175:1192	Moreover, forty-nine lipids were altered between HFD and CTRL groups, seven between MED and CTRL groups, and five between MED and HFD groups.
36769208	1	51	theme	diets	124:128	arg1	consumption					109:119	The consumption	105:119	The consumption of diets rich in saturated fats	105:151	The consumption of diets rich in saturated fats is known to be associated with higher mortality.
36769208	5	52	theme	high-fat	778:785	arg1	diet					787:790	a high-fat diet	776:790	a high-fat diet (HFD group)	776:802	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	5	52	theme	high-fat	778:785	arg1	group					797:801	HFD group	793:801	HFD group	793:801	During twelve weeks, hamsters were fed a normal fat diet (CTRL group), a high-fat diet (HFD group), and a high-fat diet followed by a Mediterranean-like diet (MED group).
36769208	6	53	theme	identified	895:904	arg1	N-glycans					906:914	seventy-two identified N-glycans	883:914	seventy-two identified N-glycans	883:914	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	6	54	theme	CTRL	1004:1007	arg1	groups					1009:1014	MED and CTRL groups	996:1014	MED and CTRL groups	996:1014	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	6	55	theme	MED	1033:1035	arg1	groups					1045:1050	MED and HFD groups	1033:1050	MED and HFD groups	1033:1050	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	1	56	theme	rich	130:133	arg1	diets					124:128	diets	124:128	diets rich in saturated fats	124:151	The consumption of diets rich in saturated fats is known to be associated with higher mortality.
36769208	4	57	theme	Mediterranean-like	654:671	arg1	diet					673:676	a Mediterranean-like diet	652:676	a Mediterranean-like diet	652:676	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
36769208	0	58	theme	High-Fat	65:72	arg1	Diet					74:77	a High-Fat Diet	63:77	a High-Fat Diet in Dyslipidemic Hamsters	63:102	Brain N-Glycosylation and Lipidomic Profile Changes Induced by a High-Fat Diet in Dyslipidemic Hamsters.
36769208	8	59	theme	N-glycan	1226:1233	arg1	composition					1235:1245	brain N-glycan composition	1220:1245	brain N-glycan composition in high-fat diet-fed hamsters	1220:1275	Our results suggest that brain N-glycan composition in high-fat diet-fed hamsters can produce events comparable to those found in some neurodegenerative diseases, and may promote brain ageing.
36769208	6	60	theme	HFD	962:964	arg1	groups					975:980	HFD and CTRL groups	962:980	groups	975:980	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	6	61	theme	p	944:944	arg1	<					946:946	p < 0.05	944:951	p < 0.05	944:951	Out of seventy-two identified N-glycans, fourteen were significant (p < 0.05) between HFD and CTRL groups, nine between MED and CTRL groups, and one between MED and HFD groups.
36769208	2	62	theme	habits	226:231	arg1	adoption					206:213	The adoption	202:213	The adoption of healthy habits	202:231	The adoption of healthy habits, for instance adhering to a Mediterranean diet, has proved to exert a preventive effect towards cardiovascular diseases and dyslipidemia.
36769208	2	63	theme	cardiovascular	329:342	arg1	diseases					344:351	cardiovascular diseases	329:351	cardiovascular diseases	329:351	The adoption of healthy habits, for instance adhering to a Mediterranean diet, has proved to exert a preventive effect towards cardiovascular diseases and dyslipidemia.
36769208	4	64	theme	brain	555:559	arg1	N-glycan					561:568	brain N-glycan	555:568	brain N-glycan	555:568	The aims of this study were to examine how a high-fat diet can alter the brain N-glycan and lipid profile in male Golden Syrian hamsters and to evaluate the potential of a Mediterranean-like diet to reverse this situation.
35871410	6	0	theme	virulence	1051:1059	arg1	leakage					1004:1010	leakage	1004:1010	leakage at the hyphal tips	1004:1029	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	0	theme	virulence	1051:1059	arg1	properties					913:922	properties	913:922	properties that included high temperature and drug sensitivity	913:974	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	0	theme	virulence	1051:1059	arg1	formation					993:1001	reduced conidia formation	977:1001	reduced conidia formation	977:1001	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	0	theme	virulence	1051:1059	arg1	attenuation					1036:1046	attenuation	1036:1046	attenuation of virulence	1036:1059	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	4	1	theme	glycosyl	568:575	arg1	phosphorylceramides					586:604	glycosyl inositol phosphorylceramides	568:604	glycosyl inositol phosphorylceramides in Aspergillus fumigatus	568:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	8	2	from	structure	1280:1288	arg1	strain					1315:1320	the Δmnt1 strain	1305:1320	the Δmnt1 strain	1305:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	6	3	theme	∆mnt1	874:878	arg1	strain					880:885	the mutant ∆mnt1 strain	863:885	the mutant ∆mnt1 strain	863:885	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	10	4	theme	α-	1466:1467	arg1	-mannosyltransferase					1475:1494	an α-(1 → 2)-mannosyltransferase	1463:1494	an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans	1463:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	10	4	theme	α-	1466:1467	arg1	Mnt1					1444:1447	Mnt1	1444:1447	Mnt1	1444:1447	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	4	5	from	present	466:472	arg1	N-glycans					515:523	N-glycans	515:523	N-glycans	515:523	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	5	from	present	466:472	arg1	phosphorylceramides					586:604	glycosyl inositol phosphorylceramides	568:604	glycosyl inositol phosphorylceramides in Aspergillus fumigatus	568:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	5	from	present	466:472	arg1	anchors					555:561	glycosylphosphatidylinositol anchors	526:561	glycosylphosphatidylinositol anchors	526:561	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	5	from	present	466:472	arg1	O-glycans					504:512	O-glycans	504:512	O-glycans	504:512	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	5	from	present	466:472	arg1	galactomannan					489:501	fungal-type galactomannan	477:501	fungal-type galactomannan	477:501	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	8	6	from	strain	1315:1320	arg1	product					1267:1273	the Mnt1 reaction product	1249:1273	the Mnt1 reaction product	1249:1273	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	8	6	from	strain	1315:1320	arg1	structure					1280:1288	the structure	1276:1288	the structure of O-glycan in the Δmnt1 strain	1276:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	2	7	theme	responsible	250:260	arg1	glycosyltransferases					229:248	glycosyltransferases	229:248	glycosyltransferases responsible for the synthesis of cell wall polysaccharides	229:307	Therefore, glycosyltransferases responsible for the synthesis of cell wall polysaccharides may be suitable targets for drug development.
35871410	12	8	theme	protein	1855:1861	arg1	structure					1863:1871	its predicted protein structure	1841:1871	its predicted protein structure	1841:1871	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	11	9	from	result	1686:1691	arg1	O-glycans					1730:1738	O-glycans	1730:1738	O-glycans	1730:1738	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	9	from	result	1686:1691	arg1	N-glycans					1744:1752	N-glycans	1744:1752	N-glycans	1744:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	2	10	theme	wall	288:291	arg1	polysaccharides					293:307	cell wall polysaccharides	283:307	cell wall polysaccharides	283:307	Therefore, glycosyltransferases responsible for the synthesis of cell wall polysaccharides may be suitable targets for drug development.
35871410	9	11	theme	N-glycans	1350:1358	arg1	length					1340:1345	the length	1336:1345	the length of N-glycans attached to invertase	1336:1380	In addition, the length of N-glycans attached to invertase was evaluated in the Δmnt1 strain.
35871410	6	12	theme	high	938:941	arg1	temperature					943:953	high temperature	938:953	high temperature	938:953	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	10	13	theme	1 → 2	1469:1473	arg1	-mannosyltransferase					1475:1494	an α-(1 → 2)-mannosyltransferase	1463:1494	an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans	1463:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	10	13	theme	1 → 2	1469:1473	arg1	Mnt1					1444:1447	Mnt1	1444:1447	Mnt1	1444:1447	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	5	14	dep	found	756:760	arg1	cmsB/ktr7					822:830	cmsB/ktr7	822:830	cmsB/ktr7	822:830	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	14	dep	found	756:760	arg1	mnt1					837:840	mnt1	837:840	mnt1	837:840	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	14	dep	found	756:760	arg1	cmsA/ktr4					811:819	cmsA/ktr4	811:819	cmsA/ktr4	811:819	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	3	15	theme	sugar	409:413	arg1	chains					415:420	sugar chains	409:420	sugar chains	409:420	Mannose is a monosaccharide that is commonly found in sugar chains in the walls of fungi.
35871410	7	16	theme	bona	1103:1106	arg1	-mannosyltransferase					1122:1141	a bona fide α-(1 → 2)-mannosyltransferase	1101:1141	a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo	1101:1200	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	7	16	theme	bona	1103:1106	arg1	Mnt1					1093:1096	Mnt1	1093:1096	Mnt1	1093:1096	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	4	17	located	present	466:472	arg1	phosphorylceramides					586:604	glycosyl inositol phosphorylceramides	568:604	glycosyl inositol phosphorylceramides in Aspergillus fumigatus	568:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	17	located	present	466:472	arg1	galactomannan					489:501	fungal-type galactomannan	477:501	fungal-type galactomannan	477:501	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	17	located	present	466:472	arg2	residues					453:460	Mannose residues	445:460	Mannose residues	445:460	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	17	located	present	466:472	arg1	anchors					555:561	glycosylphosphatidylinositol anchors	526:561	glycosylphosphatidylinositol anchors	526:561	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	17	located	present	466:472	arg1	O-glycans					504:512	O-glycans	504:512	O-glycans	504:512	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	17	located	present	466:472	arg1	N-glycans					515:523	N-glycans	515:523	N-glycans	515:523	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	6	18	theme	wide	899:902	arg1	range					904:908	a wide range	897:908	a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence	897:1059	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	9	19	theme	Δmnt1	1403:1407	arg1	strain					1409:1414	the Δmnt1 strain	1399:1414	the Δmnt1 strain	1399:1414	In addition, the length of N-glycans attached to invertase was evaluated in the Δmnt1 strain.
35871410	0	20	theme	responsible	39:49	arg1	Mnt1					0:3	Mnt1	0:3	Mnt1	0:3	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	0	20	theme	responsible	39:49	arg1	-mannosyltransferase					18:37	an α-(1 → 2)-mannosyltransferase	6:37	an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus	6:120	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	1	21	theme	fungal	127:132	arg1	necessary					147:155	necessary	147:155	necessary	147:155	The fungal cell wall is necessary for survival as it serves a barrier for physical protection.
35871410	1	21	theme	fungal	127:132	arg1	wall					139:142	The fungal cell wall	123:142	The fungal cell wall	123:142	The fungal cell wall is necessary for survival as it serves a barrier for physical protection.
35871410	6	22	theme	reduced	977:983	arg1	properties					913:922	properties	913:922	properties that included high temperature and drug sensitivity	913:974	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	22	theme	reduced	977:983	arg1	formation					993:1001	reduced conidia formation	977:1001	reduced conidia formation	977:1001	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	7	23	dep	bona	1103:1106	arg1	fide					1108:1111	fide	1108:1111	fide	1108:1111	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	11	24	theme	gene	1665:1668	arg1	disruption					1642:1651	the disruption	1638:1651	the disruption of the mnt1 gene	1638:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	5	25	theme	A.	769:770	arg1	Af293/A1163					790:800	Af293/A1163	790:800	Af293/A1163	790:800	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	25	theme	A.	769:770	arg1	strain					782:787	the A. fumigatus strain	765:787	the A. fumigatus strain	765:787	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	4	26	theme	fungal-type	477:487	arg1	galactomannan					489:501	fungal-type galactomannan	477:501	fungal-type galactomannan	477:501	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	8	27	theme	reaction	1258:1265	arg1	product					1267:1273	the Mnt1 reaction product	1249:1273	the Mnt1 reaction product	1249:1273	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	8	27	theme	reaction	1258:1265	arg1	structure					1280:1288	the structure	1276:1288	the structure of O-glycan in the Δmnt1 strain	1276:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	3	28	theme	fungi	438:442	arg1	walls					429:433	the walls	425:433	the walls of fungi	425:442	Mannose is a monosaccharide that is commonly found in sugar chains in the walls of fungi.
35871410	0	29	theme	1 → 2	12:16	arg1	Mnt1					0:3	Mnt1	0:3	Mnt1	0:3	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	0	29	theme	1 → 2	12:16	arg1	-mannosyltransferase					18:37	an α-(1 → 2)-mannosyltransferase	6:37	an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus	6:120	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	4	30	from	anchors	555:561	arg1	fumigatus					621:629	Aspergillus fumigatus	609:629	Aspergillus fumigatus	609:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	30	from	anchors	555:561	arg1	present					466:472	present	466:472	present	466:472	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	12	31	theme	enzymatic	1777:1785	arg1	properties					1787:1796	enzymatic properties	1777:1796	enzymatic properties	1777:1796	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	8	32	theme	O-glycan	1293:1300	arg1	product					1267:1273	the Mnt1 reaction product	1249:1273	the Mnt1 reaction product	1249:1273	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	8	32	theme	O-glycan	1293:1300	arg1	structure					1280:1288	the structure	1276:1288	the structure of O-glycan in the Δmnt1 strain	1276:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	10	33	theme	residue	1572:1578	arg1	synthesis					1540:1548	synthesis	1540:1548	synthesis	1540:1548	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	10	33	theme	residue	1572:1578	arg1	N-glycans					1526:1534	N-glycans	1526:1534	N-glycans	1526:1534	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	3	34	located	found	400:404	arg1	chains					415:420	sugar chains	409:420	sugar chains	409:420	Mannose is a monosaccharide that is commonly found in sugar chains in the walls of fungi.
35871410	3	34	located	found	400:404	arg1	walls					429:433	the walls	425:433	the walls of fungi	425:442	Mannose is a monosaccharide that is commonly found in sugar chains in the walls of fungi.
35871410	3	34	located	found	400:404	arg2	monosaccharide					368:381	a monosaccharide	366:381	a monosaccharide that is commonly found in sugar chains in the walls of fungi	366:442	Mannose is a monosaccharide that is commonly found in sugar chains in the walls of fungi.
35871410	3	34	located	found	400:404	arg2	Mannose					355:361	Mannose	355:361	Mannose	355:361	Mannose is a monosaccharide that is commonly found in sugar chains in the walls of fungi.
35871410	10	35	theme	second	1557:1562	arg1	O-glycans					1583:1591	O-glycans	1583:1591	O-glycans	1583:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	10	35	theme	second	1557:1562	arg1	residue					1572:1578	the second mannose residue	1553:1578	the second mannose residue of O-glycans	1553:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	4	36	attach	present	466:472	arg1	phosphorylceramides					586:604	glycosyl inositol phosphorylceramides	568:604	glycosyl inositol phosphorylceramides in Aspergillus fumigatus	568:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	36	attach	present	466:472	arg1	galactomannan					489:501	fungal-type galactomannan	477:501	fungal-type galactomannan	477:501	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	36	attach	present	466:472	arg2	residues					453:460	Mannose residues	445:460	Mannose residues	445:460	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	36	attach	present	466:472	arg1	anchors					555:561	glycosylphosphatidylinositol anchors	526:561	glycosylphosphatidylinositol anchors	526:561	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	36	attach	present	466:472	arg1	O-glycans					504:512	O-glycans	504:512	O-glycans	504:512	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	36	attach	present	466:472	arg1	N-glycans					515:523	N-glycans	515:523	N-glycans	515:523	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	10	37	theme	O-glycans	1583:1591	arg1	O-glycans					1583:1591	O-glycans	1583:1591	O-glycans	1583:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	10	37	theme	O-glycans	1583:1591	arg1	residue					1572:1578	the second mannose residue	1553:1578	the second mannose residue of O-glycans	1553:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	11	38	theme	abnormal	1609:1616	arg1	result					1686:1691	the combined result	1673:1691	the combined result of the loss of mannose residues from O-glycans and N-glycans	1673:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	38	theme	abnormal	1609:1616	arg1	phenotype					1618:1626	The widespread abnormal phenotype	1594:1626	The widespread abnormal phenotype caused by the disruption of the mnt1 gene	1594:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	1	39	theme	physical	197:204	arg1	protection					206:215	physical protection	197:215	physical protection	197:215	The fungal cell wall is necessary for survival as it serves a barrier for physical protection.
35871410	4	40	from	galactomannan	489:501	arg1	fumigatus					621:629	Aspergillus fumigatus	609:629	Aspergillus fumigatus	609:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	40	from	galactomannan	489:501	arg1	present					466:472	present	466:472	present	466:472	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	2	41	theme	drug	337:340	arg1	development					342:352	drug development	337:352	drug development	337:352	Therefore, glycosyltransferases responsible for the synthesis of cell wall polysaccharides may be suitable targets for drug development.
35871410	5	42	theme	α-	667:668	arg1	genes					697:701	α-(1 → 2)-mannosyltransferase genes	667:701	α-(1 → 2)-mannosyltransferase genes	667:701	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	6	43	from	tips	1026:1029	arg1	leakage					1004:1010	leakage	1004:1010	leakage at the hyphal tips	1004:1029	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	43	from	tips	1026:1029	arg1	properties					913:922	properties	913:922	properties that included high temperature and drug sensitivity	913:974	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	43	from	tips	1026:1029	arg1	formation					993:1001	reduced conidia formation	977:1001	reduced conidia formation	977:1001	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	43	from	tips	1026:1029	arg1	attenuation					1036:1046	attenuation	1036:1046	attenuation of virulence	1036:1059	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	44	theme	mutant	867:872	arg1	strain					880:885	the mutant ∆mnt1 strain	863:885	the mutant ∆mnt1 strain	863:885	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	4	45	theme	inositol	577:584	arg1	phosphorylceramides					586:604	glycosyl inositol phosphorylceramides	568:604	glycosyl inositol phosphorylceramides in Aspergillus fumigatus	568:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	12	46	dep	properties	1787:1796	arg1	the					1773:1775	the	1773:1775	the	1773:1775	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	7	47	theme	mannose	1153:1159	arg1	residues					1161:1168	mannose residues	1153:1168	mannose residues	1153:1168	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	2	48	theme	polysaccharides	293:307	arg1	synthesis					270:278	the synthesis	266:278	the synthesis of cell wall polysaccharides	266:307	Therefore, glycosyltransferases responsible for the synthesis of cell wall polysaccharides may be suitable targets for drug development.
35871410	12	49	theme	predicted	1845:1853	arg1	structure					1863:1871	its predicted protein structure	1841:1871	its predicted protein structure	1841:1871	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	2	50	theme	cell	283:286	arg1	polysaccharides					293:307	cell wall polysaccharides	283:307	cell wall polysaccharides	283:307	Therefore, glycosyltransferases responsible for the synthesis of cell wall polysaccharides may be suitable targets for drug development.
35871410	5	51	dep	A.	769:770	arg1	fumigatus					772:780	fumigatus	772:780	fumigatus	772:780	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	0	52	from	elongation	59:68	arg1	fumigatus					112:120	Aspergillus fumigatus	100:120	Aspergillus fumigatus	100:120	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	11	53	theme	combined	1677:1684	arg1	result					1686:1691	the combined result	1673:1691	the combined result of the loss of mannose residues from O-glycans and N-glycans	1673:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	53	theme	combined	1677:1684	arg1	phenotype					1618:1626	The widespread abnormal phenotype	1594:1626	The widespread abnormal phenotype caused by the disruption of the mnt1 gene	1594:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	12	54	theme	Mnt1	1827:1830	arg1	properties					1787:1796	enzymatic properties	1777:1796	enzymatic properties	1777:1796	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	12	54	theme	Mnt1	1827:1830	arg1	specificity					1812:1822	substrate specificity	1802:1822	substrate specificity	1802:1822	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	6	55	theme	properties	913:922	arg1	range					904:908	a wide range	897:908	a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence	897:1059	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	5	56	theme	glycosyltransferase	721:739	arg1	family					741:746	the glycosyltransferase family 15	717:749	the glycosyltransferase family 15	717:749	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	57	theme	1 → 2	670:674	arg1	genes					697:701	α-(1 → 2)-mannosyltransferase genes	667:701	α-(1 → 2)-mannosyltransferase genes	667:701	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	58	located	found	756:760	arg1	Af293/A1163					790:800	Af293/A1163	790:800	Af293/A1163	790:800	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	58	located	found	756:760	arg1	strain					782:787	the A. fumigatus strain	765:787	the A. fumigatus strain	765:787	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	5	58	located	found	756:760	arg2	genes					638:642	Three genes	632:642	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15	632:749	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	11	59	theme	loss	1700:1703	arg1	result					1686:1691	the combined result	1673:1691	the combined result of the loss of mannose residues from O-glycans and N-glycans	1673:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	59	theme	loss	1700:1703	arg1	phenotype					1618:1626	The widespread abnormal phenotype	1594:1626	The widespread abnormal phenotype caused by the disruption of the mnt1 gene	1594:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	5	60	theme	-mannosyltransferase	676:695	arg1	genes					697:701	α-(1 → 2)-mannosyltransferase genes	667:701	α-(1 → 2)-mannosyltransferase genes	667:701	Three genes that are homologous to α-(1 → 2)-mannosyltransferase genes and belong to the glycosyltransferase family 15 were found in the A. fumigatus strain, Af293/A1163, genome: cmsA/ktr4, cmsB/ktr7, and mnt1.
35871410	11	61	theme	residues	1716:1723	arg1	loss					1700:1703	the loss	1696:1703	the loss of mannose residues from O-glycans and N-glycans	1696:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	6	62	theme	conidia	985:991	arg1	properties					913:922	properties	913:922	properties that included high temperature and drug sensitivity	913:974	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	6	62	theme	conidia	985:991	arg1	formation					993:1001	reduced conidia formation	977:1001	reduced conidia formation	977:1001	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	12	63	theme	substrate	1802:1810	arg1	specificity					1812:1822	substrate specificity	1802:1822	substrate specificity	1802:1822	We also clarified the enzymatic properties and substrate specificity of Mnt1 based on its predicted protein structure.
35871410	1	64	theme	cell	134:137	arg1	necessary					147:155	necessary	147:155	necessary	147:155	The fungal cell wall is necessary for survival as it serves a barrier for physical protection.
35871410	1	64	theme	cell	134:137	arg1	wall					139:142	The fungal cell wall	123:142	The fungal cell wall	123:142	The fungal cell wall is necessary for survival as it serves a barrier for physical protection.
35871410	11	65	from	N-glycans	1744:1752	arg1	result					1686:1691	the combined result	1673:1691	the combined result of the loss of mannose residues from O-glycans and N-glycans	1673:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	65	from	N-glycans	1744:1752	arg1	loss					1700:1703	the loss	1696:1703	the loss of mannose residues from O-glycans and N-glycans	1696:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	65	from	N-glycans	1744:1752	arg1	phenotype					1618:1626	The widespread abnormal phenotype	1594:1626	The widespread abnormal phenotype caused by the disruption of the mnt1 gene	1594:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	0	66	theme	N-glycans	73:81	arg1	elongation					59:68	the elongation	55:68	the elongation of N-glycans and O-glycans in Aspergillus fumigatus	55:120	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	6	67	theme	drug	959:962	arg1	sensitivity					964:974	drug sensitivity	959:974	drug sensitivity	959:974	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	4	68	theme	Mannose	445:451	arg1	residues					453:460	Mannose residues	445:460	Mannose residues	445:460	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	8	69	theme	Mnt1	1253:1256	arg1	product					1267:1273	the Mnt1 reaction product	1249:1273	the Mnt1 reaction product	1249:1273	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	8	69	theme	Mnt1	1253:1256	arg1	structure					1280:1288	the structure	1276:1288	the structure of O-glycan in the Δmnt1 strain	1276:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	11	70	theme	mnt1	1660:1663	arg1	gene					1665:1668	the mnt1 gene	1656:1668	the mnt1 gene	1656:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	0	71	theme	O-glycans	87:95	arg1	elongation					59:68	the elongation	55:68	the elongation of N-glycans and O-glycans in Aspergillus fumigatus	55:120	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	9	72	attach	attached	1360:1367	arg1	invertase					1372:1380	invertase	1372:1380	invertase	1372:1380	In addition, the length of N-glycans attached to invertase was evaluated in the Δmnt1 strain.
35871410	9	72	attach	attached	1360:1367	arg2	N-glycans					1350:1358	N-glycans	1350:1358	N-glycans attached to invertase	1350:1380	In addition, the length of N-glycans attached to invertase was evaluated in the Δmnt1 strain.
35871410	8	73	theme	product	1267:1273	arg1	structure					1236:1244	the structure	1232:1244	the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain	1232:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	7	74	theme	1 → 2	1116:1120	arg1	-mannosyltransferase					1122:1141	a bona fide α-(1 → 2)-mannosyltransferase	1101:1141	a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo	1101:1200	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	7	74	theme	1 → 2	1116:1120	arg1	Mnt1					1093:1096	Mnt1	1093:1096	Mnt1	1093:1096	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	7	75	theme	α-	1113:1114	arg1	-mannosyltransferase					1122:1141	a bona fide α-(1 → 2)-mannosyltransferase	1101:1141	a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo	1101:1200	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	7	75	theme	α-	1113:1114	arg1	Mnt1					1093:1096	Mnt1	1093:1096	Mnt1	1093:1096	However, it is unclear whether Mnt1 is a bona fide α-(1 → 2)-mannosyltransferase and which mannose residues are synthesized by Mnt1 in vivo.
35871410	4	76	theme	glycosylphosphatidylinositol	526:553	arg1	anchors					555:561	glycosylphosphatidylinositol anchors	526:561	glycosylphosphatidylinositol anchors	526:561	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	11	77	from	O-glycans	1730:1738	arg1	result					1686:1691	the combined result	1673:1691	the combined result of the loss of mannose residues from O-glycans and N-glycans	1673:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	77	from	O-glycans	1730:1738	arg1	loss					1700:1703	the loss	1696:1703	the loss of mannose residues from O-glycans and N-glycans	1696:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	77	from	O-glycans	1730:1738	arg1	phenotype					1618:1626	The widespread abnormal phenotype	1594:1626	The widespread abnormal phenotype caused by the disruption of the mnt1 gene	1594:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	4	78	from	phosphorylceramides	586:604	arg1	fumigatus					621:629	Aspergillus fumigatus	609:629	Aspergillus fumigatus	609:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	78	from	phosphorylceramides	586:604	arg1	present					466:472	present	466:472	present	466:472	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	10	79	theme	N-glycans	1526:1534	arg1	elongation					1512:1521	the elongation	1508:1521	the elongation of N-glycans and synthesis of the second mannose residue of O-glycans	1508:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	0	80	theme	α-	9:10	arg1	Mnt1					0:3	Mnt1	0:3	Mnt1	0:3	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	0	80	theme	α-	9:10	arg1	-mannosyltransferase					18:37	an α-(1 → 2)-mannosyltransferase	6:37	an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus	6:120	Mnt1, an α-(1 → 2)-mannosyltransferase responsible for the elongation of N-glycans and O-glycans in Aspergillus fumigatus.
35871410	6	81	theme	hyphal	1019:1024	arg1	tips					1026:1029	the hyphal tips	1015:1029	the hyphal tips	1015:1029	It is reported that the mutant ∆mnt1 strain exhibited a wide range of properties that included high temperature and drug sensitivity, reduced conidia formation, leakage at the hyphal tips, and attenuation of virulence.
35871410	10	82	theme	mannose	1564:1570	arg1	O-glycans					1583:1591	O-glycans	1583:1591	O-glycans	1583:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	10	82	theme	mannose	1564:1570	arg1	residue					1572:1578	the second mannose residue	1553:1578	the second mannose residue of O-glycans	1553:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	4	83	from	N-glycans	515:523	arg1	fumigatus					621:629	Aspergillus fumigatus	609:629	Aspergillus fumigatus	609:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	83	from	N-glycans	515:523	arg1	present					466:472	present	466:472	present	466:472	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	84	from	O-glycans	504:512	arg1	fumigatus					621:629	Aspergillus fumigatus	609:629	Aspergillus fumigatus	609:629	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	4	84	from	O-glycans	504:512	arg1	present					466:472	present	466:472	present	466:472	Mannose residues are present in fungal-type galactomannan, O-glycans, N-glycans, glycosylphosphatidylinositol anchors, and glycosyl inositol phosphorylceramides in Aspergillus fumigatus.
35871410	8	85	theme	Δmnt1	1309:1313	arg1	strain					1315:1320	the Δmnt1 strain	1305:1320	the Δmnt1 strain	1305:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	2	86	theme	suitable	316:323	arg1	targets					325:331	suitable targets	316:331	suitable targets for drug development	316:352	Therefore, glycosyltransferases responsible for the synthesis of cell wall polysaccharides may be suitable targets for drug development.
35871410	11	87	theme	widespread	1598:1607	arg1	result					1686:1691	the combined result	1673:1691	the combined result of the loss of mannose residues from O-glycans and N-glycans	1673:1752	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	11	87	theme	widespread	1598:1607	arg1	phenotype					1618:1626	The widespread abnormal phenotype	1594:1626	The widespread abnormal phenotype caused by the disruption of the mnt1 gene	1594:1668	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
35871410	10	88	theme	synthesis	1540:1548	arg1	elongation					1512:1521	the elongation	1508:1521	the elongation of N-glycans and synthesis of the second mannose residue of O-glycans	1508:1591	The results indicated that Mnt1 functioned as an α-(1 → 2)-mannosyltransferase involved in the elongation of N-glycans and synthesis of the second mannose residue of O-glycans.
35871410	8	89	from	O-glycan	1293:1300	arg1	strain					1315:1320	the Δmnt1 strain	1305:1320	the Δmnt1 strain	1305:1320	In this study, we elucidated the structure of the Mnt1 reaction product, the structure of O-glycan in the Δmnt1 strain.
35871410	11	90	theme	mannose	1708:1714	arg1	residues					1716:1723	mannose residues	1708:1723	mannose residues	1708:1723	The widespread abnormal phenotype caused by the disruption of the mnt1 gene is the combined result of the loss of mannose residues from O-glycans and N-glycans.
36637420	4	0	theme	matriptase	864:873	arg1	inhibitor					851:859	an inhibitor	848:859	an inhibitor of matriptase and prostasin	848:887	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	0	theme	matriptase	864:873	arg1	complex-type					740:751	complex-type	740:751	complex-type	740:751	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	6	1	theme	form	1267:1270	arg1	form					1206:1209	the form	1202:1209	the form with oligomannose-type N-glycan	1202:1241	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	6	1	theme	form	1267:1270	arg1	precursor					1250:1258	the precursor	1246:1258	the precursor of the form with complex-type N-glycan	1246:1297	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	3	2	theme	HAI-2	506:510	arg1	moiety					496:501	The N-glycan moiety	483:501	The N-glycan moiety of HAI-2	483:510	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	3	2	theme	HAI-2	506:510	arg1	signal					552:557	a subcellular targeting signal	528:557	a subcellular targeting signal	528:557	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	4	3	theme	prostasin	879:887	arg1	inhibitor					851:859	an inhibitor	848:859	an inhibitor of matriptase and prostasin	848:887	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	3	theme	prostasin	879:887	arg1	complex-type					740:751	complex-type	740:751	complex-type	740:751	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	6	4	theme	HAI-2	1171:1175	arg1	species					1177:1183	both HAI-2 species	1166:1183	both HAI-2 species	1166:1183	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	3	5	theme	targeting	542:550	arg1	moiety					496:501	The N-glycan moiety	483:501	The N-glycan moiety of HAI-2	483:510	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	3	5	theme	targeting	542:550	arg1	signal					552:557	a subcellular targeting signal	528:557	a subcellular targeting signal	528:557	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	9	6	gly	N-glycosylation	1746:1760	arg1	Asn-57					1765:1770	Asn-57	1765:1770	Asn-57	1765:1770	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	1	7	theme	matriptase	260:269	arg1	proteolysis					245:255	the proteolysis	241:255	the proteolysis of matriptase and prostasin	241:283	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	7	8	theme	distorted	1470:1478	arg1	conformations					1480:1492	distorted conformations	1470:1492	distorted conformations caused by the disarrayed disulfide linkages	1470:1536	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	7	9	theme	protease	1426:1433	arg1	function					1446:1453	protease inhibitory function	1426:1453	protease inhibitory function	1426:1453	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	7	10	gly	non-glycosylated	1335:1350	arg1	HAI-2					1352:1356	non-glycosylated HAI-2	1335:1356	non-glycosylated HAI-2	1335:1356	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	5	11	gly	N-glycosylation	918:932	arg2	Asn-57					941:946	Asn-57	941:946	Asn-57	941:946	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	11	gly	N-glycosylation	918:932	arg2	sites					934:938	two putative N-glycosylation sites	905:938	two putative N-glycosylation sites	905:938	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	11	gly	N-glycosylation	918:932	arg2	two					905:907	two	905:907	two	905:907	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	11	gly	N-glycosylation	918:932	arg2	Asn-94					952:957	Asn-94	952:957	Asn-94	952:957	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	1	12	theme	membrane	179:186	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	12	theme	membrane	179:186	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	13	theme	growth	121:126	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	13	theme	growth	121:126	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	7	14	theme	multiple	1378:1385	arg1	oligomers					1404:1412	multiple disulfide-linked oligomers	1378:1412	multiple disulfide-linked oligomers	1378:1412	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	4	15	theme	oligomannose-type	638:654	arg1	oligomannose-type					638:654	oligomannose-type	638:654	oligomannose-type	638:654	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	15	theme	oligomannose-type	638:654	arg1	one					631:633	one	631:633	one	631:633	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	1	16	theme	serine	200:205	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	16	theme	serine	200:205	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	4	17	dep	modifications	616:628	arg1	oligomannose-type					638:654	oligomannose-type	638:654	oligomannose-type	638:654	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	17	dep	modifications	616:628	arg1	one					631:633	one	631:633	one	631:633	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	17	dep	modifications	616:628	arg1	another					729:735	another	729:735	another	729:735	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	5	18	theme	N-glycosylation	918:932	arg1	Asn-94					952:957	Asn-94	952:957	Asn-94	952:957	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	18	theme	N-glycosylation	918:932	arg1	Asn-57					941:946	Asn-57	941:946	Asn-57	941:946	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	18	theme	N-glycosylation	918:932	arg1	sites					934:938	two putative N-glycosylation sites	905:938	two putative N-glycosylation sites	905:938	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	7	19	theme	HAI-2	1352:1356	arg1	majority					1323:1330	the vast majority	1314:1330	the vast majority of non-glycosylated HAI-2	1314:1356	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	6	20	theme	complex-type	1277:1288	arg1	N-glycan					1290:1297	complex-type N-glycan	1277:1297	complex-type N-glycan	1277:1297	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	5	21	theme	putative	909:916	arg1	Asn-94					952:957	Asn-94	952:957	Asn-94	952:957	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	21	theme	putative	909:916	arg1	Asn-57					941:946	Asn-57	941:946	Asn-57	941:946	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	21	theme	putative	909:916	arg1	sites					934:938	two putative N-glycosylation sites	905:938	two putative N-glycosylation sites	905:938	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	9	22	with	HAI-2	1814:1818	arg1	signal					1894:1899	correct subcellular targeting signal	1864:1899	correct subcellular targeting signal	1864:1899	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	9	22	with	HAI-2	1814:1818	arg1	activity					1851:1858	full protease suppressive activity	1825:1858	full protease suppressive activity	1825:1858	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	1	23	theme	activator	135:143	arg1	HAI					156:158	activator inhibitor (HAI)-2	135:161	activator inhibitor (HAI)-2	135:161	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	5	24	contain	contains	896:903	arg2	Asn-57					941:946	Asn-57	941:946	Asn-57	941:946	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	24	contain	contains	896:903	arg2	sites					934:938	two putative N-glycosylation sites	905:938	two putative N-glycosylation sites	905:938	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	24	contain	contains	896:903	arg1	HAI-2					890:894	HAI-2	890:894	HAI-2	890:894	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	5	24	contain	contains	896:903	arg2	Asn-94					952:957	Asn-94	952:957	Asn-94	952:957	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	0	25	theme	HAI-2	54:58	arg1	folding					68:74	the correct HAI-2 protein folding	42:74	the correct HAI-2 protein folding	42:74	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	4	26	from	surface	790:796	arg1	structures					814:823	vesicle-like structures	801:823	vesicle-like structures	801:823	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	9	27	theme	functional	1803:1812	arg1	HAI-2					1814:1818	a functional HAI-2	1801:1818	a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal	1801:1899	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	4	28	theme	reticulum/Golgi	698:712	arg1	apparatus					714:722	the endoplasmic reticulum/Golgi apparatus	682:722	the endoplasmic reticulum/Golgi apparatus	682:722	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	0	29	from	N-glycosylation	0:14	arg1	Asn-57					19:24	Asn-57	19:24	Asn-57	19:24	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	1	30	dep	factor	128:133	arg1	HAI					156:158	activator inhibitor (HAI)-2	135:161	activator inhibitor (HAI)-2	135:161	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	0	31	theme	protease	80:87	arg1	activity					100:107	protease inhibitory activity	80:107	protease inhibitory activity	80:107	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	9	32	from	N-glycosylation	1746:1760	arg1	Asn-57					1765:1770	Asn-57	1765:1770	Asn-57	1765:1770	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	9	33	theme	protease	1830:1837	arg1	activity					1851:1858	full protease suppressive activity	1825:1858	full protease suppressive activity	1825:1858	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	2	34	from	locations	453:461	arg1	proximity					472:480	close proximity	466:480	close proximity	466:480	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	6	35	theme	HAI-2	1071:1075	arg1	mutants					1077:1083	the HAI-2 mutants	1067:1083	the HAI-2 mutants	1067:1083	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	9	36	theme	correct	1864:1870	arg1	signal					1894:1899	correct subcellular targeting signal	1864:1899	correct subcellular targeting signal	1864:1899	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	8	37	theme	HAI-2	1569:1573	arg1	expression					1555:1564	forced expression	1548:1564	forced expression of HAI-2 in HAI-2 knockout cells	1548:1597	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	2	38	theme	target	422:427	arg1	enzymes					429:435	the inhibitor and potential target enzymes	394:435	enzymes	429:435	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	8	39	located	observed	1689:1696	arg1	cells					1712:1716	unmodified cells	1701:1716	unmodified cells	1701:1716	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	8	39	located	observed	1689:1696	arg2	oligomers					1667:1675	disulfide-linked HAI-2 oligomers	1644:1675	disulfide-linked HAI-2 oligomers	1644:1675	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	6	40	theme	expression	1045:1054	arg1	profile					1056:1062	The protein expression profile	1033:1062	The protein expression profile of the HAI-2 mutants	1033:1083	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	9	41	theme	targeting	1884:1892	arg1	signal					1894:1899	correct subcellular targeting signal	1864:1899	correct subcellular targeting signal	1864:1899	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	8	42	theme	HAI-2	1578:1582	arg1	cells					1593:1597	HAI-2 knockout cells	1578:1597	HAI-2 knockout cells	1578:1597	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	8	43	from	expression	1555:1564	arg1	cells					1593:1597	HAI-2 knockout cells	1578:1597	HAI-2 knockout cells	1578:1597	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	1	44	theme	cell-type	290:298	arg1	manner					310:315	a cell-type selective manner	288:315	a cell-type selective manner	288:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	3	45	theme	N-glycan	487:494	arg1	moiety					496:501	The N-glycan moiety	483:501	The N-glycan moiety of HAI-2	483:510	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	3	45	theme	N-glycan	487:494	arg1	signal					552:557	a subcellular targeting signal	528:557	a subcellular targeting signal	528:557	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	6	46	theme	species	1177:1183	arg1	N-glycosylation					1147:1161	the N-glycosylation	1143:1161	the N-glycosylation of both HAI-2 species	1143:1183	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	2	47	theme	cell-type	322:330	arg1	nature					342:347	The cell-type selective nature	318:347	The cell-type selective nature of HAI-2 function	318:365	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	1	48	theme	protease	207:214	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	48	theme	protease	207:214	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	7	49	theme	disarrayed	1508:1517	arg1	linkages					1529:1536	the disarrayed disulfide linkages	1504:1536	the disarrayed disulfide linkages	1504:1536	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	4	50	theme	vesicle-like	801:812	arg1	structures					814:823	vesicle-like structures	801:823	vesicle-like structures	801:823	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	6	51	with	form	1267:1270	arg1	N-glycan					1290:1297	complex-type N-glycan	1277:1297	complex-type N-glycan	1277:1297	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	8	52	theme	disulfide-linked	1644:1659	arg1	oligomers					1667:1675	disulfide-linked HAI-2 oligomers	1644:1675	disulfide-linked HAI-2 oligomers	1644:1675	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	2	53	theme	HAI-2	352:356	arg1	function					358:365	HAI-2 function	352:365	HAI-2 function	352:365	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	3	54	theme	subcellular	530:540	arg1	moiety					496:501	The N-glycan moiety	483:501	The N-glycan moiety of HAI-2	483:510	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	3	54	theme	subcellular	530:540	arg1	signal					552:557	a subcellular targeting signal	528:557	a subcellular targeting signal	528:557	The N-glycan moiety of HAI-2 can function as a subcellular targeting signal.
36637420	7	55	theme	inhibitory	1435:1444	arg1	function					1446:1453	protease inhibitory function	1426:1453	protease inhibitory function	1426:1453	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	1	56	theme	integral	170:177	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	56	theme	integral	170:177	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	57	theme	Kunitz-type	188:198	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	57	theme	Kunitz-type	188:198	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	7	58	theme	disulfide-linked	1387:1402	arg1	oligomers					1404:1412	multiple disulfide-linked oligomers	1378:1412	multiple disulfide-linked oligomers	1378:1412	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	6	59	gly	N-glycosylation	1147:1161	arg1	species					1177:1183	both HAI-2 species	1166:1183	both HAI-2 species	1166:1183	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	1	60	theme	Hepatocyte	110:119	arg1	factor					128:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor	110:133	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	1	60	theme	Hepatocyte	110:119	arg1	inhibitor					216:224	an integral membrane Kunitz-type serine protease inhibitor	167:224	an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner	167:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	5	61	theme	sites	934:938	arg1	mutations					966:974	point mutations	960:974	point mutations	960:974	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	6	62	with	form	1206:1209	arg1	N-glycan					1234:1241	oligomannose-type N-glycan	1216:1241	oligomannose-type N-glycan	1216:1241	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	0	63	theme	protein	60:66	arg1	folding					68:74	the correct HAI-2 protein folding	42:74	the correct HAI-2 protein folding	42:74	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	1	64	theme	inhibitor	145:153	arg1	HAI					156:158	activator inhibitor (HAI)-2	135:161	activator inhibitor (HAI)-2	135:161	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	7	65	theme	non-glycosylated	1335:1350	arg1	HAI-2					1352:1356	non-glycosylated HAI-2	1335:1356	non-glycosylated HAI-2	1335:1356	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	4	66	theme	endoplasmic	686:696	arg1	apparatus					714:722	the endoplasmic reticulum/Golgi apparatus	682:722	the endoplasmic reticulum/Golgi apparatus	682:722	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	0	67	theme	inhibitory	89:98	arg1	activity					100:107	protease inhibitory activity	80:107	protease inhibitory activity	80:107	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	7	68	theme	vast	1318:1321	arg1	majority					1323:1330	the vast majority	1314:1330	the vast majority of non-glycosylated HAI-2	1314:1356	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	5	69	theme	point	960:964	arg1	mutations					966:974	point mutations	960:974	point mutations	960:974	HAI-2 contains two putative N-glycosylation sites, Asn-57 and Asn-94, point mutations of which were generated and characterized in this study.
36637420	9	70	theme	full	1825:1828	arg1	activity					1851:1858	full protease suppressive activity	1825:1858	full protease suppressive activity	1825:1858	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	8	71	theme	forced	1548:1553	arg1	expression					1555:1564	forced expression	1548:1564	forced expression of HAI-2 in HAI-2 knockout cells	1548:1597	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	6	72	theme	mutants	1077:1083	arg1	profile					1056:1062	The protein expression profile	1033:1062	The protein expression profile of the HAI-2 mutants	1033:1083	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	9	73	theme	suppressive	1839:1849	arg1	activity					1851:1858	full protease suppressive activity	1825:1858	full protease suppressive activity	1825:1858	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	1	74	theme	prostasin	275:283	arg1	proteolysis					245:255	the proteolysis	241:255	the proteolysis of matriptase and prostasin	241:283	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	6	75	theme	oligomannose-type	1216:1232	arg1	N-glycan					1234:1241	oligomannose-type N-glycan	1216:1241	oligomannose-type N-glycan	1216:1241	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	9	76	theme	subcellular	1872:1882	arg1	signal					1894:1899	correct subcellular targeting signal	1864:1899	correct subcellular targeting signal	1864:1899	These results suggest that N-glycosylation on Asn-57 is required for folding into a functional HAI-2 with full protease suppressive activity and correct subcellular targeting signal.
36637420	8	77	theme	knockout	1584:1591	arg1	cells					1593:1597	HAI-2 knockout cells	1578:1597	HAI-2 knockout cells	1578:1597	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	2	78	theme	potential	412:420	arg1	enzymes					429:435	the inhibitor and potential target enzymes	394:435	enzymes	429:435	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	0	79	gly	N-glycosylation	0:14	arg1	Asn-57					19:24	Asn-57	19:24	Asn-57	19:24	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	0	79	gly	N-glycosylation	0:14	arg1	HAI-2					54:58	the correct HAI-2 protein folding	42:74	the correct HAI-2 protein folding	42:74	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	0	79	gly	N-glycosylation	0:14	arg1	protein					60:66	the correct HAI-2 protein folding	42:74	the correct HAI-2 protein folding	42:74	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	0	79	gly	N-glycosylation	0:14	arg1	protease					80:87	protease inhibitory activity	80:107	protease inhibitory activity	80:107	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	8	80	theme	unmodified	1701:1710	arg1	cells					1712:1716	unmodified cells	1701:1716	unmodified cells	1701:1716	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	6	81	theme	protein	1037:1043	arg1	profile					1056:1062	The protein expression profile	1033:1062	The protein expression profile of the HAI-2 mutants	1033:1083	The protein expression profile of the HAI-2 mutants indicates that Asn-57, and not Asn-94, is responsible for the N-glycosylation of both HAI-2 species, suggesting that the form with oligomannose-type N-glycan is the precursor of the form with complex-type N-glycan.
36637420	2	82	theme	close	466:470	arg1	proximity					472:480	close proximity	466:480	close proximity	466:480	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	4	83	theme	modifications	616:628	arg1	one					586:588	one	586:588	one	586:588	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	83	theme	modifications	616:628	arg1	modifications					616:628	two different N-glycan modifications	593:628	two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin	593:887	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	0	84	theme	correct	46:52	arg1	folding					68:74	the correct HAI-2 protein folding	42:74	the correct HAI-2 protein folding	42:74	N-glycosylation on Asn-57 is required for the correct HAI-2 protein folding and protease inhibitory activity.
36637420	1	85	theme	selective	300:308	arg1	manner					310:315	a cell-type selective manner	288:315	a cell-type selective manner	288:315	Hepatocyte growth factor activator inhibitor (HAI)-2, is an integral membrane Kunitz-type serine protease inhibitor that regulates the proteolysis of matriptase and prostasin in a cell-type selective manner.
36637420	7	86	link	disulfide-linked	1387:1402	arg1	oligomers					1404:1412	multiple disulfide-linked oligomers	1378:1412	multiple disulfide-linked oligomers	1378:1412	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	8	87	theme	HAI-2	1621:1625	arg1	oligomerization					1627:1641	HAI-2 oligomerization	1621:1641	HAI-2 oligomerization	1621:1641	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	2	88	theme	selective	332:340	arg1	nature					342:347	The cell-type selective nature	318:347	The cell-type selective nature of HAI-2 function	318:365	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
36637420	8	89	link	disulfide-linked	1644:1659	arg1	oligomers					1667:1675	disulfide-linked HAI-2 oligomers	1644:1675	disulfide-linked HAI-2 oligomers	1644:1675	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	4	90	theme	different	597:605	arg1	modifications					616:628	two different N-glycan modifications	593:628	two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin	593:887	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	4	91	theme	apical	783:788	arg1	surface					790:796	the apical surface	779:796	the apical surface in vesicle-like structures	779:823	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	7	92	theme	disulfide	1519:1527	arg1	linkages					1529:1536	the disarrayed disulfide linkages	1504:1536	the disarrayed disulfide linkages	1504:1536	Unexpectedly, the vast majority of non-glycosylated HAI-2 is synthesized into multiple disulfide-linked oligomers, which lack protease inhibitory function, likely due to distorted conformations caused by the disarrayed disulfide linkages.
36637420	8	93	theme	HAI-2	1661:1665	arg1	oligomers					1667:1675	disulfide-linked HAI-2 oligomers	1644:1675	disulfide-linked HAI-2 oligomers	1644:1675	Although forced expression of HAI-2 in HAI-2 knockout cells artificially enhances HAI-2 oligomerization, disulfide-linked HAI-2 oligomers can also be observed in unmodified cells.
36637420	4	94	theme	N-glycan	607:614	arg1	modifications					616:628	two different N-glycan modifications	593:628	two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin	593:887	HAI-2 is synthesized with one of two different N-glycan modifications: one of oligomannose-type, which largely remains in the endoplasmic reticulum/Golgi apparatus, and another of complex-type, which is targeted toward the apical surface in vesicle-like structures, and could function as an inhibitor of matriptase and prostasin.
36637420	2	95	theme	function	358:365	arg1	nature					342:347	The cell-type selective nature	318:347	The cell-type selective nature of HAI-2 function	318:365	The cell-type selective nature of HAI-2 function depends largely on whether the inhibitor and potential target enzymes are targeted to locations in close proximity.
35622127	10	0	theme	0.869	1974:1978	arg1	AUCs					1956:1959	AUCs	1956:1959	AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively	1956:2033	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	1	1	theme	type	239:242	arg1	onset					255:259	type 1 diabetes onset	239:259	type 1 diabetes onset	239:259	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	4	2	theme	244	830:832	arg1	siblings					845:852	their 244 unaffected siblings	824:852	their 244 unaffected siblings	824:852	A follow-up study compared the results for 188 of these participants with those for their 244 unaffected siblings.
35622127	7	3	theme	high-mannose	1328:1339	arg1	structures					1362:1371	IgG high-mannose and bisecting GlcNAc structures	1324:1371	IgG high-mannose and bisecting GlcNAc structures	1324:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	9	4	theme	branched	1781:1788	arg1	N-glycans					1797:1805	the highly branched plasma N-glycans	1770:1805	the highly branched plasma N-glycans	1770:1805	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	12	5	theme	tests	2269:2273	arg1	power					2260:2264	the power	2256:2264	the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials	2256:2396	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	3	6	from	METHODS	483:489	arg1	part					504:507	the first part	494:507	the first part of the study	494:520	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	3	6	from	METHODS	483:489	arg1	N-glycans					538:546	IgG N-glycans	534:546	IgG N-glycans	534:546	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	3	6	from	METHODS	483:489	arg1	plasma					523:528	plasma	523:528	plasma	523:528	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	1	7	theme	diabetes	246:253	arg1	onset					255:259	type 1 diabetes onset	239:259	type 1 diabetes onset	239:259	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	2	8	with	patients	372:379	arg1	diabetes					406:413	recent onset type 1 diabetes	386:413	recent onset type 1 diabetes	386:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	6	9	theme	disease	1071:1077	arg1	model					1090:1094	A disease predictive model	1069:1094	A disease predictive model	1069:1094	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	10	10	theme	plasma	1996:2001	arg1	N-glycans					2011:2019	plasma and IgG N-glycans	1996:2019	N-glycans	2011:2019	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	3	11	theme	first	498:502	arg1	part					504:507	the first part	494:507	the first part of the study	494:520	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	7	12	theme	GlcNAc	1355:1360	arg1	structures					1362:1371	IgG high-mannose and bisecting GlcNAc structures	1324:1371	IgG high-mannose and bisecting GlcNAc structures	1324:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	9	13	theme	autoantibodies	1590:1603	arg1	number					1580:1585	the number	1576:1585	the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody)	1576:1708	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	2	14	from	characterisation	319:334	arg1	patients					372:379	patients	372:379	patients with recent onset type 1 diabetes	372:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	10	15	theme	notable	1856:1862	arg1	power					1879:1883	notable discriminative power	1856:1883	notable discriminative power between children with type 1 diabetes and their healthy siblings	1856:1948	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	10	16	with	siblings	1941:1948	arg1	diabetes					1914:1921	type 1 diabetes	1907:1921	type 1 diabetes	1907:1921	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	3	17	theme	study	516:520	arg1	part					504:507	the first part	494:507	the first part of the study	494:520	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	3	17	theme	study	516:520	arg1	N-glycans					538:546	IgG N-glycans	534:546	IgG N-glycans	534:546	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	3	17	theme	study	516:520	arg1	plasma					523:528	plasma	523:528	plasma	523:528	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	1	18	theme	Individual	110:119	arg1	variation					121:129	AIMS/HYPOTHESIS Individual variation	94:129	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation	94:155	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	10	19	theme	IgG	2007:2009	arg1	N-glycans					2011:2019	plasma and IgG N-glycans	1996:2019	N-glycans	2011:2019	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	1	20	theme	complications	208:220	arg1	context					188:194	the context	184:194	the context of diabetes complications	184:220	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	6	21	theme	elastic	1133:1139	arg1	regression					1145:1154	logistic mixed-model elastic net regression	1112:1154	logistic mixed-model elastic net regression	1112:1154	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	3	22	theme	type	723:726	arg1	diabetes					730:737	type 1 diabetes	723:737	type 1 diabetes	723:737	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	1	23	from	role	231:234	arg1	onset					255:259	type 1 diabetes onset	239:259	type 1 diabetes onset	239:259	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	3	24	theme	IgG	534:536	arg1	N-glycans					538:546	IgG N-glycans	534:546	IgG N-glycans	534:546	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	5	25	theme	N-glycan	870:877	arg1	abundance					879:887	N-glycan abundance	870:887	N-glycan abundance	870:887	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	9	26	from	increase	1564:1571	arg1	number					1580:1585	the number	1576:1585	the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody)	1576:1708	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	9	27	theme	progression	1637:1647	arg1	autoantibodies					1590:1603	autoantibodies	1590:1603	autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody)	1590:1708	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	9	27	theme	progression	1637:1647	arg1	predictor					1624:1632	a better predictor	1615:1632	a better predictor of progression to overt diabetes than the level of any individual antibody	1615:1707	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	11	28	contain	have	2201:2204	arg1	profiles					2181:2188	N-glycan profiles	2172:2188	N-glycan profiles that could have valuable potential in risk assessment	2172:2242	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	11	28	contain	have	2201:2204	arg2	potential					2215:2223	valuable potential	2206:2223	valuable potential	2206:2223	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	6	29	theme	logistic	1112:1119	arg1	regression					1145:1154	logistic mixed-model elastic net regression	1112:1154	logistic mixed-model elastic net regression	1112:1154	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	9	30	theme	overt	1652:1656	arg1	diabetes					1658:1665	overt diabetes	1652:1665	overt diabetes	1652:1665	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	10	31	theme	0.915	1964:1968	arg1	AUCs					1956:1959	AUCs	1956:1959	AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively	1956:2033	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	10	32	with	children	1893:1900	arg1	diabetes					1914:1921	type 1 diabetes	1907:1921	type 1 diabetes	1907:1921	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	10	33	theme	type	1907:1910	arg1	diabetes					1914:1921	type 1 diabetes	1907:1921	type 1 diabetes	1907:1921	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	0	34	theme	altered	42:48	arg1	N-glycosylation					50:64	altered N-glycosylation	42:64	altered N-glycosylation of plasma proteins and IgG	42:91	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	0	35	from	onset	12:16	arg1	Children					0:7	Children	0:7	Children at onset of type 1 diabetes	0:35	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	0	36	theme	proteins	76:83	arg1	N-glycosylation					50:64	altered N-glycosylation	42:64	altered N-glycosylation of plasma proteins and IgG	42:91	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	5	37	theme	various	919:925	arg1	autoantibodies					927:940	various autoantibodies	919:940	various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W)	919:974	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	12	38	theme	prevention	2380:2389	arg1	trials					2391:2396	type 1 diabetes prevention trials	2364:2396	type 1 diabetes prevention trials	2364:2396	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	0	39	theme	IgG	89:91	arg1	N-glycosylation					50:64	altered N-glycosylation	42:64	altered N-glycosylation of plasma proteins and IgG	42:91	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	1	40	from	variation	121:129	arg1	N-glycosylation					141:155	plasma N-glycosylation	134:155	plasma N-glycosylation	134:155	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	7	41	theme	type	1244:1247	arg1	diabetes					1251:1258	type 1 diabetes	1244:1258	type 1 diabetes	1244:1258	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	9	42	theme	antibody	1700:1707	arg1	level					1676:1680	the level	1672:1680	the level of any individual antibody	1672:1707	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	2	43	theme	risk	466:469	arg1	assessment					471:480	risk assessment	466:480	risk assessment	466:480	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	2	44	theme	IgG	354:356	arg1	N-glycomes					358:367	the plasma and IgG N-glycomes	339:367	the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes	339:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	8	45	theme	ZnT8R	1447:1451	arg1	levels					1466:1471	ZnT8R autoantibody levels	1447:1471	ZnT8R autoantibody levels	1447:1471	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
35622127	2	46	theme	onset	393:397	arg1	diabetes					406:413	recent onset type 1 diabetes	386:413	recent onset type 1 diabetes	386:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	7	47	from	increase	1283:1290	arg1	disialylation					1432:1444	IgG disialylation	1428:1444	IgG disialylation	1428:1444	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	47	from	increase	1283:1290	arg1	proportion					1299:1308	the proportion	1295:1308	the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures	1295:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	47	from	increase	1283:1290	arg1	monogalactosylation					1388:1406	monogalactosylation	1388:1406	monogalactosylation	1388:1406	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	12	48	theme	diabetes	2371:2378	arg1	trials					2391:2396	type 1 diabetes prevention trials	2364:2396	type 1 diabetes prevention trials	2364:2396	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	0	49	theme	type	21:24	arg1	diabetes					28:35	type 1 diabetes	21:35	type 1 diabetes	21:35	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	5	50	theme	general	1043:1049	arg1	modelling					1058:1066	general linear modelling	1043:1066	general linear modelling	1043:1066	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	11	51	theme	N-glycan	2074:2081	arg1	changes					2083:2089	N-glycan changes	2074:2089	N-glycan changes accompanying onset of type 1 diabetes	2074:2127	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	2	52	theme	detailed	310:317	arg1	characterisation					319:334	a detailed characterisation	308:334	a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes	308:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	0	53	theme	diabetes	28:35	arg1	onset					12:16	onset	12:16	onset of type 1 diabetes	12:35	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	8	54	theme	higher	1494:1499	arg1	glycan					1522:1527	higher IgG digalactosylated glycan	1494:1527	higher IgG digalactosylated glycan with bisecting GlcNAc	1494:1549	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
35622127	4	55	theme	follow-up	742:750	arg1	study					752:756	A follow-up study	740:756	A follow-up study	740:756	A follow-up study compared the results for 188 of these participants with those for their 244 unaffected siblings.
35622127	8	56	theme	digalactosylated	1505:1520	arg1	glycan					1522:1527	higher IgG digalactosylated glycan	1494:1527	higher IgG digalactosylated glycan with bisecting GlcNAc	1494:1549	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
35622127	2	57	theme	plasma	343:348	arg1	N-glycomes					358:367	the plasma and IgG N-glycomes	339:367	the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes	339:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	9	58	from	decrease	1731:1738	arg1	proportions					1747:1757	the proportions	1743:1757	the proportions of some of the highly branched plasma N-glycans	1743:1805	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	7	59	from	increase	1416:1423	arg1	disialylation					1432:1444	IgG disialylation	1428:1444	IgG disialylation	1428:1444	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	59	from	increase	1416:1423	arg1	proportion					1299:1308	the proportion	1295:1308	the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures	1295:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	59	from	increase	1416:1423	arg1	monogalactosylation					1388:1406	monogalactosylation	1388:1406	monogalactosylation	1388:1406	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	11	60	theme	risk	2228:2231	arg1	assessment					2233:2242	risk assessment	2228:2242	risk assessment	2228:2242	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	6	61	theme	10-fold	1179:1185	arg1	cross-validation					1187:1202	a 10-fold cross-validation	1177:1202	a 10-fold cross-validation	1177:1202	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	7	62	theme	structures	1362:1371	arg1	proportion					1299:1308	the proportion	1295:1308	the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures	1295:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	6	63	theme	predictive	1079:1088	arg1	model					1090:1094	A disease predictive model	1069:1094	A disease predictive model	1069:1094	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	9	64	theme	plasma	1790:1795	arg1	N-glycans					1797:1805	the highly branched plasma N-glycans	1770:1805	the highly branched plasma N-glycans	1770:1805	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	8	65	with	glycan	1522:1527	arg1	GlcNAc					1544:1549	bisecting GlcNAc	1534:1549	bisecting GlcNAc	1534:1549	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
35622127	7	66	theme	bisecting	1345:1353	arg1	GlcNAc					1355:1360	bisecting GlcNAc	1345:1360	bisecting GlcNAc	1345:1360	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	67	theme	IgG	1324:1326	arg1	high-mannose					1328:1339	IgG high-mannose	1324:1339	IgG high-mannose	1324:1339	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	11	68	theme	predictive	2146:2155	arg1	model					2157:2161	a predictive model	2144:2161	a predictive model based on N-glycan profiles that could have valuable potential in risk assessment	2144:2242	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	12	69	theme	development	2318:2328	arg1	risk					2302:2305	risk	2302:2305	risk of disease development	2302:2328	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	12	69	theme	development	2318:2328	arg1	asset					2354:2358	a considerable asset	2339:2358	a considerable asset for type 1 diabetes prevention trials	2339:2396	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	11	70	theme	type	2113:2116	arg1	diabetes					2120:2127	type 1 diabetes	2113:2127	type 1 diabetes	2113:2127	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	4	71	theme	participants	796:807	arg1	participants					796:807	these participants	790:807	these participants	790:807	A follow-up study compared the results for 188 of these participants with those for their 244 unaffected siblings.
35622127	4	71	theme	participants	796:807	arg1	188					783:785	188	783:785	188	783:785	A follow-up study compared the results for 188 of these participants with those for their 244 unaffected siblings.
35622127	7	72	theme	plasma	1313:1318	arg1	proportion					1299:1308	the proportion	1295:1308	the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures	1295:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	10	73	theme	N-glycans	2011:2019	arg1	addition					1984:1991	addition	1984:1991	addition of plasma and IgG N-glycans	1984:2019	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	1	74	theme	diabetes	199:206	arg1	complications					208:220	diabetes complications	199:220	diabetes complications	199:220	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	7	75	from	decrease	1376:1383	arg1	disialylation					1432:1444	IgG disialylation	1428:1444	IgG disialylation	1428:1444	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	75	from	decrease	1376:1383	arg1	proportion					1299:1308	the proportion	1295:1308	the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures	1295:1371	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	7	75	from	decrease	1376:1383	arg1	monogalactosylation					1388:1406	monogalactosylation	1388:1406	monogalactosylation	1388:1406	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	9	76	theme	better	1617:1622	arg1	autoantibodies					1590:1603	autoantibodies	1590:1603	autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody)	1590:1708	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	9	76	theme	better	1617:1622	arg1	predictor					1624:1632	a better predictor	1615:1632	a better predictor of progression to overt diabetes than the level of any individual antibody	1615:1707	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	6	77	theme	net	1141:1143	arg1	regression					1145:1154	logistic mixed-model elastic net regression	1112:1154	logistic mixed-model elastic net regression	1112:1154	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	12	78	theme	disease	2310:2316	arg1	development					2318:2328	disease development	2310:2328	disease development	2310:2328	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	1	79	theme	AIMS/HYPOTHESIS	94:108	arg1	variation					121:129	AIMS/HYPOTHESIS Individual variation	94:129	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation	94:155	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	4	80	theme	unaffected	834:843	arg1	siblings					845:852	their 244 unaffected siblings	824:852	their 244 unaffected siblings	824:852	A follow-up study compared the results for 188 of these participants with those for their 244 unaffected siblings.
35622127	6	81	theme	mixed-model	1121:1131	arg1	regression					1145:1154	logistic mixed-model elastic net regression	1112:1154	logistic mixed-model elastic net regression	1112:1154	A disease predictive model was built using logistic mixed-model elastic net regression, and evaluated using a 10-fold cross-validation.
35622127	10	82	theme	discriminative	1864:1877	arg1	power					1879:1883	notable discriminative power	1856:1883	notable discriminative power between children with type 1 diabetes and their healthy siblings	1856:1948	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	5	83	theme	abundance	879:887	arg1	Correlation					855:865	Correlation	855:865	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis,	855:1017	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	1	84	theme	plasma	134:139	arg1	N-glycosylation					141:155	plasma N-glycosylation	134:155	plasma N-glycosylation	134:155	AIMS/HYPOTHESIS Individual variation in plasma N-glycosylation has mainly been studied in the context of diabetes complications, and its role in type 1 diabetes onset is largely unknown.
35622127	11	85	theme	diabetes	2120:2127	arg1	onset					2104:2108	onset	2104:2108	onset of type 1 diabetes	2104:2127	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	7	86	theme	diabetes	1251:1258	arg1	onset					1235:1239	onset	1235:1239	onset of type 1 diabetes	1235:1258	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	0	87	theme	plasma	69:74	arg1	proteins					76:83	plasma proteins	69:83	plasma proteins	69:83	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	2	88	theme	discriminative	438:451	arg1	potential					453:461	their discriminative potential	432:461	their discriminative potential	432:461	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	5	89	with	Correlation	855:865	arg1	age					1001:1003	age	1001:1003	age	1001:1003	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	5	89	with	Correlation	855:865	arg1	sex					993:995	sex	993:995	sex	993:995	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	5	89	with	Correlation	855:865	arg1	levels					898:903	the levels	894:903	the levels	894:903	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	10	90	theme	healthy	1933:1939	arg1	siblings					1941:1948	their healthy siblings	1927:1948	their healthy siblings	1927:1948	Models including age, sex and N-glycans yielded notable discriminative power between children with type 1 diabetes and their healthy siblings, with AUCs of 0.915 and 0.869 for addition of plasma and IgG N-glycans, respectively.
35622127	0	91	gly	N-glycosylation	50:64	arg1	IgG					89:91	IgG	89:91	IgG	89:91	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	0	91	gly	N-glycosylation	50:64	arg1	proteins					76:83	plasma proteins	69:83	plasma proteins	69:83	Children at onset of type 1 diabetes show altered N-glycosylation of plasma proteins and IgG.
35622127	11	92	theme	N-glycan	2172:2179	arg1	profiles					2181:2188	N-glycan profiles	2172:2188	N-glycan profiles that could have valuable potential in risk assessment	2172:2242	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	5	93	theme	autoantibodies	927:940	arg1	number					909:914	number	909:914	number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W)	909:974	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	9	94	theme	individual	1689:1698	arg1	antibody					1700:1707	any individual antibody	1685:1707	any individual antibody	1685:1707	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	2	95	theme	N-glycomes	358:367	arg1	characterisation					319:334	a detailed characterisation	308:334	a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes	308:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	5	96	from	diagnosis	1008:1016	arg1	age					1001:1003	age	1001:1003	age	1001:1003	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	5	96	from	diagnosis	1008:1016	arg1	sex					993:995	sex	993:995	sex	993:995	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	8	97	theme	autoantibody	1453:1464	arg1	levels					1466:1471	ZnT8R autoantibody levels	1447:1471	ZnT8R autoantibody levels	1447:1471	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
35622127	2	98	theme	type	399:402	arg1	diabetes					406:413	recent onset type 1 diabetes	386:413	recent onset type 1 diabetes	386:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	12	99	theme	considerable	2341:2352	arg1	asset					2354:2358	a considerable asset	2339:2358	a considerable asset for type 1 diabetes prevention trials	2339:2396	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	12	99	theme	considerable	2341:2352	arg1	risk					2302:2305	risk	2302:2305	risk of disease development	2302:2328	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	12	100	theme	type	2364:2367	arg1	diabetes					2371:2378	type 1 diabetes	2364:2378	type 1 diabetes prevention trials	2364:2396	Increasing the power of tests to identify individuals at risk of disease development would be a considerable asset for type 1 diabetes prevention trials.
35622127	2	101	theme	recent	386:391	arg1	diabetes					406:413	recent onset type 1 diabetes	386:413	recent onset type 1 diabetes	386:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	11	102	theme	valuable	2206:2213	arg1	potential					2215:2223	valuable potential	2206:2223	valuable potential	2206:2223	CONCLUSIONS/INTERPRETATION We defined N-glycan changes accompanying onset of type 1 diabetes, and developed a predictive model based on N-glycan profiles that could have valuable potential in risk assessment.
35622127	3	103	theme	study	587:591	arg1	population					593:602	a study population	585:602	a study population	585:602	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	5	104	theme	linear	1051:1056	arg1	modelling					1058:1066	general linear modelling	1043:1066	general linear modelling	1043:1066	Correlation of N-glycan abundance with the levels and number of various autoantibodies (against IA-2, GAD, ZnT8R, ZnT8W), as well as with sex and age at diagnosis, were estimated by using general linear modelling.
35622127	7	105	theme	IgG	1428:1430	arg1	disialylation					1432:1444	IgG disialylation	1428:1444	IgG disialylation	1428:1444	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	8	106	theme	IgG	1501:1503	arg1	glycan					1522:1527	higher IgG digalactosylated glycan	1494:1527	higher IgG digalactosylated glycan with bisecting GlcNAc	1494:1549	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
35622127	7	107	dep	RESULTS	1205:1211	arg1	showed					1223:1228	showed	1223:1228	showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation	1223:1444	RESULTS Our study showed that onset of type 1 diabetes was associated with an increase in the proportion of plasma and IgG high-mannose and bisecting GlcNAc structures, a decrease in monogalactosylation, and an increase in IgG disialylation.
35622127	2	108	from	N-glycomes	358:367	arg1	patients					372:379	patients	372:379	patients with recent onset type 1 diabetes	372:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	3	109	theme	DanDiabKids	613:623	arg1	registry					625:632	the DanDiabKids registry	609:632	the DanDiabKids registry	609:632	METHODS In the first part of the study, plasma and IgG N-glycans were chromatographically analysed in a study population from the DanDiabKids registry, comprising 1917 children and adolescents (0.6-19.1 years) who were newly diagnosed with type 1 diabetes.
35622127	2	110	from	patients	372:379	arg1	characterisation					319:334	a detailed characterisation	308:334	a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes	308:413	Our aims were to undertake a detailed characterisation of the plasma and IgG N-glycomes in patients with recent onset type 1 diabetes, and to evaluate their discriminative potential in risk assessment.
35622127	9	111	theme	some	1762:1765	arg1	proportions					1747:1757	the proportions	1743:1757	the proportions of some of the highly branched plasma N-glycans	1743:1805	Finally, an increase in the number of autoantibodies (which is a better predictor of progression to overt diabetes than the level of any individual antibody) was accompanied by a decrease in the proportions of some of the highly branched plasma N-glycans.
35622127	8	112	theme	bisecting	1534:1542	arg1	GlcNAc					1544:1549	bisecting GlcNAc	1534:1549	bisecting GlcNAc	1534:1549	ZnT8R autoantibody levels were associated with higher IgG digalactosylated glycan with bisecting GlcNAc.
36089065	4	0	gly	glycoproteins	749:761	arg1	glycoproteins					749:761	reporter N-linked glycoproteins	731:761	reporter N-linked glycoproteins	731:761	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	3	1	theme	local	568:572	arg1	factors					599:605	local steric and electrostatic factors	568:605	local steric and electrostatic factors surrounding each site	568:627	To understand the factors that influence glycan microheterogeneity, we hypothesized that local steric and electrostatic factors surrounding each site influence glycan availability for enzymatic modification.
36089065	8	2	theme	enzymatic	1538:1546	arg1	modification					1548:1559	enzymatic modification	1538:1559	enzymatic modification	1538:1559	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	4	3	theme	glycoproteins	749:761	arg1	expression					717:726	expression	717:726	expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null	717:807	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	5	4	theme	biantennary	989:999	arg1	structures					1028:1037	biantennary, core-fucosylated, complex structures	989:1037	biantennary, core-fucosylated, complex structures	989:1037	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	4	5	theme	N-acetylglucosaminyltransferase	766:796	arg1	MGAT1-null					798:807	N-acetylglucosaminyltransferase MGAT1-null	766:807	N-acetylglucosaminyltransferase MGAT1-null	766:807	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	9	6	from	microheterogeneity	1890:1907	arg1	glycoproteins					1921:1933	N-linked glycoproteins	1912:1933	N-linked glycoproteins	1912:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	6	7	theme	modification	1279:1290	arg1	rates					1292:1296	modification rates	1279:1296	modification rates	1279:1296	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	4	8	from	expression	717:726	arg1	MGAT1-null					798:807	N-acetylglucosaminyltransferase MGAT1-null	766:807	N-acetylglucosaminyltransferase MGAT1-null	766:807	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	9	9	from	spectrum	1878:1885	arg1	glycoproteins					1921:1933	N-linked glycoproteins	1912:1933	N-linked glycoproteins	1912:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	4	10	theme	reporter	731:738	arg1	glycoproteins					749:761	reporter N-linked glycoproteins	731:761	reporter N-linked glycoproteins	731:761	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	5	11	theme	high	956:959	arg1	mannose					961:967	high mannose	956:967	high mannose	956:967	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	8	12	theme	WT	1631:1632	arg1	cells					1634:1638	WT cells	1631:1638	WT cells	1631:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	6	13	theme	same	1246:1249	arg1	protein					1251:1257	the same protein	1242:1257	the same protein	1242:1257	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	4	14	theme	Man5GlcNAc2	842:852	arg1	sites					876:880	38 glycan sites total	866:886	38 glycan sites total	866:886	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	4	14	theme	Man5GlcNAc2	842:852	arg1	glycoforms					854:863	immature Man5GlcNAc2 glycoforms	833:863	immature Man5GlcNAc2 glycoforms (38 glycan sites total)	833:887	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	3	15	theme	enzymatic	663:671	arg1	modification					673:684	enzymatic modification	663:684	enzymatic modification	663:684	To understand the factors that influence glycan microheterogeneity, we hypothesized that local steric and electrostatic factors surrounding each site influence glycan availability for enzymatic modification.
36089065	1	16	theme	posttranslational	156:172	arg1	modification					174:185	an essential eukaryotic posttranslational modification	132:185	an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life	132:306	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	16	theme	posttranslational	156:172	arg1	N-glycosylation					113:127	N-glycosylation	113:127	N-glycosylation	113:127	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	17	gly	glycoprotein	208:219	arg1	glycoprotein					208:219	various glycoprotein properties	200:230	various glycoprotein properties	200:230	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	5	18	theme	N-glycosylation	1053:1067	arg1	enzymes					1069:1075	N-glycosylation enzymes	1053:1075	N-glycosylation enzymes	1053:1075	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	6	19	theme	modification	1191:1202	arg1	rates					1163:1167	rates	1163:1167	rates of in vitro enzymatic modification	1163:1202	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	1	20	theme	various	200:206	arg1	half-life					298:306	half-life	298:306	half-life	298:306	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	20	theme	various	200:206	arg1	folding					243:249	folding	243:249	folding	243:249	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	20	theme	various	200:206	arg1	interactions					280:291	protein-protein interactions	264:291	protein-protein interactions	264:291	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	20	theme	various	200:206	arg1	solubility					252:261	solubility	252:261	solubility	252:261	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	20	theme	various	200:206	arg1	properties					221:230	various glycoprotein properties	200:230	various glycoprotein properties	200:230	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	6	21	theme	Substantial	1136:1146	arg1	differences					1148:1158	Substantial differences	1136:1158	Substantial differences in rates of in vitro enzymatic modification	1136:1202	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	8	22	theme	enzymatic	1665:1673	arg1	bottlenecks					1675:1685	the enzymatic bottlenecks	1661:1685	the enzymatic bottlenecks observed in vivo	1661:1702	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	6	23	from	differences	1148:1158	arg1	rates					1163:1167	rates	1163:1167	rates of in vitro enzymatic modification	1163:1202	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	0	24	theme	processing	101:110	arg1	rates					80:84	site-specific rates	66:84	site-specific rates of glycoenzyme processing	66:110	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	9	25	theme	order	1731:1735	arg1	structures					1743:1752	higher order local structures	1724:1752	higher order local structures surrounding each glycosylation site	1724:1788	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	2	26	gly	glycoprotein	434:445	arg1	glycoprotein					434:445	a glycoprotein	432:445	a glycoprotein	432:445	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
36089065	7	27	theme	enzymatic	1469:1477	arg1	modification					1479:1490	in vitro enzymatic modification	1460:1490	in vitro enzymatic modification	1460:1490	In comparison, proteolytic digestion of the reporters prior to N-glycan processing eliminated differences in in vitro enzymatic modification.
36089065	8	28	theme	rates	1529:1533	arg1	comparison					1506:1515	comparison	1506:1515	comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells	1506:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	0	29	theme	glycoenzyme	89:99	arg1	processing					101:110	glycoenzyme processing	89:110	glycoenzyme processing	89:110	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	4	30	theme	glycan	869:874	arg1	sites					876:880	38 glycan sites total	866:886	38 glycan sites total	866:886	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	4	30	theme	glycan	869:874	arg1	glycoforms					854:863	immature Man5GlcNAc2 glycoforms	833:863	immature Man5GlcNAc2 glycoforms (38 glycan sites total)	833:887	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	0	31	theme	Sequential	0:9	arg1	modification					45:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	4	32	theme	total	882:886	arg1	sites					876:880	38 glycan sites total	866:886	38 glycan sites total	866:886	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	4	32	theme	total	882:886	arg1	glycoforms					854:863	immature Man5GlcNAc2 glycoforms	833:863	immature Man5GlcNAc2 glycoforms (38 glycan sites total)	833:887	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	0	33	theme	enzymatic	20:28	arg1	modification					45:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	3	34	theme	electrostatic	585:597	arg1	factors					599:605	local steric and electrostatic factors	568:605	local steric and electrostatic factors surrounding each site	568:627	To understand the factors that influence glycan microheterogeneity, we hypothesized that local steric and electrostatic factors surrounding each site influence glycan availability for enzymatic modification.
36089065	1	35	theme	essential	135:143	arg1	modification					174:185	an essential eukaryotic posttranslational modification	132:185	an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life	132:306	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	35	theme	essential	135:143	arg1	N-glycosylation					113:127	N-glycosylation	113:127	N-glycosylation	113:127	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	6	36	theme	enzymatic	1181:1189	arg1	modification					1191:1202	in vitro enzymatic modification	1172:1202	in vitro enzymatic modification	1172:1202	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	8	37	theme	glycan	1570:1575	arg1	structures					1577:1586	the glycan structures	1566:1586	the glycan structures found on the mature reporters expressed in WT cells	1566:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	7	38	from	differences	1445:1455	arg1	modification					1479:1490	in vitro enzymatic modification	1460:1490	in vitro enzymatic modification	1460:1490	In comparison, proteolytic digestion of the reporters prior to N-glycan processing eliminated differences in in vitro enzymatic modification.
36089065	0	39	theme	site-specific	66:78	arg1	rates					80:84	site-specific rates	66:84	site-specific rates of glycoenzyme processing	66:110	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	0	40	gly	N-glycoprotein	30:43	arg1	N-glycoprotein					30:43	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	9	41	gly	glycosylation	1771:1783	arg2	site					1785:1788	each glycosylation site	1766:1788	each glycosylation site	1766:1788	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	9	42	theme	modification	1822:1833	arg1	efficiency					1808:1817	the efficiency	1804:1817	the efficiency of modification both in vitro	1804:1847	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	7	43	theme	N-glycan	1414:1421	arg1	processing					1423:1432	N-glycan processing	1414:1432	N-glycan processing	1414:1432	In comparison, proteolytic digestion of the reporters prior to N-glycan processing eliminated differences in in vitro enzymatic modification.
36089065	6	44	from	sites	1233:1237	arg1	protein					1251:1257	the same protein	1242:1257	the same protein	1242:1257	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	3	45	theme	steric	574:579	arg1	factors					599:605	local steric and electrostatic factors	568:605	local steric and electrostatic factors surrounding each site	568:627	To understand the factors that influence glycan microheterogeneity, we hypothesized that local steric and electrostatic factors surrounding each site influence glycan availability for enzymatic modification.
36089065	9	46	link	N-linked	1912:1919	arg1	glycoproteins					1921:1933	N-linked glycoproteins	1912:1933	N-linked glycoproteins	1912:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	2	47	theme	secretory	340:348	arg1	pathway					350:356	the secretory pathway to form varied ensembles of structures	336:395	the secretory pathway to form varied ensembles of structures	336:395	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
36089065	4	48	theme	N-linked	740:747	arg1	glycoproteins					749:761	reporter N-linked glycoproteins	731:761	reporter N-linked glycoproteins	731:761	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	3	49	theme	glycan	639:644	arg1	availability					646:657	glycan availability	639:657	glycan availability	639:657	To understand the factors that influence glycan microheterogeneity, we hypothesized that local steric and electrostatic factors surrounding each site influence glycan availability for enzymatic modification.
36089065	9	50	gly	glycoproteins	1921:1933	arg1	glycoproteins					1921:1933	N-linked glycoproteins	1912:1933	N-linked glycoproteins	1912:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	9	51	theme	microheterogeneity	1890:1907	arg1	spectrum					1878:1885	the spectrum	1874:1885	the spectrum of microheterogeneity in N-linked glycoproteins	1874:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	2	52	from	site	424:427	arg1	glycoprotein					434:445	a glycoprotein	432:445	a glycoprotein	432:445	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
36089065	2	52	from	site	424:427	arg1	diversity					402:410	diversity	402:410	diversity at a single site on a glycoprotein	402:445	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
36089065	2	53	theme	varied	366:371	arg1	ensembles					373:381	varied ensembles	366:381	varied ensembles of structures	366:395	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
36089065	8	54	located	found	1588:1592	arg2	structures					1577:1586	the glycan structures	1566:1586	the glycan structures found on the mature reporters expressed in WT cells	1566:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	8	54	located	found	1588:1592	arg1	reporters					1608:1616	the mature reporters	1597:1616	the mature reporters expressed in WT cells	1597:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	9	55	theme	N-linked	1912:1919	arg1	glycoproteins					1921:1933	N-linked glycoproteins	1912:1933	N-linked glycoproteins	1912:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	5	56	mod	modified	933:940	arg3	panel					1044:1048	a panel	1042:1048	a panel of N-glycosylation enzymes	1042:1075	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	5	56	mod	modified	933:940	arg1	glycoproteins					896:908	These glycoproteins	890:908	These glycoproteins	890:908	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	4	57	gly	glycoforms	854:863	arg1	Man5GlcNAc2					842:852	immature Man5GlcNAc2 glycoforms	833:863	immature Man5GlcNAc2 glycoforms (38 glycan sites total)	833:887	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	1	58	theme	protein-protein	264:278	arg1	interactions					280:291	protein-protein interactions	264:291	protein-protein interactions	264:291	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	9	59	dep	modification	1822:1833	arg1	both					1835:1838	both	1835:1838	both	1835:1838	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	5	60	from	on	983:984	arg1	in vitro					942:949	in vitro	942:949	in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures	942:1037	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	1	61	theme	eukaryotic	145:154	arg1	modification					174:185	an essential eukaryotic posttranslational modification	132:185	an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life	132:306	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	61	theme	eukaryotic	145:154	arg1	N-glycosylation					113:127	N-glycosylation	113:127	N-glycosylation	113:127	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	4	62	link	N-linked	740:747	arg1	glycoproteins					749:761	reporter N-linked glycoproteins	731:761	reporter N-linked glycoproteins	731:761	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	4	63	theme	immature	833:840	arg1	sites					876:880	38 glycan sites total	866:886	38 glycan sites total	866:886	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	4	63	theme	immature	833:840	arg1	glycoforms					854:863	immature Man5GlcNAc2 glycoforms	833:863	immature Man5GlcNAc2 glycoforms (38 glycan sites total)	833:887	We tested this hypothesis via expression of reporter N-linked glycoproteins in N-acetylglucosaminyltransferase MGAT1-null HEK293 cells to produce immature Man5GlcNAc2 glycoforms (38 glycan sites total).
36089065	9	64	theme	higher	1724:1729	arg1	structures					1743:1752	higher order local structures	1724:1752	higher order local structures surrounding each glycosylation site	1724:1788	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	7	65	theme	proteolytic	1366:1376	arg1	digestion					1378:1386	proteolytic digestion	1366:1386	proteolytic digestion of the reporters prior to N-glycan processing	1366:1432	In comparison, proteolytic digestion of the reporters prior to N-glycan processing eliminated differences in in vitro enzymatic modification.
36089065	8	66	with	comparison	1506:1515	arg1	structures					1577:1586	the glycan structures	1566:1586	the glycan structures found on the mature reporters expressed in WT cells	1566:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	1	67	theme	glycoprotein	208:219	arg1	half-life					298:306	half-life	298:306	half-life	298:306	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	67	theme	glycoprotein	208:219	arg1	folding					243:249	folding	243:249	folding	243:249	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	67	theme	glycoprotein	208:219	arg1	interactions					280:291	protein-protein interactions	264:291	protein-protein interactions	264:291	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	67	theme	glycoprotein	208:219	arg1	solubility					252:261	solubility	252:261	solubility	252:261	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	1	67	theme	glycoprotein	208:219	arg1	properties					221:230	various glycoprotein properties	200:230	various glycoprotein properties	200:230	N-glycosylation is an essential eukaryotic posttranslational modification that affects various glycoprotein properties, including folding, solubility, protein-protein interactions, and half-life.
36089065	9	68	from	glycoproteins	1921:1933	arg1	spectrum					1878:1885	the spectrum	1874:1885	the spectrum of microheterogeneity in N-linked glycoproteins	1874:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	5	69	theme	reaction	1087:1094	arg1	course					1101:1106	each reaction time course	1082:1106	each reaction time course	1082:1106	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	5	70	theme	time	1096:1099	arg1	course					1101:1106	each reaction time course	1082:1106	each reaction time course	1082:1106	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	5	71	from	mannose	961:967	arg1	in vitro					942:949	in vitro	942:949	in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures	942:1037	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	9	72	theme	local	1737:1741	arg1	structures					1743:1752	higher order local structures	1724:1752	higher order local structures surrounding each glycosylation site	1724:1788	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	6	73	theme	glycan	1226:1231	arg1	sites					1233:1237	glycan sites	1226:1237	glycan sites on the same protein	1226:1257	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	8	74	theme	in vitro	1520:1527	arg1	rates					1529:1533	in vitro rates	1520:1533	in vitro rates of enzymatic modification	1520:1559	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	0	75	theme	in vitro	11:18	arg1	modification					45:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	5	76	theme	enzymes	1069:1075	arg1	panel					1044:1048	a panel	1042:1048	a panel of N-glycosylation enzymes	1042:1075	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	9	77	dep	suggest	1716:1722	arg1	contribute					1790:1799	contribute	1790:1799	contribute to the efficiency of modification both in vitro	1790:1847	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	9	77	dep	suggest	1716:1722	arg1	in vivo					1853:1859	in vivo	1853:1859	in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins	1853:1933	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	0	78	theme	N-glycoprotein	30:43	arg1	modification					45:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification	0:56	Sequential in vitro enzymatic N-glycoprotein modification reveals site-specific rates of glycoenzyme processing.
36089065	9	79	theme	glycosylation	1771:1783	arg1	site					1785:1788	each glycosylation site	1766:1788	each glycosylation site	1766:1788	These data suggest higher order local structures surrounding each glycosylation site contribute to the efficiency of modification both in vitro and in vivo to establish the spectrum of microheterogeneity in N-linked glycoproteins.
36089065	7	80	theme	in vitro	1460:1467	arg1	modification					1479:1490	in vitro enzymatic modification	1460:1490	in vitro enzymatic modification	1460:1490	In comparison, proteolytic digestion of the reporters prior to N-glycan processing eliminated differences in in vitro enzymatic modification.
36089065	5	81	gly	glycoproteins	896:908	arg1	glycoproteins					896:908	These glycoproteins	890:908	These glycoproteins	890:908	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	8	82	theme	modification	1548:1559	arg1	rates					1529:1533	in vitro rates	1520:1533	in vitro rates of enzymatic modification	1520:1559	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	3	83	theme	glycan	520:525	arg1	microheterogeneity					527:544	glycan microheterogeneity	520:544	glycan microheterogeneity	520:544	To understand the factors that influence glycan microheterogeneity, we hypothesized that local steric and electrostatic factors surrounding each site influence glycan availability for enzymatic modification.
36089065	6	84	theme	in vitro	1172:1179	arg1	modification					1191:1202	in vitro enzymatic modification	1172:1202	in vitro enzymatic modification	1172:1202	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	5	85	dep	biantennary	989:999	arg1	complex					1020:1026	complex	1020:1026	complex	1020:1026	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	5	85	dep	biantennary	989:999	arg1	core-fucosylated					1002:1017	core-fucosylated	1002:1017	core-fucosylated	1002:1017	These glycoproteins were then sequentially modified in vitro from high mannose to hybrid and on to biantennary, core-fucosylated, complex structures by a panel of N-glycosylation enzymes, and each reaction time course was quantified by LC-MS/MS.
36089065	6	86	from	differences	1264:1274	arg1	rates					1292:1296	modification rates	1279:1296	modification rates	1279:1296	Substantial differences in rates of in vitro enzymatic modification were observed between glycan sites on the same protein, and differences in modification rates varied depending on the glycoenzyme being evaluated.
36089065	2	87	theme	structures	386:395	arg1	ensembles					373:381	varied ensembles	366:381	varied ensembles of structures	366:395	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
36089065	7	88	theme	reporters	1395:1403	arg1	digestion					1378:1386	proteolytic digestion	1366:1386	proteolytic digestion of the reporters prior to N-glycan processing	1366:1432	In comparison, proteolytic digestion of the reporters prior to N-glycan processing eliminated differences in in vitro enzymatic modification.
36089065	8	89	theme	mature	1601:1606	arg1	reporters					1608:1616	the mature reporters	1597:1616	the mature reporters expressed in WT cells	1597:1638	Furthermore, comparison of in vitro rates of enzymatic modification with the glycan structures found on the mature reporters expressed in WT cells correlated well with the enzymatic bottlenecks observed in vivo.
36089065	2	90	theme	single	417:422	arg1	site					424:427	a single site	415:427	a single site on a glycoprotein	415:445	N-glycans are processed in the secretory pathway to form varied ensembles of structures, and diversity at a single site on a glycoprotein is termed 'microheterogeneity'.
35594729	5	0	theme	recombinant	729:739	arg1	BOD					741:743	recombinant BOD	729:743	recombinant BOD overexpressed in Pichia pastoris	729:776	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	2	1	link	N-linked	325:332	arg1	N-glycans					343:351	N-glycans	343:351	N-glycans	343:351	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	2	1	link	N-linked	325:332	arg1	glycans					334:340	two N-linked glycans	321:340	two N-linked glycans (N-glycans)	321:352	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	1	2	theme	direct	257:262	arg1	DET					283:285	DET	283:285	DET	283:285	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	2	theme	direct	257:262	arg1	transfer					273:280	direct electron transfer	257:280	direct electron transfer (DET)-type bioelectrocatalysis	257:311	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	0	3	theme	transfer-type	68:80	arg1	bioelectrocatalysis					82:100	direct electron transfer-type bioelectrocatalysis	52:100	direct electron transfer-type bioelectrocatalysis	52:100	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	1	4	theme	promising	161:169	arg1	enzyme					171:176	a promising enzyme	159:176	a promising enzyme for catalyzing the four-electron reduction of dioxygen into water	159:242	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	4	theme	promising	161:169	arg1	oxidase					113:119	Bilirubin oxidase	103:119	Bilirubin oxidase from Myrothecium verrucaria (mBOD)	103:154	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	5	theme	electron	264:271	arg1	DET					283:285	DET	283:285	DET	283:285	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	5	theme	electron	264:271	arg1	transfer					273:280	direct electron transfer	257:280	direct electron transfer (DET)-type bioelectrocatalysis	257:311	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	4	6	from	effect	531:536	arg1	bioelectrocatalysis					563:581	DET-type bioelectrocatalysis	554:581	DET-type bioelectrocatalysis	554:581	We investigated the effect of N-glycans on DET-type bioelectrocatalysis by performing electrochemical measurements using electrodes with controlled surface charges.
35594729	0	7	from	Effects	0:6	arg1	bioelectrocatalysis					82:100	direct electron transfer-type bioelectrocatalysis	52:100	direct electron transfer-type bioelectrocatalysis	52:100	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	7	8	theme	favorable	1055:1063	arg1	orientation					1065:1075	the most favorable orientation	1046:1075	the most favorable orientation	1046:1075	Interestingly, the most favorable orientation was achieved with pBOD, which has the largest N-glycans.
35594729	0	9	link	N-linked	11:18	arg1	glycans					20:26	N-linked glycans	11:26	N-linked glycans of bilirubin oxidase	11:47	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	5	10	theme	different	699:707	arg1	N-glycans					709:717	different N-glycans	699:717	different N-glycans	699:717	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	3	11	theme	electrode-active	481:496	arg1	BOD					506:508	BOD	506:508	BOD	506:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	11	theme	electrode-active	481:496	arg1	Cu					464:465	the type I (T1) Cu	448:465	the type I (T1) Cu	448:465	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	11	theme	electrode-active	481:496	arg1	site					498:501	the electrode-active site	477:501	the electrode-active site of BOD	477:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	12	theme	type	452:455	arg1	I					457:457	type I	452:457	the type I (T1) Cu	448:465	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	12	theme	type	452:455	arg1	T1					460:461	T1	460:461	T1	460:461	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	5	13	theme	deglycosylated	796:809	arg1	forms					811:815	their deglycosylated forms	790:815	their deglycosylated forms (dg-mBOD and dg-pBOD)	790:837	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	14	with	BODs	689:692	arg1	N-glycans					709:717	different N-glycans	699:717	different N-glycans	699:717	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	6	15	theme	adsorbed	998:1005	arg1	BODs					1007:1010	adsorbed BODs	998:1010	adsorbed BODs	998:1010	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	8	16	with	cooperative	1205:1215	arg1	interaction					1236:1246	electrostatic interaction	1222:1246	electrostatic interaction	1222:1246	Furthermore, the effect of the orientation control by the N-glycans is cooperative with electrostatic interaction.
35594729	3	17	theme	located	420:426	arg1	sites					414:418	Both binding sites	401:418	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD	401:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	7	18	theme	largest	1115:1121	arg1	N-glycans					1123:1131	the largest N-glycans	1111:1131	the largest N-glycans	1111:1131	Interestingly, the most favorable orientation was achieved with pBOD, which has the largest N-glycans.
35594729	6	19	from	orientation	983:993	arg1	electrodes					1019:1028	the electrodes	1015:1028	the electrodes	1015:1028	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	3	20	theme	BOD	506:508	arg1	BOD					506:508	BOD	506:508	BOD	506:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	20	theme	BOD	506:508	arg1	Cu					464:465	the type I (T1) Cu	448:465	the type I (T1) Cu	448:465	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	20	theme	BOD	506:508	arg1	site					498:501	the electrode-active site	477:501	the electrode-active site of BOD	477:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	6	21	theme	waves	911:915	arg1	analysis					872:879	Kinetic analysis	864:879	Kinetic analysis of the steady-state catalytic waves	864:915	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	5	22	gly	deglycosylated	796:809	arg1	forms					811:815	their deglycosylated forms	790:815	their deglycosylated forms (dg-mBOD and dg-pBOD)	790:837	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	22	gly	deglycosylated	796:809	arg1	BODs					689:692	BODs	689:692	BODs with different N-glycans	689:717	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	1	23	theme	Bilirubin	103:111	arg1	enzyme					171:176	a promising enzyme	159:176	a promising enzyme for catalyzing the four-electron reduction of dioxygen into water	159:242	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	23	theme	Bilirubin	103:111	arg1	oxidase					113:119	Bilirubin oxidase	103:119	Bilirubin oxidase from Myrothecium verrucaria (mBOD)	103:154	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	3	24	theme	binding	406:412	arg1	sites					414:418	Both binding sites	401:418	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD	401:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	0	25	theme	glycans	20:26	arg1	Effects					0:6	Effects	0:6	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis	0:100	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	1	26	from	verrucaria	138:147	arg1	enzyme					171:176	a promising enzyme	159:176	a promising enzyme for catalyzing the four-electron reduction of dioxygen into water	159:242	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	26	from	verrucaria	138:147	arg1	oxidase					113:119	Bilirubin oxidase	103:119	Bilirubin oxidase from Myrothecium verrucaria (mBOD)	103:154	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	1	27	theme	four-electron	197:209	arg1	reduction					211:219	the four-electron reduction	193:219	the four-electron reduction of dioxygen	193:231	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	0	28	theme	N-linked	11:18	arg1	glycans					20:26	N-linked glycans	11:26	N-linked glycans of bilirubin oxidase	11:47	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	1	29	theme	-type	287:291	arg1	bioelectrocatalysis					293:311	-type bioelectrocatalysis	287:311	direct electron transfer (DET)-type bioelectrocatalysis	257:311	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	6	30	theme	N-glycans	960:968	arg1	composition					945:955	composition	945:955	composition	945:955	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	6	30	theme	N-glycans	960:968	arg1	size					936:939	size	936:939	size	936:939	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	4	31	theme	surface	659:665	arg1	charges					667:673	controlled surface charges	648:673	controlled surface charges	648:673	We investigated the effect of N-glycans on DET-type bioelectrocatalysis by performing electrochemical measurements using electrodes with controlled surface charges.
35594729	0	32	theme	bilirubin	31:39	arg1	oxidase					41:47	bilirubin oxidase	31:47	bilirubin oxidase	31:47	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	6	33	theme	catalytic	901:909	arg1	waves					911:915	the steady-state catalytic waves	884:915	the steady-state catalytic waves	884:915	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	4	34	theme	electrochemical	597:611	arg1	measurements					613:624	electrochemical measurements	597:624	electrochemical measurements using electrodes	597:641	We investigated the effect of N-glycans on DET-type bioelectrocatalysis by performing electrochemical measurements using electrodes with controlled surface charges.
35594729	2	35	theme	binding	386:392	arg1	sites					394:398	binding sites	386:398	binding sites	386:398	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	2	35	theme	binding	386:392	arg1	N482					368:371	N482	368:371	N482	368:371	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	2	35	theme	binding	386:392	arg1	N472					359:362	N472	359:362	N472	359:362	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	6	36	theme	steady-state	888:899	arg1	waves					911:915	the steady-state catalytic waves	884:915	the steady-state catalytic waves	884:915	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	5	37	theme	BODs	689:692	arg1	types					680:684	Two types	676:684	Two types of BODs with different N-glycans	676:717	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	37	theme	BODs	689:692	arg1	pBOD					779:782	pBOD	779:782	pBOD	779:782	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	37	theme	BODs	689:692	arg1	forms					811:815	their deglycosylated forms	790:815	their deglycosylated forms (dg-mBOD and dg-pBOD)	790:837	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	37	theme	BODs	689:692	arg1	mBOD					720:723	mBOD	720:723	mBOD	720:723	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	37	theme	BODs	689:692	arg1	BOD					741:743	recombinant BOD	729:743	recombinant BOD overexpressed in Pichia pastoris	729:776	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	8	38	theme	electrostatic	1222:1234	arg1	interaction					1236:1246	electrostatic interaction	1222:1246	electrostatic interaction	1222:1246	Furthermore, the effect of the orientation control by the N-glycans is cooperative with electrostatic interaction.
35594729	5	39	used	used	844:847	arg2	pBOD					779:782	pBOD	779:782	pBOD	779:782	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	39	used	used	844:847	arg2	types					680:684	Two types	676:684	Two types of BODs with different N-glycans	676:717	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	39	used	used	844:847	arg2	forms					811:815	their deglycosylated forms	790:815	their deglycosylated forms (dg-mBOD and dg-pBOD)	790:837	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	39	used	used	844:847	arg2	mBOD					720:723	mBOD	720:723	mBOD	720:723	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	1	40	theme	dioxygen	224:231	arg1	reduction					211:219	the four-electron reduction	193:219	the four-electron reduction of dioxygen	193:231	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	5	41	theme	Pichia	762:767	arg1	pastoris					769:776	Pichia pastoris	762:776	Pichia pastoris	762:776	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	7	42	contain	has	1107:1109	arg2	N-glycans					1123:1131	the largest N-glycans	1111:1131	the largest N-glycans	1111:1131	Interestingly, the most favorable orientation was achieved with pBOD, which has the largest N-glycans.
35594729	7	42	contain	has	1107:1109	arg1	pBOD					1095:1098	pBOD	1095:1098	pBOD	1095:1098	Interestingly, the most favorable orientation was achieved with pBOD, which has the largest N-glycans.
35594729	3	43	theme	I	457:457	arg1	BOD					506:508	BOD	506:508	BOD	506:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	43	theme	I	457:457	arg1	Cu					464:465	the type I (T1) Cu	448:465	the type I (T1) Cu	448:465	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	3	43	theme	I	457:457	arg1	site					498:501	the electrode-active site	477:501	the electrode-active site of BOD	477:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	0	44	theme	oxidase	41:47	arg1	glycans					20:26	N-linked glycans	11:26	N-linked glycans of bilirubin oxidase	11:47	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	2	45	contain	has	317:319	arg1	It					314:315	It	314:315	It	314:315	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	2	45	contain	has	317:319	arg2	N-glycans					343:351	N-glycans	343:351	N-glycans	343:351	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	2	45	contain	has	317:319	arg2	glycans					334:340	two N-linked glycans	321:340	two N-linked glycans (N-glycans)	321:352	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	1	46	dep	transfer	273:280	arg1	bioelectrocatalysis					293:311	-type bioelectrocatalysis	287:311	direct electron transfer (DET)-type bioelectrocatalysis	257:311	Bilirubin oxidase from Myrothecium verrucaria (mBOD) is a promising enzyme for catalyzing the four-electron reduction of dioxygen into water and realizes direct electron transfer (DET)-type bioelectrocatalysis.
35594729	4	47	theme	N-glycans	541:549	arg1	effect					531:536	the effect	527:536	the effect of N-glycans on DET-type bioelectrocatalysis	527:581	We investigated the effect of N-glycans on DET-type bioelectrocatalysis by performing electrochemical measurements using electrodes with controlled surface charges.
35594729	5	48	dep	forms	811:815	arg1	dg-mBOD					818:824	dg-mBOD	818:824	dg-mBOD	818:824	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	5	48	dep	forms	811:815	arg1	dg-pBOD					830:836	dg-pBOD	830:836	dg-pBOD	830:836	Two types of BODs with different N-glycans, mBOD and recombinant BOD overexpressed in Pichia pastoris (pBOD), and their deglycosylated forms (dg-mBOD and dg-pBOD) were used in this study.
35594729	2	49	theme	N-linked	325:332	arg1	N-glycans					343:351	N-glycans	343:351	N-glycans	343:351	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	2	49	theme	N-linked	325:332	arg1	glycans					334:340	two N-linked glycans	321:340	two N-linked glycans (N-glycans)	321:352	It has two N-linked glycans (N-glycans), and N472 and N482 are known as binding sites.
35594729	8	50	theme	orientation	1165:1175	arg1	control					1177:1183	the orientation control	1161:1183	the orientation control	1161:1183	Furthermore, the effect of the orientation control by the N-glycans is cooperative with electrostatic interaction.
35594729	0	51	theme	electron	59:66	arg1	bioelectrocatalysis					82:100	direct electron transfer-type bioelectrocatalysis	52:100	direct electron transfer-type bioelectrocatalysis	52:100	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	3	52	theme	opposite	431:438	arg1	side					440:443	opposite side	431:443	opposite side of the type I (T1) Cu, which is the electrode-active site of BOD	431:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	6	53	theme	BODs	1007:1010	arg1	orientation					983:993	the orientation	979:993	the orientation of adsorbed BODs on the electrodes	979:1028	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	3	54	theme	Cu	464:465	arg1	side					440:443	opposite side	431:443	opposite side of the type I (T1) Cu, which is the electrode-active site of BOD	431:508	Both binding sites located on opposite side of the type I (T1) Cu, which is the electrode-active site of BOD.
35594729	8	55	theme	control	1177:1183	arg1	cooperative					1205:1215	cooperative	1205:1215	cooperative	1205:1215	Furthermore, the effect of the orientation control by the N-glycans is cooperative with electrostatic interaction.
35594729	8	55	theme	control	1177:1183	arg1	effect					1151:1156	the effect	1147:1156	the effect of the orientation control by the N-glycans	1147:1200	Furthermore, the effect of the orientation control by the N-glycans is cooperative with electrostatic interaction.
35594729	4	56	theme	DET-type	554:561	arg1	bioelectrocatalysis					563:581	DET-type bioelectrocatalysis	554:581	DET-type bioelectrocatalysis	554:581	We investigated the effect of N-glycans on DET-type bioelectrocatalysis by performing electrochemical measurements using electrodes with controlled surface charges.
35594729	0	57	theme	direct	52:57	arg1	bioelectrocatalysis					82:100	direct electron transfer-type bioelectrocatalysis	52:100	direct electron transfer-type bioelectrocatalysis	52:100	Effects of N-linked glycans of bilirubin oxidase on direct electron transfer-type bioelectrocatalysis.
35594729	6	58	theme	Kinetic	864:870	arg1	analysis					872:879	Kinetic analysis	864:879	Kinetic analysis of the steady-state catalytic waves	864:915	Kinetic analysis of the steady-state catalytic waves revealed that both size and composition of N-glycans affected the orientation of adsorbed BODs on the electrodes.
35594729	4	59	theme	controlled	648:657	arg1	charges					667:673	controlled surface charges	648:673	controlled surface charges	648:673	We investigated the effect of N-glycans on DET-type bioelectrocatalysis by performing electrochemical measurements using electrodes with controlled surface charges.
36830744	5	0	from	differences	1001:1011	arg1	composition					1030:1040	IgG N-glycome composition	1016:1040	IgG N-glycome composition	1016:1040	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	2	1	from	response	515:522	arg1	CAD					527:529	CAD	527:529	CAD	527:529	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	7	2	theme	obtained	1189:1196	arg1	chromatograms					1198:1210	The obtained chromatograms	1185:1210	The obtained chromatograms	1185:1210	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	7	3	from	insight	1220:1226	arg1	CAD					1325:1327	CAD	1325:1327	CAD	1325:1327	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	5	4	theme	N-glycome	1020:1028	arg1	composition					1030:1040	IgG N-glycome composition	1016:1040	IgG N-glycome composition	1016:1040	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	4	5	theme	ultra-high	811:820	arg1	chromatography					841:854	ultra-high performance liquid chromatography	811:854	ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR)	811:934	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	5	6	theme	cases	986:990	arg1	analysis					952:959	Sex-stratified analysis	937:959	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases	937:990	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	4	7	theme	purified	677:684	arg1	IgGs					686:689	The purified IgGs	673:689	The purified IgGs	673:689	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	1	8	theme	regulated	230:238	arg1	N-glycosylation					204:218	N-glycosylation	204:218	N-glycosylation	204:218	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	8	theme	regulated	230:238	arg1	modification					258:269	a highly regulated posttranslational modification	221:269	a highly regulated posttranslational modification	221:269	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	2	9	theme	IgG	475:477	arg1	functions					462:470	the effector functions	449:470	the effector functions of IgG	449:477	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	3	10	theme	clean	648:652	arg1	CAD-					666:669	CAD-	666:669	CAD-	666:669	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	3	10	theme	clean	648:652	arg1	coronaries					654:663	clean coronaries	648:663	clean coronaries (CAD-)	648:670	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	1	11	theme	Coronary	59:66	arg1	CAD					84:86	CAD	84:86	CAD	84:86	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	11	theme	Coronary	59:66	arg1	disease					75:81	Coronary artery disease	59:81	Coronary artery disease (CAD)	59:87	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	11	theme	Coronary	59:66	arg1	disease					123:129	the most common cardiovascular disease	92:129	the most common cardiovascular disease (CVD)	92:135	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	12	theme	posttranslational	240:256	arg1	N-glycosylation					204:218	N-glycosylation	204:218	N-glycosylation	204:218	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	12	theme	posttranslational	240:256	arg1	modification					258:269	a highly regulated posttranslational modification	221:269	a highly regulated posttranslational modification	221:269	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	13	theme	artery	68:73	arg1	CAD					84:86	CAD	84:86	CAD	84:86	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	13	theme	artery	68:73	arg1	disease					75:81	Coronary artery disease	59:81	Coronary artery disease (CAD)	59:87	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	13	theme	artery	68:73	arg1	disease					123:129	the most common cardiovascular disease	92:129	the most common cardiovascular disease (CVD)	92:135	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	4	14	with	interactions	877:888	arg1	HILIC-UHPLC-FLR					919:933	HILIC-UHPLC-FLR	919:933	HILIC-UHPLC-FLR	919:933	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	4	14	with	interactions	877:888	arg1	detection					908:916	fluorescence detection	895:916	fluorescence detection (HILIC-UHPLC-FLR)	895:934	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	2	15	theme	G	385:385	arg1	N-glycome					357:365	the N-glycome	353:365	the N-glycome of immunoglobulin G (IgG)	353:391	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	3	16	from	subjects	579:586	arg1	IgG					570:572	IgG	570:572	IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-)	570:670	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	6	17	gly	sialylated	1118:1127	arg1	structures					1138:1147	sialylated N-glycan structures	1118:1147	sialylated N-glycan structures	1118:1147	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	2	18	theme	immunoglobulin	370:383	arg1	IgG					388:390	IgG	388:390	IgG	388:390	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	2	18	theme	immunoglobulin	370:383	arg1	G					385:385	immunoglobulin G	370:385	immunoglobulin G (IgG)	370:391	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	3	19	from	subjects	634:641	arg1	IgG					570:572	IgG	570:572	IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-)	570:670	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	7	20	from	composition	1251:1261	arg1	CAD					1266:1268	CAD	1266:1268	CAD	1266:1268	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	6	21	theme	sialylated	1118:1127	arg1	structures					1138:1147	sialylated N-glycan structures	1118:1147	sialylated N-glycan structures	1118:1147	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	1	22	theme	previous	142:149	arg1	studies					151:157	previous studies	142:157	previous studies	142:157	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	0	23	theme	IgG	0:2	arg1	N-Glycosylation					4:18	IgG N-Glycosylation	0:18	IgG N-Glycosylation	0:18	IgG N-Glycosylation Is Altered in Coronary Artery Disease.
36830744	4	24	theme	labelled	775:782	arg1	N-glycans					784:792	the released and fluorescently labelled N-glycans	744:792	the released and fluorescently labelled N-glycans	744:792	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	7	25	theme	N-glycans	1312:1320	arg1	potential					1295:1303	the biomarker potential	1281:1303	insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD	1220:1327	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	7	25	theme	N-glycans	1312:1320	arg1	insight					1220:1226	insight	1220:1226	insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD	1220:1327	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	4	26	theme	hydrophilic	865:875	arg1	interactions					877:888	hydrophilic interactions	865:888	hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR)	865:934	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	7	27	from	potential	1295:1303	arg1	CAD					1325:1327	CAD	1325:1327	CAD	1325:1327	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	5	28	theme	Sex-stratified	937:950	arg1	analysis					952:959	Sex-stratified analysis	937:959	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases	937:990	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	6	29	theme	notable	1052:1058	arg1	differences					1060:1070	The most notable differences	1043:1070	The most notable differences	1043:1070	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	0	30	theme	Coronary	34:41	arg1	Disease					50:56	Coronary Artery Disease	34:56	Coronary Artery Disease	34:56	IgG N-Glycosylation Is Altered in Coronary Artery Disease.
36830744	6	31	located	observed	1077:1084	arg1	women					1089:1093	women	1089:1093	women	1089:1093	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	6	31	located	observed	1077:1084	arg2	differences					1060:1070	The most notable differences	1043:1070	The most notable differences	1043:1070	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	3	32	with	subjects	579:586	arg1	CAD+					619:622	CAD+	619:622	CAD+	619:622	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	3	32	with	subjects	579:586	arg1	atherosclerosis					602:616	coronary atherosclerosis	593:616	coronary atherosclerosis (CAD+)	593:623	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	6	33	theme	most	1047:1050	arg1	differences					1060:1070	The most notable differences	1043:1070	The most notable differences	1043:1070	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	0	34	gly	N-Glycosylation	4:18	arg1	Disease					50:56	Coronary Artery Disease	34:56	Coronary Artery Disease	34:56	IgG N-Glycosylation Is Altered in Coronary Artery Disease.
36830744	1	35	theme	significant	172:182	arg1	association					184:194	a significant association	170:194	a significant association between N-glycosylation, a highly regulated posttranslational modification,	170:270	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	4	36	theme	liquid	834:839	arg1	chromatography					841:854	ultra-high performance liquid chromatography	811:854	ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR)	811:934	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	4	37	theme	released	748:755	arg1	N-glycans					784:792	the released and fluorescently labelled N-glycans	744:792	the released and fluorescently labelled N-glycans	744:792	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	0	38	theme	Artery	43:48	arg1	Disease					50:56	Coronary Artery Disease	34:56	Coronary Artery Disease	34:56	IgG N-Glycosylation Is Altered in Coronary Artery Disease.
36830744	1	39	theme	atherosclerotic	295:309	arg1	plaques					311:317	atherosclerotic plaques	295:317	atherosclerotic plaques	295:317	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	4	40	theme	performance	822:832	arg1	chromatography					841:854	ultra-high performance liquid chromatography	811:854	ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR)	811:934	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	7	41	theme	IgG	1308:1310	arg1	N-glycans					1312:1320	IgG N-glycans	1308:1320	IgG N-glycans	1308:1320	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	3	42	with	subjects	634:641	arg1	CAD-					666:669	CAD-	666:669	CAD-	666:669	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	3	42	with	subjects	634:641	arg1	coronaries					654:663	clean coronaries	648:663	clean coronaries (CAD-)	648:670	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	1	43	theme	plaques	311:317	arg1	association					184:194	a significant association	170:194	a significant association between N-glycosylation, a highly regulated posttranslational modification,	170:270	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	43	theme	plaques	311:317	arg1	development					280:290	the development	276:290	the development of atherosclerotic plaques	276:317	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	5	44	theme	CAD+	981:984	arg1	cases					986:990	156 CAD+ cases	977:990	156 CAD+ cases	977:990	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	4	45	gly	deglycosylated	724:737	arg1	IgGs					686:689	The purified IgGs	673:689	The purified IgGs	673:689	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	1	46	theme	common	101:106	arg1	disease					75:81	Coronary artery disease	59:81	Coronary artery disease (CAD)	59:87	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	46	theme	common	101:106	arg1	CVD					132:134	CVD	132:134	CVD	132:134	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	46	theme	common	101:106	arg1	disease					123:129	the most common cardiovascular disease	92:129	the most common cardiovascular disease (CVD)	92:135	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	2	47	theme	inflammatory	502:513	arg1	response					515:522	the inflammatory response	498:522	the inflammatory response in CAD	498:529	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	5	48	theme	IgG	1016:1018	arg1	composition					1030:1040	IgG N-glycome composition	1016:1040	IgG N-glycome composition	1016:1040	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	5	49	theme	316	964:966	arg1	CAD-					968:971	316 CAD-	964:971	316 CAD-	964:971	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	1	50	theme	cardiovascular	108:121	arg1	disease					75:81	Coronary artery disease	59:81	Coronary artery disease (CAD)	59:87	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	50	theme	cardiovascular	108:121	arg1	CVD					132:134	CVD	132:134	CVD	132:134	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	1	50	theme	cardiovascular	108:121	arg1	disease					123:129	the most common cardiovascular disease	92:129	the most common cardiovascular disease (CVD)	92:135	Coronary artery disease (CAD) is the most common cardiovascular disease (CVD), and previous studies have shown a significant association between N-glycosylation, a highly regulated posttranslational modification, and the development of atherosclerotic plaques.
36830744	7	51	theme	biomarker	1285:1293	arg1	potential					1295:1303	the biomarker potential	1281:1303	insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD	1220:1327	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	7	52	theme	N-glycome	1241:1249	arg1	composition					1251:1261	the IgG N-glycome composition	1233:1261	the IgG N-glycome composition in CAD	1233:1268	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	2	53	theme	effector	453:460	arg1	functions					462:470	the effector functions	449:470	the effector functions of IgG	449:477	Our aim was to determine whether the N-glycome of immunoglobulin G (IgG) is associated with CAD, as N-glycans are known to alter the effector functions of IgG, which may enhance the inflammatory response in CAD.
36830744	3	54	theme	coronary	593:600	arg1	CAD+					619:622	CAD+	619:622	CAD+	619:622	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	3	54	theme	coronary	593:600	arg1	atherosclerosis					602:616	coronary atherosclerosis	593:616	coronary atherosclerosis (CAD+)	593:623	Therefore, in this study, we isolated IgG from subjects with coronary atherosclerosis (CAD+) and from subjects with clean coronaries (CAD-).
36830744	5	55	theme	CAD-	968:971	arg1	analysis					952:959	Sex-stratified analysis	937:959	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases	937:990	Sex-stratified analysis of 316 CAD- and 156 CAD+ cases revealed differences in IgG N-glycome composition.
36830744	6	56	theme	N-glycan	1129:1136	arg1	structures					1138:1147	sialylated N-glycan structures	1118:1147	sialylated N-glycan structures	1118:1147	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	6	57	theme	structures	1138:1147	arg1	presence					1106:1113	the presence	1102:1113	the presence of sialylated N-glycan structures	1102:1147	The most notable differences were observed in women, where the presence of sialylated N-glycan structures was negatively associated with CAD.
36830744	7	58	theme	IgG	1237:1239	arg1	composition					1251:1261	the IgG N-glycome composition	1233:1261	the IgG N-glycome composition in CAD	1233:1268	The obtained chromatograms provide insight into the IgG N-glycome composition in CAD as well as the biomarker potential of IgG N-glycans in CAD.
36830744	4	59	theme	fluorescence	895:906	arg1	HILIC-UHPLC-FLR					919:933	HILIC-UHPLC-FLR	919:933	HILIC-UHPLC-FLR	919:933	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
36830744	4	59	theme	fluorescence	895:906	arg1	detection					908:916	fluorescence detection	895:916	fluorescence detection (HILIC-UHPLC-FLR)	895:934	The purified IgGs were denatured and enzymatically deglycosylated, and the released and fluorescently labelled N-glycans were analysed by ultra-high performance liquid chromatography based on hydrophilic interactions with fluorescence detection (HILIC-UHPLC-FLR).
35245040	0	0	theme	Chromatography-Mass	75:93	arg1	Spectrometry					95:106	C18 Nanoliquid Chromatography-Mass Spectrometry	60:106	C18 Nanoliquid Chromatography-Mass Spectrometry	60:106	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	5	1	theme	sample	826:831	arg1	preparation					833:843	sample preparation	826:843	sample preparation	826:843	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	2	2	theme	O-glycan	386:393	arg1	types					395:399	differentially regulated O-glycan types	361:399	differentially regulated O-glycan types	361:399	The functions are governed by differentially regulated O-glycan types and terminal structures.
35245040	9	3	theme	well-characterized	1637:1654	arg1	standards					1656:1664	the now well-characterized standards	1629:1664	the now well-characterized standards	1629:1664	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	7	4	with	combination	1110:1120	arg1	library					1129:1135	a library	1127:1135	a library of genetically glycoengineered cells displaying defined O-glycan types and structures	1127:1221	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	0	5	theme	Nanoliquid	64:73	arg1	Spectrometry					95:106	C18 Nanoliquid Chromatography-Mass Spectrometry	60:106	C18 Nanoliquid Chromatography-Mass Spectrometry	60:106	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	0	6	from	Profiling	9:17	arg1	Cells					48:52	Human Cells	42:52	Human Cells	42:52	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	8	7	theme	model	1337:1341	arg1	system					1343:1348	a model system	1335:1348	a model system of human keratinocytes	1335:1371	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	2	8	theme	regulated	376:384	arg1	types					395:399	differentially regulated O-glycan types	361:399	differentially regulated O-glycan types	361:399	The functions are governed by differentially regulated O-glycan types and terminal structures.
35245040	7	9	theme	cells	1168:1172	arg1	library					1129:1135	a library	1127:1135	a library of genetically glycoengineered cells displaying defined O-glycan types and structures	1127:1221	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	4	10	theme	various	556:562	arg1	strategies					575:584	various successful strategies	556:584	various successful strategies for the in-depth profiling of released O-glycans	556:633	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	5	11	dep	release	875:881	arg1	the					858:860	the	858:860	the	858:860	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	1	12	theme	cellular	280:287	arg1	signaling					289:297	cellular signaling	280:297	cellular signaling	280:297	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	9	13	theme	mainstream	1766:1775	arg1	equipment					1788:1796	rather mainstream analytical equipment	1759:1796	rather mainstream analytical equipment	1759:1796	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	9	14	theme	human	1721:1725	arg1	tissue					1727:1732	human tissue and disease models	1721:1751	tissue	1727:1732	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	4	15	theme	isomers	780:786	arg1	abundance					747:755	the high abundance	738:755	the high abundance of O-glycan structural isomers	738:786	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	4	16	theme	structural	769:778	arg1	isomers					780:786	O-glycan structural isomers	760:786	O-glycan structural isomers	760:786	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	8	17	contain	carrying	1507:1514	arg1	latter					1500:1505	latter	1500:1505	latter	1500:1505	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	17	contain	carrying	1507:1514	arg2	numbers					1570:1576	varying numbers	1562:1576	varying numbers of fucoses and sialic acids	1562:1604	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	17	contain	carrying	1507:1514	arg2	structures					1547:1556	elongated core1 and core2 structures	1521:1556	elongated core1 and core2 structures	1521:1556	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	18	theme	varying	1562:1568	arg1	numbers					1570:1576	varying numbers	1562:1576	varying numbers of fucoses and sialic acids	1562:1604	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	7	19	from	method	1100:1105	arg1	combination					1110:1120	combination	1110:1120	combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures	1110:1221	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	1	20	theme	proteome	187:194	arg1	O-Glycosylation					127:141	O-Glycosylation	127:141	O-Glycosylation	127:141	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	20	theme	proteome	187:194	arg1	modification					161:172	an omnipresent modification	146:172	an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking	146:328	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	5	21	theme	nonreductive	862:873	arg1	release					875:881	nonreductive release	862:881	nonreductive release	862:881	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	6	22	theme	efficient	973:981	arg1	separation					990:999	efficient isomer separation	973:999	efficient isomer separation	973:999	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	7	23	theme	complex	1295:1301	arg1	mixture					1303:1309	a complex mixture	1293:1309	a complex mixture	1293:1309	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	6	24	theme	Orbitrap	1062:1069	arg1	spectrometry					1076:1087	Orbitrap mass spectrometry	1062:1087	Orbitrap mass spectrometry	1062:1087	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	8	25	theme	O-GalNAc	1467:1474	arg1	glycosylation					1476:1488	O-GalNAc glycosylation	1467:1488	O-GalNAc glycosylation	1467:1488	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	6	26	theme	isomer	983:988	arg1	separation					990:999	efficient isomer separation	973:999	efficient isomer separation	973:999	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	1	27	theme	many	206:209	arg1	cleavage					249:256	protein cleavage	241:256	protein cleavage	241:256	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	27	theme	many	206:209	arg1	folding					267:273	protein folding	259:273	protein folding	259:273	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	27	theme	many	206:209	arg1	functions					220:228	many cellular functions	206:228	many cellular functions	206:228	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	27	theme	many	206:209	arg1	signaling					289:297	cellular signaling	280:297	cellular signaling	280:297	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	0	28	theme	In-Depth	0:7	arg1	Profiling					9:17	In-Depth Profiling	0:17	In-Depth Profiling of O-Glycan Isomers in Human Cells	0:52	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	8	29	theme	fucoses	1581:1587	arg1	structures					1547:1556	elongated core1 and core2 structures	1521:1556	elongated core1 and core2 structures	1521:1556	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	29	theme	fucoses	1581:1587	arg1	numbers					1570:1576	varying numbers	1562:1576	varying numbers of fucoses and sialic acids	1562:1604	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	7	30	theme	defined	1185:1191	arg1	types					1202:1206	defined O-glycan types	1185:1206	defined O-glycan types	1185:1206	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	9	31	theme	analytical	1777:1786	arg1	equipment					1788:1796	rather mainstream analytical equipment	1759:1796	rather mainstream analytical equipment	1759:1796	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	9	32	from	changes	1710:1716	arg1	tissue					1727:1732	human tissue and disease models	1721:1751	tissue	1727:1732	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	9	32	from	changes	1710:1716	arg1	models					1746:1751	human tissue and disease models	1721:1751	models	1746:1751	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	3	33	theme	analytical	463:472	arg1	methods					474:480	analytical methods	463:480	analytical methods that facilitate the annotation of O-glycans in biological material	463:547	It is therefore essential to develop analytical methods that facilitate the annotation of O-glycans in biological material.
35245040	0	34	theme	O-Glycan	22:29	arg1	Isomers					31:37	O-Glycan Isomers	22:37	O-Glycan Isomers	22:37	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	6	35	theme	mass	1071:1074	arg1	spectrometry					1076:1087	Orbitrap mass spectrometry	1062:1087	Orbitrap mass spectrometry	1062:1087	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	8	36	theme	acids	1600:1604	arg1	structures					1547:1556	elongated core1 and core2 structures	1521:1556	elongated core1 and core2 structures	1521:1556	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	36	theme	acids	1600:1604	arg1	numbers					1570:1576	varying numbers	1562:1576	varying numbers of fucoses and sialic acids	1562:1604	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	5	37	theme	O-glycans	907:915	arg1	characterization					887:902	characterization	887:902	characterization	887:902	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	5	37	theme	O-glycans	907:915	arg1	release					875:881	nonreductive release	862:881	nonreductive release	862:881	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	4	38	theme	O-glycans	625:633	arg1	profiling					603:611	the in-depth profiling	590:611	the in-depth profiling of released O-glycans	590:633	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	1	39	theme	human	181:185	arg1	proteome					187:194	the human proteome	177:194	the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking	177:328	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	7	40	theme	structural	1269:1278	arg1	isomers					1280:1286	individual O-glycan structural isomers	1249:1286	individual O-glycan structural isomers	1249:1286	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	4	41	theme	released	616:623	arg1	O-glycans					625:633	released O-glycans	616:633	released O-glycans	616:633	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	6	42	theme	Reducing-end	943:954	arg1	labeling					956:963	Reducing-end labeling	943:963	Reducing-end labeling	943:963	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	2	43	theme	terminal	405:412	arg1	structures					414:423	terminal structures	405:423	terminal structures	405:423	The functions are governed by differentially regulated O-glycan types and terminal structures.
35245040	5	44	theme	human	922:926	arg1	material					933:940	human cell material	922:940	human cell material	922:940	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	0	45	theme	Isomers	31:37	arg1	Profiling					9:17	In-Depth Profiling	0:17	In-Depth Profiling of O-Glycan Isomers in Human Cells	0:52	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	5	46	dep	high-throughput	810:824	arg1	preparation					833:843	sample preparation	826:843	sample preparation	826:843	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	8	47	theme	wide	1385:1388	arg1	O-fucose					1432:1439	O-fucose	1432:1439	O-fucose	1432:1439	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	47	theme	wide	1385:1388	arg1	variety					1390:1396	a wide variety	1383:1396	a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation,	1383:1489	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	47	theme	wide	1385:1388	arg1	glycosylation					1476:1488	O-GalNAc glycosylation	1467:1488	O-GalNAc glycosylation	1467:1488	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	47	theme	wide	1385:1388	arg1	O-glucose					1442:1450	O-glucose	1442:1450	O-glucose	1442:1450	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	47	theme	wide	1385:1388	arg1	structures					1410:1419	O-glycan structures	1401:1419	O-glycan structures	1401:1419	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	47	theme	wide	1385:1388	arg1	O-GlcNAc					1453:1460	O-GlcNAc	1453:1460	O-GlcNAc	1453:1460	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	9	48	theme	glycomic	1701:1708	arg1	changes					1710:1716	glycomic changes	1701:1716	glycomic changes in human tissue and disease models using rather mainstream analytical equipment	1701:1796	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	4	49	theme	successful	564:573	arg1	strategies					575:584	various successful strategies	556:584	various successful strategies for the in-depth profiling of released O-glycans	556:633	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	1	50	theme	protein	241:247	arg1	cleavage					249:256	protein cleavage	241:256	protein cleavage	241:256	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	7	51	theme	individual	1249:1258	arg1	isomers					1280:1286	individual O-glycan structural isomers	1249:1286	individual O-glycan structural isomers	1249:1286	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	7	52	theme	glycoengineered	1152:1166	arg1	cells					1168:1172	genetically glycoengineered cells	1140:1172	genetically glycoengineered cells displaying defined O-glycan types and structures	1140:1221	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	8	53	theme	keratinocytes	1359:1371	arg1	system					1343:1348	a model system	1335:1348	a model system of human keratinocytes	1335:1371	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	1	54	theme	cellular	211:218	arg1	cleavage					249:256	protein cleavage	241:256	protein cleavage	241:256	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	54	theme	cellular	211:218	arg1	folding					267:273	protein folding	259:273	protein folding	259:273	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	54	theme	cellular	211:218	arg1	functions					220:228	many cellular functions	206:228	many cellular functions	206:228	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	54	theme	cellular	211:218	arg1	signaling					289:297	cellular signaling	280:297	cellular signaling	280:297	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	3	55	theme	biological	529:538	arg1	material					540:547	biological material	529:547	biological material	529:547	It is therefore essential to develop analytical methods that facilitate the annotation of O-glycans in biological material.
35245040	0	56	theme	Human	42:46	arg1	Cells					48:52	Human Cells	42:52	Human Cells	42:52	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	4	57	theme	in-depth	594:601	arg1	profiling					603:611	the in-depth profiling	590:611	the in-depth profiling of released O-glycans	590:633	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	7	58	theme	O-glycan	1193:1200	arg1	types					1202:1206	defined O-glycan types	1185:1206	defined O-glycan types	1185:1206	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	3	59	from	annotation	502:511	arg1	material					540:547	biological material	529:547	biological material	529:547	It is therefore essential to develop analytical methods that facilitate the annotation of O-glycans in biological material.
35245040	4	60	theme	O-glycan	760:767	arg1	isomers					780:786	O-glycan structural isomers	760:786	O-glycan structural isomers	760:786	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	8	61	theme	core2	1541:1545	arg1	structures					1547:1556	elongated core1 and core2 structures	1521:1556	elongated core1 and core2 structures	1521:1556	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	6	62	theme	nanoliquid	1025:1034	arg1	chromatography					1036:1049	C18 nanoliquid chromatography	1021:1049	C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry	1021:1087	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	8	63	theme	elongated	1521:1529	arg1	structures					1547:1556	elongated core1 and core2 structures	1521:1556	elongated core1 and core2 structures	1521:1556	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	7	64	theme	O-glycan	1260:1267	arg1	isomers					1280:1286	individual O-glycan structural isomers	1249:1286	individual O-glycan structural isomers	1249:1286	Using the method in combination with a library of genetically glycoengineered cells displaying defined O-glycan types and structures, we were able to annotate individual O-glycan structural isomers from a complex mixture.
35245040	9	65	theme	disease	1738:1744	arg1	models					1746:1751	human tissue and disease models	1721:1751	models	1746:1751	The method, including the now well-characterized standards, provides the opportunity to study glycomic changes in human tissue and disease models using rather mainstream analytical equipment.
35245040	3	66	theme	O-glycans	516:524	arg1	annotation					502:511	the annotation	498:511	the annotation of O-glycans in biological material	498:547	It is therefore essential to develop analytical methods that facilitate the annotation of O-glycans in biological material.
35245040	8	67	theme	sialic	1593:1598	arg1	acids					1600:1604	sialic acids	1593:1604	sialic acids	1593:1604	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	1	68	theme	omnipresent	149:159	arg1	O-Glycosylation					127:141	O-Glycosylation	127:141	O-Glycosylation	127:141	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	1	68	theme	omnipresent	149:159	arg1	modification					161:172	an omnipresent modification	146:172	an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking	146:328	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	8	69	theme	structures	1410:1419	arg1	O-fucose					1432:1439	O-fucose	1432:1439	O-fucose	1432:1439	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	69	theme	structures	1410:1419	arg1	variety					1390:1396	a wide variety	1383:1396	a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation,	1383:1489	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	69	theme	structures	1410:1419	arg1	glycosylation					1476:1488	O-GalNAc glycosylation	1467:1488	O-GalNAc glycosylation	1467:1488	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	69	theme	structures	1410:1419	arg1	O-glucose					1442:1450	O-glucose	1442:1450	O-glucose	1442:1450	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	69	theme	structures	1410:1419	arg1	structures					1410:1419	O-glycan structures	1401:1419	O-glycan structures	1401:1419	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	69	theme	structures	1410:1419	arg1	O-GlcNAc					1453:1460	O-GlcNAc	1453:1460	O-GlcNAc	1453:1460	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	0	70	theme	C18	60:62	arg1	Spectrometry					95:106	C18 Nanoliquid Chromatography-Mass Spectrometry	60:106	C18 Nanoliquid Chromatography-Mass Spectrometry	60:106	In-Depth Profiling of O-Glycan Isomers in Human Cells Using C18 Nanoliquid Chromatography-Mass Spectrometry and Glycogenomics.
35245040	5	71	theme	cell	928:931	arg1	material					933:940	human cell material	922:940	human cell material	922:940	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	4	72	theme	high	742:745	arg1	abundance					747:755	the high abundance	738:755	the high abundance of O-glycan structural isomers	738:786	While various successful strategies for the in-depth profiling of released O-glycans have been reported, these methods are often limitedly accessible to the nonspecialist or challenged by the high abundance of O-glycan structural isomers.
35245040	8	73	theme	O-glycan	1401:1408	arg1	O-GlcNAc					1453:1460	O-GlcNAc	1453:1460	O-GlcNAc	1453:1460	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	73	theme	O-glycan	1401:1408	arg1	glycosylation					1476:1488	O-GalNAc glycosylation	1467:1488	O-GalNAc glycosylation	1467:1488	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	73	theme	O-glycan	1401:1408	arg1	O-glucose					1442:1450	O-glucose	1442:1450	O-glucose	1442:1450	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	73	theme	O-glycan	1401:1408	arg1	structures					1410:1419	O-glycan structures	1401:1419	O-glycan structures	1401:1419	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	8	73	theme	O-glycan	1401:1408	arg1	O-fucose					1432:1439	O-fucose	1432:1439	O-fucose	1432:1439	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	1	74	theme	protein	259:265	arg1	folding					267:273	protein folding	259:273	protein folding	259:273	O-Glycosylation is an omnipresent modification of the human proteome affecting many cellular functions, including protein cleavage, protein folding, and cellular signaling, interactions, and trafficking.
35245040	5	75	theme	high-throughput	810:824	arg1	approach					845:852	a high-throughput sample preparation approach	808:852	a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material	808:940	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	6	76	theme	C18	1021:1023	arg1	chromatography					1036:1049	C18 nanoliquid chromatography	1021:1049	C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry	1021:1087	Reducing-end labeling allowed efficient isomer separation and detection using C18 nanoliquid chromatography coupled to Orbitrap mass spectrometry.
35245040	8	77	theme	core1	1531:1535	arg1	structures					1547:1556	elongated core1 and core2 structures	1521:1556	elongated core1 and core2 structures	1521:1556	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
35245040	5	78	from	material	933:940	arg1	characterization					887:902	characterization	887:902	characterization	887:902	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	5	78	from	material	933:940	arg1	release					875:881	nonreductive release	862:881	nonreductive release	862:881	Here, we developed a high-throughput sample preparation approach for the nonreductive release and characterization of O-glycans from human cell material.
35245040	8	79	theme	human	1353:1357	arg1	keratinocytes					1359:1371	human keratinocytes	1353:1371	human keratinocytes	1353:1371	Applying the method in a model system of human keratinocytes, we found a wide variety of O-glycan structures, including O-fucose, O-glucose, O-GlcNAc, and O-GalNAc glycosylation, with the latter carrying both elongated core1 and core2 structures and varying numbers of fucoses and sialic acids.
34499167	3	0	theme	regenerative	370:381	arg1	potential					383:391	its robust regenerative potential	359:391	its robust regenerative potential	359:391	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	11	1	from	role	1485:1488	arg1	adulthood					1561:1569	adulthood	1561:1569	adulthood	1561:1569	Our results indicate a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood.
34499167	13	2	from	glycosylation	1712:1724	arg1	glycome					1746:1752	the invertebrate glycome	1729:1752	the invertebrate glycome	1729:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	1	3	theme	cell-matrix	166:176	arg1	interaction					198:208	cell-cell, cell-matrix and receptor-ligand interaction	155:208	cell-cell, cell-matrix and receptor-ligand interaction	155:208	O-Glycans on cell surfaces play important roles in cell-cell, cell-matrix and receptor-ligand interaction.
34499167	9	4	theme	other	1161:1165	arg1	systems					1180:1186	other invertebrate systems	1161:1186	other invertebrate systems	1161:1186	These genes shared homology with those in other invertebrate systems.
34499167	4	5	dep	composition	507:517	arg1	the					503:505	the	503:505	the	503:505	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	3	6	theme	potential	383:391	arg1	interest					406:413	great interest	400:413	great interest	400:413	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	11	7	theme	spatial	1477:1483	arg1	role					1485:1488	a unique temporal and spatial role	1455:1488	a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood	1455:1569	Our results indicate a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood.
34499167	5	8	theme	planarian	706:714	arg1	mediterranea					719:730	planarian S. mediterranea	706:730	planarian S. mediterranea	706:730	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	12	9	from	report	1602:1607	arg1	summary					1575:1581	summary	1575:1581	summary	1575:1581	In summary, this is the first report on O-glycans in planaria.
34499167	12	9	from	report	1602:1607	arg1	O-glycans					1612:1620	O-glycans	1612:1620	O-glycans	1612:1620	In summary, this is the first report on O-glycans in planaria.
34499167	12	9	from	report	1602:1607	arg1	planaria					1625:1632	planaria	1625:1632	planaria	1625:1632	In summary, this is the first report on O-glycans in planaria.
34499167	9	10	theme	invertebrate	1167:1178	arg1	systems					1180:1186	other invertebrate systems	1161:1186	other invertebrate systems	1161:1186	These genes shared homology with those in other invertebrate systems.
34499167	0	11	from	Glycomic	0:7	arg1	mediterranea					90:101	planarian Schmidtea mediterranea	70:101	planarian Schmidtea mediterranea	70:101	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	5	12	theme	S.	716:717	arg1	mediterranea					719:730	planarian S. mediterranea	706:730	planarian S. mediterranea	706:730	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	10	13	from	genes	1352:1356	arg1	class					1373:1377	each enzyme class	1361:1377	each enzyme class	1361:1377	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	10	14	theme	enzyme	1366:1371	arg1	class					1373:1377	each enzyme class	1361:1377	each enzyme class	1361:1377	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	5	15	theme	mediterranea	719:730	arg1	O-glycans					693:701	mucin-type O-glycans	682:701	mucin-type O-glycans of planarian S. mediterranea	682:730	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	8	16	theme	O-glycan	1096:1103	arg1	biosynthesis					1105:1116	mucin-type O-glycan biosynthesis	1085:1116	mucin-type O-glycan biosynthesis	1085:1116	From glycotranscriptomic analysis, 60 genes belonging to five distinct enzyme classes were identified to be involved in mucin-type O-glycan biosynthesis.
34499167	6	17	theme	isomeric	780:787	arg1	structures					873:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	13	18	from	role	1816:1819	arg1	regeneration					1855:1866	tissue regeneration	1848:1866	tissue regeneration using planarians	1848:1883	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	8	19	theme	glycotranscriptomic	970:988	arg1	analysis					990:997	glycotranscriptomic analysis	970:997	glycotranscriptomic analysis	970:997	From glycotranscriptomic analysis, 60 genes belonging to five distinct enzyme classes were identified to be involved in mucin-type O-glycan biosynthesis.
34499167	13	20	theme	O-glycans	1835:1843	arg1	role					1816:1819	the biological role	1801:1819	the biological role of mucin-type O-glycans in tissue regeneration using planarians	1801:1883	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	5	21	theme	related	657:663	arg1	transcriptome					665:677	the related transcriptome	653:677	the related transcriptome	653:677	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	10	22	theme	early	1413:1417	arg1	embryogenesis					1419:1431	early embryogenesis	1413:1431	early embryogenesis	1413:1431	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	1	23	theme	receptor-ligand	182:196	arg1	interaction					198:208	cell-cell, cell-matrix and receptor-ligand interaction	155:208	cell-cell, cell-matrix and receptor-ligand interaction	155:208	O-Glycans on cell surfaces play important roles in cell-cell, cell-matrix and receptor-ligand interaction.
34499167	0	24	theme	O-glycans	57:65	arg1	Glycomic					0:7	Glycomic	0:7	Glycomic	0:7	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	0	24	theme	O-glycans	57:65	arg1	profiling					33:41	glycotranscriptomic profiling	13:41	glycotranscriptomic profiling	13:41	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	4	25	theme	O-glycans	536:544	arg1	structure					523:531	structure	523:531	structure	523:531	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	4	25	theme	O-glycans	536:544	arg1	composition					507:517	composition	507:517	composition	507:517	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	3	26	theme	Free-living	303:313	arg1	mediterranea					334:345	Free-living flatworm Schmidtea mediterranea	303:345	Free-living flatworm Schmidtea mediterranea	303:345	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	13	27	theme	biological	1805:1814	arg1	role					1816:1819	the biological role	1801:1819	the biological role of mucin-type O-glycans in tissue regeneration using planarians	1801:1883	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	10	28	theme	genes	1216:1220	arg1	majority					1200:1207	a majority	1198:1207	a majority of the genes involved in mucin-type O-glycan biosynthesis	1198:1265	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	11	29	theme	temporal	1464:1471	arg1	role					1485:1488	a unique temporal and spatial role	1455:1488	a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood	1455:1569	Our results indicate a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood.
34499167	4	30	from	structure	523:531	arg1	planaria					549:556	planaria	549:556	planaria	549:556	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	5	31	dep	in	598:599	arg1	silico					601:606	silico	601:606	silico	601:606	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	3	32	theme	regeneration	460:471	arg1	field					422:426	the field	418:426	the field of stem cell biology and tissue regeneration	418:471	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	3	33	theme	stem	431:434	arg1	biology					441:447	stem cell biology	431:447	stem cell biology	431:447	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	13	34	from	possibilities	1686:1698	arg1	glycosylation					1712:1724	cellular glycosylation	1703:1724	cellular glycosylation in the invertebrate glycome	1703:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	5	35	theme	O-glycans	693:701	arg1	transcriptome					665:677	the related transcriptome	653:677	the related transcriptome	653:677	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	5	35	theme	O-glycans	693:701	arg1	glycome					641:647	the glycome	637:647	the glycome	637:647	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	6	36	theme	O-N-acetylgalactosamine	849:871	arg1	structures					873:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	10	37	theme	few	1341:1343	arg1	genes					1352:1356	a few select genes	1339:1356	a few select genes in each enzyme class	1339:1377	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	10	38	theme	O-glycan	1245:1252	arg1	biosynthesis					1254:1265	mucin-type O-glycan biosynthesis	1234:1265	mucin-type O-glycan biosynthesis	1234:1265	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	4	39	from	composition	507:517	arg1	planaria					549:556	planaria	549:556	planaria	549:556	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	6	40	theme	disubstituted	835:847	arg1	structures					873:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	1	41	theme	cell	117:120	arg1	surfaces					122:129	cell surfaces	117:129	cell surfaces	117:129	O-Glycans on cell surfaces play important roles in cell-cell, cell-matrix and receptor-ligand interaction.
34499167	13	42	theme	biosynthetic	1673:1684	arg1	possibilities					1686:1698	the structural and biosynthetic possibilities	1654:1698	the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome	1654:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	0	43	theme	glycotranscriptomic	13:31	arg1	profiling					33:41	glycotranscriptomic profiling	13:41	glycotranscriptomic profiling	13:41	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	10	44	theme	mucin-type	1234:1243	arg1	biosynthesis					1254:1265	mucin-type O-glycan biosynthesis	1234:1265	mucin-type O-glycan biosynthesis	1234:1265	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	13	45	theme	invertebrate	1733:1744	arg1	glycome					1746:1752	the invertebrate glycome	1729:1752	the invertebrate glycome	1729:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	6	46	theme	Mucin-type	733:742	arg1	O-glycans					744:752	Mucin-type O-glycans	733:752	Mucin-type O-glycans	733:752	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	0	47	theme	mucin-type	46:55	arg1	O-glycans					57:65	mucin-type O-glycans	46:65	mucin-type O-glycans	46:65	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	5	48	theme	mucin-type	682:691	arg1	O-glycans					693:701	mucin-type O-glycans	682:701	mucin-type O-glycans of planarian S. mediterranea	682:730	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	3	49	theme	flatworm	315:322	arg1	mediterranea					334:345	Free-living flatworm Schmidtea mediterranea	303:345	Free-living flatworm Schmidtea mediterranea	303:345	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	4	50	from	information	488:498	arg1	structure					523:531	structure	523:531	structure	523:531	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	4	50	from	information	488:498	arg1	composition					507:517	composition	507:517	composition	507:517	Nevertheless, information on the composition and structure of O-glycans in planaria is unknown.
34499167	7	51	theme	3-O-methyl	916:925	arg1	hexoses					927:933	3-O-methyl hexoses	916:933	3-O-methyl hexoses	916:933	Extensions made of hexoses and 3-O-methyl hexoses were the glycoforms observed.
34499167	3	52	theme	tissue	453:458	arg1	regeneration					460:471	tissue regeneration	453:471	tissue regeneration	453:471	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	12	53	theme	first	1596:1600	arg1	report					1602:1607	the first report	1592:1607	the first report on O-glycans in planaria	1592:1632	In summary, this is the first report on O-glycans in planaria.
34499167	12	53	theme	first	1596:1600	arg1	this					1584:1587	this	1584:1587	this	1584:1587	In summary, this is the first report on O-glycans in planaria.
34499167	3	54	theme	Schmidtea	324:332	arg1	mediterranea					334:345	Free-living flatworm Schmidtea mediterranea	303:345	Free-living flatworm Schmidtea mediterranea	303:345	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	3	55	from	interest	406:413	arg1	field					422:426	the field	418:426	the field of stem cell biology and tissue regeneration	418:471	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	2	56	theme	tissue	266:271	arg1	regeneration					273:284	tissue regeneration	266:284	tissue regeneration	266:284	Therefore, glycan-based interactions are important for tissue regeneration and homeostasis.
34499167	8	57	theme	distinct	1027:1034	arg1	classes					1043:1049	five distinct enzyme classes	1022:1049	five distinct enzyme classes	1022:1049	From glycotranscriptomic analysis, 60 genes belonging to five distinct enzyme classes were identified to be involved in mucin-type O-glycan biosynthesis.
34499167	3	58	theme	great	400:404	arg1	interest					406:413	great interest	400:413	great interest	400:413	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	3	59	theme	cell	436:439	arg1	biology					441:447	stem cell biology	431:447	stem cell biology	431:447	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	13	60	gly	glycosylation	1712:1724	arg1	glycome					1746:1752	the invertebrate glycome	1729:1752	the invertebrate glycome	1729:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	5	61	theme	in	598:599	arg1	approaches					608:617	in silico approaches	598:617	in silico approaches	598:617	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	3	62	theme	biology	441:447	arg1	field					422:426	the field	418:426	the field of stem cell biology and tissue regeneration	418:471	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	13	63	theme	mucin-type	1824:1833	arg1	O-glycans					1835:1843	mucin-type O-glycans	1824:1843	mucin-type O-glycans	1824:1843	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	3	64	theme	robust	363:368	arg1	potential					383:391	its robust regenerative potential	359:391	its robust regenerative potential	359:391	Free-living flatworm Schmidtea mediterranea, because of its robust regenerative potential, is of great interest in the field of stem cell biology and tissue regeneration.
34499167	13	65	theme	cellular	1703:1710	arg1	glycosylation					1712:1724	cellular glycosylation	1703:1724	cellular glycosylation in the invertebrate glycome	1703:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	6	66	theme	extended	816:823	arg1	structures					873:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	1	67	theme	important	136:144	arg1	roles					146:150	important roles	136:150	important roles	136:150	O-Glycans on cell surfaces play important roles in cell-cell, cell-matrix and receptor-ligand interaction.
34499167	8	68	theme	enzyme	1036:1041	arg1	classes					1043:1049	five distinct enzyme classes	1022:1049	five distinct enzyme classes	1022:1049	From glycotranscriptomic analysis, 60 genes belonging to five distinct enzyme classes were identified to be involved in mucin-type O-glycan biosynthesis.
34499167	8	69	theme	mucin-type	1085:1094	arg1	biosynthesis					1105:1116	mucin-type O-glycan biosynthesis	1085:1116	mucin-type O-glycan biosynthesis	1085:1116	From glycotranscriptomic analysis, 60 genes belonging to five distinct enzyme classes were identified to be involved in mucin-type O-glycan biosynthesis.
34499167	6	70	theme	methylated	790:799	arg1	structures					873:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	6	71	theme	mono-	825:829	arg1	structures					873:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures	771:882	Mucin-type O-glycans were composed of multiple isomeric, methylated, and unusually extended mono- and disubstituted O-N-acetylgalactosamine structures.
34499167	2	72	theme	glycan-based	222:233	arg1	interactions					235:246	glycan-based interactions	222:246	glycan-based interactions	222:246	Therefore, glycan-based interactions are important for tissue regeneration and homeostasis.
34499167	11	73	theme	mucin-type	1494:1503	arg1	O-glycans					1505:1513	mucin-type O-glycans	1494:1513	mucin-type O-glycans	1494:1513	Our results indicate a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood.
34499167	1	74	from	O-Glycans	104:112	arg1	surfaces					122:129	cell surfaces	117:129	cell surfaces	117:129	O-Glycans on cell surfaces play important roles in cell-cell, cell-matrix and receptor-ligand interaction.
34499167	0	75	theme	Schmidtea	80:88	arg1	mediterranea					90:101	planarian Schmidtea mediterranea	70:101	planarian Schmidtea mediterranea	70:101	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	13	76	theme	tissue	1848:1853	arg1	regeneration					1855:1866	tissue regeneration	1848:1866	tissue regeneration using planarians	1848:1883	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	13	77	theme	structural	1658:1667	arg1	possibilities					1686:1698	the structural and biosynthetic possibilities	1654:1698	the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome	1654:1752	This study expands the structural and biosynthetic possibilities in cellular glycosylation in the invertebrate glycome and provides a framework towards understanding the biological role of mucin-type O-glycans in tissue regeneration using planarians.
34499167	1	78	theme	cell-cell	155:163	arg1	interaction					198:208	cell-cell, cell-matrix and receptor-ligand interaction	155:208	cell-cell, cell-matrix and receptor-ligand interaction	155:208	O-Glycans on cell surfaces play important roles in cell-cell, cell-matrix and receptor-ligand interaction.
34499167	10	79	theme	select	1345:1350	arg1	genes					1352:1356	a few select genes	1339:1356	a few select genes in each enzyme class	1339:1377	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
34499167	0	80	theme	planarian	70:78	arg1	mediterranea					90:101	planarian Schmidtea mediterranea	70:101	planarian Schmidtea mediterranea	70:101	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	0	81	from	profiling	33:41	arg1	mediterranea					90:101	planarian Schmidtea mediterranea	70:101	planarian Schmidtea mediterranea	70:101	Glycomic and glycotranscriptomic profiling of mucin-type O-glycans in planarian Schmidtea mediterranea.
34499167	11	82	theme	unique	1457:1462	arg1	role					1485:1488	a unique temporal and spatial role	1455:1488	a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood	1455:1569	Our results indicate a unique temporal and spatial role for mucin-type O-glycans during embryogenesis and organogenesis and in adulthood.
34499167	5	83	theme	mass	576:579	arg1	spectrometry					581:592	mass spectrometry	576:592	mass spectrometry	576:592	Using mass spectrometry and in silico approaches, we characterized the glycome and the related transcriptome of mucin-type O-glycans of planarian S. mediterranea.
34499167	10	84	theme	differentiated	1317:1330	arg1	cells					1332:1336	differentiated cells	1317:1336	differentiated cells	1317:1336	Although a majority of the genes involved in mucin-type O-glycan biosynthesis were highly expressed during organogenesis and in differentiated cells, a few select genes in each enzyme class were specifically enriched during early embryogenesis.
35995210	3	0	from	influence	388:396	arg1	activity					428:435	enzymatic activity	418:435	enzymatic activity	418:435	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	3	0	from	influence	388:396	arg1	stability					452:460	structural stability	441:460	structural stability	441:460	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	4	1	theme	ovary	584:588	arg1	cells					595:599	Chinese hamster ovary Lec1 cells	568:599	Chinese hamster ovary Lec1 cells	568:599	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	10	2	theme	enzyme	1642:1647	arg1	family					1649:1654	the TS enzyme family	1635:1654	the TS enzyme family	1635:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	3	3	theme	African	500:506	arg1	congolense					529:538	the African parasite Trypanosoma congolense	496:538	the African parasite Trypanosoma congolense	496:538	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	7	4	from	elements	1075:1082	arg1	experiments					1118:1128	CD experiments	1115:1128	CD experiments	1115:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	4	5	theme	TS	659:660	arg1	pattern					678:684	the TS N-glycosylation pattern in vivo	655:692	the TS N-glycosylation pattern in vivo	655:692	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	7	6	theme	CD	1115:1116	arg1	experiments					1118:1128	CD experiments	1115:1128	CD experiments	1115:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	10	7	theme	catalytic	1499:1507	arg1	activity					1509:1516	catalytic activity	1499:1516	catalytic activity	1499:1516	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	1	8	theme	enzymes	192:198	arg1	factor					245:250	a key virulence factor	229:250	a key virulence factor	229:250	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	1	8	theme	enzymes	192:198	arg1	action					161:166	the action	157:166	the action of trans-sialidase (TS) enzymes harbored on their surface	157:224	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	8	9	theme	monosaccharide	1218:1231	arg1	units					1233:1237	monosaccharide units	1218:1237	monosaccharide units of the highly flexible N-glycans	1218:1270	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	8	10	theme	amino	1291:1295	arg1	acids					1297:1301	some conserved amino acids	1276:1301	some conserved amino acids located at the catalytic site	1276:1331	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	2	11	gly	N-glycosylated	268:281	arg1	enzymes					256:262	TS enzymes	253:262	TS enzymes	253:262	TS enzymes are N-glycosylated, but the biological functions of their glycans have remained elusive.
35995210	7	12	theme	TconTS1	1104:1110	arg1	elements					1075:1082	secondary structure elements	1055:1082	secondary structure elements of hypoglycosylated TconTS1 in CD experiments	1055:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	8	13	theme	located	1303:1309	arg1	acids					1297:1301	some conserved amino acids	1276:1301	some conserved amino acids located at the catalytic site	1276:1331	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	5	14	theme	spectrometry	714:725	arg1	data					727:730	Our MALDI-TOF mass spectrometry data	695:730	Our MALDI-TOF mass spectrometry data	695:730	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	7	15	theme	structure	1065:1073	arg1	elements					1075:1082	secondary structure elements	1055:1082	secondary structure elements of hypoglycosylated TconTS1 in CD experiments	1055:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	8	16	theme	N-glycans	1262:1270	arg1	units					1233:1237	monosaccharide units	1218:1237	monosaccharide units of the highly flexible N-glycans	1218:1270	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	8	16	theme	N-glycans	1262:1270	arg1	acids					1297:1301	some conserved amino acids	1276:1301	some conserved amino acids located at the catalytic site	1276:1331	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	6	17	theme	untreated	957:965	arg1	enzyme					967:972	the untreated enzyme	953:972	the untreated enzyme	953:972	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	5	18	theme	MALDI-TOF	699:707	arg1	spectrometry					714:725	MALDI-TOF mass spectrometry	699:725	Our MALDI-TOF mass spectrometry data	695:730	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	5	19	theme	N-glycosylation	767:781	arg1	sites					783:787	up to eight putative N-glycosylation sites	746:787	up to eight putative N-glycosylation sites	746:787	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	2	20	theme	TS	253:254	arg1	enzymes					256:262	TS enzymes	253:262	TS enzymes	253:262	TS enzymes are N-glycosylated, but the biological functions of their glycans have remained elusive.
35995210	1	21	theme	trans-sialidase	171:185	arg1	enzymes					192:198	trans-sialidase (TS) enzymes	171:198	trans-sialidase (TS) enzymes harbored on their surface	171:224	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	6	22	theme	conversion	999:1008	arg1	rate					1010:1013	the conversion rate	995:1013	the conversion rate	995:1013	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	5	23	gly	N-glycosylation	767:781	arg2	sites					783:787	up to eight putative N-glycosylation sites	746:787	up to eight putative N-glycosylation sites	746:787	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	5	23	gly	N-glycosylation	767:781	arg2	eight					752:756	eight	752:756	eight	752:756	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	8	24	from	site	1328:1331	arg1	located					1303:1309	located	1303:1309	located	1303:1309	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	10	25	theme	so-far-unknown	1545:1558	arg1	relationship					1579:1590	a so-far-unknown structure-function relationship	1543:1590	a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family	1543:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	3	26	theme	enzymatic	418:426	arg1	activity					428:435	enzymatic activity	418:435	enzymatic activity	418:435	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	1	27	theme	disease	123:129	arg1	trypanosomiasis					131:145	the devastating disease trypanosomiasis	107:145	the devastating disease trypanosomiasis	107:145	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	7	28	from	TconTS1	1104:1110	arg1	experiments					1118:1128	CD experiments	1115:1128	CD experiments	1115:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	10	29	theme	several	1616:1622	arg1	members					1624:1630	several members	1616:1630	several members of the TS enzyme family	1616:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	3	30	theme	TconTS1	465:471	arg1	activity					428:435	enzymatic activity	418:435	enzymatic activity	418:435	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	3	30	theme	TconTS1	465:471	arg1	stability					452:460	structural stability	441:460	structural stability	441:460	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	0	31	theme	enzymatic	26:34	arg1	activity					36:43	enzymatic activity	26:43	enzymatic activity of Trypanosoma congolense trans-sialidase	26:85	N-glycosylation modulates enzymatic activity of Trypanosoma congolense trans-sialidase.
35995210	6	32	theme	TconTS1	893:899	arg1	treatment					880:888	endoglycosidase Hf treatment	861:888	endoglycosidase Hf treatment of TconTS1	861:899	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	10	33	theme	inherent	1604:1611	arg1	relationship					1579:1590	a so-far-unknown structure-function relationship	1543:1590	a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family	1543:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	9	34	theme	substrate	1403:1411	arg1	accessibility					1413:1425	substrate accessibility	1403:1425	substrate accessibility	1403:1425	These interactions led to conformational changes, possibly enhancing substrate accessibility and enzyme-substrate complex stability.
35995210	3	35	dep	activity	428:435	arg1	the					414:416	the	414:416	the	414:416	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	10	36	theme	TS	1639:1640	arg1	family					1649:1654	the TS enzyme family	1635:1654	the TS enzyme family	1635:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	0	37	theme	congolense	60:69	arg1	trans-sialidase					71:85	Trypanosoma congolense trans-sialidase	48:85	Trypanosoma congolense trans-sialidase	48:85	N-glycosylation modulates enzymatic activity of Trypanosoma congolense trans-sialidase.
35995210	6	38	theme	endoglycosidase	861:875	arg1	treatment					880:888	endoglycosidase Hf treatment	861:888	endoglycosidase Hf treatment of TconTS1	861:899	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	9	39	theme	complex	1448:1454	arg1	stability					1456:1464	enzyme-substrate complex stability	1431:1464	enzyme-substrate complex stability	1431:1464	These interactions led to conformational changes, possibly enhancing substrate accessibility and enzyme-substrate complex stability.
35995210	4	40	theme	high-mannose	616:627	arg1	N-glycans					634:642	high-mannose type N-glycans	616:642	high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo	616:692	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	3	41	theme	parasite	508:515	arg1	congolense					529:538	the African parasite Trypanosoma congolense	496:538	the African parasite Trypanosoma congolense	496:538	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	6	42	theme	relative	941:948	arg1	affinity					932:939	substrate affinity	922:939	substrate affinity relative to the untreated enzyme	922:972	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	10	43	theme	family	1649:1654	arg1	members					1624:1630	several members	1616:1630	several members of the TS enzyme family	1616:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	8	44	theme	dynamics	1154:1161	arg1	simulations					1163:1173	our molecular dynamics simulations	1140:1173	our molecular dynamics simulations	1140:1173	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	6	45	theme	substrate	922:930	arg1	affinity					932:939	substrate affinity	922:939	substrate affinity relative to the untreated enzyme	922:972	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	4	46	theme	hamster	576:582	arg1	cells					595:599	Chinese hamster ovary Lec1 cells	568:599	Chinese hamster ovary Lec1 cells	568:599	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	2	47	theme	biological	292:301	arg1	functions					303:311	the biological functions	288:311	the biological functions of their glycans	288:328	TS enzymes are N-glycosylated, but the biological functions of their glycans have remained elusive.
35995210	4	48	theme	Lec1	590:593	arg1	cells					595:599	Chinese hamster ovary Lec1 cells	568:599	Chinese hamster ovary Lec1 cells	568:599	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	6	49	from	decrease	910:917	arg1	affinity					932:939	substrate affinity	922:939	substrate affinity relative to the untreated enzyme	922:972	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	7	50	theme	hypoglycosylated	1087:1102	arg1	TconTS1					1104:1110	hypoglycosylated TconTS1	1087:1110	hypoglycosylated TconTS1 in CD experiments	1087:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	2	51	theme	glycans	322:328	arg1	functions					303:311	the biological functions	288:311	the biological functions of their glycans	288:328	TS enzymes are N-glycosylated, but the biological functions of their glycans have remained elusive.
35995210	8	52	theme	conserved	1281:1289	arg1	acids					1297:1301	some conserved amino acids	1276:1301	some conserved amino acids located at the catalytic site	1276:1331	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	5	53	theme	mass	709:712	arg1	spectrometry					714:725	MALDI-TOF mass spectrometry	699:725	Our MALDI-TOF mass spectrometry data	695:730	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	10	54	theme	here-observed	1471:1483	arg1	modulation					1485:1494	The here-observed modulation	1467:1494	The here-observed modulation of catalytic activity via N-glycans	1467:1530	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	4	55	theme	type	629:632	arg1	N-glycans					634:642	high-mannose type N-glycans	616:642	high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo	616:692	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	7	56	theme	secondary	1055:1063	arg1	elements					1075:1082	secondary structure elements	1055:1082	secondary structure elements of hypoglycosylated TconTS1 in CD experiments	1055:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	4	57	theme	N-glycosylation	662:676	arg1	pattern					678:684	the TS N-glycosylation pattern in vivo	655:692	the TS N-glycosylation pattern in vivo	655:692	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	10	58	from	members	1624:1630	arg1	inherent					1604:1611	inherent	1604:1611	inherent	1604:1611	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	4	59	theme	similar	644:650	arg1	N-glycans					634:642	high-mannose type N-glycans	616:642	high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo	616:692	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	1	60	from	factor	245:250	arg1	trypanosomiasis					131:145	the devastating disease trypanosomiasis	107:145	the devastating disease trypanosomiasis	107:145	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	8	61	theme	flexible	1253:1260	arg1	N-glycans					1262:1270	the highly flexible N-glycans	1242:1270	the highly flexible N-glycans	1242:1270	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	5	62	dep	eight	752:756	arg1	to					749:750	to	749:750	to	749:750	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	8	63	theme	catalytic	1318:1326	arg1	site					1328:1331	the catalytic site	1314:1331	the catalytic site	1314:1331	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	10	64	from	inherent	1604:1611	arg1	members					1624:1630	several members	1616:1630	several members of the TS enzyme family	1616:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	5	65	theme	putative	758:765	arg1	sites					783:787	up to eight putative N-glycosylation sites	746:787	up to eight putative N-glycosylation sites	746:787	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	1	66	theme	key	231:233	arg1	factor					245:250	a key virulence factor	229:250	a key virulence factor	229:250	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	1	66	theme	key	231:233	arg1	action					161:166	the action	157:166	the action of trans-sialidase (TS) enzymes harbored on their surface	157:224	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	3	67	from	congolense	529:538	arg1	TS					488:489	a recombinant TS	474:489	a recombinant TS from the African parasite Trypanosoma congolense	474:538	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	3	67	from	congolense	529:538	arg1	TconTS1					465:471	TconTS1	465:471	TconTS1	465:471	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	9	68	dep	changes	1375:1381	arg1	enhancing					1393:1401	enhancing	1393:1401	enhancing substrate accessibility and enzyme-substrate complex stability	1393:1464	These interactions led to conformational changes, possibly enhancing substrate accessibility and enzyme-substrate complex stability.
35995210	10	69	theme	activity	1509:1516	arg1	modulation					1485:1494	The here-observed modulation	1467:1494	The here-observed modulation of catalytic activity via N-glycans	1467:1530	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	7	70	gly	hypoglycosylated	1087:1102	arg1	TconTS1					1104:1110	hypoglycosylated TconTS1	1087:1110	hypoglycosylated TconTS1 in CD experiments	1087:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	10	71	theme	structure-function	1560:1577	arg1	relationship					1579:1590	a so-far-unknown structure-function relationship	1543:1590	a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family	1543:1654	The here-observed modulation of catalytic activity via N-glycans represents a so-far-unknown structure-function relationship potentially inherent in several members of the TS enzyme family.
35995210	3	72	theme	structural	441:450	arg1	stability					452:460	structural stability	441:460	structural stability	441:460	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	9	73	theme	conformational	1360:1373	arg1	changes					1375:1381	conformational changes	1360:1381	conformational changes	1360:1381	These interactions led to conformational changes, possibly enhancing substrate accessibility and enzyme-substrate complex stability.
35995210	1	74	theme	devastating	111:121	arg1	trypanosomiasis					131:145	the devastating disease trypanosomiasis	107:145	the devastating disease trypanosomiasis	107:145	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	4	75	from	enzyme	558:563	arg1	cells					595:599	Chinese hamster ovary Lec1 cells	568:599	Chinese hamster ovary Lec1 cells	568:599	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	4	76	theme	Chinese	568:574	arg1	cells					595:599	Chinese hamster ovary Lec1 cells	568:599	Chinese hamster ovary Lec1 cells	568:599	We expressed the enzyme in Chinese hamster ovary Lec1 cells, which produce high-mannose type N-glycans similar to the TS N-glycosylation pattern in vivo.
35995210	0	77	theme	Trypanosoma	48:58	arg1	trans-sialidase					71:85	Trypanosoma congolense trans-sialidase	48:85	Trypanosoma congolense trans-sialidase	48:85	N-glycosylation modulates enzymatic activity of Trypanosoma congolense trans-sialidase.
35995210	7	78	from	experiments	1118:1128	arg1	elements					1075:1082	secondary structure elements	1055:1082	secondary structure elements of hypoglycosylated TconTS1 in CD experiments	1055:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	6	79	contain	had	978:980	arg2	impact					985:990	no impact	982:990	no impact	982:990	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	6	79	contain	had	978:980	arg1	removal					849:855	N-glycan removal	840:855	N-glycan removal via endoglycosidase Hf treatment of TconTS1	840:899	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	0	80	theme	trans-sialidase	71:85	arg1	activity					36:43	enzymatic activity	26:43	enzymatic activity of Trypanosoma congolense trans-sialidase	26:85	N-glycosylation modulates enzymatic activity of Trypanosoma congolense trans-sialidase.
35995210	6	81	theme	Hf	877:878	arg1	treatment					880:888	endoglycosidase Hf treatment	861:888	endoglycosidase Hf treatment of TconTS1	861:899	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	3	82	theme	N-glycans	401:409	arg1	influence					388:396	the influence	384:396	the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense	384:538	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	9	83	theme	enzyme-substrate	1431:1446	arg1	stability					1456:1464	enzyme-substrate complex stability	1431:1464	enzyme-substrate complex stability	1431:1464	These interactions led to conformational changes, possibly enhancing substrate accessibility and enzyme-substrate complex stability.
35995210	5	84	gly	glycosylated	794:805	arg1	sites					783:787	up to eight putative N-glycosylation sites	746:787	up to eight putative N-glycosylation sites	746:787	Our MALDI-TOF mass spectrometry data revealed that up to eight putative N-glycosylation sites were glycosylated.
35995210	3	85	theme	recombinant	476:486	arg1	TS					488:489	a recombinant TS	474:489	a recombinant TS from the African parasite Trypanosoma congolense	474:538	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	3	85	theme	recombinant	476:486	arg1	TconTS1					465:471	TconTS1	465:471	TconTS1	465:471	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35995210	1	86	theme	virulence	235:243	arg1	factor					245:250	a key virulence factor	229:250	a key virulence factor	229:250	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	1	86	theme	virulence	235:243	arg1	action					161:166	the action	157:166	the action of trans-sialidase (TS) enzymes harbored on their surface	157:224	Trypanosomes cause the devastating disease trypanosomiasis, in which the action of trans-sialidase (TS) enzymes harbored on their surface is a key virulence factor.
35995210	8	87	theme	molecular	1144:1152	arg1	simulations					1163:1173	our molecular dynamics simulations	1140:1173	our molecular dynamics simulations	1140:1173	Finally, our molecular dynamics simulations provided evidence for interactions between monosaccharide units of the highly flexible N-glycans and some conserved amino acids located at the catalytic site.
35995210	6	88	theme	N-glycan	840:847	arg1	removal					849:855	N-glycan removal	840:855	N-glycan removal via endoglycosidase Hf treatment of TconTS1	840:899	In addition, we determined that N-glycan removal via endoglycosidase Hf treatment of TconTS1 led to a decrease in substrate affinity relative to the untreated enzyme but had no impact on the conversion rate.
35995210	7	89	from	changes	1044:1050	arg1	elements					1075:1082	secondary structure elements	1055:1082	secondary structure elements of hypoglycosylated TconTS1 in CD experiments	1055:1128	Furthermore, we observed no changes in secondary structure elements of hypoglycosylated TconTS1 in CD experiments.
35995210	3	90	theme	Trypanosoma	517:527	arg1	congolense					529:538	the African parasite Trypanosoma congolense	496:538	the African parasite Trypanosoma congolense	496:538	In this study, we investigated the influence of N-glycans on the enzymatic activity and structural stability of TconTS1, a recombinant TS from the African parasite Trypanosoma congolense.
35312770	7	0	from	deregulation	1353:1364	arg1	cancers					1398:1404	several epithelial cancers	1379:1404	several epithelial cancers	1379:1404	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	6	1	theme	GALNTs	1119:1124	arg1	levels					1100:1105	altered levels	1092:1105	altered levels of specific GALNTs	1092:1124	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	2	2	theme	O-linked	361:368	arg1	glycosylation					370:382	mucin type O-linked glycosylation	350:382	mucin type O-linked glycosylation	350:382	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	8	3	theme	increased	1925:1933	arg1	capacity					1945:1952	increased migratory capacity	1925:1952	increased migratory capacity	1925:1952	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	2	4	from	initiation	336:345	arg1	responsible					254:264	responsible	254:264	responsible	254:264	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	8	5	theme	migratory	1935:1943	arg1	capacity					1945:1952	increased migratory capacity	1925:1952	increased migratory capacity	1925:1952	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	6	theme	cancer	1748:1753	arg1	cells					1755:1759	epithelial cancer cells	1737:1759	epithelial cancer cells	1737:1759	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	7	7	theme	metastasis	1439:1448	arg1	feature					1411:1417	a feature	1409:1417	a feature of different stages metastasis	1409:1448	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	7	7	theme	metastasis	1439:1448	arg1	deregulation					1353:1364	deregulation	1353:1364	deregulation of GALNTs in several epithelial cancers	1353:1404	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	4	8	theme	expression	680:689	arg1	levels					664:669	Altered levels	656:669	Altered levels of GALNT expression or distribution	656:705	Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers.
35312770	7	9	theme	different	1422:1430	arg1	stages					1432:1437	different stages	1422:1437	different stages metastasis	1422:1448	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	4	10	theme	distribution	694:705	arg1	levels					664:669	Altered levels	656:669	Altered levels of GALNT expression or distribution	656:705	Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers.
35312770	8	11	theme	cell-cell	1772:1780	arg1	junctions					1782:1790	their cell-cell junctions	1766:1790	their cell-cell junctions	1766:1790	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	4	12	theme	Altered	656:662	arg1	levels					664:669	Altered levels	656:669	Altered levels of GALNT expression or distribution	656:705	Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers.
35312770	2	13	theme	Tn	321:322	arg1	antigen					324:330	Tn antigen	321:330	Tn antigen	321:330	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	3	14	from	unelaborated	576:587	arg1	cancers					546:552	cancers	546:552	cancers	546:552	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	7	15	theme	epithelial	1387:1396	arg1	cancers					1398:1404	several epithelial cancers	1379:1404	several epithelial cancers	1379:1404	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	8	16	with	interactions	1828:1839	arg1	membrane					1855:1862	basement membrane	1846:1862	basement membrane	1846:1862	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	17	theme	adhesive	1819:1826	arg1	interactions					1828:1839	adhesive interactions	1819:1839	adhesive interactions	1819:1839	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	1	18	theme	galactosamine	117:129	arg1	N-acetylgalactosaminyltransferases					143:176	UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases	107:176	the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs)	103:218	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	3	19	link	O-linked	518:525	arg1	structures					527:536	more complex linear or branched O-linked structures	486:536	more complex linear or branched O-linked structures	486:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	4	20	theme	wide	748:751	arg1	range					753:757	a wide range	746:757	a wide range of cancers	746:768	Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers.
35312770	2	21	theme	initial	274:280	arg1	synthesis					282:290	the initial synthesis	270:290	the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen	270:330	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	5	22	theme	glycan	954:959	arg1	structures					961:970	the glycan structures	950:970	the glycan structures	950:970	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	22	theme	glycan	954:959	arg1	exposure					1004:1011	exposure	1004:1011	exposure	1004:1011	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	6	23	theme	cell	1217:1220	arg1	behaviour					1222:1230	cell behaviour	1217:1230	cell behaviour	1217:1230	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	5	24	theme	GalNAc	839:844	arg1	glycosylation					855:867	GalNAc O-linked glycosylation	839:867	GalNAc O-linked glycosylation	839:867	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	25	theme	O-linked	912:919	arg1	glycosylation					921:933	site specific O-linked glycosylation	898:933	site specific O-linked glycosylation	898:933	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	8	26	theme	consequent	1525:1534	arg1	alterations					1536:1546	consequent alterations	1525:1546	consequent alterations in GalNAc O-linked glycosylation	1525:1579	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	4	27	theme	cancers	762:768	arg1	range					753:757	a wide range	746:757	a wide range of cancers	746:768	Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers.
35312770	1	28	theme	polypeptide	131:141	arg1	N-acetylgalactosaminyltransferases					143:176	UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases	107:176	the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs)	103:218	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	3	29	theme	glycosytransferases	457:475	arg1	action					447:452	the further sequential action	424:452	the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures	424:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	8	30	theme	O-linked	1558:1565	arg1	glycosylation					1567:1579	GalNAc O-linked glycosylation	1551:1579	GalNAc O-linked glycosylation	1551:1579	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	5	31	from	changes	939:945	arg1	structures					961:970	the glycan structures	950:970	the glycan structures	950:970	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	31	from	changes	939:945	arg1	exposure					1004:1011	exposure	1004:1011	exposure	1004:1011	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	3	32	theme	complex	491:497	arg1	structures					527:536	more complex linear or branched O-linked structures	486:536	more complex linear or branched O-linked structures	486:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	0	33	theme	master	8:13	arg1	regulators					15:24	master regulators	8:24	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?	0:90	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	1	34	theme	N-acetylgalactosaminyltransferases	143:176	arg1	family					178:183	the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family	103:183	the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs)	103:218	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	3	35	theme	further	428:434	arg1	action					447:452	the further sequential action	424:452	the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures	424:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	5	36	link	O-linked	912:919	arg1	glycosylation					921:933	site specific O-linked glycosylation	898:933	site specific O-linked glycosylation	898:933	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	37	theme	Tn	1044:1045	arg1	antigen					1047:1053	Tn antigen	1044:1053	Tn antigen	1044:1053	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	6	38	theme	Many	1056:1059	arg1	reports					1061:1067	Many reports	1056:1067	Many reports	1056:1067	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	2	39	theme	type	356:359	arg1	glycosylation					370:382	mucin type O-linked glycosylation	350:382	mucin type O-linked glycosylation	350:382	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	3	40	theme	O-linked	518:525	arg1	structures					527:536	more complex linear or branched O-linked structures	486:536	more complex linear or branched O-linked structures	486:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	0	41	theme	epithelial-mesenchymal	51:72	arg1	EMT					86:88	EMT	86:88	EMT	86:88	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	0	41	theme	epithelial-mesenchymal	51:72	arg1	transition					74:83	metastasis-associated epithelial-mesenchymal transition	29:83	metastasis-associated epithelial-mesenchymal transition (EMT)	29:89	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	3	42	theme	poor	632:635	arg1	prognosis					645:653	poor patient prognosis	632:653	poor patient prognosis	632:653	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	8	43	theme	fundamental	1683:1693	arg1	transition					1663:1672	epithelial-mesenchymal transition	1640:1672	epithelial-mesenchymal transition (EMT)	1640:1678	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	43	theme	fundamental	1683:1693	arg1	aspect					1695:1700	a fundamental aspect	1681:1700	a fundamental aspect of cancer metastasis	1681:1721	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	6	44	from	metastasis	1292:1301	arg1	models					1313:1318	animal models	1306:1318	animal models	1306:1318	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	5	45	theme	truncated	1016:1024	arg1	O-glycans					1026:1034	truncated O-glycans	1016:1034	truncated O-glycans such as Tn antigen	1016:1053	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	45	theme	truncated	1016:1024	arg1	antigen					1047:1053	Tn antigen	1044:1053	Tn antigen	1044:1053	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	0	46	dep	GALNTs	0:5	arg1	regulators					15:24	master regulators	8:24	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?	0:90	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	8	47	link	O-linked	1558:1565	arg1	glycosylation					1567:1579	GalNAc O-linked glycosylation	1551:1579	GalNAc O-linked glycosylation	1551:1579	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	48	theme	transition	1663:1672	arg1	aspects					1629:1635	aspects	1629:1635	aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal	1629:1885	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	6	49	theme	animal	1306:1311	arg1	models					1313:1318	animal models	1306:1318	animal models	1306:1318	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	2	50	theme	glycosylation	370:382	arg1	initiation					336:345	initiation	336:345	initiation of mucin type O-linked glycosylation	336:382	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	8	51	theme	metastasis	1712:1721	arg1	transition					1663:1672	epithelial-mesenchymal transition	1640:1672	epithelial-mesenchymal transition (EMT)	1640:1678	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	51	theme	metastasis	1712:1721	arg1	aspect					1695:1700	a fundamental aspect	1681:1700	a fundamental aspect of cancer metastasis	1681:1721	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	6	52	from	invasion	1269:1276	arg1	models					1313:1318	animal models	1306:1318	animal models	1306:1318	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	6	53	theme	specific	1110:1117	arg1	GALNTs					1119:1124	specific GALNTs	1110:1124	specific GALNTs	1110:1124	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	5	54	from	levels	888:893	arg1	structures					961:970	the glycan structures	950:970	the glycan structures	950:970	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	54	from	levels	888:893	arg1	exposure					1004:1011	exposure	1004:1011	exposure	1004:1011	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	6	55	from	growth	1281:1286	arg1	models					1313:1318	animal models	1306:1318	animal models	1306:1318	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	2	56	link	O-linked	361:368	arg1	glycosylation					370:382	mucin type O-linked glycosylation	350:382	mucin type O-linked glycosylation	350:382	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	3	57	from	cancers	546:552	arg1	unelaborated					576:587	unelaborated	576:587	unelaborated	576:587	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	2	58	theme	α-GalNAc1,3-O-Ser/Thr	295:315	arg1	synthesis					282:290	the initial synthesis	270:290	the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen	270:330	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	8	59	theme	epithelial	1737:1746	arg1	cells					1755:1759	epithelial cancer cells	1737:1759	epithelial cancer cells	1737:1759	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	5	60	theme	altered	880:886	arg1	levels					888:893	altered levels	880:893	altered levels of site specific O-linked glycosylation	880:933	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	4	61	theme	GALNT	674:678	arg1	expression					680:689	GALNT expression	674:689	GALNT expression	674:689	Altered levels of GALNT expression or distribution have also been extensively reported in a wide range of cancers.
35312770	7	62	theme	stages	1432:1437	arg1	metastasis					1439:1448	different stages metastasis	1422:1448	different stages metastasis	1422:1448	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	8	63	with	polarity	1806:1813	arg1	membrane					1855:1862	basement membrane	1846:1862	basement membrane	1846:1862	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	2	64	theme	antigen	324:330	arg1	synthesis					282:290	the initial synthesis	270:290	the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen	270:330	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	5	65	theme	O-linked	846:853	arg1	glycosylation					855:867	GalNAc O-linked glycosylation	839:867	GalNAc O-linked glycosylation	839:867	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	8	66	theme	apical-basal	1793:1804	arg1	polarity					1806:1813	apical-basal polarity	1793:1813	apical-basal polarity	1793:1813	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	1	67	theme	UDP-N-α-D	107:115	arg1	N-acetylgalactosaminyltransferases					143:176	UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases	107:176	the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs)	103:218	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	8	68	theme	GALNT	1493:1497	arg1	expression					1499:1508	GALNT expression	1493:1508	GALNT expression	1493:1508	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	6	69	from	proliferation	1243:1255	arg1	models					1313:1318	animal models	1306:1318	animal models	1306:1318	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	3	70	theme	patient	637:643	arg1	prognosis					645:653	poor patient prognosis	632:653	poor patient prognosis	632:653	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	7	71	theme	several	1379:1385	arg1	cancers					1398:1404	several epithelial cancers	1379:1404	several epithelial cancers	1379:1404	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	6	72	from	migration	1258:1266	arg1	models					1313:1318	animal models	1306:1318	animal models	1306:1318	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	8	73	from	changes	1482:1488	arg1	expression					1499:1508	GALNT expression	1493:1508	GALNT expression	1493:1508	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	5	74	theme	specific	903:910	arg1	glycosylation					921:933	site specific O-linked glycosylation	898:933	site specific O-linked glycosylation	898:933	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	7	75	theme	GALNTs	1369:1374	arg1	feature					1411:1417	a feature	1409:1417	a feature of different stages metastasis	1409:1448	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	7	75	theme	GALNTs	1369:1374	arg1	deregulation					1353:1364	deregulation	1353:1364	deregulation of GALNTs in several epithelial cancers	1353:1404	We have previously reviewed how deregulation of GALNTs in several epithelial cancers is a feature of different stages metastasis.
35312770	8	76	theme	basement	1846:1853	arg1	membrane					1855:1862	basement membrane	1846:1862	basement membrane	1846:1862	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	5	77	theme	glycosylation	921:933	arg1	levels					888:893	altered levels	880:893	altered levels of site specific O-linked glycosylation	880:933	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	77	theme	glycosylation	921:933	arg1	changes					939:945	changes	939:945	changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen	939:1053	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	78	link	O-linked	846:853	arg1	glycosylation					855:867	GalNAc O-linked glycosylation	839:867	GalNAc O-linked glycosylation	839:867	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	8	79	theme	GalNAc	1551:1556	arg1	glycosylation					1567:1579	GalNAc O-linked glycosylation	1551:1579	GalNAc O-linked glycosylation	1551:1579	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	80	with	junctions	1782:1790	arg1	membrane					1855:1862	basement membrane	1846:1862	basement membrane	1846:1862	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	6	81	from	changes	1206:1212	arg1	behaviour					1222:1230	cell behaviour	1217:1230	cell behaviour	1217:1230	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	5	82	theme	marked	817:822	arg1	alterations					824:834	marked alterations	817:834	marked alterations	817:834	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	82	theme	marked	817:822	arg1	changes					939:945	changes	939:945	changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen	939:1053	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	82	theme	marked	817:822	arg1	levels					888:893	altered levels	880:893	altered levels of site specific O-linked glycosylation	880:933	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	5	83	from	alterations	824:834	arg1	glycosylation					855:867	GalNAc O-linked glycosylation	839:867	GalNAc O-linked glycosylation	839:867	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	6	84	theme	altered	1092:1098	arg1	levels					1100:1105	altered levels	1092:1105	altered levels of specific GALNTs	1092:1124	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	8	85	theme	spindle-shaped	1895:1908	arg1	morphology					1910:1919	a spindle-shaped morphology	1893:1919	a spindle-shaped morphology	1893:1919	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	1	86	dep	family	178:183	arg1	GALNTs					212:217	GALNTs	212:217	GALNTs	212:217	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	1	86	dep	family	178:183	arg1	GalNAc-Ts					199:207	GalNAc-Ts	199:207	GalNAc-Ts	199:207	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	1	86	dep	family	178:183	arg1	ppGalNAc-Ts					186:196	ppGalNAc-Ts	186:196	ppGalNAc-Ts	186:196	In humans, the UDP-N-α-D galactosamine:polypeptide N-acetylgalactosaminyltransferases family (ppGalNAc-Ts, GalNAc-Ts or GALNTs) comprises 20 isoenzymes.
35312770	3	87	theme	linear	499:504	arg1	structures					527:536	more complex linear or branched O-linked structures	486:536	more complex linear or branched O-linked structures	486:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	0	88	theme	metastasis-associated	29:49	arg1	EMT					86:88	EMT	86:88	EMT	86:88	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	0	88	theme	metastasis-associated	29:49	arg1	transition					74:83	metastasis-associated epithelial-mesenchymal transition	29:83	metastasis-associated epithelial-mesenchymal transition (EMT)	29:89	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	3	89	theme	sequential	436:445	arg1	action					447:452	the further sequential action	424:452	the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures	424:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	0	90	theme	transition	74:83	arg1	regulators					15:24	master regulators	8:24	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?	0:90	GALNTs: master regulators of metastasis-associated epithelial-mesenchymal transition (EMT)?
35312770	2	91	theme	mucin	350:354	arg1	glycosylation					370:382	mucin type O-linked glycosylation	350:382	mucin type O-linked glycosylation	350:382	They are responsible for the initial synthesis of α-GalNAc1,3-O-Ser/Thr, or Tn antigen, at initiation of mucin type O-linked glycosylation.
35312770	8	92	theme	epithelial-mesenchymal	1640:1661	arg1	transition					1663:1672	epithelial-mesenchymal transition	1640:1672	epithelial-mesenchymal transition (EMT)	1640:1678	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	92	theme	epithelial-mesenchymal	1640:1661	arg1	aspect					1695:1700	a fundamental aspect	1681:1700	a fundamental aspect of cancer metastasis	1681:1721	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	8	92	theme	epithelial-mesenchymal	1640:1661	arg1	EMT					1675:1677	EMT	1675:1677	EMT	1675:1677	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	3	93	theme	branched	509:516	arg1	structures					527:536	more complex linear or branched O-linked structures	486:536	more complex linear or branched O-linked structures	486:536	This structure is normally extended by the further sequential action of glycosytransferases to build more complex linear or branched O-linked structures, but in cancers it is frequently left unelaborated, and its presence is often associated with poor patient prognosis.
35312770	8	94	theme	cancer	1705:1710	arg1	metastasis					1712:1721	cancer metastasis	1705:1721	cancer metastasis	1705:1721	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35312770	5	95	theme	O-glycans	1026:1034	arg1	exposure					1004:1011	exposure	1004:1011	exposure	1004:1011	These changes would be predicted to result in marked alterations in GalNAc O-linked glycosylation, including altered levels of site specific O-linked glycosylation and changes in the glycan structures formed, including, potentially, exposure of truncated O-glycans such as Tn antigen.
35312770	6	96	theme	prognostic	1131:1140	arg1	significance					1142:1153	prognostic significance	1131:1153	prognostic significance	1131:1153	Many reports have demonstrated that altered levels of specific GALNTs have prognostic significance in cancers, or shown that they are associated with changes in cell behaviour, including proliferation, migration, invasion or growth and metastasis in animal models.
35312770	8	97	from	alterations	1536:1546	arg1	glycosylation					1567:1579	GalNAc O-linked glycosylation	1551:1579	GalNAc O-linked glycosylation	1551:1579	Here we consider evidence that changes in GALNT expression, and therefore consequent alterations in GalNAc O-linked glycosylation, may directly influence molecules implicated in aspects of epithelial-mesenchymal transition (EMT), a fundamental aspect of cancer metastasis, during which epithelial cancer cells lose their cell-cell junctions, apical-basal polarity and adhesive interactions with basement membrane and become mesenchymal, with a spindle-shaped morphology and increased migratory capacity.
35687881	7	0	theme	reducing	1364:1371	arg1	end					1373:1375	the reducing end	1360:1375	the reducing end	1360:1375	In contrast, antibodies raised by N-glycan-Qβ immunogens with a triazole linker preferentially recognized the innermost N-acetylglucosamine moiety at the reducing end.
35687881	4	1	theme	different	574:582	arg1	N-glycans					590:598	five different human N-glycans	569:598	five different human N-glycans	569:598	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	7	2	theme	N-glycan-Qβ	1244:1254	arg1	immunogens					1256:1265	N-glycan-Qβ immunogens	1244:1265	N-glycan-Qβ immunogens with a triazole linker	1244:1288	In contrast, antibodies raised by N-glycan-Qβ immunogens with a triazole linker preferentially recognized the innermost N-acetylglucosamine moiety at the reducing end.
35687881	9	3	theme	glycan-specific	1555:1569	arg1	titers					1580:1585	higher glycan-specific antibody titers	1548:1585	higher glycan-specific antibody titers	1548:1585	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	0	4	theme	Antibody	90:97	arg1	Responses					99:107	Dominant Antibody Responses	81:107	Dominant Antibody Responses to the Conserved Chitobiose Core	81:140	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	6	5	with	specificity	1038:1048	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	10	6	theme	N-glycan-specific	1696:1712	arg1	antibodies					1714:1723	mammalian N-glycan-specific antibodies	1686:1723	mammalian N-glycan-specific antibodies	1686:1723	These findings delineate several challenges in eliciting mammalian N-glycan-specific antibodies through the conventional glycoconjugate vaccine design and immunization.
35687881	3	7	theme	bacteriophage	393:405	arg1	conjugates					410:419	bacteriophage Qβ conjugates	393:419	bacteriophage Qβ conjugates with representative N-glycans	393:449	In this study, we sought to synthesize bacteriophage Qβ conjugates with representative N-glycans and investigate their immunogenicity for raising N-glycan-specific antibodies.
35687881	2	8	theme	therapeutic	329:339	arg1	development					341:351	therapeutic development	329:351	therapeutic development	329:351	However, very few N-glycan-specific antibodies are available for functional studies and potentially for therapeutic development.
35687881	6	9	theme	capable	1116:1122	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	3	10	theme	Qβ	407:408	arg1	conjugates					410:419	bacteriophage Qβ conjugates	393:419	bacteriophage Qβ conjugates with representative N-glycans	393:449	In this study, we sought to synthesize bacteriophage Qβ conjugates with representative N-glycans and investigate their immunogenicity for raising N-glycan-specific antibodies.
35687881	4	11	theme	glycoconjugates	545:559	arg1	array					533:537	An array	530:537	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers	530:633	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	5	12	theme	N-glycan-Qβ	745:755	arg1	conjugates					757:766	the N-glycan-Qβ conjugates	741:766	the N-glycan-Qβ conjugates	741:766	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	7	13	theme	triazole	1274:1281	arg1	linker					1283:1288	a triazole linker	1272:1288	a triazole linker	1272:1288	In contrast, antibodies raised by N-glycan-Qβ immunogens with a triazole linker preferentially recognized the innermost N-acetylglucosamine moiety at the reducing end.
35687881	0	14	theme	Chitobiose	126:135	arg1	Core					137:140	the Conserved Chitobiose Core	112:140	the Conserved Chitobiose Core	112:140	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	4	15	theme	Qβ	542:543	arg1	glycoconjugates					545:559	Qβ glycoconjugates	542:559	Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers	542:633	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	5	16	theme	N-glycan	967:974	arg1	structures					976:985	respective N-glycan structures	956:985	respective N-glycan structures	956:985	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	1	17	theme	many	186:189	arg1	processes					214:222	many biological recognition processes	186:222	many biological recognition processes	186:222	N-Glycosylation plays an important role in many biological recognition processes.
35687881	0	18	theme	Conserved	116:124	arg1	Core					137:140	the Conserved Chitobiose Core	112:140	the Conserved Chitobiose Core	112:140	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	5	19	theme	glycan-dependent	859:874	arg1	antibodies					876:885	the glycan-dependent antibodies	855:885	the glycan-dependent antibodies	855:885	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	6	20	theme	N-acetylglucosamine	1148:1166	arg1	moieties					1177:1184	both the N-acetylglucosamine (GlcNAc) moieties	1139:1184	moieties	1177:1184	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	1	21	theme	biological	191:200	arg1	processes					214:222	many biological recognition processes	186:222	many biological recognition processes	186:222	N-Glycosylation plays an important role in many biological recognition processes.
35687881	3	22	theme	representative	426:439	arg1	N-glycans					441:449	representative N-glycans	426:449	representative N-glycans	426:449	In this study, we sought to synthesize bacteriophage Qβ conjugates with representative N-glycans and investigate their immunogenicity for raising N-glycan-specific antibodies.
35687881	6	23	theme	linker	992:997	arg1	chemistry					999:1007	The linker chemistry	988:1007	The linker chemistry	988:1007	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	9	24	theme	N-glycan-Qβ	1489:1499	arg1	immunogens					1501:1510	the N-glycan-Qβ immunogens	1485:1510	the N-glycan-Qβ immunogens with an adipic acid linker	1485:1537	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	3	25	with	conjugates	410:419	arg1	N-glycans					441:449	representative N-glycans	426:449	representative N-glycans	426:449	In this study, we sought to synthesize bacteriophage Qβ conjugates with representative N-glycans and investigate their immunogenicity for raising N-glycan-specific antibodies.
35687881	6	26	theme	chitobiose	1193:1202	arg1	core					1204:1207	the chitobiose core	1189:1207	the chitobiose core	1189:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	1	27	theme	recognition	202:212	arg1	processes					214:222	many biological recognition processes	186:222	many biological recognition processes	186:222	N-Glycosylation plays an important role in many biological recognition processes.
35687881	7	28	theme	innermost	1320:1328	arg1	moiety					1350:1355	the innermost N-acetylglucosamine moiety	1316:1355	the innermost N-acetylglucosamine moiety	1316:1355	In contrast, antibodies raised by N-glycan-Qβ immunogens with a triazole linker preferentially recognized the innermost N-acetylglucosamine moiety at the reducing end.
35687881	6	29	theme	raising	1097:1103	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	10	30	theme	several	1654:1660	arg1	challenges					1662:1671	several challenges	1654:1671	several challenges	1654:1671	These findings delineate several challenges in eliciting mammalian N-glycan-specific antibodies through the conventional glycoconjugate vaccine design and immunization.
35687881	5	31	theme	shared	908:913	arg1	core					926:929	the shared chitobiose core	904:929	the shared chitobiose core	904:929	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	6	32	theme	immunogens	1086:1095	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	9	33	with	immunogens	1501:1510	arg1	linker					1532:1537	an adipic acid linker	1517:1537	an adipic acid linker	1517:1537	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	6	34	theme	core	1204:1207	arg1	moieties					1177:1184	both the N-acetylglucosamine (GlcNAc) moieties	1139:1184	moieties	1177:1184	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	0	35	theme	Immunological	14:26	arg1	Study					28:32	Immunological Study	14:32	Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates	14:72	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	6	36	theme	N-glycan-Qβ	1074:1084	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	7	37	with	immunogens	1256:1265	arg1	linker					1283:1288	a triazole linker	1272:1288	a triazole linker	1272:1288	In contrast, antibodies raised by N-glycan-Qβ immunogens with a triazole linker preferentially recognized the innermost N-acetylglucosamine moiety at the reducing end.
35687881	0	38	theme	N-Glycan-Bacteriophage	37:58	arg1	Conjugates					63:72	N-Glycan-Bacteriophage Qβ Conjugates	37:72	N-Glycan-Bacteriophage Qβ Conjugates	37:72	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	6	39	theme	acid-linked	1062:1072	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	7	40	theme	N-acetylglucosamine	1330:1348	arg1	moiety					1350:1355	the innermost N-acetylglucosamine moiety	1316:1355	the innermost N-acetylglucosamine moiety	1316:1355	In contrast, antibodies raised by N-glycan-Qβ immunogens with a triazole linker preferentially recognized the innermost N-acetylglucosamine moiety at the reducing end.
35687881	3	41	theme	N-glycan-specific	500:516	arg1	antibodies					518:527	N-glycan-specific antibodies	500:527	N-glycan-specific antibodies	500:527	In this study, we sought to synthesize bacteriophage Qβ conjugates with representative N-glycans and investigate their immunogenicity for raising N-glycan-specific antibodies.
35687881	4	42	theme	different	608:616	arg1	linkers					627:633	two different chemical linkers	604:633	two different chemical linkers	604:633	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	10	43	theme	mammalian	1686:1694	arg1	antibodies					1714:1723	mammalian N-glycan-specific antibodies	1686:1723	mammalian N-glycan-specific antibodies	1686:1723	These findings delineate several challenges in eliciting mammalian N-glycan-specific antibodies through the conventional glycoconjugate vaccine design and immunization.
35687881	6	44	link	acid-linked	1062:1072	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	6	45	theme	antibody	1029:1036	arg1	specificity					1038:1048	antibody specificity	1029:1048	antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1029:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	0	46	theme	Conjugates	63:72	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis	0:8	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	0	46	theme	Conjugates	63:72	arg1	Study					28:32	Immunological Study	14:32	Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates	14:72	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	6	47	theme	adipic	1055:1060	arg1	antibodies					1105:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies	1055:1114	adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core	1055:1207	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	10	48	theme	vaccine	1765:1771	arg1	design					1773:1778	the conventional glycoconjugate vaccine design	1733:1778	the conventional glycoconjugate vaccine design	1733:1778	These findings delineate several challenges in eliciting mammalian N-glycan-specific antibodies through the conventional glycoconjugate vaccine design and immunization.
35687881	8	49	gly	sialylation	1397:1407	arg1	N-glycans					1416:1424	the N-glycans	1412:1424	the N-glycans	1412:1424	We also found that sialylation of the N-glycans significantly suppressed the immune response.
35687881	2	50	theme	N-glycan-specific	243:259	arg1	antibodies					261:270	very few N-glycan-specific antibodies	234:270	very few N-glycan-specific antibodies	234:270	However, very few N-glycan-specific antibodies are available for functional studies and potentially for therapeutic development.
35687881	10	51	theme	conventional	1737:1748	arg1	design					1773:1778	the conventional glycoconjugate vaccine design	1733:1778	the conventional glycoconjugate vaccine design	1733:1778	These findings delineate several challenges in eliciting mammalian N-glycan-specific antibodies through the conventional glycoconjugate vaccine design and immunization.
35687881	0	52	theme	Qβ	60:61	arg1	Conjugates					63:72	N-Glycan-Bacteriophage Qβ Conjugates	37:72	N-Glycan-Bacteriophage Qβ Conjugates	37:72	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	10	53	theme	glycoconjugate	1750:1763	arg1	design					1773:1778	the conventional glycoconjugate vaccine design	1733:1778	the conventional glycoconjugate vaccine design	1733:1778	These findings delineate several challenges in eliciting mammalian N-glycan-specific antibodies through the conventional glycoconjugate vaccine design and immunization.
35687881	2	54	theme	few	239:241	arg1	antibodies					261:270	very few N-glycan-specific antibodies	234:270	very few N-glycan-specific antibodies	234:270	However, very few N-glycan-specific antibodies are available for functional studies and potentially for therapeutic development.
35687881	4	55	theme	chemical	618:625	arg1	linkers					627:633	two different chemical linkers	604:633	two different chemical linkers	604:633	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	5	56	theme	significant	775:785	arg1	antibodies					791:800	significant IgG antibodies	775:800	significant IgG antibodies that recognize N-glycans	775:825	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	9	57	theme	higher	1548:1553	arg1	titers					1580:1585	higher glycan-specific antibody titers	1548:1585	higher glycan-specific antibody titers	1548:1585	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	4	58	theme	conjugates	693:702	arg1	immunization					661:672	the immunization	657:672	the immunization of the N-glycan-Qβ conjugates	657:702	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	5	59	theme	IgG	787:789	arg1	antibodies					791:800	significant IgG antibodies	775:800	significant IgG antibodies that recognize N-glycans	775:825	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	2	60	theme	functional	290:299	arg1	studies					301:307	functional studies	290:307	functional studies	290:307	However, very few N-glycan-specific antibodies are available for functional studies and potentially for therapeutic development.
35687881	8	61	theme	immune	1455:1460	arg1	response					1462:1469	the immune response	1451:1469	the immune response	1451:1469	We also found that sialylation of the N-glycans significantly suppressed the immune response.
35687881	9	62	theme	adipic	1520:1525	arg1	linker					1532:1537	an adipic acid linker	1517:1537	an adipic acid linker	1517:1537	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	4	63	theme	N-glycan-Qβ	681:691	arg1	conjugates					693:702	the N-glycan-Qβ conjugates	677:702	the N-glycan-Qβ conjugates	677:702	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	0	64	theme	Dominant	81:88	arg1	Responses					99:107	Dominant Antibody Responses	81:107	Dominant Antibody Responses to the Conserved Chitobiose Core	81:140	Synthesis and Immunological Study of N-Glycan-Bacteriophage Qβ Conjugates Reveal Dominant Antibody Responses to the Conserved Chitobiose Core.
35687881	8	65	theme	N-glycans	1416:1424	arg1	sialylation					1397:1407	sialylation	1397:1407	sialylation of the N-glycans	1397:1424	We also found that sialylation of the N-glycans significantly suppressed the immune response.
35687881	6	66	dep	moieties	1177:1184	arg1	both					1139:1142	both	1139:1142	both	1139:1142	The linker chemistry was found to affect antibody specificity with adipic acid-linked N-glycan-Qβ immunogens raising antibodies capable of recognizing both the N-acetylglucosamine (GlcNAc) moieties of the chitobiose core.
35687881	5	67	theme	respective	956:965	arg1	structures					976:985	respective N-glycan structures	956:985	respective N-glycan structures	956:985	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	9	68	theme	antibody	1571:1578	arg1	titers					1580:1585	higher glycan-specific antibody titers	1548:1585	higher glycan-specific antibody titers	1548:1585	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	9	69	theme	N-glycan-triazole-Qβ	1596:1615	arg1	immunogens					1617:1626	the N-glycan-triazole-Qβ immunogens	1592:1626	the N-glycan-triazole-Qβ immunogens	1592:1626	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
35687881	4	70	theme	human	584:588	arg1	N-glycans					590:598	five different human N-glycans	569:598	five different human N-glycans	569:598	An array of Qβ glycoconjugates bearing five different human N-glycans and two different chemical linkers were synthesized, and the immunization of the N-glycan-Qβ conjugates was performed in mice.
35687881	5	71	theme	chitobiose	915:924	arg1	core					926:929	the shared chitobiose core	904:929	the shared chitobiose core	904:929	We found that the N-glycan-Qβ conjugates raised significant IgG antibodies that recognize N-glycans, but, surprisingly, most of the glycan-dependent antibodies were directed to the shared chitobiose core and were nonspecific for respective N-glycan structures.
35687881	1	72	theme	important	168:176	arg1	role					178:181	an important role	165:181	an important role	165:181	N-Glycosylation plays an important role in many biological recognition processes.
35687881	9	73	theme	acid	1527:1530	arg1	linker					1532:1537	an adipic acid linker	1517:1537	an adipic acid linker	1517:1537	Furthermore, the N-glycan-Qβ immunogens with an adipic acid linker elicited higher glycan-specific antibody titers than the N-glycan-triazole-Qβ immunogens.
34379775	7	0	theme	Galβ1-3[SO3-GlcNAcβ1-6	1348:1369	arg1	glycan					1392:1397	fucosylated glycan	1380:1397	fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc)	1380:1481	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	0	theme	Galβ1-3[SO3-GlcNAcβ1-6	1348:1369	arg1	GalNAc					1371:1376	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	1	theme	glycan	1340:1345	arg1	glycan					1392:1397	fucosylated glycan	1380:1397	fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc)	1380:1481	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	1	theme	glycan	1340:1345	arg1	GalNAc					1371:1376	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	6	2	theme	hormones	1150:1157	arg1	use					1133:1135	The use	1129:1135	The use of exogenous hormones for synchronization	1129:1177	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	3	3	with	insemination	644:655	arg1	semen					676:680	frozen-thawed semen	662:680	frozen-thawed semen	662:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	1	4	theme	normal	243:248	arg1	sperm					250:254	motile and morphological normal sperm	218:254	motile and morphological normal sperm	218:254	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	5	5	theme	fucosylated	1078:1088	arg1	glycans					1090:1096	fucosylated glycans	1078:1096	fucosylated glycans	1078:1096	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	4	6	dep	Ireland	820:826	arg1	Sheep					915:919	White Sheep	909:919	White Sheep	909:919	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	6	dep	Ireland	820:826	arg1	both					936:939	both	936:939	both	936:939	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	1	7	theme	female	171:176	arg1	fertility					178:186	female fertility	171:186	female fertility	171:186	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	0	8	link	O-linked	39:46	arg1	glycans					48:54	O-linked glycans	39:54	O-linked glycans in cervical mucus	39:72	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	9	9	theme	species	1767:1773	arg1	range					1758:1762	a range	1756:1762	a range of species including human	1756:1789	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	9	9	theme	species	1767:1773	arg1	human					1785:1789	human	1785:1789	human	1785:1789	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	3	10	theme	cervical	724:731	arg1	transport					739:747	cervical sperm transport	724:747	cervical sperm transport	724:747	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	0	11	theme	novel	110:114	arg1	model					122:126	A novel sheep model	108:126	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.	0:127	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	0	12	from	mucus	68:72	arg1	characterization					19:34	characterization	19:34	characterization	19:34	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	0	12	from	mucus	68:72	arg1	Identification					0:13	Identification	0:13	Identification	0:13	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	3	13	theme	ewe	553:555	arg1	breeds					557:562	six European ewe breeds	540:562	six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	540:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	3	14	theme	pregnancy	590:598	arg1	rates					600:604	pregnancy rates	590:604	pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	590:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	8	15	theme	mucus	1614:1618	arg1	viscosity					1620:1628	mucus viscosity	1614:1628	mucus viscosity	1614:1628	In addition, core 4 glycans were negatively correlated with mucus viscosity.
34379775	0	16	from	characterization	19:34	arg1	mucus					68:72	cervical mucus	59:72	cervical mucus	59:72	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	3	17	from	composition	503:513	arg1	mucus					531:535	the cervical mucus	518:535	the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	518:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	0	18	from	Identification	0:13	arg1	mucus					68:72	cervical mucus	59:72	cervical mucus	59:72	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	0	19	theme	sperm	91:95	arg1	transport					97:105	sperm transport	91:105	sperm transport	91:105	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	3	20	from	differences	575:585	arg1	rates					600:604	pregnancy rates	590:604	pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	590:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	6	21	theme	ewe	1242:1244	arg1	breeds					1246:1251	both high-fertility ewe breeds	1222:1251	both high-fertility ewe breeds	1222:1251	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	5	22	gly	fucosylated	1078:1088	arg1	glycans					1090:1096	fucosylated glycans	1078:1096	fucosylated glycans	1078:1096	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	5	23	from	O-glycans	1014:1022	arg1	glycans					1054:1060	the major glycans	1044:1060	the major glycans with core 2	1044:1072	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	5	23	from	O-glycans	1014:1022	arg1	glycans					1090:1096	fucosylated glycans	1078:1096	fucosylated glycans	1078:1096	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	5	23	from	O-glycans	1014:1022	arg1	51					1036:1037	51	1036:1037	51	1036:1037	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	1	24	theme	sperm	250:254	arg1	entry					209:213	the entry	205:213	the entry of motile and morphological normal sperm	205:254	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	7	25	theme	low-fertility	1490:1502	arg1	breed					1512:1516	the low-fertility Suffolk breed	1486:1516	the low-fertility Suffolk breed	1486:1516	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	3	26	theme	artificial	633:642	arg1	insemination					644:655	cervical/vaginal artificial insemination	616:655	cervical/vaginal artificial insemination with frozen-thawed semen	616:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	2	27	theme	rheological	373:383	arg1	properties					385:394	its rheological properties	369:394	its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins	369:462	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	0	28	theme	O-linked	39:46	arg1	glycans					48:54	O-linked glycans	39:54	O-linked glycans in cervical mucus	39:72	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	6	29	theme	ewe	1283:1285	arg1	breeds					1287:1292	the other four ewe breeds	1268:1292	the other four ewe breeds	1268:1292	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	7	30	theme	fucosylated	1380:1390	arg1	glycan					1392:1397	fucosylated glycan	1380:1397	fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc)	1380:1481	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	30	theme	fucosylated	1380:1390	arg1	GalNAc					1371:1376	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	2	31	theme	O-glycosylated	425:438	arg1	proteins					440:447	O-glycosylated proteins	425:447	O-glycosylated proteins	425:447	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	1	32	from	vagina	306:311	arg1	ascent					277:282	the ascent	273:282	the ascent of pathogens from the vagina	273:311	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	5	33	theme	major	1048:1052	arg1	glycans					1054:1060	the major glycans	1044:1060	the major glycans with core 2	1044:1072	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	5	33	theme	major	1048:1052	arg1	51					1036:1037	51	1036:1037	51	1036:1037	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	2	34	attach	linked	359:364	arg1	properties					385:394	its rheological properties	369:394	its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins	369:462	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	2	34	attach	linked	359:364	arg2	function					318:325	The function	314:325	The function of cervical mucus	314:343	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	2	35	gly	O-glycosylated	425:438	arg1	proteins					440:447	O-glycosylated proteins	425:447	O-glycosylated proteins	425:447	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	5	36	with	glycans	1090:1096	arg1	core					1067:1070	core 2	1067:1072	core 2	1067:1072	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	9	37	theme	cervical	1696:1703	arg1	transport					1711:1719	cervical sperm transport	1696:1719	cervical sperm transport	1696:1719	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	2	38	theme	mucus	339:343	arg1	function					318:325	The function	314:325	The function of cervical mucus	314:343	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	0	39	dep	Identification	0:13	arg1	model					122:126	A novel sheep model	108:126	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.	0:127	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	1	40	theme	motile	218:223	arg1	sperm					250:254	motile and morphological normal sperm	218:254	motile and morphological normal sperm	218:254	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	7	41	theme	sulfated	1331:1338	arg1	glycan					1392:1397	fucosylated glycan	1380:1397	fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc)	1380:1481	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	41	theme	sulfated	1331:1338	arg1	GalNAc					1371:1376	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	5	42	with	glycans	1054:1060	arg1	core					1067:1070	core 2	1067:1072	core 2	1067:1072	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	1	43	theme	morphological	229:241	arg1	sperm					250:254	motile and morphological normal sperm	218:254	motile and morphological normal sperm	218:254	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	6	44	theme	exogenous	1140:1148	arg1	hormones					1150:1157	exogenous hormones	1140:1157	exogenous hormones	1140:1157	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	3	45	theme	O-glycan	494:501	arg1	composition					503:513	the O-glycan composition	490:513	the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	490:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	1	46	theme	important	153:161	arg1	role					163:166	an important role	150:166	an important role	150:166	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	6	47	theme	other	1272:1276	arg1	breeds					1287:1292	the other four ewe breeds	1268:1292	the other four ewe breeds	1268:1292	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	7	48	theme	higher	1307:1312	arg1	abundance					1314:1322	a higher abundance	1305:1322	a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed	1305:1516	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	1	49	theme	pathogens	287:295	arg1	ascent					277:282	the ascent	273:282	the ascent of pathogens from the vagina	273:311	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	3	50	theme	reported	700:707	arg1	differences					709:719	reported differences	700:719	reported differences in cervical sperm transport	700:747	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	7	51	from	abundance	1314:1322	arg1	breed					1512:1516	the low-fertility Suffolk breed	1486:1516	the low-fertility Suffolk breed	1486:1516	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	9	52	contain	have	1731:1734	arg1	O-glycans					1663:1671	O-glycans	1663:1671	O-glycans that are important for cervical sperm transport and could have applications across a range of species including human	1663:1789	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	9	52	contain	have	1731:1734	arg2	applications					1736:1747	applications	1736:1747	applications	1736:1747	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	3	53	from	differences	709:719	arg1	transport					739:747	cervical sperm transport	724:747	cervical sperm transport	724:747	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	4	54	with	Suffolk	761:767	arg1	fertility					951:959	high fertility	946:959	high fertility	946:959	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	0	55	theme	sheep	116:120	arg1	model					122:126	A novel sheep model	108:126	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.	0:127	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	3	56	theme	cervical	522:529	arg1	mucus					531:535	the cervical mucus	518:535	the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	518:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	4	57	theme	medium	866:871	arg1	fertility					873:881	medium fertility	866:881	medium fertility	866:881	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	3	58	theme	sperm	733:737	arg1	transport					739:747	cervical sperm transport	724:747	cervical sperm transport	724:747	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	3	59	theme	breeds	557:562	arg1	mucus					531:535	the cervical mucus	518:535	the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	518:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	8	60	theme	core	1567:1570	arg1	glycans					1574:1580	core 4 glycans	1567:1580	core 4 glycans	1567:1580	In addition, core 4 glycans were negatively correlated with mucus viscosity.
34379775	7	61	theme	GlcNAcβ1-3[GlcNAcβ1-6	1453:1473	arg1	GalNAc					1475:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	6	62	theme	O-glycan	1198:1205	arg1	composition					1207:1217	the O-glycan composition	1194:1217	the O-glycan composition in both high-fertility ewe breeds	1194:1251	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	3	63	theme	European	544:551	arg1	breeds					557:562	six European ewe breeds	540:562	six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	540:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	7	64	theme	glycan	1445:1450	arg1	GalNAc					1475:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	6	65	theme	high-fertility	1227:1240	arg1	breeds					1246:1251	both high-fertility ewe breeds	1222:1251	both high-fertility ewe breeds	1222:1251	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	7	66	dep	Fucα1-2Galβ1-3	1411:1424	arg1	GalNAc					1426:1431	GalNAc	1426:1431	GalNAc	1426:1431	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	4	67	from	Belclare	789:796	arg1	Ireland					820:826	Ireland	820:826	Ireland	820:826	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	67	from	Belclare	789:796	arg1	Norway					965:970	Norway	965:970	Norway	965:970	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	67	from	Belclare	789:796	arg1	ewes/breed					983:992	n = 28-30 ewes/breed	973:992	n = 28-30 ewes/breed	973:992	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	67	from	Belclare	789:796	arg1	NWS					922:924	NWS	922:924	NWS	922:924	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	7	68	theme	core	1438:1441	arg1	GalNAc					1475:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	3	69	theme	known	569:573	arg1	differences					575:585	known differences	569:585	known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	569:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	1	70	theme	Cervical	129:136	arg1	mucus					138:142	Cervical mucus	129:142	Cervical mucus	129:142	Cervical mucus plays an important role in female fertility, since it allows the entry of motile and morphological normal sperm while preventing the ascent of pathogens from the vagina.
34379775	4	71	theme	White	909:913	arg1	Sheep					915:919	White Sheep	909:919	White Sheep	909:919	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	72	with	Belclare	789:796	arg1	fertility					951:959	high fertility	946:959	high fertility	946:959	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	0	73	theme	transport	97:105	arg1	biomarkers					77:86	biomarkers	77:86	biomarkers of sperm transport	77:105	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	4	74	from	Suffolk	761:767	arg1	Ireland					820:826	Ireland	820:826	Ireland	820:826	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	74	from	Suffolk	761:767	arg1	Norway					965:970	Norway	965:970	Norway	965:970	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	74	from	Suffolk	761:767	arg1	ewes/breed					983:992	n = 28-30 ewes/breed	973:992	n = 28-30 ewes/breed	973:992	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	74	from	Suffolk	761:767	arg1	NWS					922:924	NWS	922:924	NWS	922:924	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	7	75	gly	fucosylated	1380:1390	arg1	glycan					1392:1397	fucosylated glycan	1380:1397	fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc)	1380:1481	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	75	gly	fucosylated	1380:1390	arg1	GalNAc					1371:1376	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc)	1327:1377	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	3	76	with	breeds	557:562	arg1	differences					575:585	known differences	569:585	known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen	569:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	7	77	theme	high	1537:1540	arg1	NWS					1532:1534	NWS	1532:1534	NWS (high fertility)	1532:1551	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	77	theme	high	1537:1540	arg1	fertility					1542:1550	high fertility	1537:1550	high fertility	1537:1550	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	0	78	from	glycans	48:54	arg1	mucus					68:72	cervical mucus	59:72	cervical mucus	59:72	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	7	79	dep	glycan	1392:1397	arg1	GalNAc					1475:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc	1438:1480	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	7	79	dep	glycan	1392:1397	arg1	GlcNAcβ1-3					1400:1409	GlcNAcβ1-3	1400:1409	GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc)	1400:1432	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	4	80	dep	fertility	873:881	arg1	both					856:859	both	856:859	both	856:859	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	9	81	theme	novel	1636:1640	arg1	study					1642:1646	This novel study	1631:1646	This novel study	1631:1646	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	6	82	from	composition	1207:1217	arg1	breeds					1246:1251	both high-fertility ewe breeds	1222:1251	both high-fertility ewe breeds	1222:1251	The use of exogenous hormones for synchronization did not affect the O-glycan composition in both high-fertility ewe breeds, but it did in the other four ewe breeds.
34379775	4	83	theme	high	946:949	arg1	fertility					951:959	high fertility	946:959	high fertility	946:959	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	3	84	theme	cervical/vaginal	616:631	arg1	insemination					644:655	cervical/vaginal artificial insemination	616:655	cervical/vaginal artificial insemination with frozen-thawed semen	616:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	0	85	theme	glycans	48:54	arg1	characterization					19:34	characterization	19:34	characterization	19:34	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	0	85	theme	glycans	48:54	arg1	Identification					0:13	Identification	0:13	Identification	0:13	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	7	86	theme	Suffolk	1504:1510	arg1	breed					1512:1516	the low-fertility Suffolk breed	1486:1516	the low-fertility Suffolk breed	1486:1516	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	0	87	theme	cervical	59:66	arg1	mucus					68:72	cervical mucus	59:72	cervical mucus	59:72	Identification and characterization of O-linked glycans in cervical mucus as biomarkers of sperm transport: A novel sheep model.
34379775	3	88	theme	frozen-thawed	662:674	arg1	semen					676:680	frozen-thawed semen	662:680	frozen-thawed semen	662:680	We aimed to characterize the O-glycan composition in the cervical mucus of six European ewe breeds with known differences in pregnancy rates following cervical/vaginal artificial insemination with frozen-thawed semen, which are due to reported differences in cervical sperm transport.
34379775	4	89	theme	medium	799:804	arg1	Belclare					789:796	Belclare	789:796	Belclare (medium fertility)	789:815	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	89	theme	medium	799:804	arg1	fertility					806:814	medium fertility	799:814	medium fertility	799:814	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	90	theme	low	770:772	arg1	Suffolk					761:767	Suffolk	761:767	Suffolk (low fertility)	761:783	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	4	90	theme	low	770:772	arg1	fertility					774:782	low fertility	770:782	low fertility	770:782	These were Suffolk (low fertility) and Belclare (medium fertility) in Ireland, Ile de France and Romanov (both with medium fertility) in France, and Norwegian White Sheep (NWS) and Fur (both with high fertility) in Norway (n = 28-30 ewes/breed).
34379775	5	91	theme	common	1110:1115	arg1	O-glycans					1014:1022	124 O-glycans	1010:1022	124 O-glycans	1010:1022	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	5	91	theme	common	1110:1115	arg1	structures					1117:1126	the most common structures	1101:1126	the most common structures	1101:1126	We identified 124 O-glycans, from which 51 were the major glycans with core 2 and fucosylated glycans as the most common structures.
34379775	7	92	theme	GalNAc	1371:1376	arg1	abundance					1314:1322	a higher abundance	1305:1322	a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed	1305:1516	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
34379775	9	93	theme	sperm	1705:1709	arg1	transport					1711:1719	cervical sperm transport	1696:1719	cervical sperm transport	1696:1719	This novel study has identified O-glycans that are important for cervical sperm transport and could have applications across a range of species including human.
34379775	2	94	theme	cervical	330:337	arg1	mucus					339:343	cervical mucus	330:343	cervical mucus	330:343	The function of cervical mucus is critically linked to its rheological properties that are in turn dictated by O-glycosylated proteins, called mucins.
34379775	7	95	dep	GlcNAcβ1-3	1400:1409	arg1	Fucα1-2Galβ1-3					1411:1424	Fucα1-2Galβ1-3	1411:1424	Fucα1-2Galβ1-3	1411:1424	There was a higher abundance of the sulfated glycan (Galβ1-3[SO3-GlcNAcβ1-6]GalNAc), fucosylated glycan (GlcNAcβ1-3(Fucα1-2Galβ1-3)GalNAc) and core 4 glycan (GlcNAcβ1-3[GlcNAcβ1-6]GalNAc) in the low-fertility Suffolk breed compared with NWS (high fertility).
36048150	0	0	theme	crystal	86:92	arg1	structure					94:102	a low-resolution crystal structure	69:102	a low-resolution crystal structure of human myeloperoxidase	69:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	1	1	theme	front-line	329:338	arg1	defence					340:346	the front-line defence	325:346	the front-line defence against pathogens	325:364	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	0	2	theme	low-resolution	71:84	arg1	structure					94:102	a low-resolution crystal structure	69:102	a low-resolution crystal structure of human myeloperoxidase	69:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	0	3	from	glycosylation	7:19	arg1	structure					94:102	a low-resolution crystal structure	69:102	a low-resolution crystal structure of human myeloperoxidase	69:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	7	4	theme	crystal	938:944	arg1	structure					946:954	The crystal structure	934:954	The crystal structure	934:954	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	1	5	theme	hydrogen	167:174	arg1	peroxide					176:183	hydrogen peroxide	167:183	hydrogen peroxide	167:183	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	1	6	theme	cell-component	253:266	arg1	synthesis					268:276	cell-component synthesis	253:276	cell-component synthesis	253:276	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	7	7	theme	MPO	1088:1090	arg1	inhibitor					1075:1083	an irreversible inhibitor	1059:1083	an irreversible inhibitor of MPO	1059:1090	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	7	theme	MPO	1088:1090	arg1	blocker					990:996	a blocker	988:996	a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO	988:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	4	8	theme	Data	584:587	arg1	PDB					595:597	PDB	595:597	PDB	595:597	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	4	8	theme	Data	584:587	arg1	Bank					589:592	the Protein Data Bank	572:592	the Protein Data Bank (PDB)	572:598	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	5	9	theme	MPO	706:708	arg1	structure					693:701	a newly obtained crystal structure	668:701	a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans	668:795	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	4	10	theme	Protein	576:582	arg1	PDB					595:597	PDB	595:597	PDB	595:597	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	4	10	theme	Protein	576:582	arg1	Bank					589:592	the Protein Data Bank	572:592	the Protein Data Bank (PDB)	572:598	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	0	11	theme	myeloperoxidase	113:127	arg1	structure					94:102	a low-resolution crystal structure	69:102	a low-resolution crystal structure of human myeloperoxidase	69:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	5	12	dep	collection	775:784	arg1	elaborate					765:773	elaborate	765:773	elaborate	765:773	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	0	13	theme	human	107:111	arg1	myeloperoxidase					113:127	human myeloperoxidase	107:127	human myeloperoxidase	107:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	7	14	theme	MPO	1154:1156	arg1	thiocyanate					1112:1122	thiocyanate	1112:1122	thiocyanate	1112:1122	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	14	theme	MPO	1154:1156	arg1	substrate					1141:1149	a physiological substrate	1125:1149	a physiological substrate of MPO	1125:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	5	15	theme	glycans	789:795	arg1	collection					775:784	an elaborate collection	762:784	an elaborate collection of glycans	762:795	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	6	16	theme	proteomics	860:869	arg1	studies					871:877	proteomics studies	860:877	proteomics studies	860:877	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	1	17	dep	utilizes	158:165	arg1	plays					226:230	plays	226:230	plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens	226:364	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	4	18	theme	glycosylation	647:659	arg1	identification					623:636	only a partial identification	608:636	only a partial identification of their glycosylation	608:659	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	0	19	theme	Native	0:5	arg1	glycosylation					7:19	Native glycosylation	0:19	Native glycosylation	0:19	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	4	20	theme	crystal	540:546	arg1	structures					548:557	Mammalian MPO crystal structures	526:557	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB)	526:598	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	7	21	theme	irreversible	1062:1073	arg1	inhibitor					1075:1083	an irreversible inhibitor	1059:1083	an irreversible inhibitor of MPO	1059:1090	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	21	theme	irreversible	1062:1073	arg1	blocker					990:996	a blocker	988:996	a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO	988:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	1	22	theme	organic	196:202	arg1	compounds					204:212	organic compounds	196:212	organic compounds	196:212	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	4	23	theme	MPO	536:538	arg1	structures					548:557	Mammalian MPO crystal structures	526:557	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB)	526:598	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	5	24	link	disulfide-linked	726:741	arg1	dimers					743:748	four disulfide-linked dimers	721:748	four disulfide-linked dimers	721:748	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	7	25	dep	contains	961:968	arg1	bound					970:974	bound	970:974	contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO	961:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	26	theme	physiological	1127:1139	arg1	thiocyanate					1112:1122	thiocyanate	1112:1122	thiocyanate	1112:1122	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	26	theme	physiological	1127:1139	arg1	substrate					1141:1149	a physiological substrate	1125:1149	a physiological substrate of MPO	1125:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	5	27	theme	obtained	676:683	arg1	structure					693:701	a newly obtained crystal structure	668:701	a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans	668:795	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	6	28	theme	MPO	897:899	arg1	structures					901:910	18 human MPO structures	888:910	18 human MPO structures available in the PDB	888:931	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	7	29	theme	thiocyanate	1112:1122	arg1	presence					1100:1107	the presence	1096:1107	the presence of thiocyanate, a physiological substrate of MPO	1096:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	1	30	theme	elimination	296:306	arg1	pathways					308:315	elimination pathways	296:315	elimination pathways	296:315	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	5	31	theme	crystal	685:691	arg1	structure					693:701	a newly obtained crystal structure	668:701	a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans	668:795	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	4	32	theme	partial	615:621	arg1	identification					623:636	only a partial identification	608:636	only a partial identification of their glycosylation	608:659	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	6	33	dep	glycans	838:844	arg1	are					816:818	are	816:818	are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB	816:931	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	0	34	gly	glycosylation	7:19	arg1	structure					94:102	a low-resolution crystal structure	69:102	a low-resolution crystal structure of human myeloperoxidase	69:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	0	34	gly	glycosylation	7:19	arg1	paroxetine					55:64	the antidepressant paroxetine	36:64	the antidepressant paroxetine	36:64	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	3	35	theme	enzymatic	448:456	arg1	activity					458:465	The enzymatic activity	444:465	The enzymatic activity of MPO	444:472	The enzymatic activity of MPO has also been shown to depend on its glycosylation.
36048150	0	36	theme	paroxetine	55:64	arg1	binding					25:31	binding	25:31	binding	25:31	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	0	36	theme	paroxetine	55:64	arg1	glycosylation					7:19	Native glycosylation	0:19	Native glycosylation	0:19	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	7	37	theme	serotonin	1001:1009	arg1	reuptake					1011:1018	serotonin reuptake	1001:1018	serotonin reuptake	1001:1018	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	0	38	theme	antidepressant	40:53	arg1	paroxetine					55:64	the antidepressant paroxetine	36:64	the antidepressant paroxetine	36:64	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
36048150	4	39	theme	Mammalian	526:534	arg1	structures					548:557	Mammalian MPO crystal structures	526:557	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB)	526:598	Mammalian MPO crystal structures deposited in the Protein Data Bank (PDB) present only a partial identification of their glycosylation.
36048150	6	40	from	available	912:920	arg1	PDB					929:931	the PDB	925:931	the PDB	925:931	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	6	41	theme	human	891:895	arg1	structures					901:910	18 human MPO structures	888:910	18 human MPO structures available in the PDB	888:931	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	1	42	theme	Human	130:134	arg1	myeloperoxidase					136:150	Human myeloperoxidase	130:150	Human myeloperoxidase (MPO)	130:156	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	1	42	theme	Human	130:134	arg1	MPO					153:155	MPO	153:155	MPO	153:155	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	6	43	theme	available	912:920	arg1	structures					901:910	18 human MPO structures	888:910	18 human MPO structures available in the PDB	888:931	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	6	44	from	PDB	929:931	arg1	available					912:920	available	912:920	available	912:920	These are compared with the glycans identified in proteomics studies and from 18 human MPO structures available in the PDB.
36048150	3	45	theme	MPO	470:472	arg1	activity					458:465	The enzymatic activity	444:465	The enzymatic activity of MPO	444:472	The enzymatic activity of MPO has also been shown to depend on its glycosylation.
36048150	7	46	theme	reuptake	1011:1018	arg1	inhibitor					1075:1083	an irreversible inhibitor	1059:1083	an irreversible inhibitor of MPO	1059:1090	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	46	theme	reuptake	1011:1018	arg1	paroxetine					976:985	paroxetine	976:985	paroxetine	976:985	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	7	46	theme	reuptake	1011:1018	arg1	blocker					990:996	a blocker	988:996	a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO	988:1156	The crystal structure also contains bound paroxetine, a blocker of serotonin reuptake that has previously been identified as an irreversible inhibitor of MPO, in the presence of thiocyanate, a physiological substrate of MPO.
36048150	5	47	theme	disulfide-linked	726:741	arg1	dimers					743:748	four disulfide-linked dimers	721:748	four disulfide-linked dimers	721:748	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	1	48	theme	essential	235:243	arg1	role					245:248	an essential role	232:248	an essential role	232:248	Human myeloperoxidase (MPO) utilizes hydrogen peroxide to oxidize organic compounds and as such plays an essential role in cell-component synthesis, in metabolic and elimination pathways, and in the front-line defence against pathogens.
36048150	5	49	dep	structure	693:701	arg1	containing					710:719	containing	710:719	containing four disulfide-linked dimers	710:748	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	5	49	dep	structure	693:701	arg1	showing					754:760	showing	754:760	showing an elaborate collection of glycans	754:795	Here, a newly obtained crystal structure of MPO containing four disulfide-linked dimers and showing an elaborate collection of glycans is reported.
36048150	0	50	from	binding	25:31	arg1	structure					94:102	a low-resolution crystal structure	69:102	a low-resolution crystal structure of human myeloperoxidase	69:127	Native glycosylation and binding of the antidepressant paroxetine in a low-resolution crystal structure of human myeloperoxidase.
35990620	5	0	theme	antibiotics	698:708	arg1	course					688:693	a 2- to 3-week course	673:693	a 2- to 3-week course of antibiotics	673:708	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	4	1	theme	N-glycan	466:473	arg1	responses					475:483	Immunoglobulin G (IgG) N-glycan responses	443:483	Immunoglobulin G (IgG) N-glycan responses to LD	443:489	Immunoglobulin G (IgG) N-glycan responses to LD have not been characterized.
35990620	5	2	theme	LD	601:602	arg1	serum					612:616	acute LD patient serum	595:616	acute LD patient serum	595:616	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	7	3	theme	direct	973:978	arg1	contrast					980:987	direct contrast	973:987	direct contrast to what is reported for other inflammatory diseases	973:1039	This unexpected result is in direct contrast to what is reported for other inflammatory diseases.
35990620	1	4	theme	burgdorferi	137:147	arg1	Bb					161:162	Bb	161:162	Bb	161:162	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	1	4	theme	burgdorferi	137:147	arg1	lato					155:158	Borrelia burgdorferi sensu lato	128:158	Borrelia burgdorferi sensu lato (Bb)	128:163	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	8	5	theme	acute	1085:1089	arg1	infection					1094:1102	acute LD infection	1085:1102	acute LD infection	1085:1102	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	5	6	theme	patient	604:610	arg1	serum					612:616	acute LD patient serum	595:616	acute LD patient serum	595:616	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	1	7	theme	sensu	149:153	arg1	Bb					161:162	Bb	161:162	Bb	161:162	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	1	7	theme	sensu	149:153	arg1	lato					155:158	Borrelia burgdorferi sensu lato	128:158	Borrelia burgdorferi sensu lato (Bb)	128:163	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	6	8	theme	N-glycan	924:931	arg1	signature					933:941	the classic proinflammatory IgG N-glycan signature	892:941	the classic proinflammatory IgG N-glycan signature	892:941	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	6	9	theme	glycosylation	819:831	arg1	profile					833:839	its glycosylation profile	815:839	its glycosylation profile	815:839	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	6	10	theme	IgG	920:922	arg1	signature					933:941	the classic proinflammatory IgG N-glycan signature	892:941	the classic proinflammatory IgG N-glycan signature	892:941	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	2	11	from	presence	185:192	arg1	bloodstream					218:228	the bloodstream	214:228	the bloodstream in humans	214:238	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	2	12	attach	presence	185:192	arg2	pathogen					202:209	this pathogen	197:209	this pathogen	197:209	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	2	12	attach	presence	185:192	arg1	bloodstream					218:228	the bloodstream	214:228	the bloodstream in humans	214:238	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	4	13	theme	G	458:458	arg1	responses					475:483	Immunoglobulin G (IgG) N-glycan responses	443:483	Immunoglobulin G (IgG) N-glycan responses to LD	443:489	Immunoglobulin G (IgG) N-glycan responses to LD have not been characterized.
35990620	5	14	theme	healthy	577:583	arg1	controls					585:592	healthy controls	577:592	healthy controls	577:592	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	8	15	theme	%	1190:1190	arg1	specificity					1196:1206	specificity	1196:1206	specificity of 94.7-100%	1196:1219	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	8	15	theme	%	1190:1190	arg1	sensitivity					1169:1179	a sensitivity	1167:1179	a sensitivity of 75-100%	1167:1190	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	5	16	theme	3-week	681:686	arg1	course					688:693	a 2- to 3-week course	673:693	a 2- to 3-week course of antibiotics	673:708	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	3	17	gly	glycosylated	352:363	arg1	Immunoglobulins					283:297	Immunoglobulins	283:297	Immunoglobulins produced in response to infection	283:331	Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system.
35990620	0	18	theme	lyme	6:9	arg1	disease					11:17	Acute lyme disease	0:17	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	7	19	theme	other	1013:1017	arg1	diseases					1032:1039	other inflammatory diseases	1013:1039	other inflammatory diseases	1013:1039	This unexpected result is in direct contrast to what is reported for other inflammatory diseases.
35990620	5	20	theme	controls	585:592	arg1	serum					612:616	acute LD patient serum	595:616	acute LD patient serum	595:616	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	5	20	theme	controls	585:592	arg1	cohorts					566:572	cohorts	566:572	cohorts of healthy controls	566:592	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	5	20	theme	controls	585:592	arg1	serum					623:627	serum	623:627	serum	623:627	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	1	21	theme	Lyme	87:90	arg1	disease					92:98	Lyme disease	87:98	Lyme disease (LD) infection	87:113	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	1	21	theme	Lyme	87:90	arg1	LD					101:102	LD	101:102	LD	101:102	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	3	22	theme	inflammatory	398:409	arg1	responses					411:419	downstream inflammatory responses	387:419	downstream inflammatory responses	387:419	Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system.
35990620	0	23	theme	Acute	0:4	arg1	disease					11:17	Acute lyme disease	0:17	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	6	24	theme	proinflammatory	904:918	arg1	signature					933:941	the classic proinflammatory IgG N-glycan signature	892:941	the classic proinflammatory IgG N-glycan signature	892:941	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	5	25	theme	acute	595:599	arg1	serum					612:616	acute LD patient serum	595:616	acute LD patient serum	595:616	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	1	26	theme	disease	92:98	arg1	infection					105:113	Lyme disease (LD) infection	87:113	Lyme disease (LD) infection	87:113	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	8	27	theme	LD	1091:1092	arg1	infection					1094:1102	acute LD infection	1085:1102	acute LD infection	1085:1102	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	0	28	theme	IgG	19:21	arg1	glycans					32:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	6	29	theme	classic	896:902	arg1	signature					933:941	the classic proinflammatory IgG N-glycan signature	892:941	the classic proinflammatory IgG N-glycan signature	892:941	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	5	30	theme	acute	645:649	arg1	patients					654:661	acute LD patients	645:661	acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days	645:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	0	31	link	N-linked	23:30	arg1	glycans					32:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	2	32	theme	LD	254:255	arg1	diagnosis					241:249	diagnosis	241:249	diagnosis of LD	241:255	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	0	33	theme	disease	11:17	arg1	glycans					32:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	5	34	theme	LD	651:652	arg1	patients					654:661	acute LD patients	645:661	acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days	645:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	2	35	from	bloodstream	218:228	arg1	humans					233:238	humans	233:238	humans	233:238	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	8	36	theme	%	1219:1219	arg1	specificity					1196:1206	specificity	1196:1206	specificity of 94.7-100%	1196:1219	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	8	36	theme	%	1219:1219	arg1	sensitivity					1169:1179	a sensitivity	1167:1179	a sensitivity of 75-100%	1167:1190	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	6	37	theme	infection	793:801	arg1	phase					781:785	the acute phase	771:785	the acute phase of Bb infection	771:801	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	3	38	theme	immune	428:433	arg1	system					435:440	the immune system	424:440	the immune system	424:440	Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system.
35990620	0	39	theme	N-linked	23:30	arg1	glycans					32:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans	0:38	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	5	40	from	serum	612:616	arg1	N-glycans					551:559	IgG N-glycans	547:559	IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days	547:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	3	41	theme	downstream	387:396	arg1	responses					411:419	downstream inflammatory responses	387:419	downstream inflammatory responses	387:419	Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system.
35990620	4	42	theme	Immunoglobulin	443:456	arg1	IgG					461:463	IgG	461:463	IgG	461:463	Immunoglobulin G (IgG) N-glycan responses to LD have not been characterized.
35990620	4	42	theme	Immunoglobulin	443:456	arg1	G					458:458	Immunoglobulin G	443:458	Immunoglobulin G (IgG) N-glycan responses to LD	443:489	Immunoglobulin G (IgG) N-glycan responses to LD have not been characterized.
35990620	8	43	theme	treated	1146:1152	arg1	cohorts					1154:1160	treated cohorts	1146:1160	treated cohorts	1146:1160	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	6	44	theme	acute	775:779	arg1	phase					781:785	the acute phase	771:785	the acute phase of Bb infection	771:801	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	5	45	dep	3-week	681:686	arg1	to					678:679	to	678:679	to	678:679	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	2	46	theme	limited	177:183	arg1	presence					185:192	the limited presence	173:192	the limited presence of this pathogen in the bloodstream in humans	173:238	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	6	47	theme	Bb	790:791	arg1	infection					793:801	Bb infection	790:801	Bb infection	790:801	Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature.
35990620	5	48	theme	IgG	547:549	arg1	N-glycans					551:559	IgG N-glycans	547:559	IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days	547:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	5	49	dep	patients	654:661	arg1	convalesced					714:724	convalesced	714:724	convalesced for 70-90 days	714:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	5	49	dep	patients	654:661	arg1	completed					663:671	completed	663:671	completed a 2- to 3-week course of antibiotics	663:708	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	7	50	theme	unexpected	949:958	arg1	result					960:965	This unexpected result	944:965	This unexpected result	944:965	This unexpected result is in direct contrast to what is reported for other inflammatory diseases.
35990620	3	51	dep	infection	323:331	arg1	response					311:318	response	311:318	response	311:318	Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system.
35990620	7	52	theme	inflammatory	1019:1030	arg1	diseases					1032:1039	other inflammatory diseases	1013:1039	other inflammatory diseases	1013:1039	This unexpected result is in direct contrast to what is reported for other inflammatory diseases.
35990620	0	53	theme	inflammatory	63:74	arg1	signature					76:84	the canonical inflammatory signature	49:84	the canonical inflammatory signature	49:84	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	5	54	from	cohorts	566:572	arg1	N-glycans					551:559	IgG N-glycans	547:559	IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days	547:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35990620	0	55	theme	canonical	53:61	arg1	signature					76:84	the canonical inflammatory signature	49:84	the canonical inflammatory signature	49:84	Acute lyme disease IgG N-linked glycans contrast the canonical inflammatory signature.
35990620	2	56	theme	pathogen	202:209	arg1	presence					185:192	the limited presence	173:192	the limited presence of this pathogen in the bloodstream in humans	173:238	Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion.
35990620	1	57	theme	Borrelia	128:135	arg1	Bb					161:162	Bb	161:162	Bb	161:162	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	1	57	theme	Borrelia	128:135	arg1	lato					155:158	Borrelia burgdorferi sensu lato	128:158	Borrelia burgdorferi sensu lato (Bb)	128:163	Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb).
35990620	8	58	theme	IgG	1055:1057	arg1	N-glycans					1059:1067	IgG N-glycans	1055:1067	IgG N-glycans detected during acute LD infection	1055:1102	Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
35990620	5	59	from	serum	623:627	arg1	N-glycans					551:559	IgG N-glycans	547:559	IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days	547:739	In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days.
35022400	2	0	link	Asn-linked	325:334	arg1	glycosylation					367:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation	325:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice	325:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	3	1	from	sequence	458:465	arg1	complex					447:453	complex	447:453	complex	447:453	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	1	2	theme	prior	160:164	arg1	studies					166:172	prior studies	160:172	prior studies	160:172	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
35022400	8	3	from	disease	1172:1178	arg1	studies					1123:1129	future studies	1116:1129	future studies of glycosylation in neurodevelopment and disease	1116:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	6	4	theme	other	950:954	arg1	tissues					956:962	other tissues	950:962	other tissues	950:962	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	1	5	theme	sex-specific	256:267	arg1	analyses					269:276	excluded region- and sex-specific analyses	235:276	excluded region- and sex-specific analyses	235:276	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
35022400	2	6	link	Ser/Thr/Tyr-linked	340:357	arg1	glycosylation					367:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation	325:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice	325:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	7	7	theme	protein	1015:1021	arg1	glycans					1023:1029	protein glycans	1015:1029	protein glycans	1015:1029	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	2	8	theme	several	291:297	arg1	methodologies					299:311	several methodologies	291:311	several methodologies	291:311	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	8	9	from	neurodevelopment	1151:1166	arg1	studies					1123:1129	future studies	1116:1129	future studies of glycosylation in neurodevelopment and disease	1116:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	4	10	dep	unbranched	609:618	arg1	sialylated					621:630	sialylated	621:630	sialylated	621:630	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	6	11	theme	RNA	807:809	arg1	expression					811:820	RNA expression	807:820	RNA expression of their synthetic enzymes	807:847	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	7	12	theme	restricted	990:999	arg1	repertoire					1001:1010	this restricted repertoire	985:1010	this restricted repertoire of protein glycans	985:1029	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	7	12	theme	restricted	990:999	arg1	glycans					1023:1029	protein glycans	1015:1029	protein glycans	1015:1029	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	4	13	theme	O-GalNAc	632:639	arg1	structures					655:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	4	13	theme	O-GalNAc	632:639	arg1	O-glycans					595:603	Most brain O-glycans	584:603	Most brain O-glycans	584:603	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	2	14	theme	protein	359:365	arg1	glycosylation					367:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation	325:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice	325:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	5	15	theme	consistent	669:678	arg1	pattern					680:686	A consistent pattern	667:686	A consistent pattern	667:686	A consistent pattern is observed between regions, and sex differences are minimal compared to those in plasma.
35022400	3	16	theme	fucosylated/bisected	551:570	arg1	structures					572:581	high-mannose and fucosylated/bisected structures	534:581	structures	572:581	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	6	17	theme	synthetic	831:839	arg1	enzymes					841:847	their synthetic enzymes	825:847	their synthetic enzymes	825:847	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	6	18	theme	enzymes	841:847	arg1	expression					811:820	RNA expression	807:820	RNA expression of their synthetic enzymes	807:847	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	0	19	theme	brain	10:14	arg1	glycoproteins					16:28	Mammalian brain glycoproteins	0:28	Mammalian brain glycoproteins	0:28	Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues.
35022400	2	20	from	glycosylation	367:379	arg1	mice					416:419	mice	416:419	mice	416:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	8	21	gly	glycosylation	1134:1146	arg1	neurodevelopment					1151:1166	neurodevelopment	1151:1166	neurodevelopment	1151:1166	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	8	21	gly	glycosylation	1134:1146	arg1	disease					1172:1178	disease	1172:1178	disease	1172:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	0	22	theme	Mammalian	0:8	arg1	glycoproteins					16:28	Mammalian brain glycoproteins	0:28	Mammalian brain glycoproteins	0:28	Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues.
35022400	6	23	from	analysis	854:861	arg1	humans					889:894	humans	889:894	humans	889:894	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	6	24	from	downregulation	910:923	arg1	brain					932:936	the brain	928:936	the brain	928:936	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	4	25	theme	brain	589:593	arg1	O-glycans					595:603	Most brain O-glycans	584:603	Most brain O-glycans	584:603	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	4	25	theme	brain	589:593	arg1	structures					655:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	6	26	theme	Brain	778:782	arg1	glycans					784:790	Brain glycans	778:790	Brain glycans	778:790	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	4	27	theme	unbranched	609:618	arg1	structures					655:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	4	27	theme	unbranched	609:618	arg1	O-glycans					595:603	Most brain O-glycans	584:603	Most brain O-glycans	584:603	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	8	28	theme	future	1116:1121	arg1	studies					1123:1129	future studies	1116:1129	future studies of glycosylation in neurodevelopment and disease	1116:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	7	29	from	regulation	1055:1064	arg1	brain					1073:1077	the brain	1069:1077	the brain	1069:1077	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	0	30	theme	glycan	49:54	arg1	complexity					56:65	diminished glycan complexity	38:65	diminished glycan complexity	38:65	Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues.
35022400	2	31	gly	glycosylation	367:379	arg1	mice					416:419	mice	416:419	mice	416:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	6	32	theme	global	903:908	arg1	downregulation					910:923	a global downregulation	901:923	a global downregulation in the brain compared to other tissues	901:962	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	1	33	theme	single	203:208	arg1	technique					221:229	a single analytical technique	201:229	a single analytical technique	201:229	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
35022400	0	34	theme	diminished	38:47	arg1	complexity					56:65	diminished glycan complexity	38:65	diminished glycan complexity	38:65	Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues.
35022400	8	35	from	studies	1123:1129	arg1	neurodevelopment					1151:1166	neurodevelopment	1151:1166	neurodevelopment	1151:1166	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	8	35	from	studies	1123:1129	arg1	disease					1172:1178	disease	1172:1178	disease	1172:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	1	36	theme	analytical	210:219	arg1	technique					221:229	a single analytical technique	201:229	a single analytical technique	201:229	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
35022400	6	37	from	humans	889:894	arg1	analysis					854:861	analysis	854:861	analysis of glycosylation genes in humans	854:894	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	5	38	theme	sex	721:723	arg1	differences					725:735	sex differences	721:735	sex differences	721:735	A consistent pattern is observed between regions, and sex differences are minimal compared to those in plasma.
35022400	0	39	gly	glycoproteins	16:28	arg1	glycoproteins					16:28	Mammalian brain glycoproteins	0:28	Mammalian brain glycoproteins	0:28	Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues.
35022400	3	40	from	variety	471:477	arg1	complex					447:453	complex	447:453	complex	447:453	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	1	41	theme	brain	124:128	arg1	development					130:140	brain development	124:140	brain development	124:140	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
35022400	3	42	theme	Brain	422:426	arg1	N-glycans					428:436	Brain N-glycans	422:436	Brain N-glycans	422:436	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	4	43	theme	Most	584:587	arg1	O-glycans					595:603	Most brain O-glycans	584:603	Most brain O-glycans	584:603	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	4	43	theme	Most	584:587	arg1	structures					655:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	7	44	theme	tight	1049:1053	arg1	regulation					1055:1064	their tight regulation	1043:1064	their tight regulation in the brain	1043:1077	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	2	45	theme	Ser/Thr/Tyr-linked	340:357	arg1	glycosylation					367:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation	325:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice	325:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	8	46	theme	glycosylation	1134:1146	arg1	studies					1123:1129	future studies	1116:1129	future studies of glycosylation in neurodevelopment and disease	1116:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	3	47	theme	other	491:495	arg1	tissues					497:503	other tissues	491:503	other tissues	491:503	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	8	48	from	glycosylation	1134:1146	arg1	neurodevelopment					1151:1166	neurodevelopment	1151:1166	neurodevelopment	1151:1166	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	8	48	from	glycosylation	1134:1146	arg1	disease					1172:1178	disease	1172:1178	disease	1172:1178	These results provide a roadmap for future studies of glycosylation in neurodevelopment and disease.
35022400	6	49	theme	genes	880:884	arg1	analysis					854:861	analysis	854:861	analysis of glycosylation genes in humans	854:894	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	2	50	theme	Asn-linked	325:334	arg1	glycosylation					367:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation	325:379	Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice	325:419	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	4	51	theme	O-mannose	645:653	arg1	structures					655:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	unbranched, sialylated O-GalNAc and O-mannose structures	609:664	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	4	51	theme	O-mannose	645:653	arg1	O-glycans					595:603	Most brain O-glycans	584:603	Most brain O-glycans	584:603	Most brain O-glycans are unbranched, sialylated O-GalNAc and O-mannose structures.
35022400	0	52	theme	other	79:83	arg1	tissues					85:91	other tissues	79:91	other tissues	79:91	Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues.
35022400	6	53	theme	glycosylation	866:878	arg1	genes					880:884	glycosylation genes	866:884	glycosylation genes in humans	866:894	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	3	54	from	complex	447:453	arg1	variety					471:477	variety	471:477	variety	471:477	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	3	54	from	complex	447:453	arg1	sequence					458:465	sequence	458:465	sequence	458:465	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	3	55	theme	high-mannose	534:545	arg1	structures					572:581	high-mannose and fucosylated/bisected structures	534:581	structures	572:581	Brain N-glycans are less complex in sequence and variety compared to other tissues, consisting predominantly of high-mannose and fucosylated/bisected structures.
35022400	1	56	theme	excluded	235:242	arg1	analyses					269:276	excluded region- and sex-specific analyses	235:276	excluded region- and sex-specific analyses	235:276	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
35022400	6	57	from	genes	880:884	arg1	humans					889:894	humans	889:894	humans	889:894	Brain glycans correlate with RNA expression of their synthetic enzymes, and analysis of glycosylation genes in humans show a global downregulation in the brain compared to other tissues.
35022400	7	58	theme	glycans	1023:1029	arg1	repertoire					1001:1010	this restricted repertoire	985:1010	this restricted repertoire of protein glycans	985:1029	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	7	58	theme	glycans	1023:1029	arg1	glycans					1023:1029	protein glycans	1015:1029	protein glycans	1015:1029	We hypothesize that this restricted repertoire of protein glycans arises from their tight regulation in the brain.
35022400	2	59	theme	brain	389:393	arg1	regions					395:401	brain regions	389:401	brain regions	389:401	Here, using several methodologies, we analyze Asn-linked and Ser/Thr/Tyr-linked protein glycosylation between brain regions and sexes in mice.
35022400	1	60	theme	region-	244:250	arg1	analyses					269:276	excluded region- and sex-specific analyses	235:276	excluded region- and sex-specific analyses	235:276	Glycosylation is essential to brain development and function, but prior studies have often been limited to a single analytical technique and excluded region- and sex-specific analyses.
34864901	0	0	theme	proteins	59:66	arg1	shielding					33:41	glycan shielding	26:41	glycan shielding of glycosylated proteins	26:66	GLYCO: a tool to quantify glycan shielding of glycosylated proteins.
34864901	8	1	theme	Supplementary	1210:1222	arg1	data					1224:1227	SUPPLEMENTARY INFORMATION Supplementary data	1184:1227	SUPPLEMENTARY INFORMATION Supplementary data	1184:1227	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
34864901	1	2	theme	important	93:101	arg1	roles					103:107	important roles	93:107	important roles	93:107	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	5	3	theme	structure	916:924	arg1	determination					926:938	nuclear magnetic resonance spectroscopy structure determination	876:938	nuclear magnetic resonance spectroscopy structure determination	876:938	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	1	4	gly	glycosylation	173:185	arg1	antigens					198:205	protein antigens	190:205	protein antigens	190:205	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	0	5	gly	glycosylated	46:57	arg1	proteins					59:66	glycosylated proteins	46:66	glycosylated proteins	46:66	GLYCO: a tool to quantify glycan shielding of glycosylated proteins.
34864901	5	6	theme	spectroscopy	903:914	arg1	determination					926:938	nuclear magnetic resonance spectroscopy structure determination	876:938	nuclear magnetic resonance spectroscopy structure determination	876:938	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	8	7	theme	INFORMATION	1198:1208	arg1	data					1224:1227	SUPPLEMENTARY INFORMATION Supplementary data	1184:1227	SUPPLEMENTARY INFORMATION Supplementary data	1184:1227	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
34864901	2	8	theme	surface	338:344	arg1	shielding					303:311	glycan shielding	296:311	glycan shielding	296:311	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	2	8	theme	surface	338:344	arg1	coverage					316:323	coverage	316:323	coverage	316:323	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	3	9	theme	GLYcan	506:511	arg1	GLYCO					499:503	GLYCO	499:503	GLYCO (GLYcan COverage)	499:521	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	3	9	theme	GLYcan	506:511	arg1	COverage					513:520	GLYcan COverage	506:520	GLYcan COverage	506:520	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	4	10	theme	entire	650:655	arg1	surface					665:671	the entire protein surface	646:671	the entire protein surface	646:671	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	8	11	theme	SUPPLEMENTARY	1184:1196	arg1	data					1224:1227	SUPPLEMENTARY INFORMATION Supplementary data	1184:1227	SUPPLEMENTARY INFORMATION Supplementary data	1184:1227	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
34864901	7	12	dep	https	1145:1149	arg1	//github.com/myungjinlee/GLYCO					1151:1180	//github.com/myungjinlee/GLYCO	1151:1180	https://github.com/myungjinlee/GLYCO	1145:1180	AVAILABILITY AND IMPLEMENTATION GLYCO is freely available at GitHub (https://github.com/myungjinlee/GLYCO).
34864901	5	13	theme	dynamics	969:976	arg1	analysis					950:957	analysis	950:957	analysis of glycan dynamics	950:976	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	3	14	theme	in	479:480	arg1	GLYCO					499:503	GLYCO	499:503	GLYCO (GLYcan COverage)	499:521	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	3	14	theme	in	479:480	arg1	approach					489:496	an in silico approach	476:496	an in silico approach	476:496	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	2	15	theme	tools	378:382	arg1	none					347:350	none	347:350	none of the publicly available tools	347:382	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	7	16	dep	AVAILABILITY	1076:1087	arg1	GLYCO					1108:1112	GLYCO	1108:1112	GLYCO	1108:1112	AVAILABILITY AND IMPLEMENTATION GLYCO is freely available at GitHub (https://github.com/myungjinlee/GLYCO).
34864901	8	17	from	online	1261:1266	arg1	available					1233:1241	available	1233:1241	available	1233:1241	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
34864901	5	18	theme	glycan	726:731	arg1	shielding					733:741	glycan shielding	726:741	glycan shielding	726:741	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	1	19	theme	MOTIVATION	69:78	arg1	Glycans					80:86	MOTIVATION Glycans	69:86	MOTIVATION Glycans	69:86	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	6	20	theme	proteins	1066:1073	arg1	shielding					1040:1048	the glycan shielding	1029:1048	the glycan shielding of glycosylated proteins	1029:1073	Overall, GLYCO provides fundamental insights into the glycan shielding of glycosylated proteins.
34864901	2	21	theme	available	368:376	arg1	tools					378:382	the publicly available tools	355:382	the publicly available tools	355:382	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	5	22	theme	multiple	781:788	arg1	files					801:805	multiple coordinate files	781:805	multiple coordinate files	781:805	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	3	23	theme	glycan	540:545	arg1	shielding					547:555	the glycan shielding	536:555	the glycan shielding of a protein surface	536:576	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	5	24	theme	molecular	839:847	arg1	simulations					858:868	molecular dynamics simulations	839:868	molecular dynamics simulations	839:868	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	2	25	theme	atomistic	432:440	arg1	level					442:446	an atomistic level	429:446	an atomistic level	429:446	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	8	26	theme	Bioinformatics	1246:1259	arg1	online					1261:1266	Bioinformatics online	1246:1266	Bioinformatics online	1246:1266	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
34864901	1	27	theme	protein	190:196	arg1	antigens					198:205	protein antigens	190:205	protein antigens	190:205	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	4	28	theme	surface	700:706	arg1	subset					678:683	a subset	676:683	a subset of the protein surface	676:706	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	4	28	theme	surface	700:706	arg1	regions					635:641	glycan-dense/sparse regions	615:641	glycan-dense/sparse regions of the entire protein surface	615:671	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	3	29	dep	in	479:480	arg1	silico					482:487	silico	482:487	silico	482:487	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	2	30	theme	glycan	296:301	arg1	shielding					303:311	glycan shielding	296:311	glycan shielding	296:311	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	1	31	theme	antigens	198:205	arg1	glycosylation					173:185	glycosylation	173:185	glycosylation of protein antigens	173:205	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	5	32	theme	single	750:755	arg1	file					768:771	a single coordinate file	748:771	a single coordinate file	748:771	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	5	33	theme	magnetic	884:891	arg1	resonance					893:901	nuclear magnetic resonance	876:901	nuclear magnetic resonance spectroscopy structure determination	876:938	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	6	34	theme	glycan	1033:1038	arg1	shielding					1040:1048	the glycan shielding	1029:1048	the glycan shielding of glycosylated proteins	1029:1073	Overall, GLYCO provides fundamental insights into the glycan shielding of glycosylated proteins.
34864901	6	35	theme	glycosylated	1053:1064	arg1	proteins					1066:1073	glycosylated proteins	1053:1073	glycosylated proteins	1053:1073	Overall, GLYCO provides fundamental insights into the glycan shielding of glycosylated proteins.
34864901	4	36	theme	glycan-dense/sparse	615:633	arg1	regions					635:641	glycan-dense/sparse regions	615:641	glycan-dense/sparse regions of the entire protein surface	615:671	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	4	37	theme	surface	665:671	arg1	subset					678:683	a subset	676:683	a subset of the protein surface	676:706	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	4	37	theme	surface	665:671	arg1	regions					635:641	glycan-dense/sparse regions	615:641	glycan-dense/sparse regions of the entire protein surface	615:671	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	5	38	theme	coordinate	757:766	arg1	file					768:771	a single coordinate file	748:771	a single coordinate file	748:771	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	3	39	theme	protein	562:568	arg1	surface					570:576	a protein surface	560:576	a protein surface	560:576	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	2	40	theme	glycan	393:398	arg1	shielding					400:408	glycan shielding	393:408	glycan shielding	393:408	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	5	41	theme	dynamics	849:856	arg1	simulations					858:868	molecular dynamics simulations	839:868	molecular dynamics simulations	839:868	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	2	42	dep	shielding	303:311	arg1	the					292:294	the	292:294	the	292:294	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	0	43	theme	glycan	26:31	arg1	shielding					33:41	glycan shielding	26:41	glycan shielding of glycosylated proteins	26:66	GLYCO: a tool to quantify glycan shielding of glycosylated proteins.
34864901	5	44	theme	coordinate	790:799	arg1	files					801:805	multiple coordinate files	781:805	multiple coordinate files	781:805	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	2	45	theme	protein	330:336	arg1	surface					338:344	a protein surface	328:344	a protein surface	328:344	While there have been attempts to quantify the glycan shielding or coverage of a protein surface, none of the publicly available tools analyzes glycan shielding computationally at an atomistic level.
34864901	7	46	from	GitHub	1137:1142	arg1	available					1124:1132	available	1124:1132	available	1124:1132	AVAILABILITY AND IMPLEMENTATION GLYCO is freely available at GitHub (https://github.com/myungjinlee/GLYCO).
34864901	6	47	gly	glycosylated	1053:1064	arg1	proteins					1066:1073	glycosylated proteins	1053:1073	glycosylated proteins	1053:1073	Overall, GLYCO provides fundamental insights into the glycan shielding of glycosylated proteins.
34864901	3	48	dep	RESULTS	449:455	arg1	developed					466:474	developed	466:474	developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface	466:576	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	0	49	dep	tool	9:12	arg1	GLYCO					0:4	GLYCO	0:4	GLYCO	0:4	GLYCO: a tool to quantify glycan shielding of glycosylated proteins.
34864901	1	50	theme	protein	112:118	arg1	folding					120:126	protein folding	112:126	protein folding	112:126	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	5	51	theme	resonance	893:901	arg1	determination					926:938	nuclear magnetic resonance spectroscopy structure determination	876:938	nuclear magnetic resonance spectroscopy structure determination	876:938	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	5	52	theme	nuclear	876:882	arg1	resonance					893:901	nuclear magnetic resonance	876:901	nuclear magnetic resonance spectroscopy structure determination	876:938	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	4	53	theme	protein	692:698	arg1	surface					700:706	the protein surface	688:706	the protein surface	688:706	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	4	54	theme	protein	657:663	arg1	surface					665:671	the entire protein surface	646:671	the entire protein surface	646:671	The software provides insights into glycan-dense/sparse regions of the entire protein surface or a subset of the protein surface.
34864901	1	55	theme	immune	231:236	arg1	responses					238:246	immune responses	231:246	immune responses	231:246	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	0	56	theme	glycosylated	46:57	arg1	proteins					59:66	glycosylated proteins	46:66	glycosylated proteins	46:66	GLYCO: a tool to quantify glycan shielding of glycosylated proteins.
34864901	5	57	theme	glycan	962:967	arg1	dynamics					969:976	glycan dynamics	962:976	glycan dynamics	962:976	GLYCO calculates glycan shielding from a single coordinate file or from multiple coordinate files, for instance, as obtained from molecular dynamics simulations or by nuclear magnetic resonance spectroscopy structure determination, enabling analysis of glycan dynamics.
34864901	3	58	theme	surface	570:576	arg1	shielding					547:555	the glycan shielding	536:555	the glycan shielding of a protein surface	536:576	RESULTS Here, we developed an in silico approach, GLYCO (GLYcan COverage), to quantify the glycan shielding of a protein surface.
34864901	1	59	dep	play	88:91	arg1	impact					224:229	impact	224:229	impact	224:229	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
34864901	6	60	theme	fundamental	1003:1013	arg1	insights					1015:1022	fundamental insights	1003:1022	fundamental insights into the glycan shielding of glycosylated proteins	1003:1073	Overall, GLYCO provides fundamental insights into the glycan shielding of glycosylated proteins.
34864901	7	61	dep	GitHub	1137:1142	arg1	https					1145:1149	https	1145:1149	https://github.com/myungjinlee/GLYCO	1145:1180	AVAILABILITY AND IMPLEMENTATION GLYCO is freely available at GitHub (https://github.com/myungjinlee/GLYCO).
34864901	1	62	theme	cell-cell	132:140	arg1	interactions-and					142:157	cell-cell interactions-and	132:157	cell-cell interactions-and	132:157	MOTIVATION Glycans play important roles in protein folding and cell-cell interactions-and, furthermore, glycosylation of protein antigens can dramatically impact immune responses.
35172879	3	0	theme	venepunctured	487:499	arg1	blood					501:505	venepunctured blood	487:505	venepunctured blood	487:505	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	4	1	theme	intra-day	570:578	arg1	repeatability					580:592	the intra-day repeatability	566:592	the intra-day repeatability of the three mentioned self-sampling methods	566:637	We have also tested the intra-day repeatability of the three mentioned self-sampling methods.
35172879	7	2	theme	Noviplex	1106:1113	arg1	cards					1115:1119	Noviplex cards	1106:1119	Noviplex cards	1106:1119	In repeatability testing, similar results were obtained, with Noviplex cards and Neoteryx sticks performing substantially better than DBS (CVs = 4.831% and 7.098%, compared to 14.305%, respectively).
35172879	8	3	theme	satisfactory	1360:1371	arg1	performance					1373:1383	their satisfactory performance	1354:1383	their satisfactory performance in both the comparability and repeatability testing	1354:1435	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	3	4	theme	proteins	536:543	arg1	N-glycoprofiling					510:525	N-glycoprofiling	510:525	N-glycoprofiling of total proteins	510:543	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	1	5	theme	OBJECTIVE	75:83	arg1	Self-sampling					85:97	OBJECTIVE Self-sampling	75:97	OBJECTIVE Self-sampling of capillary blood	75:116	OBJECTIVE Self-sampling of capillary blood provides easier sample collection, handling, and shipping compared to more invasive blood sampling via venepuncture.
35172879	8	6	theme	Noviplex	1293:1300	arg1	use					1273:1275	the use	1269:1275	the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis	1269:1339	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	2	7	theme	Noviplex	346:353	arg1	cards					355:359	Noviplex cards	346:359	Noviplex cards	346:359	Recently, other means of capillary blood collection were introduced to the market, such as Neoteryx sticks and Noviplex cards.
35172879	3	8	theme	blood	442:446	arg1	DBS					455:457	DBS	455:457	DBS	455:457	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	3	8	theme	blood	442:446	arg1	spots					448:452	dried blood spots	436:452	dried blood spots (DBS)	436:458	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	3	9	theme	self-sampling	403:415	arg1	methods					417:423	these two self-sampling methods	393:423	these two self-sampling methods	393:423	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	6	10	theme	Noviplex	1028:1035	arg1	cards					1037:1041	Noviplex cards	1028:1041	Noviplex cards	1028:1041	RESULTS Comparability with plasma was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards.
35172879	3	11	theme	total	530:534	arg1	proteins					536:543	total proteins	530:543	total proteins	530:543	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	8	12	dep	comparability	1397:1409	arg1	the					1393:1395	the	1393:1395	the	1393:1395	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	8	12	dep	comparability	1397:1409	arg1	testing					1429:1435	testing	1429:1435	testing	1429:1435	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	5	13	theme	Capillary	640:648	arg1	collection					656:665	Capillary blood collection	640:665	Capillary blood collection with Neoteryx, Noviplex and DBS	640:697	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	1	14	theme	capillary	102:110	arg1	blood					112:116	capillary blood	102:116	capillary blood	102:116	OBJECTIVE Self-sampling of capillary blood provides easier sample collection, handling, and shipping compared to more invasive blood sampling via venepuncture.
35172879	6	15	theme	relative	943:950	arg1	deviance					952:959	the relative deviance	939:959	the relative deviance	939:959	RESULTS Comparability with plasma was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards.
35172879	6	15	theme	relative	943:950	arg1	0.674					972:976	0.674	972:976	0.674	972:976	RESULTS Comparability with plasma was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards.
35172879	1	16	theme	invasive	193:200	arg1	blood					202:206	more invasive blood	188:206	more invasive blood sampling via venepuncture	188:232	OBJECTIVE Self-sampling of capillary blood provides easier sample collection, handling, and shipping compared to more invasive blood sampling via venepuncture.
35172879	5	17	theme	ultra-performance	836:852	arg1	chromatography					861:874	ultra-performance liquid chromatography	836:874	ultra-performance liquid chromatography	836:874	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	6	18	dep	RESULTS	877:883	arg1	assessed					915:922	assessed	915:922	was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards	911:1041	RESULTS Comparability with plasma was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards.
35172879	5	19	theme	blood	650:654	arg1	collection					656:665	Capillary blood collection	640:665	Capillary blood collection with Neoteryx, Noviplex and DBS	640:697	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	1	20	theme	blood	112:116	arg1	Self-sampling					85:97	OBJECTIVE Self-sampling	75:97	OBJECTIVE Self-sampling of capillary blood	75:116	OBJECTIVE Self-sampling of capillary blood provides easier sample collection, handling, and shipping compared to more invasive blood sampling via venepuncture.
35172879	3	21	theme	dried	436:440	arg1	DBS					455:457	DBS	455:457	DBS	455:457	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	3	21	theme	dried	436:440	arg1	spots					448:452	dried blood spots	436:452	dried blood spots (DBS)	436:458	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	0	22	theme	blood	28:32	arg1	collection					34:43	self-sampling blood collection	14:43	self-sampling blood collection	14:43	Comparison of self-sampling blood collection for N-glycosylation analysis.
35172879	0	23	theme	self-sampling	14:26	arg1	collection					34:43	self-sampling blood collection	14:43	self-sampling blood collection	14:43	Comparison of self-sampling blood collection for N-glycosylation analysis.
35172879	6	24	theme	Neoteryx	997:1004	arg1	sticks					1006:1011	Neoteryx sticks	997:1011	Neoteryx sticks	997:1011	RESULTS Comparability with plasma was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards.
35172879	1	25	theme	easier	127:132	arg1	collection					141:150	easier sample collection	127:150	easier sample collection	127:150	OBJECTIVE Self-sampling of capillary blood provides easier sample collection, handling, and shipping compared to more invasive blood sampling via venepuncture.
35172879	4	26	theme	methods	631:637	arg1	repeatability					580:592	the intra-day repeatability	566:592	the intra-day repeatability of the three mentioned self-sampling methods	566:637	We have also tested the intra-day repeatability of the three mentioned self-sampling methods.
35172879	3	27	theme	methods	417:423	arg1	comparability					376:388	the comparability	372:388	the comparability of these two self-sampling methods	372:423	We tested the comparability of these two self-sampling methods, alongside dried blood spots (DBS), with plasma acquired from venepunctured blood in N-glycoprofiling of total proteins.
35172879	8	28	theme	preliminary	1248:1258	arg1	study					1260:1264	Our preliminary study	1244:1264	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis	1244:1339	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	0	29	theme	collection	34:43	arg1	Comparison					0:9	Comparison	0:9	Comparison of self-sampling blood collection for N-glycosylation analysis.	0:73	Comparison of self-sampling blood collection for N-glycosylation analysis.
35172879	5	30	with	collection	656:665	arg1	DBS					695:697	DBS	695:697	DBS	695:697	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	5	30	with	collection	656:665	arg1	Noviplex					682:689	Noviplex	682:689	Noviplex	682:689	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	5	31	theme	N-glycans	807:815	arg1	N-glycoprofiling					754:769	N-glycoprofiling	754:769	N-glycoprofiling of released, fluorescently labelled N-glycans	754:815	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	8	32	theme	larger	1480:1485	arg1	collaborations					1487:1500	larger collaborations	1480:1500	larger collaborations	1480:1500	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	2	33	theme	other	245:249	arg1	means					251:255	other means	245:255	other means of capillary blood collection	245:285	Recently, other means of capillary blood collection were introduced to the market, such as Neoteryx sticks and Noviplex cards.
35172879	8	34	from	study	1260:1264	arg1	use					1273:1275	the use	1269:1275	the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis	1269:1339	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	5	35	theme	liquid	854:859	arg1	chromatography					861:874	ultra-performance liquid chromatography	836:874	ultra-performance liquid chromatography	836:874	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	7	36	theme	similar	1070:1076	arg1	results					1078:1084	similar results	1070:1084	similar results	1070:1084	In repeatability testing, similar results were obtained, with Noviplex cards and Neoteryx sticks performing substantially better than DBS (CVs = 4.831% and 7.098%, compared to 14.305%, respectively).
35172879	7	37	theme	repeatability	1047:1059	arg1	testing					1061:1067	repeatability testing	1047:1067	repeatability testing	1047:1067	In repeatability testing, similar results were obtained, with Noviplex cards and Neoteryx sticks performing substantially better than DBS (CVs = 4.831% and 7.098%, compared to 14.305%, respectively).
35172879	1	38	theme	sample	134:139	arg1	collection					141:150	easier sample collection	127:150	easier sample collection	127:150	OBJECTIVE Self-sampling of capillary blood provides easier sample collection, handling, and shipping compared to more invasive blood sampling via venepuncture.
35172879	0	39	theme	N-glycosylation	49:63	arg1	analysis					65:72	N-glycosylation analysis	49:72	N-glycosylation analysis	49:72	Comparison of self-sampling blood collection for N-glycosylation analysis.
35172879	7	40	theme	Neoteryx	1125:1132	arg1	sticks					1134:1139	Neoteryx sticks	1125:1139	Neoteryx sticks	1125:1139	In repeatability testing, similar results were obtained, with Noviplex cards and Neoteryx sticks performing substantially better than DBS (CVs = 4.831% and 7.098%, compared to 14.305%, respectively).
35172879	8	41	theme	Neoteryx	1280:1287	arg1	use					1273:1275	the use	1269:1275	the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis	1269:1339	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	5	42	dep	released	774:781	arg1	labelled					798:805	labelled	798:805	labelled	798:805	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	8	43	dep	Neoteryx	1280:1287	arg1	devices					1316:1322	self-sampling devices	1302:1322	self-sampling devices	1302:1322	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	2	44	theme	collection	276:285	arg1	means					251:255	other means	245:255	other means of capillary blood collection	245:285	Recently, other means of capillary blood collection were introduced to the market, such as Neoteryx sticks and Noviplex cards.
35172879	8	45	theme	self-sampling	1302:1314	arg1	devices					1316:1322	self-sampling devices	1302:1322	self-sampling devices	1302:1322	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	8	46	from	performance	1373:1383	arg1	repeatability					1415:1427	repeatability	1415:1427	repeatability	1415:1427	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	8	46	from	performance	1373:1383	arg1	comparability					1397:1409	comparability	1397:1409	comparability	1397:1409	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	2	47	theme	blood	270:274	arg1	collection					276:285	capillary blood collection	260:285	capillary blood collection	260:285	Recently, other means of capillary blood collection were introduced to the market, such as Neoteryx sticks and Noviplex cards.
35172879	2	48	theme	Neoteryx	326:333	arg1	sticks					335:340	Neoteryx sticks	326:340	Neoteryx sticks	326:340	Recently, other means of capillary blood collection were introduced to the market, such as Neoteryx sticks and Noviplex cards.
35172879	6	49	with	Comparability	885:897	arg1	plasma					904:909	plasma	904:909	plasma	904:909	RESULTS Comparability with plasma was assessed by calculating the relative deviance, which was 0.674 for DBS, 0.092 for Neoteryx sticks, and 0.069 for Noviplex cards.
35172879	2	50	theme	capillary	260:268	arg1	collection					276:285	capillary blood collection	260:285	capillary blood collection	260:285	Recently, other means of capillary blood collection were introduced to the market, such as Neoteryx sticks and Noviplex cards.
35172879	8	51	from	use	1273:1275	arg1	glycoanalysis					1327:1339	glycoanalysis	1327:1339	glycoanalysis	1327:1339	Our preliminary study on the use of Neoteryx and Noviplex self-sampling devices in glycoanalysis demonstrates their satisfactory performance in both the comparability and repeatability testing, however, they should be further tested in larger collaborations and cohorts.
35172879	4	52	theme	self-sampling	617:629	arg1	methods					631:637	the three mentioned self-sampling methods	597:637	the three mentioned self-sampling methods	597:637	We have also tested the intra-day repeatability of the three mentioned self-sampling methods.
35172879	5	53	theme	released	774:781	arg1	N-glycans					807:815	released, fluorescently labelled N-glycans	774:815	released, fluorescently labelled N-glycans	774:815	Capillary blood collection with Neoteryx, Noviplex and DBS was done following the manufacturers' instructions and N-glycoprofiling of released, fluorescently labelled N-glycans was performed with ultra-performance liquid chromatography.
35172879	7	54	dep	better	1166:1171	arg1	%					1194:1194	CVs = 4.831%	1183:1194	CVs = 4.831%	1183:1194	In repeatability testing, similar results were obtained, with Noviplex cards and Neoteryx sticks performing substantially better than DBS (CVs = 4.831% and 7.098%, compared to 14.305%, respectively).
35172879	7	54	dep	better	1166:1171	arg1	%					1205:1205	7.098%	1200:1205	7.098%	1200:1205	In repeatability testing, similar results were obtained, with Noviplex cards and Neoteryx sticks performing substantially better than DBS (CVs = 4.831% and 7.098%, compared to 14.305%, respectively).
35172879	4	55	theme	mentioned	607:615	arg1	methods					631:637	the three mentioned self-sampling methods	597:637	the three mentioned self-sampling methods	597:637	We have also tested the intra-day repeatability of the three mentioned self-sampling methods.
36985724	4	0	theme	human	768:772	arg1	origins					774:780	bacterial and human origins	754:780	bacterial and human origins	754:780	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	2	1	from	functions	306:314	arg1	glycoprotein					354:365	a particular glycoprotein	341:365	a particular glycoprotein	341:365	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	4	2	gly	glycoprotein	848:859	arg1	glycoprotein					848:859	in vitro processing glycoprotein N-glycans	828:869	in vitro processing glycoprotein N-glycans	828:869	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	5	3	theme	step-wise	998:1006	arg1	reactions					1019:1027	step-wise or one-pot reactions	998:1027	step-wise or one-pot reactions	998:1027	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	4	4	dep	in	828:829	arg1	vitro					831:835	vitro	831:835	vitro	831:835	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	6	5	theme	glycoproteins	1110:1122	arg1	engineering					1083:1093	N-glycan engineering	1074:1093	N-glycan engineering of therapeutic glycoproteins	1074:1122	The platform can find broad applications in N-glycan engineering of therapeutic glycoproteins.
36985724	3	6	dep	in	402:403	arg1	vitro					405:409	vitro	405:409	vitro	405:409	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	1	7	gly	glycoproteins	219:231	arg1	glycoproteins					219:231	glycoproteins	219:231	glycoproteins	219:231	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	3	8	theme	N-glycans	587:595	arg1	functions					574:582	the specific functions	561:582	the specific functions of N-glycans	561:595	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	9	theme	better	609:614	arg1	therapeutics					629:640	better glycoprotein therapeutics	609:640	better glycoprotein therapeutics	609:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	6	10	theme	therapeutic	1098:1108	arg1	glycoproteins					1110:1122	therapeutic glycoproteins	1098:1122	therapeutic glycoproteins	1098:1122	The platform can find broad applications in N-glycan engineering of therapeutic glycoproteins.
36985724	2	11	theme	N-glycans	328:336	arg1	functions					306:314	the functions	302:314	the functions of specific N-glycans on a particular glycoprotein	302:365	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	2	11	theme	N-glycans	328:336	arg1	clear					382:386	clear	382:386	clear	382:386	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	5	12	from	efficient	985:993	arg1	reactions					1019:1027	step-wise or one-pot reactions	998:1027	step-wise or one-pot reactions	998:1027	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	4	13	theme	in	828:829	arg1	N-glycans					861:869	in vitro processing glycoprotein N-glycans	828:869	in vitro processing glycoprotein N-glycans	828:869	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	3	14	theme	homogeneous	523:533	arg1	N-glycoforms					535:546	homogeneous N-glycoforms	523:546	homogeneous N-glycoforms	523:546	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	15	with	glycoproteins	504:516	arg1	N-glycoforms					535:546	homogeneous N-glycoforms	523:546	homogeneous N-glycoforms	523:546	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	4	16	theme	enzymatic	805:813	arg1	platform					815:822	a robust enzymatic platform	796:822	a robust enzymatic platform for in vitro processing glycoprotein N-glycans	796:869	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	2	17	theme	glycoproteins	287:299	arg1	heterogeneity					250:262	N-glycan heterogeneity	241:262	N-glycan heterogeneity of naturally occurring glycoproteins	241:299	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	5	18	theme	recombinant	954:964	arg1	enzymes					966:972	The recombinant enzymes	950:972	The recombinant enzymes	950:972	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	5	18	theme	recombinant	954:964	arg1	efficient					985:993	efficient	985:993	efficient	985:993	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	2	19	gly	glycoproteins	287:299	arg1	glycoproteins					287:299	naturally occurring glycoproteins	267:299	naturally occurring glycoproteins	267:299	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	4	20	theme	complex	936:942	arg1	type					944:947	α2-3-disialylated biantennary complex type	906:947	α2-3-disialylated biantennary complex type	906:947	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	2	21	theme	occurring	277:285	arg1	glycoproteins					287:299	naturally occurring glycoproteins	267:299	naturally occurring glycoproteins	267:299	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	4	22	theme	glycoside	703:711	arg1	hydrolases					713:722	E. coli glycoside hydrolases	695:722	E. coli glycoside hydrolases	695:722	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	0	23	theme	In	13:14	arg1	Processing					31:40	Glycoprotein In Vitro N-Glycan Processing	0:40	Glycoprotein In Vitro N-Glycan Processing	0:40	Glycoprotein In Vitro N-Glycan Processing Using Enzymes Expressed in E. coli.
36985724	1	24	theme	Protein	78:84	arg1	modification					133:144	a common post-translational modification	105:144	a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins	105:231	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	1	24	theme	Protein	78:84	arg1	N-glycosylation					86:100	Protein N-glycosylation	78:100	Protein N-glycosylation	78:100	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	3	25	theme	recombinant	447:457	arg1	enzymes					459:465	purified recombinant enzymes	438:465	purified recombinant enzymes	438:465	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	0	26	theme	Glycoprotein	0:11	arg1	Processing					31:40	Glycoprotein In Vitro N-Glycan Processing	0:40	Glycoprotein In Vitro N-Glycan Processing	0:40	Glycoprotein In Vitro N-Glycan Processing Using Enzymes Expressed in E. coli.
36985724	2	27	theme	specific	319:326	arg1	N-glycans					328:336	specific N-glycans	319:336	specific N-glycans	319:336	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	0	28	theme	N-Glycan	22:29	arg1	Processing					31:40	Glycoprotein In Vitro N-Glycan Processing	0:40	Glycoprotein In Vitro N-Glycan Processing	0:40	Glycoprotein In Vitro N-Glycan Processing Using Enzymes Expressed in E. coli.
36985724	4	29	theme	robust	798:803	arg1	platform					815:822	a robust enzymatic platform	796:822	a robust enzymatic platform for in vitro processing glycoprotein N-glycans	796:869	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	4	30	theme	α2-3-disialylated	906:922	arg1	type					944:947	α2-3-disialylated biantennary complex type	906:947	α2-3-disialylated biantennary complex type	906:947	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	5	31	from	reactions	1019:1027	arg1	enzymes					966:972	The recombinant enzymes	950:972	The recombinant enzymes	950:972	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	5	31	from	reactions	1019:1027	arg1	efficient					985:993	efficient	985:993	efficient	985:993	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	2	32	gly	heterogeneity	250:262	arg1	glycoproteins					287:299	naturally occurring glycoproteins	267:299	naturally occurring glycoproteins	267:299	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	4	33	theme	glycoprotein	848:859	arg1	N-glycans					861:869	in vitro processing glycoprotein N-glycans	828:869	in vitro processing glycoprotein N-glycans	828:869	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	3	34	gly	glycoproteins	504:516	arg1	glycoproteins					504:516	glycoproteins	504:516	glycoproteins with homogeneous N-glycoforms	504:546	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	35	theme	Glycoprotein	389:400	arg1	engineering					420:430	Glycoprotein in vitro N-glycan engineering	389:430	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes	389:465	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	35	theme	Glycoprotein	389:400	arg1	strategy					484:491	an attractive strategy	470:491	an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics	470:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	2	36	theme	particular	343:352	arg1	glycoprotein					354:365	a particular glycoprotein	341:365	a particular glycoprotein	341:365	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	4	37	from	origins	774:780	arg1	hydrolases					713:722	E. coli glycoside hydrolases	695:722	E. coli glycoside hydrolases	695:722	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	4	37	from	origins	774:780	arg1	glycosyltransferases					728:747	glycosyltransferases	728:747	glycosyltransferases	728:747	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	3	38	theme	attractive	473:482	arg1	strategy					484:491	an attractive strategy	470:491	an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics	470:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	38	theme	attractive	473:482	arg1	engineering					420:430	Glycoprotein in vitro N-glycan engineering	389:430	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes	389:465	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	39	theme	purified	438:445	arg1	enzymes					459:465	purified recombinant enzymes	438:465	purified recombinant enzymes	438:465	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	6	40	theme	broad	1052:1056	arg1	applications					1058:1069	broad applications	1052:1069	broad applications	1052:1069	The platform can find broad applications in N-glycan engineering of therapeutic glycoproteins.
36985724	3	41	gly	glycoprotein	616:627	arg1	glycoprotein					616:627	better glycoprotein therapeutics	609:640	better glycoprotein therapeutics	609:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	4	42	gly	α2-3-disialylated	906:922	arg1	type					944:947	α2-3-disialylated biantennary complex type	906:947	α2-3-disialylated biantennary complex type	906:947	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	6	43	gly	glycoproteins	1110:1122	arg1	glycoproteins					1110:1122	therapeutic glycoproteins	1098:1122	therapeutic glycoproteins	1098:1122	The platform can find broad applications in N-glycan engineering of therapeutic glycoproteins.
36985724	4	44	theme	E.	695:696	arg1	hydrolases					713:722	E. coli glycoside hydrolases	695:722	E. coli glycoside hydrolases	695:722	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	3	45	theme	N-glycan	411:418	arg1	engineering					420:430	Glycoprotein in vitro N-glycan engineering	389:430	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes	389:465	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	45	theme	N-glycan	411:418	arg1	strategy					484:491	an attractive strategy	470:491	an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics	470:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	6	46	theme	N-glycan	1074:1081	arg1	engineering					1083:1093	N-glycan engineering	1074:1093	N-glycan engineering of therapeutic glycoproteins	1074:1122	The platform can find broad applications in N-glycan engineering of therapeutic glycoproteins.
36985724	4	47	theme	biantennary	924:934	arg1	type					944:947	α2-3-disialylated biantennary complex type	906:947	α2-3-disialylated biantennary complex type	906:947	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	1	48	theme	common	107:112	arg1	modification					133:144	a common post-translational modification	105:144	a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins	105:231	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	1	48	theme	common	107:112	arg1	N-glycosylation					86:100	Protein N-glycosylation	78:100	Protein N-glycosylation	78:100	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	2	49	gly	glycoprotein	354:365	arg1	glycoprotein					354:365	a particular glycoprotein	341:365	a particular glycoprotein	341:365	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	1	50	dep	structure	182:190	arg1	the					178:180	the	178:180	the	178:180	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	1	51	theme	post-translational	114:131	arg1	modification					133:144	a common post-translational modification	105:144	a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins	105:231	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	1	51	theme	post-translational	114:131	arg1	N-glycosylation					86:100	Protein N-glycosylation	78:100	Protein N-glycosylation	78:100	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	3	52	theme	glycoprotein	616:627	arg1	therapeutics					629:640	better glycoprotein therapeutics	609:640	better glycoprotein therapeutics	609:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	4	53	dep	E.	695:696	arg1	coli					698:701	coli	698:701	coli	698:701	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	1	54	theme	glycoproteins	219:231	arg1	property					193:200	property	193:200	property	193:200	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	1	54	theme	glycoproteins	219:231	arg1	function					207:214	function	207:214	function	207:214	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	1	54	theme	glycoproteins	219:231	arg1	structure					182:190	structure	182:190	structure	182:190	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
36985724	4	55	theme	processing	837:846	arg1	N-glycans					861:869	in vitro processing glycoprotein N-glycans	828:869	in vitro processing glycoprotein N-glycans	828:869	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	5	56	theme	one-pot	1011:1017	arg1	reactions					1019:1027	step-wise or one-pot reactions	998:1027	step-wise or one-pot reactions	998:1027	The recombinant enzymes are highly efficient in step-wise or one-pot reactions.
36985724	3	57	theme	specific	565:572	arg1	functions					574:582	the specific functions	561:582	the specific functions of N-glycans	561:595	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	4	58	dep	α2-6-	897:901	arg1	high-mannose-type					876:892	high-mannose-type	876:892	high-mannose-type	876:892	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	0	59	dep	In	13:14	arg1	Vitro					16:20	Vitro	16:20	Vitro	16:20	Glycoprotein In Vitro N-Glycan Processing Using Enzymes Expressed in E. coli.
36985724	4	60	theme	bacterial	754:762	arg1	origins					774:780	bacterial and human origins	754:780	bacterial and human origins	754:780	Toward this goal, we have successfully expressed in E. coli glycoside hydrolases and glycosyltransferases from bacterial and human origins and developed a robust enzymatic platform for in vitro processing glycoprotein N-glycans from high-mannose-type to α2-6- or α2-3-disialylated biantennary complex type.
36985724	3	61	theme	in	402:403	arg1	engineering					420:430	Glycoprotein in vitro N-glycan engineering	389:430	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes	389:465	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	3	61	theme	in	402:403	arg1	strategy					484:491	an attractive strategy	470:491	an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics	470:640	Glycoprotein in vitro N-glycan engineering using purified recombinant enzymes is an attractive strategy to produce glycoproteins with homogeneous N-glycoforms to elucidate the specific functions of N-glycans and develop better glycoprotein therapeutics.
36985724	2	62	theme	N-glycan	241:248	arg1	heterogeneity					250:262	N-glycan heterogeneity	241:262	N-glycan heterogeneity of naturally occurring glycoproteins	241:299	Due to N-glycan heterogeneity of naturally occurring glycoproteins, the functions of specific N-glycans on a particular glycoprotein are not always clear.
36985724	1	63	theme	significant	157:167	arg1	roles					169:173	significant roles	157:173	significant roles	157:173	Protein N-glycosylation is a common post-translational modification that plays significant roles on the structure, property, and function of glycoproteins.
37371476	4	0	from	separation	624:633	arg1	RPLC-FD-MS					748:757	RPLC-FD-MS	748:757	RPLC-FD-MS	748:757	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	0	from	separation	624:633	arg1	spectrometry					734:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry	669:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	669:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	6	1	theme	histological	1347:1358	arg1	data					1373:1376	histological and clinical data	1347:1376	histological and clinical data	1347:1376	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	1	2	theme	serum	162:166	arg1	N-glycome					168:176	the total serum N-glycome	152:176	the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention	152:254	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	5	3	theme	di-antennary	1040:1051	arg1	structures					1053:1062	di-antennary structures	1040:1062	di-antennary structures with core fucosylation	1040:1085	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	5	4	from	N-glycans	1142:1150	arg1	sera					1167:1170	CRC patient sera	1155:1170	CRC patient sera	1155:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	2	5	from	alterations	318:328	arg1	CRC					333:335	CRC	333:335	CRC	333:335	In this cohort, it was previously found that serum N-glycome alterations in CRC were associated with patient survival.
37371476	6	6	theme	previous	1306:1313	arg1	dataset					1324:1330	the previous MALDI-MS dataset	1302:1330	the previous MALDI-MS dataset	1302:1330	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	5	7	from	increase	1094:1101	arg1	structures					1053:1062	di-antennary structures	1040:1062	di-antennary structures with core fucosylation	1040:1085	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	5	7	from	increase	1094:1101	arg1	N-glycans					1142:1150	sialylated tri- and tetra-antennary N-glycans	1106:1150	sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1106:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	3	8	theme	ethyl	542:546	arg1	esterification					548:561	ethyl esterification	542:561	ethyl esterification	542:561	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	3	9	theme	fluorescent	382:392	arg1	labeling					394:401	fluorescent labeling	382:401	fluorescent labeling of serum N-glycans	382:420	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	4	10	theme	laser	830:834	arg1	desorption/ionization					836:856	matrix-assisted laser desorption/ionization	814:856	matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations	814:905	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	10	theme	laser	830:834	arg1	MALDI					859:863	MALDI	859:863	MALDI	859:863	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	3	11	theme	acid	476:479	arg1	derivatization					481:494	sialic acid derivatization	469:494	sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively	469:589	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	6	12	theme	Pre-operative	1173:1185	arg1	abundances					1187:1196	Pre-operative abundances	1173:1196	Pre-operative abundances of N-glycans	1173:1209	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	3	13	theme	N-glycans	412:420	arg1	labeling					394:401	fluorescent labeling	382:401	fluorescent labeling of serum N-glycans	382:420	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	4	14	theme	chromatography-fluorescence	691:717	arg1	RPLC-FD-MS					748:757	RPLC-FD-MS	748:757	RPLC-FD-MS	748:757	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	14	theme	chromatography-fluorescence	691:717	arg1	spectrometry					734:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry	669:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	669:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	5	15	with	structures	1053:1062	arg1	fucosylation					1074:1085	core fucosylation	1069:1085	core fucosylation	1069:1085	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	7	16	contain	has	1393:1395	arg1	strategy					1384:1391	This strategy	1379:1391	This strategy	1379:1391	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	7	16	contain	has	1393:1395	arg2	potential					1401:1409	the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery	1397:1518	the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery	1397:1518	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	6	17	theme	clinical	1364:1371	arg1	data					1373:1376	histological and clinical data	1347:1376	histological and clinical data	1347:1376	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	4	18	theme	efficient	614:622	arg1	separation					624:633	efficient separation	614:633	efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	614:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	19	theme	liquid	684:689	arg1	RPLC-FD-MS					748:757	RPLC-FD-MS	748:757	RPLC-FD-MS	748:757	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	19	theme	liquid	684:689	arg1	spectrometry					734:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry	669:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	669:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	0	20	theme	N-Glycosylation	6:20	arg1	RPLC-FD-MS					22:31	Serum N-Glycosylation RPLC-FD-MS	0:31	Serum N-Glycosylation RPLC-FD-MS	0:31	Serum N-Glycosylation RPLC-FD-MS Assay to Assess Colorectal Cancer Surgical Interventions.
37371476	5	21	with	agreement	987:995	arg1	studies					1002:1008	studies	1002:1008	studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1002:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	2	22	theme	serum	302:306	arg1	alterations					318:328	serum N-glycome alterations	302:328	serum N-glycome alterations in CRC	302:335	In this cohort, it was previously found that serum N-glycome alterations in CRC were associated with patient survival.
37371476	1	23	theme	colorectal	184:193	arg1	CRC					203:205	CRC	203:205	CRC	203:205	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	1	23	theme	colorectal	184:193	arg1	cancer					195:200	colorectal cancer	184:200	64 colorectal cancer (CRC) patients before and after surgical intervention	181:254	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	0	24	theme	Serum	0:4	arg1	RPLC-FD-MS					22:31	Serum N-Glycosylation RPLC-FD-MS	0:31	Serum N-Glycosylation RPLC-FD-MS	0:31	Serum N-Glycosylation RPLC-FD-MS Assay to Assess Colorectal Cancer Surgical Interventions.
37371476	4	25	theme	previous	781:788	arg1	data					800:803	the previous glycomics data	777:803	the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations	777:905	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	1	26	theme	developed	99:107	arg1	strategy					120:127	A newly developed analytical strategy	91:127	A newly developed analytical strategy	91:127	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	1	27	theme	cancer	195:200	arg1	patients					208:215	64 colorectal cancer (CRC) patients	181:215	64 colorectal cancer (CRC) patients before and after surgical intervention	181:254	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	7	28	theme	clinical	1465:1472	arg1	therapy					1500:1506	therapy	1500:1506	therapy	1500:1506	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	7	28	theme	clinical	1465:1472	arg1	events					1474:1479	clinical events	1465:1479	clinical events such as treatment, therapy, or surgery	1465:1518	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	7	28	theme	clinical	1465:1472	arg1	treatment					1489:1497	treatment	1489:1497	treatment	1489:1497	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	7	28	theme	clinical	1465:1472	arg1	surgery					1512:1518	surgery	1512:1518	surgery	1512:1518	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	6	29	dep	the	1287:1289	arg1	revisit					1291:1297	revisit	1291:1297	revisit	1291:1297	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	4	30	theme	such	890:893	arg1	separations					895:905	such separations	890:905	such separations	890:905	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	1	31	theme	analytical	109:118	arg1	strategy					120:127	A newly developed analytical strategy	91:127	A newly developed analytical strategy	91:127	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	4	32	theme	isomers	658:664	arg1	separation					624:633	efficient separation	614:633	efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	614:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	6	33	theme	adenocarcinoma	1261:1274	arg1	classification					1243:1256	the classification	1239:1256	the classification of adenocarcinoma	1239:1274	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	5	34	theme	patient	1159:1165	arg1	sera					1167:1170	CRC patient sera	1155:1170	CRC patient sera	1155:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	7	35	theme	patient	1422:1428	arg1	profiles					1430:1437	patient profiles	1422:1437	patient profiles	1422:1437	This strategy has the potential to monitor patient profiles before, during, and after clinical events such as treatment, therapy, or surgery and should also be further explored.
37371476	4	36	theme	positional	647:656	arg1	isomers					658:664	specific positional isomers	638:664	specific positional isomers	638:664	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	2	37	located	found	291:295	arg1	cohort					265:270	this cohort	260:270	this cohort	260:270	In this cohort, it was previously found that serum N-glycome alterations in CRC were associated with patient survival.
37371476	2	37	located	found	291:295	arg2	it					273:274	it	273:274	it	273:274	In this cohort, it was previously found that serum N-glycome alterations in CRC were associated with patient survival.
37371476	5	38	gly	sialylated	1106:1115	arg1	N-glycans					1142:1150	sialylated tri- and tetra-antennary N-glycans	1106:1150	sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1106:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	4	39	theme	detection-mass	719:732	arg1	RPLC-FD-MS					748:757	RPLC-FD-MS	748:757	RPLC-FD-MS	748:757	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	39	theme	detection-mass	719:732	arg1	spectrometry					734:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry	669:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	669:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	40	theme	reversed-phase	669:682	arg1	RPLC-FD-MS					748:757	RPLC-FD-MS	748:757	RPLC-FD-MS	748:757	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	40	theme	reversed-phase	669:682	arg1	spectrometry					734:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry	669:745	reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS)	669:758	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	3	41	theme	serum	406:410	arg1	N-glycans					412:420	serum N-glycans	406:420	serum N-glycans	406:420	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	5	42	gly	fucosylation	1074:1085	arg1	structures					1053:1062	di-antennary structures	1040:1062	di-antennary structures with core fucosylation	1040:1085	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	5	43	theme	sialylated	1106:1115	arg1	N-glycans					1142:1150	sialylated tri- and tetra-antennary N-glycans	1106:1150	sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1106:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	1	44	theme	patients	208:215	arg1	N-glycome					168:176	the total serum N-glycome	152:176	the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention	152:254	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	0	45	theme	Cancer	60:65	arg1	Interventions					76:88	Colorectal Cancer Surgical Interventions	49:88	Colorectal Cancer Surgical Interventions	49:88	Serum N-Glycosylation RPLC-FD-MS Assay to Assess Colorectal Cancer Surgical Interventions.
37371476	5	46	theme	post-operative	956:969	arg1	samples					971:977	post-operative samples	956:977	post-operative samples	956:977	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	5	47	theme	tri-	1117:1120	arg1	N-glycans					1142:1150	sialylated tri- and tetra-antennary N-glycans	1106:1150	sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1106:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	6	48	theme	N-glycans	1201:1209	arg1	abundances					1187:1196	Pre-operative abundances	1173:1196	Pre-operative abundances of N-glycans	1173:1209	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	0	49	theme	Colorectal	49:58	arg1	Interventions					76:88	Colorectal Cancer Surgical Interventions	49:88	Colorectal Cancer Surgical Interventions	49:88	Serum N-Glycosylation RPLC-FD-MS Assay to Assess Colorectal Cancer Surgical Interventions.
37371476	5	50	theme	tetra-antennary	1126:1140	arg1	N-glycans					1142:1150	sialylated tri- and tetra-antennary N-glycans	1106:1150	sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1106:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	1	51	theme	total	156:160	arg1	N-glycome					168:176	the total serum N-glycome	152:176	the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention	152:254	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
37371476	3	52	theme	specific	496:503	arg1	derivatization					481:494	sialic acid derivatization	469:494	sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively	469:589	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	5	53	from	decrease	1028:1035	arg1	structures					1053:1062	di-antennary structures	1040:1062	di-antennary structures with core fucosylation	1040:1085	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	5	53	from	decrease	1028:1035	arg1	N-glycans					1142:1150	sialylated tri- and tetra-antennary N-glycans	1106:1150	sialylated tri- and tetra-antennary N-glycans in CRC patient sera	1106:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	6	54	theme	MALDI-MS	1315:1322	arg1	dataset					1324:1330	the previous MALDI-MS dataset	1302:1330	the previous MALDI-MS dataset	1302:1330	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	3	55	theme	sialic	469:474	arg1	acid					476:479	sialic acid	469:479	sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively	469:589	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	4	56	theme	matrix-assisted	814:828	arg1	desorption/ionization					836:856	matrix-assisted laser desorption/ionization	814:856	matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations	814:905	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	4	56	theme	matrix-assisted	814:828	arg1	MALDI					859:863	MALDI	859:863	MALDI	859:863	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	5	57	theme	core	1069:1072	arg1	fucosylation					1074:1085	core fucosylation	1069:1085	core fucosylation	1069:1085	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	4	58	theme	desorption/ionization	836:856	arg1	-MS					865:867	matrix-assisted laser desorption/ionization (MALDI)-MS	814:867	matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations	814:905	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	2	59	theme	N-glycome	308:316	arg1	alterations					318:328	serum N-glycome alterations	302:328	serum N-glycome alterations in CRC	302:335	In this cohort, it was previously found that serum N-glycome alterations in CRC were associated with patient survival.
37371476	4	60	theme	glycomics	790:798	arg1	data					800:803	the previous glycomics data	777:803	the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations	777:905	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	5	61	theme	CRC	1155:1157	arg1	sera					1167:1170	CRC patient sera	1155:1170	CRC patient sera	1155:1170	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	2	62	theme	patient	358:364	arg1	survival					366:373	patient survival	358:373	patient survival	358:373	In this cohort, it was previously found that serum N-glycome alterations in CRC were associated with patient survival.
37371476	5	63	theme	pre-operative	935:947	arg1	CRC					949:951	pre-operative CRC	935:951	pre-operative CRC	935:951	The results from comparing pre-operative CRC to post-operative samples were in agreement with studies that identified a decrease in di-antennary structures with core fucosylation and an increase in sialylated tri- and tetra-antennary N-glycans in CRC patient sera.
37371476	4	64	theme	specific	638:645	arg1	isomers					658:664	specific positional isomers	638:664	specific positional isomers	638:664	This strategy allowed efficient separation of specific positional isomers on reversed-phase liquid chromatography-fluorescence detection-mass spectrometry (RPLC-FD-MS) and complemented the previous glycomics data based on matrix-assisted laser desorption/ionization (MALDI)-MS that did not include such separations.
37371476	0	65	theme	Surgical	67:74	arg1	Interventions					76:88	Colorectal Cancer Surgical Interventions	49:88	Colorectal Cancer Surgical Interventions	49:88	Serum N-Glycosylation RPLC-FD-MS Assay to Assess Colorectal Cancer Surgical Interventions.
37371476	6	66	theme	good	1218:1221	arg1	performance					1223:1233	good performance	1218:1233	good performance for the classification of adenocarcinoma	1218:1274	Pre-operative abundances of N-glycans showed good performance for the classification of adenocarcinoma and led to the revisit of the previous MALDI-MS dataset with regard to histological and clinical data.
37371476	3	67	theme	α2,3-linkage	519:530	arg1	types					532:536	α2,3-linkage types	519:536	α2,3-linkage types	519:536	Here, fluorescent labeling of serum N-glycans was applied using procainamide and followed by sialic acid derivatization specific for α2,6- and α2,3-linkage types via ethyl esterification and amidation, respectively.
37371476	1	68	theme	surgical	234:241	arg1	intervention					243:254	surgical intervention	234:254	surgical intervention	234:254	A newly developed analytical strategy was applied to profile the total serum N-glycome of 64 colorectal cancer (CRC) patients before and after surgical intervention.
36565355	0	0	theme	secondary	62:70	arg1	structure					72:80	secondary structure	62:80	secondary structure of mouse NOTCH1 EGF27	62:102	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	6	1	theme	glycans	671:677	arg1	addition					650:657	the addition	646:657	the addition of O-linked glycans	646:677	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	6	2	mod	modified	632:639	arg1	repeats					620:626	Certain EGF repeats	608:626	Certain EGF repeats	608:626	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	6	2	mod	modified	632:639	arg3	addition					650:657	the addition	646:657	the addition of O-linked glycans	646:677	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	7	3	theme	site	810:813	arg1	loss					789:792	the loss	785:792	the loss of the O-fucose site of EGF27	785:822	It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
36565355	2	4	contain	contains	208:215	arg2	domain					234:239	an extracellular domain	217:239	an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats	217:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	2	4	contain	contains	208:215	arg1	receptor					199:206	The receptor	195:206	The receptor	195:206	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	2	4	contain	contains	208:215	arg2	ECD					242:244	ECD	242:244	ECD	242:244	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	4	5	theme	conserved	476:484	arg1	bonds					496:500	3 conserved disulfide bonds	474:500	3 conserved disulfide bonds	474:500	Each EGF repeat consists of approximately 40 amino acids and 3 conserved disulfide bonds.
36565355	8	6	theme	resonance	939:947	arg1	spectroscopy					949:960	nuclear magnetic resonance spectroscopy	922:960	nuclear magnetic resonance spectroscopy	922:960	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	1	7	from	receptor	131:138	arg1	metazoans					143:151	metazoans	143:151	metazoans	143:151	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	9	8	theme	unmodified	1122:1131	arg1	protein					1139:1145	the unmodified EGF27 protein	1118:1145	the unmodified EGF27 protein	1118:1145	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	9	9	theme	EGF27	1133:1137	arg1	protein					1139:1145	the unmodified EGF27 protein	1118:1145	the unmodified EGF27 protein	1118:1145	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	9	10	theme	assigned	1202:1209	arg1	shifts					1220:1225	the assigned chemical shifts	1198:1225	the assigned chemical shifts	1198:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	6	11	link	O-linked	662:669	arg1	glycans					671:677	O-linked glycans	662:677	O-linked glycans	662:677	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	6	12	theme	unique	745:750	arg1	function					752:759	a unique function	743:759	a unique function	743:759	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	9	13	theme	1H	1076:1077	arg1	assignments					1103:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments	1049:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein	1049:1145	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	9	14	theme	chemical	1211:1218	arg1	shifts					1220:1225	the assigned chemical shifts	1198:1225	the assigned chemical shifts	1198:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	8	15	theme	signaling	903:911	arg1	pathway					913:919	the NOTCH1 signaling pathway	892:919	the NOTCH1 signaling pathway	892:919	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	6	16	theme	O-linked	662:669	arg1	glycans					671:677	O-linked glycans	662:677	O-linked glycans	662:677	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	0	17	theme	NOTCH1	91:96	arg1	EGF27					98:102	mouse NOTCH1 EGF27	85:102	mouse NOTCH1 EGF27	85:102	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	8	18	theme	NOTCH1	896:901	arg1	pathway					913:919	the NOTCH1 signaling pathway	892:919	the NOTCH1 signaling pathway	892:919	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	9	19	attach	derived	1185:1191	arg2	structure					1175:1183	the predicted secondary structure	1151:1183	the predicted secondary structure derived from the assigned chemical shifts	1151:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	9	19	attach	derived	1185:1191	arg1	shifts					1220:1225	the assigned chemical shifts	1198:1225	the assigned chemical shifts	1198:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	0	20	theme	mouse	85:89	arg1	EGF27					98:102	mouse NOTCH1 EGF27	85:102	mouse NOTCH1 EGF27	85:102	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	4	21	theme	amino	458:462	arg1	acids					464:468	approximately 40 amino acids	441:468	approximately 40 amino acids	441:468	Each EGF repeat consists of approximately 40 amino acids and 3 conserved disulfide bonds.
36565355	6	22	theme	EGF	732:734	arg1	repeat					736:741	each EGF repeat	727:741	each EGF repeat	727:741	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	3	23	with	interactions	376:387	arg1	cells					406:410	neighboring cells	394:410	neighboring cells	394:410	The ECD is responsible for intercellular signaling via protein-ligand interactions with neighboring cells.
36565355	9	24	theme	protein	1139:1145	arg1	assignments					1103:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments	1049:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein	1049:1145	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	9	24	theme	protein	1139:1145	arg1	structure					1175:1183	the predicted secondary structure	1151:1183	the predicted secondary structure derived from the assigned chemical shifts	1151:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	2	25	theme	growth	272:277	arg1	repeats					297:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	3	26	theme	intercellular	333:345	arg1	signaling					347:355	intercellular signaling	333:355	intercellular signaling via protein-ligand interactions with neighboring cells	333:410	The ECD is responsible for intercellular signaling via protein-ligand interactions with neighboring cells.
36565355	9	27	theme	15N	1080:1082	arg1	assignments					1103:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments	1049:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein	1049:1145	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	5	28	theme	missense	588:595	arg1	mutations					597:605	its missense mutations	584:605	its missense mutations	584:605	The Abruptex region (EGF24-29) is critical for NOTCH1 signaling and is known for its missense mutations.
36565355	8	29	theme	magnetic	930:937	arg1	resonance					939:947	nuclear magnetic resonance	922:947	nuclear magnetic resonance spectroscopy	922:960	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	2	30	theme	epidermal	262:270	arg1	repeats					297:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	3	31	theme	neighboring	394:404	arg1	cells					406:410	neighboring cells	394:410	neighboring cells	394:410	The ECD is responsible for intercellular signaling via protein-ligand interactions with neighboring cells.
36565355	8	32	theme	nuclear	922:928	arg1	resonance					939:947	nuclear magnetic resonance	922:947	nuclear magnetic resonance spectroscopy	922:960	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	2	33	theme	tandem	255:260	arg1	repeats					297:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	5	34	theme	NOTCH1	550:555	arg1	signaling					557:565	NOTCH1 signaling	550:565	NOTCH1 signaling	550:565	The Abruptex region (EGF24-29) is critical for NOTCH1 signaling and is known for its missense mutations.
36565355	0	35	theme	EGF27	98:102	arg1	15N					4:6	15N	4:6	15N	4:6	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	0	35	theme	EGF27	98:102	arg1	1H					0:1	1H	0:1	1H	0:1	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	0	35	theme	EGF27	98:102	arg1	13C					9:11	13C backbone and sidechain resonance assignments	9:56	13C	9:11	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	0	35	theme	EGF27	98:102	arg1	structure					72:80	secondary structure	62:80	secondary structure of mouse NOTCH1 EGF27	62:102	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	0	35	theme	EGF27	98:102	arg1	assignments					46:56	sidechain resonance assignments	26:56	sidechain resonance assignments	26:56	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	4	36	theme	EGF	418:420	arg1	repeat					422:427	Each EGF repeat	413:427	Each EGF repeat	413:427	Each EGF repeat consists of approximately 40 amino acids and 3 conserved disulfide bonds.
36565355	3	37	theme	protein-ligand	361:374	arg1	interactions					376:387	protein-ligand interactions	361:387	protein-ligand interactions with neighboring cells	361:410	The ECD is responsible for intercellular signaling via protein-ligand interactions with neighboring cells.
36565355	4	38	theme	Each	413:416	arg1	repeat					422:427	Each EGF repeat	413:427	Each EGF repeat	413:427	Each EGF repeat consists of approximately 40 amino acids and 3 conserved disulfide bonds.
36565355	7	39	theme	EGF27	818:822	arg1	EGF27					818:822	EGF27	818:822	EGF27	818:822	It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
36565355	7	39	theme	EGF27	818:822	arg1	site					810:813	the O-fucose site	797:813	the O-fucose site of EGF27	797:822	It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
36565355	8	40	from	role	867:870	arg1	pathway					913:919	the NOTCH1 signaling pathway	892:919	the NOTCH1 signaling pathway	892:919	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	8	41	theme	EGF27	1007:1011	arg1	structures					993:1002	the structures	989:1002	the structures of EGF27 and its glycoforms	989:1030	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	1	42	attach	linked	161:166	arg1	disorders					184:192	disorders	184:192	disorders	184:192	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	1	42	attach	linked	161:166	arg2	receptor					131:138	a transmembrane receptor	115:138	a transmembrane receptor in metazoans that is linked to a variety of disorders	115:192	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	1	42	attach	linked	161:166	arg1	variety					173:179	a variety	171:179	a variety of disorders	171:192	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	1	42	attach	linked	161:166	arg2	NOTCH1					105:110	NOTCH1	105:110	NOTCH1	105:110	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	5	43	theme	Abruptex	507:514	arg1	critical					537:544	critical	537:544	critical	537:544	The Abruptex region (EGF24-29) is critical for NOTCH1 signaling and is known for its missense mutations.
36565355	5	43	theme	Abruptex	507:514	arg1	region					516:521	The Abruptex region	503:521	The Abruptex region (EGF24-29)	503:532	The Abruptex region (EGF24-29) is critical for NOTCH1 signaling and is known for its missense mutations.
36565355	5	43	theme	Abruptex	507:514	arg1	EGF24-29					524:531	EGF24-29	524:531	EGF24-29	524:531	The Abruptex region (EGF24-29) is critical for NOTCH1 signaling and is known for its missense mutations.
36565355	8	44	gly	glycosylation	875:887	arg1	NOTCH1					896:901	the NOTCH1 signaling pathway	892:919	the NOTCH1 signaling pathway	892:919	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	8	44	gly	glycosylation	875:887	arg1	signaling					903:911	the NOTCH1 signaling pathway	892:919	the NOTCH1 signaling pathway	892:919	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	0	45	theme	sidechain	26:34	arg1	assignments					46:56	sidechain resonance assignments	26:56	sidechain resonance assignments	26:56	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	4	46	theme	disulfide	486:494	arg1	bonds					496:500	3 conserved disulfide bonds	474:500	3 conserved disulfide bonds	474:500	Each EGF repeat consists of approximately 40 amino acids and 3 conserved disulfide bonds.
36565355	8	47	theme	glycoforms	1021:1030	arg1	structures					993:1002	the structures	989:1002	the structures of EGF27 and its glycoforms	989:1030	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	6	48	contain	have	688:691	arg1	many					683:686	many	683:686	many	683:686	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	6	48	contain	have	688:691	arg2	sites					709:713	calcium binding sites	693:713	calcium binding sites	693:713	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	2	49	with	domain	234:239	arg1	repeats					297:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	0	50	dep	13C	9:11	arg1	backbone					13:20	backbone	13:20	backbone	13:20	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	6	51	theme	binding	701:707	arg1	sites					709:713	calcium binding sites	693:713	calcium binding sites	693:713	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	2	52	theme	EGF	292:294	arg1	repeats					297:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	6	53	theme	EGF	616:618	arg1	repeats					620:626	Certain EGF repeats	608:626	Certain EGF repeats	608:626	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	9	54	theme	sidechain	1066:1074	arg1	1H					1076:1077	backbone and sidechain 1H	1053:1077	1H	1076:1077	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	9	55	theme	13C-resonance	1089:1101	arg1	assignments					1103:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments	1049:1113	the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein	1049:1145	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	6	56	theme	calcium	693:699	arg1	sites					709:713	calcium binding sites	693:713	calcium binding sites	693:713	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	6	57	theme	Certain	608:614	arg1	repeats					620:626	Certain EGF repeats	608:626	Certain EGF repeats	608:626	Certain EGF repeats are modified with the addition of O-linked glycans and many have calcium binding sites, which give each EGF repeat a unique function.
36565355	1	58	theme	disorders	184:192	arg1	disorders					184:192	disorders	184:192	disorders	184:192	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	1	58	theme	disorders	184:192	arg1	variety					173:179	a variety	171:179	a variety of disorders	171:192	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	9	59	theme	secondary	1165:1173	arg1	structure					1175:1183	the predicted secondary structure	1151:1183	the predicted secondary structure derived from the assigned chemical shifts	1151:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	2	60	theme	extracellular	220:232	arg1	ECD					242:244	ECD	242:244	ECD	242:244	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	2	60	theme	extracellular	220:232	arg1	domain					234:239	an extracellular domain	217:239	an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats	217:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	9	61	theme	backbone	1053:1060	arg1	1H					1076:1077	backbone and sidechain 1H	1053:1077	1H	1076:1077	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	2	62	theme	factor-like	279:289	arg1	repeats					297:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	36 tandem epidermal growth factor-like (EGF) repeats	252:303	The receptor contains an extracellular domain (ECD) with 36 tandem epidermal growth factor-like (EGF) repeats.
36565355	9	63	theme	predicted	1155:1163	arg1	structure					1175:1183	the predicted secondary structure	1151:1183	the predicted secondary structure derived from the assigned chemical shifts	1151:1225	Here, we report the backbone and sidechain 1H, 15N, and 13C-resonance assignments of the unmodified EGF27 protein and the predicted secondary structure derived from the assigned chemical shifts.
36565355	7	64	theme	NOTCH1	831:836	arg1	activity					838:845	NOTCH1 activity	831:845	NOTCH1 activity	831:845	It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
36565355	0	65	theme	resonance	36:44	arg1	assignments					46:56	sidechain resonance assignments	26:56	sidechain resonance assignments	26:56	1H, 15N, 13C backbone and sidechain resonance assignments and secondary structure of mouse NOTCH1 EGF27.
36565355	8	66	theme	glycosylation	875:887	arg1	role					867:870	the role	863:870	the role of glycosylation in the NOTCH1 signaling pathway	863:919	To investigate the role of glycosylation in the NOTCH1 signaling pathway, nuclear magnetic resonance spectroscopy has been employed to study the structures of EGF27 and its glycoforms.
36565355	1	67	theme	transmembrane	117:129	arg1	NOTCH1					105:110	NOTCH1	105:110	NOTCH1	105:110	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	1	67	theme	transmembrane	117:129	arg1	receptor					131:138	a transmembrane receptor	115:138	a transmembrane receptor in metazoans that is linked to a variety of disorders	115:192	NOTCH1 is a transmembrane receptor in metazoans that is linked to a variety of disorders.
36565355	7	68	theme	O-fucose	801:808	arg1	EGF27					818:822	EGF27	818:822	EGF27	818:822	It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
36565355	7	68	theme	O-fucose	801:808	arg1	site					810:813	the O-fucose site	797:813	the O-fucose site of EGF27	797:822	It has been shown that the loss of the O-fucose site of EGF27 alters NOTCH1 activity.
36906118	1	0	link	N-linked	79:86	arg1	modification					134:145	a crucial post-translational modification	105:145	a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA)	105:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	0	link	N-linked	79:86	arg1	glycosylation					88:100	N-linked glycosylation	79:100	N-linked glycosylation	79:100	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	4	1	theme	CHO	888:890	arg1	cells					893:897	Chinese hamster ovary (CHO) cells	865:897	Chinese hamster ovary (CHO) cells	865:897	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	5	2	link	linked	1114:1119	arg1	feature					1160:1166	an important glycan feature	1140:1166	an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1140:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	2	link	linked	1114:1119	arg1	core-fucosylation					1121:1137	α-1,6 linked core-fucosylation	1108:1137	α-1,6 linked core-fucosylation	1108:1137	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	6	3	from	impact	1298:1303	arg1	pathway					1334:1340	the cellular fucosylation pathway	1308:1340	the cellular fucosylation pathway	1308:1340	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	3	4	theme	pathways	695:702	arg1	modulation					667:676	modulation	667:676	modulation of glycosylation pathways	667:702	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	6	5	theme	impact	1298:1303	arg1	mode					1275:1278	the intra-cellular mode	1256:1278	the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation	1256:1377	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	3	6	theme	Small	526:530	arg1	regulators					572:581	known regulators	566:581	known regulators of entire gene networks	566:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	6	theme	Small	526:530	arg1	miRNAs					554:559	miRNAs	554:559	miRNAs	554:559	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	6	theme	Small	526:530	arg1	microRNAs					543:551	Small non-coding microRNAs	526:551	Small non-coding microRNAs (miRNAs)	526:560	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	7	7	theme	pathways	1660:1667	arg1	engineering					1622:1632	engineering	1622:1632	engineering of N-linked glycosylation pathways	1622:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	5	8	theme	antibody-dependent	1180:1197	arg1	ADCC					1213:1216	ADCC	1213:1216	ADCC	1213:1216	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	8	theme	antibody-dependent	1180:1197	arg1	cytotoxicity					1199:1210	antibody-dependent cytotoxicity	1180:1210	antibody-dependent cytotoxicity (ADCC)	1180:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	6	9	theme	fucosylation	1321:1332	arg1	pathway					1334:1340	the cellular fucosylation pathway	1308:1340	the cellular fucosylation pathway	1308:1340	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	5	10	theme	various	1047:1053	arg1	core-fucosylation					1121:1137	α-1,6 linked core-fucosylation	1108:1137	α-1,6 linked core-fucosylation	1108:1137	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	10	theme	various	1047:1053	arg1	sialylation					1091:1101	sialylation	1091:1101	sialylation	1091:1101	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	10	theme	various	1047:1053	arg1	galactosylation					1074:1088	galactosylation	1074:1088	galactosylation	1074:1088	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	10	theme	various	1047:1053	arg1	moieties					1055:1062	various moieties	1047:1062	various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1047:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	11	theme	complete	974:981	arg1	library					995:1001	a complete miRNA mimic library	972:1001	a complete miRNA mimic library	972:1001	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	7	12	theme	biology	1473:1479	arg1	approach					1481:1488	a synthetic biology approach	1461:1488	a synthetic biology approach utilizing rational design of artificial miRNAs	1461:1535	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	3	13	contain	have	611:614	arg1	regulators					572:581	known regulators	566:581	known regulators of entire gene networks	566:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	13	contain	have	611:614	arg2	potential					630:638	the potential	626:638	the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering	626:727	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	13	contain	have	611:614	arg1	miRNAs					554:559	miRNAs	554:559	miRNAs	554:559	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	13	contain	have	611:614	arg1	microRNAs					543:551	Small non-coding microRNAs	526:551	Small non-coding microRNAs (miRNAs)	526:560	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	5	14	theme	high-throughput	943:957	arg1	screening					959:967	a functional high-throughput screening	930:967	a functional high-throughput screening of a complete miRNA mimic library	930:1001	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	15	theme	miRNA	983:987	arg1	library					995:1001	a complete miRNA mimic library	972:1001	a complete miRNA mimic library	972:1001	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	6	16	theme	cellular	1312:1319	arg1	pathway					1334:1340	the cellular fucosylation pathway	1308:1340	the cellular fucosylation pathway	1308:1340	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	4	17	theme	natural	773:779	arg1	miRNAs					781:786	novel identified natural miRNAs	756:786	novel identified natural miRNAs	756:786	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	5	18	theme	functional	932:941	arg1	screening					959:967	a functional high-throughput screening	930:967	a functional high-throughput screening of a complete miRNA mimic library	930:1001	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	4	19	theme	Chinese	865:871	arg1	cells					893:897	Chinese hamster ovary (CHO) cells	865:897	Chinese hamster ovary (CHO) cells	865:897	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	4	20	link	N-linked	812:819	arg1	patterns					835:842	N-linked glycosylation patterns	812:842	N-linked glycosylation patterns	812:842	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	6	21	theme	Subsequent	1220:1229	arg1	validation					1231:1240	Subsequent validation	1220:1240	Subsequent validation	1220:1240	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	7	22	from	effects	1428:1434	arg1	structure					1450:1458	the glycan structure	1439:1458	the glycan structure	1439:1458	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	1	23	theme	monoclonal	185:194	arg1	mAbs					208:211	mAbs	208:211	mAbs	208:211	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	23	theme	monoclonal	185:194	arg1	antibodies					196:205	monoclonal antibodies	185:205	monoclonal antibodies (mAbs)	185:212	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	7	24	theme	N-linked	1637:1644	arg1	pathways					1660:1667	N-linked glycosylation pathways	1637:1667	N-linked glycosylation pathways	1637:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	25	theme	miRNAs	1530:1535	arg1	design					1509:1514	rational design	1500:1514	rational design of artificial miRNAs	1500:1535	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	26	theme	glycosylation	1646:1658	arg1	pathways					1660:1667	N-linked glycosylation pathways	1637:1667	N-linked glycosylation pathways	1637:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	5	27	theme	library	995:1001	arg1	screening					959:967	a functional high-throughput screening	930:967	a functional high-throughput screening of a complete miRNA mimic library	930:1001	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	2	28	theme	patterns	391:398	arg1	expression					340:349	expression	340:349	expression of desired and consistent glycosylation patterns	340:398	However, expression of desired and consistent glycosylation patterns remains a constant challenge for the biopharmaceutical industry and constitutes the need for tools to engineer glycosylation.
36906118	0	29	theme	novel	2:6	arg1	system					8:13	A novel system	0:13	A novel system for glycosylation engineering by natural and artificial miRNAs	0:76	A novel system for glycosylation engineering by natural and artificial miRNAs.
36906118	5	30	theme	important	1143:1151	arg1	feature					1160:1166	an important glycan feature	1140:1166	an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1140:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	30	theme	important	1143:1151	arg1	core-fucosylation					1121:1137	α-1,6 linked core-fucosylation	1108:1137	α-1,6 linked core-fucosylation	1108:1137	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	4	31	theme	ovary	881:885	arg1	cells					893:897	Chinese hamster ovary (CHO) cells	865:897	Chinese hamster ovary (CHO) cells	865:897	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	1	32	theme	N-linked	79:86	arg1	modification					134:145	a crucial post-translational modification	105:145	a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA)	105:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	32	theme	N-linked	79:86	arg1	glycosylation					88:100	N-linked glycosylation	79:100	N-linked glycosylation	79:100	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	2	33	theme	glycosylation	377:389	arg1	patterns					391:398	desired and consistent glycosylation patterns	354:398	desired and consistent glycosylation patterns	354:398	However, expression of desired and consistent glycosylation patterns remains a constant challenge for the biopharmaceutical industry and constitutes the need for tools to engineer glycosylation.
36906118	4	34	theme	hamster	873:879	arg1	cells					893:897	Chinese hamster ovary (CHO) cells	865:897	Chinese hamster ovary (CHO) cells	865:897	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	3	35	theme	entire	586:591	arg1	networks					598:605	entire gene networks	586:605	entire gene networks	586:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	2	36	theme	consistent	366:375	arg1	patterns					391:398	desired and consistent glycosylation patterns	354:398	desired and consistent glycosylation patterns	354:398	However, expression of desired and consistent glycosylation patterns remains a constant challenge for the biopharmaceutical industry and constitutes the need for tools to engineer glycosylation.
36906118	2	37	theme	biopharmaceutical	437:453	arg1	industry					455:462	the biopharmaceutical industry	433:462	the biopharmaceutical industry	433:462	However, expression of desired and consistent glycosylation patterns remains a constant challenge for the biopharmaceutical industry and constitutes the need for tools to engineer glycosylation.
36906118	7	38	theme	phenotypic	1417:1426	arg1	effects					1428:1434	phenotypic effects	1417:1434	phenotypic effects on the glycan structure	1417:1458	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	3	39	theme	known	566:570	arg1	regulators					572:581	known regulators	566:581	known regulators of entire gene networks	566:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	39	theme	known	566:570	arg1	microRNAs					543:551	Small non-coding microRNAs	526:551	Small non-coding microRNAs (miRNAs)	526:560	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	7	40	theme	miRNAs	1571:1576	arg1	tools					1612:1616	novel, versatile and tune-able tools	1581:1616	novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways	1581:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	40	theme	miRNAs	1571:1576	arg1	potential					1558:1566	the potential	1554:1566	the potential of miRNAs	1554:1576	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	41	theme	rational	1500:1507	arg1	design					1509:1514	rational design	1500:1514	rational design of artificial miRNAs	1500:1535	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	4	42	theme	novel	756:760	arg1	miRNAs					781:786	novel identified natural miRNAs	756:786	novel identified natural miRNAs	756:786	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	3	43	theme	non-coding	532:541	arg1	regulators					572:581	known regulators	566:581	known regulators of entire gene networks	566:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	43	theme	non-coding	532:541	arg1	miRNAs					554:559	miRNAs	554:559	miRNAs	554:559	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	43	theme	non-coding	532:541	arg1	microRNAs					543:551	Small non-coding microRNAs	526:551	Small non-coding microRNAs (miRNAs)	526:560	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	1	44	theme	critical	297:304	arg1	attribute					314:322	a critical quality attribute	295:322	a critical quality attribute (CQA)	295:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	44	theme	critical	297:304	arg1	CQA					325:327	CQA	325:327	CQA	325:327	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	45	theme	capable	215:221	arg1	mAbs					208:211	mAbs	208:211	mAbs	208:211	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	45	theme	capable	215:221	arg1	antibodies					196:205	monoclonal antibodies	185:205	monoclonal antibodies (mAbs)	185:212	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	6	46	from	action	1283:1288	arg1	pathway					1334:1340	the cellular fucosylation pathway	1308:1340	the cellular fucosylation pathway	1308:1340	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	2	47	theme	constant	410:417	arg1	challenge					419:427	a constant challenge	408:427	a constant challenge for the biopharmaceutical industry	408:462	However, expression of desired and consistent glycosylation patterns remains a constant challenge for the biopharmaceutical industry and constitutes the need for tools to engineer glycosylation.
36906118	0	48	theme	glycosylation	19:31	arg1	engineering					33:43	glycosylation engineering	19:43	glycosylation engineering by natural and artificial miRNAs	19:76	A novel system for glycosylation engineering by natural and artificial miRNAs.
36906118	1	49	theme	quality	306:312	arg1	attribute					314:322	a critical quality attribute	295:322	a critical quality attribute (CQA)	295:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	49	theme	quality	306:312	arg1	CQA					325:327	CQA	325:327	CQA	325:327	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	7	50	theme	synthetic	1463:1471	arg1	approach					1481:1488	a synthetic biology approach	1461:1488	a synthetic biology approach utilizing rational design of artificial miRNAs	1461:1535	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	5	51	theme	α-1,6	1108:1112	arg1	feature					1160:1166	an important glycan feature	1140:1166	an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1140:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	51	theme	α-1,6	1108:1112	arg1	core-fucosylation					1121:1137	α-1,6 linked core-fucosylation	1108:1137	α-1,6 linked core-fucosylation	1108:1137	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	6	52	theme	action	1283:1288	arg1	mode					1275:1278	the intra-cellular mode	1256:1278	the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation	1256:1377	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	7	53	theme	glycan	1443:1448	arg1	structure					1450:1458	the glycan structure	1439:1458	the glycan structure	1439:1458	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	54	theme	favourable	1714:1723	arg1	phenotypes					1725:1734	favourable phenotypes	1714:1734	favourable phenotypes	1714:1734	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	0	55	theme	natural	48:54	arg1	miRNAs					71:76	natural and artificial miRNAs	48:76	natural and artificial miRNAs	48:76	A novel system for glycosylation engineering by natural and artificial miRNAs.
36906118	5	56	theme	linked	1114:1119	arg1	feature					1160:1166	an important glycan feature	1140:1166	an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1140:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	56	theme	linked	1114:1119	arg1	core-fucosylation					1121:1137	α-1,6 linked core-fucosylation	1108:1137	α-1,6 linked core-fucosylation	1108:1137	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	3	57	theme	gene	593:596	arg1	networks					598:605	entire gene networks	586:605	entire gene networks	586:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	1	58	theme	crucial	107:113	arg1	modification					134:145	a crucial post-translational modification	105:145	a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA)	105:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	58	theme	crucial	107:113	arg1	glycosylation					88:100	N-linked glycosylation	79:100	N-linked glycosylation	79:100	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	7	59	theme	multiplex	1386:1394	arg1	approaches					1396:1405	multiplex approaches	1386:1405	multiplex approaches	1386:1405	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	60	theme	versatile	1588:1596	arg1	tools					1612:1616	novel, versatile and tune-able tools	1581:1616	novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways	1581:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	60	theme	versatile	1588:1596	arg1	potential					1558:1566	the potential	1554:1566	the potential of miRNAs	1554:1576	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	3	61	theme	networks	598:605	arg1	regulators					572:581	known regulators	566:581	known regulators of entire gene networks	566:605	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	3	61	theme	networks	598:605	arg1	microRNAs					543:551	Small non-coding microRNAs	526:551	Small non-coding microRNAs (miRNAs)	526:560	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	1	62	theme	post-translational	115:132	arg1	modification					134:145	a crucial post-translational modification	105:145	a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA)	105:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	62	theme	post-translational	115:132	arg1	glycosylation					88:100	N-linked glycosylation	79:100	N-linked glycosylation	79:100	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	5	63	theme	miRNA	1021:1025	arg1	sequences					1027:1035	82 miRNA sequences	1018:1035	82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1018:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	3	64	theme	glycosylation	681:693	arg1	pathways					695:702	glycosylation pathways	681:702	glycosylation pathways	681:702	Small non-coding microRNAs (miRNAs) are known regulators of entire gene networks and have therefore the potential of being used as tools for modulation of glycosylation pathways and for glycoengineering.
36906118	6	65	theme	intra-cellular	1260:1273	arg1	mode					1275:1278	the intra-cellular mode	1256:1278	the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation	1256:1377	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	7	66	link	N-linked	1637:1644	arg1	pathways					1660:1667	N-linked glycosylation pathways	1637:1667	N-linked glycosylation pathways	1637:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	4	67	theme	identified	762:771	arg1	miRNAs					781:786	novel identified natural miRNAs	756:786	novel identified natural miRNAs	756:786	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	7	68	theme	glycosylation	1683:1695	arg1	patterns					1697:1704	glycosylation patterns	1683:1704	glycosylation patterns	1683:1704	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	6	69	theme	miRNAs	1345:1350	arg1	action					1283:1288	action	1283:1288	action	1283:1288	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	6	69	theme	miRNAs	1345:1350	arg1	impact					1298:1303	the impact	1294:1303	the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation	1294:1377	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	7	70	theme	novel	1581:1585	arg1	tools					1612:1616	novel, versatile and tune-able tools	1581:1616	novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways	1581:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	70	theme	novel	1581:1585	arg1	potential					1558:1566	the potential	1554:1566	the potential of miRNAs	1554:1576	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	1	71	theme	biopharmaceuticals	155:172	arg1	modification					134:145	a crucial post-translational modification	105:145	a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA)	105:328	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	71	theme	biopharmaceuticals	155:172	arg1	glycosylation					88:100	N-linked glycosylation	79:100	N-linked glycosylation	79:100	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	0	72	theme	artificial	60:69	arg1	miRNAs					71:76	natural and artificial miRNAs	48:76	natural and artificial miRNAs	48:76	A novel system for glycosylation engineering by natural and artificial miRNAs.
36906118	7	73	theme	artificial	1519:1528	arg1	miRNAs					1530:1535	artificial miRNAs	1519:1535	artificial miRNAs	1519:1535	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	4	74	theme	glycosylation	821:833	arg1	patterns					835:842	N-linked glycosylation patterns	812:842	N-linked glycosylation patterns	812:842	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	5	75	dep	library	995:1001	arg1	mimic					989:993	mimic	989:993	mimic	989:993	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	1	76	theme	many	150:153	arg1	biopharmaceuticals					155:172	many biopharmaceuticals	150:172	many biopharmaceuticals	150:172	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	1	76	theme	many	150:153	arg1	antibodies					196:205	monoclonal antibodies	185:205	monoclonal antibodies (mAbs)	185:212	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	6	77	from	mode	1275:1278	arg1	pathway					1334:1340	the cellular fucosylation pathway	1308:1340	the cellular fucosylation pathway	1308:1340	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36906118	1	78	theme	biological	242:251	arg1	effect					253:258	their biological effect	236:258	their biological effect	236:258	N-linked glycosylation is a crucial post-translational modification of many biopharmaceuticals, including monoclonal antibodies (mAbs), capable of modifying their biological effect in patients and thus considered as a critical quality attribute (CQA).
36906118	5	79	theme	glycan	1153:1158	arg1	feature					1160:1166	an important glycan feature	1140:1166	an important glycan feature influencing antibody-dependent cytotoxicity (ADCC)	1140:1217	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	5	79	theme	glycan	1153:1158	arg1	core-fucosylation					1121:1137	α-1,6 linked core-fucosylation	1108:1137	α-1,6 linked core-fucosylation	1108:1137	We established a workflow for a functional high-throughput screening of a complete miRNA mimic library and identified 82 miRNA sequences affecting various moieties including galactosylation, sialylation, and α-1,6 linked core-fucosylation, an important glycan feature influencing antibody-dependent cytotoxicity (ADCC).
36906118	4	80	theme	N-linked	812:819	arg1	patterns					835:842	N-linked glycosylation patterns	812:842	N-linked glycosylation patterns	812:842	Here, we demonstrate that novel identified natural miRNAs are capable of altering N-linked glycosylation patterns on mAbs expressed in Chinese hamster ovary (CHO) cells.
36906118	7	81	theme	tune-able	1602:1610	arg1	tools					1612:1616	novel, versatile and tune-able tools	1581:1616	novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways	1581:1667	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	7	81	theme	tune-able	1602:1610	arg1	potential					1558:1566	the potential	1554:1566	the potential of miRNAs	1554:1576	While multiplex approaches increased phenotypic effects on the glycan structure, a synthetic biology approach utilizing rational design of artificial miRNAs further enhanced the potential of miRNAs as novel, versatile and tune-able tools for engineering of N-linked glycosylation pathways and expressed glycosylation patterns towards favourable phenotypes.
36906118	2	82	theme	desired	354:360	arg1	patterns					391:398	desired and consistent glycosylation patterns	354:398	desired and consistent glycosylation patterns	354:398	However, expression of desired and consistent glycosylation patterns remains a constant challenge for the biopharmaceutical industry and constitutes the need for tools to engineer glycosylation.
36906118	6	83	from	pathway	1334:1340	arg1	mode					1275:1278	the intra-cellular mode	1256:1278	the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation	1256:1377	Subsequent validation shed light on the intra-cellular mode of action and the impact on the cellular fucosylation pathway of miRNAs reducing core-fucosylation.
36282863	8	0	theme	transcript	1069:1078	arg1	overrepresentation					1080:1097	improved transcript overrepresentation analyses and glycosylation pathway identification	1060:1147	overrepresentation	1080:1097	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	5	1	theme	glycosylation	679:691	arg1	initiation					693:702	glycosylation initiation	679:702	glycosylation initiation	679:702	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases is described.
36282863	6	2	theme	linear	778:783	arg1	strings					785:791	IUPAC linear strings	772:791	IUPAC linear strings	772:791	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	1	3	theme	enzymatic	140:148	arg1	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	7	4	theme	Gene	998:1001	arg1	Ontology					1003:1010	Gene Ontology	998:1010	the Gene Ontology (GO) biological processes	994:1036	All GlycoEnzOnto knowledge is integrated with the Gene Ontology (GO) biological processes.
36282863	8	5	dep	KEGG	1190:1193	arg1	e.g.					1185:1188	e.g.	1185:1188	e.g.	1185:1188	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	10	6	dep	//github.com/neel-lab/GlycoEnzOnto	1326:1359	arg1	https					1320:1324	AVAILABILITY https	1307:1324	AVAILABILITY https	1307:1324	AVAILABILITY https://github.com/neel-lab/GlycoEnzOnto.
36282863	5	7	theme	initiation	693:702	arg1	phases					751:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases is described.
36282863	7	8	dep	Ontology	1003:1010	arg1	GO					1013:1014	GO	1013:1014	GO	1013:1014	All GlycoEnzOnto knowledge is integrated with the Gene Ontology (GO) biological processes.
36282863	11	9	from	online	1439:1444	arg1	available					1411:1419	available	1411:1419	available	1411:1419	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
36282863	6	10	theme	knowledge-based	898:912	arg1	curation					914:921	automated knowledge-based curation	888:921	automated knowledge-based curation of biochemical networks	888:945	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	11	11	theme	INFORMATION	1376:1386	arg1	data					1402:1405	SUPPLEMENTARY INFORMATION Supplementary data	1362:1405	SUPPLEMENTARY INFORMATION Supplementary data	1362:1405	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
36282863	7	12	theme	biological	1017:1026	arg1	processes					1028:1036	the Gene Ontology (GO) biological processes	994:1036	the Gene Ontology (GO) biological processes	994:1036	All GlycoEnzOnto knowledge is integrated with the Gene Ontology (GO) biological processes.
36282863	8	13	theme	improved	1060:1067	arg1	overrepresentation					1080:1097	improved transcript overrepresentation analyses and glycosylation pathway identification	1060:1147	overrepresentation	1080:1097	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	5	14	theme	elongation/branching	705:724	arg1	phases					751:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases is described.
36282863	6	15	theme	automated	888:896	arg1	curation					914:921	automated knowledge-based curation	888:921	automated knowledge-based curation of biochemical networks	888:945	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	11	16	theme	Supplementary	1388:1400	arg1	data					1402:1405	SUPPLEMENTARY INFORMATION Supplementary data	1362:1405	SUPPLEMENTARY INFORMATION Supplementary data	1362:1405	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
36282863	6	17	theme	IUPAC	772:776	arg1	strings					785:791	IUPAC linear strings	772:791	IUPAC linear strings	772:791	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	1	18	theme	proteins	116:123	arg1	proteins					116:123	proteins	116:123	proteins having related enzymatic, metabolic, transport, structural and cofactor functions	116:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	1	18	theme	proteins	116:123	arg1	set					109:111	a set	107:111	a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions	107:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	1	19	dep	MOTIVATION	69:78	arg1	glycoEnzymes					85:96	glycoEnzymes	85:96	MOTIVATION The 'glycoEnzymes'	69:97	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	8	20	theme	glycosylation	1112:1124	arg1	pathway					1126:1132	glycosylation pathway	1112:1132	glycosylation pathway	1112:1132	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	2	21	theme	glycoEnzyme	263:273	arg1	properties					275:284	glycoEnzyme properties	263:284	glycoEnzyme properties	263:284	Currently there is no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways.
36282863	1	22	theme	metabolic	151:159	arg1	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	0	23	theme	Molecular	40:48	arg1	Ontology					59:66	Molecular Function Ontology	40:66	Molecular Function Ontology	40:66	GlycoEnzOnto: A GlycoEnzyme Pathway and Molecular Function Ontology.
36282863	5	24	theme	enzyme	665:670	arg1	role					652:655	The role	648:655	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases	648:756	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases is described.
36282863	11	25	theme	SUPPLEMENTARY	1362:1374	arg1	data					1402:1405	SUPPLEMENTARY INFORMATION Supplementary data	1362:1405	SUPPLEMENTARY INFORMATION Supplementary data	1362:1405	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
36282863	1	26	contain	having	125:130	arg2	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	1	26	contain	having	125:130	arg1	proteins					116:123	proteins	116:123	proteins having related enzymatic, metabolic, transport, structural and cofactor functions	116:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	8	27	theme	other	1161:1165	arg1	schema					1177:1182	other available schema	1161:1182	other available schema	1161:1182	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	6	28	theme	steps	871:875	arg1	descriptions					835:846	systematic human/machine readable descriptions	801:846	systematic human/machine readable descriptions of individual reaction steps	801:875	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	7	29	theme	GlycoEnzOnto	952:963	arg1	knowledge					965:973	All GlycoEnzOnto knowledge	948:973	All GlycoEnzOnto knowledge	948:973	All GlycoEnzOnto knowledge is integrated with the Gene Ontology (GO) biological processes.
36282863	1	30	theme	transport	162:170	arg1	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	6	31	theme	reaction	862:869	arg1	steps					871:875	individual reaction steps	851:875	individual reaction steps	851:875	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	3	32	theme	139	431:433	arg1	pathways					449:456	139 glycosylation pathways	431:456	139 glycosylation pathways	431:456	RESULTS We present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments.
36282863	0	33	theme	GlycoEnzyme	16:26	arg1	Pathway					28:34	A GlycoEnzyme Pathway	14:34	A GlycoEnzyme Pathway	14:34	GlycoEnzOnto: A GlycoEnzyme Pathway and Molecular Function Ontology.
36282863	4	34	theme	glycosyl-substrate/donor	574:597	arg1	transport					599:607	glycosyl-substrate/donor transport	574:607	glycosyl-substrate/donor transport	574:607	The pathways described regulate nucleotide-sugar metabolism, glycosyl-substrate/donor transport, glycan biosynthesis, and degradation.
36282863	6	35	theme	individual	851:860	arg1	steps					871:875	individual reaction steps	851:875	individual reaction steps	851:875	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	9	36	theme	holistic	1244:1251	arg1	resource					1270:1277	a holistic glycoinformatics resource	1242:1277	a holistic glycoinformatics resource for systems-level analyses	1242:1304	Overall, GlycoEnzOnto represents a holistic glycoinformatics resource for systems-level analyses.
36282863	1	37	theme	structural	173:182	arg1	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	4	38	theme	glycan	610:615	arg1	biosynthesis					617:628	glycan biosynthesis	610:628	glycan biosynthesis	610:628	The pathways described regulate nucleotide-sugar metabolism, glycosyl-substrate/donor transport, glycan biosynthesis, and degradation.
36282863	9	39	theme	glycoinformatics	1253:1268	arg1	resource					1270:1277	a holistic glycoinformatics resource	1242:1277	a holistic glycoinformatics resource for systems-level analyses	1242:1304	Overall, GlycoEnzOnto represents a holistic glycoinformatics resource for systems-level analyses.
36282863	11	40	theme	Bioinformatics	1424:1437	arg1	online					1439:1444	Bioinformatics online	1424:1444	Bioinformatics online	1424:1444	SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
36282863	2	41	dep	ontology	242:249	arg1	relate					293:298	relate	293:298	to relate them to glycan biosynthesis pathways	290:335	Currently there is no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways.
36282863	2	41	dep	ontology	242:249	arg1	describe					254:261	describe	254:261	to describe glycoEnzyme properties	251:284	Currently there is no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways.
36282863	1	42	theme	cofactor	188:195	arg1	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36282863	3	43	theme	glycosylation	435:447	arg1	pathways					449:456	139 glycosylation pathways	431:456	139 glycosylation pathways	431:456	RESULTS We present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments.
36282863	4	44	theme	nucleotide-sugar	545:560	arg1	metabolism					562:571	nucleotide-sugar metabolism	545:571	nucleotide-sugar metabolism	545:571	The pathways described regulate nucleotide-sugar metabolism, glycosyl-substrate/donor transport, glycan biosynthesis, and degradation.
36282863	0	45	theme	Function	50:57	arg1	Ontology					59:66	Molecular Function Ontology	40:66	Molecular Function Ontology	40:66	GlycoEnzOnto: A GlycoEnzyme Pathway and Molecular Function Ontology.
36282863	3	46	dep	RESULTS	338:344	arg1	present					349:355	present	349:355	present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments	349:510	RESULTS We present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments.
36282863	9	47	theme	systems-level	1283:1295	arg1	analyses					1297:1304	systems-level analyses	1283:1304	systems-level analyses	1283:1304	Overall, GlycoEnzOnto represents a holistic glycoinformatics resource for systems-level analyses.
36282863	3	48	theme	cellular	490:497	arg1	compartments					499:510	22 cellular compartments	487:510	22 cellular compartments	487:510	RESULTS We present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments.
36282863	3	49	theme	human	398:402	arg1	glycoEnzymes					404:415	403 human glycoEnzymes	394:415	403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments	394:510	RESULTS We present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments.
36282863	6	50	theme	readable	826:833	arg1	descriptions					835:846	systematic human/machine readable descriptions	801:846	systematic human/machine readable descriptions of individual reaction steps	801:875	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	8	51	dep	overrepresentation	1080:1097	arg1	analyses					1099:1106	analyses	1099:1106	analyses	1099:1106	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	8	51	dep	overrepresentation	1080:1097	arg1	identification					1134:1147	identification	1134:1147	identification	1134:1147	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	10	52	theme	AVAILABILITY	1307:1318	arg1	https					1320:1324	AVAILABILITY https	1307:1324	AVAILABILITY https	1307:1324	AVAILABILITY https://github.com/neel-lab/GlycoEnzOnto.
36282863	5	53	theme	capping/termination	731:749	arg1	phases					751:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases is described.
36282863	6	54	theme	networks	938:945	arg1	curation					914:921	automated knowledge-based curation	888:921	automated knowledge-based curation of biochemical networks	888:945	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	6	55	theme	human/machine	812:824	arg1	descriptions					835:846	systematic human/machine readable descriptions	801:846	systematic human/machine readable descriptions of individual reaction steps	801:875	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	2	56	theme	biosynthesis	315:326	arg1	pathways					328:335	glycan biosynthesis pathways	308:335	glycan biosynthesis pathways	308:335	Currently there is no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways.
36282863	6	57	theme	biochemical	926:936	arg1	networks					938:945	biochemical networks	926:945	biochemical networks	926:945	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	6	58	theme	systematic	801:810	arg1	descriptions					835:846	systematic human/machine readable descriptions	801:846	systematic human/machine readable descriptions of individual reaction steps	801:875	IUPAC linear strings present systematic human/machine readable descriptions of individual reaction steps and enable automated knowledge-based curation of biochemical networks.
36282863	2	59	theme	glycan	308:313	arg1	pathways					328:335	glycan biosynthesis pathways	308:335	glycan biosynthesis pathways	308:335	Currently there is no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways.
36282863	7	60	theme	Ontology	1003:1010	arg1	processes					1028:1036	the Gene Ontology (GO) biological processes	994:1036	the Gene Ontology (GO) biological processes	994:1036	All GlycoEnzOnto knowledge is integrated with the Gene Ontology (GO) biological processes.
36282863	2	61	theme	established	230:240	arg1	ontology					242:249	no established ontology	227:249	no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways	227:335	Currently there is no established ontology to describe glycoEnzyme properties and to relate them to glycan biosynthesis pathways.
36282863	3	62	theme	molecular	463:471	arg1	functions					473:481	134 molecular functions	459:481	134 molecular functions	459:481	RESULTS We present GlycoEnzOnto, an ontology describing 403 human glycoEnzymes curated along 139 glycosylation pathways, 134 molecular functions and 22 cellular compartments.
36282863	5	63	from	role	652:655	arg1	phases					751:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	the glycosylation initiation, elongation/branching, and capping/termination phases	675:756	The role of each enzyme in the glycosylation initiation, elongation/branching, and capping/termination phases is described.
36282863	8	64	theme	available	1167:1175	arg1	schema					1177:1182	other available schema	1161:1182	other available schema	1161:1182	GlycoEnzOnto enables improved transcript overrepresentation analyses and glycosylation pathway identification compared to other available schema, e.g. KEGG and Reactome.
36282863	0	65	dep	GlycoEnzOnto	0:11	arg1	Ontology					59:66	Molecular Function Ontology	40:66	Molecular Function Ontology	40:66	GlycoEnzOnto: A GlycoEnzyme Pathway and Molecular Function Ontology.
36282863	0	65	dep	GlycoEnzOnto	0:11	arg1	Pathway					28:34	A GlycoEnzyme Pathway	14:34	A GlycoEnzyme Pathway	14:34	GlycoEnzOnto: A GlycoEnzyme Pathway and Molecular Function Ontology.
36282863	1	66	theme	related	132:138	arg1	functions					197:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	related enzymatic, metabolic, transport, structural and cofactor functions	132:205	MOTIVATION The 'glycoEnzymes' include a set of proteins having related enzymatic, metabolic, transport, structural and cofactor functions.
36825496	3	0	theme	vibrational	310:320	arg1	spectroscopy					322:333	ion vibrational spectroscopy	306:333	ion vibrational spectroscopy	306:333	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	5	1	theme	initial	855:861	arg1	residue					863:869	the initial residue	851:869	the initial residue	851:869	Additionally, we report a new type of fucose migration, which does not feature any change of mass and therefore had not been previously reported: it consists of a local migration where the fucose changes its position remaining on the initial residue.
36825496	2	2	gly	fucosylated	181:191	arg1	glycans					193:199	fucosylated glycans	181:199	fucosylated glycans	181:199	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	5	3	theme	new	647:649	arg1	type					651:654	a new type	645:654	a new type	645:654	Additionally, we report a new type of fucose migration, which does not feature any change of mass and therefore had not been previously reported: it consists of a local migration where the fucose changes its position remaining on the initial residue.
36825496	6	4	theme	glycomics	956:964	arg1	data					966:969	glycomics data	956:969	glycomics data	956:969	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	3	5	dep	Lewis	389:393	arg1	trisaccharides					421:434	trisaccharides	421:434	trisaccharides	421:434	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	0	6	theme	Fucose	0:5	arg1	Pathways					17:24	Fucose Migration Pathways	0:24	Fucose Migration Pathways	0:24	Fucose Migration Pathways Identified Using Infrared Spectroscopy.
36825496	4	7	theme	fucose	582:587	arg1	migration					589:597	fucose migration	582:597	fucose migration	582:597	Our findings demonstrate that the structure of fragment ions resulting from fucose migration can be characterized.
36825496	5	8	theme	mass	714:717	arg1	change					704:709	any change	700:709	any change of mass	700:717	Additionally, we report a new type of fucose migration, which does not feature any change of mass and therefore had not been previously reported: it consists of a local migration where the fucose changes its position remaining on the initial residue.
36825496	2	9	theme	spectrometry	271:282	arg1	analysis					284:291	mass spectrometry analysis	266:291	mass spectrometry analysis	266:291	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	6	10	theme	mass	1029:1032	arg1	spectrometry					1034:1045	mass spectrometry	1029:1045	mass spectrometry	1029:1045	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	2	11	theme	main	146:149	arg1	obstacle					151:158	A main obstacle	144:158	A main obstacle to the sequencing of fucosylated glycans	144:199	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	2	11	theme	main	146:149	arg1	migration					208:216	the migration	204:216	the migration	204:216	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	3	12	theme	group	405:409	arg1	antigen					413:419	blood group H antigen	399:419	blood group H antigen	399:419	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	1	13	theme	ubiquitous	78:87	arg1	Fucose					66:71	Fucose	66:71	Fucose	66:71	Fucose is a ubiquitous monosaccharide associated to major classes of glycans.
36825496	1	13	theme	ubiquitous	78:87	arg1	monosaccharide					89:102	a ubiquitous monosaccharide	76:102	a ubiquitous monosaccharide associated to major classes of glycans	76:141	Fucose is a ubiquitous monosaccharide associated to major classes of glycans.
36825496	0	14	theme	Migration	7:15	arg1	Pathways					17:24	Fucose Migration Pathways	0:24	Fucose Migration Pathways	0:24	Fucose Migration Pathways Identified Using Infrared Spectroscopy.
36825496	5	15	theme	migration	666:674	arg1	type					651:654	a new type	645:654	a new type	645:654	Additionally, we report a new type of fucose migration, which does not feature any change of mass and therefore had not been previously reported: it consists of a local migration where the fucose changes its position remaining on the initial residue.
36825496	3	16	theme	antigen	413:419	arg1	fragments					376:384	fucosylated fragments	364:384	fucosylated fragments of Lewis and blood group H antigen trisaccharides	364:434	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	3	17	theme	Lewis	389:393	arg1	fragments					376:384	fucosylated fragments	364:384	fucosylated fragments of Lewis and blood group H antigen trisaccharides	364:434	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	3	18	gly	fucosylated	364:374	arg1	fragments					376:384	fucosylated fragments	364:384	fucosylated fragments of Lewis and blood group H antigen trisaccharides	364:434	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	3	19	theme	fucosylated	364:374	arg1	fragments					376:384	fucosylated fragments	364:384	fucosylated fragments of Lewis and blood group H antigen trisaccharides	364:434	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	6	20	theme	essential	928:936	arg1	glycans					916:922	glycans	916:922	glycans	916:922	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	6	20	theme	essential	928:936	arg1	step					938:941	an essential step	925:941	an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry	925:1045	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	3	21	theme	fragments	376:384	arg1	structure					351:359	the structure	347:359	the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides	347:434	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	4	22	theme	ions	562:565	arg1	structure					540:548	the structure	536:548	the structure of fragment ions resulting from fucose migration	536:597	Our findings demonstrate that the structure of fragment ions resulting from fucose migration can be characterized.
36825496	2	23	theme	fucosylated	181:191	arg1	glycans					193:199	fucosylated glycans	181:199	fucosylated glycans	181:199	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	1	24	theme	major	118:122	arg1	classes					124:130	major classes	118:130	major classes of glycans	118:141	Fucose is a ubiquitous monosaccharide associated to major classes of glycans.
36825496	6	25	theme	underlying	997:1006	arg1	processes					1008:1016	underlying processes	997:1016	underlying processes	997:1016	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	0	26	theme	Infrared	43:50	arg1	Spectroscopy					52:63	Infrared Spectroscopy	43:63	Infrared Spectroscopy	43:63	Fucose Migration Pathways Identified Using Infrared Spectroscopy.
36825496	4	27	theme	fragment	553:560	arg1	ions					562:565	fragment ions	553:565	fragment ions	553:565	Our findings demonstrate that the structure of fragment ions resulting from fucose migration can be characterized.
36825496	2	28	from	misinterpretations	244:261	arg1	analysis					284:291	mass spectrometry analysis	266:291	mass spectrometry analysis	266:291	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	3	29	theme	H	411:411	arg1	antigen					413:419	blood group H antigen	399:419	blood group H antigen	399:419	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	6	30	theme	glycans	916:922	arg1	characterization					896:911	the characterization	892:911	the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry	892:1045	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	5	31	theme	fucose	659:664	arg1	migration					666:674	fucose migration	659:674	fucose migration	659:674	Additionally, we report a new type of fucose migration, which does not feature any change of mass and therefore had not been previously reported: it consists of a local migration where the fucose changes its position remaining on the initial residue.
36825496	2	32	theme	fucose	221:226	arg1	obstacle					151:158	A main obstacle	144:158	A main obstacle to the sequencing of fucosylated glycans	144:199	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	2	32	theme	fucose	221:226	arg1	migration					208:216	the migration	204:216	the migration	204:216	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	3	33	theme	blood	399:403	arg1	antigen					413:419	blood group H antigen	399:419	blood group H antigen	399:419	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	3	34	theme	ion	306:308	arg1	spectroscopy					322:333	ion vibrational spectroscopy	306:333	ion vibrational spectroscopy	306:333	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	3	35	theme	fucose	482:487	arg1	linkage					467:473	linkage	467:473	linkage	467:473	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	3	35	theme	fucose	482:487	arg1	position					454:461	position	454:461	position	454:461	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	1	36	theme	glycans	135:141	arg1	classes					124:130	major classes	118:130	major classes of glycans	118:141	Fucose is a ubiquitous monosaccharide associated to major classes of glycans.
36825496	2	37	theme	mass	266:269	arg1	analysis					284:291	mass spectrometry analysis	266:291	mass spectrometry analysis	266:291	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	6	38	dep	step	938:941	arg1	understand					986:995	understand	986:995	to understand underlying processes at play in mass spectrometry	983:1045	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	6	38	dep	step	938:941	arg1	interpret					946:954	interpret	946:954	to interpret glycomics data	943:969	Our approach allows the characterization of glycans, an essential step to interpret glycomics data, as well as to understand underlying processes at play in mass spectrometry.
36825496	2	39	theme	glycans	193:199	arg1	sequencing					167:176	the sequencing	163:176	the sequencing of fucosylated glycans	163:199	A main obstacle to the sequencing of fucosylated glycans is the migration of fucose, which leads to misinterpretations in mass spectrometry analysis.
36825496	3	40	dep	position	454:461	arg1	the					450:452	the	450:452	the	450:452	Here, using ion vibrational spectroscopy, we resolve the structure of fucosylated fragments of Lewis and blood group H antigen trisaccharides and we unveil the position and linkage of the fucose after migration.
36825496	5	41	theme	local	784:788	arg1	migration					790:798	a local migration	782:798	a local migration where the fucose changes its position remaining on the initial residue	782:869	Additionally, we report a new type of fucose migration, which does not feature any change of mass and therefore had not been previously reported: it consists of a local migration where the fucose changes its position remaining on the initial residue.
36977665	5	0	dep	tag	747:749	arg1	group					767:771	a carrier group	757:771	a carrier group for the neutral glycan	757:794	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	3	1	theme	small	348:352	arg1	size					364:367	small molecular size	348:367	small molecular size	348:367	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	6	2	theme	branched	946:953	arg1	glycans					955:961	distinct branched glycans	937:961	distinct branched glycans	937:961	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	3	theme	obtained	802:809	arg1	data					820:823	The obtained nanopore data	798:823	The obtained nanopore data	798:823	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	3	4	theme	charge	377:382	arg1	density					384:390	low charge density	373:390	low charge density	373:390	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	4	5	theme	aerolysin	523:531	arg1	nanopore					533:540	a wild-type aerolysin nanopore	511:540	a wild-type aerolysin nanopore	511:540	Here we show that glycan sensing can be achieved using a wild-type aerolysin nanopore by introducing a facile glycan derivatization strategy.
36977665	5	6	theme	impressive	629:638	arg1	blockages					648:656	impressive current blockages	629:656	impressive current blockages	629:656	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	2	7	theme	sequence	318:325	arg1	glycan					327:332	sequence glycan	318:332	sequence glycan	318:332	Nanopore-based single-molecule sensing offers the potential to elucidate glycan structure and even sequence glycan.
36977665	6	8	theme	machine	1004:1010	arg1	learning					1012:1019	machine learning	1004:1019	machine learning methods	1004:1027	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	5	9	theme	current	640:646	arg1	blockages					648:656	impressive current blockages	629:656	impressive current blockages	629:656	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	1	10	theme	Structural	58:67	arg1	complexity					69:78	Structural complexity	58:78	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching	58:171	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	6	11	theme	learning	1012:1019	arg1	methods					1021:1027	machine learning methods	1004:1027	machine learning methods	1004:1027	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	12	with	glycans	887:893	arg1	numbers					924:930	variable monosaccharide numbers	900:930	variable monosaccharide numbers	900:930	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	3	13	theme	low	373:375	arg1	density					384:390	low charge density	373:390	low charge density	373:390	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	6	14	theme	nanopore	811:818	arg1	data					820:823	The obtained nanopore data	798:823	The obtained nanopore data	798:823	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	15	theme	monosaccharide	909:922	arg1	numbers					924:930	variable monosaccharide numbers	900:930	variable monosaccharide numbers	900:930	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	5	16	theme	glycan	602:607	arg1	molecule					609:616	The glycan molecule	598:616	The glycan molecule	598:616	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	1	17	theme	glycans	83:89	arg1	complexity					69:78	Structural complexity	58:78	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching	58:171	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	3	18	theme	glycan	448:453	arg1	detection					435:443	direct nanopore detection	419:443	direct nanopore detection of glycan	419:453	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	4	19	theme	derivatization	573:586	arg1	strategy					588:595	a facile glycan derivatization strategy	557:595	a facile glycan derivatization strategy	557:595	Here we show that glycan sensing can be achieved using a wild-type aerolysin nanopore by introducing a facile glycan derivatization strategy.
36977665	1	20	from	diversities	108:118	arg1	composition					123:133	composition	123:133	composition	123:133	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	1	20	from	diversities	108:118	arg1	configuration					144:156	configuration	144:156	configuration	144:156	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	1	20	from	diversities	108:118	arg1	branching					163:171	branching	163:171	branching	163:171	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	1	20	from	diversities	108:118	arg1	linage					136:141	linage	136:141	linage	136:141	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	6	21	theme	stereoisomers	872:884	arg1	identification					836:849	the identification	832:849	the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans	832:961	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	0	22	theme	glycans	25:31	arg1	Identification					0:13	Identification	0:13	Identification of tagged glycans with a protein	0:46	Identification of tagged glycans with a protein nanopore.
36977665	4	23	theme	glycan	566:571	arg1	strategy					588:595	a facile glycan derivatization strategy	557:595	a facile glycan derivatization strategy	557:595	Here we show that glycan sensing can be achieved using a wild-type aerolysin nanopore by introducing a facile glycan derivatization strategy.
36977665	7	24	theme	nanopore	1104:1111	arg1	profiling					1120:1128	nanopore glycan profiling	1104:1128	nanopore glycan profiling	1104:1128	The presented nanopore sensing strategy for glycans paves the way towards nanopore glycan profiling and potentially sequencing.
36977665	6	25	dep	permit	825:830	arg1	use					997:999	the use	993:999	the use of machine learning methods	993:1027	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	25	dep	permit	825:830	arg1	either					964:969	either	964:969	either	964:969	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	1	26	theme	structural	198:207	arg1	analysis					209:216	structural analysis	198:216	structural analysis	198:216	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	3	27	theme	glycans	395:401	arg1	size					364:367	small molecular size	348:367	small molecular size	348:367	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	3	27	theme	glycans	395:401	arg1	density					384:390	low charge density	373:390	low charge density	373:390	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	7	28	theme	glycan	1113:1118	arg1	profiling					1120:1128	nanopore glycan profiling	1104:1128	nanopore glycan profiling	1104:1128	The presented nanopore sensing strategy for glycans paves the way towards nanopore glycan profiling and potentially sequencing.
36977665	6	29	theme	variable	900:907	arg1	numbers					924:930	variable monosaccharide numbers	900:930	variable monosaccharide numbers	900:930	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	30	dep	either	964:969	arg1	independently					971:983	independently	971:983	independently	971:983	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	31	with	stereoisomers	872:884	arg1	numbers					924:930	variable monosaccharide numbers	900:930	variable monosaccharide numbers	900:930	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	5	32	theme	neutral	781:787	arg1	glycan					789:794	the neutral glycan	777:794	the neutral glycan	777:794	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	1	33	attach	derived	91:97	arg1	diversities					108:118	the diversities	104:118	the diversities in composition, linage, configuration, and branching	104:171	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	1	33	attach	derived	91:97	arg2	glycans					83:89	glycans	83:89	glycans derived from the diversities in composition, linage, configuration, and branching	83:171	Structural complexity of glycans derived from the diversities in composition, linage, configuration, and branching considerably complicates structural analysis.
36977665	3	34	dep	size	364:367	arg1	the					344:346	the	344:346	the	344:346	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	0	35	with	glycans	25:31	arg1	protein					40:46	a protein	38:46	a protein	38:46	Identification of tagged glycans with a protein nanopore.
36977665	3	36	theme	direct	419:424	arg1	detection					435:443	direct nanopore detection	419:443	direct nanopore detection of glycan	419:453	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	5	37	theme	carrier	759:765	arg1	group					767:771	a carrier group	757:771	a carrier group for the neutral glycan	757:794	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	4	38	theme	glycan	474:479	arg1	sensing					481:487	glycan sensing	474:487	glycan sensing	474:487	Here we show that glycan sensing can be achieved using a wild-type aerolysin nanopore by introducing a facile glycan derivatization strategy.
36977665	3	39	theme	nanopore	426:433	arg1	detection					435:443	direct nanopore detection	419:443	direct nanopore detection of glycan	419:453	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	4	40	theme	facile	559:564	arg1	strategy					588:595	a facile glycan derivatization strategy	557:595	a facile glycan derivatization strategy	557:595	Here we show that glycan sensing can be achieved using a wild-type aerolysin nanopore by introducing a facile glycan derivatization strategy.
36977665	2	41	theme	Nanopore-based	219:232	arg1	sensing					250:256	Nanopore-based single-molecule sensing	219:256	Nanopore-based single-molecule sensing	219:256	Nanopore-based single-molecule sensing offers the potential to elucidate glycan structure and even sequence glycan.
36977665	2	42	theme	single-molecule	234:248	arg1	sensing					250:256	Nanopore-based single-molecule sensing	219:256	Nanopore-based single-molecule sensing	219:256	Nanopore-based single-molecule sensing offers the potential to elucidate glycan structure and even sequence glycan.
36977665	7	43	theme	presented	1034:1042	arg1	strategy					1061:1068	The presented nanopore sensing strategy	1030:1068	The presented nanopore sensing strategy for glycans	1030:1080	The presented nanopore sensing strategy for glycans paves the way towards nanopore glycan profiling and potentially sequencing.
36977665	5	44	theme	aromatic	721:728	arg1	tag					747:749	an aromatic group-containing tag	718:749	an aromatic group-containing tag (plus a carrier group for the neutral glycan)	718:795	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	2	45	theme	glycan	292:297	arg1	structure					299:307	glycan structure	292:307	glycan structure	292:307	Nanopore-based single-molecule sensing offers the potential to elucidate glycan structure and even sequence glycan.
36977665	7	46	theme	nanopore	1044:1051	arg1	strategy					1061:1068	The presented nanopore sensing strategy	1030:1068	The presented nanopore sensing strategy for glycans	1030:1080	The presented nanopore sensing strategy for glycans paves the way towards nanopore glycan profiling and potentially sequencing.
36977665	5	47	theme	group-containing	730:745	arg1	tag					747:749	an aromatic group-containing tag	718:749	an aromatic group-containing tag (plus a carrier group for the neutral glycan)	718:795	The glycan molecule can induce impressive current blockages when moving through the nanopore after being connected with an aromatic group-containing tag (plus a carrier group for the neutral glycan).
36977665	6	48	theme	regio-	861:866	arg1	identification					836:849	the identification	832:849	the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans	832:961	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	7	49	theme	sensing	1053:1059	arg1	strategy					1061:1068	The presented nanopore sensing strategy	1030:1068	The presented nanopore sensing strategy for glycans	1030:1080	The presented nanopore sensing strategy for glycans paves the way towards nanopore glycan profiling and potentially sequencing.
36977665	6	50	with	glycans	955:961	arg1	numbers					924:930	variable monosaccharide numbers	900:930	variable monosaccharide numbers	900:930	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	3	51	theme	molecular	354:362	arg1	size					364:367	small molecular size	348:367	small molecular size	348:367	However, the small molecular size and low charge density of glycans have restricted direct nanopore detection of glycan.
36977665	6	52	theme	glycan	854:859	arg1	regio-					861:866	glycan regio-	854:866	glycan regio-	854:866	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	53	with	regio-	861:866	arg1	numbers					924:930	variable monosaccharide numbers	900:930	variable monosaccharide numbers	900:930	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	54	theme	distinct	937:944	arg1	glycans					955:961	distinct branched glycans	937:961	distinct branched glycans	937:961	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	6	55	theme	methods	1021:1027	arg1	use					997:999	the use	993:999	the use of machine learning methods	993:1027	The obtained nanopore data permit the identification of glycan regio- and stereoisomers, glycans with variable monosaccharide numbers, and distinct branched glycans, either independently or with the use of machine learning methods.
36977665	4	56	theme	wild-type	513:521	arg1	nanopore					533:540	a wild-type aerolysin nanopore	511:540	a wild-type aerolysin nanopore	511:540	Here we show that glycan sensing can be achieved using a wild-type aerolysin nanopore by introducing a facile glycan derivatization strategy.
36977665	0	57	theme	tagged	18:23	arg1	glycans					25:31	tagged glycans	18:31	tagged glycans with a protein	18:46	Identification of tagged glycans with a protein nanopore.
37218360	11	0	theme	CD16a	1425:1429	arg1	region					1431:1436	a single CD16a region	1416:1436	a single CD16a region	1416:1436	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	2	1	theme	therapies	374:382	arg1	efficacy					335:342	the efficacy	331:342	the efficacy of many monoclonal antibodies therapies	331:382	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	7	2	with	treatment	913:921	arg1	kifunensine					928:938	kifunensine	928:938	kifunensine	928:938	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	7	2	with	treatment	913:921	arg1	inhibitor					944:952	an inhibitor	941:952	an inhibitor of asparagine-linked (N-)glycan processing	941:995	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	4	3	theme	multiple	588:595	arg1	therapies					597:605	multiple therapies	588:605	multiple therapies	588:605	Thus, strategies to increase NK cell activity are expected to improve multiple therapies.
37218360	11	4	theme	N162	1455:1458	arg1	glycan					1460:1465	the N162 glycan	1451:1465	the N162 glycan	1451:1465	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	9	5	theme	YTS-CD16a	1205:1213	arg1	cells					1215:1219	cultured YTS-CD16a cells	1196:1219	cultured YTS-CD16a cells	1196:1219	Treating primary human NK cells and cultured YTS-CD16a cells with kifunensine doubled ADCC in a CD16a-dependent manner.
37218360	14	6	gly	glycoforms	1845:1854	arg1	CD16a					1839:1843	optimal antibody and CD16a glycoforms	1818:1854	CD16a	1839:1843	Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.
37218360	5	7	theme	cell	639:642	arg1	engineering					653:663	NK cell receptor engineering	636:663	NK cell receptor engineering	636:663	Both cytokine treatment and NK cell receptor engineering are being explored to increase ADCC.
37218360	6	8	theme	cellular	799:806	arg1	processes					808:816	cellular processes	799:816	cellular processes	799:816	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	13	9	theme	cell	1794:1797	arg1	ADCC					1799:1802	NK cell ADCC	1791:1802	NK cell ADCC	1791:1802	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	9	10	theme	CD16a-dependent	1256:1270	arg1	manner					1272:1277	a CD16a-dependent manner	1254:1277	a CD16a-dependent manner	1254:1277	Treating primary human NK cells and cultured YTS-CD16a cells with kifunensine doubled ADCC in a CD16a-dependent manner.
37218360	7	11	theme	cultured	1024:1031	arg1	cells					1042:1046	cultured human NK cells	1024:1046	cultured human NK cells	1024:1046	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	12	12	theme	afucosylated	1632:1643	arg1	antibodies					1645:1654	afucosylated antibodies	1632:1654	afucosylated antibodies	1632:1654	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	10	13	from	affinity	1338:1345	arg1	surface					1371:1377	the NK cell surface	1359:1377	the NK cell surface	1359:1377	Kifunensine treatment also increased the antibody-binding affinity of CD16a on the NK cell surface.
37218360	1	14	theme	Novel	124:128	arg1	approaches					130:139	Novel approaches	124:139	Novel approaches	124:139	Novel approaches are required to improve the efficacy of immunotherapies and increase the proportion of patients who experience a benefit.
37218360	2	15	theme	Antibody-dependent	263:280	arg1	ADCC					310:313	ADCC	310:313	ADCC	310:313	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	2	15	theme	Antibody-dependent	263:280	arg1	cytotoxicity					296:307	Antibody-dependent cell-mediated cytotoxicity	263:307	Antibody-dependent cell-mediated cytotoxicity (ADCC)	263:314	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	12	16	theme	kifunensine	1594:1604	arg1	treatment					1606:1614	kifunensine treatment	1594:1614	kifunensine treatment	1594:1614	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	11	17	theme	N-glycan	1520:1527	arg1	composition					1529:1539	the N-glycan composition	1516:1539	the N-glycan composition	1516:1539	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	7	18	link	asparagine-linked	957:973	arg1	processing					986:995	asparagine-linked (N-)glycan processing	957:995	asparagine-linked (N-)glycan processing	957:995	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	13	19	theme	important	1762:1770	arg1	factor					1772:1777	an important factor	1759:1777	an important factor that limits NK cell ADCC	1759:1802	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	13	19	theme	important	1762:1770	arg1	processing					1745:1754	native N-glycan processing	1729:1754	native N-glycan processing	1729:1754	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	4	20	dep	strategies	524:533	arg1	increase					538:545	increase	538:545	to increase NK cell activity	535:562	Thus, strategies to increase NK cell activity are expected to improve multiple therapies.
37218360	7	21	theme	glycan	979:984	arg1	processing					986:995	asparagine-linked (N-)glycan processing	957:995	asparagine-linked (N-)glycan processing	957:995	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	14	22	theme	greatest	1885:1892	arg1	activity					1899:1906	the greatest ADCC activity	1881:1906	the greatest ADCC activity	1881:1906	Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.
37218360	12	23	theme	NK	1567:1568	arg1	activity					1575:1582	NK cell activity	1567:1582	NK cell activity following kifunensine treatment	1567:1614	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	3	24	theme	Natural	385:391	arg1	NK					401:402	NK	401:402	NK	401:402	Natural killer (NK) cells mediate ADCC, though responses are highly variable and depend on prior treatment as well as other factors.
37218360	3	24	theme	Natural	385:391	arg1	killer					393:398	Natural killer	385:398	Natural killer (NK) cells	385:409	Natural killer (NK) cells mediate ADCC, though responses are highly variable and depend on prior treatment as well as other factors.
37218360	0	25	theme	human	96:100	arg1	cells					117:121	human natural killer cells	96:121	human natural killer cells	96:121	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	13	26	theme	N-glycan	1736:1743	arg1	factor					1772:1777	an important factor	1759:1777	an important factor that limits NK cell ADCC	1759:1802	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	13	26	theme	N-glycan	1736:1743	arg1	processing					1745:1754	native N-glycan processing	1729:1754	native N-glycan processing	1729:1754	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	10	27	theme	antibody-binding	1321:1336	arg1	affinity					1338:1345	the antibody-binding affinity	1317:1345	the antibody-binding affinity of CD16a on the NK cell surface	1317:1377	Kifunensine treatment also increased the antibody-binding affinity of CD16a on the NK cell surface.
37218360	0	28	theme	killer	110:115	arg1	cells					117:121	human natural killer cells	96:121	human natural killer cells	96:121	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	7	29	theme	asparagine-linked	957:973	arg1	processing					986:995	asparagine-linked (N-)glycan processing	957:995	asparagine-linked (N-)glycan processing	957:995	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	4	30	theme	NK	547:548	arg1	activity					555:562	NK cell activity	547:562	NK cell activity	547:562	Thus, strategies to increase NK cell activity are expected to improve multiple therapies.
37218360	8	31	theme	binding	1079:1085	arg1	assays					1087:1092	binding assays	1079:1092	binding assays	1079:1092	We also probed affinity using binding assays and CD16a structure with nuclear magnetic resonance spectroscopy.
37218360	12	32	theme	observed	1546:1553	arg1	increase					1555:1562	The observed increase	1542:1562	The observed increase in NK cell activity following kifunensine treatment	1542:1614	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	2	33	theme	antibodies	363:372	arg1	therapies					374:382	many monoclonal antibodies therapies	347:382	many monoclonal antibodies therapies	347:382	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	0	34	theme	binding	54:60	arg1	affinity					62:69	antibody binding affinity	45:69	antibody binding affinity	45:69	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	14	35	theme	CD16a	1839:1843	arg1	glycoforms					1845:1854	optimal antibody and CD16a glycoforms	1818:1854	glycoforms	1845:1854	Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.
37218360	10	36	theme	NK	1363:1364	arg1	surface					1371:1377	the NK cell surface	1359:1377	the NK cell surface	1359:1377	Kifunensine treatment also increased the antibody-binding affinity of CD16a on the NK cell surface.
37218360	2	37	theme	many	347:350	arg1	therapies					374:382	many monoclonal antibodies therapies	347:382	many monoclonal antibodies therapies	347:382	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	1	38	theme	patients	228:235	arg1	proportion					214:223	the proportion	210:223	the proportion of patients who experience a benefit	210:260	Novel approaches are required to improve the efficacy of immunotherapies and increase the proportion of patients who experience a benefit.
37218360	8	39	theme	nuclear	1119:1125	arg1	resonance					1136:1144	nuclear magnetic resonance	1119:1144	nuclear magnetic resonance spectroscopy	1119:1157	We also probed affinity using binding assays and CD16a structure with nuclear magnetic resonance spectroscopy.
37218360	9	40	theme	human	1177:1181	arg1	cells					1186:1190	primary human NK cells	1169:1190	primary human NK cells	1169:1190	Treating primary human NK cells and cultured YTS-CD16a cells with kifunensine doubled ADCC in a CD16a-dependent manner.
37218360	8	41	theme	resonance	1136:1144	arg1	spectroscopy					1146:1157	nuclear magnetic resonance spectroscopy	1119:1157	nuclear magnetic resonance spectroscopy	1119:1157	We also probed affinity using binding assays and CD16a structure with nuclear magnetic resonance spectroscopy.
37218360	11	42	theme	single	1418:1423	arg1	region					1431:1436	a single CD16a region	1416:1436	a single CD16a region	1416:1436	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	5	43	theme	receptor	644:651	arg1	engineering					653:663	NK cell receptor engineering	636:663	NK cell receptor engineering	636:663	Both cytokine treatment and NK cell receptor engineering are being explored to increase ADCC.
37218360	3	44	theme	other	503:507	arg1	factors					509:515	other factors	503:515	prior treatment as well as other factors	476:515	Natural killer (NK) cells mediate ADCC, though responses are highly variable and depend on prior treatment as well as other factors.
37218360	7	45	theme	treatment	913:921	arg1	impact					903:908	the impact	899:908	the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC	899:1004	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	9	46	theme	cultured	1196:1203	arg1	cells					1215:1219	cultured YTS-CD16a cells	1196:1219	cultured YTS-CD16a cells	1196:1219	Treating primary human NK cells and cultured YTS-CD16a cells with kifunensine doubled ADCC in a CD16a-dependent manner.
37218360	11	47	theme	proximal	1439:1446	arg1	region					1431:1436	a single CD16a region	1416:1436	a single CD16a region	1416:1436	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	5	48	theme	NK	636:637	arg1	engineering					653:663	NK cell receptor engineering	636:663	NK cell receptor engineering	636:663	Both cytokine treatment and NK cell receptor engineering are being explored to increase ADCC.
37218360	6	49	theme	processes	808:816	arg1	modifications					721:733	Post-translational modifications	702:733	Post-translational modifications	702:733	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	49	theme	processes	808:816	arg1	glycosylation					746:758	glycosylation	746:758	glycosylation	746:758	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	49	theme	processes	808:816	arg1	mediators					786:794	mediators	786:794	mediators of cellular processes	786:816	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	12	50	gly	afucosylated	1632:1643	arg1	antibodies					1645:1654	afucosylated antibodies	1632:1654	afucosylated antibodies	1632:1654	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	1	51	theme	immunotherapies	181:195	arg1	efficacy					169:176	the efficacy	165:176	the efficacy of immunotherapies	165:195	Novel approaches are required to improve the efficacy of immunotherapies and increase the proportion of patients who experience a benefit.
37218360	12	52	from	increase	1555:1562	arg1	activity					1575:1582	NK cell activity	1567:1582	NK cell activity following kifunensine treatment	1567:1614	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	13	53	theme	NK	1791:1792	arg1	ADCC					1799:1802	NK cell ADCC	1791:1802	NK cell ADCC	1791:1802	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	10	54	theme	Kifunensine	1280:1290	arg1	treatment					1292:1300	Kifunensine treatment	1280:1300	Kifunensine treatment	1280:1300	Kifunensine treatment also increased the antibody-binding affinity of CD16a on the NK cell surface.
37218360	11	55	theme	Structural	1380:1389	arg1	interrogation					1391:1403	Structural interrogation	1380:1403	Structural interrogation	1380:1403	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	7	56	theme	human	1033:1037	arg1	cells					1042:1046	cultured human NK cells	1024:1046	cultured human NK cells	1024:1046	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	7	57	theme	NK	1039:1040	arg1	cells					1042:1046	cultured human NK cells	1024:1046	cultured human NK cells	1024:1046	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	2	58	theme	cell-mediated	282:294	arg1	ADCC					310:313	ADCC	310:313	ADCC	310:313	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	2	58	theme	cell-mediated	282:294	arg1	cytotoxicity					296:307	Antibody-dependent cell-mediated cytotoxicity	263:307	Antibody-dependent cell-mediated cytotoxicity (ADCC)	263:314	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	0	59	theme	effector	75:82	arg1	function					84:91	effector function	75:91	effector function	75:91	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	14	60	theme	ADCC	1894:1897	arg1	activity					1899:1906	the greatest ADCC activity	1881:1906	the greatest ADCC activity	1881:1906	Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.
37218360	12	61	theme	cell	1570:1573	arg1	activity					1575:1582	NK cell activity	1567:1582	NK cell activity following kifunensine treatment	1567:1614	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	7	62	dep	asparagine-linked	957:973	arg1	N-					976:977	N-	976:977	N-	976:977	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	0	63	theme	natural	102:108	arg1	cells					117:121	human natural killer cells	96:121	human natural killer cells	96:121	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	7	64	theme	processing	986:995	arg1	kifunensine					928:938	kifunensine	928:938	kifunensine	928:938	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	7	64	theme	processing	986:995	arg1	inhibitor					944:952	an inhibitor	941:952	an inhibitor of asparagine-linked (N-)glycan processing	941:995	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	3	65	theme	killer	393:398	arg1	cells					405:409	Natural killer (NK) cells	385:409	Natural killer (NK) cells	385:409	Natural killer (NK) cells mediate ADCC, though responses are highly variable and depend on prior treatment as well as other factors.
37218360	7	66	from	impact	903:908	arg1	ADCC					1001:1004	ADCC	1001:1004	ADCC	1001:1004	We evaluated the impact of treatment with kifunensine, an inhibitor of asparagine-linked (N-)glycan processing, on ADCC using primary and cultured human NK cells.
37218360	0	67	theme	cells	117:121	arg1	function					84:91	effector function	75:91	effector function	75:91	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	0	67	theme	cells	117:121	arg1	affinity					62:69	antibody binding affinity	45:69	antibody binding affinity	45:69	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	5	68	theme	cytokine	613:620	arg1	treatment					622:630	cytokine treatment	613:630	cytokine treatment	613:630	Both cytokine treatment and NK cell receptor engineering are being explored to increase ADCC.
37218360	6	69	theme	Post-translational	702:719	arg1	glycosylation					746:758	glycosylation	746:758	glycosylation	746:758	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	69	theme	Post-translational	702:719	arg1	modifications					721:733	Post-translational modifications	702:733	Post-translational modifications	702:733	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	69	theme	Post-translational	702:719	arg1	strategy					859:866	an alternative strategy	844:866	an alternative strategy to increase ADCC	844:883	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	69	theme	Post-translational	702:719	arg1	mediators					786:794	mediators	786:794	mediators of cellular processes	786:816	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	0	70	theme	N-glycan	11:18	arg1	processing					20:29	N-glycan processing	11:29	N-glycan processing	11:29	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	4	71	theme	cell	550:553	arg1	activity					555:562	NK cell activity	547:562	NK cell activity	547:562	Thus, strategies to increase NK cell activity are expected to improve multiple therapies.
37218360	12	72	theme	additional	1687:1696	arg1	%					1700:1700	an additional 33%	1684:1700	an additional 33%	1684:1700	The observed increase in NK cell activity following kifunensine treatment synergized with afucosylated antibodies, further increasing ADCC by an additional 33%.
37218360	10	73	theme	CD16a	1350:1354	arg1	affinity					1338:1345	the antibody-binding affinity	1317:1345	the antibody-binding affinity of CD16a on the NK cell surface	1317:1377	Kifunensine treatment also increased the antibody-binding affinity of CD16a on the NK cell surface.
37218360	3	74	theme	prior	476:480	arg1	treatment					482:490	prior treatment	476:490	prior treatment as well as other factors	476:515	Natural killer (NK) cells mediate ADCC, though responses are highly variable and depend on prior treatment as well as other factors.
37218360	0	75	theme	antibody	45:52	arg1	affinity					62:69	antibody binding affinity	45:69	antibody binding affinity	45:69	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	11	76	theme	antibody-binding	1475:1490	arg1	interface					1492:1500	the antibody-binding interface	1471:1500	the antibody-binding interface	1471:1500	Structural interrogation identified a single CD16a region, proximal to the N162 glycan and the antibody-binding interface, perturbed by the N-glycan composition.
37218360	8	77	theme	CD16a	1098:1102	arg1	structure					1104:1112	CD16a structure	1098:1112	CD16a structure	1098:1112	We also probed affinity using binding assays and CD16a structure with nuclear magnetic resonance spectroscopy.
37218360	0	78	dep	affinity	62:69	arg1	the					41:43	the	41:43	the	41:43	Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells.
37218360	13	79	theme	native	1729:1734	arg1	factor					1772:1777	an important factor	1759:1777	an important factor that limits NK cell ADCC	1759:1802	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	13	79	theme	native	1729:1734	arg1	processing					1745:1754	native N-glycan processing	1729:1754	native N-glycan processing	1729:1754	These results demonstrate native N-glycan processing is an important factor that limits NK cell ADCC.
37218360	10	80	theme	cell	1366:1369	arg1	surface					1371:1377	the NK cell surface	1359:1377	the NK cell surface	1359:1377	Kifunensine treatment also increased the antibody-binding affinity of CD16a on the NK cell surface.
37218360	2	81	theme	monoclonal	352:361	arg1	therapies					374:382	many monoclonal antibodies therapies	347:382	many monoclonal antibodies therapies	347:382	Antibody-dependent cell-mediated cytotoxicity (ADCC) contributes to the efficacy of many monoclonal antibodies therapies.
37218360	8	82	theme	magnetic	1127:1134	arg1	resonance					1136:1144	nuclear magnetic resonance	1119:1144	nuclear magnetic resonance spectroscopy	1119:1157	We also probed affinity using binding assays and CD16a structure with nuclear magnetic resonance spectroscopy.
37218360	9	83	theme	primary	1169:1175	arg1	cells					1186:1190	primary human NK cells	1169:1190	primary human NK cells	1169:1190	Treating primary human NK cells and cultured YTS-CD16a cells with kifunensine doubled ADCC in a CD16a-dependent manner.
37218360	14	84	theme	optimal	1818:1824	arg1	antibody					1826:1833	optimal antibody and CD16a glycoforms	1818:1854	antibody	1826:1833	Furthermore, optimal antibody and CD16a glycoforms are defined that provide the greatest ADCC activity.
37218360	6	85	theme	alternative	847:857	arg1	modifications					721:733	Post-translational modifications	702:733	Post-translational modifications	702:733	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	85	theme	alternative	847:857	arg1	strategy					859:866	an alternative strategy	844:866	an alternative strategy to increase ADCC	844:883	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	6	85	theme	alternative	847:857	arg1	glycosylation					746:758	glycosylation	746:758	glycosylation	746:758	Post-translational modifications, including glycosylation, are widely recognized as mediators of cellular processes but minimally explored as an alternative strategy to increase ADCC.
37218360	9	86	theme	NK	1183:1184	arg1	cells					1186:1190	primary human NK cells	1169:1190	primary human NK cells	1169:1190	Treating primary human NK cells and cultured YTS-CD16a cells with kifunensine doubled ADCC in a CD16a-dependent manner.
36435009	1	0	theme	segment	275:281	arg1	residue					249:255	the innermost N-acetylglucosamine (GlcNAc) residue	206:255	the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans	206:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	0	theme	segment	275:281	arg1	segment					275:281	the chitobiose segment	260:281	the chitobiose segment of core-fucosylated N-glycans	260:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	1	theme	hexasaccharide	376:389	arg1	structure					391:399	a hexasaccharide structure	374:399	a hexasaccharide structure	374:399	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	2	with	probe	363:367	arg1	structure					391:399	a hexasaccharide structure	374:399	a hexasaccharide structure	374:399	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	3	3	theme	reaction	593:600	arg1	occurrence					566:575	The occurrence	562:575	The occurrence of a hydrolysis reaction	562:600	The occurrence of a hydrolysis reaction was detected by observing an increased fluorescence intensity, ultimately allowing the ENGase activities to be easily and quantitatively evaluated, with the exception of Endo-S.
36435009	1	4	theme	core-fucosylated	286:301	arg1	N-glycans					303:311	core-fucosylated N-glycans	286:311	core-fucosylated N-glycans	286:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	5	theme	fluorescence-quenching-based	68:95	arg1	system					103:108	A fluorescence-quenching-based assay system	66:108	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans,	66:312	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	6	theme	N-glycans	303:311	arg1	segment					275:281	the chitobiose segment	260:281	the chitobiose segment of core-fucosylated N-glycans	260:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	2	7	theme	fucosylated	539:549	arg1	N-glycans					551:559	core fucosylated N-glycans	534:559	core fucosylated N-glycans	534:559	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	3	8	theme	Endo-S	772:777	arg1	exception					759:767	the exception	755:767	the exception of Endo-S	755:777	The occurrence of a hydrolysis reaction was detected by observing an increased fluorescence intensity, ultimately allowing the ENGase activities to be easily and quantitatively evaluated, with the exception of Endo-S.
36435009	1	9	theme	assay	97:101	arg1	system					103:108	A fluorescence-quenching-based assay system	66:108	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans,	66:312	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	2	10	theme	core	534:537	arg1	N-glycans					551:559	core fucosylated N-glycans	534:559	core fucosylated N-glycans	534:559	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	2	11	gly	fucosylated	539:549	arg1	N-glycans					551:559	core fucosylated N-glycans	534:559	core fucosylated N-glycans	534:559	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	0	12	theme	fluorogenic	2:12	arg1	probe					14:18	A fluorogenic probe	0:18	A fluorogenic probe for core-fucosylated glycan-preferred ENGase	0:63	A fluorogenic probe for core-fucosylated glycan-preferred ENGase.
36435009	2	13	theme	W251N	483:487	arg1	mutant					489:494	Endo-M W251N mutant	476:494	Endo-M W251N mutant	476:494	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	1	14	theme	innermost	210:218	arg1	residue					249:255	the innermost N-acetylglucosamine (GlcNAc) residue	206:255	the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans	206:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	14	theme	innermost	210:218	arg1	segment					275:281	the chitobiose segment	260:281	the chitobiose segment of core-fucosylated N-glycans	260:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	2	15	theme	Endo-M	476:481	arg1	mutant					489:494	Endo-M W251N mutant	476:494	Endo-M W251N mutant	476:494	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	4	16	theme	examined	854:861	arg1	ENGases					863:869	the examined ENGases	850:869	the examined ENGases	850:869	The obtained results clearly indicated the substrate specificities of the examined ENGases.
36435009	1	17	gly	core-fucosylated	286:301	arg1	N-glycans					303:311	core-fucosylated N-glycans	286:311	core-fucosylated N-glycans	286:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	3	18	theme	hydrolysis	582:591	arg1	reaction					593:600	a hydrolysis reaction	580:600	a hydrolysis reaction	580:600	The occurrence of a hydrolysis reaction was detected by observing an increased fluorescence intensity, ultimately allowing the ENGase activities to be easily and quantitatively evaluated, with the exception of Endo-S.
36435009	1	19	theme	N-acetylglucosamine	220:238	arg1	residue					249:255	the innermost N-acetylglucosamine (GlcNAc) residue	206:255	the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans	206:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	19	theme	N-acetylglucosamine	220:238	arg1	segment					275:281	the chitobiose segment	260:281	the chitobiose segment of core-fucosylated N-glycans	260:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	4	20	theme	substrate	823:831	arg1	specificities					833:845	the substrate specificities	819:845	the substrate specificities of the examined ENGases	819:869	The obtained results clearly indicated the substrate specificities of the examined ENGases.
36435009	3	21	theme	ENGase	689:694	arg1	activities					696:705	the ENGase activities	685:705	the ENGase activities	685:705	The occurrence of a hydrolysis reaction was detected by observing an increased fluorescence intensity, ultimately allowing the ENGase activities to be easily and quantitatively evaluated, with the exception of Endo-S.
36435009	1	22	theme	hydrolytic	127:136	arg1	activity					138:145	the hydrolytic activity	123:145	the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans,	123:312	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	2	23	theme	ENGases	457:463	arg1	Endo-F3					497:503	Endo-F3	497:503	Endo-F3	497:503	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	2	23	theme	ENGases	457:463	arg1	Endo-S					510:515	Endo-S	510:515	Endo-S	510:515	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	2	23	theme	ENGases	457:463	arg1	mutant					489:494	Endo-M W251N mutant	476:494	Endo-M W251N mutant	476:494	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	2	23	theme	ENGases	457:463	arg1	ENGases					457:463	ENGases	457:463	ENGases	457:463	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	2	23	theme	ENGases	457:463	arg1	variety					446:452	a variety	444:452	a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans	444:559	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	0	24	theme	glycan-preferred	41:56	arg1	ENGase					58:63	core-fucosylated glycan-preferred ENGase	24:63	core-fucosylated glycan-preferred ENGase	24:63	A fluorogenic probe for core-fucosylated glycan-preferred ENGase.
36435009	1	25	theme	GlcNAc	241:246	arg1	residue					249:255	the innermost N-acetylglucosamine (GlcNAc) residue	206:255	the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans	206:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	25	theme	GlcNAc	241:246	arg1	segment					275:281	the chitobiose segment	260:281	the chitobiose segment of core-fucosylated N-glycans	260:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	0	26	theme	core-fucosylated	24:39	arg1	ENGase					58:63	core-fucosylated glycan-preferred ENGase	24:63	core-fucosylated glycan-preferred ENGase	24:63	A fluorogenic probe for core-fucosylated glycan-preferred ENGase.
36435009	3	27	theme	increased	631:639	arg1	intensity					654:662	an increased fluorescence intensity	628:662	an increased fluorescence intensity	628:662	The occurrence of a hydrolysis reaction was detected by observing an increased fluorescence intensity, ultimately allowing the ENGase activities to be easily and quantitatively evaluated, with the exception of Endo-S.
36435009	1	28	theme	dual-labeled	338:349	arg1	probe					363:367	a dual-labeled fluorescent probe	336:367	a dual-labeled fluorescent probe with a hexasaccharide structure	336:399	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	29	theme	fluorescent	351:361	arg1	probe					363:367	a dual-labeled fluorescent probe	336:367	a dual-labeled fluorescent probe with a hexasaccharide structure	336:399	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	1	30	dep	system	103:108	arg1	determine					113:121	determine	113:121	to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans,	110:312	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	0	31	gly	core-fucosylated	24:39	arg1	ENGase					58:63	core-fucosylated glycan-preferred ENGase	24:63	core-fucosylated glycan-preferred ENGase	24:63	A fluorogenic probe for core-fucosylated glycan-preferred ENGase.
36435009	4	32	theme	ENGases	863:869	arg1	specificities					833:845	the substrate specificities	819:845	the substrate specificities of the examined ENGases	819:869	The obtained results clearly indicated the substrate specificities of the examined ENGases.
36435009	1	33	theme	endo-β-N-acetylglucosaminidases	150:180	arg1	activity					138:145	the hydrolytic activity	123:145	the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans,	123:312	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
36435009	4	34	theme	obtained	784:791	arg1	results					793:799	The obtained results	780:799	The obtained results	780:799	The obtained results clearly indicated the substrate specificities of the examined ENGases.
36435009	3	35	theme	fluorescence	641:652	arg1	intensity					654:662	an increased fluorescence intensity	628:662	an increased fluorescence intensity	628:662	The occurrence of a hydrolysis reaction was detected by observing an increased fluorescence intensity, ultimately allowing the ENGase activities to be easily and quantitatively evaluated, with the exception of Endo-S.
36435009	2	36	theme	fluorogenic	406:416	arg1	probe					418:422	The fluorogenic probe	402:422	The fluorogenic probe	402:422	The fluorogenic probe was evaluated using a variety of ENGases, including Endo-M W251N mutant, Endo-F3, and Endo-S, which recognize core fucosylated N-glycans.
36435009	1	37	theme	chitobiose	264:273	arg1	segment					275:281	the chitobiose segment	260:281	the chitobiose segment of core-fucosylated N-glycans	260:311	A fluorescence-quenching-based assay system to determine the hydrolytic activity of endo-β-N-acetylglucosaminidases (ENGases), which act on the innermost N-acetylglucosamine (GlcNAc) residue of the chitobiose segment of core-fucosylated N-glycans, was constructed using a dual-labeled fluorescent probe with a hexasaccharide structure.
35370997	4	0	theme	N-oligosaccharides	799:816	arg1	remodeling					781:790	remodeling	781:790	remodeling of its N-oligosaccharides	781:816	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	3	1	theme	Fc	646:647	arg1	fragment					649:656	the Fc fragment	642:656	the Fc fragment	642:656	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	0	2	theme	Inflammation	153:164	arg1	Severity					141:148	the Severity	137:148	the Severity of Inflammation	137:164	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	9	3	theme	F	2196:2196	arg1	digestion					2198:2206	PNGase F digestion	2189:2206	PNGase F digestion	2189:2206	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	13	4	with	content	2924:2930	arg1	fucose					2996:3001	core fucose	2991:3001	core fucose	2991:3001	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	7	5	with	donors	2048:2053	arg1	IgG					1871:1873	up-regulated IgG	1858:1873	up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62)	1858:1939	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	5	with	donors	2048:2053	arg1	patients					1735:1742	HT patients	1732:1742	HT patients	1732:1742	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	5	with	donors	2048:2053	arg1	IgGs					1684:1687	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	IgGs	1684:1687	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	5	with	donors	2048:2053	arg1	Tg					1646:1647	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	Tg	1646:1647	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	6	theme	hypothyroidism	1709:1722	arg1	symptoms					1697:1704	symptoms	1697:1704	symptoms of hypothyroidism (n=68)	1697:1729	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	12	7	theme	sialylation	2725:2735	arg1	modifications					2704:2716	modifications	2704:2716	modifications of IgG sialylation, galactosylation and core-fucosylation	2704:2774	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	7	8	theme	study	2021:2025	arg1	therapy					2012:2018	methimazole therapy	2000:2018	methimazole therapy (study groups)	2000:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	8	theme	study	2021:2025	arg1	groups					2027:2032	study groups	2021:2032	study groups	2021:2032	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	13	9	dep	sialylated	2939:2948	arg1	the					2935:2937	the	2935:2937	the	2935:2937	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	11	10	theme	non-parametric	2574:2587	arg1	test					2589:2592	The Kruskal-Wallis non-parametric test	2555:2592	The Kruskal-Wallis non-parametric test	2555:2592	The Kruskal-Wallis non-parametric test was used to determine the statistical significance of the results (p<0.05).
35370997	7	11	theme	therapy	2012:2018	arg1	result					1990:1995	a result	1988:1995	a result of methimazole therapy (study groups)	1988:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	3	12	theme	IgG	534:536	arg1	structure					538:546	The IgG structure	530:546	The IgG structure	530:546	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	3	12	theme	IgG	534:536	arg1	dependent					588:596	dependent	588:596	dependent	588:596	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	3	13	attach	attached	630:637	arg2	N-glycans					620:628	N-glycans	620:628	N-glycans attached to the Fc fragment	620:656	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	3	13	attach	attached	630:637	arg1	fragment					649:656	the Fc fragment	642:656	the Fc fragment	642:656	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	2	14	theme	inflammatory	508:519	arg1	process					521:527	an ongoing inflammatory process	497:527	an ongoing inflammatory process	497:527	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	7	15	theme	TPO	1679:1681	arg1	IgGs					1684:1687	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	IgGs	1684:1687	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	12	16	theme	IgG	2721:2723	arg1	sialylation					2725:2735	IgG sialylation	2721:2735	IgG sialylation	2721:2735	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	6	17	from	profile	1514:1520	arg1	patients					1528:1535	GD patients	1525:1535	GD patients	1525:1535	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	0	18	from	Effect	71:76	arg1	Disease					104:110	Graves' Disease	96:110	Graves' Disease	96:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	18	from	Effect	71:76	arg1	Thyroiditis					181:191	Hashimoto's Thyroiditis	169:191	Hashimoto's Thyroiditis	169:191	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	3	19	theme	effector	556:563	arg1	functions					565:573	its effector functions	552:573	its effector functions	552:573	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	6	20	theme	N-glycan	1505:1512	arg1	profile					1514:1520	the N-glycan profile	1501:1520	the N-glycan profile in GD patients	1501:1535	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	8	21	attach	isolated	2086:2093	arg2	IgG					2078:2080	IgG	2078:2080	IgG	2078:2080	IgG was isolated from blood serum using protein G affinity chromatography.
35370997	8	21	attach	isolated	2086:2093	arg1	serum					2106:2110	blood serum	2100:2110	blood serum	2100:2110	IgG was isolated from blood serum using protein G affinity chromatography.
35370997	13	22	theme	IgG	2885:2887	arg1	profile					2898:2904	the IgG N-glycan profile	2881:2904	the IgG N-glycan profile	2881:2904	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	14	23	theme	immunosuppressive	3212:3228	arg1	therapy					3230:3236	immunosuppressive therapy	3212:3236	immunosuppressive therapy	3212:3236	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	7	24	theme	level	1979:1983	arg1	stabilization					1958:1970	(n=47) stabilization	1951:1970	(n=47) stabilization of TSH level as a result of methimazole therapy (study groups)	1951:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	3	25	theme	sugar	707:711	arg1	moieties					713:720	Fab sugar moieties	703:720	Fab sugar moieties	703:720	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	1	26	theme	disease	378:384	arg1	therapy					386:392	disease therapy	378:392	disease therapy	378:392	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	10	27	theme	detected	2540:2547	arg1	ions					2549:2552	the detected ions	2536:2552	the detected ions	2536:2552	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	1	28	gly	glycoprotein	253:264	arg1	glycoprotein					253:264	the most abundant glycoprotein	235:264	the most abundant glycoprotein in human blood serum	235:285	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	1	28	gly	glycoprotein	253:264	arg1	G					226:226	immunoglobulin G	211:226	immunoglobulin G (IgG)	211:232	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	14	29	gly	N-glycosylation	3054:3068	arg1	IgG					3073:3075	IgG	3073:3075	IgG	3073:3075	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	4	30	from	role	746:749	arg1	function					771:778	IgG function	767:778	IgG function	767:778	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	13	31	theme	GD	2860:2861	arg1	patients					2863:2870	GD patients	2860:2870	GD patients	2860:2870	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	7	32	with	donors	1605:1610	arg1	IgG					1871:1873	up-regulated IgG	1858:1873	up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62)	1858:1939	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	32	with	donors	1605:1610	arg1	patients					1735:1742	HT patients	1732:1742	HT patients	1732:1742	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	32	with	donors	1605:1610	arg1	IgGs					1684:1687	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	IgGs	1684:1687	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	32	with	donors	1605:1610	arg1	Tg					1646:1647	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	Tg	1646:1647	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	5	33	theme	composition	1208:1218	arg1	alterations					1189:1199	alterations	1189:1199	alterations of the composition of IgG N-glycans	1189:1235	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	6	34	theme	glycosylation	1296:1308	arg1	investigation					1275:1287	a more in-depth investigation	1259:1287	a more in-depth investigation	1259:1287	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	34	theme	glycosylation	1296:1308	arg1	study					1250:1254	The present study	1238:1254	The present study	1238:1254	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	5	35	theme	thyroid	1080:1086	arg1	diseases					1088:1095	autoimmune thyroid diseases	1069:1095	autoimmune thyroid diseases (AITDs)	1069:1103	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	5	35	theme	thyroid	1080:1086	arg1	thyroiditis					1128:1138	Hashimoto's thyroiditis	1116:1138	Hashimoto's thyroiditis (HT)	1116:1143	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	5	35	theme	thyroid	1080:1086	arg1	disease					1157:1163	Graves' disease	1149:1163	Graves' disease (GD)	1149:1168	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	5	35	theme	thyroid	1080:1086	arg1	AITDs					1098:1102	AITDs	1098:1102	AITDs	1098:1102	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	7	36	theme	anti-thyroglobulin	1626:1643	arg1	patients					1735:1742	HT patients	1732:1742	HT patients	1732:1742	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	36	theme	anti-thyroglobulin	1626:1643	arg1	Tg					1646:1647	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	Tg	1646:1647	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	2	37	theme	N-glycan	451:458	arg1	profile					460:466	the IgG N-glycan profile	443:466	the IgG N-glycan profile	443:466	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	2	37	theme	N-glycan	451:458	arg1	indicator					484:492	an indicator	481:492	an indicator of an ongoing inflammatory process	481:527	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	11	38	used	used	2598:2601	arg2	test					2589:2592	The Kruskal-Wallis non-parametric test	2555:2592	The Kruskal-Wallis non-parametric test	2555:2592	The Kruskal-Wallis non-parametric test was used to determine the statistical significance of the results (p<0.05).
35370997	13	39	theme	Methimazole	2825:2835	arg1	therapy					2837:2843	Methimazole therapy	2825:2843	Methimazole therapy implemented in GD patients	2825:2870	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	4	40	theme	autoimmunity	899:910	arg1	development					884:894	the development	880:894	the development of autoimmunity	880:910	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	0	41	from	Changes	0:6	arg1	Autoimmunity					42:53	Thyroid Autoimmunity	34:53	Thyroid Autoimmunity	34:53	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	10	42	from	peaks	2378:2382	arg1	Waters					2396:2401	the Waters	2392:2401	the Waters UNIFI Scientific Information System	2392:2437	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	0	43	theme	Methimazole	81:91	arg1	Effect					71:76	The Modulatory Effect	56:76	The Modulatory Effect of Methimazole in Graves' Disease	56:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	43	theme	Methimazole	81:91	arg1	Changes					0:6	Changes	0:6	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.	0:192	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	43	theme	Methimazole	81:91	arg1	Association					120:130	the Association	116:130	the Association With the Severity of Inflammation in Hashimoto's Thyroiditis	116:191	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	1	44	theme	autoimmunity	324:335	arg1	conditions					310:319	pathological conditions	297:319	pathological conditions of autoimmunity	297:335	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	0	45	from	Autoimmunity	42:53	arg1	Effect					71:76	The Modulatory Effect	56:76	The Modulatory Effect of Methimazole in Graves' Disease	56:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	45	from	Autoimmunity	42:53	arg1	Changes					0:6	Changes	0:6	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.	0:192	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	45	from	Autoimmunity	42:53	arg1	Association					120:130	the Association	116:130	the Association With the Severity of Inflammation in Hashimoto's Thyroiditis	116:191	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	10	46	theme	Information	2420:2430	arg1	System					2432:2437	Scientific Information System	2409:2437	Scientific Information System	2409:2437	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	10	47	dep	values	2494:2499	arg1	the					2477:2479	the	2477:2479	the	2477:2479	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	6	48	from	investigation	1275:1287	arg1	AITDs					1318:1322	both AITDs	1313:1322	both AITDs	1313:1322	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	12	49	theme	symptoms	2815:2822	arg1	severity					2800:2807	the severity	2796:2807	the severity of HT symptoms	2796:2822	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	7	50	theme	gland	1826:1830	arg1	titers					1779:1784	high autoantibody titers	1761:1784	high autoantibody titers	1761:1784	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	50	theme	gland	1826:1830	arg1	destruction					1799:1809	advanced destruction	1790:1809	advanced destruction	1790:1809	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	51	theme	human	1570:1574	arg1	samples					1582:1588	human serum samples	1570:1588	human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors	1570:2053	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	4	52	theme	symptoms	998:1005	arg1	reduction					977:985	the reduction	973:985	the reduction of disease symptoms	973:1005	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	5	53	theme	IgG	1223:1225	arg1	N-glycans					1227:1235	IgG N-glycans	1223:1235	IgG N-glycans	1223:1235	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	0	54	theme	IgG	11:13	arg1	N-Glycosylation					15:29	IgG N-Glycosylation	11:29	IgG N-Glycosylation in Thyroid Autoimmunity	11:53	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	4	55	theme	N-glycans	754:762	arg1	role					746:749	the crucial role	734:749	the crucial role of N-glycans in IgG function	734:778	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	11	56	theme	Kruskal-Wallis	2559:2572	arg1	test					2589:2592	The Kruskal-Wallis non-parametric test	2555:2592	The Kruskal-Wallis non-parametric test	2555:2592	The Kruskal-Wallis non-parametric test was used to determine the statistical significance of the results (p<0.05).
35370997	1	57	theme	human	269:273	arg1	serum					281:285	human blood serum	269:285	human blood serum	269:285	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	8	58	theme	protein	2118:2124	arg1	chromatography					2137:2150	protein G affinity chromatography	2118:2150	protein G affinity chromatography	2118:2150	IgG was isolated from blood serum using protein G affinity chromatography.
35370997	14	59	from	intensification	3114:3128	arg1	HT					3148:3149	HT	3148:3149	HT	3148:3149	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	2	60	theme	N-glycosylation	426:440	arg1	sensitivity					411:421	the high sensitivity	402:421	the high sensitivity of N-glycosylation	402:440	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	4	61	theme	IgG	767:769	arg1	function					771:778	IgG function	767:778	IgG function	767:778	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	12	62	theme	galactosylation	2738:2752	arg1	modifications					2704:2716	modifications	2704:2716	modifications of IgG sialylation, galactosylation and core-fucosylation	2704:2774	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	8	63	theme	affinity	2128:2135	arg1	chromatography					2137:2150	protein G affinity chromatography	2118:2150	protein G affinity chromatography	2118:2150	IgG was isolated from blood serum using protein G affinity chromatography.
35370997	14	64	from	thyroiditis	3133:3143	arg1	HT					3148:3149	HT	3148:3149	HT	3148:3149	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	7	65	theme	HT	1732:1733	arg1	patients					1735:1742	HT patients	1732:1742	HT patients	1732:1742	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	65	theme	HT	1732:1733	arg1	Tg					1646:1647	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	Tg	1646:1647	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	13	66	theme	sialylated	2939:2948	arg1	content					2924:2930	the content	2920:2930	the content of the sialylated and galactosylated oligosaccharides with core fucose	2920:3001	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	10	67	theme	mass-to-charge	2505:2518	arg1	m/z					2528:2530	m/z	2528:2530	m/z	2528:2530	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	10	67	theme	mass-to-charge	2505:2518	arg1	ratios					2520:2525	mass-to-charge ratios	2505:2525	mass-to-charge ratios (m/z)	2505:2531	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	7	68	theme	control	2056:2062	arg1	group					2064:2068	control group	2056:2068	control group	2056:2068	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	69	theme	autoantibody	1766:1777	arg1	titers					1779:1784	high autoantibody titers	1761:1784	high autoantibody titers	1761:1784	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	13	70	theme	galactosylated	2954:2967	arg1	oligosaccharides					2969:2984	galactosylated oligosaccharides	2954:2984	galactosylated oligosaccharides	2954:2984	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	6	71	theme	thyroid	1388:1394	arg1	inflammation					1396:1407	thyroid inflammation	1388:1407	thyroid inflammation	1388:1407	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	1	72	theme	G	226:226	arg1	sensitive					344:352	sensitive	344:352	sensitive	344:352	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	1	72	theme	G	226:226	arg1	N-glycome					198:206	The N-glycome	194:206	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum,	194:286	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	6	73	from	severity	1376:1383	arg1	HT					1440:1441	HT	1440:1441	HT	1440:1441	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	4	74	theme	structure	948:956	arg1	restoration					913:923	restoration	913:923	restoration of their physiological structure	913:956	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	9	75	theme	PNGase	2189:2194	arg1	digestion					2198:2206	PNGase F digestion	2189:2206	PNGase F digestion	2189:2206	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	5	76	theme	diseases	1088:1095	arg1	pathology					1056:1064	the pathology	1052:1064	the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD),	1052:1169	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	0	77	with	Effect	71:76	arg1	Severity					141:148	the Severity	137:148	the Severity of Inflammation	137:164	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	10	78	theme	glucose	2481:2487	arg1	values					2494:2499	glucose unit values	2481:2499	glucose unit values	2481:2499	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	3	79	theme	antigens	678:685	arg1	binding					667:673	the binding	663:673	the binding of antigens	663:685	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	1	80	from	glycoprotein	253:264	arg1	serum					281:285	human blood serum	269:285	human blood serum	269:285	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	14	81	from	HT	3148:3149	arg1	intensification					3114:3128	the intensification	3110:3128	the intensification of thyroiditis in HT	3110:3149	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	10	82	theme	UPLC-MS	2332:2338	arg1	chromatograms					2340:2352	UPLC-MS chromatograms	2332:2352	UPLC-MS chromatograms	2332:2352	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	4	83	theme	physiological	934:946	arg1	structure					948:956	their physiological structure	928:956	their physiological structure	928:956	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	9	84	theme	ultra-performance	2224:2240	arg1	UPLC-MS					2283:2289	UPLC-MS	2283:2289	UPLC-MS	2283:2289	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	9	84	theme	ultra-performance	2224:2240	arg1	spectrometry					2269:2280	ultra-performance liquid chromatography-mass spectrometry	2224:2280	ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)	2224:2290	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	6	85	theme	immunosuppressive	1472:1488	arg1	therapy					1490:1496	immunosuppressive therapy	1472:1496	immunosuppressive therapy	1472:1496	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	7	86	theme	study	1542:1546	arg1	material					1548:1555	The study material	1538:1555	The study material	1538:1555	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	3	87	theme	Fab	703:705	arg1	moieties					713:720	Fab sugar moieties	703:720	Fab sugar moieties	703:720	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	10	88	theme	unit	2489:2492	arg1	values					2494:2499	glucose unit values	2481:2499	glucose unit values	2481:2499	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	9	89	theme	chromatography-mass	2249:2267	arg1	UPLC-MS					2283:2289	UPLC-MS	2283:2289	UPLC-MS	2283:2289	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	9	89	theme	chromatography-mass	2249:2267	arg1	spectrometry					2269:2280	ultra-performance liquid chromatography-mass spectrometry	2224:2280	ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)	2224:2290	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	7	90	theme	hormone	1903:1909	arg1	TSHR					1921:1924	TSHR	1921:1924	TSHR	1921:1924	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	90	theme	hormone	1903:1909	arg1	receptor					1911:1918	thyroid-stimulating hormone receptor	1883:1918	thyroid-stimulating hormone receptor (TSHR) before (n=62)	1883:1939	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	2	91	theme	ongoing	500:506	arg1	process					521:527	an ongoing inflammatory process	497:527	an ongoing inflammatory process	497:527	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	7	92	with	patients	1844:1851	arg1	IgG					1871:1873	up-regulated IgG	1858:1873	up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62)	1858:1939	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	92	with	patients	1844:1851	arg1	patients					1735:1742	HT patients	1732:1742	HT patients	1732:1742	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	92	with	patients	1844:1851	arg1	IgGs					1684:1687	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	IgGs	1684:1687	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	92	with	patients	1844:1851	arg1	Tg					1646:1647	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	Tg	1646:1647	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	93	theme	methimazole	2000:2010	arg1	therapy					2012:2018	methimazole therapy	2000:2018	methimazole therapy (study groups)	2000:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	93	theme	methimazole	2000:2010	arg1	groups					2027:2032	study groups	2021:2032	study groups	2021:2032	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	6	94	theme	present	1242:1248	arg1	investigation					1275:1287	a more in-depth investigation	1259:1287	a more in-depth investigation	1259:1287	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	94	theme	present	1242:1248	arg1	study					1250:1254	The present study	1238:1254	The present study	1238:1254	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	95	theme	N-glycan	1417:1424	arg1	structures					1426:1435	IgG N-glycan structures	1413:1435	IgG N-glycan structures in HT	1413:1441	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	9	96	attach	released	2168:2175	arg2	N-glycans					2153:2161	N-glycans	2153:2161	N-glycans	2153:2161	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	9	96	attach	released	2168:2175	arg1	IgG					2182:2184	IgG	2182:2184	IgG	2182:2184	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	7	97	theme	thyroid-stimulating	1883:1901	arg1	TSHR					1921:1924	TSHR	1921:1924	TSHR	1921:1924	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	97	theme	thyroid-stimulating	1883:1901	arg1	receptor					1911:1918	thyroid-stimulating hormone receptor	1883:1918	thyroid-stimulating hormone receptor (TSHR) before (n=62)	1883:1939	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	98	dep	samples	1582:1588	arg1	group					2064:2068	control group	2056:2068	control group	2056:2068	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	14	99	theme	thyroiditis	3133:3143	arg1	intensification					3114:3128	the intensification	3110:3128	the intensification of thyroiditis in HT	3110:3149	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	7	100	theme	up-regulated	1858:1869	arg1	IgG					1871:1873	up-regulated IgG	1858:1873	up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62)	1858:1939	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	13	101	theme	N-glycan	2889:2896	arg1	profile					2898:2904	the IgG N-glycan profile	2881:2904	the IgG N-glycan profile	2881:2904	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	4	102	theme	pathological	829:840	arg1	changes					842:848	pathological changes	829:848	pathological changes that ultimately contribute to the development of autoimmunity	829:910	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	10	103	theme	ions	2549:2552	arg1	m/z					2528:2530	m/z	2528:2530	m/z	2528:2530	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	10	103	theme	ions	2549:2552	arg1	values					2494:2499	glucose unit values	2481:2499	glucose unit values	2481:2499	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	10	103	theme	ions	2549:2552	arg1	ratios					2520:2525	mass-to-charge ratios	2505:2525	mass-to-charge ratios (m/z)	2505:2531	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	0	104	with	Association	120:130	arg1	Severity					141:148	the Severity	137:148	the Severity of Inflammation	137:164	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	11	105	theme	results	2652:2658	arg1	significance					2632:2643	the statistical significance	2616:2643	the statistical significance of the results (p<0.05)	2616:2667	The Kruskal-Wallis non-parametric test was used to determine the statistical significance of the results (p<0.05).
35370997	9	106	theme	2-aminobenzamide	2298:2313	arg1	labeling					2322:2329	2-aminobenzamide (2-AB) labeling	2298:2329	2-aminobenzamide (2-AB) labeling	2298:2329	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	6	107	theme	therapy	1490:1496	arg1	impact					1462:1467	the impact	1458:1467	the impact of immunosuppressive therapy on the N-glycan profile in GD patients	1458:1535	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	7	108	theme	anti-thyroperoxidase	1657:1676	arg1	IgGs					1684:1687	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	IgGs	1684:1687	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	2	109	theme	process	521:527	arg1	profile					460:466	the IgG N-glycan profile	443:466	the IgG N-glycan profile	443:466	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	2	109	theme	process	521:527	arg1	indicator					484:492	an indicator	481:492	an indicator of an ongoing inflammatory process	481:527	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	7	110	theme	TSH	1975:1977	arg1	level					1979:1983	TSH level	1975:1983	TSH level as a result of methimazole therapy (study groups)	1975:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	12	111	theme	core-fucosylation	2758:2774	arg1	modifications					2704:2716	modifications	2704:2716	modifications of IgG sialylation, galactosylation and core-fucosylation	2704:2774	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	0	112	theme	Modulatory	60:69	arg1	Effect					71:76	The Modulatory Effect	56:76	The Modulatory Effect of Methimazole in Graves' Disease	56:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	112	theme	Modulatory	60:69	arg1	Changes					0:6	Changes	0:6	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.	0:192	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	5	113	theme	published	1021:1029	arg1	data					1031:1034	Our recently published data	1008:1034	Our recently published data	1008:1034	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	6	114	from	impact	1462:1467	arg1	profile					1514:1520	the N-glycan profile	1501:1520	the N-glycan profile in GD patients	1501:1535	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	12	115	theme	obtained	2674:2681	arg1	results					2683:2689	The obtained results	2670:2689	The obtained results	2670:2689	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	0	116	from	N-Glycosylation	15:29	arg1	Autoimmunity					42:53	Thyroid Autoimmunity	34:53	Thyroid Autoimmunity	34:53	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	6	117	theme	in-depth	1266:1273	arg1	investigation					1275:1287	a more in-depth investigation	1259:1287	a more in-depth investigation	1259:1287	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	117	theme	in-depth	1266:1273	arg1	study					1250:1254	The present study	1238:1254	The present study	1238:1254	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	118	theme	IgG	1292:1294	arg1	glycosylation					1296:1308	IgG glycosylation	1292:1308	IgG glycosylation	1292:1308	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	1	119	theme	pathological	297:308	arg1	conditions					310:319	pathological conditions	297:319	pathological conditions of autoimmunity	297:335	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	7	120	theme	GD	1841:1842	arg1	patients					1844:1851	GD patients	1841:1851	GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups)	1841:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	14	121	theme	dynamic	3087:3093	arg1	changes					3095:3101	dynamic changes	3087:3101	dynamic changes	3087:3101	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	2	122	theme	IgG	447:449	arg1	profile					460:466	the IgG N-glycan profile	443:466	the IgG N-glycan profile	443:466	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	2	122	theme	IgG	447:449	arg1	indicator					484:492	an indicator	481:492	an indicator of an ongoing inflammatory process	481:527	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	14	123	theme	GD	3164:3165	arg1	autoimmunity					3167:3178	GD autoimmunity	3164:3178	GD autoimmunity	3164:3178	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	7	124	theme	n=47	1952:1955	arg1	stabilization					1958:1970	(n=47) stabilization	1951:1970	(n=47) stabilization of TSH level as a result of methimazole therapy (study groups)	1951:2033	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	9	125	theme	liquid	2242:2247	arg1	UPLC-MS					2283:2289	UPLC-MS	2283:2289	UPLC-MS	2283:2289	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	9	125	theme	liquid	2242:2247	arg1	spectrometry					2269:2280	ultra-performance liquid chromatography-mass spectrometry	2224:2280	ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)	2224:2290	N-glycans were released from IgG by PNGase F digestion and analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) after 2-aminobenzamide (2-AB) labeling.
35370997	14	126	theme	IgG	3073:3075	arg1	N-glycosylation					3054:3068	N-glycosylation	3054:3068	N-glycosylation of IgG	3054:3075	Our results suggest that N-glycosylation of IgG undergoes dynamic changes during the intensification of thyroiditis in HT, and that in GD autoimmunity it is affected significantly by immunosuppressive therapy.
35370997	7	127	theme	elevated	1617:1624	arg1	patients					1735:1742	HT patients	1732:1742	HT patients	1732:1742	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	127	theme	elevated	1617:1624	arg1	Tg					1646:1647	elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs	1617:1687	Tg	1646:1647	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	10	128	theme	Scientific	2409:2418	arg1	System					2432:2437	Scientific Information System	2409:2437	Scientific Information System	2409:2437	UPLC-MS chromatograms were integrated into 25 peaks (GP) in the Waters UNIFI Scientific Information System, and N-glycans were assigned based on the glucose unit values and mass-to-charge ratios (m/z) of the detected ions.
35370997	5	129	theme	autoimmune	1069:1078	arg1	diseases					1088:1095	autoimmune thyroid diseases	1069:1095	autoimmune thyroid diseases (AITDs)	1069:1103	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	5	129	theme	autoimmune	1069:1078	arg1	thyroiditis					1128:1138	Hashimoto's thyroiditis	1116:1138	Hashimoto's thyroiditis (HT)	1116:1143	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	5	129	theme	autoimmune	1069:1078	arg1	disease					1157:1163	Graves' disease	1149:1163	Graves' disease (GD)	1149:1168	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	5	129	theme	autoimmune	1069:1078	arg1	AITDs					1098:1102	AITDs	1098:1102	AITDs	1098:1102	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	7	130	theme	thyroid	1818:1824	arg1	n=113					1833:1837	n=113	1833:1837	n=113	1833:1837	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	7	130	theme	thyroid	1818:1824	arg1	gland					1826:1830	the thyroid gland	1814:1830	the thyroid gland (n=113)	1814:1838	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	6	131	theme	GD	1525:1526	arg1	patients					1528:1535	GD patients	1525:1535	GD patients	1525:1535	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	132	from	structures	1426:1435	arg1	HT					1440:1441	HT	1440:1441	HT	1440:1441	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	2	133	theme	high	406:409	arg1	sensitivity					411:421	the high sensitivity	402:421	the high sensitivity of N-glycosylation	402:440	Due to the high sensitivity of N-glycosylation, the IgG N-glycan profile may serve as an indicator of an ongoing inflammatory process.
35370997	12	134	theme	HT	2812:2813	arg1	symptoms					2815:2822	HT symptoms	2812:2822	HT symptoms	2812:2822	The obtained results suggest that modifications of IgG sialylation, galactosylation and core-fucosylation are associated with the severity of HT symptoms.
35370997	0	135	theme	N-Glycosylation	15:29	arg1	Effect					71:76	The Modulatory Effect	56:76	The Modulatory Effect of Methimazole in Graves' Disease	56:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	135	theme	N-Glycosylation	15:29	arg1	Changes					0:6	Changes	0:6	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.	0:192	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	135	theme	N-Glycosylation	15:29	arg1	Association					120:130	the Association	116:130	the Association With the Severity of Inflammation in Hashimoto's Thyroiditis	116:191	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	1	136	theme	abundant	244:251	arg1	glycoprotein					253:264	the most abundant glycoprotein	235:264	the most abundant glycoprotein in human blood serum	235:285	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	1	136	theme	abundant	244:251	arg1	G					226:226	immunoglobulin G	211:226	immunoglobulin G (IgG)	211:232	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	7	137	theme	serum	1576:1580	arg1	samples					1582:1588	human serum samples	1570:1588	human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors	1570:2053	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	13	138	theme	oligosaccharides	2969:2984	arg1	content					2924:2930	the content	2920:2930	the content of the sialylated and galactosylated oligosaccharides with core fucose	2920:3001	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	4	139	theme	disease	990:996	arg1	symptoms					998:1005	disease symptoms	990:1005	disease symptoms	990:1005	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
35370997	5	140	theme	N-glycans	1227:1235	arg1	composition					1208:1218	the composition	1204:1218	the composition of IgG N-glycans	1204:1235	Our recently published data have shown that the pathology of autoimmune thyroid diseases (AITDs), including Hashimoto's thyroiditis (HT) and Graves' disease (GD), is accompanied by alterations of the composition of IgG N-glycans.
35370997	0	141	theme	Thyroid	34:40	arg1	Autoimmunity					42:53	Thyroid Autoimmunity	34:53	Thyroid Autoimmunity	34:53	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	7	142	theme	advanced	1790:1797	arg1	destruction					1799:1809	advanced destruction	1790:1809	advanced destruction	1790:1809	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	8	143	theme	blood	2100:2104	arg1	serum					2106:2110	blood serum	2100:2110	blood serum	2100:2110	IgG was isolated from blood serum using protein G affinity chromatography.
35370997	13	144	theme	core	2991:2994	arg1	fucose					2996:3001	core fucose	2991:3001	core fucose	2991:3001	Methimazole therapy implemented in GD patients affected the IgG N-glycan profile; as a result, the content of the sialylated and galactosylated oligosaccharides with core fucose differed after treatment.
35370997	1	145	theme	blood	275:279	arg1	serum					281:285	human blood serum	269:285	human blood serum	269:285	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	11	146	theme	statistical	2620:2630	arg1	significance					2632:2643	the statistical significance	2616:2643	the statistical significance of the results (p<0.05)	2616:2667	The Kruskal-Wallis non-parametric test was used to determine the statistical significance of the results (p<0.05).
35370997	6	147	theme	IgG	1413:1415	arg1	structures					1426:1435	IgG N-glycan structures	1413:1435	IgG N-glycan structures in HT	1413:1441	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	0	148	dep	Changes	0:6	arg1	Effect					71:76	The Modulatory Effect	56:76	The Modulatory Effect of Methimazole in Graves' Disease	56:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	148	dep	Changes	0:6	arg1	Changes					0:6	Changes	0:6	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.	0:192	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	148	dep	Changes	0:6	arg1	Association					120:130	the Association	116:130	the Association With the Severity of Inflammation in Hashimoto's Thyroiditis	116:191	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	7	149	theme	high	1761:1764	arg1	titers					1779:1784	high autoantibody titers	1761:1784	high autoantibody titers	1761:1784	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	8	150	theme	G	2126:2126	arg1	chromatography					2137:2150	protein G affinity chromatography	2118:2150	protein G affinity chromatography	2118:2150	IgG was isolated from blood serum using protein G affinity chromatography.
35370997	0	151	from	Association	120:130	arg1	Disease					104:110	Graves' Disease	96:110	Graves' Disease	96:110	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	0	151	from	Association	120:130	arg1	Thyroiditis					181:191	Hashimoto's Thyroiditis	169:191	Hashimoto's Thyroiditis	169:191	Changes of IgG N-Glycosylation in Thyroid Autoimmunity: The Modulatory Effect of Methimazole in Graves' Disease and the Association With the Severity of Inflammation in Hashimoto's Thyroiditis.
35370997	3	152	theme	N-glycans	620:628	arg1	composition					605:615	the composition	601:615	the composition of N-glycans attached to the Fc fragment	601:656	The IgG structure and its effector functions are strongly dependent on the composition of N-glycans attached to the Fc fragment, and the binding of antigens is regulated by Fab sugar moieties.
35370997	7	153	theme	healthy	2040:2046	arg1	donors					2048:2053	healthy donors	2040:2053	healthy donors	2040:2053	The study material consisted of human serum samples collected from donors with elevated anti-thyroglobulin (Tg) and/or anti-thyroperoxidase (TPO) IgGs without symptoms of hypothyroidism (n=68), HT patients characterized by high autoantibody titers and advanced destruction of the thyroid gland (n=113), GD patients with up-regulated IgG against thyroid-stimulating hormone receptor (TSHR) before (n=62) and after (n=47) stabilization of TSH level as a result of methimazole therapy (study groups), and healthy donors (control group, n=90).
35370997	6	154	theme	inflammation	1396:1407	arg1	severity					1376:1383	the severity	1372:1383	the severity of thyroid inflammation	1372:1407	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	6	154	theme	inflammation	1396:1407	arg1	structures					1426:1435	IgG N-glycan structures	1413:1435	IgG N-glycan structures in HT	1413:1441	The present study is a more in-depth investigation of IgG glycosylation in both AITDs, designed to determine the relationship between the severity of thyroid inflammation and IgG N-glycan structures in HT, and to assess the impact of immunosuppressive therapy on the N-glycan profile in GD patients.
35370997	1	155	theme	immunoglobulin	211:224	arg1	G					226:226	immunoglobulin G	211:226	immunoglobulin G (IgG)	211:232	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	1	155	theme	immunoglobulin	211:224	arg1	glycoprotein					253:264	the most abundant glycoprotein	235:264	the most abundant glycoprotein in human blood serum	235:285	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	1	155	theme	immunoglobulin	211:224	arg1	IgG					229:231	IgG	229:231	IgG	229:231	The N-glycome of immunoglobulin G (IgG), the most abundant glycoprotein in human blood serum, reflects pathological conditions of autoimmunity and is sensitive to medicines applied in disease therapy.
35370997	4	156	theme	crucial	738:744	arg1	role					746:749	the crucial role	734:749	the crucial role of N-glycans in IgG function	734:778	Because of the crucial role of N-glycans in IgG function, remodeling of its N-oligosaccharides can induce pathological changes that ultimately contribute to the development of autoimmunity; restoration of their physiological structure is critical to the reduction of disease symptoms.
36852982	2	0	theme	diversity	373:381	arg1	significance					345:356	the significance	341:356	the significance of high glycan diversity	341:381	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	2	0	theme	diversity	373:381	arg1	antigenicity					314:325	glycan antigenicity	307:325	glycan antigenicity in humans	307:335	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	9	1	theme	N.	1743:1744	arg1	meningitidis					1746:1757	N. meningitidis	1743:1757	N. meningitidis	1743:1757	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	2	2	from	significance	345:356	arg1	humans					330:335	humans	330:335	humans	330:335	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	2	2	from	significance	345:356	arg1	mechanisms					400:409	immune escape mechanisms	386:409	immune escape mechanisms	386:409	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	10	3	theme	Neisseria	2046:2054	arg1	meningitidis					2056:2067	Neisseria meningitidis	2046:2067	Neisseria meningitidis	2046:2067	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	2	4	theme	glycan	307:312	arg1	antigenicity					314:325	glycan antigenicity	307:325	glycan antigenicity in humans	307:335	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	4	5	theme	insertion	722:730	arg1	element					750:756	An insertion sequence (IS1655) element	719:756	An insertion sequence (IS1655) element in pglH	719:764	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	10	6	theme	organisms	2033:2041	arg1	organisms					2033:2041	the major causative organisms	2013:2041	the major causative organisms	2013:2041	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	10	6	theme	organisms	2033:2041	arg1	one					2006:2008	one	2006:2008	one	2006:2008	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	13	7	theme	such	2613:2616	arg1	diversity					2633:2641	such high glycoform diversity	2613:2641	such high glycoform diversity	2613:2641	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	1	8	theme	general	178:184	arg1	system					217:222	a general O-linked protein glycosylation system	176:222	a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated	176:289	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	7	9	theme	protein	1492:1498	arg1	antigens					1507:1514	these protein glycan antigens	1486:1514	these protein glycan antigens	1486:1514	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	6	10	theme	protein	1320:1326	arg1	antigens					1335:1342	various neisserial protein glycan antigens	1301:1342	various neisserial protein glycan antigens	1301:1342	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	1	11	theme	protein	195:201	arg1	system					217:222	a general O-linked protein glycosylation system	176:222	a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated	176:289	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	7	12	from	antibodies	1555:1564	arg1	sera					1577:1580	patient sera	1569:1580	patient sera	1569:1580	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	11	13	theme	genes	2188:2192	arg1	variation					2153:2161	phase variation	2147:2161	phase variation of protein glycosylation genes and polymorphic gene content and function	2147:2234	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	6	14	theme	mutant	1214:1219	arg1	strains					1221:1227	glycan-expressing mutant strains	1196:1227	glycan-expressing mutant strains	1196:1227	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	0	15	theme	Serogroup	117:125	arg1	Isolates					134:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	3	16	theme	protein	615:621	arg1	pgl					638:640	pgl	638:640	pgl	638:640	The 37 meningococcal isolates were sequenced, and their protein glycosylation (pgl) genotypes and protein glycosylation phenotypes were investigated in detail.
36852982	3	16	theme	protein	615:621	arg1	glycosylation					623:635	their protein glycosylation	609:635	their protein glycosylation (pgl) genotypes	609:651	The 37 meningococcal isolates were sequenced, and their protein glycosylation (pgl) genotypes and protein glycosylation phenotypes were investigated in detail.
36852982	9	17	theme	human	1798:1802	arg1	serum					1804:1808	human serum	1798:1808	human serum	1798:1808	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	6	18	theme	neisserial	1309:1318	arg1	antigens					1335:1342	various neisserial protein glycan antigens	1301:1342	various neisserial protein glycan antigens	1301:1342	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	11	19	from	variability	2080:2090	arg1	antigenicity					2124:2135	antigenicity	2124:2135	antigenicity	2124:2135	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	11	19	from	variability	2080:2090	arg1	structure					2110:2118	protein glycan structure	2095:2118	protein glycan structure	2095:2118	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	12	20	theme	exact	2241:2245	arg1	s					2252:2252	s	2252:2252	s	2252:2252	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	12	20	theme	exact	2241:2245	arg1	role					2247:2250	The exact role	2237:2250	The exact role(s) of glycosylation in Neisseria	2237:2283	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	0	21	theme	ST-7	129:132	arg1	Isolates					134:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	9	22	theme	meningococcal	1911:1923	arg1	disease					1925:1931	meningococcal disease	1911:1931	meningococcal disease	1911:1931	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	11	23	theme	content	2215:2221	arg1	variation					2153:2161	phase variation	2147:2161	phase variation of protein glycosylation genes and polymorphic gene content and function	2147:2234	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	12	24	theme	immune	2432:2437	arg1	system					2439:2444	the human immune system	2422:2444	the human immune system	2422:2444	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	13	25	link	O-linked	2469:2476	arg1	glycosylation					2486:2498	the O-linked protein glycosylation	2465:2498	the O-linked protein glycosylation system	2465:2505	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	5	26	theme	isolates	988:995	arg1	isolates					988:995	the 37 isolates	981:995	the 37 isolates	981:995	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	5	26	theme	isolates	988:995	arg1	eight					972:976	eight	972:976	eight	972:976	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	11	27	theme	polymorphic	2198:2208	arg1	content					2215:2221	polymorphic gene content	2198:2221	polymorphic gene content	2198:2221	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	7	28	theme	glycosylation-null	1436:1453	arg1	strain					1463:1468	a glycosylation-null variant strain	1434:1468	a glycosylation-null variant strain	1434:1468	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	6	29	theme	IgG	1278:1280	arg1	antibodies					1282:1291	IgG antibodies	1278:1291	IgG antibodies against various neisserial protein glycan antigens	1278:1342	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	5	30	theme	whole	1114:1118	arg1	locus					1124:1128	the whole pgl locus	1110:1128	the whole pgl locus	1110:1128	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	10	31	theme	Bacterial	1945:1953	arg1	problem					1993:1999	a serious global health problem	1969:1999	a serious global health problem	1969:1999	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	10	31	theme	Bacterial	1945:1953	arg1	meningitis					1955:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	2	32	from	antigenicity	314:325	arg1	humans					330:335	humans	330:335	humans	330:335	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	2	32	from	antigenicity	314:325	arg1	mechanisms					400:409	immune escape mechanisms	386:409	immune escape mechanisms	386:409	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	13	33	theme	glycoform	2623:2631	arg1	diversity					2633:2641	such high glycoform diversity	2613:2641	such high glycoform diversity	2613:2641	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	9	34	theme	protein	1831:1837	arg1	epitopes					1839:1846	protein epitopes	1831:1846	protein epitopes important for bactericidal killing	1831:1881	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	0	35	from	System	84:89	arg1	Isolates					134:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	5	36	theme	Homologous	900:909	arg1	events					925:930	Homologous recombination events	900:930	Homologous recombination events within the pgl genes	900:951	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	2	37	with	patients	522:529	arg1	disease					550:556	meningococcal disease	536:556	meningococcal disease	536:556	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	1	38	theme	Neisseria	144:152	arg1	meningitidis					154:165	Neisseria meningitidis	144:165	Neisseria meningitidis	144:165	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	2	39	theme	meningococcal	536:548	arg1	disease					550:556	meningococcal disease	536:556	meningococcal disease	536:556	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	12	40	theme	glycan	2375:2380	arg1	variability					2382:2392	glycan variability	2375:2392	glycan variability	2375:2392	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	12	40	theme	glycan	2375:2380	arg1	strategy					2403:2410	a strategy	2401:2410	a strategy to escape the human immune system	2401:2444	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	0	41	theme	Protein	62:68	arg1	Glycosylation					70:82	the O-Linked Protein Glycosylation	49:82	the O-Linked Protein Glycosylation	49:82	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	9	42	theme	bactericidal	1862:1873	arg1	killing					1875:1881	bactericidal killing	1862:1881	bactericidal killing	1862:1881	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	1	43	link	O-linked	186:193	arg1	system					217:222	a general O-linked protein glycosylation system	176:222	a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated	176:289	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	4	44	theme	phase	828:832	arg1	variation					834:842	phase variation	828:842	phase variation	828:842	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	0	45	theme	Neisseria	94:102	arg1	Isolates					134:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	13	46	from	variation	2579:2587	arg1	genes					2596:2600	pgl genes	2592:2600	pgl genes	2592:2600	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	0	47	theme	Genetic	0:6	arg1	Analyses					37:44	Genetic, Functional, and Immunogenic Analyses	0:44	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation	0:82	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	5	48	theme	phenotypic	1006:1015	arg1	consequences					1017:1028	the phenotypic consequences	1002:1028	the phenotypic consequences ranged from none	1002:1045	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	7	49	theme	meningococcal	1407:1419	arg1	strain					1423:1428	a wild-type meningococcal A strain	1395:1428	a wild-type meningococcal A strain	1395:1428	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	2	50	theme	serum	463:467	arg1	samples					469:475	serum samples	463:475	serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease	463:556	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	10	51	theme	IMPORTANCE	1934:1943	arg1	problem					1993:1999	a serious global health problem	1969:1999	a serious global health problem	1969:1999	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	10	51	theme	IMPORTANCE	1934:1943	arg1	meningitis					1955:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	0	52	theme	Functional	9:18	arg1	Analyses					37:44	Genetic, Functional, and Immunogenic Analyses	0:44	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation	0:82	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	8	53	theme	glycosylation	1642:1654	arg1	phenotype					1656:1664	glycosylation phenotype	1642:1664	glycosylation phenotype	1642:1664	Altogether, we were largely able to link pgl genotype with glycosylation phenotype.
36852982	10	54	theme	serious	1971:1977	arg1	problem					1993:1999	a serious global health problem	1969:1999	a serious global health problem	1969:1999	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	10	54	theme	serious	1971:1977	arg1	meningitis					1955:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	2	55	theme	A	435:435	arg1	strains					451:457	serogroup A meningococcal strains	425:457	serogroup A meningococcal strains	425:457	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	13	56	theme	human	2660:2664	arg1	response					2673:2680	the human immune response	2656:2680	the human immune response	2656:2680	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	9	57	theme	protein	1690:1696	arg1	glycans					1698:1704	protein glycans	1690:1704	protein glycans	1690:1704	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	2	58	theme	laboratory-confirmed	491:510	arg1	patients					522:529	laboratory-confirmed Ethiopian patients	491:529	laboratory-confirmed Ethiopian patients with meningococcal disease	491:556	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	2	59	theme	glycan	366:371	arg1	diversity					373:381	high glycan diversity	361:381	high glycan diversity	361:381	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	13	60	theme	glycosylation	2486:2498	arg1	system					2500:2505	the O-linked protein glycosylation system	2465:2505	the O-linked protein glycosylation system	2465:2505	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	3	61	theme	glycosylation	665:677	arg1	phenotypes					679:688	protein glycosylation phenotypes	657:688	protein glycosylation phenotypes	657:688	The 37 meningococcal isolates were sequenced, and their protein glycosylation (pgl) genotypes and protein glycosylation phenotypes were investigated in detail.
36852982	12	62	theme	glycosylation	2258:2270	arg1	s					2252:2252	s	2252:2252	s	2252:2252	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	12	62	theme	glycosylation	2258:2270	arg1	role					2247:2250	The exact role	2237:2250	The exact role(s) of glycosylation in Neisseria	2237:2283	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	13	63	theme	O-linked	2469:2476	arg1	glycosylation					2486:2498	the O-linked protein glycosylation	2465:2498	the O-linked protein glycosylation system	2465:2505	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	10	64	theme	health	1986:1991	arg1	problem					1993:1999	a serious global health problem	1969:1999	a serious global health problem	1969:1999	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	10	64	theme	health	1986:1991	arg1	meningitis					1955:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	3	65	theme	meningococcal	566:578	arg1	isolates					580:587	The 37 meningococcal isolates	559:587	The 37 meningococcal isolates	559:587	The 37 meningococcal isolates were sequenced, and their protein glycosylation (pgl) genotypes and protein glycosylation phenotypes were investigated in detail.
36852982	1	66	theme	other	242:246	arg1	proteins					265:272	other extracytoplasmic proteins	242:272	other extracytoplasmic proteins	242:272	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	6	67	theme	sera	1163:1166	arg1	Immunoblotting					1145:1158	Immunoblotting	1145:1158	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains	1145:1227	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	9	68	theme	important	1848:1856	arg1	epitopes					1839:1846	protein epitopes	1831:1846	protein epitopes important for bactericidal killing	1831:1881	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	4	69	from	element	750:756	arg1	pglH					761:764	pglH	761:764	pglH	761:764	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	7	70	theme	patient	1569:1575	arg1	sera					1577:1580	patient sera	1569:1580	patient sera	1569:1580	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	13	71	theme	high	2618:2621	arg1	diversity					2633:2641	such high glycoform diversity	2613:2641	such high glycoform diversity	2613:2641	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	13	72	theme	protein	2478:2484	arg1	glycosylation					2486:2498	the O-linked protein glycosylation	2465:2498	the O-linked protein glycosylation system	2465:2505	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	9	73	theme	meningitidis	1746:1757	arg1	ability					1732:1738	the ability	1728:1738	the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing	1728:1881	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	7	74	theme	bactericidal	1531:1542	arg1	killing					1544:1550	bactericidal killing	1531:1550	bactericidal killing by antibodies in patient sera	1531:1580	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	5	75	theme	pgl	943:945	arg1	genes					947:951	the pgl genes	939:951	the pgl genes	939:951	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	11	76	theme	protein	2095:2101	arg1	structure					2110:2118	protein glycan structure	2095:2118	protein glycan structure	2095:2118	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	10	77	theme	causative	2023:2031	arg1	organisms					2033:2041	the major causative organisms	2013:2041	the major causative organisms	2013:2041	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	6	78	theme	glycan	1328:1333	arg1	antigens					1335:1342	various neisserial protein glycan antigens	1301:1342	various neisserial protein glycan antigens	1301:1342	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	3	79	theme	glycosylation	623:635	arg1	genotypes					643:651	their protein glycosylation (pgl) genotypes	609:651	their protein glycosylation (pgl) genotypes	609:651	The 37 meningococcal isolates were sequenced, and their protein glycosylation (pgl) genotypes and protein glycosylation phenotypes were investigated in detail.
36852982	5	80	from	glycoforms	1067:1076	arg1	two					1081:1083	two	1081:1083	two	1081:1083	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	5	80	from	glycoforms	1067:1076	arg1	isolates					1092:1099	the isolates	1088:1099	the isolates in which the whole pgl locus was exchanged	1088:1142	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	1	81	theme	O-linked	186:193	arg1	system					217:222	a general O-linked protein glycosylation system	176:222	a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated	176:289	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	9	82	theme	bactericidal	1773:1784	arg1	activity					1786:1793	the bactericidal activity	1769:1793	the bactericidal activity of human serum	1769:1808	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	6	83	theme	strains	1221:1227	arg1	panel					1187:1191	a complete panel	1176:1191	a complete panel of glycan-expressing mutant strains	1176:1227	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	4	84	theme	sequence	732:739	arg1	element					750:756	An insertion sequence (IS1655) element	719:756	An insertion sequence (IS1655) element in pglH	719:764	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	0	85	theme	A	127:127	arg1	Isolates					134:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	1	86	theme	glycosylation	203:215	arg1	system					217:222	a general O-linked protein glycosylation system	176:222	a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated	176:289	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	7	87	theme	glycan	1500:1505	arg1	antigens					1507:1514	these protein glycan antigens	1486:1514	these protein glycan antigens	1486:1514	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	2	88	theme	escape	393:398	arg1	mechanisms					400:409	immune escape mechanisms	386:409	immune escape mechanisms	386:409	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	12	89	theme	human	2426:2430	arg1	system					2439:2444	the human immune system	2422:2444	the human immune system	2422:2444	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	6	90	theme	glycan-expressing	1196:1212	arg1	strains					1221:1227	glycan-expressing mutant strains	1196:1227	glycan-expressing mutant strains	1196:1227	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	11	91	theme	Extensive	2070:2078	arg1	variability					2080:2090	Extensive variability	2070:2090	Extensive variability in protein glycan structure and antigenicity	2070:2135	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	9	92	theme	serum	1804:1808	arg1	activity					1786:1793	the bactericidal activity	1769:1793	the bactericidal activity of human serum	1769:1808	Our study reveals that protein glycans seem to contribute to the ability of N. meningitidis to resist the bactericidal activity of human serum, possibly by masking protein epitopes important for bactericidal killing and thus protection against meningococcal disease.
36852982	6	93	theme	various	1301:1307	arg1	antigens					1335:1342	various neisserial protein glycan antigens	1301:1342	various neisserial protein glycan antigens	1301:1342	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	13	94	dep	utilize	2571:2577	arg1	produce					2605:2611	produce	2605:2611	to produce such high glycoform diversity	2602:2641	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	13	94	dep	utilize	2571:2577	arg1	evade					2650:2654	evade	2650:2654	to evade the human immune response	2647:2680	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	11	95	theme	glycan	2103:2108	arg1	structure					2110:2118	protein glycan structure	2095:2118	protein glycan structure	2095:2118	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	11	96	theme	gene	2210:2213	arg1	content					2215:2221	polymorphic gene content	2198:2221	polymorphic gene content	2198:2221	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	7	97	theme	variant	1455:1461	arg1	strain					1463:1468	a glycosylation-null variant strain	1434:1468	a glycosylation-null variant strain	1434:1468	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	4	98	theme	glycan	774:779	arg1	variability					781:791	glycan variability	774:791	glycan variability	774:791	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	0	99	theme	O-Linked	53:60	arg1	Glycosylation					70:82	the O-Linked Protein Glycosylation	49:82	the O-Linked Protein Glycosylation	49:82	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	5	100	theme	pgl	1120:1122	arg1	locus					1124:1128	the whole pgl locus	1110:1128	the whole pgl locus	1110:1128	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	3	101	theme	protein	657:663	arg1	phenotypes					679:688	protein glycosylation phenotypes	657:688	protein glycosylation phenotypes	657:688	The 37 meningococcal isolates were sequenced, and their protein glycosylation (pgl) genotypes and protein glycosylation phenotypes were investigated in detail.
36852982	5	102	theme	recombination	911:923	arg1	events					925:930	Homologous recombination events	900:930	Homologous recombination events within the pgl genes	900:951	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	6	103	theme	patient	1261:1267	arg1	sera					1269:1272	these patient sera	1255:1272	these patient sera	1255:1272	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	0	104	theme	Glycosylation	70:82	arg1	Analyses					37:44	Genetic, Functional, and Immunogenic Analyses	0:44	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation	0:82	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	13	105	theme	pgl	2592:2594	arg1	genes					2596:2600	pgl genes	2592:2600	pgl genes	2592:2600	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	11	106	theme	phase	2147:2151	arg1	variation					2153:2161	phase variation	2147:2161	phase variation of protein glycosylation genes and polymorphic gene content and function	2147:2234	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	4	107	theme	isolates	812:819	arg1	majority					800:807	the majority	796:807	the majority of isolates	796:819	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	0	108	theme	meningitidis	104:115	arg1	Isolates					134:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Neisseria meningitidis Serogroup A ST-7 Isolates	94:141	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	7	109	theme	A	1421:1421	arg1	strain					1423:1428	a wild-type meningococcal A strain	1395:1428	a wild-type meningococcal A strain	1395:1428	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	8	110	theme	pgl	1624:1626	arg1	genotype					1628:1635	pgl genotype	1624:1635	pgl genotype	1624:1635	Altogether, we were largely able to link pgl genotype with glycosylation phenotype.
36852982	13	111	theme	system	2500:2505	arg1	complexity					2451:2460	The complexity	2447:2460	The complexity of the O-linked protein glycosylation system	2447:2505	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	7	112	theme	wild-type	1397:1405	arg1	strain					1423:1428	a wild-type meningococcal A strain	1395:1428	a wild-type meningococcal A strain	1395:1428	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	11	113	theme	protein	2166:2172	arg1	genes					2188:2192	protein glycosylation genes	2166:2192	protein glycosylation genes	2166:2192	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	1	114	gly	glycosylated	278:289	arg1	system					217:222	a general O-linked protein glycosylation system	176:222	a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated	176:289	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	1	114	gly	glycosylated	278:289	arg1	pili					233:236	pili	233:236	pili	233:236	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	1	114	gly	glycosylated	278:289	arg2	proteins					265:272	other extracytoplasmic proteins	242:272	other extracytoplasmic proteins	242:272	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	1	114	gly	glycosylated	278:289	arg1	proteins					265:272	other extracytoplasmic proteins	242:272	other extracytoplasmic proteins	242:272	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	1	114	gly	glycosylated	278:289	arg2	pili					233:236	pili	233:236	pili	233:236	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36852982	13	115	theme	further	2516:2522	arg1	studies					2524:2530	further studies	2516:2530	further studies	2516:2530	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	10	116	theme	global	1979:1984	arg1	problem					1993:1999	a serious global health problem	1969:1999	a serious global health problem	1969:1999	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	10	116	theme	global	1979:1984	arg1	meningitis					1955:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis	1934:1964	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	12	117	theme	increasing	2315:2324	arg1	evidence					2326:2333	increasing evidence	2315:2333	increasing evidence	2315:2333	The exact role(s) of glycosylation in Neisseria remains to be determined, but increasing evidence, supported by this study, suggests that glycan variability can be a strategy to escape the human immune system.
36852982	2	118	theme	meningococcal	437:449	arg1	strains					451:457	serogroup A meningococcal strains	425:457	serogroup A meningococcal strains	425:457	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	0	119	theme	Immunogenic	25:35	arg1	Analyses					37:44	Genetic, Functional, and Immunogenic Analyses	0:44	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation	0:82	Genetic, Functional, and Immunogenic Analyses of the O-Linked Protein Glycosylation System in Neisseria meningitidis Serogroup A ST-7 Isolates.
36852982	7	120	theme	bactericidal	1366:1377	arg1	assay					1379:1383	a bactericidal assay	1364:1383	a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain	1364:1468	Furthermore, using a bactericidal assay comparing a wild-type meningococcal A strain and a glycosylation-null variant strain, we showed that these protein glycan antigens interfere with bactericidal killing by antibodies in patient sera.
36852982	2	121	theme	Ethiopian	512:520	arg1	patients					522:529	laboratory-confirmed Ethiopian patients	491:529	laboratory-confirmed Ethiopian patients with meningococcal disease	491:556	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	2	122	theme	serogroup	425:433	arg1	strains					451:457	serogroup A meningococcal strains	425:457	serogroup A meningococcal strains	425:457	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	13	123	theme	immune	2666:2671	arg1	response					2673:2680	the human immune response	2656:2680	the human immune response	2656:2680	The complexity of the O-linked protein glycosylation system requires further studies to fully comprehend how these bacteria utilize variation in pgl genes to produce such high glycoform diversity and to evade the human immune response.
36852982	5	124	theme	isolates	1092:1099	arg1	two					1081:1083	two	1081:1083	two	1081:1083	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	5	124	theme	isolates	1092:1099	arg1	isolates					1092:1099	the isolates	1088:1099	the isolates in which the whole pgl locus was exchanged	1088:1142	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	11	125	theme	glycosylation	2174:2186	arg1	genes					2188:2192	protein glycosylation genes	2166:2192	protein glycosylation genes	2166:2192	Extensive variability in protein glycan structure and antigenicity is due to phase variation of protein glycosylation genes and polymorphic gene content and function.
36852982	6	126	contain	had	1274:1276	arg1	most					1247:1250	most	1247:1250	most	1247:1250	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	6	126	contain	had	1274:1276	arg2	antibodies					1282:1291	IgG antibodies	1278:1291	IgG antibodies against various neisserial protein glycan antigens	1278:1342	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	6	126	contain	had	1274:1276	arg1	sera					1269:1272	these patient sera	1255:1272	these patient sera	1255:1272	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	2	127	theme	high	361:364	arg1	diversity					373:381	high glycan diversity	361:381	high glycan diversity	361:381	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	5	128	theme	altered	1059:1065	arg1	glycoforms					1067:1076	altered glycoforms	1059:1076	altered glycoforms in two of the isolates in which the whole pgl locus was exchanged	1059:1142	Homologous recombination events within the pgl genes were identified in eight of the 37 isolates, and the phenotypic consequences ranged from none detected to altered glycoforms in two of the isolates in which the whole pgl locus was exchanged.
36852982	6	129	theme	complete	1178:1185	arg1	panel					1187:1191	a complete panel	1176:1191	a complete panel of glycan-expressing mutant strains	1176:1227	Immunoblotting of sera against a complete panel of glycan-expressing mutant strains demonstrated that most of these patient sera had IgG antibodies against various neisserial protein glycan antigens.
36852982	10	130	theme	major	2017:2021	arg1	organisms					2033:2041	the major causative organisms	2013:2041	the major causative organisms	2013:2041	IMPORTANCE Bacterial meningitis is a serious global health problem, and one of the major causative organisms is Neisseria meningitidis.
36852982	4	131	theme	glycan	857:862	arg1	variability					864:874	glycan variability	857:874	glycan variability	857:874	An insertion sequence (IS1655) element in pglH reduced glycan variability in the majority of isolates, while phase variation strengthened glycan variability and microheterogeneity.
36852982	2	132	theme	immune	386:391	arg1	mechanisms					400:409	immune escape mechanisms	386:409	immune escape mechanisms	386:409	To investigate glycan antigenicity in humans and the significance of high glycan diversity on immune escape mechanisms, we exploited serogroup A meningococcal strains and serum samples obtained from laboratory-confirmed Ethiopian patients with meningococcal disease.
36852982	1	133	theme	extracytoplasmic	248:263	arg1	proteins					265:272	other extracytoplasmic proteins	242:272	other extracytoplasmic proteins	242:272	Neisseria meningitidis exhibits a general O-linked protein glycosylation system in which pili and other extracytoplasmic proteins are glycosylated.
36136114	10	0	theme	traditional	1667:1677	arg1	glycoproteomics					1694:1708	traditional reversed-phase glycoproteomics	1667:1708	traditional reversed-phase glycoproteomics	1667:1708	The results described herein demonstrate the advantages of nanoHILIC-MS to elucidate glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics.
36136114	7	1	theme	retention	1125:1133	arg1	window					1140:1145	a narrow retention time window	1116:1145	a narrow retention time window	1116:1145	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	7	2	theme	time	1135:1138	arg1	window					1140:1145	a narrow retention time window	1116:1145	a narrow retention time window	1116:1145	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	3	3	theme	in-depth	402:409	arg1	characterization					411:426	in-depth characterization	402:426	in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes	402:519	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	4	4	theme	fragment	609:616	arg1	domain					638:643	the fragment crystallizable (Fc) domain	605:643	the fragment crystallizable (Fc) domain	605:643	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	6	5	theme	heterogeneity	893:905	arg1	necessary					931:939	necessary	931:939	necessary	931:939	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	7	6	theme	glycopeptide	1152:1163	arg1	ionization					1165:1174	glycopeptide ionization	1152:1174	glycopeptide ionization	1152:1174	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	6	7	gly	glycoprotein	980:991	arg1	glycoprotein					980:991	glycoprotein quality control	980:1007	glycoprotein quality control	980:1007	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	4	8	theme	linker	654:659	arg1	peptides					661:668	the linker peptides	650:668	the linker peptides	650:668	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	3	9	theme	integrity	443:451	arg1	characterization					411:426	in-depth characterization	402:426	in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes	402:519	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	2	10	theme	effector	325:332	arg1	functions					334:342	effector functions	325:342	effector functions	325:342	Importantly, glycosylation modulates glycoprotein therapeutic pharmacokinetics, pharmacodynamics, and effector functions.
36136114	7	11	theme	non-modified	1204:1215	arg1	peptides					1217:1224	co-eluting non-modified peptides	1193:1224	co-eluting non-modified peptides	1193:1224	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	6	12	theme	inherent	884:891	arg1	heterogeneity					893:905	the inherent heterogeneity	880:905	the inherent heterogeneity of glycosylation	880:922	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	7	13	gly	glycopeptide	1152:1163	arg2	glycopeptide					1152:1163	glycopeptide ionization	1152:1174	glycopeptide ionization	1152:1174	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	5	14	theme	expression	793:802	arg1	conditions					811:820	the expression system conditions	789:820	the expression system conditions that significantly impact safety and efficacy	789:866	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	5	15	theme	given	740:744	arg1	glycosite					746:754	a given glycosite	738:754	a given glycosite	738:754	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	8	16	used	used	1257:1260	arg2	we					1254:1255	we	1254:1255	we	1254:1255	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	5	17	theme	system	804:809	arg1	conditions					811:820	the expression system conditions	789:820	the expression system conditions that significantly impact safety and efficacy	789:866	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	5	18	theme	glycosylation	693:705	arg1	type					685:688	the type	681:688	the type of glycosylation	681:705	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	5	18	theme	glycosylation	693:705	arg1	distribution					722:733	the glycan distribution	711:733	the glycan distribution at a given glycosite	711:754	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	8	19	gly	glycosylation	1303:1315	arg1	UTI-Fc					1320:1325	UTI-Fc	1320:1325	UTI-Fc	1320:1325	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	8	19	gly	glycosylation	1303:1315	arg1	protein					1337:1343	a fusion protein	1328:1343	a fusion protein that greatly increases the half-life of ulinastatin	1328:1395	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	9	20	gly	glycopeptides	1463:1475	arg2	glycopeptides					1463:1475	ulinastatin glycopeptides	1451:1475	ulinastatin glycopeptides	1451:1475	By this methodology, we identified and characterized ulinastatin glycopeptides at the Fc domain and linker peptide.
36136114	3	21	theme	protein	435:441	arg1	integrity					443:451	the protein integrity	431:451	the protein integrity	431:451	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	4	22	theme	active	589:594	arg1	peptide					596:602	the active peptide	585:602	the active peptide	585:602	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	0	23	theme	glycosylated	48:59	arg1	proteins					68:75	engineered heavily glycosylated fusion proteins	29:75	engineered heavily glycosylated fusion proteins	29:75	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
36136114	7	24	theme	reversed-phase	1029:1042	arg1	methods					1050:1056	conventional reversed-phase LC-MS methods	1016:1056	conventional reversed-phase LC-MS methods	1016:1056	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	1	25	theme	Recombinant	97:107	arg1	protein					109:115	Recombinant protein	97:115	Recombinant protein engineering design	97:134	Recombinant protein engineering design affects therapeutic properties including protein efficacy, safety, and immunogenicity.
36136114	8	26	theme	fusion	1330:1335	arg1	UTI-Fc					1320:1325	UTI-Fc	1320:1325	UTI-Fc	1320:1325	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	8	26	theme	fusion	1330:1335	arg1	protein					1337:1343	a fusion protein	1328:1343	a fusion protein that greatly increases the half-life of ulinastatin	1328:1395	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	6	27	theme	glycan	951:956	arg1	detail					969:974	glycan structural detail	951:974	glycan structural detail	951:974	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	7	28	theme	LC-MS	1044:1048	arg1	methods					1050:1056	conventional reversed-phase LC-MS methods	1016:1056	conventional reversed-phase LC-MS methods	1016:1056	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	6	29	theme	quality	993:999	arg1	control					1001:1007	glycoprotein quality control	980:1007	glycoprotein quality control	980:1007	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	0	30	theme	O-Glycoproteomic	0:15	arg1	analysis					17:24	O-Glycoproteomic analysis	0:24	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins	0:75	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
36136114	4	31	from	glycosylation	568:580	arg1	peptide					596:602	the active peptide	585:602	the active peptide	585:602	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	31	from	glycosylation	568:580	arg1	peptides					661:668	the linker peptides	650:668	the linker peptides	650:668	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	31	from	glycosylation	568:580	arg1	domain					638:643	the fragment crystallizable (Fc) domain	605:643	the fragment crystallizable (Fc) domain	605:643	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	32	theme	Fc-fusion	522:530	arg1	proteins					532:539	Fc-fusion proteins	522:539	Fc-fusion proteins	522:539	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	33	gly	glycosylation	568:580	arg1	peptide					596:602	the active peptide	585:602	the active peptide	585:602	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	33	gly	glycosylation	568:580	arg1	peptides					661:668	the linker peptides	650:668	the linker peptides	650:668	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	33	gly	glycosylation	568:580	arg1	domain					638:643	the fragment crystallizable (Fc) domain	605:643	the fragment crystallizable (Fc) domain	605:643	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	7	34	from	glycosite	1095:1103	arg1	glycoforms					1073:1082	the different glycoforms	1059:1082	the different glycoforms at a given glycosite	1059:1103	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	0	35	theme	engineered	29:38	arg1	proteins					68:75	engineered heavily glycosylated fusion proteins	29:75	engineered heavily glycosylated fusion proteins	29:75	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
36136114	5	36	theme	host	770:773	arg1	line					780:783	the host cell line	766:783	the host cell line	766:783	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	7	37	theme	conventional	1016:1027	arg1	methods					1050:1056	conventional reversed-phase LC-MS methods	1016:1056	conventional reversed-phase LC-MS methods	1016:1056	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	8	38	theme	UTI-Fc	1320:1325	arg1	glycosylation					1303:1315	the complex glycosylation	1291:1315	the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin	1291:1395	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	7	39	theme	co-eluting	1193:1202	arg1	peptides					1217:1224	co-eluting non-modified peptides	1193:1224	co-eluting non-modified peptides	1193:1224	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	6	40	theme	glycoprotein	980:991	arg1	control					1001:1007	glycoprotein quality control	980:1007	glycoprotein quality control	980:1007	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	3	41	theme	glycosylation	461:473	arg1	characterization					411:426	in-depth characterization	402:426	in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes	402:519	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	9	42	theme	ulinastatin	1451:1461	arg1	glycopeptides					1463:1475	ulinastatin glycopeptides	1451:1475	ulinastatin glycopeptides	1451:1475	By this methodology, we identified and characterized ulinastatin glycopeptides at the Fc domain and linker peptide.
36136114	5	43	theme	cell	775:778	arg1	line					780:783	the host cell line	766:783	the host cell line	766:783	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	3	44	theme	quality	502:508	arg1	attributes					510:519	their critical quality attributes	487:519	their critical quality attributes	487:519	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	7	45	gly	glycoforms	1073:1082	arg2	glycosite					1095:1103	a given glycosite	1087:1103	a given glycosite	1087:1103	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	0	46	theme	fusion	61:66	arg1	proteins					68:75	engineered heavily glycosylated fusion proteins	29:75	engineered heavily glycosylated fusion proteins	29:75	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
36136114	4	47	theme	complex	560:566	arg1	glycosylation					568:580	complex glycosylation	560:580	complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides	560:668	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	7	48	gly	glycosite	1095:1103	arg2	glycosite					1095:1103	a given glycosite	1087:1103	a given glycosite	1087:1103	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	0	49	theme	proteins	68:75	arg1	analysis					17:24	O-Glycoproteomic analysis	0:24	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins	0:75	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
36136114	4	50	theme	crystallizable	618:631	arg1	domain					638:643	the fragment crystallizable (Fc) domain	605:643	the fragment crystallizable (Fc) domain	605:643	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	3	51	theme	fusion	377:382	arg1	proteins					384:391	fusion proteins	377:391	fusion proteins	377:391	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	6	52	theme	structural	958:967	arg1	detail					969:974	glycan structural detail	951:974	glycan structural detail	951:974	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	1	53	theme	therapeutic	144:154	arg1	safety					195:200	safety	195:200	safety	195:200	Recombinant protein engineering design affects therapeutic properties including protein efficacy, safety, and immunogenicity.
36136114	1	53	theme	therapeutic	144:154	arg1	properties					156:165	therapeutic properties	144:165	therapeutic properties including protein efficacy, safety, and immunogenicity	144:220	Recombinant protein engineering design affects therapeutic properties including protein efficacy, safety, and immunogenicity.
36136114	1	53	theme	therapeutic	144:154	arg1	efficacy					185:192	protein efficacy	177:192	protein efficacy	177:192	Recombinant protein engineering design affects therapeutic properties including protein efficacy, safety, and immunogenicity.
36136114	1	53	theme	therapeutic	144:154	arg1	immunogenicity					207:220	immunogenicity	207:220	immunogenicity	207:220	Recombinant protein engineering design affects therapeutic properties including protein efficacy, safety, and immunogenicity.
36136114	3	54	theme	critical	493:500	arg1	attributes					510:519	their critical quality attributes	487:519	their critical quality attributes	487:519	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	9	55	theme	Fc	1484:1485	arg1	domain					1487:1492	the Fc domain	1480:1492	the Fc domain	1480:1492	By this methodology, we identified and characterized ulinastatin glycopeptides at the Fc domain and linker peptide.
36136114	3	56	theme	proteins	384:391	arg1	development					362:372	the development	358:372	the development of fusion proteins	358:391	Furthermore, the development of fusion proteins requires in-depth characterization of the protein integrity and its glycosylation to evaluate their critical quality attributes.
36136114	2	57	theme	glycoprotein	260:271	arg1	pharmacokinetics					285:300	glycoprotein therapeutic pharmacokinetics	260:300	glycoprotein therapeutic pharmacokinetics	260:300	Importantly, glycosylation modulates glycoprotein therapeutic pharmacokinetics, pharmacodynamics, and effector functions.
36136114	2	58	theme	therapeutic	273:283	arg1	pharmacokinetics					285:300	glycoprotein therapeutic pharmacokinetics	260:300	glycoprotein therapeutic pharmacokinetics	260:300	Importantly, glycosylation modulates glycoprotein therapeutic pharmacokinetics, pharmacodynamics, and effector functions.
36136114	5	59	theme	glycan	715:720	arg1	distribution					722:733	the glycan distribution	711:733	the glycan distribution at a given glycosite	711:754	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	4	60	theme	Fc	634:635	arg1	domain					638:643	the fragment crystallizable (Fc) domain	605:643	the fragment crystallizable (Fc) domain	605:643	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	7	61	theme	narrow	1118:1123	arg1	window					1140:1145	a narrow retention time window	1116:1145	a narrow retention time window	1116:1145	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	7	62	theme	different	1063:1071	arg1	glycoforms					1073:1082	the different glycoforms	1059:1082	the different glycoforms at a given glycosite	1059:1103	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	2	63	gly	glycoprotein	260:271	arg1	glycoprotein					260:271	glycoprotein therapeutic pharmacokinetics	260:300	glycoprotein therapeutic pharmacokinetics	260:300	Importantly, glycosylation modulates glycoprotein therapeutic pharmacokinetics, pharmacodynamics, and effector functions.
36136114	4	64	mod	modified	548:555	arg1	proteins					532:539	Fc-fusion proteins	522:539	Fc-fusion proteins	522:539	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	4	64	mod	modified	548:555	arg3	glycosylation					568:580	complex glycosylation	560:580	complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides	560:668	Fc-fusion proteins can be modified by complex glycosylation on the active peptide, the fragment crystallizable (Fc) domain, and the linker peptides.
36136114	6	65	theme	glycosylation	910:922	arg1	heterogeneity					893:905	the inherent heterogeneity	880:905	the inherent heterogeneity of glycosylation	880:922	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
36136114	0	66	gly	glycosylated	48:59	arg1	proteins					68:75	engineered heavily glycosylated fusion proteins	29:75	engineered heavily glycosylated fusion proteins	29:75	O-Glycoproteomic analysis of engineered heavily glycosylated fusion proteins using nanoHILIC-MS.
36136114	10	67	theme	glycan	1599:1604	arg1	features					1606:1613	glycan features	1599:1613	glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics	1599:1708	The results described herein demonstrate the advantages of nanoHILIC-MS to elucidate glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics.
36136114	1	68	theme	protein	177:183	arg1	efficacy					185:192	protein efficacy	177:192	protein efficacy	177:192	Recombinant protein engineering design affects therapeutic properties including protein efficacy, safety, and immunogenicity.
36136114	9	69	theme	linker	1498:1503	arg1	peptide					1505:1511	linker peptide	1498:1511	linker peptide	1498:1511	By this methodology, we identified and characterized ulinastatin glycopeptides at the Fc domain and linker peptide.
36136114	10	70	theme	nanoHILIC-MS	1573:1584	arg1	advantages					1559:1568	the advantages	1555:1568	the advantages of nanoHILIC-MS to elucidate glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics	1555:1708	The results described herein demonstrate the advantages of nanoHILIC-MS to elucidate glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics.
36136114	7	71	theme	given	1089:1093	arg1	glycosite					1095:1103	a given glycosite	1087:1103	a given glycosite	1087:1103	Using conventional reversed-phase LC-MS methods, the different glycoforms at a given glycosite elute over a narrow retention time window, and glycopeptide ionization is suppressed by co-eluting non-modified peptides.
36136114	10	72	from	features	1606:1613	arg1	glycotherapeutics					1618:1634	glycotherapeutics	1618:1634	glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics	1618:1708	The results described herein demonstrate the advantages of nanoHILIC-MS to elucidate glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics.
36136114	5	73	from	glycosite	746:754	arg1	type					685:688	the type	681:688	the type of glycosylation	681:705	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	5	73	from	glycosite	746:754	arg1	distribution					722:733	the glycan distribution	711:733	the glycan distribution at a given glycosite	711:754	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	10	74	theme	reversed-phase	1679:1692	arg1	glycoproteomics					1694:1708	traditional reversed-phase glycoproteomics	1667:1708	traditional reversed-phase glycoproteomics	1667:1708	The results described herein demonstrate the advantages of nanoHILIC-MS to elucidate glycan features on glycotherapeutics that fail to be detected using traditional reversed-phase glycoproteomics.
36136114	8	75	theme	complex	1295:1301	arg1	glycosylation					1303:1315	the complex glycosylation	1291:1315	the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin	1291:1395	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	5	76	gly	glycosite	746:754	arg2	glycosite					746:754	a given glycosite	738:754	a given glycosite	738:754	Moreover, the type of glycosylation and the glycan distribution at a given glycosite depend on the host cell line and the expression system conditions that significantly impact safety and efficacy.
36136114	8	77	theme	ulinastatin	1385:1395	arg1	half-life					1372:1380	the half-life	1368:1380	the half-life of ulinastatin	1368:1395	To overcome this drawback, we used nanoHILIC-MS to characterize the complex glycosylation of UTI-Fc, a fusion protein that greatly increases the half-life of ulinastatin.
36136114	6	78	gly	heterogeneity	893:905	arg1	glycosylation					910:922	glycosylation	910:922	glycosylation	910:922	Because of the inherent heterogeneity of glycosylation, it is necessary to assign glycan structural detail for glycoprotein quality control.
37293957	0	0	theme	N-linked	83:90	arg1	Glycosylation					92:104	Immune Cell-Specific N-linked Glycosylation	62:104	Immune Cell-Specific N-linked Glycosylation	62:104	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	4	1	theme	structural	696:705	arg1	information					707:717	structural information	696:717	structural information	696:717	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	0	2	theme	Cell-Specific	69:81	arg1	Glycosylation					92:104	Immune Cell-Specific N-linked Glycosylation	62:104	Immune Cell-Specific N-linked Glycosylation	62:104	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	4	3	theme	N-glycan	853:860	arg1	study					862:866	N-glycan study	853:866	N-glycan study	853:866	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	1	4	theme	innate	166:171	arg1	response					193:200	both the innate and adaptive immune response	157:200	response	193:200	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	4	5	from	lack	688:691	arg1	sample					670:675	a single sample	661:675	a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification	661:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	5	6	theme	antibody	912:919	arg1	approach					933:940	a rapid antibody array-based approach	904:940	a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	904:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	6	7	theme	unique	1221:1226	arg1	avenues					1228:1234	unique avenues	1221:1234	unique avenues of analysis that have otherwise not been explored in immune cell populations	1221:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	8	theme	immune	1289:1294	arg1	populations					1301:1311	immune cell populations	1289:1311	immune cell populations	1289:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	4	9	theme	starting	751:758	arg1	materials					760:768	starting materials	751:768	starting materials	751:768	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	1	10	theme	general	262:268	arg1	interactions					283:294	general cell-to-cell interactions	262:294	the modulation of cell surface receptors as well as general cell-to-cell interactions	210:294	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	0	11	theme	Glycosylation	92:104	arg1	Analysis					50:57	the Analysis	46:57	the Analysis of Immune Cell-Specific N-linked Glycosylation	46:104	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	7	12	theme	glycoimmunology	1485:1499	arg1	field					1476:1480	the field	1472:1480	the field of glycoimmunology	1472:1499	The reproducibility, sensitivity, and versatility of this assay provide an invaluable tool for researchers and clinical applications, significantly expanding the field of glycoimmunology.
37293957	6	13	theme	sialic	1190:1195	arg1	residues					1202:1209	terminal sialic acid residues	1181:1209	terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations	1181:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	14	theme	N-glycan	1094:1101	arg1	approaches					1111:1120	multiple N-glycan imaging approaches	1085:1120	multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations	1085:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	14	theme	N-glycan	1094:1101	arg1	stabilization					1145:1157	stabilization	1145:1157	stabilization	1145:1157	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	14	theme	N-glycan	1094:1101	arg1	removal					1134:1140	the removal	1130:1140	the removal	1130:1140	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	4	15	from	time	682:685	arg1	sample					670:675	a single sample	661:675	a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification	661:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	1	16	theme	cell-to-cell	270:281	arg1	interactions					283:294	general cell-to-cell interactions	262:294	the modulation of cell surface receptors as well as general cell-to-cell interactions	210:294	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	6	17	theme	terminal	1181:1188	arg1	residues					1202:1209	terminal sialic acid residues	1181:1209	terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations	1181:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	2	18	theme	N-glycan	414:421	arg1	analysis					423:430	cell-type-specific N-glycan analysis	395:430	cell-type-specific N-glycan analysis	395:430	The study of immune cell N-glycosylation is gaining interest but is hindered by the complexity of cell-type-specific N-glycan analysis.
37293957	4	19	theme	poor	618:621	arg1	throughput					623:632	poor throughput	618:632	poor throughput	618:632	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	3	20	theme	cellular	546:553	arg1	glycosylation					555:567	cellular glycosylation	546:567	cellular glycosylation	546:567	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	6	21	theme	multiple	1085:1092	arg1	approaches					1111:1120	multiple N-glycan imaging approaches	1085:1120	multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations	1085:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	21	theme	multiple	1085:1092	arg1	stabilization					1145:1157	stabilization	1145:1157	stabilization	1145:1157	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	21	theme	multiple	1085:1092	arg1	removal					1134:1140	the removal	1130:1140	the removal	1130:1140	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	1	22	theme	adaptive	177:184	arg1	response					193:200	both the innate and adaptive immune response	157:200	response	193:200	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	0	23	theme	Immune	62:67	arg1	Glycosylation					92:104	Immune Cell-Specific N-linked Glycosylation	62:104	Immune Cell-Specific N-linked Glycosylation	62:104	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	2	24	theme	N-glycosylation	322:336	arg1	study					301:305	The study	297:305	The study of immune cell N-glycosylation	297:336	The study of immune cell N-glycosylation is gaining interest but is hindered by the complexity of cell-type-specific N-glycan analysis.
37293957	1	25	theme	immune	186:191	arg1	response					193:200	both the innate and adaptive immune response	157:200	response	193:200	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	2	26	theme	cell	317:320	arg1	N-glycosylation					322:336	immune cell N-glycosylation	310:336	immune cell N-glycosylation	310:336	The study of immune cell N-glycosylation is gaining interest but is hindered by the complexity of cell-type-specific N-glycan analysis.
37293957	6	27	theme	cell	1296:1299	arg1	populations					1301:1311	immune cell populations	1289:1311	immune cell populations	1289:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	0	28	theme	Antibody-Based	18:31	arg1	Platform					33:40	an Antibody-Based Platform	15:40	an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation	15:104	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	1	29	theme	N-linked	107:114	arg1	glycosylation					116:128	N-linked glycosylation	107:128	N-linked glycosylation	107:128	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	5	30	theme	array-based	921:931	arg1	approach					933:940	a rapid antibody array-based approach	904:940	a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	904:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	4	31	theme	analytical	588:597	arg1	techniques					599:608	these analytical techniques	582:608	these analytical techniques	582:608	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	6	32	theme	acid	1197:1200	arg1	residues					1202:1209	terminal sialic acid residues	1181:1209	terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations	1181:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	4	33	theme	large	735:739	arg1	amount					741:746	a large amount	733:746	a large amount of starting materials	733:768	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	4	33	theme	large	735:739	arg1	materials					760:768	starting materials	751:768	starting materials	751:768	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	7	34	theme	clinical	1425:1432	arg1	applications					1434:1445	clinical applications	1425:1445	clinical applications	1425:1445	The reproducibility, sensitivity, and versatility of this assay provide an invaluable tool for researchers and clinical applications, significantly expanding the field of glycoimmunology.
37293957	3	35	theme	Analytical	433:442	arg1	chromatography					463:476	chromatography	463:476	chromatography	463:476	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	35	theme	Analytical	433:442	arg1	use					497:499	the use	493:499	the use of lectins	493:510	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	35	theme	Analytical	433:442	arg1	LC-MS/MS					479:486	LC-MS/MS	479:486	LC-MS/MS	479:486	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	35	theme	Analytical	433:442	arg1	techniques					444:453	Analytical techniques	433:453	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins	433:510	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	4	36	theme	single	663:668	arg1	sample					670:675	a single sample	661:675	a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification	661:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	0	37	theme	Platform	33:40	arg1	Development					0:10	Development	0:10	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.	0:105	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	1	38	dep	response	193:200	arg1	both					157:160	both	157:160	both	157:160	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	0	39	link	N-linked	83:90	arg1	Glycosylation					92:104	Immune Cell-Specific N-linked Glycosylation	62:104	Immune Cell-Specific N-linked Glycosylation	62:104	Development of an Antibody-Based Platform for the Analysis of Immune Cell-Specific N-linked Glycosylation.
37293957	2	40	theme	analysis	423:430	arg1	complexity					381:390	the complexity	377:390	the complexity of cell-type-specific N-glycan analysis	377:430	The study of immune cell N-glycosylation is gaining interest but is hindered by the complexity of cell-type-specific N-glycan analysis.
37293957	6	41	theme	analysis	1239:1246	arg1	avenues					1228:1234	unique avenues	1221:1234	unique avenues of analysis that have otherwise not been explored in immune cell populations	1221:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	4	42	with	Issues	570:575	arg1	techniques					599:608	these analytical techniques	582:608	these analytical techniques	582:608	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	3	43	theme	lectins	504:510	arg1	chromatography					463:476	chromatography	463:476	chromatography	463:476	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	43	theme	lectins	504:510	arg1	use					497:499	the use	493:499	the use of lectins	493:510	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	43	theme	lectins	504:510	arg1	LC-MS/MS					479:486	LC-MS/MS	479:486	LC-MS/MS	479:486	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	5	44	theme	approach	933:940	arg1	development					889:899	the development	885:899	the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	885:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	5	45	theme	cellular	1029:1036	arg1	N-glycosylation					1038:1052	cellular N-glycosylation	1029:1052	cellular N-glycosylation	1029:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	7	46	theme	invaluable	1389:1398	arg1	tool					1400:1403	an invaluable tool	1386:1403	an invaluable tool for researchers and clinical applications	1386:1445	The reproducibility, sensitivity, and versatility of this assay provide an invaluable tool for researchers and clinical applications, significantly expanding the field of glycoimmunology.
37293957	4	47	theme	information	707:717	arg1	requirement					779:789	the requirement	775:789	the requirement for cell purification	775:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	4	47	theme	information	707:717	arg1	need					724:727	the need	720:727	the need for a large amount of starting materials	720:768	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	4	47	theme	information	707:717	arg1	lack					688:691	lack	688:691	lack of structural information	688:717	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	4	47	theme	information	707:717	arg1	time					682:685	a time	680:685	a time	680:685	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	4	48	from	need	724:727	arg1	sample					670:675	a single sample	661:675	a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification	661:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	6	49	theme	residues	1202:1209	arg1	derivatization					1163:1176	derivatization	1163:1176	derivatization	1163:1176	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	49	theme	residues	1202:1209	arg1	stabilization					1145:1157	stabilization	1145:1157	stabilization	1145:1157	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	49	theme	residues	1202:1209	arg1	removal					1134:1140	the removal	1130:1140	the removal	1130:1140	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	7	50	theme	assay	1372:1376	arg1	reproducibility					1318:1332	reproducibility	1318:1332	reproducibility	1318:1332	The reproducibility, sensitivity, and versatility of this assay provide an invaluable tool for researchers and clinical applications, significantly expanding the field of glycoimmunology.
37293957	7	50	theme	assay	1372:1376	arg1	sensitivity					1335:1345	sensitivity	1335:1345	sensitivity	1335:1345	The reproducibility, sensitivity, and versatility of this assay provide an invaluable tool for researchers and clinical applications, significantly expanding the field of glycoimmunology.
37293957	7	50	theme	assay	1372:1376	arg1	versatility					1352:1362	versatility	1352:1362	versatility	1352:1362	The reproducibility, sensitivity, and versatility of this assay provide an invaluable tool for researchers and clinical applications, significantly expanding the field of glycoimmunology.
37293957	5	51	theme	nonadherent	970:980	arg1	cells					989:993	specific nonadherent immune cells	961:993	specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	961:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	4	52	theme	cell	795:798	arg1	purification					800:811	cell purification	795:811	cell purification	795:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	1	53	theme	important	139:147	arg1	role					149:152	an important role	136:152	an important role	136:152	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	2	54	theme	immune	310:315	arg1	N-glycosylation					322:336	immune cell N-glycosylation	310:336	immune cell N-glycosylation	310:336	The study of immune cell N-glycosylation is gaining interest but is hindered by the complexity of cell-type-specific N-glycan analysis.
37293957	1	55	theme	cell	228:231	arg1	receptors					241:249	cell surface receptors	228:249	cell surface receptors	228:249	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	4	56	theme	materials	760:768	arg1	amount					741:746	a large amount	733:746	a large amount of starting materials	733:768	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	4	56	theme	materials	760:768	arg1	materials					760:768	starting materials	751:768	starting materials	751:768	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	5	57	theme	immune	982:987	arg1	cells					989:993	specific nonadherent immune cells	961:993	specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	961:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	5	58	theme	rapid	906:910	arg1	approach					933:940	a rapid antibody array-based approach	904:940	a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	904:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	1	59	theme	surface	233:239	arg1	receptors					241:249	cell surface receptors	228:249	cell surface receptors	228:249	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	1	60	link	N-linked	107:114	arg1	glycosylation					116:128	N-linked glycosylation	107:128	N-linked glycosylation	107:128	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	6	61	theme	imaging	1103:1109	arg1	approaches					1111:1120	multiple N-glycan imaging approaches	1085:1120	multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations	1085:1311	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	61	theme	imaging	1103:1109	arg1	stabilization					1145:1157	stabilization	1145:1157	stabilization	1145:1157	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	6	61	theme	imaging	1103:1109	arg1	removal					1134:1140	the removal	1130:1140	the removal	1130:1140	This workflow is adaptable to multiple N-glycan imaging approaches such as the removal or stabilization and derivatization of terminal sialic acid residues providing unique avenues of analysis that have otherwise not been explored in immune cell populations.
37293957	5	62	theme	cells	989:993	arg1	capture					950:956	the capture	946:956	the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	946:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
37293957	4	63	from	requirement	779:789	arg1	sample					670:675	a single sample	661:675	a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification	661:811	Issues with these analytical techniques include poor throughput, which is often limited to a single sample at a time, lack of structural information, the need for a large amount of starting materials, and the requirement for cell purification, thereby reducing their feasibility for N-glycan study.
37293957	2	64	theme	cell-type-specific	395:412	arg1	analysis					423:430	cell-type-specific N-glycan analysis	395:430	cell-type-specific N-glycan analysis	395:430	The study of immune cell N-glycosylation is gaining interest but is hindered by the complexity of cell-type-specific N-glycan analysis.
37293957	1	65	theme	receptors	241:249	arg1	interactions					283:294	general cell-to-cell interactions	262:294	the modulation of cell surface receptors as well as general cell-to-cell interactions	210:294	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	1	65	theme	receptors	241:249	arg1	modulation					214:223	the modulation	210:223	the modulation of cell surface receptors as well as general cell-to-cell interactions	210:294	N-linked glycosylation plays an important role in both the innate and adaptive immune response through the modulation of cell surface receptors as well as general cell-to-cell interactions.
37293957	3	66	used	used	530:533	arg2	techniques					444:453	Analytical techniques	433:453	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins	433:510	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	66	used	used	530:533	arg2	use					497:499	the use	493:499	the use of lectins	493:510	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	66	used	used	530:533	arg2	LC-MS/MS					479:486	LC-MS/MS	479:486	LC-MS/MS	479:486	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	3	66	used	used	530:533	arg2	chromatography					463:476	chromatography	463:476	chromatography	463:476	Analytical techniques such as chromatography, LC-MS/MS, and the use of lectins are all currently used to analyze cellular glycosylation.
37293957	5	67	theme	specific	961:968	arg1	cells					989:993	specific nonadherent immune cells	961:993	specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation	961:1052	Here, we report the development of a rapid antibody array-based approach for the capture of specific nonadherent immune cells coupled with MALDI-IMS to analyze cellular N-glycosylation.
35344340	3	0	gly	aglycosylated	597:609	arg1	antibody					611:618	an aglycosylated antibody	594:618	an aglycosylated antibody	594:618	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	1	1	theme	common	154:159	arg1	modifications					191:203	the most common and complex posttranslational modifications	145:203	the most common and complex posttranslational modifications	145:203	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	1	2	theme	therapeutic	276:286	arg1	antibodies					288:297	therapeutic antibodies	276:297	therapeutic antibodies	276:297	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	0	3	theme	Aglycosylated	67:79	arg1	Antibodies					100:109	Aglycosylated and N-Glycosylated Antibodies	67:109	Aglycosylated and N-Glycosylated Antibodies	67:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	3	4	theme	N-linked	728:735	arg1	glycans					737:743	N-linked glycans	728:743	N-linked glycans	728:743	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	1	5	theme	antibodies	288:297	arg1	properties					262:271	physicochemical properties	246:271	physicochemical properties	246:271	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	1	5	theme	antibodies	288:297	arg1	functions					232:240	biological functions	221:240	biological functions	221:240	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	0	6	theme	Antibodies	100:109	arg1	Stabilities					52:62	Thermal and Metabolic Stabilities	30:62	Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies	30:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	2	7	attach	attached	396:403	arg1	loop					416:419	the C'E loop	408:419	the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain	408:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	2	7	attach	attached	396:403	arg2	payloads					387:394	payloads	387:394	payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain	387:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	2	8	theme	metabolic	325:333	arg1	stabilities					335:345	thermal and metabolic stabilities	313:345	thermal and metabolic stabilities of antibody-drug conjugates (ADCs)	313:380	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	2	9	theme	conjugates	364:373	arg1	stabilities					335:345	thermal and metabolic stabilities	313:345	thermal and metabolic stabilities of antibody-drug conjugates (ADCs)	313:380	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	0	10	theme	N-Glycosylated	85:98	arg1	Antibodies					100:109	Aglycosylated and N-Glycosylated Antibodies	67:109	Aglycosylated and N-Glycosylated Antibodies	67:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	4	11	theme	positive	798:805	arg1	effects					820:826	both positive and negative effects	793:826	both positive and negative effects	793:826	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	0	12	gly	Aglycosylated	67:79	arg1	Antibodies					100:109	Aglycosylated and N-Glycosylated Antibodies	67:109	Aglycosylated and N-Glycosylated Antibodies	67:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	2	13	theme	E	414:414	arg1	loop					416:419	the C'E loop	408:419	the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain	408:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	1	14	theme	complex	165:171	arg1	modifications					191:203	the most common and complex posttranslational modifications	145:203	the most common and complex posttranslational modifications	145:203	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	2	15	theme	ADC	514:516	arg1	variants					518:525	aglycosylated Fc ADC variants	497:525	aglycosylated Fc ADC variants	497:525	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	4	16	theme	negative	811:818	arg1	effects					820:826	both positive and negative effects	793:826	both positive and negative effects	793:826	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	1	17	theme	posttranslational	173:189	arg1	modifications					191:203	the most common and complex posttranslational modifications	145:203	the most common and complex posttranslational modifications	145:203	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	2	18	theme	CH2	454:456	arg1	domain					458:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	4	19	contain	had	789:791	arg2	effects					820:826	both positive and negative effects	793:826	both positive and negative effects	793:826	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	4	19	contain	had	789:791	arg1	glycans					781:787	glycans	781:787	glycans	781:787	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	2	20	gly	aglycosylated	497:509	arg1	variants					518:525	aglycosylated Fc ADC variants	497:525	aglycosylated Fc ADC variants	497:525	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	1	21	theme	modifications	191:203	arg1	one					138:140	one	138:140	one	138:140	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	1	21	theme	modifications	191:203	arg1	modifications					191:203	the most common and complex posttranslational modifications	145:203	the most common and complex posttranslational modifications	145:203	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	2	22	theme	Fc	451:452	arg1	domain					458:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	3	23	theme	small-molecule	568:581	arg1	drugs					583:587	small-molecule drugs	568:587	small-molecule drugs	568:587	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	2	24	theme	antibody-drug	350:362	arg1	ADCs					376:379	ADCs	376:379	ADCs	376:379	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	2	24	theme	antibody-drug	350:362	arg1	conjugates					364:373	antibody-drug conjugates	350:373	antibody-drug conjugates (ADCs)	350:380	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	3	25	link	N-linked	728:735	arg1	glycans					737:743	N-linked glycans	728:743	N-linked glycans	728:743	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	2	26	theme	C'	412:413	arg1	loop					416:419	the C'E loop	408:419	the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain	408:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	0	27	theme	Conjugation	15:25	arg1	Impact					0:5	Impact	0:5	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.	0:110	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	0	28	theme	Drug	10:13	arg1	Conjugation					15:25	Drug Conjugation	10:25	Drug Conjugation	10:25	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	2	29	theme	thermal	313:319	arg1	stabilities					335:345	thermal and metabolic stabilities	313:345	thermal and metabolic stabilities of antibody-drug conjugates (ADCs)	313:380	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	3	30	theme	structural	680:689	arg1	distortions					691:701	structural distortions	680:701	structural distortions caused by elimination of N-linked glycans	680:743	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	1	31	theme	N-linked	112:119	arg1	glycosylation					121:133	N-linked glycosylation	112:133	N-linked glycosylation	112:133	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	2	32	theme	G	443:443	arg1	domain					458:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	0	33	theme	Thermal	30:36	arg1	Stabilities					52:62	Thermal and Metabolic Stabilities	30:62	Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies	30:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	2	34	theme	immunoglobulin	428:441	arg1	IgG					446:448	IgG	446:448	IgG	446:448	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	2	34	theme	immunoglobulin	428:441	arg1	G					443:443	immunoglobulin G	428:443	the immunoglobulin G (IgG) Fc CH2 domain	424:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	1	35	theme	biological	221:230	arg1	functions					232:240	biological functions	221:240	biological functions	221:240	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	5	36	theme	consideration	898:910	arg1	importance					884:893	the importance	880:893	the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability	880:1013	The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
35344340	4	37	theme	ADCs	851:854	arg1	stability					838:846	plasma stability	831:846	plasma stability of ADCs	831:854	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	0	38	theme	Metabolic	42:50	arg1	Stabilities					52:62	Thermal and Metabolic Stabilities	30:62	Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies	30:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	2	39	theme	aglycosylated	497:509	arg1	variants					518:525	aglycosylated Fc ADC variants	497:525	aglycosylated Fc ADC variants	497:525	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	5	40	theme	desirable	957:965	arg1	properties					983:992	desirable physicochemical properties	957:992	desirable physicochemical properties	957:992	The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
35344340	0	41	from	Impact	0:5	arg1	Stabilities					52:62	Thermal and Metabolic Stabilities	30:62	Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies	30:109	Impact of Drug Conjugation on Thermal and Metabolic Stabilities of Aglycosylated and N-Glycosylated Antibodies.
35344340	3	42	theme	aglycosylated	597:609	arg1	antibody					611:618	an aglycosylated antibody	594:618	an aglycosylated antibody	594:618	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	5	43	theme	physicochemical	967:981	arg1	properties					983:992	desirable physicochemical properties	957:992	desirable physicochemical properties	957:992	The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
35344340	3	44	theme	drugs	583:587	arg1	introduction					552:563	introduction	552:563	introduction of small-molecule drugs into an aglycosylated antibody	552:618	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	5	45	theme	plasma	998:1003	arg1	stability					1005:1013	plasma stability	998:1013	plasma stability	998:1013	The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
35344340	4	46	theme	plasma	831:836	arg1	stability					838:846	plasma stability	831:846	plasma stability of ADCs	831:854	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	3	47	theme	thermal	639:645	arg1	destabilization					647:661	thermal destabilization	639:661	thermal destabilization originating from structural distortions caused by elimination of N-linked glycans	639:743	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	2	48	from	loop	416:419	arg1	domain					458:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	the immunoglobulin G (IgG) Fc CH2 domain	424:463	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	1	49	dep	functions	232:240	arg1	the					217:219	the	217:219	the	217:219	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	4	50	theme	conjugation	763:773	arg1	site					775:778	the conjugation site	759:778	the conjugation site	759:778	Depending on the conjugation site, glycans had both positive and negative effects on plasma stability of ADCs.
35344340	1	51	theme	physicochemical	246:260	arg1	properties					262:271	physicochemical properties	246:271	physicochemical properties	246:271	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	2	52	theme	Fc	511:512	arg1	variants					518:525	aglycosylated Fc ADC variants	497:525	aglycosylated Fc ADC variants	497:525	We evaluated thermal and metabolic stabilities of antibody-drug conjugates (ADCs) with payloads attached to the C'E loop in the immunoglobulin G (IgG) Fc CH2 domain, comparing the glycosylated and aglycosylated Fc ADC variants.
35344340	3	53	theme	glycans	737:743	arg1	elimination					713:723	elimination	713:723	elimination of N-linked glycans	713:743	Our study revealed that introduction of small-molecule drugs into an aglycosylated antibody can compensate for thermal destabilization originating from structural distortions caused by elimination of N-linked glycans.
35344340	5	54	theme	conjugation	929:939	arg1	site					941:944	conjugation site	929:944	conjugation site	929:944	The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
35344340	1	55	link	N-linked	112:119	arg1	glycosylation					121:133	N-linked glycosylation	112:133	N-linked glycosylation	112:133	N-linked glycosylation is one of the most common and complex posttranslational modifications that govern the biological functions and physicochemical properties of therapeutic antibodies.
35344340	5	56	theme	site	941:944	arg1	selection					916:924	selection	916:924	selection of conjugation site to achieve desirable physicochemical properties and plasma stability	916:1013	The findings highlight the importance of consideration for selection of conjugation site to achieve desirable physicochemical properties and plasma stability.
36813232	0	0	theme	N-acetylgalactosamine-specific	88:117	arg1	hexosaminidase					119:132	the HEX-4 N-acetylgalactosamine-specific hexosaminidase	78:132	the HEX-4 N-acetylgalactosamine-specific hexosaminidase	78:132	N-glycan antennal modifications are altered in Caenorhabditis elegans lacking the HEX-4 N-acetylgalactosamine-specific hexosaminidase.
36813232	6	1	from	N-acetylgalactosamine	1437:1457	arg1	mutants					1472:1478	the hex-4 mutants	1462:1478	the hex-4 mutants	1462:1478	In keeping with the specificity of HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared to isomeric chito-oligomer motifs in the wild-type.
36813232	4	2	theme	Ar-released	916:926	arg1	pools					928:932	the PNGase Ar-released pools	905:932	the PNGase Ar-released pools	905:932	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	4	3	theme	various	950:956	arg1	modifications					963:975	various core modifications	950:975	various core modifications	950:975	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	2	4	theme	fractionation	400:412	arg1	use					383:385	use	383:385	use of optimised fractionation	383:412	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	0	5	theme	HEX-4	82:86	arg1	hexosaminidase					119:132	the HEX-4 N-acetylgalactosamine-specific hexosaminidase	78:132	the HEX-4 N-acetylgalactosamine-specific hexosaminidase	78:132	N-glycan antennal modifications are altered in Caenorhabditis elegans lacking the HEX-4 N-acetylgalactosamine-specific hexosaminidase.
36813232	3	6	theme	phase	734:738	arg1	resin					744:748	a reversed phase C18 resin	723:748	a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released	723:804	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	4	7	theme	PNGase	909:914	arg1	pools					928:932	the PNGase Ar-released pools	905:932	the PNGase Ar-released pools	905:932	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	2	8	theme	optimised	390:398	arg1	fractionation					400:412	optimised fractionation	390:412	optimised fractionation	390:412	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	3	9	with	resin	744:748	arg1	water					762:766	water	762:766	water	762:766	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	3	9	with	resin	744:748	arg1	methanol					775:782	15% methanol or PNGase Ar-released	771:804	methanol	775:782	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	1	10	theme	variable	298:305	arg1	core					307:310	highly variable core	291:310	highly variable core	291:310	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	2	11	theme	N-glycomic	582:591	arg1	potential					593:601	a total N-glycomic potential	574:601	a total N-glycomic potential of 300 verified isomers	574:625	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	3	12	theme	C18	740:742	arg1	resin					744:748	a reversed phase C18 resin	723:748	a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released	723:804	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	5	13	theme	Ar-released	1340:1350	arg1	pools					1352:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	5	14	theme	mutant	1272:1277	arg1	strains					1279:1285	the hex-4 mutant strains	1262:1285	the hex-4 mutant strains	1262:1285	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	2	15	contain	has	570:572	arg2	potential					593:601	a total N-glycomic potential	574:601	a total N-glycomic potential of 300 verified isomers	574:625	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	2	15	contain	has	570:572	arg1	nematode					561:568	the model nematode	551:568	the model nematode	551:568	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	7	16	theme	HEX-4	1613:1617	arg1	protein					1632:1638	a HEX-4::eGFP fusion protein	1611:1638	a HEX-4::eGFP fusion protein	1611:1638	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	8	17	theme	glycan-processing	1897:1913	arg1	enzymes					1915:1921	glycan-processing enzymes	1897:1921	glycan-processing enzymes occurring in other nematodes	1897:1950	Furthermore, finding more 'parasite-like' structures in the model worm may facilitate the discovery of glycan-processing enzymes occurring in other nematodes.
36813232	8	18	theme	parasite-like	1821:1833	arg1	structures					1836:1845	finding more 'parasite-like' structures	1807:1845	finding more 'parasite-like' structures in the model worm	1807:1863	Furthermore, finding more 'parasite-like' structures in the model worm may facilitate the discovery of glycan-processing enzymes occurring in other nematodes.
36813232	4	19	from	residues	1147:1154	arg1	series					1159:1164	series	1159:1164	series	1159:1164	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	3	20	theme	15	771:772	arg1	%					773:773	%	773:773	%	773:773	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	7	21	theme	Caenorhabditis	1770:1783	arg1	elegans					1785:1791	Caenorhabditis elegans	1770:1791	Caenorhabditis elegans	1770:1791	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	7	22	from	processing	1743:1752	arg1	elegans					1785:1791	Caenorhabditis elegans	1770:1791	Caenorhabditis elegans	1770:1791	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	6	23	theme	more	1412:1415	arg1	glycans					1417:1423	more glycans	1412:1423	more glycans capped with N-acetylgalactosamine in the hex-4 mutants	1412:1478	In keeping with the specificity of HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared to isomeric chito-oligomer motifs in the wild-type.
36813232	4	24	theme	oligomannosidic	877:891	arg1	glycans					893:899	oligomannosidic glycans	877:899	oligomannosidic glycans	877:899	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	7	25	theme	significant	1706:1716	arg1	role					1718:1721	a significant role	1704:1721	a significant role	1704:1721	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	5	26	theme	altered	1297:1303	arg1	sets					1305:1308	altered sets	1297:1308	altered sets of methanol-eluted and PNGase Ar-released pools	1297:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	5	26	theme	altered	1297:1303	arg1	pools					1352:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	1	27	theme	plentiful	202:210	arg1	pauci-					212:217	plentiful pauci-	202:217	plentiful pauci-	202:217	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	0	28	theme	antennal	9:16	arg1	modifications					18:30	N-glycan antennal modifications	0:30	N-glycan antennal modifications	0:30	N-glycan antennal modifications are altered in Caenorhabditis elegans lacking the HEX-4 N-acetylgalactosamine-specific hexosaminidase.
36813232	1	29	contain	have	176:179	arg2	glycomes					188:195	simple glycomes	181:195	simple glycomes	181:195	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	1	29	contain	have	176:179	arg1	organisms					142:150	Simple organisms	135:150	Simple organisms	135:150	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	4	30	dep	three	1092:1096	arg1	to					1089:1090	to	1089:1090	to	1089:1090	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	5	31	theme	mutant	1242:1247	arg1	strains					1249:1255	the C. elegans wild-type and hex-5 mutant strains	1207:1255	the C. elegans wild-type and hex-5 mutant strains	1207:1255	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	7	32	theme	N-glycans	1757:1765	arg1	processing					1743:1752	late-stage Golgi processing	1726:1752	late-stage Golgi processing of N-glycans in Caenorhabditis elegans	1726:1791	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	8	33	from	structures	1836:1845	arg1	worm					1860:1863	the model worm	1850:1863	the model worm	1850:1863	Furthermore, finding more 'parasite-like' structures in the model worm may facilitate the discovery of glycan-processing enzymes occurring in other nematodes.
36813232	0	34	theme	N-glycan	0:7	arg1	modifications					18:30	N-glycan antennal modifications	0:30	N-glycan antennal modifications	0:30	N-glycan antennal modifications are altered in Caenorhabditis elegans lacking the HEX-4 N-acetylgalactosamine-specific hexosaminidase.
36813232	1	35	theme	antennal	316:323	arg1	modifications					325:337	antennal modifications	316:337	antennal modifications	316:337	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	8	36	theme	other	1936:1940	arg1	nematodes					1942:1950	other nematodes	1936:1950	other nematodes	1936:1950	Furthermore, finding more 'parasite-like' structures in the model worm may facilitate the discovery of glycan-processing enzymes occurring in other nematodes.
36813232	7	37	theme	Golgi	1737:1741	arg1	processing					1743:1752	late-stage Golgi processing	1726:1752	late-stage Golgi processing of N-glycans in Caenorhabditis elegans	1726:1791	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	7	38	theme	eGFP	1620:1623	arg1	protein					1632:1638	a HEX-4::eGFP fusion protein	1611:1638	a HEX-4::eGFP fusion protein	1611:1638	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	6	39	theme	isomeric	1496:1503	arg1	motifs					1520:1525	isomeric chito-oligomer motifs	1496:1525	isomeric chito-oligomer motifs in the wild-type	1496:1542	In keeping with the specificity of HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared to isomeric chito-oligomer motifs in the wild-type.
36813232	3	40	theme	PNGase	787:792	arg1	Ar-released					794:804	15% methanol or PNGase Ar-released	771:804	Ar-released	794:804	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	2	41	theme	verified	610:617	arg1	isomers					619:625	300 verified isomers	606:625	300 verified isomers	606:625	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	7	42	theme	fusion	1625:1630	arg1	protein					1632:1638	a HEX-4::eGFP fusion protein	1611:1638	a HEX-4::eGFP fusion protein	1611:1638	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	1	43	theme	Simple	135:140	arg1	organisms					142:150	Simple organisms	135:150	Simple organisms	135:150	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	4	44	theme	typical	858:864	arg1	pauci-					866:871	typical pauci-	858:871	typical pauci-	858:871	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	1	45	theme	oligomannosidic	223:237	arg1	glycans					239:245	oligomannosidic glycans	223:245	oligomannosidic glycans	223:245	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	3	46	theme	%	773:773	arg1	methanol					775:782	15% methanol or PNGase Ar-released	771:804	methanol	775:782	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	7	47	theme	::	1618:1619	arg1	protein					1632:1638	a HEX-4::eGFP fusion protein	1611:1638	a HEX-4::eGFP fusion protein	1611:1638	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	7	48	theme	late-stage	1726:1735	arg1	processing					1743:1752	late-stage Golgi processing	1726:1752	late-stage Golgi processing of N-glycans in Caenorhabditis elegans	1726:1791	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	5	49	theme	PNGase	1333:1338	arg1	pools					1352:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	4	50	theme	structures	1070:1079	arg1	range					1034:1038	a huge range	1027:1038	a huge range of phosphorylcholine-modified structures	1027:1079	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	8	51	theme	enzymes	1915:1921	arg1	discovery					1884:1892	the discovery	1880:1892	the discovery of glycan-processing enzymes occurring in other nematodes	1880:1950	Furthermore, finding more 'parasite-like' structures in the model worm may facilitate the discovery of glycan-processing enzymes occurring in other nematodes.
36813232	4	52	theme	N-acetylhexosamine	1128:1145	arg1	residues					1147:1154	four N-acetylhexosamine residues	1123:1154	four N-acetylhexosamine residues in series	1123:1164	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	2	53	dep	strains	462:468	arg1	comparison					441:450	comparison	441:450	comparison	441:450	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	4	54	with	glycans	937:943	arg1	modifications					963:975	various core modifications	950:975	various core modifications	950:975	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	4	55	theme	phosphorylcholine-modified	1043:1068	arg1	structures					1070:1079	phosphorylcholine-modified structures	1043:1079	phosphorylcholine-modified structures	1043:1079	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	6	56	theme	HEX-4	1394:1398	arg1	specificity					1379:1389	the specificity	1375:1389	the specificity of HEX-4	1375:1398	In keeping with the specificity of HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared to isomeric chito-oligomer motifs in the wild-type.
36813232	6	57	from	motifs	1520:1525	arg1	wild-type					1534:1542	wild-type	1534:1542	wild-type	1534:1542	In keeping with the specificity of HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared to isomeric chito-oligomer motifs in the wild-type.
36813232	2	58	theme	mutant	455:460	arg1	strains					462:468	mutant strains	455:468	mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases	455:531	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	4	59	theme	methanol-eluted	991:1005	arg1	fractions					1007:1015	the methanol-eluted fractions	987:1015	the methanol-eluted fractions	987:1015	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	3	60	theme	PNGase	689:694	arg1	F-released					696:705	either PNGase F-released	682:705	either PNGase F-released	682:705	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	4	61	contain	contained	1017:1025	arg1	fractions					1007:1015	the methanol-eluted fractions	987:1015	the methanol-eluted fractions	987:1015	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	4	61	contain	contained	1017:1025	arg2	range					1034:1038	a huge range	1027:1038	a huge range of phosphorylcholine-modified structures	1027:1079	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	6	62	theme	chito-oligomer	1505:1518	arg1	motifs					1520:1525	isomeric chito-oligomer motifs	1496:1525	isomeric chito-oligomer motifs in the wild-type	1496:1542	In keeping with the specificity of HEX-4, there were more glycans capped with N-acetylgalactosamine in the hex-4 mutants, as compared to isomeric chito-oligomer motifs in the wild-type.
36813232	0	63	theme	Caenorhabditis	47:60	arg1	elegans					62:68	Caenorhabditis elegans	47:68	Caenorhabditis elegans lacking the HEX-4 N-acetylgalactosamine-specific hexosaminidase	47:132	N-glycan antennal modifications are altered in Caenorhabditis elegans lacking the HEX-4 N-acetylgalactosamine-specific hexosaminidase.
36813232	5	64	theme	major	1181:1185	arg1	differences					1187:1197	no major differences	1178:1197	no major differences between the C. elegans wild-type and hex-5 mutant strains	1178:1255	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	3	65	theme	glycans	643:649	arg1	pools					634:638	Three pools	628:638	Three pools of glycans	628:649	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	5	66	theme	pools	1352:1356	arg1	sets					1305:1308	altered sets	1297:1308	altered sets of methanol-eluted and PNGase Ar-released pools	1297:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	5	66	theme	pools	1352:1356	arg1	pools					1352:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	4	67	theme	core	958:961	arg1	modifications					963:975	various core modifications	950:975	various core modifications	950:975	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	3	68	theme	reversed	725:732	arg1	resin					744:748	a reversed phase C18 resin	723:748	a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released	723:804	Three pools of glycans were analysed for each strain: either PNGase F-released and eluted from a reversed phase C18 resin with either water or 15% methanol or PNGase Ar-released.
36813232	2	69	theme	isomers	619:625	arg1	potential					593:601	a total N-glycomic potential	574:601	a total N-glycomic potential of 300 verified isomers	574:625	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	7	70	theme	fluorescence	1576:1587	arg1	microscopy					1589:1598	fluorescence microscopy	1576:1598	fluorescence microscopy	1576:1598	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	4	71	theme	water-eluted	817:828	arg1	fractions					830:838	the water-eluted fractions	813:838	the water-eluted fractions	813:838	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	1	72	with	N-glycans	276:284	arg1	core					307:310	highly variable core	291:310	highly variable core	291:310	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	1	72	with	N-glycans	276:284	arg1	modifications					325:337	antennal modifications	316:337	antennal modifications	316:337	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	1	73	theme	simple	181:186	arg1	glycomes					188:195	simple glycomes	181:195	simple glycomes	181:195	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	1	74	theme	abundant	267:274	arg1	N-glycans					276:284	the less abundant N-glycans	258:284	the less abundant N-glycans with highly variable core and antennal modifications	258:337	Simple organisms are often considered to have simple glycomes, but plentiful pauci- and oligomannosidic glycans overshadow the less abundant N-glycans with highly variable core and antennal modifications; Caenorhabditis elegans is no exception.
36813232	4	75	theme	huge	1029:1032	arg1	range					1034:1038	a huge range	1027:1038	a huge range of phosphorylcholine-modified structures	1027:1079	While the water-eluted fractions were dominated by typical pauci- and oligomannosidic glycans and the PNGase Ar-released pools by glycans with various core modifications, we found the methanol-eluted fractions contained a huge range of phosphorylcholine-modified structures with up to three antennae, sometimes with four N-acetylhexosamine residues in series.
36813232	8	76	theme	model	1854:1858	arg1	worm					1860:1863	the model worm	1850:1863	the model worm	1850:1863	Furthermore, finding more 'parasite-like' structures in the model worm may facilitate the discovery of glycan-processing enzymes occurring in other nematodes.
36813232	2	77	theme	model	555:559	arg1	nematode					561:568	the model nematode	551:568	the model nematode	551:568	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	5	78	theme	wild-type	1222:1230	arg1	strains					1249:1255	the C. elegans wild-type and hex-5 mutant strains	1207:1255	the C. elegans wild-type and hex-5 mutant strains	1207:1255	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	7	79	theme	Golgi	1660:1664	arg1	tracker					1666:1672	a Golgi tracker	1658:1672	a Golgi tracker	1658:1672	Additionally, considering that fluorescence microscopy shows that a HEX-4::eGFP fusion protein co-localises with a Golgi tracker, we conclude that HEX-4 plays a significant role in late-stage Golgi processing of N-glycans in Caenorhabditis elegans.
36813232	2	80	theme	HEX-5	498:502	arg1	β-N-acetylgalactosaminidases					504:531	HEX-5 β-N-acetylgalactosaminidases	498:531	HEX-5 β-N-acetylgalactosaminidases	498:531	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
36813232	5	81	theme	methanol-eluted	1313:1327	arg1	pools					1352:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	methanol-eluted and PNGase Ar-released pools	1313:1356	There were no major differences between the C. elegans wild-type and hex-5 mutant strains, but the hex-4 mutant strains displayed altered sets of methanol-eluted and PNGase Ar-released pools.
36813232	2	82	theme	total	576:580	arg1	potential					593:601	a total N-glycomic potential	574:601	a total N-glycomic potential of 300 verified isomers	574:625	By use of optimised fractionation and assessing wild-type in comparison to mutant strains lacking either the HEX-4 or HEX-5 β-N-acetylgalactosaminidases, we conclude that the model nematode has a total N-glycomic potential of 300 verified isomers.
37342334	10	0	theme	promising	1583:1591	arg1	potential					1593:1601	the promising potential	1579:1601	the promising potential of glycans as biomarkers of COVID-19 severity	1579:1647	Our findings show the promising potential of glycans as biomarkers of COVID-19 severity.
37342334	7	1	theme	N-glycosylation	1114:1128	arg1	profiles					1130:1137	different N-glycosylation profiles	1104:1137	different N-glycosylation profiles	1104:1137	Results We determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity.
37342334	9	2	theme	plasma	1459:1464	arg1	glycosignature					1466:1479	the global plasma glycosignature	1448:1479	the global plasma glycosignature	1448:1479	Conclusion In this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease.
37342334	3	3	theme	N-glycan	502:509	arg1	traits					511:516	N-glycan traits	502:516	N-glycan traits	502:516	Methods Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19.
37342334	10	4	theme	glycans	1606:1612	arg1	potential					1593:1601	the promising potential	1579:1601	the promising potential of glycans as biomarkers of COVID-19 severity	1579:1647	Our findings show the promising potential of glycans as biomarkers of COVID-19 severity.
37342334	9	5	theme	global	1452:1457	arg1	glycosignature					1466:1479	the global plasma glycosignature	1448:1479	the global plasma glycosignature	1448:1479	Conclusion In this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease.
37342334	3	6	from	patients	537:544	arg1	plasma					521:526	plasma	521:526	plasma from 196 patients with COVID-19	521:558	Methods Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19.
37342334	1	7	theme	COVID-19	170:177	arg1	progression					179:189	COVID-19 progression	170:189	COVID-19 progression	170:189	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	2	8	theme	biomarkers	316:325	arg1	discovery					303:311	the discovery	299:311	the discovery of biomarkers	299:325	Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage.
37342334	9	9	dep	Conclusion	1411:1420	arg1	study					1430:1434	this study	1425:1434	this study	1425:1434	Conclusion In this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease.
37342334	7	10	theme	different	1104:1112	arg1	profiles					1130:1137	different N-glycosylation profiles	1104:1137	different N-glycosylation profiles	1104:1137	Results We determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity.
37342334	4	11	theme	follow-up	714:722	arg1	weeks					705:709	4 weeks	703:709	4 weeks of follow-up (postdiagnosis)	703:738	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	3	12	theme	new	475:477	arg1	biomarkers					479:488	new biomarkers	475:488	new biomarkers	475:488	Methods Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19.
37342334	7	13	theme	SARS-CoV-2-infected	1067:1085	arg1	patients					1087:1094	SARS-CoV-2-infected patients	1067:1094	SARS-CoV-2-infected patients	1067:1094	Results We determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity.
37342334	8	14	theme	critical	1392:1399	arg1	outcomes					1401:1408	critical outcomes	1392:1408	critical outcomes	1392:1408	Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes.
37342334	1	15	theme	progression	179:189	arg1	unpredictability					150:165	the unpredictability	146:165	the unpredictability of COVID-19 progression	146:189	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	0	16	theme	COVID-19	45:52	arg1	severity					54:61	COVID-19 severity	45:61	COVID-19 severity	45:61	Fucosylated N-glycans as early biomarkers of COVID-19 severity.
37342334	1	17	theme	pathological	79:90	arg1	mechanisms					92:101	The pathological mechanisms	75:101	The pathological mechanisms of SARS-CoV-2 in humans	75:125	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	4	18	theme	severe	638:643	arg1	severity					622:629	their severity	616:629	their severity (mild, severe and critical)	616:657	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	7	19	from	patients	1087:1094	arg1	plasma					1055:1060	plasma	1055:1060	plasma from SARS-CoV-2-infected patients	1055:1094	Results We determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity.
37342334	3	20	dep	analysed	493:500	arg1	identify					466:473	identify	466:473	to identify new biomarkers	463:488	Methods Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19.
37342334	2	21	theme	critical	432:439	arg1	stage					441:445	a critical stage	430:445	a critical stage	430:445	Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage.
37342334	1	22	theme	disease	279:285	arg1	prognosis					261:269	the prognosis	257:269	the prognosis of this disease	257:285	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	4	23	dep	groups	596:601	arg1	according					603:611	according	603:611	according to their severity (mild, severe and critical)	603:657	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	4	23	dep	groups	596:601	arg1	obtained					663:670	obtained	663:670	obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis)	663:738	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	4	24	theme	critical	649:656	arg1	severity					622:629	their severity	616:629	their severity (mild, severe and critical)	616:657	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	0	25	theme	early	25:29	arg1	N-glycans					12:20	N-glycans	12:20	N-glycans	12:20	Fucosylated N-glycans as early biomarkers of COVID-19 severity.
37342334	0	25	theme	early	25:29	arg1	biomarkers					31:40	early biomarkers	25:40	early biomarkers of COVID-19 severity	25:61	Fucosylated N-glycans as early biomarkers of COVID-19 severity.
37342334	1	26	theme	SARS-CoV-2	106:115	arg1	mechanisms					92:101	The pathological mechanisms	75:101	The pathological mechanisms of SARS-CoV-2 in humans	75:125	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	8	27	theme	fucosylation	1198:1209	arg1	levels					1188:1193	levels	1188:1193	levels of fucosylation and galactosylation	1188:1229	Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes.
37342334	6	28	theme	structural	922:931	arg1	identification					933:946	The Simglycan structural identification tool and Glycostore database	908:975	The Simglycan structural identification tool and Glycostore database	908:975	The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans.
37342334	2	29	theme	risk	350:353	arg1	stratification					355:368	reliable risk stratification	341:368	reliable risk stratification	341:368	Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage.
37342334	6	30	theme	glycans	1019:1025	arg1	structure					1006:1014	the structure	1002:1014	the structure of glycans	1002:1025	The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans.
37342334	6	31	theme	Simglycan	912:920	arg1	identification					933:946	The Simglycan structural identification tool and Glycostore database	908:975	The Simglycan structural identification tool and Glycostore database	908:975	The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans.
37342334	9	32	theme	inflammatory	1497:1508	arg1	state					1510:1514	the inflammatory state	1493:1514	the inflammatory state of the organs during the infectious disease	1493:1558	Conclusion In this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease.
37342334	7	33	theme	disease	1156:1162	arg1	severity					1164:1171	the disease severity	1152:1171	the disease severity	1152:1171	Results We determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity.
37342334	8	34	theme	galactosylation	1215:1229	arg1	levels					1188:1193	levels	1188:1193	levels of fucosylation and galactosylation	1188:1229	Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes.
37342334	9	35	theme	organs	1523:1528	arg1	state					1510:1514	the inflammatory state	1493:1514	the inflammatory state of the organs during the infectious disease	1493:1558	Conclusion In this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease.
37342334	10	36	theme	severity	1640:1647	arg1	biomarkers					1617:1626	biomarkers	1617:1626	biomarkers of COVID-19 severity	1617:1647	Our findings show the promising potential of glycans as biomarkers of COVID-19 severity.
37342334	3	37	theme	Methods	448:454	arg1	Aiming					456:461	Methods Aiming	448:461	Methods Aiming	448:461	Methods Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19.
37342334	0	38	theme	severity	54:61	arg1	N-glycans					12:20	N-glycans	12:20	N-glycans	12:20	Fucosylated N-glycans as early biomarkers of COVID-19 severity.
37342334	0	38	theme	severity	54:61	arg1	biomarkers					31:40	early biomarkers	25:40	early biomarkers of COVID-19 severity	25:61	Fucosylated N-glycans as early biomarkers of COVID-19 severity.
37342334	2	39	theme	reliable	341:348	arg1	stratification					355:368	reliable risk stratification	341:368	reliable risk stratification	341:368	Therefore, the discovery of biomarkers is needed for reliable risk stratification and to identify patients who are more likely to progress to a critical stage.
37342334	3	40	with	patients	537:544	arg1	COVID-19					551:558	COVID-19	551:558	COVID-19	551:558	Methods Aiming to identify new biomarkers we analysed N-glycan traits in plasma from 196 patients with COVID-19.
37342334	4	41	theme	disease	777:783	arg1	progression					785:795	disease progression	777:795	disease progression	777:795	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	8	42	theme	suitable	1313:1320	arg1	Fuc1Hex5HexNAc5					1270:1284	Fuc1Hex5HexNAc5	1270:1284	Fuc1Hex5HexNAc5	1270:1284	Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes.
37342334	8	42	theme	suitable	1313:1320	arg1	biomarker					1322:1330	the most suitable biomarker	1304:1330	the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes	1304:1408	Specifically, levels of fucosylation and galactosylation decreased with increasing severity and Fuc1Hex5HexNAc5 was identified as the most suitable biomarker to stratify patients at diagnosis and distinguish mild from critical outcomes.
37342334	9	43	theme	infectious	1541:1550	arg1	disease					1552:1558	the infectious disease	1537:1558	the infectious disease	1537:1558	Conclusion In this study we explored the global plasma glycosignature, reflecting the inflammatory state of the organs during the infectious disease.
37342334	1	44	theme	biomarkers	227:236	arg1	absence					216:222	the absence	212:222	the absence of biomarkers that contribute to the prognosis of this disease	212:285	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	1	45	dep	Background	64:73	arg1	attributed					198:207	attributed	198:207	may be attributed to the absence of biomarkers that contribute to the prognosis of this disease	191:285	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	1	45	dep	Background	64:73	arg1	remain					127:132	remain	127:132	remain unclear	127:140	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	1	46	from	mechanisms	92:101	arg1	humans					120:125	humans	120:125	humans	120:125	Background The pathological mechanisms of SARS-CoV-2 in humans remain unclear and the unpredictability of COVID-19 progression may be attributed to the absence of biomarkers that contribute to the prognosis of this disease.
37342334	7	47	dep	Results	1028:1034	arg1	determined					1039:1048	determined	1039:1048	determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity	1039:1171	Results We determined that plasma from SARS-CoV-2-infected patients display different N-glycosylation profiles depending on the disease severity.
37342334	4	48	theme	mild	632:635	arg1	severity					622:629	their severity	616:629	their severity (mild, severe and critical)	616:657	Samples were classified into three groups according to their severity (mild, severe and critical) and obtained at diagnosis (baseline) and at 4 weeks of follow-up (postdiagnosis), to evaluate their behaviour through disease progression.
37342334	6	49	dep	identification	933:946	arg1	database					968:975	Glycostore database	957:975	Glycostore database	957:975	The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans.
37342334	6	49	dep	identification	933:946	arg1	tool					948:951	tool	948:951	tool	948:951	The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans.
37342334	5	50	theme	PNGase	827:832	arg1	F					834:834	PNGase F	827:834	PNGase F	827:834	N-glycans were released with PNGase F and labelled with Rapifluor-MS, followed by their analysis by LC-MS/MS.
37342334	6	51	theme	Glycostore	957:966	arg1	database					968:975	Glycostore database	957:975	Glycostore database	957:975	The Simglycan structural identification tool and Glycostore database were employed to predict the structure of glycans.
37342334	10	52	theme	COVID-19	1631:1638	arg1	severity					1640:1647	COVID-19 severity	1631:1647	COVID-19 severity	1631:1647	Our findings show the promising potential of glycans as biomarkers of COVID-19 severity.
36354960	0	0	theme	Tetrasaccharide	93:107	arg1	Synthesis					9:17	Chemical Synthesis	0:17	Chemical Synthesis	0:17	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	0	0	theme	Tetrasaccharide	93:107	arg1	Evaluation					36:45	Antigenicity Evaluation	23:45	Antigenicity Evaluation	23:45	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	4	1	theme	serotype	500:507	arg1	tetrasaccharide					522:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide	479:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	479:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	8	2	theme	-4,6-O-pyruvylated	1067:1084	arg1	tetrasaccharides					1105:1120	tetrasaccharides	1105:1120	tetrasaccharides	1105:1120	In addition, (R)-4,6-O-pyruvylated and nonpyruvylated tetrasaccharides and three further fragments were synthesized.
36354960	6	3	theme	glycosyl	773:780	arg1	donor					782:786	the glycosyl donor	769:786	the glycosyl donor	769:786	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	11	4	theme	other	1578:1582	arg1	glycans					1594:1600	other bacterial glycans	1578:1600	other bacterial glycans containing pyruvyl ketals	1578:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	0	5	theme	O-Antigen	83:91	arg1	Tetrasaccharide					93:107	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	4	6	theme	tetrasaccharide	522:536	arg1	synthesis					466:474	the first total synthesis	450:474	the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	450:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	5	7	theme	&	620:620	arg1	epimerization					625:637	The 1,2-trans-β-glycosylation & C2 epimerization	590:637	The 1,2-trans-β-glycosylation & C2 epimerization	590:637	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	1	8	theme	second	163:168	arg1	pathogen					192:199	the second most common etiologic pathogen	159:199	the second most common etiologic pathogen responsible for childhood acute diarrhea	159:240	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	1	8	theme	second	163:168	arg1	Shigella					147:154	Shigella	147:154	Shigella	147:154	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	7	9	theme	-4,6-O-pyruvyl	920:933	arg1	ketal					935:939	The (S)-4,6-O-pyruvyl ketal	913:939	The (S)-4,6-O-pyruvyl ketal	913:939	The (S)-4,6-O-pyruvyl ketal was introduced at the final stage due to its influence on the glycosylation stereospecificity and efficiency.
36354960	4	10	theme	O-antigen	512:520	arg1	tetrasaccharide					522:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide	479:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	479:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	8	11	theme	nonpyruvylated	1090:1103	arg1	tetrasaccharides					1105:1120	tetrasaccharides	1105:1120	tetrasaccharides	1105:1120	In addition, (R)-4,6-O-pyruvylated and nonpyruvylated tetrasaccharides and three further fragments were synthesized.
36354960	5	12	theme	C2	622:623	arg1	epimerization					625:637	The 1,2-trans-β-glycosylation & C2 epimerization	590:637	The 1,2-trans-β-glycosylation & C2 epimerization	590:637	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	9	13	theme	key	1252:1254	arg1	epitope					1266:1272	the key antigenic epitope	1248:1272	the key antigenic epitope of the O-antigen	1248:1289	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	9	13	theme	key	1252:1254	arg1	unit					1240:1243	the tetrasaccharide repeating unit	1210:1243	the tetrasaccharide repeating unit	1210:1243	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	11	14	theme	-4,6-O-pyruvylated	1484:1501	arg1	glycan					1503:1508	the (S)-4,6-O-pyruvylated glycan	1477:1508	the (S)-4,6-O-pyruvylated glycan	1477:1508	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	4	15	theme	immune	419:424	arg1	epitopes					426:433	the immune epitopes	415:433	the immune epitopes of the glycan	415:447	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	7	16	theme	S	918:918	arg1	ketal					935:939	The (S)-4,6-O-pyruvyl ketal	913:939	The (S)-4,6-O-pyruvyl ketal	913:939	The (S)-4,6-O-pyruvyl ketal was introduced at the final stage due to its influence on the glycosylation stereospecificity and efficiency.
36354960	11	17	contain	containing	1602:1611	arg1	glycans					1594:1600	other bacterial glycans	1578:1600	other bacterial glycans containing pyruvyl ketals	1578:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	11	17	contain	containing	1602:1611	arg2	ketals					1621:1626	pyruvyl ketals	1613:1626	pyruvyl ketals	1613:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	3	18	theme	Shigella	353:360	arg1	target					395:400	a promising vaccine target	375:400	a promising vaccine target	375:400	The Shigella O-antigen is a promising vaccine target.
36354960	3	18	theme	Shigella	353:360	arg1	O-antigen					362:370	The Shigella O-antigen	349:370	The Shigella O-antigen	349:370	The Shigella O-antigen is a promising vaccine target.
36354960	11	19	theme	its	1514:1516	arg1	-epimer					1521:1527	its (R)-epimer	1514:1527	its (R)-epimer	1514:1527	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	5	20	theme	conformational	643:656	arg1	strategies					666:675	conformational locking strategies	643:675	conformational locking strategies	643:675	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	11	21	theme	glycans	1594:1600	arg1	evaluation					1564:1573	biological evaluation	1553:1573	biological evaluation of other bacterial glycans containing pyruvyl ketals	1553:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	4	22	contain	containing	538:547	arg2	ketal					569:573	a (S)-4,6-O-pyruvyl ketal	549:573	a (S)-4,6-O-pyruvyl ketal	549:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	4	22	contain	containing	538:547	arg1	tetrasaccharide					522:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide	479:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	479:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	9	23	theme	antigenic	1256:1264	arg1	epitope					1266:1272	the key antigenic epitope	1248:1272	the key antigenic epitope of the O-antigen	1248:1289	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	9	23	theme	antigenic	1256:1264	arg1	unit					1240:1243	the tetrasaccharide repeating unit	1210:1243	the tetrasaccharide repeating unit	1210:1243	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	11	24	theme	S	1482:1482	arg1	glycan					1503:1508	the (S)-4,6-O-pyruvylated glycan	1477:1508	the (S)-4,6-O-pyruvylated glycan	1477:1508	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	4	25	theme	dysenteriae	488:498	arg1	tetrasaccharide					522:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide	479:536	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	479:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	5	26	theme	locking	658:664	arg1	strategies					666:675	conformational locking strategies	643:675	conformational locking strategies	643:675	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	9	27	theme	O-antigen	1281:1289	arg1	epitope					1266:1272	the key antigenic epitope	1248:1272	the key antigenic epitope of the O-antigen	1248:1289	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	9	27	theme	O-antigen	1281:1289	arg1	unit					1240:1243	the tetrasaccharide repeating unit	1210:1243	the tetrasaccharide repeating unit	1210:1243	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	10	28	theme	dysenteriae	1434:1444	arg1	serotype					1446:1453	S. dysenteriae serotype 10	1431:1456	S. dysenteriae serotype 10	1431:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	1	29	theme	common	175:180	arg1	pathogen					192:199	the second most common etiologic pathogen	159:199	the second most common etiologic pathogen responsible for childhood acute diarrhea	159:240	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	1	29	theme	common	175:180	arg1	Shigella					147:154	Shigella	147:154	Shigella	147:154	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	4	30	theme	Shigella	479:486	arg1	dysenteriae					488:498	Shigella dysenteriae	479:498	Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	479:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	8	31	theme	further	1132:1138	arg1	fragments					1140:1148	three further fragments	1126:1148	three further fragments	1126:1148	In addition, (R)-4,6-O-pyruvylated and nonpyruvylated tetrasaccharides and three further fragments were synthesized.
36354960	10	32	theme	carbohydrate-based	1395:1412	arg1	vaccines					1414:1421	carbohydrate-based vaccines	1395:1421	carbohydrate-based vaccines against S. dysenteriae serotype 10	1395:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	0	33	theme	S	123:123	arg1	Ketal					140:144	a (S)-4,6-O-Pyruvyl Ketal	120:144	a (S)-4,6-O-Pyruvyl Ketal	120:144	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	10	34	theme	essential	1336:1344	arg1	feature					1357:1363	an essential structural feature	1333:1363	an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10	1333:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	10	34	theme	essential	1336:1344	arg1	ketal					1324:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	1	35	theme	etiologic	182:190	arg1	pathogen					192:199	the second most common etiologic pathogen	159:199	the second most common etiologic pathogen responsible for childhood acute diarrhea	159:240	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	1	35	theme	etiologic	182:190	arg1	Shigella					147:154	Shigella	147:154	Shigella	147:154	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	0	36	theme	Chemical	0:7	arg1	Synthesis					9:17	Chemical Synthesis	0:17	Chemical Synthesis	0:17	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	4	37	theme	-4,6-O-pyruvyl	554:567	arg1	ketal					569:573	a (S)-4,6-O-pyruvyl ketal	549:573	a (S)-4,6-O-pyruvyl ketal	549:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	6	38	theme	benzyl	843:848	arg1	groups					850:855	electron-donating benzyl groups	825:855	electron-donating benzyl groups	825:855	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	8	39	dep	-4,6-O-pyruvylated	1067:1084	arg1	R					1065:1065	R	1065:1065	R	1065:1065	In addition, (R)-4,6-O-pyruvylated and nonpyruvylated tetrasaccharides and three further fragments were synthesized.
36354960	3	40	theme	promising	377:385	arg1	target					395:400	a promising vaccine target	375:400	a promising vaccine target	375:400	The Shigella O-antigen is a promising vaccine target.
36354960	3	40	theme	promising	377:385	arg1	O-antigen					362:370	The Shigella O-antigen	349:370	The Shigella O-antigen	349:370	The Shigella O-antigen is a promising vaccine target.
36354960	0	41	theme	-4,6-O-Pyruvyl	125:138	arg1	Ketal					140:144	a (S)-4,6-O-Pyruvyl Ketal	120:144	a (S)-4,6-O-Pyruvyl Ketal	120:144	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	5	42	theme	1,2-trans-β-glycosylation	594:618	arg1	epimerization					625:637	The 1,2-trans-β-glycosylation & C2 epimerization	590:637	The 1,2-trans-β-glycosylation & C2 epimerization	590:637	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	2	43	theme	drug	315:318	arg1	resistance					320:329	the increasing drug resistance	300:329	the increasing drug resistance of this pathogen	300:346	An anti-Shigella vaccine is still eagerly awaited due to the increasing drug resistance of this pathogen.
36354960	7	44	theme	glycosylation	1003:1015	arg1	stereospecificity					1017:1033	the glycosylation stereospecificity	999:1033	the glycosylation stereospecificity	999:1033	The (S)-4,6-O-pyruvyl ketal was introduced at the final stage due to its influence on the glycosylation stereospecificity and efficiency.
36354960	1	45	theme	responsible	201:211	arg1	pathogen					192:199	the second most common etiologic pathogen	159:199	the second most common etiologic pathogen responsible for childhood acute diarrhea	159:240	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	1	45	theme	responsible	201:211	arg1	Shigella					147:154	Shigella	147:154	Shigella	147:154	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	3	46	theme	vaccine	387:393	arg1	target					395:400	a promising vaccine target	375:400	a promising vaccine target	375:400	The Shigella O-antigen is a promising vaccine target.
36354960	3	46	theme	vaccine	387:393	arg1	O-antigen					362:370	The Shigella O-antigen	349:370	The Shigella O-antigen	349:370	The Shigella O-antigen is a promising vaccine target.
36354960	9	47	theme	tetrasaccharide	1214:1228	arg1	epitope					1266:1272	the key antigenic epitope	1248:1272	the key antigenic epitope of the O-antigen	1248:1289	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	9	47	theme	tetrasaccharide	1214:1228	arg1	unit					1240:1243	the tetrasaccharide repeating unit	1210:1243	the tetrasaccharide repeating unit	1210:1243	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	2	48	theme	increasing	304:313	arg1	resistance					320:329	the increasing drug resistance	300:329	the increasing drug resistance of this pathogen	300:346	An anti-Shigella vaccine is still eagerly awaited due to the increasing drug resistance of this pathogen.
36354960	10	49	theme	antigen	1373:1379	arg1	feature					1357:1363	an essential structural feature	1333:1363	an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10	1333:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	10	49	theme	antigen	1373:1379	arg1	ketal					1324:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	9	50	theme	Glycan	1168:1173	arg1	screening					1186:1194	Glycan microarray screening	1168:1194	Glycan microarray screening	1168:1194	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	11	51	theme	biological	1553:1562	arg1	evaluation					1564:1573	biological evaluation	1553:1573	biological evaluation of other bacterial glycans containing pyruvyl ketals	1553:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	2	52	theme	anti-Shigella	246:258	arg1	vaccine					260:266	An anti-Shigella vaccine	243:266	An anti-Shigella vaccine	243:266	An anti-Shigella vaccine is still eagerly awaited due to the increasing drug resistance of this pathogen.
36354960	1	53	theme	childhood	217:225	arg1	diarrhea					233:240	childhood acute diarrhea	217:240	childhood acute diarrhea	217:240	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	4	54	theme	total	460:464	arg1	synthesis					466:474	the first total synthesis	450:474	the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	450:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	0	55	theme	Antigenicity	23:34	arg1	Evaluation					36:45	Antigenicity Evaluation	23:45	Antigenicity Evaluation	23:45	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	10	56	theme	S.	1431:1432	arg1	serotype					1446:1453	S. dysenteriae serotype 10	1431:1456	S. dysenteriae serotype 10	1431:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	1	57	theme	acute	227:231	arg1	diarrhea					233:240	childhood acute diarrhea	217:240	childhood acute diarrhea	217:240	Shigella is the second most common etiologic pathogen responsible for childhood acute diarrhea.
36354960	0	58	theme	dysenteriae	59:69	arg1	Tetrasaccharide					93:107	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	5	59	theme	1,2-cis-β-glycosidic	713:732	arg1	linkages					734:741	two 1,2-cis-β-glycosidic linkages	709:741	two 1,2-cis-β-glycosidic linkages	709:741	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	4	60	theme	first	454:458	arg1	synthesis					466:474	the first total synthesis	450:474	the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal	450:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	0	61	theme	Shigella	50:57	arg1	dysenteriae					59:69	Shigella dysenteriae	50:69	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	4	62	theme	S	552:552	arg1	ketal					569:573	a (S)-4,6-O-pyruvyl ketal	549:573	a (S)-4,6-O-pyruvyl ketal	549:573	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	5	63	theme	linkages	734:741	arg1	construction					693:704	the construction	689:704	the construction of two 1,2-cis-β-glycosidic linkages	689:741	The 1,2-trans-β-glycosylation & C2 epimerization and conformational locking strategies facilitated the construction of two 1,2-cis-β-glycosidic linkages.
36354960	11	64	theme	pyruvyl	1613:1619	arg1	ketals					1621:1626	pyruvyl ketals	1613:1626	pyruvyl ketals	1613:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	9	65	theme	microarray	1175:1184	arg1	screening					1186:1194	Glycan microarray screening	1168:1194	Glycan microarray screening	1168:1194	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	7	66	theme	final	963:967	arg1	stage					969:973	the final stage	959:973	the final stage due to its influence on the glycosylation stereospecificity and efficiency	959:1048	The (S)-4,6-O-pyruvyl ketal was introduced at the final stage due to its influence on the glycosylation stereospecificity and efficiency.
36354960	6	67	theme	electron-donating	825:841	arg1	groups					850:855	electron-donating benzyl groups	825:855	electron-donating benzyl groups	825:855	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	6	68	theme	tetrasaccharide	896:910	arg1	assembly					880:887	an efficient assembly	867:887	an efficient assembly of the tetrasaccharide	867:910	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	11	69	theme	bacterial	1584:1592	arg1	glycans					1594:1600	other bacterial glycans	1578:1600	other bacterial glycans containing pyruvyl ketals	1578:1626	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	6	70	theme	efficient	870:878	arg1	assembly					880:887	an efficient assembly	867:887	an efficient assembly of the tetrasaccharide	867:910	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	2	71	theme	pathogen	339:346	arg1	resistance					320:329	the increasing drug resistance	300:329	the increasing drug resistance of this pathogen	300:346	An anti-Shigella vaccine is still eagerly awaited due to the increasing drug resistance of this pathogen.
36354960	10	72	theme	S	1307:1307	arg1	feature					1357:1363	an essential structural feature	1333:1363	an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10	1333:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	10	72	theme	S	1307:1307	arg1	ketal					1324:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	9	73	theme	repeating	1230:1238	arg1	epitope					1266:1272	the key antigenic epitope	1248:1272	the key antigenic epitope of the O-antigen	1248:1289	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	9	73	theme	repeating	1230:1238	arg1	unit					1240:1243	the tetrasaccharide repeating unit	1210:1243	the tetrasaccharide repeating unit	1210:1243	Glycan microarray screening revealed that the tetrasaccharide repeating unit is the key antigenic epitope of the O-antigen.
36354960	4	74	theme	glycan	442:447	arg1	epitopes					426:433	the immune epitopes	415:433	the immune epitopes of the glycan	415:447	To identify the immune epitopes of the glycan, the first total synthesis of Shigella dysenteriae serotype 10 O-antigen tetrasaccharide containing a (S)-4,6-O-pyruvyl ketal was completed.
36354960	6	75	theme	acceptor	792:799	arg1	reactivities					748:759	The reactivities	744:759	The reactivities of both the glycosyl donor and acceptor	744:799	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	7	76	from	influence	986:994	arg1	efficiency					1039:1048	efficiency	1039:1048	efficiency	1039:1048	The (S)-4,6-O-pyruvyl ketal was introduced at the final stage due to its influence on the glycosylation stereospecificity and efficiency.
36354960	7	76	from	influence	986:994	arg1	stereospecificity					1017:1033	the glycosylation stereospecificity	999:1033	the glycosylation stereospecificity	999:1033	The (S)-4,6-O-pyruvyl ketal was introduced at the final stage due to its influence on the glycosylation stereospecificity and efficiency.
36354960	10	77	theme	structural	1346:1355	arg1	feature					1357:1363	an essential structural feature	1333:1363	an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10	1333:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	10	77	theme	structural	1346:1355	arg1	ketal					1324:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	10	78	theme	-4,6-O-pyruvyl	1309:1322	arg1	feature					1357:1363	an essential structural feature	1333:1363	an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10	1333:1456	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	10	78	theme	-4,6-O-pyruvyl	1309:1322	arg1	ketal					1324:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	the (S)-4,6-O-pyruvyl ketal	1302:1328	Moreover, the (S)-4,6-O-pyruvyl ketal is an essential structural feature of this antigen for designing carbohydrate-based vaccines against S. dysenteriae serotype 10.
36354960	11	79	theme	-epimer	1521:1527	arg1	comparison					1463:1472	The comparison	1459:1472	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer	1459:1527	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36354960	0	80	theme	Serotype	71:78	arg1	Tetrasaccharide					93:107	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide	50:107	Chemical Synthesis and Antigenicity Evaluation of Shigella dysenteriae Serotype 10 O-Antigen Tetrasaccharide Containing a (S)-4,6-O-Pyruvyl Ketal.
36354960	6	81	theme	donor	782:786	arg1	reactivities					748:759	The reactivities	744:759	The reactivities of both the glycosyl donor and acceptor	744:799	The reactivities of both the glycosyl donor and acceptor were improved by adding electron-donating benzyl groups, enabling an efficient assembly of the tetrasaccharide.
36354960	11	82	theme	glycan	1503:1508	arg1	comparison					1463:1472	The comparison	1459:1472	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer	1459:1527	The comparison of the (S)-4,6-O-pyruvylated glycan and its (R)-epimer will set an example for biological evaluation of other bacterial glycans containing pyruvyl ketals.
36181511	3	0	theme	mannose	769:775	arg1	glycans					777:783	high mannose glycans	764:783	high mannose glycans	764:783	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	1	1	gly	glycopeptides	190:202	arg2	glycopeptides					190:202	glycopeptides	190:202	glycopeptides	190:202	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	3	2	theme	mixed	558:562	arg1	approaches					585:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	4	3	theme	HILIC	838:842	arg1	capacity					801:808	capacity	801:808	capacity	801:808	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	3	theme	HILIC	838:842	arg1	rate					823:826	recovery rate	814:826	recovery rate	814:826	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	4	theme	enrichment	929:938	arg1	performance					940:950	a reasonable glycopeptide enrichment performance	903:950	a reasonable glycopeptide enrichment performance (~6% recovery)	903:965	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	4	theme	enrichment	929:938	arg1	recovery					957:964	~6% recovery	953:964	~6% recovery	953:964	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	3	5	theme	anion-exchange	564:577	arg1	approaches					585:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	5	6	theme	optional	1035:1042	arg1	HILIC					1011:1015	cotton HILIC	1004:1015	cotton HILIC	1004:1015	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	5	6	theme	optional	1035:1042	arg1	approach					1068:1075	an optional glycopeptide enrichment approach	1032:1075	an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit	1032:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	4	7	theme	~6	953:954	arg1	performance					940:950	a reasonable glycopeptide enrichment performance	903:950	a reasonable glycopeptide enrichment performance (~6% recovery)	903:965	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	7	theme	~6	953:954	arg1	recovery					957:964	~6% recovery	953:964	~6% recovery	953:964	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	1	8	theme	Selecting	60:68	arg1	approaches					115:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	4	9	theme	recovery	814:821	arg1	rate					823:826	recovery rate	814:826	recovery rate	814:826	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	1	10	gly	glycopeptide	91:102	arg2	glycopeptide					91:102	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	2	11	theme	interaction	329:339	arg1	HILIC					364:368	HILIC	364:368	HILIC	364:368	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	11	theme	interaction	329:339	arg1	chromatography					348:361	a cotton hydrophilic interaction liquid chromatography	308:361	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	1	12	theme	proper	70:75	arg1	approaches					115:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	3	13	theme	HILIC	548:552	arg1	approaches					585:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	3	14	gly	glycopeptide	648:659	arg2	glycopeptide					648:659	overall glycopeptide enrichment	640:670	overall glycopeptide enrichment	640:670	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	2	15	theme	hydrophilic	317:327	arg1	HILIC					364:368	HILIC	364:368	HILIC	364:368	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	15	theme	hydrophilic	317:327	arg1	chromatography					348:361	a cotton hydrophilic interaction liquid chromatography	308:361	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	3	16	theme	cotton	522:527	arg1	HILIC					529:533	cotton HILIC	522:533	cotton HILIC	522:533	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	2	17	theme	cotton	310:315	arg1	HILIC					364:368	HILIC	364:368	HILIC	364:368	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	17	theme	cotton	310:315	arg1	chromatography					348:361	a cotton hydrophilic interaction liquid chromatography	308:361	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	18	theme	trifluoroacetic	445:459	arg1	acid					461:464	80% acetonitrile/1% trifluoroacetic acid	425:464	80% acetonitrile/1% trifluoroacetic acid	425:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	19	theme	liquid	341:346	arg1	HILIC					364:368	HILIC	364:368	HILIC	364:368	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	19	theme	liquid	341:346	arg1	chromatography					348:361	a cotton hydrophilic interaction liquid chromatography	308:361	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	5	20	theme	cotton	1004:1009	arg1	HILIC					1011:1015	cotton HILIC	1004:1015	cotton HILIC	1004:1015	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	5	20	theme	cotton	1004:1009	arg1	approach					1068:1075	an optional glycopeptide enrichment approach	1032:1075	an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit	1032:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	4	21	theme	glycopeptide	916:927	arg1	performance					940:950	a reasonable glycopeptide enrichment performance	903:950	a reasonable glycopeptide enrichment performance (~6% recovery)	903:965	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	21	theme	glycopeptide	916:927	arg1	recovery					957:964	~6% recovery	953:964	~6% recovery	953:964	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	5	22	theme	glycopeptide	1044:1055	arg1	HILIC					1011:1015	cotton HILIC	1004:1015	cotton HILIC	1004:1015	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	5	22	theme	glycopeptide	1044:1055	arg1	approach					1068:1075	an optional glycopeptide enrichment approach	1032:1075	an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit	1032:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	1	23	theme	glycopeptide	91:102	arg1	approaches					115:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	4	24	theme	%	955:955	arg1	performance					940:950	a reasonable glycopeptide enrichment performance	903:950	a reasonable glycopeptide enrichment performance (~6% recovery)	903:965	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	24	theme	%	955:955	arg1	recovery					957:964	~6% recovery	953:964	~6% recovery	953:964	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	25	theme	reasonable	905:914	arg1	performance					940:950	a reasonable glycopeptide enrichment performance	903:950	a reasonable glycopeptide enrichment performance (~6% recovery)	903:965	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	4	25	theme	reasonable	905:914	arg1	recovery					957:964	~6% recovery	953:964	~6% recovery	953:964	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	1	26	theme	enrichment	104:113	arg1	approaches					115:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	4	27	theme	cotton	831:836	arg1	HILIC					838:842	cotton HILIC	831:842	cotton HILIC	831:842	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	3	28	theme	glycan	716:721	arg1	structures					723:732	complex glycan structures	708:732	complex glycan structures	708:732	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	0	29	theme	cotton	24:29	arg1	Evaluation					0:9	Evaluation	0:9	Evaluation of absorbent cotton for glycopeptide enrichment.	0:58	Evaluation of absorbent cotton for glycopeptide enrichment.
36181511	4	30	theme	capacity	801:808	arg1	Exploration					786:796	Exploration	786:796	Exploration of capacity and recovery rate of cotton HILIC	786:842	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	3	31	with	comparison	508:517	arg1	approaches					585:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	Venusil HILIC and mixed anion-exchange (MAX) approaches	540:594	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	4	32	theme	200μL	884:888	arg1	tip					890:892	a 200μL tip	882:892	a 200μL tip	882:892	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	3	33	theme	cotton	611:616	arg1	HILIC					618:622	cotton HILIC	611:622	cotton HILIC	611:622	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	2	34	theme	sample	481:486	arg1	approach					371:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach	308:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	34	theme	sample	481:486	arg1	buffer					496:501	the optimal sample loading buffer	469:501	the optimal sample loading buffer	469:501	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	35	theme	loading	488:494	arg1	approach					371:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach	308:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	35	theme	loading	488:494	arg1	buffer					496:501	the optimal sample loading buffer	469:501	the optimal sample loading buffer	469:501	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	3	36	dep	anion-exchange	564:577	arg1	MAX					580:582	MAX	580:582	MAX	580:582	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	4	37	theme	~0.5mg	972:977	arg1	peptides					979:986	~0.5mg peptides	972:986	~0.5mg peptides	972:986	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	3	38	theme	complex	708:714	arg1	structures					723:732	complex glycan structures	708:732	complex glycan structures	708:732	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	2	39	theme	chromatography	348:361	arg1	approach					371:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach	308:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	39	theme	chromatography	348:361	arg1	buffer					496:501	the optimal sample loading buffer	469:501	the optimal sample loading buffer	469:501	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	5	40	from	approach	1068:1075	arg1	analysis					1094:1101	glycosylation analysis	1080:1101	glycosylation analysis with its specific merit	1080:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	2	41	theme	optimal	473:479	arg1	approach					371:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach	308:378	a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid	308:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	2	41	theme	optimal	473:479	arg1	buffer					496:501	the optimal sample loading buffer	469:501	the optimal sample loading buffer	469:501	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	0	42	theme	glycopeptide	35:46	arg1	enrichment					48:57	glycopeptide enrichment	35:57	glycopeptide enrichment	35:57	Evaluation of absorbent cotton for glycopeptide enrichment.
36181511	2	43	with	approach	371:378	arg1	acid					461:464	80% acetonitrile/1% trifluoroacetic acid	425:464	80% acetonitrile/1% trifluoroacetic acid	425:464	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	3	44	theme	glycopeptide	648:659	arg1	enrichment					661:670	overall glycopeptide enrichment	640:670	overall glycopeptide enrichment	640:670	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	3	45	from	enrichment	661:670	arg1	superior					628:635	superior	628:635	superior	628:635	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	1	46	theme	most	261:264	arg1	samples					277:283	most biological samples	261:283	most biological samples	261:283	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	5	47	theme	glycosylation	1080:1092	arg1	analysis					1094:1101	glycosylation analysis	1080:1101	glycosylation analysis with its specific merit	1080:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	2	48	theme	glycopeptide	396:407	arg1	enrichment					409:418	large-scale glycopeptide enrichment	384:418	large-scale glycopeptide enrichment	384:418	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	5	49	gly	glycopeptide	1044:1055	arg2	glycopeptide					1044:1055	an optional glycopeptide enrichment approach	1032:1075	an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit	1032:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	2	50	gly	glycopeptide	396:407	arg2	glycopeptide					396:407	large-scale glycopeptide enrichment	384:418	large-scale glycopeptide enrichment	384:418	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	3	51	theme	overall	640:646	arg1	enrichment					661:670	overall glycopeptide enrichment	640:670	overall glycopeptide enrichment	640:670	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	2	52	theme	large-scale	384:394	arg1	enrichment					409:418	large-scale glycopeptide enrichment	384:418	large-scale glycopeptide enrichment	384:418	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	5	53	theme	enrichment	1057:1066	arg1	HILIC					1011:1015	cotton HILIC	1004:1015	cotton HILIC	1004:1015	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	5	53	theme	enrichment	1057:1066	arg1	approach					1068:1075	an optional glycopeptide enrichment approach	1032:1075	an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit	1032:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	4	54	theme	5mg	861:863	arg1	cotton					865:870	5mg cotton	861:870	5mg cotton packed in a 200μL tip	861:892	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	3	55	theme	Venusil	681:687	arg1	HILIC					689:693	Venusil HILIC	681:693	Venusil HILIC preferred in complex glycan structures and MAX	681:740	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	1	56	from	abundance	248:256	arg1	samples					277:283	most biological samples	261:283	most biological samples	261:283	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	4	57	theme	rate	823:826	arg1	Exploration					786:796	Exploration	786:796	Exploration of capacity and recovery rate of cotton HILIC	786:842	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	1	58	theme	biological	266:275	arg1	samples					277:283	most biological samples	261:283	most biological samples	261:283	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	1	59	theme	efficient	81:89	arg1	approaches					115:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches	60:124	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	5	60	theme	specific	1112:1119	arg1	merit					1121:1125	its specific merit	1108:1125	its specific merit	1108:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	0	61	gly	glycopeptide	35:46	arg2	glycopeptide					35:46	glycopeptide enrichment	35:57	glycopeptide enrichment	35:57	Evaluation of absorbent cotton for glycopeptide enrichment.
36181511	1	62	from	microheterogeneity	221:238	arg1	samples					277:283	most biological samples	261:283	most biological samples	261:283	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	1	63	theme	spectrometry-based	149:166	arg1	glycoproteomics					168:182	mass spectrometry-based glycoproteomics	144:182	mass spectrometry-based glycoproteomics	144:182	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	3	64	theme	HILIC	529:533	arg1	comparison					508:517	The comparison	504:517	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches	504:594	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	4	65	gly	glycopeptide	916:927	arg2	glycopeptide					916:927	a reasonable glycopeptide enrichment performance	903:950	a reasonable glycopeptide enrichment performance (~6% recovery)	903:965	Exploration of capacity and recovery rate of cotton HILIC illustrated that 5mg cotton packed in a 200μL tip achieved a reasonable glycopeptide enrichment performance (~6% recovery) from ~0.5mg peptides.
36181511	5	66	used	used	1024:1027	arg2	HILIC					1011:1015	cotton HILIC	1004:1015	cotton HILIC	1004:1015	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	5	66	used	used	1024:1027	arg2	approach					1068:1075	an optional glycopeptide enrichment approach	1032:1075	an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit	1032:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
36181511	1	67	theme	low	244:246	arg1	abundance					248:256	low abundance	244:256	low abundance	244:256	Selecting proper and efficient glycopeptide enrichment approaches are essential for mass spectrometry-based glycoproteomics since glycopeptides are usually with microheterogeneity and low abundance in most biological samples.
36181511	2	68	theme	%	427:427	arg1	%					443:443	80% acetonitrile/1%	425:443	80% acetonitrile/1%	425:443	Herein, we introduced a cotton hydrophilic interaction liquid chromatography (HILIC) approach for large-scale glycopeptide enrichment with 80% acetonitrile/1% trifluoroacetic acid as the optimal sample loading buffer.
36181511	3	69	from	superior	628:635	arg1	enrichment					661:670	overall glycopeptide enrichment	640:670	overall glycopeptide enrichment	640:670	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	3	70	theme	high	764:767	arg1	glycans					777:783	high mannose glycans	764:783	high mannose glycans	764:783	The comparison of cotton HILIC with Venusil HILIC and mixed anion-exchange (MAX) approaches indicated that cotton HILIC was superior in overall glycopeptide enrichment, whereas Venusil HILIC preferred in complex glycan structures and MAX performed better with high mannose glycans.
36181511	0	71	theme	absorbent	14:22	arg1	cotton					24:29	absorbent cotton	14:29	absorbent cotton	14:29	Evaluation of absorbent cotton for glycopeptide enrichment.
36181511	5	72	with	analysis	1094:1101	arg1	merit					1121:1125	its specific merit	1108:1125	its specific merit	1108:1125	In conclusion, cotton HILIC can be used as an optional glycopeptide enrichment approach in glycosylation analysis with its specific merit.
37316505	6	0	from	sites	957:961	arg1	protein					975:981	the PD-1 protein	966:981	the PD-1 protein	966:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	5	1	theme	mucin-type	826:835	arg1	core					851:854	sialylated mucin-type O-glycan with core 1-	815:857	sialylated mucin-type O-glycan with core 1-	815:857	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	6	2	theme	novel	938:942	arg1	sites					957:961	potential novel modification sites	928:961	potential novel modification sites on the PD-1 protein	928:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	0	3	theme	stalk	69:73	arg1	region					75:80	the stalk region	65:80	the stalk region of PD-1 protein	65:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	6	4	from	method	1001:1006	arg1	sites					957:961	potential novel modification sites	928:961	potential novel modification sites on the PD-1 protein	928:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	5	5	theme	O-glycan	837:844	arg1	core					851:854	sialylated mucin-type O-glycan with core 1-	815:857	sialylated mucin-type O-glycan with core 1-	815:857	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	6	6	theme	potential	928:936	arg1	sites					957:961	potential novel modification sites	928:961	potential novel modification sites on the PD-1 protein	928:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	0	7	theme	PD-1	85:88	arg1	protein					90:96	PD-1 protein	85:96	PD-1 protein	85:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	3	8	theme	posttranslational	469:485	arg1	modification					487:498	the posttranslational modification	465:498	the posttranslational modification of this protein	465:514	Although the PD-1 structure has been studied for more than two decades, the posttranslational modification of this protein has been incompletely characterized.
37316505	4	9	theme	O-protease	689:698	arg1	coupling					710:717	O-protease digestion coupling	689:717	O-protease digestion coupling	689:717	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	0	10	from	glycosylation	48:60	arg1	region					75:80	the stalk region	65:80	the stalk region of PD-1 protein	65:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	4	11	theme	PD-1	670:673	arg1	protein					675:681	PD-1 protein	670:681	PD-1 protein	670:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	1	12	theme	promising	213:221	arg1	target					223:228	a promising target	211:228	a promising target for cancer therapy	211:247	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	12	theme	promising	213:221	arg1	protein					121:127	Programmed cell death protein 1	99:129	Programmed cell death protein 1 (PD-1)	99:136	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	5	13	theme	with	846:849	arg1	core					851:854	sialylated mucin-type O-glycan with core 1-	815:857	sialylated mucin-type O-glycan with core 1-	815:857	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	4	14	theme	mass	731:734	arg1	analysis					736:743	intact mass analysis	724:743	intact mass analysis	724:743	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	4	15	from	sites	622:626	arg1	region					660:665	the stalk region	650:665	the stalk region of PD-1 protein	650:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	4	16	theme	modification	609:620	arg1	sites					622:626	the previously undescribed modification sites	582:626	the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein	582:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	4	16	theme	modification	609:620	arg1	glycan					640:645	O-linked glycan	631:645	O-linked glycan	631:645	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	0	17	theme	protein	90:96	arg1	region					75:80	the stalk region	65:80	the stalk region of PD-1 protein	65:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	6	18	from	information	913:923	arg1	sites					957:961	potential novel modification sites	928:961	potential novel modification sites on the PD-1 protein	928:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	4	19	theme	intact	724:729	arg1	analysis					736:743	intact mass analysis	724:743	intact mass analysis	724:743	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	6	20	theme	O-linked	1024:1031	arg1	glycosylation					1033:1045	O-linked glycosylation	1024:1045	O-linked glycosylation using a specific enzyme and intact mass analysis	1024:1094	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	4	21	theme	undescribed	597:607	arg1	sites					622:626	the previously undescribed modification sites	582:626	the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein	582:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	4	21	theme	undescribed	597:607	arg1	glycan					640:645	O-linked glycan	631:645	O-linked glycan	631:645	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	0	22	theme	mass	7:10	arg1	analysis					12:19	Intact mass analysis	0:19	Intact mass analysis	0:19	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	6	23	theme	PD-1	970:973	arg1	protein					975:981	the PD-1 protein	966:981	the PD-1 protein	966:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	0	24	link	O-linked	39:46	arg1	glycosylation					48:60	the novel O-linked glycosylation	29:60	the novel O-linked glycosylation on the stalk region of PD-1 protein	29:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	3	25	theme	protein	508:514	arg1	modification					487:498	the posttranslational modification	465:498	the posttranslational modification of this protein	465:514	Although the PD-1 structure has been studied for more than two decades, the posttranslational modification of this protein has been incompletely characterized.
37316505	1	26	theme	key	143:145	arg1	receptor					147:154	a key receptor	141:154	a key receptor	141:154	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	26	theme	key	143:145	arg1	protein					121:127	Programmed cell death protein 1	99:129	Programmed cell death protein 1 (PD-1)	99:136	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	0	27	theme	Intact	0:5	arg1	analysis					12:19	Intact mass analysis	0:19	Intact mass analysis	0:19	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	4	28	theme	protein	675:681	arg1	region					660:665	the stalk region	650:665	the stalk region of PD-1 protein	650:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	6	29	theme	attractive	990:999	arg1	method					1001:1006	an attractive method	987:1006	an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis	987:1094	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	2	30	theme	stalk	379:383	arg1	region					385:390	the stalk region	375:390	the stalk region	375:390	PD-1 consists of an intracellular domain followed by a transmembrane domain that is connected to the extracellular domain by the stalk region.
37316505	4	31	theme	digestion	700:708	arg1	coupling					710:717	O-protease digestion coupling	689:717	O-protease digestion coupling	689:717	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	3	32	theme	PD-1	406:409	arg1	structure					411:419	the PD-1 structure	402:419	the PD-1 structure	402:419	Although the PD-1 structure has been studied for more than two decades, the posttranslational modification of this protein has been incompletely characterized.
37316505	5	33	theme	2-based	868:874	arg1	structures					876:885	2-based structures	868:885	2-based structures	868:885	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	1	34	theme	cancer	234:239	arg1	therapy					241:247	cancer therapy	234:247	cancer therapy	234:247	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	4	35	link	O-linked	631:638	arg1	glycan					640:645	O-linked glycan	631:645	O-linked glycan	631:645	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	0	36	theme	novel	33:37	arg1	glycosylation					48:60	the novel O-linked glycosylation	29:60	the novel O-linked glycosylation on the stalk region of PD-1 protein	29:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	4	37	theme	stalk	654:658	arg1	region					660:665	the stalk region	650:665	the stalk region of PD-1 protein	650:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	2	38	theme	extracellular	351:363	arg1	domain					365:370	the extracellular domain	347:370	the extracellular domain	347:370	PD-1 consists of an intracellular domain followed by a transmembrane domain that is connected to the extracellular domain by the stalk region.
37316505	1	39	theme	immune	163:168	arg1	pathway					181:187	the immune checkpoint pathway	159:187	the immune checkpoint pathway	159:187	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	5	40	mod	modified	803:810	arg1	S159					784:787	S159	784:787	S159	784:787	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	5	40	mod	modified	803:810	arg1	T168					794:797	T168	794:797	T168	794:797	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	5	40	mod	modified	803:810	arg1	S157					778:781	S157	778:781	S157	778:781	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	5	40	mod	modified	803:810	arg3	core					863:866	core	863:866	core	863:866	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	5	40	mod	modified	803:810	arg3	core					851:854	sialylated mucin-type O-glycan with core 1-	815:857	sialylated mucin-type O-glycan with core 1-	815:857	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	1	41	theme	checkpoint	170:179	arg1	pathway					181:187	the immune checkpoint pathway	159:187	the immune checkpoint pathway	159:187	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	5	42	gly	sialylated	815:824	arg1	core					851:854	sialylated mucin-type O-glycan with core 1-	815:857	sialylated mucin-type O-glycan with core 1-	815:857	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	1	43	theme	Programmed	99:108	arg1	target					223:228	a promising target	211:228	a promising target for cancer therapy	211:247	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	43	theme	Programmed	99:108	arg1	protein					121:127	Programmed cell death protein 1	99:129	Programmed cell death protein 1 (PD-1)	99:136	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	43	theme	Programmed	99:108	arg1	PD-1					132:135	PD-1	132:135	PD-1	132:135	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	43	theme	Programmed	99:108	arg1	receptor					147:154	a key receptor	141:154	a key receptor	141:154	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	0	44	theme	O-linked	39:46	arg1	glycosylation					48:60	the novel O-linked glycosylation	29:60	the novel O-linked glycosylation on the stalk region of PD-1 protein	29:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	1	45	theme	cell	110:113	arg1	target					223:228	a promising target	211:228	a promising target for cancer therapy	211:247	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	45	theme	cell	110:113	arg1	protein					121:127	Programmed cell death protein 1	99:129	Programmed cell death protein 1 (PD-1)	99:136	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	45	theme	cell	110:113	arg1	PD-1					132:135	PD-1	132:135	PD-1	132:135	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	45	theme	cell	110:113	arg1	receptor					147:154	a key receptor	141:154	a key receptor	141:154	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	6	46	link	O-linked	1024:1031	arg1	glycosylation					1033:1045	O-linked glycosylation	1024:1045	O-linked glycosylation using a specific enzyme and intact mass analysis	1024:1094	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	1	47	theme	death	115:119	arg1	target					223:228	a promising target	211:228	a promising target for cancer therapy	211:247	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	47	theme	death	115:119	arg1	protein					121:127	Programmed cell death protein 1	99:129	Programmed cell death protein 1 (PD-1)	99:136	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	47	theme	death	115:119	arg1	PD-1					132:135	PD-1	132:135	PD-1	132:135	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	1	47	theme	death	115:119	arg1	receptor					147:154	a key receptor	141:154	a key receptor	141:154	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	6	48	theme	specific	1055:1062	arg1	enzyme					1064:1069	a specific enzyme	1053:1069	a specific enzyme	1053:1069	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	5	49	dep	core	851:854	arg1	structures					876:885	2-based structures	868:885	2-based structures	868:885	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	4	50	theme	O-linked	631:638	arg1	glycan					640:645	O-linked glycan	631:645	O-linked glycan	631:645	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	6	51	theme	intact	1075:1080	arg1	analysis					1087:1094	intact mass analysis	1075:1094	intact mass analysis	1075:1094	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	2	52	theme	intracellular	270:282	arg1	domain					284:289	an intracellular domain	267:289	an intracellular domain followed by a transmembrane domain that is connected to the extracellular domain by the stalk region	267:390	PD-1 consists of an intracellular domain followed by a transmembrane domain that is connected to the extracellular domain by the stalk region.
37316505	5	53	theme	sialylated	815:824	arg1	core					851:854	sialylated mucin-type O-glycan with core 1-	815:857	sialylated mucin-type O-glycan with core 1-	815:857	The result indicates that T153, S157, S159, and T168 are modified by sialylated mucin-type O-glycan with core 1- and core 2-based structures.
37316505	1	54	from	receptor	147:154	arg1	pathway					181:187	the immune checkpoint pathway	159:187	the immune checkpoint pathway	159:187	Programmed cell death protein 1 (PD-1) is a key receptor in the immune checkpoint pathway and has emerged to be a promising target for cancer therapy.
37316505	4	55	theme	glycan	640:645	arg1	sites					622:626	the previously undescribed modification sites	582:626	the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein	582:681	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	4	55	theme	glycan	640:645	arg1	glycan					640:645	O-linked glycan	631:645	O-linked glycan	631:645	In this study, we identified the previously undescribed modification sites of O-linked glycan on the stalk region of PD-1 protein using O-protease digestion coupling with intact mass analysis.
37316505	6	56	theme	mass	1082:1085	arg1	analysis					1087:1094	intact mass analysis	1075:1094	intact mass analysis	1075:1094	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37316505	0	57	gly	glycosylation	48:60	arg1	region					75:80	the stalk region	65:80	the stalk region of PD-1 protein	65:96	Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein.
37316505	2	58	theme	transmembrane	305:317	arg1	domain					319:324	a transmembrane domain	303:324	a transmembrane domain that is connected to the extracellular domain by the stalk region	303:390	PD-1 consists of an intracellular domain followed by a transmembrane domain that is connected to the extracellular domain by the stalk region.
37316505	6	59	theme	modification	944:955	arg1	sites					957:961	potential novel modification sites	928:961	potential novel modification sites on the PD-1 protein	928:981	This study provides both information on potential novel modification sites on the PD-1 protein and an attractive method for identifying O-linked glycosylation using a specific enzyme and intact mass analysis.
37287875	4	0	theme	glycans	656:662	arg1	fragments					630:638	separate fragments	621:638	separate fragments of peptides and glycans	621:662	To ensure the accuracy of results, two collision energies are implemented in instrument settings for each precursor to separate fragments of peptides and glycans.
37287875	6	1	theme	in-house	964:971	arg1	software					973:980	our in-house software	960:980	our in-house software "GlycoVisualTool"	960:998	In this protocol, the use of StrucGP is demonstrated, including environment configuration, data preprocessing as well as result inspection and visualization using our in-house software "GlycoVisualTool".
37287875	6	2	theme	environment	861:871	arg1	configuration					873:885	environment configuration	861:885	environment configuration	861:885	In this protocol, the use of StrucGP is demonstrated, including environment configuration, data preprocessing as well as result inspection and visualization using our in-house software "GlycoVisualTool".
37287875	7	3	with	anyone	1058:1063	arg1	knowledge					1086:1094	basic proteomic knowledge	1070:1094	basic proteomic knowledge	1070:1094	The described workflow should be able to be performed by anyone with basic proteomic knowledge.
37287875	3	4	from	level	495:499	arg1	interpretation					440:453	the structural interpretation	425:453	the structural interpretation of N-glycoproteins at the site-specific level	425:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	5	5	theme	peptides	713:720	arg1	FDR					705:707	FDR	705:707	FDR	705:707	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	5	theme	peptides	713:720	arg1	rates					698:702	the false discovery rates	678:702	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	5	theme	peptides	713:720	arg1	probabilities					745:757	probabilities	745:757	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	0	6	gly	N-glycopeptides	19:33	arg2	N-glycopeptides					19:33	intact N-glycopeptides	12:33	intact N-glycopeptides	12:33	Identifying intact N-glycopeptides from tandem mass spectrometry data using StrucGP.
37287875	4	7	theme	collision	541:549	arg1	energies					551:558	two collision energies	537:558	two collision energies	537:558	To ensure the accuracy of results, two collision energies are implemented in instrument settings for each precursor to separate fragments of peptides and glycans.
37287875	7	8	theme	described	1005:1013	arg1	workflow					1015:1022	The described workflow	1001:1022	The described workflow	1001:1022	The described workflow should be able to be performed by anyone with basic proteomic knowledge.
37287875	7	8	theme	described	1005:1013	arg1	able					1034:1037	able	1034:1037	able	1034:1037	The described workflow should be able to be performed by anyone with basic proteomic knowledge.
37287875	2	9	gly	Glycosylation	160:172	arg1	level					232:236	the intact glycopeptide level	208:236	the intact glycopeptide level	208:236	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	3	10	theme	search	407:412	arg1	engine					414:419	a glycan database-independent search engine	377:419	a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level	377:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	3	10	theme	search	407:412	arg1	StrucGP					366:372	StrucGP	366:372	StrucGP	366:372	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	3	11	gly	N-glycoproteins	458:472	arg1	N-glycoproteins					458:472	N-glycoproteins	458:472	N-glycoproteins	458:472	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	5	12	theme	false	682:686	arg1	FDR					705:707	FDR	705:707	FDR	705:707	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	12	theme	false	682:686	arg1	rates					698:702	the false discovery rates	678:702	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	2	13	theme	different	313:321	arg1	conditions					354:363	different physiological and pathological conditions	313:363	different physiological and pathological conditions	313:363	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	3	14	theme	site-specific	481:493	arg1	level					495:499	the site-specific level	477:499	the site-specific level	477:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	1	15	theme	Protein	85:91	arg1	glycosylation					93:105	Protein glycosylation	85:105	Protein glycosylation	85:105	Protein glycosylation is of great importance in many biological processes.
37287875	6	16	dep	result	918:923	arg1	inspection					925:934	inspection	925:934	inspection	925:934	In this protocol, the use of StrucGP is demonstrated, including environment configuration, data preprocessing as well as result inspection and visualization using our in-house software "GlycoVisualTool".
37287875	0	17	theme	intact	12:17	arg1	N-glycopeptides					19:33	intact N-glycopeptides	12:33	intact N-glycopeptides	12:33	Identifying intact N-glycopeptides from tandem mass spectrometry data using StrucGP.
37287875	6	18	theme	StrucGP	826:832	arg1	use					819:821	the use	815:821	the use of StrucGP	815:832	In this protocol, the use of StrucGP is demonstrated, including environment configuration, data preprocessing as well as result inspection and visualization using our in-house software "GlycoVisualTool".
37287875	3	19	theme	N-glycoproteins	458:472	arg1	interpretation					440:453	the structural interpretation	425:453	the structural interpretation of N-glycoproteins at the site-specific level	425:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	1	20	from	importance	119:128	arg1	processes					149:157	many biological processes	133:157	many biological processes	133:157	Protein glycosylation is of great importance in many biological processes.
37287875	5	21	theme	discovery	688:696	arg1	FDR					705:707	FDR	705:707	FDR	705:707	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	21	theme	discovery	688:696	arg1	rates					698:702	the false discovery rates	678:702	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	3	22	theme	structural	429:438	arg1	interpretation					440:453	the structural interpretation	425:453	the structural interpretation of N-glycoproteins at the site-specific level	425:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	4	23	theme	separate	621:628	arg1	fragments					630:638	separate fragments	621:638	separate fragments of peptides and glycans	621:662	To ensure the accuracy of results, two collision energies are implemented in instrument settings for each precursor to separate fragments of peptides and glycans.
37287875	6	24	dep	demonstrated	837:848	arg1	using					954:958	using	954:958	using our in-house software "GlycoVisualTool"	954:998	In this protocol, the use of StrucGP is demonstrated, including environment configuration, data preprocessing as well as result inspection and visualization using our in-house software "GlycoVisualTool".
37287875	4	25	theme	peptides	643:650	arg1	fragments					630:638	separate fragments	621:638	separate fragments of peptides and glycans	621:662	To ensure the accuracy of results, two collision energies are implemented in instrument settings for each precursor to separate fragments of peptides and glycans.
37287875	1	26	theme	great	113:117	arg1	importance					119:128	great importance	113:128	great importance	113:128	Protein glycosylation is of great importance in many biological processes.
37287875	0	27	theme	mass	47:50	arg1	spectrometry					52:63	tandem mass spectrometry	40:63	tandem mass spectrometry data using StrucGP	40:82	Identifying intact N-glycopeptides from tandem mass spectrometry data using StrucGP.
37287875	5	28	theme	detailed	762:769	arg1	structures					771:780	detailed structures	762:780	detailed structures	762:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	0	29	theme	tandem	40:45	arg1	spectrometry					52:63	tandem mass spectrometry	40:63	tandem mass spectrometry data using StrucGP	40:82	Identifying intact N-glycopeptides from tandem mass spectrometry data using StrucGP.
37287875	5	30	theme	structures	771:780	arg1	FDR					705:707	FDR	705:707	FDR	705:707	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	30	theme	structures	771:780	arg1	rates					698:702	the false discovery rates	678:702	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	30	theme	structures	771:780	arg1	probabilities					745:757	probabilities	745:757	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	31	theme	glycans	726:732	arg1	FDR					705:707	FDR	705:707	FDR	705:707	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	31	theme	glycans	726:732	arg1	rates					698:702	the false discovery rates	678:702	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	5	31	theme	glycans	726:732	arg1	probabilities					745:757	probabilities	745:757	the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures	678:780	In addition, the false discovery rates (FDR) of peptides and glycans as well as probabilities of detailed structures are estimated.
37287875	4	32	theme	results	528:534	arg1	accuracy					516:523	the accuracy	512:523	the accuracy of results	512:534	To ensure the accuracy of results, two collision energies are implemented in instrument settings for each precursor to separate fragments of peptides and glycans.
37287875	2	33	theme	mass	244:247	arg1	spectrometry					249:260	mass spectrometry	244:260	mass spectrometry	244:260	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	7	34	theme	basic	1070:1074	arg1	knowledge					1086:1094	basic proteomic knowledge	1070:1094	basic proteomic knowledge	1070:1094	The described workflow should be able to be performed by anyone with basic proteomic knowledge.
37287875	0	35	theme	spectrometry	52:63	arg1	data					65:68	tandem mass spectrometry data	40:68	tandem mass spectrometry data using StrucGP	40:82	Identifying intact N-glycopeptides from tandem mass spectrometry data using StrucGP.
37287875	6	36	theme	"	998:998	arg1	software					973:980	our in-house software	960:980	our in-house software "GlycoVisualTool"	960:998	In this protocol, the use of StrucGP is demonstrated, including environment configuration, data preprocessing as well as result inspection and visualization using our in-house software "GlycoVisualTool".
37287875	2	37	gly	glycopeptide	219:230	arg2	glycopeptide					219:230	the intact glycopeptide level	208:236	the intact glycopeptide level	208:236	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	7	38	theme	proteomic	1076:1084	arg1	knowledge					1086:1094	basic proteomic knowledge	1070:1094	basic proteomic knowledge	1070:1094	The described workflow should be able to be performed by anyone with basic proteomic knowledge.
37287875	2	39	theme	glycopeptide	219:230	arg1	level					232:236	the intact glycopeptide level	208:236	the intact glycopeptide level	208:236	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	4	40	theme	instrument	579:588	arg1	settings					590:597	instrument settings	579:597	instrument settings for each precursor to separate fragments of peptides and glycans	579:662	To ensure the accuracy of results, two collision energies are implemented in instrument settings for each precursor to separate fragments of peptides and glycans.
37287875	1	41	theme	many	133:136	arg1	processes					149:157	many biological processes	133:157	many biological processes	133:157	Protein glycosylation is of great importance in many biological processes.
37287875	2	42	theme	intact	212:217	arg1	level					232:236	the intact glycopeptide level	208:236	the intact glycopeptide level	208:236	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	2	43	theme	glycosylation	285:297	arg1	changes					299:305	site-specific glycosylation changes	271:305	site-specific glycosylation changes	271:305	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	1	44	theme	biological	138:147	arg1	processes					149:157	many biological processes	133:157	many biological processes	133:157	Protein glycosylation is of great importance in many biological processes.
37287875	3	45	theme	glycan	379:384	arg1	engine					414:419	a glycan database-independent search engine	377:419	a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level	377:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	3	45	theme	glycan	379:384	arg1	StrucGP					366:372	StrucGP	366:372	StrucGP	366:372	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	2	46	theme	site-specific	271:283	arg1	changes					299:305	site-specific glycosylation changes	271:305	site-specific glycosylation changes	271:305	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	2	47	dep	different	313:321	arg1	physiological					323:335	physiological	323:335	physiological	323:335	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	2	47	dep	different	313:321	arg1	pathological					341:352	pathological	341:352	pathological	341:352	Glycosylation has been increasingly analyzed at the intact glycopeptide level using mass spectrometry to study site-specific glycosylation changes under different physiological and pathological conditions.
37287875	3	48	theme	database-independent	386:405	arg1	engine					414:419	a glycan database-independent search engine	377:419	a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level	377:499	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
37287875	3	48	theme	database-independent	386:405	arg1	StrucGP					366:372	StrucGP	366:372	StrucGP	366:372	StrucGP is a glycan database-independent search engine for the structural interpretation of N-glycoproteins at the site-specific level.
36580234	0	0	theme	macrophages	89:99	arg1	analysis					77:84	site-specific N-glycoproteomic analysis	46:84	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.	0:100	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	1	1	theme	innate	163:168	arg1	immunity					183:190	innate and adaptive immunity	163:190	innate and adaptive immunity	163:190	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	7	2	located	detected	1141:1148	arg2	moiety					1130:1135	the LacNAc moiety	1119:1135	the LacNAc moiety	1119:1135	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	7	2	located	detected	1141:1148	arg1	Asn-200					1165:1171	Asn-200	1165:1171	Asn-200	1165:1171	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	7	2	located	detected	1141:1148	arg1	Asn-192					1153:1159	Asn-192	1153:1159	Asn-192	1153:1159	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	0	3	from	Application	0:10	arg1	immunology					34:43	medical immunology	26:43	medical immunology	26:43	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	5	4	gly	sialylated	812:821	arg1	glycans					823:829	sialylated glycans	812:829	sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1)	812:870	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	5	4	gly	sialylated	812:821	arg1	N4H5F1S1					862:869	N4H5F1S1	862:869	N4H5F1S1	862:869	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	4	5	theme	site-specific	706:718	arg1	structures					727:736	site-specific glycan structures	706:736	site-specific glycan structures	706:736	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	4	6	theme	-based	633:638	arg1	approaches					655:664	mass spectrometry (MS)-based glycoproteomic approaches	611:664	mass spectrometry (MS)-based glycoproteomic approaches	611:664	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	5	7	theme	core	790:793	arg1	fucosylated					795:805	core fucosylated	790:805	core fucosylated	790:805	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	7	8	located	observed	1087:1094	arg1	addition					1038:1045	addition	1038:1045	addition	1038:1045	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	7	8	located	observed	1087:1094	arg2	level					1055:1059	a high level	1048:1059	a high level of glycosylated PD-L1	1048:1081	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	7	8	located	observed	1087:1094	arg1	macrophages					1102:1112	M1 macrophages	1099:1112	M1 macrophages	1099:1112	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	3	9	theme	N-glycoproteomic	511:526	arg1	analysis					528:535	N-glycoproteomic analysis	511:535	N-glycoproteomic analysis	511:535	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	7	10	theme	Lewis	1205:1209	arg1	epitopes					1211:1218	Lewis epitopes	1205:1218	Lewis epitopes	1205:1218	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	8	11	theme	related	1342:1348	arg1	glycosyltransferases					1350:1369	related glycosyltransferases	1342:1369	related glycosyltransferases	1342:1369	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	5	12	dep	HexNAc4Hex5Fuc1Neu5Ac1	838:859	arg1	e.g.					832:835	e.g.	832:835	e.g.	832:835	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	5	13	theme	M1	890:891	arg1	macrophages					900:910	M1 and M2 macrophages	890:910	M1 and M2 macrophages	890:910	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	8	14	theme	new	1413:1415	arg1	approaches					1444:1453	new diagnostic and therapeutic approaches	1413:1453	new diagnostic and therapeutic approaches for different diseases	1413:1476	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	15	theme	subsequent	1290:1299	arg1	intervention					1301:1312	subsequent intervention	1290:1312	subsequent intervention of target glycoproteins and related glycosyltransferases	1290:1369	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	1	16	theme	adaptive	174:181	arg1	immunity					183:190	innate and adaptive immunity	163:190	innate and adaptive immunity	163:190	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	4	17	gly	glycopeptides	549:561	arg1	macrophages					566:576	macrophages	566:576	macrophages	566:576	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	4	17	gly	glycopeptides	549:561	arg2	glycopeptides					549:561	The intact glycopeptides	538:561	The intact glycopeptides of macrophages	538:576	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	3	18	theme	N-glycan	460:467	arg1	StrucGP					500:506	a N-glycan structural interpretation tool StrucGP	458:506	a N-glycan structural interpretation tool StrucGP	458:506	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	3	19	used	used	385:388	arg2	we					382:383	we	382:383	we	382:383	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	2	20	theme	glycosylation	343:355	arg1	functions					357:365	specific glycosylation functions	334:365	specific glycosylation functions	334:365	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	4	21	theme	structures	727:736	arg1	mapping					695:701	the large-scale mapping	679:701	the large-scale mapping of site-specific glycan structures via StrucGP	679:748	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	7	22	theme	PD-L1	1176:1180	arg1	Asn-200					1165:1171	Asn-200	1165:1171	Asn-200	1165:1171	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	7	22	theme	PD-L1	1176:1180	arg1	Asn-192					1153:1159	Asn-192	1153:1159	Asn-192	1153:1159	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	8	23	gly	glycoproteins	1324:1336	arg1	glycoproteins					1324:1336	target glycoproteins	1317:1336	target glycoproteins	1317:1336	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	7	24	contain	contained	1195:1203	arg1	Asn-200					1187:1193	Asn-200	1187:1193	Asn-200	1187:1193	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	7	24	contain	contained	1195:1203	arg2	epitopes					1211:1218	Lewis epitopes	1205:1218	Lewis epitopes	1205:1218	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	2	25	theme	specific	334:341	arg1	functions					357:365	specific glycosylation functions	334:365	specific glycosylation functions	334:365	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	1	26	theme	sensing	196:202	arg1	signals					218:224	sensing environmental signals	196:224	sensing environmental signals	196:224	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	3	27	theme	THP-1-derived	390:402	arg1	examples					419:426	examples	419:426	examples	419:426	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	3	27	theme	THP-1-derived	390:402	arg1	macrophages					404:414	THP-1-derived macrophages	390:414	THP-1-derived macrophages	390:414	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	6	28	theme	macrophage	1010:1019	arg1	polarization					1021:1032	macrophage polarization	1010:1032	macrophage polarization	1010:1032	The findings indicated that these structures may be closely related to macrophage polarization.
36580234	8	29	theme	glycosyltransferases	1350:1369	arg1	interpretation					1246:1259	The precision structural interpretation	1221:1259	The precision structural interpretation of site-specific glycans	1221:1284	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	29	theme	glycosyltransferases	1350:1369	arg1	intervention					1301:1312	subsequent intervention	1290:1312	subsequent intervention of target glycoproteins and related glycosyltransferases	1290:1369	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	30	theme	approaches	1444:1453	arg1	development					1398:1408	the development	1394:1408	the development of new diagnostic and therapeutic approaches for different diseases	1394:1476	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	1	31	theme	environmental	204:216	arg1	signals					218:224	sensing environmental signals	196:224	sensing environmental signals	196:224	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	0	32	theme	StrucGP	15:21	arg1	Application					0:10	Application	0:10	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.	0:100	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	4	33	theme	spectrometry	616:627	arg1	approaches					655:664	mass spectrometry (MS)-based glycoproteomic approaches	611:664	mass spectrometry (MS)-based glycoproteomic approaches	611:664	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	7	34	theme	high	1050:1053	arg1	level					1055:1059	a high level	1048:1059	a high level of glycosylated PD-L1	1048:1081	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	8	35	theme	therapeutic	1432:1442	arg1	approaches					1444:1453	new diagnostic and therapeutic approaches	1413:1453	new diagnostic and therapeutic approaches for different diseases	1413:1476	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	3	36	theme	StrucGP	500:506	arg1	potential					445:453	the vast potential	436:453	the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis	436:535	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	8	37	theme	structural	1235:1244	arg1	interpretation					1246:1259	The precision structural interpretation	1221:1259	The precision structural interpretation of site-specific glycans	1221:1284	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	4	38	theme	mass	611:614	arg1	MS					630:631	MS	630:631	MS	630:631	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	4	38	theme	mass	611:614	arg1	spectrometry					616:627	mass spectrometry	611:627	mass spectrometry (MS)-based glycoproteomic approaches	611:664	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	5	39	theme	bisected	773:780	arg1	GlcNAc					782:787	bisected GlcNAc	773:787	bisected GlcNAc	773:787	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	8	40	theme	glycoproteins	1324:1336	arg1	interpretation					1246:1259	The precision structural interpretation	1221:1259	The precision structural interpretation of site-specific glycans	1221:1284	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	40	theme	glycoproteins	1324:1336	arg1	intervention					1301:1312	subsequent intervention	1290:1312	subsequent intervention of target glycoproteins and related glycosyltransferases	1290:1369	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	41	theme	different	1459:1467	arg1	diseases					1469:1476	different diseases	1459:1476	different diseases	1459:1476	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	4	42	theme	glycan	720:725	arg1	structures					727:736	site-specific glycan structures	706:736	site-specific glycan structures	706:736	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	3	43	theme	structural	469:478	arg1	StrucGP					500:506	a N-glycan structural interpretation tool StrucGP	458:506	a N-glycan structural interpretation tool StrucGP	458:506	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	0	44	theme	medical	26:32	arg1	immunology					34:43	medical immunology	26:43	medical immunology	26:43	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	3	45	theme	vast	440:443	arg1	potential					445:453	the vast potential	436:453	the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis	436:535	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	2	46	theme	structural	242:251	arg1	diversity					253:261	the structural diversity	238:261	the structural diversity of N-glycans	238:274	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	2	46	theme	structural	242:251	arg1	Meanwhile					227:235	Meanwhile	227:235	Meanwhile	227:235	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	5	47	theme	M2	897:898	arg1	macrophages					900:910	M1 and M2 macrophages	890:910	M1 and M2 macrophages	890:910	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	3	48	theme	interpretation	480:493	arg1	StrucGP					500:506	a N-glycan structural interpretation tool StrucGP	458:506	a N-glycan structural interpretation tool StrucGP	458:506	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	0	49	theme	site-specific	46:58	arg1	analysis					77:84	site-specific N-glycoproteomic analysis	46:84	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.	0:100	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	4	50	theme	macrophages	566:576	arg1	glycopeptides					549:561	The intact glycopeptides	538:561	The intact glycopeptides of macrophages	538:576	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	8	51	theme	precision	1225:1233	arg1	interpretation					1246:1259	The precision structural interpretation	1221:1259	The precision structural interpretation of site-specific glycans	1221:1284	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	5	52	theme	sialylated	812:821	arg1	glycans					823:829	sialylated glycans	812:829	sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1)	812:870	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	5	52	theme	sialylated	812:821	arg1	N4H5F1S1					862:869	N4H5F1S1	862:869	N4H5F1S1	862:869	Results revealed that bisected GlcNAc, core fucosylated, and sialylated glycans (e.g., HexNAc4Hex5Fuc1Neu5Ac1, N4H5F1S1) were increased in M1 and M2 macrophages, especially in the latter.
36580234	7	53	gly	glycosylated	1064:1075	arg1	PD-L1					1077:1081	glycosylated PD-L1	1064:1081	glycosylated PD-L1	1064:1081	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	8	54	theme	diagnostic	1417:1426	arg1	approaches					1444:1453	new diagnostic and therapeutic approaches	1413:1453	new diagnostic and therapeutic approaches for different diseases	1413:1476	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	1	55	theme	N-glycans	119:127	arg1	structure					106:114	The structure	102:114	The structure of N-glycans on specific proteins	102:148	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	7	56	theme	M1	1099:1100	arg1	macrophages					1102:1112	M1 macrophages	1099:1112	M1 macrophages	1099:1112	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	1	57	from	structure	106:114	arg1	proteins					141:148	specific proteins	132:148	specific proteins	132:148	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	7	58	theme	glycosylated	1064:1075	arg1	PD-L1					1077:1081	glycosylated PD-L1	1064:1081	glycosylated PD-L1	1064:1081	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	2	59	theme	analytical	282:291	arg1	challenges					293:302	analytical challenges	282:302	analytical challenges that limit the exploration of specific glycosylation functions	282:365	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	3	60	link	THP-1-derived	390:402	arg1	examples					419:426	examples	419:426	examples	419:426	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	3	60	link	THP-1-derived	390:402	arg1	macrophages					404:414	THP-1-derived macrophages	390:414	THP-1-derived macrophages	390:414	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	7	61	theme	LacNAc	1123:1128	arg1	moiety					1130:1135	the LacNAc moiety	1119:1135	the LacNAc moiety	1119:1135	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	1	62	theme	specific	132:139	arg1	proteins					141:148	specific proteins	132:148	specific proteins	132:148	The structure of N-glycans on specific proteins can regulate innate and adaptive immunity via sensing environmental signals.
36580234	8	63	theme	target	1317:1322	arg1	glycoproteins					1324:1336	target glycoproteins	1317:1336	target glycoproteins	1317:1336	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	7	64	theme	PD-L1	1077:1081	arg1	level					1055:1059	a high level	1048:1059	a high level of glycosylated PD-L1	1048:1081	In addition, a high level of glycosylated PD-L1 was observed in M1 macrophages, and the LacNAc moiety was detected at Asn-192 and Asn-200 of PD-L1, and Asn-200 contained Lewis epitopes.
36580234	3	65	from	potential	445:453	arg1	analysis					528:535	N-glycoproteomic analysis	511:535	N-glycoproteomic analysis	511:535	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	2	66	theme	functions	357:365	arg1	exploration					319:329	the exploration	315:329	the exploration of specific glycosylation functions	315:365	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	4	67	theme	glycoproteomic	640:653	arg1	approaches					655:664	mass spectrometry (MS)-based glycoproteomic approaches	611:664	mass spectrometry (MS)-based glycoproteomic approaches	611:664	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	4	68	theme	large-scale	683:693	arg1	mapping					695:701	the large-scale mapping	679:701	the large-scale mapping of site-specific glycan structures via StrucGP	679:748	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	2	69	theme	N-glycans	266:274	arg1	diversity					253:261	the structural diversity	238:261	the structural diversity of N-glycans	238:274	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	2	69	theme	N-glycans	266:274	arg1	Meanwhile					227:235	Meanwhile	227:235	Meanwhile	227:235	Meanwhile, the structural diversity of N-glycans poses analytical challenges that limit the exploration of specific glycosylation functions.
36580234	3	70	theme	tool	495:498	arg1	StrucGP					500:506	a N-glycan structural interpretation tool StrucGP	458:506	a N-glycan structural interpretation tool StrucGP	458:506	In this work, we used THP-1-derived macrophages as examples to show the vast potential of a N-glycan structural interpretation tool StrucGP in N-glycoproteomic analysis.
36580234	8	71	theme	great	1378:1382	arg1	value					1384:1388	great value	1378:1388	great value for the development of new diagnostic and therapeutic approaches for different diseases	1378:1476	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	72	theme	site-specific	1264:1276	arg1	glycans					1278:1284	site-specific glycans	1264:1284	site-specific glycans	1264:1284	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	0	73	theme	N-glycoproteomic	60:75	arg1	analysis					77:84	site-specific N-glycoproteomic analysis	46:84	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.	0:100	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	4	74	theme	intact	542:547	arg1	glycopeptides					549:561	The intact glycopeptides	538:561	The intact glycopeptides of macrophages	538:576	The intact glycopeptides of macrophages were enriched and analyzed using mass spectrometry (MS)-based glycoproteomic approaches, followed by the large-scale mapping of site-specific glycan structures via StrucGP.
36580234	0	75	dep	Application	0:10	arg1	analysis					77:84	site-specific N-glycoproteomic analysis	46:84	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.	0:100	Application of StrucGP in medical immunology: site-specific N-glycoproteomic analysis of macrophages.
36580234	8	76	theme	glycans	1278:1284	arg1	interpretation					1246:1259	The precision structural interpretation	1221:1259	The precision structural interpretation of site-specific glycans	1221:1284	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
36580234	8	76	theme	glycans	1278:1284	arg1	intervention					1301:1312	subsequent intervention	1290:1312	subsequent intervention of target glycoproteins and related glycosyltransferases	1290:1369	The precision structural interpretation of site-specific glycans and subsequent intervention of target glycoproteins and related glycosyltransferases are of great value for the development of new diagnostic and therapeutic approaches for different diseases.
37319314	1	0	theme	glycan	338:343	arg1	position					322:329	the position	318:329	the position of the glycan at specific sites	318:361	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	0	theme	glycan	338:343	arg1	compositions					295:306	glycan compositions	288:306	glycan compositions	288:306	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	1	from	position	322:329	arg1	sites					357:361	specific sites	348:361	specific sites	348:361	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	2	2	theme	linkages	508:515	arg1	linkages					508:515	biologically relevant linkages	486:515	biologically relevant linkages	486:515	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	2	theme	linkages	508:515	arg1	properties					527:536	isomeric properties	518:536	isomeric properties that are invisible when the readout is mass alone	518:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	2	theme	linkages	508:515	arg1	variety					475:481	a variety	473:481	a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone	473:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	4	3	theme	galactosylation/sialylation	893:919	arg1	terms					880:884	terms	880:884	terms of the galactosylation/sialylation branching and linkage	880:941	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	1	4	theme	mass	194:197	arg1	MS					213:214	MS	213:214	MS	213:214	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	4	theme	mass	194:197	arg1	spectrometry					199:210	mass spectrometry	194:210	mass spectrometry (MS)	194:215	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	5	theme	specific	348:355	arg1	sites					357:361	specific sites	348:361	specific sites	348:361	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	6	with	proteins	179:186	arg1	MS					213:214	MS	213:214	MS	213:214	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	6	with	proteins	179:186	arg1	spectrometry					199:210	mass spectrometry	194:210	mass spectrometry (MS)	194:215	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	6	7	theme	broad	1228:1232	arg1	application					1234:1244	a broad application	1226:1244	a broad application of the method	1226:1258	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	5	8	theme	relative	1017:1024	arg1	quantification					1026:1039	relative quantification	1017:1039	relative quantification of isomerism within mixtures	1017:1068	These behaviors were developed into component variables that allowed for relative quantification of isomerism within mixtures.
37319314	6	9	theme	peptide	1183:1189	arg1	portion					1191:1197	the peptide portion	1179:1197	the peptide portion of the conjugate	1179:1214	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	2	10	from	variety	475:481	arg1	interconnected					455:468	interconnected	455:468	interconnected	455:468	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	1	11	theme	essential	99:107	arg1	modification					117:128	an essential protein modification	96:128	an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics	96:381	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	11	theme	essential	99:107	arg1	Glycosylation					79:91	Glycosylation	79:91	Glycosylation	79:91	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	3	12	gly	glycopeptide	651:662	arg2	glycopeptide					651:662	glycopeptide isomer ratios	651:676	glycopeptide isomer ratios	651:676	Here, we developed an LC-MS/MS-based workflow for determining glycopeptide isomer ratios.
37319314	2	13	theme	relevant	499:506	arg1	linkages					508:515	biologically relevant linkages	486:515	biologically relevant linkages	486:515	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	13	theme	relevant	499:506	arg1	properties					527:536	isomeric properties	518:536	isomeric properties that are invisible when the readout is mass alone	518:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	1	14	theme	protein	109:115	arg1	modification					117:128	an essential protein modification	96:128	an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics	96:381	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	14	theme	protein	109:115	arg1	Glycosylation					79:91	Glycosylation	79:91	Glycosylation	79:91	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	0	15	theme	MS/MS-Based	27:37	arg1	Quantification					39:52	Glycoproteomics-Compatible MS/MS-Based Quantification	0:52	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.	0:77	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.
37319314	2	16	with	structures	423:432	arg1	monosaccharides					439:453	monosaccharides	439:453	monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone	439:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	4	17	theme	defined	706:712	arg1	standards					729:737	isomerically defined glyco(peptide) standards	693:737	isomerically defined glyco(peptide) standards	693:737	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	0	18	theme	Glycoproteomics-Compatible	0:25	arg1	Quantification					39:52	Glycoproteomics-Compatible MS/MS-Based Quantification	0:52	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.	0:77	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.
37319314	1	19	theme	glycan	288:293	arg1	compositions					295:306	glycan compositions	288:306	glycan compositions	288:306	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	20	from	compositions	295:306	arg1	sites					357:361	specific sites	348:361	specific sites	348:361	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	4	21	from	differences	759:769	arg1	behavior					788:795	fragmentation behavior	774:795	fragmentation behavior	774:795	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	4	22	theme	marked	752:757	arg1	differences					759:769	marked differences	752:769	marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients	752:861	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	1	23	from	sites	357:361	arg1	position					322:329	the position	318:329	the position of the glycan at specific sites	318:361	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	23	from	sites	357:361	arg1	compositions					295:306	glycan compositions	288:306	glycan compositions	288:306	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	23	from	sites	357:361	arg1	glycan					338:343	the glycan	334:343	the glycan at specific sites	334:361	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	6	24	theme	conjugate	1206:1214	arg1	portion					1191:1197	the peptide portion	1179:1197	the peptide portion of the conjugate	1179:1214	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	4	25	theme	fragmentation	774:786	arg1	behavior					788:795	fragmentation behavior	774:795	fragmentation behavior	774:795	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	6	26	theme	isomer	1117:1122	arg1	independent					1162:1172	independent	1162:1172	independent	1162:1172	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	6	26	theme	isomer	1117:1122	arg1	quantification					1124:1137	the isomer quantification	1113:1137	the isomer quantification	1113:1137	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	5	27	theme	isomerism	1044:1052	arg1	quantification					1026:1039	relative quantification	1017:1039	relative quantification of isomerism within mixtures	1017:1068	These behaviors were developed into component variables that allowed for relative quantification of isomerism within mixtures.
37319314	4	28	theme	peptide	720:726	arg1	standards					729:737	isomerically defined glyco(peptide) standards	693:737	isomerically defined glyco(peptide) standards	693:737	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	0	29	theme	Isomers	70:76	arg1	Quantification					39:52	Glycoproteomics-Compatible MS/MS-Based Quantification	0:52	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.	0:77	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.
37319314	1	30	theme	indispensable	226:238	arg1	majority					147:154	the majority	143:154	the majority of extracellular human proteins, with mass spectrometry (MS)	143:215	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	30	theme	indispensable	226:238	arg1	tool					240:243	an indispensable tool	223:243	an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics	223:381	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	2	31	theme	branching	413:421	arg1	glycans					393:399	glycans	393:399	glycans	393:399	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	31	theme	branching	413:421	arg1	structures					423:432	complex branching structures	405:432	complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone	405:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	0	32	theme	Glycopeptide	57:68	arg1	Isomers					70:76	Glycopeptide Isomers	57:76	Glycopeptide Isomers	57:76	Glycoproteomics-Compatible MS/MS-Based Quantification of Glycopeptide Isomers.
37319314	3	33	theme	isomer	664:669	arg1	ratios					671:676	glycopeptide isomer ratios	651:676	glycopeptide isomer ratios	651:676	Here, we developed an LC-MS/MS-based workflow for determining glycopeptide isomer ratios.
37319314	2	34	theme	interconnected	455:468	arg1	monosaccharides					439:453	monosaccharides	439:453	monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone	439:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	6	35	from	portion	1191:1197	arg1	independent					1162:1172	independent	1162:1172	independent	1162:1172	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	6	35	from	portion	1191:1197	arg1	quantification					1124:1137	the isomer quantification	1113:1137	the isomer quantification	1113:1137	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	2	36	theme	complex	405:411	arg1	glycans					393:399	glycans	393:399	glycans	393:399	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	36	theme	complex	405:411	arg1	structures					423:432	complex branching structures	405:432	complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone	405:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	4	37	dep	galactosylation/sialylation	893:919	arg1	branching					921:929	branching	921:929	branching	921:929	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	4	37	dep	galactosylation/sialylation	893:919	arg1	linkage					935:941	linkage	935:941	linkage	935:941	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	4	38	theme	standards	729:737	arg1	use					686:688	use	686:688	use of isomerically defined glyco(peptide) standards	686:737	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	4	39	theme	energy	846:851	arg1	gradients					853:861	collision energy gradients	836:861	collision energy gradients	836:861	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	3	40	theme	LC-MS/MS-based	611:624	arg1	workflow					626:633	an LC-MS/MS-based workflow	608:633	an LC-MS/MS-based workflow for determining glycopeptide isomer ratios	608:676	Here, we developed an LC-MS/MS-based workflow for determining glycopeptide isomer ratios.
37319314	1	41	theme	extracellular	159:171	arg1	proteins					179:186	extracellular human proteins	159:186	extracellular human proteins	159:186	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	6	42	theme	small	1097:1101	arg1	peptides					1103:1110	small peptides	1097:1110	small peptides	1097:1110	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	4	43	theme	isomer	805:810	arg1	pairs					812:816	isomer pairs	805:816	isomer pairs when subjected to collision energy gradients	805:861	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	3	44	theme	glycopeptide	651:662	arg1	ratios					671:676	glycopeptide isomer ratios	651:676	glycopeptide isomer ratios	651:676	Here, we developed an LC-MS/MS-based workflow for determining glycopeptide isomer ratios.
37319314	1	45	theme	human	173:177	arg1	proteins					179:186	extracellular human proteins	159:186	extracellular human proteins	159:186	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	5	46	theme	component	980:988	arg1	variables					990:998	component variables	980:998	component variables that allowed for relative quantification of isomerism within mixtures	980:1068	These behaviors were developed into component variables that allowed for relative quantification of isomerism within mixtures.
37319314	4	47	theme	collision	836:844	arg1	gradients					853:861	collision energy gradients	836:861	collision energy gradients	836:861	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
37319314	1	48	theme	proteins	179:186	arg1	majority					147:154	the majority	143:154	the majority of extracellular human proteins, with mass spectrometry (MS)	143:215	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	1	48	theme	proteins	179:186	arg1	tool					240:243	an indispensable tool	223:243	an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics	223:381	Glycosylation is an essential protein modification occurring on the majority of extracellular human proteins, with mass spectrometry (MS) being an indispensable tool for its analysis, that not only determines glycan compositions, but also the position of the glycan at specific sites via glycoproteomics.
37319314	2	49	theme	isomeric	518:525	arg1	linkages					508:515	biologically relevant linkages	486:515	biologically relevant linkages	486:515	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	49	theme	isomeric	518:525	arg1	properties					527:536	isomeric properties	518:536	isomeric properties that are invisible when the readout is mass alone	518:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	50	from	interconnected	455:468	arg1	linkages					508:515	biologically relevant linkages	486:515	biologically relevant linkages	486:515	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	50	from	interconnected	455:468	arg1	properties					527:536	isomeric properties	518:536	isomeric properties that are invisible when the readout is mass alone	518:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	2	50	from	interconnected	455:468	arg1	variety					475:481	a variety	473:481	a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone	473:586	However, glycans are complex branching structures with monosaccharides interconnected in a variety of biologically relevant linkages, isomeric properties that are invisible when the readout is mass alone.
37319314	6	51	theme	method	1253:1258	arg1	application					1234:1244	a broad application	1226:1244	a broad application of the method	1226:1258	Importantly, at least for small peptides, the isomer quantification appeared to be largely independent from the peptide portion of the conjugate, allowing a broad application of the method.
37319314	4	52	theme	glyco	714:718	arg1	standards					729:737	isomerically defined glyco(peptide) standards	693:737	isomerically defined glyco(peptide) standards	693:737	Making use of isomerically defined glyco(peptide) standards, we observed marked differences in fragmentation behavior between isomer pairs when subjected to collision energy gradients, specifically in terms of the galactosylation/sialylation branching and linkage.
35380345	0	0	theme	activated	85:93	arg1	monosaccharides					95:109	activated monosaccharides	85:109	activated monosaccharides	85:109	Hyperglycemia alters N-glycans on colon cancer cells through increased production of activated monosaccharides.
35380345	0	1	from	N-glycans	21:29	arg1	cells					47:51	colon cancer cells	34:51	colon cancer cells	34:51	Hyperglycemia alters N-glycans on colon cancer cells through increased production of activated monosaccharides.
35380345	6	2	theme	N-glycans	893:901	arg1	proportion					838:847	the proportion	834:847	the proportion of sialylated, fucosylated and mannosylated N-glycans	834:901	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	5	3	theme	MC38	691:694	arg1	cells					696:700	MC38 cells	691:700	MC38 cells cultured in LG and HG	691:722	N-glycans, 67, were identified in MC38 cells cultured in LG and HG.
35380345	6	4	theme	LNG	804:806	arg1	cells					808:812	LNG cells	804:812	LNG cells	804:812	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	4	5	theme	hyperglycemic-like	621:638	arg1	HG					652:653	HG	652:653	HG	652:653	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	4	5	theme	hyperglycemic-like	621:638	arg1	conditions					640:649	hyperglycemic-like conditions	621:649	hyperglycemic-like conditions (HG)	621:654	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	0	6	theme	monosaccharides	95:109	arg1	production					71:80	increased production	61:80	increased production of activated monosaccharides	61:109	Hyperglycemia alters N-glycans on colon cancer cells through increased production of activated monosaccharides.
35380345	5	7	theme	67	668:669	arg1	N-glycans					657:665	N-glycans	657:665	N-glycans	657:665	N-glycans, 67, were identified in MC38 cells cultured in LG and HG.
35380345	3	8	theme	aberrant	379:386	arg1	glycosylation					388:400	aberrant glycosylation	379:400	aberrant glycosylation of CRC cells	379:413	Previously, hyperglycemia, the DM hallmark, has been shown to lead to aberrant glycosylation of CRC cells, heightening their malignancy both in vivo and in vitro.
35380345	6	9	theme	N-glycans	777:785	arg1	abundance					764:772	a greater abundance	754:772	a greater abundance of N-glycans	754:785	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	6	10	gly	sialylated	852:861	arg1	N-glycans					893:901	sialylated, fucosylated and mannosylated N-glycans	852:901	sialylated, fucosylated and mannosylated N-glycans	852:901	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	2	11	theme	CRC	242:244	arg1	incidence					229:237	the incidence	225:237	the incidence of CRC	225:244	Besides favoring the incidence of CRC, DM also accelerates its progression, worsening its prognosis.
35380345	1	12	theme	known	161:165	arg1	factor					172:177	a known risk factor	159:177	a known risk factor for colorectal cancer (CRC)	159:205	Diabetes Mellitus (DM) is both, correlated and a known risk factor for colorectal cancer (CRC).
35380345	9	13	from	CRC	1431:1433	arg1	patients					1447:1454	diabetic patients	1438:1454	diabetic patients	1438:1454	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	1	14	theme	risk	167:170	arg1	factor					172:177	a known risk factor	159:177	a known risk factor for colorectal cancer (CRC)	159:205	Diabetes Mellitus (DM) is both, correlated and a known risk factor for colorectal cancer (CRC).
35380345	4	15	theme	mass	484:487	arg1	spectrometry					489:500	mass spectrometry	484:500	mass spectrometry	484:500	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	6	16	theme	greater	756:762	arg1	abundance					764:772	a greater abundance	754:772	a greater abundance of N-glycans	754:785	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	6	17	theme	sialylated	852:861	arg1	N-glycans					893:901	sialylated, fucosylated and mannosylated N-glycans	852:901	sialylated, fucosylated and mannosylated N-glycans	852:901	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	9	18	theme	CRC	1350:1352	arg1	progression					1335:1345	the progression	1331:1345	the progression of CRC	1331:1352	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	1	19	theme	Diabetes	112:119	arg1	DM					131:132	DM	131:132	DM	131:132	Diabetes Mellitus (DM) is both, correlated and a known risk factor for colorectal cancer (CRC).
35380345	1	19	theme	Diabetes	112:119	arg1	Mellitus					121:128	Diabetes Mellitus	112:128	Diabetes Mellitus (DM)	112:133	Diabetes Mellitus (DM) is both, correlated and a known risk factor for colorectal cancer (CRC).
35380345	3	20	theme	cells	409:413	arg1	glycosylation					388:400	aberrant glycosylation	379:400	aberrant glycosylation of CRC cells	379:413	Previously, hyperglycemia, the DM hallmark, has been shown to lead to aberrant glycosylation of CRC cells, heightening their malignancy both in vivo and in vitro.
35380345	3	21	theme	DM	340:341	arg1	hallmark					343:350	the DM hallmark	336:350	the DM hallmark	336:350	Previously, hyperglycemia, the DM hallmark, has been shown to lead to aberrant glycosylation of CRC cells, heightening their malignancy both in vivo and in vitro.
35380345	3	21	theme	DM	340:341	arg1	hyperglycemia					321:333	hyperglycemia	321:333	hyperglycemia	321:333	Previously, hyperglycemia, the DM hallmark, has been shown to lead to aberrant glycosylation of CRC cells, heightening their malignancy both in vivo and in vitro.
35380345	1	22	theme	colorectal	183:192	arg1	CRC					202:204	CRC	202:204	CRC	202:204	Diabetes Mellitus (DM) is both, correlated and a known risk factor for colorectal cancer (CRC).
35380345	1	22	theme	colorectal	183:192	arg1	cancer					194:199	colorectal cancer	183:199	colorectal cancer (CRC)	183:205	Diabetes Mellitus (DM) is both, correlated and a known risk factor for colorectal cancer (CRC).
35380345	0	23	theme	cancer	40:45	arg1	cells					47:51	colon cancer cells	34:51	colon cancer cells	34:51	Hyperglycemia alters N-glycans on colon cancer cells through increased production of activated monosaccharides.
35380345	9	24	theme	treatments	1412:1421	arg1	repositioning					1385:1397	repositioning	1385:1397	repositioning	1385:1397	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	9	24	theme	treatments	1412:1421	arg1	development					1370:1380	development	1370:1380	development	1370:1380	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	4	25	dep	composition	519:529	arg1	the					515:517	the	515:517	the	515:517	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	7	26	gly	mannosylated	977:988	arg1	16					936:937	16	936:937	16	936:937	Among the identified N-glycans, 16 were differentially expressed, mostly mannosylated and fucosylated, with a minority of them being sialylated.
35380345	8	27	theme	monosaccharides	1181:1195	arg1	pool					1197:1200	the activated monosaccharides pool	1167:1200	the activated monosaccharides pool	1167:1200	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	0	28	theme	colon	34:38	arg1	cells					47:51	colon cancer cells	34:51	colon cancer cells	34:51	Hyperglycemia alters N-glycans on colon cancer cells through increased production of activated monosaccharides.
35380345	7	29	gly	sialylated	1037:1046	arg1	minority					1014:1021	a minority	1012:1021	a minority of them	1012:1029	Among the identified N-glycans, 16 were differentially expressed, mostly mannosylated and fucosylated, with a minority of them being sialylated.
35380345	3	30	theme	CRC	405:407	arg1	cells					409:413	CRC cells	405:413	CRC cells	405:413	Previously, hyperglycemia, the DM hallmark, has been shown to lead to aberrant glycosylation of CRC cells, heightening their malignancy both in vivo and in vitro.
35380345	7	31	theme	them	1026:1029	arg1	minority					1014:1021	a minority	1012:1021	a minority of them	1012:1029	Among the identified N-glycans, 16 were differentially expressed, mostly mannosylated and fucosylated, with a minority of them being sialylated.
35380345	6	32	from	changes	823:829	arg1	proportion					838:847	the proportion	834:847	the proportion of sialylated, fucosylated and mannosylated N-glycans	834:901	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	8	33	located	observed	1102:1109	arg1	N-glycosylation					1118:1132	the N-glycosylation	1114:1132	the N-glycosylation	1114:1132	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	8	33	located	observed	1102:1109	arg2	increase					1155:1162	increase	1155:1162	increase of the activated monosaccharides pool	1155:1200	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	8	33	located	observed	1102:1109	arg2	alterations					1090:1100	the alterations	1086:1100	the alterations observed in the N-glycosylation	1086:1132	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	7	34	theme	identified	914:923	arg1	N-glycans					925:933	the identified N-glycans	910:933	the identified N-glycans	910:933	Among the identified N-glycans, 16 were differentially expressed, mostly mannosylated and fucosylated, with a minority of them being sialylated.
35380345	9	35	theme	effective	1402:1410	arg1	treatments					1412:1421	effective treatments	1402:1421	effective treatments against CRC in diabetic patients	1402:1454	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	9	36	from	literature	1310:1319	arg1	data					1296:1299	data	1296:1299	data from the literature regarding the progression of CRC	1296:1352	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	8	37	theme	pool	1197:1200	arg1	increase					1155:1162	increase	1155:1162	increase of the activated monosaccharides pool	1155:1200	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	8	37	theme	pool	1197:1200	arg1	alterations					1090:1100	the alterations	1086:1100	the alterations observed in the N-glycosylation	1086:1132	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	3	38	gly	glycosylation	388:400	arg1	cells					409:413	CRC cells	405:413	CRC cells	405:413	Previously, hyperglycemia, the DM hallmark, has been shown to lead to aberrant glycosylation of CRC cells, heightening their malignancy both in vivo and in vitro.
35380345	8	39	theme	activated	1171:1179	arg1	pool					1197:1200	the activated monosaccharides pool	1167:1200	the activated monosaccharides pool	1167:1200	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	9	40	theme	diabetic	1438:1445	arg1	patients					1447:1454	diabetic patients	1438:1454	diabetic patients	1438:1454	The alterations found here corroborate data from the literature regarding the progression of CRC, advocating for development or repositioning of effective treatments against CRC in diabetic patients.
35380345	4	41	theme	putative	535:542	arg1	structures					544:553	putative structures	535:553	putative structures	535:553	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	6	42	dep	sialylated	852:861	arg1	mannosylated					880:891	mannosylated	880:891	mannosylated	880:891	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	6	42	dep	sialylated	852:861	arg1	fucosylated					864:874	fucosylated	864:874	fucosylated	864:874	The cells grown in HG showed a greater abundance of N-glycans when compared to LNG cells, without changes in the proportion of sialylated, fucosylated and mannosylated N-glycans.
35380345	8	43	theme	glucose	1224:1230	arg1	entrance					1232:1239	an increased glucose entrance	1211:1239	an increased glucose entrance into the cells	1211:1254	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	4	44	theme	N-glycans	558:566	arg1	composition					519:529	composition	519:529	composition	519:529	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	4	44	theme	N-glycans	558:566	arg1	structures					544:553	putative structures	535:553	putative structures	535:553	Here we use mass spectrometry to elucidate the composition and putative structures of N-glycans expressed by MC38 cultured in normoglycemic (LG) and hyperglycemic-like conditions (HG).
35380345	0	45	theme	increased	61:69	arg1	production					71:80	increased production	61:80	increased production of activated monosaccharides	61:109	Hyperglycemia alters N-glycans on colon cancer cells through increased production of activated monosaccharides.
35380345	8	46	theme	increased	1214:1222	arg1	entrance					1232:1239	an increased glucose entrance	1211:1239	an increased glucose entrance into the cells	1211:1254	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
35380345	8	47	theme	Metabolomics	1049:1060	arg1	analysis					1062:1069	Metabolomics analysis	1049:1069	Metabolomics analysis	1049:1069	Metabolomics analysis indicates that the alterations observed in the N-glycosylation may be mostly due to increase of the activated monosaccharides pool, through an increased glucose entrance into the cells.
37257536	4	0	theme	disulfide	685:693	arg1	bonds					695:699	disulfide bonds	685:699	disulfide bonds	685:699	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	7	1	theme	dispersibility	978:991	arg1	index					993:997	polymer dispersibility index	970:997	polymer dispersibility index (PDI)	970:1003	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	1	theme	dispersibility	978:991	arg1	size					961:964	Its particle size	948:964	Its particle size	948:964	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	1	theme	dispersibility	978:991	arg1	smallest					1019:1026	smallest	1019:1026	smallest	1019:1026	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	1	theme	dispersibility	978:991	arg1	PDI					1000:1002	PDI	1000:1002	PDI	1000:1002	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	1	2	theme	anhydride	150:158	arg1	acylation					165:173	succinic anhydride (SA) acylation	141:173	succinic anhydride (SA) acylation	141:173	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	2	3	theme	carboxyl	449:456	arg1	groups					458:463	carboxyl groups	449:463	carboxyl groups	449:463	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	2	4	dep	dextran	423:429	arg1	groups					458:463	carboxyl groups	449:463	carboxyl groups	449:463	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	0	5	theme	nanogel	109:115	arg1	characterization					16:31	characterization	16:31	characterization	16:31	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	0	5	theme	nanogel	109:115	arg1	Fabrication					0:10	Fabrication	0:10	Fabrication	0:10	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	0	6	theme	self-assembled	94:107	arg1	nanogel					109:115	its self-assembled nanogel	90:115	its self-assembled nanogel	90:115	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	6	7	theme	maximum	876:882	arg1	turbidity					884:892	the maximum turbidity	872:892	the maximum turbidity	872:892	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	3	8	theme	soybean	518:524	arg1	surface					534:540	the soybean protein surface	514:540	the soybean protein surface	514:540	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	4	9	theme	surface	714:720	arg1	H0					738:739	H0	738:739	H0	738:739	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	4	9	theme	surface	714:720	arg1	hydrophobicity					722:735	surface hydrophobicity	714:735	surface hydrophobicity (H0)	714:740	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	8	10	theme	shell-core	1166:1175	arg1	structures					1177:1186	subspherical shell-core structures	1153:1186	subspherical shell-core structures	1153:1186	Transmission electron microscopy showed that nanogels had subspherical shell-core structures.
37257536	5	11	theme	%	798:798	arg1	SPI-SA3-DX					817:826	SPI-SA3-DX	817:826	SPI-SA3-DX	817:826	H0 was lowest at 33,750 ± 1008.29 when SA content = 10 % protein content (SPI-SA3-DX).
37257536	5	11	theme	%	798:798	arg1	content					808:814	content = 10 % protein content	785:814	content = 10 % protein content (SPI-SA3-DX)	785:827	H0 was lowest at 33,750 ± 1008.29 when SA content = 10 % protein content (SPI-SA3-DX).
37257536	2	12	theme	amino	372:376	arg1	group					378:382	the amino group	368:382	the amino group of the SPI	368:393	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	2	12	theme	amino	372:376	arg1	SPI					391:393	the SPI	387:393	the SPI	387:393	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	5	13	theme	content = 10 	785:797	arg1	%					798:798	%	798:798	%	798:798	H0 was lowest at 33,750 ± 1008.29 when SA content = 10 % protein content (SPI-SA3-DX).
37257536	7	14	theme	0.21 ± 0.009	1067:1078	arg1	values					1034:1039	values	1034:1039	values	1034:1039	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	1	15	used	used	136:139	arg2	we					133:134	we	133:134	we	133:134	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	9	16	theme	strength	1236:1243	arg1	conditions					1276:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	7	17	with	smallest	1019:1026	arg1	values					1034:1039	values	1034:1039	values	1034:1039	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	2	18	theme	hydrophilic	411:421	arg1	dextran					423:429	hydrophilic dextran	411:429	hydrophilic dextran	411:429	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	3	19	theme	group	494:498	arg1	attachment					500:509	Dextran chain and anhydride group attachment	466:509	attachment	500:509	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	5	20	theme	protein	800:806	arg1	SPI-SA3-DX					817:826	SPI-SA3-DX	817:826	SPI-SA3-DX	817:826	H0 was lowest at 33,750 ± 1008.29 when SA content = 10 % protein content (SPI-SA3-DX).
37257536	5	20	theme	protein	800:806	arg1	content					808:814	content = 10 % protein content	785:814	content = 10 % protein content (SPI-SA3-DX)	785:827	H0 was lowest at 33,750 ± 1008.29 when SA content = 10 % protein content (SPI-SA3-DX).
37257536	7	21	theme	nm	1060:1061	arg1	values					1034:1039	values	1034:1039	values	1034:1039	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	9	22	theme	different	1216:1224	arg1	pH					1226:1227	different pH	1216:1227	different pH	1216:1227	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	6	23	contain	had	868:870	arg2	solution					916:923	clear transparent solution	898:923	clear transparent solution	898:923	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	6	23	contain	had	868:870	arg1	based					848:852	The nanometer gel based	830:852	The nanometer gel based on SPI-SA3-DX	830:866	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	6	23	contain	had	868:870	arg2	turbidity					884:892	the maximum turbidity	872:892	the maximum turbidity	872:892	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	8	24	theme	subspherical	1153:1164	arg1	structures					1177:1186	subspherical shell-core structures	1153:1186	subspherical shell-core structures	1153:1186	Transmission electron microscopy showed that nanogels had subspherical shell-core structures.
37257536	7	25	theme	particle	952:959	arg1	index					993:997	polymer dispersibility index	970:997	polymer dispersibility index (PDI)	970:1003	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	25	theme	particle	952:959	arg1	size					961:964	Its particle size	948:964	Its particle size	948:964	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	25	theme	particle	952:959	arg1	smallest					1019:1026	smallest	1019:1026	smallest	1019:1026	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	3	26	theme	protein	526:532	arg1	surface					534:540	the soybean protein surface	514:540	the soybean protein surface	514:540	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	3	27	theme	site	578:581	arg1	blocking					583:590	spatial site blocking	570:590	spatial site blocking	570:590	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	2	28	theme	SPI	391:393	arg1	group					378:382	the amino group	368:382	the amino group of the SPI	368:393	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	2	28	theme	SPI	391:393	arg1	SPI					391:393	the SPI	387:393	the SPI	387:393	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	6	29	from	based	848:852	arg1	SPI-SA3-DX					857:866	SPI-SA3-DX	857:866	SPI-SA3-DX	857:866	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	1	30	theme	self-assembled	256:269	arg1	nanogels					294:301	self-assembled SPI-SA-DX adduct-based nanogels	256:301	self-assembled SPI-SA-DX adduct-based nanogels	256:301	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	4	31	theme	Modification-induced	593:612	arg1	unfolding					632:640	Modification-induced protein structure unfolding	593:640	Modification-induced protein structure unfolding	593:640	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	6	32	theme	clear	898:902	arg1	solution					916:923	clear transparent solution	898:923	clear transparent solution	898:923	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	3	33	theme	anhydride	484:492	arg1	attachment					500:509	Dextran chain and anhydride group attachment	466:509	attachment	500:509	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	1	34	theme	SPI-SA-DX	271:279	arg1	nanogels					294:301	self-assembled SPI-SA-DX adduct-based nanogels	256:301	self-assembled SPI-SA-DX adduct-based nanogels	256:301	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	9	35	theme	ionic	1230:1234	arg1	strength					1236:1243	ionic strength	1230:1243	ionic strength	1230:1243	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	1	36	dep	acylation	165:173	arg1	SPI					240:242	SPI	240:242	SPI	240:242	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	1	36	dep	acylation	165:173	arg1	protein					231:237	glycosylation modified soybean isolate protein	192:237	glycosylation modified soybean isolate protein (SPI)	192:243	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	4	37	theme	sulfhydryl	648:657	arg1	groups					659:664	free sulfhydryl groups	643:664	free sulfhydryl groups	643:664	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	0	38	theme	succinylated	36:47	arg1	isolate					78:84	succinylated and glycosylated soy protein isolate	36:84	succinylated and glycosylated soy protein isolate	36:84	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	1	39	theme	adduct-based	281:292	arg1	nanogels					294:301	self-assembled SPI-SA-DX adduct-based nanogels	256:301	self-assembled SPI-SA-DX adduct-based nanogels	256:301	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	2	40	theme	succinic	435:442	arg1	acid					444:447	succinic acid	435:447	succinic acid	435:447	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	6	41	theme	gel	844:846	arg1	based					848:852	The nanometer gel based	830:852	The nanometer gel based on SPI-SA3-DX	830:866	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	4	42	theme	structure	622:630	arg1	unfolding					632:640	Modification-induced protein structure unfolding	593:640	Modification-induced protein structure unfolding	593:640	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	4	43	theme	free	643:646	arg1	groups					659:664	free sulfhydryl groups	643:664	free sulfhydryl groups	643:664	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	0	44	theme	soy	66:68	arg1	isolate					78:84	succinylated and glycosylated soy protein isolate	36:84	succinylated and glycosylated soy protein isolate	36:84	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	6	45	theme	nanometer	834:842	arg1	based					848:852	The nanometer gel based	830:852	The nanometer gel based on SPI-SA3-DX	830:866	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	2	46	theme	SDS-PAGE	328:335	arg1	Degree					304:309	Degree	304:309	Degree of modification, SDS-PAGE, and FT-IR studies	304:354	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	0	47	theme	glycosylated	53:64	arg1	isolate					78:84	succinylated and glycosylated soy protein isolate	36:84	succinylated and glycosylated soy protein isolate	36:84	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	9	48	theme	storage	1268:1274	arg1	conditions					1276:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	9	49	theme	high	1246:1249	arg1	temperature					1251:1261	high temperature	1246:1261	high temperature	1246:1261	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	3	50	theme	spatial	570:576	arg1	blocking					583:590	spatial site blocking	570:590	spatial site blocking	570:590	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	3	51	theme	Dextran	466:472	arg1	chain					474:478	Dextran chain and anhydride group attachment	466:509	chain	474:478	Dextran chain and anhydride group attachment to the soybean protein surface enhanced hydrophilicity and spatial site blocking.
37257536	9	52	theme	pH	1226:1227	arg1	conditions					1276:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	8	53	theme	Transmission	1095:1106	arg1	microscopy					1117:1126	Transmission electron microscopy	1095:1126	Transmission electron microscopy	1095:1126	Transmission electron microscopy showed that nanogels had subspherical shell-core structures.
37257536	9	54	theme	temperature	1251:1261	arg1	conditions					1276:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	different pH, ionic strength, high temperature, and storage conditions	1216:1285	Nanogels were stable under different pH, ionic strength, high temperature, and storage conditions.
37257536	2	55	theme	modification	314:325	arg1	Degree					304:309	Degree	304:309	Degree of modification, SDS-PAGE, and FT-IR studies	304:354	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	1	56	theme	glycosylation	192:204	arg1	SPI					240:242	SPI	240:242	SPI	240:242	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	1	56	theme	glycosylation	192:204	arg1	protein					231:237	glycosylation modified soybean isolate protein	192:237	glycosylation modified soybean isolate protein (SPI)	192:243	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	8	57	contain	had	1149:1151	arg2	structures					1177:1186	subspherical shell-core structures	1153:1186	subspherical shell-core structures	1153:1186	Transmission electron microscopy showed that nanogels had subspherical shell-core structures.
37257536	8	57	contain	had	1149:1151	arg1	nanogels					1140:1147	nanogels	1140:1147	nanogels	1140:1147	Transmission electron microscopy showed that nanogels had subspherical shell-core structures.
37257536	1	58	theme	succinic	141:148	arg1	SA					161:162	SA	161:162	SA	161:162	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	1	58	theme	succinic	141:148	arg1	anhydride					150:158	succinic anhydride	141:158	succinic anhydride (SA) acylation	141:173	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	8	59	theme	electron	1108:1115	arg1	microscopy					1117:1126	Transmission electron microscopy	1095:1126	Transmission electron microscopy	1095:1126	Transmission electron microscopy showed that nanogels had subspherical shell-core structures.
37257536	1	60	theme	modified	206:213	arg1	SPI					240:242	SPI	240:242	SPI	240:242	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	1	60	theme	modified	206:213	arg1	protein					231:237	glycosylation modified soybean isolate protein	192:237	glycosylation modified soybean isolate protein (SPI)	192:243	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	0	61	theme	isolate	78:84	arg1	characterization					16:31	characterization	16:31	characterization	16:31	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	0	61	theme	isolate	78:84	arg1	Fabrication					0:10	Fabrication	0:10	Fabrication	0:10	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	0	62	gly	glycosylated	53:64	arg1	isolate					78:84	succinylated and glycosylated soy protein isolate	36:84	succinylated and glycosylated soy protein isolate	36:84	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	2	63	theme	studies	348:354	arg1	Degree					304:309	Degree	304:309	Degree of modification, SDS-PAGE, and FT-IR studies	304:354	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	1	64	theme	soybean	215:221	arg1	SPI					240:242	SPI	240:242	SPI	240:242	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	1	64	theme	soybean	215:221	arg1	protein					231:237	glycosylation modified soybean isolate protein	192:237	glycosylation modified soybean isolate protein (SPI)	192:243	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	0	65	theme	protein	70:76	arg1	isolate					78:84	succinylated and glycosylated soy protein isolate	36:84	succinylated and glycosylated soy protein isolate	36:84	Fabrication and characterization of succinylated and glycosylated soy protein isolate and its self-assembled nanogel.
37257536	6	66	theme	transparent	904:914	arg1	solution					916:923	clear transparent solution	898:923	clear transparent solution	898:923	The nanometer gel based on SPI-SA3-DX had the maximum turbidity and clear transparent solution without precipitation.
37257536	4	67	theme	protein	614:620	arg1	unfolding					632:640	Modification-induced protein structure unfolding	593:640	Modification-induced protein structure unfolding	593:640	Modification-induced protein structure unfolding, free sulfhydryl groups to be converted to disulfide bonds, and reduced surface hydrophobicity (H0).
37257536	7	68	theme	polymer	970:976	arg1	index					993:997	polymer dispersibility index	970:997	polymer dispersibility index (PDI)	970:1003	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	68	theme	polymer	970:976	arg1	size					961:964	Its particle size	948:964	Its particle size	948:964	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	68	theme	polymer	970:976	arg1	smallest					1019:1026	smallest	1019:1026	smallest	1019:1026	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	7	68	theme	polymer	970:976	arg1	PDI					1000:1002	PDI	1000:1002	PDI	1000:1002	Its particle size and polymer dispersibility index (PDI) were also the smallest, with values of (106.87 ± 4.51) nm and 0.21 ± 0.009, respectively.
37257536	2	69	theme	FT-IR	342:346	arg1	studies					348:354	FT-IR studies	342:354	FT-IR studies	342:354	Degree of modification, SDS-PAGE, and FT-IR studies showed that the amino group of the SPI was replaced by hydrophilic dextran and succinic acid carboxyl groups.
37257536	1	70	theme	isolate	223:229	arg1	SPI					240:242	SPI	240:242	SPI	240:242	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37257536	1	70	theme	isolate	223:229	arg1	protein					231:237	glycosylation modified soybean isolate protein	192:237	glycosylation modified soybean isolate protein (SPI)	192:243	In this study, we used succinic anhydride (SA) acylation and dextran (DX) glycosylation modified soybean isolate protein (SPI) to develop self-assembled SPI-SA-DX adduct-based nanogels.
37258966	0	0	theme	N-Linked	89:96	arg1	Hydrolysis					105:114	N-Linked Glycan Hydrolysis	89:114	N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases	89:149	Mass Spectrometry-Based Methods to Determine the Substrate Specificities and Kinetics of N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases.
37258966	6	1	theme	novel	1090:1094	arg1	technique					1120:1128	a novel mass spectrometry-based technique	1088:1128	a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently	1088:1226	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	1	2	theme	polysaccharides	279:293	arg1	chains					269:274	chains	269:274	chains of polysaccharides	269:293	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	1	2	theme	polysaccharides	279:293	arg1	glycans					260:266	glycans	260:266	glycans	260:266	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	0	3	theme	Hydrolysis	105:114	arg1	Kinetics					77:84	Kinetics	77:84	Kinetics	77:84	Mass Spectrometry-Based Methods to Determine the Substrate Specificities and Kinetics of N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases.
37258966	0	3	theme	Hydrolysis	105:114	arg1	Specificities					59:71	the Substrate Specificities	45:71	the Substrate Specificities	45:71	Mass Spectrometry-Based Methods to Determine the Substrate Specificities and Kinetics of N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases.
37258966	4	4	from	glycans	793:799	arg1	addition					726:733	addition	726:733	addition	726:733	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	4	4	from	glycans	793:799	arg1	saccharides					776:786	individual or multiple saccharides	753:786	individual or multiple saccharides from glycans	753:799	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	4	4	from	glycans	793:799	arg1	subtraction					738:748	subtraction	738:748	subtraction	738:748	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	3	5	theme	autoimmune	565:574	arg1	conditions					576:585	autoimmune conditions	565:585	autoimmune conditions	565:585	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	0	6	theme	Glycan	98:103	arg1	Hydrolysis					105:114	N-Linked Glycan Hydrolysis	89:114	N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases	89:149	Mass Spectrometry-Based Methods to Determine the Substrate Specificities and Kinetics of N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases.
37258966	4	7	theme	saccharides	776:786	arg1	addition					726:733	addition	726:733	addition	726:733	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	4	7	theme	saccharides	776:786	arg1	subtraction					738:748	subtraction	738:748	subtraction	738:748	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	5	8	theme	enzymatic	934:942	arg1	activity					944:951	enzymatic activity	934:951	enzymatic activity	934:951	One of the hurdles in studying these enzymes is determining the types of substrates each enzyme is specific for and the kinetics of enzymatic activity.
37258966	6	9	used	used	1010:1013	arg2	methods					982:988	methods	982:988	methods which are currently used to study the substrate specificity and kinetics of CAZymes	982:1072	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	6	10	theme	CAZymes	1066:1072	arg1	kinetics					1054:1061	kinetics	1054:1061	kinetics	1054:1061	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	6	10	theme	CAZymes	1066:1072	arg1	specificity					1038:1048	substrate specificity	1028:1048	substrate specificity	1028:1048	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	1	11	theme	proteins	212:219	arg1	modification					196:207	a common posttranslational modification	169:207	a common posttranslational modification of proteins	169:219	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	1	11	theme	proteins	212:219	arg1	Glycosylation					152:164	Glycosylation	152:164	Glycosylation	152:164	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	0	12	theme	Substrate	49:57	arg1	Specificities					59:71	the Substrate Specificities	45:71	the Substrate Specificities	45:71	Mass Spectrometry-Based Methods to Determine the Substrate Specificities and Kinetics of N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases.
37258966	5	13	theme	activity	944:951	arg1	kinetics					922:929	and the kinetics	914:929	kinetics	922:929	One of the hurdles in studying these enzymes is determining the types of substrates each enzyme is specific for and the kinetics of enzymatic activity.
37258966	5	14	theme	substrates	875:884	arg1	types					866:870	the types	862:870	the types of substrates	862:884	One of the hurdles in studying these enzymes is determining the types of substrates each enzyme is specific for and the kinetics of enzymatic activity.
37258966	0	15	theme	Spectrometry-Based	5:22	arg1	Methods					24:30	Mass Spectrometry-Based Methods	0:30	Mass Spectrometry-Based Methods	0:30	Mass Spectrometry-Based Methods to Determine the Substrate Specificities and Kinetics of N-Linked Glycan Hydrolysis by Endo-β-N-Acetylglucosaminidases.
37258966	4	16	theme	individual	753:762	arg1	saccharides					776:786	individual or multiple saccharides	753:786	individual or multiple saccharides from glycans	753:799	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	3	17	theme	immune	448:453	arg1	system					455:460	the immune system	444:460	the immune system	444:460	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	4	18	theme	multiple	767:774	arg1	saccharides					776:786	individual or multiple saccharides	753:786	individual or multiple saccharides from glycans	753:799	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	4	19	theme	Carbohydrate-active	599:617	arg1	CAZymes					628:634	CAZymes	628:634	CAZymes	628:634	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	4	19	theme	Carbohydrate-active	599:617	arg1	enzymes					619:625	Carbohydrate-active enzymes	599:625	Carbohydrate-active enzymes (CAZymes)	599:635	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	1	20	theme	covalent	239:246	arg1	addition					248:255	the covalent addition	235:255	the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins	235:332	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	3	21	contain	have	500:503	arg1	proteins					491:498	aberrantly glycosylated proteins	467:498	aberrantly glycosylated proteins	467:498	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	3	21	contain	have	500:503	arg2	effects					518:524	wide ranging effects	505:524	wide ranging effects	505:524	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	1	22	gly	glycoproteins	320:332	arg1	glycoproteins					320:332	glycoproteins	320:332	glycoproteins	320:332	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	3	23	theme	glycosylated	478:489	arg1	proteins					491:498	aberrantly glycosylated proteins	467:498	aberrantly glycosylated proteins	467:498	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	3	24	theme	integral	427:434	arg1	role					436:439	an integral role	424:439	an integral role	424:439	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	5	25	theme	hurdles	813:819	arg1	One					802:804	One	802:804	One	802:804	One of the hurdles in studying these enzymes is determining the types of substrates each enzyme is specific for and the kinetics of enzymatic activity.
37258966	5	25	theme	hurdles	813:819	arg1	hurdles					813:819	the hurdles	809:819	the hurdles in studying these enzymes	809:845	One of the hurdles in studying these enzymes is determining the types of substrates each enzyme is specific for and the kinetics of enzymatic activity.
37258966	3	26	gly	glycosylated	478:489	arg1	proteins					491:498	aberrantly glycosylated proteins	467:498	aberrantly glycosylated proteins	467:498	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	6	27	theme	spectrometry-based	1101:1118	arg1	technique					1120:1128	a novel mass spectrometry-based technique	1088:1128	a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently	1088:1226	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	2	28	theme	proteins	399:406	arg1	function					372:379	function	372:379	function	372:379	The glycans influence the structure, function, and stability of proteins.
37258966	2	28	theme	proteins	399:406	arg1	stability					386:394	stability	386:394	stability	386:394	The glycans influence the structure, function, and stability of proteins.
37258966	2	28	theme	proteins	399:406	arg1	structure					361:369	structure	361:369	structure	361:369	The glycans influence the structure, function, and stability of proteins.
37258966	4	29	from	subtraction	738:748	arg1	glycans					793:799	glycans	793:799	glycans	793:799	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	2	30	dep	structure	361:369	arg1	the					357:359	the	357:359	the	357:359	The glycans influence the structure, function, and stability of proteins.
37258966	4	31	dep	addition	726:733	arg1	the					722:724	the	722:724	the	722:724	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	1	32	theme	glycans	260:266	arg1	addition					248:255	the covalent addition	235:255	the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins	235:332	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	6	33	theme	CAZymes	1176:1182	arg1	kinetics					1164:1171	kinetics	1164:1171	kinetics	1164:1171	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	6	33	theme	CAZymes	1176:1182	arg1	specificity					1148:1158	specificity	1148:1158	specificity	1148:1158	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	6	34	dep	specificity	1038:1048	arg1	the					1024:1026	the	1024:1026	the	1024:1026	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	3	35	theme	ranging	510:516	arg1	effects					518:524	wide ranging effects	505:524	wide ranging effects	505:524	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	4	36	from	addition	726:733	arg1	glycans					793:799	glycans	793:799	glycans	793:799	Carbohydrate-active enzymes (CAZymes) are produced in bacteria, fungi, and humans and are enzymes which modify glycans via the addition or subtraction of individual or multiple saccharides from glycans.
37258966	3	37	theme	wide	505:508	arg1	effects					518:524	wide ranging effects	505:524	wide ranging effects	505:524	They also play an integral role in the immune system, and aberrantly glycosylated proteins have wide ranging effects, including leading to diseases such as autoimmune conditions and cancer.
37258966	6	38	theme	substrate	1028:1036	arg1	specificity					1038:1048	substrate specificity	1028:1048	substrate specificity	1028:1048	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	1	39	theme	common	171:176	arg1	modification					196:207	a common posttranslational modification	169:207	a common posttranslational modification of proteins	169:219	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	1	39	theme	common	171:176	arg1	Glycosylation					152:164	Glycosylation	152:164	Glycosylation	152:164	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	6	40	dep	specificity	1148:1158	arg1	the					1144:1146	the	1144:1146	the	1144:1146	In this chapter, we discuss methods which are currently used to study the substrate specificity and kinetics of CAZymes and introduce a novel mass spectrometry-based technique which enables the specificity and kinetics of CAZymes to be determined accurately and efficiently.
37258966	5	41	dep	determining	850:860	arg1	specific					901:908	specific	901:908	specific	901:908	One of the hurdles in studying these enzymes is determining the types of substrates each enzyme is specific for and the kinetics of enzymatic activity.
37258966	1	42	theme	posttranslational	178:194	arg1	modification					196:207	a common posttranslational modification	169:207	a common posttranslational modification of proteins	169:219	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
37258966	1	42	theme	posttranslational	178:194	arg1	Glycosylation					152:164	Glycosylation	152:164	Glycosylation	152:164	Glycosylation is a common posttranslational modification of proteins and refers to the covalent addition of glycans, chains of polysaccharides, onto proteins producing glycoproteins.
35311852	8	0	theme	N-glycan	1157:1164	arg1	isomers					1166:1172	branch-fucosylated N-glycan isomers	1138:1172	branch-fucosylated N-glycan isomers	1138:1172	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	5	1	theme	biomolecule	638:648	arg1	analysis					650:657	biomolecule analysis	638:657	biomolecule analysis	638:657	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	14	2	theme	isomeric	2218:2225	arg1	separations					2227:2237	isomeric separations	2218:2237	isomeric separations of glycans	2218:2248	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	11	3	theme	isomers	1561:1567	arg1	performance					1533:1543	the separation performance	1518:1543	the separation performance of high-mannose isomers	1518:1567	However, the separation performance of high-mannose isomers needs further improvement.
35311852	5	4	from	reliability	708:718	arg1	time					733:736	retention time	723:736	retention time	723:736	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	5	4	from	reliability	708:718	arg1	resolution					753:762	separation resolution	742:762	separation resolution	742:762	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	10	5	theme	Baseline	1434:1441	arg1	separations					1443:1453	Baseline separations	1434:1453	Baseline separations	1434:1453	Baseline separations were observed on multiple sialylated linkage isomers.
35311852	14	6	theme	good	2183:2186	arg1	alternative					2202:2212	a good complementary alternative	2181:2212	it a good complementary alternative for isomeric separations of glycans	2178:2248	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	10	7	theme	multiple	1472:1479	arg1	isomers					1500:1506	multiple sialylated linkage isomers	1472:1506	multiple sialylated linkage isomers	1472:1506	Baseline separations were observed on multiple sialylated linkage isomers.
35311852	13	8	theme	baseline	1958:1965	arg1	separations					1967:1977	baseline separations	1958:1977	baseline separations	1958:1977	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	12	9	theme	C18	1643:1645	arg1	column					1647:1652	this long C18 column	1633:1652	this long C18 column	1633:1652	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	10	10	located	observed	1460:1467	arg2	separations					1443:1453	Baseline separations	1434:1453	Baseline separations	1434:1453	Baseline separations were observed on multiple sialylated linkage isomers.
35311852	10	10	located	observed	1460:1467	arg1	isomers					1500:1506	multiple sialylated linkage isomers	1472:1506	multiple sialylated linkage isomers	1472:1506	Baseline separations were observed on multiple sialylated linkage isomers.
35311852	5	11	theme	retention	723:731	arg1	time					733:736	retention time	723:736	retention time	723:736	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	9	12	theme	optimal	1256:1262	arg1	strategy					1275:1282	the optimal separation strategy	1252:1282	the optimal separation strategy	1252:1282	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	12	13	theme	multiple	1755:1762	arg1	glycans					1764:1770	multiple glycans	1755:1770	multiple glycans	1755:1770	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	7	14	theme	isomeric	913:920	arg1	separation					922:931	the isomeric separation	909:931	the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column	909:996	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	7	15	theme	reversed-phase	973:986	arg1	column					991:996	a 500 mm reversed-phase LC column	964:996	a 500 mm reversed-phase LC column	964:996	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	0	16	theme	liquid	74:79	arg1	RPLC					97:100	RPLC	97:100	RPLC	97:100	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	0	16	theme	liquid	74:79	arg1	chromatography					81:94	extra-long reversed-phase liquid chromatography	48:94	extra-long reversed-phase liquid chromatography (RPLC)	48:101	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	7	17	theme	500	966:968	arg1	mm					970:971	mm	970:971	mm	970:971	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	1	18	theme	biological	147:156	arg1	process					158:164	a critical biological process	136:164	a critical biological process that can largely affect the properties and the functions of proteins	136:233	Glycosylation is known as a critical biological process that can largely affect the properties and the functions of proteins.
35311852	1	18	theme	biological	147:156	arg1	Glycosylation					110:122	Glycosylation	110:122	Glycosylation	110:122	Glycosylation is known as a critical biological process that can largely affect the properties and the functions of proteins.
35311852	4	19	theme	effective	484:492	arg1	techniques					505:514	effective and stable techniques	484:514	effective and stable techniques	484:514	Therefore, effective and stable techniques have been investigated over the last few decades to improve isomeric separations of glycans.
35311852	14	20	theme	robust	2142:2147	arg1	reproducibility					2149:2163	more robust reproducibility	2137:2163	more robust reproducibility	2137:2163	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	11	21	theme	high-mannose	1548:1559	arg1	isomers					1561:1567	high-mannose isomers	1548:1567	high-mannose isomers	1548:1567	However, the separation performance of high-mannose isomers needs further improvement.
35311852	8	22	theme	better	1010:1015	arg1	resolutions					1017:1027	better resolutions	1010:1027	better resolutions on permethylated glycans	1010:1052	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	12	23	theme	times	1746:1750	arg1	comparisons					1721:1731	run-to-run, day-to-day and month-to-month comparisons	1679:1731	run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans	1679:1770	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	4	24	theme	stable	498:503	arg1	techniques					505:514	effective and stable techniques	484:514	effective and stable techniques	484:514	Therefore, effective and stable techniques have been investigated over the last few decades to improve isomeric separations of glycans.
35311852	14	25	theme	C18	2096:2098	arg1	column					2100:2105	the RPLC C18 column	2087:2105	the RPLC C18 column	2087:2105	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	13	26	theme	blood	1924:1928	arg1	serum					1930:1934	blood serum	1924:1934	blood serum	1924:1934	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	7	27	theme	permethylated	936:948	arg1	glycans					950:956	permethylated glycans	936:956	permethylated glycans using a 500 mm reversed-phase LC column	936:996	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	14	28	theme	separation	2041:2050	arg1	efficiency					2052:2061	the separation efficiency	2037:2061	the separation efficiency of PGC and MGC columns	2037:2084	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	12	29	theme	day-to-day	1691:1700	arg1	comparisons					1721:1731	run-to-run, day-to-day and month-to-month comparisons	1679:1731	run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans	1679:1770	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	14	30	theme	lower	2116:2120	arg1	resolution					2122:2131	lower resolution	2116:2131	lower resolution	2116:2131	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	12	31	theme	month-to-month	1706:1719	arg1	comparisons					1721:1731	run-to-run, day-to-day and month-to-month comparisons	1679:1731	run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans	1679:1770	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	3	32	theme	isomers	373:379	arg1	separation					333:342	separation	333:342	separation	333:342	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	3	32	theme	isomers	373:379	arg1	challenge					392:400	a challenge	390:400	a challenge for years due to the microheterogeneity of glycan isomeric structures	390:470	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	3	32	theme	isomers	373:379	arg1	identification					348:361	identification	348:361	identification	348:361	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	10	33	theme	sialylated	1481:1490	arg1	isomers					1500:1506	multiple sialylated linkage isomers	1472:1506	multiple sialylated linkage isomers	1472:1506	Baseline separations were observed on multiple sialylated linkage isomers.
35311852	13	34	theme	biological	1894:1903	arg1	samples					1905:1911	complex biological samples	1886:1911	complex biological samples	1886:1911	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	34	theme	biological	1894:1903	arg1	serum					1930:1934	blood serum	1924:1934	blood serum	1924:1934	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	34	theme	biological	1894:1903	arg1	lines					1945:1949	cell lines	1940:1949	cell lines	1940:1949	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	0	35	theme	Isomeric	0:7	arg1	separation					9:18	Isomeric separation	0:18	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)	0:101	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	9	36	theme	isomers	1338:1344	arg1	separations					1307:1317	separations	1307:1317	separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein	1307:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	8	37	theme	different	1055:1063	arg1	conditions					1068:1077	different LC conditions	1055:1077	different LC conditions	1055:1077	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	14	38	theme	RPLC	2091:2094	arg1	column					2100:2105	the RPLC C18 column	2087:2105	the RPLC C18 column	2087:2105	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	13	39	theme	separate	1849:1856	arg1	isomers					1865:1871	separate glycan isomers	1849:1871	separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures	1849:2022	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	3	40	theme	glycan	445:450	arg1	structures					461:470	glycan isomeric structures	445:470	glycan isomeric structures	445:470	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	12	41	theme	run-to-run	1679:1688	arg1	comparisons					1721:1731	run-to-run, day-to-day and month-to-month comparisons	1679:1731	run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans	1679:1770	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	4	42	theme	few	553:555	arg1	decades					557:563	the last few decades	544:563	the last few decades	544:563	Therefore, effective and stable techniques have been investigated over the last few decades to improve isomeric separations of glycans.
35311852	0	43	theme	glycans	37:43	arg1	separation					9:18	Isomeric separation	0:18	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)	0:101	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	14	44	theme	MGC	2074:2076	arg1	columns					2078:2084	PGC and MGC columns	2066:2084	PGC and MGC columns	2066:2084	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	0	45	theme	extra-long	48:57	arg1	RPLC					97:100	RPLC	97:100	RPLC	97:100	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	0	45	theme	extra-long	48:57	arg1	chromatography					81:94	extra-long reversed-phase liquid chromatography	48:94	extra-long reversed-phase liquid chromatography (RPLC)	48:101	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	8	46	theme	glycan	1100:1105	arg1	standards					1107:1115	glycan standards	1100:1115	glycan standards	1100:1115	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	8	46	theme	glycan	1100:1105	arg1	core-					1128:1132	core-	1128:1132	core-	1128:1132	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	8	46	theme	glycan	1100:1105	arg1	isomers					1166:1172	branch-fucosylated N-glycan isomers	1138:1172	branch-fucosylated N-glycan isomers	1138:1172	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	8	46	theme	glycan	1100:1105	arg1	acid					1185:1188	sialic acid	1178:1188	sialic acid	1178:1188	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	14	47	theme	PGC	2066:2068	arg1	columns					2078:2084	PGC and MGC columns	2066:2084	PGC and MGC columns	2066:2084	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	12	48	dep	reproducibility	1600:1614	arg1	The					1596:1598	The	1596:1598	The	1596:1598	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	3	49	theme	structures	461:470	arg1	microheterogeneity					423:440	the microheterogeneity	419:440	the microheterogeneity of glycan isomeric structures	419:470	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	6	50	theme	glycan	826:831	arg1	isomers					833:839	glycan isomers	826:839	glycan isomers	826:839	However, so far, no studies have achieved high resolution of glycan isomers using this technique.
35311852	9	51	theme	ribonuclease	1405:1416	arg1	B					1418:1418	ribonuclease B	1405:1418	ribonuclease B	1405:1418	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	14	52	theme	glycans	2242:2248	arg1	separations					2227:2237	isomeric separations	2218:2237	isomeric separations of glycans	2218:2248	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	8	53	theme	branch-fucosylated	1138:1155	arg1	isomers					1166:1172	branch-fucosylated N-glycan isomers	1138:1172	branch-fucosylated N-glycan isomers	1138:1172	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	6	54	theme	high	807:810	arg1	resolution					812:821	high resolution	807:821	high resolution of glycan isomers	807:839	However, so far, no studies have achieved high resolution of glycan isomers using this technique.
35311852	4	55	theme	isomeric	576:583	arg1	separations					585:595	isomeric separations	576:595	isomeric separations of glycans	576:606	Therefore, effective and stable techniques have been investigated over the last few decades to improve isomeric separations of glycans.
35311852	13	56	theme	several	1996:2002	arg1	structures					2013:2022	several isomeric structures	1996:2022	several isomeric structures	1996:2022	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	8	57	theme	sialic	1178:1183	arg1	acid					1185:1188	sialic acid	1178:1188	sialic acid	1178:1188	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	12	58	theme	%	1780:1780	arg1	RSD					1781:1783	the %RSD	1776:1783	the %RSD	1776:1783	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	14	59	theme	complementary	2188:2200	arg1	alternative					2202:2212	a good complementary alternative	2181:2212	it a good complementary alternative for isomeric separations of glycans	2178:2248	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	2	60	theme	disease	298:304	arg1	progressions					306:317	disease progressions	298:317	disease progressions	298:317	Glycan isomers have been shown to be involved in a variety of disease progressions.
35311852	8	61	theme	linked	1190:1195	arg1	isomers					1197:1203	linked isomers	1190:1203	linked isomers	1190:1203	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	12	62	theme	column	1647:1652	arg1	stability					1620:1628	stability	1620:1628	stability	1620:1628	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	12	62	theme	column	1647:1652	arg1	reproducibility					1600:1614	reproducibility	1600:1614	reproducibility	1600:1614	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	8	63	from	resolutions	1017:1027	arg1	glycans					1046:1052	permethylated glycans	1032:1052	permethylated glycans	1032:1052	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	2	64	theme	Glycan	236:241	arg1	isomers					243:249	Glycan isomers	236:249	Glycan isomers	236:249	Glycan isomers have been shown to be involved in a variety of disease progressions.
35311852	12	65	theme	long	1638:1641	arg1	column					1647:1652	this long C18 column	1633:1652	this long C18 column	1633:1652	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	5	66	theme	extraordinary	674:686	arg1	reproducibility					688:702	its extraordinary reproducibility	670:702	its extraordinary reproducibility	670:702	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	9	67	theme	separation	1264:1273	arg1	strategy					1275:1282	the optimal separation strategy	1252:1282	the optimal separation strategy	1252:1282	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	13	68	theme	cell	1940:1943	arg1	lines					1945:1949	cell lines	1940:1949	cell lines	1940:1949	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	7	69	theme	LC	988:989	arg1	column					991:996	a 500 mm reversed-phase LC column	964:996	a 500 mm reversed-phase LC column	964:996	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	1	70	theme	critical	138:145	arg1	process					158:164	a critical biological process	136:164	a critical biological process that can largely affect the properties and the functions of proteins	136:233	Glycosylation is known as a critical biological process that can largely affect the properties and the functions of proteins.
35311852	1	70	theme	critical	138:145	arg1	Glycosylation					110:122	Glycosylation	110:122	Glycosylation	110:122	Glycosylation is known as a critical biological process that can largely affect the properties and the functions of proteins.
35311852	12	71	from	comparisons	1721:1731	arg1	glycans					1764:1770	multiple glycans	1755:1770	multiple glycans	1755:1770	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	13	72	attach	derived	1873:1879	arg1	samples					1905:1911	complex biological samples	1886:1911	complex biological samples	1886:1911	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	72	attach	derived	1873:1879	arg2	isomers					1865:1871	separate glycan isomers	1849:1871	separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures	1849:2022	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	72	attach	derived	1873:1879	arg1	serum					1930:1934	blood serum	1924:1934	blood serum	1924:1934	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	72	attach	derived	1873:1879	arg1	lines					1945:1949	cell lines	1940:1949	cell lines	1940:1949	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	7	73	theme	mm	970:971	arg1	column					991:996	a 500 mm reversed-phase LC column	964:996	a 500 mm reversed-phase LC column	964:996	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	11	74	theme	separation	1522:1531	arg1	performance					1533:1543	the separation performance	1518:1543	the separation performance of high-mannose isomers	1518:1567	However, the separation performance of high-mannose isomers needs further improvement.
35311852	8	75	theme	permethylated	1032:1044	arg1	glycans					1046:1052	permethylated glycans	1032:1052	permethylated glycans	1032:1052	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	12	76	theme	retention	1736:1744	arg1	times					1746:1750	retention times	1736:1750	retention times	1736:1750	The reproducibility and stability of this long C18 column was also tested by doing run-to-run, day-to-day and month-to-month comparisons of retention times on multiple glycans and the %RSD was found less than 0.92%.
35311852	5	77	theme	separation	742:751	arg1	resolution					753:762	separation resolution	742:762	separation resolution	742:762	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	9	78	theme	N-	1322:1323	arg1	isomers					1338:1344	N- and O-glycan isomers	1322:1344	N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein	1322:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	8	79	link	linked	1190:1195	arg1	isomers					1197:1203	linked isomers	1190:1203	linked isomers	1190:1203	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	10	80	theme	linkage	1492:1498	arg1	isomers					1500:1506	multiple sialylated linkage isomers	1472:1506	multiple sialylated linkage isomers	1472:1506	Baseline separations were observed on multiple sialylated linkage isomers.
35311852	1	81	theme	proteins	226:233	arg1	properties					194:203	the properties	190:203	the properties	190:203	Glycosylation is known as a critical biological process that can largely affect the properties and the functions of proteins.
35311852	1	81	theme	proteins	226:233	arg1	functions					213:221	the functions	209:221	the functions	209:221	Glycosylation is known as a critical biological process that can largely affect the properties and the functions of proteins.
35311852	13	82	theme	complex	1886:1892	arg1	samples					1905:1911	complex biological samples	1886:1911	complex biological samples	1886:1911	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	82	theme	complex	1886:1892	arg1	serum					1930:1934	blood serum	1924:1934	blood serum	1924:1934	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	13	82	theme	complex	1886:1892	arg1	lines					1945:1949	cell lines	1940:1949	cell lines	1940:1949	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	9	83	theme	O-glycan	1329:1336	arg1	isomers					1338:1344	N- and O-glycan isomers	1322:1344	N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein	1322:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	8	84	theme	LC	1065:1066	arg1	conditions					1068:1077	different LC conditions	1055:1077	different LC conditions	1055:1077	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	4	85	theme	last	548:551	arg1	decades					557:563	the last few decades	544:563	the last few decades	544:563	Therefore, effective and stable techniques have been investigated over the last few decades to improve isomeric separations of glycans.
35311852	8	86	dep	core-	1128:1132	arg1	isomers					1197:1203	linked isomers	1190:1203	linked isomers	1190:1203	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	9	87	gly	glycoproteins	1365:1377	arg1	κ-casein					1424:1431	κ-casein	1424:1431	κ-casein	1424:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	87	gly	glycoproteins	1365:1377	arg1	fetuin					1397:1402	bovine fetuin	1390:1402	bovine fetuin	1390:1402	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	87	gly	glycoproteins	1365:1377	arg1	B					1418:1418	ribonuclease B	1405:1418	ribonuclease B	1405:1418	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	87	gly	glycoproteins	1365:1377	arg1	glycoproteins					1365:1377	model glycoproteins	1359:1377	model glycoproteins	1359:1377	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	3	88	theme	due	412:414	arg1	years					406:410	years	406:410	years due to the microheterogeneity of glycan isomeric structures	406:470	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	0	89	theme	permethylated	23:35	arg1	glycans					37:43	permethylated glycans	23:43	permethylated glycans	23:43	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	7	90	theme	glycans	950:956	arg1	separation					922:931	the isomeric separation	909:931	the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column	909:996	In this study, we focused on further boosting the isomeric separation of permethylated glycans using a 500 mm reversed-phase LC column.
35311852	3	91	theme	glycan	366:371	arg1	isomers					373:379	glycan isomers	366:379	glycan isomers	366:379	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	13	92	theme	glycan	1858:1863	arg1	isomers					1865:1871	separate glycan isomers	1849:1871	separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures	1849:2022	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	3	93	theme	isomeric	452:459	arg1	structures					461:470	glycan isomeric structures	445:470	glycan isomeric structures	445:470	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	9	94	theme	model	1359:1363	arg1	κ-casein					1424:1431	κ-casein	1424:1431	κ-casein	1424:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	94	theme	model	1359:1363	arg1	fetuin					1397:1402	bovine fetuin	1390:1402	bovine fetuin	1390:1402	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	94	theme	model	1359:1363	arg1	B					1418:1418	ribonuclease B	1405:1418	ribonuclease B	1405:1418	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	94	theme	model	1359:1363	arg1	glycoproteins					1365:1377	model glycoproteins	1359:1377	model glycoproteins	1359:1377	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	14	95	dep	it	2178:2179	arg1	alternative					2202:2212	a good complementary alternative	2181:2212	it a good complementary alternative for isomeric separations of glycans	2178:2248	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	14	96	theme	columns	2078:2084	arg1	efficiency					2052:2061	the separation efficiency	2037:2061	the separation efficiency of PGC and MGC columns	2037:2084	Compared to the separation efficiency of PGC and MGC columns, the RPLC C18 column provides lower resolution but more robust reproducibility, which makes it a good complementary alternative for isomeric separations of glycans.
35311852	9	97	attach	derived	1346:1352	arg2	isomers					1338:1344	N- and O-glycan isomers	1322:1344	N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein	1322:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	97	attach	derived	1346:1352	arg1	fetuin					1397:1402	bovine fetuin	1390:1402	bovine fetuin	1390:1402	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	97	attach	derived	1346:1352	arg1	B					1418:1418	ribonuclease B	1405:1418	ribonuclease B	1405:1418	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	97	attach	derived	1346:1352	arg1	glycoproteins					1365:1377	model glycoproteins	1359:1377	model glycoproteins	1359:1377	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	9	97	attach	derived	1346:1352	arg1	κ-casein					1424:1431	κ-casein	1424:1431	κ-casein	1424:1431	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	0	98	theme	reversed-phase	59:72	arg1	RPLC					97:100	RPLC	97:100	RPLC	97:100	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	0	98	theme	reversed-phase	59:72	arg1	chromatography					81:94	extra-long reversed-phase liquid chromatography	48:94	extra-long reversed-phase liquid chromatography (RPLC)	48:101	Isomeric separation of permethylated glycans by extra-long reversed-phase liquid chromatography (RPLC)-MS/MS.
35311852	3	99	dep	separation	333:342	arg1	the					329:331	the	329:331	the	329:331	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	3	100	gly	microheterogeneity	423:440	arg1	structures					461:470	glycan isomeric structures	445:470	glycan isomeric structures	445:470	However, the separation and identification of glycan isomers has been a challenge for years due to the microheterogeneity of glycan isomeric structures.
35311852	8	101	gly	branch-fucosylated	1138:1155	arg1	isomers					1166:1172	branch-fucosylated N-glycan isomers	1138:1172	branch-fucosylated N-glycan isomers	1138:1172	To achieve better resolutions on permethylated glycans, different LC conditions were optimized using glycan standards, including core- and branch-fucosylated N-glycan isomers and sialic acid linked isomers, which were both successfully separated.
35311852	9	102	theme	bovine	1390:1395	arg1	fetuin					1397:1402	bovine fetuin	1390:1402	bovine fetuin	1390:1402	Then, the optimal separation strategy was applied to achieve separations of N- and O-glycan isomers derived from model glycoproteins, including bovine fetuin, ribonuclease B and κ-casein.
35311852	6	103	theme	isomers	833:839	arg1	resolution					812:821	high resolution	807:821	high resolution of glycan isomers	807:839	However, so far, no studies have achieved high resolution of glycan isomers using this technique.
35311852	4	104	theme	glycans	600:606	arg1	separations					585:595	isomeric separations	576:595	isomeric separations of glycans	576:606	Therefore, effective and stable techniques have been investigated over the last few decades to improve isomeric separations of glycans.
35311852	13	105	theme	isomeric	2004:2011	arg1	structures					2013:2022	several isomeric structures	1996:2022	several isomeric structures	1996:2022	Finally, we applied this approach to separate glycan isomers derived from complex biological samples, including blood serum and cell lines, where baseline separations were attained on several isomeric structures.
35311852	2	106	theme	progressions	306:317	arg1	variety					287:293	a variety	285:293	a variety of disease progressions	285:317	Glycan isomers have been shown to be involved in a variety of disease progressions.
35311852	2	106	theme	progressions	306:317	arg1	progressions					306:317	disease progressions	298:317	disease progressions	298:317	Glycan isomers have been shown to be involved in a variety of disease progressions.
35311852	5	107	from	reproducibility	688:702	arg1	time					733:736	retention time	723:736	retention time	723:736	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	5	107	from	reproducibility	688:702	arg1	resolution					753:762	separation resolution	742:762	separation resolution	742:762	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	5	108	used	used	630:633	arg2	RPLC					609:612	RPLC	609:612	RPLC	609:612	RPLC has been widely used in biomolecule analysis because of its extraordinary reproducibility and reliability in retention time and separation resolution.
35311852	10	109	gly	sialylated	1481:1490	arg1	isomers					1500:1506	multiple sialylated linkage isomers	1472:1506	multiple sialylated linkage isomers	1472:1506	Baseline separations were observed on multiple sialylated linkage isomers.
35586945	4	0	from	enzyme	674:679	arg1	biosynthesis					688:699	the biosynthesis	684:699	the biosynthesis of specific N-glycans	684:721	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	7	1	theme	adhesion	1369:1376	arg1	complex					1378:1384	an extracellular adhesion complex	1352:1384	an extracellular adhesion complex	1352:1384	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	4	2	theme	adhesion	762:769	arg1	complex					771:777	the Menorin adhesion complex	750:777	the Menorin adhesion complex	750:777	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	7	3	theme	complex	1378:1384	arg1	activity					1340:1347	the activity	1336:1347	the activity of an extracellular adhesion complex	1336:1384	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	7	4	theme	specific	1262:1269	arg1	structures					1280:1289	specific N-glycan structures	1262:1289	specific N-glycan structures	1262:1289	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	3	5	from	patterning	544:553	arg1	elegans					600:606	Caenorhabditis elegans	585:606	Caenorhabditis elegans	585:606	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
35586945	1	6	theme	proteins	166:173	arg1	%					161:161	over 70%	154:161	over 70% of proteins transiting the secretory pathway	154:206	N-glycans are molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway and have been implicated in protein folding, stability, and localization.
35586945	1	6	theme	proteins	166:173	arg1	proteins					166:173	proteins	166:173	proteins transiting the secretory pathway	166:206	N-glycans are molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway and have been implicated in protein folding, stability, and localization.
35586945	6	7	theme	receptor	1138:1145	arg1	function					1147:1154	DMA-1/LRR-TM receptor function	1125:1154	DMA-1/LRR-TM receptor function	1125:1154	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	2	8	theme	glycosylation	365:377	arg1	disorders					352:360	congenital disorders	341:360	congenital disorders of glycosylation that are often associated with intellectual disability	341:432	Mutations in genes important for N-glycosylation result in congenital disorders of glycosylation that are often associated with intellectual disability.
35586945	2	9	theme	important	301:309	arg1	genes					295:299	genes	295:299	genes important for N-glycosylation	295:329	Mutations in genes important for N-glycosylation result in congenital disorders of glycosylation that are often associated with intellectual disability.
35586945	4	10	theme	conserved	660:668	arg1	enzyme					674:679	a conserved key enzyme	658:679	a conserved key enzyme in the biosynthesis of specific N-glycans	658:721	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	4	10	theme	conserved	660:668	arg1	alpha-mannosidase					636:652	aman-2/Golgi alpha-mannosidase II	623:655	aman-2/Golgi alpha-mannosidase II	623:655	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	7	11	theme	extracellular	1355:1367	arg1	complex					1378:1384	an extracellular adhesion complex	1352:1384	an extracellular adhesion complex	1352:1384	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	6	12	theme	adhesion	1232:1239	arg1	complex					1241:1247	the Menorin adhesion complex	1220:1247	the Menorin adhesion complex	1220:1247	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	4	13	theme	Menorin	754:760	arg1	complex					771:777	the Menorin adhesion complex	750:777	the Menorin adhesion complex	750:777	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	7	14	theme	molecular	1407:1415	arg1	diversity					1417:1425	the molecular diversity	1403:1425	the molecular diversity of N-glycans	1403:1438	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	6	15	theme	other	1184:1188	arg1	proteins					1204:1211	three other extracellular proteins	1178:1211	three other extracellular proteins	1178:1211	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	4	16	theme	components	853:862	arg1	stability					819:827	protein stability	811:827	protein stability	811:827	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	4	16	theme	components	853:862	arg1	localization					833:844	localization	833:844	localization	833:844	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	5	17	theme	receptor	954:961	arg1	DMA-1/LRR-TM					963:974	the neuronal transmembrane receptor DMA-1/LRR-TM	927:974	the neuronal transmembrane receptor DMA-1/LRR-TM	927:974	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	4	18	dep	stability	819:827	arg1	the					807:809	the	807:809	the	807:809	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	5	19	theme	high-mannose/hybrid/paucimannose	1000:1031	arg1	N-glycans					1033:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	6	20	gly	N-glycosylation	1094:1108	arg2	sites					1110:1114	specific N-glycosylation sites	1085:1114	specific N-glycosylation sites	1085:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	3	21	theme	Caenorhabditis	585:598	arg1	elegans					600:606	Caenorhabditis elegans	585:606	Caenorhabditis elegans	585:606	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
35586945	6	22	theme	Menorin	1224:1230	arg1	complex					1241:1247	the Menorin adhesion complex	1220:1247	the Menorin adhesion complex	1220:1247	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	2	23	theme	intellectual	410:421	arg1	disability					423:432	intellectual disability	410:432	intellectual disability	410:432	Mutations in genes important for N-glycosylation result in congenital disorders of glycosylation that are often associated with intellectual disability.
35586945	4	24	theme	protein	811:817	arg1	stability					819:827	protein stability	811:827	protein stability	811:827	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	1	25	theme	secretory	190:198	arg1	pathway					200:206	the secretory pathway	186:206	the secretory pathway	186:206	N-glycans are molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway and have been implicated in protein folding, stability, and localization.
35586945	0	26	theme	Specific	0:7	arg1	N-glycans					9:17	Specific N-glycans	0:17	Specific N-glycans	0:17	Specific N-glycans regulate an extracellular adhesion complex during somatosensory dendrite patterning.
35586945	5	27	theme	DMA-1/LRR-TM	963:974	arg1	decoration					913:922	decoration	913:922	decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans	913:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	7	28	theme	nervous	1491:1497	arg1	system					1499:1504	the nervous system	1487:1504	the nervous system	1487:1504	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	6	29	theme	N-glycosylation	1094:1108	arg1	sites					1110:1114	specific N-glycosylation sites	1085:1114	specific N-glycosylation sites	1085:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	3	30	theme	an extracellular	495:510	arg1	complex					520:526	an extracellular protein complex	495:526	an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans	495:606	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
35586945	5	31	with	decoration	913:922	arg1	set					993:995	the correct set	981:995	the correct set of high-mannose/hybrid/paucimannose N-glycans	981:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	5	31	with	decoration	913:922	arg1	N-glycans					1033:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	6	32	theme	specific	1085:1092	arg1	sites					1110:1114	specific N-glycosylation sites	1085:1114	specific N-glycosylation sites	1085:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	1	33	theme	diverse	130:136	arg1	sugars					138:143	molecularly diverse sugars	118:143	molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway	118:206	N-glycans are molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway and have been implicated in protein folding, stability, and localization.
35586945	1	33	theme	diverse	130:136	arg1	N-glycans					104:112	N-glycans	104:112	N-glycans	104:112	N-glycans are molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway and have been implicated in protein folding, stability, and localization.
35586945	3	34	theme	protein	512:518	arg1	complex					520:526	an extracellular protein complex	495:526	an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans	495:606	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
35586945	0	35	theme	adhesion	45:52	arg1	complex					54:60	an extracellular adhesion complex	28:60	an extracellular adhesion complex	28:60	Specific N-glycans regulate an extracellular adhesion complex during somatosensory dendrite patterning.
35586945	4	36	theme	aman-2/Golgi	623:634	arg1	enzyme					674:679	a conserved key enzyme	658:679	a conserved key enzyme in the biosynthesis of specific N-glycans	658:721	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	4	36	theme	aman-2/Golgi	623:634	arg1	alpha-mannosidase					636:652	aman-2/Golgi alpha-mannosidase II	623:655	aman-2/Golgi alpha-mannosidase II	623:655	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	6	37	from	sites	1110:1114	arg1	types					1063:1067	distinct types	1054:1067	distinct types of N-glycans on specific N-glycosylation sites	1054:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	5	38	theme	neuronal	931:938	arg1	DMA-1/LRR-TM					963:974	the neuronal transmembrane receptor DMA-1/LRR-TM	927:974	the neuronal transmembrane receptor DMA-1/LRR-TM	927:974	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	7	39	theme	developmental	1458:1470	arg1	specificity					1472:1482	developmental specificity	1458:1482	developmental specificity in the nervous system	1458:1504	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	4	40	theme	N-glycans	713:721	arg1	biosynthesis					688:699	the biosynthesis	684:699	the biosynthesis of specific N-glycans	684:721	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	0	41	theme	extracellular	31:43	arg1	complex					54:60	an extracellular adhesion complex	28:60	an extracellular adhesion complex	28:60	Specific N-glycans regulate an extracellular adhesion complex during somatosensory dendrite patterning.
35586945	6	42	theme	N-glycans	1072:1080	arg1	types					1063:1067	distinct types	1054:1067	distinct types of N-glycans on specific N-glycosylation sites	1054:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	7	43	theme	dendrite	1300:1307	arg1	patterning					1309:1318	dendrite patterning	1300:1318	dendrite patterning	1300:1318	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	4	44	theme	specific	704:711	arg1	N-glycans					713:721	specific N-glycans	704:721	specific N-glycans	704:721	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	7	45	theme	N-glycan	1271:1278	arg1	structures					1280:1289	specific N-glycan structures	1262:1289	specific N-glycan structures	1262:1289	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	5	46	theme	correct	985:991	arg1	set					993:995	the correct set	981:995	the correct set of high-mannose/hybrid/paucimannose N-glycans	981:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	5	46	theme	correct	985:991	arg1	N-glycans					1033:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	6	47	from	types	1063:1067	arg1	sites					1110:1114	specific N-glycosylation sites	1085:1114	specific N-glycosylation sites	1085:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	5	48	theme	N-glycans	1033:1041	arg1	set					993:995	the correct set	981:995	the correct set of high-mannose/hybrid/paucimannose N-glycans	981:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	5	48	theme	N-glycans	1033:1041	arg1	N-glycans					1033:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	high-mannose/hybrid/paucimannose N-glycans	1000:1041	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	4	49	theme	key	670:672	arg1	enzyme					674:679	a conserved key enzyme	658:679	a conserved key enzyme in the biosynthesis of specific N-glycans	658:721	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	4	49	theme	key	670:672	arg1	alpha-mannosidase					636:652	aman-2/Golgi alpha-mannosidase II	623:655	aman-2/Golgi alpha-mannosidase II	623:655	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	7	50	from	specificity	1472:1482	arg1	system					1499:1504	the nervous system	1487:1504	the nervous system	1487:1504	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	4	51	theme	complex	771:777	arg1	activity					738:745	the activity	734:745	the activity of the Menorin adhesion complex	734:777	Specifically, aman-2/Golgi alpha-mannosidase II, a conserved key enzyme in the biosynthesis of specific N-glycans, regulates the activity of the Menorin adhesion complex without obviously affecting the protein stability and localization of its components.
35586945	2	52	from	Mutations	282:290	arg1	genes					295:299	genes	295:299	genes important for N-glycosylation	295:329	Mutations in genes important for N-glycosylation result in congenital disorders of glycosylation that are often associated with intellectual disability.
35586945	6	53	theme	distinct	1054:1061	arg1	types					1063:1067	distinct types	1054:1067	distinct types of N-glycans on specific N-glycosylation sites	1054:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	6	54	from	N-glycans	1072:1080	arg1	sites					1110:1114	specific N-glycosylation sites	1085:1114	specific N-glycosylation sites	1085:1114	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	2	55	theme	congenital	341:350	arg1	disorders					352:360	congenital disorders	341:360	congenital disorders of glycosylation that are often associated with intellectual disability	341:432	Mutations in genes important for N-glycosylation result in congenital disorders of glycosylation that are often associated with intellectual disability.
35586945	6	56	theme	DMA-1/LRR-TM	1125:1136	arg1	function					1147:1154	DMA-1/LRR-TM receptor function	1125:1154	DMA-1/LRR-TM receptor function	1125:1154	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	7	57	theme	N-glycans	1430:1438	arg1	diversity					1417:1425	the molecular diversity	1403:1425	the molecular diversity of N-glycans	1403:1438	In summary, specific N-glycan structures regulate dendrite patterning by coordinating the activity of an extracellular adhesion complex, suggesting that the molecular diversity of N-glycans can contribute to developmental specificity in the nervous system.
35586945	1	58	theme	protein	236:242	arg1	folding					244:250	protein folding	236:250	protein folding	236:250	N-glycans are molecularly diverse sugars borne by over 70% of proteins transiting the secretory pathway and have been implicated in protein folding, stability, and localization.
35586945	0	59	theme	dendrite	83:90	arg1	patterning					92:101	somatosensory dendrite patterning	69:101	somatosensory dendrite patterning	69:101	Specific N-glycans regulate an extracellular adhesion complex during somatosensory dendrite patterning.
35586945	5	60	theme	transmembrane	940:952	arg1	DMA-1/LRR-TM					963:974	the neuronal transmembrane receptor DMA-1/LRR-TM	927:974	the neuronal transmembrane receptor DMA-1/LRR-TM	927:974	AMAN-2 functions cell-autonomously to allow for decoration of the neuronal transmembrane receptor DMA-1/LRR-TM with the correct set of high-mannose/hybrid/paucimannose N-glycans.
35586945	6	61	theme	extracellular	1190:1202	arg1	proteins					1204:1211	three other extracellular proteins	1178:1211	three other extracellular proteins	1178:1211	Moreover, distinct types of N-glycans on specific N-glycosylation sites regulate DMA-1/LRR-TM receptor function, which, together with three other extracellular proteins, forms the Menorin adhesion complex.
35586945	3	62	theme	somatosensory	558:570	arg1	dendrites					572:580	somatosensory dendrites	558:580	somatosensory dendrites	558:580	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
35586945	3	63	theme	distinct	467:474	arg1	N-glycans					476:484	structurally distinct N-glycans	454:484	structurally distinct N-glycans	454:484	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
35586945	0	64	theme	somatosensory	69:81	arg1	patterning					92:101	somatosensory dendrite patterning	69:101	somatosensory dendrite patterning	69:101	Specific N-glycans regulate an extracellular adhesion complex during somatosensory dendrite patterning.
35586945	3	65	theme	dendrites	572:580	arg1	patterning					544:553	the patterning	540:553	the patterning of somatosensory dendrites in Caenorhabditis elegans	540:606	Here, we show that structurally distinct N-glycans regulate an extracellular protein complex involved in the patterning of somatosensory dendrites in Caenorhabditis elegans.
34611869	4	0	theme	present	921:927	arg1	residues					912:919	hydrophobic and aromatic residues	887:919	hydrophobic and aromatic residues present in the APRs	887:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	3	1	theme	structural	589:598	arg1	features					600:607	the structural features	585:607	the structural features of the proteins	585:623	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	6	2	theme	5DK3	1122:1125	arg1	structures					1099:1108	the 3D structures	1092:1108	the 3D structures of 1HZH and 5DK3	1092:1125	However, in the 3D structures of 1HZH and 5DK3 the glycans do not appear to influence the likely APRs of the antibodies.
34611869	1	3	theme	unwanted	237:244	arg1	production					275:284	the production	271:284	the production of anti-drug antibodies (ADA)	271:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	3	theme	unwanted	237:244	arg1	responses					253:261	unwanted immune responses	237:261	unwanted immune responses such as the production of anti-drug antibodies (ADA)	237:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	7	4	theme	side	1307:1310	arg1	chains					1312:1317	the glycosylated asparagine side chains	1279:1317	the glycosylated asparagine side chains	1279:1317	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	7	5	theme	glycan	1251:1256	arg1	regions					1258:1264	the Fc glycan regions	1244:1264	the Fc glycan regions	1244:1264	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	10	6	theme	antibody	1707:1714	arg1	glycans					1716:1722	antibody glycans	1707:1722	antibody glycans	1707:1722	This report is based on in silico studies to show how antibody glycans can influence aggregation.
34611869	6	7	theme	1HZH	1113:1116	arg1	structures					1099:1108	the 3D structures	1092:1108	the 3D structures of 1HZH and 5DK3	1092:1125	However, in the 3D structures of 1HZH and 5DK3 the glycans do not appear to influence the likely APRs of the antibodies.
34611869	7	8	theme	glycosylated	1283:1294	arg1	chains					1312:1317	the glycosylated asparagine side chains	1279:1317	the glycosylated asparagine side chains	1279:1317	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	3	9	theme	proteins	616:623	arg1	features					600:607	the structural features	585:607	the structural features of the proteins	585:623	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	9	theme	proteins	616:623	arg1	glycans					653:659	the associated N-linked glycans	629:659	the associated N-linked glycans in the CH2 domains of the Fc region	629:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	10	theme	available	487:495	arg1	antibodies					476:485	four antibodies	471:485	four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3)	471:535	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	9	11	from	structure	1642:1650	arg1	present					1624:1630	present	1624:1630	present	1624:1630	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	10	12	theme	in	1677:1678	arg1	studies					1687:1693	in silico studies	1677:1693	in silico studies	1677:1693	This report is based on in silico studies to show how antibody glycans can influence aggregation.
34611869	3	13	theme	N-linked	644:651	arg1	glycans					653:659	the associated N-linked glycans	629:659	the associated N-linked glycans in the CH2 domains of the Fc region	629:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	14	from	features	600:607	arg1	domains					672:678	the CH2 domains	664:678	the CH2 domains of the Fc region	664:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	14	from	features	600:607	arg1	region					690:695	the Fc region	683:695	the Fc region	683:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	4	15	from	regions	816:822	arg1	antibodies					837:846	the antibodies	833:846	the antibodies	833:846	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	15	from	regions	816:822	arg1	residues					912:919	hydrophobic and aromatic residues	887:919	hydrophobic and aromatic residues present in the APRs	887:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	1	16	theme	quality	206:212	arg1	dosage					225:230	increased dosage	215:230	increased dosage	215:230	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	16	theme	quality	206:212	arg1	production					275:284	the production	271:284	the production of anti-drug antibodies (ADA)	271:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	16	theme	quality	206:212	arg1	loss					193:196	loss	193:196	loss of drug quality	193:212	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	16	theme	quality	206:212	arg1	responses					253:261	unwanted immune responses	237:261	unwanted immune responses such as the production of anti-drug antibodies (ADA)	237:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	3	17	theme	CH2	668:670	arg1	domains					672:678	the CH2 domains	664:678	the CH2 domains of the Fc region	664:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	17	theme	CH2	668:670	arg1	region					690:695	the Fc region	683:695	the Fc region	683:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	1	18	theme	antibodies	122:131	arg1	issue					144:148	a major issue	136:148	a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA)	136:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	18	theme	antibodies	122:131	arg1	aggregation					95:105	The aggregation	91:105	The aggregation of therapeutic antibodies	91:131	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	9	19	theme	glycosylation	1539:1551	arg1	influence					1526:1534	the influence	1522:1534	the influence of glycosylation on the APRs of the antibody	1522:1579	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	3	20	theme	Fc	687:688	arg1	region					690:695	the Fc region	683:695	the Fc region	683:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	5	21	theme	hydrophobic	1059:1069	arg1	regions					1071:1077	these hydrophobic regions	1053:1077	these hydrophobic regions	1053:1077	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	5	22	theme	1IGY	975:978	arg1	structures					952:961	the 3D structures	945:961	the 3D structures of 1IGT and 1IGY	945:978	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	9	23	attach	present	1624:1630	arg1	structure					1642:1650	the 3D structure	1635:1650	the 3D structure	1635:1650	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	9	23	attach	present	1624:1630	arg2	glycans					1616:1622	the glycans	1612:1622	the glycans present in the 3D structure	1612:1650	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	3	24	from	available	487:495	arg1	PDB					504:506	the PDB	500:506	the PDB (1IGT, 1IGY, 1HZH, and 5DK3)	500:535	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	5	25	theme	glycan	984:989	arg1	chains					991:996	the glycan chains	980:996	the glycan chains	980:996	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	4	26	from	present	921:927	arg1	APRs					936:939	the APRs	932:939	the APRs	932:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	9	27	theme	antibody	1572:1579	arg1	APRs					1560:1563	the APRs	1556:1563	the APRs of the antibody	1556:1579	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	7	28	gly	glycosylated	1283:1294	arg1	chains					1312:1317	the glycosylated asparagine side chains	1279:1317	the glycosylated asparagine side chains	1279:1317	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	8	29	from	influence	1470:1478	arg1	aggregation					1483:1493	aggregation	1483:1493	aggregation	1483:1493	We successfully adjusted the glycan chains of 1HZH and 5DK3 and reduced the distance between them and the APRs to show potential influence on aggregation.
34611869	2	30	theme	development	363:373	arg1	stages					353:358	various stages	345:358	various stages of development and storage	345:385	As aggregation can occur at various stages of development and storage, much work has been performed to reduce or eliminate it.
34611869	5	31	theme	1IGT	966:969	arg1	structures					952:961	the 3D structures	945:961	the 3D structures of 1IGT and 1IGY	945:978	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	0	32	theme	In	0:1	arg1	Analysis					10:17	In Silico Analysis	0:17	In Silico Analysis of Therapeutic Antibody Aggregation	0:53	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	2	33	theme	much	388:391	arg1	work					393:396	much work	388:396	much work	388:396	As aggregation can occur at various stages of development and storage, much work has been performed to reduce or eliminate it.
34611869	3	34	dep	PDB	504:506	arg1	1HZH					521:524	1HZH	521:524	1HZH	521:524	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	34	dep	PDB	504:506	arg1	5DK3					531:534	5DK3	531:534	5DK3	531:534	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	34	dep	PDB	504:506	arg1	1IGY					515:518	1IGY	515:518	1IGY	515:518	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	34	dep	PDB	504:506	arg1	1IGT					509:512	1IGT	509:512	1IGT	509:512	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	4	35	theme	Fc	873:874	arg1	glycans					876:882	the Fc glycans	869:882	the Fc glycans	869:882	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	8	36	theme	1HZH	1387:1390	arg1	chains					1377:1382	the glycan chains	1366:1382	the glycan chains of 1HZH and 5DK3	1366:1399	We successfully adjusted the glycan chains of 1HZH and 5DK3 and reduced the distance between them and the APRs to show potential influence on aggregation.
34611869	3	37	theme	UCSF	563:566	arg1	Chimera					568:574	the online software UCSF Chimera	543:574	the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region	543:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	4	38	theme	antibody	707:714	arg1	aggregation					716:726	antibody aggregation	707:726	antibody aggregation in silico	707:736	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	2	39	theme	storage	379:385	arg1	stages					353:358	various stages	345:358	various stages of development and storage	345:385	As aggregation can occur at various stages of development and storage, much work has been performed to reduce or eliminate it.
34611869	0	40	theme	Therapeutic	22:32	arg1	Aggregation					43:53	Therapeutic Antibody Aggregation	22:53	Therapeutic Antibody Aggregation	22:53	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	4	41	used	used	741:744	arg2	we					738:739	we	738:739	we	738:739	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	9	42	theme	present	1624:1630	arg1	glycans					1616:1622	the glycans	1612:1622	the glycans present in the 3D structure	1612:1650	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	8	43	theme	5DK3	1396:1399	arg1	chains					1377:1382	the glycan chains	1366:1382	the glycan chains of 1HZH and 5DK3	1366:1399	We successfully adjusted the glycan chains of 1HZH and 5DK3 and reduced the distance between them and the APRs to show potential influence on aggregation.
34611869	3	44	theme	online	547:552	arg1	Chimera					568:574	the online software UCSF Chimera	543:574	the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region	543:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	0	45	theme	Aggregation	43:53	arg1	Analysis					10:17	In Silico Analysis	0:17	In Silico Analysis of Therapeutic Antibody Aggregation	0:53	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	0	45	theme	Aggregation	43:53	arg1	Influence					63:71	the Influence	59:71	the Influence of Glycosylation	59:88	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	5	46	theme	close	1005:1009	arg1	proximity					1018:1026	close enough proximity	1005:1026	close enough proximity	1005:1026	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	6	47	theme	3D	1096:1097	arg1	structures					1099:1108	the 3D structures	1092:1108	the 3D structures of 1HZH and 5DK3	1092:1125	However, in the 3D structures of 1HZH and 5DK3 the glycans do not appear to influence the likely APRs of the antibodies.
34611869	8	48	theme	potential	1460:1468	arg1	influence					1470:1478	potential influence	1460:1478	potential influence on aggregation	1460:1493	We successfully adjusted the glycan chains of 1HZH and 5DK3 and reduced the distance between them and the APRs to show potential influence on aggregation.
34611869	7	49	theme	glycosidic	1323:1332	arg1	bonds					1334:1338	glycosidic bonds	1323:1338	glycosidic bonds	1323:1338	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	9	50	from	present	1624:1630	arg1	structure					1642:1650	the 3D structure	1635:1650	the 3D structure	1635:1650	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	0	51	dep	In	0:1	arg1	Silico					3:8	Silico	3:8	Silico	3:8	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	7	52	theme	asparagine	1296:1305	arg1	chains					1312:1317	the glycosylated asparagine side chains	1279:1317	the glycosylated asparagine side chains	1279:1317	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	4	53	theme	online	750:755	arg1	software					757:764	the online software	746:764	the online software TANGO and AGGRESCAN	746:784	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	1	54	theme	immune	246:251	arg1	production					275:284	the production	271:284	the production of anti-drug antibodies (ADA)	271:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	54	theme	immune	246:251	arg1	responses					253:261	unwanted immune responses	237:261	unwanted immune responses such as the production of anti-drug antibodies (ADA)	237:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	4	55	theme	TANGO	766:770	arg1	software					757:764	the online software	746:764	the online software TANGO and AGGRESCAN	746:784	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	3	56	theme	associated	633:642	arg1	glycans					653:659	the associated N-linked glycans	629:659	the associated N-linked glycans in the CH2 domains of the Fc region	629:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	1	57	theme	pharmaceutical	158:171	arg1	industry					173:180	the pharmaceutical industry	154:180	the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA)	154:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	7	58	theme	Fc	1248:1249	arg1	regions					1258:1264	the Fc glycan regions	1244:1264	the Fc glycan regions	1244:1264	Therefore, in these structures we modified the Fc glycan regions by adjusting the glycosylated asparagine side chains and glycosidic bonds.
34611869	1	59	theme	antibodies	299:308	arg1	production					275:284	the production	271:284	the production of anti-drug antibodies (ADA)	271:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	5	60	from	proximity	1018:1026	arg1	structures					952:961	the 3D structures	945:961	the 3D structures of 1IGT and 1IGY	945:978	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	6	61	theme	likely	1170:1175	arg1	APRs					1177:1180	the likely APRs	1166:1180	the likely APRs of the antibodies	1166:1198	However, in the 3D structures of 1HZH and 5DK3 the glycans do not appear to influence the likely APRs of the antibodies.
34611869	4	62	theme	prone	810:814	arg1	regions					816:822	aggregation prone regions	798:822	aggregation prone regions (APR) in the antibodies	798:846	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	62	theme	prone	810:814	arg1	APR					825:827	APR	825:827	APR	825:827	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	1	63	theme	major	138:142	arg1	issue					144:148	a major issue	136:148	a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA)	136:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	63	theme	major	138:142	arg1	aggregation					95:105	The aggregation	91:105	The aggregation of therapeutic antibodies	91:131	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	9	64	gly	glycosylation	1539:1551	arg1	antibody					1572:1579	the antibody	1568:1579	the antibody	1568:1579	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	1	65	theme	drug	201:204	arg1	quality					206:212	drug quality	201:212	drug quality	201:212	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	5	66	theme	3D	949:950	arg1	structures					952:961	the 3D structures	945:961	the 3D structures of 1IGT and 1IGY	945:978	In the 3D structures of 1IGT and 1IGY the glycan chains are in close enough proximity to influence and protect these hydrophobic regions.
34611869	4	67	from	aggregation	716:726	arg1	silico					731:736	silico	731:736	silico	731:736	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	1	68	theme	therapeutic	110:120	arg1	antibodies					122:131	therapeutic antibodies	110:131	therapeutic antibodies	110:131	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	4	69	theme	AGGRESCAN	776:784	arg1	software					757:764	the online software	746:764	the online software TANGO and AGGRESCAN	746:784	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	3	70	from	PDB	504:506	arg1	available					487:495	available	487:495	available	487:495	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	71	link	N-linked	644:651	arg1	glycans					653:659	the associated N-linked glycans	629:659	the associated N-linked glycans in the CH2 domains of the Fc region	629:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	4	72	from	APRs	936:939	arg1	present					921:927	present	921:927	present	921:927	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	9	73	from	influence	1526:1534	arg1	APRs					1560:1563	the APRs	1556:1563	the APRs of the antibody	1556:1579	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	3	74	theme	region	690:695	arg1	domains					672:678	the CH2 domains	664:678	the CH2 domains of the Fc region	664:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	74	theme	region	690:695	arg1	region					690:695	the Fc region	683:695	the Fc region	683:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	0	75	theme	Glycosylation	76:88	arg1	Analysis					10:17	In Silico Analysis	0:17	In Silico Analysis of Therapeutic Antibody Aggregation	0:53	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	0	75	theme	Glycosylation	76:88	arg1	Influence					63:71	the Influence	59:71	the Influence of Glycosylation	59:88	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	6	76	theme	antibodies	1189:1198	arg1	APRs					1177:1180	the likely APRs	1166:1180	the likely APRs of the antibodies	1166:1198	However, in the 3D structures of 1HZH and 5DK3 the glycans do not appear to influence the likely APRs of the antibodies.
34611869	4	77	attach	present	921:927	arg2	residues					912:919	hydrophobic and aromatic residues	887:919	hydrophobic and aromatic residues present in the APRs	887:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	77	attach	present	921:927	arg1	APRs					936:939	the APRs	932:939	the APRs	932:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	8	78	theme	glycan	1370:1375	arg1	chains					1377:1382	the glycan chains	1366:1382	the glycan chains of 1HZH and 5DK3	1366:1399	We successfully adjusted the glycan chains of 1HZH and 5DK3 and reduced the distance between them and the APRs to show potential influence on aggregation.
34611869	3	79	from	glycans	653:659	arg1	domains					672:678	the CH2 domains	664:678	the CH2 domains of the Fc region	664:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	3	79	from	glycans	653:659	arg1	region					690:695	the Fc region	683:695	the Fc region	683:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	1	80	theme	increased	215:223	arg1	dosage					225:230	increased dosage	215:230	increased dosage	215:230	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	4	81	theme	hydrophobic	887:897	arg1	residues					912:919	hydrophobic and aromatic residues	887:919	hydrophobic and aromatic residues present in the APRs	887:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	2	82	theme	various	345:351	arg1	stages					353:358	various stages	345:358	various stages of development and storage	345:385	As aggregation can occur at various stages of development and storage, much work has been performed to reduce or eliminate it.
34611869	4	83	theme	aromatic	903:910	arg1	residues					912:919	hydrophobic and aromatic residues	887:919	hydrophobic and aromatic residues present in the APRs	887:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	3	84	theme	software	554:561	arg1	Chimera					568:574	the online software UCSF Chimera	543:574	the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region	543:695	In this report we analyzed four antibodies available in the PDB (1IGT, 1IGY, 1HZH, and 5DK3) using the online software UCSF Chimera to study the structural features of the proteins and the associated N-linked glycans in the CH2 domains of the Fc region.
34611869	0	85	theme	Antibody	34:41	arg1	Aggregation					43:53	Therapeutic Antibody Aggregation	22:53	Therapeutic Antibody Aggregation	22:53	In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.
34611869	9	86	theme	glycans	1616:1622	arg1	size					1604:1607	the size	1600:1607	the size of the glycans present in the 3D structure	1600:1650	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	10	87	dep	in	1677:1678	arg1	silico					1680:1685	silico	1680:1685	silico	1680:1685	This report is based on in silico studies to show how antibody glycans can influence aggregation.
34611869	1	88	theme	anti-drug	289:297	arg1	ADA					311:313	ADA	311:313	ADA	311:313	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	1	88	theme	anti-drug	289:297	arg1	antibodies					299:308	anti-drug antibodies	289:308	anti-drug antibodies (ADA)	289:314	The aggregation of therapeutic antibodies is a major issue for the pharmaceutical industry leading to loss of drug quality, increased dosage, and unwanted immune responses such as the production of anti-drug antibodies (ADA).
34611869	4	89	theme	glycans	876:882	arg1	regions					816:822	aggregation prone regions	798:822	aggregation prone regions (APR) in the antibodies	798:846	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	89	theme	glycans	876:882	arg1	influence					856:864	the influence	852:864	the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs	852:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	89	theme	glycans	876:882	arg1	APR					825:827	APR	825:827	APR	825:827	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	9	90	theme	3D	1639:1640	arg1	structure					1642:1650	the 3D structure	1635:1650	the 3D structure	1635:1650	However, similar to 5DK3, the influence of glycosylation on the APRs of the antibody was limited due to the size of the glycans present in the 3D structure.
34611869	4	91	from	influence	856:864	arg1	antibodies					837:846	the antibodies	833:846	the antibodies	833:846	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	91	from	influence	856:864	arg1	residues					912:919	hydrophobic and aromatic residues	887:919	hydrophobic and aromatic residues present in the APRs	887:939	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
34611869	4	92	dep	used	741:744	arg1	study					701:705	study	701:705	To study antibody aggregation in silico	698:736	To study antibody aggregation in silico we used the online software TANGO and AGGRESCAN to identify aggregation prone regions (APR) in the antibodies and the influence of the Fc glycans on hydrophobic and aromatic residues present in the APRs.
35077869	6	0	dep	basal	1044:1048	arg1	apical					1053:1058	apical	1053:1058	apical	1053:1058	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	6	0	dep	basal	1044:1048	arg1	to					1050:1051	to	1050:1051	to	1050:1051	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	2	1	theme	mucin	346:350	arg1	production					352:361	mucin production	346:361	mucin production	346:361	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	6	2	theme	transport	1060:1068	arg1	rate					1015:1018	the rate	1011:1018	the rate of mucin production and basal to apical transport in both stomach and intestine	1011:1098	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	5	3	theme	intestinal	806:815	arg1	mucus					817:821	intestinal mucus	806:821	intestinal mucus	806:821	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	6	4	theme	metabolic	857:865	arg1	labelling					873:881	In vivo metabolic mucin labelling	849:881	In vivo metabolic mucin labelling	849:881	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	8	5	theme	size	1382:1385	arg1	distribution					1387:1398	size distribution	1382:1398	size distribution	1382:1398	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	9	6	theme	epithelial	1479:1488	arg1	sites					1490:1494	epithelial sites	1479:1494	epithelial sites	1479:1494	Thus, the mucus production and organization differ between epithelial sites but provide a barrier to bacteria in both stomach and intestine.
35077869	7	7	theme	mass	1107:1110	arg1	spectrometry					1112:1123	mass spectrometry	1107:1123	mass spectrometry	1107:1123	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	4	8	theme	secreted	512:519	arg1	mucus					521:525	The secreted mucus	508:525	The secreted mucus covering the gastric epithelium	508:557	The secreted mucus covering the gastric epithelium predominantly contained sialylated mucins.
35077869	6	9	theme	In	849:850	arg1	labelling					873:881	In vivo metabolic mucin labelling	849:881	In vivo metabolic mucin labelling	849:881	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	2	10	theme	trout	277:281	arg1	function					336:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	10	11	dep	basal	1595:1599	arg1	apical					1604:1609	apical	1604:1609	apical	1604:1609	Furthermore, mucin production and basal to apical transport was stimulated by lipopolysaccharide in all regions, suggesting a mechanism to combat infections.
35077869	10	11	dep	basal	1595:1599	arg1	to					1601:1602	to	1601:1602	to	1601:1602	Furthermore, mucin production and basal to apical transport was stimulated by lipopolysaccharide in all regions, suggesting a mechanism to combat infections.
35077869	5	12	theme	gastric	642:648	arg1	pits					650:653	the gastric pits	638:653	the gastric pits	638:653	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	2	13	theme	rainbow	269:275	arg1	trout					277:281	rainbow trout	269:281	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	2	13	theme	rainbow	269:275	arg1	mykiss					297:302	Oncorhynchus mykiss	284:302	Oncorhynchus mykiss	284:302	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	6	14	theme	basal	1044:1048	arg1	transport					1060:1068	basal to apical transport	1044:1068	basal to apical transport	1044:1068	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	5	15	theme	gland	775:779	arg1	cells					791:795	gland secretory cells	775:795	gland secretory cells	775:795	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	8	16	theme	relative	1348:1355	arg1	abundance					1357:1365	relative abundance	1348:1365	relative abundance of components	1348:1379	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	10	17	theme	combat	1700:1705	arg1	infections					1707:1716	combat infections	1700:1716	combat infections	1700:1716	Furthermore, mucin production and basal to apical transport was stimulated by lipopolysaccharide in all regions, suggesting a mechanism to combat infections.
35077869	1	18	theme	major	164:168	arg1	mucins					151:156	the highly glycosylated mucins	127:156	the highly glycosylated mucins	127:156	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	1	18	theme	major	164:168	arg1	component					170:178	a major component	162:178	a major component	162:178	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	5	19	theme	secretory	781:789	arg1	cells					791:795	gland secretory cells	775:795	gland secretory cells	775:795	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	4	20	dep	contained	573:581	arg1	sialylated					583:592	sialylated	583:592	contained sialylated mucins	573:599	The secreted mucus covering the gastric epithelium predominantly contained sialylated mucins.
35077869	5	21	dep	sialylated	665:674	arg1	whereas					798:804	whereas	798:804	whereas	798:804	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	6	22	from	differences	901:911	arg1	transport					953:961	basal to apical transport	937:961	basal to apical transport	937:961	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	6	22	from	differences	901:911	arg1	production					922:931	mucin production	916:931	mucin production	916:931	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	8	23	theme	O-glycan	1326:1333	arg1	components					1370:1379	components	1370:1379	components	1370:1379	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	8	23	theme	O-glycan	1326:1333	arg1	repertoires					1335:1345	O-glycan repertoires	1326:1345	O-glycan repertoires	1326:1345	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	10	24	theme	basal	1595:1599	arg1	transport					1611:1619	basal to apical transport	1595:1619	basal to apical transport	1595:1619	Furthermore, mucin production and basal to apical transport was stimulated by lipopolysaccharide in all regions, suggesting a mechanism to combat infections.
35077869	5	25	theme	Plume-like	602:611	arg1	structures					613:622	Plume-like structures	602:622	Plume-like structures emerging from the gastric pits	602:653	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	5	26	theme	gastric	721:727	arg1	mucus					729:733	gastric mucus	721:733	gastric mucus secreted by the surface mucus cells and gland secretory cells	721:795	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	0	27	theme	Rainbow	0:6	arg1	trout					8:12	Rainbow trout	0:12	Rainbow trout	0:12	Rainbow trout gastrointestinal mucus, mucin production, mucin glycosylation and response to lipopolysaccharide.
35077869	7	28	theme	abundance	1188:1196	arg1	abundance					1188:1196	the relative abundance	1175:1196	the relative abundance	1175:1196	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	7	28	theme	abundance	1188:1196	arg1	%					1170:1170	∼70%	1167:1170	∼70% of the relative abundance	1167:1196	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	6	29	dep	In	849:850	arg1	vivo					852:855	vivo	852:855	vivo	852:855	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	3	30	theme	intestinal	431:440	arg1	mucus					442:446	Both gastric and intestinal mucus	414:446	Both gastric and intestinal mucus	414:446	Both gastric and intestinal mucus was thick and impenetrable to bacteria-sized beads ex vivo.
35077869	6	31	theme	production	1029:1038	arg1	rate					1015:1018	the rate	1011:1018	the rate of mucin production and basal to apical transport in both stomach and intestine	1011:1098	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	7	32	theme	34	1126:1127	arg1	O-glycans					1135:1143	34 mucin O-glycans	1126:1143	34 mucin O-glycans	1126:1143	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	2	33	theme	Oncorhynchus	284:295	arg1	trout					277:281	rainbow trout	269:281	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	2	33	theme	Oncorhynchus	284:295	arg1	mykiss					297:302	Oncorhynchus mykiss	284:302	Oncorhynchus mykiss	284:302	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	9	34	theme	mucus	1430:1434	arg1	production					1436:1445	the mucus production	1426:1445	the mucus production	1426:1445	Thus, the mucus production and organization differ between epithelial sites but provide a barrier to bacteria in both stomach and intestine.
35077869	6	35	theme	mucin	1023:1027	arg1	production					1029:1038	mucin production	1023:1038	mucin production	1023:1038	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	7	36	theme	mucin	1129:1133	arg1	O-glycans					1135:1143	34 mucin O-glycans	1126:1143	34 mucin O-glycans	1126:1143	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	1	37	theme	epithelial	194:203	arg1	surfaces					213:220	the epithelial mucosal surfaces	190:220	the epithelial mucosal surfaces	190:220	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	0	38	theme	mucin	38:42	arg1	production					44:53	mucin production	38:53	mucin production	38:53	Rainbow trout gastrointestinal mucus, mucin production, mucin glycosylation and response to lipopolysaccharide.
35077869	5	39	theme	surface	751:757	arg1	cells					765:769	the surface mucus cells	747:769	the surface mucus cells	747:769	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	6	40	theme	mucin	916:920	arg1	production					922:931	mucin production	916:931	mucin production	916:931	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	8	41	theme	treatment	1292:1300	arg1	effects					1262:1268	No effects	1259:1268	No effects of lipopolysaccharide treatment	1259:1300	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	1	42	theme	mucosal	205:211	arg1	surfaces					213:220	the epithelial mucosal surfaces	190:220	the epithelial mucosal surfaces	190:220	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	3	43	theme	gastric	419:425	arg1	mucus					442:446	Both gastric and intestinal mucus	414:446	Both gastric and intestinal mucus	414:446	Both gastric and intestinal mucus was thick and impenetrable to bacteria-sized beads ex vivo.
35077869	5	44	theme	mucus	759:763	arg1	cells					765:769	the surface mucus cells	747:769	the surface mucus cells	747:769	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	5	45	gly	sialylated	665:674	arg1	structures					613:622	Plume-like structures	602:622	Plume-like structures emerging from the gastric pits	602:653	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	5	46	from	heterogeneity	704:716	arg1	mucus					729:733	gastric mucus	721:733	gastric mucus secreted by the surface mucus cells and gland secretory cells	721:795	Plume-like structures emerging from the gastric pits were both sialylated and fucosylated, indicating heterogeneity in gastric mucus secreted by the surface mucus cells and gland secretory cells, whereas intestinal mucus appeared more homogenous.
35077869	6	47	theme	basal	937:941	arg1	transport					953:961	basal to apical transport	937:961	basal to apical transport	937:961	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	8	48	theme	components	1370:1379	arg1	abundance					1357:1365	relative abundance	1348:1365	relative abundance of components	1348:1379	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	8	48	theme	components	1370:1379	arg1	structures					1408:1417	core structures	1403:1417	core structures	1403:1417	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	8	48	theme	components	1370:1379	arg1	distribution					1387:1398	size distribution	1382:1398	size distribution	1382:1398	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	8	48	theme	components	1370:1379	arg1	components					1370:1379	components	1370:1379	components	1370:1379	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	8	48	theme	components	1370:1379	arg1	repertoires					1335:1345	O-glycan repertoires	1326:1345	O-glycan repertoires	1326:1345	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	7	49	theme	relative	1179:1186	arg1	abundance					1188:1196	the relative abundance	1175:1196	the relative abundance	1175:1196	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	1	50	gly	glycosylated	138:149	arg1	mucins					151:156	the highly glycosylated mucins	127:156	the highly glycosylated mucins	127:156	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	1	50	gly	glycosylated	138:149	arg1	component					170:178	a major component	162:178	a major component	162:178	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	6	51	theme	regional	892:899	arg1	differences					901:911	regional differences	892:911	regional differences in mucin production and basal to apical transport	892:961	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	2	52	theme	barrier	328:334	arg1	function					336:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	4	53	theme	gastric	540:546	arg1	epithelium					548:557	the gastric epithelium	536:557	the gastric epithelium	536:557	The secreted mucus covering the gastric epithelium predominantly contained sialylated mucins.
35077869	6	54	from	rate	1015:1018	arg1	intestine					1090:1098	intestine	1090:1098	intestine	1090:1098	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	6	54	from	rate	1015:1018	arg1	stomach					1078:1084	stomach	1078:1084	stomach	1078:1084	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	2	55	theme	mucus	322:326	arg1	function					336:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	6	56	dep	basal	937:941	arg1	to					943:944	to	943:944	to	943:944	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	6	56	dep	basal	937:941	arg1	apical					946:951	apical	946:951	apical	946:951	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	8	57	theme	core	1403:1406	arg1	structures					1408:1417	core structures	1403:1417	core structures	1403:1417	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35077869	9	58	from	barrier	1510:1516	arg1	intestine					1550:1558	intestine	1550:1558	intestine	1550:1558	Thus, the mucus production and organization differ between epithelial sites but provide a barrier to bacteria in both stomach and intestine.
35077869	9	58	from	barrier	1510:1516	arg1	stomach					1538:1544	stomach	1538:1544	stomach	1538:1544	Thus, the mucus production and organization differ between epithelial sites but provide a barrier to bacteria in both stomach and intestine.
35077869	2	59	theme	gastrointestinal	305:320	arg1	function					336:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function	265:343	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	3	60	theme	bacteria-sized	478:491	arg1	beads					493:497	bacteria-sized beads	478:497	bacteria-sized beads	478:497	Both gastric and intestinal mucus was thick and impenetrable to bacteria-sized beads ex vivo.
35077869	6	61	theme	mucin	867:871	arg1	labelling					873:881	In vivo metabolic mucin labelling	849:881	In vivo metabolic mucin labelling	849:881	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	2	62	theme	study	239:243	arg1	aim					227:229	The aim	223:229	The aim of this study	223:243	The aim of this study was to characterize the rainbow trout (Oncorhynchus mykiss) gastrointestinal mucus barrier function, mucin production, glycosylation and response to lipopolysaccharide.
35077869	10	63	theme	mucin	1574:1578	arg1	production					1580:1589	mucin production	1574:1589	mucin production	1574:1589	Furthermore, mucin production and basal to apical transport was stimulated by lipopolysaccharide in all regions, suggesting a mechanism to combat infections.
35077869	1	64	theme	glycosylated	138:149	arg1	mucins					151:156	the highly glycosylated mucins	127:156	the highly glycosylated mucins	127:156	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	1	64	theme	glycosylated	138:149	arg1	component					170:178	a major component	162:178	a major component	162:178	Mucus, whereof the highly glycosylated mucins are a major component, protects the epithelial mucosal surfaces.
35077869	0	65	theme	mucin	56:60	arg1	glycosylation					62:74	mucin glycosylation	56:74	mucin glycosylation	56:74	Rainbow trout gastrointestinal mucus, mucin production, mucin glycosylation and response to lipopolysaccharide.
35077869	6	66	theme	lipopolysaccharide	970:987	arg1	stimulation					989:999	lipopolysaccharide stimulation	970:999	lipopolysaccharide stimulation	970:999	In vivo metabolic mucin labelling revealed regional differences in mucin production and basal to apical transport, while lipopolysaccharide stimulation increased the rate of mucin production and basal to apical transport in both stomach and intestine.
35077869	7	67	gly	sialylated	1204:1213	arg1	abundance					1188:1196	the relative abundance	1175:1196	the relative abundance	1175:1196	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	7	67	gly	sialylated	1204:1213	arg1	%					1170:1170	∼70%	1167:1170	∼70% of the relative abundance	1167:1196	Using mass spectrometry, 34 mucin O-glycans were identified, with ∼70% of the relative abundance being sialylated, ∼40% di-sialylated and 20-25% fucosylated.
35077869	8	68	theme	lipopolysaccharide	1273:1290	arg1	treatment					1292:1300	lipopolysaccharide treatment	1273:1300	lipopolysaccharide treatment	1273:1300	No effects of lipopolysaccharide treatment were apparent regarding O-glycan repertoires, relative abundance of components, size distribution or core structures.
35366731	3	0	theme	R.	353:354	arg1	homothallicus					356:368	R. homothallicus	353:368	R. homothallicus	353:368	A new gene encoding glucanase RhGlu16B was identified in R. homothallicus.
35366731	9	1	theme	square	1145:1150	arg1	deviation					1152:1160	the overall root mean square deviation	1123:1160	the overall root mean square deviation of the enzyme structure	1123:1184	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	6	2	theme	catalytic	644:652	arg1	efficiency					654:663	catalytic efficiency	644:663	catalytic efficiency	644:663	It was found that N-glycosylation increased its Tm value and catalytic efficiency by 5.1 °C and 59%, respectively.
35366731	0	3	theme	Rhizopus	92:99	arg1	homothallicus					101:113	Rhizopus homothallicus	92:113	Rhizopus homothallicus	92:113	Asn57 N-glycosylation promotes the degradation of hemicellulose by β-1,3-1,4-glucanase from Rhizopus homothallicus.
35366731	7	4	from	Talaromyces	781:791	arg1	TlGlu16A					766:773	TlGlu16A	766:773	GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	743:804	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	1	5	from	ways	188:191	arg1	properties					143:152	the properties	139:152	the properties of different enzymes in different ways	139:191	N-glycosylation alters the properties of different enzymes in different ways.
35366731	10	6	theme	GH16	1311:1314	arg1	glucanases					1323:1332	GH16 family glucanases	1311:1332	GH16 family glucanases	1311:1332	This study provided a reference for the molecular modification of GH16 family glucanases and guided the utilization of β-glucan in hemicellulose.
35366731	7	7	theme	GH16	743:746	arg1	glucanases					755:764	GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	743:804	GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	743:804	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	7	8	theme	same	728:731	arg1	region					733:738	the same region	724:738	the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	724:804	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	8	9	theme	family	934:939	arg1	BisGlu16B					952:960	BisGlu16B	952:960	BisGlu16B	952:960	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	8	9	theme	family	934:939	arg1	glucanases					941:950	GH16 family glucanases	929:950	GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed	929:1013	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	5	10	contain	has	524:526	arg1	RhGlu16B					515:522	RhGlu16B	515:522	RhGlu16B	515:522	RhGlu16B has only one N-glycosylation site in its Ala55-Gly64 loop.
35366731	5	10	contain	has	524:526	arg2	site					553:556	only one N-glycosylation site	528:556	only one N-glycosylation site	528:556	RhGlu16B has only one N-glycosylation site in its Ala55-Gly64 loop.
35366731	4	11	used	used	436:439	arg2	glucan					425:430	barley glucan	418:430	barley glucan	418:430	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	4	11	used	used	436:439	arg2	a substrate					444:454	a substrate	444:454	a substrate	444:454	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	7	12	dep	Talaromyces	781:791	arg1	leycettanus					793:803	Talaromyces leycettanus	781:803	Talaromyces leycettanus	781:803	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	10	13	theme	family	1316:1321	arg1	glucanases					1323:1332	GH16 family glucanases	1311:1332	GH16 family glucanases	1311:1332	This study provided a reference for the molecular modification of GH16 family glucanases and guided the utilization of β-glucan in hemicellulose.
35366731	9	14	theme	overall	1220:1226	arg1	thermostability					1228:1242	overall thermostability	1220:1242	overall thermostability	1220:1242	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	8	15	theme	catalytic	1077:1085	arg1	efficiency					1087:1096	catalytic efficiency	1077:1096	catalytic efficiency	1077:1096	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	8	16	gly	N-glycosylation	987:1001	arg1	BisGlu16B					952:960	BisGlu16B	952:960	BisGlu16B	952:960	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	8	16	gly	N-glycosylation	987:1001	arg1	glucanases					941:950	GH16 family glucanases	929:950	GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed	929:1013	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	2	17	from	soil	277:280	arg1	Guatemala					285:293	Guatemala	285:293	Guatemala	285:293	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	2	17	from	soil	277:280	arg1	isolate					257:263	an environmental isolate	240:263	an environmental isolate from desert soil in Guatemala	240:293	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	2	17	from	soil	277:280	arg1	homothallicus					203:215	Rhizopus homothallicus	194:215	Rhizopus homothallicus	194:215	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	4	18	contain	had	374:376	arg2	activity					392:399	high specific activity	378:399	high specific activity (9673 U/mg)	378:411	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	4	18	contain	had	374:376	arg1	It					371:372	It	371:372	It	371:372	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	4	18	contain	had	374:376	arg2	U/mg					407:410	9673 U/mg	402:410	9673 U/mg	402:410	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	6	19	theme	Tm	631:632	arg1	value					634:638	its Tm value	627:638	its Tm value	627:638	It was found that N-glycosylation increased its Tm value and catalytic efficiency by 5.1 °C and 59%, respectively.
35366731	1	20	from	enzymes	167:173	arg1	ways					188:191	different ways	178:191	different ways	178:191	N-glycosylation alters the properties of different enzymes in different ways.
35366731	9	21	theme	root	1135:1138	arg1	deviation					1152:1160	the overall root mean square deviation	1123:1160	the overall root mean square deviation of the enzyme structure	1123:1184	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	0	22	theme	Asn57	0:4	arg1	N-glycosylation					6:20	Asn57 N-glycosylation	0:20	Asn57 N-glycosylation	0:20	Asn57 N-glycosylation promotes the degradation of hemicellulose by β-1,3-1,4-glucanase from Rhizopus homothallicus.
35366731	1	23	from	properties	143:152	arg1	ways					188:191	different ways	178:191	different ways	178:191	N-glycosylation alters the properties of different enzymes in different ways.
35366731	9	24	theme	mean	1140:1143	arg1	deviation					1152:1160	the overall root mean square deviation	1123:1160	the overall root mean square deviation of the enzyme structure	1123:1184	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	10	25	theme	β-glucan	1364:1371	arg1	utilization					1349:1359	the utilization	1345:1359	the utilization of β-glucan in hemicellulose	1345:1388	This study provided a reference for the molecular modification of GH16 family glucanases and guided the utilization of β-glucan in hemicellulose.
35366731	4	26	theme	barley	418:423	arg1	a substrate					444:454	a substrate	444:454	a substrate	444:454	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	4	26	theme	barley	418:423	arg1	glucan					425:430	barley glucan	418:430	barley glucan	418:430	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	3	27	theme	glucanase	316:324	arg1	RhGlu16B					326:333	glucanase RhGlu16B	316:333	glucanase RhGlu16B	316:333	A new gene encoding glucanase RhGlu16B was identified in R. homothallicus.
35366731	0	28	from	homothallicus	101:113	arg1	β-1,3-1,4-glucanase					67:85	β-1,3-1,4-glucanase	67:85	β-1,3-1,4-glucanase from Rhizopus homothallicus	67:113	Asn57 N-glycosylation promotes the degradation of hemicellulose by β-1,3-1,4-glucanase from Rhizopus homothallicus.
35366731	7	29	theme	catalytic	840:848	arg1	efficiency					850:859	catalytic efficiency	840:859	catalytic efficiency	840:859	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	3	30	theme	new	298:300	arg1	gene					302:305	A new gene	296:305	A new gene encoding glucanase RhGlu16B	296:333	A new gene encoding glucanase RhGlu16B was identified in R. homothallicus.
35366731	7	31	dep	glucanases	755:764	arg1	TlGlu16A					766:773	TlGlu16A	766:773	GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	743:804	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	8	32	from	Bisporus	968:975	arg1	BisGlu16B					952:960	BisGlu16B	952:960	BisGlu16B	952:960	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	8	32	from	Bisporus	968:975	arg1	glucanases					941:950	GH16 family glucanases	929:950	GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed	929:1013	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	5	33	gly	N-glycosylation	537:551	arg2	one					533:535	one	533:535	one	533:535	RhGlu16B has only one N-glycosylation site in its Ala55-Gly64 loop.
35366731	5	33	gly	N-glycosylation	537:551	arg2	site					553:556	only one N-glycosylation site	528:556	only one N-glycosylation site	528:556	RhGlu16B has only one N-glycosylation site in its Ala55-Gly64 loop.
35366731	2	34	theme	desert	270:275	arg1	soil					277:280	desert soil	270:280	desert soil in Guatemala	270:293	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	4	35	theme	high	378:381	arg1	U/mg					407:410	9673 U/mg	402:410	9673 U/mg	402:410	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	4	35	theme	high	378:381	arg1	activity					392:399	high specific activity	378:399	high specific activity (9673 U/mg)	378:411	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	2	36	theme	Rhizopus	194:201	arg1	isolate					257:263	an environmental isolate	240:263	an environmental isolate from desert soil in Guatemala	240:293	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	2	36	theme	Rhizopus	194:201	arg1	homothallicus					203:215	Rhizopus homothallicus	194:215	Rhizopus homothallicus	194:215	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	10	37	from	utilization	1349:1359	arg1	hemicellulose					1376:1388	hemicellulose	1376:1388	hemicellulose	1376:1388	This study provided a reference for the molecular modification of GH16 family glucanases and guided the utilization of β-glucan in hemicellulose.
35366731	5	38	theme	Ala55-Gly64	565:575	arg1	loop					577:580	its Ala55-Gly64 loop	561:580	its Ala55-Gly64 loop	561:580	RhGlu16B has only one N-glycosylation site in its Ala55-Gly64 loop.
35366731	0	39	theme	hemicellulose	50:62	arg1	degradation					35:45	the degradation	31:45	the degradation of hemicellulose	31:62	Asn57 N-glycosylation promotes the degradation of hemicellulose by β-1,3-1,4-glucanase from Rhizopus homothallicus.
35366731	2	40	theme	environmental	243:255	arg1	isolate					257:263	an environmental isolate	240:263	an environmental isolate from desert soil in Guatemala	240:293	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	2	40	theme	environmental	243:255	arg1	homothallicus					203:215	Rhizopus homothallicus	194:215	Rhizopus homothallicus	194:215	Rhizopus homothallicus was first described as an environmental isolate from desert soil in Guatemala.
35366731	9	41	theme	structure	1176:1184	arg1	deviation					1152:1160	the overall root mean square deviation	1123:1160	the overall root mean square deviation of the enzyme structure	1123:1184	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	4	42	theme	specific	383:390	arg1	U/mg					407:410	9673 U/mg	402:410	9673 U/mg	402:410	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	4	42	theme	specific	383:390	arg1	activity					392:399	high specific activity	378:399	high specific activity (9673 U/mg)	378:411	It had high specific activity (9673 U/mg) when barley glucan was used as a substrate, and β-glucan is hemicellulose that is abundant in nature.
35366731	1	43	theme	different	157:165	arg1	enzymes					167:173	different enzymes	157:173	different enzymes in different ways	157:191	N-glycosylation alters the properties of different enzymes in different ways.
35366731	10	44	theme	molecular	1285:1293	arg1	modification					1295:1306	the molecular modification	1281:1306	the molecular modification of GH16 family glucanases	1281:1332	This study provided a reference for the molecular modification of GH16 family glucanases and guided the utilization of β-glucan in hemicellulose.
35366731	9	45	theme	enzyme	1169:1174	arg1	structure					1176:1184	the enzyme structure	1165:1184	the enzyme structure	1165:1184	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	9	46	dep	reduced	1115:1121	arg1	creating					1187:1194	creating	1187:1194	creating rigidity	1187:1203	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	9	46	dep	reduced	1115:1121	arg1	increasing					1209:1218	increasing	1209:1218	increasing overall thermostability	1209:1242	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	1	47	theme	enzymes	167:173	arg1	properties					143:152	the properties	139:152	the properties of different enzymes in different ways	139:191	N-glycosylation alters the properties of different enzymes in different ways.
35366731	9	48	theme	overall	1127:1133	arg1	deviation					1152:1160	the overall root mean square deviation	1123:1160	the overall root mean square deviation of the enzyme structure	1123:1184	N-glycosylation reduced the overall root mean square deviation of the enzyme structure, creating rigidity and increasing overall thermostability.
35366731	5	49	theme	N-glycosylation	537:551	arg1	site					553:556	only one N-glycosylation site	528:556	only one N-glycosylation site	528:556	RhGlu16B has only one N-glycosylation site in its Ala55-Gly64 loop.
35366731	7	50	theme	family	748:753	arg1	glucanases					755:764	GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	743:804	GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	743:804	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
35366731	8	51	theme	verification	899:910	arg1	experiment					912:921	a verification experiment	897:921	a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed	897:1013	In a verification experiment using GH16 family glucanases BisGlu16B (from Bisporus) in which N-glycosylation was removed, N-glycosylation also appeared to promote thermostability and catalytic efficiency.
35366731	1	52	theme	different	178:186	arg1	ways					188:191	different ways	178:191	different ways	178:191	N-glycosylation alters the properties of different enzymes in different ways.
35366731	10	53	theme	glucanases	1323:1332	arg1	modification					1295:1306	the molecular modification	1281:1306	the molecular modification of GH16 family glucanases	1281:1332	This study provided a reference for the molecular modification of GH16 family glucanases and guided the utilization of β-glucan in hemicellulose.
35366731	7	54	theme	glucanases	755:764	arg1	region					733:738	the same region	724:738	the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus)	724:804	Adding N-glycosylation to the same region of GH16 family glucanases TlGlu16A (from Talaromyces leycettanus) increased its thermostability and catalytic efficiency by 6.4 °C and 38%, respectively.
37354227	0	0	from	profiles	32:39	arg1	variants					102:109	the Alpha, Beta, Gamma, and Delta variants	68:109	the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	68:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	8	1	from	conditions	1545:1554	arg1	results					1476:1482	the results	1472:1482	the results for individual glycosylation sites from different experiment conditions	1472:1554	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	8	2	theme	different	1524:1532	arg1	conditions					1545:1554	different experiment conditions	1524:1554	different experiment conditions	1524:1554	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	3	3	theme	primary	582:588	arg1	sequence					590:597	the primary sequence	578:597	the primary sequence	578:597	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	6	4	theme	forms	1166:1170	arg1	distribution					1143:1154	the distribution	1139:1154	the distribution of glycan forms	1139:1170	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	2	5	theme	protein	313:319	arg1	folding					321:327	protein folding	313:327	protein folding	313:327	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	8	6	theme	glycopeptides	1608:1620	arg1	quantification					1590:1603	quantification	1590:1603	quantification	1590:1603	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	8	6	theme	glycopeptides	1608:1620	arg1	identification					1571:1584	identification	1571:1584	identification	1571:1584	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	1	7	theme	proteins	221:228	arg1	function					187:194	function	187:194	function	187:194	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	1	7	theme	proteins	221:228	arg1	structure					173:181	structure	173:181	structure	173:181	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	7	8	theme	site-specific	1349:1361	arg1	content					1370:1376	the site-specific glycan content	1345:1376	the site-specific glycan content	1345:1376	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	7	9	theme	later	1304:1308	arg1	variants					1310:1317	later variants	1304:1317	later variants	1304:1317	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	9	10	theme	effective	1852:1860	arg1	vaccines					1862:1869	effective vaccines	1852:1869	effective vaccines	1852:1869	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	3	11	gly	N-glycosylation	522:536	arg2	N-glycosylation					522:536	N-glycosylation	522:536	N-glycosylation	522:536	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	11	gly	N-glycosylation	522:536	arg2	sites					513:517	22 potential sites	500:517	22 potential sites of N-glycosylation per protein protomer	500:557	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	12	theme	protein	461:467	arg1	example					484:490	a prime example	476:490	a prime example	476:490	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	12	theme	protein	461:467	arg1	S					470:470	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	7	13	from	similarity	1331:1340	arg1	content					1370:1376	the site-specific glycan content	1345:1376	the site-specific glycan content	1345:1376	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	9	14	from	understanding	1742:1754	arg1	function					1824:1831	function	1824:1831	function	1824:1831	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	14	from	understanding	1742:1754	arg1	structure					1810:1818	viral protein structure	1796:1818	viral protein structure	1796:1818	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	6	15	from	variants	1127:1134	arg1	distribution					1143:1154	the distribution	1139:1154	the distribution of glycan forms	1139:1170	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	5	16	gly	glycosylation	1008:1020	arg2	sites					1022:1026	glycosylation sites	1008:1026	glycosylation sites of the spike protein	1008:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	16	gly	glycosylation	1008:1020	arg1	protein					1041:1047	the spike protein	1031:1047	the spike protein	1031:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	16	gly	glycosylation	1008:1020	arg2	protein					1041:1047	the spike protein	1031:1047	the spike protein	1031:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	9	17	from	role	1763:1766	arg1	function					1824:1831	function	1824:1831	function	1824:1831	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	17	from	role	1763:1766	arg1	structure					1810:1818	viral protein structure	1796:1818	viral protein structure	1796:1818	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	3	18	theme	prime	478:482	arg1	example					484:490	a prime example	476:490	a prime example	476:490	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	18	theme	prime	478:482	arg1	S					470:470	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	7	19	with	comparison	1176:1185	arg1	analysis					1237:1244	our previously reported site-specific glycan analysis	1192:1244	our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein	1192:1285	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	9	20	theme	site-specific	1632:1644	arg1	analysis					1653:1660	Detailed site-specific glycan analysis	1623:1660	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants	1623:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	7	21	theme	ancestral	1269:1277	arg1	protein					1279:1285	its ancestral protein	1265:1285	its ancestral protein	1265:1285	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	0	22	theme	Delta	96:100	arg1	variants					102:109	the Alpha, Beta, Gamma, and Delta variants	68:109	the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	68:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	7	23	dep	S-D614G	1253:1259	arg1	the					1249:1251	the	1249:1251	the	1249:1251	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	5	24	theme	acid	914:917	arg1	substitutions					919:931	the amino acid substitutions	904:931	the amino acid substitutions	904:931	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	4	25	attach	derived	719:725	arg2	Beta					815:818	Beta	815:818	Beta	815:818	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	25	attach	derived	719:725	arg1	variants					755:762	four common SARS-CoV-2 variants	732:762	four common SARS-CoV-2 variants classified as Variant of Concern	732:795	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	25	attach	derived	719:725	arg2	Delta					832:836	Delta	832:836	Delta	832:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	25	attach	derived	719:725	arg2	Gamma					821:825	Gamma	821:825	Gamma	821:825	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	25	attach	derived	719:725	arg2	proteins					710:717	recombinant spike proteins	692:717	recombinant spike proteins	692:717	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	25	attach	derived	719:725	arg2	Alpha					808:812	Alpha	808:812	Alpha	808:812	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	3	26	theme	N-glycosylation	522:536	arg1	sites					513:517	22 potential sites	500:517	22 potential sites of N-glycosylation per protein protomer	500:557	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	26	theme	N-glycosylation	522:536	arg1	N-glycosylation					522:536	N-glycosylation	522:536	N-glycosylation	522:536	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	2	27	theme	shield	430:435	arg1	"					436:436	a "glycan shield"	420:436	a "glycan shield"	420:436	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	7	28	from	types	1295:1299	arg1	variants					1310:1317	later variants	1304:1317	later variants	1304:1317	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	9	29	theme	variety	1672:1678	arg1	analysis					1653:1660	Detailed site-specific glycan analysis	1623:1660	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants	1623:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	0	30	theme	proteins	54:61	arg1	profiles					32:39	the N-glycosylation profiles	12:39	the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	12:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	5	31	theme	glycans	997:1003	arg1	type					989:992	type	989:992	type	989:992	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	31	theme	glycans	997:1003	arg1	abundance					975:983	abundance	975:983	abundance	975:983	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	9	32	theme	SARS-CoV-2	1683:1692	arg1	variants					1694:1701	SARS-CoV-2 variants	1683:1701	SARS-CoV-2 variants	1683:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	2	33	from	recognition	382:392	arg1	virus					364:368	the virus	360:368	the virus from immune recognition by its host (described as a "glycan shield")	360:437	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	5	34	theme	glycosylation	1008:1020	arg1	protein					1041:1047	the spike protein	1031:1047	the spike protein	1031:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	34	theme	glycosylation	1008:1020	arg1	sites					1022:1026	glycosylation sites	1008:1026	glycosylation sites of the spike protein	1008:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	7	35	from	analysis	1237:1244	arg1	S-D614G					1253:1259	S-D614G	1253:1259	S-D614G	1253:1259	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	7	35	from	analysis	1237:1244	arg1	protein					1279:1285	its ancestral protein	1265:1285	its ancestral protein	1265:1285	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	4	36	theme	D614G	849:853	arg1	spike					863:867	D614G variant spike	849:867	D614G variant spike as a control	849:880	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	37	theme	profiles	680:687	arg1	analysis					648:655	mass spectrometric analysis	629:655	mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta	629:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	8	38	theme	experiment	1534:1543	arg1	conditions					1545:1554	different experiment conditions	1524:1554	different experiment conditions	1524:1554	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	7	39	theme	glycan	1230:1235	arg1	analysis					1237:1244	our previously reported site-specific glycan analysis	1192:1244	our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein	1192:1285	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	8	40	theme	digestion	1424:1432	arg1	methods					1434:1440	multiple digestion methods	1415:1440	multiple digestion methods	1415:1440	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	4	41	theme	mass	629:632	arg1	analysis					648:655	mass spectrometric analysis	629:655	mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta	629:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	7	42	theme	reported	1207:1214	arg1	analysis					1237:1244	our previously reported site-specific glycan analysis	1192:1244	our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein	1192:1285	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	2	43	theme	immune	375:380	arg1	recognition					382:392	immune recognition	375:392	immune recognition by its host (described as a "glycan shield")	375:437	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	9	44	theme	role	1763:1766	arg1	understanding					1742:1754	the understanding	1738:1754	the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics	1738:1886	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	0	45	theme	profiles	32:39	arg1	Analysis					0:7	Analysis	0:7	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.	0:124	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	9	46	theme	protein	1771:1777	arg1	glycosylation					1779:1791	protein glycosylation	1771:1791	protein glycosylation	1771:1791	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	3	47	theme	protein	542:548	arg1	protomer					550:557	protein protomer	542:557	protein protomer	542:557	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	4	48	theme	common	737:742	arg1	variants					755:762	four common SARS-CoV-2 variants	732:762	four common SARS-CoV-2 variants classified as Variant of Concern	732:795	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	5	49	theme	spike	1035:1039	arg1	protein					1041:1047	the spike protein	1031:1047	the spike protein	1031:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	50	theme	amino	908:912	arg1	substitutions					919:931	the amino acid substitutions	904:931	the amino acid substitutions	904:931	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	2	51	gly	glycosylated	287:298	arg1	proteins					237:244	Viral proteins	231:244	Viral proteins used in cell entry	231:263	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	1	52	dep	structure	173:181	arg1	the					169:171	the	169:171	the	169:171	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	9	53	theme	protein	1802:1808	arg1	structure					1810:1818	viral protein structure	1796:1818	viral protein structure	1796:1818	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	4	54	theme	proteins	710:717	arg1	profiles					680:687	the N-glycosylation profiles	660:687	the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta	660:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	1	55	theme	membrane	199:206	arg1	function					187:194	function	187:194	function	187:194	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	1	55	theme	membrane	199:206	arg1	structure					173:181	structure	173:181	structure	173:181	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	8	56	theme	glycosylation	1499:1511	arg1	sites					1513:1517	individual glycosylation sites	1488:1517	individual glycosylation sites	1488:1517	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	6	57	gly	N-glycosylation	1062:1076	arg2	sequons					1078:1084	the N-glycosylation sequons	1058:1084	the N-glycosylation sequons in S	1058:1089	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	4	58	gly	N-glycosylation	664:678	arg1	Beta					815:818	Beta	815:818	Beta	815:818	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	58	gly	N-glycosylation	664:678	arg1	Delta					832:836	Delta	832:836	Delta	832:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	58	gly	N-glycosylation	664:678	arg1	proteins					710:717	recombinant spike proteins	692:717	recombinant spike proteins	692:717	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	58	gly	N-glycosylation	664:678	arg1	Alpha					808:812	Alpha	808:812	Alpha	808:812	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	58	gly	N-glycosylation	664:678	arg1	Gamma					821:825	Gamma	821:825	Gamma	821:825	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	1	59	theme	secreted	212:219	arg1	proteins					221:228	secreted proteins	212:228	secreted proteins	212:228	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	7	60	theme	glycan	1363:1368	arg1	content					1370:1376	the site-specific glycan content	1345:1376	the site-specific glycan content	1345:1376	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	6	61	theme	glycan	1159:1164	arg1	forms					1166:1170	glycan forms	1159:1170	glycan forms	1159:1170	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	2	62	theme	cell	254:257	arg1	entry					259:263	cell entry	254:263	cell entry	254:263	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	4	63	theme	Concern	789:795	arg1	Variant					778:784	Variant	778:784	Variant of Concern	778:795	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	7	64	theme	high	1326:1329	arg1	similarity					1331:1340	high similarity	1326:1340	high similarity on the site-specific glycan content to S-D614G	1326:1387	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	3	65	contain	having	493:498	arg2	N-glycosylation					522:536	N-glycosylation	522:536	N-glycosylation	522:536	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	65	contain	having	493:498	arg1	example					484:490	a prime example	476:490	a prime example	476:490	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	65	contain	having	493:498	arg1	S					470:470	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	65	contain	having	493:498	arg2	sites					513:517	22 potential sites	500:517	22 potential sites of N-glycosylation per protein protomer	500:557	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	66	theme	spike	455:459	arg1	example					484:490	a prime example	476:490	a prime example	476:490	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	66	theme	spike	455:459	arg1	S					470:470	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	67	dep	example	484:490	arg1	predicted					563:571	predicted	563:571	predicted from the primary sequence	563:597	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	4	68	theme	SARS-CoV-2	744:753	arg1	variants					755:762	four common SARS-CoV-2 variants	732:762	four common SARS-CoV-2 variants classified as Variant of Concern	732:795	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	9	69	from	function	1824:1831	arg1	understanding					1742:1754	the understanding	1738:1754	the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics	1738:1886	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	70	theme	vaccines	1862:1869	arg1	function					1824:1831	function	1824:1831	function	1824:1831	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	70	theme	vaccines	1862:1869	arg1	structure					1810:1818	viral protein structure	1796:1818	viral protein structure	1796:1818	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	70	theme	vaccines	1862:1869	arg1	development					1837:1847	development	1837:1847	development	1837:1847	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	1	71	theme	important	151:159	arg1	role					161:164	an important role	148:164	an important role	148:164	N-Glycosylation plays an important role in the structure and function of membrane and secreted proteins.
37354227	8	72	gly	glycopeptides	1608:1620	arg2	glycopeptides					1608:1620	glycopeptides	1608:1620	glycopeptides	1608:1620	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	9	73	from	structure	1810:1818	arg1	understanding					1742:1754	the understanding	1738:1754	the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics	1738:1886	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	74	theme	therapeutics	1875:1886	arg1	function					1824:1831	function	1824:1831	function	1824:1831	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	74	theme	therapeutics	1875:1886	arg1	structure					1810:1818	viral protein structure	1796:1818	viral protein structure	1796:1818	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	74	theme	therapeutics	1875:1886	arg1	development					1837:1847	development	1837:1847	development	1837:1847	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	0	75	gly	N-glycosylation	16:30	arg1	proteins					54:61	the spike proteins	44:61	the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	44:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	9	76	theme	Detailed	1623:1630	arg1	analysis					1653:1660	Detailed site-specific glycan analysis	1623:1660	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants	1623:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	7	77	theme	glycan	1288:1293	arg1	types					1295:1299	glycan types	1288:1299	glycan types on later variants	1288:1317	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	9	78	theme	glycan	1646:1651	arg1	analysis					1653:1660	Detailed site-specific glycan analysis	1623:1660	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants	1623:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	5	79	from	impact	964:969	arg1	protein					1041:1047	the spike protein	1031:1047	the spike protein	1031:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	79	from	impact	964:969	arg1	sites					1022:1026	glycosylation sites	1008:1026	glycosylation sites of the spike protein	1008:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	0	80	theme	SARS-CoV-2	114:123	arg1	variants					102:109	the Alpha, Beta, Gamma, and Delta variants	68:109	the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	68:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	4	81	theme	recombinant	692:702	arg1	Beta					815:818	Beta	815:818	Beta	815:818	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	81	theme	recombinant	692:702	arg1	Delta					832:836	Delta	832:836	Delta	832:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	81	theme	recombinant	692:702	arg1	proteins					710:717	recombinant spike proteins	692:717	recombinant spike proteins	692:717	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	81	theme	recombinant	692:702	arg1	Alpha					808:812	Alpha	808:812	Alpha	808:812	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	81	theme	recombinant	692:702	arg1	Gamma					821:825	Gamma	821:825	Gamma	821:825	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	2	82	theme	Viral	231:235	arg1	proteins					237:244	Viral proteins	231:244	Viral proteins used in cell entry	231:263	Viral proteins used in cell entry are often extensively glycosylated to assist in protein folding, provide stability, and shield the virus from immune recognition by its host (described as a "glycan shield").
37354227	9	83	theme	wide	1667:1670	arg1	variety					1672:1678	a wide variety	1665:1678	a wide variety of SARS-CoV-2 variants	1665:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	83	theme	wide	1667:1670	arg1	variants					1694:1701	SARS-CoV-2 variants	1683:1701	SARS-CoV-2 variants	1683:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	8	84	dep	identification	1571:1584	arg1	the					1567:1569	the	1567:1569	the	1567:1569	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	3	85	theme	potential	503:511	arg1	sites					513:517	22 potential sites	500:517	22 potential sites of N-glycosylation per protein protomer	500:557	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	85	theme	potential	503:511	arg1	N-glycosylation					522:536	N-glycosylation	522:536	N-glycosylation	522:536	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	4	86	theme	variant	855:861	arg1	spike					863:867	D614G variant spike	849:867	D614G variant spike as a control	849:880	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	6	87	theme	N-glycosylation	1062:1076	arg1	sequons					1078:1084	the N-glycosylation sequons	1058:1084	the N-glycosylation sequons in S	1058:1089	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	8	88	theme	individual	1488:1497	arg1	sites					1513:1517	individual glycosylation sites	1488:1517	individual glycosylation sites	1488:1517	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	6	89	from	sequons	1078:1084	arg1	S					1089:1089	S	1089:1089	S	1089:1089	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	0	90	theme	Alpha	72:76	arg1	variants					102:109	the Alpha, Beta, Gamma, and Delta variants	68:109	the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	68:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	9	91	theme	variants	1694:1701	arg1	variety					1672:1678	a wide variety	1665:1678	a wide variety of SARS-CoV-2 variants	1665:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	9	91	theme	variants	1694:1701	arg1	variants					1694:1701	SARS-CoV-2 variants	1683:1701	SARS-CoV-2 variants	1683:1701	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	0	92	theme	Beta	79:82	arg1	variants					102:109	the Alpha, Beta, Gamma, and Delta variants	68:109	the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	68:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	9	93	theme	useful	1712:1717	arg1	information					1719:1729	useful information	1712:1729	useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics	1712:1886	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	8	94	theme	multiple	1415:1422	arg1	methods					1434:1440	multiple digestion methods	1415:1440	multiple digestion methods	1415:1440	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	0	95	theme	Gamma	85:89	arg1	variants					102:109	the Alpha, Beta, Gamma, and Delta variants	68:109	the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	68:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	7	96	theme	site-specific	1216:1228	arg1	analysis					1237:1244	our previously reported site-specific glycan analysis	1192:1244	our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein	1192:1285	In comparison with our previously reported site-specific glycan analysis on the S-D614G and its ancestral protein, glycan types on later variants showed high similarity on the site-specific glycan content to S-D614G.
37354227	4	97	theme	N-glycosylation	664:678	arg1	profiles					680:687	the N-glycosylation profiles	660:687	the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta	660:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	0	98	theme	N-glycosylation	16:30	arg1	profiles					32:39	the N-glycosylation profiles	12:39	the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	12:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	6	99	theme	SARS-CoV-2	1116:1125	arg1	variants					1127:1134	SARS-CoV-2 variants	1116:1134	SARS-CoV-2 variants in the distribution of glycan forms	1116:1170	Some of the N-glycosylation sequons in S show differences between SARS-CoV-2 variants in the distribution of glycan forms.
37354227	4	100	theme	spectrometric	634:646	arg1	analysis					648:655	mass spectrometric analysis	629:655	mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta	629:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	0	101	theme	spike	48:52	arg1	proteins					54:61	the spike proteins	44:61	the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	44:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	8	102	gly	glycosylation	1499:1511	arg2	sites					1513:1517	individual glycosylation sites	1488:1517	individual glycosylation sites	1488:1517	Additionally, we applied multiple digestion methods on each sample, and confirmed the results for individual glycosylation sites from different experiment conditions to improve the identification and quantification of glycopeptides.
37354227	9	103	theme	glycosylation	1779:1791	arg1	role					1763:1766	the role	1759:1766	the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics	1759:1886	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	5	104	dep	abundance	975:983	arg1	the					971:973	the	971:973	the	971:973	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	105	theme	protein	1041:1047	arg1	protein					1041:1047	the spike protein	1031:1047	the spike protein	1031:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	5	105	theme	protein	1041:1047	arg1	sites					1022:1026	glycosylation sites	1008:1026	glycosylation sites of the spike protein	1008:1047	Our data reveal that the amino acid substitutions and deletions between variants impact the abundance and type of glycans on glycosylation sites of the spike protein.
37354227	9	106	theme	viral	1796:1800	arg1	structure					1810:1818	viral protein structure	1796:1818	viral protein structure	1796:1818	Detailed site-specific glycan analysis of a wide variety of SARS-CoV-2 variants provides useful information toward the understanding of the role of protein glycosylation on viral protein structure and function and development of effective vaccines and therapeutics.
37354227	0	107	from	variants	102:109	arg1	proteins					54:61	the spike proteins	44:61	the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	44:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	0	107	from	variants	102:109	arg1	profiles					32:39	the N-glycosylation profiles	12:39	the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2	12:123	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.
37354227	4	108	theme	spike	704:708	arg1	Beta					815:818	Beta	815:818	Beta	815:818	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	108	theme	spike	704:708	arg1	Delta					832:836	Delta	832:836	Delta	832:836	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	108	theme	spike	704:708	arg1	proteins					710:717	recombinant spike proteins	692:717	recombinant spike proteins	692:717	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	108	theme	spike	704:708	arg1	Alpha					808:812	Alpha	808:812	Alpha	808:812	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	4	108	theme	spike	704:708	arg1	Gamma					821:825	Gamma	821:825	Gamma	821:825	In this report, we conducted mass spectrometric analysis of the N-glycosylation profiles of recombinant spike proteins derived from four common SARS-CoV-2 variants classified as Variant of Concern, including Alpha, Beta, Gamma, and Delta along with D614G variant spike as a control.
37354227	3	109	theme	SARS-CoV-2	444:453	arg1	example					484:490	a prime example	476:490	a prime example	476:490	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37354227	3	109	theme	SARS-CoV-2	444:453	arg1	S					470:470	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S)	440:471	The SARS-CoV-2 spike protein (S) is a prime example, having 22 potential sites of N-glycosylation per protein protomer, as predicted from the primary sequence.
37110538	6	0	theme	whole	1016:1020	arg1	level					1031:1035	site-specific and whole molecule level	998:1035	site-specific and whole molecule level	998:1035	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	4	1	theme	standardized	615:626	arg1	approach					628:635	a standardized approach	613:635	a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles	613:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	5	2	theme	liquid	836:841	arg1	method					898:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	The analytical workflow is based on a liquid chromatography-mass spectrometry-based multi-attribute method.
37110538	3	3	theme	manufacturing	540:552	arg1	strategies					562:571	manufacturing control strategies	540:571	manufacturing control strategies	540:571	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	6	4	theme	comprehensive	1080:1092	arg1	fingerprint					1116:1126	a comprehensive product glycosylation fingerprint	1078:1126	a comprehensive product glycosylation fingerprint	1078:1126	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	6	5	theme	site-specific	998:1010	arg1	level					1031:1035	site-specific and whole molecule level	998:1035	site-specific and whole molecule level	998:1035	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	2	6	theme	comprehensive	345:357	arg1	characterization					359:374	comprehensive characterization	345:374	comprehensive characterization	345:374	Due to the heterogenic and complex nature of protein glycosylation, comprehensive characterization is demanding.
37110538	5	7	theme	analytical	802:811	arg1	workflow					813:820	The analytical workflow	798:820	The analytical workflow	798:820	The analytical workflow is based on a liquid chromatography-mass spectrometry-based multi-attribute method.
37110538	7	8	theme	versatile	1221:1229	arg1	approach					1231:1238	a standardized and versatile approach	1202:1238	a standardized and versatile approach for reporting all dimensions of the glycosylation profile	1202:1296	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	7	8	theme	versatile	1221:1229	arg1	applicability					1161:1173	the applicability	1157:1173	the applicability of the proposed indices	1157:1197	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	8	9	theme	proposed	1303:1310	arg1	approach					1312:1319	The proposed approach	1299:1319	The proposed approach	1299:1319	The proposed approach further facilitates the assessments of risks associated with changes in the glycosylation profile that may affect efficacy, clearance, and immunogenicity.
37110538	4	10	theme	objective	750:758	arg1	comparison					760:769	the reporting and objective comparison	732:769	the reporting and objective comparison of glycosylation profiles	732:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	1	11	theme	critical	116:123	arg1	attribute					133:141	a critical quality attribute	114:141	a critical quality attribute	114:141	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	11	theme	critical	116:123	arg1	Glycosylation					97:109	Glycosylation	97:109	Glycosylation	97:109	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	5	12	theme	chromatography-mass	843:861	arg1	method					898:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	The analytical workflow is based on a liquid chromatography-mass spectrometry-based multi-attribute method.
37110538	1	13	from	attribute	133:141	arg1	biotherapeutics					146:160	biotherapeutics	146:160	biotherapeutics	146:160	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	8	14	theme	risks	1360:1364	arg1	assessments					1345:1355	the assessments	1341:1355	the assessments of risks associated with changes in the glycosylation profile that may affect efficacy, clearance, and immunogenicity	1341:1473	The proposed approach further facilitates the assessments of risks associated with changes in the glycosylation profile that may affect efficacy, clearance, and immunogenicity.
37110538	7	15	theme	profile	1290:1296	arg1	dimensions					1258:1267	all dimensions	1254:1267	all dimensions of the glycosylation profile	1254:1296	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	6	16	theme	attributes	978:987	arg1	computed					1042:1049	computed	1042:1049	computed	1042:1049	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	6	16	theme	attributes	978:987	arg1	matrix					938:943	a matrix	936:943	a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level,	936:1036	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	7	17	theme	indices	1191:1197	arg1	approach					1231:1238	a standardized and versatile approach	1202:1238	a standardized and versatile approach for reporting all dimensions of the glycosylation profile	1202:1296	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	7	17	theme	indices	1191:1197	arg1	applicability					1161:1173	the applicability	1157:1173	the applicability of the proposed indices	1157:1197	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	1	18	theme	protein	192:198	arg1	rate					233:236	clearance rate	223:236	clearance rate	223:236	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	18	theme	protein	192:198	arg1	stability					200:208	protein stability	192:208	protein stability	192:208	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	18	theme	protein	192:198	arg1	efficacy					239:246	efficacy	239:246	efficacy	239:246	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	18	theme	protein	192:198	arg1	solubility					211:220	solubility	211:220	solubility	211:220	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	18	theme	protein	192:198	arg1	immunogenicity					249:262	immunogenicity	249:262	immunogenicity	249:262	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	18	theme	protein	192:198	arg1	safety					269:274	safety	269:274	safety	269:274	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	0	19	theme	Innovative	0:9	arg1	Metrics					11:17	Innovative Metrics	0:17	Innovative Metrics for Reporting	0:31	Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.
37110538	6	20	theme	analytical	919:928	arg1	data					930:933	the analytical data	915:933	the analytical data	915:933	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	2	21	theme	complex	304:310	arg1	nature					312:317	the heterogenic and complex nature	284:317	the heterogenic and complex nature of protein glycosylation	284:342	Due to the heterogenic and complex nature of protein glycosylation, comprehensive characterization is demanding.
37110538	6	22	theme	product	1094:1100	arg1	fingerprint					1116:1126	a comprehensive product glycosylation fingerprint	1078:1126	a comprehensive product glycosylation fingerprint	1078:1126	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	5	23	theme	multi-attribute	882:896	arg1	method					898:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	The analytical workflow is based on a liquid chromatography-mass spectrometry-based multi-attribute method.
37110538	4	24	theme	comprehensive	666:678	arg1	fingerprint					694:704	a comprehensive glycosylation fingerprint	664:704	a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles	664:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	7	25	theme	glycosylation	1276:1288	arg1	profile					1290:1296	the glycosylation profile	1272:1296	the glycosylation profile	1272:1296	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	7	26	theme	proposed	1182:1189	arg1	indices					1191:1197	the proposed indices	1178:1197	the proposed indices	1178:1197	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	6	27	theme	quality	970:976	arg1	both					990:993	both	990:993	both	990:993	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	6	27	theme	quality	970:976	arg1	attributes					978:987	glycosylation-related quality attributes	948:987	glycosylation-related quality attributes	948:987	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	2	28	theme	heterogenic	288:298	arg1	nature					312:317	the heterogenic and complex nature	284:317	the heterogenic and complex nature of protein glycosylation	284:342	Due to the heterogenic and complex nature of protein glycosylation, comprehensive characterization is demanding.
37110538	3	29	theme	comparability	493:505	arg1	studies					507:513	comparability studies	493:513	comparability studies	493:513	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	3	30	theme	standardized	412:423	arg1	metrics					425:431	standardized metrics	412:431	standardized metrics for evaluating and comparing glycosylation profiles	412:483	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	2	31	theme	glycosylation	330:342	arg1	nature					312:317	the heterogenic and complex nature	284:317	the heterogenic and complex nature of protein glycosylation	284:342	Due to the heterogenic and complex nature of protein glycosylation, comprehensive characterization is demanding.
37110538	6	32	theme	glycosylation-related	948:968	arg1	both					990:993	both	990:993	both	990:993	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	6	32	theme	glycosylation-related	948:968	arg1	attributes					978:987	glycosylation-related quality attributes	948:987	glycosylation-related quality attributes	948:987	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	3	33	theme	glycosylation	462:474	arg1	profiles					476:483	glycosylation profiles	462:483	glycosylation profiles	462:483	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	3	34	theme	metrics	425:431	arg1	lack					404:407	the lack	400:407	the lack of standardized metrics for evaluating and comparing glycosylation profiles	400:483	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	5	35	theme	spectrometry-based	863:880	arg1	method					898:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	a liquid chromatography-mass spectrometry-based multi-attribute method	834:903	The analytical workflow is based on a liquid chromatography-mass spectrometry-based multi-attribute method.
37110538	8	36	from	changes	1382:1388	arg1	profile					1411:1417	the glycosylation profile	1393:1417	the glycosylation profile that may affect efficacy, clearance, and immunogenicity	1393:1473	The proposed approach further facilitates the assessments of risks associated with changes in the glycosylation profile that may affect efficacy, clearance, and immunogenicity.
37110538	4	37	theme	glycosylation	680:692	arg1	fingerprint					694:704	a comprehensive glycosylation fingerprint	664:704	a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles	664:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	0	38	theme	Glycan	51:56	arg1	Profile					69:75	the Glycan Structural Profile	47:75	the Glycan Structural Profile	47:75	Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.
37110538	4	39	theme	glycosylation	774:786	arg1	profiles					788:795	glycosylation profiles	774:795	glycosylation profiles	774:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	7	40	theme	standardized	1204:1215	arg1	approach					1231:1238	a standardized and versatile approach	1202:1238	a standardized and versatile approach for reporting all dimensions of the glycosylation profile	1202:1296	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	7	40	theme	standardized	1204:1215	arg1	applicability					1161:1173	the applicability	1157:1173	the applicability of the proposed indices	1157:1197	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	1	41	theme	quality	125:131	arg1	attribute					133:141	a critical quality attribute	114:141	a critical quality attribute	114:141	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	41	theme	quality	125:131	arg1	Glycosylation					97:109	Glycosylation	97:109	Glycosylation	97:109	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	7	42	theme	case	1133:1136	arg1	studies					1138:1144	Two case studies	1129:1144	Two case studies	1129:1144	Two case studies illustrate the applicability of the proposed indices as a standardized and versatile approach for reporting all dimensions of the glycosylation profile.
37110538	4	43	theme	reporting	736:744	arg1	comparison					760:769	the reporting and objective comparison	732:769	the reporting and objective comparison of glycosylation profiles	732:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	2	44	theme	protein	322:328	arg1	glycosylation					330:342	protein glycosylation	322:342	protein glycosylation	322:342	Due to the heterogenic and complex nature of protein glycosylation, comprehensive characterization is demanding.
37110538	4	45	theme	novel	646:650	arg1	metrics					652:658	novel metrics	646:658	novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles	646:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	4	46	theme	profiles	788:795	arg1	comparison					760:769	the reporting and objective comparison	732:769	the reporting and objective comparison of glycosylation profiles	732:795	To address both challenges, we propose a standardized approach based on novel metrics for a comprehensive glycosylation fingerprint which greatly facilitates the reporting and objective comparison of glycosylation profiles.
37110538	1	47	theme	clearance	223:231	arg1	rate					233:236	clearance rate	223:236	clearance rate	223:236	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	1	47	theme	clearance	223:231	arg1	stability					200:208	protein stability	192:208	protein stability	192:208	Glycosylation is a critical quality attribute in biotherapeutics, impacting properties such as protein stability, solubility, clearance rate, efficacy, immunogenicity, and safety.
37110538	8	48	theme	glycosylation	1397:1409	arg1	profile					1411:1417	the glycosylation profile	1393:1417	the glycosylation profile that may affect efficacy, clearance, and immunogenicity	1393:1473	The proposed approach further facilitates the assessments of risks associated with changes in the glycosylation profile that may affect efficacy, clearance, and immunogenicity.
37110538	3	49	theme	control	554:560	arg1	strategies					562:571	manufacturing control strategies	540:571	manufacturing control strategies	540:571	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	0	50	theme	Structural	58:67	arg1	Profile					69:75	the Glycan Structural Profile	47:75	the Glycan Structural Profile	47:75	Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.
37110538	6	51	theme	molecule	1022:1029	arg1	level					1031:1035	site-specific and whole molecule level	998:1035	site-specific and whole molecule level	998:1035	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
37110538	3	52	theme	strategies	562:571	arg1	studies					507:513	comparability studies	493:513	comparability studies	493:513	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	3	52	theme	strategies	562:571	arg1	establishment					523:535	the establishment	519:535	the establishment of manufacturing control strategies	519:571	Moreover, the lack of standardized metrics for evaluating and comparing glycosylation profiles hinders comparability studies and the establishment of manufacturing control strategies.
37110538	6	53	theme	glycosylation	1102:1114	arg1	fingerprint					1116:1126	a comprehensive product glycosylation fingerprint	1078:1126	a comprehensive product glycosylation fingerprint	1078:1126	Based on the analytical data, a matrix of glycosylation-related quality attributes, both at site-specific and whole molecule level, are computed, which provide metrics for a comprehensive product glycosylation fingerprint.
36542493	4	0	theme	absolute	558:565	arg1	configuration					570:582	an absolute C6 configuration	555:582	an absolute C6 configuration	555:582	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	7	1	theme	novel	1212:1216	arg1	class					1218:1222	a novel class	1210:1222	various C6 chiral centers but also a novel class of antiadhesion therapeutic agents	1175:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	7	2	theme	unknown	1128:1134	arg1	proteins					1158:1165	unknown serine O-heptosylated proteins	1128:1165	unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection	1128:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	5	3	gly	glycopeptides	641:653	arg2	haptens					658:664	haptens	658:664	haptens	658:664	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	5	3	gly	glycopeptides	641:653	arg2	glycopeptides					641:653	glycopeptides	641:653	glycopeptides	641:653	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	7	4	theme	various	1175:1181	arg1	centers					1193:1199	various C6 chiral centers	1175:1199	various C6 chiral centers but also a novel class of antiadhesion therapeutic agents	1175:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	7	5	theme	C6	1183:1184	arg1	centers					1193:1199	various C6 chiral centers	1175:1199	various C6 chiral centers but also a novel class of antiadhesion therapeutic agents	1175:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	6	6	dep	Escherichia	948:958	arg1	coli					960:963	coli	960:963	coli	960:963	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	7	7	theme	infection	1290:1298	arg1	treatment					1267:1275	the treatment	1263:1275	the treatment of bacterial infection	1263:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	7	8	theme	bacterial	1280:1288	arg1	infection					1290:1298	bacterial infection	1280:1298	bacterial infection	1280:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	4	9	theme	glycan	534:539	arg1	structure					541:549	this atypical glycan structure	520:549	this atypical glycan structure	520:549	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	5	10	theme	first-in-class	680:693	arg1	poly-					695:699	first-in-class poly-	680:699	first-in-class poly-	680:699	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	7	11	dep	tools	1101:1105	arg1	only					1089:1092	only	1089:1092	only	1089:1092	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	5	12	theme	high	840:843	arg1	specificity					845:855	high specificity	840:855	high specificity	840:855	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	1	13	theme	Alternative	99:109	arg1	therapies					125:133	Alternative antibacterial therapies	99:133	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance	99:192	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance are urgently needed.
36542493	6	14	theme	Ser	1020:1022	arg1	manner					1040:1045	Ser O-Hep-dependent manner	1020:1045	Ser O-Hep-dependent manner	1020:1045	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	6	15	theme	HeLa	982:985	arg1	cells					987:991	HeLa cells	982:991	HeLa cells	982:991	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	5	16	theme	monoclonal	705:714	arg1	antibodies					716:725	monoclonal antibodies	705:725	monoclonal antibodies	705:725	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	1	17	theme	antibacterial	111:123	arg1	therapies					125:133	Alternative antibacterial therapies	99:133	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance	99:192	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance are urgently needed.
36542493	7	18	theme	serine	1136:1141	arg1	proteins					1158:1165	unknown serine O-heptosylated proteins	1128:1165	unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection	1128:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	0	19	theme	Configuration-Specific	0:21	arg1	Antibody					23:30	Configuration-Specific Antibody	0:30	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.	0:97	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.
36542493	4	20	theme	building	618:625	arg1	blocks					627:632	Ser O-Hep building blocks	608:632	Ser O-Hep building blocks	608:632	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	3	21	theme	Ser	294:296	arg1	glycosylation					383:395	a novel glycosylation	375:395	a novel glycosylation	375:395	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	3	21	theme	Ser	294:296	arg1	O-heptosylation					298:312	Ser O-heptosylation	294:312	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria	294:370	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	3	21	theme	Ser	294:296	arg1	O-Hep					319:323	Ser O-Hep	315:323	Ser O-Hep	315:323	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	0	22	theme	Bacterial	36:44	arg1	Heptosylation					46:58	Bacterial Heptosylation	36:58	Bacterial Heptosylation	36:58	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.
36542493	4	23	theme	O-Hep	612:616	arg1	blocks					627:632	Ser O-Hep building blocks	608:632	Ser O-Hep building blocks	608:632	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	1	24	theme	refractory	135:144	arg1	therapies					125:133	Alternative antibacterial therapies	99:133	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance	99:192	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance are urgently needed.
36542493	5	25	with	O-heptosylation	805:819	arg1	specificity					845:855	high specificity	840:855	high specificity	840:855	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	6	26	from	adhesion	970:977	arg1	mice					1000:1003	mice	1000:1003	mice	1000:1003	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	3	27	from	O-heptosylation	298:312	arg1	autotransporters					329:344	autotransporters	329:344	autotransporters of Gram-negative bacteria	329:370	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	5	28	theme	Ser	801:803	arg1	d/l-glycero					822:832	d/l-glycero	822:832	d/l-glycero	822:832	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	5	28	theme	Ser	801:803	arg1	O-heptosylation					805:819	Ser O-heptosylation	801:819	Ser O-heptosylation (d/l-glycero) with high specificity	801:855	Using glycopeptides as haptens, we generated first-in-class poly- and monoclonal antibodies, termed Anti-SerHep1a and Anti-SerHep1b, that stereoselectively recognize Ser O-heptosylation (d/l-glycero) with high specificity in vitro and in vivo.
36542493	2	29	theme	attractive	224:233	arg1	therapy					235:241	One such attractive therapy	215:241	One such attractive therapy	215:241	One such attractive therapy is to inhibit bacterial adhesion and colonization.
36542493	7	30	theme	therapeutic	1240:1250	arg1	agents					1252:1257	antiadhesion therapeutic agents	1227:1257	antiadhesion therapeutic agents	1227:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	4	31	theme	blocks	627:632	arg1	assembly					596:603	the assembly	592:603	the assembly of Ser O-Hep building blocks	592:632	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	3	32	theme	Ser	315:317	arg1	O-heptosylation					298:312	Ser O-heptosylation	294:312	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria	294:370	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	3	32	theme	Ser	315:317	arg1	O-Hep					319:323	Ser O-Hep	315:323	Ser O-Hep	315:323	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	2	33	theme	such	219:222	arg1	therapy					235:241	One such attractive therapy	215:241	One such attractive therapy	215:241	One such attractive therapy is to inhibit bacterial adhesion and colonization.
36542493	7	34	theme	agents	1252:1257	arg1	centers					1193:1199	various C6 chiral centers	1175:1199	various C6 chiral centers but also a novel class of antiadhesion therapeutic agents	1175:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	7	34	theme	agents	1252:1257	arg1	class					1218:1222	a novel class	1210:1222	various C6 chiral centers but also a novel class of antiadhesion therapeutic agents	1175:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	6	35	dep	adhering	939:946	arg1	Escherichia					948:958	Escherichia	948:958	Escherichia	948:958	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	7	36	theme	proteins	1158:1165	arg1	discovery					1115:1123	the discovery	1111:1123	the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection	1111:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	4	37	theme	atypical	525:532	arg1	structure					541:549	this atypical glycan structure	520:549	this atypical glycan structure	520:549	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	4	38	contain	containing	509:518	arg2	configuration					570:582	an absolute C6 configuration	555:582	an absolute C6 configuration	555:582	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	4	38	contain	containing	509:518	arg2	structure					541:549	this atypical glycan structure	520:549	this atypical glycan structure	520:549	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	4	38	contain	containing	509:518	arg1	glycopeptides					495:507	glycopeptides	495:507	glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks	495:632	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	3	39	theme	bacterial	437:445	arg1	colonization					447:458	bacterial colonization	437:458	bacterial colonization	437:458	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	6	40	theme	O-Hep-dependent	1024:1038	arg1	manner					1040:1045	Ser O-Hep-dependent manner	1020:1045	Ser O-Hep-dependent manner	1020:1045	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	3	41	theme	Gram-negative	349:361	arg1	bacteria					363:370	Gram-negative bacteria	349:370	Gram-negative bacteria	349:370	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	0	42	theme	Therapeutic	77:87	arg1	Strategy					89:96	An Antiadhesion Therapeutic Strategy	61:96	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.	0:97	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.
36542493	1	43	theme	existing	149:156	arg1	mechanisms					158:167	existing mechanisms	149:167	existing mechanisms of antibiotic resistance	149:192	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance are urgently needed.
36542493	7	44	theme	antiadhesion	1227:1238	arg1	agents					1252:1257	antiadhesion therapeutic agents	1227:1257	antiadhesion therapeutic agents	1227:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	4	45	theme	Ser	608:610	arg1	blocks					627:632	Ser O-Hep building blocks	608:632	Ser O-Hep building blocks	608:632	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	3	46	theme	bacteria	363:370	arg1	autotransporters					329:344	autotransporters	329:344	autotransporters of Gram-negative bacteria	329:370	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	2	47	theme	bacterial	257:265	arg1	adhesion					267:274	bacterial adhesion	257:274	bacterial adhesion	257:274	One such attractive therapy is to inhibit bacterial adhesion and colonization.
36542493	7	48	theme	useful	1094:1099	arg1	tools					1101:1105	not only useful tools	1085:1105	not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection	1085:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	6	49	theme	2787	965:968	arg1	adhesion					970:977	diffusely adhering Escherichia coli 2787 adhesion	929:977	diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice	929:1003	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	4	50	gly	glycopeptides	495:507	arg2	glycopeptides					495:507	glycopeptides	495:507	glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks	495:632	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	6	51	theme	adhering	939:946	arg1	adhesion					970:977	diffusely adhering Escherichia coli 2787 adhesion	929:977	diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice	929:1003	Importantly, these antibodies effectively blocked diffusely adhering Escherichia coli 2787 adhesion to HeLa cells and in mice in a dose- and Ser O-Hep-dependent manner.
36542493	1	52	theme	antibiotic	172:181	arg1	resistance					183:192	antibiotic resistance	172:192	antibiotic resistance	172:192	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance are urgently needed.
36542493	7	53	theme	chiral	1186:1191	arg1	centers					1193:1199	various C6 chiral centers	1175:1199	various C6 chiral centers but also a novel class of antiadhesion therapeutic agents	1175:1257	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
36542493	3	54	theme	novel	377:381	arg1	glycosylation					383:395	a novel glycosylation	375:395	a novel glycosylation	375:395	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	3	54	theme	novel	377:381	arg1	O-heptosylation					298:312	Ser O-heptosylation	294:312	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria	294:370	Ser O-heptosylation (Ser O-Hep) on autotransporters of Gram-negative bacteria is a novel glycosylation and has been proven to be essential for bacterial colonization.
36542493	0	55	dep	Antibody	23:30	arg1	Strategy					89:96	An Antiadhesion Therapeutic Strategy	61:96	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.	0:97	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.
36542493	1	56	theme	resistance	183:192	arg1	mechanisms					158:167	existing mechanisms	149:167	existing mechanisms of antibiotic resistance	149:192	Alternative antibacterial therapies refractory to existing mechanisms of antibiotic resistance are urgently needed.
36542493	0	57	theme	Antiadhesion	64:75	arg1	Strategy					89:96	An Antiadhesion Therapeutic Strategy	61:96	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.	0:97	Configuration-Specific Antibody for Bacterial Heptosylation: An Antiadhesion Therapeutic Strategy.
36542493	4	58	theme	C6	567:568	arg1	configuration					570:582	an absolute C6 configuration	555:582	an absolute C6 configuration	555:582	Herein, we chemically synthesized glycopeptides containing this atypical glycan structure and an absolute C6 configuration through the assembly of Ser O-Hep building blocks.
36542493	7	59	theme	O-heptosylated	1143:1156	arg1	proteins					1158:1165	unknown serine O-heptosylated proteins	1128:1165	unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection	1128:1298	Together, these antibodies represent not only useful tools for the discovery of unknown serine O-heptosylated proteins bearing various C6 chiral centers but also a novel class of antiadhesion therapeutic agents for the treatment of bacterial infection.
37330473	13	0	theme	polished	2219:2226	arg1	figures					2228:2234	polished figures	2219:2234	polished figures	2219:2234	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	3	1	theme	MS	505:506	arg1	data					508:511	MS data	505:511	MS data	505:511	Most of glycan analysis requires dedicated glycobioinformatics tools to process MS data, identify glycan structure, and display the results.
37330473	13	2	theme	current	2337:2343	arg1	workflow					2361:2368	the current manual analysis workflow	2333:2368	the current manual analysis workflow	2333:2368	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	10	3	theme	GlyKAn	1607:1612	arg1	app					1617:1619	The GlyKAn AZ app	1603:1619	The GlyKAn AZ app	1603:1619	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	7	4	theme	mass	1108:1111	arg1	algorithms					1120:1129	MS1 and MS2 mass search algorithms	1096:1129	MS1 and MS2 mass search algorithms along with glycan databases	1096:1157	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	14	5	theme	glycan	2423:2428	arg1	identification					2430:2443	glycan identification	2423:2443	glycan identification	2423:2443	Overall, this app serves as a tool for streamlining glycan identification for both academic and industrial needs.
37330473	5	6	theme	few	831:833	arg1	tools					835:839	few tools	831:839	few tools	831:839	Additionally, few tools provide the capability to generate report-ready annotated MS/MS glycan spectra.
37330473	1	7	theme	significant	173:183	arg1	role					185:188	a significant role	171:188	a significant role	171:188	BACKGROUND Glycosylation is an important modification to proteins that plays a significant role in biological processes.
37330473	8	8	theme	graphical	1273:1281	arg1	interface					1288:1296	A user-friendly graphical user interface	1257:1296	A user-friendly graphical user interface (GUI)	1257:1302	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	8	8	theme	graphical	1273:1281	arg1	GUI					1299:1301	GUI	1299:1301	GUI	1299:1301	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	5	9	theme	glycan	905:910	arg1	spectra					912:918	report-ready annotated MS/MS glycan spectra	876:918	report-ready annotated MS/MS glycan spectra	876:918	Additionally, few tools provide the capability to generate report-ready annotated MS/MS glycan spectra.
37330473	12	10	theme	AZ	2062:2063	arg1	app					2065:2067	The GlyKAn AZ app	2051:2067	The GlyKAn AZ app	2051:2067	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	2	11	theme	data	362:365	arg1	interpretation					328:341	data interpretation	323:341	data interpretation of LC/MS and MS/MS data	323:365	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	13	12	theme	user	2206:2209	arg1	inputs					2211:2216	The app's customizable user inputs	2183:2216	The app's customizable user inputs	2183:2216	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	9	13	theme	Fragment	1499:1506	arg1	functionality					1518:1530	the Fragment Generator functionality	1495:1530	the Fragment Generator functionality which automatically identifies fragmentation patterns for new glycans	1495:1600	The databases provided with the app can be expanded through the Fragment Generator functionality which automatically identifies fragmentation patterns for new glycans.
37330473	12	14	theme	accuracy	2145:2152	arg1	level					2136:2140	a high level	2129:2140	a high level of accuracy in positive identifications	2129:2180	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	11	15	theme	laser	1869:1873	arg1	desorption/ionization-time					1875:1900	matrix-assisted laser desorption/ionization-time	1853:1900	matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS	1853:1925	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	4	16	dep	either	614:619	arg1	costly					625:630	costly	625:630	costly	625:630	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	13	17	theme	manual	2345:2350	arg1	workflow					2361:2368	the current manual analysis workflow	2333:2368	the current manual analysis workflow	2333:2368	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	6	18	theme	MATLAB-based	948:959	arg1	app					961:963	a MATLAB-based app	946:963	a MATLAB-based app	946:963	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	6	18	theme	MATLAB-based	948:959	arg1	AZ					973:974	AZ	973:974	AZ	973:974	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	8	19	theme	data	1320:1323	arg1	analysis					1325:1332	data analysis	1320:1332	the data analysis process	1316:1340	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	12	20	from	level	2136:2140	arg1	identifications					2166:2180	positive identifications	2157:2180	positive identifications	2157:2180	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	12	21	theme	positive	2157:2164	arg1	identifications					2166:2180	positive identifications	2157:2180	positive identifications	2157:2180	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	2	22	theme	liquid	254:259	arg1	chromatography					261:274	liquid chromatography	254:274	liquid chromatography (LC) combined with mass spectrometry (MS)	254:316	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	2	22	theme	liquid	254:259	arg1	LC					277:278	LC	277:278	LC	277:278	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	9	23	theme	fragmentation	1563:1575	arg1	patterns					1577:1584	fragmentation patterns	1563:1584	fragmentation patterns for new glycans	1563:1600	The databases provided with the app can be expanded through the Fragment Generator functionality which automatically identifies fragmentation patterns for new glycans.
37330473	6	24	theme	glycan	1013:1018	arg1	identification					1020:1033	glycan identification	1013:1033	glycan identification	1013:1033	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	0	25	theme	glycan	66:71	arg1	identification					78:91	N-linked glycan peak identification	57:91	N-linked glycan peak identification	57:91	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	6	26	dep	result	1053:1058	arg1	displays					1060:1067	displays	1060:1067	displays	1060:1067	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	7	27	link	N-linked	1209:1216	arg1	species					1225:1231	the fluorescent labeled N-linked glycan species	1185:1231	the fluorescent labeled N-linked glycan species based on accurate mass	1185:1254	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	7	28	theme	N-linked	1209:1216	arg1	species					1225:1231	the fluorescent labeled N-linked glycan species	1185:1231	the fluorescent labeled N-linked glycan species based on accurate mass	1185:1254	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	0	29	theme	N-linked	57:64	arg1	identification					78:91	N-linked glycan peak identification	57:91	N-linked glycan peak identification	57:91	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	8	30	theme	software	1375:1382	arg1	tool					1384:1387	the software tool	1371:1387	the software tool in biopharmaceutical analytical laboratories	1371:1432	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	10	31	theme	display	1681:1687	arg1	feature					1689:1695	this data display feature	1671:1695	this data display feature	1671:1695	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	7	32	theme	fluorescent	1189:1199	arg1	species					1225:1231	the fluorescent labeled N-linked glycan species	1185:1231	the fluorescent labeled N-linked glycan species based on accurate mass	1185:1254	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	4	33	theme	standardized	755:766	arg1	analysis					781:788	the standardized LC/MS glycan analysis	751:788	the standardized LC/MS glycan analysis	751:788	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	13	34	theme	similar	2296:2302	arg1	software					2304:2311	similar software	2296:2311	similar software	2296:2311	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	10	35	theme	report-ready	1788:1799	arg1	figures					1809:1815	individual report-ready spectra figures	1777:1815	individual report-ready spectra figures	1777:1815	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	3	36	theme	glycan	433:438	arg1	analysis					440:447	glycan analysis	433:447	glycan analysis	433:447	Most of glycan analysis requires dedicated glycobioinformatics tools to process MS data, identify glycan structure, and display the results.
37330473	8	37	theme	analytical	1410:1419	arg1	laboratories					1421:1432	biopharmaceutical analytical laboratories	1392:1432	biopharmaceutical analytical laboratories	1392:1432	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	11	38	theme	glycan	1982:1987	arg1	species					1989:1995	all glycan species	1978:1995	all glycan species that were previously identified manually	1978:2036	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	13	39	theme	calculated	2259:2268	arg1	outputs					2270:2276	unique calculated outputs	2252:2276	unique calculated outputs	2252:2276	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	6	40	theme	customizable	1040:1051	arg1	result					1053:1058	customizable result displays	1040:1067	customizable result displays	1040:1067	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	0	41	theme	data	39:42	arg1	analysis					44:51	LC-MS/MS data analysis	30:51	LC-MS/MS data analysis for N-linked glycan peak identification	30:91	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	0	42	link	N-linked	57:64	arg1	identification					78:91	N-linked glycan peak identification	57:91	N-linked glycan peak identification	57:91	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	3	43	theme	glycobioinformatics	468:486	arg1	tools					488:492	dedicated glycobioinformatics tools	458:492	dedicated glycobioinformatics tools	458:492	Most of glycan analysis requires dedicated glycobioinformatics tools to process MS data, identify glycan structure, and display the results.
37330473	10	44	theme	individual	1777:1786	arg1	figures					1809:1815	individual report-ready spectra figures	1777:1815	individual report-ready spectra figures	1777:1815	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	2	45	theme	MS/MS	356:360	arg1	data					362:365	MS/MS data	356:365	MS/MS data	356:365	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	5	46	theme	annotated	889:897	arg1	spectra					912:918	report-ready annotated MS/MS glycan spectra	876:918	report-ready annotated MS/MS glycan spectra	876:918	Additionally, few tools provide the capability to generate report-ready annotated MS/MS glycan spectra.
37330473	6	47	dep	RESULTS	921:927	arg1	present					938:944	present	938:944	present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow	938:1093	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	2	48	theme	LC/MS	346:350	arg1	interpretation					328:341	data interpretation	323:341	data interpretation of LC/MS and MS/MS data	323:365	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	8	49	from	tool	1384:1387	arg1	laboratories					1421:1432	biopharmaceutical analytical laboratories	1392:1432	biopharmaceutical analytical laboratories	1392:1432	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	7	50	theme	search	1113:1118	arg1	algorithms					1120:1129	MS1 and MS2 mass search algorithms	1096:1129	MS1 and MS2 mass search algorithms along with glycan databases	1096:1157	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	2	51	theme	mass	295:298	arg1	MS					314:315	MS	314:315	MS	314:315	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	2	51	theme	mass	295:298	arg1	spectrometry					300:311	mass spectrometry	295:311	mass spectrometry (MS)	295:316	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	4	52	theme	software	575:582	arg1	tools					584:588	software tools	575:588	software tools currently available	575:608	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	10	53	theme	AZ	1614:1615	arg1	app					1617:1619	The GlyKAn AZ app	1603:1619	The GlyKAn AZ app	1603:1619	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	7	54	theme	MS2	1104:1106	arg1	mass					1108:1111	MS2 mass	1104:1111	MS2 mass	1104:1111	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	3	55	theme	glycan	523:528	arg1	structure					530:538	glycan structure	523:538	glycan structure	523:538	Most of glycan analysis requires dedicated glycobioinformatics tools to process MS data, identify glycan structure, and display the results.
37330473	5	56	theme	report-ready	876:887	arg1	spectra					912:918	report-ready annotated MS/MS glycan spectra	876:918	report-ready annotated MS/MS glycan spectra	876:918	Additionally, few tools provide the capability to generate report-ready annotated MS/MS glycan spectra.
37330473	10	57	theme	MS/MS	1652:1656	arg1	spectra					1658:1664	the MS/MS spectra	1648:1664	the MS/MS spectra	1648:1664	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	7	58	theme	MS1	1096:1098	arg1	algorithms					1120:1129	MS1 and MS2 mass search algorithms	1096:1129	MS1 and MS2 mass search algorithms along with glycan databases	1096:1157	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	5	59	theme	MS/MS	899:903	arg1	spectra					912:918	report-ready annotated MS/MS glycan spectra	876:918	report-ready annotated MS/MS glycan spectra	876:918	Additionally, few tools provide the capability to generate report-ready annotated MS/MS glycan spectra.
37330473	13	60	theme	analysis	2352:2359	arg1	workflow					2361:2368	the current manual analysis workflow	2333:2368	the current manual analysis workflow	2333:2368	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	8	61	theme	user-friendly	1259:1271	arg1	interface					1288:1296	A user-friendly graphical user interface	1257:1296	A user-friendly graphical user interface (GUI)	1257:1302	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	8	61	theme	user-friendly	1259:1271	arg1	GUI					1299:1301	GUI	1299:1301	GUI	1299:1301	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	7	62	dep	along	1131:1135	arg1	with					1137:1140	with	1137:1140	with	1137:1140	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	11	63	theme	matrix-assisted	1853:1867	arg1	desorption/ionization-time					1875:1900	matrix-assisted laser desorption/ionization-time	1853:1900	matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS	1853:1925	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	1	64	theme	biological	193:202	arg1	processes					204:212	biological processes	193:212	biological processes	193:212	BACKGROUND Glycosylation is an important modification to proteins that plays a significant role in biological processes.
37330473	12	65	theme	GlyKAn	2055:2060	arg1	app					2065:2067	The GlyKAn AZ app	2051:2067	The GlyKAn AZ app	2051:2067	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	8	66	theme	user	1283:1286	arg1	interface					1288:1296	A user-friendly graphical user interface	1257:1296	A user-friendly graphical user interface (GUI)	1257:1302	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	8	66	theme	user	1283:1286	arg1	GUI					1299:1301	GUI	1299:1301	GUI	1299:1301	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	2	67	theme	data	323:326	arg1	interpretation					328:341	data interpretation	323:341	data interpretation of LC/MS and MS/MS data	323:365	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	13	68	theme	customizable	2193:2204	arg1	inputs					2211:2216	The app's customizable user inputs	2183:2216	The app's customizable user inputs	2183:2216	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37330473	4	69	theme	academic	654:661	arg1	applications					663:674	academic applications	654:674	academic applications	654:674	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	14	70	dep	industrial	2467:2476	arg1	needs					2478:2482	needs	2478:2482	needs	2478:2482	Overall, this app serves as a tool for streamlining glycan identification for both academic and industrial needs.
37330473	11	71	theme	flight	1905:1910	arg1	MS					1924:1925	flight (MALDI-TOF) MS	1905:1925	flight (MALDI-TOF) MS	1905:1925	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	9	72	theme	Generator	1508:1516	arg1	functionality					1518:1530	the Fragment Generator functionality	1495:1530	the Fragment Generator functionality which automatically identifies fragmentation patterns for new glycans	1495:1600	The databases provided with the app can be expanded through the Fragment Generator functionality which automatically identifies fragmentation patterns for new glycans.
37330473	1	73	theme	important	125:133	arg1	modification					135:146	an important modification	122:146	an important modification to proteins that plays a significant role in biological processes	122:212	BACKGROUND Glycosylation is an important modification to proteins that plays a significant role in biological processes.
37330473	1	73	theme	important	125:133	arg1	Glycosylation					105:117	BACKGROUND Glycosylation	94:117	BACKGROUND Glycosylation	94:117	BACKGROUND Glycosylation is an important modification to proteins that plays a significant role in biological processes.
37330473	4	74	theme	glycan	774:779	arg1	analysis					781:788	the standardized LC/MS glycan analysis	751:788	the standardized LC/MS glycan analysis	751:788	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	4	75	theme	biopharmaceutical	707:723	arg1	industry					725:732	the biopharmaceutical industry	703:732	the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner	703:814	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	7	76	theme	accurate	1242:1249	arg1	mass					1251:1254	accurate mass	1242:1254	accurate mass	1242:1254	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	8	77	theme	analysis	1325:1332	arg1	process					1334:1340	the data analysis process	1316:1340	the data analysis process	1316:1340	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	0	78	theme	peak	73:76	arg1	identification					78:91	N-linked glycan peak identification	57:91	N-linked glycan peak identification	57:91	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	11	79	dep	OrbiTrap	1840:1847	arg1	data					1927:1930	data	1927:1930	data	1927:1930	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	12	80	theme	high	2131:2134	arg1	level					2136:2140	a high level	2129:2140	a high level of accuracy in positive identifications	2129:2180	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	7	81	theme	glycan	1218:1223	arg1	species					1225:1231	the fluorescent labeled N-linked glycan species	1185:1231	the fluorescent labeled N-linked glycan species based on accurate mass	1185:1254	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	9	82	theme	new	1590:1592	arg1	glycans					1594:1600	new glycans	1590:1600	new glycans	1590:1600	The databases provided with the app can be expanded through the Fragment Generator functionality which automatically identifies fragmentation patterns for new glycans.
37330473	6	83	theme	data	996:999	arg1	processing					1001:1010	data processing	996:1010	data processing	996:1010	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	4	84	theme	LC/MS	768:772	arg1	analysis					781:788	the standardized LC/MS glycan analysis	751:788	the standardized LC/MS glycan analysis	751:788	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	7	85	theme	labeled	1201:1207	arg1	species					1225:1231	the fluorescent labeled N-linked glycan species	1185:1231	the fluorescent labeled N-linked glycan species based on accurate mass	1185:1254	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	0	86	theme	MATLAB-based	2:13	arg1	app					15:17	A MATLAB-based app	0:17	A MATLAB-based app	0:17	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	6	87	theme	streamlined	1074:1084	arg1	workflow					1086:1093	a streamlined workflow	1072:1093	a streamlined workflow	1072:1093	RESULTS Here, we present a MATLAB-based app, GlyKAn AZ, which can automate data processing, glycan identification, and customizable result displays in a streamlined workflow.
37330473	12	88	dep	CONCLUSIONS	2039:2049	arg1	developed					2073:2081	developed	2073:2081	was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications	2069:2180	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	10	89	theme	data	1676:1679	arg1	feature					1689:1695	this data display feature	1671:1695	this data display feature	1671:1695	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	1	90	theme	BACKGROUND	94:103	arg1	modification					135:146	an important modification	122:146	an important modification to proteins that plays a significant role in biological processes	122:212	BACKGROUND Glycosylation is an important modification to proteins that plays a significant role in biological processes.
37330473	1	90	theme	BACKGROUND	94:103	arg1	Glycosylation					105:117	BACKGROUND Glycosylation	94:117	BACKGROUND Glycosylation	94:117	BACKGROUND Glycosylation is an important modification to proteins that plays a significant role in biological processes.
37330473	10	91	theme	spectra	1801:1807	arg1	figures					1809:1815	individual report-ready spectra figures	1777:1815	individual report-ready spectra figures	1777:1815	The GlyKAn AZ app can automatically annotate the MS/MS spectra, yet this data display feature remains flexible and customizable by users, saving analysts' time in generating individual report-ready spectra figures.
37330473	3	92	theme	dedicated	458:466	arg1	tools					488:492	dedicated glycobioinformatics tools	458:492	dedicated glycobioinformatics tools	458:492	Most of glycan analysis requires dedicated glycobioinformatics tools to process MS data, identify glycan structure, and display the results.
37330473	0	93	theme	LC-MS/MS	30:37	arg1	analysis					44:51	LC-MS/MS data analysis	30:51	LC-MS/MS data analysis for N-linked glycan peak identification	30:91	A MATLAB-based app to improve LC-MS/MS data analysis for N-linked glycan peak identification.
37330473	8	94	theme	biopharmaceutical	1392:1408	arg1	laboratories					1421:1432	biopharmaceutical analytical laboratories	1392:1432	biopharmaceutical analytical laboratories	1392:1432	A user-friendly graphical user interface (GUI) streamlines the data analysis process, making it easy to implement the software tool in biopharmaceutical analytical laboratories.
37330473	7	95	theme	glycan	1142:1147	arg1	databases					1149:1157	glycan databases	1142:1157	MS1 and MS2 mass search algorithms along with glycan databases	1096:1157	MS1 and MS2 mass search algorithms along with glycan databases were developed to confirm the fluorescent labeled N-linked glycan species based on accurate mass.
37330473	2	96	theme	Glycan	215:220	arg1	structures					222:231	Glycan structures	215:231	Glycan structures	215:231	Glycan structures are characterized by liquid chromatography (LC) combined with mass spectrometry (MS), but data interpretation of LC/MS and MS/MS data can be time-consuming and arduous when analyzed manually.
37330473	11	97	theme	MS	1924:1925	arg1	desorption/ionization-time					1875:1900	matrix-assisted laser desorption/ionization-time	1853:1900	matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS	1853:1925	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	11	97	theme	MS	1924:1925	arg1	OrbiTrap					1840:1847	OrbiTrap	1840:1847	OrbiTrap	1840:1847	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	4	98	theme	available	600:608	arg1	tools					584:588	software tools	575:588	software tools currently available	575:608	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	4	99	theme	high-throughput	793:807	arg1	manner					809:814	high-throughput manner	793:814	high-throughput manner	793:814	However, software tools currently available are either too costly or heavily focused on academic applications, limiting their use within the biopharmaceutical industry for implementing the standardized LC/MS glycan analysis in high-throughput manner.
37330473	11	100	theme	MALDI-TOF	1913:1921	arg1	MS					1924:1925	flight (MALDI-TOF) MS	1905:1925	flight (MALDI-TOF) MS	1905:1925	This app accepts both OrbiTrap and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS data and was successfully validated by identifying all glycan species that were previously identified manually.
37330473	12	101	theme	glycan	2095:2100	arg1	analysis					2102:2109	glycan analysis	2095:2109	glycan analysis	2095:2109	CONCLUSIONS The GlyKAn AZ app was developed to expedite glycan analysis while maintaining a high level of accuracy in positive identifications.
37330473	13	102	theme	unique	2252:2257	arg1	outputs					2270:2276	unique calculated outputs	2252:2276	unique calculated outputs	2252:2276	The app's customizable user inputs, polished figures and tables, and unique calculated outputs set it apart from similar software and greatly improve the current manual analysis workflow.
37121976	2	0	theme	cellular	482:489	arg1	function					491:498	its cellular function	478:498	its cellular function	478:498	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	5	1	gly	deglycosylation	884:898	arg1	LRG1					999:1002	LRG1	999:1002	LRG1	999:1002	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	1	gly	deglycosylation	884:898	arg1	removal					926:932	particularly the removal	909:932	particularly the removal of glycans on N325	909:951	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	1	gly	deglycosylation	884:898	arg1	LRG1					903:906	LRG1	903:906	LRG1	903:906	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	2	theme	glucose	1133:1139	arg1	conditions					1141:1150	normal glucose conditions	1126:1150	normal glucose conditions	1126:1150	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	2	3	theme	molecular	358:366	arg1	weights					368:374	different molecular weights	348:374	different molecular weights due to differences in glycosylation	348:410	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	7	4	theme	molecular	1396:1404	arg1	switches					1406:1413	molecular switches	1396:1413	molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis	1396:1510	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	0	5	theme	glycan	66:71	arg1	structure					8:16	Crystal structure	0:16	Crystal structure of LRG1	0:24	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	0	5	theme	glycan	66:71	arg1	significance					45:56	the functional significance	30:56	the functional significance of LRG1 glycan for LPHN2 activation	30:92	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	7	6	theme	functions	1458:1466	arg1	range					1433:1437	the range	1429:1437	the range of LRG1's cellular functions	1429:1466	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	2	7	theme	different	348:356	arg1	weights					368:374	different molecular weights	348:374	different molecular weights due to differences in glycosylation	348:410	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	4	8	gly	N-glycosylation	788:802	arg2	LRG1					770:773	LRG1	770:773	LRG1	770:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	4	8	gly	N-glycosylation	788:802	arg2	sites					804:808	its four N-glycosylation sites	779:808	its four N-glycosylation sites	779:808	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	4	8	gly	N-glycosylation	788:802	arg1	LRG1					770:773	LRG1	770:773	LRG1	770:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	4	8	gly	N-glycosylation	788:802	arg2	four					783:786	four	783:786	four	783:786	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	2	9	contain	have	343:346	arg1	LRG1					338:341	neutrophil-derived LRG1	319:341	neutrophil-derived LRG1	319:341	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	2	9	contain	have	343:346	arg2	weights					368:374	different molecular weights	348:374	different molecular weights due to differences in glycosylation	348:410	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	2	9	contain	have	343:346	arg1	LRG1					310:313	Serum LRG1	304:313	Serum LRG1	304:313	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	5	10	from	removal	926:932	arg1	N325					948:951	N325	948:951	N325	948:951	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	6	11	from	model	1240:1244	arg1	administration					1182:1195	the intracavernous administration	1163:1195	the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model	1163:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	1	12	theme	various	253:259	arg1	cascades					271:278	various signaling cascades	253:278	various signaling cascades	253:278	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	0	13	theme	LPHN2	77:81	arg1	activation					83:92	LPHN2 activation	77:92	LPHN2 activation	77:92	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	5	14	theme	high-affinity	974:986	arg1	binding					988:994	the high-affinity binding	970:994	the high-affinity binding of LRG1 to LPHN2	970:1011	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	4	15	theme	LRG1	711:714	arg1	structure					698:706	the crystal structure	686:706	the crystal structure of LRG1	686:714	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	6	16	from	LRG1	1215:1218	arg1	model					1240:1244	a diabetic mouse model	1223:1244	a diabetic mouse model	1223:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	1	17	theme	signaling	261:269	arg1	cascades					271:278	various signaling cascades	253:278	various signaling cascades	253:278	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	2	18	from	composition	455:465	arg1	LRG1					470:473	LRG1	470:473	LRG1	470:473	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	7	19	theme	cellular	1449:1456	arg1	functions					1458:1466	LRG1's cellular functions	1442:1466	LRG1's cellular functions	1442:1466	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	4	20	theme	N-glycosylation	788:802	arg1	sites					804:808	its four N-glycosylation sites	779:808	its four N-glycosylation sites	779:808	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	4	20	theme	N-glycosylation	788:802	arg1	LRG1					770:773	LRG1	770:773	LRG1	770:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	7	21	theme	LRG1	1380:1383	arg1	glycans					1385:1391	LRG1 glycans	1380:1391	LRG1 glycans	1380:1391	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	2	22	theme	composition	455:465	arg1	unknown					511:517	unknown	511:517	unknown	511:517	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	2	22	theme	composition	455:465	arg1	impact					421:426	the impact	417:426	the impact of the differential glycan composition in LRG1 on its cellular function	417:498	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	5	23	theme	normal	1126:1131	arg1	conditions					1141:1150	normal glucose conditions	1126:1150	normal glucose conditions	1126:1150	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	6	24	theme	erectile	1311:1318	arg1	function					1320:1327	erectile function	1311:1327	erectile function	1311:1327	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	2	25	theme	differential	435:446	arg1	composition					455:465	the differential glycan composition	431:465	the differential glycan composition in LRG1	431:473	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	7	26	theme	signaling	1497:1505	arg1	axis					1507:1510	the LRG1/LPHN2 signaling axis	1482:1510	the LRG1/LPHN2 signaling axis	1482:1510	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	7	27	theme	glycans	1385:1391	arg1	role					1372:1375	a novel role	1364:1375	a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis	1364:1510	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	2	28	theme	glycan	448:453	arg1	composition					455:465	the differential glycan composition	431:465	the differential glycan composition in LRG1	431:473	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	2	29	from	LRG1	470:473	arg1	unknown					511:517	unknown	511:517	unknown	511:517	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	2	29	from	LRG1	470:473	arg1	impact					421:426	the impact	417:426	the impact of the differential glycan composition in LRG1 on its cellular function	417:498	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	5	30	from	N325	948:951	arg1	removal					926:932	particularly the removal	909:932	particularly the removal of glycans on N325	909:951	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	30	from	N325	948:951	arg1	LRG1					903:906	LRG1	903:906	LRG1	903:906	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	0	31	theme	Crystal	0:6	arg1	structure					8:16	Crystal structure	0:16	Crystal structure of LRG1	0:24	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	6	32	theme	mouse	1234:1238	arg1	model					1240:1244	a diabetic mouse model	1223:1244	a diabetic mouse model	1223:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	2	33	theme	Serum	304:308	arg1	LRG1					310:313	Serum LRG1	304:313	Serum LRG1	304:313	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	5	34	theme	LRG1	903:906	arg1	critical					957:964	critical	957:964	critical	957:964	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	34	theme	LRG1	903:906	arg1	deglycosylation					884:898	the deglycosylation	880:898	the deglycosylation of LRG1, particularly the removal of glycans on N325,	880:952	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	0	35	theme	LRG1	21:24	arg1	structure					8:16	Crystal structure	0:16	Crystal structure of LRG1	0:24	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	0	35	theme	LRG1	21:24	arg1	significance					45:56	the functional significance	30:56	the functional significance of LRG1 glycan for LPHN2 activation	30:92	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	4	36	theme	solenoid	748:755	arg1	structure					757:765	the horseshoe-like solenoid structure	729:765	the horseshoe-like solenoid structure of LRG1	729:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	1	37	gly	glycoprotein	105:116	arg1	glycoprotein					105:116	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1	95:148	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1)	95:155	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	5	38	theme	angiogenic	1051:1060	arg1	processes					1079:1087	LRG1/LPHN2-mediated angiogenic and neurotrophic processes	1031:1087	LRG1/LPHN2-mediated angiogenic and neurotrophic processes	1031:1087	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	4	39	theme	LRG1	770:773	arg1	sites					804:808	its four N-glycosylation sites	779:808	its four N-glycosylation sites	779:808	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	4	39	theme	LRG1	770:773	arg1	LRG1					770:773	LRG1	770:773	LRG1	770:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	4	39	theme	LRG1	770:773	arg1	structure					757:765	the horseshoe-like solenoid structure	729:765	the horseshoe-like solenoid structure of LRG1	729:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	5	40	theme	cell-biological	844:858	arg1	analyses					860:867	our biochemical and cell-biological analyses	824:867	our biochemical and cell-biological analyses	824:867	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	3	41	theme	angiogenic	570:579	arg1	processes					598:606	both angiogenic and neurotrophic processes	565:606	both angiogenic and neurotrophic processes	565:606	We previously reported that LRG1 can promote both angiogenic and neurotrophic processes under hyperglycemic conditions by interacting with LPHN2.
37121976	6	42	theme	LRG1	1215:1218	arg1	administration					1182:1195	the intracavernous administration	1163:1195	the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model	1163:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	5	43	theme	mouse	1092:1096	arg1	explants					1105:1112	mouse tissue explants	1092:1112	mouse tissue explants	1092:1112	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	7	44	theme	novel	1366:1370	arg1	role					1372:1375	a novel role	1364:1375	a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis	1364:1510	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	5	45	theme	glycans	937:943	arg1	removal					926:932	particularly the removal	909:932	particularly the removal of glycans on N325	909:951	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	45	theme	glycans	937:943	arg1	LRG1					903:906	LRG1	903:906	LRG1	903:906	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	1	46	gly	ɑ-2-glycoprotein	131:146	arg1	ɑ-2-glycoprotein					131:146	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1	95:148	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1)	95:155	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	46	gly	ɑ-2-glycoprotein	131:146	arg1	LRG1					151:154	LRG1	151:154	LRG1	151:154	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	46	gly	ɑ-2-glycoprotein	131:146	arg1	protein					230:236	a multifunctional protein	212:236	a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling	212:301	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	5	47	theme	tissue	1098:1103	arg1	explants					1105:1112	mouse tissue explants	1092:1112	mouse tissue explants	1092:1112	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	6	48	from	administration	1182:1195	arg1	model					1240:1244	a diabetic mouse model	1223:1244	a diabetic mouse model	1223:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	5	49	theme	biochemical	828:838	arg1	analyses					860:867	our biochemical and cell-biological analyses	824:867	our biochemical and cell-biological analyses	824:867	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	2	50	from	differences	383:393	arg1	glycosylation					398:410	glycosylation	398:410	glycosylation	398:410	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	6	51	gly	deglycosylated	1200:1213	arg1	LRG1					1215:1218	deglycosylated LRG1	1200:1218	deglycosylated LRG1 in a diabetic mouse model	1200:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	5	52	theme	LRG1/LPHN2-mediated	1031:1049	arg1	processes					1079:1087	LRG1/LPHN2-mediated angiogenic and neurotrophic processes	1031:1087	LRG1/LPHN2-mediated angiogenic and neurotrophic processes	1031:1087	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	7	53	theme	LRG1/LPHN2	1486:1495	arg1	axis					1507:1510	the LRG1/LPHN2 signaling axis	1482:1510	the LRG1/LPHN2 signaling axis	1482:1510	Collectively, these data indicate a novel role of LRG1 glycans as molecular switches that can tune the range of LRG1's cellular functions, particularly the LRG1/LPHN2 signaling axis.
37121976	1	54	theme	serum	99:103	arg1	ɑ-2-glycoprotein					131:146	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1	95:148	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1)	95:155	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	54	theme	serum	99:103	arg1	LRG1					151:154	LRG1	151:154	LRG1	151:154	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	54	theme	serum	99:103	arg1	protein					230:236	a multifunctional protein	212:236	a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling	212:301	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	0	55	theme	functional	34:43	arg1	significance					45:56	the functional significance	30:56	the functional significance of LRG1 glycan for LPHN2 activation	30:92	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	3	56	theme	neurotrophic	585:596	arg1	processes					598:606	both angiogenic and neurotrophic processes	565:606	both angiogenic and neurotrophic processes	565:606	We previously reported that LRG1 can promote both angiogenic and neurotrophic processes under hyperglycemic conditions by interacting with LPHN2.
37121976	1	57	theme	glycoprotein	105:116	arg1	ɑ-2-glycoprotein					131:146	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1	95:148	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1)	95:155	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	57	theme	glycoprotein	105:116	arg1	LRG1					151:154	LRG1	151:154	LRG1	151:154	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	57	theme	glycoprotein	105:116	arg1	protein					230:236	a multifunctional protein	212:236	a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling	212:301	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	6	58	theme	vascular	1258:1265	arg1	abnormalities					1284:1296	vascular and neurological abnormalities	1258:1296	vascular and neurological abnormalities	1258:1296	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	5	59	from	glycans	937:943	arg1	N325					948:951	N325	948:951	N325	948:951	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	60	theme	neurotrophic	1066:1077	arg1	processes					1079:1087	LRG1/LPHN2-mediated angiogenic and neurotrophic processes	1031:1087	LRG1/LPHN2-mediated angiogenic and neurotrophic processes	1031:1087	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	5	61	theme	LRG1	999:1002	arg1	binding					988:994	the high-affinity binding	970:994	the high-affinity binding of LRG1 to LPHN2	970:1011	In addition, our biochemical and cell-biological analyses found that the deglycosylation of LRG1, particularly the removal of glycans on N325, is critical for the high-affinity binding of LRG1 to LPHN2 and thus promotes LRG1/LPHN2-mediated angiogenic and neurotrophic processes in mouse tissue explants, even under normal glucose conditions.
37121976	6	62	theme	neurological	1271:1282	arg1	abnormalities					1284:1296	vascular and neurological abnormalities	1258:1296	vascular and neurological abnormalities	1258:1296	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	1	63	theme	leucine-rich	118:129	arg1	ɑ-2-glycoprotein					131:146	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1	95:148	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1)	95:155	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	63	theme	leucine-rich	118:129	arg1	LRG1					151:154	LRG1	151:154	LRG1	151:154	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	63	theme	leucine-rich	118:129	arg1	protein					230:236	a multifunctional protein	212:236	a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling	212:301	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	6	64	theme	intracavernous	1167:1180	arg1	administration					1182:1195	the intracavernous administration	1163:1195	the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model	1163:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	6	65	theme	deglycosylated	1200:1213	arg1	LRG1					1215:1218	deglycosylated LRG1	1200:1218	deglycosylated LRG1 in a diabetic mouse model	1200:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	4	66	theme	horseshoe-like	733:746	arg1	structure					757:765	the horseshoe-like solenoid structure	729:765	the horseshoe-like solenoid structure of LRG1	729:773	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
37121976	2	67	theme	neutrophil-derived	319:336	arg1	LRG1					338:341	neutrophil-derived LRG1	319:341	neutrophil-derived LRG1	319:341	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	0	68	theme	LRG1	61:64	arg1	glycan					66:71	LRG1 glycan	61:71	LRG1 glycan	61:71	Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.
37121976	3	69	theme	hyperglycemic	614:626	arg1	conditions					628:637	hyperglycemic conditions	614:637	hyperglycemic conditions	614:637	We previously reported that LRG1 can promote both angiogenic and neurotrophic processes under hyperglycemic conditions by interacting with LPHN2.
37121976	2	70	theme	due	376:378	arg1	weights					368:374	different molecular weights	348:374	different molecular weights due to differences in glycosylation	348:410	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	1	71	theme	multifunctional	214:228	arg1	protein					230:236	a multifunctional protein	212:236	a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling	212:301	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	1	71	theme	multifunctional	214:228	arg1	ɑ-2-glycoprotein					131:146	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1	95:148	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1)	95:155	The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1), primarily produced by hepatocytes and neutrophils, is a multifunctional protein that modulates various signaling cascades, mainly TGFβ signaling.
37121976	2	72	link	neutrophil-derived	319:336	arg1	LRG1					338:341	neutrophil-derived LRG1	319:341	neutrophil-derived LRG1	319:341	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	6	73	theme	diabetic	1225:1232	arg1	model					1240:1244	a diabetic mouse model	1223:1244	a diabetic mouse model	1223:1244	Moreover, the intracavernous administration of deglycosylated LRG1 in a diabetic mouse model ameliorated vascular and neurological abnormalities and restored erectile function.
37121976	2	74	from	impact	421:426	arg1	function					491:498	its cellular function	478:498	its cellular function	478:498	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	2	74	from	impact	421:426	arg1	LRG1					470:473	LRG1	470:473	LRG1	470:473	Serum LRG1 and neutrophil-derived LRG1 have different molecular weights due to differences in glycosylation, but the impact of the differential glycan composition in LRG1 on its cellular function is largely unknown.
37121976	4	75	theme	crystal	690:696	arg1	structure					698:706	the crystal structure	686:706	the crystal structure of LRG1	686:714	Here, we determined the crystal structure of LRG1, identifying the horseshoe-like solenoid structure of LRG1 and its four N-glycosylation sites.
35065273	10	0	theme	IgG	1663:1665	arg1	binding					1667:1673	IgG binding	1663:1673	IgG binding to the parasite glycans	1663:1697	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	6	1	link	N-linked	900:907	arg1	glycans					909:915	N-linked glycans	900:915	N-linked glycans	900:915	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	8	2	theme	several	1254:1260	arg1	motifs					1281:1286	several putative antigenic motifs	1254:1286	several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid	1254:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	2	theme	several	1254:1260	arg1	phosphorylcholine					1296:1312	phosphorylcholine	1296:1312	phosphorylcholine	1296:1312	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	2	theme	several	1254:1260	arg1	acid					1338:1341	terminal glucuronic acid	1318:1341	terminal glucuronic acid	1318:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	3	theme	antigenic	1271:1279	arg1	motifs					1281:1286	several putative antigenic motifs	1254:1286	several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid	1254:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	3	theme	antigenic	1271:1279	arg1	phosphorylcholine					1296:1312	phosphorylcholine	1296:1312	phosphorylcholine	1296:1312	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	3	theme	antigenic	1271:1279	arg1	acid					1338:1341	terminal glucuronic acid	1318:1341	terminal glucuronic acid	1318:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	6	4	theme	enzymatic	963:971	arg1	release					973:979	enzymatic release	963:979	enzymatic release	963:979	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	10	5	theme	parasite	1682:1689	arg1	glycans					1691:1697	the parasite glycans	1678:1697	the parasite glycans	1678:1697	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	0	6	theme	Mass	0:3	arg1	Spectrometric					5:17	Mass Spectrometric	0:17	Mass Spectrometric	0:17	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	9	7	theme	immunoglobulin	1569:1582	arg1	G					1584:1584	anti-glycan immunoglobulin G	1557:1584	anti-glycan immunoglobulin G	1557:1584	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	10	8	theme	infected	1720:1727	arg1	plasma					1735:1740	infected human plasma	1720:1740	infected human plasma	1720:1740	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	1	9	theme	filarial	208:215	arg1	nematodes					217:225	filarial nematodes	208:225	filarial nematodes	208:225	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	6	10	theme	techniques	1057:1066	arg1	combination					1007:1017	a combination	1005:1017	a combination of MALDI-TOF-MS and glycan sequencing techniques	1005:1066	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	2	11	from	rate	387:390	arg1	areas					416:420	certain areas	408:420	certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	408:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	7	12	theme	anti-glycan	1153:1163	arg1	response					1174:1181	the host anti-glycan antibody response	1144:1181	the host anti-glycan antibody response	1144:1181	Next, glycans were purified by HPLC and printed onto microarrays to assess the host anti-glycan antibody response.
35065273	2	13	theme	Elimination	318:328	arg1	programs					330:337	Elimination programs	318:337	Elimination programs	318:337	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	4	14	from	role	664:667	arg1	interactions					686:697	host-parasite interactions	672:697	host-parasite interactions	672:697	However, despite its crucial role in host-parasite interactions, filarial glycosylation is still largely, structurally, and functionally uncharacterized.
35065273	8	15	theme	terminal	1318:1325	arg1	acid					1338:1341	terminal glucuronic acid	1318:1341	terminal glucuronic acid	1318:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	6	16	theme	glycan	1039:1044	arg1	techniques					1057:1066	glycan sequencing techniques	1039:1066	glycan sequencing techniques	1039:1066	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	4	17	theme	host-parasite	672:684	arg1	interactions					686:697	host-parasite interactions	672:697	host-parasite interactions	672:697	However, despite its crucial role in host-parasite interactions, filarial glycosylation is still largely, structurally, and functionally uncharacterized.
35065273	9	18	theme	microarray	1351:1360	arg1	screening					1362:1370	Glycan microarray screening	1344:1370	Glycan microarray screening	1344:1370	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	5	19	theme	malayi	870:875	arg1	repertoire					827:836	the glycan repertoire	816:836	the glycan repertoire of the filarial nematode Brugia malayi	816:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	5	19	theme	malayi	870:875	arg1	malayi					870:875	the filarial nematode Brugia malayi	841:875	the filarial nematode Brugia malayi	841:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	6	20	theme	MALDI-TOF-MS	1022:1033	arg1	combination					1007:1017	a combination	1005:1017	a combination of MALDI-TOF-MS and glycan sequencing techniques	1005:1066	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	3	21	theme	diagnostic	616:625	arg1	assays					627:632	diagnostic assays	616:632	diagnostic assays	616:632	Glycans from parasitic helminths are emerging as potential antigens for use in diagnostic assays.
35065273	9	22	theme	brugian	1620:1626	arg1	filariasis					1628:1637	brugian filariasis	1620:1637	brugian filariasis	1620:1637	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	3	23	from	use	609:611	arg1	assays					627:632	diagnostic assays	616:632	diagnostic assays	616:632	Glycans from parasitic helminths are emerging as potential antigens for use in diagnostic assays.
35065273	1	24	theme	other	274:278	arg1	diseases					280:287	other diseases	274:287	other diseases causing chronic disablement	274:315	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	9	25	theme	most	1396:1399	arg1	glycans					1411:1417	most B. malayi glycans	1396:1417	most B. malayi glycans	1396:1417	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	0	26	theme	Brugia	89:94	arg1	malayi					96:101	the Filarial Nematode Brugia malayi Glycome	67:109	the Filarial Nematode Brugia malayi Glycome	67:109	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	1	27	theme	worldwide	180:188	arg1	Millions					161:168	Millions	161:168	Millions of people worldwide	161:188	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	0	28	theme	Anionic	119:125	arg1	Antigens					151:158	Anionic and Zwitterionic Glycan Antigens	119:158	Anionic and Zwitterionic Glycan Antigens	119:158	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	5	29	theme	Brugia	863:868	arg1	malayi					870:875	the filarial nematode Brugia malayi	841:875	the filarial nematode Brugia malayi	841:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	2	30	theme	diagnostic	451:460	arg1	tools					462:466	improved diagnostic tools	442:466	improved diagnostic tools	442:466	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	9	31	theme	different	1462:1470	arg1	points					1477:1482	different time points	1462:1482	different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis	1462:1637	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	6	32	theme	several	937:943	arg1	life-stages					945:955	several life-stages	937:955	several life-stages using enzymatic release	937:979	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	10	33	theme	anthelmintic	1788:1799	arg1	treatment					1801:1809	anthelmintic treatment	1788:1809	anthelmintic treatment	1788:1809	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	0	34	theme	Microarray-Based	30:45	arg1	Characterization					47:62	Glycan Microarray-Based Characterization	23:62	Glycan Microarray-Based Characterization	23:62	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	2	35	theme	robust	481:486	arg1	surveillance					499:510	robust population surveillance	481:510	robust population surveillance	481:510	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	0	36	theme	Filarial	71:78	arg1	malayi					96:101	the Filarial Nematode Brugia malayi Glycome	67:109	the Filarial Nematode Brugia malayi Glycome	67:109	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	5	37	theme	filarial	845:852	arg1	malayi					870:875	the filarial nematode Brugia malayi	841:875	the filarial nematode Brugia malayi	841:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	8	38	theme	glycomic	1198:1205	arg1	analysis					1207:1214	Comprehensive glycomic analysis	1184:1214	Comprehensive glycomic analysis of B. malayi	1184:1227	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	2	39	from	areas	416:420	arg1	reduction					370:378	a substantial reduction	356:378	a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	356:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	10	40	theme	significant	1642:1652	arg1	level					1654:1658	A significant level	1640:1658	A significant level of IgG binding to the parasite glycans	1640:1697	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	11	41	theme	glycan	1854:1859	arg1	antigens					1861:1868	B. malayi glycan antigens	1844:1868	B. malayi glycan antigens	1844:1868	Altogether, our work identifies B. malayi glycan antigens and reveals antibody responses from the host that could be exploited as potential markers for LF.
35065273	1	42	theme	lymphatic	244:252	arg1	LF					266:267	LF	266:267	LF	266:267	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	1	42	theme	lymphatic	244:252	arg1	filariasis					254:263	lymphatic filariasis	244:263	lymphatic filariasis (LF)	244:268	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	11	43	theme	B.	1844:1845	arg1	antigens					1861:1868	B. malayi glycan antigens	1844:1868	B. malayi glycan antigens	1844:1868	Altogether, our work identifies B. malayi glycan antigens and reveals antibody responses from the host that could be exploited as potential markers for LF.
35065273	10	44	located	detected	1708:1715	arg2	level					1654:1658	A significant level	1640:1658	A significant level of IgG binding to the parasite glycans	1640:1697	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	10	44	located	detected	1708:1715	arg1	plasma					1735:1740	infected human plasma	1720:1740	infected human plasma	1720:1740	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	10	45	theme	binding	1667:1673	arg1	level					1654:1658	A significant level	1640:1658	A significant level of IgG binding to the parasite glycans	1640:1697	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	9	46	theme	dynamics	1545:1552	arg1	characterization					1521:1536	the characterization	1517:1536	the characterization of the dynamics of anti-glycan immunoglobulin G and M	1517:1590	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	2	47	from	reduction	370:378	arg1	areas					416:420	certain areas	408:420	certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	408:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	9	48	theme	anti-glycan	1557:1567	arg1	G					1584:1584	anti-glycan immunoglobulin G	1557:1584	anti-glycan immunoglobulin G	1557:1584	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	8	49	theme	putative	1262:1269	arg1	motifs					1281:1286	several putative antigenic motifs	1254:1286	several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid	1254:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	49	theme	putative	1262:1269	arg1	phosphorylcholine					1296:1312	phosphorylcholine	1296:1312	phosphorylcholine	1296:1312	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	8	49	theme	putative	1262:1269	arg1	acid					1338:1341	terminal glucuronic acid	1318:1341	terminal glucuronic acid	1318:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	10	50	theme	human	1729:1733	arg1	plasma					1735:1740	infected human plasma	1720:1740	infected human plasma	1720:1740	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	5	51	theme	glycan	820:825	arg1	repertoire					827:836	the glycan repertoire	816:836	the glycan repertoire of the filarial nematode Brugia malayi	816:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	5	51	theme	glycan	820:825	arg1	malayi					870:875	the filarial nematode Brugia malayi	841:875	the filarial nematode Brugia malayi	841:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	7	52	theme	antibody	1165:1172	arg1	response					1174:1181	the host anti-glycan antibody response	1144:1181	the host anti-glycan antibody response	1144:1181	Next, glycans were purified by HPLC and printed onto microarrays to assess the host anti-glycan antibody response.
35065273	9	53	theme	G	1584:1584	arg1	dynamics					1545:1552	the dynamics	1541:1552	the dynamics of anti-glycan immunoglobulin G and M	1541:1590	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	8	54	theme	motifs	1281:1286	arg1	presence					1242:1249	the presence	1238:1249	the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid	1238:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	4	55	theme	filarial	700:707	arg1	glycosylation					709:721	filarial glycosylation	700:721	filarial glycosylation	700:721	However, despite its crucial role in host-parasite interactions, filarial glycosylation is still largely, structurally, and functionally uncharacterized.
35065273	0	56	theme	Glycan	144:149	arg1	Antigens					151:158	Anionic and Zwitterionic Glycan Antigens	119:158	Anionic and Zwitterionic Glycan Antigens	119:158	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	3	57	theme	potential	586:594	arg1	antigens					596:603	potential antigens	586:603	potential antigens for use in diagnostic assays	586:632	Glycans from parasitic helminths are emerging as potential antigens for use in diagnostic assays.
35065273	9	58	theme	M	1590:1590	arg1	dynamics					1545:1552	the dynamics	1541:1552	the dynamics of anti-glycan immunoglobulin G and M	1541:1590	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	6	59	theme	sequencing	1046:1055	arg1	techniques					1057:1066	glycan sequencing techniques	1039:1066	glycan sequencing techniques	1039:1066	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	4	60	theme	crucial	656:662	arg1	role					664:667	its crucial role	652:667	its crucial role in host-parasite interactions	652:697	However, despite its crucial role in host-parasite interactions, filarial glycosylation is still largely, structurally, and functionally uncharacterized.
35065273	10	61	theme	IgG	1749:1751	arg1	binding					1753:1759	IgG binding	1749:1759	IgG binding to glycans	1749:1770	A significant level of IgG binding to the parasite glycans was also detected in infected human plasma, while IgG binding to glycans decreased after anthelmintic treatment.
35065273	9	62	theme	Glycan	1344:1349	arg1	screening					1362:1370	Glycan microarray screening	1344:1370	Glycan microarray screening	1344:1370	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	1	63	theme	responsible	228:238	arg1	nematodes					217:225	filarial nematodes	208:225	filarial nematodes	208:225	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	8	64	theme	glucuronic	1327:1336	arg1	acid					1338:1341	terminal glucuronic acid	1318:1341	terminal glucuronic acid	1318:1341	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	7	65	theme	host	1148:1151	arg1	response					1174:1181	the host anti-glycan antibody response	1144:1181	the host anti-glycan antibody response	1144:1181	Next, glycans were purified by HPLC and printed onto microarrays to assess the host anti-glycan antibody response.
35065273	11	66	theme	potential	1942:1950	arg1	markers					1952:1958	potential markers	1942:1958	potential markers for LF	1942:1965	Altogether, our work identifies B. malayi glycan antigens and reveals antibody responses from the host that could be exploited as potential markers for LF.
35065273	11	66	theme	potential	1942:1950	arg1	host					1910:1913	the host	1906:1913	the host that could be exploited as potential markers for LF	1906:1965	Altogether, our work identifies B. malayi glycan antigens and reveals antibody responses from the host that could be exploited as potential markers for LF.
35065273	9	67	theme	filariasis	1628:1637	arg1	establishment					1603:1615	the establishment	1599:1615	the establishment of brugian filariasis	1599:1637	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	11	68	theme	antibody	1882:1889	arg1	responses					1891:1899	antibody responses	1882:1899	antibody responses	1882:1899	Altogether, our work identifies B. malayi glycan antigens and reveals antibody responses from the host that could be exploited as potential markers for LF.
35065273	0	69	theme	Nematode	80:87	arg1	malayi					96:101	the Filarial Nematode Brugia malayi Glycome	67:109	the Filarial Nematode Brugia malayi Glycome	67:109	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	2	70	theme	LF	522:523	arg1	resurgence					525:534	LF resurgence	522:534	LF resurgence	522:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	3	71	from	helminths	560:568	arg1	Glycans					537:543	Glycans	537:543	Glycans from parasitic helminths	537:568	Glycans from parasitic helminths are emerging as potential antigens for use in diagnostic assays.
35065273	0	72	theme	malayi	96:101	arg1	Characterization					47:62	Glycan Microarray-Based Characterization	23:62	Glycan Microarray-Based Characterization	23:62	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	0	72	theme	malayi	96:101	arg1	Spectrometric					5:17	Mass Spectrometric	0:17	Mass Spectrometric	0:17	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	9	73	theme	B.	1401:1402	arg1	glycans					1411:1417	most B. malayi glycans	1396:1417	most B. malayi glycans	1396:1417	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	1	74	theme	people	173:178	arg1	worldwide					180:188	people worldwide	173:188	people worldwide	173:188	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	0	75	theme	Zwitterionic	131:142	arg1	Antigens					151:158	Anionic and Zwitterionic Glycan Antigens	119:158	Anionic and Zwitterionic Glycan Antigens	119:158	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	9	76	theme	glycans	1411:1417	arg1	recognition					1381:1391	a recognition	1379:1391	a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques	1379:1457	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	2	77	theme	certain	408:414	arg1	areas					416:420	certain areas	408:420	certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	408:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	5	78	theme	nematode	854:861	arg1	malayi					870:875	the filarial nematode Brugia malayi	841:875	the filarial nematode Brugia malayi	841:875	Therefore, we investigated the glycan repertoire of the filarial nematode Brugia malayi.
35065273	9	79	theme	rhesus	1443:1448	arg1	macaques					1450:1457	rhesus macaques	1443:1457	rhesus macaques	1443:1457	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	9	80	from	macaques	1450:1457	arg1	immunoglobulins					1422:1436	immunoglobulins	1422:1436	immunoglobulins from rhesus macaques	1422:1457	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	0	81	dep	malayi	96:101	arg1	Glycome					103:109	Glycome	103:109	the Filarial Nematode Brugia malayi Glycome	67:109	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	2	82	theme	infection	395:403	arg1	rate					387:390	the rate	383:390	the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	383:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	0	83	theme	Glycan	23:28	arg1	Characterization					47:62	Glycan Microarray-Based Characterization	23:62	Glycan Microarray-Based Characterization	23:62	Mass Spectrometric and Glycan Microarray-Based Characterization of the Filarial Nematode Brugia malayi Glycome Reveals Anionic and Zwitterionic Glycan Antigens.
35065273	1	84	theme	chronic	297:303	arg1	disablement					305:315	chronic disablement	297:315	chronic disablement	297:315	Millions of people worldwide are infected with filarial nematodes, responsible for lymphatic filariasis (LF) and other diseases causing chronic disablement.
35065273	2	85	theme	improved	442:449	arg1	tools					462:466	improved diagnostic tools	442:466	improved diagnostic tools	442:466	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	9	86	theme	time	1472:1475	arg1	points					1477:1482	different time points	1462:1482	different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis	1462:1637	Glycan microarray screening showed a recognition of most B. malayi glycans by immunoglobulins from rhesus macaques at different time points after infection, which permitted the characterization of the dynamics of anti-glycan immunoglobulin G and M during the establishment of brugian filariasis.
35065273	8	87	theme	Comprehensive	1184:1196	arg1	analysis					1207:1214	Comprehensive glycomic analysis	1184:1214	Comprehensive glycomic analysis of B. malayi	1184:1227	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	2	88	theme	population	488:497	arg1	surveillance					499:510	robust population surveillance	481:510	robust population surveillance	481:510	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	2	89	theme	substantial	358:368	arg1	reduction					370:378	a substantial reduction	356:378	a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	356:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	8	90	theme	B.	1219:1220	arg1	analysis					1207:1214	Comprehensive glycomic analysis	1184:1214	Comprehensive glycomic analysis of B. malayi	1184:1227	Comprehensive glycomic analysis of B. malayi revealed the presence of several putative antigenic motifs such as phosphorylcholine and terminal glucuronic acid.
35065273	6	91	theme	N-linked	900:907	arg1	glycans					909:915	N-linked glycans	900:915	N-linked glycans	900:915	Glycosphingolipid and N-linked glycans were extracted from several life-stages using enzymatic release and characterized using a combination of MALDI-TOF-MS and glycan sequencing techniques.
35065273	2	92	theme	rate	387:390	arg1	reduction					370:378	a substantial reduction	356:378	a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence	356:534	Elimination programs have resulted in a substantial reduction of the rate of infection in certain areas creating a need for improved diagnostic tools to establish robust population surveillance and avoid LF resurgence.
35065273	3	93	theme	parasitic	550:558	arg1	helminths					560:568	parasitic helminths	550:568	parasitic helminths	550:568	Glycans from parasitic helminths are emerging as potential antigens for use in diagnostic assays.
35871894	5	0	theme	physicochemical	615:629	arg1	properties					646:655	the physicochemical and biological properties	611:655	the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition	611:799	Glycosylation dictates the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition.
35871894	4	1	theme	structural	479:488	arg1	properties					490:499	structural properties	479:499	structural properties of proteins that could not be analyzed otherwise, such as the impact of glycosylation	479:585	This enables to elucidate structural properties of proteins that could not be analyzed otherwise, such as the impact of glycosylation.
35871894	6	2	theme	compositional	836:848	arg1	diversity					850:858	the high conformational and compositional diversity	808:858	the high conformational and compositional diversity of the glycan chains	808:879	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	3	3	dep	tools	345:349	arg1	perform					354:360	perform	354:360	to perform molecular simulations	351:382	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	7	4	attach	present	1013:1019	arg2	we					1010:1011	we	1010:1011	we	1010:1011	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	7	4	attach	present	1013:1019	arg1	manuscript					998:1007	this manuscript	993:1007	this manuscript	993:1007	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	7	5	from	impact	1160:1165	arg1	stabilization					1191:1203	structure stabilization	1181:1203	structure stabilization	1181:1203	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	7	5	from	impact	1160:1165	arg1	occlusion					1218:1226	antibody occlusion	1209:1226	antibody occlusion	1209:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	7	6	theme	SPIKE	1111:1115	arg1	glycoprotein					1117:1128	the SPIKE glycoprotein	1107:1128	the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1107:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	7	7	theme	structure	1181:1189	arg1	stabilization					1191:1203	structure stabilization	1181:1203	structure stabilization	1181:1203	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	3	8	theme	molecular	362:370	arg1	simulations					372:382	molecular simulations	362:382	molecular simulations	362:382	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	6	9	theme	chains	874:879	arg1	diversity					850:858	the high conformational and compositional diversity	808:858	the high conformational and compositional diversity of the glycan chains	808:879	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	5	10	theme	enzymatic	757:765	arg1	activity					767:774	enzymatic activity	757:774	enzymatic activity	757:774	Glycosylation dictates the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition.
35871894	1	11	theme	Molecular	84:92	arg1	method					113:118	a method	111:118	a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science	111:218	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	1	11	theme	Molecular	84:92	arg1	MD					104:105	MD	104:105	MD	104:105	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	1	11	theme	Molecular	84:92	arg1	Dynamics					94:101	Molecular Dynamics	84:101	Molecular Dynamics (MD)	84:106	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	1	12	theme	atoms	154:158	arg1	movement					142:149	the movement	138:149	the movement of atoms and molecules	138:172	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	0	13	theme	molecular	13:21	arg1	dynamics					23:30	Glycoprotein molecular dynamics	0:30	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	6	14	theme	glycan	867:872	arg1	chains					874:879	the glycan chains	863:879	the glycan chains	863:879	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	7	15	theme	glycans	1170:1176	arg1	impact					1160:1165	the impact	1156:1165	the impact of glycans in structure stabilization and antibody occlusion	1156:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	7	16	gly	glycoproteins	1081:1093	arg1	glycoproteins					1081:1093	glycoproteins	1081:1093	glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1081:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	0	17	theme	Glycoprotein	0:11	arg1	dynamics					23:30	Glycoprotein molecular dynamics	0:30	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	6	18	theme	protein	915:921	arg1	structure					923:931	the protein structure	911:931	the protein structure	911:931	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	2	19	theme	first	278:282	arg1	glance					284:289	first glance	278:289	first glance	278:289	It involves computational simulation, which makes it, at first glance, not easily accessible.
35871894	1	20	theme	molecules	164:172	arg1	movement					142:149	the movement	138:149	the movement of atoms and molecules	138:172	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	3	21	theme	several	327:333	arg1	tools					345:349	several automated tools	327:349	several automated tools to perform molecular simulations	327:382	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	6	22	theme	analytical	967:976	arg1	techniques					978:987	conventional analytical techniques	954:987	conventional analytical techniques	954:987	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	7	23	theme	MD	1066:1067	arg1	analysis					1069:1076	MD analysis	1066:1076	MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1066:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	3	24	theme	various	432:438	arg1	steps					440:444	the various steps	428:444	the various steps of MD	428:450	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	3	25	theme	automated	335:343	arg1	tools					345:349	several automated tools	327:349	several automated tools to perform molecular simulations	327:382	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	6	26	theme	conventional	954:965	arg1	techniques					978:987	conventional analytical techniques	954:987	conventional analytical techniques	954:987	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	7	27	gly	glycoprotein	1117:1128	arg1	glycoprotein					1117:1128	the SPIKE glycoprotein	1107:1128	the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1107:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	0	28	theme	SARS-CoV-2	42:51	arg1	study					77:81	SARS-CoV-2 spike glycoprotein case study	42:81	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	7	29	theme	SARS-CoV-2	1133:1142	arg1	glycoprotein					1117:1128	the SPIKE glycoprotein	1107:1128	the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1107:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	0	30	theme	dynamics	23:30	arg1	analysis					32:39	Glycoprotein molecular dynamics analysis	0:39	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	4	31	theme	glycosylation	573:585	arg1	impact					563:568	the impact	559:568	the impact of glycosylation	559:585	This enables to elucidate structural properties of proteins that could not be analyzed otherwise, such as the impact of glycosylation.
35871894	1	32	theme	several	193:199	arg1	aspects					201:207	several aspects	193:207	several aspects of science	193:218	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	0	33	theme	glycoprotein	59:70	arg1	study					77:81	SARS-CoV-2 spike glycoprotein case study	42:81	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	5	34	theme	interaction	735:745	arg1	partners					747:754	interaction partners	735:754	interaction partners	735:754	Glycosylation dictates the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition.
35871894	7	35	theme	step-by-step	1023:1034	arg1	workflow					1036:1043	a step-by-step workflow	1021:1043	a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1021:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	0	36	theme	spike	53:57	arg1	study					77:81	SARS-CoV-2 spike glycoprotein case study	42:81	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	5	37	theme	biological	635:644	arg1	properties					646:655	the physicochemical and biological properties	611:655	the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition	611:799	Glycosylation dictates the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition.
35871894	4	38	theme	proteins	504:511	arg1	properties					490:499	structural properties	479:499	structural properties of proteins that could not be analyzed otherwise, such as the impact of glycosylation	479:585	This enables to elucidate structural properties of proteins that could not be analyzed otherwise, such as the impact of glycosylation.
35871894	5	39	theme	protein	662:668	arg1	properties					646:655	the physicochemical and biological properties	611:655	the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition	611:799	Glycosylation dictates the physicochemical and biological properties of a protein modulating its solubility, stability, resistance to proteolysis, interaction partners, enzymatic activity, binding and recognition.
35871894	6	40	theme	conformational	817:830	arg1	diversity					850:858	the high conformational and compositional diversity	808:858	the high conformational and compositional diversity of the glycan chains	808:879	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	0	41	dep	analysis	32:39	arg1	study					77:81	SARS-CoV-2 spike glycoprotein case study	42:81	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	6	42	theme	high	812:815	arg1	diversity					850:858	the high conformational and compositional diversity	808:858	the high conformational and compositional diversity of the glycan chains	808:879	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	2	43	theme	computational	233:245	arg1	simulation					247:256	computational simulation	233:256	computational simulation	233:256	It involves computational simulation, which makes it, at first glance, not easily accessible.
35871894	3	44	theme	MD	449:450	arg1	steps					440:444	the various steps	428:444	the various steps of MD	428:450	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	7	45	theme	glycoproteins	1081:1093	arg1	analysis					1069:1076	MD analysis	1066:1076	MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion	1066:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35871894	6	46	from	influence	898:906	arg1	structure					923:931	the protein structure	911:931	the protein structure	911:931	Given the high conformational and compositional diversity of the glycan chains, assessing their influence on the protein structure is challenging using conventional analytical techniques.
35871894	1	47	theme	science	212:218	arg1	aspects					201:207	several aspects	193:207	several aspects of science	193:218	Molecular Dynamics (MD) is a method used to calculate the movement of atoms and molecules broadly applied to several aspects of science.
35871894	0	48	theme	case	72:75	arg1	study					77:81	SARS-CoV-2 spike glycoprotein case study	42:81	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	0	49	gly	glycoprotein	59:70	arg1	glycoprotein					59:70	SARS-CoV-2 spike glycoprotein case study	42:81	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.	0:82	Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study.
35871894	3	50	theme	tools	345:349	arg1	rise					319:322	The rise	315:322	The rise of several automated tools to perform molecular simulations	315:382	The rise of several automated tools to perform molecular simulations has allowed researchers to navigate through the various steps of MD.
35871894	7	51	theme	antibody	1209:1216	arg1	occlusion					1218:1226	antibody occlusion	1209:1226	antibody occlusion	1209:1226	In this manuscript, we present a step-by-step workflow to build and perform MD analysis of glycoproteins focusing on the SPIKE glycoprotein of SARS-CoV-2 to appraise the impact of glycans in structure stabilization and antibody occlusion.
35670527	0	0	theme	Matriglycan	94:104	arg1	Scaffolding					79:89	Ribitol Phosphate Scaffolding	61:89	Ribitol Phosphate Scaffolding of Matriglycan	61:104	Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
35670527	3	1	theme	glycosyltransferases	759:778	arg1	series					749:754	a series	747:754	a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE)	747:913	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	2	gly	glycosylated	716:727	arg1	product					704:710	its product	700:710	its product	700:710	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	3	dep	transferase	651:661	arg1	FKRP					664:667	FKRP	664:667	FKRP	664:667	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	3	dep	transferase	651:661	arg1	protein					686:692	fukutin-related protein	670:692	fukutin-related protein	670:692	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	4	theme	series	749:754	arg1	actions					736:742	the actions	732:742	the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE)	732:913	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	5	theme	aglycon	594:600	arg1	part					602:605	the aglycon part	590:605	the aglycon part	590:605	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	2	6	dep	Rbo5P-3GalNAcβ	400:413	arg1	N-acetyl-d-galactosamine					511:534	N-acetyl-d-galactosamine	511:534	N-acetyl-d-galactosamine	511:534	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	6	dep	Rbo5P-3GalNAcβ	400:413	arg1	d-xylose					542:549	d-xylose	542:549	d-xylose	542:549	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	6	dep	Rbo5P-3GalNAcβ	400:413	arg1	GalNAc					503:508	GalNAc	503:508	GalNAc	503:508	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	6	dep	Rbo5P-3GalNAcβ	400:413	arg1	d-ribitol-5-phosphate					480:500	d-ribitol-5-phosphate	480:500	d-ribitol-5-phosphate	480:500	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	6	dep	Rbo5P-3GalNAcβ	400:413	arg1	Xyl					537:539	Xyl	537:539	Xyl	537:539	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	3	7	theme	ribitol	633:639	arg1	transferase					651:661	ribitol phosphate transferase	633:661	ribitol phosphate transferase (FKRP, fukutin-related protein)	633:693	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	4	8	theme	alkyne-type	948:958	arg1	aglycon					960:966	an alkyne-type aglycon	945:966	an alkyne-type aglycon	945:966	Rbo5P-3GalNAcβ equipped with an alkyne-type aglycon was also active for FKRP.
35670527	5	9	theme	molecular	998:1006	arg1	information					1008:1018	The molecular information	994:1018	The molecular information obtained on FKRP	994:1035	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	3	10	theme	ribitol	789:795	arg1	xylosyltransferase					797:814	ribitol xylosyltransferase 1	789:816	ribitol xylosyltransferase 1 (RXYLT1)	789:825	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	10	theme	ribitol	789:795	arg1	RXYLT1					819:824	RXYLT1	819:824	RXYLT1	819:824	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	10	theme	ribitol	789:795	arg1	glycosyltransferases					759:778	glycosyltransferases	759:778	glycosyltransferases	759:778	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	11	from	part	602:605	arg1	substrate					619:627	a substrate	617:627	a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein)	617:693	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	11	from	part	602:605	arg1	Rbo5P-3GalNAcβ					553:566	Rbo5P-3GalNAcβ	553:566	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part	553:605	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	2	12	theme	glycan	308:313	arg1	structures					271:280	Three sequentially extended partial structures	235:280	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate	235:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	12	theme	glycan	308:313	arg1	phosphate					342:350	a tandem ribitol phosphate	325:350	a tandem ribitol phosphate	325:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	3	13	with	Rbo5P-3GalNAcβ	553:566	arg1	p-nitrophenyl					573:585	p-nitrophenyl	573:585	p-nitrophenyl	573:585	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	2	14	theme	O-mannosyl	297:306	arg1	glycan					308:313	the core M3 O-mannosyl glycan	285:313	the core M3 O-mannosyl glycan	285:313	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	3	15	theme	phosphate	641:649	arg1	transferase					651:661	ribitol phosphate transferase	633:661	ribitol phosphate transferase (FKRP, fukutin-related protein)	633:693	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	1	16	theme	functional	194:203	arg1	maturation					205:214	the functional maturation	190:214	the functional maturation of α-dystroglycan	190:232	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	0	17	theme	Chemical	0:7	arg1	Syntheses					29:37	Chemical and Chemo-Enzymatic Syntheses	0:37	Chemical and Chemo-Enzymatic Syntheses of Glycans	0:48	Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
35670527	1	18	theme	Ribitol	107:113	arg1	modifications					125:137	Ribitol phosphate modifications	107:137	Ribitol phosphate modifications to the core M3 O-mannosyl glycan	107:170	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	2	19	theme	ribitol	334:340	arg1	phosphate					342:350	a tandem ribitol phosphate	325:350	a tandem ribitol phosphate	325:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	20	dep	regio-	357:362	arg1	Rbo5P-3GalNAcβ					400:413	Rbo5P-3GalNAcβ	400:413	Rbo5P-3GalNAcβ	400:413	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	20	dep	regio-	357:362	arg1	Rbo5P					473:477	Rbo5P	473:477	Rbo5P	473:477	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	20	dep	regio-	357:362	arg1	Rbo5P-1Rbo5P-3GalNAcβ					416:436	Rbo5P-1Rbo5P-3GalNAcβ	416:436	Rbo5P-1Rbo5P-3GalNAcβ	416:436	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	5	21	theme	Rbo5P-3GalNAcβ	1051:1064	arg1	units					1094:1098	the minimal units	1082:1098	the minimal units required as the acceptor glycan for Rbo5P transfer	1082:1149	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	5	21	theme	Rbo5P-3GalNAcβ	1051:1064	arg1	precursor					1170:1178	a precursor	1168:1178	a precursor for the elongation of the core M3 O-mannosyl glycan	1168:1230	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	5	21	theme	Rbo5P-3GalNAcβ	1051:1064	arg1	derivatives					1066:1076	Rbo5P-3GalNAcβ derivatives	1051:1076	Rbo5P-3GalNAcβ derivatives	1051:1076	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	2	22	theme	tandem	327:332	arg1	phosphate					342:350	a tandem ribitol phosphate	325:350	a tandem ribitol phosphate	325:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	1	23	theme	α-dystroglycan	219:232	arg1	maturation					205:214	the functional maturation	190:214	the functional maturation of α-dystroglycan	190:232	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	0	24	theme	Glycans	42:48	arg1	Syntheses					29:37	Chemical and Chemo-Enzymatic Syntheses	0:37	Chemical and Chemo-Enzymatic Syntheses of Glycans	0:48	Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
35670527	5	25	theme	M3	1211:1212	arg1	glycan					1225:1230	the core M3 O-mannosyl glycan	1202:1230	the core M3 O-mannosyl glycan	1202:1230	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	2	26	theme	partial	263:269	arg1	structures					271:280	Three sequentially extended partial structures	235:280	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate	235:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	26	theme	partial	263:269	arg1	phosphate					342:350	a tandem ribitol phosphate	325:350	a tandem ribitol phosphate	325:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	0	27	theme	Ribitol	61:67	arg1	Scaffolding					79:89	Ribitol Phosphate Scaffolding	61:89	Ribitol Phosphate Scaffolding of Matriglycan	61:104	Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
35670527	5	28	theme	O-mannosyl	1214:1223	arg1	glycan					1225:1230	the core M3 O-mannosyl glycan	1202:1230	the core M3 O-mannosyl glycan	1202:1230	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	2	29	theme	extended	254:261	arg1	structures					271:280	Three sequentially extended partial structures	235:280	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate	235:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	2	29	theme	extended	254:261	arg1	phosphate					342:350	a tandem ribitol phosphate	325:350	a tandem ribitol phosphate	325:350	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	5	30	theme	core	1206:1209	arg1	glycan					1225:1230	the core M3 O-mannosyl glycan	1202:1230	the core M3 O-mannosyl glycan	1202:1230	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	5	31	theme	glycan	1225:1230	arg1	elongation					1188:1197	the elongation	1184:1197	the elongation of the core M3 O-mannosyl glycan	1184:1230	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	5	32	theme	acceptor	1116:1123	arg1	glycan					1125:1130	the acceptor glycan	1112:1130	the acceptor glycan	1112:1130	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	3	33	dep	like-acetyl-glucosaminyltransferase	871:905	arg1	LARGE					908:912	LARGE	908:912	LARGE	908:912	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	2	34	theme	M3	294:295	arg1	glycan					308:313	the core M3 O-mannosyl glycan	285:313	the core M3 O-mannosyl glycan	285:313	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	3	35	theme	fukutin-related	670:684	arg1	FKRP					664:667	FKRP	664:667	FKRP	664:667	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	3	35	theme	fukutin-related	670:684	arg1	protein					686:692	fukutin-related protein	670:692	fukutin-related protein	670:692	Rbo5P-3GalNAcβ with p-nitrophenyl at the aglycon part served as a substrate for ribitol phosphate transferase (FKRP, fukutin-related protein), and its product was glycosylated by the actions of a series of glycosyltransferases, namely, ribitol xylosyltransferase 1 (RXYLT1), β1,4-glucuronyltransferase 1 (B4GAT1), and like-acetyl-glucosaminyltransferase (LARGE).
35670527	1	36	theme	core	146:149	arg1	glycan					165:170	the core M3 O-mannosyl glycan	142:170	the core M3 O-mannosyl glycan	142:170	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	1	37	theme	phosphate	115:123	arg1	modifications					125:137	Ribitol phosphate modifications	107:137	Ribitol phosphate modifications to the core M3 O-mannosyl glycan	107:170	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	5	38	theme	Rbo5P	1136:1140	arg1	transfer					1142:1149	Rbo5P transfer	1136:1149	Rbo5P transfer	1136:1149	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	2	39	theme	core	289:292	arg1	glycan					308:313	the core M3 O-mannosyl glycan	285:313	the core M3 O-mannosyl glycan	285:313	Three sequentially extended partial structures of the core M3 O-mannosyl glycan including a tandem ribitol phosphate were regio- and stereo-selectively synthesized: Rbo5P-3GalNAcβ, Rbo5P-1Rbo5P-3GalNAcβ, and Xylβ1-4Rbo5P-1Rbo5P-3GalNAcβ (Rbo5P, d-ribitol-5-phosphate; GalNAc, N-acetyl-d-galactosamine; Xyl, d-xylose).
35670527	1	40	theme	M3	151:152	arg1	glycan					165:170	the core M3 O-mannosyl glycan	142:170	the core M3 O-mannosyl glycan	142:170	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	5	41	theme	minimal	1086:1092	arg1	units					1094:1098	the minimal units	1082:1098	the minimal units required as the acceptor glycan for Rbo5P transfer	1082:1149	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	5	41	theme	minimal	1086:1092	arg1	derivatives					1066:1076	Rbo5P-3GalNAcβ derivatives	1051:1076	Rbo5P-3GalNAcβ derivatives	1051:1076	The molecular information obtained on FKRP suggests that Rbo5P-3GalNAcβ derivatives are the minimal units required as the acceptor glycan for Rbo5P transfer and may serve as a precursor for the elongation of the core M3 O-mannosyl glycan.
35670527	1	42	theme	O-mannosyl	154:163	arg1	glycan					165:170	the core M3 O-mannosyl glycan	142:170	the core M3 O-mannosyl glycan	142:170	Ribitol phosphate modifications to the core M3 O-mannosyl glycan are important for the functional maturation of α-dystroglycan.
35670527	0	43	theme	Phosphate	69:77	arg1	Scaffolding					79:89	Ribitol Phosphate Scaffolding	61:89	Ribitol Phosphate Scaffolding of Matriglycan	61:104	Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
35670527	0	44	theme	Chemo-Enzymatic	13:27	arg1	Syntheses					29:37	Chemical and Chemo-Enzymatic Syntheses	0:37	Chemical and Chemo-Enzymatic Syntheses of Glycans	0:48	Chemical and Chemo-Enzymatic Syntheses of Glycans Containing Ribitol Phosphate Scaffolding of Matriglycan.
35104505	0	0	theme	glycoprotein	106:117	arg1	substrates					119:128	glycoprotein substrates	106:128	glycoprotein substrates	106:128	N-acetylglucosaminyltransferase-V requires a specific noncatalytic luminal domain for its activity toward glycoprotein substrates.
35104505	9	1	theme	critical	1665:1672	arg1	role					1674:1677	a critical role	1663:1677	a critical role	1663:1677	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	4	2	from	role	793:796	arg1	action					807:812	GnT-V action	801:812	GnT-V action	801:812	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	4	3	theme	uncharacterized	624:638	arg1	domain					640:645	an uncharacterized domain	621:645	an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure	621:766	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	9	4	theme	N-glycans	1807:1815	arg1	biosynthesis					1791:1802	substrate-selective biosynthesis	1771:1802	substrate-selective biosynthesis of N-glycans	1771:1815	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	8	5	theme	N	1544:1544	arg1	domain					1546:1551	the N domain	1540:1551	the N domain	1540:1551	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	7	6	gly	glycoprotein	1329:1340	arg1	glycoprotein					1329:1340	the glycoprotein substrates	1325:1351	the glycoprotein substrates	1325:1351	Surprisingly, GnT-VΔN showed substantially reduced activity toward the glycoprotein substrates, whereas it almost fully maintained its activity toward the oligosaccharides and the glycopeptide substrates.
35104505	1	7	from	formation	196:204	arg1	proteins					260:267	selective target proteins	243:267	selective target proteins in the Golgi apparatus	243:290	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	5	8	theme	GnT-VΔN	902:908	arg1	mutant					910:915	a GnT-VΔN mutant	900:915	a GnT-VΔN mutant lacking the N domain	900:936	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	5	9	from	activity	967:974	arg1	cells					979:983	cells	979:983	cells	979:983	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	6	10	dep	substrates	1161:1170	arg1	glycohexapeptide					1190:1205	glycohexapeptide	1190:1205	glycohexapeptide	1190:1205	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	6	10	dep	substrates	1161:1170	arg1	glycoprotein					1212:1223	glycoprotein	1212:1223	glycoprotein	1212:1223	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	6	10	dep	substrates	1161:1170	arg1	oligosaccharide					1173:1187	oligosaccharide	1173:1187	oligosaccharide	1173:1187	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	6	10	dep	substrates	1161:1170	arg1	substrates					1161:1170	substrates	1161:1170	substrates (oligosaccharide, glycohexapeptide, and glycoprotein)	1161:1224	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	8	11	gly	glycoproteins	1511:1523	arg1	glycoproteins					1511:1523	substrate glycoproteins	1501:1523	substrate glycoproteins	1501:1523	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	3	12	theme	glycoprotein	567:578	arg1	substrates					580:589	glycoprotein substrates	567:589	glycoprotein substrates	567:589	However, it is still unclear how GnT-V selectively acts on glycoprotein substrates.
35104505	9	13	gly	glycoprotein	1701:1712	arg1	glycoprotein					1701:1712	glycoprotein substrates	1701:1723	glycoprotein substrates	1701:1723	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	3	14	gly	glycoprotein	567:578	arg1	glycoprotein					567:578	glycoprotein substrates	567:589	glycoprotein substrates	567:589	However, it is still unclear how GnT-V selectively acts on glycoprotein substrates.
35104505	5	15	theme	N	929:929	arg1	domain					931:936	the N domain	925:936	the N domain	925:936	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	6	16	theme	GnT-VΔN	1129:1135	arg1	activity					1108:1115	the in vitro activity	1095:1115	the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein)	1095:1224	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	5	17	theme	fluorescence	841:852	arg1	sorting					868:874	fluorescence assisted cell sorting	841:874	fluorescence assisted cell sorting analysis	841:883	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	2	18	theme	oligosaccharide	467:481	arg1	substrate					483:491	the oligosaccharide substrate	463:491	the oligosaccharide substrate	463:491	Several three-dimensional structures of GnT-V were recently solved, and the recognition mechanism of the oligosaccharide substrate was clarified.
35104505	7	19	theme	glycopeptide	1438:1449	arg1	substrates					1451:1460	the glycopeptide substrates	1434:1460	the glycopeptide substrates	1434:1460	Surprisingly, GnT-VΔN showed substantially reduced activity toward the glycoprotein substrates, whereas it almost fully maintained its activity toward the oligosaccharides and the glycopeptide substrates.
35104505	5	20	theme	sorting	868:874	arg1	analysis					876:883	fluorescence assisted cell sorting analysis	841:883	fluorescence assisted cell sorting analysis	841:883	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	7	21	gly	glycopeptide	1438:1449	arg2	glycopeptide					1438:1449	the glycopeptide substrates	1434:1460	the glycopeptide substrates	1434:1460	Surprisingly, GnT-VΔN showed substantially reduced activity toward the glycoprotein substrates, whereas it almost fully maintained its activity toward the oligosaccharides and the glycopeptide substrates.
35104505	0	22	gly	glycoprotein	106:117	arg1	glycoprotein					106:117	glycoprotein substrates	106:128	glycoprotein substrates	106:128	N-acetylglucosaminyltransferase-V requires a specific noncatalytic luminal domain for its activity toward glycoprotein substrates.
35104505	8	23	with	models	1480:1485	arg1	glycoproteins					1511:1523	substrate glycoproteins	1501:1523	substrate glycoproteins	1501:1523	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	2	24	theme	recognition	438:448	arg1	mechanism					450:458	the recognition mechanism	434:458	the recognition mechanism of the oligosaccharide substrate	434:491	Several three-dimensional structures of GnT-V were recently solved, and the recognition mechanism of the oligosaccharide substrate was clarified.
35104505	6	25	theme	UDP-Glo	1243:1249	arg1	assay					1251:1255	a UDP-Glo assay	1241:1255	a UDP-Glo assay	1241:1255	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	4	26	theme	N	693:693	arg1	region					685:690	the luminal region	673:690	the luminal region (N domain)	673:701	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	4	26	theme	N	693:693	arg1	domain					695:700	N domain	693:700	N domain	693:700	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	2	27	theme	Several	362:368	arg1	structures					388:397	Several three-dimensional structures	362:397	Several three-dimensional structures of GnT-V	362:406	Several three-dimensional structures of GnT-V were recently solved, and the recognition mechanism of the oligosaccharide substrate was clarified.
35104505	9	28	theme	glycoprotein	1701:1712	arg1	substrates					1714:1723	glycoprotein substrates	1701:1723	glycoprotein substrates	1701:1723	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	1	29	theme	β1,6-GlcNAc	221:231	arg1	branch					233:238	an N-glycan β1,6-GlcNAc branch	209:238	an N-glycan β1,6-GlcNAc branch	209:238	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	9	30	theme	new	1736:1738	arg1	insights					1740:1747	new insights	1736:1747	new insights into the mechanism of substrate-selective biosynthesis of N-glycans	1736:1815	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	1	31	theme	cancer	311:316	arg1	malignancy					318:327	cancer malignancy and autoimmune disease etiology	311:359	malignancy	318:327	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	8	32	theme	substrate	1501:1509	arg1	glycoproteins					1511:1523	substrate glycoproteins	1501:1523	substrate glycoproteins	1501:1523	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	4	33	theme	crystal	750:756	arg1	structure					758:766	a crystal structure	748:766	a crystal structure	748:766	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	1	34	theme	branch	233:238	arg1	formation					196:204	the formation	192:204	the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus	192:290	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	0	35	theme	specific	45:52	arg1	domain					75:80	a specific noncatalytic luminal domain	43:80	a specific noncatalytic luminal domain for its activity toward glycoprotein substrates	43:128	N-acetylglucosaminyltransferase-V requires a specific noncatalytic luminal domain for its activity toward glycoprotein substrates.
35104505	5	36	theme	impaired	945:952	arg1	activity					967:974	impaired biosynthetic activity	945:974	impaired biosynthetic activity in cells	945:983	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	2	37	theme	substrate	483:491	arg1	mechanism					450:458	the recognition mechanism	434:458	the recognition mechanism of the oligosaccharide substrate	434:491	Several three-dimensional structures of GnT-V were recently solved, and the recognition mechanism of the oligosaccharide substrate was clarified.
35104505	7	38	theme	reduced	1301:1307	arg1	activity					1309:1316	substantially reduced activity	1287:1316	substantially reduced activity toward the glycoprotein substrates	1287:1351	Surprisingly, GnT-VΔN showed substantially reduced activity toward the glycoprotein substrates, whereas it almost fully maintained its activity toward the oligosaccharides and the glycopeptide substrates.
35104505	8	39	theme	docking	1472:1478	arg1	models					1480:1485	docking models	1472:1485	docking models of GnT-V with substrate glycoproteins	1472:1523	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	5	40	theme	biosynthetic	954:965	arg1	activity					967:974	impaired biosynthetic activity	945:974	impaired biosynthetic activity in cells	945:983	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	1	41	theme	selective	243:251	arg1	proteins					260:267	selective target proteins	243:267	selective target proteins in the Golgi apparatus	243:290	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	0	42	theme	luminal	67:73	arg1	domain					75:80	a specific noncatalytic luminal domain	43:80	a specific noncatalytic luminal domain for its activity toward glycoprotein substrates	43:128	N-acetylglucosaminyltransferase-V requires a specific noncatalytic luminal domain for its activity toward glycoprotein substrates.
35104505	1	43	theme	autoimmune	333:342	arg1	etiology					352:359	cancer malignancy and autoimmune disease etiology	311:359	etiology	352:359	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	9	44	theme	substrates	1714:1723	arg1	recognition					1686:1696	the recognition	1682:1696	the recognition of glycoprotein substrates	1682:1723	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	5	45	theme	assisted	854:861	arg1	sorting					868:874	fluorescence assisted cell sorting	841:874	fluorescence assisted cell sorting analysis	841:883	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	7	46	theme	glycoprotein	1329:1340	arg1	substrates					1342:1351	the glycoprotein substrates	1325:1351	the glycoprotein substrates	1325:1351	Surprisingly, GnT-VΔN showed substantially reduced activity toward the glycoprotein substrates, whereas it almost fully maintained its activity toward the oligosaccharides and the glycopeptide substrates.
35104505	1	47	theme	target	253:258	arg1	proteins					260:267	selective target proteins	243:267	selective target proteins in the Golgi apparatus	243:290	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	0	48	theme	noncatalytic	54:65	arg1	domain					75:80	a specific noncatalytic luminal domain	43:80	a specific noncatalytic luminal domain for its activity toward glycoprotein substrates	43:128	N-acetylglucosaminyltransferase-V requires a specific noncatalytic luminal domain for its activity toward glycoprotein substrates.
35104505	1	49	theme	disease	344:350	arg1	etiology					352:359	cancer malignancy and autoimmune disease etiology	311:359	etiology	352:359	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	9	50	theme	biosynthesis	1791:1802	arg1	mechanism					1758:1766	the mechanism	1754:1766	the mechanism of substrate-selective biosynthesis of N-glycans	1754:1815	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	5	51	theme	lectin	821:826	arg1	blotting					828:835	lectin blotting	821:835	lectin blotting	821:835	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	4	52	theme	region	685:690	arg1	side					665:668	the N-terminal side	650:668	the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure	650:766	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	6	53	theme	in vitro	1099:1106	arg1	activity					1108:1115	the in vitro activity	1095:1115	the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein)	1095:1224	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	6	54	gly	glycoprotein	1212:1223	arg1	glycoprotein					1212:1223	glycoprotein	1212:1223	glycoprotein	1212:1223	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	6	54	gly	glycoprotein	1212:1223	arg1	substrates					1161:1170	substrates	1161:1170	substrates (oligosaccharide, glycohexapeptide, and glycoprotein)	1161:1224	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	9	55	theme	N	1639:1639	arg1	GnT-V					1651:1655	GnT-V	1651:1655	GnT-V	1651:1655	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	9	55	theme	N	1639:1639	arg1	domain					1641:1646	the N domain	1635:1646	the N domain of GnT-V	1635:1655	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	1	56	from	proteins	260:267	arg1	apparatus					282:290	the Golgi apparatus	272:290	the Golgi apparatus	272:290	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	2	57	theme	GnT-V	402:406	arg1	structures					388:397	Several three-dimensional structures	362:397	Several three-dimensional structures of GnT-V	362:406	Several three-dimensional structures of GnT-V were recently solved, and the recognition mechanism of the oligosaccharide substrate was clarified.
35104505	5	58	theme	efficient	1031:1039	arg1	glycosylation					1041:1053	efficient glycosylation	1031:1053	efficient glycosylation	1031:1053	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	8	59	theme	GnT-V	1490:1494	arg1	models					1480:1485	docking models	1472:1485	docking models of GnT-V with substrate glycoproteins	1472:1523	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	6	60	theme	purified	1120:1127	arg1	GnT-VΔN					1129:1135	purified GnT-VΔN	1120:1135	purified GnT-VΔN	1120:1135	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	5	61	theme	N	1006:1006	arg1	domain					1008:1013	the N domain	1002:1013	the N domain	1002:1013	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	8	62	theme	substrate	1577:1585	arg1	polypeptide					1587:1597	the substrate polypeptide	1573:1597	the substrate polypeptide	1573:1597	Finally, docking models of GnT-V with substrate glycoproteins suggested that the N domain could interact with the substrate polypeptide directly.
35104505	6	63	theme	various	1144:1150	arg1	kinds					1152:1156	various kinds	1144:1156	various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein)	1144:1224	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	4	64	theme	N-terminal	654:663	arg1	side					665:668	the N-terminal side	650:668	the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure	650:766	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	6	65	theme	substrates	1161:1170	arg1	kinds					1152:1156	various kinds	1144:1156	various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein)	1144:1224	To clarify this mechanism, we measured the in vitro activity of purified GnT-VΔN toward various kinds of substrates (oligosaccharide, glycohexapeptide, and glycoprotein) using HPLC and a UDP-Glo assay.
35104505	9	66	theme	GnT-V	1651:1655	arg1	GnT-V					1651:1655	GnT-V	1651:1655	GnT-V	1651:1655	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	9	66	theme	GnT-V	1651:1655	arg1	domain					1641:1646	the N domain	1635:1646	the N domain of GnT-V	1635:1655	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	2	67	theme	three-dimensional	370:386	arg1	structures					388:397	Several three-dimensional structures	362:397	Several three-dimensional structures of GnT-V	362:406	Several three-dimensional structures of GnT-V were recently solved, and the recognition mechanism of the oligosaccharide substrate was clarified.
35104505	9	68	theme	substrate-selective	1771:1789	arg1	biosynthesis					1791:1802	substrate-selective biosynthesis	1771:1802	substrate-selective biosynthesis of N-glycans	1771:1815	Our findings suggest that the N domain of GnT-V plays a critical role in the recognition of glycoprotein substrates, providing new insights into the mechanism of substrate-selective biosynthesis of N-glycans.
35104505	5	69	theme	cell	863:866	arg1	sorting					868:874	fluorescence assisted cell sorting	841:874	fluorescence assisted cell sorting analysis	841:883	Using lectin blotting and fluorescence assisted cell sorting analysis, we found that a GnT-VΔN mutant lacking the N domain showed impaired biosynthetic activity in cells, indicating that the N domain is required for efficient glycosylation.
35104505	4	70	theme	luminal	677:683	arg1	region					685:690	the luminal region	673:690	the luminal region (N domain)	673:701	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	4	70	theme	luminal	677:683	arg1	domain					695:700	N domain	693:700	N domain	693:700	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	1	71	dep	N-acetylglucosaminyltransferase-V	131:163	arg1	MGAT5					175:179	MGAT5	175:179	MGAT5	175:179	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	1	71	dep	N-acetylglucosaminyltransferase-V	131:163	arg1	GnT-V					166:170	GnT-V	166:170	GnT-V	166:170	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	1	72	theme	N-glycan	212:219	arg1	branch					233:238	an N-glycan β1,6-GlcNAc branch	209:238	an N-glycan β1,6-GlcNAc branch	209:238	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	1	73	theme	Golgi	276:280	arg1	apparatus					282:290	the Golgi apparatus	272:290	the Golgi apparatus	272:290	N-acetylglucosaminyltransferase-V (GnT-V or MGAT5) catalyzes the formation of an N-glycan β1,6-GlcNAc branch on selective target proteins in the Golgi apparatus and is involved in cancer malignancy and autoimmune disease etiology.
35104505	4	74	from	side	665:668	arg1	domain					640:645	an uncharacterized domain	621:645	an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure	621:766	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	4	75	theme	GnT-V	801:805	arg1	action					807:812	GnT-V action	801:812	GnT-V action	801:812	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	4	76	theme	GnT-V	706:710	arg1	region					685:690	the luminal region	673:690	the luminal region (N domain)	673:701	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
35104505	4	76	theme	GnT-V	706:710	arg1	domain					695:700	N domain	693:700	N domain	693:700	In this study, we focused on an uncharacterized domain at the N-terminal side of the luminal region (N domain) of GnT-V, which was previously identified in a crystal structure, and aimed to reveal its role in GnT-V action.
36436856	3	0	theme	healthy	482:488	arg1	milk					490:493	healthy milk	482:493	healthy milk	482:493	A total of 56 putative N-glycans were detected, among which 12 N-glycans were significantly different between GDM and healthy milk.
36436856	1	1	theme	glycosylation	233:245	arg1	level					247:251	the glycosylation level	229:251	the glycosylation level of milk proteins	229:268	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	0	2	theme	N/O-glycans	81:91	arg1	levels					71:76	the fucosylation and sialylation levels	38:76	the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins	38:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	7	3	theme	formula	1030:1036	arg1	design					1013:1018	the design	1009:1018	the design of infant formula for newborns	1009:1049	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	7	4	theme	in-depth	909:916	arg1	study					918:922	in-depth study	909:922	in-depth study on the structure-activity relationship of milk N/O-glycans	909:981	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	2	5	theme	individuals	323:333	arg1	N/O-glycome					292:302	the human milk N/O-glycome	277:302	the human milk N/O-glycome of healthy and GDM individuals	277:333	Here, the human milk N/O-glycome of healthy and GDM individuals was analyzed by HILIC-MS/MS.
36436856	0	6	theme	milk	102:105	arg1	glycoproteins					107:119	human milk glycoproteins	96:119	human milk glycoproteins	96:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	4	7	theme	them	554:557	arg1	them					554:557	them	554:557	them	554:557	A total of 25 putative O-glycans were detected, and 11 of them varied greatly between GDM and healthy milk, especially H1N1S1 and H2N2S1.
36436856	4	7	theme	them	554:557	arg1	11					548:549	11	548:549	11	548:549	A total of 25 putative O-glycans were detected, and 11 of them varied greatly between GDM and healthy milk, especially H1N1S1 and H2N2S1.
36436856	0	8	theme	human	96:100	arg1	glycoproteins					107:119	human milk glycoproteins	96:119	human milk glycoproteins	96:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	6	9	theme	O-glycans	841:849	arg1	lower					856:860	lower	856:860	lower	856:860	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	6	9	theme	O-glycans	841:849	arg1	proportion					816:825	the proportion	812:825	the proportion of sialylated O-glycans	812:849	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	6	10	theme	GDM	745:747	arg1	milk					749:752	GDM milk	745:752	GDM milk	745:752	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	1	11	theme	milk	256:259	arg1	proteins					261:268	milk proteins	256:268	milk proteins	256:268	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	1	12	theme	Gestational	122:132	arg1	mellitus					143:150	Gestational diabetes mellitus	122:150	Gestational diabetes mellitus (GDM)	122:156	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	1	12	theme	Gestational	122:132	arg1	GDM					153:155	GDM	153:155	GDM	153:155	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	5	13	theme	healthy	728:734	arg1	milk					736:739	healthy milk	728:739	healthy milk	728:739	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36436856	5	14	from	content	656:662	arg1	milk					686:689	GDM milk	682:689	GDM milk	682:689	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36436856	3	15	theme	putative	378:385	arg1	N-glycans					387:395	56 putative N-glycans	375:395	56 putative N-glycans	375:395	A total of 56 putative N-glycans were detected, among which 12 N-glycans were significantly different between GDM and healthy milk.
36436856	6	16	gly	fucosylated	755:765	arg1	N-glycans					767:775	fucosylated N-glycans	755:775	fucosylated N-glycans	755:775	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	0	17	theme	diabetes	12:19	arg1	mellitus					21:28	Gestational diabetes mellitus	0:28	Gestational diabetes mellitus	0:28	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	6	18	theme	sialylated	830:839	arg1	O-glycans					841:849	sialylated O-glycans	830:849	sialylated O-glycans	830:849	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	1	19	contain	has	158:160	arg1	mellitus					143:150	Gestational diabetes mellitus	122:150	Gestational diabetes mellitus (GDM)	122:156	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	1	19	contain	has	158:160	arg2	effects					171:177	negative effects	162:177	negative effects	162:177	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	1	19	contain	has	158:160	arg1	GDM					153:155	GDM	153:155	GDM	153:155	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	0	20	theme	Gestational	0:10	arg1	mellitus					21:28	Gestational diabetes mellitus	0:28	Gestational diabetes mellitus	0:28	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	1	21	theme	proteins	261:268	arg1	level					247:251	the glycosylation level	229:251	the glycosylation level of milk proteins	229:268	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	2	22	theme	milk	287:290	arg1	N/O-glycome					292:302	the human milk N/O-glycome	277:302	the human milk N/O-glycome of healthy and GDM individuals	277:333	Here, the human milk N/O-glycome of healthy and GDM individuals was analyzed by HILIC-MS/MS.
36436856	4	23	theme	O-glycans	519:527	arg1	total					498:502	A total	496:502	A total of 25 putative O-glycans	496:527	A total of 25 putative O-glycans were detected, and 11 of them varied greatly between GDM and healthy milk, especially H1N1S1 and H2N2S1.
36436856	5	24	theme	relative	647:654	arg1	content					656:662	the relative content	643:662	the relative content of N/O-glycans in GDM milk	643:689	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36436856	5	24	theme	relative	647:654	arg1	lower					709:713	lower	709:713	lower	709:713	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36436856	0	25	gly	glycoproteins	107:119	arg1	glycoproteins					107:119	human milk glycoproteins	96:119	human milk glycoproteins	96:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	4	26	theme	healthy	590:596	arg1	milk					598:601	healthy milk	590:601	healthy milk	590:601	A total of 25 putative O-glycans were detected, and 11 of them varied greatly between GDM and healthy milk, especially H1N1S1 and H2N2S1.
36436856	7	27	theme	infant	1023:1028	arg1	formula					1030:1036	infant formula	1023:1036	infant formula for newborns	1023:1049	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	1	28	theme	negative	162:169	arg1	effects					171:177	negative effects	162:177	negative effects	162:177	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	0	29	theme	fucosylation	42:53	arg1	levels					71:76	the fucosylation and sialylation levels	38:76	the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins	38:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	6	30	attach	present	777:783	arg1	milk					749:752	GDM milk	745:752	GDM milk	745:752	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	6	30	attach	present	777:783	arg2	N-glycans					767:775	fucosylated N-glycans	755:775	fucosylated N-glycans	755:775	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	7	31	from	study	918:922	arg1	relationship					950:961	the structure-activity relationship	927:961	the structure-activity relationship of milk N/O-glycans	927:981	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	3	32	theme	N-glycans	387:395	arg1	total					366:370	A total	364:370	A total of 56 putative N-glycans	364:395	A total of 56 putative N-glycans were detected, among which 12 N-glycans were significantly different between GDM and healthy milk.
36436856	5	33	theme	N/O-glycans	667:677	arg1	content					656:662	the relative content	643:662	the relative content of N/O-glycans in GDM milk	643:689	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36436856	5	33	theme	N/O-glycans	667:677	arg1	lower					709:713	lower	709:713	lower	709:713	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36436856	7	34	theme	N/O-glycans	971:981	arg1	relationship					950:961	the structure-activity relationship	927:961	the structure-activity relationship of milk N/O-glycans	927:981	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	0	35	theme	sialylation	59:69	arg1	levels					71:76	the fucosylation and sialylation levels	38:76	the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins	38:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	0	36	from	levels	71:76	arg1	glycoproteins					107:119	human milk glycoproteins	96:119	human milk glycoproteins	96:119	Gestational diabetes mellitus affects the fucosylation and sialylation levels of N/O-glycans in human milk glycoproteins.
36436856	2	37	theme	GDM	319:321	arg1	individuals					323:333	healthy and GDM individuals	307:333	individuals	323:333	Here, the human milk N/O-glycome of healthy and GDM individuals was analyzed by HILIC-MS/MS.
36436856	4	38	theme	putative	510:517	arg1	O-glycans					519:527	25 putative O-glycans	507:527	25 putative O-glycans	507:527	A total of 25 putative O-glycans were detected, and 11 of them varied greatly between GDM and healthy milk, especially H1N1S1 and H2N2S1.
36436856	6	39	theme	higher	785:790	arg1	proportion					792:801	higher proportion	785:801	higher proportion	785:801	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	1	40	theme	diabetes	134:141	arg1	mellitus					143:150	Gestational diabetes mellitus	122:150	Gestational diabetes mellitus (GDM)	122:156	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	1	40	theme	diabetes	134:141	arg1	GDM					153:155	GDM	153:155	GDM	153:155	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	6	41	gly	sialylated	830:839	arg1	O-glycans					841:849	sialylated O-glycans	830:849	sialylated O-glycans	830:849	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	7	42	theme	milk	966:969	arg1	N/O-glycans					971:981	milk N/O-glycans	966:981	milk N/O-glycans	966:981	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	2	43	theme	healthy	307:313	arg1	individuals					323:333	healthy and GDM individuals	307:333	individuals	323:333	Here, the human milk N/O-glycome of healthy and GDM individuals was analyzed by HILIC-MS/MS.
36436856	2	44	theme	human	281:285	arg1	N/O-glycome					292:302	the human milk N/O-glycome	277:302	the human milk N/O-glycome of healthy and GDM individuals	277:333	Here, the human milk N/O-glycome of healthy and GDM individuals was analyzed by HILIC-MS/MS.
36436856	7	45	theme	structure-activity	931:948	arg1	relationship					950:961	the structure-activity relationship	927:961	the structure-activity relationship of milk N/O-glycans	927:981	These findings would provide a foundation for in-depth study on the structure-activity relationship of milk N/O-glycans and are expected to drive the design of infant formula for newborns.
36436856	6	46	theme	fucosylated	755:765	arg1	N-glycans					767:775	fucosylated N-glycans	755:775	fucosylated N-glycans	755:775	In GDM milk, fucosylated N-glycans present higher proportion, whereas the proportion of sialylated O-glycans were lower.
36436856	1	47	from	effects	171:177	arg1	mothers					182:188	mothers	182:188	mothers	182:188	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	1	47	from	effects	171:177	arg1	offspring					194:202	offspring	194:202	offspring	194:202	Gestational diabetes mellitus (GDM) has negative effects on mothers and offspring, which may be related to the glycosylation level of milk proteins.
36436856	5	48	theme	GDM	682:684	arg1	milk					686:689	GDM milk	682:689	GDM milk	682:689	Overall, the relative content of N/O-glycans in GDM milk was significantly lower than that of healthy milk.
36268609	5	0	theme	laminin-α2	871:880	arg1	interactions					784:795	interactions	784:795	interactions between matriglycan hexasaccharides	784:831	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	5	0	theme	laminin-α2	871:880	arg1	laminin-α2					871:880	laminin-α2	871:880	laminin-α2	871:880	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	5	0	theme	laminin-α2	871:880	arg1	domains					852:858	laminin-G-like domains 4 and 5	837:866	laminin-G-like domains 4 and 5 of laminin-α2	837:880	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	3	1	link	α-linked	467:474	arg1	glycoside					484:492	an α-linked xylosyl glycoside	464:492	an α-linked xylosyl glycoside	464:492	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	3	2	from	step	439:442	arg1	formation					451:459	the formation	447:459	the formation of an α-linked xylosyl glycoside	447:492	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	5	3	theme	laminin-G-like	837:850	arg1	laminin-α2					871:880	laminin-α2	871:880	laminin-α2	871:880	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	5	3	theme	laminin-G-like	837:850	arg1	domains					852:858	laminin-G-like domains 4 and 5	837:866	laminin-G-like domains 4 and 5 of laminin-α2	837:880	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	6	4	theme	dissociation	928:939	arg1	M					1031:1031	7.5 × 10<sup>-8</sup> M	1009:1031	7.5 × 10<sup>-8</sup> M	1009:1031	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	6	4	theme	dissociation	928:939	arg1	constant					941:948	The dissociation constant	924:948	The dissociation constant obtained from bio-layer interferometry	924:987	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	4	5	theme	biotin	745:750	arg1	conjugate					752:760	the biotin conjugate	741:760	the biotin conjugate	741:760	Successful glycan elongation was regio- and stereoselectively performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate.
36268609	4	6	theme	C<sub>2</sub>H<sub>4</sub>O	678:704	arg1	<sub>3</sub>CH<sub>2</sub>CCH					706:735	(-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH	646:735	(-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH	646:735	Successful glycan elongation was regio- and stereoselectively performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate.
36268609	0	7	with	interaction	76:86	arg1	laminin					93:99	laminin	93:99	laminin	93:99	Synthesis of the matriglycan hexasaccharide, -3Xylα1-3GlcAβ1-trimer and its interaction with laminin.
36268609	3	8	from	mixture	555:561	arg1	separation					527:536	solvent-specific separation	510:536	solvent-specific separation from an anomeric mixture	510:561	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	1	9	theme	core	162:165	arg1	glycan					188:193	the core M3 <i>O</i>-mannosyl glycan	158:193	the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	158:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	4	10	dep	regio-	597:602	arg1	performed					626:634	performed	626:634	performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate	626:760	Successful glycan elongation was regio- and stereoselectively performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate.
36268609	1	11	theme	M3	167:168	arg1	glycan					188:193	the core M3 <i>O</i>-mannosyl glycan	158:193	the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	158:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	6	12	theme	×	1013:1013	arg1	M					1031:1031	7.5 × 10<sup>-8</sup> M	1009:1031	7.5 × 10<sup>-8</sup> M	1009:1031	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	6	12	theme	×	1013:1013	arg1	constant					941:948	The dissociation constant	924:948	The dissociation constant obtained from bio-layer interferometry	924:987	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	1	13	theme	<i>O</i>-mannosyl	170:186	arg1	glycan					188:193	the core M3 <i>O</i>-mannosyl glycan	158:193	the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	158:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	1	14	theme	muscle	288:293	arg1	tissue					295:300	muscle tissue	288:300	muscle tissue	288:300	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	1	15	theme	glycan	188:193	arg1	part					150:153	a pivotal part	140:153	a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	140:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	1	15	theme	glycan	188:193	arg1	polysaccharide					117:130	a polysaccharide	115:130	a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	115:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	1	15	theme	glycan	188:193	arg1	Matriglycan					102:112	Matriglycan	102:112	Matriglycan	102:112	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	0	16	theme	matriglycan	17:27	arg1	hexasaccharide					29:42	the matriglycan hexasaccharide	13:42	the matriglycan hexasaccharide	13:42	Synthesis of the matriglycan hexasaccharide, -3Xylα1-3GlcAβ1-trimer and its interaction with laminin.
36268609	7	17	theme	chemical	1064:1071	arg1	approach					1073:1080	a chemical approach	1062:1080	a chemical approach	1062:1080	These results indicate that a chemical approach may be applied to the reconstruction of muscle tissue.
36268609	3	18	theme	glycoside	484:492	arg1	formation					451:459	the formation	447:459	the formation of an α-linked xylosyl glycoside	447:492	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	7	19	theme	tissue	1129:1134	arg1	reconstruction					1104:1117	the reconstruction	1100:1117	the reconstruction of muscle tissue	1100:1134	These results indicate that a chemical approach may be applied to the reconstruction of muscle tissue.
36268609	5	20	theme	matriglycan	805:815	arg1	hexasaccharides					817:831	matriglycan hexasaccharides	805:831	matriglycan hexasaccharides	805:831	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	6	21	theme	7.5	1009:1011	arg1	×					1013:1013	×	1013:1013	×	1013:1013	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	1	22	theme	pivotal	142:148	arg1	part					150:153	a pivotal part	140:153	a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	140:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	1	22	theme	pivotal	142:148	arg1	polysaccharide					117:130	a polysaccharide	115:130	a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-	115:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	1	22	theme	pivotal	142:148	arg1	Matriglycan					102:112	Matriglycan	102:112	Matriglycan	102:112	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	5	23	theme	saturation	888:897	arg1	difference-NMR					908:921	saturation transfer difference-NMR	888:921	saturation transfer difference-NMR	888:921	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	3	24	theme	α-linked	467:474	arg1	glycoside					484:492	an α-linked xylosyl glycoside	464:492	an α-linked xylosyl glycoside	464:492	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	0	25	theme	hexasaccharide	29:42	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of the matriglycan hexasaccharide	0:42	Synthesis of the matriglycan hexasaccharide, -3Xylα1-3GlcAβ1-trimer and its interaction with laminin.
36268609	0	25	theme	hexasaccharide	29:42	arg1	-3Xylα1-3GlcAβ1-trimer					45:66	-3Xylα1-3GlcAβ1-trimer	45:66	-3Xylα1-3GlcAβ1-trimer	45:66	Synthesis of the matriglycan hexasaccharide, -3Xylα1-3GlcAβ1-trimer and its interaction with laminin.
36268609	0	25	theme	hexasaccharide	29:42	arg1	interaction					76:86	its interaction	72:86	its interaction with laminin	72:99	Synthesis of the matriglycan hexasaccharide, -3Xylα1-3GlcAβ1-trimer and its interaction with laminin.
36268609	4	26	theme	Successful	564:573	arg1	elongation					582:591	Successful glycan elongation	564:591	Successful glycan elongation	564:591	Successful glycan elongation was regio- and stereoselectively performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate.
36268609	5	27	theme	transfer	899:906	arg1	difference-NMR					908:921	saturation transfer difference-NMR	888:921	saturation transfer difference-NMR	888:921	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	3	28	theme	xylosyl	476:482	arg1	glycoside					484:492	an α-linked xylosyl glycoside	464:492	an α-linked xylosyl glycoside	464:492	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	6	29	theme	10<sup>-8</sup>	1015:1029	arg1	M					1031:1031	7.5 × 10<sup>-8</sup> M	1009:1031	7.5 × 10<sup>-8</sup> M	1009:1031	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	6	29	theme	10<sup>-8</sup>	1015:1029	arg1	constant					941:948	The dissociation constant	924:948	The dissociation constant obtained from bio-layer interferometry	924:987	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	3	30	theme	solvent-specific	510:525	arg1	separation					527:536	solvent-specific separation	510:536	solvent-specific separation from an anomeric mixture	510:561	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	3	31	theme	key	435:437	arg1	step					439:442	The key step	431:442	The key step in the formation of an α-linked xylosyl glycoside	431:492	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	2	32	theme	hexasaccharides	359:373	arg1	synthesis					324:332	the synthesis	320:332	the synthesis of matriglycan-repeating hexasaccharides equipped with an alkyne linker to form glycoconjugates	320:428	We herein report the synthesis of matriglycan-repeating hexasaccharides equipped with an alkyne linker to form glycoconjugates.
36268609	4	33	theme	glycan	575:580	arg1	elongation					582:591	Successful glycan elongation	564:591	Successful glycan elongation	564:591	Successful glycan elongation was regio- and stereoselectively performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate.
36268609	2	34	theme	matriglycan-repeating	337:357	arg1	hexasaccharides					359:373	matriglycan-repeating hexasaccharides	337:373	matriglycan-repeating hexasaccharides equipped with an alkyne linker to form glycoconjugates	337:428	We herein report the synthesis of matriglycan-repeating hexasaccharides equipped with an alkyne linker to form glycoconjugates.
36268609	1	35	theme	disaccharide	221:232	arg1	-3Xylα1-3GlcAβ1-					234:249	the repeating disaccharide -3Xylα1-3GlcAβ1-	207:249	the repeating disaccharide -3Xylα1-3GlcAβ1-	207:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	5	36	dep	domains	852:858	arg1	4					860:860	4	860:860	4	860:860	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	5	36	dep	domains	852:858	arg1	5					866:866	5	866:866	5	866:866	We also investigated interactions between matriglycan hexasaccharides and laminin-G-like domains 4 and 5 of laminin-α2 using saturation transfer difference-NMR.
36268609	6	37	theme	bio-layer	964:972	arg1	interferometry					974:987	bio-layer interferometry	964:987	bio-layer interferometry	964:987	The dissociation constant obtained from bio-layer interferometry was estimated to be 7.5 × 10<sup>-8</sup> M.
36268609	7	38	theme	muscle	1122:1127	arg1	tissue					1129:1134	muscle tissue	1122:1134	muscle tissue	1122:1134	These results indicate that a chemical approach may be applied to the reconstruction of muscle tissue.
36268609	1	39	theme	repeating	211:219	arg1	disaccharide					221:232	the repeating disaccharide	207:232	the repeating disaccharide -3Xylα1-3GlcAβ1-	207:249	Matriglycan, a polysaccharide that is a pivotal part of the core M3 <i>O</i>-mannosyl glycan composed of the repeating disaccharide -3Xylα1-3GlcAβ1-, interacts with laminin to stabilize muscle tissue.
36268609	0	40	with	-3Xylα1-3GlcAβ1-trimer	45:66	arg1	laminin					93:99	laminin	93:99	laminin	93:99	Synthesis of the matriglycan hexasaccharide, -3Xylα1-3GlcAβ1-trimer and its interaction with laminin.
36268609	3	41	theme	anomeric	546:553	arg1	mixture					555:561	an anomeric mixture	543:561	an anomeric mixture	543:561	The key step in the formation of an α-linked xylosyl glycoside was resolved by solvent-specific separation from an anomeric mixture.
36268609	2	42	theme	alkyne	392:397	arg1	linker					399:404	an alkyne linker	389:404	an alkyne linker	389:404	We herein report the synthesis of matriglycan-repeating hexasaccharides equipped with an alkyne linker to form glycoconjugates.
36268609	4	43	theme	<sub>3</sub>-O	663:676	arg1	<sub>3</sub>CH<sub>2</sub>CCH					706:735	(-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH	646:735	(-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH	646:735	Successful glycan elongation was regio- and stereoselectively performed to obtain (-3Xylα1-3GlcAβ1)<sub>3</sub>-O(C<sub>2</sub>H<sub>4</sub>O)<sub>3</sub>CH<sub>2</sub>CCH and the biotin conjugate.
36935145	4	0	theme	comprehensive	1326:1338	arg1	N-glycosite					1340:1350	comprehensive N-glycosite	1326:1350	comprehensive N-glycosite	1326:1350	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	1	theme	S	1070:1070	arg1	protein					1072:1078	the S protein	1066:1078	the S protein of SARS-Cov-2 as well as malignant diseases	1066:1122	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	1	2	dep	modifications	353:365	arg1	such					368:371	such	368:371	such	368:371	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	3	theme	loss-of-glycosylation	871:891	arg1	gain					902:905	gain	902:905	gain of such a new motif and thus gain-of-glycosylation (GoG)	902:962	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	3	theme	loss-of-glycosylation	871:891	arg1	loss					831:834	loss	831:834	loss of such an original motif and thus loss-of-glycosylation (LoG)	831:897	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	4	theme	mammalian	292:300	arg1	proteins					302:309	mammalian proteins	292:309	mammalian proteins	292:309	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	5	from	cells	1302:1306	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	6	theme	N-glycan	1356:1363	arg1	information					1375:1385	N-glycan structure information	1356:1385	N-glycan structure information	1356:1385	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	7	theme	glycoproteins	1024:1036	arg1	functions					1011:1019	functions	1011:1019	functions	1011:1019	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	3	7	theme	glycoproteins	1024:1036	arg1	structures					996:1005	new structures	992:1005	new structures	992:1005	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	1	8	theme	proteins	302:309	arg1	half					284:287	more than half	274:287	more than half of mammalian proteins	274:309	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	0	9	theme	site-	119:123	arg1	N-glycoproteomics					148:164	site- and structure-specific N-glycoproteomics	119:164	site- and structure-specific N-glycoproteomics	119:164	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	0	10	from	Gain-of-glycosylation	0:20	arg1	cells					96:100	cancer stem cells	84:100	cancer stem cells	84:100	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	0	10	from	Gain-of-glycosylation	0:20	arg1	cells					74:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	4	11	theme	qualitative	1163:1173	arg1	characterization					1193:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization	1140:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs)	1140:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	1	12	theme	monosaccharide	497:510	arg1	composition					512:522	monosaccharide composition	497:522	monosaccharide composition	497:522	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	12	theme	monosaccharide	497:510	arg1	anomer					544:549	anomer	544:549	anomer	544:549	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	12	theme	monosaccharide	497:510	arg1	linkage					535:541	linkage	535:541	linkage	535:541	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	12	theme	monosaccharide	497:510	arg1	sequence					525:532	sequence	525:532	sequence	525:532	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	13	from	cells	1268:1272	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	14	theme	new	992:994	arg1	structures					996:1005	new structures	992:1005	new structures	992:1005	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	2	15	gly	N-glycosylation	696:710	arg2	residue					730:736	the Asn residue	722:736	the Asn residue among the consensus N-X-S/T/C (X≠P) motif	722:778	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	4	16	theme	drug	1246:1249	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	17	theme	Adriamycin	1235:1244	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	18	theme	cells	1268:1272	arg1	characterization					1193:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization	1140:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs)	1140:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	19	theme	glycoproteome-wide	1144:1161	arg1	characterization					1193:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization	1140:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs)	1140:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	20	located	observed	1054:1061	arg2	functions					1011:1019	functions	1011:1019	functions	1011:1019	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	3	20	located	observed	1054:1061	arg1	protein					1072:1078	the S protein	1066:1078	the S protein of SARS-Cov-2 as well as malignant diseases	1066:1122	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	3	20	located	observed	1054:1061	arg2	structures					996:1005	new structures	992:1005	new structures	992:1005	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	0	21	theme	structure-specific	129:146	arg1	N-glycoproteomics					148:164	site- and structure-specific N-glycoproteomics	119:164	site- and structure-specific N-glycoproteomics	119:164	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	4	22	theme	MCF-7/ADR	1309:1317	arg1	cells					1302:1306	cancer stem cells	1290:1306	cancer stem cells (MCF-7/ADR CSCs)	1290:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	22	theme	MCF-7/ADR	1309:1317	arg1	CSCs					1319:1322	MCF-7/ADR CSCs	1309:1322	MCF-7/ADR CSCs	1309:1322	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	23	gly	glycoproteins	1024:1036	arg1	glycoproteins					1024:1036	glycoproteins	1024:1036	glycoproteins	1024:1036	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	4	24	gly	N-glycosite	1340:1350	arg2	N-glycosite					1340:1350	comprehensive N-glycosite	1326:1350	comprehensive N-glycosite	1326:1350	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	24	gly	N-glycosite	1340:1350	arg2	level					1416:1420	the intact N-glycopeptide level	1390:1420	the intact N-glycopeptide level	1390:1420	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	1	25	contain	has	451:453	arg1	N-glycosylation					435:449	N-glycosylation	435:449	N-glycosylation	435:449	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	25	contain	has	451:453	arg2	features					487:494	multiple dimensional structural features	455:494	multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer)	455:550	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	26	theme	new	917:919	arg1	motif					921:925	such a new motif	910:925	such a new motif and thus gain-of-glycosylation (GoG)	910:962	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	27	theme	motif	921:925	arg1	gain					902:905	gain	902:905	gain of such a new motif and thus gain-of-glycosylation (GoG)	902:962	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	27	theme	motif	921:925	arg1	loss					831:834	loss	831:834	loss of such an original motif and thus loss-of-glycosylation (LoG)	831:897	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	28	dep	has	451:453	arg1	generates					559:567	generates	559:567	generates enormous N-glycan structures	559:596	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	29	theme	acid	807:810	arg1	change					812:817	mutation-originated amino acid change	781:817	mutation-originated amino acid change	781:817	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	30	theme	common	213:218	arg1	glycosylation					176:188	N-linked glycosylation	167:188	N-linked glycosylation (N-glycosylation)	167:206	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	30	theme	common	213:218	arg1	modification					247:258	a common protein post-translational modification	211:258	a common protein post-translational modification	211:258	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	31	theme	single	416:421	arg1	structures					423:432	only single structures	411:432	only single structures	411:432	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	32	theme	modification	677:688	arg1	site					690:693	the modification site	673:693	the modification site	673:693	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	33	theme	gain-of-glycosylation	936:956	arg1	gain					902:905	gain	902:905	gain of such a new motif and thus gain-of-glycosylation (GoG)	902:962	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	33	theme	gain-of-glycosylation	936:956	arg1	loss					831:834	loss	831:834	loss of such an original motif and thus loss-of-glycosylation (LoG)	831:897	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	4	34	from	resistance	1251:1260	arg1	characterization					1193:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization	1140:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs)	1140:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	2	35	theme	amino	801:805	arg1	change					812:817	mutation-originated amino acid change	781:817	mutation-originated amino acid change	781:817	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	36	theme	protein	220:226	arg1	glycosylation					176:188	N-linked glycosylation	167:188	N-linked glycosylation (N-glycosylation)	167:206	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	36	theme	protein	220:226	arg1	modification					247:258	a common protein post-translational modification	211:258	a common protein post-translational modification	211:258	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	37	from	level	1416:1420	arg1	N-glycosite					1340:1350	comprehensive N-glycosite	1326:1350	comprehensive N-glycosite	1326:1350	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	37	from	level	1416:1420	arg1	information					1375:1385	N-glycan structure information	1356:1385	N-glycan structure information	1356:1385	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	1	38	theme	striking	315:322	arg1	contract					324:331	striking contract	315:331	striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures	315:432	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	3	39	theme	SARS-Cov-2	1083:1092	arg1	diseases					1115:1122	SARS-Cov-2 as well as malignant diseases	1083:1122	SARS-Cov-2 as well as malignant diseases	1083:1122	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	1	40	theme	post-translational	228:245	arg1	glycosylation					176:188	N-linked glycosylation	167:188	N-linked glycosylation (N-glycosylation)	167:206	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	40	theme	post-translational	228:245	arg1	modification					247:258	a common protein post-translational modification	211:258	a common protein post-translational modification	211:258	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	0	41	theme	multi-drug-resistant	32:51	arg1	cells					74:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	4	42	theme	intact	1394:1399	arg1	level					1416:1420	the intact N-glycopeptide level	1390:1420	the intact N-glycopeptide level	1390:1420	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	43	theme	diseases	1115:1122	arg1	protein					1072:1078	the S protein	1066:1078	the S protein of SARS-Cov-2 as well as malignant diseases	1066:1122	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	1	44	with	contract	324:331	arg1	modifications					353:365	small molecule modifications	338:365	small molecule modifications (such as methylation, phosphorylation)	338:404	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	44	with	contract	324:331	arg1	structures					423:432	only single structures	411:432	only single structures	411:432	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	0	45	theme	breast	25:30	arg1	cells					74:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	4	46	theme	N-glycoproteomics	1175:1191	arg1	characterization					1193:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization	1140:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs)	1140:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	47	theme	breast	1221:1226	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	48	theme	stem	1297:1300	arg1	cells					1302:1306	cancer stem cells	1290:1306	cancer stem cells (MCF-7/ADR CSCs)	1290:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	48	theme	stem	1297:1300	arg1	CSCs					1319:1322	MCF-7/ADR CSCs	1309:1322	MCF-7/ADR CSCs	1309:1322	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	1	49	theme	protein	636:642	arg1	structure					644:652	protein structure	636:652	protein structure	636:652	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	0	50	theme	adenocarcinoma	59:72	arg1	cells					74:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	1	51	theme	small	338:342	arg1	modifications					353:365	small molecule modifications	338:365	small molecule modifications (such as methylation, phosphorylation)	338:404	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	52	theme	cancer	1290:1295	arg1	cells					1302:1306	cancer stem cells	1290:1306	cancer stem cells (MCF-7/ADR CSCs)	1290:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	52	theme	cancer	1290:1295	arg1	CSCs					1319:1322	MCF-7/ADR CSCs	1309:1322	MCF-7/ADR CSCs	1309:1322	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	0	53	gly	Gain-of-glycosylation	0:20	arg1	cells					96:100	cancer stem cells	84:100	cancer stem cells	84:100	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	0	53	gly	Gain-of-glycosylation	0:20	arg1	cells					74:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	0	54	theme	MCF-7	53:57	arg1	cells					74:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	breast multi-drug-resistant MCF-7 adenocarcinoma cells	25:78	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	1	55	theme	molecule	344:351	arg1	modifications					353:365	small molecule modifications	338:365	small molecule modifications (such as methylation, phosphorylation)	338:404	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	56	dep	features	487:494	arg1	composition					512:522	monosaccharide composition	497:522	monosaccharide composition	497:522	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	56	dep	features	487:494	arg1	anomer					544:549	anomer	544:549	anomer	544:549	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	56	dep	features	487:494	arg1	linkage					535:541	linkage	535:541	linkage	535:541	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	56	dep	features	487:494	arg1	sequence					525:532	sequence	525:532	sequence	525:532	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	57	theme	X≠P	769:771	arg1	motif					774:778	the consensus N-X-S/T/C (X≠P) motif	744:778	the consensus N-X-S/T/C (X≠P) motif	744:778	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	4	58	theme	N-glycopeptide	1401:1414	arg1	level					1416:1420	the intact N-glycopeptide level	1390:1420	the intact N-glycopeptide level	1390:1420	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	59	theme	structure	1365:1373	arg1	information					1375:1385	N-glycan structure information	1356:1385	N-glycan structure information	1356:1385	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	1	60	link	N-linked	167:174	arg1	N-glycosylation					191:205	N-glycosylation	191:205	N-glycosylation	191:205	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	60	link	N-linked	167:174	arg1	glycosylation					176:188	N-linked glycosylation	167:188	N-linked glycosylation (N-glycosylation)	167:206	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	60	link	N-linked	167:174	arg1	modification					247:258	a common protein post-translational modification	211:258	a common protein post-translational modification	211:258	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	61	theme	cells	1302:1306	arg1	characterization					1193:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization	1140:1208	our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs)	1140:1323	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	62	gly	N-glycopeptide	1401:1414	arg2	N-glycopeptide					1401:1414	the intact N-glycopeptide level	1390:1420	the intact N-glycopeptide level	1390:1420	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	3	63	theme	malignant	1105:1113	arg1	diseases					1115:1122	SARS-Cov-2 as well as malignant diseases	1083:1122	SARS-Cov-2 as well as malignant diseases	1083:1122	Both LoG and GoG generates new structures and functions of glycoproteins, which has been observed in the S protein of SARS-Cov-2 as well as malignant diseases.
36935145	1	64	theme	multiple	455:462	arg1	features					487:494	multiple dimensional structural features	455:494	multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer)	455:550	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	65	theme	N-X-S/T/C	758:766	arg1	motif					774:778	the consensus N-X-S/T/C (X≠P) motif	744:778	the consensus N-X-S/T/C (X≠P) motif	744:778	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	4	66	theme	cancer	1228:1233	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	2	67	theme	motif	856:860	arg1	gain					902:905	gain	902:905	gain of such a new motif and thus gain-of-glycosylation (GoG)	902:962	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	67	theme	motif	856:860	arg1	loss					831:834	loss	831:834	loss of such an original motif and thus loss-of-glycosylation (LoG)	831:897	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	2	68	theme	Asn	726:728	arg1	residue					730:736	the Asn residue	722:736	the Asn residue among the consensus N-X-S/T/C (X≠P) motif	722:778	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	69	theme	dimensional	464:474	arg1	features					487:494	multiple dimensional structural features	455:494	multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer)	455:550	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	70	from	characterization	1193:1208	arg1	resistance					1251:1260	breast cancer Adriamycin drug resistance	1221:1260	breast cancer Adriamycin drug resistance	1221:1260	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	2	71	theme	consensus	748:756	arg1	motif					774:778	the consensus N-X-S/T/C (X≠P) motif	744:778	the consensus N-X-S/T/C (X≠P) motif	744:778	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	72	theme	N-linked	167:174	arg1	N-glycosylation					191:205	N-glycosylation	191:205	N-glycosylation	191:205	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	72	theme	N-linked	167:174	arg1	glycosylation					176:188	N-linked glycosylation	167:188	N-linked glycosylation (N-glycosylation)	167:206	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	72	theme	N-linked	167:174	arg1	modification					247:258	a common protein post-translational modification	211:258	a common protein post-translational modification	211:258	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	2	73	theme	original	847:854	arg1	motif					856:860	such an original motif	839:860	such an original motif	839:860	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	74	theme	more	274:277	arg1	half					284:287	more than half	274:287	more than half of mammalian proteins	274:309	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	1	75	theme	structural	476:485	arg1	features					487:494	multiple dimensional structural features	455:494	multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer)	455:550	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	4	76	theme	GoGs	1213:1216	arg1	ADR					1263:1265	ADR	1263:1265	ADR	1263:1265	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	76	theme	GoGs	1213:1216	arg1	MCF-7/ADR					1275:1283	MCF-7/ADR	1275:1283	MCF-7/ADR	1275:1283	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	4	76	theme	GoGs	1213:1216	arg1	cells					1268:1272	GoGs in breast cancer Adriamycin drug resistance (ADR) cells	1213:1272	GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR)	1213:1284	Here we report our glycoproteome-wide qualitative N-glycoproteomics characterization of GoGs in breast cancer Adriamycin drug resistance (ADR) cells (MCF-7/ADR) and cancer stem cells (MCF-7/ADR CSCs); comprehensive N-glycosite and N-glycan structure information at the intact N-glycopeptide level were reported.
36935145	2	77	theme	mutation-originated	781:799	arg1	change					812:817	mutation-originated amino acid change	781:817	mutation-originated amino acid change	781:817	For the modification site, N-glycosylation occurs on the Asn residue among the consensus N-X-S/T/C (X≠P) motif; mutation-originated amino acid change may lead to loss of such an original motif and thus loss-of-glycosylation (LoG) or gain of such a new motif and thus gain-of-glycosylation (GoG).
36935145	1	78	theme	than	279:282	arg1	half					284:287	more than half	274:287	more than half of mammalian proteins	274:309	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	0	79	theme	stem	91:94	arg1	cells					96:100	cancer stem cells	84:100	cancer stem cells	84:100	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	1	80	theme	enormous	569:576	arg1	structures					587:596	enormous N-glycan structures	569:596	enormous N-glycan structures	569:596	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
36935145	0	81	theme	cancer	84:89	arg1	cells					96:100	cancer stem cells	84:100	cancer stem cells	84:100	Gain-of-glycosylation in breast multi-drug-resistant MCF-7 adenocarcinoma cells and cancer stem cells characterized by site- and structure-specific N-glycoproteomics.
36935145	1	82	theme	N-glycan	578:585	arg1	structures					587:596	enormous N-glycan structures	569:596	enormous N-glycan structures	569:596	N-linked glycosylation (N-glycosylation) is a common protein post-translational modification, occurring on more than half of mammalian proteins; in striking contract with small molecule modifications (such as methylation, phosphorylation) with only single structures, N-glycosylation has multiple dimensional structural features (monosaccharide composition, sequence, linkage, anomer), which generates enormous N-glycan structures; and these structures widely regulate protein structure and functions.
37240090	3	0	theme	MALDI-TOF	740:748	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	0	theme	MALDI-TOF	740:748	arg1	MS					770:771	MS	770:771	MS	770:771	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	0	theme	MALDI-TOF	740:748	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	0	theme	MALDI-TOF	740:748	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	4	1	theme	microarray	888:897	arg1	slides					899:904	microarray slides	888:904	microarray slides	888:904	For microarray analysis, the samples printed on microarray slides were incubated with biotinylated lectins and detected using the fluorescent conjugate of streptavidin by a microarray scanner.
37240090	2	2	with	controls	438:445	arg1	ADHD					408:411	ADHD	408:411	ADHD	408:411	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	2	with	controls	438:445	arg1	disorder					398:405	attention-deficit hyperactivity disorder	366:405	attention-deficit hyperactivity disorder (ADHD)	366:412	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	3	theme	hyperactivity	384:396	arg1	ADHD					408:411	ADHD	408:411	ADHD	408:411	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	3	theme	hyperactivity	384:396	arg1	disorder					398:405	attention-deficit hyperactivity disorder	366:405	attention-deficit hyperactivity disorder (ADHD)	366:412	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	5	4	gly	found	1065:1069	arg1	samples					1053:1059	the ADHD patient samples	1036:1059	the ADHD patient samples	1036:1059	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	0	5	theme	Hyperactivity	82:94	arg1	Disorder					96:103	Attention-Deficit Hyperactivity Disorder	64:103	Attention-Deficit Hyperactivity Disorder	64:103	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	3	6	theme	desorption/ionization	702:722	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	6	theme	desorption/ionization	702:722	arg1	MS					770:771	MS	770:771	MS	770:771	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	6	theme	desorption/ionization	702:722	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	6	theme	desorption/ionization	702:722	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	8	7	from	ADHD	1608:1611	arg1	associations					1570:1581	functional associations	1559:1581	functional associations of glycan alterations in ADHD	1559:1611	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	5	8	with	sialylation	1206:1216	arg1	N-acetylglucosamine					1157:1175	bisecting N-acetylglucosamine	1147:1175	bisecting N-acetylglucosamine (GlcNAc)	1147:1184	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	5	8	with	sialylation	1206:1216	arg1	GlcNAc					1178:1183	GlcNAc	1178:1183	GlcNAc	1178:1183	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	2	9	theme	attention-deficit	366:382	arg1	ADHD					408:411	ADHD	408:411	ADHD	408:411	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	9	theme	attention-deficit	366:382	arg1	disorder					398:405	attention-deficit hyperactivity disorder	366:405	attention-deficit hyperactivity disorder (ADHD)	366:412	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	8	10	from	alterations	1593:1603	arg1	ADHD					1608:1611	ADHD	1608:1611	ADHD	1608:1611	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	5	11	theme	increased	1071:1079	arg1	fucosylation					1091:1102	increased antennary fucosylation	1071:1102	increased antennary fucosylation	1071:1102	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	0	12	from	Alterations	0:10	arg1	Composition					26:36	the Glycan Composition	15:36	the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder	15:103	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	4	13	theme	microarray	1013:1022	arg1	scanner					1024:1030	a microarray scanner	1011:1030	a microarray scanner	1011:1030	For microarray analysis, the samples printed on microarray slides were incubated with biotinylated lectins and detected using the fluorescent conjugate of streptavidin by a microarray scanner.
37240090	4	14	theme	fluorescent	970:980	arg1	conjugate					982:990	the fluorescent conjugate	966:990	the fluorescent conjugate of streptavidin by a microarray scanner	966:1030	For microarray analysis, the samples printed on microarray slides were incubated with biotinylated lectins and detected using the fluorescent conjugate of streptavidin by a microarray scanner.
37240090	8	15	from	associations	1570:1581	arg1	ADHD					1608:1611	ADHD	1608:1611	ADHD	1608:1611	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	7	16	theme	sample	1297:1302	arg1	size					1304:1307	The study's sample size	1285:1307	The study's sample size	1285:1307	The study's sample size and design do not allow far-reaching conclusions to be drawn.
37240090	3	17	theme	mass	751:754	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	17	theme	mass	751:754	arg1	MS					770:771	MS	770:771	MS	770:771	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	17	theme	mass	751:754	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	17	theme	mass	751:754	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	2	18	theme	proteins	517:524	arg1	depletion					495:503	depletion	495:503	depletion of abundant proteins (albumin and IgG)	495:542	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	5	19	theme	bisecting	1147:1155	arg1	N-acetylglucosamine					1157:1175	bisecting N-acetylglucosamine	1147:1175	bisecting N-acetylglucosamine (GlcNAc)	1147:1184	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	5	19	theme	bisecting	1147:1155	arg1	GlcNAc					1178:1183	GlcNAc	1178:1183	GlcNAc	1178:1183	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	5	20	with	fucosylation	1091:1102	arg1	N-acetylglucosamine					1157:1175	bisecting N-acetylglucosamine	1147:1175	bisecting N-acetylglucosamine (GlcNAc)	1147:1184	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	5	20	with	fucosylation	1091:1102	arg1	GlcNAc					1178:1183	GlcNAc	1178:1183	GlcNAc	1178:1183	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	3	21	gly	glycoprotein	611:622	arg1	glycoprotein					611:622	a lectin-based glycoprotein microarray	596:633	a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures	596:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	2	22	theme	abundant	508:515	arg1	proteins					517:524	abundant proteins	508:524	abundant proteins (albumin and IgG)	508:542	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	22	theme	abundant	508:515	arg1	IgG					539:541	IgG	539:541	IgG	539:541	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	22	theme	abundant	508:515	arg1	albumin					527:533	albumin	527:533	albumin	527:533	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	8	23	theme	functional	1559:1568	arg1	associations					1570:1581	functional associations	1559:1581	functional associations of glycan alterations in ADHD	1559:1611	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	8	24	theme	better	1415:1420	arg1	diagnosis					1445:1453	a better and more comprehensive diagnosis	1413:1453	a better and more comprehensive diagnosis of ADHD	1413:1461	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	4	25	theme	streptavidin	995:1006	arg1	conjugate					982:990	the fluorescent conjugate	966:990	the fluorescent conjugate of streptavidin by a microarray scanner	966:1030	For microarray analysis, the samples printed on microarray slides were incubated with biotinylated lectins and detected using the fluorescent conjugate of streptavidin by a microarray scanner.
37240090	2	26	theme	samples	462:468	arg1	types					453:457	3 types	451:457	3 types of samples	451:468	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	0	27	from	Composition	26:36	arg1	Disorder					96:103	Attention-Deficit Hyperactivity Disorder	64:103	Attention-Deficit Hyperactivity Disorder	64:103	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	7	28	theme	far-reaching	1333:1344	arg1	conclusions					1346:1356	far-reaching conclusions	1333:1356	far-reaching conclusions	1333:1356	The study's sample size and design do not allow far-reaching conclusions to be drawn.
37240090	8	29	theme	strong	1395:1400	arg1	demand					1402:1407	a strong demand	1393:1407	a strong demand for a better and more comprehensive diagnosis of ADHD	1393:1461	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	8	30	theme	new	1534:1536	arg1	horizons					1538:1545	new horizons	1534:1545	new horizons	1534:1545	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	8	31	theme	comprehensive	1431:1443	arg1	diagnosis					1445:1453	a better and more comprehensive diagnosis	1413:1453	a better and more comprehensive diagnosis of ADHD	1413:1461	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	5	32	theme	decreased	1105:1113	arg1	N-glycans					1132:1140	decreased di-/triantennary N-glycans	1105:1140	decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc)	1105:1184	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	0	33	theme	Glycan	19:24	arg1	Composition					26:36	the Glycan Composition	15:36	the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder	15:103	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	8	34	theme	ADHD	1458:1461	arg1	diagnosis					1445:1453	a better and more comprehensive diagnosis	1413:1453	a better and more comprehensive diagnosis of ADHD	1413:1461	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	2	35	dep	proteins	517:524	arg1	proteins					517:524	abundant proteins	508:524	abundant proteins (albumin and IgG)	508:542	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	35	dep	proteins	517:524	arg1	IgG					539:541	IgG	539:541	IgG	539:541	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	35	dep	proteins	517:524	arg1	albumin					527:533	albumin	527:533	albumin	527:533	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	4	36	theme	microarray	844:853	arg1	analysis					855:862	microarray analysis	844:862	microarray analysis	844:862	For microarray analysis, the samples printed on microarray slides were incubated with biotinylated lectins and detected using the fluorescent conjugate of streptavidin by a microarray scanner.
37240090	5	37	with	N-glycans	1132:1140	arg1	N-acetylglucosamine					1157:1175	bisecting N-acetylglucosamine	1147:1175	bisecting N-acetylglucosamine (GlcNAc)	1147:1184	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	5	37	with	N-glycans	1132:1140	arg1	GlcNAc					1178:1183	GlcNAc	1178:1183	GlcNAc	1178:1183	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	1	38	theme	glycomic	208:215	arg1	analysis					217:224	glycomic analysis	208:224	glycomic analysis	208:224	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	1	39	theme	neurodevelopmental	298:315	arg1	field					317:321	the neurodevelopmental field	294:321	the neurodevelopmental field	294:321	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	3	40	theme	high-throughput	644:658	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	40	theme	high-throughput	644:658	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	40	theme	high-throughput	644:658	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	1	41	theme	protein	117:123	arg1	glycosylation					125:137	protein glycosylation	117:137	protein glycosylation	117:137	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	8	42	theme	alterations	1593:1603	arg1	associations					1570:1581	functional associations	1559:1581	functional associations of glycan alterations in ADHD	1559:1611	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	1	43	theme	analysis	217:224	arg1	importance					194:203	the importance	190:203	the importance of glycomic analysis in the research of disorders	190:253	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	8	44	theme	glycan	1586:1591	arg1	alterations					1593:1603	glycan alterations	1586:1603	glycan alterations in ADHD	1586:1611	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	3	45	theme	glycan	660:665	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	45	theme	glycan	660:665	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	45	theme	glycan	660:665	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	5	46	theme	patient	1045:1051	arg1	samples					1053:1059	the ADHD patient samples	1036:1059	the ADHD patient samples	1036:1059	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	2	47	theme	healthy	430:436	arg1	controls					438:445	10 matching healthy controls	418:445	10 matching healthy controls for 3 types of samples	418:468	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	5	48	theme	decreased	1191:1199	arg1	sialylation					1206:1216	decreased α2-3 sialylation	1191:1216	decreased α2-3 sialylation	1191:1216	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	5	49	theme	di-/triantennary	1115:1130	arg1	N-glycans					1132:1140	decreased di-/triantennary N-glycans	1105:1140	decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc)	1105:1184	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	2	50	theme	matching	421:428	arg1	controls					438:445	10 matching healthy controls	418:445	10 matching healthy controls for 3 types of samples	418:468	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	0	51	theme	Glycoproteins	47:59	arg1	Composition					26:36	the Glycan Composition	15:36	the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder	15:103	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	5	52	theme	α2-3	1201:1204	arg1	sialylation					1206:1216	decreased α2-3 sialylation	1191:1216	decreased α2-3 sialylation	1191:1216	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	2	53	with	children	352:359	arg1	ADHD					408:411	ADHD	408:411	ADHD	408:411	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	53	with	children	352:359	arg1	disorder					398:405	attention-deficit hyperactivity disorder	366:405	attention-deficit hyperactivity disorder (ADHD)	366:412	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	8	54	theme	presented	1508:1516	arg1	approach					1518:1525	the presented approach	1504:1525	the presented approach	1504:1525	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	0	55	theme	Serum	41:45	arg1	Glycoproteins					47:59	Serum Glycoproteins	41:59	Serum Glycoproteins	41:59	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	3	56	theme	standard	779:786	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	56	theme	standard	779:786	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	56	theme	standard	779:786	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	57	theme	matrix-assisted	680:694	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	57	theme	matrix-assisted	680:694	arg1	MS					770:771	MS	770:771	MS	770:771	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	57	theme	matrix-assisted	680:694	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	57	theme	matrix-assisted	680:694	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	58	theme	analytical	567:576	arg1	methods					578:584	The analytical methods	563:584	The analytical methods used	563:589	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	58	theme	analytical	567:576	arg1	microarray					624:633	a lectin-based glycoprotein microarray	596:633	a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures	596:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	8	59	theme	obtained	1472:1479	arg1	results					1481:1487	the obtained results	1468:1487	the obtained results	1468:1487	In any case, there is a strong demand for a better and more comprehensive diagnosis of ADHD, and the obtained results emphasize that the presented approach brings new horizons to studying functional associations of glycan alterations in ADHD.
37240090	2	60	theme	isolated	549:556	arg1	IgG					558:560	isolated IgG	549:560	isolated IgG	549:560	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	3	61	theme	laser	696:700	arg1	method					788:793	a standard method	777:793	a standard method for the identification of glycan structures	777:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	61	theme	laser	696:700	arg1	MS					770:771	MS	770:771	MS	770:771	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	61	theme	laser	696:700	arg1	spectrometry					756:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry	680:767	matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS)	680:772	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	61	theme	laser	696:700	arg1	analysis					667:674	high-throughput glycan analysis	644:674	high-throughput glycan analysis	644:674	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	62	theme	lectin-based	598:609	arg1	methods					578:584	The analytical methods	563:584	The analytical methods used	563:589	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	62	theme	lectin-based	598:609	arg1	microarray					624:633	a lectin-based glycoprotein microarray	596:633	a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures	596:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	63	theme	glycan	821:826	arg1	structures					828:837	glycan structures	821:837	glycan structures	821:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	4	64	theme	biotinylated	926:937	arg1	lectins					939:945	biotinylated lectins	926:945	biotinylated lectins	926:945	For microarray analysis, the samples printed on microarray slides were incubated with biotinylated lectins and detected using the fluorescent conjugate of streptavidin by a microarray scanner.
37240090	5	65	theme	antennary	1081:1089	arg1	fucosylation					1091:1102	increased antennary fucosylation	1071:1102	increased antennary fucosylation	1071:1102	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	3	66	theme	glycoprotein	611:622	arg1	methods					578:584	The analytical methods	563:584	The analytical methods used	563:589	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	3	66	theme	glycoprotein	611:622	arg1	microarray					624:633	a lectin-based glycoprotein microarray	596:633	a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures	596:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	1	67	from	importance	194:203	arg1	research					233:240	the research	229:240	the research of disorders	229:253	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	2	68	dep	glycoprofiled	327:339	arg1	IgG					558:560	isolated IgG	549:560	isolated IgG	549:560	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	68	dep	glycoprofiled	327:339	arg1	sera					484:487	sera	484:487	sera after depletion of abundant proteins (albumin and IgG)	484:542	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	2	68	dep	glycoprofiled	327:339	arg1	serum					477:481	whole serum	471:481	whole serum	471:481	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	3	69	theme	structures	828:837	arg1	identification					803:816	the identification	799:816	the identification of glycan structures	799:837	The analytical methods used were a lectin-based glycoprotein microarray enabling high-throughput glycan analysis and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) as a standard method for the identification of glycan structures.
37240090	0	70	theme	Attention-Deficit	64:80	arg1	Disorder					96:103	Attention-Deficit Hyperactivity Disorder	64:103	Attention-Deficit Hyperactivity Disorder	64:103	Alterations in the Glycan Composition of Serum Glycoproteins in Attention-Deficit Hyperactivity Disorder.
37240090	6	71	theme	independent	1248:1258	arg1	methods					1260:1266	both independent methods	1243:1266	both independent methods	1243:1266	The results obtained by both independent methods were consistent.
37240090	1	72	theme	most	159:162	arg1	processes					175:183	most biological processes	159:183	most biological processes	159:183	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	1	73	from	Changes	106:112	arg1	glycosylation					125:137	protein glycosylation	117:137	protein glycosylation	117:137	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	1	74	theme	disorders	245:253	arg1	research					233:240	the research	229:240	the research of disorders	229:253	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
37240090	2	75	theme	whole	471:475	arg1	serum					477:481	whole serum	471:481	whole serum	471:481	We glycoprofiled sera in 10 children with attention-deficit hyperactivity disorder (ADHD) and 10 matching healthy controls for 3 types of samples: whole serum, sera after depletion of abundant proteins (albumin and IgG), and isolated IgG.
37240090	5	76	theme	ADHD	1040:1043	arg1	samples					1053:1059	the ADHD patient samples	1036:1059	the ADHD patient samples	1036:1059	In the ADHD patient samples, we found increased antennary fucosylation, decreased di-/triantennary N-glycans with bisecting N-acetylglucosamine (GlcNAc), and decreased α2-3 sialylation.
37240090	1	77	theme	biological	164:173	arg1	processes					175:183	most biological processes	159:183	most biological processes	159:183	Changes in protein glycosylation are associated with most biological processes, and the importance of glycomic analysis in the research of disorders is constantly increasing, including in the neurodevelopmental field.
35343965	5	0	from	interaction	860:870	arg1	understanding					797:809	understanding	797:809	understanding of the role of glycoproteins in pathogenicity or interaction with the environment	797:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	7	1	theme	specific	1218:1225	arg1	genes					1227:1231	specific genes	1218:1231	specific genes thought to be involved in the glycosylation process	1218:1283	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	9	2	theme	chain	1520:1524	arg1	length					1526:1531	chain length	1520:1531	chain length	1520:1531	Flagellar glycans show diversity in carbohydrate composition and chain length between Aeromonas strains.
35343965	7	3	from	expression	1320:1329	arg1	mutation					1206:1213	mutation	1206:1213	mutation of specific genes thought to be involved in the glycosylation process	1206:1283	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	7	3	from	expression	1320:1329	arg1	study					1293:1297	the study	1289:1297	the study of its impact on the expression of the target glycoprotein and the modifying glycan	1289:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	12	4	theme	flagellar	2068:2076	arg1	glycan					2078:2083	a flagellar glycan	2066:2083	a flagellar glycan	2066:2083	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	6	5	theme	biosynthetic	1030:1041	arg1	lipopolysaccharide					1061:1078	lipopolysaccharide	1061:1078	lipopolysaccharide	1061:1078	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	6	5	theme	biosynthetic	1030:1041	arg1	pathways					1105:1112	capsule biosynthetic pathways	1084:1112	capsule biosynthetic pathways	1084:1112	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	6	5	theme	biosynthetic	1030:1041	arg1	pathways					1043:1050	other polysaccharide biosynthetic pathways	1009:1050	other polysaccharide biosynthetic pathways	1009:1050	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	4	6	gly	glycoproteins	519:531	arg1	glycoproteins					519:531	glycoproteins	519:531	glycoproteins	519:531	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	6	7	theme	other	1009:1013	arg1	lipopolysaccharide					1061:1078	lipopolysaccharide	1061:1078	lipopolysaccharide	1061:1078	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	6	7	theme	other	1009:1013	arg1	pathways					1105:1112	capsule biosynthetic pathways	1084:1112	capsule biosynthetic pathways	1084:1112	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	6	7	theme	other	1009:1013	arg1	pathways					1043:1050	other polysaccharide biosynthetic pathways	1009:1050	other polysaccharide biosynthetic pathways	1009:1050	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	14	8	theme	glycan	2245:2250	arg1	mutant					2262:2267	the glycan deficient mutant	2241:2267	the glycan deficient mutant	2241:2267	This will be achieved by comparing the glycan deficient mutant to the wild-type strain.
35343965	7	9	theme	glycosylation	1144:1156	arg1	importance					1130:1139	The functional importance	1115:1139	The functional importance of glycosylation	1115:1156	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	3	10	theme	higher	322:327	arg1	diversity					329:337	higher diversity	322:337	higher diversity in sugar composition and structure	322:372	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	7	11	from	study	1293:1297	arg1	expression					1320:1329	the expression	1316:1329	the expression of the target glycoprotein and the modifying glycan	1316:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	3	12	with	interaction	461:471	arg1	environment					482:492	the environment	478:492	the environment	478:492	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	13	13	theme	glycan	2198:2203	arg1	role					2186:2189	the role	2182:2189	the role of the glycan	2182:2203	This includes the potential to understand the function of the glycosyltransferases involved and the role of the glycan.
35343965	13	13	theme	glycan	2198:2203	arg1	function					2132:2139	the function	2128:2139	the function of the glycosyltransferases involved	2128:2176	This includes the potential to understand the function of the glycosyltransferases involved and the role of the glycan.
35343965	8	14	theme	Mesophilic	1384:1393	arg1	Aeromonas					1395:1403	Mesophilic Aeromonas	1384:1403	Mesophilic Aeromonas	1384:1403	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	5	15	theme	glycan	739:744	arg1	composition					746:756	glycan composition	739:756	glycan composition	739:756	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	5	16	from	understanding	797:809	arg1	interaction					860:870	interaction	860:870	interaction with the environment	860:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	5	16	from	understanding	797:809	arg1	pathogenicity					843:855	pathogenicity	843:855	pathogenicity	843:855	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	6	17	theme	biosynthetic	1092:1103	arg1	pathways					1105:1112	capsule biosynthetic pathways	1084:1112	capsule biosynthetic pathways	1084:1112	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	8	18	theme	single	1412:1417	arg1	flagellum					1444:1452	a single and O-glycosylated polar flagellum	1410:1452	a single and O-glycosylated polar flagellum	1410:1452	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	0	19	theme	Glycosyltransferases	62:81	arg1	Role					44:47	the Role	40:47	the Role of Bacterial Glycosyltransferases in Bacterial Motility	40:103	Generation of Null Mutants to Elucidate the Role of Bacterial Glycosyltransferases in Bacterial Motility.
35343965	12	20	theme	regions	1994:2000	arg1	involvement					1963:1973	the involvement	1959:1973	the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan	1959:2083	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	8	21	theme	O-glycosylated	1423:1436	arg1	flagellum					1444:1452	a single and O-glycosylated polar flagellum	1410:1452	a single and O-glycosylated polar flagellum	1410:1452	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	0	22	theme	Bacterial	86:94	arg1	Motility					96:103	Bacterial Motility	86:103	Bacterial Motility	86:103	Generation of Null Mutants to Elucidate the Role of Bacterial Glycosyltransferases in Bacterial Motility.
35343965	12	23	theme	putative	2013:2020	arg1	glycosyltransferases					2022:2041	putative glycosyltransferases	2013:2041	putative glycosyltransferases	2013:2041	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	11	24	from	impact	1791:1796	arg1	colonization					1834:1845	colonization	1834:1845	colonization	1834:1845	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	11	24	from	impact	1791:1796	arg1	adhesion					1801:1808	adhesion	1801:1808	adhesion	1801:1808	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	11	24	from	impact	1791:1796	arg1	formation					1819:1827	biofilm formation	1811:1827	biofilm formation	1811:1827	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	13	25	theme	glycosyltransferases	2148:2167	arg1	role					2186:2189	the role	2182:2189	the role of the glycan	2182:2203	This includes the potential to understand the function of the glycosyltransferases involved and the role of the glycan.
35343965	13	25	theme	glycosyltransferases	2148:2167	arg1	function					2132:2139	the function	2128:2139	the function of the glycosyltransferases involved	2128:2176	This includes the potential to understand the function of the glycosyltransferases involved and the role of the glycan.
35343965	0	26	theme	Bacterial	52:60	arg1	Glycosyltransferases					62:81	Bacterial Glycosyltransferases	52:81	Bacterial Glycosyltransferases	52:81	Generation of Null Mutants to Elucidate the Role of Bacterial Glycosyltransferases in Bacterial Motility.
35343965	7	27	theme	glycosylation	1263:1275	arg1	process					1277:1283	the glycosylation process	1259:1283	the glycosylation process	1259:1283	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	1	28	from	study	110:114	arg1	prokaryotes					136:146	prokaryotes	136:146	prokaryotes	136:146	The study of glycosylation in prokaryotes is a rapidly growing area.
35343965	4	29	theme	process	590:596	arg1	stages					565:570	different stages	555:570	different stages of the infectious process	555:596	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	0	30	theme	Null	14:17	arg1	Mutants					19:25	Null Mutants	14:25	Null Mutants	14:25	Generation of Null Mutants to Elucidate the Role of Bacterial Glycosyltransferases in Bacterial Motility.
35343965	3	31	theme	recognition	435:445	arg1	processes					447:455	bacterial-host recognition processes	420:455	bacterial-host recognition processes	420:455	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	9	32	theme	Aeromonas	1541:1549	arg1	strains					1551:1557	Aeromonas strains	1541:1557	Aeromonas strains	1541:1557	Flagellar glycans show diversity in carbohydrate composition and chain length between Aeromonas strains.
35343965	5	33	theme	glycoproteins	826:838	arg1	role					818:821	the role	814:821	the role of glycoproteins in pathogenicity or interaction with the environment	814:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	7	34	theme	glycan	1376:1381	arg1	expression					1320:1329	the expression	1316:1329	the expression of the target glycoprotein and the modifying glycan	1316:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	7	35	from	mutation	1206:1213	arg1	expression					1320:1329	the expression	1316:1329	the expression of the target glycoprotein and the modifying glycan	1316:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	11	36	theme	pseudaminic	1702:1712	arg1	derivative					1719:1728	The pseudaminic acid derivative	1698:1728	The pseudaminic acid derivative	1698:1728	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	12	37	theme	mutants	1925:1931	arg1	construction					1904:1915	the construction	1900:1915	the construction of null mutants	1900:1931	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	12	38	theme	null	1920:1923	arg1	mutants					1925:1931	null mutants	1920:1931	null mutants	1920:1931	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	10	39	theme	acid	1617:1620	arg1	derivative					1622:1631	a pseudaminic acid derivative	1603:1631	a pseudaminic acid derivative as the linking sugar that modifies serine or threonine residues	1603:1695	However, all strains analyzed to date show a pseudaminic acid derivative as the linking sugar that modifies serine or threonine residues.
35343965	2	40	theme	glycosylated	201:212	arg1	structures					214:223	different glycosylated structures	191:223	different glycosylated structures	191:223	Bacteria harbor different glycosylated structures on their surface whose glycans constitute a strain-specific barcode.
35343965	5	41	gly	glycoproteins	826:838	arg1	glycoproteins					826:838	glycoproteins	826:838	glycoproteins	826:838	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	7	42	theme	glycoprotein	1345:1356	arg1	expression					1320:1329	the expression	1316:1329	the expression of the target glycoprotein and the modifying glycan	1316:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	4	43	theme	specific	643:650	arg1	functions					652:660	specific functions	643:660	specific functions of glycoproteins	643:677	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	3	44	from	interaction	461:471	arg1	important					407:415	important	407:415	important	407:415	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	3	44	from	interaction	461:471	arg1	glycans					309:315	The associated glycans	294:315	The associated glycans	294:315	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	9	45	theme	carbohydrate	1491:1502	arg1	composition					1504:1514	carbohydrate composition	1491:1514	carbohydrate composition	1491:1514	Flagellar glycans show diversity in carbohydrate composition and chain length between Aeromonas strains.
35343965	6	46	theme	protein	971:977	arg1	glycosylation					979:991	protein glycosylation	971:991	protein glycosylation	971:991	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	10	47	theme	linking	1640:1646	arg1	sugar					1648:1652	the linking sugar	1636:1652	the linking sugar that modifies serine or threonine residues	1636:1695	However, all strains analyzed to date show a pseudaminic acid derivative as the linking sugar that modifies serine or threonine residues.
35343965	11	48	theme	polar	1746:1750	arg1	assembly					1761:1768	polar flagella assembly	1746:1768	polar flagella assembly	1746:1768	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	5	49	with	pathogenicity	843:855	arg1	environment					881:891	the environment	877:891	the environment	877:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	7	50	theme	several	1181:1187	arg1	bacteria					1189:1196	several bacteria	1181:1196	several bacteria	1181:1196	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	1	51	theme	growing	161:167	arg1	study					110:114	The study	106:114	The study of glycosylation in prokaryotes	106:146	The study of glycosylation in prokaryotes is a rapidly growing area.
35343965	1	51	theme	growing	161:167	arg1	area					169:172	a rapidly growing area	151:172	a rapidly growing area	151:172	The study of glycosylation in prokaryotes is a rapidly growing area.
35343965	3	52	with	processes	447:455	arg1	environment					482:492	the environment	478:492	the environment	478:492	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	14	53	theme	wild-type	2276:2284	arg1	strain					2286:2291	the wild-type strain	2272:2291	the wild-type strain	2272:2291	This will be achieved by comparing the glycan deficient mutant to the wild-type strain.
35343965	5	54	theme	role	818:821	arg1	understanding					797:809	understanding	797:809	understanding of the role of glycoproteins in pathogenicity or interaction with the environment	797:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	12	55	from	involvement	1963:1973	arg1	biosynthesis					2050:2061	the biosynthesis	2046:2061	the biosynthesis of a flagellar glycan	2046:2083	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	12	56	used	used	1940:1943	arg2	construction					1904:1915	the construction	1900:1915	the construction of null mutants	1900:1931	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	10	57	dep	serine	1668:1673	arg1	residues					1688:1695	residues	1688:1695	residues	1688:1695	However, all strains analyzed to date show a pseudaminic acid derivative as the linking sugar that modifies serine or threonine residues.
35343965	12	58	theme	glycan	2078:2083	arg1	biosynthesis					2050:2061	the biosynthesis	2046:2061	the biosynthesis of a flagellar glycan	2046:2083	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	6	59	theme	polysaccharide	1015:1028	arg1	lipopolysaccharide					1061:1078	lipopolysaccharide	1061:1078	lipopolysaccharide	1061:1078	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	6	59	theme	polysaccharide	1015:1028	arg1	pathways					1105:1112	capsule biosynthetic pathways	1084:1112	capsule biosynthetic pathways	1084:1112	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	6	59	theme	polysaccharide	1015:1028	arg1	pathways					1043:1050	other polysaccharide biosynthetic pathways	1009:1050	other polysaccharide biosynthetic pathways	1009:1050	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	3	60	theme	associated	298:307	arg1	important					407:415	important	407:415	important	407:415	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	3	60	theme	associated	298:307	arg1	glycans					309:315	The associated glycans	294:315	The associated glycans	294:315	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	5	61	with	interaction	860:870	arg1	environment					881:891	the environment	877:891	the environment	877:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	14	62	theme	deficient	2252:2260	arg1	mutant					2262:2267	the glycan deficient mutant	2241:2267	the glycan deficient mutant	2241:2267	This will be achieved by comparing the glycan deficient mutant to the wild-type strain.
35343965	5	63	theme	structure	759:767	arg1	understanding					722:734	the understanding	718:734	the understanding of glycan composition, structure, and biosynthesis pathways	718:794	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	8	64	contain	have	1405:1408	arg2	flagellum					1444:1452	a single and O-glycosylated polar flagellum	1410:1452	a single and O-glycosylated polar flagellum	1410:1452	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	8	64	contain	have	1405:1408	arg1	Aeromonas					1395:1403	Mesophilic Aeromonas	1384:1403	Mesophilic Aeromonas	1384:1403	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	4	65	theme	pathogenic	498:507	arg1	bacteria					509:516	pathogenic bacteria	498:516	pathogenic bacteria	498:516	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	7	66	theme	functional	1119:1128	arg1	importance					1130:1139	The functional importance	1115:1139	The functional importance of glycosylation	1115:1156	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	7	67	gly	glycoprotein	1345:1356	arg1	glycoprotein					1345:1356	the target glycoprotein	1334:1356	the target glycoprotein	1334:1356	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	5	68	theme	composition	746:756	arg1	understanding					722:734	the understanding	718:734	the understanding of glycan composition, structure, and biosynthesis pathways	718:794	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	2	69	gly	glycosylated	201:212	arg1	structures					214:223	different glycosylated structures	191:223	different glycosylated structures	191:223	Bacteria harbor different glycosylated structures on their surface whose glycans constitute a strain-specific barcode.
35343965	5	70	from	role	818:821	arg1	interaction					860:870	interaction	860:870	interaction with the environment	860:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	5	70	from	role	818:821	arg1	pathogenicity					843:855	pathogenicity	843:855	pathogenicity	843:855	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	2	71	theme	strain-specific	269:283	arg1	barcode					285:291	a strain-specific barcode	267:291	a strain-specific barcode	267:291	Bacteria harbor different glycosylated structures on their surface whose glycans constitute a strain-specific barcode.
35343965	1	72	theme	glycosylation	119:131	arg1	study					110:114	The study	106:114	The study of glycosylation in prokaryotes	106:146	The study of glycosylation in prokaryotes is a rapidly growing area.
35343965	1	72	theme	glycosylation	119:131	arg1	area					169:172	a rapidly growing area	151:172	a rapidly growing area	151:172	The study of glycosylation in prokaryotes is a rapidly growing area.
35343965	7	73	from	impact	1306:1311	arg1	expression					1320:1329	the expression	1316:1329	the expression of the target glycoprotein and the modifying glycan	1316:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	7	74	theme	impact	1306:1311	arg1	mutation					1206:1213	mutation	1206:1213	mutation of specific genes thought to be involved in the glycosylation process	1206:1283	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	7	74	theme	impact	1306:1311	arg1	study					1293:1297	the study	1289:1297	the study of its impact on the expression of the target glycoprotein and the modifying glycan	1289:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	6	75	theme	capsule	1084:1090	arg1	pathways					1105:1112	capsule biosynthetic pathways	1084:1112	capsule biosynthetic pathways	1084:1112	Furthermore, in some bacteria, the enzymes required for protein glycosylation are shared with other polysaccharide biosynthetic pathways, such as lipopolysaccharide and capsule biosynthetic pathways.
35343965	5	76	theme	biosynthesis	774:785	arg1	pathways					787:794	biosynthesis pathways	774:794	biosynthesis pathways	774:794	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	5	77	from	pathogenicity	843:855	arg1	understanding					797:809	understanding	797:809	understanding of the role of glycoproteins in pathogenicity or interaction with the environment	797:891	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	11	78	contain	has	1784:1786	arg2	impact					1791:1796	an impact	1788:1796	an impact on adhesion, biofilm formation, and colonization	1788:1845	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	11	78	contain	has	1784:1786	arg1	loss					1779:1782	its loss	1775:1782	its loss	1775:1782	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	3	79	theme	sugar	342:346	arg1	composition					348:358	sugar composition	342:358	sugar composition	342:358	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	4	80	theme	different	555:563	arg1	stages					565:570	different stages	555:570	different stages of the infectious process	555:596	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	3	81	from	processes	447:455	arg1	important					407:415	important	407:415	important	407:415	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	3	81	from	processes	447:455	arg1	glycans					309:315	The associated glycans	294:315	The associated glycans	294:315	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	0	82	from	Role	44:47	arg1	Motility					96:103	Bacterial Motility	86:103	Bacterial Motility	86:103	Generation of Null Mutants to Elucidate the Role of Bacterial Glycosyltransferases in Bacterial Motility.
35343965	5	83	theme	pathways	787:794	arg1	understanding					722:734	the understanding	718:734	the understanding of glycan composition, structure, and biosynthesis pathways	718:794	However, despite the advances made in the understanding of glycan composition, structure, and biosynthesis pathways, understanding of the role of glycoproteins in pathogenicity or interaction with the environment remains very limited.
35343965	12	84	theme	genes	1978:1982	arg1	involvement					1963:1973	the involvement	1959:1973	the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan	1959:2083	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	4	85	gly	glycoproteins	665:677	arg1	glycoproteins					665:677	glycoproteins	665:677	glycoproteins	665:677	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	8	86	theme	polar	1438:1442	arg1	flagellum					1444:1452	a single and O-glycosylated polar flagellum	1410:1452	a single and O-glycosylated polar flagellum	1410:1452	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	3	87	from	important	407:415	arg1	interaction					461:471	interaction	461:471	interaction with the environment	461:492	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	3	87	from	important	407:415	arg1	processes					447:455	bacterial-host recognition processes	420:455	bacterial-host recognition processes	420:455	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	12	88	theme	genome	1987:1992	arg1	regions					1994:2000	genome regions	1987:2000	genome regions	1987:2000	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	0	89	theme	Mutants	19:25	arg1	Generation					0:9	Generation	0:9	Generation of Null Mutants	0:25	Generation of Null Mutants to Elucidate the Role of Bacterial Glycosyltransferases in Bacterial Motility.
35343965	8	90	gly	O-glycosylated	1423:1436	arg1	flagellum					1444:1452	a single and O-glycosylated polar flagellum	1410:1452	a single and O-glycosylated polar flagellum	1410:1452	Mesophilic Aeromonas have a single and O-glycosylated polar flagellum.
35343965	4	91	theme	glycan	603:608	arg1	modifications					610:622	glycan modifications	603:622	glycan modifications	603:622	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	7	92	theme	modifying	1366:1374	arg1	glycan					1376:1381	the modifying glycan	1362:1381	the modifying glycan	1362:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	12	93	contain	containing	2002:2011	arg2	glycosyltransferases					2022:2041	putative glycosyltransferases	2013:2041	putative glycosyltransferases	2013:2041	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	12	93	contain	containing	2002:2011	arg1	genes					1978:1982	genes	1978:1982	genes	1978:1982	The protocol detailed in this article describes how the construction of null mutants can be used to understand the involvement of genes or genome regions containing putative glycosyltransferases in the biosynthesis of a flagellar glycan.
35343965	7	94	theme	genes	1227:1231	arg1	mutation					1206:1213	mutation	1206:1213	mutation of specific genes thought to be involved in the glycosylation process	1206:1283	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	7	94	theme	genes	1227:1231	arg1	study					1293:1297	the study	1289:1297	the study of its impact on the expression of the target glycoprotein and the modifying glycan	1289:1381	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	9	95	theme	Flagellar	1455:1463	arg1	glycans					1465:1471	Flagellar glycans	1455:1471	Flagellar glycans	1455:1471	Flagellar glycans show diversity in carbohydrate composition and chain length between Aeromonas strains.
35343965	3	96	theme	bacterial-host	420:433	arg1	processes					447:455	bacterial-host recognition processes	420:455	bacterial-host recognition processes	420:455	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	4	97	theme	infectious	579:588	arg1	process					590:596	the infectious process	575:596	the infectious process	575:596	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	11	98	theme	biofilm	1811:1817	arg1	formation					1819:1827	biofilm formation	1811:1827	biofilm formation	1811:1827	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	9	99	from	diversity	1478:1486	arg1	composition					1504:1514	carbohydrate composition	1491:1514	carbohydrate composition	1491:1514	Flagellar glycans show diversity in carbohydrate composition and chain length between Aeromonas strains.
35343965	9	99	from	diversity	1478:1486	arg1	length					1526:1531	chain length	1520:1531	chain length	1520:1531	Flagellar glycans show diversity in carbohydrate composition and chain length between Aeromonas strains.
35343965	7	100	theme	target	1338:1343	arg1	glycoprotein					1345:1356	the target glycoprotein	1334:1356	the target glycoprotein	1334:1356	The functional importance of glycosylation has been elucidated in several bacteria through mutation of specific genes thought to be involved in the glycosylation process and the study of its impact on the expression of the target glycoprotein and the modifying glycan.
35343965	10	101	theme	pseudaminic	1605:1615	arg1	derivative					1622:1631	a pseudaminic acid derivative	1603:1631	a pseudaminic acid derivative as the linking sugar that modifies serine or threonine residues	1603:1695	However, all strains analyzed to date show a pseudaminic acid derivative as the linking sugar that modifies serine or threonine residues.
35343965	2	102	theme	different	191:199	arg1	structures					214:223	different glycosylated structures	191:223	different glycosylated structures	191:223	Bacteria harbor different glycosylated structures on their surface whose glycans constitute a strain-specific barcode.
35343965	4	103	theme	glycoproteins	665:677	arg1	functions					652:660	specific functions	643:660	specific functions of glycoproteins	643:677	In pathogenic bacteria, glycoproteins have been involved in different stages of the infectious process, and glycan modifications can interfere with specific functions of glycoproteins.
35343965	11	104	theme	flagella	1752:1759	arg1	assembly					1761:1768	polar flagella assembly	1746:1768	polar flagella assembly	1746:1768	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	11	105	theme	acid	1714:1717	arg1	derivative					1719:1728	The pseudaminic acid derivative	1698:1728	The pseudaminic acid derivative	1698:1728	The pseudaminic acid derivative is required for polar flagella assembly, and its loss has an impact on adhesion, biofilm formation, and colonization.
35343965	3	106	from	diversity	329:337	arg1	composition					348:358	sugar composition	342:358	sugar composition	342:358	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
35343965	3	106	from	diversity	329:337	arg1	structure					364:372	structure	364:372	structure	364:372	The associated glycans show higher diversity in sugar composition and structure than those of eukaryotes and are important in bacterial-host recognition processes and interaction with the environment.
36447399	7	0	theme	auristatin	1466:1475	arg1	MMAE					1480:1483	MMAE	1480:1483	MMAE	1480:1483	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	7	0	theme	auristatin	1466:1475	arg1	E					1477:1477	monomethyl auristatin E	1455:1477	monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO)	1455:1563	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	4	1	theme	cetuximab	1042:1050	arg1	glycan					1032:1037	the Fab glycan	1024:1037	the Fab glycan of cetuximab	1024:1050	Using a bacterial sialytransferase, we incorporated N-azidoacetylneuraminic acid (Neu5NAz) into the Fab glycan of cetuximab.
36447399	1	2	theme	regulatory	424:433	arg1	agencies					435:442	regulatory agencies	424:442	regulatory agencies	424:442	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	2	3	dep	residues	539:546	arg1	Cys					566:568	Cys	566:568	Cys	566:568	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	3	dep	residues	539:546	arg1	residues					539:546	antibody surface residues	522:546	antibody surface residues (typically Lys or Cys)	522:569	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	3	dep	residues	539:546	arg1	Lys					559:561	Lys	559:561	Lys	559:561	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	4	theme	product	648:654	arg1	heterogeneity					656:668	overall product heterogeneity	640:668	overall product heterogeneity	640:668	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	3	5	from	glycans	859:865	arg1	range					885:889	a narrow ratio range	870:889	a narrow ratio range through functionalized sialic acids	870:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	7	6	theme	incorporated	1429:1440	arg1	Neu5NAz					1442:1448	the incorporated Neu5NAz	1425:1448	the incorporated Neu5NAz	1425:1448	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	9	7	from	potent	1767:1772	arg1	assays					1790:1795	cytotoxicity assays	1777:1795	cytotoxicity assays	1777:1795	We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols.
36447399	2	8	theme	epitope	597:603	arg1	binding					605:611	epitope binding	597:611	epitope binding	597:611	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	10	9	theme	interference	1951:1962	arg1	benefit					1921:1927	the additional benefit	1906:1927	the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure	1906:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	8	10	with	cetuximab-MMAE	1600:1613	arg1	ratios					1655:1660	drug/antibody ratios	1641:1660	drug/antibody ratios in the range of 1.3 to 2.5	1641:1687	Through this process, we obtained cetuximab-MMAE and trastuzumab-MMAE with drug/antibody ratios in the range of 1.3 to 2.5.
36447399	1	11	theme	payload	191:197	arg1	incorporation					170:182	site-specific incorporation	156:182	: 1) site-specific incorporation of the payload	151:197	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	10	12	theme	avoiding	1932:1939	arg1	interference					1951:1962	avoiding potential interference	1932:1962	avoiding potential interference with effector functions that depend on Fc glycan structure	1932:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	3	13	theme	controlled	761:770	arg1	process					772:778	a more controlled process	754:778	a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids	754:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	1	14	theme	homogeneous	378:388	arg1	product					390:396	a homogeneous product	376:396	a homogeneous product	376:396	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	5	15	theme	approach	1143:1150	arg1	application					1123:1133	the application	1119:1133	the application of this approach	1119:1150	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	10	16	with	interference	1951:1962	arg1	functions					1978:1986	effector functions	1969:1986	effector functions that depend on Fc glycan structure	1969:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	2	17	theme	colloidal	681:689	arg1	instability					691:701	long-term colloidal instability	671:701	long-term colloidal instability	671:701	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	10	18	theme	effector	1969:1976	arg1	functions					1978:1986	effector functions	1969:1986	effector functions that depend on Fc glycan structure	1969:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	2	19	attach	attached	501:508	arg1	Lys					559:561	Lys	559:561	Lys	559:561	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	19	attach	attached	501:508	arg1	Cys					566:568	Cys	566:568	Cys	566:568	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	19	attach	attached	501:508	arg1	residues					539:546	antibody surface residues	522:546	antibody surface residues (typically Lys or Cys)	522:569	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	19	attach	attached	501:508	arg2	molecules					476:484	the drug molecules	467:484	the drug molecules	467:484	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	19	attach	attached	501:508	arg3	ADCs					461:464	conventional ADCs	448:464	conventional ADCs	448:464	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	3	20	theme	Fab	846:848	arg1	glycans					859:865	only Fab N-linked glycans	841:865	only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids	841:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	5	21	theme	therapeutic	1251:1261	arg1	antibodies					1274:1283	other therapeutic monoclonal antibodies	1245:1283	other therapeutic monoclonal antibodies	1245:1283	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	10	22	theme	glycan	2006:2011	arg1	structure					2013:2021	Fc glycan structure	2003:2021	Fc glycan structure	2003:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	3	23	link	N-linked	850:857	arg1	glycans					859:865	only Fab N-linked glycans	841:865	only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids	841:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	5	24	theme	antibodies	1274:1283	arg1	region					1235:1240	the Fab constant region	1218:1240	the Fab constant region of other therapeutic monoclonal antibodies	1218:1283	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	6	25	theme	novel	1357:1361	arg1	glycans					1367:1373	the novel Fab glycans	1353:1373	the novel Fab glycans that we designed	1353:1390	We used trastuzumab as a model for the incorporation of Neu5NAz in the novel Fab glycans that we designed.
36447399	5	26	theme	Fab	1095:1097	arg1	glycan					1099:1104	a Fab glycan	1093:1104	a Fab glycan	1093:1104	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	5	27	theme	constant	1226:1233	arg1	region					1235:1240	the Fab constant region	1218:1240	the Fab constant region of other therapeutic monoclonal antibodies	1218:1283	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	1	28	theme	site-specific	156:168	arg1	incorporation					170:182	site-specific incorporation	156:182	: 1) site-specific incorporation of the payload	151:197	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	2	29	theme	antibody	522:529	arg1	Cys					566:568	Cys	566:568	Cys	566:568	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	29	theme	antibody	522:529	arg1	residues					539:546	antibody surface residues	522:546	antibody surface residues (typically Lys or Cys)	522:569	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	29	theme	antibody	522:529	arg1	Lys					559:561	Lys	559:561	Lys	559:561	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	5	30	gly	N-glycosylation	1193:1207	arg2	sites					1209:1213	N-glycosylation sites	1193:1213	N-glycosylation sites	1193:1213	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	8	31	from	ratios	1655:1660	arg1	range					1669:1673	the range	1665:1673	the range of 1.3 to 2.5	1665:1687	Through this process, we obtained cetuximab-MMAE and trastuzumab-MMAE with drug/antibody ratios in the range of 1.3 to 2.5.
36447399	5	32	theme	human	1077:1081	arg1	IgG1					1083:1086	human IgG1	1077:1086	human IgG1	1077:1086	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	3	33	theme	ratio	879:883	arg1	range					885:889	a narrow ratio range	870:889	a narrow ratio range through functionalized sialic acids	870:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	4	34	theme	Fab	1028:1030	arg1	glycan					1032:1037	the Fab glycan	1024:1037	the Fab glycan of cetuximab	1024:1050	Using a bacterial sialytransferase, we incorporated N-azidoacetylneuraminic acid (Neu5NAz) into the Fab glycan of cetuximab.
36447399	8	35	dep	2.5	1685:1687	arg1	to					1682:1683	to	1682:1683	to	1682:1683	Through this process, we obtained cetuximab-MMAE and trastuzumab-MMAE with drug/antibody ratios in the range of 1.3 to 2.5.
36447399	1	36	theme	optimal	260:266	arg1	ratio					282:286	optimal drug/antibody ratio	260:286	optimal drug/antibody ratio	260:286	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	3	37	theme	sialic	914:919	arg1	acids					921:925	functionalized sialic acids	899:925	functionalized sialic acids	899:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	0	38	theme	site-specific	33:45	arg1	conjugation					47:57	site-specific conjugation	33:57	site-specific conjugation	33:57	A glyco-engineering approach for site-specific conjugation to Fab glycans.
36447399	9	39	theme	control	1800:1806	arg1	ADCs					1808:1811	control ADCs	1800:1811	control ADCs obtained by standard conjugation protocols	1800:1854	We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols.
36447399	1	40	dep	incorporation	170:182	arg1	1					153:153	1	153:153	1	153:153	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	5	41	theme	N-glycosylation	1193:1207	arg1	sites					1209:1213	N-glycosylation sites	1193:1213	N-glycosylation sites	1193:1213	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	9	42	theme	standard	1825:1832	arg1	protocols					1846:1854	standard conjugation protocols	1825:1854	standard conjugation protocols	1825:1854	We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols.
36447399	8	43	theme	drug/antibody	1641:1653	arg1	ratios					1655:1660	drug/antibody ratios	1641:1660	drug/antibody ratios in the range of 1.3 to 2.5	1641:1687	Through this process, we obtained cetuximab-MMAE and trastuzumab-MMAE with drug/antibody ratios in the range of 1.3 to 2.5.
36447399	7	44	theme	monomethyl	1455:1464	arg1	MMAE					1480:1483	MMAE	1480:1483	MMAE	1480:1483	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	7	44	theme	monomethyl	1455:1464	arg1	E					1477:1477	monomethyl auristatin E	1455:1477	monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO)	1455:1563	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	10	45	theme	Fab	1890:1892	arg1	glycans					1894:1900	Fab glycans	1890:1900	Fab glycans	1890:1900	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	5	46	theme	molecular	1161:1169	arg1	modeling					1171:1178	molecular modeling	1161:1178	molecular modeling	1161:1178	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	9	47	from	assays	1790:1795	arg1	potent					1767:1772	potent	1767:1772	potent	1767:1772	We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols.
36447399	1	48	dep	facilitate	401:410	arg1	3					373:373	3	373:373	3	373:373	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	10	49	theme	additional	1910:1919	arg1	benefit					1921:1927	the additional benefit	1906:1927	the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure	1906:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	4	50	theme	N-azidoacetylneuraminic	980:1002	arg1	Neu5NAz					1010:1016	Neu5NAz	1010:1016	Neu5NAz	1010:1016	Using a bacterial sialytransferase, we incorporated N-azidoacetylneuraminic acid (Neu5NAz) into the Fab glycan of cetuximab.
36447399	4	50	theme	N-azidoacetylneuraminic	980:1002	arg1	acid					1004:1007	N-azidoacetylneuraminic acid	980:1007	N-azidoacetylneuraminic acid (Neu5NAz)	980:1017	Using a bacterial sialytransferase, we incorporated N-azidoacetylneuraminic acid (Neu5NAz) into the Fab glycan of cetuximab.
36447399	8	51	theme	2.5	1685:1687	arg1	range					1669:1673	the range	1665:1673	the range of 1.3 to 2.5	1665:1687	Through this process, we obtained cetuximab-MMAE and trastuzumab-MMAE with drug/antibody ratios in the range of 1.3 to 2.5.
36447399	10	52	contain	has	1902:1904	arg2	benefit					1921:1927	the additional benefit	1906:1927	the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure	1906:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	10	52	contain	has	1902:1904	arg1	conjugation					1875:1885	The site-directed conjugation	1857:1885	The site-directed conjugation to Fab glycans	1857:1900	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	10	53	theme	potential	1941:1949	arg1	interference					1951:1962	avoiding potential interference	1932:1962	avoiding potential interference with effector functions that depend on Fc glycan structure	1932:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	6	54	used	used	1289:1292	arg2	We					1286:1287	We	1286:1287	We	1286:1287	We used trastuzumab as a model for the incorporation of Neu5NAz in the novel Fab glycans that we designed.
36447399	2	55	theme	surface	531:537	arg1	Cys					566:568	Cys	566:568	Cys	566:568	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	55	theme	surface	531:537	arg1	residues					539:546	antibody surface residues	522:546	antibody surface residues (typically Lys or Cys)	522:569	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	2	55	theme	surface	531:537	arg1	Lys					559:561	Lys	559:561	Lys	559:561	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	4	56	theme	bacterial	936:944	arg1	sialytransferase					946:961	a bacterial sialytransferase	934:961	a bacterial sialytransferase	934:961	Using a bacterial sialytransferase, we incorporated N-azidoacetylneuraminic acid (Neu5NAz) into the Fab glycan of cetuximab.
36447399	2	57	theme	long-term	671:679	arg1	instability					691:701	long-term colloidal instability	671:701	long-term colloidal instability	671:701	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	5	58	theme	other	1245:1249	arg1	antibodies					1274:1283	other therapeutic monoclonal antibodies	1245:1283	other therapeutic monoclonal antibodies	1245:1283	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	3	59	theme	N-linked	850:857	arg1	glycans					859:865	only Fab N-linked glycans	841:865	only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids	841:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	5	60	theme	monoclonal	1263:1272	arg1	antibodies					1274:1283	other therapeutic monoclonal antibodies	1245:1283	other therapeutic monoclonal antibodies	1245:1283	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	10	61	theme	Fc	2003:2004	arg1	structure					2013:2021	Fc glycan structure	2003:2021	Fc glycan structure	2003:2021	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	6	62	theme	Fab	1363:1365	arg1	glycans					1367:1373	the novel Fab glycans	1353:1373	the novel Fab glycans that we designed	1353:1390	We used trastuzumab as a model for the incorporation of Neu5NAz in the novel Fab glycans that we designed.
36447399	3	63	theme	only	841:844	arg1	glycans					859:865	only Fab N-linked glycans	841:865	only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids	841:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	2	64	theme	unfavorable	707:717	arg1	pharmacokinetics					719:734	unfavorable pharmacokinetics	707:734	unfavorable pharmacokinetics	707:734	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	5	65	theme	Fab	1222:1224	arg1	region					1235:1240	the Fab constant region	1218:1240	the Fab constant region of other therapeutic monoclonal antibodies	1218:1283	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	1	66	theme	aggregation	333:343	arg1	problems					359:366	aggregation or solubility problems	333:366	aggregation or solubility problems	333:366	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	3	67	theme	narrow	872:877	arg1	range					885:889	a narrow ratio range	870:889	a narrow ratio range through functionalized sialic acids	870:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	2	68	theme	drug	471:474	arg1	molecules					476:484	the drug molecules	467:484	the drug molecules	467:484	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	6	69	theme	Neu5NAz	1342:1348	arg1	incorporation					1325:1337	the incorporation	1321:1337	the incorporation of Neu5NAz in the novel Fab glycans that we designed	1321:1390	We used trastuzumab as a model for the incorporation of Neu5NAz in the novel Fab glycans that we designed.
36447399	1	70	theme	solubility	348:357	arg1	problems					359:366	aggregation or solubility problems	333:366	aggregation or solubility problems	333:366	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	5	71	contain	have	1088:1091	arg2	glycan					1099:1104	a Fab glycan	1093:1104	a Fab glycan	1093:1104	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	5	71	contain	have	1088:1091	arg1	%					1072:1072	only about 20%	1059:1072	only about 20% of human IgG1	1059:1086	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	5	71	contain	have	1088:1091	arg1	IgG1					1083:1086	human IgG1	1077:1086	human IgG1	1077:1086	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	5	72	theme	IgG1	1083:1086	arg1	%					1072:1072	only about 20%	1059:1072	only about 20% of human IgG1	1059:1086	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	5	72	theme	IgG1	1083:1086	arg1	IgG1					1083:1086	human IgG1	1077:1086	human IgG1	1077:1086	Since only about 20% of human IgG1 have a Fab glycan, we extended the application of this approach by using molecular modeling to introduce N-glycosylation sites in the Fab constant region of other therapeutic monoclonal antibodies.
36447399	1	73	theme	Effective	75:83	arg1	processes					85:93	Effective processes	75:93	Effective processes for synthesizing antibody-drug conjugates (ADCs)	75:142	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	3	74	theme	functionalized	899:912	arg1	acids					921:925	functionalized sialic acids	899:925	functionalized sialic acids	899:925	Here, we present a more controlled process for generating ADCs where drug is specifically conjugated to only Fab N-linked glycans in a narrow ratio range through functionalized sialic acids.
36447399	1	75	dep	achieve	291:297	arg1	2					257:257	2	257:257	2	257:257	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	0	76	theme	glyco-engineering	2:18	arg1	approach					20:27	A glyco-engineering approach	0:27	A glyco-engineering approach for site-specific conjugation to Fab glycans	0:72	A glyco-engineering approach for site-specific conjugation to Fab glycans.
36447399	2	77	theme	overall	640:646	arg1	heterogeneity					656:668	overall product heterogeneity	640:668	overall product heterogeneity	640:668	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	1	78	theme	drug/antibody	268:280	arg1	ratio					282:286	optimal drug/antibody ratio	260:286	optimal drug/antibody ratio	260:286	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	1	79	with	interference	208:219	arg1	binding					226:232	binding	226:232	binding to the target epitope	226:254	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	1	80	theme	antibody-drug	112:124	arg1	ADCs					138:141	ADCs	138:141	ADCs	138:141	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	1	80	theme	antibody-drug	112:124	arg1	conjugates					126:135	antibody-drug conjugates	112:135	antibody-drug conjugates (ADCs)	112:142	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	9	81	theme	cytotoxicity	1777:1788	arg1	assays					1790:1795	cytotoxicity assays	1777:1795	cytotoxicity assays	1777:1795	We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols.
36447399	7	82	theme	self-immolative	1500:1514	arg1	linker					1516:1521	a self-immolative linker	1498:1521	a self-immolative linker terminated with dibenzocyclooctyne (DBCO)	1498:1563	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	8	83	with	trastuzumab-MMAE	1619:1634	arg1	ratios					1655:1660	drug/antibody ratios	1641:1660	drug/antibody ratios in the range of 1.3 to 2.5	1641:1687	Through this process, we obtained cetuximab-MMAE and trastuzumab-MMAE with drug/antibody ratios in the range of 1.3 to 2.5.
36447399	7	84	attach	attached	1486:1493	arg2	E					1477:1477	monomethyl auristatin E	1455:1477	monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO)	1455:1563	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	7	84	attach	attached	1486:1493	arg1	linker					1516:1521	a self-immolative linker	1498:1521	a self-immolative linker terminated with dibenzocyclooctyne (DBCO)	1498:1563	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	7	84	attach	attached	1486:1493	arg2	MMAE					1480:1483	MMAE	1480:1483	MMAE	1480:1483	ADCs were generated by clicking the incorporated Neu5NAz with monomethyl auristatin E (MMAE) attached to a self-immolative linker terminated with dibenzocyclooctyne (DBCO).
36447399	0	85	theme	Fab	62:64	arg1	glycans					66:72	Fab glycans	62:72	Fab glycans	62:72	A glyco-engineering approach for site-specific conjugation to Fab glycans.
36447399	1	86	theme	sufficient	299:308	arg1	potency					310:316	sufficient potency	299:316	sufficient potency	299:316	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36447399	2	87	theme	conventional	448:459	arg1	ADCs					461:464	conventional ADCs	448:464	conventional ADCs	448:464	In conventional ADCs, the drug molecules are chemically attached randomly to antibody surface residues (typically Lys or Cys), which can interfere with epitope binding and targeting, and lead to overall product heterogeneity, long-term colloidal instability and unfavorable pharmacokinetics.
36447399	10	88	theme	site-directed	1861:1873	arg1	conjugation					1875:1885	The site-directed conjugation	1857:1885	The site-directed conjugation to Fab glycans	1857:1900	The site-directed conjugation to Fab glycans has the additional benefit of avoiding potential interference with effector functions that depend on Fc glycan structure.
36447399	6	89	from	incorporation	1325:1337	arg1	glycans					1367:1373	the novel Fab glycans	1353:1373	the novel Fab glycans that we designed	1353:1390	We used trastuzumab as a model for the incorporation of Neu5NAz in the novel Fab glycans that we designed.
36447399	9	90	theme	conjugation	1834:1844	arg1	protocols					1846:1854	standard conjugation protocols	1825:1854	standard conjugation protocols	1825:1854	We confirmed that these ADCs still bind their targets efficiently and are as potent in cytotoxicity assays as control ADCs obtained by standard conjugation protocols.
36447399	1	91	theme	target	241:246	arg1	epitope					248:254	the target epitope	237:254	the target epitope	237:254	Effective processes for synthesizing antibody-drug conjugates (ADCs) require: 1) site-specific incorporation of the payload to avoid interference with binding to the target epitope, 2) optimal drug/antibody ratio to achieve sufficient potency while avoiding aggregation or solubility problems, and 3) a homogeneous product to facilitate approval by regulatory agencies.
36095053	4	0	theme	modified	645:652	arg1	cells					663:667	modified reporter cells	645:667	modified reporter cells	645:667	In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79.
36095053	3	1	theme	cultured	457:464	arg1	cells					473:477	cultured Jurkat cells	457:477	cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	457:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	6	2	dep	novel	1207:1211	arg1	therapeutic					1213:1223	therapeutic	1213:1223	therapeutic	1213:1223	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	0	3	from	role	4:7	arg1	trafficking					31:41	trafficking	31:41	trafficking to the cell surface and signal transduction of TREM2	31:94	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	3	4	theme	Jurkat	466:471	arg1	cells					473:477	cultured Jurkat cells	457:477	cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	457:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	6	5	theme	microglial	1006:1015	arg1	dysfunction					1017:1027	microglial dysfunction	1006:1027	microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders	1006:1095	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	5	6	theme	intracellular	893:905	arg1	transduction					914:925	intracellular signal transduction	893:925	intracellular signal transduction	893:925	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	4	7	from	N79	721:723	arg1	role					688:691	the role	684:691	the role of the N-glycans at N20 and N79	684:723	In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79.
36095053	3	8	theme	luciferase	499:508	arg1	gene					519:522	a luciferase reporter gene	497:522	a luciferase reporter gene	497:522	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	4	9	theme	N-glycans	700:708	arg1	role					688:691	the role	684:691	the role of the N-glycans at N20 and N79	684:723	In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79.
36095053	0	10	theme	signal	67:72	arg1	transduction					74:85	signal transduction	67:85	signal transduction	67:85	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	5	11	from	N79	756:758	arg1	N-glycans					743:751	the N-glycans	739:751	the N-glycans at N79	739:758	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	6	12	theme	N-glycosylation	1141:1155	arg1	integrity					1122:1130	the integrity	1118:1130	the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases	1118:1196	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	3	13	theme	reporter	510:517	arg1	gene					519:522	a luciferase reporter gene	497:522	a luciferase reporter gene	497:522	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	3	14	theme	cell	436:439	arg1	model					441:445	a sensitive and specific reporter cell model	402:445	a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	402:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	0	15	theme	TREM2	90:94	arg1	surface					55:61	cell surface	50:61	cell surface	50:61	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	0	15	theme	TREM2	90:94	arg1	transduction					74:85	signal transduction	67:85	signal transduction	67:85	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	5	16	theme	requisite	767:775	arg1	role					777:780	a requisite role	765:780	a requisite role	765:780	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	4	17	from	N20	713:715	arg1	role					688:691	the role	684:691	the role of the N-glycans at N20 and N79	684:723	In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79.
36095053	5	18	theme	critical	876:883	arg1	role					885:888	a critical role	874:888	a critical role	874:888	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	6	19	theme	TREM2	980:984	arg1	N-glycans					986:994	the TREM2 N-glycans	976:994	the TREM2 N-glycans	976:994	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	6	20	theme	novel	1207:1211	arg1	strategy					1225:1232	a novel therapeutic strategy	1205:1232	a novel therapeutic strategy to treat these disorders	1205:1257	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	4	21	theme	present	618:624	arg1	study					626:630	the present study	614:630	the present study	614:630	In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79.
36095053	5	22	contain	have	869:872	arg2	role					885:888	a critical role	874:888	a critical role	874:888	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	5	22	contain	have	869:872	arg1	N-glycans					839:847	the N-glycans	835:847	the N-glycans at both N20 and N79	835:867	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	5	23	theme	TREM2	802:806	arg1	translocation					785:797	translocation	785:797	translocation of TREM2 to the cell surface	785:826	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	0	24	dep	surface	55:61	arg1	the					46:48	the	46:48	the	46:48	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	4	25	theme	reporter	654:661	arg1	cells					663:667	modified reporter cells	645:667	modified reporter cells	645:667	In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79.
36095053	0	26	theme	TREM2	12:16	arg1	N-glycans					18:26	TREM2 N-glycans	12:26	TREM2 N-glycans	12:26	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	6	27	theme	TREM2	1135:1139	arg1	N-glycosylation					1141:1155	TREM2 N-glycosylation and the responsible glycosyltransferases	1135:1196	N-glycosylation	1141:1155	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	6	28	theme	neurodegenerative	1069:1085	arg1	disorders					1087:1095	neurodegenerative disorders	1069:1095	neurodegenerative disorders	1069:1095	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	6	29	theme	disorders	1087:1095	arg1	pathogenesis					1053:1064	the pathogenesis	1049:1064	the pathogenesis of neurodegenerative disorders	1049:1095	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	5	30	contain	have	760:763	arg1	N-glycans					743:751	the N-glycans	739:751	the N-glycans at N79	739:758	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	5	30	contain	have	760:763	arg2	role					777:780	a requisite role	765:780	a requisite role	765:780	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	1	31	theme	myeloid	142:148	arg1	cells					150:154	myeloid cells 2 (TREM2)	142:164	myeloid cells 2 (TREM2)	142:164	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	3	32	theme	specific	418:425	arg1	model					441:445	a sensitive and specific reporter cell model	402:445	a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	402:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	1	33	theme	other	244:248	arg1	disorders					268:276	other neurodegenerative disorders	244:276	other neurodegenerative disorders	244:276	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	6	34	theme	responsible	1165:1175	arg1	glycosyltransferases					1177:1196	TREM2 N-glycosylation and the responsible glycosyltransferases	1135:1196	glycosyltransferases	1177:1196	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	6	35	theme	structural	954:963	arg1	changes					965:971	structural changes	954:971	structural changes to the TREM2 N-glycans	954:994	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	3	36	theme	TREM2DAP12	546:555	arg1	protein					564:570	a TREM2DAP12 fusion protein	544:570	a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	544:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	2	37	theme	modification	351:362	arg1	significance					331:342	the significance	327:342	the significance of the modification	327:362	TREM2 is glycosylated in vitro and in vivo, but the significance of the modification is unknown.
36095053	2	37	theme	modification	351:362	arg1	unknown					367:373	unknown	367:373	unknown	367:373	TREM2 is glycosylated in vitro and in vivo, but the significance of the modification is unknown.
36095053	0	38	theme	N-glycans	18:26	arg1	role					4:7	The role	0:7	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.	0:95	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	1	39	theme	neurodegenerative	250:266	arg1	disorders					268:276	other neurodegenerative disorders	244:276	other neurodegenerative disorders	244:276	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	3	40	theme	fusion	557:562	arg1	protein					564:570	a TREM2DAP12 fusion protein	544:570	a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	544:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	3	41	theme	sensitive	404:412	arg1	model					441:445	a sensitive and specific reporter cell model	402:445	a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	402:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	1	42	dep	cells	150:154	arg1	TREM2					159:163	TREM2	159:163	TREM2	159:163	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	1	42	dep	cells	150:154	arg1	2					156:156	2	156:156	2	156:156	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	6	43	theme	glycosyltransferases	1177:1196	arg1	integrity					1122:1130	the integrity	1118:1130	the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases	1118:1196	Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.
36095053	3	44	theme	reporter	427:434	arg1	model					441:445	a sensitive and specific reporter cell model	402:445	a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling	402:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	5	45	from	N79	865:867	arg1	N-glycans					839:847	the N-glycans	835:847	the N-glycans at both N20 and N79	835:867	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	2	46	gly	glycosylated	288:299	arg1	TREM2					279:283	TREM2	279:283	TREM2	279:283	TREM2 is glycosylated in vitro and in vivo, but the significance of the modification is unknown.
36095053	3	47	theme	TREM2-dependent	583:597	arg1	signalling					599:608	TREM2-dependent signalling	583:608	TREM2-dependent signalling	583:608	We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling.
36095053	1	48	theme	triggering	109:118	arg1	receptor					120:127	triggering receptor	109:127	triggering receptor expressed on myeloid cells 2 (TREM2)	109:164	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	1	49	theme	increased	189:197	arg1	incidence					199:207	an increased incidence	186:207	an increased incidence of Alzheimer's disease	186:230	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	0	50	theme	cell	50:53	arg1	surface					55:61	cell surface	50:61	cell surface	50:61	The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2.
36095053	5	51	theme	signal	907:912	arg1	transduction					914:925	intracellular signal transduction	893:925	intracellular signal transduction	893:925	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	1	52	theme	receptor	120:127	arg1	Variants					97:104	Variants	97:104	Variants of triggering receptor expressed on myeloid cells 2 (TREM2)	97:164	Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer's disease, as well as other neurodegenerative disorders.
36095053	5	53	from	N20	857:859	arg1	N-glycans					839:847	the N-glycans	835:847	the N-glycans at both N20 and N79	835:867	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
36095053	5	54	theme	cell	815:818	arg1	surface					820:826	the cell surface	811:826	the cell surface	811:826	We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction.
35397991	5	0	theme	GlcNAc-extended	1076:1090	arg1	N-glycans					1092:1100	GlcNAc-extended N-glycans	1076:1100	GlcNAc-extended N-glycans	1076:1100	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	4	1	theme	N-glycan	708:715	arg1	alterations					717:727	the temporal N-glycan alterations	695:727	the temporal N-glycan alterations in the middle silk gland (MSG)	695:758	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	1	2	theme	important	148:156	arg1	modification					177:188	an important post-translational modification	145:188	an important post-translational modification in eukaryotic cells	145:208	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	1	2	theme	important	148:156	arg1	N-glycosylation					114:128	N-glycosylation	114:128	N-glycosylation of proteins	114:140	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	4	3	from	alterations	717:727	arg1	MSG					755:757	MSG	755:757	MSG	755:757	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	4	3	from	alterations	717:727	arg1	gland					748:752	the middle silk gland	732:752	the middle silk gland (MSG)	732:758	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	0	4	theme	silk	78:81	arg1	gland					83:87	the middle silk gland	67:87	the middle silk gland of silkworm Bombyx mori	67:111	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	0	5	from	analysis	9:16	arg1	gland					83:87	the middle silk gland	67:87	the middle silk gland of silkworm Bombyx mori	67:111	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	7	6	with	ratio	1553:1557	arg1	s					1592:1592	GlcNAc residue(s)	1577:1593	GlcNAc residue(s) in MSG	1577:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	1	7	theme	post-translational	158:175	arg1	modification					177:188	an important post-translational modification	145:188	an important post-translational modification in eukaryotic cells	145:208	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	1	7	theme	post-translational	158:175	arg1	N-glycosylation					114:128	N-glycosylation	114:128	N-glycosylation of proteins	114:140	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	0	8	theme	silkworm	92:99	arg1	gland					83:87	the middle silk gland	67:87	the middle silk gland of silkworm Bombyx mori	67:111	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	4	9	theme	key	794:796	arg1	GNTI					853:856	GNTI	853:856	GNTI	853:856	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	4	9	theme	key	794:796	arg1	enzyme					798:803	key enzyme	794:803	key enzyme for complex-type N-glycan biosynthesis	794:842	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	5	10	from	MSG	912:914	arg1	analysis					877:884	N-glycan analysis	868:884	N-glycan analysis of N-glycoproteins in the MSG	868:914	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	5	11	dep	BmGNTI	934:939	arg1	characterized					956:968	characterized	956:968	characterized in this study	956:982	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	5	11	dep	BmGNTI	934:939	arg1	identified					941:950	identified	941:950	identified	941:950	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	7	12	from	formations	1519:1528	arg1	ratio					1553:1557	the ratio	1549:1557	the ratio of N-glycans with GlcNAc residue(s) in MSG	1549:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	4	13	theme	GlcNAc	625:630	arg1	extension					632:640	GlcNAc extension	625:640	GlcNAc extension of N-glycan in the silkworm Bombyx mori	625:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	5	14	from	analysis	877:884	arg1	MSG					912:914	the MSG	908:914	the MSG	908:914	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	7	15	from	changes	1538:1544	arg1	ratio					1553:1557	the ratio	1549:1557	the ratio of N-glycans with GlcNAc residue(s) in MSG	1549:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	5	16	from	N-glycoproteins	889:903	arg1	MSG					912:914	the MSG	908:914	the MSG	908:914	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	2	17	theme	N-glycan	378:385	arg1	maturation					387:396	N-glycan maturation	378:396	N-glycan maturation	378:396	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	2	18	from	modifications	226:238	arg1	N-glycosylation					251:265	protein N-glycosylation	243:265	protein N-glycosylation	243:265	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	3	19	theme	GlcNAc	517:522	arg1	extension					524:532	GlcNAc extension	517:532	GlcNAc extension	517:532	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	6	20	theme	stage-specific	1291:1304	arg1	expressions					1306:1316	stage-specific expressions	1291:1316	stage-specific expressions	1291:1316	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	3	21	from	structures	561:570	arg1	insects					575:581	insects	575:581	insects	575:581	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	0	22	dep	silkworm	92:99	arg1	mori					108:111	Bombyx mori	101:111	silkworm Bombyx mori	92:111	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	7	23	dep	glycosylhydrolases	1463:1480	arg1	influenced					1493:1502	influenced	1493:1502	glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG	1463:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	0	24	theme	Bombyx	101:106	arg1	mori					108:111	Bombyx mori	101:111	silkworm Bombyx mori	92:111	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	5	25	theme	MSG	1143:1145	arg1	development					1147:1157	the MSG development	1139:1157	the MSG development	1139:1157	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	2	26	theme	hybrid-	424:430	arg1	structures					449:458	hybrid- and complex-type structures	424:458	hybrid- and complex-type structures in Golgi	424:467	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	4	27	from	extension	632:640	arg1	mori					677:680	the silkworm Bombyx mori	657:680	the silkworm Bombyx mori	657:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	6	28	theme	genes	1211:1215	arg1	profile					1175:1181	The expression profile	1160:1181	The expression profile of GlcNAc extension-related genes	1160:1215	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	6	29	theme	N-glycans	1373:1381	arg1	accumulations					1340:1352	accumulations	1340:1352	accumulations of the end product N-glycans of the enzyme	1340:1395	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	1	30	theme	eukaryotic	193:202	arg1	cells					204:208	eukaryotic cells	193:208	eukaryotic cells	193:208	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	0	31	theme	Temporal	0:7	arg1	analysis					9:16	Temporal analysis	0:16	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.	0:112	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	7	32	theme	structural	1508:1517	arg1	formations					1519:1528	the structural formations	1504:1528	the structural formations	1504:1528	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	4	33	theme	silk	743:746	arg1	MSG					755:757	MSG	755:757	MSG	755:757	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	4	33	theme	silk	743:746	arg1	gland					748:752	the middle silk gland	732:752	the middle silk gland (MSG)	732:758	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	7	34	theme	N-glycans	1562:1570	arg1	ratio					1553:1557	the ratio	1549:1557	the ratio of N-glycans with GlcNAc residue(s) in MSG	1549:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	6	35	theme	extension-related	1193:1209	arg1	genes					1211:1215	GlcNAc extension-related genes	1186:1215	GlcNAc extension-related genes	1186:1215	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	4	36	from	mori	677:680	arg1	extension					632:640	GlcNAc extension	625:640	GlcNAc extension of N-glycan in the silkworm Bombyx mori	625:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	0	37	theme	N-acetylglucosamine	21:39	arg1	extension					41:49	N-acetylglucosamine extension	21:49	N-acetylglucosamine extension of N-glycans	21:62	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	1	38	gly	N-glycosylation	114:128	arg1	proteins					133:140	proteins	133:140	proteins	133:140	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	2	39	theme	N-acetylglucosaminyltransferase	321:351	arg1	GNTI					356:359	GNTI	356:359	GNTI	356:359	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	2	39	theme	N-acetylglucosaminyltransferase	321:351	arg1	I					353:353	N-acetylglucosaminyltransferase I	321:353	N-acetylglucosaminyltransferase I (GNTI)	321:360	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	2	40	dep	structures	449:458	arg1	high-mannose-type					403:419	high-mannose-type	403:419	high-mannose-type	403:419	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	4	41	theme	silkworm	661:668	arg1	mori					677:680	the silkworm Bombyx mori	657:680	the silkworm Bombyx mori	657:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	5	42	theme	N-glycans	1092:1100	arg1	accumulation					1060:1071	the accumulation	1056:1071	the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development	1056:1157	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	3	43	theme	resultant	542:550	arg1	structures					561:570	the resultant N-glycan structures	538:570	the resultant N-glycan structures in insects	538:581	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	3	44	theme	GNTI	509:512	arg1	contributions					492:504	the temporal contributions	479:504	the temporal contributions of GNTI to GlcNAc extension	479:532	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	3	44	theme	GNTI	509:512	arg1	structures					561:570	the resultant N-glycan structures	538:570	the resultant N-glycan structures in insects	538:581	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	6	45	theme	GlcNAc	1277:1282	arg1	hydrolysis					1263:1272	the hydrolysis	1259:1272	the hydrolysis of GlcNAc	1259:1282	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	2	46	theme	protein	243:249	arg1	N-glycosylation					251:265	protein N-glycosylation	243:265	protein N-glycosylation	243:265	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	3	47	theme	temporal	483:490	arg1	contributions					492:504	the temporal contributions	479:504	the temporal contributions of GNTI to GlcNAc extension	479:532	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	0	48	theme	extension	41:49	arg1	analysis					9:16	Temporal analysis	0:16	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.	0:112	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	5	49	theme	predominant	1105:1115	arg1	structures					1117:1126	predominant structures	1105:1126	predominant structures throughout the MSG development	1105:1157	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	4	50	theme	N-glycan	822:829	arg1	biosynthesis					831:842	complex-type N-glycan biosynthesis	809:842	complex-type N-glycan biosynthesis	809:842	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	2	51	theme	complex-type	436:447	arg1	structures					449:458	hybrid- and complex-type structures	424:458	hybrid- and complex-type structures in Golgi	424:467	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	7	52	theme	GlcNAc	1577:1582	arg1	s					1592:1592	GlcNAc residue(s)	1577:1593	GlcNAc residue(s) in MSG	1577:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	5	53	theme	N-glycoproteins	889:903	arg1	analysis					877:884	N-glycan analysis	868:884	N-glycan analysis of N-glycoproteins in the MSG	868:914	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	6	54	theme	enzyme	1390:1395	arg1	N-glycans					1373:1381	the end product N-glycans	1357:1381	the end product N-glycans of the enzyme	1357:1395	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	2	55	theme	modifications	226:238	arg1	One					211:213	One	211:213	One	211:213	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	2	55	theme	modifications	226:238	arg1	modifications					226:238	the key modifications	218:238	the key modifications in protein N-glycosylation	218:265	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	3	56	from	contributions	492:504	arg1	insects					575:581	insects	575:581	insects	575:581	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	4	57	theme	middle	736:741	arg1	MSG					755:757	MSG	755:757	MSG	755:757	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	4	57	theme	middle	736:741	arg1	gland					748:752	the middle silk gland	732:752	the middle silk gland (MSG)	732:758	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	0	58	theme	N-glycans	54:62	arg1	extension					41:49	N-acetylglucosamine extension	21:49	N-acetylglucosamine extension of N-glycans	21:62	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	5	59	gly	N-glycoproteins	889:903	arg1	N-glycoproteins					889:903	N-glycoproteins	889:903	N-glycoproteins in the MSG	889:914	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	7	60	theme	residue	1584:1590	arg1	s					1592:1592	GlcNAc residue(s)	1577:1593	GlcNAc residue(s) in MSG	1577:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	2	61	theme	key	222:224	arg1	modifications					226:238	the key modifications	218:238	the key modifications in protein N-glycosylation	218:265	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	6	62	theme	expression	1164:1173	arg1	profile					1175:1181	The expression profile	1160:1181	The expression profile of GlcNAc extension-related genes	1160:1215	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	6	63	theme	product	1365:1371	arg1	N-glycans					1373:1381	the end product N-glycans	1357:1381	the end product N-glycans of the enzyme	1357:1395	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	5	64	theme	GlcNAc	1012:1017	arg1	extension					1019:1027	GlcNAc extension	1012:1027	GlcNAc extension	1012:1027	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	4	65	theme	enzyme	798:803	arg1	property					782:789	the property	778:789	the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI)	778:865	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	6	66	theme	GlcNAc	1186:1191	arg1	genes					1211:1215	GlcNAc extension-related genes	1186:1215	GlcNAc extension-related genes	1186:1215	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	6	67	theme	end	1361:1363	arg1	N-glycans					1373:1381	the end product N-glycans	1357:1381	the end product N-glycans of the enzyme	1357:1395	The expression profile of GlcNAc extension-related genes revealed that the enzymes contributing to the hydrolysis of GlcNAc showed stage-specific expressions, thereby resulting in accumulations of the end product N-glycans of the enzyme.
35397991	2	68	theme	N-acetylglucosamine	270:288	arg1	extension					299:307	N-acetylglucosamine (GlcNAc) extension	270:307	N-acetylglucosamine (GlcNAc) extension	270:307	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	2	69	from	structures	449:458	arg1	Golgi					463:467	Golgi	463:467	Golgi	463:467	One of the key modifications in protein N-glycosylation is N-acetylglucosamine (GlcNAc) extension mediated by N-acetylglucosaminyltransferase I (GNTI), which triggers N-glycan maturation from high-mannose-type to hybrid- and complex-type structures in Golgi.
35397991	1	70	theme	proteins	133:140	arg1	modification					177:188	an important post-translational modification	145:188	an important post-translational modification in eukaryotic cells	145:208	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	1	70	theme	proteins	133:140	arg1	N-glycosylation					114:128	N-glycosylation	114:128	N-glycosylation of proteins	114:140	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	0	71	theme	middle	71:76	arg1	gland					83:87	the middle silk gland	67:87	the middle silk gland of silkworm Bombyx mori	67:111	Temporal analysis of N-acetylglucosamine extension of N-glycans in the middle silk gland of silkworm Bombyx mori.
35397991	4	72	theme	Bombyx	670:675	arg1	mori					677:680	the silkworm Bombyx mori	657:680	the silkworm Bombyx mori	657:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	4	73	theme	complex-type	809:820	arg1	biosynthesis					831:842	complex-type N-glycan biosynthesis	809:842	complex-type N-glycan biosynthesis	809:842	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	3	74	theme	N-glycan	552:559	arg1	structures					561:570	the resultant N-glycan structures	538:570	the resultant N-glycan structures in insects	538:581	However, the temporal contributions of GNTI to GlcNAc extension and the resultant N-glycan structures in insects have not been analyzed.
35397991	5	75	theme	N-glycan	868:875	arg1	analysis					877:884	N-glycan analysis	868:884	N-glycan analysis of N-glycoproteins in the MSG	868:914	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	4	76	from	N-glycan	645:652	arg1	mori					677:680	the silkworm Bombyx mori	657:680	the silkworm Bombyx mori	657:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	7	77	from	s	1592:1592	arg1	MSG					1598:1600	MSG	1598:1600	MSG	1598:1600	These results lead to the speculation that not BmGNTI but rather glycosylhydrolases critically influenced the structural formations and the changes in the ratio of N-glycans with GlcNAc residue(s) in MSG.
35397991	5	78	theme	N-glycans	1032:1040	arg1	extension					1019:1027	GlcNAc extension	1012:1027	GlcNAc extension	1012:1027	N-glycan analysis of N-glycoproteins in the MSG demonstrated that BmGNTI identified and characterized in this study consistently contributed to GlcNAc extension of N-glycans, which led to the accumulation of GlcNAc-extended N-glycans as predominant structures throughout the MSG development.
35397991	1	79	from	modification	177:188	arg1	cells					204:208	eukaryotic cells	193:208	eukaryotic cells	193:208	N-glycosylation of proteins is an important post-translational modification in eukaryotic cells.
35397991	4	80	theme	temporal	699:706	arg1	alterations					717:727	the temporal N-glycan alterations	695:727	the temporal N-glycan alterations in the middle silk gland (MSG)	695:758	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
35397991	4	81	theme	N-glycan	645:652	arg1	extension					632:640	GlcNAc extension	625:640	GlcNAc extension of N-glycan in the silkworm Bombyx mori	625:680	Here, focusing on GlcNAc extension of N-glycan in the silkworm Bombyx mori, we analyzed the temporal N-glycan alterations in the middle silk gland (MSG) and characterized the property of key enzyme for complex-type N-glycan biosynthesis, B. mori GNTI (BmGNTI).
36959283	2	0	theme	downstream	428:437	arg1	analyses					439:446	downstream analyses	428:446	downstream analyses	428:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	1	theme	quantitative	783:794	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	0	2	theme	Highly-sensitive	0:15	arg1	profiling					33:41	Highly-sensitive label-free deep profiling	0:41	Highly-sensitive label-free deep profiling of N-glycans	0:54	Highly-sensitive label-free deep profiling of N-glycans released from biomedically-relevant samples.
36959283	7	3	theme	CZE-MS	1558:1563	arg1	analysis					1565:1572	a single CZE-MS analysis	1549:1572	a single CZE-MS analysis	1549:1572	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	6	4	theme	identified	1249:1258	arg1	N-glycans					1260:1268	identified N-glycans	1249:1268	identified N-glycans	1249:1268	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	6	5	theme	sample	1337:1342	arg1	amounts					1344:1350	sample amounts	1337:1350	sample amounts as low as sub-0.2 nL of plasma volume equivalents	1337:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	2	6	theme	sample	393:398	arg1	loss					400:403	sample loss	393:403	sample loss	393:403	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	7	theme	oligosaccharides	259:274	arg1	detectability					242:254	detectability	242:254	detectability	242:254	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	7	theme	oligosaccharides	259:274	arg1	separation					227:236	improved separation	218:236	improved separation	218:236	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	7	8	theme	untreated	1495:1503	arg1	isomers					1525:1531	untreated sialic acid-linkage isomers	1495:1531	untreated sialic acid-linkage isomers	1495:1531	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	5	9	theme	serum	833:837	arg1	IgG					839:841	purified human serum IgG	818:841	purified human serum IgG	818:841	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	3	10	theme	underivatized	596:608	arg1	N-glycans					619:627	native underivatized released N-glycans	589:627	native underivatized released N-glycans	589:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	5	11	theme	results	960:966	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	2	12	theme	several	281:287	arg1	loss					400:403	sample loss	393:403	sample loss	393:403	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	12	theme	several	281:287	arg1	drawbacks					289:297	several drawbacks	281:297	several drawbacks	281:297	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	12	theme	several	281:287	arg1	side-products					337:349	side-products	337:349	side-products	337:349	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	12	theme	several	281:287	arg1	interference					410:421	interference	410:421	interference with downstream analyses	410:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	12	theme	several	281:287	arg1	desialylation/defucosylation					363:390	noticeable desialylation/defucosylation	352:390	noticeable desialylation/defucosylation	352:390	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	12	theme	several	281:287	arg1	derivatization					321:334	incomplete derivatization	310:334	incomplete derivatization	310:334	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	6	13	theme	sensitive	1315:1323	arg1	analysis					1325:1332	highly sensitive analysis	1308:1332	highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents	1308:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	6	14	dep	~15-fold	1289:1296	arg1	up					1283:1284	up	1283:1284	up	1283:1284	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	6	15	theme	equivalents	1390:1400	arg1	nL					1370:1371	sub-0.2 nL	1362:1371	sub-0.2 nL of plasma volume equivalents	1362:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	5	16	theme	plasma-derived	1124:1137	arg1	samples					1139:1145	plasma-derived samples	1124:1145	plasma-derived samples	1124:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	17	link	blood-derived	897:909	arg1	isolates					933:940	blood-derived extracellular vesicle isolates	897:940	blood-derived extracellular vesicle isolates	897:940	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	18	theme	purified	818:825	arg1	IgG					839:841	purified human serum IgG	818:841	purified human serum IgG	818:841	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	2	19	theme	incomplete	310:319	arg1	derivatization					321:334	incomplete derivatization	310:334	incomplete derivatization	310:334	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	20	link	plasma-derived	1124:1137	arg1	samples					1139:1145	plasma-derived samples	1124:1145	plasma-derived samples	1124:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	21	theme	pancreas	872:879	arg1	B					894:894	bovine pancreas ribonuclease B	865:894	bovine pancreas ribonuclease B	865:894	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	0	22	theme	deep	28:31	arg1	profiling					33:41	Highly-sensitive label-free deep profiling	0:41	Highly-sensitive label-free deep profiling of N-glycans	0:54	Highly-sensitive label-free deep profiling of N-glycans released from biomedically-relevant samples.
36959283	5	23	from	detection	975:983	arg1	Qualitative					767:777	Qualitative	767:777	Qualitative	767:777	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	1	24	theme	disease	174:180	arg1	Alterations					101:111	Alterations	101:111	Alterations of protein glycosylation	101:136	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	1	24	theme	disease	174:180	arg1	biomarkers					182:191	sensitive and specific disease biomarkers	151:191	sensitive and specific disease biomarkers	151:191	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	6	25	theme	plasma	1376:1381	arg1	equivalents					1390:1400	plasma volume equivalents	1376:1400	plasma volume equivalents	1376:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	5	26	theme	B	894:894	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	2	27	with	desialylation/defucosylation	363:390	arg1	analyses					439:446	downstream analyses	428:446	downstream analyses	428:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	28	theme	serum	851:855	arg1	fetuin					857:862	bovine serum fetuin	844:862	bovine serum fetuin	844:862	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	29	theme	injected	1052:1059	arg1	amounts					1061:1067	injected amounts	1052:1067	injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples	1052:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	3	30	theme	capillary	514:522	arg1	spectrometry					550:561	high sensitivity capillary zone electrophoresis-mass spectrometry	497:561	high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans	497:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	3	30	theme	capillary	514:522	arg1	CZE-MS					564:569	CZE-MS	564:569	CZE-MS	564:569	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	5	31	theme	equivalent	1069:1078	arg1	amounts					1061:1067	injected amounts	1052:1067	injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples	1052:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	7	32	theme	sialylated	1423:1432	arg1	N-glycans					1434:1442	highly sialylated N-glycans	1416:1442	highly sialylated N-glycans	1416:1442	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	3	33	theme	high	497:500	arg1	spectrometry					550:561	high sensitivity capillary zone electrophoresis-mass spectrometry	497:561	high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans	497:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	3	33	theme	high	497:500	arg1	CZE-MS					564:569	CZE-MS	564:569	CZE-MS	564:569	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	4	34	from	increase	663:670	arg1	intensity					682:690	signal intensity	675:690	signal intensity	675:690	Our workflow provides a >45-fold increase in signal intensity compared to the conventional CZE-MS approaches used for N-glycan analysis.
36959283	1	35	theme	protein	116:122	arg1	glycosylation					124:136	protein glycosylation	116:136	protein glycosylation	116:136	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	5	36	theme	total	947:951	arg1	results					960:966	total plasma results	947:966	total plasma results	947:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	0	37	theme	biomedically-relevant	70:90	arg1	samples					92:98	biomedically-relevant samples	70:98	biomedically-relevant samples	70:98	Highly-sensitive label-free deep profiling of N-glycans released from biomedically-relevant samples.
36959283	3	38	theme	electrophoresis-mass	529:548	arg1	spectrometry					550:561	high sensitivity capillary zone electrophoresis-mass spectrometry	497:561	high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans	497:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	3	38	theme	electrophoresis-mass	529:548	arg1	CZE-MS					564:569	CZE-MS	564:569	CZE-MS	564:569	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	5	39	theme	blood-derived	897:909	arg1	isolates					933:940	blood-derived extracellular vesicle isolates	897:940	blood-derived extracellular vesicle isolates	897:940	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	3	40	theme	label-free	468:477	arg1	workflow					479:486	a label-free workflow	466:486	a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans	466:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	2	41	theme	Labeling	194:201	arg1	procedures					203:212	Labeling procedures	194:212	Labeling procedures for improved separation and detectability of oligosaccharides	194:274	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	42	theme	vesicle	925:931	arg1	isolates					933:940	blood-derived extracellular vesicle isolates	897:940	blood-derived extracellular vesicle isolates	897:940	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	6	43	theme	complexity	1223:1232	arg1	samples					1192:1198	biological samples	1181:1198	biological samples of similar amounts and complexity	1181:1232	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	6	44	theme	amounts	1211:1217	arg1	samples					1192:1198	biological samples	1181:1198	biological samples of similar amounts and complexity	1181:1232	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	3	45	theme	released	610:617	arg1	N-glycans					619:627	native underivatized released N-glycans	589:627	native underivatized released N-glycans	589:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	5	46	theme	model	1093:1097	arg1	protein					1099:1105	model protein	1093:1105	model protein	1093:1105	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	4	47	theme	CZE-MS	721:726	arg1	approaches					728:737	the conventional CZE-MS approaches	704:737	the conventional CZE-MS approaches used for N-glycan analysis	704:764	Our workflow provides a >45-fold increase in signal intensity compared to the conventional CZE-MS approaches used for N-glycan analysis.
36959283	3	48	theme	native	589:594	arg1	N-glycans					619:627	native underivatized released N-glycans	589:627	native underivatized released N-glycans	589:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	6	49	theme	biological	1181:1190	arg1	samples					1192:1198	biological samples	1181:1198	biological samples of similar amounts and complexity	1181:1232	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	4	50	theme	signal	675:680	arg1	intensity					682:690	signal intensity	675:690	signal intensity	675:690	Our workflow provides a >45-fold increase in signal intensity compared to the conventional CZE-MS approaches used for N-glycan analysis.
36959283	2	51	theme	noticeable	352:361	arg1	desialylation/defucosylation					363:390	noticeable desialylation/defucosylation	352:390	noticeable desialylation/defucosylation	352:390	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	7	52	theme	acid-linkage	1512:1523	arg1	isomers					1525:1531	untreated sialic acid-linkage isomers	1495:1531	untreated sialic acid-linkage isomers	1495:1531	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	6	53	theme	low	1355:1357	arg1	amounts					1344:1350	sample amounts	1337:1350	sample amounts as low as sub-0.2 nL of plasma volume equivalents	1337:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	7	54	theme	single	1551:1556	arg1	analysis					1565:1572	a single CZE-MS analysis	1549:1572	a single CZE-MS analysis	1549:1572	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	6	55	theme	N-glycans	1260:1268	arg1	number					1239:1244	the number	1235:1244	the number of identified N-glycans	1235:1268	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	6	56	theme	amounts	1344:1350	arg1	analysis					1325:1332	highly sensitive analysis	1308:1332	highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents	1308:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	5	57	theme	human	827:831	arg1	IgG					839:841	purified human serum IgG	818:841	purified human serum IgG	818:841	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	58	theme	plasma	953:958	arg1	results					960:966	total plasma results	947:966	total plasma results	947:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	7	59	theme	sialic	1505:1510	arg1	isomers					1525:1531	untreated sialic acid-linkage isomers	1495:1531	untreated sialic acid-linkage isomers	1495:1531	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	5	60	theme	IgG	839:841	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	4	61	theme	N-glycan	748:755	arg1	analysis					757:764	N-glycan analysis	748:764	N-glycan analysis	748:764	Our workflow provides a >45-fold increase in signal intensity compared to the conventional CZE-MS approaches used for N-glycan analysis.
36959283	5	62	theme	N-glycan	796:803	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	2	63	with	derivatization	321:334	arg1	analyses					439:446	downstream analyses	428:446	downstream analyses	428:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	6	64	theme	volume	1383:1388	arg1	equivalents					1390:1400	plasma volume equivalents	1376:1400	plasma volume equivalents	1376:1400	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	5	65	theme	samples	1139:1145	arg1	nL-levels					1111:1119	nL-levels	1111:1119	nL-levels of plasma-derived samples	1111:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	65	theme	samples	1139:1145	arg1	protein					1099:1105	model protein	1093:1105	model protein	1093:1105	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	1	66	theme	sensitive	151:159	arg1	Alterations					101:111	Alterations	101:111	Alterations of protein glycosylation	101:136	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	1	66	theme	sensitive	151:159	arg1	biomarkers					182:191	sensitive and specific disease biomarkers	151:191	sensitive and specific disease biomarkers	151:191	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	2	67	with	side-products	337:349	arg1	analyses					439:446	downstream analyses	428:446	downstream analyses	428:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	68	theme	bovine	865:870	arg1	B					894:894	bovine pancreas ribonuclease B	865:894	bovine pancreas ribonuclease B	865:894	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	1	69	theme	specific	165:172	arg1	Alterations					101:111	Alterations	101:111	Alterations of protein glycosylation	101:136	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	1	69	theme	specific	165:172	arg1	biomarkers					182:191	sensitive and specific disease biomarkers	151:191	sensitive and specific disease biomarkers	151:191	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	5	70	theme	ribonuclease	881:892	arg1	B					894:894	bovine pancreas ribonuclease B	865:894	bovine pancreas ribonuclease B	865:894	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	71	theme	bovine	844:849	arg1	fetuin					857:862	bovine serum fetuin	844:862	bovine serum fetuin	844:862	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	2	72	with	loss	400:403	arg1	analyses					439:446	downstream analyses	428:446	downstream analyses	428:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	73	theme	fetuin	857:862	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	7	74	gly	sialylated	1423:1432	arg1	N-glycans					1434:1442	highly sialylated N-glycans	1416:1442	highly sialylated N-glycans	1416:1442	Furthermore, highly sialylated N-glycans are identified and structurally characterized, and untreated sialic acid-linkage isomers are resolved in a single CZE-MS analysis.
36959283	3	75	theme	zone	524:527	arg1	spectrometry					550:561	high sensitivity capillary zone electrophoresis-mass spectrometry	497:561	high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans	497:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	3	75	theme	zone	524:527	arg1	CZE-MS					564:569	CZE-MS	564:569	CZE-MS	564:569	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	5	76	theme	isolates	933:940	arg1	profiling					805:813	quantitative N-glycan profiling	783:813	quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results	783:966	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	77	theme	N-glycans	1021:1029	arg1	detection					975:983	the detection	971:983	the detection of >250, >400, >150, >310, and >520 N-glycans	971:1029	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	6	78	theme	reported	1160:1167	arg1	results					1169:1175	reported results	1160:1175	reported results for biological samples of similar amounts and complexity	1160:1232	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	4	79	theme	>45-fold	654:661	arg1	increase					663:670	a >45-fold increase	652:670	a >45-fold increase in signal intensity	652:690	Our workflow provides a >45-fold increase in signal intensity compared to the conventional CZE-MS approaches used for N-glycan analysis.
36959283	3	80	theme	sensitivity	502:512	arg1	spectrometry					550:561	high sensitivity capillary zone electrophoresis-mass spectrometry	497:561	high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans	497:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	3	80	theme	sensitivity	502:512	arg1	CZE-MS					564:569	CZE-MS	564:569	CZE-MS	564:569	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	1	81	theme	glycosylation	124:136	arg1	Alterations					101:111	Alterations	101:111	Alterations of protein glycosylation	101:136	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	1	81	theme	glycosylation	124:136	arg1	biomarkers					182:191	sensitive and specific disease biomarkers	151:191	sensitive and specific disease biomarkers	151:191	Alterations of protein glycosylation can serve as sensitive and specific disease biomarkers.
36959283	2	82	theme	improved	218:225	arg1	separation					227:236	improved separation	218:236	improved separation	218:236	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	0	83	theme	N-glycans	46:54	arg1	profiling					33:41	Highly-sensitive label-free deep profiling	0:41	Highly-sensitive label-free deep profiling of N-glycans	0:54	Highly-sensitive label-free deep profiling of N-glycans released from biomedically-relevant samples.
36959283	5	84	theme	protein	1099:1105	arg1	<25 ng					1083:1088	<25 ng	1083:1088	<25 ng of model protein and nL-levels of plasma-derived samples	1083:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	85	theme	extracellular	911:923	arg1	isolates					933:940	blood-derived extracellular vesicle isolates	897:940	blood-derived extracellular vesicle isolates	897:940	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	2	86	with	interference	410:421	arg1	analyses					439:446	downstream analyses	428:446	downstream analyses	428:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	5	87	theme	nL-levels	1111:1119	arg1	<25 ng					1083:1088	<25 ng	1083:1088	<25 ng of model protein and nL-levels of plasma-derived samples	1083:1145	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	5	88	from	Qualitative	767:777	arg1	detection					975:983	the detection	971:983	the detection of >250, >400, >150, >310, and >520 N-glycans	971:1029	Qualitative and quantitative N-glycan profiling of purified human serum IgG, bovine serum fetuin, bovine pancreas ribonuclease B, blood-derived extracellular vesicle isolates, and total plasma results in the detection of >250, >400, >150, >310, and >520 N-glycans, respectively, using injected amounts equivalent to <25 ng of model protein and nL-levels of plasma-derived samples.
36959283	4	89	theme	conventional	708:719	arg1	approaches					728:737	the conventional CZE-MS approaches	704:737	the conventional CZE-MS approaches used for N-glycan analysis	704:764	Our workflow provides a >45-fold increase in signal intensity compared to the conventional CZE-MS approaches used for N-glycan analysis.
36959283	3	90	theme	N-glycans	619:627	arg1	profiling					576:584	profiling	576:584	profiling of native underivatized released N-glycans	576:627	Here, we develop a label-free workflow based on high sensitivity capillary zone electrophoresis-mass spectrometry (CZE-MS) for profiling of native underivatized released N-glycans.
36959283	2	91	contain	have	276:279	arg2	derivatization					321:334	incomplete derivatization	310:334	incomplete derivatization	310:334	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	91	contain	have	276:279	arg2	desialylation/defucosylation					363:390	noticeable desialylation/defucosylation	352:390	noticeable desialylation/defucosylation	352:390	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	91	contain	have	276:279	arg2	interference					410:421	interference	410:421	interference with downstream analyses	410:446	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	91	contain	have	276:279	arg2	loss					400:403	sample loss	393:403	sample loss	393:403	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	91	contain	have	276:279	arg2	drawbacks					289:297	several drawbacks	281:297	several drawbacks	281:297	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	91	contain	have	276:279	arg1	procedures					203:212	Labeling procedures	194:212	Labeling procedures for improved separation and detectability of oligosaccharides	194:274	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	2	91	contain	have	276:279	arg2	side-products					337:349	side-products	337:349	side-products	337:349	Labeling procedures for improved separation and detectability of oligosaccharides have several drawbacks, including incomplete derivatization, side-products, noticeable desialylation/defucosylation, sample loss, and interference with downstream analyses.
36959283	6	92	theme	similar	1203:1209	arg1	amounts					1211:1217	similar amounts	1203:1217	similar amounts	1203:1217	Compared to reported results for biological samples of similar amounts and complexity, the number of identified N-glycans is increased up to ~15-fold, enabling highly sensitive analysis of sample amounts as low as sub-0.2 nL of plasma volume equivalents.
36959283	0	93	theme	label-free	17:26	arg1	profiling					33:41	Highly-sensitive label-free deep profiling	0:41	Highly-sensitive label-free deep profiling of N-glycans	0:54	Highly-sensitive label-free deep profiling of N-glycans released from biomedically-relevant samples.
36037649	3	0	link	N-linked	593:600	arg1	tetrasaccharide					577:591	a tetrasaccharide	575:591	a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt	575:769	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	7	1	from	facet	1219:1223	arg1	Archaea					1247:1253	Archaea	1247:1253	Archaea	1247:1253	As such, this may represent yet another unique facet of N-glycosylation in Archaea.
36037649	2	2	theme	post-translational	350:367	arg1	processing					377:386	such post-translational protein processing	345:386	such post-translational protein processing in this microorganism	345:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	5	3	theme	iduronic	991:998	arg1	acid					1000:1003	iduronic acid	991:1003	iduronic acid	991:1003	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	2	4	theme	such	345:348	arg1	processing					377:386	such post-translational protein processing	345:386	such post-translational protein processing in this microorganism	345:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	7	5	theme	unique	1212:1217	arg1	facet					1219:1223	yet another unique facet	1200:1223	yet another unique facet of N-glycosylation in Archaea	1200:1253	As such, this may represent yet another unique facet of N-glycosylation in Archaea.
36037649	0	6	theme	iduronic	101:108	arg1	acid					110:113	iduronic acid	101:113	iduronic acid	101:113	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	3	7	theme	S-layer	697:703	arg1	glycoprotein					705:716	the S-layer glycoprotein	693:716	the S-layer glycoprotein that comprises the protein shell surrounding the Hbt	693:769	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	4	8	theme	-β-GlcA-	827:834	arg1	-β-Glc-Asn					842:851	(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn	820:851	(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn	820:851	salinarum cell as β-GlcA(2S)-(1 → 4)-α-IdoA(3S)-(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn.
36037649	3	9	theme	resonance	533:541	arg1	spectroscopy					543:554	nuclear magnetic resonance spectroscopy	516:554	nuclear magnetic resonance spectroscopy	516:554	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	1	10	theme	N-glycosylation	264:278	arg1	example					253:259	the first example	243:259	the first example of N-glycosylation outside Eukarya	243:294	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	5	11	from	glycan	1029:1034	arg1	confirmation					946:957	confirmation	946:957	confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan	946:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	3	12	theme	protein	737:743	arg1	shell					745:749	the protein shell	733:749	the protein shell surrounding the Hbt	733:769	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	4	13	theme	salinarum	772:780	arg1	cell					782:785	salinarum cell	772:785	salinarum cell as β-GlcA(2S)-(1 → 4)-α-IdoA(3S)	772:818	salinarum cell as β-GlcA(2S)-(1 → 4)-α-IdoA(3S)-(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn.
36037649	0	14	link	N-linked	3:10	arg1	tetrasaccharide					12:26	An N-linked tetrasaccharide	0:26	An N-linked tetrasaccharide from Halobacterium salinarum	0:55	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	3	15	theme	nuclear	516:522	arg1	resonance					533:541	nuclear magnetic resonance	516:541	nuclear magnetic resonance spectroscopy	516:554	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	5	16	from	confirmation	946:957	arg1	glycan					1029:1034	an archaeal N-linked glycan	1008:1034	an archaeal N-linked glycan	1008:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	2	17	from	aspects	334:340	arg1	microorganism					396:408	this microorganism	391:408	this microorganism	391:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	5	18	theme	previous	918:925	arg1	confirmation					946:957	confirmation	946:957	confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan	946:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	5	18	theme	previous	918:925	arg1	studies					927:933	previous studies	918:933	previous studies	918:933	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	1	19	theme	halophilic	163:172	arg1	salinarum					150:158	Halobacterium salinarum	136:158	Halobacterium salinarum	136:158	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	1	19	theme	halophilic	163:172	arg1	archaeon					174:181	a halophilic archaeon	161:181	a halophilic archaeon that grows at near-saturating salt concentrations	161:231	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	0	20	theme	acid	110:113	arg1	sulfation					88:96	sulfation	88:96	sulfation of iduronic acid at the O-3 position	88:133	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	0	20	theme	acid	110:113	arg1	modification					74:85	a novel modification	66:85	a novel modification	66:85	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	0	21	from	salinarum	47:55	arg1	tetrasaccharide					12:26	An N-linked tetrasaccharide	0:26	An N-linked tetrasaccharide from Halobacterium salinarum	0:55	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	6	22	from	position	1102:1109	arg1	sulfation					1059:1067	the sulfation	1055:1067	the sulfation of this iduronic acid at the O-3 position	1055:1109	At the same time, the sulfation of this iduronic acid at the O-3 position has not, to the best of our knowledge, been previously seen.
36037649	0	23	theme	N-linked	3:10	arg1	tetrasaccharide					12:26	An N-linked tetrasaccharide	0:26	An N-linked tetrasaccharide from Halobacterium salinarum	0:55	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	6	24	theme	acid	1086:1089	arg1	sulfation					1059:1067	the sulfation	1055:1067	the sulfation of this iduronic acid at the O-3 position	1055:1109	At the same time, the sulfation of this iduronic acid at the O-3 position has not, to the best of our knowledge, been previously seen.
36037649	3	25	theme	N-linked	593:600	arg1	tetrasaccharide					577:591	a tetrasaccharide	575:591	a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt	575:769	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	2	26	from	processing	377:386	arg1	microorganism					396:408	this microorganism	391:408	this microorganism	391:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	5	27	theme	tetrasaccharide	876:890	arg1	structure					858:866	The structure	854:866	The structure of this tetrasaccharide	854:890	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	0	28	theme	O-3	122:124	arg1	position					126:133	the O-3 position	118:133	the O-3 position	118:133	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	5	29	from	inclusion	978:986	arg1	glycan					1029:1034	an archaeal N-linked glycan	1008:1034	an archaeal N-linked glycan	1008:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	4	30	dep	-α-IdoA	808:814	arg1	1 → 4					802:806	1 → 4	802:806	1 → 4	802:806	salinarum cell as β-GlcA(2S)-(1 → 4)-α-IdoA(3S)-(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn.
36037649	6	31	theme	iduronic	1077:1084	arg1	acid					1086:1089	this iduronic acid	1072:1089	this iduronic acid	1072:1089	At the same time, the sulfation of this iduronic acid at the O-3 position has not, to the best of our knowledge, been previously seen.
36037649	3	32	theme	magnetic	524:531	arg1	resonance					533:541	nuclear magnetic resonance	516:541	nuclear magnetic resonance spectroscopy	516:554	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	1	33	theme	near-saturating	197:211	arg1	concentrations					218:231	near-saturating salt concentrations	197:231	near-saturating salt concentrations	197:231	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	5	34	theme	archaeal	1011:1018	arg1	glycan					1029:1034	an archaeal N-linked glycan	1008:1034	an archaeal N-linked glycan	1008:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	1	35	theme	salt	213:216	arg1	concentrations					218:231	near-saturating salt concentrations	197:231	near-saturating salt concentrations	197:231	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	0	36	theme	Halobacterium	33:45	arg1	salinarum					47:55	Halobacterium salinarum	33:55	Halobacterium salinarum	33:55	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	3	37	theme	swimming	655:662	arg1	device					664:669	the archaeal swimming device	642:669	the archaeal swimming device (the archaellum)	642:686	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	37	theme	swimming	655:662	arg1	archaellum					676:685	the archaellum	672:685	the archaellum	672:685	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	38	theme	building	623:630	arg1	blocks					632:637	building blocks	623:637	building blocks of the archaeal swimming device (the archaellum)	623:686	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	2	39	theme	glycans	484:490	arg1	architecture					449:460	the architecture	445:460	the architecture of glycoprotein-bound glycans	445:490	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	3	40	gly	glycoprotein	705:716	arg1	glycoprotein					705:716	the S-layer glycoprotein	693:716	the S-layer glycoprotein that comprises the protein shell surrounding the Hbt	693:769	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	41	theme	device	664:669	arg1	glycoprotein					705:716	the S-layer glycoprotein	693:716	the S-layer glycoprotein that comprises the protein shell surrounding the Hbt	693:769	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	41	theme	device	664:669	arg1	archaellins					610:620	archaellins	610:620	archaellins	610:620	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	41	theme	device	664:669	arg1	blocks					632:637	building blocks	623:637	building blocks of the archaeal swimming device (the archaellum)	623:686	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	5	42	theme	known	972:976	arg1	inclusion					978:986	the first known inclusion	962:986	the first known inclusion of iduronic acid in an archaeal N-linked glycan	962:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	6	43	theme	same	1044:1047	arg1	time					1049:1052	the same time	1040:1052	the same time	1040:1052	At the same time, the sulfation of this iduronic acid at the O-3 position has not, to the best of our knowledge, been previously seen.
36037649	2	44	theme	glycoprotein-bound	465:482	arg1	glycans					484:490	glycoprotein-bound glycans	465:490	glycoprotein-bound glycans	465:490	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	6	45	theme	O-3	1098:1100	arg1	position					1102:1109	the O-3 position	1094:1109	the O-3 position	1094:1109	At the same time, the sulfation of this iduronic acid at the O-3 position has not, to the best of our knowledge, been previously seen.
36037649	5	46	theme	inclusion	978:986	arg1	confirmation					946:957	confirmation	946:957	confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan	946:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	5	47	theme	N-linked	1020:1027	arg1	glycan					1029:1034	an archaeal N-linked glycan	1008:1034	an archaeal N-linked glycan	1008:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	5	48	theme	first	966:970	arg1	inclusion					978:986	the first known inclusion	962:986	the first known inclusion of iduronic acid in an archaeal N-linked glycan	962:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	1	49	theme	Halobacterium	136:148	arg1	salinarum					150:158	Halobacterium salinarum	136:158	Halobacterium salinarum	136:158	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	1	49	theme	Halobacterium	136:148	arg1	archaeon					174:181	a halophilic archaeon	161:181	a halophilic archaeon that grows at near-saturating salt concentrations	161:231	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36037649	2	50	from	microorganism	396:408	arg1	aspects					334:340	numerous aspects	325:340	numerous aspects of such post-translational protein processing in this microorganism	325:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	2	51	theme	numerous	325:332	arg1	aspects					334:340	numerous aspects	325:340	numerous aspects of such post-translational protein processing in this microorganism	325:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	5	52	theme	acid	1000:1003	arg1	inclusion					978:986	the first known inclusion	962:986	the first known inclusion of iduronic acid in an archaeal N-linked glycan	962:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	3	53	theme	archaeal	646:653	arg1	device					664:669	the archaeal swimming device	642:669	the archaeal swimming device (the archaellum)	642:686	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	53	theme	archaeal	646:653	arg1	archaellum					676:685	the archaellum	672:685	the archaellum	672:685	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	3	54	theme	present	500:506	arg1	report					508:513	the present report	496:513	the present report	496:513	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	0	55	from	position	126:133	arg1	sulfation					88:96	sulfation	88:96	sulfation of iduronic acid at the O-3 position	88:133	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	0	55	from	position	126:133	arg1	modification					74:85	a novel modification	66:85	a novel modification	66:85	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	4	56	dep	-β-Glc-Asn	842:851	arg1	1 → 4					821:825	1 → 4	821:825	1 → 4	821:825	salinarum cell as β-GlcA(2S)-(1 → 4)-α-IdoA(3S)-(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn.
36037649	4	56	dep	-β-Glc-Asn	842:851	arg1	1 → 4					836:840	1 → 4	836:840	1 → 4	836:840	salinarum cell as β-GlcA(2S)-(1 → 4)-α-IdoA(3S)-(1 → 4)-β-GlcA-(1 → 4)-β-Glc-Asn.
36037649	3	57	used	used	560:563	arg2	spectroscopy					543:554	nuclear magnetic resonance spectroscopy	516:554	nuclear magnetic resonance spectroscopy	516:554	In the present report, nuclear magnetic resonance spectroscopy was used to define a tetrasaccharide N-linked to both archaellins, building blocks of the archaeal swimming device (the archaellum), and the S-layer glycoprotein that comprises the protein shell surrounding the Hbt.
36037649	2	58	theme	processing	377:386	arg1	aspects					334:340	numerous aspects	325:340	numerous aspects of such post-translational protein processing in this microorganism	325:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	0	59	theme	novel	68:72	arg1	sulfation					88:96	sulfation	88:96	sulfation of iduronic acid at the O-3 position	88:133	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	0	59	theme	novel	68:72	arg1	modification					74:85	a novel modification	66:85	a novel modification	66:85	An N-linked tetrasaccharide from Halobacterium salinarum presents a novel modification, sulfation of iduronic acid at the O-3 position.
36037649	7	60	theme	N-glycosylation	1228:1242	arg1	facet					1219:1223	yet another unique facet	1200:1223	yet another unique facet of N-glycosylation in Archaea	1200:1253	As such, this may represent yet another unique facet of N-glycosylation in Archaea.
36037649	2	61	theme	protein	369:375	arg1	processing					377:386	such post-translational protein processing	345:386	such post-translational protein processing in this microorganism	345:408	Yet, almost 50 years later, numerous aspects of such post-translational protein processing in this microorganism remain to be determined, including the architecture of glycoprotein-bound glycans.
36037649	5	62	link	N-linked	1020:1027	arg1	glycan					1029:1034	an archaeal N-linked glycan	1008:1034	an archaeal N-linked glycan	1008:1034	The structure of this tetrasaccharide fills gaps remaining from previous studies, including confirmation of the first known inclusion of iduronic acid in an archaeal N-linked glycan.
36037649	1	63	theme	first	247:251	arg1	example					253:259	the first example	243:259	the first example of N-glycosylation outside Eukarya	243:294	Halobacterium salinarum, a halophilic archaeon that grows at near-saturating salt concentrations, provided the first example of N-glycosylation outside Eukarya.
36781790	7	0	theme	comprehensive	1670:1682	arg1	view					1684:1687	a comprehensive view	1668:1687	a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome	1668:1752	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	3	1	theme	protein	803:809	arg1	extracts					811:818	protein extracts	803:818	protein extracts	803:818	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	7	2	dep	complexity	1696:1705	arg1	the					1692:1694	the	1692:1694	the	1692:1694	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	3	3	theme	graphitized	831:841	arg1	carbon-LC-MS/MS					843:857	porous graphitized carbon-LC-MS/MS	824:857	porous graphitized carbon-LC-MS/MS	824:857	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	3	4	theme	-omics	636:641	arg1	technology					643:652	an integrated -omics technology	622:652	an integrated -omics technology	622:652	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	7	5	theme	glycomics-assisted	1604:1621	arg1	method					1639:1644	The glycomics-assisted glycoproteomics method	1600:1644	The glycomics-assisted glycoproteomics method	1600:1644	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	4	6	theme	same	1011:1014	arg1	samples					1024:1030	the same protein samples	1007:1030	the same protein samples	1007:1030	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	2	7	theme	integrated	376:385	arg1	workflows					387:395	integrated workflows	376:395	integrated workflows employing both glycomics and glycoproteomics	376:440	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	1	8	theme	glycopeptides	233:245	arg1	profiling					192:200	the system-wide profiling	176:200	the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively	176:283	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	8	theme	glycopeptides	233:245	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	9	theme	biological	252:261	arg1	samples					263:269	biological samples	252:269	biological samples	252:269	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	6	10	theme	biological	1580:1589	arg1	samples					1591:1597	biological samples	1580:1597	biological samples	1580:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	1	11	from	samples	263:269	arg1	profiling					192:200	the system-wide profiling	176:200	the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively	176:283	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	11	from	samples	263:269	arg1	glycans					214:220	detached glycans	205:220	detached glycans	205:220	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	11	from	samples	263:269	arg1	glycopeptides					233:245	intact glycopeptides	226:245	intact glycopeptides	226:245	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	11	from	samples	263:269	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	6	12	theme	carriers	1471:1478	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	12	theme	carriers	1471:1478	arg1	s					1489:1489	s	1489:1489	s	1489:1489	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	12	theme	carriers	1471:1478	arg1	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	12	theme	carriers	1471:1478	arg1	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	12	theme	carriers	1471:1478	arg1	glycosylation					1495:1507	glycosylation	1495:1507	glycosylation	1495:1507	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	12	theme	carriers	1471:1478	arg1	information					1444:1454	quantitative information	1431:1454	quantitative information of the protein carriers	1431:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	12	theme	carriers	1471:1478	arg1	site					1484:1487	site	1484:1487	site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples	1484:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	13	theme	quantitative	1431:1442	arg1	information					1444:1454	quantitative information	1431:1454	quantitative information of the protein carriers	1431:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	5	14	theme	N-glycomics	1116:1126	arg1	data					1150:1153	the N-glycomics and N-glycoproteomics data	1112:1153	the N-glycomics and N-glycoproteomics data collection, analysis, and integration	1112:1191	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	14	theme	N-glycomics	1116:1126	arg1	analysis					1167:1174	analysis	1167:1174	analysis	1167:1174	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	14	theme	N-glycomics	1116:1126	arg1	integration					1181:1191	integration	1181:1191	integration	1181:1191	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	14	theme	N-glycomics	1116:1126	arg1	collection					1155:1164	collection	1155:1164	collection	1155:1164	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	3	15	theme	N-glycan	731:738	arg1	structures					745:754	the N-glycan fine structures	727:754	the N-glycan fine structures	727:754	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	2	16	dep	Efforts	357:363	arg1	develop					368:374	develop	368:374	to develop integrated workflows employing both glycomics and glycoproteomics	365:440	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	0	17	theme	Biological	98:107	arg1	Specimens					109:117	Complex Biological Specimens	90:117	Complex Biological Specimens	90:117	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	1	18	theme	detached	205:212	arg1	glycans					214:220	detached glycans	205:220	detached glycans	205:220	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	7	19	theme	glycoproteome	1740:1752	arg1	dynamics					1711:1718	dynamics	1711:1718	dynamics	1711:1718	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	7	19	theme	glycoproteome	1740:1752	arg1	complexity					1696:1705	complexity	1696:1705	complexity	1696:1705	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	0	20	theme	Glycomics-Assisted	0:17	arg1	Glycoproteomics					19:33	Glycomics-Assisted Glycoproteomics	0:33	Glycomics-Assisted Glycoproteomics	0:33	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	1	21	theme	heterogenous	329:340	arg1	glycoproteome					342:354	the heterogenous glycoproteome	325:354	the heterogenous glycoproteome	325:354	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	22	theme	Mass	120:123	arg1	profiling					192:200	the system-wide profiling	176:200	the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively	176:283	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	22	theme	Mass	120:123	arg1	glycoproteomics					159:173	glycoproteomics	159:173	glycoproteomics	159:173	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	22	theme	Mass	120:123	arg1	approaches					299:308	powerful approaches	290:308	powerful approaches	290:308	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	22	theme	Mass	120:123	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	6	23	theme	method	1259:1264	arg1	Benefits					1208:1215	Benefits	1208:1215	Benefits	1208:1215	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	2	24	theme	approaches	516:525	arg1	application					481:491	the concerted application	467:491	the concerted application of these complementary approaches	467:525	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	6	25	theme	glycomics-assisted	1224:1241	arg1	method					1259:1264	the glycomics-assisted glycoproteomics method	1220:1264	the glycomics-assisted glycoproteomics method	1220:1264	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	s					1489:1489	s	1489:1489	s	1489:1489	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	glycosylation					1495:1507	glycosylation	1495:1507	glycosylation	1495:1507	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	information					1444:1454	quantitative information	1431:1454	quantitative information of the protein carriers	1431:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	26	theme	structures	1555:1564	arg1	site					1484:1487	site	1484:1487	site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples	1484:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	4	27	theme	intact	979:984	arg1	N-glycopeptides					986:1000	intact N-glycopeptides	979:1000	intact N-glycopeptides	979:1000	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	6	28	theme	site-specific	1534:1546	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	29	gly	glycosylation	1495:1507	arg2	glycosylation					1495:1507	glycosylation	1495:1507	glycosylation	1495:1507	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	29	gly	glycosylation	1495:1507	arg2	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	29	gly	glycosylation	1495:1507	arg2	site					1484:1487	site	1484:1487	site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples	1484:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	29	gly	glycosylation	1495:1507	arg2	s					1489:1489	s	1489:1489	s	1489:1489	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	29	gly	glycosylation	1495:1507	arg2	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	29	gly	glycosylation	1495:1507	arg2	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	3	30	theme	distribution	779:790	arg1	pattern					792:798	their quantitative distribution pattern	760:798	their quantitative distribution pattern of protein extracts	760:818	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	4	31	theme	reversed-phase	936:949	arg1	profiling					966:974	the challenging reversed-phase LC-MS/MS-based profiling	920:974	the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides	920:1000	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	3	32	theme	porous	824:829	arg1	carbon-LC-MS/MS					843:857	porous graphitized carbon-LC-MS/MS	824:857	porous graphitized carbon-LC-MS/MS	824:857	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	1	33	theme	powerful	290:297	arg1	glycoproteomics					159:173	glycoproteomics	159:173	glycoproteomics	159:173	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	33	theme	powerful	290:297	arg1	approaches					299:308	powerful approaches	290:308	powerful approaches	290:308	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	33	theme	powerful	290:297	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	4	34	theme	protein	1016:1022	arg1	samples					1024:1030	the same protein samples	1007:1030	the same protein samples	1007:1030	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	3	35	theme	extracts	811:818	arg1	technology					643:652	an integrated -omics technology	622:652	an integrated -omics technology	622:652	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	3	35	theme	extracts	811:818	arg1	pattern					792:798	their quantitative distribution pattern	760:798	their quantitative distribution pattern of protein extracts	760:818	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	3	35	theme	extracts	811:818	arg1	method					696:701	the "glycomics-assisted glycoproteomics" method	655:701	the "glycomics-assisted glycoproteomics" method	655:701	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	1	36	gly	glycopeptides	233:245	arg1	samples					263:269	biological samples	252:269	biological samples	252:269	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	36	gly	glycopeptides	233:245	arg2	glycopeptides					233:245	intact glycopeptides	226:245	intact glycopeptides	226:245	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	7	37	theme	glycoproteomics	1623:1637	arg1	method					1639:1644	The glycomics-assisted glycoproteomics method	1600:1644	The glycomics-assisted glycoproteomics method	1600:1644	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	3	38	theme	integrated	625:634	arg1	technology					643:652	an integrated -omics technology	622:652	an integrated -omics technology	622:652	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	1	39	theme	glycans	214:220	arg1	profiling					192:200	the system-wide profiling	176:200	the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively	176:283	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	39	theme	glycans	214:220	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	0	40	theme	N-Glycoproteome	61:75	arg1	Profiling					77:85	Deep and Unbiased N-Glycoproteome Profiling	43:85	Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens	43:117	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	4	41	theme	N-glycopeptides	986:1000	arg1	profiling					966:974	the challenging reversed-phase LC-MS/MS-based profiling	920:974	the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides	920:1000	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	6	42	theme	protein	1352:1358	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	s					1489:1489	s	1489:1489	s	1489:1489	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	glycosylation					1495:1507	glycosylation	1495:1507	glycosylation	1495:1507	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	information					1444:1454	quantitative information	1431:1454	quantitative information of the protein carriers	1431:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	43	theme	occupancy	1515:1523	arg1	site					1484:1487	site	1484:1487	site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples	1484:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	3	44	theme	glycomics-assisted	660:677	arg1	method					696:701	the "glycomics-assisted glycoproteomics" method	655:701	the "glycomics-assisted glycoproteomics" method	655:701	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	1	45	theme	intact	226:231	arg1	glycopeptides					233:245	intact glycopeptides	226:245	intact glycopeptides	226:245	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	4	46	gly	N-glycopeptides	986:1000	arg2	N-glycopeptides					986:1000	intact N-glycopeptides	979:1000	intact N-glycopeptides	979:1000	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	3	47	theme	glycoproteomics	679:693	arg1	method					696:701	the "glycomics-assisted glycoproteomics" method	655:701	the "glycomics-assisted glycoproteomics" method	655:701	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	6	48	theme	biological	1323:1332	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	48	theme	biological	1323:1332	arg1	specimens					1334:1342	both simple and complex biological specimens	1299:1342	both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1299:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	5	49	theme	Experimental	1033:1044	arg1	details					1046:1052	Experimental details	1033:1052	Experimental details	1033:1052	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	6	50	from	samples	1591:1597	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	50	from	samples	1591:1597	arg1	s					1489:1489	s	1489:1489	s	1489:1489	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	50	from	samples	1591:1597	arg1	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	50	from	samples	1591:1597	arg1	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	50	from	samples	1591:1597	arg1	glycosylation					1495:1507	glycosylation	1495:1507	glycosylation	1495:1507	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	50	from	samples	1591:1597	arg1	information					1444:1454	quantitative information	1431:1454	quantitative information of the protein carriers	1431:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	50	from	samples	1591:1597	arg1	site					1484:1487	site	1484:1487	site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples	1484:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	3	51	theme	"	694:694	arg1	method					696:701	the "glycomics-assisted glycoproteomics" method	655:701	the "glycomics-assisted glycoproteomics" method	655:701	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	6	52	theme	bodily	1394:1399	arg1	fluids					1401:1406	bodily fluids	1394:1406	bodily fluids (e.g., serum)	1394:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	53	from	fluids	1401:1406	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	54	theme	protein	1463:1469	arg1	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	5	55	theme	sample	1089:1094	arg1	preparation					1096:1106	the sample preparation	1085:1106	the sample preparation	1085:1106	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	56	dep	data	1150:1153	arg1	data					1150:1153	the N-glycomics and N-glycoproteomics data	1112:1153	the N-glycomics and N-glycoproteomics data collection, analysis, and integration	1112:1191	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	56	dep	data	1150:1153	arg1	analysis					1167:1174	analysis	1167:1174	analysis	1167:1174	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	56	dep	data	1150:1153	arg1	integration					1181:1191	integration	1181:1191	integration	1181:1191	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	56	dep	data	1150:1153	arg1	collection					1155:1164	collection	1155:1164	collection	1155:1164	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	0	57	theme	Complex	90:96	arg1	Specimens					109:117	Complex Biological Specimens	90:117	Complex Biological Specimens	90:117	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	1	58	theme	system-wide	180:190	arg1	profiling					192:200	the system-wide profiling	176:200	the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively	176:283	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	58	theme	system-wide	180:190	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	6	59	from	tissues	1381:1387	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	0	60	theme	Specimens	109:117	arg1	Profiling					77:85	Deep and Unbiased N-Glycoproteome Profiling	43:85	Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens	43:117	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	6	61	theme	site	1510:1513	arg1	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	5	62	theme	N-glycoproteomics	1132:1148	arg1	data					1150:1153	the N-glycomics and N-glycoproteomics data	1112:1153	the N-glycomics and N-glycoproteomics data collection, analysis, and integration	1112:1191	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	62	theme	N-glycoproteomics	1132:1148	arg1	analysis					1167:1174	analysis	1167:1174	analysis	1167:1174	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	62	theme	N-glycoproteomics	1132:1148	arg1	integration					1181:1191	integration	1181:1191	integration	1181:1191	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	5	62	theme	N-glycoproteomics	1132:1148	arg1	collection					1155:1164	collection	1155:1164	collection	1155:1164	Experimental details and considerations relating to the sample preparation and the N-glycomics and N-glycoproteomics data collection, analysis, and integration are discussed.
36781790	7	63	theme	heterogenous	1727:1738	arg1	glycoproteome					1740:1752	the heterogenous glycoproteome	1723:1752	the heterogenous glycoproteome	1723:1752	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	6	64	theme	glycosylation	1495:1507	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	64	theme	glycosylation	1495:1507	arg1	s					1489:1489	s	1489:1489	s	1489:1489	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	64	theme	glycosylation	1495:1507	arg1	occupancy					1515:1523	site occupancy	1510:1523	site occupancy	1510:1523	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	64	theme	glycosylation	1495:1507	arg1	carriers					1471:1478	the protein carriers	1459:1478	the protein carriers	1459:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	64	theme	glycosylation	1495:1507	arg1	glycosylation					1495:1507	glycosylation	1495:1507	glycosylation	1495:1507	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	64	theme	glycosylation	1495:1507	arg1	information					1444:1454	quantitative information	1431:1454	quantitative information of the protein carriers	1431:1478	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	64	theme	glycosylation	1495:1507	arg1	site					1484:1487	site	1484:1487	site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples	1484:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	1	65	from	profiling	192:200	arg1	samples					263:269	biological samples	252:269	biological samples	252:269	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	6	66	from	cells	1374:1378	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	2	67	theme	concerted	471:479	arg1	application					481:491	the concerted application	467:491	the concerted application of these complementary approaches	467:525	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	2	68	theme	deeper	537:542	arg1	exploration					544:554	a deeper exploration	535:554	a deeper exploration of the glycoproteome	535:575	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	4	69	theme	N-glycome	864:872	arg1	information					874:884	The N-glycome information	860:884	The N-glycome information	860:884	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	0	70	theme	Deep	43:46	arg1	Profiling					77:85	Deep and Unbiased N-Glycoproteome Profiling	43:85	Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens	43:117	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	6	71	from	site	1484:1487	arg1	samples					1591:1597	biological samples	1580:1597	biological samples	1580:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	1	72	theme	spectrometry-driven	125:143	arg1	profiling					192:200	the system-wide profiling	176:200	the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively	176:283	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	72	theme	spectrometry-driven	125:143	arg1	glycoproteomics					159:173	glycoproteomics	159:173	glycoproteomics	159:173	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	72	theme	spectrometry-driven	125:143	arg1	approaches					299:308	powerful approaches	290:308	powerful approaches	290:308	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	1	72	theme	spectrometry-driven	125:143	arg1	glycomics					145:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics	120:153	Mass spectrometry-driven glycomics and glycoproteomics, the system-wide profiling of detached glycans and intact glycopeptides from biological samples, respectively, are powerful approaches to interrogate the heterogenous glycoproteome.
36781790	6	73	theme	glycoproteomics	1243:1257	arg1	method					1259:1264	the glycomics-assisted glycoproteomics method	1220:1264	the glycomics-assisted glycoproteomics method	1220:1264	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	2	74	theme	complementary	502:514	arg1	approaches					516:525	these complementary approaches	496:525	these complementary approaches	496:525	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	0	75	theme	Unbiased	52:59	arg1	Profiling					77:85	Deep and Unbiased N-Glycoproteome Profiling	43:85	Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens	43:117	Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens.
36781790	2	76	theme	glycoproteome	563:575	arg1	exploration					544:554	a deeper exploration	535:554	a deeper exploration of the glycoproteome	535:575	Efforts to develop integrated workflows employing both glycomics and glycoproteomics have been invested since the concerted application of these complementary approaches enables a deeper exploration of the glycoproteome.
36781790	3	77	theme	fine	740:743	arg1	structures					745:754	the N-glycan fine structures	727:754	the N-glycan fine structures	727:754	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	4	78	theme	LC-MS/MS-based	951:964	arg1	profiling					966:974	the challenging reversed-phase LC-MS/MS-based profiling	920:974	the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides	920:1000	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	6	79	theme	glycan	1548:1553	arg1	structures					1555:1564	the site-specific glycan structures	1530:1564	the site-specific glycan structures directly from biological samples	1530:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	7	80	theme	dynamics	1711:1718	arg1	view					1684:1687	a comprehensive view	1668:1687	a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome	1668:1752	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	6	81	theme	complex	1315:1321	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	81	theme	complex	1315:1321	arg1	specimens					1334:1342	both simple and complex biological specimens	1299:1342	both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1299:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	7	82	theme	complexity	1696:1705	arg1	view					1684:1687	a comprehensive view	1668:1687	a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome	1668:1752	The glycomics-assisted glycoproteomics method therefore facilitates a comprehensive view of the complexity and dynamics of the heterogenous glycoproteome.
36781790	6	83	theme	simple	1304:1309	arg1	extracts					1360:1367	protein extracts	1352:1367	protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1352:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	6	83	theme	simple	1304:1309	arg1	specimens					1334:1342	both simple and complex biological specimens	1299:1342	both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum)	1299:1420	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	3	84	theme	quantitative	766:777	arg1	pattern					792:798	their quantitative distribution pattern	760:798	their quantitative distribution pattern of protein extracts	760:818	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	3	85	theme	protocol	583:590	arg1	paper					592:596	This protocol paper	578:596	This protocol paper	578:596	This protocol paper outlines, step-by-step, an integrated -omics technology, the "glycomics-assisted glycoproteomics" method, that first establishes the N-glycan fine structures and their quantitative distribution pattern of protein extracts via porous graphitized carbon-LC-MS/MS.
36781790	4	86	used	used	894:897	arg2	information					874:884	The N-glycome information	860:884	The N-glycome information	860:884	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	6	87	dep	serum	1415:1419	arg1	e.g.					1409:1412	e.g.	1409:1412	e.g.	1409:1412	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
36781790	4	88	theme	challenging	924:934	arg1	profiling					966:974	the challenging reversed-phase LC-MS/MS-based profiling	920:974	the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides	920:1000	The N-glycome information is then used to augment and guide the challenging reversed-phase LC-MS/MS-based profiling of intact N-glycopeptides from the same protein samples.
36781790	6	89	from	information	1444:1454	arg1	samples					1591:1597	biological samples	1580:1597	biological samples	1580:1597	Benefits of the glycomics-assisted glycoproteomics method, which can be readily applied to both simple and complex biological specimens such as protein extracts from cells, tissues, and bodily fluids (e.g., serum), include quantitative information of the protein carriers and site(s) of glycosylation, site occupancy, and the site-specific glycan structures directly from biological samples.
37071393	7	0	theme	structural	1503:1512	arg1	integrity					1514:1522	the overall structural integrity	1491:1522	the overall structural integrity of the enzyme	1491:1536	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	1	1	contain	carrying	315:322	arg1	backbone					306:313	an extended α-1,6-mannan backbone	281:313	an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths	281:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	1	1	contain	carrying	315:322	arg2	number					326:331	a number	324:331	a number of α-1,2- and α-1,3-mannose substituents of varying lengths	324:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	5	2	from	mannoimidazole	1058:1071	arg1	NnGH92					987:992	NnGH92	987:992	NnGH92	987:992	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	2	from	mannoimidazole	1058:1071	arg1	novalis					978:984	Neobacillus novalis	966:984	Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	966:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	1	3	theme	extended	284:291	arg1	backbone					306:313	an extended α-1,6-mannan backbone	281:313	an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths	281:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	6	4	theme	Bacteroides	1227:1237	arg1	thetaiotaomicron					1239:1254	Bacteroides thetaiotaomicron	1227:1254	Bacteroides thetaiotaomicron	1227:1254	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	3	5	theme	characterized	577:589	arg1	α-mannosidases					596:609	Most characterized GH92 α-mannosidases	572:609	Most characterized GH92 α-mannosidases	572:609	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	8	6	theme	α-mannan	1788:1795	arg1	degradation					1767:1777	the degradation	1763:1777	the degradation of yeast α-mannan or mannose-rich glycans	1763:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	1	7	theme	N-glycan	212:219	arg1	core					221:224	a high-mannose N-glycan core	197:224	a high-mannose N-glycan core	197:224	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	3	8	theme	single	624:629	arg1	domain					641:646	a single catalytic domain	622:646	a single catalytic domain	622:646	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	8	9	theme	mannose-rich	1800:1811	arg1	glycans					1813:1819	mannose-rich glycans	1800:1819	mannose-rich glycans	1800:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	5	10	theme	five-domain	926:936	arg1	α-1,2-mannosidase					943:959	the full-length five-domain GH92 α-1,2-mannosidase	910:959	the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	910:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	6	11	theme	GH92	1196:1199	arg1	Bt3990					1215:1220	the GH92 α-mannosidase Bt3990	1192:1220	the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron	1192:1254	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	1	12	gly	N-glycosylated	148:161	arg2	proteins					135:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	1	12	gly	N-glycosylated	148:161	arg1	proteins					135:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	1	12	gly	N-glycosylated	148:161	arg1	case					247:250	the specific case	234:250	the specific case of yeast cell-wall proteins	234:278	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	1	13	theme	specific	238:245	arg1	case					247:250	the specific case	234:250	the specific case of yeast cell-wall proteins	234:278	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	5	14	from	investigation	871:883	arg1	NnGH92					987:992	NnGH92	987:992	NnGH92	987:992	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	14	from	investigation	871:883	arg1	novalis					978:984	Neobacillus novalis	966:984	Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	966:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	3	15	theme	extra	666:670	arg1	domains					672:678	extra domains	666:678	extra domains including putative carbohydrate-binding modules (CBMs)	666:733	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	3	15	theme	extra	666:670	arg1	modules					720:726	putative carbohydrate-binding modules	690:726	putative carbohydrate-binding modules (CBMs)	690:733	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	0	16	theme	α-1,2-mannosidase	66:82	arg1	characterization					26:41	Structural and functional characterization	0:41	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.	0:108	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	1	17	theme	α-1,3-mannose	347:359	arg1	substituents					361:372	α-1,3-mannose substituents	347:372	α-1,3-mannose substituents of varying lengths	347:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	5	18	theme	biochemical	859:869	arg1	investigation					871:883	biochemical investigation	859:883	biochemical investigation	859:883	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	19	theme	α-1,2-mannosidase	943:959	arg1	mannoimidazole					1058:1071	an additional mannoimidazole	1044:1071	an additional mannoimidazole bound to the N-terminal CBM32	1044:1101	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	19	theme	α-1,2-mannosidase	943:959	arg1	investigation					871:883	biochemical investigation	859:883	biochemical investigation	859:883	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	19	theme	α-1,2-mannosidase	943:959	arg1	structure					897:905	crystal structure	889:905	crystal structure	889:905	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	0	20	theme	Neobacillus	89:99	arg1	novalis					101:107	Neobacillus novalis	89:107	Neobacillus novalis	89:107	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	5	21	theme	Neobacillus	966:976	arg1	NnGH92					987:992	NnGH92	987:992	NnGH92	987:992	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	21	theme	Neobacillus	966:976	arg1	novalis					978:984	Neobacillus novalis	966:984	Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	966:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	4	22	theme	GH92	802:805	arg1	CBM					821:823	a multi-domain GH92 α-mannosidase CBM	787:823	a multi-domain GH92 α-mannosidase CBM	787:823	To date, neither the function nor the structure of a multi-domain GH92 α-mannosidase CBM has been characterized.
37071393	1	23	theme	lengths	385:391	arg1	α-1,2-					336:341	α-1,2-	336:341	α-1,2-	336:341	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	1	23	theme	lengths	385:391	arg1	substituents					361:372	α-1,3-mannose substituents	347:372	α-1,3-mannose substituents of varying lengths	347:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	5	24	theme	active	1028:1033	arg1	site					1035:1038	the active site	1024:1038	the active site	1024:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	7	25	theme	α-mannan	1610:1617	arg1	substrate					1619:1627	the yeast α-mannan substrate	1600:1627	the yeast α-mannan substrate	1600:1627	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	2	26	theme	α-mannan	553:560	arg1	backbone					562:569	the α-mannan backbone	549:569	the α-mannan backbone	549:569	α-Mannosidases from CAZy family GH92 release terminal mannose residues from these N-glycans, providing access for the α-endomannanases, which then degrade the α-mannan backbone.
37071393	4	27	theme	CBM	821:823	arg1	structure					774:782	the structure	770:782	the structure of a multi-domain GH92 α-mannosidase CBM	770:823	To date, neither the function nor the structure of a multi-domain GH92 α-mannosidase CBM has been characterized.
37071393	1	28	from	N-glycosylated	148:161	arg1	case					247:250	the specific case	234:250	the specific case of yeast cell-wall proteins	234:278	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	5	29	with	novalis	978:984	arg1	mannoimidazole					1000:1013	mannoimidazole	1000:1013	mannoimidazole bound in the active site	1000:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	6	30	from	thetaiotaomicron	1239:1254	arg1	Bt3990					1215:1220	the GH92 α-mannosidase Bt3990	1192:1220	the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron	1192:1254	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	2	31	theme	family	419:424	arg1	GH92					426:429	CAZy family GH92	414:429	CAZy family GH92	414:429	α-Mannosidases from CAZy family GH92 release terminal mannose residues from these N-glycans, providing access for the α-endomannanases, which then degrade the α-mannan backbone.
37071393	0	32	theme	Structural	0:9	arg1	characterization					26:41	Structural and functional characterization	0:41	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.	0:108	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	1	33	theme	α-1,6-mannan	293:304	arg1	backbone					306:313	an extended α-1,6-mannan backbone	281:313	an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths	281:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	5	34	from	novalis	978:984	arg1	mannoimidazole					1058:1071	an additional mannoimidazole	1044:1071	an additional mannoimidazole bound to the N-terminal CBM32	1044:1101	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	34	from	novalis	978:984	arg1	investigation					871:883	biochemical investigation	859:883	biochemical investigation	859:883	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	34	from	novalis	978:984	arg1	structure					897:905	crystal structure	889:905	crystal structure	889:905	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	34	from	novalis	978:984	arg1	α-1,2-mannosidase					943:959	the full-length five-domain GH92 α-1,2-mannosidase	910:959	the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	910:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	1	35	theme	Many	110:113	arg1	proteins					135:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	7	36	theme	sequential	1391:1400	arg1	deletion					1402:1409	their sequential deletion	1385:1409	their sequential deletion	1385:1409	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	0	37	theme	functional	15:24	arg1	characterization					26:41	Structural and functional characterization	0:41	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.	0:108	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	1	38	theme	eukaryotic	124:133	arg1	proteins					135:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	3	39	theme	carbohydrate-binding	699:718	arg1	CBMs					729:732	CBMs	729:732	CBMs	729:732	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	3	39	theme	carbohydrate-binding	699:718	arg1	modules					720:726	putative carbohydrate-binding modules	690:726	putative carbohydrate-binding modules (CBMs)	690:733	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	2	40	theme	mannose	448:454	arg1	residues					456:463	terminal mannose residues	439:463	terminal mannose residues	439:463	α-Mannosidases from CAZy family GH92 release terminal mannose residues from these N-glycans, providing access for the α-endomannanases, which then degrade the α-mannan backbone.
37071393	7	41	theme	binding	1580:1586	arg1	affinity					1588:1595	the binding affinity	1576:1595	the binding affinity to the yeast α-mannan substrate	1576:1627	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	0	42	theme	multi-domain	48:59	arg1	α-1,2-mannosidase					66:82	a multi-domain GH92 α-1,2-mannosidase	46:82	a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis	46:107	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	1	43	theme	α-1,2-	336:341	arg1	number					326:331	a number	324:331	a number of α-1,2- and α-1,3-mannose substituents of varying lengths	324:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	7	44	theme	NnGH92	1350:1355	arg1	domains					1357:1363	other NnGH92 domains	1344:1363	other NnGH92 domains	1344:1363	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	7	45	theme	little	1559:1564	arg1	impact					1566:1571	little impact	1559:1571	little impact	1559:1571	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	5	46	theme	additional	1047:1056	arg1	mannoimidazole					1058:1071	an additional mannoimidazole	1044:1071	an additional mannoimidazole bound to the N-terminal CBM32	1044:1101	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	47	dep	investigation	871:883	arg1	the					855:857	the	855:857	the	855:857	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	8	48	theme	multi-domain	1716:1727	arg1	α-mannosidases					1744:1757	other multi-domain bacterial GH92 α-mannosidases	1710:1757	other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans	1710:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	1	49	theme	yeast	255:259	arg1	proteins					271:278	yeast cell-wall proteins	255:278	yeast cell-wall proteins	255:278	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	3	50	contain	have	661:664	arg1	few					657:659	few	657:659	few	657:659	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	3	50	contain	have	661:664	arg2	modules					720:726	putative carbohydrate-binding modules	690:726	putative carbohydrate-binding modules (CBMs)	690:733	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	3	50	contain	have	661:664	arg2	domains					672:678	extra domains	666:678	extra domains including putative carbohydrate-binding modules (CBMs)	666:733	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	8	51	theme	GH92	1739:1742	arg1	α-mannosidases					1744:1757	other multi-domain bacterial GH92 α-mannosidases	1710:1757	other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans	1710:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	1	52	theme	proteins	271:278	arg1	case					247:250	the specific case	234:250	the specific case of yeast cell-wall proteins	234:278	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	6	53	theme	domain	1148:1153	arg1	similar					1163:1169	similar	1163:1169	similar	1163:1169	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	6	53	theme	domain	1148:1153	arg1	structure					1121:1129	The structure	1117:1129	The structure of the catalytic domain	1117:1153	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	3	54	theme	GH92	591:594	arg1	α-mannosidases					596:609	Most characterized GH92 α-mannosidases	572:609	Most characterized GH92 α-mannosidases	572:609	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	7	55	theme	enzyme	1531:1536	arg1	integrity					1514:1522	the overall structural integrity	1491:1522	the overall structural integrity of the enzyme	1491:1536	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	1	56	theme	high-mannose	199:210	arg1	core					221:224	a high-mannose N-glycan core	197:224	a high-mannose N-glycan core	197:224	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	7	57	theme	overall	1495:1501	arg1	integrity					1514:1522	the overall structural integrity	1491:1522	the overall structural integrity of the enzyme	1491:1536	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	8	58	theme	yeast	1782:1786	arg1	α-mannan					1788:1795	yeast α-mannan	1782:1795	yeast α-mannan	1782:1795	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	5	59	theme	full-length	914:924	arg1	α-1,2-mannosidase					943:959	the full-length five-domain GH92 α-1,2-mannosidase	910:959	the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	910:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	6	60	theme	α-mannosidase	1201:1213	arg1	Bt3990					1215:1220	the GH92 α-mannosidase Bt3990	1192:1220	the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron	1192:1254	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	0	61	from	novalis	101:107	arg1	α-1,2-mannosidase					66:82	a multi-domain GH92 α-1,2-mannosidase	46:82	a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis	46:107	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	0	61	from	novalis	101:107	arg1	characterization					26:41	Structural and functional characterization	0:41	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.	0:108	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	8	62	theme	glycans	1813:1819	arg1	degradation					1767:1777	the degradation	1763:1777	the degradation of yeast α-mannan or mannose-rich glycans	1763:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	5	63	theme	crystal	889:895	arg1	structure					897:905	crystal structure	889:905	crystal structure	889:905	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	7	64	theme	catalytic	1458:1466	arg1	domain					1468:1473	the catalytic domain	1454:1473	the catalytic domain	1454:1473	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	3	65	theme	catalytic	631:639	arg1	domain					641:646	a single catalytic domain	622:646	a single catalytic domain	622:646	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	5	66	from	structure	897:905	arg1	NnGH92					987:992	NnGH92	987:992	NnGH92	987:992	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	5	66	from	structure	897:905	arg1	novalis					978:984	Neobacillus novalis	966:984	Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	966:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	1	67	from	case	247:250	arg1	N-glycosylated					148:161	N-glycosylated	148:161	N-glycosylated	148:161	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	6	68	theme	substrate-binding	1266:1282	arg1	site					1284:1287	the substrate-binding site	1262:1287	the substrate-binding site	1262:1287	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	5	69	theme	GH92	938:941	arg1	α-1,2-mannosidase					943:959	the full-length five-domain GH92 α-1,2-mannosidase	910:959	the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site	910:1038	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	0	70	from	characterization	26:41	arg1	novalis					101:107	Neobacillus novalis	89:107	Neobacillus novalis	89:107	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	1	71	theme	substituents	361:372	arg1	number					326:331	a number	324:331	a number of α-1,2- and α-1,3-mannose substituents of varying lengths	324:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	7	72	contain	have	1554:1557	arg2	impact					1566:1571	little impact	1559:1571	little impact	1559:1571	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	7	72	contain	have	1554:1557	arg1	they					1539:1542	they	1539:1542	they	1539:1542	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	1	73	theme	varying	377:383	arg1	lengths					385:391	varying lengths	377:391	varying lengths	377:391	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	7	74	theme	yeast	1604:1608	arg1	substrate					1619:1627	the yeast α-mannan substrate	1600:1627	the yeast α-mannan substrate	1600:1627	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	4	75	theme	multi-domain	789:800	arg1	CBM					821:823	a multi-domain GH92 α-mannosidase CBM	787:823	a multi-domain GH92 α-mannosidase CBM	787:823	To date, neither the function nor the structure of a multi-domain GH92 α-mannosidase CBM has been characterized.
37071393	1	76	with	N-glycosylated	148:161	arg1	oligosaccharides					168:183	oligosaccharides	168:183	oligosaccharides composed of a high-mannose N-glycan core	168:224	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	6	77	theme	catalytic	1138:1146	arg1	domain					1148:1153	the catalytic domain	1134:1153	the catalytic domain	1134:1153	The structure of the catalytic domain is very similar to that reported for the GH92 α-mannosidase Bt3990 from Bacteroides thetaiotaomicron, with the substrate-binding site being highly conserved.
37071393	4	78	theme	α-mannosidase	807:819	arg1	CBM					821:823	a multi-domain GH92 α-mannosidase CBM	787:823	a multi-domain GH92 α-mannosidase CBM	787:823	To date, neither the function nor the structure of a multi-domain GH92 α-mannosidase CBM has been characterized.
37071393	2	79	theme	CAZy	414:417	arg1	GH92					426:429	CAZy family GH92	414:429	CAZy family GH92	414:429	α-Mannosidases from CAZy family GH92 release terminal mannose residues from these N-glycans, providing access for the α-endomannanases, which then degrade the α-mannan backbone.
37071393	1	80	theme	secreted	115:122	arg1	proteins					135:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins	110:142	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
37071393	3	81	theme	putative	690:697	arg1	CBMs					729:732	CBMs	729:732	CBMs	729:732	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	3	81	theme	putative	690:697	arg1	modules					720:726	putative carbohydrate-binding modules	690:726	putative carbohydrate-binding modules (CBMs)	690:733	Most characterized GH92 α-mannosidases consist of a single catalytic domain, while a few have extra domains including putative carbohydrate-binding modules (CBMs).
37071393	7	82	theme	domains	1357:1363	arg1	function					1317:1324	The function	1313:1324	The function of the CBM32s and other NnGH92 domains	1313:1363	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	8	83	theme	new	1636:1638	arg1	findings					1640:1647	These new findings	1630:1647	These new findings	1630:1647	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	2	84	theme	terminal	439:446	arg1	residues					456:463	terminal mannose residues	439:463	terminal mannose residues	439:463	α-Mannosidases from CAZy family GH92 release terminal mannose residues from these N-glycans, providing access for the α-endomannanases, which then degrade the α-mannan backbone.
37071393	0	85	theme	GH92	61:64	arg1	α-1,2-mannosidase					66:82	a multi-domain GH92 α-1,2-mannosidase	46:82	a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis	46:107	Structural and functional characterization of a multi-domain GH92 α-1,2-mannosidase from Neobacillus novalis.
37071393	5	86	theme	N-terminal	1086:1095	arg1	CBM32					1097:1101	the N-terminal CBM32	1082:1101	the N-terminal CBM32	1082:1101	Here, the biochemical investigation and crystal structure of the full-length five-domain GH92 α-1,2-mannosidase from Neobacillus novalis (NnGH92) with mannoimidazole bound in the active site and an additional mannoimidazole bound to the N-terminal CBM32 are reported.
37071393	7	87	theme	other	1344:1348	arg1	domains					1357:1363	other NnGH92 domains	1344:1363	other NnGH92 domains	1344:1363	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	8	88	theme	other	1710:1714	arg1	α-mannosidases					1744:1757	other multi-domain bacterial GH92 α-mannosidases	1710:1757	other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans	1710:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	2	89	from	GH92	426:429	arg1	α-Mannosidases					394:407	α-Mannosidases	394:407	α-Mannosidases from CAZy family GH92	394:429	α-Mannosidases from CAZy family GH92 release terminal mannose residues from these N-glycans, providing access for the α-endomannanases, which then degrade the α-mannan backbone.
37071393	7	90	theme	CBM32s	1333:1338	arg1	function					1317:1324	The function	1313:1324	The function of the CBM32s and other NnGH92 domains	1313:1363	The function of the CBM32s and other NnGH92 domains was investigated by their sequential deletion and suggested that whilst their binding to the catalytic domain was crucial for the overall structural integrity of the enzyme, they appear to have little impact on the binding affinity to the yeast α-mannan substrate.
37071393	8	91	theme	better	1659:1664	arg1	understanding					1666:1678	a better understanding	1657:1678	a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans	1657:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	8	92	theme	bacterial	1729:1737	arg1	α-mannosidases					1744:1757	other multi-domain bacterial GH92 α-mannosidases	1710:1757	other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans	1710:1819	These new findings provide a better understanding of how to select and optimize other multi-domain bacterial GH92 α-mannosidases for the degradation of yeast α-mannan or mannose-rich glycans.
37071393	1	93	theme	cell-wall	261:269	arg1	proteins					271:278	yeast cell-wall proteins	255:278	yeast cell-wall proteins	255:278	Many secreted eukaryotic proteins are N-glycosylated with oligosaccharides composed of a high-mannose N-glycan core and, in the specific case of yeast cell-wall proteins, an extended α-1,6-mannan backbone carrying a number of α-1,2- and α-1,3-mannose substituents of varying lengths.
36698045	9	0	theme	PNGase	1221:1226	arg1	strategies					1230:1239	PNGase F strategies	1221:1239	PNGase F strategies	1221:1239	Trypsin and Glu-C digestion coupled with PNGase F strategies were adopted, and effective LC-MS/MS methods were applied to analyze samples.
36698045	11	1	theme	released	1464:1471	arg1	glycan					1473:1478	released glycan	1464:1478	released glycan	1464:1478	Quantitative analysis of released glycan by LC-MS/MS was also performed, and 31 high-abundance N-glycans were identified.
36698045	6	2	theme	great	818:822	arg1	significance					824:835	great significance	818:835	great significance	818:835	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	2	3	theme	SARS-CoV-2	279:288	arg1	infection					290:298	SARS-CoV-2 infection	279:298	SARS-CoV-2 infection	279:298	Vaccination has proved to be an effective way of preventing SARS-CoV-2 infection and alleviating the hospitalization burden.
36698045	1	4	theme	pandemics	180:188	arg1	one					161:163	one	161:163	one	161:163	COVID-19 is caused by SARS-CoV-2 infection and remains one of the biggest pandemics around the world since 2019.
36698045	1	4	theme	pandemics	180:188	arg1	pandemics					180:188	the biggest pandemics	168:188	the biggest pandemics	168:188	COVID-19 is caused by SARS-CoV-2 infection and remains one of the biggest pandemics around the world since 2019.
36698045	6	5	theme	spike	790:794	arg1	N-glycosylation					796:810	spike N-glycosylation	790:810	spike N-glycosylation	790:810	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	2	6	theme	the hospitalization	316:334	arg1	burden					336:341	the hospitalization burden	316:341	the hospitalization burden	316:341	Vaccination has proved to be an effective way of preventing SARS-CoV-2 infection and alleviating the hospitalization burden.
36698045	5	7	theme	expression	704:713	arg1	systems					715:721	different expression systems	694:721	different expression systems	694:721	Besides, N-glycosylation might vary greatly on different expression systems and sequence variant designs.
36698045	9	8	theme	LC-MS/MS	1269:1276	arg1	methods					1278:1284	effective LC-MS/MS methods	1259:1284	effective LC-MS/MS methods	1259:1284	Trypsin and Glu-C digestion coupled with PNGase F strategies were adopted, and effective LC-MS/MS methods were applied to analyze samples.
36698045	1	9	theme	SARS-CoV-2	128:137	arg1	infection					139:147	SARS-CoV-2 infection	128:147	SARS-CoV-2 infection	128:147	COVID-19 is caused by SARS-CoV-2 infection and remains one of the biggest pandemics around the world since 2019.
36698045	4	10	contain	had	592:594	arg1	glycosylation					578:590	glycosylation	578:590	glycosylation	578:590	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	10	contain	had	592:594	arg2	impact					604:609	a great impact	596:609	a great impact	596:609	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	10	contain	had	592:594	arg2	protein					492:498	a surface protein	482:498	a surface protein on the virus envelop	482:519	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	10	contain	had	592:594	arg2	spike					526:530	the spike	522:530	the spike	522:530	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	12	11	theme	structure	1629:1637	arg1	confirmation					1639:1650	glycan structure confirmation	1622:1650	glycan structure confirmation	1622:1650	Sequencing analysis of glycan was further provided to assist glycan structure confirmation.
36698045	13	12	theme	batch-to-batch	1812:1825	arg1	consistency					1827:1837	good batch-to-batch consistency	1807:1837	good batch-to-batch consistency	1807:1837	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	7	13	theme	spike	1027:1031	arg1	protein					1033:1039	a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein	965:1039	a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein	965:1039	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	14	14	theme	protein	1959:1965	arg1	analysis					1967:1974	SARS-CoV-2 spike protein analysis	1942:1974	SARS-CoV-2 spike protein analysis	1942:1974	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	2	15	theme	effective	251:259	arg1	Vaccination					219:229	Vaccination	219:229	Vaccination	219:229	Vaccination has proved to be an effective way of preventing SARS-CoV-2 infection and alleviating the hospitalization burden.
36698045	2	15	theme	effective	251:259	arg1	way					261:263	an effective way	248:263	an effective way of preventing SARS-CoV-2 infection and alleviating the hospitalization burden	248:341	Vaccination has proved to be an effective way of preventing SARS-CoV-2 infection and alleviating the hospitalization burden.
36698045	7	16	theme	expressed	1000:1008	arg1	protein					1033:1039	a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein	965:1039	a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein	965:1039	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	14	17	theme	SARS-CoV-2	1942:1951	arg1	analysis					1967:1974	SARS-CoV-2 spike protein analysis	1942:1974	SARS-CoV-2 spike protein analysis	1942:1974	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	3	18	theme	different	350:358	arg1	forms					360:364	different forms	350:364	different forms of COVID-19 vaccine design	350:391	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	11	19	theme	high-abundance	1519:1532	arg1	N-glycans					1534:1542	31 high-abundance N-glycans	1516:1542	31 high-abundance N-glycans	1516:1542	Quantitative analysis of released glycan by LC-MS/MS was also performed, and 31 high-abundance N-glycans were identified.
36698045	0	20	theme	variant-design	68:81	arg1	protein					97:103	a COVID-19 variant-design vaccine spike protein	57:103	a COVID-19 variant-design vaccine spike protein	57:103	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	0	21	theme	spike	91:95	arg1	protein					97:103	a COVID-19 variant-design vaccine spike protein	57:103	a COVID-19 variant-design vaccine spike protein	57:103	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	8	22	theme	spike	1046:1050	arg1	protein					1052:1058	The spike protein	1042:1058	The spike protein	1042:1058	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	3	23	theme	vaccine	378:384	arg1	design					386:391	COVID-19 vaccine design	369:391	COVID-19 vaccine design	369:391	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	4	24	theme	virus	507:511	arg1	envelop					513:519	the virus envelop	503:519	the virus envelop	503:519	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	10	25	theme	N-glycopeptide	1417:1430	arg1	level					1432:1436	intact N-glycopeptide level	1410:1436	intact N-glycopeptide level	1410:1436	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	3	26	used	used	442:445	arg2	antigen					470:476	a candidate vaccine antigen	450:476	a candidate vaccine antigen	450:476	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	3	26	used	used	442:445	arg2	protein					404:410	the spike protein	394:410	the spike protein of SARS-CoV-2 virus	394:430	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	5	27	theme	variant	736:742	arg1	designs					744:750	sequence variant designs	727:750	sequence variant designs	727:750	Besides, N-glycosylation might vary greatly on different expression systems and sequence variant designs.
36698045	7	28	theme	Hamster	975:981	arg1	Ovary					983:987	Chinese Hamster Ovary	967:987	Chinese Hamster Ovary (CHO) cell	967:998	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	7	28	theme	Hamster	975:981	arg1	CHO					990:992	CHO	990:992	CHO	990:992	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	8	29	theme	latest	1073:1078	arg1	design					1105:1110	the latest six-proline substitution design	1069:1110	the latest six-proline substitution design together with the incorporation of a combination of mutation sites	1069:1177	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	4	30	gly	N-glycosylated	559:572	arg1	spike					526:530	the spike	522:530	the spike	522:530	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	30	gly	N-glycosylated	559:572	arg1	N-glycosylated					559:572	N-glycosylated	559:572	N-glycosylated	559:572	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	30	gly	N-glycosylated	559:572	arg1	protein					492:498	a surface protein	482:498	a surface protein on the virus envelop	482:519	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	30	gly	N-glycosylated	559:572	arg1	impact					604:609	a great impact	596:609	a great impact	596:609	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	3	31	theme	spike	398:402	arg1	protein					404:410	the spike protein	394:410	the spike protein of SARS-CoV-2 virus	394:430	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	3	31	theme	spike	398:402	arg1	antigen					470:476	a candidate vaccine antigen	450:476	a candidate vaccine antigen	450:476	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	4	32	theme	surface	484:490	arg1	spike					526:530	the spike	522:530	the spike	522:530	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	32	theme	surface	484:490	arg1	protein					492:498	a surface protein	482:498	a surface protein on the virus envelop	482:519	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	32	theme	surface	484:490	arg1	impact					604:609	a great impact	596:609	a great impact	596:609	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	13	33	theme	glycosylation	1748:1760	arg1	results					1762:1768	the glycosylation results	1744:1768	the glycosylation results on both glycosite and glycans	1744:1798	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	0	34	theme	In-depth	0:7	arg1	characterization					9:24	In-depth characterization	0:24	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.	0:104	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	8	35	theme	substitution	1092:1103	arg1	design					1105:1110	the latest six-proline substitution design	1069:1110	the latest six-proline substitution design together with the incorporation of a combination of mutation sites	1069:1177	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	14	36	theme	N-glycosylation	1883:1897	arg1	information					1899:1909	N-glycosylation information	1883:1909	N-glycosylation information	1883:1909	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	3	37	theme	virus	426:430	arg1	protein					404:410	the spike protein	394:410	the spike protein of SARS-CoV-2 virus	394:430	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	3	37	theme	virus	426:430	arg1	antigen					470:476	a candidate vaccine antigen	450:476	a candidate vaccine antigen	450:476	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	13	38	theme	manufactured	1719:1730	arg1	batches					1732:1738	three consecutive manufactured batches	1701:1738	three consecutive manufactured batches	1701:1738	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	3	39	theme	candidate	452:460	arg1	protein					404:410	the spike protein	394:410	the spike protein of SARS-CoV-2 virus	394:430	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	3	39	theme	candidate	452:460	arg1	antigen					470:476	a candidate vaccine antigen	450:476	a candidate vaccine antigen	450:476	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	0	40	theme	N-glycosylation	37:51	arg1	characterization					9:24	In-depth characterization	0:24	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.	0:104	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	6	41	theme	comprehensive	764:776	arg1	analysis					778:785	comprehensive analysis	764:785	comprehensive analysis of spike N-glycosylation	764:810	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	14	42	theme	reported	1850:1857	arg1	strategy					1870:1877	the reported analytical strategy	1846:1877	the reported analytical strategy	1846:1877	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	6	43	theme	vaccine	848:854	arg1	understanding					856:868	better vaccine understanding	841:868	better vaccine understanding	841:868	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	8	44	theme	sites	1173:1177	arg1	combination					1149:1159	a combination	1147:1159	a combination of mutation sites	1147:1177	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	10	45	theme	recombinant	1382:1392	arg1	protein					1399:1405	the recombinant pike protein	1378:1405	the recombinant pike protein	1378:1405	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	7	46	theme	full	906:909	arg1	characterization					911:926	full characterization	906:926	full characterization of N-glycosylation	906:945	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	6	47	theme	quality	874:880	arg1	control					882:888	quality control	874:888	quality control	874:888	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	9	48	theme	F	1228:1228	arg1	strategies					1230:1239	PNGase F strategies	1221:1239	PNGase F strategies	1221:1239	Trypsin and Glu-C digestion coupled with PNGase F strategies were adopted, and effective LC-MS/MS methods were applied to analyze samples.
36698045	14	49	from	studies	1931:1937	arg1	studies					1988:1994	quality studies	1980:1994	quality studies	1980:1994	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	14	49	from	studies	1931:1937	arg1	analysis					1967:1974	SARS-CoV-2 spike protein analysis	1942:1974	SARS-CoV-2 spike protein analysis	1942:1974	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	11	50	theme	Quantitative	1439:1450	arg1	analysis					1452:1459	Quantitative analysis	1439:1459	Quantitative analysis of released glycan by LC-MS/MS	1439:1490	Quantitative analysis of released glycan by LC-MS/MS was also performed, and 31 high-abundance N-glycans were identified.
36698045	4	51	from	protein	492:498	arg1	envelop					513:519	the virus envelop	503:519	the virus envelop	503:519	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	10	52	theme	intact	1410:1415	arg1	level					1432:1436	intact N-glycopeptide level	1410:1436	intact N-glycopeptide level	1410:1436	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	1	53	theme	biggest	172:178	arg1	pandemics					180:188	the biggest pandemics	168:188	the biggest pandemics	168:188	COVID-19 is caused by SARS-CoV-2 infection and remains one of the biggest pandemics around the world since 2019.
36698045	3	54	theme	SARS-CoV-2	415:424	arg1	virus					426:430	SARS-CoV-2 virus	415:430	SARS-CoV-2 virus	415:430	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	6	55	theme	N-glycosylation	796:810	arg1	analysis					778:785	comprehensive analysis	764:785	comprehensive analysis of spike N-glycosylation	764:810	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	5	56	theme	different	694:702	arg1	systems					715:721	different expression systems	694:721	different expression systems	694:721	Besides, N-glycosylation might vary greatly on different expression systems and sequence variant designs.
36698045	9	57	theme	effective	1259:1267	arg1	methods					1278:1284	effective LC-MS/MS methods	1259:1284	effective LC-MS/MS methods	1259:1284	Trypsin and Glu-C digestion coupled with PNGase F strategies were adopted, and effective LC-MS/MS methods were applied to analyze samples.
36698045	10	58	gly	19 N-glycosites	1343:1357	arg2	19 N-glycosites					1343:1357	19 N-glycosites	1343:1357	19 N-glycosites	1343:1357	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	14	59	theme	quality	1980:1986	arg1	studies					1988:1994	quality studies	1980:1994	quality studies	1980:1994	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	13	60	theme	good	1807:1810	arg1	consistency					1827:1837	good batch-to-batch consistency	1807:1837	good batch-to-batch consistency	1807:1837	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	14	61	theme	spike	1953:1957	arg1	analysis					1967:1974	SARS-CoV-2 spike protein analysis	1942:1974	SARS-CoV-2 spike protein analysis	1942:1974	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	0	62	theme	vaccine	83:89	arg1	protein					97:103	a COVID-19 variant-design vaccine spike protein	57:103	a COVID-19 variant-design vaccine spike protein	57:103	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	7	63	theme	variant-designed	1010:1025	arg1	protein					1033:1039	a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein	965:1039	a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein	965:1039	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	13	64	gly	glycosite	1778:1786	arg2	glycosite					1778:1786	glycosite	1778:1786	glycosite	1778:1786	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	12	65	theme	glycan	1622:1627	arg1	confirmation					1639:1650	glycan structure confirmation	1622:1650	glycan structure confirmation	1622:1650	Sequencing analysis of glycan was further provided to assist glycan structure confirmation.
36698045	12	66	theme	glycan	1584:1589	arg1	analysis					1572:1579	Sequencing analysis	1561:1579	Sequencing analysis of glycan	1561:1589	Sequencing analysis of glycan was further provided to assist glycan structure confirmation.
36698045	5	67	theme	sequence	727:734	arg1	designs					744:750	sequence variant designs	727:750	sequence variant designs	727:750	Besides, N-glycosylation might vary greatly on different expression systems and sequence variant designs.
36698045	3	68	theme	design	386:391	arg1	forms					360:364	different forms	350:364	different forms of COVID-19 vaccine design	350:391	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	8	69	theme	six-proline	1080:1090	arg1	design					1105:1110	the latest six-proline substitution design	1069:1110	the latest six-proline substitution design together with the incorporation of a combination of mutation sites	1069:1177	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	7	70	theme	Ovary	983:987	arg1	cell					995:998	Chinese Hamster Ovary (CHO) cell	967:998	Chinese Hamster Ovary (CHO) cell	967:998	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	3	71	theme	COVID-19	369:376	arg1	design					386:391	COVID-19 vaccine design	369:391	COVID-19 vaccine design	369:391	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	11	72	theme	glycan	1473:1478	arg1	analysis					1452:1459	Quantitative analysis	1439:1459	Quantitative analysis of released glycan by LC-MS/MS	1439:1490	Quantitative analysis of released glycan by LC-MS/MS was also performed, and 31 high-abundance N-glycans were identified.
36698045	7	73	theme	Chinese	967:973	arg1	Ovary					983:987	Chinese Hamster Ovary	967:987	Chinese Hamster Ovary (CHO) cell	967:998	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	7	73	theme	Chinese	967:973	arg1	CHO					990:992	CHO	990:992	CHO	990:992	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	10	74	theme	19 N-glycosites	1343:1357	arg1	result					1324:1329	a result	1322:1329	a result	1322:1329	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	10	74	theme	19 N-glycosites	1343:1357	arg1	total					1334:1338	a total	1332:1338	a total of 19 N-glycosites	1332:1357	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	0	75	theme	protein	29:35	arg1	N-glycosylation					37:51	protein N-glycosylation	29:51	protein N-glycosylation	29:51	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	13	76	from	results	1762:1768	arg1	glycans					1792:1798	glycans	1792:1798	glycans	1792:1798	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	13	76	from	results	1762:1768	arg1	glycosite					1778:1786	glycosite	1778:1786	glycosite	1778:1786	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	13	77	theme	consecutive	1707:1717	arg1	batches					1732:1738	three consecutive manufactured batches	1701:1738	three consecutive manufactured batches	1701:1738	Moreover, all of the analyses were performed on three consecutive manufactured batches and the glycosylation results on both glycosite and glycans showed good batch-to-batch consistency.
36698045	7	78	dep	expressed	1000:1008	arg1	cell					995:998	Chinese Hamster Ovary (CHO) cell	967:998	Chinese Hamster Ovary (CHO) cell	967:998	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	3	79	theme	vaccine	462:468	arg1	protein					404:410	the spike protein	394:410	the spike protein of SARS-CoV-2 virus	394:430	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	3	79	theme	vaccine	462:468	arg1	antigen					470:476	a candidate vaccine antigen	450:476	a candidate vaccine antigen	450:476	Among different forms of COVID-19 vaccine design, the spike protein of SARS-CoV-2 virus is widely used as a candidate vaccine antigen.
36698045	0	80	theme	COVID-19	59:66	arg1	protein					97:103	a COVID-19 variant-design vaccine spike protein	57:103	a COVID-19 variant-design vaccine spike protein	57:103	In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein.
36698045	14	81	theme	analytical	1859:1868	arg1	strategy					1870:1877	the reported analytical strategy	1846:1877	the reported analytical strategy	1846:1877	Thus, the reported analytical strategy and N-glycosylation information may well facilitate studies on SARS-CoV-2 spike protein analysis and quality studies.
36698045	8	82	theme	combination	1149:1159	arg1	the incorporation					1126:1142	the incorporation	1126:1142	the incorporation of a combination of mutation sites	1126:1177	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	12	83	theme	Sequencing	1561:1570	arg1	analysis					1572:1579	Sequencing analysis	1561:1579	Sequencing analysis of glycan	1561:1589	Sequencing analysis of glycan was further provided to assist glycan structure confirmation.
36698045	10	84	gly	N-glycopeptide	1417:1430	arg2	N-glycopeptide					1417:1430	intact N-glycopeptide level	1410:1436	intact N-glycopeptide level	1410:1436	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
36698045	9	85	theme	Trypsin	1180:1186	arg1	digestion					1198:1206	Trypsin and Glu-C digestion	1180:1206	Trypsin and Glu-C digestion coupled with PNGase F strategies	1180:1239	Trypsin and Glu-C digestion coupled with PNGase F strategies were adopted, and effective LC-MS/MS methods were applied to analyze samples.
36698045	7	86	theme	N-glycosylation	931:945	arg1	characterization					911:926	full characterization	906:926	full characterization of N-glycosylation	906:945	In this study, full characterization of N-glycosylation was performed for a Chinese Hamster Ovary (CHO) cell expressed variant-designed spike protein.
36698045	8	87	theme	mutation	1164:1171	arg1	sites					1173:1177	mutation sites	1164:1177	mutation sites	1164:1177	The spike protein featured the latest six-proline substitution design together with the incorporation of a combination of mutation sites.
36698045	4	88	theme	great	598:602	arg1	spike					526:530	the spike	522:530	the spike	522:530	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	88	theme	great	598:602	arg1	protein					492:498	a surface protein	482:498	a surface protein on the virus envelop	482:519	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	4	88	theme	great	598:602	arg1	impact					604:609	a great impact	596:609	a great impact	596:609	As a surface protein on the virus envelop, the spike was reported to be heavily N-glycosylated and glycosylation had a great impact on its immunogenicity and efficacy.
36698045	9	89	theme	Glu-C	1192:1196	arg1	digestion					1198:1206	Trypsin and Glu-C digestion	1180:1206	Trypsin and Glu-C digestion coupled with PNGase F strategies	1180:1239	Trypsin and Glu-C digestion coupled with PNGase F strategies were adopted, and effective LC-MS/MS methods were applied to analyze samples.
36698045	6	90	theme	better	841:846	arg1	understanding					856:868	better vaccine understanding	841:868	better vaccine understanding	841:868	Therefore, comprehensive analysis of spike N-glycosylation is of great significance for better vaccine understanding and quality control.
36698045	10	91	theme	pike	1394:1397	arg1	protein					1399:1405	the recombinant pike protein	1378:1405	the recombinant pike protein	1378:1405	As a result, a total of 19 N-glycosites were identified in the recombinant pike protein at intact N-glycopeptide level.
37037133	0	0	theme	proteome	101:108	arg1	profiling					62:70	site-specific N-glycosylation profiling	32:70	site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk	32:154	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	4	1	theme	donkey	693:698	arg1	colostrum					700:708	donkey colostrum	693:708	donkey colostrum (DC)	693:713	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	1	theme	donkey	693:698	arg1	DC					711:712	DC	711:712	DC	711:712	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	6	2	theme	physiological	1247:1259	arg1	roles					1261:1265	their potential physiological roles	1231:1265	their potential physiological roles	1231:1265	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	1	3	theme	fat	162:164	arg1	proteins					190:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	2	4	from	information	294:304	arg1	N-glycosylation					323:337	site-specific N-glycosylation	309:337	site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk	309:384	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	1	5	theme	biological	247:256	arg1	processes					258:266	various biological processes	239:266	various biological processes within the body	239:282	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	0	6	theme	membrane	92:99	arg1	proteome					101:108	milk fat globule membrane proteome	75:108	milk fat globule membrane proteome	75:108	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	6	7	gly	glycoproteins	1107:1119	arg1	glycoproteins					1107:1119	donkey and human MFGM glycoproteins	1085:1119	donkey and human MFGM glycoproteins	1085:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	8	theme	potential	1237:1245	arg1	roles					1261:1265	their potential physiological roles	1231:1265	their potential physiological roles	1231:1265	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	4	9	from	colostrum	747:755	arg1	colostrum					700:708	donkey colostrum	693:708	donkey colostrum (DC)	693:713	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	9	from	colostrum	747:755	arg1	N-glycans					637:645	1,360, 457, 2,617, and 986 site-specific N-glycans	596:645	1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM)	596:788	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	9	from	colostrum	747:755	arg1	HM					786:787	HM	786:787	HM	786:787	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	9	from	colostrum	747:755	arg1	DC					711:712	DC	711:712	DC	711:712	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	1	10	theme	globule	166:172	arg1	proteins					190:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	2	11	from	N-glycosylation	323:337	arg1	donkey					364:369	donkey	364:369	donkey	364:369	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	2	11	from	N-glycosylation	323:337	arg1	milk					381:384	human milk	375:384	human milk	375:384	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	5	12	theme	MFGM	900:903	arg1	N-glycoproteins					905:919	HM MFGM N-glycoproteins	897:919	HM MFGM N-glycoproteins	897:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	6	13	theme	composition	1174:1184	arg1	understanding					1153:1165	our understanding	1149:1165	our understanding of the composition of donkey and human MFGM N-glycoproteins	1149:1225	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	13	theme	composition	1174:1184	arg1	roles					1261:1265	their potential physiological roles	1231:1265	their potential physiological roles	1231:1265	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	14	theme	donkey	1085:1090	arg1	glycoproteins					1107:1119	donkey and human MFGM glycoproteins	1085:1119	donkey and human MFGM glycoproteins	1085:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	15	theme	MFGM	1102:1105	arg1	glycoproteins					1107:1119	donkey and human MFGM glycoproteins	1085:1119	donkey and human MFGM glycoproteins	1085:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	16	theme	human	1096:1100	arg1	MFGM					1102:1105	human MFGM	1096:1105	human MFGM	1096:1105	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	4	17	gly	N-glycoproteins	674:688	arg1	DM					736:737	DM	736:737	DM	736:737	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	17	gly	N-glycoproteins	674:688	arg1	N-glycoproteins					674:688	296, 77, 214, and 196 N-glycoproteins	652:688	296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC)	652:713	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	5	18	theme	DC	881:882	arg1	relationships					864:876	the structure-activity relationships	841:876	the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins	841:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	4	19	from	N-glycoproteins	674:688	arg1	colostrum					700:708	donkey colostrum	693:708	donkey colostrum (DC)	693:713	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	19	from	N-glycoproteins	674:688	arg1	N-glycans					637:645	1,360, 457, 2,617, and 986 site-specific N-glycans	596:645	1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM)	596:788	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	19	from	N-glycoproteins	674:688	arg1	HM					786:787	HM	786:787	HM	786:787	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	19	from	N-glycoproteins	674:688	arg1	DC					711:712	DC	711:712	DC	711:712	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	3	20	theme	human	509:513	arg1	glycoproteins					520:532	donkey and human MFGM glycoproteins	498:532	donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	498:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	0	21	theme	human	124:128	arg1	colostrum					130:138	human colostrum	124:138	human colostrum	124:138	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	5	22	theme	structure-activity	845:862	arg1	relationships					864:876	the structure-activity relationships	841:876	the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins	841:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	6	23	gly	N-glycosylation	1066:1080	arg1	glycoproteins					1107:1119	donkey and human MFGM glycoproteins	1085:1119	donkey and human MFGM glycoproteins	1085:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	24	theme	N-glycoproteins	1009:1023	arg1	composition					972:982	the molecular composition	958:982	the molecular composition of donkey and human MFGM N-glycoproteins	958:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	5	25	theme	HM	897:898	arg1	N-glycoproteins					905:919	HM MFGM N-glycoproteins	897:919	HM MFGM N-glycoproteins	897:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	6	26	theme	human	998:1002	arg1	N-glycoproteins					1009:1023	human MFGM N-glycoproteins	998:1023	human MFGM N-glycoproteins	998:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	1	27	theme	membrane	174:181	arg1	proteins					190:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	0	28	from	profiling	62:70	arg1	donkey					113:118	donkey	113:118	donkey	113:118	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	0	28	from	profiling	62:70	arg1	colostrum					130:138	human colostrum	124:138	human colostrum	124:138	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	6	29	theme	MFGM	1206:1209	arg1	N-glycoproteins					1211:1225	human MFGM N-glycoproteins	1200:1225	human MFGM N-glycoproteins	1200:1225	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	30	from	differences	943:953	arg1	composition					972:982	the molecular composition	958:982	the molecular composition of donkey and human MFGM N-glycoproteins	958:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	4	31	theme	site-specific	623:635	arg1	N-glycans					637:645	1,360, 457, 2,617, and 986 site-specific N-glycans	596:645	1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM)	596:788	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	31	theme	site-specific	623:635	arg1	HM					786:787	HM	786:787	HM	786:787	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	3	32	theme	site-specific	450:462	arg1	fingerprinting					480:493	the most comprehensive site-specific N-glycosylation fingerprinting	427:493	the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	427:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	5	33	gly	N-glycoproteins	905:919	arg1	N-glycoproteins					905:919	HM MFGM N-glycoproteins	897:919	HM MFGM N-glycoproteins	897:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	3	34	theme	glycoproteomics	556:570	arg1	strategy					572:579	a site-specific glycoproteomics strategy	540:579	a site-specific glycoproteomics strategy	540:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	1	35	gly	glycosylated	210:221	arg1	proteins					190:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	3	36	gly	glycoproteins	520:532	arg1	glycoproteins					520:532	donkey and human MFGM glycoproteins	498:532	donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	498:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	1	37	theme	MFGM	184:187	arg1	proteins					190:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	6	38	theme	N-glycoproteins	1211:1225	arg1	composition					1174:1184	the composition	1170:1184	the composition of donkey and human MFGM N-glycoproteins	1170:1225	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	4	39	from	milk	730:733	arg1	colostrum					700:708	donkey colostrum	693:708	donkey colostrum (DC)	693:713	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	39	from	milk	730:733	arg1	N-glycans					637:645	1,360, 457, 2,617, and 986 site-specific N-glycans	596:645	1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM)	596:788	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	39	from	milk	730:733	arg1	HM					786:787	HM	786:787	HM	786:787	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	39	from	milk	730:733	arg1	DC					711:712	DC	711:712	DC	711:712	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	2	40	theme	site-specific	309:321	arg1	N-glycosylation					323:337	site-specific N-glycosylation	309:337	site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk	309:384	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	6	41	gly	N-glycoproteins	1211:1225	arg1	N-glycoproteins					1211:1225	human MFGM N-glycoproteins	1200:1225	human MFGM N-glycoproteins	1200:1225	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	0	42	theme	site-specific	32:44	arg1	profiling					62:70	site-specific N-glycosylation profiling	32:70	site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk	32:154	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	5	43	used	used	824:827	arg2	Bioinformatics					805:818	Bioinformatics	805:818	Bioinformatics	805:818	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	6	44	theme	donkey	1189:1194	arg1	composition					1174:1184	the composition	1170:1184	the composition of donkey and human MFGM N-glycoproteins	1170:1225	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	45	theme	donkey	987:992	arg1	composition					972:982	the molecular composition	958:982	the molecular composition of donkey and human MFGM N-glycoproteins	958:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	4	46	theme	mature	723:728	arg1	milk					730:733	donkey mature milk	716:733	donkey mature milk	716:733	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	5	47	theme	DM	885:886	arg1	relationships					864:876	the structure-activity relationships	841:876	the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins	841:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	5	48	theme	HC	889:890	arg1	relationships					864:876	the structure-activity relationships	841:876	the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins	841:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	3	49	theme	donkey	498:503	arg1	glycoproteins					520:532	donkey and human MFGM glycoproteins	498:532	donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	498:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	3	50	theme	glycoproteins	520:532	arg1	fingerprinting					480:493	the most comprehensive site-specific N-glycosylation fingerprinting	427:493	the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	427:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	4	51	theme	human	767:771	arg1	milk					780:783	human mature milk	767:783	human mature milk	767:783	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	3	52	theme	N-glycosylation	464:478	arg1	fingerprinting					480:493	the most comprehensive site-specific N-glycosylation fingerprinting	427:493	the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	427:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	0	53	theme	N-glycosylation	46:60	arg1	profiling					62:70	site-specific N-glycosylation profiling	32:70	site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk	32:154	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	0	54	theme	mature	144:149	arg1	milk					151:154	mature milk	144:154	mature milk	144:154	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	4	55	from	milk	780:783	arg1	colostrum					700:708	donkey colostrum	693:708	donkey colostrum (DC)	693:713	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	55	from	milk	780:783	arg1	N-glycans					637:645	1,360, 457, 2,617, and 986 site-specific N-glycans	596:645	1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM)	596:788	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	55	from	milk	780:783	arg1	HM					786:787	HM	786:787	HM	786:787	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	55	from	milk	780:783	arg1	DC					711:712	DC	711:712	DC	711:712	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	6	56	theme	molecular	962:970	arg1	composition					972:982	the molecular composition	958:982	the molecular composition of donkey and human MFGM N-glycoproteins	958:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	0	57	theme	milk	75:78	arg1	fat					80:82	milk fat	75:82	milk fat globule membrane proteome	75:108	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	2	58	gly	glycoproteins	347:359	arg1	glycoproteins					347:359	MFGM glycoproteins	342:359	MFGM glycoproteins	342:359	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	0	59	theme	fat	80:82	arg1	proteome					101:108	milk fat globule membrane proteome	75:108	milk fat globule membrane proteome	75:108	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	0	60	dep	profiling	62:70	arg1	comparison					21:30	comparison	21:30	comparison	21:30	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	0	60	dep	profiling	62:70	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	6	61	theme	site-specific	1052:1064	arg1	N-glycosylation					1066:1080	site-specific N-glycosylation	1052:1080	site-specific N-glycosylation of donkey and human MFGM glycoproteins	1052:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	3	62	theme	MFGM	515:518	arg1	glycoproteins					520:532	donkey and human MFGM glycoproteins	498:532	donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	498:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	6	63	gly	N-glycoproteins	1009:1023	arg1	N-glycoproteins					1009:1023	human MFGM N-glycoproteins	998:1023	human MFGM N-glycoproteins	998:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	4	64	theme	mature	773:778	arg1	milk					780:783	human mature milk	767:783	human mature milk	767:783	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	2	65	theme	glycoproteins	347:359	arg1	N-glycosylation					323:337	site-specific N-glycosylation	309:337	site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk	309:384	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	3	66	theme	comprehensive	436:448	arg1	fingerprinting					480:493	the most comprehensive site-specific N-glycosylation fingerprinting	427:493	the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy	427:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	5	67	theme	N-glycoproteins	905:919	arg1	relationships					864:876	the structure-activity relationships	841:876	the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins	841:919	Bioinformatics was used to describe the structure-activity relationships of DC, DM, HC, and HM MFGM N-glycoproteins.
37037133	6	68	theme	human	1200:1204	arg1	N-glycoproteins					1211:1225	human MFGM N-glycoproteins	1200:1225	human MFGM N-glycoproteins	1200:1225	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	2	69	theme	MFGM	342:345	arg1	glycoproteins					347:359	MFGM glycoproteins	342:359	MFGM glycoproteins	342:359	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	4	70	theme	human	741:745	arg1	HC					758:759	HC	758:759	HC	758:759	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	4	70	theme	human	741:745	arg1	colostrum					747:755	human colostrum	741:755	human colostrum (HC)	741:760	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	2	71	theme	human	375:379	arg1	milk					381:384	human milk	375:384	human milk	375:384	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	4	72	theme	donkey	716:721	arg1	milk					730:733	donkey mature milk	716:733	donkey mature milk	716:733	We identified 1,360, 457, 2,617, and 986 site-specific N-glycans from 296, 77, 214, and 196 N-glycoproteins in donkey colostrum (DC), donkey mature milk (DM), human colostrum (HC), and human mature milk (HM), respectively.
37037133	0	73	theme	globule	84:90	arg1	proteome					101:108	milk fat globule membrane proteome	75:108	milk fat globule membrane proteome	75:108	Characterization and comparison site-specific N-glycosylation profiling of milk fat globule membrane proteome in donkey and human colostrum and mature milk.
37037133	6	74	theme	dynamic	1033:1039	arg1	changes					1041:1047	the dynamic changes	1029:1047	the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins	1029:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	6	75	theme	glycoproteins	1107:1119	arg1	N-glycosylation					1066:1080	site-specific N-glycosylation	1052:1080	site-specific N-glycosylation of donkey and human MFGM glycoproteins	1052:1119	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	3	76	theme	site-specific	542:554	arg1	strategy					572:579	a site-specific glycoproteomics strategy	540:579	a site-specific glycoproteomics strategy	540:579	This study aimed to map the most comprehensive site-specific N-glycosylation fingerprinting of donkey and human MFGM glycoproteins using a site-specific glycoproteomics strategy.
37037133	6	77	theme	MFGM	1004:1007	arg1	N-glycoproteins					1009:1023	human MFGM N-glycoproteins	998:1023	human MFGM N-glycoproteins	998:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	2	78	gly	N-glycosylation	323:337	arg1	glycoproteins					347:359	MFGM glycoproteins	342:359	MFGM glycoproteins	342:359	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	2	78	gly	N-glycosylation	323:337	arg1	donkey					364:369	donkey	364:369	donkey	364:369	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	2	78	gly	N-glycosylation	323:337	arg1	milk					381:384	human milk	375:384	human milk	375:384	However, information on site-specific N-glycosylation of MFGM glycoproteins in donkey and human milk remains limited.
37037133	6	79	from	changes	1041:1047	arg1	composition					972:982	the molecular composition	958:982	the molecular composition of donkey and human MFGM N-glycoproteins	958:1023	The results revealed differences in the molecular composition of donkey and human MFGM N-glycoproteins and the dynamic changes to site-specific N-glycosylation of donkey and human MFGM glycoproteins during lactation, deepening our understanding of the composition of donkey and human MFGM N-glycoproteins and their potential physiological roles.
37037133	1	80	theme	Milk	157:160	arg1	proteins					190:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins	157:197	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
37037133	1	81	theme	various	239:245	arg1	processes					258:266	various biological processes	239:266	various biological processes within the body	239:282	Milk fat globule membrane (MFGM) proteins are highly glycosylated and involved in various biological processes within the body.
35307819	8	0	with	composition	1363:1373	arg1	capacity					1380:1387	capacity	1380:1387	capacity to stratify patients at diagnosis	1380:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	2	1	theme	urgent	341:346	arg1	need					348:351	an urgent need	338:351	an urgent need in the field for predictive biomarkers of COVID-19	338:402	Given the unpredictability for developing a severe/complicated disease, there is an urgent need in the field for predictive biomarkers of COVID-19.
35307819	4	2	theme	Fc	551:552	arg1	glyco-variations					554:569	IgG Fc glyco-variations	547:569	IgG Fc glyco-variations	547:569	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	7	3	theme	pro-inflammatory	1186:1201	arg1	immunoglobulins					1203:1217	pro-inflammatory immunoglobulins	1186:1217	pro-inflammatory immunoglobulins	1186:1217	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	7	4	theme	immune	1230:1235	arg1	activation					1237:1246	higher immune activation	1223:1246	higher immune activation	1223:1246	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	4	5	theme	IgG	547:549	arg1	glyco-variations					554:569	IgG Fc glyco-variations	547:569	IgG Fc glyco-variations	547:569	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	5	6	from	variations	765:774	arg1	composition					791:801	the glycans composition	779:801	the glycans composition of circulating IgGs	779:821	We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs.
35307819	7	7	theme	NK	1080:1081	arg1	cells					1083:1087	NK cells	1080:1087	NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course	1080:1285	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	8	8	theme	novel	1317:1321	arg1	biomarker					1329:1337	a novel blood biomarker	1315:1337	a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis	1315:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	8	9	theme	IgG	1348:1350	arg1	composition					1363:1373	IgG Fc glycome composition	1348:1373	IgG Fc glycome composition with capacity to stratify patients at diagnosis	1348:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	7	10	theme	cells	1083:1087	arg1	activation					1089:1098	NK cells activation	1080:1098	NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course	1080:1285	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	7	11	theme	higher	1223:1228	arg1	activation					1237:1246	higher immune activation	1223:1246	higher immune activation	1223:1246	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	4	12	theme	glyco-variations	554:569	arg1	impact					537:542	the impact	533:542	the impact of IgG Fc glyco-variations	533:569	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	5	13	theme	SARS-CoV-2+	718:728	arg1	individuals					730:740	SARS-CoV-2+ individuals	718:740	SARS-CoV-2+ individuals	718:740	We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs.
35307819	4	14	theme	cells	594:598	arg1	activation					600:609	NK cells activation	591:609	NK cells activation	591:609	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	2	15	theme	predictive	370:379	arg1	biomarkers					381:390	predictive biomarkers	370:390	predictive biomarkers of COVID-19	370:402	Given the unpredictability for developing a severe/complicated disease, there is an urgent need in the field for predictive biomarkers of COVID-19.
35307819	0	16	from	diagnosis	38:46	arg1	glycosylation					12:24	Altered IgG glycosylation	0:24	Altered IgG glycosylation at COVID-19 diagnosis	0:46	Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
35307819	5	17	theme	glycans	783:789	arg1	composition					791:801	the glycans composition	779:801	the glycans composition of circulating IgGs	779:821	We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs.
35307819	6	18	from	levels	837:842	arg1	IgGs					887:890	IgGs	887:890	IgGs	887:890	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	3	19	theme	IgG	422:424	arg1	traits					438:443	IgG Fc N-glycan traits	422:443	IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients	422:483	We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS.
35307819	0	20	theme	IgG	8:10	arg1	glycosylation					12:24	Altered IgG glycosylation	0:24	Altered IgG glycosylation at COVID-19 diagnosis	0:46	Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
35307819	6	21	theme	sialic	861:866	arg1	acid					868:871	sialic acid	861:871	sialic acid	861:871	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	7	22	theme	disease	1272:1278	arg1	course					1280:1285	a poor disease course	1265:1285	a poor disease course	1265:1285	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	2	23	theme	severe/complicated	301:318	arg1	disease					320:326	a severe/complicated disease	299:326	a severe/complicated disease	299:326	Given the unpredictability for developing a severe/complicated disease, there is an urgent need in the field for predictive biomarkers of COVID-19.
35307819	7	24	theme	TNF-α	1147:1151	arg1	release					1126:1132	increased release	1116:1132	increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins	1116:1217	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	7	24	theme	TNF-α	1147:1151	arg1	activation					1237:1246	higher immune activation	1223:1246	higher immune activation	1223:1246	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	0	25	theme	Altered	0:6	arg1	glycosylation					12:24	Altered IgG glycosylation	0:24	Altered IgG glycosylation at COVID-19 diagnosis	0:46	Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
35307819	6	26	theme	disease	947:953	arg1	development					916:926	the development	912:926	the development of a poor COVID-19 disease	912:953	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	8	27	from	diagnosis	1413:1421	arg1	patients					1401:1408	patients	1401:1408	patients at diagnosis	1401:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	6	28	theme	galactose	847:855	arg1	levels					837:842	levels	837:842	levels of galactose and sialic acid structures on IgGs	837:890	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	7	29	theme	IFN-γ	1137:1141	arg1	release					1126:1132	increased release	1116:1132	increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins	1116:1217	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	7	29	theme	IFN-γ	1137:1141	arg1	activation					1237:1246	higher immune activation	1223:1246	higher immune activation	1223:1246	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	6	30	theme	COVID-19	938:945	arg1	disease					947:953	a poor COVID-19 disease	931:953	a poor COVID-19 disease	931:953	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	2	31	from	need	348:351	arg1	field					360:364	the field	356:364	the field	356:364	Given the unpredictability for developing a severe/complicated disease, there is an urgent need in the field for predictive biomarkers of COVID-19.
35307819	1	32	theme	immune	93:98	arg1	responses					100:108	the immune responses	89:108	the immune responses associated with COVID-19 pathogenesis and disease severity	89:167	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	4	33	theme	activation	600:609	arg1	induction					578:586	the induction	574:586	the induction of NK cells activation	574:609	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	5	34	theme	circulating	806:816	arg1	IgGs					818:821	circulating IgGs	806:821	circulating IgGs	806:821	We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs.
35307819	6	35	theme	poor	933:936	arg1	disease					947:953	a poor COVID-19 disease	931:953	a poor COVID-19 disease	931:953	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	8	36	theme	glycome	1355:1361	arg1	composition					1363:1373	IgG Fc glycome composition	1348:1373	IgG Fc glycome composition with capacity to stratify patients at diagnosis	1348:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	1	37	theme	responses	100:108	arg1	nature					79:84	The nature	75:84	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity	75:167	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	37	theme	responses	100:108	arg1	breadth					185:191	the breadth	181:191	the breadth of vaccine coverage and duration of immunity	181:236	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	37	theme	responses	100:108	arg1	unclear					248:254	unclear	248:254	unclear	248:254	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	2	38	theme	COVID-19	395:402	arg1	biomarkers					381:390	predictive biomarkers	370:390	predictive biomarkers of COVID-19	370:402	Given the unpredictability for developing a severe/complicated disease, there is an urgent need in the field for predictive biomarkers of COVID-19.
35307819	8	39	theme	blood	1323:1327	arg1	biomarker					1329:1337	a novel blood biomarker	1315:1337	a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis	1315:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	4	40	theme	disease	676:682	arg1	severity/prognosis					684:701	disease severity/prognosis	676:701	disease severity/prognosis	676:701	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	7	41	theme	IgG	1034:1036	arg1	Fc					1038:1039	IgG Fc	1034:1039	IgG Fc	1034:1039	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	1	42	theme	vaccine	196:202	arg1	coverage					204:211	vaccine coverage	196:211	vaccine coverage	196:211	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	3	43	theme	Fc	426:427	arg1	traits					438:443	IgG Fc N-glycan traits	422:443	IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients	422:483	We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS.
35307819	7	44	from	structures	1020:1029	arg1	Fc					1038:1039	IgG Fc	1034:1039	IgG Fc	1034:1039	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	1	45	theme	coverage	204:211	arg1	nature					79:84	The nature	75:84	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity	75:167	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	45	theme	coverage	204:211	arg1	breadth					185:191	the breadth	181:191	the breadth of vaccine coverage and duration of immunity	181:236	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	45	theme	coverage	204:211	arg1	unclear					248:254	unclear	248:254	unclear	248:254	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	0	46	theme	disease	57:63	arg1	severity					65:72	disease severity	57:72	disease severity	57:72	Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
35307819	0	47	gly	glycosylation	12:24	arg1	diagnosis					38:46	COVID-19 diagnosis	29:46	COVID-19 diagnosis	29:46	Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
35307819	0	47	gly	glycosylation	12:24	arg2	diagnosis					38:46	COVID-19 diagnosis	29:46	COVID-19 diagnosis	29:46	Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity.
35307819	6	48	theme	acid	868:871	arg1	levels					837:842	levels	837:842	levels of galactose and sialic acid structures on IgGs	837:890	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	3	49	theme	unvaccinated	463:474	arg1	patients					476:483	82 SARS-CoV-2+ unvaccinated patients	448:483	82 SARS-CoV-2+ unvaccinated patients	448:483	We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS.
35307819	7	50	theme	increased	1116:1124	arg1	release					1126:1132	increased release	1116:1132	increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins	1116:1217	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	3	51	theme	patients	476:483	arg1	traits					438:443	IgG Fc N-glycan traits	422:443	IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients	422:483	We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS.
35307819	6	52	dep	galactose	847:855	arg1	structures					873:882	structures	873:882	structures	873:882	Importantly, levels of galactose and sialic acid structures on IgGs are able to predict the development of a poor COVID-19 disease.
35307819	4	53	theme	IgG	655:657	arg1	N-glycans					662:670	IgG Fc N-glycans	655:670	IgG Fc N-glycans	655:670	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	1	54	theme	COVID-19	126:133	arg1	pathogenesis					135:146	COVID-19 pathogenesis	126:146	COVID-19 pathogenesis	126:146	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	8	55	theme	Fc	1352:1353	arg1	composition					1363:1373	IgG Fc glycome composition	1348:1373	IgG Fc glycome composition with capacity to stratify patients at diagnosis	1348:1421	This study brings to light a novel blood biomarker based on IgG Fc glycome composition with capacity to stratify patients at diagnosis.
35307819	7	56	theme	galactose	1010:1018	arg1	structures					1020:1029	galactose structures	1010:1029	galactose structures on IgG Fc	1010:1039	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	3	57	theme	SARS-CoV-2+	451:461	arg1	patients					476:483	82 SARS-CoV-2+ unvaccinated patients	448:483	82 SARS-CoV-2+ unvaccinated patients	448:483	We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS.
35307819	1	58	theme	duration	217:224	arg1	nature					79:84	The nature	75:84	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity	75:167	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	58	theme	duration	217:224	arg1	breadth					185:191	the breadth	181:191	the breadth of vaccine coverage and duration of immunity	181:236	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	58	theme	duration	217:224	arg1	unclear					248:254	unclear	248:254	unclear	248:254	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	7	59	theme	immunoglobulins	1203:1217	arg1	presence					1174:1181	the presence	1170:1181	the presence of pro-inflammatory immunoglobulins	1170:1217	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	3	60	theme	N-glycan	429:436	arg1	traits					438:443	IgG Fc N-glycan traits	422:443	IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients	422:483	We have analyzed IgG Fc N-glycan traits of 82 SARS-CoV-2+ unvaccinated patients, at diagnosis, by nano-LC-ESI-MS.
35307819	5	61	theme	IgGs	818:821	arg1	composition					791:801	the glycans composition	779:801	the glycans composition of circulating IgGs	779:821	We found that SARS-CoV-2+ individuals display, at diagnosis, variations in the glycans composition of circulating IgGs.
35307819	4	62	theme	Fc	659:660	arg1	N-glycans					662:670	IgG Fc N-glycans	655:670	IgG Fc N-glycans	655:670	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	4	63	theme	NK	591:592	arg1	cells					594:598	NK cells	591:598	NK cells activation	591:609	We determined the impact of IgG Fc glyco-variations in the induction of NK cells activation, further evaluating the association between IgG Fc N-glycans and disease severity/prognosis.
35307819	7	64	from	deficiency	996:1005	arg1	structures					1020:1029	galactose structures	1010:1029	galactose structures on IgG Fc	1010:1039	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	7	64	from	deficiency	996:1005	arg1	patients					1053:1060	COVID-19 patients	1044:1060	COVID-19 patients	1044:1060	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	7	65	theme	poor	1267:1270	arg1	course					1280:1285	a poor disease course	1265:1285	a poor disease course	1265:1285	Mechanistically, we demonstrated that a deficiency on galactose structures on IgG Fc in COVID-19 patients appears to induce NK cells activation associated with increased release of IFN-γ and TNF-α, which indicates the presence of pro-inflammatory immunoglobulins and higher immune activation, associated with a poor disease course.
35307819	1	66	theme	disease	152:158	arg1	severity					160:167	disease severity	152:167	disease severity	152:167	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	67	theme	immunity	229:236	arg1	duration					217:224	duration	217:224	duration of immunity	217:236	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
35307819	1	67	theme	immunity	229:236	arg1	coverage					204:211	vaccine coverage	196:211	vaccine coverage	196:211	The nature of the immune responses associated with COVID-19 pathogenesis and disease severity, as well as the breadth of vaccine coverage and duration of immunity, is still unclear.
36269466	8	0	theme	hexoses	1218:1224	arg1	masses					1160:1165	masses	1160:1165	masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1160:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	9	1	theme	incomplete	1354:1363	arg1	removal					1365:1371	incomplete removal	1354:1371	incomplete removal of hexoses from these N-glycans	1354:1403	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	8	2	from	controls	1293:1300	arg1	plants					1256:1261	the infected plants	1243:1261	the infected plants which were absent in the mock controls	1243:1300	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	8	2	from	controls	1293:1300	arg1	absent					1274:1279	absent	1274:1279	absent	1274:1279	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	3	3	theme	N-glycan	516:523	arg1	composition					525:535	the plants N-glycan composition	505:535	the plants N-glycan composition	505:535	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	3	4	theme	emphasis	346:353	arg1	emphasis					346:353	emphasis	346:353	emphasis	346:353	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	3	4	theme	emphasis	346:353	arg1	lot					339:341	a lot	337:341	a lot of emphasis	337:353	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	8	5	from	absent	1274:1279	arg1	controls					1293:1300	the mock controls	1284:1300	the mock controls	1284:1300	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	10	6	theme	infected	1516:1523	arg1	plants					1525:1530	the infected plants	1512:1530	the infected plants	1512:1530	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	6	7	theme	oligomannosidic	874:888	arg1	N-glycans					890:898	oligomannosidic N-glycans	874:898	oligomannosidic N-glycans	874:898	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	7	8	gly	glycoforms	947:956	arg1	oligomannosidic					931:945	certain oligomannosidic glycoforms	923:956	certain oligomannosidic glycoforms	923:956	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	10	9	theme	reticulum	1563:1571	arg1	stress					1578:1583	endoplasmic reticulum (ER) stress	1551:1583	endoplasmic reticulum (ER) stress	1551:1583	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	10	10	theme	glycoproteins	1495:1507	arg1	accumulation					1469:1480	the accumulation	1465:1480	the accumulation of misfolded glycoproteins in the infected plants	1465:1530	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	9	11	from	N-glycans	1395:1403	arg1	removal					1365:1371	incomplete removal	1354:1371	incomplete removal of hexoses from these N-glycans	1354:1403	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	10	12	theme	misfolded	1485:1493	arg1	glycoproteins					1495:1507	misfolded glycoproteins	1485:1507	misfolded glycoproteins	1485:1507	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	8	13	theme	multiple	1119:1126	arg1	isomers					1147:1153	multiple different N-glycan isomers	1119:1153	multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1119:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	10	14	gly	glycoproteins	1495:1507	arg1	glycoproteins					1495:1507	misfolded glycoproteins	1485:1507	misfolded glycoproteins	1485:1507	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	1	15	dep	Pseudomonas	158:168	arg1	syringae					170:177	syringae	170:177	syringae	170:177	Studying the interaction between the hemibiotrophic bacterium Pseudomonas syringae pv.
36269466	8	16	with	isomers	1147:1153	arg1	masses					1160:1165	masses	1160:1165	masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1160:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	4	17	theme	P.	605:606	arg1	seedlings					662:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	9	18	theme	hexoses	1376:1382	arg1	removal					1365:1371	incomplete removal	1354:1371	incomplete removal of hexoses from these N-glycans	1354:1403	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	7	19	theme	carbon	1034:1039	arg1	-analysis					1046:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	2	20	theme	pathogen	314:321	arg1	attack					323:328	pathogen attack	314:328	pathogen attack	314:328	tomato DC3000 and Arabidopsis thaliana has shed light onto the various forms of mechanisms plants use to defend themselves against pathogen attack.
36269466	7	21	theme	certain	923:929	arg1	glycoforms					947:956	certain oligomannosidic glycoforms	923:956	certain oligomannosidic glycoforms	923:956	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	11	22	theme	α-amylase	1637:1645	arg1	treatment					1647:1655	α-amylase treatment	1637:1655	α-amylase treatment	1637:1655	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	2	23	theme	tomato	183:188	arg1	DC3000					190:195	tomato DC3000	183:195	tomato DC3000	183:195	tomato DC3000 and Arabidopsis thaliana has shed light onto the various forms of mechanisms plants use to defend themselves against pathogen attack.
36269466	8	24	theme	N-glycan	1138:1145	arg1	isomers					1147:1153	multiple different N-glycan isomers	1119:1153	multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1119:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	6	25	theme	increased	853:861	arg1	amounts					863:869	increased amounts	853:869	increased amounts of oligomannosidic N-glycans	853:898	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	6	25	theme	increased	853:861	arg1	N-glycans					890:898	oligomannosidic N-glycans	874:898	oligomannosidic N-glycans	874:898	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	7	26	theme	individual	1082:1091	arg1	isomers					1102:1108	separate individual N-glycan isomers	1073:1108	separate individual N-glycan isomers	1073:1108	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	7	27	theme	oligomannosidic	931:945	arg1	glycoforms					947:956	certain oligomannosidic glycoforms	923:956	certain oligomannosidic glycoforms	923:956	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	3	28	from	expression	404:413	arg1	plants					427:432	infected plants	418:432	infected plants	418:432	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	8	29	theme	different	1128:1136	arg1	isomers					1147:1153	multiple different N-glycan isomers	1119:1153	multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1119:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	7	30	theme	porous	1017:1022	arg1	-analysis					1046:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	8	31	theme	infected	1247:1254	arg1	plants					1256:1261	the infected plants	1243:1261	the infected plants which were absent in the mock controls	1243:1300	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	8	31	theme	infected	1247:1254	arg1	absent					1274:1279	absent	1274:1279	absent	1274:1279	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	11	32	theme	infection	1754:1762	arg1	process					1764:1770	the infection process	1750:1770	the infection process	1750:1770	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	4	33	theme	total	570:574	arg1	N-glycans					576:584	total N-glycans	570:584	total N-glycans	570:584	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	7	34	theme	graphitic	1024:1032	arg1	-analysis					1046:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	0	35	from	N-glycans	61:69	arg1	thaliana					86:93	Arabidopsis thaliana	74:93	Arabidopsis thaliana	74:93	Pseudomonas syringae DC3000 infection increases glucosylated N-glycans in Arabidopsis thaliana.
36269466	3	36	theme	little	440:445	arg1	information					447:457	only little information	435:457	only little information	435:457	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	0	37	theme	Pseudomonas	0:10	arg1	DC3000					21:26	Pseudomonas syringae DC3000	0:26	Pseudomonas syringae DC3000 infection	0:36	Pseudomonas syringae DC3000 infection increases glucosylated N-glycans in Arabidopsis thaliana.
36269466	11	38	theme	poly-hexose	1599:1609	arg1	structures					1611:1620	poly-hexose structures	1599:1620	poly-hexose structures susceptible to α-amylase treatment	1599:1655	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	11	39	theme	susceptible	1622:1632	arg1	structures					1611:1620	poly-hexose structures	1599:1620	poly-hexose structures susceptible to α-amylase treatment	1599:1655	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	8	40	located	detected	1231:1238	arg2	isomers					1147:1153	multiple different N-glycan isomers	1119:1153	multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1119:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	8	40	located	detected	1231:1238	arg1	plants					1256:1261	the infected plants	1243:1261	the infected plants which were absent in the mock controls	1243:1300	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	8	40	located	detected	1231:1238	arg1	absent					1274:1279	absent	1274:1279	absent	1274:1279	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	9	41	with	Treatment	1303:1311	arg1	α-mannosidase					1328:1340	jack bean α-mannosidase	1318:1340	jack bean α-mannosidase	1318:1340	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	7	42	theme	PGC	1042:1044	arg1	-analysis					1046:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	a porous graphitic carbon (PGC)-analysis	1015:1054	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	3	43	theme	effect	479:484	arg1	infection					486:494	the effect infection	475:494	the effect infection	475:494	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	3	44	theme	protein	396:402	arg1	expression					404:413	protein expression	396:413	protein expression in infected plants	396:432	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	4	45	dep	P.	605:606	arg1	syringae					608:615	syringae	608:615	syringae	608:615	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	4	46	theme	treated	642:648	arg1	seedlings					662:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	0	47	theme	glucosylated	48:59	arg1	N-glycans					61:69	glucosylated N-glycans	48:69	glucosylated N-glycans in Arabidopsis thaliana	48:93	Pseudomonas syringae DC3000 infection increases glucosylated N-glycans in Arabidopsis thaliana.
36269466	3	48	theme	plants	509:514	arg1	composition					525:535	the plants N-glycan composition	505:535	the plants N-glycan composition	505:535	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	8	49	theme	N-acetylhexosamine	1174:1191	arg1	residues					1193:1200	two N-acetylhexosamine residues	1170:1200	two N-acetylhexosamine residues	1170:1200	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	2	50	theme	mechanisms	263:272	arg1	plants					274:279	mechanisms plants	263:279	mechanisms plants	263:279	tomato DC3000 and Arabidopsis thaliana has shed light onto the various forms of mechanisms plants use to defend themselves against pathogen attack.
36269466	0	51	theme	DC3000	21:26	arg1	infection					28:36	Pseudomonas syringae DC3000 infection	0:36	Pseudomonas syringae DC3000 infection	0:36	Pseudomonas syringae DC3000 infection increases glucosylated N-glycans in Arabidopsis thaliana.
36269466	4	52	from	gap	552:554	arg1	knowledge					559:567	knowledge	559:567	knowledge	559:567	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	2	53	theme	Arabidopsis	201:211	arg1	thaliana					213:220	Arabidopsis thaliana	201:220	Arabidopsis thaliana	201:220	tomato DC3000 and Arabidopsis thaliana has shed light onto the various forms of mechanisms plants use to defend themselves against pathogen attack.
36269466	7	54	theme	N-glycan	1093:1100	arg1	isomers					1102:1108	separate individual N-glycan isomers	1073:1108	separate individual N-glycan isomers	1073:1108	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	3	55	theme	infected	418:425	arg1	plants					427:432	infected plants	418:432	infected plants	418:432	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	9	56	theme	glucose	1433:1439	arg1	residues					1441:1448	glucose residues	1433:1448	glucose residues	1433:1448	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	3	57	from	changes	385:391	arg1	expression					404:413	protein expression	396:413	protein expression in infected plants	396:432	While a lot of emphasis has been put on investigating changes in protein expression in infected plants, only little information is available on the effect infection plays on the plants N-glycan composition.
36269466	1	58	theme	hemibiotrophic	133:146	arg1	pv					179:180	the hemibiotrophic bacterium Pseudomonas syringae pv	129:180	the hemibiotrophic bacterium Pseudomonas syringae pv	129:180	Studying the interaction between the hemibiotrophic bacterium Pseudomonas syringae pv.
36269466	10	59	theme	endoplasmic	1551:1561	arg1	ER					1574:1575	ER	1574:1575	ER	1574:1575	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	10	59	theme	endoplasmic	1551:1561	arg1	reticulum					1563:1571	endoplasmic reticulum	1551:1571	endoplasmic reticulum (ER) stress	1551:1583	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	9	60	theme	residues	1441:1448	arg1	presence					1421:1428	the presence	1417:1428	the presence of glucose residues	1417:1448	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	8	61	theme	residues	1193:1200	arg1	masses					1160:1165	masses	1160:1165	masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses	1160:1224	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	2	62	theme	various	246:252	arg1	forms					254:258	the various forms	242:258	the various forms of mechanisms plants	242:279	tomato DC3000 and Arabidopsis thaliana has shed light onto the various forms of mechanisms plants use to defend themselves against pathogen attack.
36269466	7	63	theme	separate	1073:1080	arg1	isomers					1102:1108	separate individual N-glycan isomers	1073:1108	separate individual N-glycan isomers	1073:1108	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	1	64	theme	bacterium	148:156	arg1	pv					179:180	the hemibiotrophic bacterium Pseudomonas syringae pv	129:180	the hemibiotrophic bacterium Pseudomonas syringae pv	129:180	Studying the interaction between the hemibiotrophic bacterium Pseudomonas syringae pv.
36269466	7	65	theme	liquid	992:997	arg1	chromatography					999:1012	liquid chromatography	992:1012	liquid chromatography	992:1012	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	0	66	dep	Pseudomonas	0:10	arg1	syringae					12:19	syringae	12:19	syringae	12:19	Pseudomonas syringae DC3000 infection increases glucosylated N-glycans in Arabidopsis thaliana.
36269466	11	67	from	alterations	1710:1720	arg1	metabolism					1732:1741	starch metabolism	1725:1741	starch metabolism	1725:1741	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	9	68	theme	bean	1323:1326	arg1	α-mannosidase					1328:1340	jack bean α-mannosidase	1318:1340	jack bean α-mannosidase	1318:1340	Treatment with jack bean α-mannosidase resulted in incomplete removal of hexoses from these N-glycans, indicating the presence of glucose residues.
36269466	6	69	theme	infected	795:802	arg1	plants					804:809	infected plants	795:809	infected plants	795:809	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	1	70	theme	Pseudomonas	158:168	arg1	pv					179:180	the hemibiotrophic bacterium Pseudomonas syringae pv	129:180	the hemibiotrophic bacterium Pseudomonas syringae pv	129:180	Studying the interaction between the hemibiotrophic bacterium Pseudomonas syringae pv.
36269466	4	71	theme	DC3000-infected	617:631	arg1	seedlings					662:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	5	72	theme	labelled	731:738	arg1	N-glycans					740:748	fluorescently labelled N-glycans	717:748	fluorescently labelled N-glycans	717:748	Additionally, fluorescently labelled N-glycans were quantified via HPLC-FLD.
36269466	7	73	theme	multiple	904:911	arg1	peaks					913:917	multiple peaks	904:917	multiple peaks for certain oligomannosidic glycoforms	904:956	As multiple peaks for certain oligomannosidic glycoforms were detected upon separation via liquid chromatography, a porous graphitic carbon (PGC)-analysis was conducted to separate individual N-glycan isomers.
36269466	8	74	theme	mock	1288:1291	arg1	controls					1293:1300	the mock controls	1284:1300	the mock controls	1284:1300	Indeed, multiple different N-glycan isomers with masses of two N-acetylhexosamine residues plus 8, 9 or 10 hexoses were detected in the infected plants which were absent in the mock controls.
36269466	6	75	from	plants	804:809	arg1	N-glycans					780:788	N-glycans	780:788	N-glycans from infected plants	780:809	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	6	76	theme	N-glycans	890:898	arg1	amounts					863:869	increased amounts	853:869	increased amounts of oligomannosidic N-glycans	853:898	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	6	76	theme	N-glycans	890:898	arg1	N-glycans					890:898	oligomannosidic N-glycans	874:898	oligomannosidic N-glycans	874:898	N-glycans from infected plants were overall less processed and displayed increased amounts of oligomannosidic N-glycans.
36269466	4	77	theme	Arabidopsis	650:660	arg1	seedlings					662:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	4	78	theme	mock	637:640	arg1	seedlings					662:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	P. syringae DC3000-infected and mock treated Arabidopsis seedlings	605:670	To close this gap in knowledge, total N-glycans were enriched from P. syringae DC3000-infected and mock treated Arabidopsis seedlings and analyzed via MALDI-TOF-MS.
36269466	0	79	theme	Arabidopsis	74:84	arg1	thaliana					86:93	Arabidopsis thaliana	74:93	Arabidopsis thaliana	74:93	Pseudomonas syringae DC3000 infection increases glucosylated N-glycans in Arabidopsis thaliana.
36269466	11	80	theme	starch	1725:1730	arg1	metabolism					1732:1741	starch metabolism	1725:1741	starch metabolism	1725:1741	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	2	81	theme	plants	274:279	arg1	forms					254:258	the various forms	242:258	the various forms of mechanisms plants	242:279	tomato DC3000 and Arabidopsis thaliana has shed light onto the various forms of mechanisms plants use to defend themselves against pathogen attack.
36269466	11	82	theme	DC3000-infected	1675:1689	arg1	plants					1691:1696	the DC3000-infected plants	1671:1696	the DC3000-infected plants	1671:1696	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	10	83	from	accumulation	1469:1480	arg1	plants					1525:1530	the infected plants	1512:1530	the infected plants	1512:1530	This hints at the accumulation of misfolded glycoproteins in the infected plants, likely because of endoplasmic reticulum (ER) stress.
36269466	11	84	located	found	1662:1666	arg1	plants					1691:1696	the DC3000-infected plants	1671:1696	the DC3000-infected plants	1671:1696	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	11	84	located	found	1662:1666	arg1	addition					1589:1596	addition	1589:1596	addition	1589:1596	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
36269466	11	84	located	found	1662:1666	arg2	structures					1611:1620	poly-hexose structures	1599:1620	poly-hexose structures susceptible to α-amylase treatment	1599:1655	In addition, poly-hexose structures susceptible to α-amylase treatment were found in the DC3000-infected plants, indicating alterations in starch metabolism due to the infection process.
37079606	12	0	theme	IgA	2093:2095	arg1	N-glycans					2097:2105	plasma protein, IgG and IgA N-glycans	2069:2105	plasma protein, IgG and IgA N-glycans	2069:2105	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	7	1	theme	negative	1483:1490	arg1	association					1492:1502	negative association	1483:1502	negative association with low-branched plasma glycans	1483:1535	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	10	2	theme	tested	1823:1828	arg1	traits					1837:1842	the tested glycan traits	1819:1842	the tested glycan traits	1819:1842	None of the tested glycan traits showed a significant difference between GDM and normoglycemic pregnancies.
37079606	8	3	theme	glycosylation	1636:1648	arg1	features					1650:1657	glycosylation features	1636:1657	glycosylation features describing IgG sialylation	1636:1684	Additionally, HOMA2-%B index was significantly correlated with glycosylation features describing IgG sialylation.
37079606	7	4	with	association	1492:1502	arg1	glycans					1436:1442	high-branched plasma glycans	1415:1442	high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03)	1415:1477	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	7	4	with	association	1492:1502	arg1	glycans					1529:1535	low-branched plasma glycans	1509:1535	low-branched plasma glycans	1509:1535	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	12	5	theme	protein	2076:2082	arg1	N-glycans					2097:2105	plasma protein, IgG and IgA N-glycans	2069:2105	plasma protein, IgG and IgA N-glycans	2069:2105	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	7	6	theme	high-branched	1415:1427	arg1	glycans					1436:1442	high-branched plasma glycans	1415:1442	high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03)	1415:1477	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	5	7	gly	afucosylated	1114:1125	arg1	glycan					1149:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	6	8	theme	Insulin	1247:1253	arg1	HOMA2-IR					1274:1281	HOMA2-IR	1274:1281	HOMA2-IR	1274:1281	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	8	theme	Insulin	1247:1253	arg1	B					1294:1294	HOMA2-%B	1287:1294	HOMA2-%B	1287:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	8	theme	Insulin	1247:1253	arg1	markers					1266:1272	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	2	9	theme	aberrant	279:286	arg1	metabolism					301:310	aberrant carbohydrate metabolism	279:310	aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM)	279:349	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	4	10	theme	metabolic	850:858	arg1	markers					860:866	metabolic markers	850:866	metabolic markers	850:866	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	2	11	from	alterations	367:377	arg1	N-glycosylation					448:462	plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation	382:462	N-glycosylation	448:462	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	4	12	used	used	781:784	arg2	models					719:724	Linear mixed models	706:724	Linear mixed models adjusting for age and multiple testing (FDR<0.05)	706:774	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	9	13	theme	IgG	1711:1713	arg1	glycans					1723:1729	Multiple plasma protein IgG and IgA glycans	1687:1729	Multiple plasma protein IgG and IgA glycans	1687:1729	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	0	14	theme	gestational	111:121	arg1	diabetes					123:130	gestational diabetes	111:130	gestational diabetes	111:130	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	2	15	theme	gestational	315:325	arg1	GDM					346:348	GDM	346:348	GDM	346:348	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	15	theme	gestational	315:325	arg1	mellitus					336:343	gestational diabetes mellitus	315:343	gestational diabetes mellitus (GDM)	315:349	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	12	16	from	impact	2265:2270	arg1	glycosylation					2290:2302	protein glycosylation	2282:2302	protein glycosylation	2282:2302	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	9	17	theme	IgA	1719:1721	arg1	glycans					1723:1729	Multiple plasma protein IgG and IgA glycans	1687:1729	Multiple plasma protein IgG and IgA glycans	1687:1729	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	3	18	theme	normal	608:613	arg1	tolerance					623:631	normal glucose tolerance	608:631	normal glucose tolerance	608:631	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	11	19	from	metabolism	1971:1980	arg1	pregnancy					1985:1993	pregnancy	1985:1993	pregnancy	1985:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	4	20	theme	Linear	706:711	arg1	models					719:724	Linear mixed models	706:724	Linear mixed models adjusting for age and multiple testing (FDR<0.05)	706:774	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	11	21	theme	extensive	2000:2008	arg1	associations					2010:2021	extensive associations	2000:2021	extensive associations to various N-glycosylation features	2000:2057	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	5	22	theme	significant	918:928	arg1	associations					930:941	significant associations	918:941	significant associations	918:941	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	11	23	from	pregnancy	1985:1993	arg1	Markers					1930:1936	CONCLUSION Markers	1919:1936	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy	1919:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	6	24	theme	%	1293:1293	arg1	B					1294:1294	HOMA2-%B	1287:1294	HOMA2-%B	1287:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	24	theme	%	1293:1293	arg1	markers					1266:1272	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	10	25	theme	significant	1853:1863	arg1	difference					1865:1874	a significant difference	1851:1874	a significant difference between GDM and normoglycemic pregnancies	1851:1916	None of the tested glycan traits showed a significant difference between GDM and normoglycemic pregnancies.
37079606	1	26	theme	BACKGROUND	133:142	arg1	N-glycome					173:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome could provide valuable insight into an individual's metabolic status.
37079606	9	27	theme	total	1768:1772	arg1	cholesterol					1774:1784	total cholesterol	1768:1784	total cholesterol	1768:1784	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	0	28	from	markers	86:92	arg1	pregnancy					97:105	pregnancy	97:105	pregnancy	97:105	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	0	28	from	markers	86:92	arg1	diabetes					123:130	gestational diabetes	111:130	gestational diabetes	111:130	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	5	29	theme	afucosylated	1114:1125	arg1	glycan					1149:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	11	30	theme	N-glycosylation	2034:2048	arg1	features					2050:2057	various N-glycosylation features	2026:2057	various N-glycosylation features	2026:2057	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	1	31	theme	human	155:159	arg1	N-glycome					173:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome could provide valuable insight into an individual's metabolic status.
37079606	0	32	theme	metabolic	69:77	arg1	markers					86:92	metabolic health markers	69:92	metabolic health markers	69:92	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	2	33	dep	N-glycosylation	448:462	arg1	G					413:413	immunoglobulin G	398:413	immunoglobulin G (IgG)	398:419	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	33	dep	N-glycosylation	448:462	arg1	IgA					443:445	IgA	443:445	IgA	443:445	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	33	dep	N-glycosylation	448:462	arg1	A					440:440	immunoglobulin A	425:440	immunoglobulin A (IgA)	425:446	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	33	dep	N-glycosylation	448:462	arg1	IgG					416:418	IgG	416:418	IgG	416:418	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	12	34	theme	protein	2282:2288	arg1	glycosylation					2290:2302	protein glycosylation	2282:2302	protein glycosylation	2282:2302	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	3	35	with	women	597:601	arg1	tolerance					623:631	normal glucose tolerance	608:631	normal glucose tolerance	608:631	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	35	with	women	597:601	arg1	GDM					660:662	GDM	660:662	GDM	660:662	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	5	36	theme	plasma	980:985	arg1	bisection					1058:1066	bisection	1058:1066	bisection	1058:1066	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	36	theme	plasma	980:985	arg1	branching					1025:1033	branching	1025:1033	branching	1025:1033	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	36	theme	plasma	980:985	arg1	fucosylation					1041:1052	core fucosylation	1036:1052	core fucosylation	1036:1052	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	36	theme	plasma	980:985	arg1	sialylation					1012:1022	sialylation	1012:1022	sialylation	1012:1022	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	36	theme	plasma	980:985	arg1	galactosylation					995:1009	plasma protein galactosylation	980:1009	plasma protein galactosylation	980:1009	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	12	37	theme	pregnant	2138:2145	arg1	women					2147:2151	pregnant women	2138:2151	pregnant women with and without GDM	2138:2172	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	11	38	from	Markers	1930:1936	arg1	pregnancy					1985:1993	pregnancy	1985:1993	pregnancy	1985:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	9	39	with	associations	1750:1761	arg1	cholesterol					1774:1784	total cholesterol	1768:1784	total cholesterol	1768:1784	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	9	39	with	associations	1750:1761	arg1	levels					1803:1808	triglyceride levels	1790:1808	triglyceride levels	1790:1808	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	6	40	theme	glycan	1331:1336	arg1	structures					1338:1347	the same glycan structures	1322:1347	the same glycan structures as fasting insulin	1322:1366	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	2	41	theme	immunoglobulin	398:411	arg1	G					413:413	immunoglobulin G	398:413	immunoglobulin G (IgG)	398:419	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	41	theme	immunoglobulin	398:411	arg1	IgG					416:418	IgG	416:418	IgG	416:418	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	5	42	theme	IgA	1163:1165	arg1	glycan					1203:1208	IgA trisialylated triantennary (A3G3S3) glycan	1163:1208	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	43	theme	glycan	955:960	arg1	traits					962:967	numerous glycan traits	946:967	numerous glycan traits	946:967	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	43	theme	glycan	955:960	arg1	galactosylation					995:1009	plasma protein galactosylation	980:1009	plasma protein galactosylation	980:1009	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	11	44	theme	various	2026:2032	arg1	features					2050:2057	various N-glycosylation features	2026:2057	various N-glycosylation features	2026:2057	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	12	45	theme	GDM	2275:2277	arg1	impact					2265:2270	the impact	2261:2270	the impact of GDM on protein glycosylation	2261:2302	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	2	46	theme	immunoglobulin	425:438	arg1	IgA					443:445	IgA	443:445	IgA	443:445	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	46	theme	immunoglobulin	425:438	arg1	A					440:440	immunoglobulin A	425:440	immunoglobulin A (IgA)	425:446	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	0	47	theme	plasma	21:26	arg1	protein					28:34	plasma protein	21:34	plasma protein	21:34	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	5	48	theme	triantennary	1181:1192	arg1	glycan					1203:1208	IgA trisialylated triantennary (A3G3S3) glycan	1163:1208	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	11	49	theme	lipid	1965:1969	arg1	metabolism					1971:1980	lipid metabolism	1965:1980	lipid metabolism	1965:1980	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	5	50	theme	core	1036:1039	arg1	fucosylation					1041:1052	core fucosylation	1036:1052	core fucosylation	1036:1052	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	50	theme	core	1036:1039	arg1	galactosylation					995:1009	plasma protein galactosylation	980:1009	plasma protein galactosylation	980:1009	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	7	51	theme	low-branched	1509:1520	arg1	glycans					1529:1535	low-branched plasma glycans	1509:1535	low-branched plasma glycans	1509:1535	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	9	52	theme	Multiple	1687:1694	arg1	glycans					1723:1729	Multiple plasma protein IgG and IgA glycans	1687:1729	Multiple plasma protein IgG and IgA glycans	1687:1729	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	5	53	gly	fucosylated	1081:1091	arg1	glycan					1149:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	12	54	theme	physiological	2200:2212	arg1	changes					2214:2220	numerous physiological changes	2191:2220	numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation	2191:2302	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	5	55	theme	padj	1211:1214	arg1	range					1216:1220	padj range	1211:1220	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	56	dep	bisected	1094:1101	arg1	FA2B					1104:1107	FA2B	1104:1107	FA2B	1104:1107	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	2	57	theme	protein	389:395	arg1	N-glycosylation					448:462	plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation	382:462	N-glycosylation	448:462	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	8	58	theme	IgG	1670:1672	arg1	sialylation					1674:1684	IgG sialylation	1670:1684	IgG sialylation	1670:1684	Additionally, HOMA2-%B index was significantly correlated with glycosylation features describing IgG sialylation.
37079606	5	59	dep	fucosylated	1081:1091	arg1	disialylated					1127:1138	disialylated	1127:1138	disialylated	1127:1138	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	59	dep	fucosylated	1081:1091	arg1	A2G2S2					1141:1146	A2G2S2	1141:1146	A2G2S2	1141:1146	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	3	60	theme	gestation	695:703	arg1	weeks					686:690	24-28 weeks	680:690	24-28 weeks of gestation	680:703	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	6	61	theme	HOMA2-	1287:1292	arg1	%					1293:1293	%	1293:1293	%	1293:1293	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	3	62	theme	IgA	497:499	arg1	N-glycans					501:509	IgA N-glycans	497:509	IgA N-glycans	497:509	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	62	theme	IgA	497:499	arg1	METHODS					465:471	METHODS	465:471	METHODS Plasma protein, IgG and IgA N-glycans	465:509	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	5	63	theme	A3G3S3	1195:1200	arg1	glycan					1203:1208	IgA trisialylated triantennary (A3G3S3) glycan	1163:1208	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	9	64	theme	plasma	1696:1701	arg1	IgG					1711:1713	plasma protein IgG	1696:1713	plasma protein IgG	1696:1713	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	6	65	dep	markers	1266:1272	arg1	HOMA2-IR					1274:1281	HOMA2-IR	1274:1281	HOMA2-IR	1274:1281	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	65	dep	markers	1266:1272	arg1	B					1294:1294	HOMA2-%B	1287:1294	HOMA2-%B	1287:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	65	dep	markers	1266:1272	arg1	markers					1266:1272	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	4	66	theme	GDM	872:874	arg1	status					876:881	GDM status	872:881	GDM status	872:881	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	5	67	theme	Fasting	892:898	arg1	insulin					900:906	Fasting insulin	892:906	Fasting insulin	892:906	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	6	68	theme	resistance	1255:1264	arg1	HOMA2-IR					1274:1281	HOMA2-IR	1274:1281	HOMA2-IR	1274:1281	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	68	theme	resistance	1255:1264	arg1	B					1294:1294	HOMA2-%B	1287:1294	HOMA2-%B	1287:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	6	68	theme	resistance	1255:1264	arg1	markers					1266:1272	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B	1247:1294	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	2	69	theme	carbohydrate	288:299	arg1	metabolism					301:310	aberrant carbohydrate metabolism	279:310	aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM)	279:349	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	12	70	theme	plasma	2069:2074	arg1	protein					2076:2082	plasma protein	2069:2082	plasma protein	2069:2082	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	4	71	theme	glycosylation	826:838	arg1	features					840:847	glycosylation features	826:847	glycosylation features	826:847	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	7	72	theme	plasma	1429:1434	arg1	glycans					1436:1442	high-branched plasma glycans	1415:1442	high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03)	1415:1477	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	1	73	theme	valuable	197:204	arg1	insight					206:212	valuable insight	197:212	valuable insight into an individual's metabolic status	197:250	BACKGROUND Monitoring human circulating N-glycome could provide valuable insight into an individual's metabolic status.
37079606	9	74	theme	protein	1703:1709	arg1	IgG					1711:1713	plasma protein IgG	1696:1713	plasma protein IgG	1696:1713	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	6	75	theme	same	1326:1329	arg1	structures					1338:1347	the same glycan structures	1322:1347	the same glycan structures as fasting insulin	1322:1366	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	2	76	theme	diabetes	327:334	arg1	GDM					346:348	GDM	346:348	GDM	346:348	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	76	theme	diabetes	327:334	arg1	mellitus					336:343	gestational diabetes mellitus	315:343	gestational diabetes mellitus (GDM)	315:349	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	3	77	with	women	649:653	arg1	tolerance					623:631	normal glucose tolerance	608:631	normal glucose tolerance	608:631	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	77	with	women	649:653	arg1	GDM					660:662	GDM	660:662	GDM	660:662	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	7	78	theme	positive	1389:1396	arg1	association					1398:1408	positive association	1389:1408	positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03)	1389:1477	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	5	79	theme	fucosylated	1081:1091	arg1	glycan					1149:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	10	80	theme	traits	1837:1842	arg1	None					1811:1814	None	1811:1814	None of the tested glycan traits	1811:1842	None of the tested glycan traits showed a significant difference between GDM and normoglycemic pregnancies.
37079606	5	81	gly	trisialylated	1167:1179	arg1	glycan					1203:1208	IgA trisialylated triantennary (A3G3S3) glycan	1163:1208	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	82	theme	bisected	1094:1101	arg1	glycan					1149:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan	1072:1154	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	3	83	theme	pregnant	588:595	arg1	all					665:667	all	665:667	all	665:667	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	83	theme	pregnant	588:595	arg1	women					597:601	48 pregnant women	585:601	48 pregnant women with normal glucose tolerance	585:631	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	9	84	theme	significant	1738:1748	arg1	associations					1750:1761	significant associations	1738:1761	significant associations with total cholesterol and triglyceride levels	1738:1808	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	5	85	dep	glycan	1203:1208	arg1	range					1216:1220	padj range	1211:1220	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	7	86	dep	glycans	1436:1442	arg1	=					1450:1450	=	1450:1450	=	1450:1450	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	4	87	theme	mixed	713:717	arg1	models					719:724	Linear mixed models	706:724	Linear mixed models adjusting for age and multiple testing (FDR<0.05)	706:774	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	3	88	theme	glucose	615:621	arg1	tolerance					623:631	normal glucose tolerance	608:631	normal glucose tolerance	608:631	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	1	89	theme	Monitoring	144:153	arg1	N-glycome					173:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome could provide valuable insight into an individual's metabolic status.
37079606	2	90	from	metabolism	301:310	arg1	GDM					346:348	GDM	346:348	GDM	346:348	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	2	90	from	metabolism	301:310	arg1	mellitus					336:343	gestational diabetes mellitus	315:343	gestational diabetes mellitus (GDM)	315:349	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
37079606	0	91	from	protein	28:34	arg1	pregnancy					97:105	pregnancy	97:105	pregnancy	97:105	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	0	91	from	protein	28:34	arg1	diabetes					123:130	gestational diabetes	111:130	gestational diabetes	111:130	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	11	92	from	homeostasis	1949:1959	arg1	pregnancy					1985:1993	pregnancy	1985:1993	pregnancy	1985:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	1	93	theme	metabolic	235:243	arg1	status					245:250	an individual's metabolic status	219:250	an individual's metabolic status	219:250	BACKGROUND Monitoring human circulating N-glycome could provide valuable insight into an individual's metabolic status.
37079606	0	94	theme	health	79:84	arg1	markers					86:92	metabolic health markers	69:92	metabolic health markers	69:92	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	1	95	theme	circulating	161:171	arg1	N-glycome					173:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome	133:181	BACKGROUND Monitoring human circulating N-glycome could provide valuable insight into an individual's metabolic status.
37079606	9	96	theme	triglyceride	1790:1801	arg1	levels					1803:1808	triglyceride levels	1790:1808	triglyceride levels	1790:1808	Multiple plasma protein IgG and IgA glycans showed significant associations with total cholesterol and triglyceride levels.
37079606	6	97	theme	fasting	1352:1358	arg1	insulin					1360:1366	fasting insulin	1352:1366	fasting insulin	1352:1366	Insulin resistance markers HOMA2-IR and HOMA2-%B were mostly associated to the same glycan structures as fasting insulin.
37079606	0	98	from	IgA	45:47	arg1	pregnancy					97:105	pregnancy	97:105	pregnancy	97:105	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	0	98	from	IgA	45:47	arg1	diabetes					123:130	gestational diabetes	111:130	gestational diabetes	111:130	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	4	99	theme	multiple	748:755	arg1	testing					757:763	multiple testing	748:763	multiple testing (FDR<0.05)	748:774	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	4	99	theme	multiple	748:755	arg1	FDR<0.05					766:773	FDR<0.05	766:773	FDR<0.05	766:773	Linear mixed models adjusting for age and multiple testing (FDR<0.05) were used to investigate the associations between glycosylation features, metabolic markers and GDM status.
37079606	5	100	theme	protein	987:993	arg1	bisection					1058:1066	bisection	1058:1066	bisection	1058:1066	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	100	theme	protein	987:993	arg1	branching					1025:1033	branching	1025:1033	branching	1025:1033	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	100	theme	protein	987:993	arg1	fucosylation					1041:1052	core fucosylation	1036:1052	core fucosylation	1036:1052	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	100	theme	protein	987:993	arg1	sialylation					1012:1022	sialylation	1012:1022	sialylation	1012:1022	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	100	theme	protein	987:993	arg1	galactosylation					995:1009	plasma protein galactosylation	980:1009	plasma protein galactosylation	980:1009	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	0	101	from	IgG	37:39	arg1	pregnancy					97:105	pregnancy	97:105	pregnancy	97:105	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	0	101	from	IgG	37:39	arg1	diabetes					123:130	gestational diabetes	111:130	gestational diabetes	111:130	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	8	102	theme	%	1593:1593	arg1	index					1596:1600	HOMA2-%B index	1587:1600	HOMA2-%B index	1587:1600	Additionally, HOMA2-%B index was significantly correlated with glycosylation features describing IgG sialylation.
37079606	5	103	theme	numerous	946:953	arg1	traits					962:967	numerous glycan traits	946:967	numerous glycan traits	946:967	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	5	103	theme	numerous	946:953	arg1	galactosylation					995:1009	plasma protein galactosylation	980:1009	plasma protein galactosylation	980:1009	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	11	104	theme	CONCLUSION	1919:1928	arg1	Markers					1930:1936	CONCLUSION Markers	1919:1936	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy	1919:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	11	105	theme	glucose	1941:1947	arg1	homeostasis					1949:1959	glucose homeostasis	1941:1959	glucose homeostasis	1941:1959	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	7	106	with	association	1398:1408	arg1	glycans					1436:1442	high-branched plasma glycans	1415:1442	high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03)	1415:1477	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	7	106	with	association	1398:1408	arg1	glycans					1529:1535	low-branched plasma glycans	1509:1535	low-branched plasma glycans	1509:1535	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	5	107	theme	trisialylated	1167:1179	arg1	glycan					1203:1208	IgA trisialylated triantennary (A3G3S3) glycan	1163:1208	IgA trisialylated triantennary (A3G3S3) glycan (padj range	1163:1220	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	10	108	theme	normoglycemic	1892:1904	arg1	pregnancies					1906:1916	normoglycemic pregnancies	1892:1916	normoglycemic pregnancies	1892:1916	None of the tested glycan traits showed a significant difference between GDM and normoglycemic pregnancies.
37079606	5	109	dep	RESULTS	884:890	arg1	exhibited					908:916	exhibited	908:916	exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02)	908:1244	RESULTS Fasting insulin exhibited significant associations to numerous glycan traits, including plasma protein galactosylation, sialylation, branching, core fucosylation and bisection, to IgG core fucosylated, bisected (FA2B) and afucosylated disialylated (A2G2S2) glycan and to IgA trisialylated triantennary (A3G3S3) glycan (padj range: 4.37x10-05-4.94x10-02).
37079606	3	110	theme	Plasma	473:478	arg1	protein					480:486	Plasma protein	473:486	Plasma protein	473:486	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	110	theme	Plasma	473:478	arg1	METHODS					465:471	METHODS	465:471	METHODS Plasma protein, IgG and IgA N-glycans	465:509	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	11	111	theme	homeostasis	1949:1959	arg1	Markers					1930:1936	CONCLUSION Markers	1919:1936	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy	1919:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	3	112	theme	pregnant	640:647	arg1	women					649:653	41 pregnant women	637:653	41 pregnant women with GDM	637:662	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	11	113	theme	metabolism	1971:1980	arg1	Markers					1930:1936	CONCLUSION Markers	1919:1936	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy	1919:1993	CONCLUSION Markers of glucose homeostasis and lipid metabolism in pregnancy show extensive associations to various N-glycosylation features.
37079606	0	114	dep	IgG	37:39	arg1	N-glycosylation					49:63	N-glycosylation	49:63	N-glycosylation	49:63	Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes.
37079606	8	115	theme	HOMA2-	1587:1592	arg1	%					1593:1593	%	1593:1593	%	1593:1593	Additionally, HOMA2-%B index was significantly correlated with glycosylation features describing IgG sialylation.
37079606	7	116	theme	plasma	1522:1527	arg1	glycans					1529:1535	low-branched plasma glycans	1509:1535	low-branched plasma glycans	1509:1535	Both markers showed positive association with high-branched plasma glycans (padj = 1.12x10-02 and 2.03x10-03) and negative association with low-branched plasma glycans (padj = 1.21x10-02 and 2.05x10-03).
37079606	10	117	theme	glycan	1830:1835	arg1	traits					1837:1842	the tested glycan traits	1819:1842	the tested glycan traits	1819:1842	None of the tested glycan traits showed a significant difference between GDM and normoglycemic pregnancies.
37079606	8	118	theme	B	1594:1594	arg1	index					1596:1600	HOMA2-%B index	1587:1600	HOMA2-%B index	1587:1600	Additionally, HOMA2-%B index was significantly correlated with glycosylation features describing IgG sialylation.
37079606	12	119	theme	numerous	2191:2198	arg1	changes					2214:2220	numerous physiological changes	2191:2220	numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation	2191:2302	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	12	120	theme	IgG	2085:2087	arg1	N-glycans					2097:2105	plasma protein, IgG and IgA N-glycans	2069:2105	plasma protein, IgG and IgA N-glycans	2069:2105	However, plasma protein, IgG and IgA N-glycans were not able to differentiate pregnant women with and without GDM, possibly due to numerous physiological changes accompanying pregnancy, which confound the impact of GDM on protein glycosylation.
37079606	3	121	dep	METHODS	465:471	arg1	IgG					489:491	IgG	489:491	IgG	489:491	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	121	dep	METHODS	465:471	arg1	N-glycans					501:509	IgA N-glycans	497:509	IgA N-glycans	497:509	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	121	dep	METHODS	465:471	arg1	protein					480:486	Plasma protein	473:486	Plasma protein	473:486	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	3	121	dep	METHODS	465:471	arg1	METHODS					465:471	METHODS	465:471	METHODS Plasma protein, IgG and IgA N-glycans	465:509	METHODS Plasma protein, IgG and IgA N-glycans were enzymatically released, purified and chromatographically profiled in 48 pregnant women with normal glucose tolerance and 41 pregnant women with GDM, all sampled at 24-28 weeks of gestation.
37079606	2	122	theme	plasma	382:387	arg1	N-glycosylation					448:462	plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation	382:462	N-glycosylation	448:462	Therefore, we examined if aberrant carbohydrate metabolism in gestational diabetes mellitus (GDM) associates with alterations in plasma protein, immunoglobulin G (IgG) and immunoglobulin A (IgA) N-glycosylation.
36202042	1	0	link	N-linked	102:109	arg1	glycosylation					111:123	N-linked glycosylation	102:123	N-linked glycosylation	102:123	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	2	1	used	used	233:236	arg2	techniques					218:227	Various analytical techniques	199:227	Various analytical techniques	199:227	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	7	2	theme	side	1012:1015	arg1	reaction					1017:1024	this side reaction	1007:1024	this side reaction	1007:1024	The product of this side reaction interfered with the structural identification N-glycans.
36202042	1	3	theme	modification	173:184	arg1	modification					173:184	the most important post translational modification	135:184	the most important post translational modification of proteins	135:196	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	1	3	theme	modification	173:184	arg1	one					128:130	one	128:130	one	128:130	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	5	4	from	proteins	753:760	arg1	release					727:733	the ammonia-catalyzed release	705:733	the ammonia-catalyzed release of N-glycans from proteins	705:760	Recently, the ammonia-catalyzed release of N-glycans from proteins has been reported to be associated with no typical side reactions.
36202042	0	5	theme	N-glycans	91:99	arg1	release					80:86	the ammonia-catalyzed release	58:86	the ammonia-catalyzed release of N-glycans	58:99	Identification of side-reaction products generated during the ammonia-catalyzed release of N-glycans.
36202042	9	6	from	proteins	1311:1318	arg1	release					1298:1304	N-glycan release	1289:1304	N-glycan release from proteins	1289:1318	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	4	7	theme	chemical	547:554	arg1	methods					556:562	chemical methods	547:562	chemical methods	547:562	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	2	8	theme	enzymatic	328:336	arg1	methods					351:357	various enzymatic and chemical methods	320:357	various enzymatic and chemical methods	320:357	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	3	9	theme	N-glycans	447:455	arg1	release					436:442	the enzymatic release	422:442	the enzymatic release of N-glycans	422:455	Although very few side-reaction products are generated during the enzymatic release of N-glycans, this method is expensive and suitable only for small quantities of samples.
36202042	6	10	theme	present	927:933	arg1	N-acetylglucosamine					907:925	N-acetylglucosamine	907:925	N-acetylglucosamine present at the reducing end of N-glycans	907:966	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	6	11	theme	present	836:842	arg1	study					844:848	the present study	832:848	the present study	832:848	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	2	12	theme	various	320:326	arg1	methods					351:357	various enzymatic and chemical methods	320:357	various enzymatic and chemical methods	320:357	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	3	13	theme	samples	525:531	arg1	quantities					511:520	small quantities	505:520	small quantities of samples	505:531	Although very few side-reaction products are generated during the enzymatic release of N-glycans, this method is expensive and suitable only for small quantities of samples.
36202042	6	14	theme	N-acetylglucosamine	907:925	arg1	epimerization					890:902	the epimerization	886:902	the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine	886:989	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	4	15	used	used	571:574	arg2	methods					556:562	chemical methods	547:562	chemical methods	547:562	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	1	16	theme	proteins	189:196	arg1	modification					173:184	the most important post translational modification	135:184	the most important post translational modification of proteins	135:196	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	9	17	theme	alkaline	1381:1388	arg1	solutions					1390:1398	any other alkaline solutions	1371:1398	any other alkaline solutions	1371:1398	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	9	18	theme	ammonia-catalyzed	1257:1273	arg1	reactions					1275:1283	ammonia-catalyzed reactions	1257:1283	ammonia-catalyzed reactions	1257:1283	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	6	19	attach	present	927:933	arg1	end					951:953	the reducing end	938:953	the reducing end of N-glycans	938:966	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	6	19	attach	present	927:933	arg2	N-acetylglucosamine					907:925	N-acetylglucosamine	907:925	N-acetylglucosamine present at the reducing end of N-glycans	907:966	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	5	20	theme	typical	805:811	arg1	reactions					818:826	no typical side reactions	802:826	no typical side reactions	802:826	Recently, the ammonia-catalyzed release of N-glycans from proteins has been reported to be associated with no typical side reactions.
36202042	9	21	theme	reactions	1275:1283	arg1	applicability					1240:1252	the applicability	1236:1252	the applicability of ammonia-catalyzed reactions for N-glycan release from proteins	1236:1318	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	1	22	theme	N-linked	102:109	arg1	glycosylation					111:123	N-linked glycosylation	102:123	N-linked glycosylation	102:123	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	8	23	theme	artifact	1138:1145	arg1	isomer					1156:1161	this artifact N-glycan isomer	1133:1161	this artifact N-glycan isomer	1133:1161	We propose a simple method that can help identify this artifact N-glycan isomer and eliminate the aforementioned interference.
36202042	6	24	theme	new	867:869	arg1	reaction					876:883	a new side reaction	865:883	a new side reaction	865:883	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	0	25	theme	products	32:39	arg1	Identification					0:13	Identification	0:13	Identification of side-reaction products	0:39	Identification of side-reaction products generated during the ammonia-catalyzed release of N-glycans.
36202042	4	26	theme	large	580:584	arg1	quantities					586:595	large quantities	580:595	large quantities of samples	580:606	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	5	27	theme	N-glycans	738:746	arg1	release					727:733	the ammonia-catalyzed release	705:733	the ammonia-catalyzed release of N-glycans from proteins	705:760	Recently, the ammonia-catalyzed release of N-glycans from proteins has been reported to be associated with no typical side reactions.
36202042	9	28	theme	N-glycan	1289:1296	arg1	release					1298:1304	N-glycan release	1289:1304	N-glycan release from proteins	1289:1318	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	2	29	theme	chemical	342:349	arg1	methods					351:357	various enzymatic and chemical methods	320:357	various enzymatic and chemical methods	320:357	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	3	30	theme	small	505:509	arg1	quantities					511:520	small quantities	505:520	small quantities of samples	505:531	Although very few side-reaction products are generated during the enzymatic release of N-glycans, this method is expensive and suitable only for small quantities of samples.
36202042	0	31	theme	side-reaction	18:30	arg1	products					32:39	side-reaction products	18:39	side-reaction products	18:39	Identification of side-reaction products generated during the ammonia-catalyzed release of N-glycans.
36202042	4	32	theme	samples	600:606	arg1	quantities					586:595	large quantities	580:595	large quantities of samples	580:606	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	2	33	theme	analytical	207:216	arg1	techniques					218:227	Various analytical techniques	199:227	Various analytical techniques	199:227	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	6	34	theme	reducing	942:949	arg1	end					951:953	the reducing end	938:953	the reducing end of N-glycans	938:966	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	5	35	theme	side	813:816	arg1	reactions					818:826	no typical side reactions	802:826	no typical side reactions	802:826	Recently, the ammonia-catalyzed release of N-glycans from proteins has been reported to be associated with no typical side reactions.
36202042	9	36	theme	other	1375:1379	arg1	solutions					1390:1398	any other alkaline solutions	1371:1398	any other alkaline solutions	1371:1398	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	2	37	theme	Various	199:205	arg1	techniques					218:227	Various analytical techniques	199:227	Various analytical techniques	199:227	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	8	38	theme	simple	1096:1101	arg1	method					1103:1108	a simple method	1094:1108	a simple method that can help identify this artifact N-glycan isomer and eliminate the aforementioned interference	1094:1207	We propose a simple method that can help identify this artifact N-glycan isomer and eliminate the aforementioned interference.
36202042	8	39	theme	aforementioned	1181:1194	arg1	interference					1196:1207	the aforementioned interference	1177:1207	the aforementioned interference	1177:1207	We propose a simple method that can help identify this artifact N-glycan isomer and eliminate the aforementioned interference.
36202042	7	40	theme	structural	1046:1055	arg1	N-glycans					1072:1080	the structural identification N-glycans	1042:1080	the structural identification N-glycans	1042:1080	The product of this side reaction interfered with the structural identification N-glycans.
36202042	0	41	theme	ammonia-catalyzed	62:78	arg1	release					80:86	the ammonia-catalyzed release	58:86	the ammonia-catalyzed release of N-glycans	58:99	Identification of side-reaction products generated during the ammonia-catalyzed release of N-glycans.
36202042	8	42	theme	N-glycan	1147:1154	arg1	isomer					1156:1161	this artifact N-glycan isomer	1133:1161	this artifact N-glycan isomer	1133:1161	We propose a simple method that can help identify this artifact N-glycan isomer and eliminate the aforementioned interference.
36202042	6	43	theme	side	871:874	arg1	reaction					876:883	a new side reaction	865:883	a new side reaction	865:883	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	2	44	theme	structural	246:255	arg1	identification					257:270	the structural identification	242:270	the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods	242:357	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	7	45	theme	identification	1057:1070	arg1	N-glycans					1072:1080	the structural identification N-glycans	1042:1080	the structural identification N-glycans	1042:1080	The product of this side reaction interfered with the structural identification N-glycans.
36202042	6	46	theme	N-glycans	958:966	arg1	end					951:953	the reducing end	938:953	the reducing end of N-glycans	938:966	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36202042	5	47	theme	ammonia-catalyzed	709:725	arg1	release					727:733	the ammonia-catalyzed release	705:733	the ammonia-catalyzed release of N-glycans from proteins	705:760	Recently, the ammonia-catalyzed release of N-glycans from proteins has been reported to be associated with no typical side reactions.
36202042	4	48	theme	various	618:624	arg1	products					640:647	various side-reaction products	618:647	various side-reaction products	618:647	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	4	49	used	used	689:692	arg2	methods					677:683	chemical methods	668:683	chemical methods	668:683	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	2	50	attach	released	289:296	arg2	N-glycans					279:287	the N-glycans	275:287	the N-glycans released from proteins through various enzymatic and chemical methods	275:357	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	2	50	attach	released	289:296	arg1	proteins					303:310	proteins	303:310	proteins	303:310	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	7	51	theme	reaction	1017:1024	arg1	product					996:1002	The product	992:1002	The product of this side reaction	992:1024	The product of this side reaction interfered with the structural identification N-glycans.
36202042	1	52	theme	important	144:152	arg1	modification					173:184	the most important post translational modification	135:184	the most important post translational modification of proteins	135:196	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	4	53	theme	side-reaction	626:638	arg1	products					640:647	various side-reaction products	618:647	various side-reaction products	618:647	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	3	54	theme	few	374:376	arg1	products					392:399	very few side-reaction products	369:399	very few side-reaction products	369:399	Although very few side-reaction products are generated during the enzymatic release of N-glycans, this method is expensive and suitable only for small quantities of samples.
36202042	2	55	theme	N-glycans	279:287	arg1	identification					257:270	the structural identification	242:270	the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods	242:357	Various analytical techniques are used for the structural identification of the N-glycans released from proteins through various enzymatic and chemical methods.
36202042	4	56	theme	chemical	668:675	arg1	methods					677:683	chemical methods	668:683	chemical methods	668:683	By contrast, chemical methods can be used for large quantities of samples; however, various side-reaction products are generated when chemical methods are used.
36202042	1	57	theme	post	154:157	arg1	modification					173:184	the most important post translational modification	135:184	the most important post translational modification of proteins	135:196	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	3	58	theme	side-reaction	378:390	arg1	products					392:399	very few side-reaction products	369:399	very few side-reaction products	369:399	Although very few side-reaction products are generated during the enzymatic release of N-glycans, this method is expensive and suitable only for small quantities of samples.
36202042	3	59	theme	enzymatic	426:434	arg1	release					436:442	the enzymatic release	422:442	the enzymatic release of N-glycans	422:455	Although very few side-reaction products are generated during the enzymatic release of N-glycans, this method is expensive and suitable only for small quantities of samples.
36202042	9	60	theme	simple	1215:1220	arg1	method					1222:1227	This simple method	1210:1227	This simple method	1210:1227	This simple method widens the applicability of ammonia-catalyzed reactions for N-glycan release from proteins, and is also suitable for N-glycans released using any other alkaline solutions.
36202042	1	61	theme	translational	159:171	arg1	modification					173:184	the most important post translational modification	135:184	the most important post translational modification of proteins	135:196	N-linked glycosylation is one of the most important post translational modification of proteins.
36202042	6	62	from	end	951:953	arg1	present					927:933	present	927:933	present	927:933	In the present study, we discovered a new side reaction: the epimerization of N-acetylglucosamine present at the reducing end of N-glycans to N-acetylmannosamine.
36670130	8	0	theme	immune	1528:1533	arg1	response					1535:1542	host immune response	1523:1542	host immune response	1523:1542	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	6	1	theme	uptake	914:919	arg1	assays					921:926	In vitro adhesion and uptake assays	892:926	assays	921:926	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	4	2	theme	xylose/xylose	729:741	arg1	extents					695:701	different extents	685:701	different extents of hypermannosylation and xylose/xylose phosphate addition	685:760	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	6	3	theme	adhesion	985:992	arg1	affinities					994:1003	adhesion affinities	985:1003	adhesion affinities to host cells	985:1017	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	8	4	theme	MPs	1454:1456	arg1	interaction					1439:1449	the interaction	1435:1449	the interaction of MPs with host cells	1435:1472	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	4	5	dep	hypermannosylation	706:723	arg1	addition					753:760	phosphate addition	743:760	phosphate addition	743:760	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	0	6	with	interaction	113:123	arg1	cells					135:139	host cells	130:139	host cells	130:139	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	0	7	from	Effects	0:6	arg1	interaction					113:123	interaction	113:123	interaction with host cells	113:139	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	6	8	theme	cells	1104:1108	arg1	response					1062:1069	the immune response	1051:1069	the immune response of bone-marrow derived dendritic cells (BMDCs)	1051:1116	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	8	9	theme	structure-dependent	1350:1368	arg1	effects					1370:1376	the structure-dependent effects	1346:1376	the structure-dependent effects of N-glycans	1346:1389	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	7	10	contain	carrying	1312:1319	arg1	MP84					1307:1310	MP84	1307:1310	MP84 carrying WT N-glycans	1307:1332	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	7	10	contain	carrying	1312:1319	arg2	N-glycans					1324:1332	WT N-glycans	1321:1332	WT N-glycans	1321:1332	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	6	11	theme	dendritic	1094:1102	arg1	BMDCs					1111:1115	BMDCs	1111:1115	BMDCs	1111:1115	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	6	11	theme	dendritic	1094:1102	arg1	cells					1104:1108	bone-marrow derived dendritic cells	1074:1108	bone-marrow derived dendritic cells (BMDCs)	1074:1116	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	8	12	theme	host	1463:1466	arg1	cells					1468:1472	host cells	1463:1472	host cells	1463:1472	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	4	13	theme	hypermannosylation	706:723	arg1	extents					695:701	different extents	685:701	different extents of hypermannosylation and xylose/xylose phosphate addition	685:760	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	5	14	contain	containing	817:826	arg2	forms					870:874	M5 and M7 forms	860:874	forms	870:874	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	5	14	contain	containing	817:826	arg1	N-glycans					806:814	truncated core N-glycans	791:814	truncated core N-glycans	791:814	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	5	14	contain	containing	817:826	arg2	mannoses					850:857	five and seven mannoses	835:857	five and seven mannoses (M5 and M7 forms)	835:875	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	2	15	theme	wall	264:267	arg1	MPs					284:286	MPs	284:286	MPs	284:286	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	2	15	theme	wall	264:267	arg1	mannoproteins					269:281	several cell wall mannoproteins	251:281	several cell wall mannoproteins (MPs) identified as immunoreactive antigens	251:325	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	2	16	contain	has	247:249	arg2	mannoproteins					269:281	several cell wall mannoproteins	251:281	several cell wall mannoproteins (MPs) identified as immunoreactive antigens	251:325	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	2	16	contain	has	247:249	arg2	MPs					284:286	MPs	284:286	MPs	284:286	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	2	16	contain	has	247:249	arg1	It					244:245	It	244:245	It	244:245	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	5	17	theme	core	801:804	arg1	N-glycans					806:814	truncated core N-glycans	791:814	truncated core N-glycans	791:814	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	4	18	theme	MALDI-TOF	586:594	arg1	analysis					596:603	HPLC and MALDI-TOF analysis	577:603	analysis	596:603	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	7	19	gly	N-glycosylation	1162:1176	arg2	sites					1178:1182	all N-glycosylation sites	1158:1182	all N-glycosylation sites	1158:1182	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	2	20	theme	cell	259:262	arg1	MPs					284:286	MPs	284:286	MPs	284:286	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	2	20	theme	cell	259:262	arg1	mannoproteins					269:281	several cell wall mannoproteins	251:281	several cell wall mannoproteins (MPs) identified as immunoreactive antigens	251:325	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	3	21	theme	wall	414:417	arg1	MPs					419:421	cryptococcal cell wall MPs	396:421	cryptococcal cell wall MPs in host cell interactions	396:447	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	7	22	theme	cytokine	1255:1262	arg1	secretion					1264:1272	cytokine secretion	1255:1272	cytokine secretion from BMDCs	1255:1283	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	6	23	link	derived	1086:1092	arg1	BMDCs					1111:1115	BMDCs	1111:1115	BMDCs	1111:1115	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	6	23	link	derived	1086:1092	arg1	cells					1104:1108	bone-marrow derived dendritic cells	1074:1108	bone-marrow derived dendritic cells (BMDCs)	1074:1116	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	8	24	dep	adherence	1495:1503	arg1	hyperactivation					1544:1558	hyperactivation	1544:1558	hyperactivation	1544:1558	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	2	25	theme	several	251:257	arg1	MPs					284:286	MPs	284:286	MPs	284:286	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	2	25	theme	several	251:257	arg1	mannoproteins					269:281	several cell wall mannoproteins	251:281	several cell wall mannoproteins (MPs) identified as immunoreactive antigens	251:325	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	8	26	theme	complex	1407:1413	arg1	roles					1415:1419	their complex roles	1401:1419	their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation	1401:1558	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	3	27	theme	host	426:429	arg1	interactions					436:447	host cell interactions	426:447	host cell interactions	426:447	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	6	28	theme	In	892:893	arg1	adhesion					901:908	In vitro adhesion and uptake assays	892:926	adhesion	901:908	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	8	29	with	interaction	1439:1449	arg1	cells					1468:1472	host cells	1463:1472	host cells	1463:1472	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	4	30	theme	different	685:693	arg1	extents					695:701	different extents	685:701	different extents of hypermannosylation and xylose/xylose phosphate addition	685:760	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	4	31	from	analysis	596:603	arg1	WT					633:634	the WT	629:634	the WT	629:634	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	1	32	theme	Cryptococcus	142:153	arg1	neoformans					155:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	1	32	theme	Cryptococcus	142:153	arg1	pathogen					199:206	an opportunistic human fungal pathogen	169:206	an opportunistic human fungal pathogen causing lethal meningoencephalitis	169:241	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	3	33	theme	N-glycans	373:381	arg1	function					361:368	function	361:368	function	361:368	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	3	33	theme	N-glycans	373:381	arg1	structure					347:355	structure	347:355	structure	347:355	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	8	34	theme	nonspecific	1483:1493	arg1	adherence					1495:1503	nonspecific adherence	1483:1503	nonspecific adherence to host cells	1483:1517	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	6	35	theme	derived	1086:1092	arg1	BMDCs					1111:1115	BMDCs	1111:1115	BMDCs	1111:1115	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	6	35	theme	derived	1086:1092	arg1	cells					1104:1108	bone-marrow derived dendritic cells	1074:1108	bone-marrow derived dendritic cells (BMDCs)	1074:1116	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	0	36	theme	N-glycan	19:26	arg1	structures					28:37	altered N-glycan structures	11:37	altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3),	11:108	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	5	37	contain	had	787:789	arg1	MP98					773:776	MP98	773:776	MP98	773:776	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	5	37	contain	had	787:789	arg2	N-glycans					806:814	truncated core N-glycans	791:814	truncated core N-glycans	791:814	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	5	37	contain	had	787:789	arg1	MP84					782:785	MP84	782:785	MP84	782:785	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	6	38	theme	bone-marrow	1074:1084	arg1	BMDCs					1111:1115	BMDCs	1111:1115	BMDCs	1111:1115	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	6	38	theme	bone-marrow	1074:1084	arg1	cells					1104:1108	bone-marrow derived dendritic cells	1074:1108	bone-marrow derived dendritic cells (BMDCs)	1074:1116	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	0	39	dep	neoformans	55:64	arg1	mannoproteins					66:78	mannoproteins	66:78	Cryptococcus neoformans mannoproteins	42:78	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	4	40	theme	HPLC	577:580	arg1	analysis					596:603	HPLC and MALDI-TOF analysis	577:603	analysis	596:603	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	0	41	theme	altered	11:17	arg1	structures					28:37	altered N-glycan structures	11:37	altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3),	11:108	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	4	42	theme	phosphate	743:751	arg1	addition					753:760	phosphate addition	743:760	phosphate addition	743:760	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	8	43	theme	N-glycans	1381:1389	arg1	effects					1370:1376	the structure-dependent effects	1346:1376	the structure-dependent effects of N-glycans	1346:1389	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	7	44	theme	N-glycosylation	1162:1176	arg1	sites					1178:1182	all N-glycosylation sites	1158:1182	all N-glycosylation sites	1158:1182	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	5	45	theme	truncated	791:799	arg1	N-glycans					806:814	truncated core N-glycans	791:814	truncated core N-glycans	791:814	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	3	46	theme	cryptococcal	396:407	arg1	MPs					419:421	cryptococcal cell wall MPs	396:421	cryptococcal cell wall MPs in host cell interactions	396:447	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	4	47	theme	MP	612:613	arg1	proteins					615:622	the MP proteins	608:622	the MP proteins from the WT	608:634	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	7	48	from	BMDCs	1279:1283	arg1	induction					1242:1250	the induction	1238:1250	the induction of cytokine secretion from BMDCs	1238:1283	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	7	48	from	BMDCs	1279:1283	arg1	secretion					1264:1272	cytokine secretion	1255:1272	cytokine secretion from BMDCs	1255:1283	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	3	49	theme	cell	431:434	arg1	interactions					436:447	host cell interactions	426:447	host cell interactions	426:447	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	3	50	theme	alg3	548:551	arg1	alg3Δ					561:565	alg3Δ	561:565	alg3Δ	561:565	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	3	50	theme	alg3	548:551	arg1	mutant					553:558	N-glycosylation-defective alg3 mutant	522:558	N-glycosylation-defective alg3 mutant (alg3Δ)	522:566	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	1	51	theme	opportunistic	172:184	arg1	neoformans					155:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	1	51	theme	opportunistic	172:184	arg1	pathogen					199:206	an opportunistic human fungal pathogen	169:206	an opportunistic human fungal pathogen causing lethal meningoencephalitis	169:241	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	0	52	theme	structures	28:37	arg1	Effects					0:6	Effects	0:6	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.	0:140	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	3	53	theme	cell	409:412	arg1	MPs					419:421	cryptococcal cell wall MPs	396:421	cryptococcal cell wall MPs in host cell interactions	396:447	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	1	54	theme	human	186:190	arg1	neoformans					155:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	1	54	theme	human	186:190	arg1	pathogen					199:206	an opportunistic human fungal pathogen	169:206	an opportunistic human fungal pathogen causing lethal meningoencephalitis	169:241	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	0	55	theme	neoformans	55:64	arg1	structures					28:37	altered N-glycan structures	11:37	altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3),	11:108	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	8	56	theme	host	1508:1511	arg1	cells					1513:1517	host cells	1508:1517	host cells	1508:1517	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	4	57	theme	protein-specific	645:660	arg1	structures					669:678	protein-specific glycan structures	645:678	protein-specific glycan structures	645:678	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	0	58	theme	Cryptococcus	42:53	arg1	MP98					81:84	MP98	81:84	MP98	81:84	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	0	58	theme	Cryptococcus	42:53	arg1	MP84					97:100	MP84	97:100	MP84	97:100	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	0	58	theme	Cryptococcus	42:53	arg1	neoformans					55:64	Cryptococcus neoformans mannoproteins	42:78	Cryptococcus neoformans mannoproteins	42:78	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	8	59	theme	host	1523:1526	arg1	response					1535:1542	host immune response	1523:1542	host immune response	1523:1542	Therefore, the structure-dependent effects of N-glycans suggested their complex roles in modulating the interaction of MPs with host cells to avoid nonspecific adherence to host cells and host immune response hyperactivation.
36670130	7	60	theme	sites	1178:1182	arg1	removal					1147:1153	the removal	1143:1153	the removal of all N-glycosylation sites on MP84	1143:1190	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	3	61	theme	N-glycosylation-defective	522:546	arg1	alg3Δ					561:565	alg3Δ	561:565	alg3Δ	561:565	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	3	61	theme	N-glycosylation-defective	522:546	arg1	mutant					553:558	N-glycosylation-defective alg3 mutant	522:558	N-glycosylation-defective alg3 mutant (alg3Δ)	522:566	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	7	62	theme	secretion	1264:1272	arg1	induction					1242:1250	the induction	1238:1250	the induction of cytokine secretion from BMDCs	1238:1283	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	6	63	theme	immune	1055:1060	arg1	response					1062:1069	the immune response	1051:1069	the immune response of bone-marrow derived dendritic cells (BMDCs)	1051:1116	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	7	64	from	removal	1147:1153	arg1	MP84					1187:1190	MP84	1187:1190	MP84	1187:1190	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	0	65	theme	host	130:133	arg1	cells					135:139	host cells	130:139	host cells	130:139	Effects of altered N-glycan structures of Cryptococcus neoformans mannoproteins, MP98 (Cda2) and MP84 (Cda3), on interaction with host cells.
36670130	6	66	dep	In	892:893	arg1	vitro					895:899	vitro	895:899	vitro	895:899	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	6	67	theme	core	955:958	arg1	N-glycans					960:968	the altered core N-glycans	943:968	the altered core N-glycans	943:968	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	2	68	theme	immunoreactive	303:316	arg1	antigens					318:325	immunoreactive antigens	303:325	immunoreactive antigens	303:325	It has several cell wall mannoproteins (MPs) identified as immunoreactive antigens.
36670130	7	69	theme	WT	1321:1322	arg1	N-glycans					1324:1332	WT N-glycans	1321:1332	WT N-glycans	1321:1332	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	1	70	theme	fungal	192:197	arg1	neoformans					155:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans	142:164	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	1	70	theme	fungal	192:197	arg1	pathogen					199:206	an opportunistic human fungal pathogen	169:206	an opportunistic human fungal pathogen causing lethal meningoencephalitis	169:241	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
36670130	3	71	dep	structure	347:355	arg1	the					343:345	the	343:345	the	343:345	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	5	72	theme	M5	860:861	arg1	mannoses					850:857	five and seven mannoses	835:857	five and seven mannoses (M5 and M7 forms)	835:875	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	5	72	theme	M5	860:861	arg1	forms					870:874	M5 and M7 forms	860:874	forms	870:874	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	7	73	from	induction	1242:1250	arg1	BMDCs					1279:1283	BMDCs	1279:1283	BMDCs	1279:1283	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	4	74	theme	glycan	662:667	arg1	structures					669:678	protein-specific glycan structures	645:678	protein-specific glycan structures	645:678	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	5	75	theme	M7	867:868	arg1	mannoses					850:857	five and seven mannoses	835:857	five and seven mannoses (M5 and M7 forms)	835:875	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	5	75	theme	M7	867:868	arg1	forms					870:874	M5 and M7 forms	860:874	forms	870:874	In alg3Δ, MP98 and MP84 had truncated core N-glycans, containing mostly five and seven mannoses (M5 and M7 forms), respectively.
36670130	3	76	from	MPs	419:421	arg1	interactions					436:447	host cell interactions	426:447	host cell interactions	426:447	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	3	77	dep	wild-type	503:511	arg1	WT					514:515	WT	514:515	WT	514:515	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	3	77	dep	wild-type	503:511	arg1	strains					568:574	strains	568:574	strains	568:574	To investigate the structure and function of N-glycans assembled on cryptococcal cell wall MPs in host cell interactions, we purified MP98 (Cda2) and MP84 (Cda3) expressed in wild-type (WT) and N-glycosylation-defective alg3 mutant (alg3Δ) strains.
36670130	6	78	theme	host	1008:1011	arg1	cells					1013:1017	host cells	1008:1017	host cells	1008:1017	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	6	79	theme	altered	947:953	arg1	N-glycans					960:968	the altered core N-glycans	943:968	the altered core N-glycans	943:968	In vitro adhesion and uptake assays indicated that the altered core N-glycans did not affect adhesion affinities to host cells although the capacity to induce the immune response of bone-marrow derived dendritic cells (BMDCs) decreased.
36670130	7	80	theme	host	1214:1217	arg1	cells					1219:1223	host cells	1214:1223	host cells	1214:1223	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	7	81	attach	removal	1147:1153	arg3	MP84					1187:1190	MP84	1187:1190	MP84	1187:1190	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	7	81	attach	removal	1147:1153	arg2	sites					1178:1182	all N-glycosylation sites	1158:1182	all N-glycosylation sites	1158:1182	Intriguingly, the removal of all N-glycosylation sites on MP84 increased adhesion to host cells and enhanced the induction of cytokine secretion from BMDCs compared with that on MP84 carrying WT N-glycans.
36670130	4	82	theme	proteins	615:622	arg1	analysis					596:603	HPLC and MALDI-TOF analysis	577:603	analysis	596:603	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	4	83	from	WT	633:634	arg1	proteins					615:622	the MP proteins	608:622	the MP proteins from the WT	608:634	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	4	83	from	WT	633:634	arg1	analysis					596:603	HPLC and MALDI-TOF analysis	577:603	analysis	596:603	HPLC and MALDI-TOF analysis of the MP proteins from the WT revealed protein-specific glycan structures with different extents of hypermannosylation and xylose/xylose phosphate addition.
36670130	1	84	theme	lethal	216:221	arg1	meningoencephalitis					223:241	lethal meningoencephalitis	216:241	lethal meningoencephalitis	216:241	Cryptococcus neoformans is an opportunistic human fungal pathogen causing lethal meningoencephalitis.
35507105	3	0	theme	glycosylation	526:538	arg1	patterns					540:547	certain O-linked glycosylation patterns	509:547	certain O-linked glycosylation patterns	509:547	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	0	1	from	signatures	12:21	arg1	insulin					91:97	O-glycosylated insulin	76:97	O-glycosylated insulin using molecular simulation	76:124	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	6	2	theme	useful	1167:1172	arg1	metrics					1174:1180	useful metrics	1167:1180	useful metrics predicting the proteolytic stability and dimerization propensity of insulin	1167:1256	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	5	3	theme	multiple	1051:1058	arg1	structures					1078:1087	multiple wild-type crystal structures	1051:1087	multiple wild-type crystal structures	1051:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	3	4	theme	proteolytic	573:583	arg1	stability					585:593	insulin's proteolytic stability	563:593	insulin's proteolytic stability	563:593	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	0	5	theme	molecular	105:113	arg1	simulation					115:124	molecular simulation	105:124	molecular simulation	105:124	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	6	6	theme	insulin	1250:1256	arg1	stability					1209:1217	proteolytic stability	1197:1217	proteolytic stability	1197:1217	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	6	6	theme	insulin	1250:1256	arg1	propensity					1236:1245	dimerization propensity	1223:1245	dimerization propensity	1223:1245	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	2	7	theme	insulin	277:283	arg1	development					257:267	The development	253:267	The development of oral insulin	253:283	The development of oral insulin remains elusive over decades owing to its susceptibility to the enzymes in the gastrointestinal tract and poor permeability through the intestinal epithelium upon dimerization.
35507105	1	8	theme	peptide	166:172	arg1	Insulin					127:133	Insulin	127:133	Insulin	127:133	Insulin has been commonly adopted as a peptide drug to treat diabetes as it facilitates the uptake of glucose from the blood.
35507105	1	8	theme	peptide	166:172	arg1	drug					174:177	a peptide drug	164:177	a peptide drug to treat diabetes as it facilitates the uptake of glucose from the blood	164:250	Insulin has been commonly adopted as a peptide drug to treat diabetes as it facilitates the uptake of glucose from the blood.
35507105	6	9	theme	proteolytic	1197:1207	arg1	stability					1209:1217	proteolytic stability	1197:1217	proteolytic stability	1197:1217	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	6	10	theme	dimerization	1223:1234	arg1	propensity					1236:1245	dimerization propensity	1223:1245	dimerization propensity	1223:1245	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	5	11	from	[Formula	951:958	arg1	properties					923:932	the properties	919:932	the properties of interest from [Formula	919:958	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	2	12	theme	oral	272:275	arg1	insulin					277:283	oral insulin	272:283	oral insulin	272:283	The development of oral insulin remains elusive over decades owing to its susceptibility to the enzymes in the gastrointestinal tract and poor permeability through the intestinal epithelium upon dimerization.
35507105	5	13	theme	aggregate	971:979	arg1	dynamics					991:998	aggregate molecular dynamics	971:998	aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures	971:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	2	14	theme	poor	391:394	arg1	permeability					396:407	poor permeability	391:407	poor permeability through the intestinal epithelium upon dimerization	391:459	The development of oral insulin remains elusive over decades owing to its susceptibility to the enzymes in the gastrointestinal tract and poor permeability through the intestinal epithelium upon dimerization.
35507105	8	15	theme	insulin	1599:1605	arg1	glycoforms					1607:1616	insulin glycoforms	1599:1616	insulin glycoforms	1599:1616	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	8	16	theme	molecular	1579:1587	arg1	design					1589:1594	rational molecular design	1570:1594	rational molecular design of insulin glycoforms	1570:1616	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	2	17	from	enzymes	349:355	arg1	tract					381:385	the gastrointestinal tract	360:385	the gastrointestinal tract	360:385	The development of oral insulin remains elusive over decades owing to its susceptibility to the enzymes in the gastrointestinal tract and poor permeability through the intestinal epithelium upon dimerization.
35507105	8	18	theme	O-linked	1445:1452	arg1	glycosylation					1454:1466	O-linked glycosylation	1445:1466	O-linked glycosylation	1445:1466	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	8	19	theme	insulin	1533:1539	arg1	propensity					1519:1528	monomeric propensity	1509:1528	monomeric propensity	1509:1528	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	8	19	theme	insulin	1533:1539	arg1	stability					1495:1503	proteolytic stability	1483:1503	proteolytic stability	1483:1503	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	5	20	theme	wild-type	1060:1068	arg1	structures					1078:1087	multiple wild-type crystal structures	1051:1087	multiple wild-type crystal structures	1051:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	7	21	theme	plausible	1361:1369	arg1	metrics					1371:1377	other plausible metrics	1355:1377	other plausible metrics	1355:1377	However, other plausible metrics were not generally predictive.
35507105	6	22	theme	glycan-dimer	1139:1150	arg1	occlusion					1152:1160	glycan-dimer occlusion	1139:1160	glycan-dimer occlusion	1139:1160	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	6	23	theme	sites	1339:1343	arg1	area					1319:1322	the solvent-accessible surface area	1288:1322	the solvent-accessible surface area of proteolytic sites	1288:1343	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	3	24	theme	dimerization	610:621	arg1	propensity					623:632	its dimerization propensity	606:632	its dimerization propensity	606:632	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	2	25	theme	gastrointestinal	364:379	arg1	tract					381:385	the gastrointestinal tract	360:385	the gastrointestinal tract	360:385	The development of oral insulin remains elusive over decades owing to its susceptibility to the enzymes in the gastrointestinal tract and poor permeability through the intestinal epithelium upon dimerization.
35507105	0	26	theme	proteolytic	26:36	arg1	stability					38:46	proteolytic stability	26:46	proteolytic stability	26:46	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	4	27	theme	dimerization	862:873	arg1	propensity					875:884	dimerization propensity	862:884	dimerization propensity	862:884	To address this challenge, we proposed and tested several structural determinants that could potentially influence insulin's proteolytic stability and dimerization propensity.
35507105	8	28	theme	rational	1570:1577	arg1	design					1589:1594	rational molecular design	1570:1594	rational molecular design of insulin glycoforms	1570:1616	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	5	29	theme	each	1003:1006	arg1	dynamics					991:998	aggregate molecular dynamics	971:998	aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures	971:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	8	30	theme	monomeric	1509:1517	arg1	propensity					1519:1528	monomeric propensity	1509:1528	monomeric propensity	1509:1528	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	2	31	theme	intestinal	421:430	arg1	epithelium					432:441	the intestinal epithelium	417:441	the intestinal epithelium upon dimerization	417:459	The development of oral insulin remains elusive over decades owing to its susceptibility to the enzymes in the gastrointestinal tract and poor permeability through the intestinal epithelium upon dimerization.
35507105	4	32	theme	structural	769:778	arg1	determinants					780:791	several structural determinants	761:791	several structural determinants that could potentially influence insulin's proteolytic stability and dimerization propensity	761:884	To address this challenge, we proposed and tested several structural determinants that could potentially influence insulin's proteolytic stability and dimerization propensity.
35507105	5	33	theme	insulin	1023:1029	arg1	glyco-variants					1031:1044	12 targeted insulin glyco-variants	1011:1044	12 targeted insulin glyco-variants from multiple wild-type crystal structures	1011:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	8	34	theme	proteolytic	1483:1493	arg1	stability					1495:1503	proteolytic stability	1483:1503	proteolytic stability	1483:1503	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	5	35	from	structures	1078:1087	arg1	glyco-variants					1031:1044	12 targeted insulin glyco-variants	1011:1044	12 targeted insulin glyco-variants from multiple wild-type crystal structures	1011:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	6	36	theme	hydrogen	1120:1127	arg1	bonds					1129:1133	glycan-involved hydrogen bonds	1104:1133	glycan-involved hydrogen bonds	1104:1133	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	1	37	from	blood	246:250	arg1	uptake					219:224	the uptake	215:224	the uptake of glucose from the blood	215:250	Insulin has been commonly adopted as a peptide drug to treat diabetes as it facilitates the uptake of glucose from the blood.
35507105	6	38	theme	glycan-involved	1104:1118	arg1	bonds					1129:1133	glycan-involved hydrogen bonds	1104:1133	glycan-involved hydrogen bonds	1104:1133	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	6	39	theme	proteolytic	1327:1337	arg1	sites					1339:1343	proteolytic sites	1327:1343	proteolytic sites	1327:1343	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	5	40	theme	interest	937:944	arg1	properties					923:932	the properties	919:932	the properties of interest from [Formula	919:958	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	3	41	theme	Recent	462:467	arg1	studies					482:488	Recent experimental studies	462:488	Recent experimental studies	462:488	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	0	42	theme	stability	38:46	arg1	signatures					12:21	signatures	12:21	signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation	12:124	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	3	43	theme	molecular	675:683	arg1	level					685:689	the molecular level	671:689	the molecular level	671:689	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	3	44	theme	experimental	469:480	arg1	studies					482:488	Recent experimental studies	462:488	Recent experimental studies	462:488	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	0	45	theme	propensity	62:71	arg1	signatures					12:21	signatures	12:21	signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation	12:124	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	5	46	used	used	890:893	arg2	We					887:888	We	887:888	We	887:888	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	8	47	link	O-linked	1445:1452	arg1	glycosylation					1454:1466	O-linked glycosylation	1445:1466	O-linked glycosylation	1445:1466	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	5	48	theme	targeted	1014:1021	arg1	glyco-variants					1031:1044	12 targeted insulin glyco-variants	1011:1044	12 targeted insulin glyco-variants from multiple wild-type crystal structures	1011:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	3	49	theme	certain	509:515	arg1	patterns					540:547	certain O-linked glycosylation patterns	509:547	certain O-linked glycosylation patterns	509:547	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	0	50	theme	monomeric	52:60	arg1	propensity					62:71	monomeric propensity	52:71	monomeric propensity	52:71	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	6	51	theme	surface	1311:1317	arg1	area					1319:1322	the solvent-accessible surface area	1288:1322	the solvent-accessible surface area of proteolytic sites	1288:1343	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	3	52	theme	O-linked	517:524	arg1	patterns					540:547	certain O-linked glycosylation patterns	509:547	certain O-linked glycosylation patterns	509:547	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	6	53	from	area	1319:1322	arg1	part					1283:1286	part	1283:1286	part	1283:1286	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	6	54	dep	stability	1209:1217	arg1	the					1193:1195	the	1193:1195	the	1193:1195	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	6	55	theme	solvent-accessible	1292:1309	arg1	area					1319:1322	the solvent-accessible surface area	1288:1322	the solvent-accessible surface area of proteolytic sites	1288:1343	We found that glycan-involved hydrogen bonds and glycan-dimer occlusion were useful metrics predicting the proteolytic stability and dimerization propensity of insulin, respectively, as was in part the solvent-accessible surface area of proteolytic sites.
35507105	4	56	theme	several	761:767	arg1	determinants					780:791	several structural determinants	761:791	several structural determinants that could potentially influence insulin's proteolytic stability and dimerization propensity	761:884	To address this challenge, we proposed and tested several structural determinants that could potentially influence insulin's proteolytic stability and dimerization propensity.
35507105	3	57	link	O-linked	517:524	arg1	patterns					540:547	certain O-linked glycosylation patterns	509:547	certain O-linked glycosylation patterns	509:547	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	8	58	theme	glycoforms	1607:1616	arg1	design					1589:1594	rational molecular design	1570:1594	rational molecular design of insulin glycoforms	1570:1616	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	4	59	theme	proteolytic	836:846	arg1	stability					848:856	insulin's proteolytic stability	826:856	insulin's proteolytic stability	826:856	To address this challenge, we proposed and tested several structural determinants that could potentially influence insulin's proteolytic stability and dimerization propensity.
35507105	5	60	theme	molecular	981:989	arg1	dynamics					991:998	aggregate molecular dynamics	971:998	aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures	971:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	1	61	theme	glucose	229:235	arg1	uptake					219:224	the uptake	215:224	the uptake of glucose from the blood	215:250	Insulin has been commonly adopted as a peptide drug to treat diabetes as it facilitates the uptake of glucose from the blood.
35507105	0	62	theme	O-glycosylated	76:89	arg1	insulin					91:97	O-glycosylated insulin	76:97	O-glycosylated insulin using molecular simulation	76:124	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	8	63	gly	glycoforms	1607:1616	arg1	insulin					1599:1605	insulin glycoforms	1599:1616	insulin glycoforms	1599:1616	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	3	64	theme	such	653:656	arg1	phenomena					658:666	such phenomena	653:666	such phenomena	653:666	Recent experimental studies have revealed that certain O-linked glycosylation patterns could enhance insulin's proteolytic stability and reduce its dimerization propensity, but understanding such phenomena at the molecular level is still difficult.
35507105	0	65	gly	O-glycosylated	76:89	arg1	insulin					91:97	O-glycosylated insulin	76:97	O-glycosylated insulin using molecular simulation	76:124	Identifying signatures of proteolytic stability and monomeric propensity in O-glycosylated insulin using molecular simulation.
35507105	8	66	dep	stability	1495:1503	arg1	the					1479:1481	the	1479:1481	the	1479:1481	This work helps better explain how O-linked glycosylation influences the proteolytic stability and monomeric propensity of insulin, illuminating a path towards rational molecular design of insulin glycoforms.
35507105	5	67	theme	crystal	1070:1076	arg1	structures					1078:1087	multiple wild-type crystal structures	1051:1087	multiple wild-type crystal structures	1051:1087	We used these metrics to assess the properties of interest from [Formula: see text] aggregate molecular dynamics of each of 12 targeted insulin glyco-variants from multiple wild-type crystal structures.
35507105	7	68	theme	other	1355:1359	arg1	metrics					1371:1377	other plausible metrics	1355:1377	other plausible metrics	1355:1377	However, other plausible metrics were not generally predictive.
36253324	3	0	gly	α1,3-fucosylation	451:467	arg1	glycans					480:486	complex glycans	472:486	complex glycans containing multiple LacNAc units	472:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	2	1	link	α1,3-linked	267:277	arg1	fucose					279:284	the α1,3-linked fucose	263:284	the α1,3-linked fucose to the oligo-LacNAc substrates	263:315	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	4	2	gly	enabling	817:824	arg1	sites					879:883	intact LacNAc sites	865:883	intact LacNAc sites	865:883	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	3	theme	simple	572:577	arg1	module					596:601	an operationally simple oxidation enzyme module	555:601	an operationally simple oxidation enzyme module	555:601	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	2	4	theme	known	215:219	arg1	FucTs					242:246	FucTs	242:246	FucTs	242:246	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	2	4	theme	known	215:219	arg1	fucosyltransferases					221:239	known fucosyltransferases	215:239	known fucosyltransferases (FucTs)	215:247	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	1	5	theme	glycans	189:195	arg1	modifications					131:143	the most common modifications	115:143	the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans	115:195	Fucosylation is one of the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans.
36253324	5	6	theme	glycans	1070:1076	arg1	fucosides					1021:1029	structurally well-defined fucosides	995:1029	structurally well-defined fucosides of linear and branched O- and N-linked glycans	995:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	5	7	dep	applicability	898:910	arg1	The					886:888	The	886:888	The	886:888	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	5	8	link	N-linked	1061:1068	arg1	glycans					1070:1076	linear and branched O- and N-linked glycans	1034:1076	glycans	1070:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	3	9	theme	general	373:379	arg1	strategy					420:427	a facile and general redox-controlled substrate engineering strategy	360:427	a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	360:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	5	10	theme	linear	1034:1039	arg1	O-					1054:1055	linear and branched O- and N-linked glycans	1034:1076	O-	1054:1055	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	5	11	theme	variety	984:990	arg1	synthesis					969:977	the synthesis	965:977	the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans	965:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	5	12	theme	general	890:896	arg1	applicability					898:910	general applicability	890:910	general applicability	890:910	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	2	13	theme	oligo-LacNAc	293:304	arg1	substrates					306:315	the oligo-LacNAc substrates	289:315	the oligo-LacNAc substrates	289:315	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	3	14	theme	glycans	480:486	arg1	α1,3-fucosylation					451:467	the site-specific α1,3-fucosylation	433:467	the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	433:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	3	15	theme	facile	362:367	arg1	strategy					420:427	a facile and general redox-controlled substrate engineering strategy	360:427	a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	360:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	5	16	theme	branched	1045:1052	arg1	O-					1054:1055	linear and branched O- and N-linked glycans	1034:1076	O-	1054:1055	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	0	17	theme	Redox-Controlled	2:17	arg1	Strategy					41:48	A Redox-Controlled Substrate Engineering Strategy	0:48	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation	0:89	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation.
36253324	4	18	theme	galactose	612:620	arg1	GOase					631:635	GOase	631:635	GOase	631:635	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	18	theme	galactose	612:620	arg1	oxidase					622:628	galactose oxidase	612:628	galactose oxidase (GOase)	612:636	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	19	from	strain	790:795	arg1	α1,3-FucT					755:763	recombinant α1,3-FucT	743:763	recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT)	743:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	20	theme	pylori	783:788	arg1	strain					790:795	Helicobacter pylori strain 26695	770:801	Helicobacter pylori strain 26695 (Hpα1,3FucT)	770:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	20	theme	pylori	783:788	arg1	Hpα1,3FucT					804:813	Hpα1,3FucT	804:813	Hpα1,3FucT	804:813	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	3	21	theme	complex	472:478	arg1	glycans					480:486	complex glycans	472:486	complex glycans containing multiple LacNAc units	472:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	0	22	theme	Engineering	29:39	arg1	Strategy					41:48	A Redox-Controlled Substrate Engineering Strategy	0:48	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation	0:89	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation.
36253324	5	23	theme	N-linked	1061:1068	arg1	glycans					1070:1076	linear and branched O- and N-linked glycans	1034:1076	glycans	1070:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	2	24	theme	site-specific	322:334	arg1	manner					336:341	a site-specific manner	320:341	a site-specific manner	320:341	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	4	25	theme	C6'-aldehyde	679:690	arg1	substrate					729:737	a good substrate	722:737	a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT)	722:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	25	theme	C6'-aldehyde	679:690	arg1	sequence					699:706	oxidized C6'-aldehyde LacNAc sequence	670:706	oxidized C6'-aldehyde LacNAc sequence	670:706	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	3	26	theme	substrate	398:406	arg1	strategy					420:427	a facile and general redox-controlled substrate engineering strategy	360:427	a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	360:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	5	27	theme	fucosides	1021:1029	arg1	fucosides					1021:1029	structurally well-defined fucosides	995:1029	structurally well-defined fucosides of linear and branched O- and N-linked glycans	995:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	5	27	theme	fucosides	1021:1029	arg1	variety					984:990	a variety	982:990	a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans	982:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	4	28	theme	oxidized	670:677	arg1	substrate					729:737	a good substrate	722:737	a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT)	722:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	28	theme	oxidized	670:677	arg1	sequence					699:706	oxidized C6'-aldehyde LacNAc sequence	670:706	oxidized C6'-aldehyde LacNAc sequence	670:706	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	3	29	theme	site-specific	437:449	arg1	α1,3-fucosylation					451:467	the site-specific α1,3-fucosylation	433:467	the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	433:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	4	30	theme	recombinant	743:753	arg1	α1,3-FucT					755:763	recombinant α1,3-FucT	743:763	recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT)	743:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	31	theme	LacNAc	872:877	arg1	sites					879:883	intact LacNAc sites	865:883	intact LacNAc sites	865:883	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	5	32	theme	strategy	935:942	arg1	applicability					898:910	general applicability	890:910	general applicability	890:910	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	5	32	theme	strategy	935:942	arg1	robustness					916:925	robustness	916:925	robustness	916:925	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	3	33	theme	multiple	499:506	arg1	units					515:519	multiple LacNAc units	499:519	multiple LacNAc units	499:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	4	34	theme	enzyme	589:594	arg1	module					596:601	an operationally simple oxidation enzyme module	555:601	an operationally simple oxidation enzyme module	555:601	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	3	35	theme	redox-controlled	381:396	arg1	strategy					420:427	a facile and general redox-controlled substrate engineering strategy	360:427	a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	360:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	3	36	theme	LacNAc	508:513	arg1	units					515:519	multiple LacNAc units	499:519	multiple LacNAc units	499:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	0	37	theme	Enzymatic	68:76	arg1	Fucosylation					78:89	Site-Specific Enzymatic Fucosylation	54:89	Site-Specific Enzymatic Fucosylation	54:89	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation.
36253324	4	38	theme	oxidation	579:587	arg1	module					596:601	an operationally simple oxidation enzyme module	555:601	an operationally simple oxidation enzyme module	555:601	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	1	39	theme	common	124:129	arg1	modifications					131:143	the most common modifications	115:143	the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans	115:195	Fucosylation is one of the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans.
36253324	0	40	theme	Site-Specific	54:66	arg1	Fucosylation					78:89	Site-Specific Enzymatic Fucosylation	54:89	Site-Specific Enzymatic Fucosylation	54:89	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation.
36253324	1	41	theme	oligo-LacNAc	175:186	arg1	glycans					189:195	oligo-N-acetyllactosamine (oligo-LacNAc) glycans	148:195	oligo-N-acetyllactosamine (oligo-LacNAc) glycans	148:195	Fucosylation is one of the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans.
36253324	1	42	theme	modifications	131:143	arg1	modifications					131:143	the most common modifications	115:143	the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans	115:195	Fucosylation is one of the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans.
36253324	1	42	theme	modifications	131:143	arg1	one					108:110	one	108:110	one	108:110	Fucosylation is one of the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans.
36253324	4	43	theme	module	596:601	arg1	advantage					542:550	advantage	542:550	advantage of an operationally simple oxidation enzyme module	542:601	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	2	44	theme	fucosyltransferases	221:239	arg1	none					207:210	none	207:210	none of known fucosyltransferases (FucTs)	207:247	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	4	45	theme	site-specific	830:842	arg1	α1,3-fucosylation					844:860	the site-specific α1,3-fucosylation	826:860	the site-specific α1,3-fucosylation	826:860	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	46	theme	intact	865:870	arg1	sites					879:883	intact LacNAc sites	865:883	intact LacNAc sites	865:883	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	47	theme	Helicobacter	770:781	arg1	strain					790:795	Helicobacter pylori strain 26695	770:801	Helicobacter pylori strain 26695 (Hpα1,3FucT)	770:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	47	theme	Helicobacter	770:781	arg1	Hpα1,3FucT					804:813	Hpα1,3FucT	804:813	Hpα1,3FucT	804:813	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	5	48	theme	well-defined	1008:1019	arg1	fucosides					1021:1029	structurally well-defined fucosides	995:1029	structurally well-defined fucosides of linear and branched O- and N-linked glycans	995:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	4	49	theme	LacNAc	653:658	arg1	unit					660:663	the LacNAc unit	649:663	the LacNAc unit	649:663	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	3	50	contain	containing	488:497	arg1	glycans					480:486	complex glycans	472:486	complex glycans containing multiple LacNAc units	472:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	3	50	contain	containing	488:497	arg2	units					515:519	multiple LacNAc units	499:519	multiple LacNAc units	499:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
36253324	1	51	theme	oligo-N-acetyllactosamine	148:172	arg1	glycans					189:195	oligo-N-acetyllactosamine (oligo-LacNAc) glycans	148:195	oligo-N-acetyllactosamine (oligo-LacNAc) glycans	148:195	Fucosylation is one of the most common modifications of oligo-N-acetyllactosamine (oligo-LacNAc) glycans.
36253324	4	52	theme	LacNAc	692:697	arg1	substrate					729:737	a good substrate	722:737	a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT)	722:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	52	theme	LacNAc	692:697	arg1	sequence					699:706	oxidized C6'-aldehyde LacNAc sequence	670:706	oxidized C6'-aldehyde LacNAc sequence	670:706	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	2	53	theme	α1,3-linked	267:277	arg1	fucose					279:284	the α1,3-linked fucose	263:284	the α1,3-linked fucose to the oligo-LacNAc substrates	263:315	However, none of known fucosyltransferases (FucTs) could install the α1,3-linked fucose to the oligo-LacNAc substrates in a site-specific manner.
36253324	4	54	theme	good	724:727	arg1	substrate					729:737	a good substrate	722:737	a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT)	722:814	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	4	54	theme	good	724:727	arg1	sequence					699:706	oxidized C6'-aldehyde LacNAc sequence	670:706	oxidized C6'-aldehyde LacNAc sequence	670:706	This strategy takes advantage of an operationally simple oxidation enzyme module by using galactose oxidase (GOase) to convert the LacNAc unit into oxidized C6'-aldehyde LacNAc sequence, which is not a good substrate for recombinant α1,3-FucT from Helicobacter pylori strain 26695 (Hpα1,3FucT), enabling the site-specific α1,3-fucosylation at intact LacNAc sites.
36253324	5	55	theme	O-	1054:1055	arg1	fucosides					1021:1029	structurally well-defined fucosides	995:1029	structurally well-defined fucosides of linear and branched O- and N-linked glycans	995:1076	The general applicability and robustness of this strategy were demonstrated by the synthesis of a variety of structurally well-defined fucosides of linear and branched O- and N-linked glycans.
36253324	0	56	theme	Substrate	19:27	arg1	Strategy					41:48	A Redox-Controlled Substrate Engineering Strategy	0:48	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation	0:89	A Redox-Controlled Substrate Engineering Strategy for Site-Specific Enzymatic Fucosylation.
36253324	3	57	theme	engineering	408:418	arg1	strategy					420:427	a facile and general redox-controlled substrate engineering strategy	360:427	a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units	360:519	Here, we report a facile and general redox-controlled substrate engineering strategy for the site-specific α1,3-fucosylation of complex glycans containing multiple LacNAc units.
35913158	5	0	link	plant-derived	1243:1255	arg1	nutrients					1257:1265	plant-derived nutrients	1243:1265	plant-derived nutrients that widely vary in size and structure	1243:1304	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	2	1	theme	tuber	369:373	arg1	crops					375:379	root and tuber crops	360:379	crops	375:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	9	2	theme	hydrolytic	1750:1759	arg1	complexes					1771:1779	hydrolytic enzymatic complexes	1750:1779	hydrolytic enzymatic complexes	1750:1779	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	2	3	from	scab	352:355	arg1	crops					375:379	root and tuber crops	360:379	crops	375:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	3	4	theme	types	769:773	arg1	moiety					748:753	the glucose moiety	736:753	the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	736:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	6	5	theme	only	1337:1340	arg1	substrate					1342:1350	the only substrate	1333:1350	the only substrate commonly hydrolyzed by both BglC and BcpE2, thereby generating the potent virulence inhibitor scopoletin	1333:1455	Importantly, scopolin was the only substrate commonly hydrolyzed by both BglC and BcpE2, thereby generating the potent virulence inhibitor scopoletin.
35913158	6	5	theme	only	1337:1340	arg1	scopolin					1320:1327	scopolin	1320:1327	scopolin	1320:1327	Importantly, scopolin was the only substrate commonly hydrolyzed by both BglC and BcpE2, thereby generating the potent virulence inhibitor scopoletin.
35913158	7	6	theme	virulence	1536:1544	arg1	strength					1524:1531	the strength	1520:1531	the strength of virulence	1520:1544	Next to fueling glycolysis, both enzymes would also fine-tune the strength of virulence.
35913158	9	7	theme	complexes	1771:1779	arg1	arsenal					1739:1745	an arsenal	1736:1745	an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides	1736:1866	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	4	8	theme	BcpE2	914:918	arg1	analysis					930:937	BcpE2 structure analysis	914:937	BcpE2 structure analysis	914:937	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	1	9	theme	key	218:220	arg1	Cellulose					102:110	Cellulose	102:110	Cellulose being the most abundant polysaccharide on earth	102:158	Cellulose being the most abundant polysaccharide on earth, beta-glucosidases hydrolyzing cello-oligosaccharides are key enzymes to fuel glycolysis in microorganisms developing on plant material.
35913158	1	9	theme	key	218:220	arg1	enzymes					222:228	key enzymes	218:228	key enzymes	218:228	Cellulose being the most abundant polysaccharide on earth, beta-glucosidases hydrolyzing cello-oligosaccharides are key enzymes to fuel glycolysis in microorganisms developing on plant material.
35913158	3	10	theme	plant-derived	778:790	arg1	heterosides					792:802	plant-derived heterosides	778:802	plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	778:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	11	theme	compensating	592:603	arg1	able					720:723	able	720:723	able	720:723	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	11	theme	compensating	592:603	arg1	beta-glucosidase					637:652	the GH3-family beta-glucosidase	622:652	the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	622:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	11	theme	compensating	592:603	arg1	BcpE2					612:616	the BglC compensating enzyme BcpE2	583:616	the BglC compensating enzyme BcpE2	583:616	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	9	12	contain	possess	1728:1734	arg1	microorganisms					1713:1726	microorganisms	1713:1726	microorganisms	1713:1726	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	9	12	contain	possess	1728:1734	arg2	arsenal					1739:1745	an arsenal	1736:1745	an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides	1736:1866	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	3	13	theme	monolignol	824:833	arg1	glucosides					835:844	monolignol glucosides	824:844	monolignol glucosides	824:844	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	9	14	theme	polysaccharides	1813:1827	arg1	types					1804:1808	the various types	1792:1808	the various types of polysaccharides, oligosaccharides, and monosaccharides	1792:1866	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	10	15	theme	multitude	2041:2049	arg1	moiety					2029:2034	the glucose moiety	2017:2034	the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin	2017:2118	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	11	16	link	plant-derived	2235:2247	arg1	material					2249:2256	plant-derived material	2235:2256	plant-derived material	2235:2256	This enzyme would provide the microorganisms with a tool that would allow them to find nutrients from any type of plant-derived material.
35913158	9	17	theme	oligosaccharides	1830:1845	arg1	types					1804:1808	the various types	1792:1808	the various types of polysaccharides, oligosaccharides, and monosaccharides	1792:1866	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	4	18	from	cavity	959:964	arg1	domain					978:983	the PA14 domain	969:983	the PA14 domain that covered the active site	969:1012	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	3	19	theme	highest	673:679	arg1	promiscuity					700:710	the highest reported substrate promiscuity	669:710	the highest reported substrate promiscuity	669:710	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	2	20	theme	alternative	529:539	arg1	beta-glucosidases					541:557	alternative beta-glucosidases	529:557	alternative beta-glucosidases	529:557	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	8	21	theme	Plant	1558:1562	arg1	provider					1602:1609	the most abundant provider	1584:1609	the most abundant provider of carbon sources for soil-dwelling microorganisms	1584:1660	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	8	21	theme	Plant	1558:1562	arg1	biomass					1573:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	0	22	theme	Promiscuous	42:52	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	22	theme	Promiscuous	42:52	arg1	Beta-Glucosidase					84:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	10	23	theme	expression	1910:1919	arg1	studies					1921:1927	expression studies	1910:1927	expression studies	1910:1927	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	9	24	theme	various	1796:1802	arg1	types					1804:1808	the various types	1792:1808	the various types of polysaccharides, oligosaccharides, and monosaccharides	1792:1866	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	11	25	theme	material	2249:2256	arg1	type					2227:2230	any type	2223:2230	any type of plant-derived material	2223:2256	This enzyme would provide the microorganisms with a tool that would allow them to find nutrients from any type of plant-derived material.
35913158	0	26	theme	Glucose	65:71	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	26	theme	Glucose	65:71	arg1	Beta-Glucosidase					84:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	4	27	theme	active	1002:1007	arg1	site					1009:1012	the active site	998:1012	the active site	998:1012	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	6	28	theme	virulence	1426:1434	arg1	scopoletin					1446:1455	the potent virulence inhibitor scopoletin	1415:1455	the potent virulence inhibitor scopoletin	1415:1455	Importantly, scopolin was the only substrate commonly hydrolyzed by both BglC and BcpE2, thereby generating the potent virulence inhibitor scopoletin.
35913158	5	29	theme	substrate	1143:1151	arg1	promiscuity					1153:1163	The exceptional substrate promiscuity	1127:1163	The exceptional substrate promiscuity of BcpE2	1127:1172	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	8	30	theme	abundant	1593:1600	arg1	provider					1602:1609	the most abundant provider	1584:1609	the most abundant provider of carbon sources for soil-dwelling microorganisms	1584:1660	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	8	30	theme	abundant	1593:1600	arg1	biomass					1573:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	2	31	theme	cello-oligosaccharide	461:481	arg1	BglC					493:496	the cello-oligosaccharide hydrolase BglC	457:496	the cello-oligosaccharide hydrolase BglC	457:496	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	2	32	theme	compensation	392:403	arg1	phenomenon					405:414	a genetic compensation phenomenon	382:414	a genetic compensation phenomenon	382:414	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	8	33	theme	sources	1621:1627	arg1	provider					1602:1609	the most abundant provider	1584:1609	the most abundant provider of carbon sources for soil-dwelling microorganisms	1584:1660	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	8	33	theme	sources	1621:1627	arg1	biomass					1573:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	8	34	theme	soil-dwelling	1633:1645	arg1	microorganisms					1647:1660	soil-dwelling microorganisms	1633:1660	soil-dwelling microorganisms	1633:1660	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	0	35	theme	BcpE2	26:30	arg1	Function					14:21	Function	14:21	Function	14:21	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	35	theme	BcpE2	26:30	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	35	theme	BcpE2	26:30	arg1	Beta-Glucosidase					84:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	9	36	theme	such	1686:1689	arg1	niches					1705:1710	such environmental niches	1686:1710	such environmental niches	1686:1710	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	3	37	theme	substrate	690:698	arg1	promiscuity					700:710	the highest reported substrate promiscuity	669:710	the highest reported substrate promiscuity	669:710	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	5	38	theme	scavenging	1219:1228	arg1	glucose					1230:1236	scavenging glucose	1219:1236	scavenging glucose from plant-derived nutrients that widely vary in size and structure	1219:1304	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	2	39	from	safeguards	416:425	arg1	agent					336:340	the causative agent	322:340	the causative agent of common scab in root and tuber crops	322:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	2	39	from	safeguards	416:425	arg1	scabiei					313:319	Streptomyces scabiei	300:319	Streptomyces scabiei	300:319	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	10	40	theme	"	1974:1974	arg1	able					2000:2003	able	2000:2003	able	2000:2003	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	40	theme	"	1974:1974	arg1	BcpE2					1984:1988	BcpE2	1984:1988	BcpE2	1984:1988	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	40	theme	"	1974:1974	arg1	enzyme					1976:1981	a "swiss-army knife" enzyme	1955:1981	a "swiss-army knife" enzyme	1955:1981	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	41	theme	swiss-army	1958:1967	arg1	able					2000:2003	able	2000:2003	able	2000:2003	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	41	theme	swiss-army	1958:1967	arg1	BcpE2					1984:1988	BcpE2	1984:1988	BcpE2	1984:1988	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	41	theme	swiss-army	1958:1967	arg1	enzyme					1976:1981	a "swiss-army knife" enzyme	1955:1981	a "swiss-army knife" enzyme	1955:1981	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	2	42	from	agent	336:340	arg1	crops					375:379	root and tuber crops	360:379	crops	375:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	10	43	theme	substrates	2068:2077	arg1	multitude					2041:2049	a multitude	2039:2049	a multitude of plant-derived substrates that vary in size, structure, and origin	2039:2118	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	4	44	theme	cavity	1093:1098	arg1	adjustment					1074:1083	proper adjustment	1067:1083	proper adjustment of this cavity for disparate heterosides	1067:1124	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	11	45	from	type	2227:2230	arg1	nutrients					2208:2216	nutrients	2208:2216	nutrients from any type of plant-derived material	2208:2256	This enzyme would provide the microorganisms with a tool that would allow them to find nutrients from any type of plant-derived material.
35913158	1	46	theme	plant	281:285	arg1	material					287:294	plant material	281:294	plant material	281:294	Cellulose being the most abundant polysaccharide on earth, beta-glucosidases hydrolyzing cello-oligosaccharides are key enzymes to fuel glycolysis in microorganisms developing on plant material.
35913158	4	47	theme	structure	920:928	arg1	analysis					930:937	BcpE2 structure analysis	914:937	BcpE2 structure analysis	914:937	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	4	48	theme	disparate	1104:1112	arg1	heterosides					1114:1124	disparate heterosides	1104:1124	disparate heterosides	1104:1124	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	3	49	theme	glucose	740:746	arg1	moiety					748:753	the glucose moiety	736:753	the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	736:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	2	50	theme	common	345:350	arg1	scab					352:355	common scab	345:355	common scab in root and tuber crops	345:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	9	51	theme	enzymatic	1761:1769	arg1	complexes					1771:1779	hydrolytic enzymatic complexes	1750:1779	hydrolytic enzymatic complexes	1750:1779	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	10	52	theme	glucose	2021:2027	arg1	moiety					2029:2034	the glucose moiety	2017:2034	the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin	2017:2118	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	5	53	from	nutrients	1257:1265	arg1	glucose					1230:1236	scavenging glucose	1219:1236	scavenging glucose from plant-derived nutrients that widely vary in size and structure	1219:1304	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	2	54	theme	hydrolase	483:491	arg1	BglC					493:496	the cello-oligosaccharide hydrolase BglC	457:496	the cello-oligosaccharide hydrolase BglC	457:496	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	2	55	from	crops	375:379	arg1	agent					336:340	the causative agent	322:340	the causative agent of common scab in root and tuber crops	322:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	2	55	from	crops	375:379	arg1	scabiei					313:319	Streptomyces scabiei	300:319	Streptomyces scabiei	300:319	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	3	56	theme	tested	762:767	arg1	types					769:773	all tested types	758:773	all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	758:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	57	theme	enzyme	605:610	arg1	able					720:723	able	720:723	able	720:723	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	57	theme	enzyme	605:610	arg1	beta-glucosidase					637:652	the GH3-family beta-glucosidase	622:652	the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	622:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	57	theme	enzyme	605:610	arg1	BcpE2					612:616	the BglC compensating enzyme BcpE2	583:616	the BglC compensating enzyme BcpE2	583:616	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	58	theme	aryl	805:808	arg1	β-glucosides					810:821	aryl β-glucosides	805:821	aryl β-glucosides	805:821	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	59	theme	BglC	587:590	arg1	able					720:723	able	720:723	able	720:723	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	59	theme	BglC	587:590	arg1	beta-glucosidase					637:652	the GH3-family beta-glucosidase	622:652	the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	622:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	59	theme	BglC	587:590	arg1	BcpE2					612:616	the BglC compensating enzyme BcpE2	583:616	the BglC compensating enzyme BcpE2	583:616	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	4	60	theme	PA14	973:976	arg1	domain					978:983	the PA14 domain	969:983	the PA14 domain that covered the active site	969:1012	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	3	61	theme	heterosides	792:802	arg1	types					769:773	all tested types	758:773	all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	758:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	62	theme	GH3-family	626:635	arg1	able					720:723	able	720:723	able	720:723	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	62	theme	GH3-family	626:635	arg1	beta-glucosidase					637:652	the GH3-family beta-glucosidase	622:652	the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	622:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	62	theme	GH3-family	626:635	arg1	BcpE2					612:616	the BglC compensating enzyme BcpE2	583:616	the BglC compensating enzyme BcpE2	583:616	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	5	63	theme	exceptional	1131:1141	arg1	promiscuity					1153:1163	The exceptional substrate promiscuity	1127:1163	The exceptional substrate promiscuity of BcpE2	1127:1172	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	1	64	from	glycolysis	238:247	arg1	microorganisms					252:265	microorganisms	252:265	microorganisms developing on plant material	252:294	Cellulose being the most abundant polysaccharide on earth, beta-glucosidases hydrolyzing cello-oligosaccharides are key enzymes to fuel glycolysis in microorganisms developing on plant material.
35913158	4	65	theme	large	953:957	arg1	cavity					959:964	a large cavity	951:964	a large cavity in the PA14 domain that covered the active site	951:1012	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	8	66	theme	IMPORTANCE	1547:1556	arg1	provider					1602:1609	the most abundant provider	1584:1609	the most abundant provider of carbon sources for soil-dwelling microorganisms	1584:1660	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	8	66	theme	IMPORTANCE	1547:1556	arg1	biomass					1573:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	1	67	theme	abundant	127:134	arg1	polysaccharide					136:149	the most abundant polysaccharide	118:149	the most abundant polysaccharide on earth	118:158	Cellulose being the most abundant polysaccharide on earth, beta-glucosidases hydrolyzing cello-oligosaccharides are key enzymes to fuel glycolysis in microorganisms developing on plant material.
35913158	10	68	link	plant-derived	2054:2066	arg1	substrates					2068:2077	plant-derived substrates	2054:2077	plant-derived substrates that vary in size, structure, and origin	2054:2118	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	8	69	theme	decaying	1564:1571	arg1	provider					1602:1609	the most abundant provider	1584:1609	the most abundant provider of carbon sources for soil-dwelling microorganisms	1584:1660	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	8	69	theme	decaying	1564:1571	arg1	biomass					1573:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass	1547:1579	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	3	70	link	plant-derived	778:790	arg1	heterosides					792:802	plant-derived heterosides	778:802	plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides)	778:911	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	0	71	theme	GH3-Family	54:63	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	71	theme	GH3-Family	54:63	arg1	Beta-Glucosidase					84:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	9	72	theme	monosaccharides	1852:1866	arg1	types					1804:1808	the various types	1792:1808	the various types of polysaccharides, oligosaccharides, and monosaccharides	1792:1866	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	3	73	theme	cyanogenic	847:856	arg1	glucosides					858:867	cyanogenic glucosides	847:867	cyanogenic glucosides	847:867	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	0	74	theme	Scavenging	73:82	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	74	theme	Scavenging	73:82	arg1	Beta-Glucosidase					84:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	3	75	dep	heterosides	792:802	arg1	glucosides					858:867	cyanogenic glucosides	847:867	cyanogenic glucosides	847:867	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	75	dep	heterosides	792:802	arg1	heterosides					900:910	coumarin heterosides	891:910	coumarin heterosides	891:910	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	75	dep	heterosides	792:802	arg1	anthocyanosides					870:884	anthocyanosides	870:884	anthocyanosides	870:884	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	75	dep	heterosides	792:802	arg1	β-glucosides					810:821	aryl β-glucosides	805:821	aryl β-glucosides	805:821	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	3	75	dep	heterosides	792:802	arg1	glucosides					835:844	monolignol glucosides	824:844	monolignol glucosides	824:844	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	4	76	theme	high	1023:1026	arg1	flexibility					1028:1038	the high flexibility	1019:1038	the high flexibility of this domain	1019:1053	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	3	77	theme	coumarin	891:898	arg1	heterosides					900:910	coumarin heterosides	891:910	coumarin heterosides	891:910	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	6	78	theme	inhibitor	1436:1444	arg1	scopoletin					1446:1455	the potent virulence inhibitor scopoletin	1415:1455	the potent virulence inhibitor scopoletin	1415:1455	Importantly, scopolin was the only substrate commonly hydrolyzed by both BglC and BcpE2, thereby generating the potent virulence inhibitor scopoletin.
35913158	5	79	theme	versatile	1200:1208	arg1	tool					1210:1213	a versatile tool	1198:1213	a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure	1198:1304	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	2	80	theme	causative	326:334	arg1	agent					336:340	the causative agent	322:340	the causative agent of common scab in root and tuber crops	322:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	2	80	theme	causative	326:334	arg1	scabiei					313:319	Streptomyces scabiei	300:319	Streptomyces scabiei	300:319	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	6	81	theme	potent	1419:1424	arg1	scopoletin					1446:1455	the potent virulence inhibitor scopoletin	1415:1455	the potent virulence inhibitor scopoletin	1415:1455	Importantly, scopolin was the only substrate commonly hydrolyzed by both BglC and BcpE2, thereby generating the potent virulence inhibitor scopoletin.
35913158	2	82	theme	beta-glucosidases	541:557	arg1	expression					515:524	the expression	511:524	the expression of alternative beta-glucosidases	511:557	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	8	83	theme	carbon	1614:1619	arg1	sources					1621:1627	carbon sources	1614:1627	carbon sources	1614:1627	IMPORTANCE Plant decaying biomass is the most abundant provider of carbon sources for soil-dwelling microorganisms.
35913158	5	84	theme	BcpE2	1168:1172	arg1	promiscuity					1153:1163	The exceptional substrate promiscuity	1127:1163	The exceptional substrate promiscuity of BcpE2	1127:1172	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	1	85	from	polysaccharide	136:149	arg1	earth					154:158	earth	154:158	earth	154:158	Cellulose being the most abundant polysaccharide on earth, beta-glucosidases hydrolyzing cello-oligosaccharides are key enzymes to fuel glycolysis in microorganisms developing on plant material.
35913158	2	86	theme	genetic	384:390	arg1	phenomenon					405:414	a genetic compensation phenomenon	382:414	a genetic compensation phenomenon	382:414	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	5	87	theme	plant-derived	1243:1255	arg1	nutrients					1257:1265	plant-derived nutrients	1243:1265	plant-derived nutrients that widely vary in size and structure	1243:1304	The exceptional substrate promiscuity of BcpE2 provides microorganisms a versatile tool for scavenging glucose from plant-derived nutrients that widely vary in size and structure.
35913158	2	88	theme	gene	443:446	arg1	loss					431:434	the loss	427:434	the loss of the gene encoding the cello-oligosaccharide hydrolase BglC	427:496	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	11	89	theme	plant-derived	2235:2247	arg1	material					2249:2256	plant-derived material	2235:2256	plant-derived material	2235:2256	This enzyme would provide the microorganisms with a tool that would allow them to find nutrients from any type of plant-derived material.
35913158	3	90	theme	reported	681:688	arg1	promiscuity					700:710	the highest reported substrate promiscuity	669:710	the highest reported substrate promiscuity	669:710	Here, we revealed that the BglC compensating enzyme BcpE2 was the GH3-family beta-glucosidase that displayed the highest reported substrate promiscuity and was able to release the glucose moiety of all tested types of plant-derived heterosides (aryl β-glucosides, monolignol glucosides, cyanogenic glucosides, anthocyanosides, and coumarin heterosides).
35913158	0	91	theme	Most	37:40	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	0	91	theme	Most	37:40	arg1	Beta-Glucosidase					84:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase	33:99	Structure and Function of BcpE2, the Most Promiscuous GH3-Family Glucose Scavenging Beta-Glucosidase.
35913158	10	92	theme	plant-derived	2054:2066	arg1	substrates					2068:2077	plant-derived substrates	2054:2077	plant-derived substrates that vary in size, structure, and origin	2054:2118	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	9	93	theme	environmental	1691:1703	arg1	niches					1705:1710	such environmental niches	1686:1710	such environmental niches	1686:1710	To optimally evolve in such environmental niches, microorganisms possess an arsenal of hydrolytic enzymatic complexes to feed on the various types of polysaccharides, oligosaccharides, and monosaccharides.
35913158	4	94	theme	domain	1048:1053	arg1	flexibility					1028:1038	the high flexibility	1019:1038	the high flexibility of this domain	1019:1053	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
35913158	10	95	theme	enzyme	1976:1981	arg1	existence					1942:1950	the existence	1938:1950	the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin	1938:2118	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	2	96	theme	root	360:363	arg1	crops					375:379	root and tuber crops	360:379	crops	375:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	10	97	theme	knife	1969:1973	arg1	able					2000:2003	able	2000:2003	able	2000:2003	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	97	theme	knife	1969:1973	arg1	BcpE2					1984:1988	BcpE2	1984:1988	BcpE2	1984:1988	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	10	97	theme	knife	1969:1973	arg1	enzyme					1976:1981	a "swiss-army knife" enzyme	1955:1981	a "swiss-army knife" enzyme	1955:1981	In this work, structural, enzymatic, and expression studies revealed the existence of a "swiss-army knife" enzyme, BcpE2, that was able to retrieve the glucose moiety of a multitude of plant-derived substrates that vary in size, structure, and origin.
35913158	2	98	theme	scab	352:355	arg1	agent					336:340	the causative agent	322:340	the causative agent of common scab in root and tuber crops	322:379	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	2	98	theme	scab	352:355	arg1	scabiei					313:319	Streptomyces scabiei	300:319	Streptomyces scabiei	300:319	In Streptomyces scabiei, the causative agent of common scab in root and tuber crops, a genetic compensation phenomenon safeguards the loss of the gene encoding the cello-oligosaccharide hydrolase BglC by awakening the expression of alternative beta-glucosidases.
35913158	4	99	theme	proper	1067:1072	arg1	adjustment					1074:1083	proper adjustment	1067:1083	proper adjustment of this cavity for disparate heterosides	1067:1124	BcpE2 structure analysis highlighted a large cavity in the PA14 domain that covered the active site, and the high flexibility of this domain would allow proper adjustment of this cavity for disparate heterosides.
36740532	0	0	theme	glycoprotein	35:46	arg1	analysis					14:21	Comprehensive analysis	0:21	Comprehensive analysis of platelet glycoprotein	0:46	Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation.
36740532	6	1	theme	blood	1050:1054	arg1	antigens					1062:1069	ABO(H) blood group antigens	1043:1069	ABO(H) blood group antigens	1043:1069	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	10	2	located	located	1347:1353	arg2	Glycosites					1327:1336	Glycosites	1327:1336	Glycosites	1327:1336	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	10	2	located	located	1347:1353	arg1	domain					1384:1389	macroglycopeptide domain	1366:1389	macroglycopeptide domain	1366:1389	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	10	2	located	located	1347:1353	arg1	domain					1410:1415	mechanosensory domain	1395:1415	mechanosensory domain	1395:1415	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	2	3	theme	factor	337:342	arg1	binding					344:350	von Willebrand factor binding	322:350	von Willebrand factor binding	322:350	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	2	3	theme	factor	337:342	arg1	clearance					311:319	platelet clearance	302:319	platelet clearance	302:319	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	5	4	gly	glycosites	873:882	arg2	glycosites					873:882	glycosites	873:882	glycosites	873:882	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	5	4	gly	glycosites	873:882	arg2	glycans					919:925	the attached glycans	906:925	the attached glycans	906:925	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	5	4	gly	glycosites	873:882	arg1	glycans					919:925	the attached glycans	906:925	the attached glycans	906:925	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	1	5	theme	major	127:131	arg1	subunit					148:154	the major ligand-binding subunit	123:154	the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor	123:212	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	5	theme	major	127:131	arg1	Ibα					116:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	4	6	theme	GPIbα	584:588	arg1	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	6	theme	GPIbα	584:588	arg1	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	6	theme	GPIbα	584:588	arg1	sites					601:605	GPIbα amino acid sites	584:605	GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	584:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	5	7	dep	blot	784:787	arg1	analysis					854:861	glycopeptide analysis	841:861	glycopeptide analysis	841:861	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	8	8	theme	protein	1188:1194	arg1	analysis					1161:1168	the analysis	1157:1168	the analysis of the endogenous protein purified from platelets	1157:1218	In the analysis of the endogenous protein purified from platelets, we identified 48 unique O-glycosites and 1 N-glycosite.
36740532	5	9	theme	spectrometry	795:806	arg1	glycomics					808:816	mass spectrometry glycomics	790:816	mass spectrometry glycomics	790:816	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	5	10	gly	glycopeptide	841:852	arg2	glycopeptide					841:852	glycopeptide analysis	841:861	glycopeptide analysis	841:861	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	10	11	theme	macroglycopeptide	1366:1382	arg1	domain					1384:1389	macroglycopeptide domain	1366:1389	macroglycopeptide domain	1366:1389	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	1	12	theme	von	192:194	arg1	factor					207:212	von Willebrand factor	192:212	von Willebrand factor	192:212	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	2	13	theme	key	289:291	arg1	roles					293:297	key roles	289:297	key roles	289:297	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	5	14	theme	mass	823:826	arg1	spectrometry					828:839	mass spectrometry	823:839	mass spectrometry	823:839	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	6	15	theme	diverse	952:958	arg1	repertoire					960:969	a diverse repertoire	950:969	a diverse repertoire	950:969	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	15	theme	diverse	952:958	arg1	O-glycans					981:989	O-glycans	981:989	O-glycans	981:989	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	15	theme	diverse	952:958	arg1	N-					974:975	N-	974:975	N-	974:975	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	16	dep	RESULTS	928:934	arg1	identified					939:948	identified	939:948	identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens	939:1069	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	5	17	theme	glycopeptide	841:852	arg1	analysis					854:861	glycopeptide analysis	841:861	glycopeptide analysis	841:861	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	8	18	theme	unique	1238:1243	arg1	O-glycosites					1245:1256	48 unique O-glycosites	1235:1256	48 unique O-glycosites	1235:1256	In the analysis of the endogenous protein purified from platelets, we identified 48 unique O-glycosites and 1 N-glycosite.
36740532	5	19	theme	attached	910:917	arg1	glycans					919:925	the attached glycans	906:925	the attached glycans	906:925	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	11	20	dep	CONCLUSIONS	1418:1428	arg1	lays					1481:1484	lays	1481:1484	lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans	1481:1585	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	1	21	theme	ligand-binding	133:146	arg1	subunit					148:154	the major ligand-binding subunit	123:154	the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor	123:212	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	21	theme	ligand-binding	133:146	arg1	Ibα					116:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	6	22	theme	Tn	1016:1017	arg1	antigen					1019:1025	Tn antigen	1016:1025	Tn antigen	1016:1025	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	11	23	theme	glycosylation	1467:1479	arg1	analysis					1449:1456	This comprehensive analysis	1430:1456	This comprehensive analysis of GPIbα glycosylation	1430:1479	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	5	24	theme	Western	776:782	arg1	blot					784:787	Western blot	776:787	Western blot	776:787	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	4	25	dep	OBJECTIVES	520:529	arg1	was					553:555	was	553:555	was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	553:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	1	26	theme	GPIb-IX-V	163:171	arg1	complex					173:179	the GPIb-IX-V complex	159:179	the GPIb-IX-V complex	159:179	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	27	theme	BACKGROUND	78:87	arg1	GP					112:113	GP	112:113	GP	112:113	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	27	theme	BACKGROUND	78:87	arg1	glycoprotein					98:109	BACKGROUND Platelet glycoprotein	78:109	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	7	28	gly	O-glycosites	1140:1151	arg2	O-glycosites					1140:1151	62 unique O-glycosites	1130:1151	62 unique O-glycosites	1130:1151	In the analysis of the recombinant protein, we identified 62 unique O-glycosites.
36740532	1	29	theme	glycoprotein	98:109	arg1	subunit					148:154	the major ligand-binding subunit	123:154	the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor	123:212	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	29	theme	glycoprotein	98:109	arg1	Ibα					116:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	9	30	gly	O-glycosylated	1311:1324	arg1	domain					1293:1298	The GPIbα mucin domain	1277:1298	The GPIbα mucin domain	1277:1298	The GPIbα mucin domain is densely O-glycosylated.
36740532	9	30	gly	O-glycosylated	1311:1324	arg1	O-glycosylated					1311:1324	O-glycosylated	1311:1324	O-glycosylated	1311:1324	The GPIbα mucin domain is densely O-glycosylated.
36740532	2	31	theme	target	360:365	arg1	antigens					367:374	target antigens	360:374	target antigens	360:374	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	0	32	theme	Comprehensive	0:12	arg1	analysis					14:21	Comprehensive analysis	0:21	Comprehensive analysis of platelet glycoprotein	0:46	Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation.
36740532	9	33	theme	GPIbα	1281:1285	arg1	domain					1293:1298	The GPIbα mucin domain	1277:1298	The GPIbα mucin domain	1277:1298	The GPIbα mucin domain is densely O-glycosylated.
36740532	9	33	theme	GPIbα	1281:1285	arg1	O-glycosylated					1311:1324	O-glycosylated	1311:1324	O-glycosylated	1311:1324	The GPIbα mucin domain is densely O-glycosylated.
36740532	4	34	theme	study	547:551	arg1	aim					535:537	The aim	531:537	The aim of this study	531:551	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	2	35	theme	thrombocytopenia	386:401	arg1	syndromes					403:411	immune thrombocytopenia syndromes	379:411	immune thrombocytopenia syndromes	379:411	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	11	36	theme	comprehensive	1435:1447	arg1	analysis					1449:1456	This comprehensive analysis	1430:1456	This comprehensive analysis of GPIbα glycosylation	1430:1479	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	3	37	theme	platelet	440:447	arg1	biology					449:455	platelet biology	440:455	platelet biology	440:455	Despite its importance in platelet biology, the glycosylation profile of GPIbα is not well characterized.
36740532	4	38	theme	glycan	641:646	arg1	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	7	39	theme	protein	1107:1113	arg1	analysis					1079:1086	the analysis	1075:1086	the analysis of the recombinant protein	1075:1113	In the analysis of the recombinant protein, we identified 62 unique O-glycosites.
36740532	2	40	theme	Willebrand	326:335	arg1	factor					337:342	von Willebrand factor	322:342	von Willebrand factor binding	322:350	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	0	41	theme	ectodomain	52:61	arg1	glycosylation					63:75	ectodomain glycosylation	52:75	ectodomain glycosylation	52:75	Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation.
36740532	11	42	theme	glycans	1579:1585	arg1	roles					1564:1568	the functional and structural roles	1534:1568	the functional and structural roles of GPIbα glycans	1534:1585	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	3	43	theme	glycosylation	462:474	arg1	profile					476:482	the glycosylation profile	458:482	the glycosylation profile of GPIbα	458:491	Despite its importance in platelet biology, the glycosylation profile of GPIbα is not well characterized.
36740532	4	44	theme	amino	590:594	arg1	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	44	theme	amino	590:594	arg1	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	44	theme	amino	590:594	arg1	sites					601:605	GPIbα amino acid sites	584:605	GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	584:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	10	45	dep	domain	1384:1389	arg1	the					1362:1364	the	1362:1364	the	1362:1364	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	6	46	theme	group	1056:1060	arg1	antigens					1062:1069	ABO(H) blood group antigens	1043:1069	ABO(H) blood group antigens	1043:1069	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	11	47	theme	functional	1538:1547	arg1	roles					1564:1568	the functional and structural roles	1534:1568	the functional and structural roles of GPIbα glycans	1534:1585	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	4	48	gly	glycosylation	610:622	arg2	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	48	gly	glycosylation	610:622	arg2	sites					601:605	GPIbα amino acid sites	584:605	GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	584:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	48	gly	glycosylation	610:622	arg2	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	1	49	theme	complex	173:179	arg1	subunit					148:154	the major ligand-binding subunit	123:154	the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor	123:212	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	49	theme	complex	173:179	arg1	Ibα					116:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	8	50	theme	endogenous	1177:1186	arg1	protein					1188:1194	the endogenous protein	1173:1194	the endogenous protein purified from platelets	1173:1218	In the analysis of the endogenous protein purified from platelets, we identified 48 unique O-glycosites and 1 N-glycosite.
36740532	4	51	gly	glycosites	625:634	arg2	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	51	gly	glycosites	625:634	arg2	glycosites					625:634	glycosites	625:634	glycosites	625:634	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	2	52	theme	platelet	302:309	arg1	binding					344:350	von Willebrand factor binding	322:350	von Willebrand factor binding	322:350	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	2	52	theme	platelet	302:309	arg1	clearance					311:319	platelet clearance	302:319	platelet clearance	302:319	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	8	53	gly	O-glycosites	1245:1256	arg2	O-glycosites					1245:1256	48 unique O-glycosites	1235:1256	48 unique O-glycosites	1235:1256	In the analysis of the endogenous protein purified from platelets, we identified 48 unique O-glycosites and 1 N-glycosite.
36740532	6	54	theme	N-	974:975	arg1	repertoire					960:969	a diverse repertoire	950:969	a diverse repertoire	950:969	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	54	theme	N-	974:975	arg1	O-glycans					981:989	O-glycans	981:989	O-glycans	981:989	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	54	theme	N-	974:975	arg1	N-					974:975	N-	974:975	N-	974:975	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	4	55	theme	structures	648:657	arg1	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	55	theme	structures	648:657	arg1	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	55	theme	structures	648:657	arg1	sites					601:605	GPIbα amino acid sites	584:605	GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	584:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	11	56	theme	structural	1553:1562	arg1	roles					1564:1568	the functional and structural roles	1534:1568	the functional and structural roles of GPIbα glycans	1534:1585	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	1	57	theme	Willebrand	196:205	arg1	factor					207:212	von Willebrand factor	192:212	von Willebrand factor	192:212	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	4	58	theme	glycosylation	610:622	arg1	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	58	theme	glycosylation	610:622	arg1	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	58	theme	glycosylation	610:622	arg1	sites					601:605	GPIbα amino acid sites	584:605	GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	584:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	2	59	gly	glycosylated	232:243	arg1	GPIbα					215:219	GPIbα	215:219	GPIbα	215:219	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	2	60	theme	von	322:324	arg1	factor					337:342	von Willebrand factor	322:342	von Willebrand factor binding	322:350	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	5	61	theme	glycans	919:925	arg1	structures					892:901	the structures	888:901	the structures of the attached glycans	888:925	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	5	61	theme	glycans	919:925	arg1	glycans					919:925	the attached glycans	906:925	the attached glycans	906:925	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	5	61	theme	glycans	919:925	arg1	glycosites					873:882	glycosites	873:882	glycosites	873:882	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	11	62	theme	GPIbα	1461:1465	arg1	glycosylation					1467:1479	GPIbα glycosylation	1461:1479	GPIbα glycosylation	1461:1479	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	5	63	theme	human	744:748	arg1	platelets					750:758	human platelets	744:758	human platelets	744:758	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	11	64	theme	further	1505:1511	arg1	studies					1513:1519	further studies	1505:1519	further studies	1505:1519	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	1	65	gly	glycoprotein	98:109	arg1	GP					112:113	GP	112:113	GP	112:113	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	65	gly	glycoprotein	98:109	arg1	glycoprotein					98:109	BACKGROUND Platelet glycoprotein	78:109	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	6	66	theme	O-glycans	981:989	arg1	repertoire					960:969	a diverse repertoire	950:969	a diverse repertoire	950:969	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	66	theme	O-glycans	981:989	arg1	O-glycans					981:989	O-glycans	981:989	O-glycans	981:989	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	6	66	theme	O-glycans	981:989	arg1	N-					974:975	N-	974:975	N-	974:975	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	10	67	theme	mechanosensory	1395:1408	arg1	domain					1410:1415	mechanosensory domain	1395:1415	mechanosensory domain	1395:1415	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	7	68	theme	unique	1133:1138	arg1	O-glycosites					1140:1151	62 unique O-glycosites	1130:1151	62 unique O-glycosites	1130:1151	In the analysis of the recombinant protein, we identified 62 unique O-glycosites.
36740532	8	69	gly	N-glycosite	1264:1274	arg2	N-glycosite					1264:1274	1 N-glycosite	1262:1274	1 N-glycosite	1262:1274	In the analysis of the endogenous protein purified from platelets, we identified 48 unique O-glycosites and 1 N-glycosite.
36740532	1	70	theme	Platelet	89:96	arg1	GP					112:113	GP	112:113	GP	112:113	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	1	70	theme	Platelet	89:96	arg1	glycoprotein					98:109	BACKGROUND Platelet glycoprotein	78:109	BACKGROUND Platelet glycoprotein (GP) Ibα	78:118	BACKGROUND Platelet glycoprotein (GP) Ibα is the major ligand-binding subunit of the GPIb-IX-V complex that binds von Willebrand factor.
36740532	6	71	theme	H	1047:1047	arg1	antigens					1062:1069	ABO(H) blood group antigens	1043:1069	ABO(H) blood group antigens	1043:1069	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	5	72	theme	mass	790:793	arg1	glycomics					808:816	mass spectrometry glycomics	790:816	mass spectrometry glycomics	790:816	METHODS GPIbα ectodomain that was recombinantly expressed or that was purified from human platelets was analyzed by Western blot, mass spectrometry glycomics, and mass spectrometry glycopeptide analysis to define glycosites and the structures of the attached glycans.
36740532	6	73	theme	ABO	1043:1045	arg1	antigens					1062:1069	ABO(H) blood group antigens	1043:1069	ABO(H) blood group antigens	1043:1069	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	0	74	theme	platelet	26:33	arg1	glycoprotein					35:46	platelet glycoprotein	26:46	platelet glycoprotein	26:46	Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation.
36740532	9	75	theme	mucin	1287:1291	arg1	domain					1293:1298	The GPIbα mucin domain	1277:1298	The GPIbα mucin domain	1277:1298	The GPIbα mucin domain is densely O-glycosylated.
36740532	9	75	theme	mucin	1287:1291	arg1	O-glycosylated					1311:1324	O-glycosylated	1311:1324	O-glycosylated	1311:1324	The GPIbα mucin domain is densely O-glycosylated.
36740532	10	76	gly	macroglycopeptide	1366:1382	arg2	macroglycopeptide					1366:1382	macroglycopeptide domain	1366:1389	macroglycopeptide domain	1366:1389	Glycosites are also located within the macroglycopeptide domain and mechanosensory domain.
36740532	3	77	gly	glycosylation	462:474	arg1	GPIbα					487:491	GPIbα	487:491	GPIbα	487:491	Despite its importance in platelet biology, the glycosylation profile of GPIbα is not well characterized.
36740532	7	78	theme	recombinant	1095:1105	arg1	protein					1107:1113	the recombinant protein	1091:1113	the recombinant protein	1091:1113	In the analysis of the recombinant protein, we identified 62 unique O-glycosites.
36740532	6	79	theme	T	1028:1028	arg1	antigen					1030:1036	T antigen	1028:1036	T antigen	1028:1036	RESULTS We identified a diverse repertoire of N- and O-glycans, including sialoglycans, Tn antigen, T antigen, and ABO(H) blood group antigens.
36740532	2	80	theme	immune	379:384	arg1	syndromes					403:411	immune thrombocytopenia syndromes	379:411	immune thrombocytopenia syndromes	379:411	GPIbα is heavily glycosylated, and its glycans have been proposed to play key roles in platelet clearance, von Willebrand factor binding, and as target antigens in immune thrombocytopenia syndromes.
36740532	11	81	theme	GPIbα	1573:1577	arg1	glycans					1579:1585	GPIbα glycans	1573:1585	GPIbα glycans	1573:1585	CONCLUSIONS This comprehensive analysis of GPIbα glycosylation lays the foundation for further studies to determine the functional and structural roles of GPIbα glycans.
36740532	3	82	theme	GPIbα	487:491	arg1	profile					476:482	the glycosylation profile	458:482	the glycosylation profile of GPIbα	458:491	Despite its importance in platelet biology, the glycosylation profile of GPIbα is not well characterized.
36740532	0	83	gly	glycoprotein	35:46	arg1	glycoprotein					35:46	platelet glycoprotein	26:46	platelet glycoprotein	26:46	Comprehensive analysis of platelet glycoprotein Ibα ectodomain glycosylation.
36740532	4	84	theme	acid	596:599	arg1	structures					648:657	glycan structures	641:657	glycan structures	641:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	84	theme	acid	596:599	arg1	glycosylation					610:622	glycosylation	610:622	glycosylation (glycosites)	610:635	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	4	84	theme	acid	596:599	arg1	sites					601:605	GPIbα amino acid sites	584:605	GPIbα amino acid sites of glycosylation (glycosites) and glycan structures	584:657	OBJECTIVES The aim of this study was to comprehensively analyze GPIbα amino acid sites of glycosylation (glycosites) and glycan structures.
36740532	3	85	from	importance	426:435	arg1	biology					449:455	platelet biology	440:455	platelet biology	440:455	Despite its importance in platelet biology, the glycosylation profile of GPIbα is not well characterized.
36493594	3	0	gly	glycosylation	788:800	arg2	site					802:805	a single glycosylation site	779:805	a single glycosylation site	779:805	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	1	1	from	N-glycans	192:200	arg1	glycoproteins					205:217	glycoproteins	205:217	glycoproteins	205:217	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	2	2	gly	glycoproteins	584:596	arg1	glycoproteins					584:596	mammalian glycoproteins	574:596	mammalian glycoproteins	574:596	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	3	3	theme	fluorescent	828:838	arg1	AB					863:864	AB	863:864	AB	863:864	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	3	theme	fluorescent	828:838	arg1	[2-aminobenzamide					844:860	a fluorescent tag [2-aminobenzamide	826:860	a fluorescent tag [2-aminobenzamide (AB)	826:865	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	9	4	gly	glycoprotein	1780:1791	arg1	glycoprotein					1780:1791	glycoprotein	1780:1791	glycoprotein	1780:1791	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	10	5	dep	identification	1875:1888	arg1	the					1871:1873	the	1871:1873	the	1871:1873	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	10	6	from	identification	1875:1888	arg1	glycoproteins					1947:1959	glycoproteins	1947:1959	glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS	1947:2008	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	8	7	theme	N-glycans	1549:1557	arg1	pmol					1536:1539	pmol	1536:1539	pmol	1536:1539	However, the absolute quantities (pmol) of the N-glycans estimated using UPLC and LC-MS/MS were more efficiently determined with ProA-labeling than with AB-labeling.
36493594	8	7	theme	N-glycans	1549:1557	arg1	quantities					1524:1533	the absolute quantities	1511:1533	the absolute quantities (pmol) of the N-glycans estimated using UPLC and LC-MS/MS	1511:1591	However, the absolute quantities (pmol) of the N-glycans estimated using UPLC and LC-MS/MS were more efficiently determined with ProA-labeling than with AB-labeling.
36493594	3	8	theme	tag	840:842	arg1	AB					863:864	AB	863:864	AB	863:864	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	8	theme	tag	840:842	arg1	[2-aminobenzamide					844:860	a fluorescent tag [2-aminobenzamide	826:860	a fluorescent tag [2-aminobenzamide (AB)	826:865	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	2	9	theme	mammalian	574:582	arg1	glycoproteins					584:596	mammalian glycoproteins	574:596	mammalian glycoproteins	574:596	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	1	10	theme	preparation	375:385	arg1	methods					387:393	the preparation methods	371:393	the preparation methods	371:393	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	1	11	gly	glycoproteins	205:217	arg1	glycoproteins					205:217	glycoproteins	205:217	glycoproteins	205:217	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	3	12	theme	METHODS	599:605	arg1	N-glycans					607:615	METHODS N-glycans	599:615	METHODS N-glycans	599:615	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	1	13	theme	reported	284:291	arg1	structures					302:311	some reported N-glycan structures	279:311	some reported N-glycan structures	279:311	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	0	14	theme	N-glycans	106:114	arg1	quantification					88:101	quantification	88:101	quantification	88:101	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	0	14	theme	N-glycans	106:114	arg1	identification					69:82	identification	69:82	identification	69:82	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	1	15	theme	methods	387:393	arg1	type					347:350	the type	343:350	the type of glycoprotein or the preparation methods	343:393	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	7	16	contain	had	1478:1480	arg1	%					1350:1350	%	1350:1350	%	1350:1350	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	16	contain	had	1478:1480	arg1	quantities					1338:1347	The quantities	1334:1347	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1334:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	16	contain	had	1478:1480	arg2	tendency					1492:1499	a similar tendency	1482:1499	a similar tendency	1482:1499	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	1	17	theme	N-glycan	293:300	arg1	structures					302:311	some reported N-glycan structures	279:311	some reported N-glycan structures	279:311	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	10	18	from	quantification	1916:1929	arg1	glycoproteins					1947:1959	glycoproteins	1947:1959	glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS	1947:2008	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	1	19	gly	glycoprotein	355:366	arg1	glycoprotein					355:366	glycoprotein	355:366	glycoprotein	355:366	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	1	20	theme	BACKGROUND	181:190	arg1	N-glycans					192:200	BACKGROUND N-glycans	181:200	BACKGROUND N-glycans in glycoproteins	181:217	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	4	21	dep	structure	896:904	arg1	The					892:894	The	892:894	The	892:894	The structure and quantity of each N-glycan were determined using UPLC and LC-MS/MS.
36493594	3	22	theme	glycosylation	738:750	arg1	sites					752:756	three glycosylation sites	732:756	three glycosylation sites	732:756	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	9	23	dep	PF-AB	1771:1775	arg1	fetuin					1814:1819	bovine fetuin	1807:1819	bovine fetuin	1807:1819	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	6	24	theme	8-13	1130:1133	arg1	N-glycans					1135:1143	8-13 N-glycans	1130:1143	8-13 N-glycans	1130:1143	The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
36493594	7	25	theme	N-glycans	1360:1368	arg1	%					1350:1350	%	1350:1350	%	1350:1350	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	25	theme	N-glycans	1360:1368	arg1	quantities					1338:1347	The quantities	1334:1347	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1334:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	10	26	gly	glycoproteins	1947:1959	arg1	glycoproteins					1947:1959	glycoproteins	1947:1959	glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS	1947:2008	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	3	27	with	IgG	769:771	arg1	sites					752:756	three glycosylation sites	732:756	three glycosylation sites	732:756	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	27	with	IgG	769:771	arg1	site					802:805	a single glycosylation site	779:805	a single glycosylation site	779:805	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	5	28	from	RESULTS	977:983	arg1	IgG					1040:1042	IgG	1040:1042	IgG by either PF-ProA or PA-ProA	1040:1071	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36493594	2	29	theme	consistent	416:425	arg1	results					427:433	consistent results	416:433	consistent results	416:433	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	0	30	theme	Peptide-N-glycosidase	0:20	arg1	F					22:22	Peptide-N-glycosidase F	0:22	Peptide-N-glycosidase F	0:22	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	10	31	theme	comparative	1846:1856	arg1	analysis					1858:1865	the first comparative analysis	1836:1865	the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS	1836:2008	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	10	31	theme	comparative	1846:1856	arg1	study					1827:1831	This study	1822:1831	This study	1822:1831	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	7	32	theme	total	1395:1399	arg1	amount					1401:1406	the total amount	1391:1406	the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1391:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	32	theme	total	1395:1399	arg1	N-glycans					1411:1419	N-glycans	1411:1419	N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1411:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	32	theme	total	1395:1399	arg1	%					1426:1426	100 %	1422:1426	100 %	1422:1426	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	3	33	theme	peptide-N-glycosidase	633:653	arg1	PF					658:659	PF	658:659	PF	658:659	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	33	theme	peptide-N-glycosidase	633:653	arg1	F					655:655	peptide-N-glycosidase F	633:655	peptide-N-glycosidase F (PF)	633:660	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	34	theme	model	681:685	arg1	glycoproteins					697:709	two model mammalian glycoproteins	677:709	two model mammalian glycoproteins	677:709	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	34	theme	model	681:685	arg1	fetuin					719:724	bovine fetuin	712:724	bovine fetuin (with three glycosylation sites)	712:757	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	34	theme	model	681:685	arg1	IgG					769:771	human IgG	763:771	human IgG (with a single glycosylation site)	763:806	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	2	35	theme	N-glycans	480:488	arg1	analyses					468:475	qualitative and quantitative analyses	439:475	qualitative and quantitative analyses of N-glycans	439:488	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	10	36	theme	first	1840:1844	arg1	analysis					1858:1865	the first comparative analysis	1836:1865	the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS	1836:2008	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	10	36	theme	first	1840:1844	arg1	study					1827:1831	This study	1822:1831	This study	1822:1831	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	0	37	theme	mammalian	132:140	arg1	glycoproteins					142:154	mammalian glycoproteins	132:154	mammalian glycoproteins using UPLC and LC-MS/MS	132:178	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	6	38	from	N-glycans	1109:1117	arg1	fetuin					1122:1127	fetuin	1122:1127	fetuin (8-13 N-glycans were previously reported)	1122:1169	The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
36493594	6	38	from	N-glycans	1109:1117	arg1	IgG					1178:1180	IgG	1178:1180	IgG (19 N-glycans were previously reported)	1178:1220	The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
36493594	9	39	theme	effective	1709:1717	arg1	identification					1719:1732	identification	1719:1732	identification	1719:1732	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	3	40	theme	human	763:767	arg1	glycoproteins					697:709	two model mammalian glycoproteins	677:709	two model mammalian glycoproteins	677:709	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	40	theme	human	763:767	arg1	IgG					769:771	human IgG	763:771	human IgG (with a single glycosylation site)	763:806	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	6	41	theme	used	1273:1276	arg1	PF-AB					1278:1282	the widely used PF-AB	1262:1282	the widely used PF-AB	1262:1282	The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
36493594	10	42	theme	N-glycans	1934:1942	arg1	quantification					1916:1929	relative and absolute quantification	1894:1929	relative and absolute quantification of N-glycans	1894:1942	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	10	42	theme	N-glycans	1934:1942	arg1	identification					1875:1888	identification	1875:1888	identification	1875:1888	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	5	43	from	N-glycans	992:1000	arg1	fetuin					1005:1010	fetuin	1005:1010	fetuin	1005:1010	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36493594	2	44	theme	quantitative	455:466	arg1	analyses					468:475	qualitative and quantitative analyses	439:475	qualitative and quantitative analyses of N-glycans	439:488	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	2	45	theme	preparation	523:533	arg1	methods					535:541	different preparation methods	513:541	different preparation methods	513:541	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	3	46	gly	glycosylation	738:750	arg2	sites					752:756	three glycosylation sites	732:756	three glycosylation sites	732:756	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	46	gly	glycosylation	738:750	arg2	three					732:736	three	732:736	three	732:736	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	0	47	from	quantification	88:101	arg1	types					123:127	two types	119:127	two types of mammalian glycoproteins using UPLC and LC-MS/MS	119:178	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	6	48	dep	fetuin	1122:1127	arg1	reported					1161:1168	reported	1161:1168	were previously reported	1145:1168	The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
36493594	1	49	theme	physicochemical	230:244	arg1	properties					246:255	physicochemical properties	230:255	physicochemical properties of proteins	230:267	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	2	50	theme	different	513:521	arg1	methods					535:541	different preparation methods	513:541	different preparation methods	513:541	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	3	51	theme	glycosylation	788:800	arg1	site					802:805	a single glycosylation site	779:805	a single glycosylation site	779:805	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	0	52	theme	glycoproteins	142:154	arg1	types					123:127	two types	119:127	two types of mammalian glycoproteins using UPLC and LC-MS/MS	119:178	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	7	53	theme	N-glycans	1411:1419	arg1	amount					1401:1406	the total amount	1391:1406	the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1391:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	53	theme	N-glycans	1411:1419	arg1	N-glycans					1411:1419	N-glycans	1411:1419	N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1411:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	53	theme	N-glycans	1411:1419	arg1	%					1426:1426	100 %	1422:1426	100 %	1422:1426	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	10	54	theme	relative	1894:1901	arg1	quantification					1916:1929	relative and absolute quantification	1894:1929	relative and absolute quantification of N-glycans	1894:1942	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	2	55	theme	qualitative	439:449	arg1	analyses					468:475	qualitative and quantitative analyses	439:475	qualitative and quantitative analyses of N-glycans	439:488	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	7	56	theme	similar	1484:1490	arg1	tendency					1492:1499	a similar tendency	1482:1499	a similar tendency	1482:1499	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	4	57	theme	N-glycan	927:934	arg1	quantity					910:917	quantity	910:917	quantity	910:917	The structure and quantity of each N-glycan were determined using UPLC and LC-MS/MS.
36493594	4	57	theme	N-glycan	927:934	arg1	structure					896:904	structure	896:904	structure	896:904	The structure and quantity of each N-glycan were determined using UPLC and LC-MS/MS.
36493594	0	58	from	identification	69:82	arg1	types					123:127	two types	119:127	two types of mammalian glycoproteins using UPLC and LC-MS/MS	119:178	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	2	59	theme	glycoproteins	584:596	arg1	types					565:569	two types	561:569	two types of mammalian glycoproteins	561:596	OBJECTIVE To obtain consistent results for qualitative and quantitative analyses of N-glycans, N-glycans obtained by different preparation methods were compared for two types of mammalian glycoproteins.
36493594	7	60	theme	relative	1379:1386	arg1	N-glycans					1360:1368	the N-glycans	1356:1368	the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS	1356:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	7	60	theme	relative	1379:1386	arg1	%					1376:1376	>0.1 %	1371:1376	>0.1 %	1371:1376	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	0	61	dep	treatment	29:37	arg1	A					27:27	A	27:27	A	27:27	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	3	62	theme	single	781:786	arg1	site					802:805	a single glycosylation site	779:805	a single glycosylation site	779:805	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	63	theme	bovine	712:717	arg1	glycoproteins					697:709	two model mammalian glycoproteins	677:709	two model mammalian glycoproteins	677:709	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	63	theme	bovine	712:717	arg1	fetuin					719:724	bovine fetuin	712:724	bovine fetuin (with three glycosylation sites)	712:757	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	10	64	with	glycoproteins	1947:1959	arg1	PF-ProA					1966:1972	PF-ProA	1966:1972	PF-ProA	1966:1972	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	10	64	with	glycoproteins	1947:1959	arg1	PA-ProA					1978:1984	PA-ProA	1978:1984	PA-ProA	1978:1984	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	0	65	gly	glycoproteins	142:154	arg1	glycoproteins					142:154	mammalian glycoproteins	132:154	mammalian glycoproteins using UPLC and LC-MS/MS	132:178	Peptide-N-glycosidase F or A treatment and procainamide-labeling for identification and quantification of N-glycans in two types of mammalian glycoproteins using UPLC and LC-MS/MS.
36493594	8	66	theme	absolute	1515:1522	arg1	pmol					1536:1539	pmol	1536:1539	pmol	1536:1539	However, the absolute quantities (pmol) of the N-glycans estimated using UPLC and LC-MS/MS were more efficiently determined with ProA-labeling than with AB-labeling.
36493594	8	66	theme	absolute	1515:1522	arg1	quantities					1524:1533	the absolute quantities	1511:1533	the absolute quantities (pmol) of the N-glycans estimated using UPLC and LC-MS/MS	1511:1591	However, the absolute quantities (pmol) of the N-glycans estimated using UPLC and LC-MS/MS were more efficiently determined with ProA-labeling than with AB-labeling.
36493594	7	67	theme	using	1463:1467	arg1	LC-MS/MS					1469:1476	ProA-labeling using LC-MS/MS	1449:1476	ProA-labeling using LC-MS/MS	1449:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
36493594	3	68	theme	mammalian	687:695	arg1	glycoproteins					697:709	two model mammalian glycoproteins	677:709	two model mammalian glycoproteins	677:709	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	68	theme	mammalian	687:695	arg1	fetuin					719:724	bovine fetuin	712:724	bovine fetuin (with three glycosylation sites)	712:757	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	68	theme	mammalian	687:695	arg1	IgG					769:771	human IgG	763:771	human IgG (with a single glycosylation site)	763:806	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	9	69	from	PF-AB	1771:1775	arg1	glycoprotein					1780:1791	glycoprotein	1780:1791	glycoprotein	1780:1791	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	1	70	theme	proteins	260:267	arg1	properties					246:255	physicochemical properties	230:255	physicochemical properties of proteins	230:267	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	5	71	from	N-glycans	1027:1035	arg1	fetuin					1005:1010	fetuin	1005:1010	fetuin	1005:1010	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36493594	5	72	dep	RESULTS	977:983	arg1	N-glycans					1027:1035	another 21 N-glycans	1016:1035	another 21 N-glycans	1016:1035	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36493594	5	72	dep	RESULTS	977:983	arg1	RESULTS					977:983	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans	977:1035	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA	977:1071	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36493594	5	72	dep	RESULTS	977:983	arg1	N-glycans					992:1000	The 21 N-glycans	985:1000	The 21 N-glycans in fetuin	985:1010	RESULTS The 21 N-glycans in fetuin and another 21 N-glycans in IgG by either PF-ProA or PA-ProA were identified using LC-MS/MS.
36493594	10	73	theme	absolute	1907:1914	arg1	quantification					1916:1929	relative and absolute quantification	1894:1929	relative and absolute quantification of N-glycans	1894:1942	This study is the first comparative analysis for the identification and relative and absolute quantification of N-glycans in glycoproteins with PF-ProA and PA-ProA using UPLC and LC-MS/MS.
36493594	9	74	theme	N-glycans	1756:1764	arg1	quantification					1738:1751	quantification	1738:1751	quantification	1738:1751	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	9	74	theme	N-glycans	1756:1764	arg1	identification					1719:1732	identification	1719:1732	identification	1719:1732	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	3	75	gly	glycoproteins	697:709	arg1	glycoproteins					697:709	two model mammalian glycoproteins	677:709	two model mammalian glycoproteins	677:709	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	75	gly	glycoproteins	697:709	arg1	fetuin					719:724	bovine fetuin	712:724	bovine fetuin (with three glycosylation sites)	712:757	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	75	gly	glycoproteins	697:709	arg1	IgG					769:771	human IgG	763:771	human IgG (with a single glycosylation site)	763:806	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	9	76	theme	bovine	1807:1812	arg1	fetuin					1814:1819	bovine fetuin	1807:1819	bovine fetuin	1807:1819	Thus, PF-ProA or PA-ProA allows for more effective identification and quantification of N-glycans than PF-AB in glycoprotein, particularly bovine fetuin.
36493594	1	77	theme	glycoprotein	355:366	arg1	type					347:350	the type	343:350	the type of glycoprotein or the preparation methods	343:393	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	1	78	dep	affect	223:228	arg1	inconsistent					317:328	inconsistent	317:328	inconsistent	317:328	BACKGROUND N-glycans in glycoproteins can affect physicochemical properties of proteins; however, some reported N-glycan structures are inconsistent depending on the type of glycoprotein or the preparation methods.
36493594	6	79	dep	IgG	1178:1180	arg1	reported					1212:1219	reported	1212:1219	were previously reported	1196:1219	The N-glycans in fetuin (8-13 N-glycans were previously reported) and in IgG (19 N-glycans were previously reported), which could not be identified by using the widely used PF-AB, were all identified by using PF-ProA or PA-ProA.
36493594	3	80	with	fetuin	719:724	arg1	sites					752:756	three glycosylation sites	732:756	three glycosylation sites	732:756	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	3	80	with	fetuin	719:724	arg1	site					802:805	a single glycosylation site	779:805	a single glycosylation site	779:805	METHODS N-glycans are released by peptide-N-glycosidase F (PF) or A (PA) from two model mammalian glycoproteins, bovine fetuin (with three glycosylation sites) and human IgG (with a single glycosylation site), and labeled with a fluorescent tag [2-aminobenzamide (AB) or procainamide (ProA)].
36493594	7	81	theme	ProA-labeling	1449:1461	arg1	LC-MS/MS					1469:1476	ProA-labeling using LC-MS/MS	1449:1476	ProA-labeling using LC-MS/MS	1449:1476	The quantities (%) of the N-glycans (>0.1 %) relative to the total amount of N-glycans (100 %) obtained by AB- and ProA-labeling using LC-MS/MS had a similar tendency.
37129482	7	0	dep	structures	1072:1081	arg1	addition					1053:1060	addition	1053:1060	addition	1053:1060	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
37129482	4	1	from	Center	670:675	arg1	portal					647:652	a chemistry-based portal	629:652	a chemistry-based portal at the National Center for Biotechnology Information (NCBI)	629:712	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	4	1	from	Center	670:675	arg1	PubChem					598:604	PubChem	598:604	PubChem	598:604	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	9	2	theme	content	1425:1431	arg1	type					1417:1420	the type	1413:1420	the type of content that can be investigated	1413:1456	Use cases are described illustrating and highlighting the type of content that can be investigated.
37129482	5	3	theme	resources	866:874	arg1	hundreds					849:856	hundreds	849:856	hundreds of data resources from around the world	849:896	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	2	4	theme	glycan-related	294:307	arg1	UniCarb-DR					359:368	UniCarb-DR	359:368	UniCarb-DR	359:368	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	2	4	theme	glycan-related	294:307	arg1	GlycoPOST					344:352	GlycoPOST	344:352	GlycoPOST	344:352	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	2	4	theme	glycan-related	294:307	arg1	repositories					309:320	glycan-related repositories	294:320	glycan-related repositories	294:320	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	2	4	theme	glycan-related	294:307	arg1	GlyTouCan					333:341	GlyTouCan	333:341	GlyTouCan	333:341	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	4	5	theme	chemistry-based	631:645	arg1	portal					647:652	a chemistry-based portal	629:652	a chemistry-based portal at the National Center for Biotechnology Information (NCBI)	629:712	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	4	5	theme	chemistry-based	631:645	arg1	PubChem					598:604	PubChem	598:604	PubChem	598:604	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	3	6	gly	glycoproteins	490:502	arg1	glycoproteins					490:502	glycoproteins	490:502	glycoproteins	490:502	Glycogenes, glycoproteins, lectins, pathways, and disease information related to glycans are accessible from GlyCosmos.
37129482	10	7	dep	researchers	1509:1519	arg1	improved					1521:1528	improved	1521:1528	improved awareness	1521:1538	In total, these integrations provide life science researchers improved awareness and enhanced access to glycan-related information.
37129482	10	7	dep	researchers	1509:1519	arg1	enhanced					1544:1551	enhanced	1544:1551	enhanced access to glycan-related information	1544:1588	In total, these integrations provide life science researchers improved awareness and enhanced access to glycan-related information.
37129482	10	8	theme	life	1496:1499	arg1	researchers					1509:1519	life science researchers	1496:1519	life science researchers improved awareness and enhanced access to glycan-related information	1496:1588	In total, these integrations provide life science researchers improved awareness and enhanced access to glycan-related information.
37129482	4	9	theme	other	614:618	arg1	hand					620:623	the other hand	610:623	the other hand	610:623	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	4	10	from	portal	647:652	arg1	hand					620:623	the other hand	610:623	the other hand	610:623	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	2	11	theme	data	401:404	arg1	resources					406:414	glycan-related data resources	386:414	glycan-related data resources that have been integrated from a variety of 'omics databases	386:475	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	2	12	theme	databases	467:475	arg1	variety					449:455	a variety	447:455	a variety of 'omics databases	447:475	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	2	12	theme	databases	467:475	arg1	databases					467:475	'omics databases	460:475	'omics databases	460:475	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	1	13	dep	https	133:137	arg1	//glycosmos.org					139:153	//glycosmos.org	139:153	https://glycosmos.org	133:153	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	2	14	theme	glycan-related	386:399	arg1	resources					406:414	glycan-related data resources	386:414	glycan-related data resources that have been integrated from a variety of 'omics databases	386:475	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	7	15	theme	key	1084:1086	arg1	information					1088:1098	key information	1084:1098	key information	1084:1098	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
37129482	1	16	dep	PubChem	160:166	arg1	https					169:173	https	169:173	https://pubchem.ncbi.nlm.nih.gov/	169:201	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	17	theme	GlyCosmos	102:110	arg1	PubChem					160:166	PubChem	160:166	PubChem (https://pubchem.ncbi.nlm.nih.gov/)	160:202	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	17	theme	GlyCosmos	102:110	arg1	portals					214:220	major portals	208:220	major portals for glycoscience and chemistry, respectively	208:265	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	17	theme	GlyCosmos	102:110	arg1	Portal					125:130	The GlyCosmos Glycoscience Portal	98:130	The GlyCosmos Glycoscience Portal (https://glycosmos.org)	98:154	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	6	18	theme	complementary	980:992	arg1	data					994:997	their complementary data	974:997	their complementary data	974:997	In this work, these two portals have made substantial efforts to integrate their complementary data to allow users to cross between these two domains.
37129482	5	19	from	hundreds	849:856	arg1	information					732:742	information	732:742	information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world	732:896	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	3	20	theme	related	548:554	arg1	Glycogenes					478:487	Glycogenes	478:487	Glycogenes	478:487	Glycogenes, glycoproteins, lectins, pathways, and disease information related to glycans are accessible from GlyCosmos.
37129482	9	21	theme	Use	1359:1361	arg1	cases					1363:1367	Use cases	1359:1367	Use cases	1359:1367	Use cases are described illustrating and highlighting the type of content that can be investigated.
37129482	3	22	from	GlyCosmos	587:595	arg1	accessible					571:580	accessible	571:580	accessible	571:580	Glycogenes, glycoproteins, lectins, pathways, and disease information related to glycans are accessible from GlyCosmos.
37129482	1	23	theme	major	208:212	arg1	PubChem					160:166	PubChem	160:166	PubChem (https://pubchem.ncbi.nlm.nih.gov/)	160:202	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	23	theme	major	208:212	arg1	portals					214:220	major portals	208:220	major portals for glycoscience and chemistry, respectively	208:265	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	23	theme	major	208:212	arg1	Portal					125:130	The GlyCosmos Glycoscience Portal	98:130	The GlyCosmos Glycoscience Portal (https://glycosmos.org)	98:154	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	0	24	theme	integration	47:57	arg1	efforts					59:65	integration efforts	47:65	integration efforts between GlyCosmos and PubChem	47:95	Bridging Glycoinformatics and cheminformatics: integration efforts between GlyCosmos and PubChem.
37129482	7	25	gly	glycoproteins	1150:1162	arg1	glycoproteins					1150:1162	glycoproteins	1150:1162	glycoproteins	1150:1162	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
37129482	2	26	theme	omics	461:465	arg1	databases					467:475	'omics databases	460:475	'omics databases	460:475	GlyCosmos is a portal for glycan-related repositories, including GlyTouCan, GlycoPOST, and UniCarb-DR, as well as for glycan-related data resources that have been integrated from a variety of 'omics databases.
37129482	7	27	theme	glycan	1065:1070	arg1	structures					1072:1081	glycan structures	1065:1081	glycan structures	1065:1081	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
37129482	10	28	theme	glycan-related	1563:1576	arg1	information					1578:1588	glycan-related information	1563:1588	glycan-related information	1563:1588	In total, these integrations provide life science researchers improved awareness and enhanced access to glycan-related information.
37129482	1	29	dep	https	169:173	arg1	//pubchem.ncbi.nlm.nih.gov/					175:201	//pubchem.ncbi.nlm.nih.gov/	175:201	https://pubchem.ncbi.nlm.nih.gov/	169:201	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	10	30	theme	science	1501:1507	arg1	researchers					1509:1519	life science researchers	1496:1519	life science researchers improved awareness and enhanced access to glycan-related information	1496:1588	In total, these integrations provide life science researchers improved awareness and enhanced access to glycan-related information.
37129482	4	31	theme	Biotechnology	681:693	arg1	Information					695:705	Biotechnology Information	681:705	Biotechnology Information (NCBI)	681:712	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	4	31	theme	Biotechnology	681:693	arg1	NCBI					708:711	NCBI	708:711	NCBI	708:711	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	8	32	theme	reuse	1312:1316	arg1	data					1318:1321	reuse data	1312:1321	reuse data	1312:1321	The interfaces were designed to enable users to easily find, access, download, and reuse data of interest across these resources.
37129482	1	33	theme	Glycoscience	112:123	arg1	PubChem					160:166	PubChem	160:166	PubChem (https://pubchem.ncbi.nlm.nih.gov/)	160:202	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	33	theme	Glycoscience	112:123	arg1	portals					214:220	major portals	208:220	major portals for glycoscience and chemistry, respectively	208:265	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	1	33	theme	Glycoscience	112:123	arg1	Portal					125:130	The GlyCosmos Glycoscience Portal	98:130	The GlyCosmos Glycoscience Portal (https://glycosmos.org)	98:154	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	6	34	theme	substantial	941:951	arg1	efforts					953:959	substantial efforts	941:959	substantial efforts	941:959	In this work, these two portals have made substantial efforts to integrate their complementary data to allow users to cross between these two domains.
37129482	5	35	from	information	732:742	arg1	patents					814:820	patents	814:820	but also genes, proteins, pathways, as well as patents	767:820	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	5	35	from	information	732:742	arg1	chemicals					756:764	chemicals	756:764	chemicals	756:764	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	5	35	from	information	732:742	arg1	genes					776:780	genes	776:780	genes	776:780	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	5	35	from	information	732:742	arg1	bioassays					823:831	bioassays	823:831	bioassays	823:831	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	3	36	theme	disease	528:534	arg1	information					536:546	disease information	528:546	disease information	528:546	Glycogenes, glycoproteins, lectins, pathways, and disease information related to glycans are accessible from GlyCosmos.
37129482	5	37	theme	data	861:864	arg1	resources					866:874	data resources	861:874	data resources from around the world	861:896	PubChem provides information not only on chemicals, but also genes, proteins, pathways, as well as patents, bioassays, and more, from hundreds of data resources from around the world.
37129482	7	38	theme	relevant	1131:1138	arg1	diseases					1140:1147	relevant diseases	1131:1147	relevant diseases	1131:1147	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
37129482	7	39	dep	one	1216:1218	arg1	another					1220:1226	another	1220:1226	another	1220:1226	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
37129482	4	40	theme	National	661:668	arg1	Center					670:675	the National Center	657:675	the National Center	657:675	PubChem, on the other hand, is a chemistry-based portal at the National Center for Biotechnology Information (NCBI).
37129482	0	41	dep	Bridging	0:7	arg1	efforts					59:65	integration efforts	47:65	integration efforts between GlyCosmos and PubChem	47:95	Bridging Glycoinformatics and cheminformatics: integration efforts between GlyCosmos and PubChem.
37129482	1	42	dep	Portal	125:130	arg1	https					133:137	https	133:137	https://glycosmos.org	133:153	The GlyCosmos Glycoscience Portal (https://glycosmos.org) and PubChem (https://pubchem.ncbi.nlm.nih.gov/) are major portals for glycoscience and chemistry, respectively.
37129482	7	43	theme	glycan-related	1109:1122	arg1	genes					1124:1128	glycan-related genes	1109:1128	glycan-related genes	1109:1128	In addition to glycan structures, key information, such as glycan-related genes, relevant diseases, glycoproteins, and pathways were integrated and cross-linked with one another.
35262690	12	0	theme	pathogenic	1687:1696	arg1	variants					1698:1705	pathogenic variants	1687:1705	pathogenic variants in a member of the TRC pathway	1687:1736	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	1	1	theme	lipid	238:242	arg1	bilayer					244:250	the lipid bilayer	234:250	the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane	234:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	2	2	dep	GET3	484:487	arg1	ASNA1					497:501	ASNA1	497:501	ASNA1	497:501	In order to facilitate correct insertion, the recognition complex (consisting of BAG6, GET4 and UBL4A) must first bind to TA proteins and then to GET3 (TRC40, ASNA1), which chaperones the protein to the ER membrane.
35262690	2	2	dep	GET3	484:487	arg1	TRC40					490:494	TRC40	490:494	TRC40	490:494	In order to facilitate correct insertion, the recognition complex (consisting of BAG6, GET4 and UBL4A) must first bind to TA proteins and then to GET3 (TRC40, ASNA1), which chaperones the protein to the ER membrane.
35262690	8	3	from	Mislocalization	1106:1120	arg1	fibroblasts					1147:1157	patient fibroblasts	1139:1157	patient fibroblasts	1139:1157	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	8	3	from	Mislocalization	1106:1120	arg1	cells					1187:1191	siCAMLG deleted Hela cells	1166:1191	siCAMLG deleted Hela cells	1166:1191	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	10	4	theme	possible	1474:1481	arg1	mechanism					1483:1491	a possible mechanism	1472:1491	a possible mechanism behind the hyposialylation of N and O-glycans	1472:1537	It also points towards a possible mechanism behind the hyposialylation of N and O-glycans.
35262690	7	5	theme	combined	1035:1042	arg1	defect					1088:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	Biochemically, a combined O-linked and type II N-linked glycosylation defect was found.
35262690	5	6	link	patient-derived	844:858	arg1	fibroblasts					860:870	patient-derived fibroblasts	844:870	patient-derived fibroblasts	844:870	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	5	7	theme	aberrant	792:799	arg1	splicing					801:808	aberrant splicing	792:808	aberrant splicing	792:808	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	8	8	theme	deleted	1174:1180	arg1	cells					1187:1191	siCAMLG deleted Hela cells	1166:1191	siCAMLG deleted Hela cells	1166:1191	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	11	9	theme	reported	1558:1565	arg1	patient					1567:1573	the first reported patient	1548:1573	the first reported patient with pathogenic variants in CAMLG	1548:1607	This is the first reported patient with pathogenic variants in CAMLG.
35262690	11	9	theme	reported	1558:1565	arg1	This					1540:1543	This	1540:1543	This	1540:1543	This is the first reported patient with pathogenic variants in CAMLG.
35262690	3	10	theme	protein	639:645	arg1	integration					617:627	integration	617:627	integration of the TA protein	617:645	Subsequently, GET1 (WRB) and CAML form a receptor that enables integration of the TA protein within the lipid bilayer.
35262690	9	11	theme	fundamental	1371:1381	arg1	role					1383:1386	a fundamental role	1369:1386	a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes	1369:1446	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	1	12	theme	C-terminal	190:199	arg1	proteins					220:227	C-terminal tail-anchored (TA) proteins	190:227	C-terminal tail-anchored (TA) proteins	190:227	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	6	13	with	phenotype	923:931	arg1	hypotonia					962:970	hypotonia	962:970	hypotonia	962:970	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	6	13	with	phenotype	923:931	arg1	abnormalities					1003:1015	structural brain abnormalities	986:1015	structural brain abnormalities	986:1015	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	6	13	with	phenotype	923:931	arg1	disability					950:959	psychomotor disability	938:959	psychomotor disability	938:959	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	6	13	with	phenotype	923:931	arg1	epilepsy					973:980	epilepsy	973:980	epilepsy	973:980	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	10	14	theme	O-glycans	1529:1537	arg1	hyposialylation					1504:1518	the hyposialylation	1500:1518	the hyposialylation of N and O-glycans	1500:1537	It also points towards a possible mechanism behind the hyposialylation of N and O-glycans.
35262690	9	15	theme	TRC	1395:1397	arg1	complex					1399:1405	the TRC complex	1391:1405	the TRC complex	1391:1405	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	8	16	theme	cellular	1223:1230	arg1	marker					1232:1237	a consistent cellular marker	1210:1237	a consistent cellular marker of TRC dysfunction	1210:1256	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	10	17	theme	N	1523:1523	arg1	hyposialylation					1504:1518	the hyposialylation	1500:1518	the hyposialylation of N and O-glycans	1500:1537	It also points towards a possible mechanism behind the hyposialylation of N and O-glycans.
35262690	1	18	theme	recognition	123:133	arg1	pathway					149:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	12	19	theme	third	1627:1631	arg1	disorder					1633:1640	the third disorder	1623:1640	the third disorder	1623:1640	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	12	19	theme	third	1627:1631	arg1	CAMLG-CDG					1610:1618	CAMLG-CDG	1610:1618	CAMLG-CDG	1610:1618	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	8	20	theme	dysfunction	1246:1256	arg1	marker					1232:1237	a consistent cellular marker	1210:1237	a consistent cellular marker of TRC dysfunction	1210:1256	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	9	21	theme	Golgi	1426:1430	arg1	complexes					1438:1446	Golgi SNARE complexes	1426:1446	Golgi SNARE complexes	1426:1446	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	6	22	theme	neurological	910:921	arg1	phenotype					923:931	a predominantly neurological phenotype	894:931	a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities	894:1015	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	4	23	with	individual	686:695	arg1	variant					737:743	the homozygous c.633 + 4A>G splice variant	702:743	the homozygous c.633 + 4A>G splice variant in CAMLG	702:752	We report an individual with the homozygous c.633 + 4A>G splice variant in CAMLG, encoding CAML.
35262690	0	24	theme	defective	66:74	arg1	trafficking					85:95	defective membrane trafficking	66:95	defective membrane trafficking	66:95	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	9	25	theme	complexes	1438:1446	arg1	assembly					1414:1421	the assembly	1410:1421	the assembly of Golgi SNARE complexes	1410:1446	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	11	26	from	variants	1591:1598	arg1	CAMLG					1603:1607	CAMLG	1603:1607	CAMLG	1603:1607	This is the first reported patient with pathogenic variants in CAMLG.
35262690	4	27	from	variant	737:743	arg1	CAMLG					748:752	CAMLG	748:752	CAMLG	748:752	We report an individual with the homozygous c.633 + 4A>G splice variant in CAMLG, encoding CAML.
35262690	6	28	theme	structural	986:995	arg1	abnormalities					1003:1015	structural brain abnormalities	986:1015	structural brain abnormalities	986:1015	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	2	29	theme	correct	361:367	arg1	insertion					369:377	correct insertion	361:377	correct insertion	361:377	In order to facilitate correct insertion, the recognition complex (consisting of BAG6, GET4 and UBL4A) must first bind to TA proteins and then to GET3 (TRC40, ASNA1), which chaperones the protein to the ER membrane.
35262690	1	30	theme	specific	255:262	arg1	organelles					278:287	specific intracellular organelles	255:287	specific intracellular organelles such as the endoplasmic reticulum (ER) membrane	255:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	1	30	theme	specific	255:262	arg1	membrane					328:335	the endoplasmic reticulum (ER) membrane	297:335	the endoplasmic reticulum (ER) membrane	297:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	12	31	theme	disorders	1777:1785	arg1	disorders					1777:1785	disorders	1777:1785	disorders	1777:1785	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	12	31	theme	disorders	1777:1785	arg1	group					1768:1772	this novel group	1757:1772	this novel group of disorders	1757:1785	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	5	32	theme	functional	822:831	arg1	protein					833:839	functional protein	822:839	functional protein	822:839	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	1	33	theme	organelles	278:287	arg1	bilayer					244:250	the lipid bilayer	234:250	the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane	234:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	1	34	theme	transmembrane	102:114	arg1	pathway					149:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	7	35	link	O-linked	1044:1051	arg1	defect					1088:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	Biochemically, a combined O-linked and type II N-linked glycosylation defect was found.
35262690	2	36	theme	recognition	384:394	arg1	complex					396:402	the recognition complex	380:402	the recognition complex (consisting of BAG6, GET4 and UBL4A)	380:439	In order to facilitate correct insertion, the recognition complex (consisting of BAG6, GET4 and UBL4A) must first bind to TA proteins and then to GET3 (TRC40, ASNA1), which chaperones the protein to the ER membrane.
35262690	0	37	theme	congenital	19:28	arg1	disorder					30:37	a novel congenital disorder	11:37	CAMLG-CDG: a novel congenital disorder of glycosylation	0:54	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	7	38	theme	glycosylation	1074:1086	arg1	defect					1088:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	Biochemically, a combined O-linked and type II N-linked glycosylation defect was found.
35262690	0	39	attach	linked	56:61	arg2	CAMLG-CDG					0:8	CAMLG-CDG	0:8	CAMLG-CDG: a novel congenital disorder of glycosylation	0:54	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	0	39	attach	linked	56:61	arg1	trafficking					85:95	defective membrane trafficking	66:95	defective membrane trafficking	66:95	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	4	40	theme	c.633 + 4A>G	717:728	arg1	variant					737:743	the homozygous c.633 + 4A>G splice variant	702:743	the homozygous c.633 + 4A>G splice variant in CAMLG	702:752	We report an individual with the homozygous c.633 + 4A>G splice variant in CAMLG, encoding CAML.
35262690	9	41	theme	Bet1L	1299:1303	arg1	level					1278:1282	the level	1274:1282	the level of the v-SNARE Bet1L	1274:1303	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	4	42	theme	splice	730:735	arg1	variant					737:743	the homozygous c.633 + 4A>G splice variant	702:743	the homozygous c.633 + 4A>G splice variant in CAMLG	702:752	We report an individual with the homozygous c.633 + 4A>G splice variant in CAMLG, encoding CAML.
35262690	9	43	from	role	1383:1386	arg1	assembly					1414:1421	the assembly	1410:1421	the assembly of Golgi SNARE complexes	1410:1446	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	1	44	dep	tail-anchored	201:213	arg1	TA					216:217	TA	216:217	TA	216:217	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	11	45	with	patient	1567:1573	arg1	variants					1591:1598	pathogenic variants	1580:1598	pathogenic variants in CAMLG	1580:1607	This is the first reported patient with pathogenic variants in CAMLG.
35262690	12	46	theme	pathway	1730:1736	arg1	member					1712:1717	a member	1710:1717	a member of the TRC pathway	1710:1736	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	8	47	theme	siCAMLG	1166:1172	arg1	cells					1187:1191	siCAMLG deleted Hela cells	1166:1191	siCAMLG deleted Hela cells	1166:1191	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	1	48	theme	proteins	220:227	arg1	insertion					177:185	the insertion	173:185	the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane	173:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	0	49	dep	CAMLG-CDG	0:8	arg1	disorder					30:37	a novel congenital disorder	11:37	CAMLG-CDG: a novel congenital disorder of glycosylation	0:54	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	7	50	theme	O-linked	1044:1051	arg1	defect					1088:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	Biochemically, a combined O-linked and type II N-linked glycosylation defect was found.
35262690	12	51	theme	GET3	1658:1661	arg1	deficiencies					1663:1674	GET3 deficiencies	1658:1674	GET3 deficiencies	1658:1674	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	11	52	theme	pathogenic	1580:1589	arg1	variants					1591:1598	pathogenic variants	1580:1598	pathogenic variants in CAMLG	1580:1607	This is the first reported patient with pathogenic variants in CAMLG.
35262690	2	53	theme	ER	541:542	arg1	membrane					544:551	the ER membrane	537:551	the ER membrane	537:551	In order to facilitate correct insertion, the recognition complex (consisting of BAG6, GET4 and UBL4A) must first bind to TA proteins and then to GET3 (TRC40, ASNA1), which chaperones the protein to the ER membrane.
35262690	1	54	theme	endoplasmic	301:311	arg1	ER					324:325	ER	324:325	ER	324:325	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	1	54	theme	endoplasmic	301:311	arg1	reticulum					313:321	the endoplasmic reticulum	297:321	the endoplasmic reticulum (ER) membrane	297:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	8	55	theme	Hela	1182:1185	arg1	cells					1187:1191	siCAMLG deleted Hela cells	1166:1191	siCAMLG deleted Hela cells	1166:1191	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	8	56	theme	syntaxin-5	1125:1134	arg1	Mislocalization					1106:1120	Mislocalization	1106:1120	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells	1106:1191	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	3	57	theme	TA	636:637	arg1	protein					639:645	the TA protein	632:645	the TA protein	632:645	Subsequently, GET1 (WRB) and CAML form a receptor that enables integration of the TA protein within the lipid bilayer.
35262690	10	58	dep	mechanism	1483:1491	arg1	behind					1493:1498	behind	1493:1498	behind the hyposialylation of N and O-glycans	1493:1537	It also points towards a possible mechanism behind the hyposialylation of N and O-glycans.
35262690	1	59	theme	tail-anchored	201:213	arg1	proteins					220:227	C-terminal tail-anchored (TA) proteins	190:227	C-terminal tail-anchored (TA) proteins	190:227	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	8	60	theme	patient	1139:1145	arg1	fibroblasts					1147:1157	patient fibroblasts	1139:1157	patient fibroblasts	1139:1157	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	7	61	link	N-linked	1065:1072	arg1	defect					1088:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	Biochemically, a combined O-linked and type II N-linked glycosylation defect was found.
35262690	9	62	theme	complex	1399:1405	arg1	role					1383:1386	a fundamental role	1369:1386	a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes	1369:1446	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	8	63	theme	consistent	1212:1221	arg1	marker					1232:1237	a consistent cellular marker	1210:1237	a consistent cellular marker of TRC dysfunction	1210:1256	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	3	64	theme	lipid	658:662	arg1	bilayer					664:670	the lipid bilayer	654:670	the lipid bilayer	654:670	Subsequently, GET1 (WRB) and CAML form a receptor that enables integration of the TA protein within the lipid bilayer.
35262690	1	65	theme	complex	135:141	arg1	pathway					149:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	6	66	theme	psychomotor	938:948	arg1	disability					950:959	psychomotor disability	938:959	psychomotor disability	938:959	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	1	67	theme	TRC	144:146	arg1	pathway					149:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	8	68	theme	TRC	1242:1244	arg1	dysfunction					1246:1256	TRC dysfunction	1242:1256	TRC dysfunction	1242:1256	Mislocalization of syntaxin-5 in patient fibroblasts and in siCAMLG deleted Hela cells confirms this as a consistent cellular marker of TRC dysfunction.
35262690	0	69	theme	membrane	76:83	arg1	trafficking					85:95	defective membrane trafficking	66:95	defective membrane trafficking	66:95	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	9	70	theme	SNARE	1432:1436	arg1	complexes					1438:1446	Golgi SNARE complexes	1426:1446	Golgi SNARE complexes	1426:1446	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	5	71	theme	patient-derived	844:858	arg1	fibroblasts					860:870	patient-derived fibroblasts	844:870	patient-derived fibroblasts	844:870	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	1	72	theme	domain	116:121	arg1	pathway					149:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway	98:155	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	6	73	theme	brain	997:1001	arg1	abnormalities					1003:1015	structural brain abnormalities	986:1015	structural brain abnormalities	986:1015	The patient displays a predominantly neurological phenotype with psychomotor disability, hypotonia, epilepsy and structural brain abnormalities.
35262690	2	74	theme	TA	460:461	arg1	proteins					463:470	TA proteins	460:470	TA proteins	460:470	In order to facilitate correct insertion, the recognition complex (consisting of BAG6, GET4 and UBL4A) must first bind to TA proteins and then to GET3 (TRC40, ASNA1), which chaperones the protein to the ER membrane.
35262690	10	75	gly	hyposialylation	1504:1518	arg1	O-glycans					1529:1537	O-glycans	1529:1537	O-glycans	1529:1537	It also points towards a possible mechanism behind the hyposialylation of N and O-glycans.
35262690	10	75	gly	hyposialylation	1504:1518	arg1	N					1523:1523	N	1523:1523	N	1523:1523	It also points towards a possible mechanism behind the hyposialylation of N and O-glycans.
35262690	5	76	from	lack	814:817	arg1	fibroblasts					860:870	patient-derived fibroblasts	844:870	patient-derived fibroblasts	844:870	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	0	77	theme	novel	13:17	arg1	disorder					30:37	a novel congenital disorder	11:37	CAMLG-CDG: a novel congenital disorder of glycosylation	0:54	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	1	78	theme	intracellular	264:276	arg1	organelles					278:287	specific intracellular organelles	255:287	specific intracellular organelles such as the endoplasmic reticulum (ER) membrane	255:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	1	78	theme	intracellular	264:276	arg1	membrane					328:335	the endoplasmic reticulum (ER) membrane	297:335	the endoplasmic reticulum (ER) membrane	297:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	5	79	from	splicing	801:808	arg1	fibroblasts					860:870	patient-derived fibroblasts	844:870	patient-derived fibroblasts	844:870	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	5	80	theme	protein	833:839	arg1	splicing					801:808	aberrant splicing	792:808	aberrant splicing	792:808	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	5	80	theme	protein	833:839	arg1	lack					814:817	lack	814:817	lack of functional protein in patient-derived fibroblasts	814:870	This variant leads to aberrant splicing and lack of functional protein in patient-derived fibroblasts.
35262690	7	81	theme	N-linked	1065:1072	arg1	defect					1088:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	a combined O-linked and type II N-linked glycosylation defect	1033:1093	Biochemically, a combined O-linked and type II N-linked glycosylation defect was found.
35262690	12	82	theme	novel	1762:1766	arg1	disorders					1777:1785	disorders	1777:1785	disorders	1777:1785	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	12	82	theme	novel	1762:1766	arg1	group					1768:1772	this novel group	1757:1772	this novel group of disorders	1757:1785	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	0	83	theme	glycosylation	42:54	arg1	disorder					30:37	a novel congenital disorder	11:37	CAMLG-CDG: a novel congenital disorder of glycosylation	0:54	CAMLG-CDG: a novel congenital disorder of glycosylation linked to defective membrane trafficking.
35262690	9	84	theme	v-SNARE	1291:1297	arg1	Bet1L					1299:1303	the v-SNARE Bet1L	1287:1303	the v-SNARE Bet1L	1287:1303	Interestingly, the level of the v-SNARE Bet1L is also drastically reduced in both of these models, indicating a fundamental role of the TRC complex in the assembly of Golgi SNARE complexes.
35262690	12	85	theme	TRC	1726:1728	arg1	pathway					1730:1736	the TRC pathway	1722:1736	the TRC pathway	1722:1736	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
35262690	4	86	theme	homozygous	706:715	arg1	variant					737:743	the homozygous c.633 + 4A>G splice variant	702:743	the homozygous c.633 + 4A>G splice variant in CAMLG	702:752	We report an individual with the homozygous c.633 + 4A>G splice variant in CAMLG, encoding CAML.
35262690	1	87	theme	reticulum	313:321	arg1	membrane					328:335	the endoplasmic reticulum (ER) membrane	297:335	the endoplasmic reticulum (ER) membrane	297:335	The transmembrane domain recognition complex (TRC) pathway is required for the insertion of C-terminal tail-anchored (TA) proteins into the lipid bilayer of specific intracellular organelles such as the endoplasmic reticulum (ER) membrane.
35262690	12	88	from	variants	1698:1705	arg1	member					1712:1717	a member	1710:1717	a member of the TRC pathway	1710:1736	CAMLG-CDG is the third disorder, after GET4 and GET3 deficiencies, caused by pathogenic variants in a member of the TRC pathway, further expanding this novel group of disorders.
37235553	0	0	theme	Eukaryotic	94:103	arg1	Pathways					118:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	5	1	theme	high	867:870	arg1	isomers					889:895	many high mannose N-glycan isomers	862:895	many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi	862:963	LODES/MS identified many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi.
37235553	1	2	theme	important	170:178	arg1	modifications					199:211	the most important post-translational modifications	161:211	the most important post-translational modifications of proteins	161:223	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	0	3	theme	Multicellular	80:92	arg1	Pathways					118:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	1	4	theme	post-translational	180:197	arg1	modifications					199:211	the most important post-translational modifications	161:211	the most important post-translational modifications of proteins	161:223	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	7	5	theme	Many	1214:1217	arg1	N-glycans					1219:1227	Many N-glycans	1214:1227	Many N-glycans in this database	1214:1244	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	4	6	theme	sequence	674:681	arg1	LODES/MS					709:716	LODES/MS	709:716	LODES/MS	709:716	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	6	theme	sequence	674:681	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	6	theme	sequence	674:681	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	2	7	theme	endoplasmic	346:356	arg1	reticulum					358:366	the endoplasmic reticulum	342:366	the endoplasmic reticulum	342:366	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	4	8	theme	high	734:737	arg1	N-glycans					747:755	high mannose N-glycans	734:755	high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants	734:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	3	9	theme	Man7GlcNAc2	483:493	arg1	isomers					495:501	four Man7GlcNAc2 isomers	478:501	four Man7GlcNAc2 isomers	478:501	According to conventional biosynthetic pathways, four Man7GlcNAc2 isomers, three Man6GlcNAc2 isomers, and one Man5GlcNAc2 isomer are generated during this process.
37235553	0	10	theme	Biosynthetic	105:116	arg1	Pathways					118:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	6	11	theme	retention	991:999	arg1	time					1001:1004	retention time	991:1004	retention time	991:1004	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	4	12	theme	multicellular	780:792	arg1	mutants					833:839	glycosylation mutants	819:839	glycosylation mutants	819:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	12	theme	multicellular	780:792	arg1	eukaryotes					794:803	various multicellular eukaryotes	772:803	various multicellular eukaryotes which are not glycosylation mutants	772:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	13	theme	derived	666:672	arg1	LODES/MS					709:716	LODES/MS	709:716	LODES/MS	709:716	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	13	theme	derived	666:672	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	13	theme	derived	666:672	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	14	theme	various	772:778	arg1	mutants					833:839	glycosylation mutants	819:839	glycosylation mutants	819:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	14	theme	various	772:778	arg1	eukaryotes					794:803	various multicellular eukaryotes	772:803	various multicellular eukaryotes which are not glycosylation mutants	772:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	7	15	from	N-glycans	1219:1227	arg1	database					1237:1244	this database	1232:1244	this database	1232:1244	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	8	16	theme	rapid	1332:1336	arg1	identification					1369:1382	rapid high mannose N-glycan isomeric identification	1332:1382	rapid high mannose N-glycan isomeric identification	1332:1382	The database is useful for rapid high mannose N-glycan isomeric identification.
37235553	3	17	theme	Man6GlcNAc2	510:520	arg1	isomers					522:528	three Man6GlcNAc2 isomers	504:528	three Man6GlcNAc2 isomers	504:528	According to conventional biosynthetic pathways, four Man7GlcNAc2 isomers, three Man6GlcNAc2 isomers, and one Man5GlcNAc2 isomer are generated during this process.
37235553	1	18	theme	modifications	199:211	arg1	one					154:156	one	154:156	one	154:156	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	1	18	theme	modifications	199:211	arg1	modifications					199:211	the most important post-translational modifications	161:211	the most important post-translational modifications of proteins	161:223	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	5	19	theme	N-glycan	880:887	arg1	isomers					889:895	many high mannose N-glycan isomers	862:895	many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi	862:963	LODES/MS identified many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi.
37235553	8	20	theme	high	1338:1341	arg1	identification					1369:1382	rapid high mannose N-glycan isomeric identification	1332:1382	rapid high mannose N-glycan isomeric identification	1332:1382	The database is useful for rapid high mannose N-glycan isomeric identification.
37235553	6	21	theme	arbitrary	1133:1141	arg1	numbers					1143:1149	arbitrary numbers	1133:1149	arbitrary numbers	1133:1149	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	8	22	theme	N-glycan	1351:1358	arg1	identification					1369:1382	rapid high mannose N-glycan isomeric identification	1332:1382	rapid high mannose N-glycan isomeric identification	1332:1382	The database is useful for rapid high mannose N-glycan isomeric identification.
37235553	3	23	theme	biosynthetic	455:466	arg1	pathways					468:475	conventional biosynthetic pathways	442:475	conventional biosynthetic pathways	442:475	According to conventional biosynthetic pathways, four Man7GlcNAc2 isomers, three Man6GlcNAc2 isomers, and one Man5GlcNAc2 isomer are generated during this process.
37235553	7	24	theme	current	1263:1269	arg1	libraries					1294:1302	current N-glycan mass spectrum libraries	1263:1302	current N-glycan mass spectrum libraries	1263:1302	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	6	25	theme	ManGlcNAc2	1063:1072	arg1	isomers					1088:1094	all possible ManGlcNAc2 (n = 5, 6, 7) isomers	1050:1094	all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2	1050:1211	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	1	26	theme	proteins	216:223	arg1	modifications					199:211	the most important post-translational modifications	161:211	the most important post-translational modifications of proteins	161:223	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	4	27	theme	mass	630:633	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	27	theme	mass	630:633	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	2	28	theme	Golgi	372:376	arg1	apparatus					378:386	Golgi apparatus	372:386	Golgi apparatus	372:386	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	4	29	theme	mannose	739:745	arg1	N-glycans					747:755	high mannose N-glycans	734:755	high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants	734:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	0	30	theme	High	22:25	arg1	Isomers					44:50	the High Mannose N-Glycan Isomers	18:50	the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways	18:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	4	31	theme	latest	623:628	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	31	theme	latest	623:628	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	32	theme	glycosylation	819:831	arg1	mutants					833:839	glycosylation mutants	819:839	glycosylation mutants	819:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	32	theme	glycosylation	819:831	arg1	eukaryotes					794:803	various multicellular eukaryotes	772:803	various multicellular eukaryotes which are not glycosylation mutants	772:839	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	1	33	theme	N-linked	128:135	arg1	glycosylation					137:149	N-linked glycosylation	128:149	N-linked glycosylation	128:149	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	6	34	theme	CID	1010:1012	arg1	spectra					1022:1028	CID MS mass spectra	1010:1028	CID MS mass spectra	1010:1028	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	5	35	theme	cancer	941:946	arg1	cells					948:952	cancer cells	941:952	cancer cells	941:952	LODES/MS identified many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi.
37235553	0	36	theme	N-Glycan	35:42	arg1	Isomers					44:50	the High Mannose N-Glycan Isomers	18:50	the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways	18:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	4	37	theme	spectrometry	635:646	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	37	theme	spectrometry	635:646	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	0	38	theme	Mannose	27:33	arg1	Isomers					44:50	the High Mannose N-Glycan Isomers	18:50	the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways	18:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	5	39	theme	mannose	872:878	arg1	isomers					889:895	many high mannose N-glycan isomers	862:895	many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi	862:963	LODES/MS identified many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi.
37235553	2	40	theme	biosynthesis	280:291	arg1	knowledge					234:242	Current knowledge	226:242	Current knowledge of multicellular eukaryote N-glycan biosynthesis	226:291	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	7	41	located	found	1254:1258	arg2	N-glycans					1219:1227	Many N-glycans	1214:1227	Many N-glycans in this database	1214:1244	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	7	41	located	found	1254:1258	arg1	libraries					1294:1302	current N-glycan mass spectrum libraries	1263:1302	current N-glycan mass spectrum libraries	1263:1302	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	3	42	theme	Man5GlcNAc2	539:549	arg1	isomer					551:556	one Man5GlcNAc2 isomer	535:556	one Man5GlcNAc2 isomer	535:556	According to conventional biosynthetic pathways, four Man7GlcNAc2 isomers, three Man6GlcNAc2 isomers, and one Man5GlcNAc2 isomer are generated during this process.
37235553	0	43	theme	Undescribed	52:62	arg1	Isomers					44:50	the High Mannose N-Glycan Isomers	18:50	the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways	18:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	5	44	theme	many	862:865	arg1	isomers					889:895	many high mannose N-glycan isomers	862:895	many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi	862:963	LODES/MS identified many high mannose N-glycan isomers previously unreported in plantae, animalia, cancer cells, and fungi.
37235553	2	45	theme	N-glycan	271:278	arg1	biosynthesis					280:291	multicellular eukaryote N-glycan biosynthesis	247:291	multicellular eukaryote N-glycan biosynthesis	247:291	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	6	46	theme	mannose	1168:1174	arg1	positions					1155:1163	positions	1155:1163	positions	1155:1163	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	6	46	theme	mannose	1168:1174	arg1	numbers					1143:1149	arbitrary numbers	1133:1149	arbitrary numbers	1133:1149	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	6	47	theme	canonical	1181:1189	arg1	Man9GlcNAc2					1201:1211	Man9GlcNAc2	1201:1211	Man9GlcNAc2	1201:1211	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	6	47	theme	canonical	1181:1189	arg1	N-glycan					1191:1198	canonical N-glycan	1181:1198	canonical N-glycan	1181:1198	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	0	48	theme	Isomers	44:50	arg1	Identification					0:13	Identification	0:13	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.	0:126	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	7	49	theme	N-glycan	1271:1278	arg1	libraries					1294:1302	current N-glycan mass spectrum libraries	1263:1302	current N-glycan mass spectrum libraries	1263:1302	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	2	50	theme	multicellular	247:259	arg1	biosynthesis					280:291	multicellular eukaryote N-glycan biosynthesis	247:291	multicellular eukaryote N-glycan biosynthesis	247:291	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	2	51	theme	eukaryote	261:269	arg1	biosynthesis					280:291	multicellular eukaryote N-glycan biosynthesis	247:291	multicellular eukaryote N-glycan biosynthesis	247:291	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	2	52	theme	biosynthetic	406:417	arg1	pathways					419:426	conserved biosynthetic pathways	396:426	conserved biosynthetic pathways	396:426	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	6	53	theme	mass	1017:1020	arg1	spectra					1022:1028	CID MS mass spectra	1010:1028	CID MS mass spectra	1010:1028	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	4	54	link	derived	666:672	arg1	LODES/MS					709:716	LODES/MS	709:716	LODES/MS	709:716	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	54	link	derived	666:672	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	54	link	derived	666:672	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	2	55	theme	conserved	396:404	arg1	pathways					419:426	conserved biosynthetic pathways	396:426	conserved biosynthetic pathways	396:426	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	4	56	theme	mass	690:693	arg1	LODES/MS					709:716	LODES/MS	709:716	LODES/MS	709:716	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	56	theme	mass	690:693	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	56	theme	mass	690:693	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	6	57	dep	ManGlcNAc2	1063:1072	arg1	=					1077:1077	=	1077:1077	=	1077:1077	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	8	58	theme	mannose	1343:1349	arg1	identification					1369:1382	rapid high mannose N-glycan isomeric identification	1332:1382	rapid high mannose N-glycan isomeric identification	1332:1382	The database is useful for rapid high mannose N-glycan isomeric identification.
37235553	6	59	theme	possible	1054:1061	arg1	ManGlcNAc2					1063:1072	possible ManGlcNAc2	1054:1072	all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2	1050:1211	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	4	60	theme	tandem	683:688	arg1	LODES/MS					709:716	LODES/MS	709:716	LODES/MS	709:716	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	60	theme	tandem	683:688	arg1	spectrometry					695:706	sequence tandem mass spectrometry	674:706	logically derived sequence tandem mass spectrometry (LODES/MS)	656:717	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	4	60	theme	tandem	683:688	arg1	method					648:653	our latest mass spectrometry method	619:653	our latest mass spectrometry method	619:653	In this study, we applied our latest mass spectrometry method, logically derived sequence tandem mass spectrometry (LODES/MS), to re-examine high mannose N-glycans extracted from various multicellular eukaryotes which are not glycosylation mutants.
37235553	0	61	theme	Conventional	67:78	arg1	Pathways					118:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Conventional Multicellular Eukaryotic Biosynthetic Pathways	67:125	Identification of the High Mannose N-Glycan Isomers Undescribed by Conventional Multicellular Eukaryotic Biosynthetic Pathways.
37235553	2	62	theme	Current	226:232	arg1	knowledge					234:242	Current knowledge	226:242	Current knowledge of multicellular eukaryote N-glycan biosynthesis	226:291	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	2	63	theme	mannose	307:313	arg1	N-glycans					315:323	high mannose N-glycans	302:323	high mannose N-glycans	302:323	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	7	64	theme	mass	1280:1283	arg1	libraries					1294:1302	current N-glycan mass spectrum libraries	1263:1302	current N-glycan mass spectrum libraries	1263:1302	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	1	65	link	N-linked	128:135	arg1	glycosylation					137:149	N-linked glycosylation	128:149	N-linked glycosylation	128:149	N-linked glycosylation is one of the most important post-translational modifications of proteins.
37235553	6	66	theme	MS	1014:1015	arg1	spectra					1022:1028	CID MS mass spectra	1010:1028	CID MS mass spectra	1010:1028	A database consisting of retention time and CID MS mass spectra was constructed for all possible ManGlcNAc2 (n = 5, 6, 7) isomers that include the isomers by removing arbitrary numbers and positions of mannose from canonical N-glycan, Man9GlcNAc2.
37235553	2	67	theme	high	302:305	arg1	N-glycans					315:323	high mannose N-glycans	302:323	high mannose N-glycans	302:323	Current knowledge of multicellular eukaryote N-glycan biosynthesis suggests high mannose N-glycans are generated in the endoplasmic reticulum and Golgi apparatus through conserved biosynthetic pathways.
37235553	8	68	theme	isomeric	1360:1367	arg1	identification					1369:1382	rapid high mannose N-glycan isomeric identification	1332:1382	rapid high mannose N-glycan isomeric identification	1332:1382	The database is useful for rapid high mannose N-glycan isomeric identification.
37235553	7	69	theme	spectrum	1285:1292	arg1	libraries					1294:1302	current N-glycan mass spectrum libraries	1263:1302	current N-glycan mass spectrum libraries	1263:1302	Many N-glycans in this database are not found in current N-glycan mass spectrum libraries.
37235553	3	70	theme	conventional	442:453	arg1	pathways					468:475	conventional biosynthetic pathways	442:475	conventional biosynthetic pathways	442:475	According to conventional biosynthetic pathways, four Man7GlcNAc2 isomers, three Man6GlcNAc2 isomers, and one Man5GlcNAc2 isomer are generated during this process.
35373202	9	0	from	glycosylation	1837:1849	arg1	relevance					1807:1815	the relevance	1803:1815	the relevance of GalNAc-T4 in the glycosylation of this epitope	1803:1865	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	6	1	theme	lectin-assisted	1211:1225	arg1	manner					1227:1232	a lectin-assisted manner	1209:1232	a lectin-assisted manner	1209:1232	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	6	2	theme	acceptor	1175:1182	arg1	sites					1184:1188	acceptor sites	1175:1188	acceptor sites	1175:1188	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	9	3	theme	GalNAc-T4	1684:1692	arg1	isoform					1694:1700	the GalNAc-T4 isoform	1680:1700	the GalNAc-T4 isoform	1680:1700	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	9	3	theme	GalNAc-T4	1684:1692	arg1	isoform					1714:1720	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	10	4	theme	other	1935:1939	arg1	C1GalT1					1971:1977	C1GalT1	1971:1977	C1GalT1	1971:1977	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	10	4	theme	other	1935:1939	arg1	glycosyltransferases					1941:1960	other glycosyltransferases	1935:1960	other glycosyltransferases	1935:1960	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	10	4	theme	other	1935:1939	arg1	ST6GalNAc-I					1983:1993	ST6GalNAc-I	1983:1993	ST6GalNAc-I	1983:1993	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	3	5	theme	full	509:512	arg1	process					514:520	the full process	505:520	the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms	505:572	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	1	6	theme	polypeptide	178:188	arg1	GalNAc-transferases					190:208	polypeptide GalNAc-transferases	178:208	polypeptide GalNAc-transferases (GalNAc-Ts)	178:220	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	1	6	theme	polypeptide	178:188	arg1	GalNAc-Ts					211:219	GalNAc-Ts	211:219	GalNAc-Ts	211:219	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	4	7	theme	site	847:850	arg1	selection					852:860	the glycosylation site selection	829:860	the glycosylation site selection	829:860	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	3	8	theme	GalNAc-T2/T3/T4	549:563	arg1	isoforms					565:572	GalNAc-T2/T3/T4 isoforms	549:572	GalNAc-T2/T3/T4 isoforms	549:572	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	9	9	theme	only	1709:1712	arg1	isoform					1694:1700	the GalNAc-T4 isoform	1680:1700	the GalNAc-T4 isoform	1680:1700	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	9	9	theme	only	1709:1712	arg1	isoform					1714:1720	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	3	10	theme	O-glycosylation	530:544	arg1	process					514:520	the full process	505:520	the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms	505:572	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	9	11	theme	glycosylating	1722:1734	arg1	isoform					1694:1700	the GalNAc-T4 isoform	1680:1700	the GalNAc-T4 isoform	1680:1700	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	9	11	theme	glycosylating	1722:1734	arg1	isoform					1714:1720	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	0	12	theme	Molecular	138:146	arg1	Modeling					148:155	Molecular Modeling	138:155	Molecular Modeling	138:155	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	9	13	theme	GalNAc-T4	1820:1828	arg1	relevance					1807:1815	the relevance	1803:1815	the relevance of GalNAc-T4 in the glycosylation of this epitope	1803:1865	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	8	14	theme	specific	1468:1475	arg1	motifs					1579:1584	the main structural motifs	1559:1584	the main structural motifs behind the GalNAc-T4 specificity toward this region	1559:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	14	theme	specific	1468:1475	arg1	salt-bridge					1477:1487	a specific salt-bridge	1466:1487	a specific salt-bridge	1466:1487	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	14	theme	specific	1468:1475	arg1	conformation					1512:1523	the inverse γ-turn conformation	1493:1523	the inverse γ-turn conformation of the PDTRP sequence in MUC1	1493:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	7	15	theme	GalNAc-T2/T3/T4	1371:1385	arg1	specificities					1392:1404	GalNAc-T2/T3/T4 fine specificities	1371:1404	GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate	1371:1430	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	6	16	gly	glycosylation	1158:1170	arg1	sites					1184:1188	acceptor sites	1175:1188	acceptor sites	1175:1188	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	4	17	theme	GalNAc	894:899	arg1	residue					901:907	the first GalNAc residue	884:907	the first GalNAc residue	884:907	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	10	18	theme	complex	2032:2038	arg1	substrates					2055:2064	complex mucin acceptor substrates	2032:2064	complex mucin acceptor substrates	2032:2064	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	3	19	theme	modeling	616:623	arg1	protocols					625:633	molecular modeling protocols	606:633	molecular modeling protocols	606:633	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	4	20	from	importance	794:803	arg1	selection					852:860	the glycosylation site selection	829:860	the glycosylation site selection	829:860	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	9	21	theme	epitope	1763:1769	arg1	PDTRP					1771:1775	the immunogenic epitope PDTRP	1747:1775	the immunogenic epitope PDTRP	1747:1775	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	8	22	theme	inverse	1497:1503	arg1	salt-bridge					1477:1487	a specific salt-bridge	1466:1487	a specific salt-bridge	1466:1487	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	22	theme	inverse	1497:1503	arg1	conformation					1512:1523	the inverse γ-turn conformation	1493:1523	the inverse γ-turn conformation of the PDTRP sequence in MUC1	1493:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	22	theme	inverse	1497:1503	arg1	motifs					1579:1584	the main structural motifs	1559:1584	the main structural motifs behind the GalNAc-T4 specificity toward this region	1559:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	4	23	theme	repeat	668:673	arg1	domains					675:681	four tandem repeat domains	656:681	four tandem repeat domains as a substrate	656:696	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	6	24	from	manner	1227:1232	arg1	critical					1137:1144	critical	1137:1144	critical	1137:1144	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	0	25	theme	Process	58:64	arg1	Specificity					11:21	Specificity	11:21	Specificity	11:21	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	0	25	theme	Process	58:64	arg1	Atomic					0:5	Atomic	0:5	Atomic	0:5	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	9	26	theme	immunogenic	1751:1761	arg1	PDTRP					1771:1775	the immunogenic epitope PDTRP	1747:1775	the immunogenic epitope PDTRP	1747:1775	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	0	27	theme	Multiple	69:76	arg1	Isoforms					109:116	Multiple Polypeptide GalNAc-Transferase Isoforms	69:116	Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling	69:155	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	4	28	theme	different	745:753	arg1	isoforms					765:772	different GalNAc-Ts isoforms	745:772	different GalNAc-Ts isoforms	745:772	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	10	29	theme	acceptor	2046:2053	arg1	substrates					2055:2064	complex mucin acceptor substrates	2032:2064	complex mucin acceptor substrates	2032:2064	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	0	30	theme	GalNAc-Transferase	90:107	arg1	Isoforms					109:116	Multiple Polypeptide GalNAc-Transferase Isoforms	69:116	Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling	69:155	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	5	31	theme	multiple	948:955	arg1	sites					966:970	yet multiple acceptor sites	944:970	yet multiple acceptor sites	944:970	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	8	32	theme	sequence	1538:1545	arg1	conformation					1512:1523	the inverse γ-turn conformation	1493:1523	the inverse γ-turn conformation of the PDTRP sequence in MUC1	1493:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	32	theme	sequence	1538:1545	arg1	salt-bridge					1477:1487	a specific salt-bridge	1466:1487	a specific salt-bridge	1466:1487	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	32	theme	sequence	1538:1545	arg1	motifs					1579:1584	the main structural motifs	1559:1584	the main structural motifs behind the GalNAc-T4 specificity toward this region	1559:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	4	33	theme	isoforms	765:772	arg1	preferences					730:740	the glycosylation preferences	712:740	the glycosylation preferences of different GalNAc-Ts isoforms	712:772	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	9	34	gly	glycosylation	1837:1849	arg1	epitope					1859:1865	this epitope	1854:1865	this epitope	1854:1865	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	7	35	theme	residues	1341:1348	arg1	incorporation					1317:1329	incorporation	1317:1329	incorporation	1317:1329	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	1	36	theme	tandem	284:289	arg1	regions					298:304	the tandem repeat regions	280:304	the tandem repeat regions of mucins (e.g., MUC1)	280:327	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	2	37	theme	O-glycans	425:433	arg1	patterns					413:420	well-defined and clustered patterns	386:420	well-defined and clustered patterns of O-glycans	386:433	However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood.
35373202	2	38	theme	patterns	413:420	arg1	creation					374:381	the creation	370:381	the creation of well-defined and clustered patterns of O-glycans in mucins	370:443	However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood.
35373202	8	39	from	conformation	1512:1523	arg1	MUC1					1550:1553	MUC1	1550:1553	MUC1	1550:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	40	theme	structural	1568:1577	arg1	salt-bridge					1477:1487	a specific salt-bridge	1466:1487	a specific salt-bridge	1466:1487	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	40	theme	structural	1568:1577	arg1	conformation					1512:1523	the inverse γ-turn conformation	1493:1523	the inverse γ-turn conformation of the PDTRP sequence in MUC1	1493:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	40	theme	structural	1568:1577	arg1	motifs					1579:1584	the main structural motifs	1559:1584	the main structural motifs behind the GalNAc-T4 specificity toward this region	1559:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	6	41	from	critical	1137:1144	arg1	manner					1227:1232	a lectin-assisted manner	1209:1232	a lectin-assisted manner	1209:1232	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	1	42	theme	mucins	309:314	arg1	regions					298:304	the tandem repeat regions	280:304	the tandem repeat regions of mucins (e.g., MUC1)	280:327	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	7	43	theme	peptide	1293:1299	arg1	backbone					1301:1308	the peptide backbone	1289:1308	the peptide backbone	1289:1308	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	4	44	theme	domain	819:824	arg1	importance					794:803	the importance	790:803	the importance of the lectin domain in the glycosylation site selection	790:860	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	5	45	theme	acceptor	1016:1023	arg1	sites					1025:1029	acceptor sites	1016:1029	acceptor sites	1016:1029	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	6	46	theme	neighboring	1106:1116	arg1	repeats					1125:1131	neighboring tandem repeats	1106:1131	neighboring tandem repeats	1106:1131	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	9	47	theme	epitope	1859:1865	arg1	glycosylation					1837:1849	the glycosylation	1833:1849	the glycosylation of this epitope	1833:1865	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	8	48	theme	GalNAc-T4	1597:1605	arg1	specificity					1607:1617	the GalNAc-T4 specificity	1593:1617	the GalNAc-T4 specificity toward this region	1593:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	7	49	theme	conformational	1263:1276	arg1	changes					1278:1284	local conformational changes	1257:1284	local conformational changes in the peptide backbone	1257:1308	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	1	50	theme	GalNAc	250:255	arg1	O-glycans					257:265	GalNAc O-glycans	250:265	GalNAc O-glycans	250:265	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	0	51	dep	Atomic	0:5	arg1	Details					23:29	Details	23:29	Details	23:29	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	9	52	from	GalNAc-T4	1820:1828	arg1	glycosylation					1837:1849	the glycosylation	1833:1849	the glycosylation of this epitope	1833:1865	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	9	53	from	relevance	1807:1815	arg1	glycosylation					1837:1849	the glycosylation	1833:1849	the glycosylation of this epitope	1833:1865	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	6	54	theme	further	1150:1156	arg1	glycosylation					1158:1170	further glycosylation	1150:1170	further glycosylation of acceptor sites	1150:1188	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	9	55	dep	isoform	1714:1720	arg1	Thr					1740:1742	the Thr	1736:1742	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	9	56	gly	glycosylating	1722:1734	arg0	isoform					1714:1720	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	9	56	gly	glycosylating	1722:1734	arg0	isoform					1694:1700	the GalNAc-T4 isoform	1680:1700	the GalNAc-T4 isoform	1680:1700	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	1	57	theme	GalNAc-transferases	190:208	arg1	family					168:173	The large family	158:173	The large family of polypeptide GalNAc-transferases (GalNAc-Ts)	158:220	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	4	58	theme	glycosylation	833:845	arg1	selection					852:860	the glycosylation site selection	829:860	the glycosylation site selection	829:860	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	7	59	from	changes	1278:1284	arg1	backbone					1301:1308	the peptide backbone	1289:1308	the peptide backbone	1289:1308	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	3	60	theme	MUC1	525:528	arg1	O-glycosylation					530:544	MUC1 O-glycosylation	525:544	MUC1 O-glycosylation	525:544	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	4	61	theme	residue	901:907	arg1	addition					872:879	the addition	868:879	the addition of the first GalNAc residue	868:907	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	7	62	theme	MUC1	1417:1420	arg1	substrate					1422:1430	the MUC1 substrate	1413:1430	the MUC1 substrate	1413:1430	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	3	63	theme	NMR	577:579	arg1	spectroscopy					581:592	NMR spectroscopy	577:592	NMR spectroscopy assisted by molecular modeling protocols	577:633	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	4	64	gly	glycosylation	833:845	arg2	site					847:850	the glycosylation site selection	829:860	the glycosylation site selection	829:860	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	4	64	gly	glycosylation	833:845	arg2	selection					852:860	the glycosylation site selection	829:860	the glycosylation site selection	829:860	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	7	65	theme	fine	1387:1390	arg1	specificities					1392:1404	GalNAc-T2/T3/T4 fine specificities	1371:1404	GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate	1371:1430	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	3	66	theme	molecular	606:614	arg1	protocols					625:633	molecular modeling protocols	606:633	molecular modeling protocols	606:633	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	4	67	theme	first	888:892	arg1	residue					901:907	the first GalNAc residue	884:907	the first GalNAc residue	884:907	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	8	68	theme	γ-turn	1505:1510	arg1	salt-bridge					1477:1487	a specific salt-bridge	1466:1487	a specific salt-bridge	1466:1487	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	68	theme	γ-turn	1505:1510	arg1	conformation					1512:1523	the inverse γ-turn conformation	1493:1523	the inverse γ-turn conformation of the PDTRP sequence in MUC1	1493:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	68	theme	γ-turn	1505:1510	arg1	motifs					1579:1584	the main structural motifs	1559:1584	the main structural motifs behind the GalNAc-T4 specificity toward this region	1559:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	69	from	salt-bridge	1477:1487	arg1	MUC1					1550:1553	MUC1	1550:1553	MUC1	1550:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	5	70	theme	catalytic	1038:1046	arg1	domain					1048:1053	the catalytic domain	1034:1053	the catalytic domain	1034:1053	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	3	71	theme	assisted	594:601	arg1	spectroscopy					581:592	NMR spectroscopy	577:592	NMR spectroscopy assisted by molecular modeling protocols	577:633	In this context, herein, we disclose the full process of MUC1 O-glycosylation by GalNAc-T2/T3/T4 isoforms by NMR spectroscopy assisted by molecular modeling protocols.
35373202	9	72	theme	PDTRP	1771:1775	arg1	Thr					1740:1742	the Thr	1736:1742	the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo	1705:1783	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	6	73	theme	sites	1184:1188	arg1	glycosylation					1158:1170	further glycosylation	1150:1170	further glycosylation of acceptor sites	1150:1188	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	4	74	theme	tandem	661:666	arg1	domains					675:681	four tandem repeat domains	656:681	four tandem repeat domains as a substrate	656:696	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	0	75	theme	Polypeptide	78:88	arg1	Isoforms					109:116	Multiple Polypeptide GalNAc-Transferase Isoforms	69:116	Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling	69:155	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	1	76	theme	large	162:166	arg1	family					168:173	The large family	158:173	The large family of polypeptide GalNAc-transferases (GalNAc-Ts)	158:220	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	8	77	theme	PDTRP	1532:1536	arg1	sequence					1538:1545	the PDTRP sequence	1528:1545	the PDTRP sequence	1528:1545	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	5	78	gly	glycosylated	915:926	arg1	substrate					928:936	a glycosylated substrate	913:936	a glycosylated substrate	913:936	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	10	79	theme	mucin	2040:2044	arg1	substrates					2055:2064	complex mucin acceptor substrates	2032:2064	complex mucin acceptor substrates	2032:2064	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	5	80	theme	acceptor	957:964	arg1	sites					966:970	yet multiple acceptor sites	944:970	yet multiple acceptor sites	944:970	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	7	81	theme	GalNAc	1334:1339	arg1	residues					1341:1348	GalNAc residues	1334:1348	GalNAc residues	1334:1348	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	4	82	theme	GalNAc-Ts	755:763	arg1	isoforms					765:772	different GalNAc-Ts isoforms	745:772	different GalNAc-Ts isoforms	745:772	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	5	83	theme	glycosylated	915:926	arg1	substrate					928:936	a glycosylated substrate	913:936	a glycosylated substrate	913:936	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	8	84	theme	main	1563:1566	arg1	salt-bridge					1477:1487	a specific salt-bridge	1466:1487	a specific salt-bridge	1466:1487	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	84	theme	main	1563:1566	arg1	conformation					1512:1523	the inverse γ-turn conformation	1493:1523	the inverse γ-turn conformation of the PDTRP sequence in MUC1	1493:1553	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	8	84	theme	main	1563:1566	arg1	motifs					1579:1584	the main structural motifs	1559:1584	the main structural motifs behind the GalNAc-T4 specificity toward this region	1559:1636	Interestingly, we postulate that a specific salt-bridge and the inverse γ-turn conformation of the PDTRP sequence in MUC1 are the main structural motifs behind the GalNAc-T4 specificity toward this region.
35373202	1	85	theme	repeat	291:296	arg1	regions					298:304	the tandem repeat regions	280:304	the tandem repeat regions of mucins (e.g., MUC1)	280:327	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	1	86	dep	MUC1	323:326	arg1	e.g.					317:320	e.g.	317:320	e.g.	317:320	The large family of polypeptide GalNAc-transferases (GalNAc-Ts) controls with precision how GalNAc O-glycans are added in the tandem repeat regions of mucins (e.g., MUC1).
35373202	4	87	theme	glycosylation	716:728	arg1	preferences					730:740	the glycosylation preferences	712:740	the glycosylation preferences of different GalNAc-Ts isoforms	712:772	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	2	88	theme	clustered	403:411	arg1	patterns					413:420	well-defined and clustered patterns	386:420	well-defined and clustered patterns of O-glycans	386:433	However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood.
35373202	0	89	theme	Mucin	34:38	arg1	Process					58:64	Mucin 1 O-Glycosylation Process	34:64	Mucin 1 O-Glycosylation Process	34:64	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	2	90	theme	well-defined	386:397	arg1	patterns					413:420	well-defined and clustered patterns	386:420	well-defined and clustered patterns of O-glycans	386:433	However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood.
35373202	0	91	theme	O-Glycosylation	42:56	arg1	Process					58:64	Mucin 1 O-Glycosylation Process	34:64	Mucin 1 O-Glycosylation Process	34:64	Atomic and Specificity Details of Mucin 1 O-Glycosylation Process by Multiple Polypeptide GalNAc-Transferase Isoforms Unveiled by NMR and Molecular Modeling.
35373202	6	92	theme	tandem	1118:1123	arg1	repeats					1125:1131	neighboring tandem repeats	1106:1131	neighboring tandem repeats	1106:1131	Our experiments suggest that during this process, neighboring tandem repeats are critical for further glycosylation of acceptor sites by GalNAc-T2/T4 in a lectin-assisted manner.
35373202	4	93	theme	lectin	812:817	arg1	domain					819:824	the lectin domain	808:824	the lectin domain	808:824	By using MUC1, with four tandem repeat domains as a substrate, we confirmed the glycosylation preferences of different GalNAc-Ts isoforms and highlighted the importance of the lectin domain in the glycosylation site selection after the addition of the first GalNAc residue.
35373202	9	94	theme	in-cell	1652:1658	arg1	analysis					1660:1667	in-cell analysis	1652:1667	in-cell analysis	1652:1667	In addition, in-cell analysis shows that the GalNAc-T4 isoform is the only isoform glycosylating the Thr of the immunogenic epitope PDTRP in vivo, which highlights the relevance of GalNAc-T4 in the glycosylation of this epitope.
35373202	2	95	from	creation	374:381	arg1	mucins					438:443	mucins	438:443	mucins	438:443	However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood.
35373202	7	96	theme	local	1257:1261	arg1	changes					1278:1284	local conformational changes	1257:1284	local conformational changes in the peptide backbone	1257:1308	Our studies also show local conformational changes in the peptide backbone during incorporation of GalNAc residues, which might explain GalNAc-T2/T3/T4 fine specificities toward the MUC1 substrate.
35373202	10	97	theme	NMR	1881:1883	arg1	methodology					1885:1895	the NMR methodology	1877:1895	the NMR methodology established herein	1877:1914	Finally, the NMR methodology established herein can be extended to other glycosyltransferases, such as C1GalT1 and ST6GalNAc-I, to determine the specificity toward complex mucin acceptor substrates.
35373202	5	98	theme	lectin	977:982	arg1	domain					984:989	the lectin domain	973:989	the lectin domain	973:989	In a glycosylated substrate, with yet multiple acceptor sites, the lectin domain contributes to orientate acceptor sites to the catalytic domain.
35373202	2	99	theme	structural	343:352	arg1	features					354:361	the structural features	339:361	the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins	339:443	However, the structural features behind the creation of well-defined and clustered patterns of O-glycans in mucins are poorly understood.
35452121	4	0	theme	samples	888:894	arg1	thousands					875:883	thousands	875:883	thousands of samples, also known as high-throughput (HT) glycomics	875:940	Driven by these challenges, methods have emerged, which can tackle the complexity of glycosylation in thousands of samples, also known as high-throughput (HT) glycomics.
35452121	7	1	theme	HT	1414:1415	arg1	glycomics					1417:1425	HT glycomics	1414:1425	HT glycomics	1414:1425	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	8	2	theme	wider	1604:1608	arg1	use					1610:1612	wider use	1604:1612	wider use	1604:1612	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	3	3	theme	patho	755:759	arg1	physiology					761:770	human (patho)physiology	748:770	human (patho)physiology	748:770	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	2	4	theme	Recent	291:296	arg1	research					314:321	Recent glycobiological research	291:321	Recent glycobiological research	291:321	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	5	5	theme	non-specialized	1175:1189	arg1	laboratories					1191:1202	non-specialized laboratories	1175:1202	non-specialized laboratories	1175:1202	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	4	6	theme	glycosylation	858:870	arg1	complexity					844:853	the complexity	840:853	the complexity of glycosylation	840:870	Driven by these challenges, methods have emerged, which can tackle the complexity of glycosylation in thousands of samples, also known as high-throughput (HT) glycomics.
35452121	3	7	theme	human	748:752	arg1	physiology					761:770	human (patho)physiology	748:770	human (patho)physiology	748:770	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	6	8	theme	glycomics	1216:1224	arg1	methods					1226:1232	Current HT glycomics methods	1205:1232	Current HT glycomics methods	1205:1232	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	2	9	theme	painting	326:333	arg1	picture					337:343	painting a picture	326:343	painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes	326:585	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	1	10	theme	magnitude	189:197	arg1	orders					179:184	several orders	171:184	several orders of magnitude	171:197	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	3	11	theme	interindividual	594:608	arg1	differences					610:620	interindividual differences	594:620	interindividual differences in glycosylation	594:637	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	2	12	theme	pathological	564:575	arg1	processes					577:585	many biological and pathological processes	544:585	many biological and pathological processes	544:585	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	6	13	theme	HT	1213:1214	arg1	methods					1226:1232	Current HT glycomics methods	1205:1232	Current HT glycomics methods	1205:1232	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	8	14	theme	prospective	1699:1709	arg1	methods					1711:1717	methods	1711:1717	methods	1711:1717	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	8	15	theme	life	1819:1822	arg1	complexity					1805:1814	the complexity	1801:1814	the complexity of life	1801:1822	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	7	16	theme	biomedical	1565:1574	arg1	research					1576:1583	(basic) biomedical research	1557:1583	(basic) biomedical research	1557:1583	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	2	17	from	mechanism	531:539	arg1	processes					577:585	many biological and pathological processes	544:585	many biological and pathological processes	544:585	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	1	18	theme	structural	134:143	arg1	complexity					145:154	the structural complexity	130:154	the structural complexity of proteins	130:166	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	7	19	theme	basic	1558:1562	arg1	research					1576:1583	(basic) biomedical research	1557:1583	(basic) biomedical research	1557:1583	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	2	20	theme	regulatory	520:529	arg1	glycosylation					464:476	alternative glycosylation	452:476	alternative glycosylation of proteins and lipids	452:499	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	20	theme	regulatory	520:529	arg1	mechanism					531:539	an important regulatory mechanism	507:539	an important regulatory mechanism	507:539	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	6	21	theme	various	1365:1371	arg1	samples					1384:1390	various biological samples	1365:1390	various biological samples	1365:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	5	22	theme	long	1098:1101	arg1	period					1103:1108	a long period	1096:1108	a long period of time (months/years)	1096:1131	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	8	23	theme	applications	1737:1748	arg1	methods					1711:1717	methods	1711:1717	methods	1711:1717	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	7	24	from	goal	1406:1409	arg1	glycomics					1417:1425	HT glycomics	1414:1425	HT glycomics	1414:1425	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	0	25	from	perspectives	17:28	arg1	glycomics					57:65	high-throughput protein glycomics	33:65	high-throughput protein glycomics	33:65	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	2	26	theme	biological	549:558	arg1	processes					577:585	many biological and pathological processes	544:585	many biological and pathological processes	544:585	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	0	27	from	Developments	0:11	arg1	glycomics					57:65	high-throughput protein glycomics	33:65	high-throughput protein glycomics	33:65	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	0	28	theme	thousands	93:101	arg1	analysis					81:88	the analysis	77:88	the analysis of thousands of samples	77:112	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	6	29	from	glycome	1337:1343	arg1	numbers					1354:1360	large numbers	1348:1360	large numbers of various biological samples	1348:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	1	30	theme	biomedical	270:279	arg1	research					281:288	biomedical research	270:288	biomedical research	270:288	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	8	31	theme	molecular	1782:1790	arg1	layer					1792:1796	a largely unexplored molecular layer	1761:1796	a largely unexplored molecular layer of the complexity of life	1761:1822	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	5	32	theme	glycomics	993:1001	arg1	technology					1003:1012	HT glycomics technology	990:1012	HT glycomics technology	990:1012	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	8	33	dep	present	1656:1662	arg1	Aiming					1586:1591	Aiming	1586:1591	Aiming to promote wider use and development of HT glycomics	1586:1644	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	2	34	theme	functional	397:406	arg1	component					408:416	a crucial structural and functional component	372:416	a crucial structural and functional component of the majority of proteins	372:444	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	6	35	from	subset	1317:1322	arg1	numbers					1354:1360	large numbers	1348:1360	large numbers of various biological samples	1348:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	5	36	theme	facile	947:952	arg1	dissemination					954:966	facile dissemination	947:966	facile dissemination	947:966	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	2	37	theme	proteins	437:444	arg1	majority					425:432	the majority	421:432	the majority of proteins	421:444	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	0	38	dep	enabling	68:75	arg1	perspectives					17:28	perspectives	17:28	perspectives	17:28	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	0	38	dep	enabling	68:75	arg1	Developments					0:11	Developments	0:11	Developments	0:11	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	2	39	theme	lipids	494:499	arg1	glycosylation					464:476	alternative glycosylation	452:476	alternative glycosylation of proteins and lipids	452:499	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	39	theme	lipids	494:499	arg1	mechanism					531:539	an important regulatory mechanism	507:539	an important regulatory mechanism	507:539	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	40	theme	majority	425:432	arg1	component					408:416	a crucial structural and functional component	372:416	a crucial structural and functional component of the majority of proteins	372:444	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	0	41	theme	high-throughput	33:47	arg1	glycomics					57:65	high-throughput protein glycomics	33:65	high-throughput protein glycomics	33:65	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	2	42	theme	proteins	481:488	arg1	glycosylation					464:476	alternative glycosylation	452:476	alternative glycosylation of proteins and lipids	452:499	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	42	theme	proteins	481:488	arg1	mechanism					531:539	an important regulatory mechanism	507:539	an important regulatory mechanism	507:539	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	3	43	gly	glycosylation	731:743	arg1	patho					755:759	human (patho)physiology	748:770	human (patho)physiology	748:770	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	4	44	dep	high-throughput	911:925	arg1	HT					928:929	HT	928:929	HT	928:929	Driven by these challenges, methods have emerged, which can tackle the complexity of glycosylation in thousands of samples, also known as high-throughput (HT) glycomics.
35452121	6	45	theme	samples	1384:1390	arg1	numbers					1354:1360	large numbers	1348:1360	large numbers of various biological samples	1348:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	7	46	theme	human	1489:1493	arg1	glycome					1495:1501	the complete human glycome	1476:1501	the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research	1476:1583	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	1	47	theme	tremendous	215:224	arg1	challenge					237:245	a tremendous analytical challenge	213:245	a tremendous analytical challenge when including them in biomedical research	213:288	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	2	48	gly	glycosylation	464:476	arg1	proteins					481:488	proteins	481:488	proteins	481:488	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	48	gly	glycosylation	464:476	arg1	lipids					494:499	lipids	494:499	lipids	494:499	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	49	theme	structural	382:391	arg1	component					408:416	a crucial structural and functional component	372:416	a crucial structural and functional component of the majority of proteins	372:444	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	5	50	theme	sample	1019:1024	arg1	stable					1084:1089	stable	1084:1089	stable	1084:1089	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	5	50	theme	sample	1019:1024	arg1	preparation					1026:1036	the sample preparation	1015:1036	the sample preparation	1015:1036	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	8	51	theme	complexity	1805:1814	arg1	layer					1792:1796	a largely unexplored molecular layer	1761:1796	a largely unexplored molecular layer of the complexity of life	1761:1822	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	8	52	theme	HT	1633:1634	arg1	glycomics					1636:1644	HT glycomics	1633:1644	HT glycomics	1633:1644	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	6	53	theme	protein	1250:1256	arg1	N-glycosylation					1258:1272	protein N-glycosylation	1250:1272	protein N-glycosylation	1250:1272	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	2	54	theme	glycobiological	298:312	arg1	research					314:321	Recent glycobiological research	291:321	Recent glycobiological research	291:321	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	1	55	theme	several	171:177	arg1	orders					179:184	several orders	171:184	several orders of magnitude	171:197	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	6	56	theme	human	1331:1335	arg1	glycome					1337:1343	the human glycome	1327:1343	the human glycome in large numbers of various biological samples	1327:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	2	57	theme	a	335:335	arg1	picture					337:343	painting a picture	326:343	painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes	326:585	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	7	58	theme	ultimate	1397:1404	arg1	goal					1406:1409	The ultimate goal	1393:1409	The ultimate goal in HT glycomics	1393:1425	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	8	59	theme	available	1674:1682	arg1	methods					1711:1717	methods	1711:1717	methods	1711:1717	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	3	60	from	role	723:726	arg1	physiology					761:770	human (patho)physiology	748:770	human (patho)physiology	748:770	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	8	61	theme	emerging	1685:1692	arg1	methods					1711:1717	methods	1711:1717	methods	1711:1717	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	6	62	theme	Current	1205:1211	arg1	methods					1226:1232	Current HT glycomics methods	1205:1232	Current HT glycomics methods	1205:1232	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	4	63	theme	high-throughput	911:925	arg1	glycomics					932:940	high-throughput (HT) glycomics	911:940	high-throughput (HT) glycomics	911:940	Driven by these challenges, methods have emerged, which can tackle the complexity of glycosylation in thousands of samples, also known as high-throughput (HT) glycomics.
35452121	3	64	from	differences	610:620	arg1	glycosylation					625:637	glycosylation	625:637	glycosylation	625:637	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	6	65	theme	biological	1373:1382	arg1	samples					1384:1390	various biological samples	1365:1390	various biological samples	1365:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	3	66	theme	large	654:658	arg1	studies					660:666	large studies	654:666	large studies	654:666	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	2	67	theme	important	510:518	arg1	glycosylation					464:476	alternative glycosylation	452:476	alternative glycosylation of proteins and lipids	452:499	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	67	theme	important	510:518	arg1	mechanism					531:539	an important regulatory mechanism	507:539	an important regulatory mechanism	507:539	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	6	68	from	numbers	1354:1360	arg1	subset					1317:1322	this subset	1312:1322	this subset of the human glycome in large numbers of various biological samples	1312:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	1	69	theme	proteins	159:166	arg1	complexity					145:154	the structural complexity	130:154	the structural complexity of proteins	130:166	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	6	70	theme	large	1348:1352	arg1	numbers					1354:1360	large numbers	1348:1360	large numbers of various biological samples	1348:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	5	71	theme	time	1113:1116	arg1	period					1103:1108	a long period	1096:1108	a long period of time (months/years)	1096:1131	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	2	72	theme	many	544:547	arg1	processes					577:585	many biological and pathological processes	544:585	many biological and pathological processes	544:585	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	6	73	theme	glycome	1337:1343	arg1	subset					1317:1322	this subset	1312:1322	this subset of the human glycome in large numbers of various biological samples	1312:1390	Current HT glycomics methods mainly focus on protein N-glycosylation and allow to extensively characterize this subset of the human glycome in large numbers of various biological samples.
35452121	5	74	theme	HT	990:991	arg1	technology					1003:1012	HT glycomics technology	990:1012	HT glycomics technology	990:1012	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	8	75	theme	unexplored	1771:1780	arg1	layer					1792:1796	a largely unexplored molecular layer	1761:1796	a largely unexplored molecular layer of the complexity of life	1761:1822	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	2	76	theme	alternative	452:462	arg1	glycosylation					464:476	alternative glycosylation	452:476	alternative glycosylation of proteins and lipids	452:499	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	2	76	theme	alternative	452:462	arg1	mechanism					531:539	an important regulatory mechanism	507:539	an important regulatory mechanism	507:539	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	0	77	theme	protein	49:55	arg1	glycomics					57:65	high-throughput protein glycomics	33:65	high-throughput protein glycomics	33:65	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	0	78	theme	samples	106:112	arg1	thousands					93:101	thousands	93:101	thousands of samples	93:112	Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.
35452121	7	79	dep	better	1438:1443	arg1	knowledge					1445:1453	knowledge	1445:1453	knowledge	1445:1453	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	5	80	theme	technology	1003:1012	arg1	dissemination					954:966	facile dissemination	947:966	facile dissemination	947:966	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	5	80	theme	technology	1003:1012	arg1	implementation					972:985	implementation	972:985	implementation	972:985	For facile dissemination and implementation of HT glycomics technology, the sample preparation, analysis, as well as data mining, need to be stable over a long period of time (months/years), amenable to automation, and available to non-specialized laboratories.
35452121	1	81	theme	analytical	226:235	arg1	challenge					237:245	a tremendous analytical challenge	213:245	a tremendous analytical challenge when including them in biomedical research	213:288	Glycans expand the structural complexity of proteins by several orders of magnitude, resulting in a tremendous analytical challenge when including them in biomedical research.
35452121	7	82	theme	complete	1480:1487	arg1	glycome					1495:1501	the complete human glycome	1476:1501	the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research	1476:1583	The ultimate goal in HT glycomics is to gain better knowledge and understanding of the complete human glycome using methods that are easy to adapt and implement in (basic) biomedical research.
35452121	3	83	theme	glycosylation	731:743	arg1	role					723:726	the role	719:726	the role of glycosylation in human (patho)physiology	719:770	Since interindividual differences in glycosylation are extensive, large studies are needed to map the structures and to understand the role of glycosylation in human (patho)physiology.
35452121	2	84	theme	crucial	374:380	arg1	component					408:416	a crucial structural and functional component	372:416	a crucial structural and functional component of the majority of proteins	372:444	Recent glycobiological research is painting a picture in which glycans represent a crucial structural and functional component of the majority of proteins, with alternative glycosylation of proteins and lipids being an important regulatory mechanism in many biological and pathological processes.
35452121	8	85	theme	glycomics	1636:1644	arg1	development					1618:1628	development	1618:1628	development	1618:1628	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
35452121	8	85	theme	glycomics	1636:1644	arg1	use					1610:1612	wider use	1604:1612	wider use	1604:1612	Aiming to promote wider use and development of HT glycomics, here, we present currently available, emerging, and prospective methods and some of their applications, revealing a largely unexplored molecular layer of the complexity of life.
36014368	4	0	gly	glycosylated	613:624	arg1	protein					594:600	The SARS-CoV-2 S protein	577:600	The SARS-CoV-2 S protein	577:600	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	0	1	contain	Contained	65:73	arg2	Investigation					0:12	Investigation	0:12	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein	0:63	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	0	1	contain	Contained	65:73	arg1	VLPs					78:81	VLPs	78:81	VLPs Produced in Nicotiana benthamiana	78:115	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	1	2	theme	coronavirus	150:160	arg1	pandemic					162:169	the SARS-CoV-2 coronavirus pandemic	135:169	the SARS-CoV-2 coronavirus pandemic in China in late 2019	135:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	1	3	theme	therapeutics	234:245	arg1	development					209:219	the fast development	200:219	the fast development of efficient therapeutics	200:245	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	7	4	theme	Nicotiana	1089:1097	arg1	benthamiana					1099:1109	Nicotiana benthamiana	1089:1109	Nicotiana benthamiana (N. benthamiana)	1089:1126	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	7	4	theme	Nicotiana	1089:1097	arg1	benthamiana					1115:1125	N. benthamiana	1112:1125	N. benthamiana	1112:1125	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	1	5	theme	pandemic	162:169	arg1	emergence					122:130	The emergence	118:130	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019	118:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	8	6	gly	N-glycosylation	1217:1231	arg2	sites					1233:1237	the 22 predicted N-glycosylation sites	1200:1237	the 22 predicted N-glycosylation sites	1200:1237	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	8	6	gly	N-glycosylation	1217:1231	arg2	22					1204:1205	22	1204:1205	22	1204:1205	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	4	7	gly	O-glycosylation	707:721	arg2	sites					723:727	numerous mucin-type O-glycosylation sites	687:727	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	1	8	from	pandemic	162:169	arg1	China					174:178	China	174:178	China	174:178	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	1	8	from	pandemic	162:169	arg1	2019					188:191	late 2019	183:191	late 2019	183:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	1	9	from	China	174:178	arg1	emergence					122:130	The emergence	118:130	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019	118:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	6	10	theme	antigenic	961:969	arg1	recognition					971:981	the virus antigenic recognition	951:981	the virus antigenic recognition	951:981	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	6	11	theme	virus	955:959	arg1	recognition					971:981	the virus antigenic recognition	951:981	the virus antigenic recognition	951:981	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	7	12	theme	N.	1112:1113	arg1	benthamiana					1099:1109	Nicotiana benthamiana	1089:1109	Nicotiana benthamiana (N. benthamiana)	1089:1126	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	7	12	theme	N.	1112:1113	arg1	benthamiana					1115:1125	N. benthamiana	1112:1125	N. benthamiana	1112:1125	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	9	13	theme	SARS-CoV-2	1334:1343	arg1	protein					1347:1353	the SARS-CoV-2 S protein	1330:1353	the SARS-CoV-2 S protein produced in N. benthamiana	1330:1380	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	4	14	theme	numerous	687:694	arg1	sites					723:727	numerous mucin-type O-glycosylation sites	687:727	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	9	15	theme	N.	1367:1368	arg1	benthamiana					1370:1380	N. benthamiana	1367:1380	N. benthamiana	1367:1380	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	8	16	theme	predicted	1207:1215	arg1	sites					1233:1237	the 22 predicted N-glycosylation sites	1200:1237	the 22 predicted N-glycosylation sites	1200:1237	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	8	17	theme	N-glycosylation	1217:1231	arg1	sites					1233:1237	the 22 predicted N-glycosylation sites	1200:1237	the 22 predicted N-glycosylation sites	1200:1237	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	2	18	theme	structural	261:270	arg1	proteins					272:279	the major structural proteins	251:279	the major structural proteins encoded by the SARS-CoV-2 genome	251:312	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	4	19	theme	predicted	634:642	arg1	sites					670:674	22 predicted N-glycosylation consensus sites	631:674	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	0	20	theme	Nicotiana	95:103	arg1	benthamiana					105:115	Nicotiana benthamiana	95:115	Nicotiana benthamiana	95:115	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	2	21	dep	role	405:408	arg1	plays					413:417	plays	413:417	plays in virus entry into host cells	413:448	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	1	22	from	emergence	122:130	arg1	China					174:178	China	174:178	China	174:178	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	1	22	from	emergence	122:130	arg1	2019					188:191	late 2019	183:191	late 2019	183:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	2	23	theme	major	255:259	arg1	proteins					272:279	the major structural proteins	251:279	the major structural proteins encoded by the SARS-CoV-2 genome	251:312	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	2	24	theme	research	364:371	arg1	interest					373:380	considerable research interest	351:380	considerable research interest	351:380	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	5	25	theme	viral	780:784	arg1	protein					786:792	this viral protein	775:792	this viral protein	775:792	As a consequence, O- and N-glycosylations of this viral protein have received particular attention.
36014368	7	26	theme	virus-like	1049:1058	arg1	VLPs					1071:1074	VLPs	1071:1074	VLPs	1071:1074	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	7	26	theme	virus-like	1049:1058	arg1	particles					1060:1068	virus-like particles	1049:1068	virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana)	1049:1126	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	2	27	theme	considerable	351:362	arg1	interest					373:380	considerable research interest	351:380	considerable research interest	351:380	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	5	28	theme	protein	786:792	arg1	N-glycosylations					755:770	N-glycosylations	755:770	N-glycosylations	755:770	As a consequence, O- and N-glycosylations of this viral protein have received particular attention.
36014368	5	28	theme	protein	786:792	arg1	O-					748:749	O-	748:749	O-	748:749	As a consequence, O- and N-glycosylations of this viral protein have received particular attention.
36014368	3	29	theme	neutralizing	516:527	arg1	antibodies					529:538	neutralizing antibodies	516:538	neutralizing antibodies against the surface viral S protein	516:574	Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein.
36014368	9	30	theme	overall	1392:1398	arg1	structure					1403:1411	an overall 3D structure	1389:1411	an overall 3D structure similar to that of recombinant homologues produced in mammalian cells	1389:1481	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	2	31	theme	SARS-CoV-2	296:305	arg1	genome					307:312	the SARS-CoV-2 genome	292:312	the SARS-CoV-2 genome	292:312	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	1	32	theme	late	183:186	arg1	2019					188:191	late 2019	183:191	late 2019	183:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	0	33	theme	N-Glycosylation	21:35	arg1	Investigation					0:12	Investigation	0:12	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein	0:63	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	7	34	theme	protein	1034:1040	arg1	status					1018:1023	the N-glycosylation status	998:1023	the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana)	998:1126	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	3	35	theme	surface	552:558	arg1	protein					568:574	the surface viral S protein	548:574	the surface viral S protein	548:574	Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein.
36014368	9	36	theme	recombinant	1432:1442	arg1	homologues					1444:1453	recombinant homologues	1432:1453	recombinant homologues produced in mammalian cells	1432:1481	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	2	37	theme	central	397:403	arg1	role					405:408	the central role	393:408	the central role it plays in virus entry into host cells	393:448	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	4	38	theme	O-glycosylation	707:721	arg1	sites					723:727	numerous mucin-type O-glycosylation sites	687:727	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	3	39	theme	immunization	476:487	arg1	strategies					489:498	most immunization strategies	471:498	most immunization strategies	471:498	Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein.
36014368	6	40	theme	S	854:854	arg1	protein					856:862	the S protein	850:862	the S protein	850:862	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	2	41	dep	SPIKE	319:323	arg1	S					326:326	S	326:326	S	326:326	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	9	42	theme	3D	1400:1401	arg1	structure					1403:1411	an overall 3D structure	1389:1411	an overall 3D structure similar to that of recombinant homologues produced in mammalian cells	1389:1481	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	4	43	theme	S	592:592	arg1	protein					594:600	The SARS-CoV-2 S protein	577:600	The SARS-CoV-2 S protein	577:600	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	2	44	theme	host	439:442	arg1	cells					444:448	host cells	439:448	host cells	439:448	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	6	45	link	N-linked	838:845	arg1	Glycans					830:836	Glycans	830:836	Glycans N-linked to the S protein	830:862	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	9	46	theme	mammalian	1467:1475	arg1	cells					1477:1481	mammalian cells	1467:1481	mammalian cells	1467:1481	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	3	47	theme	viral	560:564	arg1	protein					568:574	the surface viral S protein	548:574	the surface viral S protein	548:574	Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein.
36014368	6	48	theme	specific	924:931	arg1	epitope					933:939	a shield-masking specific epitope	907:939	a shield-masking specific epitope to escape the virus antigenic recognition	907:981	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	7	49	theme	S	1032:1032	arg1	protein					1034:1040	the S protein	1028:1040	the S protein	1028:1040	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	3	50	theme	S	566:566	arg1	protein					568:574	the surface viral S protein	548:574	the surface viral S protein	548:574	Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein.
36014368	7	51	theme	glycoproteomic	1153:1166	arg1	approach					1168:1175	a glycoproteomic approach	1151:1175	a glycoproteomic approach	1151:1175	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	0	52	theme	S	55:55	arg1	Protein					57:63	the SARS-CoV-2 S Protein	40:63	the SARS-CoV-2 S Protein	40:63	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	6	53	theme	shield-masking	909:922	arg1	epitope					933:939	a shield-masking specific epitope	907:939	a shield-masking specific epitope to escape the virus antigenic recognition	907:981	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	4	54	gly	N-glycosylation	644:658	arg2	22					631:632	22	631:632	22	631:632	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	4	54	gly	N-glycosylation	644:658	arg2	sites					670:674	22 predicted N-glycosylation consensus sites	631:674	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	6	55	theme	N-linked	838:845	arg1	Glycans					830:836	Glycans	830:836	Glycans N-linked to the S protein	830:862	Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition.
36014368	8	56	theme	complex	1256:1262	arg1	N-glycans					1270:1278	complex plant N-glycans	1256:1278	complex plant N-glycans	1256:1278	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	0	57	theme	SARS-CoV-2	44:53	arg1	Protein					57:63	the SARS-CoV-2 S Protein	40:63	the SARS-CoV-2 S Protein	40:63	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	9	58	theme	S	1345:1345	arg1	protein					1347:1353	the SARS-CoV-2 S protein	1330:1353	the SARS-CoV-2 S protein produced in N. benthamiana	1330:1380	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	8	59	contain	carries	1288:1294	arg2	oligomannoses					1296:1308	oligomannoses	1296:1308	oligomannoses	1296:1308	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	8	59	contain	carries	1288:1294	arg1	one					1284:1286	one	1284:1286	one	1284:1286	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	2	60	theme	virus	422:426	arg1	entry					428:432	virus entry	422:432	virus entry into host cells	422:448	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	0	61	gly	N-Glycosylation	21:35	arg1	Protein					57:63	the SARS-CoV-2 S Protein	40:63	the SARS-CoV-2 S Protein	40:63	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	1	62	from	2019	188:191	arg1	emergence					122:130	The emergence	118:130	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019	118:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	2	63	theme	SPIKE	319:323	arg1	protein					329:335	the SPIKE (S) protein	315:335	the SPIKE (S) protein	315:335	Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells.
36014368	4	64	theme	N-glycosylation	644:658	arg1	sites					670:674	22 predicted N-glycosylation consensus sites	631:674	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	4	65	theme	mucin-type	696:705	arg1	sites					723:727	numerous mucin-type O-glycosylation sites	687:727	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	1	66	theme	fast	204:207	arg1	development					209:219	the fast development	200:219	the fast development of efficient therapeutics	200:245	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	7	67	theme	N-glycosylation	1002:1016	arg1	status					1018:1023	the N-glycosylation status	998:1023	the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana)	998:1126	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	9	68	theme	similar	1413:1419	arg1	structure					1403:1411	an overall 3D structure	1389:1411	an overall 3D structure similar to that of recombinant homologues produced in mammalian cells	1389:1481	This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
36014368	3	69	theme	most	471:474	arg1	strategies					489:498	most immunization strategies	471:498	most immunization strategies	471:498	Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein.
36014368	7	70	gly	N-glycosylation	1002:1016	arg1	protein					1034:1040	the S protein	1028:1040	the S protein	1028:1040	In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach.
36014368	5	71	theme	particular	808:817	arg1	consequence					735:745	a consequence	733:745	a consequence	733:745	As a consequence, O- and N-glycosylations of this viral protein have received particular attention.
36014368	5	71	theme	particular	808:817	arg1	attention					819:827	particular attention	808:827	particular attention	808:827	As a consequence, O- and N-glycosylations of this viral protein have received particular attention.
36014368	4	72	theme	consensus	660:668	arg1	sites					670:674	22 predicted N-glycosylation consensus sites	631:674	22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites	631:727	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	8	73	theme	plant	1264:1268	arg1	N-glycans					1270:1278	complex plant N-glycans	1256:1278	complex plant N-glycans	1256:1278	We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses.
36014368	4	74	theme	SARS-CoV-2	581:590	arg1	protein					594:600	The SARS-CoV-2 S protein	577:600	The SARS-CoV-2 S protein	577:600	The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites.
36014368	0	75	theme	Protein	57:63	arg1	N-Glycosylation					21:35	the N-Glycosylation	17:35	the N-Glycosylation of the SARS-CoV-2 S Protein	17:63	Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana.
36014368	1	76	theme	SARS-CoV-2	139:148	arg1	pandemic					162:169	the SARS-CoV-2 coronavirus pandemic	135:169	the SARS-CoV-2 coronavirus pandemic in China in late 2019	135:191	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
36014368	1	77	theme	efficient	224:232	arg1	therapeutics					234:245	efficient therapeutics	224:245	efficient therapeutics	224:245	The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics.
37016806	3	0	theme	ultrasonic	480:489	arg1	UAG					517:519	UAG	517:519	UAG	517:519	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	3	0	theme	ultrasonic	480:489	arg1	glycosylation					502:514	ultrasonic associated glycosylation	480:514	ultrasonic associated glycosylation (UAG)	480:520	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	9	1	theme	bound	1560:1564	arg1	water					1582:1586	more bound and immobilized water	1555:1586	more bound and immobilized water	1555:1586	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	6	2	theme	hardness	1109:1116	arg1	values					1142:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	8	3	theme	Rheological	1278:1288	arg1	results					1290:1296	Rheological results	1278:1296	Rheological results	1278:1296	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	1	4	theme	optimal	243:249	arg1	alternative					251:261	the optimal alternative	239:261	the optimal alternative to MG	239:267	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	1	4	theme	optimal	243:249	arg1	it					213:214	it	213:214	it	213:214	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	5	5	theme	higher	852:857	arg1	power					859:863	higher power	852:863	higher power	852:863	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	4	6	theme	FG	794:795	arg1	properties					699:708	the functional properties	684:708	the functional properties (emulsifying, gelling and rheological properties)	684:758	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	6	theme	FG	794:795	arg1	characteristics					775:789	structural characteristics	764:789	structural characteristics of FG	764:795	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	6	7	theme	strength	1099:1106	arg1	values					1142:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	1	8	contain	has	143:145	arg2	properties					163:172	multifunctional properties	147:172	multifunctional properties similar to mammalian gelatin (MG)	147:206	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	1	8	contain	has	143:145	arg1	FG					139:140	FG	139:140	FG	139:140	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	1	8	contain	has	143:145	arg1	gelatin					130:136	BACKGROUND Fish gelatin	114:136	BACKGROUND Fish gelatin (FG)	114:141	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	4	9	from	UAG	629:631	arg1	properties					699:708	the functional properties	684:708	the functional properties (emulsifying, gelling and rheological properties)	684:758	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	9	from	UAG	629:631	arg1	characteristics					775:789	structural characteristics	764:789	structural characteristics of FG	764:795	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	3	10	theme	structural	541:550	arg1	characteristics					552:566	the gelling and structural characteristics	525:566	the gelling and structural characteristics of FG	525:572	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	3	11	theme	gelling	529:535	arg1	characteristics					552:566	the gelling and structural characteristics	525:566	the gelling and structural characteristics of FG	525:572	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	8	12	theme	gelatin	1355:1361	arg1	procedure					1342:1350	the gelation procedure	1329:1350	the gelation procedure of gelatin with advanced gelation time	1329:1389	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	9	13	theme	gelling	1619:1625	arg1	properties					1627:1636	higher gelling properties	1612:1636	higher gelling properties	1612:1636	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	8	14	theme	advanced	1368:1375	arg1	time					1386:1389	advanced gelation time	1368:1389	advanced gelation time	1368:1389	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	7	15	contain	had	1226:1228	arg2	properties					1266:1275	emulsifying and gelling properties	1242:1275	the highest emulsifying and gelling properties	1230:1275	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	7	15	contain	had	1226:1228	arg1	gelatin					1218:1224	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	7	16	theme	gelling	1258:1264	arg1	properties					1266:1275	emulsifying and gelling properties	1242:1275	the highest emulsifying and gelling properties	1230:1275	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	5	17	theme	ultrasonic	868:877	arg1	time					843:846	longer time	836:846	longer time	836:846	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	5	17	theme	ultrasonic	868:877	arg1	power					859:863	higher power	852:863	higher power	852:863	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	7	18	theme	emulsifying	1242:1252	arg1	properties					1266:1275	emulsifying and gelling properties	1242:1275	the highest emulsifying and gelling properties	1230:1275	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	4	19	theme	0.5-1	644:648	arg1	h					650:650	0.5-1 h	644:650	0.5-1 h	644:650	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	19	theme	0.5-1	644:648	arg1	100-200W					634:641	100-200W	634:641	100-200W	634:641	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	10	20	theme	promising	1705:1713	arg1	method					1715:1720	a promising method	1703:1720	a promising method to produce high gelling and emulsifying properties of FG that could replace MG	1703:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	10	20	theme	promising	1705:1713	arg1	UAG					1674:1676	UAG	1674:1676	UAG with κC	1674:1684	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	5	21	theme	longer	836:841	arg1	time					843:846	longer time	836:846	longer time	836:846	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	0	22	from	glycosylation	20:32	arg1	properties					86:95	the functional and structural properties	56:95	the functional and structural properties of fish gelatin	56:111	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	4	23	dep	properties	699:708	arg1	gelling					724:730	gelling	724:730	gelling	724:730	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	23	dep	properties	699:708	arg1	properties					748:757	rheological properties	736:757	rheological properties	736:757	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	23	dep	properties	699:708	arg1	emulsifying					711:721	emulsifying	711:721	emulsifying	711:721	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	10	24	with	UAG	1674:1676	arg1	κC					1683:1684	κC	1683:1684	κC	1683:1684	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	3	25	gly	glycosylation	502:514	arg1	FG					571:572	FG	571:572	FG	571:572	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	0	26	theme	fish	100:103	arg1	gelatin					105:111	fish gelatin	100:111	fish gelatin	100:111	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	3	27	used	used	413:416	arg2	glycosylation					377:389	glycosylation	377:389	glycosylation	377:389	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	10	28	dep	CONCLUSIONS	1639:1649	arg1	showed					1662:1667	showed	1662:1667	showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG	1662:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	7	29	theme	highest	1234:1240	arg1	properties					1266:1275	emulsifying and gelling properties	1242:1275	the highest emulsifying and gelling properties	1230:1275	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	5	30	dep	time	843:846	arg1	the					832:834	the	832:834	the	832:834	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	0	31	theme	Ultrasonic	0:9	arg1	glycosylation					20:32	Ultrasonic assisted glycosylation	0:32	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.	0:112	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	9	32	theme	immobilized	1570:1580	arg1	water					1582:1586	more bound and immobilized water	1555:1586	more bound and immobilized water	1555:1586	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	6	33	theme	FG-κC	1014:1018	arg1	mixture					1020:1026	FG-κC mixture	1014:1026	FG-κC mixture	1014:1026	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	6	34	theme	melting	1122:1128	arg1	temperature					1130:1140	melting temperature	1122:1140	melting temperature	1122:1140	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	4	35	theme	functional	688:697	arg1	properties					699:708	the functional properties	684:708	the functional properties (emulsifying, gelling and rheological properties)	684:758	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	1	36	theme	BACKGROUND	114:123	arg1	FG					139:140	FG	139:140	FG	139:140	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	1	36	theme	BACKGROUND	114:123	arg1	gelatin					130:136	BACKGROUND Fish gelatin	114:136	BACKGROUND Fish gelatin (FG)	114:141	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	7	37	theme	modified	1209:1216	arg1	gelatin					1218:1224	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	3	38	theme	surface	430:436	arg1	properties					445:454	surface active properties	430:454	surface active properties of FG	430:460	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	5	39	theme	values	979:984	arg1	increase					927:934	the increase	923:934	the increase of glycosylation degree and browning index values	923:984	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	10	40	theme	high	1733:1736	arg1	properties					1762:1771	high gelling and emulsifying properties	1733:1771	high gelling and emulsifying properties of FG that could replace MG	1733:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	0	41	with	glycosylation	20:32	arg1	κ-carrageenan					39:51	κ-carrageenan	39:51	κ-carrageenan	39:51	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	2	42	theme	gelling	306:312	arg1	properties					314:323	it's poor surface-active and gelling properties	277:323	it's poor surface-active and gelling properties	277:323	While, it's poor surface-active and gelling properties significantly limit its application values.
37016806	9	43	theme	covalent	1514:1521	arg1	bonds					1536:1540	covalent and hydrogen bonds	1514:1540	bonds	1536:1540	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	10	44	theme	gelling	1738:1744	arg1	properties					1762:1771	high gelling and emulsifying properties	1733:1771	high gelling and emulsifying properties of FG that could replace MG	1733:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	10	45	theme	FG	1776:1777	arg1	properties					1762:1771	high gelling and emulsifying properties	1733:1771	high gelling and emulsifying properties of FG that could replace MG	1733:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	8	46	theme	gelation	1333:1340	arg1	procedure					1342:1350	the gelation procedure	1329:1350	the gelation procedure of gelatin with advanced gelation time	1329:1389	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	2	47	theme	surface-active	287:300	arg1	properties					314:323	it's poor surface-active and gelling properties	277:323	it's poor surface-active and gelling properties	277:323	While, it's poor surface-active and gelling properties significantly limit its application values.
37016806	5	48	theme	degree	953:958	arg1	increase					927:934	the increase	923:934	the increase of glycosylation degree and browning index values	923:984	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	10	49	used	used	1695:1698	arg2	method					1715:1720	a promising method	1703:1720	a promising method to produce high gelling and emulsifying properties of FG that could replace MG	1703:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	10	49	used	used	1695:1698	arg2	UAG					1674:1676	UAG	1674:1676	UAG with κC	1674:1684	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	3	50	theme	associated	491:500	arg1	UAG					517:519	UAG	517:519	UAG	517:519	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	3	50	theme	associated	491:500	arg1	glycosylation					502:514	ultrasonic associated glycosylation	480:514	ultrasonic associated glycosylation (UAG)	480:520	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	5	51	theme	browning	964:971	arg1	values					979:984	browning index values	964:984	browning index values	964:984	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	6	52	theme	UAG	1048:1050	arg1	FG					1061:1062	UAG modified FG	1048:1062	UAG modified FG	1048:1062	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	6	53	contain	possessed	1064:1072	arg2	values					1142:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	6	53	contain	possessed	1064:1072	arg1	FG					1061:1062	UAG modified FG	1048:1062	UAG modified FG	1048:1062	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	7	54	theme	proper	1166:1171	arg1	condition					1184:1192	proper ultrasonic condition	1166:1192	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	7	54	theme	proper	1166:1171	arg1	W					1199:1199	200 W	1195:1199	200 W	1195:1199	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	1	55	theme	similar	174:180	arg1	properties					163:172	multifunctional properties	147:172	multifunctional properties similar to mammalian gelatin (MG)	147:206	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	6	56	theme	gel	1095:1097	arg1	strength					1099:1106	gel strength	1095:1106	gel strength	1095:1106	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	1	57	theme	mammalian	185:193	arg1	MG					204:205	MG	204:205	MG	204:205	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	1	57	theme	mammalian	185:193	arg1	gelatin					195:201	mammalian gelatin	185:201	mammalian gelatin (MG)	185:206	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	6	58	theme	ESI	1090:1092	arg1	values					1142:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	3	59	from	influence	467:475	arg1	characteristics					552:566	the gelling and structural characteristics	525:566	the gelling and structural characteristics of FG	525:572	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	6	60	theme	EAI	1085:1087	arg1	values					1142:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	3	61	theme	FG	571:572	arg1	characteristics					552:566	the gelling and structural characteristics	525:566	the gelling and structural characteristics of FG	525:572	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	9	62	theme	higher	1612:1617	arg1	properties					1627:1636	higher gelling properties	1612:1636	higher gelling properties	1612:1636	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	8	63	theme	gelation	1377:1384	arg1	time					1386:1389	advanced gelation time	1368:1389	advanced gelation time	1368:1389	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	8	64	with	procedure	1342:1350	arg1	time					1386:1389	advanced gelation time	1368:1389	advanced gelation time	1368:1389	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	1	65	theme	Fish	125:128	arg1	FG					139:140	FG	139:140	FG	139:140	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	1	65	theme	Fish	125:128	arg1	gelatin					130:136	BACKGROUND Fish gelatin	114:136	BACKGROUND Fish gelatin (FG)	114:141	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	6	66	theme	temperature	1130:1140	arg1	values					1142:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	the higher EAI, ESI, gel strength, hardness and melting temperature values	1074:1147	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	9	67	dep	promoted	1466:1473	arg1	κC					1475:1476	κC	1475:1476	promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties	1466:1636	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	3	68	theme	FG	459:460	arg1	properties					445:454	surface active properties	430:454	surface active properties of FG	430:460	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	0	69	theme	structural	75:84	arg1	properties					86:95	the functional and structural properties	56:95	the functional and structural properties of fish gelatin	56:111	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	9	70	theme	Structural	1427:1436	arg1	analysis					1438:1445	Structural analysis	1427:1445	Structural analysis	1427:1445	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	8	71	theme	high	1411:1414	arg1	viscosity					1416:1424	high viscosity	1411:1424	high viscosity	1411:1424	Rheological results showed that UAG contributed to the gelation procedure of gelatin with advanced gelation time and endow them with high viscosity.
37016806	1	72	theme	multifunctional	147:161	arg1	properties					163:172	multifunctional properties	147:172	multifunctional properties similar to mammalian gelatin (MG)	147:206	BACKGROUND Fish gelatin (FG) has multifunctional properties similar to mammalian gelatin (MG), and it has been recognized as the optimal alternative to MG.
37016806	0	73	theme	gelatin	105:111	arg1	properties					86:95	the functional and structural properties	56:95	the functional and structural properties of fish gelatin	56:111	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	9	74	theme	hydrogen	1527:1534	arg1	bonds					1536:1540	covalent and hydrogen bonds	1514:1540	bonds	1536:1540	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	2	75	theme	poor	282:285	arg1	properties					314:323	it's poor surface-active and gelling properties	277:323	it's poor surface-active and gelling properties	277:323	While, it's poor surface-active and gelling properties significantly limit its application values.
37016806	7	76	dep	W	1199:1199	arg1	h					1206:1206	0.5 h	1202:1206	0.5 h	1202:1206	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	6	77	theme	bovine	1032:1037	arg1	gelatin					1039:1045	bovine gelatin	1032:1045	bovine gelatin	1032:1045	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	0	78	theme	assisted	11:18	arg1	glycosylation					20:32	Ultrasonic assisted glycosylation	0:32	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.	0:112	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	2	79	theme	application	349:359	arg1	values					361:366	its application values	345:366	its application values	345:366	While, it's poor surface-active and gelling properties significantly limit its application values.
37016806	4	80	dep	UAG	629:631	arg1	h					650:650	0.5-1 h	644:650	0.5-1 h	644:650	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	80	dep	UAG	629:631	arg1	100-200W					634:641	100-200W	634:641	100-200W	634:641	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	5	81	theme	glycosylation	895:907	arg1	reaction					909:916	the glycosylation reaction	891:916	the glycosylation reaction	891:916	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	10	82	theme	emulsifying	1750:1760	arg1	properties					1762:1771	high gelling and emulsifying properties	1733:1771	high gelling and emulsifying properties of FG that could replace MG	1733:1799	CONCLUSIONS This works showed that UAG with κC could be used as a promising method to produce high gelling and emulsifying properties of FG that could replace MG.
37016806	6	83	theme	modified	1052:1059	arg1	FG					1061:1062	UAG modified FG	1048:1062	UAG modified FG	1048:1062	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	5	84	theme	index	973:977	arg1	values					979:984	browning index values	964:984	browning index values	964:984	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	6	85	theme	original	1001:1008	arg1	FG					1010:1011	original FG	1001:1011	original FG	1001:1011	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	4	86	with	UAG	629:631	arg1	κappa-carrageenan					658:674	κappa-carrageenan	658:674	κappa-carrageenan (κC)	658:679	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	4	86	with	UAG	629:631	arg1	κC					677:678	κC	677:678	κC	677:678	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	3	87	theme	active	438:443	arg1	properties					445:454	surface active properties	430:454	surface active properties of FG	430:460	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
37016806	0	88	theme	functional	60:69	arg1	properties					86:95	the functional and structural properties	56:95	the functional and structural properties of fish gelatin	56:111	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	0	89	gly	glycosylation	20:32	arg1	properties					86:95	the functional and structural properties	56:95	the functional and structural properties of fish gelatin	56:111	Ultrasonic assisted glycosylation with κ-carrageenan on the functional and structural properties of fish gelatin.
37016806	6	90	theme	higher	1078:1083	arg1	EAI					1085:1087	the higher EAI	1074:1087	the higher EAI	1074:1087	Compared with original FG, FG-κC mixture and bovine gelatin, UAG modified FG possessed the higher EAI, ESI, gel strength, hardness and melting temperature values.
37016806	4	91	theme	structural	764:773	arg1	characteristics					775:789	structural characteristics	764:789	structural characteristics of FG	764:795	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	5	92	theme	glycosylation	939:951	arg1	degree					953:958	glycosylation degree	939:958	glycosylation degree	939:958	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	5	93	dep	RESULTS	798:804	arg1	revealed					818:825	revealed	818:825	revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values	818:984	RESULTS The results revealed that the longer time and higher power of ultrasonic accelerated the glycosylation reaction with the increase of glycosylation degree and browning index values.
37016806	7	94	theme	condition	1184:1192	arg1	gelatin					1218:1224	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	9	95	theme	bonds	1536:1540	arg1	formation					1501:1509	the formation	1497:1509	the formation of covalent and hydrogen bonds	1497:1540	Structural analysis indicated that UAG promoted κC to link with FG by the formation of covalent and hydrogen bonds, restricting more bound and immobilized water in the gels, exhibiting higher gelling properties.
37016806	7	96	theme	ultrasonic	1173:1182	arg1	condition					1184:1192	proper ultrasonic condition	1166:1192	proper ultrasonic condition (200 W, 0.5 h) modified gelatin	1166:1224	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	7	96	theme	ultrasonic	1173:1182	arg1	W					1199:1199	200 W	1195:1199	200 W	1195:1199	And among them, proper ultrasonic condition (200 W, 0.5 h) modified gelatin had the highest emulsifying and gelling properties.
37016806	4	97	theme	rheological	736:746	arg1	properties					748:757	rheological properties	736:757	rheological properties	736:757	This article is to explore UAG (100-200W, 0.5-1 h) with κappa-carrageenan (κC) on the functional properties (emulsifying, gelling and rheological properties) and structural characteristics of FG.
37016806	3	98	theme	glycosylation	502:514	arg1	influence					467:475	the influence	463:475	the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG	463:572	Though, glycosylation has been successfully used to increase surface active properties of FG, the influence of ultrasonic associated glycosylation (UAG) on the gelling and structural characteristics of FG were still rarely reported.
35605405	0	0	theme	superhelix	60:69	arg1	surface					44:50	the inner surface	34:50	the inner surface of BRI1 superhelix	34:69	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	8	1	theme	key	1400:1402	arg1	N-glycans					1404:1412	key N-glycans	1400:1412	key N-glycans	1400:1412	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	2	2	theme	N154Q	337:341	arg1	mutation					325:332	the mutation	321:332	the mutation of N154Q	321:341	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	1	3	theme	protein	251:257	arg1	folding					259:265	protein folding	251:265	protein folding	251:265	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	7	4	theme	bri1	1230:1233	arg1	retention					1217:1225	the retention	1213:1225	the retention of bri1 carrying S156A mutation in the ER	1213:1267	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	6	5	theme	polar	919:923	arg1	contacts					925:932	polar contacts	919:932	polar contacts around N154 site	919:949	The 3D modeling suggested that there existed polar contacts around N154 site and the mutations not only destroyed the addition of N-glycan on the site, but also led to the disorder of hydrogen bonds formation.
35605405	8	6	dep	residues	1387:1394	arg1	those					1381:1385	those	1381:1385	those	1381:1385	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	1	7	dep	glycosylation	135:147	arg1	ALG					150:152	ALG	150:152	ALG	150:152	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	1	7	dep	glycosylation	135:147	arg1	N-glycosylation					155:169	N-glycosylation	155:169	N-glycosylation	155:169	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	0	8	theme	native	96:101	arg1	conformation					103:114	protein native conformation	88:114	protein native conformation	88:114	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	8	9	theme	N-glycans	1404:1412	arg1	role					1373:1376	the role	1369:1376	the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation	1369:1467	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	5	10	theme	various	787:793	arg1	mutations					795:803	the various mutations	783:803	the various mutations on N154 site	783:816	In addition, the various mutations on N154 site resulted in bri1 retention in the ER, except for N154D.
35605405	4	11	theme	membrane	727:734	arg1	localization					736:747	plasma membrane localization	720:747	plasma membrane localization	720:747	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	4	12	theme	N154-glycan	608:618	arg1	removal					597:603	the removal	593:603	the removal of N154-glycan with S156A replacement	593:641	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	6	13	theme	N-glycan	1004:1011	arg1	addition					992:999	the addition	988:999	the addition of N-glycan	988:1011	The 3D modeling suggested that there existed polar contacts around N154 site and the mutations not only destroyed the addition of N-glycan on the site, but also led to the disorder of hydrogen bonds formation.
35605405	0	14	theme	protein	88:94	arg1	conformation					103:114	protein native conformation	88:114	protein native conformation	88:114	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	4	15	theme	plasma	720:725	arg1	localization					736:747	plasma membrane localization	720:747	plasma membrane localization	720:747	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	7	16	theme	sequence	1088:1095	arg1	analysis					1097:1104	The sequence analysis	1084:1104	The sequence analysis	1084:1104	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	0	17	theme	conserved	2:10	arg1	residue					23:29	A conserved asparagine residue	0:29	A conserved asparagine residue in the inner surface of BRI1 superhelix	0:69	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	0	17	theme	conserved	2:10	arg1	essential					74:82	essential	74:82	essential	74:82	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	7	18	theme	N275-glycan	1184:1194	arg1	removal					1173:1179	the removal	1169:1179	the removal of N275-glycan	1169:1194	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	6	19	theme	hydrogen	1058:1065	arg1	bonds					1067:1071	hydrogen bonds	1058:1071	hydrogen bonds	1058:1071	The 3D modeling suggested that there existed polar contacts around N154 site and the mutations not only destroyed the addition of N-glycan on the site, but also led to the disorder of hydrogen bonds formation.
35605405	2	20	theme	ER	368:369	arg1	retention					371:379	the ER retention	364:379	the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs)	364:460	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	8	21	theme	inner	1431:1435	arg1	surface					1437:1443	the LRR inner surface	1423:1443	the LRR inner surface	1423:1443	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	4	22	theme	bri1	681:684	arg1	ability					670:676	the ability	666:676	the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q	666:767	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	8	23	theme	LRR	1427:1429	arg1	surface					1437:1443	the LRR inner surface	1423:1443	the LRR inner surface	1423:1443	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	5	24	from	retention	835:843	arg1	ER					852:853	the ER	848:853	the ER	848:853	In addition, the various mutations on N154 site resulted in bri1 retention in the ER, except for N154D.
35605405	4	25	theme	bri1-301	700:707	arg1	mutant					709:714	bri1-301 mutant	700:714	bri1-301 mutant	700:714	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	0	26	theme	asparagine	12:21	arg1	residue					23:29	A conserved asparagine residue	0:29	A conserved asparagine residue in the inner surface of BRI1 superhelix	0:69	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	0	26	theme	asparagine	12:21	arg1	essential					74:82	essential	74:82	essential	74:82	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	8	27	theme	BRI1	1341:1344	arg1	structure					1346:1354	BRI1 structure	1341:1354	BRI1 structure	1341:1354	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	3	28	theme	BRI1	515:518	arg1	structure					520:528	BRI1 structure	515:528	BRI1 structure	515:528	However, the mechanism of how the N154 site affects BRI1 structure is still not completely clear.
35605405	5	29	theme	bri1	830:833	arg1	retention					835:843	bri1 retention	830:843	bri1 retention in the ER	830:853	In addition, the various mutations on N154 site resulted in bri1 retention in the ER, except for N154D.
35605405	1	30	theme	prevalent	191:199	arg1	modifications					209:221	the most prevalent protein modifications	182:221	the most prevalent protein modifications in eukaryotes	182:235	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	2	31	theme	insensitive	401:411	arg1	BRI1					416:419	BRI1	416:419	BRI1	416:419	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	2	31	theme	insensitive	401:411	arg1	receptor					427:434	the receptor	423:434	the receptor of brassinosteroids (BRs)	423:460	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	2	31	theme	insensitive	401:411	arg1	brassinosteroids					384:399	brassinosteroids insensitive 1	384:413	brassinosteroids insensitive 1 (BRI1)	384:420	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	2	32	theme	brassinosteroids	439:454	arg1	brassinosteroids					384:399	brassinosteroids insensitive 1	384:413	brassinosteroids insensitive 1 (BRI1)	384:420	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	2	32	theme	brassinosteroids	439:454	arg1	receptor					427:434	the receptor	423:434	the receptor of brassinosteroids (BRs)	423:460	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	6	33	theme	3D	878:879	arg1	modeling					881:888	The 3D modeling	874:888	The 3D modeling	874:888	The 3D modeling suggested that there existed polar contacts around N154 site and the mutations not only destroyed the addition of N-glycan on the site, but also led to the disorder of hydrogen bonds formation.
35605405	4	34	with	removal	597:603	arg1	replacement					631:641	S156A replacement	625:641	S156A replacement	625:641	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	5	35	from	mutations	795:803	arg1	site					813:816	N154 site	808:816	N154 site	808:816	In addition, the various mutations on N154 site resulted in bri1 retention in the ER, except for N154D.
35605405	1	36	theme	protein	201:207	arg1	modifications					209:221	the most prevalent protein modifications	182:221	the most prevalent protein modifications in eukaryotes	182:235	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	8	37	theme	protein	1448:1454	arg1	conformation					1456:1467	protein conformation	1448:1467	protein conformation	1448:1467	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	1	38	link	Asparagine-linked	117:133	arg1	glycosylation					135:147	Asparagine-linked glycosylation	117:147	Asparagine-linked glycosylation (ALG, N-glycosylation)	117:170	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	0	39	theme	inner	38:42	arg1	surface					44:50	the inner surface	34:50	the inner surface of BRI1 superhelix	34:69	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	8	40	theme	residues	1387:1394	arg1	role					1373:1376	the role	1369:1376	the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation	1369:1467	Our results showed that N154 was special and essential for maintaining BRI1 structure and explored the role of those residues and key N-glycans lying in the LRR inner surface on protein conformation.
35605405	1	41	from	modifications	209:221	arg1	eukaryotes					226:235	eukaryotes	226:235	eukaryotes	226:235	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	1	42	theme	Asparagine-linked	117:133	arg1	glycosylation					135:147	Asparagine-linked glycosylation	117:147	Asparagine-linked glycosylation (ALG, N-glycosylation)	117:170	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	1	43	theme	modifications	209:221	arg1	one					175:177	one	175:177	one	175:177	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	1	43	theme	modifications	209:221	arg1	modifications					209:221	the most prevalent protein modifications	182:221	the most prevalent protein modifications in eukaryotes	182:235	Asparagine-linked glycosylation (ALG, N-glycosylation) is one of the most prevalent protein modifications in eukaryotes and regulates protein folding, trafficking and function.
35605405	6	44	theme	bonds	1067:1071	arg1	disorder					1046:1053	the disorder	1042:1053	the disorder of hydrogen bonds	1042:1071	The 3D modeling suggested that there existed polar contacts around N154 site and the mutations not only destroyed the addition of N-glycan on the site, but also led to the disorder of hydrogen bonds formation.
35605405	7	45	contain	carrying	1235:1242	arg1	bri1					1230:1233	bri1	1230:1233	bri1 carrying S156A mutation in the ER	1230:1267	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	7	45	contain	carrying	1235:1242	arg2	mutation					1250:1257	S156A mutation	1244:1257	S156A mutation	1244:1257	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	0	46	theme	BRI1	55:58	arg1	superhelix					60:69	BRI1 superhelix	55:69	BRI1 superhelix	55:69	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	2	47	theme	brassinosteroids	384:399	arg1	retention					371:379	the ER retention	364:379	the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs)	364:460	Recently, we reported that the mutation of N154Q significantly led to the ER retention of brassinosteroids insensitive 1 (BRI1), the receptor of brassinosteroids (BRs).
35605405	7	48	theme	S156A	1244:1248	arg1	mutation					1250:1257	S156A mutation	1244:1257	S156A mutation	1244:1257	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	4	49	theme	S156A	625:629	arg1	replacement					631:641	S156A replacement	625:641	S156A replacement	625:641	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35605405	7	50	theme	more	1134:1137	arg1	similarity					1139:1148	more similarity	1134:1148	more similarity	1134:1148	The sequence analysis showed that the N275 shared more similarity with N154 site and the removal of N275-glycan further enhanced the retention of bri1 carrying S156A mutation in the ER.
35605405	0	51	from	residue	23:29	arg1	surface					44:50	the inner surface	34:50	the inner surface of BRI1 superhelix	34:69	A conserved asparagine residue in the inner surface of BRI1 superhelix is essential for protein native conformation.
35605405	4	52	theme	current	564:570	arg1	study					572:576	current study	564:576	current study	564:576	In current study, we found that the removal of N154-glycan with S156A replacement significantly enhanced the ability of bri1 to complement bri1-301 mutant and plasma membrane localization compared with N154Q.
35316032	8	0	theme	wide	1821:1824	arg1	applications					1826:1837	wide applications	1821:1837	wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins	1821:1925	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	6	1	theme	SPR	1413:1415	arg1	analysis					1425:1432	SPR binding analysis	1413:1432	SPR binding analysis	1413:1432	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	8	2	theme	proteins	1918:1925	arg1	degradation					1876:1886	antibody-based lysosome-targeted degradation	1843:1886	antibody-based lysosome-targeted degradation of extracellular and membrane proteins	1843:1925	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	7	3	theme	Preliminary	1584:1594	arg1	assays					1607:1612	Preliminary cell-based assays	1584:1612	Preliminary cell-based assays	1584:1612	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	2	4	theme	chemoenzymatic	295:308	arg1	method					310:315	an efficient chemoenzymatic method	282:315	an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties	282:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	2	5	theme	membrane-associated	642:660	arg1	proteins					662:669	membrane-associated proteins	642:669	membrane-associated proteins	642:669	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	3	6	theme	simultaneous	840:851	arg1	transfer					853:860	the antibody deglycosylation and simultaneous transfer	807:860	transfer	853:860	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	1	7	theme	extracellular	206:218	arg1	proteins					244:251	extracellular and membrane-associated proteins	206:251	extracellular and membrane-associated proteins of interest	206:263	Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of extracellular and membrane-associated proteins of interest.
35316032	4	8	theme	two-step	1036:1043	arg1	efficient					1172:1180	efficient	1172:1180	efficient	1172:1180	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	4	8	theme	two-step	1036:1043	arg1	procedure					1045:1053	A two-step procedure	1034:1053	A two-step procedure	1034:1053	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	1	9	theme	membrane-associated	224:242	arg1	proteins					244:251	extracellular and membrane-associated proteins	206:251	extracellular and membrane-associated proteins of interest	206:263	Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of extracellular and membrane-associated proteins of interest.
35316032	3	10	gly	deglycosylated	924:937	arg1	antibody					939:946	the deglycosylated antibody	920:946	the deglycosylated antibody	920:946	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	3	11	theme	M6P-glycan	868:877	arg1	deglycosylation					820:834	the antibody deglycosylation and simultaneous transfer	807:860	deglycosylation	820:834	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	3	11	theme	M6P-glycan	868:877	arg1	transfer					853:860	the antibody deglycosylation and simultaneous transfer	807:860	transfer	853:860	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	6	12	theme	M6P	1453:1455	arg1	conjugates					1457:1466	the M6P conjugates	1449:1466	the M6P conjugates	1449:1466	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	2	13	theme	proteins	662:669	arg1	degradation					627:637	targeted degradation	618:637	targeted degradation of membrane-associated proteins	618:669	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	3	14	theme	one-pot	953:959	arg1	manner					961:966	a one-pot manner	951:966	a one-pot manner	951:966	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	2	15	theme	efficient	285:293	arg1	method					310:315	an efficient chemoenzymatic method	282:315	an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties	282:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	3	16	theme	M6P-glycan	896:905	arg1	oxazoline					907:915	a synthetic M6P-glycan oxazoline	884:915	a synthetic M6P-glycan oxazoline	884:915	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	6	17	contain	possessed	1468:1476	arg1	conjugates					1457:1466	the M6P conjugates	1449:1466	the M6P conjugates	1449:1466	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	6	17	contain	possessed	1468:1476	arg2	range					1490:1494	a nanomolar range	1478:1494	a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR)	1478:1581	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	2	18	theme	unnatural	541:549	arg1	moieties					552:559	"unnatural" moieties	540:559	"unnatural" moieties	540:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	5	19	theme	Fc-glycan	1378:1386	arg1	remodeling					1388:1397	the selective Fc-glycan remodeling	1364:1397	the selective Fc-glycan remodeling of cetuximab	1364:1410	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	3	20	theme	deglycosylated	924:937	arg1	antibody					939:946	the deglycosylated antibody	920:946	the deglycosylated antibody	920:946	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	6	21	theme	affinities	1507:1516	arg1	range					1490:1494	a nanomolar range	1478:1494	a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR)	1478:1581	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	2	22	theme	antibody-M6P	583:594	arg1	conjugates					603:612	homogeneous antibody-M6P glycan conjugates	571:612	homogeneous antibody-M6P glycan conjugates	571:612	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	0	23	theme	Protein	104:110	arg1	Degradation					112:122	Targeted Protein Degradation	95:122	Targeted Protein Degradation	95:122	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	6	24	theme	nanomolar	1480:1488	arg1	range					1490:1494	a nanomolar range	1478:1494	a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR)	1478:1581	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	5	25	theme	chemoenzymatic	1229:1242	arg1	approach					1244:1251	The chemoenzymatic approach	1225:1251	The chemoenzymatic approach	1225:1251	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	5	25	theme	chemoenzymatic	1229:1242	arg1	specific					1264:1271	specific	1264:1271	specific	1264:1271	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	3	26	theme	antibody-M6P	1002:1013	arg1	conjugates					1022:1031	structurally well-defined antibody-M6P glycan conjugates	976:1031	structurally well-defined antibody-M6P glycan conjugates	976:1031	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	2	27	theme	click	503:507	arg1	reactions					509:517	conventional click reactions	490:517	conventional click reactions that would introduce "unnatural" moieties	490:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	3	28	gly	deglycosylation	820:834	arg1	manner					961:966	a one-pot manner	951:966	a one-pot manner	951:966	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	3	28	gly	deglycosylation	820:834	arg1	M6P-glycan					868:877	an M6P-glycan	865:877	an M6P-glycan	865:877	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	0	29	theme	Site-Specific	0:12	arg1	Conjugation					29:39	Site-Specific Chemoenzymatic Conjugation	0:39	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation	0:122	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	5	30	gly	glycosylated	1332:1343	arg1	domains					1319:1325	both Fc and Fab domains	1303:1325	domains	1319:1325	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	2	31	theme	protein	466:472	arg1	engineering					474:484	protein engineering	466:484	protein engineering	466:484	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	7	32	theme	membrane-associated	1712:1730	arg1	HER2					1732:1735	the membrane-associated HER2	1708:1735	the membrane-associated HER2	1708:1735	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	1	33	theme	Lysosome-targeting	125:142	arg1	LYTACs					154:159	LYTACs	154:159	LYTACs	154:159	Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of extracellular and membrane-associated proteins of interest.
35316032	1	33	theme	Lysosome-targeting	125:142	arg1	chimeras					144:151	Lysosome-targeting chimeras	125:151	Lysosome-targeting chimeras (LYTACs)	125:160	Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of extracellular and membrane-associated proteins of interest.
35316032	0	34	theme	High-Affinity	44:56	arg1	Ligands					69:75	High-Affinity M6P Glycan Ligands	44:75	High-Affinity M6P Glycan Ligands	44:75	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	5	35	theme	Fc	1277:1278	arg1	remodeling					1287:1296	Fc glycan remodeling	1277:1296	Fc glycan remodeling	1277:1296	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	4	36	with	transglycosylation	1112:1129	arg1	D184M					1155:1159	D184M	1155:1159	D184M	1155:1159	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	4	36	with	transglycosylation	1112:1129	arg1	mutant					1147:1152	an Endo-S2 mutant	1136:1152	an Endo-S2 mutant (D184M)	1136:1160	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	2	37	theme	mannose-6-phosphate	391:409	arg1	ligands					424:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	0	38	theme	Glycan	62:67	arg1	Ligands					69:75	High-Affinity M6P Glycan Ligands	44:75	High-Affinity M6P Glycan Ligands	44:75	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	4	39	theme	M6P	1193:1195	arg1	conjugates					1213:1222	M6P glycan-antibody conjugates	1193:1222	M6P glycan-antibody conjugates	1193:1222	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	8	40	theme	modular	1766:1772	arg1	strategy					1792:1799	This modular glycan-remodeling strategy	1761:1799	This modular glycan-remodeling strategy	1761:1799	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	3	41	theme	S	770:770	arg1	Endo-S					773:778	the wild-type endoglycosidase S (Endo-S)	740:779	the wild-type endoglycosidase S (Endo-S)	740:779	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	8	42	theme	antibody-based	1843:1856	arg1	degradation					1876:1886	antibody-based lysosome-targeted degradation	1843:1886	antibody-based lysosome-targeted degradation of extracellular and membrane proteins	1843:1925	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	1	43	theme	interest	256:263	arg1	proteins					244:251	extracellular and membrane-associated proteins	206:251	extracellular and membrane-associated proteins of interest	206:263	Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of extracellular and membrane-associated proteins of interest.
35316032	3	44	theme	wild-type	744:752	arg1	Endo-S					773:778	the wild-type endoglycosidase S (Endo-S)	740:779	the wild-type endoglycosidase S (Endo-S)	740:779	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	2	45	theme	glycan	417:422	arg1	ligands					424:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	7	46	theme	M6P-cetuximab	1650:1662	arg1	able					1680:1683	able	1680:1683	able	1680:1683	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	7	46	theme	M6P-cetuximab	1650:1662	arg1	conjugates					1664:1673	the M6P-trastuzumab and M6P-cetuximab conjugates	1626:1673	the M6P-trastuzumab and M6P-cetuximab conjugates	1626:1673	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	6	47	theme	binding	1417:1423	arg1	analysis					1425:1432	SPR binding analysis	1413:1432	SPR binding analysis	1413:1432	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	2	48	theme	M6P	412:414	arg1	ligands					424:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	8	49	theme	extracellular	1891:1903	arg1	degradation					1876:1886	antibody-based lysosome-targeted degradation	1843:1886	antibody-based lysosome-targeted degradation of extracellular and membrane proteins	1843:1925	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	7	50	theme	M6P-trastuzumab	1630:1644	arg1	able					1680:1683	able	1680:1683	able	1680:1683	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	7	50	theme	M6P-trastuzumab	1630:1644	arg1	conjugates					1664:1673	the M6P-trastuzumab and M6P-cetuximab conjugates	1626:1673	the M6P-trastuzumab and M6P-cetuximab conjugates	1626:1673	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	8	51	theme	membrane	1909:1916	arg1	proteins					1918:1925	membrane proteins	1909:1925	membrane proteins	1909:1925	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	7	52	theme	cell-based	1596:1605	arg1	assays					1607:1612	Preliminary cell-based assays	1584:1612	Preliminary cell-based assays	1584:1612	Preliminary cell-based assays showed that the M6P-trastuzumab and M6P-cetuximab conjugates were able to selectively degrade the membrane-associated HER2 and EGFR, respectively.
35316032	3	53	theme	antibody	811:818	arg1	deglycosylation					820:834	the antibody deglycosylation and simultaneous transfer	807:860	deglycosylation	820:834	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	2	54	theme	reactions	509:517	arg1	need					458:461	the need	454:461	the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties	454:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	2	55	theme	site-specific	348:360	arg1	conjugation					362:372	a single-step and site-specific conjugation	330:372	a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies	330:444	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	2	56	theme	single-step	332:342	arg1	conjugation					362:372	a single-step and site-specific conjugation	330:372	a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies	330:444	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	1	57	theme	proteins	244:251	arg1	degradation					191:201	the degradation	187:201	the degradation of extracellular and membrane-associated proteins of interest	187:263	Lysosome-targeting chimeras (LYTACs) offer an opportunity for the degradation of extracellular and membrane-associated proteins of interest.
35316032	2	58	theme	glycan	596:601	arg1	conjugates					603:612	homogeneous antibody-M6P glycan conjugates	571:612	homogeneous antibody-M6P glycan conjugates	571:612	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	4	59	theme	wild-type	1062:1070	arg1	Endo-S2					1072:1078	wild-type Endo-S2	1062:1078	wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M)	1062:1160	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	2	60	theme	targeted	618:625	arg1	degradation					627:637	targeted degradation	618:637	targeted degradation of membrane-associated proteins	618:669	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	5	61	theme	cetuximab	1402:1410	arg1	remodeling					1388:1397	the selective Fc-glycan remodeling	1364:1397	the selective Fc-glycan remodeling of cetuximab	1364:1410	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	3	62	theme	model	707:711	arg1	trastuzumab					678:688	trastuzumab	678:688	trastuzumab	678:688	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	3	62	theme	model	707:711	arg1	cetuximab					694:702	cetuximab	694:702	cetuximab	694:702	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	3	62	theme	model	707:711	arg1	antibodies					713:722	model antibodies	707:722	model antibodies	707:722	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	6	63	theme	cation-independent	1526:1543	arg1	CI-MPR					1575:1580	CI-MPR	1575:1580	CI-MPR	1575:1580	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	6	63	theme	cation-independent	1526:1543	arg1	receptor					1565:1572	the cation-independent mannose-6-phosphate receptor	1522:1572	the cation-independent mannose-6-phosphate receptor (CI-MPR)	1522:1581	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	2	64	theme	"	550:550	arg1	moieties					552:559	"unnatural" moieties	540:559	"unnatural" moieties	540:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	5	65	theme	selective	1368:1376	arg1	remodeling					1388:1397	the selective Fc-glycan remodeling	1364:1397	the selective Fc-glycan remodeling of cetuximab	1364:1410	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	3	66	theme	synthetic	886:894	arg1	oxazoline					907:915	a synthetic M6P-glycan oxazoline	884:915	a synthetic M6P-glycan oxazoline	884:915	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	0	67	theme	Targeted	95:102	arg1	Degradation					112:122	Targeted Protein Degradation	95:122	Targeted Protein Degradation	95:122	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	3	68	theme	well-defined	989:1000	arg1	conjugates					1022:1031	structurally well-defined antibody-M6P glycan conjugates	976:1031	structurally well-defined antibody-M6P glycan conjugates	976:1031	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	6	69	theme	binding	1499:1505	arg1	affinities					1507:1516	binding affinities	1499:1516	binding affinities	1499:1516	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	2	70	theme	homogeneous	571:581	arg1	conjugates					603:612	homogeneous antibody-M6P glycan conjugates	571:612	homogeneous antibody-M6P glycan conjugates	571:612	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	0	71	theme	Chemoenzymatic	14:27	arg1	Conjugation					29:39	Site-Specific Chemoenzymatic Conjugation	0:39	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation	0:122	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	3	72	theme	glycan	1015:1020	arg1	conjugates					1022:1031	structurally well-defined antibody-M6P glycan conjugates	976:1031	structurally well-defined antibody-M6P glycan conjugates	976:1031	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	2	73	theme	conventional	490:501	arg1	reactions					509:517	conventional click reactions	490:517	conventional click reactions that would introduce "unnatural" moieties	490:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	2	74	theme	ligands	424:430	arg1	conjugation					362:372	a single-step and site-specific conjugation	330:372	a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies	330:444	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	5	75	theme	Fc	1308:1309	arg1	domains					1319:1325	both Fc and Fab domains	1303:1325	domains	1319:1325	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	2	76	theme	engineering	474:484	arg1	need					458:461	the need	454:461	the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties	454:559	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	0	77	theme	M6P	58:60	arg1	Ligands					69:75	High-Affinity M6P Glycan Ligands	44:75	High-Affinity M6P Glycan Ligands	44:75	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	5	78	theme	Fab	1315:1317	arg1	domains					1319:1325	both Fc and Fab domains	1303:1325	domains	1319:1325	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	0	79	theme	Ligands	69:75	arg1	Conjugation					29:39	Site-Specific Chemoenzymatic Conjugation	0:39	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation	0:122	Site-Specific Chemoenzymatic Conjugation of High-Affinity M6P Glycan Ligands to Antibodies for Targeted Protein Degradation.
35316032	5	80	theme	glycan	1280:1285	arg1	remodeling					1287:1296	Fc glycan remodeling	1277:1296	Fc glycan remodeling	1277:1296	The chemoenzymatic approach was highly specific for Fc glycan remodeling when both Fc and Fab domains were glycosylated, as exemplified by the selective Fc-glycan remodeling of cetuximab.
35316032	4	81	theme	Endo-S2	1139:1145	arg1	D184M					1155:1159	D184M	1155:1159	D184M	1155:1159	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	4	81	theme	Endo-S2	1139:1145	arg1	mutant					1147:1152	an Endo-S2 mutant	1136:1152	an Endo-S2 mutant (D184M)	1136:1160	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
35316032	8	82	theme	glycan-remodeling	1774:1790	arg1	strategy					1792:1799	This modular glycan-remodeling strategy	1761:1799	This modular glycan-remodeling strategy	1761:1799	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	3	83	theme	endoglycosidase	754:768	arg1	Endo-S					773:778	the wild-type endoglycosidase S (Endo-S)	740:779	the wild-type endoglycosidase S (Endo-S)	740:779	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	2	84	theme	high-affinity	377:389	arg1	ligands					424:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	high-affinity mannose-6-phosphate (M6P) glycan ligands	377:430	Here, we report an efficient chemoenzymatic method that enables a single-step and site-specific conjugation of high-affinity mannose-6-phosphate (M6P) glycan ligands to antibodies without the need of protein engineering and conventional click reactions that would introduce "unnatural" moieties, yielding homogeneous antibody-M6P glycan conjugates for targeted degradation of membrane-associated proteins.
35316032	8	85	theme	lysosome-targeted	1858:1874	arg1	degradation					1876:1886	antibody-based lysosome-targeted degradation	1843:1886	antibody-based lysosome-targeted degradation of extracellular and membrane proteins	1843:1925	This modular glycan-remodeling strategy is expected to find wide applications for antibody-based lysosome-targeted degradation of extracellular and membrane proteins.
35316032	3	86	from	oxazoline	907:915	arg1	deglycosylation					820:834	the antibody deglycosylation and simultaneous transfer	807:860	deglycosylation	820:834	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	3	86	from	oxazoline	907:915	arg1	transfer					853:860	the antibody deglycosylation and simultaneous transfer	807:860	transfer	853:860	Using trastuzumab and cetuximab as model antibodies, we showed that the wild-type endoglycosidase S (Endo-S) could efficiently perform the antibody deglycosylation and simultaneous transfer of an M6P-glycan from a synthetic M6P-glycan oxazoline to the deglycosylated antibody in a one-pot manner, giving structurally well-defined antibody-M6P glycan conjugates.
35316032	6	87	theme	mannose-6-phosphate	1545:1563	arg1	CI-MPR					1575:1580	CI-MPR	1575:1580	CI-MPR	1575:1580	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	6	87	theme	mannose-6-phosphate	1545:1563	arg1	receptor					1565:1572	the cation-independent mannose-6-phosphate receptor	1522:1572	the cation-independent mannose-6-phosphate receptor (CI-MPR)	1522:1581	SPR binding analysis indicated that the M6P conjugates possessed a nanomolar range of binding affinities for the cation-independent mannose-6-phosphate receptor (CI-MPR).
35316032	4	88	theme	glycan-antibody	1197:1211	arg1	conjugates					1213:1222	M6P glycan-antibody conjugates	1193:1222	M6P glycan-antibody conjugates	1193:1222	A two-step procedure, using wild-type Endo-S2 for deglycosylation followed by transglycosylation with an Endo-S2 mutant (D184M), was also efficient to provide M6P glycan-antibody conjugates.
37106096	5	0	theme	reversible	914:923	arg1	deactivation					925:936	the reversible deactivation	910:936	the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species	910:1014	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	6	1	theme	facile	1039:1044	arg1	pathway					1059:1065	a facile and scalable pathway	1037:1065	a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan	1037:1179	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	7	2	theme	precision	1233:1241	arg1	polysaccharides					1243:1257	precision polysaccharides	1233:1257	precision polysaccharides	1233:1257	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	6	3	dep	multiple	1070:1077	arg1	relevant					1092:1099	relevant	1092:1099	relevant	1092:1099	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	4	theme	unusual	1164:1170	arg1	L-glucan					1172:1179	an unusual L-glucan	1161:1179	an unusual L-glucan	1161:1179	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	5	theme	multiple	1070:1077	arg1	L-glucan					1172:1179	an unusual L-glucan	1161:1179	an unusual L-glucan	1161:1179	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	5	theme	multiple	1070:1077	arg1	D-mannan					1148:1155	D-mannan	1148:1155	D-mannan	1148:1155	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	5	theme	multiple	1070:1077	arg1	polysaccharides					1111:1125	multiple biologically relevant precision polysaccharides	1070:1125	multiple biologically relevant precision polysaccharides	1070:1125	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	5	theme	multiple	1070:1077	arg1	D-glucan					1138:1145	D-glucan	1138:1145	D-glucan	1138:1145	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	4	6	theme	molecular	622:630	arg1	weight					632:637	tunable molecular weight	614:637	tunable molecular weight	614:637	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	4	7	theme	trifluoride	713:723	arg1	catalyst					734:741	a boron trifluoride etherate catalyst	705:741	a boron trifluoride etherate catalyst	705:741	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	3	8	theme	chemical	416:423	arg1	approach					425:432	a chemical approach	414:432	a chemical approach to precision polysaccharides with native glycosidic linkages	414:493	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	1	9	theme	linkage	135:141	arg1	composition					82:92	composition	82:92	composition	82:92	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	1	9	theme	linkage	135:141	arg1	type					116:119	type	116:119	type	116:119	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	1	9	theme	linkage	135:141	arg1	length					105:110	length	105:110	length	105:110	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	1	9	theme	linkage	135:141	arg1	sequence					95:102	sequence	95:102	sequence	95:102	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	6	10	theme	scalable	1050:1057	arg1	pathway					1059:1065	a facile and scalable pathway	1037:1065	a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan	1037:1179	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	7	11	theme	thermal	1388:1394	arg1	properties					1411:1420	tailored thermal and mechanical properties	1379:1420	tailored thermal and mechanical properties	1379:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	5	12	theme	dormant	1000:1006	arg1	species					1008:1014	the glycosyl fluoride dormant species	978:1014	the glycosyl fluoride dormant species	978:1014	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	7	13	with	materials	1364:1372	arg1	properties					1411:1420	tailored thermal and mechanical properties	1379:1420	tailored thermal and mechanical properties	1379:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	3	14	theme	cationic	506:513	arg1	polymerization					528:541	cationic ring-opening polymerization	506:541	cationic ring-opening polymerization of 1,6-anhydrosugars	506:562	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	4	15	theme	boron	707:711	arg1	catalyst					734:741	a boron trifluoride etherate catalyst	705:741	a boron trifluoride etherate catalyst	705:741	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	7	16	theme	materials	1364:1372	arg1	utility					1320:1326	their potential utility	1304:1326	their potential utility	1304:1326	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	7	16	theme	materials	1364:1372	arg1	class					1333:1337	a class	1331:1337	a class of chemically recyclable materials with tailored thermal and mechanical properties	1331:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	7	17	theme	mechanical	1400:1409	arg1	properties					1411:1420	tailored thermal and mechanical properties	1379:1420	tailored thermal and mechanical properties	1379:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	1	18	theme	biological	186:195	arg1	properties					210:219	their biological and physical properties	180:219	their biological and physical properties	180:219	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	3	19	theme	precision	437:445	arg1	polysaccharides					447:461	precision polysaccharides	437:461	precision polysaccharides with native glycosidic linkages	437:493	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	4	20	theme	well-defined	580:591	arg1	polysaccharides					593:607	well-defined polysaccharides	580:607	well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators	580:774	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	0	21	theme	Precision	0:8	arg1	polysaccharides					17:31	Precision native polysaccharides	0:31	Precision native polysaccharides from	0:36	Precision native polysaccharides from living polymerization of anhydrosugars.
37106096	5	22	theme	Computational	777:789	arg1	studies					791:797	Computational studies	777:797	Computational studies	777:797	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	7	23	theme	potential	1310:1318	arg1	utility					1320:1326	their potential utility	1304:1326	their potential utility	1304:1326	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	7	23	theme	potential	1310:1318	arg1	class					1333:1337	a class	1331:1337	a class of chemically recyclable materials with tailored thermal and mechanical properties	1331:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	1	24	theme	physical	201:208	arg1	properties					210:219	their biological and physical properties	180:219	their biological and physical properties	180:219	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	7	25	theme	tailored	1379:1386	arg1	properties					1411:1420	tailored thermal and mechanical properties	1379:1420	tailored thermal and mechanical properties	1379:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	4	26	theme	excellent	659:667	arg1	regio-					669:674	excellent regio-	659:674	excellent regio-	659:674	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	5	27	theme	monomer	849:855	arg1	α-addition					857:866	the monomer α-addition	845:866	the monomer α-addition	845:866	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	2	28	theme	well-defined	344:355	arg1	polysaccharides					357:371	well-defined polysaccharides	344:371	well-defined polysaccharides	344:371	However, investigation of the structure-function relationship of polysaccharides is hampered by difficulties in accessing well-defined polysaccharides in sufficient quantities.
37106096	3	29	theme	1,6-anhydrosugars	546:562	arg1	polymerization					528:541	cationic ring-opening polymerization	506:541	cationic ring-opening polymerization of 1,6-anhydrosugars	506:562	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	5	30	theme	glycosyl	982:989	arg1	species					1008:1014	the glycosyl fluoride dormant species	978:1014	the glycosyl fluoride dormant species	978:1014	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	3	31	with	polysaccharides	447:461	arg1	linkages					486:493	native glycosidic linkages	468:493	native glycosidic linkages	468:493	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	4	32	theme	fluoride	756:763	arg1	initiators					765:774	a boron trifluoride etherate catalyst and glycosyl fluoride initiators	705:774	a boron trifluoride etherate catalyst and glycosyl fluoride initiators	705:774	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	3	33	theme	glycosidic	475:484	arg1	linkages					486:493	native glycosidic linkages	468:493	native glycosidic linkages	468:493	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	2	34	theme	structure-function	252:269	arg1	relationship					271:282	the structure-function relationship	248:282	the structure-function relationship of polysaccharides	248:301	However, investigation of the structure-function relationship of polysaccharides is hampered by difficulties in accessing well-defined polysaccharides in sufficient quantities.
37106096	4	35	theme	low	640:642	arg1	dispersity					644:653	low dispersity	640:653	low dispersity	640:653	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	0	36	theme	anhydrosugars	63:75	arg1	polymerization					45:58	polymerization	45:58	polymerization of anhydrosugars	45:75	Precision native polysaccharides from living polymerization of anhydrosugars.
37106096	5	37	theme	oxocarbenium	957:968	arg1	deactivation					925:936	the reversible deactivation	910:936	the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species	910:1014	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	7	38	theme	catalytic	1203:1211	arg1	depolymerization					1213:1228	catalytic depolymerization	1203:1228	catalytic depolymerization of precision polysaccharides	1203:1257	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	3	39	theme	native	468:473	arg1	linkages					486:493	native glycosidic linkages	468:493	native glycosidic linkages	468:493	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	7	40	theme	polysaccharides	1243:1257	arg1	depolymerization					1213:1228	catalytic depolymerization	1203:1228	catalytic depolymerization of precision polysaccharides	1203:1257	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	1	41	theme	polysaccharides	146:160	arg1	linkage					135:141	glycosidic linkage	124:141	glycosidic linkage of polysaccharides	124:160	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	6	42	theme	precision	1101:1109	arg1	L-glucan					1172:1179	an unusual L-glucan	1161:1179	an unusual L-glucan	1161:1179	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	42	theme	precision	1101:1109	arg1	D-mannan					1148:1155	D-mannan	1148:1155	D-mannan	1148:1155	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	42	theme	precision	1101:1109	arg1	polysaccharides					1111:1125	multiple biologically relevant precision polysaccharides	1070:1125	multiple biologically relevant precision polysaccharides	1070:1125	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	6	42	theme	precision	1101:1109	arg1	D-glucan					1138:1145	D-glucan	1138:1145	D-glucan	1138:1145	Our method afforded a facile and scalable pathway to multiple biologically relevant precision polysaccharides, including D-glucan, D-mannan and an unusual L-glucan.
37106096	7	43	theme	recyclable	1353:1362	arg1	materials					1364:1372	chemically recyclable materials	1342:1372	chemically recyclable materials with tailored thermal and mechanical properties	1342:1420	We demonstrated that catalytic depolymerization of precision polysaccharides efficiently regenerated monomers, suggesting their potential utility as a class of chemically recyclable materials with tailored thermal and mechanical properties.
37106096	1	44	theme	glycosidic	124:133	arg1	linkage					135:141	glycosidic linkage	124:141	glycosidic linkage of polysaccharides	124:160	The composition, sequence, length and type of glycosidic linkage of polysaccharides profoundly affect their biological and physical properties.
37106096	4	45	theme	catalyst	734:741	arg1	initiators					765:774	a boron trifluoride etherate catalyst and glycosyl fluoride initiators	705:774	a boron trifluoride etherate catalyst and glycosyl fluoride initiators	705:774	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	2	46	theme	polysaccharides	287:301	arg1	relationship					271:282	the structure-function relationship	248:282	the structure-function relationship of polysaccharides	248:301	However, investigation of the structure-function relationship of polysaccharides is hampered by difficulties in accessing well-defined polysaccharides in sufficient quantities.
37106096	2	47	theme	sufficient	376:385	arg1	quantities					387:396	sufficient quantities	376:396	sufficient quantities	376:396	However, investigation of the structure-function relationship of polysaccharides is hampered by difficulties in accessing well-defined polysaccharides in sufficient quantities.
37106096	4	48	theme	etherate	725:732	arg1	catalyst					734:741	a boron trifluoride etherate catalyst	705:741	a boron trifluoride etherate catalyst	705:741	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	5	49	theme	fluoride	991:998	arg1	species					1008:1014	the glycosyl fluoride dormant species	978:1014	the glycosyl fluoride dormant species	978:1014	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	4	50	with	polysaccharides	593:607	arg1	dispersity					644:653	low dispersity	640:653	low dispersity	640:653	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	4	50	with	polysaccharides	593:607	arg1	regio-					669:674	excellent regio-	659:674	excellent regio-	659:674	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	4	50	with	polysaccharides	593:607	arg1	weight					632:637	tunable molecular weight	614:637	tunable molecular weight	614:637	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	3	51	theme	ring-opening	515:526	arg1	polymerization					528:541	cationic ring-opening polymerization	506:541	cationic ring-opening polymerization of 1,6-anhydrosugars	506:562	Here we report a chemical approach to precision polysaccharides with native glycosidic linkages via living cationic ring-opening polymerization of 1,6-anhydrosugars.
37106096	4	52	theme	glycosyl	747:754	arg1	fluoride					756:763	glycosyl fluoride	747:763	glycosyl fluoride	747:763	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	5	53	theme	propagating	945:955	arg1	oxocarbenium					957:968	the propagating oxocarbenium to form the glycosyl fluoride dormant species	941:1014	the propagating oxocarbenium to form the glycosyl fluoride dormant species	941:1014	Computational studies revealed that the reaction propagated through the monomer α-addition to the oxocarbenium and was controlled by the reversible deactivation of the propagating oxocarbenium to form the glycosyl fluoride dormant species.
37106096	4	54	theme	tunable	614:620	arg1	weight					632:637	tunable molecular weight	614:637	tunable molecular weight	614:637	We synthesized well-defined polysaccharides with tunable molecular weight, low dispersity and excellent regio- and stereo-selectivity using a boron trifluoride etherate catalyst and glycosyl fluoride initiators.
37106096	2	55	theme	relationship	271:282	arg1	investigation					231:243	investigation	231:243	investigation of the structure-function relationship of polysaccharides	231:301	However, investigation of the structure-function relationship of polysaccharides is hampered by difficulties in accessing well-defined polysaccharides in sufficient quantities.
37106096	0	56	theme	native	10:15	arg1	polysaccharides					17:31	Precision native polysaccharides	0:31	Precision native polysaccharides from	0:36	Precision native polysaccharides from living polymerization of anhydrosugars.
36377874	6	0	from	2.6 Å	997:1001	arg1	mutant					979:984	a deletion mutant	968:984	a deletion mutant at 2.5 and 2.6 Å, respectively,	968:1016	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	0	from	2.6 Å	997:1001	arg1	structures					931:940	Crystal structures	923:940	Crystal structures of the ZIKV E protein	923:962	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	10	1	theme	loop	1645:1648	arg1	mutants					1659:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	11	2	theme	neonatal	1957:1964	arg1	neurovirulence					1972:1985	neonatal mouse neurovirulence	1957:1985	neonatal mouse neurovirulence	1957:1985	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	1	3	theme	envelope	141:148	arg1	protein					150:156	Zika virus (ZIKV) envelope protein	123:156	Zika virus (ZIKV) envelope protein (E)	123:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	3	theme	envelope	141:148	arg1	E					159:159	E	159:159	E	159:159	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	9	4	theme	Asian	1609:1613	arg1	lineages					1615:1622	the contemporary Asian lineages	1592:1622	the contemporary Asian lineages	1592:1622	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	6	5	theme	conformational	1097:1110	arg1	appearance					1139:1148	the appearance	1135:1148	the appearance of perforations on the surface	1135:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	5	theme	conformational	1097:1110	arg1	change					1193:1198	a clear change	1185:1198	a clear change in the topology of the loops	1185:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	5	theme	conformational	1097:1110	arg1	alterations					1112:1122	encephalitic flavivirus-like conformational alterations	1068:1122	encephalitic flavivirus-like conformational alterations	1068:1122	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	6	theme	clear	1187:1191	arg1	change					1193:1198	a clear change	1185:1198	a clear change in the topology of the loops	1185:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	3	7	theme	specific	506:513	arg1	deletions					515:523	specific deletions	506:523	specific deletions in the E glycan loop	506:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	5	8	theme	enhanced	812:819	arg1	neurovirulence					821:834	an enhanced neurovirulence	809:834	an enhanced neurovirulence phenotype	809:844	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	6	9	theme	encephalitic	1068:1079	arg1	appearance					1139:1148	the appearance	1135:1148	the appearance of perforations on the surface	1135:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	9	theme	encephalitic	1068:1079	arg1	change					1193:1198	a clear change	1185:1198	a clear change in the topology of the loops	1185:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	9	theme	encephalitic	1068:1079	arg1	alterations					1112:1122	encephalitic flavivirus-like conformational alterations	1068:1122	encephalitic flavivirus-like conformational alterations	1068:1122	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	12	10	theme	mutants	2053:2059	arg1	role					2024:2027	the critical role	2011:2027	the critical role of glycan loop deletion mutants in ZIKV pathogenesis	2011:2080	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	11	11	theme	neurovirulence	1972:1985	arg1	enhancement					1942:1952	a significant enhancement	1928:1952	a significant enhancement of neonatal mouse neurovirulence	1928:1985	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	5	12	theme	glycan	770:775	arg1	mutants					791:797	these glycan loop deletion mutants	764:797	these glycan loop deletion mutants	764:797	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	0	13	from	Deletions	69:77	arg1	Protein					95:101	the Envelope Protein	82:101	the Envelope Protein	82:101	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	7	14	theme	mouse	1315:1319	arg1	markers					1336:1342	neonatal mouse neurovirulence markers	1306:1342	neonatal mouse neurovirulence markers of ZIKV	1306:1350	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	4	15	theme	in	577:578	arg1	characterization					598:613	Extensive in vitro and in vivo characterization	567:613	Extensive in vitro and in vivo characterization of these deletion mutants	567:639	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	3	16	theme	E	532:532	arg1	loop					541:544	the E glycan loop	528:544	the E glycan loop	528:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	5	17	theme	deletion	782:789	arg1	mutants					791:797	these glycan loop deletion mutants	764:797	these glycan loop deletion mutants	764:797	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	10	18	theme	A129	1719:1722	arg1	model					1730:1734	adult A129 mouse model	1713:1734	adult A129 mouse model	1713:1734	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	1	19	theme	glycan	108:113	arg1	loop					115:118	The glycan loop	104:118	The glycan loop of Zika virus (ZIKV) envelope protein (E)	104:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	19	theme	glycan	108:113	arg1	important					229:237	important	229:237	important	229:237	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	7	20	theme	loop	1281:1284	arg1	deletions					1286:1294	the E glycan loop deletions	1268:1294	the E glycan loop deletions	1268:1294	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	11	21	from	alteration	1884:1893	arg1	homodimer					1904:1912	the E homodimer	1898:1912	the E homodimer	1898:1912	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	4	22	theme	attenuated	657:666	arg1	phenotype					668:676	an attenuated phenotype	654:676	an attenuated phenotype	654:676	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	3	23	theme	reverse	549:555	arg1	genetics					557:564	reverse genetics	549:564	reverse genetics	549:564	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	6	24	theme	protein	956:962	arg1	mutant					979:984	a deletion mutant	968:984	a deletion mutant at 2.5 and 2.6 Å, respectively,	968:1016	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	24	theme	protein	956:962	arg1	structures					931:940	Crystal structures	923:940	Crystal structures of the ZIKV E protein	923:962	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	7	25	theme	E	1272:1272	arg1	deletions					1286:1294	the E glycan loop deletions	1268:1294	the E glycan loop deletions	1268:1294	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	0	26	theme	Glycan	57:62	arg1	Deletions					69:77	Glycan Loop Deletions	57:77	Glycan Loop Deletions in the Envelope Protein	57:101	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	10	27	theme	reduced	1740:1746	arg1	infections					1753:1762	reduced oral infections	1740:1762	reduced oral infections in mosquitoes	1740:1776	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	1	28	theme	virus	128:132	arg1	protein					150:156	Zika virus (ZIKV) envelope protein	123:156	Zika virus (ZIKV) envelope protein (E)	123:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	28	theme	virus	128:132	arg1	E					159:159	E	159:159	E	159:159	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	6	29	theme	ZIKV	949:952	arg1	protein					956:962	the ZIKV E protein	945:962	the ZIKV E protein	945:962	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	4	30	theme	deletion	624:631	arg1	mutants					633:639	these deletion mutants	618:639	these deletion mutants	618:639	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	6	31	from	appearance	1139:1148	arg1	surface					1173:1179	the surface	1169:1179	the surface	1169:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	31	from	appearance	1139:1148	arg1	topology					1207:1214	the topology	1203:1214	the topology of the loops	1203:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	1	32	theme	ZIKV	135:138	arg1	protein					150:156	Zika virus (ZIKV) envelope protein	123:156	Zika virus (ZIKV) envelope protein (E)	123:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	32	theme	ZIKV	135:138	arg1	E					159:159	E	159:159	E	159:159	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	4	33	theme	mouse	695:699	arg1	model					701:705	an adult A129 mouse model	681:705	an adult A129 mouse model	681:705	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	6	34	from	perforations	1153:1164	arg1	surface					1173:1179	the surface	1169:1179	the surface	1169:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	5	35	theme	mouse	909:913	arg1	models					915:920	neonatal mouse models	900:920	neonatal mouse models	900:920	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	6	36	theme	Crystal	923:929	arg1	structures					931:940	Crystal structures	923:940	Crystal structures of the ZIKV E protein	923:962	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	2	37	theme	Asian	443:447	arg1	lineages					449:456	their contemporary Asian lineages	424:456	their contemporary Asian lineages	424:456	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	8	38	theme	evolutionary	1442:1453	arg1	mutations					1455:1463	acquired evolutionary mutations	1433:1463	acquired evolutionary mutations since its discovery	1433:1483	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	2	39	theme	E	334:334	arg1	loop					343:346	the E glycan loop	330:346	the E glycan loop	330:346	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	2	40	theme	African	372:378	arg1	strains					385:391	African ZIKV strains	372:391	African ZIKV strains	372:391	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	11	41	theme	deletion	1813:1820	arg1	mutants					1822:1828	the glycan loop deletion mutants	1797:1828	the glycan loop deletion mutants	1797:1828	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	5	42	theme	microcephalic	877:889	arg1	brain					891:895	a more severe microcephalic brain	863:895	a more severe microcephalic brain in neonatal mouse models	863:920	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	6	43	theme	2.5 and	989:995	arg1	2.6 Å					997:1001	2.5 and 2.6 Å	989:1001	2.5 and 2.6 Å	989:1001	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	10	44	theme	oral	1748:1751	arg1	infections					1753:1762	reduced oral infections	1740:1762	reduced oral infections in mosquitoes	1740:1776	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	4	45	theme	adult	684:688	arg1	model					701:705	an adult A129 mouse model	681:705	an adult A129 mouse model	681:705	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	11	46	theme	conformational	1869:1882	arg1	alteration					1884:1893	an encephalitic flavivirus-like conformational alteration	1837:1893	an encephalitic flavivirus-like conformational alteration in the E homodimer	1837:1912	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	0	47	theme	Structural	18:27	arg1	Basis					29:33	Structural Basis	18:33	Structural Basis	18:33	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	9	48	theme	glycan	1516:1521	arg1	loop					1523:1526	the E glycan loop	1510:1526	the E glycan loop	1510:1526	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	1	49	theme	Zika	123:126	arg1	protein					150:156	Zika virus (ZIKV) envelope protein	123:156	Zika virus (ZIKV) envelope protein (E)	123:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	49	theme	Zika	123:126	arg1	E					159:159	E	159:159	E	159:159	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	3	50	contain	containing	495:504	arg1	ZIKV					490:493	recombinant ZIKV	478:493	recombinant ZIKV containing specific deletions in the E glycan loop	478:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	3	50	contain	containing	495:504	arg2	deletions					515:523	specific deletions	506:523	specific deletions in the E glycan loop	506:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	11	51	theme	encephalitic	1840:1851	arg1	alteration					1884:1893	an encephalitic flavivirus-like conformational alteration	1837:1893	an encephalitic flavivirus-like conformational alteration in the E homodimer	1837:1912	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	12	52	theme	ZIKV	2148:2151	arg1	variants					2153:2160	such ZIKV variants	2143:2160	such ZIKV variants	2143:2160	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	10	53	theme	glycan	1638:1643	arg1	mutants					1659:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	0	54	theme	Variants	43:50	arg1	Pathogenicity					0:12	Pathogenicity	0:12	Pathogenicity	0:12	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	0	54	theme	Variants	43:50	arg1	Basis					29:33	Structural Basis	18:33	Structural Basis	18:33	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	6	55	theme	glycan	1048:1053	arg1	loop					1055:1058	the glycan loop	1044:1058	the glycan loop	1044:1058	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	1	56	contain	contains	162:169	arg1	loop					115:118	The glycan loop	104:118	The glycan loop of Zika virus (ZIKV) envelope protein (E)	104:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	56	contain	contains	162:169	arg1	important					229:237	important	229:237	important	229:237	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	56	contain	contains	162:169	arg2	site					189:192	the glycosylation site	171:192	the glycosylation site	171:192	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	8	57	theme	Zika	1364:1367	arg1	ZIKV					1376:1379	ZIKV	1376:1379	ZIKV	1376:1379	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	8	57	theme	Zika	1364:1367	arg1	virus					1369:1373	IMPORTANCE Zika virus	1353:1373	IMPORTANCE Zika virus (ZIKV)	1353:1380	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	8	57	theme	Zika	1364:1367	arg1	cause					1407:1411	a cause	1405:1411	a cause of microcephaly and acquired evolutionary mutations since its discovery	1405:1483	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	0	58	with	Pathogenicity	0:12	arg1	Deletions					69:77	Glycan Loop Deletions	57:77	Glycan Loop Deletions in the Envelope Protein	57:101	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	1	59	theme	glycosylation	175:187	arg1	site					189:192	the glycosylation site	171:192	the glycosylation site	171:192	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	4	60	dep	in	590:591	arg1	vivo					593:596	vivo	593:596	vivo	593:596	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	11	61	theme	flavivirus-like	1853:1867	arg1	alteration					1884:1893	an encephalitic flavivirus-like conformational alteration	1837:1893	an encephalitic flavivirus-like conformational alteration in the E homodimer	1837:1912	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	12	62	theme	virological	2114:2124	arg1	surveillance					2126:2137	global virological surveillance	2107:2137	global virological surveillance for such ZIKV variants	2107:2160	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	11	63	theme	glycan	1801:1806	arg1	mutants					1822:1828	the glycan loop deletion mutants	1797:1828	the glycan loop deletion mutants	1797:1828	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	6	64	theme	loops	1223:1227	arg1	topology					1207:1214	the topology	1203:1214	the topology of the loops	1203:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	10	65	theme	deletion	1650:1657	arg1	mutants					1659:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	6	66	from	change	1193:1198	arg1	surface					1173:1179	the surface	1169:1179	the surface	1169:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	66	from	change	1193:1198	arg1	topology					1207:1214	the topology	1203:1214	the topology of the loops	1203:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	7	67	theme	ZIKV	1347:1350	arg1	markers					1336:1342	neonatal mouse neurovirulence markers	1306:1342	neonatal mouse neurovirulence markers of ZIKV	1306:1350	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	12	68	theme	critical	2015:2022	arg1	role					2024:2027	the critical role	2011:2027	the critical role of glycan loop deletion mutants in ZIKV pathogenesis	2011:2080	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	11	69	theme	significant	1930:1940	arg1	enhancement					1942:1952	a significant enhancement	1928:1952	a significant enhancement of neonatal mouse neurovirulence	1928:1985	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	9	70	theme	contemporary	1596:1607	arg1	lineages					1615:1622	the contemporary Asian lineages	1592:1622	the contemporary Asian lineages	1592:1622	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	10	71	theme	adult	1713:1717	arg1	model					1730:1734	adult A129 mouse model	1713:1734	adult A129 mouse model	1713:1734	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	1	72	theme	protein	150:156	arg1	loop					115:118	The glycan loop	104:118	The glycan loop of Zika virus (ZIKV) envelope protein (E)	104:160	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	1	72	theme	protein	150:156	arg1	important					229:237	important	229:237	important	229:237	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	6	73	theme	flavivirus-like	1081:1095	arg1	appearance					1139:1148	the appearance	1135:1148	the appearance of perforations on the surface	1135:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	73	theme	flavivirus-like	1081:1095	arg1	change					1193:1198	a clear change	1185:1198	a clear change in the topology of the loops	1185:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	73	theme	flavivirus-like	1081:1095	arg1	alterations					1112:1122	encephalitic flavivirus-like conformational alterations	1068:1122	encephalitic flavivirus-like conformational alterations	1068:1122	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	4	74	theme	in	590:591	arg1	characterization					598:613	Extensive in vitro and in vivo characterization	567:613	Extensive in vitro and in vivo characterization of these deletion mutants	567:639	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	3	75	theme	recombinant	478:488	arg1	ZIKV					490:493	recombinant ZIKV	478:493	recombinant ZIKV containing specific deletions in the E glycan loop	478:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	12	76	theme	deletion	2044:2051	arg1	mutants					2053:2059	glycan loop deletion mutants	2032:2059	glycan loop deletion mutants	2032:2059	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	11	77	theme	E	1902:1902	arg1	homodimer					1904:1912	the E homodimer	1898:1912	the E homodimer	1898:1912	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	5	78	theme	loop	777:780	arg1	mutants					791:797	these glycan loop deletion mutants	764:797	these glycan loop deletion mutants	764:797	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	7	79	theme	neurovirulence	1321:1334	arg1	markers					1336:1342	neonatal mouse neurovirulence markers	1306:1342	neonatal mouse neurovirulence markers of ZIKV	1306:1350	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	4	80	theme	Extensive	567:575	arg1	characterization					598:613	Extensive in vitro and in vivo characterization	567:613	Extensive in vitro and in vivo characterization of these deletion mutants	567:639	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	10	81	theme	mouse	1724:1728	arg1	model					1730:1734	adult A129 mouse model	1713:1734	adult A129 mouse model	1713:1734	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	7	82	theme	neonatal	1306:1313	arg1	markers					1336:1342	neonatal mouse neurovirulence markers	1306:1342	neonatal mouse neurovirulence markers of ZIKV	1306:1350	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	4	83	theme	mutants	633:639	arg1	characterization					598:613	Extensive in vitro and in vivo characterization	567:613	Extensive in vitro and in vivo characterization of these deletion mutants	567:639	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	6	84	from	surface	1173:1179	arg1	appearance					1139:1148	the appearance	1135:1148	the appearance of perforations on the surface	1135:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	84	from	surface	1173:1179	arg1	change					1193:1198	a clear change	1185:1198	a clear change in the topology of the loops	1185:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	4	85	theme	oral	719:722	arg1	infections					724:733	oral infections	719:733	oral infections	719:733	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	12	86	from	role	2024:2027	arg1	pathogenesis					2069:2080	ZIKV pathogenesis	2064:2080	ZIKV pathogenesis	2064:2080	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	11	87	theme	mouse	1966:1970	arg1	neurovirulence					1972:1985	neonatal mouse neurovirulence	1957:1985	neonatal mouse neurovirulence	1957:1985	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
36377874	6	88	theme	perforations	1153:1164	arg1	appearance					1139:1148	the appearance	1135:1148	the appearance of perforations on the surface	1135:1179	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	6	88	theme	perforations	1153:1164	arg1	change					1193:1198	a clear change	1185:1198	a clear change in the topology of the loops	1185:1227	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	12	89	theme	glycan	2032:2037	arg1	mutants					2053:2059	glycan loop deletion mutants	2032:2059	glycan loop deletion mutants	2032:2059	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	0	90	theme	Loop	64:67	arg1	Deletions					69:77	Glycan Loop Deletions	57:77	Glycan Loop Deletions in the Envelope Protein	57:101	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	3	91	theme	glycan	534:539	arg1	loop					541:544	the E glycan loop	528:544	the E glycan loop	528:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	5	92	theme	neurovirulence	821:834	arg1	phenotype					836:844	an enhanced neurovirulence phenotype	809:844	an enhanced neurovirulence phenotype	809:844	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	6	93	theme	E	954:954	arg1	protein					956:962	the ZIKV E protein	945:962	the ZIKV E protein	945:962	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	8	94	theme	microcephaly	1416:1427	arg1	virus					1369:1373	IMPORTANCE Zika virus	1353:1373	IMPORTANCE Zika virus (ZIKV)	1353:1380	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	8	94	theme	microcephaly	1416:1427	arg1	cause					1407:1411	a cause	1405:1411	a cause of microcephaly and acquired evolutionary mutations since its discovery	1405:1483	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	7	95	theme	glycan	1274:1279	arg1	deletions					1286:1294	the E glycan loop deletions	1268:1294	the E glycan loop deletions	1268:1294	Overall, our results demonstrate that the E glycan loop deletions represent neonatal mouse neurovirulence markers of ZIKV.
36377874	9	96	from	deletions	1497:1505	arg1	loop					1523:1526	the E glycan loop	1510:1526	the E glycan loop	1510:1526	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	8	97	theme	acquired	1433:1440	arg1	mutations					1455:1463	acquired evolutionary mutations	1433:1463	acquired evolutionary mutations since its discovery	1433:1483	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	0	98	theme	Envelope	86:93	arg1	Protein					95:101	the Envelope Protein	82:101	the Envelope Protein	82:101	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	9	99	theme	ZIKV	1553:1556	arg1	strains					1558:1564	African ZIKV strains	1545:1564	African ZIKV strains	1545:1564	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	1	100	gly	glycosylation	175:187	arg2	site					189:192	the glycosylation site	171:192	the glycosylation site	171:192	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	5	101	theme	neonatal	900:907	arg1	models					915:920	neonatal mouse models	900:920	neonatal mouse models	900:920	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	8	102	theme	mutations	1455:1463	arg1	virus					1369:1373	IMPORTANCE Zika virus	1353:1373	IMPORTANCE Zika virus (ZIKV)	1353:1380	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	8	102	theme	mutations	1455:1463	arg1	cause					1407:1411	a cause	1405:1411	a cause of microcephaly and acquired evolutionary mutations since its discovery	1405:1483	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	4	103	theme	A129	690:693	arg1	model					701:705	an adult A129 mouse model	681:705	an adult A129 mouse model	681:705	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	2	104	theme	contemporary	430:441	arg1	lineages					449:456	their contemporary Asian lineages	424:456	their contemporary Asian lineages	424:456	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	5	105	theme	severe	870:875	arg1	brain					891:895	a more severe microcephalic brain	863:895	a more severe microcephalic brain in neonatal mouse models	863:920	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	10	106	from	model	1730:1734	arg1	mosquitoes					1767:1776	mosquitoes	1767:1776	mosquitoes	1767:1776	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	3	107	from	deletions	515:523	arg1	loop					541:544	the E glycan loop	528:544	the E glycan loop	528:544	Here, we generated recombinant ZIKV containing specific deletions in the E glycan loop by reverse genetics.
36377874	9	108	theme	E	1514:1514	arg1	loop					1523:1526	the E glycan loop	1510:1526	the E glycan loop	1510:1526	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	0	109	theme	Zika	38:41	arg1	Variants					43:50	Zika Variants	38:50	Zika Variants	38:50	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	1	110	theme	viral	243:247	arg1	pathogenesis					249:260	viral pathogenesis	243:260	viral pathogenesis	243:260	The glycan loop of Zika virus (ZIKV) envelope protein (E) contains the glycosylation site and has been well documented to be important for viral pathogenesis and transmission.
36377874	12	111	theme	ZIKV	2064:2067	arg1	pathogenesis					2069:2080	ZIKV pathogenesis	2064:2080	ZIKV pathogenesis	2064:2080	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	4	112	dep	in	577:578	arg1	vitro					580:584	vitro	580:584	vitro	580:584	Extensive in vitro and in vivo characterization of these deletion mutants demonstrated an attenuated phenotype in an adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	10	113	from	infections	1753:1762	arg1	mosquitoes					1767:1776	mosquitoes	1767:1776	mosquitoes	1767:1776	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	6	114	theme	deletion	970:977	arg1	mutant					979:984	a deletion mutant	968:984	a deletion mutant at 2.5 and 2.6 Å, respectively,	968:1016	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	0	115	with	Basis	29:33	arg1	Deletions					69:77	Glycan Loop Deletions	57:77	Glycan Loop Deletions in the Envelope Protein	57:101	Pathogenicity and Structural Basis of Zika Variants with Glycan Loop Deletions in the Envelope Protein.
36377874	2	116	theme	glycan	336:341	arg1	loop					343:346	the E glycan loop	330:346	the E glycan loop	330:346	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	2	117	from	deletions	317:325	arg1	loop					343:346	the E glycan loop	330:346	the E glycan loop	330:346	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	6	118	theme	loop	1055:1058	arg1	deletion					1032:1039	deletion	1032:1039	deletion of the glycan loop	1032:1058	Crystal structures of the ZIKV E protein and a deletion mutant at 2.5 and 2.6 Å, respectively, revealed that deletion of the glycan loop induces encephalitic flavivirus-like conformational alterations, including the appearance of perforations on the surface and a clear change in the topology of the loops.
36377874	2	119	theme	ZIKV	380:383	arg1	strains					385:391	African ZIKV strains	372:391	African ZIKV strains	372:391	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	12	120	theme	such	2143:2146	arg1	variants					2153:2160	such ZIKV variants	2143:2160	such ZIKV variants	2143:2160	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	2	121	theme	present	287:293	arg1	study					295:299	the present study	283:299	the present study	283:299	In the present study, we report that deletions in the E glycan loop, which were recorded in African ZIKV strains previously, have re-emerged in their contemporary Asian lineages.
36377874	5	122	from	brain	891:895	arg1	models					915:920	neonatal mouse models	900:920	neonatal mouse models	900:920	Surprisingly, these glycan loop deletion mutants exhibited an enhanced neurovirulence phenotype, and resulted in a more severe microcephalic brain in neonatal mouse models.
36377874	10	123	gly	glycosylated	1675:1686	arg1	mutants					1659:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants	1634:1665	The glycan loop deletion mutants are not glycosylated, which are attenuated in adult A129 mouse model and reduced oral infections in mosquitoes.
36377874	9	124	theme	African	1545:1551	arg1	strains					1558:1564	African ZIKV strains	1545:1564	African ZIKV strains	1545:1564	Previously deletions in the E glycan loop were recorded in African ZIKV strains, which have re-emerged in the contemporary Asian lineages recently.
36377874	8	125	theme	IMPORTANCE	1353:1362	arg1	ZIKV					1376:1379	ZIKV	1376:1379	ZIKV	1376:1379	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	8	125	theme	IMPORTANCE	1353:1362	arg1	virus					1369:1373	IMPORTANCE Zika virus	1353:1373	IMPORTANCE Zika virus (ZIKV)	1353:1380	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	8	125	theme	IMPORTANCE	1353:1362	arg1	cause					1407:1411	a cause	1405:1411	a cause of microcephaly and acquired evolutionary mutations since its discovery	1405:1483	IMPORTANCE Zika virus (ZIKV) has been identified as a cause of microcephaly and acquired evolutionary mutations since its discovery.
36377874	12	126	theme	loop	2039:2042	arg1	mutants					2053:2059	glycan loop deletion mutants	2032:2059	glycan loop deletion mutants	2032:2059	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	12	127	theme	global	2107:2112	arg1	surveillance					2126:2137	global virological surveillance	2107:2137	global virological surveillance for such ZIKV variants	2107:2160	This study underscores the critical role of glycan loop deletion mutants in ZIKV pathogenesis, highlighting a need for global virological surveillance for such ZIKV variants.
36377874	11	128	theme	loop	1808:1811	arg1	mutants					1822:1828	the glycan loop deletion mutants	1797:1828	the glycan loop deletion mutants	1797:1828	More importantly, the glycan loop deletion mutants induce an encephalitic flavivirus-like conformational alteration in the E homodimer, resulting in a significant enhancement of neonatal mouse neurovirulence.
34735575	1	0	theme	receptor	420:427	arg1	binding					429:435	efficient host receptor binding	405:435	efficient host receptor binding	405:435	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	1	theme	subtle	1484:1489	arg1	changes					1491:1497	other more subtle changes	1473:1497	other more subtle changes in glycosylation features detected at other sites	1473:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	3	2	attach	derived	689:695	arg1	lineage					712:718	the D614G lineage	702:718	the D614G lineage	702:718	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	3	2	attach	derived	689:695	arg2	variant					681:687	The Alpha variant	671:687	The Alpha variant derived from the D614G lineage	671:718	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	3	3	theme	D614G	706:710	arg1	lineage					712:718	the D614G lineage	702:718	the D614G lineage	702:718	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	1	4	theme	major	274:278	arg1	part					280:283	the major part	270:283	the major part of it	270:289	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	2	5	theme	spike	603:607	arg1	protein					609:615	the spike protein	599:615	the spike protein	599:615	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	4	6	theme	Alpha	1144:1148	arg1	variant					1150:1156	Alpha variant	1144:1156	Alpha variant	1144:1156	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	1	7	theme	spike	182:186	arg1	protein					188:194	the spike protein	178:194	the spike protein of severe acute respiratory syndrome coronavirus 2 virus	178:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	8	theme	crucial	1557:1563	arg1	information					1573:1583	crucial missing information	1557:1583	crucial missing information	1557:1583	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	4	9	theme	specific	1239:1246	arg1	site					1252:1255	one specific NTD site	1235:1255	one specific NTD site	1235:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	0	10	theme	D614G	125:129	arg1	variants					141:148	the D614G and Alpha variants	121:148	variants	141:148	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	1	11	theme	acute	206:210	arg1	virus					247:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	2	12	theme	coronavirus	515:525	arg1	disease					527:533	the coronavirus disease	511:533	the coronavirus disease of 2019 pandemic	511:550	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	4	13	theme	D614G	1134:1138	arg1	mutations					1158:1166	the D614G and Alpha variant mutations	1130:1166	the D614G and Alpha variant mutations	1130:1166	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	3	14	theme	deletion	759:766	arg1	mutations					768:776	deletion mutations	759:776	deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	759:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	0	15	theme	Alpha	135:139	arg1	variants					141:148	the D614G and Alpha variants	121:148	variants	141:148	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	1	16	from	sites	343:347	arg1	glycans					323:329	glycans	323:329	glycans at specific sites	323:347	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	1	17	theme	syndrome	224:231	arg1	virus					247:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	18	theme	electron	1635:1642	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	3	19	theme	domain	848:853	arg1	domain					848:853	the spike N-terminal domain	827:853	the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	827:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	3	19	theme	domain	848:853	arg1	supersite					814:822	an immunogenic supersite	799:822	an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	799:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	2	20	theme	pandemic	543:550	arg1	disease					527:533	the coronavirus disease	511:533	the coronavirus disease of 2019 pandemic	511:550	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	1	21	gly	glycosylation	161:173	arg1	protein					188:194	the spike protein	178:194	the spike protein of severe acute respiratory syndrome coronavirus 2 virus	178:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	1	22	theme	efficient	405:413	arg1	binding					429:435	efficient host receptor binding	405:435	efficient host receptor binding	405:435	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	23	theme	available	1615:1623	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	3	24	theme	spike	831:835	arg1	domain					848:853	the spike N-terminal domain	827:853	the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	827:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	3	24	theme	spike	831:835	arg1	NTD					856:858	NTD	856:858	NTD	856:858	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	5	25	theme	type	1307:1310	arg1	structures					1312:1321	complex type structures	1299:1321	complex type structures	1299:1321	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	3	26	theme	located	778:784	arg1	mutations					768:776	deletion mutations	759:776	deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	759:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	6	27	link	microscopy-derived	1644:1661	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	1	28	theme	Extensive	151:159	arg1	glycosylation					161:173	Extensive glycosylation	151:173	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus	151:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	4	29	theme	similar	978:984	arg1	conformation					997:1008	an overall similar structural conformation	967:1008	an overall similar structural conformation	967:1008	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	4	30	theme	NTD	1248:1250	arg1	site					1252:1255	one specific NTD site	1235:1255	one specific NTD site	1235:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	5	31	theme	higher	1278:1283	arg1	proportion					1285:1294	a higher proportion	1276:1294	a higher proportion of complex type structures	1276:1321	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	3	32	theme	immunogenic	802:812	arg1	domain					848:853	the spike N-terminal domain	827:853	the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	827:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	3	32	theme	immunogenic	802:812	arg1	supersite					814:822	an immunogenic supersite	799:822	an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	799:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	0	33	theme	arising	100:106	arg1	mutations					108:116	arising mutations	100:116	arising mutations in the D614G and Alpha variants	100:148	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	5	34	theme	spatial	1348:1354	arg1	accessibility					1356:1368	altered spatial accessibility	1340:1368	altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility	1340:1461	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	6	35	theme	protein	1687:1693	arg1	variants					1695:1702	the spike protein variants	1677:1702	the spike protein variants	1677:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	4	36	theme	spectrometry-based	1020:1037	arg1	analyses					1067:1074	our mass spectrometry-based site-specific glycosylation analyses	1011:1074	our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations	1011:1166	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	4	37	theme	N-glycans	1222:1230	arg1	state					1213:1217	the processing state	1198:1217	the processing state of N-glycans on one specific NTD site	1198:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	1	38	dep	glycosylation	161:173	arg1	only					257:260	only	257:260	only	257:260	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	5	39	theme	attributable	1370:1381	arg1	accessibility					1356:1368	altered spatial accessibility	1340:1368	altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility	1340:1461	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	0	40	theme	Distinct	0:7	arg1	shifts					9:14	Distinct shifts	0:14	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2	0:67	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	4	41	theme	glycosylation	1053:1065	arg1	analyses					1067:1074	our mass spectrometry-based site-specific glycosylation analyses	1011:1074	our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations	1011:1166	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	2	42	theme	site-specific	634:646	arg1	pattern					662:668	its site-specific glycosylation pattern	630:668	its site-specific glycosylation pattern	630:668	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	1	43	theme	it	288:289	arg1	part					280:283	the major part	270:283	the major part of it	270:289	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	3	44	theme	neutralizing	893:904	arg1	antibodies					906:915	most neutralizing antibodies	888:915	most neutralizing antibodies directed against this domain	888:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	0	45	theme	glycosylation	33:45	arg1	pattern					47:53	site-specific glycosylation pattern	19:53	site-specific glycosylation pattern of SARS-CoV-2	19:67	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	1	46	theme	host	296:299	arg1	responses					308:316	host immune responses	296:316	host immune responses	296:316	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	4	47	from	state	1213:1217	arg1	site					1252:1255	one specific NTD site	1235:1255	one specific NTD site	1235:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	5	48	theme	Alpha	1412:1416	arg1	variant					1418:1424	the Alpha variant	1408:1424	the Alpha variant that may impact its transmissibility	1408:1461	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	4	49	gly	glycosylation	1053:1065	arg1	proteins					1104:1111	similarly produced spike proteins	1079:1111	similarly produced spike proteins	1079:1111	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	4	50	theme	proteins	1104:1111	arg1	analyses					1067:1074	our mass spectrometry-based site-specific glycosylation analyses	1011:1074	our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations	1011:1166	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	1	51	theme	coronavirus	233:243	arg1	virus					247:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	4	52	from	shift	1189:1193	arg1	site					1252:1255	one specific NTD site	1235:1255	one specific NTD site	1235:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	4	52	from	shift	1189:1193	arg1	state					1213:1217	the processing state	1198:1217	the processing state of N-glycans on one specific NTD site	1198:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	6	53	from	apparent	1599:1606	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	6	54	theme	glycosylation	1502:1514	arg1	features					1516:1523	glycosylation features	1502:1523	glycosylation features detected at other sites	1502:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	1	55	theme	virus	247:251	arg1	protein					188:194	the spike protein	178:194	the spike protein of severe acute respiratory syndrome coronavirus 2 virus	178:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	56	from	changes	1491:1497	arg1	features					1516:1523	glycosylation features	1502:1523	glycosylation features detected at other sites	1502:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	4	57	theme	produced	1089:1096	arg1	proteins					1104:1111	similarly produced spike proteins	1079:1111	similarly produced spike proteins	1079:1111	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	3	58	theme	Alpha	675:679	arg1	variant					681:687	The Alpha variant	671:687	The Alpha variant derived from the D614G lineage	671:718	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	4	59	theme	variant	1150:1156	arg1	mutations					1158:1166	the D614G and Alpha variant mutations	1130:1166	the D614G and Alpha variant mutations	1130:1166	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	6	60	theme	missing	1565:1571	arg1	information					1573:1583	crucial missing information	1557:1583	crucial missing information	1557:1583	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	1	61	theme	protein	188:194	arg1	glycosylation					161:173	Extensive glycosylation	151:173	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus	151:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	1	62	theme	severe	199:204	arg1	virus					247:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	2	63	theme	disease	527:533	arg1	course					501:506	the course	497:506	the course of the coronavirus disease of 2019 pandemic	497:550	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	1	64	theme	conformation	365:376	arg1	dynamics					378:385	its conformation dynamics	361:385	its conformation dynamics	361:385	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	65	theme	other	1537:1541	arg1	sites					1543:1547	other sites	1537:1547	other sites	1537:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	1	66	theme	respiratory	212:222	arg1	virus					247:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	severe acute respiratory syndrome coronavirus 2 virus	199:251	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	4	67	theme	processing	1202:1211	arg1	state					1213:1217	the processing state	1198:1217	the processing state of N-glycans on one specific NTD site	1198:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	6	68	theme	microscopy-derived	1644:1661	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	6	69	theme	cryogenic	1625:1633	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	6	70	from	structures	1663:1672	arg1	apparent					1599:1606	apparent	1599:1606	apparent	1599:1606	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	2	71	theme	2019	538:541	arg1	pandemic					543:550	2019 pandemic	538:550	2019 pandemic	538:550	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	0	72	from	mutations	108:116	arg1	variants					141:148	the D614G and Alpha variants	121:148	variants	141:148	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	4	73	theme	significant	1177:1187	arg1	shift					1189:1193	a significant shift	1175:1193	a significant shift in the processing state of N-glycans on one specific NTD site	1175:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	5	74	theme	complex	1299:1305	arg1	structures					1312:1321	complex type structures	1299:1321	complex type structures	1299:1321	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	1	75	theme	host	415:418	arg1	binding					429:435	efficient host receptor binding	405:435	efficient host receptor binding	405:435	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	3	76	theme	N-terminal	837:846	arg1	domain					848:853	the spike N-terminal domain	827:853	the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain	827:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	3	76	theme	N-terminal	837:846	arg1	NTD					856:858	NTD	856:858	NTD	856:858	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	2	77	theme	concern	476:482	arg1	variants					464:471	variants	464:471	variants of concern	464:482	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	4	78	theme	overall	970:976	arg1	conformation					997:1008	an overall similar structural conformation	967:1008	an overall similar structural conformation	967:1008	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	0	79	from	shifts	9:14	arg1	pattern					47:53	site-specific glycosylation pattern	19:53	site-specific glycosylation pattern of SARS-CoV-2	19:67	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	1	80	theme	specific	334:341	arg1	sites					343:347	specific sites	334:347	specific sites	334:347	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	5	81	theme	altered	1340:1346	arg1	accessibility					1356:1368	altered spatial accessibility	1340:1368	altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility	1340:1461	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	6	82	theme	variants	1695:1702	arg1	structures					1663:1672	the available cryogenic electron microscopy-derived structures	1611:1672	the available cryogenic electron microscopy-derived structures of the spike protein variants	1611:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	4	83	from	site	1252:1255	arg1	shift					1189:1193	a significant shift	1175:1193	a significant shift in the processing state of N-glycans on one specific NTD site	1175:1255	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	3	84	theme	most	888:891	arg1	antibodies					906:915	most neutralizing antibodies	888:915	most neutralizing antibodies directed against this domain	888:944	The Alpha variant derived from the D614G lineage is distinguished from others by having deletion mutations located right within an immunogenic supersite of the spike N-terminal domain (NTD) that make it refractory to most neutralizing antibodies directed against this domain.
34735575	5	85	theme	accessibility	1356:1368	arg1	indicative					1326:1335	indicative	1326:1335	indicative	1326:1335	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	6	86	theme	other	1473:1477	arg1	changes					1491:1497	other more subtle changes	1473:1497	other more subtle changes in glycosylation features detected at other sites	1473:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	6	87	theme	spike	1681:1685	arg1	variants					1695:1702	the spike protein variants	1677:1702	the spike protein variants	1677:1702	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	2	88	theme	glycosylation	648:660	arg1	pattern					662:668	its site-specific glycosylation pattern	630:668	its site-specific glycosylation pattern	630:668	As variants of concern arise during the course of the coronavirus disease of 2019 pandemic, it is unclear if mutations accumulated within the spike protein would affect its site-specific glycosylation pattern.
34735575	5	89	theme	structures	1312:1321	arg1	proportion					1285:1294	a higher proportion	1276:1294	a higher proportion of complex type structures	1276:1321	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
34735575	0	90	theme	site-specific	19:31	arg1	pattern					47:53	site-specific glycosylation pattern	19:53	site-specific glycosylation pattern of SARS-CoV-2	19:67	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	4	91	theme	site-specific	1039:1051	arg1	analyses					1067:1074	our mass spectrometry-based site-specific glycosylation analyses	1011:1074	our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations	1011:1166	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	4	92	theme	structural	986:995	arg1	conformation					997:1008	an overall similar structural conformation	967:1008	an overall similar structural conformation	967:1008	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	0	93	theme	SARS-CoV-2	58:67	arg1	pattern					47:53	site-specific glycosylation pattern	19:53	site-specific glycosylation pattern of SARS-CoV-2	19:67	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	1	94	theme	immune	301:306	arg1	responses					308:316	host immune responses	296:316	host immune responses	296:316	Extensive glycosylation of the spike protein of severe acute respiratory syndrome coronavirus 2 virus not only shields the major part of it from host immune responses, but glycans at specific sites also act on its conformation dynamics and contribute to efficient host receptor binding, and hence infectivity.
34735575	6	95	located	detected	1525:1532	arg2	features					1516:1523	glycosylation features	1502:1523	glycosylation features detected at other sites	1502:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	6	95	located	detected	1525:1532	arg1	sites					1543:1547	other sites	1537:1547	other sites	1537:1547	This and other more subtle changes in glycosylation features detected at other sites provide crucial missing information otherwise not apparent in the available cryogenic electron microscopy-derived structures of the spike protein variants.
34735575	0	96	gly	glycosylation	33:45	arg1	SARS-CoV-2					58:67	SARS-CoV-2	58:67	SARS-CoV-2	58:67	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
34735575	4	97	theme	spike	1098:1102	arg1	proteins					1104:1111	similarly produced spike proteins	1079:1111	similarly produced spike proteins	1079:1111	Despite maintaining an overall similar structural conformation, our mass spectrometry-based site-specific glycosylation analyses of similarly produced spike proteins with and without the D614G and Alpha variant mutations reveal a significant shift in the processing state of N-glycans on one specific NTD site.
34735575	5	98	theme	specific	1396:1403	arg1	mutations					1386:1394	mutations	1386:1394	mutations specific to the Alpha variant that may impact its transmissibility	1386:1461	Its conversion to a higher proportion of complex type structures is indicative of altered spatial accessibility attributable to mutations specific to the Alpha variant that may impact its transmissibility.
36902272	6	0	theme	tandem	946:951	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	0	theme	tandem	946:951	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	0	theme	tandem	946:951	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	9	1	theme	novel	1653:1657	arg1	glyco-biomarkers					1659:1674	novel glyco-biomarkers	1653:1674	novel glyco-biomarkers of CRC	1653:1681	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	6	2	theme	electrospray	922:933	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	2	theme	electrospray	922:933	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	2	theme	electrospray	922:933	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	3	theme	nano-liquid	895:905	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	3	theme	nano-liquid	895:905	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	3	theme	nano-liquid	895:905	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	4	4	theme	in-depth	374:381	arg1	analysis					394:401	an in-depth N-glycomic analysis	371:401	an in-depth N-glycomic analysis of 25 CRC cell lines	371:422	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	1	5	theme	second	144:149	arg1	cause					159:163	the second leading cause	140:163	the second leading cause of cancer deaths worldwide	140:190	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	6	6	theme	graphitized	876:886	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	6	theme	graphitized	876:886	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	6	theme	graphitized	876:886	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	5	7	theme	profound	652:659	arg1	diversity					672:680	profound N-glycomic diversity	652:680	profound N-glycomic diversity	652:680	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	8	8	theme	significant	1248:1258	arg1	correlations					1260:1271	no significant correlations	1245:1271	no significant correlations between the glycosylation features and GTs	1245:1314	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	6	9	theme	laser	1012:1016	arg1	desorption/ionization					1018:1038	matrix-assisted laser desorption/ionization	996:1038	matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)	996:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	9	10	theme	cell	1593:1596	arg1	lines					1598:1602	CRC cell lines	1589:1602	CRC cell lines	1589:1602	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	1	11	theme	cancer	168:173	arg1	worldwide					182:190	cancer deaths worldwide	168:190	cancer deaths worldwide	168:190	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	8	12	theme	s	1470:1470	arg1	antigen					1475:1481	the (s)Le antigen	1465:1481	the (s)Le antigen	1465:1481	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	2	13	theme	well-known	195:204	arg1	glycosylation					236:248	altered glycosylation	228:248	altered glycosylation	228:248	A well-known hallmark of cancer is altered glycosylation.
36902272	2	13	theme	well-known	195:204	arg1	hallmark					206:213	A well-known hallmark	193:213	A well-known hallmark of cancer	193:223	A well-known hallmark of cancer is altered glycosylation.
36902272	1	14	theme	worldwide	182:190	arg1	cause					159:163	the second leading cause	140:163	the second leading cause of cancer deaths worldwide	140:190	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	1	14	theme	worldwide	182:190	arg1	cancer					129:134	the third most commonly diagnosed cancer	95:134	the third most commonly diagnosed cancer	95:134	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	1	14	theme	worldwide	182:190	arg1	cancer					79:84	Colorectal cancer	68:84	Colorectal cancer (CRC)	68:90	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	8	15	theme	glycosylation	1285:1297	arg1	features					1299:1306	the glycosylation features	1281:1306	the glycosylation features	1281:1306	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	3	16	theme	CRC	284:286	arg1	lines					293:297	CRC cell lines	284:297	CRC cell lines	284:297	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	8	17	theme	Le	1472:1473	arg1	antigen					1475:1481	the (s)Le antigen	1465:1481	the (s)Le antigen	1465:1481	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	8	18	theme	TF	1352:1353	arg1	CDX1					1355:1358	TF CDX1 and (s)Le antigen expression	1352:1387	CDX1	1355:1358	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	5	19	theme	CRC	700:702	arg1	lines					709:713	the studied CRC cell lines	688:713	the studied CRC cell lines with the elucidation of a number of 139 N-glycans	688:763	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	0	20	theme	Cell	56:59	arg1	Lines					61:65	Colorectal Cancer Cell Lines	38:65	Colorectal Cancer Cell Lines	38:65	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines.
36902272	1	21	theme	diagnosed	119:127	arg1	cancer					129:134	the third most commonly diagnosed cancer	95:134	the third most commonly diagnosed cancer	95:134	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	1	21	theme	diagnosed	119:127	arg1	cancer					79:84	Colorectal cancer	68:84	Colorectal cancer (CRC)	68:90	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	3	22	theme	lines	293:297	arg1	N-glycosylation					265:279	the N-glycosylation	261:279	the N-glycosylation of CRC cell lines	261:297	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	4	23	theme	nano-liquid	470:480	arg1	chromatography					482:495	porous graphitized carbon nano-liquid chromatography	444:495	porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry	444:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	8	24	theme	Le	1367:1368	arg1	s					1365:1365	s	1365:1365	s	1365:1365	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	8	24	theme	Le	1367:1368	arg1	expression					1378:1387	TF CDX1 and (s)Le antigen expression	1352:1387	expression	1378:1387	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	5	25	theme	isomers	592:598	arg1	separation					578:587	the separation	574:587	the separation of isomers and performs structural characterization	574:639	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	6	26	theme	flight-mass	1048:1058	arg1	MALDI-TOF-MS					1074:1085	MALDI-TOF-MS	1074:1085	MALDI-TOF-MS	1074:1085	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	26	theme	flight-mass	1048:1058	arg1	spectrometry					1060:1071	flight-mass spectrometry	1048:1071	flight-mass spectrometry (MALDI-TOF-MS)	1048:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	3	27	theme	diagnostic	336:345	arg1	targets					347:353	potential therapeutic or diagnostic targets	311:353	potential therapeutic or diagnostic targets	311:353	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	5	28	theme	number	741:746	arg1	elucidation					724:734	the elucidation	720:734	the elucidation of a number of 139 N-glycans	720:763	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	5	29	theme	performs	604:611	arg1	characterization					624:639	performs structural characterization	604:639	performs structural characterization	604:639	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	8	30	theme	relevant	1393:1400	arg1	FUT3/6					1406:1411	relevant GTs FUT3/6	1393:1411	relevant GTs FUT3/6	1393:1411	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	1	31	theme	Colorectal	68:77	arg1	cancer					129:134	the third most commonly diagnosed cancer	95:134	the third most commonly diagnosed cancer	95:134	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	1	31	theme	Colorectal	68:77	arg1	CRC					87:89	CRC	87:89	CRC	87:89	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	1	31	theme	Colorectal	68:77	arg1	cancer					79:84	Colorectal cancer	68:84	Colorectal cancer (CRC)	68:90	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	5	32	with	lines	709:713	arg1	elucidation					724:734	the elucidation	720:734	the elucidation of a number of 139 N-glycans	720:763	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	4	33	theme	graphitized	451:461	arg1	chromatography					482:495	porous graphitized carbon nano-liquid chromatography	444:495	porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry	444:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	0	34	theme	Lines	61:65	arg1	N-Glycome					25:33	the N-Glycome	21:33	the N-Glycome of Colorectal Cancer Cell Lines	21:65	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines.
36902272	0	35	theme	In-Depth	0:7	arg1	Analysis					9:16	In-Depth Analysis	0:16	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines	0:65	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines.
36902272	7	36	theme	glycosylation	1154:1166	arg1	features					1168:1175	glycosylation features	1154:1175	glycosylation features	1154:1175	Furthermore, we studied the associations between glycosylation features, glycosyltransferases (GTs), and transcription factors (TFs).
36902272	6	37	theme	porous	869:874	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	37	theme	porous	869:874	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	37	theme	porous	869:874	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	7	38	theme	transcription	1210:1222	arg1	TFs					1233:1235	TFs	1233:1235	TFs	1233:1235	Furthermore, we studied the associations between glycosylation features, glycosyltransferases (GTs), and transcription factors (TFs).
36902272	7	38	theme	transcription	1210:1222	arg1	factors					1224:1230	transcription factors	1210:1230	transcription factors (TFs)	1210:1236	Furthermore, we studied the associations between glycosylation features, glycosyltransferases (GTs), and transcription factors (TFs).
36902272	0	39	theme	N-Glycome	25:33	arg1	Analysis					9:16	In-Depth Analysis	0:16	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines	0:65	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines.
36902272	4	40	theme	ionization	521:530	arg1	spectrometry					537:548	electrospray ionization mass spectrometry	508:548	electrospray ionization mass spectrometry	508:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	0	41	theme	Colorectal	38:47	arg1	Lines					61:65	Colorectal Cancer Cell Lines	38:65	Colorectal Cancer Cell Lines	38:65	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines.
36902272	4	42	theme	mass	532:535	arg1	spectrometry					537:548	electrospray ionization mass spectrometry	508:548	electrospray ionization mass spectrometry	508:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	9	43	theme	future	1633:1638	arg1	discovery					1640:1648	the future discovery	1629:1648	the future discovery of novel glyco-biomarkers of CRC	1629:1681	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	6	44	theme	mass	953:956	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	44	theme	mass	953:956	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	44	theme	mass	953:956	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	4	45	theme	electrospray	508:519	arg1	spectrometry					537:548	electrospray ionization mass spectrometry	508:548	electrospray ionization mass spectrometry	508:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	5	46	theme	N-glycomic	661:670	arg1	diversity					672:680	profound N-glycomic diversity	652:680	profound N-glycomic diversity	652:680	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	3	47	gly	N-glycosylation	265:279	arg1	lines					293:297	CRC cell lines	284:297	CRC cell lines	284:297	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	6	48	theme	ionization	935:944	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	48	theme	ionization	935:944	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	48	theme	ionization	935:944	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	9	49	theme	glyco-biomarkers	1659:1674	arg1	discovery					1640:1648	the future discovery	1629:1648	the future discovery of novel glyco-biomarkers of CRC	1629:1681	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	6	50	theme	N-glycan	810:817	arg1	datasets					819:826	the two N-glycan datasets	802:826	the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	802:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	51	theme	chromatography	907:920	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	51	theme	chromatography	907:920	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	51	theme	chromatography	907:920	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	9	52	theme	CRC	1679:1681	arg1	glyco-biomarkers					1659:1674	novel glyco-biomarkers	1653:1674	novel glyco-biomarkers of CRC	1653:1681	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	4	53	theme	N-glycomic	383:392	arg1	analysis					394:401	an in-depth N-glycomic analysis	371:401	an in-depth N-glycomic analysis of 25 CRC cell lines	371:422	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	5	54	theme	characterization	624:639	arg1	separation					578:587	the separation	574:587	the separation of isomers and performs structural characterization	574:639	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	6	55	theme	carbon	888:893	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	55	theme	carbon	888:893	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	55	theme	carbon	888:893	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	56	theme	similarity	783:792	arg1	degree					773:778	A high degree	766:778	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	766:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	1	57	theme	leading	151:157	arg1	cause					159:163	the second leading cause	140:163	the second leading cause of cancer deaths worldwide	140:190	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	6	58	theme	desorption/ionization	1018:1038	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	58	theme	desorption/ionization	1018:1038	arg1	time					1040:1043	matrix-assisted laser desorption/ionization time	996:1043	matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)	996:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	59	theme	matrix-assisted	996:1010	arg1	desorption/ionization					1018:1038	matrix-assisted laser desorption/ionization	996:1038	matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)	996:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	4	60	theme	lines	418:422	arg1	analysis					394:401	an in-depth N-glycomic analysis	371:401	an in-depth N-glycomic analysis of 25 CRC cell lines	371:422	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	1	61	theme	deaths	175:180	arg1	worldwide					182:190	cancer deaths worldwide	168:190	cancer deaths worldwide	168:190	Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer deaths worldwide.
36902272	8	62	theme	antigen	1475:1481	arg1	expression					1451:1460	the expression	1447:1460	the expression of the (s)Le antigen	1447:1481	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	5	63	theme	studied	692:698	arg1	lines					709:713	the studied CRC cell lines	688:713	the studied CRC cell lines with the elucidation of a number of 139 N-glycans	688:763	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	3	64	theme	cell	288:291	arg1	lines					293:297	CRC cell lines	284:297	CRC cell lines	284:297	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	5	65	theme	cell	704:707	arg1	lines					709:713	the studied CRC cell lines	688:713	the studied CRC cell lines with the elucidation of a number of 139 N-glycans	688:763	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	2	66	theme	altered	228:234	arg1	glycosylation					236:248	altered glycosylation	228:248	altered glycosylation	228:248	A well-known hallmark of cancer is altered glycosylation.
36902272	2	66	theme	altered	228:234	arg1	hallmark					206:213	A well-known hallmark	193:213	A well-known hallmark of cancer	193:223	A well-known hallmark of cancer is altered glycosylation.
36902272	4	67	theme	CRC	409:411	arg1	lines					418:422	25 CRC cell lines	406:422	25 CRC cell lines	406:422	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	5	68	theme	N-glycans	755:763	arg1	number					741:746	a number	739:746	a number of 139 N-glycans	739:763	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	2	69	theme	cancer	218:223	arg1	glycosylation					236:248	altered glycosylation	228:248	altered glycosylation	228:248	A well-known hallmark of cancer is altered glycosylation.
36902272	2	69	theme	cancer	218:223	arg1	hallmark					206:213	A well-known hallmark	193:213	A well-known hallmark of cancer	193:223	A well-known hallmark of cancer is altered glycosylation.
36902272	3	70	theme	potential	311:319	arg1	targets					347:353	potential therapeutic or diagnostic targets	311:353	potential therapeutic or diagnostic targets	311:353	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	9	71	theme	comprehensive	1538:1550	arg1	characterization					1552:1567	a comprehensive characterization	1536:1567	a comprehensive characterization	1536:1567	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	6	72	theme	spectrometry	1060:1071	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	72	theme	spectrometry	1060:1071	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	72	theme	spectrometry	1060:1071	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	72	theme	spectrometry	1060:1071	arg1	time					1040:1043	matrix-assisted laser desorption/ionization time	996:1043	matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)	996:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	4	73	theme	porous	444:449	arg1	chromatography					482:495	porous graphitized carbon nano-liquid chromatography	444:495	porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry	444:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	8	74	theme	antigen	1370:1376	arg1	s					1365:1365	s	1365:1365	s	1365:1365	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	8	74	theme	antigen	1370:1376	arg1	expression					1378:1387	TF CDX1 and (s)Le antigen expression	1352:1387	expression	1378:1387	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	5	75	theme	structural	613:622	arg1	characterization					624:639	performs structural characterization	604:639	performs structural characterization	604:639	This method allows for the separation of isomers and performs structural characterization, revealing profound N-glycomic diversity among the studied CRC cell lines with the elucidation of a number of 139 N-glycans.
36902272	9	76	theme	N-glycome	1576:1584	arg1	characterization					1552:1567	a comprehensive characterization	1536:1567	a comprehensive characterization	1536:1567	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	4	77	theme	carbon	463:468	arg1	chromatography					482:495	porous graphitized carbon nano-liquid chromatography	444:495	porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry	444:548	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	9	78	theme	CRC	1589:1591	arg1	lines					1598:1602	CRC cell lines	1589:1602	CRC cell lines	1589:1602	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	8	79	theme	GTs	1402:1404	arg1	FUT3/6					1406:1411	relevant GTs FUT3/6	1393:1411	relevant GTs FUT3/6	1393:1411	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36902272	4	80	theme	cell	413:416	arg1	lines					418:422	25 CRC cell lines	406:422	25 CRC cell lines	406:422	In this study, an in-depth N-glycomic analysis of 25 CRC cell lines was conducted using porous graphitized carbon nano-liquid chromatography coupled to electrospray ionization mass spectrometry.
36902272	9	81	theme	lines	1598:1602	arg1	N-glycome					1576:1584	the N-glycome	1572:1584	the N-glycome of CRC cell lines	1572:1602	Our study provides a comprehensive characterization of the N-glycome of CRC cell lines, which may contribute to the future discovery of novel glyco-biomarkers of CRC.
36902272	6	82	dep	platforms	858:866	arg1	PGC-nano-LC-ESI-MS					972:989	PGC-nano-LC-ESI-MS	972:989	PGC-nano-LC-ESI-MS	972:989	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	82	dep	platforms	858:866	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	82	dep	platforms	858:866	arg1	time					1040:1043	matrix-assisted laser desorption/ionization time	996:1043	matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)	996:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	82	dep	platforms	858:866	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	3	83	dep	potential	311:319	arg1	therapeutic					321:331	therapeutic	321:331	therapeutic	321:331	Analyzing the N-glycosylation of CRC cell lines may provide potential therapeutic or diagnostic targets.
36902272	6	84	theme	high	768:771	arg1	degree					773:778	A high degree	766:778	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	766:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	0	85	theme	Cancer	49:54	arg1	Lines					61:65	Colorectal Cancer Cell Lines	38:65	Colorectal Cancer Cell Lines	38:65	In-Depth Analysis of the N-Glycome of Colorectal Cancer Cell Lines.
36902272	6	86	theme	different	848:856	arg1	platforms					858:866	the two different platforms	840:866	the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS))	840:1087	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	86	theme	different	848:856	arg1	time					1040:1043	matrix-assisted laser desorption/ionization time	996:1043	matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)	996:1086	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	6	86	theme	different	848:856	arg1	spectrometry					958:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry	869:969	porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS)	869:990	A high degree of similarity between the two N-glycan datasets measured on the two different platforms (porous graphitized carbon nano-liquid chromatography electrospray ionization tandem mass spectrometry (PGC-nano-LC-ESI-MS) and matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS)) was discovered.
36902272	8	87	theme	FUT3/6	1509:1514	arg1	regulation					1495:1504	the regulation	1491:1504	the regulation of FUT3/6	1491:1514	While no significant correlations between the glycosylation features and GTs were found, the association between TF CDX1 and (s)Le antigen expression and relevant GTs FUT3/6 suggests that CDX1 contributes to the expression of the (s)Le antigen through the regulation of FUT3/6.
36565991	1	0	theme	immunity	148:155	arg1	efficacy					127:134	the efficacy	123:134	the efficacy of existing immunity	123:155	The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity, whether arisen naturally or through vaccination.
36565991	0	1	theme	dynamics	69:76	arg1	glycan					22:27	the glycan shield	18:34	the glycan shield of SARS-CoV-2 impact viral spike dynamics	18:76	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.
36565991	8	2	theme	viral	1185:1189	arg1	sites					1205:1209	viral glycosylation sites	1185:1209	viral glycosylation sites	1185:1209	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	4	3	theme	B.1.351	579:585	arg1	mimetics					567:574	recombinant viral spike mimetics	543:574	recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	543:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	3	4	contain	have	395:398	arg2	capacity					404:411	the capacity to influence the antigenic structure beyond the immediate site of attachment	400:488	the capacity to influence the antigenic structure beyond the immediate site of attachment	400:488	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	3	4	contain	have	395:398	arg1	sites					382:386	glycosylation attachment sites	357:386	glycosylation attachment sites	357:386	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	5	5	link	N-linked	687:694	arg1	sites					703:707	two additional N-linked glycan sites	672:707	two additional N-linked glycan sites	672:707	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	2	6	theme	mutations	291:299	arg1	impact					281:286	the impact	277:286	the impact of mutations on the antigenic surface	277:324	Understanding the structure of the viral spike assists in determining the impact of mutations on the antigenic surface.
36565991	3	7	theme	glycosylation	357:369	arg1	sites					382:386	glycosylation attachment sites	357:386	glycosylation attachment sites	357:386	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	6	8	with	consistent	894:903	arg1	accessibility					925:937	limited enzyme accessibility	910:937	limited enzyme accessibility	910:937	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	7	9	located	located	1003:1009	arg1	cavity					1020:1025	a cavity	1018:1025	a cavity by the receptor binding domain, which influences the dynamics of these attachment domains	1018:1115	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	7	9	located	located	1003:1009	arg2	N188					995:998	N188	995:998	N188	995:998	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	5	10	theme	N-linked	687:694	arg1	sites					703:707	two additional N-linked glycan sites	672:707	two additional N-linked glycan sites	672:707	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	7	11	theme	binding	1043:1049	arg1	domain					1051:1056	the receptor binding domain	1030:1056	the receptor binding domain	1030:1056	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	8	12	contain	have	1211:1214	arg2	impact					1229:1234	a structural impact	1216:1234	a structural impact	1216:1234	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	8	12	contain	have	1211:1214	arg1	mutations					1165:1173	mutations	1165:1173	mutations affecting viral glycosylation sites	1165:1209	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	3	13	theme	antigenic	430:438	arg1	structure					440:448	the antigenic structure	426:448	the antigenic structure	426:448	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	3	14	theme	mutation	340:347	arg1	class					331:335	One class	327:335	One class of mutation	327:347	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	6	15	theme	N188	832:835	arg1	site					837:840	The acquired N188 site	819:840	The acquired N188 site	819:840	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	6	16	theme	glycan	875:880	arg1	maturation					882:891	very limited glycan maturation	862:891	very limited glycan maturation	862:891	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	6	17	theme	acquired	823:830	arg1	site					837:840	The acquired N188 site	819:840	The acquired N188 site	819:840	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	6	18	theme	enzyme	918:923	arg1	accessibility					925:937	limited enzyme accessibility	910:937	limited enzyme accessibility	910:937	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	2	19	theme	antigenic	308:316	arg1	surface					318:324	the antigenic surface	304:324	the antigenic surface	304:324	Understanding the structure of the viral spike assists in determining the impact of mutations on the antigenic surface.
36565991	8	20	theme	structural	1218:1227	arg1	impact					1229:1234	a structural impact	1216:1234	a structural impact	1216:1234	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	4	21	theme	spike	561:565	arg1	mimetics					567:574	recombinant viral spike mimetics	543:574	recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	543:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	7	22	theme	receptor	1034:1041	arg1	domain					1051:1056	the receptor binding domain	1030:1056	the receptor binding domain	1030:1056	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	3	23	theme	attachment	371:380	arg1	sites					382:386	glycosylation attachment sites	357:386	glycosylation attachment sites	357:386	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	4	24	theme	viral	555:559	arg1	mimetics					567:574	recombinant viral spike mimetics	543:574	recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	543:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	3	25	gly	glycosylation	357:369	arg2	sites					382:386	glycosylation attachment sites	357:386	glycosylation attachment sites	357:386	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	8	26	gly	glycosylation	1191:1203	arg2	sites					1205:1209	viral glycosylation sites	1185:1209	viral glycosylation sites	1185:1209	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	3	27	theme	immediate	461:469	arg1	attachment					479:488	attachment	479:488	attachment	479:488	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	3	27	theme	immediate	461:469	arg1	site					471:474	the immediate site	457:474	the immediate site of attachment	457:488	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	5	28	theme	P.1	652:654	arg1	strain					656:661	The P.1 strain	648:661	The P.1 strain	648:661	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	1	29	theme	SARS-CoV-2	96:105	arg1	variants					107:114	SARS-CoV-2 variants	96:114	SARS-CoV-2 variants	96:114	The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity, whether arisen naturally or through vaccination.
36565991	5	30	theme	other	725:729	arg1	variants					731:738	the other variants	721:738	the other variants analyzed	721:747	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	4	31	theme	mimetics	567:574	arg1	glycosylation					526:538	the site-specific glycosylation	508:538	the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	508:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	8	32	theme	protein	1247:1253	arg1	surface					1255:1261	the protein surface	1243:1261	the protein surface	1243:1261	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	5	33	theme	glycans	788:794	arg1	impact					772:777	the impact	768:777	the impact of these glycans by molecular dynamics	768:816	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	5	34	theme	molecular	799:807	arg1	dynamics					809:816	molecular dynamics	799:816	molecular dynamics	799:816	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	7	35	theme	attachment	1098:1107	arg1	domains					1109:1115	these attachment domains	1092:1115	these attachment domains	1092:1115	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	7	36	theme	domains	1109:1115	arg1	dynamics					1080:1087	the dynamics	1076:1087	the dynamics of these attachment domains	1076:1115	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	5	37	theme	glycan	696:701	arg1	sites					703:707	two additional N-linked glycan sites	672:707	two additional N-linked glycan sites	672:707	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
36565991	0	38	theme	impact	50:55	arg1	dynamics					69:76	SARS-CoV-2 impact viral spike dynamics	39:76	SARS-CoV-2 impact viral spike dynamics	39:76	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.
36565991	4	39	theme	site-specific	512:524	arg1	glycosylation					526:538	the site-specific glycosylation	508:538	the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	508:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	6	40	theme	limited	910:916	arg1	accessibility					925:937	limited enzyme accessibility	910:937	limited enzyme accessibility	910:937	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	1	41	theme	variants	107:114	arg1	emergence					83:91	The emergence	79:91	The emergence of SARS-CoV-2 variants	79:114	The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity, whether arisen naturally or through vaccination.
36565991	0	42	theme	SARS-CoV-2	39:48	arg1	dynamics					69:76	SARS-CoV-2 impact viral spike dynamics	39:76	SARS-CoV-2 impact viral spike dynamics	39:76	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.
36565991	4	43	theme	recombinant	543:553	arg1	mimetics					567:574	recombinant viral spike mimetics	543:574	recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	543:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	6	44	theme	limited	867:873	arg1	maturation					882:891	very limited glycan maturation	862:891	very limited glycan maturation	862:891	The acquired N188 site is shown to exhibit very limited glycan maturation, consistent with limited enzyme accessibility.
36565991	0	45	dep	glycan	22:27	arg1	shield					29:34	shield	29:34	shield	29:34	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.
36565991	7	46	theme	molecular	964:972	arg1	dynamics					974:981	molecular dynamics	964:981	molecular dynamics	964:981	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	7	47	theme	Structural	940:949	arg1	modeling					951:958	Structural modeling	940:958	Structural modeling	940:958	Structural modeling and molecular dynamics reveal that N188 is located within a cavity by the receptor binding domain, which influences the dynamics of these attachment domains.
36565991	3	48	theme	attachment	479:488	arg1	attachment					479:488	attachment	479:488	attachment	479:488	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	3	48	theme	attachment	479:488	arg1	site					471:474	the immediate site	457:474	the immediate site of attachment	457:488	One class of mutation impacts glycosylation attachment sites, which have the capacity to influence the antigenic structure beyond the immediate site of attachment.
36565991	8	49	theme	glycosylation	1191:1203	arg1	sites					1205:1209	viral glycosylation sites	1185:1209	viral glycosylation sites	1185:1209	These observations suggest a mechanism whereby mutations affecting viral glycosylation sites have a structural impact across the protein surface.
36565991	0	50	theme	spike	63:67	arg1	dynamics					69:76	SARS-CoV-2 impact viral spike dynamics	39:76	SARS-CoV-2 impact viral spike dynamics	39:76	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.
36565991	2	51	theme	spike	248:252	arg1	structure					225:233	the structure	221:233	the structure of the viral spike	221:252	Understanding the structure of the viral spike assists in determining the impact of mutations on the antigenic surface.
36565991	4	52	gly	glycosylation	526:538	arg1	mimetics					567:574	recombinant viral spike mimetics	543:574	recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron)	543:645	Here, we compare the site-specific glycosylation of recombinant viral spike mimetics of B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), B.1.1.529 (Omicron).
36565991	2	53	from	impact	281:286	arg1	surface					318:324	the antigenic surface	304:324	the antigenic surface	304:324	Understanding the structure of the viral spike assists in determining the impact of mutations on the antigenic surface.
36565991	0	54	theme	viral	57:61	arg1	dynamics					69:76	SARS-CoV-2 impact viral spike dynamics	39:76	SARS-CoV-2 impact viral spike dynamics	39:76	Variations within the glycan shield of SARS-CoV-2 impact viral spike dynamics.
36565991	2	55	theme	viral	242:246	arg1	spike					248:252	the viral spike	238:252	the viral spike	238:252	Understanding the structure of the viral spike assists in determining the impact of mutations on the antigenic surface.
36565991	1	56	theme	existing	139:146	arg1	immunity					148:155	existing immunity	139:155	existing immunity	139:155	The emergence of SARS-CoV-2 variants alters the efficacy of existing immunity, whether arisen naturally or through vaccination.
36565991	5	57	theme	additional	676:685	arg1	sites					703:707	two additional N-linked glycan sites	672:707	two additional N-linked glycan sites	672:707	The P.1 strain exhibits two additional N-linked glycan sites compared to the other variants analyzed and we investigate the impact of these glycans by molecular dynamics.
35766466	0	0	theme	Imaging	90:96	arg1	Spectrometry					103:114	MALDI Imaging Mass Spectrometry	84:114	MALDI Imaging Mass Spectrometry	84:114	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	9	1	from	utilization	1451:1461	arg1	MALDI-IMS					1466:1474	MALDI-IMS	1466:1474	MALDI-IMS	1466:1474	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	0	2	theme	MALDI	84:88	arg1	Spectrometry					103:114	MALDI Imaging Mass Spectrometry	84:114	MALDI Imaging Mass Spectrometry	84:114	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	4	3	used	utilized	612:619	arg2	Enzymes					578:584	Enzymes	578:584	Enzymes that have previously been utilized to cleave N-glycans	578:639	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	8	4	theme	N-glycans	1287:1295	arg1	detection					1260:1268	detection	1260:1268	detection of nonsialylated N-glycans	1260:1295	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	3	5	gly	glycoproteins	563:575	arg1	glycoproteins					563:575	associated glycoproteins	552:575	associated glycoproteins	552:575	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	3	6	theme	MALDI	362:366	arg1	spectrometry					381:392	A novel MALDI imaging mass spectrometry	354:392	A novel MALDI imaging mass spectrometry workflow	354:401	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	8	7	theme	low	1416:1418	arg1	structures					1429:1438	low abundant structures	1416:1438	low abundant structures	1416:1438	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	9	8	theme	on-tissue	1525:1533	arg1	efficiency					1551:1560	on-tissue endoglycosidase efficiency	1525:1560	on-tissue endoglycosidase efficiency	1525:1560	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	0	9	theme	Mass	98:101	arg1	Spectrometry					103:114	MALDI Imaging Mass Spectrometry	84:114	MALDI Imaging Mass Spectrometry	84:114	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	8	10	theme	features	1356:1363	arg1	analysis					1324:1331	a more thorough analysis	1308:1331	a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures	1308:1438	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	9	11	theme	Sialidase	1441:1449	arg1	utilization					1451:1461	Sialidase utilization	1441:1461	Sialidase utilization in MALDI-IMS	1441:1474	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	4	12	theme	target	757:762	arg1	N-glycans					781:789	target core fucosylated N-glycans	757:789	target core fucosylated N-glycans	757:789	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	5	13	theme	cleaving	851:858	arg1	enzymes					860:866	additional N-glycan cleaving enzymes	831:866	additional N-glycan cleaving enzymes	831:866	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	9	14	gly	nonsialylated	1630:1642	arg1	N-glycans					1644:1652	nonsialylated N-glycans	1630:1652	nonsialylated N-glycans	1630:1652	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	7	15	theme	nonsialylated	1210:1222	arg1	peaks					1243:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	This work aims to utilize sialidase, in conjunction with PNGase F/Endo F3, to enzymatically remove sialic acids from N-glycans in an effort to increase sensitivity for nonsialylated N-glycan MALDI-IMS peaks.
35766466	2	16	from	interest	344:351	arg1	cases					234:238	many cases	229:238	many cases	229:238	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	8	17	theme	structures	1429:1438	arg1	branching					1389:1397	branching	1389:1397	branching	1389:1397	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	8	17	theme	structures	1429:1438	arg1	features					1356:1363	specific structural features	1336:1363	specific structural features	1336:1363	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	8	17	theme	structures	1429:1438	arg1	fucosylation					1373:1384	fucosylation	1373:1384	fucosylation	1373:1384	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	4	18	theme	endoglycosidase	725:739	arg1	F3					741:742	endoglycosidase F3	725:742	endoglycosidase F3 (Endo F3)	725:752	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	4	18	theme	endoglycosidase	725:739	arg1	F3					750:751	F3	750:751	F3	750:751	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	7	19	theme	sialic	1141:1146	arg1	acids					1148:1152	sialic acids	1141:1152	sialic acids	1141:1152	This work aims to utilize sialidase, in conjunction with PNGase F/Endo F3, to enzymatically remove sialic acids from N-glycans in an effort to increase sensitivity for nonsialylated N-glycan MALDI-IMS peaks.
35766466	3	20	theme	novel	356:360	arg1	spectrometry					381:392	A novel MALDI imaging mass spectrometry	354:392	A novel MALDI imaging mass spectrometry workflow	354:401	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	6	21	theme	termed	939:944	arg1	neuraminidases					946:959	also termed neuraminidases	934:959	also termed neuraminidases	934:959	Sialidases, also termed neuraminidases, are a family of enzymes that remove terminal sialic acids from glycoconjugates.
35766466	6	21	theme	termed	939:944	arg1	Sialidases					922:931	Sialidases	922:931	Sialidases	922:931	Sialidases, also termed neuraminidases, are a family of enzymes that remove terminal sialic acids from glycoconjugates.
35766466	7	22	theme	MALDI-IMS	1233:1241	arg1	peaks					1243:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	This work aims to utilize sialidase, in conjunction with PNGase F/Endo F3, to enzymatically remove sialic acids from N-glycans in an effort to increase sensitivity for nonsialylated N-glycan MALDI-IMS peaks.
35766466	4	23	theme	peptide-N-glycosidase	649:669	arg1	F					671:671	peptide-N-glycosidase F	649:671	peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans	649:789	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	4	23	theme	peptide-N-glycosidase	649:669	arg1	F					681:681	PNGase F	674:681	PNGase F	674:681	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	1	24	theme	various	187:193	arg1	diseases					195:202	various diseases	187:202	various diseases	187:202	Alterations to N-glycan expression are relevant to the progression of various diseases, particularly cancer.
35766466	1	24	theme	various	187:193	arg1	cancer					218:223	cancer	218:223	cancer	218:223	Alterations to N-glycan expression are relevant to the progression of various diseases, particularly cancer.
35766466	0	25	theme	Combined	6:13	arg1	Approach					25:32	Novel Combined Enzymatic Approach	0:32	Novel Combined Enzymatic Approach	0:32	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	8	26	gly	nonsialylated	1273:1285	arg1	N-glycans					1287:1295	nonsialylated N-glycans	1273:1295	nonsialylated N-glycans	1273:1295	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	7	27	theme	N-glycan	1224:1231	arg1	peaks					1243:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	This work aims to utilize sialidase, in conjunction with PNGase F/Endo F3, to enzymatically remove sialic acids from N-glycans in an effort to increase sensitivity for nonsialylated N-glycan MALDI-IMS peaks.
35766466	1	28	theme	diseases	195:202	arg1	progression					172:182	the progression	168:182	the progression of various diseases, particularly cancer	168:223	Alterations to N-glycan expression are relevant to the progression of various diseases, particularly cancer.
35766466	0	29	theme	Novel	0:4	arg1	Approach					25:32	Novel Combined Enzymatic Approach	0:32	Novel Combined Enzymatic Approach	0:32	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	6	30	theme	enzymes	978:984	arg1	Sialidases					922:931	Sialidases	922:931	Sialidases	922:931	Sialidases, also termed neuraminidases, are a family of enzymes that remove terminal sialic acids from glycoconjugates.
35766466	6	30	theme	enzymes	978:984	arg1	family					968:973	a family	966:973	a family of enzymes that remove terminal sialic acids from glycoconjugates	966:1039	Sialidases, also termed neuraminidases, are a family of enzymes that remove terminal sialic acids from glycoconjugates.
35766466	4	31	theme	fucosylated	769:779	arg1	N-glycans					781:789	target core fucosylated N-glycans	757:789	target core fucosylated N-glycans	757:789	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	3	32	theme	mass	376:379	arg1	spectrometry					381:392	A novel MALDI imaging mass spectrometry	354:392	A novel MALDI imaging mass spectrometry workflow	354:401	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	0	33	gly	Nonsialylated	45:57	arg1	Glycans					68:74	Nonsialylated N-Linked Glycans	45:74	Nonsialylated N-Linked Glycans	45:74	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	3	34	theme	spectrometry	381:392	arg1	workflow					394:401	A novel MALDI imaging mass spectrometry workflow	354:401	A novel MALDI imaging mass spectrometry workflow	354:401	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	5	35	dep	endoglycosidases	813:828	arg1	addition					795:802	addition	795:802	addition	795:802	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	9	36	theme	endoglycosidase	1535:1549	arg1	efficiency					1551:1560	on-tissue endoglycosidase efficiency	1525:1560	on-tissue endoglycosidase efficiency	1525:1560	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	8	37	theme	nonsialylated	1273:1285	arg1	N-glycans					1287:1295	nonsialylated N-glycans	1273:1295	nonsialylated N-glycans	1273:1295	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	6	38	theme	sialic	1007:1012	arg1	acids					1014:1018	terminal sialic acids	998:1018	terminal sialic acids	998:1018	Sialidases, also termed neuraminidases, are a family of enzymes that remove terminal sialic acids from glycoconjugates.
35766466	5	39	theme	specific	892:899	arg1	features					912:919	specific structural features	892:919	specific structural features	892:919	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	2	40	theme	specific	241:248	arg1	branching					318:326	branching	318:326	branching	318:326	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	40	theme	specific	241:248	arg1	fucosylation					300:311	fucosylation	300:311	fucosylation	300:311	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	40	theme	specific	241:248	arg1	features					270:277	specific N-glycan structural features	241:277	specific N-glycan structural features such as sialylation, fucosylation, and branching	241:326	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	40	theme	specific	241:248	arg1	sialylation					287:297	sialylation	287:297	sialylation	287:297	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	3	41	theme	N-glycosylation	460:474	arg1	features					448:455	these features	442:455	these features of N-glycosylation	442:474	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	0	42	theme	Enzymatic	15:23	arg1	Approach					25:32	Novel Combined Enzymatic Approach	0:32	Novel Combined Enzymatic Approach	0:32	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	6	43	theme	terminal	998:1005	arg1	acids					1014:1018	terminal sialic acids	998:1018	terminal sialic acids	998:1018	Sialidases, also termed neuraminidases, are a family of enzymes that remove terminal sialic acids from glycoconjugates.
35766466	5	44	theme	additional	831:840	arg1	enzymes					860:866	additional N-glycan cleaving enzymes	831:866	additional N-glycan cleaving enzymes	831:866	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	8	45	theme	structural	1345:1354	arg1	branching					1389:1397	branching	1389:1397	branching	1389:1397	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	8	45	theme	structural	1345:1354	arg1	features					1356:1363	specific structural features	1336:1363	specific structural features	1336:1363	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	8	45	theme	structural	1345:1354	arg1	fucosylation					1373:1384	fucosylation	1373:1384	fucosylation	1373:1384	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	5	46	theme	structural	901:910	arg1	features					912:919	specific structural features	892:919	specific structural features	892:919	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	0	47	theme	N-Linked	59:66	arg1	Glycans					68:74	Nonsialylated N-Linked Glycans	45:74	Nonsialylated N-Linked Glycans	45:74	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	4	48	gly	fucosylated	769:779	arg1	N-glycans					781:789	target core fucosylated N-glycans	757:789	target core fucosylated N-glycans	757:789	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	5	49	used	used	877:880	arg2	enzymes					860:866	additional N-glycan cleaving enzymes	831:866	additional N-glycan cleaving enzymes	831:866	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	9	50	theme	useful	1580:1585	arg1	technique					1597:1605	a very useful companion technique	1573:1605	a very useful companion technique to specifically detect nonsialylated N-glycans	1573:1652	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	3	51	theme	enzymes	519:525	arg1	utilization					488:498	the utilization	484:498	the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins	484:575	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	0	52	theme	Nonsialylated	45:57	arg1	Glycans					68:74	Nonsialylated N-Linked Glycans	45:74	Nonsialylated N-Linked Glycans	45:74	Novel Combined Enzymatic Approach to Analyze Nonsialylated N-Linked Glycans through MALDI Imaging Mass Spectrometry.
35766466	2	53	theme	many	229:232	arg1	cases					234:238	many cases	229:238	many cases	229:238	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	1	54	theme	N-glycan	132:139	arg1	expression					141:150	N-glycan expression	132:150	N-glycan expression	132:150	Alterations to N-glycan expression are relevant to the progression of various diseases, particularly cancer.
35766466	4	55	dep	N-glycans	694:702	arg1	indiscriminately					704:719	indiscriminately	704:719	indiscriminately	704:719	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	7	56	gly	nonsialylated	1210:1222	arg1	peaks					1243:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	nonsialylated N-glycan MALDI-IMS peaks	1210:1247	This work aims to utilize sialidase, in conjunction with PNGase F/Endo F3, to enzymatically remove sialic acids from N-glycans in an effort to increase sensitivity for nonsialylated N-glycan MALDI-IMS peaks.
35766466	8	57	theme	thorough	1315:1322	arg1	analysis					1324:1331	a more thorough analysis	1308:1331	a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures	1308:1438	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	2	58	theme	specific	335:342	arg1	interest					344:351	specific interest	335:351	specific interest	335:351	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	8	59	theme	abundant	1420:1427	arg1	structures					1429:1438	low abundant structures	1416:1438	low abundant structures	1416:1438	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	3	60	theme	endoglycosidase	503:517	arg1	enzymes					519:525	endoglycosidase enzymes	503:525	endoglycosidase enzymes	503:525	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	4	61	theme	core	764:767	arg1	N-glycans					781:789	target core fucosylated N-glycans	757:789	target core fucosylated N-glycans	757:789	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	9	62	theme	companion	1587:1595	arg1	technique					1597:1605	a very useful companion technique	1573:1605	a very useful companion technique to specifically detect nonsialylated N-glycans	1573:1652	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	8	63	theme	specific	1336:1343	arg1	branching					1389:1397	branching	1389:1397	branching	1389:1397	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	8	63	theme	specific	1336:1343	arg1	features					1356:1363	specific structural features	1336:1363	specific structural features	1336:1363	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	8	63	theme	specific	1336:1343	arg1	fucosylation					1373:1384	fucosylation	1373:1384	fucosylation	1373:1384	Improving detection of nonsialylated N-glycans allows for a more thorough analysis of specific structural features such as fucosylation or branching, particularly of low abundant structures.
35766466	2	64	theme	structural	259:268	arg1	branching					318:326	branching	318:326	branching	318:326	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	64	theme	structural	259:268	arg1	fucosylation					300:311	fucosylation	300:311	fucosylation	300:311	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	64	theme	structural	259:268	arg1	features					270:277	specific N-glycan structural features	241:277	specific N-glycan structural features such as sialylation, fucosylation, and branching	241:326	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	64	theme	structural	259:268	arg1	sialylation					287:297	sialylation	287:297	sialylation	287:297	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	9	65	theme	nonsialylated	1630:1642	arg1	N-glycans					1644:1652	nonsialylated N-glycans	1630:1652	nonsialylated N-glycans	1630:1652	Sialidase utilization in MALDI-IMS dramatically increases sensitivity and increases on-tissue endoglycosidase efficiency, making it a very useful companion technique to specifically detect nonsialylated N-glycans.
35766466	7	66	with	conjunction	1082:1092	arg1	F3					1113:1114	F3	1113:1114	F3	1113:1114	This work aims to utilize sialidase, in conjunction with PNGase F/Endo F3, to enzymatically remove sialic acids from N-glycans in an effort to increase sensitivity for nonsialylated N-glycan MALDI-IMS peaks.
35766466	4	67	theme	PNGase	674:679	arg1	F					671:671	peptide-N-glycosidase F	649:671	peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans	649:789	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	4	67	theme	PNGase	674:679	arg1	F					681:681	PNGase F	674:681	PNGase F	674:681	Enzymes that have previously been utilized to cleave N-glycans include peptide-N-glycosidase F (PNGase F) to target N-glycans indiscriminately and endoglycosidase F3 (Endo F3) to target core fucosylated N-glycans.
35766466	5	68	theme	N-glycan	842:849	arg1	enzymes					860:866	additional N-glycan cleaving enzymes	831:866	additional N-glycan cleaving enzymes	831:866	In addition to these endoglycosidases, additional N-glycan cleaving enzymes could be used to target specific structural features.
35766466	2	69	theme	N-glycan	250:257	arg1	branching					318:326	branching	318:326	branching	318:326	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	69	theme	N-glycan	250:257	arg1	fucosylation					300:311	fucosylation	300:311	fucosylation	300:311	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	69	theme	N-glycan	250:257	arg1	features					270:277	specific N-glycan structural features	241:277	specific N-glycan structural features such as sialylation, fucosylation, and branching	241:326	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	2	69	theme	N-glycan	250:257	arg1	sialylation					287:297	sialylation	287:297	sialylation	287:297	In many cases, specific N-glycan structural features such as sialylation, fucosylation, and branching are of specific interest.
35766466	3	70	theme	associated	552:561	arg1	glycoproteins					563:575	associated glycoproteins	552:575	associated glycoproteins	552:575	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	3	71	from	glycoproteins	563:575	arg1	N-glycans					537:545	N-glycans	537:545	N-glycans from associated glycoproteins	537:575	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
35766466	3	72	theme	imaging	368:374	arg1	spectrometry					381:392	A novel MALDI imaging mass spectrometry	354:392	A novel MALDI imaging mass spectrometry workflow	354:401	A novel MALDI imaging mass spectrometry workflow has been recently developed to analyze these features of N-glycosylation through the utilization of endoglycosidase enzymes to cleave N-glycans from associated glycoproteins.
37158310	9	0	theme	determined	1525:1534	arg1	structures					1536:1545	previously determined structures	1514:1545	previously determined structures of the catalytic domain of GtfC	1514:1577	These structures are compared with previously determined structures of the catalytic domain of GtfC.
37158310	3	1	from	generation	632:641	arg1	end					693:695	the reducing end	680:695	the reducing end	680:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	4	2	theme	glucan	830:835	arg1	chain					845:849	a growing glucan polymer chain	820:849	a growing glucan polymer chain made up of glucose molecules	820:878	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	3	3	from	fructose	598:605	arg1	end					693:695	the reducing end	680:695	the reducing end	680:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	4	theme	reducing	684:691	arg1	end					693:695	the reducing end	680:695	the reducing end	680:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	5	theme	overall	499:505	arg1	activity					517:524	the overall enzymatic activity	495:524	the overall enzymatic activity	495:524	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	9	6	theme	catalytic	1554:1562	arg1	domain					1564:1569	the catalytic domain	1550:1569	the catalytic domain of GtfC	1550:1577	These structures are compared with previously determined structures of the catalytic domain of GtfC.
37158310	9	6	theme	catalytic	1554:1562	arg1	GtfC					1574:1577	GtfC	1574:1577	GtfC	1574:1577	These structures are compared with previously determined structures of the catalytic domain of GtfC.
37158310	3	7	from	release	608:614	arg1	end					693:695	the reducing end	680:695	the reducing end	680:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	10	8	theme	inhibitor-complex	1615:1631	arg1	structures					1633:1642	inhibitor-complex structures	1615:1642	inhibitor-complex structures with acarbose	1615:1656	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	7	9	theme	glycosidic	1296:1305	arg1	glucans					1271:1277	both soluble and insoluble glucans	1244:1277	both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages)	1244:1315	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	7	9	theme	glycosidic	1296:1305	arg1	linkages					1307:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	11	10	with	GtfC	1737:1740	arg1	maltose					1747:1753	maltose	1747:1753	maltose	1747:1753	The structure of GtfC with maltose allows further identification and comparison of active-site residues.
37158310	4	11	theme	glucose	862:868	arg1	molecules					870:878	glucose molecules	862:878	glucose molecules	862:878	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	3	12	from	end	693:695	arg1	generation					632:641	generation	632:641	generation of a glycosyl-enzyme intermediate in the reducing end	632:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	12	from	end	693:695	arg1	release					608:614	release	608:614	release of fructose	608:626	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	12	from	end	693:695	arg1	fructose					598:605	fructose	598:605	fructose	598:605	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	12	from	end	693:695	arg1	glucose					586:592	glucose	586:592	glucose	586:592	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	5	13	theme	domain	998:1003	arg1	site					976:979	the same active site	960:979	the same active site of the catalytic domain	960:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	5	13	theme	domain	998:1003	arg1	domain					998:1003	the catalytic domain	984:1003	the catalytic domain	984:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	1	14	theme	caries	204:209	arg1	pathogenesis					181:192	the pathogenesis	177:192	the pathogenesis of dental caries	177:209	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	12	15	theme	binding	1844:1850	arg1	model					1827:1831	A model	1825:1831	A model of sucrose binding to GtfB	1825:1858	A model of sucrose binding to GtfB is also included.
37158310	7	16	theme	insoluble	1261:1269	arg1	glucans					1271:1277	both soluble and insoluble glucans	1244:1277	both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages)	1244:1315	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	7	16	theme	insoluble	1261:1269	arg1	linkages					1307:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	3	17	from	intermediate	664:675	arg1	end					693:695	the reducing end	680:695	the reducing end	680:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	18	theme	hydrolytic	541:550	arg1	cleavage					563:570	hydrolytic glycosidic cleavage	541:570	hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end	541:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	6	19	theme	glycoside	1127:1135	arg1	family					1147:1152	glycoside hydrolase family 70	1127:1155	glycoside hydrolase family 70 (GH70)	1127:1162	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	6	19	theme	glycoside	1127:1135	arg1	GH70					1158:1161	GH70	1158:1161	GH70	1158:1161	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	7	20	theme	soluble	1249:1255	arg1	glucans					1271:1277	both soluble and insoluble glucans	1244:1277	both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages)	1244:1315	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	7	20	theme	soluble	1249:1255	arg1	linkages					1307:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	6	21	theme	hydrolase	1199:1207	arg1	family					1209:1214	glycoside hydrolase family 13	1189:1217	glycoside hydrolase family 13 (GH13)	1189:1224	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	6	21	theme	hydrolase	1199:1207	arg1	GH13					1220:1223	GH13	1220:1223	GH13	1220:1223	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	13	22	theme	S.	1973:1974	arg1	glycosyltransferases					1983:2002	the three S. mutans glycosyltransferases	1963:2002	the three S. mutans glycosyltransferases	1963:2002	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	2	23	theme	distinct	255:262	arg1	types					264:268	three genetically distinct types	237:268	three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque	237:404	This bacterium expresses three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque.
37158310	1	24	theme	oral	132:135	arg1	cavity					137:142	the human oral cavity	122:142	the human oral cavity	122:142	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	10	25	theme	GtfC	1705:1708	arg1	domains					1694:1700	the catalytic domains	1680:1700	the catalytic domains of GtfC and GtfB	1680:1717	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	25	theme	GtfC	1705:1708	arg1	GtfB					1714:1717	GtfB	1714:1717	GtfB	1714:1717	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	25	theme	GtfC	1705:1708	arg1	GtfC					1705:1708	GtfC	1705:1708	GtfC	1705:1708	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	26	theme	GtfB	1714:1717	arg1	domains					1694:1700	the catalytic domains	1680:1700	the catalytic domains of GtfC and GtfB	1680:1717	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	26	theme	GtfB	1714:1717	arg1	GtfB					1714:1717	GtfB	1714:1717	GtfB	1714:1717	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	26	theme	GtfB	1714:1717	arg1	GtfC					1705:1708	GtfC	1705:1708	GtfC	1705:1708	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	14	27	theme	domain	2185:2190	arg1	domain					2185:2190	domain IV	2185:2193	domain IV	2185:2193	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	14	27	theme	domain	2185:2190	arg1	residues					2173:2180	approximately 200 N-terminal residues	2144:2180	approximately 200 N-terminal residues of domain IV	2144:2193	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	5	28	theme	active	1019:1024	arg1	site					1026:1029	the active site	1015:1029	the active site	1015:1029	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	5	28	theme	active	1019:1024	arg1	large					1053:1057	large	1053:1057	large	1053:1057	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	10	29	with	available	1666:1674	arg1	work					1590:1593	this work	1585:1593	this work	1585:1593	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	2	30	theme	critical	355:362	arg1	roles					364:368	critical roles	355:368	critical roles	355:368	This bacterium expresses three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque.
37158310	13	31	theme	GtfD	1923:1926	arg1	GtfD					1923:1926	GtfD	1923:1926	GtfD	1923:1926	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	13	31	theme	GtfD	1923:1926	arg1	domain					1913:1918	the catalytic domain	1899:1918	the catalytic domain of GtfD	1899:1926	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	3	32	from	glucose	586:592	arg1	end					693:695	the reducing end	680:695	the reducing end	680:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	13	33	theme	mutans	1976:1981	arg1	glycosyltransferases					1983:2002	the three S. mutans glycosyltransferases	1963:2002	the three S. mutans glycosyltransferases	1963:2002	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	0	34	dep	analysis	81:88	arg1	domains					14:20	The catalytic domains	0:20	The catalytic domains of Streptococcus mutans glucosyltransferases	0:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	0	34	dep	analysis	81:88	arg1	glucosyltransferases					46:65	Streptococcus mutans glucosyltransferases	25:65	Streptococcus mutans glucosyltransferases	25:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	2	35	theme	dental	392:397	arg1	plaque					399:404	dental plaque	392:404	dental plaque	392:404	This bacterium expresses three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque.
37158310	4	36	theme	subsequent	703:712	arg1	step					733:736	a subsequent transglycosylation step	701:736	a subsequent transglycosylation step	701:736	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	8	37	theme	domains	1440:1446	arg1	structures					1412:1421	crystal structures	1404:1421	crystal structures of the catalytic domains of GtfB and GtfD	1404:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	14	38	theme	truncated	2118:2126	arg1	protein					2128:2134	a truncated protein	2116:2134	a truncated protein lacking approximately 200 N-terminal residues of domain IV	2116:2193	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	11	39	theme	active-site	1803:1813	arg1	residues					1815:1822	active-site residues	1803:1822	active-site residues	1803:1822	The structure of GtfC with maltose allows further identification and comparison of active-site residues.
37158310	0	40	theme	Streptococcus	25:37	arg1	glucosyltransferases					46:65	Streptococcus mutans glucosyltransferases	25:65	Streptococcus mutans glucosyltransferases	25:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	8	41	theme	GtfB	1451:1454	arg1	domains					1440:1446	the catalytic domains	1426:1446	the catalytic domains of GtfB and GtfD	1426:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	8	41	theme	GtfB	1451:1454	arg1	GtfD					1460:1463	GtfD	1460:1463	GtfD	1460:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	8	41	theme	GtfB	1451:1454	arg1	GtfB					1451:1454	GtfB	1451:1454	GtfB	1451:1454	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	3	42	theme	GtfC	438:441	arg1	GtfC					438:441	GtfC	438:441	GtfC	438:441	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	42	theme	GtfC	438:441	arg1	domains					421:427	The catalytic domains	407:427	The catalytic domains of GtfB, GtfC and GtfD	407:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	42	theme	GtfC	438:441	arg1	GtfD					447:450	GtfD	447:450	GtfD	447:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	0	43	theme	glucosyltransferases	46:65	arg1	domains					14:20	The catalytic domains	0:20	The catalytic domains of Streptococcus mutans glucosyltransferases	0:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	0	43	theme	glucosyltransferases	46:65	arg1	glucosyltransferases					46:65	Streptococcus mutans glucosyltransferases	25:65	Streptococcus mutans glucosyltransferases	25:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	1	44	located	found	113:117	arg2	mutans					105:110	Streptococcus mutans	91:110	Streptococcus mutans	91:110	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	1	44	located	found	113:117	arg2	contributor					162:172	a significant contributor	148:172	a significant contributor to the pathogenesis of dental caries	148:209	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	1	44	located	found	113:117	arg1	cavity					137:142	the human oral cavity	122:142	the human oral cavity	122:142	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	5	45	theme	active	969:974	arg1	site					976:979	the same active site	960:979	the same active site of the catalytic domain	960:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	5	45	theme	active	969:974	arg1	domain					998:1003	the catalytic domain	984:1003	the catalytic domain	984:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	8	46	theme	GtfD	1460:1463	arg1	domains					1440:1446	the catalytic domains	1426:1446	the catalytic domains of GtfB and GtfD	1426:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	8	46	theme	GtfD	1460:1463	arg1	GtfD					1460:1463	GtfD	1460:1463	GtfD	1460:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	8	46	theme	GtfD	1460:1463	arg1	GtfB					1451:1454	GtfB	1451:1454	GtfB	1451:1454	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	13	47	theme	catalytic	1903:1911	arg1	GtfD					1923:1926	GtfD	1923:1926	GtfD	1923:1926	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	13	47	theme	catalytic	1903:1911	arg1	domain					1913:1918	the catalytic domain	1899:1918	the catalytic domain of GtfD	1899:1926	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	5	48	theme	glucan	934:939	arg1	synthesis					941:949	glucan synthesis	934:949	glucan synthesis	934:949	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	11	49	theme	residues	1815:1822	arg1	comparison					1789:1798	comparison	1789:1798	comparison	1789:1798	The structure of GtfC with maltose allows further identification and comparison of active-site residues.
37158310	11	49	theme	residues	1815:1822	arg1	identification					1770:1783	identification	1770:1783	identification	1770:1783	The structure of GtfC with maltose allows further identification and comparison of active-site residues.
37158310	3	50	theme	conserved	460:468	arg1	residues					482:489	conserved active-site residues	460:489	conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end	460:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	7	51	theme	soluble	1367:1373	arg1	glucans					1375:1381	only insoluble or soluble glucans	1349:1381	only insoluble or soluble glucans	1349:1381	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	3	52	theme	intermediate	664:675	arg1	generation					632:641	generation	632:641	generation of a glycosyl-enzyme intermediate in the reducing end	632:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	52	theme	intermediate	664:675	arg1	release					608:614	release	608:614	release of fructose	608:626	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	52	theme	intermediate	664:675	arg1	fructose					598:605	fructose	598:605	fructose	598:605	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	52	theme	intermediate	664:675	arg1	glucose					586:592	glucose	586:592	glucose	586:592	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	6	53	theme	glycoside	1189:1197	arg1	family					1209:1214	glycoside hydrolase family 13	1189:1217	glycoside hydrolase family 13 (GH13)	1189:1224	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	6	53	theme	glycoside	1189:1197	arg1	GH13					1220:1223	GH13	1220:1223	GH13	1220:1223	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	13	54	theme	new	1882:1884	arg1	structure					1886:1894	The new structure	1878:1894	The new structure of the catalytic domain of GtfD	1878:1926	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	3	55	theme	GtfD	447:450	arg1	GtfC					438:441	GtfC	438:441	GtfC	438:441	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	55	theme	GtfD	447:450	arg1	domains					421:427	The catalytic domains	407:427	The catalytic domains of GtfB, GtfC and GtfD	407:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	55	theme	GtfD	447:450	arg1	GtfD					447:450	GtfD	447:450	GtfD	447:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	7	56	theme	insoluble	1354:1362	arg1	glucans					1375:1381	only insoluble or soluble glucans	1349:1381	only insoluble or soluble glucans	1349:1381	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	4	57	theme	growing	822:828	arg1	chain					845:849	a growing glucan polymer chain	820:849	a growing glucan polymer chain made up of glucose molecules	820:878	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	2	58	theme	glucosyltransferases	273:292	arg1	types					264:268	three genetically distinct types	237:268	three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque	237:404	This bacterium expresses three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque.
37158310	1	59	theme	significant	150:160	arg1	mutans					105:110	Streptococcus mutans	91:110	Streptococcus mutans	91:110	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	1	59	theme	significant	150:160	arg1	contributor					162:172	a significant contributor	148:172	a significant contributor to the pathogenesis of dental caries	148:209	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	9	60	theme	domain	1564:1569	arg1	structures					1536:1545	previously determined structures	1514:1545	previously determined structures of the catalytic domain of GtfC	1514:1577	These structures are compared with previously determined structures of the catalytic domain of GtfC.
37158310	4	61	theme	acceptor	803:810	arg1	end					793:795	the nonreducing end	777:795	the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules	777:878	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	3	62	theme	enzymatic	507:515	arg1	activity					517:524	the overall enzymatic activity	495:524	the overall enzymatic activity	495:524	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	7	63	theme	α-1,6	1290:1294	arg1	glucans					1271:1277	both soluble and insoluble glucans	1244:1277	both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages)	1244:1315	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	7	63	theme	α-1,6	1290:1294	arg1	linkages					1307:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	9	64	theme	GtfC	1574:1577	arg1	domain					1564:1569	the catalytic domain	1550:1569	the catalytic domain of GtfC	1550:1577	These structures are compared with previously determined structures of the catalytic domain of GtfC.
37158310	9	64	theme	GtfC	1574:1577	arg1	GtfC					1574:1577	GtfC	1574:1577	GtfC	1574:1577	These structures are compared with previously determined structures of the catalytic domain of GtfC.
37158310	3	65	theme	glycosidic	552:561	arg1	cleavage					563:570	hydrolytic glycosidic cleavage	541:570	hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end	541:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	1	66	theme	dental	197:202	arg1	caries					204:209	dental caries	197:209	dental caries	197:209	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	7	67	theme	α-1,3	1280:1284	arg1	glucans					1271:1277	both soluble and insoluble glucans	1244:1277	both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages)	1244:1315	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	7	67	theme	α-1,3	1280:1284	arg1	linkages					1307:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	α-1,3 and α-1,6 glycosidic linkages	1280:1314	GtfC synthesizes both soluble and insoluble glucans (α-1,3 and α-1,6 glycosidic linkages), while GtfB and GtfD synthesize only insoluble or soluble glucans, respectively.
37158310	14	68	theme	catalytic	2024:2032	arg1	domain					2034:2039	the catalytic domain	2020:2039	the catalytic domain of GtfD	2020:2047	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	14	68	theme	catalytic	2024:2032	arg1	GtfD					2044:2047	GtfD	2044:2047	GtfD	2044:2047	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	14	68	theme	catalytic	2024:2032	arg1	complete					2056:2063	complete	2056:2063	complete	2056:2063	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	10	69	theme	catalytic	1684:1692	arg1	domains					1694:1700	the catalytic domains	1680:1700	the catalytic domains of GtfC and GtfB	1680:1717	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	69	theme	catalytic	1684:1692	arg1	GtfB					1714:1717	GtfB	1714:1717	GtfB	1714:1717	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	69	theme	catalytic	1684:1692	arg1	GtfC					1705:1708	GtfC	1705:1708	GtfC	1705:1708	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	12	70	theme	sucrose	1836:1842	arg1	binding					1844:1850	sucrose binding	1836:1850	sucrose binding to GtfB	1836:1858	A model of sucrose binding to GtfB is also included.
37158310	4	71	theme	polymer	837:843	arg1	chain					845:849	a growing glucan polymer chain	820:849	a growing glucan polymer chain made up of glucose molecules	820:878	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	6	72	theme	hydrolase	1137:1145	arg1	family					1147:1152	glycoside hydrolase family 70	1127:1155	glycoside hydrolase family 70 (GH70)	1127:1162	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	6	72	theme	hydrolase	1137:1145	arg1	GH70					1158:1161	GH70	1158:1161	GH70	1158:1161	These three enzymes belong to glycoside hydrolase family 70 (GH70), which shows homology to glycoside hydrolase family 13 (GH13).
37158310	1	73	theme	human	126:130	arg1	cavity					137:142	the human oral cavity	122:142	the human oral cavity	122:142	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	10	74	with	structures	1633:1642	arg1	acarbose					1649:1656	acarbose	1649:1656	acarbose	1649:1656	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	0	75	theme	structural	70:79	arg1	analysis					81:88	a structural analysis	68:88	a structural analysis	68:88	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	5	76	theme	catalytic	988:996	arg1	domain					998:1003	the catalytic domain	984:1003	the catalytic domain	984:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	3	77	contain	contain	452:458	arg1	GtfC					438:441	GtfC	438:441	GtfC	438:441	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	77	contain	contain	452:458	arg2	residues					482:489	conserved active-site residues	460:489	conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end	460:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	77	contain	contain	452:458	arg1	domains					421:427	The catalytic domains	407:427	The catalytic domains of GtfB, GtfC and GtfD	407:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	77	contain	contain	452:458	arg1	GtfD					447:450	GtfD	447:450	GtfD	447:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	14	78	theme	GtfD	2044:2047	arg1	domain					2034:2039	the catalytic domain	2020:2039	the catalytic domain of GtfD	2020:2047	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	14	78	theme	GtfD	2044:2047	arg1	GtfD					2044:2047	GtfD	2044:2047	GtfD	2044:2047	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	14	78	theme	GtfD	2044:2047	arg1	complete					2056:2063	complete	2056:2063	complete	2056:2063	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	13	79	theme	structural	1938:1947	arg1	comparison					1949:1958	a structural comparison	1936:1958	a structural comparison of the three S. mutans glycosyltransferases	1936:2002	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	3	80	theme	sucrose	575:581	arg1	cleavage					563:570	hydrolytic glycosidic cleavage	541:570	hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end	541:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	13	81	theme	domain	1913:1918	arg1	structure					1886:1894	The new structure	1878:1894	The new structure of the catalytic domain of GtfD	1878:1926	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	13	82	theme	glycosyltransferases	1983:2002	arg1	comparison					1949:1958	a structural comparison	1936:1958	a structural comparison of the three S. mutans glycosyltransferases	1936:2002	The new structure of the catalytic domain of GtfD affords a structural comparison of the three S. mutans glycosyltransferases.
37158310	8	83	theme	crystal	1404:1410	arg1	structures					1412:1421	crystal structures	1404:1421	crystal structures of the catalytic domains of GtfB and GtfD	1404:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	4	84	theme	transglycosylation	714:731	arg1	step					733:736	a subsequent transglycosylation step	701:736	a subsequent transglycosylation step	701:736	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	5	85	theme	sucrose	912:918	arg1	breakdown					920:928	sucrose breakdown	912:928	sucrose breakdown	912:928	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	14	86	theme	N-terminal	2162:2171	arg1	domain					2185:2190	domain IV	2185:2193	domain IV	2185:2193	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	14	86	theme	N-terminal	2162:2171	arg1	residues					2173:2180	approximately 200 N-terminal residues	2144:2180	approximately 200 N-terminal residues of domain IV	2144:2193	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	0	87	theme	catalytic	4:12	arg1	domains					14:20	The catalytic domains	0:20	The catalytic domains of Streptococcus mutans glucosyltransferases	0:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	0	87	theme	catalytic	4:12	arg1	glucosyltransferases					46:65	Streptococcus mutans glucosyltransferases	25:65	Streptococcus mutans glucosyltransferases	25:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	1	88	theme	Streptococcus	91:103	arg1	mutans					105:110	Streptococcus mutans	91:110	Streptococcus mutans	91:110	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	1	88	theme	Streptococcus	91:103	arg1	contributor					162:172	a significant contributor	148:172	a significant contributor to the pathogenesis of dental caries	148:209	Streptococcus mutans, found in the human oral cavity, is a significant contributor to the pathogenesis of dental caries.
37158310	2	89	theme	plaque	399:404	arg1	development					377:387	the development	373:387	the development of dental plaque	373:404	This bacterium expresses three genetically distinct types of glucosyltransferases named GtfB (GTF-I), GtfC (GTF-SI) and GtfD (GTF-S) that play critical roles in the development of dental plaque.
37158310	8	90	theme	catalytic	1430:1438	arg1	domains					1440:1446	the catalytic domains	1426:1446	the catalytic domains of GtfB and GtfD	1426:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	8	90	theme	catalytic	1430:1438	arg1	GtfD					1460:1463	GtfD	1460:1463	GtfD	1460:1463	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	8	90	theme	catalytic	1430:1438	arg1	GtfB					1451:1454	GtfB	1451:1454	GtfB	1451:1454	Here, crystal structures of the catalytic domains of GtfB and GtfD are reported.
37158310	3	91	theme	fructose	619:626	arg1	generation					632:641	generation	632:641	generation of a glycosyl-enzyme intermediate in the reducing end	632:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	91	theme	fructose	619:626	arg1	release					608:614	release	608:614	release of fructose	608:626	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	91	theme	fructose	619:626	arg1	fructose					598:605	fructose	598:605	fructose	598:605	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	91	theme	fructose	619:626	arg1	glucose					586:592	glucose	586:592	glucose	586:592	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	14	92	theme	protein	2128:2134	arg1	structure					2103:2111	the structure	2099:2111	the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV	2099:2193	Unfortunately, the catalytic domain of GtfD is not complete since crystallization resulted in the structure of a truncated protein lacking approximately 200 N-terminal residues of domain IV.
37158310	0	93	theme	mutans	39:44	arg1	glucosyltransferases					46:65	Streptococcus mutans glucosyltransferases	25:65	Streptococcus mutans glucosyltransferases	25:65	The catalytic domains of Streptococcus mutans glucosyltransferases: a structural analysis.
37158310	3	94	theme	catalytic	411:419	arg1	GtfC					438:441	GtfC	438:441	GtfC	438:441	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	94	theme	catalytic	411:419	arg1	domains					421:427	The catalytic domains	407:427	The catalytic domains of GtfB, GtfC and GtfD	407:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	94	theme	catalytic	411:419	arg1	GtfD					447:450	GtfD	447:450	GtfD	447:450	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	5	95	theme	same	964:967	arg1	site					976:979	the same active site	960:979	the same active site of the catalytic domain	960:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	5	95	theme	same	964:967	arg1	domain					998:1003	the catalytic domain	984:1003	the catalytic domain	984:1003	It has been proposed that both sucrose breakdown and glucan synthesis occur in the same active site of the catalytic domain, although the active site does not appear to be large enough to accommodate both functions.
37158310	4	96	theme	nonreducing	781:791	arg1	end					793:795	the nonreducing end	777:795	the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules	777:878	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	11	97	theme	GtfC	1737:1740	arg1	structure					1724:1732	The structure	1720:1732	The structure of GtfC with maltose	1720:1753	The structure of GtfC with maltose allows further identification and comparison of active-site residues.
37158310	4	98	theme	glucosyl	743:750	arg1	moiety					752:757	the glucosyl moiety	739:757	the glucosyl moiety	739:757	In a subsequent transglycosylation step, the glucosyl moiety is transferred to the nonreducing end of an acceptor to form a growing glucan polymer chain made up of glucose molecules.
37158310	10	99	with	structures	1600:1609	arg1	acarbose					1649:1656	acarbose	1649:1656	acarbose	1649:1656	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	10	100	theme	apo	1596:1598	arg1	structures					1600:1609	apo structures	1596:1609	apo structures	1596:1609	With this work, apo structures and inhibitor-complex structures with acarbose are now available for the catalytic domains of GtfC and GtfB.
37158310	3	101	theme	glycosyl-enzyme	648:662	arg1	intermediate					664:675	a glycosyl-enzyme intermediate	646:675	a glycosyl-enzyme intermediate in the reducing end	646:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37158310	3	102	theme	active-site	470:480	arg1	residues					482:489	conserved active-site residues	460:489	conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end	460:695	The catalytic domains of GtfB, GtfC and GtfD contain conserved active-site residues for the overall enzymatic activity that relate to hydrolytic glycosidic cleavage of sucrose to glucose and fructose, release of fructose and generation of a glycosyl-enzyme intermediate in the reducing end.
37238633	7	0	theme	2.05	1376:1379	arg1	×					1381:1381	×	1381:1381	×	1381:1381	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	8	1	theme	exercise	1749:1756	arg1	introduction					1758:1769	exercise introduction	1749:1769	exercise introduction	1749:1769	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	2	2	theme	exercise	358:365	arg1	impact					340:345	the impact	336:345	the impact of regular exercise on overall inflammatory status	336:396	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	4	3	theme	IgG	861:863	arg1	glycosylation					865:877	IgG glycosylation	861:877	IgG glycosylation	861:877	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	2	4	theme	G	249:249	arg1	N-glycosylation					257:271	Immunoglobulin G (IgG) N-glycosylation	234:271	Immunoglobulin G (IgG) N-glycosylation	234:271	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	8	5	theme	pro-inflammatory	1599:1614	arg1	potential					1620:1628	an increased pro-inflammatory IgG potential	1586:1628	an increased pro-inflammatory IgG potential	1586:1628	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	7	6	theme	structure	1338:1346	arg1	G1					1354:1355	glycan structure FA2[3]G1	1331:1355	glycan structure FA2[3]G1	1331:1355	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	1	7	theme	immune	185:190	arg1	system					192:197	the immune system	181:197	the immune system	181:197	Regular exercise improves health, modulating the immune system and impacting inflammatory status.
37238633	3	8	theme	N	563:563	arg1	participants					549:560	Study participants	543:560	Study participants (N = 397)	543:570	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	3	8	theme	N	563:563	arg1	397					567:569	N = 397	563:569	N = 397	563:569	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	3	9	theme	intervention	703:714	arg1	end					696:698	the end	692:698	the end of intervention	692:714	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	1	10	theme	inflammatory	213:224	arg1	status					226:231	inflammatory status	213:231	inflammatory status	213:231	Regular exercise improves health, modulating the immune system and impacting inflammatory status.
37238633	7	11	theme	significant	1302:1312	arg1	increase					1314:1321	a significant increase	1300:1321	a significant increase	1300:1321	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	8	12	theme	inactive	1656:1663	arg1	population					1680:1689	a previously inactive and overweight population	1643:1689	a previously inactive and overweight population	1643:1689	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	4	13	dep	age	793:795	arg1	adjustment					805:814	adjustment	805:814	adjustment	805:814	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	7	14	theme	regular	1493:1499	arg1	exercise					1501:1508	regular exercise	1493:1508	regular exercise	1493:1508	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	2	15	theme	Immunoglobulin	234:247	arg1	IgG					252:254	IgG	252:254	IgG	252:254	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	15	theme	Immunoglobulin	234:247	arg1	G					249:249	Immunoglobulin G	234:249	Immunoglobulin G (IgG) N-glycosylation	234:271	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	8	16	theme	overweight	1669:1678	arg1	population					1680:1689	a previously inactive and overweight population	1643:1689	a previously inactive and overweight population	1643:1689	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	5	17	theme	significant	910:920	arg1	changes					922:928	significant changes	910:928	significant changes in IgG N-glycome composition	910:957	Exercise intervention induced significant changes in IgG N-glycome composition.
37238633	3	18	theme	different	595:603	arg1	programs					614:621	three different exercise programs	589:621	three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention	589:714	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	2	19	theme	9.23	512:515	arg1	±					534:534	BMI 30.57 ± 4.81	524:539	BMI 30.57 ± 4.81	524:539	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	19	theme	9.23	512:515	arg1	years					517:521	50.30 ± 9.23 years	504:521	50.30 ± 9.23 years	504:521	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	0	20	theme	N-Glycan	66:73	arg1	Composition					75:85	Immunoglobulin G N-Glycan Composition	49:85	Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population	49:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	8	21	theme	metabolic	1698:1706	arg1	remodeling					1708:1717	metabolic remodeling	1698:1717	metabolic remodeling	1698:1717	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	7	22	dep	GP9	1326:1328	arg1	=					1360:1360	=	1360:1360	=	1360:1360	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	2	23	theme	50.30	504:508	arg1	±					534:534	BMI 30.57 ± 4.81	524:539	BMI 30.57 ± 4.81	524:539	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	23	theme	50.30	504:508	arg1	years					517:521	50.30 ± 9.23 years	504:521	50.30 ± 9.23 years	504:521	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	6	24	dep	N-glycans	1206:1214	arg1	=					1222:1222	=	1222:1222	=	1222:1222	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	25	from	decrease	1152:1159	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	25	from	decrease	1152:1159	arg1	N-glycans					1206:1214	digalactosylated, mono- and di-sialylated N-glycans	1164:1214	digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively)	1164:1280	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	4	26	from	effects	850:856	arg1	glycosylation					865:877	IgG glycosylation	861:877	IgG glycosylation	861:877	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	2	27	theme	30.57	528:532	arg1	±					534:534	BMI 30.57 ± 4.81	524:539	BMI 30.57 ± 4.81	524:539	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	27	theme	30.57	528:532	arg1	years					517:521	50.30 ± 9.23 years	504:521	50.30 ± 9.23 years	504:521	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	28	gly	N-glycosylation	416:430	arg1	population					492:501	a previously inactive, middle-aged, overweight and obese population	435:501	a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81)	435:540	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	4	29	theme	IgG	753:755	arg1	N-glycans					757:765	chromatographically profiling IgG N-glycans	723:765	chromatographically profiling IgG N-glycans	723:765	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	7	30	theme	protective	1421:1430	arg1	role					1447:1450	a protective cardiovascular role	1419:1450	a protective cardiovascular role	1419:1450	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	2	31	theme	IgG	412:414	arg1	N-glycosylation					416:430	IgG N-glycosylation	412:430	IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81)	412:540	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	32	dep	inactive	448:455	arg1	middle-aged					458:468	middle-aged	458:468	middle-aged	458:468	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	32	dep	inactive	448:455	arg1	obese					486:490	obese	486:490	obese	486:490	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	32	dep	inactive	448:455	arg1	overweight					471:480	overweight	471:480	overweight	471:480	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	5	33	from	changes	922:928	arg1	composition					947:957	IgG N-glycome composition	933:957	IgG N-glycome composition	933:957	Exercise intervention induced significant changes in IgG N-glycome composition.
37238633	0	34	from	Changes	38:44	arg1	Composition					75:85	Immunoglobulin G N-Glycan Composition	49:85	Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population	49:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	0	35	theme	Physical	0:7	arg1	Exercise					9:16	Physical Exercise	0:16	Physical Exercise	0:16	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	5	36	theme	N-glycome	937:945	arg1	composition					947:957	IgG N-glycome composition	933:957	IgG N-glycome composition	933:957	Exercise intervention induced significant changes in IgG N-glycome composition.
37238633	1	37	dep	improves	153:160	arg1	impacting					203:211	impacting	203:211	impacting inflammatory status	203:231	Regular exercise improves health, modulating the immune system and impacting inflammatory status.
37238633	1	37	dep	improves	153:160	arg1	modulating					170:179	modulating	170:179	modulating the immune system	170:197	Regular exercise improves health, modulating the immune system and impacting inflammatory status.
37238633	8	38	from	alterations	1543:1553	arg1	N-glycosylation					1562:1576	IgG N-glycosylation	1558:1576	IgG N-glycosylation	1558:1576	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	2	39	from	changes	282:288	arg1	status					306:311	inflammatory status	293:311	inflammatory status	293:311	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	6	40	from	increase	975:982	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	40	from	increase	975:982	arg1	N-glycans					1206:1214	digalactosylated, mono- and di-sialylated N-glycans	1164:1214	digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively)	1164:1280	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	3	41	theme	programs	614:621	arg1	programs					614:621	three different exercise programs	589:621	three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention	589:714	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	3	41	theme	programs	614:621	arg1	one					582:584	one	582:584	one	582:584	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	2	42	theme	regular	350:356	arg1	exercise					358:365	regular exercise	350:365	regular exercise	350:365	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	0	43	theme	Immunoglobulin	49:62	arg1	Composition					75:85	Immunoglobulin G N-Glycan Composition	49:85	Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population	49:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	7	44	dep	=	1360:1360	arg1	G1					1354:1355	glycan structure FA2[3]G1	1331:1355	glycan structure FA2[3]G1	1331:1355	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	4	45	theme	mixed	775:779	arg1	models					781:786	linear mixed models	768:786	linear mixed models with age and sex adjustment	768:814	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	6	46	theme	1.51	1101:1104	arg1	×					1106:1106	1.51 × 10-21 and 3.38 × 10-30	1101:1129	×	1106:1106	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	46	theme	1.51	1101:1104	arg1	×					1092:1092	2.41 × 10-25	1087:1098	2.41 × 10-25	1087:1098	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	47	gly	core-fucosylated	1039:1054	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	2	48	theme	inflammatory	378:389	arg1	status					391:396	overall inflammatory status	370:396	overall inflammatory status	370:396	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	6	49	gly	asialylated	1023:1033	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	8	50	theme	IgG	1558:1560	arg1	N-glycosylation					1562:1576	IgG N-glycosylation	1558:1576	IgG N-glycosylation	1558:1576	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	4	51	theme	exercise	841:848	arg1	effects					850:856	exercise effects	841:856	exercise effects on IgG glycosylation	841:877	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	2	52	from	impact	340:345	arg1	status					391:396	overall inflammatory status	370:396	overall inflammatory status	370:396	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	6	53	gly	di-sialylated	1192:1204	arg1	N-glycans					1206:1214	digalactosylated, mono- and di-sialylated N-glycans	1164:1214	digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively)	1164:1280	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	2	54	theme	inflammatory	293:304	arg1	status					306:311	inflammatory status	293:311	inflammatory status	293:311	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	8	55	theme	increased	1589:1597	arg1	potential					1620:1628	an increased pro-inflammatory IgG potential	1586:1628	an increased pro-inflammatory IgG potential	1586:1628	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	6	56	theme	monogalctosylated	1004:1020	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	7	57	theme	FA2[3	1348:1352	arg1	G1					1354:1355	glycan structure FA2[3]G1	1331:1355	glycan structure FA2[3]G1	1331:1355	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	8	58	theme	IgG	1616:1618	arg1	potential					1620:1628	an increased pro-inflammatory IgG potential	1586:1628	an increased pro-inflammatory IgG potential	1586:1628	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	7	59	theme	cardiovascular	1514:1527	arg1	health					1529:1534	cardiovascular health	1514:1534	cardiovascular health	1514:1534	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	7	60	theme	glycan	1331:1336	arg1	G1					1354:1355	glycan structure FA2[3]G1	1331:1355	glycan structure FA2[3]G1	1331:1355	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	3	61	theme	Study	543:547	arg1	participants					549:560	Study participants	543:560	Study participants (N = 397)	543:570	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	3	61	theme	Study	543:547	arg1	397					567:569	N = 397	563:569	N = 397	563:569	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	7	62	theme	exercise	1501:1508	arg1	importance					1479:1488	the importance	1475:1488	the importance of regular exercise for cardiovascular health	1475:1534	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	0	63	from	Composition	75:85	arg1	Population					124:133	a Previously Inactive, Overweight Population	90:133	a Previously Inactive, Overweight Population	90:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	6	64	theme	di-sialylated	1192:1204	arg1	N-glycans					1206:1214	digalactosylated, mono- and di-sialylated N-glycans	1164:1214	digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively)	1164:1280	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	3	65	theme	=	565:565	arg1	participants					549:560	Study participants	543:560	Study participants (N = 397)	543:570	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	3	65	theme	=	565:565	arg1	397					567:569	N = 397	563:569	N = 397	563:569	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	6	66	theme	mono-	1182:1186	arg1	N-glycans					1206:1214	digalactosylated, mono- and di-sialylated N-glycans	1164:1214	digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively)	1164:1280	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	1	67	theme	Regular	136:142	arg1	exercise					144:151	Regular exercise	136:151	Regular exercise	136:151	Regular exercise improves health, modulating the immune system and impacting inflammatory status.
37238633	6	68	theme	core-fucosylated	1039:1054	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	69	theme	digalactosylated	1164:1179	arg1	N-glycans					1206:1214	digalactosylated, mono- and di-sialylated N-glycans	1164:1214	digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively)	1164:1280	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	6	70	theme	asialylated	1023:1033	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	2	71	theme	±	510:510	arg1	±					534:534	BMI 30.57 ± 4.81	524:539	BMI 30.57 ± 4.81	524:539	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	71	theme	±	510:510	arg1	years					517:521	50.30 ± 9.23 years	504:521	50.30 ± 9.23 years	504:521	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	5	72	theme	Exercise	880:887	arg1	intervention					889:900	Exercise intervention	880:900	Exercise intervention	880:900	Exercise intervention induced significant changes in IgG N-glycome composition.
37238633	7	73	theme	cardiovascular	1432:1445	arg1	role					1447:1450	a protective cardiovascular role	1419:1450	a protective cardiovascular role	1419:1450	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	4	74	with	models	781:786	arg1	sex					801:803	sex	801:803	sex	801:803	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	4	74	with	models	781:786	arg1	age					793:795	age	793:795	age	793:795	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	0	75	theme	Inactive	103:110	arg1	Population					124:133	a Previously Inactive, Overweight Population	90:133	a Previously Inactive, Overweight Population	90:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	2	76	dep	population	492:501	arg1	±					534:534	BMI 30.57 ± 4.81	524:539	BMI 30.57 ± 4.81	524:539	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	76	dep	population	492:501	arg1	years					517:521	50.30 ± 9.23 years	504:521	50.30 ± 9.23 years	504:521	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	6	77	theme	agalactosylated	987:1001	arg1	N-glycans					1056:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans	987:1064	agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively)	987:1144	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	2	78	theme	BMI	524:526	arg1	±					534:534	BMI 30.57 ± 4.81	524:539	BMI 30.57 ± 4.81	524:539	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	78	theme	BMI	524:526	arg1	years					517:521	50.30 ± 9.23 years	504:521	50.30 ± 9.23 years	504:521	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	6	79	dep	N-glycans	1056:1064	arg1	=					1072:1072	=	1072:1072	=	1072:1072	We observed an increase in agalactosylated, monogalctosylated, asialylated and core-fucosylated N-glycans (padj = 1.00 × 10-4, 2.41 × 10-25, 1.51 × 10-21 and 3.38 × 10-30, respectively) and a decrease in digalactosylated, mono- and di-sialylated N-glycans (padj = 4.93 × 10-12, 7.61 × 10-9 and 1.09 × 10-28, respectively).
37238633	4	80	theme	profiling	743:751	arg1	N-glycans					757:765	chromatographically profiling IgG N-glycans	723:765	chromatographically profiling IgG N-glycans	723:765	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	0	81	dep	Inactive	103:110	arg1	Overweight					113:122	Overweight	113:122	Overweight	113:122	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	8	82	theme	early	1729:1733	arg1	stages					1735:1740	the early stages	1725:1740	the early stages due to exercise introduction	1725:1769	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	5	83	theme	IgG	933:935	arg1	composition					947:957	IgG N-glycome composition	933:957	IgG N-glycome composition	933:957	Exercise intervention induced significant changes in IgG N-glycome composition.
37238633	0	84	theme	Significant	26:36	arg1	Changes					38:44	Significant Changes	26:44	Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population	26:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	8	85	theme	due	1742:1744	arg1	stages					1735:1740	the early stages	1725:1740	the early stages due to exercise introduction	1725:1769	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	2	86	theme	inactive	448:455	arg1	population					492:501	a previously inactive, middle-aged, overweight and obese population	435:501	a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81)	435:540	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	7	87	from	increase	1314:1321	arg1	GP9					1326:1328	GP9	1326:1328	GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16)	1326:1388	We also observed a significant increase in GP9 (glycan structure FA2[3]G1, β = 0.126, padj = 2.05 × 10-16), previously reported to have a protective cardiovascular role in women, highlighting the importance of regular exercise for cardiovascular health.
37238633	3	88	theme	exercise	605:612	arg1	programs					614:621	three different exercise programs	589:621	three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention	589:714	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	0	89	theme	G	64:64	arg1	Composition					75:85	Immunoglobulin G N-Glycan Composition	49:85	Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population	49:133	Physical Exercise Induces Significant Changes in Immunoglobulin G N-Glycan Composition in a Previously Inactive, Overweight Population.
37238633	3	90	theme	blood	649:653	arg1	samples					655:661	blood samples	649:661	blood samples collected at baseline and at the end of intervention	649:714	Study participants (N = 397) underwent one of three different exercise programs lasting three months with blood samples collected at baseline and at the end of intervention.
37238633	8	91	theme	Other	1537:1541	arg1	alterations					1543:1553	Other alterations	1537:1553	Other alterations in IgG N-glycosylation	1537:1576	Other alterations in IgG N-glycosylation reflect an increased pro-inflammatory IgG potential, expected in a previously inactive and overweight population, where metabolic remodeling is in the early stages due to exercise introduction.
37238633	4	92	used	used	821:824	arg2	models					781:786	linear mixed models	768:786	linear mixed models with age and sex adjustment	768:814	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	4	93	theme	linear	768:773	arg1	models					781:786	linear mixed models	768:786	linear mixed models with age and sex adjustment	768:814	After chromatographically profiling IgG N-glycans, linear mixed models with age and sex adjustment were used to investigate exercise effects on IgG glycosylation.
37238633	2	94	from	N-glycosylation	416:430	arg1	population					492:501	a previously inactive, middle-aged, overweight and obese population	435:501	a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81)	435:540	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37238633	2	95	theme	overall	370:376	arg1	status					391:396	overall inflammatory status	370:396	overall inflammatory status	370:396	Immunoglobulin G (IgG) N-glycosylation reflects changes in inflammatory status; thus, we investigated the impact of regular exercise on overall inflammatory status by monitoring IgG N-glycosylation in a previously inactive, middle-aged, overweight and obese population (50.30 ± 9.23 years, BMI 30.57 ± 4.81).
37341462	0	0	theme	O-Glycopeptide	74:87	arg1	Identification					89:102	O-Glycopeptide Identification	74:102	O-Glycopeptide Identification	74:102	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.
37341462	5	1	theme	O-glycan	870:877	arg1	patterns					885:892	theoretical O-glycan Y-ion patterns	858:892	theoretical O-glycan Y-ion patterns	858:892	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	8	2	dep	sceHCD	1612:1617	arg1	energy					1638:1643	stepped collision energy	1620:1643	stepped collision energy higher-energy collisional dissociation	1620:1682	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	1	3	theme	N-linked	163:170	arg1	glycosylation					172:184	N-linked glycosylation	163:184	N-linked glycosylation	163:184	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	5	4	theme	O-glycopeptide	946:959	arg1	spectra					961:967	O-glycopeptide spectra	946:967	O-glycopeptide spectra	946:967	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	5	5	theme	experimental	923:934	arg1	Y-ions					936:941	the experimental Y-ions	919:941	the experimental Y-ions	919:941	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	8	6	theme	stepped	1620:1626	arg1	energy					1638:1643	stepped collision energy	1620:1643	stepped collision energy higher-energy collisional dissociation	1620:1682	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	1	7	from	glycosylation	172:184	arg1	Different					148:156	Different	148:156	Different	148:156	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	4	8	theme	special	742:748	arg1	approach					757:764	a special search approach	740:764	a special search approach	740:764	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	3	9	from	pattern	559:565	arg1	O-glycopeptides					580:594	O-glycopeptides	580:594	O-glycopeptides	580:594	However, the pattern of Y ions in O-glycopeptides has not been well studied.
37341462	3	10	theme	ions	572:575	arg1	pattern					559:565	the pattern	555:565	the pattern of Y ions in O-glycopeptides	555:594	However, the pattern of Y ions in O-glycopeptides has not been well studied.
37341462	2	11	link	N-linked	445:452	arg1	glycosylation					454:466	N-linked glycosylation	445:466	N-linked glycosylation	445:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	7	12	theme	software	1401:1408	arg1	tools					1410:1414	other state-of-the-art software tools	1378:1414	other state-of-the-art software tools	1378:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	1	13	theme	sensitive	262:270	arg1	interpretation					272:285	the sensitive interpretation	258:285	the sensitive interpretation of O-glycopeptide spectra	258:311	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	5	14	gly	O-glycopeptide	946:959	arg2	O-glycopeptide					946:959	O-glycopeptide spectra	946:967	O-glycopeptide spectra	946:967	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	4	15	theme	O-glycopeptides	719:733	arg1	spectra					708:714	the spectra	704:714	the spectra of O-glycopeptides	704:733	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	2	16	theme	known	377:381	arg1	gaps					388:391	known mass gaps	377:391	known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation	377:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	7	17	theme	O-glycopeptide-spectrum	1272:1294	arg1	OGPSMs					1305:1310	OGPSMs	1305:1310	OGPSMs	1305:1310	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	7	17	theme	O-glycopeptide-spectrum	1272:1294	arg1	matches					1296:1302	O-glycopeptide-spectrum matches	1272:1302	O-glycopeptide-spectrum matches (OGPSMs)	1272:1311	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	4	18	theme	Y-ion	824:828	arg1	patterns					830:837	the Y-ion patterns	820:837	the Y-ion patterns	820:837	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	4	19	theme	search	750:755	arg1	approach					757:764	a special search approach	740:764	a special search approach	740:764	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	2	20	theme	mass	383:386	arg1	gaps					388:391	known mass gaps	377:391	known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation	377:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	2	21	theme	N-linked	445:452	arg1	glycosylation					454:466	N-linked glycosylation	445:466	N-linked glycosylation	445:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	8	22	theme	search	1510:1515	arg1	software					1517:1524	our database search software	1497:1524	our database search software	1497:1524	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	8	22	theme	search	1510:1515	arg1	MS-Decipher					1527:1537	MS-Decipher	1527:1537	MS-Decipher	1527:1537	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	2	23	gly	N-glycopeptide	496:509	arg2	N-glycopeptide					496:509	N-glycopeptide identification	496:524	N-glycopeptide identification	496:524	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	7	24	theme	data	1240:1243	arg1	set					1245:1247	a human serum data set	1226:1247	a human serum data set	1226:1247	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	1	25	theme	core	191:194	arg1	structures					196:205	the core structures	187:205	the core structures of mucin type O-glycans	187:229	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	1	25	theme	core	191:194	arg1	diverse					245:251	diverse	245:251	diverse	245:251	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	7	26	theme	state-of-the-art	1384:1399	arg1	tools					1410:1414	other state-of-the-art software tools	1378:1414	other state-of-the-art software tools	1378:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	5	27	theme	theoretical	858:868	arg1	patterns					885:892	theoretical O-glycan Y-ion patterns	858:892	theoretical O-glycan Y-ion patterns	858:892	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	0	28	theme	Searching	20:28	arg1	Tool					30:33	A Searching Tool	18:33	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.	0:146	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.
37341462	8	29	theme	database	1501:1508	arg1	software					1517:1524	our database search software	1497:1524	our database search software	1497:1524	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	8	29	theme	database	1501:1508	arg1	MS-Decipher					1527:1537	MS-Decipher	1527:1537	MS-Decipher	1527:1537	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	0	30	theme	O-GalNAc	124:131	arg1	Glycoproteome					133:145	O-GalNAc Glycoproteome	124:145	O-GalNAc Glycoproteome	124:145	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.
37341462	7	31	theme	%	1321:1321	arg1	%					1328:1328	19.6%-107.1%	1317:1328	19.6%-107.1%	1317:1328	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	7	32	theme	more	1330:1333	arg1	identifications					1357:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications	1254:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools	1254:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	2	33	theme	penta-saccharide	410:425	arg1	structure					432:440	the penta-saccharide core structure	406:440	the penta-saccharide core structure of N-linked glycosylation	406:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	2	34	theme	core	427:430	arg1	structure					432:440	the penta-saccharide core structure	406:440	the penta-saccharide core structure of N-linked glycosylation	406:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	1	35	theme	O-glycopeptide	290:303	arg1	spectra					305:311	O-glycopeptide spectra	290:311	O-glycopeptide spectra	290:311	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	8	36	dep	higher-energy	1645:1657	arg1	dissociation					1671:1682	collisional dissociation	1659:1682	collisional dissociation	1659:1682	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	3	37	theme	Y	570:570	arg1	ions					572:575	Y ions	570:575	Y ions	570:575	However, the pattern of Y ions in O-glycopeptides has not been well studied.
37341462	7	38	theme	sequence	1348:1355	arg1	identifications					1357:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications	1254:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools	1254:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	1	39	theme	mucin	210:214	arg1	O-glycans					221:229	mucin type O-glycans	210:229	mucin type O-glycans	210:229	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	1	40	theme	spectra	305:311	arg1	interpretation					272:285	the sensitive interpretation	258:285	the sensitive interpretation of O-glycopeptide spectra	258:311	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	5	41	theme	mass	1009:1012	arg1	determination					988:1000	the determination	984:1000	the determination of the mass of some glycans	984:1028	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	7	42	theme	more	1267:1270	arg1	identifications					1357:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications	1254:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools	1254:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	1	43	theme	type	216:219	arg1	O-glycans					221:229	mucin type O-glycans	210:229	mucin type O-glycans	210:229	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	7	44	theme	search	1188:1193	arg1	strategy					1195:1202	The new search strategy	1180:1202	The new search strategy	1180:1202	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	0	45	theme	Glycoproteome	133:145	arg1	Analysis					112:119	the Analysis	108:119	the Analysis of O-GalNAc Glycoproteome	108:145	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.
37341462	2	46	attach	derived	393:399	arg2	gaps					388:391	known mass gaps	377:391	known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation	377:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	2	46	attach	derived	393:399	arg1	structure					432:440	the penta-saccharide core structure	406:440	the penta-saccharide core structure of N-linked glycosylation	406:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	7	47	dep	more	1267:1270	arg1	OGPSMs					1305:1310	OGPSMs	1305:1310	OGPSMs	1305:1310	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	7	47	dep	more	1267:1270	arg1	matches					1296:1302	O-glycopeptide-spectrum matches	1272:1302	O-glycopeptide-spectrum matches (OGPSMs)	1272:1311	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	1	48	theme	O-glycans	221:229	arg1	structures					196:205	the core structures	187:205	the core structures of mucin type O-glycans	187:229	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	1	48	theme	O-glycans	221:229	arg1	diverse					245:251	diverse	245:251	diverse	245:251	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	0	49	theme	Y-Ion	49:53	arg1	Pattern					55:61	the Y-Ion Pattern	45:61	the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome	45:145	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.
37341462	4	50	theme	Y-ion	656:660	arg1	patterns					662:669	the Y-ion patterns	652:669	the Y-ion patterns	652:669	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	7	51	gly	glycopeptide	1335:1346	arg2	glycopeptide					1335:1346	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications	1254:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools	1254:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	6	52	theme	deisotope	1114:1122	arg1	process					1124:1130	a Y-ion pattern-based deisotope process	1092:1130	a Y-ion pattern-based deisotope process	1092:1130	In addition, a Y-ion pattern-based deisotope process is also developed to correct the precursor m/z.
37341462	2	53	theme	glycosylation	454:466	arg1	structure					432:440	the penta-saccharide core structure	406:440	the penta-saccharide core structure of N-linked glycosylation	406:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	1	54	link	N-linked	163:170	arg1	glycosylation					172:184	N-linked glycosylation	163:184	N-linked glycosylation	163:184	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	8	55	theme	search	1436:1441	arg1	mode					1443:1446	This search mode	1431:1446	This search mode	1431:1446	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	8	55	theme	search	1436:1441	arg1	O-Search-Pattern					1453:1468	the O-Search-Pattern	1449:1468	the O-Search-Pattern	1449:1468	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	5	56	theme	glycans	1022:1028	arg1	mass					1009:1012	the mass	1005:1012	the mass of some glycans	1005:1028	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	7	57	theme	new	1184:1186	arg1	strategy					1195:1202	The new search strategy	1180:1202	The new search strategy	1180:1202	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	6	58	theme	pattern-based	1100:1112	arg1	process					1124:1130	a Y-ion pattern-based deisotope process	1092:1130	a Y-ion pattern-based deisotope process	1092:1130	In addition, a Y-ion pattern-based deisotope process is also developed to correct the precursor m/z.
37341462	7	59	theme	human	1228:1232	arg1	set					1245:1247	a human serum data set	1226:1247	a human serum data set	1226:1247	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	8	60	theme	O-glycopeptide	1577:1590	arg1	spectra					1592:1598	the O-glycopeptide spectra	1573:1598	the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation)	1573:1683	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	8	61	gly	O-glycopeptide	1577:1590	arg2	O-glycopeptide					1577:1590	O-glycopeptide	1577:1590	O-glycopeptide	1577:1590	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	1	62	gly	O-glycopeptide	290:303	arg2	O-glycopeptide					290:303	O-glycopeptide spectra	290:311	O-glycopeptide spectra	290:311	Different from N-linked glycosylation, the core structures of mucin type O-glycans are much more diverse, and the sensitive interpretation of O-glycopeptide spectra remains a challenge.
37341462	2	63	theme	Y-ion	338:342	arg1	pattern					344:350	The Y-ion pattern	334:350	The Y-ion pattern	334:350	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	2	63	theme	Y-ion	338:342	arg1	series					355:360	a series	353:360	a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation	353:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	7	64	theme	glycopeptide	1335:1346	arg1	identifications					1357:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications	1254:1371	15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools	1254:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	7	65	theme	other	1378:1382	arg1	tools					1410:1414	other state-of-the-art software tools	1378:1414	other state-of-the-art software tools	1378:1414	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	2	66	with	Y-ions	365:370	arg1	gaps					388:391	known mass gaps	377:391	known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation	377:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	6	67	theme	precursor	1165:1173	arg1	m/z					1175:1177	the precursor m/z	1161:1177	the precursor m/z	1161:1177	In addition, a Y-ion pattern-based deisotope process is also developed to correct the precursor m/z.
37341462	5	68	theme	Y-ion	879:883	arg1	patterns					885:892	theoretical O-glycan Y-ion patterns	858:892	theoretical O-glycan Y-ion patterns	858:892	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	8	69	theme	collision	1628:1636	arg1	energy					1638:1643	stepped collision energy	1620:1643	stepped collision energy higher-energy collisional dissociation	1620:1682	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	6	70	theme	Y-ion	1094:1098	arg1	process					1124:1130	a Y-ion pattern-based deisotope process	1092:1130	a Y-ion pattern-based deisotope process	1092:1130	In addition, a Y-ion pattern-based deisotope process is also developed to correct the precursor m/z.
37341462	3	71	gly	O-glycopeptides	580:594	arg2	O-glycopeptides					580:594	O-glycopeptides	580:594	O-glycopeptides	580:594	However, the pattern of Y ions in O-glycopeptides has not been well studied.
37341462	7	72	theme	%	1258:1258	arg1	%					1265:1265	15.4%-199.0%	1254:1265	15.4%-199.0%	1254:1265	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	2	73	theme	Y-ions	365:370	arg1	pattern					344:350	The Y-ion pattern	334:350	The Y-ion pattern	334:350	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	2	73	theme	Y-ions	365:370	arg1	series					355:360	a series	353:360	a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation	353:466	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	5	74	from	Y-ions	936:941	arg1	spectra					961:967	O-glycopeptide spectra	946:967	O-glycopeptide spectra	946:967	In this strategy, theoretical O-glycan Y-ion patterns are constructed to match the experimental Y-ions in O-glycopeptide spectra, which enables the determination of the mass of some glycans and results in the reduction of searching space.
37341462	8	75	theme	collisional	1659:1669	arg1	dissociation					1671:1682	collisional dissociation	1659:1682	collisional dissociation	1659:1682	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	2	76	theme	N-glycopeptide	496:509	arg1	identification					511:524	N-glycopeptide identification	496:524	N-glycopeptide identification	496:524	The Y-ion pattern, a series of Y-ions with known mass gaps derived from the penta-saccharide core structure of N-linked glycosylation, is exploited to facilitate N-glycopeptide identification from their spectra.
37341462	4	77	located	observed	692:699	arg2	patterns					662:669	the Y-ion patterns	652:669	the Y-ion patterns	652:669	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	4	77	located	observed	692:699	arg1	spectra					708:714	the spectra	704:714	the spectra of O-glycopeptides	704:733	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	0	78	dep	O-Search-Pattern	0:15	arg1	Tool					30:33	A Searching Tool	18:33	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.	0:146	O-Search-Pattern: A Searching Tool Utilizing the Y-Ion Pattern to Enhance O-Glycopeptide Identification for the Analysis of O-GalNAc Glycoproteome.
37341462	7	79	theme	serum	1234:1238	arg1	set					1245:1247	a human serum data set	1226:1247	a human serum data set	1226:1247	The new search strategy was applied to search a human serum data set, and 15.4%-199.0% more O-glycopeptide-spectrum matches (OGPSMs) and 19.6%-107.1% more glycopeptide sequence identifications than other state-of-the-art software tools were observed.
37341462	4	80	gly	O-glycopeptides	791:805	arg2	O-glycopeptides					791:805	O-glycopeptides	791:805	O-glycopeptides	791:805	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
37341462	8	81	theme	higher-energy	1645:1657	arg1	energy					1638:1643	stepped collision energy	1620:1643	stepped collision energy higher-energy collisional dissociation	1620:1682	This search mode, the O-Search-Pattern, has been implemented into our database search software, MS-Decipher, and is recommended for searching the O-glycopeptide spectra acquired by sceHCD (stepped collision energy higher-energy collisional dissociation).
37341462	4	82	gly	O-glycopeptides	719:733	arg2	O-glycopeptides					719:733	O-glycopeptides	719:733	O-glycopeptides	719:733	In this study, we found that the Y-ion patterns were also frequently observed in the spectra of O-glycopeptides, and a special search approach is presented to identify O-glycopeptides by utilizing the Y-ion patterns.
34611862	9	0	theme	available	980:988	arg1	tools					1002:1006	available informatics tools	980:1006	available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	980:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	1	theme	informatics	990:1000	arg1	tools					1002:1006	available informatics tools	980:1006	available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	980:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	6	2	theme	critical	657:664	arg1	bottleneck					666:675	a critical bottleneck	655:675	a critical bottleneck because data collection has increasingly become high-throughput	655:739	Of these, data analysis has emerged as a critical bottleneck because data collection has increasingly become high-throughput.
34611862	7	3	theme	rapid	793:797	arg1	analytics					818:826	rapid and automated data analytics	793:826	rapid and automated data analytics	793:826	This has resulted in data-rich workflows that lack rapid and automated data analytics.
34611862	4	4	dep	understanding	427:439	arg1	the					423:425	the	423:425	the	423:425	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	9	5	from	analysis	1034:1041	arg1	data					1024:1027	data	1024:1027	data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1024:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	5	from	analysis	1034:1041	arg1	analysis					1012:1019	analysis	1012:1019	analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1012:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	8	6	theme	studies	936:942	arg1	interpretation					895:908	interpretation	895:908	interpretation of quantitative glycomics studies	895:942	To address this issue, the field has been developing software for interpretation of quantitative glycomics studies.
34611862	8	7	theme	glycomics	926:934	arg1	studies					936:942	quantitative glycomics studies	913:942	quantitative glycomics studies	913:942	To address this issue, the field has been developing software for interpretation of quantitative glycomics studies.
34611862	9	8	theme	high-/ultraperformance	1069:1090	arg1	H/UPLC					1115:1120	H/UPLC	1115:1120	H/UPLC	1115:1120	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	8	theme	high-/ultraperformance	1069:1090	arg1	chromatography					1099:1112	high-/ultraperformance liquid chromatography	1069:1112	high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1069:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	9	theme	released	1046:1053	arg1	glycans					1055:1061	released glycans	1046:1061	released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1046:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	0	10	theme	Glycoinformatics	0:15	arg1	Tools					17:21	Glycoinformatics Tools	0:21	Glycoinformatics Tools for Comprehensive Characterization of Glycans	0:67	Glycoinformatics Tools for Comprehensive Characterization of Glycans Enzymatically Released from Proteins.
34611862	5	11	theme	sample	552:557	arg1	preparation					559:569	sample preparation	552:569	sample preparation	552:569	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	9	12	theme	data	1024:1027	arg1	analysis					1012:1019	analysis	1012:1019	analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1012:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	13	theme	liquid	1092:1097	arg1	H/UPLC					1115:1120	H/UPLC	1115:1120	H/UPLC	1115:1120	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	13	theme	liquid	1092:1097	arg1	chromatography					1099:1112	high-/ultraperformance liquid chromatography	1069:1112	high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1069:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	4	14	with	characterization	445:460	arg1	biology					506:512	biology	506:512	biology	506:512	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	1	15	from	biology	137:143	arg1	important					124:132	important	124:132	important	124:132	Glycosylation is important in biology, contributing to both protein conformation and function.
34611862	4	16	with	correlation	489:499	arg1	biology					506:512	biology	506:512	biology	506:512	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	0	17	theme	Comprehensive	27:39	arg1	Characterization					41:56	Comprehensive Characterization	27:56	Comprehensive Characterization of Glycans	27:67	Glycoinformatics Tools for Comprehensive Characterization of Glycans Enzymatically Released from Proteins.
34611862	4	18	with	understanding	427:439	arg1	biology					506:512	biology	506:512	biology	506:512	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	8	19	theme	quantitative	913:924	arg1	studies					936:942	quantitative glycomics studies	913:942	quantitative glycomics studies	913:942	To address this issue, the field has been developing software for interpretation of quantitative glycomics studies.
34611862	5	20	theme	analytical	527:536	arg1	measurements					583:594	instrument measurements	572:594	instrument measurements	572:594	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	5	20	theme	analytical	527:536	arg1	steps					538:542	analytical steps	527:542	analytical steps such as sample preparation, instrument measurements, and data analyses	527:613	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	5	20	theme	analytical	527:536	arg1	analyses					606:613	data analyses	601:613	data analyses	601:613	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	5	20	theme	analytical	527:536	arg1	preparation					559:569	sample preparation	552:569	sample preparation	552:569	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	6	21	theme	data	626:629	arg1	analysis					631:638	data analysis	626:638	data analysis	626:638	Of these, data analysis has emerged as a critical bottleneck because data collection has increasingly become high-throughput.
34611862	7	22	theme	data-rich	763:771	arg1	workflows					773:781	data-rich workflows	763:781	data-rich workflows that lack rapid and automated data analytics	763:826	This has resulted in data-rich workflows that lack rapid and automated data analytics.
34611862	9	23	from	analysis	1012:1019	arg1	analysis					1034:1041	analysis	1034:1041	analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1034:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	24	theme	glycans	1055:1061	arg1	analysis					1034:1041	analysis	1034:1041	analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS)	1034:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	5	25	theme	data	601:604	arg1	analyses					606:613	data analyses	601:613	data analyses	601:613	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	0	26	theme	Glycans	61:67	arg1	Characterization					41:56	Comprehensive Characterization	27:56	Comprehensive Characterization of Glycans	27:67	Glycoinformatics Tools for Comprehensive Characterization of Glycans Enzymatically Released from Proteins.
34611862	4	27	theme	complexity	470:479	arg1	characterization					445:460	characterization	445:460	characterization	445:460	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	4	27	theme	complexity	470:479	arg1	correlation					489:499	its correlation	485:499	its correlation with biology	485:512	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	4	27	theme	complexity	470:479	arg1	understanding					427:439	understanding	427:439	understanding	427:439	Glycoanalytics is a discipline that addresses the understanding and characterization of this complexity and its correlation with biology.
34611862	1	28	from	important	124:132	arg1	biology					137:143	biology	137:143	biology	137:143	Glycosylation is important in biology, contributing to both protein conformation and function.
34611862	3	29	theme	monosaccharide	313:326	arg1	linkages					328:335	monosaccharide linkages	313:335	monosaccharide linkages	313:335	This complexity is reflected in the topology, composition, monosaccharide linkages, and isomerism of each oligosaccharide.
34611862	6	30	dep	bottleneck	666:675	arg1	become					718:723	become	718:723	has increasingly become high-throughput	701:739	Of these, data analysis has emerged as a critical bottleneck because data collection has increasingly become high-throughput.
34611862	7	31	theme	data	813:816	arg1	analytics					818:826	rapid and automated data analytics	793:826	rapid and automated data analytics	793:826	This has resulted in data-rich workflows that lack rapid and automated data analytics.
34611862	9	32	theme	mass	1136:1139	arg1	MS					1155:1156	MS	1155:1156	MS	1155:1156	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	9	32	theme	mass	1136:1139	arg1	spectrometry					1141:1152	mass spectrometry	1136:1152	mass spectrometry (MS)	1136:1157	Here, we describe a protocol using available informatics tools for analysis of data from analysis of released glycans using high-/ultraperformance liquid chromatography (H/UPLC) coupled with mass spectrometry (MS).
34611862	5	33	theme	instrument	572:581	arg1	measurements					583:594	instrument measurements	572:594	instrument measurements	572:594	It includes analytical steps such as sample preparation, instrument measurements, and data analyses.
34611862	6	34	theme	data	685:688	arg1	collection					690:699	data collection	685:699	data collection	685:699	Of these, data analysis has emerged as a critical bottleneck because data collection has increasingly become high-throughput.
34611862	3	35	theme	oligosaccharide	360:374	arg1	composition					300:310	composition	300:310	composition	300:310	This complexity is reflected in the topology, composition, monosaccharide linkages, and isomerism of each oligosaccharide.
34611862	3	35	theme	oligosaccharide	360:374	arg1	linkages					328:335	monosaccharide linkages	313:335	monosaccharide linkages	313:335	This complexity is reflected in the topology, composition, monosaccharide linkages, and isomerism of each oligosaccharide.
34611862	3	35	theme	oligosaccharide	360:374	arg1	topology					290:297	topology	290:297	topology	290:297	This complexity is reflected in the topology, composition, monosaccharide linkages, and isomerism of each oligosaccharide.
34611862	3	35	theme	oligosaccharide	360:374	arg1	isomerism					342:350	isomerism	342:350	isomerism	342:350	This complexity is reflected in the topology, composition, monosaccharide linkages, and isomerism of each oligosaccharide.
34611862	1	36	theme	protein	167:173	arg1	conformation					175:186	protein conformation	167:186	protein conformation	167:186	Glycosylation is important in biology, contributing to both protein conformation and function.
34611862	7	37	theme	automated	803:811	arg1	analytics					818:826	rapid and automated data analytics	793:826	rapid and automated data analytics	793:826	This has resulted in data-rich workflows that lack rapid and automated data analytics.
35650982	2	0	theme	%	441:441	arg1	degree					409:414	the degree	405:414	the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively	405:542	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	1	1	theme	interfacial	308:318	arg1	properties					336:345	the structural, interfacial and emulsifying properties	292:345	the structural, interfacial and emulsifying properties of coconut protein isolate (CPI)	292:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	0	2	theme	coconut	159:165	arg1	isolate					175:181	coconut protein isolate	159:181	coconut protein isolate	159:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	2	3	theme	citrus	480:485	arg1	pectin					487:492	citrus pectin	480:492	citrus pectin	480:492	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	6	4	theme	sulfhydryl	1003:1012	arg1	content					1014:1020	soluble free sulfhydryl content	990:1020	soluble free sulfhydryl content	990:1020	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	0	5	theme	mango	58:62	arg1	pectin					64:69	mango pectin	58:69	mango pectin	58:69	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	4	6	theme	loose	794:798	arg1	structure					808:816	more flexible and loose protein structure	776:816	more flexible and loose protein structure	776:816	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	2	7	theme	sugar	512:516	arg1	beet					518:521	sugar beet	512:521	sugar beet	512:521	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	6	8	theme	free	998:1001	arg1	content					1014:1020	soluble free sulfhydryl content	990:1020	soluble free sulfhydryl content	990:1020	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	8	9	theme	pectin	1400:1405	arg1	CPI					1362:1364	CPI	1362:1364	CPI	1362:1364	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	8	9	theme	pectin	1400:1405	arg1	sources					1389:1395	the four different sources	1370:1395	the four different sources of pectin	1370:1405	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	0	10	theme	sugar	75:79	arg1	beet					81:84	sugar beet	75:84	sugar beet	75:84	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	11	from	Effect	0:5	arg1	properties					145:154	the physicochemical, interfacial and emulsifying properties	96:154	the physicochemical, interfacial and emulsifying properties of coconut protein isolate	96:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	12	theme	isolate	175:181	arg1	properties					145:154	the physicochemical, interfacial and emulsifying properties	96:154	the physicochemical, interfacial and emulsifying properties of coconut protein isolate	96:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	13	gly	glycosylation	10:22	arg1	isolate					175:181	coconut protein isolate	159:181	coconut protein isolate	159:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	5	14	theme	steric	862:867	arg1	hindrance					869:877	the strong steric hindrance	851:877	the strong steric hindrance	851:877	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	5	15	theme	strong	855:860	arg1	hindrance					869:877	the strong steric hindrance	851:877	the strong steric hindrance	851:877	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	1	16	theme	glycosylation	237:249	arg1	effect					227:232	the effect	223:232	the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI)	223:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	3	17	theme	FT-IR	642:646	arg1	spectra					648:654	FT-IR spectra	642:654	FT-IR spectra	642:654	The covalent bonding of the conjugates was further confirmed by SDS-PAGE gel electrophoresis and FT-IR spectra.
35650982	0	18	theme	protein	167:173	arg1	isolate					175:181	coconut protein isolate	159:181	coconut protein isolate	159:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	4	19	theme	CD	670:671	arg1	spectra					673:679	CD spectra	670:679	CD spectra	670:679	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	7	20	theme	interfacial	1232:1242	arg1	pressure					1244:1251	interfacial pressure	1232:1251	interfacial pressure	1232:1251	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	4	21	theme	more	745:748	arg1	coil					757:760	more random coil	745:760	more random coil	745:760	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	7	22	theme	rearrangement	1269:1281	arg1	rates					1283:1287	rearrangement rates	1269:1287	rearrangement rates of CPI at the oil-water interface	1269:1321	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	6	23	theme	soluble	990:996	arg1	content					1014:1020	soluble free sulfhydryl content	990:1020	soluble free sulfhydryl content	990:1020	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	2	24	theme	%	449:449	arg1	degree					409:414	the degree	405:414	the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively	405:542	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	1	25	theme	coconut	350:356	arg1	CPI					375:377	CPI	375:377	CPI	375:377	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	1	25	theme	coconut	350:356	arg1	isolate					366:372	coconut protein isolate	350:372	coconut protein isolate (CPI)	350:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	7	26	from	interface	1313:1321	arg1	adsorption					1254:1263	adsorption	1254:1263	adsorption	1254:1263	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	7	26	from	interface	1313:1321	arg1	rates					1283:1287	rearrangement rates	1269:1287	rearrangement rates of CPI at the oil-water interface	1269:1321	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	7	26	from	interface	1313:1321	arg1	pressure					1244:1251	interfacial pressure	1232:1251	interfacial pressure	1232:1251	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	2	27	theme	graft	419:423	arg1	degree					409:414	the degree	405:414	the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively	405:542	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	1	28	theme	protein	358:364	arg1	CPI					375:377	CPI	375:377	CPI	375:377	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	1	28	theme	protein	358:364	arg1	isolate					366:372	coconut protein isolate	350:372	coconut protein isolate (CPI)	350:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	5	29	theme	glycosylation	833:845	arg1	effects					879:885	glycosylation and the strong steric hindrance effects	833:885	glycosylation and the strong steric hindrance effects of pectin	833:895	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	4	30	theme	flexible	781:788	arg1	structure					808:816	more flexible and loose protein structure	776:816	more flexible and loose protein structure	776:816	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	8	31	theme	sugar	1496:1500	arg1	beet					1502:1505	sugar beet	1496:1505	sugar beet	1496:1505	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	2	32	theme	apple	466:470	arg1	pectin					472:477	apple pectin	466:477	apple pectin	466:477	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	4	33	theme	random	750:755	arg1	coil					757:760	more random coil	745:760	more random coil	745:760	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	6	34	theme	emulsifying	1072:1082	arg1	stability					1084:1092	emulsifying stability	1072:1092	emulsifying stability	1072:1092	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	1	35	theme	different	261:269	arg1	sources					271:277	four different sources	256:277	four different sources of pectin	256:287	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	1	36	gly	glycosylation	237:249	arg1	CPI					375:377	CPI	375:377	CPI	375:377	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	1	36	gly	glycosylation	237:249	arg1	isolate					366:372	coconut protein isolate	350:372	coconut protein isolate (CPI)	350:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	0	37	theme	glycosylation	10:22	arg1	Effect					0:5	Effect	0:5	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.	0:182	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	8	38	theme	citrus	1478:1483	arg1	pectin					1485:1490	citrus pectin	1478:1490	citrus pectin	1478:1490	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	1	39	theme	isolate	366:372	arg1	properties					336:345	the structural, interfacial and emulsifying properties	292:345	the structural, interfacial and emulsifying properties of coconut protein isolate (CPI)	292:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	2	40	theme	%	433:433	arg1	degree					409:414	the degree	405:414	the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively	405:542	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	5	41	theme	conjugates	928:937	arg1	intensity					911:919	fluorescence intensity	898:919	fluorescence intensity of the conjugates	898:937	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	5	42	theme	hindrance	869:877	arg1	effects					879:885	glycosylation and the strong steric hindrance effects	833:885	glycosylation and the strong steric hindrance effects of pectin	833:895	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	1	43	from	effect	227:232	arg1	properties					336:345	the structural, interfacial and emulsifying properties	292:345	the structural, interfacial and emulsifying properties of coconut protein isolate (CPI)	292:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	8	44	theme	emulsifying	1439:1449	arg1	properties					1451:1460	their emulsifying properties	1433:1460	their emulsifying properties	1433:1460	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	1	45	theme	present	188:194	arg1	study					196:200	The present study	184:200	The present study	184:200	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	0	46	theme	apple	29:33	arg1	pectin					35:40	apple pectin	29:40	apple pectin	29:40	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	1	47	theme	pectin	282:287	arg1	sources					271:277	four different sources	256:277	four different sources of pectin	256:287	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	0	48	theme	physicochemical	100:114	arg1	properties					145:154	the physicochemical, interfacial and emulsifying properties	96:154	the physicochemical, interfacial and emulsifying properties of coconut protein isolate	96:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	7	49	theme	CPI	1292:1294	arg1	adsorption					1254:1263	adsorption	1254:1263	adsorption	1254:1263	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	7	49	theme	CPI	1292:1294	arg1	rates					1283:1287	rearrangement rates	1269:1287	rearrangement rates of CPI at the oil-water interface	1269:1321	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	7	49	theme	CPI	1292:1294	arg1	pressure					1244:1251	interfacial pressure	1232:1251	interfacial pressure	1232:1251	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	1	50	with	glycosylation	237:249	arg1	sources					271:277	four different sources	256:277	four different sources of pectin	256:287	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	2	51	dep	pectin	472:477	arg1	pectin					523:528	pectin	523:528	pectin	523:528	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	0	52	theme	citrus	43:48	arg1	pectin					50:55	citrus pectin	43:55	citrus pectin	43:55	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	2	53	theme	%	460:460	arg1	degree					409:414	the degree	405:414	the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively	405:542	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	2	54	theme	mango	495:499	arg1	pectin					501:506	mango pectin	495:506	mango pectin	495:506	The conjugates achieved the degree of graft of 59.11%, 52.80%, 41.39% and 39.26% for apple pectin, citrus pectin, mango pectin and sugar beet pectin, respectively.
35650982	3	55	theme	covalent	549:556	arg1	bonding					558:564	The covalent bonding	545:564	The covalent bonding of the conjugates	545:582	The covalent bonding of the conjugates was further confirmed by SDS-PAGE gel electrophoresis and FT-IR spectra.
35650982	0	56	dep	pectin	35:40	arg1	pectin					86:91	pectin	86:91	pectin	86:91	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	57	with	glycosylation	10:22	arg1	pectin					35:40	apple pectin	29:40	apple pectin	29:40	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	57	with	glycosylation	10:22	arg1	pectin					50:55	citrus pectin	43:55	citrus pectin	43:55	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	57	with	glycosylation	10:22	arg1	pectin					64:69	mango pectin	58:69	mango pectin	58:69	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	0	57	with	glycosylation	10:22	arg1	beet					81:84	sugar beet	75:84	sugar beet	75:84	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	6	58	theme	emulsifying	1047:1057	arg1	activity					1059:1066	emulsifying activity	1047:1066	emulsifying activity	1047:1066	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	1	59	theme	emulsifying	324:334	arg1	properties					336:345	the structural, interfacial and emulsifying properties	292:345	the structural, interfacial and emulsifying properties of coconut protein isolate (CPI)	292:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	6	60	theme	conjugates	1101:1110	arg1	content					1014:1020	soluble free sulfhydryl content	990:1020	soluble free sulfhydryl content	990:1020	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	6	60	theme	conjugates	1101:1110	arg1	solubility					978:987	solubility	978:987	solubility	978:987	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	6	60	theme	conjugates	1101:1110	arg1	activity					1059:1066	emulsifying activity	1047:1066	emulsifying activity	1047:1066	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	6	60	theme	conjugates	1101:1110	arg1	stability					1084:1092	emulsifying stability	1072:1092	emulsifying stability	1072:1092	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	6	60	theme	conjugates	1101:1110	arg1	hydrophobicity					1031:1044	surface hydrophobicity	1023:1044	surface hydrophobicity	1023:1044	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	0	61	theme	interfacial	117:127	arg1	properties					145:154	the physicochemical, interfacial and emulsifying properties	96:154	the physicochemical, interfacial and emulsifying properties of coconut protein isolate	96:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	8	62	theme	different	1379:1387	arg1	sources					1389:1395	the four different sources	1370:1395	the four different sources of pectin	1370:1405	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	1	63	theme	structural	296:305	arg1	properties					336:345	the structural, interfacial and emulsifying properties	292:345	the structural, interfacial and emulsifying properties of coconut protein isolate (CPI)	292:378	The present study aimed to investigate the effect of glycosylation with four different sources of pectin on the structural, interfacial and emulsifying properties of coconut protein isolate (CPI).
35650982	4	64	theme	protein	800:806	arg1	structure					808:816	more flexible and loose protein structure	776:816	more flexible and loose protein structure	776:816	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	5	65	theme	pectin	890:895	arg1	effects					879:885	glycosylation and the strong steric hindrance effects	833:885	glycosylation and the strong steric hindrance effects of pectin	833:895	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	4	66	contain	had	711:713	arg2	β-sheet					732:738	β-sheet	732:738	β-sheet	732:738	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	4	66	contain	had	711:713	arg1	conjugates					700:709	the conjugates	696:709	the conjugates	696:709	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	4	66	contain	had	711:713	arg2	α-helix					720:726	α-helix	720:726	α-helix	720:726	In addition, CD spectra exhibited that the conjugates had less α-helix and β-sheet, and more random coil, resulting in more flexible and loose protein structure.
35650982	0	67	theme	emulsifying	133:143	arg1	properties					145:154	the physicochemical, interfacial and emulsifying properties	96:154	the physicochemical, interfacial and emulsifying properties of coconut protein isolate	96:181	Effect of glycosylation with apple pectin, citrus pectin, mango pectin and sugar beet pectin on the physicochemical, interfacial and emulsifying properties of coconut protein isolate.
35650982	8	68	contain	have	1514:1517	arg1	pectin					1485:1490	citrus pectin	1478:1490	citrus pectin	1478:1490	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	8	68	contain	have	1514:1517	arg2	effects					1536:1542	more significant effects	1519:1542	more significant effects	1519:1542	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	8	68	contain	have	1514:1517	arg1	beet					1502:1505	sugar beet	1496:1505	sugar beet	1496:1505	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	6	69	theme	surface	1023:1029	arg1	hydrophobicity					1031:1044	surface hydrophobicity	1023:1044	surface hydrophobicity	1023:1044	Moreover, the solubility, soluble free sulfhydryl content, surface hydrophobicity, emulsifying activity and emulsifying stability of the conjugates improved significantly after glycosylation.
35650982	3	70	theme	conjugates	573:582	arg1	bonding					558:564	The covalent bonding	545:564	The covalent bonding of the conjugates	545:582	The covalent bonding of the conjugates was further confirmed by SDS-PAGE gel electrophoresis and FT-IR spectra.
35650982	5	71	theme	fluorescence	898:909	arg1	intensity					911:919	fluorescence intensity	898:919	fluorescence intensity of the conjugates	898:937	Attributed to glycosylation and the strong steric hindrance effects of pectin, fluorescence intensity of the conjugates decreased significantly.
35650982	8	72	dep	pectin	1485:1490	arg1	pectin					1507:1512	pectin	1507:1512	pectin	1507:1512	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35650982	7	73	theme	adsorption	1171:1180	arg1	kinetics					1182:1189	adsorption kinetics	1171:1189	adsorption kinetics	1171:1189	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	3	74	theme	SDS-PAGE	609:616	arg1	electrophoresis					622:636	SDS-PAGE gel electrophoresis	609:636	SDS-PAGE gel electrophoresis	609:636	The covalent bonding of the conjugates was further confirmed by SDS-PAGE gel electrophoresis and FT-IR spectra.
35650982	7	75	theme	oil-water	1303:1311	arg1	interface					1313:1321	the oil-water interface	1299:1321	the oil-water interface	1299:1321	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	3	76	theme	gel	618:620	arg1	electrophoresis					622:636	SDS-PAGE gel electrophoresis	609:636	SDS-PAGE gel electrophoresis	609:636	The covalent bonding of the conjugates was further confirmed by SDS-PAGE gel electrophoresis and FT-IR spectra.
35650982	7	77	theme	kinetics	1182:1189	arg1	results					1160:1166	The results	1156:1166	The results of adsorption kinetics	1156:1189	The results of adsorption kinetics showed that glycosylation could increase interfacial pressure, adsorption and rearrangement rates of CPI at the oil-water interface.
35650982	8	78	theme	significant	1524:1534	arg1	effects					1536:1542	more significant effects	1519:1542	more significant effects	1519:1542	In summary, the glycosylation between CPI and the four different sources of pectin can significantly improve their emulsifying properties, in particular, citrus pectin and sugar beet pectin have more significant effects.
35413075	4	0	theme	pancreatic	557:566	arg1	cancer					568:573	pancreatic cancer	557:573	pancreatic cancer	557:573	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	6	1	theme	increased	820:828	arg1	levels					830:835	increased levels	820:835	increased levels of glycans in some cancer patients	820:870	Comparison of the glycan profiles revealed increased levels of glycans in some cancer patients.
35413075	4	2	with	patients	527:534	arg1	cholangiocarcinoma					576:593	cholangiocarcinoma	576:593	cholangiocarcinoma	576:593	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	4	2	with	patients	527:534	arg1	cancer					549:554	gastric cancer	541:554	gastric cancer	541:554	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	4	2	with	patients	527:534	arg1	cancer					568:573	pancreatic cancer	557:573	pancreatic cancer	557:573	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	4	2	with	patients	527:534	arg1	cancer					610:615	colorectal cancer	599:615	colorectal cancer	599:615	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	7	3	theme	Structural	873:882	arg1	analysis					884:891	Structural analysis	873:891	Structural analysis of the glycans	873:906	Structural analysis of the glycans was carried out by performing chromatography and mass spectrometry together with enzymatic or chemical treatments.
35413075	6	4	theme	profiles	802:809	arg1	Comparison					777:786	Comparison	777:786	Comparison of the glycan profiles	777:809	Comparison of the glycan profiles revealed increased levels of glycans in some cancer patients.
35413075	0	5	theme	Increased	0:8	arg1	levels					10:15	Increased levels	0:15	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.	0:128	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	1	6	theme	urinary	171:177	arg1	free-glycans					179:190	urinary free-glycans	171:190	urinary free-glycans	171:190	We recently reported increased levels of urinary free-glycans in some cancer patients.
35413075	13	7	theme	processing	2061:2070	arg1	pathways					2072:2079	their processing pathways	2055:2079	their processing pathways in cancer	2055:2089	This study provides further insights into free-glycans as potential tumor markers and their processing pathways in cancer.
35413075	2	8	theme	weight	296:301	arg1	free-glycans					303:314	high molecular weight free-glycans	281:314	high molecular weight free-glycans	281:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	13	9	from	markers	2043:2049	arg1	cancer					2084:2089	cancer	2084:2089	cancer	2084:2089	This study provides further insights into free-glycans as potential tumor markers and their processing pathways in cancer.
35413075	0	10	theme	cancer	113:118	arg1	patients					120:127	cancer patients	113:127	cancer patients	113:127	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	2	11	theme	high	281:284	arg1	weight					296:301	high molecular weight	281:301	high molecular weight free-glycans	281:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	1	12	theme	cancer	200:205	arg1	patients					207:214	some cancer patients	195:214	some cancer patients	195:214	We recently reported increased levels of urinary free-glycans in some cancer patients.
35413075	4	13	theme	normal	621:626	arg1	controls					628:635	normal controls	621:635	normal controls	621:635	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	5	14	theme	extracted	656:664	arg1	free-glycans					666:677	The extracted free-glycans	652:677	The extracted free-glycans	652:677	The extracted free-glycans were fluorescently labeled with 2-aminopyridine and analyzed by multi-step liquid chromatography.
35413075	13	15	from	pathways	2072:2079	arg1	cancer					2084:2089	cancer	2084:2089	cancer	2084:2089	This study provides further insights into free-glycans as potential tumor markers and their processing pathways in cancer.
35413075	12	16	theme	tri-antennary	1790:1802	arg1	free-N-glycan					1804:1816	one tri-antennary free-N-glycan	1786:1816	one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients	1786:1873	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	13	17	theme	potential	2027:2035	arg1	markers					2043:2049	potential tumor markers	2027:2049	potential tumor markers	2027:2049	This study provides further insights into free-glycans as potential tumor markers and their processing pathways in cancer.
35413075	2	18	theme	related	244:250	arg1	alterations					252:262	cancer related alterations	237:262	cancer related alterations in the levels of high molecular weight free-glycans	237:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	7	19	theme	chemical	1002:1009	arg1	treatments					1011:1020	enzymatic or chemical treatments	989:1020	enzymatic or chemical treatments	989:1020	Structural analysis of the glycans was carried out by performing chromatography and mass spectrometry together with enzymatic or chemical treatments.
35413075	3	20	gly	sialylation	395:405	arg1	cancer					500:505	cancer	500:505	cancer	500:505	The rationale for this study was that branching, elongation, fucosylation and sialylation, which lead to increases in the molecular weight of glycans, are known to be up-regulated in cancer.
35413075	7	21	theme	enzymatic	989:997	arg1	treatments					1011:1020	enzymatic or chemical treatments	989:1020	enzymatic or chemical treatments	989:1020	Structural analysis of the glycans was carried out by performing chromatography and mass spectrometry together with enzymatic or chemical treatments.
35413075	8	22	theme	high	1069:1072	arg1	sensitivity					1074:1084	high sensitivity	1069:1084	high sensitivity	1069:1084	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	0	23	gly	fucosylated	73:83	arg1	structures					85:94	fucosylated structures	73:94	fucosylated structures	73:94	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	5	24	theme	multi-step	743:752	arg1	chromatography					761:774	multi-step liquid chromatography	743:774	multi-step liquid chromatography	743:774	The extracted free-glycans were fluorescently labeled with 2-aminopyridine and analyzed by multi-step liquid chromatography.
35413075	9	25	theme	tetra-antennary	1385:1399	arg1	structures					1414:1423	tetra-antennary complex-type structures	1385:1423	tetra-antennary complex-type structures	1385:1423	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	7	26	theme	mass	957:960	arg1	spectrometry					962:973	mass spectrometry	957:973	mass spectrometry	957:973	Structural analysis of the glycans was carried out by performing chromatography and mass spectrometry together with enzymatic or chemical treatments.
35413075	10	27	theme	α2,6-sialylated	1517:1531	arg1	structures					1547:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	0	28	theme	fucosylated	73:83	arg1	structures					85:94	fucosylated structures	73:94	fucosylated structures	73:94	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	4	29	from	patients	527:534	arg1	samples					514:520	Urine samples	508:520	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls	508:635	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	11	30	theme	simple	1641:1646	arg1	α2,3-sialylation					1648:1663	α2,3-sialylation	1648:1663	α2,3-sialylation	1648:1663	However, simple α2,3-sialylation and α1,6-core-fucosylation did not appear to contribute to the observed increase in the level of glycans.
35413075	6	31	from	levels	830:835	arg1	patients					863:870	some cancer patients	851:870	some cancer patients	851:870	Comparison of the glycan profiles revealed increased levels of glycans in some cancer patients.
35413075	10	32	theme	Man3	1568:1571	arg1	GlcNAc1-core					1573:1584	a (Man3)GlcNAc1-core	1565:1584	a (Man3)GlcNAc1-core	1565:1584	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	3	33	theme	molecular	439:447	arg1	weight					449:454	the molecular weight	435:454	the molecular weight of glycans	435:465	The rationale for this study was that branching, elongation, fucosylation and sialylation, which lead to increases in the molecular weight of glycans, are known to be up-regulated in cancer.
35413075	2	34	from	alterations	252:262	arg1	levels					271:276	the levels	267:276	the levels of high molecular weight free-glycans	267:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	12	35	from	elevation	1841:1849	arg1	patients					1866:1873	some cancer patients	1854:1873	some cancer patients	1854:1873	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	10	36	gly	α1,3-fucosylation	1468:1484	arg1	glycans					1455:1461	glycans	1455:1461	glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core	1455:1584	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	0	37	theme	free-N-glycans	27:40	arg1	levels					10:15	Increased levels	0:15	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.	0:128	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	8	38	theme	reversed-phase	1132:1145	arg1	monitoring					1182:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	10	39	theme	elevated	1596:1603	arg1	levels					1605:1610	elevated levels	1596:1610	elevated levels in cancer patients	1596:1629	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	4	40	with	controls	628:635	arg1	cholangiocarcinoma					576:593	cholangiocarcinoma	576:593	cholangiocarcinoma	576:593	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	4	40	with	controls	628:635	arg1	cancer					549:554	gastric cancer	541:554	gastric cancer	541:554	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	4	40	with	controls	628:635	arg1	cancer					568:573	pancreatic cancer	557:573	pancreatic cancer	557:573	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	4	40	with	controls	628:635	arg1	cancer					610:615	colorectal cancer	599:615	colorectal cancer	599:615	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	8	41	theme	chromatography-selected	1154:1176	arg1	monitoring					1182:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	6	42	theme	cancer	856:861	arg1	patients					863:870	some cancer patients	851:870	some cancer patients	851:870	Comparison of the glycan profiles revealed increased levels of glycans in some cancer patients.
35413075	12	43	theme	remarkable	1830:1839	arg1	elevation					1841:1849	remarkable elevation	1830:1849	remarkable elevation in some cancer patients	1830:1873	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	12	44	theme	reducing	1955:1962	arg1	end					1964:1966	the reducing end	1951:1966	the reducing end	1951:1966	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	12	45	theme	unique	1887:1892	arg1	Glcβ1-4GlcNAc-core					1894:1911	a unique Glcβ1-4GlcNAc-core	1885:1911	a unique Glcβ1-4GlcNAc-core	1885:1911	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	10	46	with	glycans	1455:1461	arg1	α1,3-fucosylation					1468:1484	α1,3-fucosylation	1468:1484	α1,3-fucosylation ((+/- sialyl) Lewis X)	1468:1507	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	46	with	glycans	1455:1461	arg1	GlcNAc1-core					1573:1584	a (Man3)GlcNAc1-core	1565:1584	a (Man3)GlcNAc1-core	1565:1584	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	46	with	glycans	1455:1461	arg1	X					1506:1506	(+/- sialyl) Lewis X	1487:1506	X	1506:1506	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	46	with	glycans	1455:1461	arg1	structures					1547:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	3	47	from	increases	422:430	arg1	weight					449:454	the molecular weight	435:454	the molecular weight of glycans	435:465	The rationale for this study was that branching, elongation, fucosylation and sialylation, which lead to increases in the molecular weight of glycans, are known to be up-regulated in cancer.
35413075	12	48	theme	cancer	1859:1864	arg1	patients					1866:1873	some cancer patients	1854:1873	some cancer patients	1854:1873	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	4	49	theme	gastric	541:547	arg1	cancer					549:554	gastric cancer	541:554	gastric cancer	541:554	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	10	50	theme	sialyl	1492:1497	arg1	α1,3-fucosylation					1468:1484	α1,3-fucosylation	1468:1484	α1,3-fucosylation ((+/- sialyl) Lewis X)	1468:1507	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	50	theme	sialyl	1492:1497	arg1	X					1506:1506	(+/- sialyl) Lewis X	1487:1506	X	1506:1506	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	9	51	theme	lactose-core	1254:1265	arg1	result					1240:1245	a result	1238:1245	a result	1238:1245	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	9	51	theme	lactose-core	1254:1265	arg1	glycans					1267:1273	three lactose-core glycans	1248:1273	three lactose-core glycans	1248:1273	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	9	51	theme	lactose-core	1254:1265	arg1	free-N-glycans					1282:1295	78 free-N-glycans	1279:1295	78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures)	1279:1424	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	8	52	theme	glycan	1034:1039	arg1	levels					1041:1046	glycan levels	1034:1046	glycan levels between samples	1034:1062	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	6	53	theme	glycan	795:800	arg1	profiles					802:809	the glycan profiles	791:809	the glycan profiles	791:809	Comparison of the glycan profiles revealed increased levels of glycans in some cancer patients.
35413075	2	54	theme	free-glycans	303:314	arg1	levels					271:276	the levels	267:276	the levels of high molecular weight free-glycans	267:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	4	55	from	controls	628:635	arg1	samples					514:520	Urine samples	508:520	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls	508:635	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	1	56	theme	free-glycans	179:190	arg1	levels					161:166	increased levels	151:166	increased levels of urinary free-glycans in some cancer patients	151:214	We recently reported increased levels of urinary free-glycans in some cancer patients.
35413075	0	57	theme	patients	120:127	arg1	urine					104:108	the urine	100:108	the urine of cancer patients	100:127	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	2	58	theme	molecular	286:294	arg1	weight					296:301	high molecular weight	281:301	high molecular weight free-glycans	281:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	4	59	theme	colorectal	599:608	arg1	cancer					610:615	colorectal cancer	599:615	colorectal cancer	599:615	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	13	60	theme	tumor	2037:2041	arg1	markers					2043:2049	potential tumor markers	2027:2049	potential tumor markers	2027:2049	This study provides further insights into free-glycans as potential tumor markers and their processing pathways in cancer.
35413075	5	61	theme	liquid	754:759	arg1	chromatography					761:774	multi-step liquid chromatography	743:774	multi-step liquid chromatography	743:774	The extracted free-glycans were fluorescently labeled with 2-aminopyridine and analyzed by multi-step liquid chromatography.
35413075	2	62	theme	cancer	237:242	arg1	alterations					252:262	cancer related alterations	237:262	cancer related alterations in the levels of high molecular weight free-glycans	237:314	Here, we focused on cancer related alterations in the levels of high molecular weight free-glycans.
35413075	13	63	theme	further	1989:1995	arg1	insights					1997:2004	further insights	1989:2004	further insights into free-glycans as potential tumor markers and their processing pathways in cancer	1989:2089	This study provides further insights into free-glycans as potential tumor markers and their processing pathways in cancer.
35413075	1	64	theme	increased	151:159	arg1	levels					161:166	increased levels	151:166	increased levels of urinary free-glycans in some cancer patients	151:214	We recently reported increased levels of urinary free-glycans in some cancer patients.
35413075	9	65	dep	free-N-glycans	1282:1295	arg1	bi-					1371:1373	73 bi-	1368:1373	73 bi-	1368:1373	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	9	65	dep	free-N-glycans	1282:1295	arg1	oligomannose-type					1317:1333	oligomannose-type	1317:1333	oligomannose-type	1317:1333	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	9	65	dep	free-N-glycans	1282:1295	arg1	free-N-glycans					1282:1295	78 free-N-glycans	1279:1295	78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures)	1279:1424	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	9	65	dep	free-N-glycans	1282:1295	arg1	hybrid-type					1352:1362	hybrid-type	1352:1362	hybrid-type	1352:1362	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	0	66	from	levels	10:15	arg1	urine					104:108	the urine	100:108	the urine of cancer patients	100:127	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	3	67	gly	fucosylation	378:389	arg1	cancer					500:505	cancer	500:505	cancer	500:505	The rationale for this study was that branching, elongation, fucosylation and sialylation, which lead to increases in the molecular weight of glycans, are known to be up-regulated in cancer.
35413075	12	68	contain	contained	1875:1883	arg2	free-N-glycan					1804:1816	one tri-antennary free-N-glycan	1786:1816	one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients	1786:1873	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	12	68	contain	contained	1875:1883	arg1	end					1964:1966	the reducing end	1951:1966	the reducing end	1951:1966	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	12	68	contain	contained	1875:1883	arg1	free-N-glycan					1804:1816	one tri-antennary free-N-glycan	1786:1816	one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients	1786:1873	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	12	68	contain	contained	1875:1883	arg2	Glcβ1-4GlcNAc-core					1894:1911	a unique Glcβ1-4GlcNAc-core	1885:1911	a unique Glcβ1-4GlcNAc-core	1885:1911	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	1	69	from	levels	161:166	arg1	patients					207:214	some cancer patients	195:214	some cancer patients	195:214	We recently reported increased levels of urinary free-glycans in some cancer patients.
35413075	10	70	theme	Lewis	1500:1504	arg1	α1,3-fucosylation					1468:1484	α1,3-fucosylation	1468:1484	α1,3-fucosylation ((+/- sialyl) Lewis X)	1468:1507	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	70	theme	Lewis	1500:1504	arg1	X					1506:1506	(+/- sialyl) Lewis X	1487:1506	X	1506:1506	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	71	theme	tri-antennary	1533:1545	arg1	structures					1547:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	9	72	theme	complex-type	1401:1412	arg1	structures					1414:1423	tetra-antennary complex-type structures	1385:1423	tetra-antennary complex-type structures	1385:1423	As a result, three lactose-core glycans and 78 free-N-glycans (one phosphorylated oligomannose-type, four sialylated hybrid-type and 73 bi-, tri- and tetra-antennary complex-type structures) were identified.
35413075	8	73	theme	simultaneous	1103:1114	arg1	measurements					1116:1127	simultaneous measurements	1103:1127	simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry	1103:1212	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	0	74	theme	acidic	20:25	arg1	structures					85:94	fucosylated structures	73:94	fucosylated structures	73:94	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	0	74	theme	acidic	20:25	arg1	free-N-glycans					27:40	acidic free-N-glycans	20:40	acidic free-N-glycans	20:40	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	0	74	theme	acidic	20:25	arg1	multi-antennary					53:67	multi-antennary	53:67	multi-antennary	53:67	Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients.
35413075	8	75	theme	liquid	1147:1152	arg1	monitoring					1182:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	10	76	from	levels	1605:1610	arg1	patients					1622:1629	cancer patients	1615:1629	cancer patients	1615:1629	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	11	77	theme	glycans	1762:1768	arg1	level					1753:1757	the level	1749:1757	the level of glycans	1749:1768	However, simple α2,3-sialylation and α1,6-core-fucosylation did not appear to contribute to the observed increase in the level of glycans.
35413075	8	78	theme	ion	1178:1180	arg1	monitoring					1182:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	reversed-phase liquid chromatography-selected ion monitoring	1132:1191	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	8	79	theme	mass	1196:1199	arg1	spectrometry					1201:1212	mass spectrometry	1196:1212	mass spectrometry	1196:1212	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	11	80	from	increase	1737:1744	arg1	level					1753:1757	the level	1749:1757	the level of glycans	1749:1768	However, simple α2,3-sialylation and α1,6-core-fucosylation did not appear to contribute to the observed increase in the level of glycans.
35413075	4	81	theme	Urine	508:512	arg1	samples					514:520	Urine samples	508:520	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls	508:635	Urine samples from patients with gastric cancer, pancreatic cancer, cholangiocarcinoma and colorectal cancer and normal controls were analyzed.
35413075	12	82	theme	common	1928:1933	arg1	GlcNAc2-core					1935:1946	the common GlcNAc2-core	1924:1946	the common GlcNAc2-core	1924:1946	Interestingly, one tri-antennary free-N-glycan that showed remarkable elevation in some cancer patients contained a unique Glcβ1-4GlcNAc-core instead of the common GlcNAc2-core at the reducing end.
35413075	3	83	theme	glycans	459:465	arg1	weight					449:454	the molecular weight	435:454	the molecular weight of glycans	435:465	The rationale for this study was that branching, elongation, fucosylation and sialylation, which lead to increases in the molecular weight of glycans, are known to be up-regulated in cancer.
35413075	8	84	theme	spectrometry	1201:1212	arg1	measurements					1116:1127	simultaneous measurements	1103:1127	simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry	1103:1212	To compare glycan levels between samples with high sensitivity and selectivity, simultaneous measurements by reversed-phase liquid chromatography-selected ion monitoring of mass spectrometry were also performed.
35413075	6	85	theme	glycans	840:846	arg1	levels					830:835	increased levels	820:835	increased levels of glycans in some cancer patients	820:870	Comparison of the glycan profiles revealed increased levels of glycans in some cancer patients.
35413075	10	86	gly	α2,6-sialylated	1517:1531	arg1	structures					1547:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	triply α2,6-sialylated tri-antennary structures	1510:1556	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	10	87	theme	cancer	1615:1620	arg1	patients					1622:1629	cancer patients	1615:1629	cancer patients	1615:1629	Among them, glycans with α1,3-fucosylation ((+/- sialyl) Lewis X), triply α2,6-sialylated tri-antennary structures and/or a (Man3)GlcNAc1-core displayed elevated levels in cancer patients.
35413075	11	88	theme	observed	1728:1735	arg1	increase					1737:1744	the observed increase	1724:1744	the observed increase in the level of glycans	1724:1768	However, simple α2,3-sialylation and α1,6-core-fucosylation did not appear to contribute to the observed increase in the level of glycans.
35413075	7	89	theme	glycans	900:906	arg1	analysis					884:891	Structural analysis	873:891	Structural analysis of the glycans	873:906	Structural analysis of the glycans was carried out by performing chromatography and mass spectrometry together with enzymatic or chemical treatments.
37028137	0	0	theme	bilirubin	78:86	arg1	bioelectrocatalysts					96:114	bilirubin oxidase bioelectrocatalysts	78:114	bilirubin oxidase bioelectrocatalysts	78:114	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	5	1	theme	individual	712:721	arg1	unclear					869:875	unclear	869:875	unclear	869:875	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	1	theme	individual	712:721	arg1	function					723:730	the individual function	708:730	the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions	708:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	9	2	theme	binding	1422:1428	arg1	site					1430:1433	the original binding site	1409:1433	the original binding site	1409:1433	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	1	3	theme	electron	226:233	arg1	transfer					235:242	direct electron transfer	219:242	direct electron transfer (DET)	219:248	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	1	3	theme	electron	226:233	arg1	DET					245:247	DET	245:247	DET	245:247	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	5	4	from	N-glycans	743:751	arg1	reactions					849:857	DET-type reactions	840:857	DET-type reactions	840:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	7	5	theme	specific	1077:1084	arg1	binding					1086:1092	specific binding	1077:1092	specific binding of maleimide to Cys residues	1077:1121	Site-specific enzyme-PEG crosslinking was carried out by specific binding of maleimide to Cys residues.
37028137	2	6	contain	has	381:383	arg2	activity					396:403	strong DET activity	385:403	strong DET activity	385:403	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	2	6	contain	has	381:383	arg1	BOD					314:316	BOD	314:316	BOD from Myrothecium verrucaria (mBOD)	314:351	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	1	7	theme	transfer	235:242	arg1	capable					208:214	capable	208:214	capable	208:214	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	9	8	dep	modification	1393:1404	arg1	mimic					1387:1391	mimic	1387:1391	mimic	1387:1391	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	8	9	contain	have	1193:1196	arg2	system					1214:1219	a glycosylation system	1198:1219	a glycosylation system	1198:1219	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	8	9	contain	have	1193:1196	arg1	eBOD					1171:1174	eBOD	1171:1174	eBOD	1171:1174	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	8	9	contain	have	1193:1196	arg1	coli					1165:1168	Escherichia coli	1153:1168	Escherichia coli (eBOD)	1153:1175	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	3	10	theme	T1	496:497	arg1	Cu					499:500	T1 Cu	496:500	T1 Cu	496:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	6	11	theme	polyethylene	929:940	arg1	glycol					942:947	maleimide-functionalized polyethylene glycol	904:947	maleimide-functionalized polyethylene glycol (MAL-PEG)	904:957	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	6	11	theme	polyethylene	929:940	arg1	N-glycan					965:972	N-glycan	965:972	N-glycan	965:972	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	6	11	theme	polyethylene	929:940	arg1	MAL-PEG					950:956	MAL-PEG	950:956	MAL-PEG	950:956	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	0	12	theme	oxidase	88:94	arg1	bioelectrocatalysts					96:114	bilirubin oxidase bioelectrocatalysts	78:114	bilirubin oxidase bioelectrocatalysts	78:114	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	5	13	from	effects	761:767	arg1	reactions					849:857	DET-type reactions	840:857	DET-type reactions	840:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	6	14	dep	N-glycan	965:972	arg1	mimic					974:978	mimic	974:978	mimic	974:978	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	3	15	theme	distal	486:491	arg1	sites					480:484	N472 and N482 binding sites	458:484	N472 and N482 binding sites distal to T1 Cu	458:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	9	16	theme	site-specific	1366:1378	arg1	modification					1393:1404	site-specific glycan mimic modification	1366:1404	site-specific glycan mimic modification to the original binding site	1366:1433	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	6	17	theme	maleimide-functionalized	904:927	arg1	glycol					942:947	maleimide-functionalized polyethylene glycol	904:947	maleimide-functionalized polyethylene glycol (MAL-PEG)	904:957	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	6	17	theme	maleimide-functionalized	904:927	arg1	N-glycan					965:972	N-glycan	965:972	N-glycan	965:972	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	6	17	theme	maleimide-functionalized	904:927	arg1	MAL-PEG					950:956	MAL-PEG	950:956	MAL-PEG	950:956	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	8	18	theme	Recombinant	1124:1134	arg1	benchmark					1236:1244	a benchmark	1234:1244	a benchmark	1234:1244	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	8	18	theme	Recombinant	1124:1134	arg1	BOD					1136:1138	Recombinant BOD	1124:1138	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system,	1124:1220	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	9	19	dep	residue	1303:1309	arg1	N482					1320:1323	N482	1320:1323	N482	1320:1323	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	9	19	dep	residue	1303:1309	arg1	N472					1312:1315	N472	1312:1315	N472	1312:1315	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	9	20	theme	glycan	1380:1385	arg1	modification					1393:1404	site-specific glycan mimic modification	1366:1404	site-specific glycan mimic modification to the original binding site	1366:1433	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	5	21	theme	N-glycans	743:751	arg1	unclear					869:875	unclear	869:875	unclear	869:875	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	21	theme	N-glycans	743:751	arg1	function					723:730	the individual function	708:730	the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions	708:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	3	22	with	glycans	433:439	arg1	sites					480:484	N472 and N482 binding sites	458:484	N472 and N482 binding sites distal to T1 Cu	458:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	3	23	theme	binding	472:478	arg1	sites					480:484	N472 and N482 binding sites	458:484	N472 and N482 binding sites distal to T1 Cu	458:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	7	24	theme	Site-specific	1020:1032	arg1	crosslinking					1045:1056	Site-specific enzyme-PEG crosslinking	1020:1056	Site-specific enzyme-PEG crosslinking	1020:1056	Site-specific enzyme-PEG crosslinking was carried out by specific binding of maleimide to Cys residues.
37028137	6	25	theme	aforementioned	996:1009	arg1	effects					1011:1017	the aforementioned effects	992:1017	the aforementioned effects	992:1017	In this study, we utilize maleimide-functionalized polyethylene glycol (MAL-PEG) as an N-glycan mimic to evaluate the aforementioned effects.
37028137	2	26	theme	DET	392:394	arg1	activity					396:403	strong DET activity	385:403	strong DET activity	385:403	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	7	27	theme	enzyme-PEG	1034:1043	arg1	crosslinking					1045:1056	Site-specific enzyme-PEG crosslinking	1020:1056	Site-specific enzyme-PEG crosslinking	1020:1056	Site-specific enzyme-PEG crosslinking was carried out by specific binding of maleimide to Cys residues.
37028137	2	28	from	verrucaria	335:344	arg1	BOD					314:316	BOD	314:316	BOD from Myrothecium verrucaria (mBOD)	314:351	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	4	29	theme	deglycosylation	675:689	arg1	method					691:696	the deglycosylation method	671:696	the deglycosylation method	671:696	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	2	30	theme	strong	385:390	arg1	activity					396:403	strong DET activity	385:403	strong DET activity	385:403	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	1	31	theme	-type	249:253	arg1	bioelectrocatalysis					255:273	capable of direct electron transfer (DET)-type bioelectrocatalysis	208:273	capable of direct electron transfer (DET)-type bioelectrocatalysis	208:273	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	5	32	from	reactions	849:857	arg1	unclear					869:875	unclear	869:875	unclear	869:875	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	32	from	reactions	849:857	arg1	function					723:730	the individual function	708:730	the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions	708:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	4	33	from	orientation	584:594	arg1	electrode					603:611	the electrode	599:611	the electrode	599:611	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	4	34	theme	enzymatic	574:582	arg1	orientation					584:594	the enzymatic orientation	570:594	the enzymatic orientation on the electrode	570:611	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	0	35	theme	distal	13:18	arg1	glycan					20:25	distal glycan	13:25	distal glycan	13:25	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	9	36	theme	original	1413:1420	arg1	site					1430:1433	the original binding site	1409:1433	the original binding site	1409:1433	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	1	37	theme	Bilirubin	117:125	arg1	BOD					136:138	BOD	136:138	BOD	136:138	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	1	37	theme	Bilirubin	117:125	arg1	oxidase					127:133	Bilirubin oxidase	117:133	Bilirubin oxidase (BOD)	117:139	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	1	37	theme	Bilirubin	117:125	arg1	bioelectrocatalyst					146:163	a bioelectrocatalyst	144:163	a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu)	144:311	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	9	38	used	utilized	1346:1353	arg2	mutagenesis					1284:1294	Site-directed mutagenesis	1270:1294	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue	1270:1341	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	5	39	theme	composition	781:791	arg1	N-glycans					743:751	the two N-glycans	735:751	the two N-glycans	735:751	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	39	theme	composition	781:791	arg1	effects					761:767	the effects	757:767	the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions	757:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	7	40	theme	maleimide	1097:1105	arg1	binding					1086:1092	specific binding	1077:1092	specific binding of maleimide to Cys residues	1077:1121	Site-specific enzyme-PEG crosslinking was carried out by specific binding of maleimide to Cys residues.
37028137	9	41	theme	Site-directed	1270:1282	arg1	mutagenesis					1284:1294	Site-directed mutagenesis	1270:1294	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue	1270:1341	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	8	42	used	used	1226:1229	arg2	BOD					1136:1138	Recombinant BOD	1124:1138	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system,	1124:1220	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	8	42	used	used	1226:1229	arg2	benchmark					1236:1244	a benchmark	1234:1244	a benchmark	1234:1244	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	9	43	theme	residue	1303:1309	arg1	mutagenesis					1284:1294	Site-directed mutagenesis	1270:1294	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue	1270:1341	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	0	44	theme	glycan	20:25	arg1	Influence					0:8	Influence	0:8	Influence of distal glycan	0:25	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	5	45	theme	effects	761:767	arg1	unclear					869:875	unclear	869:875	unclear	869:875	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	45	theme	effects	761:767	arg1	function					723:730	the individual function	708:730	the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions	708:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	0	46	theme	electron	44:51	arg1	transfer					53:60	direct electron transfer	37:60	direct electron transfer performance for bilirubin oxidase bioelectrocatalysts	37:114	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	1	47	theme	electrode-active	283:298	arg1	site					300:303	its electrode-active site	279:303	its electrode-active site (T1 Cu)	279:311	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	1	47	theme	electrode-active	283:298	arg1	Cu					309:310	T1 Cu	306:310	T1 Cu	306:310	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	3	48	link	N-linked	424:431	arg1	N-glycans					442:450	N-glycans	442:450	N-glycans	442:450	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	3	48	link	N-linked	424:431	arg1	glycans					433:439	two N-linked glycans	420:439	two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu	420:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	3	49	contain	contains	411:418	arg1	mBOD					406:409	mBOD	406:409	mBOD	406:409	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	3	49	contain	contains	411:418	arg2	N-glycans					442:450	N-glycans	442:450	N-glycans	442:450	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	3	49	contain	contains	411:418	arg2	glycans					433:439	two N-linked glycans	420:439	two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu	420:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	5	50	theme	DET-type	840:847	arg1	reactions					849:857	DET-type reactions	840:857	DET-type reactions	840:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	0	51	theme	direct	37:42	arg1	transfer					53:60	direct electron transfer	37:60	direct electron transfer performance for bilirubin oxidase bioelectrocatalysts	37:114	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	9	52	theme	Asn	1299:1301	arg1	residue					1303:1309	Asn residue	1299:1309	Asn residue (N472 or N482)	1299:1324	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	4	53	theme	Pichia	651:656	arg1	pastoris					658:665	Pichia pastoris	651:665	Pichia pastoris	651:665	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	7	54	theme	Cys	1110:1112	arg1	residues					1114:1121	Cys residues	1110:1121	Cys residues	1110:1121	Site-specific enzyme-PEG crosslinking was carried out by specific binding of maleimide to Cys residues.
37028137	5	55	from	function	723:730	arg1	reactions					849:857	DET-type reactions	840:857	DET-type reactions	840:857	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	3	56	theme	N-linked	424:431	arg1	N-glycans					442:450	N-glycans	442:450	N-glycans	442:450	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	3	56	theme	N-linked	424:431	arg1	glycans					433:439	two N-linked glycans	420:439	two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu	420:500	mBOD contains two N-linked glycans (N-glycans) with N472 and N482 binding sites distal to T1 Cu.
37028137	4	57	theme	N-glycan	541:548	arg1	compositions					550:561	different N-glycan compositions	531:561	different N-glycan compositions	531:561	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	9	58	theme	Cys	1331:1333	arg1	residue					1335:1341	Cys residue	1331:1341	Cys residue	1331:1341	Site-directed mutagenesis of Asn residue (N472 or N482) into Cys residue is utilized to realize site-specific glycan mimic modification to the original binding site.
37028137	4	59	theme	recombinant	622:632	arg1	BOD					634:636	recombinant BOD	622:636	recombinant BOD expressed in Pichia pastoris	622:665	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	1	60	theme	capable	208:214	arg1	bioelectrocatalysis					255:273	capable of direct electron transfer (DET)-type bioelectrocatalysis	208:273	capable of direct electron transfer (DET)-type bioelectrocatalysis	208:273	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	8	61	theme	glycosylation	1200:1212	arg1	system					1214:1219	a glycosylation system	1198:1219	a glycosylation system	1198:1219	Recombinant BOD expressed in Escherichia coli (eBOD), which does not have a glycosylation system, was used as a benchmark to evaluate the effect.
37028137	5	62	theme	N-glycan	772:779	arg1	composition					781:791	N-glycan composition	772:791	N-glycan composition (size, structure, and non-reducing termini)	772:835	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	63	theme	non-reducing	815:826	arg1	termini					828:834	non-reducing termini	815:834	non-reducing termini	815:834	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	0	64	theme	transfer	53:60	arg1	performance					62:72	direct electron transfer performance	37:72	direct electron transfer performance for bilirubin oxidase bioelectrocatalysts	37:114	Influence of distal glycan mimics on direct electron transfer performance for bilirubin oxidase bioelectrocatalysts.
37028137	1	65	theme	T1	306:307	arg1	site					300:303	its electrode-active site	279:303	its electrode-active site (T1 Cu)	279:311	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	1	65	theme	T1	306:307	arg1	Cu					309:310	T1 Cu	306:310	T1 Cu	306:310	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	5	66	dep	composition	781:791	arg1	structure					800:808	structure	800:808	structure	800:808	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	66	dep	composition	781:791	arg1	size					794:797	size	794:797	size	794:797	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	5	66	dep	composition	781:791	arg1	termini					828:834	non-reducing termini	815:834	non-reducing termini	815:834	However, the individual function of the two N-glycans and the effects of N-glycan composition (size, structure, and non-reducing termini) on DET-type reactions are still unclear.
37028137	4	67	theme	different	531:539	arg1	compositions					550:561	different N-glycan compositions	531:561	different N-glycan compositions	531:561	We previously reported that different N-glycan compositions affect the enzymatic orientation on the electrode by using recombinant BOD expressed in Pichia pastoris and the deglycosylation method.
37028137	2	68	theme	Myrothecium	323:333	arg1	mBOD					347:350	mBOD	347:350	mBOD	347:350	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	2	68	theme	Myrothecium	323:333	arg1	verrucaria					335:344	Myrothecium verrucaria	323:344	Myrothecium verrucaria (mBOD)	323:351	BOD from Myrothecium verrucaria (mBOD) has been widely studied and has strong DET activity.
37028137	1	69	theme	direct	219:224	arg1	transfer					235:242	direct electron transfer	219:242	direct electron transfer (DET)	219:248	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
37028137	1	69	theme	direct	219:224	arg1	DET					245:247	DET	245:247	DET	245:247	Bilirubin oxidase (BOD) is a bioelectrocatalyst that reduces dioxygen (O2) to water and is capable of direct electron transfer (DET)-type bioelectrocatalysis via its electrode-active site (T1 Cu).
35773089	7	0	theme	significant	1255:1265	arg1	changes					1267:1273	statistically significant changes	1241:1273	statistically significant changes in IgG glycome composition	1241:1300	FINDINGS Multiple statistically significant changes in IgG glycome composition were observed during severe COVID-19.
35773089	10	1	theme	decreased	2079:2087	arg1	action					2107:2112	decreased immunosuppressive action	2079:2112	decreased immunosuppressive action of circulating immunoglobulins	2079:2143	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	6	2	theme	HR2	1004:1006	arg1	cohort					1008:1013	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	3	theme	median	1112:1117	arg1	males					1105:1109	17% males	1101:1109	17% males	1101:1109	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	3	theme	median	1112:1117	arg1	age					1119:1121	median age 50	1112:1124	median age 50	1112:1124	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	2	4	theme	Fc	316:317	arg1	portion					319:325	the Fc portion	312:325	the Fc portion of immunoglobulin G (IgG)	312:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	8	5	theme	adjusted	1462:1469	arg1	<0.0001					1488:1494	adjusted meta-analysis P= <0.0001	1462:1494	adjusted meta-analysis P= <0.0001	1462:1494	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	5	theme	adjusted	1462:1469	arg1	%					1443:1443	meta-analysis 95%	1427:1443	meta-analysis 95% CI [0.03, 0.07]	1427:1459	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	6	from	cohort	1093:1098	arg1	males					1185:1189	71% males	1181:1189	71% males	1181:1189	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	6	from	cohort	1093:1098	arg1	cases					991:995	31 severe cases	981:995	31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86)	981:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	6	from	cohort	1093:1098	arg1	cases					912:916	77 severe COVID-19 cases	893:916	77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80)	893:978	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	6	from	cohort	1093:1098	arg1	cases					1075:1079	18 mild COVID-19 cases	1058:1079	18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71)	1058:1140	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	6	from	cohort	1093:1098	arg1	cases					1154:1158	28 mild cases	1146:1158	28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78)	1146:1220	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	11	7	from	mechanism	2339:2347	arg1	COVID-19					2352:2359	COVID-19	2352:2359	COVID-19	2352:2359	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	12	8	theme	Nottingham	2713:2722	arg1	Centre					2744:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	11	9	theme	observed	2163:2170	arg1	changes					2172:2178	observed changes	2163:2178	observed changes	2163:2178	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	8	10	theme	bisecting	1644:1652	arg1	N-acetylglucosamine					1654:1672	bisecting N-acetylglucosamine	1644:1672	bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity	1644:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	11	theme	P=	1485:1486	arg1	<0.0001					1488:1494	adjusted meta-analysis P= <0.0001	1462:1494	adjusted meta-analysis P= <0.0001	1462:1494	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	11	theme	P=	1485:1486	arg1	%					1443:1443	meta-analysis 95%	1427:1443	meta-analysis 95% CI [0.03, 0.07]	1427:1459	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	12	from	lack	1598:1601	arg1	IgG					1677:1679	IgG	1677:1679	IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001)	1677:1752	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	10	13	theme	circulating	2117:2127	arg1	immunoglobulins					2129:2143	circulating immunoglobulins	2117:2143	circulating immunoglobulins	2117:2143	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	9	14	theme	mild	1939:1942	arg1	COVID-19					1944:1951	mild COVID-19	1939:1951	mild COVID-19	1939:1951	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	6	15	theme	17	1101:1102	arg1	%					1103:1103	%	1103:1103	%	1103:1103	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	2	16	attach	attached	300:307	arg2	Glycans					292:298	Glycans	292:298	Glycans attached to the Fc portion of immunoglobulin G (IgG)	292:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	2	16	attach	attached	300:307	arg2	modulators					367:376	important modulators	357:376	important modulators of IgG effector functions	357:402	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	2	16	attach	attached	300:307	arg1	portion					319:325	the Fc portion	312:325	the Fc portion of immunoglobulin G (IgG)	312:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	3	17	theme	response	513:520	arg1	type					498:501	the type	494:501	the type of immune response	494:520	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
35773089	12	18	from	Centre	2501:2506	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	18	from	Centre	2501:2506	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	18	from	Centre	2501:2506	arg1	European					2552:2559	The European	2548:2559	The European Structural	2548:2570	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	19	theme	Biomedical	2724:2733	arg1	Centre					2744:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	20	theme	proinflammatory	1514:1528	arg1	actions					1530:1536	proinflammatory actions	1514:1536	proinflammatory actions of IgG	1514:1543	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	5	21	theme	total	799:803	arg1	N-glycome					809:817	the total IgG N-glycome	795:817	the total IgG N-glycome	795:817	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	6	22	theme	HR1	927:929	arg1	cohort					931:936	the HR1 cohort	923:936	the HR1 cohort	923:936	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	23	theme	UK	1090:1091	arg1	cohort					1093:1098	the UK cohort	1086:1098	the UK cohort (17% males, median age 50, age IQR 26-71)	1086:1140	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	11	24	from	changes	2280:2286	arg1	glycosylation					2295:2307	IgG glycosylation	2291:2307	IgG glycosylation	2291:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	5	25	theme	N-glycome	809:817	arg1	composition					780:790	the composition	776:790	the composition of the total IgG N-glycome	776:817	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	12	26	theme	Competence	2511:2520	arg1	IP-CORONA-2020-04-2052					2456:2477	project IP-CORONA-2020-04-2052	2448:2477	project IP-CORONA-2020-04-2052	2448:2477	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	26	theme	Competence	2511:2520	arg1	Centre					2501:2506	Croatian National Centre	2483:2506	Croatian National Centre of Competence	2483:2520	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	11	27	theme	IgG	2253:2255	arg1	composition					2265:2275	aberrant IgG glycome composition	2244:2275	aberrant IgG glycome composition	2244:2275	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	27	theme	IgG	2253:2255	arg1	mechanism					2339:2347	an important molecular mechanism	2316:2347	an important molecular mechanism in COVID-19	2316:2359	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	27	theme	IgG	2253:2255	arg1	changes					2280:2286	changes	2280:2286	changes in IgG glycosylation	2280:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	4	28	theme	altered	648:654	arg1	glycosylation					660:672	altered IgG glycosylation	648:672	altered IgG glycosylation	648:672	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	6	29	theme	age	1127:1129	arg1	IQR					1131:1133	age IQR 26-71	1127:1139	age IQR 26-71	1127:1139	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	29	theme	age	1127:1129	arg1	males					1105:1109	17% males	1101:1109	17% males	1101:1109	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	1	30	theme	acute	106:110	arg1	syndrome					124:131	The severe acute respiratory syndrome coronavirus-2	95:145	The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)	95:158	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	30	theme	acute	106:110	arg1	SARS-CoV-2					148:157	SARS-CoV-2	148:157	SARS-CoV-2	148:157	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	6	31	theme	COVID-19	903:910	arg1	cases					912:916	77 severe COVID-19 cases	893:916	77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80)	893:978	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	12	32	theme	Molecular	2525:2533	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	32	theme	Molecular	2525:2533	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	32	theme	Molecular	2525:2533	arg1	European					2552:2559	The European	2548:2559	The European Structural	2548:2570	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	6	33	theme	COVID-19	1066:1073	arg1	cases					1075:1079	18 mild COVID-19 cases	1058:1079	18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71)	1058:1140	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	12	34	theme	National	2492:2499	arg1	Centre					2501:2506	Croatian National Centre	2483:2506	Croatian National Centre of Competence	2483:2520	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	6	35	from	cases	1075:1079	arg1	cohort					1008:1013	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	8	36	theme	system	1560:1565	arg1	activation					1567:1576	complement system activation	1549:1576	complement system activation	1549:1576	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	12	37	theme	Higher	2779:2784	arg1	Education					2786:2794	Higher Education	2779:2794	Higher Education	2779:2794	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	10	38	theme	severe	1988:1993	arg1	patients					2004:2011	severe COVID-19 patients	1988:2011	severe COVID-19 patients	1988:2011	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	1	39	dep	BACKGROUND	84:93	arg1	causes					160:165	causes	160:165	causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019	160:289	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	8	40	theme	antibody-dependent	1780:1797	arg1	cytotoxicity					1813:1824	antibody-dependent cell-mediated cytotoxicity	1780:1824	antibody-dependent cell-mediated cytotoxicity	1780:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	5	41	theme	chromatography	719:732	arg1	analysis					734:741	ultra-high-performance liquid chromatography analysis	689:741	ultra-high-performance liquid chromatography analysis of released glycans	689:761	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	6	42	from	cohort	1173:1178	arg1	males					1185:1189	71% males	1181:1189	71% males	1181:1189	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	42	from	cohort	1173:1178	arg1	cases					991:995	31 severe cases	981:995	31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86)	981:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	42	from	cohort	1173:1178	arg1	cases					912:916	77 severe COVID-19 cases	893:916	77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80)	893:978	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	42	from	cohort	1173:1178	arg1	cases					1075:1079	18 mild COVID-19 cases	1058:1079	18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71)	1058:1140	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	42	from	cohort	1173:1178	arg1	cases					1154:1158	28 mild cases	1146:1158	28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78)	1146:1220	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	5	43	theme	independent	860:870	arg1	cohorts					872:878	four independent cohorts	855:878	four independent cohorts	855:878	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	8	44	dep	IgG	1677:1679	arg1	CI					1700:1701	meta-analysis 95% CI [-0.11, -0.08]	1682:1716	CI	1700:1701	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	45	dep	%	1443:1443	arg1	CI					1445:1446	CI	1445:1446	CI	1445:1446	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	46	theme	BiH	1169:1171	arg1	cohort					1173:1178	the BiH cohort	1165:1178	the BiH cohort	1165:1178	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	5	47	from	cohorts	872:878	arg1	COVID-19					841:848	COVID-19	841:848	COVID-19 from four independent cohorts	841:878	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	11	48	theme	IgG	2291:2293	arg1	glycosylation					2295:2307	IgG glycosylation	2291:2307	IgG glycosylation	2291:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	6	49	from	cases	1154:1158	arg1	cohort					1008:1013	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	50	theme	%	941:941	arg1	IQR					969:971	age IQR 25-80	965:977	age IQR 25-80	965:977	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	50	theme	%	941:941	arg1	males					943:947	74% males	939:947	74% males	939:947	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	50	theme	%	941:941	arg1	age					957:959	median age 72	950:962	median age 72	950:962	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	11	51	theme	molecular	2329:2337	arg1	composition					2265:2275	aberrant IgG glycome composition	2244:2275	aberrant IgG glycome composition	2244:2275	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	51	theme	molecular	2329:2337	arg1	mechanism					2339:2347	an important molecular mechanism	2316:2347	an important molecular mechanism in COVID-19	2316:2359	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	51	theme	molecular	2329:2337	arg1	changes					2280:2286	changes	2280:2286	changes in IgG glycosylation	2280:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	5	52	theme	ultra-high-performance	689:710	arg1	analysis					734:741	ultra-high-performance liquid chromatography analysis	689:741	ultra-high-performance liquid chromatography analysis of released glycans	689:761	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	5	53	theme	released	746:753	arg1	glycans					755:761	released glycans	746:761	released glycans	746:761	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	8	54	theme	sialylation	1606:1616	arg1	presence					1632:1639	decreased presence	1622:1639	decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity	1622:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	54	theme	sialylation	1606:1616	arg1	lack					1598:1601	a lack	1596:1601	a lack of sialylation	1596:1616	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	0	55	dep	study	77:81	arg1	changes					14:20	IgG N-glycome changes	0:20	IgG N-glycome changes during the course of severe COVID-19	0:57	IgG N-glycome changes during the course of severe COVID-19: An observational study.
35773089	12	56	theme	Research	2704:2711	arg1	Centre					2744:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	57	theme	meta-analysis	1728:1740	arg1	P=					1742:1743	adjusted meta-analysis P=	1719:1743	adjusted meta-analysis P= <0.0001	1719:1751	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	9	58	located	observed	1913:1920	arg2	changes					1873:1879	no statistically significant changes	1844:1879	no statistically significant changes in IgG glycome composition	1844:1906	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	9	58	located	observed	1913:1920	arg1	patients					1925:1932	patients	1925:1932	patients with mild COVID-19	1925:1951	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	9	58	located	observed	1913:1920	arg1	contrary					1834:1841	the contrary	1830:1841	the contrary	1830:1841	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	0	59	theme	IgG	0:2	arg1	changes					14:20	IgG N-glycome changes	0:20	IgG N-glycome changes during the course of severe COVID-19	0:57	IgG N-glycome changes during the course of severe COVID-19: An observational study.
35773089	8	60	theme	decreased	1622:1630	arg1	presence					1632:1639	decreased presence	1622:1639	decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity	1622:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	10	61	dep	INTERPRETATION	1954:1967	arg1	altered					2044:2050	altered	2044:2050	is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins	2013:2143	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	2	62	theme	effector	385:392	arg1	functions					394:402	IgG effector functions	381:402	IgG effector functions	381:402	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	6	63	from	cohort	931:936	arg1	males					1185:1189	71% males	1181:1189	71% males	1181:1189	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	63	from	cohort	931:936	arg1	cases					991:995	31 severe cases	981:995	31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86)	981:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	63	from	cohort	931:936	arg1	cases					912:916	77 severe COVID-19 cases	893:916	77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80)	893:978	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	63	from	cohort	931:936	arg1	cases					1075:1079	18 mild COVID-19 cases	1058:1079	18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71)	1058:1140	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	63	from	cohort	931:936	arg1	cases					1154:1158	28 mild cases	1146:1158	28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78)	1146:1220	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	12	64	theme	Science	2770:2776	arg1	Youth					2800:2804	Youth	2800:2804	Youth	2800:2804	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	64	theme	Science	2770:2776	arg1	Education					2786:2794	Higher Education	2779:2794	Higher Education	2779:2794	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	64	theme	Science	2770:2776	arg1	Ministry					2758:2765	Ministry	2758:2765	Ministry Of Science	2758:2776	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	65	theme	cell-mediated	1799:1811	arg1	cytotoxicity					1813:1824	antibody-dependent cell-mediated cytotoxicity	1780:1824	antibody-dependent cell-mediated cytotoxicity	1780:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	1	66	theme	global	257:262	arg1	problems					271:278	the main global health problems	248:278	the main global health problems since 2019	248:289	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	4	67	theme	COVID-19	619:626	arg1	severity					594:601	severity	594:601	severity	594:601	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	4	67	theme	COVID-19	619:626	arg1	duration					607:614	duration	607:614	duration	607:614	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	8	68	from	presence	1632:1639	arg1	IgG					1677:1679	IgG	1677:1679	IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001)	1677:1752	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	2	69	theme	important	357:365	arg1	Glycans					292:298	Glycans	292:298	Glycans attached to the Fc portion of immunoglobulin G (IgG)	292:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	2	69	theme	important	357:365	arg1	modulators					367:376	important modulators	357:376	important modulators of IgG effector functions	357:402	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	3	70	theme	Fc	405:406	arg1	region					408:413	Fc region	405:413	Fc region	405:413	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
35773089	5	71	theme	glycans	755:761	arg1	analysis					734:741	ultra-high-performance liquid chromatography analysis	689:741	ultra-high-performance liquid chromatography analysis of released glycans	689:761	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	1	72	theme	problems	271:278	arg1	illness					181:187	a respiratory illness	167:187	a respiratory illness	167:187	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	72	theme	problems	271:278	arg1	one					241:243	one	241:243	one	241:243	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	72	theme	problems	271:278	arg1	problems					271:278	the main global health problems	248:278	the main global health problems since 2019	248:289	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	6	73	from	cases	912:916	arg1	cohort					1008:1013	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	0	74	theme	COVID-19	50:57	arg1	course					33:38	the course	29:38	the course of severe COVID-19	29:57	IgG N-glycome changes during the course of severe COVID-19: An observational study.
35773089	6	75	theme	%	1183:1183	arg1	males					1185:1189	71% males	1181:1189	71% males	1181:1189	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	75	theme	%	1183:1183	arg1	age					1199:1201	median age 60	1192:1204	median age 60	1192:1204	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	75	theme	%	1183:1183	arg1	cases					1154:1158	28 mild cases	1146:1158	28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78)	1146:1220	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	7	76	theme	IgG	1278:1280	arg1	composition					1290:1300	IgG glycome composition	1278:1300	IgG glycome composition	1278:1300	FINDINGS Multiple statistically significant changes in IgG glycome composition were observed during severe COVID-19.
35773089	12	77	theme	Structural	2561:2570	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	77	theme	Structural	2561:2570	arg1	European					2552:2559	The European	2548:2559	The European Structural	2548:2570	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	78	theme	significant	1363:1373	arg1	changes					1375:1381	The most statistically significant changes	1340:1381	The most statistically significant changes	1340:1381	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	3	79	theme	different	424:432	arg1	receptors					434:442	different receptors	424:442	different receptors	424:442	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
35773089	6	80	theme	77	1016:1017	arg1	%					1018:1018	%	1018:1018	%	1018:1018	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	9	81	with	patients	1925:1932	arg1	COVID-19					1944:1951	mild COVID-19	1939:1951	mild COVID-19	1939:1951	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	9	82	theme	glycome	1888:1894	arg1	composition					1896:1906	IgG glycome composition	1884:1906	IgG glycome composition	1884:1906	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	3	83	theme	various	462:468	arg1	cells					477:481	various immune cells	462:481	various immune cells	462:481	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
35773089	6	84	dep	cohort	1093:1098	arg1	IQR					1131:1133	age IQR 26-71	1127:1139	age IQR 26-71	1127:1139	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	84	dep	cohort	1093:1098	arg1	males					1105:1109	17% males	1101:1109	17% males	1101:1109	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	84	dep	cohort	1093:1098	arg1	age					1119:1121	median age 50	1112:1124	median age 50	1112:1124	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	85	theme	severe	896:901	arg1	cases					912:916	77 severe COVID-19 cases	893:916	77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80)	893:978	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	11	86	theme	changes	2172:2178	arg1	magnitude					2150:2158	The magnitude	2146:2158	The magnitude of observed changes	2146:2178	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	4	87	theme	large	544:548	arg1	study					563:567	a large longitudinal study	542:567	a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation	542:672	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	9	88	from	changes	1873:1879	arg1	composition					1896:1906	IgG glycome composition	1884:1906	IgG glycome composition	1884:1906	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	12	89	theme	#	2599:2599	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	89	theme	#	2599:2599	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	90	theme	Research	2735:2742	arg1	Centre					2744:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	91	theme	grant	2593:2597	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	91	theme	grant	2593:2597	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	9	92	theme	significant	1861:1871	arg1	changes					1873:1879	no statistically significant changes	1844:1879	no statistically significant changes in IgG glycome composition	1844:1906	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	8	93	theme	IgG	1422:1424	arg1	agalactosylation					1402:1417	increased agalactosylation	1392:1417	increased agalactosylation	1392:1417	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	94	theme	N-acetylglucosamine	1654:1672	arg1	presence					1632:1639	decreased presence	1622:1639	decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity	1622:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	94	theme	N-acetylglucosamine	1654:1672	arg1	lack					1598:1601	a lack	1596:1601	a lack of sialylation	1596:1616	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	12	95	dep	IP-CORONA-2020-04-2052	2456:2477	arg1	the					2444:2446	the	2444:2446	the	2444:2446	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	96	theme	project	2448:2454	arg1	IP-CORONA-2020-04-2052					2456:2477	project IP-CORONA-2020-04-2052	2448:2477	project IP-CORONA-2020-04-2052	2448:2477	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	97	theme	meta-analysis	1427:1439	arg1	<0.0001					1488:1494	adjusted meta-analysis P= <0.0001	1462:1494	adjusted meta-analysis P= <0.0001	1462:1494	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	97	theme	meta-analysis	1427:1439	arg1	%					1443:1443	meta-analysis 95%	1427:1443	meta-analysis 95% CI [0.03, 0.07]	1427:1459	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	98	theme	%	1103:1103	arg1	IQR					1131:1133	age IQR 26-71	1127:1139	age IQR 26-71	1127:1139	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	98	theme	%	1103:1103	arg1	males					1105:1109	17% males	1101:1109	17% males	1101:1109	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	98	theme	%	1103:1103	arg1	age					1119:1121	median age 50	1112:1124	median age 50	1112:1124	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	99	from	cases	991:995	arg1	cohort					1008:1013	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	the HR2 cohort (77% males, median age 64, age IQR 41-86)	1000:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	3	100	theme	cells	477:481	arg1	surface					451:457	the surface	447:457	the surface of various immune cells	447:481	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
35773089	8	101	theme	meta-analysis	1471:1483	arg1	<0.0001					1488:1494	adjusted meta-analysis P= <0.0001	1462:1494	adjusted meta-analysis P= <0.0001	1462:1494	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	101	theme	meta-analysis	1471:1483	arg1	%					1443:1443	meta-analysis 95%	1427:1443	meta-analysis 95% CI [0.03, 0.07]	1427:1459	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	102	dep	P=	1742:1743	arg1	<0.0001					1745:1751	<0.0001	1745:1751	adjusted meta-analysis P= <0.0001	1719:1751	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	103	theme	age	1042:1044	arg1	IQR					1046:1048	age IQR 41-86	1042:1054	age IQR 41-86	1042:1054	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	103	theme	age	1042:1044	arg1	males					1020:1024	77% males	1016:1024	77% males	1016:1024	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	8	104	theme	meta-analysis	1682:1694	arg1	CI					1700:1701	meta-analysis 95% CI [-0.11, -0.08]	1682:1716	CI	1700:1701	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	3	105	theme	immune	506:511	arg1	response					513:520	immune response	506:520	immune response	506:520	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
35773089	1	106	theme	respiratory	169:179	arg1	illness					181:187	a respiratory illness	167:187	a respiratory illness	167:187	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	106	theme	respiratory	169:179	arg1	one					241:243	one	241:243	one	241:243	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	106	theme	respiratory	169:179	arg1	problems					271:278	the main global health problems	248:278	the main global health problems since 2019	248:289	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	6	107	theme	74	939:940	arg1	%					941:941	%	941:941	%	941:941	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	10	108	theme	immunosuppressive	2089:2105	arg1	action					2107:2112	decreased immunosuppressive action	2079:2112	decreased immunosuppressive action of circulating immunoglobulins	2079:2143	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	8	109	theme	adjusted	1719:1726	arg1	P=					1742:1743	adjusted meta-analysis P=	1719:1743	adjusted meta-analysis P= <0.0001	1719:1751	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	12	110	theme	Investment	2576:2585	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	110	theme	Investment	2576:2585	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	111	theme	%	1698:1698	arg1	CI					1700:1701	meta-analysis 95% CI [-0.11, -0.08]	1682:1716	CI	1700:1701	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	112	dep	cases	912:916	arg1	IQR					969:971	age IQR 25-80	965:977	age IQR 25-80	965:977	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	112	dep	cases	912:916	arg1	males					943:947	74% males	939:947	74% males	939:947	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	112	dep	cases	912:916	arg1	age					957:959	median age 72	950:962	median age 72	950:962	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	113	theme	median	1027:1032	arg1	males					1020:1024	77% males	1016:1024	77% males	1016:1024	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	113	theme	median	1027:1032	arg1	age					1034:1036	median age 64	1027:1039	median age 64	1027:1039	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	10	114	from	glycome	1977:1983	arg1	patients					2004:2011	severe COVID-19 patients	1988:2011	severe COVID-19 patients	1988:2011	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	5	115	theme	IgG	805:807	arg1	N-glycome					809:817	the total IgG N-glycome	795:817	the total IgG N-glycome	795:817	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	10	116	theme	immunoglobulins	2129:2143	arg1	action					2107:2112	decreased immunosuppressive action	2079:2112	decreased immunosuppressive action of circulating immunoglobulins	2079:2143	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	12	117	from	IP-CORONA-2020-04-2052	2456:2477	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	117	from	IP-CORONA-2020-04-2052	2456:2477	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	117	from	IP-CORONA-2020-04-2052	2456:2477	arg1	European					2552:2559	The European	2548:2559	The European Structural	2548:2570	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	10	118	theme	IgG	1973:1975	arg1	glycome					1977:1983	The IgG glycome	1969:1983	The IgG glycome in severe COVID-19 patients	1969:2011	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	1	119	theme	severe	99:104	arg1	syndrome					124:131	The severe acute respiratory syndrome coronavirus-2	95:145	The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)	95:158	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	119	theme	severe	99:104	arg1	SARS-CoV-2					148:157	SARS-CoV-2	148:157	SARS-CoV-2	148:157	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	12	120	theme	Sarajevo	2816:2823	arg1	Youth					2800:2804	Youth	2800:2804	Youth	2800:2804	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	120	theme	Sarajevo	2816:2823	arg1	Education					2786:2794	Higher Education	2779:2794	Higher Education	2779:2794	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	120	theme	Sarajevo	2816:2823	arg1	Ministry					2758:2765	Ministry	2758:2765	Ministry Of Science	2758:2776	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	121	theme	IgG	1541:1543	arg1	actions					1530:1536	proinflammatory actions	1514:1536	proinflammatory actions of IgG	1514:1543	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	1	122	theme	respiratory	112:122	arg1	syndrome					124:131	The severe acute respiratory syndrome coronavirus-2	95:145	The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)	95:158	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	122	theme	respiratory	112:122	arg1	SARS-CoV-2					148:157	SARS-CoV-2	148:157	SARS-CoV-2	148:157	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	6	123	theme	age	965:967	arg1	IQR					969:971	age IQR 25-80	965:977	age IQR 25-80	965:977	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	123	theme	age	965:967	arg1	males					943:947	74% males	939:947	74% males	939:947	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	124	theme	mild	1061:1064	arg1	cases					1075:1079	18 mild COVID-19 cases	1058:1079	18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71)	1058:1140	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	10	125	theme	COVID-19	1995:2002	arg1	patients					2004:2011	severe COVID-19 patients	1988:2011	severe COVID-19 patients	1988:2011	INTERPRETATION The IgG glycome in severe COVID-19 patients is statistically significantly altered in a way that it indicates decreased immunosuppressive action of circulating immunoglobulins.
35773089	4	126	theme	IgG	656:658	arg1	glycosylation					660:672	altered IgG glycosylation	648:672	altered IgG glycosylation	648:672	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	5	127	theme	liquid	712:717	arg1	analysis					734:741	ultra-high-performance liquid chromatography analysis	689:741	ultra-high-performance liquid chromatography analysis of released glycans	689:761	METHODS Using ultra-high-performance liquid chromatography analysis of released glycans, we analysed the composition of the total IgG N-glycome longitudinally during COVID-19 from four independent cohorts.
35773089	12	128	theme	grant	2826:2830	arg1	Sarajevo					2816:2823	Sarajevo	2816:2823	Sarajevo	2816:2823	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	128	theme	grant	2826:2830	arg1	number					2832:2837	grant number 27-02-11-4375-10/21	2826:2857	grant number 27-02-11-4375-10/21	2826:2857	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	129	theme	complement	1549:1558	arg1	activation					1567:1576	complement system activation	1549:1576	complement system activation	1549:1576	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	1	130	theme	coronavirus-2	133:145	arg1	syndrome					124:131	The severe acute respiratory syndrome coronavirus-2	95:145	The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)	95:158	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	130	theme	coronavirus-2	133:145	arg1	SARS-CoV-2					148:157	SARS-CoV-2	148:157	SARS-CoV-2	148:157	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	12	131	theme	National	2673:2680	arg1	Institutes					2682:2691	the National Institutes	2669:2691	the National Institutes for Health Research Nottingham Biomedical Research Centre	2669:2749	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	11	132	theme	glycome	2257:2263	arg1	composition					2265:2275	aberrant IgG glycome composition	2244:2275	aberrant IgG glycome composition	2244:2275	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	132	theme	glycome	2257:2263	arg1	mechanism					2339:2347	an important molecular mechanism	2316:2347	an important molecular mechanism in COVID-19	2316:2359	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	132	theme	glycome	2257:2263	arg1	changes					2280:2286	changes	2280:2286	changes in IgG glycosylation	2280:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	0	133	theme	observational	63:75	arg1	study					77:81	An observational study	60:81	An observational study	60:81	IgG N-glycome changes during the course of severe COVID-19: An observational study.
35773089	6	134	theme	median	950:955	arg1	males					943:947	74% males	939:947	74% males	939:947	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	134	theme	median	950:955	arg1	age					957:959	median age 72	950:962	median age 72	950:962	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	8	135	dep	IgG	1422:1424	arg1	<0.0001					1488:1494	adjusted meta-analysis P= <0.0001	1462:1494	adjusted meta-analysis P= <0.0001	1462:1494	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	135	dep	IgG	1422:1424	arg1	%					1443:1443	meta-analysis 95%	1427:1443	meta-analysis 95% CI [0.03, 0.07]	1427:1459	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	7	136	theme	severe	1323:1328	arg1	COVID-19					1330:1337	severe COVID-19	1323:1337	severe COVID-19	1323:1337	FINDINGS Multiple statistically significant changes in IgG glycome composition were observed during severe COVID-19.
35773089	11	137	theme	important	2319:2327	arg1	composition					2265:2275	aberrant IgG glycome composition	2244:2275	aberrant IgG glycome composition	2244:2275	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	137	theme	important	2319:2327	arg1	mechanism					2339:2347	an important molecular mechanism	2316:2347	an important molecular mechanism in COVID-19	2316:2359	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	137	theme	important	2319:2327	arg1	changes					2280:2286	changes	2280:2286	changes in IgG glycosylation	2280:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	1	138	theme	coronavirus	195:205	arg1	disease					207:213	coronavirus disease 2019	195:218	coronavirus disease 2019 (COVID-19)	195:229	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	1	138	theme	coronavirus	195:205	arg1	COVID-19					221:228	COVID-19	221:228	COVID-19	221:228	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	11	139	theme	disease	2219:2225	arg1	severity					2203:2210	the severity	2199:2210	the severity of the disease	2199:2225	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	140	from	composition	2265:2275	arg1	glycosylation					2295:2307	IgG glycosylation	2291:2307	IgG glycosylation	2291:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	0	141	theme	N-glycome	4:12	arg1	changes					14:20	IgG N-glycome changes	0:20	IgG N-glycome changes during the course of severe COVID-19	0:57	IgG N-glycome changes during the course of severe COVID-19: An observational study.
35773089	12	142	dep	Diagnostics	2535:2545	arg1	KK.01.2.2.03.0006					2600:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	Investment Funds grant #KK.01.2.2.03.0006	2576:2616	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	142	dep	Diagnostics	2535:2545	arg1	Diagnostics					2535:2545	Molecular Diagnostics	2525:2545	Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006)	2525:2617	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	12	142	dep	Diagnostics	2535:2545	arg1	European					2552:2559	The European	2548:2559	The European Structural	2548:2570	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	6	143	theme	severe	984:989	arg1	cases					991:995	31 severe cases	981:995	31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86)	981:1055	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	2	144	theme	functions	394:402	arg1	Glycans					292:298	Glycans	292:298	Glycans attached to the Fc portion of immunoglobulin G (IgG)	292:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	2	144	theme	functions	394:402	arg1	modulators					367:376	important modulators	357:376	important modulators of IgG effector functions	357:402	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	8	145	from	N-acetylglucosamine	1654:1672	arg1	IgG					1677:1679	IgG	1677:1679	IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001)	1677:1752	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	2	146	theme	G	345:345	arg1	portion					319:325	the Fc portion	312:325	the Fc portion of immunoglobulin G (IgG)	312:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	1	147	theme	main	252:255	arg1	problems					271:278	the main global health problems	248:278	the main global health problems since 2019	248:289	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	6	148	dep	males	1185:1189	arg1	age					1207:1209	age IQR 12-78	1207:1219	age IQR 12-78	1207:1219	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	2	149	theme	IgG	381:383	arg1	functions					394:402	IgG effector functions	381:402	IgG effector functions	381:402	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	2	150	theme	immunoglobulin	330:343	arg1	IgG					348:350	IgG	348:350	IgG	348:350	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	2	150	theme	immunoglobulin	330:343	arg1	G					345:345	immunoglobulin G	330:345	immunoglobulin G (IgG)	330:351	Glycans attached to the Fc portion of immunoglobulin G (IgG) are important modulators of IgG effector functions.
35773089	6	151	theme	median	1192:1197	arg1	males					1185:1189	71% males	1181:1189	71% males	1181:1189	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	151	theme	median	1192:1197	arg1	age					1199:1201	median age 60	1192:1204	median age 60	1192:1204	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	1	152	theme	health	264:269	arg1	problems					271:278	the main global health problems	248:278	the main global health problems since 2019	248:289	BACKGROUND The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes a respiratory illness named coronavirus disease 2019 (COVID-19), which is one of the main global health problems since 2019.
35773089	8	153	dep	CI	1700:1701	arg1	P=					1742:1743	adjusted meta-analysis P=	1719:1743	adjusted meta-analysis P= <0.0001	1719:1751	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	154	theme	mild	1149:1152	arg1	cases					1154:1158	28 mild cases	1146:1158	28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78)	1146:1220	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	154	theme	mild	1149:1152	arg1	males					1185:1189	71% males	1181:1189	71% males	1181:1189	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	0	155	theme	severe	43:48	arg1	COVID-19					50:57	severe COVID-19	43:57	severe COVID-19	43:57	IgG N-glycome changes during the course of severe COVID-19: An observational study.
35773089	12	156	theme	Health	2697:2702	arg1	Centre					2744:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	Health Research Nottingham Biomedical Research Centre	2697:2749	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	8	157	from	IgG	1677:1679	arg1	presence					1632:1639	decreased presence	1622:1639	decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity	1622:1824	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	8	157	from	IgG	1677:1679	arg1	lack					1598:1601	a lack	1596:1601	a lack of sialylation	1596:1616	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	6	158	dep	cohort	1008:1013	arg1	IQR					1046:1048	age IQR 41-86	1042:1054	age IQR 41-86	1042:1054	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	158	dep	cohort	1008:1013	arg1	males					1020:1024	77% males	1016:1024	77% males	1016:1024	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	158	dep	cohort	1008:1013	arg1	age					1034:1036	median age 64	1027:1039	median age 64	1027:1039	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	7	159	theme	glycome	1282:1288	arg1	composition					1290:1300	IgG glycome composition	1278:1300	IgG glycome composition	1278:1300	FINDINGS Multiple statistically significant changes in IgG glycome composition were observed during severe COVID-19.
35773089	6	160	theme	%	1018:1018	arg1	IQR					1046:1048	age IQR 41-86	1042:1054	age IQR 41-86	1042:1054	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	160	theme	%	1018:1018	arg1	males					1020:1024	77% males	1016:1024	77% males	1016:1024	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	6	160	theme	%	1018:1018	arg1	age					1034:1036	median age 64	1027:1039	median age 64	1027:1039	We analysed 77 severe COVID-19 cases from the HR1 cohort (74% males, median age 72, age IQR 25-80); 31 severe cases in the HR2 cohort (77% males, median age 64, age IQR 41-86), 18 mild COVID-19 cases from the UK cohort (17% males, median age 50, age IQR 26-71) and 28 mild cases from the BiH cohort (71% males, median age 60, age IQR 12-78).
35773089	8	161	theme	increased	1392:1400	arg1	agalactosylation					1402:1417	increased agalactosylation	1392:1417	increased agalactosylation	1392:1417	The most statistically significant changes included increased agalactosylation of IgG (meta-analysis 95% CI [0.03, 0.07], adjusted meta-analysis P= <0.0001), which regulates proinflammatory actions of IgG via complement system activation and indirectly as a lack of sialylation and decreased presence of bisecting N-acetylglucosamine on IgG (meta-analysis 95% CI [-0.11, -0.08], adjusted meta-analysis P= <0.0001), which indirectly affects antibody-dependent cell-mediated cytotoxicity.
35773089	9	162	theme	IgG	1884:1886	arg1	composition					1896:1906	IgG glycome composition	1884:1906	IgG glycome composition	1884:1906	On the contrary, no statistically significant changes in IgG glycome composition were observed in patients with mild COVID-19.
35773089	11	163	theme	aberrant	2244:2251	arg1	composition					2265:2275	aberrant IgG glycome composition	2244:2275	aberrant IgG glycome composition	2244:2275	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	163	theme	aberrant	2244:2251	arg1	mechanism					2339:2347	an important molecular mechanism	2316:2347	an important molecular mechanism in COVID-19	2316:2359	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	11	163	theme	aberrant	2244:2251	arg1	changes					2280:2286	changes	2280:2286	changes in IgG glycosylation	2280:2307	The magnitude of observed changes is associated with the severity of the disease, indicating that aberrant IgG glycome composition or changes in IgG glycosylation may be an important molecular mechanism in COVID-19.
35773089	12	164	theme	Croatian	2483:2490	arg1	Centre					2501:2506	Croatian National Centre	2483:2506	Croatian National Centre of Competence	2483:2520	FUNDING This work has been supported in part by Croatian Science Foundation under the project IP-CORONA-2020-04-2052 and Croatian National Centre of Competence in Molecular Diagnostics (The European Structural and Investment Funds grant #KK.01.2.2.03.0006), by the UKRI/MRC (Cov-0331 - MR/V027883/1) and by the National Institutes for Health Research Nottingham Biomedical Research Centre and by Ministry Of Science, Higher Education and Youth Of Canton Sarajevo, grant number 27-02-11-4375-10/21.
35773089	7	165	from	changes	1267:1273	arg1	composition					1290:1300	IgG glycome composition	1278:1300	IgG glycome composition	1278:1300	FINDINGS Multiple statistically significant changes in IgG glycome composition were observed during severe COVID-19.
35773089	4	166	dep	severity	594:601	arg1	the					590:592	the	590:592	the	590:592	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	4	167	theme	longitudinal	550:561	arg1	study					563:567	a large longitudinal study	542:567	a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation	542:672	Here, we performed a large longitudinal study to determine whether the severity and duration of COVID-19 are associated with altered IgG glycosylation.
35773089	3	168	theme	immune	470:475	arg1	cells					477:481	various immune cells	462:481	various immune cells	462:481	Fc region binds to different receptors on the surface of various immune cells, dictating the type of immune response.
36870540	2	0	from	liver	434:438	arg1	cells					419:423	cells	419:423	cells from the liver and parts of the brain in the rat	419:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	0	from	liver	434:438	arg1	rat					470:472	the rat	466:472	the rat	466:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	0	from	liver	434:438	arg1	glycosylation					402:414	the nuclear O-GalNAc glycosylation	381:414	the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	381:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	7	1	theme	cerebral	1324:1331	arg1	cortex					1333:1338	cerebral cortex	1324:1338	cerebral cortex	1324:1338	RESULTS The perinatal protein deficit reduced progeny weight, as well as cerebral cortex and cerebellum weight.
36870540	8	2	dep	cytoplasm	1388:1396	arg1	the					1384:1386	the	1384:1386	the	1384:1386	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	9	3	theme	ppGalNAc-transferase	1561:1580	arg1	activity					1582:1589	the ppGalNAc-transferase activity	1557:1589	the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus	1557:1680	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	6	4	theme	western	1141:1147	arg1	blotting					1149:1156	western blotting	1141:1156	western blotting	1141:1156	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	10	5	from	offspring	1817:1825	arg1	nucleoplasm					1781:1791	liver nucleoplasm	1775:1791	liver nucleoplasm from protein-restricted offspring	1775:1825	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	9	6	theme	localized	1591:1599	arg1	activity					1582:1589	the ppGalNAc-transferase activity	1557:1589	the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus	1557:1680	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	2	7	from	period	371:376	arg1	glycosylation					402:414	the nuclear O-GalNAc glycosylation	381:414	the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	381:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	10	8	theme	glycans	1890:1896	arg1	expression					1867:1876	the expression	1863:1876	the expression of O-GalNAc glycans on important nuclear proteins	1863:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	7	9	theme	progeny	1297:1303	arg1	weight					1305:1310	progeny weight	1297:1310	progeny weight	1297:1310	RESULTS The perinatal protein deficit reduced progeny weight, as well as cerebral cortex and cerebellum weight.
36870540	11	10	from	modulation	2064:2073	arg1	glycosylation					2116:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	0	11	theme	Rat	115:117	arg1	Structures					97:106	Liver and Brain Structures	81:106	Liver and Brain Structures of the Rat	81:117	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	3	12	theme	pregnancy	546:554	arg1	day					536:538	day 14	536:541	day 14 of pregnancy	536:554	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	1	13	theme	protein	209:215	arg1	functions					217:225	nuclear protein functions	201:225	nuclear protein functions controlling cell physiology and an individual's health	201:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	10	14	from	reduction	1850:1858	arg1	expression					1867:1876	the expression	1863:1876	the expression of O-GalNAc glycans on important nuclear proteins	1863:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	10	14	from	reduction	1850:1858	arg1	proteins					1919:1926	important nuclear proteins	1901:1926	important nuclear proteins	1901:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	6	15	theme	sorbent	1214:1220	arg1	assay					1222:1226	enzyme-lectin sorbent assay	1200:1226	enzyme-lectin sorbent assay	1200:1226	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	7	16	theme	perinatal	1263:1271	arg1	deficit					1281:1287	The perinatal protein deficit	1259:1287	The perinatal protein deficit	1259:1287	RESULTS The perinatal protein deficit reduced progeny weight, as well as cerebral cortex and cerebellum weight.
36870540	10	17	theme	protein-restricted	1798:1815	arg1	offspring					1817:1825	protein-restricted offspring	1798:1825	protein-restricted offspring	1798:1825	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	10	18	theme	important	1901:1909	arg1	proteins					1919:1926	important nuclear proteins	1901:1926	important nuclear proteins	1901:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	11	19	dep	CONCLUSIONS	1929:1939	arg1	report					1953:1958	report	1953:1958	report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions	1953:2185	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	6	20	theme	Cell	853:856	arg1	nuclei					858:863	Cell nuclei	853:863	Cell nuclei	853:863	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	11	21	theme	protein-restricted	2004:2021	arg1	diet					2023:2026	a protein-restricted diet	2002:2026	a protein-restricted diet	2002:2026	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	8	22	theme	UDP-GalNAc	1363:1372	arg1	levels					1374:1379	UDP-GalNAc levels	1363:1379	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus	1363:1460	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	6	23	theme	O-GalNAc	1104:1111	arg1	product					1095:1101	the glycosylation product	1077:1101	the glycosylation product (O-GalNAc glycans)	1077:1120	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	23	theme	O-GalNAc	1104:1111	arg1	glycans					1113:1119	O-GalNAc glycans	1104:1119	O-GalNAc glycans	1104:1119	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	24	theme	enzyme	1183:1188	arg1	activity					1190:1197	enzyme activity	1183:1197	enzyme activity	1183:1197	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	7	25	dep	cortex	1333:1338	arg1	weight					1355:1360	weight	1355:1360	weight	1355:1360	RESULTS The perinatal protein deficit reduced progeny weight, as well as cerebral cortex and cerebellum weight.
36870540	6	26	theme	factors	929:935	arg1	cytoplasm					912:920	cytoplasm	912:920	cytoplasm	912:920	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	26	theme	factors	929:935	arg1	nucleus					900:906	nucleus	900:906	nucleus	900:906	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	3	27	theme	isocaloric	586:595	arg1	diets					597:601	two isocaloric diets	582:601	two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein	582:666	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	2	28	from	parts	444:448	arg1	cells					419:423	cells	419:423	cells from the liver and parts of the brain in the rat	419:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	28	from	parts	444:448	arg1	rat					470:472	the rat	466:472	the rat	466:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	28	from	parts	444:448	arg1	glycosylation					402:414	the nuclear O-GalNAc glycosylation	381:414	the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	381:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	0	29	theme	Liver	81:85	arg1	Structures					97:106	Liver and Brain Structures	81:106	Liver and Brain Structures of the Rat	81:117	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	10	30	from	expression	1867:1876	arg1	proteins					1919:1926	important nuclear proteins	1901:1926	important nuclear proteins	1901:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	0	31	theme	Brain	91:95	arg1	Structures					97:106	Liver and Brain Structures	81:106	Liver and Brain Structures of the Rat	81:117	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	1	32	theme	Post-translational	131:148	arg1	modifications					150:162	BACKGROUND Post-translational modifications	120:162	BACKGROUND Post-translational modifications	120:162	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	1	32	theme	Post-translational	131:148	arg1	factors					172:178	key factors	168:178	key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health	168:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	11	33	theme	nuclear	2161:2167	arg1	functions					2177:2185	nuclear protein functions	2161:2185	nuclear protein functions	2161:2185	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	8	34	theme	liver	1412:1416	arg1	nuclei					1402:1407	nuclei	1402:1407	nuclei	1402:1407	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	8	34	theme	liver	1412:1416	arg1	cytoplasm					1388:1396	cytoplasm	1388:1396	cytoplasm	1388:1396	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	2	35	theme	cells	419:423	arg1	glycosylation					402:414	the nuclear O-GalNAc glycosylation	381:414	the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	381:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	6	36	theme	biosynthesis	984:995	arg1	initiation					954:963	the initiation	950:963	the initiation	950:963	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	2	37	theme	brain	457:461	arg1	parts					444:448	parts	444:448	parts	444:448	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	37	theme	brain	457:461	arg1	liver					434:438	liver	434:438	liver	434:438	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	38	from	rat	470:472	arg1	parts					444:448	parts	444:448	parts	444:448	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	38	from	rat	470:472	arg1	liver					434:438	liver	434:438	liver	434:438	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	0	39	theme	Perinatal	0:8	arg1	Restriction					18:28	Perinatal Protein Restriction	0:28	Perinatal Protein Restriction	0:28	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	6	40	theme	O-GalNAc	968:975	arg1	biosynthesis					984:995	O-GalNAc glycan biosynthesis	968:995	O-GalNAc glycan biosynthesis	968:995	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	9	41	theme	writing	1702:1708	arg1	activity					1732:1739	the "writing" ppGalNAc-transferase activity	1697:1739	the "writing" ppGalNAc-transferase activity of O-GalNAc glycans	1697:1759	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	4	42	theme	Male	697:700	arg1	pups					702:705	Male pups	697:705	Male pups	697:705	Male pups were studied after weaning at 30 days of life.
36870540	9	43	theme	ppGalNAc-transferase	1711:1730	arg1	activity					1732:1739	the "writing" ppGalNAc-transferase activity	1697:1739	the "writing" ppGalNAc-transferase activity of O-GalNAc glycans	1697:1759	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	6	44	from	presence	888:895	arg1	cytoplasm					912:920	cytoplasm	912:920	cytoplasm	912:920	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	44	from	presence	888:895	arg1	nucleus					900:906	nucleus	900:906	nucleus	900:906	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	4	45	theme	life	748:751	arg1	days					740:743	30 days	737:743	30 days of life	737:751	Male pups were studied after weaning at 30 days of life.
36870540	0	46	theme	Nuclear	38:44	arg1	Glycosylation					55:67	Nuclear O-GalNAc Glycosylation	38:67	Nuclear O-GalNAc Glycosylation	38:67	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	9	47	from	nucleus	1674:1680	arg1	localized					1591:1599	localized	1591:1599	localized	1591:1599	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	2	48	from	glycosylation	402:414	arg1	parts					444:448	parts	444:448	parts	444:448	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	48	from	glycosylation	402:414	arg1	liver					434:438	liver	434:438	liver	434:438	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	11	49	theme	nuclei	2100:2105	arg1	glycosylation					2116:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	3	50	theme	Wistar	492:497	arg1	rats					499:502	METHODS Pregnant Wistar rats	475:502	METHODS Pregnant Wistar rats	475:502	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	9	51	theme	glycans	1753:1759	arg1	activity					1732:1739	the "writing" ppGalNAc-transferase activity	1697:1739	the "writing" ppGalNAc-transferase activity of O-GalNAc glycans	1697:1759	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	5	52	dep	organ/tissues	772:784	arg1	organ/tissues					772:784	their organ/tissues	766:784	their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus)	766:837	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	5	52	dep	organ/tissues	772:784	arg1	hippocampus					826:836	hippocampus	826:836	hippocampus	826:836	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	5	52	dep	organ/tissues	772:784	arg1	cerebellum					811:820	cerebellum	811:820	cerebellum	811:820	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	5	52	dep	organ/tissues	772:784	arg1	liver					787:791	liver	787:791	liver	787:791	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	5	52	dep	organ/tissues	772:784	arg1	cortex					803:808	cerebral cortex	794:808	cerebral cortex	794:808	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	3	53	theme	METHODS	475:481	arg1	rats					499:502	METHODS Pregnant Wistar rats	475:502	METHODS Pregnant Wistar rats	475:502	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	1	54	theme	cell	239:242	arg1	physiology					244:253	cell physiology	239:253	cell physiology	239:253	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	2	55	theme	nuclear	385:391	arg1	glycosylation					402:414	the nuclear O-GalNAc glycosylation	381:414	the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	381:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	8	56	theme	dietary	1497:1503	arg1	deficits					1513:1520	the perinatal dietary protein deficits	1483:1520	the perinatal dietary protein deficits	1483:1520	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	3	57	theme	protein-restricted	636:653	arg1	diet					655:658	protein-restricted diet	636:658	protein-restricted diet	636:658	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	3	57	theme	protein-restricted	636:653	arg1	%					633:633	8%	632:633	8% (protein-restricted diet)	632:659	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	6	58	theme	fluorescent	1159:1169	arg1	microscopy					1171:1180	fluorescent microscopy	1159:1180	fluorescent microscopy	1159:1180	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	2	59	theme	perinatal	361:369	arg1	period					371:376	the perinatal period	357:376	the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	357:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	11	60	theme	O-GalNAc	2107:2114	arg1	glycosylation					2116:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	10	61	theme	significant	1838:1848	arg1	reduction					1850:1858	a significant reduction	1836:1858	a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins	1836:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	2	62	theme	protein	330:336	arg1	restriction					338:348	protein restriction	330:348	protein restriction	330:348	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	5	63	theme	cerebral	794:801	arg1	organ/tissues					772:784	their organ/tissues	766:784	their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus)	766:837	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	5	63	theme	cerebral	794:801	arg1	cortex					803:808	cerebral cortex	794:808	cerebral cortex	794:808	Animals and their organ/tissues (liver, cerebral cortex, cerebellum and hippocampus) were weighed.
36870540	9	64	from	localized	1591:1599	arg1	cortex					1617:1622	the cerebral cortex	1604:1622	the cerebral cortex	1604:1622	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	9	64	from	localized	1591:1599	arg1	nucleus					1674:1680	the liver nucleus	1664:1680	the liver nucleus	1664:1680	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	10	65	theme	O-GalNAc	1881:1888	arg1	glycans					1890:1896	O-GalNAc glycans	1881:1896	O-GalNAc glycans	1881:1896	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	6	66	theme	mass	1232:1235	arg1	spectrometry					1237:1248	mass spectrometry	1232:1248	mass spectrometry	1232:1248	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	1	67	theme	nuclear	201:207	arg1	functions					217:225	nuclear protein functions	201:225	nuclear protein functions controlling cell physiology and an individual's health	201:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	9	68	theme	cerebral	1608:1615	arg1	cortex					1617:1622	the cerebral cortex	1604:1622	the cerebral cortex	1604:1622	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	3	69	theme	experiment	685:694	arg1	end					678:680	the end	674:680	the end of experiment	674:694	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	7	70	dep	RESULTS	1251:1257	arg1	reduced					1289:1295	reduced	1289:1295	reduced progeny weight, as well as cerebral cortex and cerebellum weight	1289:1360	RESULTS The perinatal protein deficit reduced progeny weight, as well as cerebral cortex and cerebellum weight.
36870540	10	71	theme	nuclear	1911:1917	arg1	proteins					1919:1926	important nuclear proteins	1901:1926	important nuclear proteins	1901:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	6	72	theme	enzyme-lectin	1200:1212	arg1	assay					1222:1226	enzyme-lectin sorbent assay	1200:1226	enzyme-lectin sorbent assay	1200:1226	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	3	73	theme	ad	564:565	arg1	libitum					567:573	ad libitum one	564:577	ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein	564:666	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	7	74	theme	protein	1273:1279	arg1	deficit					1281:1287	The perinatal protein deficit	1259:1287	The perinatal protein deficit	1259:1287	RESULTS The perinatal protein deficit reduced progeny weight, as well as cerebral cortex and cerebellum weight.
36870540	3	75	theme	diets	597:601	arg1	libitum					567:573	ad libitum one	564:577	ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein	564:666	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	1	76	theme	BACKGROUND	120:129	arg1	modifications					150:162	BACKGROUND Post-translational modifications	120:162	BACKGROUND Post-translational modifications	120:162	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	1	76	theme	BACKGROUND	120:129	arg1	factors					172:178	key factors	168:178	key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health	168:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	6	77	theme	enzyme	1034:1039	arg1	activity					1041:1048	enzyme activity	1034:1048	enzyme activity (ppGalNAc-transferase)	1034:1071	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	77	theme	enzyme	1034:1039	arg1	ppGalNAc-transferase					1051:1070	ppGalNAc-transferase	1051:1070	ppGalNAc-transferase	1051:1070	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	11	78	theme	diet	2023:2026	arg1	progeny					2047:2053	her progeny	2043:2053	her progeny	2043:2053	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	11	78	theme	diet	2023:2026	arg1	consumption					1987:1997	the consumption	1983:1997	the consumption of a protein-restricted diet by the dam	1983:2037	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	9	79	dep	cortex	1617:1622	arg1	cytoplasm					1640:1648	cytoplasm	1640:1648	cytoplasm	1640:1648	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	8	80	theme	cerebral	1419:1426	arg1	liver					1412:1416	liver	1412:1416	liver	1412:1416	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	8	80	theme	cerebral	1419:1426	arg1	cortex					1428:1433	cerebral cortex	1419:1433	cerebral cortex	1419:1433	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	6	81	theme	glycosylation	1081:1093	arg1	product					1095:1101	the glycosylation product	1077:1101	the glycosylation product (O-GalNAc glycans)	1077:1120	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	81	theme	glycosylation	1081:1093	arg1	glycans					1113:1119	O-GalNAc glycans	1104:1119	O-GalNAc glycans	1104:1119	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	2	82	dep	OBJECTIVE	283:291	arg1	examined					304:311	examined	304:311	examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	304:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	3	83	from	groups	526:531	arg1	day					536:538	day 14	536:541	day 14 of pregnancy	536:554	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	1	84	theme	key	168:170	arg1	modifications					150:162	BACKGROUND Post-translational modifications	120:162	BACKGROUND Post-translational modifications	120:162	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	1	84	theme	key	168:170	arg1	factors					172:178	key factors	168:178	key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health	168:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	9	85	from	cortex	1617:1622	arg1	localized					1591:1599	localized	1591:1599	localized	1591:1599	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	9	86	theme	liver	1668:1672	arg1	nucleus					1674:1680	the liver nucleus	1664:1680	the liver nucleus	1664:1680	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	2	87	from	brain	457:461	arg1	rat					470:472	the rat	466:472	the rat	466:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	0	88	theme	Structures	97:106	arg1	Cells					72:76	Cells	72:76	Cells of Liver and Brain Structures of the Rat	72:117	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	1	89	from	factors	172:178	arg1	modulation					187:196	the modulation	183:196	the modulation of nuclear protein functions controlling cell physiology and an individual's health	183:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	3	90	theme	Pregnant	483:490	arg1	rats					499:502	METHODS Pregnant Wistar rats	475:502	METHODS Pregnant Wistar rats	475:502	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	8	91	from	levels	1374:1379	arg1	nuclei					1402:1407	nuclei	1402:1407	nuclei	1402:1407	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	8	91	from	levels	1374:1379	arg1	cytoplasm					1388:1396	cytoplasm	1388:1396	cytoplasm	1388:1396	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	11	92	theme	protein	2169:2175	arg1	functions					2177:2185	nuclear protein functions	2161:2185	nuclear protein functions	2161:2185	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	0	93	theme	Protein	10:16	arg1	Restriction					18:28	Perinatal Protein Restriction	0:28	Perinatal Protein Restriction	0:28	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	10	94	from	proteins	1919:1926	arg1	reduction					1850:1858	a significant reduction	1836:1858	a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins	1836:1926	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	6	95	theme	glycan	977:982	arg1	biosynthesis					984:995	O-GalNAc glycan biosynthesis	968:995	O-GalNAc glycan biosynthesis	968:995	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	11	96	theme	liver	2094:2098	arg1	glycosylation					2116:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	the offsprings' liver nuclei O-GalNAc glycosylation	2078:2128	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	2	97	gly	glycosylation	402:414	arg1	cells					419:423	cells	419:423	cells from the liver and parts of the brain in the rat	419:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	2	98	theme	O-GalNAc	393:400	arg1	glycosylation					402:414	the nuclear O-GalNAc glycosylation	381:414	the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat	381:472	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	11	99	with	association	1963:1973	arg1	modulation					2064:2073	the modulation	2060:2073	the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions	2060:2185	CONCLUSIONS Our results report an association between the consumption of a protein-restricted diet by the dam and her progeny with the modulation in the offsprings' liver nuclei O-GalNAc glycosylation, which may ultimately regulate nuclear protein functions.
36870540	9	100	theme	"	1709:1709	arg1	activity					1732:1739	the "writing" ppGalNAc-transferase activity	1697:1739	the "writing" ppGalNAc-transferase activity of O-GalNAc glycans	1697:1759	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	0	101	theme	O-GalNAc	46:53	arg1	Glycosylation					55:67	Nuclear O-GalNAc Glycosylation	38:67	Nuclear O-GalNAc Glycosylation	38:67	Perinatal Protein Restriction Impacts Nuclear O-GalNAc Glycosylation in Cells of Liver and Brain Structures of the Rat.
36870540	1	102	theme	functions	217:225	arg1	modulation					187:196	the modulation	183:196	the modulation of nuclear protein functions controlling cell physiology and an individual's health	183:280	BACKGROUND Post-translational modifications are key factors in the modulation of nuclear protein functions controlling cell physiology and an individual's health.
36870540	3	103	contain	containing	603:612	arg2	%					633:633	8%	632:633	8% (protein-restricted diet)	632:659	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	3	103	contain	containing	603:612	arg1	diets					597:601	two isocaloric diets	582:601	two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein	582:666	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	3	103	contain	containing	603:612	arg2	%					616:616	24%	614:616	24% (well-fed)	614:627	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	3	103	contain	containing	603:612	arg2	diet					655:658	protein-restricted diet	636:658	protein-restricted diet	636:658	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	9	104	theme	O-GalNAc	1744:1751	arg1	glycans					1753:1759	O-GalNAc glycans	1744:1759	O-GalNAc glycans	1744:1759	However, this deficiency affected the ppGalNAc-transferase activity localized in the cerebral cortex and hippocampus cytoplasm as well as in the liver nucleus, thus reducing the "writing" ppGalNAc-transferase activity of O-GalNAc glycans.
36870540	2	105	dep	liver	434:438	arg1	the					430:432	the	430:432	the	430:432	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	8	106	theme	perinatal	1487:1495	arg1	deficits					1513:1520	the perinatal dietary protein deficits	1483:1520	the perinatal dietary protein deficits	1483:1520	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36870540	10	107	theme	liver	1775:1779	arg1	nucleoplasm					1781:1791	liver nucleoplasm	1775:1791	liver nucleoplasm from protein-restricted offspring	1775:1825	In addition, liver nucleoplasm from protein-restricted offspring revealed a significant reduction in the expression of O-GalNAc glycans on important nuclear proteins.
36870540	6	108	dep	donor	1014:1018	arg1	i.e.					998:1001	i.e.	998:1001	i.e.	998:1001	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	2	109	theme	restriction	338:348	arg1	influence					317:325	the influence	313:325	the influence of protein restriction	313:348	OBJECTIVE This study examined the influence of protein restriction during the perinatal period on the nuclear O-GalNAc glycosylation of cells from the liver and parts of the brain in the rat.
36870540	3	110	dep	%	616:616	arg1	well-fed					619:626	well-fed	619:626	well-fed	619:626	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	3	110	dep	%	616:616	arg1	casein					661:666	casein	661:666	casein	661:666	METHODS Pregnant Wistar rats were divided into two groups on day 14 of pregnancy and fed ad libitum one of two isocaloric diets containing 24% (well-fed) or 8% (protein-restricted diet) casein until the end of experiment.
36870540	6	111	theme	sugar	1008:1012	arg1	UDP-GalNAc					1021:1030	UDP-GalNAc	1021:1030	UDP-GalNAc	1021:1030	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	6	111	theme	sugar	1008:1012	arg1	donor					1014:1018	the sugar donor	1004:1018	the sugar donor (UDP-GalNAc)	1004:1031	Cell nuclei were purified, and the presence in nucleus and cytoplasm of all factors required for the initiation of O-GalNAc glycan biosynthesis, i.e., the sugar donor (UDP-GalNAc), enzyme activity (ppGalNAc-transferase) and the glycosylation product (O-GalNAc glycans), were evaluated by western blotting, fluorescent microscopy, enzyme activity, enzyme-lectin sorbent assay and mass spectrometry.
36870540	8	112	theme	protein	1505:1511	arg1	deficits					1513:1520	the perinatal dietary protein deficits	1483:1520	the perinatal dietary protein deficits	1483:1520	UDP-GalNAc levels in the cytoplasm and nuclei of liver, cerebral cortex, cerebellum or hippocampus were not affected by the perinatal dietary protein deficits.
36838558	8	0	theme	structural	959:968	arg1	information					970:980	structural information	959:980	structural information regarding the glycosylation site and glycan structure	959:1034	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	4	1	theme	present	539:545	arg1	hydrolysis					516:525	hydrolysis	516:525	hydrolysis of α-GalNAc present on GcMAF	516:554	Upon hydrolysis of α-GalNAc present on GcMAF, the protein loses the macrophage-activating effect.
36838558	5	2	theme	in	686:687	arg1	activity					719:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	2	3	theme	O-linked	314:321	arg1	glycans					323:329	O-linked glycans	314:329	O-linked glycans in Gc proteins from human plasma	314:362	O-linked glycans in Gc proteins from human plasma mainly consist of trisaccharides.
36838558	7	4	theme	spectrometric	865:877	arg1	analyses					879:886	Detailed mass spectrometric analyses	851:886	Detailed mass spectrometric analyses	851:886	Detailed mass spectrometric analyses revealed the protective effect of the inhibitor on GcMAF.
36838558	1	5	theme	GalNAc-attached	228:242	arg1	form					244:247	the GalNAc-attached form	224:247	the GalNAc-attached form of Gc protein	224:261	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	0	6	theme	Glycan	84:89	arg1	Structure					91:99	the Glycan Structure	80:99	the Glycan Structure of Gc Protein	80:113	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	8	7	theme	mass	1062:1065	arg1	analysis					1089:1096	tandem mass spectrometric (MS/MS) analysis	1055:1096	tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides	1055:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	6	8	theme	iminocyclitol	782:794	arg1	effects					771:777	the protective effects	756:777	the protective effects of iminocyclitol against GcMAF	756:808	In this study, we examined the protective effects of iminocyclitol against GcMAF via inhibition of α-GalNAc-ase activity.
36838558	8	9	theme	tandem	1055:1060	arg1	analysis					1089:1096	tandem mass spectrometric (MS/MS) analysis	1055:1096	tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides	1055:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	1	10	from	α-N-acetylgalactosamine	125:147	arg1	protein					170:176	the Gc protein	163:176	the Gc protein	163:176	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	7	11	theme	Detailed	851:858	arg1	analyses					879:886	Detailed mass spectrometric analyses	851:886	Detailed mass spectrometric analyses	851:886	Detailed mass spectrometric analyses revealed the protective effect of the inhibitor on GcMAF.
36838558	8	12	gly	glycosylated	1105:1116	arg1	peptides					1118:1125	the glycosylated peptides	1101:1125	the glycosylated peptides	1101:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	2	13	link	O-linked	314:321	arg1	glycans					323:329	O-linked glycans	314:329	O-linked glycans in Gc proteins from human plasma	314:362	O-linked glycans in Gc proteins from human plasma mainly consist of trisaccharides.
36838558	8	14	theme	glycosylation	996:1008	arg1	site					1010:1013	the glycosylation site	992:1013	the glycosylation site	992:1013	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	8	15	theme	peptides	1118:1125	arg1	analysis					1089:1096	tandem mass spectrometric (MS/MS) analysis	1055:1096	tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides	1055:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	7	16	theme	mass	860:863	arg1	analyses					879:886	Detailed mass spectrometric analyses	851:886	Detailed mass spectrometric analyses	851:886	Detailed mass spectrometric analyses revealed the protective effect of the inhibitor on GcMAF.
36838558	8	17	theme	spectrometric	1067:1079	arg1	analysis					1089:1096	tandem mass spectrometric (MS/MS) analysis	1055:1096	tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides	1055:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	2	18	from	glycans	323:329	arg1	proteins					337:344	Gc proteins	334:344	Gc proteins	334:344	O-linked glycans in Gc proteins from human plasma mainly consist of trisaccharides.
36838558	2	19	theme	human	351:355	arg1	plasma					357:362	human plasma	351:362	human plasma	351:362	O-linked glycans in Gc proteins from human plasma mainly consist of trisaccharides.
36838558	5	20	dep	in	686:687	arg1	vitro					689:693	vitro	689:693	vitro	689:693	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	6	21	theme	protective	760:769	arg1	effects					771:777	the protective effects	756:777	the protective effects of iminocyclitol against GcMAF	756:808	In this study, we examined the protective effects of iminocyclitol against GcMAF via inhibition of α-GalNAc-ase activity.
36838558	5	22	theme	pyrrolidine-type	638:653	arg1	iminocyclitol					655:667	our synthesized pyrrolidine-type iminocyclitol	622:667	our synthesized pyrrolidine-type iminocyclitol	622:667	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	1	23	theme	Gc	167:168	arg1	protein					170:176	the Gc protein	163:176	the Gc protein	163:176	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	4	24	from	hydrolysis	516:525	arg1	GcMAF					550:554	GcMAF	550:554	GcMAF	550:554	Upon hydrolysis of α-GalNAc present on GcMAF, the protein loses the macrophage-activating effect.
36838558	1	25	theme	Gc	252:253	arg1	protein					255:261	Gc protein	252:261	Gc protein	252:261	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	8	26	theme	MS/MS	1082:1086	arg1	analysis					1089:1096	tandem mass spectrometric (MS/MS) analysis	1055:1096	tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides	1055:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	7	27	theme	inhibitor	926:934	arg1	effect					912:917	the protective effect	897:917	the protective effect of the inhibitor on GcMAF	897:943	Detailed mass spectrometric analyses revealed the protective effect of the inhibitor on GcMAF.
36838558	7	28	from	effect	912:917	arg1	GcMAF					939:943	GcMAF	939:943	GcMAF	939:943	Detailed mass spectrometric analyses revealed the protective effect of the inhibitor on GcMAF.
36838558	5	29	theme	inhibitory	708:717	arg1	activity					719:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	0	30	theme	Protective	21:30	arg1	Effect					32:37	the Protective Effect	17:37	the Protective Effect for GcMAF by a Glycosidase Inhibitor	17:74	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	1	31	theme	protein	255:261	arg1	form					244:247	the GalNAc-attached form	224:247	the GalNAc-attached form of Gc protein	224:261	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	0	32	theme	Protein	107:113	arg1	Investigation					0:12	Investigation	0:12	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor	0:74	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	0	32	theme	Protein	107:113	arg1	Structure					91:99	the Glycan Structure	80:99	the Glycan Structure of Gc Protein	80:113	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	4	33	theme	macrophage-activating	579:599	arg1	effect					601:606	the macrophage-activating effect	575:606	the macrophage-activating effect	575:606	Upon hydrolysis of α-GalNAc present on GcMAF, the protein loses the macrophage-activating effect.
36838558	0	34	theme	Gc	104:105	arg1	Protein					107:113	Gc Protein	104:113	Gc Protein	104:113	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	8	35	theme	glycosylated	1105:1116	arg1	peptides					1118:1125	the glycosylated peptides	1101:1125	the glycosylated peptides	1101:1125	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	0	36	theme	Effect	32:37	arg1	Investigation					0:12	Investigation	0:12	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor	0:74	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	0	36	theme	Effect	32:37	arg1	Structure					91:99	the Glycan Structure	80:99	the Glycan Structure of Gc Protein	80:113	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	1	37	theme	Gc	273:274	arg1	GcMAF					306:310	GcMAF	306:310	GcMAF	306:310	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	37	theme	Gc	273:274	arg1	factor					298:303	Gc macrophage activating factor	273:303	Gc macrophage activating factor (GcMAF)	273:311	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	4	38	theme	α-GalNAc	530:537	arg1	present					539:545	α-GalNAc present	530:545	α-GalNAc present	530:545	Upon hydrolysis of α-GalNAc present on GcMAF, the protein loses the macrophage-activating effect.
36838558	8	39	gly	glycosylation	996:1008	arg2	site					1010:1013	the glycosylation site	992:1013	the glycosylation site	992:1013	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	1	40	theme	macrophage	195:204	arg1	activation					206:215	macrophage activation	195:215	macrophage activation	195:215	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	41	theme	macrophage	276:285	arg1	GcMAF					306:310	GcMAF	306:310	GcMAF	306:310	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	41	theme	macrophage	276:285	arg1	factor					298:303	Gc macrophage activating factor	273:303	Gc macrophage activating factor (GcMAF)	273:311	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	5	42	theme	synthesized	626:636	arg1	iminocyclitol					655:667	our synthesized pyrrolidine-type iminocyclitol	622:667	our synthesized pyrrolidine-type iminocyclitol	622:667	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	6	43	theme	activity	841:848	arg1	inhibition					814:823	inhibition	814:823	inhibition of α-GalNAc-ase activity	814:848	In this study, we examined the protective effects of iminocyclitol against GcMAF via inhibition of α-GalNAc-ase activity.
36838558	3	44	from	glycans	421:427	arg1	protein					439:445	the Gc protein	432:445	the Gc protein	432:445	GcMAF is produced when glycans on the Gc protein are hydrolyzed by α-Sia-ase and β-Gal-ase, leaving an α-GalNAc.
36838558	5	45	contain	possessed	669:677	arg1	iminocyclitol					655:667	our synthesized pyrrolidine-type iminocyclitol	622:667	our synthesized pyrrolidine-type iminocyclitol	622:667	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	5	45	contain	possessed	669:677	arg2	activity					719:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	5	46	theme	α-GalNAc-ase	695:706	arg1	activity					719:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
36838558	1	47	theme	activating	287:296	arg1	GcMAF					306:310	GcMAF	306:310	GcMAF	306:310	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	47	theme	activating	287:296	arg1	factor					298:303	Gc macrophage activating factor	273:303	Gc macrophage activating factor (GcMAF)	273:311	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	48	link	O-linked	116:123	arg1	α-GalNAc					150:157	α-GalNAc	150:157	α-GalNAc	150:157	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	48	link	O-linked	116:123	arg1	α-N-acetylgalactosamine					125:147	O-linked α-N-acetylgalactosamine	116:147	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein	116:176	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	6	49	theme	α-GalNAc-ase	828:839	arg1	activity					841:848	α-GalNAc-ase activity	828:848	α-GalNAc-ase activity	828:848	In this study, we examined the protective effects of iminocyclitol against GcMAF via inhibition of α-GalNAc-ase activity.
36838558	2	50	from	plasma	357:362	arg1	glycans					323:329	O-linked glycans	314:329	O-linked glycans in Gc proteins from human plasma	314:362	O-linked glycans in Gc proteins from human plasma mainly consist of trisaccharides.
36838558	8	51	theme	glycan	1019:1024	arg1	structure					1026:1034	glycan structure	1019:1034	glycan structure	1019:1034	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	3	52	theme	Gc	436:437	arg1	protein					439:445	the Gc protein	432:445	the Gc protein	432:445	GcMAF is produced when glycans on the Gc protein are hydrolyzed by α-Sia-ase and β-Gal-ase, leaving an α-GalNAc.
36838558	8	53	theme	tryptic	1133:1139	arg1	digestion					1141:1149	tryptic digestion	1133:1149	tryptic digestion	1133:1149	Furthermore, structural information regarding the glycosylation site and glycan structure was obtained using tandem mass spectrometric (MS/MS) analysis of the glycosylated peptides after tryptic digestion.
36838558	1	54	theme	O-linked	116:123	arg1	α-GalNAc					150:157	α-GalNAc	150:157	α-GalNAc	150:157	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	1	54	theme	O-linked	116:123	arg1	α-N-acetylgalactosamine					125:147	O-linked α-N-acetylgalactosamine	116:147	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein	116:176	O-linked α-N-acetylgalactosamine (α-GalNAc) in the Gc protein is essential for macrophage activation; thus, the GalNAc-attached form of Gc protein is called Gc macrophage activating factor (GcMAF).
36838558	7	55	theme	protective	901:910	arg1	effect					912:917	the protective effect	897:917	the protective effect of the inhibitor on GcMAF	897:943	Detailed mass spectrometric analyses revealed the protective effect of the inhibitor on GcMAF.
36838558	0	56	theme	Glycosidase	54:64	arg1	Inhibitor					66:74	a Glycosidase Inhibitor	52:74	a Glycosidase Inhibitor	52:74	Investigation of the Protective Effect for GcMAF by a Glycosidase Inhibitor and the Glycan Structure of Gc Protein.
36838558	2	57	theme	Gc	334:335	arg1	proteins					337:344	Gc proteins	334:344	Gc proteins	334:344	O-linked glycans in Gc proteins from human plasma mainly consist of trisaccharides.
36838558	5	58	theme	strong	679:684	arg1	activity					719:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	strong in vitro α-GalNAc-ase inhibitory activity	679:726	In contrast, our synthesized pyrrolidine-type iminocyclitol possessed strong in vitro α-GalNAc-ase inhibitory activity.
34611877	6	0	dep	structures on	878:890	arg1	membrane					912:919	the neuronal plasma membrane	892:919	highly sialylated structures on the neuronal plasma membrane	860:919	We also observe highly sialylated structures on the neuronal plasma membrane, which warrant further investigation.
34611877	1	1	theme	neurotransmitter	141:156	arg1	release					158:164	neurotransmitter release	141:164	neurotransmitter release	141:164	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	2	theme	activity	244:251	arg1	modulation					218:227	modulation	218:227	modulation of ion channel activity	218:251	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	2	theme	activity	244:251	arg1	function					265:272	immune function	258:272	immune function	258:272	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	2	theme	activity	244:251	arg1	communication					190:202	cell-cell communication	180:202	cell-cell communication	180:202	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	2	theme	activity	244:251	arg1	release					158:164	neurotransmitter release	141:164	neurotransmitter release	141:164	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	2	theme	activity	244:251	arg1	adhesion					208:215	adhesion	208:215	adhesion	208:215	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	2	theme	activity	244:251	arg1	reuptake					170:177	reuptake	170:177	reuptake	170:177	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	5	3	theme	GlcNAz	759:764	arg1	patterns					747:754	different patterns	737:754	different patterns of GlcNAz, GalNAz, and ManNAz distribution	737:797	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	6	4	theme	plasma	905:910	arg1	membrane					912:919	the neuronal plasma membrane	892:919	highly sialylated structures on the neuronal plasma membrane	860:919	We also observe highly sialylated structures on the neuronal plasma membrane, which warrant further investigation.
34611877	4	5	theme	different	668:676	arg1	forms					678:682	different forms	668:682	different forms of glycosylation	668:699	In addition, we use high resolution confocal and STED microscopy to image and analyze different forms of glycosylation in ultrahigh resolution.
34611877	6	6	theme	neuronal	896:903	arg1	membrane					912:919	the neuronal plasma membrane	892:919	highly sialylated structures on the neuronal plasma membrane	860:919	We also observe highly sialylated structures on the neuronal plasma membrane, which warrant further investigation.
34611877	2	7	theme	click	288:292	arg1	technique					318:326	a powerful technique	307:326	a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo	307:399	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	2	7	theme	click	288:292	arg1	chemistry					294:302	Carbohydrate click chemistry	275:302	Carbohydrate click chemistry	275:302	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	3	8	theme	primary	552:558	arg1	neurons					573:579	primary rat cortical neurons	552:579	primary rat cortical neurons	552:579	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	2	9	theme	Carbohydrate	275:286	arg1	technique					318:326	a powerful technique	307:326	a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo	307:399	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	2	9	theme	Carbohydrate	275:286	arg1	chemistry					294:302	Carbohydrate click chemistry	275:302	Carbohydrate click chemistry	275:302	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	1	10	theme	immune	258:263	arg1	function					265:272	immune function	258:272	immune function	258:272	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	2	11	theme	glycan	341:346	arg1	function					348:355	glycan function	341:355	glycan function	341:355	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	6	12	theme	sialylated	867:876	arg1	structures on					878:890	highly sialylated structures on	860:890	highly sialylated structures on the neuronal plasma membrane	860:919	We also observe highly sialylated structures on the neuronal plasma membrane, which warrant further investigation.
34611877	5	13	theme	distribution	786:797	arg1	patterns					747:754	different patterns	737:754	different patterns of GlcNAz, GalNAz, and ManNAz distribution	737:797	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	4	14	theme	STED	631:634	arg1	microscopy					636:645	high resolution confocal and STED microscopy	602:645	microscopy	636:645	In addition, we use high resolution confocal and STED microscopy to image and analyze different forms of glycosylation in ultrahigh resolution.
34611877	5	15	theme	ManNAz	779:784	arg1	distribution					786:797	ManNAz distribution	779:797	ManNAz distribution	779:797	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	2	16	theme	powerful	309:316	arg1	technique					318:326	a powerful technique	307:326	a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo	307:399	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	2	16	theme	powerful	309:316	arg1	chemistry					294:302	Carbohydrate click chemistry	275:302	Carbohydrate click chemistry	275:302	Carbohydrate click chemistry is a powerful technique for studying glycan function and dynamics in vitro, in vivo, and ex vivo.
34611877	0	17	theme	Metabolic	0:8	arg1	Labeling					10:17	Metabolic Labeling	0:17	Metabolic Labeling of Primary Neurons	0:36	Metabolic Labeling of Primary Neurons Using Carbohydrate Click Chemistry.
34611877	3	18	theme	rat	560:562	arg1	neurons					573:579	primary rat cortical neurons	552:579	primary rat cortical neurons	552:579	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	1	19	theme	cell-cell	180:188	arg1	communication					190:202	cell-cell communication	180:202	cell-cell communication	180:202	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	0	20	theme	Primary	22:28	arg1	Neurons					30:36	Primary Neurons	22:36	Primary Neurons	22:36	Metabolic Labeling of Primary Neurons Using Carbohydrate Click Chemistry.
34611877	3	21	theme	available	428:436	arg1	sugars					470:475	commercially available synthetic tetraacetylated azido sugars	415:475	commercially available synthetic tetraacetylated azido sugars	415:475	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	1	22	theme	important	90:98	arg1	role					100:103	an important role	87:103	an important role	87:103	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	3	23	theme	synthetic	438:446	arg1	sugars					470:475	commercially available synthetic tetraacetylated azido sugars	415:475	commercially available synthetic tetraacetylated azido sugars	415:475	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	5	24	theme	neuronal	822:829	arg1	development					831:841	neuronal development	822:841	neuronal development	822:841	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	0	25	theme	Neurons	30:36	arg1	Labeling					10:17	Metabolic Labeling	0:17	Metabolic Labeling of Primary Neurons	0:36	Metabolic Labeling of Primary Neurons Using Carbohydrate Click Chemistry.
34611877	5	26	theme	GalNAz	767:772	arg1	patterns					747:754	different patterns	737:754	different patterns of GlcNAz, GalNAz, and ManNAz distribution	737:797	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	5	27	theme	development	831:841	arg1	stages					812:817	different stages	802:817	different stages of neuronal development	802:841	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	0	28	theme	Click	57:61	arg1	Chemistry					63:71	Carbohydrate Click Chemistry	44:71	Carbohydrate Click Chemistry	44:71	Metabolic Labeling of Primary Neurons Using Carbohydrate Click Chemistry.
34611877	6	29	theme	further	936:942	arg1	investigation					944:956	further investigation	936:956	further investigation	936:956	We also observe highly sialylated structures on the neuronal plasma membrane, which warrant further investigation.
34611877	3	30	theme	cortical	564:571	arg1	neurons					573:579	primary rat cortical neurons	552:579	primary rat cortical neurons	552:579	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	1	31	theme	many	108:111	arg1	modulation					218:227	modulation	218:227	modulation of ion channel activity	218:251	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	31	theme	many	108:111	arg1	function					265:272	immune function	258:272	immune function	258:272	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	31	theme	many	108:111	arg1	communication					190:202	cell-cell communication	180:202	cell-cell communication	180:202	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	31	theme	many	108:111	arg1	release					158:164	neurotransmitter release	141:164	neurotransmitter release	141:164	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	31	theme	many	108:111	arg1	processes					122:130	many neuronal processes	108:130	many neuronal processes	108:130	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	31	theme	many	108:111	arg1	reuptake					170:177	reuptake	170:177	reuptake	170:177	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	0	32	theme	Carbohydrate	44:55	arg1	Chemistry					63:71	Carbohydrate Click Chemistry	44:71	Carbohydrate Click Chemistry	44:71	Metabolic Labeling of Primary Neurons Using Carbohydrate Click Chemistry.
34611877	1	33	theme	neuronal	113:120	arg1	modulation					218:227	modulation	218:227	modulation of ion channel activity	218:251	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	33	theme	neuronal	113:120	arg1	function					265:272	immune function	258:272	immune function	258:272	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	33	theme	neuronal	113:120	arg1	communication					190:202	cell-cell communication	180:202	cell-cell communication	180:202	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	33	theme	neuronal	113:120	arg1	release					158:164	neurotransmitter release	141:164	neurotransmitter release	141:164	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	33	theme	neuronal	113:120	arg1	processes					122:130	many neuronal processes	108:130	many neuronal processes	108:130	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	1	33	theme	neuronal	113:120	arg1	reuptake					170:177	reuptake	170:177	reuptake	170:177	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	4	34	theme	glycosylation	687:699	arg1	forms					678:682	different forms	668:682	different forms of glycosylation	668:699	In addition, we use high resolution confocal and STED microscopy to image and analyze different forms of glycosylation in ultrahigh resolution.
34611877	3	35	theme	tetraacetylated	448:462	arg1	sugars					470:475	commercially available synthetic tetraacetylated azido sugars	415:475	commercially available synthetic tetraacetylated azido sugars	415:475	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	3	36	theme	azido	464:468	arg1	sugars					470:475	commercially available synthetic tetraacetylated azido sugars	415:475	commercially available synthetic tetraacetylated azido sugars	415:475	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	4	37	theme	ultrahigh	704:712	arg1	resolution					714:723	ultrahigh resolution	704:723	ultrahigh resolution	704:723	In addition, we use high resolution confocal and STED microscopy to image and analyze different forms of glycosylation in ultrahigh resolution.
34611877	5	38	theme	different	737:745	arg1	patterns					747:754	different patterns	737:754	different patterns of GlcNAz, GalNAz, and ManNAz distribution	737:797	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	3	39	theme	copper-free	489:499	arg1	chemistry					507:515	copper-free click chemistry	489:515	copper-free click chemistry	489:515	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	6	40	gly	sialylated	867:876	arg1	structures on					878:890	highly sialylated structures on	860:890	highly sialylated structures on the neuronal plasma membrane	860:919	We also observe highly sialylated structures on the neuronal plasma membrane, which warrant further investigation.
34611877	1	41	theme	ion	232:234	arg1	activity					244:251	ion channel activity	232:251	ion channel activity	232:251	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
34611877	5	42	theme	different	802:810	arg1	stages					812:817	different stages	802:817	different stages of neuronal development	802:841	We observe different patterns of GlcNAz, GalNAz, and ManNAz distribution at different stages of neuronal development.
34611877	3	43	theme	click	501:505	arg1	chemistry					507:515	copper-free click chemistry	489:515	copper-free click chemistry	489:515	Here, we use commercially available synthetic tetraacetylated azido sugars, copper and copper-free click chemistry to metabolically label and analyze primary rat cortical neurons.
34611877	1	44	theme	channel	236:242	arg1	activity					244:251	ion channel activity	232:251	ion channel activity	232:251	Glycans play an important role in many neuronal processes, such as neurotransmitter release and reuptake, cell-cell communication and adhesion, modulation of ion channel activity, and immune function.
37202422	0	0	theme	IgG	82:84	arg1	nanobody					86:93	an anti-afucosylated IgG nanobody	61:93	an anti-afucosylated IgG nanobody	61:93	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	7	1	theme	afucosylated	1078:1089	arg1	interactions					1105:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	1	2	theme	complex	140:146	arg1	N-glycan					148:155	a complex N-glycan	138:155	a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers	138:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	6	3	gly	afucosylated	884:895	arg1	N-glycan					901:908	the afucosylated IgG N-glycan	880:908	the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue	880:993	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	0	4	theme	anti-afucosylated	64:80	arg1	nanobody					86:93	an anti-afucosylated IgG nanobody	61:93	an anti-afucosylated IgG nanobody	61:93	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	7	5	theme	IgG1-FcγRIIIa	1091:1103	arg1	interactions					1105:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	6	6	theme	buried	805:810	arg1	N-glycan					812:819	the buried N-glycan	801:819	the buried N-glycan	801:819	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	5	7	from	structure	624:632	arg1	complex					663:669	complex	663:669	complex with the Fc fragment of afucosylated IgG1	663:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	7	8	theme	infection	1161:1169	arg1	model					1139:1143	a model	1137:1143	a model of dengue virus infection	1137:1169	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	6	9	theme	hydrogen	860:867	arg1	bonds					869:873	hydrogen bonds	860:873	hydrogen bonds	860:873	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	2	10	theme	Fc	289:290	arg1	domain					292:297	the Fc domain	285:297	the Fc domain	285:297	This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses.
37202422	7	11	theme	virus	1155:1159	arg1	infection					1161:1169	dengue virus infection	1148:1169	dengue virus infection	1148:1169	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	5	12	theme	IgG1	708:711	arg1	fragment					683:690	the Fc fragment	676:690	the Fc fragment of afucosylated IgG1	676:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	7	13	theme	pathogenic	1067:1076	arg1	interactions					1105:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	7	14	theme	rescue	1122:1127	arg1	mice					1129:1132	rescue mice	1122:1132	rescue mice	1122:1132	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	7	15	theme	dengue	1148:1153	arg1	infection					1161:1169	dengue virus infection	1148:1169	dengue virus infection	1148:1169	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	5	16	theme	one	637:639	arg1	structure					624:632	the structure	620:632	the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1	620:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	0	17	gly	anti-afucosylated	64:80	arg1	nanobody					86:93	an anti-afucosylated IgG nanobody	61:93	an anti-afucosylated IgG nanobody	61:93	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	1	18	theme	embedded	157:164	arg1	N-glycan					148:155	a complex N-glycan	138:155	a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers	138:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	3	19	gly	glycoproteins	491:503	arg1	glycoproteins					491:503	highly-related, but non-equivalent glycoproteins	456:503	highly-related, but non-equivalent glycoproteins known as glycoforms	456:523	The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms.
37202422	3	20	theme	glycan	430:435	arg1	structure					437:445	this glycan structure	425:445	this glycan structure	425:445	The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms.
37202422	2	21	theme	structural	258:267	arg1	organization					269:280	the structural organization	254:280	the structural organization of the Fc domain	254:297	This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses.
37202422	1	22	contain	contain	130:136	arg2	N-glycan					148:155	a complex N-glycan	138:155	a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers	138:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	1	22	contain	contain	130:136	arg1	antibodies					119:128	Immunoglobulin G (IgG) antibodies	96:128	Immunoglobulin G (IgG) antibodies	96:128	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	7	23	theme	X0	1033:1034	arg1	constructs					1043:1052	X0 fusion constructs	1033:1052	X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection	1033:1169	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	6	24	theme	conformational	770:783	arg1	shift					785:789	a conformational shift	768:789	a conformational shift to access the buried N-glycan and acts as a 'glycan sensor'	768:849	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	2	25	theme	cellular	376:383	arg1	responses					385:393	distinct cellular responses	367:393	distinct cellular responses	367:393	This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses.
37202422	4	26	theme	IgG	587:589	arg1	glycoforms					591:600	IgG glycoforms	587:600	IgG glycoforms	587:600	We previously reported synthetic nanobodies that distinguish IgG glycoforms.
37202422	7	27	theme	fusion	1036:1041	arg1	constructs					1043:1052	X0 fusion constructs	1033:1052	X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection	1033:1169	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	2	28	theme	distinct	367:374	arg1	responses					385:393	distinct cellular responses	367:393	distinct cellular responses	367:393	This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses.
37202422	0	29	theme	specificity	23:33	arg1	Mechanism					0:8	Mechanism	0:8	Mechanism of glycoform specificity	0:33	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	0	29	theme	specificity	23:33	arg1	protection					47:56	in vivo protection	39:56	in vivo protection by an anti-afucosylated IgG nanobody	39:93	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	5	30	theme	afucosylated	695:706	arg1	IgG1					708:711	afucosylated IgG1	695:711	afucosylated IgG1	695:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	2	31	theme	domain	292:297	arg1	organization					269:280	the structural organization	254:280	the structural organization of the Fc domain	254:297	This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses.
37202422	0	32	theme	glycoform	13:21	arg1	specificity					23:33	glycoform specificity	13:33	glycoform specificity	13:33	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	4	33	gly	glycoforms	591:600	arg1	IgG					587:589	IgG glycoforms	587:600	IgG glycoforms	587:600	We previously reported synthetic nanobodies that distinguish IgG glycoforms.
37202422	1	34	theme	G	111:111	arg1	antibodies					119:128	Immunoglobulin G (IgG) antibodies	96:128	Immunoglobulin G (IgG) antibodies	96:128	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	7	35	gly	afucosylated	1078:1089	arg1	interactions					1105:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	pathogenic afucosylated IgG1-FcγRIIIa interactions	1067:1116	Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.
37202422	0	36	theme	in	39:40	arg1	protection					47:56	in vivo protection	39:56	in vivo protection by an anti-afucosylated IgG nanobody	39:93	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	6	37	theme	glycan	836:841	arg1	sensor					843:848	a 'glycan sensor'	833:849	a 'glycan sensor'	833:849	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	1	38	theme	hydrophobic	173:183	arg1	pocket					185:190	the hydrophobic pocket	169:190	the hydrophobic pocket between its heavy chain protomers	169:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	3	39	theme	structure	437:445	arg1	construction					409:420	The variable construction	396:420	The variable construction of this glycan structure	396:445	The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms.
37202422	4	40	theme	synthetic	549:557	arg1	nanobodies					559:568	synthetic nanobodies	549:568	synthetic nanobodies that distinguish IgG glycoforms	549:600	We previously reported synthetic nanobodies that distinguish IgG glycoforms.
37202422	6	41	theme	X0	755:756	arg1	loop					747:750	the elongated CDR3 loop	728:750	the elongated CDR3 loop of X0	728:756	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	1	42	theme	heavy	204:208	arg1	chain					210:214	its heavy chain	200:214	its heavy chain protomers	200:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	0	43	dep	in	39:40	arg1	vivo					42:45	vivo	42:45	vivo	42:45	Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
37202422	2	44	theme	Fcγ	334:336	arg1	receptors					338:346	Fcγ receptors	334:346	Fcγ receptors	334:346	This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses.
37202422	3	45	theme	variable	400:407	arg1	construction					409:420	The variable construction	396:420	The variable construction of this glycan structure	396:445	The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms.
37202422	5	46	theme	Fc	680:681	arg1	fragment					683:690	the Fc fragment	676:690	the Fc fragment of afucosylated IgG1	676:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	1	47	from	pocket	185:190	arg1	embedded					157:164	embedded	157:164	embedded	157:164	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	5	48	gly	afucosylated	695:706	arg1	IgG1					708:711	afucosylated IgG1	695:711	afucosylated IgG1	695:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	6	49	theme	IgG	897:899	arg1	N-glycan					901:908	the afucosylated IgG N-glycan	880:908	the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue	880:993	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	6	50	theme	CDR3	742:745	arg1	loop					747:750	the elongated CDR3 loop	728:750	the elongated CDR3 loop of X0	728:756	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	3	51	theme	non-equivalent	476:489	arg1	glycoproteins					491:503	highly-related, but non-equivalent glycoproteins	456:503	highly-related, but non-equivalent glycoproteins known as glycoforms	456:523	The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms.
37202422	1	52	theme	Immunoglobulin	96:109	arg1	IgG					114:116	IgG	114:116	IgG	114:116	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	1	52	theme	Immunoglobulin	96:109	arg1	G					111:111	Immunoglobulin G	96:111	Immunoglobulin G (IgG) antibodies	96:128	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	1	53	theme	chain	210:214	arg1	protomers					216:224	its heavy chain protomers	200:224	its heavy chain protomers	200:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	6	54	theme	elongated	732:740	arg1	loop					747:750	the elongated CDR3 loop	728:750	the elongated CDR3 loop of X0	728:756	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	6	55	theme	fucose	980:985	arg1	residue					987:993	a core fucose residue	973:993	a core fucose residue	973:993	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	3	56	theme	highly-related	456:469	arg1	glycoproteins					491:503	highly-related, but non-equivalent glycoproteins	456:503	highly-related, but non-equivalent glycoproteins known as glycoforms	456:523	The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms.
37202422	5	57	with	complex	663:669	arg1	fragment					683:690	the Fc fragment	676:690	the Fc fragment of afucosylated IgG1	676:711	Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.
37202422	6	58	theme	core	975:978	arg1	residue					987:993	a core fucose residue	973:993	a core fucose residue	973:993	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	6	59	theme	afucosylated	884:895	arg1	N-glycan					901:908	the afucosylated IgG N-glycan	880:908	the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue	880:993	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
37202422	1	60	from	embedded	157:164	arg1	pocket					185:190	the hydrophobic pocket	169:190	the hydrophobic pocket between its heavy chain protomers	169:224	Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers.
37202422	6	61	theme	residue	987:993	arg1	presence					961:968	the presence	957:968	the presence of a core fucose residue	957:993	Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue.
36398945	0	0	theme	Preactivated	99:110	arg1	Macromolecules					139:152	Preactivated N-Methyloxyamine Precision Macromolecules	99:152	Preactivated N-Methyloxyamine Precision Macromolecules	99:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	7	1	with	oligosaccharides	1537:1552	arg1	variability					1564:1574	high variability	1559:1574	high variability	1559:1574	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	6	2	link	α2,6-linked	1217:1227	arg1	acid					1245:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	2	3	theme	protecting	418:427	arg1	groups					429:434	protecting groups	418:434	protecting groups	418:434	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	6	4	theme	terminal	1229:1236	arg1	acid					1245:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	6	5	theme	polyomavirus	1296:1307	arg1	proteins					1316:1323	polyomavirus capsid proteins	1296:1323	polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein	1296:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	6	6	theme	α2,3-	1208:1212	arg1	acid					1245:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	6	7	theme	α2,6-linked	1217:1227	arg1	acid					1245:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	0	8	theme	Precision	129:137	arg1	Macromolecules					139:152	Preactivated N-Methyloxyamine Precision Macromolecules	99:152	Preactivated N-Methyloxyamine Precision Macromolecules	99:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	7	9	dep	route	1492:1496	arg1	derive					1501:1506	derive	1501:1506	derive glycoconjugates from complex oligosaccharides with high variability	1501:1574	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	7	9	dep	route	1492:1496	arg1	control					1580:1586	control	1580:1586	control in the multivalent scaffold	1580:1614	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	6	10	with	contacts	1438:1445	arg1	protein					1456:1462	the protein	1452:1462	the protein	1452:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	4	11	dep	oligomeric	829:838	arg1	to					826:827	to	826:827	to	826:827	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	0	12	theme	N-Methyloxyamine	112:127	arg1	Macromolecules					139:152	Preactivated N-Methyloxyamine Precision Macromolecules	99:152	Preactivated N-Methyloxyamine Precision Macromolecules	99:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	3	13	dep	carbohydrates	571:583	arg1	isolated					585:592	isolated	585:592	isolated from biological sources	585:616	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	3	13	dep	carbohydrates	571:583	arg1	derived					621:627	derived	621:627	derived through biotechnological methods	621:660	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	3	14	theme	biological	599:608	arg1	sources					610:616	biological sources	599:616	biological sources	599:616	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	4	15	theme	polymeric	843:851	arg1	use					870:872	polymeric scaffolds─making use	843:872	polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	843:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	7	16	theme	complex	1529:1535	arg1	oligosaccharides					1537:1552	complex oligosaccharides	1529:1552	complex oligosaccharides with high variability	1529:1574	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	6	17	theme	capsid	1309:1314	arg1	proteins					1316:1323	polyomavirus capsid proteins	1296:1323	polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein	1296:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	6	18	theme	binding	1264:1270	arg1	study					1272:1276	a binding study	1262:1276	a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein	1262:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	4	19	theme	monodisperse	919:930	arg1	macromolecules					949:962	monodisperse sequence-defined macromolecules	919:962	monodisperse sequence-defined macromolecules	919:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	1	20	theme	versatile	227:235	arg1	class					237:241	a versatile class	225:241	a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy	225:341	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	1	20	theme	versatile	227:235	arg1	Glycoconjugates					205:219	Glycoconjugates	205:219	Glycoconjugates	205:219	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	6	21	link	N-methyloxyamine-derived	1379:1402	arg1	scaffolds					1404:1412	the N-methyloxyamine-derived scaffolds	1375:1412	the N-methyloxyamine-derived scaffolds	1375:1412	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	3	22	theme	biotechnological	637:652	arg1	methods					654:660	biotechnological methods	637:660	biotechnological methods	637:660	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	5	23	theme	human	1042:1046	arg1	oligosaccharides					1053:1068	human milk oligosaccharides	1042:1068	human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates	1042:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	6	24	theme	side	1184:1187	arg1	chains					1189:1194	oligosaccharide side chains	1168:1194	oligosaccharide side chains	1168:1194	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	7	25	link	derived	1655:1661	arg1	structures					1663:1672	the derived structures	1651:1672	the derived structures	1651:1672	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	2	26	theme	carbohydrate	443:454	arg1	component					456:464	the carbohydrate component	439:464	the carbohydrate component in order to ensure efficient and selective conjugation	439:519	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	6	27	used	used	1254:1257	arg2	Glycomacromolecules					1137:1155	Glycomacromolecules	1137:1155	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid	1137:1248	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	6	28	theme	N-methyloxyamine-derived	1379:1402	arg1	scaffolds					1404:1412	the N-methyloxyamine-derived scaffolds	1375:1412	the N-methyloxyamine-derived scaffolds	1375:1412	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	5	29	theme	oligosaccharides	1053:1068	arg1	types					1033:1037	different types	1023:1037	different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates	1023:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	2	30	theme	selective	499:507	arg1	conjugation					509:519	efficient and selective conjugation	485:519	efficient and selective conjugation	485:519	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	1	31	theme	cancer	328:333	arg1	therapy					335:341	cancer therapy	328:341	cancer therapy	328:341	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	5	32	theme	glycoconjugates	1120:1134	arg1	library					1081:1087	a library	1079:1087	a library of homo- and heteromultivalent glycoconjugates	1079:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	4	33	theme	polymer	889:895	arg1	synthesis					897:905	solid-phase polymer synthesis	877:905	solid-phase polymer synthesis	877:905	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	2	34	theme	efficient	485:493	arg1	conjugation					509:519	efficient and selective conjugation	485:519	efficient and selective conjugation	485:519	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	0	35	theme	Homo-	13:17	arg1	Conjugates					84:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates	13:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules	13:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	4	36	theme	solid-phase	877:887	arg1	synthesis					897:905	solid-phase polymer synthesis	877:905	solid-phase polymer synthesis	877:905	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	1	37	theme	bioactive	246:254	arg1	molecules					256:264	bioactive molecules	246:264	bioactive molecules that have found application as vaccines and antivirals and in cancer therapy	246:341	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	0	38	theme	Fucosylated	41:51	arg1	Conjugates					84:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates	13:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules	13:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	6	39	theme	multivalent	1342:1352	arg1	presentation					1354:1365	the multivalent presentation	1338:1365	the multivalent presentation through the N-methyloxyamine-derived scaffolds	1338:1412	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	0	40	theme	Polyomavirus	175:186	arg1	Proteins					195:202	Polyomavirus Capsid Proteins	175:202	Polyomavirus Capsid Proteins	175:202	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	5	41	theme	different	1023:1031	arg1	types					1033:1037	different types	1023:1037	different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates	1023:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	7	42	theme	high	1559:1562	arg1	variability					1564:1574	high variability	1559:1574	high variability	1559:1574	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	1	43	theme	molecules	256:264	arg1	class					237:241	a versatile class	225:241	a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy	225:341	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	1	43	theme	molecules	256:264	arg1	Glycoconjugates					205:219	Glycoconjugates	205:219	Glycoconjugates	205:219	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	0	44	theme	Heteromultivalent	23:39	arg1	Conjugates					84:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates	13:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules	13:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	6	45	theme	oligosaccharide	1168:1182	arg1	chains					1189:1194	oligosaccharide side chains	1168:1194	oligosaccharide side chains	1168:1194	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	5	46	theme	milk	1048:1051	arg1	oligosaccharides					1053:1068	human milk oligosaccharides	1042:1068	human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates	1042:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	4	47	theme	synthesis	897:905	arg1	use					870:872	polymeric scaffolds─making use	843:872	polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	843:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	4	48	theme	N-methyloxyamine	751:766	arg1	groups					768:773	such N-methyloxyamine groups	746:773	such N-methyloxyamine groups	746:773	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	0	49	theme	Sialylated	57:66	arg1	Conjugates					84:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates	13:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules	13:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	1	50	from	application	282:292	arg1	therapy					335:341	cancer therapy	328:341	cancer therapy	328:341	Glycoconjugates are a versatile class of bioactive molecules that have found application as vaccines and antivirals and in cancer therapy.
36398945	3	51	theme	N-methyloxyamine	693:708	arg1	groups					710:715	N-methyloxyamine groups	693:715	N-methyloxyamine groups	693:715	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	5	52	theme	homo-	1092:1096	arg1	glycoconjugates					1120:1134	homo- and heteromultivalent glycoconjugates	1092:1134	homo- and heteromultivalent glycoconjugates	1092:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	0	53	theme	Capsid	188:193	arg1	Proteins					195:202	Polyomavirus Capsid Proteins	175:202	Polyomavirus Capsid Proteins	175:202	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	4	54	theme	oligomeric	829:838	arg1	scaffolds─from					805:818	multivalent scaffolds─from	793:818	multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	793:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	6	55	theme	contacts	1438:1445	arg1	number					1428:1433	the number	1424:1433	the number of contacts with the protein	1424:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	2	56	dep	involves	370:377	arg1	elaborate					379:387	elaborate	379:387	involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation	370:519	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	7	57	theme	derived	1655:1661	arg1	structures					1663:1672	the derived structures	1651:1672	the derived structures	1651:1672	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	7	58	theme	structures	1663:1672	arg1	applicability					1634:1646	applicability	1634:1646	applicability of the derived structures	1634:1672	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	5	59	theme	heteromultivalent	1102:1118	arg1	glycoconjugates					1120:1134	homo- and heteromultivalent glycoconjugates	1092:1134	homo- and heteromultivalent glycoconjugates	1092:1134	These scaffolds are then successfully functionalized with different types of human milk oligosaccharides deriving a library of homo- and heteromultivalent glycoconjugates.
36398945	6	60	with	study	1272:1276	arg1	types					1287:1291	two types	1283:1291	two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein	1283:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	4	61	theme	sequence-defined	932:947	arg1	macromolecules					949:962	monodisperse sequence-defined macromolecules	919:962	monodisperse sequence-defined macromolecules	919:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	4	62	theme	multivalent	793:803	arg1	scaffolds─from					805:818	multivalent scaffolds─from	793:818	multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	793:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	4	63	theme	scaffolds─making	853:868	arg1	use					870:872	polymeric scaffolds─making use	843:872	polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	843:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	0	64	theme	Conjugates	84:93	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules	0:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	0	64	theme	Conjugates	84:93	arg1	Binding					164:170	Their Binding	158:170	Their Binding to Polyomavirus Capsid Proteins	158:202	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	6	65	theme	proteins	1316:1323	arg1	types					1287:1291	two types	1283:1291	two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein	1283:1462	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36398945	3	66	dep	non-functionalized	537:554	arg1	non-protected					557:569	non-protected	557:569	non-protected	557:569	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	3	67	theme	non-functionalized	537:554	arg1	carbohydrates					571:583	non-functionalized, non-protected carbohydrates	537:583	non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods	537:660	Alternatively, non-functionalized, non-protected carbohydrates isolated from biological sources or derived through biotechnological methods can be directly conjugated via N-methyloxyamine groups.
36398945	4	68	theme	scaffolds─from	805:818	arg1	variety					782:788	a variety	780:788	a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	780:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	4	68	theme	scaffolds─from	805:818	arg1	scaffolds─from					805:818	multivalent scaffolds─from	793:818	multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules	793:962	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	7	69	theme	multivalent	1595:1605	arg1	scaffold					1607:1614	the multivalent scaffold	1591:1614	the multivalent scaffold	1591:1614	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	0	70	theme	Oligosaccharide	68:82	arg1	Conjugates					84:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates	13:93	Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules	13:152	Synthesis of Homo- and Heteromultivalent Fucosylated and Sialylated Oligosaccharide Conjugates via Preactivated N-Methyloxyamine Precision Macromolecules and Their Binding to Polyomavirus Capsid Proteins.
36398945	4	71	theme	such	746:749	arg1	groups					768:773	such N-methyloxyamine groups	746:773	such N-methyloxyamine groups	746:773	In this study, we introduce such N-methyloxyamine groups into a variety of multivalent scaffolds─from small to oligomeric to polymeric scaffolds─making use of solid-phase polymer synthesis to assemble monodisperse sequence-defined macromolecules.
36398945	2	72	theme	groups	429:434	arg1	use					411:413	use	411:413	use of protecting groups	411:434	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	2	72	theme	groups	429:434	arg1	functionalization					389:405	functionalization	389:405	functionalization	389:405	Their synthesis typically involves elaborate functionalization and use of protecting groups on the carbohydrate component in order to ensure efficient and selective conjugation.
36398945	7	73	theme	straightforward	1476:1490	arg1	route					1492:1496	a straightforward route	1474:1496	a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold	1474:1614	Overall, a straightforward route to derive glycoconjugates from complex oligosaccharides with high variability yet control in the multivalent scaffold is presented, and applicability of the derived structures is demonstrated.
36398945	6	74	theme	sialic	1238:1243	arg1	acid					1245:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	either α2,3- or α2,6-linked terminal sialic acid	1201:1248	Glycomacromolecules presenting oligosaccharide side chains with either α2,3- or α2,6-linked terminal sialic acid are used in a binding study with two types of polyomavirus capsid proteins showing that the multivalent presentation through the N-methyloxyamine-derived scaffolds increases the number of contacts with the protein.
36255676	9	0	theme	binding	1578:1584	arg1	proteins					1586:1593	glycan binding proteins	1571:1593	glycan binding proteins	1571:1593	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	2	1	theme	signal	365:370	arg1	transmission					338:349	transmission	338:349	transmission	338:349	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	2	1	theme	signal	365:370	arg1	propagation					322:332	propagation	322:332	propagation	322:332	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	5	2	theme	other	781:785	arg1	cells					787:791	other cells	781:791	other cells	781:791	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	10	3	theme	necessary	1858:1866	arg1	information					1846:1856	instructive information	1834:1856	instructive information necessary for fundamental processes in axon physiology	1834:1911	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	2	4	theme	output	358:363	arg1	signal					365:370	the output signal	354:370	the output signal	354:370	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	0	5	from	Glycans	0:6	arg1	Physiology					63:72	Axon Physiology	58:72	Axon Physiology	58:72	Glycans and Carbohydrate-Binding/Transforming Proteins in Axon Physiology.
36255676	10	6	theme	fundamental	1872:1882	arg1	processes					1884:1892	fundamental processes	1872:1892	fundamental processes in axon physiology	1872:1911	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	8	7	theme	importance	1375:1384	arg1	functions					1348:1356	functions	1348:1356	functions of the outermost importance	1348:1384	Throughout all these steps, glycans perform functions of the outermost importance.
36255676	4	8	theme	environmental	608:620	arg1	functions					630:638	environmental sensing functions	608:638	environmental sensing functions	608:638	During the development of the nervous system, axons perform environmental sensing functions, which allow them to navigate through other regions until a final target is reached.
36255676	1	9	theme	mature	79:84	arg1	system					94:99	The mature nervous system	75:99	The mature nervous system	75:99	The mature nervous system relies on the polarized morphology of neurons for a directed flow of information.
36255676	9	10	theme	surrounding	1438:1448	arg1	environment					1450:1460	their surrounding environment	1432:1460	their surrounding environment	1432:1460	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	6	11	theme	Mature	889:894	arg1	axons					896:900	Mature axons	889:900	Mature axons	889:900	Mature axons must then acquire the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron.
36255676	7	12	dep	injury	1112:1117	arg1	event					1100:1104	event	1100:1104	event	1100:1104	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	7	12	dep	injury	1112:1117	arg1	the					1096:1098	the	1096:1098	the	1096:1098	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	5	13	theme	glial	844:848	arg1	cells					850:854	myelinating glial cells	832:854	myelinating glial cells in the case of myelinated axons	832:886	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	1	14	theme	nervous	86:92	arg1	system					94:99	The mature nervous system	75:99	The mature nervous system	75:99	The mature nervous system relies on the polarized morphology of neurons for a directed flow of information.
36255676	1	15	theme	information	170:180	arg1	flow					162:165	a directed flow	151:165	a directed flow of information	151:180	The mature nervous system relies on the polarized morphology of neurons for a directed flow of information.
36255676	4	16	theme	sensing	622:628	arg1	functions					630:638	environmental sensing functions	608:638	environmental sensing functions	608:638	During the development of the nervous system, axons perform environmental sensing functions, which allow them to navigate through other regions until a final target is reached.
36255676	7	17	theme	damaged	1142:1148	arg1	axons					1150:1154	damaged axons	1142:1154	damaged axons	1142:1154	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	7	18	theme	regeneration	1222:1233	arg1	successful					1260:1269	successful	1260:1269	successful	1260:1269	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	7	18	theme	regeneration	1222:1233	arg1	attempt					1235:1241	a regeneration attempt	1220:1241	a regeneration attempt	1220:1241	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	10	19	theme	axon	1897:1900	arg1	physiology					1902:1911	axon physiology	1897:1911	axon physiology	1897:1911	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	10	20	from	processes	1884:1892	arg1	physiology					1902:1911	axon physiology	1897:1911	axon physiology	1897:1911	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	5	21	theme	myelinated	871:880	arg1	axons					882:886	myelinated axons	871:886	myelinated axons	871:886	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	9	22	theme	glycan	1571:1576	arg1	proteins					1586:1593	glycan binding proteins	1571:1593	glycan binding proteins	1571:1593	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	5	23	theme	myelinating	832:842	arg1	cells					850:854	myelinating glial cells	832:854	myelinating glial cells in the case of myelinated axons	832:886	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	0	24	theme	Carbohydrate-Binding/Transforming	12:44	arg1	Proteins					46:53	Carbohydrate-Binding/Transforming Proteins	12:53	Carbohydrate-Binding/Transforming Proteins	12:53	Glycans and Carbohydrate-Binding/Transforming Proteins in Axon Physiology.
36255676	4	25	theme	system	586:591	arg1	development					559:569	the development	555:569	the development of the nervous system	555:591	During the development of the nervous system, axons perform environmental sensing functions, which allow them to navigate through other regions until a final target is reached.
36255676	9	26	theme	key	1491:1493	arg1	Glycans					1387:1393	Glycans	1387:1393	Glycans	1387:1393	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	9	26	theme	key	1491:1493	arg1	information					1495:1505	key information	1491:1505	key information	1491:1505	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	1	27	theme	polarized	115:123	arg1	morphology					125:134	the polarized morphology	111:134	the polarized morphology of neurons for a directed flow of information	111:180	The mature nervous system relies on the polarized morphology of neurons for a directed flow of information.
36255676	4	28	theme	final	700:704	arg1	target					706:711	a final target	698:711	a final target	698:711	During the development of the nervous system, axons perform environmental sensing functions, which allow them to navigate through other regions until a final target is reached.
36255676	0	29	theme	Axon	58:61	arg1	Physiology					63:72	Axon Physiology	58:72	Axon Physiology	58:72	Glycans and Carbohydrate-Binding/Transforming Proteins in Axon Physiology.
36255676	4	30	theme	nervous	578:584	arg1	system					586:591	the nervous system	574:591	the nervous system	574:591	During the development of the nervous system, axons perform environmental sensing functions, which allow them to navigate through other regions until a final target is reached.
36255676	10	31	theme	binding/transforming	1788:1807	arg1	proteins					1809:1816	their binding/transforming proteins	1782:1816	their binding/transforming proteins	1782:1816	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	10	32	theme	illustrative	1741:1752	arg1	examples					1754:1761	illustrative examples	1741:1761	illustrative examples of how glycans and their binding/transforming proteins code	1741:1821	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	9	33	theme	contacting	1466:1475	arg1	cells					1477:1481	contacting cells	1466:1481	contacting cells	1466:1481	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	4	34	theme	other	678:682	arg1	regions					684:690	other regions	678:690	other regions	678:690	During the development of the nervous system, axons perform environmental sensing functions, which allow them to navigate through other regions until a final target is reached.
36255676	7	35	theme	nervous	1126:1132	arg1	system					1134:1139	the nervous system	1122:1139	the nervous system	1122:1139	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	9	36	theme	glycan	1531:1536	arg1	enzymes					1548:1554	glycan modifying enzymes	1531:1554	glycan modifying enzymes	1531:1554	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	5	37	from	cells	850:854	arg1	case					863:866	the case	859:866	the case of myelinated axons	859:886	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	6	38	theme	processing	1031:1040	arg1	part					1007:1010	part	1007:1010	part of the information processing	1007:1040	Mature axons must then acquire the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron.
36255676	5	39	theme	axons	882:886	arg1	case					863:866	the case	859:866	the case of myelinated axons	859:886	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	9	40	theme	electrical	1647:1656	arg1	functions					1671:1679	electrical transmission functions	1647:1679	electrical transmission functions	1647:1679	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	9	41	theme	modifying	1538:1546	arg1	enzymes					1548:1554	glycan modifying enzymes	1531:1554	glycan modifying enzymes	1531:1554	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	7	42	from	successful	1260:1269	arg1	PNS					1278:1280	the PNS	1274:1280	the PNS	1274:1280	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	3	43	theme	different	404:412	arg1	functions					414:422	different functions	404:422	different functions	404:422	However, the axon must perform different functions throughout development before being fully functional for the transmission of information in the form of electrical signals.
36255676	9	44	theme	transmission	1658:1669	arg1	functions					1671:1679	electrical transmission functions	1647:1679	electrical transmission functions	1647:1679	Glycans expressed by the axon, as well as by their surrounding environment and contacting cells, encode key information, which is fine-tuned by glycan modifying enzymes and decoded by glycan binding proteins so that the development, guidance, myelination, and electrical transmission functions can be reliably performed.
36255676	10	45	theme	instructive	1834:1844	arg1	information					1846:1856	instructive information	1834:1856	instructive information necessary for fundamental processes in axon physiology	1834:1911	In this chapter, we will provide illustrative examples of how glycans and their binding/transforming proteins code and decode instructive information necessary for fundamental processes in axon physiology.
36255676	2	46	theme	somatodendritic	222:236	arg1	domain					238:243	their somatodendritic domain	216:243	their somatodendritic domain	216:243	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	6	47	theme	structural	924:933	arg1	characteristics					950:964	the structural and functional characteristics	920:964	the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron	920:1081	Mature axons must then acquire the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron.
36255676	8	48	theme	outermost	1365:1373	arg1	importance					1375:1384	the outermost importance	1361:1384	the outermost importance	1361:1384	Throughout all these steps, glycans perform functions of the outermost importance.
36255676	3	49	from	transmission	485:496	arg1	form					520:523	the form	516:523	the form of electrical signals	516:545	However, the axon must perform different functions throughout development before being fully functional for the transmission of information in the form of electrical signals.
36255676	1	50	theme	neurons	139:145	arg1	morphology					125:134	the polarized morphology	111:134	the polarized morphology of neurons for a directed flow of information	111:180	The mature nervous system relies on the polarized morphology of neurons for a directed flow of information.
36255676	6	51	theme	information	1019:1029	arg1	processing					1031:1040	the information processing	1015:1040	the information processing	1015:1040	Mature axons must then acquire the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron.
36255676	2	52	theme	input	270:274	arg1	signals					276:282	input signals	270:282	input signals	270:282	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	7	53	from	PNS	1278:1280	arg1	successful					1260:1269	successful	1260:1269	successful	1260:1269	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	7	53	from	PNS	1278:1280	arg1	attempt					1235:1241	a regeneration attempt	1220:1241	a regeneration attempt	1220:1241	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	3	54	theme	information	501:511	arg1	transmission					485:496	the transmission	481:496	the transmission of information in the form of electrical signals	481:545	However, the axon must perform different functions throughout development before being fully functional for the transmission of information in the form of electrical signals.
36255676	2	55	dep	propagation	322:332	arg1	the					318:320	the	318:320	the	318:320	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	5	56	theme	regulated	758:766	arg1	contact					768:774	a regulated contact	756:774	a regulated contact with other cells	756:791	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	2	57	theme	polarized	196:204	arg1	cells					206:210	These highly polarized cells	183:210	These highly polarized cells	183:210	These highly polarized cells use their somatodendritic domain to receive and integrate input signals while the axon is responsible for the propagation and transmission of the output signal.
36255676	1	58	theme	directed	153:160	arg1	flow					162:165	a directed flow	151:165	a directed flow of information	151:180	The mature nervous system relies on the polarized morphology of neurons for a directed flow of information.
36255676	3	59	theme	electrical	528:537	arg1	signals					539:545	electrical signals	528:545	electrical signals	528:545	However, the axon must perform different functions throughout development before being fully functional for the transmission of information in the form of electrical signals.
36255676	7	60	theme	immature	1192:1199	arg1	characteristics					1201:1215	their immature characteristics	1186:1215	their immature characteristics	1186:1215	Finally, in the event of an injury to the nervous system, damaged axons must try to reacquire some of their immature characteristics in a regeneration attempt, which is mostly successful in the PNS but fails in the CNS.
36255676	0	61	from	Proteins	46:53	arg1	Physiology					63:72	Axon Physiology	58:72	Axon Physiology	58:72	Glycans and Carbohydrate-Binding/Transforming Proteins in Axon Physiology.
36255676	5	62	with	contact	768:774	arg1	cells					787:791	other cells	781:791	other cells	781:791	Some axons must also establish a regulated contact with other cells before reaching maturity, such as with myelinating glial cells in the case of myelinated axons.
36255676	3	63	theme	signals	539:545	arg1	form					520:523	the form	516:523	the form of electrical signals	516:545	However, the axon must perform different functions throughout development before being fully functional for the transmission of information in the form of electrical signals.
36255676	6	64	theme	functional	939:948	arg1	characteristics					950:964	the structural and functional characteristics	920:964	the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron	920:1081	Mature axons must then acquire the structural and functional characteristics that allow them to perform their role as part of the information processing and transmitting unit that is the neuron.
36824920	0	0	theme	virus	82:86	arg1	infectivity					88:98	virus infectivity	82:98	virus infectivity	82:98	Integrated analyses reveal a hinge glycan regulates coronavirus spike tilting and virus infectivity.
36824920	3	1	theme	mass	751:754	arg1	spectroscopy					756:767	mass spectroscopy	751:767	mass spectroscopy	751:767	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	2	2	theme	viral	367:371	arg1	envelope					379:386	viral lipid envelope	367:386	viral lipid envelope	367:386	How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood.
36824920	5	3	theme	glycosylated	1057:1068	arg1	spike					1083:1087	the glycosylated, full-length spike	1053:1087	the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending	1053:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	5	4	theme	molecular	981:989	arg1	simulations					999:1009	all-atom molecular dynamic simulations	972:1009	all-atom molecular dynamic simulations	972:1009	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	1	5	theme	receptor	173:180	arg1	binding					182:188	receptor binding	173:188	receptor binding	173:188	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	7	6	theme	glycan-dependent	1369:1384	arg1	motion					1386:1391	this glycan-dependent motion	1364:1391	this glycan-dependent motion	1364:1391	Subsequent infectivity assays support the hypothesis that this glycan-dependent motion impacts virus entry.
36824920	4	7	theme	SARS-CoV-2	836:845	arg1	spikes					847:852	SARS-CoV-2 spikes	836:852	HCoV-NL63 spikes than on SARS-CoV-2 spikes	811:852	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	6	8	from	portion	1210:1216	arg1	glycosylation					1174:1186	glycosylation	1174:1186	glycosylation at N1242 at the upper portion of the stalk	1174:1229	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	3	9	theme	cryogenic	613:621	arg1	tomography					632:641	cryogenic electron tomography	613:641	cryogenic electron tomography (cryoET)	613:650	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	3	9	theme	cryogenic	613:621	arg1	cryoET					644:649	cryoET	644:649	cryoET	644:649	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	5	10	theme	all-atom	972:979	arg1	simulations					999:1009	all-atom molecular dynamic simulations	972:1009	all-atom molecular dynamic simulations	972:1009	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	3	11	theme	chemical	592:599	arg1	fixation					601:608	chemical fixation	592:608	chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging	592:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	4	12	theme	HCoV-NL63	811:819	arg1	spikes					821:826	HCoV-NL63 spikes	811:826	HCoV-NL63 spikes than on SARS-CoV-2 spikes	811:852	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	6	13	theme	spike	1293:1297	arg1	crown					1299:1303	the spike crown	1289:1303	the spike crown	1289:1303	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	3	14	theme	vitrified	531:539	arg1	virions					576:582	vitrified human coronavirus NL63 (HCoV-NL63) virions	531:582	vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging	531:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	5	15	theme	cryoET-derived	925:938	arg1	conformations					953:965	cryoET-derived native spike conformations	925:965	cryoET-derived native spike conformations	925:965	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	5	16	gly	glycosylated	1057:1068	arg1	spike					1083:1087	the glycosylated, full-length spike	1053:1087	the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending	1053:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	5	17	theme	spike	1083:1087	arg1	landscape					1040:1048	the conformational landscape	1021:1048	the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending	1021:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	2	18	theme	virus	408:412	arg1	infectivity					414:424	the virus infectivity	404:424	the virus infectivity	404:424	How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood.
36824920	5	19	theme	dynamic	991:997	arg1	simulations					999:1009	all-atom molecular dynamic simulations	972:1009	all-atom molecular dynamic simulations	972:1009	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	4	20	theme	HCoV-NL63	897:905	arg1	evasion					886:892	stronger immune evasion	870:892	stronger immune evasion of HCoV-NL63	870:905	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	5	21	theme	native	940:945	arg1	conformations					953:965	cryoET-derived native spike conformations	925:965	cryoET-derived native spike conformations	925:965	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	7	22	theme	Subsequent	1306:1315	arg1	assays					1329:1334	Subsequent infectivity assays	1306:1334	Subsequent infectivity assays	1306:1334	Subsequent infectivity assays support the hypothesis that this glycan-dependent motion impacts virus entry.
36824920	5	23	link	cryoET-derived	925:938	arg1	conformations					953:965	cryoET-derived native spike conformations	925:965	cryoET-derived native spike conformations	925:965	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	4	24	dep	than	828:831	arg1	on					833:834	on	833:834	on	833:834	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	5	25	theme	spike	947:951	arg1	conformations					953:965	cryoET-derived native spike conformations	925:965	cryoET-derived native spike conformations	925:965	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	0	26	theme	Integrated	0:9	arg1	analyses					11:18	Integrated analyses	0:18	Integrated analyses	0:18	Integrated analyses reveal a hinge glycan regulates coronavirus spike tilting and virus infectivity.
36824920	1	27	theme	drug	280:283	arg1	development					285:295	drug development	280:295	drug development	280:295	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	4	28	dep	glycan	794:799	arg1	shield					801:806	shield	801:806	shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes	801:852	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	4	29	theme	oligomannose	781:792	arg1	glycan					794:799	The higher oligomannose glycan	770:799	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes	770:852	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	5	30	dep	glycosylated	1057:1068	arg1	full-length					1071:1081	full-length	1071:1081	full-length	1071:1081	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	1	31	theme	membrane	195:202	arg1	fusion					204:209	membrane fusion	195:209	membrane fusion	195:209	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	5	32	theme	conformational	1025:1038	arg1	landscape					1040:1048	the conformational landscape	1021:1048	the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending	1021:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	2	33	theme	structure	306:314	arg1	dynamics					316:323	the structure dynamics	302:323	the structure dynamics of the full-length spikes incorporated in viral lipid envelope	302:386	How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood.
36824920	8	34	dep	potential	1436:1444	arg1	therapeutic					1446:1456	therapeutic	1446:1456	therapeutic	1446:1456	Our results suggest a potential therapeutic target site for HCoV-NL63.
36824920	6	35	theme	upper	1204:1208	arg1	portion					1210:1216	the upper portion	1200:1216	the upper portion of the stalk	1200:1229	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	1	36	gly	glycoproteins	119:131	arg1	glycoproteins					119:131	Coronavirus spike glycoproteins	101:131	Coronavirus spike glycoproteins presented on the virion surface	101:163	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	1	37	theme	spike	113:117	arg1	glycoproteins					119:131	Coronavirus spike glycoproteins	101:131	Coronavirus spike glycoproteins presented on the virion surface	101:163	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	5	38	theme	glycans	1124:1130	arg1	role					1110:1113	a novel role	1102:1113	a novel role of stalk glycans in modulating spike bending	1102:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	3	39	theme	coronavirus	547:557	arg1	virions					576:582	vitrified human coronavirus NL63 (HCoV-NL63) virions	531:582	vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging	531:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	7	40	theme	virus	1401:1405	arg1	entry					1407:1411	virus entry	1401:1411	virus entry	1401:1411	Subsequent infectivity assays support the hypothesis that this glycan-dependent motion impacts virus entry.
36824920	4	41	theme	immune	879:884	arg1	evasion					886:892	stronger immune evasion	870:892	stronger immune evasion of HCoV-NL63	870:905	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	5	42	theme	conformations	953:965	arg1	Incorporation					908:920	Incorporation	908:920	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations	908:1009	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	1	43	theme	virus	218:222	arg1	entry					224:228	virus entry	218:228	virus entry	218:228	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	0	44	theme	hinge	29:33	arg1	glycan					35:40	a hinge glycan	27:40	a hinge glycan regulates coronavirus spike tilting and virus infectivity	27:98	Integrated analyses reveal a hinge glycan regulates coronavirus spike tilting and virus infectivity.
36824920	4	45	theme	stronger	870:877	arg1	evasion					886:892	stronger immune evasion	870:892	stronger immune evasion of HCoV-NL63	870:905	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	3	46	from	structures	469:478	arg1	virions					576:582	vitrified human coronavirus NL63 (HCoV-NL63) virions	531:582	vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging	531:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	0	47	theme	coronavirus	52:62	arg1	tilting					70:76	coronavirus spike tilting	52:76	coronavirus spike tilting	52:76	Integrated analyses reveal a hinge glycan regulates coronavirus spike tilting and virus infectivity.
36824920	8	48	theme	target	1458:1463	arg1	site					1465:1468	a potential therapeutic target site	1434:1468	a potential therapeutic target site for HCoV-NL63	1434:1482	Our results suggest a potential therapeutic target site for HCoV-NL63.
36824920	0	49	dep	glycan	35:40	arg1	regulates					42:50	regulates	42:50	regulates coronavirus spike tilting and virus infectivity	42:98	Integrated analyses reveal a hinge glycan regulates coronavirus spike tilting and virus infectivity.
36824920	3	50	theme	conformations	514:526	arg1	distributions					484:496	distributions	484:496	distributions	484:496	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	3	50	theme	conformations	514:526	arg1	structures					469:478	structures	469:478	structures	469:478	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	6	51	theme	orientational	1264:1276	arg1	freedom					1278:1284	the extensive orientational freedom	1250:1284	the extensive orientational freedom of the spike crown	1250:1303	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	6	52	gly	glycosylation	1174:1186	arg1	portion					1210:1216	the upper portion	1200:1216	the upper portion of the stalk	1200:1229	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	6	52	gly	glycosylation	1174:1186	arg2	portion					1210:1216	the upper portion	1200:1216	the upper portion of the stalk	1200:1229	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	6	52	gly	glycosylation	1174:1186	arg1	N1242					1191:1195	N1242	1191:1195	N1242	1191:1195	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	6	52	gly	glycosylation	1174:1186	arg2	N1242					1191:1195	N1242	1191:1195	N1242	1191:1195	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	3	53	theme	electron	623:630	arg1	tomography					632:641	cryogenic electron tomography	613:641	cryogenic electron tomography (cryoET)	613:650	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	3	53	theme	electron	623:630	arg1	cryoET					644:649	cryoET	644:649	cryoET	644:649	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	3	54	theme	human	541:545	arg1	virions					576:582	vitrified human coronavirus NL63 (HCoV-NL63) virions	531:582	vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging	531:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	2	55	theme	spikes	344:349	arg1	dynamics					316:323	the structure dynamics	302:323	the structure dynamics of the full-length spikes incorporated in viral lipid envelope	302:386	How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood.
36824920	4	56	theme	higher	774:779	arg1	glycan					794:799	The higher oligomannose glycan	770:799	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes	770:852	The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63.
36824920	5	57	theme	spike	1146:1150	arg1	bending					1152:1158	spike bending	1146:1158	spike bending	1146:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	6	58	theme	crown	1299:1303	arg1	freedom					1278:1284	the extensive orientational freedom	1250:1284	the extensive orientational freedom of the spike crown	1250:1303	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	5	59	theme	stalk	1118:1122	arg1	glycans					1124:1130	stalk glycans	1118:1130	stalk glycans	1118:1130	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	2	60	theme	full-length	332:342	arg1	spikes					344:349	the full-length spikes	328:349	the full-length spikes incorporated in viral lipid envelope	328:386	How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood.
36824920	1	61	theme	Coronavirus	101:111	arg1	glycoproteins					119:131	Coronavirus spike glycoproteins	101:131	Coronavirus spike glycoproteins presented on the virion surface	101:163	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	3	62	theme	site-specific	690:702	arg1	composition					711:721	site-specific glycan composition	690:721	site-specific glycan composition	690:721	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	3	63	theme	subtomogram	656:666	arg1	averaging					668:676	subtomogram averaging	656:676	subtomogram averaging	656:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	6	64	from	N1242	1191:1195	arg1	glycosylation					1174:1186	glycosylation	1174:1186	glycosylation at N1242 at the upper portion of the stalk	1174:1229	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	3	65	theme	spike	508:512	arg1	conformations					514:526	native spike conformations	501:526	native spike conformations	501:526	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	8	66	theme	potential	1436:1444	arg1	site					1465:1468	a potential therapeutic target site	1434:1468	a potential therapeutic target site for HCoV-NL63	1434:1482	Our results suggest a potential therapeutic target site for HCoV-NL63.
36824920	3	67	theme	native	501:506	arg1	conformations					514:526	native spike conformations	501:526	native spike conformations	501:526	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	7	68	theme	infectivity	1317:1327	arg1	assays					1329:1334	Subsequent infectivity assays	1306:1334	Subsequent infectivity assays	1306:1334	Subsequent infectivity assays support the hypothesis that this glycan-dependent motion impacts virus entry.
36824920	3	69	theme	glycan	704:709	arg1	composition					711:721	site-specific glycan composition	690:721	site-specific glycan composition	690:721	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	5	70	theme	novel	1104:1108	arg1	role					1110:1113	a novel role	1102:1113	a novel role of stalk glycans in modulating spike bending	1102:1158	Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a novel role of stalk glycans in modulating spike bending.
36824920	3	71	from	distributions	484:496	arg1	virions					576:582	vitrified human coronavirus NL63 (HCoV-NL63) virions	531:582	vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging	531:676	Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectroscopy.
36824920	1	72	theme	virion	150:155	arg1	surface					157:163	the virion surface	146:163	the virion surface	146:163	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
36824920	6	73	theme	extensive	1254:1262	arg1	freedom					1278:1284	the extensive orientational freedom	1250:1284	the extensive orientational freedom of the spike crown	1250:1303	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	0	74	theme	spike	64:68	arg1	tilting					70:76	coronavirus spike tilting	52:76	coronavirus spike tilting	52:76	Integrated analyses reveal a hinge glycan regulates coronavirus spike tilting and virus infectivity.
36824920	6	75	theme	stalk	1225:1229	arg1	portion					1210:1216	the upper portion	1200:1216	the upper portion of the stalk	1200:1229	We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown.
36824920	2	76	theme	lipid	373:377	arg1	envelope					379:386	viral lipid envelope	367:386	viral lipid envelope	367:386	How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood.
36824920	1	77	theme	primary	249:255	arg1	target					257:262	the primary target	245:262	the primary target for vaccine and drug development	245:295	Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development.
35234395	9	0	theme	increased	1473:1481	arg1	interactions					1483:1494	the increased interactions	1469:1494	the increased interactions between residues and substrate	1469:1525	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	8	1	theme	variant	1183:1189	arg1	D182C					1191:1195	the variant D182C	1179:1195	the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT	1179:1263	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	9	2	theme	docking	1354:1360	arg1	analysis					1362:1369	docking analysis	1354:1369	docking analysis	1354:1369	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	5	3	theme	higher	663:668	arg1	ratio					681:685	a 13.42% higher conversion ratio	654:685	a 13.42% higher conversion ratio	654:685	Compared with the wild-type (WT), the variant D182C showed a 13.42% higher conversion ratio.
35234395	0	4	gly	glycosylated	66:77	arg1	synthesis					89:97	glycosylated genistein synthesis	66:97	glycosylated genistein synthesis	66:97	[Engineering the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis].
35234395	8	5	theme	enhanced	1299:1306	arg1	affinity					1308:1315	enhanced affinity	1299:1315	enhanced affinity to substrate	1299:1328	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	5	6	theme	conversion	670:679	arg1	ratio					681:685	a 13.42% higher conversion ratio	654:685	a 13.42% higher conversion ratio	654:685	Compared with the wild-type (WT), the variant D182C showed a 13.42% higher conversion ratio.
35234395	7	7	theme	enzyme	950:955	arg1	higher					1040:1045	higher	1040:1045	higher	1040:1045	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	7	theme	enzyme	950:955	arg1	activities					957:966	the enzyme activities	946:966	the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C	946:1033	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	6	8	theme	sophoricoside	716:728	arg1	monoglucoside					730:742	sophoricoside monoglucoside	716:742	sophoricoside monoglucoside	716:742	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	8	theme	sophoricoside	716:728	arg1	products					707:714	the main products	698:714	the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C	698:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	9	9	theme	D182C	1442:1446	arg1	efficiency					1416:1425	the improved glycosylation efficiency	1389:1425	the improved glycosylation efficiency of the variant D182C	1389:1446	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	5	10	theme	variant	633:639	arg1	D182C					641:645	the variant D182C	629:645	the variant D182C	629:645	Compared with the wild-type (WT), the variant D182C showed a 13.42% higher conversion ratio.
35234395	9	11	theme	improved	1393:1400	arg1	efficiency					1416:1425	the improved glycosylation efficiency	1389:1425	the improved glycosylation efficiency of the variant D182C	1389:1446	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	0	12	theme	glucosyltransferase	42:60	arg1	site					21:24	the 182 site	13:24	the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis	13:97	[Engineering the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis].
35234395	0	12	theme	glucosyltransferase	42:60	arg1	glucosyltransferase					42:60	cyclodextrin glucosyltransferase	29:60	cyclodextrin glucosyltransferase	29:60	[Engineering the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis].
35234395	7	13	theme	D182C	1118:1122	arg1	temperature					1091:1101	temperature	1091:1101	temperature	1091:1101	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	13	theme	D182C	1118:1122	arg1	6					1129:1129	6	1129:1129	6	1129:1129	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	13	theme	D182C	1118:1122	arg1	pH					1084:1085	the optimal pH	1072:1085	the optimal pH	1072:1085	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	3	14	from	macerans	512:519	arg1	glucosyltransferase					474:492	a cyclodextrin glucosyltransferase	459:492	a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase)	459:530	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	8	15	theme	variant	1281:1287	arg1	D182C					1289:1293	the variant D182C	1277:1293	the variant D182C has enhanced affinity to substrate	1277:1328	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	6	16	theme	main	702:705	arg1	monoglucoside					730:742	sophoricoside monoglucoside	716:742	sophoricoside monoglucoside	716:742	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	16	theme	main	702:705	arg1	diglucoside					759:769	sophoricoside diglucoside	745:769	sophoricoside diglucoside	745:769	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	16	theme	main	702:705	arg1	products					707:714	the main products	698:714	the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C	698:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	16	theme	main	702:705	arg1	triglucoside					790:801	sophoricoside triglucoside	776:801	sophoricoside triglucoside	776:801	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	3	17	gly	glycosylation	379:391	arg1	monoglucoside					421:433	genistein monoglucoside	411:433	genistein monoglucoside	411:433	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	3	17	gly	glycosylation	379:391	arg1	sophoricoside					396:408	sophoricoside	396:408	sophoricoside (genistein monoglucoside)	396:434	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	3	17	gly	glycosylation	379:391	arg1	paper					368:372	this paper	363:372	this paper	363:372	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	6	18	theme	variant	810:816	arg1	D182C					818:822	the variant D182C	806:822	the variant D182C	806:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	1	19	dep	food	169:172	arg1	fields					194:199	fields	194:199	fields	194:199	Genistein and its monoglucoside derivatives play important roles in food and pharmaceuticals fields, whereas their applications are limited by the low water solubility.
35234395	8	20	theme	Km	1209:1210	arg1	value					1212:1216	a lower Km value	1201:1216	a lower Km value	1201:1216	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	3	21	theme	sophoricoside	396:408	arg1	glycosylation					379:391	the glycosylation	375:391	the glycosylation of sophoricoside (genistein monoglucoside)	375:434	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	8	22	dep	D182C	1289:1293	arg1	has					1295:1297	has	1295:1297	has enhanced affinity to substrate	1295:1328	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	2	23	theme	approaches	320:329	arg1	one					299:301	one	299:301	one	299:301	Glycosylation is regarded as one of the effective approaches to improve water solubility.
35234395	2	23	theme	approaches	320:329	arg1	Glycosylation					270:282	Glycosylation	270:282	Glycosylation	270:282	Glycosylation is regarded as one of the effective approaches to improve water solubility.
35234395	2	23	theme	approaches	320:329	arg1	approaches					320:329	the effective approaches	306:329	the effective approaches	306:329	Glycosylation is regarded as one of the effective approaches to improve water solubility.
35234395	8	24	theme	lower	1203:1207	arg1	value					1212:1216	a lower Km value	1201:1216	a lower Km value	1201:1216	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	8	25	dep	D182C	1191:1195	arg1	has					1197:1199	has	1197:1199	has a lower Km value and a higher kcat/Km value than that of the WT	1197:1263	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	6	26	dep	products	707:714	arg1	monoglucoside					730:742	sophoricoside monoglucoside	716:742	sophoricoside monoglucoside	716:742	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	26	dep	products	707:714	arg1	diglucoside					759:769	sophoricoside diglucoside	745:769	sophoricoside diglucoside	745:769	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	26	dep	products	707:714	arg1	products					707:714	the main products	698:714	the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C	698:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	26	dep	products	707:714	arg1	triglucoside					790:801	sophoricoside triglucoside	776:801	sophoricoside triglucoside	776:801	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	2	27	theme	effective	310:318	arg1	approaches					320:329	the effective approaches	306:329	the effective approaches	306:329	Glycosylation is regarded as one of the effective approaches to improve water solubility.
35234395	7	28	theme	variant	1021:1027	arg1	D182C					1029:1033	the variant D182C	1017:1033	the variant D182C	1017:1033	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	8	29	theme	Kinetics	1154:1161	arg1	analysis					1163:1170	Kinetics analysis	1154:1170	Kinetics analysis	1154:1170	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	3	30	theme	Penibacillus	499:510	arg1	PmCGTase					522:529	PmCGTase	522:529	PmCGTase	522:529	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	3	30	theme	Penibacillus	499:510	arg1	macerans					512:519	Penibacillus macerans	499:519	Penibacillus macerans (PmCGTase)	499:530	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	0	31	theme	cyclodextrin	29:40	arg1	glucosyltransferase					42:60	cyclodextrin glucosyltransferase	29:60	cyclodextrin glucosyltransferase	29:60	[Engineering the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis].
35234395	8	32	theme	higher	1224:1229	arg1	value					1239:1243	a higher kcat/Km value	1222:1243	a higher kcat/Km value	1222:1243	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	9	33	theme	glycosylation	1402:1414	arg1	efficiency					1416:1425	the improved glycosylation efficiency	1389:1425	the improved glycosylation efficiency of the variant D182C	1389:1446	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	3	34	theme	cyclodextrin	461:472	arg1	glucosyltransferase					474:492	a cyclodextrin glucosyltransferase	459:492	a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase)	459:530	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	4	35	from	PmCGTase	569:576	arg1	mutagenesis					544:554	Saturation mutagenesis	533:554	Saturation mutagenesis of D182 from PmCGTase	533:576	Saturation mutagenesis of D182 from PmCGTase was carried out.
35234395	9	36	theme	Structure	1331:1339	arg1	modeling					1341:1348	Structure modeling	1331:1348	Structure modeling	1331:1348	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	9	37	theme	variant	1434:1440	arg1	D182C					1442:1446	the variant D182C	1430:1446	the variant D182C	1430:1446	Structure modeling and docking analysis demonstrated that the improved glycosylation efficiency of the variant D182C may be attributed to the increased interactions between residues and substrate.
35234395	4	38	theme	D182	559:562	arg1	mutagenesis					544:554	Saturation mutagenesis	533:554	Saturation mutagenesis of D182 from PmCGTase	533:576	Saturation mutagenesis of D182 from PmCGTase was carried out.
35234395	6	39	theme	sophoricoside	776:788	arg1	products					707:714	the main products	698:714	the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C	698:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	39	theme	sophoricoside	776:788	arg1	triglucoside					790:801	sophoricoside triglucoside	776:801	sophoricoside triglucoside	776:801	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	1	40	theme	monoglucoside	119:131	arg1	derivatives					133:143	its monoglucoside derivatives	115:143	its monoglucoside derivatives	115:143	Genistein and its monoglucoside derivatives play important roles in food and pharmaceuticals fields, whereas their applications are limited by the low water solubility.
35234395	3	41	theme	genistein	411:419	arg1	sophoricoside					396:408	sophoricoside	396:408	sophoricoside (genistein monoglucoside)	396:434	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	3	41	theme	genistein	411:419	arg1	monoglucoside					421:433	genistein monoglucoside	411:433	genistein monoglucoside	411:433	In this paper, the glycosylation of sophoricoside (genistein monoglucoside) was investigated using a cyclodextrin glucosyltransferase from Penibacillus macerans (PmCGTase).
35234395	7	42	theme	optimal	1076:1082	arg1	6					1129:1129	6	1129:1129	6	1129:1129	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	42	theme	optimal	1076:1082	arg1	pH					1084:1085	the optimal pH	1072:1085	the optimal pH	1072:1085	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	8	43	theme	kcat/Km	1231:1237	arg1	value					1239:1243	a higher kcat/Km value	1222:1243	a higher kcat/Km value	1222:1243	Kinetics analysis showed the variant D182C has a lower Km value and a higher kcat/Km value than that of the WT, indicating the variant D182C has enhanced affinity to substrate.
35234395	7	44	theme	D182C	1029:1033	arg1	higher					1040:1045	higher	1040:1045	higher	1040:1045	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	44	theme	D182C	1029:1033	arg1	activities					957:966	the enzyme activities	946:966	the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C	946:1033	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	6	45	theme	D182C	818:822	arg1	monoglucoside					730:742	sophoricoside monoglucoside	716:742	sophoricoside monoglucoside	716:742	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	45	theme	D182C	818:822	arg1	diglucoside					759:769	sophoricoside diglucoside	745:769	sophoricoside diglucoside	745:769	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	45	theme	D182C	818:822	arg1	products					707:714	the main products	698:714	the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C	698:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	45	theme	D182C	818:822	arg1	triglucoside					790:801	sophoricoside triglucoside	776:801	sophoricoside triglucoside	776:801	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	7	46	theme	variant	1110:1116	arg1	D182C					1118:1122	the variant D182C	1106:1122	the variant D182C	1106:1122	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	2	47	theme	water	342:346	arg1	solubility					348:357	water solubility	342:357	water solubility	342:357	Glycosylation is regarded as one of the effective approaches to improve water solubility.
35234395	7	48	theme	Enzymatic	907:915	arg1	characterization					917:932	Enzymatic characterization	907:932	Enzymatic characterization	907:932	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	1	49	dep	play	145:148	arg1	whereas					202:208	whereas	202:208	whereas	202:208	Genistein and its monoglucoside derivatives play important roles in food and pharmaceuticals fields, whereas their applications are limited by the low water solubility.
35234395	1	50	theme	important	150:158	arg1	roles					160:164	important roles	150:164	important roles	150:164	Genistein and its monoglucoside derivatives play important roles in food and pharmaceuticals fields, whereas their applications are limited by the low water solubility.
35234395	0	51	theme	genistein	79:87	arg1	synthesis					89:97	glycosylated genistein synthesis	66:97	glycosylated genistein synthesis	66:97	[Engineering the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis].
35234395	6	52	theme	sophoricoside	745:757	arg1	diglucoside					759:769	sophoricoside diglucoside	745:769	sophoricoside diglucoside	745:769	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	6	52	theme	sophoricoside	745:757	arg1	products					707:714	the main products	698:714	the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C	698:822	Moreover, the main products sophoricoside monoglucoside, sophoricoside diglucoside, and sophoricoside triglucoside of the variant D182C increased by 39.35%, 56.05% and 64.81% compared with that of the WT, respectively.
35234395	7	53	dep	activities	957:966	arg1	disproportionation					994:1011	disproportionation	994:1011	disproportionation	994:1011	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	53	dep	activities	957:966	arg1	hydrolysis					982:991	hydrolysis	982:991	hydrolysis	982:991	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	7	53	dep	activities	957:966	arg1	cyclization					969:979	cyclization	969:979	cyclization	969:979	Enzymatic characterization showed that the enzyme activities (cyclization, hydrolysis, disproportionation) of the variant D182C were higher than that of the WT, and the optimal pH and temperature of the variant D182C were 6 and 40℃, respectively.
35234395	1	54	theme	low	248:250	arg1	solubility					258:267	the low water solubility	244:267	the low water solubility	244:267	Genistein and its monoglucoside derivatives play important roles in food and pharmaceuticals fields, whereas their applications are limited by the low water solubility.
35234395	0	55	theme	glycosylated	66:77	arg1	synthesis					89:97	glycosylated genistein synthesis	66:97	glycosylated genistein synthesis	66:97	[Engineering the 182 site of cyclodextrin glucosyltransferase for glycosylated genistein synthesis].
35234395	4	56	theme	Saturation	533:542	arg1	mutagenesis					544:554	Saturation mutagenesis	533:554	Saturation mutagenesis of D182 from PmCGTase	533:576	Saturation mutagenesis of D182 from PmCGTase was carried out.
35234395	5	57	dep	wild-type	613:621	arg1	WT					624:625	WT	624:625	WT	624:625	Compared with the wild-type (WT), the variant D182C showed a 13.42% higher conversion ratio.
35234395	1	58	theme	water	252:256	arg1	solubility					258:267	the low water solubility	244:267	the low water solubility	244:267	Genistein and its monoglucoside derivatives play important roles in food and pharmaceuticals fields, whereas their applications are limited by the low water solubility.
35393560	2	0	gly	glycoproteins	194:206	arg1	glycoproteins					194:206	therapeutic glycoproteins	182:206	therapeutic glycoproteins	182:206	Frequently, therapeutic glycoproteins exhibit a heterogeneous array of glycans that are intended to mimic human glycopatterns.
35393560	4	1	theme	glycoengineering	557:572	arg1	strategies					574:583	glycoengineering strategies	557:583	glycoengineering strategies	557:583	Therefore, close attention has been drawn to the development of glycoengineering strategies to control the glycan structures.
35393560	4	2	theme	close	504:508	arg1	attention					510:518	close attention	504:518	close attention	504:518	Therefore, close attention has been drawn to the development of glycoengineering strategies to control the glycan structures.
35393560	7	3	theme	binding	1220:1226	arg1	affinity					1228:1235	native IgG binding affinity	1209:1235	native IgG binding affinity	1209:1235	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	3	4	theme	glycosylation	387:399	arg1	control					376:382	enabling exquisite control	357:382	enabling exquisite control of glycosylation with minimized microheterogeneity	357:433	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
35393560	6	5	theme	pharmaceutical	987:1000	arg1	field					1002:1006	the pharmaceutical field	983:1006	the pharmaceutical field	983:1006	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	5	6	theme	potential	732:740	arg1	strategy					742:749	a potential strategy	730:749	a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility	730:831	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	5	7	theme	glycan	664:669	arg1	enzymes					684:690	the glycan biosynthesis enzymes	660:690	the glycan biosynthesis enzymes	660:690	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	3	8	theme	exquisite	366:374	arg1	control					376:382	enabling exquisite control	357:382	enabling exquisite control of glycosylation with minimized microheterogeneity	357:433	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
35393560	7	9	theme	native	1209:1214	arg1	affinity					1228:1235	native IgG binding affinity	1209:1235	native IgG binding affinity	1209:1235	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	5	10	theme	biosynthesis	671:682	arg1	enzymes					684:690	the glycan biosynthesis enzymes	660:690	the glycan biosynthesis enzymes	660:690	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	7	11	theme	IgG	1216:1218	arg1	affinity					1228:1235	native IgG binding affinity	1209:1235	native IgG binding affinity	1209:1235	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	5	12	theme	enzymatic	693:701	arg1	remodeling					710:719	enzymatic glycan remodeling	693:719	enzymatic glycan remodeling	693:719	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	7	13	with	N-glycoforms	1149:1160	arg1	yield					1172:1176	high yield	1167:1176	high yield	1167:1176	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	7	13	with	N-glycoforms	1149:1160	arg1	efficiency					1182:1191	efficiency	1182:1191	efficiency	1182:1191	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	0	14	theme	Successive	0:9	arg1	remodeling					11:20	Successive remodeling	0:20	Successive remodeling of IgG glycans	0:35	Successive remodeling of IgG glycans using a solid-phase enzymatic platform.
35393560	5	15	theme	glycan	703:708	arg1	remodeling					710:719	enzymatic glycan remodeling	693:719	enzymatic glycan remodeling	693:719	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	7	16	theme	successive	1024:1033	arg1	remodeling					1042:1051	successive glycan remodeling	1024:1051	successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity	1024:1235	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	6	17	theme	impactful	951:959	arg1	class					974:978	an impactful glycoprotein class	948:978	an impactful glycoprotein class	948:978	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	6	17	theme	impactful	951:959	arg1	G					945:945	glycoengineering immobilized immunoglobulin G	901:945	glycoengineering immobilized immunoglobulin G	901:945	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	0	18	theme	IgG	25:27	arg1	glycans					29:35	IgG glycans	25:35	IgG glycans	25:35	Successive remodeling of IgG glycans using a solid-phase enzymatic platform.
35393560	4	19	theme	glycan	600:605	arg1	structures					607:616	the glycan structures	596:616	the glycan structures	596:616	Therefore, close attention has been drawn to the development of glycoengineering strategies to control the glycan structures.
35393560	5	20	theme	ordered	771:777	arg1	glycans					779:785	highly ordered glycans	764:785	highly ordered glycans	764:785	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	5	21	theme	knowledge	644:652	arg1	accumulation					628:639	the accumulation	624:639	the accumulation of knowledge about the glycan biosynthesis enzymes	624:690	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	1	22	theme	glycoprotein-based	92:109	arg1	drugs					111:115	glycoprotein-based drugs	92:115	glycoprotein-based drugs	92:115	The success of glycoprotein-based drugs in various disease treatments has become widespread.
35393560	6	23	gly	glycoprotein	961:972	arg1	glycoprotein					961:972	an impactful glycoprotein class	948:978	an impactful glycoprotein class	948:978	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	3	24	theme	minimized	406:414	arg1	microheterogeneity					416:433	minimized microheterogeneity	406:433	minimized microheterogeneity	406:433	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
35393560	3	25	theme	immunogenic	303:313	arg1	responses					315:323	immunogenic responses	303:323	immunogenic responses to biologic drugs	303:341	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
35393560	6	26	theme	glycoprotein	961:972	arg1	class					974:978	an impactful glycoprotein class	948:978	an impactful glycoprotein class	948:978	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	6	26	theme	glycoprotein	961:972	arg1	G					945:945	glycoengineering immobilized immunoglobulin G	901:945	glycoengineering immobilized immunoglobulin G	901:945	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	1	27	theme	drugs	111:115	arg1	success					81:87	The success	77:87	The success of glycoprotein-based drugs in various disease treatments	77:145	The success of glycoprotein-based drugs in various disease treatments has become widespread.
35393560	7	28	theme	solid-phase	1058:1068	arg1	platform					1070:1077	a solid-phase platform	1056:1077	a solid-phase platform	1056:1077	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	7	29	theme	high	1167:1170	arg1	yield					1172:1176	high yield	1167:1176	high yield	1167:1176	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	2	30	theme	therapeutic	182:192	arg1	glycoproteins					194:206	therapeutic glycoproteins	182:206	therapeutic glycoproteins	182:206	Frequently, therapeutic glycoproteins exhibit a heterogeneous array of glycans that are intended to mimic human glycopatterns.
35393560	6	31	from	enzymes	889:895	arg1	field					1002:1006	the pharmaceutical field	983:1006	the pharmaceutical field	983:1006	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	0	32	theme	glycans	29:35	arg1	remodeling					11:20	Successive remodeling	0:20	Successive remodeling of IgG glycans	0:35	Successive remodeling of IgG glycans using a solid-phase enzymatic platform.
35393560	5	33	theme	improved	792:799	arg1	efficiency					801:810	improved efficiency	792:810	improved efficiency	792:810	With the accumulation of knowledge about the glycan biosynthesis enzymes, enzymatic glycan remodeling provides a potential strategy to construct highly ordered glycans with improved efficiency and biocompatibility.
35393560	3	34	with	control	376:382	arg1	microheterogeneity					416:433	minimized microheterogeneity	406:433	minimized microheterogeneity	406:433	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
35393560	0	35	theme	solid-phase	45:55	arg1	platform					67:74	a solid-phase enzymatic platform	43:74	a solid-phase enzymatic platform	43:74	Successive remodeling of IgG glycans using a solid-phase enzymatic platform.
35393560	4	36	theme	strategies	574:583	arg1	development					542:552	the development	538:552	the development of glycoengineering strategies to control the glycan structures	538:616	Therefore, close attention has been drawn to the development of glycoengineering strategies to control the glycan structures.
35393560	3	37	theme	biologic	328:335	arg1	drugs					337:341	biologic drugs	328:341	biologic drugs	328:341	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
35393560	0	38	theme	enzymatic	57:65	arg1	platform					67:74	a solid-phase enzymatic platform	43:74	a solid-phase enzymatic platform	43:74	Successive remodeling of IgG glycans using a solid-phase enzymatic platform.
35393560	2	39	theme	glycans	241:247	arg1	array					232:236	a heterogeneous array	216:236	a heterogeneous array of glycans that are intended to mimic human glycopatterns	216:294	Frequently, therapeutic glycoproteins exhibit a heterogeneous array of glycans that are intended to mimic human glycopatterns.
35393560	6	40	theme	immunoglobulin	930:943	arg1	class					974:978	an impactful glycoprotein class	948:978	an impactful glycoprotein class	948:978	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	6	40	theme	immunoglobulin	930:943	arg1	G					945:945	glycoengineering immobilized immunoglobulin G	901:945	glycoengineering immobilized immunoglobulin G	901:945	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	1	41	theme	various	120:126	arg1	treatments					136:145	various disease treatments	120:145	various disease treatments	120:145	The success of glycoprotein-based drugs in various disease treatments has become widespread.
35393560	7	42	theme	glycan	1035:1040	arg1	remodeling					1042:1051	successive glycan remodeling	1024:1051	successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity	1024:1235	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	2	43	theme	heterogeneous	218:230	arg1	array					232:236	a heterogeneous array	216:236	a heterogeneous array of glycans that are intended to mimic human glycopatterns	216:294	Frequently, therapeutic glycoproteins exhibit a heterogeneous array of glycans that are intended to mimic human glycopatterns.
35393560	2	44	theme	human	276:280	arg1	glycopatterns					282:294	human glycopatterns	276:294	human glycopatterns	276:294	Frequently, therapeutic glycoproteins exhibit a heterogeneous array of glycans that are intended to mimic human glycopatterns.
35393560	1	45	theme	disease	128:134	arg1	treatments					136:145	various disease treatments	120:145	various disease treatments	120:145	The success of glycoprotein-based drugs in various disease treatments has become widespread.
35393560	7	46	theme	complex-type	1136:1147	arg1	N-glycoforms					1149:1160	complex-type N-glycoforms	1136:1160	complex-type N-glycoforms with high yield and efficiency	1136:1191	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	6	47	theme	immobilized	918:928	arg1	class					974:978	an impactful glycoprotein class	948:978	an impactful glycoprotein class	948:978	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	6	47	theme	immobilized	918:928	arg1	G					945:945	glycoengineering immobilized immunoglobulin G	901:945	glycoengineering immobilized immunoglobulin G	901:945	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	7	48	theme	IgG	1094:1096	arg1	harmonization					1105:1117	IgG glycan harmonization	1094:1117	IgG glycan harmonization	1094:1117	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	1	49	from	success	81:87	arg1	treatments					136:145	various disease treatments	120:145	various disease treatments	120:145	The success of glycoprotein-based drugs in various disease treatments has become widespread.
35393560	7	50	from	remodeling	1042:1051	arg1	platform					1070:1077	a solid-phase platform	1056:1077	a solid-phase platform	1056:1077	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	6	51	theme	glycoengineering	901:916	arg1	class					974:978	an impactful glycoprotein class	948:978	an impactful glycoprotein class	948:978	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	6	51	theme	glycoengineering	901:916	arg1	G					945:945	glycoengineering immobilized immunoglobulin G	901:945	glycoengineering immobilized immunoglobulin G	901:945	In this study, we quantitatively evaluate more than 30 enzymes for glycoengineering immobilized immunoglobulin G, an impactful glycoprotein class in the pharmaceutical field.
35393560	7	52	theme	N-glycoforms	1149:1160	arg1	series					1126:1131	a series	1124:1131	a series of complex-type N-glycoforms with high yield and efficiency	1124:1191	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	7	53	theme	glycan	1098:1103	arg1	harmonization					1105:1117	IgG glycan harmonization	1094:1117	IgG glycan harmonization	1094:1117	We demonstrate successive glycan remodeling in a solid-phase platform, which enabled IgG glycan harmonization into a series of complex-type N-glycoforms with high yield and efficiency while retaining native IgG binding affinity.
35393560	3	54	theme	enabling	357:364	arg1	control					376:382	enabling exquisite control	357:382	enabling exquisite control of glycosylation with minimized microheterogeneity	357:433	While immunogenic responses to biologic drugs are uncommon, enabling exquisite control of glycosylation with minimized microheterogeneity would improve their safety, efficacy and bioavailability.
36637423	12	0	theme	glycan	1833:1838	arg1	structures					1840:1849	glycan structures	1833:1849	glycan structures	1833:1849	This platform offers a flexible method for optimal engineering of glycan structures in E. coli.
36637423	10	1	theme	heptasaccharide	1544:1558	arg1	glycan					1560:1565	heptasaccharide glycan	1544:1565	the C. jejuni heptasaccharide glycan	1530:1565	We engineered reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan.
36637423	5	2	from	organism	731:738	arg1	bloc					710:713	en bloc	707:713	en bloc from the native organism	707:738	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	8	3	theme	assembly	1157:1164	arg1	methods					1166:1172	DNA assembly methods	1153:1172	DNA assembly methods	1153:1172	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	12	4	theme	flexible	1790:1797	arg1	method					1799:1804	a flexible method	1788:1804	a flexible method for optimal engineering of glycan structures in E. coli	1788:1860	This platform offers a flexible method for optimal engineering of glycan structures in E. coli.
36637423	8	5	theme	convenient	1185:1194	arg1	assembly					1196:1203	the convenient assembly	1181:1203	the convenient assembly of such pathways	1181:1220	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	5	6	theme	glycan	655:660	arg1	locus					675:679	the glycan biosynthesis locus	651:679	the glycan biosynthesis locus	651:679	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	6	7	theme	gene	779:782	arg1	expression					784:793	gene expression	779:793	gene expression within these pathways	779:815	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	3	8	theme	Biosynthetic	273:284	arg1	production					301:310	Biosynthetic glycoconjugate production	273:310	Biosynthetic glycoconjugate production	273:310	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	8	9	theme	coding	1268:1273	arg1	sequences					1275:1283	the requisite coding sequences	1254:1283	the requisite coding sequences in a single step	1254:1300	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	8	10	theme	pathways	1213:1220	arg1	assembly					1196:1203	the convenient assembly	1181:1203	the convenient assembly of such pathways	1181:1220	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	7	11	from	challenges	1009:1018	arg1	expression					1036:1045	heterologous expression	1023:1045	heterologous expression of multi-gene systems	1023:1067	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	5	12	theme	en	707:708	arg1	bloc					710:713	en bloc	707:713	en bloc from the native organism	707:738	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	8	13	theme	single	1290:1295	arg1	step					1297:1300	a single step	1288:1300	a single step	1288:1300	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	7	14	theme	multi-gene	1050:1059	arg1	systems					1061:1067	multi-gene systems	1050:1067	multi-gene systems	1050:1067	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	1	15	theme	glycans	118:124	arg1	field					168:172	a rapidly evolving field	149:172	a rapidly evolving field	149:172	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	1	15	theme	glycans	118:124	arg1	Glycoengineering					86:101	Glycoengineering	86:101	Glycoengineering of recombinant glycans and glycoconjugates	86:144	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	7	16	theme	synthetic	977:985	arg1	biology					987:993	synthetic biology	977:993	synthetic biology	977:993	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	1	17	theme	glycoconjugates	130:144	arg1	field					168:172	a rapidly evolving field	149:172	a rapidly evolving field	149:172	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	1	17	theme	glycoconjugates	130:144	arg1	Glycoengineering					86:101	Glycoengineering	86:101	Glycoengineering of recombinant glycans and glycoconjugates	86:144	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	0	18	theme	N-linked	57:64	arg1	glycans					66:72	N-linked glycans	57:72	N-linked glycans	57:72	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	9	19	from	biosynthesis	1370:1381	arg1	coli					1447:1450	E. coli	1444:1450	E. coli	1444:1450	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	1	20	theme	evolving	159:166	arg1	field					168:172	a rapidly evolving field	149:172	a rapidly evolving field	149:172	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	1	20	theme	evolving	159:166	arg1	Glycoengineering					86:101	Glycoengineering	86:101	Glycoengineering of recombinant glycans and glycoconjugates	86:144	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	3	21	theme	components	362:371	arg1	cooperation					337:347	the coordinated cooperation	321:347	the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	321:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	0	22	from	biosynthesis	41:52	arg1	coli					80:83	E. coli	77:83	E. coli	77:83	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	10	23	theme	reconstructed	1467:1479	arg1	clusters					1494:1501	reconstructed biosynthesis clusters	1467:1501	reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan	1467:1565	We engineered reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan.
36637423	5	24	theme	E.	754:755	arg1	strain					762:767	a suitable E. coli strain	743:767	a suitable E. coli strain	743:767	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	4	25	theme	acceptor	500:507	arg1	oligosaccharyltransferase					521:545	oligosaccharyltransferase	521:545	oligosaccharyltransferase	521:545	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	4	25	theme	acceptor	500:507	arg1	products					555:562	the products	551:562	the products of single genes	551:578	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	4	25	theme	acceptor	500:507	arg1	protein					509:515	the acceptor protein	496:515	the acceptor protein	496:515	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	0	26	theme	glycans	66:72	arg1	biosynthesis					41:52	biosynthesis	41:52	biosynthesis of N-linked glycans in E. coli	41:83	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	5	27	theme	native	724:729	arg1	organism					731:738	the native organism	720:738	the native organism	720:738	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	0	28	theme	DNA	16:18	arg1	approach					29:36	A combinatorial DNA assembly approach	0:36	A combinatorial DNA assembly approach	0:36	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	9	29	theme	combinatorial	1327:1339	arg1	assembly					1341:1348	combinatorial assembly	1327:1348	combinatorial assembly	1327:1348	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	11	30	theme	native	1736:1741	arg1	cluster					1758:1764	the native unmodified pgl cluster	1732:1764	the native unmodified pgl cluster	1732:1764	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	3	31	theme	glycan	463:468	arg1	locus					483:487	a glycan biosynthesis locus	461:487	a glycan biosynthesis locus	461:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	31	theme	glycan	463:468	arg1	components					362:371	three key components	352:371	three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	352:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	32	dep	components	362:371	arg1	oligosaccharyltransferase					430:454	a coupling oligosaccharyltransferase	419:454	a coupling oligosaccharyltransferase	419:454	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	32	dep	components	362:371	arg1	locus					483:487	a glycan biosynthesis locus	461:487	a glycan biosynthesis locus	461:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	32	dep	components	362:371	arg1	components					362:371	three key components	352:371	three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	352:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	32	dep	components	362:371	arg1	protein					410:416	a substrate protein	398:416	a substrate protein	398:416	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	11	33	theme	assembly	1623:1630	arg1	round					1600:1604	a single round	1591:1604	a single round of combinatorial assembly and screening	1591:1644	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	9	34	theme	heterologous	1357:1368	arg1	biosynthesis					1370:1381	the heterologous biosynthesis	1353:1381	the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli	1353:1450	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	0	35	dep	approach	29:36	arg1	biosynthesis					41:52	biosynthesis	41:52	biosynthesis of N-linked glycans in E. coli	41:83	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	4	36	theme	single	567:572	arg1	genes					574:578	single genes	567:578	single genes	567:578	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	4	37	theme	multi-gene	610:619	arg1	pathway					631:637	a multi-gene metabolic pathway	608:637	a multi-gene metabolic pathway	608:637	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	11	38	theme	pgl	1754:1756	arg1	cluster					1758:1764	the native unmodified pgl cluster	1732:1764	the native unmodified pgl cluster	1732:1764	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	9	39	theme	Campylobacter	1390:1402	arg1	pathway					1433:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	6	40	theme	heterologous	910:921	arg1	production					923:932	heterologous production	910:932	heterologous production in an unrelated organism	910:957	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	12	41	theme	structures	1840:1849	arg1	engineering					1818:1828	optimal engineering	1810:1828	optimal engineering of glycan structures in E. coli	1810:1860	This platform offers a flexible method for optimal engineering of glycan structures in E. coli.
36637423	4	42	theme	pathway	631:637	arg1	glycan					585:590	the glycan	581:590	the glycan	581:590	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	4	42	theme	pathway	631:637	arg1	product					597:603	a product	595:603	a product of a multi-gene metabolic pathway	595:637	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	5	43	theme	biosynthesis	662:673	arg1	locus					675:679	the glycan biosynthesis locus	651:679	the glycan biosynthesis locus	651:679	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	11	44	theme	screening	1636:1644	arg1	round					1600:1604	a single round	1591:1604	a single round of combinatorial assembly and screening	1591:1644	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	9	45	theme	N-glycosylation	1411:1425	arg1	pathway					1433:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	12	46	from	engineering	1818:1828	arg1	coli					1857:1860	E. coli	1854:1860	E. coli	1854:1860	This platform offers a flexible method for optimal engineering of glycan structures in E. coli.
36637423	11	47	theme	pathway	1661:1667	arg1	clones					1669:1674	pathway clones	1661:1674	pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster	1661:1764	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	9	48	theme	pgl	1428:1430	arg1	pathway					1433:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	8	49	theme	DNA	1153:1155	arg1	methods					1166:1172	DNA assembly methods	1153:1172	DNA assembly methods	1153:1172	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	12	50	theme	optimal	1810:1816	arg1	engineering					1818:1828	optimal engineering	1810:1828	optimal engineering of glycan structures in E. coli	1810:1860	This platform offers a flexible method for optimal engineering of glycan structures in E. coli.
36637423	9	51	theme	pathway	1433:1439	arg1	biosynthesis					1370:1381	the heterologous biosynthesis	1353:1381	the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli	1353:1450	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
36637423	8	52	theme	methods	1166:1172	arg1	use					1146:1148	The use	1142:1148	The use of DNA assembly methods	1142:1172	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	8	53	theme	defined	1235:1241	arg1	parts					1243:1247	defined parts	1235:1247	defined parts	1235:1247	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	11	54	theme	single	1593:1598	arg1	round					1600:1604	a single round	1591:1604	a single round of combinatorial assembly and screening	1591:1644	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	6	55	from	production	923:932	arg1	organism					950:957	an unrelated organism	937:957	an unrelated organism	937:957	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	3	56	theme	glycoconjugate	286:299	arg1	production					301:310	Biosynthetic glycoconjugate production	273:310	Biosynthetic glycoconjugate production	273:310	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	8	57	theme	requisite	1258:1266	arg1	sequences					1275:1283	the requisite coding sequences	1254:1283	the requisite coding sequences in a single step	1254:1300	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	7	58	theme	systems	1061:1067	arg1	expression					1036:1045	heterologous expression	1023:1045	heterologous expression of multi-gene systems	1023:1067	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	8	59	theme	such	1208:1211	arg1	pathways					1213:1220	such pathways	1208:1220	such pathways	1208:1220	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	6	60	theme	unrelated	940:948	arg1	organism					950:957	an unrelated organism	937:957	an unrelated organism	937:957	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	6	61	from	selection	847:855	arg1	host					871:874	the native host	860:874	the native host	860:874	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	2	62	theme	glycans	219:225	arg1	production					188:197	production	188:197	production	188:197	However, the production and exploitation of glycans has lagged behind proteins and nucleic acids.
36637423	2	62	theme	glycans	219:225	arg1	exploitation					203:214	exploitation	203:214	exploitation	203:214	However, the production and exploitation of glycans has lagged behind proteins and nucleic acids.
36637423	1	63	theme	recombinant	106:116	arg1	glycans					118:124	recombinant glycans	106:124	recombinant glycans	106:124	Glycoengineering of recombinant glycans and glycoconjugates is a rapidly evolving field.
36637423	3	64	theme	coordinated	325:335	arg1	cooperation					337:347	the coordinated cooperation	321:347	the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	321:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	7	65	theme	heterologous	1023:1034	arg1	expression					1036:1045	heterologous expression	1023:1045	heterologous expression of multi-gene systems	1023:1067	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	2	66	theme	nucleic	258:264	arg1	acids					266:270	nucleic acids	258:270	nucleic acids	258:270	However, the production and exploitation of glycans has lagged behind proteins and nucleic acids.
36637423	5	67	theme	coli	757:760	arg1	strain					762:767	a suitable E. coli strain	743:767	a suitable E. coli strain	743:767	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	8	68	from	sequences	1275:1283	arg1	step					1297:1300	a single step	1288:1300	a single step	1288:1300	The use of DNA assembly methods allows the convenient assembly of such pathways by combining defined parts with the requisite coding sequences in a single step.
36637423	3	69	theme	key	358:360	arg1	oligosaccharyltransferase					430:454	a coupling oligosaccharyltransferase	419:454	a coupling oligosaccharyltransferase	419:454	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	69	theme	key	358:360	arg1	locus					483:487	a glycan biosynthesis locus	461:487	a glycan biosynthesis locus	461:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	69	theme	key	358:360	arg1	protein					410:416	a substrate protein	398:416	a substrate protein	398:416	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	69	theme	key	358:360	arg1	components					362:371	three key components	352:371	three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	352:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	4	70	theme	metabolic	621:629	arg1	pathway					631:637	a multi-gene metabolic pathway	608:637	a multi-gene metabolic pathway	608:637	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	10	71	dep	jejuni	1537:1542	arg1	glycan					1560:1565	heptasaccharide glycan	1544:1565	the C. jejuni heptasaccharide glycan	1530:1565	We engineered reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan.
36637423	7	72	theme	recent	963:968	arg1	years					970:974	recent years	963:974	recent years	963:974	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	3	73	theme	bacterial	382:390	arg1	cell					392:395	a bacterial cell	380:395	a bacterial cell	380:395	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	5	74	theme	suitable	745:752	arg1	strain					762:767	a suitable E. coli strain	743:767	a suitable E. coli strain	743:767	Typically, the glycan biosynthesis locus is cloned and transferred en bloc from the native organism to a suitable E. coli strain.
36637423	0	75	theme	combinatorial	2:14	arg1	approach					29:36	A combinatorial DNA assembly approach	0:36	A combinatorial DNA assembly approach	0:36	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	3	76	theme	substrate	400:408	arg1	components					362:371	three key components	352:371	three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	352:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	76	theme	substrate	400:408	arg1	protein					410:416	a substrate protein	398:416	a substrate protein	398:416	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	0	77	theme	assembly	20:27	arg1	approach					29:36	A combinatorial DNA assembly approach	0:36	A combinatorial DNA assembly approach	0:36	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	7	78	theme	bottom	1131:1136	arg1	up					1138:1139	the bottom up	1127:1139	the bottom up	1127:1139	In recent years, synthetic biology has addressed challenges in heterologous expression of multi-gene systems by deconstructing these pathways and rebuilding them from the bottom up.
36637423	6	79	theme	native	864:869	arg1	host					871:874	the native host	860:874	the native host	860:874	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	3	80	theme	coupling	421:428	arg1	oligosaccharyltransferase					430:454	a coupling oligosaccharyltransferase	419:454	a coupling oligosaccharyltransferase	419:454	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	80	theme	coupling	421:428	arg1	components					362:371	three key components	352:371	three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	352:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	10	81	theme	biosynthesis	1481:1492	arg1	clusters					1494:1501	reconstructed biosynthesis clusters	1467:1501	reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan	1467:1565	We engineered reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan.
36637423	11	82	theme	combinatorial	1609:1621	arg1	assembly					1623:1630	combinatorial assembly	1609:1630	combinatorial assembly	1609:1630	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	3	83	theme	biosynthesis	470:481	arg1	locus					483:487	a glycan biosynthesis locus	461:487	a glycan biosynthesis locus	461:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	3	83	theme	biosynthesis	470:481	arg1	components					362:371	three key components	352:371	three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus	352:487	Biosynthetic glycoconjugate production requires the coordinated cooperation of three key components within a bacterial cell: a substrate protein, a coupling oligosaccharyltransferase, and a glycan biosynthesis locus.
36637423	4	84	theme	genes	574:578	arg1	oligosaccharyltransferase					521:545	oligosaccharyltransferase	521:545	oligosaccharyltransferase	521:545	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	4	84	theme	genes	574:578	arg1	products					555:562	the products	551:562	the products of single genes	551:578	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	4	84	theme	genes	574:578	arg1	protein					509:515	the acceptor protein	496:515	the acceptor protein	496:515	While the acceptor protein and oligosaccharyltransferase are the products of single genes, the glycan is a product of a multi-gene metabolic pathway.
36637423	10	85	theme	C.	1534:1535	arg1	jejuni					1537:1542	the C. jejuni heptasaccharide glycan	1530:1565	the C. jejuni heptasaccharide glycan	1530:1565	We engineered reconstructed biosynthesis clusters that faithfully reproduced the C. jejuni heptasaccharide glycan.
36637423	11	86	theme	cluster	1758:1764	arg1	production					1718:1727	production	1718:1727	production of the native unmodified pgl cluster	1718:1764	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	6	87	theme	natural	839:845	arg1	selection					847:855	natural selection	839:855	natural selection in the native host	839:874	However, gene expression within these pathways has been optimised by natural selection in the native host and is unlikely to be optimal for heterologous production in an unrelated organism.
36637423	0	88	link	N-linked	57:64	arg1	glycans					66:72	N-linked glycans	57:72	N-linked glycans	57:72	A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.
36637423	2	89	dep	production	188:197	arg1	the					184:186	the	184:186	the	184:186	However, the production and exploitation of glycans has lagged behind proteins and nucleic acids.
36637423	11	90	theme	unmodified	1743:1752	arg1	cluster					1758:1764	the native unmodified pgl cluster	1732:1764	the native unmodified pgl cluster	1732:1764	Furthermore, following a single round of combinatorial assembly and screening, we identified pathway clones that outperform glycan and glycoconjugate production of the native unmodified pgl cluster.
36637423	9	91	theme	jejuni	1404:1409	arg1	pathway					1433:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	the Campylobacter jejuni N-glycosylation (pgl) pathway	1386:1439	In this study, we apply combinatorial assembly to the heterologous biosynthesis of the Campylobacter jejuni N-glycosylation (pgl) pathway in E. coli.
37289618	4	0	dep	mode	713:716	arg1	spectrometry					723:734	mass spectrometry	718:734	negative-ion mode mass spectrometry	700:734	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	2	1	gly	sialylated	398:407	arg1	glycans					418:424	intact sialylated N-linked glycans	391:424	intact sialylated N-linked glycans	391:424	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	6	2	theme	confident	976:984	arg1	annotations					993:1003	confident glycan annotations	976:1003	confident glycan annotations	976:1003	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	6	3	theme	mass	1038:1041	arg1	measurements					1043:1054	accurate mass measurements	1029:1054	accurate mass measurements	1029:1054	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	2	4	theme	electrospray	336:347	arg1	ionization					349:358	infrared matrix-assisted laser desorption electrospray ionization	294:358	infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI)	294:371	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	4	theme	electrospray	336:347	arg1	IR-MALDESI					361:370	IR-MALDESI	361:370	IR-MALDESI	361:370	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	5	5	theme	sialic	862:867	arg1	acids					869:873	#sialic acids	861:873	#sialic acids	861:873	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	2	6	theme	Previous	265:272	arg1	work					274:277	Previous work	265:277	Previous work	265:277	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	0	7	theme	Chlorine	81:88	arg1	Pattern					70:76	the Isotopic Pattern	57:76	the Isotopic Pattern of Chlorine	57:88	Predicting Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine.
37289618	6	8	theme	IR-MALDESI	1101:1110	arg1	capability					1087:1096	the capability	1083:1096	the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues	1083:1173	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	6	9	theme	N-linked	1132:1139	arg1	glycans					1141:1147	sialylated N-linked glycans	1121:1147	sialylated N-linked glycans	1121:1147	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	5	10	theme	chlorine	924:931	arg1	adducts					933:939	chlorine adducts	924:939	chlorine adducts	924:939	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	5	11	theme	charge	891:896	arg1	state					898:902	the charge state	887:902	the charge state	887:902	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	4	12	theme	negative-ion	700:711	arg1	mode					713:716	negative-ion mode mass spectrometry	700:734	negative-ion mode mass spectrometry	700:734	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	4	13	theme	kidney	603:608	arg1	tissue					610:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	5	14	theme	adducts	933:939	arg1	number					914:919	the number	910:919	the number of chlorine adducts	910:939	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	6	15	gly	sialylated	1121:1130	arg1	glycans					1141:1147	sialylated N-linked glycans	1121:1147	sialylated N-linked glycans	1121:1147	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	6	16	link	N-linked	1132:1139	arg1	glycans					1141:1147	sialylated N-linked glycans	1121:1147	sialylated N-linked glycans	1121:1147	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	6	17	theme	accurate	1029:1036	arg1	measurements					1043:1054	accurate mass measurements	1029:1054	accurate mass measurements	1029:1054	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	0	18	theme	Sialic	11:16	arg1	Content					23:29	Sialic Acid Content	11:29	Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine	11:88	Predicting Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine.
37289618	3	19	theme	new	498:500	arg1	rule					502:505	a new rule	496:505	a new rule that can predict the number of sialic acids on a glycan	496:561	In this work, we describe a new rule that can predict the number of sialic acids on a glycan.
37289618	5	20	theme	experimental	747:758	arg1	distribution					769:780	the experimental isotopic distribution	743:780	the experimental isotopic distribution of a detected glycan	743:801	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	6	21	theme	new	960:962	arg1	rule					964:967	This new rule	955:967	This new rule	955:967	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	1	22	theme	mass	246:249	arg1	spectrometry					251:262	mass spectrometry	246:262	mass spectrometry	246:262	Sialic acids play several roles in both physiological and pathological processes; however, due to their labile nature, they are difficult to analyze using mass spectrometry.
37289618	3	23	theme	sialic	538:543	arg1	acids					545:549	sialic acids	538:549	sialic acids	538:549	In this work, we describe a new rule that can predict the number of sialic acids on a glycan.
37289618	4	24	theme	established	647:657	arg1	methods					659:665	previously established methods	636:665	previously established methods	636:665	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	1	25	theme	Sialic	91:96	arg1	acids					98:102	Sialic acids	91:102	Sialic acids	91:102	Sialic acids play several roles in both physiological and pathological processes; however, due to their labile nature, they are difficult to analyze using mass spectrometry.
37289618	2	26	theme	N-linked	409:416	arg1	glycans					418:424	intact sialylated N-linked glycans	391:424	intact sialylated N-linked glycans	391:424	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	0	27	theme	Acid	18:21	arg1	Content					23:29	Sialic Acid Content	11:29	Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine	11:88	Predicting Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine.
37289618	6	28	theme	sialylated	1121:1130	arg1	glycans					1141:1147	sialylated N-linked glycans	1121:1147	sialylated N-linked glycans	1121:1147	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	1	29	theme	pathological	149:160	arg1	processes					162:170	both physiological and pathological processes	126:170	both physiological and pathological processes	126:170	Sialic acids play several roles in both physiological and pathological processes; however, due to their labile nature, they are difficult to analyze using mass spectrometry.
37289618	2	30	theme	sialylated	398:407	arg1	glycans					418:424	intact sialylated N-linked glycans	391:424	intact sialylated N-linked glycans	391:424	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	0	31	theme	N-Linked	34:41	arg1	Glycans					43:49	N-Linked Glycans	34:49	N-Linked Glycans Using the Isotopic Pattern of Chlorine	34:88	Predicting Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine.
37289618	2	32	theme	laser	319:323	arg1	ionization					349:358	infrared matrix-assisted laser desorption electrospray ionization	294:358	infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI)	294:371	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	32	theme	laser	319:323	arg1	IR-MALDESI					361:370	IR-MALDESI	361:370	IR-MALDESI	361:370	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	5	33	theme	sialic	833:838	arg1	acids					840:844	sialic acids	833:844	sialic acids	833:844	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	2	34	theme	intact	391:396	arg1	glycans					418:424	intact sialylated N-linked glycans	391:424	intact sialylated N-linked glycans	391:424	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	35	theme	derivatization	454:467	arg1	use					438:440	the use	434:440	the use of chemical derivatization	434:467	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	5	36	theme	detected	787:794	arg1	glycan					796:801	a detected glycan	785:801	a detected glycan	785:801	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	1	37	theme	labile	195:200	arg1	nature					202:207	their labile nature	189:207	their labile nature	189:207	Sialic acids play several roles in both physiological and pathological processes; however, due to their labile nature, they are difficult to analyze using mass spectrometry.
37289618	2	38	theme	chemical	445:452	arg1	derivatization					454:467	chemical derivatization	445:467	chemical derivatization	445:467	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	5	39	theme	isotopic	760:767	arg1	distribution					769:780	the experimental isotopic distribution	743:780	the experimental isotopic distribution of a detected glycan	743:801	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	3	40	theme	acids	545:549	arg1	number					528:533	the number	524:533	the number of sialic acids on a glycan	524:561	In this work, we describe a new rule that can predict the number of sialic acids on a glycan.
37289618	2	41	theme	desorption	325:334	arg1	ionization					349:358	infrared matrix-assisted laser desorption electrospray ionization	294:358	infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI)	294:371	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	41	theme	desorption	325:334	arg1	IR-MALDESI					361:370	IR-MALDESI	361:370	IR-MALDESI	361:370	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	0	42	theme	Glycans	43:49	arg1	Content					23:29	Sialic Acid Content	11:29	Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine	11:88	Predicting Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine.
37289618	5	43	from	number	823:828	arg1	glycan					853:858	the glycan	849:858	the glycan	849:858	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	1	44	theme	several	109:115	arg1	roles					117:121	several roles	109:121	several roles	109:121	Sialic acids play several roles in both physiological and pathological processes; however, due to their labile nature, they are difficult to analyze using mass spectrometry.
37289618	2	45	theme	matrix-assisted	303:317	arg1	ionization					349:358	infrared matrix-assisted laser desorption electrospray ionization	294:358	infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI)	294:371	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	45	theme	matrix-assisted	303:317	arg1	IR-MALDESI					361:370	IR-MALDESI	361:370	IR-MALDESI	361:370	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	3	46	from	number	528:533	arg1	glycan					556:561	a glycan	554:561	a glycan	554:561	In this work, we describe a new rule that can predict the number of sialic acids on a glycan.
37289618	4	47	theme	Formalin-fixed	564:577	arg1	tissue					610:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	2	48	link	N-linked	409:416	arg1	glycans					418:424	intact sialylated N-linked glycans	391:424	intact sialylated N-linked glycans	391:424	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	49	theme	infrared	294:301	arg1	ionization					349:358	infrared matrix-assisted laser desorption electrospray ionization	294:358	infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI)	294:371	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	2	49	theme	infrared	294:301	arg1	IR-MALDESI					361:370	IR-MALDESI	361:370	IR-MALDESI	361:370	Previous work has shown that infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) is able to detect intact sialylated N-linked glycans without the use of chemical derivatization.
37289618	4	50	theme	mass	718:721	arg1	spectrometry					723:734	mass spectrometry	718:734	negative-ion mode mass spectrometry	700:734	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	0	51	theme	Isotopic	61:68	arg1	Pattern					70:76	the Isotopic Pattern	57:76	the Isotopic Pattern of Chlorine	57:88	Predicting Sialic Acid Content of N-Linked Glycans Using the Isotopic Pattern of Chlorine.
37289618	5	52	theme	acids	840:844	arg1	number					823:828	the number	819:828	the number of sialic acids on the glycan	819:858	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	6	53	theme	biological	1156:1165	arg1	tissues					1167:1173	biological tissues	1156:1173	biological tissues	1156:1173	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	6	54	theme	glycan	986:991	arg1	annotations					993:1003	confident glycan annotations	976:1003	confident glycan annotations	976:1003	This new rule grants confident glycan annotations and compositions beyond accurate mass measurements, thereby further improving the capability of IR-MALDESI to study sialylated N-linked glycans within biological tissues.
37289618	5	55	theme	#	861:861	arg1	acids					869:873	#sialic acids	861:873	#sialic acids	861:873	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	4	56	theme	human	597:601	arg1	tissue					610:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	5	57	theme	glycan	796:801	arg1	distribution					769:780	the experimental isotopic distribution	743:780	the experimental isotopic distribution of a detected glycan	743:801	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	5	58	theme	#	949:949	arg1	Cl-					950:952	#Cl-	949:952	#Cl-	949:952	Using the experimental isotopic distribution of a detected glycan, we can predict the number of sialic acids on the glycan; #sialic acids is equal to the charge state minus the number of chlorine adducts, or z - #Cl-.
37289618	1	59	theme	physiological	131:143	arg1	processes					162:170	both physiological and pathological processes	126:170	both physiological and pathological processes	126:170	Sialic acids play several roles in both physiological and pathological processes; however, due to their labile nature, they are difficult to analyze using mass spectrometry.
37289618	4	60	from	IR-MALDESI	686:695	arg1	mode					713:716	negative-ion mode mass spectrometry	700:734	negative-ion mode mass spectrometry	700:734	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
37289618	4	61	theme	paraffin-embedded	579:595	arg1	tissue					610:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue	564:615	Formalin-fixed paraffin-embedded human kidney tissue was prepared using previously established methods and analyzed using IR-MALDESI in negative-ion mode mass spectrometry.
35604098	2	0	theme	glycans	458:464	arg1	function					423:430	the function	419:430	the function of asparagine-linked (N-) glycans in the organelles	419:482	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	1	1	from	stability	220:228	arg1	surfaces					259:266	the cell surfaces	250:266	the cell surfaces	250:266	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	1	1	from	stability	220:228	arg1	fluids					280:285	body fluids	275:285	body fluids	275:285	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	1	2	theme	glycoproteins	233:245	arg1	stability					220:228	stability	220:228	stability	220:228	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	1	2	theme	glycoproteins	233:245	arg1	activity					207:214	biological activity	196:214	biological activity	196:214	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	2	3	from	function	423:430	arg1	organelles					473:482	the organelles	469:482	the organelles	469:482	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	1	4	theme	proteins	149:156	arg1	Glycosylation					132:144	Glycosylation	132:144	Glycosylation of proteins	132:156	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	0	5	theme	Glycoprotein	76:87	arg1	Trafficking					89:99	Glycoprotein Trafficking	76:99	Glycoprotein Trafficking	76:99	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	4	6	theme	N-glycans	715:723	arg1	heptasaccharide					647:661	heptasaccharide	647:661	heptasaccharide	647:661	The heptasaccharide, the intermediate structure of various complex-type N-glycans, was introduced to the CTB.
35604098	4	6	theme	N-glycans	715:723	arg1	structure					681:689	the intermediate structure	664:689	the intermediate structure of various complex-type N-glycans	664:723	The heptasaccharide, the intermediate structure of various complex-type N-glycans, was introduced to the CTB.
35604098	1	7	theme	cell	254:257	arg1	surfaces					259:266	the cell surfaces	250:266	the cell surfaces	250:266	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	5	8	theme	synthesized	757:767	arg1	glycosyl-CTB					779:790	The synthesized monomeric glycosyl-CTB	753:790	The synthesized monomeric glycosyl-CTB	753:790	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	2	9	theme	Golgi	372:376	arg1	apparatus					378:386	the Golgi apparatus	368:386	the Golgi apparatus	368:386	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	0	10	theme	Trafficking	89:99	arg1	Tracer					66:71	a Tracer	64:71	a Tracer of Glycoprotein Trafficking in Organelles of Living Cells	64:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	2	11	theme	N-	454:455	arg1	glycans					458:464	asparagine-linked (N-) glycans	435:464	asparagine-linked (N-) glycans	435:464	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	2	12	link	asparagine-linked	435:451	arg1	glycans					458:464	asparagine-linked (N-) glycans	435:464	asparagine-linked (N-) glycans	435:464	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	5	13	from	functions	951:959	arg1	organelles					998:1007	specific organelles	989:1007	specific organelles of living cells	989:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	5	14	theme	monomeric	769:777	arg1	glycosyl-CTB					779:790	The synthesized monomeric glycosyl-CTB	753:790	The synthesized monomeric glycosyl-CTB	753:790	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	1	15	gly	glycoproteins	233:245	arg1	glycoproteins					233:245	glycoproteins	233:245	glycoproteins	233:245	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	4	16	theme	complex-type	702:713	arg1	N-glycans					715:723	various complex-type N-glycans	694:723	various complex-type N-glycans	694:723	The heptasaccharide, the intermediate structure of various complex-type N-glycans, was introduced to the CTB.
35604098	4	17	theme	various	694:700	arg1	N-glycans					715:723	various complex-type N-glycans	694:723	various complex-type N-glycans	694:723	The heptasaccharide, the intermediate structure of various complex-type N-glycans, was introduced to the CTB.
35604098	5	18	theme	CTB	916:918	arg1	use					899:901	the potential use	885:901	the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells	885:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	5	19	theme	mammalian	813:821	arg1	cells					823:827	mammalian cells	813:827	mammalian cells	813:827	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	5	20	theme	synthetic	906:914	arg1	CTB					916:918	synthetic CTB	906:918	synthetic CTB	906:918	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	0	21	from	Tracer	66:71	arg1	Organelles					104:113	Organelles	104:113	Organelles of Living Cells	104:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	2	22	theme	endoplasmic	337:347	arg1	reticulum					349:357	the endoplasmic reticulum	333:357	the endoplasmic reticulum (ER)	333:362	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	2	22	theme	endoplasmic	337:347	arg1	ER					360:361	ER	360:361	ER	360:361	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	2	23	theme	asparagine-linked	435:451	arg1	glycans					458:464	asparagine-linked (N-) glycans	435:464	asparagine-linked (N-) glycans	435:464	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	0	24	theme	Cholera	37:43	arg1	Toxin					45:49	Cholera Toxin	37:49	Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells	24:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	1	25	theme	body	275:278	arg1	fluids					280:285	body fluids	275:285	body fluids	275:285	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	0	26	theme	Cells	125:129	arg1	Organelles					104:113	Organelles	104:113	Organelles of Living Cells	104:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	5	27	theme	living	1012:1017	arg1	cells					1019:1023	living cells	1012:1023	living cells	1012:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	0	28	theme	Glycosylated	24:35	arg1	Subunit					53:59	Glycosylated Cholera Toxin B Subunit	24:59	Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells	24:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	0	29	theme	Living	118:123	arg1	Cells					125:129	Living Cells	118:129	Living Cells	118:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	3	30	theme	B-subunit	571:579	arg1	toxin					565:569	cholera toxin B-subunit	557:579	an intentionally glycosylated cholera toxin B-subunit (CTB)	527:585	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	3	30	theme	B-subunit	571:579	arg1	CTB					582:584	CTB	582:584	CTB	582:584	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	1	31	theme	biological	196:205	arg1	activity					207:214	biological activity	196:214	biological activity	196:214	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	0	32	theme	B	51:51	arg1	Subunit					53:59	Glycosylated Cholera Toxin B Subunit	24:59	Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells	24:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	1	33	gly	Glycosylation	132:144	arg1	proteins					149:156	proteins	149:156	proteins	149:156	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	5	34	theme	cells	1019:1023	arg1	organelles					998:1007	specific organelles	989:1007	specific organelles of living cells	989:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	3	35	theme	glycosylated	544:555	arg1	toxin					565:569	cholera toxin B-subunit	557:579	an intentionally glycosylated cholera toxin B-subunit (CTB)	527:585	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	3	35	theme	glycosylated	544:555	arg1	CTB					582:584	CTB	582:584	CTB	582:584	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	4	36	theme	intermediate	668:679	arg1	heptasaccharide					647:661	heptasaccharide	647:661	heptasaccharide	647:661	The heptasaccharide, the intermediate structure of various complex-type N-glycans, was introduced to the CTB.
35604098	4	36	theme	intermediate	668:679	arg1	structure					681:689	the intermediate structure	664:689	the intermediate structure of various complex-type N-glycans	664:723	The heptasaccharide, the intermediate structure of various complex-type N-glycans, was introduced to the CTB.
35604098	0	37	theme	Toxin	45:49	arg1	Subunit					53:59	Glycosylated Cholera Toxin B Subunit	24:59	Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells	24:129	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	3	38	theme	mammalian	626:634	arg1	cells					636:640	mammalian cells	626:640	mammalian cells	626:640	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	3	39	theme	cholera	557:563	arg1	toxin					565:569	cholera toxin B-subunit	557:579	an intentionally glycosylated cholera toxin B-subunit (CTB)	527:585	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	3	39	theme	cholera	557:563	arg1	CTB					582:584	CTB	582:584	CTB	582:584	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	1	40	from	activity	207:214	arg1	surfaces					259:266	the cell surfaces	250:266	the cell surfaces	250:266	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	1	40	from	activity	207:214	arg1	fluids					280:285	body fluids	275:285	body fluids	275:285	Glycosylation of proteins is known to be essential for changing biological activity and stability of glycoproteins on the cell surfaces and in body fluids.
35604098	3	41	theme	cells	636:640	arg1	organelles					612:621	the organelles	608:621	the organelles of mammalian cells	608:640	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	5	42	theme	specific	989:996	arg1	organelles					998:1007	specific organelles	989:1007	specific organelles of living cells	989:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	5	43	theme	potential	889:897	arg1	use					899:901	the potential use	885:901	the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells	885:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	2	44	gly	glycoproteins	314:326	arg1	glycoproteins					314:326	homogeneous glycoproteins	302:326	homogeneous glycoproteins	302:326	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	2	45	theme	homogeneous	302:312	arg1	glycoproteins					314:326	homogeneous glycoproteins	302:326	homogeneous glycoproteins	302:326	Delivering of homogeneous glycoproteins into the endoplasmic reticulum (ER) and the Golgi apparatus would enable us to investigate the function of asparagine-linked (N-) glycans in the organelles.
35604098	3	46	gly	glycosylated	544:555	arg1	toxin					565:569	cholera toxin B-subunit	557:579	an intentionally glycosylated cholera toxin B-subunit (CTB)	527:585	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	3	46	gly	glycosylated	544:555	arg1	CTB					582:584	CTB	582:584	CTB	582:584	In this work, we designed and synthesized an intentionally glycosylated cholera toxin B-subunit (CTB) to be transported to the organelles of mammalian cells.
35604098	5	47	theme	homogeneous	964:974	arg1	N-glycans					976:984	homogeneous N-glycans	964:984	homogeneous N-glycans	964:984	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
35604098	0	48	theme	Subunit	53:59	arg1	Synthesis					11:19	Synthesis	11:19	Synthesis	11:19	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	0	48	theme	Subunit	53:59	arg1	Design					0:5	Design	0:5	Design	0:5	Design and Synthesis of Glycosylated Cholera Toxin B Subunit as a Tracer of Glycoprotein Trafficking in Organelles of Living Cells.
35604098	5	49	theme	N-glycans	976:984	arg1	functions					951:959	the functions	947:959	the functions of homogeneous N-glycans in specific organelles of living cells	947:1023	The synthesized monomeric glycosyl-CTB successfully entered mammalian cells and was transported to the Golgi and the ER, suggesting the potential use of synthetic CTB to deliver and investigate the functions of homogeneous N-glycans in specific organelles of living cells.
36797772	4	0	dep	do	1014:1015	arg1	as					1011:1012	as	1011:1012	as	1011:1012	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	5	1	dep	examined	1067:1074	arg1	demonstrated					1163:1174	demonstrated	1163:1174	demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12	1163:1333	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	8	2	theme	major	1696:1700	arg1	sequence					1650:1657	The AG glycomotif sequence	1632:1657	The AG glycomotif sequence closest to the GPI-anchor (AG2)	1632:1689	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	8	2	theme	major	1696:1700	arg1	feature					1702:1708	a major feature	1694:1708	a major feature differentiating FLA11 from FLA12	1694:1741	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	3	3	link	N-linked	696:703	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	2	4	theme	FASCICLIN-LIKE	297:310	arg1	example					405:411	an excellent example	392:411	an excellent example of a glycoprotein family with a complex multidomain structure	392:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	2	4	theme	FASCICLIN-LIKE	297:310	arg1	FLAs					338:341	FLAs	338:341	FLAs	338:341	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	2	4	theme	FASCICLIN-LIKE	297:310	arg1	PROTEINs					328:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs	297:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs)	297:342	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	3	5	theme	signal	744:749	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	9	6	theme	FLAs	1814:1817	arg1	structure					1791:1799	the multidomain structure	1775:1799	the multidomain structure of different FLAs	1775:1817	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	4	7	theme	glycosylation	880:892	arg1	roles					871:875	The roles	867:875	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants	867:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	3	8	from	peptide	751:757	arg1	domains					725:731	the FAS1 domains	716:731	the FAS1 domains	716:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	9	theme	O-linked	599:606	arg1	AG					625:626	AG	625:626	AG	625:626	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	9	theme	O-linked	599:606	arg1	arabinogalactan					608:622	O-linked arabinogalactan	599:622	O-linked arabinogalactan (AG) glycans	599:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	4	10	theme	extracellular	964:976	arg1	matrix					978:983	the polysaccharide-rich extracellular matrix	940:983	the polysaccharide-rich extracellular matrix of plants	940:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	5	11	theme	Arabidopsis	1121:1131	arg1	thaliana					1146:1153	Arabidopsis (Arabidopsis thaliana) FLA11	1121:1160	Arabidopsis (Arabidopsis thaliana) FLA11	1121:1160	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	4	12	gly	glycosylation	880:892	arg1	plants					988:993	plants	988:993	plants	988:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	4	13	theme	FAS1	915:918	arg1	functions					927:935	FAS1 domain functions	915:935	FAS1 domain functions	915:935	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	1	14	theme	cell	122:125	arg1	molecules					135:143	key cell surface molecules	118:143	key cell surface molecules	118:143	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	4	15	theme	functions	927:935	arg1	roles					871:875	The roles	867:875	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants	867:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	3	16	theme	signal	832:837	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	17	theme	additional	642:651	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	17	theme	additional	642:651	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	17	theme	additional	642:651	arg1	modifications					672:684	additional post-translational modifications	642:684	additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	642:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	17	theme	additional	642:651	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	9	18	theme	different	1804:1812	arg1	FLAs					1814:1817	different FLAs	1804:1817	different FLAs	1804:1817	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	7	19	theme	cell	1620:1623	arg1	walls					1625:1629	cell walls	1620:1629	cell walls	1620:1629	The GPI-anchor and AG glycosylation co-regulate the cell surface location and release of FLAs into cell walls.
36797772	0	20	theme	domain	71:76	arg1	structure					78:86	domain structure	71:86	domain structure	71:86	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS relate to domain structure.
36797772	7	21	theme	FLAs	1610:1613	arg1	release					1599:1605	release	1599:1605	release of FLAs into cell walls	1599:1629	The GPI-anchor and AG glycosylation co-regulate the cell surface location and release of FLAs into cell walls.
36797772	7	21	theme	FLAs	1610:1613	arg1	location					1586:1593	the cell surface location	1569:1593	the cell surface location	1569:1593	The GPI-anchor and AG glycosylation co-regulate the cell surface location and release of FLAs into cell walls.
36797772	2	22	gly	glycoprotein	418:429	arg1	glycoprotein					418:429	a glycoprotein family	416:436	a glycoprotein family	416:436	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	6	23	from	roles	1428:1432	arg1	development					1441:1451	SCW development	1437:1451	SCW development	1437:1451	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	5	24	theme	Arabidopsis	1134:1144	arg1	thaliana					1146:1153	Arabidopsis (Arabidopsis thaliana) FLA11	1121:1160	Arabidopsis (Arabidopsis thaliana) FLA11	1121:1160	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	3	25	from	N-terminus	766:775	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	25	from	N-terminus	766:775	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	25	from	N-terminus	766:775	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	1	26	gly	glycoproteins	101:113	arg1	glycoproteins					101:113	glycoproteins	101:113	glycoproteins	101:113	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	4	27	from	roles	871:875	arg1	matrix					978:983	the polysaccharide-rich extracellular matrix	940:983	the polysaccharide-rich extracellular matrix of plants	940:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	2	28	theme	multidomain	453:463	arg1	structure					465:473	a complex multidomain structure	443:473	a complex multidomain structure	443:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	0	29	theme	Distinct	0:7	arg1	functions					9:17	Distinct functions	0:17	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS	0:59	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS relate to domain structure.
36797772	5	30	theme	wall	1208:1211	arg1	development					1219:1229	secondary cell wall (SCW) development	1193:1229	secondary cell wall (SCW) development	1193:1229	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	2	31	theme	family	431:436	arg1	example					405:411	an excellent example	392:411	an excellent example of a glycoprotein family with a complex multidomain structure	392:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	2	31	theme	family	431:436	arg1	PROTEINs					328:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs	297:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs)	297:342	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	9	32	theme	sub-cellular	1836:1847	arg1	location					1849:1856	their sub-cellular location	1830:1856	their sub-cellular location	1830:1856	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	3	33	from	C-terminus	855:864	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	33	from	C-terminus	855:864	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	33	from	C-terminus	855:864	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	34	theme	N-linked	696:703	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	0	35	theme	ARABINOGALACTAN	36:50	arg1	PROTEINS					52:59	FASCILIN-LIKE ARABINOGALACTAN PROTEINS	22:59	FASCILIN-LIKE ARABINOGALACTAN PROTEINS	22:59	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS relate to domain structure.
36797772	2	36	theme	plant	358:362	arg1	growth					364:369	plant growth	358:369	plant growth	358:369	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	5	37	theme	secondary	1193:1201	arg1	SCW					1214:1216	SCW	1214:1216	SCW	1214:1216	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	5	37	theme	secondary	1193:1201	arg1	wall					1208:1211	secondary cell wall	1193:1211	secondary cell wall (SCW) development	1193:1229	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	3	38	theme	FAS1	720:723	arg1	domains					725:731	the FAS1 domains	716:731	the FAS1 domains	716:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	39	theme	globular	489:496	arg1	domains					520:526	globular fasciclin-like (FAS1) domains	489:526	globular fasciclin-like (FAS1) domains	489:526	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	39	theme	globular	489:496	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	39	theme	globular	489:496	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	39	theme	globular	489:496	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	5	40	theme	domain	1247:1252	arg1	mutations					1254:1262	domain mutations	1247:1262	domain mutations	1247:1262	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	9	41	theme	plant	1890:1894	arg1	development					1896:1906	plant development	1890:1906	plant development	1890:1906	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	3	42	from	glycans	705:711	arg1	domains					725:731	the FAS1 domains	716:731	the FAS1 domains	716:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	43	theme	cleaved	736:742	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	1	44	theme	functional	255:264	arg1	mechanisms					266:275	functional mechanisms	255:275	functional mechanisms	255:275	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	2	45	with	example	405:411	arg1	structure					465:473	a complex multidomain structure	443:473	a complex multidomain structure	443:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	8	46	theme	glycomotif	1639:1648	arg1	sequence					1650:1657	The AG glycomotif sequence	1632:1657	The AG glycomotif sequence closest to the GPI-anchor (AG2)	1632:1689	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	8	46	theme	glycomotif	1639:1648	arg1	feature					1702:1708	a major feature	1694:1708	a major feature differentiating FLA11 from FLA12	1694:1741	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	2	47	theme	ARABINOGALACTAN	312:326	arg1	example					405:411	an excellent example	392:411	an excellent example of a glycoprotein family with a complex multidomain structure	392:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	2	47	theme	ARABINOGALACTAN	312:326	arg1	FLAs					338:341	FLAs	338:341	FLAs	338:341	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	2	47	theme	ARABINOGALACTAN	312:326	arg1	PROTEINs					328:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs	297:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs)	297:342	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	4	48	theme	GPI-anchor	899:908	arg1	roles					871:875	The roles	867:875	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants	867:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	8	49	theme	closest	1659:1665	arg1	sequence					1650:1657	The AG glycomotif sequence	1632:1657	The AG glycomotif sequence closest to the GPI-anchor (AG2)	1632:1689	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	8	49	theme	closest	1659:1665	arg1	feature					1702:1708	a major feature	1694:1708	a major feature differentiating FLA11 from FLA12	1694:1741	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	4	50	theme	polysaccharide-rich	944:962	arg1	matrix					978:983	the polysaccharide-rich extracellular matrix	940:983	the polysaccharide-rich extracellular matrix of plants	940:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	6	51	theme	FAS1	1350:1353	arg1	domains					1355:1361	FAS1 domains	1350:1361	FAS1 domains	1350:1361	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	3	52	theme	arabinogalactan	608:622	arg1	glycans					629:635	O-linked arabinogalactan (AG) glycans	599:635	O-linked arabinogalactan (AG) glycans	599:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	1	53	theme	key	118:120	arg1	molecules					135:143	key cell surface molecules	118:143	key cell surface molecules	118:143	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	1	54	theme	surface	127:133	arg1	molecules					135:143	key cell surface molecules	118:143	key cell surface molecules	118:143	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	4	55	theme	domain	920:925	arg1	functions					927:935	FAS1 domain functions	915:935	FAS1 domain functions	915:935	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	5	56	theme	sequence-structure-function	1076:1102	arg1	relationships					1104:1116	sequence-structure-function relationships	1076:1116	sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11	1076:1160	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	3	57	theme	glycans	629:635	arg1	addition					587:594	addition	587:594	addition of O-linked arabinogalactan (AG) glycans	587:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	9	58	theme	study	1759:1763	arg1	Results					1744:1750	Results	1744:1750	Results of our study	1744:1763	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	3	59	theme	-anchor	824:830	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	5	60	with	swaps	1309:1313	arg1	FLA3					1320:1323	FLA3	1320:1323	FLA3	1320:1323	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	5	60	with	swaps	1309:1313	arg1	FLA12					1329:1333	FLA12	1329:1333	FLA12	1329:1333	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	3	61	link	O-linked	599:606	arg1	AG					625:626	AG	625:626	AG	625:626	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	61	link	O-linked	599:606	arg1	arabinogalactan					608:622	O-linked arabinogalactan	599:622	O-linked arabinogalactan (AG) glycans	599:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	5	62	theme	domain	1302:1307	arg1	swaps					1309:1313	domain swaps	1302:1313	domain swaps with FLA3 and FLA12	1302:1333	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	7	63	theme	surface	1578:1584	arg1	location					1586:1593	the cell surface location	1569:1593	the cell surface location	1569:1593	The GPI-anchor and AG glycosylation co-regulate the cell surface location and release of FLAs into cell walls.
36797772	9	64	theme	multidomain	1779:1789	arg1	structure					1791:1799	the multidomain structure	1775:1799	the multidomain structure of different FLAs	1775:1817	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	5	65	theme	thaliana	1146:1153	arg1	relationships					1104:1116	sequence-structure-function relationships	1076:1116	sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11	1076:1160	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	4	66	theme	plants	988:993	arg1	matrix					978:983	the polysaccharide-rich extracellular matrix	940:983	the polysaccharide-rich extracellular matrix of plants	940:993	The roles of glycosylation, the GPI-anchor, and FAS1 domain functions in the polysaccharide-rich extracellular matrix of plants remain unclear, as do the relationships between them.
36797772	2	67	theme	excellent	395:403	arg1	example					405:411	an excellent example	392:411	an excellent example of a glycoprotein family with a complex multidomain structure	392:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	2	67	theme	excellent	395:403	arg1	PROTEINs					328:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs	297:335	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs)	297:342	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	6	68	theme	specific	1465:1472	arg1	FLA3					1459:1462	FLA3	1459:1462	FLA3	1459:1462	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	2	69	theme	complex	445:451	arg1	structure					465:473	a complex multidomain structure	443:473	a complex multidomain structure	443:473	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	0	70	theme	FASCILIN-LIKE	22:34	arg1	PROTEINS					52:59	FASCILIN-LIKE ARABINOGALACTAN PROTEINS	22:59	FASCILIN-LIKE ARABINOGALACTAN PROTEINS	22:59	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS relate to domain structure.
36797772	1	71	theme	glycoproteins	101:113	arg1	role					93:96	The role	89:96	The role of glycoproteins as key cell surface molecules during development and stress	89:173	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	2	72	theme	glycoprotein	418:429	arg1	family					431:436	a glycoprotein family	416:436	a glycoprotein family	416:436	FASCICLIN-LIKE ARABINOGALACTAN PROTEINs (FLAs), which impact plant growth and development, are an excellent example of a glycoprotein family with a complex multidomain structure.
36797772	0	73	theme	PROTEINS	52:59	arg1	functions					9:17	Distinct functions	0:17	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS	0:59	Distinct functions of FASCILIN-LIKE ARABINOGALACTAN PROTEINS relate to domain structure.
36797772	7	74	theme	cell	1573:1576	arg1	location					1586:1593	the cell surface location	1569:1593	the cell surface location	1569:1593	The GPI-anchor and AG glycosylation co-regulate the cell surface location and release of FLAs into cell walls.
36797772	3	75	contain	containing	550:559	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	75	contain	containing	550:559	arg1	sequences					540:548	disordered sequences	529:548	disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans	529:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	75	contain	containing	550:559	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	75	contain	containing	550:559	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	75	contain	containing	550:559	arg2	glycomotifs					561:571	glycomotifs	561:571	glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans	561:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	76	theme	post-translational	653:670	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	76	theme	post-translational	653:670	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	76	theme	post-translational	653:670	arg1	modifications					672:684	additional post-translational modifications	642:684	additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	642:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	76	theme	post-translational	653:670	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	6	77	theme	FLA	1380:1382	arg1	function					1384:1391	FLA function	1380:1391	FLA function	1380:1391	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	6	78	theme	SCW	1437:1439	arg1	development					1441:1451	SCW development	1437:1451	SCW development	1437:1451	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	9	79	theme	biological	1862:1871	arg1	functions					1873:1881	biological functions	1862:1881	biological functions	1862:1881	Results of our study show that the multidomain structure of different FLAs influences their sub-cellular location and biological functions during plant development.
36797772	3	80	theme	FAS1	514:517	arg1	domains					520:526	globular fasciclin-like (FAS1) domains	489:526	globular fasciclin-like (FAS1) domains	489:526	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	80	theme	FAS1	514:517	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	80	theme	FAS1	514:517	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	80	theme	FAS1	514:517	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	5	81	theme	cell	1203:1206	arg1	SCW					1214:1216	SCW	1214:1216	SCW	1214:1216	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	5	81	theme	cell	1203:1206	arg1	wall					1208:1211	secondary cell wall	1193:1211	secondary cell wall (SCW) development	1193:1229	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
36797772	7	82	theme	AG	1540:1541	arg1	glycosylation					1543:1555	AG glycosylation	1540:1555	AG glycosylation	1540:1555	The GPI-anchor and AG glycosylation co-regulate the cell surface location and release of FLAs into cell walls.
36797772	3	83	from	sequence	839:846	arg1	domains					725:731	the FAS1 domains	716:731	the FAS1 domains	716:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	84	theme	fasciclin-like	498:511	arg1	domains					520:526	globular fasciclin-like (FAS1) domains	489:526	globular fasciclin-like (FAS1) domains	489:526	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	84	theme	fasciclin-like	498:511	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	84	theme	fasciclin-like	498:511	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	84	theme	fasciclin-like	498:511	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	6	85	theme	pollen	1501:1506	arg1	development					1508:1518	pollen development	1501:1518	pollen development	1501:1518	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	1	86	theme	structural	231:240	arg1	features					242:249	their structural features	225:249	their structural features	225:249	The role of glycoproteins as key cell surface molecules during development and stress is well established, yet the relationship between their structural features and functional mechanisms are poorly defined.
36797772	8	87	theme	AG	1636:1637	arg1	sequence					1650:1657	The AG glycomotif sequence	1632:1657	The AG glycomotif sequence closest to the GPI-anchor (AG2)	1632:1689	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	8	87	theme	AG	1636:1637	arg1	feature					1702:1708	a major feature	1694:1708	a major feature differentiating FLA11 from FLA12	1694:1741	The AG glycomotif sequence closest to the GPI-anchor (AG2) is a major feature differentiating FLA11 from FLA12.
36797772	3	88	theme	disordered	529:538	arg1	peptide					751:757	a cleaved signal peptide	734:757	a cleaved signal peptide at the N-terminus	734:775	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	88	theme	disordered	529:538	arg1	sequences					540:548	disordered sequences	529:548	disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans	529:635	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	88	theme	disordered	529:538	arg1	sequence					839:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence	788:846	a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus	788:864	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	3	88	theme	disordered	529:538	arg1	glycans					705:711	N-linked glycans	696:711	N-linked glycans in the FAS1 domains	696:731	FLAs combine globular fasciclin-like (FAS1) domains, disordered sequences containing glycomotifs for directing addition of O-linked arabinogalactan (AG) glycans, and additional post-translational modifications including N-linked glycans in the FAS1 domains, a cleaved signal peptide at the N-terminus, and often a glycosylphosphatidylinositol (GPI)-anchor signal sequence at the C-terminus.
36797772	6	89	theme	involved	1489:1496	arg1	FLA3					1459:1462	FLA3	1459:1462	FLA3	1459:1462	We identified FAS1 domains as essential for FLA function, differentiating FLA11/FLA12, with roles in SCW development, from FLA3, specific to flowers and involved in pollen development.
36797772	5	90	theme	functional	1268:1277	arg1	specialisation					1279:1292	functional specialisation	1268:1292	functional specialisation	1268:1292	In this study, we examined sequence-structure-function relationships of Arabidopsis (Arabidopsis thaliana) FLA11, demonstrated to have roles in secondary cell wall (SCW) development, by introducing domain mutations and functional specialisation through domain swaps with FLA3 and FLA12.
37184080	5	0	theme	A	1672:1672	arg1	position					1645:1652	the 1-phosphate position	1629:1652	the 1-phosphate position of modified lipid A	1629:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	1	1	from	species	312:318	arg1	A					281:281	lipid A	275:281	lipid A from Gram-negative bacterial species from a single bacterial colony	275:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	5	2	theme	positive	1532:1539	arg1	charge					1541:1546	the positive charge	1528:1546	the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A	1528:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	3	3	with	glycosylation	1004:1016	arg1	Ara4N					1023:1027	Ara4N	1023:1027	Ara4N	1023:1027	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	5	4	dep	found	1611:1615	arg1	attached					1617:1624	attached	1617:1624	attached to the 1-phosphate position of modified lipid A	1617:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	2	5	theme	phosphate	627:635	arg1	modifications					637:649	terminal phosphate modifications	618:649	terminal phosphate modifications in a variety of pathogenic and environmental species	618:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	6	theme	Ara4N	1484:1488	arg1	modification					1490:1501	Ara4N modification	1484:1501	Ara4N modification	1484:1501	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	5	7	attach	attached	1617:1624	arg1	position					1645:1652	the 1-phosphate position	1629:1652	the 1-phosphate position of modified lipid A	1629:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	5	7	attach	attached	1617:1624	arg2	modification					1575:1586	the phosphoethanolamine modification	1551:1586	the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A	1551:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	3	8	theme	lipid	739:743	arg1	structure					747:755	the lipid A structure	735:755	the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	735:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	9	theme	additional	522:531	arg1	data					559:562	additional structural and diagnostic data	522:562	additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	522:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	10	from	role	1396:1399	arg1	adaptation					1455:1464	environmental species adaptation	1433:1464	environmental species adaptation	1433:1464	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	4	11	theme	psychrophilic	1159:1171	arg1	species					1173:1179	some environmental psychrophilic species	1140:1179	some environmental psychrophilic species	1140:1179	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	1	12	theme	spectral	201:208	arg1	information					210:220	spectral information	201:220	spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	201:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	2	13	theme	FLATn	569:573	arg1	samples					575:581	FLATn samples	569:581	FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	569:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	3	14	from	position	967:974	arg1	modification					935:946	4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification	893:946	4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position	893:974	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	15	theme	several	762:768	arg1	structures					805:814	novel structures	799:814	novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	799:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	15	theme	several	762:768	arg1	species					780:786	several bacterial species	762:786	several bacterial species	762:786	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	16	theme	Massilia	866:873	arg1	bacterioplankton					828:843	arctic bacterioplankton	821:843	arctic bacterioplankton of the Duganella and Massilia genera	821:880	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	1	17	used	used	176:179	arg2	technique					154:162	a tandem mass spectrometric technique	126:162	a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	126:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	2	18	theme	species	696:702	arg1	species					696:702	pathogenic and environmental species	667:702	pathogenic and environmental species	667:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	18	theme	species	696:702	arg1	variety					656:662	a variety	654:662	a variety of pathogenic and environmental species	654:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	19	from	variety	656:662	arg1	discrimination					600:613	the discrimination	596:613	the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	596:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	3	20	theme	Duganella	852:860	arg1	bacterioplankton					828:843	arctic bacterioplankton	821:843	arctic bacterioplankton of the Duganella and Massilia genera	821:880	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	21	theme	fragments	487:495	arg1	fragmentation					424:436	tandem MS fragmentation	414:436	tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	414:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	1	22	theme	single	327:332	arg1	colony					344:349	a single bacterial colony	325:349	a single bacterial colony	325:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	1	23	theme	mass	135:138	arg1	spectrometric					140:152	a tandem mass spectrometric	126:152	a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	126:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	3	24	theme	4-amino-4-deoxy-l-arabinopyranose	893:925	arg1	modification					935:946	4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification	893:946	4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position	893:974	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	25	theme	anions	476:481	arg1	fragmentation					424:436	tandem MS fragmentation	414:436	tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	414:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	4	26	theme	lipid	1219:1223	arg1	use					1196:1198	extensive use	1186:1198	extensive use of this structural lipid	1186:1223	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	0	27	theme	Tandem	72:77	arg1	MS					79:80	Tandem MS	72:80	Tandem MS of Lithium-Adducted Negative Ions	72:114	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	3	28	dep	Duganella	852:860	arg1	genera					875:880	genera	875:880	genera	875:880	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	28	dep	Duganella	852:860	arg1	the					848:850	the	848:850	the	848:850	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	29	from	species	780:786	arg1	structure					747:755	the lipid A structure	735:755	the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	735:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	30	theme	arctic	821:826	arg1	bacterioplankton					828:843	arctic bacterioplankton	821:843	arctic bacterioplankton of the Duganella and Massilia genera	821:880	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	31	theme	modifications	637:649	arg1	discrimination					600:613	the discrimination	596:613	the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	596:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	32	theme	modification	1414:1425	arg1	s					1427:1427	phosphate modification(s)	1404:1428	phosphate modification(s)	1404:1428	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	0	33	theme	Negative	102:109	arg1	Ions					111:114	Lithium-Adducted Negative Ions	85:114	Lithium-Adducted Negative Ions	85:114	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	3	34	theme	Ara4N	928:932	arg1	modification					935:946	4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification	893:946	4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position	893:974	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	5	35	theme	phosphoethanolamine	1555:1573	arg1	modification					1575:1586	the phosphoethanolamine modification	1551:1586	the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A	1551:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	5	36	theme	s	1427:1427	arg1	role					1396:1399	the role	1392:1399	the role of phosphate modification(s) in environmental species adaptation	1392:1464	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	0	37	theme	Structure	0:8	arg1	Determination					10:22	Structure Determination	0:22	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.	0:115	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	1	38	theme	lipid	275:279	arg1	A					281:281	lipid A	275:281	lipid A from Gram-negative bacterial species from a single bacterial colony	275:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	2	39	theme	tandem	414:419	arg1	fragmentation					424:436	tandem MS fragmentation	414:436	tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	414:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	40	from	samples	575:581	arg1	data					559:562	additional structural and diagnostic data	522:562	additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	522:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	41	theme	1-phosphate	1633:1643	arg1	position					1645:1652	the 1-phosphate position	1629:1652	the 1-phosphate position of modified lipid A	1629:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	2	42	theme	FLATn	405:409	arg1	capability					391:400	capability	391:400	capability	391:400	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	42	theme	FLATn	405:409	arg1	scope					381:385	scope	381:385	scope	381:385	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	43	theme	lipid	468:472	arg1	anions					476:481	lithium-adducted molecular lipid A anions	441:481	lithium-adducted molecular lipid A anions	441:481	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	0	44	theme	A	33:33	arg1	Determination					10:22	Structure Determination	0:22	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.	0:115	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	1	45	theme	bacterial	302:310	arg1	species					312:318	Gram-negative bacterial species	288:318	Gram-negative bacterial species from a single bacterial colony	288:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	3	46	theme	double	997:1002	arg1	glycosylation					1004:1016	double glycosylation	997:1016	double glycosylation with Ara4N at the 1 and 4' phosphate positions	997:1063	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	47	theme	lithium-adducted	441:456	arg1	anions					476:481	lithium-adducted molecular lipid A anions	441:481	lithium-adducted molecular lipid A anions	441:481	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	48	from	discrimination	600:613	arg1	species					696:702	pathogenic and environmental species	667:702	pathogenic and environmental species	667:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	48	from	discrimination	600:613	arg1	variety					656:662	a variety	654:662	a variety of pathogenic and environmental species	654:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	0	49	theme	Multiple	40:47	arg1	Sites					63:67	Multiple Glycosylation Sites	40:67	Multiple Glycosylation Sites	40:67	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	3	50	from	positions	1055:1063	arg1	glycosylation					1004:1016	double glycosylation	997:1016	double glycosylation with Ara4N at the 1 and 4' phosphate positions	997:1063	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	4	51	theme	resistance	1320:1329	arg1	adaptation					1281:1290	a pathogenic adaptation	1268:1290	a pathogenic adaptation	1268:1290	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	4	51	theme	resistance	1320:1329	arg1	basis					1311:1315	the structural basis	1296:1315	the structural basis of resistance to cationic antimicrobial peptides	1296:1364	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	4	52	theme	cationic	1334:1341	arg1	peptides					1357:1364	cationic antimicrobial peptides	1334:1364	cationic antimicrobial peptides	1334:1364	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	2	53	dep	scope	381:385	arg1	the					377:379	the	377:379	the	377:379	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	54	theme	species	1447:1453	arg1	adaptation					1455:1464	environmental species adaptation	1433:1464	environmental species adaptation	1433:1464	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	5	55	theme	lipid	1666:1670	arg1	A					1672:1672	modified lipid A	1657:1672	modified lipid A	1657:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	1	56	theme	lipids	263:268	arg1	elucidation					248:258	structural elucidation	237:258	structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	237:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	4	57	theme	extensive	1186:1194	arg1	use					1196:1198	extensive use	1186:1198	extensive use of this structural lipid	1186:1223	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	2	58	theme	terminal	618:625	arg1	modifications					637:649	terminal phosphate modifications	618:649	terminal phosphate modifications in a variety of pathogenic and environmental species	618:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	3	59	theme	phosphate	1045:1053	arg1	positions					1055:1063	the 1 and 4' phosphate positions	1032:1063	the 1 and 4' phosphate positions	1032:1063	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	60	gly	glycosylation	1004:1016	arg1	positions					1055:1063	the 1 and 4' phosphate positions	1032:1063	the 1 and 4' phosphate positions	1032:1063	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	60	gly	glycosylation	1004:1016	arg2	positions					1055:1063	the 1 and 4' phosphate positions	1032:1063	the 1 and 4' phosphate positions	1032:1063	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	61	theme	structural	533:542	arg1	data					559:562	additional structural and diagnostic data	522:562	additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	522:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	4	62	theme	environmental	1145:1157	arg1	species					1173:1179	some environmental psychrophilic species	1140:1179	some environmental psychrophilic species	1140:1179	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	3	63	theme	A	745:745	arg1	structure					747:755	the lipid A structure	735:755	the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	735:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	64	from	modifications	637:649	arg1	species					696:702	pathogenic and environmental species	667:702	pathogenic and environmental species	667:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	2	64	from	modifications	637:649	arg1	variety					656:662	a variety	654:662	a variety of pathogenic and environmental species	654:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	3	65	theme	bacterial	770:778	arg1	structures					805:814	novel structures	799:814	novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	799:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	3	65	theme	bacterial	770:778	arg1	species					780:786	several bacterial species	762:786	several bacterial species	762:786	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	66	theme	diagnostic	548:557	arg1	data					559:562	additional structural and diagnostic data	522:562	additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	522:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	4	67	theme	structural	1208:1217	arg1	lipid					1219:1223	this structural lipid	1203:1223	this structural lipid	1203:1223	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	1	68	theme	tandem	128:133	arg1	spectrometric					140:152	a tandem mass spectrometric	126:152	a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	126:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	3	69	theme	novel	799:803	arg1	structures					805:814	novel structures	799:814	novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	799:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	1	70	theme	bacterial	334:342	arg1	colony					344:349	a single bacterial colony	325:349	a single bacterial colony	325:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	1	71	theme	spectrometric	140:152	arg1	technique					154:162	a tandem mass spectrometric technique	126:162	a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	126:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	2	72	theme	A	474:474	arg1	anions					476:481	lithium-adducted molecular lipid A anions	441:481	lithium-adducted molecular lipid A anions	441:481	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	4	73	theme	structural	1300:1309	arg1	basis					1311:1315	the structural basis	1296:1315	the structural basis of resistance to cationic antimicrobial peptides	1296:1364	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	0	74	theme	Lithium-Adducted	85:100	arg1	Ions					111:114	Lithium-Adducted Negative Ions	85:114	Lithium-Adducted Negative Ions	85:114	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	5	75	theme	phosphate	1404:1412	arg1	modification					1414:1425	phosphate modification	1404:1425	phosphate modification(s)	1404:1428	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	0	76	theme	Ions	111:114	arg1	MS					79:80	Tandem MS	72:80	Tandem MS of Lithium-Adducted Negative Ions	72:114	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	4	77	theme	pathogenic	1270:1279	arg1	adaptation					1281:1290	a pathogenic adaptation	1268:1290	a pathogenic adaptation	1268:1290	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	2	78	theme	MS	421:422	arg1	fragmentation					424:436	tandem MS fragmentation	414:436	tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species	414:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	79	theme	modification	1575:1586	arg1	charge					1541:1546	the positive charge	1528:1546	the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A	1528:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	2	80	theme	pathogenic	667:676	arg1	species					696:702	pathogenic and environmental species	667:702	pathogenic and environmental species	667:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	0	81	theme	Lipid	27:31	arg1	A					33:33	Lipid A	27:33	Lipid A	27:33	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	3	82	from	bacterioplankton	828:843	arg1	structures					805:814	novel structures	799:814	novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously	799:1078	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	1	83	from	colony	344:349	arg1	species					312:318	Gram-negative bacterial species	288:318	Gram-negative bacterial species from a single bacterial colony	288:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	1	84	theme	Gram-negative	288:300	arg1	species					312:318	Gram-negative bacterial species	288:318	Gram-negative bacterial species from a single bacterial colony	288:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	3	85	theme	1-phosphate	955:965	arg1	position					967:974	the 1-phosphate position	951:974	the 1-phosphate position	951:974	Using FLATn-Li, we elucidated the lipid A structure from several bacterial species, including novel structures from arctic bacterioplankton of the Duganella and Massilia genera that favor 4-amino-4-deoxy-l-arabinopyranose (Ara4N) modification at the 1-phosphate position and that demonstrate double glycosylation with Ara4N at the 1 and 4' phosphate positions simultaneously.
37184080	2	86	theme	molecular	458:466	arg1	anions					476:481	lithium-adducted molecular lipid A anions	441:481	lithium-adducted molecular lipid A anions	441:481	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	5	87	theme	modified	1657:1664	arg1	A					1672:1672	modified lipid A	1657:1672	modified lipid A	1657:1672	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	0	88	theme	Glycosylation	49:61	arg1	Sites					63:67	Multiple Glycosylation Sites	40:67	Multiple Glycosylation Sites	40:67	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	0	89	with	Determination	10:22	arg1	Sites					63:67	Multiple Glycosylation Sites	40:67	Multiple Glycosylation Sites	40:67	Structure Determination of Lipid A with Multiple Glycosylation Sites by Tandem MS of Lithium-Adducted Negative Ions.
37184080	2	90	theme	environmental	682:694	arg1	species					696:702	pathogenic and environmental species	667:702	pathogenic and environmental species	667:702	In this study, we extend the scope and capability of FLATn by tandem MS fragmentation of lithium-adducted molecular lipid A anions and fragments (FLATn-Li) that provides additional structural and diagnostic data from FLATn samples allowing for the discrimination of terminal phosphate modifications in a variety of pathogenic and environmental species.
37184080	4	91	theme	antimicrobial	1343:1355	arg1	peptides					1357:1364	cationic antimicrobial peptides	1334:1364	cationic antimicrobial peptides	1334:1364	The structures characterized in this work demonstrate that some environmental psychrophilic species make extensive use of this structural lipid A modification previously characterized as a pathogenic adaptation and the structural basis of resistance to cationic antimicrobial peptides.
37184080	1	92	theme	applicable	222:231	arg1	information					210:220	spectral information	201:220	spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	201:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
37184080	5	93	theme	environmental	1433:1445	arg1	adaptation					1455:1464	environmental species adaptation	1433:1464	environmental species adaptation	1433:1464	This observation extends the role of phosphate modification(s) in environmental species adaptation and suggests that Ara4N modification can functionally replace the positive charge of the phosphoethanolamine modification that is more typically found attached to the 1-phosphate position of modified lipid A.
37184080	1	94	theme	structural	237:246	arg1	elucidation					248:258	structural elucidation	237:258	structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony	237:349	FLATn is a tandem mass spectrometric technique that can be used to rapidly generate spectral information applicable for structural elucidation of lipids like lipid A from Gram-negative bacterial species from a single bacterial colony.
35247772	2	0	with	conjugates	378:387	arg1	attributes					414:423	improved functional attributes	394:423	improved functional attributes	394:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	2	1	theme	constructing	346:357	arg1	conjugates					378:387	constructing pea protein-inulin conjugates	346:387	constructing pea protein-inulin conjugates with improved functional attributes	346:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	5	2	theme	pea	771:773	arg1	conjugates					790:799	The pea protein-inulin conjugates	767:799	The pea protein-inulin conjugates	767:799	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	2	3	theme	functional	403:412	arg1	attributes					414:423	improved functional attributes	394:423	improved functional attributes	394:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	6	4	theme	antioxidant	940:950	arg1	activity					952:959	antioxidant activity	940:959	antioxidant activity	940:959	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	7	5	theme	functional	1165:1174	arg1	properties					1176:1185	the functional properties	1161:1185	the functional properties of pea proteins	1161:1201	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	5	6	theme	pea	828:830	arg1	proteins					832:839	pea proteins	828:839	pea proteins alone	828:845	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	0	7	theme	Structural	108:117	arg1	properties					134:143	Structural and functional properties	108:143	Structural and functional properties	108:143	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	5	8	theme	protein-inulin	775:788	arg1	conjugates					790:799	The pea protein-inulin conjugates	767:799	The pea protein-inulin conjugates	767:799	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	4	9	theme	pea	736:738	arg1	conjugates					755:764	pea protein-inulin conjugates	736:764	pea protein-inulin conjugates	736:764	SDS-PAGE confirmed the formation of pea protein-inulin conjugates.
35247772	6	10	theme	thermal	921:927	arg1	stability					929:937	thermal stability	921:937	thermal stability	921:937	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	5	11	theme	isoelectric	870:880	arg1	point					882:886	the isoelectric point	866:886	the isoelectric point of the protein	866:901	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	3	12	theme	combined	548:555	arg1	method					557:562	This combined method	543:562	This combined method	543:562	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	1	13	theme	food	185:188	arg1	industry					190:197	the food industry	181:197	the food industry	181:197	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	0	14	theme	functional	123:132	arg1	properties					134:143	Structural and functional properties	108:143	Structural and functional properties	108:143	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	1	15	from	application	150:160	arg1	industry					190:197	the food industry	181:197	the food industry	181:197	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	2	16	theme	improved	394:401	arg1	attributes					414:423	improved functional attributes	394:423	improved functional attributes	394:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	0	17	theme	protein	4:10	arg1	conjugates					27:36	Pea protein isolate-inulin conjugates	0:36	Pea protein isolate-inulin conjugates	0:36	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	5	18	theme	higher	805:810	arg1	solubility					812:821	higher solubility	805:821	higher solubility	805:821	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	0	19	theme	ultrasonic-enhanced	73:91	arg1	glycosylation					93:105	ultrasonic-enhanced glycosylation	73:105	ultrasonic-enhanced glycosylation	73:105	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	0	20	theme	Pea	0:2	arg1	conjugates					27:36	Pea protein isolate-inulin conjugates	0:36	Pea protein isolate-inulin conjugates	0:36	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	3	21	theme	wet	680:682	arg1	method					692:697	the traditional wet heating method	664:697	the traditional wet heating method	664:697	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	4	22	theme	conjugates	755:764	arg1	formation					723:731	the formation	719:731	the formation of pea protein-inulin conjugates	719:764	SDS-PAGE confirmed the formation of pea protein-inulin conjugates.
35247772	2	23	theme	conjugates	378:387	arg1	method					336:341	a novel method	328:341	a novel method of constructing pea protein-inulin conjugates with improved functional attributes	328:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	6	24	theme	conjugates	1004:1013	arg1	properties					986:995	emulsifying properties	974:995	emulsifying properties	974:995	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	6	24	theme	conjugates	1004:1013	arg1	foaming					962:968	foaming	962:968	foaming	962:968	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	6	24	theme	conjugates	1004:1013	arg1	stability					929:937	thermal stability	921:937	thermal stability	921:937	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	6	24	theme	conjugates	1004:1013	arg1	activity					952:959	antioxidant activity	940:959	antioxidant activity	940:959	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	7	25	theme	wet	1109:1111	arg1	method					1121:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	7	25	theme	wet	1109:1111	arg1	effective					1138:1146	effective	1138:1146	effective	1138:1146	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	3	26	theme	Maillard	577:584	arg1	reaction					586:593	the Maillard reaction	573:593	the Maillard reaction	573:593	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	0	27	theme	isolate-inulin	12:25	arg1	conjugates					27:36	Pea protein isolate-inulin conjugates	0:36	Pea protein isolate-inulin conjugates	0:36	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	7	28	theme	combined	1080:1087	arg1	method					1121:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	7	28	theme	combined	1080:1087	arg1	effective					1138:1146	effective	1138:1146	effective	1138:1146	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	7	29	theme	heating	1113:1119	arg1	method					1121:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	7	29	theme	heating	1113:1119	arg1	effective					1138:1146	effective	1138:1146	effective	1138:1146	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	1	30	theme	pea	165:167	arg1	proteins					169:176	pea proteins	165:176	pea proteins	165:176	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	7	31	theme	pea	1190:1192	arg1	proteins					1194:1201	pea proteins	1190:1201	pea proteins	1190:1201	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	5	32	contain	had	801:803	arg1	conjugates					790:799	The pea protein-inulin conjugates	767:799	The pea protein-inulin conjugates	767:799	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	5	32	contain	had	801:803	arg2	solubility					812:821	higher solubility	805:821	higher solubility	805:821	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	3	33	theme	grafting	609:616	arg1	degree					618:623	a grafting degree	607:623	a grafting degree that was 2.3-times higher than that of the traditional wet heating method	607:697	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	3	33	theme	grafting	609:616	arg1	higher					644:649	higher	644:649	higher	644:649	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	2	34	theme	ultrasonic	486:495	arg1	treatment					497:505	a high-intensity ultrasonic treatment	469:505	a high-intensity ultrasonic treatment with a pH-shift wet heating method	469:540	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	7	35	theme	proteins	1194:1201	arg1	properties					1176:1185	the functional properties	1161:1185	the functional properties of pea proteins	1161:1201	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	2	36	theme	heating	527:533	arg1	method					535:540	a pH-shift wet heating method	512:540	a pH-shift wet heating method	512:540	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	2	37	theme	high-intensity	471:484	arg1	treatment					497:505	a high-intensity ultrasonic treatment	469:505	a high-intensity ultrasonic treatment with a pH-shift wet heating method	469:540	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	6	38	theme	emulsifying	974:984	arg1	properties					986:995	emulsifying properties	974:995	emulsifying properties	974:995	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	7	39	theme	ultrasound/pH-shift	1089:1107	arg1	method					1121:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	the combined ultrasound/pH-shift wet heating method	1076:1126	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	7	39	theme	ultrasound/pH-shift	1089:1107	arg1	effective					1138:1146	effective	1138:1146	effective	1138:1146	This study shows that the combined ultrasound/pH-shift wet heating method is highly effective at improving the functional properties of pea proteins.
35247772	0	40	theme	pH-shift	50:57	arg1	treatment					59:67	pH-shift treatment	50:67	pH-shift treatment	50:67	Pea protein isolate-inulin conjugates prepared by pH-shift treatment and ultrasonic-enhanced glycosylation: Structural and functional properties.
35247772	3	41	theme	heating	684:690	arg1	method					692:697	the traditional wet heating method	664:697	the traditional wet heating method	664:697	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	2	42	theme	novel	330:334	arg1	method					336:341	a novel method	328:341	a novel method of constructing pea protein-inulin conjugates with improved functional attributes	328:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	4	43	theme	protein-inulin	740:753	arg1	conjugates					755:764	pea protein-inulin conjugates	736:764	pea protein-inulin conjugates	736:764	SDS-PAGE confirmed the formation of pea protein-inulin conjugates.
35247772	1	44	theme	functional	230:239	arg1	gelation					293:300	gelation	293:300	gelation	293:300	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	1	44	theme	functional	230:239	arg1	solubility					261:270	solubility	261:270	solubility	261:270	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	1	44	theme	functional	230:239	arg1	properties					241:250	their poor functional properties	219:250	their poor functional properties	219:250	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	1	44	theme	functional	230:239	arg1	emulsification					273:286	emulsification	273:286	emulsification	273:286	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	3	45	theme	traditional	668:678	arg1	method					692:697	the traditional wet heating method	664:697	the traditional wet heating method	664:697	This combined method promoted the Maillard reaction, leading to a grafting degree that was 2.3-times higher than that of the traditional wet heating method.
35247772	1	46	theme	proteins	169:176	arg1	application					150:160	The application	146:160	The application of pea proteins in the food industry	146:197	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	2	47	theme	wet	523:525	arg1	method					535:540	a pH-shift wet heating method	512:540	a pH-shift wet heating method	512:540	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	1	48	theme	poor	225:228	arg1	gelation					293:300	gelation	293:300	gelation	293:300	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	1	48	theme	poor	225:228	arg1	solubility					261:270	solubility	261:270	solubility	261:270	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	1	48	theme	poor	225:228	arg1	properties					241:250	their poor functional properties	219:250	their poor functional properties	219:250	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	1	48	theme	poor	225:228	arg1	emulsification					273:286	emulsification	273:286	emulsification	273:286	The application of pea proteins in the food industry is often limited by their poor functional properties, such as solubility, emulsification, and gelation.
35247772	2	49	theme	protein-inulin	363:376	arg1	conjugates					378:387	constructing pea protein-inulin conjugates	346:387	constructing pea protein-inulin conjugates with improved functional attributes	346:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	5	50	theme	protein	895:901	arg1	point					882:886	the isoelectric point	866:886	the isoelectric point of the protein	866:901	The pea protein-inulin conjugates had higher solubility than pea proteins alone, especially around the isoelectric point of the protein.
35247772	6	51	dep	stability	929:937	arg1	the					917:919	the	917:919	the	917:919	Furthermore, the thermal stability, antioxidant activity, foaming and emulsifying properties of the conjugates were better than those of the protein.
35247772	2	52	theme	pH-shift	514:521	arg1	method					535:540	a pH-shift wet heating method	512:540	a pH-shift wet heating method	512:540	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	2	53	with	treatment	497:505	arg1	method					535:540	a pH-shift wet heating method	512:540	a pH-shift wet heating method	512:540	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
35247772	2	54	theme	pea	359:361	arg1	conjugates					378:387	constructing pea protein-inulin conjugates	346:387	constructing pea protein-inulin conjugates with improved functional attributes	346:423	To address this problem, a novel method of constructing pea protein-inulin conjugates with improved functional attributes was developed, which consisted of combining a high-intensity ultrasonic treatment with a pH-shift wet heating method.
36606688	0	0	theme	activity	69:76	arg1	secretion					38:46	the secretion	34:46	the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells	34:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	6	1	theme	structure	816:824	arg1	level					791:795	a high level	784:795	a high level of the core fucose structure	784:824	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	1	2	theme	anticancer	127:136	arg1	controversial					188:200	controversial	188:200	controversial	188:200	The anticancer function of superoxide dismutases (SODs) is still controversial.
36606688	1	2	theme	anticancer	127:136	arg1	function					138:145	The anticancer function	123:145	The anticancer function of superoxide dismutases (SODs)	123:177	The anticancer function of superoxide dismutases (SODs) is still controversial.
36606688	6	3	theme	mass	888:891	arg1	analysis					906:913	mass spectrometry analysis	888:913	mass spectrometry analysis	888:913	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	0	4	theme	enzymatic	59:67	arg1	activity					69:76	and the enzymatic activity	51:76	activity	69:76	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	6	5	theme	fucose	809:814	arg1	structure					816:824	the core fucose structure	800:824	the core fucose structure	800:824	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	7	6	theme	α1,6-fucosyltransferase	994:1016	arg1	gene					1019:1022	FUT8 (α1,6-fucosyltransferase) gene	988:1022	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	8	7	theme	core	1082:1085	arg1	structure					1094:1102	the core fucose structure	1078:1102	the core fucose structure of SOD3	1078:1110	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	7	8	theme	FUT8	988:991	arg1	gene					1019:1022	FUT8 (α1,6-fucosyltransferase) gene	988:1022	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	0	9	theme	SOD3	81:84	arg1	activity					69:76	and the enzymatic activity	51:76	activity	69:76	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	6	10	theme	core	804:807	arg1	structure					816:824	the core fucose structure	800:824	the core fucose structure	800:824	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	5	11	theme	fucose	620:625	arg1	structure					627:635	the fucose structure	616:635	the fucose structure of the N-glycan in SOD3	616:659	We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36606688	6	12	theme	cancer	749:754	arg1	lines					725:729	cell lines	720:729	cell lines of non-small lung cancer cell (NSCLC)	720:767	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	8	13	theme	cells	1228:1232	arg1	growth					1212:1217	cell growth	1207:1217	cell growth of NSCLC cells	1207:1232	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	6	14	theme	lectin	868:873	arg1	blotting					875:882	lectin blotting	868:882	lectin blotting	868:882	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	6	15	theme	lung	744:747	arg1	cancer					749:754	non-small lung cancer cell (NSCLC)	734:767	non-small lung cancer cell (NSCLC)	734:767	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	4	16	theme	lung	559:562	arg1	cancer					564:569	lung cancer	559:569	lung cancer	559:569	Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	3	17	theme	extracellular	323:335	arg1	dismutase					348:356	an extracellular superoxide dismutase	320:356	an extracellular superoxide dismutase	320:356	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	3	17	theme	extracellular	323:335	arg1	SOD3					312:315	SOD3	312:315	SOD3	312:315	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	0	18	from	secretion	38:46	arg1	cells					116:120	non-small cell lung cancer cells	89:120	non-small cell lung cancer cells	89:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	6	19	theme	non-small	734:742	arg1	cancer					749:754	non-small lung cancer cell (NSCLC)	734:767	non-small lung cancer cell (NSCLC)	734:767	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	8	20	theme	growth	1212:1217	arg1	suppression					1192:1202	the suppression	1188:1202	the suppression of cell growth of NSCLC cells	1188:1232	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	9	21	theme	fucose	1301:1306	arg1	structures					1308:1317	core fucose structures	1296:1317	core fucose structures	1296:1317	These data demonstrate that N-glycans, especially those with core fucose structures, regulate the anti-tumor functions of SOD3 against NSCLC.
36606688	3	22	theme	superoxide	337:346	arg1	dismutase					348:356	an extracellular superoxide dismutase	320:356	an extracellular superoxide dismutase	320:356	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	3	22	theme	superoxide	337:346	arg1	SOD3					312:315	SOD3	312:315	SOD3	312:315	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	8	23	theme	cell	1207:1210	arg1	growth					1212:1217	cell growth	1207:1217	cell growth of NSCLC cells	1207:1232	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	7	24	theme	structure	956:964	arg1	roles					931:935	the roles	927:935	the roles of the core fucose structure of SOD3	927:972	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	3	25	theme	N-glycan	380:387	arg1	chain					389:393	a single N-glycan chain	371:393	a single N-glycan chain	371:393	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	1	26	theme	superoxide	150:159	arg1	dismutases					161:170	superoxide dismutases	150:170	superoxide dismutases (SODs)	150:177	The anticancer function of superoxide dismutases (SODs) is still controversial.
36606688	1	26	theme	superoxide	150:159	arg1	SODs					173:176	SODs	173:176	SODs	173:176	The anticancer function of superoxide dismutases (SODs) is still controversial.
36606688	3	27	theme	single	373:378	arg1	chain					389:393	a single N-glycan chain	371:393	a single N-glycan chain	371:393	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	6	28	theme	high	786:789	arg1	level					791:795	a high level	784:795	a high level of the core fucose structure	784:824	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	3	29	contain	contains	362:369	arg1	dismutase					348:356	an extracellular superoxide dismutase	320:356	an extracellular superoxide dismutase	320:356	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	3	29	contain	contains	362:369	arg1	SOD3					312:315	SOD3	312:315	SOD3	312:315	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	3	29	contain	contains	362:369	arg2	chain					389:393	a single N-glycan chain	371:393	a single N-glycan chain	371:393	SOD3 is an extracellular superoxide dismutase and contains a single N-glycan chain.
36606688	8	30	theme	NSCLC	1222:1226	arg1	cells					1228:1232	NSCLC cells	1222:1232	NSCLC cells	1222:1232	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	1	31	theme	dismutases	161:170	arg1	controversial					188:200	controversial	188:200	controversial	188:200	The anticancer function of superoxide dismutases (SODs) is still controversial.
36606688	1	31	theme	dismutases	161:170	arg1	function					138:145	The anticancer function	123:145	The anticancer function of superoxide dismutases (SODs)	123:177	The anticancer function of superoxide dismutases (SODs) is still controversial.
36606688	0	32	theme	Core	0:3	arg1	fucosylation					5:16	Core fucosylation	0:16	Core fucosylation	0:16	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	7	33	theme	SOD3	969:972	arg1	structure					956:964	the core fucose structure	940:964	the core fucose structure of SOD3	940:972	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	6	34	theme	cell	720:723	arg1	lines					725:729	cell lines	720:729	cell lines of non-small lung cancer cell (NSCLC)	720:767	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	2	35	theme	anti-tumor	292:301	arg1	effects					303:309	both pro- and anti-tumor effects	278:309	both pro- and anti-tumor effects	278:309	Removing superoxide and/or producing oxygen and hydrogen peroxide exhibits both pro- and anti-tumor effects.
36606688	8	36	theme	SOD3	1107:1110	arg1	structure					1094:1102	the core fucose structure	1078:1102	the core fucose structure of SOD3	1078:1110	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	4	37	theme	SOD3	536:539	arg1	N-glycosylation					517:531	the N-glycosylation	513:531	the N-glycosylation of SOD3	513:539	Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	0	38	theme	lung	104:107	arg1	cells					116:120	non-small cell lung cancer cells	89:120	non-small cell lung cancer cells	89:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	8	39	theme	enzymatic	1147:1155	arg1	activity					1157:1164	enzymatic activity	1147:1164	enzymatic activity	1147:1164	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	0	40	theme	cell	99:102	arg1	cells					116:120	non-small cell lung cancer cells	89:120	non-small cell lung cancer cells	89:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	0	41	from	activity	69:76	arg1	cells					116:120	non-small cell lung cancer cells	89:120	non-small cell lung cancer cells	89:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	2	42	theme	pro-	283:286	arg1	effects					303:309	both pro- and anti-tumor effects	278:309	both pro- and anti-tumor effects	278:309	Removing superoxide and/or producing oxygen and hydrogen peroxide exhibits both pro- and anti-tumor effects.
36606688	7	43	theme	knockout	1024:1031	arg1	cells					1038:1042	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	0	44	theme	non-small	89:97	arg1	cells					116:120	non-small cell lung cancer cells	89:120	non-small cell lung cancer cells	89:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	6	45	dep	cancer	749:754	arg1	NSCLC					762:766	NSCLC	762:766	NSCLC	762:766	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	6	45	dep	cancer	749:754	arg1	cell					756:759	cell	756:759	non-small lung cancer cell (NSCLC)	734:767	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	7	46	theme	A549	1033:1036	arg1	cells					1038:1042	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	6	47	theme	SOD3	845:848	arg1	N-glycan					833:840	the N-glycan	829:840	the N-glycan of SOD3	829:848	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36606688	0	48	theme	cancer	109:114	arg1	cells					116:120	non-small cell lung cancer cells	89:120	non-small cell lung cancer cells	89:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	0	49	gly	fucosylation	5:16	arg1	activity					69:76	and the enzymatic activity	51:76	activity	69:76	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	5	50	theme	patients	690:697	arg1	sera					682:685	the sera	678:685	the sera of patients with lung cancer	678:714	We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36606688	8	51	theme	fucose	1087:1092	arg1	structure					1094:1102	the core fucose structure	1078:1102	the core fucose structure of SOD3	1078:1110	Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells.
36606688	5	52	from	structure	627:635	arg1	SOD3					656:659	SOD3	656:659	SOD3	656:659	We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36606688	4	53	theme	SOD3	456:459	arg1	essential					465:473	essential	465:473	essential	465:473	Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	4	53	theme	SOD3	456:459	arg1	N-glycosylation					437:451	the N-glycosylation	433:451	the N-glycosylation of SOD3	433:459	Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	7	54	theme	core	944:947	arg1	structure					956:964	the core fucose structure	940:964	the core fucose structure of SOD3	940:972	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	7	55	theme	gene	1019:1022	arg1	cells					1038:1042	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells	988:1042	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	7	56	theme	fucose	949:954	arg1	structure					956:964	the core fucose structure	940:964	the core fucose structure of SOD3	940:972	To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells.
36606688	4	57	gly	N-glycosylation	437:451	arg1	SOD3					456:459	SOD3	456:459	SOD3	456:459	Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	5	58	theme	N-glycan	644:651	arg1	structure					627:635	the fucose structure	616:635	the fucose structure of the N-glycan in SOD3	616:659	We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36606688	5	59	with	patients	690:697	arg1	cancer					709:714	lung cancer	704:714	lung cancer	704:714	We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36606688	9	60	theme	SOD3	1357:1360	arg1	functions					1344:1352	the anti-tumor functions	1329:1352	the anti-tumor functions of SOD3 against NSCLC	1329:1374	These data demonstrate that N-glycans, especially those with core fucose structures, regulate the anti-tumor functions of SOD3 against NSCLC.
36606688	0	61	from	cells	116:120	arg1	secretion					38:46	the secretion	34:46	the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells	34:120	Core fucosylation is required for the secretion of and the enzymatic activity of SOD3 in non-small cell lung cancer cells.
36606688	2	62	theme	hydrogen	251:258	arg1	peroxide					260:267	hydrogen peroxide	251:267	hydrogen peroxide	251:267	Removing superoxide and/or producing oxygen and hydrogen peroxide exhibits both pro- and anti-tumor effects.
36606688	9	63	theme	anti-tumor	1333:1342	arg1	functions					1344:1352	the anti-tumor functions	1329:1352	the anti-tumor functions of SOD3 against NSCLC	1329:1374	These data demonstrate that N-glycans, especially those with core fucose structures, regulate the anti-tumor functions of SOD3 against NSCLC.
36606688	9	64	theme	core	1296:1299	arg1	structures					1308:1317	core fucose structures	1296:1317	core fucose structures	1296:1317	These data demonstrate that N-glycans, especially those with core fucose structures, regulate the anti-tumor functions of SOD3 against NSCLC.
36606688	5	65	theme	lung	704:707	arg1	cancer					709:714	lung cancer	704:714	lung cancer	704:714	We report herein that the fucose structure of the N-glycan in SOD3 was increased in the sera of patients with lung cancer.
36606688	4	66	gly	N-glycosylation	517:531	arg1	SOD3					536:539	SOD3	536:539	SOD3	536:539	Although we reported previously that the N-glycosylation of SOD3 was essential for its secretion, the role played by the N-glycosylation of SOD3, as it relates to lung cancer, is poorly understood.
36606688	6	67	theme	spectrometry	893:904	arg1	analysis					906:913	mass spectrometry analysis	888:913	mass spectrometry analysis	888:913	In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N-glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis.
36233140	2	0	theme	diverse	426:432	arg1	polysaccharides					434:448	structurally diverse polysaccharides	413:448	structurally diverse polysaccharides	413:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	8	1	theme	experimental	1686:1697	arg1	data					1699:1702	experimental data	1686:1702	experimental data	1686:1702	Our findings explain the differences in acceptor binding specificity between non-specific and specific XETs and associate theoretical to experimental data.
36233140	8	2	theme	non-specific	1626:1637	arg1	XETs					1652:1655	non-specific and specific XETs	1626:1655	non-specific and specific XETs	1626:1655	Our findings explain the differences in acceptor binding specificity between non-specific and specific XETs and associate theoretical to experimental data.
36233140	2	3	theme	acceptor	335:342	arg1	substrates					344:353	xyloglucan-derived donor and acceptor substrates	306:353	xyloglucan-derived donor and acceptor substrates	306:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	7	4	dep	linkages	1487:1494	arg1	1,3					1469:1471	1,3	1469:1471	1,3	1469:1471	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	2	5	theme	donor	325:329	arg1	substrates					344:353	xyloglucan-derived donor and acceptor substrates	306:353	xyloglucan-derived donor and acceptor substrates	306:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	7	6	attach	derived	1405:1411	arg1	1,3					1423:1425	1,3	1423:1425	1,3	1423:1425	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	7	6	attach	derived	1405:1411	arg2	acceptors					1395:1403	acceptors	1395:1403	acceptors derived from (1,4;1,3)	1395:1426	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	3	7	theme	molecular	640:648	arg1	simulations					686:696	molecular docking and molecular dynamics (MD) simulations	640:696	simulations	686:696	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	7	8	theme	complexes	1380:1388	arg1	simulations					1342:1352	MD simulations	1339:1352	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)	1339:1426	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	3	9	theme	Populus	586:592	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	1	10	theme	plant	226:230	arg1	walls					237:241	plant cell walls	226:241	plant cell walls	226:241	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	0	11	from	Endotransglycosylases	77:97	arg1	Definition					0:9	Definition	0:9	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases	0:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	6	12	theme	saccharide	1216:1225	arg1	moieties					1227:1234	the saccharide moieties	1212:1234	the saccharide moieties	1212:1234	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	6	13	link	-β-linked	1176:1184	arg1	acceptors					1201:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	5	14	theme	-β-linked	1084:1092	arg1	moieties					1098:1105	the (1,6)-β-linked Glc moieties	1075:1105	the (1,6)-β-linked Glc moieties	1075:1105	Conversely, the acceptors with the (1,6)-β-linked Glc moieties were bound stably in TmXET6.3 but not in PttXET16A.
36233140	3	15	theme	dynamics	672:679	arg1	simulations					686:696	molecular docking and molecular dynamics (MD) simulations	640:696	simulations	686:696	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	1	16	theme	walls	237:241	arg1	reconstruction					208:221	reconstruction	208:221	reconstruction	208:221	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	1	16	theme	walls	237:241	arg1	remodelling					192:202	remodelling	192:202	remodelling	192:202	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	6	17	theme	containing	1190:1199	arg1	acceptors					1201:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	6	18	theme	-β-linked	1176:1184	arg1	acceptors					1201:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	0	19	theme	Plant	60:64	arg1	Endotransglycosylases					77:97	Plant Xyloglucan Endotransglycosylases	60:97	Plant Xyloglucan Endotransglycosylases	60:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	2	20	theme	homo-transglycosylation	267:289	arg1	reactions					291:299	homo-transglycosylation reactions	267:299	homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates	267:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	1	21	theme	key	175:177	arg1	roles					179:183	key roles	175:183	key roles	175:183	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	5	22	link	-β-linked	1084:1092	arg1	moieties					1098:1105	the (1,6)-β-linked Glc moieties	1075:1105	the (1,6)-β-linked Glc moieties	1075:1105	Conversely, the acceptors with the (1,6)-β-linked Glc moieties were bound stably in TmXET6.3 but not in PttXET16A.
36233140	3	23	from	basis	481:485	arg1	TmXET6.3					563:570	TmXET6.3	563:570	TmXET6.3	563:570	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	23	from	basis	481:485	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	23	from	basis	481:485	arg1	majus					556:560	non-specific Tropaeolum majus	532:560	non-specific Tropaeolum majus (TmXET6.3)	532:571	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	4	24	dep	complexes	839:847	arg1	XG-OS7					822:827	XG-OS7	822:827	XG-OS7	822:827	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	24	dep	complexes	839:847	arg1	complexes					839:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes	769:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages,	769:977	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	24	dep	complexes	839:847	arg1	heptaoligosaccharide					798:817	xyloglucan heptaoligosaccharide	787:817	xyloglucan heptaoligosaccharide	787:817	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	0	25	from	Definition	0:9	arg1	Endotransglycosylases					77:97	Plant Xyloglucan Endotransglycosylases	60:97	Plant Xyloglucan Endotransglycosylases	60:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	2	26	link	xyloglucan-derived	306:323	arg1	substrates					344:353	xyloglucan-derived donor and acceptor substrates	306:353	xyloglucan-derived donor and acceptor substrates	306:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	0	27	theme	Computational	105:117	arg1	Chemistry					119:127	Computational Chemistry	105:127	Computational Chemistry	105:127	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	6	28	theme	Glc	1186:1188	arg1	acceptors					1201:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	the (1,4)-β-linked Glc containing acceptors	1167:1209	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	2	29	with	reactions	385:393	arg1	polysaccharides					434:448	structurally diverse polysaccharides	413:448	structurally diverse polysaccharides	413:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	2	29	with	reactions	385:393	arg1	substrates					344:353	xyloglucan-derived donor and acceptor substrates	306:353	xyloglucan-derived donor and acceptor substrates	306:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	2	29	with	reactions	385:393	arg1	variety					402:408	a variety	400:408	a variety of structurally diverse polysaccharides	400:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	0	30	from	Specificity	45:55	arg1	Endotransglycosylases					77:97	Plant Xyloglucan Endotransglycosylases	60:97	Plant Xyloglucan Endotransglycosylases	60:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	4	31	theme	linear	858:863	arg1	acceptors					865:873	the linear acceptors	854:873	the linear acceptors	854:873	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	3	32	theme	binding	509:515	arg1	specificity					517:527	acceptor substrate binding specificity	490:527	acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs	490:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	33	theme	acceptor	490:497	arg1	specificity					517:527	acceptor substrate binding specificity	490:527	acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs	490:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	34	dep	Populus	586:592	arg1	tremula					594:600	tremula	594:600	tremula	594:600	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	4	35	theme	/acceptor	829:837	arg1	XG-OS7					822:827	XG-OS7	822:827	XG-OS7	822:827	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	35	theme	/acceptor	829:837	arg1	complexes					839:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes	769:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages,	769:977	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	35	theme	/acceptor	829:837	arg1	heptaoligosaccharide					798:817	xyloglucan heptaoligosaccharide	787:817	xyloglucan heptaoligosaccharide	787:817	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	3	36	theme	Tropaeolum	545:554	arg1	TmXET6.3					563:570	TmXET6.3	563:570	TmXET6.3	563:570	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	36	theme	Tropaeolum	545:554	arg1	majus					556:560	non-specific Tropaeolum majus	532:560	non-specific Tropaeolum majus (TmXET6.3)	532:571	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	6	37	from	stability	1315:1323	arg1	PttXET16A					1328:1336	PttXET16A	1328:1336	PttXET16A	1328:1336	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	7	38	theme	chain	1505:1509	arg1	positions					1511:1519	side chain positions	1500:1519	side chain positions	1500:1519	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	1	39	theme	Xyloglucan	130:139	arg1	XETs					164:167	XETs	164:167	XETs	164:167	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	1	39	theme	Xyloglucan	130:139	arg1	endotransglycosylases					141:161	Xyloglucan endotransglycosylases	130:161	Xyloglucan endotransglycosylases (XETs)	130:168	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	4	40	theme	TmXET6.3	1020:1027	arg1	PttXET16A					1033:1041	PttXET16A	1033:1041	PttXET16A	1033:1041	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	40	theme	TmXET6.3	1020:1027	arg1	TmXET6.3					1020:1027	TmXET6.3	1020:1027	TmXET6.3	1020:1027	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	40	theme	TmXET6.3	1020:1027	arg1	sites					1011:1015	the active sites	1000:1015	the active sites of TmXET6.3 and PttXET16A	1000:1041	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	3	41	theme	free	720:723	arg1	calculations					732:743	binding free energy calculations	712:743	binding free energy calculations	712:743	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	0	42	theme	Substrate	27:35	arg1	Specificity					45:55	the Acceptor Substrate Binding Specificity	14:55	the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases	14:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	4	43	theme	PttXET16A	1033:1041	arg1	PttXET16A					1033:1041	PttXET16A	1033:1041	PttXET16A	1033:1041	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	43	theme	PttXET16A	1033:1041	arg1	TmXET6.3					1020:1027	TmXET6.3	1020:1027	TmXET6.3	1020:1027	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	43	theme	PttXET16A	1033:1041	arg1	sites					1011:1015	the active sites	1000:1015	the active sites of TmXET6.3 and PttXET16A	1000:1041	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	44	theme	glucose	906:912	arg1	moieties					920:927	glucose (Glc) moieties	906:927	glucose (Glc) moieties	906:927	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	45	dep	linked	929:934	arg1	linkages					969:976	-β-glycosidic linkages	955:976	-β-glycosidic linkages	955:976	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	45	dep	linked	929:934	arg1	1,4					941:943	1,4	941:943	1,4	941:943	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	7	46	dep	-β-glucans	1427:1436	arg1	highlighted					1438:1448	highlighted	1438:1448	-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates	1427:1546	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	7	47	theme	-β-glycosidic	1473:1485	arg1	linkages					1487:1494	-β-glycosidic linkages	1473:1494	(1,3)-β-glycosidic linkages	1468:1494	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	3	48	from	majus	556:560	arg1	basis					481:485	the basis	477:485	the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs	477:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	49	from	specificity	517:527	arg1	TmXET6.3					563:570	TmXET6.3	563:570	TmXET6.3	563:570	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	49	from	specificity	517:527	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	49	from	specificity	517:527	arg1	majus					556:560	non-specific Tropaeolum majus	532:560	non-specific Tropaeolum majus (TmXET6.3)	532:571	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	2	50	theme	polysaccharides	434:448	arg1	polysaccharides					434:448	structurally diverse polysaccharides	413:448	structurally diverse polysaccharides	413:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	2	50	theme	polysaccharides	434:448	arg1	variety					402:408	a variety	400:408	a variety of structurally diverse polysaccharides	400:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	8	51	theme	binding	1598:1604	arg1	specificity					1606:1616	acceptor binding specificity	1589:1616	acceptor binding specificity	1589:1616	Our findings explain the differences in acceptor binding specificity between non-specific and specific XETs and associate theoretical to experimental data.
36233140	3	52	theme	PttXET16A	617:625	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	53	theme	tremuloides	604:614	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	0	54	theme	Specificity	45:55	arg1	Definition					0:9	Definition	0:9	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases	0:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	2	55	theme	hetero-transglycosylation	359:383	arg1	reactions					385:393	hetero-transglycosylation reactions	359:393	hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides	359:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	3	56	theme	specific	577:584	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	4	57	with	complexes	839:847	arg1	acceptors					865:873	the linear acceptors	854:873	the linear acceptors	854:873	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	8	58	from	differences	1574:1584	arg1	specificity					1606:1616	acceptor binding specificity	1589:1616	acceptor binding specificity	1589:1616	Our findings explain the differences in acceptor binding specificity between non-specific and specific XETs and associate theoretical to experimental data.
36233140	1	59	theme	cell	232:235	arg1	walls					237:241	plant cell walls	226:241	plant cell walls	226:241	Xyloglucan endotransglycosylases (XETs) play key roles in the remodelling and reconstruction of plant cell walls.
36233140	7	60	from	importance	1454:1463	arg1	substrates					1537:1546	the acceptor substrates	1524:1546	the acceptor substrates	1524:1546	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	2	61	with	reactions	291:299	arg1	polysaccharides					434:448	structurally diverse polysaccharides	413:448	structurally diverse polysaccharides	413:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	2	61	with	reactions	291:299	arg1	substrates					344:353	xyloglucan-derived donor and acceptor substrates	306:353	xyloglucan-derived donor and acceptor substrates	306:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	2	61	with	reactions	291:299	arg1	variety					402:408	a variety	400:408	a variety of structurally diverse polysaccharides	400:448	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	4	62	theme	-β-glycosidic	955:967	arg1	linkages					969:976	-β-glycosidic linkages	955:976	-β-glycosidic linkages	955:976	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	7	63	theme	XET-donor/acceptor	1361:1378	arg1	complexes					1380:1388	the XET-donor/acceptor complexes	1357:1388	the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)	1357:1426	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	5	64	theme	Glc	1094:1096	arg1	moieties					1098:1105	the (1,6)-β-linked Glc moieties	1075:1105	the (1,6)-β-linked Glc moieties	1075:1105	Conversely, the acceptors with the (1,6)-β-linked Glc moieties were bound stably in TmXET6.3 but not in PttXET16A.
36233140	3	65	theme	docking	650:656	arg1	simulations					686:696	molecular docking and molecular dynamics (MD) simulations	640:696	simulations	686:696	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	4	66	theme	enzyme-donor	773:784	arg1	XG-OS7					822:827	XG-OS7	822:827	XG-OS7	822:827	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	66	theme	enzyme-donor	773:784	arg1	complexes					839:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes	769:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages,	769:977	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	66	theme	enzyme-donor	773:784	arg1	heptaoligosaccharide					798:817	xyloglucan heptaoligosaccharide	787:817	xyloglucan heptaoligosaccharide	787:817	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	3	67	from	XETs	628:631	arg1	basis					481:485	the basis	477:485	the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs	477:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	2	68	theme	xyloglucan-derived	306:323	arg1	substrates					344:353	xyloglucan-derived donor and acceptor substrates	306:353	xyloglucan-derived donor and acceptor substrates	306:353	These enzymes catalyse homo-transglycosylation reactions with xyloglucan-derived donor and acceptor substrates and hetero-transglycosylation reactions with a variety of structurally diverse polysaccharides.
36233140	7	69	theme	MD	1339:1340	arg1	simulations					1342:1352	MD simulations	1339:1352	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)	1339:1426	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	4	70	theme	xyloglucan	787:796	arg1	complexes					839:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes	769:847	the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages,	769:977	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	70	theme	xyloglucan	787:796	arg1	heptaoligosaccharide					798:817	xyloglucan heptaoligosaccharide	787:817	xyloglucan heptaoligosaccharide	787:817	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	0	71	theme	Xyloglucan	66:75	arg1	Endotransglycosylases					77:97	Plant Xyloglucan Endotransglycosylases	60:97	Plant Xyloglucan Endotransglycosylases	60:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	6	72	dep	acceptors	1201:1209	arg1	1,4					1172:1174	1,4	1172:1174	1,4	1172:1174	When in the (1,4)-β-linked Glc containing acceptors, the saccharide moieties were replaced with mannose or xylose, they bound stably in TmXET6.3 but lacked stability in PttXET16A.
36233140	7	73	theme	acceptor	1528:1535	arg1	substrates					1537:1546	the acceptor substrates	1524:1546	the acceptor substrates	1524:1546	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	4	74	theme	active	1004:1009	arg1	PttXET16A					1033:1041	PttXET16A	1033:1041	PttXET16A	1033:1041	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	74	theme	active	1004:1009	arg1	TmXET6.3					1020:1027	TmXET6.3	1020:1027	TmXET6.3	1020:1027	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	4	74	theme	active	1004:1009	arg1	sites					1011:1015	the active sites	1000:1015	the active sites of TmXET6.3 and PttXET16A	1000:1041	The data indicate that the enzyme-donor (xyloglucan heptaoligosaccharide or XG-OS7)/acceptor complexes with the linear acceptors, where a backbone consisted of glucose (Glc) moieties linked via (1,4)- or (1,3)-β-glycosidic linkages, were bound stably in the active sites of TmXET6.3 and PttXET16A.
36233140	5	75	with	acceptors	1060:1068	arg1	moieties					1098:1105	the (1,6)-β-linked Glc moieties	1075:1105	the (1,6)-β-linked Glc moieties	1075:1105	Conversely, the acceptors with the (1,6)-β-linked Glc moieties were bound stably in TmXET6.3 but not in PttXET16A.
36233140	3	76	theme	specificity	517:527	arg1	basis					481:485	the basis	477:485	the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs	477:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	7	77	with	complexes	1380:1388	arg1	acceptors					1395:1403	acceptors	1395:1403	acceptors derived from (1,4;1,3)	1395:1426	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	3	78	theme	substrate	499:507	arg1	specificity					517:527	acceptor substrate binding specificity	490:527	acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs	490:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	0	79	theme	Acceptor	18:25	arg1	Specificity					45:55	the Acceptor Substrate Binding Specificity	14:55	the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases	14:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	3	80	theme	binding	712:718	arg1	calculations					732:743	binding free energy calculations	712:743	binding free energy calculations	712:743	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	0	81	theme	Binding	37:43	arg1	Specificity					45:55	the Acceptor Substrate Binding Specificity	14:55	the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases	14:97	Definition of the Acceptor Substrate Binding Specificity in Plant Xyloglucan Endotransglycosylases Using Computational Chemistry.
36233140	7	82	theme	positions	1511:1519	arg1	importance					1454:1463	the importance	1450:1463	the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates	1450:1546	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	3	83	theme	non-specific	532:543	arg1	TmXET6.3					563:570	TmXET6.3	563:570	TmXET6.3	563:570	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	3	83	theme	non-specific	532:543	arg1	majus					556:560	non-specific Tropaeolum majus	532:560	non-specific Tropaeolum majus (TmXET6.3)	532:571	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	7	84	theme	side	1500:1503	arg1	positions					1511:1519	side chain positions	1500:1519	side chain positions	1500:1519	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	8	85	theme	specific	1643:1650	arg1	XETs					1652:1655	non-specific and specific XETs	1626:1655	non-specific and specific XETs	1626:1655	Our findings explain the differences in acceptor binding specificity between non-specific and specific XETs and associate theoretical to experimental data.
36233140	7	86	theme	linkages	1487:1494	arg1	importance					1454:1463	the importance	1450:1463	the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates	1450:1546	MD simulations of the XET-donor/acceptor complexes with acceptors derived from (1,4;1,3)-β-glucans highlighted the importance of (1,3)-β-glycosidic linkages and side chain positions in the acceptor substrates.
36233140	3	87	theme	energy	725:730	arg1	calculations					732:743	binding free energy calculations	712:743	binding free energy calculations	712:743	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36233140	8	88	theme	acceptor	1589:1596	arg1	specificity					1606:1616	acceptor binding specificity	1589:1616	acceptor binding specificity	1589:1616	Our findings explain the differences in acceptor binding specificity between non-specific and specific XETs and associate theoretical to experimental data.
36233140	3	89	theme	x	602:602	arg1	XETs					628:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	specific Populus tremula x tremuloides (PttXET16A) XETs	577:631	In this work, we describe the basis of acceptor substrate binding specificity in non-specific Tropaeolum majus (TmXET6.3) and specific Populus tremula x tremuloides (PttXET16A) XETs, using molecular docking and molecular dynamics (MD) simulations combined with binding free energy calculations.
36425181	7	0	theme	glycosylated	1475:1486	arg1	nanoparticles					1493:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	10	1	theme	lab	2082:2084	arg1	user					2086:2089	a lab user	2080:2089	a lab user	2080:2089	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	3	2	from	laboratories	624:635	arg1	available					600:608	available	600:608	available	600:608	Micro-arrays allow for the interrogation of 100's of glycans but are not widely available in individual laboratories.
36425181	7	3	theme	gold	1404:1407	arg1	parameters					1343:1352	the key parameters	1335:1352	the key parameters of nanoparticle size	1335:1373	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	3	theme	gold	1404:1407	arg1	concentration					1409:1421	gold concentration	1404:1421	gold concentration	1404:1421	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	5	4	dep	red	1059:1061	arg1	blue					1066:1069	blue	1066:1069	blue	1066:1069	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	5	4	dep	red	1059:1061	arg1	to					1063:1064	to	1063:1064	to	1063:1064	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	1	5	theme	crucial	279:285	arg1	players					287:293	crucial players	279:293	crucial players in the immune system	279:314	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	6	6	theme	large	1171:1175	arg1	number					1177:1182	the large number	1167:1182	the large number of reports	1167:1193	Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology.
36425181	9	7	theme	core	1879:1882	arg1	size					1884:1887	a gold core size	1872:1887	a gold core size	1872:1887	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	5	8	dep	colourimetric	1044:1056	arg1	red					1059:1061	red	1059:1061	red	1059:1061	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	6	9	theme	recommended	1246:1256	arg1	points					1264:1269	recommended start points	1246:1269	recommended start points	1246:1269	Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology.
36425181	4	10	theme	binding	856:862	arg1	understanding					832:844	detailed understanding	823:844	detailed understanding of glycan binding	823:862	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	7	11	theme	polymeric	1376:1384	arg1	parameters					1343:1352	the key parameters	1335:1352	the key parameters of nanoparticle size	1335:1373	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	11	theme	polymeric	1376:1384	arg1	length					1393:1398	polymeric tether length	1376:1398	polymeric tether length	1376:1398	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	12	theme	size	1370:1373	arg1	parameters					1343:1352	the key parameters	1335:1352	the key parameters of nanoparticle size	1335:1373	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	12	theme	size	1370:1373	arg1	length					1393:1398	polymeric tether length	1376:1398	polymeric tether length	1376:1398	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	12	theme	size	1370:1373	arg1	concentration					1409:1421	gold concentration	1404:1421	gold concentration	1404:1421	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	10	13	theme	glycan	2151:2156	arg1	quantities					2133:2142	minimal quantities	2125:2142	minimal quantities of the glycan and lectin	2125:2167	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	10	14	dep	glycan	2151:2156	arg1	the					2147:2149	the	2147:2149	the	2147:2149	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	7	15	theme	key	1339:1341	arg1	parameters					1343:1352	the key parameters	1335:1352	the key parameters of nanoparticle size	1335:1373	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	15	theme	key	1339:1341	arg1	length					1393:1398	polymeric tether length	1376:1398	polymeric tether length	1376:1398	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	7	15	theme	key	1339:1341	arg1	concentration					1409:1421	gold concentration	1404:1421	gold concentration	1404:1421	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	9	16	theme	sufficient	1930:1939	arg1	stability					1951:1959	sufficient colloidal stability	1930:1959	sufficient colloidal stability	1930:1959	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	4	17	theme	isothermal	669:678	arg1	calorimetry					690:700	isothermal titration calorimetry	669:700	isothermal titration calorimetry	669:700	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	3	18	theme	glycans	573:579	arg1	's					567:568	100's	564:568	100's of glycans	564:579	Micro-arrays allow for the interrogation of 100's of glycans but are not widely available in individual laboratories.
36425181	9	19	dep	length	1908:1913	arg1	tether					1901:1906	tether	1901:1906	tether	1901:1906	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	1	20	theme	Glycan-lectin	146:158	arg1	interactions					160:171	Glycan-lectin interactions	146:171	Glycan-lectin interactions	146:171	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	2	21	theme	non-trivial	450:460	arg1	problem					462:468	a non-trivial problem	448:468	a non-trivial problem	448:468	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	2	22	theme	new	401:403	arg1	protein					405:411	a new protein	399:411	a new protein (or mutant)	399:423	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	4	23	theme	Biophysical	638:648	arg1	techniques					650:659	Biophysical techniques	638:659	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all	638:813	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	4	23	theme	Biophysical	638:648	arg1	interferometry					752:765	biolayer interferometry	743:765	biolayer interferometry	743:765	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	4	23	theme	Biophysical	638:648	arg1	spectrometry					729:740	surface plasmon resonance spectrometry	703:740	surface plasmon resonance spectrometry	703:740	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	4	23	theme	Biophysical	638:648	arg1	spectroscopy					798:809	nuclear magnetic resonance spectroscopy	771:809	nuclear magnetic resonance spectroscopy	771:809	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	4	23	theme	Biophysical	638:648	arg1	calorimetry					690:700	isothermal titration calorimetry	669:700	isothermal titration calorimetry	669:700	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	0	24	theme	structural	80:89	arg1	parameters					108:117	structural and experimental parameters	80:117	structural and experimental parameters	80:117	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	5	25	theme	simple	1117:1122	arg1	spectrometer					1135:1146	a simple UV-visible spectrometer	1115:1146	a simple UV-visible spectrometer	1115:1146	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	3	26	theme	's	567:568	arg1	interrogation					547:559	the interrogation	543:559	the interrogation of 100's of glycans	543:579	Micro-arrays allow for the interrogation of 100's of glycans but are not widely available in individual laboratories.
36425181	5	27	theme	Glycosylated	894:905	arg1	nanoparticles					917:929	Glycosylated plasmonic nanoparticles	894:929	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers	894:972	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	7	28	theme	minimal	1568:1574	arg1	barriers					1589:1596	minimal optimisation barriers	1568:1596	minimal optimisation barriers	1568:1596	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	0	29	theme	experimental	95:106	arg1	parameters					108:117	structural and experimental parameters	80:117	structural and experimental parameters	80:117	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	2	30	theme	few	476:478	arg1	tools					503:507	few accessible or low-cost tools	476:507	few accessible or low-cost tools available	476:517	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	2	31	dep	glycan	338:343	arg1	unnatural					357:365	unnatural	357:365	unnatural	357:365	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	2	31	dep	glycan	338:343	arg1	natural					346:352	natural	346:352	natural	346:352	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	4	32	dep	techniques	650:659	arg1	all					811:813	all	811:813	all	811:813	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	7	33	theme	glycan/protein	1534:1547	arg1	interactions					1549:1560	a new glycan/protein interactions	1528:1560	a new glycan/protein interactions	1528:1560	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	4	34	theme	surface	703:709	arg1	resonance					719:727	surface plasmon resonance	703:727	surface plasmon resonance spectrometry	703:740	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	0	35	theme	Polymer-tethered	0:15	arg1	biosensors					49:58	Polymer-tethered glyconanoparticle colourimetric biosensors	0:58	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding	0:77	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	5	36	theme	polymeric	956:964	arg1	tethers					966:972	polymeric tethers	956:972	polymeric tethers	956:972	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	7	37	gly	glycosylated	1475:1486	arg1	nanoparticles					1493:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	9	38	theme	gold	1786:1789	arg1	core					1791:1794	the gold core	1782:1794	the gold core	1782:1794	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	7	39	used	used	1514:1517	arg2	nanoparticles					1493:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	4	40	theme	resonance	719:727	arg1	spectrometry					729:740	surface plasmon resonance spectrometry	703:740	surface plasmon resonance spectrometry	703:740	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	0	41	theme	colourimetric	35:47	arg1	biosensors					49:58	Polymer-tethered glyconanoparticle colourimetric biosensors	0:58	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding	0:77	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	4	42	theme	detailed	823:830	arg1	understanding					832:844	detailed understanding	823:844	detailed understanding of glycan binding	823:862	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	9	43	theme	strong	1818:1823	arg1	responses					1825:1833	balance strong responses	1810:1833	balance strong responses	1810:1833	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	4	44	theme	nuclear	771:777	arg1	spectroscopy					798:809	nuclear magnetic resonance spectroscopy	771:809	nuclear magnetic resonance spectroscopy	771:809	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	2	45	theme	new	334:336	arg1	glycan					338:343	a new glycan	332:343	a new glycan (natural or unnatural)	332:366	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	7	46	theme	gold	1488:1491	arg1	nanoparticles					1493:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	5	47	theme	glycan-protein	1011:1024	arg1	binding					1026:1032	glycan-protein binding	1011:1032	glycan-protein binding	1011:1032	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	1	48	theme	essential	178:186	arg1	attachment					221:230	attachment	221:230	attachment	221:230	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	1	48	theme	essential	178:186	arg1	roles					188:192	essential roles	178:192	essential roles	178:192	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	1	48	theme	essential	178:186	arg1	site					213:216	the site	209:216	the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system	209:314	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	3	49	from	available	600:608	arg1	laboratories					624:635	individual laboratories	613:635	individual laboratories	613:635	Micro-arrays allow for the interrogation of 100's of glycans but are not widely available in individual laboratories.
36425181	4	50	theme	resonance	788:796	arg1	spectroscopy					798:809	nuclear magnetic resonance spectroscopy	771:809	nuclear magnetic resonance spectroscopy	771:809	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	8	51	theme	chemical	1645:1652	arg1	space					1671:1675	chemical and nanoparticle space	1645:1675	chemical and nanoparticle space	1645:1675	This work aimed to remove the need to explore chemical and nanoparticle space and hence remove a barrier for other users when deploying this system.
36425181	1	52	theme	cell-cell	247:255	arg1	communication					257:269	cell-cell communication	247:269	cell-cell communication	247:269	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	7	53	theme	polymer-tethered	1458:1473	arg1	nanoparticles					1493:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	polymer-tethered glycosylated gold nanoparticles	1458:1505	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	8	54	theme	nanoparticle	1658:1669	arg1	space					1671:1675	chemical and nanoparticle space	1645:1675	chemical and nanoparticle space	1645:1675	This work aimed to remove the need to explore chemical and nanoparticle space and hence remove a barrier for other users when deploying this system.
36425181	9	55	theme	gold	1874:1877	arg1	size					1884:1887	a gold core size	1872:1887	a gold core size	1872:1887	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	6	56	theme	start	1258:1262	arg1	points					1264:1269	recommended start points	1246:1269	recommended start points	1246:1269	Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology.
36425181	1	57	from	players	287:293	arg1	system					309:314	the immune system	298:314	the immune system	298:314	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	4	58	theme	glycan	849:854	arg1	binding					856:862	glycan binding	849:862	glycan binding	849:862	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	9	59	theme	polymer	1893:1899	arg1	length					1908:1913	polymer tether length	1893:1913	polymer tether length	1893:1913	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	8	60	theme	other	1708:1712	arg1	users					1714:1718	other users	1708:1718	other users	1708:1718	This work aimed to remove the need to explore chemical and nanoparticle space and hence remove a barrier for other users when deploying this system.
36425181	2	61	theme	low-cost	494:501	arg1	tools					503:507	few accessible or low-cost tools	476:507	few accessible or low-cost tools available	476:517	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	10	62	theme	minimal	2125:2131	arg1	quantities					2133:2142	minimal quantities	2125:2142	minimal quantities of the glycan and lectin	2125:2167	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	1	63	theme	attachment	221:230	arg1	attachment					221:230	attachment	221:230	attachment	221:230	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	1	63	theme	attachment	221:230	arg1	roles					188:192	essential roles	178:192	essential roles	178:192	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	1	63	theme	attachment	221:230	arg1	site					213:216	the site	209:216	the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system	209:314	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	2	64	theme	accessible	480:489	arg1	tools					503:507	few accessible or low-cost tools	476:507	few accessible or low-cost tools available	476:517	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	7	65	theme	nanoparticle	1357:1368	arg1	size					1370:1373	nanoparticle size	1357:1373	nanoparticle size	1357:1373	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	10	66	theme	lectin	2162:2167	arg1	quantities					2133:2142	minimal quantities	2125:2142	minimal quantities of the glycan and lectin	2125:2167	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	7	67	dep	length	1393:1398	arg1	tether					1386:1391	tether	1386:1391	tether	1386:1391	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	6	68	theme	standard	1208:1215	arg1	protocols					1217:1225	no standard protocols	1205:1225	no standard protocols for each system	1205:1241	Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology.
36425181	9	69	theme	colloidal	1941:1949	arg1	stability					1951:1959	sufficient colloidal stability	1930:1959	sufficient colloidal stability	1930:1959	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	6	70	theme	new	1283:1285	arg1	user					1287:1290	a new user	1281:1290	a new user to deploy this technology	1281:1316	Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology.
36425181	5	71	theme	gold	940:943	arg1	cores					945:949	gold cores	940:949	gold cores with polymeric tethers	940:972	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	7	72	theme	optimisation	1576:1587	arg1	barriers					1589:1596	minimal optimisation barriers	1568:1596	minimal optimisation barriers	1568:1596	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	2	73	theme	available	509:517	arg1	tools					503:507	few accessible or low-cost tools	476:507	few accessible or low-cost tools available	476:517	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	4	74	theme	titration	680:688	arg1	calorimetry					690:700	isothermal titration calorimetry	669:700	isothermal titration calorimetry	669:700	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	6	75	theme	reports	1187:1193	arg1	number					1177:1182	the large number	1167:1182	the large number of reports	1167:1193	Despite the large number of reports there are no standard protocols for each system or recommended start points, to allow a new user to deploy this technology.
36425181	10	76	theme	subtle	1980:1985	arg1	differences					1987:1997	subtle differences	1980:1997	subtle differences between glycans/lectins	1980:2021	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	5	77	theme	UV-visible	1124:1133	arg1	spectrometer					1135:1146	a simple UV-visible spectrometer	1115:1146	a simple UV-visible spectrometer	1115:1146	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	5	78	theme	plasmonic	907:915	arg1	nanoparticles					917:929	Glycosylated plasmonic nanoparticles	894:929	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers	894:972	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	7	79	theme	new	1530:1532	arg1	interactions					1549:1560	a new glycan/protein interactions	1528:1560	a new glycan/protein interactions	1528:1560	Here we explore the key parameters of nanoparticle size, polymeric tether length and gold concentration to provide some guidelines for how polymer-tethered glycosylated gold nanoparticles can be used to probe a new glycan/protein interactions, with minimal optimisation barriers.
36425181	10	80	theme	further	2195:2201	arg1	study					2203:2207	further study	2195:2207	further study	2195:2207	Whilst subtle differences between glycans/lectins will impact the outcomes, these parameters should enable a lab user to quickly evaluate binding using minimal quantities of the glycan and lectin, to select candidates for further study.
36425181	0	81	theme	robust	131:136	arg1	output					138:143	a robust output	129:143	a robust output	129:143	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	2	82	dep	protein	405:411	arg1	mutant					417:422	mutant	417:422	mutant	417:422	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	0	83	dep	ensure	122:127	arg1	biosensors					49:58	Polymer-tethered glyconanoparticle colourimetric biosensors	0:58	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding	0:77	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	5	84	with	cores	945:949	arg1	tethers					966:972	polymeric tethers	956:972	polymeric tethers	956:972	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	4	85	theme	biolayer	743:750	arg1	interferometry					752:765	biolayer interferometry	743:765	biolayer interferometry	743:765	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	2	86	theme	protein	376:382	arg1	partner					384:390	a protein partner	374:390	a protein partner	374:390	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	0	87	theme	glyconanoparticle	17:33	arg1	biosensors					49:58	Polymer-tethered glyconanoparticle colourimetric biosensors	0:58	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding	0:77	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	2	88	with	problem	462:468	arg1	tools					503:507	few accessible or low-cost tools	476:507	few accessible or low-cost tools available	476:517	Identifying if a new glycan (natural or unnatural) binds a protein partner, or if a new protein (or mutant) binds a glycan remains a non-trivial problem, with few accessible or low-cost tools available.
36425181	9	89	theme	core	1791:1794	arg1	crucial					1799:1805	crucial	1799:1805	crucial	1799:1805	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	9	89	theme	core	1791:1794	arg1	concentration					1765:1777	the concentration	1761:1777	the concentration of the gold core	1761:1794	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	4	90	theme	plasmon	711:717	arg1	resonance					719:727	surface plasmon resonance	703:727	surface plasmon resonance spectrometry	703:740	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
36425181	0	91	theme	lectin	64:69	arg1	binding					71:77	lectin binding	64:77	lectin binding	64:77	Polymer-tethered glyconanoparticle colourimetric biosensors for lectin binding: structural and experimental parameters to ensure a robust output.
36425181	1	92	theme	immune	302:307	arg1	system					309:314	the immune system	298:314	the immune system	298:314	Glycan-lectin interactions play essential roles in biology; as the site of attachment for pathogens, cell-cell communication, and as crucial players in the immune system.
36425181	5	93	theme	colourimetric	1044:1056	arg1	outputs					1072:1078	colourimetric (red to blue) outputs	1044:1078	colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye	1044:1156	Glycosylated plasmonic nanoparticles based on gold cores with polymeric tethers have emerged as biosensors to detect glycan-protein binding, based on colourimetric (red to blue) outputs which can be easily interpreted by a simple UV-visible spectrometer or by eye.
36425181	9	94	theme	balance	1810:1816	arg1	responses					1825:1833	balance strong responses	1810:1833	balance strong responses	1810:1833	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	3	95	theme	individual	613:622	arg1	laboratories					624:635	individual laboratories	613:635	individual laboratories	613:635	Micro-arrays allow for the interrogation of 100's of glycans but are not widely available in individual laboratories.
36425181	9	96	theme	false	1842:1846	arg1	positives					1848:1856	false positives	1842:1856	false positives	1842:1856	We show that the concentration of the gold core is crucial to balance strong responses versus false positives and recommend a gold core size and polymer tether length which balances sufficient colloidal stability and output.
36425181	4	97	theme	magnetic	779:786	arg1	spectroscopy					798:809	nuclear magnetic resonance spectroscopy	771:809	nuclear magnetic resonance spectroscopy	771:809	Biophysical techniques such as isothermal titration calorimetry, surface plasmon resonance spectrometry, biolayer interferometry and nuclear magnetic resonance spectroscopy all provide detailed understanding of glycan binding but are relatively expensive.
37071468	1	0	theme	chimeric	179:186	arg1	chMC813-70					208:217	the chimeric anti-SSEA4 antibody chMC813-70	175:217	the chimeric anti-SSEA4 antibody chMC813-70	175:217	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	0	theme	chimeric	179:186	arg1	model					224:228	a model	222:228	a model	222:228	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	1	theme	anti-SSEA4	188:197	arg1	chMC813-70					208:217	the chimeric anti-SSEA4 antibody chMC813-70	175:217	the chimeric anti-SSEA4 antibody chMC813-70	175:217	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	1	theme	anti-SSEA4	188:197	arg1	model					224:228	a model	222:228	a model	222:228	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	2	2	theme	significant	329:339	arg1	enhancement					341:351	significant enhancement	329:351	significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	329:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	3	theme	antibody	356:363	arg1	ADCC					433:436	ADCC	433:436	ADCC	433:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	3	theme	antibody	356:363	arg1	functions					374:382	antibody effector functions	356:382	antibody effector functions	356:382	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	3	theme	antibody	356:363	arg1	binding					395:401	binding	395:401	binding to different Fc receptors	395:427	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	1	4	theme	comprehensive	69:81	arg1	relationship					102:113	A comprehensive structure-activity relationship	67:113	A comprehensive structure-activity relationship study on antibody Fc-glycosylation	67:148	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	5	theme	antibody	199:206	arg1	chMC813-70					208:217	the chimeric anti-SSEA4 antibody chMC813-70	175:217	the chimeric anti-SSEA4 antibody chMC813-70	175:217	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	5	theme	antibody	199:206	arg1	model					224:228	a model	222:228	a model	222:228	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	6	theme	structure-activity	83:100	arg1	relationship					102:113	A comprehensive structure-activity relationship	67:113	A comprehensive structure-activity relationship study on antibody Fc-glycosylation	67:148	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	1	7	theme	relationship	102:113	arg1	study					115:119	A comprehensive structure-activity relationship study	67:119	A comprehensive structure-activity relationship study on antibody Fc-glycosylation	67:148	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	0	8	theme	antibody	9:16	arg1	Fc-glycosylation					18:33	antibody Fc-glycosylation	9:33	antibody Fc-glycosylation for optimal effector functions	9:64	Study on antibody Fc-glycosylation for optimal effector functions.
37071468	2	9	theme	optimal	306:312	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	9	theme	optimal	306:312	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	1	10	theme	antibody	124:131	arg1	Fc-glycosylation					133:148	antibody Fc-glycosylation	124:148	antibody Fc-glycosylation	124:148	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	0	11	theme	optimal	39:45	arg1	functions					56:64	optimal effector functions	39:64	optimal effector functions	39:64	Study on antibody Fc-glycosylation for optimal effector functions.
37071468	2	12	theme	type	272:275	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	12	theme	type	272:275	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	13	theme	complex	264:270	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	13	theme	complex	264:270	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	14	gly	sialylated	241:250	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	14	gly	sialylated	241:250	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	15	theme	biantennary	252:262	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	15	theme	biantennary	252:262	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	0	16	theme	effector	47:54	arg1	functions					56:64	optimal effector functions	39:64	optimal effector functions	39:64	Study on antibody Fc-glycosylation for optimal effector functions.
37071468	2	17	theme	α-2,6	235:239	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	17	theme	α-2,6	235:239	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	18	theme	sialylated	241:250	arg1	Fc-glycan					314:322	the optimal Fc-glycan	302:322	the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	302:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	18	theme	sialylated	241:250	arg1	glycan					277:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan	231:282	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	19	theme	effector	365:372	arg1	ADCC					433:436	ADCC	433:436	ADCC	433:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	19	theme	effector	365:372	arg1	functions					374:382	antibody effector functions	356:382	antibody effector functions	356:382	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	19	theme	effector	365:372	arg1	binding					395:401	binding	395:401	binding to different Fc receptors	395:427	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	20	theme	Fc	416:417	arg1	receptors					419:427	different Fc receptors	406:427	different Fc receptors	406:427	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	1	21	from	study	115:119	arg1	Fc-glycosylation					133:148	antibody Fc-glycosylation	124:148	antibody Fc-glycosylation	124:148	A comprehensive structure-activity relationship study on antibody Fc-glycosylation has been performed using the chimeric anti-SSEA4 antibody chMC813-70 as a model.
37071468	2	22	theme	different	406:414	arg1	receptors					419:427	different Fc receptors	406:427	different Fc receptors	406:427	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	23	from	enhancement	341:351	arg1	ADCC					433:436	ADCC	433:436	ADCC	433:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	23	from	enhancement	341:351	arg1	functions					374:382	antibody effector functions	356:382	antibody effector functions	356:382	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	23	from	enhancement	341:351	arg1	binding					395:401	binding	395:401	binding to different Fc receptors	395:427	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
37071468	2	24	with	Fc-glycan	314:322	arg1	enhancement					341:351	significant enhancement	329:351	significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC	329:436	The α-2,6 sialylated biantennary complex type glycan was identified as the optimal Fc-glycan with significant enhancement in antibody effector functions, including binding to different Fc receptors and ADCC.
36049519	5	0	theme	suggestive	745:754	arg1	features					736:743	features	736:743	features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization	736:879	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	10	1	theme	carbohydrate-binding	1555:1574	arg1	module					1576:1581	a carbohydrate-binding module	1553:1581	a carbohydrate-binding module that may assist in substrate recognition	1553:1622	Additional modeling analyses suggest the presence of a carbohydrate-binding module that may assist in substrate recognition.
36049519	2	2	theme	gut	344:346	arg1	environment					348:358	the gut environment	340:358	the gut environment	340:358	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	10	3	theme	modeling	1511:1518	arg1	analyses					1520:1527	Additional modeling analyses	1500:1527	Additional modeling analyses	1500:1527	Additional modeling analyses suggest the presence of a carbohydrate-binding module that may assist in substrate recognition.
36049519	8	4	dep	Tn-antigen	1391:1400	arg1	i.e.					1381:1384	i.e., the Tn-antigen	1381:1400	i.e.	1381:1384	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	6	5	theme	unique	970:975	arg1	support					925:931	structural and functional support	899:931	structural and functional support for the assignment of AMUC_1438	899:963	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	6	5	theme	unique	970:975	arg1	O-glycopeptidase					977:992	a unique O-glycopeptidase	968:992	a unique O-glycopeptidase with mucin-degrading capacity	968:1022	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	10	6	theme	substrate	1602:1610	arg1	recognition					1612:1622	substrate recognition	1602:1622	substrate recognition	1602:1622	Additional modeling analyses suggest the presence of a carbohydrate-binding module that may assist in substrate recognition.
36049519	5	7	contain	has	732:734	arg2	features					736:743	features	736:743	features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization	736:879	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	5	7	contain	has	732:734	arg1	protein					724:730	This uncharacterized protein	703:730	This uncharacterized protein	703:730	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	9	8	theme	bond	1443:1446	arg1	hydrolysis					1425:1434	hydrolysis	1425:1434	hydrolysis of the bond immediately N-terminal to the glycosylated residue	1425:1497	The enzyme catalyzes hydrolysis of the bond immediately N-terminal to the glycosylated residue.
36049519	4	9	theme	protein	582:588	arg1	AMUC_1438					590:598	The uncharacterized protein AMUC_1438	562:598	The uncharacterized protein AMUC_1438	562:598	The uncharacterized protein AMUC_1438 is encoded by a gene that was previously shown to be upregulated when the bacterium is grown on mucin.
36049519	8	10	link	α-linked	1348:1355	arg1	residue					1340:1346	a GalNAc residue	1331:1346	a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1331:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	7	11	theme	host-adapted	1121:1132	arg1	microbes					1134:1141	host-adapted microbes	1121:1141	host-adapted microbes that colonize or invade mucus layers	1121:1178	O-glycopeptidase enzymes recognize glycans but hydrolyze the peptide backbone and are common in host-adapted microbes that colonize or invade mucus layers.
36049519	8	12	theme	α-linked	1348:1355	arg1	residue					1340:1346	a GalNAc residue	1331:1346	a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1331:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	4	13	theme	uncharacterized	566:580	arg1	AMUC_1438					590:598	The uncharacterized protein AMUC_1438	562:598	The uncharacterized protein AMUC_1438	562:598	The uncharacterized protein AMUC_1438 is encoded by a gene that was previously shown to be upregulated when the bacterium is grown on mucin.
36049519	0	14	theme	bond	127:130	arg1	cleavage					103:110	cleavage	103:110	cleavage of the peptide bond	103:130	A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila requires the Tn-antigen for cleavage of the peptide bond.
36049519	0	15	from	muciniphila	63:73	arg1	O-glycopeptidase					29:44	A previously uncharacterized O-glycopeptidase	0:44	A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila	0:73	A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila requires the Tn-antigen for cleavage of the peptide bond.
36049519	2	16	from	abundant	328:335	arg1	ability					369:375	its ability to metabolize mucin as a nutrient source	365:416	its ability to metabolize mucin as a nutrient source	365:416	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	2	16	from	abundant	328:335	arg1	environment					348:358	the gut environment	340:358	the gut environment	340:358	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	1	17	theme	human	178:182	arg1	microbiota					188:197	the human gut microbiota	174:197	the human gut microbiota	174:197	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	0	18	theme	peptide	119:125	arg1	bond					127:130	the peptide bond	115:130	the peptide bond	115:130	A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila requires the Tn-antigen for cleavage of the peptide bond.
36049519	11	19	theme	wider	1683:1687	arg1	understanding					1689:1701	a wider understanding	1681:1701	a wider understanding of the O-glycopeptidase class of enzymes	1681:1742	We anticipate that these results will be fundamental to a wider understanding of the O-glycopeptidase class of enzymes and how they may contribute to host adaptation.
36049519	2	20	theme	bacterium	273:281	arg1	characteristic					250:263	A major characteristic	242:263	A major characteristic of this bacterium	242:281	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	2	20	theme	bacterium	273:281	arg1	interaction					290:300	its interaction	286:300	its interaction	286:300	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	1	21	theme	gut	184:186	arg1	microbiota					188:197	the human gut microbiota	174:197	the human gut microbiota	174:197	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	1	22	theme	microbiota	188:197	arg1	member					164:169	key member	160:169	key member of the human gut microbiota that impacts many features of host health	160:239	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	8	23	theme	kinetic	1193:1199	arg1	analyses					1216:1223	Structural, kinetic, and mutagenic analyses	1181:1223	Structural, kinetic, and mutagenic analyses	1181:1223	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	6	24	theme	AMUC_1438	955:963	arg1	assignment					941:950	the assignment	937:950	the assignment of AMUC_1438	937:963	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	8	25	theme	metalloprotease	1246:1260	arg1	motif					1272:1276	a metzincin metalloprotease catalytic motif	1234:1276	a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1234:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	8	26	theme	catalytic	1262:1270	arg1	motif					1272:1276	a metzincin metalloprotease catalytic motif	1234:1276	a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1234:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	8	27	theme	mutagenic	1206:1214	arg1	analyses					1216:1223	Structural, kinetic, and mutagenic analyses	1181:1223	Structural, kinetic, and mutagenic analyses	1181:1223	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	11	28	dep	fundamental	1666:1676	arg1	contribute					1761:1770	contribute	1761:1770	may contribute to host adaptation	1757:1789	We anticipate that these results will be fundamental to a wider understanding of the O-glycopeptidase class of enzymes and how they may contribute to host adaptation.
36049519	2	29	from	environment	348:358	arg1	abundant					328:335	abundant	328:335	abundant	328:335	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	2	30	theme	host	307:310	arg1	mucin					312:316	host mucin	307:316	host mucin	307:316	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	8	31	dep	threonine	1370:1378	arg1	Tn-antigen					1391:1400	the Tn-antigen	1387:1400	the Tn-antigen	1387:1400	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	2	32	theme	nutrient	402:409	arg1	mucin					391:395	mucin	391:395	mucin	391:395	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	2	32	theme	nutrient	402:409	arg1	source					411:416	a nutrient source	400:416	a nutrient source	400:416	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	7	33	theme	peptide	1086:1092	arg1	backbone					1094:1101	the peptide backbone	1082:1101	the peptide backbone	1082:1101	O-glycopeptidase enzymes recognize glycans but hydrolyze the peptide backbone and are common in host-adapted microbes that colonize or invade mucus layers.
36049519	7	34	from	microbes	1134:1141	arg1	common					1111:1116	common	1111:1116	common	1111:1116	O-glycopeptidase enzymes recognize glycans but hydrolyze the peptide backbone and are common in host-adapted microbes that colonize or invade mucus layers.
36049519	1	35	theme	many	212:215	arg1	features					217:224	many features	212:224	many features of host health	212:239	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	5	36	theme	carbohydrate-recognition	759:782	arg1	suggestive					745:754	suggestive	745:754	suggestive	745:754	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	7	37	from	common	1111:1116	arg1	microbes					1134:1141	host-adapted microbes	1121:1141	host-adapted microbes that colonize or invade mucus layers	1121:1178	O-glycopeptidase enzymes recognize glycans but hydrolyze the peptide backbone and are common in host-adapted microbes that colonize or invade mucus layers.
36049519	10	38	theme	Additional	1500:1509	arg1	analyses					1520:1527	Additional modeling analyses	1500:1527	Additional modeling analyses	1500:1527	Additional modeling analyses suggest the presence of a carbohydrate-binding module that may assist in substrate recognition.
36049519	9	39	theme	glycosylated	1478:1489	arg1	residue					1491:1497	the glycosylated residue	1474:1497	the glycosylated residue	1474:1497	The enzyme catalyzes hydrolysis of the bond immediately N-terminal to the glycosylated residue.
36049519	11	40	theme	enzymes	1736:1742	arg1	class					1727:1731	the O-glycopeptidase class	1706:1731	the O-glycopeptidase class of enzymes	1706:1742	We anticipate that these results will be fundamental to a wider understanding of the O-glycopeptidase class of enzymes and how they may contribute to host adaptation.
36049519	9	41	theme	N-terminal	1460:1469	arg1	bond					1443:1446	the bond	1439:1446	the bond immediately N-terminal to the glycosylated residue	1439:1497	The enzyme catalyzes hydrolysis of the bond immediately N-terminal to the glycosylated residue.
36049519	8	42	theme	active	1290:1295	arg1	site					1297:1300	an active site	1287:1300	an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1287:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	0	43	theme	uncharacterized	13:27	arg1	O-glycopeptidase					29:44	A previously uncharacterized O-glycopeptidase	0:44	A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila	0:73	A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila requires the Tn-antigen for cleavage of the peptide bond.
36049519	7	44	theme	mucus	1167:1171	arg1	layers					1173:1178	mucus layers	1167:1178	mucus layers	1167:1178	O-glycopeptidase enzymes recognize glycans but hydrolyze the peptide backbone and are common in host-adapted microbes that colonize or invade mucus layers.
36049519	11	45	theme	O-glycopeptidase	1710:1725	arg1	class					1727:1731	the O-glycopeptidase class	1706:1731	the O-glycopeptidase class of enzymes	1706:1742	We anticipate that these results will be fundamental to a wider understanding of the O-glycopeptidase class of enzymes and how they may contribute to host adaptation.
36049519	6	46	theme	mucin-degrading	999:1013	arg1	capacity					1015:1022	mucin-degrading capacity	999:1022	mucin-degrading capacity	999:1022	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	8	47	theme	Structural	1181:1190	arg1	analyses					1216:1223	Structural, kinetic, and mutagenic analyses	1181:1223	Structural, kinetic, and mutagenic analyses	1181:1223	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	5	48	theme	peptidase	788:796	arg1	activity					798:805	peptidase activity	788:805	peptidase activity	788:805	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	5	49	theme	mucin	858:862	arg1	depolymerization					864:879	mucin depolymerization	858:879	mucin depolymerization	858:879	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	10	50	theme	module	1576:1581	arg1	presence					1541:1548	the presence	1537:1548	the presence of a carbohydrate-binding module that may assist in substrate recognition	1537:1622	Additional modeling analyses suggest the presence of a carbohydrate-binding module that may assist in substrate recognition.
36049519	5	51	theme	activity	798:805	arg1	suggestive					745:754	suggestive	745:754	suggestive	745:754	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	6	52	theme	functional	914:923	arg1	support					925:931	structural and functional support	899:931	structural and functional support for the assignment of AMUC_1438	899:963	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	6	52	theme	functional	914:923	arg1	O-glycopeptidase					977:992	a unique O-glycopeptidase	968:992	a unique O-glycopeptidase with mucin-degrading capacity	968:1022	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	8	53	with	motif	1272:1276	arg1	site					1297:1300	an active site	1287:1300	an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1287:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	1	54	theme	Akkermansia	133:143	arg1	muciniphila					145:155	Akkermansia muciniphila	133:155	Akkermansia muciniphila	133:155	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	7	55	theme	O-glycopeptidase	1025:1040	arg1	enzymes					1042:1048	O-glycopeptidase enzymes	1025:1048	O-glycopeptidase enzymes	1025:1048	O-glycopeptidase enzymes recognize glycans but hydrolyze the peptide backbone and are common in host-adapted microbes that colonize or invade mucus layers.
36049519	2	56	from	ability	369:375	arg1	abundant					328:335	abundant	328:335	abundant	328:335	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	1	57	theme	host	229:232	arg1	health					234:239	host health	229:239	host health	229:239	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	8	58	theme	GalNAc	1333:1338	arg1	residue					1340:1346	a GalNAc residue	1331:1346	a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1331:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	5	59	from	role	850:853	arg1	depolymerization					864:879	mucin depolymerization	858:879	mucin depolymerization	858:879	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	1	60	theme	health	234:239	arg1	features					217:224	many features	212:224	many features of host health	212:239	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	9	61	gly	glycosylated	1478:1489	arg1	residue					1491:1497	the glycosylated residue	1474:1497	the glycosylated residue	1474:1497	The enzyme catalyzes hydrolysis of the bond immediately N-terminal to the glycosylated residue.
36049519	6	62	with	O-glycopeptidase	977:992	arg1	capacity					1015:1022	mucin-degrading capacity	999:1022	mucin-degrading capacity	999:1022	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	1	63	theme	key	160:162	arg1	member					164:169	key member	160:169	key member of the human gut microbiota that impacts many features of host health	160:239	Akkermansia muciniphila is key member of the human gut microbiota that impacts many features of host health.
36049519	8	64	theme	metzincin	1236:1244	arg1	motif					1272:1276	a metzincin metalloprotease catalytic motif	1234:1276	a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen)	1234:1401	Structural, kinetic, and mutagenic analyses point to a metzincin metalloprotease catalytic motif but with an active site that specifically recognizes a GalNAc residue α-linked to serine or threonine (i.e., the Tn-antigen).
36049519	2	65	with	interaction	290:300	arg1	mucin					312:316	host mucin	307:316	host mucin	307:316	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	5	66	contain	has	844:846	arg1	it					841:842	it	841:842	it	841:842	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	5	66	contain	has	844:846	arg2	role					850:853	a role	848:853	a role in mucin depolymerization	848:879	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
36049519	6	67	theme	structural	899:908	arg1	support					925:931	structural and functional support	899:931	structural and functional support for the assignment of AMUC_1438	899:963	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	6	67	theme	structural	899:908	arg1	O-glycopeptidase					977:992	a unique O-glycopeptidase	968:992	a unique O-glycopeptidase with mucin-degrading capacity	968:1022	Here, we provide structural and functional support for the assignment of AMUC_1438 as a unique O-glycopeptidase with mucin-degrading capacity.
36049519	2	68	theme	major	244:248	arg1	characteristic					250:263	A major characteristic	242:263	A major characteristic of this bacterium	242:281	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	2	68	theme	major	244:248	arg1	interaction					290:300	its interaction	286:300	its interaction	286:300	A major characteristic of this bacterium is its interaction with host mucin, which is abundant in the gut environment, and its ability to metabolize mucin as a nutrient source.
36049519	11	69	theme	host	1775:1778	arg1	adaptation					1780:1789	host adaptation	1775:1789	host adaptation	1775:1789	We anticipate that these results will be fundamental to a wider understanding of the O-glycopeptidase class of enzymes and how they may contribute to host adaptation.
36049519	11	70	theme	class	1727:1731	arg1	understanding					1689:1701	a wider understanding	1681:1701	a wider understanding of the O-glycopeptidase class of enzymes	1681:1742	We anticipate that these results will be fundamental to a wider understanding of the O-glycopeptidase class of enzymes and how they may contribute to host adaptation.
36049519	5	71	theme	uncharacterized	708:722	arg1	protein					724:730	This uncharacterized protein	703:730	This uncharacterized protein	703:730	This uncharacterized protein has features suggestive of carbohydrate-recognition and peptidase activity, which led us to hypothesize that it has a role in mucin depolymerization.
35776110	4	0	theme	isomeric	534:541	arg1	glycans					543:549	isomeric glycans	534:549	isomeric glycans from their MS/MS spectra in complex biological samples	534:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	5	1	theme	matching	697:704	arg1	glycan-spectrum					681:695	reciprocal best-hit glycan-spectrum matching	661:704	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans	653:754	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	5	1	theme	matching	697:704	arg1	RB-GSM					707:712	RB-GSM	707:712	RB-GSM	707:712	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	1	2	theme	biological	176:185	arg1	functions					187:195	many important biological functions	161:195	many important biological functions	161:195	Glycosylation is a post-translational modification involved in many important biological functions.
35776110	6	3	from	glycan	1172:1177	arg1	set					1227:1229	the input data set	1212:1229	the input data set	1212:1229	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	7	4	attach	released	1361:1368	arg2	those					1355:1359	those	1355:1359	those	1355:1359	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	7	4	attach	released	1361:1368	arg1	fetuin					1398:1403	the model glycoprotein fetuin	1375:1403	the model glycoprotein fetuin	1375:1403	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	7	4	attach	released	1361:1368	arg1	samples					1440:1446	human serum samples	1428:1446	human serum samples	1428:1446	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	7	4	attach	released	1361:1368	arg1	G					1421:1421	immunoglobulin G	1406:1421	immunoglobulin G	1406:1421	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	0	5	theme	Mass	79:82	arg1	Spectrometry					84:95	Tandem Mass Spectrometry	72:95	Tandem Mass Spectrometry	72:95	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans Using Tandem Mass Spectrometry.
35776110	6	6	theme	precursor	864:872	arg1	mass					874:877	the matched precursor mass	852:877	the matched precursor mass using customized scoring functions	852:912	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	7	theme	matched	1187:1193	arg1	spectra					1201:1207	all matched MS/MS spectra	1183:1207	all matched MS/MS spectra in the input data set	1183:1229	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	3	8	theme	mass	401:404	arg1	LC-MS/MS					420:427	LC-MS/MS	420:427	LC-MS/MS	420:427	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	3	8	theme	mass	401:404	arg1	spectrometry					406:417	Liquid chromatography tandem mass spectrometry	372:417	Liquid chromatography tandem mass spectrometry (LC-MS/MS)	372:428	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	6	9	theme	respective	1161:1170	arg1	glycan					1172:1177	the respective glycan	1157:1177	the respective glycan	1157:1177	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	10	theme	highest	1036:1042	arg1	score					1044:1048	the highest score	1032:1048	the highest score among not only the GSMs between the respective spectrum and all matched glycans	1032:1128	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	2	11	contain	possess	284:290	arg2	significance					302:313	potential significance	292:313	potential significance in medical diagnosis of complex diseases such as cancer	292:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	2	11	contain	possess	284:290	arg1	alteration					211:220	The aberrant alteration	198:220	The aberrant alteration of glycan structure	198:240	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	6	12	theme	matching	939:946	arg1	glycan-spectrum					923:937	a glycan-spectrum matching	921:946	a glycan-spectrum matching (GSM)	921:952	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	12	theme	matching	939:946	arg1	GSM					949:951	GSM	949:951	GSM	949:951	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	12	theme	matching	939:946	arg1	true					974:977	true	974:977	true	974:977	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	2	13	theme	medical	318:324	arg1	diagnosis					326:334	medical diagnosis	318:334	medical diagnosis of complex diseases such as cancer	318:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	6	14	theme	reciprocal	990:999	arg1	it					982:983	it	982:983	it	982:983	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	14	theme	reciprocal	990:999	arg1	best-hit					1001:1008	a reciprocal best-hit	988:1008	a reciprocal best-hit	988:1008	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	14	theme	reciprocal	990:999	arg1	receives					1023:1030	receives	1023:1030	receives the highest score among not only the GSMs between the respective spectrum and all matched glycans	1023:1128	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	3	15	theme	chromatography	379:392	arg1	LC-MS/MS					420:427	LC-MS/MS	420:427	LC-MS/MS	420:427	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	3	15	theme	chromatography	379:392	arg1	spectrometry					406:417	Liquid chromatography tandem mass spectrometry	372:417	Liquid chromatography tandem mass spectrometry (LC-MS/MS)	372:428	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	7	16	theme	serum	1434:1438	arg1	samples					1440:1446	human serum samples	1428:1446	human serum samples	1428:1446	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	5	17	theme	novel	655:659	arg1	approach					715:722	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach	653:722	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans	653:754	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	7	18	theme	glycoprotein	1385:1396	arg1	fetuin					1398:1403	the model glycoprotein fetuin	1375:1403	the model glycoprotein fetuin	1375:1403	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	7	19	gly	glycoprotein	1385:1396	arg1	glycoprotein					1385:1396	the model glycoprotein fetuin	1375:1403	the model glycoprotein fetuin	1375:1403	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	6	20	theme	input	1216:1220	arg1	set					1227:1229	the input data set	1212:1229	the input data set	1212:1229	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	3	21	theme	tandem	394:399	arg1	LC-MS/MS					420:427	LC-MS/MS	420:427	LC-MS/MS	420:427	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	3	21	theme	tandem	394:399	arg1	spectrometry					406:417	Liquid chromatography tandem mass spectrometry	372:417	Liquid chromatography tandem mass spectrometry (LC-MS/MS)	372:428	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	4	22	from	characterization	514:529	arg1	spectra					568:574	their MS/MS spectra	556:574	their MS/MS spectra in complex biological samples	556:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	3	23	theme	complex	475:481	arg1	samples					492:498	complex glycomic samples	475:498	complex glycomic samples	475:498	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	0	24	theme	Reciprocal	2:11	arg1	Approach					22:29	A Reciprocal Best-hit Approach	0:29	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans	0:64	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans Using Tandem Mass Spectrometry.
35776110	5	25	theme	best-hit	672:679	arg1	glycan-spectrum					681:695	reciprocal best-hit glycan-spectrum matching	661:704	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans	653:754	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	5	25	theme	best-hit	672:679	arg1	RB-GSM					707:712	RB-GSM	707:712	RB-GSM	707:712	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	5	26	attach	present	645:651	arg2	we					642:643	we	642:643	we	642:643	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	5	26	attach	present	645:651	arg1	paper					635:639	this paper	630:639	this paper	630:639	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	7	27	theme	model	1379:1383	arg1	fetuin					1398:1403	the model glycoprotein fetuin	1375:1403	the model glycoprotein fetuin	1375:1403	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	5	28	theme	glycan-spectrum	681:695	arg1	approach					715:722	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach	653:722	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans	653:754	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	2	29	theme	diseases	347:354	arg1	diagnosis					326:334	medical diagnosis	318:334	medical diagnosis of complex diseases such as cancer	318:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	7	30	theme	MS/MS	1299:1303	arg1	spectra					1305:1311	MS/MS spectra	1299:1311	MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans	1299:1517	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	4	31	theme	biological	587:596	arg1	samples					598:604	complex biological samples	579:604	complex biological samples	579:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	6	32	theme	MS/MS	1195:1199	arg1	spectra					1201:1207	all matched MS/MS spectra	1183:1207	all matched MS/MS spectra in the input data set	1183:1229	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	2	33	theme	complex	339:345	arg1	diseases					347:354	complex diseases	339:354	complex diseases such as cancer	339:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	2	33	theme	complex	339:345	arg1	cancer					364:369	cancer	364:369	cancer	364:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	6	34	with	glycans	839:845	arg1	mass					874:877	the matched precursor mass	852:877	the matched precursor mass using customized scoring functions	852:912	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	0	35	theme	Best-hit	13:20	arg1	Approach					22:29	A Reciprocal Best-hit Approach	0:29	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans	0:64	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans Using Tandem Mass Spectrometry.
35776110	7	36	theme	isomeric	1502:1509	arg1	glycans					1511:1517	isomeric glycans	1502:1517	isomeric glycans	1502:1517	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	6	37	dep	GSMs	1069:1072	arg1	only					1060:1063	only	1060:1063	only	1060:1063	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	7	38	theme	RB-GSM	1250:1255	arg1	approach					1257:1264	this RB-GSM approach	1245:1264	this RB-GSM approach on N-glycan identification	1245:1291	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	2	39	theme	aberrant	202:209	arg1	alteration					211:220	The aberrant alteration	198:220	The aberrant alteration of glycan structure	198:240	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	3	40	theme	glycomic	483:490	arg1	samples					492:498	complex glycomic samples	475:498	complex glycomic samples	475:498	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	6	41	from	spectra	783:789	arg1	set					809:811	the input data set	794:811	the input data set	794:811	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	7	42	dep	RB-GSM	1466:1471	arg1	capable					1476:1482	capable	1476:1482	capable	1476:1482	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	6	43	theme	scoring	896:902	arg1	functions					904:912	customized scoring functions	885:912	customized scoring functions	885:912	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	44	theme	data	804:807	arg1	set					809:811	the input data set	794:811	the input data set	794:811	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	3	45	theme	samples	492:498	arg1	analysis					463:470	the analysis	459:470	the analysis of complex glycomic samples	459:498	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	4	46	from	spectra	568:574	arg1	characterization					514:529	the characterization	510:529	the characterization of isomeric glycans from their MS/MS spectra in complex biological samples	510:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	4	46	from	spectra	568:574	arg1	glycans					543:549	isomeric glycans	534:549	isomeric glycans from their MS/MS spectra in complex biological samples	534:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	4	46	from	spectra	568:574	arg1	samples					598:604	complex biological samples	579:604	complex biological samples	579:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	4	47	theme	MS/MS	562:566	arg1	spectra					568:574	their MS/MS spectra	556:574	their MS/MS spectra in complex biological samples	556:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	7	48	theme	human	1428:1432	arg1	samples					1440:1446	human serum samples	1428:1446	human serum samples	1428:1446	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	6	49	theme	customized	885:894	arg1	functions					904:912	customized scoring functions	885:912	customized scoring functions	885:912	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	7	50	from	approach	1257:1264	arg1	identification					1278:1291	N-glycan identification	1269:1291	N-glycan identification	1269:1291	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	6	51	theme	input	798:802	arg1	set					809:811	the input data set	794:811	the input data set	794:811	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	1	52	theme	post-translational	117:134	arg1	Glycosylation					98:110	Glycosylation	98:110	Glycosylation	98:110	Glycosylation is a post-translational modification involved in many important biological functions.
35776110	1	52	theme	post-translational	117:134	arg1	modification					136:147	a post-translational modification	115:147	a post-translational modification involved in many important biological functions	115:195	Glycosylation is a post-translational modification involved in many important biological functions.
35776110	0	53	theme	Isomeric	47:54	arg1	N-Glycans					56:64	Isomeric N-Glycans	47:64	Isomeric N-Glycans	47:64	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans Using Tandem Mass Spectrometry.
35776110	4	54	theme	complex	579:585	arg1	samples					598:604	complex biological samples	579:604	complex biological samples	579:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	5	55	theme	reciprocal	661:670	arg1	glycan-spectrum					681:695	reciprocal best-hit glycan-spectrum matching	661:704	a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans	653:754	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	5	55	theme	reciprocal	661:670	arg1	RB-GSM					707:712	RB-GSM	707:712	RB-GSM	707:712	In this paper, we present a novel reciprocal best-hit glycan-spectrum matching (RB-GSM) approach toward characterizing N-glycans.
35776110	6	56	theme	matched	1114:1120	arg1	glycans					1122:1128	all matched glycans	1110:1128	all matched glycans	1110:1128	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	57	from	spectra	1201:1207	arg1	set					1227:1229	the input data set	1212:1229	the input data set	1212:1229	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	7	58	theme	glycan	1327:1332	arg1	standards					1334:1342	glycan standards	1327:1342	glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans	1327:1517	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	2	59	theme	structure	232:240	arg1	alteration					211:220	The aberrant alteration	198:220	The aberrant alteration of glycan structure	198:240	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	2	60	theme	potential	292:300	arg1	significance					302:313	potential significance	292:313	potential significance in medical diagnosis of complex diseases such as cancer	292:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	6	61	theme	data	1222:1225	arg1	set					1227:1229	the input data set	1212:1229	the input data set	1212:1229	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	2	62	from	significance	302:313	arg1	diagnosis					326:334	medical diagnosis	318:334	medical diagnosis of complex diseases such as cancer	318:369	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	2	63	theme	glycan	225:230	arg1	structure					232:240	glycan structure	225:240	glycan structure	225:240	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	7	64	theme	immunoglobulin	1406:1419	arg1	G					1421:1421	immunoglobulin G	1406:1421	immunoglobulin G	1406:1421	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	6	65	theme	respective	1086:1095	arg1	spectrum					1097:1104	the respective spectrum	1082:1104	the respective spectrum	1082:1104	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	0	66	theme	Tandem	72:77	arg1	Spectrometry					84:95	Tandem Mass Spectrometry	72:95	Tandem Mass Spectrometry	72:95	A Reciprocal Best-hit Approach to Characterize Isomeric N-Glycans Using Tandem Mass Spectrometry.
35776110	6	67	theme	matched	856:862	arg1	mass					874:877	the matched precursor mass	852:877	the matched precursor mass using customized scoring functions	852:912	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	6	68	theme	MS/MS	777:781	arg1	spectra					783:789	the MS/MS spectra	773:789	the MS/MS spectra in the input data set	773:811	In this method, the MS/MS spectra in the input data set are evaluated against all glycans with the matched precursor mass using customized scoring functions, where a glycan-spectrum matching (GSM) is considered to be true if it is a reciprocal best-hit, that is, it receives the highest score among not only the GSMs between the respective spectrum and all matched glycans, but also the GSMs between the respective glycan and all matched MS/MS spectra in the input data set.
35776110	1	69	theme	many	161:164	arg1	functions					187:195	many important biological functions	161:195	many important biological functions	161:195	Glycosylation is a post-translational modification involved in many important biological functions.
35776110	7	70	theme	N-glycan	1269:1276	arg1	identification					1278:1291	N-glycan identification	1269:1291	N-glycan identification	1269:1291	We evaluated this RB-GSM approach on N-glycan identification using MS/MS spectra acquired from glycan standards as well as those released from the model glycoprotein fetuin, immunoglobulin G, and human serum samples, which showed the RB-GSM is capable of distinguishing isomeric glycans.
35776110	3	71	theme	Liquid	372:377	arg1	LC-MS/MS					420:427	LC-MS/MS	420:427	LC-MS/MS	420:427	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	3	71	theme	Liquid	372:377	arg1	spectrometry					406:417	Liquid chromatography tandem mass spectrometry	372:417	Liquid chromatography tandem mass spectrometry (LC-MS/MS)	372:428	Liquid chromatography tandem mass spectrometry (LC-MS/MS) has been commonly applied to the analysis of complex glycomic samples.
35776110	4	72	theme	glycans	543:549	arg1	characterization					514:529	the characterization	510:529	the characterization of isomeric glycans from their MS/MS spectra in complex biological samples	510:604	However, the characterization of isomeric glycans from their MS/MS spectra in complex biological samples remains challenging.
35776110	2	73	theme	cells	274:278	arg1	malfunction					259:269	malfunction	259:269	malfunction of cells	259:278	The aberrant alteration of glycan structure is implicit with malfunction of cells and possess potential significance in medical diagnosis of complex diseases such as cancer.
35776110	1	74	theme	important	166:174	arg1	functions					187:195	many important biological functions	161:195	many important biological functions	161:195	Glycosylation is a post-translational modification involved in many important biological functions.
37289534	2	0	theme	lipid	336:340	arg1	derivatives					344:354	two monodisperse lipid A derivatives	319:354	two monodisperse lipid A derivatives based on simplified bacterial LPS structures	319:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	0	1	theme	Aqueous	75:81	arg1	Solutions					83:91	Aqueous Solutions	75:91	Aqueous Solutions	75:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	4	2	theme	Kdo2-lipid	858:867	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	2	theme	Kdo2-lipid	858:867	arg1	A					869:869	Kdo2-lipid A	858:869	Kdo2-lipid A	858:869	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	2	3	theme	monodisperse	323:334	arg1	derivatives					344:354	two monodisperse lipid A derivatives	319:354	two monodisperse lipid A derivatives based on simplified bacterial LPS structures	319:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	2	4	from	self-assembly	293:305	arg1	water					310:314	water	310:314	water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures	310:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	2	5	theme	cryogenic	506:514	arg1	microscopy					538:547	cryogenic transmission electron microscopy	506:547	cryogenic transmission electron microscopy	506:547	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	0	6	from	Effect	0:5	arg1	Self-Assembly					27:39	Self-Assembly	27:39	Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions	27:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	2	7	dep	Escherichia	446:456	arg1	coli					458:461	coli	458:461	coli	458:461	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	4	8	theme	synthetic	768:776	arg1	analogues					778:786	the synthetic analogues	764:786	the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A)	764:897	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	1	9	theme	simpler	240:246	arg1	components					258:267	simpler synthetic components	240:267	simpler synthetic components	240:267	Lipopolysaccharides (LPSs) based on lipid A produced by bacteria are of interest due to their bioactivity in stimulating immune responses, as are simpler synthetic components or analogues.
37289534	1	10	theme	synthetic	248:256	arg1	components					258:267	simpler synthetic components	240:267	simpler synthetic components	240:267	Lipopolysaccharides (LPSs) based on lipid A produced by bacteria are of interest due to their bioactivity in stimulating immune responses, as are simpler synthetic components or analogues.
37289534	4	11	theme	head	845:848	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	11	theme	head	845:848	arg1	A					869:869	Kdo2-lipid A	858:869	Kdo2-lipid A	858:869	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	11	theme	head	845:848	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	12	dep	E.	708:709	arg1	coli					711:714	coli	711:714	coli	711:714	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	2	13	theme	bacterial	376:384	arg1	structures					390:399	simplified bacterial LPS structures	365:399	simplified bacterial LPS structures	365:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	2	14	theme	X-ray	485:489	arg1	scattering					491:500	small-angle X-ray scattering	473:500	small-angle X-ray scattering	473:500	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	4	15	theme	saccharide	834:843	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	15	theme	saccharide	834:843	arg1	A					869:869	Kdo2-lipid A	858:869	Kdo2-lipid A	858:869	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	15	theme	saccharide	834:843	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	2	16	theme	simplified	365:374	arg1	structures					390:399	simplified bacterial LPS structures	365:399	simplified bacterial LPS structures	365:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	0	17	from	Self-Assembly	27:39	arg1	Solutions					83:91	Aqueous Solutions	75:91	Aqueous Solutions	75:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	3	18	theme	aggregation	563:573	arg1	concentration					575:587	The critical aggregation concentration	550:587	The critical aggregation concentration	550:587	The critical aggregation concentration is obtained from fluorescence probe experiments, and conformation is probed using circular dichroism spectroscopy.
37289534	4	19	dep	groups	850:855	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	19	dep	groups	850:855	arg1	A					869:869	Kdo2-lipid A	858:869	Kdo2-lipid A	858:869	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	19	dep	groups	850:855	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	20	theme	wormlike	737:744	arg1	micelles					746:753	wormlike micelles	737:753	wormlike micelles	737:753	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	5	21	theme	surfactant	1011:1020	arg1	parameter					1030:1038	the surfactant packing parameter	1007:1038	the surfactant packing parameter	1007:1038	These observations are rationalized by considering the surfactant packing parameter.
37289534	0	22	theme	Glycosylation	10:22	arg1	Effect					0:5	Effect	0:5	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.	0:92	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	0	23	from	Solutions	83:91	arg1	Self-Assembly					27:39	Self-Assembly	27:39	Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions	27:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	3	24	theme	critical	554:561	arg1	concentration					575:587	The critical aggregation concentration	550:587	The critical aggregation concentration	550:587	The critical aggregation concentration is obtained from fluorescence probe experiments, and conformation is probed using circular dichroism spectroscopy.
37289534	4	25	theme	E.	708:709	arg1	LPS					716:718	The E. coli LPS	704:718	The E. coli LPS	704:718	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	2	26	theme	Escherichia	446:456	arg1	LPS					463:465	a native Escherichia coli LPS	437:465	a native Escherichia coli LPS	437:465	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	2	27	theme	electron	529:536	arg1	microscopy					538:547	cryogenic transmission electron microscopy	506:547	cryogenic transmission electron microscopy	506:547	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	4	28	theme	four	822:825	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	28	theme	four	822:825	arg1	A					869:869	Kdo2-lipid A	858:869	Kdo2-lipid A	858:869	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	28	theme	four	822:825	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	2	29	theme	native	439:444	arg1	LPS					463:465	a native Escherichia coli LPS	437:465	a native Escherichia coli LPS	437:465	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	2	30	theme	transmission	516:527	arg1	microscopy					538:547	cryogenic transmission electron microscopy	506:547	cryogenic transmission electron microscopy	506:547	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	3	31	theme	fluorescence	606:617	arg1	experiments					625:635	fluorescence probe experiments	606:635	fluorescence probe experiments	606:635	The critical aggregation concentration is obtained from fluorescence probe experiments, and conformation is probed using circular dichroism spectroscopy.
37289534	2	32	theme	LPS	386:388	arg1	structures					390:399	simplified bacterial LPS structures	365:399	simplified bacterial LPS structures	365:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	0	33	theme	A	50:50	arg1	Lipopolysaccharides					52:70	Lipid A Lipopolysaccharides	44:70	Lipid A Lipopolysaccharides in Aqueous Solutions	44:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	0	34	from	Lipopolysaccharides	52:70	arg1	Solutions					83:91	Aqueous Solutions	75:91	Aqueous Solutions	75:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	4	35	theme	two	830:832	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	35	theme	two	830:832	arg1	A					869:869	Kdo2-lipid A	858:869	Kdo2-lipid A	858:869	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	35	theme	two	830:832	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	0	36	theme	Lipid	44:48	arg1	Lipopolysaccharides					52:70	Lipid A Lipopolysaccharides	44:70	Lipid A Lipopolysaccharides in Aqueous Solutions	44:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	4	37	theme	lipid	890:894	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	37	theme	lipid	890:894	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	38	theme	monophosphoryl	875:888	arg1	groups					850:855	four or two saccharide head groups	822:855	groups	850:855	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	38	theme	monophosphoryl	875:888	arg1	A					896:896	monophosphoryl lipid A	875:896	monophosphoryl lipid A	875:896	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	4	39	theme	lipid	800:804	arg1	chains					806:811	six lipid chains	796:811	six lipid chains	796:811	The E. coli LPS is found to form wormlike micelles, whereas the synthetic analogues bearing six lipid chains and with four or two saccharide head groups (Kdo2-lipid A and monophosphoryl lipid A) self-assemble into nanosheets or vesicles, respectively.
37289534	3	40	theme	circular	671:678	arg1	spectroscopy					690:701	circular dichroism spectroscopy	671:701	circular dichroism spectroscopy	671:701	The critical aggregation concentration is obtained from fluorescence probe experiments, and conformation is probed using circular dichroism spectroscopy.
37289534	1	41	theme	lipid	130:134	arg1	A					136:136	lipid A	130:136	lipid A produced by bacteria	130:157	Lipopolysaccharides (LPSs) based on lipid A produced by bacteria are of interest due to their bioactivity in stimulating immune responses, as are simpler synthetic components or analogues.
37289534	1	42	theme	immune	215:220	arg1	responses					222:230	immune responses	215:230	immune responses	215:230	Lipopolysaccharides (LPSs) based on lipid A produced by bacteria are of interest due to their bioactivity in stimulating immune responses, as are simpler synthetic components or analogues.
37289534	2	43	theme	small-angle	473:483	arg1	scattering					491:500	small-angle X-ray scattering	473:500	small-angle X-ray scattering	473:500	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	3	44	theme	dichroism	680:688	arg1	spectroscopy					690:701	circular dichroism spectroscopy	671:701	circular dichroism spectroscopy	671:701	The critical aggregation concentration is obtained from fluorescence probe experiments, and conformation is probed using circular dichroism spectroscopy.
37289534	3	45	theme	probe	619:623	arg1	experiments					625:635	fluorescence probe experiments	606:635	fluorescence probe experiments	606:635	The critical aggregation concentration is obtained from fluorescence probe experiments, and conformation is probed using circular dichroism spectroscopy.
37289534	2	46	theme	derivatives	344:354	arg1	water					310:314	water	310:314	water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures	310:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
37289534	0	47	theme	Lipopolysaccharides	52:70	arg1	Self-Assembly					27:39	Self-Assembly	27:39	Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions	27:91	Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aqueous Solutions.
37289534	5	48	theme	packing	1022:1028	arg1	parameter					1030:1038	the surfactant packing parameter	1007:1038	the surfactant packing parameter	1007:1038	These observations are rationalized by considering the surfactant packing parameter.
37289534	2	49	theme	A	342:342	arg1	derivatives					344:354	two monodisperse lipid A derivatives	319:354	two monodisperse lipid A derivatives based on simplified bacterial LPS structures	319:399	Here, the self-assembly in water of two monodisperse lipid A derivatives based on simplified bacterial LPS structures is examined and compared to that of a native Escherichia coli LPS using small-angle X-ray scattering and cryogenic transmission electron microscopy.
35696957	6	0	with	droplets	1007:1014	arg1	distribution					1031:1042	monomodal distribution	1021:1042	monomodal distribution	1021:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	1	theme	mean	949:952	arg1	363.07 ± 34.56 nm					968:984	363.07 ± 34.56 nm	968:984	363.07 ± 34.56 nm	968:984	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	1	theme	mean	949:952	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	1	theme	mean	949:952	arg1	potential					1062:1070	the highest zeta potential	1045:1070	the highest zeta potential (-27.70 ± 0.70 mV)	1045:1089	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	1	theme	mean	949:952	arg1	stability					1105:1113	high storage stability	1092:1113	high storage stability (no creaming or oil-off)	1092:1138	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	1	theme	mean	949:952	arg1	droplets					1007:1014	orderly-packed oil droplets	988:1014	orderly-packed oil droplets with monomodal distribution	988:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	4	2	theme	emulsifying	732:742	arg1	properties					744:753	emulsifying properties	732:753	emulsifying properties	732:753	Under the optimized reaction conditions, SC-AHSG conjugates exhibited the highest glycation degree and emulsifying properties.
35696957	5	3	theme	physical	854:861	arg1	stability					863:871	physical stability	854:871	physical stability	854:871	Next, HIPEs were made using the optimized conjugates, and their microstructure, droplet size, and physical stability were evaluated.
35696957	1	4	theme	emulsions	170:178	arg1	production					132:141	the production	128:141	the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates	128:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	7	5	theme	emulsion-based	1249:1262	arg1	foods					1264:1268	emulsion-based foods	1249:1268	emulsion-based foods with novel functionality	1249:1293	Results of this research are helpful for development of emulsion-based foods with novel functionality.
35696957	6	6	theme	lowest	942:947	arg1	363.07 ± 34.56 nm					968:984	363.07 ± 34.56 nm	968:984	363.07 ± 34.56 nm	968:984	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	6	theme	lowest	942:947	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	6	theme	lowest	942:947	arg1	potential					1062:1070	the highest zeta potential	1045:1070	the highest zeta potential (-27.70 ± 0.70 mV)	1045:1089	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	6	theme	lowest	942:947	arg1	stability					1105:1113	high storage stability	1092:1113	high storage stability (no creaming or oil-off)	1092:1138	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	6	theme	lowest	942:947	arg1	droplets					1007:1014	orderly-packed oil droplets	988:1014	orderly-packed oil droplets with monomodal distribution	988:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	7	theme	no	1116:1117	arg1	creaming					1119:1126	no creaming	1116:1126	no creaming	1116:1126	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	8	theme	highest	1049:1055	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	8	theme	highest	1049:1055	arg1	-27.70 ± 0.70 mV					1073:1088	-27.70 ± 0.70 mV	1073:1088	-27.70 ± 0.70 mV	1073:1088	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	8	theme	highest	1049:1055	arg1	potential					1062:1070	the highest zeta potential	1045:1070	the highest zeta potential (-27.70 ± 0.70 mV)	1045:1089	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	2	9	theme	SPI	313:315	arg1	proteins					343:350	soy protein isolate (SPI) or sodium caseinate (SC) proteins	292:350	soy protein isolate (SPI) or sodium caseinate (SC) proteins	292:350	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	3	10	dep	transform	521:529	arg1	infrared					531:538	infrared	531:538	infrared	531:538	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	6	11	theme	monomodal	1021:1029	arg1	distribution					1031:1042	monomodal distribution	1021:1042	monomodal distribution	1021:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	2	12	theme	Alyssum	356:362	arg1	AHSG					387:390	Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides	356:433	AHSG	387:390	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	4	13	theme	reaction	649:656	arg1	conditions					658:667	the optimized reaction conditions	635:667	the optimized reaction conditions	635:667	Under the optimized reaction conditions, SC-AHSG conjugates exhibited the highest glycation degree and emulsifying properties.
35696957	2	14	theme	isolate	304:310	arg1	SPI					313:315	soy protein isolate (SPI) or sodium caseinate	292:336	SPI	313:315	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	2	14	theme	isolate	304:310	arg1	SC					339:340	SC	339:340	SC	339:340	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	4	15	theme	highest	703:709	arg1	degree					721:726	the highest glycation degree	699:726	the highest glycation degree	699:726	Under the optimized reaction conditions, SC-AHSG conjugates exhibited the highest glycation degree and emulsifying properties.
35696957	6	16	theme	SC-AHSG	916:922	arg1	conjugate					924:932	SC-AHSG conjugate	916:932	SC-AHSG conjugate	916:932	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	5	17	theme	droplet	836:842	arg1	size					844:847	droplet size	836:847	droplet size	836:847	Next, HIPEs were made using the optimized conjugates, and their microstructure, droplet size, and physical stability were evaluated.
35696957	2	18	theme	protein	296:302	arg1	SPI					313:315	soy protein isolate (SPI) or sodium caseinate	292:336	SPI	313:315	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	2	18	theme	protein	296:302	arg1	SC					339:340	SC	339:340	SC	339:340	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	0	19	theme	high	13:16	arg1	emulsions					33:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	7	20	theme	foods	1264:1268	arg1	development					1234:1244	development	1234:1244	development of emulsion-based foods with novel functionality	1234:1293	Results of this research are helpful for development of emulsion-based foods with novel functionality.
35696957	2	21	theme	caseinate	328:336	arg1	proteins					343:350	soy protein isolate (SPI) or sodium caseinate (SC) proteins	292:350	soy protein isolate (SPI) or sodium caseinate (SC) proteins	292:350	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	4	22	theme	SC-AHSG	670:676	arg1	conjugates					678:687	SC-AHSG conjugates	670:687	SC-AHSG conjugates	670:687	Under the optimized reaction conditions, SC-AHSG conjugates exhibited the highest glycation degree and emulsifying properties.
35696957	0	23	theme	Ultra-stable	0:11	arg1	emulsions					33:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	7	24	theme	novel	1275:1279	arg1	functionality					1281:1293	novel functionality	1275:1293	novel functionality	1275:1293	Results of this research are helpful for development of emulsion-based foods with novel functionality.
35696957	2	25	theme	sodium	321:326	arg1	caseinate					328:336	soy protein isolate (SPI) or sodium caseinate	292:336	caseinate	328:336	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	2	26	theme	gum	382:384	arg1	AHSG					387:390	Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides	356:433	AHSG	387:390	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	0	27	theme	phase	27:31	arg1	emulsions					33:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	6	28	theme	oil	1003:1005	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	28	theme	oil	1003:1005	arg1	droplets					1007:1014	orderly-packed oil droplets	988:1014	orderly-packed oil droplets with monomodal distribution	988:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	3	29	dep	Fourier	513:519	arg1	transform					521:529	transform	521:529	transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry	521:626	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	2	30	theme	kC	415:416	arg1	polysaccharides					419:433	Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides	356:433	polysaccharides	419:433	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	0	31	theme	internal	18:25	arg1	emulsions					33:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions	0:41	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	6	32	theme	orderly-packed	988:1001	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	32	theme	orderly-packed	988:1001	arg1	droplets					1007:1014	orderly-packed oil droplets	988:1014	orderly-packed oil droplets with monomodal distribution	988:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	2	33	theme	seed	377:380	arg1	AHSG					387:390	Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides	356:433	AHSG	387:390	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	3	34	theme	fluorescence	561:572	arg1	spectroscopies					574:587	fluorescence spectroscopies	561:587	fluorescence spectroscopies	561:587	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	1	35	theme	Maillard	225:232	arg1	conjugates					234:243	protein-anionic polysaccharide Maillard conjugates	194:243	protein-anionic polysaccharide Maillard conjugates	194:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	3	36	theme	conjugation	440:450	arg1	process					452:458	The conjugation process	436:458	The conjugation process	436:458	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	3	37	theme	scanning	607:614	arg1	calorimetry					616:626	differential scanning calorimetry	594:626	differential scanning calorimetry	594:626	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	1	38	theme	protein-anionic	194:208	arg1	conjugates					234:243	protein-anionic polysaccharide Maillard conjugates	194:243	protein-anionic polysaccharide Maillard conjugates	194:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	2	39	theme	kappa-carrageenan	396:412	arg1	polysaccharides					419:433	Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides	356:433	polysaccharides	419:433	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	6	40	theme	storage	1097:1103	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	40	theme	storage	1097:1103	arg1	stability					1105:1113	high storage stability	1092:1113	high storage stability (no creaming or oil-off)	1092:1138	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	2	41	theme	Maillard	253:260	arg1	conjugates					262:271	Maillard conjugates	253:271	Maillard conjugates	253:271	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	6	42	contain	had	934:936	arg2	potential					1062:1070	the highest zeta potential	1045:1070	the highest zeta potential (-27.70 ± 0.70 mV)	1045:1089	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	42	contain	had	934:936	arg1	ultra-stable					1148:1159	ultra-stable	1148:1159	ultra-stable	1148:1159	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	42	contain	had	934:936	arg2	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	42	contain	had	934:936	arg2	stability					1105:1113	high storage stability	1092:1113	high storage stability (no creaming or oil-off)	1092:1138	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	42	contain	had	934:936	arg2	363.07 ± 34.56 nm					968:984	363.07 ± 34.56 nm	968:984	363.07 ± 34.56 nm	968:984	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	42	contain	had	934:936	arg2	droplets					1007:1014	orderly-packed oil droplets	988:1014	orderly-packed oil droplets with monomodal distribution	988:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	42	contain	had	934:936	arg1	emulsion					893:900	The emulsion	889:900	The emulsion stabilized by SC-AHSG conjugate	889:932	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	0	43	theme	protein-anionic	57:71	arg1	conjugates					97:106	protein-anionic polysaccharide Maillard conjugates	57:106	protein-anionic polysaccharide Maillard conjugates	57:106	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	5	44	theme	optimized	788:796	arg1	conjugates					798:807	the optimized conjugates	784:807	the optimized conjugates	784:807	Next, HIPEs were made using the optimized conjugates, and their microstructure, droplet size, and physical stability were evaluated.
35696957	6	45	theme	high	1092:1095	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	45	theme	high	1092:1095	arg1	stability					1105:1113	high storage stability	1092:1113	high storage stability (no creaming or oil-off)	1092:1138	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	46	theme	droplet	954:960	arg1	363.07 ± 34.56 nm					968:984	363.07 ± 34.56 nm	968:984	363.07 ± 34.56 nm	968:984	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	46	theme	droplet	954:960	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	46	theme	droplet	954:960	arg1	potential					1062:1070	the highest zeta potential	1045:1070	the highest zeta potential (-27.70 ± 0.70 mV)	1045:1089	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	46	theme	droplet	954:960	arg1	stability					1105:1113	high storage stability	1092:1113	high storage stability (no creaming or oil-off)	1092:1138	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	46	theme	droplet	954:960	arg1	droplets					1007:1014	orderly-packed oil droplets	988:1014	orderly-packed oil droplets with monomodal distribution	988:1042	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	47	dep	stability	1105:1113	arg1	oil-off					1131:1137	oil-off	1131:1137	oil-off	1131:1137	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	47	dep	stability	1105:1113	arg1	creaming					1119:1126	no creaming	1116:1126	no creaming	1116:1126	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	3	48	theme	differential	594:605	arg1	calorimetry					616:626	differential scanning calorimetry	594:626	differential scanning calorimetry	594:626	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	3	49	theme	UV	491:492	arg1	Fourier					513:519	Fourier	513:519	Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry	513:626	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	3	49	theme	UV	491:492	arg1	spectrophotometry					494:510	UV spectrophotometry	491:510	UV spectrophotometry	491:510	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	2	50	theme	soy	292:294	arg1	SPI					313:315	soy protein isolate (SPI) or sodium caseinate	292:336	SPI	313:315	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	2	50	theme	soy	292:294	arg1	SC					339:340	SC	339:340	SC	339:340	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	4	51	theme	glycation	711:719	arg1	degree					721:726	the highest glycation degree	699:726	the highest glycation degree	699:726	Under the optimized reaction conditions, SC-AHSG conjugates exhibited the highest glycation degree and emulsifying properties.
35696957	1	52	theme	O/W	146:148	arg1	HIPEs					181:185	HIPEs	181:185	HIPEs	181:185	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	1	52	theme	O/W	146:148	arg1	emulsions					170:178	O/W high internal phase emulsions	146:178	O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates	146:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	6	53	theme	environmental	1169:1181	arg1	stresses					1183:1190	environmental stresses	1169:1190	environmental stresses	1169:1190	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	2	54	dep	Alyssum	356:362	arg1	homolocarpum					364:375	homolocarpum	364:375	homolocarpum	364:375	First, Maillard conjugates were prepared from soy protein isolate (SPI) or sodium caseinate (SC) proteins and Alyssum homolocarpum seed gum (AHSG) or kappa-carrageenan (kC) polysaccharides.
35696957	1	55	theme	high	150:153	arg1	HIPEs					181:185	HIPEs	181:185	HIPEs	181:185	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	1	55	theme	high	150:153	arg1	emulsions					170:178	O/W high internal phase emulsions	146:178	O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates	146:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	6	56	theme	zeta	1057:1060	arg1	size					962:965	the lowest mean droplet size	938:965	the lowest mean droplet size (363.07 ± 34.56 nm)	938:985	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	56	theme	zeta	1057:1060	arg1	-27.70 ± 0.70 mV					1073:1088	-27.70 ± 0.70 mV	1073:1088	-27.70 ± 0.70 mV	1073:1088	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	6	56	theme	zeta	1057:1060	arg1	potential					1062:1070	the highest zeta potential	1045:1070	the highest zeta potential (-27.70 ± 0.70 mV)	1045:1089	The emulsion stabilized by SC-AHSG conjugate had the lowest mean droplet size (363.07 ± 34.56 nm), orderly-packed oil droplets with monomodal distribution, the highest zeta potential (-27.70 ± 0.70 mV), high storage stability (no creaming or oil-off) and was ultra-stable against environmental stresses.
35696957	0	57	theme	Maillard	88:95	arg1	conjugates					97:106	protein-anionic polysaccharide Maillard conjugates	57:106	protein-anionic polysaccharide Maillard conjugates	57:106	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	7	58	with	foods	1264:1268	arg1	functionality					1281:1293	novel functionality	1275:1293	novel functionality	1275:1293	Results of this research are helpful for development of emulsion-based foods with novel functionality.
35696957	1	59	theme	polysaccharide	210:223	arg1	conjugates					234:243	protein-anionic polysaccharide Maillard conjugates	194:243	protein-anionic polysaccharide Maillard conjugates	194:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	1	60	theme	internal	155:162	arg1	HIPEs					181:185	HIPEs	181:185	HIPEs	181:185	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	1	60	theme	internal	155:162	arg1	emulsions					170:178	O/W high internal phase emulsions	146:178	O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates	146:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	4	61	theme	optimized	639:647	arg1	conditions					658:667	the optimized reaction conditions	635:667	the optimized reaction conditions	635:667	Under the optimized reaction conditions, SC-AHSG conjugates exhibited the highest glycation degree and emulsifying properties.
35696957	0	62	theme	polysaccharide	73:86	arg1	conjugates					97:106	protein-anionic polysaccharide Maillard conjugates	57:106	protein-anionic polysaccharide Maillard conjugates	57:106	Ultra-stable high internal phase emulsions stabilized by protein-anionic polysaccharide Maillard conjugates.
35696957	3	63	theme	circular	541:548	arg1	dichroism					550:558	circular dichroism	541:558	circular dichroism	541:558	The conjugation process was confirmed and monitored by UV spectrophotometry, Fourier transform infrared, circular dichroism, fluorescence spectroscopies, and differential scanning calorimetry.
35696957	1	64	theme	phase	164:168	arg1	HIPEs					181:185	HIPEs	181:185	HIPEs	181:185	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	1	64	theme	phase	164:168	arg1	emulsions					170:178	O/W high internal phase emulsions	146:178	O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates	146:243	This paper reports the production of O/W high internal phase emulsions (HIPEs) using protein-anionic polysaccharide Maillard conjugates.
35696957	7	65	theme	research	1209:1216	arg1	Results					1193:1199	Results	1193:1199	Results of this research	1193:1216	Results of this research are helpful for development of emulsion-based foods with novel functionality.
35473855	3	0	theme	comprehensive	532:544	arg1	characterization					546:561	a rapid and comprehensive characterization	520:561	a rapid and comprehensive characterization of glycan isomers	520:579	However, a rapid and comprehensive characterization of glycan isomers can be challenging owing to limitations associated with their separation.
35473855	1	1	theme	cell-to-cell	262:273	arg1	signaling					275:283	cell-to-cell signaling	262:283	cell-to-cell signaling	262:283	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	8	2	contain	has	1508:1510	arg1	spectrum					1499:1506	Each DMS spectrum	1490:1506	Each DMS spectrum	1490:1506	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	8	2	contain	has	1508:1510	arg2	peak					1541:1544	at least one differentiating peak	1512:1544	at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers	1512:1692	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	7	3	theme	disaccharide	1163:1174	arg1	concentrations					1176:1189	relatively high disaccharide concentrations	1147:1189	relatively high disaccharide concentrations	1147:1189	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	9	4	theme	disaccharide	1713:1724	arg1	concentrations					1726:1739	relatively low disaccharide concentrations	1698:1739	relatively low disaccharide concentrations	1698:1739	At relatively low disaccharide concentrations, mixtures of disaccharide epimers can also be readily separated by DMS.
35473855	4	5	theme	disaccharide	704:715	arg1	isomers					717:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	2	6	theme	Functional	286:295	arg1	specificity					297:307	Functional specificity	286:307	Functional specificity	286:307	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	6	7	from	gas	1112:1114	arg1	fraction					1074:1081	the fraction	1070:1081	the fraction of helium in the ion carrier gas	1070:1114	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	10	8	theme	high-resolution	1832:1846	arg1	DMS					1866:1868	high-resolution, ambient pressure DMS	1832:1868	high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows	1832:1970	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	1	9	theme	specific	198:205	arg1	roles					219:223	specific and general roles	198:223	specific and general roles involving metabolism, structure, and cell-to-cell signaling	198:283	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	7	10	theme	bound	1455:1459	arg1	oligomers					1461:1469	ionic non-covalently bound oligomers	1434:1469	ionic non-covalently bound oligomers	1434:1469	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	10	11	dep	high-resolution	1832:1846	arg1	ambient					1849:1855	ambient	1849:1855	ambient	1849:1855	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	10	12	theme	biomolecules	2049:2060	arg1	characterization					2004:2019	the characterization	2000:2019	the characterization of glycans and glycosylated biomolecules	2000:2060	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	1	13	theme	general	211:217	arg1	roles					219:223	specific and general roles	198:223	specific and general roles involving metabolism, structure, and cell-to-cell signaling	198:283	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	10	14	with	DMS	1866:1868	arg1	glycomics					1932:1940	complementary reduced-pressure ion mobility and MS-based glycomics	1875:1940	glycomics	1932:1940	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	10	14	with	DMS	1866:1868	arg1	workflows					1962:1970	glycoproteomics workflows	1946:1970	glycoproteomics workflows	1946:1970	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	10	14	with	DMS	1866:1868	arg1	mobility					1910:1917	complementary reduced-pressure ion mobility and MS-based glycomics	1875:1940	mobility	1910:1917	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	9	15	theme	epimers	1767:1773	arg1	mixtures					1742:1749	mixtures	1742:1749	mixtures of disaccharide epimers	1742:1773	At relatively low disaccharide concentrations, mixtures of disaccharide epimers can also be readily separated by DMS.
35473855	7	16	theme	ionic	1434:1438	arg1	oligomers					1461:1469	ionic non-covalently bound oligomers	1434:1469	ionic non-covalently bound oligomers	1434:1469	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	10	17	theme	DMS	1866:1868	arg1	useful					1979:1984	useful	1979:1984	useful	1979:1984	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	10	17	theme	DMS	1866:1868	arg1	integration					1817:1827	The integration	1813:1827	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows	1813:1970	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	6	18	theme	DMS	1005:1007	arg1	power					1019:1023	DMS resolving power	1005:1023	DMS resolving power	1005:1023	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	7	19	with	spectra	1262:1268	arg1	peaks					1314:1318	up to ten fully and partially resolved peaks	1275:1318	up to ten fully and partially resolved peaks	1275:1318	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	4	20	theme	differential	775:786	arg1	spectrometry					806:817	high-resolution differential ion mobility-mass spectrometry	759:817	high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS)	759:847	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	4	21	theme	mobility-mass	792:804	arg1	spectrometry					806:817	high-resolution differential ion mobility-mass spectrometry	759:817	high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS)	759:847	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	10	22	theme	ion	1906:1908	arg1	mobility					1910:1917	complementary reduced-pressure ion mobility and MS-based glycomics	1875:1940	mobility	1910:1917	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	5	23	theme	hydroxyl	989:996	arg1	group					998:1002	a single hydroxyl group	980:1002	a single hydroxyl group	980:1002	Focus was primarily directed to compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group.
35473855	6	24	theme	helium	1086:1091	arg1	fraction					1074:1081	the fraction	1070:1081	the fraction of helium in the ion carrier gas	1070:1114	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	7	25	theme	DMS	1388:1390	arg1	separation					1392:1401	DMS separation	1388:1401	DMS separation	1388:1401	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	0	26	theme	isomers	61:67	arg1	Separation					0:9	Separation	0:9	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.	0:131	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	5	27	theme	compositional	882:894	arg1	isomers					896:902	compositional isomers	882:902	compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group	882:1002	Focus was primarily directed to compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group.
35473855	0	28	theme	high	72:75	arg1	spectrometry					119:130	high resolution differential ion mobility mass spectrometry	72:130	high resolution differential ion mobility mass spectrometry	72:130	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	0	29	theme	differential	88:99	arg1	spectrometry					119:130	high resolution differential ion mobility mass spectrometry	72:130	high resolution differential ion mobility mass spectrometry	72:130	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	4	30	dep	spectrometry	806:817	arg1	DMS-MS					820:825	DMS-MS	820:825	DMS-MS	820:825	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	8	31	theme	other	1565:1569	arg1	spectra					1571:1577	the other spectra	1561:1577	the other spectra	1561:1577	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	0	32	theme	mobility	105:112	arg1	spectrometry					119:130	high resolution differential ion mobility mass spectrometry	72:130	high resolution differential ion mobility mass spectrometry	72:130	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	2	33	theme	glycosidic	454:463	arg1	connectivity					470:481	glycosidic bond connectivity	454:481	glycosidic bond connectivity	454:481	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	1	34	dep	ubiquitous	145:154	arg1	diverse					170:176	diverse	170:176	diverse	170:176	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	2	35	theme	branching	443:451	arg1	connectivity					470:481	glycosidic bond connectivity	454:481	glycosidic bond connectivity	454:481	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	2	35	theme	branching	443:451	arg1	extent					433:438	extent	433:438	extent of branching	433:451	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	2	35	theme	branching	443:451	arg1	length					425:430	length	425:430	length	425:430	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	2	35	theme	branching	443:451	arg1	configuration					496:508	anomeric configuration	487:508	anomeric configuration	487:508	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	2	35	theme	branching	443:451	arg1	composition					412:422	their subunit composition	398:422	their subunit composition	398:422	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	0	36	theme	disaccharide	14:25	arg1	epimers					27:33	disaccharide epimers	14:33	disaccharide epimers	14:33	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	6	37	theme	carrier	1104:1110	arg1	gas					1112:1114	the ion carrier gas	1096:1114	the ion carrier gas	1096:1114	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	7	38	dep	ten	1281:1283	arg1	to					1278:1279	to	1278:1279	to	1278:1279	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	1	39	contain	have	193:196	arg1	Glycans					133:139	Glycans	133:139	Glycans	133:139	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	1	39	contain	have	193:196	arg1	molecules					178:186	ubiquitous, structurally diverse molecules	145:186	ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling	145:283	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	1	39	contain	have	193:196	arg2	roles					219:223	specific and general roles	198:223	specific and general roles involving metabolism, structure, and cell-to-cell signaling	198:283	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	7	40	theme	disaccharide	1207:1218	arg1	DMS-MS					1192:1197	DMS-MS	1192:1197	DMS-MS of each disaccharide	1192:1218	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	2	41	theme	anomeric	487:494	arg1	configuration					496:508	anomeric configuration	487:508	anomeric configuration	487:508	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	10	42	theme	complementary	1875:1887	arg1	mobility					1910:1917	complementary reduced-pressure ion mobility and MS-based glycomics	1875:1940	mobility	1910:1917	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	3	43	theme	isomers	573:579	arg1	characterization					546:561	a rapid and comprehensive characterization	520:561	a rapid and comprehensive characterization of glycan isomers	520:579	However, a rapid and comprehensive characterization of glycan isomers can be challenging owing to limitations associated with their separation.
35473855	10	44	theme	glycoproteomics	1946:1960	arg1	workflows					1962:1970	glycoproteomics workflows	1946:1970	glycoproteomics workflows	1946:1970	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	8	45	theme	DMS	1495:1497	arg1	spectrum					1499:1506	Each DMS spectrum	1490:1506	Each DMS spectrum	1490:1506	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	8	46	theme	composition	1642:1652	arg1	isomers					1686:1692	composition, configuration and connectivity isomers	1642:1692	composition, configuration and connectivity isomers	1642:1692	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	8	47	theme	configuration	1655:1667	arg1	isomers					1686:1692	composition, configuration and connectivity isomers	1642:1692	composition, configuration and connectivity isomers	1642:1692	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	7	48	theme	high	1158:1161	arg1	concentrations					1176:1189	relatively high disaccharide concentrations	1147:1189	relatively high disaccharide concentrations	1147:1189	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	9	49	theme	low	1709:1711	arg1	concentrations					1726:1739	relatively low disaccharide concentrations	1698:1739	relatively low disaccharide concentrations	1698:1739	At relatively low disaccharide concentrations, mixtures of disaccharide epimers can also be readily separated by DMS.
35473855	8	50	theme	connectivity	1673:1684	arg1	isomers					1686:1692	composition, configuration and connectivity isomers	1642:1692	composition, configuration and connectivity isomers	1642:1692	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	10	51	theme	glycans	2024:2030	arg1	characterization					2004:2019	the characterization	2000:2019	the characterization of glycans and glycosylated biomolecules	2000:2060	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	3	52	theme	glycan	566:571	arg1	isomers					573:579	glycan isomers	566:579	glycan isomers	566:579	However, a rapid and comprehensive characterization of glycan isomers can be challenging owing to limitations associated with their separation.
35473855	4	53	theme	connectivity	691:702	arg1	isomers					717:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	7	54	theme	monomer	1476:1482	arg1	ions					1484:1487	monomer ions	1476:1487	monomer ions	1476:1487	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	9	55	theme	disaccharide	1754:1765	arg1	epimers					1767:1773	disaccharide epimers	1754:1773	disaccharide epimers	1754:1773	At relatively low disaccharide concentrations, mixtures of disaccharide epimers can also be readily separated by DMS.
35473855	7	56	theme	oligomers	1461:1469	arg1	separation					1392:1401	DMS separation	1388:1401	DMS separation	1388:1401	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	7	56	theme	oligomers	1461:1469	arg1	dissociation					1418:1429	subsequent dissociation	1407:1429	subsequent dissociation	1407:1429	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	4	57	theme	composition	665:675	arg1	isomers					717:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	10	58	theme	glycosylated	2036:2047	arg1	biomolecules					2049:2060	glycosylated biomolecules	2036:2060	glycosylated biomolecules	2036:2060	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	6	59	theme	resolving	1009:1017	arg1	power					1019:1023	DMS resolving power	1005:1023	DMS resolving power	1005:1023	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	4	60	theme	anomeric	678:685	arg1	isomers					717:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	ten composition, anomeric and connectivity disaccharide isomers	661:723	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	10	61	theme	pressure	1857:1864	arg1	DMS					1866:1868	high-resolution, ambient pressure DMS	1832:1868	high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows	1832:1970	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	8	62	theme	differentiating	1525:1539	arg1	peak					1541:1544	at least one differentiating peak	1512:1544	at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers	1512:1692	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	4	63	theme	high-resolution	759:773	arg1	spectrometry					806:817	high-resolution differential ion mobility-mass spectrometry	759:817	high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS)	759:847	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	5	64	theme	single	982:987	arg1	group					998:1002	a single hydroxyl group	980:1002	a single hydroxyl group	980:1002	Focus was primarily directed to compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group.
35473855	7	65	theme	subsequent	1407:1416	arg1	dissociation					1418:1429	subsequent dissociation	1407:1429	subsequent dissociation	1407:1429	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	4	66	theme	ion	788:790	arg1	spectrometry					806:817	high-resolution differential ion mobility-mass spectrometry	759:817	high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS)	759:847	Here, ten composition, anomeric and connectivity disaccharide isomers were separated and detected using high-resolution differential ion mobility-mass spectrometry (DMS-MS, also known as FAIMS).
35473855	10	67	theme	reduced-pressure	1889:1904	arg1	mobility					1910:1917	complementary reduced-pressure ion mobility and MS-based glycomics	1875:1940	mobility	1910:1917	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	5	68	theme	axial	948:952	arg1	position					968:975	the axial or equatorial position	944:975	the axial or equatorial position of a single hydroxyl group	944:1002	Focus was primarily directed to compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group.
35473855	0	69	theme	resolution	77:86	arg1	spectrometry					119:130	high resolution differential ion mobility mass spectrometry	72:130	high resolution differential ion mobility mass spectrometry	72:130	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	5	70	theme	equatorial	957:966	arg1	position					968:975	the axial or equatorial position	944:975	the axial or equatorial position of a single hydroxyl group	944:1002	Focus was primarily directed to compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group.
35473855	6	71	from	fraction	1074:1081	arg1	gas					1112:1114	the ion carrier gas	1096:1114	the ion carrier gas	1096:1114	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	0	72	theme	ion	101:103	arg1	spectrometry					119:130	high resolution differential ion mobility mass spectrometry	72:130	high resolution differential ion mobility mass spectrometry	72:130	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	6	73	from	helium	1086:1091	arg1	gas					1112:1114	the ion carrier gas	1096:1114	the ion carrier gas	1096:1114	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	2	74	dep	adopt	383:387	arg1	based					389:393	based	389:393	can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration	379:508	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	0	75	theme	mass	114:117	arg1	spectrometry					119:130	high resolution differential ion mobility mass spectrometry	72:130	high resolution differential ion mobility mass spectrometry	72:130	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	7	76	dep	separation	1392:1401	arg1	the					1384:1386	the	1384:1386	the	1384:1386	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	6	77	theme	flow	1133:1136	arg1	rate					1138:1141	the flow rate	1129:1141	the flow rate	1129:1141	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	7	78	theme	unique	1244:1249	arg1	spectra					1262:1268	complex and unique multi-peak spectra	1232:1268	complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions	1232:1487	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	7	79	theme	complex	1232:1238	arg1	spectra					1262:1268	complex and unique multi-peak spectra	1232:1268	complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions	1232:1487	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	5	80	theme	group	998:1002	arg1	position					968:975	the axial or equatorial position	944:975	the axial or equatorial position of a single hydroxyl group	944:1002	Focus was primarily directed to compositional isomers corresponding to epimers that differ by the axial or equatorial position of a single hydroxyl group.
35473855	2	81	theme	bond	465:468	arg1	connectivity					470:481	glycosidic bond connectivity	454:481	glycosidic bond connectivity	454:481	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	2	82	theme	subunit	404:410	arg1	composition					412:422	their subunit composition	398:422	their subunit composition	398:422	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	0	83	theme	epimers	27:33	arg1	Separation					0:9	Separation	0:9	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.	0:131	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	10	84	gly	glycosylated	2036:2047	arg1	biomolecules					2049:2060	glycosylated biomolecules	2036:2060	glycosylated biomolecules	2036:2060	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	0	85	theme	anomers	36:42	arg1	Separation					0:9	Separation	0:9	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.	0:131	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	6	86	theme	ion	1100:1102	arg1	gas					1112:1114	the ion carrier gas	1096:1114	the ion carrier gas	1096:1114	DMS resolving power was enhanced 14-fold primarily by increasing the fraction of helium in the ion carrier gas and lowering the flow rate.
35473855	10	87	theme	MS-based	1923:1930	arg1	glycomics					1932:1940	complementary reduced-pressure ion mobility and MS-based glycomics	1875:1940	glycomics	1932:1940	The integration of high-resolution, ambient pressure DMS with complementary reduced-pressure ion mobility and MS-based glycomics and glycoproteomics workflows may be useful for improving the characterization of glycans and glycosylated biomolecules.
35473855	7	88	theme	multi-peak	1251:1260	arg1	spectra					1262:1268	complex and unique multi-peak spectra	1232:1268	complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions	1232:1487	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35473855	0	89	theme	connectivity	48:59	arg1	isomers					61:67	connectivity isomers	48:67	connectivity isomers	48:67	Separation of disaccharide epimers, anomers and connectivity isomers by high resolution differential ion mobility mass spectrometry.
35473855	3	90	theme	rapid	522:526	arg1	characterization					546:561	a rapid and comprehensive characterization	520:561	a rapid and comprehensive characterization of glycan isomers	520:579	However, a rapid and comprehensive characterization of glycan isomers can be challenging owing to limitations associated with their separation.
35473855	1	91	theme	ubiquitous	145:154	arg1	Glycans					133:139	Glycans	133:139	Glycans	133:139	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	1	91	theme	ubiquitous	145:154	arg1	molecules					178:186	ubiquitous, structurally diverse molecules	145:186	ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling	145:283	Glycans are ubiquitous, structurally diverse molecules that have specific and general roles involving metabolism, structure, and cell-to-cell signaling.
35473855	8	92	used	used	1607:1610	arg2	DMS					1596:1598	DMS	1596:1598	DMS	1596:1598	Each DMS spectrum has at least one differentiating peak that is not in the other spectra, indicating that DMS can be used to fully or partially resolve composition, configuration and connectivity isomers.
35473855	2	93	theme	structures	347:356	arg1	complexity					333:342	the complexity	329:342	the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration	329:508	Functional specificity depends strongly on the complexity of structures that polysaccharides can adopt based on their subunit composition, length, extent of branching, glycosidic bond connectivity and anomeric configuration.
35473855	7	94	theme	resolved	1305:1312	arg1	peaks					1314:1318	up to ten fully and partially resolved peaks	1275:1318	up to ten fully and partially resolved peaks	1275:1318	At relatively high disaccharide concentrations, DMS-MS of each disaccharide resulted in complex and unique multi-peak spectra with up to ten fully and partially resolved peaks for β-1,4-mannobiose (Man-1,4β-Man), which can be attributed to the DMS separation and subsequent dissociation of ionic non-covalently bound oligomers into monomer ions.
35447261	6	0	theme	-GalpA-	1170:1176	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	0	theme	-GalpA-	1170:1176	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	0	theme	-GalpA-	1170:1176	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	0	theme	-GalpA-	1170:1176	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	1	1	from	radish	199:204	arg1	REPI					143:146	REPI	143:146	REPI	143:146	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	1	1	from	radish	199:204	arg1	fraction					185:192	an immunostimulatory polysaccharide fraction	149:192	an immunostimulatory polysaccharide fraction from radish leaves	149:211	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	1	2	theme	polysaccharide	170:183	arg1	REPI					143:146	REPI	143:146	REPI	143:146	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	1	2	theme	polysaccharide	170:183	arg1	fraction					185:192	an immunostimulatory polysaccharide fraction	149:192	an immunostimulatory polysaccharide fraction from radish leaves	149:211	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	6	3	theme	main	1127:1130	arg1	chain					1132:1136	a main chain	1125:1136	a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain	1125:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	4	theme	residue	1349:1355	arg1	position					1328:1335	the C(O)4 position	1318:1335	the C(O)4 position of each Rha residue in the REP-I main chain	1318:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	5	theme	repeating	1143:1151	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	5	theme	repeating	1143:1151	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	5	theme	repeating	1143:1151	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	5	theme	repeating	1143:1151	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	5	6	theme	methylation	968:978	arg1	basis					940:944	the basis	936:944	the basis of sugar composition, methylation, and MS/MS spectra	936:997	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	6	7	theme	-Rhap-	1157:1162	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	7	theme	-Rhap-	1157:1162	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	7	theme	-Rhap-	1157:1162	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	7	theme	-Rhap-	1157:1162	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	8	theme	α	1230:1230	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	8	theme	α	1230:1230	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	9	theme	linkage	1182:1188	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	9	theme	linkage	1182:1188	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	9	theme	linkage	1182:1188	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	9	theme	linkage	1182:1188	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	10	theme	Rha	1345:1347	arg1	residue					1349:1355	each Rha residue	1340:1355	each Rha residue in the REP-I main chain	1340:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	11	theme	branched	1221:1228	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	11	theme	branched	1221:1228	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	12	theme	RG-I	1098:1101	arg1	structure					1085:1093	the structure	1081:1093	the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain	1081:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	2	13	theme	different	289:297	arg1	Ara					353:355	Ara	353:355	Ara (27.5%)	353:363	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	13	theme	different	289:297	arg1	GalA					326:329	GalA	326:329	GalA (22.2%)	326:337	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	13	theme	different	289:297	arg1	Rha					370:372	Rha	370:372	Rha (10.2%)	370:380	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	13	theme	different	289:297	arg1	Gal					340:342	Gal	340:342	Gal (32.6%)	340:350	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	13	theme	different	289:297	arg1	sugars					390:395	main sugars	385:395	main sugars	385:395	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	13	theme	different	289:297	arg1	monosaccharides					299:313	nine different monosaccharides	284:313	nine different monosaccharides	284:313	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	4	14	link	3,6-linked	724:733	arg1	Galp					735:738	3,6-linked Galp	724:738	3,6-linked Galp (7.9%)	724:745	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	14	link	3,6-linked	724:733	arg1	%					744:744	7.9%	741:744	7.9%	741:744	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	15	theme	5-linked	697:704	arg1	Araf					706:709	5-linked Araf	697:709	5-linked Araf (10.1%)	697:717	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	15	theme	5-linked	697:704	arg1	%					716:716	10.1%	712:716	10.1%	712:716	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	16	theme	methylated-product	528:545	arg1	analysis					547:554	methylated-product analysis	528:554	methylated-product analysis	528:554	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	3	17	theme	Yariv	437:441	arg1	reagent					443:449	β-glucosyl Yariv reagent	426:449	β-glucosyl Yariv reagent (29.8%)	426:457	REP-I was also reacted with β-glucosyl Yariv reagent (29.8%), suggesting the presence of the arabino-β-3,6-galactan.
35447261	3	17	theme	Yariv	437:441	arg1	%					456:456	29.8%	452:456	29.8%	452:456	REP-I was also reacted with β-glucosyl Yariv reagent (29.8%), suggesting the presence of the arabino-β-3,6-galactan.
35447261	6	18	from	residue	1349:1355	arg1	chain					1375:1379	the REP-I main chain	1360:1379	the REP-I main chain	1360:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	4	19	link	4-linked	627:634	arg1	GalpA					636:640	4-linked GalpA	627:640	4-linked GalpA (21.0%)	627:648	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	19	link	4-linked	627:634	arg1	%					647:647	21.0%	643:647	21.0%	643:647	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	20	theme	RG-I	776:779	arg1	characteristic					758:771	characteristic	758:771	characteristic	758:771	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	5	21	theme	sugar	949:953	arg1	composition					955:965	sugar composition	949:965	sugar composition	949:965	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	4	22	theme	different	588:596	arg1	GalpA					636:640	4-linked GalpA	627:640	4-linked GalpA (21.0%)	627:648	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	22	theme	different	588:596	arg1	Galp					684:687	4-linked Galp	675:687	4-linked Galp (5.8%)	675:694	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	22	theme	different	588:596	arg1	Rhap					662:665	2,4-linked Rhap	651:665	2,4-linked Rhap (7.0%)	651:672	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	22	theme	different	588:596	arg1	Araf					706:709	5-linked Araf	697:709	5-linked Araf (10.1%)	697:717	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	22	theme	different	588:596	arg1	linkages					607:614	13 different glycosyl linkages	585:614	13 different glycosyl linkages	585:614	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	22	theme	different	588:596	arg1	Galp					735:738	3,6-linked Galp	724:738	3,6-linked Galp (7.9%)	724:745	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	6	23	from	chain	1375:1379	arg1	position					1328:1335	the C(O)4 position	1318:1335	the C(O)4 position of each Rha residue in the REP-I main chain	1318:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	2	24	contain	contains	275:282	arg2	sugars					390:395	main sugars	385:395	main sugars	385:395	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	24	contain	contains	275:282	arg2	monosaccharides					299:313	nine different monosaccharides	284:313	nine different monosaccharides	284:313	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	24	contain	contains	275:282	arg2	GalA					326:329	GalA	326:329	GalA (22.2%)	326:337	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	24	contain	contains	275:282	arg2	Gal					340:342	Gal	340:342	Gal (32.6%)	340:350	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	24	contain	contains	275:282	arg2	Rha					370:372	Rha	370:372	Rha (10.2%)	370:380	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	24	contain	contains	275:282	arg2	Ara					353:355	Ara	353:355	Ara (27.5%)	353:363	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	24	contain	contains	275:282	arg1	REP-I					269:273	REP-I	269:273	REP-I	269:273	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	0	25	theme	structural	21:30	arg1	features					32:39	the structural features	17:39	the structural features of Rhamnogalacturonan-I type polysaccharide	17:83	Clarification of the structural features of Rhamnogalacturonan-I type polysaccharide purified from radish leaves.
35447261	6	26	theme	immunostimulatory	1026:1042	arg1	activity					1044:1051	the immunostimulatory activity	1022:1051	the immunostimulatory activity of REP-I	1022:1060	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	26	theme	immunostimulatory	1026:1042	arg1	due					1074:1076	due	1074:1076	due	1074:1076	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	27	theme	[→2	1153:1155	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	27	theme	[→2	1153:1155	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	27	theme	[→2	1153:1155	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	27	theme	[→2	1153:1155	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	5	28	theme	linkage-specific	860:875	arg1	glycosylases					877:888	four linkage-specific glycosylases	855:888	four linkage-specific glycosylases	855:888	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	4	29	theme	2,4-linked	651:660	arg1	Rhap					662:665	2,4-linked Rhap	651:665	2,4-linked Rhap (7.0%)	651:672	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	29	theme	2,4-linked	651:660	arg1	%					671:671	7.0%	668:671	7.0%	668:671	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	6	30	theme	O	1324:1324	arg1	position					1328:1335	the C(O)4 position	1318:1335	the C(O)4 position of each Rha residue in the REP-I main chain	1318:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	5	31	theme	Microstructural	782:796	arg1	information					798:808	Microstructural information	782:808	Microstructural information	782:808	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	4	32	link	4-linked	675:682	arg1	Galp					684:687	4-linked Galp	675:687	4-linked Galp (5.8%)	675:694	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	32	link	4-linked	675:682	arg1	%					693:693	5.8%	690:693	5.8%	690:693	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	2	33	theme	main	385:388	arg1	Ara					353:355	Ara	353:355	Ara (27.5%)	353:363	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	33	theme	main	385:388	arg1	GalA					326:329	GalA	326:329	GalA (22.2%)	326:337	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	33	theme	main	385:388	arg1	Rha					370:372	Rha	370:372	Rha (10.2%)	370:380	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	33	theme	main	385:388	arg1	Gal					340:342	Gal	340:342	Gal (32.6%)	340:350	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	33	theme	main	385:388	arg1	sugars					390:395	main sugars	385:395	main sugars	385:395	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	2	33	theme	main	385:388	arg1	monosaccharides					299:313	nine different monosaccharides	284:313	nine different monosaccharides	284:313	Herein, we show that REP-I contains nine different monosaccharides, including GalA (22.2%), Gal (32.6%), Ara (27.5%), and Rha (10.2%) as main sugars.
35447261	6	34	with	chain	1132:1136	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	34	with	chain	1132:1136	arg1	side-chains					1206:1216	three side-chains	1200:1216	three side-chains	1200:1216	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	34	with	chain	1132:1136	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	34	with	chain	1132:1136	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	34	with	chain	1132:1136	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	35	from	position	1328:1335	arg1	chain					1375:1379	the REP-I main chain	1360:1379	the REP-I main chain	1360:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	36	theme	β	1250:1250	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	36	theme	β	1250:1250	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	1	37	theme	important	220:228	arg1	objective					237:245	an important health objective	217:245	an important health objective	217:245	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	0	38	theme	features	32:39	arg1	Clarification					0:12	Clarification	0:12	Clarification of the structural features of Rhamnogalacturonan-I type polysaccharide purified from radish	0:104	Clarification of the structural features of Rhamnogalacturonan-I type polysaccharide purified from radish leaves.
35447261	6	39	dep	units	1190:1194	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	39	dep	units	1190:1194	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	39	dep	units	1190:1194	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	39	dep	units	1190:1194	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	1	40	theme	health	230:235	arg1	objective					237:245	an important health objective	217:245	an important health objective	217:245	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	4	41	link	5-linked	697:704	arg1	Araf					706:709	5-linked Araf	697:709	5-linked Araf (10.1%)	697:717	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	41	link	5-linked	697:704	arg1	%					716:716	10.1%	712:716	10.1%	712:716	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	5	42	theme	MS/MS	985:989	arg1	spectra					991:997	MS/MS spectra	985:997	MS/MS spectra	985:997	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	4	43	theme	3,6-linked	724:733	arg1	Galp					735:738	3,6-linked Galp	724:738	3,6-linked Galp (7.9%)	724:745	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	43	theme	3,6-linked	724:733	arg1	%					744:744	7.9%	741:744	7.9%	741:744	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	0	44	theme	polysaccharide	70:83	arg1	features					32:39	the structural features	17:39	the structural features of Rhamnogalacturonan-I type polysaccharide	17:83	Clarification of the structural features of Rhamnogalacturonan-I type polysaccharide purified from radish leaves.
35447261	6	45	theme	C	1322:1322	arg1	position					1328:1335	the C(O)4 position	1318:1335	the C(O)4 position of each Rha residue in the REP-I main chain	1318:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	0	46	theme	Rhamnogalacturonan-I	44:63	arg1	polysaccharide					70:83	Rhamnogalacturonan-I type polysaccharide	44:83	Rhamnogalacturonan-I type polysaccharide	44:83	Clarification of the structural features of Rhamnogalacturonan-I type polysaccharide purified from radish leaves.
35447261	5	47	theme	spectra	991:997	arg1	basis					940:944	the basis	936:944	the basis of sugar composition, methylation, and MS/MS spectra	936:997	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	6	48	theme	main	1370:1373	arg1	chain					1375:1379	the REP-I main chain	1360:1379	the REP-I main chain	1360:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	1	49	dep	radish	199:204	arg1	leaves					206:211	leaves	206:211	leaves	206:211	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	4	50	theme	4-linked	627:634	arg1	GalpA					636:640	4-linked GalpA	627:640	4-linked GalpA (21.0%)	627:648	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	50	theme	4-linked	627:634	arg1	%					647:647	21.0%	643:647	21.0%	643:647	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	6	51	theme	REP-I	1056:1060	arg1	activity					1044:1051	the immunostimulatory activity	1022:1051	the immunostimulatory activity of REP-I	1022:1060	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	51	theme	REP-I	1056:1060	arg1	due					1074:1076	due	1074:1076	due	1074:1076	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	5	52	theme	sequential	826:835	arg1	degradation					837:847	sequential degradation	826:847	sequential degradation using four linkage-specific glycosylases and β-elimination	826:906	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	6	53	theme	REP-I	1364:1368	arg1	chain					1375:1379	the REP-I main chain	1360:1379	the REP-I main chain	1360:1379	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	4	54	theme	glycosyl	598:605	arg1	GalpA					636:640	4-linked GalpA	627:640	4-linked GalpA (21.0%)	627:648	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	54	theme	glycosyl	598:605	arg1	Galp					684:687	4-linked Galp	675:687	4-linked Galp (5.8%)	675:694	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	54	theme	glycosyl	598:605	arg1	Rhap					662:665	2,4-linked Rhap	651:665	2,4-linked Rhap (7.0%)	651:672	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	54	theme	glycosyl	598:605	arg1	Araf					706:709	5-linked Araf	697:709	5-linked Araf (10.1%)	697:717	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	54	theme	glycosyl	598:605	arg1	linkages					607:614	13 different glycosyl linkages	585:614	13 different glycosyl linkages	585:614	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	54	theme	glycosyl	598:605	arg1	Galp					735:738	3,6-linked Galp	724:738	3,6-linked Galp (7.9%)	724:745	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	1	55	theme	REPI	143:146	arg1	structure					130:138	the structure	126:138	the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves,	126:212	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	1	56	theme	immunostimulatory	152:168	arg1	REPI					143:146	REPI	143:146	REPI	143:146	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	1	56	theme	immunostimulatory	152:168	arg1	fraction					185:192	an immunostimulatory polysaccharide fraction	149:192	an immunostimulatory polysaccharide fraction from radish leaves	149:211	Determining the structure of REPI, an immunostimulatory polysaccharide fraction from radish leaves, is an important health objective.
35447261	6	57	theme	1→	1178:1179	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	57	theme	1→	1178:1179	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	57	theme	1→	1178:1179	arg1	galactan					1258:1265	a β(1 → 4)galactan	1248:1265	a β(1 → 4)galactan	1248:1265	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	57	theme	1→	1178:1179	arg1	arabino-β-3,6-galactan					1272:1293	arabino-β-3,6-galactan	1272:1293	arabino-β-3,6-galactan	1272:1293	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	4	58	contain	contains	576:583	arg2	Galp					735:738	3,6-linked Galp	724:738	3,6-linked Galp (7.9%)	724:745	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	58	contain	contains	576:583	arg2	GalpA					636:640	4-linked GalpA	627:640	4-linked GalpA (21.0%)	627:648	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	58	contain	contains	576:583	arg2	Galp					684:687	4-linked Galp	675:687	4-linked Galp (5.8%)	675:694	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	58	contain	contains	576:583	arg2	Rhap					662:665	2,4-linked Rhap	651:665	2,4-linked Rhap (7.0%)	651:672	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	58	contain	contains	576:583	arg1	REP-I					570:574	REP-I	570:574	REP-I	570:574	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	58	contain	contains	576:583	arg2	linkages					607:614	13 different glycosyl linkages	585:614	13 different glycosyl linkages	585:614	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	58	contain	contains	576:583	arg2	Araf					706:709	5-linked Araf	697:709	5-linked Araf (10.1%)	697:717	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	3	59	theme	arabino-β-3,6-galactan	491:512	arg1	presence					475:482	the presence	471:482	the presence of the arabino-β-3,6-galactan	471:512	REP-I was also reacted with β-glucosyl Yariv reagent (29.8%), suggesting the presence of the arabino-β-3,6-galactan.
35447261	4	60	link	2,4-linked	651:660	arg1	Rhap					662:665	2,4-linked Rhap	651:665	2,4-linked Rhap (7.0%)	651:672	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	60	link	2,4-linked	651:660	arg1	%					671:671	7.0%	668:671	7.0%	668:671	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	0	61	theme	type	65:68	arg1	polysaccharide					70:83	Rhamnogalacturonan-I type polysaccharide	44:83	Rhamnogalacturonan-I type polysaccharide	44:83	Clarification of the structural features of Rhamnogalacturonan-I type polysaccharide purified from radish leaves.
35447261	5	62	theme	composition	955:965	arg1	basis					940:944	the basis	936:944	the basis of sugar composition, methylation, and MS/MS spectra	936:997	Microstructural information was obtained by sequential degradation using four linkage-specific glycosylases and β-elimination, with fragments analyzed on the basis of sugar composition, methylation, and MS/MS spectra.
35447261	4	63	theme	4-linked	675:682	arg1	Galp					684:687	4-linked Galp	675:687	4-linked Galp (5.8%)	675:694	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	4	63	theme	4-linked	675:682	arg1	%					693:693	5.8%	690:693	5.8%	690:693	Furthermore, methylated-product analysis revealed that REP-I contains 13 different glycosyl linkages, including 4-linked GalpA (21.0%), 2,4-linked Rhap (7.0%), 4-linked Galp (5.8%), 5-linked Araf (10.1%), and 3,6-linked Galp (7.9%), which are characteristic of RG-I.
35447261	3	64	theme	β-glucosyl	426:435	arg1	reagent					443:449	β-glucosyl Yariv reagent	426:449	β-glucosyl Yariv reagent (29.8%)	426:457	REP-I was also reacted with β-glucosyl Yariv reagent (29.8%), suggesting the presence of the arabino-β-3,6-galactan.
35447261	3	64	theme	β-glucosyl	426:435	arg1	%					456:456	29.8%	452:456	29.8%	452:456	REP-I was also reacted with β-glucosyl Yariv reagent (29.8%), suggesting the presence of the arabino-β-3,6-galactan.
35447261	6	65	theme	1 → 5	1232:1236	arg1	units					1190:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units	1143:1194	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
35447261	6	65	theme	1 → 5	1232:1236	arg1	arabinan					1238:1245	a branched α(1 → 5)arabinan	1219:1245	a branched α(1 → 5)arabinan	1219:1245	The results show that the immunostimulatory activity of REP-I is possibly due to the structure of RG-I, which is composed of a main chain with repeating [→2)-Rhap-(1 → 4)-GalpA-(1→] linkage units and three side-chains: a branched α(1 → 5)arabinan, a β(1 → 4)galactan, and arabino-β-3,6-galactan, which are branched at the C(O)4 position of each Rha residue in the REP-I main chain.
36812846	5	0	theme	regioselective	752:765	arg1	α-mannosylation					767:781	Sequential regioselective α-mannosylation	741:781	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	741:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	1	1	from	system	218:223	arg1	reticulum					244:252	the endoplasmic reticulum	228:252	the endoplasmic reticulum	228:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	1	2	theme	glycoprotein	189:200	arg1	system					218:223	the glycoprotein quality control system	185:223	the glycoprotein quality control system in the endoplasmic reticulum	185:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	0	3	theme	structures	93:102	arg1	construction					70:81	step-economical construction	54:81	step-economical construction of branch structures	54:102	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures.
36812846	1	4	theme	quality	202:208	arg1	system					218:223	the glycoprotein quality control system	185:223	the glycoprotein quality control system in the endoplasmic reticulum	185:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	5	5	from	residues	845:852	arg1	derivatives					878:888	galactosylchitobiose derivatives	857:888	galactosylchitobiose derivatives	857:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	2	6	theme	dolichol	344:351	arg1	oligosaccharides					374:389	dolichol pyrophosphate-linked oligosaccharides	344:389	dolichol pyrophosphate-linked oligosaccharides	344:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	7	7	theme	protection-deprotection	1113:1135	arg1	reactions					1137:1145	the protection-deprotection reactions	1109:1145	the protection-deprotection reactions	1109:1145	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	6	8	from	positions	1002:1010	arg1	inversion					926:934	the inversion	922:934	the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety	922:1034	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	5	9	theme	galactosylchitobiose	857:876	arg1	derivatives					878:888	galactosylchitobiose derivatives	857:888	galactosylchitobiose derivatives	857:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	6	10	theme	moiety	1029:1034	arg1	positions					1002:1010	the C-2 and C-4 positions	986:1010	the C-2 and C-4 positions of the galactose moiety	986:1034	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	4	11	theme	simple	670:675	arg1	strategy					701:708	a simple and efficient synthetic strategy	668:708	a simple and efficient synthetic strategy for oligomannose-type glycans	668:738	In this study, we demonstrate a simple and efficient synthetic strategy for oligomannose-type glycans.
36812846	1	12	gly	glycoproteins	134:146	arg1	glycoproteins					134:146	glycoproteins	134:146	glycoproteins	134:146	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	6	13	theme	galactose	1019:1027	arg1	moiety					1029:1034	the galactose moiety	1015:1034	the galactose moiety	1015:1034	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	6	14	theme	configuration	943:955	arg1	inversion					926:934	the inversion	922:934	the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety	922:1034	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	2	15	theme	glycoproteins	327:339	arg1	hydrolysis					313:322	the hydrolysis	309:322	the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides	309:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	1	16	theme	control	210:216	arg1	system					218:223	the glycoprotein quality control system	185:223	the glycoprotein quality control system in the endoplasmic reticulum	185:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	2	17	gly	glycoproteins	327:339	arg1	glycoproteins					327:339	glycoproteins	327:339	glycoproteins	327:339	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	6	18	theme	C-2	990:992	arg1	positions					1002:1010	the C-2 and C-4 positions	986:1010	the C-2 and C-4 positions of the galactose moiety	986:1034	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	3	19	theme	high	466:469	arg1	demand					471:476	a high demand	464:476	a high demand for pure oligomannose-type glycans for biochemical experiments	464:539	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	7	20	theme	different	1180:1188	arg1	patterns					1200:1207	different branching patterns	1180:1207	different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B	1180:1262	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	7	21	theme	branching	1190:1198	arg1	patterns					1200:1207	different branching patterns	1180:1207	different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B	1180:1262	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	1	22	from	molecules	172:180	arg1	system					218:223	the glycoprotein quality control system	185:223	the glycoprotein quality control system in the endoplasmic reticulum	185:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	1	23	theme	Oligomannose-type	105:121	arg1	glycans					123:129	Oligomannose-type glycans	105:129	Oligomannose-type glycans on glycoproteins	105:146	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	1	23	theme	Oligomannose-type	105:121	arg1	molecules					172:180	important signaling molecules	152:180	important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum	152:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	0	24	theme	Convergent	0:9	arg1	synthesis					11:19	Convergent synthesis	0:19	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures	0:102	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures.
36812846	5	25	theme	Sequential	741:750	arg1	α-mannosylation					767:781	Sequential regioselective α-mannosylation	741:781	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	741:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	0	26	theme	oligomannose-type	24:40	arg1	glycans					42:48	oligomannose-type glycans	24:48	oligomannose-type glycans	24:48	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures.
36812846	2	27	theme	oligosaccharides	374:389	arg1	hydrolysis					313:322	the hydrolysis	309:322	the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides	309:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	1	28	theme	endoplasmic	232:242	arg1	reticulum					244:252	the endoplasmic reticulum	228:252	the endoplasmic reticulum	228:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	7	29	theme	oligomannose-type	1212:1228	arg1	glycans					1230:1236	oligomannose-type glycans	1212:1236	oligomannose-type glycans	1212:1236	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	7	29	theme	oligomannose-type	1212:1228	arg1	M5A					1251:1253	M5A	1251:1253	M5A	1251:1253	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	7	29	theme	oligomannose-type	1212:1228	arg1	M5B					1260:1262	M5B	1260:1262	M5B	1260:1262	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	7	29	theme	oligomannose-type	1212:1228	arg1	M9					1247:1248	M9	1247:1248	M9	1247:1248	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	5	30	theme	2,3,4,6-unprotected	815:833	arg1	residues					845:852	2,3,4,6-unprotected galactose residues	815:852	2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	815:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	5	31	from	derivatives	878:888	arg1	positions					802:810	the C-3 and C-6 positions	786:810	the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	786:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	2	32	theme	pyrophosphate-linked	353:372	arg1	oligosaccharides					374:389	dolichol pyrophosphate-linked oligosaccharides	344:389	dolichol pyrophosphate-linked oligosaccharides	344:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	4	33	theme	oligomannose-type	714:730	arg1	glycans					732:738	oligomannose-type glycans	714:738	oligomannose-type glycans	714:738	In this study, we demonstrate a simple and efficient synthetic strategy for oligomannose-type glycans.
36812846	3	34	theme	pure	482:485	arg1	glycans					505:511	pure oligomannose-type glycans	482:511	pure oligomannose-type glycans	482:511	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	3	35	theme	glycans	577:583	arg1	synthesis					564:572	the chemical synthesis	551:572	the chemical synthesis of glycans to achieve high-concentration products	551:622	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	3	35	theme	glycans	577:583	arg1	laborious					627:635	laborious	627:635	laborious	627:635	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	5	36	theme	galactose	835:843	arg1	residues					845:852	2,3,4,6-unprotected galactose residues	815:852	2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	815:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	6	37	theme	C-4	998:1000	arg1	positions					1002:1010	the C-2 and C-4 positions	986:1010	the C-2 and C-4 positions of the galactose moiety	986:1034	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	5	38	theme	residues	845:852	arg1	positions					802:810	the C-3 and C-6 positions	786:810	the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	786:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	0	39	theme	glycans	42:48	arg1	synthesis					11:19	Convergent synthesis	0:19	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures	0:102	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures.
36812846	3	40	theme	oligomannose-type	487:503	arg1	glycans					505:511	pure oligomannose-type glycans	482:511	pure oligomannose-type glycans	482:511	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	2	41	theme	oligomannose-type	270:286	arg1	signals					420:426	important signals	410:426	important signals for immunogenicity	410:445	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	2	41	theme	oligomannose-type	270:286	arg1	glycans					288:294	free oligomannose-type glycans	265:294	free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides	265:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	2	42	link	pyrophosphate-linked	353:372	arg1	oligosaccharides					374:389	dolichol pyrophosphate-linked oligosaccharides	344:389	dolichol pyrophosphate-linked oligosaccharides	344:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	5	43	theme	C-3	790:792	arg1	positions					802:810	the C-3 and C-6 positions	786:810	the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	786:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	3	44	theme	biochemical	517:527	arg1	experiments					529:539	biochemical experiments	517:539	biochemical experiments	517:539	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	2	45	theme	free	265:268	arg1	signals					420:426	important signals	410:426	important signals for immunogenicity	410:445	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	2	45	theme	free	265:268	arg1	glycans					288:294	free oligomannose-type glycans	265:294	free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides	265:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	5	46	gly	α-mannosylation	767:781	arg1	positions					802:810	the C-3 and C-6 positions	786:810	the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	786:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	7	47	theme	glycans	1230:1236	arg1	patterns					1200:1207	different branching patterns	1180:1207	different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B	1180:1262	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	0	48	theme	step-economical	54:68	arg1	construction					70:81	step-economical construction	54:81	step-economical construction of branch structures	54:102	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures.
36812846	3	49	theme	chemical	555:562	arg1	synthesis					564:572	the chemical synthesis	551:572	the chemical synthesis of glycans to achieve high-concentration products	551:622	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	3	49	theme	chemical	555:562	arg1	laborious					627:635	laborious	627:635	laborious	627:635	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	1	50	theme	important	152:160	arg1	glycans					123:129	Oligomannose-type glycans	105:129	Oligomannose-type glycans on glycoproteins	105:146	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	1	50	theme	important	152:160	arg1	molecules					172:180	important signaling molecules	152:180	important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum	152:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	5	51	theme	C-6	798:800	arg1	positions					802:810	the C-3 and C-6 positions	786:810	the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	786:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	7	52	theme	synthetic	1071:1079	arg1	route					1081:1085	This synthetic route	1066:1085	This synthetic route	1066:1085	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	1	53	theme	signaling	162:170	arg1	glycans					123:129	Oligomannose-type glycans	105:129	Oligomannose-type glycans on glycoproteins	105:146	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	1	53	theme	signaling	162:170	arg1	molecules					172:180	important signaling molecules	152:180	important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum	152:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	4	54	theme	synthetic	691:699	arg1	strategy					701:708	a simple and efficient synthetic strategy	668:708	a simple and efficient synthetic strategy for oligomannose-type glycans	668:738	In this study, we demonstrate a simple and efficient synthetic strategy for oligomannose-type glycans.
36812846	1	55	gly	glycoprotein	189:200	arg1	glycoprotein					189:200	the glycoprotein quality control system	185:223	the glycoprotein quality control system in the endoplasmic reticulum	185:252	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	6	56	theme	groups	976:981	arg1	configuration					943:955	the configuration	939:955	the configuration of the two hydroxy groups	939:981	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	7	57	theme	reactions	1137:1145	arg1	number					1099:1104	the number	1095:1104	the number of the protection-deprotection reactions	1095:1145	This synthetic route reduces the number of the protection-deprotection reactions and is suitable for constructing different branching patterns of oligomannose-type glycans, such as M9, M5A, and M5B.
36812846	2	58	theme	important	410:418	arg1	signals					420:426	important signals	410:426	important signals for immunogenicity	410:445	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	2	58	theme	important	410:418	arg1	glycans					288:294	free oligomannose-type glycans	265:294	free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides	265:389	Recently, free oligomannose-type glycans generated by the hydrolysis of glycoproteins or dolichol pyrophosphate-linked oligosaccharides were recognized as important signals for immunogenicity.
36812846	0	59	theme	branch	86:91	arg1	structures					93:102	branch structures	86:102	branch structures	86:102	Convergent synthesis of oligomannose-type glycans via step-economical construction of branch structures.
36812846	6	60	theme	hydroxy	968:974	arg1	groups					976:981	the two hydroxy groups	960:981	the two hydroxy groups	960:981	Subsequently, the inversion of the configuration of the two hydroxy groups at the C-2 and C-4 positions of the galactose moiety was successfully carried out.
36812846	5	61	from	positions	802:810	arg1	derivatives					878:888	galactosylchitobiose derivatives	857:888	galactosylchitobiose derivatives	857:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	5	61	from	positions	802:810	arg1	α-mannosylation					767:781	Sequential regioselective α-mannosylation	741:781	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives	741:888	Sequential regioselective α-mannosylation at the C-3 and C-6 positions of 2,3,4,6-unprotected galactose residues in galactosylchitobiose derivatives was demonstrated.
36812846	3	62	theme	high-concentration	596:613	arg1	products					615:622	high-concentration products	596:622	high-concentration products	596:622	Hence, there is a high demand for pure oligomannose-type glycans for biochemical experiments; however, the chemical synthesis of glycans to achieve high-concentration products is laborious.
36812846	1	63	from	glycans	123:129	arg1	glycoproteins					134:146	glycoproteins	134:146	glycoproteins	134:146	Oligomannose-type glycans on glycoproteins are important signaling molecules in the glycoprotein quality control system in the endoplasmic reticulum.
36812846	4	64	theme	efficient	681:689	arg1	strategy					701:708	a simple and efficient synthetic strategy	668:708	a simple and efficient synthetic strategy for oligomannose-type glycans	668:738	In this study, we demonstrate a simple and efficient synthetic strategy for oligomannose-type glycans.
35854001	5	0	theme	C-terminal	681:690	arg1	region					692:697	mouse GnT-IVa's C-terminal region	665:697	mouse GnT-IVa's C-terminal region	665:697	Here, we identify the lectin domain in mouse GnT-IVa's C-terminal region.
35854001	1	1	from	number	184:189	arg1	N-glycans					213:221	N-glycans	213:221	N-glycans	213:221	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	7	2	theme	product	948:954	arg1	N-glycans					956:964	the product N-glycans	944:964	the product N-glycans	944:964	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	0	3	theme	mouse	63:67	arg1	MGAT4A					106:111	MGAT4A	106:111	MGAT4A	106:111	Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A).
35854001	0	3	theme	mouse	63:67	arg1	N-acetylglucosaminyltransferase-IVa					69:103	mouse N-acetylglucosaminyltransferase-IVa	63:103	mouse N-acetylglucosaminyltransferase-IVa (MGAT4A)	63:112	Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A).
35854001	9	4	theme	N-glycans	1242:1250	arg1	structures					1228:1237	branching structures	1218:1237	branching structures of N-glycans	1218:1250	Our findings provide insights into how branching structures of N-glycans are biosynthesized.
35854001	2	5	theme	mannose	367:373	arg1	arm					375:377	the α1-3 mannose arm	358:377	the α1-3 mannose arm	358:377	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
35854001	4	6	theme	GnT-IVa	556:562	arg1	importance					542:551	the physiological importance	524:551	the physiological importance of GnT-IVa	524:562	Despite the physiological importance of GnT-IVa, its structure and catalytic mechanism are poorly understood.
35854001	2	7	from	branch	348:353	arg1	arm					375:377	the α1-3 mannose arm	358:377	the α1-3 mannose arm	358:377	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
35854001	5	8	theme	lectin	648:653	arg1	domain					655:660	the lectin domain	644:660	the lectin domain in mouse GnT-IVa's C-terminal region	644:697	Here, we identify the lectin domain in mouse GnT-IVa's C-terminal region.
35854001	6	9	theme	structural	749:758	arg1	similarity					760:769	structural similarity	749:769	structural similarity to a bacterial GlcNAc-binding lectin	749:806	The crystal structure of the lectin domain shows structural similarity to a bacterial GlcNAc-binding lectin.
35854001	7	10	theme	lectin	903:908	arg1	domain					910:915	the GnT-IVa lectin domain	891:915	the GnT-IVa lectin domain	891:915	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	8	11	theme	sugar	1037:1041	arg1	recognition					1043:1053	sugar recognition	1037:1053	sugar recognition	1037:1053	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	4	12	theme	physiological	528:540	arg1	importance					542:551	the physiological importance	524:551	the physiological importance of GnT-IVa	524:562	Despite the physiological importance of GnT-IVa, its structure and catalytic mechanism are poorly understood.
35854001	5	13	theme	mouse	665:669	arg1	GnT-IVa					671:677	mouse GnT-IVa's	665:679	mouse GnT-IVa's C-terminal region	665:697	Here, we identify the lectin domain in mouse GnT-IVa's C-terminal region.
35854001	7	14	theme	Comprehensive	809:821	arg1	assay					838:842	Comprehensive glycan binding assay	809:842	Comprehensive glycan binding assay using 157 glycans	809:860	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	6	15	theme	domain	736:741	arg1	structure					712:720	The crystal structure	700:720	The crystal structure of the lectin domain	700:741	The crystal structure of the lectin domain shows structural similarity to a bacterial GlcNAc-binding lectin.
35854001	3	16	theme	glucose	471:477	arg1	transporter-2					479:491	glucose transporter-2	471:491	glucose transporter-2 in pancreatic β-cells	471:513	Downregulation or loss of GnT-IVa causes diabetic phenotypes by dysregulating glucose transporter-2 in pancreatic β-cells.
35854001	2	17	theme	GlcNAc	341:346	arg1	branch					348:353	a β1-4 GlcNAc branch	334:353	a β1-4 GlcNAc branch on the α1-3 mannose arm	334:377	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
35854001	6	18	theme	lectin	729:734	arg1	domain					736:741	the lectin domain	725:741	the lectin domain	725:741	The crystal structure of the lectin domain shows structural similarity to a bacterial GlcNAc-binding lectin.
35854001	7	19	theme	GlcNAc	980:985	arg1	branch					987:992	a β1-4 GlcNAc branch	973:992	a β1-4 GlcNAc branch	973:992	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	2	20	theme	β1-4	336:339	arg1	branch					348:353	a β1-4 GlcNAc branch	334:353	a β1-4 GlcNAc branch on the α1-3 mannose arm	334:377	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
35854001	1	21	theme	GlcNAc	194:199	arg1	branches					201:208	GlcNAc branches	194:208	GlcNAc branches	194:208	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	0	22	theme	lectin	15:20	arg1	domain					22:27	a lectin domain	13:27	a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A)	13:112	Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A).
35854001	7	23	theme	solution	866:873	arg1	NMR					875:877	solution NMR	866:877	solution NMR	866:877	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	8	24	theme	enzymatic	1067:1075	arg1	activity					1077:1084	the enzymatic activity	1063:1084	the enzymatic activity	1063:1084	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	1	25	theme	branches	201:208	arg1	number					184:189	the number	180:189	the number of GlcNAc branches in N-glycans	180:221	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	9	26	theme	branching	1218:1226	arg1	structures					1228:1237	branching structures	1218:1237	branching structures of N-glycans	1218:1250	Our findings provide insights into how branching structures of N-glycans are biosynthesized.
35854001	8	27	theme	regulatory	1126:1135	arg1	domain					1114:1119	the lectin domain	1103:1119	the lectin domain	1103:1119	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	8	27	theme	regulatory	1126:1135	arg1	subunit					1137:1143	a regulatory subunit	1124:1143	a regulatory subunit for efficient catalytic reaction	1124:1176	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	6	28	theme	crystal	704:710	arg1	structure					712:720	The crystal structure	700:720	The crystal structure of the lectin domain	700:741	The crystal structure of the lectin domain shows structural similarity to a bacterial GlcNAc-binding lectin.
35854001	8	29	theme	efficient	1149:1157	arg1	reaction					1169:1176	efficient catalytic reaction	1149:1176	efficient catalytic reaction	1149:1176	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	5	30	from	domain	655:660	arg1	region					692:697	mouse GnT-IVa's C-terminal region	665:697	mouse GnT-IVa's C-terminal region	665:697	Here, we identify the lectin domain in mouse GnT-IVa's C-terminal region.
35854001	2	31	dep	N-Acetylglucosaminyltransferase-IVa	255:289	arg1	designated					306:315	designated	306:315	designated as MGAT4A	306:325	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
35854001	3	32	theme	diabetic	434:441	arg1	phenotypes					443:452	diabetic phenotypes	434:452	diabetic phenotypes	434:452	Downregulation or loss of GnT-IVa causes diabetic phenotypes by dysregulating glucose transporter-2 in pancreatic β-cells.
35854001	0	33	theme	domain	22:27	arg1	Discovery					0:8	Discovery	0:8	Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A).	0:113	Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A).
35854001	3	34	from	transporter-2	479:491	arg1	β-cells					507:513	pancreatic β-cells	496:513	pancreatic β-cells	496:513	Downregulation or loss of GnT-IVa causes diabetic phenotypes by dysregulating glucose transporter-2 in pancreatic β-cells.
35854001	0	35	theme	enzyme	44:49	arg1	activity					51:58	enzyme activity	44:58	enzyme activity	44:58	Discovery of a lectin domain that regulates enzyme activity in mouse N-acetylglucosaminyltransferase-IVa (MGAT4A).
35854001	8	36	theme	critical	1025:1032	arg1	residue					1017:1023	the residue	1013:1023	the residue critical to sugar recognition	1013:1053	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	2	37	theme	α1-3	362:365	arg1	arm					375:377	the α1-3 mannose arm	358:377	the α1-3 mannose arm	358:377	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
35854001	3	38	theme	GnT-IVa	419:425	arg1	loss					411:414	loss	411:414	loss	411:414	Downregulation or loss of GnT-IVa causes diabetic phenotypes by dysregulating glucose transporter-2 in pancreatic β-cells.
35854001	3	38	theme	GnT-IVa	419:425	arg1	Downregulation					393:406	Downregulation	393:406	Downregulation	393:406	Downregulation or loss of GnT-IVa causes diabetic phenotypes by dysregulating glucose transporter-2 in pancreatic β-cells.
35854001	4	39	theme	catalytic	583:591	arg1	mechanism					593:601	catalytic mechanism	583:601	catalytic mechanism	583:601	Despite the physiological importance of GnT-IVa, its structure and catalytic mechanism are poorly understood.
35854001	8	40	theme	catalytic	1159:1167	arg1	reaction					1169:1176	efficient catalytic reaction	1149:1176	efficient catalytic reaction	1149:1176	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	8	41	theme	lectin	1107:1112	arg1	domain					1114:1119	the lectin domain	1103:1119	the lectin domain	1103:1119	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	8	41	theme	lectin	1107:1112	arg1	subunit					1137:1143	a regulatory subunit	1124:1143	a regulatory subunit for efficient catalytic reaction	1124:1176	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	8	42	theme	Point	995:999	arg1	mutation					1001:1008	Point mutation	995:1008	Point mutation of the residue critical to sugar recognition	995:1053	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	7	43	theme	binding	830:836	arg1	assay					838:842	Comprehensive glycan binding assay	809:842	Comprehensive glycan binding assay using 157 glycans	809:860	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	1	44	gly	glycoprotein	231:242	arg1	glycoprotein					231:242	glycoprotein functions	231:252	glycoprotein functions	231:252	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	7	45	theme	glycan	823:828	arg1	assay					838:842	Comprehensive glycan binding assay	809:842	Comprehensive glycan binding assay using 157 glycans	809:860	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	7	46	theme	β1-4	975:978	arg1	branch					987:992	a β1-4 GlcNAc branch	973:992	a β1-4 GlcNAc branch	973:992	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	1	47	theme	glycoprotein	231:242	arg1	functions					244:252	glycoprotein functions	231:252	glycoprotein functions	231:252	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	6	48	theme	GlcNAc-binding	786:799	arg1	lectin					801:806	a bacterial GlcNAc-binding lectin	774:806	a bacterial GlcNAc-binding lectin	774:806	The crystal structure of the lectin domain shows structural similarity to a bacterial GlcNAc-binding lectin.
35854001	6	49	theme	bacterial	776:784	arg1	lectin					801:806	a bacterial GlcNAc-binding lectin	774:806	a bacterial GlcNAc-binding lectin	774:806	The crystal structure of the lectin domain shows structural similarity to a bacterial GlcNAc-binding lectin.
35854001	1	50	theme	common	136:141	arg1	modification					162:173	a common post-translational modification	134:173	a common post-translational modification	134:173	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	1	50	theme	common	136:141	arg1	N-Glycosylation					115:129	N-Glycosylation	115:129	N-Glycosylation	115:129	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	7	51	theme	GnT-IVa	895:901	arg1	domain					910:915	the GnT-IVa lectin domain	891:915	the GnT-IVa lectin domain	891:915	Comprehensive glycan binding assay using 157 glycans and solution NMR reveal that the GnT-IVa lectin domain selectively interacts with the product N-glycans having a β1-4 GlcNAc branch.
35854001	3	52	theme	pancreatic	496:505	arg1	β-cells					507:513	pancreatic β-cells	496:513	pancreatic β-cells	496:513	Downregulation or loss of GnT-IVa causes diabetic phenotypes by dysregulating glucose transporter-2 in pancreatic β-cells.
35854001	1	53	theme	post-translational	143:160	arg1	modification					162:173	a common post-translational modification	134:173	a common post-translational modification	134:173	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	1	53	theme	post-translational	143:160	arg1	N-Glycosylation					115:129	N-Glycosylation	115:129	N-Glycosylation	115:129	N-Glycosylation is a common post-translational modification, and the number of GlcNAc branches in N-glycans impacts glycoprotein functions.
35854001	8	54	theme	residue	1017:1023	arg1	mutation					1001:1008	Point mutation	995:1008	Point mutation of the residue critical to sugar recognition	995:1053	Point mutation of the residue critical to sugar recognition impairs the enzymatic activity, suggesting that the lectin domain is a regulatory subunit for efficient catalytic reaction.
35854001	2	55	dep	designated	306:315	arg1	also					301:304	also	301:304	also	301:304	N-Acetylglucosaminyltransferase-IVa (GnT-IVa, also designated as MGAT4A) forms a β1-4 GlcNAc branch on the α1-3 mannose arm in N-glycans.
36304448	9	0	theme	shift	2031:2035	arg1	perturbations					2037:2049	chemical shift perturbations	2022:2049	chemical shift perturbations	2022:2049	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	1	1	theme	anti-cancer	254:264	arg1	properties					288:297	their anti-cancer and anti-inflammatory properties	248:297	their anti-cancer and anti-inflammatory properties	248:297	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	7	2	theme	antenna	1609:1615	arg1	galactosylation					1559:1573	galactosylation	1559:1573	galactosylation of the α6 antenna, but not the α3 antenna,	1559:1616	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	7	3	theme	α6	1582:1583	arg1	antenna					1585:1591	the α6 antenna	1578:1591	the α6 antenna	1578:1591	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	8	4	theme	ADCC	1770:1773	arg1	assay					1784:1788	an adapted ADCC reporter assay	1759:1788	an adapted ADCC reporter assay	1759:1788	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	5	5	from	galactosylation	1111:1125	arg1	mAb					1193:1195	an afucosylated anti-viral mAb	1166:1195	an afucosylated anti-viral mAb	1166:1195	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	1	6	theme	anti-inflammatory	270:286	arg1	properties					288:297	their anti-cancer and anti-inflammatory properties	248:297	their anti-cancer and anti-inflammatory properties	248:297	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	4	7	theme	glycosylation	924:936	arg1	profiles					938:945	certain glycosylation profiles	916:945	certain glycosylation profiles (that can occur during manufacturing)	916:983	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	6	8	gly	afucosylated	1469:1480	arg1	mAb					1482:1484	an afucosylated mAb	1466:1484	an afucosylated mAb	1466:1484	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	9	9	from	location	2003:2010	arg1	galactosylation					1976:1990	galactosylation	1976:1990	galactosylation of at this location	1976:2010	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	5	10	from	location	1141:1148	arg1	galactosylation					1111:1125	galactosylation	1111:1125	galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb	1111:1195	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	1	11	theme	therapeutics	193:204	arg1	type					176:179	an essential type	163:179	an essential type of biologic therapeutics	163:204	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	4	12	theme	product	1011:1017	arg1	quality					1019:1025	product quality	1011:1025	product quality	1011:1025	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	6	13	theme	asymmetric	1345:1354	arg1	N-glycans					1396:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	5	14	theme	anti-viral	1182:1191	arg1	mAb					1193:1195	an afucosylated anti-viral mAb	1166:1195	an afucosylated anti-viral mAb	1166:1195	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	3	15	theme	diverse	618:624	arg1	structures					635:644	diverse chemical structures	618:644	diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging	618:801	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	6	16	theme	complex	1388:1394	arg1	N-glycans					1396:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	6	17	from	N-glycans	1396:1404	arg1	bioactivity					1430:1440	bioactivity	1430:1440	bioactivity	1430:1440	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	6	18	theme	mono-galactosylated	1356:1374	arg1	N-glycans					1396:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	5	19	theme	N-glycans	1153:1161	arg1	location					1141:1148	a specific location	1130:1148	a specific location of N-glycans	1130:1161	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	9	20	theme	galactose	1875:1883	arg1	antenna					1903:1909	the α6 antenna	1896:1909	the α6 antenna	1896:1909	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	9	20	theme	galactose	1875:1883	arg1	residue					1885:1891	the galactose residue	1871:1891	the galactose residue of the α6 antenna	1871:1909	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	6	21	theme	purified	1336:1343	arg1	N-glycans					1396:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	7	22	theme	plasmon	1508:1514	arg1	resonance					1516:1524	surface plasmon resonance	1500:1524	surface plasmon resonance	1500:1524	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	6	23	theme	facile	1312:1317	arg1	method					1319:1324	a facile method	1310:1324	a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb	1310:1484	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	10	24	theme	glycan	2183:2188	arg1	isomers					2190:2196	specific glycan isomers	2174:2196	specific glycan isomers	2174:2196	Our results highlight the importance of identifying and quantifying specific glycan isomers to ensure adequate quality control in batch-to-batch and biosimilar comparisons.
36304448	0	25	theme	monoclonal	66:75	arg1	antibody					77:84	an afucosylated antiviral monoclonal antibody	40:84	an afucosylated antiviral monoclonal antibody	40:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	5	26	theme	antibody-dependent	1237:1254	arg1	ADCC					1284:1287	ADCC	1284:1287	ADCC	1284:1287	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	5	26	theme	antibody-dependent	1237:1254	arg1	cytotoxicity					1270:1281	antibody-dependent cell-mediated cytotoxicity	1237:1281	antibody-dependent cell-mediated cytotoxicity (ADCC) activity	1237:1297	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	3	27	theme	manufacturing	680:692	arg1	conditions					694:703	manufacturing conditions	680:703	manufacturing conditions	680:703	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	9	28	theme	α6	1900:1901	arg1	antenna					1903:1909	the α6 antenna	1896:1909	the α6 antenna	1896:1909	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	5	29	theme	cytotoxicity	1270:1281	arg1	activity					1290:1297	antibody-dependent cell-mediated cytotoxicity (ADCC) activity	1237:1297	antibody-dependent cell-mediated cytotoxicity (ADCC) activity	1237:1297	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	1	30	theme	essential	166:174	arg1	type					176:179	an essential type	163:179	an essential type of biologic therapeutics	163:204	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	10	31	theme	adequate	2208:2215	arg1	control					2225:2231	adequate quality control	2208:2231	adequate quality control	2208:2231	Our results highlight the importance of identifying and quantifying specific glycan isomers to ensure adequate quality control in batch-to-batch and biosimilar comparisons.
36304448	0	32	theme	FcγRIIIA	98:105	arg1	affinity					115:122	its FcγRIIIA binding affinity	94:122	its FcγRIIIA binding affinity	94:122	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	9	33	theme	protein	1920:1926	arg1	backbone					1928:1935	the protein backbone	1916:1935	the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue	1916:2103	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	4	34	theme	glycans	857:863	arg1	effects					837:843	the effects	833:843	the effects of specific glycans on mAb bioactivity	833:882	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	0	35	theme	Specific	0:7	arg1	location					9:16	Specific location	0:16	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody	0:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	5	36	theme	enzymatic	1034:1042	arg1	transglycosylation					1044:1061	enzymatic transglycosylation	1034:1061	enzymatic transglycosylation with chemically-defined N-glycans	1034:1095	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	3	37	contain	have	613:616	arg2	structures					635:644	diverse chemical structures	618:644	diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging	618:801	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	3	37	contain	have	613:616	arg1	glycans					583:589	These glycans	577:589	These glycans	577:589	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	2	38	theme	mAb	508:510	arg1	pharmacokinetics					559:574	pharmacokinetics	559:574	pharmacokinetics	559:574	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	2	38	theme	mAb	508:510	arg1	bioactivities					512:524	mAb bioactivities	508:524	mAb bioactivities including effector functions and pharmacokinetics	508:574	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	2	38	theme	mAb	508:510	arg1	functions					545:553	effector functions	536:553	effector functions	536:553	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	5	39	theme	specific	1132:1139	arg1	location					1141:1148	a specific location	1130:1148	a specific location of N-glycans	1130:1161	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	0	40	theme	afucosylated	43:54	arg1	antibody					77:84	an afucosylated antiviral monoclonal antibody	40:84	an afucosylated antiviral monoclonal antibody	40:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	1	41	theme	respiratory	337:347	arg1	infections					349:358	respiratory infections	337:358	respiratory infections	337:358	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	7	42	theme	binding	1650:1656	arg1	affinity					1658:1665	FcγRIIIA binding affinity	1641:1665	FcγRIIIA binding affinity	1641:1665	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	10	43	theme	biosimilar	2255:2264	arg1	comparisons					2266:2276	batch-to-batch and biosimilar comparisons	2236:2276	batch-to-batch and biosimilar comparisons	2236:2276	Our results highlight the importance of identifying and quantifying specific glycan isomers to ensure adequate quality control in batch-to-batch and biosimilar comparisons.
36304448	8	44	theme	respiratory	1719:1729	arg1	RSV					1748:1750	RSV	1748:1750	RSV	1748:1750	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	8	44	theme	respiratory	1719:1729	arg1	virus					1741:1745	respiratory syncytial virus	1719:1745	respiratory syncytial virus (RSV)	1719:1751	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	4	45	theme	mAb	868:870	arg1	bioactivity					872:882	mAb bioactivity	868:882	mAb bioactivity	868:882	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	8	46	theme	reporter	1775:1782	arg1	assay					1784:1788	an adapted ADCC reporter assay	1759:1788	an adapted ADCC reporter assay	1759:1788	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	10	47	theme	batch-to-batch	2236:2249	arg1	comparisons					2266:2276	batch-to-batch and biosimilar comparisons	2236:2276	batch-to-batch and biosimilar comparisons	2236:2276	Our results highlight the importance of identifying and quantifying specific glycan isomers to ensure adequate quality control in batch-to-batch and biosimilar comparisons.
36304448	8	48	theme	virus	1741:1745	arg1	model					1710:1714	an anti-viral model	1696:1714	an anti-viral model of respiratory syncytial virus (RSV)	1696:1751	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	3	49	theme	specific	741:748	arg1	structures					757:766	specific glycan structures	741:766	specific glycan structures	741:766	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	9	50	theme	chemical	2022:2029	arg1	perturbations					2037:2049	chemical shift perturbations	2022:2049	chemical shift perturbations	2022:2049	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	3	51	theme	challenging	791:801	arg1	bioactivity					779:789	mAb bioactivity challenging	775:801	mAb bioactivity challenging	775:801	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	7	52	theme	α3	1606:1607	arg1	antenna					1609:1615	the α3 antenna	1602:1615	the α3 antenna	1602:1615	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	5	53	gly	afucosylated	1169:1180	arg1	mAb					1193:1195	an afucosylated anti-viral mAb	1166:1195	an afucosylated anti-viral mAb	1166:1195	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	3	54	theme	mAb	775:777	arg1	bioactivity					779:789	mAb bioactivity challenging	775:801	mAb bioactivity challenging	775:801	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	7	55	theme	antenna	1585:1591	arg1	galactosylation					1559:1573	galactosylation	1559:1573	galactosylation of the α6 antenna, but not the α3 antenna,	1559:1616	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	8	56	theme	adapted	1762:1768	arg1	assay					1784:1788	an adapted ADCC reporter assay	1759:1788	an adapted ADCC reporter assay	1759:1788	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	4	57	theme	certain	916:922	arg1	profiles					938:945	certain glycosylation profiles	916:945	certain glycosylation profiles (that can occur during manufacturing)	916:983	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	5	58	with	transglycosylation	1044:1061	arg1	N-glycans					1087:1095	chemically-defined N-glycans	1068:1095	chemically-defined N-glycans	1068:1095	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	3	59	theme	chemical	626:633	arg1	structures					635:644	diverse chemical structures	618:644	diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging	618:801	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	1	60	theme	biologic	184:191	arg1	therapeutics					193:204	biologic therapeutics	184:204	biologic therapeutics	184:204	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	9	61	theme	structure-function	1817:1834	arg1	relationship					1836:1847	this structure-function relationship	1812:1847	this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue	1812:2103	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	9	62	theme	galactose	2087:2095	arg1	residue					2097:2103	this galactose residue	2082:2103	this galactose residue	2082:2103	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	1	63	used	used	214:217	arg2	mAbs					148:151	mAbs	148:151	mAbs	148:151	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	1	63	used	used	214:217	arg2	antibodies					136:145	Monoclonal antibodies	125:145	Monoclonal antibodies (mAbs)	125:152	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	6	64	theme	afucosylated	1469:1480	arg1	mAb					1482:1484	an afucosylated mAb	1466:1484	an afucosylated mAb	1466:1484	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	4	65	from	changes	905:911	arg1	profiles					938:945	certain glycosylation profiles	916:945	certain glycosylation profiles (that can occur during manufacturing)	916:983	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	1	66	theme	Monoclonal	125:134	arg1	mAbs					148:151	mAbs	148:151	mAbs	148:151	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	1	66	theme	Monoclonal	125:134	arg1	antibodies					136:145	Monoclonal antibodies	125:145	Monoclonal antibodies (mAbs)	125:152	Monoclonal antibodies (mAbs) comprise an essential type of biologic therapeutics and are used to treat diseases because of their anti-cancer and anti-inflammatory properties, and their ability to protect against respiratory infections.
36304448	7	67	theme	flow	1530:1533	arg1	cytometry					1535:1543	flow cytometry	1530:1543	flow cytometry	1530:1543	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	9	68	theme	residue	1885:1891	arg1	interaction					1856:1866	the interaction	1852:1866	the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue	1852:2103	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	5	69	theme	afucosylated	1169:1180	arg1	mAb					1193:1195	an afucosylated anti-viral mAb	1166:1195	an afucosylated anti-viral mAb	1166:1195	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	2	70	theme	effector	536:543	arg1	functions					545:553	effector functions	536:553	effector functions	536:553	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	7	71	theme	surface	1500:1506	arg1	resonance					1516:1524	surface plasmon resonance	1500:1524	surface plasmon resonance	1500:1524	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	10	72	theme	specific	2174:2181	arg1	isomers					2190:2196	specific glycan isomers	2174:2196	specific glycan isomers	2174:2196	Our results highlight the importance of identifying and quantifying specific glycan isomers to ensure adequate quality control in batch-to-batch and biosimilar comparisons.
36304448	5	73	theme	cell-mediated	1256:1268	arg1	ADCC					1284:1287	ADCC	1284:1287	ADCC	1284:1287	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	5	73	theme	cell-mediated	1256:1268	arg1	cytotoxicity					1270:1281	antibody-dependent cell-mediated cytotoxicity	1237:1281	antibody-dependent cell-mediated cytotoxicity (ADCC) activity	1237:1297	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	9	74	theme	antenna	1903:1909	arg1	antenna					1903:1909	the α6 antenna	1896:1909	the α6 antenna	1896:1909	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	9	74	theme	antenna	1903:1909	arg1	residue					1885:1891	the galactose residue	1871:1891	the galactose residue of the α6 antenna	1871:1909	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	0	75	from	location	9:16	arg1	antibody					77:84	an afucosylated antiviral monoclonal antibody	40:84	an afucosylated antiviral monoclonal antibody	40:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	10	76	theme	quality	2217:2223	arg1	control					2225:2231	adequate quality control	2208:2231	adequate quality control	2208:2231	Our results highlight the importance of identifying and quantifying specific glycan isomers to ensure adequate quality control in batch-to-batch and biosimilar comparisons.
36304448	0	77	theme	binding	107:113	arg1	affinity					115:122	its FcγRIIIA binding affinity	94:122	its FcγRIIIA binding affinity	94:122	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	5	78	theme	chemically-defined	1068:1085	arg1	N-glycans					1087:1095	chemically-defined N-glycans	1068:1095	chemically-defined N-glycans	1068:1095	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	5	79	theme	FcγRIIIA	1216:1223	arg1	binding					1225:1231	FcγRIIIA binding	1216:1231	FcγRIIIA binding	1216:1231	Using enzymatic transglycosylation with chemically-defined N-glycans, we show that galactosylation at a specific location of N-glycans in an afucosylated anti-viral mAb is responsible for FcγRIIIA binding and antibody-dependent cell-mediated cytotoxicity (ADCC) activity.
36304448	4	80	from	effects	837:843	arg1	bioactivity					872:882	mAb bioactivity	868:882	mAb bioactivity	868:882	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	4	81	theme	specific	848:855	arg1	glycans					857:863	specific glycans	848:863	specific glycans	848:863	There is a need to delineate the effects of specific glycans on mAb bioactivity to determine whether changes in certain glycosylation profiles (that can occur during manufacturing) will significantly affect product quality.
36304448	2	82	theme	biosynthetic	421:432	arg1	process					434:440	a biosynthetic process	419:440	a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics	419:574	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	2	82	theme	biosynthetic	421:432	arg1	glycosylation					404:416	post-translational glycosylation	385:416	post-translational glycosylation	385:416	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	0	83	theme	galactosylation	21:35	arg1	location					9:16	Specific location	0:16	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody	0:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	8	84	theme	anti-viral	1699:1708	arg1	model					1710:1714	an anti-viral model	1696:1714	an anti-viral model of respiratory syncytial virus (RSV)	1696:1751	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	9	85	with	interaction	1856:1866	arg1	backbone					1928:1935	the protein backbone	1916:1935	the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue	1916:2103	We further correlate this structure-function relationship to the interaction of the galactose residue of the α6 antenna with the protein backbone using 2D-1H-15N-NMR, which showed that galactosylation of at this location exhibited chemical shift perturbations compared to glycoforms lacking this galactose residue.
36304448	0	86	theme	antiviral	56:64	arg1	antibody					77:84	an afucosylated antiviral monoclonal antibody	40:84	an afucosylated antiviral monoclonal antibody	40:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	2	87	theme	crucial	491:497	arg1	roles					499:503	crucial roles	491:503	crucial roles	491:503	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	8	88	theme	syncytial	1731:1739	arg1	RSV					1748:1750	RSV	1748:1750	RSV	1748:1750	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	8	88	theme	syncytial	1731:1739	arg1	virus					1741:1745	respiratory syncytial virus	1719:1745	respiratory syncytial virus (RSV)	1719:1751	We confirm its relevance in an anti-viral model of respiratory syncytial virus (RSV) using an adapted ADCC reporter assay.
36304448	3	89	theme	glycan	750:755	arg1	structures					757:766	specific glycan structures	741:766	specific glycan structures	741:766	These glycans are heterogeneous and have diverse chemical structures whose composition is sensitive to manufacturing conditions, rendering the understanding of how specific glycan structures affect mAb bioactivity challenging.
36304448	6	90	theme	biantennary	1376:1386	arg1	N-glycans					1396:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	purified asymmetric mono-galactosylated biantennary complex N-glycans	1336:1404	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	6	91	from	influence	1417:1425	arg1	bioactivity					1430:1440	bioactivity	1430:1440	bioactivity	1430:1440	We report a facile method to obtain purified asymmetric mono-galactosylated biantennary complex N-glycans, and their influence on bioactivity upon incorporation into an afucosylated mAb.
36304448	7	92	theme	FcγRIIIA	1641:1648	arg1	affinity					1658:1665	FcγRIIIA binding affinity	1641:1665	FcγRIIIA binding affinity	1641:1665	Using ELISA, surface plasmon resonance and flow cytometry, we show that galactosylation of the α6 antenna, but not the α3 antenna, consistently increases FcγRIIIA binding affinity.
36304448	0	93	gly	afucosylated	43:54	arg1	antibody					77:84	an afucosylated antiviral monoclonal antibody	40:84	an afucosylated antiviral monoclonal antibody	40:84	Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcγRIIIA binding affinity.
36304448	2	94	theme	post-translational	385:402	arg1	process					434:440	a biosynthetic process	419:440	a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics	419:574	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
36304448	2	94	theme	post-translational	385:402	arg1	glycosylation					404:416	post-translational glycosylation	385:416	post-translational glycosylation	385:416	Its production involves post-translational glycosylation, a biosynthetic process that conjugates glycans to proteins, which plays crucial roles in mAb bioactivities including effector functions and pharmacokinetics.
35364207	7	0	dep	efficiency	1004:1013	arg1	the					983:985	the	983:985	the	983:985	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	9	1	with	glycosylation	1443:1455	arg1	saccharides					1462:1472	saccharides	1462:1472	saccharides	1462:1472	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	1	2	theme	protein	160:166	arg1	development					134:144	the development	130:144	the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields	130:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	0	3	theme	lactoferrin	80:90	arg1	property					68:75	the emulsifying property	52:75	the emulsifying property of lactoferrin	52:90	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	8	4	with	glycation	1149:1157	arg1	COS					1164:1166	COS	1164:1166	COS	1164:1166	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	7	5	theme	emulsifying	992:1002	arg1	efficiency					1004:1013	emulsifying efficiency	992:1013	emulsifying efficiency	992:1013	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	8	6	from	droplets	1274:1281	arg1	emulsions					1306:1314	the emulsions	1302:1314	the emulsions	1302:1314	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	0	7	from	Effect	0:5	arg1	property					68:75	the emulsifying property	52:75	the emulsifying property of lactoferrin	52:90	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	7	8	theme	droplet	1043:1049	arg1	size					1051:1054	the emulsion droplet size	1030:1054	the emulsion droplet size	1030:1054	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	8	9	theme	thicker	1253:1259	arg1	layer					1261:1265	thicker layer	1253:1265	thicker layer	1253:1265	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	2	10	theme	chitosan	306:313	arg1	oligosaccharide					315:329	chitosan oligosaccharide	306:329	chitosan oligosaccharide (COS)	306:335	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	2	10	theme	chitosan	306:313	arg1	COS					332:334	COS	332:334	COS	332:334	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	4	11	theme	hydrophobic	592:602	arg1	groups					604:609	more hydrophobic groups	587:609	more hydrophobic groups exposed to the surface of the structure and particle size increase of LF	587:682	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	9	12	theme	alimentary	1415:1424	arg1	proteins					1426:1433	alimentary proteins	1415:1433	alimentary proteins	1415:1433	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	4	13	with	glycation	564:572	arg1	COS					579:581	COS	579:581	COS	579:581	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	2	14	theme	degree	294:299	arg1	effect					274:279	the effect	270:279	the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF)	270:385	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	8	15	dep	droplets	1274:1281	arg1	the					1270:1272	the	1270:1272	the	1270:1272	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	4	16	theme	more	587:590	arg1	groups					604:609	more hydrophobic groups	587:609	more hydrophobic groups exposed to the surface of the structure and particle size increase of LF	587:682	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	5	17	theme	oil	710:712	arg1	phase					714:718	50% (v/v) oil phase	700:718	50% (v/v) oil phase	700:718	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	8	18	theme	LF	1205:1206	arg1	activity					1193:1200	the interfacial activity	1177:1200	the interfacial activity of LF	1177:1206	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	5	19	with	Emulsions	685:693	arg1	phase					714:718	50% (v/v) oil phase	700:718	50% (v/v) oil phase	700:718	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	5	19	with	Emulsions	685:693	arg1	concentration					732:744	protein concentration	724:744	protein concentration of 2% (w/v)	724:756	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	2	20	theme	glycation	284:292	arg1	degree					294:299	glycation degree	284:299	glycation degree with chitosan oligosaccharide (COS)	284:335	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	4	21	theme	increase	669:676	arg1	surface					626:632	the surface	622:632	the surface of the structure and particle size increase of LF	622:682	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	2	22	theme	Maillard	395:402	arg1	reaction					404:411	Maillard reaction	395:411	Maillard reaction	395:411	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	7	23	theme	emulsion	1034:1041	arg1	size					1051:1054	the emulsion droplet size	1030:1054	the emulsion droplet size	1030:1054	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	9	24	theme	proteins	1426:1433	arg1	properties					1401:1410	emulsifying properties	1389:1410	emulsifying properties of alimentary proteins	1389:1433	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	8	25	dep	enhanced	1168:1175	arg1	leading					1208:1214	leading	1208:1214	leading to more adsorbing amount	1208:1239	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	8	25	dep	enhanced	1168:1175	arg1	forming					1245:1251	forming	1245:1251	forming thicker layer on the droplets and gel network in the emulsions	1245:1314	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	1	26	theme	due	189:191	arg1	emulsions					179:187	emulsions	179:187	emulsions due to their potential applications in functional food fields	179:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	7	27	theme	stability	1019:1027	arg1	size					1051:1054	the emulsion droplet size	1030:1054	the emulsion droplet size	1030:1054	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	7	27	theme	stability	1019:1027	arg1	CI					1064:1065	the CI	1060:1065	the CI	1060:1065	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	9	28	theme	protein-based	1492:1504	arg1	emulsifiers					1506:1516	novel protein-based emulsifiers	1486:1516	novel protein-based emulsifiers	1486:1516	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	7	29	contain	had	979:981	arg2	stability					1019:1027	stability	1019:1027	stability	1019:1027	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	7	29	contain	had	979:981	arg2	efficiency					1004:1013	emulsifying efficiency	992:1013	emulsifying efficiency	992:1013	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	7	29	contain	had	979:981	arg1	conjugates					958:967	LF-COS conjugates	951:967	LF-COS conjugates under 4 h	951:977	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	3	30	theme	present	421:427	arg1	study					429:433	the present study	417:433	the present study	417:433	In the present study, SDS-PAGE and FT-IR were used to confirm LF and COS covalently binding together successfully.
35364207	7	31	theme	best	987:990	arg1	efficiency					1004:1013	emulsifying efficiency	992:1013	emulsifying efficiency	992:1013	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	8	32	from	network	1291:1297	arg1	emulsions					1306:1314	the emulsions	1302:1314	the emulsions	1302:1314	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	6	33	theme	droplet	886:892	arg1	size					894:897	smaller droplet size	878:897	smaller droplet size	878:897	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	1	34	from	interest	118:125	arg1	development					134:144	the development	130:144	the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields	130:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	4	35	theme	size	664:667	arg1	increase					669:676	particle size increase	655:676	particle size increase	655:676	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	0	36	theme	oligosaccharide	19:33	arg1	glycosylation					35:47	chitosan oligosaccharide glycosylation	10:47	chitosan oligosaccharide glycosylation	10:47	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	7	37	theme	efficiency	1004:1013	arg1	size					1051:1054	the emulsion droplet size	1030:1054	the emulsion droplet size	1030:1054	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	7	37	theme	efficiency	1004:1013	arg1	CI					1064:1065	the CI	1060:1065	the CI	1060:1065	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	1	38	theme	fast	102:105	arg1	interest					118:125	fast increasing interest	102:125	fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields	102:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	1	39	theme	potential	202:210	arg1	applications					212:223	their potential applications	196:223	their potential applications in functional food fields	196:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	0	40	theme	chitosan	10:17	arg1	glycosylation					35:47	chitosan oligosaccharide glycosylation	10:47	chitosan oligosaccharide glycosylation	10:47	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	5	41	theme	50	700:701	arg1	%					702:702	%	702:702	%	702:702	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	1	42	theme	increasing	107:116	arg1	interest					118:125	fast increasing interest	102:125	fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields	102:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	2	43	from	effect	274:279	arg1	properties					356:365	the emulsifying properties	340:365	the emulsifying properties of lactoferrin (LF)	340:385	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	5	44	theme	shear	790:794	arg1	method					796:801	one-step shear method	781:801	one-step shear method	781:801	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	6	45	theme	creaming	909:916	arg1	index					918:922	lower creaming index	903:922	lower creaming index (CI)	903:927	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	6	45	theme	creaming	909:916	arg1	CI					925:926	CI	925:926	CI	925:926	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	5	46	theme	%	702:702	arg1	phase					714:718	50% (v/v) oil phase	700:718	50% (v/v) oil phase	700:718	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	6	47	theme	native	818:823	arg1	LF					825:826	native LF	818:826	native LF	818:826	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	4	48	dep	structure	641:649	arg1	the					637:639	the	637:639	the	637:639	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	4	49	theme	structure	641:649	arg1	surface					626:632	the surface	622:632	the surface of the structure and particle size increase of LF	622:682	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	0	50	theme	glycosylation	35:47	arg1	Effect					0:5	Effect	0:5	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.	0:91	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	6	51	theme	lower	903:907	arg1	index					918:922	lower creaming index	903:922	lower creaming index (CI)	903:927	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	6	51	theme	lower	903:907	arg1	CI					925:926	CI	925:926	CI	925:926	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	5	52	theme	%	750:750	arg1	phase					714:718	50% (v/v) oil phase	700:718	50% (v/v) oil phase	700:718	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	5	52	theme	%	750:750	arg1	concentration					732:744	protein concentration	724:744	protein concentration of 2% (w/v)	724:756	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	7	53	theme	LF-COS	951:956	arg1	conjugates					958:967	LF-COS conjugates	951:967	LF-COS conjugates under 4 h	951:977	Among these samples, LF-COS conjugates under 4 h had the best emulsifying efficiency and stability, the emulsion droplet size and the CI of which decreased 39.66% and 28.55% compared with LF, respectively.
35364207	1	54	theme	functional	228:237	arg1	fields					244:249	functional food fields	228:249	functional food fields	228:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	0	55	theme	emulsifying	56:66	arg1	property					68:75	the emulsifying property	52:75	the emulsifying property of lactoferrin	52:90	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	2	56	theme	emulsifying	344:354	arg1	properties					356:365	the emulsifying properties	340:365	the emulsifying properties of lactoferrin (LF)	340:385	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	6	57	theme	LF-COS	853:858	arg1	conjugates					860:869	LF-COS conjugates	853:869	LF-COS conjugates	853:869	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	9	58	theme	emulsifying	1389:1399	arg1	properties					1401:1410	emulsifying properties	1389:1410	emulsifying properties of alimentary proteins	1389:1433	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	9	59	theme	properties	1401:1410	arg1	modification					1373:1384	the modification	1369:1384	the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides	1369:1472	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	4	60	theme	Intrinsic	529:537	arg1	fluorescence					539:550	Intrinsic fluorescence	529:550	Intrinsic fluorescence	529:550	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	0	61	gly	glycosylation	35:47	arg1	lactoferrin					80:90	lactoferrin	80:90	lactoferrin	80:90	Effect of chitosan oligosaccharide glycosylation on the emulsifying property of lactoferrin.
35364207	1	62	from	applications	212:223	arg1	fields					244:249	functional food fields	228:249	functional food fields	228:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	3	63	used	used	460:463	arg2	FT-IR					449:453	FT-IR	449:453	FT-IR	449:453	In the present study, SDS-PAGE and FT-IR were used to confirm LF and COS covalently binding together successfully.
35364207	3	63	used	used	460:463	arg2	SDS-PAGE					436:443	SDS-PAGE	436:443	SDS-PAGE	436:443	In the present study, SDS-PAGE and FT-IR were used to confirm LF and COS covalently binding together successfully.
35364207	1	64	theme	food	239:242	arg1	fields					244:249	functional food fields	228:249	functional food fields	228:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	9	65	theme	novel	1486:1490	arg1	emulsifiers					1506:1516	novel protein-based emulsifiers	1486:1516	novel protein-based emulsifiers	1486:1516	This finding would make sense to further understand the modification of emulsifying properties of alimentary proteins through glycosylation with saccharides and develop novel protein-based emulsifiers.
35364207	8	66	theme	adsorbing	1224:1232	arg1	amount					1234:1239	more adsorbing amount	1219:1239	more adsorbing amount	1219:1239	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	1	67	theme	alimentary	149:158	arg1	protein					160:166	alimentary protein	149:166	alimentary protein stabilized emulsions due to their potential applications in functional food fields	149:249	There is fast increasing interest in the development of alimentary protein stabilized emulsions due to their potential applications in functional food fields.
35364207	5	68	dep	%	702:702	arg1	v/v					705:707	v/v	705:707	v/v	705:707	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	8	69	theme	gel	1287:1289	arg1	network					1291:1297	gel network	1287:1297	gel network	1287:1297	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	8	70	theme	interfacial	1181:1191	arg1	activity					1193:1200	the interfacial activity	1177:1200	the interfacial activity of LF	1177:1206	Furthermore, glycation with COS enhanced the interfacial activity of LF leading to more adsorbing amount and forming thicker layer on the droplets and gel network in the emulsions.
35364207	5	71	theme	one-step	781:788	arg1	method					796:801	one-step shear method	781:801	one-step shear method	781:801	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	4	72	theme	LF	681:682	arg1	structure					641:649	structure	641:649	structure	641:649	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	4	72	theme	LF	681:682	arg1	increase					669:676	particle size increase	655:676	particle size increase	655:676	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	4	73	theme	particle	655:662	arg1	increase					669:676	particle size increase	655:676	particle size increase	655:676	Intrinsic fluorescence showed that glycation with COS led more hydrophobic groups exposed to the surface of the structure and particle size increase of LF.
35364207	5	74	theme	protein	724:730	arg1	concentration					732:744	protein concentration	724:744	protein concentration of 2% (w/v)	724:756	Emulsions with 50% (v/v) oil phase and protein concentration of 2% (w/v) was fabricated through one-step shear method.
35364207	6	75	theme	smaller	878:884	arg1	size					894:897	smaller droplet size	878:897	smaller droplet size	878:897	Compared with native LF, emulsions stabilized by LF-COS conjugates showed smaller droplet size and lower creaming index (CI).
35364207	2	76	theme	lactoferrin	370:380	arg1	properties					356:365	the emulsifying properties	340:365	the emulsifying properties of lactoferrin (LF)	340:385	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	2	77	with	degree	294:299	arg1	oligosaccharide					315:329	chitosan oligosaccharide	306:329	chitosan oligosaccharide (COS)	306:335	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
35364207	2	77	with	degree	294:299	arg1	COS					332:334	COS	332:334	COS	332:334	This work studied the effect of glycation degree with chitosan oligosaccharide (COS) on the emulsifying properties of lactoferrin (LF) through Maillard reaction.
36990248	0	0	from	role	15:18	arg1	O-glycosylation					82:96	mucin-type O-glycosylation	71:96	mucin-type O-glycosylation in Silkworm Bombyx mori	71:120	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	1	1	theme	proteins	170:177	arg1	modification					214:225	an important post-translational modification	182:225	an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability	182:308	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	1	1	theme	proteins	170:177	arg1	O-glycosylation					123:137	O-glycosylation	123:137	O-glycosylation of secreted and membrane-bound proteins	123:177	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	1	2	theme	protein	279:285	arg1	folding					287:293	protein folding	279:293	protein folding	279:293	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	0	3	theme	mucin-type	71:80	arg1	O-glycosylation					82:96	mucin-type O-glycosylation	71:96	mucin-type O-glycosylation in Silkworm Bombyx mori	71:120	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	10	4	theme	O-glycosylation	1683:1697	arg1	comprehension					1666:1678	the practical comprehension	1652:1678	the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system	1652:1764	Our findings allow the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system.
36990248	2	5	theme	biological	370:379	arg1	functions					381:389	their biological functions	364:389	their biological functions	364:389	However, despite the importance of O-linked glycans, their biological functions have not yet been fully elucidated and the synthetic pathway of O-glycosylation has not been investigated in detail, especially in the silkworm.
36990248	10	6	theme	productive	1737:1746	arg1	system					1759:1764	a productive expression system	1735:1764	a productive expression system	1735:1764	Our findings allow the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system.
36990248	10	6	theme	productive	1737:1746	arg1	silkworms					1722:1730	silkworms	1722:1730	silkworms	1722:1730	Our findings allow the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system.
36990248	0	7	theme	Silkworm	101:108	arg1	mori					117:120	Silkworm Bombyx mori	101:120	Silkworm Bombyx mori	101:120	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	6	8	theme	transcriptional	1022:1036	arg1	variants					1038:1045	Five transcriptional variants	1017:1045	Five transcriptional variants	1017:1045	Five transcriptional variants and four protein isoforms were identified in silkworms, and the biological functions of these isoforms were investigated.
36990248	7	9	theme	cultured	1297:1304	arg1	cells					1306:1310	cultured cells	1297:1310	cultured cells	1297:1310	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	8	10	theme	T-synthase	1373:1382	arg1	T-synthase					1373:1382	T-synthase	1373:1382	T-synthase	1373:1382	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	10	theme	T-synthase	1373:1382	arg1	essential					1425:1433	essential	1425:1433	essential	1425:1433	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	10	theme	T-synthase	1373:1382	arg1	domain					1363:1368	a specific functional domain	1341:1368	a specific functional domain	1341:1368	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	5	11	theme	many	1003:1006	arg1	animals					1008:1014	many animals	1003:1014	many animals	1003:1014	Furthermore, we characterized the 1 b1,3-galactosyltransferase (T-synthase) required for synthesis of the core 1 structure, common to many animals.
36990248	2	12	theme	O-linked	346:353	arg1	glycans					355:361	O-linked glycans	346:361	O-linked glycans	346:361	However, despite the importance of O-linked glycans, their biological functions have not yet been fully elucidated and the synthetic pathway of O-glycosylation has not been investigated in detail, especially in the silkworm.
36990248	9	13	dep	profile	1581:1587	arg1	the					1568:1570	the	1568:1570	the	1568:1570	Altogether, our results elucidated the O-glycan profile and function of T-synthase in the silkworm.
36990248	4	14	theme	O-glycan	807:814	arg1	components					789:798	major components	783:798	major components of the O-glycan attached to secreted proteins produced in silkworms	783:866	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	4	15	theme	GalNAc	695:700	arg1	monosaccharide					712:725	GalNAc or GlcNAc monosaccharide	695:725	GalNAc or GlcNAc monosaccharide	695:725	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	0	16	theme	Bombyx	110:115	arg1	mori					117:120	Silkworm Bombyx mori	101:120	Silkworm Bombyx mori	101:120	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	4	17	attach	attached	816:823	arg2	O-glycan					807:814	the O-glycan	803:814	the O-glycan attached to secreted proteins produced in silkworms	803:866	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	4	17	attach	attached	816:823	arg1	proteins					837:844	secreted proteins	828:844	secreted proteins produced in silkworms	828:866	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	7	18	located	localized	1218:1226	arg1	apparatus					1241:1249	the Golgi apparatus	1231:1249	the Golgi apparatus	1231:1249	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	7	18	located	localized	1218:1226	arg2	2					1211:1211	2	1211:1211	2	1211:1211	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	7	18	located	localized	1218:1226	arg2	isoforms					1196:1203	BmT-synthase isoforms 1 and 2	1183:1211	isoforms	1196:1203	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	7	18	located	localized	1218:1226	arg1	cells					1268:1272	cultured BmN4 cells	1254:1272	cultured BmN4 cells	1254:1272	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	0	19	gly	O-glycosylation	82:96	arg1	mori					117:120	Silkworm Bombyx mori	101:120	Silkworm Bombyx mori	101:120	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	1	20	theme	important	185:193	arg1	modification					214:225	an important post-translational modification	182:225	an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability	182:308	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	1	20	theme	important	185:193	arg1	O-glycosylation					123:137	O-glycosylation	123:137	O-glycosylation of secreted and membrane-bound proteins	123:177	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	0	21	theme	biological	4:13	arg1	role					15:18	The biological role	0:18	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.	0:121	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	7	22	theme	cultured	1254:1261	arg1	cells					1268:1272	cultured BmN4 cells	1254:1272	cultured BmN4 cells	1254:1272	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	1	23	theme	post-translational	195:212	arg1	modification					214:225	an important post-translational modification	182:225	an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability	182:308	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	1	23	theme	post-translational	195:212	arg1	O-glycosylation					123:137	O-glycosylation	123:137	O-glycosylation of secreted and membrane-bound proteins	123:177	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	5	24	theme	structure	982:990	arg1	synthesis					958:966	synthesis	958:966	synthesis of the core 1 structure	958:990	Furthermore, we characterized the 1 b1,3-galactosyltransferase (T-synthase) required for synthesis of the core 1 structure, common to many animals.
36990248	9	25	theme	O-glycan	1572:1579	arg1	profile					1581:1587	O-glycan profile	1572:1587	O-glycan profile	1572:1587	Altogether, our results elucidated the O-glycan profile and function of T-synthase in the silkworm.
36990248	2	26	theme	O-glycosylation	455:469	arg1	pathway					444:450	the synthetic pathway	430:450	the synthetic pathway of O-glycosylation	430:469	However, despite the importance of O-linked glycans, their biological functions have not yet been fully elucidated and the synthetic pathway of O-glycosylation has not been investigated in detail, especially in the silkworm.
36990248	9	27	from	function	1593:1600	arg1	silkworm					1623:1630	the silkworm	1619:1630	the silkworm	1619:1630	Altogether, our results elucidated the O-glycan profile and function of T-synthase in the silkworm.
36990248	1	28	gly	O-glycosylation	123:137	arg1	proteins					170:177	secreted and membrane-bound proteins	142:177	secreted and membrane-bound proteins	142:177	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	5	29	theme	core	975:978	arg1	structure					982:990	the core 1 structure	971:990	the core 1 structure	971:990	Furthermore, we characterized the 1 b1,3-galactosyltransferase (T-synthase) required for synthesis of the core 1 structure, common to many animals.
36990248	2	30	link	O-linked	346:353	arg1	glycans					355:361	O-linked glycans	346:361	O-linked glycans	346:361	However, despite the importance of O-linked glycans, their biological functions have not yet been fully elucidated and the synthetic pathway of O-glycosylation has not been investigated in detail, especially in the silkworm.
36990248	8	31	theme	stem	1396:1399	arg1	domain					1401:1406	the stem domain	1392:1406	the stem domain	1392:1406	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	0	32	from	O-glycosylation	82:96	arg1	mori					117:120	Silkworm Bombyx mori	101:120	Silkworm Bombyx mori	101:120	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	5	33	theme	common	993:998	arg1	T-synthase					933:942	T-synthase	933:942	T-synthase	933:942	Furthermore, we characterized the 1 b1,3-galactosyltransferase (T-synthase) required for synthesis of the core 1 structure, common to many animals.
36990248	5	33	theme	common	993:998	arg1	b1,3-galactosyltransferase					905:930	the 1 b1,3-galactosyltransferase	899:930	the 1 b1,3-galactosyltransferase (T-synthase)	899:943	Furthermore, we characterized the 1 b1,3-galactosyltransferase (T-synthase) required for synthesis of the core 1 structure, common to many animals.
36990248	2	34	theme	synthetic	434:442	arg1	pathway					444:450	the synthetic pathway	430:450	the synthetic pathway of O-glycosylation	430:469	However, despite the importance of O-linked glycans, their biological functions have not yet been fully elucidated and the synthetic pathway of O-glycosylation has not been investigated in detail, especially in the silkworm.
36990248	0	35	theme	1β1-3galactosyltransferase	28:53	arg1	role					15:18	The biological role	0:18	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.	0:121	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	4	36	theme	core	731:734	arg1	Galβ1-3-GalNAcα1-Ser/Thr					752:775	Galβ1-3-GalNAcα1-Ser/Thr	752:775	Galβ1-3-GalNAcα1-Ser/Thr	752:775	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	4	36	theme	core	731:734	arg1	disaccharide					738:749	core 1 disaccharide	731:749	core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr)	731:776	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	8	37	theme	functional	1352:1361	arg1	T-synthase					1373:1382	T-synthase	1373:1382	T-synthase	1373:1382	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	37	theme	functional	1352:1361	arg1	essential					1425:1433	essential	1425:1433	essential	1425:1433	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	37	theme	functional	1352:1361	arg1	domain					1363:1368	a specific functional domain	1341:1368	a specific functional domain	1341:1368	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	0	38	theme	core	23:26	arg1	1β1-3galactosyltransferase					28:53	core 1β1-3galactosyltransferase	23:53	core 1β1-3galactosyltransferase (T-synthase)	23:66	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	0	38	theme	core	23:26	arg1	T-synthase					56:65	T-synthase	56:65	T-synthase	56:65	The biological role of core 1β1-3galactosyltransferase (T-synthase) in mucin-type O-glycosylation in Silkworm Bombyx mori.
36990248	3	39	theme	mucin-type	652:661	arg1	O-glycans					663:671	mucin-type O-glycans	652:671	mucin-type O-glycans using LC-MS	652:683	In this study, we aimed to investigate O-glycosylation in silkworms by analyzing the overall structural profiles of mucin-type O-glycans using LC-MS.
36990248	6	40	theme	protein	1056:1062	arg1	isoforms					1064:1071	four protein isoforms	1051:1071	four protein isoforms	1051:1071	Five transcriptional variants and four protein isoforms were identified in silkworms, and the biological functions of these isoforms were investigated.
36990248	9	41	theme	T-synthase	1605:1614	arg1	profile					1581:1587	O-glycan profile	1572:1587	O-glycan profile	1572:1587	Altogether, our results elucidated the O-glycan profile and function of T-synthase in the silkworm.
36990248	9	41	theme	T-synthase	1605:1614	arg1	function					1593:1600	function	1593:1600	function	1593:1600	Altogether, our results elucidated the O-glycan profile and function of T-synthase in the silkworm.
36990248	7	42	theme	Golgi	1235:1239	arg1	apparatus					1241:1249	the Golgi apparatus	1231:1249	the Golgi apparatus	1231:1249	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	3	43	theme	O-glycans	663:671	arg1	profiles					640:647	the overall structural profiles	617:647	the overall structural profiles of mucin-type O-glycans using LC-MS	617:683	In this study, we aimed to investigate O-glycosylation in silkworms by analyzing the overall structural profiles of mucin-type O-glycans using LC-MS.
36990248	8	44	theme	galactosyltransferase	1501:1521	arg1	activity					1523:1530	galactosyltransferase activity	1501:1530	galactosyltransferase activity	1501:1530	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	45	theme	specific	1343:1350	arg1	T-synthase					1373:1382	T-synthase	1373:1382	T-synthase	1373:1382	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	45	theme	specific	1343:1350	arg1	essential					1425:1433	essential	1425:1433	essential	1425:1433	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	8	45	theme	specific	1343:1350	arg1	domain					1363:1368	a specific functional domain	1341:1368	a specific functional domain	1341:1368	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	7	46	theme	BmT-synthase	1183:1194	arg1	isoforms					1196:1203	BmT-synthase isoforms 1 and 2	1183:1211	isoforms	1196:1203	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	8	47	theme	dimer	1481:1485	arg1	formation					1487:1495	dimer formation	1481:1495	dimer formation	1481:1495	Additionally, a specific functional domain of T-synthase, called the stem domain, was found to be essential for activity and is presumed to be needed for dimer formation and galactosyltransferase activity.
36990248	10	48	theme	expression	1748:1757	arg1	system					1759:1764	a productive expression system	1735:1764	a productive expression system	1735:1764	Our findings allow the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system.
36990248	10	48	theme	expression	1748:1757	arg1	silkworms					1722:1730	silkworms	1722:1730	silkworms	1722:1730	Our findings allow the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system.
36990248	3	49	gly	O-glycosylation	575:589	arg1	silkworms					594:602	silkworms	594:602	silkworms	594:602	In this study, we aimed to investigate O-glycosylation in silkworms by analyzing the overall structural profiles of mucin-type O-glycans using LC-MS.
36990248	4	50	theme	secreted	828:835	arg1	proteins					837:844	secreted proteins	828:844	secreted proteins produced in silkworms	828:866	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	10	51	theme	practical	1656:1664	arg1	comprehension					1666:1678	the practical comprehension	1652:1678	the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system	1652:1764	Our findings allow the practical comprehension of O-glycosylation required for employing silkworms as a productive expression system.
36990248	2	52	theme	glycans	355:361	arg1	importance					332:341	the importance	328:341	the importance of O-linked glycans	328:361	However, despite the importance of O-linked glycans, their biological functions have not yet been fully elucidated and the synthetic pathway of O-glycosylation has not been investigated in detail, especially in the silkworm.
36990248	4	53	theme	major	783:787	arg1	components					789:798	major components	783:798	major components of the O-glycan attached to secreted proteins produced in silkworms	783:866	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	1	54	theme	cell	255:258	arg1	receptors					268:276	cell surface receptors	255:276	cell surface receptors	255:276	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	4	55	dep	found	689:693	arg1	components					789:798	major components	783:798	major components of the O-glycan attached to secreted proteins produced in silkworms	783:866	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	1	56	theme	secreted	142:149	arg1	proteins					170:177	secreted and membrane-bound proteins	142:177	secreted and membrane-bound proteins	142:177	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	3	57	from	O-glycosylation	575:589	arg1	silkworms					594:602	silkworms	594:602	silkworms	594:602	In this study, we aimed to investigate O-glycosylation in silkworms by analyzing the overall structural profiles of mucin-type O-glycans using LC-MS.
36990248	1	58	theme	surface	260:266	arg1	receptors					268:276	cell surface receptors	255:276	cell surface receptors	255:276	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	7	59	theme	BmN4	1263:1266	arg1	cells					1268:1272	cultured BmN4 cells	1254:1272	cultured BmN4 cells	1254:1272	We found that BmT-synthase isoforms 1 and 2 were localized in the Golgi apparatus in cultured BmN4 cells and functioned both in cultured cells and silkworms.
36990248	6	60	theme	isoforms	1141:1148	arg1	functions					1122:1130	the biological functions	1107:1130	the biological functions of these isoforms	1107:1148	Five transcriptional variants and four protein isoforms were identified in silkworms, and the biological functions of these isoforms were investigated.
36990248	3	61	theme	overall	621:627	arg1	profiles					640:647	the overall structural profiles	617:647	the overall structural profiles of mucin-type O-glycans using LC-MS	617:683	In this study, we aimed to investigate O-glycosylation in silkworms by analyzing the overall structural profiles of mucin-type O-glycans using LC-MS.
36990248	4	62	theme	GlcNAc	705:710	arg1	monosaccharide					712:725	GalNAc or GlcNAc monosaccharide	695:725	GalNAc or GlcNAc monosaccharide	695:725	We found GalNAc or GlcNAc monosaccharide and core 1 disaccharide (Galβ1-3-GalNAcα1-Ser/Thr) were major components of the O-glycan attached to secreted proteins produced in silkworms.
36990248	6	63	theme	biological	1111:1120	arg1	functions					1122:1130	the biological functions	1107:1130	the biological functions of these isoforms	1107:1148	Five transcriptional variants and four protein isoforms were identified in silkworms, and the biological functions of these isoforms were investigated.
36990248	1	64	theme	receptors	268:276	arg1	folding					287:293	protein folding	279:293	protein folding	279:293	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	1	64	theme	receptors	268:276	arg1	stability					300:308	stability	300:308	stability	300:308	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	1	64	theme	receptors	268:276	arg1	recognition					240:250	recognition	240:250	recognition of cell surface receptors	240:276	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	3	65	theme	structural	629:638	arg1	profiles					640:647	the overall structural profiles	617:647	the overall structural profiles of mucin-type O-glycans using LC-MS	617:683	In this study, we aimed to investigate O-glycosylation in silkworms by analyzing the overall structural profiles of mucin-type O-glycans using LC-MS.
36990248	1	66	theme	membrane-bound	155:168	arg1	proteins					170:177	secreted and membrane-bound proteins	142:177	secreted and membrane-bound proteins	142:177	O-glycosylation of secreted and membrane-bound proteins is an important post-translational modification that affects recognition of cell surface receptors, protein folding, and stability.
36990248	9	67	from	profile	1581:1587	arg1	silkworm					1623:1630	the silkworm	1619:1630	the silkworm	1619:1630	Altogether, our results elucidated the O-glycan profile and function of T-synthase in the silkworm.
37040463	11	0	theme	glycan	1731:1736	arg1	structures					1738:1747	possible noncanonical glycan structures	1709:1747	possible noncanonical glycan structures	1709:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	7	1	theme	protein	945:951	arg1	system					963:968	an Escherichia coli-based cell-free protein synthesis system	909:968	an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency	909:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	4	2	theme	Cell-free	418:426	arg1	systems					446:452	Cell-free protein synthesis systems	418:452	Cell-free protein synthesis systems	418:452	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	7	3	theme	coli-based	924:933	arg1	system					963:968	an Escherichia coli-based cell-free protein synthesis system	909:968	an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency	909:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	8	4	theme	α2,6	1239:1242	arg1	C5-azido-sialyllactose					1244:1265	α2,6 C5-azido-sialyllactose	1239:1265	α2,6 C5-azido-sialyllactose	1239:1265	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	4	5	theme	synthesis	436:444	arg1	systems					446:452	Cell-free protein synthesis systems	418:452	Cell-free protein synthesis systems	418:452	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	10	6	theme	model	1489:1493	arg1	fluorophore					1495:1505	a model fluorophore	1487:1505	a model fluorophore using both strain-promoted and copper-catalyzed click chemistry	1487:1569	We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry.
37040463	6	7	dep	azido-sialoglycoproteins	838:861	arg1	called					864:869	called	864:869	called GlycoCAP	864:878	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	6	8	theme	clickable	828:836	arg1	azido-sialoglycoproteins					838:861	clickable azido-sialoglycoproteins	828:861	clickable azido-sialoglycoproteins (called GlycoCAP)	828:879	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	2	9	theme	glycan-based	325:336	arg1	drugs					338:342	building glycan-based drugs	316:342	building glycan-based drugs	316:342	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	4	10	gly	glycoproteins	502:514	arg1	glycoproteins					502:514	glycoproteins	502:514	glycoproteins that may overcome current limitations and enable new glycoprotein medicines	502:590	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	8	11	theme	α2,6	1272:1275	arg1	C9-azido-sialyllactose					1277:1298	α2,6 C9-azido-sialyllactose	1272:1298	α2,6 C9-azido-sialyllactose	1272:1298	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	7	12	with	proteins	1034:1041	arg1	degree					1055:1060	a high degree	1048:1060	a high degree of homogeneity and efficiency	1048:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	4	13	theme	promising	472:480	arg1	approach					482:489	a promising approach	470:489	a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines	470:590	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	8	14	dep	allergen	1161:1168	arg1	C5-azido-sialyllactose					1186:1207	α2,3 C5-azido-sialyllactose	1181:1207	α2,3 C5-azido-sialyllactose	1181:1207	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	14	dep	allergen	1161:1168	arg1	C9-azido-sialyllactose					1215:1236	α2,3 C9-azido-sialyllactose	1210:1236	α2,3 C9-azido-sialyllactose	1210:1236	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	14	dep	allergen	1161:1168	arg1	C5-azido-sialyllactose					1244:1265	α2,6 C5-azido-sialyllactose	1239:1265	α2,6 C5-azido-sialyllactose	1239:1265	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	14	dep	allergen	1161:1168	arg1	C9-azido-sialyllactose					1277:1298	α2,6 C9-azido-sialyllactose	1272:1298	α2,6 C9-azido-sialyllactose	1272:1298	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	9	15	theme	optimizations	1321:1333	arg1	series					1311:1316	a series	1309:1316	a series of optimizations	1309:1333	Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid.
37040463	2	16	theme	targeting	233:241	arg1	lectins					243:249	targeting lectins	233:249	targeting lectins	233:249	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	2	17	from	limitations	291:301	arg1	tools					306:310	tools	306:310	tools for building glycan-based drugs	306:342	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	2	17	from	limitations	291:301	arg1	part					283:286	part	283:286	part	283:286	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	4	18	theme	current	534:540	arg1	limitations					542:552	current limitations	534:552	current limitations	534:552	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	10	19	theme	strain-promoted	1518:1532	arg1	chemistry					1561:1569	both strain-promoted and copper-catalyzed click chemistry	1513:1569	both strain-promoted and copper-catalyzed click chemistry	1513:1569	We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry.
37040463	11	20	gly	glycoproteins	1798:1810	arg1	glycoproteins					1798:1810	glycoproteins	1798:1810	glycoproteins	1798:1810	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	0	21	theme	Clickable	69:77	arg1	Azido-Sialoglycoproteins					79:102	Clickable Azido-Sialoglycoproteins	69:102	Clickable Azido-Sialoglycoproteins	69:102	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
37040463	9	22	theme	sialylation	1361:1371	arg1	efficiency					1373:1382	more than 60% sialylation efficiency	1347:1382	more than 60% sialylation efficiency	1347:1382	Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid.
37040463	7	23	theme	high	1050:1053	arg1	degree					1055:1060	a high degree	1048:1060	a high degree of homogeneity and efficiency	1048:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	1	24	theme	therapeutic	178:188	arg1	targets					190:196	potential therapeutic targets	168:196	potential therapeutic targets	168:196	Glycan-binding receptors known as lectins represent a class of potential therapeutic targets.
37040463	3	25	theme	desirable	358:366	arg1	structures					368:377	desirable structures	358:377	desirable structures	358:377	One group of desirable structures is proteins with noncanonical glycans.
37040463	6	26	theme	glycoprotein	743:754	arg1	platform					766:773	a cell-free glycoprotein synthesis platform	731:773	a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP)	731:879	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	9	27	theme	noncanonical	1391:1402	arg1	acid					1417:1420	a noncanonical azido-sialic acid	1389:1420	a noncanonical azido-sialic acid	1389:1420	Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid.
37040463	8	28	theme	noncanonical	1123:1134	arg1	glycans					1136:1142	four noncanonical glycans	1118:1142	four noncanonical glycans	1118:1142	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	28	theme	noncanonical	1123:1134	arg1	model					1098:1102	a model	1096:1102	a model	1096:1102	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	0	29	gly	Azido-Sialoglycoproteins	79:102	arg1	Azido-Sialoglycoproteins					79:102	Clickable Azido-Sialoglycoproteins	69:102	Clickable Azido-Sialoglycoproteins	69:102	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
37040463	10	30	theme	copper-catalyzed	1538:1553	arg1	chemistry					1561:1569	both strain-promoted and copper-catalyzed click chemistry	1513:1569	both strain-promoted and copper-catalyzed click chemistry	1513:1569	We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry.
37040463	7	31	theme	noncanonical	1008:1019	arg1	glycans					1021:1027	noncanonical glycans	1008:1027	noncanonical glycans	1008:1027	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	1	32	theme	Glycan-binding	105:118	arg1	receptors					120:128	Glycan-binding receptors	105:128	Glycan-binding receptors known as lectins	105:145	Glycan-binding receptors known as lectins represent a class of potential therapeutic targets.
37040463	9	33	dep	efficiency	1373:1382	arg1	%					1359:1359	%	1359:1359	%	1359:1359	Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid.
37040463	4	34	gly	glycoprotein	569:580	arg1	glycoprotein					569:580	new glycoprotein medicines	565:590	new glycoprotein medicines	565:590	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	8	35	theme	dust	1151:1154	arg1	allergen					1161:1168	a dust mite allergen	1149:1168	a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose	1149:1298	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	35	theme	dust	1151:1154	arg1	p					1175:1175	Der p 2	1171:1177	Der p 2	1171:1177	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	9	36	dep	%	1359:1359	arg1	60					1357:1358	60	1357:1358	60	1357:1358	Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid.
37040463	11	37	theme	click	1815:1819	arg1	conjugation					1831:1841	click chemistry conjugation	1815:1841	click chemistry conjugation	1815:1841	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	4	38	theme	new	565:567	arg1	medicines					582:590	new glycoprotein medicines	565:590	new glycoprotein medicines	565:590	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	11	39	theme	wider	1692:1696	arg1	structures					1738:1747	possible noncanonical glycan structures	1709:1747	possible noncanonical glycan structures	1709:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	11	39	theme	wider	1692:1696	arg1	variety					1698:1704	a wider variety	1690:1704	a wider variety of possible noncanonical glycan structures	1690:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	0	40	theme	Glycosylation	33:45	arg1	Platform					47:54	A Cell-Free, Bacterial Glycosylation Platform	10:54	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.	0:103	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
37040463	8	41	theme	Der	1171:1173	arg1	allergen					1161:1168	a dust mite allergen	1149:1168	a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose	1149:1298	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	41	theme	Der	1171:1173	arg1	p					1175:1175	Der p 2	1171:1177	Der p 2	1171:1177	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	6	42	gly	glycoprotein	743:754	arg1	glycoprotein					743:754	a cell-free glycoprotein synthesis platform	731:773	a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP)	731:879	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	11	43	dep	development	1620:1630	arg1	the					1616:1618	the	1616:1618	the	1616:1618	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	11	44	theme	noncanonical	1718:1729	arg1	structures					1738:1747	possible noncanonical glycan structures	1709:1747	possible noncanonical glycan structures	1709:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	7	45	theme	site-specific	978:990	arg1	installation					992:1003	the site-specific installation	974:1003	the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency	974:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	0	46	dep	GlycoCAP	0:7	arg1	Platform					47:54	A Cell-Free, Bacterial Glycosylation Platform	10:54	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.	0:103	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
37040463	4	47	theme	protein	428:434	arg1	systems					446:452	Cell-free protein synthesis systems	418:452	Cell-free protein synthesis systems	418:452	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	11	48	theme	structures	1738:1747	arg1	structures					1738:1747	possible noncanonical glycan structures	1709:1747	possible noncanonical glycan structures	1709:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	11	48	theme	structures	1738:1747	arg1	variety					1698:1704	a wider variety	1690:1704	a wider variety of possible noncanonical glycan structures	1690:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	7	49	theme	synthesis	953:961	arg1	system					963:968	an Escherichia coli-based cell-free protein synthesis system	909:968	an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency	909:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	8	50	theme	α2,3	1210:1213	arg1	C9-azido-sialyllactose					1215:1236	α2,3 C9-azido-sialyllactose	1210:1236	α2,3 C9-azido-sialyllactose	1210:1236	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	5	51	theme	proteins	656:663	arg1	construction					640:651	the construction	636:651	the construction of proteins with noncanonical glycans	636:689	Yet, this approach has not been applied to the construction of proteins with noncanonical glycans.
37040463	10	52	theme	click	1451:1455	arg1	handle					1457:1462	the azide click handle	1441:1462	the azide click handle	1441:1462	We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry.
37040463	7	53	theme	cell-free	935:943	arg1	system					963:968	an Escherichia coli-based cell-free protein synthesis system	909:968	an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency	909:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	1	54	theme	targets	190:196	arg1	class					159:163	a class	157:163	a class of potential therapeutic targets	157:196	Glycan-binding receptors known as lectins represent a class of potential therapeutic targets.
37040463	5	55	theme	noncanonical	670:681	arg1	glycans					683:689	noncanonical glycans	670:689	noncanonical glycans	670:689	Yet, this approach has not been applied to the construction of proteins with noncanonical glycans.
37040463	11	56	theme	granting	1671:1678	arg1	access					1680:1685	granting access	1671:1685	granting access to a wider variety of possible noncanonical glycan structures	1671:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	6	57	gly	azido-sialoglycoproteins	838:861	arg1	azido-sialoglycoproteins					838:861	clickable azido-sialoglycoproteins	828:861	clickable azido-sialoglycoproteins (called GlycoCAP)	828:879	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	11	58	theme	glycan-based	1649:1660	arg1	drugs					1662:1666	glycan-based drugs	1649:1666	glycan-based drugs	1649:1666	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	11	59	theme	drugs	1662:1666	arg1	discovery					1636:1644	discovery	1636:1644	discovery	1636:1644	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	11	59	theme	drugs	1662:1666	arg1	development					1620:1630	development	1620:1630	development	1620:1630	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	2	60	theme	building	316:323	arg1	drugs					338:342	building glycan-based drugs	316:342	building glycan-based drugs	316:342	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	7	61	theme	GlycoCAP	886:893	arg1	platform					895:902	The GlycoCAP platform	882:902	The GlycoCAP platform	882:902	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	2	62	theme	lectins	243:249	arg1	potential					220:228	the therapeutic potential	204:228	the therapeutic potential of targeting lectins	204:249	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	3	63	with	proteins	382:389	arg1	glycans					409:415	noncanonical glycans	396:415	noncanonical glycans	396:415	One group of desirable structures is proteins with noncanonical glycans.
37040463	7	64	theme	efficiency	1081:1090	arg1	degree					1055:1060	a high degree	1048:1060	a high degree of homogeneity and efficiency	1048:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	7	65	theme	homogeneity	1065:1075	arg1	degree					1055:1060	a high degree	1048:1060	a high degree of homogeneity and efficiency	1048:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	1	66	theme	potential	168:176	arg1	targets					190:196	potential therapeutic targets	168:196	potential therapeutic targets	168:196	Glycan-binding receptors known as lectins represent a class of potential therapeutic targets.
37040463	2	67	theme	therapeutic	208:218	arg1	potential					220:228	the therapeutic potential	204:228	the therapeutic potential of targeting lectins	204:249	Yet, the therapeutic potential of targeting lectins remains largely untapped due in part to limitations in tools for building glycan-based drugs.
37040463	10	68	theme	azide	1445:1449	arg1	handle					1457:1462	the azide click handle	1441:1462	the azide click handle	1441:1462	We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry.
37040463	6	69	theme	synthesis	756:764	arg1	platform					766:773	a cell-free glycoprotein synthesis platform	731:773	a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP)	731:879	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	3	70	theme	structures	368:377	arg1	group					349:353	One group	345:353	One group of desirable structures	345:377	One group of desirable structures is proteins with noncanonical glycans.
37040463	3	70	theme	structures	368:377	arg1	structures					368:377	desirable structures	358:377	desirable structures	358:377	One group of desirable structures is proteins with noncanonical glycans.
37040463	10	71	theme	click	1555:1559	arg1	chemistry					1561:1569	both strain-promoted and copper-catalyzed click chemistry	1513:1569	both strain-promoted and copper-catalyzed click chemistry	1513:1569	We then show that the azide click handle can be conjugated with a model fluorophore using both strain-promoted and copper-catalyzed click chemistry.
37040463	6	72	theme	cell-free	733:741	arg1	platform					766:773	a cell-free glycoprotein synthesis platform	731:773	a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP)	731:879	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	9	73	theme	azido-sialic	1404:1415	arg1	acid					1417:1420	a noncanonical azido-sialic acid	1389:1420	a noncanonical azido-sialic acid	1389:1420	Through a series of optimizations, we achieve more than 60% sialylation efficiency with a noncanonical azido-sialic acid.
37040463	0	74	theme	Cell-Free	12:20	arg1	Platform					47:54	A Cell-Free, Bacterial Glycosylation Platform	10:54	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.	0:103	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
37040463	6	75	theme	noncanonical	788:799	arg1	glycans					801:807	noncanonical glycans	788:807	noncanonical glycans	788:807	To address this limitation, we develop a cell-free glycoprotein synthesis platform for building noncanonical glycans and, specifically, clickable azido-sialoglycoproteins (called GlycoCAP).
37040463	8	76	theme	mite	1156:1159	arg1	allergen					1161:1168	a dust mite allergen	1149:1168	a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose	1149:1298	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	8	76	theme	mite	1156:1159	arg1	p					1175:1175	Der p 2	1171:1177	Der p 2	1171:1177	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
37040463	7	77	theme	glycans	1021:1027	arg1	installation					992:1003	the site-specific installation	974:1003	the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency	974:1090	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	3	78	theme	noncanonical	396:407	arg1	glycans					409:415	noncanonical glycans	396:415	noncanonical glycans	396:415	One group of desirable structures is proteins with noncanonical glycans.
37040463	4	79	theme	glycoprotein	569:580	arg1	medicines					582:590	new glycoprotein medicines	565:590	new glycoprotein medicines	565:590	Cell-free protein synthesis systems have matured as a promising approach for making glycoproteins that may overcome current limitations and enable new glycoprotein medicines.
37040463	7	80	dep	coli-based	924:933	arg1	Escherichia					912:922	Escherichia	912:922	Escherichia	912:922	The GlycoCAP platform uses an Escherichia coli-based cell-free protein synthesis system for the site-specific installation of noncanonical glycans onto proteins with a high degree of homogeneity and efficiency.
37040463	0	81	dep	Cell-Free	12:20	arg1	Bacterial					23:31	Bacterial	23:31	Bacterial	23:31	GlycoCAP: A Cell-Free, Bacterial Glycosylation Platform for Building Clickable Azido-Sialoglycoproteins.
37040463	5	82	with	proteins	656:663	arg1	glycans					683:689	noncanonical glycans	670:689	noncanonical glycans	670:689	Yet, this approach has not been applied to the construction of proteins with noncanonical glycans.
37040463	11	83	theme	chemistry	1821:1829	arg1	conjugation					1831:1841	click chemistry conjugation	1815:1841	click chemistry conjugation	1815:1841	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	11	84	theme	possible	1709:1716	arg1	structures					1738:1747	possible noncanonical glycan structures	1709:1747	possible noncanonical glycan structures	1709:1747	We anticipate that GlycoCAP will facilitate the development and discovery of glycan-based drugs by granting access to a wider variety of possible noncanonical glycan structures and also provide an approach for functionalizing glycoproteins by click chemistry conjugation.
37040463	8	85	theme	α2,3	1181:1184	arg1	C5-azido-sialyllactose					1186:1207	α2,3 C5-azido-sialyllactose	1181:1207	α2,3 C5-azido-sialyllactose	1181:1207	As a model, we construct four noncanonical glycans onto a dust mite allergen (Der p 2): α2,3 C5-azido-sialyllactose, α2,3 C9-azido-sialyllactose, α2,6 C5-azido-sialyllactose, and α2,6 C9-azido-sialyllactose.
36499311	3	0	theme	dimeric	774:780	arg1	protein					782:788	the dimeric protein	770:788	the dimeric protein	770:788	This region is not required for activity but could provide a molecular tool to target the dimeric protein to its receptor cellular compartment in the yeast.
36499311	5	1	theme	binding	1137:1143	arg1	mode					1145:1148	the substrate binding mode	1123:1148	the substrate binding mode	1123:1148	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	2	2	theme	protruding	650:659	arg1	loop					661:664	a protruding loop	648:664	a protruding loop within the dimer	648:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	0	3	theme	Rhodotorula	66:76	arg1	dairenensis					78:88	Rhodotorula dairenensis	66:88	Rhodotorula dairenensis	66:88	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	1	4	theme	glycosylated	187:198	arg1	enzyme					200:205	a highly glycosylated enzyme	178:205	a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols	178:421	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	4	theme	glycosylated	187:198	arg1	β-fructofuranosidase					154:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	5	theme	mixture	288:294	arg1	synthesis					259:267	the synthesis	255:267	the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS)	255:346	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	4	6	theme	acceptor	995:1002	arg1	substrate					1004:1012	a putative acceptor substrate	984:1012	a putative acceptor substrate	984:1012	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	1	7	theme	carbohydrates	377:389	arg1	variety					366:372	a variety	364:372	a variety of carbohydrates and other molecules	364:409	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	7	theme	carbohydrates	377:389	arg1	alditols					414:421	alditols	414:421	alditols	414:421	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	7	theme	carbohydrates	377:389	arg1	carbohydrates					377:389	carbohydrates	377:389	carbohydrates	377:389	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	7	theme	carbohydrates	377:389	arg1	molecules					401:409	other molecules	395:409	other molecules	395:409	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	3	8	from	compartment	815:825	arg1	yeast					834:838	the yeast	830:838	the yeast	830:838	This region is not required for activity but could provide a molecular tool to target the dimeric protein to its receptor cellular compartment in the yeast.
36499311	2	9	contain	containing	567:576	arg2	sites					604:608	extensive O-glycosylation sites	578:608	extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer	578:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	2	9	contain	containing	567:576	arg1	N-terminus					556:565	its N-terminus	552:565	its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer	552:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	2	10	with	arrangement	631:641	arg1	loop					661:664	a protruding loop	648:664	a protruding loop within the dimer	648:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	7	11	theme	key	1384:1386	arg1	role					1388:1391	their key role	1378:1391	their key role	1378:1391	All changes decrease the hydrolytic efficiency against sucrose, proving their key role in the activity.
36499311	0	12	theme	Biotechnological	102:117	arg1	Potential					119:127	Its Biotechnological Potential	98:127	Its Biotechnological Potential	98:127	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	1	13	theme	other	395:399	arg1	molecules					401:409	other molecules	395:409	other molecules	395:409	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	8	14	theme	generated	1432:1440	arg1	variants					1442:1449	the generated variants	1428:1449	the generated variants	1428:1449	Moreover, some of the generated variants exhibit redesigned transfructosylating specificity, which may be used for biotechnological purposes to produce novel fructosyl-derivatives.
36499311	1	15	theme	molecules	401:409	arg1	variety					366:372	a variety	364:372	a variety of carbohydrates and other molecules	364:409	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	15	theme	molecules	401:409	arg1	alditols					414:421	alditols	414:421	alditols	414:421	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	15	theme	molecules	401:409	arg1	carbohydrates					377:389	carbohydrates	377:389	carbohydrates	377:389	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	15	theme	molecules	401:409	arg1	molecules					401:409	other molecules	395:409	other molecules	395:409	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	4	16	theme	putative	986:993	arg1	substrate					1004:1012	a putative acceptor substrate	984:1012	a putative acceptor substrate	984:1012	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	1	17	theme	broad	212:216	arg1	specificity					228:238	broad substrate specificity	212:238	broad substrate specificity	212:238	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	6	18	theme	transfructosylating	1276:1294	arg1	activity					1296:1303	their hydrolytic and transfructosylating activity	1255:1303	their hydrolytic and transfructosylating activity	1255:1303	Relevant residues were selected for mutagenesis, the variants being biochemically characterized through their hydrolytic and transfructosylating activity.
36499311	1	19	theme	substrate	218:226	arg1	specificity					228:238	broad substrate specificity	212:238	broad substrate specificity	212:238	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	20	theme	series	309:314	arg1	6-kestose					272:280	6-kestose	272:280	6-kestose	272:280	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	20	theme	series	309:314	arg1	mixture					288:294	a mixture	286:294	a mixture of the three series of fructooligosaccharides (FOS)	286:346	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	8	21	used	used	1516:1519	arg2	specificity					1490:1500	redesigned transfructosylating specificity	1459:1500	redesigned transfructosylating specificity	1459:1500	Moreover, some of the generated variants exhibit redesigned transfructosylating specificity, which may be used for biotechnological purposes to produce novel fructosyl-derivatives.
36499311	2	22	theme	three-dimensional	443:459	arg1	structure					461:469	its three-dimensional structure	439:469	its three-dimensional structure	439:469	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	2	23	theme	O-glycosylation	588:602	arg1	sites					604:608	extensive O-glycosylation sites	578:608	extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer	578:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	0	24	from	dairenensis	78:88	arg1	Ffase					55:59	the Highly Glycosylated Ffase	31:59	the Highly Glycosylated Ffase from Rhodotorula dairenensis	31:88	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	0	24	from	dairenensis	78:88	arg1	Structure					18:26	the Structure	14:26	the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis	14:88	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	6	25	theme	Relevant	1151:1158	arg1	residues					1160:1167	Relevant residues	1151:1167	Relevant residues	1151:1167	Relevant residues were selected for mutagenesis, the variants being biochemically characterized through their hydrolytic and transfructosylating activity.
36499311	2	26	theme	bimodular	493:501	arg1	arrangement					503:513	the expected bimodular arrangement	480:513	the expected bimodular arrangement	480:513	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	1	27	theme	fructooligosaccharides	319:340	arg1	series					309:314	the three series	299:314	the three series of fructooligosaccharides (FOS)	299:346	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	2	28	theme	extensive	578:586	arg1	sites					604:608	extensive O-glycosylation sites	578:608	extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer	578:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	5	29	theme	active	1086:1091	arg1	site					1093:1096	the active site	1082:1096	the active site	1082:1096	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	4	30	theme	truncated	843:851	arg1	form					865:868	A truncated inactivated form	841:868	A truncated inactivated form	841:868	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	3	31	theme	cellular	806:813	arg1	compartment					815:825	its receptor cellular compartment	793:825	its receptor cellular compartment in the yeast	793:838	This region is not required for activity but could provide a molecular tool to target the dimeric protein to its receptor cellular compartment in the yeast.
36499311	4	32	theme	Bis-Tris	943:950	arg1	molecule					952:959	a Bis-Tris molecule	941:959	a Bis-Tris molecule	941:959	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	5	33	theme	site	1093:1096	arg1	traits					1072:1077	the major traits	1062:1077	the major traits of the active site	1062:1096	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	6	34	theme	hydrolytic	1261:1270	arg1	activity					1296:1303	their hydrolytic and transfructosylating activity	1255:1303	their hydrolytic and transfructosylating activity	1255:1303	Relevant residues were selected for mutagenesis, the variants being biochemically characterized through their hydrolytic and transfructosylating activity.
36499311	4	35	used	used	874:877	arg2	form					865:868	A truncated inactivated form	841:868	A truncated inactivated form	841:868	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	0	36	theme	Glycosylated	42:53	arg1	Ffase					55:59	the Highly Glycosylated Ffase	31:59	the Highly Glycosylated Ffase from Rhodotorula dairenensis	31:88	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	2	37	theme	peculiar	622:629	arg1	arrangement					631:641	a peculiar arrangement	620:641	a peculiar arrangement with a protruding loop within the dimer	620:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	2	38	theme	unique	526:531	arg1	elongation					538:547	a unique long elongation	524:547	a unique long elongation	524:547	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	5	39	theme	complexes	1044:1052	arg1	structure					1027:1035	The crystal structure	1015:1035	The crystal structure of the complexes	1015:1052	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	1	40	with	enzyme	200:205	arg1	specificity					228:238	broad substrate specificity	212:238	broad substrate specificity	212:238	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	2	41	theme	expected	484:491	arg1	arrangement					503:513	the expected bimodular arrangement	480:513	the expected bimodular arrangement	480:513	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	5	42	theme	substrate	1127:1135	arg1	mode					1145:1148	the substrate binding mode	1123:1148	the substrate binding mode	1123:1148	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	8	43	theme	biotechnological	1525:1540	arg1	purposes					1542:1549	biotechnological purposes	1525:1549	biotechnological purposes	1525:1549	Moreover, some of the generated variants exhibit redesigned transfructosylating specificity, which may be used for biotechnological purposes to produce novel fructosyl-derivatives.
36499311	4	44	theme	inactivated	853:863	arg1	form					865:868	A truncated inactivated form	841:868	A truncated inactivated form	841:868	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	1	45	theme	Rhodotorula	130:140	arg1	enzyme					200:205	a highly glycosylated enzyme	178:205	a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols	178:421	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	45	theme	Rhodotorula	130:140	arg1	β-fructofuranosidase					154:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	3	46	theme	receptor	797:804	arg1	compartment					815:825	its receptor cellular compartment	793:825	its receptor cellular compartment in the yeast	793:838	This region is not required for activity but could provide a molecular tool to target the dimeric protein to its receptor cellular compartment in the yeast.
36499311	1	47	gly	glycosylated	187:198	arg1	enzyme					200:205	a highly glycosylated enzyme	178:205	a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols	178:421	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	47	gly	glycosylated	187:198	arg1	β-fructofuranosidase					154:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	5	48	theme	major	1066:1070	arg1	traits					1072:1077	the major traits	1062:1077	the major traits of the active site	1062:1096	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	8	49	theme	transfructosylating	1470:1488	arg1	specificity					1490:1500	redesigned transfructosylating specificity	1459:1500	redesigned transfructosylating specificity	1459:1500	Moreover, some of the generated variants exhibit redesigned transfructosylating specificity, which may be used for biotechnological purposes to produce novel fructosyl-derivatives.
36499311	1	50	theme	dairenensis	142:152	arg1	enzyme					200:205	a highly glycosylated enzyme	178:205	a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols	178:421	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	1	50	theme	dairenensis	142:152	arg1	β-fructofuranosidase					154:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase	130:173	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	8	51	theme	redesigned	1459:1468	arg1	specificity					1490:1500	redesigned transfructosylating specificity	1459:1500	redesigned transfructosylating specificity	1459:1500	Moreover, some of the generated variants exhibit redesigned transfructosylating specificity, which may be used for biotechnological purposes to produce novel fructosyl-derivatives.
36499311	8	52	theme	novel	1562:1566	arg1	fructosyl-derivatives					1568:1588	novel fructosyl-derivatives	1562:1588	novel fructosyl-derivatives	1562:1588	Moreover, some of the generated variants exhibit redesigned transfructosylating specificity, which may be used for biotechnological purposes to produce novel fructosyl-derivatives.
36499311	2	53	theme	long	533:536	arg1	elongation					538:547	a unique long elongation	524:547	a unique long elongation	524:547	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	5	54	theme	crystal	1019:1025	arg1	structure					1027:1035	The crystal structure	1015:1035	The crystal structure of the complexes	1015:1052	The crystal structure of the complexes reveals the major traits of the active site, with Asn387 controlling the substrate binding mode.
36499311	2	55	gly	O-glycosylation	588:602	arg2	sites					604:608	extensive O-glycosylation sites	578:608	extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer	578:681	We report here its three-dimensional structure, showing the expected bimodular arrangement and also a unique long elongation at its N-terminus containing extensive O-glycosylation sites that form a peculiar arrangement with a protruding loop within the dimer.
36499311	4	56	with	complexes	889:897	arg1	fructose					904:911	fructose	904:911	fructose	904:911	A truncated inactivated form was used to obtain complexes with fructose, sucrose and raffinose, and a Bis-Tris molecule was trapped, mimicking a putative acceptor substrate.
36499311	1	57	theme	6-kestose	272:280	arg1	synthesis					259:267	the synthesis	255:267	the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS)	255:346	Rhodotorula dairenensis β-fructofuranosidase is a highly glycosylated enzyme with broad substrate specificity that catalyzes the synthesis of 6-kestose and a mixture of the three series of fructooligosaccharides (FOS), fructosylating a variety of carbohydrates and other molecules as alditols.
36499311	0	58	theme	Ffase	55:59	arg1	Structure					18:26	the Structure	14:26	the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis	14:88	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	0	59	from	Structure	18:26	arg1	dairenensis					78:88	Rhodotorula dairenensis	66:88	Rhodotorula dairenensis	66:88	Insights into the Structure of the Highly Glycosylated Ffase from Rhodotorula dairenensis Enhance Its Biotechnological Potential.
36499311	7	60	theme	hydrolytic	1331:1340	arg1	efficiency					1342:1351	the hydrolytic efficiency	1327:1351	the hydrolytic efficiency against sucrose	1327:1367	All changes decrease the hydrolytic efficiency against sucrose, proving their key role in the activity.
36499311	3	61	theme	molecular	745:753	arg1	tool					755:758	a molecular tool	743:758	a molecular tool to target the dimeric protein to its receptor cellular compartment in the yeast	743:838	This region is not required for activity but could provide a molecular tool to target the dimeric protein to its receptor cellular compartment in the yeast.
37094167	5	0	theme	structural	745:754	arg1	evidence					756:763	structural evidence	745:763	structural evidence for Delta's attenuated dependency on cellular factors for fusion activation	745:839	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	1	1	theme	SARS-CoV-2	135:144	arg1	variant					164:170	SARS-CoV-2 B.1.617.2 (Delta) variant	135:170	SARS-CoV-2 B.1.617.2 (Delta) variant	135:170	Among the current five Variants of Concern, infections caused by SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity.
37094167	5	2	theme	evidence	756:763	arg1	pieces					735:740	pieces	735:740	pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation	735:839	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	5	3	theme	membrane	877:884	arg1	fusion					886:891	S-mediated membrane fusion	866:891	S-mediated membrane fusion	866:891	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	1	4	theme	B.1.617.2	146:154	arg1	variant					164:170	SARS-CoV-2 B.1.617.2 (Delta) variant	135:170	SARS-CoV-2 B.1.617.2 (Delta) variant	135:170	Among the current five Variants of Concern, infections caused by SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity.
37094167	6	5	theme	native	987:992	arg1	S					1000:1000	native Delta S	987:1000	native Delta S	987:1000	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	6	6	theme	S	1000:1000	arg1	glycosylation					970:982	increased oligomannose-type glycosylation	942:982	increased oligomannose-type glycosylation of native Delta S	942:1000	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	2	7	theme	intact	342:347	arg1	virions					355:361	intact Delta virions	342:361	intact Delta virions	342:361	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	6	8	theme	Delta	994:998	arg1	S					1000:1000	native Delta S	987:1000	native Delta S	987:1000	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	5	9	theme	fusion	823:828	arg1	activation					830:839	fusion activation	823:839	fusion activation	823:839	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	2	10	theme	molecular	252:260	arg1	basis					262:266	the molecular basis	248:266	the molecular basis of elevated pathogenicity using recombinant proteins	248:319	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	4	11	theme	Delta	657:661	arg1	variant					663:669	the authentic Delta variant	643:669	the authentic Delta variant	643:669	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	4	12	from	nature	520:525	arg1	beam					558:561	electron beam	549:561	electron beam	549:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	4	13	from	beam	558:561	arg1	nature					520:525	the pleomorphic nature	504:525	the pleomorphic nature of Delta virions from electron beam	504:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	4	13	from	beam	558:561	arg1	virions					536:542	Delta virions	530:542	Delta virions from electron beam	530:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	5	14	theme	fusion	886:891	arg1	model					857:861	a model	855:861	a model of S-mediated membrane fusion	855:891	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	6	15	theme	SARS-CoV-2	1111:1120	arg1	variant					1122:1128	the most virulent SARS-CoV-2 variant	1093:1128	the most virulent SARS-CoV-2 variant	1093:1128	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	6	16	theme	Delta	1081:1085	arg1	factors					1070:1076	distinctive factors	1058:1076	distinctive factors of Delta	1058:1085	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	1	17	theme	Delta	157:161	arg1	variant					164:170	SARS-CoV-2 B.1.617.2 (Delta) variant	135:170	SARS-CoV-2 B.1.617.2 (Delta) variant	135:170	Among the current five Variants of Concern, infections caused by SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity.
37094167	6	18	dep	S.	1022:1023	arg1	disclose					1049:1056	disclose	1049:1056	disclose distinctive factors of Delta	1049:1085	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	4	19	from	structure	608:616	arg1	variant					663:669	the authentic Delta variant	643:669	the authentic Delta variant	643:669	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	2	20	theme	recombinant	300:310	arg1	proteins					312:319	recombinant proteins	300:319	recombinant proteins	300:319	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	3	21	theme	evidence	409:416	arg1	pieces					389:394	pieces	389:394	pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion	389:473	Moreover, pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion are missing.
37094167	0	22	theme	In	0:1	arg1	architecture					8:19	In situ architecture	0:19	In situ architecture	0:19	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	4	23	theme	virions	536:542	arg1	nature					520:525	the pleomorphic nature	504:525	the pleomorphic nature of Delta virions from electron beam	504:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	1	24	theme	current	80:86	arg1	Variants					93:100	the current five Variants	76:100	the current five Variants of Concern	76:111	Among the current five Variants of Concern, infections caused by SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity.
37094167	4	25	theme	authentic	647:655	arg1	variant					663:669	the authentic Delta variant	643:669	the authentic Delta variant	643:669	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	5	26	theme	cellular	802:809	arg1	factors					811:817	cellular factors	802:817	cellular factors for fusion activation	802:839	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	4	27	theme	Delta	530:534	arg1	virions					536:542	Delta virions	530:542	Delta virions from electron beam	530:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	6	28	gly	glycosylation	970:982	arg1	S					1000:1000	native Delta S	987:1000	native Delta S	987:1000	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	2	29	theme	pathogenicity	280:292	arg1	basis					262:266	the molecular basis	248:266	the molecular basis of elevated pathogenicity using recombinant proteins	248:319	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	3	30	theme	S-mediated	448:457	arg1	fusion					468:473	S-mediated membrane fusion	448:473	S-mediated membrane fusion	448:473	Moreover, pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion are missing.
37094167	6	31	theme	virulent	1102:1109	arg1	variant					1122:1128	the most virulent SARS-CoV-2 variant	1093:1128	the most virulent SARS-CoV-2 variant	1093:1128	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	4	32	theme	electron	549:556	arg1	beam					558:561	electron beam	549:561	electron beam	549:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	2	33	theme	elevated	271:278	arg1	pathogenicity					280:292	elevated pathogenicity	271:292	elevated pathogenicity using recombinant proteins	271:319	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	4	34	from	distribution	622:633	arg1	variant					663:669	the authentic Delta variant	643:669	the authentic Delta variant	643:669	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	3	35	theme	membrane	459:466	arg1	fusion					468:473	S-mediated membrane fusion	448:473	S-mediated membrane fusion	448:473	Moreover, pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion are missing.
37094167	6	36	theme	oligomannose-type	952:968	arg1	glycosylation					970:982	increased oligomannose-type glycosylation	942:982	increased oligomannose-type glycosylation of native Delta S	942:1000	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	5	37	theme	virus-virus	693:703	arg1	events					712:717	the virus-virus fusion events	689:717	the virus-virus fusion events	689:717	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	2	38	from	advances	236:243	arg1	basis					262:266	the molecular basis	248:266	the molecular basis of elevated pathogenicity using recombinant proteins	248:319	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	4	39	theme	S	638:638	arg1	distribution					622:633	distribution	622:633	distribution	622:633	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	4	39	theme	S	638:638	arg1	structure					608:616	in situ structure	600:616	in situ structure	600:616	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	0	40	theme	membrane	25:32	arg1	fusion					34:39	membrane fusion	25:39	membrane fusion	25:39	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	4	41	theme	pleomorphic	508:518	arg1	nature					520:525	the pleomorphic nature	504:525	the pleomorphic nature of Delta virions from electron beam	504:561	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	3	42	theme	molecular	399:407	arg1	evidence					409:416	molecular evidence	399:416	molecular evidence for the detailed mechanism of S-mediated membrane fusion	399:473	Moreover, pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion are missing.
37094167	6	43	theme	distinctive	1058:1068	arg1	factors					1070:1076	distinctive factors	1058:1076	distinctive factors of Delta	1058:1085	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	0	44	theme	SARS-CoV-2	44:53	arg1	variant					61:67	SARS-CoV-2 Delta variant	44:67	SARS-CoV-2 Delta variant	44:67	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	4	45	dep	showed	497:502	arg1	inactivated					563:573	inactivated	563:573	inactivated samples	563:581	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	4	45	dep	showed	497:502	arg1	reported					587:594	reported	587:594	reported the in situ structure and distribution of S on the authentic Delta variant	587:669	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	5	46	theme	attenuated	777:786	arg1	dependency					788:797	Delta's attenuated dependency	769:797	Delta's attenuated dependency on cellular factors for fusion activation	769:839	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	5	47	from	dependency	788:797	arg1	factors					811:817	cellular factors	802:817	cellular factors for fusion activation	802:839	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	5	48	theme	fusion	705:710	arg1	events					712:717	the virus-virus fusion events	689:717	the virus-virus fusion events	689:717	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	4	49	dep	structure	608:616	arg1	the					596:598	the	596:598	the	596:598	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
37094167	1	50	theme	Concern	105:111	arg1	Variants					93:100	the current five Variants	76:100	the current five Variants of Concern	76:111	Among the current five Variants of Concern, infections caused by SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity.
37094167	6	51	theme	glycan	917:922	arg1	analysis					924:931	site-specific glycan analysis	903:931	site-specific glycan analysis	903:931	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	6	52	theme	increased	942:950	arg1	glycosylation					970:982	increased oligomannose-type glycosylation	942:982	increased oligomannose-type glycosylation of native Delta S	942:1000	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	3	53	theme	fusion	468:473	arg1	mechanism					435:443	the detailed mechanism	422:443	the detailed mechanism of S-mediated membrane fusion	422:473	Moreover, pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion are missing.
37094167	5	54	theme	S-mediated	866:875	arg1	fusion					886:891	S-mediated membrane fusion	866:891	S-mediated membrane fusion	866:891	We also captured the virus-virus fusion events, which provided pieces of structural evidence for Delta's attenuated dependency on cellular factors for fusion activation, and proposed a model of S-mediated membrane fusion.
37094167	1	55	theme	greatest	202:209	arg1	severity					211:218	the greatest severity	198:218	the greatest severity	198:218	Among the current five Variants of Concern, infections caused by SARS-CoV-2 B.1.617.2 (Delta) variant are often associated with the greatest severity.
37094167	0	56	theme	variant	61:67	arg1	architecture					8:19	In situ architecture	0:19	In situ architecture	0:19	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	0	56	theme	variant	61:67	arg1	fusion					34:39	membrane fusion	25:39	membrane fusion	25:39	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	2	57	theme	recent	229:234	arg1	advances					236:243	recent advances	229:243	recent advances on the molecular basis of elevated pathogenicity using recombinant proteins	229:319	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	2	58	theme	virions	355:361	arg1	architecture					326:337	the architecture	322:337	the architecture of intact Delta virions	322:361	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	3	59	theme	detailed	426:433	arg1	mechanism					435:443	the detailed mechanism	422:443	the detailed mechanism of S-mediated membrane fusion	422:473	Moreover, pieces of molecular evidence for the detailed mechanism of S-mediated membrane fusion are missing.
37094167	0	60	theme	Delta	55:59	arg1	variant					61:67	SARS-CoV-2 Delta variant	44:67	SARS-CoV-2 Delta variant	44:67	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	6	61	theme	site-specific	903:915	arg1	analysis					924:931	site-specific glycan analysis	903:931	site-specific glycan analysis	903:931	Besides, site-specific glycan analysis revealed increased oligomannose-type glycosylation of native Delta S than that of the WT S. Together, these results disclose distinctive factors of Delta being the most virulent SARS-CoV-2 variant.
37094167	0	62	dep	In	0:1	arg1	situ					3:6	situ	3:6	situ	3:6	In situ architecture and membrane fusion of SARS-CoV-2 Delta variant.
37094167	2	63	theme	Delta	349:353	arg1	virions					355:361	intact Delta virions	342:361	intact Delta virions	342:361	Despite recent advances on the molecular basis of elevated pathogenicity using recombinant proteins, the architecture of intact Delta virions remains veiled.
37094167	4	64	theme	in situ	600:606	arg1	structure					608:616	in situ structure	600:616	in situ structure	600:616	Here, we showed the pleomorphic nature of Delta virions from electron beam inactivated samples and reported the in situ structure and distribution of S on the authentic Delta variant.
35380435	8	0	gly	glycosylated	1678:1689	arg1	abundance					1659:1667	low abundance	1655:1667	low abundance	1655:1667	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	8	0	gly	glycosylated	1678:1689	arg1	proteoforms					1691:1701	heavily glycosylated proteoforms	1670:1701	heavily glycosylated proteoforms that may be missed by using glycopeptide data alone	1670:1753	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	6	1	theme	mass	1329:1332	arg1	MS					1348:1349	MS	1348:1349	MS	1348:1349	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	1	theme	mass	1329:1332	arg1	spectrometry					1334:1345	top-down mass spectrometry	1320:1345	top-down mass spectrometry (MS)	1320:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	7	2	theme	glycan	1502:1507	arg1	groups					1509:1514	neutral glycan groups	1494:1514	neutral glycan groups	1494:1514	Within the conditions we explored, the HILIC method was superior to RPLC and CZE at separating RBD glycoforms, which differ significantly in neutral glycan groups.
35380435	4	3	theme	mass	644:647	arg1	spectrometry					649:660	mass spectrometry	644:660	mass spectrometry	644:660	Liquid chromatography coupled to mass spectrometry has been widely used to characterize post-translational modifications in proteins, including glycosylation.
35380435	2	4	theme	domain	308:313	arg1	versions					253:260	Recombinant versions	241:260	Recombinant versions of the spike protein and the receptor-binding domain (RBD)	241:319	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	2	4	theme	domain	308:313	arg1	vaccines					390:397	vaccines	390:397	vaccines against viral infection	390:421	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	5	5	theme	heterogeneous	937:949	arg1	glycans					951:957	highly heterogeneous glycans	930:957	highly heterogeneous glycans	930:957	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	6	6	dep	chromatography	1200:1213	arg1	3					1145:1145	3	1145:1145	3	1145:1145	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	9	7	from	biosimilars	1875:1885	arg1	applications					1906:1917	quality control applications	1890:1917	quality control applications	1890:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	6	8	theme	glycosylations	1288:1301	arg1	combinations					1272:1283	varying combinations	1264:1283	varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1264:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	1	9	theme	glycosylated	213:224	arg1	protein					232:238	the heavily glycosylated spike protein	201:238	the heavily glycosylated spike protein	201:238	SARS-CoV-2 cellular infection is mediated by the heavily glycosylated spike protein.
35380435	8	10	gly	glycopeptide	1731:1742	arg2	glycopeptide					1731:1742	glycopeptide data	1731:1747	glycopeptide data alone	1731:1753	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	6	11	theme	hydrophilic	1176:1186	arg1	HILIC					1216:1220	HILIC	1216:1220	HILIC	1216:1220	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	11	theme	hydrophilic	1176:1186	arg1	chromatography					1200:1213	monolithic hydrophilic interaction chromatography	1165:1213	(3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1144:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	0	12	theme	Receptor-Binding	131:146	arg1	Domain					148:153	the SARS-CoV-2 Spike Receptor-Binding Domain	110:153	the SARS-CoV-2 Spike Receptor-Binding Domain	110:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	5	13	theme	challenges	906:915	arg1	level					875:879	released glycan level	859:879	released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level	859:985	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	5	13	theme	challenges	906:915	arg1	peptide					825:831	the proteolytic peptide	809:831	the proteolytic peptide (bottom-up proteomics)	809:854	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	5	13	theme	challenges	906:915	arg1	proteomics					844:853	bottom-up proteomics	834:853	bottom-up proteomics	834:853	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	2	14	theme	viral	407:411	arg1	infection					413:421	viral infection	407:421	viral infection	407:421	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	4	15	theme	post-translational	699:716	arg1	modifications					718:730	post-translational modifications	699:730	post-translational modifications in proteins, including glycosylation	699:767	Liquid chromatography coupled to mass spectrometry has been widely used to characterize post-translational modifications in proteins, including glycosylation.
35380435	8	16	dep	cysteinylation	1601:1614	arg1	e.g.					1595:1598	e.g.	1595:1598	e.g.	1595:1598	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	6	17	theme	online	1017:1022	arg1	techniques					1035:1044	several online separation techniques	1009:1044	several online separation techniques	1009:1044	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	18	theme	varying	1264:1270	arg1	combinations					1272:1283	varying combinations	1264:1283	varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1264:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	19	theme	top-down	1320:1327	arg1	MS					1348:1349	MS	1348:1349	MS	1348:1349	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	19	theme	top-down	1320:1327	arg1	spectrometry					1334:1345	top-down mass spectrometry	1320:1345	top-down mass spectrometry (MS)	1320:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	9	20	theme	top-down	1766:1773	arg1	platform					1778:1785	The HILIC top-down MS platform	1756:1785	The HILIC top-down MS platform	1756:1785	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	5	21	theme	Most	770:773	arg1	studies					775:781	Most studies	770:781	Most studies of RBDs	770:789	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	1	22	theme	SARS-CoV-2	156:165	arg1	infection					176:184	SARS-CoV-2 cellular infection	156:184	SARS-CoV-2 cellular infection	156:184	SARS-CoV-2 cellular infection is mediated by the heavily glycosylated spike protein.
35380435	6	23	theme	intact	1235:1240	arg1	RBDs					1254:1257	separate intact recombinant RBDs	1226:1257	separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1226:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	0	24	theme	Top-Down	63:70	arg1	Spectrometry					77:88	Top-Down Mass Spectrometry	63:88	Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain	63:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	2	25	theme	protein	275:281	arg1	versions					253:260	Recombinant versions	241:260	Recombinant versions of the spike protein and the receptor-binding domain (RBD)	241:319	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	2	25	theme	protein	275:281	arg1	vaccines					390:397	vaccines	390:397	vaccines against viral infection	390:421	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	9	26	gly	glycoproteins	1836:1848	arg1	glycoproteins					1836:1848	heterogeneous glycoproteins	1822:1848	heterogeneous glycoproteins	1822:1848	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	5	27	theme	intact	966:971	arg1	level					981:985	the intact protein level	962:985	the intact protein level	962:985	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	9	28	theme	great	1793:1797	arg1	potential					1799:1807	great potential	1793:1807	great potential	1793:1807	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	0	29	theme	Spectrometry	77:88	arg1	Characterization					90:105	Top-Down Mass Spectrometry Characterization	63:105	Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain	63:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	6	30	theme	reverse-phase	1054:1066	arg1	RPLC					1091:1094	RPLC	1091:1094	RPLC	1091:1094	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	30	theme	reverse-phase	1054:1066	arg1	chromatography					1075:1088	reverse-phase liquid chromatography	1054:1088	(1) C2 reverse-phase liquid chromatography (RPLC)	1047:1095	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	7	31	theme	HILIC	1392:1396	arg1	superior					1409:1416	superior	1409:1416	superior	1409:1416	Within the conditions we explored, the HILIC method was superior to RPLC and CZE at separating RBD glycoforms, which differ significantly in neutral glycan groups.
35380435	7	31	theme	HILIC	1392:1396	arg1	method					1398:1403	the HILIC method	1388:1403	the HILIC method	1388:1403	Within the conditions we explored, the HILIC method was superior to RPLC and CZE at separating RBD glycoforms, which differ significantly in neutral glycan groups.
35380435	4	32	used	used	678:681	arg2	chromatography					618:631	Liquid chromatography	611:631	Liquid chromatography coupled to mass spectrometry	611:660	Liquid chromatography coupled to mass spectrometry has been widely used to characterize post-translational modifications in proteins, including glycosylation.
35380435	9	33	theme	heterogeneous	1822:1834	arg1	glycoproteins					1836:1848	heterogeneous glycoproteins	1822:1848	heterogeneous glycoproteins	1822:1848	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	8	34	theme	top-down	1534:1541	arg1	analysis					1543:1550	our top-down analysis	1530:1550	our top-down analysis	1530:1550	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	0	35	theme	SARS-CoV-2	114:123	arg1	Domain					148:153	the SARS-CoV-2 Spike Receptor-Binding Domain	110:153	the SARS-CoV-2 Spike Receptor-Binding Domain	110:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	0	36	theme	Online	0:5	arg1	HILIC					47:51	HILIC	47:51	HILIC	47:51	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	0	36	theme	Online	0:5	arg1	Chromatography					31:44	Online Hydrophilic Interaction Chromatography	0:44	Online Hydrophilic Interaction Chromatography (HILIC)	0:52	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	6	37	theme	capillary	1102:1110	arg1	CZE					1134:1136	CZE	1134:1136	CZE	1134:1136	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	37	theme	capillary	1102:1110	arg1	electrophoresis					1117:1131	(2) capillary zone electrophoresis	1098:1131	(2) capillary zone electrophoresis (CZE)	1098:1137	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	8	38	theme	unexpected	1569:1578	arg1	modifications					1580:1592	unexpected modifications	1569:1592	unexpected modifications (e.g., cysteinylation and N-terminal sequence variation)	1569:1649	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	0	39	theme	Interaction	19:29	arg1	HILIC					47:51	HILIC	47:51	HILIC	47:51	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	0	39	theme	Interaction	19:29	arg1	Chromatography					31:44	Online Hydrophilic Interaction Chromatography	0:44	Online Hydrophilic Interaction Chromatography (HILIC)	0:52	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	9	40	theme	biosimilars	1875:1885	arg1	comparison					1861:1870	facile comparison	1854:1870	facile comparison of biosimilars in quality control applications	1854:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	9	41	theme	quality	1890:1896	arg1	applications					1906:1917	quality control applications	1890:1917	quality control applications	1890:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	5	42	theme	glycan	868:873	arg1	level					875:879	released glycan level	859:879	released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level	859:985	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	8	43	theme	glycosylated	1678:1689	arg1	abundance					1659:1667	low abundance	1655:1667	low abundance	1655:1667	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	8	43	theme	glycosylated	1678:1689	arg1	proteoforms					1691:1701	heavily glycosylated proteoforms	1670:1701	heavily glycosylated proteoforms that may be missed by using glycopeptide data alone	1670:1753	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	8	44	theme	sequence	1631:1638	arg1	variation					1640:1648	N-terminal sequence variation	1620:1648	N-terminal sequence variation	1620:1648	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	3	45	theme	recombinant	535:545	arg1	RBD					547:549	recombinant RBD	535:549	recombinant RBD	535:549	RBD plays key roles in the spike protein's structure and function, and thus, comprehensive characterization of recombinant RBD is critically important for biopharmaceutical applications.
35380435	7	46	theme	neutral	1494:1500	arg1	groups					1509:1514	neutral glycan groups	1494:1514	neutral glycan groups	1494:1514	Within the conditions we explored, the HILIC method was superior to RPLC and CZE at separating RBD glycoforms, which differ significantly in neutral glycan groups.
35380435	8	47	theme	low	1655:1657	arg1	abundance					1659:1667	low abundance	1655:1667	low abundance	1655:1667	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	8	47	theme	low	1655:1657	arg1	proteoforms					1691:1701	heavily glycosylated proteoforms	1670:1701	heavily glycosylated proteoforms that may be missed by using glycopeptide data alone	1670:1753	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	1	48	gly	glycosylated	213:224	arg1	protein					232:238	the heavily glycosylated spike protein	201:238	the heavily glycosylated spike protein	201:238	SARS-CoV-2 cellular infection is mediated by the heavily glycosylated spike protein.
35380435	7	49	gly	glycoforms	1452:1461	arg1	RBD					1448:1450	RBD glycoforms	1448:1461	RBD glycoforms	1448:1461	Within the conditions we explored, the HILIC method was superior to RPLC and CZE at separating RBD glycoforms, which differ significantly in neutral glycan groups.
35380435	9	50	from	comparison	1861:1870	arg1	applications					1906:1917	quality control applications	1890:1917	quality control applications	1890:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	8	51	theme	glycopeptide	1731:1742	arg1	data					1744:1747	glycopeptide data	1731:1747	glycopeptide data alone	1731:1753	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	9	52	theme	control	1898:1904	arg1	applications					1906:1917	quality control applications	1890:1917	quality control applications	1890:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	7	53	theme	RBD	1448:1450	arg1	glycoforms					1452:1461	RBD glycoforms	1448:1461	RBD glycoforms	1448:1461	Within the conditions we explored, the HILIC method was superior to RPLC and CZE at separating RBD glycoforms, which differ significantly in neutral glycan groups.
35380435	2	54	theme	seropositivity	339:352	arg1	assays					354:359	seropositivity assays	339:359	seropositivity assays	339:359	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	4	55	from	modifications	718:730	arg1	proteins					735:742	proteins	735:742	proteins	735:742	Liquid chromatography coupled to mass spectrometry has been widely used to characterize post-translational modifications in proteins, including glycosylation.
35380435	4	55	from	modifications	718:730	arg1	glycosylation					755:767	glycosylation	755:767	glycosylation	755:767	Liquid chromatography coupled to mass spectrometry has been widely used to characterize post-translational modifications in proteins, including glycosylation.
35380435	6	56	theme	interaction	1188:1198	arg1	HILIC					1216:1220	HILIC	1216:1220	HILIC	1216:1220	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	56	theme	interaction	1188:1198	arg1	chromatography					1200:1213	monolithic hydrophilic interaction chromatography	1165:1213	(3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1144:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	0	57	theme	Domain	148:153	arg1	Characterization					90:105	Top-Down Mass Spectrometry Characterization	63:105	Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain	63:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	3	58	theme	biopharmaceutical	579:595	arg1	applications					597:608	biopharmaceutical applications	579:608	biopharmaceutical applications	579:608	RBD plays key roles in the spike protein's structure and function, and thus, comprehensive characterization of recombinant RBD is critically important for biopharmaceutical applications.
35380435	1	59	theme	spike	226:230	arg1	protein					232:238	the heavily glycosylated spike protein	201:238	the heavily glycosylated spike protein	201:238	SARS-CoV-2 cellular infection is mediated by the heavily glycosylated spike protein.
35380435	6	60	theme	monolithic	1165:1174	arg1	HILIC					1216:1220	HILIC	1216:1220	HILIC	1216:1220	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	60	theme	monolithic	1165:1174	arg1	chromatography					1200:1213	monolithic hydrophilic interaction chromatography	1165:1213	(3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1144:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	5	61	theme	RBDs	786:789	arg1	studies					775:781	Most studies	770:781	Most studies of RBDs	770:789	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	2	62	theme	spike	269:273	arg1	protein					275:281	the spike protein	265:281	the spike protein	265:281	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	6	63	theme	separation	1024:1033	arg1	techniques					1035:1044	several online separation techniques	1009:1044	several online separation techniques	1009:1044	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	64	theme	several	1009:1015	arg1	techniques					1035:1044	several online separation techniques	1009:1044	several online separation techniques	1009:1044	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	9	65	theme	HILIC	1760:1764	arg1	platform					1778:1785	The HILIC top-down MS platform	1756:1785	The HILIC top-down MS platform	1756:1785	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	2	66	theme	receptor-binding	291:306	arg1	RBD					316:318	RBD	316:318	RBD	316:318	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	2	66	theme	receptor-binding	291:306	arg1	domain					308:313	the receptor-binding domain	287:313	the receptor-binding domain (RBD)	287:319	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	9	67	from	applications	1906:1917	arg1	comparison					1861:1870	facile comparison	1854:1870	facile comparison of biosimilars in quality control applications	1854:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	9	68	theme	MS	1775:1776	arg1	platform					1778:1785	The HILIC top-down MS platform	1756:1785	The HILIC top-down MS platform	1756:1785	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	6	69	theme	recombinant	1242:1252	arg1	RBDs					1254:1257	separate intact recombinant RBDs	1226:1257	separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1226:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	0	70	theme	Mass	72:75	arg1	Spectrometry					77:88	Top-Down Mass Spectrometry	63:88	Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain	63:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	5	71	theme	technical	896:904	arg1	challenges					906:915	the technical challenges	892:915	the technical challenges in resolving highly heterogeneous glycans at the intact protein level	892:985	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	1	72	theme	cellular	167:174	arg1	infection					176:184	SARS-CoV-2 cellular infection	156:184	SARS-CoV-2 cellular infection	156:184	SARS-CoV-2 cellular infection is mediated by the heavily glycosylated spike protein.
35380435	6	73	dep	C2	1051:1052	arg1	RPLC					1091:1094	RPLC	1091:1094	RPLC	1091:1094	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	73	dep	C2	1051:1052	arg1	chromatography					1075:1088	reverse-phase liquid chromatography	1054:1088	(1) C2 reverse-phase liquid chromatography (RPLC)	1047:1095	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	73	dep	C2	1051:1052	arg1	1					1048:1048	1	1048:1048	1	1048:1048	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	74	theme	separate	1226:1233	arg1	RBDs					1254:1257	separate intact recombinant RBDs	1226:1257	separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1226:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	5	75	theme	bottom-up	834:842	arg1	peptide					825:831	the proteolytic peptide	809:831	the proteolytic peptide (bottom-up proteomics)	809:854	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	5	75	theme	bottom-up	834:842	arg1	proteomics					844:853	bottom-up proteomics	834:853	bottom-up proteomics	834:853	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	5	76	theme	protein	973:979	arg1	level					981:985	the intact protein level	962:985	the intact protein level	962:985	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	6	77	theme	liquid	1068:1073	arg1	RPLC					1091:1094	RPLC	1091:1094	RPLC	1091:1094	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	77	theme	liquid	1068:1073	arg1	chromatography					1075:1088	reverse-phase liquid chromatography	1054:1088	(1) C2 reverse-phase liquid chromatography (RPLC)	1047:1095	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	78	with	RBDs	1254:1257	arg1	combinations					1272:1283	varying combinations	1264:1283	varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1264:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	0	79	theme	Spike	125:129	arg1	Domain					148:153	the SARS-CoV-2 Spike Receptor-Binding Domain	110:153	the SARS-CoV-2 Spike Receptor-Binding Domain	110:153	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	0	80	theme	Hydrophilic	7:17	arg1	HILIC					47:51	HILIC	47:51	HILIC	47:51	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	0	80	theme	Hydrophilic	7:17	arg1	Chromatography					31:44	Online Hydrophilic Interaction Chromatography	0:44	Online Hydrophilic Interaction Chromatography (HILIC)	0:52	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain.
35380435	6	81	theme	zone	1112:1115	arg1	CZE					1134:1136	CZE	1134:1136	CZE	1134:1136	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	81	theme	zone	1112:1115	arg1	electrophoresis					1117:1131	(2) capillary zone electrophoresis	1098:1131	(2) capillary zone electrophoresis (CZE)	1098:1137	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	9	82	theme	facile	1854:1859	arg1	comparison					1861:1870	facile comparison	1854:1870	facile comparison of biosimilars in quality control applications	1854:1917	The HILIC top-down MS platform holds great potential in resolving heterogeneous glycoproteins for facile comparison of biosimilars in quality control applications.
35380435	3	83	theme	spike	451:455	arg1	structure					467:475	the spike protein's structure	447:475	the spike protein's structure	447:475	RBD plays key roles in the spike protein's structure and function, and thus, comprehensive characterization of recombinant RBD is critically important for biopharmaceutical applications.
35380435	4	84	theme	Liquid	611:616	arg1	chromatography					618:631	Liquid chromatography	611:631	Liquid chromatography coupled to mass spectrometry	611:660	Liquid chromatography coupled to mass spectrometry has been widely used to characterize post-translational modifications in proteins, including glycosylation.
35380435	6	85	dep	electrophoresis	1117:1131	arg1	2					1099:1099	2	1099:1099	2	1099:1099	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	5	86	theme	proteolytic	813:823	arg1	peptide					825:831	the proteolytic peptide	809:831	the proteolytic peptide (bottom-up proteomics)	809:854	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	5	86	theme	proteolytic	813:823	arg1	proteomics					844:853	bottom-up proteomics	834:853	bottom-up proteomics	834:853	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	5	87	theme	released	859:866	arg1	level					875:879	released glycan level	859:879	released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level	859:985	Most studies of RBDs were performed at the proteolytic peptide (bottom-up proteomics) or released glycan level because of the technical challenges in resolving highly heterogeneous glycans at the intact protein level.
35380435	6	88	theme	acrylamide-based	1148:1163	arg1	HILIC					1216:1220	HILIC	1216:1220	HILIC	1216:1220	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	6	88	theme	acrylamide-based	1148:1163	arg1	chromatography					1200:1213	monolithic hydrophilic interaction chromatography	1165:1213	(3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS)	1144:1350	Herein, we evaluated several online separation techniques: (1) C2 reverse-phase liquid chromatography (RPLC), (2) capillary zone electrophoresis (CZE), and (3) acrylamide-based monolithic hydrophilic interaction chromatography (HILIC) to separate intact recombinant RBDs with varying combinations of glycosylations (glycoforms) for top-down mass spectrometry (MS).
35380435	3	89	theme	key	434:436	arg1	roles					438:442	key roles	434:442	key roles	434:442	RBD plays key roles in the spike protein's structure and function, and thus, comprehensive characterization of recombinant RBD is critically important for biopharmaceutical applications.
35380435	8	90	theme	N-terminal	1620:1629	arg1	variation					1640:1648	N-terminal sequence variation	1620:1648	N-terminal sequence variation	1620:1648	In addition, our top-down analysis readily captured unexpected modifications (e.g., cysteinylation and N-terminal sequence variation) and low abundance, heavily glycosylated proteoforms that may be missed by using glycopeptide data alone.
35380435	2	91	theme	Recombinant	241:251	arg1	versions					253:260	Recombinant versions	241:260	Recombinant versions of the spike protein and the receptor-binding domain (RBD)	241:319	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	2	91	theme	Recombinant	241:251	arg1	vaccines					390:397	vaccines	390:397	vaccines against viral infection	390:421	Recombinant versions of the spike protein and the receptor-binding domain (RBD) are necessary for seropositivity assays and can potentially serve as vaccines against viral infection.
35380435	3	92	theme	comprehensive	501:513	arg1	characterization					515:530	comprehensive characterization	501:530	comprehensive characterization of recombinant RBD	501:549	RBD plays key roles in the spike protein's structure and function, and thus, comprehensive characterization of recombinant RBD is critically important for biopharmaceutical applications.
35380435	3	93	theme	RBD	547:549	arg1	characterization					515:530	comprehensive characterization	501:530	comprehensive characterization of recombinant RBD	501:549	RBD plays key roles in the spike protein's structure and function, and thus, comprehensive characterization of recombinant RBD is critically important for biopharmaceutical applications.
35065968	0	0	theme	flagellar	77:85	arg1	C					105:105	Clostridioides difficile flagellar protein flagellin C	52:105	Clostridioides difficile flagellar protein flagellin C	52:105	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	7	1	used	used	1578:1581	arg2	results					1554:1560	the results	1550:1560	the results obtained	1550:1569	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	1	2	theme	glycan	149:154	arg1	modification					156:167	The type A glycan modification	138:167	The type A glycan modification found in human pathogen Clostridioides difficile	138:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	0	3	theme	difficile	67:75	arg1	C					105:105	Clostridioides difficile flagellar protein flagellin C	52:105	Clostridioides difficile flagellar protein flagellin C	52:105	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	7	4	theme	A	1518:1518	arg1	modification					1527:1538	a type A glycan modification	1511:1538	a type A glycan modification	1511:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	5	5	theme	affinity	924:931	arg1	peptides					965:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	5	6	theme	chromatography-captured	933:955	arg1	peptides					965:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	0	7	theme	flagellin	95:103	arg1	C					105:105	Clostridioides difficile flagellar protein flagellin C	52:105	Clostridioides difficile flagellar protein flagellin C	52:105	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	7	8	theme	glycan	1520:1525	arg1	modification					1527:1538	a type A glycan modification	1511:1538	a type A glycan modification	1511:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	5	9	theme	type	1085:1088	arg1	structures					1092:1101	truncated/modified type A structures	1066:1101	truncated/modified type A structures	1066:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	4	10	theme	Fe3+-immobilized	754:769	arg1	approach					701:708	an approach	698:708	an approach that is commonly used in phosphoproteomics	698:751	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	10	theme	Fe3+-immobilized	754:769	arg1	chromatography					786:799	Fe3+-immobilized metal affinity chromatography	754:799	Fe3+-immobilized metal affinity chromatography	754:799	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	11	used	used	727:730	arg2	chromatography					786:799	Fe3+-immobilized metal affinity chromatography	754:799	Fe3+-immobilized metal affinity chromatography	754:799	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	11	used	used	727:730	arg2	approach					701:708	an approach	698:708	an approach that is commonly used in phosphoproteomics	698:751	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	0	12	theme	protein	87:93	arg1	C					105:105	Clostridioides difficile flagellar protein flagellin C	52:105	Clostridioides difficile flagellar protein flagellin C	52:105	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	3	13	theme	enrichment	561:570	arg1	strategy					572:579	enrichment strategy	561:579	enrichment strategy	561:579	The study of post-translational modifications often relies on some type of enrichment strategy; however, a procedure for enrichment of this modification has not yet been demonstrated.
35065968	3	14	theme	modifications	518:530	arg1	study					490:494	The study	486:494	The study of post-translational modifications	486:530	The study of post-translational modifications often relies on some type of enrichment strategy; however, a procedure for enrichment of this modification has not yet been demonstrated.
35065968	6	15	theme	analyses	1166:1173	arg1	set					1141:1143	an elaborate set	1128:1143	an elaborate set of mass spectrometry analyses	1128:1173	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	6	15	theme	analyses	1166:1173	arg1	analyses					1166:1173	mass spectrometry analyses	1148:1173	mass spectrometry analyses	1148:1173	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	7	16	contain	carrying	1502:1509	arg1	peptides					1493:1500	peptides	1493:1500	peptides carrying a type A glycan modification	1493:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	7	16	contain	carrying	1502:1509	arg2	modification					1527:1538	a type A glycan modification	1511:1538	a type A glycan modification	1511:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	4	17	theme	post-translational	846:863	arg1	modification					865:876	this unique post-translational modification	834:876	this unique post-translational modification	834:876	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	18	theme	affinity	777:784	arg1	approach					701:708	an approach	698:708	an approach that is commonly used in phosphoproteomics	698:751	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	18	theme	affinity	777:784	arg1	chromatography					786:799	Fe3+-immobilized metal affinity chromatography	754:799	Fe3+-immobilized metal affinity chromatography	754:799	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	2	19	theme	flagellar	383:391	arg1	C					411:411	the flagellar protein flagellin C	379:411	the flagellar protein flagellin C of several C. difficile strains	379:443	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	2	20	theme	flagellin	401:409	arg1	C					411:411	the flagellar protein flagellin C	379:411	the flagellar protein flagellin C of several C. difficile strains	379:443	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	0	21	theme	C	105:105	arg1	modification					36:47	A glycan modification	27:47	A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis	27:135	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	7	22	theme	peptides	1493:1500	arg1	identification					1475:1488	reliable identification	1466:1488	reliable identification of peptides carrying a type A glycan modification	1466:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	4	23	theme	unique	839:844	arg1	modification					865:876	this unique post-translational modification	834:876	this unique post-translational modification	834:876	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	24	theme	metal	771:775	arg1	approach					701:708	an approach	698:708	an approach that is commonly used in phosphoproteomics	698:751	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	4	24	theme	metal	771:775	arg1	chromatography					786:799	Fe3+-immobilized metal affinity chromatography	754:799	Fe3+-immobilized metal affinity chromatography	754:799	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	2	25	theme	protein	393:399	arg1	C					411:411	the flagellar protein flagellin C	379:411	the flagellar protein flagellin C of several C. difficile strains	379:443	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	7	26	theme	reliable	1466:1473	arg1	identification					1475:1488	reliable identification	1466:1488	reliable identification of peptides carrying a type A glycan modification	1466:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	7	27	theme	type	1513:1516	arg1	modification					1527:1538	a type A glycan modification	1511:1538	a type A glycan modification	1511:1538	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	1	28	theme	human	178:182	arg1	difficile					208:216	human pathogen Clostridioides difficile	178:216	human pathogen Clostridioides difficile	178:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	0	29	theme	New	0:2	arg1	insights					4:11	New insights	0:11	New insights into the type	0:25	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	1	30	theme	pathogen	184:191	arg1	difficile					208:216	human pathogen Clostridioides difficile	178:216	human pathogen Clostridioides difficile	178:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	6	31	theme	A	1242:1242	arg1	structure					1244:1252	a type A structure	1235:1252	a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile	1235:1395	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	3	32	theme	strategy	572:579	arg1	type					553:556	some type	548:556	some type of enrichment strategy	548:579	The study of post-translational modifications often relies on some type of enrichment strategy; however, a procedure for enrichment of this modification has not yet been demonstrated.
35065968	1	33	theme	Clostridioides	193:206	arg1	difficile					208:216	human pathogen Clostridioides difficile	178:216	human pathogen Clostridioides difficile	178:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	2	34	theme	strains	437:443	arg1	C					411:411	the flagellar protein flagellin C	379:411	the flagellar protein flagellin C of several C. difficile strains	379:443	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	1	35	theme	N-methylated	277:288	arg1	threonine					290:298	an N-methylated threonine	274:298	an N-methylated threonine	274:298	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	0	36	theme	phosphoproteomics	110:126	arg1	analysis					128:135	phosphoproteomics analysis	110:135	phosphoproteomics analysis	110:135	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	5	37	theme	type	996:999	arg1	peptides					1035:1042	type A-modified C. difficile flagellin peptides	996:1042	not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures	987:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	2	38	theme	several	416:422	arg1	strains					437:443	several C. difficile strains	416:443	several C. difficile strains	416:443	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	5	39	theme	peptides	965:972	arg1	analyses					894:901	LC-MS/MS analyses	885:901	LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides	885:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	6	40	theme	phosphonate	1267:1277	arg1	modification					1308:1319	a modification	1306:1319	a modification that is rarely observed and has hitherto not been described in C. difficile	1306:1395	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	6	40	theme	phosphonate	1267:1277	arg1	2-aminoethylphosphonate					1280:1302	a phosphonate (2-aminoethylphosphonate)	1265:1303	a phosphonate (2-aminoethylphosphonate)	1265:1303	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	1	41	located	found	169:173	arg2	modification					156:167	The type A glycan modification	138:167	The type A glycan modification found in human pathogen Clostridioides difficile	138:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	1	41	located	found	169:173	arg1	difficile					208:216	human pathogen Clostridioides difficile	178:216	human pathogen Clostridioides difficile	178:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	0	42	dep	modification	36:47	arg1	insights					4:11	New insights	0:11	New insights into the type	0:25	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	5	43	theme	truncated/modified	1066:1083	arg1	structures					1092:1101	truncated/modified type A structures	1066:1101	truncated/modified type A structures	1066:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	2	44	theme	bacterial	466:474	arg1	motility					476:483	bacterial motility	466:483	bacterial motility	466:483	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	5	45	theme	immobilized	906:916	arg1	peptides					965:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	5	46	theme	C. difficile	1012:1023	arg1	peptides					1035:1042	type A-modified C. difficile flagellin peptides	996:1042	not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures	987:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	6	47	theme	mass	1148:1151	arg1	analyses					1166:1173	mass spectrometry analyses	1148:1173	mass spectrometry analyses	1148:1173	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	5	48	theme	tryptic	957:963	arg1	peptides					965:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	0	49	theme	glycan	29:34	arg1	modification					36:47	A glycan modification	27:47	A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis	27:135	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	1	50	theme	phosphodiester	310:323	arg1	bond					325:328	a phosphodiester bond	308:328	a phosphodiester bond	308:328	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	5	51	theme	structures	1092:1101	arg1	structures					1092:1101	truncated/modified type A structures	1066:1101	truncated/modified type A structures	1066:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	5	51	theme	structures	1092:1101	arg1	variety					1055:1061	a variety	1053:1061	not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures	987:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	5	51	theme	structures	1092:1101	arg1	peptides					1035:1042	type A-modified C. difficile flagellin peptides	996:1042	not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures	987:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	5	52	theme	A	1090:1090	arg1	structures					1092:1101	truncated/modified type A structures	1066:1101	truncated/modified type A structures	1066:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	3	53	theme	post-translational	499:516	arg1	modifications					518:530	post-translational modifications	499:530	post-translational modifications	499:530	The study of post-translational modifications often relies on some type of enrichment strategy; however, a procedure for enrichment of this modification has not yet been demonstrated.
35065968	6	54	contain	containing	1254:1263	arg1	structure					1244:1252	a type A structure	1235:1252	a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile	1235:1395	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	6	54	contain	containing	1254:1263	arg2	2-aminoethylphosphonate					1280:1302	a phosphonate (2-aminoethylphosphonate)	1265:1303	a phosphonate (2-aminoethylphosphonate)	1265:1303	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	6	54	contain	containing	1254:1263	arg2	modification					1308:1319	a modification	1306:1319	a modification that is rarely observed and has hitherto not been described in C. difficile	1306:1395	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	3	55	theme	modification	626:637	arg1	enrichment					607:616	enrichment	607:616	enrichment of this modification	607:637	The study of post-translational modifications often relies on some type of enrichment strategy; however, a procedure for enrichment of this modification has not yet been demonstrated.
35065968	6	56	dep	set	1141:1143	arg1	elaborate					1131:1139	elaborate	1131:1139	elaborate	1131:1139	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	7	57	theme	common	1428:1433	arg1	strategy					1446:1453	a common enrichment strategy	1426:1453	a common enrichment strategy	1426:1453	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	7	58	theme	enrichment	1435:1444	arg1	strategy					1446:1453	a common enrichment strategy	1426:1453	a common enrichment strategy	1426:1453	In conclusion, we show that a common enrichment strategy results in reliable identification of peptides carrying a type A glycan modification, and that the results obtained can be used to advance models about its biosynthesis.
35065968	6	59	theme	modifications	1209:1221	arg1	one					1196:1198	one	1196:1198	one	1196:1198	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	6	59	theme	modifications	1209:1221	arg1	modifications					1209:1221	these modifications	1203:1221	these modifications	1203:1221	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	5	60	theme	A-modified	1001:1010	arg1	peptides					1035:1042	type A-modified C. difficile flagellin peptides	996:1042	not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures	987:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	5	61	theme	metal	918:922	arg1	peptides					965:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	immobilized metal affinity chromatography-captured tryptic peptides	906:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	0	62	theme	Clostridioides	52:65	arg1	C					105:105	Clostridioides difficile flagellar protein flagellin C	52:105	Clostridioides difficile flagellar protein flagellin C	52:105	New insights into the type A glycan modification of Clostridioides difficile flagellar protein flagellin C by phosphoproteomics analysis.
35065968	5	63	theme	flagellin	1025:1033	arg1	peptides					1035:1042	type A-modified C. difficile flagellin peptides	996:1042	not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures	987:1101	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	1	64	attach	linked	264:269	arg1	threonine					290:298	an N-methylated threonine	274:298	an N-methylated threonine	274:298	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	1	64	attach	linked	264:269	arg2	GlcNAc					248:253	GlcNAc	248:253	GlcNAc	248:253	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	1	64	attach	linked	264:269	arg2	monosaccharide					232:245	a monosaccharide	230:245	a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond	230:328	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	2	65	theme	C. difficile	424:435	arg1	strains					437:443	several C. difficile strains	416:443	several C. difficile strains	416:443	This structure has previously been described on the flagellar protein flagellin C of several C. difficile strains and is important for bacterial motility.
35065968	1	66	theme	type	142:145	arg1	modification					156:167	The type A glycan modification	138:167	The type A glycan modification found in human pathogen Clostridioides difficile	138:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
35065968	5	67	theme	LC-MS/MS	885:892	arg1	analyses					894:901	LC-MS/MS analyses	885:901	LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides	885:972	Using LC-MS/MS analyses of immobilized metal affinity chromatography-captured tryptic peptides, we observed not only type A-modified C. difficile flagellin peptides but also a variety of truncated/modified type A structures on these peptides.
35065968	4	68	with	peptides	820:827	arg1	modification					865:876	this unique post-translational modification	834:876	this unique post-translational modification	834:876	In this study, we show that an approach that is commonly used in phosphoproteomics, Fe3+-immobilized metal affinity chromatography, also enriches for peptides with this unique post-translational modification.
35065968	6	69	theme	spectrometry	1153:1164	arg1	analyses					1166:1173	mass spectrometry analyses	1148:1173	mass spectrometry analyses	1148:1173	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	6	70	theme	type	1237:1240	arg1	structure					1244:1252	a type A structure	1235:1252	a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile	1235:1395	Using an elaborate set of mass spectrometry analyses, we demonstrate that one of these modifications consists of a type A structure containing a phosphonate (2-aminoethylphosphonate), a modification that is rarely observed and has hitherto not been described in C. difficile.
35065968	1	71	theme	A	147:147	arg1	modification					156:167	The type A glycan modification	138:167	The type A glycan modification found in human pathogen Clostridioides difficile	138:216	The type A glycan modification found in human pathogen Clostridioides difficile consists of a monosaccharide (GlcNAc) that is linked to an N-methylated threonine through a phosphodiester bond.
36007953	0	0	theme	broad-spectrum	67:80	arg1	inhibitor					82:90	a potent broad-spectrum inhibitor	58:90	a potent broad-spectrum inhibitor of SARS-CoV-2 infection	58:114	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	1	1	theme	other	285:289	arg1	molecules					291:299	other molecules	285:299	other molecules	285:299	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	2	2	theme	antibodies	520:529	arg1	efficacy					499:506	the efficacy	495:506	the efficacy of existing antibodies	495:529	Most of the variants of concern have mutations in this area, which could reduce the efficacy of existing antibodies.
36007953	7	3	theme	Cryogenic	1166:1174	arg1	microscopy					1185:1194	Cryogenic electron microscopy	1166:1194	Cryogenic electron microscopy	1166:1194	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	0	4	theme	potent	60:65	arg1	inhibitor					82:90	a potent broad-spectrum inhibitor	58:90	a potent broad-spectrum inhibitor of SARS-CoV-2 infection	58:114	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	1	5	theme	molecules	291:299	arg1	access					275:280	the access	271:280	the access of other molecules	271:299	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	2	6	theme	existing	511:518	arg1	antibodies					520:529	existing antibodies	511:529	existing antibodies	511:529	Most of the variants of concern have mutations in this area, which could reduce the efficacy of existing antibodies.
36007953	7	7	theme	electron	1176:1183	arg1	microscopy					1185:1194	Cryogenic electron microscopy	1166:1194	Cryogenic electron microscopy	1166:1194	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	5	8	gly	core-fucosylated	957:972	arg1	N-glycans					974:982	the core-fucosylated N-glycans	953:982	the core-fucosylated N-glycans at the micromolar level	953:1006	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	9	9	theme	PhoSL	1685:1689	arg1	engineering					1670:1680	the engineering	1666:1680	the engineering of PhoSL	1666:1689	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	9	10	theme	protein	1443:1449	arg1	complex					1451:1457	the PhoSL-S protein complex	1431:1457	the PhoSL-S protein complex	1431:1457	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	4	11	theme	40-amino-acid	761:773	arg1	peptide					798:804	a 40-amino-acid chemically synthesised peptide	759:804	a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans	759:843	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	11	theme	40-amino-acid	761:773	arg1	lectin					743:748	Pholiota squarrosa lectin	724:748	Pholiota squarrosa lectin (PhoSL)	724:756	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	7	12	theme	S	1245:1245	arg1	protein					1247:1253	the S protein	1241:1253	the S protein	1241:1253	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	7	13	theme	PhoSL	1318:1322	arg1	multivalence					1284:1295	the multivalence	1280:1295	the multivalence of both the trimeric PhoSL and S protein	1280:1336	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	9	14	theme	amino	1504:1508	arg1	acids					1510:1514	the amino acids	1500:1514	the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL	1500:1689	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	5	15	theme	low	871:873	arg1	stronger					915:922	stronger	915:922	stronger	915:922	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	5	15	theme	low	871:873	arg1	level					885:889	a low nanomolar level	869:889	a low nanomolar level	869:889	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	1	16	theme	glycan	237:242	arg1	"					250:250	a "glycan shield"	234:250	a "glycan shield"	234:250	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	0	17	theme	infection	106:114	arg1	inhibitor					82:90	a potent broad-spectrum inhibitor	58:90	a potent broad-spectrum inhibitor of SARS-CoV-2 infection	58:114	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	9	18	theme	S	1576:1576	arg1	protein					1578:1584	S protein	1576:1584	S protein	1576:1584	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	1	19	gly	N-glycosylated	214:227	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	19	gly	N-glycosylated	214:227	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	4	20	theme	ancestral	676:684	arg1	proteins					660:667	the S proteins	654:667	the S proteins of the ancestral (Wuhan) and Omicron strains	654:712	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	5	21	from	level	1002:1006	arg1	PhoSL					943:947	PhoSL	943:947	PhoSL	943:947	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	5	21	from	level	1002:1006	arg1	N-glycans					974:982	the core-fucosylated N-glycans	953:982	the core-fucosylated N-glycans at the micromolar level	953:1006	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	1	22	theme	SARS-CoV-2	166:175	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	22	theme	SARS-CoV-2	166:175	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	0	23	theme	SARS-CoV-2	95:104	arg1	infection					106:114	SARS-CoV-2 infection	95:114	SARS-CoV-2 infection	95:114	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	4	24	theme	Pholiota squarrosa	724:741	arg1	peptide					798:804	a 40-amino-acid chemically synthesised peptide	759:804	a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans	759:843	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	24	theme	Pholiota squarrosa	724:741	arg1	PhoSL					751:755	PhoSL	751:755	PhoSL	751:755	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	24	theme	Pholiota squarrosa	724:741	arg1	lectin					743:748	Pholiota squarrosa lectin	724:748	Pholiota squarrosa lectin (PhoSL)	724:756	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	6	25	theme	similar	1075:1081	arg1	levels					1097:1102	similar submicromolar levels	1075:1102	similar submicromolar levels	1075:1102	We demonstrated that PhoSL inhibited infection by both strains at similar submicromolar levels, suggesting its broad-spectrum effect on SARS-CoV-2 variants.
36007953	3	26	from	contrast	535:542	arg1	invariant					582:590	invariant	582:590	invariant	582:590	In contrast, N-glycosylation sites are relatively invariant, and some are essential for infection.
36007953	2	27	theme	concern	439:445	arg1	variants					427:434	the variants	423:434	the variants of concern	423:445	Most of the variants of concern have mutations in this area, which could reduce the efficacy of existing antibodies.
36007953	9	28	theme	complex	1451:1457	arg1	modelling					1418:1426	Structural modelling	1407:1426	Structural modelling of the PhoSL-S protein complex	1407:1457	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	1	29	theme	small	313:317	arg1	area					324:327	a small open area	311:327	a small open area	311:327	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	30	theme	neutralising	390:401	arg1	antibodies					403:412	neutralising antibodies	390:412	neutralising antibodies	390:412	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	31	theme	spike	178:182	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	31	theme	spike	178:182	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	9	32	theme	significant	1609:1619	arg1	potential					1621:1629	the significant potential	1605:1629	the significant potential for developing specific binders by the engineering of PhoSL	1605:1689	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	1	33	theme	shield	244:249	arg1	"					250:250	a "glycan shield"	234:250	a "glycan shield"	234:250	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	7	34	theme	S	1328:1328	arg1	protein					1330:1336	S protein	1328:1336	S protein	1328:1336	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	9	35	theme	enhanced	1553:1560	arg1	affinity					1562:1569	the enhanced affinity	1549:1569	the enhanced affinity with S protein	1549:1584	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	0	36	theme	squarrosa	30:38	arg1	PhoSL					48:52	PhoSL	48:52	PhoSL	48:52	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	0	36	theme	squarrosa	30:38	arg1	lectin					40:45	Pholiota squarrosa lectin	21:45	Pholiota squarrosa lectin (PhoSL)	21:53	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	4	37	theme	core-fucosylated	818:833	arg1	N-glycans					835:843	core-fucosylated N-glycans	818:843	core-fucosylated N-glycans	818:843	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	38	theme	S	658:658	arg1	proteins					660:667	the S proteins	654:667	the S proteins of the ancestral (Wuhan) and Omicron strains	654:712	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	0	39	theme	Pholiota	21:28	arg1	PhoSL					48:52	PhoSL	48:52	PhoSL	48:52	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	0	39	theme	Pholiota	21:28	arg1	lectin					40:45	Pholiota squarrosa lectin	21:45	Pholiota squarrosa lectin (PhoSL)	21:53	Core fucose-specific Pholiota squarrosa lectin (PhoSL) as a potent broad-spectrum inhibitor of SARS-CoV-2 infection.
36007953	5	40	theme	nanomolar	875:883	arg1	stronger					915:922	stronger	915:922	stronger	915:922	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	5	40	theme	nanomolar	875:883	arg1	level					885:889	a low nanomolar level	869:889	a low nanomolar level	869:889	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	1	41	theme	open	319:322	arg1	area					324:327	a small open area	311:327	a small open area	311:327	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	7	42	theme	protein	1247:1253	arg1	aggregation					1226:1236	an aggregation	1223:1236	an aggregation	1223:1236	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	7	42	theme	protein	1247:1253	arg1	due					1273:1275	due	1273:1275	due	1273:1275	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	1	43	theme	S	193:193	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	43	theme	S	193:193	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	4	44	gly	core-fucosylated	818:833	arg1	N-glycans					835:843	core-fucosylated N-glycans	818:843	core-fucosylated N-glycans	818:843	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	3	45	gly	N-glycosylation	545:559	arg2	sites					561:565	N-glycosylation sites	545:565	N-glycosylation sites	545:565	In contrast, N-glycosylation sites are relatively invariant, and some are essential for infection.
36007953	6	46	from	effect	1135:1140	arg1	variants					1156:1163	SARS-CoV-2 variants	1145:1163	SARS-CoV-2 variants	1145:1163	We demonstrated that PhoSL inhibited infection by both strains at similar submicromolar levels, suggesting its broad-spectrum effect on SARS-CoV-2 variants.
36007953	4	47	theme	strains	706:712	arg1	proteins					660:667	the S proteins	654:667	the S proteins of the ancestral (Wuhan) and Omicron strains	654:712	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	3	48	theme	N-glycosylation	545:559	arg1	sites					561:565	N-glycosylation sites	545:565	N-glycosylation sites	545:565	In contrast, N-glycosylation sites are relatively invariant, and some are essential for infection.
36007953	4	49	theme	Omicron	698:704	arg1	strains					706:712	the ancestral (Wuhan) and Omicron strains	672:712	strains	706:712	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	50	theme	synthesised	786:796	arg1	peptide					798:804	a 40-amino-acid chemically synthesised peptide	759:804	a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans	759:843	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	50	theme	synthesised	786:796	arg1	lectin					743:748	Pholiota squarrosa lectin	724:748	Pholiota squarrosa lectin (PhoSL)	724:756	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	5	51	theme	micromolar	991:1000	arg1	level					1002:1006	the micromolar level	987:1006	the micromolar level	987:1006	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	6	52	theme	SARS-CoV-2	1145:1154	arg1	variants					1156:1163	SARS-CoV-2 variants	1145:1163	SARS-CoV-2 variants	1145:1163	We demonstrated that PhoSL inhibited infection by both strains at similar submicromolar levels, suggesting its broad-spectrum effect on SARS-CoV-2 variants.
36007953	9	53	theme	specific	1646:1653	arg1	binders					1655:1661	specific binders	1646:1661	specific binders	1646:1661	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	9	54	theme	Structural	1407:1416	arg1	modelling					1418:1426	Structural modelling	1407:1426	Structural modelling of the PhoSL-S protein complex	1407:1457	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	8	55	theme	inhibitory	1385:1394	arg1	mechanism					1396:1404	the inhibitory mechanism	1381:1404	the inhibitory mechanism	1381:1404	This characteristic is likely relevant to the inhibitory mechanism.
36007953	9	56	theme	S	1523:1523	arg1	protein					1525:1531	the S protein	1519:1531	the S protein	1519:1531	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	1	57	theme	Severe	117:122	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	57	theme	Severe	117:122	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	9	58	with	affinity	1562:1569	arg1	protein					1578:1584	S protein	1576:1584	S protein	1576:1584	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	4	59	theme	specific	806:813	arg1	peptide					798:804	a 40-amino-acid chemically synthesised peptide	759:804	a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans	759:843	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	4	59	theme	specific	806:813	arg1	lectin					743:748	Pholiota squarrosa lectin	724:748	Pholiota squarrosa lectin (PhoSL)	724:756	Here, we observed that the S proteins of the ancestral (Wuhan) and Omicron strains bind with Pholiota squarrosa lectin (PhoSL), a 40-amino-acid chemically synthesised peptide specific to core-fucosylated N-glycans.
36007953	9	60	theme	protein	1525:1531	arg1	acids					1510:1514	the amino acids	1500:1514	the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL	1500:1689	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	7	61	theme	protein	1330:1336	arg1	multivalence					1284:1295	the multivalence	1280:1295	the multivalence of both the trimeric PhoSL and S protein	1280:1336	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	1	62	theme	acute	124:128	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	62	theme	acute	124:128	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	7	63	theme	trimeric	1309:1316	arg1	PhoSL					1318:1322	the trimeric PhoSL	1305:1322	the trimeric PhoSL	1305:1322	Cryogenic electron microscopy revealed that PhoSL caused an aggregation of the S protein, which was likely due to the multivalence of both the trimeric PhoSL and S protein.
36007953	6	64	theme	broad-spectrum	1120:1133	arg1	effect					1135:1140	its broad-spectrum effect	1116:1140	its broad-spectrum effect on SARS-CoV-2 variants	1116:1163	We demonstrated that PhoSL inhibited infection by both strains at similar submicromolar levels, suggesting its broad-spectrum effect on SARS-CoV-2 variants.
36007953	1	65	theme	respiratory	130:140	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	65	theme	respiratory	130:140	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	3	66	from	invariant	582:590	arg1	contrast					535:542	contrast	535:542	contrast	535:542	In contrast, N-glycosylation sites are relatively invariant, and some are essential for infection.
36007953	5	67	theme	core-fucosylated	957:972	arg1	N-glycans					974:982	the core-fucosylated N-glycans	953:982	the core-fucosylated N-glycans at the micromolar level	953:1006	The affinities were at a low nanomolar level, which were ~ 1000-fold stronger than those between PhoSL and the core-fucosylated N-glycans at the micromolar level.
36007953	9	68	with	contact	1487:1493	arg1	acids					1510:1514	the amino acids	1500:1514	the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL	1500:1689	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	9	69	theme	PhoSL-S	1435:1441	arg1	complex					1451:1457	the PhoSL-S protein complex	1431:1457	the PhoSL-S protein complex	1431:1457	Structural modelling of the PhoSL-S protein complex indicated that PhoSL was in contact with the amino acids of the S protein, which explains the enhanced affinity with S protein and also indicates the significant potential for developing specific binders by the engineering of PhoSL.
36007953	1	70	theme	syndrome	142:149	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	70	theme	syndrome	142:149	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	6	71	theme	submicromolar	1083:1095	arg1	levels					1097:1102	similar submicromolar levels	1075:1102	similar submicromolar levels	1075:1102	We demonstrated that PhoSL inhibited infection by both strains at similar submicromolar levels, suggesting its broad-spectrum effect on SARS-CoV-2 variants.
36007953	2	72	contain	have	447:450	arg2	mutations					452:460	mutations	452:460	mutations	452:460	Most of the variants of concern have mutations in this area, which could reduce the efficacy of existing antibodies.
36007953	2	72	contain	have	447:450	arg1	Most					415:418	Most	415:418	Most	415:418	Most of the variants of concern have mutations in this area, which could reduce the efficacy of existing antibodies.
36007953	2	72	contain	have	447:450	arg1	variants					427:434	the variants	423:434	the variants of concern	423:445	Most of the variants of concern have mutations in this area, which could reduce the efficacy of existing antibodies.
36007953	1	73	theme	coronavirus	151:161	arg1	protein					184:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein	117:190	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein)	117:202	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
36007953	1	73	theme	coronavirus	151:161	arg1	protein					195:201	S protein	193:201	S protein	193:201	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S protein) is highly N-glycosylated, and a "glycan shield" is formed to limit the access of other molecules; however, a small open area coincides with the interface to the host's receptor and also neutralising antibodies.
35320367	0	0	from	discovery	26:34	arg1	myeloma					48:54	multiple myeloma	39:54	multiple myeloma	39:54	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	10	1	theme	biomarker	1308:1316	arg1	discovery					1318:1326	Isomer-specific biomarker discovery	1292:1326	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans	1292:1378	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	1	2	theme	vital	180:184	arg1	role					186:189	vital role	180:189	vital role	180:189	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	6	3	theme	significant	856:866	arg1	difference					868:877	significant difference	856:877	significant difference between multiple myeloma cases and healthy controls	856:929	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	3	4	dep	potential	394:402	arg1	biological					404:413	biological	404:413	biological	404:413	Structure-specific glycan profiling may provide more potential biological information than compositional profiling.
35320367	8	5	theme	sample	1133:1138	arg1	sets					1140:1143	sample sets	1133:1143	sample sets	1133:1143	PCA is also employed to establish the differences among sample sets.
35320367	9	6	theme	specific	1165:1172	arg1	isomers					1174:1180	these specific isomers	1159:1180	these specific isomers	1159:1180	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	9	7	theme	early	1206:1210	arg1	detection					1212:1220	early detection	1206:1220	early detection of multiple myeloma	1206:1240	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	5	8	theme	different	755:763	arg1	isomers					765:771	different isomers	755:771	different isomers	755:771	In addition, α 2-3 neuraminidase was also applied for distinguishing the linkage types of sialic acid corresponding to different isomers.
35320367	10	9	theme	multiple	1331:1338	arg1	myeloma					1340:1346	multiple myeloma	1331:1346	multiple myeloma	1331:1346	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	9	10	theme	myeloma	1234:1240	arg1	detection					1212:1220	early detection	1206:1220	early detection of multiple myeloma	1206:1240	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	4	11	theme	human	495:499	arg1	samples					507:513	human serum samples	495:513	human serum samples	495:513	In this work, N-glycans released from human serum samples were derivatized with reduction and methylamination prior to profiling using nanoLC-ESI-MS with PGC as stationary phase.
35320367	7	12	theme	altered	978:984	arg1	glycans					995:1001	the significantly altered isomeric glycans	960:1001	the significantly altered isomeric glycans	960:1001	ROC was performed to assess the significantly altered isomeric glycans and 6 AUCs have exceeded 0.80, providing high diagnostic accuracy for MM.
35320367	4	13	with	nanoLC-ESI-MS	592:604	arg1	PGC					611:613	PGC	611:613	PGC	611:613	In this work, N-glycans released from human serum samples were derivatized with reduction and methylamination prior to profiling using nanoLC-ESI-MS with PGC as stationary phase.
35320367	5	14	theme	linkage	709:715	arg1	types					717:721	the linkage types	705:721	the linkage types of sialic acid corresponding to different isomers	705:771	In addition, α 2-3 neuraminidase was also applied for distinguishing the linkage types of sialic acid corresponding to different isomers.
35320367	10	15	with	discovery	1318:1326	arg1	N-glycans					1370:1378	dual-derivatized N-glycans	1353:1378	dual-derivatized N-glycans	1353:1378	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	6	16	theme	N-glycans	810:818	arg1	abundances					783:792	Relative abundances	774:792	Relative abundances of 280 isomeric N-glycans	774:818	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	3	17	theme	compositional	432:444	arg1	profiling					446:454	compositional profiling	432:454	compositional profiling	432:454	Structure-specific glycan profiling may provide more potential biological information than compositional profiling.
35320367	7	18	theme	diagnostic	1049:1058	arg1	accuracy					1060:1067	high diagnostic accuracy	1044:1067	high diagnostic accuracy	1044:1067	ROC was performed to assess the significantly altered isomeric glycans and 6 AUCs have exceeded 0.80, providing high diagnostic accuracy for MM.
35320367	2	19	theme	branching	323:331	arg1	styles					333:338	branching styles	323:338	branching styles	323:338	With multitudinous glycosyltransferases, N-glycans present structural diversity in linkages and branching styles.
35320367	6	20	theme	isomeric	801:808	arg1	N-glycans					810:818	280 isomeric N-glycans	797:818	280 isomeric N-glycans	797:818	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	1	21	theme	various	194:200	arg1	processes					216:224	various physiological processes	194:224	various physiological processes	194:224	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	0	22	theme	biomarker	16:24	arg1	discovery					26:34	Isomer-specific biomarker discovery	0:34	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans	0:86	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	3	23	theme	potential	394:402	arg1	information					415:425	more potential biological information	389:425	more potential biological information than compositional profiling	389:454	Structure-specific glycan profiling may provide more potential biological information than compositional profiling.
35320367	5	24	theme	sialic	726:731	arg1	acid					733:736	sialic acid	726:736	sialic acid corresponding to different isomers	726:771	In addition, α 2-3 neuraminidase was also applied for distinguishing the linkage types of sialic acid corresponding to different isomers.
35320367	1	25	theme	physiological	202:214	arg1	processes					216:224	various physiological processes	194:224	various physiological processes	194:224	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	0	26	theme	Isomer-specific	0:14	arg1	discovery					26:34	Isomer-specific biomarker discovery	0:34	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans	0:86	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	5	27	theme	acid	733:736	arg1	types					717:721	the linkage types	705:721	the linkage types of sialic acid corresponding to different isomers	705:771	In addition, α 2-3 neuraminidase was also applied for distinguishing the linkage types of sialic acid corresponding to different isomers.
35320367	6	28	theme	myeloma	896:902	arg1	cases					904:908	multiple myeloma cases	887:908	multiple myeloma cases	887:908	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	6	29	theme	multiple	887:894	arg1	cases					904:908	multiple myeloma cases	887:908	multiple myeloma cases	887:908	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	2	30	from	diversity	297:305	arg1	linkages					310:317	linkages	310:317	linkages	310:317	With multitudinous glycosyltransferases, N-glycans present structural diversity in linkages and branching styles.
35320367	2	30	from	diversity	297:305	arg1	styles					333:338	branching styles	323:338	branching styles	323:338	With multitudinous glycosyltransferases, N-glycans present structural diversity in linkages and branching styles.
35320367	9	31	used	used	1197:1200	arg2	isomers					1174:1180	these specific isomers	1159:1180	these specific isomers	1159:1180	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	3	32	theme	Structure-specific	341:358	arg1	profiling					367:375	Structure-specific glycan profiling	341:375	Structure-specific glycan profiling	341:375	Structure-specific glycan profiling may provide more potential biological information than compositional profiling.
35320367	1	33	theme	important	108:116	arg1	modifications					137:149	the most important post-translational modifications	99:149	the most important post-translational modifications	99:149	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	6	34	theme	Relative	774:781	arg1	abundances					783:792	Relative abundances	774:792	Relative abundances of 280 isomeric N-glycans	774:818	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	7	35	theme	isomeric	986:993	arg1	glycans					995:1001	the significantly altered isomeric glycans	960:1001	the significantly altered isomeric glycans	960:1001	ROC was performed to assess the significantly altered isomeric glycans and 6 AUCs have exceeded 0.80, providing high diagnostic accuracy for MM.
35320367	10	36	from	discovery	1318:1326	arg1	myeloma					1340:1346	multiple myeloma	1331:1346	multiple myeloma	1331:1346	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	2	37	theme	structural	286:295	arg1	diversity					297:305	structural diversity	286:305	structural diversity in linkages and branching styles	286:338	With multitudinous glycosyltransferases, N-glycans present structural diversity in linkages and branching styles.
35320367	0	38	theme	multiple	39:46	arg1	myeloma					48:54	multiple myeloma	39:54	multiple myeloma	39:54	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	9	39	theme	multiple	1225:1232	arg1	myeloma					1234:1240	multiple myeloma	1225:1240	multiple myeloma	1225:1240	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	0	40	theme	dual-derivatized	61:76	arg1	N-glycans					78:86	dual-derivatized N-glycans	61:86	dual-derivatized N-glycans	61:86	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	4	41	theme	stationary	618:627	arg1	phase					629:633	stationary phase	618:633	stationary phase	618:633	In this work, N-glycans released from human serum samples were derivatized with reduction and methylamination prior to profiling using nanoLC-ESI-MS with PGC as stationary phase.
35320367	0	42	with	discovery	26:34	arg1	N-glycans					78:86	dual-derivatized N-glycans	61:86	dual-derivatized N-glycans	61:86	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	1	43	theme	post-translational	118:135	arg1	modifications					137:149	the most important post-translational modifications	99:149	the most important post-translational modifications	99:149	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	4	44	theme	serum	501:505	arg1	samples					507:513	human serum samples	495:513	human serum samples	495:513	In this work, N-glycans released from human serum samples were derivatized with reduction and methylamination prior to profiling using nanoLC-ESI-MS with PGC as stationary phase.
35320367	5	45	theme	α	649:649	arg1	neuraminidase					655:667	α 2-3 neuraminidase	649:667	α 2-3 neuraminidase	649:667	In addition, α 2-3 neuraminidase was also applied for distinguishing the linkage types of sialic acid corresponding to different isomers.
35320367	1	46	theme	modifications	137:149	arg1	one					92:94	one	92:94	one	92:94	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	1	46	theme	modifications	137:149	arg1	modifications					137:149	the most important post-translational modifications	99:149	the most important post-translational modifications	99:149	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	7	47	theme	high	1044:1047	arg1	accuracy					1060:1067	high diagnostic accuracy	1044:1067	high diagnostic accuracy	1044:1067	ROC was performed to assess the significantly altered isomeric glycans and 6 AUCs have exceeded 0.80, providing high diagnostic accuracy for MM.
35320367	3	48	theme	glycan	360:365	arg1	profiling					367:375	Structure-specific glycan profiling	341:375	Structure-specific glycan profiling	341:375	Structure-specific glycan profiling may provide more potential biological information than compositional profiling.
35320367	2	49	theme	multitudinous	232:244	arg1	glycosyltransferases					246:265	multitudinous glycosyltransferases	232:265	multitudinous glycosyltransferases	232:265	With multitudinous glycosyltransferases, N-glycans present structural diversity in linkages and branching styles.
35320367	5	50	theme	2-3	651:653	arg1	neuraminidase					655:667	α 2-3 neuraminidase	649:667	α 2-3 neuraminidase	649:667	In addition, α 2-3 neuraminidase was also applied for distinguishing the linkage types of sialic acid corresponding to different isomers.
35320367	9	51	theme	important	1254:1262	arg1	value					1285:1289	important clinical application value	1254:1289	important clinical application value	1254:1289	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	1	52	theme	protein	152:158	arg1	glycosylation					160:172	protein glycosylation	152:172	protein glycosylation	152:172	As one of the most important post-translational modifications, protein glycosylation plays vital role in various physiological processes.
35320367	6	53	theme	healthy	914:920	arg1	controls					922:929	healthy controls	914:929	healthy controls	914:929	Relative abundances of 280 isomeric N-glycans were compared and 20 isomers showed significant difference between multiple myeloma cases and healthy controls.
35320367	4	54	attach	released	481:488	arg2	N-glycans					471:479	N-glycans	471:479	N-glycans released from human serum samples	471:513	In this work, N-glycans released from human serum samples were derivatized with reduction and methylamination prior to profiling using nanoLC-ESI-MS with PGC as stationary phase.
35320367	4	54	attach	released	481:488	arg1	samples					507:513	human serum samples	495:513	human serum samples	495:513	In this work, N-glycans released from human serum samples were derivatized with reduction and methylamination prior to profiling using nanoLC-ESI-MS with PGC as stationary phase.
35320367	9	55	theme	clinical	1264:1271	arg1	value					1285:1289	important clinical application value	1254:1289	important clinical application value	1254:1289	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
35320367	10	56	theme	dual-derivatized	1353:1368	arg1	N-glycans					1370:1378	dual-derivatized N-glycans	1353:1378	dual-derivatized N-glycans	1353:1378	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	10	57	theme	Isomer-specific	1292:1306	arg1	discovery					1318:1326	Isomer-specific biomarker discovery	1292:1326	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans	1292:1378	Isomer-specific biomarker discovery in multiple myeloma with dual-derivatized N-glycans.
35320367	9	58	theme	application	1273:1283	arg1	value					1285:1289	important clinical application value	1254:1289	important clinical application value	1254:1289	Furthermore, these specific isomers have also been used for early detection of multiple myeloma, presenting important clinical application value.
36881660	2	0	theme	in-depth	350:357	arg1	characterization					359:374	in-depth characterization	350:374	in-depth characterization of antibody glycosylation	350:400	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	4	1	theme	glycan	834:839	arg1	analysis					841:848	accurate glycan analysis	825:848	accurate glycan analysis for a desired application	825:874	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	2	2	theme	glycans	295:301	arg1	analysis					319:326	their LC/MS analysis	307:326	their LC/MS analysis	307:326	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	2	2	theme	glycans	295:301	arg1	labeling					260:267	fluorescent labeling	248:267	fluorescent labeling of enzymatically released glycans	248:301	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	4	3	theme	labeling	790:797	arg1	chemistry					799:807	the labeling chemistry	786:807	the labeling chemistry	786:807	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	3	4	with	labeling	629:636	arg1	dye					657:659	a fluorescent dye	643:659	a fluorescent dye carrying an NHS-carbamate moiety	643:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	2	5	theme	released	286:293	arg1	glycans					295:301	enzymatically released glycans	272:301	enzymatically released glycans	272:301	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	3	6	dep	Endoglycosidase-S2	563:580	arg1	Peptide-N-Glycosidase-F					593:615	Peptide-N-Glycosidase-F	593:615	Peptide-N-Glycosidase-F	593:615	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	0	7	from	structures	43:52	arg1	IgGs					77:80	IgGs	77:80	IgGs	77:80	Novel method to specifically determine the structures of non-N297 glycans in IgGs.
36881660	3	8	theme	glycans	478:484	arg1	characterization					458:473	facile characterization	451:473	facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	451:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	9	theme	enzymatic	540:548	arg1	digests					550:556	sequential enzymatic digests	529:556	sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	529:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	2	10	from	importance	211:220	arg1	antibodies					236:245	antibodies	236:245	antibodies	236:245	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	4	11	theme	desired	856:862	arg1	application					864:874	a desired application	854:874	a desired application	854:874	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	2	12	from	glycans	225:231	arg1	antibodies					236:245	antibodies	236:245	antibodies	236:245	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	0	13	theme	Novel	0:4	arg1	method					6:11	Novel method	0:11	Novel method	0:11	Novel method to specifically determine the structures of non-N297 glycans in IgGs.
36881660	4	14	theme	glycosidases	762:773	arg1	critical					812:819	critical	812:819	critical	812:819	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	4	14	theme	glycosidases	762:773	arg1	choice					752:757	the choice	748:757	the choice of glycosidases along with the labeling chemistry	748:807	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	2	15	used	used	341:344	arg2	analysis					319:326	their LC/MS analysis	307:326	their LC/MS analysis	307:326	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	2	15	used	used	341:344	arg2	labeling					260:267	fluorescent labeling	248:267	fluorescent labeling of enzymatically released glycans	248:301	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	1	16	theme	Monoclonal	83:92	arg1	antibodies					94:103	Monoclonal antibodies	83:103	Monoclonal antibodies	83:103	Monoclonal antibodies comprise a major class of biologic therapeutics and are also extensively studied in immunology.
36881660	2	17	theme	glycosylation	388:400	arg1	characterization					359:374	in-depth characterization	350:374	in-depth characterization of antibody glycosylation	350:400	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	3	18	from	region	502:507	arg1	characterization					458:473	facile characterization	451:473	facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	451:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	2	19	from	antibodies	236:245	arg1	importance					211:220	the importance	207:220	the importance of glycans on antibodies	207:245	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	2	20	theme	LC/MS	313:317	arg1	analysis					319:326	their LC/MS analysis	307:326	their LC/MS analysis	307:326	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	4	21	theme	accurate	825:832	arg1	analysis					841:848	accurate glycan analysis	825:848	accurate glycan analysis for a desired application	825:874	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	3	22	theme	antibodies	512:521	arg1	region					502:507	the variable region	489:507	the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	489:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	1	23	theme	biologic	131:138	arg1	therapeutics					140:151	biologic therapeutics	131:151	biologic therapeutics	131:151	Monoclonal antibodies comprise a major class of biologic therapeutics and are also extensively studied in immunology.
36881660	4	24	theme	proposed	711:718	arg1	mechanism					720:728	proposed mechanism	711:728	proposed mechanism	711:728	The results and proposed mechanism also suggest that the choice of glycosidases along with the labeling chemistry is critical for accurate glycan analysis for a desired application.
36881660	3	25	theme	facile	451:456	arg1	characterization					458:473	facile characterization	451:473	facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	451:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	26	with	digests	550:556	arg1	Rapid™					586:591	Rapid™	586:591	Rapid™	586:591	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	26	with	digests	550:556	arg1	Endoglycosidase-S2					563:580	Endoglycosidase-S2	563:580	Endoglycosidase-S2	563:580	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	27	theme	NHS-carbamate	673:685	arg1	moiety					687:692	an NHS-carbamate moiety	670:692	an NHS-carbamate moiety	670:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	2	28	theme	glycans	225:231	arg1	importance					211:220	the importance	207:220	the importance of glycans on antibodies	207:245	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	3	29	theme	technical	411:419	arg1	note					421:424	this technical note	406:424	this technical note	406:424	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	30	from	characterization	458:473	arg1	region					502:507	the variable region	489:507	the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	489:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	31	theme	variable	493:500	arg1	region					502:507	the variable region	489:507	the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	489:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	1	32	theme	major	116:120	arg1	class					122:126	a major class	114:126	a major class of biologic therapeutics	114:151	Monoclonal antibodies comprise a major class of biologic therapeutics and are also extensively studied in immunology.
36881660	3	33	from	glycans	478:484	arg1	region					502:507	the variable region	489:507	the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	489:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	2	34	theme	fluorescent	248:258	arg1	labeling					260:267	fluorescent labeling	248:267	fluorescent labeling of enzymatically released glycans	248:301	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	3	35	theme	sequential	529:538	arg1	digests					550:556	sequential enzymatic digests	529:556	sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety	529:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	0	36	theme	glycans	66:72	arg1	structures					43:52	the structures	39:52	the structures of non-N297 glycans in IgGs	39:80	Novel method to specifically determine the structures of non-N297 glycans in IgGs.
36881660	3	37	theme	fluorescent	645:655	arg1	dye					657:659	a fluorescent dye	643:659	a fluorescent dye carrying an NHS-carbamate moiety	643:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	2	38	theme	antibody	379:386	arg1	glycosylation					388:400	antibody glycosylation	379:400	antibody glycosylation	379:400	Given the importance of glycans on antibodies, fluorescent labeling of enzymatically released glycans and their LC/MS analysis is routinely used for in-depth characterization of antibody glycosylation.
36881660	0	39	theme	non-N297	57:64	arg1	glycans					66:72	non-N297 glycans	57:72	non-N297 glycans	57:72	Novel method to specifically determine the structures of non-N297 glycans in IgGs.
36881660	1	40	theme	therapeutics	140:151	arg1	class					122:126	a major class	114:126	a major class of biologic therapeutics	114:151	Monoclonal antibodies comprise a major class of biologic therapeutics and are also extensively studied in immunology.
36881660	3	41	contain	carrying	661:668	arg1	dye					657:659	a fluorescent dye	643:659	a fluorescent dye carrying an NHS-carbamate moiety	643:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36881660	3	41	contain	carrying	661:668	arg2	moiety					687:692	an NHS-carbamate moiety	670:692	an NHS-carbamate moiety	670:692	In this technical note, we propose a method for facile characterization of glycans in the variable region of antibodies using sequential enzymatic digests with Endoglycosidase-S2 and Rapid™ Peptide-N-Glycosidase-F followed by labeling with a fluorescent dye carrying an NHS-carbamate moiety.
36870654	2	0	theme	isothermal	487:496	arg1	calorimetry					508:518	isothermal titration calorimetry	487:518	isothermal titration calorimetry	487:518	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	5	1	theme	O-mannosylation	1154:1168	arg1	role					1146:1149	an evolutionary role	1130:1149	an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs	1130:1275	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	4	2	theme	solid	900:904	arg1	cellulose					906:914	solid cellulose	900:914	solid cellulose	900:914	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	5	3	theme	binding	1200:1206	arg1	features					1208:1215	the substrate binding features	1186:1215	the substrate binding features of TrCBM1	1186:1225	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	1	4	theme	carbohydrate	146:157	arg1	substrates					159:168	carbohydrate substrates	146:168	carbohydrate substrates	146:168	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates has not been well understood.
36870654	3	5	from	variations	554:563	arg1	patterns					582:589	glycosylation patterns	568:589	glycosylation patterns	568:589	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	6	6	theme	glycosylation	1382:1394	arg1	role					1374:1377	the role	1370:1377	the role of glycosylation in protein-carbohydrate interactions	1370:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	6	7	from	interactions	1420:1431	arg1	basis					1361:1365	the molecular basis	1347:1365	the molecular basis of the role of glycosylation in protein-carbohydrate interactions	1347:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	3	8	theme	entropy-driven	665:678	arg1	process					680:686	an entropy-driven process	662:686	an entropy-driven process	662:686	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	5	9	theme	type	1241:1244	arg1	CBMs					1248:1251	type A CBMs	1241:1251	type A CBMs	1241:1251	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	5	10	theme	TrCBM1	1220:1225	arg1	features					1208:1215	the substrate binding features	1186:1215	the substrate binding features of TrCBM1	1186:1225	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	2	11	theme	glycosylation	284:296	arg1	patterns					298:305	the glycosylation patterns	280:305	the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1),	280:379	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	5	12	theme	A	1246:1246	arg1	CBMs					1248:1251	type A CBMs	1241:1251	type A CBMs	1241:1251	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	2	13	gly	glycosylation	284:296	arg1	glycoprotein					318:329	a model glycoprotein	310:329	a model glycoprotein	310:329	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	13	gly	glycosylation	284:296	arg1	binding					436:442	its binding	432:442	its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation	432:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	13	gly	glycosylation	284:296	arg1	module					364:369	a Family 1 carbohydrate-binding module	332:369	a Family 1 carbohydrate-binding module (TrCBM1)	332:378	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	3	14	theme	glycan-induced	751:764	arg1	shift					766:770	the glycan-induced shift	747:770	the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding	747:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	3	15	theme	glycosylation	568:580	arg1	patterns					582:589	glycosylation patterns	568:589	glycosylation patterns	568:589	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	2	16	theme	carbohydrate-binding	343:362	arg1	TrCBM1					372:377	TrCBM1	372:377	TrCBM1	372:377	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	16	theme	carbohydrate-binding	343:362	arg1	module					364:369	a Family 1 carbohydrate-binding module	332:369	a Family 1 carbohydrate-binding module (TrCBM1)	332:378	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	16	theme	carbohydrate-binding	343:362	arg1	glycoprotein					318:329	a model glycoprotein	310:329	a model glycoprotein	310:329	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	5	17	gly	O-mannosylation	1154:1168	arg1	binding					1200:1206	the substrate binding features	1186:1215	the substrate binding features of TrCBM1	1186:1225	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	5	17	gly	O-mannosylation	1154:1168	arg1	TrCBM1					1220:1225	TrCBM1	1220:1225	TrCBM1	1220:1225	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	1	18	gly	glycosylation	97:109	arg1	glycoproteins					129:141	glycoproteins	129:141	glycoproteins	129:141	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates has not been well understood.
36870654	6	19	theme	new	1317:1319	arg1	insights					1333:1340	new fundamental insights	1317:1340	new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions	1317:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	6	20	theme	fundamental	1321:1331	arg1	insights					1333:1340	new fundamental insights	1317:1340	new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions	1317:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	3	21	from	process	680:686	arg1	cellohexaose					644:655	soluble cellohexaose	636:655	soluble cellohexaose from an entropy-driven process	636:686	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	4	22	contain	have	935:938	arg2	distribution					957:968	a more dispersed distribution	940:968	a more dispersed distribution	940:968	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	4	22	contain	have	935:938	arg1	glycans					917:923	glycans	917:923	glycans on TrCBM1	917:933	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	3	23	from	interactions	822:833	arg1	shift					766:770	the glycan-induced shift	747:770	the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding	747:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	4	24	theme	interaction	1023:1033	arg1	forces					1035:1040	the hydrophobic interaction forces	1007:1040	the hydrophobic interaction forces	1007:1040	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	2	25	theme	computational	524:536	arg1	simulation					538:547	computational simulation	524:547	computational simulation	524:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	26	theme	binding	436:442	arg1	properties					418:427	the thermodynamic and structural properties	385:427	the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation	385:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	26	theme	binding	436:442	arg1	patterns					298:305	the glycosylation patterns	280:305	the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1),	280:379	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	6	27	from	role	1374:1377	arg1	interactions					1420:1431	protein-carbohydrate interactions	1399:1431	protein-carbohydrate interactions	1399:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	6	28	theme	protein-carbohydrate	1399:1418	arg1	interactions					1420:1431	protein-carbohydrate interactions	1399:1431	protein-carbohydrate interactions	1399:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	2	29	theme	model	312:316	arg1	glycoprotein					318:329	a model glycoprotein	310:329	a model glycoprotein	310:329	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	29	theme	model	312:316	arg1	module					364:369	a Family 1 carbohydrate-binding module	332:369	a Family 1 carbohydrate-binding module (TrCBM1)	332:378	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	4	30	from	glycans	917:923	arg1	TrCBM1					928:933	TrCBM1	928:933	TrCBM1	928:933	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	6	31	theme	further	1471:1477	arg1	studies					1479:1485	further studies	1471:1485	further studies	1471:1485	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	3	32	theme	predominant	779:789	arg1	force					799:803	the predominant binding force	775:803	the predominant binding force	775:803	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	4	33	theme	large	883:887	arg1	surface					889:895	a large surface	881:895	a large surface of solid cellulose	881:914	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	3	34	theme	gradual	599:605	arg1	transition					607:616	a gradual transition	597:616	a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding	597:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	4	35	theme	improved	1062:1069	arg1	binding					1071:1077	overall improved binding	1054:1077	overall improved binding	1054:1077	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	3	36	theme	binding	791:797	arg1	force					799:803	the predominant binding force	775:803	the predominant binding force	775:803	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	2	37	theme	structural	407:416	arg1	properties					418:427	the thermodynamic and structural properties	385:427	the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation	385:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	4	38	theme	overall	1054:1060	arg1	binding					1071:1077	overall improved binding	1054:1077	overall improved binding	1054:1077	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	6	39	from	basis	1361:1365	arg1	interactions					1420:1431	protein-carbohydrate interactions	1399:1431	protein-carbohydrate interactions	1399:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	6	40	theme	molecular	1351:1359	arg1	basis					1361:1365	the molecular basis	1347:1365	the molecular basis of the role of glycosylation in protein-carbohydrate interactions	1347:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	4	41	theme	dispersed	947:955	arg1	distribution					957:968	a more dispersed distribution	940:968	a more dispersed distribution	940:968	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	1	42	theme	glycosylation	97:109	arg1	role					89:92	The role	85:92	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates	85:168	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates has not been well understood.
36870654	6	43	theme	role	1374:1377	arg1	basis					1361:1365	the molecular basis	1347:1365	the molecular basis of the role of glycosylation in protein-carbohydrate interactions	1347:1431	Taken together, these findings provide new fundamental insights into the molecular basis of the role of glycosylation in protein-carbohydrate interactions and are expected to better facilitate further studies in this area.
36870654	0	44	theme	protein	28:34	arg1	glycosylation					36:48	protein glycosylation	28:48	protein glycosylation	28:48	Insights into the effect of protein glycosylation on carbohydrate substrate binding.
36870654	5	45	theme	simulation	1098:1107	arg1	results					1109:1115	our simulation results	1094:1115	our simulation results	1094:1115	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	2	46	theme	knowledge	233:241	arg1	gap					243:245	this knowledge gap	228:245	this knowledge gap	228:245	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	47	theme	thermodynamic	389:401	arg1	properties					418:427	the thermodynamic and structural properties	385:427	the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation	385:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	48	theme	carbohydrate	457:468	arg1	substrates					470:479	different carbohydrate substrates	447:479	different carbohydrate substrates using isothermal titration calorimetry and computational simulation	447:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	3	49	theme	hydrophobic	810:820	arg1	interactions					822:833	hydrophobic interactions	810:833	hydrophobic interactions	810:833	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	4	50	theme	hydrophobic	1011:1021	arg1	forces					1035:1040	the hydrophobic interaction forces	1007:1040	the hydrophobic interaction forces	1007:1040	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	3	51	theme	binding	625:631	arg1	transition					607:616	a gradual transition	597:616	a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding	597:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	4	52	contain	have	979:982	arg1	glycans					917:923	glycans	917:923	glycans on TrCBM1	917:933	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	4	52	contain	have	979:982	arg2	impact					997:1002	less adverse impact	984:1002	less adverse impact	984:1002	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	2	53	theme	different	447:455	arg1	substrates					470:479	different carbohydrate substrates	447:479	different carbohydrate substrates using isothermal titration calorimetry and computational simulation	447:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	5	54	theme	substrate	1190:1198	arg1	features					1208:1215	the substrate binding features	1186:1215	the substrate binding features of TrCBM1	1186:1225	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	0	55	theme	carbohydrate	53:64	arg1	binding					76:82	carbohydrate substrate binding	53:82	carbohydrate substrate binding	53:82	Insights into the effect of protein glycosylation on carbohydrate substrate binding.
36870654	5	56	theme	type	1265:1268	arg1	CBMs					1272:1275	type B CBMs	1265:1275	type B CBMs	1265:1275	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	2	57	theme	Family	334:339	arg1	TrCBM1					372:377	TrCBM1	372:377	TrCBM1	372:377	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	57	theme	Family	334:339	arg1	module					364:369	a Family 1 carbohydrate-binding module	332:369	a Family 1 carbohydrate-binding module (TrCBM1)	332:378	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	57	theme	Family	334:339	arg1	glycoprotein					318:329	a model glycoprotein	310:329	a model glycoprotein	310:329	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	0	58	theme	glycosylation	36:48	arg1	effect					18:23	the effect	14:23	the effect of protein glycosylation on carbohydrate substrate binding	14:82	Insights into the effect of protein glycosylation on carbohydrate substrate binding.
36870654	3	59	theme	force	799:803	arg1	shift					766:770	the glycan-induced shift	747:770	the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding	747:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	1	60	gly	glycoproteins	129:141	arg1	glycoproteins					129:141	glycoproteins	129:141	glycoproteins	129:141	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates has not been well understood.
36870654	2	61	theme	present	204:210	arg1	study					212:216	The present study	200:216	The present study	200:216	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	4	62	theme	adverse	989:995	arg1	impact					997:1002	less adverse impact	984:1002	less adverse impact	984:1002	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	4	63	theme	less	984:987	arg1	impact					997:1002	less adverse impact	984:1002	less adverse impact	984:1002	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	2	64	gly	glycoprotein	318:329	arg1	glycoprotein					318:329	a model glycoprotein	310:329	a model glycoprotein	310:329	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	64	gly	glycoprotein	318:329	arg1	module					364:369	a Family 1 carbohydrate-binding module	332:369	a Family 1 carbohydrate-binding module (TrCBM1)	332:378	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	65	theme	glycoprotein	318:329	arg1	properties					418:427	the thermodynamic and structural properties	385:427	the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation	385:547	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	2	65	theme	glycoprotein	318:329	arg1	patterns					298:305	the glycosylation patterns	280:305	the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1),	280:379	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	4	66	theme	cellulose	906:914	arg1	surface					889:895	a large surface	881:895	a large surface of solid cellulose	881:914	However, when binding to a large surface of solid cellulose, glycans on TrCBM1 have a more dispersed distribution and thus have less adverse impact on the hydrophobic interaction forces, leading to overall improved binding.
36870654	0	67	theme	substrate	66:74	arg1	binding					76:82	carbohydrate substrate binding	53:82	carbohydrate substrate binding	53:82	Insights into the effect of protein glycosylation on carbohydrate substrate binding.
36870654	3	68	theme	enthalpy-driven	694:708	arg1	one					710:712	an enthalpy-driven one	691:712	an enthalpy-driven one	691:712	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	3	68	theme	enthalpy-driven	694:708	arg1	trend					717:721	a trend	715:721	a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding	715:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	0	69	gly	glycosylation	36:48	arg1	substrate					66:74	carbohydrate substrate binding	53:82	carbohydrate substrate binding	53:82	Insights into the effect of protein glycosylation on carbohydrate substrate binding.
36870654	1	70	theme	glycoproteins	129:141	arg1	binding					118:124	the binding	114:124	the binding of glycoproteins to carbohydrate substrates	114:168	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates has not been well understood.
36870654	1	71	from	role	89:92	arg1	binding					118:124	the binding	114:124	the binding of glycoproteins to carbohydrate substrates	114:168	The role of glycosylation in the binding of glycoproteins to carbohydrate substrates has not been well understood.
36870654	2	72	theme	titration	498:506	arg1	calorimetry					508:518	isothermal titration calorimetry	487:518	isothermal titration calorimetry	487:518	The present study addresses this knowledge gap by elucidating the links between the glycosylation patterns of a model glycoprotein, a Family 1 carbohydrate-binding module (TrCBM1), and the thermodynamic and structural properties of its binding to different carbohydrate substrates using isothermal titration calorimetry and computational simulation.
36870654	0	73	from	effect	18:23	arg1	binding					76:82	carbohydrate substrate binding	53:82	carbohydrate substrate binding	53:82	Insights into the effect of protein glycosylation on carbohydrate substrate binding.
36870654	3	74	theme	soluble	636:642	arg1	cellohexaose					644:655	soluble cellohexaose	636:655	soluble cellohexaose from an entropy-driven process	636:686	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36870654	5	75	theme	evolutionary	1133:1144	arg1	role					1146:1149	an evolutionary role	1130:1149	an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs	1130:1275	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	5	76	theme	B	1270:1270	arg1	CBMs					1272:1275	type B CBMs	1265:1275	type B CBMs	1265:1275	Unexpectedly, our simulation results also suggest an evolutionary role of O-mannosylation in transforming the substrate binding features of TrCBM1 from those of type A CBMs to those of type B CBMs.
36870654	3	77	theme	hydrogen	838:845	arg1	bonding					847:853	hydrogen bonding	838:853	hydrogen bonding	838:853	The variations in glycosylation patterns cause a gradual transition of the binding to soluble cellohexaose from an entropy-driven process to an enthalpy-driven one, a trend closely correlated with the glycan-induced shift of the predominant binding force from hydrophobic interactions to hydrogen bonding.
36322419	6	0	theme	substrates	1565:1574	arg1	binding					1545:1551	the binding	1541:1551	the binding of branched substrates	1541:1574	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	1	theme	stereochemical	277:290	arg1	complexity					292:301	the stereochemical complexity	273:301	the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin	273:489	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	8	2	theme	new	1891:1893	arg1	type					1895:1898	a new type	1889:1898	a new type of substituted heteromannan	1889:1926	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	2	3	theme	diversity	708:716	arg1	exploration					674:684	the exploration	670:684	the exploration of sequence/taxonomic diversity	670:716	GH5 has been divided into subfamilies, many with higher functional specificity, several of which have not been characterized to date and some that have yet to be discovered with the exploration of sequence/taxonomic diversity.
36322419	8	4	theme	heteromannan	1915:1926	arg1	type					1895:1898	a new type	1889:1898	a new type of substituted heteromannan	1889:1926	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	6	5	from	absent	1455:1460	arg1	CapGH5_57					1465:1473	CapGH5_57	1465:1473	CapGH5_57	1465:1473	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	6	theme	action	211:216	arg1	modes					202:206	modes	202:206	modes	202:206	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	1	6	theme	action	211:216	arg1	specificities					184:196	diverse substrate specificities	166:196	diverse substrate specificities	166:196	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	6	7	theme	typical	1320:1326	arg1	absent					1455:1460	absent	1455:1460	absent	1455:1460	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	7	theme	typical	1320:1326	arg1	platforms					1337:1345	The typical aromatic platforms	1316:1345	The typical aromatic platforms	1316:1345	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	8	theme	hetero	410:415	arg1	xylan					417:421	(hetero)xylan	409:421	(hetero)xylan	409:421	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	4	9	dep	6	1103:1103	arg1	to					1100:1101	to	1100:1101	to	1100:1101	Biochemical characterization showed that CapGH5_57 is active on glucomannan, releasing oligosaccharides with a degree of polymerization from 2 to 6, indicating it to be an endo-β-mannanase.
36322419	7	10	theme	perpendicular	1647:1659	arg1	residue					1626:1632	a tryptophan residue	1613:1632	a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety	1613:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	2	11	theme	functional	548:557	arg1	specificity					559:569	higher functional specificity	541:569	higher functional specificity	541:569	GH5 has been divided into subfamilies, many with higher functional specificity, several of which have not been characterized to date and some that have yet to be discovered with the exploration of sequence/taxonomic diversity.
36322419	3	12	theme	GH5_57	807:812	arg1	subfamily					814:822	the GH5_57 subfamily	803:822	the GH5_57 subfamily	803:822	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	7	13	theme	adjacent	1634:1641	arg1	residue					1626:1632	a tryptophan residue	1613:1632	a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety	1613:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	9	14	theme	great	1987:1991	arg1	potential					1993:2001	the still great potential	1977:2001	the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family	1977:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	9	15	theme	subfamily	2242:2250	arg1	establishment					2214:2226	the establishment	2210:2226	the establishment of the GH5_57 subfamily	2210:2250	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	7	16	theme	tryptophan	1615:1624	arg1	residue					1626:1632	a tryptophan residue	1613:1632	a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety	1613:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	3	17	theme	subfamily	814:822	arg1	discovery					790:798	the discovery	786:798	the discovery of the GH5_57 subfamily	786:822	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	3	18	theme	GH5	745:747	arg1	inventory					759:767	the current GH5 subfamily inventory	733:767	the current GH5 subfamily inventory	733:767	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	0	19	theme	catalytic	66:74	arg1	interface					76:84	a highly redesigned catalytic interface	46:84	a highly redesigned catalytic interface to process complex hetero-β-mannans	46:120	Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans.
36322419	4	20	theme	Biochemical	957:967	arg1	characterization					969:984	Biochemical characterization	957:984	Biochemical characterization	957:984	Biochemical characterization showed that CapGH5_57 is active on glucomannan, releasing oligosaccharides with a degree of polymerization from 2 to 6, indicating it to be an endo-β-mannanase.
36322419	1	21	theme	diverse	166:172	arg1	specificities					184:196	diverse substrate specificities	166:196	diverse substrate specificities	166:196	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	9	22	theme	mechanistic	2033:2043	arg1	diversity					2060:2068	the mechanistic and functional diversity	2029:2068	the mechanistic and functional diversity of this large and polyspecific GH family	2029:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	5	23	theme	redesigned	1255:1264	arg1	interface					1276:1284	a massively redesigned catalytic interface	1243:1284	a massively redesigned catalytic interface compared with GH5 mannanases	1243:1313	The crystal structure, which was solved using single-wavelength anomalous diffraction, revealed a massively redesigned catalytic interface compared with GH5 mannanases.
36322419	6	24	theme	α-helix-containing	1370:1387	arg1	absent					1455:1460	absent	1455:1460	absent	1455:1460	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	24	theme	α-helix-containing	1370:1387	arg1	loop					1395:1398	the characteristic α-helix-containing β6-α6 loop	1351:1398	the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases	1351:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	25	theme	mixed-linkage	374:386	arg1	β-glucan					388:395	mixed-linkage β-glucan	374:395	mixed-linkage β-glucan	374:395	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	8	26	theme	endo	1840:1843	arg1	activity					1845:1852	endo activity	1840:1852	endo activity on glucomannan	1840:1867	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	9	27	theme	functional	2049:2058	arg1	diversity					2060:2068	the mechanistic and functional diversity	2029:2068	the mechanistic and functional diversity of this large and polyspecific GH family	2029:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	7	28	theme	anchoring	1700:1708	arg1	site					1710:1713	an anchoring site	1697:1713	an anchoring site for a substrate with a substitution at the -1 glycosyl moiety	1697:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	0	29	theme	Glycoside	0:8	arg1	GH5_57					30:35	Glycoside hydrolase subfamily GH5_57	0:35	Glycoside hydrolase subfamily GH5_57	0:35	Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans.
36322419	3	30	theme	Bacteroidales	889:901	arg1	bacterium					903:911	an uncultured Bacteroidales bacterium	875:911	an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota	875:954	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	9	31	theme	large	2078:2082	arg1	family					2104:2109	this large and polyspecific GH family	2073:2109	this large and polyspecific GH family	2073:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	0	32	theme	subfamily	20:28	arg1	GH5_57					30:35	Glycoside hydrolase subfamily GH5_57	0:35	Glycoside hydrolase subfamily GH5_57	0:35	Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans.
36322419	1	33	theme	Glycoside	123:131	arg1	family					143:148	Glycoside hydrolase family 5 (GH5)	123:156	Glycoside hydrolase family 5 (GH5)	123:156	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	9	34	theme	polyspecific	2088:2099	arg1	family					2104:2109	this large and polyspecific GH family	2073:2109	this large and polyspecific GH family	2073:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	6	35	theme	GH5_7	1434:1438	arg1	mannanases					1440:1449	GH5_7 mannanases	1434:1449	GH5_7 mannanases	1434:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	9	36	theme	family	2104:2109	arg1	diversity					2060:2068	the mechanistic and functional diversity	2029:2068	the mechanistic and functional diversity of this large and polyspecific GH family	2029:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	6	37	theme	catalytic	1504:1512	arg1	interface					1514:1522	a large and open catalytic interface	1487:1522	a large and open catalytic interface that might favor the binding of branched substrates	1487:1574	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	38	theme	notable	230:236	arg1	adaptations					248:258	notable molecular adaptations	230:258	notable molecular adaptations	230:258	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	7	39	theme	indicative	1683:1692	arg1	site					1677:1680	the cleavage site	1664:1680	the cleavage site	1664:1680	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	4	40	theme	polymerization	1078:1091	arg1	degree					1068:1073	a degree	1066:1073	a degree of polymerization from 2 to 6	1066:1103	Biochemical characterization showed that CapGH5_57 is active on glucomannan, releasing oligosaccharides with a degree of polymerization from 2 to 6, indicating it to be an endo-β-mannanase.
36322419	9	41	theme	novel	2126:2130	arg1	interface					2142:2150	a novel catalytic interface	2124:2150	a novel catalytic interface	2124:2150	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	3	42	theme	subfamily	749:757	arg1	inventory					759:767	the current GH5 subfamily inventory	733:767	the current GH5 subfamily inventory	733:767	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	3	43	theme	gut	941:943	arg1	microbiota					945:954	the capybara gut microbiota	928:954	the capybara gut microbiota	928:954	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	2	44	with	many	531:534	arg1	specificity					559:569	higher functional specificity	541:569	higher functional specificity	541:569	GH5 has been divided into subfamilies, many with higher functional specificity, several of which have not been characterized to date and some that have yet to be discovered with the exploration of sequence/taxonomic diversity.
36322419	2	45	theme	specificity	559:569	arg1	several					572:578	several	572:578	several	572:578	GH5 has been divided into subfamilies, many with higher functional specificity, several of which have not been characterized to date and some that have yet to be discovered with the exploration of sequence/taxonomic diversity.
36322419	9	46	theme	complex	2174:2180	arg1	heteromannans					2182:2194	complex heteromannans	2174:2194	complex heteromannans	2174:2194	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	6	47	theme	branched	1556:1563	arg1	substrates					1565:1574	branched substrates	1556:1574	branched substrates	1556:1574	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	48	theme	substrate	174:182	arg1	specificities					184:196	diverse substrate specificities	166:196	diverse substrate specificities	166:196	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	8	49	theme	substituted	1903:1913	arg1	heteromannan					1915:1926	substituted heteromannan	1903:1926	substituted heteromannan	1903:1926	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	7	50	theme	cleavage	1668:1675	arg1	site					1677:1680	the cleavage site	1664:1680	the cleavage site	1664:1680	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	8	51	contain	have	1884:1887	arg1	CapGH5_57					1870:1878	CapGH5_57	1870:1878	CapGH5_57	1870:1878	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	8	51	contain	have	1884:1887	arg2	type					1895:1898	a new type	1889:1898	a new type of substituted heteromannan	1889:1926	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	8	52	theme	natural	1935:1941	arg1	substrate					1943:1951	its natural substrate	1931:1951	its natural substrate	1931:1951	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	3	53	theme	current	737:743	arg1	inventory					759:767	the current GH5 subfamily inventory	733:767	the current GH5 subfamily inventory	733:767	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	1	54	theme	hydrolase	133:141	arg1	family					143:148	Glycoside hydrolase family 5 (GH5)	123:156	Glycoside hydrolase family 5 (GH5)	123:156	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	2	55	theme	higher	541:546	arg1	specificity					559:569	higher functional specificity	541:569	higher functional specificity	541:569	GH5 has been divided into subfamilies, many with higher functional specificity, several of which have not been characterized to date and some that have yet to be discovered with the exploration of sequence/taxonomic diversity.
36322419	5	56	theme	catalytic	1266:1274	arg1	interface					1276:1284	a massively redesigned catalytic interface	1243:1284	a massively redesigned catalytic interface compared with GH5 mannanases	1243:1313	The crystal structure, which was solved using single-wavelength anomalous diffraction, revealed a massively redesigned catalytic interface compared with GH5 mannanases.
36322419	9	57	theme	GH5_57	2235:2240	arg1	subfamily					2242:2250	the GH5_57 subfamily	2231:2250	the GH5_57 subfamily	2231:2250	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	4	58	from	degree	1068:1073	arg1	6					1103:1103	6	1103:1103	6	1103:1103	Biochemical characterization showed that CapGH5_57 is active on glucomannan, releasing oligosaccharides with a degree of polymerization from 2 to 6, indicating it to be an endo-β-mannanase.
36322419	7	59	theme	glycosyl	1761:1768	arg1	moiety					1770:1775	the -1 glycosyl moiety	1754:1775	the -1 glycosyl moiety	1754:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	2	60	theme	sequence/taxonomic	689:706	arg1	diversity					708:716	sequence/taxonomic diversity	689:716	sequence/taxonomic diversity	689:716	GH5 has been divided into subfamilies, many with higher functional specificity, several of which have not been characterized to date and some that have yet to be discovered with the exploration of sequence/taxonomic diversity.
36322419	6	61	theme	positive-subsite	1407:1422	arg1	region					1424:1429	the positive-subsite region	1403:1429	the positive-subsite region of GH5_7 mannanases	1403:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	62	theme	hetero	425:430	arg1	mannan					432:437	(hetero)mannan	424:437	(hetero)mannan	424:437	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	4	63	from	6	1103:1103	arg1	degree					1068:1073	a degree	1066:1073	a degree of polymerization from 2 to 6	1066:1103	Biochemical characterization showed that CapGH5_57 is active on glucomannan, releasing oligosaccharides with a degree of polymerization from 2 to 6, indicating it to be an endo-β-mannanase.
36322419	4	63	from	6	1103:1103	arg1	polymerization					1078:1091	polymerization	1078:1091	polymerization from 2 to 6	1078:1103	Biochemical characterization showed that CapGH5_57 is active on glucomannan, releasing oligosaccharides with a degree of polymerization from 2 to 6, indicating it to be an endo-β-mannanase.
36322419	7	64	with	substrate	1721:1729	arg1	substitution					1738:1749	a substitution	1736:1749	a substitution at the -1 glycosyl moiety	1736:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	5	65	theme	single-wavelength	1193:1209	arg1	diffraction					1221:1231	single-wavelength anomalous diffraction	1193:1231	single-wavelength anomalous diffraction	1193:1231	The crystal structure, which was solved using single-wavelength anomalous diffraction, revealed a massively redesigned catalytic interface compared with GH5 mannanases.
36322419	0	66	theme	complex	97:103	arg1	hetero-β-mannans					105:120	complex hetero-β-mannans	97:120	complex hetero-β-mannans	97:120	Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans.
36322419	6	67	from	loop	1395:1398	arg1	region					1424:1429	the positive-subsite region	1403:1429	the positive-subsite region of GH5_7 mannanases	1403:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	8	68	from	activity	1845:1852	arg1	glucomannan					1857:1867	glucomannan	1857:1867	glucomannan	1857:1867	Taken together, these results suggest that despite presenting endo activity on glucomannan, CapGH5_57 may have a new type of substituted heteromannan as its natural substrate.
36322419	6	69	theme	β6-α6	1389:1393	arg1	absent					1455:1460	absent	1455:1460	absent	1455:1460	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	69	theme	β6-α6	1389:1393	arg1	loop					1395:1398	the characteristic α-helix-containing β6-α6 loop	1351:1398	the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases	1351:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	70	theme	characteristic	1355:1368	arg1	absent					1455:1460	absent	1455:1460	absent	1455:1460	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	70	theme	characteristic	1355:1368	arg1	loop					1395:1398	the characteristic α-helix-containing β6-α6 loop	1351:1398	the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases	1351:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	1	71	theme	molecular	238:246	arg1	adaptations					248:258	notable molecular adaptations	230:258	notable molecular adaptations	230:258	Glycoside hydrolase family 5 (GH5) harbors diverse substrate specificities and modes of action, exhibiting notable molecular adaptations to cope with the stereochemical complexity imposed by glycosides and carbohydrates such as cellulose, xyloglucan, mixed-linkage β-glucan, laminarin, (hetero)xylan, (hetero)mannan, galactan, chitosan, N-glycan, rutin and hesperidin.
36322419	0	72	theme	hydrolase	10:18	arg1	GH5_57					30:35	Glycoside hydrolase subfamily GH5_57	0:35	Glycoside hydrolase subfamily GH5_57	0:35	Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans.
36322419	7	73	theme	site	1710:1713	arg1	indicative					1683:1692	indicative	1683:1692	indicative	1683:1692	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	6	74	theme	aromatic	1328:1335	arg1	absent					1455:1460	absent	1455:1460	absent	1455:1460	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	74	theme	aromatic	1328:1335	arg1	platforms					1337:1345	The typical aromatic platforms	1316:1345	The typical aromatic platforms	1316:1345	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	5	75	theme	GH5	1300:1302	arg1	mannanases					1304:1313	GH5 mannanases	1300:1313	GH5 mannanases	1300:1313	The crystal structure, which was solved using single-wavelength anomalous diffraction, revealed a massively redesigned catalytic interface compared with GH5 mannanases.
36322419	5	76	theme	crystal	1151:1157	arg1	structure					1159:1167	The crystal structure	1147:1167	The crystal structure	1147:1167	The crystal structure, which was solved using single-wavelength anomalous diffraction, revealed a massively redesigned catalytic interface compared with GH5 mannanases.
36322419	6	77	theme	mannanases	1440:1449	arg1	region					1424:1429	the positive-subsite region	1403:1429	the positive-subsite region of GH5_7 mannanases	1403:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	78	from	platforms	1337:1345	arg1	region					1424:1429	the positive-subsite region	1403:1429	the positive-subsite region of GH5_7 mannanases	1403:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	3	79	theme	uncultured	878:887	arg1	bacterium					903:911	an uncultured Bacteroidales bacterium	875:911	an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota	875:954	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	9	80	theme	GH	2101:2102	arg1	family					2104:2109	this large and polyspecific GH family	2073:2109	this large and polyspecific GH family	2073:2109	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	0	81	theme	redesigned	55:64	arg1	interface					76:84	a highly redesigned catalytic interface	46:84	a highly redesigned catalytic interface to process complex hetero-β-mannans	46:120	Glycoside hydrolase subfamily GH5_57 features a highly redesigned catalytic interface to process complex hetero-β-mannans.
36322419	3	82	theme	capybara	932:939	arg1	microbiota					945:954	the capybara gut microbiota	928:954	the capybara gut microbiota	928:954	In this work, the current GH5 subfamily inventory is expanded with the discovery of the GH5_57 subfamily by describing an endo-β-mannanase (CapGH5_57) from an uncultured Bacteroidales bacterium recovered from the capybara gut microbiota.
36322419	7	83	from	moiety	1770:1775	arg1	substitution					1738:1749	a substitution	1736:1749	a substitution at the -1 glycosyl moiety	1736:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	6	84	from	CapGH5_57	1465:1473	arg1	absent					1455:1460	absent	1455:1460	absent	1455:1460	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	84	from	CapGH5_57	1465:1473	arg1	platforms					1337:1345	The typical aromatic platforms	1316:1345	The typical aromatic platforms	1316:1345	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	6	84	from	CapGH5_57	1465:1473	arg1	loop					1395:1398	the characteristic α-helix-containing β6-α6 loop	1351:1398	the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases	1351:1449	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	7	85	contain	contains	1604:1611	arg2	residue					1626:1632	a tryptophan residue	1613:1632	a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety	1613:1775	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	7	85	contain	contains	1604:1611	arg1	CapGH5_57					1594:1602	CapGH5_57	1594:1602	CapGH5_57	1594:1602	Supporting this, CapGH5_57 contains a tryptophan residue adjacent and perpendicular to the cleavage site, indicative of an anchoring site for a substrate with a substitution at the -1 glycosyl moiety.
36322419	6	86	theme	open	1499:1502	arg1	interface					1514:1522	a large and open catalytic interface	1487:1522	a large and open catalytic interface that might favor the binding of branched substrates	1487:1574	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
36322419	5	87	theme	anomalous	1211:1219	arg1	diffraction					1221:1231	single-wavelength anomalous diffraction	1193:1231	single-wavelength anomalous diffraction	1193:1231	The crystal structure, which was solved using single-wavelength anomalous diffraction, revealed a massively redesigned catalytic interface compared with GH5 mannanases.
36322419	9	88	theme	catalytic	2132:2140	arg1	interface					2142:2150	a novel catalytic interface	2124:2150	a novel catalytic interface	2124:2150	This work demonstrates the still great potential for discoveries regarding the mechanistic and functional diversity of this large and polyspecific GH family by unveiling a novel catalytic interface sculpted to recognize complex heteromannans, which led to the establishment of the GH5_57 subfamily.
36322419	6	89	theme	large	1489:1493	arg1	interface					1514:1522	a large and open catalytic interface	1487:1522	a large and open catalytic interface that might favor the binding of branched substrates	1487:1574	The typical aromatic platforms and the characteristic α-helix-containing β6-α6 loop in the positive-subsite region of GH5_7 mannanases are absent in CapGH5_57, generating a large and open catalytic interface that might favor the binding of branched substrates.
37253063	5	0	dep	=	1159:1159	arg1	kJ/mol					1165:1170	+72 kJ/mol	1161:1170	+72 kJ/mol	1161:1170	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	3	1	from	direction	639:647	arg1	rate-limiting					582:594	rate-limiting	582:594	rate-limiting	582:594	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	4	2	dep	heat	912:915	arg1	ΔH⧧					918:920	ΔH⧧	918:920	ΔH⧧ = 72 ± 5.2 kJ/mol	918:938	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	4	3	from	complex	861:867	arg1	Approach					840:847	Approach	840:847	Approach from the ES complex to the transition state	840:891	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	8	4	theme	lower	1481:1485	arg1	reactivity					1487:1496	The 103-fold lower reactivity	1468:1496	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation	1468:1558	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	8	4	theme	lower	1481:1485	arg1	kcat/Km					1499:1505	kcat/Km	1499:1505	kcat/Km	1499:1505	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	1	5	theme	phosphate	175:183	arg1	ions					185:188	phosphate ions	175:188	phosphate ions	175:188	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	5	theme	phosphate	175:183	arg1	nucleophile					214:224	the nucleophile	210:224	the nucleophile of the reaction	210:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	3	6	theme	°C.	683:685	arg1	association					704:714	30 °C. Enzyme-substrate association	680:714	30 °C. Enzyme-substrate association	680:714	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	5	7	from	cleavage	1044:1051	arg1	substrate					1060:1068	the substrate	1056:1068	the substrate	1056:1068	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	3	8	theme	α-glucose	549:557	arg1	Glc1P					572:576	Glc1P	572:576	Glc1P	572:576	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	8	theme	α-glucose	549:557	arg1	1-phosphate					559:569	α-glucose 1-phosphate	549:569	α-glucose 1-phosphate (Glc1P)	549:577	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	8	9	theme	transition	1747:1756	arg1	stabilization					1764:1776	optimum transition state stabilization	1739:1776	optimum transition state stabilization by enthalpic forces	1739:1796	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	8	10	theme	major	1569:1573	arg1	losses					1575:1580	major losses	1569:1580	major losses in the activation entropy	1569:1606	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	4	11	from	change	961:966	arg1	entropy					971:977	entropy	971:977	entropy	971:977	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	2	12	theme	hydrolysis	254:263	arg1	reaction					265:272	the hydrolysis reaction	250:272	the hydrolysis reaction	250:272	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	3	13	theme	TΔSb	738:741	arg1	kJ/mol					749:754	TΔSb ≥ +23 kJ/mol	738:754	TΔSb ≥ +23 kJ/mol	738:754	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	13	theme	TΔSb	738:741	arg1	entropy					729:735	entropy	729:735	entropy (TΔSb ≥ +23 kJ/mol)	729:755	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	8	14	theme	enthalpic	1781:1789	arg1	forces					1791:1796	enthalpic forces	1781:1796	enthalpic forces	1781:1796	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	8	15	theme	activation	1589:1598	arg1	entropy					1600:1606	the activation entropy	1585:1606	the activation entropy	1585:1606	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	4	16	theme	transition	876:885	arg1	state					887:891	the transition state	872:891	the transition state	872:891	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	5	17	dep	lower	1078:1082	arg1	=					1138:1138	=	1138:1138	= ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose	1138:1179	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	6	18	theme	virtual	1218:1224	arg1	affinity					1234:1241	the virtual binding affinity	1214:1241	the virtual binding affinity of the enzyme for the activated substrate	1214:1283	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	5	19	theme	energy	989:994	arg1	barrier					996:1002	The free energy barrier	980:1002	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate	980:1068	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	5	19	theme	energy	989:994	arg1	lower					1078:1082	lower	1078:1082	lower	1078:1082	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	1	20	theme	glycoside	145:153	arg1	hydrolase					155:163	a specialized glycoside hydrolase	131:163	a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction	131:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	20	theme	glycoside	145:153	arg1	phosphorylase					114:126	sucrose phosphorylase	106:126	sucrose phosphorylase	106:126	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	4	21	theme	ES	858:859	arg1	complex					861:867	the ES complex	854:867	the ES complex	854:867	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	3	22	from	sucrose	537:543	arg1	glycosylation					518:530	Enzyme glycosylation	511:530	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P)	511:577	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	6	23	from	enthalpic	1341:1349	arg1	origin					1354:1359	origin	1354:1359	origin	1354:1359	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	7	24	theme	enzymatic	1366:1374	arg1	kcat/knon					1395:1403	kcat/knon	1395:1403	kcat/knon	1395:1403	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	7	24	theme	enzymatic	1366:1374	arg1	∼1012-fold					1409:1418	∼1012-fold	1409:1418	∼1012-fold	1409:1418	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	7	24	theme	enzymatic	1366:1374	arg1	acceleration					1381:1392	The enzymatic rate acceleration	1362:1392	The enzymatic rate acceleration (kcat/knon)	1362:1404	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	2	25	theme	enzyme	490:495	arg1	intermediate					497:508	a covalent glycosyl enzyme intermediate	470:508	a covalent glycosyl enzyme intermediate	470:508	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	2	26	theme	effects	373:379	arg1	study					352:356	the study	348:356	the study of temperature effects on kinetic parameters	348:401	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	6	27	theme	enzyme	1250:1255	arg1	affinity					1234:1241	the virtual binding affinity	1214:1241	the virtual binding affinity of the enzyme for the activated substrate	1214:1283	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	8	28	theme	group	1650:1654	arg1	recognition					1656:1666	nucleophile/leaving group recognition	1630:1666	nucleophile/leaving group recognition by the enzyme	1630:1680	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	6	29	from	origin	1354:1359	arg1	enthalpic					1341:1349	enthalpic	1341:1349	enthalpic	1341:1349	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	4	30	theme	=	922:922	arg1	ΔH⧧					918:920	ΔH⧧	918:920	ΔH⧧ = 72 ± 5.2 kJ/mol	918:938	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	2	31	theme	covalent	472:479	arg1	intermediate					497:508	a covalent glycosyl enzyme intermediate	470:508	a covalent glycosyl enzyme intermediate	470:508	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	6	32	theme	activated	1265:1273	arg1	substrate					1275:1283	the activated substrate	1261:1283	the activated substrate	1261:1283	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	4	33	theme	±	927:927	arg1	kJ/mol					933:938	72 ± 5.2 kJ/mol	924:938	72 ± 5.2 kJ/mol	924:938	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	8	34	from	reactivity	1487:1496	arg1	deglycosylation					1544:1558	enzyme deglycosylation	1537:1558	enzyme deglycosylation	1537:1558	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	7	35	theme	Glc1P	1461:1465	arg1	reactions					1436:1444	reactions	1436:1444	reactions of sucrose and Glc1P	1436:1465	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	2	36	theme	catalytic	448:456	arg1	process					458:464	the complete catalytic process	435:464	the complete catalytic process	435:464	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	0	37	theme	Phosphorylase	57:69	arg1	Reactions					36:44	the Glycosyl Transfer Reactions	14:44	the Glycosyl Transfer Reactions of Sucrose Phosphorylase	14:69	Energetics of the Glycosyl Transfer Reactions of Sucrose Phosphorylase.
37253063	3	38	from	rate-limiting	582:594	arg1	s-1					660:662	kcat = 22 s-1	650:662	kcat = 22 s-1	650:662	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	38	from	rate-limiting	582:594	arg1	direction					639:647	the forward (kcat = 84 s-1) and reverse direction	599:647	the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction	599:675	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	2	39	theme	kinetic	384:390	arg1	parameters					392:401	kinetic parameters	384:401	kinetic parameters	384:401	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	0	40	theme	Transfer	27:34	arg1	Reactions					36:44	the Glycosyl Transfer Reactions	14:44	the Glycosyl Transfer Reactions of Sucrose Phosphorylase	14:69	Energetics of the Glycosyl Transfer Reactions of Sucrose Phosphorylase.
37253063	5	41	theme	enzyme-catalyzed	1012:1027	arg1	cleavage					1044:1051	the enzyme-catalyzed glycoside bond cleavage	1008:1051	the enzyme-catalyzed glycoside bond cleavage in the substrate	1008:1068	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	3	42	theme	=	617:617	arg1	s-1					622:624	kcat = 84 s-1	612:624	kcat = 84 s-1	612:624	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	5	43	theme	bond	1039:1042	arg1	cleavage					1044:1051	the enzyme-catalyzed glycoside bond cleavage	1008:1051	the enzyme-catalyzed glycoside bond cleavage in the substrate	1008:1068	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	4	44	theme	further	953:959	arg1	change					961:966	little further change	946:966	little further change in entropy	946:977	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	5	45	theme	non-enzymatic	1102:1114	arg1	knon					1126:1129	knon	1126:1129	knon	1126:1129	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	5	45	theme	non-enzymatic	1102:1114	arg1	reaction					1116:1123	the non-enzymatic reaction	1098:1123	the non-enzymatic reaction (knon)	1098:1130	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	6	46	theme	transition	1292:1301	arg1	state					1303:1307	the transition state	1288:1307	the transition state (∼1014 M-1)	1288:1319	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	6	46	theme	transition	1292:1301	arg1	M-1					1316:1318	∼1014 M-1	1310:1318	∼1014 M-1	1310:1318	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	5	47	dep	ΔGnon⧧	1140:1145	arg1	sucrose					1173:1179	sucrose	1173:1179	ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose	1140:1179	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	5	47	dep	ΔGnon⧧	1140:1145	arg1	ΔGenzyme⧧					1149:1157	ΔGenzyme⧧	1149:1157	ΔGenzyme⧧	1149:1157	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	3	48	theme	kcat	650:653	arg1	s-1					660:662	kcat = 22 s-1	650:662	kcat = 22 s-1	650:662	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	48	theme	kcat	650:653	arg1	direction					639:647	the forward (kcat = 84 s-1) and reverse direction	599:647	the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction	599:675	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	2	49	theme	phosphate	279:287	arg1	reaction					289:296	the phosphate reaction	275:296	the phosphate reaction	275:296	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	2	49	theme	phosphate	279:287	arg1	reversible					309:318	reversible	309:318	reversible	309:318	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	3	50	theme	reaction	668:675	arg1	s-1					660:662	kcat = 22 s-1	650:662	kcat = 22 s-1	650:662	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	50	theme	reaction	668:675	arg1	direction					639:647	the forward (kcat = 84 s-1) and reverse direction	599:647	the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction	599:675	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	8	51	theme	active-site	1698:1708	arg1	preorganization					1710:1724	the active-site preorganization	1694:1724	the active-site preorganization required for optimum transition state stabilization by enthalpic forces	1694:1796	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	3	52	theme	Enzyme	511:516	arg1	glycosylation					518:530	Enzyme glycosylation	511:530	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P)	511:577	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	8	53	from	losses	1575:1580	arg1	entropy					1600:1606	the activation entropy	1585:1606	the activation entropy	1585:1606	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	4	54	dep	=	922:922	arg1	kJ/mol					933:938	72 ± 5.2 kJ/mol	924:938	72 ± 5.2 kJ/mol	924:938	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	8	55	theme	glycerol	1511:1518	arg1	reactivity					1487:1496	The 103-fold lower reactivity	1468:1496	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation	1468:1558	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	8	55	theme	glycerol	1511:1518	arg1	kcat/Km					1499:1505	kcat/Km	1499:1505	kcat/Km	1499:1505	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	7	56	theme	sucrose	1449:1455	arg1	reactions					1436:1444	reactions	1436:1444	reactions of sucrose and Glc1P	1436:1465	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	3	57	theme	Enzyme-substrate	687:702	arg1	association					704:714	30 °C. Enzyme-substrate association	680:714	30 °C. Enzyme-substrate association	680:714	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	8	58	theme	optimum	1739:1745	arg1	stabilization					1764:1776	optimum transition state stabilization	1739:1776	optimum transition state stabilization by enthalpic forces	1739:1796	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	3	59	theme	30	680:681	arg1	°C.					683:685	°C.	683:685	°C.	683:685	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	8	60	theme	state	1758:1762	arg1	stabilization					1764:1776	optimum transition state stabilization	1739:1776	optimum transition state stabilization by enthalpic forces	1739:1796	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	8	61	theme	enzyme	1537:1542	arg1	deglycosylation					1544:1558	enzyme deglycosylation	1537:1558	enzyme deglycosylation	1537:1558	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	3	62	dep	forward	603:609	arg1	s-1					622:624	kcat = 84 s-1	612:624	kcat = 84 s-1	612:624	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	1	63	theme	sucrose	106:112	arg1	hydrolase					155:163	a specialized glycoside hydrolase	131:163	a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction	131:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	63	theme	sucrose	106:112	arg1	phosphorylase					114:126	sucrose phosphorylase	106:126	sucrose phosphorylase	106:126	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	3	64	theme	forward	603:609	arg1	s-1					660:662	kcat = 22 s-1	650:662	kcat = 22 s-1	650:662	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	64	theme	forward	603:609	arg1	direction					639:647	the forward (kcat = 84 s-1) and reverse direction	599:647	the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction	599:675	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	65	theme	enzyme	778:783	arg1	desolvation					785:795	enzyme desolvation	778:795	enzyme desolvation	778:795	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	66	from	1-phosphate	559:569	arg1	glycosylation					518:530	Enzyme glycosylation	511:530	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P)	511:577	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	67	theme	≥	743:743	arg1	kJ/mol					749:754	TΔSb ≥ +23 kJ/mol	738:754	TΔSb ≥ +23 kJ/mol	738:754	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	67	theme	≥	743:743	arg1	entropy					729:735	entropy	729:735	entropy (TΔSb ≥ +23 kJ/mol)	729:755	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	6	68	theme	binding	1226:1232	arg1	affinity					1234:1241	the virtual binding affinity	1214:1241	the virtual binding affinity of the enzyme for the activated substrate	1214:1283	This ΔΔG⧧, which also describes the virtual binding affinity of the enzyme for the activated substrate in the transition state (∼1014 M-1), is almost entirely enthalpic in origin.
37253063	1	69	theme	specialized	133:143	arg1	hydrolase					155:163	a specialized glycoside hydrolase	131:163	a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction	131:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	69	theme	specialized	133:143	arg1	phosphorylase					114:126	sucrose phosphorylase	106:126	sucrose phosphorylase	106:126	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	3	70	theme	binding	804:810	arg1	site					812:815	the binding site	800:815	the binding site for the leaving group	800:837	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	7	71	theme	rate	1376:1379	arg1	kcat/knon					1395:1403	kcat/knon	1395:1403	kcat/knon	1395:1403	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	7	71	theme	rate	1376:1379	arg1	∼1012-fold					1409:1418	∼1012-fold	1409:1418	∼1012-fold	1409:1418	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	7	71	theme	rate	1376:1379	arg1	acceleration					1381:1392	The enzymatic rate acceleration	1362:1392	The enzymatic rate acceleration (kcat/knon)	1362:1404	The enzymatic rate acceleration (kcat/knon) is ∼1012-fold and similar for reactions of sucrose and Glc1P.
37253063	2	72	theme	process	458:464	arg1	profile					424:430	the energetic profile	410:430	the energetic profile of the complete catalytic process	410:464	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	3	73	theme	leaving	825:831	arg1	group					833:837	the leaving group	821:837	the leaving group	821:837	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	2	74	theme	glycosyl	481:488	arg1	intermediate					497:508	a covalent glycosyl enzyme intermediate	470:508	a covalent glycosyl enzyme intermediate	470:508	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	2	75	theme	temperature	361:371	arg1	effects					373:379	temperature effects	361:379	temperature effects	361:379	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	5	76	theme	free	984:987	arg1	barrier					996:1002	The free energy barrier	980:1002	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate	980:1068	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	5	76	theme	free	984:987	arg1	lower					1078:1082	lower	1078:1082	lower	1078:1082	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	8	77	theme	nucleophile/leaving	1630:1648	arg1	recognition					1656:1666	nucleophile/leaving group recognition	1630:1666	nucleophile/leaving group recognition by the enzyme	1630:1680	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	2	78	theme	energetic	414:422	arg1	profile					424:430	the energetic profile	410:430	the energetic profile of the complete catalytic process	410:464	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	0	79	theme	Glycosyl	18:25	arg1	Reactions					36:44	the Glycosyl Transfer Reactions	14:44	the Glycosyl Transfer Reactions of Sucrose Phosphorylase	14:69	Energetics of the Glycosyl Transfer Reactions of Sucrose Phosphorylase.
37253063	8	80	theme	recognition	1656:1666	arg1	role					1622:1625	a role	1620:1625	a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces	1620:1796	The 103-fold lower reactivity (kcat/Km) of glycerol than fructose in enzyme deglycosylation reflects major losses in the activation entropy, suggesting a role of nucleophile/leaving group recognition by the enzyme in inducing the active-site preorganization required for optimum transition state stabilization by enthalpic forces.
37253063	0	81	theme	Reactions	36:44	arg1	Energetics					0:9	Energetics	0:9	Energetics of the Glycosyl Transfer Reactions of Sucrose Phosphorylase	0:69	Energetics of the Glycosyl Transfer Reactions of Sucrose Phosphorylase.
37253063	2	82	theme	complete	439:446	arg1	process					458:464	the complete catalytic process	435:464	the complete catalytic process	435:464	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	3	83	theme	kcat	612:615	arg1	s-1					622:624	kcat = 84 s-1	612:624	kcat = 84 s-1	612:624	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	0	84	theme	Sucrose	49:55	arg1	Phosphorylase					57:69	Sucrose Phosphorylase	49:69	Sucrose Phosphorylase	49:69	Energetics of the Glycosyl Transfer Reactions of Sucrose Phosphorylase.
37253063	5	85	theme	glycoside	1029:1037	arg1	cleavage					1044:1051	the enzyme-catalyzed glycoside bond cleavage	1008:1051	the enzyme-catalyzed glycoside bond cleavage in the substrate	1008:1068	The free energy barrier for the enzyme-catalyzed glycoside bond cleavage in the substrate is much lower than that for the non-enzymatic reaction (knon), ΔΔG⧧ = ΔGnon⧧ - ΔGenzyme⧧ = +72 kJ/mol; sucrose.
37253063	2	86	from	study	352:356	arg1	parameters					392:401	kinetic parameters	384:401	kinetic parameters	384:401	Unlike the hydrolysis reaction, the phosphate reaction is readily reversible and, here, this has enabled the study of temperature effects on kinetic parameters to map the energetic profile of the complete catalytic process via a covalent glycosyl enzyme intermediate.
37253063	4	87	theme	heat	912:915	arg1	uptake					902:907	uptake	902:907	uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol)	902:939	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	3	88	theme	reverse	631:637	arg1	s-1					660:662	kcat = 22 s-1	650:662	kcat = 22 s-1	650:662	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	88	theme	reverse	631:637	arg1	direction					639:647	the forward (kcat = 84 s-1) and reverse direction	599:647	the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction	599:675	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	1	89	from	mechanism	95:103	arg1	hydrolase					155:163	a specialized glycoside hydrolase	131:163	a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction	131:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	89	from	mechanism	95:103	arg1	phosphorylase					114:126	sucrose phosphorylase	106:126	sucrose phosphorylase	106:126	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	4	90	theme	little	946:951	arg1	change					961:966	little further change	946:966	little further change in entropy	946:977	Approach from the ES complex to the transition state involves uptake of heat (ΔH⧧ = 72 ± 5.2 kJ/mol) with little further change in entropy.
37253063	1	91	from	structure	81:89	arg1	hydrolase					155:163	a specialized glycoside hydrolase	131:163	a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction	131:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	91	from	structure	81:89	arg1	phosphorylase					114:126	sucrose phosphorylase	106:126	sucrose phosphorylase	106:126	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	3	92	theme	=	655:655	arg1	s-1					660:662	kcat = 22 s-1	650:662	kcat = 22 s-1	650:662	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	3	92	theme	=	655:655	arg1	direction					639:647	the forward (kcat = 84 s-1) and reverse direction	599:647	the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction	599:675	Enzyme glycosylation from sucrose and α-glucose 1-phosphate (Glc1P) is rate-limiting in the forward (kcat = 84 s-1) and reverse direction (kcat = 22 s-1) of reaction at 30 °C. Enzyme-substrate association is driven by entropy (TΔSb ≥ +23 kJ/mol), likely arising from enzyme desolvation at the binding site for the leaving group.
37253063	1	93	theme	reaction	233:240	arg1	ions					185:188	phosphate ions	175:188	phosphate ions	175:188	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
37253063	1	93	theme	reaction	233:240	arg1	nucleophile					214:224	the nucleophile	210:224	the nucleophile of the reaction	210:240	From its structure and mechanism, sucrose phosphorylase is a specialized glycoside hydrolase that uses phosphate ions instead of water as the nucleophile of the reaction.
36332576	2	0	theme	structural	378:387	arg1	changes					389:395	the structural changes	374:395	the structural changes of CN	374:401	The glycation level and the structural changes of CN were analyzed by multiple spectra.
36332576	6	1	theme	milk	949:952	arg1	powder					954:959	milk powder	949:959	milk powder	949:959	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	0	2	from	analysis	14:21	arg1	aggregation					74:84	aggregation	74:84	aggregation	74:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	2	from	analysis	14:21	arg1	structure					60:68	casein structure	53:68	casein structure	53:68	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	2	from	analysis	14:21	arg1	concentration					116:128	lactose concentration	108:128	lactose concentration	108:128	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	4	3	theme	constant	575:582	arg1	means					590:594	A higher quenching constant, KSV, means	556:594	A higher quenching constant, KSV, means that the 1:1.5 group	556:615	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	3	4	theme	dynamic	524:530	arg1	quenching					532:540	the dynamic quenching	520:540	the dynamic quenching of collision	520:553	The results showed that the interaction between Lac and CN molecules was based on the dynamic quenching of collision.
36332576	6	5	theme	protein	894:900	arg1	glycation					902:910	protein glycation	894:910	protein glycation	894:910	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	4	6	theme	distinct	629:636	arg1	levels					648:653	more distinct glycation levels	624:653	more distinct glycation levels	624:653	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	1	7	dep	m	326:326	arg1	m					328:328	m	328:328	m:m	326:328	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	6	8	theme	positive	843:850	arg1	correlation					852:862	no positive correlation	840:862	no positive correlation found between Lac content and protein glycation	840:910	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	6	9	theme	storage	1012:1018	arg1	stability					1020:1028	storage stability	1012:1028	storage stability	1012:1028	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	5	10	theme	heating	735:741	arg1	treatment					743:751	heating treatment	735:751	heating treatment	735:751	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	2	11	theme	CN	400:401	arg1	changes					389:395	the structural changes	374:395	the structural changes of CN	374:401	The glycation level and the structural changes of CN were analyzed by multiple spectra.
36332576	2	11	theme	CN	400:401	arg1	level					364:368	The glycation level	350:368	The glycation level	350:368	The glycation level and the structural changes of CN were analyzed by multiple spectra.
36332576	1	12	with	powders	247:253	arg1	CN					294:295	CN	294:295	CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m)	294:329	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	12	with	powders	247:253	arg1	contents					284:291	different lactose (Lac) contents	260:291	different lactose (Lac) contents	260:291	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	4	13	theme	glycation	638:646	arg1	levels					648:653	more distinct glycation levels	624:653	more distinct glycation levels	624:653	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	6	14	theme	Lac	934:936	arg1	content					938:944	the Lac content	930:944	the Lac content of milk powder	930:959	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	5	15	theme	CN	669:670	arg1	glycation					672:680	CN glycation	669:680	CN glycation	669:680	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	0	16	from	effect	30:35	arg1	aggregation					74:84	aggregation	74:84	aggregation	74:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	16	from	effect	30:35	arg1	structure					60:68	casein structure	53:68	casein structure	53:68	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	4	17	theme	1:1.5	605:609	arg1	group					611:615	the 1:1.5 group	601:615	the 1:1.5 group	601:615	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	1	18	theme	glycation	163:171	arg1	effect					153:158	the effect	149:158	the effect of glycation on the molecular structure of casein (CN)	149:213	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	0	19	theme	Spectroscopic	0:12	arg1	analysis					14:21	Spectroscopic analysis	0:21	Spectroscopic analysis of the effect of glycation on casein structure and aggregation	0:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	1	20	theme	simulated	232:240	arg1	powders					247:253	simulated milk powders	232:253	simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m),	232:330	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	21	theme	milk	242:245	arg1	powders					247:253	simulated milk powders	232:253	simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m),	232:330	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	5	22	theme	heating	813:819	arg1	process					821:827	the heating process	809:827	the heating process	809:827	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	1	23	theme	powders	247:253	arg1	powders					247:253	simulated milk powders	232:253	simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m),	232:330	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	23	theme	powders	247:253	arg1	groups					222:227	three groups	216:227	three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m),	216:330	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	0	24	theme	lactose	108:114	arg1	concentration					116:128	lactose concentration	108:128	lactose concentration	108:128	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	25	from	aggregation	74:84	arg1	dependence					94:103	its dependence	90:103	its dependence on lactose concentration	90:128	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	25	from	aggregation	74:84	arg1	analysis					14:21	Spectroscopic analysis	0:21	Spectroscopic analysis of the effect of glycation on casein structure and aggregation	0:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	5	26	theme	structural	770:779	arg1	damage					781:786	the structural damage	766:786	the structural damage of CN induced during the heating process	766:827	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	1	27	theme	molecular	180:188	arg1	structure					190:198	the molecular structure	176:198	the molecular structure of casein (CN)	176:213	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	3	28	theme	Lac	486:488	arg1	molecules					497:505	Lac and CN molecules	486:505	Lac and CN molecules	486:505	The results showed that the interaction between Lac and CN molecules was based on the dynamic quenching of collision.
36332576	5	29	theme	casein	709:714	arg1	micelles					716:723	casein micelles	709:723	casein micelles caused by heating treatment	709:751	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	0	30	theme	effect	30:35	arg1	dependence					94:103	its dependence	90:103	its dependence on lactose concentration	90:128	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	30	theme	effect	30:35	arg1	analysis					14:21	Spectroscopic analysis	0:21	Spectroscopic analysis of the effect of glycation on casein structure and aggregation	0:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	1	31	theme	different	260:268	arg1	CN					294:295	CN	294:295	CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m)	294:329	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	31	theme	different	260:268	arg1	contents					284:291	different lactose (Lac) contents	260:291	different lactose (Lac) contents	260:291	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	2	32	theme	multiple	420:427	arg1	spectra					429:435	multiple spectra	420:435	multiple spectra	420:435	The glycation level and the structural changes of CN were analyzed by multiple spectra.
36332576	0	33	from	structure	60:68	arg1	dependence					94:103	its dependence	90:103	its dependence on lactose concentration	90:128	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	33	from	structure	60:68	arg1	analysis					14:21	Spectroscopic analysis	0:21	Spectroscopic analysis of the effect of glycation on casein structure and aggregation	0:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	5	34	theme	micelles	716:723	arg1	aggregation					694:704	the aggregation	690:704	the aggregation of casein micelles caused by heating treatment	690:751	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	1	35	dep	Lac = 1:1.5	297:307	arg1	m					326:326	m	326:326	m:m	326:328	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	2	36	theme	glycation	354:362	arg1	level					364:368	The glycation level	350:368	The glycation level	350:368	The glycation level and the structural changes of CN were analyzed by multiple spectra.
36332576	1	37	theme	lactose	270:276	arg1	CN					294:295	CN	294:295	CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m)	294:329	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	37	theme	lactose	270:276	arg1	contents					284:291	different lactose (Lac) contents	260:291	different lactose (Lac) contents	260:291	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	38	dep	CN	294:295	arg1	1:2.5					319:323	1:2.5	319:323	1:2.5	319:323	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	38	dep	CN	294:295	arg1	Lac = 1:1.5					297:307	Lac = 1:1.5	297:307	Lac = 1:1.5	297:307	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	38	dep	CN	294:295	arg1	1:2					310:312	1:2	310:312	1:2	310:312	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	0	39	theme	glycation	40:48	arg1	effect					30:35	the effect	26:35	the effect of glycation on casein structure and aggregation	26:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	1	40	theme	Lac	279:281	arg1	CN					294:295	CN	294:295	CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m)	294:329	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	1	40	theme	Lac	279:281	arg1	contents					284:291	different lactose (Lac) contents	260:291	different lactose (Lac) contents	260:291	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	0	41	from	dependence	94:103	arg1	aggregation					74:84	aggregation	74:84	aggregation	74:84	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	41	from	dependence	94:103	arg1	structure					60:68	casein structure	53:68	casein structure	53:68	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	0	41	from	dependence	94:103	arg1	concentration					116:128	lactose concentration	108:128	lactose concentration	108:128	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	5	42	theme	CN	791:792	arg1	damage					781:786	the structural damage	766:786	the structural damage of CN induced during the heating process	766:827	In addition, CN glycation reduced the aggregation of casein micelles caused by heating treatment and repaired the structural damage of CN induced during the heating process.
36332576	6	43	theme	effective	984:992	arg1	method					994:999	an effective method	981:999	an effective method to prolong storage stability	981:1028	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	1	44	theme	casein	203:208	arg1	structure					190:198	the molecular structure	176:198	the molecular structure of casein (CN)	176:213	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	6	45	theme	powder	954:959	arg1	content					938:944	the Lac content	930:944	the Lac content of milk powder	930:959	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
36332576	3	46	theme	collision	545:553	arg1	quenching					532:540	the dynamic quenching	520:540	the dynamic quenching of collision	520:553	The results showed that the interaction between Lac and CN molecules was based on the dynamic quenching of collision.
36332576	3	47	theme	CN	494:495	arg1	molecules					497:505	Lac and CN molecules	486:505	Lac and CN molecules	486:505	The results showed that the interaction between Lac and CN molecules was based on the dynamic quenching of collision.
36332576	4	48	theme	quenching	565:573	arg1	constant					575:582	quenching constant	565:582	quenching constant	565:582	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	4	48	theme	quenching	565:573	arg1	KSV					585:587	KSV	585:587	KSV	585:587	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	0	49	theme	casein	53:58	arg1	structure					60:68	casein structure	53:68	casein structure	53:68	Spectroscopic analysis of the effect of glycation on casein structure and aggregation and its dependence on lactose concentration.
36332576	1	50	from	effect	153:158	arg1	structure					190:198	the molecular structure	176:198	the molecular structure of casein (CN)	176:213	In order to study the effect of glycation on the molecular structure of casein (CN), three groups of simulated milk powders with different lactose (Lac) contents, CN:Lac = 1:1.5, 1:2, and 1:2.5 (m:m), were constructed.
36332576	4	51	theme	higher	558:563	arg1	means					590:594	A higher quenching constant, KSV, means	556:594	A higher quenching constant, KSV, means that the 1:1.5 group	556:615	A higher quenching constant, KSV, means that the 1:1.5 group showed more distinct glycation levels.
36332576	6	52	theme	Lac	878:880	arg1	content					882:888	Lac content	878:888	Lac content	878:888	There was no positive correlation found between Lac content and protein glycation; thus, decreasing the Lac content of milk powder is not likely to be an effective method to prolong storage stability.
35157458	1	0	theme	glycans	163:169	arg1	roles					154:158	the roles	150:158	the roles of glycans in various biological processes	150:201	Glycan structure identification is essential to understanding the roles of glycans in various biological processes.
35157458	4	1	theme	precursor	444:452	arg1	mass					454:457	the precursor mass	440:457	the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction	440:672	First, we use the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction.
35157458	6	2	theme	Experimental	782:793	arg1	results					795:801	Experimental results	782:801	Experimental results	782:801	Experimental results are provided to demonstrate the effectiveness of GlycoDeNovo2.
35157458	2	3	theme	tandem	304:309	arg1	spectra					316:322	tandem mass spectra	304:322	tandem mass spectra (MS/MS)	304:330	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	2	3	theme	tandem	304:309	arg1	MS/MS					325:329	MS/MS	325:329	MS/MS	325:329	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	1	4	from	roles	154:158	arg1	processes					193:201	various biological processes	174:201	various biological processes	174:201	Glycan structure identification is essential to understanding the roles of glycans in various biological processes.
35157458	1	5	theme	various	174:180	arg1	processes					193:201	various biological processes	174:201	various biological processes	174:201	Glycan structure identification is essential to understanding the roles of glycans in various biological processes.
35157458	2	6	theme	glycan	281:286	arg1	topologies					288:297	glycan topologies	281:297	glycan topologies	281:297	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	1	7	theme	biological	182:191	arg1	processes					193:201	various biological processes	174:201	various biological processes	174:201	Glycan structure identification is essential to understanding the roles of glycans in various biological processes.
35157458	1	8	theme	Glycan	88:93	arg1	identification					105:118	Glycan structure identification	88:118	Glycan structure identification	88:118	Glycan structure identification is essential to understanding the roles of glycans in various biological processes.
35157458	4	9	theme	potential	532:540	arg1	compositions					542:553	its potential compositions	528:553	its potential compositions	528:553	First, we use the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction.
35157458	1	10	theme	structure	95:103	arg1	identification					105:118	Glycan structure identification	88:118	Glycan structure identification	88:118	Glycan structure identification is essential to understanding the roles of glycans in various biological processes.
35157458	0	11	theme	Improved	17:24	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	3	12	contain	contains	378:385	arg1	GlycoDeNovo2					360:371	GlycoDeNovo2	360:371	GlycoDeNovo2 that contains two major improvements to GlycoDeNovo	360:423	In this work, we introduce GlycoDeNovo2 that contains two major improvements to GlycoDeNovo.
35157458	3	12	contain	contains	378:385	arg2	improvements					397:408	two major improvements	387:408	two major improvements to GlycoDeNovo	387:423	In this work, we introduce GlycoDeNovo2 that contains two major improvements to GlycoDeNovo.
35157458	5	13	theme	topology	762:769	arg1	candidate					771:779	a reconstructed topology candidate	746:779	a reconstructed topology candidate	746:779	Second, we developed a procedure to calculate the empirical p-value of a reconstructed topology candidate.
35157458	2	14	theme	mass	311:314	arg1	spectra					316:322	tandem mass spectra	304:322	tandem mass spectra (MS/MS)	304:330	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	2	14	theme	mass	311:314	arg1	MS/MS					325:329	MS/MS	325:329	MS/MS	325:329	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	0	15	theme	De	38:39	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	6	16	theme	GlycoDeNovo2	852:863	arg1	effectiveness					835:847	the effectiveness	831:847	the effectiveness of GlycoDeNovo2	831:863	Experimental results are provided to demonstrate the effectiveness of GlycoDeNovo2.
35157458	2	17	theme	de	244:245	arg1	algorithm					252:260	a de novo algorithm	242:260	a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS)	242:330	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	2	17	theme	de	244:245	arg1	GlycoDeNovo					229:239	GlycoDeNovo	229:239	GlycoDeNovo	229:239	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	2	18	dep	de	244:245	arg1	novo					247:250	novo	247:250	novo	247:250	Previously, we developed GlycoDeNovo, a de novo algorithm for reconstructing glycan topologies from tandem mass spectra (MS/MS).
35157458	0	19	theme	MS/MS-Based	26:36	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	5	20	theme	reconstructed	748:760	arg1	candidate					771:779	a reconstructed topology candidate	746:779	a reconstructed topology candidate	746:779	Second, we developed a procedure to calculate the empirical p-value of a reconstructed topology candidate.
35157458	4	21	theme	parallel	609:616	arg1	computation					618:628	parallel computation	609:628	parallel computation	609:628	First, we use the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction.
35157458	3	22	theme	major	391:395	arg1	improvements					397:408	two major improvements	387:408	two major improvements to GlycoDeNovo	387:423	In this work, we introduce GlycoDeNovo2 that contains two major improvements to GlycoDeNovo.
35157458	4	23	used	used	566:569	arg2	glycan					508:513	a glycan to determine its potential compositions	506:553	a glycan to determine its potential compositions	506:553	First, we use the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction.
35157458	0	24	theme	Topology	53:60	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	0	25	dep	De	38:39	arg1	Novo					41:44	Novo	41:44	Novo	41:44	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	5	26	theme	candidate	771:779	arg1	p-value					735:741	the empirical p-value	721:741	the empirical p-value of a reconstructed topology candidate	721:779	Second, we developed a procedure to calculate the empirical p-value of a reconstructed topology candidate.
35157458	5	27	theme	empirical	725:733	arg1	p-value					735:741	the empirical p-value	721:741	the empirical p-value of a reconstructed topology candidate	721:779	Second, we developed a procedure to calculate the empirical p-value of a reconstructed topology candidate.
35157458	0	28	theme	Reconstruction	62:75	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	4	29	theme	topology	650:657	arg1	reconstruction					659:672	topology reconstruction	650:672	topology reconstruction	650:672	First, we use the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction.
35157458	0	30	theme	Glycan	46:51	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	0	31	dep	GlycoDeNovo2	0:11	arg1	Algorithm					77:85	An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm	14:85	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.	0:86	GlycoDeNovo2: An Improved MS/MS-Based De Novo Glycan Topology Reconstruction Algorithm.
35157458	4	32	theme	search	588:593	arg1	space					595:599	the search space	584:599	the search space	584:599	First, we use the precursor mass measured for a peak that likely corresponds to a glycan to determine its potential compositions, which are used to constrain the search space, enable parallel computation, and hence speed up topology reconstruction.
36925056	0	0	theme	further	76:82	arg1	changes					84:90	further changes	76:90	further changes	76:90	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	6	1	theme	branched	1269:1276	arg1	structures					1278:1287	highly branched structures	1262:1287	highly branched structures	1262:1287	HbA1c was positively associated with sialylated and highly branched structures, whereas N-glycome was not influenced by disease duration or diabetic complications.
36925056	7	2	theme	type	1461:1464	arg1	diabetes					1468:1475	type 1 diabetes	1461:1475	type 1 diabetes	1461:1475	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	6	3	dep	associated	1231:1240	arg1	whereas					1290:1296	whereas	1290:1296	whereas	1290:1296	HbA1c was positively associated with sialylated and highly branched structures, whereas N-glycome was not influenced by disease duration or diabetic complications.
36925056	3	4	from	N-glycome	481:489	arg1	adults					518:523	200 adults	514:523	200 adults with type 1 diabetes	514:544	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	4	from	N-glycome	481:489	arg1	controls					562:569	298 healthy controls	550:569	298 healthy controls	550:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	4	5	theme	measured	1031:1038	arg1	traits					1040:1045	seven directly measured traits	1016:1045	seven directly measured traits	1016:1045	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	3	6	with	controls	562:569	arg1	diabetes					537:544	type 1 diabetes	530:544	type 1 diabetes	530:544	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	4	7	dep	derived	954:960	arg1	fucosylated					942:952	fucosylated	942:952	fucosylated	942:952	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	2	8	from	aim	280:282	arg1	study					270:274	this study	265:274	this study	265:274	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	4	9	theme	digalactosylated	894:909	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	0	10	from	N-glycosylation	0:14	arg1	mellitus					59:66	adult type 1 diabetes mellitus	37:66	adult type 1 diabetes mellitus	37:66	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	7	11	theme	different	1441:1449	arg1	those					1557:1561	those	1557:1561	those	1557:1561	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	11	theme	different	1441:1449	arg1	processes					1488:1496	processes	1488:1496	processes underlying its development, the disease itself	1488:1543	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	11	theme	different	1441:1449	arg1	stages					1451:1456	different stages	1441:1456	different stages	1441:1456	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	1	12	theme	type	245:248	arg1	diabetes					252:259	type 1 diabetes	245:259	type 1 diabetes	245:259	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	7	13	theme	potential	1406:1414	arg1	involvement					1426:1436	potential N-glycome involvement	1406:1436	potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment	1406:1599	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	4	14	from	differences	809:819	arg1	increase					882:889	an increase	879:889	an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children	879:1093	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	14	from	differences	809:819	arg1	monogalactosylated					859:876	monogalactosylated	859:876	monogalactosylated	859:876	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	14	from	differences	809:819	arg1	groups					834:839	19 glycan groups	824:839	19 glycan groups	824:839	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	15	theme	glycan	827:832	arg1	groups					834:839	19 glycan groups	824:839	19 glycan groups	824:839	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	2	16	from	changes	305:311	arg1	adults					316:321	adults	316:321	adults with T1DM	316:331	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	3	17	theme	serum	494:498	arg1	proteins					500:507	serum proteins	494:507	serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	494:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	4	18	theme	monosialylated	912:925	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	7	19	theme	diabetes	1468:1475	arg1	those					1557:1561	those	1557:1561	those	1557:1561	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	19	theme	diabetes	1468:1475	arg1	processes					1488:1496	processes	1488:1496	processes underlying its development, the disease itself	1488:1543	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	19	theme	diabetes	1468:1475	arg1	stages					1451:1456	different stages	1441:1456	different stages	1441:1456	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	1	20	gly	N-glycosylation	190:204	arg1	children					220:227	children	220:227	children	220:227	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	1	20	gly	N-glycosylation	190:204	arg1	onset					236:240	the onset	232:240	the onset of type 1 diabetes	232:259	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	3	21	theme	METHODS	473:479	arg1	N-glycome					481:489	METHODS N-glycome	473:489	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	473:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	6	22	theme	disease	1330:1336	arg1	duration					1338:1345	disease duration	1330:1345	disease duration	1330:1345	HbA1c was positively associated with sialylated and highly branched structures, whereas N-glycome was not influenced by disease duration or diabetic complications.
36925056	3	23	theme	measured	665:672	arg1	groups					681:686	39 directly measured glycan groups	653:686	39 directly measured glycan groups from which 16 derived traits were calculated	653:731	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	24	theme	glycan	674:679	arg1	groups					681:686	39 directly measured glycan groups	653:686	39 directly measured glycan groups from which 16 derived traits were calculated	653:731	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	25	theme	derived	702:708	arg1	traits					710:715	16 derived traits	699:715	16 derived traits	699:715	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	1	26	dep	Previously	145:154	arg1	OBJECTIVE					135:143	OBJECTIVE	135:143	OBJECTIVE	135:143	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	3	27	from	controls	562:569	arg1	N-glycome					481:489	METHODS N-glycome	473:489	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	473:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	27	from	controls	562:569	arg1	proteins					500:507	serum proteins	494:507	serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	494:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	7	28	dep	CONCLUSIONS	1374:1384	arg1	suggest					1398:1404	suggest	1398:1404	suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment	1398:1599	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	1	29	theme	diabetes	252:259	arg1	onset					236:240	the onset	232:240	the onset of type 1 diabetes	232:259	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	4	30	link	derived	954:960	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	7	31	theme	N-glycome	1416:1424	arg1	involvement					1426:1436	potential N-glycome involvement	1406:1436	potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment	1406:1599	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	1	32	theme	plasma	175:180	arg1	N-glycosylation					190:204	plasma protein N-glycosylation	175:204	plasma protein N-glycosylation	175:204	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	0	33	theme	proteins	25:32	arg1	N-glycosylation					0:14	N-glycosylation	0:14	N-glycosylation of serum proteins in adult type 1 diabetes mellitus	0:66	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	3	34	theme	proteins	500:507	arg1	N-glycome					481:489	METHODS N-glycome	473:489	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	473:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	1	35	theme	protein	182:188	arg1	N-glycosylation					190:204	plasma protein N-glycosylation	175:204	plasma protein N-glycosylation	175:204	OBJECTIVE Previously we have shown that plasma protein N-glycosylation is changed in children at the onset of type 1 diabetes.
36925056	0	36	theme	serum	19:23	arg1	proteins					25:32	serum proteins	19:32	serum proteins	19:32	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	4	37	from	changes	981:987	arg1	traits					1040:1045	seven directly measured traits	1016:1045	seven directly measured traits	1016:1045	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	37	from	changes	981:987	arg1	monogalactosylation					992:1010	monogalactosylation	992:1010	monogalactosylation	992:1010	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	38	from	increase	882:889	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	39	gly	monosialylated	912:925	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	0	40	theme	adult	37:41	arg1	mellitus					59:66	adult type 1 diabetes mellitus	37:66	adult type 1 diabetes mellitus	37:66	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	3	41	theme	ultra-high	591:600	arg1	chromatography					621:634	ultra-high performance liquid chromatography	591:634	ultra-high performance liquid chromatography	591:634	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	0	42	gly	N-glycosylation	0:14	arg1	proteins					25:32	serum proteins	19:32	serum proteins	19:32	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	0	42	gly	N-glycosylation	0:14	arg1	mellitus					59:66	adult type 1 diabetes mellitus	37:66	adult type 1 diabetes mellitus	37:66	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	4	43	theme	derived	954:960	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	44	theme	antennary	932:940	arg1	traits					962:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	digalactosylated, monosialylated, and antennary fucosylated derived traits	894:967	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	0	45	theme	disease	120:126	arg1	onset					128:132	the disease onset	116:132	the disease onset	116:132	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	5	46	theme	derived	1138:1144	arg1	traits					1146:1151	two derived traits	1134:1151	two derived traits	1134:1151	Changes in four directly measured and two derived traits previously seen in children were not detected in adults.
36925056	2	47	theme	disease	409:415	arg1	duration					417:424	disease duration	409:424	disease duration	409:424	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	6	48	theme	diabetic	1350:1357	arg1	complications					1359:1371	diabetic complications	1350:1371	diabetic complications	1350:1371	HbA1c was positively associated with sialylated and highly branched structures, whereas N-glycome was not influenced by disease duration or diabetic complications.
36925056	0	49	theme	diabetes	50:57	arg1	mellitus					59:66	adult type 1 diabetes mellitus	37:66	adult type 1 diabetes mellitus	37:66	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	4	50	theme	type	786:789	arg1	diabetes					793:800	type 1 diabetes	786:800	type 1 diabetes	786:800	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	5	51	link	derived	1138:1144	arg1	traits					1146:1151	two derived traits	1134:1151	two derived traits	1134:1151	Changes in four directly measured and two derived traits previously seen in children were not detected in adults.
36925056	0	52	theme	type	43:46	arg1	mellitus					59:66	adult type 1 diabetes mellitus	37:66	adult type 1 diabetes mellitus	37:66	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	5	53	from	Changes	1096:1102	arg1	measured					1121:1128	measured	1121:1128	measured	1121:1128	Changes in four directly measured and two derived traits previously seen in children were not detected in adults.
36925056	5	53	from	Changes	1096:1102	arg1	traits					1146:1151	two derived traits	1134:1151	two derived traits	1134:1151	Changes in four directly measured and two derived traits previously seen in children were not detected in adults.
36925056	2	54	with	adults	316:321	arg1	T1DM					328:331	T1DM	328:331	T1DM	328:331	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	3	55	theme	type	530:533	arg1	diabetes					537:544	type 1 diabetes	530:544	type 1 diabetes	530:544	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	2	56	with	associations	391:402	arg1	duration					417:424	disease duration	409:424	disease duration	409:424	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	2	56	with	associations	391:402	arg1	complications					427:439	complications	427:439	complications	427:439	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	2	56	with	associations	391:402	arg1	status					452:457	glycaemic status	442:457	glycaemic status	442:457	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	2	56	with	associations	391:402	arg1	smoking					464:470	smoking	464:470	smoking	464:470	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	2	57	theme	N-glycan	296:303	arg1	changes					305:311	N-glycan changes	296:311	N-glycan changes in adults with T1DM	296:331	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	4	58	theme	healthy	754:760	arg1	controls					762:769	healthy controls	754:769	healthy controls	754:769	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	59	from	decrease	847:854	arg1	increase					882:889	an increase	879:889	an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children	879:1093	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	59	from	decrease	847:854	arg1	monogalactosylated					859:876	monogalactosylated	859:876	monogalactosylated	859:876	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	4	59	from	decrease	847:854	arg1	groups					834:839	19 glycan groups	824:839	19 glycan groups	824:839	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	3	60	theme	healthy	554:560	arg1	controls					562:569	298 healthy controls	550:569	298 healthy controls	550:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	0	61	from	onset	128:132	arg1	children					104:111	children	104:111	children at the disease onset	104:132	N-glycosylation of serum proteins in adult type 1 diabetes mellitus exposes further changes compared to children at the disease onset.
36925056	3	62	theme	performance	602:612	arg1	chromatography					621:634	ultra-high performance liquid chromatography	591:634	ultra-high performance liquid chromatography	591:634	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	63	theme	liquid	614:619	arg1	chromatography					621:634	ultra-high performance liquid chromatography	591:634	ultra-high performance liquid chromatography	591:634	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	5	64	located	detected	1190:1197	arg1	adults					1202:1207	adults	1202:1207	adults	1202:1207	Changes in four directly measured and two derived traits previously seen in children were not detected in adults.
36925056	5	64	located	detected	1190:1197	arg2	Changes					1096:1102	Changes	1096:1102	Changes in four directly measured and two derived traits previously seen in children	1096:1179	Changes in four directly measured and two derived traits previously seen in children were not detected in adults.
36925056	3	65	from	adults	518:523	arg1	N-glycome					481:489	METHODS N-glycome	473:489	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	473:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	65	from	adults	518:523	arg1	proteins					500:507	serum proteins	494:507	serum proteins from 200 adults with type 1 diabetes and 298 healthy controls	494:569	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	4	66	with	subjects	772:779	arg1	diabetes					793:800	type 1 diabetes	786:800	type 1 diabetes	786:800	RESULTS Compared to healthy controls, subjects with type 1 diabetes showed differences in 19 glycan groups and a decrease in monogalactosylated, an increase in digalactosylated, monosialylated, and antennary fucosylated derived traits, from which changes in monogalactosylation and seven directly measured traits overlapped with previously reported in children.
36925056	2	67	theme	glycaemic	442:450	arg1	status					452:457	glycaemic status	442:457	glycaemic status	442:457	In this study, we aim to identify N-glycan changes in adults with T1DM, compare them to those in children, and investigate their associations with disease duration, complications, glycaemic status, and smoking.
36925056	3	68	with	adults	518:523	arg1	diabetes					537:544	type 1 diabetes	530:544	type 1 diabetes	530:544	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	3	69	link	derived	702:708	arg1	traits					710:715	16 derived traits	699:715	16 derived traits	699:715	METHODS N-glycome of serum proteins from 200 adults with type 1 diabetes and 298 healthy controls were analysed using ultra-high performance liquid chromatography and divided into 39 directly measured glycan groups from which 16 derived traits were calculated.
36925056	7	70	from	involvement	1426:1436	arg1	those					1557:1561	those	1557:1561	those	1557:1561	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	70	from	involvement	1426:1436	arg1	processes					1488:1496	processes	1488:1496	processes underlying its development, the disease itself	1488:1543	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	70	from	involvement	1426:1436	arg1	stages					1451:1456	different stages	1441:1456	different stages	1441:1456	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36925056	7	71	theme	disease	1579:1585	arg1	establishment					1587:1599	disease establishment	1579:1599	disease establishment	1579:1599	CONCLUSIONS Our results suggest potential N-glycome involvement in different stages of type 1 diabetes, including processes underlying its development, the disease itself, as well as those occurring after disease establishment.
36175623	8	0	dep	principle	985:993	arg1	the					981:983	the	981:983	the	981:983	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	5	1	theme	time	641:644	arg1	data					646:649	the elution time data	629:649	the elution time data with known data	629:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	7	2	theme	mass	925:928	arg1	spectrometry					930:941	mass spectrometry	925:941	mass spectrometry	925:941	It also enables the discrimination of isomers, which is difficult via mass spectrometry.
36175623	0	3	theme	N-Glycans	85:93	arg1	Analysis					73:80	the Structural Analysis	58:80	the Structural Analysis of N-Glycans	58:93	High-Performance Liquid Chromatography Mapping Method for the Structural Analysis of N-Glycans at the Molecular, Cellular, and Tissue Levels.
36175623	4	4	theme	glycan	509:514	arg1	structures					516:525	glycan structures	509:525	glycan structures	509:525	We developed a multidimensional HPLC mapping method that identifies glycan structures.
36175623	5	5	with	data	646:649	arg1	data					662:665	known data	656:665	known data	656:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	2	6	from	characterization	307:322	arg1	important					290:298	important	290:298	important	290:298	Investigating the structure of glycans may be important in the characterization of viruses.
36175623	5	7	dep	glycans	573:579	arg1	using					581:585	using	581:585	using three types of HPLC columns	581:613	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	5	7	dep	glycans	573:579	arg1	comparing					619:627	comparing	619:627	comparing the elution time data with known data	619:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	4	8	theme	multidimensional	456:471	arg1	method					486:491	a multidimensional HPLC mapping method	454:491	a multidimensional HPLC mapping method that identifies glycan structures	454:525	We developed a multidimensional HPLC mapping method that identifies glycan structures.
36175623	5	9	theme	known	656:660	arg1	data					662:665	known data	656:665	known data	656:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	5	10	theme	HPLC	602:605	arg1	columns					607:613	HPLC columns	602:613	HPLC columns	602:613	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	2	11	theme	glycans	275:281	arg1	structure					262:270	the structure	258:270	the structure of glycans	258:281	Investigating the structure of glycans may be important in the characterization of viruses.
36175623	1	12	from	Glycans	142:148	arg1	viruses					153:159	viruses	153:159	viruses	153:159	Glycans on viruses are major molecules that mediate the communication of the viruses with host cells.
36175623	6	13	theme	easy	692:695	arg1	profiling					697:705	the easy profiling	688:705	the easy profiling of glycans	688:716	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	3	14	theme	used	414:417	arg1	chromatography					380:393	the high-performance liquid chromatography	352:393	the high-performance liquid chromatography (HPLC)	352:400	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	3	14	theme	used	414:417	arg1	technique					430:438	a widely used analytical technique	405:438	a widely used analytical technique	405:438	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	4	15	theme	mapping	478:484	arg1	method					486:491	a multidimensional HPLC mapping method	454:491	a multidimensional HPLC mapping method that identifies glycan structures	454:525	We developed a multidimensional HPLC mapping method that identifies glycan structures.
36175623	5	16	theme	purifying	563:571	arg1	glycans					573:579	separating and purifying glycans	548:579	separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data	548:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	1	17	theme	major	165:169	arg1	molecules					171:179	major molecules	165:179	major molecules that mediate the communication of the viruses with host cells	165:241	Glycans on viruses are major molecules that mediate the communication of the viruses with host cells.
36175623	1	17	theme	major	165:169	arg1	Glycans					142:148	Glycans	142:148	Glycans on viruses	142:159	Glycans on viruses are major molecules that mediate the communication of the viruses with host cells.
36175623	0	18	theme	Liquid	17:22	arg1	Chromatography					24:37	High-Performance Liquid Chromatography	0:37	High-Performance Liquid Chromatography	0:37	High-Performance Liquid Chromatography Mapping Method for the Structural Analysis of N-Glycans at the Molecular, Cellular, and Tissue Levels.
36175623	4	19	theme	HPLC	473:476	arg1	method					486:491	a multidimensional HPLC mapping method	454:491	a multidimensional HPLC mapping method that identifies glycan structures	454:525	We developed a multidimensional HPLC mapping method that identifies glycan structures.
36175623	7	20	theme	isomers	893:899	arg1	discrimination					875:888	the discrimination	871:888	the discrimination	871:888	It also enables the discrimination of isomers, which is difficult via mass spectrometry.
36175623	7	20	theme	isomers	893:899	arg1	difficult					911:919	difficult	911:919	difficult	911:919	It also enables the discrimination of isomers, which is difficult via mass spectrometry.
36175623	0	21	theme	High-Performance	0:15	arg1	Chromatography					24:37	High-Performance Liquid Chromatography	0:37	High-Performance Liquid Chromatography	0:37	High-Performance Liquid Chromatography Mapping Method for the Structural Analysis of N-Glycans at the Molecular, Cellular, and Tissue Levels.
36175623	5	22	theme	elution	633:639	arg1	data					646:649	the elution time data	629:649	the elution time data with known data	629:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	6	23	theme	tissue	750:755	arg1	levels					757:762	the molecular, cellular, and tissue levels	721:762	the molecular, cellular, and tissue levels	721:762	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	1	24	with	communication	198:210	arg1	cells					237:241	host cells	232:241	host cells	232:241	Glycans on viruses are major molecules that mediate the communication of the viruses with host cells.
36175623	5	25	theme	columns	607:613	arg1	types					593:597	three types	587:597	three types of HPLC columns	587:613	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	3	26	theme	high-performance	356:371	arg1	HPLC					396:399	HPLC	396:399	HPLC	396:399	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	3	26	theme	high-performance	356:371	arg1	chromatography					380:393	the high-performance liquid chromatography	352:393	the high-performance liquid chromatography (HPLC)	352:400	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	3	26	theme	high-performance	356:371	arg1	technique					430:438	a widely used analytical technique	405:438	a widely used analytical technique	405:438	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	8	27	theme	analysis	1024:1031	arg1	principle					985:993	principle	985:993	principle	985:993	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	8	27	theme	analysis	1024:1031	arg1	method					999:1004	method	999:1004	method	999:1004	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	6	28	used	used	775:778	arg2	method					673:678	This method	668:678	This method	668:678	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	0	29	theme	Tissue	127:132	arg1	Levels					134:139	Tissue Levels	127:139	Tissue Levels	127:139	High-Performance Liquid Chromatography Mapping Method for the Structural Analysis of N-Glycans at the Molecular, Cellular, and Tissue Levels.
36175623	6	30	theme	samples	816:822	arg1	glycans					793:799	the glycans	789:799	the glycans of virological samples such as virus and their hosts	789:852	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	6	30	theme	samples	816:822	arg1	virus					832:836	virus	832:836	virus	832:836	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	6	30	theme	samples	816:822	arg1	hosts					848:852	their hosts	842:852	their hosts	842:852	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	3	31	from	technique	430:438	arg1	regard					344:349	this regard	339:349	this regard	339:349	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	0	32	theme	Structural	62:71	arg1	Analysis					73:80	the Structural Analysis	58:80	the Structural Analysis of N-Glycans	58:93	High-Performance Liquid Chromatography Mapping Method for the Structural Analysis of N-Glycans at the Molecular, Cellular, and Tissue Levels.
36175623	8	33	theme	N-type	1036:1041	arg1	glycans					1043:1049	N-type glycans	1036:1049	N-type glycans using the proposed method	1036:1075	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	6	34	theme	virological	804:814	arg1	samples					816:822	virological samples	804:822	virological samples	804:822	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	6	35	theme	cellular	736:743	arg1	levels					757:762	the molecular, cellular, and tissue levels	721:762	the molecular, cellular, and tissue levels	721:762	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	8	36	theme	structural	1013:1022	arg1	analysis					1024:1031	the structural analysis	1009:1031	the structural analysis of N-type glycans using the proposed method	1009:1075	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	5	37	theme	separating	548:557	arg1	glycans					573:579	separating and purifying glycans	548:579	separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data	548:665	This is achieved by separating and purifying glycans using three types of HPLC columns and comparing the elution time data with known data.
36175623	2	38	theme	viruses	327:333	arg1	characterization					307:322	the characterization	303:322	the characterization of viruses	303:333	Investigating the structure of glycans may be important in the characterization of viruses.
36175623	6	39	theme	molecular	725:733	arg1	levels					757:762	the molecular, cellular, and tissue levels	721:762	the molecular, cellular, and tissue levels	721:762	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	8	40	theme	glycans	1043:1049	arg1	analysis					1024:1031	the structural analysis	1009:1031	the structural analysis of N-type glycans using the proposed method	1009:1075	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	1	41	theme	viruses	219:225	arg1	communication					198:210	the communication	194:210	the communication of the viruses with host cells	194:241	Glycans on viruses are major molecules that mediate the communication of the viruses with host cells.
36175623	8	42	theme	proposed	1061:1068	arg1	method					1070:1075	the proposed method	1057:1075	the proposed method	1057:1075	In this paper, we describe in detail the principle and method of the structural analysis of N-type glycans using the proposed method.
36175623	3	43	theme	analytical	419:428	arg1	chromatography					380:393	the high-performance liquid chromatography	352:393	the high-performance liquid chromatography (HPLC)	352:400	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	3	43	theme	analytical	419:428	arg1	technique					430:438	a widely used analytical technique	405:438	a widely used analytical technique	405:438	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	6	44	theme	glycans	710:716	arg1	profiling					697:705	the easy profiling	688:705	the easy profiling of glycans	688:716	This method enables the easy profiling of glycans at the molecular, cellular, and tissue levels and can be used to study the glycans of virological samples such as virus and their hosts.
36175623	3	45	theme	liquid	373:378	arg1	HPLC					396:399	HPLC	396:399	HPLC	396:399	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	3	45	theme	liquid	373:378	arg1	chromatography					380:393	the high-performance liquid chromatography	352:393	the high-performance liquid chromatography (HPLC)	352:400	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	3	45	theme	liquid	373:378	arg1	technique					430:438	a widely used analytical technique	405:438	a widely used analytical technique	405:438	In this regard, the high-performance liquid chromatography (HPLC) is a widely used analytical technique.
36175623	2	46	from	important	290:298	arg1	characterization					307:322	the characterization	303:322	the characterization of viruses	303:333	Investigating the structure of glycans may be important in the characterization of viruses.
36175623	1	47	theme	host	232:235	arg1	cells					237:241	host cells	232:241	host cells	232:241	Glycans on viruses are major molecules that mediate the communication of the viruses with host cells.
35880655	3	0	theme	individual	355:364	arg1	glycans					372:378	individual mucin glycans	355:378	individual mucin glycans	355:378	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	3	1	theme	small	547:551	arg1	library					553:559	a small library	545:559	a small library of mucin glycans which were identified as most likely to display activity	545:633	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	3	2	theme	mucin	366:370	arg1	glycans					372:378	individual mucin glycans	355:378	individual mucin glycans	355:378	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	3	3	theme	sufficient	402:411	arg1	purity					413:418	sufficient purity	402:418	sufficient purity	402:418	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	2	4	theme	expression	319:328	arg1	mixtures					258:265	mucin O-glycan mixtures	243:265	mucin O-glycan mixtures	243:265	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	4	theme	expression	319:328	arg1	down-regulators					277:291	potent down-regulators	270:291	potent down-regulators of virulence-related gene expression in diverse pathogens	270:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	5	theme	gene	314:317	arg1	expression					319:328	virulence-related gene expression	296:328	virulence-related gene expression in diverse pathogens	296:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	4	6	theme	biological	700:709	arg1	function					711:718	biological function	700:718	biological function	700:718	The glycans have been prepared in sufficient quantity to assess biological function, studies of which are currently ongoing.
35880655	2	7	theme	virulence-related	296:312	arg1	expression					319:328	virulence-related gene expression	296:328	virulence-related gene expression in diverse pathogens	296:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	3	8	theme	structures	471:480	arg1	evaluation					448:457	biological evaluation	437:457	biological evaluation of discrete structures	437:480	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	1	9	theme	concerning	89:98	arg1	rise					100:103	the concerning rise	85:103	the concerning rise in antibiotic-resistant infections	85:138	With the concerning rise in antibiotic-resistant infections, novel treatment options against pathogens are urgently sought.
35880655	0	10	theme	O-Glycans	19:27	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of Mucin O-Glycans	0:27	Synthesis of Mucin O-Glycans Associated with Attenuation of Pathogen Virulence.
35880655	3	11	theme	optimized	504:512	arg1	approach					524:531	an optimized synthetic approach	501:531	an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity	501:633	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	0	12	theme	Mucin	13:17	arg1	O-Glycans					19:27	Mucin O-Glycans	13:27	Mucin O-Glycans	13:27	Synthesis of Mucin O-Glycans Associated with Attenuation of Pathogen Virulence.
35880655	3	13	theme	glycans	570:576	arg1	library					553:559	a small library	545:559	a small library of mucin glycans which were identified as most likely to display activity	545:633	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	2	14	theme	diverse	333:339	arg1	pathogens					341:349	diverse pathogens	333:349	diverse pathogens	333:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	3	15	theme	synthetic	514:522	arg1	approach					524:531	an optimized synthetic approach	501:531	an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity	501:633	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	2	16	from	down-regulators	277:291	arg1	pathogens					341:349	diverse pathogens	333:349	diverse pathogens	333:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	3	17	theme	discrete	462:469	arg1	structures					471:480	discrete structures	462:480	discrete structures	462:480	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	2	18	theme	O-glycan	249:256	arg1	mixtures					258:265	mucin O-glycan mixtures	243:265	mucin O-glycan mixtures	243:265	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	18	theme	O-glycan	249:256	arg1	down-regulators					277:291	potent down-regulators	270:291	potent down-regulators of virulence-related gene expression in diverse pathogens	270:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	3	19	theme	biological	437:446	arg1	evaluation					448:457	biological evaluation	437:457	biological evaluation of discrete structures	437:480	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	2	20	theme	mucin	243:247	arg1	mixtures					258:265	mucin O-glycan mixtures	243:265	mucin O-glycan mixtures	243:265	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	20	theme	mucin	243:247	arg1	down-regulators					277:291	potent down-regulators	270:291	potent down-regulators of virulence-related gene expression in diverse pathogens	270:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	1	21	theme	antibiotic-resistant	108:127	arg1	infections					129:138	antibiotic-resistant infections	108:138	antibiotic-resistant infections	108:138	With the concerning rise in antibiotic-resistant infections, novel treatment options against pathogens are urgently sought.
35880655	1	22	from	rise	100:103	arg1	infections					129:138	antibiotic-resistant infections	108:138	antibiotic-resistant infections	108:138	With the concerning rise in antibiotic-resistant infections, novel treatment options against pathogens are urgently sought.
35880655	4	23	theme	studies	721:727	arg1	ongoing					752:758	ongoing	752:758	ongoing	752:758	The glycans have been prepared in sufficient quantity to assess biological function, studies of which are currently ongoing.
35880655	2	24	theme	recent	212:217	arg1	studies					219:225	Several recent studies	204:225	Several recent studies	204:225	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	1	25	theme	novel	141:145	arg1	options					157:163	novel treatment options	141:163	novel treatment options against pathogens	141:181	With the concerning rise in antibiotic-resistant infections, novel treatment options against pathogens are urgently sought.
35880655	0	26	theme	Virulence	69:77	arg1	Attenuation					45:55	Attenuation	45:55	Attenuation of Pathogen Virulence	45:77	Synthesis of Mucin O-Glycans Associated with Attenuation of Pathogen Virulence.
35880655	2	27	theme	Several	204:210	arg1	studies					219:225	Several recent studies	204:225	Several recent studies	204:225	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	28	theme	potent	270:275	arg1	mixtures					258:265	mucin O-glycan mixtures	243:265	mucin O-glycan mixtures	243:265	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	28	theme	potent	270:275	arg1	down-regulators					277:291	potent down-regulators	270:291	potent down-regulators of virulence-related gene expression in diverse pathogens	270:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	4	29	theme	sufficient	670:679	arg1	quantity					681:688	sufficient quantity to assess biological function	670:718	sufficient quantity to assess biological function	670:718	The glycans have been prepared in sufficient quantity to assess biological function, studies of which are currently ongoing.
35880655	4	29	theme	sufficient	670:679	arg1	studies					721:727	studies	721:727	studies of which are currently ongoing	721:758	The glycans have been prepared in sufficient quantity to assess biological function, studies of which are currently ongoing.
35880655	1	30	theme	treatment	147:155	arg1	options					157:163	novel treatment options	141:163	novel treatment options against pathogens	141:181	With the concerning rise in antibiotic-resistant infections, novel treatment options against pathogens are urgently sought.
35880655	2	31	from	expression	319:328	arg1	pathogens					341:349	diverse pathogens	333:349	diverse pathogens	333:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	0	32	theme	Pathogen	60:67	arg1	Virulence					69:77	Pathogen Virulence	60:77	Pathogen Virulence	60:77	Synthesis of Mucin O-Glycans Associated with Attenuation of Pathogen Virulence.
35880655	3	33	theme	mucin	564:568	arg1	glycans					570:576	mucin glycans	564:576	mucin glycans	564:576	As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity.
35880655	2	34	from	pathogens	341:349	arg1	mixtures					258:265	mucin O-glycan mixtures	243:265	mucin O-glycan mixtures	243:265	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
35880655	2	34	from	pathogens	341:349	arg1	down-regulators					277:291	potent down-regulators	270:291	potent down-regulators of virulence-related gene expression in diverse pathogens	270:349	Several recent studies have identified mucin O-glycan mixtures as potent down-regulators of virulence-related gene expression in diverse pathogens.
36529080	0	0	theme	active-targeting	71:86	arg1	delivery					88:95	active-targeting delivery	71:95	active-targeting delivery of antisense DNA	71:112	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	9	1	gly	glycosylation	1356:1368	arg1	Dectin-1					1373:1380	Dectin-1	1373:1380	Dectin-1	1373:1380	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	8	2	dep	structure	1180:1188	arg1	the					1176:1178	the	1176:1178	the	1176:1178	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	1	3	theme	binding	139:145	arg1	receptor					147:154	A β-1,3-glucan binding receptor	124:154	A β-1,3-glucan binding receptor called Dectin-1	124:170	A β-1,3-glucan binding receptor called Dectin-1 is mainly expressed on antigen-presenting immunocytes.
36529080	5	4	dep	surface	695:701	arg1	V-1					715:717	designated V-1	704:717	designated V-1	704:717	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	4	dep	surface	695:701	arg1	etc.					725:728	etc.	725:728	etc.	725:728	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	4	dep	surface	695:701	arg1	V-2					720:722	V-2	720:722	V-2	720:722	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	8	5	theme	present	1152:1158	arg1	paper					1160:1164	the present paper	1148:1164	the present paper	1148:1164	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	10	6	theme	other	1612:1616	arg1	variants					1618:1625	two other variants	1608:1625	two other variants that are highly expressed at the plasma membrane and stabilized by the glycosylation	1608:1710	The present findings suggest that, in addition to V-1 and V-2, two other variants that are highly expressed at the plasma membrane and stabilized by the glycosylation may also be targets of the complex.
36529080	9	7	theme	ingestion	1519:1527	arg1	ingestion					1519:1527	ingestion	1519:1527	ingestion of the complex	1519:1542	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	7	theme	ingestion	1519:1527	arg1	amount					1509:1514	the amount	1505:1514	the amount of ingestion of the complex	1505:1542	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	2	8	theme	immune	356:361	arg1	system					363:368	the immune system	352:368	the immune system	352:368	Dectin-1 may be a target molecule for receptor-mediated and active-targeting delivery of drugs to regulate or interfere with the immune system.
36529080	9	9	link	N-linked	1291:1298	arg1	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	9	link	N-linked	1291:1298	arg1	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	9	link	N-linked	1291:1298	arg1	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	5	10	theme	other	852:856	arg1	variants					858:865	other variants	852:865	other variants having an incomplete CRD due to exon skipping	852:911	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	3	11	theme	Therapeutic	371:381	arg1	oligonucleotides					383:398	Therapeutic oligonucleotides	371:398	Therapeutic oligonucleotides	371:398	Therapeutic oligonucleotides are one such drug of interest.
36529080	9	12	theme	complex	1536:1542	arg1	ingestion					1519:1527	ingestion	1519:1527	ingestion of the complex	1519:1542	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	2	13	theme	active-targeting	287:302	arg1	delivery					304:311	receptor-mediated and active-targeting delivery	265:311	receptor-mediated and active-targeting delivery of drugs	265:320	Dectin-1 may be a target molecule for receptor-mediated and active-targeting delivery of drugs to regulate or interfere with the immune system.
36529080	0	14	theme	DNA	110:112	arg1	delivery					88:95	active-targeting delivery	71:95	active-targeting delivery of antisense DNA	71:112	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	8	15	theme	continuing	1131:1140	arg1	nature					1194:1199	nature	1194:1199	nature	1194:1199	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	8	15	theme	continuing	1131:1140	arg1	structure					1180:1188	structure	1180:1188	structure	1180:1188	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	8	15	theme	continuing	1131:1140	arg1	work					1142:1145	a continuing work	1129:1145	a continuing work	1129:1145	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	5	16	contain	having	867:872	arg1	variants					858:865	other variants	852:865	other variants having an incomplete CRD due to exon skipping	852:911	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	16	contain	having	867:872	arg2	CRD					888:890	an incomplete CRD	874:890	an incomplete CRD	874:890	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	0	17	theme	antisense	100:108	arg1	DNA					110:112	antisense DNA	100:112	antisense DNA	100:112	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	4	18	theme	schizophyllan	481:493	arg1	complex					470:476	the complex	466:476	the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells	466:623	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	0	19	theme	variants	32:39	arg1	assay					8:12	Binding assay	0:12	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.	0:122	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	7	20	theme	SPG/oligonucleotide	995:1013	arg1	complexes					1015:1023	SPG/oligonucleotide complexes	995:1023	SPG/oligonucleotide complexes	995:1023	By contrast, SPG/oligonucleotide complexes bind both V-1 and V-2 more strongly than SPG itself and show a certain affinity, for other variants.
36529080	2	21	theme	receptor-mediated	265:281	arg1	delivery					304:311	receptor-mediated and active-targeting delivery	265:311	receptor-mediated and active-targeting delivery of drugs	265:320	Dectin-1 may be a target molecule for receptor-mediated and active-targeting delivery of drugs to regulate or interfere with the immune system.
36529080	9	22	from	fate	1413:1416	arg1	cells					1458:1462	the cells	1454:1462	the cells	1454:1462	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	5	23	theme	no	838:839	arg1	stalk					841:845	no stalk	838:845	no stalk	838:845	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	9	24	theme	new	1287:1289	arg1	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	24	theme	new	1287:1289	arg1	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	24	theme	new	1287:1289	arg1	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	0	25	theme	Binding	0:6	arg1	assay					8:12	Binding assay	0:12	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.	0:122	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	4	26	dep	schizophyllan	481:493	arg1	SPG					496:498	SPG	496:498	SPG	496:498	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	4	26	dep	schizophyllan	481:493	arg1	family					536:541	the linear (1,3)-β-ᴅ-glucan family	508:541	the linear (1,3)-β-ᴅ-glucan family	508:541	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	4	26	dep	schizophyllan	481:493	arg1	one					501:503	one	501:503	one	501:503	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	9	27	theme	Dectin-1	1373:1380	arg1	glycosylation					1356:1368	the glycosylation	1352:1368	the glycosylation of Dectin-1	1352:1380	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	28	dep	related	1494:1500	arg1	related					1494:1500	related	1494:1500	related	1494:1500	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	28	dep	related	1494:1500	arg1	3					1470:1470	3	1470:1470	3	1470:1470	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	28	dep	related	1494:1500	arg1	glycosylation					1477:1489	the glycosylation	1473:1489	the glycosylation	1473:1489	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	0	29	theme	human	17:21	arg1	variants					32:39	human Dectin-1 variants	17:39	human Dectin-1 variants	17:39	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	0	30	dep	assay	8:12	arg1	Part					115:118	Part II	115:121	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.	0:122	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	5	31	theme	human	658:662	arg1	Dectin-1					664:671	human Dectin-1	658:671	human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.)	658:729	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	9	32	from	variants	1338:1345	arg1	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	32	from	variants	1338:1345	arg1	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	32	from	variants	1338:1345	arg1	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	2	33	theme	drugs	316:320	arg1	delivery					304:311	receptor-mediated and active-targeting delivery	265:311	receptor-mediated and active-targeting delivery of drugs	265:320	Dectin-1 may be a target molecule for receptor-mediated and active-targeting delivery of drugs to regulate or interfere with the immune system.
36529080	9	34	theme	important	1391:1399	arg1	role					1401:1404	an important role	1388:1404	an important role	1388:1404	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	4	35	theme	Dectin-1	599:606	arg1	cells					619:623	the Dectin-1 expressing cells	595:623	the Dectin-1 expressing cells	595:623	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	8	36	theme	human	1208:1212	arg1	variants					1223:1230	all human Dectin-1 variants	1204:1230	all human Dectin-1 variants expressed on the cellular surface	1204:1264	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	4	37	theme	family	536:541	arg1	SPG					496:498	SPG	496:498	SPG	496:498	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	4	37	theme	family	536:541	arg1	family					536:541	the linear (1,3)-β-ᴅ-glucan family	508:541	the linear (1,3)-β-ᴅ-glucan family	508:541	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	4	37	theme	family	536:541	arg1	one					501:503	one	501:503	one	501:503	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	5	38	theme	Dectin-1	664:671	arg1	types					649:653	at least six types	636:653	at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.)	636:729	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	8	39	theme	Dectin-1	1214:1221	arg1	variants					1223:1230	all human Dectin-1 variants	1204:1230	all human Dectin-1 variants expressed on the cellular surface	1204:1264	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	5	40	theme	carbohydrate	759:770	arg1	CRD					792:794	CRD	792:794	CRD	792:794	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	40	theme	carbohydrate	759:770	arg1	domain					784:789	a complete carbohydrate recognition domain	748:789	a complete carbohydrate recognition domain (CRD)	748:795	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	3	41	theme	interest	421:428	arg1	drug					413:416	drug	413:416	drug of interest	413:428	Therapeutic oligonucleotides are one such drug of interest.
36529080	4	42	theme	-β-ᴅ-glucan	524:534	arg1	family					536:541	the linear (1,3)-β-ᴅ-glucan family	508:541	the linear (1,3)-β-ᴅ-glucan family	508:541	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	10	43	theme	present	1549:1555	arg1	findings					1557:1564	The present findings	1545:1564	The present findings	1545:1564	The present findings suggest that, in addition to V-1 and V-2, two other variants that are highly expressed at the plasma membrane and stabilized by the glycosylation may also be targets of the complex.
36529080	5	44	theme	recognition	772:782	arg1	CRD					792:794	CRD	792:794	CRD	792:794	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	44	theme	recognition	772:782	arg1	domain					784:789	a complete carbohydrate recognition domain	748:789	a complete carbohydrate recognition domain (CRD)	748:795	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	45	theme	exon	899:902	arg1	skipping					904:911	exon skipping	899:911	exon skipping	899:911	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	1	46	theme	antigen-presenting	195:212	arg1	immunocytes					214:224	antigen-presenting immunocytes	195:224	antigen-presenting immunocytes	195:224	A β-1,3-glucan binding receptor called Dectin-1 is mainly expressed on antigen-presenting immunocytes.
36529080	0	47	theme	Dectin-1	23:30	arg1	variants					32:39	human Dectin-1 variants	17:39	human Dectin-1 variants	17:39	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	9	48	attach	present	1322:1328	arg2	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	48	attach	present	1322:1328	arg2	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	48	attach	present	1322:1328	arg2	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	48	attach	present	1322:1328	arg1	variants					1338:1345	some variants	1333:1345	some variants	1333:1345	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	49	theme	glycosylation	1300:1312	arg1	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	49	theme	glycosylation	1300:1312	arg1	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	49	theme	glycosylation	1300:1312	arg1	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	4	50	theme	expressing	608:617	arg1	cells					619:623	the Dectin-1 expressing cells	595:623	the Dectin-1 expressing cells	595:623	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	0	51	theme	DNA/	45:48	arg1	complex					59:65	DNA/ β-glucan complex	45:65	DNA/ β-glucan complex for active-targeting delivery of antisense DNA	45:112	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	4	52	with	complex	470:476	arg1	oligonucleotide					549:563	oligonucleotide	549:563	oligonucleotide	549:563	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	4	52	with	complex	470:476	arg1	mechanism					582:590	its delivery mechanism	569:590	its delivery mechanism	569:590	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	7	53	theme	certain	1088:1094	arg1	affinity					1096:1103	a certain affinity	1086:1103	a certain affinity	1086:1103	By contrast, SPG/oligonucleotide complexes bind both V-1 and V-2 more strongly than SPG itself and show a certain affinity, for other variants.
36529080	8	54	theme	cellular	1249:1256	arg1	surface					1258:1264	the cellular surface	1245:1264	the cellular surface	1245:1264	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	10	55	theme	plasma	1660:1665	arg1	membrane					1667:1674	the plasma membrane	1656:1674	the plasma membrane	1656:1674	The present findings suggest that, in addition to V-1 and V-2, two other variants that are highly expressed at the plasma membrane and stabilized by the glycosylation may also be targets of the complex.
36529080	9	56	located	present	1322:1328	arg1	variants					1338:1345	some variants	1333:1345	some variants	1333:1345	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	56	located	present	1322:1328	arg2	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	56	located	present	1322:1328	arg2	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	56	located	present	1322:1328	arg2	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	57	theme	Dectin-1	1421:1428	arg1	localization					1438:1449	its localization	1434:1449	its localization in the cells	1434:1462	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	57	theme	Dectin-1	1421:1428	arg1	fate					1413:1416	the fate	1409:1416	the fate of Dectin-1	1409:1428	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	5	58	theme	complete	821:828	arg1	CRD					830:832	a complete CRD	819:832	a complete CRD	819:832	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	9	59	from	localization	1438:1449	arg1	cells					1458:1462	the cells	1454:1462	the cells	1454:1462	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	60	from	present	1322:1328	arg1	variants					1338:1345	some variants	1333:1345	some variants	1333:1345	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	5	61	theme	incomplete	877:886	arg1	CRD					888:890	an incomplete CRD	874:890	an incomplete CRD	874:890	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	8	62	theme	variants	1223:1230	arg1	nature					1194:1199	nature	1194:1199	nature	1194:1199	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	8	62	theme	variants	1223:1230	arg1	structure					1180:1188	structure	1180:1188	structure	1180:1188	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	8	62	theme	variants	1223:1230	arg1	work					1142:1145	a continuing work	1129:1145	a continuing work	1129:1145	As a continuing work, the present paper discusses the structure and nature of all human Dectin-1 variants expressed on the cellular surface.
36529080	4	63	theme	delivery	573:580	arg1	mechanism					582:590	its delivery mechanism	569:590	its delivery mechanism	569:590	To this end, we have been studying the complex of schizophyllan (SPG, one of the linear (1,3)-β-ᴅ-glucan family) with oligonucleotide and its delivery mechanism to the Dectin-1 expressing cells.
36529080	9	64	gly	glycosylation	1300:1312	arg2	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	64	gly	glycosylation	1300:1312	arg2	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	64	gly	glycosylation	1300:1312	arg2	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	64	gly	glycosylation	1300:1312	arg1	variants					1338:1345	some variants	1333:1345	some variants	1333:1345	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	65	dep	present	1322:1328	arg1	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	65	dep	present	1322:1328	arg1	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	65	dep	present	1322:1328	arg1	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	7	66	theme	other	1110:1114	arg1	variants					1116:1123	other variants	1110:1123	other variants	1110:1123	By contrast, SPG/oligonucleotide complexes bind both V-1 and V-2 more strongly than SPG itself and show a certain affinity, for other variants.
36529080	10	67	theme	complex	1739:1745	arg1	targets					1724:1730	targets	1724:1730	targets of the complex	1724:1745	The present findings suggest that, in addition to V-1 and V-2, two other variants that are highly expressed at the plasma membrane and stabilized by the glycosylation may also be targets of the complex.
36529080	5	68	theme	designated	704:713	arg1	V-1					715:717	designated V-1	704:717	designated V-1	704:717	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	68	theme	designated	704:713	arg1	etc.					725:728	etc.	725:728	etc.	725:728	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	68	theme	designated	704:713	arg1	V-2					720:722	V-2	720:722	V-2	720:722	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	6	69	theme	previous	918:925	arg1	studies					927:933	Our previous studies	914:933	Our previous studies	914:933	Our previous studies have shown that SPG binds only to V-1 and V-2.
36529080	2	70	theme	target	245:250	arg1	molecule					252:259	a target molecule	243:259	a target molecule for receptor-mediated and active-targeting delivery of drugs	243:320	Dectin-1 may be a target molecule for receptor-mediated and active-targeting delivery of drugs to regulate or interfere with the immune system.
36529080	2	70	theme	target	245:250	arg1	Dectin-1					227:234	Dectin-1	227:234	Dectin-1	227:234	Dectin-1 may be a target molecule for receptor-mediated and active-targeting delivery of drugs to regulate or interfere with the immune system.
36529080	5	71	theme	complete	750:757	arg1	CRD					792:794	CRD	792:794	CRD	792:794	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	5	71	theme	complete	750:757	arg1	domain					784:789	a complete carbohydrate recognition domain	748:789	a complete carbohydrate recognition domain (CRD)	748:795	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36529080	9	72	dep	plays	1382:1386	arg1	2					1349:1349	2	1349:1349	2	1349:1349	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	0	73	theme	β-glucan	50:57	arg1	complex					59:65	DNA/ β-glucan complex	45:65	DNA/ β-glucan complex for active-targeting delivery of antisense DNA	45:112	Binding assay of human Dectin-1 variants for DNA/ β-glucan complex for active-targeting delivery of antisense DNA: Part II.
36529080	9	74	theme	N-linked	1291:1298	arg1	1					1282:1282	1	1282:1282	1	1282:1282	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	74	theme	N-linked	1291:1298	arg1	present					1322:1328	present	1322:1328	present	1322:1328	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	9	74	theme	N-linked	1291:1298	arg1	site					1314:1317	a new N-linked glycosylation site	1285:1317	a new N-linked glycosylation site	1285:1317	we found that (1) a new N-linked glycosylation site is present in some variants, (2) the glycosylation of Dectin-1 plays an important role in the fate of Dectin-1 and its localization in the cells, and (3) the glycosylation is related to the amount of ingestion of the complex.
36529080	1	75	theme	β-1,3-glucan	126:137	arg1	receptor					147:154	A β-1,3-glucan binding receptor	124:154	A β-1,3-glucan binding receptor called Dectin-1	124:170	A β-1,3-glucan binding receptor called Dectin-1 is mainly expressed on antigen-presenting immunocytes.
36529080	5	76	theme	cell	690:693	arg1	surface					695:701	the cell surface	686:701	the cell surface (designated V-1, V-2, etc.)	686:729	There are at least six types of human Dectin-1 expressed on the cell surface (designated V-1, V-2, etc.), with V-1 having a complete carbohydrate recognition domain (CRD) and stalk, V-2 having a complete CRD but no stalk, and other variants having an incomplete CRD due to exon skipping.
36716113	9	0	with	antibodies	2027:2036	arg1	profile					2079:2085	this unbalanced inflammatory glycan profile	2043:2085	this unbalanced inflammatory glycan profile	2043:2085	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	2	1	theme	burgdorferi	378:388	arg1	antibodies					409:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies	354:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	354:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	6	2	with	percentages	1348:1358	arg1	NeuAC					1469:1473	NeuAC	1469:1473	NeuAC (sialic acid)	1469:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	2	with	percentages	1348:1358	arg1	acid					1483:1486	sialic acid	1476:1486	sialic acid	1476:1486	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	2	with	percentages	1348:1358	arg1	fucose					1436:1441	fucose	1436:1441	fucose	1436:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	2	with	percentages	1348:1358	arg1	galactose					1422:1430	galactose	1422:1430	galactose	1422:1430	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	7	3	theme	synovitis	1544:1552	arg1	therapy					1562:1568	synovitis post-IV therapy	1544:1568	synovitis post-IV therapy	1544:1568	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	9	4	theme	unbalanced	2048:2057	arg1	profile					2079:2085	this unbalanced inflammatory glycan profile	2043:2085	this unbalanced inflammatory glycan profile	2043:2085	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	8	5	theme	antibiotic-responsive	1725:1745	arg1	LA					1747:1748	antibiotic-responsive LA	1725:1748	antibiotic-responsive LA	1725:1748	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	3	6	theme	MALDI-TOF	755:763	arg1	spectrometry					770:781	MALDI-TOF mass spectrometry	755:781	MALDI-TOF mass spectrometry	755:781	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	2	7	with	patients	423:430	arg1	arthritis					489:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis	437:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	437:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	2	7	with	patients	423:430	arg1	LA					500:501	LA	500:501	LA	500:501	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	6	8	theme	Bb-IgG1	1246:1252	arg1	antibodies					1254:1263	Bb-IgG1 antibodies	1246:1263	Bb-IgG1 antibodies	1246:1263	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	9	9	theme	glycan	2072:2077	arg1	profile					2079:2085	this unbalanced inflammatory glycan profile	2043:2085	this unbalanced inflammatory glycan profile	2043:2085	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	3	10	theme	structure	742:750	arg1	glycoblotting					667:679	glycoblotting	667:679	glycoblotting with hydrazide glycan enrichment	667:712	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	3	10	theme	structure	742:750	arg1	determination					718:730	determination	718:730	determination of glycan structure by MALDI-TOF mass spectrometry	718:781	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	6	11	theme	high	1343:1346	arg1	percentages					1348:1358	high percentages	1343:1358	high percentages of GlcNAc and bisecting GlcNAc	1343:1389	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	3	12	theme	antibodies	574:583	arg1	profiles					558:565	glycan profiles	551:565	glycan profiles of IgG antibodies	551:583	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	3	13	theme	synovial	614:621	arg1	SF					630:631	SF	630:631	SF	630:631	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	3	13	theme	synovial	614:621	arg1	fluid					623:627	synovial fluid	614:627	synovial fluid (SF)	614:632	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	1	14	theme	antibodies	206:215	arg1	portion					191:197	the Fc portion	184:197	the Fc portion of IgG antibodies	184:215	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	5	15	theme	fucose	1150:1155	arg1	percentages					1045:1055	lower percentages	1039:1055	lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc	1039:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	15	theme	fucose	1150:1155	arg1	percentages					1121:1131	higher percentages	1114:1131	higher percentages of galactose and fucose	1114:1155	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	3	16	theme	serum	604:608	arg1	samples					634:640	serum and synovial fluid (SF) samples	604:640	serum and synovial fluid (SF) samples of 21 LA patients	604:658	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	6	17	with	percentages	1405:1415	arg1	NeuAC					1469:1473	NeuAC	1469:1473	NeuAC (sialic acid)	1469:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	17	with	percentages	1405:1415	arg1	acid					1483:1486	sialic acid	1476:1486	sialic acid	1476:1486	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	17	with	percentages	1405:1415	arg1	fucose					1436:1441	fucose	1436:1441	fucose	1436:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	17	with	percentages	1405:1415	arg1	galactose					1422:1430	galactose	1422:1430	galactose	1422:1430	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	18	with	antibodies	1254:1263	arg1	profiles					1322:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	0	19	from	Fluid	93:97	arg1	Patients					102:109	Patients	102:109	Patients with Antibiotic-Refractory Lyme Arthritis	102:151	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	8	20	theme	CONCLUSION	1700:1709	arg1	Patients					1711:1718	CONCLUSION Patients	1700:1718	CONCLUSION Patients with antibiotic-responsive LA	1700:1748	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	8	21	theme	Bb-IgG1	1895:1901	arg1	antibodies					1903:1912	Bb-IgG1 antibodies	1895:1912	Bb-IgG1 antibodies	1895:1912	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	1	22	theme	antibody-triggered	234:251	arg1	responses					292:300	antibody-triggered, pro-inflammatory or anti-inflammatory responses	234:300	responses	292:300	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	9	23	theme	maladaptive	2117:2127	arg1	inflammation					2135:2146	maladaptive joint inflammation	2117:2146	maladaptive joint inflammation	2117:2146	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	6	24	theme	intermediate	1392:1403	arg1	percentages					1405:1415	intermediate percentages	1392:1415	intermediate percentages with galactose and fucose	1392:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	25	theme	GlcNAc	1384:1389	arg1	percentages					1405:1415	intermediate percentages	1392:1415	intermediate percentages with galactose and fucose	1392:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	25	theme	GlcNAc	1384:1389	arg1	percentages					1348:1358	high percentages	1343:1358	high percentages of GlcNAc and bisecting GlcNAc	1343:1389	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	25	theme	GlcNAc	1384:1389	arg1	percentages					1452:1462	low percentages	1448:1462	low percentages with NeuAC (sialic acid)	1448:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	5	26	theme	galactose	1136:1144	arg1	percentages					1045:1055	lower percentages	1039:1055	lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc	1039:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	26	theme	galactose	1136:1144	arg1	percentages					1121:1131	higher percentages	1114:1131	higher percentages of galactose and fucose	1114:1155	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	3	27	theme	LA	648:649	arg1	patients					651:658	21 LA patients	645:658	21 LA patients	645:658	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	1	28	theme	Terminal	164:171	arg1	glycans					173:179	OBJECTIVE Terminal glycans	154:179	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies	154:215	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	7	29	with	Patients	1490:1497	arg1	LA					1515:1516	refractory LA	1504:1516	refractory LA	1504:1516	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	6	30	with	percentages	1452:1462	arg1	NeuAC					1469:1473	NeuAC	1469:1473	NeuAC (sialic acid)	1469:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	30	with	percentages	1452:1462	arg1	acid					1483:1486	sialic acid	1476:1486	sialic acid	1476:1486	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	30	with	percentages	1452:1462	arg1	fucose					1436:1441	fucose	1436:1441	fucose	1436:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	30	with	percentages	1452:1462	arg1	galactose					1422:1430	galactose	1422:1430	galactose	1422:1430	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	5	31	theme	Bb-specific	953:963	arg1	glycans					979:985	total and Bb-specific IgG1 antibody glycans	943:985	total and Bb-specific IgG1 antibody glycans	943:985	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	7	32	theme	inflammatory	1654:1665	arg1	potential					1667:1675	their inflammatory potential	1648:1675	their inflammatory potential	1648:1675	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	1	33	theme	Fc	188:189	arg1	portion					191:197	the Fc portion	184:197	the Fc portion of IgG antibodies	184:215	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	5	34	contain	had	939:941	arg1	those					903:907	those	903:907	those	903:907	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	34	contain	had	939:941	arg2	glycans					979:985	total and Bb-specific IgG1 antibody glycans	943:985	total and Bb-specific IgG1 antibody glycans	943:985	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	6	35	theme	low	1448:1450	arg1	percentages					1452:1462	low percentages	1448:1462	low percentages with NeuAC (sialic acid)	1448:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	1	36	from	glycans	173:179	arg1	portion					191:197	the Fc portion	184:197	the Fc portion of IgG antibodies	184:215	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	5	37	theme	intense	997:1003	arg1	profiles					1018:1025	less intense inflammatory profiles	992:1025	less intense inflammatory profiles	992:1025	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	4	38	theme	treatment	821:829	arg1	outcomes					831:838	treatment outcomes	821:838	treatment outcomes	821:838	Glycan profiles were correlated with treatment outcomes.
36716113	0	39	theme	Antibiotic-Refractory	116:136	arg1	Arthritis					143:151	Antibiotic-Refractory Lyme Arthritis	116:151	Antibiotic-Refractory Lyme Arthritis	116:151	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	5	40	theme	N-acetylglucosamine	1060:1078	arg1	percentages					1045:1055	lower percentages	1039:1055	lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc	1039:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	40	theme	N-acetylglucosamine	1060:1078	arg1	percentages					1121:1131	higher percentages	1114:1131	higher percentages of galactose and fucose	1114:1155	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	41	with	glycans	979:985	arg1	profiles					1018:1025	less intense inflammatory profiles	992:1025	less intense inflammatory profiles	992:1025	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	0	42	theme	Synovial	84:91	arg1	Fluid					93:97	Synovial Fluid	84:97	Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis	84:151	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	2	43	theme	IgG1	404:407	arg1	antibodies					409:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies	354:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	354:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	2	44	theme	Lyme	484:487	arg1	arthritis					489:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis	437:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	437:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	2	44	theme	Lyme	484:487	arg1	LA					500:501	LA	500:501	LA	500:501	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	5	45	theme	antibiotic-refractory	877:897	arg1	LA					899:900	antibiotic-refractory LA	877:900	antibiotic-refractory LA	877:900	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	46	theme	GlcNAc	1103:1108	arg1	percentages					1045:1055	lower percentages	1039:1055	lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc	1039:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	46	theme	GlcNAc	1103:1108	arg1	percentages					1121:1131	higher percentages	1114:1131	higher percentages of galactose and fucose	1114:1155	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	3	47	theme	column	532:537	arg1	processing					539:548	affinity column processing	523:548	affinity column processing	523:548	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	0	48	theme	IgG	66:68	arg1	Antibodies					70:79	Borrelia burgdorferi IgG Antibodies	45:79	Borrelia burgdorferi IgG Antibodies	45:79	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	8	49	contain	had	1891:1893	arg1	patients					1852:1859	patients	1852:1859	patients with antibiotic-refractory LA	1852:1889	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	8	49	contain	had	1891:1893	arg2	antibodies					1903:1912	Bb-IgG1 antibodies	1895:1912	Bb-IgG1 antibodies	1895:1912	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	5	50	theme	higher	1114:1119	arg1	percentages					1121:1131	higher percentages	1114:1131	higher percentages of galactose and fucose	1114:1155	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	6	51	theme	pre-IV	1211:1216	arg1	LA					1207:1208	antibiotic-refractory LA	1185:1208	antibiotic-refractory LA	1185:1208	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	51	theme	pre-IV	1211:1216	arg1	therapy					1218:1224	pre-IV therapy	1211:1224	pre-IV therapy	1211:1224	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	9	52	theme	antibiotic	2001:2010	arg1	LA					2023:2024	antibiotic refractory LA	2001:2024	antibiotic refractory LA	2001:2024	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	2	53	theme	IgG1	360:363	arg1	antibodies					409:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies	354:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	354:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	3	54	theme	hydrazide	686:694	arg1	enrichment					703:712	hydrazide glycan enrichment	686:712	hydrazide glycan enrichment	686:712	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	8	55	theme	Bb-IgG1	1754:1760	arg1	antibodies					1762:1771	Bb-IgG1 antibodies	1754:1771	Bb-IgG1 antibodies	1754:1771	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	7	56	theme	post-IV	1554:1560	arg1	therapy					1562:1568	synovitis post-IV therapy	1544:1568	synovitis post-IV therapy	1544:1568	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	3	57	theme	glycan	735:740	arg1	structure					742:750	glycan structure	735:750	glycan structure	735:750	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	6	58	theme	bisecting	1374:1382	arg1	GlcNAc					1384:1389	bisecting GlcNAc	1374:1389	bisecting GlcNAc	1374:1389	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	3	59	with	determination	718:730	arg1	enrichment					703:712	hydrazide glycan enrichment	686:712	hydrazide glycan enrichment	686:712	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	6	60	contain	had	1227:1229	arg2	antibodies					1254:1263	Bb-IgG1 antibodies	1246:1263	Bb-IgG1 antibodies	1246:1263	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	60	contain	had	1227:1229	arg2	IgG1					1237:1240	total IgG1	1231:1240	total IgG1	1231:1240	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	60	contain	had	1227:1229	arg1	patients					1171:1178	patients	1171:1178	patients with antibiotic-refractory LA, pre-IV therapy,	1171:1225	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	61	theme	GlcNAc	1363:1368	arg1	percentages					1405:1415	intermediate percentages	1392:1415	intermediate percentages with galactose and fucose	1392:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	61	theme	GlcNAc	1363:1368	arg1	percentages					1348:1358	high percentages	1343:1358	high percentages of GlcNAc and bisecting GlcNAc	1343:1389	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	61	theme	GlcNAc	1363:1368	arg1	percentages					1452:1462	low percentages	1448:1462	low percentages with NeuAC (sialic acid)	1448:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	9	62	with	patients	1987:1994	arg1	LA					2023:2024	antibiotic refractory LA	2001:2024	antibiotic refractory LA	2001:2024	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	8	63	theme	balanced	1783:1790	arg1	profiles					1834:1841	more balanced pro-inflammatory/anti-inflammatory glycan profiles	1778:1841	more balanced pro-inflammatory/anti-inflammatory glycan profiles	1778:1841	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	6	64	with	patients	1171:1178	arg1	LA					1207:1208	antibiotic-refractory LA	1185:1208	antibiotic-refractory LA	1185:1208	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	64	with	patients	1171:1178	arg1	therapy					1218:1224	pre-IV therapy	1211:1224	pre-IV therapy	1211:1224	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	9	65	theme	inflammatory	2059:2070	arg1	profile					2079:2085	this unbalanced inflammatory glycan profile	2043:2085	this unbalanced inflammatory glycan profile	2043:2085	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	3	66	theme	mass	765:768	arg1	spectrometry					770:781	MALDI-TOF mass spectrometry	755:781	MALDI-TOF mass spectrometry	755:781	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	3	67	theme	IgG	570:572	arg1	antibodies					574:583	IgG antibodies	570:583	IgG antibodies	570:583	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	8	68	theme	glycan	1827:1832	arg1	profiles					1834:1841	more balanced pro-inflammatory/anti-inflammatory glycan profiles	1778:1841	more balanced pro-inflammatory/anti-inflammatory glycan profiles	1778:1841	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	5	69	theme	antibiotic-responsive	914:934	arg1	LA					936:937	antibiotic-responsive LA	914:937	antibiotic-responsive LA	914:937	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	7	70	theme	refractory	1504:1513	arg1	LA					1515:1516	refractory LA	1504:1516	refractory LA	1504:1516	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	1	71	theme	IgG	202:204	arg1	antibodies					206:215	IgG antibodies	202:215	IgG antibodies	202:215	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	6	72	theme	total	1231:1235	arg1	IgG1					1237:1240	total IgG1	1231:1240	total IgG1	1231:1240	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	5	73	contain	containing	1028:1037	arg2	percentages					1121:1131	higher percentages	1114:1131	higher percentages of galactose and fucose	1114:1155	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	73	contain	containing	1028:1037	arg2	percentages					1045:1055	lower percentages	1039:1055	lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc	1039:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	73	contain	containing	1028:1037	arg1	glycans					979:985	total and Bb-specific IgG1 antibody glycans	943:985	total and Bb-specific IgG1 antibody glycans	943:985	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	7	74	contain	had	1577:1579	arg1	Patients					1490:1497	Patients	1490:1497	Patients	1490:1497	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	7	74	contain	had	1577:1579	arg2	antibodies					1589:1598	Bb-IgG1 antibodies	1581:1598	Bb-IgG1 antibodies	1581:1598	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	5	75	with	patients	863:870	arg1	LA					899:900	antibiotic-refractory LA	877:900	antibiotic-refractory LA	877:900	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	0	76	with	Patients	102:109	arg1	Arthritis					143:151	Antibiotic-Refractory Lyme Arthritis	116:151	Antibiotic-Refractory Lyme Arthritis	116:151	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	2	77	theme	glycan	335:340	arg1	profiles					342:349	glycan profiles	335:349	glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	335:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	5	78	theme	antibody	970:977	arg1	glycans					979:985	total and Bb-specific IgG1 antibody glycans	943:985	total and Bb-specific IgG1 antibody glycans	943:985	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	8	79	with	Patients	1711:1718	arg1	LA					1747:1748	antibiotic-responsive LA	1725:1748	antibiotic-responsive LA	1725:1748	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	8	80	theme	antibiotic-refractory	1866:1886	arg1	LA					1888:1889	antibiotic-refractory LA	1866:1889	antibiotic-refractory LA	1866:1889	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	3	81	with	glycoblotting	667:679	arg1	enrichment					703:712	hydrazide glycan enrichment	686:712	hydrazide glycan enrichment	686:712	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	6	82	theme	glycan	1315:1320	arg1	profiles					1322:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	3	83	theme	fluid	623:627	arg1	samples					634:640	serum and synovial fluid (SF) samples	604:640	serum and synovial fluid (SF) samples of 21 LA patients	604:658	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	6	84	with	IgG1	1237:1240	arg1	profiles					1322:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	9	85	theme	joint	2129:2133	arg1	inflammation					2135:2146	maladaptive joint inflammation	2117:2146	maladaptive joint inflammation	2117:2146	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	6	86	dep	maximal	1270:1276	arg1	pro-inflammatory					1298:1313	pro-inflammatory	1298:1313	pro-inflammatory	1298:1313	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	86	dep	maximal	1270:1276	arg1	opposed					1289:1295	opposed	1289:1295	opposed	1289:1295	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	1	87	theme	OBJECTIVE	154:162	arg1	glycans					173:179	OBJECTIVE Terminal glycans	154:179	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies	154:215	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	5	88	theme	total	943:947	arg1	glycans					979:985	total and Bb-specific IgG1 antibody glycans	943:985	total and Bb-specific IgG1 antibody glycans	943:985	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	6	89	theme	sialic	1476:1481	arg1	NeuAC					1469:1473	NeuAC	1469:1473	NeuAC (sialic acid)	1469:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	89	theme	sialic	1476:1481	arg1	acid					1483:1486	sialic acid	1476:1486	sialic acid	1476:1486	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	8	90	contain	had	1750:1752	arg1	Patients					1711:1718	CONCLUSION Patients	1700:1718	CONCLUSION Patients with antibiotic-responsive LA	1700:1748	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	8	90	contain	had	1750:1752	arg2	antibodies					1762:1771	Bb-IgG1 antibodies	1754:1771	Bb-IgG1 antibodies	1754:1771	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	8	91	theme	maximal	1919:1925	arg1	profiles					1971:1978	maximal, minimally opposed, pro-inflammatory glycan profiles	1919:1978	maximal, minimally opposed, pro-inflammatory glycan profiles	1919:1978	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	6	92	theme	maximal	1270:1276	arg1	profiles					1322:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	maximal, minimally opposed, pro-inflammatory glycan profiles	1270:1329	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	8	93	dep	had	1750:1752	arg1	whereas					1844:1850	whereas	1844:1850	whereas	1844:1850	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	5	94	theme	IgG1	965:968	arg1	glycans					979:985	total and Bb-specific IgG1 antibody glycans	943:985	total and Bb-specific IgG1 antibody glycans	943:985	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	5	95	theme	lower	1039:1043	arg1	percentages					1045:1055	lower percentages	1039:1055	lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc	1039:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	2	96	from	profiles	342:349	arg1	patients					423:430	patients	423:430	patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	423:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	7	97	theme	glycan	1627:1632	arg1	profiles					1634:1641	strongly inflammatory glycan profiles	1605:1641	strongly inflammatory glycan profiles	1605:1641	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	3	98	theme	affinity	523:530	arg1	processing					539:548	affinity column processing	523:548	affinity column processing	523:548	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	0	99	theme	Lyme	138:141	arg1	Arthritis					143:151	Antibiotic-Refractory Lyme Arthritis	116:151	Antibiotic-Refractory Lyme Arthritis	116:151	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	8	100	theme	glycan	1964:1969	arg1	profiles					1971:1978	maximal, minimally opposed, pro-inflammatory glycan profiles	1919:1978	maximal, minimally opposed, pro-inflammatory glycan profiles	1919:1978	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	2	101	theme	antibodies	409:418	arg1	profiles					342:349	glycan profiles	335:349	glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	335:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	0	102	theme	Pro-inflammatory	11:26	arg1	Glycosylation					28:40	Pro-inflammatory Glycosylation	11:40	Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies	11:79	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	5	103	theme	inflammatory	1005:1016	arg1	profiles					1018:1025	less intense inflammatory profiles	992:1025	less intense inflammatory profiles	992:1025	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	8	104	with	patients	1852:1859	arg1	LA					1888:1889	antibiotic-refractory LA	1866:1889	antibiotic-refractory LA	1866:1889	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	2	105	theme	-specific	394:402	arg1	antibodies					409:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies	354:418	total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	354:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	8	106	theme	pro-inflammatory/anti-inflammatory	1792:1825	arg1	profiles					1834:1841	more balanced pro-inflammatory/anti-inflammatory glycan profiles	1778:1841	more balanced pro-inflammatory/anti-inflammatory glycan profiles	1778:1841	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	6	107	contain	containing	1332:1341	arg2	percentages					1348:1358	high percentages	1343:1358	high percentages of GlcNAc and bisecting GlcNAc	1343:1389	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	107	contain	containing	1332:1341	arg2	percentages					1452:1462	low percentages	1448:1462	low percentages with NeuAC (sialic acid)	1448:1487	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	107	contain	containing	1332:1341	arg1	IgG1					1237:1240	total IgG1	1231:1240	total IgG1	1231:1240	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	107	contain	containing	1332:1341	arg2	percentages					1405:1415	intermediate percentages	1392:1415	intermediate percentages with galactose and fucose	1392:1441	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	2	108	theme	antibiotic-refractory	462:482	arg1	arthritis					489:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis	437:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	437:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	2	108	theme	antibiotic-refractory	462:482	arg1	LA					500:501	LA	500:501	LA	500:501	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	4	109	theme	Glycan	784:789	arg1	profiles					791:798	Glycan profiles	784:798	Glycan profiles	784:798	Glycan profiles were correlated with treatment outcomes.
36716113	2	110	theme	antibiotic-responsive	437:457	arg1	arthritis					489:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis	437:497	antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	437:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	2	110	theme	antibiotic-responsive	437:457	arg1	LA					500:501	LA	500:501	LA	500:501	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	0	111	theme	burgdorferi	54:64	arg1	Antibodies					70:79	Borrelia burgdorferi IgG Antibodies	45:79	Borrelia burgdorferi IgG Antibodies	45:79	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	7	112	theme	inflammatory	1614:1625	arg1	profiles					1634:1641	strongly inflammatory glycan profiles	1605:1641	strongly inflammatory glycan profiles	1605:1641	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	5	113	theme	bisecting	1093:1101	arg1	GlcNAc					1103:1108	bisecting GlcNAc	1093:1108	bisecting GlcNAc	1093:1108	RESULTS Compared with patients with antibiotic-refractory LA, those with antibiotic-responsive LA had total and Bb-specific IgG1 antibody glycans with less intense inflammatory profiles, containing lower percentages of N-acetylglucosamine (GlcNAc) and bisecting GlcNAc and higher percentages of galactose and fucose.
36716113	3	114	theme	patients	651:658	arg1	samples					634:640	serum and synovial fluid (SF) samples	604:640	serum and synovial fluid (SF) samples of 21 LA patients	604:658	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	0	115	theme	Antibodies	70:79	arg1	Glycosylation					28:40	Pro-inflammatory Glycosylation	11:40	Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies	11:79	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	0	116	gly	Glycosylation	28:40	arg1	Antibodies					70:79	Borrelia burgdorferi IgG Antibodies	45:79	Borrelia burgdorferi IgG Antibodies	45:79	Heightened Pro-inflammatory Glycosylation of Borrelia burgdorferi IgG Antibodies in Synovial Fluid in Patients with Antibiotic-Refractory Lyme Arthritis.
36716113	3	117	theme	glycan	696:701	arg1	enrichment					703:712	hydrazide glycan enrichment	686:712	hydrazide glycan enrichment	686:712	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	3	118	theme	glycan	551:556	arg1	profiles					558:565	glycan profiles	551:565	glycan profiles of IgG antibodies	551:583	METHODS Following affinity column processing, glycan profiles of IgG antibodies were determined in serum and synovial fluid (SF) samples of 21 LA patients, using glycoblotting with hydrazide glycan enrichment and determination of glycan structure by MALDI-TOF mass spectrometry.
36716113	7	119	theme	Bb-IgG1	1581:1587	arg1	antibodies					1589:1598	Bb-IgG1 antibodies	1581:1598	Bb-IgG1 antibodies	1581:1598	Patients with refractory LA, who were first seen with synovitis post-IV therapy, still had Bb-IgG1 antibodies with strongly inflammatory glycan profiles, but their inflammatory potential appeared to be waning.
36716113	2	120	from	antibodies	409:418	arg1	patients					423:430	patients	423:430	patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	423:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	9	121	theme	refractory	2012:2021	arg1	LA					2023:2024	antibiotic refractory LA	2001:2024	antibiotic refractory LA	2001:2024	Among patients with antibiotic refractory LA, antibodies with this unbalanced inflammatory glycan profile may play a role in sustaining maladaptive joint inflammation.
36716113	2	122	theme	total	354:358	arg1	Bb					391:392	Bb	391:392	Bb	391:392	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	2	122	theme	total	354:358	arg1	IgG1					360:363	total IgG1	354:363	total IgG1	354:363	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	1	123	theme	pro-inflammatory	254:269	arg1	responses					292:300	antibody-triggered, pro-inflammatory or anti-inflammatory responses	234:300	responses	292:300	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
36716113	2	124	from	patients	423:430	arg1	profiles					342:349	glycan profiles	335:349	glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA)	335:502	Herein, our goal was to compare glycan profiles of total IgG1 and Borrelia burgdorferi (Bb)-specific IgG1 antibodies in patients with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA).
36716113	6	125	theme	antibiotic-refractory	1185:1205	arg1	LA					1207:1208	antibiotic-refractory LA	1185:1208	antibiotic-refractory LA	1185:1208	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	6	125	theme	antibiotic-refractory	1185:1205	arg1	therapy					1218:1224	pre-IV therapy	1211:1224	pre-IV therapy	1211:1224	In contrast, patients with antibiotic-refractory LA, pre-IV therapy, had total IgG1 and Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles, containing high percentages of GlcNAc and bisecting GlcNAc, intermediate percentages with galactose and fucose, and low percentages with NeuAC (sialic acid).
36716113	8	126	dep	maximal	1919:1925	arg1	pro-inflammatory					1947:1962	pro-inflammatory	1947:1962	pro-inflammatory	1947:1962	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	8	126	dep	maximal	1919:1925	arg1	opposed					1938:1944	opposed	1938:1944	opposed	1938:1944	CONCLUSION Patients with antibiotic-responsive LA had Bb-IgG1 antibodies with more balanced pro-inflammatory/anti-inflammatory glycan profiles, whereas patients with antibiotic-refractory LA had Bb-IgG1 antibodies with maximal, minimally opposed, pro-inflammatory glycan profiles.
36716113	1	127	theme	anti-inflammatory	274:290	arg1	responses					292:300	antibody-triggered, pro-inflammatory or anti-inflammatory responses	234:300	responses	292:300	OBJECTIVE Terminal glycans on the Fc portion of IgG antibodies are critical for antibody-triggered, pro-inflammatory or anti-inflammatory responses.
35234142	1	0	gly	Transglycosylating	96:113	arg0	hydrolases					125:134	Transglycosylating glycoside hydrolases	96:134	Transglycosylating glycoside hydrolases (GHs)	96:140	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	1	0	gly	Transglycosylating	96:113	arg0	GHs					137:139	GHs	137:139	GHs	137:139	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	3	1	theme	glycan	357:362	arg1	synthesis					364:372	glycan synthesis	357:372	glycan synthesis	357:372	Obtaining efficient enzymatic tools for glycan synthesis with GHs remains dependent on an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation.
35234142	5	2	dep	oligosaccharides	790:805	arg1	size					820:823	the size	816:823	oligosaccharides at least the size of cellotetraose as the donor and cellotriose	790:869	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	1	3	theme	enzymatic	172:180	arg1	synthesis					182:190	the enzymatic synthesis	168:190	the enzymatic synthesis of oligosaccharides	168:210	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	5	4	theme	cellotetraose	828:840	arg1	size					820:823	the size	816:823	oligosaccharides at least the size of cellotetraose as the donor and cellotriose	790:869	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	5	5	theme	donor	709:713	arg1	sugars					715:720	the acceptor and donor sugars	692:720	sugars	715:720	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	7	6	from	RBcel1_E135Q	1289:1300	arg1	complex					1305:1311	complex	1305:1311	complex with cellotriose	1305:1328	The structure of RBcel1_E135Q in complex with cellotriose allowed a +3 subsite to be defined, in accordance with the requirement for cellotriose as a transglycosylation acceptor.
35234142	8	7	theme	transglycosylation	1512:1529	arg1	intermediates					1531:1543	several transglycosylation intermediates	1504:1543	several transglycosylation intermediates	1504:1543	The structure of RBcel1_Y201F has been obtained with several transglycosylation intermediates, providing crystallographic evidence of transglycosylation.
35234142	6	8	with	complex	1173:1179	arg1	ligands					1186:1192	ligands	1186:1192	ligands	1186:1192	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	5	9	theme	sugars	715:720	arg1	size					684:687	The size	680:687	The size of the acceptor and donor sugars	680:720	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	5	9	theme	sugars	715:720	arg1	critical					738:745	critical	738:745	critical	738:745	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	9	10	dep	donors	1644:1649	arg1	i					1641:1641	i	1641:1641	i	1641:1641	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	10	11	theme	first	1837:1841	arg1	structure					1843:1851	the first structure	1833:1851	the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified	1833:1992	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	10	11	theme	first	1837:1841	arg1	it					1827:1828	it	1827:1828	it	1827:1828	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	3	12	theme	an improved	404:414	arg1	understanding					416:428	an improved understanding	404:428	an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation	404:517	Obtaining efficient enzymatic tools for glycan synthesis with GHs remains dependent on an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation.
35234142	7	13	from	complex	1305:1311	arg1	structure					1276:1284	The structure	1272:1284	The structure of RBcel1_E135Q in complex with cellotriose	1272:1328	The structure of RBcel1_E135Q in complex with cellotriose allowed a +3 subsite to be defined, in accordance with the requirement for cellotriose as a transglycosylation acceptor.
35234142	7	14	theme	RBcel1_E135Q	1289:1300	arg1	structure					1276:1284	The structure	1272:1284	The structure of RBcel1_E135Q in complex with cellotriose	1272:1328	The structure of RBcel1_E135Q in complex with cellotriose allowed a +3 subsite to be defined, in accordance with the requirement for cellotriose as a transglycosylation acceptor.
35234142	10	15	from	enzyme	1862:1867	arg1	complex					1872:1878	complex	1872:1878	complex with transglycosylation products	1872:1911	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	0	16	theme	GH5_5	61:65	arg1	RBcel1					88:93	the GH5_5 endo-1,4-β-glucanase RBcel1	57:93	the GH5_5 endo-1,4-β-glucanase RBcel1	57:93	Highlighting the factors governing transglycosylation in the GH5_5 endo-1,4-β-glucanase RBcel1.
35234142	4	17	theme	structural	539:548	arg1	study					550:554	This enzymatic and structural study	520:554	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium,	520:648	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	5	18	dep	donor	849:853	arg1	the					845:847	the	845:847	the	845:847	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	10	19	with	complex	1872:1878	arg1	products					1904:1911	transglycosylation products	1885:1911	transglycosylation products	1885:1911	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	6	20	theme	variants	1129:1136	arg1	structures					1104:1113	the structures	1100:1113	the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands	1100:1192	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	4	21	theme	RBcel1	559:564	arg1	study					550:554	This enzymatic and structural study	520:554	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium,	520:648	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	1	22	theme	Transglycosylating	96:113	arg1	hydrolases					125:134	Transglycosylating glycoside hydrolases	96:134	Transglycosylating glycoside hydrolases (GHs)	96:140	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	1	22	theme	Transglycosylating	96:113	arg1	GHs					137:139	GHs	137:139	GHs	137:139	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	10	23	from	complex	1872:1878	arg1	structure					1843:1851	the first structure	1833:1851	the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified	1833:1992	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	10	23	from	complex	1872:1878	arg1	it					1827:1828	it	1827:1828	it	1827:1828	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	1	24	theme	oligosaccharides	195:210	arg1	synthesis					182:190	the enzymatic synthesis	168:190	the enzymatic synthesis of oligosaccharides	168:210	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	9	25	dep	cellobiose	1726:1735	arg1	ii					1722:1723	ii	1722:1723	ii	1722:1723	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	4	26	theme	uncultured	628:637	arg1	bacterium					639:647	an uncultured bacterium	625:647	an uncultured bacterium	625:647	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	1	27	theme	glycoside	115:123	arg1	hydrolases					125:134	Transglycosylating glycoside hydrolases	96:134	Transglycosylating glycoside hydrolases (GHs)	96:140	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	1	27	theme	glycoside	115:123	arg1	GHs					137:139	GHs	137:139	GHs	137:139	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	3	28	theme	molecular	437:445	arg1	factors					447:453	the molecular factors	433:453	the molecular factors governing the balance between hydrolysis and transglycosylation	433:517	Obtaining efficient enzymatic tools for glycan synthesis with GHs remains dependent on an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation.
35234142	5	29	theme	acceptor	696:703	arg1	sugars					715:720	the acceptor and donor sugars	692:720	sugars	715:720	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	6	30	from	structures	1104:1113	arg1	complex					1173:1179	complex	1173:1179	complex with ligands	1173:1192	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	10	31	theme	transglycosylation	1885:1902	arg1	products					1904:1911	transglycosylation products	1885:1911	transglycosylation products	1885:1911	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	7	32	theme	transglycosylation	1422:1439	arg1	acceptor					1441:1448	a transglycosylation acceptor	1420:1448	a transglycosylation acceptor	1420:1448	The structure of RBcel1_E135Q in complex with cellotriose allowed a +3 subsite to be defined, in accordance with the requirement for cellotriose as a transglycosylation acceptor.
35234142	9	33	theme	negative	1699:1706	arg1	subsites					1708:1715	the negative subsites	1695:1715	the negative subsites	1695:1715	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	9	34	from	cellotriose	1741:1751	arg1	subsites					1769:1776	the positive subsites	1756:1776	the positive subsites	1756:1776	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	8	35	theme	several	1504:1510	arg1	intermediates					1531:1543	several transglycosylation intermediates	1504:1543	several transglycosylation intermediates	1504:1543	The structure of RBcel1_Y201F has been obtained with several transglycosylation intermediates, providing crystallographic evidence of transglycosylation.
35234142	4	36	attach	isolated	611:618	arg1	bacterium					639:647	an uncultured bacterium	625:647	an uncultured bacterium	625:647	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	4	36	attach	isolated	611:618	arg2	subfamily					601:609	the GH5_5 subfamily	591:609	the GH5_5 subfamily isolated from an uncultured bacterium	591:647	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	5	37	with	efficient	775:783	arg1	oligosaccharides					790:805	oligosaccharides	790:805	oligosaccharides at least the size of cellotetraose as the donor and cellotriose	790:869	The size of the acceptor and donor sugars was found to be critical since transglycosylation is efficient with oligosaccharides at least the size of cellotetraose as the donor and cellotriose as the acceptor.
35234142	0	38	theme	endo-1,4-β-glucanase	67:86	arg1	RBcel1					88:93	the GH5_5 endo-1,4-β-glucanase RBcel1	57:93	the GH5_5 endo-1,4-β-glucanase RBcel1	57:93	Highlighting the factors governing transglycosylation in the GH5_5 endo-1,4-β-glucanase RBcel1.
35234142	9	39	theme	positive	1760:1767	arg1	subsites					1769:1776	the positive subsites	1756:1776	the positive subsites	1756:1776	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	2	40	theme	unique	260:265	arg1	strategy					267:274	no unique strategy	257:274	no unique strategy to improve the transglycosylation yield	257:314	Although knowledge is progressing, there is no unique strategy to improve the transglycosylation yield.
35234142	4	41	from	subfamily	601:609	arg1	RBcel1					559:564	RBcel1	559:564	RBcel1	559:564	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	4	41	from	subfamily	601:609	arg1	transglycosylase					569:584	a transglycosylase	567:584	a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium	567:647	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	4	42	theme	GH5_5	595:599	arg1	subfamily					601:609	the GH5_5 subfamily	591:609	the GH5_5 subfamily isolated from an uncultured bacterium	591:647	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	3	43	theme	factors	447:453	arg1	understanding					416:428	an improved understanding	404:428	an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation	404:517	Obtaining efficient enzymatic tools for glycan synthesis with GHs remains dependent on an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation.
35234142	6	44	theme	pH	1008:1009	arg1	values					1011:1016	pH values	1008:1016	pH values below 8	1008:1024	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	4	45	theme	enzymatic	525:533	arg1	study					550:554	This enzymatic and structural study	520:554	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium,	520:648	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	10	46	theme	enzyme	1862:1867	arg1	structure					1843:1851	the first structure	1833:1851	the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified	1833:1992	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	10	46	theme	enzyme	1862:1867	arg1	it					1827:1828	it	1827:1828	it	1827:1828	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	10	47	theme	glutamate	1966:1974	arg1	residues					1976:1983	the catalytic glutamate residues	1952:1983	the catalytic glutamate residues modified	1952:1992	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	8	48	theme	transglycosylation	1585:1602	arg1	evidence					1573:1580	crystallographic evidence	1556:1580	crystallographic evidence of transglycosylation	1556:1602	The structure of RBcel1_Y201F has been obtained with several transglycosylation intermediates, providing crystallographic evidence of transglycosylation.
35234142	10	49	theme	catalytic	1956:1964	arg1	residues					1976:1983	the catalytic glutamate residues	1952:1983	the catalytic glutamate residues modified	1952:1992	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	10	50	theme	GH5	1858:1860	arg1	enzyme					1862:1867	a GH5 enzyme	1856:1867	a GH5 enzyme in complex with transglycosylation products	1856:1911	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	7	51	with	complex	1305:1311	arg1	cellotriose					1318:1328	cellotriose	1318:1328	cellotriose	1318:1328	The structure of RBcel1_E135Q in complex with cellotriose allowed a +3 subsite to be defined, in accordance with the requirement for cellotriose as a transglycosylation acceptor.
35234142	3	52	theme	efficient	327:335	arg1	tools					347:351	efficient enzymatic tools	327:351	efficient enzymatic tools for glycan synthesis	327:372	Obtaining efficient enzymatic tools for glycan synthesis with GHs remains dependent on an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation.
35234142	6	53	theme	reaction	892:899	arg1	important					907:915	important	907:915	important	907:915	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	6	53	theme	reaction	892:899	arg1	pH					901:902	The reaction pH	888:902	The reaction pH	888:902	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	0	54	gly	transglycosylation	35:52	arg1	RBcel1					88:93	the GH5_5 endo-1,4-β-glucanase RBcel1	57:93	the GH5_5 endo-1,4-β-glucanase RBcel1	57:93	Highlighting the factors governing transglycosylation in the GH5_5 endo-1,4-β-glucanase RBcel1.
35234142	1	55	theme	great	148:152	arg1	potential					154:162	great potential	148:162	great potential for the enzymatic synthesis of oligosaccharides	148:210	Transglycosylating glycoside hydrolases (GHs) offer great potential for the enzymatic synthesis of oligosaccharides.
35234142	3	56	theme	enzymatic	337:345	arg1	tools					347:351	efficient enzymatic tools	327:351	efficient enzymatic tools for glycan synthesis	327:372	Obtaining efficient enzymatic tools for glycan synthesis with GHs remains dependent on an improved understanding of the molecular factors governing the balance between hydrolysis and transglycosylation.
35234142	7	57	from	structure	1276:1284	arg1	complex					1305:1311	complex	1305:1311	complex with cellotriose	1305:1328	The structure of RBcel1_E135Q in complex with cellotriose allowed a +3 subsite to be defined, in accordance with the requirement for cellotriose as a transglycosylation acceptor.
35234142	8	58	theme	RBcel1_Y201F	1468:1479	arg1	structure					1455:1463	The structure	1451:1463	The structure of RBcel1_Y201F	1451:1479	The structure of RBcel1_Y201F has been obtained with several transglycosylation intermediates, providing crystallographic evidence of transglycosylation.
35234142	9	59	from	donors	1644:1649	arg1	subsites					1769:1776	the positive subsites	1756:1776	the positive subsites	1756:1776	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	4	60	theme	such	666:669	arg1	factors					671:677	such factors	666:677	such factors	666:677	This enzymatic and structural study of RBcel1, a transglycosylase from the GH5_5 subfamily isolated from an uncultured bacterium, aims to unravel such factors.
35234142	8	61	theme	crystallographic	1556:1571	arg1	evidence					1573:1580	crystallographic evidence	1556:1580	crystallographic evidence of transglycosylation	1556:1602	The structure of RBcel1_Y201F has been obtained with several transglycosylation intermediates, providing crystallographic evidence of transglycosylation.
35234142	9	62	from	cellobiose	1726:1735	arg1	subsites					1769:1776	the positive subsites	1756:1776	the positive subsites	1756:1776	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	9	63	theme	catalytic	1609:1617	arg1	cleft					1619:1623	The catalytic cleft	1605:1623	The catalytic cleft	1605:1623	The catalytic cleft is filled with (i) donors ranging from cellotriose to cellohexaose in the negative subsites and (ii) cellobiose and cellotriose in the positive subsites.
35234142	6	64	theme	RBcel1	1122:1127	arg1	RBcel1_Y201F					1156:1167	RBcel1_Y201F	1156:1167	RBcel1_Y201F	1156:1167	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	6	64	theme	RBcel1	1122:1127	arg1	RBcel1_E135Q					1139:1150	RBcel1_E135Q	1139:1150	RBcel1_E135Q	1139:1150	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	6	64	theme	RBcel1	1122:1127	arg1	variants					1129:1136	two RBcel1 variants	1118:1136	two RBcel1 variants	1118:1136	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	2	65	theme	transglycosylation	291:308	arg1	yield					310:314	the transglycosylation yield	287:314	the transglycosylation yield	287:314	Although knowledge is progressing, there is no unique strategy to improve the transglycosylation yield.
35234142	6	66	dep	transglycosylation	1033:1050	arg1	becomes					1052:1058	becomes	1052:1058	becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands	1052:1192	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	6	67	theme	molecular	1227:1235	arg1	factors					1237:1243	the molecular factors	1223:1243	the molecular factors behind transglycosylation	1223:1269	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
35234142	10	68	from	structure	1843:1851	arg1	complex					1872:1878	complex	1872:1878	complex with transglycosylation products	1872:1911	Such a structure is particularly relevant since it is the first structure of a GH5 enzyme in complex with transglycosylation products that has been obtained with neither of the catalytic glutamate residues modified.
35234142	6	69	theme	major	1064:1068	arg1	reaction					1070:1077	the major reaction	1060:1077	the major reaction	1060:1077	The reaction pH is important in driving the balance between hydrolysis and transglycosylation: hydrolysis is favored at pH values below 8, while transglycosylation becomes the major reaction at basic pH. Solving the structures of two RBcel1 variants, RBcel1_E135Q and RBcel1_Y201F, in complex with ligands has brought to light some of the molecular factors behind transglycosylation.
36318096	1	0	theme	important	202:210	arg1	activities					223:232	important biological activities	202:232	important biological activities	202:232	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	3	1	theme	first	394:398	arg1	synthesis					410:418	the first iterative synthesis	390:418	the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	390:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	3	2	theme	gram	561:564	arg1	scale					566:570	a gram scale	559:570	a gram scale	559:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	3	3	theme	inulin-type	428:438	arg1	FOSs					440:443	five inulin-type FOSs	423:443	five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	423:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	4	4	theme	fructofuranosyl	657:671	arg1	donor					687:691	the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor	621:691	the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor	621:691	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	3	5	theme	FOSs	440:443	arg1	synthesis					410:418	the first iterative synthesis	390:418	the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	390:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	4	6	theme	1-O-TIPS-6-O-picoloyl-protected	625:655	arg1	donor					687:691	the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor	621:691	the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor	621:691	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	1	7	with	subgroup	176:183	arg1	activities					223:232	important biological activities	202:232	important biological activities	202:232	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	1	8	theme	Inulin-type	111:121	arg1	FOSs					147:150	FOSs	147:150	FOSs	147:150	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	1	8	theme	Inulin-type	111:121	arg1	fructooligosaccharides					123:144	Inulin-type fructooligosaccharides	111:144	Inulin-type fructooligosaccharides (FOSs)	111:151	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	4	9	theme	hydrogen-bond-mediated	755:776	arg1	delivery					787:794	the hydrogen-bond-mediated aglycone delivery	751:794	the hydrogen-bond-mediated aglycone delivery (HAD)	751:800	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	0	10	theme	Iterative	0:8	arg1	Synthesis					10:18	Iterative Synthesis	0:18	Iterative Synthesis of Inulin-Type	0:33	Iterative Synthesis of Inulin-Type Fructooligosaccharides Enabled by Stereoselective β-d-Fructofuranosylation.
36318096	3	11	dep	7	494:494	arg1	to					491:492	to	491:492	to	491:492	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	3	12	theme	polymerization	461:474	arg1	degrees					450:456	degrees	450:456	degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	450:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	3	13	from	-d-fructofuranosylation	532:554	arg1	scale					566:570	a gram scale	559:570	a gram scale	559:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	0	14	theme	Inulin-Type	23:33	arg1	Synthesis					10:18	Iterative Synthesis	0:18	Iterative Synthesis of Inulin-Type	0:33	Iterative Synthesis of Inulin-Type Fructooligosaccharides Enabled by Stereoselective β-d-Fructofuranosylation.
36318096	0	15	dep	Fructooligosaccharides	35:56	arg1	Enabled					58:64	Enabled	58:64	Fructooligosaccharides Enabled by Stereoselective β-d-Fructofuranosylation	35:108	Iterative Synthesis of Inulin-Type Fructooligosaccharides Enabled by Stereoselective β-d-Fructofuranosylation.
36318096	2	16	from	structure	315:323	arg1	quality					344:350	quality	344:350	quality	344:350	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	2	16	from	structure	315:323	arg1	purity					333:338	high purity	328:338	high purity	328:338	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	1	17	theme	biological	212:221	arg1	activities					223:232	important biological activities	202:232	important biological activities	202:232	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	1	18	theme	fructans	188:195	arg1	subgroup					176:183	an abundant subgroup	164:183	an abundant subgroup of fructans with important biological activities	164:232	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	4	19	theme	decisive	605:612	arg1	Central					573:579	Central	573:579	Central	573:579	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	4	19	theme	decisive	605:612	arg1	use					614:616	the decisive use	601:616	the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD)	601:800	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	4	20	theme	β-selective	722:732	arg1	glycosylation					734:746	the excellent β-selective glycosylation	708:746	the excellent β-selective glycosylation	708:746	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	2	21	theme	accurate	306:313	arg1	structure					315:323	an accurate structure	303:323	an accurate structure in high purity and quality	303:350	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	3	22	theme	β-	523:524	arg1	-d-fructofuranosylation					532:554	highly stereoselective β-(2 → 1)-d-fructofuranosylation	500:554	highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	500:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	3	23	with	FOSs	440:443	arg1	degrees					450:456	degrees	450:456	degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	450:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	4	24	theme	excellent	712:720	arg1	glycosylation					734:746	the excellent β-selective glycosylation	708:746	the excellent β-selective glycosylation	708:746	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	0	25	theme	Stereoselective	69:83	arg1	β-d-Fructofuranosylation					85:108	Stereoselective β-d-Fructofuranosylation	69:108	Stereoselective β-d-Fructofuranosylation	69:108	Iterative Synthesis of Inulin-Type Fructooligosaccharides Enabled by Stereoselective β-d-Fructofuranosylation.
36318096	2	26	theme	individual	264:273	arg1	fructooligosaccharides					275:296	individual fructooligosaccharides	264:296	individual fructooligosaccharides	264:296	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	2	27	theme	fructooligosaccharides	275:296	arg1	availability					248:259	the availability	244:259	the availability of individual fructooligosaccharides with an accurate structure in high purity and quality	244:350	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	1	28	theme	abundant	167:174	arg1	subgroup					176:183	an abundant subgroup	164:183	an abundant subgroup of fructans with important biological activities	164:232	Inulin-type fructooligosaccharides (FOSs) constitute an abundant subgroup of fructans with important biological activities.
36318096	3	29	dep	β-	523:524	arg1	→					528:528	2 → 1	526:530	2 → 1	526:530	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	4	30	theme	donor	687:691	arg1	Central					573:579	Central	573:579	Central	573:579	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	4	30	theme	donor	687:691	arg1	use					614:616	the decisive use	601:616	the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD)	601:800	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	2	31	theme	high	328:331	arg1	purity					333:338	high purity	328:338	high purity	328:338	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	4	32	theme	thioglycoside	673:685	arg1	donor					687:691	the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor	621:691	the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor	621:691	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36318096	3	33	theme	iterative	400:408	arg1	synthesis					410:418	the first iterative synthesis	390:418	the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale	390:570	We herein report the first iterative synthesis of five inulin-type FOSs with degrees of polymerization ranging from 3 to 7 via highly stereoselective β-(2 → 1)-d-fructofuranosylation on a gram scale.
36318096	2	34	with	availability	248:259	arg1	structure					315:323	an accurate structure	303:323	an accurate structure in high purity and quality	303:350	However, the availability of individual fructooligosaccharides with an accurate structure in high purity and quality remains challenging.
36318096	4	35	theme	aglycone	778:785	arg1	delivery					787:794	the hydrogen-bond-mediated aglycone delivery	751:794	the hydrogen-bond-mediated aglycone delivery (HAD)	751:800	Central to the synthesis is the decisive use of the 1-O-TIPS-6-O-picoloyl-protected fructofuranosyl thioglycoside donor, which assured the excellent β-selective glycosylation by the hydrogen-bond-mediated aglycone delivery (HAD).
36096000	0	0	with	protein	27:33	arg1	maltodextrin					40:51	maltodextrin	40:51	maltodextrin	40:51	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	1	1	theme	egg	134:136	arg1	EWP					154:156	EWP	154:156	EWP	154:156	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	1	1	theme	egg	134:136	arg1	proteins					144:151	egg white proteins	134:151	egg white proteins (EWP)	134:157	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	0	2	theme	egg	17:19	arg1	protein					27:33	egg white protein	17:33	egg white protein with maltodextrin	17:51	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	6	3	theme	food	1181:1184	arg1	industry					1186:1193	the food industry	1177:1193	the food industry	1177:1193	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	3	4	theme	diffraction	588:598	arg1	spectra					606:612	circular dichroism (CD) and X-ray diffraction (XRD) spectra	554:612	circular dichroism (CD) and X-ray diffraction (XRD) spectra	554:612	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	1	5	theme	white	138:142	arg1	EWP					154:156	EWP	154:156	EWP	154:156	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	1	5	theme	white	138:142	arg1	proteins					144:151	egg white proteins	134:151	egg white proteins (EWP)	134:157	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	4	6	theme	GEWP	664:667	arg1	structures					669:678	The GEWP structures	660:678	The GEWP structures	660:678	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	2	7	theme	gel	428:430	arg1	microstructures					432:446	finer gel microstructures	422:446	finer gel microstructures	422:446	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	0	8	from	Glycosylation	0:12	arg1	state					64:68	the dry state	56:68	the dry state	56:68	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	1	9	with	glycosylation	117:129	arg1	maltodextrin					164:175	maltodextrin	164:175	maltodextrin (MD)	164:180	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	1	9	with	glycosylation	117:129	arg1	MD					178:179	MD	178:179	MD	178:179	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	1	10	theme	gel	219:221	arg1	properties					223:232	their gel properties	213:232	their gel properties	213:232	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	4	11	theme	denaturation	827:838	arg1	Td					853:854	Td	853:854	Td	853:854	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	4	11	theme	denaturation	827:838	arg1	temperature					840:850	thermal denaturation temperature	819:850	thermal denaturation temperature (Td)	819:855	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	5	12	theme	structural	949:958	arg1	changes					960:966	the protein structural changes	937:966	the protein structural changes	937:966	A correlation was also found between the gel properties and the protein structural changes.
36096000	4	13	theme	exposed	761:767	arg1	group					772:776	exposed SH group	761:776	exposed SH group	761:776	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	6	14	theme	convenient	1065:1074	arg1	approach					1076:1083	a convenient approach	1063:1083	a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry	1063:1193	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	6	15	theme	glycosylation	1036:1048	arg1	mechanism					1023:1031	the mechanism	1019:1031	the mechanism of glycosylation	1019:1048	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	3	16	theme	differential	619:630	arg1	DSC					654:656	DSC	654:656	DSC	654:656	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	16	theme	differential	619:630	arg1	calorimetry					641:651	differential scanning calorimetry	619:651	differential scanning calorimetry (DSC)	619:657	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	17	theme	protein	453:459	arg1	structures					461:470	The protein structures	449:470	The protein structures	449:470	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	1	18	theme	proteins	144:151	arg1	glycosylation					117:129	The glycosylation	113:129	The glycosylation of egg white proteins (EWP) with maltodextrin (MD)	113:180	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	0	19	theme	structural	82:91	arg1	properties					101:110	structural and gel properties	82:110	structural and gel properties	82:110	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	3	20	from	calorimetry	641:651	arg1	content					520:526	the content	516:526	the content of sulfhydryl (SH) group	516:551	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	21	from	spectra	606:612	arg1	content					520:526	the content	516:526	the content of sulfhydryl (SH) group	516:551	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	4	22	theme	β-sheet	782:788	arg1	content					750:756	increased content	740:756	increased content of exposed SH group and β-sheet	740:788	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	4	23	theme	increased	740:748	arg1	content					750:756	increased content	740:756	increased content of exposed SH group and β-sheet	740:788	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	2	24	theme	finer	422:426	arg1	microstructures					432:446	finer gel microstructures	422:446	finer gel microstructures	422:446	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	4	25	theme	group	772:776	arg1	content					750:756	increased content	740:756	increased content of exposed SH group and β-sheet	740:788	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	5	26	theme	gel	918:920	arg1	properties					922:931	the gel properties	914:931	the gel properties	914:931	A correlation was also found between the gel properties and the protein structural changes.
36096000	2	27	theme	gel	270:272	arg1	properties					274:283	The improved gel properties	257:283	The improved gel properties of glycosylated EWP (GEWP)	257:310	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	0	28	theme	white	21:25	arg1	protein					27:33	egg white protein	17:33	egg white protein with maltodextrin	17:51	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	1	29	theme	protein	238:244	arg1	structure					246:254	protein structure	238:254	protein structure	238:254	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	5	30	theme	protein	941:947	arg1	changes					960:966	the protein structural changes	937:966	the protein structural changes	937:966	A correlation was also found between the gel properties and the protein structural changes.
36096000	2	31	theme	improved	261:268	arg1	properties					274:283	The improved gel properties	257:283	The improved gel properties of glycosylated EWP (GEWP)	257:310	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	4	32	theme	extended	701:708	arg1	glycosylation					710:722	extended glycosylation	701:722	extended glycosylation	701:722	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	2	33	theme	gel	360:362	arg1	capacity					378:385	gel water holding capacity	360:385	gel water holding capacity (WHC)	360:391	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	33	theme	gel	360:362	arg1	WHC					388:390	WHC	388:390	WHC	388:390	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	34	theme	water	364:368	arg1	capacity					378:385	gel water holding capacity	360:385	gel water holding capacity (WHC)	360:391	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	34	theme	water	364:368	arg1	WHC					388:390	WHC	388:390	WHC	388:390	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	3	35	theme	scanning	632:639	arg1	DSC					654:656	DSC	654:656	DSC	654:656	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	35	theme	scanning	632:639	arg1	calorimetry					641:651	differential scanning calorimetry	619:651	differential scanning calorimetry (DSC)	619:657	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	0	36	theme	gel	97:99	arg1	properties					101:110	structural and gel properties	82:110	structural and gel properties	82:110	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	3	37	theme	dichroism	563:571	arg1	spectra					606:612	circular dichroism (CD) and X-ray diffraction (XRD) spectra	554:612	circular dichroism (CD) and X-ray diffraction (XRD) spectra	554:612	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	2	38	theme	rheological	394:404	arg1	parameters					406:415	rheological parameters	394:415	rheological parameters	394:415	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	4	39	theme	thermal	819:825	arg1	Td					853:854	Td	853:854	Td	853:854	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	4	39	theme	thermal	819:825	arg1	temperature					840:850	thermal denaturation temperature	819:850	thermal denaturation temperature (Td)	819:855	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	0	40	gly	Glycosylation	0:12	arg1	protein					27:33	egg white protein	17:33	egg white protein with maltodextrin	17:51	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	6	41	theme	gel	1102:1104	arg1	properties					1106:1115	the gel properties	1098:1115	the gel properties of EWP, which can further broaden the application of EWP in the food industry	1098:1193	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	0	42	theme	protein	27:33	arg1	Glycosylation					0:12	Glycosylation	0:12	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.	0:111	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	6	43	from	application	1155:1165	arg1	industry					1186:1193	the food industry	1177:1193	the food industry	1177:1193	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	2	44	theme	holding	370:376	arg1	capacity					378:385	gel water holding capacity	360:385	gel water holding capacity (WHC)	360:391	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	44	theme	holding	370:376	arg1	WHC					388:390	WHC	388:390	WHC	388:390	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	45	theme	gel	346:348	arg1	hardness					350:357	gel hardness	346:357	gel hardness	346:357	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	4	46	theme	SH	769:770	arg1	group					772:776	exposed SH group	761:776	exposed SH group	761:776	The GEWP structures were unfolded due to extended glycosylation, as observed by increased content of exposed SH group and β-sheet and decreased crystallinity, thermal denaturation temperature (Td), and enthalpy (ΔH).
36096000	3	47	theme	circular	554:561	arg1	dichroism					563:571	circular dichroism	554:571	circular dichroism (CD)	554:576	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	47	theme	circular	554:561	arg1	CD					574:575	CD	574:575	CD	574:575	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	1	48	gly	glycosylation	117:129	arg1	EWP					154:156	EWP	154:156	EWP	154:156	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	1	48	gly	glycosylation	117:129	arg1	proteins					144:151	egg white proteins	134:151	egg white proteins (EWP)	134:157	The glycosylation of egg white proteins (EWP) with maltodextrin (MD) was investigated by monitoring their gel properties and protein structure.
36096000	6	49	theme	EWP	1120:1122	arg1	properties					1106:1115	the gel properties	1098:1115	the gel properties of EWP, which can further broaden the application of EWP in the food industry	1098:1193	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	2	50	theme	EWP	301:303	arg1	properties					274:283	The improved gel properties	257:283	The improved gel properties of glycosylated EWP (GEWP)	257:310	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	3	51	theme	SH	543:544	arg1	group					547:551	sulfhydryl (SH) group	531:551	sulfhydryl (SH) group	531:551	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	52	theme	X-ray	582:586	arg1	XRD					601:603	XRD	601:603	XRD	601:603	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	52	theme	X-ray	582:586	arg1	diffraction					588:598	X-ray diffraction	582:598	X-ray diffraction (XRD)	582:604	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	53	theme	sulfhydryl	531:540	arg1	group					547:551	sulfhydryl (SH) group	531:551	sulfhydryl (SH) group	531:551	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	2	54	from	increase	334:341	arg1	capacity					378:385	gel water holding capacity	360:385	gel water holding capacity (WHC)	360:391	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	54	from	increase	334:341	arg1	hardness					350:357	gel hardness	346:357	gel hardness	346:357	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	54	from	increase	334:341	arg1	parameters					406:415	rheological parameters	394:415	rheological parameters	394:415	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	54	from	increase	334:341	arg1	WHC					388:390	WHC	388:390	WHC	388:390	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	54	from	increase	334:341	arg1	microstructures					432:446	finer gel microstructures	422:446	finer gel microstructures	422:446	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	55	theme	glycosylated	288:299	arg1	EWP					301:303	glycosylated EWP	288:303	glycosylated EWP (GEWP)	288:310	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	55	theme	glycosylated	288:299	arg1	GEWP					306:309	GEWP	306:309	GEWP	306:309	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	56	gly	glycosylated	288:299	arg1	EWP					301:303	glycosylated EWP	288:303	glycosylated EWP (GEWP)	288:310	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	2	56	gly	glycosylated	288:299	arg1	GEWP					306:309	GEWP	306:309	GEWP	306:309	The improved gel properties of glycosylated EWP (GEWP) were confirmed by the increase in gel hardness, gel water holding capacity (WHC), rheological parameters, and finer gel microstructures.
36096000	3	57	theme	group	547:551	arg1	content					520:526	the content	516:526	the content of sulfhydryl (SH) group	516:551	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	3	58	from	changes	505:511	arg1	content					520:526	the content	516:526	the content of sulfhydryl (SH) group	516:551	The protein structures were characterized by monitoring changes in the content of sulfhydryl (SH) group, circular dichroism (CD) and X-ray diffraction (XRD) spectra, and differential scanning calorimetry (DSC).
36096000	0	59	theme	dry	60:62	arg1	state					64:68	the dry state	56:68	the dry state	56:68	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	0	60	from	Changes	71:77	arg1	properties					101:110	structural and gel properties	82:110	structural and gel properties	82:110	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
36096000	6	61	theme	EWP	1170:1172	arg1	application					1155:1165	the application	1151:1165	the application of EWP in the food industry	1151:1193	Overall, this study is beneficial for determining the mechanism of glycosylation and provides a convenient approach to improving the gel properties of EWP, which can further broaden the application of EWP in the food industry.
36096000	0	62	dep	Glycosylation	0:12	arg1	Changes					71:77	Changes	71:77	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.	0:111	Glycosylation of egg white protein with maltodextrin in the dry state: Changes in structural and gel properties.
35889277	6	0	theme	excipient	1056:1064	arg1	separation					1042:1051	the separation	1038:1051	the separation of excipient and protein	1038:1076	The DCDR method was used and allowed the separation of excipient and protein by forming a "coffee ring".
35889277	8	1	used	used	1285:1288	arg2	strategy					1254:1261	the strategy	1250:1261	the strategy of SVD-truncation	1250:1279	Further, the strategy of SVD-truncation was used to select the number of components to resolve by MCR-ALS.
35889277	4	2	gly	glycosylation	742:754	arg1	antibodies					770:779	monoclonal antibodies	759:779	monoclonal antibodies (mAbs)	759:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	2	gly	glycosylation	742:754	arg1	mAbs					782:785	mAbs	782:785	mAbs	782:785	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	9	3	theme	vector	1388:1393	arg1	SVR					1407:1409	SVR	1407:1409	SVR	1407:1409	Raman spectra were processed by support vector regression (SVR).
35889277	9	3	theme	vector	1388:1393	arg1	regression					1395:1404	support vector regression	1380:1404	support vector regression (SVR)	1380:1410	Raman spectra were processed by support vector regression (SVR).
35889277	4	4	from	glycosylation	742:754	arg1	antibodies					770:779	monoclonal antibodies	759:779	monoclonal antibodies (mAbs)	759:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	4	from	glycosylation	742:754	arg1	mAbs					782:785	mAbs	782:785	mAbs	782:785	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	9	5	theme	Raman	1348:1352	arg1	spectra					1354:1360	Raman spectra	1348:1360	Raman spectra	1348:1360	Raman spectra were processed by support vector regression (SVR).
35889277	0	6	theme	Deposition	95:104	arg1	imaging					112:118	Drop-Coating Deposition Raman imaging	82:118	Drop-Coating Deposition Raman imaging	82:118	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	5	7	gly	glycoproteins	839:851	arg1	glycoproteins					839:851	glycoproteins	839:851	glycoproteins	839:851	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	3	8	dep	consuming	429:437	arg1	expensive					440:448	expensive	440:448	expensive	440:448	Existing methods are time consuming, expensive, and require significant sample preparation, which can alter the robustness of the analyses.
35889277	5	9	theme	reference	923:931	arg1	method					933:938	a reference method	921:938	a reference method to determine the composition in glycans and monosaccharides	921:998	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	5	9	theme	reference	923:931	arg1	glycoproteins					872:884	the glycoproteins	868:884	the glycoproteins	868:884	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	0	10	theme	Drop-Coating	82:93	arg1	imaging					112:118	Drop-Coating Deposition Raman imaging	82:118	Drop-Coating Deposition Raman imaging	82:118	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	3	11	theme	analyses	533:540	arg1	robustness					515:524	the robustness	511:524	the robustness of the analyses	511:540	Existing methods are time consuming, expensive, and require significant sample preparation, which can alter the robustness of the analyses.
35889277	2	12	theme	analytical	304:313	arg1	methods					315:321	analytical methods	304:321	analytical methods able to characterize the composition and structure of glycoproteins	304:389	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	0	13	from	Glycosylation	34:46	arg1	Antibodies					62:71	Monoclonal Antibodies	51:71	Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging	51:118	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	2	14	gly	glycoproteins	377:389	arg1	glycoproteins					377:389	glycoproteins	377:389	glycoproteins	377:389	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	6	15	used	used	1021:1024	arg2	method					1010:1015	The DCDR method	1001:1015	The DCDR method	1001:1015	The DCDR method was used and allowed the separation of excipient and protein by forming a "coffee ring".
35889277	10	16	theme	RMSECV	1471:1476	arg1	terms					1462:1466	terms	1462:1466	terms of RMSECV, R2CV	1462:1482	SVR models showed good predictive performance in terms of RMSECV, R2CV.
35889277	9	17	theme	support	1380:1386	arg1	SVR					1407:1409	SVR	1407:1409	SVR	1407:1409	Raman spectra were processed by support vector regression (SVR).
35889277	9	17	theme	support	1380:1386	arg1	regression					1395:1404	support vector regression	1380:1404	support vector regression (SVR)	1380:1410	Raman spectra were processed by support vector regression (SVR).
35889277	4	18	theme	imaging	630:636	arg1	method					645:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method	573:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	0	19	theme	Raman	106:110	arg1	imaging					112:118	Drop-Coating Deposition Raman imaging	82:118	Drop-Coating Deposition Raman imaging	82:118	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	2	20	dep	composition	348:358	arg1	the					344:346	the	344:346	the	344:346	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	2	21	theme	glycoproteins	377:389	arg1	structure					364:372	structure	364:372	structure	364:372	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	2	21	theme	glycoproteins	377:389	arg1	composition					348:358	composition	348:358	composition	348:358	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	0	22	theme	New	2:4	arg1	Tool					18:21	A New Alternative Tool	0:21	A New Alternative Tool	0:21	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	5	23	from	composition	957:967	arg1	monosaccharides					984:998	monosaccharides	984:998	monosaccharides	984:998	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	5	23	from	composition	957:967	arg1	glycans					972:978	glycans	972:978	glycans	972:978	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	1	24	theme	critical	171:178	arg1	attribute					188:196	a critical quality attribute	169:196	a critical quality attribute of therapeutic proteins	169:220	Glycosylation is considered a critical quality attribute of therapeutic proteins as it affects their stability, bioactivity, and safety.
35889277	4	25	theme	least	708:712	arg1	MCR-ALS					722:728	MCR-ALS	722:728	MCR-ALS	722:728	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	25	theme	least	708:712	arg1	square					714:719	least square	708:719	least square (MCR-ALS)	708:729	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	1	26	theme	quality	180:186	arg1	attribute					188:196	a critical quality attribute	169:196	a critical quality attribute of therapeutic proteins	169:220	Glycosylation is considered a critical quality attribute of therapeutic proteins as it affects their stability, bioactivity, and safety.
35889277	5	27	theme	hyperspectral	803:815	arg1	data					831:834	hyperspectral Raman imaging data	803:834	hyperspectral Raman imaging data	803:834	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	5	28	gly	glycoproteins	872:884	arg1	glycoproteins					872:884	the glycoproteins	868:884	the glycoproteins	868:884	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	5	28	gly	glycoproteins	872:884	arg1	method					933:938	a reference method	921:938	a reference method to determine the composition in glycans and monosaccharides	921:998	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	6	29	theme	ring	1099:1102	arg1	"					1103:1103	a "coffee ring"	1089:1103	a "coffee ring"	1089:1103	The DCDR method was used and allowed the separation of excipient and protein by forming a "coffee ring".
35889277	4	30	theme	simple	593:598	arg1	method					645:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method	573:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	0	31	theme	Alternative	6:16	arg1	Tool					18:21	A New Alternative Tool	0:21	A New Alternative Tool	0:21	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	6	32	theme	coffee	1092:1097	arg1	"					1103:1103	a "coffee ring"	1089:1103	a "coffee ring"	1089:1103	The DCDR method was used and allowed the separation of excipient and protein by forming a "coffee ring".
35889277	5	33	theme	data	831:834	arg1	database					791:798	A database	789:798	A database of hyperspectral Raman imaging data of glycoproteins	789:851	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	3	34	theme	Existing	403:410	arg1	methods					412:418	Existing methods	403:418	Existing methods	403:418	Existing methods are time consuming, expensive, and require significant sample preparation, which can alter the robustness of the analyses.
35889277	4	35	theme	multivariate	666:677	arg1	resolution					685:694	multivariate curve resolution	666:694	multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	666:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	10	36	theme	SVR	1413:1415	arg1	models					1417:1422	SVR models	1413:1422	SVR models	1413:1422	SVR models showed good predictive performance in terms of RMSECV, R2CV.
35889277	4	37	theme	deposition	613:622	arg1	imaging					630:636	drop-coating deposition Raman imaging	600:636	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	37	theme	deposition	613:622	arg1	DCDR					639:642	DCDR	639:642	DCDR	639:642	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	5	38	theme	glycoproteins	839:851	arg1	database					791:798	A database	789:798	A database of hyperspectral Raman imaging data of glycoproteins	789:851	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	1	39	theme	therapeutic	201:211	arg1	proteins					213:220	therapeutic proteins	201:220	therapeutic proteins	201:220	Glycosylation is considered a critical quality attribute of therapeutic proteins as it affects their stability, bioactivity, and safety.
35889277	5	40	theme	imaging	823:829	arg1	data					831:834	hyperspectral Raman imaging data	803:834	hyperspectral Raman imaging data	803:834	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	7	41	theme	MCR-ALS	1106:1112	arg1	analysis					1114:1121	MCR-ALS analysis	1106:1121	MCR-ALS analysis	1106:1121	MCR-ALS analysis was performed to visualize the distribution of the compounds in the drop and to extract the pure spectral components.
35889277	5	42	theme	Raman	817:821	arg1	data					831:834	hyperspectral Raman imaging data	803:834	hyperspectral Raman imaging data	803:834	A database of hyperspectral Raman imaging data of glycoproteins was built, and the glycoproteins were characterized by LC-FLR-MS as a reference method to determine the composition in glycans and monosaccharides.
35889277	1	43	theme	proteins	213:220	arg1	attribute					188:196	a critical quality attribute	169:196	a critical quality attribute of therapeutic proteins	169:220	Glycosylation is considered a critical quality attribute of therapeutic proteins as it affects their stability, bioactivity, and safety.
35889277	6	44	theme	DCDR	1005:1008	arg1	method					1010:1015	The DCDR method	1001:1015	The DCDR method	1001:1015	The DCDR method was used and allowed the separation of excipient and protein by forming a "coffee ring".
35889277	7	45	from	distribution	1154:1165	arg1	drop					1191:1194	the drop	1187:1194	the drop	1187:1194	MCR-ALS analysis was performed to visualize the distribution of the compounds in the drop and to extract the pure spectral components.
35889277	0	46	dep	Analyse	26:32	arg1	Proof					123:127	A Proof	121:127	A Proof of Concept	121:138	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	4	47	theme	curve	679:683	arg1	resolution					685:694	multivariate curve resolution	666:694	multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	666:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	48	theme	fast	575:578	arg1	method					645:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method	573:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	0	49	theme	Concept	132:138	arg1	Proof					123:127	A Proof	121:127	A Proof of Concept	121:138	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	7	50	theme	pure	1215:1218	arg1	components					1229:1238	the pure spectral components	1211:1238	the pure spectral components	1211:1238	MCR-ALS analysis was performed to visualize the distribution of the compounds in the drop and to extract the pure spectral components.
35889277	2	51	theme	able	323:326	arg1	methods					315:321	analytical methods	304:321	analytical methods able to characterize the composition and structure of glycoproteins	304:389	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	10	52	theme	predictive	1436:1445	arg1	performance					1447:1457	good predictive performance	1431:1457	good predictive performance	1431:1457	SVR models showed good predictive performance in terms of RMSECV, R2CV.
35889277	4	53	theme	monoclonal	759:768	arg1	antibodies					770:779	monoclonal antibodies	759:779	monoclonal antibodies (mAbs)	759:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	53	theme	monoclonal	759:768	arg1	mAbs					782:785	mAbs	782:785	mAbs	782:785	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	2	54	theme	methods	315:321	arg1	development					289:299	the development	285:299	the development of analytical methods able to characterize the composition and structure of glycoproteins	285:389	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	2	54	theme	methods	315:321	arg1	crucial					394:400	crucial	394:400	crucial	394:400	Hence, the development of analytical methods able to characterize the composition and structure of glycoproteins is crucial.
35889277	8	55	theme	components	1314:1323	arg1	number					1304:1309	the number	1300:1309	the number of components to resolve by MCR-ALS	1300:1345	Further, the strategy of SVD-truncation was used to select the number of components to resolve by MCR-ALS.
35889277	10	56	theme	good	1431:1434	arg1	performance					1447:1457	good predictive performance	1431:1457	good predictive performance	1431:1457	SVR models showed good predictive performance in terms of RMSECV, R2CV.
35889277	3	57	theme	sample	475:480	arg1	preparation					482:492	significant sample preparation	463:492	significant sample preparation	463:492	Existing methods are time consuming, expensive, and require significant sample preparation, which can alter the robustness of the analyses.
35889277	8	58	theme	SVD-truncation	1266:1279	arg1	strategy					1254:1261	the strategy	1250:1261	the strategy of SVD-truncation	1250:1279	Further, the strategy of SVD-truncation was used to select the number of components to resolve by MCR-ALS.
35889277	3	59	theme	significant	463:473	arg1	preparation					482:492	significant sample preparation	463:492	significant sample preparation	463:492	Existing methods are time consuming, expensive, and require significant sample preparation, which can alter the robustness of the analyses.
35889277	7	60	theme	compounds	1174:1182	arg1	distribution					1154:1165	the distribution	1150:1165	the distribution of the compounds in the drop	1150:1194	MCR-ALS analysis was performed to visualize the distribution of the compounds in the drop and to extract the pure spectral components.
35889277	4	61	theme	drop-coating	600:611	arg1	imaging					630:636	drop-coating deposition Raman imaging	600:636	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	61	theme	drop-coating	600:611	arg1	DCDR					639:642	DCDR	639:642	DCDR	639:642	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	6	62	theme	protein	1070:1076	arg1	separation					1042:1051	the separation	1038:1051	the separation of excipient and protein	1038:1076	The DCDR method was used and allowed the separation of excipient and protein by forming a "coffee ring".
35889277	4	63	theme	Raman	624:628	arg1	imaging					630:636	drop-coating deposition Raman imaging	600:636	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	4	63	theme	Raman	624:628	arg1	DCDR					639:642	DCDR	639:642	DCDR	639:642	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
35889277	0	64	theme	Monoclonal	51:60	arg1	Antibodies					62:71	Monoclonal Antibodies	51:71	Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging	51:118	A New Alternative Tool to Analyse Glycosylation in Monoclonal Antibodies Based on Drop-Coating Deposition Raman imaging: A Proof of Concept.
35889277	7	65	theme	spectral	1220:1227	arg1	components					1229:1238	the pure spectral components	1211:1238	the pure spectral components	1211:1238	MCR-ALS analysis was performed to visualize the distribution of the compounds in the drop and to extract the pure spectral components.
35889277	4	66	theme	direct	581:586	arg1	method					645:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method	573:650	a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs)	573:786	In this context, we developed a fast, direct, and simple drop-coating deposition Raman imaging (DCDR) method combined with multivariate curve resolution alternating least square (MCR-ALS) to analyze glycosylation in monoclonal antibodies (mAbs).
37254962	0	0	theme	DIS5-S6	78:84	arg1	linker					100:105	the DIS5-S6 extracellular linker	74:105	the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4	74:150	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	10	1	theme	SkMNaV1.4	1541:1549	arg1	structure					1551:1559	SkMNaV1.4 structure	1541:1559	SkMNaV1.4 structure	1541:1559	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	9	2	theme	channel	1396:1402	arg1	gating					1404:1409	channel gating	1396:1409	channel gating	1396:1409	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	4	3	theme	self-assembling	689:703	arg1	elements					726:733	self-assembling secondary structural elements	689:733	self-assembling secondary structural elements	689:733	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	1	4	theme	DIS5-S6	234:240	arg1	peptide					249:255	the 59-residue DIS5-S6 linker peptide	219:255	the 59-residue DIS5-S6 linker peptide	219:255	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	8	5	theme	conserved	1130:1138	arg1	region					1140:1145	the conserved region	1126:1145	the conserved region	1126:1145	An optimally located asparagine residue within the conserved region was investigated for N-linked glycosylation and MD simulations carried out.
37254962	10	6	theme	potential	1472:1480	arg1	glycosylation					1482:1494	potential glycosylation	1472:1494	potential glycosylation	1472:1494	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	6	7	theme	structural	868:877	arg1	implications					879:890	structural implications	868:890	structural implications	868:890	To investigate structural implications, sequences from 14 representative organisms were additionally modelled.
37254962	1	8	theme	linker	242:247	arg1	peptide					249:255	the 59-residue DIS5-S6 linker peptide	219:255	the 59-residue DIS5-S6 linker peptide	219:255	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	0	9	theme	linker	100:105	arg1	simulations					59:69	molecular dynamics simulations	40:69	molecular dynamics simulations	40:69	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	0	9	theme	linker	100:105	arg1	studies					28:34	modelling studies	18:34	modelling studies	18:34	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	10	10	theme	MD	1500:1501	arg1	simulations					1503:1513	MD simulations	1500:1513	MD simulations	1500:1513	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	8	11	theme	asparagine	1100:1109	arg1	residue					1111:1117	An optimally located asparagine residue	1079:1117	An optimally located asparagine residue within the conserved region	1079:1145	An optimally located asparagine residue within the conserved region was investigated for N-linked glycosylation and MD simulations carried out.
37254962	10	12	theme	sequence	1439:1446	arg1	relationship					1416:1427	The relationship	1412:1427	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations	1412:1513	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	9	13	theme	complex	1241:1247	arg1	glycan					1249:1254	a complex glycan	1239:1254	a complex glycan added at this site in the linker	1239:1287	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	4	14	theme	random	584:589	arg1	drift					609:613	a flexible random coil potentiating drift	573:613	a flexible random coil potentiating drift across the channel	573:632	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	0	15	theme	extracellular	86:98	arg1	linker					100:105	the DIS5-S6 extracellular linker	74:105	the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4	74:150	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	8	16	theme	located	1092:1098	arg1	residue					1111:1117	An optimally located asparagine residue	1079:1117	An optimally located asparagine residue within the conserved region	1079:1145	An optimally located asparagine residue within the conserved region was investigated for N-linked glycosylation and MD simulations carried out.
37254962	7	17	theme	N-and	992:996	arg1	residues					1009:1016	highly conserved N-and C-terminal residues	975:1016	highly conserved N-and C-terminal residues closely superimposed	975:1037	All showed highly conserved N-and C-terminal residues closely superimposed, suggesting a critical functional role.
37254962	3	18	theme	complete	532:539	arg1	channel					552:558	the complete hSkMNaV1.4 channel	528:558	the complete hSkMNaV1.4 channel	528:558	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	4	19	theme	flexible	575:582	arg1	drift					609:613	a flexible random coil potentiating drift	573:613	a flexible random coil potentiating drift across the channel	573:632	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	6	20	from	organisms	926:934	arg1	sequences					893:901	sequences	893:901	sequences from 14 representative organisms	893:934	To investigate structural implications, sequences from 14 representative organisms were additionally modelled.
37254962	6	21	theme	representative	911:924	arg1	organisms					926:934	14 representative organisms	908:934	14 representative organisms	908:934	To investigate structural implications, sequences from 14 representative organisms were additionally modelled.
37254962	9	22	dep	suggest	1231:1237	arg1	involved					1384:1391	involved	1384:1391	be mechanistically involved in channel gating	1365:1409	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	9	22	dep	suggest	1231:1237	arg1	form					1293:1296	form	1293:1296	may form electrostatic interactions with the DIV voltage sensing domain	1289:1359	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	2	23	theme	skeletal	391:398	arg1	channels					418:425	mammalian skeletal muscle sodium ion channels	381:425	mammalian skeletal muscle sodium ion channels	381:425	This peptide is intriguing - comprised of unique sequence and found only in mammalian skeletal muscle sodium ion channels.
37254962	3	24	theme	potential	437:445	arg1	significance					478:489	potential physiological and evolutionary significance	437:489	potential physiological and evolutionary significance	437:489	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	10	25	theme	simulations	1503:1513	arg1	relationship					1416:1427	The relationship	1412:1427	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations	1412:1513	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	5	26	theme	100	827:829	arg1	%					830:830	%	830:830	%	830:830	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	0	27	from	studies	28:34	arg1	insights					4:11	New insights	0:11	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.	0:151	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	5	28	with	similarity	841:850	arg1	%					821:821	between 40%	811:821	between 40%	811:821	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	7	29	theme	conserved	982:990	arg1	residues					1009:1016	highly conserved N-and C-terminal residues	975:1016	highly conserved N-and C-terminal residues closely superimposed	975:1037	All showed highly conserved N-and C-terminal residues closely superimposed, suggesting a critical functional role.
37254962	0	30	theme	New	0:2	arg1	insights					4:11	New insights	0:11	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.	0:151	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	9	31	theme	voltage	1338:1344	arg1	domain					1354:1359	the DIV voltage sensing domain	1330:1359	the DIV voltage sensing domain	1330:1359	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	5	32	theme	Analogous	736:744	arg1	sequences					746:754	Analogous sequences	736:754	Analogous sequences from 48 mammalian organisms	736:782	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	1	33	theme	hSkMNaV1.4	184:193	arg1	channel					199:205	the hSkMNaV1.4 ion channel	180:205	the hSkMNaV1.4 ion channel (PDB:6AGF)	180:216	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	1	33	theme	hSkMNaV1.4	184:193	arg1	PDB:6AGF					208:215	PDB:6AGF	208:215	PDB:6AGF	208:215	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	0	34	theme	modelling	18:26	arg1	studies					28:34	modelling studies	18:34	modelling studies	18:34	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	0	35	theme	muscle	123:128	arg1	channel					137:143	the skeletal muscle sodium channel NaV1.4	110:150	the skeletal muscle sodium channel NaV1.4	110:150	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	7	36	theme	C-terminal	998:1007	arg1	residues					1009:1016	highly conserved N-and C-terminal residues	975:1016	highly conserved N-and C-terminal residues closely superimposed	975:1037	All showed highly conserved N-and C-terminal residues closely superimposed, suggesting a critical functional role.
37254962	3	37	theme	hSkMNaV1.4	541:550	arg1	channel					552:558	the complete hSkMNaV1.4 channel	528:558	the complete hSkMNaV1.4 channel	528:558	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	9	38	with	interactions	1312:1323	arg1	domain					1354:1359	the DIV voltage sensing domain	1330:1359	the DIV voltage sensing domain	1330:1359	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	2	39	theme	muscle	400:405	arg1	channels					418:425	mammalian skeletal muscle sodium ion channels	381:425	mammalian skeletal muscle sodium ion channels	381:425	This peptide is intriguing - comprised of unique sequence and found only in mammalian skeletal muscle sodium ion channels.
37254962	2	40	theme	sodium	407:412	arg1	channels					418:425	mammalian skeletal muscle sodium ion channels	381:425	mammalian skeletal muscle sodium ion channels	381:425	This peptide is intriguing - comprised of unique sequence and found only in mammalian skeletal muscle sodium ion channels.
37254962	0	41	theme	skeletal	114:121	arg1	channel					137:143	the skeletal muscle sodium channel NaV1.4	110:150	the skeletal muscle sodium channel NaV1.4	110:150	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	3	42	theme	channel	552:558	arg1	model					519:523	an homology model	507:523	an homology model of the complete hSkMNaV1.4 channel	507:558	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	1	43	theme	channel	199:205	arg1	CryoEM-structure					160:175	the CryoEM-structure	156:175	the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF)	156:216	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	0	44	theme	channel	137:143	arg1	linker					100:105	the DIS5-S6 extracellular linker	74:105	the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4	74:150	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	8	45	link	N-linked	1168:1175	arg1	glycosylation					1177:1189	N-linked glycosylation	1168:1189	N-linked glycosylation	1168:1189	An optimally located asparagine residue within the conserved region was investigated for N-linked glycosylation and MD simulations carried out.
37254962	2	46	theme	mammalian	381:389	arg1	channels					418:425	mammalian skeletal muscle sodium ion channels	381:425	mammalian skeletal muscle sodium ion channels	381:425	This peptide is intriguing - comprised of unique sequence and found only in mammalian skeletal muscle sodium ion channels.
37254962	0	47	theme	sodium	130:135	arg1	channel					137:143	the skeletal muscle sodium channel NaV1.4	110:150	the skeletal muscle sodium channel NaV1.4	110:150	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	9	48	theme	electrostatic	1298:1310	arg1	interactions					1312:1323	electrostatic interactions	1298:1323	electrostatic interactions with the DIV voltage sensing domain	1298:1359	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	2	49	theme	ion	414:416	arg1	channels					418:425	mammalian skeletal muscle sodium ion channels	381:425	mammalian skeletal muscle sodium ion channels	381:425	This peptide is intriguing - comprised of unique sequence and found only in mammalian skeletal muscle sodium ion channels.
37254962	5	50	theme	%	830:830	arg1	similarity					841:850	100% sequence similarity	827:850	100% sequence similarity	827:850	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	0	51	theme	dynamics	50:57	arg1	simulations					59:69	molecular dynamics simulations	40:69	molecular dynamics simulations	40:69	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	1	52	theme	electron	287:294	arg1	density					296:302	electron density	287:302	electron density	287:302	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	0	53	from	simulations	59:69	arg1	insights					4:11	New insights	0:11	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.	0:151	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	4	54	theme	structural	715:724	arg1	elements					726:733	self-assembling secondary structural elements	689:733	self-assembling secondary structural elements	689:733	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	0	55	theme	molecular	40:48	arg1	simulations					59:69	molecular dynamics simulations	40:69	molecular dynamics simulations	40:69	New insights from modelling studies and molecular dynamics simulations of the DIS5-S6 extracellular linker of the skeletal muscle sodium channel NaV1.4.
37254962	1	56	theme	density	296:302	arg1	absence					276:282	absence	276:282	absence of electron density	276:302	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	8	57	theme	N-linked	1168:1175	arg1	glycosylation					1177:1189	N-linked glycosylation	1168:1189	N-linked glycosylation	1168:1189	An optimally located asparagine residue within the conserved region was investigated for N-linked glycosylation and MD simulations carried out.
37254962	7	58	theme	critical	1053:1060	arg1	role					1073:1076	a critical functional role	1051:1076	a critical functional role	1051:1076	All showed highly conserved N-and C-terminal residues closely superimposed, suggesting a critical functional role.
37254962	4	59	theme	secondary	705:713	arg1	elements					726:733	self-assembling secondary structural elements	689:733	self-assembling secondary structural elements	689:733	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	10	60	theme	glycosylation	1482:1494	arg1	relationship					1416:1427	The relationship	1412:1427	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations	1412:1513	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	8	61	theme	MD	1195:1196	arg1	simulations					1198:1208	MD simulations	1195:1208	MD simulations	1195:1208	An optimally located asparagine residue within the conserved region was investigated for N-linked glycosylation and MD simulations carried out.
37254962	4	62	theme	compact	659:665	arg1	configuration					667:679	a compact configuration	657:679	a compact configuration	657:679	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	10	63	theme	configuration	1457:1469	arg1	relationship					1416:1427	The relationship	1412:1427	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations	1412:1513	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	4	64	theme	potentiating	596:607	arg1	drift					609:613	a flexible random coil potentiating drift	573:613	a flexible random coil potentiating drift across the channel	573:632	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	7	65	theme	functional	1062:1071	arg1	role					1073:1076	a critical functional role	1051:1076	a critical functional role	1051:1076	All showed highly conserved N-and C-terminal residues closely superimposed, suggesting a critical functional role.
37254962	9	66	theme	DIV	1334:1336	arg1	domain					1354:1359	the DIV voltage sensing domain	1330:1359	the DIV voltage sensing domain	1330:1359	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	5	67	with	hypervariability	789:804	arg1	%					821:821	between 40%	811:821	between 40%	811:821	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	3	68	theme	evolutionary	465:476	arg1	significance					478:489	potential physiological and evolutionary significance	437:489	potential physiological and evolutionary significance	437:489	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	4	69	theme	coil	591:594	arg1	drift					609:613	a flexible random coil potentiating drift	573:613	a flexible random coil potentiating drift across the channel	573:632	Rather than a flexible random coil potentiating drift across the channel, the linker folds into a compact configuration through self-assembling secondary structural elements.
37254962	5	70	theme	mammalian	764:772	arg1	organisms					774:782	48 mammalian organisms	761:782	48 mammalian organisms	761:782	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	5	71	from	organisms	774:782	arg1	sequences					746:754	Analogous sequences	736:754	Analogous sequences from 48 mammalian organisms	736:782	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	3	72	dep	potential	437:445	arg1	physiological					447:459	physiological	447:459	physiological	447:459	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	1	73	theme	ion	195:197	arg1	channel					199:205	the hSkMNaV1.4 ion channel	180:205	the hSkMNaV1.4 ion channel (PDB:6AGF)	180:216	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	1	73	theme	ion	195:197	arg1	PDB:6AGF					208:215	PDB:6AGF	208:215	PDB:6AGF	208:215	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37254962	2	74	theme	unique	347:352	arg1	sequence					354:361	unique sequence	347:361	unique sequence	347:361	This peptide is intriguing - comprised of unique sequence and found only in mammalian skeletal muscle sodium ion channels.
37254962	10	75	theme	compact	1449:1455	arg1	configuration					1457:1469	compact configuration	1449:1469	compact configuration	1449:1469	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	9	76	theme	sensing	1346:1352	arg1	domain					1354:1359	the DIV voltage sensing domain	1330:1359	the DIV voltage sensing domain	1330:1359	Results suggest a complex glycan added at this site in the linker may form electrostatic interactions with the DIV voltage sensing domain and be mechanistically involved in channel gating.
37254962	5	77	theme	sequence	832:839	arg1	similarity					841:850	100% sequence similarity	827:850	100% sequence similarity	827:850	Analogous sequences from 48 mammalian organisms show hypervariability with between 40% and 100% sequence similarity.
37254962	10	78	theme	unique	1432:1437	arg1	sequence					1439:1446	unique sequence	1432:1446	unique sequence	1432:1446	The relationship of unique sequence, compact configuration, potential glycosylation and MD simulations are discussed relative to SkMNaV1.4 structure and function.
37254962	3	79	theme	homology	510:517	arg1	model					519:523	an homology model	507:523	an homology model of the complete hSkMNaV1.4 channel	507:558	To probe potential physiological and evolutionary significance, we constructed an homology model of the complete hSkMNaV1.4 channel.
37254962	1	80	theme	59-residue	223:232	arg1	peptide					249:255	the 59-residue DIS5-S6 linker peptide	219:255	the 59-residue DIS5-S6 linker peptide	219:255	In the CryoEM-structure of the hSkMNaV1.4 ion channel (PDB:6AGF), the 59-residue DIS5-S6 linker peptide was omitted due to absence of electron density.
37344746	1	0	theme	T-cell	175:180	arg1	TCRs					193:196	TCRs	193:196	TCRs	193:196	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	1	0	theme	T-cell	175:180	arg1	receptors					182:190	T-cell receptors	175:190	T-cell receptors (TCRs) that recognize a variety of antigens	175:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	2	1	from	cells	318:322	arg1	present					293:299	present	293:299	present	293:299	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	4	2	theme	stage-specific	611:624	arg1	compositions					634:645	stage-specific glycome compositions	611:645	stage-specific glycome compositions	611:645	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	0	3	theme	repertoire	86:95	arg1	diversity					97:105	repertoire diversity	86:105	repertoire diversity	86:105	Mannosylated glycans impair normal T-cell development by reprogramming commitment and repertoire diversity.
37344746	3	4	from	TCR-selection	439:451	arg1	thymocytes					459:468	DP thymocytes	456:468	DP thymocytes	456:468	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	1	5	theme	receptors	182:190	arg1	TCRs					193:196	TCRs	193:196	TCRs	193:196	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	1	5	theme	receptors	182:190	arg1	repertoires					160:170	diverse repertoires	152:170	diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens	152:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	1	5	theme	receptors	182:190	arg1	receptors					182:190	T-cell receptors	175:190	T-cell receptors (TCRs) that recognize a variety of antigens	175:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	7	6	theme	mannosylated	1295:1306	arg1	thymocytes					1308:1317	mannosylated thymocytes	1295:1317	mannosylated thymocytes	1295:1317	In conclusion, we revealed that mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.
37344746	3	7	dep	unclear	477:483	arg1	regulate					497:504	regulate	497:504	regulate other thymic development processes	497:539	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	3	7	dep	unclear	477:483	arg1	influence					554:562	influence	554:562	influence susceptibility to disease	554:588	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	2	8	theme	all	314:316	arg1	cells					318:322	virtually all cells	304:322	virtually all cells	304:322	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	8	theme	all	314:316	arg1	T-lymphocytes					335:347	T-lymphocytes	335:347	T-lymphocytes	335:347	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	5	9	theme	increased	1039:1047	arg1	susceptibility					1049:1062	increased susceptibility	1039:1062	increased susceptibility to colon and kidney inflammation and infection	1039:1109	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	10	theme	thymocytes	786:795	arg1	profile					775:781	the N-glycosylation profile	755:781	the N-glycosylation profile of thymocytes	755:795	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	7	11	gly	mannosylated	1295:1306	arg1	thymocytes					1308:1317	mannosylated thymocytes	1295:1317	mannosylated thymocytes	1295:1317	In conclusion, we revealed that mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.
37344746	7	12	theme	T-cell	1346:1351	arg1	development					1353:1363	T-cell development	1346:1363	T-cell development	1346:1363	In conclusion, we revealed that mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.
37344746	5	13	theme	regulatory	968:977	arg1	generation					986:995	regulatory T-cell generation	968:995	regulatory T-cell generation	968:995	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	3	14	theme	other	506:510	arg1	processes					531:539	other thymic development processes	506:539	other thymic development processes	506:539	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	5	15	dep	colon	1067:1071	arg1	infection					1101:1109	infection	1101:1109	infection	1101:1109	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	15	dep	colon	1067:1071	arg1	inflammation					1084:1095	inflammation	1084:1095	inflammation	1084:1095	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	6	16	theme	single	1143:1148	arg1	condition					1223:1231	the sine-qua-non condition	1206:1231	the sine-qua-non condition to ensure normal development	1206:1260	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	6	16	theme	single	1143:1148	arg1	antenna					1159:1165	a single N-glycan antenna	1141:1165	a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice)	1141:1201	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	5	17	theme	developmental	918:930	arg1	checkpoints					932:942	key developmental checkpoints	914:942	key developmental checkpoints	914:942	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	17	theme	developmental	918:930	arg1	ß-selection					955:965	ß-selection	955:965	ß-selection	955:965	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	17	theme	developmental	918:930	arg1	generation					986:995	regulatory T-cell generation	968:995	regulatory T-cell generation	968:995	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	17	theme	developmental	918:930	arg1	development					1010:1020	γδT-cell development	1001:1020	γδT-cell development	1001:1020	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	4	18	theme	glycome	626:632	arg1	compositions					634:645	stage-specific glycome compositions	611:645	stage-specific glycome compositions	611:645	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	5	19	theme	T-cell	979:984	arg1	generation					986:995	regulatory T-cell generation	968:995	regulatory T-cell generation	968:995	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	2	20	theme	present	293:299	arg1	Glycosylation					237:249	Glycosylation	237:249	Glycosylation	237:249	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	20	theme	present	293:299	arg1	modification					280:291	a major posttranslational modification	254:291	a major posttranslational modification	254:291	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	6	21	theme	Rag1CreMgat2fl/fl	1179:1195	arg1	mice					1197:1200	Rag1CreMgat2fl/fl mice	1179:1200	Rag1CreMgat2fl/fl mice	1179:1200	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	5	22	theme	specific	831:838	arg1	Rag1CreMgat1fl/fl					862:878	Rag1CreMgat1fl/fl	862:878	Rag1CreMgat1fl/fl	862:878	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	22	theme	specific	831:838	arg1	mice					856:859	specific glycoengineered mice	831:859	specific glycoengineered mice (Rag1CreMgat1fl/fl)	831:879	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	3	23	theme	DP	456:457	arg1	thymocytes					459:468	DP thymocytes	456:468	DP thymocytes	456:468	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	0	24	theme	Mannosylated	0:11	arg1	glycans					13:19	Mannosylated glycans	0:19	Mannosylated glycans	0:19	Mannosylated glycans impair normal T-cell development by reprogramming commitment and repertoire diversity.
37344746	7	25	from	dysregulation	1329:1341	arg1	development					1353:1363	T-cell development	1346:1363	T-cell development	1346:1363	In conclusion, we revealed that mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.
37344746	1	26	theme	T-cell	108:113	arg1	development					115:125	T-cell development	108:125	T-cell development	108:125	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	0	27	theme	normal	28:33	arg1	development					42:52	normal T-cell development	28:52	normal T-cell development	28:52	Mannosylated glycans impair normal T-cell development by reprogramming commitment and repertoire diversity.
37344746	6	28	theme	normal	1243:1248	arg1	development					1250:1260	normal development	1243:1260	normal development	1243:1260	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	5	29	theme	high-mannose	800:811	arg1	structures					813:822	high-mannose structures	800:822	high-mannose structures	800:822	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	30	theme	remarkable	892:901	arg1	defects					903:909	remarkable defects	892:909	remarkable defects	892:909	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	31	gly	N-glycosylation	759:773	arg1	thymocytes					786:795	thymocytes	786:795	thymocytes	786:795	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	4	32	theme	human	676:680	arg1	thymocytes					693:702	human and murine thymocytes	676:702	human and murine thymocytes	676:702	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	5	33	theme	glycoengineered	840:854	arg1	Rag1CreMgat1fl/fl					862:878	Rag1CreMgat1fl/fl	862:878	Rag1CreMgat1fl/fl	862:878	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	33	theme	glycoengineered	840:854	arg1	mice					856:859	specific glycoengineered mice	831:859	specific glycoengineered mice (Rag1CreMgat1fl/fl)	831:879	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	7	34	theme	inflammation	1389:1400	arg1	susceptibility					1402:1415	inflammation susceptibility	1389:1415	inflammation susceptibility	1389:1415	In conclusion, we revealed that mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.
37344746	5	35	theme	N-glycosylation	759:773	arg1	profile					775:781	the N-glycosylation profile	755:781	the N-glycosylation profile of thymocytes	755:795	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	0	36	theme	T-cell	35:40	arg1	development					42:52	normal T-cell development	28:52	normal T-cell development	28:52	Mannosylated glycans impair normal T-cell development by reprogramming commitment and repertoire diversity.
37344746	4	37	theme	murine	686:691	arg1	thymocytes					693:702	human and murine thymocytes	676:702	human and murine thymocytes	676:702	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	3	38	theme	thymic	512:517	arg1	processes					531:539	other thymic development processes	506:539	other thymic development processes	506:539	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	2	39	attach	present	293:299	arg2	modification					280:291	a major posttranslational modification	254:291	a major posttranslational modification	254:291	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	39	attach	present	293:299	arg1	T-lymphocytes					335:347	T-lymphocytes	335:347	T-lymphocytes	335:347	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	39	attach	present	293:299	arg1	cells					318:322	virtually all cells	304:322	virtually all cells	304:322	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	39	attach	present	293:299	arg2	Glycosylation					237:249	Glycosylation	237:249	Glycosylation	237:249	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	3	40	theme	development	519:529	arg1	processes					531:539	other thymic development processes	506:539	other thymic development processes	506:539	Although these structures are known to be involved in TCR-selection in DP thymocytes, it is unclear how glycans regulate other thymic development processes and how they influence susceptibility to disease.
37344746	4	41	theme	dynamic	716:722	arg1	alterations					724:734	dynamic alterations	716:734	dynamic alterations	716:734	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	5	42	theme	γδT-cell	1001:1008	arg1	development					1010:1020	γδT-cell development	1001:1020	γδT-cell development	1001:1020	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	2	43	from	present	293:299	arg1	cells					318:322	virtually all cells	304:322	virtually all cells	304:322	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	43	from	present	293:299	arg1	T-lymphocytes					335:347	T-lymphocytes	335:347	T-lymphocytes	335:347	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	1	44	theme	antigens	227:234	arg1	antigens					227:234	antigens	227:234	antigens	227:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	1	44	theme	antigens	227:234	arg1	variety					216:222	a variety	214:222	a variety of antigens	214:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	5	45	from	defects	903:909	arg1	checkpoints					932:942	key developmental checkpoints	914:942	key developmental checkpoints	914:942	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	45	from	defects	903:909	arg1	ß-selection					955:965	ß-selection	955:965	ß-selection	955:965	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	45	from	defects	903:909	arg1	generation					986:995	regulatory T-cell generation	968:995	regulatory T-cell generation	968:995	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	45	from	defects	903:909	arg1	development					1010:1020	γδT-cell development	1001:1020	γδT-cell development	1001:1020	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	2	46	theme	posttranslational	262:278	arg1	Glycosylation					237:249	Glycosylation	237:249	Glycosylation	237:249	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	46	theme	posttranslational	262:278	arg1	modification					280:291	a major posttranslational modification	254:291	a major posttranslational modification	254:291	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	1	47	theme	diverse	152:158	arg1	TCRs					193:196	TCRs	193:196	TCRs	193:196	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	1	47	theme	diverse	152:158	arg1	repertoires					160:170	diverse repertoires	152:170	diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens	152:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	1	47	theme	diverse	152:158	arg1	receptors					182:190	T-cell receptors	175:190	T-cell receptors (TCRs) that recognize a variety of antigens	175:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	6	48	theme	sine-qua-non	1210:1221	arg1	condition					1223:1231	the sine-qua-non condition	1206:1231	the sine-qua-non condition to ensure normal development	1206:1260	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	6	48	theme	sine-qua-non	1210:1221	arg1	antenna					1159:1165	a single N-glycan antenna	1141:1165	a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice)	1141:1201	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	5	49	theme	key	914:916	arg1	checkpoints					932:942	key developmental checkpoints	914:942	key developmental checkpoints	914:942	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	49	theme	key	914:916	arg1	ß-selection					955:965	ß-selection	955:965	ß-selection	955:965	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	49	theme	key	914:916	arg1	generation					986:995	regulatory T-cell generation	968:995	regulatory T-cell generation	968:995	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	5	49	theme	key	914:916	arg1	development					1010:1020	γδT-cell development	1001:1020	γδT-cell development	1001:1020	After restricting the N-glycosylation profile of thymocytes to high-mannose structures, using specific glycoengineered mice (Rag1CreMgat1fl/fl), we showed remarkable defects in key developmental checkpoints, including ß-selection, regulatory T-cell generation and γδT-cell development, associated with increased susceptibility to colon and kidney inflammation and infection.
37344746	2	50	theme	major	256:260	arg1	Glycosylation					237:249	Glycosylation	237:249	Glycosylation	237:249	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	2	50	theme	major	256:260	arg1	modification					280:291	a major posttranslational modification	254:291	a major posttranslational modification	254:291	Glycosylation is a major posttranslational modification present in virtually all cells, including T-lymphocytes, that regulates activity/functions.
37344746	6	51	theme	N-glycan	1150:1157	arg1	condition					1223:1231	the sine-qua-non condition	1206:1231	the sine-qua-non condition to ensure normal development	1206:1260	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	6	51	theme	N-glycan	1150:1157	arg1	antenna					1159:1165	a single N-glycan antenna	1141:1165	a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice)	1141:1201	We further demonstrated that a single N-glycan antenna (modeled in Rag1CreMgat2fl/fl mice) is the sine-qua-non condition to ensure normal development.
37344746	1	52	theme	repertoires	160:170	arg1	formation					139:147	the formation	135:147	the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens	135:234	T-cell development ensures the formation of diverse repertoires of T-cell receptors (TCRs) that recognize a variety of antigens.
37344746	4	53	from	development	661:671	arg1	thymocytes					693:702	human and murine thymocytes	676:702	human and murine thymocytes	676:702	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	4	53	from	development	661:671	arg1	alterations					724:734	dynamic alterations	716:734	dynamic alterations	716:734	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
37344746	4	54	theme	T-cell	654:659	arg1	development					661:671	T-cell development	654:671	T-cell development in human and murine thymocytes, as well as dynamic alterations	654:734	Here, we discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations.
35163200	6	0	theme	iCAG-Cos	1254:1261	arg1	mice					1263:1266	the iCAG-Cos mice	1250:1266	the iCAG-Cos mice	1250:1266	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	3	1	theme	Cosmc-knockout	492:505	arg1	mice					507:510	Cosmc-knockout mice	492:510	Cosmc-knockout mice	492:510	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	1	2	theme	glycosylation-a	211:225	arg1	modification					245:256	glycosylation-a posttranslational modification	211:256	glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	211:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	6	3	theme	severe	1158:1163	arg1	dysfunction					1171:1181	severe renal dysfunction	1158:1181	severe renal dysfunction	1158:1181	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	1	4	attach	present	258:264	arg2	modification					245:256	glycosylation-a posttranslational modification	211:256	glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	211:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	1	4	attach	present	258:264	arg1	proteins					298:305	membrane-bound and secretory proteins	269:305	membrane-bound and secretory proteins	269:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	7	5	theme	high-density	1399:1410	arg1	lipoprotein					1412:1422	high-density lipoprotein	1399:1422	high-density lipoprotein	1399:1422	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	4	6	theme	ubiquitous	646:655	arg1	mice					709:712	ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice	646:712	ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice	646:712	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	6	7	theme	high	1232:1235	arg1	mortality					1237:1245	the high mortality	1228:1245	the high mortality of the iCAG-Cos mice	1228:1266	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	7	8	theme	cholesterol	1435:1445	arg1	levels					1447:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	6	9	theme	spontaneous	1127:1137	arg1	ulcers					1147:1152	spontaneous gastric ulcers	1127:1152	spontaneous gastric ulcers	1127:1152	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	4	10	theme	inducible	661:669	arg1	mice					709:712	ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice	646:712	ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice	646:712	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	3	11	theme	core	564:567	arg1	O-glycans					579:587	core 1-derived O-glycans	564:587	core 1-derived O-glycans	564:587	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	1	12	theme	major	148:152	arg1	structure					131:139	The core 1 structure	120:139	The core 1 structure	120:139	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	1	12	theme	major	148:152	arg1	constituent					154:164	the major constituent	144:164	the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	144:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	5	13	theme	O-glycans	845:853	arg1	loss					822:825	a global loss	813:825	a global loss of core 1-derived O-glycans, high mortality,	813:870	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	7	14	theme	protein	1359:1365	arg1	levels					1367:1372	lower blood glucose and total blood protein levels	1323:1372	levels	1367:1372	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	7	15	theme	iCAG-Cos	1304:1311	arg1	mice					1313:1316	the iCAG-Cos mice	1300:1316	the iCAG-Cos mice	1300:1316	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	0	16	theme	Gastric	104:110	arg1	Ulcers					112:117	Gastric Ulcers	104:117	Gastric Ulcers	104:117	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	1	17	theme	O-glycans	180:188	arg1	structure					131:139	The core 1 structure	120:139	The core 1 structure	120:139	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	1	17	theme	O-glycans	180:188	arg1	constituent					154:164	the major constituent	144:164	the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	144:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	7	18	theme	total	1347:1351	arg1	levels					1367:1372	lower blood glucose and total blood protein levels	1323:1372	levels	1367:1372	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	3	19	theme	O-glycans	579:587	arg1	role					556:559	the biological role	541:559	the biological role of core 1-derived O-glycans in the adult stage	541:606	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	8	20	from	maintenance	1555:1565	arg1	mice					1576:1579	adult mice	1570:1579	adult mice	1570:1579	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	3	21	from	role	556:559	arg1	stage					602:606	the adult stage	592:606	the adult stage	592:606	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	7	22	contain	have	1318:1321	arg2	levels					1367:1372	lower blood glucose and total blood protein levels	1323:1372	levels	1367:1372	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	7	22	contain	have	1318:1321	arg2	levels					1447:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	7	22	contain	have	1318:1321	arg1	mice					1313:1316	the iCAG-Cos mice	1300:1316	the iCAG-Cos mice	1300:1316	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	7	22	contain	have	1318:1321	arg2	glucose					1335:1341	lower blood glucose and total blood protein levels	1323:1372	glucose	1335:1341	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	5	23	theme	thymus	921:926	arg1	weights					906:912	weights	906:912	weights of the thymus, adipose tissue, and pancreas	906:956	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	7	24	theme	lower	1323:1327	arg1	glucose					1335:1341	lower blood glucose and total blood protein levels	1323:1372	glucose	1335:1341	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	5	25	theme	drastic	885:891	arg1	reduction					893:901	a drastic reduction	883:901	a drastic reduction in weights of the thymus, adipose tissue, and pancreas	883:956	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	2	26	theme	enzymatic	466:474	arg1	activity					476:483	its enzymatic activity	462:483	its enzymatic activity	462:483	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	0	27	theme	High	57:60	arg1	Mortality					62:70	High Mortality	57:70	High Mortality	57:70	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	5	28	from	reduction	893:901	arg1	weights					906:912	weights	906:912	weights of the thymus, adipose tissue, and pancreas	906:956	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	4	29	theme	O-glycans	774:782	arg1	function					747:754	the physiological function	729:754	the physiological function of core 1-derived O-glycans	729:782	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	5	30	theme	pancreas	949:956	arg1	weights					906:912	weights	906:912	weights of the thymus, adipose tissue, and pancreas	906:956	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	2	31	theme	core	384:387	arg1	structure					391:399	the core 1 structure	380:399	the core 1 structure	380:399	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	0	32	theme	Acute	79:83	arg1	Failure					92:98	Acute Kidney Failure	79:98	Acute Kidney Failure	79:98	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	5	33	theme	iCAG-Cos	789:796	arg1	mice					798:801	The iCAG-Cos mice	785:801	The iCAG-Cos mice	785:801	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	2	34	theme	C1galt1-specific	420:435	arg1	chaperone					447:455	a C1galt1-specific molecular chaperone	418:455	a C1galt1-specific molecular chaperone	418:455	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	2	34	theme	C1galt1-specific	420:435	arg1	Cosmc					411:415	Cosmc	411:415	Cosmc	411:415	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	8	35	theme	1-derived	1519:1527	arg1	O-glycans					1529:1537	core 1-derived O-glycans	1514:1537	core 1-derived O-glycans	1514:1537	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	0	36	theme	Global	0:5	arg1	Loss					7:10	Global Loss	0:10	Global Loss of Core 1-Derived O-Glycans in Mice	0:46	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	1	37	theme	present	258:264	arg1	modification					245:256	glycosylation-a posttranslational modification	211:256	glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	211:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	5	38	theme	adipose	929:935	arg1	tissue					937:942	adipose tissue	929:942	adipose tissue	929:942	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	6	39	theme	acute	1049:1053	arg1	pancreatitis					1055:1066	severe acute pancreatitis	1042:1066	severe acute pancreatitis	1042:1066	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	4	40	theme	core	759:762	arg1	O-glycans					774:782	core 1-derived O-glycans	759:782	core 1-derived O-glycans	759:782	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	5	41	theme	core	830:833	arg1	O-glycans					845:853	core 1-derived O-glycans	830:853	core 1-derived O-glycans	830:853	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	5	41	theme	core	830:833	arg1	mortality					861:869	high mortality	856:869	high mortality	856:869	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	1	42	theme	membrane-bound	269:282	arg1	proteins					298:305	membrane-bound and secretory proteins	269:305	membrane-bound and secretory proteins	269:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	3	43	link	1-derived	569:577	arg1	O-glycans					579:587	core 1-derived O-glycans	564:587	core 1-derived O-glycans	564:587	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	0	44	theme	1-Derived	20:28	arg1	O-Glycans					30:38	Core 1-Derived O-Glycans	15:38	Core 1-Derived O-Glycans	15:38	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	1	45	theme	secretory	288:296	arg1	proteins					298:305	membrane-bound and secretory proteins	269:305	membrane-bound and secretory proteins	269:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	7	46	theme	Serological	1269:1279	arg1	analysis					1281:1288	Serological analysis	1269:1288	Serological analysis	1269:1288	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	8	47	theme	adult	1570:1574	arg1	mice					1576:1579	adult mice	1570:1579	adult mice	1570:1579	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	6	48	theme	tissue	1108:1113	arg1	thrombocytopenia					1024:1039	thrombocytopenia	1024:1039	thrombocytopenia	1024:1039	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	48	theme	tissue	1108:1113	arg1	ulcers					1147:1152	spontaneous gastric ulcers	1127:1152	spontaneous gastric ulcers	1127:1152	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	48	theme	tissue	1108:1113	arg1	atrophy					1073:1079	atrophy	1073:1079	atrophy	1073:1079	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	48	theme	tissue	1108:1113	arg1	leukocytopenia					1008:1021	leukocytopenia	1008:1021	leukocytopenia	1008:1021	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	48	theme	tissue	1108:1113	arg1	pancreatitis					1055:1066	severe acute pancreatitis	1042:1066	severe acute pancreatitis	1042:1066	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	48	theme	tissue	1108:1113	arg1	dysfunction					1171:1181	severe renal dysfunction	1158:1181	severe renal dysfunction	1158:1181	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	49	theme	renal	1165:1169	arg1	dysfunction					1171:1181	severe renal dysfunction	1158:1181	severe renal dysfunction	1158:1181	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	7	50	theme	lipoprotein	1412:1422	arg1	levels					1447:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	5	51	theme	Cosmc	972:976	arg1	deletion					978:985	Cosmc deletion	972:985	Cosmc deletion	972:985	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	6	52	theme	brown	1094:1098	arg1	tissue					1108:1113	white and brown adipose tissue	1084:1113	white and brown adipose tissue	1084:1113	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	8	53	link	1-derived	1519:1527	arg1	O-glycans					1529:1537	core 1-derived O-glycans	1514:1537	core 1-derived O-glycans	1514:1537	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	6	54	theme	mice	1263:1266	arg1	mortality					1237:1245	the high mortality	1228:1245	the high mortality of the iCAG-Cos mice	1228:1266	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	1	55	theme	posttranslational	227:243	arg1	modification					245:256	glycosylation-a posttranslational modification	211:256	glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	211:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	7	56	theme	triglyceride	1385:1396	arg1	levels					1447:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	higher triglyceride, high-density lipoprotein, and total cholesterol levels	1378:1452	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	3	57	theme	embryonic	520:528	arg1	lethality					530:538	embryonic lethality	520:538	embryonic lethality	520:538	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	7	58	theme	total	1429:1433	arg1	cholesterol					1435:1445	total cholesterol	1429:1445	total cholesterol	1429:1445	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	6	59	theme	gastric	1139:1145	arg1	ulcers					1147:1152	spontaneous gastric ulcers	1127:1152	spontaneous gastric ulcers	1127:1152	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	2	60	theme	Core	308:311	arg1	C1galt1					343:349	C1galt1	343:349	C1galt1	343:349	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	2	60	theme	Core	308:311	arg1	β1,3-galactosyltransferase					315:340	Core 1 β1,3-galactosyltransferase	308:340	Core 1 β1,3-galactosyltransferase (C1galt1)	308:350	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	2	60	theme	Core	308:311	arg1	enzyme					356:361	an enzyme	353:361	an enzyme that synthesizes the core 1 structure	353:399	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	3	61	theme	biological	545:554	arg1	role					556:559	the biological role	541:559	the biological role of core 1-derived O-glycans in the adult stage	541:606	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	5	62	theme	1-derived	835:843	arg1	O-glycans					845:853	core 1-derived O-glycans	830:853	core 1-derived O-glycans	830:853	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	5	62	theme	1-derived	835:843	arg1	mortality					861:869	high mortality	856:869	high mortality	856:869	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	7	63	theme	higher	1378:1383	arg1	triglyceride					1385:1396	higher triglyceride	1378:1396	higher triglyceride	1378:1396	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	1	64	theme	mucin-type	169:178	arg1	O-glycans					180:188	mucin-type O-glycans	169:188	mucin-type O-glycans	169:188	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	3	65	theme	1-derived	569:577	arg1	O-glycans					579:587	core 1-derived O-glycans	564:587	core 1-derived O-glycans	564:587	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	7	66	theme	blood	1353:1357	arg1	levels					1367:1372	lower blood glucose and total blood protein levels	1323:1372	levels	1367:1372	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	5	67	dep	days	961:964	arg1	deletion					978:985	Cosmc deletion	972:985	Cosmc deletion	972:985	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	3	68	theme	adult	596:600	arg1	stage					602:606	the adult stage	592:606	the adult stage	592:606	Since Cosmc-knockout mice exhibit embryonic lethality, the biological role of core 1-derived O-glycans in the adult stage is not fully understood.
35163200	7	69	theme	blood	1329:1333	arg1	glucose					1335:1341	lower blood glucose and total blood protein levels	1323:1372	glucose	1335:1341	Serological analysis indicated the iCAG-Cos mice have lower blood glucose and total blood protein levels and higher triglyceride, high-density lipoprotein, and total cholesterol levels than the controls.
35163200	4	70	theme	CAGCre-ERTM/Cosmc-knockout	671:696	arg1	mice					709:712	ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice	646:712	ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice	646:712	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	1	71	theme	core	124:127	arg1	structure					131:139	The core 1 structure	120:139	The core 1 structure	120:139	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	1	71	theme	core	124:127	arg1	constituent					154:164	the major constituent	144:164	the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins	144:305	The core 1 structure is the major constituent of mucin-type O-glycans, which are added via glycosylation-a posttranslational modification present on membrane-bound and secretory proteins.
35163200	0	72	from	Loss	7:10	arg1	Mice					43:46	Mice	43:46	Mice	43:46	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	5	73	link	1-derived	835:843	arg1	O-glycans					845:853	core 1-derived O-glycans	830:853	core 1-derived O-glycans	830:853	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	5	73	link	1-derived	835:843	arg1	mortality					861:869	high mortality	856:869	high mortality	856:869	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	8	74	theme	core	1514:1517	arg1	O-glycans					1529:1537	core 1-derived O-glycans	1514:1537	core 1-derived O-glycans	1514:1537	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	4	75	theme	1-derived	764:772	arg1	O-glycans					774:782	core 1-derived O-glycans	759:782	core 1-derived O-glycans	759:782	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	4	76	link	1-derived	764:772	arg1	O-glycans					774:782	core 1-derived O-glycans	759:782	core 1-derived O-glycans	759:782	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	0	77	theme	Kidney	85:90	arg1	Failure					92:98	Acute Kidney Failure	79:98	Acute Kidney Failure	79:98	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	8	78	theme	O-glycans	1529:1537	arg1	importance					1500:1509	the importance	1496:1509	the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice	1496:1579	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	5	79	theme	global	815:820	arg1	loss					822:825	a global loss	813:825	a global loss of core 1-derived O-glycans, high mortality,	813:870	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	8	80	theme	homeostatic	1543:1553	arg1	maintenance					1555:1565	homeostatic maintenance	1543:1565	homeostatic maintenance in adult mice	1543:1579	These data demonstrate the importance of core 1-derived O-glycans for homeostatic maintenance in adult mice.
35163200	4	81	theme	physiological	733:745	arg1	function					747:754	the physiological function	729:754	the physiological function of core 1-derived O-glycans	729:782	We generated ubiquitous and inducible CAGCre-ERTM/Cosmc-knockout (iCAG-Cos) mice to investigate the physiological function of core 1-derived O-glycans.
35163200	0	82	theme	Core	15:18	arg1	O-Glycans					30:38	Core 1-Derived O-Glycans	15:38	Core 1-Derived O-Glycans	15:38	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	5	83	theme	tissue	937:942	arg1	weights					906:912	weights	906:912	weights of the thymus, adipose tissue, and pancreas	906:956	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	6	84	theme	severe	1042:1047	arg1	pancreatitis					1055:1066	severe acute pancreatitis	1042:1066	severe acute pancreatitis	1042:1066	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	0	85	theme	O-Glycans	30:38	arg1	Loss					7:10	Global Loss	0:10	Global Loss of Core 1-Derived O-Glycans in Mice	0:46	Global Loss of Core 1-Derived O-Glycans in Mice Leads to High Mortality Due to Acute Kidney Failure and Gastric Ulcers.
35163200	2	86	theme	molecular	437:445	arg1	chaperone					447:455	a C1galt1-specific molecular chaperone	418:455	a C1galt1-specific molecular chaperone	418:455	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	2	86	theme	molecular	437:445	arg1	Cosmc					411:415	Cosmc	411:415	Cosmc	411:415	Core 1 β1,3-galactosyltransferase (C1galt1), an enzyme that synthesizes the core 1 structure, requires Cosmc, a C1galt1-specific molecular chaperone, for its enzymatic activity.
35163200	6	87	theme	adipose	1100:1106	arg1	tissue					1108:1113	white and brown adipose tissue	1084:1113	white and brown adipose tissue	1084:1113	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	6	88	theme	white	1084:1088	arg1	tissue					1108:1113	white and brown adipose tissue	1084:1113	white and brown adipose tissue	1084:1113	They also exhibited leukocytopenia, thrombocytopenia, severe acute pancreatitis, and atrophy of white and brown adipose tissue, as well as spontaneous gastric ulcers and severe renal dysfunction, which were considered the causes underlying the high mortality of the iCAG-Cos mice.
35163200	5	89	theme	high	856:859	arg1	O-glycans					845:853	core 1-derived O-glycans	830:853	core 1-derived O-glycans	830:853	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35163200	5	89	theme	high	856:859	arg1	mortality					861:869	high mortality	856:869	high mortality	856:869	The iCAG-Cos mice exhibited a global loss of core 1-derived O-glycans, high mortality, and showed a drastic reduction in weights of the thymus, adipose tissue, and pancreas 10 days after Cosmc deletion.
35941485	7	0	theme	CS/DS	2002:2006	arg1	domains					2008:2014	oversulfated CS/DS domains	1989:2014	oversulfated CS/DS domains	1989:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	2	1	theme	biological	563:572	arg1	activities					574:583	biological activities	563:583	biological activities in brain	563:592	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	2	2	theme	dermatan	360:367	arg1	sulfate					369:375	dermatan sulfate	360:375	dermatan sulfate (DS)	360:380	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	2	2	theme	dermatan	360:367	arg1	DS					378:379	DS	378:379	DS	378:379	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	1	3	theme	extracellular	291:303	arg1	ECM					313:315	ECM	313:315	ECM	313:315	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	1	3	theme	extracellular	291:303	arg1	matrix					305:310	the extracellular matrix	287:310	the extracellular matrix (ECM)	287:316	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	4	4	theme	structure	1033:1041	arg1	determination					1043:1055	their structure determination	1027:1055	their structure determination	1027:1055	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	5	5	theme	collision-induced	1420:1436	arg1	CID					1452:1454	CID	1452:1454	CID	1452:1454	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	5	5	theme	collision-induced	1420:1436	arg1	dissociation					1438:1449	collision-induced dissociation	1420:1449	collision-induced dissociation (CID)	1420:1455	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	6	6	theme	chapter	1517:1523	arg1	part					1505:1508	the second part	1494:1508	the second part of the chapter	1494:1523	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	4	7	theme	present	1112:1118	arg1	chapter					1120:1126	the present chapter	1108:1126	capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter	883:1126	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	7	theme	present	1112:1118	arg1	sensitivity					837:847	its sensitivity	833:847	its sensitivity	833:847	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	5	8	theme	fragmentation	1378:1390	arg1	analysis					1392:1399	fragmentation analysis	1378:1399	fragmentation analysis in tandem MS	1378:1412	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	3	9	theme	various	705:711	arg1	combinations					713:724	various combinations	705:724	various combinations	705:724	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	2	10	theme	chondroitin	331:341	arg1	CS					352:353	CS	352:353	CS	352:353	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	2	10	theme	chondroitin	331:341	arg1	sulfate					343:349	chondroitin sulfate	331:349	chondroitin sulfate (CS)	331:354	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	6	11	theme	second	1498:1503	arg1	part					1505:1508	the second part	1494:1508	the second part of the chapter	1494:1523	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	1	12	theme	glycosaminoglycan	231:247	arg1	chains					255:260	one or more glycosaminoglycan (GAG) chains	219:260	one or more glycosaminoglycan (GAG) chains	219:260	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	4	13	theme	zone	893:896	arg1	CZE					915:917	CZE	915:917	CZE	915:917	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	13	theme	zone	893:896	arg1	electrophoresis					898:912	capillary zone electrophoresis	883:912	capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination	883:1055	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	2	14	theme	sulfate	503:509	arg1	groups					511:516	the sulfate groups	499:516	the sulfate groups	499:516	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	1	15	gly	glycosylated	175:186	arg1	proteins					188:195	heavily glycosylated proteins	167:195	heavily glycosylated proteins	167:195	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	1	15	gly	glycosylated	175:186	arg1	Proteoglycans					149:161	Proteoglycans	149:161	Proteoglycans	149:161	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	6	16	theme	normal	1562:1567	arg1	polarity					1569:1576	normal polarity	1562:1576	normal polarity	1562:1576	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	6	17	theme	acquisition	1650:1660	arg1	mode					1662:1665	real-time data-dependent acquisition mode	1625:1665	real-time data-dependent acquisition mode for CS/DS separation	1625:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	6	18	theme	real-time	1625:1633	arg1	mode					1662:1665	real-time data-dependent acquisition mode	1625:1665	real-time data-dependent acquisition mode for CS/DS separation	1625:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	5	19	from	collection	1322:1331	arg1	MS					1411:1412	tandem MS	1404:1412	tandem MS	1404:1412	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	3	20	theme	high	764:767	arg1	methods					792:798	specific high performance analytical methods	755:798	specific high performance analytical methods for reliable elucidation	755:823	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	4	21	theme	CS/DS	938:942	arg1	oligosaccharides					944:959	CS/DS oligosaccharides	938:959	CS/DS oligosaccharides	938:959	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	22	theme	powerful	1133:1140	arg1	methods					1142:1148	two powerful methods	1129:1148	two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS	1129:1239	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	0	23	theme	Total	84:88	arg1	Analysis					90:97	Total Analysis	84:97	Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides	84:146	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	4	24	dep	chapter	1120:1126	arg1	contributed					1057:1067	contributed	1057:1067	contributed an essential progress to this field.In	1057:1106	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	2	25	theme	CS/DS	462:466	arg1	composition					436:446	the composition	432:446	the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain	432:532	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	5	26	theme	low	1460:1462	arg1	energies					1481:1488	low ion acceleration energies	1460:1488	low ion acceleration energies	1460:1488	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	7	27	theme	total	1918:1922	arg1	analysis					1924:1931	total analysis	1918:1931	total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains	1918:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	6	28	theme	tandem	1612:1617	arg1	MS					1619:1620	tandem MS	1612:1620	tandem MS in real-time data-dependent acquisition mode for CS/DS separation	1612:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	5	29	theme	acceleration	1468:1479	arg1	energies					1481:1488	low ion acceleration energies	1460:1488	low ion acceleration energies	1460:1488	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	4	30	theme	structural	1212:1221	arg1	analysis					1223:1230	structural analysis	1212:1230	structural analysis	1212:1230	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	3	31	theme	analytical	781:790	arg1	methods					792:798	specific high performance analytical methods	755:798	specific high performance analytical methods for reliable elucidation	755:823	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	0	32	theme	Sulfate	123:129	arg1	Oligosaccharides					131:146	Chondroitin/Dermatan Sulfate Oligosaccharides	102:146	Chondroitin/Dermatan Sulfate Oligosaccharides	102:146	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	7	33	theme	system	1907:1912	arg1	manufacturing					1786:1798	the in-laboratory manufacturing	1768:1798	the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS	1768:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	7	33	theme	system	1907:1912	arg1	optimization					1879:1890	the optimization	1875:1890	the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains	1875:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	5	34	theme	fraction	1313:1320	arg1	collection					1322:1331	fraction collection	1313:1331	fraction collection	1313:1331	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	2	35	theme	essential	390:398	arg1	role					400:403	an essential role	387:403	an essential role	387:403	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	0	36	theme	Capillary	0:8	arg1	Spectrometry					67:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry	0:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.	0:147	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	5	37	theme	offline	1285:1291	arg1	CZE-ESI-MS					1293:1302	offline CZE-ESI-MS	1285:1302	offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies	1285:1488	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	2	38	theme	ECM	412:414	arg1	level					416:420	the ECM level	408:420	the ECM level	408:420	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	0	39	theme	Electrophoresis-Electrospray	15:42	arg1	Spectrometry					67:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry	0:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.	0:147	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	4	40	theme	electrospray	972:983	arg1	ESI-MS					1015:1020	ESI-MS	1015:1020	ESI-MS	1015:1020	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	40	theme	electrospray	972:983	arg1	spectrometry					1001:1012	electrospray ionization mass spectrometry	972:1012	electrospray ionization mass spectrometry (ESI-MS) for their structure determination	972:1055	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	0	41	theme	Tandem	55:60	arg1	Spectrometry					67:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry	0:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.	0:147	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	7	42	theme	sturdy	1816:1821	arg1	interface					1823:1831	a simple yet sturdy interface	1803:1831	a simple yet sturdy interface for the online CZE coupling to ESI-MS	1803:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	4	43	theme	mass	996:999	arg1	ESI-MS					1015:1020	ESI-MS	1015:1020	ESI-MS	1015:1020	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	43	theme	mass	996:999	arg1	spectrometry					1001:1012	electrospray ionization mass spectrometry	972:1012	electrospray ionization mass spectrometry (ESI-MS) for their structure determination	972:1055	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	2	44	from	activities	574:583	arg1	brain					588:592	brain	588:592	brain	588:592	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	3	45	theme	elevated	599:606	arg1	diversity					619:627	The elevated structural diversity	595:627	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations,	595:725	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	7	46	theme	CZE	1848:1850	arg1	coupling					1852:1859	the online CZE coupling	1837:1859	the online CZE coupling to ESI-MS	1837:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	7	47	theme	simple	1805:1810	arg1	interface					1823:1831	a simple yet sturdy interface	1803:1831	a simple yet sturdy interface for the online CZE coupling to ESI-MS	1803:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	5	48	from	analysis	1392:1399	arg1	MS					1411:1412	tandem MS	1404:1412	tandem MS	1404:1412	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	3	49	theme	CS/DS	632:636	arg1	motifs					638:643	CS/DS motifs	632:643	CS/DS motifs	632:643	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	7	50	theme	in-laboratory	1772:1784	arg1	manufacturing					1786:1798	the in-laboratory manufacturing	1768:1798	the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS	1768:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	5	51	theme	ion	1356:1358	arg1	mode					1360:1363	negative ion mode	1347:1363	negative ion mode nanoESI	1347:1371	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	4	52	theme	capillary	883:891	arg1	CZE					915:917	CZE	915:917	CZE	915:917	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	52	theme	capillary	883:891	arg1	electrophoresis					898:912	capillary zone electrophoresis	883:912	capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination	883:1055	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	53	theme	oligosaccharides	944:959	arg1	separation					924:933	separation	924:933	separation of CS/DS oligosaccharides	924:959	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	7	54	theme	oversulfated	1989:2000	arg1	domains					2008:2014	oversulfated CS/DS domains	1989:2014	oversulfated CS/DS domains	1989:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	7	55	theme	latter	1746:1751	arg1	method					1753:1758	The latter method	1742:1758	The latter method	1742:1758	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	1	56	attach	linked	209:214	arg2	Proteoglycans					149:161	Proteoglycans	149:161	Proteoglycans	149:161	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	1	56	attach	linked	209:214	arg2	proteins					188:195	heavily glycosylated proteins	167:195	heavily glycosylated proteins	167:195	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	1	56	attach	linked	209:214	arg1	chains					255:260	one or more glycosaminoglycan (GAG) chains	219:260	one or more glycosaminoglycan (GAG) chains	219:260	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	5	57	theme	tandem	1404:1409	arg1	MS					1411:1412	tandem MS	1404:1412	tandem MS	1404:1412	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	7	58	theme	irregularly	1959:1969	arg1	analysis					1924:1931	total analysis	1918:1931	total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains	1918:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	2	59	theme	groups	511:516	arg1	distribution					483:494	the distribution	479:494	the hybrid CS/DS as well as the distribution of the sulfate groups along the chain	451:532	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	2	59	theme	groups	511:516	arg1	CS/DS					462:466	the hybrid CS/DS	451:466	the hybrid CS/DS as well as the distribution of the sulfate groups along the chain	451:532	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	6	60	theme	CS/DS	1671:1675	arg1	separation					1677:1686	CS/DS separation	1671:1686	CS/DS separation	1671:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	7	61	theme	sulfated	1946:1953	arg1	analysis					1924:1931	total analysis	1918:1931	total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains	1918:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	6	62	from	CZE-ESI-MS	1548:1557	arg1	polarity					1569:1576	normal polarity	1562:1576	normal polarity	1562:1576	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	6	62	from	CZE-ESI-MS	1548:1557	arg1	mode					1591:1594	negative mode	1582:1594	negative mode	1582:1594	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	7	63	dep	under-	1978:1983	arg1	i.e.					1972:1975	i.e.	1972:1975	i.e.	1972:1975	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	6	64	theme	data-dependent	1635:1648	arg1	mode					1662:1665	real-time data-dependent acquisition mode	1625:1665	real-time data-dependent acquisition mode for CS/DS separation	1625:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	5	65	theme	first	1260:1264	arg1	part					1266:1269	The first part	1256:1269	The first part	1256:1269	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	5	65	theme	first	1260:1264	arg1	devoted					1274:1280	devoted	1274:1280	devoted	1274:1280	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	6	66	theme	online	1541:1546	arg1	CZE-ESI-MS					1548:1557	online CZE-ESI-MS	1541:1557	online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation	1541:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	1	67	theme	glycosylated	175:186	arg1	proteins					188:195	heavily glycosylated proteins	167:195	heavily glycosylated proteins	167:195	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	1	67	theme	glycosylated	175:186	arg1	Proteoglycans					149:161	Proteoglycans	149:161	Proteoglycans	149:161	Proteoglycans are heavily glycosylated proteins, covalently linked to one or more glycosaminoglycan (GAG) chains, abundantly expressed in the extracellular matrix (ECM).
35941485	3	68	theme	performance	769:779	arg1	methods					792:798	specific high performance analytical methods	755:798	specific high performance analytical methods for reliable elucidation	755:823	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	3	69	theme	specific	755:762	arg1	methods					792:798	specific high performance analytical methods	755:798	specific high performance analytical methods for reliable elucidation	755:823	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	0	70	theme	Chondroitin/Dermatan	102:121	arg1	Oligosaccharides					131:146	Chondroitin/Dermatan Sulfate Oligosaccharides	102:146	Chondroitin/Dermatan Sulfate Oligosaccharides	102:146	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	2	71	theme	hybrid	455:460	arg1	CS/DS					462:466	the hybrid CS/DS	451:466	the hybrid CS/DS as well as the distribution of the sulfate groups along the chain	451:532	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	5	72	theme	ion	1464:1466	arg1	energies					1481:1488	low ion acceleration energies	1460:1488	low ion acceleration energies	1460:1488	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	3	73	theme	reliable	804:811	arg1	elucidation					813:823	reliable elucidation	804:823	reliable elucidation	804:823	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	0	74	theme	Oligosaccharides	131:146	arg1	Analysis					90:97	Total Analysis	84:97	Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides	84:146	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	7	75	theme	coupled	1899:1905	arg1	system					1907:1912	the coupled system	1895:1912	the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains	1895:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	2	76	theme	distribution	483:494	arg1	composition					436:446	the composition	432:446	the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain	432:532	Among GAGs, chondroitin sulfate (CS) and dermatan sulfate (DS) play an essential role at the ECM level; however, the composition of the hybrid CS/DS as well as the distribution of the sulfate groups along the chain were also shown to influence biological activities in brain.
35941485	4	77	theme	CS/DS	1235:1239	arg1	identification					1193:1206	identification	1193:1206	identification	1193:1206	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	77	theme	CS/DS	1235:1239	arg1	analysis					1223:1230	structural analysis	1212:1230	structural analysis	1212:1230	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	3	78	theme	methods	792:798	arg1	development					740:750	the development	736:750	the development of specific high performance analytical methods for reliable elucidation	736:823	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	6	79	dep	polarity	1569:1576	arg1	ESI					1596:1598	ESI	1596:1598	ESI	1596:1598	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	0	80	theme	Zone	10:13	arg1	Spectrometry					67:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry	0:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.	0:147	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	6	81	theme	negative	1582:1589	arg1	mode					1591:1594	negative mode	1582:1594	negative mode	1582:1594	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	5	82	from	screening	1334:1342	arg1	MS					1411:1412	tandem MS	1404:1412	tandem MS	1404:1412	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	0	83	theme	Ionization	44:53	arg1	Spectrometry					67:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry	0:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.	0:147	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	3	84	theme	structural	608:617	arg1	diversity					619:627	The elevated structural diversity	595:627	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations,	595:725	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	0	85	theme	Mass	62:65	arg1	Spectrometry					67:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry	0:78	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.	0:147	Capillary Zone Electrophoresis-Electrospray Ionization Tandem Mass Spectrometry for Total Analysis of Chondroitin/Dermatan Sulfate Oligosaccharides.
35941485	6	86	from	MS	1619:1620	arg1	mode					1662:1665	real-time data-dependent acquisition mode	1625:1665	real-time data-dependent acquisition mode for CS/DS separation	1625:1686	In the second part of the chapter, a strategy for online CZE-ESI-MS in normal polarity and negative mode ESI followed by tandem MS in real-time data-dependent acquisition mode for CS/DS separation, screening, and fragmentation is described in detail.
35941485	5	87	theme	mode	1360:1363	arg1	nanoESI					1365:1371	negative ion mode nanoESI	1347:1371	negative ion mode nanoESI	1347:1371	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35941485	7	88	theme	online	1841:1846	arg1	coupling					1852:1859	the online CZE coupling	1837:1859	the online CZE coupling to ESI-MS	1837:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	7	89	theme	interface	1823:1831	arg1	manufacturing					1786:1798	the in-laboratory manufacturing	1768:1798	the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS	1768:1869	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	7	89	theme	interface	1823:1831	arg1	optimization					1879:1890	the optimization	1875:1890	the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains	1875:2014	The latter method entails the in-laboratory manufacturing of a simple yet sturdy interface for the online CZE coupling to ESI-MS and the optimization of the coupled system for total analysis of regularly sulfated and irregularly, i.e., under- and oversulfated CS/DS domains.
35941485	4	90	theme	ionization	985:994	arg1	ESI-MS					1015:1020	ESI-MS	1015:1020	ESI-MS	1015:1020	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	4	90	theme	ionization	985:994	arg1	spectrometry					1001:1012	electrospray ionization mass spectrometry	972:1012	electrospray ionization mass spectrometry (ESI-MS) for their structure determination	972:1055	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	3	91	theme	motifs	638:643	arg1	diversity					619:627	The elevated structural diversity	595:627	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations,	595:725	The elevated structural diversity of CS/DS motifs, in which sulfation may occur at GalNAc and/or IdoA/GlcA in various combinations, requires the development of specific high performance analytical methods for reliable elucidation.
35941485	4	92	theme	essential	1072:1080	arg1	progress					1082:1089	an essential progress	1069:1089	an essential progress	1069:1089	Due to its sensitivity, reproducibility, and efficiency, capillary zone electrophoresis (CZE) for separation of CS/DS oligosaccharides coupled to electrospray ionization mass spectrometry (ESI-MS) for their structure determination contributed an essential progress to this field.In the present chapter, two powerful methods based on CZE for separation and ESI-MS for identification and structural analysis of CS/DS are presented.
35941485	5	93	theme	negative	1347:1354	arg1	mode					1360:1363	negative ion mode	1347:1363	negative ion mode nanoESI	1347:1371	The first part is devoted to offline CZE-ESI-MS based on fraction collection, screening by negative ion mode nanoESI, and fragmentation analysis in tandem MS using collision-induced dissociation (CID) at low ion acceleration energies.
35915640	0	0	from	Participation	18:30	arg1	Glucose					87:93	C3- and C6-Fluorinated Glucose	64:93	C3- and C6-Fluorinated Glucose	64:93	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	5	1	theme	group	825:829	arg1	participation					796:808	participation	796:808	participation of the benzoyl group in	796:832	The infrared signatures indicate that participation of the benzoyl group in enhanced by resonance effects.
35915640	4	2	theme	dominant	635:642	arg1	motif					655:659	the dominant structural motif	631:659	the dominant structural motif for all building blocks	631:683	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	2	theme	dominant	635:642	arg1	participation					579:591	neighboring group participation	561:591	neighboring group participation of the C2-benzoyl protecting group	561:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	0	3	theme	C6-Fluorinated	72:85	arg1	Glucose					87:93	C3- and C6-Fluorinated Glucose	64:93	C3- and C6-Fluorinated Glucose	64:93	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	4	4	theme	neighboring	561:571	arg1	motif					655:659	the dominant structural motif	631:659	the dominant structural motif for all building blocks	631:683	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	4	theme	neighboring	561:571	arg1	participation					579:591	neighboring group participation	561:591	neighboring group participation of the C2-benzoyl protecting group	561:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	1	5	theme	glycans	163:169	arg1	properties					149:158	chemical properties	140:158	chemical properties of glycans	140:169	Fluorination is a potent method to modulate chemical properties of glycans.
35915640	6	6	theme	groups	894:899	arg1	Participation					865:877	Participation	865:877	Participation of remote acyl groups such as Fmoc or benzyl on the other hand	865:940	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	7	7	theme	bulky	985:989	arg1	fluorine					991:998	the less bulky fluorine	976:998	the less bulky fluorine	976:998	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	6	8	theme	acyl	889:892	arg1	benzyl					917:922	benzyl	917:922	benzyl	917:922	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	6	8	theme	acyl	889:892	arg1	groups					894:899	remote acyl groups	882:899	remote acyl groups such as Fmoc or benzyl	882:922	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	6	8	theme	acyl	889:892	arg1	Fmoc					909:912	Fmoc	909:912	Fmoc	909:912	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	2	9	theme	intermediate	274:285	arg1	structure					257:265	the structure	253:265	the structure of the intermediate of the glycosylation reaction, the glycosyl cation	253:336	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	4	10	theme	structural	644:653	arg1	motif					655:659	the dominant structural motif	631:659	the dominant structural motif for all building blocks	631:683	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	10	theme	structural	644:653	arg1	participation					579:591	neighboring group participation	561:591	neighboring group participation of the C2-benzoyl protecting group	561:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	5	11	theme	benzoyl	817:823	arg1	group					825:829	the benzoyl group	813:829	the benzoyl group	813:829	The infrared signatures indicate that participation of the benzoyl group in enhanced by resonance effects.
35915640	6	12	theme	remote	882:887	arg1	benzyl					917:922	benzyl	917:922	benzyl	917:922	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	6	12	theme	remote	882:887	arg1	groups					894:899	remote acyl groups	882:899	remote acyl groups such as Fmoc or benzyl	882:922	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	6	12	theme	remote	882:887	arg1	Fmoc					909:912	Fmoc	909:912	Fmoc	909:912	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	0	13	theme	Groups	54:59	arg1	Participation					18:30	Group Participation	12:30	Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose	12:93	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	3	14	theme	fluorinated	455:465	arg1	monosaccharides					487:501	fluorinated and non-fluorinated monosaccharides	455:501	fluorinated and non-fluorinated monosaccharides	455:501	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	3	15	theme	spectroscopy	381:392	arg1	combination					347:357	a combination	345:357	a combination of gas-phase infrared spectroscopy and first-principles theory	345:420	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	5	16	theme	resonance	846:854	arg1	effects					856:862	resonance effects	846:862	resonance effects	846:862	The infrared signatures indicate that participation of the benzoyl group in enhanced by resonance effects.
35915640	4	17	theme	glycosylation	733:745	arg1	reactions					747:755	glycosylation reactions	733:755	glycosylation reactions	733:755	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	18	theme	protecting	611:620	arg1	group					622:626	the C2-benzoyl protecting group	596:626	the C2-benzoyl protecting group	596:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	7	19	theme	site	1106:1109	arg1	structure					1070:1078	the structure	1066:1078	the structure of the active dioxolenium site	1066:1109	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	2	20	theme	reaction	308:315	arg1	intermediate					274:285	the intermediate	270:285	the intermediate of the glycosylation reaction	270:315	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	2	20	theme	reaction	308:315	arg1	cation					331:336	the glycosyl cation	318:336	the glycosyl cation	318:336	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	6	21	theme	other	931:935	arg1	hand					937:940	the other hand	927:940	the other hand	927:940	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	3	22	theme	gas-phase	362:370	arg1	spectroscopy					381:392	gas-phase infrared spectroscopy	362:392	gas-phase infrared spectroscopy	362:392	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	4	23	theme	C2-benzoyl	600:609	arg1	group					622:626	the C2-benzoyl protecting group	596:626	the C2-benzoyl protecting group	596:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	7	24	theme	fluorine	991:998	arg1	introduction					960:971	The introduction	956:971	The introduction of the less bulky fluorine	956:998	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	2	25	theme	glycosylation	294:306	arg1	reaction					308:315	the glycosylation reaction	290:315	the glycosylation reaction	290:315	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	3	26	theme	infrared	372:379	arg1	spectroscopy					381:392	gas-phase infrared spectroscopy	362:392	gas-phase infrared spectroscopy	362:392	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	0	27	theme	Protecting	43:52	arg1	Groups					54:59	Benzoyl Protecting Groups	35:59	Benzoyl Protecting Groups	35:59	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	4	28	theme	group	622:626	arg1	motif					655:659	the dominant structural motif	631:659	the dominant structural motif for all building blocks	631:683	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	28	theme	group	622:626	arg1	participation					579:591	neighboring group participation	561:591	neighboring group participation of the C2-benzoyl protecting group	561:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	7	29	theme	dioxolenium	1094:1104	arg1	site					1106:1109	the active dioxolenium site	1083:1109	the active dioxolenium site	1083:1109	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	4	30	located	observed	721:728	arg1	reactions					747:755	glycosylation reactions	733:755	glycosylation reactions	733:755	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	30	located	observed	721:728	arg2	β-selectivity					707:719	the β-selectivity	703:719	the β-selectivity observed in glycosylation reactions	703:755	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	2	31	theme	building	227:234	arg1	blocks					236:241	glucosyl building blocks	218:241	glucosyl building blocks	218:241	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	0	32	theme	Benzoyl	35:41	arg1	Groups					54:59	Benzoyl Protecting Groups	35:59	Benzoyl Protecting Groups	35:59	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	3	33	theme	glycosyl	423:430	arg1	cations					432:438	glycosyl cations	423:438	glycosyl cations generated from fluorinated and non-fluorinated monosaccharides	423:501	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	2	34	theme	glucosyl	218:225	arg1	blocks					236:241	glucosyl building blocks	218:241	glucosyl building blocks	218:241	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	3	35	theme	non-fluorinated	471:485	arg1	monosaccharides					487:501	fluorinated and non-fluorinated monosaccharides	455:501	fluorinated and non-fluorinated monosaccharides	455:501	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	3	36	theme	first-principles	398:413	arg1	theory					415:420	first-principles theory	398:420	first-principles theory	398:420	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	4	37	theme	group	573:577	arg1	motif					655:659	the dominant structural motif	631:659	the dominant structural motif for all building blocks	631:683	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	4	37	theme	group	573:577	arg1	participation					579:591	neighboring group participation	561:591	neighboring group participation of the C2-benzoyl protecting group	561:626	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
35915640	1	38	theme	potent	114:119	arg1	Fluorination					96:107	Fluorination	96:107	Fluorination	96:107	Fluorination is a potent method to modulate chemical properties of glycans.
35915640	1	38	theme	potent	114:119	arg1	method					121:126	a potent method	112:126	a potent method to modulate chemical properties of glycans	112:169	Fluorination is a potent method to modulate chemical properties of glycans.
35915640	3	39	theme	theory	415:420	arg1	combination					347:357	a combination	345:357	a combination of gas-phase infrared spectroscopy and first-principles theory	345:420	Using a combination of gas-phase infrared spectroscopy and first-principles theory, glycosyl cations generated from fluorinated and non-fluorinated monosaccharides are structurally characterized.
35915640	7	40	theme	active	1087:1092	arg1	site					1106:1109	the active dioxolenium site	1083:1109	the active dioxolenium site	1083:1109	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	7	41	theme	pucker	1050:1055	arg1	conformation					1025:1036	the conformation	1021:1036	the conformation of the ring pucker	1021:1055	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	2	42	theme	glycosyl	322:329	arg1	cation					331:336	the glycosyl cation	318:336	the glycosyl cation	318:336	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	2	42	theme	glycosyl	322:329	arg1	intermediate					274:285	the intermediate	270:285	the intermediate of the glycosylation reaction	270:315	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	5	43	theme	infrared	762:769	arg1	signatures					771:780	The infrared signatures	758:780	The infrared signatures	758:780	The infrared signatures indicate that participation of the benzoyl group in enhanced by resonance effects.
35915640	7	44	from	change	1011:1016	arg1	conformation					1025:1036	the conformation	1021:1036	the conformation of the ring pucker	1021:1055	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	6	45	from	Participation	865:877	arg1	hand					937:940	the other hand	927:940	the other hand	927:940	Participation of remote acyl groups such as Fmoc or benzyl on the other hand is unfavored.
35915640	7	46	theme	ring	1045:1048	arg1	pucker					1050:1055	the ring pucker	1041:1055	the ring pucker	1041:1055	The introduction of the less bulky fluorine leads to a change in the conformation of the ring pucker, whereas the structure of the active dioxolenium site remains unchanged.
35915640	1	47	theme	chemical	140:147	arg1	properties					149:158	chemical properties	140:158	chemical properties of glycans	140:169	Fluorination is a potent method to modulate chemical properties of glycans.
35915640	0	48	theme	C3-	64:66	arg1	Glucose					87:93	C3- and C6-Fluorinated Glucose	64:93	C3- and C6-Fluorinated Glucose	64:93	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	2	49	theme	blocks	236:241	arg1	C6-fluorination					199:213	C6-fluorination	199:213	C6-fluorination	199:213	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	2	49	theme	blocks	236:241	arg1	C3-					191:193	C3-	191:193	C3-	191:193	Here, we study how C3- and C6-fluorination of glucosyl building blocks influence the structure of the intermediate of the glycosylation reaction, the glycosyl cation.
35915640	0	50	theme	Group	12:16	arg1	Participation					18:30	Group Participation	12:30	Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose	12:93	Neighboring Group Participation of Benzoyl Protecting Groups in C3- and C6-Fluorinated Glucose.
35915640	4	51	theme	building	669:676	arg1	blocks					678:683	all building blocks	665:683	all building blocks	665:683	The results indicate that neighboring group participation of the C2-benzoyl protecting group is the dominant structural motif for all building blocks, correlating with the β-selectivity observed in glycosylation reactions.
36345209	5	0	dep	N-glycome	682:690	arg1	the					678:680	the	678:680	the	678:680	Analyses included the N-glycome, O-glycome, glycolipidome, glycoproteome, and proteome providing the most extensive characterization of the glycocalyx between 3D and 2D thus far.
36345209	6	1	theme	different	886:894	arg1	ways					896:899	different ways	886:899	different ways	886:899	The different glycoconjugates were affected in different ways.
36345209	10	2	theme	biological	1204:1213	arg1	changes					1215:1221	large structural and biological changes	1183:1221	large structural and biological changes between the two models	1183:1244	The results show large structural and biological changes between the two models suggesting that the two are indeed very different potentially affecting individual outcomes in the study of diseases.
36345209	4	3	theme	3D	564:565	arg1	models					567:572	3D models	564:572	3D models	564:572	Cell-cell interactions increase in 3D models compared to 2D, indeed significant glycomic changes were observed for each cell line.
36345209	7	4	theme	high-mannose	946:957	arg1	glycosylation					959:971	high-mannose glycosylation	946:971	high-mannose glycosylation	946:971	In the N-glycome, the 3D cells increased in high-mannose glycosylation and in core fucosylation.
36345209	10	5	theme	structural	1189:1198	arg1	changes					1215:1221	large structural and biological changes	1183:1221	large structural and biological changes between the two models	1183:1244	The results show large structural and biological changes between the two models suggesting that the two are indeed very different potentially affecting individual outcomes in the study of diseases.
36345209	5	6	theme	glycocalyx	800:809	arg1	characterization					776:791	the most extensive characterization	757:791	the most extensive characterization of the glycocalyx	757:809	Analyses included the N-glycome, O-glycome, glycolipidome, glycoproteome, and proteome providing the most extensive characterization of the glycocalyx between 3D and 2D thus far.
36345209	1	7	theme	human	274:278	arg1	HCT116					310:315	HCT116	310:315	HCT116	310:315	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	7	theme	human	274:278	arg1	lines					303:307	two human colorectal cancer cell lines	270:307	two human colorectal cancer cell lines	270:307	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	7	theme	human	274:278	arg1	HT29					321:324	HT29	321:324	HT29	321:324	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	3	8	from	tool	504:507	arg1	research					519:526	cancer research	512:526	cancer research	512:526	For this reason, they have become an important tool in cancer research.
36345209	2	9	theme	cancer	382:387	arg1	representative					364:377	representative	364:377	representative	364:377	3D cell cultures are considered more representative of cancer due to their ability to mimic the microenvironment found in tumors.
36345209	10	10	theme	large	1183:1187	arg1	changes					1215:1221	large structural and biological changes	1183:1221	large structural and biological changes between the two models	1183:1244	The results show large structural and biological changes between the two models suggesting that the two are indeed very different potentially affecting individual outcomes in the study of diseases.
36345209	9	11	gly	glycoproteins	1046:1058	arg1	glycoproteins					1046:1058	Specific glycoproteins	1037:1058	Specific glycoproteins	1037:1058	Specific glycoproteins were found to increase in the 3D cell, elucidating the pathways that are affected between the two models.
36345209	2	12	located	found	440:444	arg2	microenvironment					423:438	the microenvironment	419:438	the microenvironment found in tumors	419:454	3D cell cultures are considered more representative of cancer due to their ability to mimic the microenvironment found in tumors.
36345209	2	12	located	found	440:444	arg1	tumors					449:454	tumors	449:454	tumors	449:454	3D cell cultures are considered more representative of cancer due to their ability to mimic the microenvironment found in tumors.
36345209	3	13	theme	cancer	512:517	arg1	research					519:526	cancer research	512:526	cancer research	512:526	For this reason, they have become an important tool in cancer research.
36345209	10	14	from	outcomes	1329:1336	arg1	study					1345:1349	the study	1341:1349	the study of diseases	1341:1361	The results show large structural and biological changes between the two models suggesting that the two are indeed very different potentially affecting individual outcomes in the study of diseases.
36345209	7	15	theme	3D	924:925	arg1	cells					927:931	the 3D cells	920:931	the 3D cells	920:931	In the N-glycome, the 3D cells increased in high-mannose glycosylation and in core fucosylation.
36345209	9	16	theme	3D	1090:1091	arg1	cell					1093:1096	the 3D cell	1086:1096	the 3D cell	1086:1096	Specific glycoproteins were found to increase in the 3D cell, elucidating the pathways that are affected between the two models.
36345209	1	17	theme	two-dimensional	202:216	arg1	models					258:263	two-dimensional (2D) and three-dimensional (3D) culture models	202:263	two-dimensional (2D) and three-dimensional (3D) culture models	202:263	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	0	18	theme	Multi-Glycomic	0:13	arg1	analysis					15:22	Multi-Glycomic analysis	0:22	Multi-Glycomic analysis of spheroid glycocalyx	0:45	Multi-Glycomic analysis of spheroid glycocalyx differentiates 2- and 3-dimensional cell models.
36345209	1	19	theme	colorectal	280:289	arg1	HCT116					310:315	HCT116	310:315	HCT116	310:315	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	19	theme	colorectal	280:289	arg1	lines					303:307	two human colorectal cancer cell lines	270:307	two human colorectal cancer cell lines	270:307	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	19	theme	colorectal	280:289	arg1	HT29					321:324	HT29	321:324	HT29	321:324	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	20	theme	multi-glycomic	98:111	arg1	method					113:118	A multi-glycomic method	96:118	A multi-glycomic method for characterizing the glycocalyx	96:152	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	10	21	theme	individual	1318:1327	arg1	outcomes					1329:1336	individual outcomes	1318:1336	individual outcomes in the study of diseases	1318:1361	The results show large structural and biological changes between the two models suggesting that the two are indeed very different potentially affecting individual outcomes in the study of diseases.
36345209	4	22	theme	cell	649:652	arg1	line					654:657	each cell line	644:657	each cell line	644:657	Cell-cell interactions increase in 3D models compared to 2D, indeed significant glycomic changes were observed for each cell line.
36345209	0	23	theme	spheroid	27:34	arg1	glycocalyx					36:45	spheroid glycocalyx	27:45	spheroid glycocalyx	27:45	Multi-Glycomic analysis of spheroid glycocalyx differentiates 2- and 3-dimensional cell models.
36345209	1	24	theme	cancer	291:296	arg1	HCT116					310:315	HCT116	310:315	HCT116	310:315	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	24	theme	cancer	291:296	arg1	lines					303:307	two human colorectal cancer cell lines	270:307	two human colorectal cancer cell lines	270:307	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	24	theme	cancer	291:296	arg1	HT29					321:324	HT29	321:324	HT29	321:324	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	25	theme	cell	298:301	arg1	HCT116					310:315	HCT116	310:315	HCT116	310:315	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	25	theme	cell	298:301	arg1	lines					303:307	two human colorectal cancer cell lines	270:307	two human colorectal cancer cell lines	270:307	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	1	25	theme	cell	298:301	arg1	HT29					321:324	HT29	321:324	HT29	321:324	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	4	26	theme	glycomic	609:616	arg1	changes					618:624	significant glycomic changes	597:624	significant glycomic changes	597:624	Cell-cell interactions increase in 3D models compared to 2D, indeed significant glycomic changes were observed for each cell line.
36345209	6	27	theme	different	843:851	arg1	glycoconjugates					853:867	The different glycoconjugates	839:867	The different glycoconjugates	839:867	The different glycoconjugates were affected in different ways.
36345209	1	28	dep	two-dimensional	202:216	arg1	2D					219:220	2D	219:220	2D	219:220	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	0	29	theme	glycocalyx	36:45	arg1	analysis					15:22	Multi-Glycomic analysis	0:22	Multi-Glycomic analysis of spheroid glycocalyx	0:45	Multi-Glycomic analysis of spheroid glycocalyx differentiates 2- and 3-dimensional cell models.
36345209	5	30	theme	extensive	766:774	arg1	characterization					776:791	the most extensive characterization	757:791	the most extensive characterization of the glycocalyx	757:809	Analyses included the N-glycome, O-glycome, glycolipidome, glycoproteome, and proteome providing the most extensive characterization of the glycocalyx between 3D and 2D thus far.
36345209	1	31	theme	three-dimensional	227:243	arg1	models					258:263	two-dimensional (2D) and three-dimensional (3D) culture models	202:263	two-dimensional (2D) and three-dimensional (3D) culture models	202:263	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	4	32	theme	Cell-cell	529:537	arg1	interactions					539:550	Cell-cell interactions	529:550	Cell-cell interactions	529:550	Cell-cell interactions increase in 3D models compared to 2D, indeed significant glycomic changes were observed for each cell line.
36345209	2	33	theme	cell	330:333	arg1	cultures					335:342	3D cell cultures	327:342	3D cell cultures	327:342	3D cell cultures are considered more representative of cancer due to their ability to mimic the microenvironment found in tumors.
36345209	2	34	theme	3D	327:328	arg1	cultures					335:342	3D cell cultures	327:342	3D cell cultures	327:342	3D cell cultures are considered more representative of cancer due to their ability to mimic the microenvironment found in tumors.
36345209	1	35	dep	three-dimensional	227:243	arg1	3D					246:247	3D	246:247	3D	246:247	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
36345209	0	36	theme	cell	83:86	arg1	models					88:93	3-dimensional cell models	69:93	3-dimensional cell models	69:93	Multi-Glycomic analysis of spheroid glycocalyx differentiates 2- and 3-dimensional cell models.
36345209	7	37	theme	core	980:983	arg1	fucosylation					985:996	core fucosylation	980:996	core fucosylation	980:996	In the N-glycome, the 3D cells increased in high-mannose glycosylation and in core fucosylation.
36345209	3	38	theme	important	494:502	arg1	tool					504:507	an important tool	491:507	an important tool in cancer research	491:526	For this reason, they have become an important tool in cancer research.
36345209	9	39	theme	Specific	1037:1044	arg1	glycoproteins					1046:1058	Specific glycoproteins	1037:1058	Specific glycoproteins	1037:1058	Specific glycoproteins were found to increase in the 3D cell, elucidating the pathways that are affected between the two models.
36345209	4	40	theme	significant	597:607	arg1	changes					618:624	significant glycomic changes	597:624	significant glycomic changes	597:624	Cell-cell interactions increase in 3D models compared to 2D, indeed significant glycomic changes were observed for each cell line.
36345209	0	41	theme	3-dimensional	69:81	arg1	models					88:93	3-dimensional cell models	69:93	3-dimensional cell models	69:93	Multi-Glycomic analysis of spheroid glycocalyx differentiates 2- and 3-dimensional cell models.
36345209	10	42	theme	diseases	1354:1361	arg1	study					1345:1349	the study	1341:1349	the study of diseases	1341:1361	The results show large structural and biological changes between the two models suggesting that the two are indeed very different potentially affecting individual outcomes in the study of diseases.
36345209	1	43	theme	culture	250:256	arg1	models					258:263	two-dimensional (2D) and three-dimensional (3D) culture models	202:263	two-dimensional (2D) and three-dimensional (3D) culture models	202:263	A multi-glycomic method for characterizing the glycocalyx was employed to identify the difference between two-dimensional (2D) and three-dimensional (3D) culture models with two human colorectal cancer cell lines, HCT116 and HT29.
35193013	3	0	theme	sialic	531:536	arg1	stabilization					543:555	sialic acid stabilization	531:555	sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	531:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	1	1	gly	glycoprotein	197:208	arg1	glycoprotein					197:208	serum glycoprotein N-glycans	191:218	serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	191:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	9	2	theme	mouse	1518:1522	arg1	glycoproteins					1543:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	8	3	theme	mouse	1331:1335	arg1	sera					1337:1340	BALB/c mouse sera	1324:1340	BALB/c mouse sera	1324:1340	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	10	4	theme	cheap	1680:1684	arg1	method					1686:1691	a fast and cheap method	1669:1691	a fast and cheap method for structurally conserved glycan derivatization	1669:1740	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	10	4	theme	cheap	1680:1684	arg1	methylamidation					1600:1614	DMTMM-mediated methylamidation	1585:1614	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis	1585:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	1	5	theme	serum	191:195	arg1	N-glycans					210:218	serum glycoprotein N-glycans	191:218	serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	191:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	7	6	theme	acid	1190:1193	arg1	stabilization					1166:1178	The stabilization	1162:1178	The stabilization of sialic acid	1162:1193	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	3	7	theme	acid	612:615	arg1	group					617:621	carboxylic acid group	601:621	carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	601:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	3	8	with	chloride	696:703	arg1	methylamine					718:728	methylamine	718:728	methylamine	718:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	1	9	theme	N-glycans	210:218	arg1	Characterization					171:186	Characterization	171:186	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode	171:317	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	8	10	theme	trace	1459:1463	arg1	amounts					1465:1471	only trace amounts	1454:1471	only trace amounts of N-Acetyl neuraminic acid (Neu5Ac)	1454:1508	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	10	theme	trace	1459:1463	arg1	Neu5Ac					1502:1507	Neu5Ac	1502:1507	Neu5Ac	1502:1507	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	10	theme	trace	1459:1463	arg1	acid					1496:1499	N-Acetyl neuraminic acid	1476:1499	N-Acetyl neuraminic acid (Neu5Ac)	1476:1508	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	0	11	theme	biological	133:142	arg1	fluids					144:149	biological fluids	133:149	biological fluids "via direttissima"	133:168	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	1	12	theme	matrix-assisted	225:239	arg1	MALDI-MS					288:295	MALDI-MS	288:295	MALDI-MS	288:295	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	1	12	theme	matrix-assisted	225:239	arg1	spectrometry					274:285	matrix-assisted laser desorption/ionization mass spectrometry	225:285	matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	225:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	8	13	theme	mono-	1369:1373	arg1	N-glycans					1393:1401	predominantly mono- and di-sialylated N-glycans	1355:1401	predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc)	1355:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	1	14	theme	desorption/ionization	247:267	arg1	MALDI-MS					288:295	MALDI-MS	288:295	MALDI-MS	288:295	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	1	14	theme	desorption/ionization	247:267	arg1	spectrometry					274:285	matrix-assisted laser desorption/ionization mass spectrometry	225:285	matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	225:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	9	15	gly	glycoproteins	1543:1555	arg1	glycoproteins					1543:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	8	16	theme	di-sialylated	1379:1391	arg1	N-glycans					1393:1401	predominantly mono- and di-sialylated N-glycans	1355:1401	predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc)	1355:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	5	17	used	used	972:975	arg2	proteins					959:966	Glycosylated proteins	946:966	Glycosylated proteins	946:966	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	5	17	used	used	972:975	arg2	support					992:998	solid phase support	980:998	solid phase support for glycan derivatization and purification from excess of derivatization reagents	980:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	0	18	from	residues	121:128	arg1	fluids					144:149	biological fluids	133:149	biological fluids "via direttissima"	133:168	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	3	19	theme	-4-methylmorpholinium	674:694	arg1	chloride					696:703	4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)	638:711	4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	638:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	8	20	theme	N-Glycolylneuraminic	1415:1434	arg1	Neu5Gc					1442:1447	Neu5Gc	1442:1447	Neu5Gc	1442:1447	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	20	theme	N-Glycolylneuraminic	1415:1434	arg1	acid					1436:1439	mostly N-Glycolylneuraminic acid	1408:1439	mostly N-Glycolylneuraminic acid (Neu5Gc)	1408:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	9	21	theme	BALB/c	1511:1516	arg1	glycoproteins					1543:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	3	22	theme	4,6-dimethoxy-1,3,5-triazin-2-yl	641:672	arg1	chloride					696:703	4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)	638:711	4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	638:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	4	23	from	reagent	877:883	arg1	water					939:943	water	939:943	water	939:943	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	6	24	theme	analysis	1107:1114	arg1	method					1116:1121	our glycan analysis method	1096:1121	our glycan analysis method	1096:1121	We evaluated our glycan analysis method in murine sera and intestinal lavages.
35193013	9	25	contain	contained	1557:1565	arg1	glycoproteins					1543:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	9	25	contain	contained	1557:1565	arg2	N-glycans					1574:1582	asialo N-glycans	1567:1582	asialo N-glycans	1567:1582	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	5	26	theme	phase	986:990	arg1	proteins					959:966	Glycosylated proteins	946:966	Glycosylated proteins	946:966	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	5	26	theme	phase	986:990	arg1	support					992:998	solid phase support	980:998	solid phase support for glycan derivatization and purification from excess of derivatization reagents	980:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	8	27	with	amounts	1465:1471	arg1	Neu5Gc					1442:1447	Neu5Gc	1442:1447	Neu5Gc	1442:1447	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	27	with	amounts	1465:1471	arg1	acid					1436:1439	mostly N-Glycolylneuraminic acid	1408:1439	mostly N-Glycolylneuraminic acid (Neu5Gc)	1408:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	0	28	theme	sialic	109:114	arg1	residues					121:128	structurally conserved sialic acid residues	86:128	structurally conserved sialic acid residues in biological fluids "via direttissima"	86:168	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	1	29	theme	sialic	398:403	arg1	acids					405:409	sialic acids	398:409	sialic acids	398:409	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	5	30	theme	derivatization	1058:1071	arg1	reagents					1073:1080	derivatization reagents	1058:1080	derivatization reagents	1058:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	10	31	theme	DMTMM-mediated	1585:1598	arg1	method					1686:1691	a fast and cheap method	1669:1691	a fast and cheap method for structurally conserved glycan derivatization	1669:1740	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	10	31	theme	DMTMM-mediated	1585:1598	arg1	methylamidation					1600:1614	DMTMM-mediated methylamidation	1585:1614	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis	1585:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	7	32	theme	sialic	1288:1293	arg1	acids					1295:1299	sialic acids	1288:1299	sialic acids	1288:1299	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	4	33	from	stability	926:934	arg1	water					939:943	water	939:943	water	939:943	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	0	34	theme	spectrometry	46:57	arg1	analysis					59:66	MALDI mass spectrometry analysis	35:66	MALDI mass spectrometry analysis of N-glycans	35:79	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	0	35	theme	DMTMM-mediated	0:13	arg1	methylamidation					15:29	DMTMM-mediated methylamidation	0:29	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".	0:169	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	8	36	theme	N-Acetyl	1476:1483	arg1	Neu5Ac					1502:1507	Neu5Ac	1502:1507	Neu5Ac	1502:1507	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	36	theme	N-Acetyl	1476:1483	arg1	acid					1496:1499	N-Acetyl neuraminic acid	1476:1499	N-Acetyl neuraminic acid (Neu5Ac)	1476:1508	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	4	37	theme	better	896:901	arg1	performance					903:913	its better performance	892:913	its better performance	892:913	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	1	38	theme	derivatization	327:340	arg1	step					342:345	a derivatization step	325:345	a derivatization step	325:345	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	6	39	theme	intestinal	1142:1151	arg1	lavages					1153:1159	intestinal lavages	1142:1159	intestinal lavages	1142:1159	We evaluated our glycan analysis method in murine sera and intestinal lavages.
35193013	8	40	with	N-glycans	1393:1401	arg1	Neu5Gc					1442:1447	Neu5Gc	1442:1447	Neu5Gc	1442:1447	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	40	with	N-glycans	1393:1401	arg1	acid					1436:1439	mostly N-Glycolylneuraminic acid	1408:1439	mostly N-Glycolylneuraminic acid (Neu5Gc)	1408:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	41	theme	acid	1496:1499	arg1	N-glycans					1393:1401	predominantly mono- and di-sialylated N-glycans	1355:1401	predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc)	1355:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	41	theme	acid	1496:1499	arg1	amounts					1465:1471	only trace amounts	1454:1471	only trace amounts of N-Acetyl neuraminic acid (Neu5Ac)	1454:1508	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	41	theme	acid	1496:1499	arg1	Neu5Ac					1502:1507	Neu5Ac	1502:1507	Neu5Ac	1502:1507	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	41	theme	acid	1496:1499	arg1	acid					1496:1499	N-Acetyl neuraminic acid	1476:1499	N-Acetyl neuraminic acid (Neu5Ac)	1476:1508	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	0	42	theme	mass	41:44	arg1	spectrometry					46:57	MALDI mass spectrometry	35:57	MALDI mass spectrometry analysis of N-glycans	35:79	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	0	43	theme	N-glycans	71:79	arg1	analysis					59:66	MALDI mass spectrometry analysis	35:66	MALDI mass spectrometry analysis of N-glycans	35:79	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	7	44	theme	structures	1241:1250	arg1	conservation					1214:1225	a complete conservation	1203:1225	a complete conservation of the glycan structures	1203:1250	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	1	45	with	N-glycans	210:218	arg1	MALDI-MS					288:295	MALDI-MS	288:295	MALDI-MS	288:295	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	1	45	with	N-glycans	210:218	arg1	spectrometry					274:285	matrix-assisted laser desorption/ionization mass spectrometry	225:285	matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	225:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	10	46	theme	mass	1639:1642	arg1	analysis					1657:1664	MALDI mass spectrometry analysis	1633:1664	MALDI mass spectrometry analysis	1633:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	5	47	from	excess	1048:1053	arg1	proteins					959:966	Glycosylated proteins	946:966	Glycosylated proteins	946:966	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	5	47	from	excess	1048:1053	arg1	support					992:998	solid phase support	980:998	solid phase support for glycan derivatization and purification from excess of derivatization reagents	980:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	1	48	theme	mass	269:272	arg1	MALDI-MS					288:295	MALDI-MS	288:295	MALDI-MS	288:295	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	1	48	theme	mass	269:272	arg1	spectrometry					274:285	matrix-assisted laser desorption/ionization mass spectrometry	225:285	matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	225:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	3	49	theme	acid	538:541	arg1	stabilization					543:555	sialic acid stabilization	531:555	sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	531:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	9	50	theme	lavages	1535:1541	arg1	glycoproteins					1543:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	8	51	gly	di-sialylated	1379:1391	arg1	N-glycans					1393:1401	predominantly mono- and di-sialylated N-glycans	1355:1401	predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc)	1355:1448	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	7	52	theme	complete	1205:1212	arg1	conservation					1214:1225	a complete conservation	1203:1225	a complete conservation of the glycan structures	1203:1250	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	1	53	theme	positive-ion	301:312	arg1	mode					314:317	positive-ion mode	301:317	positive-ion mode	301:317	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	9	54	theme	intestinal	1524:1533	arg1	glycoproteins					1543:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins	1511:1555	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	4	55	theme	higher	919:924	arg1	stability					926:934	higher stability	919:934	higher stability in water	919:943	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	8	56	theme	BALB/c	1324:1329	arg1	sera					1337:1340	BALB/c mouse sera	1324:1340	BALB/c mouse sera	1324:1340	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	7	57	theme	sialic	1183:1188	arg1	acid					1190:1193	sialic acid	1183:1193	sialic acid	1183:1193	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	3	58	theme	carboxylic	601:610	arg1	group					617:621	carboxylic acid group	601:621	carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	601:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	1	59	theme	glycoprotein	197:208	arg1	N-glycans					210:218	serum glycoprotein N-glycans	191:218	serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	191:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	10	60	theme	glycan	1720:1725	arg1	derivatization					1727:1740	structurally conserved glycan derivatization	1697:1740	structurally conserved glycan derivatization	1697:1740	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	9	61	theme	asialo	1567:1572	arg1	N-glycans					1574:1582	asialo N-glycans	1567:1582	asialo N-glycans	1567:1582	BALB/c mouse intestinal lavages glycoproteins contained asialo N-glycans.
35193013	1	62	theme	laser	241:245	arg1	MALDI-MS					288:295	MALDI-MS	288:295	MALDI-MS	288:295	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	1	62	theme	laser	241:245	arg1	spectrometry					274:285	matrix-assisted laser desorption/ionization mass spectrometry	225:285	matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS)	225:296	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	3	63	theme	group	617:621	arg1	derivatization					583:596	derivatization	583:596	derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine	583:728	Here, we present a method for sialic acid stabilization via modification based on derivatization of carboxylic acid group activated with 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) with methylamine.
35193013	5	64	theme	glycan	1004:1009	arg1	derivatization					1011:1024	glycan derivatization	1004:1024	glycan derivatization	1004:1024	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	6	65	theme	murine	1126:1131	arg1	sera					1133:1136	murine sera	1126:1136	murine sera	1126:1136	We evaluated our glycan analysis method in murine sera and intestinal lavages.
35193013	10	66	theme	conserved	1710:1718	arg1	derivatization					1727:1740	structurally conserved glycan derivatization	1697:1740	structurally conserved glycan derivatization	1697:1740	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	0	67	theme	conserved	99:107	arg1	residues					121:128	structurally conserved sialic acid residues	86:128	structurally conserved sialic acid residues in biological fluids "via direttissima"	86:168	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	1	68	theme	negative	379:386	arg1	charge					388:393	the negative charge	375:393	the negative charge on sialic acids	375:409	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	5	69	theme	solid	980:984	arg1	proteins					959:966	Glycosylated proteins	946:966	Glycosylated proteins	946:966	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	5	69	theme	solid	980:984	arg1	support					992:998	solid phase support	980:998	solid phase support for glycan derivatization and purification from excess of derivatization reagents	980:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	6	70	theme	glycan	1100:1105	arg1	method					1116:1121	our glycan analysis method	1096:1121	our glycan analysis method	1096:1121	We evaluated our glycan analysis method in murine sera and intestinal lavages.
35193013	4	71	theme	many	752:755	arg1	processes					757:765	many processes	752:765	many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS)	752:861	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	71	theme	many	752:755	arg1	hydrochloride					814:826	hydrochloride	814:826	hydrochloride	814:826	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	71	theme	many	752:755	arg1	N-hydroxysuccinimide					832:851	N-hydroxysuccinimide	832:851	N-hydroxysuccinimide (EDC/NHS)	832:861	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	0	72	theme	acid	116:119	arg1	residues					121:128	structurally conserved sialic acid residues	86:128	structurally conserved sialic acid residues in biological fluids "via direttissima"	86:168	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	1	73	from	Characterization	171:186	arg1	mode					314:317	positive-ion mode	301:317	positive-ion mode	301:317	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	4	74	dep	processes	757:765	arg1	EDC/NHS					854:860	EDC/NHS	854:860	EDC/NHS	854:860	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	74	dep	processes	757:765	arg1	N-hydroxysuccinimide					832:851	N-hydroxysuccinimide	832:851	N-hydroxysuccinimide (EDC/NHS)	832:861	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	74	dep	processes	757:765	arg1	processes					757:765	many processes	752:765	many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS)	752:861	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	74	dep	processes	757:765	arg1	hydrochloride					814:826	hydrochloride	814:826	hydrochloride	814:826	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	7	75	dep	methods	1274:1280	arg1	contrast					1256:1263	contrast	1256:1263	contrast	1256:1263	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	5	76	theme	reagents	1073:1080	arg1	excess					1048:1053	excess	1048:1053	excess of derivatization reagents	1048:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	7	77	theme	other	1268:1272	arg1	methods					1274:1280	other methods	1268:1280	other methods where sialic acids are partially lost	1268:1318	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	2	78	theme	glycolipids	472:482	arg1	end					450:452	the end	446:452	the end of glycoproteins, glycolipids or gangliosides	446:498	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	4	79	theme	-N'-ethylcarbodiimide	792:812	arg1	processes					757:765	many processes	752:765	many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS)	752:861	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	79	theme	-N'-ethylcarbodiimide	792:812	arg1	hydrochloride					814:826	hydrochloride	814:826	hydrochloride	814:826	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	4	79	theme	-N'-ethylcarbodiimide	792:812	arg1	N-hydroxysuccinimide					832:851	N-hydroxysuccinimide	832:851	N-hydroxysuccinimide (EDC/NHS)	832:861	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	2	80	theme	acidic	416:421	arg1	sugars					423:428	The acidic sugars	412:428	The acidic sugars	412:428	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	0	81	theme	MALDI	35:39	arg1	spectrometry					46:57	MALDI mass spectrometry	35:57	MALDI mass spectrometry analysis of N-glycans	35:79	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	2	82	theme	glycoproteins	457:469	arg1	end					450:452	the end	446:452	the end of glycoproteins, glycolipids or gangliosides	446:498	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	10	83	theme	N-glycans	1619:1627	arg1	method					1686:1691	a fast and cheap method	1669:1691	a fast and cheap method for structurally conserved glycan derivatization	1669:1740	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	10	83	theme	N-glycans	1619:1627	arg1	methylamidation					1600:1614	DMTMM-mediated methylamidation	1585:1614	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis	1585:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	5	84	theme	Glycosylated	946:957	arg1	proteins					959:966	Glycosylated proteins	946:966	Glycosylated proteins	946:966	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	5	84	theme	Glycosylated	946:957	arg1	support					992:998	solid phase support	980:998	solid phase support for glycan derivatization and purification from excess of derivatization reagents	980:1080	Glycosylated proteins are used as solid phase support for glycan derivatization and purification from excess of derivatization reagents.
35193013	1	85	from	charge	388:393	arg1	acids					405:409	sialic acids	398:409	sialic acids	398:409	Characterization of serum glycoprotein N-glycans with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) in positive-ion mode needs a derivatization step to stabilize and neutralize the negative charge on sialic acids.
35193013	8	86	theme	neuraminic	1485:1494	arg1	Neu5Ac					1502:1507	Neu5Ac	1502:1507	Neu5Ac	1502:1507	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	8	86	theme	neuraminic	1485:1494	arg1	acid					1496:1499	N-Acetyl neuraminic acid	1476:1499	N-Acetyl neuraminic acid (Neu5Ac)	1476:1508	In BALB/c mouse sera, we detected predominantly mono- and di-sialylated N-glycans with mostly N-Glycolylneuraminic acid (Neu5Gc) and only trace amounts of N-Acetyl neuraminic acid (Neu5Ac).
35193013	7	87	theme	glycan	1234:1239	arg1	structures					1241:1250	the glycan structures	1230:1250	the glycan structures	1230:1250	The stabilization of sialic acid enables a complete conservation of the glycan structures, in contrast to other methods where sialic acids are partially lost.
35193013	2	88	theme	gangliosides	487:498	arg1	end					450:452	the end	446:452	the end of glycoproteins, glycolipids or gangliosides	446:498	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	10	89	theme	spectrometry	1644:1655	arg1	analysis					1657:1664	MALDI mass spectrometry analysis	1633:1664	MALDI mass spectrometry analysis	1633:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	0	90	with	methylamidation	15:29	arg1	residues					121:128	structurally conserved sialic acid residues	86:128	structurally conserved sialic acid residues in biological fluids "via direttissima"	86:168	DMTMM-mediated methylamidation for MALDI mass spectrometry analysis of N-glycans with structurally conserved sialic acid residues in biological fluids "via direttissima".
35193013	2	91	attach	attached	434:441	arg1	end					450:452	the end	446:452	the end of glycoproteins, glycolipids or gangliosides	446:498	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	2	91	attach	attached	434:441	arg2	sugars					423:428	The acidic sugars	412:428	The acidic sugars	412:428	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	10	92	theme	MALDI	1633:1637	arg1	analysis					1657:1664	MALDI mass spectrometry analysis	1633:1664	MALDI mass spectrometry analysis	1633:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	4	93	theme	activation	866:875	arg1	reagent					877:883	activation reagent	866:883	activation reagent due to its better performance	866:913	DMTMM substitutes in many processes N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide (EDC/NHS) as activation reagent due to its better performance and higher stability in water.
35193013	2	94	gly	glycoproteins	457:469	arg1	glycoproteins					457:469	glycoproteins	457:469	glycoproteins	457:469	The acidic sugars are attached to the end of glycoproteins, glycolipids or gangliosides.
35193013	10	95	theme	fast	1671:1674	arg1	method					1686:1691	a fast and cheap method	1669:1691	a fast and cheap method for structurally conserved glycan derivatization	1669:1740	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35193013	10	95	theme	fast	1671:1674	arg1	methylamidation					1600:1614	DMTMM-mediated methylamidation	1585:1614	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis	1585:1664	DMTMM-mediated methylamidation of N-glycans for MALDI mass spectrometry analysis is a fast and cheap method for structurally conserved glycan derivatization.
35279850	1	0	with	defects	228:234	arg1	phenotype					267:275	heterogeneous multisystem phenotype	241:275	heterogeneous multisystem phenotype	241:275	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	6	1	from	N-tetrasaccharide	1095:1111	arg1	patients					1125:1132	ALG2-CDG patients	1116:1132	ALG2-CDG patients	1116:1132	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	3	2	theme	few	544:546	arg1	CDG					554:556	a few other CDG	542:556	a few other CDG	542:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	0	3	theme	Synergistic	0:10	arg1	use					12:14	Synergistic use	0:14	Synergistic use of glycomics	0:27	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	5	4	theme	inversion	896:904	arg1	smMIPs					914:919	smMIPs	914:919	smMIPs	914:919	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	5	4	theme	inversion	896:904	arg1	probes					906:911	single-molecule molecular inversion probes	870:911	single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes	870:960	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	9	5	from	profiling	1554:1562	arg1	patients					1570:1577	36 patients	1567:1577	36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing	1567:1639	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	4	6	theme	resolution	707:716	arg1	spectrometry					749:760	high resolution quadrupole time-of-flight mass spectrometry	702:760	high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	702:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	2	7	from	absence	383:389	arg1	transferrin					416:426	transferrin	416:426	transferrin	416:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	0	8	theme	type-1	136:141	arg1	disorders					109:117	congenital disorders	98:117	congenital disorders of glycosylation type-1	98:141	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	3	9	theme	structural	592:601	arg1	analysis					603:610	glycan structural analysis	585:610	glycan structural analysis	585:610	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	4	10	theme	plasma	682:687	arg1	N-glycans					689:697	total plasma N-glycans	676:697	total plasma N-glycans	676:697	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	4	11	with	patients	793:800	arg1	n = 75					814:819	n = 75	814:819	n = 75	814:819	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	4	11	with	patients	793:800	arg1	cause					851:855	known (n = 75) or unsolved (n = 36) genetic cause	807:855	cause	851:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	10	12	theme	CDG-I	1832:1836	arg1	cohorts					1846:1852	CDG-I patient cohorts	1832:1852	CDG-I patient cohorts	1832:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	5	13	theme	single-molecule	870:884	arg1	smMIPs					914:919	smMIPs	914:919	smMIPs	914:919	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	5	13	theme	single-molecule	870:884	arg1	probes					906:911	single-molecule molecular inversion probes	870:911	single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes	870:960	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	7	14	theme	hereditary	1376:1385	arg1	intolerance					1396:1406	hereditary fructose intolerance	1376:1406	hereditary fructose intolerance	1376:1406	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	3	15	theme	gene	622:625	arg1	discovery					627:635	CDG-I gene discovery	616:635	CDG-I gene discovery	616:635	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	5	16	theme	CDG-I	940:944	arg1	genes					956:960	CDG-I candidate genes	940:960	CDG-I candidate genes	940:960	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	5	17	theme	genes	956:960	arg1	sequencing					926:935	sequencing	926:935	sequencing of CDG-I candidate genes	926:960	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	5	18	theme	candidate	946:954	arg1	genes					956:960	CDG-I candidate genes	940:960	CDG-I candidate genes	940:960	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	6	19	with	patients	1031:1038	arg1	defects					1051:1057	known defects	1045:1057	known defects	1045:1057	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	4	20	theme	time-of-flight	729:742	arg1	spectrometry					749:760	high resolution quadrupole time-of-flight mass spectrometry	702:760	high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	702:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	1	21	theme	glycosylation	168:180	arg1	type					182:185	glycosylation type 1	168:187	glycosylation type 1 (CDG-I)	168:195	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	1	21	theme	glycosylation	168:180	arg1	CDG-I					190:194	CDG-I	190:194	CDG-I	190:194	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	9	22	with	patients	1570:1577	arg1	CDG-I					1602:1606	thus far unsolved CDG-I	1584:1606	thus far unsolved CDG-I	1584:1606	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	9	22	with	patients	1570:1577	arg1	sequencing					1630:1639	subsequent smMIPs sequencing	1612:1639	subsequent smMIPs sequencing	1612:1639	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	10	23	theme	smMIPs	1737:1742	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	23	theme	smMIPs	1737:1742	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	23	theme	smMIPs	1737:1742	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	0	24	theme	congenital	98:107	arg1	disorders					109:117	congenital disorders	98:117	congenital disorders of glycosylation type-1	98:141	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	5	25	theme	N-glycan	987:994	arg1	signatures					996:1005	specific N-glycan signatures	978:1005	specific N-glycan signatures	978:1005	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	6	26	theme	Glycomics	1008:1016	arg1	profiling					1018:1026	Glycomics profiling	1008:1026	Glycomics profiling in patients with known defects	1008:1057	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	6	27	from	profiling	1018:1026	arg1	patients					1031:1038	patients	1031:1038	patients with known defects	1031:1057	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	10	28	theme	Combined	1688:1695	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	28	theme	Combined	1688:1695	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	28	theme	Combined	1688:1695	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	6	29	gly	fucosylated	1146:1156	arg1	N-pentasaccharide					1158:1174	a novel fucosylated N-pentasaccharide	1138:1174	a novel fucosylated N-pentasaccharide	1138:1174	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	4	30	theme	111	783:785	arg1	patients					793:800	111 CDG-I patients	783:800	111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	783:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	2	31	theme	N-glycans	403:411	arg1	hallmark					352:359	The biochemical hallmark	336:359	The biochemical hallmark of CDG-I	336:368	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	2	31	theme	N-glycans	403:411	arg1	absence					383:389	a partial absence	373:389	a partial absence of complete N-glycans on transferrin	373:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	7	32	theme	high-mannose	1239:1250	arg1	signatures					1261:1270	group-specific high-mannose N-glycan signatures	1224:1270	group-specific high-mannose N-glycan signatures	1224:1270	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	9	33	theme	subsequent	1612:1621	arg1	sequencing					1630:1639	subsequent smMIPs sequencing	1612:1639	subsequent smMIPs sequencing	1612:1639	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	4	34	theme	patients	793:800	arg1	cohort					773:778	a large cohort	765:778	a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	765:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	10	35	theme	plasma	1697:1702	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	35	theme	plasma	1697:1702	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	35	theme	plasma	1697:1702	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	1	36	theme	nonspecific	301:311	arg1	symptoms					326:333	nonspecific neurological symptoms	301:333	nonspecific neurological symptoms	301:333	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	8	37	theme	differential	1417:1428	arg1	analysis					1430:1437	Further differential analysis	1409:1437	Further differential analysis	1409:1437	Further differential analysis revealed high-mannose profiles, characteristic for ALG12- and ALG9-CDG.
35279850	3	38	theme	N-tetrasaccharide	470:486	arg1	findings					445:452	recent findings	438:452	recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG	438:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	2	39	from	N-glycans	403:411	arg1	transferrin					416:426	transferrin	416:426	transferrin	416:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	6	40	theme	novel	1068:1072	arg1	N-tetrasaccharide					1095:1111	the N-tetrasaccharide	1091:1111	the N-tetrasaccharide in ALG2-CDG patients	1091:1132	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	6	40	theme	novel	1068:1072	arg1	features					1074:1081	novel features	1068:1081	novel features such as the N-tetrasaccharide in ALG2-CDG patients	1068:1132	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	3	41	theme	N-glycans	528:536	arg1	findings					445:452	recent findings	438:452	recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG	438:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	0	42	theme	molecular	49:57	arg1	inversion					59:67	single-molecule molecular inversion	33:67	single-molecule molecular inversion	33:67	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	2	43	from	transferrin	416:426	arg1	hallmark					352:359	The biochemical hallmark	336:359	The biochemical hallmark of CDG-I	336:368	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	2	43	from	transferrin	416:426	arg1	absence					383:389	a partial absence	373:389	a partial absence of complete N-glycans on transferrin	373:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	3	44	theme	increased	505:513	arg1	N-glycans					528:536	increased high-mannose N-glycans	505:536	increased high-mannose N-glycans for a few other CDG	505:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	1	45	theme	genetic	220:226	arg1	defects					228:234	27 genetic defects	217:234	27 genetic defects with heterogeneous multisystem phenotype	217:275	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	10	46	theme	genes	1768:1772	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	46	theme	genes	1768:1772	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	46	theme	genes	1768:1772	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	9	47	theme	solved	1659:1664	arg1	cases					1666:1670	solved cases	1659:1670	solved cases of 78% (28/36)	1659:1685	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	6	48	theme	fucosylated	1146:1156	arg1	N-pentasaccharide					1158:1174	a novel fucosylated N-pentasaccharide	1138:1174	a novel fucosylated N-pentasaccharide	1138:1174	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	8	49	theme	characteristic	1471:1484	arg1	profiles					1461:1468	high-mannose profiles	1448:1468	high-mannose profiles	1448:1468	Further differential analysis revealed high-mannose profiles, characteristic for ALG12- and ALG9-CDG.
35279850	3	50	theme	other	548:552	arg1	CDG					554:556	a few other CDG	542:556	a few other CDG	542:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	7	51	theme	N-glycan	1252:1259	arg1	signatures					1261:1270	group-specific high-mannose N-glycan signatures	1224:1270	group-specific high-mannose N-glycan signatures	1224:1270	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	2	52	theme	partial	375:381	arg1	hallmark					352:359	The biochemical hallmark	336:359	The biochemical hallmark of CDG-I	336:368	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	2	52	theme	partial	375:381	arg1	absence					383:389	a partial absence	373:389	a partial absence of complete N-glycans on transferrin	373:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	1	53	theme	multisystem	255:265	arg1	phenotype					267:275	heterogeneous multisystem phenotype	241:275	heterogeneous multisystem phenotype	241:275	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	9	54	theme	%	1677:1677	arg1	cases					1666:1670	solved cases	1659:1670	solved cases of 78% (28/36)	1659:1685	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	10	55	theme	powerful	1779:1786	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	55	theme	powerful	1779:1786	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	55	theme	powerful	1779:1786	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	3	56	theme	analysis	603:610	arg1	potential					572:580	the potential	568:580	the potential of glycan structural analysis for CDG-I gene discovery	568:635	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	10	57	theme	targeted	1728:1735	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	57	theme	targeted	1728:1735	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	57	theme	targeted	1728:1735	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	5	58	theme	molecular	886:894	arg1	smMIPs					914:919	smMIPs	914:919	smMIPs	914:919	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	5	58	theme	molecular	886:894	arg1	probes					906:911	single-molecule molecular inversion probes	870:911	single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes	870:960	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	4	59	theme	N-glycans	689:697	arg1	abundance					663:671	the relative abundance	650:671	the relative abundance of total plasma N-glycans	650:697	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	2	60	theme	biochemical	340:350	arg1	hallmark					352:359	The biochemical hallmark	336:359	The biochemical hallmark of CDG-I	336:368	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	2	60	theme	biochemical	340:350	arg1	absence					383:389	a partial absence	373:389	a partial absence of complete N-glycans on transferrin	373:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	4	61	theme	high	702:705	arg1	spectrometry					749:760	high resolution quadrupole time-of-flight mass spectrometry	702:760	high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	702:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	3	62	theme	glycan	585:590	arg1	analysis					603:610	glycan structural analysis	585:610	glycan structural analysis	585:610	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	10	63	theme	patient	1838:1844	arg1	cohorts					1846:1852	CDG-I patient cohorts	1832:1852	CDG-I patient cohorts	1832:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	4	64	theme	total	676:680	arg1	N-glycans					689:697	total plasma N-glycans	676:697	total plasma N-glycans	676:697	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	3	65	theme	CDG-I	616:620	arg1	discovery					627:635	CDG-I gene discovery	616:635	CDG-I gene discovery	616:635	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	9	66	theme	genes	1535:1539	arg1	Prediction					1511:1520	Prediction	1511:1520	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing	1511:1639	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	7	67	theme	fructose	1387:1394	arg1	intolerance					1396:1406	hereditary fructose intolerance	1376:1406	hereditary fructose intolerance	1376:1406	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	1	68	theme	Congenital	144:153	arg1	disorders					155:163	Congenital disorders	144:163	Congenital disorders of glycosylation type 1 (CDG-I)	144:195	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	4	69	theme	large	767:771	arg1	cohort					773:778	a large cohort	765:778	a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	765:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	6	70	theme	known	1045:1049	arg1	defects					1051:1057	known defects	1045:1057	known defects	1045:1057	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	4	71	theme	quadrupole	718:727	arg1	spectrometry					749:760	high resolution quadrupole time-of-flight mass spectrometry	702:760	high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	702:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	1	72	theme	type	182:185	arg1	disorders					155:163	Congenital disorders	144:163	Congenital disorders of glycosylation type 1 (CDG-I)	144:195	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	4	73	theme	mass	744:747	arg1	spectrometry					749:760	high resolution quadrupole time-of-flight mass spectrometry	702:760	high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	702:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	0	74	theme	disorders	109:117	arg1	identification					80:93	identification	80:93	identification of congenital disorders of glycosylation type-1	80:141	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	5	75	theme	specific	978:985	arg1	signatures					996:1005	specific N-glycan signatures	978:1005	specific N-glycan signatures	978:1005	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	10	76	theme	causative	1809:1817	arg1	mutations					1819:1827	causative mutations	1809:1827	causative mutations in CDG-I patient cohorts	1809:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	77	theme	glycomics	1704:1712	arg1	sequencing					1744:1753	targeted smMIPs sequencing	1728:1753	targeted smMIPs sequencing	1728:1753	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	77	theme	glycomics	1704:1712	arg1	profiling					1714:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling	1688:1722	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	10	77	theme	glycomics	1704:1712	arg1	approach					1788:1795	a powerful approach	1777:1795	a powerful approach to identify causative mutations in CDG-I patient cohorts	1777:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	0	78	theme	glycosylation	122:134	arg1	type-1					136:141	glycosylation type-1	122:141	glycosylation type-1	122:141	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	5	79	theme	signatures	996:1005	arg1	basis					969:973	the basis	965:973	the basis of specific N-glycan signatures	965:1005	We designed single-molecule molecular inversion probes (smMIPs) for sequencing of CDG-I candidate genes on the basis of specific N-glycan signatures.
35279850	10	80	from	mutations	1819:1827	arg1	cohorts					1846:1852	CDG-I patient cohorts	1832:1852	CDG-I patient cohorts	1832:1852	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	6	81	theme	ALG2-CDG	1116:1123	arg1	patients					1125:1132	ALG2-CDG patients	1116:1132	ALG2-CDG patients	1116:1132	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	3	82	theme	diagnostic	459:468	arg1	N-tetrasaccharide					470:486	a diagnostic N-tetrasaccharide	457:486	a diagnostic N-tetrasaccharide for ALG1-CDG	457:499	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	7	83	theme	group-specific	1224:1237	arg1	signatures					1261:1270	group-specific high-mannose N-glycan signatures	1224:1270	group-specific high-mannose N-glycan signatures	1224:1270	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	2	84	theme	complete	394:401	arg1	N-glycans					403:411	complete N-glycans	394:411	complete N-glycans on transferrin	394:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	0	85	theme	glycomics	19:27	arg1	use					12:14	Synergistic use	0:14	Synergistic use of glycomics	0:27	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	0	85	theme	glycomics	19:27	arg1	inversion					59:67	single-molecule molecular inversion	33:67	single-molecule molecular inversion	33:67	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	9	86	theme	smMIPs	1623:1628	arg1	sequencing					1630:1639	subsequent smMIPs sequencing	1612:1639	subsequent smMIPs sequencing	1612:1639	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	9	87	theme	unsolved	1593:1600	arg1	CDG-I					1602:1606	thus far unsolved CDG-I	1584:1606	thus far unsolved CDG-I	1584:1606	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	4	88	theme	CDG-I	787:791	arg1	patients					793:800	111 CDG-I patients	783:800	111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	783:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	10	89	theme	candidate	1758:1766	arg1	genes					1768:1772	candidate genes	1758:1772	candidate genes	1758:1772	Combined plasma glycomics profiling and targeted smMIPs sequencing of candidate genes is a powerful approach to identify causative mutations in CDG-I patient cohorts.
35279850	0	90	theme	single-molecule	33:47	arg1	inversion					59:67	single-molecule molecular inversion	33:67	single-molecule molecular inversion	33:67	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type-1.
35279850	1	91	theme	neurological	313:324	arg1	symptoms					326:333	nonspecific neurological symptoms	301:333	nonspecific neurological symptoms	301:333	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	3	92	theme	recent	438:443	arg1	findings					445:452	recent findings	438:452	recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG	438:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	8	93	theme	Further	1409:1415	arg1	analysis					1430:1437	Further differential analysis	1409:1437	Further differential analysis	1409:1437	Further differential analysis revealed high-mannose profiles, characteristic for ALG12- and ALG9-CDG.
35279850	7	94	located	found	1277:1281	arg1	DPM3-					1346:1350	DPM3-	1346:1350	DPM3-	1346:1350	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	ALG11-					1300:1305	ALG11-	1300:1305	ALG11-	1300:1305	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	MPDU1-					1353:1358	MPDU1-	1353:1358	MPDU1-	1353:1358	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	ALG12-					1308:1313	ALG12-	1308:1313	ALG12-	1308:1313	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	intolerance					1396:1406	hereditary fructose intolerance	1376:1406	hereditary fructose intolerance	1376:1406	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	DOLK-					1332:1336	DOLK-	1332:1336	DOLK-	1332:1336	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg2	signatures					1261:1270	group-specific high-mannose N-glycan signatures	1224:1270	group-specific high-mannose N-glycan signatures	1224:1270	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	ALG3-					1286:1290	ALG3-	1286:1290	ALG3-	1286:1290	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	DPM1-					1339:1343	DPM1-	1339:1343	DPM1-	1339:1343	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	ALG13-CDG					1361:1369	ALG13-CDG	1361:1369	ALG13-CDG	1361:1369	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	ALG9-					1293:1297	ALG9-	1293:1297	ALG9-	1293:1297	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	RFT1-					1316:1320	RFT1-	1316:1320	RFT1-	1316:1320	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	7	94	located	found	1277:1281	arg1	SRD5A3-					1323:1329	SRD5A3-	1323:1329	SRD5A3-	1323:1329	Moreover, group-specific high-mannose N-glycan signatures were found in ALG3-, ALG9-, ALG11-, ALG12-, RFT1-, SRD5A3-, DOLK-, DPM1-, DPM3-, MPDU1-, ALG13-CDG, and hereditary fructose intolerance.
35279850	6	95	theme	specific	1179:1186	arg1	glycomarker					1188:1198	specific glycomarker	1179:1198	specific glycomarker for ALG1-CDG	1179:1211	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	9	96	theme	glycomics	1544:1552	arg1	profiling					1554:1562	glycomics profiling	1544:1562	glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing	1544:1639	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	4	97	theme	genetic	843:849	arg1	cause					851:855	known (n = 75) or unsolved (n = 36) genetic cause	807:855	cause	851:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	2	98	theme	CDG-I	364:368	arg1	hallmark					352:359	The biochemical hallmark	336:359	The biochemical hallmark of CDG-I	336:368	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	2	98	theme	CDG-I	364:368	arg1	absence					383:389	a partial absence	373:389	a partial absence of complete N-glycans on transferrin	373:426	The biochemical hallmark of CDG-I is a partial absence of complete N-glycans on transferrin.
35279850	8	99	theme	high-mannose	1448:1459	arg1	profiles					1461:1468	high-mannose profiles	1448:1468	high-mannose profiles	1448:1468	Further differential analysis revealed high-mannose profiles, characteristic for ALG12- and ALG9-CDG.
35279850	3	100	theme	high-mannose	515:526	arg1	N-glycans					528:536	increased high-mannose N-glycans	505:536	increased high-mannose N-glycans for a few other CDG	505:556	However, recent findings of a diagnostic N-tetrasaccharide for ALG1-CDG and increased high-mannose N-glycans for a few other CDG suggested the potential of glycan structural analysis for CDG-I gene discovery.
35279850	1	101	theme	defects	228:234	arg1	group					208:212	a group	206:212	a group	206:212	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	1	101	theme	defects	228:234	arg1	defects					228:234	27 genetic defects	217:234	27 genetic defects with heterogeneous multisystem phenotype	217:275	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
35279850	9	102	theme	candidate	1525:1533	arg1	genes					1535:1539	candidate genes	1525:1539	candidate genes	1525:1539	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	9	103	theme	cases	1666:1670	arg1	yield					1650:1654	a yield	1648:1654	a yield of solved cases of 78% (28/36)	1648:1685	Prediction of candidate genes by glycomics profiling in 36 patients with thus far unsolved CDG-I and subsequent smMIPs sequencing led to a yield of solved cases of 78% (28/36).
35279850	6	104	theme	novel	1140:1144	arg1	N-pentasaccharide					1158:1174	a novel fucosylated N-pentasaccharide	1138:1174	a novel fucosylated N-pentasaccharide	1138:1174	Glycomics profiling in patients with known defects revealed novel features such as the N-tetrasaccharide in ALG2-CDG patients and a novel fucosylated N-pentasaccharide as specific glycomarker for ALG1-CDG.
35279850	4	105	theme	relative	654:661	arg1	abundance					663:671	the relative abundance	650:671	the relative abundance of total plasma N-glycans	650:697	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	4	106	theme	unsolved	825:832	arg1	cause					851:855	known (n = 75) or unsolved (n = 36) genetic cause	807:855	cause	851:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	4	107	from	spectrometry	749:760	arg1	cohort					773:778	a large cohort	765:778	a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause	765:855	We analyzed the relative abundance of total plasma N-glycans by high resolution quadrupole time-of-flight mass spectrometry in a large cohort of 111 CDG-I patients with known (n = 75) or unsolved (n = 36) genetic cause.
35279850	1	108	theme	heterogeneous	241:253	arg1	phenotype					267:275	heterogeneous multisystem phenotype	241:275	heterogeneous multisystem phenotype	241:275	Congenital disorders of glycosylation type 1 (CDG-I) comprise a group of 27 genetic defects with heterogeneous multisystem phenotype, mostly presenting with nonspecific neurological symptoms.
34972935	4	0	theme	glycan	739:744	arg1	epitopes					746:753	the glycan epitopes	735:753	the glycan epitopes in their natural presentation	735:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	2	1	theme	system	365:370	arg1	lectins					336:342	lectins	336:342	lectins of the innate immune system for triggering defense responses	336:403	These structures are often recognized by lectins of the innate immune system for triggering defense responses, although some bacterial pathogens exploit recognition by host lectins for favoring infection.
34972935	4	2	theme	real	809:812	arg1	density					814:820	their real density	803:820	their real density	803:820	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	5	3	theme	panel	954:958	arg1	arrays					942:947	the bacterial arrays	928:947	the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences	928:1013	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	2	4	theme	immune	358:363	arg1	system					365:370	the innate immune system	347:370	the innate immune system for triggering defense responses	347:403	These structures are often recognized by lectins of the innate immune system for triggering defense responses, although some bacterial pathogens exploit recognition by host lectins for favoring infection.
34972935	5	5	theme	surface	1039:1045	arg1	glycans					1047:1053	surface glycans	1039:1053	surface glycans	1039:1053	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	3	6	theme	surface	575:581	arg1	glycans					583:589	accessible bacterial surface glycans	554:589	accessible bacterial surface glycans	554:589	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	4	7	from	recognition	720:730	arg1	presentation					772:783	their natural presentation	758:783	their natural presentation	758:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	1	8	theme	given	270:274	arg1	species					286:292	a given bacterial species	268:292	a given bacterial species	268:292	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	3	9	theme	useful	528:533	arg1	tool					535:538	a useful tool	526:538	a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins	526:650	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	3	9	theme	useful	528:533	arg1	microarrays					510:520	Bacterial microarrays	500:520	Bacterial microarrays	500:520	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	1	10	theme	bacterial	276:284	arg1	species					286:292	a given bacterial species	268:292	a given bacterial species	268:292	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	3	11	theme	accessible	554:563	arg1	glycans					583:589	accessible bacterial surface glycans	554:589	accessible bacterial surface glycans	554:589	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	5	12	with	lectins	963:969	arg1	preferences					1003:1013	known carbohydrate-binding preferences	976:1013	known carbohydrate-binding preferences	976:1013	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	0	13	theme	Bacterial	0:8	arg1	Microarrays					10:20	Bacterial Microarrays	0:20	Bacterial Microarrays	0:20	Bacterial Microarrays for Examining Bacterial Glycosignatures and Recognition by Host Lectins.
34972935	3	14	theme	bacterial	565:573	arg1	glycans					583:589	accessible bacterial surface glycans	554:589	accessible bacterial surface glycans	554:589	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	4	15	theme	cells	688:692	arg1	use					657:659	The use	653:659	The use of array-printed bacterial cells	653:692	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	2	16	theme	host	463:466	arg1	lectins					468:474	host lectins	463:474	host lectins	463:474	These structures are often recognized by lectins of the innate immune system for triggering defense responses, although some bacterial pathogens exploit recognition by host lectins for favoring infection.
34972935	1	17	theme	species	286:292	arg1	strains					257:263	strains	257:263	strains of a given bacterial species	257:292	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	3	18	dep	tool	535:538	arg1	exploring					599:607	exploring	599:607	exploring their recognition by innate immune lectins	599:650	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	3	18	dep	tool	535:538	arg1	profiling					544:552	profiling	544:552	profiling accessible bacterial surface glycans	544:589	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	2	19	theme	defense	387:393	arg1	responses					395:403	defense responses	387:403	defense responses	387:403	These structures are often recognized by lectins of the innate immune system for triggering defense responses, although some bacterial pathogens exploit recognition by host lectins for favoring infection.
34972935	5	20	theme	bacterial	867:875	arg1	surfaces					877:884	bacterial surfaces	867:884	bacterial surfaces	867:884	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	4	21	from	presentation	772:783	arg1	recognition					720:730	the recognition	716:730	the recognition of the glycan epitopes in their natural presentation	716:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	5	22	theme	carbohydrate-binding	982:1001	arg1	preferences					1003:1013	known carbohydrate-binding preferences	976:1013	known carbohydrate-binding preferences	976:1013	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	5	23	theme	innate	1058:1063	arg1	lectins					1072:1078	innate immune lectins	1058:1078	innate immune lectins	1058:1078	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	1	24	theme	same	214:217	arg1	architecture					229:240	the same cell wall architecture	210:240	the same cell wall architecture	210:240	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	5	25	theme	surfaces	877:884	arg1	patterns					855:862	Glycosylation patterns	841:862	Glycosylation patterns of bacterial surfaces	841:884	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	5	26	theme	known	976:980	arg1	preferences					1003:1013	known carbohydrate-binding preferences	976:1013	known carbohydrate-binding preferences	976:1013	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	5	27	theme	similar	1109:1115	arg1	assays					1125:1130	similar binding assays	1109:1130	similar binding assays	1109:1130	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	1	28	theme	bacteria	110:117	arg1	surface					99:105	The surface	95:105	The surface of bacteria	95:117	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	1	29	theme	cell	219:222	arg1	architecture					229:240	the same cell wall architecture	210:240	the same cell wall architecture	210:240	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	4	30	theme	epitopes	746:753	arg1	recognition					720:730	the recognition	716:730	the recognition of the glycan epitopes in their natural presentation	716:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	1	31	theme	wall	224:227	arg1	architecture					229:240	the same cell wall architecture	210:240	the same cell wall architecture	210:240	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	3	32	theme	innate	630:635	arg1	lectins					644:650	innate immune lectins	630:650	innate immune lectins	630:650	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	2	33	theme	bacterial	420:428	arg1	pathogens					430:438	some bacterial pathogens	415:438	some bacterial pathogens	415:438	These structures are often recognized by lectins of the innate immune system for triggering defense responses, although some bacterial pathogens exploit recognition by host lectins for favoring infection.
34972935	0	34	theme	Bacterial	36:44	arg1	Glycosignatures					46:60	Bacterial Glycosignatures	36:60	Bacterial Glycosignatures	36:60	Bacterial Microarrays for Examining Bacterial Glycosignatures and Recognition by Host Lectins.
34972935	3	35	theme	immune	637:642	arg1	lectins					644:650	innate immune lectins	630:650	innate immune lectins	630:650	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	4	36	theme	bacterial	678:686	arg1	cells					688:692	array-printed bacterial cells	664:692	array-printed bacterial cells	664:692	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	2	37	theme	innate	351:356	arg1	system					365:370	the innate immune system	347:370	the innate immune system for triggering defense responses	347:403	These structures are often recognized by lectins of the innate immune system for triggering defense responses, although some bacterial pathogens exploit recognition by host lectins for favoring infection.
34972935	5	38	theme	Glycosylation	841:853	arg1	patterns					855:862	Glycosylation patterns	841:862	Glycosylation patterns of bacterial surfaces	841:884	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	1	39	theme	diverse	128:134	arg1	structures					149:158	diverse carbohydrate structures	128:158	diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species	128:292	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	5	40	theme	immune	1065:1070	arg1	lectins					1072:1078	innate immune lectins	1058:1078	innate immune lectins	1058:1078	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	1	41	theme	carbohydrate	136:147	arg1	structures					149:158	diverse carbohydrate structures	128:158	diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species	128:292	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	1	42	with	bacteria	196:203	arg1	architecture					229:240	the same cell wall architecture	210:240	the same cell wall architecture	210:240	The surface of bacteria displays diverse carbohydrate structures that may significantly differ among bacteria with the same cell wall architecture and even among strains of a given bacterial species.
34972935	4	43	theme	natural	764:770	arg1	presentation					772:783	their natural presentation	758:783	their natural presentation	758:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	5	44	theme	binding	1117:1123	arg1	assays					1125:1130	similar binding assays	1109:1130	similar binding assays	1109:1130	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	5	45	theme	lectins	963:969	arg1	panel					954:958	a panel	952:958	a panel of lectins with known carbohydrate-binding preferences	952:1013	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	3	46	theme	Bacterial	500:508	arg1	tool					535:538	a useful tool	526:538	a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins	526:650	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	3	46	theme	Bacterial	500:508	arg1	microarrays					510:520	Bacterial microarrays	500:520	Bacterial microarrays	500:520	Bacterial microarrays are a useful tool for profiling accessible bacterial surface glycans and for exploring their recognition by innate immune lectins.
34972935	0	47	theme	Host	81:84	arg1	Lectins					86:92	Host Lectins	81:92	Host Lectins	81:92	Bacterial Microarrays for Examining Bacterial Glycosignatures and Recognition by Host Lectins.
34972935	5	48	theme	glycans	1047:1053	arg1	recognition					1024:1034	the recognition	1020:1034	the recognition of surface glycans by innate immune lectins	1020:1078	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	4	49	theme	array-printed	664:676	arg1	cells					688:692	array-printed bacterial cells	664:692	array-printed bacterial cells	664:692	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	5	50	theme	bacterial	932:940	arg1	arrays					942:947	the bacterial arrays	928:947	the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences	928:1013	Glycosylation patterns of bacterial surfaces can be examined by testing the binding to the bacterial arrays of a panel of lectins with known carbohydrate-binding preferences, and the recognition of surface glycans by innate immune lectins can easily be assessed using similar binding assays.
34972935	4	51	from	epitopes	746:753	arg1	presentation					772:783	their natural presentation	758:783	their natural presentation	758:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
34972935	4	52	theme	recognition	720:730	arg1	evaluation					702:711	evaluation	702:711	evaluation of the recognition of the glycan epitopes in their natural presentation	702:783	The use of array-printed bacterial cells enables evaluation of the recognition of the glycan epitopes in their natural presentation, i.e., preserving their real density and accessibility.
36512577	4	0	from	role	564:567	arg1	maintenance					579:589	muscle maintenance	572:589	muscle maintenance	572:589	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	2	1	theme	glucuronic	379:388	arg1	acid					390:393	glucuronic acid	379:393	glucuronic acid	379:393	This matriglycan polymer is made with an alternating pattern of xylose and glucuronic acid monomers.
36512577	7	2	dep	GT-A	954:957	arg1	folds					959:963	folds	959:963	folds	959:963	The structure shows that this enzyme has two canonical GT-A folds within each of its catalytic domains.
36512577	4	3	theme	enzyme	620:625	arg1	unknown					665:671	unknown	665:671	unknown	665:671	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	4	3	theme	enzyme	620:625	arg1	structure					596:604	the structure	592:604	the structure of the LARGE1 enzyme and how it assembles in the Golgi	592:659	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	8	4	theme	efficient	1144:1152	arg1	shuttling					1154:1162	efficient shuttling	1144:1162	efficient shuttling of the substrates between the two domains	1144:1204	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	8	5	theme	structure	1033:1041	arg1	context					1010:1016	the context	1006:1016	the context of its dimeric structure	1006:1041	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	10	6	theme	structural	1410:1419	arg1	information					1421:1431	The structural information	1406:1431	The structural information	1406:1431	The structural information further reveals the mechanisms in which disease-causing mutations disrupt the activity of LARGE1.
36512577	6	7	theme	coiled-coil	874:884	arg1	domain					891:896	its coiled-coil stem domain	870:896	its coiled-coil stem domain	870:896	We found that LARGE1 homo-dimerizes in a configuration that is dictated by its coiled-coil stem domain.
36512577	1	8	theme	proper	280:285	arg1	function					294:301	proper muscle function	280:301	proper muscle function	280:301	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	4	9	theme	major	558:562	arg1	role					564:567	its major role	554:567	its major role in muscle maintenance	554:589	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	7	10	theme	catalytic	984:992	arg1	domains					994:1000	its catalytic domains	980:1000	its catalytic domains	980:1000	The structure shows that this enzyme has two canonical GT-A folds within each of its catalytic domains.
36512577	1	11	theme	muscle	287:292	arg1	function					294:301	proper muscle function	280:301	proper muscle function	280:301	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	5	12	theme	X-ray	744:748	arg1	crystallography					750:764	X-ray crystallography	744:764	X-ray crystallography	744:764	Here we present the structure of LARGE1, obtained by a combination of X-ray crystallography and single-particle cryo-EM.
36512577	9	13	theme	possible	1322:1329	arg1	mechanism					1331:1339	a possible mechanism	1320:1339	a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains	1320:1403	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	2	14	theme	matriglycan	309:319	arg1	polymer					321:327	This matriglycan polymer	304:327	This matriglycan polymer	304:327	This matriglycan polymer is made with an alternating pattern of xylose and glucuronic acid monomers.
36512577	3	15	theme	matriglycan	523:533	arg1	synthesis					535:543	matriglycan synthesis	523:543	matriglycan synthesis	523:543	Mutations in the LARGE1 gene have been shown to cause life-threatening dystroglycanopathies through the inhibition of matriglycan synthesis.
36512577	5	16	theme	crystallography	750:764	arg1	combination					729:739	a combination	727:739	a combination of X-ray crystallography and single-particle cryo-EM	727:792	Here we present the structure of LARGE1, obtained by a combination of X-ray crystallography and single-particle cryo-EM.
36512577	3	17	from	Mutations	405:413	arg1	gene					429:432	the LARGE1 gene	418:432	the LARGE1 gene	418:432	Mutations in the LARGE1 gene have been shown to cause life-threatening dystroglycanopathies through the inhibition of matriglycan synthesis.
36512577	8	18	theme	substrates	1171:1180	arg1	shuttling					1154:1162	efficient shuttling	1144:1162	efficient shuttling of the substrates between the two domains	1144:1204	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	8	19	from	monomers	1126:1133	arg1	proximity					1102:1110	close proximity	1096:1110	close proximity from opposing monomers	1096:1133	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	3	20	theme	synthesis	535:543	arg1	inhibition					509:518	the inhibition	505:518	the inhibition of matriglycan synthesis	505:543	Mutations in the LARGE1 gene have been shown to cause life-threatening dystroglycanopathies through the inhibition of matriglycan synthesis.
36512577	3	21	theme	life-threatening	459:474	arg1	dystroglycanopathies					476:495	life-threatening dystroglycanopathies	459:495	life-threatening dystroglycanopathies	459:495	Mutations in the LARGE1 gene have been shown to cause life-threatening dystroglycanopathies through the inhibition of matriglycan synthesis.
36512577	8	22	theme	domains	1071:1077	arg1	types					1052:1056	the two types	1044:1056	the two types of catalytic domains	1044:1077	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	11	23	theme	functional	1615:1624	arg1	significance					1626:1637	the functional significance	1611:1637	the functional significance of glycosyltransferase oligomerization	1611:1676	Collectively, these data shed light on how matriglycan is synthesized alongside the functional significance of glycosyltransferase oligomerization.
36512577	2	24	dep	pattern	357:363	arg1	monomers					395:402	monomers	395:402	monomers	395:402	This matriglycan polymer is made with an alternating pattern of xylose and glucuronic acid monomers.
36512577	9	25	theme	matriglycan	1386:1396	arg1	chains					1398:1403	long matriglycan chains	1381:1403	long matriglycan chains	1381:1403	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	0	26	theme	Structural	0:9	arg1	basis					11:15	Structural basis	0:15	Structural basis for matriglycan synthesis by the LARGE1 dual glycosyltransferase	0:80	Structural basis for matriglycan synthesis by the LARGE1 dual glycosyltransferase.
36512577	7	27	contain	has	936:938	arg1	enzyme					929:934	this enzyme	924:934	this enzyme	924:934	The structure shows that this enzyme has two canonical GT-A folds within each of its catalytic domains.
36512577	7	27	contain	has	936:938	arg2	GT-A					954:957	two canonical GT-A folds	940:963	two canonical GT-A folds	940:963	The structure shows that this enzyme has two canonical GT-A folds within each of its catalytic domains.
36512577	7	28	theme	canonical	944:952	arg1	GT-A					954:957	two canonical GT-A folds	940:963	two canonical GT-A folds	940:963	The structure shows that this enzyme has two canonical GT-A folds within each of its catalytic domains.
36512577	10	29	theme	disease-causing	1473:1487	arg1	mutations					1489:1497	disease-causing mutations	1473:1497	disease-causing mutations	1473:1497	The structural information further reveals the mechanisms in which disease-causing mutations disrupt the activity of LARGE1.
36512577	0	30	theme	matriglycan	21:31	arg1	synthesis					33:41	matriglycan synthesis	21:41	matriglycan synthesis by the LARGE1 dual glycosyltransferase	21:80	Structural basis for matriglycan synthesis by the LARGE1 dual glycosyltransferase.
36512577	8	31	theme	dimeric	1025:1031	arg1	structure					1033:1041	its dimeric structure	1021:1041	its dimeric structure	1021:1041	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	9	32	theme	putative	1222:1229	arg1	retention					1231:1239	putative retention	1222:1239	putative retention of matriglycan by electrostatic interactions	1222:1284	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	1	33	theme	bifunctional	95:106	arg1	LARGE1					83:88	LARGE1	83:88	LARGE1	83:88	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	1	33	theme	bifunctional	95:106	arg1	glycosyltransferase					108:126	a bifunctional glycosyltransferase	93:126	a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function	93:301	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	9	34	theme	LARGE1	1360:1365	arg1	ability					1349:1355	the ability	1345:1355	the ability of LARGE1 to synthesize long matriglycan chains	1345:1403	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	8	35	theme	close	1096:1100	arg1	proximity					1102:1110	close proximity	1096:1110	close proximity from opposing monomers	1096:1133	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	4	36	theme	muscle	572:577	arg1	maintenance					579:589	muscle maintenance	572:589	muscle maintenance	572:589	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	4	37	theme	LARGE1	613:618	arg1	enzyme					620:625	the LARGE1 enzyme	609:625	the LARGE1 enzyme and how it assembles in the Golgi	609:659	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	4	38	dep	enzyme	620:625	arg1	assembles					638:646	assembles	638:646	assembles in the Golgi	638:659	Despite its major role in muscle maintenance, the structure of the LARGE1 enzyme and how it assembles in the Golgi are unknown.
36512577	11	39	theme	glycosyltransferase	1642:1660	arg1	oligomerization					1662:1676	glycosyltransferase oligomerization	1642:1676	glycosyltransferase oligomerization	1642:1676	Collectively, these data shed light on how matriglycan is synthesized alongside the functional significance of glycosyltransferase oligomerization.
36512577	1	40	theme	extracellular	239:251	arg1	matrix					253:258	the extracellular matrix	235:258	the extracellular matrix	235:258	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	3	41	theme	LARGE1	422:427	arg1	gene					429:432	the LARGE1 gene	418:432	the LARGE1 gene	418:432	Mutations in the LARGE1 gene have been shown to cause life-threatening dystroglycanopathies through the inhibition of matriglycan synthesis.
36512577	9	42	theme	long	1381:1384	arg1	chains					1398:1403	long matriglycan chains	1381:1403	long matriglycan chains	1381:1403	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	0	43	theme	dual	57:60	arg1	glycosyltransferase					62:80	the LARGE1 dual glycosyltransferase	46:80	the LARGE1 dual glycosyltransferase	46:80	Structural basis for matriglycan synthesis by the LARGE1 dual glycosyltransferase.
36512577	9	44	theme	matriglycan	1244:1254	arg1	retention					1231:1239	putative retention	1222:1239	putative retention of matriglycan by electrostatic interactions	1222:1284	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	11	45	theme	oligomerization	1662:1676	arg1	significance					1626:1637	the functional significance	1611:1637	the functional significance of glycosyltransferase oligomerization	1611:1676	Collectively, these data shed light on how matriglycan is synthesized alongside the functional significance of glycosyltransferase oligomerization.
36512577	2	46	theme	xylose	368:373	arg1	acid					390:393	glucuronic acid	379:393	glucuronic acid	379:393	This matriglycan polymer is made with an alternating pattern of xylose and glucuronic acid monomers.
36512577	2	46	theme	xylose	368:373	arg1	pattern					357:363	an alternating pattern	342:363	an alternating pattern of xylose	342:373	This matriglycan polymer is made with an alternating pattern of xylose and glucuronic acid monomers.
36512577	10	47	theme	LARGE1	1523:1528	arg1	activity					1511:1518	the activity	1507:1518	the activity of LARGE1	1507:1528	The structural information further reveals the mechanisms in which disease-causing mutations disrupt the activity of LARGE1.
36512577	1	48	theme	responsible	128:138	arg1	LARGE1					83:88	LARGE1	83:88	LARGE1	83:88	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	1	48	theme	responsible	128:138	arg1	glycosyltransferase					108:126	a bifunctional glycosyltransferase	93:126	a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function	93:301	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	9	49	theme	electrostatic	1259:1271	arg1	interactions					1273:1284	electrostatic interactions	1259:1284	electrostatic interactions	1259:1284	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	6	50	theme	stem	886:889	arg1	domain					891:896	its coiled-coil stem domain	870:896	its coiled-coil stem domain	870:896	We found that LARGE1 homo-dimerizes in a configuration that is dictated by its coiled-coil stem domain.
36512577	5	51	theme	LARGE1	707:712	arg1	structure					694:702	the structure	690:702	the structure	690:702	Here we present the structure of LARGE1, obtained by a combination of X-ray crystallography and single-particle cryo-EM.
36512577	5	52	theme	cryo-EM	786:792	arg1	combination					729:739	a combination	727:739	a combination of X-ray crystallography and single-particle cryo-EM	727:792	Here we present the structure of LARGE1, obtained by a combination of X-ray crystallography and single-particle cryo-EM.
36512577	8	53	theme	opposing	1117:1124	arg1	monomers					1126:1133	opposing monomers	1117:1133	opposing monomers	1117:1133	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	2	54	theme	alternating	345:355	arg1	pattern					357:363	an alternating pattern	342:363	an alternating pattern of xylose	342:373	This matriglycan polymer is made with an alternating pattern of xylose and glucuronic acid monomers.
36512577	5	55	theme	single-particle	770:784	arg1	cryo-EM					786:792	single-particle cryo-EM	770:792	single-particle cryo-EM	770:792	Here we present the structure of LARGE1, obtained by a combination of X-ray crystallography and single-particle cryo-EM.
36512577	8	56	theme	catalytic	1061:1069	arg1	domains					1071:1077	catalytic domains	1061:1077	catalytic domains	1061:1077	In the context of its dimeric structure, the two types of catalytic domains are brought into close proximity from opposing monomers to allow efficient shuttling of the substrates between the two domains.
36512577	1	57	theme	long	157:160	arg1	polysaccharide					169:182	a long linear polysaccharide	155:182	a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function	155:301	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36512577	0	58	theme	LARGE1	50:55	arg1	glycosyltransferase					62:80	the LARGE1 dual glycosyltransferase	46:80	the LARGE1 dual glycosyltransferase	46:80	Structural basis for matriglycan synthesis by the LARGE1 dual glycosyltransferase.
36512577	9	59	theme	dimeric	1292:1298	arg1	organization					1300:1311	this dimeric organization	1287:1311	this dimeric organization	1287:1311	Together, with putative retention of matriglycan by electrostatic interactions, this dimeric organization offers a possible mechanism for the ability of LARGE1 to synthesize long matriglycan chains.
36512577	1	60	theme	linear	162:167	arg1	polysaccharide					169:182	a long linear polysaccharide	155:182	a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function	155:301	LARGE1 is a bifunctional glycosyltransferase responsible for generating a long linear polysaccharide termed matriglycan that links the cytoskeleton and the extracellular matrix and is required for proper muscle function.
36949937	11	0	theme	broad	2191:2195	arg1	repertoire					2197:2206	a broad repertoire	2189:2206	a broad repertoire of Brugia malayi	2189:2223	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	11	0	theme	broad	2191:2195	arg1	malayi					2218:2223	Brugia malayi	2211:2223	Brugia malayi	2211:2223	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	4	1	link	derived	802:808	arg1	glycans					810:816	the N-linked and glycosphingolipid derived glycans	767:816	the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi	767:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	8	2	theme	Mansonella	1716:1725	arg1	perstans					1727:1734	Mansonella perstans	1716:1734	Mansonella perstans	1716:1734	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	3	3	theme	infection	730:738	arg1	clearance					713:721	clearance	713:721	clearance of the infection	713:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	3	3	theme	infection	730:738	arg1	treatment					699:707	treatment	699:707	treatment	699:707	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	5	4	theme	filarial	1286:1293	arg1	nematodes					1295:1303	four closely related filarial nematodes	1265:1303	four closely related filarial nematodes	1265:1303	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	4	theme	filarial	1286:1293	arg1	loa					1193:1195	Loa loa	1189:1195	Loa loa	1189:1195	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	7	5	theme	total	1570:1574	arg1	responses					1580:1588	total IgG responses	1570:1588	total IgG responses similar to the ones of Brugia malayi infected individuals	1570:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	3	6	from	years	687:691	arg1	presence					647:654	the presence	643:654	the presence of residual antibodies in sera years after treatment and clearance of the infection	643:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	11	7	theme	malayi	2218:2223	arg1	repertoire					2197:2206	a broad repertoire	2189:2206	a broad repertoire of Brugia malayi	2189:2223	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	11	7	theme	malayi	2218:2223	arg1	malayi					2218:2223	Brugia malayi	2211:2223	Brugia malayi	2211:2223	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	7	8	theme	many	1512:1515	arg1	glycans					1522:1528	many more glycans	1512:1528	many more glycans	1512:1528	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	6	9	theme	cross-reactive	1336:1349	arg1	glycans					1351:1357	cross-reactive glycans	1336:1357	cross-reactive glycans	1336:1357	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	3	10	theme	antibodies	584:593	arg1	occurrence					570:579	the occurrence	566:579	the occurrence of antibodies cross-reactive between nematodes	566:626	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	4	11	theme	immunoglobulin	931:944	arg1	IgG					949:951	IgG	949:951	IgG	949:951	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	4	11	theme	immunoglobulin	931:944	arg1	G					946:946	immunoglobulin G	931:946	immunoglobulin G (IgG) responses in infected individuals	931:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	10	12	theme	parasite	2037:2044	arg1	glycans					2046:2052	parasite glycans	2037:2052	parasite glycans post-treatment with anthelminthic	2037:2086	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	11	13	dep	repertoire	2197:2206	arg1	glycans					2225:2231	glycans	2225:2231	glycans	2225:2231	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	10	14	from	reduction	2002:2010	arg1	IgG2					2029:2032	IgG2	2029:2032	IgG2	2029:2032	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	10	14	from	reduction	2002:2010	arg1	particular					2015:2024	particular	2015:2024	particular	2015:2024	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	12	15	theme	host	2441:2444	arg1	response					2467:2474	host anti-glycan antibody response	2441:2474	host anti-glycan antibody response	2441:2474	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	16	theme	infected	1475:1482	arg1	individuals					1484:1494	Mansonella perstans infected individuals	1455:1494	Mansonella perstans infected individuals	1455:1494	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	13	17	theme	disease	2628:2634	arg1	control					2636:2642	filarial disease control	2619:2642	filarial disease control	2619:2642	We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control.
36949937	2	18	theme	certain	264:270	arg1	areas					272:276	certain areas	264:276	certain areas	264:276	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	11	19	theme	IgG	2173:2175	arg1	response					2177:2184	the IgG response	2169:2184	the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes	2169:2287	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	12	20	theme	antibody	2458:2465	arg1	response					2467:2474	host anti-glycan antibody response	2441:2474	host anti-glycan antibody response	2441:2474	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	21	theme	Mansonella	1455:1464	arg1	individuals					1484:1494	Mansonella perstans infected individuals	1455:1494	Mansonella perstans infected individuals	1455:1494	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	10	22	theme	post-treatment	2054:2067	arg1	glycans					2046:2052	parasite glycans	2037:2052	parasite glycans post-treatment with anthelminthic	2037:2086	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	2	23	theme	infection	251:259	arg1	rate					243:246	the rate	239:246	the rate of infection	239:259	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	12	24	theme	filarial	2405:2412	arg1	glycosylation					2423:2435	filarial nematode glycosylation	2405:2435	filarial nematode glycosylation	2405:2435	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	10	25	with	post-treatment	2054:2067	arg1	anthelminthic					2074:2086	anthelminthic	2074:2086	anthelminthic	2074:2086	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	10	26	theme	promising	2102:2110	arg1	potential					2112:2120	a promising potential	2100:2120	a promising potential for diagnostic applications	2100:2148	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	13	27	theme	integrated	2595:2604	arg1	approach					2606:2613	an integrated approach	2592:2613	an integrated approach for filarial disease control	2592:2642	We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control.
36949937	3	28	theme	cross-reactive	595:608	arg1	antibodies					584:593	antibodies	584:593	antibodies cross-reactive between nematodes	584:626	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	1	29	theme	chronic	150:156	arg1	disablement					158:168	chronic disablement	150:168	chronic disablement in humans	150:178	Parasitic nematodes responsible for filarial diseases cause chronic disablement in humans worldwide.
36949937	12	30	theme	glycosylation	2423:2435	arg1	knowledge					2392:2400	the currently scarce knowledge	2371:2400	the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response	2371:2474	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	0	31	theme	nematode	69:76	arg1	infections					78:87	filarial nematode infections	60:87	filarial nematode infections	60:87	Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
36949937	3	32	theme	residual	659:666	arg1	antibodies					668:677	residual antibodies	659:677	residual antibodies in sera years after treatment and clearance of the infection	659:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	4	33	theme	parasitic	825:833	arg1	malayi					851:856	the parasitic nematode Brugia malayi	821:856	the parasitic nematode Brugia malayi	821:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	1	34	theme	filarial	126:133	arg1	diseases					135:142	filarial diseases	126:142	filarial diseases	126:142	Parasitic nematodes responsible for filarial diseases cause chronic disablement in humans worldwide.
36949937	5	35	from	individuals	1163:1173	arg1	plasma					1119:1124	plasma	1119:1124	plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes	1119:1303	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	13	36	theme	disease-specific	2552:2567	arg1	diagnostics					2569:2579	disease-specific diagnostics	2552:2579	disease-specific diagnostics	2552:2579	We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control.
36949937	4	37	theme	Brugia	844:849	arg1	malayi					851:856	the parasitic nematode Brugia malayi	821:856	the parasitic nematode Brugia malayi	821:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	3	38	theme	parasite	481:488	arg1	antigens					490:497	parasite antigens	481:497	parasite antigens	481:497	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	5	39	theme	Loa	1189:1191	arg1	nematodes					1295:1303	four closely related filarial nematodes	1265:1303	four closely related filarial nematodes	1265:1303	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	39	theme	Loa	1189:1191	arg1	loa					1193:1195	Loa loa	1189:1195	Loa loa	1189:1195	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	39	theme	Loa	1189:1191	arg1	volvulus					1209:1216	Onchocerca volvulus	1198:1216	Onchocerca volvulus	1198:1216	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	1	40	theme	Parasitic	90:98	arg1	nematodes					100:108	Parasitic nematodes	90:108	Parasitic nematodes responsible for filarial diseases	90:142	Parasitic nematodes responsible for filarial diseases cause chronic disablement in humans worldwide.
36949937	7	41	from	volvulus	1442:1449	arg1	plasma					1419:1424	plasma	1419:1424	plasma from Onchocerca volvulus and Mansonella perstans infected individuals	1419:1494	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	9	42	theme	major	1869:1873	arg1	IgG2					1845:1848	IgG2	1845:1848	IgG2	1845:1848	In all three infections, IgG1 and IgG2 appeared to be the major subclasses involved in response to glycan antigens.
36949937	9	42	theme	major	1869:1873	arg1	subclasses					1875:1884	the major subclasses	1865:1884	the major subclasses involved in response to glycan antigens	1865:1924	In all three infections, IgG1 and IgG2 appeared to be the major subclasses involved in response to glycan antigens.
36949937	9	42	theme	major	1869:1873	arg1	IgG1					1836:1839	IgG1	1836:1839	IgG1	1836:1839	In all three infections, IgG1 and IgG2 appeared to be the major subclasses involved in response to glycan antigens.
36949937	4	43	theme	derived	802:808	arg1	glycans					810:816	the N-linked and glycosphingolipid derived glycans	767:816	the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi	767:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	2	44	theme	elimination	412:422	arg1	targets					424:430	the elimination targets	408:430	the elimination targets	408:430	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	4	45	from	responses	954:962	arg1	individuals					976:986	infected individuals	967:986	infected individuals	967:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	1	46	theme	responsible	110:120	arg1	nematodes					100:108	Parasitic nematodes	90:108	Parasitic nematodes responsible for filarial diseases	90:142	Parasitic nematodes responsible for filarial diseases cause chronic disablement in humans worldwide.
36949937	12	47	theme	cross-reactive	2312:2325	arg1	targets					2352:2358	broadly cross-reactive and more specific glycan targets	2304:2358	broadly cross-reactive and more specific glycan targets	2304:2358	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	48	theme	malayi	1620:1625	arg1	individuals					1636:1646	Brugia malayi infected individuals	1613:1646	Brugia malayi infected individuals	1613:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	5	49	theme	binding	1023:1029	arg1	specificity					1004:1014	the specificity	1000:1014	the specificity of IgG binding to these glycan antigens	1000:1054	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	3	50	from	presence	647:654	arg1	years					687:691	sera years	682:691	sera years after treatment and clearance of the infection	682:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	0	51	theme	IgG	43:45	arg1	responses					47:55	anti-glycan IgG responses	31:55	anti-glycan IgG responses	31:55	Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
36949937	5	52	theme	Brugia	1092:1097	arg1	malayi					1099:1104	Brugia malayi	1092:1104	Brugia malayi glycans	1092:1112	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	9	53	theme	glycan	1910:1915	arg1	antigens					1917:1924	glycan antigens	1910:1924	glycan antigens	1910:1924	In all three infections, IgG1 and IgG2 appeared to be the major subclasses involved in response to glycan antigens.
36949937	8	54	theme	infection	1659:1667	arg1	groups					1669:1674	these infection groups	1653:1674	these infection groups	1653:1674	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	2	55	theme	Elimination	191:201	arg1	programs					203:210	Elimination programs	191:210	Elimination programs	191:210	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	4	56	theme	antigenic	895:903	arg1	structures					905:914	various antigenic structures	887:914	various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals	887:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	10	57	theme	infected	1959:1966	arg1	individuals					1968:1978	Brugia malayi infected individuals	1945:1978	Brugia malayi infected individuals	1945:1978	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	13	58	theme	initial	2497:2503	arg1	findings					2505:2512	our initial findings	2493:2512	our initial findings	2493:2512	We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control.
36949937	2	59	theme	current	298:304	arg1	diagnostics					306:316	current diagnostics	298:316	current diagnostics	298:316	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	7	60	theme	similar	1590:1596	arg1	responses					1580:1588	total IgG responses	1570:1588	total IgG responses similar to the ones of Brugia malayi infected individuals	1570:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	10	61	theme	Brugia	1945:1950	arg1	malayi					1952:1957	Brugia malayi	1945:1957	Brugia malayi infected individuals	1945:1978	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	11	62	theme	various	2262:2268	arg1	nematodes					2279:2287	various filarial nematodes	2262:2287	various filarial nematodes	2262:2287	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	7	63	theme	IgG	1576:1578	arg1	responses					1580:1588	total IgG responses	1570:1588	total IgG responses similar to the ones of Brugia malayi infected individuals	1570:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	6	64	located	observed	1363:1370	arg1	plasmas					1385:1391	infection plasmas	1375:1391	infection plasmas from all four species	1375:1413	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	6	64	located	observed	1363:1370	arg2	IgG					1306:1308	IgG	1306:1308	IgG to a restricted subset of cross-reactive glycans	1306:1357	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	8	65	theme	Onchocerca	1692:1701	arg1	volvulus					1703:1710	Onchocerca volvulus	1692:1710	Onchocerca volvulus	1692:1710	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	6	66	theme	infection	1375:1383	arg1	plasmas					1385:1391	infection plasmas	1375:1391	infection plasmas from all four species	1375:1413	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	8	67	theme	different	1760:1768	arg1	subclasses					1774:1783	the different IgG subclasses	1756:1783	the different IgG subclasses to Brugia malayi glycans	1756:1808	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	5	68	theme	related	1278:1284	arg1	nematodes					1295:1303	four closely related filarial nematodes	1265:1303	four closely related filarial nematodes	1265:1303	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	68	theme	related	1278:1284	arg1	loa					1193:1195	Loa loa	1189:1195	Loa loa	1189:1195	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	4	69	theme	G	946:946	arg1	responses					954:962	immunoglobulin G (IgG) responses	931:962	immunoglobulin G (IgG) responses in infected individuals	931:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	2	70	theme	population	322:331	arg1	surveillance					333:344	population surveillance	322:344	population surveillance	322:344	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	4	71	link	N-linked	771:778	arg1	glycans					810:816	the N-linked and glycosphingolipid derived glycans	767:816	the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi	767:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	6	72	theme	glycans	1351:1357	arg1	subset					1326:1331	a restricted subset	1313:1331	a restricted subset of cross-reactive glycans	1313:1357	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	2	73	theme	diagnostics	306:316	arg1	limitations					283:293	limitations	283:293	limitations of current diagnostics for population surveillance	283:344	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	8	74	theme	Brugia	1788:1793	arg1	malayi					1795:1800	Brugia malayi	1788:1800	Brugia malayi	1788:1800	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	11	75	theme	filarial	2270:2277	arg1	nematodes					2279:2287	various filarial nematodes	2262:2287	various filarial nematodes	2262:2287	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	4	76	theme	structures	905:914	arg1	presence					875:882	the presence	871:882	the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals	871:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	10	77	theme	marked	1995:2000	arg1	reduction					2002:2010	a marked reduction	1993:2010	a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic	1993:2086	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	11	78	theme	Brugia	2211:2216	arg1	malayi					2218:2223	Brugia malayi	2211:2223	Brugia malayi	2211:2223	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	13	79	theme	approach	2606:2613	arg1	part					2584:2587	part	2584:2587	part of an integrated approach for filarial disease control	2584:2642	We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control.
36949937	12	80	theme	anti-glycan	2446:2456	arg1	response					2467:2474	host anti-glycan antibody response	2441:2474	host anti-glycan antibody response	2441:2474	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	81	theme	IgG	1497:1499	arg1	binding					1501:1507	IgG binding	1497:1507	IgG binding to many more glycans	1497:1528	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	13	82	theme	filarial	2619:2626	arg1	control					2636:2642	filarial disease control	2619:2642	filarial disease control	2619:2642	We believe that our initial findings could be further exploited to develop disease-specific diagnostics as part of an integrated approach for filarial disease control.
36949937	12	83	theme	response	2467:2474	arg1	knowledge					2392:2400	the currently scarce knowledge	2371:2400	the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response	2371:2474	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	84	dep	many	1512:1515	arg1	more					1517:1520	more	1517:1520	more	1517:1520	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	12	85	theme	nematode	2414:2421	arg1	glycosylation					2423:2435	filarial nematode glycosylation	2405:2435	filarial nematode glycosylation	2405:2435	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	86	theme	perstans	1466:1473	arg1	individuals					1484:1494	Mansonella perstans infected individuals	1455:1494	Mansonella perstans infected individuals	1455:1494	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	3	87	theme	antibodies	668:677	arg1	presence					647:654	the presence	643:654	the presence of residual antibodies in sera years after treatment and clearance of the infection	643:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	7	88	located	detected	1547:1554	arg2	binding					1501:1507	IgG binding	1497:1507	IgG binding to many more glycans	1497:1528	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	7	88	located	detected	1547:1554	arg1	plasma					1419:1424	plasma	1419:1424	plasma from Onchocerca volvulus and Mansonella perstans infected individuals	1419:1494	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	4	89	theme	infected	967:974	arg1	individuals					976:986	infected individuals	967:986	infected individuals	967:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	4	90	theme	N-linked	771:778	arg1	glycans					810:816	the N-linked and glycosphingolipid derived glycans	767:816	the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi	767:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	5	91	theme	uninfected	1131:1140	arg1	individuals					1142:1152	uninfected individuals	1131:1152	uninfected individuals	1131:1152	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	12	92	theme	scarce	2385:2390	arg1	knowledge					2392:2400	the currently scarce knowledge	2371:2400	the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response	2371:2474	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	7	93	theme	Onchocerca	1431:1440	arg1	volvulus					1442:1449	Onchocerca volvulus	1431:1449	Onchocerca volvulus	1431:1449	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	11	94	from	response	2177:2184	arg1	individuals					2236:2246	individuals	2236:2246	individuals infected with various filarial nematodes	2236:2287	Thus, we compared the IgG response to a broad repertoire of Brugia malayi glycans in individuals infected with various filarial nematodes.
36949937	5	95	theme	Onchocerca	1198:1207	arg1	loa					1193:1195	Loa loa	1189:1195	Loa loa	1189:1195	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	95	theme	Onchocerca	1198:1207	arg1	volvulus					1209:1216	Onchocerca volvulus	1198:1216	Onchocerca volvulus	1198:1216	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	0	96	from	cross-reactivity	11:26	arg1	infections					78:87	filarial nematode infections	60:87	filarial nematode infections	60:87	Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
36949937	10	97	theme	diagnostic	2126:2135	arg1	applications					2137:2148	diagnostic applications	2126:2148	diagnostic applications	2126:2148	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	7	98	theme	individuals	1636:1646	arg1	ones					1605:1608	the ones	1601:1608	the ones of Brugia malayi infected individuals	1601:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	5	99	from	individuals	1142:1152	arg1	plasma					1119:1124	plasma	1119:1124	plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes	1119:1303	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	100	theme	glycan	1040:1045	arg1	antigens					1047:1054	these glycan antigens	1034:1054	these glycan antigens	1034:1054	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	4	101	theme	nematode	835:842	arg1	malayi					851:856	the parasitic nematode Brugia malayi	821:856	the parasitic nematode Brugia malayi	821:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	3	102	from	antibodies	668:677	arg1	years					687:691	sera years	682:691	sera years after treatment and clearance of the infection	682:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	1	103	from	disablement	158:168	arg1	humans					173:178	humans	173:178	humans	173:178	Parasitic nematodes responsible for filarial diseases cause chronic disablement in humans worldwide.
36949937	4	104	dep	derived	802:808	arg1	glycosphingolipid					784:800	glycosphingolipid	784:800	glycosphingolipid	784:800	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	8	105	dep	malayi	1795:1800	arg1	glycans					1802:1808	glycans	1802:1808	glycans	1802:1808	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	0	106	theme	anti-glycan	31:41	arg1	responses					47:55	anti-glycan IgG responses	31:55	anti-glycan IgG responses	31:55	Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
36949937	6	107	from	species	1407:1413	arg1	plasmas					1385:1391	infection plasmas	1375:1391	infection plasmas from all four species	1375:1413	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	5	108	theme	IgG	1019:1021	arg1	binding					1023:1029	IgG binding	1019:1029	IgG binding	1019:1029	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	6	109	theme	restricted	1315:1324	arg1	subset					1326:1331	a restricted subset	1313:1331	a restricted subset of cross-reactive glycans	1313:1357	IgG to a restricted subset of cross-reactive glycans was observed in infection plasmas from all four species.
36949937	12	110	theme	glycan	2345:2350	arg1	targets					2352:2358	broadly cross-reactive and more specific glycan targets	2304:2358	broadly cross-reactive and more specific glycan targets	2304:2358	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	0	111	theme	responses	47:55	arg1	cross-reactivity					11:26	cross-reactivity	11:26	cross-reactivity of anti-glycan IgG responses in filarial nematode infections	11:87	Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
36949937	7	112	theme	infected	1627:1634	arg1	individuals					1636:1646	Brugia malayi infected individuals	1613:1646	Brugia malayi infected individuals	1613:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	7	113	from	individuals	1484:1494	arg1	plasma					1419:1424	plasma	1419:1424	plasma from Onchocerca volvulus and Mansonella perstans infected individuals	1419:1494	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	3	114	theme	sera	682:685	arg1	years					687:691	sera years	682:691	sera years after treatment and clearance of the infection	682:738	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	3	115	theme	convenient	503:512	arg1	tests					451:455	serological tests	439:455	serological tests detecting antibodies to parasite antigens	439:497	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	3	115	theme	convenient	503:512	arg1	tools					514:518	convenient tools	503:518	convenient tools	503:518	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	0	116	theme	filarial	60:67	arg1	infections					78:87	filarial nematode infections	60:87	filarial nematode infections	60:87	Unraveling cross-reactivity of anti-glycan IgG responses in filarial nematode infections.
36949937	7	117	theme	Brugia	1613:1618	arg1	malayi					1620:1625	Brugia malayi	1613:1625	Brugia malayi infected individuals	1613:1646	In plasma from Onchocerca volvulus and Mansonella perstans infected individuals, IgG binding to many more glycans was additionally detected, resulting in total IgG responses similar to the ones of Brugia malayi infected individuals.
36949937	5	118	theme	malayi	1099:1104	arg1	glycans					1106:1112	Brugia malayi glycans	1092:1112	Brugia malayi glycans	1092:1112	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	3	119	theme	serological	439:449	arg1	tools					514:518	convenient tools	503:518	convenient tools	503:518	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	3	119	theme	serological	439:449	arg1	tests					451:455	serological tests	439:455	serological tests detecting antibodies to parasite antigens	439:497	While serological tests detecting antibodies to parasite antigens are convenient tools, those currently available are compromised by the occurrence of antibodies cross-reactive between nematodes, as well as by the presence of residual antibodies in sera years after treatment and clearance of the infection.
36949937	8	120	theme	Brugia	1677:1682	arg1	malayi					1684:1689	Brugia malayi	1677:1689	Brugia malayi	1677:1689	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
36949937	4	121	theme	various	887:893	arg1	structures					905:914	various antigenic structures	887:914	various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals	887:986	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	2	122	theme	improved	372:379	arg1	assays					381:386	improved assays	372:386	improved assays	372:386	Elimination programs have substantially reduced the rate of infection in certain areas, but limitations of current diagnostics for population surveillance have been pointed out and improved assays are needed to reach the elimination targets.
36949937	12	123	theme	specific	2336:2343	arg1	targets					2352:2358	broadly cross-reactive and more specific glycan targets	2304:2358	broadly cross-reactive and more specific glycan targets	2304:2358	We identified broadly cross-reactive and more specific glycan targets, extending the currently scarce knowledge of filarial nematode glycosylation and host anti-glycan antibody response.
36949937	10	124	theme	malayi	1952:1957	arg1	individuals					1968:1978	Brugia malayi infected individuals	1945:1978	Brugia malayi infected individuals	1945:1978	Interestingly, in Brugia malayi infected individuals, we observed a marked reduction in particular in IgG2 to parasite glycans post-treatment with anthelminthic, suggesting a promising potential for diagnostic applications.
36949937	4	125	theme	malayi	851:856	arg1	glycans					810:816	the N-linked and glycosphingolipid derived glycans	767:816	the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi	767:856	We recently characterized the N-linked and glycosphingolipid derived glycans of the parasitic nematode Brugia malayi and revealed the presence of various antigenic structures that triggered immunoglobulin G (IgG) responses in infected individuals.
36949937	5	126	contain	containing	1081:1090	arg2	glycans					1106:1112	Brugia malayi glycans	1092:1112	Brugia malayi glycans	1092:1112	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	5	126	contain	containing	1081:1090	arg1	microarrays					1069:1079	microarrays	1069:1079	microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes	1069:1303	To address the specificity of IgG binding to these glycan antigens, we screened microarrays containing Brugia malayi glycans with plasma from uninfected individuals and from individuals infected with Loa loa, Onchocerca volvulus, Mansonella perstans and Wuchereria bancrofti, four closely related filarial nematodes.
36949937	8	127	theme	IgG	1770:1772	arg1	subclasses					1774:1783	the different IgG subclasses	1756:1783	the different IgG subclasses to Brugia malayi glycans	1756:1808	For these infection groups, Brugia malayi, Onchocerca volvulus and Mansonella perstans, we further studied the different IgG subclasses to Brugia malayi glycans.
35670884	6	0	theme	SPARC-induced	947:959	arg1	changes					984:990	SPARC-induced dynamic conformational changes	947:990	SPARC-induced dynamic conformational changes in its N-glycan	947:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	7	1	theme	residues	1179:1186	arg1	mutagenesis					1158:1168	Site-specific mutagenesis	1144:1168	Site-specific mutagenesis of these residues	1144:1186	Site-specific mutagenesis of these residues also resulted in low affinity for collagen binding.
35670884	9	2	theme	cell-matrix	1432:1442	arg1	communication					1444:1456	cell-matrix communication	1432:1456	cell-matrix communication	1432:1456	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	1	3	theme	progressive	135:145	arg1	disease					152:158	a progressive lung disease	133:158	a progressive lung disease with high morbidity and mortality worldwide	133:202	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	3	theme	progressive	135:145	arg1	disease					115:121	Chronic obstructive pulmonary disease	85:121	Chronic obstructive pulmonary disease (COPD)	85:128	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	4	4	gly	glycopeptide	779:790	arg2	glycopeptide					779:790	its VCSNDNcfK glycopeptide	765:790	its VCSNDNcfK glycopeptide	765:790	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	1	5	theme	lung	147:150	arg1	disease					152:158	a progressive lung disease	133:158	a progressive lung disease with high morbidity and mortality worldwide	133:202	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	5	theme	lung	147:150	arg1	disease					115:121	Chronic obstructive pulmonary disease	85:121	Chronic obstructive pulmonary disease (COPD)	85:128	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	3	6	from	changes	541:547	arg1	organoids					557:565	lung organoids	552:565	lung organoids	552:565	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	0	7	gly	core-fucosylation	8:24	arg1	SPARC					29:33	SPARC	29:33	SPARC	29:33	Loss of core-fucosylation of SPARC impairs collagen binding and contributes to COPD.
35670884	2	8	theme	molecular	290:298	arg1	description					300:310	molecular description	290:310	molecular description for the underlying alveolar structural alterations for COPD	290:370	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	4	9	theme	mass	603:606	arg1	analysis					621:628	Site-specific mass spectrometry analysis	589:628	Site-specific mass spectrometry analysis	589:628	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	6	10	theme	core	926:929	arg1	fucosylation					931:942	core fucosylation	926:942	core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan	926:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	8	11	located	observed	1305:1312	arg2	decline					1271:1277	decline	1271:1277	decline of core fucosylation	1271:1298	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	8	11	located	observed	1305:1312	arg2	loss					1250:1253	loss	1250:1253	loss of collagen	1250:1265	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	8	11	located	observed	1305:1312	arg1	tissues					1327:1333	COPD lung tissues	1317:1333	COPD lung tissues	1317:1333	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	6	12	dep	P261	1084:1087	arg1	residues					1098:1105	residues	1098:1105	residues	1098:1105	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	4	13	from	cysteine	688:695	arg1	rich					680:683	rich	680:683	rich	680:683	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	14	theme	Site-specific	589:601	arg1	analysis					621:628	Site-specific mass spectrometry analysis	589:628	Site-specific mass spectrometry analysis	589:628	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	15	gly	core-fucosylation	739:755	arg2	site					757:760	a core-fucosylation site	737:760	a core-fucosylation site in its VCSNDNcfK glycopeptide	737:790	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	9	16	theme	new	1361:1363	arg1	insight					1377:1383	a new mechanistic insight	1359:1383	a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD	1359:1517	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	7	17	theme	Site-specific	1144:1156	arg1	mutagenesis					1158:1168	Site-specific mutagenesis	1144:1168	Site-specific mutagenesis of these residues	1144:1186	Site-specific mutagenesis of these residues also resulted in low affinity for collagen binding.
35670884	6	18	theme	collagen	1126:1133	arg1	binding					1135:1141	collagen binding	1126:1141	collagen binding	1126:1141	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	3	19	theme	alveolar	521:528	arg1	changes					541:547	alveolar structural changes	521:547	alveolar structural changes in lung organoids	521:565	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	4	20	theme	rich	680:683	arg1	protein					661:667	the secreted protein	648:667	the secreted protein acidic and rich in cysteine (SPARC)	648:703	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	20	theme	rich	680:683	arg1	SPARC					698:702	SPARC	698:702	SPARC	698:702	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	3	21	theme	α1,6-fucosyltransferase	403:425	arg1	silencing					390:398	silencing	390:398	silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells,	390:507	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	9	22	theme	mechanistic	1365:1375	arg1	insight					1377:1383	a new mechanistic insight	1359:1383	a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD	1359:1517	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	4	23	from	site	757:760	arg1	glycopeptide					779:790	its VCSNDNcfK glycopeptide	765:790	its VCSNDNcfK glycopeptide	765:790	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	3	24	theme	structural	530:539	arg1	changes					541:547	alveolar structural changes	521:547	alveolar structural changes in lung organoids	521:565	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	4	25	from	rich	680:683	arg1	cysteine					688:695	cysteine	688:695	cysteine	688:695	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	8	26	theme	core	1282:1285	arg1	fucosylation					1287:1298	core fucosylation	1282:1298	core fucosylation	1282:1298	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	9	27	gly	fucosylation	1407:1418	arg1	SPARC					1423:1427	SPARC	1423:1427	SPARC	1423:1427	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	9	28	from	role	1394:1397	arg1	communication					1444:1456	cell-matrix communication	1432:1456	cell-matrix communication	1432:1456	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	9	28	from	role	1394:1397	arg1	COPD					1514:1517	COPD	1514:1517	COPD	1514:1517	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	1	29	theme	high	165:168	arg1	morbidity					170:178	morbidity	170:178	morbidity	170:178	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	5	30	theme	reduced	823:829	arg1	binding					840:846	markedly reduced collagen binding	814:846	markedly reduced collagen binding of SPARC lacking core fucosylation	814:881	Biacore assay showed markedly reduced collagen binding of SPARC lacking core fucosylation.
35670884	6	31	theme	terminal	1018:1025	arg1	galactose					1027:1035	galactose	1027:1035	galactose	1027:1035	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	8	32	theme	fucosylation	1287:1298	arg1	loss					1250:1253	loss	1250:1253	loss of collagen	1250:1265	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	8	32	theme	fucosylation	1287:1298	arg1	decline					1271:1277	decline	1271:1277	decline of core fucosylation	1271:1298	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	1	33	theme	Chronic	85:91	arg1	COPD					124:127	COPD	124:127	COPD	124:127	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	33	theme	Chronic	85:91	arg1	disease					115:121	Chronic obstructive pulmonary disease	85:121	Chronic obstructive pulmonary disease (COPD)	85:128	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	33	theme	Chronic	85:91	arg1	disease					152:158	a progressive lung disease	133:158	a progressive lung disease with high morbidity and mortality worldwide	133:202	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	6	34	theme	Molecular	884:892	arg1	analysis					903:910	Molecular dynamics analysis	884:910	Molecular dynamics analysis	884:910	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	5	35	theme	collagen	831:838	arg1	binding					840:846	markedly reduced collagen binding	814:846	markedly reduced collagen binding of SPARC lacking core fucosylation	814:881	Biacore assay showed markedly reduced collagen binding of SPARC lacking core fucosylation.
35670884	9	36	theme	alveolar	1491:1498	arg1	structures					1500:1509	the abnormal alveolar structures	1478:1509	the abnormal alveolar structures	1478:1509	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	3	37	theme	lung	552:555	arg1	organoids					557:565	lung organoids	552:565	lung organoids	552:565	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	9	38	theme	SPARC	1423:1427	arg1	fucosylation					1407:1418	core fucosylation	1402:1418	core fucosylation of SPARC	1402:1427	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	4	39	theme	secreted	652:659	arg1	protein					661:667	the secreted protein	648:667	the secreted protein acidic and rich in cysteine (SPARC)	648:703	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	39	theme	secreted	652:659	arg1	SPARC					698:702	SPARC	698:702	SPARC	698:702	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	0	40	theme	core-fucosylation	8:24	arg1	Loss					0:3	Loss	0:3	Loss of core-fucosylation of SPARC	0:33	Loss of core-fucosylation of SPARC impairs collagen binding and contributes to COPD.
35670884	4	41	contain	contains	728:735	arg1	protein					661:667	the secreted protein	648:667	the secreted protein acidic and rich in cysteine (SPARC)	648:703	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	41	contain	contains	728:735	arg2	site					757:760	a core-fucosylation site	737:760	a core-fucosylation site in its VCSNDNcfK glycopeptide	737:790	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	41	contain	contains	728:735	arg1	SPARC					698:702	SPARC	698:702	SPARC	698:702	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	6	42	from	N-glycan	999:1006	arg1	fucosylation					931:942	core fucosylation	926:942	core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan	926:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	6	43	theme	dynamics	894:901	arg1	analysis					903:910	Molecular dynamics analysis	884:910	Molecular dynamics analysis	884:910	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	1	44	theme	pulmonary	105:113	arg1	COPD					124:127	COPD	124:127	COPD	124:127	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	44	theme	pulmonary	105:113	arg1	disease					115:121	Chronic obstructive pulmonary disease	85:121	Chronic obstructive pulmonary disease (COPD)	85:128	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	44	theme	pulmonary	105:113	arg1	disease					152:158	a progressive lung disease	133:158	a progressive lung disease with high morbidity and mortality worldwide	133:202	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	9	45	theme	abnormal	1482:1489	arg1	structures					1500:1509	the abnormal alveolar structures	1478:1509	the abnormal alveolar structures	1478:1509	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	5	46	theme	SPARC	851:855	arg1	binding					840:846	markedly reduced collagen binding	814:846	markedly reduced collagen binding of SPARC lacking core fucosylation	814:881	Biacore assay showed markedly reduced collagen binding of SPARC lacking core fucosylation.
35670884	7	47	theme	low	1205:1207	arg1	affinity					1209:1216	low affinity	1205:1216	low affinity for collagen binding	1205:1237	Site-specific mutagenesis of these residues also resulted in low affinity for collagen binding.
35670884	3	48	theme	stem	497:500	arg1	cells					502:506	lung stem cells	492:506	lung stem cells	492:506	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	9	49	from	contribution	1462:1473	arg1	communication					1444:1456	cell-matrix communication	1432:1456	cell-matrix communication	1432:1456	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	9	49	from	contribution	1462:1473	arg1	COPD					1514:1517	COPD	1514:1517	COPD	1514:1517	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	6	50	gly	fucosylation	931:942	arg1	changes					984:990	SPARC-induced dynamic conformational changes	947:990	SPARC-induced dynamic conformational changes in its N-glycan	947:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	4	51	theme	acidic	669:674	arg1	protein					661:667	the secreted protein	648:667	the secreted protein acidic and rich in cysteine (SPARC)	648:703	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	4	51	theme	acidic	669:674	arg1	SPARC					698:702	SPARC	698:702	SPARC	698:702	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	0	52	theme	SPARC	29:33	arg1	core-fucosylation					8:24	core-fucosylation	8:24	core-fucosylation of SPARC	8:33	Loss of core-fucosylation of SPARC impairs collagen binding and contributes to COPD.
35670884	9	53	theme	core	1402:1405	arg1	fucosylation					1407:1418	core fucosylation	1402:1418	core fucosylation of SPARC	1402:1427	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	5	54	theme	Biacore	793:799	arg1	assay					801:805	Biacore assay	793:805	Biacore assay	793:805	Biacore assay showed markedly reduced collagen binding of SPARC lacking core fucosylation.
35670884	1	55	dep	morbidity	170:178	arg1	worldwide					194:202	worldwide	194:202	worldwide	194:202	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	2	56	dep	mechanisms	222:231	arg1	account					236:242	account	236:242	to account for deleterious immune effects	233:273	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	9	57	theme	fucosylation	1407:1418	arg1	role					1394:1397	the role	1390:1397	the role of core fucosylation of SPARC in cell-matrix communication	1390:1456	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	9	57	theme	fucosylation	1407:1418	arg1	contribution					1462:1473	contribution	1462:1473	contribution to the abnormal alveolar structures in COPD	1462:1517	These findings provide a new mechanistic insight into the role of core fucosylation of SPARC in cell-matrix communication and contribution to the abnormal alveolar structures in COPD.
35670884	6	58	from	changes	984:990	arg1	N-glycan					999:1006	its N-glycan	995:1006	its N-glycan	995:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	2	59	theme	several	214:220	arg1	mechanisms					222:231	several mechanisms	214:231	several mechanisms to account for deleterious immune effects	214:273	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	3	60	theme	lung	492:495	arg1	cells					502:506	lung stem cells	492:506	lung stem cells	492:506	Here, silencing of α1,6-fucosyltransferase (Fut8), the enzyme for core-fucosylation and highly expressed in lung stem cells, resulted in alveolar structural changes in lung organoids, recapitulating COPD.
35670884	0	61	theme	collagen	43:50	arg1	binding					52:58	collagen binding	43:58	collagen binding	43:58	Loss of core-fucosylation of SPARC impairs collagen binding and contributes to COPD.
35670884	6	62	theme	changes	984:990	arg1	fucosylation					931:942	core fucosylation	926:942	core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan	926:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	8	63	theme	collagen	1258:1265	arg1	loss					1250:1253	loss	1250:1253	loss of collagen	1250:1265	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	8	63	theme	collagen	1258:1265	arg1	decline					1271:1277	decline	1271:1277	decline of core fucosylation	1271:1298	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	2	64	theme	structural	340:349	arg1	alterations					351:361	the underlying alveolar structural alterations	316:361	the underlying alveolar structural alterations for COPD	316:370	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	6	65	theme	conformational	969:982	arg1	changes					984:990	SPARC-induced dynamic conformational changes	947:990	SPARC-induced dynamic conformational changes in its N-glycan	947:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	1	66	with	disease	152:158	arg1	mortality					184:192	mortality	184:192	mortality	184:192	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	66	with	disease	152:158	arg1	morbidity					170:178	morbidity	170:178	morbidity	170:178	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	2	67	theme	immune	260:265	arg1	effects					267:273	deleterious immune effects	248:273	deleterious immune effects	248:273	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	2	68	theme	alveolar	331:338	arg1	alterations					351:361	the underlying alveolar structural alterations	316:361	the underlying alveolar structural alterations for COPD	316:370	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	1	69	theme	obstructive	93:103	arg1	COPD					124:127	COPD	124:127	COPD	124:127	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	69	theme	obstructive	93:103	arg1	disease					115:121	Chronic obstructive pulmonary disease	85:121	Chronic obstructive pulmonary disease (COPD)	85:128	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	1	69	theme	obstructive	93:103	arg1	disease					152:158	a progressive lung disease	133:158	a progressive lung disease with high morbidity and mortality worldwide	133:202	Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with high morbidity and mortality worldwide.
35670884	8	70	theme	lung	1322:1325	arg1	tissues					1327:1333	COPD lung tissues	1317:1333	COPD lung tissues	1317:1333	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	4	71	theme	VCSNDNcfK	769:777	arg1	glycopeptide					779:790	its VCSNDNcfK glycopeptide	765:790	its VCSNDNcfK glycopeptide	765:790	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	2	72	theme	deleterious	248:258	arg1	effects					267:273	deleterious immune effects	248:273	deleterious immune effects	248:273	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	4	73	theme	core-fucosylation	739:755	arg1	site					757:760	a core-fucosylation site	737:760	a core-fucosylation site in its VCSNDNcfK glycopeptide	737:790	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	2	74	theme	underlying	320:329	arg1	alterations					351:361	the underlying alveolar structural alterations	316:361	the underlying alveolar structural alterations for COPD	316:370	Although several mechanisms to account for deleterious immune effects were proposed, molecular description for the underlying alveolar structural alterations for COPD is lacking.
35670884	4	75	theme	spectrometry	608:619	arg1	analysis					621:628	Site-specific mass spectrometry analysis	589:628	Site-specific mass spectrometry analysis	589:628	Site-specific mass spectrometry analysis demonstrated that the secreted protein acidic and rich in cysteine (SPARC), which binds collagen, contains a core-fucosylation site in its VCSNDNcfK glycopeptide.
35670884	5	76	theme	core	865:868	arg1	fucosylation					870:881	core fucosylation	865:881	core fucosylation	865:881	Biacore assay showed markedly reduced collagen binding of SPARC lacking core fucosylation.
35670884	8	77	theme	COPD	1317:1320	arg1	tissues					1327:1333	COPD lung tissues	1317:1333	COPD lung tissues	1317:1333	Moreover, loss of collagen and decline of core fucosylation were observed in COPD lung tissues.
35670884	6	78	from	fucosylation	931:942	arg1	N-glycan					999:1006	its N-glycan	995:1006	its N-glycan	995:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	6	79	theme	dynamic	961:967	arg1	changes					984:990	SPARC-induced dynamic conformational changes	947:990	SPARC-induced dynamic conformational changes in its N-glycan	947:1006	Molecular dynamics analysis revealed that core fucosylation of SPARC-induced dynamic conformational changes in its N-glycan, allowing terminal galactose and N-acetylglucosamine to interact with K150, P261 and H264 residues, thereby promoting collagen binding.
35670884	7	80	theme	collagen	1222:1229	arg1	binding					1231:1237	collagen binding	1222:1237	collagen binding	1222:1237	Site-specific mutagenesis of these residues also resulted in low affinity for collagen binding.
34989310	5	0	dep	enzymes	889:895	arg1	[ERMan1					938:944	(1) Amb20622156 (demethylwedelolactone) [ERMan1	898:944	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	1	theme	maximum	1828:1834	arg1	dose					1846:1849	maximum tolerated dose <	1828:1851	maximum tolerated dose < 0.477	1828:1857	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	5	2	dep	-9.3 kcal/mol	1093:1105	arg1	-7.9 kcal/mol					1172:1184	-7.9 kcal/mol	1172:1184	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	2	dep	-9.3 kcal/mol	1093:1105	arg1	ST6Gal1					1137:1143	ST6Gal1	1137:1143	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	2	dep	-9.3 kcal/mol	1093:1105	arg1	-9.2 kcal/mol					1146:1158	-9.2 kcal/mol	1146:1158	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	2	dep	-9.3 kcal/mol	1093:1105	arg1	Alpha1-6FucT					1108:1119	Alpha1-6FucT	1108:1119	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	2	dep	-9.3 kcal/mol	1093:1105	arg1	-6.1 kcal/mol					1122:1134	-6.1 kcal/mol	1122:1134	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	2	dep	-9.3 kcal/mol	1093:1105	arg1	GlcNAcT-V					1161:1169	GlcNAcT-V	1161:1169	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	3	dep	[ERMan1	1084:1090	arg1	-9.3 kcal/mol					1093:1105	-9.3 kcal/mol	1093:1105	-9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol	1093:1184	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	4	theme	CNS	1806:1808	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	4	theme	CNS	1806:1808	arg1	<-3					1823:1825	CNS permeability <-3	1806:1825	CNS permeability <-3	1806:1825	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	8	5	theme	in	1887:1888	arg1	approach					1905:1912	The in silico docking approach	1883:1912	The in silico docking approach to glycosylation enzyme inhibitor prediction	1883:1957	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	5	6	theme	demethylwedelolactone	915:935	arg1	[ERMan1					938:944	(1) Amb20622156 (demethylwedelolactone) [ERMan1	898:944	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	8	7	theme	docking	1897:1903	arg1	approach					1905:1912	The in silico docking approach	1883:1912	The in silico docking approach to glycosylation enzyme inhibitor prediction	1883:1957	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	7	8	theme	ADMETox	1688:1694	arg1	properties					1696:1705	good ADMETox properties	1683:1705	good ADMETox properties	1683:1705	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	6	9	theme	residue	1350:1356	arg1	analyses					1370:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	5	10	dep	show	815:818	arg1	In					787:788	In	787:788	In	787:788	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	8	11	theme	enzyme	1931:1936	arg1	prediction					1948:1957	glycosylation enzyme inhibitor prediction	1917:1957	glycosylation enzyme inhibitor prediction	1917:1957	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	8	12	theme	aberrant	2053:2060	arg1	protein					2062:2068	aberrant protein	2053:2068	aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma	2053:2117	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	5	13	theme	Amb20622156	902:912	arg1	[ERMan1					938:944	(1) Amb20622156 (demethylwedelolactone) [ERMan1	898:944	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	14	dep	P < 5	1718:1722	arg1	i.e.					1708:1711	i.e.	1708:1711	i.e.	1708:1711	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	15	theme	>	1775:1775	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	15	theme	>	1775:1775	arg1	%					1779:1779	intestinal absorption > 30%	1753:1779	intestinal absorption > 30%	1753:1779	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	2	16	theme	cancer-associated	284:300	arg1	glycans					302:308	cancer-associated glycans	284:308	cancer-associated glycans	284:308	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	3	17	dep	enzymes	606:612	arg1	Alpha1-6FucT					616:627	Alpha1-6FucT	616:627	Alpha1-6FucT	616:627	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	17	dep	enzymes	606:612	arg1	enzymes					606:612	four glycosylation enzymes	587:612	four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V	587:659	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	17	dep	enzymes	606:612	arg1	ERMan1					639:644	ERMan1	639:644	ERMan1	639:644	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	17	dep	enzymes	606:612	arg1	GlcNAcT-V					651:659	GlcNAcT-V	651:659	GlcNAcT-V	651:659	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	17	dep	enzymes	606:612	arg1	ST6Gal1					630:636	ST6Gal1	630:636	ST6Gal1	630:636	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	7	18	theme	intestinal	1753:1762	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	18	theme	intestinal	1753:1762	arg1	%					1779:1779	intestinal absorption > 30%	1753:1779	intestinal absorption > 30%	1753:1779	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	4	19	theme	potential	743:751	arg1	binding					753:759	potential binding	743:759	potential binding against all four enzymes	743:784	The top inhibitors identified against each enzyme were subsequently analyzed for potential binding against all four enzymes.
34989310	5	20	theme	several	820:826	arg1	candidates					838:847	several promising candidates	820:847	several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	820:1323	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	0	21	theme	screening-based	10:24	arg1	discovery					26:34	In silico screening-based discovery	0:34	In silico screening-based discovery of inhibitors against glycosylation proteins	0:79	In silico screening-based discovery of inhibitors against glycosylation proteins dysregulated in cancer.
34989310	1	22	theme	glycans	168:174	arg1	biosynthesis					143:154	the biosynthesis	139:154	the biosynthesis of aberrant glycans	139:174	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	6	23	theme	putative	1393:1400	arg1	inhibitors					1402:1411	the putative inhibitors	1389:1411	the putative inhibitors	1389:1411	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	7	24	theme	permeability	1732:1743	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	24	theme	permeability	1732:1743	arg1	>					1745:1745	Caco-2 permeability > 0.90	1725:1750	Caco-2 permeability > 0.90	1725:1750	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	25	theme	prediction	1607:1616	arg1	analysis					1618:1625	pharmacokinetic property prediction analysis	1582:1625	pharmacokinetic property prediction analysis using pkCSM	1582:1637	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	5	26	theme	silico	790:795	arg1	results					807:813	silico screening results	790:813	silico screening results	790:813	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	27	theme	pharmacokinetic	1582:1596	arg1	analysis					1618:1625	pharmacokinetic property prediction analysis	1582:1625	pharmacokinetic property prediction analysis using pkCSM	1582:1637	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	8	28	theme	inhibitors	2014:2023	arg1	discovery					1995:2003	the discovery	1991:2003	the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma	1991:2117	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	0	29	theme	inhibitors	39:48	arg1	discovery					26:34	In silico screening-based discovery	0:34	In silico screening-based discovery of inhibitors against glycosylation proteins	0:79	In silico screening-based discovery of inhibitors against glycosylation proteins dysregulated in cancer.
34989310	6	30	with	interactions	1439:1450	arg1	residues					1473:1480	key active site residues	1457:1480	key active site residues in each enzyme	1457:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	7	31	theme	log	1714:1716	arg1	>					1745:1745	Caco-2 permeability > 0.90	1725:1750	Caco-2 permeability > 0.90	1725:1750	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	31	theme	log	1714:1716	arg1	<-3					1823:1825	CNS permeability <-3	1806:1825	CNS permeability <-3	1806:1825	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	31	theme	log	1714:1716	arg1	0.477					1853:1857	maximum tolerated dose < 0.477	1828:1857	maximum tolerated dose < 0.477	1828:1857	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	31	theme	log	1714:1716	arg1	%					1779:1779	intestinal absorption > 30%	1753:1779	intestinal absorption > 30%	1753:1779	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	31	theme	log	1714:1716	arg1	minnow					1860:1865	minnow toxicity<-0.3	1860:1879	minnow toxicity<-0.3	1860:1879	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	31	theme	log	1714:1716	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	31	theme	log	1714:1716	arg1	permeability>-2.5					1787:1803	skin permeability>-2.5	1782:1803	skin permeability>-2.5	1782:1803	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	0	32	theme	In	0:1	arg1	discovery					26:34	In silico screening-based discovery	0:34	In silico screening-based discovery of inhibitors against glycosylation proteins	0:79	In silico screening-based discovery of inhibitors against glycosylation proteins dysregulated in cancer.
34989310	1	33	theme	Targeting	105:113	arg1	enzymes					115:121	Targeting enzymes	105:121	Targeting enzymes associated with the biosynthesis of aberrant glycans	105:174	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	1	33	theme	Targeting	105:113	arg1	strategy					197:204	an under-utilized strategy	179:204	an under-utilized strategy in discovering potential inhibitors or drugs against cancer	179:264	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	6	34	dep	enzymes	1546:1552	arg1	sites					1562:1566	active sites	1555:1566	the four enzymes' active sites	1537:1566	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	6	35	theme	active	1461:1466	arg1	residues					1473:1480	key active site residues	1457:1480	key active site residues in each enzyme	1457:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	5	36	theme	1,2-dihydrotanshinone	1059:1079	arg1	[ERMan1					1084:1090	(2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol]	1042:1185	(2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol]	1042:1185	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	3	37	theme	natural	537:543	arg1	products					545:552	natural products	537:552	natural products	537:552	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	6	38	theme	bonding	1431:1437	arg1	interactions					1439:1450	non-covalent bonding interactions	1418:1450	non-covalent bonding interactions with key active site residues in each enzyme	1418:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	6	39	from	residues	1525:1532	arg1	enzymes					1546:1552	the four enzymes	1537:1552	the four enzymes' active sites	1537:1566	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	7	40	theme	tolerated	1836:1844	arg1	dose					1846:1849	maximum tolerated dose <	1828:1851	maximum tolerated dose < 0.477	1828:1857	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	6	41	theme	critical	1509:1516	arg1	residues					1525:1532	critical target residues	1509:1532	critical target residues in the four enzymes' active sites	1509:1566	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	5	42	theme	Amb22173588	1046:1056	arg1	[ERMan1					1084:1090	(2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol]	1042:1185	(2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol]	1042:1185	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	43	theme	B	1219:1219	arg1	[ERMan1					1222:1228	(3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	1192:1323	(3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	1192:1323	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	44	theme	permeability	1810:1821	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	44	theme	permeability	1810:1821	arg1	<-3					1823:1825	CNS permeability <-3	1806:1825	CNS permeability <-3	1806:1825	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	3	45	theme	glycosylation	592:604	arg1	Alpha1-6FucT					616:627	Alpha1-6FucT	616:627	Alpha1-6FucT	616:627	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	45	theme	glycosylation	592:604	arg1	enzymes					606:612	four glycosylation enzymes	587:612	four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V	587:659	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	45	theme	glycosylation	592:604	arg1	ERMan1					639:644	ERMan1	639:644	ERMan1	639:644	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	45	theme	glycosylation	592:604	arg1	GlcNAcT-V					651:659	GlcNAcT-V	651:659	GlcNAcT-V	651:659	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	3	45	theme	glycosylation	592:604	arg1	ST6Gal1					630:636	ST6Gal1	630:636	ST6Gal1	630:636	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	1	46	theme	under-utilized	182:195	arg1	enzymes					115:121	Targeting enzymes	105:121	Targeting enzymes associated with the biosynthesis of aberrant glycans	105:174	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	1	46	theme	under-utilized	182:195	arg1	strategy					197:204	an under-utilized strategy	179:204	an under-utilized strategy in discovering potential inhibitors or drugs against cancer	179:264	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	7	47	theme	skin	1782:1785	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	47	theme	skin	1782:1785	arg1	permeability>-2.5					1787:1803	skin permeability>-2.5	1782:1803	skin permeability>-2.5	1782:1803	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	6	48	theme	active	1555:1560	arg1	sites					1562:1566	active sites	1555:1566	the four enzymes' active sites	1537:1566	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	7	49	theme	good	1683:1686	arg1	properties					1696:1705	good ADMETox properties	1683:1705	good ADMETox properties	1683:1705	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	6	50	theme	interaction	1358:1368	arg1	analyses					1370:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	2	51	theme	dysregulated	331:342	arg1	expression					344:353	the dysregulated expression	327:353	the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function	327:467	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	1	52	theme	potential	221:229	arg1	inhibitors					231:240	potential inhibitors	221:240	potential inhibitors	221:240	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	8	53	theme	inhibitor	1938:1946	arg1	prediction					1948:1957	glycosylation enzyme inhibitor prediction	1917:1957	glycosylation enzyme inhibitor prediction	1917:1957	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	5	54	dep	-9.3 kcal/mol	1231:1243	arg1	-6.0 kcal/mol					1260:1272	-6.0 kcal/mol	1260:1272	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	54	dep	-9.3 kcal/mol	1231:1243	arg1	ST6Gal1					1275:1281	ST6Gal1	1275:1281	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	54	dep	-9.3 kcal/mol	1231:1243	arg1	-7.7 kcal/mol					1310:1322	-7.7 kcal/mol	1310:1322	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	54	dep	-9.3 kcal/mol	1231:1243	arg1	Alpha1-6FucT					1246:1257	Alpha1-6FucT	1246:1257	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	54	dep	-9.3 kcal/mol	1231:1243	arg1	-9.8 kcal/mol					1284:1296	-9.8 kcal/mol	1284:1296	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	54	dep	-9.3 kcal/mol	1231:1243	arg1	GlcNAcT-V					1299:1307	GlcNAcT-V	1299:1307	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	6	55	theme	Drug-enzyme	1326:1336	arg1	analyses					1370:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	6	56	from	residues	1473:1480	arg1	enzyme					1490:1495	each enzyme	1485:1495	each enzyme	1485:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	8	57	theme	glycosylation	1917:1929	arg1	prediction					1948:1957	glycosylation enzyme inhibitor prediction	1917:1957	glycosylation enzyme inhibitor prediction	1917:1957	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	5	58	dep	[ERMan1	1222:1228	arg1	-9.3 kcal/mol					1231:1243	-9.3 kcal/mol	1231:1243	-9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol	1231:1322	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	2	59	theme	glycans	302:308	arg1	due					320:322	due	320:322	due	320:322	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	2	59	theme	glycans	302:308	arg1	formation					271:279	The formation	267:279	The formation of cancer-associated glycans	267:308	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	6	60	theme	non-covalent	1418:1429	arg1	interactions					1439:1450	non-covalent bonding interactions	1418:1450	non-covalent bonding interactions with key active site residues in each enzyme	1418:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	1	61	theme	aberrant	159:166	arg1	glycans					168:174	aberrant glycans	159:174	aberrant glycans	159:174	Targeting enzymes associated with the biosynthesis of aberrant glycans is an under-utilized strategy in discovering potential inhibitors or drugs against cancer.
34989310	7	62	theme	absorption	1764:1773	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	62	theme	absorption	1764:1773	arg1	%					1779:1779	intestinal absorption > 30%	1753:1779	intestinal absorption > 30%	1753:1779	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	5	63	theme	promising	828:836	arg1	candidates					838:847	several promising candidates	820:847	several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	820:1323	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	64	dep	have	1678:1681	arg1	>					1745:1745	Caco-2 permeability > 0.90	1725:1750	Caco-2 permeability > 0.90	1725:1750	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	64	dep	have	1678:1681	arg1	<-3					1823:1825	CNS permeability <-3	1806:1825	CNS permeability <-3	1806:1825	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	64	dep	have	1678:1681	arg1	0.477					1853:1857	maximum tolerated dose < 0.477	1828:1857	maximum tolerated dose < 0.477	1828:1857	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	64	dep	have	1678:1681	arg1	%					1779:1779	intestinal absorption > 30%	1753:1779	intestinal absorption > 30%	1753:1779	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	64	dep	have	1678:1681	arg1	minnow					1860:1865	minnow toxicity<-0.3	1860:1879	minnow toxicity<-0.3	1860:1879	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	64	dep	have	1678:1681	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	64	dep	have	1678:1681	arg1	permeability>-2.5					1787:1803	skin permeability>-2.5	1782:1803	skin permeability>-2.5	1782:1803	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	65	theme	property	1598:1605	arg1	analysis					1618:1625	pharmacokinetic property prediction analysis	1582:1625	pharmacokinetic property prediction analysis using pkCSM	1582:1637	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	8	66	dep	in	1887:1888	arg1	silico					1890:1895	silico	1890:1895	silico	1890:1895	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	8	67	theme	novel	2008:2012	arg1	inhibitors					2014:2023	novel inhibitors	2008:2023	novel inhibitors	2008:2023	The in silico docking approach to glycosylation enzyme inhibitor prediction could help guide and streamline the discovery of novel inhibitors against enzymes involved in aberrant protein glycosylation.Communicated by Ramaswamy H. Sarma.
34989310	5	68	theme	screening	797:805	arg1	results					807:813	silico screening results	790:813	silico screening results	790:813	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	7	69	theme	Caco-2	1725:1730	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	69	theme	Caco-2	1725:1730	arg1	>					1745:1745	Caco-2 permeability > 0.90	1725:1750	Caco-2 permeability > 0.90	1725:1750	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	2	70	theme	cellular	437:444	arg1	structure					446:454	cellular structure	437:454	cellular structure	437:454	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	7	71	contain	have	1678:1681	arg2	properties					1696:1705	good ADMETox properties	1683:1705	good ADMETox properties	1683:1705	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	71	contain	have	1678:1681	arg1	all					1654:1656	all	1654:1656	all	1654:1656	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	71	contain	have	1678:1681	arg1	inhibitors					1667:1676	these inhibitors	1661:1676	these inhibitors	1661:1676	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	6	72	theme	site	1345:1348	arg1	analyses					1370:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	6	73	theme	site	1468:1471	arg1	residues					1473:1480	key active site residues	1457:1480	key active site residues in each enzyme	1457:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	5	74	theme	Amb22173591	1196:1206	arg1	[ERMan1					1222:1228	(3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	1192:1323	(3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	1192:1323	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	3	75	theme	compounds	513:521	arg1	database					484:491	a database	482:491	a database of more than 14,000 compounds consisting of natural products and drugs	482:562	We screened a database of more than 14,000 compounds consisting of natural products and drugs for inhibition against four glycosylation enzymes - Alpha1-6FucT, ST6Gal1, ERMan1, and GlcNAcT-V.
34989310	6	76	theme	key	1457:1459	arg1	residues					1473:1480	key active site residues	1457:1480	key active site residues in each enzyme	1457:1495	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	5	77	theme	tanshinol	1209:1217	arg1	[ERMan1					1222:1228	(3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	1192:1323	(3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol]	1192:1323	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	-7.3 kcal/mol					976:988	-7.3 kcal/mol	976:988	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	ST6Gal1					991:997	ST6Gal1	991:997	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	-7.2 kcal/mol					1026:1038	-7.2 kcal/mol	1026:1038	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	-9.3 kcal/mol					947:959	-9.3 kcal/mol	947:959	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	Alpha1-6FucT					962:973	Alpha1-6FucT	962:973	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	-8.4 kcal/mol					1000:1012	-8.4 kcal/mol	1000:1012	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	5	78	dep	[ERMan1	938:944	arg1	GlcNAcT-V					1015:1023	GlcNAcT-V	1015:1023	(1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol	898:1038	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	0	79	theme	glycosylation	58:70	arg1	proteins					72:79	glycosylation proteins	58:79	glycosylation proteins	58:79	In silico screening-based discovery of inhibitors against glycosylation proteins dysregulated in cancer.
34989310	5	80	theme	I	1081:1081	arg1	[ERMan1					1084:1090	(2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol]	1042:1185	(2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol]	1042:1185	In silico screening results show several promising candidates that could potentially inhibit all four enzymes: (1) Amb20622156 (demethylwedelolactone) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -7.3 kcal/mol; ST6Gal1: -8.4 kcal/mol; GlcNAcT-V: -7.2 kcal/mol], (2) Amb22173588 (1,2-dihydrotanshinone I) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.1 kcal/mol; ST6Gal1: -9.2 kcal/mol; GlcNAcT-V: -7.9 kcal/mol], and (3) Amb22173591 (tanshinol B) [ERMan1: -9.3 kcal/mol; Alpha1-6FucT: -6.0 kcal/mol; ST6Gal1: -9.8 kcal/mol; GlcNAcT-V: -7.7 kcal/mol].
34989310	6	81	theme	active	1338:1343	arg1	analyses					1370:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses	1326:1377	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	2	82	theme	glycosidases	383:394	arg1	expression					344:353	the dysregulated expression	327:353	the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function	327:467	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	0	83	dep	In	0:1	arg1	silico					3:8	silico	3:8	silico	3:8	In silico screening-based discovery of inhibitors against glycosylation proteins dysregulated in cancer.
34989310	2	84	theme	glycosyltransferases	358:377	arg1	expression					344:353	the dysregulated expression	327:353	the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function	327:467	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
34989310	6	85	theme	target	1518:1523	arg1	residues					1525:1532	critical target residues	1509:1532	critical target residues in the four enzymes' active sites	1509:1566	Drug-enzyme active site residue interaction analyses show that the putative inhibitors form non-covalent bonding interactions with key active site residues in each enzyme, suggesting critical target residues in the four enzymes' active sites.
34989310	7	86	theme	dose	1846:1849	arg1	0.477					1853:1857	maximum tolerated dose < 0.477	1828:1857	maximum tolerated dose < 0.477	1828:1857	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	7	86	theme	dose	1846:1849	arg1	P < 5					1718:1722	log P < 5	1714:1722	log P < 5	1714:1722	Furthermore, pharmacokinetic property prediction analysis using pkCSM indicates that all of these inhibitors have good ADMETox properties (i.e., log P < 5, Caco-2 permeability > 0.90, intestinal absorption > 30%, skin permeability>-2.5, CNS permeability <-3, maximum tolerated dose < 0.477, minnow toxicity<-0.3).
34989310	4	87	theme	top	666:668	arg1	inhibitors					670:679	The top inhibitors	662:679	The top inhibitors identified against each enzyme	662:710	The top inhibitors identified against each enzyme were subsequently analyzed for potential binding against all four enzymes.
34989310	2	88	theme	crucial	408:414	arg1	roles					416:420	crucial roles	408:420	crucial roles	408:420	The formation of cancer-associated glycans is mainly due to the dysregulated expression of glycosyltransferases and glycosidases, which play crucial roles in maintaining cellular structure and function.
35166741	5	0	theme	labile	907:912	arg1	Thz					914:916	an acid labile Thz	899:916	an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester	899:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	1	1	theme	homogeneous	184:194	arg1	glycoprotein					196:207	homogeneous glycoprotein	184:207	homogeneous glycoprotein	184:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	1	2	theme	glycoprotein	196:207	arg1	amount					174:179	a sufficient amount	161:179	a sufficient amount of homogeneous glycoprotein	161:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	1	2	theme	glycoprotein	196:207	arg1	glycoprotein					196:207	homogeneous glycoprotein	184:207	homogeneous glycoprotein	184:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	3	3	dep	necessary	630:638	arg1	perform					657:663	perform	657:663	to perform native chemical ligation	654:688	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	6	4	theme	SPPS	1136:1139	arg1	method					1141:1146	the conventional SPPS method	1119:1146	the conventional SPPS method	1119:1146	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	5	5	theme	optimized	863:871	arg1	conditions					873:882	These optimized conditions	857:882	These optimized conditions	857:882	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	2	6	gly	glycoproteins	484:496	arg1	glycoproteins					484:496	homogeneous glycoproteins	472:496	homogeneous glycoproteins	472:496	Herein, we report optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion.
35166741	8	7	theme	full-length	1443:1453	arg1	polypeptide					1477:1487	a full-length interferon-β glycosyl polypeptide	1441:1487	a full-length interferon-β glycosyl polypeptide as a model	1441:1498	By using these strategies, a full-length interferon-β glycosyl polypeptide as a model was successfully obtained.
35166741	6	8	theme	glycopeptide	1174:1185	arg1	coupling					1187:1194	an improved liquid phase glycopeptide coupling	1149:1194	an improved liquid phase glycopeptide coupling	1149:1194	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	6	9	theme	conventional	1123:1134	arg1	method					1141:1146	the conventional SPPS method	1119:1146	the conventional SPPS method	1119:1146	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	0	10	theme	chemical	121:128	arg1	modification					130:141	chemical modification	121:141	chemical modification	121:141	Optimizing the Semisynthesis towards glycosylated interferon-β-polypeptide by utilizing bacterial protein expression and chemical modification.
35166741	3	11	from	N-terminals	614:624	arg1	peptides					578:585	peptides	578:585	peptides	578:585	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	3	11	from	N-terminals	614:624	arg1	thioesters					563:572	Peptide thioesters	555:572	Peptide thioesters	555:572	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	5	12	theme	peptide	1031:1037	arg1	thioester					1039:1047	a peptide thioester	1029:1047	a peptide thioester	1029:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	7	13	theme	internal	1295:1302	arg1	cysteines					1304:1312	the internal cysteines	1291:1312	the internal cysteines	1291:1312	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	3	14	theme	Cys	592:594	arg1	residues					596:603	Cys residues	592:603	Cys residues	592:603	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	3	15	with	peptides	578:585	arg1	residues					596:603	Cys residues	592:603	Cys residues	592:603	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	5	16	theme	specific	977:984	arg1	cyanylation					986:996	a peptide-hydrazide and specific cyanylation	953:996	a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester	953:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	8	17	theme	glycosyl	1468:1475	arg1	polypeptide					1477:1487	a full-length interferon-β glycosyl polypeptide	1441:1487	a full-length interferon-β glycosyl polypeptide as a model	1441:1498	By using these strategies, a full-length interferon-β glycosyl polypeptide as a model was successfully obtained.
35166741	5	18	theme	Cys	1016:1018	arg1	cyanylation					986:996	a peptide-hydrazide and specific cyanylation	953:996	a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester	953:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	2	19	theme	homogeneous	472:482	arg1	glycoproteins					484:496	homogeneous glycoproteins	472:496	homogeneous glycoproteins	472:496	Herein, we report optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion.
35166741	7	20	theme	cysteines	1304:1312	arg1	protection					1277:1286	chemoselective protection	1262:1286	chemoselective protection of the internal cysteines	1262:1312	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	7	20	theme	cysteines	1304:1312	arg1	activation					1318:1327	activation	1318:1327	activation of the N-terminal cysteine	1318:1354	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	5	21	from	N-terminal	939:948	arg1	Cys					928:930	Cys	928:930	Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester	928:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	8	22	theme	interferon-β	1455:1466	arg1	polypeptide					1477:1487	a full-length interferon-β glycosyl polypeptide	1441:1487	a full-length interferon-β glycosyl polypeptide as a model	1441:1498	By using these strategies, a full-length interferon-β glycosyl polypeptide as a model was successfully obtained.
35166741	6	23	theme	good	1220:1223	arg1	yield					1225:1229	a good yield	1218:1229	a good yield (46% over four steps)	1218:1251	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	5	24	theme	C-terminal	1005:1014	arg1	Cys					1016:1018	the C-terminal Cys	1001:1018	the C-terminal Cys	1001:1018	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	1	25	from	studies	334:340	arg1	relationship					371:382	glycan structure-function relationship	345:382	glycan structure-function relationship difficult	345:392	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	7	26	theme	N-terminal	1336:1345	arg1	cysteine					1347:1354	the N-terminal cysteine	1332:1354	the N-terminal cysteine	1332:1354	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	1	27	theme	great	215:219	arg1	interest					221:228	great interest	215:228	great interest	215:228	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	2	28	theme	chemical	534:541	arg1	conversion					543:552	chemical conversion	534:552	chemical conversion	534:552	Herein, we report optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion.
35166741	1	29	gly	glycoproteins	246:258	arg1	glycoproteins					246:258	natural glycoproteins	238:258	natural glycoproteins	238:258	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	7	30	theme	chemoselective	1262:1275	arg1	protection					1277:1286	chemoselective protection	1262:1286	chemoselective protection of the internal cysteines	1262:1312	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	3	31	theme	native	665:670	arg1	ligation					681:688	native chemical ligation	665:688	native chemical ligation	665:688	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	2	32	theme	recombinant	507:517	arg1	expression					519:528	recombinant expression	507:528	recombinant expression	507:528	Herein, we report optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion.
35166741	5	33	theme	peptide-hydrazide	955:971	arg1	cyanylation					986:996	a peptide-hydrazide and specific cyanylation	953:996	a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester	953:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	1	34	theme	glycan	345:350	arg1	relationship					371:382	glycan structure-function relationship	345:382	glycan structure-function relationship difficult	345:392	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	3	35	theme	chemical	672:679	arg1	ligation					681:688	native chemical ligation	665:688	native chemical ligation	665:688	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	1	36	theme	natural	238:244	arg1	glycoproteins					246:258	natural glycoproteins	238:258	natural glycoproteins	238:258	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	1	37	theme	structure-function	352:369	arg1	relationship					371:382	glycan structure-function relationship	345:382	glycan structure-function relationship difficult	345:392	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	3	38	with	thioesters	563:572	arg1	residues					596:603	Cys residues	592:603	Cys residues	592:603	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	4	39	dep	performed	707:715	arg1	followed					808:815	followed	808:815	followed by hydrazinolysis and acidic thiolysis	808:854	We successfully performed thioesterification for a peptide prepared in E. coli via Cys-cyanylation at its C-terminal followed by hydrazinolysis and acidic thiolysis.
35166741	6	40	dep	yield	1225:1229	arg1	%					1234:1234	46%	1232:1234	46%	1232:1234	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	5	41	theme	cyanylation	986:996	arg1	N-terminal					939:948	N-terminal	939:948	N-terminal	939:948	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	0	42	theme	glycosylated	37:48	arg1	interferon-β-polypeptide					50:73	glycosylated interferon-β-polypeptide	37:73	glycosylated interferon-β-polypeptide	37:73	Optimizing the Semisynthesis towards glycosylated interferon-β-polypeptide by utilizing bacterial protein expression and chemical modification.
35166741	6	43	theme	oligosaccharide	1083:1097	arg1	amount					1064:1069	the amount	1060:1069	the amount of precious oligosaccharide that is required in the conventional SPPS method	1060:1146	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	6	43	theme	oligosaccharide	1083:1097	arg1	oligosaccharide					1083:1097	precious oligosaccharide	1074:1097	precious oligosaccharide that is required in the conventional SPPS method	1074:1146	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	6	44	gly	glycopeptide	1174:1185	arg2	glycopeptide					1174:1185	an improved liquid phase glycopeptide coupling	1149:1194	an improved liquid phase glycopeptide coupling	1149:1194	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	2	45	theme	glycoproteins	484:496	arg1	semisynthesis					455:467	the semisynthesis	451:467	the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion	451:552	Herein, we report optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion.
35166741	1	46	theme	difficult	384:392	arg1	relationship					371:382	glycan structure-function relationship	345:382	glycan structure-function relationship difficult	345:392	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	6	47	theme	phase	1168:1172	arg1	coupling					1187:1194	an improved liquid phase glycopeptide coupling	1149:1194	an improved liquid phase glycopeptide coupling	1149:1194	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	5	48	theme	acid	902:905	arg1	Thz					914:916	an acid labile Thz	899:916	an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester	899:1047	These optimized conditions could tolerate an acid labile Thz protected Cys at the N-terminal of a peptide-hydrazide and specific cyanylation of the C-terminal Cys to yield a peptide thioester.
35166741	2	49	theme	optimized	413:421	arg1	methods					423:429	optimized methods	413:429	optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion	413:552	Herein, we report optimized methods that can accelerate the semisynthesis of homogeneous glycoproteins based on recombinant expression and chemical conversion.
35166741	4	50	theme	acidic	839:844	arg1	thiolysis					846:854	acidic thiolysis	839:854	acidic thiolysis	839:854	We successfully performed thioesterification for a peptide prepared in E. coli via Cys-cyanylation at its C-terminal followed by hydrazinolysis and acidic thiolysis.
35166741	1	51	gly	glycoprotein	196:207	arg1	glycoprotein					196:207	homogeneous glycoprotein	184:207	homogeneous glycoprotein	184:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	0	52	gly	glycosylated	37:48	arg1	interferon-β-polypeptide					50:73	glycosylated interferon-β-polypeptide	37:73	glycosylated interferon-β-polypeptide	37:73	Optimizing the Semisynthesis towards glycosylated interferon-β-polypeptide by utilizing bacterial protein expression and chemical modification.
35166741	7	53	theme	long	1380:1383	arg1	peptide					1385:1391	a long peptide	1378:1391	a long peptide prepared in E. coli	1378:1411	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	1	54	theme	considerable	265:276	arg1	heterogeneity					278:290	considerable heterogeneity	265:290	considerable heterogeneity in oligosaccharide structures	265:320	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	1	55	from	heterogeneity	278:290	arg1	structures					311:320	oligosaccharide structures	295:320	oligosaccharide structures	295:320	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	1	56	theme	sufficient	163:172	arg1	amount					174:179	a sufficient amount	161:179	a sufficient amount of homogeneous glycoprotein	161:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	1	56	theme	sufficient	163:172	arg1	glycoprotein					196:207	homogeneous glycoprotein	184:207	homogeneous glycoprotein	184:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	6	57	theme	improved	1152:1159	arg1	coupling					1187:1194	an improved liquid phase glycopeptide coupling	1149:1194	an improved liquid phase glycopeptide coupling	1149:1194	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	0	58	theme	protein	98:104	arg1	expression					106:115	bacterial protein expression	88:115	bacterial protein expression	88:115	Optimizing the Semisynthesis towards glycosylated interferon-β-polypeptide by utilizing bacterial protein expression and chemical modification.
35166741	3	59	theme	Peptide	555:561	arg1	thioesters					563:572	Peptide thioesters	555:572	Peptide thioesters	555:572	Peptide thioesters and peptides with Cys residues at their N-terminals are necessary intermediates to perform native chemical ligation.
35166741	1	60	theme	amount	174:179	arg1	synthesis					148:156	The synthesis	144:156	The synthesis of a sufficient amount of homogeneous glycoprotein	144:207	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
35166741	7	61	theme	cysteine	1347:1354	arg1	protection					1277:1286	chemoselective protection	1262:1286	chemoselective protection of the internal cysteines	1262:1312	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	7	61	theme	cysteine	1347:1354	arg1	activation					1318:1327	activation	1318:1327	activation of the N-terminal cysteine	1318:1354	Lastly, chemoselective protection of the internal cysteines and activation of the N-terminal cysteine were optimized toward a long peptide prepared in E. coli.
35166741	0	62	theme	bacterial	88:96	arg1	expression					106:115	bacterial protein expression	88:115	bacterial protein expression	88:115	Optimizing the Semisynthesis towards glycosylated interferon-β-polypeptide by utilizing bacterial protein expression and chemical modification.
35166741	6	63	theme	liquid	1161:1166	arg1	coupling					1187:1194	an improved liquid phase glycopeptide coupling	1149:1194	an improved liquid phase glycopeptide coupling	1149:1194	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	6	64	theme	precious	1074:1081	arg1	oligosaccharide					1083:1097	precious oligosaccharide	1074:1097	precious oligosaccharide that is required in the conventional SPPS method	1074:1146	To reduce the amount of precious oligosaccharide that is required in the conventional SPPS method, an improved liquid phase glycopeptide coupling was also optimized in a good yield (46% over four steps).
35166741	1	65	theme	oligosaccharide	295:309	arg1	structures					311:320	oligosaccharide structures	295:320	oligosaccharide structures	295:320	The synthesis of a sufficient amount of homogeneous glycoprotein is of great interest because natural glycoproteins show considerable heterogeneity in oligosaccharide structures, making the studies on glycan structure-function relationship difficult.
36182101	6	0	theme	blood	954:958	arg1	BabA					991:994	BabA	991:994	BabA	991:994	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	0	theme	blood	954:958	arg1	adhesin					982:988	the blood group antigen-binding adhesin	950:988	the blood group antigen-binding adhesin (BabA)	950:995	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	7	1	theme	noninfected	1253:1263	arg1	individuals					1265:1275	noninfected individuals	1253:1275	noninfected individuals	1253:1275	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	11	2	from	importance	2107:2116	arg1	interactions					2135:2146	host-pathogen interactions	2121:2146	host-pathogen interactions	2121:2146	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	2	3	theme	Most	222:225	arg1	H. pylori					227:235	Most H. pylori	222:235	Most H. pylori	222:235	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	11	4	theme	host-pathogen	2121:2133	arg1	interactions					2135:2146	host-pathogen interactions	2121:2146	host-pathogen interactions	2121:2146	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	4	5	from	individual	655:664	arg1	total					620:624	a total	618:624	a total of 60 to 189 glycans in each individual	618:664	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	6	6	contain	carries	942:948	arg2	adhesin					982:988	the blood group antigen-binding adhesin	950:988	the blood group antigen-binding adhesin (BabA)	950:995	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	6	contain	carries	942:948	arg1	strain					924:929	H. pylori strain J99	914:933	H. pylori strain J99	914:933	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	6	contain	carries	942:948	arg2	BabA					991:994	BabA	991:994	BabA	991:994	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	6	contain	carries	942:948	arg2	adhesin					1022:1028	the sialic acid-binding adhesin	998:1028	the sialic acid-binding adhesin (SabA)	998:1035	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	6	contain	carries	942:948	arg2	SabA					1031:1034	SabA	1031:1034	SabA	1031:1034	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	6	contain	carries	942:948	arg2	adhesin					1063:1069	the LacdiNAc-binding adhesin	1042:1069	the LacdiNAc-binding adhesin	1042:1069	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	8	7	with	analysis	1302:1309	arg1	wt					1341:1342	J99 wt	1337:1342	J99 wt	1337:1342	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	0	8	theme	Mucin	60:64	arg1	O-Glycans					66:74	Human Gastric Mucin O-Glycans	46:74	Human Gastric Mucin O-Glycans	46:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	8	9	theme	Statistical	1278:1288	arg1	analysis					1302:1309	Statistical correlation analysis	1278:1309	Statistical correlation analysis	1278:1309	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	1	10	theme	half	192:195	arg1	stomach					181:187	the stomach	177:187	the stomach of half of the human population	177:219	Helicobacter pylori colonizes the stomach of half of the human population.
36182101	11	11	theme	glycan-based	2177:2188	arg1	therapies					2190:2198	glycan-based therapies	2177:2198	glycan-based therapies	2177:2198	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	5	12	theme	unique	690:695	arg1	structures					704:713	unique glycan structures	690:713	unique glycan structures together with an increased intraindividual diversity	690:766	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	10	13	theme	H. pylori	1834:1842	arg1	whereof					1852:1858	H. pylori binding whereof 23	1834:1861	H. pylori binding whereof 23 contained α1,2-linked fucosylation	1834:1896	We identified 24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation.
36182101	11	14	dep	investigate	2077:2087	arg1	develop					2169:2175	develop	2169:2175	to develop glycan-based therapies	2166:2198	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	8	15	theme	binding	1312:1318	arg1	experiments					1320:1330	binding experiments	1312:1330	binding experiments with J99 wt	1312:1342	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	5	16	theme	structures	704:713	arg1	number					680:685	An increased number	667:685	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation	667:803	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	1	17	theme	population	210:219	arg1	half					192:195	half	192:195	half of the human population	192:219	Helicobacter pylori colonizes the stomach of half of the human population.
36182101	9	18	theme	LacdiNAc	1576:1583	arg1	levels					1585:1590	LacdiNAc levels	1576:1590	LacdiNAc levels	1576:1590	LacdiNAc levels were lower in mucins that bound to J99 lacking BabA and SabA than in mucins that did not, suggesting that LacdiNAc did not significantly contribute to the binding.
36182101	6	19	theme	antigen-binding	966:980	arg1	BabA					991:994	BabA	991:994	BabA	991:994	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	19	theme	antigen-binding	966:980	arg1	adhesin					982:988	the blood group antigen-binding adhesin	950:988	the blood group antigen-binding adhesin (BabA)	950:995	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	10	20	link	α1,2-linked	1873:1883	arg1	fucosylation					1885:1896	α1,2-linked fucosylation	1873:1896	α1,2-linked fucosylation	1873:1896	We identified 24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation.
36182101	8	21	theme	fucosylated	1552:1562	arg1	structures					1564:1573	fucosylated structures	1552:1573	fucosylated structures	1552:1573	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	8	22	with	experiments	1378:1388	arg1	wt					1341:1342	J99 wt	1337:1342	J99 wt	1337:1342	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	0	23	theme	Gastric	52:58	arg1	O-Glycans					66:74	Human Gastric Mucin O-Glycans	46:74	Human Gastric Mucin O-Glycans	46:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	5	24	theme	Helicobacter	842:853	arg1	stomachs					869:876	Helicobacter spp.-infected stomachs	842:876	Helicobacter spp.-infected stomachs compared with noninfected stomachs	842:911	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	1	25	theme	Helicobacter	147:158	arg1	pylori					160:165	Helicobacter pylori	147:165	Helicobacter pylori	147:165	Helicobacter pylori colonizes the stomach of half of the human population.
36182101	0	26	theme	O-Glycans	66:74	arg1	Diversity					33:41	the Diversity	29:41	the Diversity of Human Gastric Mucin O-Glycans	29:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	0	27	theme	Helicobacter	77:88	arg1	Connection					10:19	A Complex Connection	0:19	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans	0:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	0	27	theme	Helicobacter	77:88	arg1	Binding					97:103	Helicobacter pylori Binding	77:103	Helicobacter pylori Binding	77:103	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	6	28	theme	acid-binding	1009:1020	arg1	SabA					1031:1034	SabA	1031:1034	SabA	1031:1034	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	28	theme	acid-binding	1009:1020	arg1	adhesin					1022:1028	the sialic acid-binding adhesin	998:1028	the sialic acid-binding adhesin (SabA)	998:1035	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	8	29	theme	synthetic	1396:1404	arg1	glycoconjugates					1406:1420	synthetic glycoconjugates	1396:1420	synthetic glycoconjugates	1396:1420	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	11	30	theme	H. pylori	1998:2006	arg1	binding					2008:2014	H. pylori binding	1998:2014	H. pylori binding	1998:2014	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	5	31	theme	increased	732:740	arg1	diversity					758:766	an increased intraindividual diversity	729:766	an increased intraindividual diversity	729:766	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	0	32	dep	Helicobacter	77:88	arg1	pylori					90:95	pylori	90:95	pylori	90:95	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	4	33	from	total	620:624	arg1	common					586:591	common	586:591	common	586:591	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	4	33	from	total	620:624	arg1	individual					655:664	each individual	650:664	each individual	650:664	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	7	34	theme	J99	1171:1173	arg1	binding					1175:1181	H. pylori J99 binding	1161:1181	H. pylori J99 binding	1161:1181	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	6	35	theme	H. pylori	914:922	arg1	strain					924:929	H. pylori strain J99	914:933	H. pylori strain J99	914:933	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	5	36	theme	variation	795:803	arg1	number					680:685	An increased number	667:685	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation	667:803	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	6	37	theme	LacdiNAc-binding	1046:1061	arg1	adhesin					1063:1069	the LacdiNAc-binding adhesin	1042:1069	the LacdiNAc-binding adhesin	1042:1069	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	8	38	with	experiments	1320:1330	arg1	wt					1341:1342	J99 wt	1337:1342	J99 wt	1337:1342	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	7	39	theme	Leb-positive	1140:1151	arg1	mucins					1153:1158	Leb-positive mucins	1140:1158	Leb-positive mucins	1140:1158	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	11	40	theme	gastric	1921:1927	arg1	library					1936:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	6	41	theme	group	960:964	arg1	BabA					991:994	BabA	991:994	BabA	991:994	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	41	theme	group	960:964	arg1	adhesin					982:988	the blood group antigen-binding adhesin	950:988	the blood group antigen-binding adhesin (BabA)	950:995	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	11	42	used	used	2026:2029	arg2	library					1936:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	3	43	theme	spp.-infected	492:504	arg1	stomachs					543:550	14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	476:550	14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	476:550	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	8	44	from	differences	1444:1454	arg1	ability					1477:1483	H. pylori-binding ability	1459:1483	H. pylori-binding ability	1459:1483	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	3	45	theme	spp.-noninfected	526:541	arg1	stomachs					543:550	14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	476:550	14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	476:550	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	5	46	theme	noninfected	892:902	arg1	stomachs					904:911	noninfected stomachs	892:911	noninfected stomachs	892:911	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	4	47	theme	glycans	639:645	arg1	total					620:624	a total	618:624	a total of 60 to 189 glycans in each individual	618:664	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	5	48	theme	larger	772:777	arg1	variation					795:803	larger interindividual variation	772:803	larger interindividual variation	772:803	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	7	49	theme	spp.-infected	1222:1234	arg1	individuals					1236:1246	Helicobacter spp.-infected individuals	1209:1246	Helicobacter spp.-infected individuals	1209:1246	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	2	50	theme	glycosylated	298:309	arg1	mucins					311:316	glycosylated mucins	298:316	glycosylated mucins	298:316	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	4	51	from	glycans	639:645	arg1	individual					655:664	each individual	650:664	each individual	650:664	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	11	52	dep	glycodeterminants	2041:2057	arg1	investigate					2077:2087	investigate	2077:2087	to experimentally investigate further for their importance in host-pathogen interactions	2059:2146	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	11	52	dep	glycodeterminants	2041:2057	arg1	candidates					2155:2164	candidates	2155:2164	candidates	2155:2164	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	6	53	theme	sialic	1002:1007	arg1	SabA					1031:1034	SabA	1031:1034	SabA	1031:1034	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	6	53	theme	sialic	1002:1007	arg1	adhesin					1022:1028	the sialic acid-binding adhesin	998:1028	the sialic acid-binding adhesin (SabA)	998:1035	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	10	54	from	mucins	1801:1806	arg1	O-glycans					1773:1781	24 O-glycans	1770:1781	24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation	1770:1896	We identified 24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation.
36182101	10	55	theme	binding	1844:1850	arg1	whereof					1852:1858	H. pylori binding whereof 23	1834:1861	H. pylori binding whereof 23 contained α1,2-linked fucosylation	1834:1896	We identified 24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation.
36182101	5	56	theme	spp.-infected	855:867	arg1	stomachs					869:876	Helicobacter spp.-infected stomachs	842:876	Helicobacter spp.-infected stomachs compared with noninfected stomachs	842:911	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	8	57	theme	correlation	1290:1300	arg1	analysis					1302:1309	Statistical correlation analysis	1278:1309	Statistical correlation analysis	1278:1309	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	5	58	theme	glycan	697:702	arg1	structures					704:713	unique glycan structures	690:713	unique glycan structures together with an increased intraindividual diversity	690:766	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	8	59	gly	fucosylated	1552:1562	arg1	structures					1564:1573	fucosylated structures	1552:1573	fucosylated structures	1552:1573	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	8	60	theme	BabA-dependent	1526:1539	arg1	binding					1541:1547	BabA-dependent binding	1526:1547	BabA-dependent binding to fucosylated structures	1526:1573	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	11	61	theme	diverse	1913:1919	arg1	library					1936:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	10	62	theme	α1,2-linked	1873:1883	arg1	fucosylation					1885:1896	α1,2-linked fucosylation	1873:1896	α1,2-linked fucosylation	1873:1896	We identified 24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation.
36182101	11	63	theme	large	1903:1907	arg1	library					1936:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	5	64	theme	increased	670:678	arg1	number					680:685	An increased number	667:685	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation	667:803	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	2	65	theme	mucus	256:260	arg1	layer					262:266	the mucus layer	252:266	the mucus layer	252:266	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	5	66	from	stomachs	869:876	arg1	O-glycans					827:835	O-glycans	827:835	O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs	827:911	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	2	67	from	layer	262:266	arg1	located					241:247	located	241:247	located	241:247	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	7	68	from	individuals	1236:1246	arg1	mucins					1197:1202	mucins	1197:1202	mucins from Helicobacter spp.-infected individuals	1197:1246	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	8	69	theme	J99	1337:1339	arg1	wt					1341:1342	J99 wt	1337:1342	J99 wt	1337:1342	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	5	70	theme	intraindividual	742:756	arg1	diversity					758:766	an increased intraindividual diversity	729:766	an increased intraindividual diversity	729:766	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	3	71	theme	mass	325:328	arg1	spectrometry					330:341	mass spectrometry	325:341	mass spectrometry	325:341	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	7	72	theme	Helicobacter	1209:1220	arg1	individuals					1236:1246	Helicobacter spp.-infected individuals	1209:1246	Helicobacter spp.-infected individuals	1209:1246	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	0	73	theme	Helicobacter	106:117	arg1	Connection					10:19	A Complex Connection	0:19	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans	0:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	0	73	theme	Helicobacter	106:117	arg1	Infection					119:127	Helicobacter Infection	106:127	Helicobacter Infection	106:127	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	3	74	dep	glycans	362:368	arg1	assigned					426:433	assigned	426:433	assigned as compositions	426:449	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	3	74	dep	glycans	362:368	arg1	characterized					394:406	characterized	394:406	were fully characterized	383:406	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	8	75	theme	J99ΔbabAΔsabA	1349:1361	arg1	experiments					1378:1388	J99ΔbabAΔsabA and inhibition experiments	1349:1388	experiments	1378:1388	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	8	76	theme	inhibition	1367:1376	arg1	experiments					1378:1388	J99ΔbabAΔsabA and inhibition experiments	1349:1388	experiments	1378:1388	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	0	77	theme	Complex	2:8	arg1	Connection					10:19	A Complex Connection	0:19	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans	0:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	0	77	theme	Complex	2:8	arg1	Fucosylation					133:144	Fucosylation	133:144	Fucosylation	133:144	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	0	77	theme	Complex	2:8	arg1	Binding					97:103	Helicobacter pylori Binding	77:103	Helicobacter pylori Binding	77:103	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	0	77	theme	Complex	2:8	arg1	Infection					119:127	Helicobacter Infection	106:127	Helicobacter Infection	106:127	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	4	78	theme	identified	562:571	arg1	glycans					573:579	Only six identified glycans	553:579	Only six identified glycans	553:579	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	7	79	theme	H. pylori	1161:1169	arg1	binding					1175:1181	H. pylori J99 binding	1161:1181	H. pylori J99 binding	1161:1181	Among Leb-positive mucins, H. pylori J99 binding was higher to mucins from Helicobacter spp.-infected individuals than noninfected individuals.
36182101	2	80	from	located	241:247	arg1	layer					262:266	the mucus layer	252:266	the mucus layer	252:266	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	5	81	theme	interindividual	779:793	arg1	variation					795:803	larger interindividual variation	772:803	larger interindividual variation	772:803	An increased number of unique glycan structures together with an increased intraindividual diversity and larger interindividual variation were identified among O-glycans from Helicobacter spp.-infected stomachs compared with noninfected stomachs.
36182101	1	82	theme	human	204:208	arg1	population					210:219	the human population	200:219	the human population	200:219	Helicobacter pylori colonizes the stomach of half of the human population.
36182101	4	83	dep	189	635:637	arg1	to					632:633	to	632:633	to	632:633	Only six identified glycans were common to all individuals, from a total of 60 to 189 glycans in each individual.
36182101	0	84	theme	Human	46:50	arg1	O-Glycans					66:74	Human Gastric Mucin O-Glycans	46:74	Human Gastric Mucin O-Glycans	46:74	A Complex Connection Between the Diversity of Human Gastric Mucin O-Glycans, Helicobacter pylori Binding, Helicobacter Infection and Fucosylation.
36182101	8	85	theme	H. pylori-binding	1459:1475	arg1	ability					1477:1483	H. pylori-binding ability	1459:1483	H. pylori-binding ability	1459:1483	Statistical correlation analysis, binding experiments with J99 wt, and J99ΔbabAΔsabA and inhibition experiments using synthetic glycoconjugates demonstrated that the differences in H. pylori-binding ability among these four groups were governed by BabA-dependent binding to fucosylated structures.
36182101	6	86	theme	Leb-negative	1113:1124	arg1	mucins					1126:1131	Lewis b (Leb)-positive and Leb-negative mucins	1086:1131	Lewis b (Leb)-positive and Leb-negative mucins	1086:1131	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	3	87	attach	isolated	462:469	arg2	mucins					455:460	mucins	455:460	mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	455:550	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	3	87	attach	isolated	462:469	arg1	stomachs					543:550	14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	476:550	14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs	476:550	Using mass spectrometry, we identified 631 glycans (whereof 145 were fully characterized and the remainder assigned as compositions) on mucins isolated from 14 Helicobacter spp.-infected and 14 Helicobacter spp.-noninfected stomachs.
36182101	11	88	theme	glycan	1929:1934	arg1	library					1936:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library	1899:1942	The large and diverse gastric glycan library identified, including structures that correlated with H. pylori binding, could be used to select glycodeterminants to experimentally investigate further for their importance in host-pathogen interactions and as candidates to develop glycan-based therapies.
36182101	6	89	theme	-positive	1099:1107	arg1	mucins					1126:1131	Lewis b (Leb)-positive and Leb-negative mucins	1086:1131	Lewis b (Leb)-positive and Leb-negative mucins	1086:1131	H. pylori strain J99, which carries the blood group antigen-binding adhesin (BabA), the sialic acid-binding adhesin (SabA), and the LacdiNAc-binding adhesin, bound both to Lewis b (Leb)-positive and Leb-negative mucins.
36182101	2	90	located	located	241:247	arg1	layer					262:266	the mucus layer	252:266	the mucus layer	252:266	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	2	90	located	located	241:247	arg2	H. pylori					227:235	Most H. pylori	222:235	Most H. pylori	222:235	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	2	91	gly	glycosylated	298:309	arg1	mucins					311:316	glycosylated mucins	298:316	glycosylated mucins	298:316	Most H. pylori are located in the mucus layer, which is mainly comprised by glycosylated mucins.
36182101	10	92	theme	Leb-negative	1788:1799	arg1	mucins					1801:1806	Leb-negative mucins	1788:1806	Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation	1788:1896	We identified 24 O-glycans from Leb-negative mucins that correlated well with H. pylori binding whereof 23 contained α1,2-linked fucosylation.
36385669	11	0	theme	bean	1654:1657	arg1	lectins					1659:1665	Tepary bean lectins	1647:1665	Tepary bean lectins	1647:1665	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	5	1	gly	glycosylation	874:886	arg2	site					888:891	a glycosylation site	872:891	a glycosylation site	872:891	Furthermore, based on sequence Ans-X-Ser/Thr, where X is any amino acid except proline, a glycosylation site was determined on asparagine 36.
36385669	0	2	with	modelling	28:36	arg1	cancer					65:70	cancer	65:70	cancer	65:70	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	1	3	theme	bean	253:256	arg1	seeds					282:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	11	4	theme	lectins	1659:1665	arg1	zones					1638:1642	N-glycan interaction zones	1617:1642	N-glycan interaction zones of Tepary bean lectins	1617:1665	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	4	5	contain	contained	713:721	arg2	glycans					736:742	high mannose glycans	723:742	high mannose glycans being mannose 6 the most abundant form	723:781	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	4	5	contain	contained	713:721	arg1	isoforms					704:711	both isoforms	699:711	both isoforms	699:711	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	10	6	theme	sites	1431:1435	arg1	analysis					1404:1411	the analysis	1400:1411	the analysis of ligand binding sites and in silico glycosylation	1400:1463	Also, the analysis of ligand binding sites and in silico glycosylation were achieved.
36385669	4	7	theme	mannose	728:734	arg1	glycans					736:742	high mannose glycans	723:742	high mannose glycans being mannose 6 the most abundant form	723:781	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	7	8	theme	lectin	1123:1128	arg1	LB					1133:1134	LB	1133:1134	LB	1133:1134	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	7	8	theme	lectin	1123:1128	arg1	B					1130:1130	lectin B	1123:1130	lectin B (LB)	1123:1135	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	11	9	theme	Tepary	1647:1652	arg1	lectins					1659:1665	Tepary bean lectins	1647:1665	Tepary bean lectins	1647:1665	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	7	10	theme	magnesium	1112:1120	arg1	presence					1100:1107	the presence	1096:1107	the presence of magnesium	1096:1120	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	11	11	theme	possible	1566:1573	arg1	interactions					1575:1586	some highly possible interactions	1554:1586	some highly possible interactions	1554:1586	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	3	12	theme	A.	551:552	arg1	Fractions					554:562	Glycanase A. Fractions	541:562	Glycanase A. Fractions resulted from the hydrolysis products	541:600	After purification, to release the N-glycans, they were digested with the endoglycosidases PNGase and Glycanase A. Fractions resulted from the hydrolysis products were analyzed to determine their carbohydrate composition.
36385669	11	13	theme	colon	1503:1507	arg1	adenocarcinoma					1509:1522	colon adenocarcinoma	1503:1522	colon adenocarcinoma	1503:1522	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	1	14	theme	Phaseolus	259:267	arg1	seeds					282:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	11	15	theme	interaction	1626:1636	arg1	zones					1638:1642	N-glycan interaction zones	1617:1642	N-glycan interaction zones of Tepary bean lectins	1617:1665	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	10	16	theme	ligand	1416:1421	arg1	sites					1431:1435	ligand binding sites	1416:1435	ligand binding sites	1416:1435	Also, the analysis of ligand binding sites and in silico glycosylation were achieved.
36385669	11	17	theme	N-glycan	1617:1624	arg1	zones					1638:1642	N-glycan interaction zones	1617:1642	N-glycan interaction zones of Tepary bean lectins	1617:1665	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	1	18	theme	acutifolius	269:279	arg1	seeds					282:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	0	19	theme	Tepary	117:122	arg1	lectins					129:135	two non-fetuin-binding Tepary bean lectins	94:135	two non-fetuin-binding Tepary bean lectins	94:135	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	1	20	theme	different	352:360	arg1	cells					369:373	different cancer cells	352:373	different cancer cells	352:373	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	2	21	theme	A-affinity	412:421	arg1	chromatography					423:436	concanavalin A-affinity chromatography	399:436	concanavalin A-affinity chromatography	399:436	They were separated by concanavalin A-affinity chromatography.
36385669	9	22	theme	identical	1302:1310	arg1	structure-model					1312:1326	an identical structure-model	1299:1326	an identical structure-model for both lectins	1299:1343	Although both lectins showed small differences in their properties, an identical structure-model for both lectins was generated by the homology modelling process.
36385669	0	23	theme	non-fetuin-binding	98:115	arg1	lectins					129:135	two non-fetuin-binding Tepary bean lectins	94:135	two non-fetuin-binding Tepary bean lectins	94:135	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	1	24	theme	cancer	362:367	arg1	cells					369:373	different cancer cells	352:373	different cancer cells	352:373	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	10	25	theme	glycosylation	1451:1463	arg1	analysis					1404:1411	the analysis	1400:1411	the analysis of ligand binding sites and in silico glycosylation	1400:1463	Also, the analysis of ligand binding sites and in silico glycosylation were achieved.
36385669	3	26	theme	Glycanase	541:549	arg1	Fractions					554:562	Glycanase A. Fractions	541:562	Glycanase A. Fractions resulted from the hydrolysis products	541:600	After purification, to release the N-glycans, they were digested with the endoglycosidases PNGase and Glycanase A. Fractions resulted from the hydrolysis products were analyzed to determine their carbohydrate composition.
36385669	5	27	theme	glycosylation	874:886	arg1	site					888:891	a glycosylation site	872:891	a glycosylation site	872:891	Furthermore, based on sequence Ans-X-Ser/Thr, where X is any amino acid except proline, a glycosylation site was determined on asparagine 36.
36385669	1	28	theme	cells	369:373	arg1	survival					340:347	the survival	336:347	the survival of different cancer cells	336:373	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	4	29	theme	abundant	769:776	arg1	form					778:781	the most abundant form	760:781	mannose 6 the most abundant form	750:781	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	0	30	theme	Comparative	0:10	arg1	study					12:16	Comparative study	0:16	Comparative study	0:16	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	10	31	theme	in	1441:1442	arg1	glycosylation					1451:1463	in silico glycosylation	1441:1463	in silico glycosylation	1441:1463	Also, the analysis of ligand binding sites and in silico glycosylation were achieved.
36385669	3	32	theme	hydrolysis	582:591	arg1	products					593:600	the hydrolysis products	578:600	the hydrolysis products	578:600	After purification, to release the N-glycans, they were digested with the endoglycosidases PNGase and Glycanase A. Fractions resulted from the hydrolysis products were analyzed to determine their carbohydrate composition.
36385669	0	33	theme	homology	19:26	arg1	modelling					28:36	homology modelling	19:36	homology modelling	19:36	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	0	34	theme	lectins	129:135	arg1	glycans					83:89	glycans	83:89	glycans of two non-fetuin-binding Tepary bean lectins	83:135	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	11	35	dep	associated-N-glycans	1524:1543	arg1	revealed					1545:1552	revealed	1545:1552	associated-N-glycans revealed some highly possible interactions	1524:1586	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	4	36	dep	mannose	750:756	arg1	form					778:781	the most abundant form	760:781	mannose 6 the most abundant form	750:781	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	4	37	theme	Mass	661:664	arg1	data					679:682	Mass spectrometry data	661:682	Mass spectrometry data	661:682	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	5	38	theme	amino	845:849	arg1	acid					851:854	any amino acid	841:854	any amino acid	841:854	Furthermore, based on sequence Ans-X-Ser/Thr, where X is any amino acid except proline, a glycosylation site was determined on asparagine 36.
36385669	11	39	theme	new	1779:1781	arg1	strategies					1783:1792	new strategies	1779:1792	new strategies	1779:1792	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	0	40	theme	bean	124:127	arg1	lectins					129:135	two non-fetuin-binding Tepary bean lectins	94:135	two non-fetuin-binding Tepary bean lectins	94:135	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	11	41	theme	binding	1705:1711	arg1	domain					1713:1718	the carbohydrate binding domain	1688:1718	the carbohydrate binding domain	1688:1718	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	1	42	theme	abundant	203:210	arg1	isoforms					212:219	the two most abundant isoforms	190:219	the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells	190:373	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	5	43	theme	sequence	806:813	arg1	Ans-X-Ser/Thr					815:827	sequence Ans-X-Ser/Thr	806:827	sequence Ans-X-Ser/Thr	806:827	Furthermore, based on sequence Ans-X-Ser/Thr, where X is any amino acid except proline, a glycosylation site was determined on asparagine 36.
36385669	6	44	theme	biological	973:982	arg1	activity					984:991	their biological activity	967:991	their biological activity	967:991	When their metal requirement to preserve their biological activity was determined, the lectins showed differences.
36385669	7	45	theme	agglutination	1061:1073	arg1	activity					1075:1082	lectin A (LA) agglutination activity	1047:1082	lectin A (LA) agglutination activity	1047:1082	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	1	46	theme	isoforms	212:219	arg1	characterization					170:185	characterization	170:185	characterization	170:185	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	1	46	theme	isoforms	212:219	arg1	purification					153:164	purification	153:164	purification	153:164	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	1	47	attach	isolated	232:239	arg2	lectins					224:230	lectins	224:230	lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells	224:373	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	1	47	attach	isolated	232:239	arg1	seeds					282:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	2	48	theme	concanavalin	399:410	arg1	chromatography					423:436	concanavalin A-affinity chromatography	399:436	concanavalin A-affinity chromatography	399:436	They were separated by concanavalin A-affinity chromatography.
36385669	4	49	theme	high	723:726	arg1	glycans					736:742	high mannose glycans	723:742	high mannose glycans being mannose 6 the most abundant form	723:781	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	4	50	theme	spectrometry	666:677	arg1	data					679:682	Mass spectrometry data	661:682	Mass spectrometry data	661:682	Mass spectrometry data indicated that both isoforms contained high mannose glycans being mannose 6 the most abundant form.
36385669	8	51	theme	human	1204:1208	arg1	erythrocytes					1217:1228	human type-A erythrocytes	1204:1228	human type-A erythrocytes	1204:1228	Additionally, only LA exhibited affinity to human type-A erythrocytes.
36385669	11	52	with	docking	1490:1496	arg1	adenocarcinoma					1509:1522	colon adenocarcinoma	1503:1522	colon adenocarcinoma	1503:1522	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	11	53	theme	carbohydrate	1692:1703	arg1	domain					1713:1718	the carbohydrate binding domain	1688:1718	the carbohydrate binding domain	1688:1718	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	7	54	theme	lectin	1047:1052	arg1	LA					1057:1058	LA	1057:1058	LA	1057:1058	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	7	54	theme	lectin	1047:1052	arg1	A					1054:1054	lectin A	1047:1054	lectin A (LA) agglutination activity	1047:1082	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	0	55	theme	molecular	42:50	arg1	docking					52:58	molecular docking	42:58	molecular docking with cancer	42:70	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	10	56	dep	in	1441:1442	arg1	silico					1444:1449	silico	1444:1449	silico	1444:1449	Also, the analysis of ligand binding sites and in silico glycosylation were achieved.
36385669	10	57	theme	binding	1423:1429	arg1	sites					1431:1435	ligand binding sites	1416:1435	ligand binding sites	1416:1435	Also, the analysis of ligand binding sites and in silico glycosylation were achieved.
36385669	11	58	theme	Molecular	1480:1488	arg1	docking					1490:1496	Molecular docking	1480:1496	Molecular docking with colon adenocarcinoma	1480:1522	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	9	59	theme	homology	1366:1373	arg1	process					1385:1391	the homology modelling process	1362:1391	the homology modelling process	1362:1391	Although both lectins showed small differences in their properties, an identical structure-model for both lectins was generated by the homology modelling process.
36385669	7	60	theme	A	1054:1054	arg1	activity					1075:1082	lectin A (LA) agglutination activity	1047:1082	lectin A (LA) agglutination activity	1047:1082	While lectin A (LA) agglutination activity was best in the presence of magnesium, lectin B (LB) was best with calcium.
36385669	11	61	theme	extended	1730:1737	arg1	part					1739:1742	an extended part	1727:1742	an extended part of their surface, which could lead new strategies to explain their biological activity	1727:1829	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	3	62	theme	carbohydrate	635:646	arg1	composition					648:658	their carbohydrate composition	629:658	their carbohydrate composition	629:658	After purification, to release the N-glycans, they were digested with the endoglycosidases PNGase and Glycanase A. Fractions resulted from the hydrolysis products were analyzed to determine their carbohydrate composition.
36385669	11	63	theme	other	1600:1604	arg1	hand					1606:1609	the other hand	1596:1609	the other hand	1596:1609	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	1	64	theme	lectins	224:230	arg1	isoforms					212:219	the two most abundant isoforms	190:219	the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells	190:373	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
36385669	0	65	with	docking	52:58	arg1	cancer					65:70	cancer	65:70	cancer	65:70	Comparative study, homology modelling and molecular docking with cancer associated glycans of two non-fetuin-binding Tepary bean lectins.
36385669	11	66	theme	surface	1753:1759	arg1	part					1739:1742	an extended part	1727:1742	an extended part of their surface, which could lead new strategies to explain their biological activity	1727:1829	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	9	67	theme	small	1260:1264	arg1	differences					1266:1276	small differences	1260:1276	small differences in their properties	1260:1296	Although both lectins showed small differences in their properties, an identical structure-model for both lectins was generated by the homology modelling process.
36385669	3	68	theme	endoglycosidases	513:528	arg1	PNGase					530:535	the endoglycosidases PNGase	509:535	the endoglycosidases PNGase	509:535	After purification, to release the N-glycans, they were digested with the endoglycosidases PNGase and Glycanase A. Fractions resulted from the hydrolysis products were analyzed to determine their carbohydrate composition.
36385669	8	69	theme	type-A	1210:1215	arg1	erythrocytes					1217:1228	human type-A erythrocytes	1204:1228	human type-A erythrocytes	1204:1228	Additionally, only LA exhibited affinity to human type-A erythrocytes.
36385669	11	70	theme	biological	1811:1820	arg1	activity					1822:1829	their biological activity	1805:1829	their biological activity	1805:1829	Molecular docking with colon adenocarcinoma associated-N-glycans revealed some highly possible interactions and, on the other hand, that N-glycan interaction zones of Tepary bean lectins is not restricted to the carbohydrate binding domain but to an extended part of their surface, which could lead new strategies to explain their biological activity.
36385669	9	71	from	differences	1266:1276	arg1	properties					1287:1296	their properties	1281:1296	their properties	1281:1296	Although both lectins showed small differences in their properties, an identical structure-model for both lectins was generated by the homology modelling process.
36385669	6	72	theme	metal	937:941	arg1	requirement					943:953	their metal requirement to preserve their biological activity	931:991	their metal requirement to preserve their biological activity	931:991	When their metal requirement to preserve their biological activity was determined, the lectins showed differences.
36385669	8	73	theme	only	1174:1177	arg1	LA					1179:1180	only LA	1174:1180	only LA	1174:1180	Additionally, only LA exhibited affinity to human type-A erythrocytes.
36385669	9	74	theme	modelling	1375:1383	arg1	process					1385:1391	the homology modelling process	1362:1391	the homology modelling process	1362:1391	Although both lectins showed small differences in their properties, an identical structure-model for both lectins was generated by the homology modelling process.
36385669	1	75	theme	Tepary	246:251	arg1	seeds					282:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	Tepary bean (Phaseolus acutifolius) seeds	246:286	We present the purification and characterization of the two most abundant isoforms of lectins isolated from Tepary bean (Phaseolus acutifolius) seeds, which have been shown to differentially affect the survival of different cancer cells.
35253441	4	0	theme	different	656:664	arg1	samples					666:672	different samples	656:672	different samples	656:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	1	located	located	679:685	arg2	located					679:685	located	679:685	located	679:685	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	1	located	located	679:685	arg2	sites					626:630	the glycation sites	612:630	the glycation sites with the highest DSP in different samples	612:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	1	located	located	679:685	arg1	region					709:714	the irregular coil region	690:714	the irregular coil region of OVA	690:721	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	1	located	located	679:685	arg1	addition					602:609	addition	602:609	addition	602:609	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	7	2	theme	theoretical	1125:1135	arg1	reference					1137:1145	a theoretical reference	1123:1145	a theoretical reference for the use of different sugars in food production	1123:1196	These findings would provide a theoretical reference for the use of different sugars in food production.
35253441	4	3	from	DSP	649:651	arg1	samples					666:672	different samples	656:672	different samples	656:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	0	4	theme	Liquid	96:101	arg1	Spectrometry					139:150	Liquid Chromatography-High-Resolution Mass Spectrometry	96:150	Liquid Chromatography-High-Resolution Mass Spectrometry	96:150	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	0	5	from	Analysis	0:7	arg1	Ovalbumin					46:54	Ovalbumin	46:54	Ovalbumin	46:54	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	2	6	theme	groups	285:290	arg1	number					264:269	The number	260:269	The number of free amino groups of OVA modified with different disaccharides	260:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	6	7	theme	disaccharide	935:946	arg1	efficiency					908:917	the glycation efficiency	894:917	the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond	894:979	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	6	7	theme	disaccharide	935:946	arg1	higher					985:990	higher	985:990	higher	985:990	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	4	8	theme	irregular	694:702	arg1	region					709:714	the irregular coil region	690:714	the irregular coil region of OVA	690:721	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	0	9	from	Ovalbumin	46:54	arg1	Analysis					0:7	Analysis	0:7	Analysis of the Structure and Antigenicity in Ovalbumin	0:54	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	2	10	theme	amino	279:283	arg1	OVA					295:297	OVA	295:297	OVA modified with different disaccharides	295:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	2	10	theme	amino	279:283	arg1	groups					285:290	free amino groups	274:290	free amino groups of OVA modified with different disaccharides	274:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	6	11	theme	reducing	926:933	arg1	disaccharide					935:946	the reducing disaccharide	922:946	the reducing disaccharide linked by a 1 → 6 glycoside bond	922:979	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	0	12	theme	Mass	134:137	arg1	Spectrometry					139:150	Liquid Chromatography-High-Resolution Mass Spectrometry	96:150	Liquid Chromatography-High-Resolution Mass Spectrometry	96:150	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	6	13	theme	→	1009:1009	arg1	bond					1023:1026	a 1 → 4 glycoside bond	1005:1026	a 1 → 4 glycoside bond	1005:1026	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	2	14	theme	free	274:277	arg1	OVA					295:297	OVA	295:297	OVA modified with different disaccharides	295:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	2	14	theme	free	274:277	arg1	groups					285:290	free amino groups	274:290	free amino groups of OVA modified with different disaccharides	274:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	0	15	theme	Chromatography-High-Resolution	103:132	arg1	Spectrometry					139:150	Liquid Chromatography-High-Resolution Mass Spectrometry	96:150	Liquid Chromatography-High-Resolution Mass Spectrometry	96:150	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	0	16	from	Antigenicity	30:41	arg1	Ovalbumin					46:54	Ovalbumin	46:54	Ovalbumin	46:54	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	4	17	from	region	709:714	arg1	sites					626:630	the glycation sites	612:630	the glycation sites with the highest DSP in different samples	612:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	17	from	region	709:714	arg1	located					679:685	located	679:685	located	679:685	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	3	18	theme	OVA	528:530	arg1	epitopes					516:523	the sensitized epitopes	501:523	the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA	501:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	4	19	theme	glycation	616:624	arg1	sites					626:630	the glycation sites	612:630	the glycation sites with the highest DSP in different samples	612:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	19	theme	glycation	616:624	arg1	located					679:685	located	679:685	located	679:685	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	7	20	from	use	1155:1157	arg1	production					1187:1196	food production	1182:1196	food production	1182:1196	These findings would provide a theoretical reference for the use of different sugars in food production.
35253441	3	21	theme	binding	551:557	arg1	ability					559:565	the binding ability	547:565	the binding ability of IgG and IgE of glycated OVA	547:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	5	22	theme	glycation	757:765	arg1	obvious					815:821	obvious	815:821	obvious	815:821	Among the six disaccharides, the glycation reaction between melibiose and OVA was the most obvious.
35253441	5	22	theme	glycation	757:765	arg1	reaction					767:774	the glycation reaction	753:774	the glycation reaction between melibiose and OVA	753:800	Among the six disaccharides, the glycation reaction between melibiose and OVA was the most obvious.
35253441	6	23	theme	β	1053:1053	arg1	type					1055:1058	β type	1053:1058	β type	1053:1058	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	2	24	theme	tertiary	370:377	arg1	structures					379:388	the secondary and tertiary structures	352:388	the secondary and tertiary structures of the modified OVA	352:408	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	0	25	theme	Structure	16:24	arg1	Analysis					0:7	Analysis	0:7	Analysis of the Structure and Antigenicity in Ovalbumin	0:54	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	2	26	theme	OVA	295:297	arg1	OVA					295:297	OVA	295:297	OVA modified with different disaccharides	295:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	2	26	theme	OVA	295:297	arg1	groups					285:290	free amino groups	274:290	free amino groups of OVA modified with different disaccharides	274:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	7	27	theme	food	1182:1185	arg1	production					1187:1196	food production	1182:1196	food production	1182:1196	These findings would provide a theoretical reference for the use of different sugars in food production.
35253441	6	28	dep	higher	985:990	arg1	better					1064:1069	better	1064:1069	better	1064:1069	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	4	29	theme	coil	704:707	arg1	region					709:714	the irregular coil region	690:714	the irregular coil region of OVA	690:721	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	30	from	addition	602:609	arg1	sites					626:630	the glycation sites	612:630	the glycation sites with the highest DSP in different samples	612:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	30	from	addition	602:609	arg1	located					679:685	located	679:685	located	679:685	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	6	31	theme	glycoside	1013:1021	arg1	bond					1023:1026	a 1 → 4 glycoside bond	1005:1026	a 1 → 4 glycoside bond	1005:1026	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	0	32	theme	Antigenicity	30:41	arg1	Analysis					0:7	Analysis	0:7	Analysis of the Structure and Antigenicity in Ovalbumin	0:54	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	6	33	theme	glycation	898:906	arg1	efficiency					908:917	the glycation efficiency	894:917	the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond	894:979	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	6	33	theme	glycation	898:906	arg1	higher					985:990	higher	985:990	higher	985:990	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	7	34	theme	sugars	1172:1177	arg1	use					1155:1157	the use	1151:1157	the use of different sugars in food production	1151:1196	These findings would provide a theoretical reference for the use of different sugars in food production.
35253441	2	35	theme	OVA	406:408	arg1	structures					379:388	the secondary and tertiary structures	352:388	the secondary and tertiary structures of the modified OVA	352:408	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	4	36	with	sites	626:630	arg1	DSP					649:651	the highest DSP	637:651	the highest DSP in different samples	637:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	3	37	theme	IgE	578:580	arg1	ability					559:565	the binding ability	547:565	the binding ability of IgG and IgE of glycated OVA	547:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	2	38	theme	modified	397:404	arg1	OVA					406:408	the modified OVA	393:408	the modified OVA	393:408	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	6	39	with	sugar	1042:1046	arg1	type					1055:1058	β type	1053:1058	β type	1053:1058	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	6	40	theme	glycoside	966:974	arg1	bond					976:979	a 1 → 6 glycoside bond	958:979	a 1 → 6 glycoside bond	958:979	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	6	41	theme	disaccharide	848:859	arg1	configuration					861:873	disaccharide configuration	848:873	disaccharide configuration	848:873	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	6	42	theme	configuration	861:873	arg1	analysis					836:843	the analysis	832:843	the analysis of disaccharide configuration	832:873	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	3	43	theme	IgG	570:572	arg1	ability					559:565	the binding ability	547:565	the binding ability of IgG and IgE of glycated OVA	547:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	7	44	theme	different	1162:1170	arg1	sugars					1172:1177	different sugars	1162:1177	different sugars	1162:1177	These findings would provide a theoretical reference for the use of different sugars in food production.
35253441	3	45	theme	OVA	594:596	arg1	ability					559:565	the binding ability	547:565	the binding ability of IgG and IgE of glycated OVA	547:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	0	46	dep	Structure	16:24	arg1	the					12:14	the	12:14	the	12:14	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	4	47	theme	highest	641:647	arg1	DSP					649:651	the highest DSP	637:651	the highest DSP in different samples	637:672	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	48	from	located	679:685	arg1	region					709:714	the irregular coil region	690:714	the irregular coil region of OVA	690:721	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	48	from	located	679:685	arg1	addition					602:609	addition	602:609	addition	602:609	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	4	49	theme	OVA	719:721	arg1	region					709:714	the irregular coil region	690:714	the irregular coil region of OVA	690:721	In addition, the glycation sites with the highest DSP in different samples were located in the irregular coil region of OVA.
35253441	2	50	theme	different	313:321	arg1	disaccharides					323:335	different disaccharides	313:335	different disaccharides	313:335	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
35253441	6	51	theme	→	962:962	arg1	bond					976:979	a 1 → 6 glycoside bond	958:979	a 1 → 6 glycoside bond	958:979	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	3	52	theme	glycation	446:454	arg1	all					494:496	all	494:496	all	494:496	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	3	52	theme	glycation	446:454	arg1	sites					456:460	the glycation sites	442:460	the glycation sites detected by HPLC-HCD-MS/MS	442:487	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	6	53	theme	α	1086:1086	arg1	type					1088:1091	α type	1086:1091	α type	1086:1091	Through the analysis of disaccharide configuration, it was found that the glycation efficiency of the reducing disaccharide linked by a 1 → 6 glycoside bond was higher than that by a 1 → 4 glycoside bond, and reducing sugar with β type was better than that with α type.
35253441	3	54	theme	sensitized	505:514	arg1	epitopes					516:523	the sensitized epitopes	501:523	the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA	501:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	0	55	from	Structure	16:24	arg1	Ovalbumin					46:54	Ovalbumin	46:54	Ovalbumin	46:54	Analysis of the Structure and Antigenicity in Ovalbumin Modified with Six Disaccharides Through Liquid Chromatography-High-Resolution Mass Spectrometry.
35253441	3	56	theme	glycated	585:592	arg1	OVA					594:596	glycated OVA	585:596	glycated OVA	585:596	Moreover, the glycation sites detected by HPLC-HCD-MS/MS were all on the sensitized epitopes of OVA, which reduced the binding ability of IgG and IgE of glycated OVA.
35253441	2	57	theme	secondary	356:364	arg1	structures					379:388	the secondary and tertiary structures	352:388	the secondary and tertiary structures of the modified OVA	352:408	The number of free amino groups of OVA modified with different disaccharides decreased, and the secondary and tertiary structures of the modified OVA also changed greatly.
36463509	7	0	theme	spectrometry-based	1708:1725	arg1	analysis					1734:1741	spectrometry-based glycan analysis	1708:1741	spectrometry-based glycan analysis	1708:1741	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	1	theme	liquid	1630:1635	arg1	spectrometry					1657:1668	automated liquid chromatography-mass spectrometry	1620:1668	automated liquid chromatography-mass spectrometry	1620:1668	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	2	from	characterization	1796:1811	arg1	biopharmaceuticals					1830:1847	biopharmaceuticals	1830:1847	biopharmaceuticals	1830:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	3	theme	chromatography-tandem	1681:1701	arg1	mass					1703:1706	liquid chromatography-tandem mass	1674:1706	liquid chromatography-tandem mass	1674:1706	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	4	gly	glycoforms	1816:1825	arg2	biopharmaceuticals					1830:1847	biopharmaceuticals	1830:1847	biopharmaceuticals	1830:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	6	5	theme	glycan	1351:1356	arg1	structures					1358:1367	additional glycan structures	1340:1367	additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1340:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	6	6	theme	based	1466:1470	arg1	analysis					1472:1479	conventional liquid chromatography-tandem mass spectrometry based analysis	1406:1479	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	7	7	theme	analytical	1593:1602	arg1	capabilities					1604:1615	pivotal analytical capabilities	1585:1615	pivotal analytical capabilities	1585:1615	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	4	8	theme	chromatography-tandem	748:768	arg1	spectrometry					775:786	liquid chromatography-tandem mass spectrometry	741:786	liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	741:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	6	9	theme	mass	1448:1451	arg1	spectrometry					1453:1464	conventional liquid chromatography-tandem mass spectrometry	1406:1464	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	5	10	theme	protein	994:1000	arg1	biosimilar					1002:1011	Fc-fusion protein biosimilar	984:1011	Fc-fusion protein biosimilar	984:1011	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	11	theme	chromatography-tandem	1426:1446	arg1	spectrometry					1453:1464	conventional liquid chromatography-tandem mass spectrometry	1406:1464	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	12	theme	glycan	719:724	arg1	analysis					726:733	released glycan analysis	710:733	released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	710:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	5	13	theme	additional	959:968	arg1	glycoforms					970:979	eight additional glycoforms	953:979	eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule	953:1136	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	14	theme	conventional	1406:1417	arg1	spectrometry					1453:1464	conventional liquid chromatography-tandem mass spectrometry	1406:1464	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	15	theme	mass	812:815	arg1	analysis					836:843	conventional mass spectrometry-based analysis	799:843	liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	741:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	2	16	theme	comprehensive	283:295	arg1	characterization					297:312	comprehensive characterization	283:312	comprehensive characterization of glycans	283:323	Thus, bioinformatics tools capable of performing comprehensive characterization of glycans are significantly important to the biopharma industry.
36463509	5	17	theme	mass	1045:1048	arg1	analysis					1063:1070	mass spectrometry analysis	1045:1070	mass spectrometry analysis of released glycans	1045:1090	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	0	18	theme	automated	73:81	arg1	tool					99:102	an automated data processing tool	70:102	an automated data processing tool	70:102	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan®.
36463509	3	19	from	tricky	453:458	arg1	terms					475:479	terms	475:479	terms of spectral interpretation	475:506	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	5	20	from	glycoforms	970:979	arg1	biosimilar					1002:1011	Fc-fusion protein biosimilar	984:1011	Fc-fusion protein biosimilar	984:1011	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	1	21	theme	biopharmaceuticals	165:182	arg1	properties					151:160	The therapeutic and immunological properties	117:160	The therapeutic and immunological properties of biopharmaceuticals	117:182	The therapeutic and immunological properties of biopharmaceuticals are governed by the glycoforms contained in them.
36463509	0	22	theme	processing	88:97	arg1	tool					99:102	an automated data processing tool	70:102	an automated data processing tool	70:102	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan®.
36463509	3	23	from	tedious	464:470	arg1	terms					475:479	terms	475:479	terms of spectral interpretation	475:506	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	4	24	theme	monoclonal	557:566	arg1	antibody					568:575	a therapeutic monoclonal antibody	543:575	a therapeutic monoclonal antibody	543:575	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	3	25	theme	structural	392:401	arg1	elucidation					403:413	The primary structural elucidation	380:413	The primary structural elucidation of glycans using mass spectrometry	380:448	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	3	25	theme	structural	392:401	arg1	tricky					453:458	tricky	453:458	tricky	453:458	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	7	26	theme	processing	1517:1526	arg1	Byos™					1547:1551	Byos™	1547:1551	Byos™	1547:1551	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	26	theme	processing	1517:1526	arg1	tools					1528:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	3	27	theme	spectral	484:491	arg1	interpretation					493:506	spectral interpretation	484:506	spectral interpretation	484:506	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	4	28	gly	glycosylation	626:638	arg1	protein					594:600	an Fc-fusion protein	581:600	an Fc-fusion protein with moderate and heavy glycosylation	581:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	4	28	gly	glycosylation	626:638	arg1	antibody					568:575	a therapeutic monoclonal antibody	543:575	a therapeutic monoclonal antibody	543:575	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	6	29	theme	glycans	1213:1219	arg1	analysis					1192:1199	liquid chromatography-tandem mass spectrometry analysis	1145:1199	liquid chromatography-tandem mass spectrometry analysis of released glycans	1145:1219	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	5	30	theme	released	1075:1082	arg1	glycans					1084:1090	released glycans	1075:1090	released glycans	1075:1090	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	31	theme	spectrometry	1179:1190	arg1	analysis					1192:1199	liquid chromatography-tandem mass spectrometry analysis	1145:1199	liquid chromatography-tandem mass spectrometry analysis of released glycans	1145:1219	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	7	32	theme	mass	1494:1497	arg1	Byos™					1547:1551	Byos™	1547:1551	Byos™	1547:1551	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	32	theme	mass	1494:1497	arg1	tools					1528:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	0	33	theme	biopharmaceuticals	42:59	arg1	glycoprofiling					24:37	Mass spectrometry-based glycoprofiling	0:37	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool	0:102	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan®.
36463509	7	34	dep	spectrometry	1657:1668	arg1	analysis					1734:1741	spectrometry-based glycan analysis	1708:1741	spectrometry-based glycan analysis	1708:1741	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	35	theme	high-throughput	1769:1783	arg1	characterization					1796:1811	high-throughput structural characterization	1769:1811	high-throughput structural characterization of glycoforms in biopharmaceuticals	1769:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	36	theme	spectrometry	1499:1510	arg1	Byos™					1547:1551	Byos™	1547:1551	Byos™	1547:1551	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	36	theme	spectrometry	1499:1510	arg1	tools					1528:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	4	37	with	antibody	568:575	arg1	glycosylation					626:638	moderate and heavy glycosylation	607:638	moderate and heavy glycosylation	607:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	5	38	theme	MS	909:910	arg1	data					912:915	tandem MS data	902:915	tandem MS data for released glycans	902:936	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	39	theme	glycan	1301:1306	arg1	profiling					1308:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	40	theme	Fc-fusion	584:592	arg1	protein					594:600	an Fc-fusion protein	581:600	an Fc-fusion protein with moderate and heavy glycosylation	581:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	7	41	theme	automated	1620:1628	arg1	spectrometry					1657:1668	automated liquid chromatography-mass spectrometry	1620:1668	automated liquid chromatography-mass spectrometry	1620:1668	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	6	42	theme	chromatography-mass	1262:1280	arg1	profiling					1308:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	6	43	theme	chromatography-tandem	1152:1172	arg1	spectrometry					1179:1190	liquid chromatography-tandem mass spectrometry	1145:1190	liquid chromatography-tandem mass spectrometry analysis of released glycans	1145:1219	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	7	44	theme	glycan	1727:1732	arg1	analysis					1734:1741	spectrometry-based glycan analysis	1708:1741	spectrometry-based glycan analysis	1708:1741	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	5	45	theme	molecule	1129:1136	arg1	analysis					1063:1070	mass spectrometry analysis	1045:1070	mass spectrometry analysis of released glycans	1045:1090	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	5	45	theme	molecule	1129:1136	arg1	mapping					1109:1115	glyco-peptide mapping	1095:1115	glyco-peptide mapping of the same molecule	1095:1136	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	46	theme	conventional	1242:1253	arg1	profiling					1308:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	7	47	theme	mass	1703:1706	arg1	workflows					1743:1751	automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows	1620:1751	automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows	1620:1751	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	5	48	gly	glycoforms	970:979	arg2	biosimilar					1002:1011	Fc-fusion protein biosimilar	984:1011	Fc-fusion protein biosimilar	984:1011	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	49	theme	mAbs	1484:1487	arg1	analysis					1472:1479	conventional liquid chromatography-tandem mass spectrometry based analysis	1406:1479	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	50	with	protein	594:600	arg1	glycosylation					626:638	moderate and heavy glycosylation	607:638	moderate and heavy glycosylation	607:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	7	51	theme	liquid	1674:1679	arg1	mass					1703:1706	liquid chromatography-tandem mass	1674:1706	liquid chromatography-tandem mass	1674:1706	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	52	theme	chromatography-mass	1637:1655	arg1	spectrometry					1657:1668	automated liquid chromatography-mass spectrometry	1620:1668	automated liquid chromatography-mass spectrometry	1620:1668	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	2	53	theme	glycans	317:323	arg1	characterization					297:312	comprehensive characterization	283:312	comprehensive characterization of glycans	283:323	Thus, bioinformatics tools capable of performing comprehensive characterization of glycans are significantly important to the biopharma industry.
36463509	7	54	theme	spectrometry	1657:1668	arg1	workflows					1743:1751	automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows	1620:1751	automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows	1620:1751	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	6	55	theme	additional	1340:1349	arg1	structures					1358:1367	additional glycan structures	1340:1367	additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1340:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	6	56	theme	spectrometry	1453:1464	arg1	analysis					1472:1479	conventional liquid chromatography-tandem mass spectrometry based analysis	1406:1479	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	2	57	theme	biopharma	360:368	arg1	industry					370:377	the biopharma industry	356:377	the biopharma industry	356:377	Thus, bioinformatics tools capable of performing comprehensive characterization of glycans are significantly important to the biopharma industry.
36463509	5	58	theme	Fc-fusion	984:992	arg1	biosimilar					1002:1011	Fc-fusion protein biosimilar	984:1011	Fc-fusion protein biosimilar	984:1011	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	4	59	theme	liquid	741:746	arg1	spectrometry					775:786	liquid chromatography-tandem mass spectrometry	741:786	liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	741:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	5	60	dep	ability	883:889	arg1	process					894:900	process	894:900	to process tandem MS data for released glycans	891:936	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	7	61	theme	pivotal	1585:1591	arg1	capabilities					1604:1615	pivotal analytical capabilities	1585:1615	pivotal analytical capabilities	1585:1615	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	2	62	theme	capable	261:267	arg1	tools					255:259	bioinformatics tools	240:259	bioinformatics tools capable of performing comprehensive characterization of glycans	240:323	Thus, bioinformatics tools capable of performing comprehensive characterization of glycans are significantly important to the biopharma industry.
36463509	6	63	theme	liquid	1419:1424	arg1	spectrometry					1453:1464	conventional liquid chromatography-tandem mass spectrometry	1406:1464	conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs	1406:1487	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	64	theme	released	710:717	arg1	analysis					726:733	released glycan analysis	710:733	released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	710:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	2	65	theme	bioinformatics	240:253	arg1	tools					255:259	bioinformatics tools	240:259	bioinformatics tools capable of performing comprehensive characterization of glycans	240:323	Thus, bioinformatics tools capable of performing comprehensive characterization of glycans are significantly important to the biopharma industry.
36463509	1	66	theme	therapeutic	121:131	arg1	properties					151:160	The therapeutic and immunological properties	117:160	The therapeutic and immunological properties of biopharmaceuticals	117:182	The therapeutic and immunological properties of biopharmaceuticals are governed by the glycoforms contained in them.
36463509	4	67	theme	conventional	799:810	arg1	analysis					836:843	conventional mass spectrometry-based analysis	799:843	liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	741:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	1	68	theme	immunological	137:149	arg1	properties					151:160	The therapeutic and immunological properties	117:160	The therapeutic and immunological properties of biopharmaceuticals	117:182	The therapeutic and immunological properties of biopharmaceuticals are governed by the glycoforms contained in them.
36463509	6	69	theme	liquid	1145:1150	arg1	spectrometry					1179:1190	liquid chromatography-tandem mass spectrometry	1145:1190	liquid chromatography-tandem mass spectrometry analysis of released glycans	1145:1219	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	70	theme	spectrometry-based	817:834	arg1	analysis					836:843	conventional mass spectrometry-based analysis	799:843	liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	741:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	0	71	theme	data	83:86	arg1	tool					99:102	an automated data processing tool	70:102	an automated data processing tool	70:102	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan®.
36463509	3	72	theme	primary	384:390	arg1	elucidation					403:413	The primary structural elucidation	380:413	The primary structural elucidation of glycans using mass spectrometry	380:448	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	3	72	theme	primary	384:390	arg1	tricky					453:458	tricky	453:458	tricky	453:458	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	4	73	theme	therapeutic	545:555	arg1	antibody					568:575	a therapeutic monoclonal antibody	543:575	a therapeutic monoclonal antibody	543:575	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	4	74	theme	mass	770:773	arg1	spectrometry					775:786	liquid chromatography-tandem mass spectrometry	741:786	liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis	741:843	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	5	75	theme	proven	876:881	arg1	ability					883:889	proven ability	876:889	proven ability to process tandem MS data for released glycans	876:936	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	4	76	theme	antibody	568:575	arg1	biosimilars					528:538	the biosimilars	524:538	the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation	524:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	4	76	theme	antibody	568:575	arg1	biopharmaceuticals					687:704	representative biopharmaceuticals	672:704	representative biopharmaceuticals	672:704	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	5	77	theme	glycans	1084:1090	arg1	analysis					1063:1070	mass spectrometry analysis	1045:1070	mass spectrometry analysis of released glycans	1045:1090	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	5	77	theme	glycans	1084:1090	arg1	mapping					1109:1115	glyco-peptide mapping	1095:1115	glyco-peptide mapping of the same molecule	1095:1136	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	7	78	theme	glycoforms	1816:1825	arg1	characterization					1796:1811	high-throughput structural characterization	1769:1811	high-throughput structural characterization of glycoforms in biopharmaceuticals	1769:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	3	79	theme	glycans	418:424	arg1	elucidation					403:413	The primary structural elucidation	380:413	The primary structural elucidation of glycans using mass spectrometry	380:448	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	3	79	theme	glycans	418:424	arg1	tricky					453:458	tricky	453:458	tricky	453:458	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	5	80	theme	glyco-peptide	1095:1107	arg1	mapping					1109:1115	glyco-peptide mapping	1095:1115	glyco-peptide mapping of the same molecule	1095:1136	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	3	81	theme	interpretation	493:506	arg1	terms					475:479	terms	475:479	terms of spectral interpretation	475:506	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	0	82	theme	spectrometry-based	5:22	arg1	glycoprofiling					24:37	Mass spectrometry-based glycoprofiling	0:37	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool	0:102	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan®.
36463509	5	83	theme	spectrometry	1050:1061	arg1	analysis					1063:1070	mass spectrometry analysis	1045:1070	mass spectrometry analysis of released glycans	1045:1090	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	84	theme	released	1204:1211	arg1	glycans					1213:1219	released glycans	1204:1219	released glycans	1204:1219	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	85	theme	moderate	607:614	arg1	glycosylation					626:638	moderate and heavy glycosylation	607:638	moderate and heavy glycosylation	607:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	5	86	theme	released	921:928	arg1	glycans					930:936	released glycans	921:936	released glycans	921:936	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	7	87	from	glycoforms	1816:1825	arg1	biopharmaceuticals					1830:1847	biopharmaceuticals	1830:1847	biopharmaceuticals	1830:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	88	theme	data	1512:1515	arg1	Byos™					1547:1551	Byos™	1547:1551	Byos™	1547:1551	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	7	88	theme	data	1512:1515	arg1	tools					1528:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools	1490:1532	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	3	89	theme	mass	432:435	arg1	spectrometry					437:448	mass spectrometry	432:448	mass spectrometry	432:448	The primary structural elucidation of glycans using mass spectrometry is tricky and tedious in terms of spectral interpretation.
36463509	4	90	theme	heavy	620:624	arg1	glycosylation					626:638	moderate and heavy glycosylation	607:638	moderate and heavy glycosylation	607:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	0	91	dep	SimGlycan®	105:114	arg1	glycoprofiling					24:37	Mass spectrometry-based glycoprofiling	0:37	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool	0:102	Mass spectrometry-based glycoprofiling of biopharmaceuticals by using an automated data processing tool: SimGlycan®.
36463509	7	92	from	biopharmaceuticals	1830:1847	arg1	characterization					1796:1811	high-throughput structural characterization	1769:1811	high-throughput structural characterization of glycoforms in biopharmaceuticals	1769:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	6	93	theme	mass	1174:1177	arg1	spectrometry					1179:1190	liquid chromatography-tandem mass spectrometry	1145:1190	liquid chromatography-tandem mass spectrometry analysis of released glycans	1145:1219	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	5	94	theme	tandem	902:907	arg1	data					912:915	tandem MS data	902:915	tandem MS data for released glycans	902:936	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	7	95	theme	structural	1785:1794	arg1	characterization					1796:1811	high-throughput structural characterization	1769:1811	high-throughput structural characterization of glycoforms in biopharmaceuticals	1769:1847	The mass spectrometry data processing tools, such as PMI Byos™, SimGlycan® , etc., can display pivotal analytical capabilities in automated liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry-based glycan analysis workflows, especially for high-throughput structural characterization of glycoforms in biopharmaceuticals.
36463509	4	96	theme	protein	594:600	arg1	biosimilars					528:538	the biosimilars	524:538	the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation	524:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	4	96	theme	protein	594:600	arg1	biopharmaceuticals					687:704	representative biopharmaceuticals	672:704	representative biopharmaceuticals	672:704	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	6	97	theme	spectrometry-based	1282:1299	arg1	profiling					1308:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	5	98	theme	same	1124:1127	arg1	molecule					1129:1136	the same molecule	1120:1136	the same molecule	1120:1136	SimGlycan® is a software with proven ability to process tandem MS data for released glycans could identify eight additional glycoforms in Fc-fusion protein biosimilar, which were not detected during mass spectrometry analysis of released glycans or glyco-peptide mapping of the same molecule.
36463509	6	99	theme	liquid	1255:1260	arg1	profiling					1308:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	conventional liquid chromatography-mass spectrometry-based glycan profiling	1242:1316	Thus, liquid chromatography-tandem mass spectrometry analysis of released glycans not only complements conventional liquid chromatography-mass spectrometry-based glycan profiling but can also identify additional glycan structures that may otherwise be omitted during conventional liquid chromatography-tandem mass spectrometry based analysis of mAbs.
36463509	4	100	theme	representative	672:685	arg1	biosimilars					528:538	the biosimilars	524:538	the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation	524:638	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
36463509	4	100	theme	representative	672:685	arg1	biopharmaceuticals					687:704	representative biopharmaceuticals	672:704	representative biopharmaceuticals	672:704	In this study, the biosimilars of a therapeutic monoclonal antibody and an Fc-fusion protein with moderate and heavy glycosylation, respectively, were employed as representative biopharmaceuticals for released glycan analysis using liquid chromatography-tandem mass spectrometry instead of conventional mass spectrometry-based analysis.
35483848	0	0	theme	complexity	71:80	arg1	subunits					47:54	subunits	47:54	subunits of high branch complexity with slow gut microbiota fermentation	47:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	2	1	theme	molecular	455:463	arg1	analysis					470:477	molecular size analysis	455:477	molecular size analysis	455:477	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	2	2	theme	repeating	565:573	arg1	subunit					586:592	a repeating structural subunit	563:592	a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity	563:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	2	3	theme	complexity	688:697	arg1	regions					672:678	regions	672:678	regions of less complexity	672:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	4	4	theme	branch	994:999	arg1	complexity					1001:1010	higher branch complexity	987:1010	higher branch complexity	987:1010	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	3	5	theme	slow	793:796	arg1	property					811:818	enhanced slow fermentation property	784:818	enhanced slow fermentation property	784:818	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	0	6	theme	branch	64:69	arg1	complexity					71:80	high branch complexity	59:80	high branch complexity	59:80	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	1	7	theme	fine	308:311	arg1	structure					313:321	fine structure	308:321	fine structure	308:321	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	3	8	theme	native	836:841	arg1	structure					843:851	the native structure	832:851	the native structure (3.3 vs. 5.9 mL gas, 4 h)	832:877	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	3	8	theme	native	836:841	arg1	related					889:895	related	889:895	related	889:895	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	3	9	theme	fermentation	798:809	arg1	property					811:818	enhanced slow fermentation property	784:818	enhanced slow fermentation property	784:818	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	0	10	theme	slow	87:90	arg1	fermentation					107:118	slow gut microbiota fermentation	87:118	slow gut microbiota fermentation	87:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	1	11	theme	structure	313:321	arg1	relationship					292:303	the relationship	288:303	the relationship of fine structure and fermentability	288:340	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	4	12	with	structures	971:980	arg1	complexity					1001:1010	higher branch complexity	987:1010	higher branch complexity	987:1010	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	4	13	theme	size	966:969	arg1	structures					971:980	Lower molecular size structures	950:980	Lower molecular size structures with higher branch complexity	950:1010	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	3	14	theme	structures	938:947	arg1	complexity					911:920	increasing complexity	900:920	increasing complexity of the branched structures	900:947	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	4	15	theme	small	1067:1071	arg1	structures					1079:1088	small fiber structures	1067:1088	small fiber structures approaching the oligosaccharide level	1067:1126	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	3	16	theme	enhanced	784:791	arg1	property					811:818	enhanced slow fermentation property	784:818	enhanced slow fermentation property	784:818	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	0	17	theme	microbiota	96:105	arg1	fermentation					107:118	slow gut microbiota fermentation	87:118	slow gut microbiota fermentation	87:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	1	18	theme	fermentability	327:340	arg1	relationship					292:303	the relationship	288:303	the relationship of fine structure and fermentability	288:340	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	19	link	wall-derived	153:164	arg1	arabinoxylan					126:137	Corn arabinoxylan	121:137	Corn arabinoxylan (CAX)	121:143	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	19	link	wall-derived	153:164	arg1	fiber					174:178	a cell wall-derived dietary fiber	146:178	a cell wall-derived dietary fiber	146:178	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	2	20	theme	branching	613:621	arg1	patterns					623:630	complex branching patterns	605:630	complex branching patterns along the xylan backbone	605:655	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	4	21	theme	fiber	1073:1077	arg1	structures					1079:1088	small fiber structures	1067:1088	small fiber structures approaching the oligosaccharide level	1067:1126	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	0	22	theme	gut	92:94	arg1	fermentation					107:118	slow gut microbiota fermentation	87:118	slow gut microbiota fermentation	87:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	0	23	contain	has	18:20	arg2	structure					34:42	a repeating structure	22:42	a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation	22:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	0	23	contain	has	18:20	arg1	arabinoxylan					5:16	Corn arabinoxylan	0:16	Corn arabinoxylan	0:16	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	2	24	theme	CAX	416:418	arg1	composition					380:390	Glycosyl composition	371:390	Glycosyl composition	371:390	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	2	24	theme	CAX	416:418	arg1	analysis					404:411	linkage analysis	396:411	linkage analysis	396:411	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	1	25	theme	cell	148:151	arg1	arabinoxylan					126:137	Corn arabinoxylan	121:137	Corn arabinoxylan (CAX)	121:143	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	25	theme	cell	148:151	arg1	fiber					174:178	a cell wall-derived dietary fiber	146:178	a cell wall-derived dietary fiber	146:178	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	2	26	dep	subunit	586:592	arg1	containing					594:603	containing	594:603	containing complex branching patterns along the xylan backbone	594:655	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	2	26	dep	subunit	586:592	arg1	flanked					661:667	flanked	661:667	flanked by regions of less complexity	661:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	3	27	dep	structure	843:851	arg1	gas					869:871	3.3 vs. 5.9 mL gas	854:871	3.3 vs. 5.9 mL gas	854:871	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	3	27	dep	structure	843:851	arg1	4 h					874:876	4 h	874:876	4 h	874:876	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	1	28	theme	wall-derived	153:164	arg1	arabinoxylan					126:137	Corn arabinoxylan	121:137	Corn arabinoxylan (CAX)	121:143	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	28	theme	wall-derived	153:164	arg1	fiber					174:178	a cell wall-derived dietary fiber	146:178	a cell wall-derived dietary fiber	146:178	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	0	29	theme	Corn	0:3	arg1	arabinoxylan					5:16	Corn arabinoxylan	0:16	Corn arabinoxylan	0:16	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	2	30	theme	structural	575:584	arg1	subunit					586:592	a repeating structural subunit	563:592	a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity	563:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	4	31	theme	molecular	956:964	arg1	structures					971:980	Lower molecular size structures	950:980	Lower molecular size structures with higher branch complexity	950:1010	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	2	32	theme	complex	605:611	arg1	patterns					623:630	complex branching patterns	605:630	complex branching patterns along the xylan backbone	605:655	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	1	33	theme	dietary	166:172	arg1	arabinoxylan					126:137	Corn arabinoxylan	121:137	Corn arabinoxylan (CAX)	121:143	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	33	theme	dietary	166:172	arg1	fiber					174:178	a cell wall-derived dietary fiber	146:178	a cell wall-derived dietary fiber	146:178	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	4	34	theme	higher	987:992	arg1	complexity					1001:1010	higher branch complexity	987:1010	higher branch complexity	987:1010	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	1	35	theme	hydrolytic	245:254	arg1	enzymes					256:262	hydrolytic enzymes	245:262	hydrolytic enzymes	245:262	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	2	36	theme	xylan	642:646	arg1	backbone					648:655	the xylan backbone	638:655	the xylan backbone	638:655	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	4	37	theme	conventional	1044:1055	arg1	view					1057:1060	a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented	1042:1165	a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented	1042:1165	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	2	38	theme	linkage	396:402	arg1	analysis					404:411	linkage analysis	396:411	linkage analysis	396:411	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	4	39	theme	oligosaccharide	1106:1120	arg1	level					1122:1126	the oligosaccharide level	1102:1126	the oligosaccharide level	1102:1126	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	1	40	theme	human	349:353	arg1	microbiota					359:368	the human gut microbiota	345:368	the human gut microbiota	345:368	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	2	41	theme	hydrolysates	428:439	arg1	composition					380:390	Glycosyl composition	371:390	Glycosyl composition	371:390	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	2	41	theme	hydrolysates	428:439	arg1	analysis					404:411	linkage analysis	396:411	linkage analysis	396:411	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	1	42	theme	gut	355:357	arg1	microbiota					359:368	the human gut microbiota	345:368	the human gut microbiota	345:368	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	0	43	theme	repeating	24:32	arg1	structure					34:42	a repeating structure	22:42	a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation	22:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	2	44	theme	structural	503:512	arg1	feature					514:520	an organized structural feature	490:520	an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity	490:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	3	45	contain	have	779:782	arg2	property					811:818	enhanced slow fermentation property	784:818	enhanced slow fermentation property	784:818	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	3	45	contain	have	779:782	arg1	lengths					708:714	The two lengths	700:714	The two lengths of the highly branched subunit	700:745	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	2	46	theme	Glycosyl	371:378	arg1	composition					380:390	Glycosyl composition	371:390	Glycosyl composition	371:390	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	0	47	theme	subunits	47:54	arg1	structure					34:42	a repeating structure	22:42	a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation	22:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	2	48	theme	organized	493:501	arg1	feature					514:520	an organized structural feature	490:520	an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity	490:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	3	49	theme	increasing	900:909	arg1	complexity					911:920	increasing complexity	900:920	increasing complexity of the branched structures	900:947	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	4	50	theme	Lower	950:954	arg1	structures					971:980	Lower molecular size structures	950:980	Lower molecular size structures with higher branch complexity	950:1010	Lower molecular size structures with higher branch complexity fermented slower, contrary to a conventional view that small fiber structures approaching the oligosaccharide level are necessarily more rapidly fermented.
35483848	3	51	theme	branched	730:737	arg1	subunit					739:745	the highly branched subunit	719:745	the highly branched subunit	719:745	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	3	52	theme	subunit	739:745	arg1	lengths					708:714	The two lengths	700:714	The two lengths of the highly branched subunit	700:745	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	2	53	theme	polymer	536:542	arg1	feature					514:520	an organized structural feature	490:520	an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity	490:697	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	1	54	theme	Corn	121:124	arg1	CAX					140:142	CAX	140:142	CAX	140:142	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	54	theme	Corn	121:124	arg1	arabinoxylan					126:137	Corn arabinoxylan	121:137	Corn arabinoxylan (CAX)	121:143	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	1	54	theme	Corn	121:124	arg1	fiber					174:178	a cell wall-derived dietary fiber	146:178	a cell wall-derived dietary fiber	146:178	Corn arabinoxylan (CAX), a cell wall-derived dietary fiber, was extracted with alkali, partially purified, and treated with hydrolytic enzymes in order to investigate the relationship of fine structure and fermentability by the human gut microbiota.
35483848	2	55	theme	native	529:534	arg1	polymer					536:542	the native polymer	525:542	the native polymer	525:542	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
35483848	0	56	with	subunits	47:54	arg1	fermentation					107:118	slow gut microbiota fermentation	87:118	slow gut microbiota fermentation	87:118	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	0	57	theme	high	59:62	arg1	complexity					71:80	high branch complexity	59:80	high branch complexity	59:80	Corn arabinoxylan has a repeating structure of subunits of high branch complexity with slow gut microbiota fermentation.
35483848	3	58	theme	branched	929:936	arg1	structures					938:947	the branched structures	925:947	the branched structures	925:947	The two lengths of the highly branched subunit were isolated and were shown to have enhanced slow fermentation property compared to the native structure (3.3 vs. 5.9 mL gas, 4 h), that was related to increasing complexity of the branched structures.
35483848	2	59	theme	size	465:468	arg1	analysis					470:477	molecular size analysis	455:477	molecular size analysis	455:477	Glycosyl composition and linkage analysis of CAX and two hydrolysates, coupled with molecular size analysis, indicated an organized structural feature of the native polymer, which consists of a repeating structural subunit containing complex branching patterns along the xylan backbone and flanked by regions of less complexity.
36068283	5	0	used	used	1254:1257	arg2	structures					1217:1226	candidate structures	1207:1226	candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products	1207:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	1	1	theme	monoclonal	173:182	arg1	mAbs					196:199	mAbs	196:199	mAbs	196:199	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	1	1	theme	monoclonal	173:182	arg1	antibodies					184:193	monoclonal antibodies	173:193	monoclonal antibodies (mAbs)	173:200	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	5	2	theme	α-galactosylated	1141:1156	arg1	glycans					1158:1164	α-galactosylated glycans	1141:1164	α-galactosylated glycans	1141:1164	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	2	3	contain	containing	269:278	arg1	glycans					261:267	non-human glycans	251:267	non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid	251:342	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	2	3	contain	containing	269:278	arg2	galactose-α1,3-galactose					289:312	terminal galactose-α1,3-galactose	280:312	terminal galactose-α1,3-galactose	280:312	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	2	3	contain	containing	269:278	arg2	acid					339:342	N-glycolylneuraminic acid	318:342	N-glycolylneuraminic acid	318:342	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	0	4	theme	drugs	88:92	arg1	structures					54:63	non-human glycan structures	37:63	non-human glycan structures of monoclonal antibody drugs	37:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	1	5	theme	antibodies	184:193	arg1	Glycosylation					130:142	Glycosylation	130:142	Glycosylation	130:142	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	1	5	theme	antibodies	184:193	arg1	attribute					160:168	an important attribute	147:168	an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality	147:236	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	5	6	theme	non-human	1106:1114	arg1	glycans					1116:1122	non-human glycans	1106:1122	non-human glycans	1106:1122	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	0	7	theme	mass	111:114	arg1	spectrometry					116:127	tandem mass spectrometry	104:127	tandem mass spectrometry	104:127	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	3	8	theme	non-human	718:726	arg1	glycans					728:734	low-abundance non-human glycans	704:734	low-abundance non-human glycans	704:734	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	4	9	theme	glycans	1049:1055	arg1	structures					1023:1032	branch-linkage structures	1008:1032	branch-linkage structures of biantennary glycans	1008:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	3	10	theme	sensitive	636:644	arg1	method					655:660	a highly sensitive LC MS/MS method	627:660	a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers	627:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	0	11	theme	tandem	104:109	arg1	spectrometry					116:127	tandem mass spectrometry	104:127	tandem mass spectrometry	104:127	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	5	12	theme	quality	1274:1280	arg1	control					1282:1288	the crucial quality control	1262:1288	the crucial quality control of therapeutic mAb products	1262:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	4	13	theme	fragments	878:886	arg1	use					822:824	the straightforward use	802:824	the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation	802:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	4	13	theme	fragments	878:886	arg1	approach					975:982	a universal approach	963:982	a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans	963:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	3	14	theme	porous	589:594	arg1	LC					613:614	porous graphitic carbon LC	589:614	porous graphitic carbon LC	589:614	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	4	15	theme	ions	855:858	arg1	use					822:824	the straightforward use	802:824	the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation	802:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	4	15	theme	ions	855:858	arg1	approach					975:982	a universal approach	963:982	a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans	963:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	4	16	theme	positive	898:905	arg1	dissociation					947:958	the positive ionization low-energy collision-induced dissociation	894:958	the positive ionization low-energy collision-induced dissociation	894:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	3	17	theme	glycopeptides	512:524	arg1	sequencing					489:498	parallel sequencing	480:498	parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC	480:614	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	3	18	theme	parallel	480:487	arg1	sequencing					489:498	parallel sequencing	480:498	parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC	480:614	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	2	19	theme	N-glycolylneuraminic	318:337	arg1	acid					339:342	N-glycolylneuraminic acid	318:342	N-glycolylneuraminic acid	318:342	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	5	20	theme	analytical	1185:1194	arg1	method					1196:1201	an analytical method	1182:1201	an analytical method	1182:1201	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	2	21	theme	mammalian	457:465	arg1	cells					467:471	non-human mammalian cells	447:471	non-human mammalian cells	447:471	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	0	22	theme	sensitive	7:15	arg1	characterization					17:32	Highly sensitive characterization	0:32	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs	0:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	5	23	theme	therapeutic	1293:1303	arg1	products					1309:1316	therapeutic mAb products	1293:1316	therapeutic mAb products	1293:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	4	24	theme	branch-linkage	1008:1021	arg1	structures					1023:1032	branch-linkage structures	1008:1032	branch-linkage structures of biantennary glycans	1008:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	2	25	theme	potential	368:376	arg1	immunogenicity					378:391	potential immunogenicity	368:391	potential immunogenicity	368:391	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	5	26	theme	structural	1082:1091	arg1	diversity					1093:1101	the structural diversity	1078:1101	the structural diversity of non-human glycans	1078:1122	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	2	27	theme	non-human	447:455	arg1	cells					467:471	non-human mammalian cells	447:471	non-human mammalian cells	447:471	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	4	28	theme	ionization	907:916	arg1	dissociation					947:958	the positive ionization low-energy collision-induced dissociation	894:958	the positive ionization low-energy collision-induced dissociation	894:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	2	29	from	expression	433:442	arg1	cells					467:471	non-human mammalian cells	447:471	non-human mammalian cells	447:471	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	2	30	dep	immunogenicity	378:391	arg1	the					364:366	the	364:366	the	364:366	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	3	31	theme	isobaric	503:510	arg1	glycopeptides					512:524	isobaric glycopeptides	503:524	isobaric glycopeptides	503:524	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	4	32	theme	diagnostic	844:853	arg1	ions					855:858	high-abundance diagnostic ions	829:858	high-abundance diagnostic ions	829:858	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	5	33	theme	crucial	1266:1272	arg1	control					1282:1288	the crucial quality control	1262:1288	the crucial quality control of therapeutic mAb products	1262:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	4	34	theme	complementary	864:876	arg1	fragments					878:886	complementary fragments	864:886	complementary fragments	864:886	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	3	35	theme	MS/MS	649:653	arg1	method					655:660	a highly sensitive LC MS/MS method	627:660	a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers	627:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	5	36	theme	products	1309:1316	arg1	control					1282:1288	the crucial quality control	1262:1288	the crucial quality control of therapeutic mAb products	1262:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	5	37	theme	glycans	1116:1122	arg1	sulfation					1128:1136	sulfation	1128:1136	sulfation of α-galactosylated glycans	1128:1164	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	5	37	theme	glycans	1116:1122	arg1	diversity					1093:1101	the structural diversity	1078:1101	the structural diversity of non-human glycans	1078:1122	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	3	38	theme	graphitic	596:604	arg1	LC					613:614	porous graphitic carbon LC	589:614	porous graphitic carbon LC	589:614	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	1	39	theme	manufacturing	216:228	arg1	quality					230:236	manufacturing quality	216:236	manufacturing quality	216:236	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	0	40	theme	glycan	47:52	arg1	structures					54:63	non-human glycan structures	37:63	non-human glycan structures of monoclonal antibody drugs	37:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	4	41	theme	straightforward	806:820	arg1	use					822:824	the straightforward use	802:824	the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation	802:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	4	41	theme	straightforward	806:820	arg1	approach					975:982	a universal approach	963:982	a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans	963:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	2	42	theme	glycans	261:267	arg1	Analysis					239:246	Analysis	239:246	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid	239:342	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	3	43	theme	isomeric	530:537	arg1	glycans					539:545	isomeric glycans	530:545	isomeric glycans	530:545	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	0	44	theme	non-human	37:45	arg1	structures					54:63	non-human glycan structures	37:63	non-human glycan structures of monoclonal antibody drugs	37:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	3	45	theme	glycans	728:734	arg1	characterization					684:699	the comprehensive characterization	666:699	the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers	666:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	2	46	theme	non-human	251:259	arg1	glycans					261:267	non-human glycans	251:267	non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid	251:342	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	3	47	theme	glycans	539:545	arg1	sequencing					489:498	parallel sequencing	480:498	parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC	480:614	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	5	48	theme	glycans	1158:1164	arg1	sulfation					1128:1136	sulfation	1128:1136	sulfation of α-galactosylated glycans	1128:1164	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	5	48	theme	glycans	1158:1164	arg1	diversity					1093:1101	the structural diversity	1078:1101	the structural diversity of non-human glycans	1078:1122	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	5	49	theme	candidate	1207:1215	arg1	structures					1217:1226	candidate structures	1207:1226	candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products	1207:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	0	50	theme	structures	54:63	arg1	characterization					17:32	Highly sensitive characterization	0:32	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs	0:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	3	51	theme	isomers	773:779	arg1	characterization					684:699	the comprehensive characterization	666:699	the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers	666:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	4	52	theme	universal	965:973	arg1	use					822:824	the straightforward use	802:824	the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation	802:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	4	52	theme	universal	965:973	arg1	approach					975:982	a universal approach	963:982	a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans	963:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	2	53	theme	insufficient	397:408	arg1	efficacy					410:417	insufficient efficacy	397:417	insufficient efficacy	397:417	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	3	54	theme	LC	646:647	arg1	method					655:660	a highly sensitive LC MS/MS method	627:660	a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers	627:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	4	55	theme	low-energy	918:927	arg1	dissociation					947:958	the positive ionization low-energy collision-induced dissociation	894:958	the positive ionization low-energy collision-induced dissociation	894:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	3	56	theme	low-abundance	704:716	arg1	glycans					728:734	low-abundance non-human glycans	704:734	low-abundance non-human glycans	704:734	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	3	57	theme	comprehensive	670:682	arg1	characterization					684:699	the comprehensive characterization	666:699	the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers	666:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	4	58	theme	high-abundance	829:842	arg1	ions					855:858	high-abundance diagnostic ions	829:858	high-abundance diagnostic ions	829:858	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	3	59	theme	related	754:760	arg1	isomers					773:779	their closely related structural isomers	740:779	their closely related structural isomers	740:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	3	60	gly	glycopeptides	512:524	arg2	glycopeptides					512:524	isobaric glycopeptides	503:524	isobaric glycopeptides	503:524	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	1	61	theme	important	150:158	arg1	Glycosylation					130:142	Glycosylation	130:142	Glycosylation	130:142	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	1	61	theme	important	150:158	arg1	attribute					160:168	an important attribute	147:168	an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality	147:236	Glycosylation is an important attribute of monoclonal antibodies (mAbs) for assessing manufacturing quality.
36068283	4	62	theme	biantennary	1037:1047	arg1	glycans					1049:1055	biantennary glycans	1037:1055	biantennary glycans	1037:1055	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	0	63	theme	antibody	79:86	arg1	drugs					88:92	monoclonal antibody drugs	68:92	monoclonal antibody drugs	68:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	3	64	theme	structural	762:771	arg1	isomers					773:779	their closely related structural isomers	740:779	their closely related structural isomers	740:779	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	2	65	theme	terminal	280:287	arg1	galactose-α1,3-galactose					289:312	terminal galactose-α1,3-galactose	280:312	terminal galactose-α1,3-galactose	280:312	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36068283	3	66	theme	carbon	606:611	arg1	LC					613:614	porous graphitic carbon LC	589:614	porous graphitic carbon LC	589:614	Using parallel sequencing of isobaric glycopeptides and isomeric glycans that were separated by reversed-phase and porous graphitic carbon LC, we report a highly sensitive LC MS/MS method for the comprehensive characterization of low-abundance non-human glycans and their closely related structural isomers.
36068283	0	67	theme	monoclonal	68:77	arg1	drugs					88:92	monoclonal antibody drugs	68:92	monoclonal antibody drugs	68:92	Highly sensitive characterization of non-human glycan structures of monoclonal antibody drugs utilizing tandem mass spectrometry.
36068283	5	68	theme	mAb	1305:1307	arg1	products					1309:1316	therapeutic mAb products	1293:1316	therapeutic mAb products	1293:1316	Our findings reveal the structural diversity of non-human glycans and sulfation of α-galactosylated glycans, providing both an analytical method and candidate structures that could potentially be used in the crucial quality control of therapeutic mAb products.
36068283	4	69	theme	collision-induced	929:945	arg1	dissociation					947:958	the positive ionization low-energy collision-induced dissociation	894:958	the positive ionization low-energy collision-induced dissociation	894:958	We demonstrate that the straightforward use of high-abundance diagnostic ions and complementary fragments under the positive ionization low-energy collision-induced dissociation is a universal approach to rapidly discriminate branch-linkage structures of biantennary glycans.
36068283	2	70	theme	mAb	429:431	arg1	expression					433:442	mAb expression	429:442	mAb expression in non-human mammalian cells	429:471	Analysis of non-human glycans containing terminal galactose-α1,3-galactose and N-glycolylneuraminic acid is essential due to the potential immunogenicity and insufficient efficacy caused by mAb expression in non-human mammalian cells.
36695498	11	0	theme	detailed	1613:1620	arg1	study					1622:1626	the detailed study	1609:1626	the detailed study of cancer glyco-immunology	1609:1653	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	8	1	theme	genome-wide	1216:1226	arg1	screen					1228:1233	genome-wide screen	1216:1233	genome-wide screen	1216:1233	Here, we outline a detailed, step-by-step protocol for completing this type of genome-wide screen.
36695498	6	2	theme	glycan	962:967	arg1	antigens					969:976	immune-regulatory glycan antigens	944:976	immune-regulatory glycan antigens	944:976	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	13	3	theme	genome-wide	1872:1882	arg1	libraries					1891:1899	genome-wide CRISPR libraries	1872:1899	genome-wide CRISPR libraries	1872:1899	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	10	4	theme	immune	1437:1442	arg1	lectins					1444:1450	immune lectins	1437:1450	immune lectins	1437:1450	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	13	5	theme	libraries	1891:1899	arg1	sorting					1957:1963	fluorescence-activated cell sorting	1929:1963	fluorescence-activated cell sorting	1929:1963	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	5	theme	libraries	1891:1899	arg1	Staining					1860:1867	Staining	1860:1867	Staining of genome-wide CRISPR libraries with Siglec-Fc reagents	1860:1923	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	9	6	theme	genome-wide	1260:1270	arg1	atlas					1272:1276	a genome-wide atlas	1258:1276	a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin	1258:1374	Our protocol produces a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin.
36695498	1	7	theme	living	186:191	arg1	cells					193:197	all living cells	182:197	all living cells	182:197	Glycans are carbohydrate molecules appended to proteins and lipids on the surface of all living cells.
36695498	5	8	theme	glycan	680:685	arg1	ligands					687:693	these glycan ligands	674:693	these glycan ligands	674:693	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	10	9	theme	regulatory	1465:1474	arg1	genes					1476:1480	regulatory genes	1465:1480	regulatory genes that drive changes in cancer-associated glycosylation	1465:1534	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	8	10	dep	detailed	1156:1163	arg1	step-by-step					1166:1177	step-by-step	1166:1177	step-by-step	1166:1177	Here, we outline a detailed, step-by-step protocol for completing this type of genome-wide screen.
36695498	5	11	theme	targets	746:752	arg1	identification					712:725	identification	712:725	identification of novel druggable targets for therapeutic intervention	712:781	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	9	12	theme	genes	1285:1289	arg1	atlas					1272:1276	a genome-wide atlas	1258:1276	a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin	1258:1374	Our protocol produces a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin.
36695498	2	13	theme	cell-surface	290:301	arg1	patterns					317:324	cell-surface glycosylation patterns	290:324	cell-surface glycosylation patterns	290:324	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	13	14	theme	K-562	1830:1834	arg1	cells					1836:1840	dCas9KRAB-expressing K-562 cells Basic Protocol 2	1809:1857	dCas9KRAB-expressing K-562 cells Basic Protocol 2	1809:1857	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	5	15	theme	therapeutic	758:768	arg1	intervention					770:781	therapeutic intervention	758:781	therapeutic intervention	758:781	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	2	16	theme	wide	228:231	arg1	array					233:237	a wide array	226:237	a wide array of biological processes	226:261	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	13	17	theme	Basic	1842:1846	arg1	Protocol					1848:1855	Basic Protocol 2	1842:1857	dCas9KRAB-expressing K-562 cells Basic Protocol 2	1809:1857	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	7	18	theme	glycan-binding	1104:1117	arg1	receptors					1126:1134	glycan-binding immune receptors	1104:1134	glycan-binding immune receptors	1104:1134	In a recent publication, we described a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors.
36695498	11	19	theme	general	1562:1568	arg1	resource					1570:1577	a general resource	1560:1577	a general resource for researchers interested in the detailed study of cancer glyco-immunology	1560:1653	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	11	19	theme	general	1562:1568	arg1	protocol					1541:1548	Our protocol	1537:1548	Our protocol	1537:1548	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	7	20	theme	ligands	1092:1098	arg1	synthesis					1079:1087	synthesis	1079:1087	synthesis of ligands for glycan-binding immune receptors	1079:1134	In a recent publication, we described a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors.
36695498	9	21	theme	cell-surface	1324:1335	arg1	binding					1337:1343	cell-surface binding	1324:1343	cell-surface binding of a recombinant immune lectin	1324:1374	Our protocol produces a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin.
36695498	2	22	theme	processes	253:261	arg1	array					233:237	a wide array	226:237	a wide array of biological processes	226:261	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	13	23	theme	Data	2038:2041	arg1	analysis					2043:2050	Data analysis	2038:2050	Data analysis	2038:2050	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	0	24	theme	CRISPR	79:84	arg1	Screening					86:94	Genome-Wide CRISPR Screening	67:94	Genome-Wide CRISPR Screening	67:94	Identifying Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening.
36695498	7	25	theme	screening	1031:1039	arg1	approach					1041:1048	a CRISPR/Cas9 screening approach	1017:1048	a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors	1017:1134	In a recent publication, we described a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors.
36695498	10	26	theme	cancer-associated	1504:1520	arg1	glycosylation					1522:1534	cancer-associated glycosylation	1504:1534	cancer-associated glycosylation	1504:1534	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	5	27	theme	novel	730:734	arg1	targets					746:752	novel druggable targets	730:752	novel druggable targets for therapeutic intervention	730:781	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	11	28	theme	interested	1595:1604	arg1	researchers					1583:1593	researchers	1583:1593	researchers interested in the detailed study of cancer glyco-immunology	1583:1653	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	9	29	theme	recombinant	1350:1360	arg1	lectin					1369:1374	a recombinant immune lectin	1348:1374	a recombinant immune lectin	1348:1374	Our protocol produces a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin.
36695498	6	30	theme	complex	844:850	arg1	regulation					860:869	extremely complex genetic regulation	834:869	extremely complex genetic regulation	834:869	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	13	31	theme	Basic	2020:2024	arg1	Protocol					2026:2033	Library amplification and sequencing Basic Protocol 4	1983:2035	Protocol	2026:2033	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	9	32	theme	lectin	1369:1374	arg1	binding					1337:1343	cell-surface binding	1324:1343	cell-surface binding of a recombinant immune lectin	1324:1374	Our protocol produces a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin.
36695498	11	33	from	interested	1595:1604	arg1	study					1622:1626	the detailed study	1609:1626	the detailed study of cancer glyco-immunology	1609:1653	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	13	34	theme	transduction	1764:1775	arg1	Protocol					1785:1792	lentiviral transduction Support Protocol	1753:1792	lentiviral transduction Support Protocol	1753:1792	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	35	theme	Library	1983:1989	arg1	amplification					1991:2003	Library amplification and sequencing Basic Protocol 4	1983:2035	amplification	1991:2003	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	1	36	theme	carbohydrate	109:120	arg1	Glycans					97:103	Glycans	97:103	Glycans	97:103	Glycans are carbohydrate molecules appended to proteins and lipids on the surface of all living cells.
36695498	1	36	theme	carbohydrate	109:120	arg1	molecules					122:130	carbohydrate molecules	109:130	carbohydrate molecules appended to proteins and lipids on the surface of all living cells	109:197	Glycans are carbohydrate molecules appended to proteins and lipids on the surface of all living cells.
36695498	13	37	theme	cell	1952:1955	arg1	sorting					1957:1963	fluorescence-activated cell sorting	1929:1963	fluorescence-activated cell sorting	1929:1963	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	38	theme	Basic	1686:1690	arg1	Protocol					1692:1699	Basic Protocol 1	1686:1701	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	39	theme	CRISPR	1732:1737	arg1	library					1739:1745	a genome-wide CRISPR library	1718:1745	a genome-wide CRISPR library using lentiviral transduction Support Protocol	1718:1792	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	40	theme	Basic	1965:1969	arg1	Protocol					1971:1978	Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3	1860:1980	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	0	41	theme	Protein-Glycan	34:47	arg1	Interactions					49:60	Protein-Glycan Interactions	34:60	Protein-Glycan Interactions with Genome-Wide CRISPR Screening	34:94	Identifying Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening.
36695498	6	42	theme	key	908:910	arg1	genes					912:916	the key genes	904:916	the key genes involved in production of immune-regulatory glycan antigens	904:976	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	8	43	theme	detailed	1156:1163	arg1	protocol					1179:1186	a detailed, step-by-step protocol	1154:1186	a detailed, step-by-step protocol for completing this type of genome-wide screen	1154:1233	Here, we outline a detailed, step-by-step protocol for completing this type of genome-wide screen.
36695498	13	44	dep	Protocol	1692:1699	arg1	Generation					1795:1804	Generation	1795:1804	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	44	dep	Protocol	1692:1699	arg1	Generation					1704:1713	Generation	1704:1713	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	44	dep	Protocol	1692:1699	arg1	amplification					1991:2003	Library amplification and sequencing Basic Protocol 4	1983:2035	amplification	1991:2003	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	44	dep	Protocol	1692:1699	arg1	analysis					2043:2050	Data analysis	2038:2050	Data analysis	2038:2050	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	44	dep	Protocol	1692:1699	arg1	Protocol					1971:1978	Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3	1860:1980	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	44	dep	Protocol	1692:1699	arg1	identification					2060:2073	hit identification	2056:2073	hit identification	2056:2073	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	44	dep	Protocol	1692:1699	arg1	Protocol					2026:2033	Library amplification and sequencing Basic Protocol 4	1983:2035	Protocol	2026:2033	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	11	45	theme	glyco-immunology	1638:1653	arg1	study					1622:1626	the detailed study	1609:1626	the detailed study of cancer glyco-immunology	1609:1653	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	6	46	theme	glycan	793:798	arg1	biosynthesis					807:818	glycan ligand biosynthesis	793:818	glycan ligand biosynthesis	793:818	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	10	47	theme	novel	1419:1423	arg1	ligands					1425:1431	novel ligands	1419:1431	novel ligands for immune lectins	1419:1450	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	2	48	theme	several	365:371	arg1	diseases					373:380	several diseases	365:380	several diseases	365:380	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	6	49	theme	antigens	969:976	arg1	production					930:939	production	930:939	production of immune-regulatory glycan antigens	930:976	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	10	50	used	used	1397:1400	arg2	dataset					1382:1388	This dataset	1377:1388	This dataset	1377:1388	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	6	51	theme	immune-regulatory	944:960	arg1	antigens					969:976	immune-regulatory glycan antigens	944:976	immune-regulatory glycan antigens	944:976	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	4	52	theme	immune	613:618	arg1	surveillance					620:631	immune surveillance	613:631	immune surveillance	613:631	These glycosylated antigens systematically inhibit immune activity and protect cancer cells from immune surveillance.
36695498	13	53	theme	CRISPR	1884:1889	arg1	libraries					1891:1899	genome-wide CRISPR libraries	1872:1899	genome-wide CRISPR libraries	1872:1899	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	6	54	theme	genetic	852:858	arg1	regulation					860:869	extremely complex genetic regulation	834:869	extremely complex genetic regulation	834:869	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	2	55	theme	structural	268:277	arg1	changes					279:285	structural changes	268:285	structural changes in cell-surface glycosylation patterns	268:324	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	8	56	theme	screen	1228:1233	arg1	type					1208:1211	this type	1203:1211	this type of genome-wide screen	1203:1233	Here, we outline a detailed, step-by-step protocol for completing this type of genome-wide screen.
36695498	12	57	dep	LLC	1681:1683	arg1	Periodicals					1669:1679	Periodicals	1669:1679	Periodicals	1669:1679	© 2023 Wiley Periodicals LLC.
36695498	4	58	gly	glycosylated	522:533	arg1	antigens					535:542	These glycosylated antigens	516:542	These glycosylated antigens	516:542	These glycosylated antigens systematically inhibit immune activity and protect cancer cells from immune surveillance.
36695498	1	59	theme	cells	193:197	arg1	surface					171:177	the surface	167:177	the surface of all living cells	167:197	Glycans are carbohydrate molecules appended to proteins and lipids on the surface of all living cells.
36695498	10	60	from	changes	1493:1499	arg1	glycosylation					1522:1534	cancer-associated glycosylation	1504:1534	cancer-associated glycosylation	1504:1534	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	13	61	theme	hit	2056:2058	arg1	identification					2060:2073	hit identification	2056:2073	hit identification	2056:2073	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	5	62	theme	druggable	736:744	arg1	targets					746:752	novel druggable targets	730:752	novel druggable targets for therapeutic intervention	730:781	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	11	63	theme	cancer	1631:1636	arg1	glyco-immunology					1638:1653	cancer glyco-immunology	1631:1653	cancer glyco-immunology	1631:1653	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	2	64	theme	glycosylation	303:315	arg1	patterns					317:324	cell-surface glycosylation patterns	290:324	cell-surface glycosylation patterns	290:324	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	3	65	from	receptors	479:487	arg1	cells					509:513	immune cells	502:513	immune cells	502:513	In particular, cancer cells frequently upregulate expression of glycans that bind to inhibitory receptors (lectins) on immune cells.
36695498	13	66	with	sorting	1957:1963	arg1	reagents					1916:1923	Siglec-Fc reagents	1906:1923	Siglec-Fc reagents	1906:1923	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	11	67	from	study	1622:1626	arg1	interested					1595:1604	interested	1595:1604	interested	1595:1604	Our protocol serves as a general resource for researchers interested in the detailed study of cancer glyco-immunology.
36695498	13	68	theme	dCas9KRAB-expressing	1809:1828	arg1	cells					1836:1840	dCas9KRAB-expressing K-562 cells Basic Protocol 2	1809:1857	dCas9KRAB-expressing K-562 cells Basic Protocol 2	1809:1857	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	7	69	theme	immune	1119:1124	arg1	receptors					1126:1134	glycan-binding immune receptors	1104:1134	glycan-binding immune receptors	1104:1134	In a recent publication, we described a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors.
36695498	10	70	dep	used	1397:1400	arg1	both					1402:1405	both	1402:1405	both	1402:1405	This dataset can be used both to identify novel ligands for immune lectins and annotate regulatory genes that drive changes in cancer-associated glycosylation.
36695498	13	71	theme	cells	1836:1840	arg1	Generation					1795:1804	Generation	1795:1804	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	2	72	theme	key	213:215	arg1	roles					217:221	key roles	213:221	key roles	213:221	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	2	73	theme	biological	242:251	arg1	processes					253:261	biological processes	242:261	biological processes	242:261	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	2	74	from	changes	279:285	arg1	patterns					317:324	cell-surface glycosylation patterns	290:324	cell-surface glycosylation patterns	290:324	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36695498	13	75	theme	Staining	1860:1867	arg1	Protocol					1971:1978	Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3	1860:1980	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	4	76	theme	glycosylated	522:533	arg1	antigens					535:542	These glycosylated antigens	516:542	These glycosylated antigens	516:542	These glycosylated antigens systematically inhibit immune activity and protect cancer cells from immune surveillance.
36695498	13	77	theme	sequencing	2009:2018	arg1	Protocol					2026:2033	Library amplification and sequencing Basic Protocol 4	1983:2035	Protocol	2026:2033	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	9	78	theme	immune	1362:1367	arg1	lectin					1369:1374	a recombinant immune lectin	1348:1374	a recombinant immune lectin	1348:1374	Our protocol produces a genome-wide atlas of all genes whose expression is required for cell-surface binding of a recombinant immune lectin.
36695498	7	79	theme	CRISPR/Cas9	1019:1029	arg1	approach					1041:1048	a CRISPR/Cas9 screening approach	1017:1048	a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors	1017:1134	In a recent publication, we described a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors.
36695498	13	80	dep	cells	1836:1840	arg1	Protocol					1848:1855	Basic Protocol 2	1842:1857	dCas9KRAB-expressing K-562 cells Basic Protocol 2	1809:1857	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	5	81	theme	cancer	652:657	arg1	cells					659:663	cancer cells	652:663	cancer cells	652:663	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	13	82	theme	lentiviral	1753:1762	arg1	Protocol					1785:1792	lentiviral transduction Support Protocol	1753:1792	lentiviral transduction Support Protocol	1753:1792	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	0	83	theme	Genetic	12:18	arg1	Regulators					20:29	Genetic Regulators	12:29	Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening	12:94	Identifying Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening.
36695498	3	84	theme	cancer	398:403	arg1	cells					405:409	cancer cells	398:409	cancer cells	398:409	In particular, cancer cells frequently upregulate expression of glycans that bind to inhibitory receptors (lectins) on immune cells.
36695498	13	85	theme	Support	1777:1783	arg1	Protocol					1785:1792	lentiviral transduction Support Protocol	1753:1792	lentiviral transduction Support Protocol	1753:1792	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	86	with	Staining	1860:1867	arg1	reagents					1916:1923	Siglec-Fc reagents	1906:1923	Siglec-Fc reagents	1906:1923	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	87	theme	fluorescence-activated	1929:1950	arg1	sorting					1957:1963	fluorescence-activated cell sorting	1929:1963	fluorescence-activated cell sorting	1929:1963	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	3	88	theme	glycans	447:453	arg1	expression					433:442	expression	433:442	expression of glycans that bind to inhibitory receptors (lectins) on immune cells	433:513	In particular, cancer cells frequently upregulate expression of glycans that bind to inhibitory receptors (lectins) on immune cells.
36695498	7	89	theme	recent	984:989	arg1	publication					991:1001	a recent publication	982:1001	a recent publication	982:1001	In a recent publication, we described a CRISPR/Cas9 screening approach to identify genes that drive synthesis of ligands for glycan-binding immune receptors.
36695498	4	90	theme	cancer	595:600	arg1	cells					602:606	cancer cells	595:606	cancer cells	595:606	These glycosylated antigens systematically inhibit immune activity and protect cancer cells from immune surveillance.
36695498	13	91	theme	genome-wide	1720:1730	arg1	library					1739:1745	a genome-wide CRISPR library	1718:1745	a genome-wide CRISPR library using lentiviral transduction Support Protocol	1718:1792	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	13	92	theme	sorting	1957:1963	arg1	Protocol					1971:1978	Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3	1860:1980	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	0	93	theme	Interactions	49:60	arg1	Regulators					20:29	Genetic Regulators	12:29	Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening	12:94	Identifying Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening.
36695498	13	94	theme	library	1739:1745	arg1	Generation					1704:1713	Generation	1704:1713	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.	1686:2074	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	3	95	theme	inhibitory	468:477	arg1	lectins					490:496	lectins	490:496	lectins	490:496	In particular, cancer cells frequently upregulate expression of glycans that bind to inhibitory receptors (lectins) on immune cells.
36695498	3	95	theme	inhibitory	468:477	arg1	receptors					479:487	inhibitory receptors	468:487	inhibitory receptors (lectins) on immune cells	468:513	In particular, cancer cells frequently upregulate expression of glycans that bind to inhibitory receptors (lectins) on immune cells.
36695498	0	96	theme	Genome-Wide	67:77	arg1	Screening					86:94	Genome-Wide CRISPR Screening	67:94	Genome-Wide CRISPR Screening	67:94	Identifying Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening.
36695498	4	97	theme	immune	567:572	arg1	activity					574:581	immune activity	567:581	immune activity	567:581	These glycosylated antigens systematically inhibit immune activity and protect cancer cells from immune surveillance.
36695498	6	98	theme	ligand	800:805	arg1	biosynthesis					807:818	glycan ligand biosynthesis	793:818	glycan ligand biosynthesis	793:818	However, glycan ligand biosynthesis is subject to extremely complex genetic regulation, making it difficult to identify the key genes involved in production of immune-regulatory glycan antigens.
36695498	3	99	theme	immune	502:507	arg1	cells					509:513	immune cells	502:513	immune cells	502:513	In particular, cancer cells frequently upregulate expression of glycans that bind to inhibitory receptors (lectins) on immune cells.
36695498	5	100	dep	Understanding	634:646	arg1	generate					665:672	generate	665:672	generate these glycan ligands	665:693	Understanding how cancer cells generate these glycan ligands can thus lead to identification of novel druggable targets for therapeutic intervention.
36695498	13	101	theme	Siglec-Fc	1906:1914	arg1	reagents					1916:1923	Siglec-Fc reagents	1906:1923	Siglec-Fc reagents	1906:1923	Basic Protocol 1: Generation of a genome-wide CRISPR library using lentiviral transduction Support Protocol: Generation of dCas9KRAB-expressing K-562 cells Basic Protocol 2: Staining of genome-wide CRISPR libraries with Siglec-Fc reagents and fluorescence-activated cell sorting Basic Protocol 3: Library amplification and sequencing Basic Protocol 4: Data analysis and hit identification.
36695498	0	102	with	Interactions	49:60	arg1	Screening					86:94	Genome-Wide CRISPR Screening	67:94	Genome-Wide CRISPR Screening	67:94	Identifying Genetic Regulators of Protein-Glycan Interactions with Genome-Wide CRISPR Screening.
36695498	2	103	theme	diseases	373:380	arg1	pathogenesis					349:360	pathogenesis	349:360	pathogenesis of several diseases	349:380	Glycans play key roles in a wide array of biological processes, and structural changes in cell-surface glycosylation patterns have been connected to pathogenesis of several diseases.
36737995	4	0	theme	base	1048:1051	arg1	ingredients					1057:1067	two base WPC ingredients	1044:1067	two base WPC ingredients (WPC 80 and WPC 35)	1044:1087	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	0	theme	base	1048:1051	arg1	WPC					1070:1072	WPC	1070:1072	WPC	1070:1072	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	0	theme	base	1048:1051	arg1	WPC					1081:1083	WPC	1081:1083	WPC	1081:1083	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	1	from	glycosylation	718:730	arg1	various					773:779	various	773:779	various	773:779	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	6	2	link	N-linked	1291:1298	arg1	analysis					1314:1321	N-linked glycosylation analysis	1291:1321	N-linked glycosylation analysis	1291:1321	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	4	3	theme	WPC	897:899	arg1	WPC					892:894	an α-lactalbumin-enriched WPC	866:894	an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	866:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	3	theme	WPC	897:899	arg1	Lac					901:903	WPC Lac	897:903	WPC Lac	897:903	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	3	4	theme	human	581:585	arg1	equivalence					592:602	human milk equivalence	581:602	human milk equivalence	581:602	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	1	5	theme	beneficial	273:282	arg1	bioactivities					284:296	many beneficial bioactivities	268:296	many beneficial bioactivities associated with their glycosylation	268:332	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	4	6	theme	microarray	1102:1111	arg1	profiling					1113:1121	lectin microarray profiling	1095:1121	lectin microarray profiling	1095:1121	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	6	7	theme	lectin	1470:1475	arg1	method					1512:1517	a valuable method	1501:1517	a valuable method to compare global glycosylation	1501:1549	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	6	7	theme	lectin	1470:1475	arg1	profiling					1488:1496	lectin microarray profiling	1470:1496	lectin microarray profiling	1470:1496	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	4	8	attach	present	1017:1023	arg2	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	8	attach	present	1017:1023	arg1	milk					1034:1037	human milk	1028:1037	human milk	1028:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	3	9	with	ingredients	468:478	arg1	depletions					508:517	depletions	508:517	depletions	508:517	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	3	9	with	ingredients	468:478	arg1	enrichments					493:503	various enrichments	485:503	various enrichments	485:503	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	4	10	dep	ingredients	820:830	arg1	HF2					860:862	lower fat HF2	850:862	lower fat HF2	850:862	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	10	dep	ingredients	820:830	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	10	dep	ingredients	820:830	arg1	HF1					842:844	high fat HF1	833:844	high fat HF1	833:844	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	7	11	theme	valuable	1574:1581	arg1	ingredient					1583:1592	a valuable ingredient	1572:1592	a valuable ingredient for providing equivalent glycosylation to MFGM supplementation	1572:1655	Thus WPC Lac may be a valuable ingredient for providing equivalent glycosylation to MFGM supplementation.
36737995	7	11	theme	valuable	1574:1581	arg1	Lac					1561:1563	WPC Lac	1557:1563	WPC Lac	1557:1563	Thus WPC Lac may be a valuable ingredient for providing equivalent glycosylation to MFGM supplementation.
36737995	4	12	theme	concentration	930:942	arg1	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	6	13	theme	similar	1439:1445	arg1	structures					1447:1456	similar structures	1439:1456	similar structures	1439:1456	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	1	14	theme	whey	204:207	arg1	proteins					209:216	Human milk fat globule membrane (MFGM) and whey proteins	161:216	proteins	209:216	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	4	15	theme	ingredients	750:760	arg1	glycosylation					718:730	the global glycosylation	707:730	the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35)	707:1087	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	16	gly	glycosylation	718:730	arg1	ingredients					750:760	commercial WPC ingredients	735:760	commercial WPC ingredients for use	735:768	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	16	gly	glycosylation	718:730	arg1	various					773:779	various	773:779	various	773:779	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	0	17	theme	whey	77:80	arg1	ingredients					90:100	whey protein ingredients	77:100	whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane	77:158	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	3	18	dep	equivalence	592:602	arg1	benefits					620:627	benefits	620:627	benefits	620:627	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	4	19	theme	commercial	735:744	arg1	ingredients					750:760	commercial WPC ingredients	735:760	commercial WPC ingredients for use	735:768	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	1	20	theme	globule	176:182	arg1	MFGM					194:197	Human milk fat globule membrane (MFGM) and whey proteins	161:216	MFGM	194:197	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	7	21	theme	MFGM	1636:1639	arg1	supplementation					1641:1655	MFGM supplementation	1636:1655	MFGM supplementation	1636:1655	Thus WPC Lac may be a valuable ingredient for providing equivalent glycosylation to MFGM supplementation.
36737995	4	22	theme	WPC	816:818	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	22	theme	WPC	816:818	arg1	HF2					860:862	lower fat HF2	850:862	lower fat HF2	850:862	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	22	theme	WPC	816:818	arg1	HF1					842:844	high fat HF1	833:844	high fat HF1	833:844	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	6	23	theme	N-linked	1291:1298	arg1	analysis					1314:1321	N-linked glycosylation analysis	1291:1321	N-linked glycosylation analysis	1291:1321	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	4	24	located	present	1017:1023	arg2	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	24	located	present	1017:1023	arg1	milk					1034:1037	human milk	1028:1037	human milk	1028:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	0	25	theme	Lectin	0:5	arg1	profiling					18:26	Lectin microarray profiling	0:26	Lectin microarray profiling	0:26	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	2	26	dep	other	376:380	arg1	than					382:385	than	382:385	than	382:385	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	5	27	theme	base	1267:1270	arg1	ingredient					1279:1288	the base WPC 80 ingredient	1263:1288	the base WPC 80 ingredient	1263:1288	WPC Lac and WPC HF1 glycosylation were highly similar to each other and both somewhat similar to WPC 35, while WPC HF2 was more similar to the base WPC 80 ingredient.
36737995	0	28	theme	equivalent	41:50	arg1	glycosylation					59:71	equivalent global glycosylation	41:71	equivalent global glycosylation	41:71	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	4	29	theme	human	1028:1032	arg1	milk					1034:1037	human milk	1028:1037	human milk	1028:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	30	theme	fat	856:858	arg1	HF2					860:862	lower fat HF2	850:862	lower fat HF2	850:862	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	30	theme	fat	856:858	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	3	31	theme	infant	531:536	arg1	formula					538:544	infant formula	531:544	infant formula (IF) formulations	531:562	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	6	32	theme	WPC	1353:1355	arg1	Lac					1357:1359	WPC Lac	1353:1359	WPC Lac	1353:1359	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	5	33	theme	WPC	1136:1138	arg1	glycosylation					1144:1156	WPC HF1 glycosylation	1136:1156	WPC HF1 glycosylation	1136:1156	WPC Lac and WPC HF1 glycosylation were highly similar to each other and both somewhat similar to WPC 35, while WPC HF2 was more similar to the base WPC 80 ingredient.
36737995	2	34	theme	milk	360:363	arg1	components					365:374	milk components	360:374	milk components other than free milk oligosaccharides	360:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	1	35	theme	milk	167:170	arg1	MFGM					194:197	Human milk fat globule membrane (MFGM) and whey proteins	161:216	MFGM	194:197	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	4	36	theme	fat	838:840	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	36	theme	fat	838:840	arg1	HF1					842:844	high fat HF1	833:844	high fat HF1	833:844	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	2	37	theme	oligosaccharides	397:412	arg1	glycosylation					343:355	glycosylation	343:355	glycosylation of milk components other than free milk oligosaccharides	343:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	3	38	theme	protein	442:448	arg1	ingredients					468:478	Whey protein concentrate (WPC) ingredients	437:478	Whey protein concentrate (WPC) ingredients with various enrichments or depletions	437:517	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	4	39	theme	WPC	1053:1055	arg1	ingredients					1057:1067	two base WPC ingredients	1044:1067	two base WPC ingredients (WPC 80 and WPC 35)	1044:1087	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	39	theme	WPC	1053:1055	arg1	WPC					1070:1072	WPC	1070:1072	WPC	1070:1072	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	39	theme	WPC	1053:1055	arg1	WPC					1081:1083	WPC	1081:1083	WPC	1081:1083	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	2	40	theme	free	387:390	arg1	oligosaccharides					397:412	free milk oligosaccharides	387:412	milk components other than free milk oligosaccharides	360:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	4	41	theme	α-lactalbumin-enriched	869:890	arg1	WPC					892:894	an α-lactalbumin-enriched WPC	866:894	an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	866:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	41	theme	α-lactalbumin-enriched	869:890	arg1	Lac					901:903	WPC Lac	897:903	WPC Lac	897:903	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	1	42	theme	many	268:271	arg1	bioactivities					284:296	many beneficial bioactivities	268:296	many beneficial bioactivities associated with their glycosylation	268:332	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	6	43	theme	microarray	1477:1486	arg1	method					1512:1517	a valuable method	1501:1517	a valuable method to compare global glycosylation	1501:1549	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	6	43	theme	microarray	1477:1486	arg1	profiling					1488:1496	lectin microarray profiling	1470:1496	lectin microarray profiling	1470:1496	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	1	44	theme	membrane	184:191	arg1	MFGM					194:197	Human milk fat globule membrane (MFGM) and whey proteins	161:216	MFGM	194:197	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	4	45	from	present	1017:1023	arg1	milk					1034:1037	human milk	1028:1037	human milk	1028:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	0	46	theme	globule	143:149	arg1	membrane					151:158	globule membrane	143:158	globule membrane	143:158	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	3	47	theme	milk	587:590	arg1	equivalence					592:602	human milk equivalence	581:602	human milk equivalence	581:602	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	4	48	theme	α-lactalbumin	916:928	arg1	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	49	theme	lectin	1095:1100	arg1	profiling					1113:1121	lectin microarray profiling	1095:1121	lectin microarray profiling	1095:1121	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	2	50	theme	components	365:374	arg1	glycosylation					343:355	glycosylation	343:355	glycosylation of milk components other than free milk oligosaccharides	343:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	7	51	theme	WPC	1557:1559	arg1	ingredient					1583:1592	a valuable ingredient	1572:1592	a valuable ingredient for providing equivalent glycosylation to MFGM supplementation	1572:1655	Thus WPC Lac may be a valuable ingredient for providing equivalent glycosylation to MFGM supplementation.
36737995	7	51	theme	WPC	1557:1559	arg1	Lac					1561:1563	WPC Lac	1557:1563	WPC Lac	1557:1563	Thus WPC Lac may be a valuable ingredient for providing equivalent glycosylation to MFGM supplementation.
36737995	4	52	theme	closer	944:949	arg1	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	6	53	theme	global	1530:1535	arg1	glycosylation					1537:1549	global glycosylation	1530:1549	global glycosylation	1530:1549	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	4	54	theme	WPC	746:748	arg1	ingredients					750:760	commercial WPC ingredients	735:760	commercial WPC ingredients for use	735:768	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	5	55	theme	WPC	1235:1237	arg1	HF2					1239:1241	WPC HF2	1235:1241	WPC HF2	1235:1241	WPC Lac and WPC HF1 glycosylation were highly similar to each other and both somewhat similar to WPC 35, while WPC HF2 was more similar to the base WPC 80 ingredient.
36737995	3	56	theme	global	651:656	arg1	glycosylation					658:670	their overall or global glycosylation	634:670	their overall or global glycosylation	634:670	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	0	57	theme	protein	82:88	arg1	ingredients					90:100	whey protein ingredients	77:100	whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane	77:158	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	3	58	theme	overall	640:646	arg1	glycosylation					658:670	their overall or global glycosylation	634:670	their overall or global glycosylation	634:670	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	6	59	theme	valuable	1503:1510	arg1	method					1512:1517	a valuable method	1501:1517	a valuable method to compare global glycosylation	1501:1549	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	6	59	theme	valuable	1503:1510	arg1	profiling					1488:1496	lectin microarray profiling	1470:1496	lectin microarray profiling	1470:1496	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	1	60	theme	Human	161:165	arg1	MFGM					194:197	Human milk fat globule membrane (MFGM) and whey proteins	161:216	MFGM	194:197	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	4	61	theme	less	983:986	arg1	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	62	theme	global	711:716	arg1	glycosylation					718:730	the global glycosylation	707:730	the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35)	707:1087	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	6	63	theme	WPC	1341:1343	arg1	HF1					1345:1347	WPC HF1	1341:1347	WPC HF1	1341:1347	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	1	64	theme	fat	172:174	arg1	MFGM					194:197	Human milk fat globule membrane (MFGM) and whey proteins	161:216	MFGM	194:197	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	5	65	theme	WPC	1124:1126	arg1	Lac					1128:1130	WPC Lac	1124:1130	WPC Lac	1124:1130	WPC Lac and WPC HF1 glycosylation were highly similar to each other and both somewhat similar to WPC 35, while WPC HF2 was more similar to the base WPC 80 ingredient.
36737995	4	66	dep	ingredients	1057:1067	arg1	ingredients					1057:1067	two base WPC ingredients	1044:1067	two base WPC ingredients (WPC 80 and WPC 35)	1044:1087	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	66	dep	ingredients	1057:1067	arg1	WPC					1070:1072	WPC	1070:1072	WPC	1070:1072	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	66	dep	ingredients	1057:1067	arg1	WPC					1081:1083	WPC	1081:1083	WPC	1081:1083	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	67	theme	human	954:958	arg1	milk					960:963	human milk	954:963	human milk	954:963	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	5	68	theme	WPC	1272:1274	arg1	ingredient					1279:1288	the base WPC 80 ingredient	1263:1288	the base WPC 80 ingredient	1263:1288	WPC Lac and WPC HF1 glycosylation were highly similar to each other and both somewhat similar to WPC 35, while WPC HF2 was more similar to the base WPC 80 ingredient.
36737995	6	69	theme	glycosylation	1300:1312	arg1	analysis					1314:1321	N-linked glycosylation analysis	1291:1321	N-linked glycosylation analysis	1291:1321	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	0	70	dep	α-lactalbumin	116:128	arg1	membrane					151:158	globule membrane	143:158	globule membrane	143:158	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	4	71	contain	has	912:914	arg1	WPC					892:894	an α-lactalbumin-enriched WPC	866:894	an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	866:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	71	contain	has	912:914	arg2	β-lactoglobulin					988:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin	916:1002	α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk	916:1037	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	71	contain	has	912:914	arg1	Lac					901:903	WPC Lac	897:903	WPC Lac	897:903	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	72	theme	MFGM-enriched	802:814	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	72	theme	MFGM-enriched	802:814	arg1	HF2					860:862	lower fat HF2	850:862	lower fat HF2	850:862	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	72	theme	MFGM-enriched	802:814	arg1	HF1					842:844	high fat HF1	833:844	high fat HF1	833:844	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	0	73	theme	milk	134:137	arg1	fat					139:141	milk fat	134:141	milk fat	134:141	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	0	74	theme	microarray	7:16	arg1	profiling					18:26	Lectin microarray profiling	0:26	Lectin microarray profiling	0:26	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	3	75	theme	Whey	437:440	arg1	ingredients					468:478	Whey protein concentrate (WPC) ingredients	437:478	Whey protein concentrate (WPC) ingredients with various enrichments or depletions	437:517	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	7	76	theme	equivalent	1608:1617	arg1	glycosylation					1619:1631	equivalent glycosylation	1608:1631	equivalent glycosylation	1608:1631	Thus WPC Lac may be a valuable ingredient for providing equivalent glycosylation to MFGM supplementation.
36737995	0	77	theme	global	52:57	arg1	glycosylation					59:71	equivalent global glycosylation	41:71	equivalent global glycosylation	41:71	Lectin microarray profiling demonstrates equivalent global glycosylation for whey protein ingredients enriched with α-lactalbumin and milk fat globule membrane.
36737995	4	78	from	milk	1034:1037	arg1	present					1017:1023	present	1017:1023	present	1017:1023	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	3	79	theme	WPC	463:465	arg1	ingredients					468:478	Whey protein concentrate (WPC) ingredients	437:478	Whey protein concentrate (WPC) ingredients with various enrichments or depletions	437:517	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	3	80	used	used	523:526	arg2	ingredients					468:478	Whey protein concentrate (WPC) ingredients	437:478	Whey protein concentrate (WPC) ingredients with various enrichments or depletions	437:517	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	3	81	theme	concentrate	450:460	arg1	ingredients					468:478	Whey protein concentrate (WPC) ingredients	437:478	Whey protein concentrate (WPC) ingredients with various enrichments or depletions	437:517	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	4	82	theme	lower	850:854	arg1	HF2					860:862	lower fat HF2	850:862	lower fat HF2	850:862	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	82	theme	lower	850:854	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	3	83	theme	formula	538:544	arg1	formulations					551:562	infant formula (IF) formulations	531:562	infant formula (IF) formulations	531:562	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	5	84	theme	HF1	1140:1142	arg1	glycosylation					1144:1156	WPC HF1 glycosylation	1136:1156	WPC HF1 glycosylation	1136:1156	WPC Lac and WPC HF1 glycosylation were highly similar to each other and both somewhat similar to WPC 35, while WPC HF2 was more similar to the base WPC 80 ingredient.
36737995	6	85	dep	one	1396:1398	arg1	another					1400:1406	another	1400:1406	another	1400:1406	N-linked glycosylation analysis demonstrated that WPC HF1 and WPC Lac were qualitatively most similar to one another, with WPC 80 and WPC 35 having similar structures, confirming lectin microarray profiling as a valuable method to compare global glycosylation.
36737995	1	86	with	valuable	253:260	arg1	bioactivities					284:296	many beneficial bioactivities	268:296	many beneficial bioactivities associated with their glycosylation	268:332	Human milk fat globule membrane (MFGM) and whey proteins are nutritionally and functionally valuable, with many beneficial bioactivities associated with their glycosylation.
36737995	3	87	theme	various	485:491	arg1	enrichments					493:503	various enrichments	485:503	various enrichments	485:503	Whey protein concentrate (WPC) ingredients with various enrichments or depletions are used in infant formula (IF) formulations to contribute to human milk equivalence and bioactivity benefits, but their overall or global glycosylation has not been compared.
36737995	2	88	gly	glycosylation	343:355	arg1	components					365:374	milk components	360:374	milk components other than free milk oligosaccharides	360:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	2	88	gly	glycosylation	343:355	arg1	oligosaccharides					397:412	free milk oligosaccharides	387:412	milk components other than free milk oligosaccharides	360:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
36737995	4	89	theme	high	833:836	arg1	ingredients					820:830	two MFGM-enriched WPC ingredients	798:830	two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2)	798:863	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	4	89	theme	high	833:836	arg1	HF1					842:844	high fat HF1	833:844	high fat HF1	833:844	We compared the global glycosylation of commercial WPC ingredients for use in various IF formulations; two MFGM-enriched WPC ingredients (high fat HF1 and lower fat HF2), an α-lactalbumin-enriched WPC (WPC Lac) which has α-lactalbumin concentration closer to human milk and significantly less β-lactoglobulin which is not present in human milk, and two base WPC ingredients (WPC 80 and WPC 35) using lectin microarray profiling.
36737995	2	90	theme	milk	392:395	arg1	oligosaccharides					397:412	free milk oligosaccharides	387:412	milk components other than free milk oligosaccharides	360:412	However glycosylation of milk components other than free milk oligosaccharides are underinvestigated.
37230641	0	0	theme	different	94:102	arg1	status					113:118	different secretor status	94:118	different secretor status	94:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	1	1	theme	glycoconjugates	169:183	arg1	components					155:164	the important components	141:164	the important components of glycoconjugates in human milk	141:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	8	2	theme	O-glycans	1244:1252	arg1	relationship					1273:1284	O-glycans structure-function relationship	1244:1284	O-glycans structure-function relationship	1244:1284	Our data will lay a foundation for the study of O-glycans structure-function relationship.
37230641	7	3	theme	milk	1118:1121	arg1	O-glycosylation					1123:1137	the milk O-glycosylation	1114:1137	the milk O-glycosylation	1114:1137	In conclusion, approximately one-third of the milk O-glycosylation was influenced by maternal FUT2-related secretor status.
37230641	1	4	from	glycoconjugates	169:183	arg1	milk					194:197	human milk	188:197	human milk	188:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	0	5	theme	secretor	104:111	arg1	status					113:118	different secretor status	94:118	different secretor status	94:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	7	6	theme	O-glycosylation	1123:1137	arg1	O-glycosylation					1123:1137	the milk O-glycosylation	1114:1137	the milk O-glycosylation	1114:1137	In conclusion, approximately one-third of the milk O-glycosylation was influenced by maternal FUT2-related secretor status.
37230641	7	6	theme	O-glycosylation	1123:1137	arg1	one-third					1101:1109	one-third	1101:1109	one-third	1101:1109	In conclusion, approximately one-third of the milk O-glycosylation was influenced by maternal FUT2-related secretor status.
37230641	3	7	theme	porous	562:567	arg1	spectrometry					646:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	1	8	theme	free	279:282	arg1	oligosaccharides					284:299	free oligosaccharides	279:299	free oligosaccharides	279:299	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	1	9	from	components	155:164	arg1	milk					194:197	human milk	188:197	human milk	188:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	8	10	theme	structure-function	1254:1271	arg1	relationship					1273:1284	O-glycans structure-function relationship	1244:1284	O-glycans structure-function relationship	1244:1284	Our data will lay a foundation for the study of O-glycans structure-function relationship.
37230641	6	11	theme	total	998:1002	arg1	fucosylation					1032:1043	fucosylation	1032:1043	fucosylation	1032:1043	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	11	theme	total	998:1002	arg1	sulfation					1050:1058	sulfation	1050:1058	sulfation	1050:1058	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	11	theme	total	998:1002	arg1	sialylation					1019:1029	sialylation	1019:1029	sialylation	1019:1029	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	11	theme	total	998:1002	arg1	glycosylation					1004:1016	the total glycosylation	994:1016	the total glycosylation	994:1016	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	0	12	from	variations	48:57	arg1	status					113:118	different secretor status	94:118	different secretor status	94:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	0	12	from	variations	48:57	arg1	O-glycopatterns					73:87	human milk O-glycopatterns	62:87	human milk O-glycopatterns from different secretor status	62:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	7	13	theme	FUT2-related	1166:1177	arg1	status					1188:1193	maternal FUT2-related secretor status	1157:1193	maternal FUT2-related secretor status	1157:1193	In conclusion, approximately one-third of the milk O-glycosylation was influenced by maternal FUT2-related secretor status.
37230641	4	14	dep	O-glycans	735:743	arg1	including					746:754	including	746:754	including 14 sulfated O-glycans	746:776	A total of 70 presumptive O-glycan structures were identified, of which 25 O-glycans (including 14 sulfated O-glycans) were reported for the first time.
37230641	1	15	theme	human	188:192	arg1	milk					194:197	human milk	188:197	human milk	188:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	6	16	theme	Se-	921:923	arg1	group					925:929	Se- group	921:929	Se- group	921:929	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	2	17	from	N-glycome	371:379	arg1	milk					384:387	milk	384:387	milk	384:387	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	2	18	theme	status	335:340	arg1	effects					306:312	The effects	302:312	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk	302:387	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	3	19	theme	milk	442:445	arg1	O-glycome					447:455	milk O-glycome	442:455	milk O-glycome of secretors (Se+) and nonsecretors (Se-)	442:497	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	6	20	theme	group	957:961	arg1	times					971:975	two times	967:975	two times more abundant	967:989	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	20	theme	group	957:961	arg1	O-glycans					936:944	the O-glycans	932:944	the O-glycans of the Se+ group	932:961	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	2	21	theme	secretor	326:333	arg1	status					335:340	maternal secretor status	317:340	maternal secretor status	317:340	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	8	22	theme	relationship	1273:1284	arg1	study					1235:1239	the study	1231:1239	the study of O-glycans structure-function relationship	1231:1284	Our data will lay a foundation for the study of O-glycans structure-function relationship.
37230641	5	23	theme	Se+	877:879	arg1	p < 0.05					898:905	p < 0.05	898:905	p < 0.05	898:905	Notably, 23 O-glycans exhibited significant differences between Se+ and Se- samples (p < 0.05).
37230641	5	23	theme	Se+	877:879	arg1	samples					889:895	Se+ and Se- samples	877:895	Se+ and Se- samples (p < 0.05)	877:906	Notably, 23 O-glycans exhibited significant differences between Se+ and Se- samples (p < 0.05).
37230641	2	24	from	oligosaccharides	350:365	arg1	milk					384:387	milk	384:387	milk	384:387	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	2	25	theme	maternal	317:324	arg1	status					335:340	maternal secretor status	317:340	maternal secretor status	317:340	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	4	26	theme	structures	695:704	arg1	total					662:666	A total	660:666	A total of 70 presumptive O-glycan structures	660:704	A total of 70 presumptive O-glycan structures were identified, of which 25 O-glycans (including 14 sulfated O-glycans) were reported for the first time.
37230641	0	27	theme	comparative	24:34	arg1	analysis					36:43	comparative analysis	24:43	comparative analysis of variations in human milk O-glycopatterns from different secretor status	24:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	6	28	theme	abundant	982:989	arg1	times					971:975	two times	967:975	two times more abundant	967:989	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	28	theme	abundant	982:989	arg1	O-glycans					936:944	the O-glycans	932:944	the O-glycans of the Se+ group	932:961	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	3	29	theme	carbon-liquid	581:593	arg1	spectrometry					646:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	4	30	theme	O-glycan	686:693	arg1	structures					695:704	70 presumptive O-glycan structures	671:704	70 presumptive O-glycan structures	671:704	A total of 70 presumptive O-glycan structures were identified, of which 25 O-glycans (including 14 sulfated O-glycans) were reported for the first time.
37230641	0	31	theme	variations	48:57	arg1	analysis					36:43	comparative analysis	24:43	comparative analysis of variations in human milk O-glycopatterns from different secretor status	24:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	3	32	theme	ionization-tandem	623:639	arg1	spectrometry					646:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	7	33	theme	secretor	1179:1186	arg1	status					1188:1193	maternal FUT2-related secretor status	1157:1193	maternal FUT2-related secretor status	1157:1193	In conclusion, approximately one-third of the milk O-glycosylation was influenced by maternal FUT2-related secretor status.
37230641	0	34	from	O-glycopatterns	73:87	arg1	analysis					36:43	comparative analysis	24:43	comparative analysis of variations in human milk O-glycopatterns from different secretor status	24:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	4	35	theme	presumptive	674:684	arg1	structures					695:704	70 presumptive O-glycan structures	671:704	70 presumptive O-glycan structures	671:704	A total of 70 presumptive O-glycan structures were identified, of which 25 O-glycans (including 14 sulfated O-glycans) were reported for the first time.
37230641	4	36	theme	first	801:805	arg1	time					807:810	the first time	797:810	the first time	797:810	A total of 70 presumptive O-glycan structures were identified, of which 25 O-glycans (including 14 sulfated O-glycans) were reported for the first time.
37230641	0	37	theme	human	62:66	arg1	O-glycopatterns					73:87	human milk O-glycopatterns	62:87	human milk O-glycopatterns from different secretor status	62:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	3	38	theme	mass	641:644	arg1	spectrometry					646:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	5	39	theme	significant	845:855	arg1	differences					857:867	significant differences	845:867	significant differences between Se+ and Se- samples (p < 0.05)	845:906	Notably, 23 O-glycans exhibited significant differences between Se+ and Se- samples (p < 0.05).
37230641	6	40	theme	Se+	953:955	arg1	group					957:961	the Se+ group	949:961	the Se+ group	949:961	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	4	41	theme	sulfated	759:766	arg1	O-glycans					768:776	14 sulfated O-glycans	756:776	14 sulfated O-glycans	756:776	A total of 70 presumptive O-glycan structures were identified, of which 25 O-glycans (including 14 sulfated O-glycans) were reported for the first time.
37230641	3	42	theme	chromatography-electrospray	595:621	arg1	spectrometry					646:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	6	43	from	times	971:975	arg1	fucosylation					1032:1043	fucosylation	1032:1043	fucosylation	1032:1043	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	43	from	times	971:975	arg1	sulfation					1050:1058	sulfation	1050:1058	sulfation	1050:1058	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	43	from	times	971:975	arg1	sialylation					1019:1029	sialylation	1019:1029	sialylation	1019:1029	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	6	43	from	times	971:975	arg1	glycosylation					1004:1016	the total glycosylation	994:1016	the total glycosylation	994:1016	Compared to Se- group, the O-glycans of the Se+ group was two times more abundant in the total glycosylation, sialylation, fucosylation, and sulfation (p < 0.01).
37230641	1	44	located	observed	267:274	arg1	oligosaccharides					284:299	free oligosaccharides	279:299	free oligosaccharides	279:299	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	1	44	located	observed	267:274	arg2	those					261:265	those	261:265	those	261:265	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	2	45	theme	free	345:348	arg1	oligosaccharides					350:365	free oligosaccharides	345:365	free oligosaccharides	345:365	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	3	46	theme	graphitized	569:579	arg1	spectrometry					646:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	562:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	1	47	theme	protective	230:239	arg1	features					241:248	protective features	230:248	protective features similar to those observed in free oligosaccharides	230:299	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	7	48	theme	maternal	1157:1164	arg1	status					1188:1193	maternal FUT2-related secretor status	1157:1193	maternal FUT2-related secretor status	1157:1193	In conclusion, approximately one-third of the milk O-glycosylation was influenced by maternal FUT2-related secretor status.
37230641	0	49	from	status	113:118	arg1	variations					48:57	variations	48:57	variations in human milk O-glycopatterns from different secretor status	48:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	0	49	from	status	113:118	arg1	O-glycopatterns					73:87	human milk O-glycopatterns	62:87	human milk O-glycopatterns from different secretor status	62:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	1	50	from	milk	194:197	arg1	components					155:164	the important components	141:164	the important components of glycoconjugates in human milk	141:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	3	51	theme	reductive	524:532	arg1	β-elimination					534:546	reductive β-elimination	524:546	reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry	524:657	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	2	52	from	effects	306:312	arg1	oligosaccharides					350:365	free oligosaccharides	345:365	free oligosaccharides	345:365	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	2	52	from	effects	306:312	arg1	N-glycome					371:379	N-glycome	371:379	N-glycome in milk	371:387	The effects of maternal secretor status on free oligosaccharides and N-glycome in milk have been well researched and documented.
37230641	3	53	theme	nonsecretors	480:491	arg1	O-glycome					447:455	milk O-glycome	442:455	milk O-glycome of secretors (Se+) and nonsecretors (Se-)	442:497	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	5	54	theme	Se-	885:887	arg1	p < 0.05					898:905	p < 0.05	898:905	p < 0.05	898:905	Notably, 23 O-glycans exhibited significant differences between Se+ and Se- samples (p < 0.05).
37230641	5	54	theme	Se-	885:887	arg1	samples					889:895	Se+ and Se- samples	877:895	Se+ and Se- samples (p < 0.05)	877:906	Notably, 23 O-glycans exhibited significant differences between Se+ and Se- samples (p < 0.05).
37230641	1	55	theme	important	145:153	arg1	components					155:164	the important components	141:164	the important components of glycoconjugates in human milk	141:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	3	56	theme	secretors	460:468	arg1	O-glycome					447:455	milk O-glycome	442:455	milk O-glycome of secretors (Se+) and nonsecretors (Se-)	442:497	Currently, milk O-glycome of secretors (Se+) and nonsecretors (Se-) was investigated through reductive β-elimination combined with porous graphitized carbon-liquid chromatography-electrospray ionization-tandem mass spectrometry.
37230641	1	57	theme	similar	250:256	arg1	features					241:248	protective features	230:248	protective features similar to those observed in free oligosaccharides	230:299	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	0	58	theme	milk	68:71	arg1	O-glycopatterns					73:87	human milk O-glycopatterns	62:87	human milk O-glycopatterns from different secretor status	62:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	0	59	from	analysis	36:43	arg1	O-glycopatterns					73:87	human milk O-glycopatterns	62:87	human milk O-glycopatterns from different secretor status	62:118	Online PGC-LC-ESI-MS/MS comparative analysis of variations in human milk O-glycopatterns from different secretor status.
37230641	1	60	theme	components	155:164	arg1	components					155:164	the important components	141:164	the important components of glycoconjugates in human milk	141:197	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
37230641	1	60	theme	components	155:164	arg1	one					134:136	one	134:136	one	134:136	O-glycome is one of the important components of glycoconjugates in human milk which is speculated to provide protective features similar to those observed in free oligosaccharides.
36478308	12	0	theme	different	1880:1888	arg1	facilities					1904:1913	different manufacturing facilities	1880:1913	different manufacturing facilities	1880:1913	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	14	1	theme	published	2204:2212	arg1	findings					2214:2221	published findings	2204:2221	published findings	2204:2221	We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.
36478308	10	2	theme	mannose	1466:1472	arg1	structures					1474:1483	high mannose structures	1461:1483	high mannose structures	1461:1483	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	1	3	theme	vaccine	282:288	arg1	proteins					244:251	recombinant spike proteins	226:251	recombinant spike proteins	226:251	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	3	theme	vaccine	282:288	arg1	antigens					290:297	candidate vaccine antigens	272:297	candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	272:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	6	4	theme	mass	949:952	arg1	spectrometry					954:965	a data dependent acquisition (DDA) mass spectrometry	914:965	a data dependent acquisition (DDA) mass spectrometry experiment	914:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	3	5	theme	processing	578:587	arg1	sets					594:597	processing data sets	578:597	processing data sets from individual batches from first principles	578:643	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	6	6	theme	DDA	944:946	arg1	spectrometry					954:965	a data dependent acquisition (DDA) mass spectrometry	914:965	a data dependent acquisition (DDA) mass spectrometry experiment	914:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	14	7	theme	obtained	2091:2098	arg1	data					2100:2103	previously obtained data	2080:2103	previously obtained data from a commercially available insect cell derived spike protein	2080:2167	We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.
36478308	6	8	theme	acquisition	931:941	arg1	spectrometry					954:965	a data dependent acquisition (DDA) mass spectrometry	914:965	a data dependent acquisition (DDA) mass spectrometry experiment	914:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	3	9	theme	individual	604:613	arg1	batches					615:621	individual batches	604:621	individual batches from first principles	604:643	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	1	10	theme	insect	206:211	arg1	developed					259:267	developed	259:267	being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	253:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	10	theme	insect	206:211	arg1	cell					213:216	a Sf9 insect cell	200:216	a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	200:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	6	11	gly	glycopeptides	848:860	arg2	glycopeptides					848:860	The glycopeptides	844:860	The glycopeptides	844:860	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	11	12	theme	spike	1627:1631	arg1	protein					1633:1639	a commercially available spike protein	1602:1639	a commercially available spike protein	1602:1639	A comparison was performed on a commercially available spike protein and our results were found to be similar to earlier reports.
36478308	5	13	theme	different	747:755	arg1	digests					766:772	Three different protease digests	741:772	Three different protease digests	741:772	Three different protease digests were utilised to generate peptides with isolated glycosylation sites.
36478308	10	14	dep	sites	1431:1435	arg1	sites					1431:1435	sites N61, N234, and N717/714	1431:1459	sites N61, N234, and N717/714	1431:1459	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	10	14	dep	sites	1431:1435	arg1	N234					1442:1445	N234	1442:1445	N234	1442:1445	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	10	14	dep	sites	1431:1435	arg1	N717/714					1452:1459	N717/714	1452:1459	N717/714	1452:1459	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	10	14	dep	sites	1431:1435	arg1	N61					1437:1439	N61	1437:1439	N61	1437:1439	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	7	15	used	used	1117:1120	arg2	workflow					1103:1110	a specialised workflow	1089:1110	a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time	1089:1201	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	7	16	theme	detected	1146:1153	arg1	glycopeptides					1155:1167	previously detected glycopeptides	1135:1167	previously detected glycopeptides	1135:1167	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	7	17	theme	specialised	1091:1101	arg1	workflow					1103:1110	a specialised workflow	1089:1110	a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time	1089:1201	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	1	18	theme	spike	238:242	arg1	proteins					244:251	recombinant spike proteins	226:251	recombinant spike proteins	226:251	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	18	theme	spike	238:242	arg1	antigens					290:297	candidate vaccine antigens	272:297	candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	272:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	12	19	theme	protein	1789:1795	arg1	variants					1797:1804	both spike protein variants	1778:1804	both spike protein variants	1778:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	10	20	theme	high	1461:1464	arg1	structures					1474:1483	high mannose structures	1461:1483	high mannose structures	1461:1483	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	1	21	gly	N-glycosylation	173:187	arg1	developed					259:267	developed	259:267	being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	253:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	21	gly	N-glycosylation	173:187	arg1	cell					213:216	a Sf9 insect cell	200:216	a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	200:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	5	22	with	peptides	800:807	arg1	sites					837:841	isolated glycosylation sites	814:841	isolated glycosylation sites	814:841	Three different protease digests were utilised to generate peptides with isolated glycosylation sites.
36478308	4	23	theme	proteolytic	720:730	arg1	enzymes					732:738	proteolytic enzymes	720:738	proteolytic enzymes	720:738	METHOD Purified spike proteins were reduced, alkylated, and digested with proteolytic enzymes.
36478308	13	24	theme	large	2032:2036	arg1	glycoprotein					2038:2049	a large glycoprotein	2030:2049	a large glycoprotein	2030:2049	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	0	25	theme	Vaccine	82:88	arg1	Candidates					90:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	13	26	theme	site-specific	1990:2002	arg1	data					2021:2024	site-specific glycan occupancy data	1990:2024	site-specific glycan occupancy data	1990:2024	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	5	27	theme	glycosylation	823:835	arg1	sites					837:841	isolated glycosylation sites	814:841	isolated glycosylation sites	814:841	Three different protease digests were utilised to generate peptides with isolated glycosylation sites.
36478308	2	28	gly	glycosylation	407:419	arg2	sites					421:425	single, isolated glycosylation sites	390:425	single, isolated glycosylation sites	390:425	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	1	29	dep	RATIONALE	149:157	arg1	We					159:160	We	159:160	We	159:160	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	13	30	theme	occupancy	2011:2019	arg1	data					2021:2024	site-specific glycan occupancy data	1990:2024	site-specific glycan occupancy data	1990:2024	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	14	31	from	cell	2142:2145	arg1	data					2100:2103	previously obtained data	2080:2103	previously obtained data from a commercially available insect cell derived spike protein	2080:2167	We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.
36478308	14	32	theme	insect	2135:2140	arg1	cell					2142:2145	a commercially available insect cell	2110:2145	a commercially available insect cell derived spike protein	2110:2167	We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.
36478308	10	33	theme	variant	1554:1560	arg1	proteins					1562:1569	both variant proteins	1549:1569	both variant proteins	1549:1569	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	5	34	gly	glycosylation	823:835	arg2	sites					837:841	isolated glycosylation sites	814:841	isolated glycosylation sites	814:841	Three different protease digests were utilised to generate peptides with isolated glycosylation sites.
36478308	10	35	theme	present	1382:1388	arg1	glycans					1374:1380	the glycans	1370:1380	the glycans present	1370:1388	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	7	36	theme	data	1000:1003	arg1	processing					1005:1014	Glycopeptide mapping data processing	979:1014	Glycopeptide mapping data processing	979:1014	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	12	37	theme	overall	1745:1751	arg1	pattern					1767:1773	the overall glycosylation pattern	1741:1773	the overall glycosylation pattern of both spike protein variants	1741:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	12	37	theme	overall	1745:1751	arg1	similar					1817:1823	similar	1817:1823	similar	1817:1823	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	8	38	dep	proteins	1232:1239	arg1	manufacturers					1248:1260	6 manufacturers	1246:1260	6 manufacturers	1246:1260	RESULTS Two different spike proteins from 6 manufacturers were analysed.
36478308	2	39	theme	single	390:395	arg1	sites					421:425	single, isolated glycosylation sites	390:425	single, isolated glycosylation sites	390:425	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	0	40	theme	Glycopeptide	0:11	arg1	Characterization					13:28	Glycopeptide Characterization	0:28	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	0:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	7	41	theme	Glycopeptide	979:990	arg1	data					1000:1003	Glycopeptide mapping data	979:1003	Glycopeptide mapping data processing	979:1014	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	11	42	theme	available	1617:1625	arg1	protein					1633:1639	a commercially available spike protein	1602:1639	a commercially available spike protein	1602:1639	A comparison was performed on a commercially available spike protein and our results were found to be similar to earlier reports.
36478308	10	43	theme	truncated	1402:1410	arg1	class					1412:1416	the truncated class	1398:1416	the truncated class	1398:1416	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	2	44	theme	multiple	433:440	arg1	digests					451:457	multiple protease digests	433:457	multiple protease digests	433:457	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	6	45	theme	dependent	921:929	arg1	spectrometry					954:965	a data dependent acquisition (DDA) mass spectrometry	914:965	a data dependent acquisition (DDA) mass spectrometry experiment	914:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	13	46	theme	libraries	1944:1952	arg1	use					1920:1922	The use	1916:1922	The use of our glycopeptide libraries	1916:1952	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	6	47	dep	Q-TOF	896:900	arg1	using					908:912	using	908:912	using a data dependent acquisition (DDA) mass spectrometry experiment	908:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	3	48	from	principles	634:643	arg1	batches					615:621	individual batches	604:621	individual batches from first principles	604:643	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	0	49	theme	SARS-CoV-2	45:54	arg1	Candidates					90:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	8	50	from	proteins	1232:1239	arg1	RESULTS					1204:1210	RESULTS	1204:1210	RESULTS Two different spike proteins from 6 manufacturers	1204:1260	RESULTS Two different spike proteins from 6 manufacturers were analysed.
36478308	0	51	theme	Protein	62:68	arg1	Candidates					90:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	14	52	theme	spike	2155:2159	arg1	protein					2161:2167	spike protein	2155:2167	spike protein	2155:2167	We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.
36478308	2	53	dep	single	390:395	arg1	isolated					398:405	isolated	398:405	isolated	398:405	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	12	54	dep	CONCLUSION	1702:1711	arg1	shows					1730:1734	shows	1730:1734	shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities	1730:1913	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	3	55	theme	glycopeptide	487:498	arg1	libraries					500:508	glycopeptide libraries	487:508	glycopeptide libraries from previous developmental phases	487:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	13	56	gly	glycopeptide	1931:1942	arg2	glycopeptide					1931:1942	our glycopeptide libraries	1927:1952	our glycopeptide libraries	1927:1952	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	6	57	theme	Waters	889:894	arg1	Q-TOF					896:900	a Waters Q-TOF	887:900	a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment	887:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	8	58	theme	spike	1226:1230	arg1	proteins					1232:1239	Two different spike proteins	1212:1239	Two different spike proteins	1212:1239	RESULTS Two different spike proteins from 6 manufacturers were analysed.
36478308	12	59	theme	manufacturing	1890:1902	arg1	facilities					1904:1913	different manufacturing facilities	1880:1913	different manufacturing facilities	1880:1913	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	4	60	theme	Purified	653:660	arg1	proteins					668:675	METHOD Purified spike proteins	646:675	METHOD Purified spike proteins	646:675	METHOD Purified spike proteins were reduced, alkylated, and digested with proteolytic enzymes.
36478308	11	61	theme	earlier	1685:1691	arg1	reports					1693:1699	earlier reports	1685:1699	earlier reports	1685:1699	A comparison was performed on a commercially available spike protein and our results were found to be similar to earlier reports.
36478308	3	62	theme	developmental	524:536	arg1	phases					538:543	previous developmental phases	515:543	previous developmental phases	515:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	1	63	theme	candidate	272:280	arg1	proteins					244:251	recombinant spike proteins	226:251	recombinant spike proteins	226:251	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	63	theme	candidate	272:280	arg1	antigens					290:297	candidate vaccine antigens	272:297	candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	272:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	6	64	theme	spectrometry	954:965	arg1	experiment					967:976	a data dependent acquisition (DDA) mass spectrometry experiment	914:976	a data dependent acquisition (DDA) mass spectrometry experiment	914:976	The glycopeptides were then analysed using a Waters Q-TOF while using a data dependent acquisition (DDA) mass spectrometry experiment.
36478308	3	65	from	phases	538:543	arg1	use					480:482	use	480:482	use	480:482	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	3	65	from	phases	538:543	arg1	libraries					500:508	glycopeptide libraries	487:508	glycopeptide libraries from previous developmental phases	487:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	3	65	from	phases	538:543	arg1	development					464:474	development	464:474	development	464:474	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	7	66	theme	processing	1187:1196	arg1	time					1198:1201	processing time	1187:1201	processing time	1187:1201	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	9	67	theme	strong	1289:1294	arg1	similarity					1296:1305	a strong similarity	1287:1305	a strong similarity	1287:1305	There was a strong similarity at each site across batches and manufacturers.
36478308	3	68	theme	faster	557:562	arg1	analysis					564:571	faster analysis	557:571	faster analysis	557:571	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	1	69	theme	Sf9	202:204	arg1	developed					259:267	developed	259:267	being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	253:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	69	theme	Sf9	202:204	arg1	cell					213:216	a Sf9 insect cell	200:216	a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	200:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	10	70	from	N1173/1170	1506:1515	arg1	dominant					1536:1543	dominant	1536:1543	dominant	1536:1543	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	7	71	theme	glycopeptides	1155:1167	arg1	libraries					1122:1130	libraries	1122:1130	libraries of previously detected glycopeptides	1122:1167	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	3	72	theme	data	589:592	arg1	sets					594:597	processing data sets	578:597	processing data sets from individual batches from first principles	578:643	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	1	73	theme	cell	213:216	arg1	pattern					189:195	the N-glycosylation pattern	169:195	the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	169:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	5	74	theme	protease	757:764	arg1	digests					766:772	Three different protease digests	741:772	Three different protease digests	741:772	Three different protease digests were utilised to generate peptides with isolated glycosylation sites.
36478308	3	75	theme	first	628:632	arg1	principles					634:643	first principles	628:643	first principles	628:643	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	1	76	theme	recombinant	226:236	arg1	proteins					244:251	recombinant spike proteins	226:251	recombinant spike proteins	226:251	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	76	theme	recombinant	226:236	arg1	antigens					290:297	candidate vaccine antigens	272:297	candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	272:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	13	77	gly	glycoprotein	2038:2049	arg1	glycoprotein					2038:2049	a large glycoprotein	2030:2049	a large glycoprotein	2030:2049	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	13	78	theme	data	2021:2024	arg1	generation					1976:1985	the generation	1972:1985	the generation of site-specific glycan occupancy data for a large glycoprotein	1972:2049	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	12	79	theme	spike	1783:1787	arg1	variants					1797:1804	both spike protein variants	1778:1804	both spike protein variants	1778:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	0	80	theme	Candidates	90:99	arg1	Characterization					13:28	Glycopeptide Characterization	0:28	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	0:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	12	81	theme	variants	1797:1804	arg1	pattern					1767:1773	the overall glycosylation pattern	1741:1773	the overall glycosylation pattern of both spike protein variants	1741:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	12	81	theme	variants	1797:1804	arg1	similar					1817:1823	similar	1817:1823	similar	1817:1823	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	7	82	gly	glycopeptides	1155:1167	arg2	glycopeptides					1155:1167	previously detected glycopeptides	1135:1167	previously detected glycopeptides	1135:1167	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	5	83	theme	isolated	814:821	arg1	sites					837:841	isolated glycosylation sites	814:841	isolated glycosylation sites	814:841	Three different protease digests were utilised to generate peptides with isolated glycosylation sites.
36478308	1	84	theme	N-glycosylation	173:187	arg1	pattern					189:195	the N-glycosylation pattern	169:195	the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	169:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	12	85	theme	glycosylation	1753:1765	arg1	pattern					1767:1773	the overall glycosylation pattern	1741:1773	the overall glycosylation pattern of both spike protein variants	1741:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	12	85	theme	glycosylation	1753:1765	arg1	similar					1817:1823	similar	1817:1823	similar	1817:1823	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	0	86	theme	Libraries	138:146	arg1	Use					118:120	the Use	114:120	the Use of Glycopeptide Libraries	114:146	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	2	87	with	peptides	376:383	arg1	sites					421:425	single, isolated glycosylation sites	390:425	single, isolated glycosylation sites	390:425	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	13	88	theme	glycan	2004:2009	arg1	data					2021:2024	site-specific glycan occupancy data	1990:2024	site-specific glycan occupancy data	1990:2024	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	0	89	theme	Glycopeptide	125:136	arg1	Libraries					138:146	Glycopeptide Libraries	125:146	Glycopeptide Libraries	125:146	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	7	90	theme	glycan	1020:1025	arg1	classification					1027:1040	glycan classification	1020:1040	glycan classification	1020:1040	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	14	91	theme	available	2125:2133	arg1	cell					2142:2145	a commercially available insect cell	2110:2145	a commercially available insect cell derived spike protein	2110:2167	We compared our method with previously obtained data from a commercially available insect cell derived spike protein and the results were comparable to published findings.
36478308	10	92	theme	glycans	1374:1380	arg1	majority					1358:1365	The majority	1354:1365	The majority of the glycans present	1354:1388	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	10	93	from	sites	1431:1435	arg1	dominant					1490:1497	dominant	1490:1497	dominant	1490:1497	The majority of the glycans present were of the truncated class, although at sites N61, N234, and N717/714 high mannose structures were dominant and at N1173/1170 aglycosylation was dominant for both variant proteins.
36478308	12	94	gly	glycosylation	1753:1765	arg1	variants					1797:1804	both spike protein variants	1778:1804	both spike protein variants	1778:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	3	95	from	batches	615:621	arg1	sets					594:597	processing data sets	578:597	processing data sets from individual batches from first principles	578:643	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	0	96	theme	Sf9-Derived	33:43	arg1	Candidates					90:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	7	97	theme	mapping	992:998	arg1	data					1000:1003	Glycopeptide mapping data	979:1003	Glycopeptide mapping data processing	979:1014	Glycopeptide mapping data processing and glycan classification was performed using Genedata Expressionist via a specialised workflow that used libraries of previously detected glycopeptides to greatly reduce processing time.
36478308	12	98	from	batch-to-batch	1830:1843	arg1	similar					1817:1823	similar	1817:1823	similar	1817:1823	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	12	98	from	batch-to-batch	1830:1843	arg1	pattern					1767:1773	the overall glycosylation pattern	1741:1773	the overall glycosylation pattern of both spike protein variants	1741:1804	CONCLUSION Our data clearly shows that the overall glycosylation pattern of both spike protein variants was highly similar from batch-to-batch, and between materials produced at different manufacturing facilities.
36478308	2	99	theme	protease	442:449	arg1	digests					451:457	multiple protease digests	433:457	multiple protease digests	433:457	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	3	100	gly	glycopeptide	487:498	arg2	glycopeptide					487:498	glycopeptide libraries	487:508	glycopeptide libraries from previous developmental phases	487:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	13	101	theme	glycopeptide	1931:1942	arg1	libraries					1944:1952	our glycopeptide libraries	1927:1952	our glycopeptide libraries	1927:1952	The use of our glycopeptide libraries greatly expedited the generation of site-specific glycan occupancy data for a large glycoprotein.
36478308	0	102	theme	Spike	56:60	arg1	Candidates					90:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	3	103	from	development	464:474	arg1	phases					538:543	previous developmental phases	515:543	previous developmental phases	515:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	2	104	theme	glycosylation	407:419	arg1	sites					421:425	single, isolated glycosylation sites	390:425	single, isolated glycosylation sites	390:425	The method has been optimised to produce peptides with single, isolated glycosylation sites using multiple protease digests.
36478308	0	105	theme	Recombinant	70:80	arg1	Candidates					90:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates	33:99	Glycopeptide Characterization of Sf9-Derived SARS-CoV-2 Spike Protein Recombinant Vaccine Candidates Expedited by the Use of Glycopeptide Libraries.
36478308	3	106	from	use	480:482	arg1	phases					538:543	previous developmental phases	515:543	previous developmental phases	515:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	3	107	theme	previous	515:522	arg1	phases					538:543	previous developmental phases	515:543	previous developmental phases	515:543	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	8	108	theme	different	1216:1224	arg1	proteins					1232:1239	Two different spike proteins	1212:1239	Two different spike proteins	1212:1239	RESULTS Two different spike proteins from 6 manufacturers were analysed.
36478308	3	109	dep	development	464:474	arg1	The					460:462	The	460:462	The	460:462	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	4	110	theme	METHOD	646:651	arg1	proteins					668:675	METHOD Purified spike proteins	646:675	METHOD Purified spike proteins	646:675	METHOD Purified spike proteins were reduced, alkylated, and digested with proteolytic enzymes.
36478308	3	111	theme	libraries	500:508	arg1	use					480:482	use	480:482	use	480:482	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	3	111	theme	libraries	500:508	arg1	development					464:474	development	464:474	development	464:474	The development and use of glycopeptide libraries from previous developmental phases allowed for faster analysis than processing data sets from individual batches from first principles.
36478308	4	112	theme	spike	662:666	arg1	proteins					668:675	METHOD Purified spike proteins	646:675	METHOD Purified spike proteins	646:675	METHOD Purified spike proteins were reduced, alkylated, and digested with proteolytic enzymes.
36478308	1	113	dep	derived	218:224	arg1	developed					259:267	developed	259:267	being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	253:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36478308	1	113	dep	derived	218:224	arg1	cell					213:216	a Sf9 insect cell	200:216	a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi)	200:332	RATIONALE We report the N-glycosylation pattern of a Sf9 insect cell derived recombinant spike proteins being developed as candidate vaccine antigens for SARS-CoV-2 (COVID-19) (Sanofi).
36422041	7	0	from	changes	1273:1279	arg1	composition					1298:1308	the cell wall composition	1284:1308	the cell wall composition	1284:1308	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	8	1	theme	complement	1562:1571	arg1	receptor					1573:1580	complement receptor 3-	1562:1583	complement receptor 3-	1562:1583	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	7	2	with	mutants	1185:1191	arg1	levels					1211:1216	intermediate levels	1198:1216	intermediate levels of ROT2 silencing	1198:1234	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	3	3	with	interaction	676:686	arg1	host					697:700	the host	693:700	the host	693:700	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	4	4	theme	N-linked	842:849	arg1	processing					863:872	the N-linked glycan core processing	838:872	the N-linked glycan core processing	838:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	1	5	theme	common	239:244	arg1	agents					258:263	the most common etiological agents	230:263	the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings	230:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	7	6	theme	chitin	1344:1349	arg1	exposure					1314:1321	exposure	1314:1321	exposure of β-1.3-glucans and chitin	1314:1349	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	7	6	theme	chitin	1344:1349	arg1	changes					1273:1279	changes	1273:1279	changes in the cell wall composition	1273:1308	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	5	7	from	reduction	975:983	arg1	content					998:1004	the total content	988:1004	the total content of N-linked glycans found in the wall	988:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	5	8	located	found	1026:1030	arg2	glycans					1018:1024	N-linked glycans	1009:1024	N-linked glycans found in the wall	1009:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	5	8	located	found	1026:1030	arg1	wall					1039:1042	the wall	1035:1042	the wall	1035:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	6	9	with	mechanism	1104:1112	arg1	content					1129:1135	increased content	1119:1135	increased content of cell wall O-linked glycans	1119:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	8	10	link	monocyte-derived	1508:1523	arg1	macrophages					1525:1535	human monocyte-derived macrophages	1502:1535	human monocyte-derived macrophages	1502:1535	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	0	11	theme	Cell	94:97	arg1	Wall					99:102	the Cell Wall	90:102	the Cell Wall	90:102	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	5	12	theme	N-linked	1009:1016	arg1	glycans					1018:1024	N-linked glycans	1009:1024	N-linked glycans found in the wall	1009:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	2	13	theme	O-linked	525:532	arg1	glycans					534:540	both N-linked and O-linked glycans	507:540	both N-linked and O-linked glycans	507:540	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	1	14	theme	Sporothrix	191:200	arg1	clade					213:217	the Sporothrix pathogenic clade	187:217	the Sporothrix pathogenic clade	187:217	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	4	15	theme	core	858:861	arg1	processing					863:872	the N-linked glycan core processing	838:872	the N-linked glycan core processing	838:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	6	16	link	O-linked	1150:1157	arg1	glycans					1159:1165	cell wall O-linked glycans	1140:1165	cell wall O-linked glycans	1140:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	0	17	theme	Sporothrix	112:121	arg1	Interaction					138:148	the Sporothrix schenckii-Host Interaction	108:148	the Sporothrix schenckii-Host Interaction	108:148	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	10	18	theme	schenckii	1736:1744	arg1	ROT2					1746:1749	S. schenckii ROT2	1733:1749	S. schenckii ROT2	1733:1749	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	4	19	dep	silenced	712:719	arg1	encodes					733:739	encodes	733:739	encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing	733:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	9	20	theme	mutant	1675:1680	arg1	cells					1682:1686	these mutant cells	1669:1686	these mutant cells	1669:1686	In an insect model of experimental sporotrichosis, these mutant cells showed virulence attenuation.
36422041	7	21	theme	cell	1288:1291	arg1	composition					1298:1308	the cell wall composition	1284:1308	the cell wall composition	1284:1308	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	6	22	theme	O-linked	1150:1157	arg1	glycans					1159:1165	cell wall O-linked glycans	1140:1165	cell wall O-linked glycans	1140:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	10	23	theme	N-linked	1774:1781	arg1	glycosylation					1783:1795	proper N-linked glycosylation	1767:1795	proper N-linked glycosylation	1767:1795	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	8	24	theme	cytokine	1410:1417	arg1	production					1419:1428	cytokine production	1410:1428	cytokine production by human mononuclear cells	1410:1455	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	6	25	theme	cell	1140:1143	arg1	glycans					1159:1165	cell wall O-linked glycans	1140:1165	cell wall O-linked glycans	1140:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	3	26	theme	glycosylation	588:600	arg1	pathway					602:608	the N-linked glycosylation pathway	575:608	the N-linked glycosylation pathway in this organism	575:625	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	0	27	theme	Reticulum	56:64	arg1	ROT2					13:16	ROT2	13:16	ROT2	13:16	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	0	27	theme	Reticulum	56:64	arg1	Gene					32:35	the Encoding Gene	19:35	the Encoding Gene of the Endoplasmic Reticulum Glucosidase II	19:79	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	5	28	link	N-linked	1009:1016	arg1	glycans					1018:1024	N-linked glycans	1009:1024	N-linked glycans found in the wall	1009:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	2	29	theme	N-linked	512:519	arg1	glycans					534:540	both N-linked and O-linked glycans	507:540	both N-linked and O-linked glycans	507:540	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	7	30	theme	wall	1293:1296	arg1	composition					1298:1308	the cell wall composition	1284:1308	the cell wall composition	1284:1308	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	1	31	theme	animal	334:339	arg1	beings					351:356	both animal and human beings	329:356	both animal and human beings	329:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	5	32	theme	Glc2Man9GlcNAC2	924:938	arg1	core					947:950	the Glc2Man9GlcNAC2 glycan core	920:950	the Glc2Man9GlcNAC2 glycan core	920:950	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	2	33	theme	fungal	370:375	arg1	pathogens					377:385	other fungal pathogens	364:385	other fungal pathogens	364:385	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	1	34	theme	human	345:349	arg1	beings					351:356	both animal and human beings	329:356	both animal and human beings	329:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	5	35	theme	core	947:950	arg1	accumulation					904:915	the accumulation	900:915	the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall	900:967	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	5	35	theme	core	947:950	arg1	reduction					975:983	a reduction	973:983	a reduction in the total content of N-linked glycans found in the wall	973:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	10	36	with	interaction	1842:1852	arg1	host					1863:1866	the host	1859:1866	the host	1859:1866	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	3	37	link	N-linked	579:586	arg1	pathway					602:608	the N-linked glycosylation pathway	575:608	the N-linked glycosylation pathway in this organism	575:625	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	1	38	theme	etiological	246:256	arg1	agents					258:263	the most common etiological agents	230:263	the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings	230:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	0	39	dep	Reticulum	56:64	arg1	Glucosidase					66:76	Glucosidase II	66:79	the Endoplasmic Reticulum Glucosidase II	40:79	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	10	40	theme	proper	1767:1772	arg1	glycosylation					1783:1795	proper N-linked glycosylation	1767:1795	proper N-linked glycosylation	1767:1795	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	2	41	theme	Sporothrix	392:401	arg1	wall					408:411	the Sporothrix cell wall	388:411	the Sporothrix cell wall	388:411	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	0	42	theme	ROT2	13:16	arg1	Silencing					0:8	Silencing	0:8	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II,	0:80	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	7	43	from	exposure	1314:1321	arg1	composition					1298:1308	the cell wall composition	1284:1308	the cell wall composition	1284:1308	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	9	44	theme	insect	1624:1629	arg1	model					1631:1635	an insect model	1621:1635	an insect model of experimental sporotrichosis	1621:1666	In an insect model of experimental sporotrichosis, these mutant cells showed virulence attenuation.
36422041	4	45	theme	reticulum	782:790	arg1	which					727:731	which	727:731	which	727:731	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	4	45	theme	reticulum	782:790	arg1	enzyme					823:828	a processing enzyme key	810:832	a processing enzyme key for the N-linked glycan core processing	810:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	4	45	theme	reticulum	782:790	arg1	subunit					755:761	the catalytic subunit	741:761	the catalytic subunit of the endoplasmic reticulum α-glucosidase II	741:807	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	2	46	theme	structural	428:437	arg1	polysaccharides					439:453	structural polysaccharides	428:453	structural polysaccharides	428:453	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	8	47	theme	human	1502:1506	arg1	macrophages					1525:1535	human monocyte-derived macrophages	1502:1535	human monocyte-derived macrophages	1502:1535	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	1	48	theme	subcutaneous	286:297	arg1	infection					306:314	a subcutaneous fungal infection	284:314	a subcutaneous fungal infection that affects both animal and human beings	284:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	1	48	theme	subcutaneous	286:297	arg1	sporotrichosis					268:281	sporotrichosis	268:281	sporotrichosis	268:281	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	7	49	theme	silencing	1226:1234	arg1	levels					1211:1216	intermediate levels	1198:1216	intermediate levels of ROT2 silencing	1198:1234	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	3	50	theme	wall	655:658	arg1	composition					660:670	cell wall composition	650:670	cell wall composition	650:670	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	1	51	theme	pathogenic	202:211	arg1	clade					213:217	the Sporothrix pathogenic clade	187:217	the Sporothrix pathogenic clade	187:217	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	10	52	with	wall	1803:1806	arg1	host					1863:1866	the host	1859:1866	the host	1859:1866	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	3	53	from	contribution	634:645	arg1	organism					618:625	this organism	613:625	this organism	613:625	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	8	54	theme	TLR4-dependent	1590:1603	arg1	stimulation					1605:1615	TLR4-dependent stimulation	1590:1615	TLR4-dependent stimulation	1590:1615	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	7	55	theme	intermediate	1198:1209	arg1	levels					1211:1216	intermediate levels	1198:1216	intermediate levels of ROT2 silencing	1198:1234	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	8	56	theme	mannose	1543:1549	arg1	receptor-					1551:1559	a mannose receptor-	1541:1559	a mannose receptor-	1541:1559	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	4	57	theme	key	830:832	arg1	enzyme					823:828	a processing enzyme key	810:832	a processing enzyme key for the N-linked glycan core processing	810:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	4	57	theme	key	830:832	arg1	subunit					755:761	the catalytic subunit	741:761	the catalytic subunit of the endoplasmic reticulum α-glucosidase II	741:807	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	7	58	theme	mutants	1185:1191	arg1	informative					1245:1255	informative	1245:1255	informative	1245:1255	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	7	58	theme	mutants	1185:1191	arg1	phenotype					1172:1180	The phenotype	1168:1180	The phenotype of mutants with intermediate levels of ROT2 silencing	1168:1234	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	6	59	theme	compensatory	1091:1102	arg1	mechanism					1104:1112	a compensatory mechanism	1089:1112	a compensatory mechanism with increased content of cell wall O-linked glycans	1089:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	6	60	theme	increased	1119:1127	arg1	content					1129:1135	increased content	1119:1135	increased content of cell wall O-linked glycans	1119:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	2	61	link	O-linked	525:532	arg1	glycans					534:540	both N-linked and O-linked glycans	507:540	both N-linked and O-linked glycans	507:540	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	10	62	dep	wall	1803:1806	arg1	composition					1825:1835	composition	1825:1835	composition	1825:1835	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	10	62	dep	wall	1803:1806	arg1	organization					1808:1819	organization	1808:1819	organization	1808:1819	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	6	63	theme	silenced	1065:1072	arg1	mutants					1074:1080	the highly silenced mutants	1054:1080	the highly silenced mutants	1054:1080	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	5	64	from	wall	964:967	arg1	accumulation					904:915	the accumulation	900:915	the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall	900:967	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	5	64	from	wall	964:967	arg1	reduction					975:983	a reduction	973:983	a reduction in the total content of N-linked glycans found in the wall	973:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	7	65	theme	cell	1358:1361	arg1	surface					1363:1369	the cell surface	1354:1369	the cell surface	1354:1369	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	4	66	link	N-linked	842:849	arg1	processing					863:872	the N-linked glycan core processing	838:872	the N-linked glycan core processing	838:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	10	67	theme	S.	1733:1734	arg1	ROT2					1746:1749	S. schenckii ROT2	1733:1749	S. schenckii ROT2	1733:1749	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	4	68	theme	processing	812:821	arg1	enzyme					823:828	a processing enzyme key	810:832	a processing enzyme key for the N-linked glycan core processing	810:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	4	68	theme	processing	812:821	arg1	subunit					755:761	the catalytic subunit	741:761	the catalytic subunit of the endoplasmic reticulum α-glucosidase II	741:807	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	5	69	theme	glycans	1018:1024	arg1	content					998:1004	the total content	988:1004	the total content of N-linked glycans found in the wall	988:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	9	70	theme	sporotrichosis	1653:1666	arg1	model					1631:1635	an insect model	1621:1635	an insect model of experimental sporotrichosis	1621:1666	In an insect model of experimental sporotrichosis, these mutant cells showed virulence attenuation.
36422041	0	71	theme	schenckii-Host	123:136	arg1	Interaction					138:148	the Sporothrix schenckii-Host Interaction	108:148	the Sporothrix schenckii-Host Interaction	108:148	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	8	72	theme	mononuclear	1439:1449	arg1	cells					1451:1455	human mononuclear cells	1433:1455	human mononuclear cells	1433:1455	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	10	73	with	glycosylation	1783:1795	arg1	host					1863:1866	the host	1859:1866	the host	1859:1866	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	4	74	theme	glycan	851:856	arg1	processing					863:872	the N-linked glycan core processing	838:872	the N-linked glycan core processing	838:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	6	75	theme	glycans	1159:1165	arg1	content					1129:1135	increased content	1119:1135	increased content of cell wall O-linked glycans	1119:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	5	76	theme	total	992:996	arg1	content					998:1004	the total content	988:1004	the total content of N-linked glycans found in the wall	988:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	5	77	theme	ROT2	888:891	arg1	Silencing					875:883	Silencing	875:883	Silencing of ROT2	875:891	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	7	78	theme	β-1.3-glucans	1326:1338	arg1	exposure					1314:1321	exposure	1314:1321	exposure of β-1.3-glucans and chitin	1314:1349	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	7	78	theme	β-1.3-glucans	1326:1338	arg1	changes					1273:1279	changes	1273:1279	changes in the cell wall composition	1273:1308	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	6	79	theme	wall	1145:1148	arg1	glycans					1159:1165	cell wall O-linked glycans	1140:1165	cell wall O-linked glycans	1140:1165	However, the highly silenced mutants showed a compensatory mechanism with increased content of cell wall O-linked glycans.
36422041	0	80	theme	Endoplasmic	44:54	arg1	Reticulum					56:64	the Endoplasmic Reticulum Glucosidase II	40:79	the Endoplasmic Reticulum Glucosidase II	40:79	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	3	81	theme	N-linked	579:586	arg1	pathway					602:608	the N-linked glycosylation pathway	575:608	the N-linked glycosylation pathway in this organism	575:625	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	9	82	theme	virulence	1695:1703	arg1	attenuation					1705:1715	virulence attenuation	1695:1715	virulence attenuation	1695:1715	In an insect model of experimental sporotrichosis, these mutant cells showed virulence attenuation.
36422041	8	83	theme	human	1433:1437	arg1	cells					1451:1455	human mononuclear cells	1433:1455	human mononuclear cells	1433:1455	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	2	84	link	N-linked	512:519	arg1	glycans					534:540	both N-linked and O-linked glycans	507:540	both N-linked and O-linked glycans	507:540	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	2	85	mod	modified	493:500	arg1	glycoproteins					459:471	glycoproteins	459:471	glycoproteins	459:471	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	2	85	mod	modified	493:500	arg1	polysaccharides					439:453	structural polysaccharides	428:453	structural polysaccharides	428:453	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	2	85	mod	modified	493:500	arg3	glycans					534:540	both N-linked and O-linked glycans	507:540	both N-linked and O-linked glycans	507:540	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	10	86	link	N-linked	1774:1781	arg1	glycosylation					1783:1795	proper N-linked glycosylation	1767:1795	proper N-linked glycosylation	1767:1795	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	5	87	theme	glycan	940:945	arg1	core					947:950	the Glc2Man9GlcNAC2 glycan core	920:950	the Glc2Man9GlcNAC2 glycan core	920:950	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	3	88	from	pathway	602:608	arg1	organism					618:625	this organism	613:625	this organism	613:625	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	2	89	theme	other	364:368	arg1	pathogens					377:385	other fungal pathogens	364:385	other fungal pathogens	364:385	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	9	90	theme	experimental	1640:1651	arg1	sporotrichosis					1653:1666	experimental sporotrichosis	1640:1666	experimental sporotrichosis	1640:1666	In an insect model of experimental sporotrichosis, these mutant cells showed virulence attenuation.
36422041	1	91	theme	agents	258:263	arg1	one					223:225	one	223:225	one	223:225	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	1	91	theme	agents	258:263	arg1	agents					258:263	the most common etiological agents	230:263	the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings	230:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	2	92	gly	glycoproteins	459:471	arg1	glycoproteins					459:471	glycoproteins	459:471	glycoproteins	459:471	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	2	93	theme	cell	403:406	arg1	wall					408:411	the Sporothrix cell wall	388:411	the Sporothrix cell wall	388:411	Like other fungal pathogens, the Sporothrix cell wall is composed of structural polysaccharides and glycoproteins that are covalently modified with both N-linked and O-linked glycans.
36422041	0	94	theme	Encoding	23:30	arg1	ROT2					13:16	ROT2	13:16	ROT2	13:16	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	0	94	theme	Encoding	23:30	arg1	Gene					32:35	the Encoding Gene	19:35	the Encoding Gene of the Endoplasmic Reticulum Glucosidase II	19:79	Silencing of ROT2, the Encoding Gene of the Endoplasmic Reticulum Glucosidase II, Affects the Cell Wall and the Sporothrix schenckii-Host Interaction.
36422041	1	95	theme	sporotrichosis	268:281	arg1	agents					258:263	the most common etiological agents	230:263	the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings	230:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	8	96	theme	monocyte-derived	1508:1523	arg1	macrophages					1525:1535	human monocyte-derived macrophages	1502:1535	human monocyte-derived macrophages	1502:1535	Furthermore, the ability to stimulate cytokine production by human mononuclear cells was affected, along with the phagocytosis by human monocyte-derived macrophages, in a mannose receptor-, complement receptor 3-, and TLR4-dependent stimulation.
36422041	10	97	theme	cell	1798:1801	arg1	wall					1803:1806	cell wall organization and composition	1798:1835	cell wall organization and composition	1798:1835	In conclusion, S. schenckii ROT2 is required for proper N-linked glycosylation, cell wall organization and composition, and interaction with the host.
36422041	4	98	theme	endoplasmic	770:780	arg1	reticulum					782:790	the endoplasmic reticulum α-glucosidase II	766:807	the endoplasmic reticulum α-glucosidase II	766:807	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	7	99	theme	ROT2	1221:1224	arg1	silencing					1226:1234	ROT2 silencing	1221:1234	ROT2 silencing	1221:1234	The phenotype of mutants with intermediate levels of ROT2 silencing was more informative, as they showed changes in the cell wall composition and exposure of β-1.3-glucans and chitin at the cell surface.
36422041	3	100	theme	cell	650:653	arg1	composition					660:670	cell wall composition	650:670	cell wall composition	650:670	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
36422041	4	101	theme	α-glucosidase	792:804	arg1	reticulum					782:790	the endoplasmic reticulum α-glucosidase II	766:807	the endoplasmic reticulum α-glucosidase II	766:807	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	5	102	from	accumulation	904:915	arg1	content					998:1004	the total content	988:1004	the total content of N-linked glycans found in the wall	988:1042	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	1	103	theme	fungal	299:304	arg1	infection					306:314	a subcutaneous fungal infection	284:314	a subcutaneous fungal infection that affects both animal and human beings	284:356	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	1	103	theme	fungal	299:304	arg1	sporotrichosis					268:281	sporotrichosis	268:281	sporotrichosis	268:281	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	4	104	theme	catalytic	745:753	arg1	which					727:731	which	727:731	which	727:731	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	4	104	theme	catalytic	745:753	arg1	enzyme					823:828	a processing enzyme key	810:832	a processing enzyme key for the N-linked glycan core processing	810:872	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	4	104	theme	catalytic	745:753	arg1	subunit					755:761	the catalytic subunit	741:761	the catalytic subunit of the endoplasmic reticulum α-glucosidase II	741:807	Here, we silenced ROT2, which encodes the catalytic subunit of the endoplasmic reticulum α-glucosidase II, a processing enzyme key for the N-linked glycan core processing.
36422041	1	105	theme	clade	213:217	arg1	schenckii					162:170	Sporothrix schenckii	151:170	Sporothrix schenckii	151:170	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	1	105	theme	clade	213:217	arg1	member					177:182	a member	175:182	a member of the Sporothrix pathogenic clade	175:217	Sporothrix schenckii is a member of the Sporothrix pathogenic clade and one of the most common etiological agents of sporotrichosis, a subcutaneous fungal infection that affects both animal and human beings.
36422041	5	106	theme	cell	959:962	arg1	wall					964:967	the cell wall	955:967	the cell wall	955:967	Silencing of ROT2 led to the accumulation of the Glc2Man9GlcNAC2 glycan core at the cell wall and a reduction in the total content of N-linked glycans found in the wall.
36422041	3	107	with	composition	660:670	arg1	host					697:700	the host	693:700	the host	693:700	Thus far, little is known about the N-linked glycosylation pathway in this organism or its contribution to cell wall composition and interaction with the host.
37211816	0	0	theme	antibody	69:76	arg1	scaffold					78:85	the camelid VHH antibody scaffold	53:85	the camelid VHH antibody scaffold	53:85	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.
37211816	5	1	theme	VHH	1220:1222	arg1	sites					1240:1244	optimal artificial VHH N-glycosylation sites	1201:1244	optimal artificial VHH N-glycosylation sites identified in this study	1201:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	5	2	theme	glycobiology	1434:1445	arg1	toolbox					1413:1419	the rapidly expanding toolbox	1391:1419	the rapidly expanding toolbox of synthetic glycobiology	1391:1445	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	1	3	theme	stable	133:138	arg1	characteristics					193:207	attractive characteristics	182:207	attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics	182:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	1	3	theme	stable	133:138	arg1	binders					162:168	small and stable high-affinity antigen binders	123:168	small and stable high-affinity antigen binders	123:168	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	4	4	theme	potential	1057:1065	arg1	application					1067:1077	one potential application	1053:1077	one potential application of glyco-engineered VHHs	1053:1102	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	1	5	theme	various	237:243	arg1	indications					253:263	various disease indications	237:263	various disease indications	237:263	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	0	6	theme	VHH	65:67	arg1	scaffold					78:85	the camelid VHH antibody scaffold	53:85	the camelid VHH antibody scaffold	53:85	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.
37211816	3	7	dep	pastoris	659:666	arg1	strain					682:687	GlycoSwitchM5 strain	668:687	the Pichia pastoris GlycoSwitchM5 strain	648:687	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	1	8	theme	high-affinity	140:152	arg1	characteristics					193:207	attractive characteristics	182:207	attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics	182:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	1	8	theme	high-affinity	140:152	arg1	binders					162:168	small and stable high-affinity antigen binders	123:168	small and stable high-affinity antigen binders	123:168	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	4	9	theme	glyco-engineered	1082:1097	arg1	VHHs					1099:1102	glyco-engineered VHHs	1082:1102	glyco-engineered VHHs	1082:1102	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	1	10	theme	disease	245:251	arg1	indications					253:263	various disease indications	237:263	various disease indications	237:263	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	2	11	theme	associated	510:519	arg1	glycan					521:526	its associated glycan	506:526	its associated glycan	506:526	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	5	12	theme	targeted	1300:1307	arg1	glyco-engineering					1309:1325	targeted glyco-engineering	1300:1325	targeted glyco-engineering of other VHHs	1300:1339	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	2	13	theme	epitope	573:579	arg1	recognition					581:591	epitope recognition	573:591	epitope recognition	573:591	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	5	14	theme	site-specific	1351:1363	arg1	functionalization					1365:1381	site-specific functionalization	1351:1381	site-specific functionalization	1351:1381	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	4	15	theme	endolysosomal	1159:1171	arg1	delivery					1180:1187	lung macrophage endolysosomal system delivery	1143:1187	lung macrophage endolysosomal system delivery	1143:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	5	16	theme	expanding	1403:1411	arg1	toolbox					1413:1419	the rapidly expanding toolbox	1391:1419	the rapidly expanding toolbox of synthetic glycobiology	1391:1445	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	4	17	dep	efficient	933:941	arg1	glycan-dependent					944:959	glycan-dependent	944:959	glycan-dependent	944:959	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	4	18	theme	glycan-based	1107:1118	arg1	approach					1130:1137	a glycan-based targeting approach	1105:1137	a glycan-based targeting approach for lung macrophage endolysosomal system delivery	1105:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	4	19	theme	macrophage	1148:1157	arg1	delivery					1180:1187	lung macrophage endolysosomal system delivery	1143:1187	lung macrophage endolysosomal system delivery	1143:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	1	20	theme	antigen	154:160	arg1	characteristics					193:207	attractive characteristics	182:207	attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics	182:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	1	20	theme	antigen	154:160	arg1	binders					162:168	small and stable high-affinity antigen binders	123:168	small and stable high-affinity antigen binders	123:168	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	2	21	theme	sequon	495:500	arg1	introduction					454:465	the introduction	450:465	the introduction of an N-glycosylation N-X-T sequon and its associated glycan	450:526	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	1	22	from	reagents	283:290	arg1	research					295:302	research	295:302	research	295:302	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	1	22	from	reagents	283:290	arg1	diagnostics					308:318	diagnostics	308:318	diagnostics	308:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	3	23	theme	antigen	818:824	arg1	binding					826:832	antigen binding	818:832	antigen binding	818:832	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	2	24	theme	VHHs	360:363	arg1	versatility					345:355	the versatility	341:355	the versatility of VHHs	341:363	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	2	25	theme	select	429:434	arg1	regions					436:442	select regions	429:442	select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition	429:591	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	3	26	theme	preferred	714:722	arg1	sites					724:728	preferred sites	714:728	preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding	714:832	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	4	27	theme	Man5GlcNAc2	866:876	arg1	N-glycan					878:885	predominantly a Man5GlcNAc2 N-glycan	850:885	predominantly a Man5GlcNAc2 N-glycan	850:885	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	2	28	theme	N-X-T	489:493	arg1	sequon					495:500	an N-glycosylation N-X-T sequon	470:500	an N-glycosylation N-X-T sequon	470:500	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	2	29	gly	N-glycosylation	473:487	arg2	sequon					495:500	an N-glycosylation N-X-T sequon	470:500	an N-glycosylation N-X-T sequon	470:500	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	4	30	theme	system	1173:1178	arg1	delivery					1180:1187	lung macrophage endolysosomal system delivery	1143:1187	lung macrophage endolysosomal system delivery	1143:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	5	31	theme	optimal	1201:1207	arg1	sites					1240:1244	optimal artificial VHH N-glycosylation sites	1201:1244	optimal artificial VHH N-glycosylation sites identified in this study	1201:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	5	32	theme	sites	1240:1244	arg1	set					1194:1196	The set	1190:1196	The set of optimal artificial VHH N-glycosylation sites identified in this study	1190:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	5	32	theme	sites	1240:1244	arg1	sites					1240:1244	optimal artificial VHH N-glycosylation sites	1201:1244	optimal artificial VHH N-glycosylation sites identified in this study	1201:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	5	32	theme	sites	1240:1244	arg1	blueprint					1286:1294	a blueprint	1284:1294	a blueprint for targeted glyco-engineering of other VHHs	1284:1339	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	5	33	theme	artificial	1209:1218	arg1	sites					1240:1244	optimal artificial VHH N-glycosylation sites	1201:1244	optimal artificial VHH N-glycosylation sites identified in this study	1201:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	4	34	theme	efficient	933:941	arg1	uptake					961:966	highly efficient, glycan-dependent uptake	926:966	highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages	926:1029	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	4	35	theme	targeting	1120:1128	arg1	approach					1130:1137	a glycan-based targeting approach	1105:1137	a glycan-based targeting approach for lung macrophage endolysosomal system delivery	1105:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	0	36	theme	optimal	10:16	arg1	sites					18:22	optimal sites	10:22	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.	0:118	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.
37211816	1	37	theme	versatile	273:281	arg1	reagents					283:290	versatile reagents	273:290	versatile reagents in research and diagnostics	273:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	0	38	theme	macrophage	99:108	arg1	delivery					110:117	macrophage delivery	99:117	macrophage delivery	99:117	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.
37211816	4	39	theme	lung	1143:1146	arg1	delivery					1180:1187	lung macrophage endolysosomal system delivery	1143:1187	lung macrophage endolysosomal system delivery	1143:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	1	40	theme	attractive	182:191	arg1	characteristics					193:207	attractive characteristics	182:207	attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics	182:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	1	40	theme	attractive	182:191	arg1	binders					162:168	small and stable high-affinity antigen binders	123:168	small and stable high-affinity antigen binders	123:168	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	4	41	theme	lung	1014:1017	arg1	macrophages					1019:1029	alveolar lung macrophages	1005:1029	alveolar lung macrophages	1005:1029	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	5	42	theme	N-glycosylation	1224:1238	arg1	sites					1240:1244	optimal artificial VHH N-glycosylation sites	1201:1244	optimal artificial VHH N-glycosylation sites identified in this study	1201:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	4	43	theme	alveolar	1005:1012	arg1	macrophages					1019:1029	alveolar lung macrophages	1005:1029	alveolar lung macrophages	1005:1029	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	3	44	theme	high	780:783	arg1	occupancy					790:798	high site occupancy	780:798	high site occupancy	780:798	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	2	45	theme	glycan	521:526	arg1	introduction					454:465	the introduction	450:465	the introduction of an N-glycosylation N-X-T sequon and its associated glycan	450:526	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	3	46	theme	glycoengineered	624:638	arg1	VHHs					640:643	such glycoengineered VHHs	619:643	such glycoengineered VHHs	619:643	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	4	47	dep	showed	919:924	arg1	approach					1130:1137	a glycan-based targeting approach	1105:1137	a glycan-based targeting approach for lung macrophage endolysosomal system delivery	1105:1187	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	2	48	theme	VHH	382:384	arg1	scaffold					386:393	the VHH scaffold	378:393	the VHH scaffold	378:393	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	3	49	theme	site	785:788	arg1	occupancy					790:798	high site occupancy	780:798	high site occupancy	780:798	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	1	50	from	use	230:232	arg1	indications					253:263	various disease indications	237:263	various disease indications	237:263	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	3	51	theme	VHHs	640:643	arg1	variants					607:614	variants	607:614	variants of such glycoengineered VHHs	607:643	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	4	52	theme	preferred	903:911	arg1	sites					913:917	these preferred sites	897:917	these preferred sites	897:917	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	3	53	theme	GlycoSwitchM5	668:680	arg1	strain					682:687	GlycoSwitchM5 strain	668:687	the Pichia pastoris GlycoSwitchM5 strain	648:687	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	5	54	gly	N-glycosylation	1224:1238	arg2	sites					1240:1244	optimal artificial VHH N-glycosylation sites	1201:1244	optimal artificial VHH N-glycosylation sites identified in this study	1201:1269	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	2	55	theme	protein	554:560	arg1	folding					562:568	protein folding	554:568	protein folding	554:568	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	4	56	theme	VHHs	1099:1102	arg1	application					1067:1077	one potential application	1053:1077	one potential application of glyco-engineered VHHs	1053:1102	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	4	57	theme	sites	913:917	arg1	sites					913:917	these preferred sites	897:917	these preferred sites	897:917	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	4	57	theme	sites	913:917	arg1	one					890:892	one	890:892	one	890:892	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	3	58	theme	Pichia	652:657	arg1	pastoris					659:666	Pichia pastoris	652:666	the Pichia pastoris GlycoSwitchM5 strain	648:687	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	3	59	theme	such	619:622	arg1	VHHs					640:643	such glycoengineered VHHs	619:643	such glycoengineered VHHs	619:643	We expressed variants of such glycoengineered VHHs in the Pichia pastoris GlycoSwitchM5 strain, allowing us to pinpoint preferred sites at which Man5GlcNAc2-glycans can be introduced at high site occupancy without affecting antigen binding.
37211816	4	60	contain	carrying	841:848	arg2	N-glycan					878:885	predominantly a Man5GlcNAc2 N-glycan	850:885	predominantly a Man5GlcNAc2 N-glycan	850:885	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	4	60	contain	carrying	841:848	arg1	VHH					837:839	A VHH	835:839	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites	835:917	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	1	61	theme	therapeutic	218:228	arg1	use					230:232	therapeutic use	218:232	therapeutic use in various disease indications	218:263	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	0	62	theme	camelid	57:63	arg1	scaffold					78:85	the camelid VHH antibody scaffold	53:85	the camelid VHH antibody scaffold	53:85	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.
37211816	2	63	theme	structure-guided	400:415	arg1	approach					417:424	a structure-guided approach	398:424	a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition	398:591	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	1	64	theme	small	123:127	arg1	characteristics					193:207	attractive characteristics	182:207	attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics	182:318	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	1	64	theme	small	123:127	arg1	binders					162:168	small and stable high-affinity antigen binders	123:168	small and stable high-affinity antigen binders	123:168	As small and stable high-affinity antigen binders, VHHs boast attractive characteristics both for therapeutic use in various disease indications, and as versatile reagents in research and diagnostics.
37211816	5	65	theme	VHHs	1336:1339	arg1	glyco-engineering					1309:1325	targeted glyco-engineering	1300:1325	targeted glyco-engineering of other VHHs	1300:1339	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	2	66	theme	N-glycosylation	473:487	arg1	sequon					495:500	an N-glycosylation N-X-T sequon	470:500	an N-glycosylation N-X-T sequon	470:500	To further increase the versatility of VHHs, we explored the VHH scaffold in a structure-guided approach to select regions where the introduction of an N-glycosylation N-X-T sequon and its associated glycan should not interfere with protein folding or epitope recognition.
37211816	0	67	dep	GlycoVHH	0:7	arg1	sites					18:22	optimal sites	10:22	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.	0:118	GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery.
37211816	5	68	theme	synthetic	1424:1432	arg1	glycobiology					1434:1445	synthetic glycobiology	1424:1445	synthetic glycobiology	1424:1445	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37211816	4	69	theme	Mf4/4	971:975	arg1	macrophages					977:987	Mf4/4 macrophages	971:987	Mf4/4 macrophages	971:987	A VHH carrying predominantly a Man5GlcNAc2 N-glycan at one of these preferred sites showed highly efficient, glycan-dependent uptake by Mf4/4 macrophages in vitro and by alveolar lung macrophages in vivo, illustrating one potential application of glyco-engineered VHHs: a glycan-based targeting approach for lung macrophage endolysosomal system delivery.
37211816	5	70	theme	other	1330:1334	arg1	VHHs					1336:1339	other VHHs	1330:1339	other VHHs	1330:1339	The set of optimal artificial VHH N-glycosylation sites identified in this study can serve as a blueprint for targeted glyco-engineering of other VHHs, enabling site-specific functionalization through the rapidly expanding toolbox of synthetic glycobiology.
37298853	5	0	theme	maltooctaose-bound	633:650	arg1	enzyme					662:667	the maltooctaose-bound branching enzyme	629:667	the maltooctaose-bound branching enzyme	629:667	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
37298853	10	1	theme	transfer	1520:1527	arg1	specificity					1535:1545	transfer chain specificity	1520:1545	transfer chain specificity involving some of these surface binding sites	1520:1591	Together, these results suggest a possible mechanism for transfer chain specificity involving some of these surface binding sites.
37298853	9	2	theme	chain	1437:1441	arg1	specificity					1450:1460	branch chain length specificity	1430:1460	branch chain length specificity	1430:1460	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	5	3	theme	branching	652:660	arg1	enzyme					662:667	the maltooctaose-bound branching enzyme	629:667	the maltooctaose-bound branching enzyme	629:667	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
37298853	6	4	theme	total	840:844	arg1	number					846:851	the total number	836:851	the total number of oligosaccharide binding sites	836:884	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	6	5	theme	sites	880:884	arg1	number					846:851	the total number	836:851	the total number of oligosaccharide binding sites	836:884	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	4	6	theme	branch	571:576	arg1	length					578:583	branch length	571:583	branch length	571:583	Key to this is the specificity of branching enzymes because they define branch length.
37298853	0	7	theme	Chain	101:105	arg1	Specificity					107:117	Donor Chain Specificity	95:117	Donor Chain Specificity	95:117	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	5	8	theme	enzyme	662:667	arg1	structure					616:624	the crystal structure	604:624	the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli	604:699	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
37298853	7	9	theme	longer	1013:1018	arg1	chain					1027:1031	a substantially longer glucan chain	997:1031	a substantially longer glucan chain ordered in the binding site	997:1059	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	0	10	theme	Donor	95:99	arg1	Specificity					107:117	Donor Chain Specificity	95:117	Donor Chain Specificity	95:117	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	7	11	theme	site	984:987	arg1	I					989:989	previously identified site I	962:989	previously identified site I	962:989	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	1	12	theme	primary	136:142	arg1	polysaccharide					152:165	the primary storage polysaccharide	132:165	the primary storage polysaccharide in bacteria and animals	132:189	Glycogen is the primary storage polysaccharide in bacteria and animals.
37298853	1	12	theme	primary	136:142	arg1	Glycogen					120:127	Glycogen	120:127	Glycogen	120:127	Glycogen is the primary storage polysaccharide in bacteria and animals.
37298853	8	13	theme	likely	1193:1198	arg1	surface					1208:1214	the likely binding surface	1189:1214	the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer	1189:1299	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	13	theme	likely	1193:1198	arg1	site					1164:1167	binding site I	1156:1169	binding site I	1156:1169	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	7	14	from	binding	951:957	arg1	I					989:989	previously identified site I	962:989	previously identified site I	962:989	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	5	15	theme	crystal	608:614	arg1	structure					616:624	the crystal structure	604:624	the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli	604:699	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
37298853	1	16	from	polysaccharide	152:165	arg1	animals					183:189	animals	183:189	animals	183:189	Glycogen is the primary storage polysaccharide in bacteria and animals.
37298853	1	16	from	polysaccharide	152:165	arg1	bacteria					170:177	bacteria	170:177	bacteria	170:177	Glycogen is the primary storage polysaccharide in bacteria and animals.
37298853	9	17	from	loops	1353:1357	arg1	enzymes					1372:1378	branching enzymes	1362:1378	branching enzymes from a diversity of organisms	1362:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	9	17	from	loops	1353:1357	arg1	diversity					1387:1395	a diversity	1385:1395	a diversity of organisms	1385:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	8	18	theme	E.	1255:1256	arg1	enzyme					1273:1278	the E. coli branching enzyme	1251:1278	the E. coli branching enzyme	1251:1278	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	9	19	theme	length	1443:1448	arg1	specificity					1450:1460	branch chain length specificity	1430:1460	branch chain length specificity	1430:1460	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	10	20	theme	possible	1497:1504	arg1	mechanism					1506:1514	a possible mechanism	1495:1514	a possible mechanism for transfer chain specificity involving some of these surface binding sites	1495:1591	Together, these results suggest a possible mechanism for transfer chain specificity involving some of these surface binding sites.
37298853	9	21	theme	organisms	1400:1408	arg1	diversity					1387:1395	a diversity	1385:1395	a diversity of organisms	1385:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	3	22	theme	branches	381:388	arg1	length					348:353	length	348:353	length	348:353	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	3	22	theme	branches	381:388	arg1	dispensation					359:370	dispensation	359:370	dispensation	359:370	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	8	23	theme	chain-bound	1094:1104	arg1	structure					1134:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	23	theme	chain-bound	1094:1104	arg1	guide					1149:1153	a guide	1147:1153	a guide	1147:1153	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	7	24	theme	identified	973:982	arg1	I					989:989	previously identified site I	962:989	previously identified site I	962:989	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	8	25	theme	branching	1263:1271	arg1	enzyme					1273:1278	the E. coli branching enzyme	1251:1278	the E. coli branching enzyme	1251:1278	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	26	theme	binding	1200:1206	arg1	surface					1208:1214	the likely binding surface	1189:1214	the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer	1189:1299	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	26	theme	binding	1200:1206	arg1	site					1164:1167	binding site I	1156:1169	binding site I	1156:1169	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	9	27	theme	analogous	1343:1351	arg1	loops					1353:1357	analogous loops	1343:1357	analogous loops in branching enzymes from a diversity of organisms	1343:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	8	28	theme	oligosaccharide	1078:1092	arg1	structure					1134:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	28	theme	oligosaccharide	1078:1092	arg1	guide					1149:1153	a guide	1147:1153	a guide	1147:1153	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	29	theme	donor	1072:1076	arg1	structure					1134:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	29	theme	donor	1072:1076	arg1	guide					1149:1153	a guide	1147:1153	a guide	1147:1153	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	9	30	from	diversity	1387:1395	arg1	loops					1353:1357	analogous loops	1343:1357	analogous loops in branching enzymes from a diversity of organisms	1343:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	9	30	from	diversity	1387:1395	arg1	enzymes					1372:1378	branching enzymes	1362:1378	branching enzymes from a diversity of organisms	1362:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	0	31	theme	Maltooctaose-Bound	17:34	arg1	Enzyme					63:68	Maltooctaose-Bound Escherichia coli Branching Enzyme	17:68	Maltooctaose-Bound Escherichia coli Branching Enzyme	17:68	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	4	32	theme	enzymes	543:549	arg1	specificity					518:528	the specificity	514:528	the specificity of branching enzymes	514:549	Key to this is the specificity of branching enzymes because they define branch length.
37298853	4	32	theme	enzymes	543:549	arg1	Key					499:501	Key	499:501	Key	499:501	Key to this is the specificity of branching enzymes because they define branch length.
37298853	8	33	theme	branching	1117:1125	arg1	structure					1134:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	33	theme	branching	1117:1125	arg1	guide					1149:1153	a guide	1147:1153	a guide	1147:1153	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	34	dep	E.	1255:1256	arg1	coli					1258:1261	coli	1258:1261	coli	1258:1261	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	7	35	theme	glucan	1020:1025	arg1	chain					1027:1031	a substantially longer glucan chain	997:1031	a substantially longer glucan chain ordered in the binding site	997:1059	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	8	36	theme	Cyanothece	1106:1115	arg1	structure					1134:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	36	theme	Cyanothece	1106:1115	arg1	guide					1149:1153	a guide	1147:1153	a guide	1147:1153	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	2	37	theme	latter	291:296	arg1	reaction					298:305	the latter reaction	287:305	the latter reaction catalyzed by branching enzymes	287:336	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	8	38	theme	donor	1233:1237	arg1	chains					1239:1244	the extended donor chains	1220:1244	the extended donor chains that the E. coli branching enzyme is known to transfer	1220:1299	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	9	39	theme	branching	1362:1370	arg1	enzymes					1372:1378	branching enzymes	1362:1378	branching enzymes from a diversity of organisms	1362:1408	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	2	40	theme	glucose	232:238	arg1	linkages					240:247	α-1,4 glucose linkages	226:247	α-1,4 glucose linkages	226:247	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	0	41	theme	Escherichia	36:46	arg1	Enzyme					63:68	Maltooctaose-Bound Escherichia coli Branching Enzyme	17:68	Maltooctaose-Bound Escherichia coli Branching Enzyme	17:68	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	8	42	theme	enzyme	1127:1132	arg1	structure					1134:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	the donor oligosaccharide chain-bound Cyanothece branching enzyme structure	1068:1142	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	42	theme	enzyme	1127:1132	arg1	guide					1149:1153	a guide	1147:1153	a guide	1147:1153	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	2	43	theme	α-1,4	226:230	arg1	linkages					240:247	α-1,4 glucose linkages	226:247	α-1,4 glucose linkages	226:247	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	6	44	theme	oligosaccharide	786:800	arg1	binding					802:808	oligosaccharide binding	786:808	oligosaccharide binding	786:808	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	3	45	theme	relative	443:450	arg1	bioavailability					452:466	relative bioavailability	443:466	relative bioavailability	443:466	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	0	46	theme	Enzyme	63:68	arg1	Structure					4:12	The Structure	0:12	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme	0:68	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	5	47	dep	E.	693:694	arg1	coli					696:699	coli	696:699	coli	696:699	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
37298853	8	48	theme	extended	1224:1231	arg1	chains					1239:1244	the extended donor chains	1220:1244	the extended donor chains that the E. coli branching enzyme is known to transfer	1220:1299	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	6	49	theme	oligosaccharide	856:870	arg1	sites					880:884	oligosaccharide binding sites	856:884	oligosaccharide binding sites	856:884	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	7	50	theme	binding	1048:1054	arg1	site					1056:1059	the binding site	1044:1059	the binding site	1044:1059	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	3	51	theme	polysaccharide	483:496	arg1	density					430:436	density	430:436	density	430:436	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	3	51	theme	polysaccharide	483:496	arg1	structure					419:427	structure	419:427	structure	419:427	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	3	51	theme	polysaccharide	483:496	arg1	bioavailability					452:466	relative bioavailability	443:466	relative bioavailability	443:466	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	0	52	theme	Branching	53:61	arg1	Enzyme					63:68	Maltooctaose-Bound Escherichia coli Branching Enzyme	17:68	Maltooctaose-Bound Escherichia coli Branching Enzyme	17:68	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	4	53	theme	branching	533:541	arg1	enzymes					543:549	branching enzymes	533:549	branching enzymes	533:549	Key to this is the specificity of branching enzymes because they define branch length.
37298853	3	54	dep	length	348:353	arg1	the					344:346	the	344:346	the	344:346	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	6	55	theme	binding	872:878	arg1	sites					880:884	oligosaccharide binding sites	856:884	oligosaccharide binding sites	856:884	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	0	56	dep	Escherichia	36:46	arg1	coli					48:51	coli	48:51	coli	48:51	The Structure of Maltooctaose-Bound Escherichia coli Branching Enzyme Suggests a Mechanism for Donor Chain Specificity.
37298853	5	57	theme	E.	693:694	arg1	enterobacteria					678:691	the enterobacteria	674:691	the enterobacteria E. coli	674:699	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
37298853	2	58	theme	glucose	200:206	arg1	It					192:193	It	192:193	It	192:193	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	2	58	theme	glucose	200:206	arg1	polymer					208:214	a glucose polymer	198:214	a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes	198:336	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	10	59	theme	surface	1571:1577	arg1	sites					1587:1591	these surface binding sites	1565:1591	these surface binding sites	1565:1591	Together, these results suggest a possible mechanism for transfer chain specificity involving some of these surface binding sites.
37298853	7	60	theme	different	941:949	arg1	binding					951:957	distinctly different binding	930:957	distinctly different binding in previously identified site I	930:989	In addition, the structure shows distinctly different binding in previously identified site I, with a substantially longer glucan chain ordered in the binding site.
37298853	10	61	theme	chain	1529:1533	arg1	specificity					1535:1545	transfer chain specificity	1520:1545	transfer chain specificity involving some of these surface binding sites	1520:1591	Together, these results suggest a possible mechanism for transfer chain specificity involving some of these surface binding sites.
37298853	9	62	theme	branch	1430:1435	arg1	specificity					1450:1460	branch chain length specificity	1430:1460	branch chain length specificity	1430:1460	Furthermore, the structure suggests that analogous loops in branching enzymes from a diversity of organisms are responsible for branch chain length specificity.
37298853	6	63	theme	binding	759:765	arg1	sites					767:771	three new malto-oligosaccharide binding sites	727:771	three new malto-oligosaccharide binding sites	727:771	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	2	64	theme	branching	320:328	arg1	enzymes					330:336	branching enzymes	320:336	branching enzymes	320:336	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	2	65	with	α-1,6-linkages	266:279	arg1	reaction					298:305	the latter reaction	287:305	the latter reaction catalyzed by branching enzymes	287:336	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	10	66	theme	binding	1579:1585	arg1	sites					1587:1591	these surface binding sites	1565:1591	these surface binding sites	1565:1591	Together, these results suggest a possible mechanism for transfer chain specificity involving some of these surface binding sites.
37298853	6	67	theme	malto-oligosaccharide	737:757	arg1	sites					767:771	three new malto-oligosaccharide binding sites	727:771	three new malto-oligosaccharide binding sites	727:771	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	1	68	theme	storage	144:150	arg1	polysaccharide					152:165	the primary storage polysaccharide	132:165	the primary storage polysaccharide in bacteria and animals	132:189	Glycogen is the primary storage polysaccharide in bacteria and animals.
37298853	1	68	theme	storage	144:150	arg1	Glycogen					120:127	Glycogen	120:127	Glycogen	120:127	Glycogen is the primary storage polysaccharide in bacteria and animals.
37298853	3	69	theme	storage	475:481	arg1	polysaccharide					483:496	the storage polysaccharide	471:496	the storage polysaccharide	471:496	Both the length and dispensation of these branches are critical in defining the structure, density, and relative bioavailability of the storage polysaccharide.
37298853	2	70	dep	polymer	208:214	arg1	linked					216:221	linked	216:221	linked by α-1,4 glucose linkages	216:247	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	2	70	dep	polymer	208:214	arg1	branched					253:260	branched	253:260	branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes	253:336	It is a glucose polymer linked by α-1,4 glucose linkages and branched via α-1,6-linkages, with the latter reaction catalyzed by branching enzymes.
37298853	8	71	theme	binding	1156:1162	arg1	site					1164:1167	binding site I	1156:1169	binding site I	1156:1169	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	8	71	theme	binding	1156:1162	arg1	surface					1208:1214	the likely binding surface	1189:1214	the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer	1189:1299	Using the donor oligosaccharide chain-bound Cyanothece branching enzyme structure as a guide, binding site I was identified as the likely binding surface for the extended donor chains that the E. coli branching enzyme is known to transfer.
37298853	6	72	theme	new	733:735	arg1	sites					767:771	three new malto-oligosaccharide binding sites	727:771	three new malto-oligosaccharide binding sites	727:771	The structure identifies three new malto-oligosaccharide binding sites and confirms oligosaccharide binding in seven others, bringing the total number of oligosaccharide binding sites to twelve.
37298853	5	73	from	enterobacteria	678:691	arg1	structure					616:624	the crystal structure	604:624	the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli	604:699	Herein, we report the crystal structure of the maltooctaose-bound branching enzyme from the enterobacteria E. coli.
35021101	0	0	theme	diverse	101:107	arg1	immunogens					130:139	diverse protein nanoparticle immunogens	101:139	diverse protein nanoparticle immunogens	101:139	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	4	1	from	accumulation	557:568	arg1	responses					627:635	antigen-specific germinal center (GC) responses	589:635	antigen-specific germinal center (GC) responses	589:635	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	4	1	from	accumulation	557:568	arg1	nodes					579:583	lymph nodes	573:583	lymph nodes	573:583	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	6	2	theme	patches/nm2	920:930	arg1	density					890:896	a minimal density	880:896	a minimal density of 2.1 × 10-3 mannose patches/nm2	880:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	6	3	theme	10-3	1047:1050	arg1	patches/nm2					1052:1062	at least ∼8.2 × 10-3 patches/nm2	1031:1062	at least ∼8.2 × 10-3 patches/nm2	1031:1062	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	7	4	theme	significant	1114:1124	arg1	impact					1126:1131	a significant impact	1112:1131	a significant impact on humoral immunity	1112:1151	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	6	5	theme	follicular	956:965	arg1	targeting					967:975	follicular targeting	956:975	follicular targeting	956:975	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	5	6	theme	GC	705:706	arg1	responses					708:716	GC responses	705:716	GC responses to influenza, HBV, and HPV particulate antigens	705:764	MBL and complement also mediate follicular trafficking and enhance GC responses to influenza, HBV, and HPV particulate antigens.
35021101	1	7	theme	immune	189:194	arg1	responses					196:204	immune responses	189:204	immune responses	189:204	Nanoparticle (NP) vaccine formulations promote immune responses through multiple mechanisms.
35021101	6	8	theme	mannose	912:918	arg1	patches/nm2					920:930	2.1 × 10-3 mannose patches/nm2	901:930	2.1 × 10-3 mannose patches/nm2	901:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	0	9	theme	nanoparticle	117:128	arg1	immunogens					130:139	diverse protein nanoparticle immunogens	101:139	diverse protein nanoparticle immunogens	101:139	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	4	10	theme	antigen	549:555	arg1	accumulation					557:568	antigen accumulation	549:568	antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses	549:635	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	6	11	theme	mannose	861:867	arg1	patches					869:875	mannose patches	861:875	mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2	861:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	2	12	theme	Env-immunogen	331:343	arg1	NPs					345:347	glycosylated HIV Env-immunogen NPs	314:347	glycosylated HIV Env-immunogen NPs	314:347	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	0	13	theme	protein	109:115	arg1	immunogens					130:139	diverse protein nanoparticle immunogens	101:139	diverse protein nanoparticle immunogens	101:139	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	2	14	theme	HIV	327:329	arg1	NPs					345:347	glycosylated HIV Env-immunogen NPs	314:347	glycosylated HIV Env-immunogen NPs	314:347	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	6	15	from	density	890:896	arg1	patches					869:875	mannose patches	861:875	mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2	861:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	5	16	dep	influenza	721:729	arg1	antigens					757:764	particulate antigens	745:764	particulate antigens	745:764	MBL and complement also mediate follicular trafficking and enhance GC responses to influenza, HBV, and HPV particulate antigens.
35021101	4	17	theme	oligomannose	489:500	arg1	recognition					474:484	MBL recognition	470:484	MBL recognition of oligomannose on gp120 nanoparticles	470:523	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	7	18	theme	humoral	1136:1142	arg1	immunity					1144:1151	humoral immunity	1136:1151	humoral immunity	1136:1151	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	2	19	theme	glycosylated	314:325	arg1	NPs					345:347	glycosylated HIV Env-immunogen NPs	314:347	glycosylated HIV Env-immunogen NPs	314:347	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	3	20	theme	viral	454:458	arg1	antigens					460:467	other viral antigens	448:467	other viral antigens	448:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	0	21	theme	immunogens	130:139	arg1	localization					57:68	follicular localization	46:68	follicular localization	46:68	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	0	21	theme	immunogens	130:139	arg1	immunogenicity					83:96	enhanced immunogenicity	74:96	enhanced immunogenicity	74:96	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	5	22	theme	follicular	670:679	arg1	trafficking					681:691	follicular trafficking	670:691	follicular trafficking	670:691	MBL and complement also mediate follicular trafficking and enhance GC responses to influenza, HBV, and HPV particulate antigens.
35021101	3	23	theme	antigens	460:467	arg1	forms					431:435	NP forms	428:435	NP forms of HIV and other viral antigens	428:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	3	24	theme	complement	414:423	arg1	effects					395:401	effects	395:401	effects of MBL and complement on NP forms of HIV and other viral antigens	395:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	4	25	theme	gp120	505:509	arg1	nanoparticles					511:523	gp120 nanoparticles	505:523	gp120 nanoparticles	505:523	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	7	26	from	impact	1126:1131	arg1	immunity					1144:1151	humoral immunity	1136:1151	humoral immunity	1136:1151	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	2	27	theme	node	358:361	arg1	follicles					363:371	lymph node follicles	352:371	lymph node follicles	352:371	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	1	28	theme	multiple	214:221	arg1	mechanisms					223:232	multiple mechanisms	214:232	multiple mechanisms	214:232	Nanoparticle (NP) vaccine formulations promote immune responses through multiple mechanisms.
35021101	0	29	theme	Mannose-binding	0:14	arg1	lectin					16:21	Mannose-binding lectin	0:21	Mannose-binding lectin	0:21	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	4	30	theme	germinal	606:613	arg1	GC					623:624	GC	623:624	GC	623:624	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	4	30	theme	germinal	606:613	arg1	center					615:620	germinal center	606:620	antigen-specific germinal center (GC) responses	589:635	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	6	31	theme	glycosylation	828:840	arg1	levels					818:823	titrated levels	809:823	titrated levels of glycosylation	809:840	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	2	32	theme	lymph	352:356	arg1	node					358:361	lymph node	352:361	lymph node follicles	352:371	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	7	33	contain	has	1108:1110	arg1	recognition					1085:1095	innate immune recognition	1071:1095	innate immune recognition of glycans	1071:1106	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	7	33	contain	has	1108:1110	arg2	impact					1126:1131	a significant impact	1112:1131	a significant impact on humoral immunity	1112:1151	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	3	34	theme	other	448:452	arg1	antigens					460:467	other viral antigens	448:467	other viral antigens	448:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	3	35	theme	MBL	406:408	arg1	effects					395:401	effects	395:401	effects of MBL and complement on NP forms of HIV and other viral antigens	395:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	4	36	theme	antigen-specific	589:604	arg1	responses					627:635	antigen-specific germinal center (GC) responses	589:635	antigen-specific germinal center (GC) responses	589:635	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	7	37	theme	glycan	1209:1214	arg1	recognition					1216:1226	glycan recognition	1209:1226	glycan recognition	1209:1226	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	7	38	theme	glycans	1100:1106	arg1	recognition					1085:1095	innate immune recognition	1071:1095	innate immune recognition of glycans	1071:1106	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	4	39	from	recognition	474:484	arg1	nanoparticles					511:523	gp120 nanoparticles	505:523	gp120 nanoparticles	505:523	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	4	40	theme	MBL	470:472	arg1	recognition					474:484	MBL recognition	470:484	MBL recognition of oligomannose on gp120 nanoparticles	470:523	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	2	41	theme	NPs	345:347	arg1	trafficking					299:309	trafficking	299:309	trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles	299:371	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	0	42	theme	follicular	46:55	arg1	localization					57:68	follicular localization	46:68	follicular localization	46:68	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
35021101	4	43	theme	center	615:620	arg1	responses					627:635	antigen-specific germinal center (GC) responses	589:635	antigen-specific germinal center (GC) responses	589:635	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	5	44	theme	particulate	745:755	arg1	antigens					757:764	particulate antigens	745:764	particulate antigens	745:764	MBL and complement also mediate follicular trafficking and enhance GC responses to influenza, HBV, and HPV particulate antigens.
35021101	6	45	theme	10-3	907:910	arg1	patches/nm2					920:930	2.1 × 10-3 mannose patches/nm2	901:930	2.1 × 10-3 mannose patches/nm2	901:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	6	46	theme	glycan	1010:1015	arg1	density					1017:1023	glycan density	1010:1023	glycan density	1010:1023	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	3	47	theme	HIV	440:442	arg1	forms					431:435	NP forms	428:435	NP forms of HIV and other viral antigens	428:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	4	48	theme	lymph	573:577	arg1	nodes					579:583	lymph nodes	573:583	lymph nodes	573:583	MBL recognition of oligomannose on gp120 nanoparticles significantly increases antigen accumulation in lymph nodes and antigen-specific germinal center (GC) responses.
35021101	3	49	from	effects	395:401	arg1	forms					431:435	NP forms	428:435	NP forms of HIV and other viral antigens	428:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	2	50	gly	glycosylated	314:325	arg1	NPs					345:347	glycosylated HIV Env-immunogen NPs	314:347	glycosylated HIV Env-immunogen NPs	314:347	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	3	51	theme	NP	428:429	arg1	forms					431:435	NP forms	428:435	NP forms of HIV and other viral antigens	428:467	Here, we investigate effects of MBL and complement on NP forms of HIV and other viral antigens.
35021101	2	52	theme	mannose-binding	261:275	arg1	lectin					277:282	mannose-binding lectin	261:282	mannose-binding lectin (MBL)	261:288	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	2	52	theme	mannose-binding	261:275	arg1	MBL					285:287	MBL	285:287	MBL	285:287	We recently reported that mannose-binding lectin (MBL) triggers trafficking of glycosylated HIV Env-immunogen NPs to lymph node follicles.
35021101	6	53	theme	titrated	809:816	arg1	levels					818:823	titrated levels	809:823	titrated levels of glycosylation	809:840	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	1	54	theme	Nanoparticle	142:153	arg1	formulations					168:179	Nanoparticle (NP) vaccine formulations	142:179	Nanoparticle (NP) vaccine formulations	142:179	Nanoparticle (NP) vaccine formulations promote immune responses through multiple mechanisms.
35021101	7	55	theme	vaccine	1240:1246	arg1	efficacy					1248:1255	vaccine efficacy	1240:1255	vaccine efficacy	1240:1255	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	6	56	theme	2.1 ×	901:905	arg1	patches/nm2					920:930	2.1 × 10-3 mannose patches/nm2	901:930	2.1 × 10-3 mannose patches/nm2	901:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	7	57	theme	innate	1071:1076	arg1	recognition					1085:1095	innate immune recognition	1071:1095	innate immune recognition of glycans	1071:1106	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	6	58	theme	minimal	882:888	arg1	density					890:896	a minimal density	880:896	a minimal density of 2.1 × 10-3 mannose patches/nm2	880:930	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	7	59	theme	immune	1078:1083	arg1	recognition					1085:1095	innate immune recognition	1071:1095	innate immune recognition of glycans	1071:1106	Thus, innate immune recognition of glycans has a significant impact on humoral immunity, and these findings provide a framework for engineering glycan recognition to optimize vaccine efficacy.
35021101	6	60	theme	protein	779:785	arg1	nanoparticles					787:799	model protein nanoparticles	773:799	model protein nanoparticles bearing titrated levels of glycosylation	773:840	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	6	61	theme	model	773:777	arg1	nanoparticles					787:799	model protein nanoparticles	773:799	model protein nanoparticles bearing titrated levels of glycosylation	773:840	Using model protein nanoparticles bearing titrated levels of glycosylation, we determine that mannose patches at a minimal density of 2.1 × 10-3 mannose patches/nm2 are required to trigger follicular targeting, which increases with increasing glycan density up to at least ∼8.2 × 10-3 patches/nm2.
35021101	1	62	theme	vaccine	160:166	arg1	formulations					168:179	Nanoparticle (NP) vaccine formulations	142:179	Nanoparticle (NP) vaccine formulations	142:179	Nanoparticle (NP) vaccine formulations promote immune responses through multiple mechanisms.
35021101	0	63	theme	enhanced	74:81	arg1	immunogenicity					83:96	enhanced immunogenicity	74:96	enhanced immunogenicity	74:96	Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.
37148536	7	0	from	cultures	1260:1267	arg1	end					1220:1222	the end	1216:1222	the end of culture duration in supplemented cultures leading to at least 11%	1216:1291	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	8	1	theme	due	1517:1519	arg1	metabolism					1506:1515	central carbon metabolism	1491:1515	central carbon metabolism due to low glycolytic fluxes	1491:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	7	2	theme	final	1324:1328	arg1	EPO-Fc titers					1330:1342	final EPO-Fc titers	1324:1342	final EPO-Fc titers	1324:1342	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	8	3	theme	low	1524:1526	arg1	fluxes					1539:1544	low glycolytic fluxes	1524:1544	low glycolytic fluxes	1524:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	10	4	dep	50	1819:1820	arg1	to					1816:1817	to	1816:1817	to	1816:1817	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	11	5	theme	2DG	1876:1878	arg1	addition					1864:1871	addition	1864:1871	addition of 2DG	1864:1878	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	0	6	gly	glycoforms	124:133	arg2	cultures					147:154	CHO cell cultures	138:154	CHO cell cultures	138:154	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	12	7	theme	5TG	2358:2360	arg1	concentrations					2340:2353	different concentrations	2330:2353	different concentrations of 5TG and 2DG, respectively	2330:2382	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	10	8	theme	tetra-antennary	1782:1796	arg1	structures					1798:1807	tetra-antennary structures	1782:1807	tetra-antennary structures	1782:1807	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	13	9	theme	glucose	2440:2446	arg1	analogs					2448:2454	these glucose analogs	2434:2454	these glucose analogs	2434:2454	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	9	10	theme	EPO-Fc revealed	1568:1582	arg1	increase					1587:1594	EPO-Fc revealed an increase	1568:1594	EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1568:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	7	11	theme	32	1308:1309	arg1	%					1310:1310	%	1310:1310	%	1310:1310	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	12	12	theme	2DG	2366:2368	arg1	concentrations					2340:2353	different concentrations	2330:2353	different concentrations of 5TG and 2DG, respectively	2330:2382	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	2	13	theme	lactate	310:316	arg1	levels					318:323	High lactate levels	305:323	High lactate levels	305:323	High lactate levels adversely impact cell growth and productivity.
37148536	11	14	theme	5TG	1965:1967	arg1	addition					1953:1960	addition	1953:1960	addition of 5TG	1953:1967	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	9	15	theme	increase	1587:1594	arg1	analysis					1556:1563	N-glycan analysis	1547:1563	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.	1547:1713	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	6	16	dep	%	1094:1094	arg1	50					1092:1093	50	1092:1093	50	1092:1093	Inhibitor supplementation led to at least 50% decrease in moles of lactate produced per mol of glucose consumed.
37148536	13	17	theme	N-glycosylation	2513:2527	arg1	processing					2529:2538	N-glycosylation processing	2513:2538	N-glycosylation processing	2513:2538	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	9	18	theme	high	1599:1602	arg1	glycans					1612:1618	high mannose glycans	1599:1618	high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1599:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	6	19	theme	glucose	1145:1151	arg1	mol					1138:1140	mol	1138:1140	mol of glucose consumed	1138:1160	Inhibitor supplementation led to at least 50% decrease in moles of lactate produced per mol of glucose consumed.
37148536	0	20	theme	CHO	138:140	arg1	cultures					147:154	CHO cell cultures	138:154	CHO cell cultures	138:154	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	8	21	dep	cultures	1466:1473	arg1	rewiring					1482:1489	rewiring	1482:1489	rewiring central carbon metabolism due to low glycolytic fluxes	1482:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	13	22	theme	analogs	2448:2454	arg1	impact					2424:2429	the impact	2420:2429	the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms	2420:2579	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	11	23	theme	EPO-Fc	1932:1937	arg1	N-glycans					1939:1947	EPO-Fc N-glycans	1932:1947	EPO-Fc N-glycans	1932:1947	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	12	24	theme	%	2208:2208	arg1	N-glycans					2217:2225	N-glycans	2217:2225	N-glycans	2217:2225	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	12	24	theme	%	2208:2208	arg1	%					2212:2212	14%-33%	2206:2212	14%-33% of N-glycans	2206:2225	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	4	25	theme	HK2	682:684	arg1	enzyme					686:691	HK2 enzyme	682:691	HK2 enzyme	682:691	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	4	26	theme	CHO	870:872	arg1	growth					879:884	CHO cell growth	870:884	CHO cell growth	870:884	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	4	27	from	impacts	859:865	arg1	growth					879:884	CHO cell growth	870:884	CHO cell growth	870:884	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	5	28	theme	Individual	887:896	arg1	2DG					898:900	Individual 2DG	887:900	Individual 2DG	887:900	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	9	29	from	%	1626:1626	arg1	cultures					1639:1646	control cultures	1631:1646	control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1631:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	9	29	from	%	1626:1626	arg1	increase					1587:1594	EPO-Fc revealed an increase	1568:1594	EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1568:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	9	29	from	%	1626:1626	arg1	glycans					1612:1618	high mannose glycans	1599:1618	high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1599:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	8	30	theme	serine	1371:1376	arg1	rates					1390:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	7	31	from	increase	1312:1319	arg1	EPO-Fc titers					1330:1342	final EPO-Fc titers	1324:1342	final EPO-Fc titers	1324:1342	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	12	32	theme	likely	2112:2117	arg1	5-thio-mannose					2119:2132	most likely 5-thio-mannose	2107:2132	most likely 5-thio-mannose	2107:2132	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	12	32	theme	likely	2112:2117	arg1	moieties					2097:2104	5TH moieties	2093:2104	5TH moieties	2093:2104	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	0	33	theme	glycosylation	78:90	arg1	processing					92:101	glycosylation processing	78:101	glycosylation processing	78:101	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	5	34	theme	combined	981:988	arg1	supplementation					990:1004	their combined supplementation	975:1004	their combined supplementation	975:1004	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	1	35	theme	hamster	165:171	arg1	cells					185:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	35	theme	hamster	165:171	arg1	hosts					204:208	predominant hosts	192:208	predominant hosts for recombinant biotherapeutics production	192:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	12	36	theme	percent	2056:2062	arg1	N-glycans					2074:2082	N-glycans	2074:2082	N-glycans	2074:2082	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	12	36	theme	percent	2056:2062	arg1	%					2069:2069	Six percent to 23%	2052:2069	Six percent to 23% of N-glycans	2052:2082	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	13	37	theme	cell	2463:2466	arg1	growth					2468:2473	CHO cell growth	2459:2473	CHO cell growth	2459:2473	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	5	38	theme	%	1022:1022	arg1	decrease					1024:1031	a 60% decrease	1018:1031	a 60% decrease in peak lactate	1018:1047	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	4	39	theme	2-deoxy-	746:753	arg1	2DG					766:768	2DG	766:768	2DG	766:768	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	4	39	theme	2-deoxy-	746:753	arg1	d-glucose					755:763	2-deoxy- d-glucose	746:763	2-deoxy- d-glucose (2DG)	746:769	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	3	40	theme	cell	424:427	arg1	cultures					429:436	CHO cell cultures	420:436	CHO cell cultures	420:436	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	5	41	theme	35	935:936	arg1	%					937:937	%	937:937	%	937:937	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	8	42	theme	growth	1430:1435	arg1	phase					1437:1441	the exponential growth phase	1414:1441	the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes	1414:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	6	43	from	decrease	1096:1103	arg1	moles					1108:1112	moles	1108:1112	moles of lactate	1108:1123	Inhibitor supplementation led to at least 50% decrease in moles of lactate produced per mol of glucose consumed.
37148536	0	44	theme	Chemical	0:7	arg1	inhibitors					9:18	Chemical inhibitors	0:18	Chemical inhibitors of hexokinase-2 enzyme	0:41	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	4	45	from	concentrations	706:719	arg1	inhibitors					668:677	Five inhibitors	663:677	Five inhibitors of HK2 enzyme at different concentrations	663:719	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	11	46	theme	observed	1996:2003	arg1	incorporation					2014:2026	the first-ever observed N-glycan incorporation	1981:2026	the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH)	1981:2049	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	3	47	theme	chemical	448:455	arg1	inhibitors					457:466	chemical inhibitors	448:466	chemical inhibitors	448:466	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	5	48	from	decrease	1024:1031	arg1	lactate					1041:1047	peak lactate	1036:1047	peak lactate	1036:1047	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	1	49	theme	glycolysis	282:291	arg1	by-product					293:302	a major glycolysis by-product	274:302	a major glycolysis by-product	274:302	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	49	theme	glycolysis	282:291	arg1	lactate					263:269	lactate	263:269	lactate	263:269	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	7	50	theme	culture	1227:1233	arg1	duration					1235:1242	culture duration	1227:1242	culture duration in supplemented cultures leading to at least 11%	1227:1291	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	4	51	theme	5-thio-	775:781	arg1	5TG					794:796	5TG	794:796	5TG	794:796	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	4	51	theme	5-thio-	775:781	arg1	d-glucose					783:791	5-thio- d-glucose	775:791	5-thio- d-glucose (5TG)	775:797	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	0	52	theme	enzyme	36:41	arg1	inhibitors					9:18	Chemical inhibitors	0:18	Chemical inhibitors of hexokinase-2 enzyme	0:41	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	5	53	theme	peak	955:958	arg1	lactate					960:966	peak lactate	955:966	peak lactate	955:966	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	11	54	theme	5-thio-hexose	2031:2043	arg1	incorporation					2014:2026	the first-ever observed N-glycan incorporation	1981:2026	the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH)	1981:2049	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	8	55	theme	treated	1458:1464	arg1	cultures					1466:1473	2DG and 5TG treated cultures	1446:1473	2DG and 5TG treated cultures	1446:1473	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	3	56	theme	cell	613:616	arg1	growth					618:623	cell growth	613:623	cell growth	613:623	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	0	57	theme	lactate	50:56	arg1	accumulation					58:69	lactate accumulation	50:69	lactate accumulation	50:69	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	6	58	theme	Inhibitor	1050:1058	arg1	supplementation					1060:1074	Inhibitor supplementation	1050:1074	Inhibitor supplementation	1050:1074	Inhibitor supplementation led to at least 50% decrease in moles of lactate produced per mol of glucose consumed.
37148536	2	59	theme	impact	335:340	arg1	cell					342:345	impact cell growth and productivity	335:369	impact cell growth and productivity	335:369	High lactate levels adversely impact cell growth and productivity.
37148536	8	60	theme	glycolytic	1528:1537	arg1	fluxes					1539:1544	low glycolytic fluxes	1524:1544	low glycolytic fluxes	1524:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	5	61	theme	-45	938:940	arg1	%					941:941	%	941:941	%	941:941	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	7	62	from	duration	1235:1242	arg1	cultures					1260:1267	supplemented cultures	1247:1267	supplemented cultures leading to at least 11%	1247:1291	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	12	63	theme	2DH	2236:2238	arg1	moieties					2240:2247	2DH moieties	2236:2247	2DH moieties	2236:2247	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	3	64	theme	 the	490:493	arg1	hexokinase-2					471:482	hexokinase-2	471:482	hexokinase-2 (HK2)	471:488	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	3	64	theme	 the	490:493	arg1	enzyme					495:500	 the enzyme	490:500	 the enzyme catalyzing the conversion of glucose to glucose 6-phosphate	490:560	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	1	65	theme	biotherapeutics	226:240	arg1	production					242:251	recombinant biotherapeutics production	214:251	recombinant biotherapeutics production	214:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	13	66	from	impact	2424:2429	arg1	growth					2468:2473	CHO cell growth	2459:2473	CHO cell growth	2459:2473	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	66	from	impact	2424:2429	arg1	production					2484:2493	protein production	2476:2493	protein production	2476:2493	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	66	from	impact	2424:2429	arg1	metabolism					2501:2510	cell metabolism	2496:2510	cell metabolism	2496:2510	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	66	from	impact	2424:2429	arg1	processing					2529:2538	N-glycosylation processing	2513:2538	N-glycosylation processing	2513:2538	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	66	from	impact	2424:2429	arg1	formation					2545:2553	formation	2545:2553	formation of alternative glycoforms	2545:2579	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	0	67	from	glycoforms	124:133	arg1	cultures					147:154	CHO cell cultures	138:154	CHO cell cultures	138:154	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	13	68	theme	glycoforms	2570:2579	arg1	growth					2468:2473	CHO cell growth	2459:2473	CHO cell growth	2459:2473	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	68	theme	glycoforms	2570:2579	arg1	production					2484:2493	protein production	2476:2493	protein production	2476:2493	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	68	theme	glycoforms	2570:2579	arg1	metabolism					2501:2510	cell metabolism	2496:2510	cell metabolism	2496:2510	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	68	theme	glycoforms	2570:2579	arg1	processing					2529:2538	N-glycosylation processing	2513:2538	N-glycosylation processing	2513:2538	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	13	68	theme	glycoforms	2570:2579	arg1	formation					2545:2553	formation	2545:2553	formation of alternative glycoforms	2545:2579	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	4	69	theme	lactate	820:826	arg1	accumulation					828:839	lactate accumulation	820:839	lactate accumulation	820:839	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	10	70	theme	Inhibitor	1715:1723	arg1	supplementation					1725:1739	Inhibitor supplementation	1715:1739	Inhibitor supplementation	1715:1739	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	9	71	theme	N-glycan	1547:1554	arg1	analysis					1556:1563	N-glycan analysis	1547:1563	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.	1547:1713	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	12	72	theme	N-glycans	2217:2225	arg1	N-glycans					2217:2225	N-glycans	2217:2225	N-glycans	2217:2225	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	12	72	theme	N-glycans	2217:2225	arg1	%					2212:2212	14%-33%	2206:2212	14%-33% of N-glycans	2206:2225	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	5	73	from	decrease	943:950	arg1	lactate					960:966	peak lactate	955:966	peak lactate	955:966	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	1	74	theme	ovary	173:177	arg1	cells					185:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	74	theme	ovary	173:177	arg1	hosts					204:208	predominant hosts	192:208	predominant hosts for recombinant biotherapeutics production	192:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	10	75	from	decrease	1755:1762	arg1	tri-					1772:1775	tri-	1772:1775	tri-	1772:1775	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	10	75	from	decrease	1755:1762	arg1	bi-					1767:1769	bi-	1767:1769	bi-	1767:1769	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	10	75	from	decrease	1755:1762	arg1	structures					1798:1807	tetra-antennary structures	1782:1807	tetra-antennary structures	1782:1807	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	9	76	from	%	1661:1661	arg1	2DG					1666:1668	2DG	1666:1668	2DG	1666:1668	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	9	76	from	%	1661:1661	arg1	5TG-supplemented cultures					1674:1698	5TG-supplemented cultures	1674:1698	5TG-supplemented cultures	1674:1698	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	11	77	theme	first-ever	1985:1994	arg1	incorporation					2014:2026	the first-ever observed N-glycan incorporation	1981:2026	the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH)	1981:2049	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	13	78	theme	cell	2496:2499	arg1	metabolism					2501:2510	cell metabolism	2496:2510	cell metabolism	2496:2510	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	3	79	theme	glucose	542:548	arg1	6-phosphate					550:560	glucose 6-phosphate	542:560	glucose 6-phosphate	542:560	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	1	80	theme	CHO	180:182	arg1	cells					185:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	80	theme	CHO	180:182	arg1	hosts					204:208	predominant hosts	192:208	predominant hosts for recombinant biotherapeutics production	192:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	7	81	theme	%	1310:1310	arg1	increase					1312:1319	32% increase	1308:1319	32% increase in final EPO-Fc titers	1308:1342	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	12	82	theme	different	2330:2338	arg1	concentrations					2340:2353	different concentrations	2330:2353	different concentrations of 5TG and 2DG, respectively	2330:2382	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	2	83	theme	High	305:308	arg1	levels					318:323	High lactate levels	305:323	High lactate levels	305:323	High lactate levels adversely impact cell growth and productivity.
37148536	9	84	from	analysis	1556:1563	arg1	glycans					1612:1618	high mannose glycans	1599:1618	high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1599:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	4	85	theme	cell	874:877	arg1	growth					879:884	CHO cell growth	870:884	CHO cell growth	870:884	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	8	86	theme	Asparagine	1345:1354	arg1	rates					1390:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	0	87	theme	cell	142:145	arg1	cultures					147:154	CHO cell cultures	138:154	CHO cell cultures	138:154	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	1	88	theme	predominant	192:202	arg1	cells					185:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	88	theme	predominant	192:202	arg1	hosts					204:208	predominant hosts	192:208	predominant hosts for recombinant biotherapeutics production	192:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	9	89	theme	mannose	1604:1610	arg1	glycans					1612:1618	high mannose glycans	1599:1618	high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1599:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	8	90	theme	pyruvate	1357:1364	arg1	rates					1390:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	6	91	dep	decrease	1096:1103	arg1	%					1094:1094	%	1094:1094	%	1094:1094	Inhibitor supplementation led to at least 50% decrease in moles of lactate produced per mol of glucose consumed.
37148536	5	92	theme	60	1020:1021	arg1	%					1022:1022	%	1022:1022	%	1022:1022	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	4	93	dep	evaluated	726:734	arg1	reduced					812:818	reduced	812:818	reduced lactate accumulation with only limited impacts on CHO cell growth	812:884	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	4	94	theme	limited	851:857	arg1	impacts					859:865	only limited impacts	846:865	only limited impacts on CHO cell growth	846:884	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	10	95	theme	lower	1823:1827	arg1	EPO-Fc sialylation					1829:1846	up to 50% lower EPO-Fc sialylation	1813:1846	up to 50% lower EPO-Fc sialylation	1813:1846	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	3	96	theme	lactate	591:597	arg1	accumulation					599:610	lactate accumulation	591:610	lactate accumulation	591:610	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	3	97	theme	glucose	531:537	arg1	conversion					517:526	the conversion	513:526	the conversion of glucose to glucose 6-phosphate	513:560	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	8	98	theme	consumption	1378:1388	arg1	rates					1390:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates	1345:1394	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	6	99	theme	lactate	1117:1123	arg1	moles					1108:1112	moles	1108:1112	moles of lactate	1108:1123	Inhibitor supplementation led to at least 50% decrease in moles of lactate produced per mol of glucose consumed.
37148536	4	100	theme	enzyme	686:691	arg1	inhibitors					668:677	Five inhibitors	663:677	Five inhibitors of HK2 enzyme at different concentrations	663:719	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	13	101	theme	protein	2476:2482	arg1	production					2484:2493	protein production	2476:2493	protein production	2476:2493	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	9	102	from	glycans	1612:1618	arg1	analysis					1556:1563	N-glycan analysis	1547:1563	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.	1547:1713	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	9	103	theme	control	1631:1637	arg1	cultures					1639:1646	control cultures	1631:1646	control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1631:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	1	104	theme	Chinese	157:163	arg1	cells					185:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells	157:189	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	104	theme	Chinese	157:163	arg1	hosts					204:208	predominant hosts	192:208	predominant hosts for recombinant biotherapeutics production	192:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	13	105	theme	CHO	2459:2461	arg1	growth					2468:2473	CHO cell growth	2459:2473	CHO cell growth	2459:2473	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
37148536	3	106	from	lactate	409:415	arg1	cultures					429:436	CHO cell cultures	420:436	CHO cell cultures	420:436	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	9	107	from	increase	1587:1594	arg1	glycans					1612:1618	high mannose glycans	1599:1618	high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1599:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	9	107	from	increase	1587:1594	arg1	%					1626:1626	5%	1625:1626	5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively	1625:1712	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	8	108	theme	exponential	1418:1428	arg1	phase					1437:1441	the exponential growth phase	1414:1441	the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes	1414:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	3	109	from	impact	581:586	arg1	growth					618:623	cell growth	613:623	cell growth	613:623	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	3	109	from	impact	581:586	arg1	titers					634:639	protein titers	626:639	protein titers	626:639	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	3	109	from	impact	581:586	arg1	N-glycosylation					646:660	N-glycosylation	646:660	N-glycosylation	646:660	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	3	109	from	impact	581:586	arg1	accumulation					599:610	lactate accumulation	591:610	lactate accumulation	591:610	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	0	110	theme	altered	116:122	arg1	glycoforms					124:133	altered glycoforms	116:133	altered glycoforms in CHO cell cultures	116:154	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	10	111	from	EPO-Fc sialylation	1829:1846	arg1	tri-					1772:1775	tri-	1772:1775	tri-	1772:1775	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	10	111	from	EPO-Fc sialylation	1829:1846	arg1	bi-					1767:1769	bi-	1767:1769	bi-	1767:1769	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	10	111	from	EPO-Fc sialylation	1829:1846	arg1	structures					1798:1807	tetra-antennary structures	1782:1807	tetra-antennary structures	1782:1807	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	7	112	theme	supplemented	1247:1258	arg1	cultures					1260:1267	supplemented cultures	1247:1267	supplemented cultures leading to at least 11%	1247:1291	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	12	113	theme	N-glycans	2074:2082	arg1	N-glycans					2074:2082	N-glycans	2074:2082	N-glycans	2074:2082	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	12	113	theme	N-glycans	2074:2082	arg1	%					2069:2069	Six percent to 23%	2052:2069	Six percent to 23% of N-glycans	2052:2082	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	5	114	theme	peak	1036:1039	arg1	lactate					1041:1047	peak lactate	1036:1047	peak lactate	1036:1047	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	7	115	theme	duration	1235:1242	arg1	end					1220:1222	the end	1216:1222	the end of culture duration in supplemented cultures leading to at least 11%	1216:1291	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	3	116	theme	study	389:393	arg1	goal					376:379	The goal	372:379	The goal of this study	372:393	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	8	117	theme	2DG	1446:1448	arg1	cultures					1466:1473	2DG and 5TG treated cultures	1446:1473	2DG and 5TG treated cultures	1446:1473	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	4	118	theme	different	696:704	arg1	concentrations					706:719	different concentrations	696:719	different concentrations	696:719	Five inhibitors of HK2 enzyme at different concentrations were evaluated, of which 2-deoxy- d-glucose (2DG) and 5-thio- d-glucose (5TG) successfully reduced lactate accumulation with only limited impacts on CHO cell growth.
37148536	3	119	theme	CHO	420:422	arg1	cultures					429:436	CHO cell cultures	420:436	CHO cell cultures	420:436	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	0	120	theme	hexokinase-2	23:34	arg1	enzyme					36:41	hexokinase-2 enzyme	23:41	hexokinase-2 enzyme	23:41	Chemical inhibitors of hexokinase-2 enzyme reduce lactate accumulation, alter glycosylation processing, and produce altered glycoforms in CHO cell cultures.
37148536	1	121	theme	major	276:280	arg1	by-product					293:302	a major glycolysis by-product	274:302	a major glycolysis by-product	274:302	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	1	121	theme	major	276:280	arg1	lactate					263:269	lactate	263:269	lactate	263:269	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	5	122	theme	5TG	906:908	arg1	supplementation					910:924	5TG supplementation	906:924	5TG supplementation	906:924	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	11	123	theme	N-glycan	2005:2012	arg1	incorporation					2014:2026	the first-ever observed N-glycan incorporation	1981:2026	the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH)	1981:2049	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	8	124	theme	5TG	1454:1456	arg1	cultures					1466:1473	2DG and 5TG treated cultures	1446:1473	2DG and 5TG treated cultures	1446:1473	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	2	125	dep	cell	342:345	arg1	productivity					358:369	productivity	358:369	productivity	358:369	High lactate levels adversely impact cell growth and productivity.
37148536	2	125	dep	cell	342:345	arg1	growth					347:352	growth	347:352	growth	347:352	High lactate levels adversely impact cell growth and productivity.
37148536	8	126	from	phase	1437:1441	arg1	cultures					1466:1473	2DG and 5TG treated cultures	1446:1473	2DG and 5TG treated cultures	1446:1473	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	12	127	theme	2-deoxy-mannose	2262:2276	arg1	moieties					2240:2247	2DH moieties	2236:2247	2DH moieties	2236:2247	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	9	128	from	%	1653:1653	arg1	2DG					1666:1668	2DG	1666:1668	2DG	1666:1668	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	9	128	from	%	1653:1653	arg1	5TG-supplemented cultures					1674:1698	5TG-supplemented cultures	1674:1698	5TG-supplemented cultures	1674:1698	N-glycan analysis of EPO-Fc revealed an increase in high mannose glycans from 5% in control cultures to 25% and 37% in 2DG and 5TG-supplemented cultures, respectively.
37148536	7	129	from	end	1220:1222	arg1	cultures					1260:1267	supplemented cultures	1247:1267	supplemented cultures leading to at least 11%	1247:1291	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	11	130	theme	2-deoxy-hexose	1908:1921	arg1	incorporation					1891:1903	the incorporation	1887:1903	the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans	1887:1947	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	12	131	theme	2-deoxy-galactose	2285:2301	arg1	moieties					2240:2247	2DH moieties	2236:2247	2DH moieties	2236:2247	Six percent to 23% of N-glycans included 5TH moieties, most likely 5-thio-mannose and/or 5-thio-galactose and/or possibly 5-thio-N-acetylglucosamine, and 14%-33% of N-glycans included 2DH moieties, most likely 2-deoxy-mannose and/or 2-deoxy-galactose, for cultures treated with different concentrations of 5TG and 2DG, respectively.
37148536	5	132	theme	%	937:937	arg1	decrease					943:950	a 35%-45% decrease	933:950	a 35%-45% decrease in peak lactate	933:966	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	10	133	gly	EPO-Fc sialylation	1829:1846	arg1	tri-					1772:1775	tri-	1772:1775	tri-	1772:1775	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	10	133	gly	EPO-Fc sialylation	1829:1846	arg1	bi-					1767:1769	bi-	1767:1769	bi-	1767:1769	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	10	133	gly	EPO-Fc sialylation	1829:1846	arg1	structures					1798:1807	tetra-antennary structures	1782:1807	tetra-antennary structures	1782:1807	Inhibitor supplementation also led to a decrease in bi-, tri-, and tetra-antennary structures and up to 50% lower EPO-Fc sialylation.
37148536	3	134	theme	protein	626:632	arg1	titers					634:639	protein titers	626:639	protein titers	626:639	The goal of this study was to reduce lactate in CHO cell cultures by adding chemical inhibitors to hexokinase-2 (HK2), the enzyme catalyzing the conversion of glucose to glucose 6-phosphate, and examine their impact on lactate accumulation, cell growth, protein titers, and N-glycosylation.
37148536	1	135	theme	recombinant	214:224	arg1	production					242:251	recombinant biotherapeutics production	214:251	recombinant biotherapeutics production	214:251	Chinese hamster ovary (CHO) cells, predominant hosts for recombinant biotherapeutics production, generate lactate as a major glycolysis by-product.
37148536	5	136	theme	%	941:941	arg1	decrease					943:950	a 35%-45% decrease	933:950	a 35%-45% decrease in peak lactate	933:966	Individual 2DG and 5TG supplementation led to a 35%-45% decrease in peak lactate, while their combined supplementation resulted in a 60% decrease in peak lactate.
37148536	7	137	theme	Recombinant	1163:1173	arg1	EPO-Fc titers					1175:1187	Recombinant EPO-Fc titers	1163:1187	Recombinant EPO-Fc titers	1163:1187	Recombinant EPO-Fc titers peaked earlier relative to the end of culture duration in supplemented cultures leading to at least 11% and as high as 32% increase in final EPO-Fc titers.
37148536	11	138	from	incorporation	1891:1903	arg1	N-glycans					1939:1947	EPO-Fc N-glycans	1932:1947	EPO-Fc N-glycans	1932:1947	Interestingly, addition of 2DG led to the incorporation of 2-deoxy-hexose (2DH) on EPO-Fc N-glycans and addition of 5TG resulted in the first-ever observed N-glycan incorporation of 5-thio-hexose (5TH).
37148536	8	139	theme	carbon	1499:1504	arg1	metabolism					1506:1515	central carbon metabolism	1491:1515	central carbon metabolism due to low glycolytic fluxes	1491:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	8	140	theme	central	1491:1497	arg1	metabolism					1506:1515	central carbon metabolism	1491:1515	central carbon metabolism due to low glycolytic fluxes	1491:1544	Asparagine, pyruvate, and serine consumption rates also increased in the exponential growth phase in 2DG and 5TG treated cultures, thus, rewiring central carbon metabolism due to low glycolytic fluxes.
37148536	13	141	theme	alternative	2558:2568	arg1	glycoforms					2570:2579	alternative glycoforms	2558:2579	alternative glycoforms	2558:2579	Our study is the first to evaluate the impact of these glucose analogs on CHO cell growth, protein production, cell metabolism, N-glycosylation processing, and formation of alternative glycoforms.
35017635	0	0	theme	regulatory	97:106	arg1	circuits					108:115	glycan-mediated immune regulatory circuits	74:115	glycan-mediated immune regulatory circuits	74:115	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	4	1	theme	glycan	709:714	arg1	profiles					716:723	These different glycan profiles	693:723	These different glycan profiles	693:723	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	2	2	theme	systematic	351:360	arg1	approach					362:369	no systematic approach	348:369	no systematic approach	348:369	Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification.
35017635	0	3	theme	immune	90:95	arg1	circuits					108:115	glycan-mediated immune regulatory circuits	74:115	glycan-mediated immune regulatory circuits	74:115	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	3	4	theme	lines	524:528	arg1	data					491:494	publicly available transcriptomic data	457:494	publicly available transcriptomic data of patient samples and cell lines	457:528	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	0	5	from	Analysis	0:7	arg1	adenocarcinoma					48:61	pancreatic ductal adenocarcinoma	30:61	pancreatic ductal adenocarcinoma	30:61	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	2	6	theme	glycosylation	279:291	arg1	patterns					293:300	glycosylation patterns	279:300	glycosylation patterns	279:300	Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification.
35017635	0	7	from	adenocarcinoma	48:61	arg1	Analysis					0:7	Analysis	0:7	Analysis of the glyco-code in pancreatic ductal adenocarcinoma	0:61	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	3	8	theme	specific	554:561	arg1	profiles					570:577	here two specific glycan profiles	545:577	here two specific glycan profiles	545:577	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	3	9	theme	cell	519:522	arg1	lines					524:528	cell lines	519:528	cell lines	519:528	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	4	10	theme	different	699:707	arg1	profiles					716:723	These different glycan profiles	693:723	These different glycan profiles	693:723	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	5	11	theme	tumour-associated	979:995	arg1	macrophages					997:1007	DC-SIGN positive tumour-associated macrophages	962:1007	DC-SIGN positive tumour-associated macrophages	962:1007	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	4	12	from	cells	852:856	arg1	present					825:831	present	825:831	present	825:831	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	4	13	theme	epithelial	841:850	arg1	cells					852:856	epithelial cells	841:856	epithelial cells	841:856	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	1	14	theme	aggressive	182:191	arg1	malignancies					193:204	the most aggressive malignancies	173:204	the most aggressive malignancies with a 5-year survival rate of only 9%	173:243	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	1	15	theme	malignancies	193:204	arg1	malignancies					193:204	the most aggressive malignancies	173:204	the most aggressive malignancies with a 5-year survival rate of only 9%	173:243	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	1	15	theme	malignancies	193:204	arg1	one					166:168	one	166:168	one	166:168	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	2	16	theme	tumour	309:314	arg1	progression					316:326	tumour progression	309:326	tumour progression	309:326	Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification.
35017635	3	17	dep	progression	608:618	arg1	status					685:690	status	685:690	status	685:690	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	0	18	theme	glyco-code	16:25	arg1	Analysis					0:7	Analysis	0:7	Analysis of the glyco-code in pancreatic ductal adenocarcinoma	0:61	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	5	19	gly	fucosylated	917:927	arg1	ligands					950:956	ligands	950:956	ligands for DC-SIGN positive tumour-associated macrophages	950:1007	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	5	19	gly	fucosylated	917:927	arg1	glycans					929:935	these fucosylated glycans	911:935	these fucosylated glycans	911:935	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	1	20	theme	Pancreatic	118:127	arg1	PDAC					152:155	PDAC	152:155	PDAC	152:155	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	1	20	theme	Pancreatic	118:127	arg1	adenocarcinoma					136:149	Pancreatic ductal adenocarcinoma	118:149	Pancreatic ductal adenocarcinoma (PDAC)	118:156	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	2	21	theme	patient	420:426	arg1	stratification					428:441	patient stratification	420:441	patient stratification	420:441	Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification.
35017635	6	22	from	microenvironment	1159:1174	arg1	PDAC					1179:1182	PDAC	1179:1182	PDAC	1179:1182	Our results show mechanisms by which the glyco-code contributes to the tolerogenic microenvironment in PDAC.
35017635	3	23	theme	mesenchymal	656:666	arg1	EMT					680:682	EMT	680:682	EMT	680:682	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	3	23	theme	mesenchymal	656:666	arg1	transition					668:677	epithelial to mesenchymal transition	642:677	epithelial to mesenchymal transition (EMT)	642:683	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	1	24	theme	ductal	129:134	arg1	PDAC					152:155	PDAC	152:155	PDAC	152:155	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	1	24	theme	ductal	129:134	arg1	adenocarcinoma					136:149	Pancreatic ductal adenocarcinoma	118:149	Pancreatic ductal adenocarcinoma (PDAC)	118:156	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	1	25	theme	5-year	213:218	arg1	rate					229:232	a 5-year survival rate	211:232	a 5-year survival rate of only 9%	211:243	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	0	26	theme	pancreatic	30:39	arg1	adenocarcinoma					48:61	pancreatic ductal adenocarcinoma	30:61	pancreatic ductal adenocarcinoma	30:61	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	6	27	theme	tolerogenic	1147:1157	arg1	microenvironment					1159:1174	the tolerogenic microenvironment	1143:1174	the tolerogenic microenvironment in PDAC	1143:1182	Our results show mechanisms by which the glyco-code contributes to the tolerogenic microenvironment in PDAC.
35017635	1	28	theme	survival	220:227	arg1	rate					229:232	a 5-year survival rate	211:232	a 5-year survival rate of only 9%	211:243	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	3	29	theme	available	466:474	arg1	data					491:494	publicly available transcriptomic data	457:494	publicly available transcriptomic data of patient samples and cell lines	457:528	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	4	30	gly	fucosylated	801:811	arg1	structures					813:822	O-glycan fucosylated structures	792:822	O-glycan fucosylated structures	792:822	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	1	31	with	malignancies	193:204	arg1	rate					229:232	a 5-year survival rate	211:232	a 5-year survival rate of only 9%	211:243	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
35017635	5	32	theme	positive	970:977	arg1	macrophages					997:1007	DC-SIGN positive tumour-associated macrophages	962:1007	DC-SIGN positive tumour-associated macrophages	962:1007	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	3	33	theme	samples	507:513	arg1	data					491:494	publicly available transcriptomic data	457:494	publicly available transcriptomic data of patient samples and cell lines	457:528	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	0	34	theme	ductal	41:46	arg1	adenocarcinoma					48:61	pancreatic ductal adenocarcinoma	30:61	pancreatic ductal adenocarcinoma	30:61	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	4	35	theme	GALNT3	893:898	arg1	expression					879:888	the expression	875:888	the expression of GALNT3	875:898	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	4	36	from	present	825:831	arg1	cells					852:856	epithelial cells	841:856	epithelial cells	841:856	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	5	37	theme	fucosylated	917:927	arg1	ligands					950:956	ligands	950:956	ligands for DC-SIGN positive tumour-associated macrophages	950:1007	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	5	37	theme	fucosylated	917:927	arg1	glycans					929:935	these fucosylated glycans	911:935	these fucosylated glycans	911:935	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	2	38	from	changes	268:274	arg1	patterns					293:300	glycosylation patterns	279:300	glycosylation patterns	279:300	Despite the fact that changes in glycosylation patterns during tumour progression have been reported, no systematic approach has been conducted to evaluate its potential for patient stratification.
35017635	4	39	theme	fucosylated	801:811	arg1	structures					813:822	O-glycan fucosylated structures	792:822	O-glycan fucosylated structures	792:822	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	5	40	theme	IL-10	1069:1073	arg1	production					1055:1064	the production	1051:1064	the production of IL-10	1051:1073	Moreover, these fucosylated glycans can serve as ligands for DC-SIGN positive tumour-associated macrophages, modulating their activation and inducing the production of IL-10.
35017635	4	41	theme	O-glycan	792:799	arg1	structures					813:822	O-glycan fucosylated structures	792:822	O-glycan fucosylated structures	792:822	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	3	42	theme	glycan	563:568	arg1	profiles					570:577	here two specific glycan profiles	545:577	here two specific glycan profiles	545:577	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	3	43	dep	available	466:474	arg1	transcriptomic					476:489	transcriptomic	476:489	transcriptomic	476:489	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	3	44	theme	patient	499:505	arg1	samples					507:513	patient samples	499:513	patient samples	499:513	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	0	45	theme	glycan-mediated	74:88	arg1	circuits					108:115	glycan-mediated immune regulatory circuits	74:115	glycan-mediated immune regulatory circuits	74:115	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	4	46	theme	structures	813:822	arg1	expression					778:787	the expression	774:787	the expression of O-glycan fucosylated structures	774:822	These different glycan profiles, confirmed by glycomics, can be distinguished by the expression of O-glycan fucosylated structures, present only in epithelial cells and regulated by the expression of GALNT3.
35017635	3	47	dep	mesenchymal	656:666	arg1	to					653:654	to	653:654	to	653:654	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	0	48	from	glyco-code	16:25	arg1	adenocarcinoma					48:61	pancreatic ductal adenocarcinoma	30:61	pancreatic ductal adenocarcinoma	30:61	Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
35017635	3	49	theme	clinical	621:628	arg1	outcome					630:636	clinical outcome	621:636	clinical outcome	621:636	By analysing publicly available transcriptomic data of patient samples and cell lines, we identified here two specific glycan profiles in PDAC that correlated with progression, clinical outcome and epithelial to mesenchymal transition (EMT) status.
35017635	1	50	theme	%	243:243	arg1	rate					229:232	a 5-year survival rate	211:232	a 5-year survival rate of only 9%	211:243	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies with a 5-year survival rate of only 9%.
36924942	5	0	theme	N-terminal	711:720	arg1	modules					737:743	The N-terminal and C-terminal modules	707:743	The N-terminal and C-terminal modules	707:743	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	2	1	with	intervention	401:412	arg1	inhibitors					446:455	small-molecule therapeutic inhibitors	419:455	small-molecule therapeutic inhibitors	419:455	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	4	2	theme	cytidine-5'-monophospho-	644:667	arg1	donor					674:678	cytidine-5'-monophospho-β-Kdo donor	644:678	cytidine-5'-monophospho-β-Kdo donor	644:678	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	7	3	theme	retaining	1138:1146	arg1	WbbB					1130:1133	WbbB	1130:1133	WbbB	1130:1133	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	3	theme	retaining	1138:1146	arg1	GT					1154:1155	a retaining β-Kdo GT	1136:1155	a retaining β-Kdo GT distantly related to KpsC	1136:1181	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	1	4	theme	other	269:273	arg1	pathogens					289:297	other Gram-negative pathogens	269:297	other Gram-negative pathogens	269:297	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	9	5	theme	linkage	1722:1728	arg1	specificity					1730:1740	linkage specificity	1722:1740	linkage specificity	1722:1740	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	5	theme	linkage	1722:1728	arg1	recognition					1695:1705	acceptor recognition	1686:1705	acceptor recognition (and therefore linkage specificity)	1686:1741	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	5	6	gly	glycosylated	883:894	arg1	core					862:865	a conserved oligosaccharide core	834:865	a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures	834:932	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	2	7	theme	virulence	319:327	arg1	Capsules					300:307	Capsules	300:307	Capsules	300:307	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	2	7	theme	virulence	319:327	arg1	determinants					329:340	vital virulence determinants	313:340	vital virulence determinants in high-profile pathogens	313:366	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	5	8	theme	capsule	915:921	arg1	structures					923:932	diverse capsule structures	907:932	diverse capsule structures	907:932	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	4	9	theme	glycolipid	686:695	arg1	acceptor					697:704	a glycolipid acceptor	684:704	a glycolipid acceptor	684:704	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	7	10	theme	recent	1110:1115	arg1	studies					1117:1123	recent studies	1110:1123	recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC,	1110:1182	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	6	11	theme	anomeric	983:990	arg1	stereochemistry					999:1013	the donor anomeric carbon stereochemistry	973:1013	the donor anomeric carbon stereochemistry	973:1013	KpsC is a retaining GT, which retains the donor anomeric carbon stereochemistry.
36924942	0	12	from	modules	84:90	arg1	biosynthesis					123:134	bacterial capsule biosynthesis	105:134	bacterial capsule biosynthesis	105:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	9	13	theme	N-terminal	1770:1779	arg1	module					1803:1808	each GT module	1795:1808	each GT module	1795:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	13	theme	N-terminal	1770:1779	arg1	domain					1785:1790	the N-terminal α/β domain	1766:1790	the N-terminal α/β domain of each GT module	1766:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	5	14	theme	alternating	749:759	arg1	residues					765:772	alternating Kdo residues	749:772	alternating Kdo residues	749:772	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	9	15	theme	crystal	1544:1550	arg1	structures					1552:1561	Additional crystal structures	1533:1561	Additional crystal structures	1533:1561	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	8	16	theme	shared	1495:1500	arg1	mechanism					1522:1530	a shared double-displacement mechanism	1493:1530	a shared double-displacement mechanism	1493:1530	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	11	17	theme	structural	1963:1972	arg1	elements					1990:1997	key structural and mechanistic elements	1959:1997	key structural and mechanistic elements	1959:1997	Altogether, we identified key structural and mechanistic elements providing a foundation for targeting KpsC.
36924942	7	18	theme	internal	1078:1085	arg1	return					1087:1092	substitution nucleophilic internal return	1052:1092	substitution nucleophilic internal return	1052:1092	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	18	theme	internal	1078:1085	arg1	SNi					1047:1049	an SNi	1044:1049	an SNi (substitution nucleophilic internal return) mechanism	1044:1103	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	8	19	theme	mass	1341:1344	arg1	spectrometry					1346:1357	mass spectrometry	1341:1357	mass spectrometry	1341:1357	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	5	20	theme	2→7	794:796	arg1	linkages					799:806	β-(2→7) linkages	791:806	β-(2→7) linkages	791:806	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	7	21	theme	Retaining	1016:1024	arg1	GTs					1026:1028	Retaining GTs	1016:1028	Retaining GTs	1016:1028	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	1	22	theme	dual-module	147:157	arg1	KpsC					137:140	KpsC	137:140	KpsC	137:140	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	1	22	theme	dual-module	147:157	arg1	GT					180:181	GT	180:181	GT	180:181	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	1	22	theme	dual-module	147:157	arg1	glycosyltransferase					159:177	a dual-module glycosyltransferase	145:177	a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens	145:297	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	9	23	theme	module	1803:1808	arg1	module					1803:1808	each GT module	1795:1808	each GT module	1795:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	23	theme	module	1803:1808	arg1	domain					1785:1790	the N-terminal α/β domain	1766:1790	the N-terminal α/β domain of each GT module	1766:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	5	24	theme	Kdo	761:763	arg1	residues					765:772	alternating Kdo residues	749:772	alternating Kdo residues	749:772	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	0	25	theme	modules	84:90	arg1	Mechanism					0:8	Mechanism	0:8	Mechanism	0:8	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	0	25	theme	modules	84:90	arg1	specificities					22:34	linkage specificities	14:34	linkage specificities	14:34	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	5	26	theme	C-terminal	726:735	arg1	modules					737:743	The N-terminal and C-terminal modules	707:743	The N-terminal and C-terminal modules	707:743	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	2	27	from	determinants	329:340	arg1	pathogens					358:366	high-profile pathogens	345:366	high-profile pathogens	345:366	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	0	28	theme	KpsC	95:98	arg1	modules					84:90	the dual retaining β-Kdo glycosyltransferase modules	39:90	the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis	39:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	9	29	dep	specificity	1730:1740	arg1	therefore					1712:1720	therefore	1712:1720	therefore	1712:1720	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	30	theme	binding	1613:1619	arg1	mode					1621:1624	the acceptor binding mode	1600:1624	the acceptor binding mode of the β-(2→4)-Kdo transferase module	1600:1662	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	5	31	theme	β-	791:792	arg1	linkages					799:806	β-(2→7) linkages	791:806	β-(2→7) linkages	791:806	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	3	32	theme	Inhibitor	458:466	arg1	development					468:478	Inhibitor development	458:478	Inhibitor development	458:478	Inhibitor development can be facilitated by understanding the mechanism of the target enzyme.
36924942	5	33	theme	conserved	836:844	arg1	core					862:865	a conserved oligosaccharide core	834:865	a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures	834:932	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	1	34	theme	Gram-negative	275:287	arg1	pathogens					289:297	other Gram-negative pathogens	269:297	other Gram-negative pathogens	269:297	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	8	35	theme	important	1419:1427	arg1	residues					1441:1448	catalytically important active site residues	1405:1448	catalytically important active site residues	1405:1448	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	11	36	theme	mechanistic	1978:1988	arg1	elements					1990:1997	key structural and mechanistic elements	1959:1997	key structural and mechanistic elements	1959:1997	Altogether, we identified key structural and mechanistic elements providing a foundation for targeting KpsC.
36924942	0	37	theme	linkage	14:20	arg1	specificities					22:34	linkage specificities	14:34	linkage specificities	14:34	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	10	38	theme	C-terminal	1895:1904	arg1	region					1925:1930	a C-terminal membrane anchoring region	1893:1930	a C-terminal membrane anchoring region	1893:1930	Finally, an Alphafold model provided insight into organization of the modules and a C-terminal membrane anchoring region.
36924942	8	39	theme	site	1436:1439	arg1	residues					1441:1448	catalytically important active site residues	1405:1448	catalytically important active site residues	1405:1448	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	2	40	theme	therapeutic	434:444	arg1	inhibitors					446:455	small-molecule therapeutic inhibitors	419:455	small-molecule therapeutic inhibitors	419:455	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	9	41	theme	-Kdo	1640:1643	arg1	module					1657:1662	the β-(2→4)-Kdo transferase module	1629:1662	the β-(2→4)-Kdo transferase module	1629:1662	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	4	42	theme	GT	565:566	arg1	modules					568:574	Two separate GT modules	552:574	Two separate GT modules in KpsC	552:582	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	0	43	theme	β-Kdo	58:62	arg1	modules					84:90	the dual retaining β-Kdo glycosyltransferase modules	39:90	the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis	39:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	0	44	theme	dual	43:46	arg1	modules					84:90	the dual retaining β-Kdo glycosyltransferase modules	39:90	the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis	39:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	9	45	theme	module	1657:1662	arg1	mode					1621:1624	the acceptor binding mode	1600:1624	the acceptor binding mode of the β-(2→4)-Kdo transferase module	1600:1662	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	2	46	theme	high-profile	345:356	arg1	pathogens					358:366	high-profile pathogens	345:366	high-profile pathogens	345:366	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	1	47	theme	capsular	208:215	arg1	biosynthesis					232:243	capsular polysaccharide biosynthesis	208:243	capsular polysaccharide biosynthesis	208:243	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	4	48	theme	β-Kdo	668:672	arg1	donor					674:678	cytidine-5'-monophospho-β-Kdo donor	644:678	cytidine-5'-monophospho-β-Kdo donor	644:678	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	2	49	theme	small-molecule	419:432	arg1	inhibitors					446:455	small-molecule therapeutic inhibitors	419:455	small-molecule therapeutic inhibitors	419:455	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	2	50	theme	viable	383:388	arg1	target					390:395	a viable target	381:395	a viable target for intervention with small-molecule therapeutic inhibitors	381:455	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	0	51	theme	retaining	48:56	arg1	modules					84:90	the dual retaining β-Kdo glycosyltransferase modules	39:90	the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis	39:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	9	52	theme	acceptor	1686:1693	arg1	specificity					1730:1740	linkage specificity	1722:1740	linkage specificity	1722:1740	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	52	theme	acceptor	1686:1693	arg1	recognition					1695:1705	acceptor recognition	1686:1705	acceptor recognition (and therefore linkage specificity)	1686:1741	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	0	53	from	biosynthesis	123:134	arg1	modules					84:90	the dual retaining β-Kdo glycosyltransferase modules	39:90	the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis	39:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	0	53	from	biosynthesis	123:134	arg1	KpsC					95:98	KpsC	95:98	KpsC from bacterial capsule biosynthesis	95:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	7	54	theme	alternative	1226:1236	arg1	mechanism					1258:1266	an alternative double-displacement mechanism	1223:1266	an alternative double-displacement mechanism	1223:1266	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	55	theme	β-Kdo	1148:1152	arg1	WbbB					1130:1133	WbbB	1130:1133	WbbB	1130:1133	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	55	theme	β-Kdo	1148:1152	arg1	GT					1154:1155	a retaining β-Kdo GT	1136:1155	a retaining β-Kdo GT distantly related to KpsC	1136:1181	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	3	56	theme	enzyme	544:549	arg1	mechanism					520:528	the mechanism	516:528	the mechanism of the target enzyme	516:549	Inhibitor development can be facilitated by understanding the mechanism of the target enzyme.
36924942	6	57	theme	retaining	945:953	arg1	KpsC					935:938	KpsC	935:938	KpsC	935:938	KpsC is a retaining GT, which retains the donor anomeric carbon stereochemistry.
36924942	6	57	theme	retaining	945:953	arg1	GT					955:956	a retaining GT	943:956	a retaining GT	943:956	KpsC is a retaining GT, which retains the donor anomeric carbon stereochemistry.
36924942	5	58	theme	diverse	907:913	arg1	structures					923:932	diverse capsule structures	907:932	diverse capsule structures	907:932	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	7	59	theme	related	1167:1173	arg1	WbbB					1130:1133	WbbB	1130:1133	WbbB	1130:1133	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	59	theme	related	1167:1173	arg1	GT					1154:1155	a retaining β-Kdo GT	1136:1155	a retaining β-Kdo GT distantly related to KpsC	1136:1181	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	60	theme	double-displacement	1238:1256	arg1	mechanism					1258:1266	an alternative double-displacement mechanism	1223:1266	an alternative double-displacement mechanism	1223:1266	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	10	61	theme	Alphafold	1823:1831	arg1	model					1833:1837	an Alphafold model	1820:1837	an Alphafold model	1820:1837	Finally, an Alphafold model provided insight into organization of the modules and a C-terminal membrane anchoring region.
36924942	1	62	theme	essential	184:192	arg1	KpsC					137:140	KpsC	137:140	KpsC	137:140	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	1	62	theme	essential	184:192	arg1	GT					180:181	GT	180:181	GT	180:181	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	1	62	theme	essential	184:192	arg1	glycosyltransferase					159:177	a dual-module glycosyltransferase	145:177	a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens	145:297	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	2	63	theme	vital	313:317	arg1	Capsules					300:307	Capsules	300:307	Capsules	300:307	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	2	63	theme	vital	313:317	arg1	determinants					329:340	vital virulence determinants	313:340	vital virulence determinants in high-profile pathogens	313:366	Capsules are vital virulence determinants in high-profile pathogens, making KpsC a viable target for intervention with small-molecule therapeutic inhibitors.
36924942	6	64	theme	carbon	992:997	arg1	stereochemistry					999:1013	the donor anomeric carbon stereochemistry	973:1013	the donor anomeric carbon stereochemistry	973:1013	KpsC is a retaining GT, which retains the donor anomeric carbon stereochemistry.
36924942	6	65	theme	donor	977:981	arg1	stereochemistry					999:1013	the donor anomeric carbon stereochemistry	973:1013	the donor anomeric carbon stereochemistry	973:1013	KpsC is a retaining GT, which retains the donor anomeric carbon stereochemistry.
36924942	8	66	theme	adducts	1304:1310	arg1	formation					1282:1290	the formation	1278:1290	the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography	1278:1383	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	7	67	theme	substitution	1052:1063	arg1	return					1087:1092	substitution nucleophilic internal return	1052:1092	substitution nucleophilic internal return	1052:1092	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	67	theme	substitution	1052:1063	arg1	SNi					1047:1049	an SNi	1044:1049	an SNi (substitution nucleophilic internal return) mechanism	1044:1103	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	9	68	theme	Additional	1533:1542	arg1	structures					1552:1561	Additional crystal structures	1533:1561	Additional crystal structures	1533:1561	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	69	theme	α/β	1781:1783	arg1	module					1803:1808	each GT module	1795:1808	each GT module	1795:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	69	theme	α/β	1781:1783	arg1	domain					1785:1790	the N-terminal α/β domain	1766:1790	the N-terminal α/β domain of each GT module	1766:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	8	70	theme	double-displacement	1502:1520	arg1	mechanism					1522:1530	a shared double-displacement mechanism	1493:1530	a shared double-displacement mechanism	1493:1530	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	7	71	theme	nucleophilic	1065:1076	arg1	return					1087:1092	substitution nucleophilic internal return	1052:1092	substitution nucleophilic internal return	1052:1092	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	71	theme	nucleophilic	1065:1076	arg1	SNi					1047:1049	an SNi	1044:1049	an SNi (substitution nucleophilic internal return) mechanism	1044:1103	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	10	72	theme	modules	1881:1887	arg1	region					1925:1930	a C-terminal membrane anchoring region	1893:1930	a C-terminal membrane anchoring region	1893:1930	Finally, an Alphafold model provided insight into organization of the modules and a C-terminal membrane anchoring region.
36924942	10	72	theme	modules	1881:1887	arg1	organization					1861:1872	organization	1861:1872	organization of the modules	1861:1887	Finally, an Alphafold model provided insight into organization of the modules and a C-terminal membrane anchoring region.
36924942	7	73	theme	SNi	1047:1049	arg1	mechanism					1095:1103	an SNi (substitution nucleophilic internal return) mechanism	1044:1103	an SNi (substitution nucleophilic internal return) mechanism	1044:1103	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	0	74	theme	glycosyltransferase	64:82	arg1	modules					84:90	the dual retaining β-Kdo glycosyltransferase modules	39:90	the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis	39:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	8	75	theme	covalent	1295:1302	arg1	adducts					1304:1310	covalent adducts	1295:1310	covalent adducts	1295:1310	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	9	76	theme	biochemical	1567:1577	arg1	experiments					1579:1589	biochemical experiments	1567:1589	biochemical experiments	1567:1589	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	9	77	theme	GT	1800:1801	arg1	module					1803:1808	each GT module	1795:1808	each GT module	1795:1808	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	4	78	from	donor	674:678	arg1	β-Kdo					632:636	β-Kdo	632:636	β-Kdo	632:636	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	4	78	from	donor	674:678	arg1	acid					626:629	3-deoxy-β-d-manno-oct-2-ulosonic acid	593:629	3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor	593:678	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	4	79	theme	separate	556:563	arg1	modules					568:574	Two separate GT modules	552:574	Two separate GT modules in KpsC	552:582	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	9	80	theme	acceptor	1604:1611	arg1	mode					1621:1624	the acceptor binding mode	1600:1624	the acceptor binding mode of the β-(2→4)-Kdo transferase module	1600:1662	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	8	81	theme	X-ray	1363:1367	arg1	crystallography					1369:1383	X-ray crystallography	1363:1383	X-ray crystallography	1363:1383	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	0	82	theme	capsule	115:121	arg1	biosynthesis					123:134	bacterial capsule biosynthesis	105:134	bacterial capsule biosynthesis	105:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	11	83	theme	key	1959:1961	arg1	elements					1990:1997	key structural and mechanistic elements	1959:1997	key structural and mechanistic elements	1959:1997	Altogether, we identified key structural and mechanistic elements providing a foundation for targeting KpsC.
36924942	4	84	theme	3-deoxy-β-d-manno-oct-2-ulosonic	593:624	arg1	β-Kdo					632:636	β-Kdo	632:636	β-Kdo	632:636	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	4	84	theme	3-deoxy-β-d-manno-oct-2-ulosonic	593:624	arg1	acid					626:629	3-deoxy-β-d-manno-oct-2-ulosonic acid	593:629	3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor	593:678	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	10	85	theme	anchoring	1915:1923	arg1	region					1925:1930	a C-terminal membrane anchoring region	1893:1930	a C-terminal membrane anchoring region	1893:1930	Finally, an Alphafold model provided insight into organization of the modules and a C-terminal membrane anchoring region.
36924942	5	86	theme	oligosaccharide	846:860	arg1	core					862:865	a conserved oligosaccharide core	834:865	a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures	834:932	The N-terminal and C-terminal modules add alternating Kdo residues with β-(2→4) and β-(2→7) linkages, respectively, generating a conserved oligosaccharide core that is further glycosylated to produce diverse capsule structures.
36924942	10	87	theme	membrane	1906:1913	arg1	region					1925:1930	a C-terminal membrane anchoring region	1893:1930	a C-terminal membrane anchoring region	1893:1930	Finally, an Alphafold model provided insight into organization of the modules and a C-terminal membrane anchoring region.
36924942	8	88	theme	active	1429:1434	arg1	residues					1441:1448	catalytically important active site residues	1405:1448	catalytically important active site residues	1405:1448	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
36924942	0	89	theme	bacterial	105:113	arg1	biosynthesis					123:134	bacterial capsule biosynthesis	105:134	bacterial capsule biosynthesis	105:134	Mechanism and linkage specificities of the dual retaining β-Kdo glycosyltransferase modules of KpsC from bacterial capsule biosynthesis.
36924942	4	90	from	modules	568:574	arg1	KpsC					579:582	KpsC	579:582	KpsC	579:582	Two separate GT modules in KpsC transfer 3-deoxy-β-d-manno-oct-2-ulosonic acid (β-Kdo) from cytidine-5'-monophospho-β-Kdo donor, to a glycolipid acceptor.
36924942	9	91	theme	transferase	1645:1655	arg1	module					1657:1662	the β-(2→4)-Kdo transferase module	1629:1662	the β-(2→4)-Kdo transferase module	1629:1662	Additional crystal structures and biochemical experiments revealed the acceptor binding mode of the β-(2→4)-Kdo transferase module and demonstrated that acceptor recognition (and therefore linkage specificity) is conferred solely by the N-terminal α/β domain of each GT module.
36924942	7	92	with	studies	1117:1123	arg1	WbbB					1130:1133	WbbB	1130:1133	WbbB	1130:1133	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	7	92	with	studies	1117:1123	arg1	GT					1154:1155	a retaining β-Kdo GT	1136:1155	a retaining β-Kdo GT distantly related to KpsC	1136:1181	Retaining GTs typically use an SNi (substitution nucleophilic internal return) mechanism, but recent studies with WbbB, a retaining β-Kdo GT distantly related to KpsC, strongly suggest that this enzyme uses an alternative double-displacement mechanism.
36924942	3	93	theme	target	537:542	arg1	enzyme					544:549	the target enzyme	533:549	the target enzyme	533:549	Inhibitor development can be facilitated by understanding the mechanism of the target enzyme.
36924942	1	94	theme	polysaccharide	217:230	arg1	biosynthesis					232:243	capsular polysaccharide biosynthesis	208:243	capsular polysaccharide biosynthesis	208:243	KpsC is a dual-module glycosyltransferase (GT) essential for "group 2" capsular polysaccharide biosynthesis in Escherichia coli and other Gram-negative pathogens.
36924942	8	95	with	formation	1282:1290	arg1	Kdo					1317:1319	Kdo	1317:1319	Kdo	1317:1319	Based on the formation of covalent adducts with Kdo, identified here by mass spectrometry and X-ray crystallography, we determined that catalytically important active site residues are conserved in WbbB and KpsC, suggesting a shared double-displacement mechanism.
35285541	2	0	dep	wherein	289:295	arg1	contributed					347:357	contributed	347:357	are contributed by the glycans	343:372	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	0	1	theme	proteins	78:85	arg1	estimation					64:73	molecular weight estimation	47:73	molecular weight estimation of proteins with variable levels of glycosylation	47:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	1	2	theme	fusion	160:165	arg1	proteins					167:174	fusion proteins	160:174	fusion proteins	160:174	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	0	3	theme	variable	92:99	arg1	levels					101:106	variable levels	92:106	variable levels of glycosylation	92:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	0	4	theme	glycosylation	111:123	arg1	levels					101:106	variable levels	92:106	variable levels of glycosylation	92:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	4	5	gly	glycoprotein	617:628	arg1	glycoprotein					617:628	the glycoprotein	613:628	the glycoprotein	613:628	Glycosylation influences the expected size of the glycoprotein, which leads to disproportionate MW estimation, in size-dependent methods.
35285541	0	6	with	estimation	64:73	arg1	levels					101:106	variable levels	92:106	variable levels of glycosylation	92:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	3	7	theme	physicochemical	486:500	arg1	characteristics					502:516	the physicochemical characteristics	482:516	the physicochemical characteristics	482:516	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	4	8	theme	disproportionate	646:661	arg1	estimation					666:675	disproportionate MW estimation	646:675	disproportionate MW estimation	646:675	Glycosylation influences the expected size of the glycoprotein, which leads to disproportionate MW estimation, in size-dependent methods.
35285541	2	9	gly	glycoproteins	274:286	arg1	wherein					289:295	wherein	289:295	wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans	289:372	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	2	9	gly	glycoproteins	274:286	arg1	glycoproteins					274:286	glycoproteins	274:286	glycoproteins	274:286	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	2	9	gly	glycoproteins	274:286	arg1	Majority					235:242	Majority	235:242	Majority of the biopharmaceuticals	235:268	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	4	10	theme	expected	596:603	arg1	size					605:608	the expected size	592:608	the expected size	592:608	Glycosylation influences the expected size of the glycoprotein, which leads to disproportionate MW estimation, in size-dependent methods.
35285541	3	11	theme	glycosylated	406:417	arg1	proteins					447:454	Fc-fusion proteins	437:454	Fc-fusion proteins	437:454	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	3	11	theme	glycosylated	406:417	arg1	proteins					419:426	heavily glycosylated proteins	398:426	heavily glycosylated proteins	398:426	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	3	12	theme	attached	543:550	arg1	carbohydrates					552:564	the attached carbohydrates	539:564	the attached carbohydrates	539:564	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	3	13	theme	MW	392:393	arg1	Determination					375:387	Determination	375:387	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins,	375:455	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	5	14	theme	used	794:797	arg1	techniques					813:822	four widely used MW estimation techniques	782:822	four widely used MW estimation techniques for three proteins having varying levels of glycosylation	782:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	7	15	theme	glycosylation	1064:1076	arg1	degree					1054:1059	the degree	1050:1059	the degree of glycosylation	1050:1076	However, MW estimation by LC-MS and SDS-PAGE was extensively hampered by the degree of glycosylation.
35285541	3	16	theme	carbohydrates	552:564	arg1	heterogeneity					522:534	heterogeneity	522:534	heterogeneity of the attached carbohydrates	522:564	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	3	16	theme	carbohydrates	552:564	arg1	characteristics					502:516	the physicochemical characteristics	482:516	the physicochemical characteristics	482:516	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	4	17	theme	MW	663:664	arg1	estimation					666:675	disproportionate MW estimation	646:675	disproportionate MW estimation	646:675	Glycosylation influences the expected size of the glycoprotein, which leads to disproportionate MW estimation, in size-dependent methods.
35285541	0	18	theme	analytical	21:30	arg1	approaches					32:41	analytical approaches	21:41	analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation	21:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	5	19	contain	having	843:848	arg1	proteins					834:841	three proteins	828:841	three proteins having varying levels of glycosylation	828:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	5	19	contain	having	843:848	arg2	levels					858:863	varying levels	850:863	varying levels of glycosylation	850:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	1	20	theme	major	183:187	arg1	mAbs					151:154	mAbs	151:154	mAbs	151:154	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	20	theme	major	183:187	arg1	class					209:213	a major and rapidly growing class	181:213	a major and rapidly growing class of pharmaceuticals	181:232	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	20	theme	major	183:187	arg1	Biotherapeutics					126:140	Biotherapeutics	126:140	Biotherapeutics	126:140	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	20	theme	major	183:187	arg1	proteins					167:174	fusion proteins	160:174	fusion proteins	160:174	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	5	21	theme	estimation	802:811	arg1	techniques					813:822	four widely used MW estimation techniques	782:822	four widely used MW estimation techniques for three proteins having varying levels of glycosylation	782:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	5	22	dep	advantages	752:761	arg1	the					748:750	the	748:750	the	748:750	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	2	23	theme	weight	331:336	arg1	%					310:310	about 1 to 30%	297:310	about 1 to 30% of their molecular weight (MW)	297:341	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	2	23	theme	weight	331:336	arg1	MW					339:340	MW	339:340	MW	339:340	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	2	23	theme	weight	331:336	arg1	weight					331:336	their molecular weight	315:336	their molecular weight (MW)	315:341	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	4	24	theme	glycoprotein	617:628	arg1	size					605:608	the expected size	592:608	the expected size	592:608	Glycosylation influences the expected size of the glycoprotein, which leads to disproportionate MW estimation, in size-dependent methods.
35285541	6	25	contain	had	916:918	arg1	glycosylation					902:914	glycosylation	902:914	glycosylation	902:914	It was proven that glycosylation had least impact on MW determination by SEC-MALS and SV-AUC.
35285541	6	25	contain	had	916:918	arg2	impact					926:931	least impact	920:931	least impact	920:931	It was proven that glycosylation had least impact on MW determination by SEC-MALS and SV-AUC.
35285541	3	26	theme	proteins	419:426	arg1	MW					392:393	MW	392:393	MW of heavily glycosylated proteins, such as Fc-fusion proteins,	392:455	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	6	27	theme	MW	936:937	arg1	determination					939:951	MW determination	936:951	MW determination by SEC-MALS and SV-AUC	936:974	It was proven that glycosylation had least impact on MW determination by SEC-MALS and SV-AUC.
35285541	5	28	theme	MW	799:800	arg1	techniques					813:822	four widely used MW estimation techniques	782:822	four widely used MW estimation techniques for three proteins having varying levels of glycosylation	782:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	1	29	theme	growing	201:207	arg1	mAbs					151:154	mAbs	151:154	mAbs	151:154	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	29	theme	growing	201:207	arg1	class					209:213	a major and rapidly growing class	181:213	a major and rapidly growing class of pharmaceuticals	181:232	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	29	theme	growing	201:207	arg1	Biotherapeutics					126:140	Biotherapeutics	126:140	Biotherapeutics	126:140	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	29	theme	growing	201:207	arg1	proteins					167:174	fusion proteins	160:174	fusion proteins	160:174	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	0	30	theme	weight	57:62	arg1	estimation					64:73	molecular weight estimation	47:73	molecular weight estimation of proteins with variable levels of glycosylation	47:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	5	31	theme	glycosylation	868:880	arg1	levels					858:863	varying levels	850:863	varying levels of glycosylation	850:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	2	32	theme	molecular	321:329	arg1	MW					339:340	MW	339:340	MW	339:340	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	2	32	theme	molecular	321:329	arg1	weight					331:336	their molecular weight	315:336	their molecular weight (MW)	315:341	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	0	33	theme	molecular	47:55	arg1	estimation					64:73	molecular weight estimation	47:73	molecular weight estimation of proteins with variable levels of glycosylation	47:123	A comparison between analytical approaches for molecular weight estimation of proteins with variable levels of glycosylation.
35285541	7	34	theme	MW	986:987	arg1	estimation					989:998	MW estimation	986:998	MW estimation by LC-MS and SDS-PAGE	986:1020	However, MW estimation by LC-MS and SDS-PAGE was extensively hampered by the degree of glycosylation.
35285541	6	35	theme	least	920:924	arg1	impact					926:931	least impact	920:931	least impact	920:931	It was proven that glycosylation had least impact on MW determination by SEC-MALS and SV-AUC.
35285541	2	36	theme	biopharmaceuticals	251:268	arg1	glycoproteins					274:286	glycoproteins	274:286	glycoproteins	274:286	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	2	36	theme	biopharmaceuticals	251:268	arg1	Majority					235:242	Majority	235:242	Majority of the biopharmaceuticals	235:268	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	3	37	gly	glycosylated	406:417	arg1	proteins					447:454	Fc-fusion proteins	437:454	Fc-fusion proteins	437:454	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	3	37	gly	glycosylated	406:417	arg1	proteins					419:426	heavily glycosylated proteins	398:426	heavily glycosylated proteins	398:426	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	2	38	dep	30	308:309	arg1	to					305:306	to	305:306	to	305:306	Majority of the biopharmaceuticals are glycoproteins, wherein about 1 to 30% of their molecular weight (MW) are contributed by the glycans.
35285541	4	39	theme	size-dependent	681:694	arg1	methods					696:702	size-dependent methods	681:702	size-dependent methods	681:702	Glycosylation influences the expected size of the glycoprotein, which leads to disproportionate MW estimation, in size-dependent methods.
35285541	8	40	theme	proteins	1148:1155	arg1	characteristics					1129:1143	the structural characteristics	1114:1143	the structural characteristics of proteins	1114:1155	It is, thus, essential to consider the structural characteristics of proteins while selecting a technique for determining their MW.
35285541	3	41	theme	Fc-fusion	437:445	arg1	proteins					447:454	Fc-fusion proteins	437:454	Fc-fusion proteins	437:454	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	5	42	theme	techniques	813:822	arg1	limitations					767:777	limitations	767:777	limitations	767:777	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	5	42	theme	techniques	813:822	arg1	advantages					752:761	advantages	752:761	advantages	752:761	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	3	43	gly	heterogeneity	522:534	arg1	carbohydrates					552:564	the attached carbohydrates	539:564	the attached carbohydrates	539:564	Determination of MW of heavily glycosylated proteins, such as Fc-fusion proteins, is seriously hampered by the physicochemical characteristics and heterogeneity of the attached carbohydrates.
35285541	5	44	theme	varying	850:856	arg1	levels					858:863	varying levels	850:863	varying levels of glycosylation	850:880	Hence, in this study, we have demonstrated the advantages and limitations of four widely used MW estimation techniques for three proteins having varying levels of glycosylation.
35285541	1	45	theme	pharmaceuticals	218:232	arg1	mAbs					151:154	mAbs	151:154	mAbs	151:154	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	45	theme	pharmaceuticals	218:232	arg1	class					209:213	a major and rapidly growing class	181:213	a major and rapidly growing class of pharmaceuticals	181:232	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	45	theme	pharmaceuticals	218:232	arg1	Biotherapeutics					126:140	Biotherapeutics	126:140	Biotherapeutics	126:140	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	1	45	theme	pharmaceuticals	218:232	arg1	proteins					167:174	fusion proteins	160:174	fusion proteins	160:174	Biotherapeutics, such as mAbs and fusion proteins, are a major and rapidly growing class of pharmaceuticals.
35285541	8	46	theme	structural	1118:1127	arg1	characteristics					1129:1143	the structural characteristics	1114:1143	the structural characteristics of proteins	1114:1155	It is, thus, essential to consider the structural characteristics of proteins while selecting a technique for determining their MW.
36892535	0	0	theme	Glycosylation	73:85	arg1	Role					57:60	the Role	53:60	the Role of Mucin 1 Glycosylation in Cell Adhesion	53:102	Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.
36892535	1	1	theme	physiological	163:175	arg1	conditions					194:203	physiological and pathological conditions	163:203	physiological and pathological conditions	163:203	Posttranslational modifications affect protein biology in physiological and pathological conditions.
36892535	4	2	theme	MUC1	497:500	arg1	glycosylation					502:514	MUC1 glycosylation	497:514	MUC1 glycosylation	497:514	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	2	3	contain	carrying	269:276	arg2	modifications					299:311	defined, homogeneous modifications	278:311	defined, homogeneous modifications	278:311	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	2	3	contain	carrying	269:276	arg1	peptides					247:254	peptides	247:254	peptides	247:254	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	8	4	theme	peptide	1155:1161	arg1	structure					1163:1171	peptide structure	1155:1171	peptide structure	1155:1171	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	6	5	theme	distinct	882:889	arg1	role					891:894	a distinct role	880:894	a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion	880:966	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	3	6	located	observed	436:443	arg2	pattern					425:431	an altered glycosylation pattern	400:431	an altered glycosylation pattern	400:431	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	3	6	located	observed	436:443	arg1	case					377:380	the case	373:380	the case of Mucin 1 (MUC1)	373:398	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	3	6	located	observed	436:443	arg1	carcinogenesis					448:461	carcinogenesis	448:461	carcinogenesis	448:461	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	0	7	theme	Cell	90:93	arg1	Adhesion					95:102	Cell Adhesion	90:102	Cell Adhesion	90:102	Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.
36892535	7	8	theme	observed	1013:1020	arg1	adhesion					1022:1029	the observed adhesion	1009:1029	the observed adhesion	1009:1029	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	5	9	theme	MCF-7	704:708	arg1	cells					717:721	MCF-7 cancer cells	704:721	MCF-7 cancer cells	704:721	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	4	10	theme	peptides	618:625	arg1	panel					575:579	a panel	573:579	a panel of homogeneously O-glycosylated MUC1 peptides	573:625	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	5	11	theme	MUC1	777:780	arg1	peptides					782:789	up to 6 differently glycosylated MUC1 peptides	744:789	up to 6 differently glycosylated MUC1 peptides	744:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	0	12	from	Role	57:60	arg1	Adhesion					95:102	Cell Adhesion	90:102	Cell Adhesion	90:102	Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.
36892535	5	13	theme	cancer	710:715	arg1	cells					717:721	MCF-7 cancer cells	704:721	MCF-7 cancer cells	704:721	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	8	14	from	differences	1140:1150	arg1	structure					1163:1171	peptide structure	1155:1171	peptide structure	1155:1171	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	2	15	theme	fundamental	317:327	arg1	tools					329:333	fundamental tools	317:333	fundamental tools for investigating these functions	317:367	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	2	15	theme	fundamental	317:327	arg1	methods					216:222	Efficient methods	206:222	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications	206:311	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	4	16	theme	MUC1	613:616	arg1	peptides					618:625	homogeneously O-glycosylated MUC1 peptides	584:625	homogeneously O-glycosylated MUC1 peptides	584:625	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	1	17	theme	pathological	181:192	arg1	conditions					194:203	physiological and pathological conditions	163:203	physiological and pathological conditions	163:203	Posttranslational modifications affect protein biology in physiological and pathological conditions.
36892535	3	18	theme	Mucin	385:389	arg1	MUC1					394:397	Mucin 1 (MUC1)	385:398	Mucin 1 (MUC1)	385:398	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	4	19	theme	O-glycosylated	598:611	arg1	peptides					618:625	homogeneously O-glycosylated MUC1 peptides	584:625	homogeneously O-glycosylated MUC1 peptides	584:625	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	0	20	theme	Chemoenzymatic	0:13	arg1	Synthesis					15:23	Chemoenzymatic Synthesis	0:23	Chemoenzymatic Synthesis of Glycopeptides	0:40	Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.
36892535	6	21	dep	cell	937:940	arg1	migration					942:950	migration	942:950	migration	942:950	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	4	22	theme	glycosylation	502:514	arg1	role					489:492	the role	485:492	the role of MUC1 glycosylation in interaction and adhesion of cancer cells	485:558	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	5	23	theme	Cell	673:676	arg1	experiments					687:697	Cell adhesion experiments	673:697	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides	673:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	4	24	gly	O-glycosylated	598:611	arg1	peptides					618:625	homogeneously O-glycosylated MUC1 peptides	584:625	homogeneously O-glycosylated MUC1 peptides	584:625	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	3	25	theme	altered	403:409	arg1	pattern					425:431	an altered glycosylation pattern	400:431	an altered glycosylation pattern	400:431	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	5	26	theme	adhesion	678:685	arg1	experiments					687:697	Cell adhesion experiments	673:697	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides	673:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	5	27	gly	glycosylated	764:775	arg1	peptides					782:789	up to 6 differently glycosylated MUC1 peptides	744:789	up to 6 differently glycosylated MUC1 peptides	744:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	5	28	theme	glycosylated	764:775	arg1	peptides					782:789	up to 6 differently glycosylated MUC1 peptides	744:789	up to 6 differently glycosylated MUC1 peptides	744:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	3	29	theme	MUC1	394:397	arg1	case					377:380	the case	373:380	the case of Mucin 1 (MUC1)	373:398	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	7	30	gly	glycosylated	1067:1078	arg1	peptides					1085:1092	the glycosylated MUC1 peptides	1063:1092	the glycosylated MUC1 peptides	1063:1092	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	4	31	from	role	489:492	arg1	adhesion					535:542	adhesion	535:542	adhesion	535:542	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	4	31	from	role	489:492	arg1	interaction					519:529	interaction	519:529	interaction	519:529	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	5	32	with	experiments	687:697	arg1	cells					717:721	MCF-7 cancer cells	704:721	MCF-7 cancer cells	704:721	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	2	33	theme	Efficient	206:214	arg1	tools					329:333	fundamental tools	317:333	fundamental tools for investigating these functions	317:367	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	2	33	theme	Efficient	206:214	arg1	methods					216:222	Efficient methods	206:222	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications	206:311	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	8	34	attach	linked	1258:1263	arg2	glycans					1250:1256	glycans	1250:1256	glycans linked to MUC1	1250:1271	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	8	34	attach	linked	1258:1263	arg1	MUC1					1268:1271	MUC1	1268:1271	MUC1	1268:1271	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	4	35	gly	glycosylation	502:514	arg1	cells					554:558	cancer cells	547:558	cancer cells	547:558	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	8	36	dep	type	1231:1234	arg1	the					1227:1229	the	1227:1229	the	1227:1229	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	6	37	theme	cancer	930:935	arg1	cell					937:940	cancer cell migration and/or invasion	930:966	cell	937:940	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	2	38	theme	proteins	260:267	arg1	preparation					232:242	the preparation	228:242	the preparation of peptides and proteins carrying defined, homogeneous modifications	228:311	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	2	39	dep	defined	278:284	arg1	homogeneous					287:297	homogeneous	287:297	homogeneous	287:297	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	4	40	theme	cells	554:558	arg1	adhesion					535:542	adhesion	535:542	adhesion	535:542	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	4	40	theme	cells	554:558	arg1	interaction					519:529	interaction	519:529	interaction	519:529	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	6	41	from	role	891:894	arg1	invasion					959:966	invasion	959:966	invasion	959:966	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	6	41	from	role	891:894	arg1	cell					937:940	cancer cell migration and/or invasion	930:966	cell	937:940	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	0	42	theme	Glycopeptides	28:40	arg1	Synthesis					15:23	Chemoenzymatic Synthesis	0:23	Chemoenzymatic Synthesis of Glycopeptides	0:40	Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.
36892535	8	43	theme	glycans	1250:1256	arg1	type					1231:1234	type	1231:1234	type	1231:1234	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	8	43	theme	glycans	1250:1256	arg1	number					1240:1245	number	1240:1245	number	1240:1245	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	3	44	theme	glycosylation	411:423	arg1	pattern					425:431	an altered glycosylation pattern	400:431	an altered glycosylation pattern	400:431	In the case of Mucin 1 (MUC1) an altered glycosylation pattern is observed in carcinogenesis.
36892535	4	45	theme	cancer	547:552	arg1	cells					554:558	cancer cells	547:558	cancer cells	547:558	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	6	46	theme	patterns	918:925	arg1	role					891:894	a distinct role	880:894	a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion	880:966	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	2	47	theme	peptides	247:254	arg1	preparation					232:242	the preparation	228:242	the preparation of peptides and proteins carrying defined, homogeneous modifications	228:311	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	1	48	theme	Posttranslational	105:121	arg1	modifications					123:135	Posttranslational modifications	105:135	Posttranslational modifications	105:135	Posttranslational modifications affect protein biology in physiological and pathological conditions.
36892535	5	49	from	experiments	687:697	arg1	surfaces					726:733	surfaces	726:733	surfaces carrying up to 6 differently glycosylated MUC1 peptides	726:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	6	50	theme	glycosylation	904:916	arg1	patterns					918:925	MUC1 glycosylation patterns	899:925	MUC1 glycosylation patterns	899:925	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	6	51	theme	MUC1	899:902	arg1	patterns					918:925	MUC1 glycosylation patterns	899:925	MUC1 glycosylation patterns	899:925	This finding suggests a distinct role of MUC1 glycosylation patterns in cancer cell migration and/or invasion.
36892535	7	52	theme	peptides	1085:1092	arg1	conformation					1047:1058	conformation	1047:1058	conformation of the glycosylated MUC1 peptides	1047:1092	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	8	53	theme	minor	1134:1138	arg1	differences					1140:1150	only minor differences	1129:1150	only minor differences in peptide structure	1129:1171	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	5	54	dep	6	750:750	arg1	to					747:748	to	747:748	to	747:748	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	5	55	contain	carrying	735:742	arg1	surfaces					726:733	surfaces	726:733	surfaces carrying up to 6 differently glycosylated MUC1 peptides	726:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	5	55	contain	carrying	735:742	arg2	peptides					782:789	up to 6 differently glycosylated MUC1 peptides	744:789	up to 6 differently glycosylated MUC1 peptides	744:789	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	7	56	theme	molecular	985:993	arg1	mechanism					995:1003	the molecular mechanism	981:1003	the molecular mechanism for the observed adhesion	981:1029	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	8	57	theme	adhesion	1205:1212	arg1	behaviour					1214:1222	the adhesion behaviour	1201:1222	the adhesion behaviour	1201:1222	These experiments revealed only minor differences in peptide structure, therefore clearly relating the adhesion behaviour to the type and number of glycans linked to MUC1.
36892535	7	58	theme	glycosylated	1067:1078	arg1	peptides					1085:1092	the glycosylated MUC1 peptides	1063:1092	the glycosylated MUC1 peptides	1063:1092	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	1	59	theme	protein	144:150	arg1	biology					152:158	protein biology	144:158	protein biology	144:158	Posttranslational modifications affect protein biology in physiological and pathological conditions.
36892535	7	60	dep	investigated	1034:1045	arg1	decipher					972:979	decipher	972:979	To decipher the molecular mechanism for the observed adhesion	969:1029	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	0	61	theme	Mucin	65:69	arg1	Glycosylation					73:85	Mucin 1 Glycosylation	65:85	Mucin 1 Glycosylation	65:85	Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.
36892535	2	62	theme	defined	278:284	arg1	modifications					299:311	defined, homogeneous modifications	278:311	defined, homogeneous modifications	278:311	Efficient methods for the preparation of peptides and proteins carrying defined, homogeneous modifications are fundamental tools for investigating these functions.
36892535	7	63	theme	MUC1	1080:1083	arg1	peptides					1085:1092	the glycosylated MUC1 peptides	1063:1092	the glycosylated MUC1 peptides	1063:1092	To decipher the molecular mechanism for the observed adhesion we investigated conformation of the glycosylated MUC1 peptides by NMR.
36892535	4	64	theme	chemoenzymatic	648:661	arg1	approach					663:670	a quantitative chemoenzymatic approach	633:670	a quantitative chemoenzymatic approach	633:670	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
36892535	5	65	theme	different	809:817	arg1	glycans					819:825	different glycans	809:825	different glycans	809:825	Cell adhesion experiments with MCF-7 cancer cells on surfaces carrying up to 6 differently glycosylated MUC1 peptides demonstrated that different glycans significantly impact adhesion.
36892535	4	66	theme	quantitative	635:646	arg1	approach					663:670	a quantitative chemoenzymatic approach	633:670	a quantitative chemoenzymatic approach	633:670	To better understand the role of MUC1 glycosylation in interaction and adhesion of cancer cells, we prepared a panel of homogeneously O-glycosylated MUC1 peptides using a quantitative chemoenzymatic approach.
35737823	3	0	theme	critical	680:687	arg1	description					648:658	the description	644:658	the description of its dynamics	644:674	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	3	0	theme	critical	680:687	arg1	Construction					583:594	Construction	583:594	Construction of the complete, membrane-bound spike model	583:638	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	3	0	theme	critical	680:687	arg1	steps					689:693	critical steps	680:693	critical steps	680:693	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	4	1	theme	molecular	846:854	arg1	simulations					870:880	molecular dynamics (MD) simulations	846:880	molecular dynamics (MD) simulations	846:880	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	9	2	theme	therapeutics	1858:1869	arg1	discovery					1833:1841	discovery	1833:1841	discovery of alternative therapeutics against the virus	1833:1887	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	6	3	theme	glycosylated	1306:1317	arg1	system					1319:1324	the fully glycosylated system	1296:1324	the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions	1296:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	9	4	theme	identified	1661:1670	arg1	regions					1678:1684	the identified hinge regions	1657:1684	the identified hinge regions	1657:1684	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	8	5	theme	domain	1580:1585	arg1	palmitoylation					1549:1562	palmitoylation	1549:1562	palmitoylation of the membrane domain	1549:1585	Furthermore, palmitoylation of the membrane domain amplifies the local curvature that may prime the fusion.
35737823	7	6	theme	nonglycosylated	1447:1461	arg1	form					1463:1466	its nonglycosylated form	1443:1466	its nonglycosylated form	1443:1466	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	4	7	theme	dynamics	856:863	arg1	simulations					870:880	molecular dynamics (MD) simulations	846:880	molecular dynamics (MD) simulations	846:880	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	1	8	theme	therapeutic	256:266	arg1	antibodies					268:277	therapeutic antibodies	256:277	therapeutic antibodies against the virus	256:295	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	0	9	theme	cell	109:112	arg1	receptors					114:122	host cell receptors	104:122	host cell receptors	104:122	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	3	10	theme	dynamics	667:674	arg1	description					648:658	the description	644:658	the description of its dynamics	644:674	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	3	10	theme	dynamics	667:674	arg1	steps					689:693	critical steps	680:693	critical steps	680:693	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	3	10	theme	dynamics	667:674	arg1	Construction					583:594	Construction	583:594	Construction of the complete, membrane-bound spike model	583:638	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	9	11	theme	alternative	1846:1856	arg1	therapeutics					1858:1869	alternative therapeutics	1846:1869	alternative therapeutics against the virus	1846:1887	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	0	12	with	interaction	87:97	arg1	receptors					114:122	host cell receptors	104:122	host cell receptors	104:122	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	5	13	theme	MD	963:964	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	13	theme	MD	963:964	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	0	14	theme	host	104:107	arg1	receptors					114:122	host cell receptors	104:122	host cell receptors	104:122	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	1	15	gly	glycoprotein	192:203	arg1	glycoprotein					192:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	15	gly	glycoprotein	192:203	arg1	target					218:223	the prime target	208:223	the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus	208:295	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	6	16	theme	flexible	1209:1216	arg1	hinges					1218:1223	three flexible hinges	1203:1223	three flexible hinges in the stalk	1203:1236	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	7	17	theme	dynamical	1387:1395	arg1	range					1397:1401	The dynamical range	1383:1401	The dynamical range of the spike	1383:1414	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	7	18	theme	host	1517:1520	arg1	surface					1527:1533	the host cell surface	1513:1533	the host cell surface	1513:1533	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	6	19	with	agreement	1147:1155	arg1	cryo-EM					1193:1199	cryo-EM	1193:1199	cryo-EM	1193:1199	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	6	19	with	agreement	1147:1155	arg1	microscopy					1181:1190	cryogenic electron microscopy	1162:1190	cryogenic electron microscopy (cryo-EM)	1162:1200	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	2	20	theme	effective	340:348	arg1	virulence					350:358	effective virulence	340:358	effective virulence	340:358	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	4	21	theme	protein-protein	817:831	arg1	docking					833:839	protein-protein docking	817:839	protein-protein docking	817:839	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	2	22	theme	structural	389:398	arg1	property					477:484	a property	475:484	a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk	475:580	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	2	22	theme	structural	389:398	arg1	flexibility					400:410	structural flexibility to recognize the host cell surface receptors and bind to them	389:472	structural flexibility to recognize the host cell surface receptors and bind to them	389:472	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	5	23	theme	conformational	1055:1068	arg1	dynamics					1070:1077	conformational dynamics	1055:1077	conformational dynamics employed by the protein to explore the surface of the host cell	1055:1141	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	0	24	theme	Posttranslational	0:16	arg1	modifications					18:30	Posttranslational modifications	0:30	Posttranslational modifications	0:30	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	1	25	theme	spike	186:190	arg1	glycoprotein					192:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	25	theme	spike	186:190	arg1	target					218:223	the prime target	208:223	the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus	208:295	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	8	26	theme	membrane	1571:1578	arg1	domain					1580:1585	the membrane domain	1567:1585	the membrane domain	1567:1585	Furthermore, palmitoylation of the membrane domain amplifies the local curvature that may prime the fusion.
35737823	7	27	theme	spike	1410:1414	arg1	range					1397:1401	The dynamical range	1383:1401	The dynamical range of the spike	1383:1414	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	4	28	theme	native	929:934	arg1	membrane					936:943	a native membrane	927:943	a native membrane	927:943	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	2	29	theme	viral	320:324	arg1	envelope					326:333	the viral envelope	316:333	the viral envelope	316:333	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	9	30	theme	hinge	1672:1676	arg1	regions					1678:1684	the identified hinge regions	1657:1684	the identified hinge regions	1657:1684	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	2	31	theme	surface	439:445	arg1	receptors					447:455	the host cell surface receptors	425:455	the host cell surface receptors	425:455	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	6	32	from	heterogeneity	1270:1282	arg1	system					1319:1324	the fully glycosylated system	1296:1324	the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions	1296:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	7	33	gly	nonglycosylated	1447:1461	arg1	form					1463:1466	its nonglycosylated form	1443:1466	its nonglycosylated form	1443:1466	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	2	34	theme	cell	434:437	arg1	receptors					447:455	the host cell surface receptors	425:455	the host cell surface receptors	425:455	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	9	35	theme	SARS	1710:1713	arg1	coronaviruses					1715:1727	SARS coronaviruses	1710:1727	SARS coronaviruses	1710:1727	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	6	36	theme	spike	1287:1291	arg1	heterogeneity					1270:1282	global conformational heterogeneity	1248:1282	global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions	1248:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	6	37	theme	cryogenic	1162:1170	arg1	cryo-EM					1193:1199	cryo-EM	1193:1199	cryo-EM	1193:1199	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	6	37	theme	cryogenic	1162:1170	arg1	microscopy					1181:1190	cryogenic electron microscopy	1162:1190	cryogenic electron microscopy (cryo-EM)	1162:1200	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	6	38	theme	glycan-glycan	1338:1350	arg1	interactions					1369:1380	glycan-glycan and glycan-lipid interactions	1338:1380	glycan-glycan and glycan-lipid interactions	1338:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	2	39	theme	host	429:432	arg1	receptors					447:455	the host cell surface receptors	425:455	the host cell surface receptors	425:455	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	5	40	theme	host	1133:1136	arg1	cell					1138:1141	the host cell	1129:1141	the host cell	1129:1141	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	3	41	theme	spike	628:632	arg1	model					634:638	the complete, membrane-bound spike model	599:638	the complete, membrane-bound spike model	599:638	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	1	42	theme	prime	212:216	arg1	glycoprotein					192:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	42	theme	prime	212:216	arg1	target					218:223	the prime target	208:223	the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus	208:295	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	9	43	theme	viral	1784:1788	arg1	infection					1790:1798	viral infection	1784:1798	viral infection	1784:1798	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	5	44	theme	cell	1138:1141	arg1	surface					1118:1124	the surface	1114:1124	the surface of the host cell	1114:1141	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	4	45	theme	full	903:906	arg1	structure					914:922	a full spike structure	901:922	a full spike structure	901:922	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	3	46	theme	model	634:638	arg1	description					648:658	the description	644:658	the description of its dynamics	644:674	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	3	46	theme	model	634:638	arg1	steps					689:693	critical steps	680:693	critical steps	680:693	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	3	46	theme	model	634:638	arg1	Construction					583:594	Construction	583:594	Construction of the complete, membrane-bound spike model	583:638	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	6	47	theme	conformational	1255:1268	arg1	heterogeneity					1270:1282	global conformational heterogeneity	1248:1282	global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions	1248:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	5	48	theme	full	1036:1039	arg1	spike					1041:1045	the full spike	1032:1045	the full spike	1032:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	49	theme	model	986:990	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	49	theme	model	986:990	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	3	50	dep	complete	603:610	arg1	membrane-bound					613:626	membrane-bound	613:626	membrane-bound	613:626	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	0	51	theme	spike	67:71	arg1	ability					45:51	the ability	41:51	the ability of SARS-CoV-2 spike for effective interaction with host cell receptors	41:122	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	4	52	theme	spike	908:912	arg1	structure					914:922	a full spike structure	901:922	a full spike structure	901:922	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	6	53	theme	global	1248:1253	arg1	heterogeneity					1270:1282	global conformational heterogeneity	1248:1282	global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions	1248:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	5	54	theme	spike	1041:1045	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	54	theme	spike	1041:1045	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	6	55	theme	electron	1172:1179	arg1	cryo-EM					1193:1199	cryo-EM	1193:1199	cryo-EM	1193:1199	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	6	55	theme	electron	1172:1179	arg1	microscopy					1181:1190	cryogenic electron microscopy	1162:1190	cryogenic electron microscopy (cryo-EM)	1162:1200	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	1	56	theme	Severe	125:130	arg1	coronavirus					159:169	Severe acute respiratory syndrome coronavirus 2	125:171	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	56	theme	Severe	125:130	arg1	SARS-CoV-2					174:183	SARS-CoV-2	174:183	SARS-CoV-2	174:183	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	0	57	theme	SARS-CoV-2	56:65	arg1	spike					67:71	SARS-CoV-2 spike	56:71	SARS-CoV-2 spike	56:71	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	3	58	theme	key	738:740	arg1	element					742:748	this key element	733:748	this key element of the viral infection by SARS-CoV-2	733:785	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	4	59	theme	MD	866:867	arg1	simulations					870:880	molecular dynamics (MD) simulations	846:880	molecular dynamics (MD) simulations	846:880	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	5	60	theme	longest	997:1003	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	60	theme	longest	997:1003	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	4	61	theme	homology	798:805	arg1	modeling					807:814	homology modeling	798:814	homology modeling	798:814	Combining homology modeling, protein-protein docking, and molecular dynamics (MD) simulations, we have developed a full spike structure in a native membrane.
35737823	1	62	theme	acute	132:136	arg1	coronavirus					159:169	Severe acute respiratory syndrome coronavirus 2	125:171	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	62	theme	acute	132:136	arg1	SARS-CoV-2					174:183	SARS-CoV-2	174:183	SARS-CoV-2	174:183	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	2	63	theme	domains	546:552	arg1	dynamics					519:526	the dynamics	515:526	the dynamics of the unresolved domains, most prominently the stalk	515:580	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	5	64	theme	known	1005:1009	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	64	theme	known	1005:1009	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	65	theme	Multimicrosecond	946:961	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	65	theme	Multimicrosecond	946:961	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	6	66	gly	glycosylated	1306:1317	arg1	system					1319:1324	the fully glycosylated system	1296:1324	the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions	1296:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	1	67	theme	respiratory	138:148	arg1	coronavirus					159:169	Severe acute respiratory syndrome coronavirus 2	125:171	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	67	theme	respiratory	138:148	arg1	SARS-CoV-2					174:183	SARS-CoV-2	174:183	SARS-CoV-2	174:183	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	8	68	theme	local	1601:1605	arg1	curvature					1607:1615	the local curvature	1597:1615	the local curvature that may prime the fusion	1597:1641	Furthermore, palmitoylation of the membrane domain amplifies the local curvature that may prime the fusion.
35737823	6	69	from	hinges	1218:1223	arg1	stalk					1232:1236	the stalk	1228:1236	the stalk	1228:1236	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	2	70	theme	unresolved	535:544	arg1	stalk					576:580	the stalk	572:580	most prominently the stalk	555:580	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	2	70	theme	unresolved	535:544	arg1	domains					546:552	the unresolved domains	531:552	the unresolved domains	531:552	While anchored in the viral envelope, for effective virulence, the spike needs to maintain structural flexibility to recognize the host cell surface receptors and bind to them, a property that can heavily depend upon the dynamics of the unresolved domains, most prominently the stalk.
35737823	5	71	theme	single	1011:1016	arg1	simulations					966:976	Multimicrosecond MD simulations	946:976	Multimicrosecond MD simulations of this model	946:990	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	5	71	theme	single	1011:1016	arg1	trajectory					1018:1027	the longest known single trajectory	993:1027	the longest known single trajectory of the full spike	993:1045	Multimicrosecond MD simulations of this model, the longest known single trajectory of the full spike, reveal conformational dynamics employed by the protein to explore the surface of the host cell.
35737823	3	72	theme	complete	603:610	arg1	model					634:638	the complete, membrane-bound spike model	599:638	the complete, membrane-bound spike model	599:638	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	1	73	theme	syndrome	150:157	arg1	coronavirus					159:169	Severe acute respiratory syndrome coronavirus 2	125:171	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	73	theme	syndrome	150:157	arg1	SARS-CoV-2					174:183	SARS-CoV-2	174:183	SARS-CoV-2	174:183	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	7	74	theme	cell	1522:1525	arg1	surface					1527:1533	the host cell surface	1513:1533	the host cell surface	1513:1533	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	0	75	theme	effective	77:85	arg1	interaction					87:97	effective interaction	77:97	effective interaction with host cell receptors	77:122	Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors.
35737823	6	76	gly	heterogeneity	1270:1282	arg1	spike					1287:1291	spike	1287:1291	spike	1287:1291	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	1	77	theme	coronavirus	159:169	arg1	glycoprotein					192:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein	125:203	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	1	77	theme	coronavirus	159:169	arg1	target					218:223	the prime target	208:223	the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus	208:295	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein is the prime target for vaccines, diagnostics, and therapeutic antibodies against the virus.
35737823	3	78	theme	viral	757:761	arg1	infection					763:771	the viral infection	753:771	the viral infection by SARS-CoV-2	753:785	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35737823	6	79	theme	glycan-lipid	1356:1367	arg1	interactions					1369:1380	glycan-glycan and glycan-lipid interactions	1338:1380	glycan-glycan and glycan-lipid interactions	1338:1380	In agreement with cryogenic electron microscopy (cryo-EM), three flexible hinges in the stalk allow for global conformational heterogeneity of spike in the fully glycosylated system mediated by glycan-glycan and glycan-lipid interactions.
35737823	7	80	from	spike	1504:1508	arg1	surface					1527:1533	the host cell surface	1513:1533	the host cell surface	1513:1533	The dynamical range of the spike is considerably reduced in its nonglycosylated form, confining the area explored by the spike on the host cell surface.
35737823	9	81	theme	functional	1749:1758	arg1	importance					1760:1769	their functional importance	1743:1769	their functional importance in enhancing viral infection	1743:1798	We show that the identified hinge regions are highly conserved in SARS coronaviruses, highlighting their functional importance in enhancing viral infection, and thereby, provide points for discovery of alternative therapeutics against the virus.
35737823	3	82	theme	infection	763:771	arg1	element					742:748	this key element	733:748	this key element of the viral infection by SARS-CoV-2	733:785	Construction of the complete, membrane-bound spike model and the description of its dynamics are critical steps in understanding the inner working of this key element of the viral infection by SARS-CoV-2.
35641432	0	0	theme	Branched	81:88	arg1	Heptadecasaccharide					90:108	a Highly Branched Heptadecasaccharide	72:108	a Highly Branched Heptadecasaccharide from Carthamus tinctorius	72:134	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	4	1	theme	coupling	774:781	arg1	strategy					783:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	3	2	theme	galectin-3-targeting	568:587	arg1	polysaccharide					589:602	the native bioactive galectin-3-targeting polysaccharide	547:602	the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	547:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	5	3	theme	pancreatic	1097:1106	arg1	growth					1120:1125	pancreatic cancer cell growth	1097:1125	pancreatic cancer cell growth	1097:1125	Biological activity tests suggest that the heptadecasaccharide can target galectin-3 and inhibit pancreatic cancer cell growth.
35641432	0	4	from	Synthesis	11:19	arg1	tinctorius					125:134	Carthamus tinctorius	115:134	Carthamus tinctorius	115:134	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	4	5	theme	ultraviolet	977:987	arg1	radiation					989:997	ultraviolet radiation	977:997	ultraviolet radiation	977:997	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	4	6	theme	approach	713:720	arg1	feature					698:704	The key feature	690:704	The key feature of the approach	690:720	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	1	7	theme	various	193:199	arg1	processes					212:220	various biological processes	193:220	various biological processes	193:220	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	2	8	theme	branched	330:337	arg1	polysaccharide					356:369	branched and long complex polysaccharide	330:369	polysaccharide	356:369	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	3	9	theme	shorter	644:650	arg1	fragments					652:660	shorter fragments	644:660	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	5	10	theme	cancer	1108:1113	arg1	growth					1120:1125	pancreatic cancer cell growth	1097:1125	pancreatic cancer cell growth	1097:1125	Biological activity tests suggest that the heptadecasaccharide can target galectin-3 and inhibit pancreatic cancer cell growth.
35641432	0	11	theme	Heptadecasaccharide	90:108	arg1	Synthesis					11:19	Convergent Synthesis	0:19	Convergent Synthesis	0:19	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	0	11	theme	Heptadecasaccharide	90:108	arg1	Activity					60:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	0	12	from	Activity	60:67	arg1	tinctorius					125:134	Carthamus tinctorius	115:134	Carthamus tinctorius	115:134	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	5	13	theme	cell	1115:1118	arg1	growth					1120:1125	pancreatic cancer cell growth	1097:1125	pancreatic cancer cell growth	1097:1125	Biological activity tests suggest that the heptadecasaccharide can target galectin-3 and inhibit pancreatic cancer cell growth.
35641432	4	14	theme	photoremovable	853:866	arg1	group					893:897	a photoremovable o-nitrobenzyl protecting group	851:897	a photoremovable o-nitrobenzyl protecting group	851:897	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	3	15	theme	native	551:556	arg1	polysaccharide					589:602	the native bioactive galectin-3-targeting polysaccharide	547:602	the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	547:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	1	16	from	resources	176:184	arg1	polysaccharides					147:161	Bioactive polysaccharides	137:161	Bioactive polysaccharides from natural resources	137:184	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	1	16	from	resources	176:184	arg1	molecules					268:276	potential target molecules	251:276	potential target molecules for drug development	251:297	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	1	17	theme	biological	201:210	arg1	processes					212:220	various biological processes	193:220	various biological processes	193:220	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	3	18	theme	efficient	464:472	arg1	synthesis					486:494	an efficient first total synthesis	461:494	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	4	19	theme	protecting	882:891	arg1	group					893:897	a photoremovable o-nitrobenzyl protecting group	851:897	a photoremovable o-nitrobenzyl protecting group	851:897	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	3	20	dep	Carthamus	609:617	arg1	L.					630:631	Carthamus tinctorius L.	609:631	Carthamus tinctorius L.	609:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	2	21	theme	polysaccharide	356:369	arg1	domains					378:384	branched and long complex polysaccharide active domains	330:384	branched and long complex polysaccharide active domains with well-defined structures	330:413	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	3	22	theme	total	480:484	arg1	synthesis					486:494	an efficient first total synthesis	461:494	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	0	23	theme	Convergent	0:9	arg1	Synthesis					11:19	Convergent Synthesis	0:19	Convergent Synthesis	0:19	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	4	24	theme	convergent	747:756	arg1	strategy					783:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	2	25	theme	complex	348:354	arg1	polysaccharide					356:369	branched and long complex polysaccharide	330:369	polysaccharide	356:369	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	4	26	theme	[6+4+7	758:763	arg1	strategy					783:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	0	27	theme	Anti-Pancreatic	25:39	arg1	Activity					60:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	3	28	from	Carthamus	609:617	arg1	polysaccharide					589:602	the native bioactive galectin-3-targeting polysaccharide	547:602	the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	547:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	3	28	from	Carthamus	609:617	arg1	moiety					537:542	a highly branched heptadecasaccharide moiety	499:542	a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	499:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	2	29	theme	long	343:346	arg1	polysaccharide					356:369	branched and long complex polysaccharide	330:369	polysaccharide	356:369	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	3	30	theme	heptadecasaccharide	517:535	arg1	moiety					537:542	a highly branched heptadecasaccharide moiety	499:542	a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	499:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	4	31	theme	heptadecasaccharide	822:840	arg1	assembly					806:813	rapid assembly	800:813	rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation	800:997	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	2	32	with	domains	378:384	arg1	structures					404:413	well-defined structures	391:413	well-defined structures	391:413	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	3	33	theme	polysaccharide	589:602	arg1	moiety					537:542	a highly branched heptadecasaccharide moiety	499:542	a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	499:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	2	34	theme	major	425:429	arg1	challenge					431:439	a major challenge	423:439	a major challenge	423:439	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	0	35	theme	Cell	48:51	arg1	Activity					60:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	3	36	theme	bioactive	558:566	arg1	polysaccharide					589:602	the native bioactive galectin-3-targeting polysaccharide	547:602	the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	547:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	4	37	theme	corresponding	923:935	arg1	acceptor					937:944	the corresponding acceptor	919:944	the corresponding acceptor for glycosylation	919:962	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	4	38	used	used	902:905	arg2	group					893:897	a photoremovable o-nitrobenzyl protecting group	851:897	a photoremovable o-nitrobenzyl protecting group	851:897	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	0	39	theme	Cancer	41:46	arg1	Activity					60:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	3	40	theme	first	474:478	arg1	synthesis					486:494	an efficient first total synthesis	461:494	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	4	41	theme	rapid	800:804	arg1	assembly					806:813	rapid assembly	800:813	rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation	800:997	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	1	42	theme	potential	251:259	arg1	polysaccharides					147:161	Bioactive polysaccharides	137:161	Bioactive polysaccharides from natural resources	137:184	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	1	42	theme	potential	251:259	arg1	molecules					268:276	potential target molecules	251:276	potential target molecules for drug development	251:297	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	5	43	theme	activity	1011:1018	arg1	tests					1020:1024	Biological activity tests	1000:1024	Biological activity tests	1000:1024	Biological activity tests suggest that the heptadecasaccharide can target galectin-3 and inhibit pancreatic cancer cell growth.
35641432	1	44	used	used	243:246	arg2	molecules					268:276	potential target molecules	251:276	potential target molecules for drug development	251:297	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	1	44	used	used	243:246	arg2	polysaccharides					147:161	Bioactive polysaccharides	137:161	Bioactive polysaccharides from natural resources	137:184	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	2	45	theme	well-defined	391:402	arg1	structures					404:413	well-defined structures	391:413	well-defined structures	391:413	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	0	46	theme	Growth	53:58	arg1	Activity					60:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	0	47	from	tinctorius	125:134	arg1	Synthesis					11:19	Convergent Synthesis	0:19	Convergent Synthesis	0:19	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	0	47	from	tinctorius	125:134	arg1	Heptadecasaccharide					90:108	a Highly Branched Heptadecasaccharide	72:108	a Highly Branched Heptadecasaccharide from Carthamus tinctorius	72:134	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	0	47	from	tinctorius	125:134	arg1	Activity					60:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Anti-Pancreatic Cancer Cell Growth Activity	25:67	Convergent Synthesis and Anti-Pancreatic Cancer Cell Growth Activity of a Highly Branched Heptadecasaccharide from Carthamus tinctorius.
35641432	3	48	theme	heptadecasaccharide	669:687	arg1	fragments					652:660	shorter fragments	644:660	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	3	48	theme	heptadecasaccharide	669:687	arg1	synthesis					486:494	an efficient first total synthesis	461:494	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	1	49	theme	Bioactive	137:145	arg1	polysaccharides					147:161	Bioactive polysaccharides	137:161	Bioactive polysaccharides from natural resources	137:184	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	1	49	theme	Bioactive	137:145	arg1	molecules					268:276	potential target molecules	251:276	potential target molecules for drug development	251:297	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	3	50	from	moiety	537:542	arg1	Carthamus					609:617	Carthamus	609:617	Carthamus	609:617	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	2	51	theme	domains	378:384	arg1	accessibility					313:325	the accessibility	309:325	the accessibility of branched and long complex polysaccharide active domains with well-defined structures	309:413	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	5	52	theme	Biological	1000:1009	arg1	tests					1020:1024	Biological activity tests	1000:1024	Biological activity tests	1000:1024	Biological activity tests suggest that the heptadecasaccharide can target galectin-3 and inhibit pancreatic cancer cell growth.
35641432	1	53	theme	target	261:266	arg1	polysaccharides					147:161	Bioactive polysaccharides	137:161	Bioactive polysaccharides from natural resources	137:184	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	1	53	theme	target	261:266	arg1	molecules					268:276	potential target molecules	251:276	potential target molecules for drug development	251:297	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	4	54	theme	o-nitrobenzyl	868:880	arg1	group					893:897	a photoremovable o-nitrobenzyl protecting group	851:897	a photoremovable o-nitrobenzyl protecting group	851:897	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	2	55	theme	active	371:376	arg1	domains					378:384	branched and long complex polysaccharide active domains	330:384	branched and long complex polysaccharide active domains with well-defined structures	330:413	However, the accessibility of branched and long complex polysaccharide active domains with well-defined structures remains a major challenge.
35641432	3	56	theme	moiety	537:542	arg1	fragments					652:660	shorter fragments	644:660	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	3	56	theme	moiety	537:542	arg1	synthesis					486:494	an efficient first total synthesis	461:494	an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide	461:687	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	4	57	theme	key	694:696	arg1	feature					698:704	The key feature	690:704	The key feature of the approach	690:720	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	3	58	theme	branched	508:515	arg1	moiety					537:542	a highly branched heptadecasaccharide moiety	499:542	a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L.	499:631	Herein we describe an efficient first total synthesis of a highly branched heptadecasaccharide moiety of the native bioactive galectin-3-targeting polysaccharide from Carthamus tinctorius L. as well as shorter fragments of the heptadecasaccharide.
35641432	1	59	theme	natural	168:174	arg1	resources					176:184	natural resources	168:184	natural resources	168:184	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35641432	4	60	theme	photo-assisted	732:745	arg1	strategy					783:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	4	61	theme	one-pot	766:772	arg1	strategy					783:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	a photo-assisted convergent [6+4+7] one-pot coupling strategy	730:790	The key feature of the approach is that a photo-assisted convergent [6+4+7] one-pot coupling strategy enables rapid assembly of the heptadecasaccharide, whereby a photoremovable o-nitrobenzyl protecting group is used to generate the corresponding acceptor for glycosylation in situ upon ultraviolet radiation.
35641432	1	62	theme	drug	282:285	arg1	development					287:297	drug development	282:297	drug development	282:297	Bioactive polysaccharides from natural resources target various biological processes and are increasingly used as potential target molecules for drug development.
35129339	2	0	theme	features	509:516	arg1	analysis					478:485	analysis	478:485	analysis	478:485	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	2	0	theme	features	509:516	arg1	identification					459:472	identification	459:472	identification	459:472	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	3	1	from	residues	717:724	arg1	motifs					743:748	GH70 homology motifs	729:748	GH70 homology motifs	729:748	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	6	2	theme	9	1068:1068	arg1	%					1069:1069	%	1069:1069	%	1069:1069	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	1	3	theme	GtfB	266:269	arg1	subfamily					271:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	2	4	theme	structural	498:507	arg1	features					509:516	further structural features	490:516	further structural features that determine its reaction and product specificity	490:568	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	3	5	theme	GH70	729:732	arg1	motifs					743:748	GH70 homology motifs	729:748	GH70 homology motifs	729:748	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	8	6	theme	acceptor	1368:1375	arg1	subsites					1395:1402	the acceptor substrate-binding subsites	1364:1402	the acceptor substrate-binding subsites	1364:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	1	7	with	polysaccharides	343:357	arg1	→					388:388	α1 → 6	385:390	α1 → 6	385:390	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	1	7	with	polysaccharides	343:357	arg1	linkages					393:400	consecutive (α1 → 6) linkages	372:400	consecutive (α1 → 6) linkages	372:400	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	6	8	theme	%	1089:1089	arg1	increase					1091:1098	an 11% increase	1084:1098	an 11% increase	1084:1098	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	0	9	theme	Reaction	110:117	arg1	Specificity					131:141	Reaction and Product Specificity	110:141	Specificity	131:141	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	1	10	theme	consecutive	372:382	arg1	→					388:388	α1 → 6	385:390	α1 → 6	385:390	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	1	10	theme	consecutive	372:382	arg1	linkages					393:400	consecutive (α1 → 6) linkages	372:400	consecutive (α1 → 6) linkages	372:400	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	6	11	from	decrease	1071:1078	arg1	ratio					1122:1126	the ratio	1118:1126	the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products	1118:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	1	12	dep	Limosilactobacillus	144:162	arg1	reuteri					164:170	reuteri	164:170	reuteri	164:170	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	9	13	theme	reaction	1488:1495	arg1	specificity					1509:1519	the reaction and product specificity	1484:1519	specificity	1509:1519	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	7	14	theme	linkage	1209:1215	arg1	type					1217:1220	linkage type	1209:1220	linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages)	1209:1267	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	6	15	theme	4	1151:1151	arg1	linkages					1154:1161	(α1 → 4) linkages	1145:1161	(α1 → 4) linkages in maltodextrin-derived products	1145:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	7	16	from	change	1199:1204	arg1	type					1217:1220	linkage type	1209:1220	linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages)	1209:1267	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	7	17	dep	type	1217:1220	arg1	linkages					1238:1245	(α1 → 6) linkages	1229:1245	(α1 → 6) linkages to (α1 → 3) linkages	1229:1266	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	2	18	theme	structure	441:449	arg1	elucidation					414:424	The recent elucidation	403:424	The recent elucidation of its crystal structure	403:449	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	0	19	theme	Product	123:129	arg1	Specificity					131:141	Reaction and Product Specificity	110:141	Specificity	131:141	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	6	20	dep	Mutants	1033:1039	arg1	H1056G					1041:1046	H1056G	1041:1046	H1056G	1041:1046	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	6	20	dep	Mutants	1033:1039	arg1	Mutants					1033:1039	Mutants	1033:1039	Mutants H1056G and Q1126I	1033:1057	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	6	20	dep	Mutants	1033:1039	arg1	Q1126I					1052:1057	Q1126I	1052:1057	Q1126I	1052:1057	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	4	21	dep	mutants	857:863	arg1	S1057P					874:879	S1057P	874:879	S1057P	874:879	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	21	dep	mutants	857:863	arg1	mutants					857:863	four Lr121 GtfB-ΔN mutants	838:863	four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I)	838:900	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	21	dep	mutants	857:863	arg1	H1056G					882:887	H1056G	882:887	H1056G	882:887	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	21	dep	mutants	857:863	arg1	Q1126I					894:899	Q1126I	894:899	Q1126I	894:899	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	5	22	theme	wild-type	932:940	arg1	GtfB-ΔN					948:954	wild-type Lr121 GtfB-ΔN	932:954	wild-type Lr121 GtfB-ΔN	932:954	Compared to wild-type Lr121 GtfB-ΔN, mutants S1057P and Q1126I had considerably improved catalytic efficiencies.
35129339	4	23	theme	Lr121	843:847	arg1	S1057P					874:879	S1057P	874:879	S1057P	874:879	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	23	theme	Lr121	843:847	arg1	mutants					857:863	four Lr121 GtfB-ΔN mutants	838:863	four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I)	838:900	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	23	theme	Lr121	843:847	arg1	H1056G					882:887	H1056G	882:887	H1056G	882:887	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	23	theme	Lr121	843:847	arg1	Q1126I					894:899	Q1126I	894:899	Q1126I	894:899	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	0	24	theme	Limosilactobacillus	36:54	arg1	GtfB					68:71	Limosilactobacillus reuteri 121 GtfB	36:71	Limosilactobacillus reuteri 121 GtfB	36:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	5	25	dep	mutants	957:963	arg1	mutants					957:963	mutants	957:963	mutants S1057P and Q1126I	957:981	Compared to wild-type Lr121 GtfB-ΔN, mutants S1057P and Q1126I had considerably improved catalytic efficiencies.
35129339	5	25	dep	mutants	957:963	arg1	Q1126I					976:981	Q1126I	976:981	Q1126I	976:981	Compared to wild-type Lr121 GtfB-ΔN, mutants S1057P and Q1126I had considerably improved catalytic efficiencies.
35129339	5	25	dep	mutants	957:963	arg1	S1057P					965:970	S1057P	965:970	S1057P	965:970	Compared to wild-type Lr121 GtfB-ΔN, mutants S1057P and Q1126I had considerably improved catalytic efficiencies.
35129339	6	26	theme	6	1137:1137	arg1	ratio					1122:1126	the ratio	1118:1126	the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products	1118:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	8	27	theme	possible	1291:1298	arg1	roles					1311:1315	The possible functional roles	1287:1315	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites	1287:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	6	28	theme	maltodextrin-derived	1166:1185	arg1	products					1187:1194	maltodextrin-derived products	1166:1194	maltodextrin-derived products	1166:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	3	29	theme	homology	734:741	arg1	motifs					743:748	GH70 homology motifs	729:748	GH70 homology motifs	729:748	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	30	with	alignments	588:597	arg1	specificities					651:663	different product linkage specificities	625:663	different product linkage specificities (4,6-α-GTase and 4,3-α-GTase)	625:693	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	30	with	alignments	588:597	arg1	4,3-α-GTase					682:692	4,3-α-GTase	682:692	4,3-α-GTase	682:692	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	30	with	alignments	588:597	arg1	4,6-α-GTase					666:676	4,6-α-GTase	666:676	4,6-α-GTase	666:676	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	31	theme	acid	712:715	arg1	residues					717:724	amino acid residues	706:724	amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity	706:808	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	8	32	theme	substrate-binding	1377:1393	arg1	subsites					1395:1402	the acceptor substrate-binding subsites	1364:1402	the acceptor substrate-binding subsites	1364:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	3	33	theme	GtfB	607:610	arg1	enzymes					612:618	GtfB enzymes	607:618	GtfB enzymes	607:618	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	7	34	theme	3	1256:1256	arg1	linkages					1259:1266	(α1 → 3) linkages	1250:1266	(α1 → 6) linkages to (α1 → 3) linkages	1229:1266	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	0	35	theme	Acid	19:22	arg1	GtfB					68:71	Limosilactobacillus reuteri 121 GtfB	36:71	Limosilactobacillus reuteri 121 GtfB	36:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	0	35	theme	Acid	19:22	arg1	Residues					24:31	Amino Acid Residues	13:31	Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB	13:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	3	36	theme	product	790:796	arg1	specificity					798:808	product specificity	790:808	product specificity	790:808	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	7	37	theme	α1	1251:1252	arg1	linkages					1259:1266	(α1 → 3) linkages	1250:1266	(α1 → 6) linkages to (α1 → 3) linkages	1229:1266	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	3	38	theme	sequence	579:586	arg1	alignments					588:597	sequence alignments	579:597	sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase)	579:693	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	4	39	theme	GtfB-ΔN	849:855	arg1	S1057P					874:879	S1057P	874:879	S1057P	874:879	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	39	theme	GtfB-ΔN	849:855	arg1	mutants					857:863	four Lr121 GtfB-ΔN mutants	838:863	four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I)	838:900	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	39	theme	GtfB-ΔN	849:855	arg1	H1056G					882:887	H1056G	882:887	H1056G	882:887	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	4	39	theme	GtfB-ΔN	849:855	arg1	Q1126I					894:899	Q1126I	894:899	Q1126I	894:899	Based on these alignments, four Lr121 GtfB-ΔN mutants (I1020M, S1057P, H1056G, and Q1126I) were constructed.
35129339	2	40	theme	product	550:556	arg1	specificity					558:568	its reaction and product specificity	533:568	specificity	558:568	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	2	41	theme	crystal	433:439	arg1	structure					441:449	its crystal structure	429:449	its crystal structure	429:449	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	8	42	theme	Lr121	1326:1330	arg1	residues					1340:1347	these Lr121 GtfB-ΔN residues	1320:1347	these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites	1320:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	7	43	theme	6	1235:1235	arg1	linkages					1238:1245	(α1 → 6) linkages	1229:1245	(α1 → 6) linkages to (α1 → 3) linkages	1229:1266	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	3	44	dep	specificities	651:663	arg1	specificities					651:663	different product linkage specificities	625:663	different product linkage specificities (4,6-α-GTase and 4,3-α-GTase)	625:693	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	44	dep	specificities	651:663	arg1	4,3-α-GTase					682:692	4,3-α-GTase	682:692	4,3-α-GTase	682:692	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	44	dep	specificities	651:663	arg1	4,6-α-GTase					666:676	4,6-α-GTase	666:676	4,6-α-GTase	666:676	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	2	45	theme	further	490:496	arg1	features					509:516	further structural features	490:516	further structural features that determine its reaction and product specificity	490:568	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	6	46	link	maltodextrin-derived	1166:1185	arg1	products					1187:1194	maltodextrin-derived products	1166:1194	maltodextrin-derived products	1166:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	3	47	theme	different	625:633	arg1	specificities					651:663	different product linkage specificities	625:663	different product linkage specificities (4,6-α-GTase and 4,3-α-GTase)	625:693	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	47	theme	different	625:633	arg1	4,3-α-GTase					682:692	4,3-α-GTase	682:692	4,3-α-GTase	682:692	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	47	theme	different	625:633	arg1	4,6-α-GTase					666:676	4,6-α-GTase	666:676	4,6-α-GTase	666:676	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	1	48	theme	glycosyl	239:246	arg1	subfamily					271:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	9	49	theme	Lr121	1524:1528	arg1	4,6-α-GTase					1535:1545	Lr121 GtfB 4,6-α-GTase	1524:1545	Lr121 GtfB 4,6-α-GTase	1524:1545	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	1	50	theme	linear	321:326	arg1	IMMPs					360:364	IMMPs	360:364	IMMPs	360:364	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	1	50	theme	linear	321:326	arg1	polysaccharides					343:357	linear isomalto/malto polysaccharides	321:357	linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages	321:400	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	9	51	theme	GtfB	1530:1533	arg1	4,6-α-GTase					1535:1545	Lr121 GtfB 4,6-α-GTase	1524:1545	Lr121 GtfB 4,6-α-GTase	1524:1545	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	8	52	theme	residues	1340:1347	arg1	roles					1311:1315	The possible functional roles	1287:1315	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites	1287:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	0	53	dep	Limosilactobacillus	36:54	arg1	reuteri					56:62	reuteri	56:62	reuteri	56:62	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	1	54	theme	hydrolase	248:256	arg1	subfamily					271:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	1	55	theme	isomalto/malto	328:341	arg1	IMMPs					360:364	IMMPs	360:364	IMMPs	360:364	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	1	55	theme	isomalto/malto	328:341	arg1	polysaccharides					343:357	linear isomalto/malto polysaccharides	321:357	linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages	321:400	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	9	56	theme	product	1501:1507	arg1	specificity					1509:1519	the reaction and product specificity	1484:1519	specificity	1509:1519	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	8	57	theme	GtfB-ΔN	1332:1338	arg1	residues					1340:1347	these Lr121 GtfB-ΔN residues	1320:1347	these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites	1320:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	7	58	dep	linkages	1238:1245	arg1	linkages					1259:1266	(α1 → 3) linkages	1250:1266	(α1 → 6) linkages to (α1 → 3) linkages	1229:1266	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	7	58	dep	linkages	1238:1245	arg1	to					1247:1248	to	1247:1248	to	1247:1248	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	7	58	dep	linkages	1238:1245	arg1	e.g.					1223:1226	e.g.	1223:1226	e.g.	1223:1226	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	0	59	from	Mutations	0:8	arg1	GtfB					68:71	Limosilactobacillus reuteri 121 GtfB	36:71	Limosilactobacillus reuteri 121 GtfB	36:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	0	59	from	Mutations	0:8	arg1	Residues					24:31	Amino Acid Residues	13:31	Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB	13:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	9	60	theme	new	1439:1441	arg1	insights					1443:1450	new insights	1439:1450	new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase	1439:1545	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	9	61	theme	4,6-α-GTase	1535:1545	arg1	specificity					1509:1519	the reaction and product specificity	1484:1519	specificity	1509:1519	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	6	62	theme	α1	1146:1147	arg1	linkages					1154:1161	(α1 → 4) linkages	1145:1161	(α1 → 4) linkages in maltodextrin-derived products	1145:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	9	63	theme	specificity	1509:1519	arg1	determinants					1468:1479	structural determinants	1457:1479	structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase	1457:1545	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	8	64	theme	located	1349:1355	arg1	residues					1340:1347	these Lr121 GtfB-ΔN residues	1320:1347	these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites	1320:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	8	65	theme	functional	1300:1309	arg1	roles					1311:1315	The possible functional roles	1287:1315	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites	1287:1402	The possible functional roles of these Lr121 GtfB-ΔN residues located around the acceptor substrate-binding subsites are discussed.
35129339	3	66	theme	product	635:641	arg1	specificities					651:663	different product linkage specificities	625:663	different product linkage specificities (4,6-α-GTase and 4,3-α-GTase)	625:693	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	66	theme	product	635:641	arg1	4,3-α-GTase					682:692	4,3-α-GTase	682:692	4,3-α-GTase	682:692	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	66	theme	product	635:641	arg1	4,6-α-GTase					666:676	4,6-α-GTase	666:676	4,6-α-GTase	666:676	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	1	67	theme	Limosilactobacillus	144:162	arg1	121					172:174	Limosilactobacillus reuteri 121	144:174	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase)	144:219	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	6	68	from	linkages	1154:1161	arg1	products					1187:1194	maltodextrin-derived products	1166:1194	maltodextrin-derived products	1166:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	9	69	theme	structural	1457:1466	arg1	determinants					1468:1479	structural determinants	1457:1479	structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase	1457:1545	The results provide new insights into structural determinants of the reaction and product specificity of Lr121 GtfB 4,6-α-GTase.
35129339	3	70	theme	amino	706:710	arg1	residues					717:724	amino acid residues	706:724	amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity	706:808	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	5	71	theme	catalytic	1009:1017	arg1	efficiencies					1019:1030	catalytic efficiencies	1009:1030	catalytic efficiencies	1009:1030	Compared to wild-type Lr121 GtfB-ΔN, mutants S1057P and Q1126I had considerably improved catalytic efficiencies.
35129339	6	72	from	increase	1091:1098	arg1	ratio					1122:1126	the ratio	1118:1126	the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products	1118:1194	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	5	73	theme	Lr121	942:946	arg1	GtfB-ΔN					948:954	wild-type Lr121 GtfB-ΔN	932:954	wild-type Lr121 GtfB-ΔN	932:954	Compared to wild-type Lr121 GtfB-ΔN, mutants S1057P and Q1126I had considerably improved catalytic efficiencies.
35129339	1	74	theme	GH	259:260	arg1	subfamily					271:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	the glycosyl hydrolase (GH) 70 GtfB subfamily	235:279	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	0	75	theme	GtfB	68:71	arg1	GtfB					68:71	Limosilactobacillus reuteri 121 GtfB	36:71	Limosilactobacillus reuteri 121 GtfB	36:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	0	75	theme	GtfB	68:71	arg1	Residues					24:31	Amino Acid Residues	13:31	Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB	13:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	2	76	theme	recent	407:412	arg1	elucidation					414:424	The recent elucidation	403:424	The recent elucidation of its crystal structure	403:449	The recent elucidation of its crystal structure allowed identification and analysis of further structural features that determine its reaction and product specificity.
35129339	3	77	theme	linkage	643:649	arg1	specificities					651:663	different product linkage specificities	625:663	different product linkage specificities (4,6-α-GTase and 4,3-α-GTase)	625:693	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	77	theme	linkage	643:649	arg1	4,3-α-GTase					682:692	4,3-α-GTase	682:692	4,3-α-GTase	682:692	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	3	77	theme	linkage	643:649	arg1	4,6-α-GTase					666:676	4,6-α-GTase	666:676	4,6-α-GTase	666:676	Herein, sequence alignments between GtfB enzymes with different product linkage specificities (4,6-α-GTase and 4,3-α-GTase) identified amino acid residues in GH70 homology motifs, which may be critical for reaction and product specificity.
35129339	6	78	theme	%	1069:1069	arg1	decrease					1071:1078	a 9% decrease	1066:1078	a 9% decrease	1066:1078	Mutants H1056G and Q1126I showed a 9% decrease and an 11% increase, respectively, in the ratio of (α1 → 6) over (α1 → 4) linkages in maltodextrin-derived products.
35129339	1	79	theme	121	172:174	arg1	4,6-α-glucanotransferase					176:199	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase	144:199	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase)	144:219	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	1	79	theme	121	172:174	arg1	4,6-α-GTase					208:218	Lr121 4,6-α-GTase	202:218	Lr121 4,6-α-GTase	202:218	Limosilactobacillus reuteri 121 4,6-α-glucanotransferase (Lr121 4,6-α-GTase), belonging to the glycosyl hydrolase (GH) 70 GtfB subfamily, converts starch and maltodextrins into linear isomalto/malto polysaccharides (IMMPs) with consecutive (α1 → 6) linkages.
35129339	7	80	theme	α1	1230:1231	arg1	linkages					1238:1245	(α1 → 6) linkages	1229:1245	(α1 → 6) linkages to (α1 → 3) linkages	1229:1266	A change in linkage type (e.g., (α1 → 6) linkages to (α1 → 3) linkages) was not observed.
35129339	0	81	theme	121	64:66	arg1	GtfB					68:71	Limosilactobacillus reuteri 121 GtfB	36:71	Limosilactobacillus reuteri 121 GtfB	36:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	0	82	theme	Amino	13:17	arg1	GtfB					68:71	Limosilactobacillus reuteri 121 GtfB	36:71	Limosilactobacillus reuteri 121 GtfB	36:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
35129339	0	82	theme	Amino	13:17	arg1	Residues					24:31	Amino Acid Residues	13:31	Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB	13:71	Mutations in Amino Acid Residues of Limosilactobacillus reuteri 121 GtfB 4,6-α-Glucanotransferase that Affect Reaction and Product Specificity.
36361822	0	0	theme	Glycation	94:102	arg1	End-Product					104:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	5	1	theme	histidine	823:831	arg1	residues					833:840	lysine, arginine, and histidine residues	801:840	lysine, arginine, and histidine residues	801:840	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	6	2	theme	intact	932:937	arg1	moiety					949:954	an intact melibiose moiety	929:954	an intact melibiose moiety	929:954	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	5	3	theme	arginine	809:816	arg1	residues					833:840	lysine, arginine, and histidine residues	801:840	lysine, arginine, and histidine residues	801:840	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	4	4	theme	myoglobin	595:603	arg1	properties					566:575	the physicochemical properties	546:575	the physicochemical properties	546:575	Using liquid chromatography coupled with mass spectrometry, we analyzed the physicochemical properties and structures of myoglobin glycated with melibiose under different conditions.
36361822	4	4	theme	myoglobin	595:603	arg1	structures					581:590	structures	581:590	structures	581:590	Using liquid chromatography coupled with mass spectrometry, we analyzed the physicochemical properties and structures of myoglobin glycated with melibiose under different conditions.
36361822	0	5	theme	Advanced	85:92	arg1	End-Product					104:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	7	6	theme	model	1159:1163	arg1	protein					1175:1181	the model myoglobin protein	1155:1181	the model myoglobin protein	1155:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	8	7	theme	MAGE	1244:1247	arg1	adduct					1249:1254	in vitro MAGE adduct	1235:1254	in vitro MAGE adduct	1235:1254	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	1	8	theme	glycation	180:188	arg1	product					190:196	the glycation product	176:196	the glycation product generated in the reaction of a model protein with melibiose	176:256	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	8	theme	glycation	180:188	arg1	MAGE					117:120	MAGE	117:120	MAGE (melibiose-derived advanced glycation end-product)	117:171	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	0	9	from	Analysis	0:7	arg1	End-Product					104:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	11	10	theme	AGEs	1544:1547	arg1	pool					1536:1539	a pool	1534:1539	a pool of AGEs accumulating locally in vivo and affecting tissue biology	1534:1605	This process can contribute to a pool of AGEs accumulating locally in vivo and affecting tissue biology.
36361822	7	11	from	changes	1117:1123	arg1	protein					1175:1181	the model myoglobin protein	1155:1181	the model myoglobin protein	1155:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	7	11	from	changes	1117:1123	arg1	group					1146:1150	a heme group	1139:1150	a heme group of the model myoglobin protein	1139:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	5	12	theme	lysine	801:806	arg1	residues					833:840	lysine, arginine, and histidine residues	801:840	lysine, arginine, and histidine residues	801:840	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	8	13	dep	in	1235:1236	arg1	vitro					1238:1242	vitro	1238:1242	vitro	1238:1242	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	5	14	theme	different	711:719	arg1	AGEs					721:724	structurally different AGEs	698:724	structurally different AGEs	698:724	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	5	14	theme	different	711:719	arg1	crosslinking					737:748	crosslinking	737:748	crosslinking	737:748	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	5	14	theme	different	711:719	arg1	modifications					771:783	non-crosslinking modifications	754:783	non-crosslinking modifications	754:783	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	2	15	theme	several	293:299	arg1	tissues					301:307	several tissues	293:307	several tissues	293:307	The in vivo analog accumulates in several tissues; however, its origin still needs explanation.
36361822	6	16	from	formation	894:902	arg1	efficient					877:885	efficient	877:885	efficient	877:885	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	7	17	theme	characteristic	1052:1065	arg1	fluorescence					1067:1078	characteristic fluorescence	1052:1078	characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein	1052:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	6	18	theme	dry	858:860	arg1	state					862:866	a dry state	856:866	a dry state	856:866	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	2	19	dep	in	263:264	arg1	vivo					266:269	vivo	266:269	vivo	266:269	The in vivo analog accumulates in several tissues; however, its origin still needs explanation.
36361822	3	20	theme	In	355:356	arg1	MAGE					364:367	In vitro MAGE	355:367	In vitro MAGE	355:367	In vitro MAGE is efficiently generated under dry conditions in contrast to the reaction carried in an aqueous solvent.
36361822	0	21	from	Modifications	40:52	arg1	End-Product					104:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	7	22	theme	heme	1141:1144	arg1	protein					1175:1181	the model myoglobin protein	1155:1181	the model myoglobin protein	1155:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	7	22	theme	heme	1141:1144	arg1	group					1146:1150	a heme group	1139:1150	a heme group of the model myoglobin protein	1139:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	10	23	theme	advanced	1459:1466	arg1	structures					1468:1477	more advanced structures	1454:1477	more advanced structures	1454:1477	The intermediate glycation product can further rearrange towards more advanced structures, including cross-links.
36361822	10	23	theme	advanced	1459:1466	arg1	cross-links					1490:1500	cross-links	1490:1500	cross-links	1490:1500	The intermediate glycation product can further rearrange towards more advanced structures, including cross-links.
36361822	4	24	theme	liquid	480:485	arg1	chromatography					487:500	liquid chromatography	480:500	liquid chromatography coupled with mass spectrometry	480:531	Using liquid chromatography coupled with mass spectrometry, we analyzed the physicochemical properties and structures of myoglobin glycated with melibiose under different conditions.
36361822	5	25	theme	targeted	661:668	arg1	analysis					678:685	The targeted peptide analysis	657:685	The targeted peptide analysis	657:685	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	11	26	dep	AGEs	1544:1547	arg1	affecting					1582:1590	affecting	1582:1590	affecting tissue biology	1582:1605	This process can contribute to a pool of AGEs accumulating locally in vivo and affecting tissue biology.
36361822	11	26	dep	AGEs	1544:1547	arg1	accumulating					1549:1560	accumulating	1549:1560	accumulating locally in vivo	1549:1576	This process can contribute to a pool of AGEs accumulating locally in vivo and affecting tissue biology.
36361822	8	27	theme	coupling	1272:1279	arg1	melibiose					1281:1289	coupling melibiose	1272:1289	coupling melibiose to a model myoglobin protein	1272:1318	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	7	28	theme	protein	1098:1104	arg1	changes					1117:1123	protein structural changes	1098:1123	protein structural changes	1098:1123	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	7	29	from	impact	1129:1134	arg1	protein					1175:1181	the model myoglobin protein	1155:1181	the model myoglobin protein	1155:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	7	29	from	impact	1129:1134	arg1	group					1146:1150	a heme group	1139:1150	a heme group of the model myoglobin protein	1139:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	5	30	theme	peptide	670:676	arg1	analysis					678:685	The targeted peptide analysis	657:685	The targeted peptide analysis	657:685	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	7	31	theme	structural	1106:1115	arg1	changes					1117:1123	protein structural changes	1098:1123	protein structural changes	1098:1123	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	11	32	theme	tissue	1592:1597	arg1	biology					1599:1605	tissue biology	1592:1605	tissue biology	1592:1605	This process can contribute to a pool of AGEs accumulating locally in vivo and affecting tissue biology.
36361822	0	33	theme	Site-Specific	16:28	arg1	Modifications					40:52	the Site-Specific Myoglobin Modifications	12:52	the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product	12:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	4	34	theme	physicochemical	550:564	arg1	properties					566:575	the physicochemical properties	546:575	the physicochemical properties	546:575	Using liquid chromatography coupled with mass spectrometry, we analyzed the physicochemical properties and structures of myoglobin glycated with melibiose under different conditions.
36361822	10	35	theme	glycation	1406:1414	arg1	product					1416:1422	The intermediate glycation product	1389:1422	The intermediate glycation product	1389:1422	The intermediate glycation product can further rearrange towards more advanced structures, including cross-links.
36361822	3	36	theme	aqueous	457:463	arg1	solvent					465:471	an aqueous solvent	454:471	an aqueous solvent	454:471	In vitro MAGE is efficiently generated under dry conditions in contrast to the reaction carried in an aqueous solvent.
36361822	9	37	theme	intact	1362:1367	arg1	moieties					1379:1386	intact melibiose moieties	1362:1386	intact melibiose moieties	1362:1386	It is confirmed by the identification of intact melibiose moieties.
36361822	5	38	theme	non-crosslinking	754:769	arg1	modifications					771:783	non-crosslinking modifications	754:783	non-crosslinking modifications	754:783	The targeted peptide analysis identified structurally different AGEs, including crosslinking and non-crosslinking modifications associated with lysine, arginine, and histidine residues.
36361822	0	39	theme	Modifications	40:52	arg1	Analysis					0:7	Analysis	0:7	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.	0:115	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	8	40	theme	myoglobin	1302:1310	arg1	protein					1312:1318	a model myoglobin protein	1294:1318	a model myoglobin protein	1294:1318	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	1	41	with	reaction	215:222	arg1	melibiose					248:256	melibiose	248:256	melibiose	248:256	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	8	42	theme	model	1296:1300	arg1	protein					1312:1318	a model myoglobin protein	1294:1318	a model myoglobin protein	1294:1318	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	7	43	theme	myoglobin	1165:1173	arg1	protein					1175:1181	the model myoglobin protein	1155:1181	the model myoglobin protein	1155:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	0	44	theme	Myoglobin	30:38	arg1	Modifications					40:52	the Site-Specific Myoglobin Modifications	12:52	the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product	12:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	6	45	theme	aqueous	992:998	arg1	conditions					1000:1009	aqueous conditions	992:1009	aqueous conditions (15.6%)	992:1017	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	6	45	theme	aqueous	992:998	arg1	%					1016:1016	15.6%	1012:1016	15.6%	1012:1016	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	6	46	from	efficient	877:885	arg1	formation					894:902	the formation	890:902	the formation of structures containing an intact melibiose moiety	890:954	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	6	47	theme	structures	907:916	arg1	formation					894:902	the formation	890:902	the formation of structures containing an intact melibiose moiety	890:954	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	1	48	theme	model	229:233	arg1	protein					235:241	a model protein	227:241	a model protein	227:241	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	3	49	theme	dry	400:402	arg1	conditions					404:413	dry conditions	400:413	dry conditions	400:413	In vitro MAGE is efficiently generated under dry conditions in contrast to the reaction carried in an aqueous solvent.
36361822	9	50	theme	moieties	1379:1386	arg1	identification					1344:1357	the identification	1340:1357	the identification of intact melibiose moieties	1340:1386	It is confirmed by the identification of intact melibiose moieties.
36361822	8	51	theme	in	1235:1236	arg1	adduct					1249:1254	in vitro MAGE adduct	1235:1254	in vitro MAGE adduct	1235:1254	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	6	52	dep	efficient	877:885	arg1	%					961:961	21.9%	957:961	21.9%	957:961	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	3	53	dep	reaction	434:441	arg1	contrast					418:425	contrast	418:425	contrast	418:425	In vitro MAGE is efficiently generated under dry conditions in contrast to the reaction carried in an aqueous solvent.
36361822	6	54	theme	melibiose	939:947	arg1	moiety					949:954	an intact melibiose moiety	929:954	an intact melibiose moiety	929:954	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	1	55	theme	melibiose-derived	123:139	arg1	end-product					160:170	melibiose-derived advanced glycation end-product	123:170	melibiose-derived advanced glycation end-product	123:170	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	55	theme	melibiose-derived	123:139	arg1	MAGE					117:120	MAGE	117:120	MAGE (melibiose-derived advanced glycation end-product)	117:171	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	4	56	theme	mass	515:518	arg1	spectrometry					520:531	mass spectrometry	515:531	mass spectrometry	515:531	Using liquid chromatography coupled with mass spectrometry, we analyzed the physicochemical properties and structures of myoglobin glycated with melibiose under different conditions.
36361822	3	57	dep	In	355:356	arg1	vitro					358:362	vitro	358:362	vitro	358:362	In vitro MAGE is efficiently generated under dry conditions in contrast to the reaction carried in an aqueous solvent.
36361822	1	58	theme	advanced	141:148	arg1	end-product					160:170	melibiose-derived advanced glycation end-product	123:170	melibiose-derived advanced glycation end-product	123:170	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	58	theme	advanced	141:148	arg1	MAGE					117:120	MAGE	117:120	MAGE (melibiose-derived advanced glycation end-product)	117:171	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	59	link	melibiose-derived	123:139	arg1	end-product					160:170	melibiose-derived advanced glycation end-product	123:170	melibiose-derived advanced glycation end-product	123:170	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	59	link	melibiose-derived	123:139	arg1	MAGE					117:120	MAGE	117:120	MAGE (melibiose-derived advanced glycation end-product)	117:171	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	7	60	theme	protein	1175:1181	arg1	protein					1175:1181	the model myoglobin protein	1155:1181	the model myoglobin protein	1155:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	7	60	theme	protein	1175:1181	arg1	group					1146:1150	a heme group	1139:1150	a heme group of the model myoglobin protein	1139:1181	The difference was reflected in characteristic fluorescence that results from protein structural changes and impact on a heme group of the model myoglobin protein.
36361822	1	61	theme	glycation	150:158	arg1	end-product					160:170	melibiose-derived advanced glycation end-product	123:170	melibiose-derived advanced glycation end-product	123:170	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	61	theme	glycation	150:158	arg1	MAGE					117:120	MAGE	117:120	MAGE (melibiose-derived advanced glycation end-product)	117:171	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	1	62	theme	protein	235:241	arg1	reaction					215:222	the reaction	211:222	the reaction of a model protein with melibiose	211:256	MAGE (melibiose-derived advanced glycation end-product) is the glycation product generated in the reaction of a model protein with melibiose.
36361822	10	63	theme	intermediate	1393:1404	arg1	product					1416:1422	The intermediate glycation product	1389:1422	The intermediate glycation product	1389:1422	The intermediate glycation product can further rearrange towards more advanced structures, including cross-links.
36361822	8	64	theme	adduct	1249:1254	arg1	formation					1222:1230	the formation	1218:1230	the formation of in vitro MAGE adduct	1218:1254	Finally, our results suggest that the formation of in vitro MAGE adduct is initiated by coupling melibiose to a model myoglobin protein.
36361822	6	65	contain	containing	918:927	arg1	structures					907:916	structures	907:916	structures containing an intact melibiose moiety	907:954	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	6	65	contain	containing	918:927	arg2	moiety					949:954	an intact melibiose moiety	929:954	an intact melibiose moiety	929:954	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	0	66	theme	Novel	79:83	arg1	End-Product					104:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	0	67	from	End-Product	104:114	arg1	Analysis					0:7	Analysis	0:7	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.	0:115	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	2	68	theme	in	263:264	arg1	analog					271:276	The in vivo analog	259:276	The in vivo analog	259:276	The in vivo analog accumulates in several tissues; however, its origin still needs explanation.
36361822	6	69	from	Glycation	843:851	arg1	state					862:866	a dry state	856:866	a dry state	856:866	Glycation in a dry state was more efficient in the formation of structures containing an intact melibiose moiety (21.9%) compared to glycation under aqueous conditions (15.6%).
36361822	9	70	theme	melibiose	1369:1377	arg1	moieties					1379:1386	intact melibiose moieties	1362:1386	intact melibiose moieties	1362:1386	It is confirmed by the identification of intact melibiose moieties.
36361822	0	71	theme	Melibiose-Derived	61:77	arg1	End-Product					104:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	the Melibiose-Derived Novel Advanced Glycation End-Product	57:114	Analysis of the Site-Specific Myoglobin Modifications in the Melibiose-Derived Novel Advanced Glycation End-Product.
36361822	4	72	theme	different	635:643	arg1	conditions					645:654	different conditions	635:654	different conditions	635:654	Using liquid chromatography coupled with mass spectrometry, we analyzed the physicochemical properties and structures of myoglobin glycated with melibiose under different conditions.
36536394	4	0	theme	rates	987:991	arg1	balance					933:939	balance	933:939	balance of the oligosaccharide priming and elongation rates	933:991	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	12	1	theme	48 mol	2282:2287	arg1	cellobiose					2270:2279	cellobiose	2270:2279	cellobiose (48 mol%)	2270:2289	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	1	theme	48 mol	2282:2287	arg1	%					2288:2288	48 mol%	2282:2288	48 mol%	2282:2288	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	7	2	theme	COS	1350:1352	arg1	~ 70 g/L					1366:1373	~ 70 g/L	1366:1373	~ 70 g/L	1366:1373	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	7	2	theme	COS	1350:1352	arg1	production					1354:1363	COS production	1350:1363	COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups	1350:1443	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	8	3	from	CbP	1635:1637	arg1	particular					1642:1651	particular	1642:1651	particular	1642:1651	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	3	4	from	sucrose	605:611	arg1	β-1,4-glycosylation					569:587	multistep iterative β-1,4-glycosylation	549:587	multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	549:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	2	5	theme	constant	422:429	arg1	quality					439:445	constant product quality	422:445	constant product quality	422:445	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	11	6	theme	substrate	2128:2136	arg1	conversion					2138:2147	≥ 95% substrate conversion	2122:2147	≥ 95% substrate conversion (sucrose 300 mM)	2122:2164	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	11	6	theme	substrate	2128:2136	arg1	300 mM					2158:2163	sucrose 300 mM	2150:2163	sucrose 300 mM	2150:2163	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	11	7	theme	≥ 95	2122:2125	arg1	%					2126:2126	%	2126:2126	%	2126:2126	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	7	8	from	production	1354:1363	arg1	vessel					1385:1390	mixed vessel	1379:1390	mixed vessel with catalyst recycle and packed-bed reactor set-ups	1379:1443	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	12	9	theme	individual	2217:2226	arg1	oligosaccharides					2228:2243	individual oligosaccharides	2217:2243	individual oligosaccharides	2217:2243	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	13	10	theme	relative	2556:2563	arg1	activities					2565:2574	suitable absolute and relative activities	2534:2574	suitable absolute and relative activities	2534:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	11	11	theme	flow	2056:2059	arg1	rate					2061:2064	an axial flow rate	2047:2064	an axial flow rate of 0.75 cm- 1	2047:2078	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	4	12	theme	oligosaccharide	948:962	arg1	priming					964:970	the oligosaccharide priming	944:970	the oligosaccharide priming	944:970	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	8	13	dep	U/g	1508:1510	arg1	material					1527:1534	37 mg cells/g material	1513:1534	270 U/g; 37 mg cells/g material	1504:1534	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	2	14	theme	one-pot	329:335	arg1	reactions					347:355	one-pot multistep reactions	329:355	one-pot multistep reactions	329:355	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	1	15	theme	well-known	212:221	arg1	strategy					235:242	a well-known engineering strategy	210:242	a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis	210:323	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	1	15	theme	well-known	212:221	arg1	processing					178:187	BACKGROUND Continuous processing	156:187	BACKGROUND Continuous processing with enzyme reuse	156:205	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	6	16	theme	dry	1271:1273	arg1	material					1283:1290	37-111 mg dry cells/g material	1261:1290	37-111 mg dry cells/g material	1261:1290	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	7	17	with	vessel	1385:1390	arg1	recycle					1406:1412	catalyst recycle	1397:1412	catalyst recycle	1397:1412	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	7	17	with	vessel	1385:1390	arg1	set-ups					1437:1443	packed-bed reactor set-ups	1418:1443	packed-bed reactor set-ups	1418:1443	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	13	18	theme	absolute	2543:2550	arg1	activities					2565:2574	suitable absolute and relative activities	2534:2574	suitable absolute and relative activities	2534:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	4	19	theme	control	843:849	arg1	Degree					813:818	Degree	813:818	Degree of polymerization (DP) control in the COS product	813:868	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	2	20	theme	continuous	358:367	arg1	processing					369:378	continuous processing	358:378	continuous processing	358:378	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	3	21	theme	Cellulomonas	721:732	arg1	CuCbP					739:743	CuCbP	739:743	CuCbP	739:743	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	21	theme	Cellulomonas	721:732	arg1	uda					734:736	Cellulomonas uda	721:736	Cellulomonas uda (CuCbP)	721:744	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	9	22	theme	packed	1795:1800	arg1	bed					1802:1804	the packed bed	1791:1804	the packed bed (volume: 40 mL; height: 7.5 cm)	1791:1836	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	8	23	theme	dry	1471:1473	arg1	activity					1494:1501	a dry mass-based overall activity	1469:1501	a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40%	1469:1552	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	10	24	theme	packed	2029:2034	arg1	bed					2036:2038	the packed bed	2025:2038	the packed bed	2025:2038	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	13	25	theme	E.	2478:2479	arg1	cells					2486:2490	E. coli cells	2478:2490	E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities	2478:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	1	26	theme	BACKGROUND	156:165	arg1	processing					178:187	BACKGROUND Continuous processing	156:187	BACKGROUND Continuous processing with enzyme reuse	156:205	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	1	26	theme	BACKGROUND	156:165	arg1	strategy					235:242	a well-known engineering strategy	210:242	a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis	210:323	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	12	27	theme	31 mol	2308:2313	arg1	cellotriose					2295:2305	cellotriose	2295:2305	cellotriose (31 mol%)	2295:2315	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	27	theme	31 mol	2308:2313	arg1	%					2314:2314	31 mol%	2308:2314	31 mol%	2308:2314	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	6	28	dep	E.	1203:1204	arg1	coli					1206:1209	coli	1206:1209	coli	1206:1209	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	10	29	theme	PAM	1874:1876	arg1	limits					1864:1869	the limits	1860:1869	the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed	1860:2038	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	0	30	theme	cello-oligosaccharides	65:86	arg1	synthesis					44:52	bottom-up synthesis	34:52	bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases	34:153	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	5	31	theme	E.	1007:1008	arg1	catalyst					1015:1022	A whole-cell E. coli catalyst	994:1022	A whole-cell E. coli catalyst	994:1022	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	8	32	theme	corresponding	1570:1582	arg1	cells					1589:1593	the corresponding free cells	1566:1593	the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization	1566:1681	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	12	33	with	oligosaccharides	2228:2243	arg1	cellobiose					2270:2279	cellobiose	2270:2279	cellobiose (48 mol%)	2270:2289	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	33	with	oligosaccharides	2228:2243	arg1	%					2288:2288	48 mol%	2282:2288	48 mol%	2282:2288	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	33	with	oligosaccharides	2228:2243	arg1	cellotriose					2295:2305	cellotriose	2295:2305	cellotriose (31 mol%)	2295:2315	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	33	with	oligosaccharides	2228:2243	arg1	%					2314:2314	31 mol%	2308:2314	31 mol%	2308:2314	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	0	34	theme	immobilized	91:101	arg1	cells					103:107	immobilized cells	91:107	immobilized cells co-expressing three saccharide phosphorylases	91:153	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	3	35	gly	β-1,4-glycosylation	569:587	arg1	glucose					592:598	glucose	592:598	glucose	592:598	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	9	36	dep	volume	1807:1812	arg1	7.5 cm					1830:1835	7.5 cm	1830:1835	volume: 40 mL; height: 7.5 cm	1807:1835	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	9	36	dep	volume	1807:1812	arg1	height					1822:1827	height	1822:1827	volume: 40 mL; height: 7.5 cm	1807:1835	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	9	36	dep	volume	1807:1812	arg1	40 mL					1815:1819	40 mL	1815:1819	volume: 40 mL; height: 7.5 cm	1807:1835	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	5	37	theme	desired	1082:1088	arg1	ratio					1099:1103	the desired activity ratio	1078:1103	the desired activity ratio	1078:1103	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	5	38	with	phosphorylases	1042:1055	arg1	CdP					1111:1113	CdP	1111:1113	CdP	1111:1113	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	2	39	theme	product	466:472	arg1	composition					474:484	the product composition	462:484	the product composition	462:484	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	0	40	theme	saccharide	129:138	arg1	phosphorylases					140:153	three saccharide phosphorylases	123:153	three saccharide phosphorylases	123:153	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	1	41	with	processing	178:187	arg1	reuse					201:205	enzyme reuse	194:205	enzyme reuse	194:205	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	5	42	from	phosphorylases	1042:1055	arg1	yield					1065:1069	high yield	1060:1069	high yield	1060:1069	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	5	42	from	phosphorylases	1042:1055	arg1	ratio					1099:1103	the desired activity ratio	1078:1103	the desired activity ratio	1078:1103	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	6	43	theme	permeabilized	1189:1201	arg1	cells					1211:1215	Freeze-thaw permeabilized E. coli cells	1177:1215	Freeze-thaw permeabilized E. coli cells	1177:1215	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	8	44	theme	enzyme	1613:1618	arg1	CbP					1635:1637	CbP	1635:1637	CbP in particular, caused by the immobilization	1635:1681	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	8	44	theme	enzyme	1613:1618	arg1	loss					1629:1632	individual enzyme activity loss	1602:1632	individual enzyme activity loss	1602:1632	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	8	45	theme	mass-based	1475:1484	arg1	activity					1494:1501	a dry mass-based overall activity	1469:1501	a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40%	1469:1552	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	0	46	theme	Continuous	0:9	arg1	technology					19:28	Continuous process technology	0:28	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.	0:154	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	9	47	theme	stable	1749:1754	arg1	~ 1 month					1777:1785	~ 1 month	1777:1785	~ 1 month	1777:1785	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	9	47	theme	stable	1749:1754	arg1	reaction					1767:1774	stable continuous reaction	1749:1774	stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm)	1749:1836	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	7	48	theme	reactor	1429:1435	arg1	set-ups					1437:1443	packed-bed reactor set-ups	1418:1443	packed-bed reactor set-ups	1418:1443	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	4	49	theme	COS	858:860	arg1	product					862:868	the COS product	854:868	the COS product	854:868	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	3	50	theme	multistep	549:557	arg1	β-1,4-glycosylation					569:587	multistep iterative β-1,4-glycosylation	549:587	multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	549:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	10	51	from	catalyst	1878:1885	arg1	combination					1926:1936	combination	1926:1936	combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed	1926:2038	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	3	52	theme	Bottom-up	487:495	arg1	production					497:506	Bottom-up production	487:506	Bottom-up production of cello-oligosaccharides (COS)	487:538	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	7	53	theme	PAM	1293:1295	arg1	particles					1297:1305	PAM particles	1293:1305	PAM particles (0.25-2.00 mm size)	1293:1325	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	7	53	theme	PAM	1293:1295	arg1	size					1321:1324	0.25-2.00 mm size	1308:1324	0.25-2.00 mm size	1308:1324	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	0	54	theme	bottom-up	34:42	arg1	synthesis					44:52	bottom-up synthesis	34:52	bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases	34:153	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	5	55	theme	rate-limiting	1122:1134	arg1	phosphorylases					1042:1055	the phosphorylases	1038:1055	the phosphorylases	1038:1055	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	5	55	theme	rate-limiting	1122:1134	arg1	enzyme					1136:1141	the rate-limiting enzyme	1118:1141	the rate-limiting enzyme	1118:1141	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	7	56	theme	catalyst	1397:1404	arg1	recycle					1406:1412	catalyst recycle	1397:1412	catalyst recycle	1397:1412	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	3	57	theme	cellodextrin	750:761	arg1	phosphorylase					763:775	cellodextrin phosphorylase	750:775	cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	750:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	11	58	theme	sucrose	2150:2156	arg1	conversion					2138:2147	≥ 95% substrate conversion	2122:2147	≥ 95% substrate conversion (sucrose 300 mM)	2122:2164	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	11	58	theme	sucrose	2150:2156	arg1	300 mM					2158:2163	sucrose 300 mM	2150:2163	sucrose 300 mM	2150:2163	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	3	59	theme	glucose	592:598	arg1	β-1,4-glycosylation					569:587	multistep iterative β-1,4-glycosylation	549:587	multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	549:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	9	60	theme	Temperature	1684:1694	arg1	studies					1696:1702	Temperature studies	1684:1702	Temperature studies	1684:1702	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	8	61	theme	cells/g	1519:1525	arg1	material					1527:1534	37 mg cells/g material	1513:1534	270 U/g; 37 mg cells/g material	1504:1534	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	13	62	theme	Continuous	2354:2363	arg1	technology					2373:2382	CONCLUSIONS Continuous process technology	2342:2382	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS	2342:2435	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	1	63	theme	enzyme	194:199	arg1	reuse					201:205	enzyme reuse	194:205	enzyme reuse	194:205	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	1	64	theme	transformations	286:300	arg1	efficiency					259:268	the efficiency	255:268	the efficiency of biocatalytic transformations for chemical synthesis	255:323	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	9	65	theme	operational	1716:1726	arg1	optimum					1728:1734	an operational optimum	1713:1734	an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm)	1713:1836	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	13	66	theme	suitable	2534:2541	arg1	activities					2565:2574	suitable absolute and relative activities	2534:2574	suitable absolute and relative activities	2534:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	2	67	theme	product	431:437	arg1	quality					439:445	constant product quality	422:445	constant product quality	422:445	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	4	68	from	Degree	813:818	arg1	product					862:868	the COS product	854:868	the COS product	854:868	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	1	69	theme	chemical	306:313	arg1	synthesis					315:323	chemical synthesis	306:323	chemical synthesis	306:323	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	4	70	theme	elongation	976:985	arg1	rates					987:991	elongation rates	976:991	elongation rates	976:991	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	10	71	theme	structural	1887:1896	arg1	stability					1913:1921	structural and biological stability	1887:1921	structural and biological stability	1887:1921	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	5	72	dep	E.	1007:1008	arg1	coli					1010:1013	coli	1010:1013	coli	1010:1013	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	11	73	theme	axial	2050:2054	arg1	rate					2061:2064	an axial flow rate	2047:2064	an axial flow rate of 0.75 cm- 1	2047:2078	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	11	74	theme	%	2126:2126	arg1	conversion					2138:2147	≥ 95% substrate conversion	2122:2147	≥ 95% substrate conversion (sucrose 300 mM)	2122:2164	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	11	74	theme	%	2126:2126	arg1	300 mM					2158:2163	sucrose 300 mM	2150:2163	sucrose 300 mM	2150:2163	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	3	75	from	phosphorylase	763:775	arg1	adeloscentis					669:680	Bifidobacterium adeloscentis	653:680	Bifidobacterium adeloscentis (BaScP)	653:688	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	75	from	phosphorylase	763:775	arg1	phosphorylase					702:714	cellobiose phosphorylase	691:714	cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	691:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	2	76	theme	multistep	337:345	arg1	reactions					347:355	one-pot multistep reactions	329:355	one-pot multistep reactions	329:355	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	8	77	dep	activity	1494:1501	arg1	U/g					1508:1510	270 U/g	1504:1510	270 U/g; 37 mg cells/g material	1504:1534	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	9	78	theme	continuous	1756:1765	arg1	~ 1 month					1777:1785	~ 1 month	1777:1785	~ 1 month	1777:1785	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	9	78	theme	continuous	1756:1765	arg1	reaction					1767:1774	stable continuous reaction	1749:1774	stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm)	1749:1836	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	6	79	theme	cells/g	1275:1281	arg1	material					1283:1290	37-111 mg dry cells/g material	1261:1290	37-111 mg dry cells/g material	1261:1290	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	10	80	theme	product	1974:1980	arg1	solubility					1982:1991	COS product solubility	1970:1991	COS product solubility	1970:1991	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	13	81	from	CcCdP	2525:2529	arg1	activities					2565:2574	suitable absolute and relative activities	2534:2574	suitable absolute and relative activities	2534:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	11	82	theme	0.75 cm- 1	2069:2078	arg1	rate					2061:2064	an axial flow rate	2047:2064	an axial flow rate of 0.75 cm- 1	2047:2078	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	1	83	theme	engineering	223:233	arg1	strategy					235:242	a well-known engineering strategy	210:242	a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis	210:323	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	1	83	theme	engineering	223:233	arg1	processing					178:187	BACKGROUND Continuous processing	156:187	BACKGROUND Continuous processing with enzyme reuse	156:205	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	9	84	from	reaction	1767:1774	arg1	bed					1802:1804	the packed bed	1791:1804	the packed bed (volume: 40 mL; height: 7.5 cm)	1791:1836	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	4	85	theme	priming	964:970	arg1	balance					933:939	balance	933:939	balance of the oligosaccharide priming and elongation rates	933:991	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	6	86	theme	37-111 mg	1261:1269	arg1	material					1283:1290	37-111 mg dry cells/g material	1261:1290	37-111 mg dry cells/g material	1261:1290	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	10	87	dep	PAM	1874:1876	arg1	catalyst					1878:1885	catalyst	1878:1885	catalyst	1878:1885	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	12	88	theme	stable	2195:2200	arg1	components					2330:2339	the major components	2320:2339	the major components	2320:2339	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	88	theme	stable	2195:2200	arg1	composition					2202:2212	a stable composition	2193:2212	a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%)	2193:2315	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	13	89	from	CuCbP	2515:2519	arg1	activities					2565:2574	suitable absolute and relative activities	2534:2574	suitable absolute and relative activities	2534:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	12	90	theme	major	2324:2328	arg1	components					2330:2339	the major components	2320:2339	the major components	2320:2339	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	90	theme	major	2324:2328	arg1	composition					2202:2212	a stable composition	2193:2212	a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%)	2193:2315	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	9	91	from	30 °C	1739:1743	arg1	optimum					1728:1734	an operational optimum	1713:1734	an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm)	1713:1836	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	10	92	theme	bed	2036:2038	arg1	clogging					2013:2020	clogging	2013:2020	clogging of the packed bed	2013:2038	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	3	93	theme	cellobiose	691:700	arg1	adeloscentis					669:680	Bifidobacterium adeloscentis	653:680	Bifidobacterium adeloscentis (BaScP)	653:688	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	93	theme	cellobiose	691:700	arg1	phosphorylase					702:714	cellobiose phosphorylase	691:714	cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	691:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	10	94	theme	biological	1902:1911	arg1	stability					1913:1921	structural and biological stability	1887:1921	structural and biological stability	1887:1921	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	6	95	dep	permeabilized	1189:1201	arg1	E.					1203:1204	E.	1203:1204	E.	1203:1204	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	4	96	theme	polymerization	823:836	arg1	control					843:849	polymerization (DP) control	823:849	polymerization (DP) control in the COS product	823:868	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	13	97	theme	coli	2481:2484	arg1	cells					2486:2490	E. coli cells	2478:2490	E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities	2478:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	1	98	theme	Continuous	167:176	arg1	processing					178:187	BACKGROUND Continuous processing	156:187	BACKGROUND Continuous processing with enzyme reuse	156:205	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	1	98	theme	Continuous	167:176	arg1	strategy					235:242	a well-known engineering strategy	210:242	a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis	210:323	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	11	99	theme	~	2106:2106	arg1	5.7 g/day					2108:2116	~ 5.7 g/day	2106:2116	~ 5.7 g/day	2106:2116	Using an axial flow rate of 0.75 cm- 1, the COS were produced at ~ 5.7 g/day and ≥ 95% substrate conversion (sucrose 300 mM).
36536394	3	100	from	adeloscentis	669:680	arg1	phosphorylase					634:646	sucrose phosphorylase	626:646	sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	626:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	5	101	theme	whole-cell	996:1005	arg1	catalyst					1015:1022	A whole-cell E. coli catalyst	994:1022	A whole-cell E. coli catalyst	994:1022	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	8	102	theme	free	1584:1587	arg1	cells					1589:1593	the corresponding free cells	1566:1593	the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization	1566:1681	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	12	103	dep	cellohexaose	2251:2262	arg1	up					2245:2246	up	2245:2246	up	2245:2246	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	13	104	from	BaScP	2508:2512	arg1	activities					2565:2574	suitable absolute and relative activities	2534:2574	suitable absolute and relative activities	2534:2574	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	8	105	theme	due	1595:1597	arg1	cells					1589:1593	the corresponding free cells	1566:1593	the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization	1566:1681	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	4	106	theme	soluble	887:893	arg1	production					895:904	soluble production	887:904	soluble production	887:904	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	8	107	theme	individual	1602:1611	arg1	CbP					1635:1637	CbP	1635:1637	CbP in particular, caused by the immobilization	1635:1681	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	8	107	theme	individual	1602:1611	arg1	loss					1629:1632	individual enzyme activity loss	1602:1632	individual enzyme activity loss	1602:1632	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	3	108	from	uda	734:736	arg1	adeloscentis					669:680	Bifidobacterium adeloscentis	653:680	Bifidobacterium adeloscentis (BaScP)	653:688	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	108	from	uda	734:736	arg1	phosphorylase					702:714	cellobiose phosphorylase	691:714	cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	691:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	4	109	from	product	862:868	arg1	Degree					813:818	Degree	813:818	Degree of polymerization (DP) control in the COS product	813:868	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	5	110	theme	activity	1090:1097	arg1	ratio					1099:1103	the desired activity ratio	1078:1103	the desired activity ratio	1078:1103	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	8	111	theme	activity	1620:1627	arg1	CbP					1635:1637	CbP	1635:1637	CbP in particular, caused by the immobilization	1635:1681	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	8	111	theme	activity	1620:1627	arg1	loss					1629:1632	individual enzyme activity loss	1602:1632	individual enzyme activity loss	1602:1632	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	0	112	theme	process	11:17	arg1	technology					19:28	Continuous process technology	0:28	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.	0:154	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	5	113	theme	high	1060:1063	arg1	yield					1065:1069	high yield	1060:1069	high yield	1060:1069	A whole-cell E. coli catalyst co-expressing the phosphorylases in high yield and in the desired activity ratio, with CdP as the rate-limiting enzyme, was reported previously.
36536394	7	114	theme	packed-bed	1418:1427	arg1	set-ups					1437:1443	packed-bed reactor set-ups	1418:1443	packed-bed reactor set-ups	1418:1443	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	6	115	dep	RESULTS	1169:1175	arg1	immobilized					1222:1232	immobilized	1222:1232	were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material	1217:1290	RESULTS Freeze-thaw permeabilized E. coli cells were immobilized in polyacrylamide (PAM) at 37-111 mg dry cells/g material.
36536394	3	116	theme	cello-oligosaccharides	511:532	arg1	production					497:506	Bottom-up production	487:506	Bottom-up production of cello-oligosaccharides (COS)	487:538	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	4	117	from	control	843:849	arg1	product					862:868	the COS product	854:868	the COS product	854:868	Degree of polymerization (DP) control in the COS product is essential for soluble production and is implemented through balance of the oligosaccharide priming and elongation rates.
36536394	13	118	theme	COS	2433:2435	arg1	production					2411:2420	bottom-up biocatalytic production	2388:2420	bottom-up biocatalytic production of soluble COS	2388:2435	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	8	119	theme	overall	1486:1492	arg1	activity					1494:1501	a dry mass-based overall activity	1469:1501	a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40%	1469:1552	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	3	120	theme	iterative	559:567	arg1	β-1,4-glycosylation					569:587	multistep iterative β-1,4-glycosylation	549:587	multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	549:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	12	121	theme	oligosaccharides	2228:2243	arg1	components					2330:2339	the major components	2320:2339	the major components	2320:2339	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	12	121	theme	oligosaccharides	2228:2243	arg1	composition					2202:2212	a stable composition	2193:2212	a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%)	2193:2315	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	13	122	theme	soluble	2425:2431	arg1	COS					2433:2435	soluble COS	2425:2435	soluble COS	2425:2435	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	2	123	theme	composition	474:484	arg1	control					451:457	control	451:457	control of the product composition	451:484	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	0	124	theme	soluble	57:63	arg1	cello-oligosaccharides					65:86	soluble cello-oligosaccharides	57:86	soluble cello-oligosaccharides	57:86	Continuous process technology for bottom-up synthesis of soluble cello-oligosaccharides by immobilized cells co-expressing three saccharide phosphorylases.
36536394	13	125	theme	biocatalytic	2398:2409	arg1	production					2411:2420	bottom-up biocatalytic production	2388:2420	bottom-up biocatalytic production of soluble COS	2388:2435	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	7	126	theme	mixed	1379:1383	arg1	vessel					1385:1390	mixed vessel	1379:1390	mixed vessel with catalyst recycle and packed-bed reactor set-ups	1379:1443	PAM particles (0.25-2.00 mm size) were characterized for COS production (~ 70 g/L) in mixed vessel with catalyst recycle and packed-bed reactor set-ups.
36536394	9	127	dep	bed	1802:1804	arg1	volume					1807:1812	volume	1807:1812	volume: 40 mL; height: 7.5 cm	1807:1835	Temperature studies revealed an operational optimum at 30 °C for stable continuous reaction (~ 1 month) in the packed bed (volume: 40 mL; height: 7.5 cm).
36536394	13	128	theme	CONCLUSIONS	2342:2352	arg1	technology					2373:2382	CONCLUSIONS Continuous process technology	2342:2382	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS	2342:2435	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	3	129	theme	Clostridium	782:792	arg1	cellulosi					794:802	Clostridium cellulosi	782:802	Clostridium cellulosi (CcCdP)	782:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	129	theme	Clostridium	782:792	arg1	CcCdP					805:809	CcCdP	805:809	CcCdP	805:809	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	8	130	theme	37 mg	1513:1517	arg1	material					1527:1534	37 mg cells/g material	1513:1534	270 U/g; 37 mg cells/g material	1504:1534	The catalyst exhibited a dry mass-based overall activity (270 U/g; 37 mg cells/g material) lowered by ~ 40% compared to the corresponding free cells due to individual enzyme activity loss, CbP in particular, caused by the immobilization.
36536394	2	131	theme	additional	391:400	arg1	benefit					402:408	the additional benefit	387:408	the additional benefit of ensuring constant product quality via control of the product composition	387:484	In one-pot multistep reactions, continuous processing offers the additional benefit of ensuring constant product quality via control of the product composition.
36536394	1	132	theme	biocatalytic	273:284	arg1	transformations					286:300	biocatalytic transformations	273:300	biocatalytic transformations	273:300	BACKGROUND Continuous processing with enzyme reuse is a well-known engineering strategy to enhance the efficiency of biocatalytic transformations for chemical synthesis.
36536394	13	133	theme	process	2365:2371	arg1	technology					2373:2382	CONCLUSIONS Continuous process technology	2342:2382	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS	2342:2435	CONCLUSIONS Continuous process technology for bottom-up biocatalytic production of soluble COS is demonstrated based on PAM immobilized E. coli cells that co-express BaScP, CuCbP and CcCdP in suitable absolute and relative activities.
36536394	10	134	with	combination	1926:1936	arg1	requirement					1947:1957	the requirement to control COS product solubility in order to prevent clogging of the packed bed	1943:2038	the requirement to control COS product solubility in order to prevent clogging of the packed bed	1943:2038	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	3	135	from	cellulosi	794:802	arg1	phosphorylase					763:775	cellodextrin phosphorylase	750:775	cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	750:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	135	from	cellulosi	794:802	arg1	CuCbP					739:743	CuCbP	739:743	CuCbP	739:743	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	3	135	from	cellulosi	794:802	arg1	uda					734:736	Cellulomonas uda	721:736	Cellulomonas uda (CuCbP)	721:744	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36536394	10	136	theme	COS	1970:1972	arg1	solubility					1982:1991	COS product solubility	1970:1991	COS product solubility	1970:1991	The optimum reflects the limits of PAM catalyst structural and biological stability in combination with the requirement to control COS product solubility in order to prevent clogging of the packed bed.
36536394	12	137	theme	product	2171:2177	arg1	stream					2179:2184	The product stream	2167:2184	The product stream	2167:2184	The product stream showed a stable composition of individual oligosaccharides up to cellohexaose, with cellobiose (48 mol%) and cellotriose (31 mol%) as the major components.
36536394	3	138	theme	sucrose	626:632	arg1	phosphorylase					634:646	sucrose phosphorylase	626:646	sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP)	626:810	Bottom-up production of cello-oligosaccharides (COS) involves multistep iterative β-1,4-glycosylation of glucose from sucrose catalyzed by sucrose phosphorylase from Bifidobacterium adeloscentis (BaScP), cellobiose phosphorylase from Cellulomonas uda (CuCbP) and cellodextrin phosphorylase from Clostridium cellulosi (CcCdP).
36926810	0	0	theme	Glycan	100:105	arg1	Construction					115:126	Hierarchical Glycan Library Construction	87:126	Hierarchical Glycan Library Construction	87:126	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	4	1	theme	glycosyl	743:750	arg1	donor					752:756	glycosyl donor	743:756	glycosyl donor	743:756	By changing the enzyme modules, a series of glycosyl donor, disaccharides, oligosaccharides, and polysaccharides bearing cofactor regeneration were efficiently prepared.
36926810	0	2	theme	Hierarchical	87:98	arg1	Construction					115:126	Hierarchical Glycan Library Construction	87:126	Hierarchical Glycan Library Construction	87:126	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	3	3	theme	compartmentalized	573:589	arg1	particles					595:603	compartmentalized MOF particles	573:603	compartmentalized MOF particles	573:603	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	6	4	theme	enzymatic	1092:1100	arg1	synthesis					1102:1110	the enzymatic synthesis	1088:1110	the enzymatic synthesis of more complex glycans	1088:1134	This robust multienzyme immobilization platform should serve to promote the enzymatic synthesis of more complex glycans.
36926810	0	5	theme	Library	107:113	arg1	Construction					115:126	Hierarchical Glycan Library Construction	87:126	Hierarchical Glycan Library Construction	87:126	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	3	6	theme	MOF	591:593	arg1	particles					595:603	compartmentalized MOF particles	573:603	compartmentalized MOF particles	573:603	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	3	7	theme	universal	502:510	arg1	platform					527:534	a universal immobilization platform	500:534	a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions	500:696	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	5	8	theme	high	946:949	arg1	concentration					961:973	high substrate concentration	946:973	high substrate concentration	946:973	This bioreactor was further successfully applied to the reaction system with high substrate concentration to demonstrate its industrial potential.
36926810	4	9	theme	enzyme	715:720	arg1	modules					722:728	the enzyme modules	711:728	the enzyme modules	711:728	By changing the enzyme modules, a series of glycosyl donor, disaccharides, oligosaccharides, and polysaccharides bearing cofactor regeneration were efficiently prepared.
36926810	4	9	theme	enzyme	715:720	arg1	series					733:738	a series	731:738	a series of glycosyl donor	731:756	By changing the enzyme modules, a series of glycosyl donor, disaccharides, oligosaccharides, and polysaccharides bearing cofactor regeneration were efficiently prepared.
36926810	3	10	theme	Modular-Enzymes	430:444	arg1	Assembly					446:453	the strategy "Modular-Enzymes Assembly	416:453	the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS)	416:484	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	1	11	theme	defined	207:213	arg1	glycans					215:221	structurally defined glycans	194:221	structurally defined glycans	194:221	The multienzyme cascade has received growing attention to obtain structurally defined glycans in vitro.
36926810	0	12	theme	Segregated	10:19	arg1	Bioreactor					25:34	Spatially Segregated MOF Bioreactor	0:34	Spatially Segregated MOF Bioreactor	0:34	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	2	13	dep	glycans	368:374	arg1	to					358:359	to	358:359	to	358:359	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	3	14	theme	Spatial	458:464	arg1	"					477:477	Spatial Segregation"	458:477	Spatial Segregation" (MASS)	458:484	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	3	14	theme	Spatial	458:464	arg1	MASS					480:483	MASS	480:483	MASS	480:483	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	3	15	theme	strategy	420:427	arg1	Assembly					446:453	the strategy "Modular-Enzymes Assembly	416:453	the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS)	416:484	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	6	16	theme	robust	1021:1026	arg1	platform					1055:1062	This robust multienzyme immobilization platform	1016:1062	This robust multienzyme immobilization platform	1016:1062	This robust multienzyme immobilization platform should serve to promote the enzymatic synthesis of more complex glycans.
36926810	2	17	theme	pathways	349:356	arg1	glycans					368:374	artificially designed multienzyme pathways to access glycans	315:374	artificially designed multienzyme pathways to access glycans	315:374	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	4	18	theme	cofactor	820:827	arg1	regeneration					829:840	cofactor regeneration	820:840	cofactor regeneration	820:840	By changing the enzyme modules, a series of glycosyl donor, disaccharides, oligosaccharides, and polysaccharides bearing cofactor regeneration were efficiently prepared.
36926810	3	19	theme	Segregation	466:476	arg1	"					477:477	Spatial Segregation"	458:477	Spatial Segregation" (MASS)	458:484	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	3	19	theme	Segregation	466:476	arg1	MASS					480:483	MASS	480:483	MASS	480:483	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	2	20	theme	multienzyme	337:347	arg1	glycans					368:374	artificially designed multienzyme pathways to access glycans	315:374	artificially designed multienzyme pathways to access glycans	315:374	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	0	21	theme	MOF	21:23	arg1	Bioreactor					25:34	Spatially Segregated MOF Bioreactor	0:34	Spatially Segregated MOF Bioreactor	0:34	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	2	22	theme	designed	328:335	arg1	glycans					368:374	artificially designed multienzyme pathways to access glycans	315:374	artificially designed multienzyme pathways to access glycans	315:374	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	0	23	theme	Versatile	44:52	arg1	Assembly					74:81	Versatile Modular Glycoenzyme Assembly	44:81	Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction	44:126	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	4	24	theme	donor	752:756	arg1	modules					722:728	the enzyme modules	711:728	the enzyme modules	711:728	By changing the enzyme modules, a series of glycosyl donor, disaccharides, oligosaccharides, and polysaccharides bearing cofactor regeneration were efficiently prepared.
36926810	4	24	theme	donor	752:756	arg1	series					733:738	a series	731:738	a series of glycosyl donor	731:756	By changing the enzyme modules, a series of glycosyl donor, disaccharides, oligosaccharides, and polysaccharides bearing cofactor regeneration were efficiently prepared.
36926810	2	25	theme	enzyme	254:259	arg1	stability					261:269	poor enzyme stability	249:269	poor enzyme stability	249:269	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	5	26	theme	substrate	951:959	arg1	concentration					961:973	high substrate concentration	946:973	high substrate concentration	946:973	This bioreactor was further successfully applied to the reaction system with high substrate concentration to demonstrate its industrial potential.
36926810	2	27	theme	poor	249:252	arg1	stability					261:269	poor enzyme stability	249:269	poor enzyme stability	249:269	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	5	28	theme	reaction	925:932	arg1	system					934:939	the reaction system	921:939	the reaction system with high substrate concentration to demonstrate its industrial potential	921:1013	This bioreactor was further successfully applied to the reaction system with high substrate concentration to demonstrate its industrial potential.
36926810	0	29	theme	Glycoenzyme	62:72	arg1	Assembly					74:81	Versatile Modular Glycoenzyme Assembly	44:81	Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction	44:126	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	6	30	theme	immobilization	1040:1053	arg1	platform					1055:1062	This robust multienzyme immobilization platform	1016:1062	This robust multienzyme immobilization platform	1016:1062	This robust multienzyme immobilization platform should serve to promote the enzymatic synthesis of more complex glycans.
36926810	3	31	theme	outside	617:623	arg1	particles					595:603	compartmentalized MOF particles	573:603	compartmentalized MOF particles	573:603	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	1	32	theme	multienzyme	133:143	arg1	cascade					145:151	The multienzyme cascade	129:151	The multienzyme cascade	129:151	The multienzyme cascade has received growing attention to obtain structurally defined glycans in vitro.
36926810	0	33	theme	Modular	54:60	arg1	Assembly					74:81	Versatile Modular Glycoenzyme Assembly	44:81	Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction	44:126	Spatially Segregated MOF Bioreactor Enables Versatile Modular Glycoenzyme Assembly for Hierarchical Glycan Library Construction.
36926810	6	34	theme	multienzyme	1028:1038	arg1	platform					1055:1062	This robust multienzyme immobilization platform	1016:1062	This robust multienzyme immobilization platform	1016:1062	This robust multienzyme immobilization platform should serve to promote the enzymatic synthesis of more complex glycans.
36926810	3	35	theme	immobilization	512:525	arg1	platform					527:534	a universal immobilization platform	500:534	a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions	500:696	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	3	36	theme	inside	606:611	arg1	particles					595:603	compartmentalized MOF particles	573:603	compartmentalized MOF particles	573:603	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	5	37	with	system	934:939	arg1	concentration					961:973	high substrate concentration	946:973	high substrate concentration	946:973	This bioreactor was further successfully applied to the reaction system with high substrate concentration to demonstrate its industrial potential.
36926810	5	38	theme	industrial	994:1003	arg1	potential					1005:1013	its industrial potential	990:1013	its industrial potential	990:1013	This bioreactor was further successfully applied to the reaction system with high substrate concentration to demonstrate its industrial potential.
36926810	2	39	theme	low	275:277	arg1	compatibility					279:291	low compatibility	275:291	low compatibility	275:291	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	2	40	theme	access	361:366	arg1	glycans					368:374	artificially designed multienzyme pathways to access glycans	315:374	artificially designed multienzyme pathways to access glycans	315:374	However, due to poor enzyme stability and low compatibility between glycoenzymes, artificially designed multienzyme pathways to access glycans are often inefficient.
36926810	6	41	theme	glycans	1128:1134	arg1	synthesis					1102:1110	the enzymatic synthesis	1088:1110	the enzymatic synthesis of more complex glycans	1088:1134	This robust multienzyme immobilization platform should serve to promote the enzymatic synthesis of more complex glycans.
36926810	1	42	theme	growing	166:172	arg1	attention					174:182	growing attention to obtain structurally defined glycans in vitro	166:230	growing attention to obtain structurally defined glycans in vitro	166:230	The multienzyme cascade has received growing attention to obtain structurally defined glycans in vitro.
36926810	6	43	theme	complex	1120:1126	arg1	glycans					1128:1134	more complex glycans	1115:1134	more complex glycans	1115:1134	This robust multienzyme immobilization platform should serve to promote the enzymatic synthesis of more complex glycans.
36926810	3	44	theme	undesired	653:661	arg1	interference					663:674	the undesired interference	649:674	the undesired interference	649:674	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36926810	3	45	theme	multiple	548:555	arg1	glycoenzymes					557:568	multiple glycoenzymes	548:568	multiple glycoenzymes	548:568	Herein, based on the strategy "Modular-Enzymes Assembly by Spatial Segregation" (MASS), we developed a universal immobilization platform to assemble multiple glycoenzymes in compartmentalized MOF particles, inside and outside, significantly reducing the undesired interference and cross-inhibitions.
36356363	0	0	theme	hypoglycemic	75:86	arg1	properties					88:97	the structural, antioxidant and hypoglycemic properties	43:97	the structural, antioxidant and hypoglycemic properties of red pitaya	43:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	7	1	theme	chief	1264:1268	arg1	composition					1204:1214	monosaccharide composition	1189:1214	monosaccharide composition	1189:1214	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	1	theme	chief	1264:1268	arg1	weight					1230:1235	molecular weight	1220:1235	molecular weight	1220:1235	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	1	theme	chief	1264:1268	arg1	factors					1270:1276	two chief factors	1260:1276	two chief factors affecting the bioactivity of pitaya stem polysaccharides	1260:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	5	2	theme	hypoglycemic	871:882	arg1	properties					884:893	better antioxidant and hypoglycemic properties	848:893	better antioxidant and hypoglycemic properties	848:893	Polysaccharide obtained by hot water showed better antioxidant and hypoglycemic properties than that of the other polysaccharides.
36356363	6	3	theme	water-alkaline	1009:1022	arg1	extractions					1024:1034	alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions	961:1034	alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions	961:1034	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	7	4	theme	molecular	1220:1228	arg1	composition					1204:1214	monosaccharide composition	1189:1214	monosaccharide composition	1189:1214	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	4	theme	molecular	1220:1228	arg1	weight					1230:1235	molecular weight	1220:1235	molecular weight	1220:1235	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	4	theme	molecular	1220:1228	arg1	factors					1270:1276	two chief factors	1260:1276	two chief factors affecting the bioactivity of pitaya stem polysaccharides	1260:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	3	5	dep	showed	626:631	arg1	had					653:655	had	653:655	showed six polysaccharides had similar glycosyl types	626:678	Nuclear magnetic resonance spectroscopy showed six polysaccharides had similar glycosyl types.
36356363	2	6	theme	hypoglycemic	530:541	arg1	properties					543:552	antioxidant and hypoglycemic properties	514:552	antioxidant and hypoglycemic properties	514:552	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	7	theme	pitaya	557:562	arg1	polysaccharides					569:583	pitaya stem polysaccharides	557:583	pitaya stem polysaccharides	557:583	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	0	8	from	Effects	0:6	arg1	properties					88:97	the structural, antioxidant and hypoglycemic properties	43:97	the structural, antioxidant and hypoglycemic properties of red pitaya	43:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	1	9	theme	chemical	280:287	arg1	characteristics					289:303	their chemical characteristics	274:303	their chemical characteristics	274:303	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	5	10	theme	hot	831:833	arg1	water					835:839	hot water	831:839	hot water	831:839	Polysaccharide obtained by hot water showed better antioxidant and hypoglycemic properties than that of the other polysaccharides.
36356363	4	11	theme	electron	690:697	arg1	microscopy					699:708	Scanning electron microscopy	681:708	Scanning electron microscopy	681:708	Scanning electron microscopy exhibited the surface morphology of the extracted six polysaccharides differed significantly.
36356363	3	12	theme	Nuclear	586:592	arg1	resonance					603:611	Nuclear magnetic resonance	586:611	Nuclear magnetic resonance spectroscopy	586:624	Nuclear magnetic resonance spectroscopy showed six polysaccharides had similar glycosyl types.
36356363	0	13	theme	pitaya	106:111	arg1	properties					88:97	the structural, antioxidant and hypoglycemic properties	43:97	the structural, antioxidant and hypoglycemic properties of red pitaya	43:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	6	14	theme	ultrasonic	990:999	arg1	alkaline					961:968	alkaline	961:968	alkaline	961:968	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	7	15	theme	stem	1314:1317	arg1	polysaccharides					1319:1333	pitaya stem polysaccharides	1307:1333	pitaya stem polysaccharides	1307:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	2	16	from	effects	368:374	arg1	properties					543:552	antioxidant and hypoglycemic properties	514:552	antioxidant and hypoglycemic properties	514:552	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	16	from	effects	368:374	arg1	features					501:508	the structural features	486:508	the structural features	486:508	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	6	17	theme	hot	1153:1155	arg1	extraction					1163:1172	hot water extraction	1153:1172	hot water extraction	1153:1172	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	0	18	theme	red	102:104	arg1	pitaya					106:111	red pitaya	102:111	red pitaya	102:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	7	19	theme	polysaccharides	1240:1254	arg1	composition					1204:1214	monosaccharide composition	1189:1214	monosaccharide composition	1189:1214	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	19	theme	polysaccharides	1240:1254	arg1	weight					1230:1235	molecular weight	1220:1235	molecular weight	1220:1235	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	19	theme	polysaccharides	1240:1254	arg1	factors					1270:1276	two chief factors	1260:1276	two chief factors affecting the bioactivity of pitaya stem polysaccharides	1260:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	6	20	theme	alkaline	961:968	arg1	extractions					1024:1034	alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions	961:1034	alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions	961:1034	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	5	21	theme	other	912:916	arg1	polysaccharides					918:932	the other polysaccharides	908:932	the other polysaccharides	908:932	Polysaccharide obtained by hot water showed better antioxidant and hypoglycemic properties than that of the other polysaccharides.
36356363	4	22	theme	surface	724:730	arg1	morphology					732:741	the surface morphology	720:741	the surface morphology of the extracted six polysaccharides differed significantly	720:801	Scanning electron microscopy exhibited the surface morphology of the extracted six polysaccharides differed significantly.
36356363	2	23	theme	water-alkaline	456:469	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	23	theme	water-alkaline	456:469	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	6	24	theme	enzymatic	979:987	arg1	alkaline					961:968	alkaline	961:968	alkaline	961:968	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	6	25	from	structure	1124:1132	arg1	comparison					1137:1146	comparison	1137:1146	comparison with hot water extraction	1137:1172	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	7	26	theme	polysaccharides	1319:1333	arg1	bioactivity					1292:1302	the bioactivity	1288:1302	the bioactivity of pitaya stem polysaccharides	1288:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	2	27	theme	hot	452:454	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	27	theme	hot	452:454	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	28	theme	water	401:405	arg1	effects					368:374	the effects	364:374	the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides	364:583	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	0	29	theme	extraction	21:30	arg1	methods					32:38	different extraction methods	11:38	different extraction methods	11:38	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	6	30	theme	polysaccharides	1082:1096	arg1	degradation					1067:1077	the degradation	1063:1077	the degradation of polysaccharides	1063:1096	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	3	31	theme	magnetic	594:601	arg1	resonance					603:611	Nuclear magnetic resonance	586:611	Nuclear magnetic resonance spectroscopy	586:624	Nuclear magnetic resonance spectroscopy showed six polysaccharides had similar glycosyl types.
36356363	1	32	theme	polysaccharides	207:221	arg1	microstructures					188:202	microstructures	188:202	microstructures	188:202	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	1	32	theme	polysaccharides	207:221	arg1	compositions					171:182	compositions	171:182	compositions	171:182	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	0	33	theme	different	11:19	arg1	methods					32:38	different extraction methods	11:38	different extraction methods	11:38	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	3	34	theme	resonance	603:611	arg1	spectroscopy					613:624	Nuclear magnetic resonance spectroscopy	586:624	Nuclear magnetic resonance spectroscopy	586:624	Nuclear magnetic resonance spectroscopy showed six polysaccharides had similar glycosyl types.
36356363	2	35	theme	enzymatic	426:434	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	35	theme	enzymatic	426:434	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	36	theme	structural	490:499	arg1	features					501:508	the structural features	486:508	the structural features	486:508	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	37	theme	polysaccharides	569:583	arg1	properties					543:552	antioxidant and hypoglycemic properties	514:552	antioxidant and hypoglycemic properties	514:552	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	37	theme	polysaccharides	569:583	arg1	features					501:508	the structural features	486:508	the structural features	486:508	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	6	38	theme	acidic	971:976	arg1	alkaline					961:968	alkaline	961:968	alkaline	961:968	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	6	39	with	comparison	1137:1146	arg1	extraction					1163:1172	hot water extraction	1153:1172	hot water extraction	1153:1172	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	6	40	contain	have	1036:1039	arg1	extractions					1024:1034	alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions	961:1034	alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions	961:1034	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	6	40	contain	have	1036:1039	arg2	influences					1049:1058	various influences	1041:1058	various influences	1041:1058	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	0	41	theme	methods	32:38	arg1	Effects					0:6	Effects	0:6	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya	0:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	2	42	theme	stem	564:567	arg1	polysaccharides					569:583	pitaya stem polysaccharides	557:583	pitaya stem polysaccharides	557:583	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	6	43	theme	major	1118:1122	arg1	structure					1124:1132	the major structure	1114:1132	the major structure in comparison with hot water extraction	1114:1172	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	3	44	theme	similar	657:663	arg1	types					674:678	similar glycosyl types	657:678	similar glycosyl types	657:678	Nuclear magnetic resonance spectroscopy showed six polysaccharides had similar glycosyl types.
36356363	2	45	theme	acidic	418:423	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	45	theme	acidic	418:423	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	0	46	theme	structural	47:56	arg1	properties					88:97	the structural, antioxidant and hypoglycemic properties	43:97	the structural, antioxidant and hypoglycemic properties of red pitaya	43:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	5	47	theme	antioxidant	855:865	arg1	properties					884:893	better antioxidant and hypoglycemic properties	848:893	better antioxidant and hypoglycemic properties	848:893	Polysaccharide obtained by hot water showed better antioxidant and hypoglycemic properties than that of the other polysaccharides.
36356363	1	48	dep	compositions	171:182	arg1	the					167:169	the	167:169	the	167:169	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	7	49	theme	monosaccharide	1189:1202	arg1	composition					1204:1214	monosaccharide composition	1189:1214	monosaccharide composition	1189:1214	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	49	theme	monosaccharide	1189:1202	arg1	weight					1230:1235	molecular weight	1220:1235	molecular weight	1220:1235	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	7	49	theme	monosaccharide	1189:1202	arg1	factors					1270:1276	two chief factors	1260:1276	two chief factors affecting the bioactivity of pitaya stem polysaccharides	1260:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	6	50	theme	hot	1005:1007	arg1	alkaline					961:968	alkaline	961:968	alkaline	961:968	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	1	51	from	effects	263:269	arg1	bioactivites					309:320	bioactivites	309:320	bioactivites	309:320	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	1	51	from	effects	263:269	arg1	characteristics					289:303	their chemical characteristics	274:303	their chemical characteristics	274:303	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	6	52	theme	various	1041:1047	arg1	influences					1049:1058	various influences	1041:1058	various influences	1041:1058	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	4	53	theme	extracted	750:758	arg1	polysaccharides					764:778	the extracted six polysaccharides	746:778	the extracted six polysaccharides differed significantly	746:801	Scanning electron microscopy exhibited the surface morphology of the extracted six polysaccharides differed significantly.
36356363	4	54	theme	polysaccharides	764:778	arg1	morphology					732:741	the surface morphology	720:741	the surface morphology of the extracted six polysaccharides differed significantly	720:801	Scanning electron microscopy exhibited the surface morphology of the extracted six polysaccharides differed significantly.
36356363	1	55	theme	favorable	237:245	arg1	effects					263:269	favorable and unfavorable effects	237:269	favorable and unfavorable effects on their chemical characteristics and bioactivites	237:320	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	1	56	theme	Processing	134:143	arg1	conditions					145:154	Processing conditions	134:154	Processing conditions	134:154	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	7	57	theme	pitaya	1307:1312	arg1	polysaccharides					1319:1333	pitaya stem polysaccharides	1307:1333	pitaya stem polysaccharides	1307:1333	Additionally, monosaccharide composition and molecular weight of polysaccharides are two chief factors affecting the bioactivity of pitaya stem polysaccharides.
36356363	0	58	theme	antioxidant	59:69	arg1	properties					88:97	the structural, antioxidant and hypoglycemic properties	43:97	the structural, antioxidant and hypoglycemic properties of red pitaya	43:111	Effects of different extraction methods on the structural, antioxidant and hypoglycemic properties of red pitaya stem polysaccharide.
36356363	6	59	theme	water	1157:1161	arg1	extraction					1163:1172	hot water extraction	1153:1172	hot water extraction	1153:1172	These data suggested that alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions have various influences on the degradation of polysaccharides without varying the major structure in comparison with hot water extraction.
36356363	3	60	theme	glycosyl	665:672	arg1	types					674:678	similar glycosyl types	657:678	similar glycosyl types	657:678	Nuclear magnetic resonance spectroscopy showed six polysaccharides had similar glycosyl types.
36356363	4	61	theme	Scanning	681:688	arg1	microscopy					699:708	Scanning electron microscopy	681:708	Scanning electron microscopy	681:708	Scanning electron microscopy exhibited the surface morphology of the extracted six polysaccharides differed significantly.
36356363	2	62	theme	hot	397:399	arg1	alkaline					408:415	alkaline	408:415	alkaline	408:415	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	62	theme	hot	397:399	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	62	theme	hot	397:399	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	1	63	theme	unfavorable	251:261	arg1	effects					263:269	favorable and unfavorable effects	237:269	favorable and unfavorable effects on their chemical characteristics and bioactivites	237:320	Processing conditions can change the compositions and microstructures of polysaccharides, resulting in favorable and unfavorable effects on their chemical characteristics and bioactivites.
36356363	2	64	theme	antioxidant	514:524	arg1	properties					543:552	antioxidant and hypoglycemic properties	514:552	antioxidant and hypoglycemic properties	514:552	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	65	theme	ultrasonic	437:446	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	65	theme	ultrasonic	437:446	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	66	theme	used	392:395	arg1	alkaline					408:415	alkaline	408:415	alkaline	408:415	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	66	theme	used	392:395	arg1	water					401:405	the commonly used hot water	379:405	the commonly used hot water	379:405	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
36356363	2	66	theme	used	392:395	arg1	extractions					471:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	acidic, enzymatic, ultrasonic and hot water-alkaline extractions	418:481	Here, this study comparatively evaluated the effects of the commonly used hot water, alkaline, acidic, enzymatic, ultrasonic and hot water-alkaline extractions on the structural features and antioxidant and hypoglycemic properties of pitaya stem polysaccharides.
35850273	7	0	theme	healthy	1130:1136	arg1	foods					1138:1142	healthy foods	1130:1142	healthy foods	1130:1142	The results lay good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods.
35850273	1	1	theme	protein	160:166	arg1	source					198:203	an excellent source	185:203	an excellent source of emulsifier	185:217	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	1	1	theme	protein	160:166	arg1	WPI					177:179	WPI	177:179	WPI	177:179	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	1	1	theme	protein	160:166	arg1	isolate					168:174	Whey protein isolate	155:174	Whey protein isolate (WPI)	155:180	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	7	2	theme	bioactive	1070:1078	arg1	polysaccharides					1080:1094	natural bioactive polysaccharides	1062:1094	natural bioactive polysaccharides	1062:1094	The results lay good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods.
35850273	0	3	theme	oxidative	101:109	arg1	stability					111:119	the oxidative stability	97:119	the oxidative stability of whey protein isolate emulsion	97:152	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	5	4	theme	WPI-RTFP	727:734	arg1	emulsion					736:743	WPI-RTFP emulsion	727:743	WPI-RTFP emulsion	727:743	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	6	5	theme	oxidative	897:905	arg1	stability					907:915	better oxidative stability	890:915	better oxidative stability	890:915	Furthermore, the emulsion coated by conjugates demonstrated better oxidative stability than WPI with less peroxides produced after accelerated oxidation for 7 days.
35850273	2	6	theme	Rosa	321:324	arg1	RTFP					366:369	RTFP	366:369	RTFP	366:369	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	2	6	theme	Rosa	321:324	arg1	polysaccharides					349:363	Rosa roxburghii Tratt fruit polysaccharides	321:363	Rosa roxburghii Tratt fruit polysaccharides (RTFP)	321:370	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	3	7	theme	electrophoresis	465:479	arg1	profile					481:487	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile	419:487	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile	419:487	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile confirmed the formation of WPI-RTFP conjugates.
35850273	5	8	theme	emulsion	736:743	arg1	3.5-fold					750:757	3.5-fold	750:757	3.5-fold	750:757	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	5	8	theme	emulsion	736:743	arg1	activity					691:698	the antioxidant activity	675:698	the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion	675:743	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	6	9	theme	better	890:895	arg1	stability					907:915	better oxidative stability	890:915	better oxidative stability	890:915	Furthermore, the emulsion coated by conjugates demonstrated better oxidative stability than WPI with less peroxides produced after accelerated oxidation for 7 days.
35850273	2	10	theme	Maillard	375:382	arg1	reaction					384:391	Maillard reaction	375:391	Maillard reaction	375:391	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	3	11	theme	conjugates	525:534	arg1	formation					503:511	the formation	499:511	the formation of WPI-RTFP conjugates	499:534	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile confirmed the formation of WPI-RTFP conjugates.
35850273	1	12	from	emulsion	274:281	arg1	unstable					262:269	unstable	262:269	unstable	262:269	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	3	13	theme	WPI-RTFP	516:523	arg1	conjugates					525:534	WPI-RTFP conjugates	516:534	WPI-RTFP conjugates	516:534	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile confirmed the formation of WPI-RTFP conjugates.
35850273	5	14	theme	WPI-RTFP	703:710	arg1	conjugates					712:721	WPI-RTFP conjugates	703:721	WPI-RTFP conjugates	703:721	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	5	15	theme	WPI	802:804	arg1	emulsion					806:813	WPI emulsion	802:813	WPI emulsion	802:813	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	1	16	from	unstable	262:269	arg1	emulsion					274:281	emulsion	274:281	emulsion	274:281	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	2	17	theme	fruit	343:347	arg1	RTFP					366:369	RTFP	366:369	RTFP	366:369	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	2	17	theme	fruit	343:347	arg1	polysaccharides					349:363	Rosa roxburghii Tratt fruit polysaccharides	321:363	Rosa roxburghii Tratt fruit polysaccharides (RTFP)	321:370	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	2	18	theme	optimum	399:405	arg1	conditions					407:416	optimum conditions	399:416	optimum conditions	399:416	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	4	19	theme	fluorescence	551:562	arg1	spectrum					564:571	The intrinsic fluorescence spectrum	537:571	The intrinsic fluorescence spectrum	537:571	The intrinsic fluorescence spectrum, CD and FT-IR indicated that the structure of WPI was affected after glycated with RTFP.
35850273	0	20	theme	protein	129:135	arg1	emulsion					145:152	whey protein isolate emulsion	124:152	whey protein isolate emulsion	124:152	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	0	21	theme	bioactive	19:27	arg1	polysaccharide					29:42	bioactive polysaccharide	19:42	bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit	19:84	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	7	22	theme	natural	1062:1068	arg1	polysaccharides					1080:1094	natural bioactive polysaccharides	1062:1094	natural bioactive polysaccharides	1062:1094	The results lay good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods.
35850273	0	23	theme	whey	124:127	arg1	emulsion					145:152	whey protein isolate emulsion	124:152	whey protein isolate emulsion	124:152	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	1	24	theme	excellent	188:196	arg1	source					198:203	an excellent source	185:203	an excellent source of emulsifier	185:217	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	1	24	theme	excellent	188:196	arg1	isolate					168:174	Whey protein isolate	155:174	Whey protein isolate (WPI)	155:180	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	6	25	theme	accelerated	961:971	arg1	oxidation					973:981	accelerated oxidation	961:981	accelerated oxidation for 7 days	961:992	Furthermore, the emulsion coated by conjugates demonstrated better oxidative stability than WPI with less peroxides produced after accelerated oxidation for 7 days.
35850273	0	26	theme	emulsion	145:152	arg1	stability					111:119	the oxidative stability	97:119	the oxidative stability of whey protein isolate emulsion	97:152	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	5	27	theme	conjugates	712:721	arg1	3.5-fold					750:757	3.5-fold	750:757	3.5-fold	750:757	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	5	27	theme	conjugates	712:721	arg1	activity					691:698	the antioxidant activity	675:698	the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion	675:743	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	7	28	from	application	1115:1125	arg1	foods					1138:1142	healthy foods	1130:1142	healthy foods	1130:1142	The results lay good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods.
35850273	0	29	theme	isolate	137:143	arg1	emulsion					145:152	whey protein isolate emulsion	124:152	whey protein isolate emulsion	124:152	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	5	30	from	addition	665:672	arg1	activity					691:698	the antioxidant activity	675:698	the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion	675:743	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	5	30	from	addition	665:672	arg1	3.5-fold					750:757	3.5-fold	750:757	3.5-fold	750:757	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	0	31	theme	roxburghii	63:72	arg1	fruit					80:84	Rosa roxburghii Tratt fruit	58:84	Rosa roxburghii Tratt fruit	58:84	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	7	32	theme	protein	1051:1057	arg1	modification					1035:1046	the modification	1031:1046	the modification of protein by natural bioactive polysaccharides	1031:1094	The results lay good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods.
35850273	3	33	theme	sulfate-polyacrylamide	438:459	arg1	electrophoresis					465:479	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis	419:479	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile	419:487	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile confirmed the formation of WPI-RTFP conjugates.
35850273	0	34	theme	Rosa	58:61	arg1	fruit					80:84	Rosa roxburghii Tratt fruit	58:84	Rosa roxburghii Tratt fruit	58:84	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	4	35	theme	intrinsic	541:549	arg1	spectrum					564:571	The intrinsic fluorescence spectrum	537:571	The intrinsic fluorescence spectrum	537:571	The intrinsic fluorescence spectrum, CD and FT-IR indicated that the structure of WPI was affected after glycated with RTFP.
35850273	4	36	with	glycated	642:649	arg1	RTFP					656:659	RTFP	656:659	RTFP	656:659	The intrinsic fluorescence spectrum, CD and FT-IR indicated that the structure of WPI was affected after glycated with RTFP.
35850273	7	37	theme	good	1011:1014	arg1	foundation					1016:1025	good foundation	1011:1025	good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods	1011:1142	The results lay good foundation for the modification of protein by natural bioactive polysaccharides as well as for the application in healthy foods.
35850273	6	38	theme	less	931:934	arg1	peroxides					936:944	less peroxides	931:944	less peroxides produced after accelerated oxidation for 7 days	931:992	Furthermore, the emulsion coated by conjugates demonstrated better oxidative stability than WPI with less peroxides produced after accelerated oxidation for 7 days.
35850273	0	39	with	Glycosylation	0:12	arg1	polysaccharide					29:42	bioactive polysaccharide	19:42	bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit	19:84	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	3	40	theme	gel	461:463	arg1	electrophoresis					465:479	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis	419:479	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile	419:487	The sodium dodecyl sulfate-polyacrylamide gel electrophoresis profile confirmed the formation of WPI-RTFP conjugates.
35850273	1	41	theme	emulsifier	208:217	arg1	source					198:203	an excellent source	185:203	an excellent source of emulsifier	185:217	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	1	41	theme	emulsifier	208:217	arg1	isolate					168:174	Whey protein isolate	155:174	Whey protein isolate (WPI)	155:180	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	5	42	theme	antioxidant	679:689	arg1	3.5-fold					750:757	3.5-fold	750:757	3.5-fold	750:757	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	5	42	theme	antioxidant	679:689	arg1	activity					691:698	the antioxidant activity	675:698	the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion	675:743	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	5	43	from	3.5-fold	750:757	arg1	addition					665:672	addition	665:672	addition	665:672	In addition, the antioxidant activity of WPI-RTFP conjugates and WPI-RTFP emulsion were 3.5-fold and 1.5-fold stronger than that of WPI and WPI emulsion, respectively.
35850273	1	44	theme	Whey	155:158	arg1	source					198:203	an excellent source	185:203	an excellent source of emulsifier	185:217	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	1	44	theme	Whey	155:158	arg1	WPI					177:179	WPI	177:179	WPI	177:179	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	1	44	theme	Whey	155:158	arg1	isolate					168:174	Whey protein isolate	155:174	Whey protein isolate (WPI)	155:180	Whey protein isolate (WPI) is an excellent source of emulsifier, but its function is limited for oxidative unstable in emulsion.
35850273	2	45	theme	Tratt	337:341	arg1	RTFP					366:369	RTFP	366:369	RTFP	366:369	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	2	45	theme	Tratt	337:341	arg1	polysaccharides					349:363	Rosa roxburghii Tratt fruit polysaccharides	321:363	Rosa roxburghii Tratt fruit polysaccharides (RTFP)	321:370	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	4	46	theme	WPI	619:621	arg1	structure					606:614	the structure	602:614	the structure of WPI	602:621	The intrinsic fluorescence spectrum, CD and FT-IR indicated that the structure of WPI was affected after glycated with RTFP.
35850273	0	47	theme	Tratt	74:78	arg1	fruit					80:84	Rosa roxburghii Tratt fruit	58:84	Rosa roxburghii Tratt fruit	58:84	Glycosylation with bioactive polysaccharide obtained from Rosa roxburghii Tratt fruit to enhance the oxidative stability of whey protein isolate emulsion.
35850273	2	48	theme	roxburghii	326:335	arg1	RTFP					366:369	RTFP	366:369	RTFP	366:369	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35850273	2	48	theme	roxburghii	326:335	arg1	polysaccharides					349:363	Rosa roxburghii Tratt fruit polysaccharides	321:363	Rosa roxburghii Tratt fruit polysaccharides (RTFP)	321:370	In this study, WPI was glycated with Rosa roxburghii Tratt fruit polysaccharides (RTFP) by Maillard reaction under optimum conditions.
35549295	3	0	theme	structure	340:348	arg1	assembly					305:312	a one-pot assembly	295:312	a one-pot assembly of the core trisaccharide structure	295:348	aureofaciens UCM B-306 via a one-pot assembly of the core trisaccharide structure.
35549295	0	1	theme	Pseudomonas	71:81	arg1	subsp					96:100	Pseudomonas chlororaphis subsp	71:100	Pseudomonas chlororaphis subsp	71:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	0	2	theme	subsp	96:100	arg1	Polysaccharide					53:66	O-Specific Polysaccharide	42:66	O-Specific Polysaccharide of Pseudomonas chlororaphis subsp	42:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	5	3	theme	repeating	580:588	arg1	units					590:594	two repeating units	576:594	two repeating units	576:594	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	5	4	theme	units	590:594	arg1	syntheses					563:571	The total syntheses	553:571	The total syntheses of two repeating units	553:594	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	0	5	theme	Total	0:4	arg1	Synthesis					6:14	Total Synthesis	0:14	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp	0:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	3	6	theme	aureofaciens	268:279	arg1	UCM					281:283	aureofaciens UCM	268:283	aureofaciens UCM	268:283	aureofaciens UCM B-306 via a one-pot assembly of the core trisaccharide structure.
35549295	4	7	theme	2-amino-2-deoxy-d-galacturonic	441:470	arg1	acid					472:475	2-amino-2-deoxy-d-galacturonic acid	441:475	2-amino-2-deoxy-d-galacturonic acid	441:475	The rare-sugar-containing trisaccharide-repeating units are comprised of d-bacillosamine, 2-amino-2-deoxy-d-galacturonic acid or amide, and d-rhamnose units linked through three consecutive α-linkages.
35549295	2	8	theme	units	227:231	arg1	syntheses					186:194	the first total syntheses	170:194	the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp	170:265	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	3	9	theme	one-pot	297:303	arg1	assembly					305:312	a one-pot assembly	295:312	a one-pot assembly of the core trisaccharide structure	295:348	aureofaciens UCM B-306 via a one-pot assembly of the core trisaccharide structure.
35549295	5	10	theme	steps	671:675	arg1	sequence					656:663	a longest-linear sequence	639:663	a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively	639:721	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	2	11	dep	Pseudomonas	236:246	arg1	chlororaphis					248:259	chlororaphis	248:259	chlororaphis	248:259	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	0	12	dep	Pseudomonas	71:81	arg1	chlororaphis					83:94	chlororaphis	83:94	chlororaphis	83:94	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	5	13	theme	total	557:561	arg1	syntheses					563:571	The total syntheses	553:571	The total syntheses of two repeating units	553:594	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	0	14	theme	Units	33:37	arg1	Synthesis					6:14	Total Synthesis	0:14	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp	0:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	5	15	from	%	692:692	arg1	sequence					656:663	a longest-linear sequence	639:663	a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively	639:721	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	2	16	theme	total	180:184	arg1	syntheses					186:194	the first total syntheses	170:194	the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp	170:265	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	2	17	theme	subsp	261:265	arg1	units					227:231	the trisaccharide-repeating units	199:231	the trisaccharide-repeating units of Pseudomonas chlororaphis subsp	199:265	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	0	18	theme	Repeating	23:31	arg1	Units					33:37	the Repeating Units	19:37	the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp	19:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	2	19	theme	first	174:178	arg1	syntheses					186:194	the first total syntheses	170:194	the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp	170:265	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	0	20	theme	O-Specific	42:51	arg1	Polysaccharide					53:66	O-Specific Polysaccharide	42:66	O-Specific Polysaccharide of Pseudomonas chlororaphis subsp	42:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	3	21	theme	core	321:324	arg1	structure					340:348	the core trisaccharide structure	317:348	the core trisaccharide structure	317:348	aureofaciens UCM B-306 via a one-pot assembly of the core trisaccharide structure.
35549295	4	22	theme	consecutive	529:539	arg1	α-linkages					541:550	three consecutive α-linkages	523:550	three consecutive α-linkages	523:550	The rare-sugar-containing trisaccharide-repeating units are comprised of d-bacillosamine, 2-amino-2-deoxy-d-galacturonic acid or amide, and d-rhamnose units linked through three consecutive α-linkages.
35549295	2	23	theme	Pseudomonas	236:246	arg1	subsp					261:265	Pseudomonas chlororaphis subsp	236:265	Pseudomonas chlororaphis subsp	236:265	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	4	24	theme	trisaccharide-repeating	377:399	arg1	units					401:405	The rare-sugar-containing trisaccharide-repeating units	351:405	The rare-sugar-containing trisaccharide-repeating units	351:405	The rare-sugar-containing trisaccharide-repeating units are comprised of d-bacillosamine, 2-amino-2-deoxy-d-galacturonic acid or amide, and d-rhamnose units linked through three consecutive α-linkages.
35549295	5	25	dep	%	692:692	arg1	yields					702:707	yields	702:707	4.4% overall yields	689:707	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	3	26	theme	trisaccharide	326:338	arg1	structure					340:348	the core trisaccharide structure	317:348	the core trisaccharide structure	317:348	aureofaciens UCM B-306 via a one-pot assembly of the core trisaccharide structure.
35549295	4	27	theme	d-rhamnose	491:500	arg1	units					502:506	d-rhamnose units	491:506	d-rhamnose units linked through three consecutive α-linkages	491:550	The rare-sugar-containing trisaccharide-repeating units are comprised of d-bacillosamine, 2-amino-2-deoxy-d-galacturonic acid or amide, and d-rhamnose units linked through three consecutive α-linkages.
35549295	5	28	from	steps	671:675	arg1	%					683:683	5.8%	680:683	5.8%	680:683	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	5	28	from	steps	671:675	arg1	%					692:692	4.4% overall yields	689:707	4.4% overall yields	689:707	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	2	29	theme	trisaccharide-repeating	203:225	arg1	units					227:231	the trisaccharide-repeating units	199:231	the trisaccharide-repeating units of Pseudomonas chlororaphis subsp	199:265	Herein we report the first total syntheses of the trisaccharide-repeating units of Pseudomonas chlororaphis subsp.
35549295	5	30	theme	longest-linear	641:654	arg1	sequence					656:663	a longest-linear sequence	639:663	a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively	639:721	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	1	31	theme	One-Pot	130:136	arg1	Glycosylation					138:150	One-Pot Glycosylation	130:150	One-Pot Glycosylation	130:150	aureofaciens UCM B-306 via One-Pot Glycosylation.
35549295	5	32	from	sequence	656:663	arg1	%					683:683	5.8%	680:683	5.8%	680:683	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	5	32	from	sequence	656:663	arg1	%					692:692	4.4% overall yields	689:707	4.4% overall yields	689:707	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	5	33	from	%	683:683	arg1	sequence					656:663	a longest-linear sequence	639:663	a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively	639:721	The total syntheses of two repeating units were completed starting from d-mannose via a longest-linear sequence of 27 steps in 5.8% and 4.4% overall yields, respectively.
35549295	0	34	theme	Polysaccharide	53:66	arg1	Units					33:37	the Repeating Units	19:37	the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp	19:100	Total Synthesis of the Repeating Units of O-Specific Polysaccharide of Pseudomonas chlororaphis subsp.
35549295	4	35	theme	rare-sugar-containing	355:375	arg1	units					401:405	The rare-sugar-containing trisaccharide-repeating units	351:405	The rare-sugar-containing trisaccharide-repeating units	351:405	The rare-sugar-containing trisaccharide-repeating units are comprised of d-bacillosamine, 2-amino-2-deoxy-d-galacturonic acid or amide, and d-rhamnose units linked through three consecutive α-linkages.
37173020	0	0	from	interactions	14:25	arg1	pattern-recognition					30:48	pattern-recognition	30:48	pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides	30:118	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	1	1	theme	plant	190:194	arg1	walls					201:205	terrestrial plant cell walls	178:205	terrestrial plant cell walls	178:205	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	1	2	theme	new	273:275	arg1	modulator					291:299	a new innate immune modulator	271:299	a new innate immune modulator	271:299	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	1	3	theme	cell	196:199	arg1	walls					201:205	terrestrial plant cell walls	178:205	terrestrial plant cell walls	178:205	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	1	4	theme	innate	277:282	arg1	modulator					291:299	a new innate immune modulator	271:299	a new innate immune modulator	271:299	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	0	5	from	Mechanisms	0:9	arg1	pattern-recognition					30:48	pattern-recognition	30:48	pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides	30:118	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	3	6	theme	common	599:604	arg1	glycostructures					606:620	common glycostructures	599:620	common glycostructures of pectic heteropolysaccharides (HPSs)	599:659	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	4	7	theme	glycosyl	724:731	arg1	residues					733:740	glycosyl residues	724:740	glycosyl residues derived from pectic HPS	724:764	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	1	8	theme	immune	284:289	arg1	modulator					291:299	a new innate immune modulator	271:299	a new innate immune modulator	271:299	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	0	9	theme	Toll-like	123:131	arg1	receptor					133:140	Toll-like receptor 4	123:142	Toll-like receptor 4	123:142	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	4	10	theme	molecular	825:833	arg1	modeling					835:842	molecular modeling	825:842	molecular modeling of representative pectic segments	825:876	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	3	11	from	interactions	559:570	arg1	pattern-recognition					575:593	pattern-recognition	575:593	pattern-recognition	575:593	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	2	12	theme	bioactive	311:319	arg1	polysaccharides					321:335	Numerous bioactive polysaccharides	302:335	Numerous bioactive polysaccharides associated with pectin	302:358	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	1	13	theme	modulator	291:299	arg1	attention					236:244	research attention	227:244	research attention	227:244	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	1	13	theme	modulator	291:299	arg1	source					261:266	a promising source	249:266	a promising source of a new innate immune modulator	249:299	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	6	14	theme	multivalent	1183:1193	arg1	aspects					1203:1209	the non-canonical and multivalent binding aspects	1161:1209	the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation	1161:1251	We experimentally demonstrated that pectic HPS exhibits the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation.
37173020	2	15	theme	Numerous	302:309	arg1	polysaccharides					321:335	Numerous bioactive polysaccharides	302:335	Numerous bioactive polysaccharides associated with pectin	302:358	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	6	16	theme	non-canonical	1165:1177	arg1	aspects					1203:1209	the non-canonical and multivalent binding aspects	1161:1209	the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation	1161:1251	We experimentally demonstrated that pectic HPS exhibits the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation.
37173020	2	17	theme	immunological	426:438	arg1	action					440:445	their immunological action	420:445	their immunological action	420:445	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	5	18	theme	carbohydrate	1005:1016	arg1	recognition					1018:1028	carbohydrate recognition	1005:1028	carbohydrate recognition	1005:1028	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	6	19	theme	binding	1195:1201	arg1	aspects					1203:1209	the non-canonical and multivalent binding aspects	1161:1209	the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation	1161:1251	We experimentally demonstrated that pectic HPS exhibits the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation.
37173020	5	20	theme	structural	883:892	arg1	investigation					894:906	structural investigation	883:906	structural investigation	883:906	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	0	21	from	pattern-recognition	30:48	arg1	Mechanisms					0:9	Mechanisms	0:9	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.	0:143	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	7	22	theme	macrophages	1413:1423	arg1	activation					1399:1408	phenotypic activation	1388:1408	phenotypic activation of macrophages	1388:1423	Furthermore, we showed that pectic HPSs were selectively clustered with TLR4 during endocytosis, inducing downstream signals to cause phenotypic activation of macrophages.
37173020	3	23	theme	heteropolysaccharides	632:652	arg1	glycostructures					606:620	common glycostructures	599:620	common glycostructures of pectic heteropolysaccharides (HPSs)	599:659	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	7	24	theme	pectic	1282:1287	arg1	HPSs					1289:1292	pectic HPSs	1282:1292	pectic HPSs	1282:1292	Furthermore, we showed that pectic HPSs were selectively clustered with TLR4 during endocytosis, inducing downstream signals to cause phenotypic activation of macrophages.
37173020	5	25	theme	TLR4	956:959	arg1	repeats					945:951	leucine-rich repeats	932:951	leucine-rich repeats of TLR4	932:959	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	5	26	theme	repeats	945:951	arg1	motif					995:999	a binding motif	985:999	a binding motif for carbohydrate recognition	985:1028	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	5	26	theme	repeats	945:951	arg1	concavity					919:927	the inner concavity	909:927	the inner concavity of leucine-rich repeats of TLR4	909:959	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	8	27	theme	pattern	1482:1488	arg1	recognition					1490:1500	the pattern recognition	1478:1500	the pattern recognition of pectic HPS	1478:1514	Overall, we have presented a better explanation for the pattern recognition of pectic HPS and further proposed an approach to understand the interaction between complex carbohydrates and proteins.
37173020	4	28	theme	residues	733:740	arg1	similarity					710:719	The compositional similarity	692:719	The compositional similarity of glycosyl residues derived from pectic HPS	692:764	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	8	29	theme	pectic	1505:1510	arg1	HPS					1512:1514	pectic HPS	1505:1514	pectic HPS	1505:1514	Overall, we have presented a better explanation for the pattern recognition of pectic HPS and further proposed an approach to understand the interaction between complex carbohydrates and proteins.
37173020	1	30	theme	research	227:234	arg1	attention					236:244	research attention	227:244	research attention	227:244	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	1	30	theme	research	227:234	arg1	source					261:266	a promising source	249:266	a promising source of a new innate immune modulator	249:299	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	0	31	theme	interactions	14:25	arg1	Mechanisms					0:9	Mechanisms	0:9	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.	0:143	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	4	32	theme	representative	847:860	arg1	segments					869:876	representative pectic segments	847:876	representative pectic segments	847:876	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	8	33	theme	HPS	1512:1514	arg1	recognition					1490:1500	the pattern recognition	1478:1500	the pattern recognition of pectic HPS	1478:1514	Overall, we have presented a better explanation for the pattern recognition of pectic HPS and further proposed an approach to understand the interaction between complex carbohydrates and proteins.
37173020	3	34	theme	pectic	625:630	arg1	HPSs					655:658	HPSs	655:658	HPSs	655:658	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	3	34	theme	pectic	625:630	arg1	heteropolysaccharides					632:652	pectic heteropolysaccharides	625:652	pectic heteropolysaccharides (HPSs)	625:659	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	4	35	theme	pectic	755:760	arg1	HPS					762:764	pectic HPS	755:764	pectic HPS	755:764	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	5	36	theme	subsequent	1035:1044	arg1	simulations					1046:1056	subsequent simulations	1035:1056	subsequent simulations	1035:1056	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	6	37	theme	receptor	1233:1240	arg1	activation					1242:1251	receptor activation	1233:1251	receptor activation	1233:1251	We experimentally demonstrated that pectic HPS exhibits the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation.
37173020	6	38	theme	pectic	1141:1146	arg1	HPS					1148:1150	pectic HPS	1141:1150	pectic HPS	1141:1150	We experimentally demonstrated that pectic HPS exhibits the non-canonical and multivalent binding aspects for TLR4 resulting in receptor activation.
37173020	2	39	theme	pectin	508:513	arg1	complexity					476:485	the complexity	472:485	the complexity	472:485	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	2	39	theme	pectin	508:513	arg1	heterogeneity					491:503	heterogeneity	491:503	heterogeneity	491:503	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	8	40	theme	complex	1587:1593	arg1	carbohydrates					1595:1607	complex carbohydrates	1587:1607	complex carbohydrates	1587:1607	Overall, we have presented a better explanation for the pattern recognition of pectic HPS and further proposed an approach to understand the interaction between complex carbohydrates and proteins.
37173020	3	41	theme	Toll-like	664:672	arg1	TLRs					685:688	TLRs	685:688	TLRs	685:688	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	3	41	theme	Toll-like	664:672	arg1	receptors					674:682	Toll-like receptors	664:682	Toll-like receptors (TLRs)	664:689	Herein, we systematically investigated the interactions in pattern-recognition for common glycostructures of pectic heteropolysaccharides (HPSs) by Toll-like receptors (TLRs).
37173020	5	42	theme	leucine-rich	932:943	arg1	repeats					945:951	leucine-rich repeats	932:951	leucine-rich repeats of TLR4	932:959	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	2	43	theme	action	440:445	arg1	mechanism					407:415	the general mechanism	395:415	the general mechanism of their immunological action	395:445	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	0	44	theme	glycostructures	60:74	arg1	pattern-recognition					30:48	pattern-recognition	30:48	pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides	30:118	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	4	45	attach	derived	742:748	arg1	HPS					762:764	pectic HPS	755:764	pectic HPS	755:764	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	4	45	attach	derived	742:748	arg2	residues					733:740	glycosyl residues	724:740	glycosyl residues derived from pectic HPS	724:764	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	2	46	gly	heterogeneity	491:503	arg1	pectin					508:513	pectin	508:513	pectin	508:513	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	1	47	theme	Complex	145:151	arg1	pectin					153:158	Complex pectin	145:158	Complex pectin	145:158	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	0	48	theme	common	53:58	arg1	glycostructures					60:74	common glycostructures	53:74	common glycostructures across pectin-derived heteropolysaccharides	53:118	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	7	49	theme	downstream	1360:1369	arg1	signals					1371:1377	downstream signals	1360:1377	downstream signals	1360:1377	Furthermore, we showed that pectic HPSs were selectively clustered with TLR4 during endocytosis, inducing downstream signals to cause phenotypic activation of macrophages.
37173020	0	50	link	pectin-derived	83:96	arg1	heteropolysaccharides					98:118	pectin-derived heteropolysaccharides	83:118	pectin-derived heteropolysaccharides	83:118	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	5	51	theme	binding	987:993	arg1	motif					995:999	a binding motif	985:999	a binding motif for carbohydrate recognition	985:1028	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	5	51	theme	binding	987:993	arg1	concavity					919:927	the inner concavity	909:927	the inner concavity of leucine-rich repeats of TLR4	909:959	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	5	52	theme	binding	1072:1078	arg1	modes					1080:1084	the binding modes	1068:1084	the binding modes	1068:1084	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	4	53	theme	segments	869:876	arg1	modeling					835:842	molecular modeling	825:842	molecular modeling of representative pectic segments	825:876	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	4	54	dep	systematic	794:803	arg1	reviews					805:811	reviews	805:811	reviews	805:811	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	1	55	theme	promising	251:259	arg1	attention					236:244	research attention	227:244	research attention	227:244	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	1	55	theme	promising	251:259	arg1	source					261:266	a promising source	249:266	a promising source of a new innate immune modulator	249:299	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37173020	4	56	theme	pectic	862:867	arg1	segments					869:876	representative pectic segments	847:876	representative pectic segments	847:876	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	7	57	theme	phenotypic	1388:1397	arg1	activation					1399:1408	phenotypic activation	1388:1408	phenotypic activation of macrophages	1388:1423	Furthermore, we showed that pectic HPSs were selectively clustered with TLR4 during endocytosis, inducing downstream signals to cause phenotypic activation of macrophages.
37173020	8	58	theme	better	1455:1460	arg1	explanation					1462:1472	a better explanation	1453:1472	a better explanation for the pattern recognition of pectic HPS	1453:1514	Overall, we have presented a better explanation for the pattern recognition of pectic HPS and further proposed an approach to understand the interaction between complex carbohydrates and proteins.
37173020	0	59	theme	pectin-derived	83:96	arg1	heteropolysaccharides					98:118	pectin-derived heteropolysaccharides	83:118	pectin-derived heteropolysaccharides	83:118	Mechanisms of interactions in pattern-recognition of common glycostructures across pectin-derived heteropolysaccharides by Toll-like receptor 4.
37173020	4	60	theme	compositional	696:708	arg1	similarity					710:719	The compositional similarity	692:719	The compositional similarity of glycosyl residues derived from pectic HPS	692:764	The compositional similarity of glycosyl residues derived from pectic HPS was confirmed by conducting systematic reviews, leading to molecular modeling of representative pectic segments.
37173020	5	61	theme	inner	913:917	arg1	motif					995:999	a binding motif	985:999	a binding motif for carbohydrate recognition	985:1028	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	5	61	theme	inner	913:917	arg1	concavity					919:927	the inner concavity	909:927	the inner concavity of leucine-rich repeats of TLR4	909:959	Via structural investigation, the inner concavity of leucine-rich repeats of TLR4 was predicted to act as a binding motif for carbohydrate recognition, and subsequent simulations predicted the binding modes and conformations.
37173020	2	62	theme	general	399:405	arg1	mechanism					407:415	the general mechanism	395:415	the general mechanism of their immunological action	395:445	Numerous bioactive polysaccharides associated with pectin are newly reported every year, but the general mechanism of their immunological action remains unclear owing to the complexity and heterogeneity of pectin.
37173020	1	63	theme	terrestrial	178:188	arg1	walls					201:205	terrestrial plant cell walls	178:205	terrestrial plant cell walls	178:205	Complex pectin, originating from terrestrial plant cell walls has been attracting research attention as a promising source of a new innate immune modulator.
37060669	5	0	theme	bacterial	814:822	arg1	strains					824:830	fourteen bacterial strains	805:830	fourteen bacterial strains	805:830	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	8	1	theme	human	1197:1201	arg1	oligosaccharides					1208:1223	fucosylated human milk oligosaccharides	1185:1223	fucosylated human milk oligosaccharides	1185:1223	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	7	2	theme	coli	1025:1028	arg1	proliferation					996:1008	the proliferation	992:1008	the proliferation of Escherichia coli	992:1028	Moreover, GFG could not promote the proliferation of Escherichia coli.
37060669	6	3	theme	short-chain	935:945	arg1	acids					953:957	more short-chain fatty acids	930:957	more short-chain fatty acids	930:957	In comparison with 2'-FL, GFG could be utilized by more beneficial bacteria, leading to generate more short-chain fatty acids.
37060669	8	4	theme	fucosylated	1185:1195	arg1	oligosaccharides					1208:1223	fucosylated human milk oligosaccharides	1185:1223	fucosylated human milk oligosaccharides	1185:1223	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	5	5	theme	prebiotic	686:694	arg1	experiments					696:706	In vitro prebiotic experiments	677:706	In vitro prebiotic experiments	677:706	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	6	6	theme	fatty	947:951	arg1	acids					953:957	more short-chain fatty acids	930:957	more short-chain fatty acids	930:957	In comparison with 2'-FL, GFG could be utilized by more beneficial bacteria, leading to generate more short-chain fatty acids.
37060669	2	7	from	M1	368:369	arg1	products					306:313	the acidolysis products	291:313	the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1	291:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	2	7	from	M1	368:369	arg1	exopolysaccharides					318:335	exopolysaccharides	318:335	exopolysaccharides from Clavibacter michiganensis M1	318:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	5	8	from	differences	739:749	arg1	utilization					758:768	the utilization	754:768	the utilization of three selected carbohydrates by fourteen bacterial strains	754:830	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	8	9	theme	milk	1203:1206	arg1	oligosaccharides					1208:1223	fucosylated human milk oligosaccharides	1185:1223	fucosylated human milk oligosaccharides	1185:1223	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	4	10	theme	resonance	518:526	arg1	analysis					528:535	Nuclear magnetic resonance analysis	501:535	Nuclear magnetic resonance analysis	501:535	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	6	11	with	comparison	836:845	arg1	2'-FL					852:856	2'-FL	852:856	2'-FL	852:856	In comparison with 2'-FL, GFG could be utilized by more beneficial bacteria, leading to generate more short-chain fatty acids.
37060669	0	12	theme	prebiotic	130:138	arg1	activity					140:147	its prebiotic activity	126:147	its prebiotic activity	126:147	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	4	13	theme	magnetic	509:516	arg1	resonance					518:526	Nuclear magnetic resonance	501:526	Nuclear magnetic resonance analysis	501:535	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	2	14	theme	acidolysis	295:304	arg1	products					306:313	the acidolysis products	291:313	the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1	291:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	1	15	theme	various	207:213	arg1	fields					215:220	various fields	207:220	various fields	207:220	Fucosylated oligosaccharides have promising prospects in various fields.
37060669	5	16	theme	carbohydrates	788:800	arg1	utilization					758:768	the utilization	754:768	the utilization of three selected carbohydrates by fourteen bacterial strains	754:830	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	8	17	theme	preparation	1095:1105	arg1	method					1107:1112	its preparation method	1091:1112	its preparation method	1091:1112	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	6	18	used	utilized	872:879	arg2	GFG					859:861	GFG	859:861	GFG	859:861	In comparison with 2'-FL, GFG could be utilized by more beneficial bacteria, leading to generate more short-chain fatty acids.
37060669	5	19	theme	selected	779:786	arg1	carbohydrates					788:800	three selected carbohydrates	773:800	three selected carbohydrates	773:800	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	1	20	contain	have	179:182	arg2	prospects					194:202	promising prospects	184:202	promising prospects	184:202	Fucosylated oligosaccharides have promising prospects in various fields.
37060669	1	20	contain	have	179:182	arg1	oligosaccharides					162:177	Fucosylated oligosaccharides	150:177	Fucosylated oligosaccharides	150:177	Fucosylated oligosaccharides have promising prospects in various fields.
37060669	3	21	theme	Structural	372:381	arg1	characterization					383:398	Structural characterization	372:398	Structural characterization	372:398	Structural characterization demonstrated that GFG consists of glucose, galactose, and fucose, with a molecular weight of 488 Da.
37060669	2	22	theme	michiganensis	354:366	arg1	M1					368:369	Clavibacter michiganensis M1	342:369	Clavibacter michiganensis M1	342:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	6	23	theme	more	930:933	arg1	acids					953:957	more short-chain fatty acids	930:957	more short-chain fatty acids	930:957	In comparison with 2'-FL, GFG could be utilized by more beneficial bacteria, leading to generate more short-chain fatty acids.
37060669	0	24	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a novel fucosylated trisaccharide	0:63	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	5	25	theme	In	677:678	arg1	experiments					696:706	In vitro prebiotic experiments	677:706	In vitro prebiotic experiments	677:706	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	8	26	theme	novel	1053:1057	arg1	oligosaccharide					1071:1085	a novel fucosylated oligosaccharide	1051:1085	a novel fucosylated oligosaccharide	1051:1085	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	2	27	theme	Clavibacter	342:352	arg1	M1					368:369	Clavibacter michiganensis M1	342:369	Clavibacter michiganensis M1	342:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	8	28	theme	fucosylated	1059:1069	arg1	oligosaccharide					1071:1085	a novel fucosylated oligosaccharide	1051:1085	a novel fucosylated oligosaccharide	1051:1085	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	5	29	dep	In	677:678	arg1	vitro					680:684	vitro	680:684	vitro	680:684	In vitro prebiotic experiments were conducted to evaluate the differences in the utilization of three selected carbohydrates by fourteen bacterial strains.
37060669	0	30	theme	activity	140:147	arg1	exopolysaccharides					89:106	bacterial exopolysaccharides	79:106	bacterial exopolysaccharides	79:106	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	0	30	theme	activity	140:147	arg1	evaluation					112:121	evaluation	112:121	evaluation of its prebiotic activity	112:147	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	2	31	theme	exopolysaccharides	318:335	arg1	products					306:313	the acidolysis products	291:313	the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1	291:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	4	32	theme	monosaccharide	649:662	arg1	composition					664:674	the same monosaccharide composition	640:674	the same monosaccharide composition	640:674	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	0	33	theme	fucosylated	39:49	arg1	trisaccharide					51:63	a novel fucosylated trisaccharide	31:63	a novel fucosylated trisaccharide	31:63	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	3	34	theme	molecular	473:481	arg1	weight					483:488	a molecular weight	471:488	a molecular weight of 488 Da	471:498	Structural characterization demonstrated that GFG consists of glucose, galactose, and fucose, with a molecular weight of 488 Da.
37060669	0	35	theme	novel	33:37	arg1	trisaccharide					51:63	a novel fucosylated trisaccharide	31:63	a novel fucosylated trisaccharide	31:63	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	4	36	theme	Nuclear	501:507	arg1	resonance					518:526	Nuclear magnetic resonance	501:526	Nuclear magnetic resonance analysis	501:535	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	3	37	theme	488 Da	493:498	arg1	weight					483:488	a molecular weight	471:488	a molecular weight of 488 Da	471:498	Structural characterization demonstrated that GFG consists of glucose, galactose, and fucose, with a molecular weight of 488 Da.
37060669	2	38	gly	fucosylated	240:250	arg1	GFG					267:269	GFG	267:269	GFG	267:269	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	2	38	gly	fucosylated	240:250	arg1	trisaccharide					252:264	a fucosylated trisaccharide	238:264	a fucosylated trisaccharide (GFG)	238:270	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	4	39	theme	different	558:566	arg1	structure					568:576	a different structure	556:576	a different structure	556:576	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	6	40	theme	beneficial	889:898	arg1	bacteria					900:907	more beneficial bacteria	884:907	more beneficial bacteria	884:907	In comparison with 2'-FL, GFG could be utilized by more beneficial bacteria, leading to generate more short-chain fatty acids.
37060669	0	41	theme	trisaccharide	51:63	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a novel fucosylated trisaccharide	0:63	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	8	42	theme	obtained	1123:1130	arg1	trisaccharide					1132:1144	the obtained trisaccharide	1119:1144	the obtained trisaccharide	1119:1144	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	8	42	theme	obtained	1123:1130	arg1	candidate					1171:1179	a promising candidate	1159:1179	a promising candidate for fucosylated human milk oligosaccharides	1159:1223	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	2	43	theme	fucosylated	240:250	arg1	GFG					267:269	GFG	267:269	GFG	267:269	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	2	43	theme	fucosylated	240:250	arg1	trisaccharide					252:264	a fucosylated trisaccharide	238:264	a fucosylated trisaccharide (GFG)	238:270	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	8	44	gly	fucosylated	1185:1195	arg1	oligosaccharides					1208:1223	fucosylated human milk oligosaccharides	1185:1223	fucosylated human milk oligosaccharides	1185:1223	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	8	45	gly	fucosylated	1059:1069	arg1	oligosaccharide					1071:1085	a novel fucosylated oligosaccharide	1051:1085	a novel fucosylated oligosaccharide	1051:1085	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	8	46	theme	promising	1161:1169	arg1	trisaccharide					1132:1144	the obtained trisaccharide	1119:1144	the obtained trisaccharide	1119:1144	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	8	46	theme	promising	1161:1169	arg1	candidate					1171:1179	a promising candidate	1159:1179	a promising candidate for fucosylated human milk oligosaccharides	1159:1223	This work describes a novel fucosylated oligosaccharide and its preparation method, and the obtained trisaccharide may serve as a promising candidate for fucosylated human milk oligosaccharides.
37060669	1	47	theme	Fucosylated	150:160	arg1	oligosaccharides					162:177	Fucosylated oligosaccharides	150:177	Fucosylated oligosaccharides	150:177	Fucosylated oligosaccharides have promising prospects in various fields.
37060669	0	48	gly	fucosylated	39:49	arg1	trisaccharide					51:63	a novel fucosylated trisaccharide	31:63	a novel fucosylated trisaccharide	31:63	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	0	49	theme	bacterial	79:87	arg1	exopolysaccharides					89:106	bacterial exopolysaccharides	79:106	bacterial exopolysaccharides	79:106	Structural characterization of a novel fucosylated trisaccharide prepared from bacterial exopolysaccharides and evaluation of its prebiotic activity.
37060669	4	50	contain	has	552:554	arg1	it					549:550	it	549:550	it	549:550	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	4	50	contain	has	552:554	arg2	structure					568:576	a different structure	556:576	a different structure	556:576	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	2	51	from	products	306:313	arg1	M1					368:369	Clavibacter michiganensis M1	342:369	Clavibacter michiganensis M1	342:369	In this study, a fucosylated trisaccharide (GFG) was separated from the acidolysis products of exopolysaccharides from Clavibacter michiganensis M1.
37060669	4	52	theme	same	644:647	arg1	composition					664:674	the same monosaccharide composition	640:674	the same monosaccharide composition	640:674	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	4	53	contain	have	635:638	arg2	composition					664:674	the same monosaccharide composition	640:674	the same monosaccharide composition	640:674	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	4	53	contain	have	635:638	arg1	they					630:633	they	630:633	they	630:633	Nuclear magnetic resonance analysis showed that it has a different structure than that of 2'-fucosyllactose (2'-FL), even though they have the same monosaccharide composition.
37060669	1	54	theme	promising	184:192	arg1	prospects					194:202	promising prospects	184:202	promising prospects	184:202	Fucosylated oligosaccharides have promising prospects in various fields.
35763488	5	0	theme	TCR-pMHC	765:772	arg1	study					807:811	a case study	800:811	a case study	800:811	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	5	0	theme	TCR-pMHC	765:772	arg1	pair					774:777	a TCR-pMHC pair	763:777	a TCR-pMHC pair found in melanoma	763:795	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	6	1	dep	duration	1246:1253	arg1	the					1242:1244	the	1242:1244	the	1242:1244	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	6	2	dep	TCR	1143:1145	arg1	the					1139:1141	the	1139:1141	the	1139:1141	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	2	3	theme	computational	342:354	arg1	model					356:360	A fully glycosylated computational model	321:360	A fully glycosylated computational model of the TCR bound to the pMHC	321:389	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	2	4	from	effects	423:429	arg1	kinetics					464:471	dissociation kinetics	451:471	dissociation kinetics from the pMHC	451:485	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	5	5	gly	N-glycosylation	842:856	arg1	TCR-pMHC					865:872	the TCR-pMHC	861:872	the TCR-pMHC	861:872	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	2	6	theme	glycosylated	329:340	arg1	model					356:360	A fully glycosylated computational model	321:360	A fully glycosylated computational model of the TCR bound to the pMHC	321:389	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	3	7	from	effects	509:515	arg1	strength					553:560	TCR-pMHC bond strength	539:560	TCR-pMHC bond strength	539:560	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	6	8	theme	overall	1186:1192	arg1	strength					1199:1206	the overall bond strength	1182:1206	the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1182:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	6	9	theme	energetic	1259:1267	arg1	strength					1269:1276	energetic strength	1259:1276	energetic strength	1259:1276	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	4	10	theme	molecules	746:754	arg1	activity					719:726	the activity	715:726	the activity of several immune molecules	715:754	N-glycosylation is a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules.
35763488	6	11	theme	TCR-pMHC	1215:1222	arg1	complex					1224:1230	the TCR-pMHC complex	1211:1230	the TCR-pMHC complex	1211:1230	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	4	12	theme	immune	739:744	arg1	molecules					746:754	several immune molecules	731:754	several immune molecules	731:754	N-glycosylation is a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules.
35763488	6	13	theme	glycan-glycan	1075:1087	arg1	interactions					1089:1100	weak glycan-protein or glycan-glycan interactions	1052:1100	weak glycan-protein or glycan-glycan interactions	1052:1100	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	7	14	theme	Ramaswamy	1478:1486	arg1	Sarma					1491:1495	Ramaswamy H. Sarma	1478:1495	Ramaswamy H. Sarma	1478:1495	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	7	15	gly	N-glycosylation	1327:1341	arg1	experimental					1441:1452	experimental	1441:1452	experimental	1441:1452	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	7	15	gly	N-glycosylation	1327:1341	arg1	computational					1423:1435	computational	1423:1435	computational	1423:1435	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	1	16	theme	histocompatibility	167:184	arg1	pMHC					195:198	pMHC	195:198	pMHC	195:198	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	1	16	theme	histocompatibility	167:184	arg1	complex					186:192	peptide-major histocompatibility complex	153:192	peptide-major histocompatibility complex (pMHC)	153:199	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	0	17	theme	N-glycosylation	38:52	arg1	effects					54:60	N-glycosylation effects	38:60	N-glycosylation effects	38:60	A molecular dynamics investigation of N-glycosylation effects on T-cell receptor kinetics.
35763488	5	18	theme	bond	923:926	arg1	lifetime					928:935	the bond lifetime	919:935	the bond lifetime	919:935	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	6	19	from	increase	1170:1177	arg1	strength					1199:1206	the overall bond strength	1182:1206	the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1182:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	6	20	theme	weak	1052:1055	arg1	interactions					1089:1100	weak glycan-protein or glycan-glycan interactions	1052:1100	weak glycan-protein or glycan-glycan interactions	1052:1100	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	7	21	theme	TCR-pMHC	1374:1381	arg1	bond					1383:1386	the TCR-pMHC bond	1370:1386	the TCR-pMHC bond	1370:1386	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	6	22	theme	pMHC	1151:1154	arg1	structure					1126:1134	the equilibrated structure	1109:1134	the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1109:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	5	23	located	found	779:783	arg1	melanoma					788:795	melanoma	788:795	melanoma	788:795	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	5	23	located	found	779:783	arg2	pair					774:777	a TCR-pMHC pair	763:777	a TCR-pMHC pair found in melanoma	763:795	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	5	23	located	found	779:783	arg2	study					807:811	a case study	800:811	a case study	800:811	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	3	24	theme	TCR-pMHC	539:546	arg1	strength					553:560	TCR-pMHC bond strength	539:560	TCR-pMHC bond strength	539:560	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	2	25	theme	TCR	369:371	arg1	model					356:360	A fully glycosylated computational model	321:360	A fully glycosylated computational model of the TCR bound to the pMHC	321:389	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	5	26	theme	case	802:805	arg1	study					807:811	a case study	800:811	a case study	800:811	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	5	26	theme	case	802:805	arg1	pair					774:777	a TCR-pMHC pair	763:777	a TCR-pMHC pair found in melanoma	763:795	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	6	27	theme	complex	1224:1230	arg1	strength					1199:1206	the overall bond strength	1182:1206	the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1182:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	1	28	theme	binding	95:101	arg1	interaction					103:113	The binding interaction	91:113	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC)	91:199	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	4	29	theme	sugar	670:674	arg1	moieties					676:683	sugar moieties	670:683	sugar moieties	670:683	N-glycosylation is a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules.
35763488	4	30	theme	several	731:737	arg1	molecules					746:754	several immune molecules	731:754	several immune molecules	731:754	N-glycosylation is a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules.
35763488	3	31	theme	N-glycosylation	520:534	arg1	effects					509:515	the effects	505:515	the effects of N-glycosylation on TCR-pMHC bond strength	505:560	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	5	32	theme	Contacts	999:1006	arg1	number					956:961	the number	952:961	the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond	952:1036	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	3	33	theme	bond	548:551	arg1	strength					553:560	TCR-pMHC bond strength	539:560	TCR-pMHC bond strength	539:560	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	1	34	theme	peptide-major	153:165	arg1	pMHC					195:198	pMHC	195:198	pMHC	195:198	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	1	34	theme	peptide-major	153:165	arg1	complex					186:192	peptide-major histocompatibility complex	153:192	peptide-major histocompatibility complex (pMHC)	153:199	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	2	35	theme	dissociation	451:462	arg1	kinetics					464:471	dissociation kinetics	451:471	dissociation kinetics from the pMHC	451:485	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	2	36	gly	glycosylated	329:340	arg1	model					356:360	A fully glycosylated computational model	321:360	A fully glycosylated computational model of the TCR bound to the pMHC	321:389	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	3	37	theme	steered	568:574	arg1	simulations					594:604	steered molecular dynamic simulations	568:604	steered molecular dynamic simulations	568:604	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	5	38	theme	TCR-pMHC	865:872	arg1	N-glycosylation					842:856	N-glycosylation	842:856	N-glycosylation of the TCR-pMHC	842:872	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	6	39	theme	glycan-protein	1057:1070	arg1	interactions					1089:1100	weak glycan-protein or glycan-glycan interactions	1052:1100	weak glycan-protein or glycan-glycan interactions	1052:1100	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	7	40	theme	H.	1488:1489	arg1	Sarma					1491:1495	Ramaswamy H. Sarma	1478:1495	Ramaswamy H. Sarma	1478:1495	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	2	41	from	pMHC	482:485	arg1	kinetics					464:471	dissociation kinetics	451:471	dissociation kinetics from the pMHC	451:485	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	3	42	theme	molecular	576:584	arg1	simulations					594:604	steered molecular dynamic simulations	568:604	steered molecular dynamic simulations	568:604	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	4	43	theme	post-translational	628:645	arg1	modification					647:658	a post-translational modification	626:658	a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules	626:754	N-glycosylation is a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules.
35763488	4	43	theme	post-translational	628:645	arg1	N-glycosylation					607:621	N-glycosylation	607:621	N-glycosylation	607:621	N-glycosylation is a post-translational modification that adds sugar moieties to molecules and can modulate the activity of several immune molecules.
35763488	2	44	theme	glycosylation	434:446	arg1	effects					423:429	the effects	419:429	the effects of glycosylation on dissociation kinetics from the pMHC	419:485	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	7	45	theme	important	1352:1360	arg1	role					1362:1365	an important role	1349:1365	an important role	1349:1365	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	1	46	dep	factors	225:231	arg1	unknown					244:250	unknown	244:250	unknown	244:250	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	1	46	dep	factors	225:231	arg1	known					234:238	known	234:238	known	234:238	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	0	47	theme	effects	54:60	arg1	investigation					21:33	investigation	21:33	investigation of N-glycosylation effects on T-cell receptor kinetics	21:88	A molecular dynamics investigation of N-glycosylation effects on T-cell receptor kinetics.
35763488	1	48	theme	glycosylation	294:306	arg1	effects					283:289	effects	283:289	effects of glycosylation	283:306	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	5	49	theme	TCR-pMHC	1024:1031	arg1	bond					1033:1036	the TCR-pMHC bond	1020:1036	the TCR-pMHC bond	1020:1036	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	2	50	gly	glycosylation	434:446	arg1	dissociation					451:462	dissociation kinetics	451:471	dissociation kinetics from the pMHC	451:485	A fully glycosylated computational model of the TCR bound to the pMHC is developed to investigate the effects of glycosylation on dissociation kinetics from the pMHC.
35763488	1	51	theme	T-cell	127:132	arg1	receptor					134:141	the T-cell receptor	123:141	the T-cell receptor (TCR)	123:147	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	1	51	theme	T-cell	127:132	arg1	TCR					144:146	TCR	144:146	TCR	144:146	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	6	52	theme	bond	1194:1197	arg1	strength					1199:1206	the overall bond strength	1182:1206	the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1182:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	5	53	theme	hydrogen	966:973	arg1	bonds					975:979	hydrogen bonds	966:979	hydrogen bonds	966:979	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	6	54	theme	equilibrated	1113:1124	arg1	structure					1126:1134	the equilibrated structure	1109:1134	the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1109:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	6	55	theme	TCR	1143:1145	arg1	structure					1126:1134	the equilibrated structure	1109:1134	the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load	1109:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	1	56	theme	several	217:223	arg1	factors					225:231	several factors	217:231	several factors (known and unknown)	217:251	The binding interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) is modulated by several factors (known and unknown), however, investigations into effects of glycosylation are limited.
35763488	6	57	theme	constant	1284:1291	arg1	load					1293:1296	constant load	1284:1296	constant load	1284:1296	We find that weak glycan-protein or glycan-glycan interactions impact the equilibrated structure of the TCR and pMHC leading to an increase in the overall bond strength of the TCR-pMHC complex including the duration and energetic strength under constant load.
35763488	5	58	theme	bonds	975:979	arg1	number					956:961	the number	952:961	the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond	952:1036	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35763488	3	59	gly	N-glycosylation	520:534	arg1	bond					548:551	TCR-pMHC bond strength	539:560	TCR-pMHC bond strength	539:560	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	7	60	dep	computational	1423:1435	arg1	studies.Communicated					1454:1473	studies.Communicated	1454:1473	studies.Communicated by Ramaswamy H. Sarma	1454:1495	These results indicate that N-glycosylation plays an important role in the TCR-pMHC bond and should be considered in future computational and experimental studies.Communicated by Ramaswamy H. Sarma.
35763488	0	61	theme	receptor	72:79	arg1	kinetics					81:88	T-cell receptor kinetics	65:88	T-cell receptor kinetics	65:88	A molecular dynamics investigation of N-glycosylation effects on T-cell receptor kinetics.
35763488	3	62	theme	dynamic	586:592	arg1	simulations					594:604	steered molecular dynamic simulations	568:604	steered molecular dynamic simulations	568:604	Here, we examine the effects of N-glycosylation on TCR-pMHC bond strength using steered molecular dynamic simulations.
35763488	0	63	theme	T-cell	65:70	arg1	kinetics					81:88	T-cell receptor kinetics	65:88	T-cell receptor kinetics	65:88	A molecular dynamics investigation of N-glycosylation effects on T-cell receptor kinetics.
35763488	0	64	from	investigation	21:33	arg1	kinetics					81:88	T-cell receptor kinetics	65:88	T-cell receptor kinetics	65:88	A molecular dynamics investigation of N-glycosylation effects on T-cell receptor kinetics.
35763488	5	65	theme	Lennard-Jones	985:997	arg1	Contacts					999:1006	Lennard-Jones Contacts	985:1006	Lennard-Jones Contacts	985:1006	Using a TCR-pMHC pair found in melanoma as a case study, our study demonstrates that N-glycosylation of the TCR-pMHC alters the proteins' conformation; increases the bond lifetime; and increases the number of hydrogen bonds and Lennard-Jones Contacts involved in the TCR-pMHC bond.
35713525	0	0	theme	synthases	77:85	arg1	Csh1					88:91	Csh1	88:91	Csh1	88:91	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	0	0	theme	synthases	77:85	arg1	stabilities					57:67	stabilities	57:67	stabilities of MIPC synthases	57:85	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	0	0	theme	synthases	77:85	arg1	activities					42:51	enzyme activities	35:51	enzyme activities	35:51	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	0	0	theme	synthases	77:85	arg1	Sur1/Csg1					97:105	Sur1/Csg1	97:105	Sur1/Csg1	97:105	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	9	1	theme	ectopic	1217:1223	arg1	insertion					1225:1233	ectopic insertion	1217:1233	ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51)	1217:1313	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	11	2	theme	Sur1	1636:1639	arg1	Csh1					1645:1648	Csh1	1645:1648	Csh1	1645:1648	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	2	theme	Sur1	1636:1639	arg1	Sur1					1636:1639	Sur1	1636:1639	Sur1	1636:1639	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	2	theme	Sur1	1636:1639	arg1	domains					1625:1631	essential luminal domains	1607:1631	essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification	1607:1738	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	2	3	theme	Golgi	329:333	arg1	lumen					335:339	the Golgi lumen	325:339	the Golgi lumen	325:339	MIPC is synthesized by 2 redundant enzymes, Sur1/Csg1 and Csh1, in the Golgi lumen.
35713525	7	4	theme	unique	913:918	arg1	structure					932:940	a unique mannan-like structure	911:940	a unique mannan-like structure containing a long backbone of mannose	911:978	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	1	5	theme	Saccharomyces	232:244	arg1	cerevisiae					246:255	Saccharomyces cerevisiae	232:255	Saccharomyces cerevisiae	232:255	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	0	6	theme	MIPC	72:75	arg1	synthases					77:85	MIPC synthases	72:85	MIPC synthases	72:85	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	0	7	from	roles	12:16	arg1	cerevisiae					125:134	Saccharomyces cerevisiae	111:134	Saccharomyces cerevisiae	111:134	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	6	8	contain	carries	720:726	arg1	Sur1					715:718	Sur1	715:718	Sur1	715:718	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	6	8	contain	carries	720:726	arg2	N-glycan					731:738	an N-glycan	728:738	an N-glycan on Asn-224	728:749	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	3	9	from	groups	445:450	arg1	moiety					468:473	the ceramide moiety	455:473	the ceramide moiety	455:473	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	11	10	theme	substrate	1663:1671	arg1	specificity					1673:1683	substrate specificity	1663:1683	substrate specificity	1663:1683	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	10	11	theme	diminished	1440:1449	arg1	stability					1451:1459	the diminished stability	1436:1459	the diminished stability of the Sur1-NST51 mutant protein	1436:1492	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	10	11	theme	diminished	1440:1449	arg1	attributable					1503:1514	attributable	1503:1514	attributable	1503:1514	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	3	12	from	position	413:420	arg1	moiety					468:473	the ceramide moiety	455:473	the ceramide moiety	455:473	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	13	theme	groups	445:450	arg1	position					413:420	position	413:420	position	413:420	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	13	theme	groups	445:450	arg1	number					426:431	number	426:431	number	426:431	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	14	theme	ceramide	459:466	arg1	moiety					468:473	the ceramide moiety	455:473	the ceramide moiety	455:473	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	11	15	theme	luminal	1617:1623	arg1	Csh1					1645:1648	Csh1	1645:1648	Csh1	1645:1648	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	15	theme	luminal	1617:1623	arg1	Sur1					1636:1639	Sur1	1636:1639	Sur1	1636:1639	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	15	theme	luminal	1617:1623	arg1	domains					1625:1631	essential luminal domains	1607:1631	essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification	1607:1738	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	4	16	theme	higher	488:493	arg1	impact					495:500	higher impact	488:500	higher impact	488:500	Sur1 exerts higher impact on synthesis of MIPC-B and MIPC-C than Csh1.
35713525	10	17	theme	Sur1-NST51	1468:1477	arg1	protein					1486:1492	the Sur1-NST51 mutant protein	1464:1492	the Sur1-NST51 mutant protein	1464:1492	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	3	18	dep	subtypes	361:368	arg1	B					374:374	B'	374:375	B'	374:375	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	18	dep	subtypes	361:368	arg1	D-type					388:393	D-type	388:393	D-type	388:393	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	18	dep	subtypes	361:368	arg1	B					378:378	B	378:378	B	378:378	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	18	dep	subtypes	361:368	arg1	subtypes					361:368	5 subtypes	359:368	5 subtypes (A, B', B, C, and D-type)	359:394	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	18	dep	subtypes	361:368	arg1	A					371:371	A	371:371	A	371:371	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	18	dep	subtypes	361:368	arg1	C					381:381	C	381:381	C	381:381	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	19	from	number	426:431	arg1	moiety					468:473	the ceramide moiety	455:473	the ceramide moiety	455:473	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	7	20	theme	mannose	972:978	arg1	backbone					960:967	a long backbone	953:967	a long backbone of mannose	953:978	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	10	21	theme	mutant	1479:1484	arg1	protein					1486:1492	the Sur1-NST51 mutant protein	1464:1492	the Sur1-NST51 mutant protein	1464:1492	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	3	22	theme	hydroxyl	436:443	arg1	groups					445:450	hydroxyl groups	436:450	hydroxyl groups on the ceramide moiety	436:473	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	10	23	theme	potential	1519:1527	arg1	alterations					1540:1550	potential structural alterations	1519:1550	potential structural alterations by the mannan	1519:1564	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	6	24	from	N-glycan	731:738	arg1	Asn-224					743:749	Asn-224	743:749	Asn-224	743:749	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	9	25	with	modification	1341:1352	arg1	mannan					1359:1364	mannan	1359:1364	mannan	1359:1364	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	7	26	theme	intracellular	811:823	arg1	proteins					825:832	intracellular proteins	811:832	intracellular proteins	811:832	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	8	27	theme	Sur1	981:984	arg1	N224Q					986:990	Sur1 N224Q and Csh1 N51Q mutants	981:1012	N224Q	986:990	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	0	28	theme	Pleiotropic	0:10	arg1	roles					12:16	Pleiotropic roles	0:16	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.	0:135	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	3	29	dep	position	413:420	arg1	the					409:411	the	409:411	the	409:411	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	7	30	contain	containing	942:951	arg2	backbone					960:967	a long backbone	953:967	a long backbone of mannose	953:978	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	7	30	contain	containing	942:951	arg1	structure					932:940	a unique mannan-like structure	911:940	a unique mannan-like structure containing a long backbone of mannose	911:978	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	7	31	from	N-glycan	874:881	arg1	Asn-51					886:891	Asn-51	886:891	Asn-51 of Csh1	886:899	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	0	32	theme	N-glycans	21:29	arg1	roles					12:16	Pleiotropic roles	0:16	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.	0:135	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	10	33	theme	structural	1529:1538	arg1	alterations					1540:1550	potential structural alterations	1519:1550	potential structural alterations by the mannan	1519:1564	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	11	34	theme	Csh1	1645:1648	arg1	Csh1					1645:1648	Csh1	1645:1648	Csh1	1645:1648	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	34	theme	Csh1	1645:1648	arg1	Sur1					1636:1639	Sur1	1636:1639	Sur1	1636:1639	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	34	theme	Csh1	1645:1648	arg1	domains					1625:1631	essential luminal domains	1607:1631	essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification	1607:1738	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	1	35	theme	membrane	177:184	arg1	lipid					186:190	a membrane lipid	175:190	a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae	175:255	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	1	35	theme	membrane	177:184	arg1	phosphorylceramide					146:163	Mannosyl phosphorylceramide	137:163	Mannosyl phosphorylceramide (MIPC)	137:170	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	5	36	attach	attached	606:613	arg2	N-glycans					596:604	N-glycans	596:604	N-glycans attached to Sur1 and Csh1	596:630	In this study, we elucidated the roles played by N-glycans attached to Sur1 and Csh1, and dissected the mechanisms underlying substrate recognition by these 2 enzymes.
35713525	5	36	attach	attached	606:613	arg1	Sur1					618:621	Sur1	618:621	Sur1	618:621	In this study, we elucidated the roles played by N-glycans attached to Sur1 and Csh1, and dissected the mechanisms underlying substrate recognition by these 2 enzymes.
35713525	5	36	attach	attached	606:613	arg1	Csh1					627:630	Csh1	627:630	Csh1	627:630	In this study, we elucidated the roles played by N-glycans attached to Sur1 and Csh1, and dissected the mechanisms underlying substrate recognition by these 2 enzymes.
35713525	6	37	dep	carries	720:726	arg1	whereas					752:758	whereas	752:758	whereas	752:758	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	7	38	theme	long	955:958	arg1	backbone					960:967	a long backbone	953:967	a long backbone of mannose	953:978	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	2	39	theme	redundant	283:291	arg1	enzymes					293:299	2 redundant enzymes	281:299	2 redundant enzymes	281:299	MIPC is synthesized by 2 redundant enzymes, Sur1/Csg1 and Csh1, in the Golgi lumen.
35713525	2	39	theme	redundant	283:291	arg1	Csh1					316:319	Csh1	316:319	Csh1	316:319	MIPC is synthesized by 2 redundant enzymes, Sur1/Csg1 and Csh1, in the Golgi lumen.
35713525	2	39	theme	redundant	283:291	arg1	Sur1/Csg1					302:310	Sur1/Csg1	302:310	Sur1/Csg1	302:310	MIPC is synthesized by 2 redundant enzymes, Sur1/Csg1 and Csh1, in the Golgi lumen.
35713525	9	40	theme	protein	1392:1398	arg1	stability					1400:1408	protein stability	1392:1408	protein stability	1392:1408	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	0	41	theme	enzyme	35:40	arg1	activities					42:51	enzyme activities	35:51	enzyme activities	35:51	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	9	42	theme	Sur1	1297:1300	arg1	insertion					1225:1233	ectopic insertion	1217:1233	ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51)	1217:1313	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	11	43	theme	protein	1696:1702	arg1	stabilities					1704:1714	the protein stabilities	1692:1714	the protein stabilities	1692:1714	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	0	44	theme	Saccharomyces	111:123	arg1	cerevisiae					125:134	Saccharomyces cerevisiae	111:134	Saccharomyces cerevisiae	111:134	Pleiotropic roles of N-glycans for enzyme activities and stabilities of MIPC synthases, Csh1 and Sur1/Csg1, in Saccharomyces cerevisiae.
35713525	8	45	theme	MIPC	1074:1077	arg1	subtypes					1079:1086	specific MIPC subtypes	1065:1086	specific MIPC subtypes for each enzyme	1065:1102	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	6	46	contain	has	765:767	arg1	Csh1					760:763	Csh1	760:763	Csh1	760:763	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	6	46	contain	has	765:767	arg2	N-glycans					769:777	N-glycans	769:777	N-glycans	769:777	Sur1 carries an N-glycan on Asn-224, whereas Csh1 has N-glycans on Asn-51 and Asn-247.
35713525	10	47	theme	protein	1486:1492	arg1	stability					1451:1459	the diminished stability	1436:1459	the diminished stability of the Sur1-NST51 mutant protein	1436:1492	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	10	47	theme	protein	1486:1492	arg1	attributable					1503:1514	attributable	1503:1514	attributable	1503:1514	Our results suggest that the diminished stability of the Sur1-NST51 mutant protein could be attributable to potential structural alterations by the mannan.
35713525	11	48	theme	mannan	1720:1725	arg1	modification					1727:1738	mannan modification	1720:1738	mannan modification	1720:1738	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	1	49	from	sphingolipid	216:227	arg1	cerevisiae					246:255	Saccharomyces cerevisiae	232:255	Saccharomyces cerevisiae	232:255	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	7	50	theme	Csh1	896:899	arg1	Asn-51					886:891	Asn-51	886:891	Asn-51 of Csh1	886:899	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	8	51	theme	substrate	1152:1160	arg1	recognition					1162:1172	substrate recognition	1152:1172	substrate recognition	1152:1172	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	5	52	theme	substrate	673:681	arg1	recognition					683:693	substrate recognition	673:693	substrate recognition	673:693	In this study, we elucidated the roles played by N-glycans attached to Sur1 and Csh1, and dissected the mechanisms underlying substrate recognition by these 2 enzymes.
35713525	9	53	theme	N-glycosylation	1241:1255	arg1	NST					1277:1279	NST	1277:1279	NST	1277:1279	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	9	53	theme	N-glycosylation	1241:1255	arg1	sequence					1267:1274	an N-glycosylation consensus sequence	1238:1274	an N-glycosylation consensus sequence (NST)	1238:1280	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	7	54	theme	mannan-like	920:930	arg1	structure					932:940	a unique mannan-like structure	911:940	a unique mannan-like structure containing a long backbone of mannose	911:978	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	9	55	from	codon	1285:1289	arg1	insertion					1225:1233	ectopic insertion	1217:1233	ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51)	1217:1313	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	9	56	theme	consensus	1257:1265	arg1	NST					1277:1279	NST	1277:1279	NST	1277:1279	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	9	56	theme	consensus	1257:1265	arg1	sequence					1267:1274	an N-glycosylation consensus sequence	1238:1274	an N-glycosylation consensus sequence (NST)	1238:1280	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	8	57	theme	Csh1	996:999	arg1	mutants					1006:1012	Sur1 N224Q and Csh1 N51Q mutants	981:1012	mutants	1006:1012	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	11	58	theme	essential	1607:1615	arg1	Csh1					1645:1648	Csh1	1645:1648	Csh1	1645:1648	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	58	theme	essential	1607:1615	arg1	Sur1					1636:1639	Sur1	1636:1639	Sur1	1636:1639	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	11	58	theme	essential	1607:1615	arg1	domains					1625:1631	essential luminal domains	1607:1631	essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification	1607:1738	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	7	59	theme	core-type	849:857	arg1	N-glycans					859:867	core-type N-glycans	849:867	core-type N-glycans	849:867	Although intracellular proteins usually harbor core-type N-glycans, the N-glycan on Asn-51 of Csh1 exhibited a unique mannan-like structure containing a long backbone of mannose.
35713525	9	60	theme	sequence	1267:1274	arg1	insertion					1225:1233	ectopic insertion	1217:1233	ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51)	1217:1313	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	11	61	theme	present	1585:1591	arg1	study					1593:1597	the present study	1581:1597	the present study	1581:1597	Collectively, the present study reveals essential luminal domains of Sur1 and Csh1 that dictate substrate specificity and/or the protein stabilities via mannan modification.
35713525	3	62	from	moiety	468:473	arg1	position					413:420	position	413:420	position	413:420	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	3	62	from	moiety	468:473	arg1	number					426:431	number	426:431	number	426:431	MIPC consists of 5 subtypes (A, B', B, C, and D-type) according to the position and number of hydroxyl groups on the ceramide moiety.
35713525	1	63	theme	complex	208:214	arg1	sphingolipid					216:227	a complex sphingolipid	206:227	a complex sphingolipid in Saccharomyces cerevisiae	206:255	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	9	64	theme	artificial	1330:1339	arg1	modification					1341:1352	an artificial modification	1327:1352	an artificial modification	1327:1352	Moreover, ectopic insertion of an N-glycosylation consensus sequence (NST) at codon 51 of Sur1 (Sur1-NST51) resulted in an artificial modification with mannan, which markedly decreased protein stability.
35713525	8	65	from	decrease	1026:1033	arg1	activity					1042:1049	the activity to synthesize specific MIPC subtypes for each enzyme	1038:1102	the activity to synthesize specific MIPC subtypes for each enzyme	1038:1102	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	4	66	theme	MIPC-C	529:534	arg1	synthesis					505:513	synthesis	505:513	synthesis of MIPC-B and MIPC-C than Csh1	505:544	Sur1 exerts higher impact on synthesis of MIPC-B and MIPC-C than Csh1.
35713525	8	67	theme	catalytic	1188:1196	arg1	domains					1198:1204	their catalytic domains	1182:1204	their catalytic domains	1182:1204	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	4	68	theme	MIPC-B	518:523	arg1	synthesis					505:513	synthesis	505:513	synthesis of MIPC-B and MIPC-C than Csh1	505:544	Sur1 exerts higher impact on synthesis of MIPC-B and MIPC-C than Csh1.
35713525	8	69	theme	N51Q	1001:1004	arg1	mutants					1006:1012	Sur1 N224Q and Csh1 N51Q mutants	981:1012	mutants	1006:1012	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	8	70	theme	specific	1065:1072	arg1	subtypes					1079:1086	specific MIPC subtypes	1065:1086	specific MIPC subtypes for each enzyme	1065:1102	Sur1 N224Q and Csh1 N51Q mutants exhibited a decrease in the activity to synthesize specific MIPC subtypes for each enzyme, suggesting that these N-glycans play a role in substrate recognition through their catalytic domains.
35713525	1	71	theme	Mannosyl	137:144	arg1	lipid					186:190	a membrane lipid	175:190	a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae	175:255	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	1	71	theme	Mannosyl	137:144	arg1	MIPC					166:169	MIPC	166:169	MIPC	166:169	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35713525	1	71	theme	Mannosyl	137:144	arg1	phosphorylceramide					146:163	Mannosyl phosphorylceramide	137:163	Mannosyl phosphorylceramide (MIPC)	137:170	Mannosyl phosphorylceramide (MIPC) is a membrane lipid classified as a complex sphingolipid in Saccharomyces cerevisiae.
35248671	11	0	theme	compounds	1412:1420	arg1	models					1387:1392	Docking models	1379:1392	Docking models of the inhibitory compounds with GnT-V	1379:1431	Docking models of the inhibitory compounds with GnT-V suggested the mechanisms of how these compounds interacted with GnT-V and inhibited its action.
35248671	8	1	theme	synthesized	1054:1064	arg1	compounds					1066:1074	the synthesized compounds	1050:1074	the synthesized compounds	1050:1074	Using this system, we assessed the inhibitory effects of the synthesized compounds on GnT-V and their specificity.
35248671	11	2	theme	Docking	1379:1385	arg1	models					1387:1392	Docking models	1379:1392	Docking models of the inhibitory compounds with GnT-V	1379:1431	Docking models of the inhibitory compounds with GnT-V suggested the mechanisms of how these compounds interacted with GnT-V and inhibited its action.
35248671	12	3	theme	Chemical	1541:1548	arg1	strategy					1605:1612	a promising strategy	1593:1612	a promising strategy to develop selective inhibitors of GnT-V	1593:1653	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	12	3	theme	Chemical	1541:1548	arg1	modification					1550:1561	CONCLUSIONS Chemical modification	1529:1561	CONCLUSIONS Chemical modification of the donor substrate	1529:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	8	4	theme	compounds	1066:1074	arg1	effects					1039:1045	the inhibitory effects	1024:1045	the inhibitory effects of the synthesized compounds on GnT-V and their specificity	1024:1105	Using this system, we assessed the inhibitory effects of the synthesized compounds on GnT-V and their specificity.
35248671	7	5	theme	N-glycan-branching	881:898	arg1	transferases					907:918	all N-glycan-branching GlcNAc transferases	877:918	all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes	877:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	12	6	theme	substrate	1576:1584	arg1	strategy					1605:1612	a promising strategy	1593:1612	a promising strategy to develop selective inhibitors of GnT-V	1593:1653	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	12	6	theme	substrate	1576:1584	arg1	modification					1550:1561	CONCLUSIONS Chemical modification	1529:1561	CONCLUSIONS Chemical modification of the donor substrate	1529:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	3	7	theme	cancer	386:391	arg1	treatment					393:401	cancer treatment	386:401	cancer treatment	386:401	This indicates that specific GnT-V inhibitors may be drug candidates for cancer treatment.
35248671	4	8	theme	GnT-V	420:424	arg1	inhibitors					426:435	novel GnT-V inhibitors	414:435	novel GnT-V inhibitors	414:435	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	11	9	with	models	1387:1392	arg1	GnT-V					1427:1431	GnT-V	1427:1431	GnT-V	1427:1431	Docking models of the inhibitory compounds with GnT-V suggested the mechanisms of how these compounds interacted with GnT-V and inhibited its action.
35248671	7	10	theme	GlcNAc	900:905	arg1	transferases					907:918	all N-glycan-branching GlcNAc transferases	877:918	all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes	877:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	13	11	theme	GENERAL	1656:1662	arg1	SIGNIFICANCE					1664:1675	GENERAL SIGNIFICANCE	1656:1675	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.	1656:1787	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
35248671	4	12	theme	donor	491:495	arg1	UDP-GlcNAc					507:516	the donor substrate UDP-GlcNAc	487:516	the donor substrate UDP-GlcNAc	487:516	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	6	13	theme	hydrophobic	784:794	arg1	groups					796:801	hydrophobic groups	784:801	hydrophobic groups	784:801	METHODS We chemically synthesized 10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups.
35248671	10	14	theme	hydrophobicity	1340:1353	arg1	tolerant					1328:1335	tolerant	1328:1335	tolerant	1328:1335	Compared with other GnTs, these compounds showed a preference for GnT-V, which suggested that GnT-V was relatively tolerant of hydrophobicity in the donor substrate.
35248671	5	15	dep	structure	565:573	arg1	the					531:533	the	531:533	the	531:533	On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
35248671	5	15	dep	structure	565:573	arg1	basis					535:539	basis	535:539	basis	535:539	On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
35248671	13	16	theme	GnT	1730:1732	arg1	inhibitors					1734:1743	GnT inhibitors	1730:1743	GnT inhibitors	1730:1743	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
35248671	1	17	theme	BACKGROUND	76:85	arg1	branching					96:104	BACKGROUND N-Glycan branching	76:104	BACKGROUND N-Glycan branching	76:104	BACKGROUND N-Glycan branching regulates various functions of glycoproteins.
35248671	9	18	theme	RESULTS	1108:1114	arg1	analogs					1135:1141	RESULTS Several UDP-GlcNAc analogs	1108:1141	RESULTS Several UDP-GlcNAc analogs	1108:1141	RESULTS Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest.
35248671	10	19	from	substrate	1368:1376	arg1	tolerant					1328:1335	tolerant	1328:1335	tolerant	1328:1335	Compared with other GnTs, these compounds showed a preference for GnT-V, which suggested that GnT-V was relatively tolerant of hydrophobicity in the donor substrate.
35248671	10	20	theme	other	1227:1231	arg1	GnTs					1233:1236	other GnTs	1227:1236	other GnTs	1227:1236	Compared with other GnTs, these compounds showed a preference for GnT-V, which suggested that GnT-V was relatively tolerant of hydrophobicity in the donor substrate.
35248671	4	21	theme	UDP-GlcNAc	507:516	arg1	recognition					472:482	the unique and weak recognition	452:482	the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V	452:525	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	13	22	theme	inhibitors	1734:1743	arg1	design					1720:1725	the design	1716:1725	the design of GnT inhibitors	1716:1743	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
35248671	7	23	theme	purified	965:972	arg1	enzymes					984:990	purified truncated enzymes	965:990	purified truncated enzymes	965:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	1	24	theme	N-Glycan	87:94	arg1	branching					96:104	BACKGROUND N-Glycan branching	76:104	BACKGROUND N-Glycan branching	76:104	BACKGROUND N-Glycan branching regulates various functions of glycoproteins.
35248671	7	25	theme	assay	860:864	arg1	system					866:871	an HPLC-based enzyme assay system	839:871	an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes	839:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	4	26	theme	substrate	497:505	arg1	UDP-GlcNAc					507:516	the donor substrate UDP-GlcNAc	487:516	the donor substrate UDP-GlcNAc	487:516	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	5	27	theme	GnT-V	654:658	arg1	inhibitors					660:669	GnT-V inhibitors	654:669	GnT-V inhibitors	654:669	On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
35248671	7	28	theme	truncated	974:982	arg1	enzymes					984:990	purified truncated enzymes	965:990	purified truncated enzymes	965:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	9	29	theme	UDP-GlcNAc	1124:1133	arg1	analogs					1135:1141	RESULTS Several UDP-GlcNAc analogs	1108:1141	RESULTS Several UDP-GlcNAc analogs	1108:1141	RESULTS Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest.
35248671	0	30	theme	Structure-based	0:14	arg1	design					16:21	Structure-based design	0:21	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors	0:73	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors.
35248671	4	31	theme	novel	414:418	arg1	inhibitors					426:435	novel GnT-V inhibitors	414:435	novel GnT-V inhibitors	414:435	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	7	32	theme	HPLC-based	842:851	arg1	system					866:871	an HPLC-based enzyme assay system	839:871	an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes	839:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	0	33	theme	UDP-GlcNAc	26:35	arg1	analogs					37:43	UDP-GlcNAc analogs	26:43	UDP-GlcNAc analogs as candidate GnT-V inhibitors	26:73	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors.
35248671	1	34	gly	glycoproteins	137:149	arg1	glycoproteins					137:149	glycoproteins	137:149	glycoproteins	137:149	BACKGROUND N-Glycan branching regulates various functions of glycoproteins.
35248671	5	35	theme	UDP-GlcNAc	597:606	arg1	analogs					608:614	UDP-GlcNAc analogs	597:614	UDP-GlcNAc analogs with increasing hydrophobicity	597:645	On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
35248671	1	36	theme	various	116:122	arg1	functions					124:132	various functions	116:132	various functions of glycoproteins	116:149	BACKGROUND N-Glycan branching regulates various functions of glycoproteins.
35248671	6	37	theme	UDP-GlcNAc	709:718	arg1	analogs					720:726	10 UDP-GlcNAc analogs	706:726	10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups	706:801	METHODS We chemically synthesized 10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups.
35248671	10	38	theme	donor	1362:1366	arg1	substrate					1368:1376	the donor substrate	1358:1376	the donor substrate	1358:1376	Compared with other GnTs, these compounds showed a preference for GnT-V, which suggested that GnT-V was relatively tolerant of hydrophobicity in the donor substrate.
35248671	4	39	theme	weak	467:470	arg1	recognition					472:482	the unique and weak recognition	452:482	the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V	452:525	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	9	40	theme	GnT-V	1153:1157	arg1	activity					1159:1166	GnT-V activity	1153:1166	GnT-V activity	1153:1166	RESULTS Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest.
35248671	2	41	theme	GlcNAc	199:204	arg1	transferase					206:216	a GlcNAc transferase	197:216	a GlcNAc transferase that acts on N-glycans	197:239	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	2	41	theme	GlcNAc	199:204	arg1	V					184:184	N-Acetylglucosaminyltransferase V	152:184	N-Acetylglucosaminyltransferase V (GnT-V)	152:192	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	12	42	mod	modification	1550:1561	arg1	substrate					1576:1584	the donor substrate	1566:1584	the donor substrate	1566:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	12	42	mod	modification	1550:1561	arg3	CONCLUSIONS					1529:1539	CONCLUSIONS	1529:1539	CONCLUSIONS Chemical modification of the donor substrate	1529:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	0	43	theme	analogs	37:43	arg1	design					16:21	Structure-based design	0:21	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors	0:73	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors.
35248671	11	44	theme	inhibitory	1401:1410	arg1	compounds					1412:1420	the inhibitory compounds	1397:1420	the inhibitory compounds	1397:1420	Docking models of the inhibitory compounds with GnT-V suggested the mechanisms of how these compounds interacted with GnT-V and inhibited its action.
35248671	12	45	theme	donor	1570:1574	arg1	substrate					1576:1584	the donor substrate	1566:1584	the donor substrate	1566:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	2	46	theme	GnT-V-producing	249:263	arg1	branch					265:270	the GnT-V-producing branch	245:270	the GnT-V-producing branch	245:270	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	2	46	theme	GnT-V-producing	249:263	arg1	related					282:288	related	282:288	related	282:288	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	5	47	theme	catalytic	548:556	arg1	structure					565:573	the catalytic pocket structure	544:573	the catalytic pocket structure	544:573	On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
35248671	0	48	theme	GnT-V	58:62	arg1	inhibitors					64:73	candidate GnT-V inhibitors	48:73	candidate GnT-V inhibitors	48:73	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors.
35248671	12	49	theme	selective	1625:1633	arg1	inhibitors					1635:1644	selective inhibitors	1625:1644	selective inhibitors of GnT-V	1625:1653	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	3	50	theme	specific	333:340	arg1	inhibitors					348:357	specific GnT-V inhibitors	333:357	specific GnT-V inhibitors	333:357	This indicates that specific GnT-V inhibitors may be drug candidates for cancer treatment.
35248671	12	51	theme	promising	1595:1603	arg1	strategy					1605:1612	a promising strategy	1593:1612	a promising strategy to develop selective inhibitors of GnT-V	1593:1653	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	12	51	theme	promising	1595:1603	arg1	modification					1550:1561	CONCLUSIONS Chemical modification	1529:1561	CONCLUSIONS Chemical modification of the donor substrate	1529:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	10	52	from	tolerant	1328:1335	arg1	substrate					1368:1376	the donor substrate	1358:1376	the donor substrate	1358:1376	Compared with other GnTs, these compounds showed a preference for GnT-V, which suggested that GnT-V was relatively tolerant of hydrophobicity in the donor substrate.
35248671	5	53	theme	pocket	558:563	arg1	structure					565:573	the catalytic pocket structure	544:573	the catalytic pocket structure	544:573	On the basis of the catalytic pocket structure, we hypothesized that UDP-GlcNAc analogs with increasing hydrophobicity may be GnT-V inhibitors.
35248671	13	54	dep	SIGNIFICANCE	1664:1675	arg1	provide					1690:1696	provide	1690:1696	provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate	1690:1786	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
35248671	0	55	theme	candidate	48:56	arg1	inhibitors					64:73	candidate GnT-V inhibitors	48:73	candidate GnT-V inhibitors	48:73	Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors.
35248671	12	56	theme	GnT-V	1649:1653	arg1	inhibitors					1635:1644	selective inhibitors	1625:1644	selective inhibitors of GnT-V	1625:1653	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	3	57	theme	GnT-V	342:346	arg1	inhibitors					348:357	specific GnT-V inhibitors	333:357	specific GnT-V inhibitors	333:357	This indicates that specific GnT-V inhibitors may be drug candidates for cancer treatment.
35248671	13	58	theme	donor	1772:1776	arg1	substrate					1778:1786	the donor substrate	1768:1786	the donor substrate	1768:1786	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
35248671	1	59	theme	glycoproteins	137:149	arg1	functions					124:132	various functions	116:132	various functions of glycoproteins	116:149	BACKGROUND N-Glycan branching regulates various functions of glycoproteins.
35248671	13	60	theme	new	1698:1700	arg1	insights					1702:1709	new insights	1698:1709	new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate	1698:1786	GENERAL SIGNIFICANCE Our findings provide new insights into the design of GnT inhibitors and how GnTs recognize the donor substrate.
35248671	8	61	theme	inhibitory	1028:1037	arg1	effects					1039:1045	the inhibitory effects	1024:1045	the inhibitory effects of the synthesized compounds on GnT-V and their specificity	1024:1105	Using this system, we assessed the inhibitory effects of the synthesized compounds on GnT-V and their specificity.
35248671	9	62	theme	inhibition	1182:1191	arg1	modest					1205:1210	modest	1205:1210	modest	1205:1210	RESULTS Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest.
35248671	9	62	theme	inhibition	1182:1191	arg1	potency					1193:1199	the inhibition potency	1178:1199	the inhibition potency	1178:1199	RESULTS Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest.
35248671	2	63	theme	cancer	293:298	arg1	progression					300:310	cancer progression	293:310	cancer progression	293:310	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	4	64	theme	unique	456:461	arg1	recognition					472:482	the unique and weak recognition	452:482	the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V	452:525	To design novel GnT-V inhibitors, we focused on the unique and weak recognition of the donor substrate UDP-GlcNAc by GnT-V.
35248671	6	65	dep	METHODS	672:678	arg1	synthesized					694:704	synthesized	694:704	synthesized 10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups	694:801	METHODS We chemically synthesized 10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups.
35248671	7	66	theme	enzyme	853:858	arg1	system					866:871	an HPLC-based enzyme assay system	839:871	an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes	839:990	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	9	67	theme	Several	1116:1122	arg1	analogs					1135:1141	RESULTS Several UDP-GlcNAc analogs	1108:1141	RESULTS Several UDP-GlcNAc analogs	1108:1141	RESULTS Several UDP-GlcNAc analogs inhibited GnT-V activity, although the inhibition potency was modest.
35248671	12	68	theme	CONCLUSIONS	1529:1539	arg1	strategy					1605:1612	a promising strategy	1593:1612	a promising strategy to develop selective inhibitors of GnT-V	1593:1653	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	12	68	theme	CONCLUSIONS	1529:1539	arg1	modification					1550:1561	CONCLUSIONS Chemical modification	1529:1561	CONCLUSIONS Chemical modification of the donor substrate	1529:1584	CONCLUSIONS Chemical modification of the donor substrate may be a promising strategy to develop selective inhibitors of GnT-V.
35248671	7	69	theme	GnT-I-V	929:935	arg1	activity					937:944	GnT-I-V activity	929:944	GnT-I-V activity	929:944	To test these compounds, we set up an HPLC-based enzyme assay system for all N-glycan-branching GlcNAc transferases in which GnT-I-V activity was measured using purified truncated enzymes.
35248671	3	70	theme	drug	366:369	arg1	candidates					371:380	drug candidates	366:380	drug candidates for cancer treatment	366:401	This indicates that specific GnT-V inhibitors may be drug candidates for cancer treatment.
35248671	2	71	theme	N-Acetylglucosaminyltransferase	152:182	arg1	transferase					206:216	a GlcNAc transferase	197:216	a GlcNAc transferase that acts on N-glycans	197:239	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	2	71	theme	N-Acetylglucosaminyltransferase	152:182	arg1	GnT-V					187:191	GnT-V	187:191	GnT-V	187:191	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	2	71	theme	N-Acetylglucosaminyltransferase	152:182	arg1	V					184:184	N-Acetylglucosaminyltransferase V	152:184	N-Acetylglucosaminyltransferase V (GnT-V)	152:192	N-Acetylglucosaminyltransferase V (GnT-V) is a GlcNAc transferase that acts on N-glycans and the GnT-V-producing branch is highly related to cancer progression.
35248671	6	72	theme	phosphate	748:756	arg1	groups					758:763	one or two phosphate groups	737:763	one or two phosphate groups	737:763	METHODS We chemically synthesized 10 UDP-GlcNAc analogs in which one or two phosphate groups were replaced with hydrophobic groups.
35248671	8	73	from	effects	1039:1045	arg1	GnT-V					1079:1083	GnT-V	1079:1083	GnT-V	1079:1083	Using this system, we assessed the inhibitory effects of the synthesized compounds on GnT-V and their specificity.
35248671	8	73	from	effects	1039:1045	arg1	specificity					1095:1105	their specificity	1089:1105	their specificity	1089:1105	Using this system, we assessed the inhibitory effects of the synthesized compounds on GnT-V and their specificity.
35112714	0	0	theme	coproduced	85:94	arg1	vesicles					110:117	coproduced extracellular vesicles	85:117	coproduced extracellular vesicles	85:117	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	7	1	theme	further	1212:1218	arg1	separation					1220:1229	further separation	1212:1229	further separation	1212:1229	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	4	2	theme	downstream	723:732	arg1	processing					734:743	downstream processing	723:743	downstream processing as well as the immune response	723:774	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	1	3	theme	virus-like	159:168	arg1	VLPs					181:184	VLPs	181:184	VLPs	181:184	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	3	theme	virus-like	159:168	arg1	nanostructures					191:204	nanostructures	191:204	nanostructures derived from the self-assembly and cell budding of Gag polyprotein	191:271	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	3	theme	virus-like	159:168	arg1	particles					170:178	Human immunodeficiency virus 1 (HIV-1) virus-like particles	120:178	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs)	120:185	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	5	4	theme	main	788:791	arg1	challenges					793:802	the main challenges	784:802	the main challenges for the development of Gag VLP production bioprocess	784:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	7	5	theme	differential	1132:1143	arg1	signatures					1152:1161	differential glycan signatures	1132:1161	differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology	1132:1351	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	1	6	theme	Gag	257:259	arg1	polyprotein					261:271	Gag polyprotein	257:271	Gag polyprotein	257:271	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	0	7	theme	vesicles	110:117	arg1	signatures					36:45	Differential N- and O-glycosylation signatures	0:45	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.	0:118	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	7	8	theme	vaccine	1323:1329	arg1	technology					1342:1351	VLP-based vaccine production technology	1313:1351	VLP-based vaccine production technology	1313:1351	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	3	9	dep	this	471:474	arg1	addition					459:466	addition	459:466	addition	459:466	In addition to this, the bounding membrane can be functionalized with exogenous antigens to target different diseases.
35112714	3	10	theme	different	555:563	arg1	diseases					565:572	different diseases	555:572	different diseases	555:572	In addition to this, the bounding membrane can be functionalized with exogenous antigens to target different diseases.
35112714	1	11	theme	polyprotein	261:271	arg1	self-assembly					223:235	self-assembly	223:235	self-assembly	223:235	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	11	theme	polyprotein	261:271	arg1	budding					246:252	cell budding	241:252	cell budding	241:252	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	0	12	theme	extracellular	96:108	arg1	vesicles					110:117	coproduced extracellular vesicles	85:117	coproduced extracellular vesicles	85:117	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	2	13	theme	native	288:293	arg1	structure					295:303	the native structure	284:303	the native structure of the virus	284:316	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	2	14	theme	promising	358:366	arg1	candidates					368:377	promising candidates	358:377	promising candidates for the development of new vaccines as they elicit a strong immune response	358:453	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	6	15	used	used	1022:1025	arg2	method					980:985	porous graphitized carbon separation method	943:985	porous graphitized carbon separation method coupled with mass spectrometry	943:1016	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	7	16	theme	production	1331:1340	arg1	technology					1342:1351	VLP-based vaccine production technology	1313:1351	VLP-based vaccine production technology	1313:1351	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	2	17	theme	new	402:404	arg1	vaccines					406:413	new vaccines	402:413	new vaccines as they elicit a strong immune response	402:453	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	2	18	theme	immune	439:444	arg1	response					446:453	a strong immune response	430:453	a strong immune response	430:453	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	5	19	theme	VLPs	878:881	arg1	challenges					793:802	the main challenges	784:802	the main challenges for the development of Gag VLP production bioprocess	784:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	19	theme	VLPs	878:881	arg1	separation					864:873	the separation	860:873	the separation of VLPs and coproduced extracellular vesicles (EVs)	860:925	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	19	theme	VLPs	878:881	arg1	One					777:779	One	777:779	One	777:779	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	0	20	theme	N-	13:14	arg1	signatures					36:45	Differential N- and O-glycosylation signatures	0:45	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.	0:118	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	6	21	theme	carbon	962:967	arg1	method					980:985	porous graphitized carbon separation method	943:985	porous graphitized carbon separation method coupled with mass spectrometry	943:1016	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	7	22	theme	separation	1220:1229	arg1	strategies					1248:1257	further separation and purification strategies	1212:1257	further separation and purification strategies	1212:1257	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	4	23	theme	immune	760:765	arg1	response					767:774	the immune response	756:774	downstream processing as well as the immune response	723:774	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	4	24	theme	glycosylation	686:698	arg1	patterns					700:707	the displayed glycosylation patterns	672:707	the displayed glycosylation patterns	672:707	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	0	25	theme	Differential	0:11	arg1	signatures					36:45	Differential N- and O-glycosylation signatures	0:45	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.	0:118	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	2	26	theme	virus	312:316	arg1	structure					295:303	the native structure	284:303	the native structure of the virus	284:316	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	4	27	theme	displayed	676:684	arg1	patterns					700:707	the displayed glycosylation patterns	672:707	the displayed glycosylation patterns	672:707	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	0	28	theme	O-glycosylation	20:34	arg1	signatures					36:45	Differential N- and O-glycosylation signatures	0:45	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.	0:118	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	5	29	theme	Gag	827:829	arg1	bioprocess					846:855	Gag VLP production bioprocess	827:855	Gag VLP production bioprocess	827:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	7	30	from	forward	1302:1308	arg1	technology					1342:1351	VLP-based vaccine production technology	1313:1351	VLP-based vaccine production technology	1313:1351	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	4	31	theme	expression	645:654	arg1	system					656:661	expression system	645:661	expression system	645:661	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	5	32	theme	production	835:844	arg1	bioprocess					846:855	Gag VLP production bioprocess	827:855	Gag VLP production bioprocess	827:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	6	33	theme	separation	969:978	arg1	method					980:985	porous graphitized carbon separation method	943:985	porous graphitized carbon separation method coupled with mass spectrometry	943:1016	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	6	34	dep	N-	1047:1048	arg1	profiles					1071:1078	glycosylation profiles	1057:1078	glycosylation profiles	1057:1078	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	1	35	theme	Human	120:124	arg1	virus					143:147	Human immunodeficiency virus 1	120:149	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs)	120:185	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	35	theme	Human	120:124	arg1	HIV-1					152:156	HIV-1	152:156	HIV-1	152:156	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	5	36	theme	VLP	831:833	arg1	bioprocess					846:855	Gag VLP production bioprocess	827:855	Gag VLP production bioprocess	827:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	37	theme	challenges	793:802	arg1	challenges					793:802	the main challenges	784:802	the main challenges for the development of Gag VLP production bioprocess	784:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	37	theme	challenges	793:802	arg1	separation					864:873	the separation	860:873	the separation of VLPs and coproduced extracellular vesicles (EVs)	860:925	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	37	theme	challenges	793:802	arg1	One					777:779	One	777:779	One	777:779	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	3	38	theme	bounding	481:488	arg1	membrane					490:497	the bounding membrane	477:497	the bounding membrane	477:497	In addition to this, the bounding membrane can be functionalized with exogenous antigens to target different diseases.
35112714	5	39	theme	coproduced	887:896	arg1	EVs					922:924	EVs	922:924	EVs	922:924	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	39	theme	coproduced	887:896	arg1	vesicles					912:919	coproduced extracellular vesicles	887:919	coproduced extracellular vesicles (EVs)	887:925	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	7	40	theme	glycan	1145:1150	arg1	signatures					1152:1161	differential glycan signatures	1132:1161	differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology	1132:1351	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	6	41	theme	VLPs	1087:1090	arg1	O-					1054:1055	O-	1054:1055	O-	1054:1055	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	6	41	theme	VLPs	1087:1090	arg1	N-					1047:1048	N-	1047:1048	N-	1047:1048	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	6	42	theme	graphitized	950:960	arg1	method					980:985	porous graphitized carbon separation method	943:985	porous graphitized carbon separation method coupled with mass spectrometry	943:1016	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	4	43	theme	Protein	575:581	arg1	glycosylation					583:595	Protein glycosylation	575:595	Protein glycosylation	575:595	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	1	44	dep	self-assembly	223:235	arg1	the					219:221	the	219:221	the	219:221	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	2	45	theme	strong	432:437	arg1	response					446:453	a strong immune response	430:453	a strong immune response	430:453	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	2	46	theme	vaccines	406:413	arg1	development					387:397	the development	383:397	the development of new vaccines as they elicit a strong immune response	383:453	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	0	47	theme	Gag	56:58	arg1	particles					71:79	HIV-1 Gag virus-like particles	50:79	HIV-1 Gag virus-like particles	50:79	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	6	48	theme	porous	943:948	arg1	method					980:985	porous graphitized carbon separation method	943:985	porous graphitized carbon separation method coupled with mass spectrometry	943:1016	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	7	49	theme	purification	1235:1246	arg1	strategies					1248:1257	further separation and purification strategies	1212:1257	further separation and purification strategies	1212:1257	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	1	50	theme	immunodeficiency	126:141	arg1	virus					143:147	Human immunodeficiency virus 1	120:149	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs)	120:185	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	50	theme	immunodeficiency	126:141	arg1	HIV-1					152:156	HIV-1	152:156	HIV-1	152:156	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	0	51	theme	HIV-1	50:54	arg1	particles					71:79	HIV-1 Gag virus-like particles	50:79	HIV-1 Gag virus-like particles	50:79	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	1	52	attach	derived	206:212	arg2	particles					170:178	Human immunodeficiency virus 1 (HIV-1) virus-like particles	120:178	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs)	120:185	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	52	attach	derived	206:212	arg1	self-assembly					223:235	self-assembly	223:235	self-assembly	223:235	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	52	attach	derived	206:212	arg1	budding					246:252	cell budding	241:252	cell budding	241:252	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	52	attach	derived	206:212	arg2	nanostructures					191:204	nanostructures	191:204	nanostructures derived from the self-assembly and cell budding of Gag polyprotein	191:271	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	53	theme	virus	143:147	arg1	VLPs					181:184	VLPs	181:184	VLPs	181:184	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	53	theme	virus	143:147	arg1	nanostructures					191:204	nanostructures	191:204	nanostructures derived from the self-assembly and cell budding of Gag polyprotein	191:271	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	1	53	theme	virus	143:147	arg1	particles					170:178	Human immunodeficiency virus 1 (HIV-1) virus-like particles	120:178	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs)	120:185	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	7	54	theme	downstream	1271:1280	arg1	processing					1282:1291	downstream processing	1271:1291	downstream processing	1271:1291	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	2	55	dep	vaccines	406:413	arg1	elicit					423:428	elicit	423:428	elicit a strong immune response	423:453	Mimicking the native structure of the virus and being noninfectious, they represent promising candidates for the development of new vaccines as they elicit a strong immune response.
35112714	6	56	theme	mass	1000:1003	arg1	spectrometry					1005:1016	mass spectrometry	1000:1016	mass spectrometry	1000:1016	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	3	57	theme	exogenous	526:534	arg1	antigens					536:543	exogenous antigens	526:543	exogenous antigens	526:543	In addition to this, the bounding membrane can be functionalized with exogenous antigens to target different diseases.
35112714	6	58	theme	glycosylation	1057:1069	arg1	profiles					1071:1078	glycosylation profiles	1057:1078	glycosylation profiles	1057:1078	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	6	59	theme	HEK293	1104:1109	arg1	cells					1111:1115	HEK293 cells	1104:1115	HEK293 cells	1104:1115	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	0	60	theme	particles	71:79	arg1	signatures					36:45	Differential N- and O-glycosylation signatures	0:45	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.	0:118	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	7	61	theme	VLP-based	1313:1321	arg1	technology					1342:1351	VLP-based vaccine production technology	1313:1351	VLP-based vaccine production technology	1313:1351	We identified differential glycan signatures between VLPs and EVs that could pave the way for further separation and purification strategies to optimize downstream processing and move forward in VLP-based vaccine production technology.
35112714	5	62	theme	bioprocess	846:855	arg1	development					812:822	the development	808:822	the development of Gag VLP production bioprocess	808:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	63	theme	extracellular	898:910	arg1	EVs					922:924	EVs	922:924	EVs	922:924	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	63	theme	extracellular	898:910	arg1	vesicles					912:919	coproduced extracellular vesicles	887:919	coproduced extracellular vesicles (EVs)	887:925	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	6	64	theme	Gag	1083:1085	arg1	VLPs					1087:1090	Gag VLPs	1083:1090	Gag VLPs produced in HEK293 cells	1083:1115	In this study, porous graphitized carbon separation method coupled with mass spectrometry was used to characterize the N- and O- glycosylation profiles of Gag VLPs produced in HEK293 cells.
35112714	1	65	theme	cell	241:244	arg1	budding					246:252	cell budding	241:252	cell budding	241:252	Human immunodeficiency virus 1 (HIV-1) virus-like particles (VLPs) are nanostructures derived from the self-assembly and cell budding of Gag polyprotein.
35112714	0	66	theme	virus-like	60:69	arg1	particles					71:79	HIV-1 Gag virus-like particles	50:79	HIV-1 Gag virus-like particles	50:79	Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles.
35112714	4	67	dep	platform	632:639	arg1	the					617:619	the	617:619	the	617:619	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
35112714	5	68	theme	vesicles	912:919	arg1	challenges					793:802	the main challenges	784:802	the main challenges for the development of Gag VLP production bioprocess	784:855	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	68	theme	vesicles	912:919	arg1	separation					864:873	the separation	860:873	the separation of VLPs and coproduced extracellular vesicles (EVs)	860:925	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	5	68	theme	vesicles	912:919	arg1	One					777:779	One	777:779	One	777:779	One of the main challenges for the development of Gag VLP production bioprocess is the separation of VLPs and coproduced extracellular vesicles (EVs).
35112714	4	69	theme	production	621:630	arg1	platform					632:639	production platform	621:639	production platform	621:639	Protein glycosylation depends strictly on the production platform and expression system used and the displayed glycosylation patterns may influence downstream processing as well as the immune response.
36031042	8	0	from	increase	1177:1184	arg1	proportion					1193:1202	the proportion	1189:1202	the proportion of unprocessed glycan structures with more mannose units	1189:1259	T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units.
36031042	10	1	theme	recent	1533:1538	arg1	cases					1550:1554	recent onset T1D cases	1533:1554	recent onset T1D cases	1533:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	11	2	theme	C3	1624:1625	arg1	model					1655:1659	Our C3 glycan-based discriminative model	1620:1659	Our C3 glycan-based discriminative model	1620:1659	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	7	3	theme	C3	1117:1118	arg1	profiles					1129:1136	C3 N-glycan profiles	1117:1136	C3 N-glycan profiles	1117:1136	Significant changes of C3 N-glycan profiles were found.
36031042	1	4	theme	oligomannose	228:239	arg1	glycans					241:247	oligomannose glycans	228:247	oligomannose glycans	228:247	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	8	5	theme	structures	1226:1235	arg1	proportion					1193:1202	the proportion	1189:1202	the proportion of unprocessed glycan structures with more mannose units	1189:1259	T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units.
36031042	9	6	with	children	1348:1355	arg1	T1D					1374:1376	early onset T1D	1362:1376	early onset T1D	1362:1376	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	9	6	with	children	1348:1355	arg1	area					1410:1413	area	1410:1413	area under curve of 0.879	1410:1434	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	0	7	theme	High-Throughput	0:14	arg1	N-Glycoprofiling					36:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	5	8	theme	affinity	800:807	arg1	enrichment					809:818	human C3 concanavalin A lectin affinity enrichment	769:818	human C3 concanavalin A lectin affinity enrichment	769:818	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	6	9	from	Register	956:963	arg1	N-glycoprofiled					1077:1091	N-glycoprofiled	1077:1091	N-glycoprofiled	1077:1091	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	10	10	theme	N-glycome	1590:1598	arg1	involvement					1572:1582	the involvement	1568:1582	the involvement of C3 N-glycome in T1D development	1568:1617	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	6	11	theme	Diabetes	947:954	arg1	Register					956:963	the Danish Childhood Diabetes Register	926:963	the Danish Childhood Diabetes Register	926:963	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	5	12	theme	C3	775:776	arg1	A					791:791	human C3 concanavalin A	769:791	human C3 concanavalin A lectin affinity enrichment	769:818	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	6	13	theme	Danish	930:935	arg1	Register					956:963	the Danish Childhood Diabetes Register	926:963	the Danish Childhood Diabetes Register	926:963	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	1	14	from	proportion	214:223	arg1	N-glycome					279:287	their total plasma protein N-glycome	252:287	their total plasma protein N-glycome	252:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	1	15	contain	have	200:203	arg2	proportion					214:223	a higher proportion	205:223	a higher proportion of oligomannose glycans in their total plasma protein N-glycome	205:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	1	15	contain	have	200:203	arg1	children					153:160	children	153:160	children at the onset of type 1 diabetes (T1D)	153:198	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	5	16	theme	A	791:791	arg1	enrichment					809:818	human C3 concanavalin A lectin affinity enrichment	769:818	human C3 concanavalin A lectin affinity enrichment	769:818	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	8	17	theme	unprocessed	1207:1217	arg1	structures					1226:1235	unprocessed glycan structures	1207:1235	unprocessed glycan structures	1207:1235	T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units.
36031042	10	18	theme	T1D	1603:1605	arg1	development					1607:1617	T1D development	1603:1617	T1D development	1603:1617	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	10	19	from	findings	1471:1478	arg1	cohort					1523:1528	a cohort	1521:1528	a cohort of recent onset T1D cases	1521:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	2	20	contain	contains	382:389	arg1	C3					378:379	glycoprotein C3	365:379	glycoprotein C3	365:379	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	2	20	contain	contains	382:389	arg1	component					354:362	The most abundant complement component	325:362	The most abundant complement component	325:362	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	2	20	contain	contains	382:389	arg2	sites					411:415	two N-glycosylation sites	391:415	two N-glycosylation sites occupied exclusively by this type of glycans	391:460	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	1	21	from	onset	169:173	arg1	children					153:160	children	153:160	children at the onset of type 1 diabetes (T1D)	153:198	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	5	22	theme	N-glycosylation	894:908	arg1	profiling					910:918	protein-specific N-glycosylation profiling	877:918	protein-specific N-glycosylation profiling	877:918	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	0	23	theme	Early	75:79	arg1	Mellitus					103:110	Early Onset Type 1 Diabetes Mellitus	75:110	Early Onset Type 1 Diabetes Mellitus in Children	75:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	9	24	theme	regression	1264:1273	arg1	model					1275:1279	A regression model	1262:1279	A regression model including C3 N-glycans	1262:1302	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	5	25	theme	LC-MS	835:839	arg1	analysis					854:861	subsequent LC-MS glycopeptide analysis	824:861	subsequent LC-MS glycopeptide analysis	824:861	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	0	26	theme	Type	87:90	arg1	Mellitus					103:110	Early Onset Type 1 Diabetes Mellitus	75:110	Early Onset Type 1 Diabetes Mellitus in Children	75:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	1	27	theme	healthy	307:313	arg1	siblings					315:322	their healthy siblings	301:322	their healthy siblings	301:322	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	11	28	from	assessment	1682:1691	arg1	children					1708:1715	children	1708:1715	children	1708:1715	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	11	28	from	assessment	1682:1691	arg1	valuable					1670:1677	valuable	1670:1677	valuable	1670:1677	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	0	29	theme	Diabetes	94:101	arg1	Mellitus					103:110	Early Onset Type 1 Diabetes Mellitus	75:110	Early Onset Type 1 Diabetes Mellitus in Children	75:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	10	30	from	cohort	1523:1528	arg1	findings					1471:1478	our previous findings	1458:1478	our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases	1458:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	0	31	from	Markers	64:70	arg1	Children					115:122	Children	115:122	Children	115:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	2	32	theme	glycoprotein	365:376	arg1	component					354:362	The most abundant complement component	325:362	The most abundant complement component	325:362	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	2	32	theme	glycoprotein	365:376	arg1	C3					378:379	glycoprotein C3	365:379	glycoprotein C3	365:379	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	9	33	theme	notable	1311:1317	arg1	power					1334:1338	notable discriminative power	1311:1338	notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879	1311:1434	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	6	34	theme	unaffected	1049:1058	arg1	siblings					1060:1067	their unaffected siblings	1043:1067	their unaffected siblings	1043:1067	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	10	35	theme	previous	1462:1469	arg1	findings					1471:1478	our previous findings	1458:1478	our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases	1458:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	0	36	theme	Onset	81:85	arg1	Mellitus					103:110	Early Onset Type 1 Diabetes Mellitus	75:110	Early Onset Type 1 Diabetes Mellitus in Children	75:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	4	37	theme	C3	690:691	arg1	profile					679:685	the glycosylation profile	661:685	the glycosylation profile of C3 in T1D	661:698	It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D.
36031042	5	38	theme	high-throughput	740:754	arg1	workflow					756:763	a novel high-throughput workflow	732:763	a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling	732:918	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	1	39	theme	glycans	241:247	arg1	proportion					214:223	a higher proportion	205:223	a higher proportion of oligomannose glycans in their total plasma protein N-glycome	205:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	11	40	from	valuable	1670:1677	arg1	assessment					1682:1691	assessment	1682:1691	assessment of T1D risk in children	1682:1715	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	10	41	theme	changes	1510:1516	arg1	findings					1471:1478	our previous findings	1458:1478	our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases	1458:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	0	42	theme	Complement	22:31	arg1	N-Glycoprofiling					36:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	10	43	theme	high-mannose	1490:1501	arg1	changes					1510:1516	plasma high-mannose glycan changes	1483:1516	plasma high-mannose glycan changes in a cohort of recent onset T1D cases	1483:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	11	44	theme	risk	1700:1703	arg1	assessment					1682:1691	assessment	1682:1691	assessment of T1D risk in children	1682:1715	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	9	45	theme	early	1362:1366	arg1	T1D					1374:1376	early onset T1D	1362:1376	early onset T1D	1362:1376	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	10	46	from	changes	1510:1516	arg1	cohort					1523:1528	a cohort	1521:1528	a cohort of recent onset T1D cases	1521:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	1	47	theme	plasma	264:269	arg1	N-glycome					279:287	their total plasma protein N-glycome	252:287	their total plasma protein N-glycome	252:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	7	48	theme	profiles	1129:1136	arg1	changes					1106:1112	Significant changes	1094:1112	Significant changes of C3 N-glycan profiles	1094:1136	Significant changes of C3 N-glycan profiles were found.
36031042	10	49	from	involvement	1572:1582	arg1	development					1607:1617	T1D development	1603:1617	T1D development	1603:1617	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	10	50	theme	cases	1550:1554	arg1	cohort					1523:1528	a cohort	1521:1528	a cohort of recent onset T1D cases	1521:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	2	51	theme	abundant	334:341	arg1	component					354:362	The most abundant complement component	325:362	The most abundant complement component	325:362	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	2	51	theme	abundant	334:341	arg1	C3					378:379	glycoprotein C3	365:379	glycoprotein C3	365:379	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	4	52	theme	inflammatory	606:617	arg1	responses					619:627	inflammatory responses	606:627	inflammatory responses	606:627	It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D.
36031042	9	53	theme	onset	1368:1372	arg1	T1D					1374:1376	early onset T1D	1362:1376	early onset T1D	1362:1376	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	10	54	theme	onset	1540:1544	arg1	cases					1550:1554	recent onset T1D cases	1533:1554	recent onset T1D cases	1533:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	3	55	theme	complement	476:485	arg1	system					487:492	complement system	476:492	complement system	476:492	Furthermore, complement system, as well as C3, was previously associated with T1D.
36031042	1	56	theme	higher	207:212	arg1	proportion					214:223	a higher proportion	205:223	a higher proportion of oligomannose glycans in their total plasma protein N-glycome	205:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	11	57	theme	glycan-based	1627:1638	arg1	model					1655:1659	Our C3 glycan-based discriminative model	1620:1659	Our C3 glycan-based discriminative model	1620:1659	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	7	58	theme	Significant	1094:1104	arg1	changes					1106:1112	Significant changes	1094:1112	Significant changes of C3 N-glycan profiles	1094:1136	Significant changes of C3 N-glycan profiles were found.
36031042	5	59	theme	lectin	793:798	arg1	enrichment					809:818	human C3 concanavalin A lectin affinity enrichment	769:818	human C3 concanavalin A lectin affinity enrichment	769:818	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	8	60	theme	glycan	1219:1224	arg1	structures					1226:1235	unprocessed glycan structures	1207:1235	unprocessed glycan structures	1207:1235	T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units.
36031042	10	61	theme	C3	1587:1588	arg1	N-glycome					1590:1598	C3 N-glycome	1587:1598	C3 N-glycome	1587:1598	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	1	62	theme	type	178:181	arg1	T1D					195:197	T1D	195:197	T1D	195:197	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	1	62	theme	type	178:181	arg1	diabetes					185:192	type 1 diabetes	178:192	type 1 diabetes (T1D)	178:198	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	6	63	theme	Childhood	937:945	arg1	Register					956:963	the Danish Childhood Diabetes Register	926:963	the Danish Childhood Diabetes Register	926:963	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	8	64	theme	mannose	1247:1253	arg1	units					1255:1259	more mannose units	1242:1259	more mannose units	1242:1259	T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units.
36031042	4	65	gly	glycosylation	665:677	arg1	C3					690:691	C3	690:691	C3	690:691	It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D.
36031042	5	66	theme	concanavalin	778:789	arg1	A					791:791	human C3 concanavalin A	769:791	human C3 concanavalin A lectin affinity enrichment	769:818	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	0	67	from	Children	115:122	arg1	Markers					64:70	Markers	64:70	Markers of Early Onset Type 1 Diabetes Mellitus in Children	64:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	5	68	theme	protein-specific	877:892	arg1	profiling					910:918	protein-specific N-glycosylation profiling	877:918	protein-specific N-glycosylation profiling	877:918	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	5	69	gly	glycopeptide	841:852	arg2	glycopeptide					841:852	subsequent LC-MS glycopeptide analysis	824:861	subsequent LC-MS glycopeptide analysis	824:861	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	0	70	from	Mellitus	103:110	arg1	Children					115:122	Children	115:122	Children	115:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	4	71	theme	glycosylation	665:677	arg1	profile					679:685	the glycosylation profile	661:685	the glycosylation profile of C3 in T1D	661:698	It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D.
36031042	4	72	from	changes	568:574	arg1	glycosylation					579:591	glycosylation	579:591	glycosylation	579:591	It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D.
36031042	5	73	theme	human	769:773	arg1	A					791:791	human C3 concanavalin A	769:791	human C3 concanavalin A lectin affinity enrichment	769:818	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	5	74	theme	subsequent	824:833	arg1	analysis					854:861	subsequent LC-MS glycopeptide analysis	824:861	subsequent LC-MS glycopeptide analysis	824:861	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	6	75	theme	children/adolescents	987:1006	arg1	samples					973:979	plasma samples	966:979	plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings	966:1067	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	11	76	from	children	1708:1715	arg1	assessment					1682:1691	assessment	1682:1691	assessment of T1D risk in children	1682:1715	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	8	77	with	proportion	1193:1202	arg1	units					1255:1259	more mannose units	1242:1259	more mannose units	1242:1259	T1D was associated with an increase in the proportion of unprocessed glycan structures with more mannose units.
36031042	5	78	theme	glycopeptide	841:852	arg1	analysis					854:861	subsequent LC-MS glycopeptide analysis	824:861	subsequent LC-MS glycopeptide analysis	824:861	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	2	79	theme	glycans	454:460	arg1	type					446:449	this type	441:449	this type of glycans	441:460	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	0	80	theme	Mellitus	103:110	arg1	Markers					64:70	Markers	64:70	Markers of Early Onset Type 1 Diabetes Mellitus in Children	64:122	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	9	81	theme	C3	1291:1292	arg1	N-glycans					1294:1302	C3 N-glycans	1291:1302	C3 N-glycans	1291:1302	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	6	82	theme	plasma	966:971	arg1	samples					973:979	plasma samples	966:979	plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings	966:1067	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	6	83	theme	siblings	1060:1067	arg1	T1D					1029:1031	T1D	1029:1031	T1D	1029:1031	From the Danish Childhood Diabetes Register, plasma samples of 61 children/adolescents newly diagnosed with T1D and 84 of their unaffected siblings were C3 N-glycoprofiled.
36031042	11	84	from	risk	1700:1703	arg1	children					1708:1715	children	1708:1715	children	1708:1715	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	2	85	gly	glycoprotein	365:376	arg1	glycoprotein					365:376	glycoprotein C3	365:379	glycoprotein C3	365:379	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	5	86	theme	novel	734:738	arg1	workflow					756:763	a novel high-throughput workflow	732:763	a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling	732:918	For this purpose, we developed a novel high-throughput workflow for human C3 concanavalin A lectin affinity enrichment and subsequent LC-MS glycopeptide analysis which enables protein-specific N-glycosylation profiling.
36031042	9	87	theme	discriminative	1319:1332	arg1	power					1334:1338	notable discriminative power	1311:1338	notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879	1311:1434	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	2	88	theme	complement	343:352	arg1	component					354:362	The most abundant complement component	325:362	The most abundant complement component	325:362	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	2	88	theme	complement	343:352	arg1	C3					378:379	glycoprotein C3	365:379	glycoprotein C3	365:379	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	0	89	theme	C3	33:34	arg1	N-Glycoprofiling					36:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
36031042	2	90	theme	N-glycosylation	395:409	arg1	sites					411:415	two N-glycosylation sites	391:415	two N-glycosylation sites occupied exclusively by this type of glycans	391:460	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	10	91	theme	glycan	1503:1508	arg1	changes					1510:1516	plasma high-mannose glycan changes	1483:1516	plasma high-mannose glycan changes in a cohort of recent onset T1D cases	1483:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	11	92	theme	T1D	1696:1698	arg1	risk					1700:1703	T1D risk	1696:1703	T1D risk in children	1696:1715	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	1	93	theme	total	258:262	arg1	N-glycome					279:287	their total plasma protein N-glycome	252:287	their total plasma protein N-glycome	252:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	1	94	theme	diabetes	185:192	arg1	onset					169:173	the onset	165:173	the onset of type 1 diabetes (T1D)	165:198	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	10	95	theme	plasma	1483:1488	arg1	changes					1510:1516	plasma high-mannose glycan changes	1483:1516	plasma high-mannose glycan changes in a cohort of recent onset T1D cases	1483:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	7	96	theme	N-glycan	1120:1127	arg1	profiles					1129:1136	C3 N-glycan profiles	1117:1136	C3 N-glycan profiles	1117:1136	Significant changes of C3 N-glycan profiles were found.
36031042	1	97	theme	protein	271:277	arg1	N-glycome					279:287	their total plasma protein N-glycome	252:287	their total plasma protein N-glycome	252:287	Recently, it was shown that children at the onset of type 1 diabetes (T1D) have a higher proportion of oligomannose glycans in their total plasma protein N-glycome compared to their healthy siblings.
36031042	4	98	from	profile	679:685	arg1	T1D					696:698	T1D	696:698	T1D	696:698	It is also known that changes in glycosylation can modulate inflammatory responses, so our aim was to characterize the glycosylation profile of C3 in T1D.
36031042	9	99	with	siblings	1396:1403	arg1	T1D					1374:1376	early onset T1D	1362:1376	early onset T1D	1362:1376	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	9	99	with	siblings	1396:1403	arg1	area					1410:1413	area	1410:1413	area under curve of 0.879	1410:1434	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	9	100	theme	healthy	1388:1394	arg1	siblings					1396:1403	their healthy siblings	1382:1403	their healthy siblings	1382:1403	A regression model including C3 N-glycans showed notable discriminative power between children with early onset T1D and their healthy siblings with area under curve of 0.879.
36031042	2	101	gly	N-glycosylation	395:409	arg2	two					391:393	two	391:393	two	391:393	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	2	101	gly	N-glycosylation	395:409	arg2	sites					411:415	two N-glycosylation sites	391:415	two N-glycosylation sites occupied exclusively by this type of glycans	391:460	The most abundant complement component, glycoprotein C3, contains two N-glycosylation sites occupied exclusively by this type of glycans.
36031042	10	102	theme	T1D	1546:1548	arg1	cases					1550:1554	recent onset T1D cases	1533:1554	recent onset T1D cases	1533:1554	This study confirmed our previous findings of plasma high-mannose glycan changes in a cohort of recent onset T1D cases, suggesting the involvement of C3 N-glycome in T1D development.
36031042	11	103	theme	discriminative	1640:1653	arg1	model					1655:1659	Our C3 glycan-based discriminative model	1620:1659	Our C3 glycan-based discriminative model	1620:1659	Our C3 glycan-based discriminative model could be valuable in assessment of T1D risk in children.
36031042	0	104	theme	Human	16:20	arg1	N-Glycoprofiling					36:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling	0:51	High-Throughput Human Complement C3 N-Glycoprofiling Identifies Markers of Early Onset Type 1 Diabetes Mellitus in Children.
37384819	2	0	theme	binding	526:532	arg1	mechanisms					534:543	glycan-aptamer binding mechanisms	511:543	glycan-aptamer binding mechanisms	511:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	7	1	theme	extensive	1275:1283	arg1	development					1294:1304	more extensive in vitro development	1270:1304	more extensive in vitro development	1270:1304	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	1	2	theme	protein	265:271	arg1	expression					273:282	protein expression	265:282	protein expression during the transformation to the diseased condition	265:334	Glycans are promising for disease diagnosis since glycan biosynthesis is significantly affected by disease states, and glycosylation changes are probably more pronounced than protein expression during the transformation to the diseased condition.
37384819	2	3	theme	glycan-aptamer	511:524	arg1	mechanisms					534:543	glycan-aptamer binding mechanisms	511:543	glycan-aptamer binding mechanisms	511:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	4	theme	challenging	383:393	arg1	applications					395:406	challenging applications	383:406	challenging applications such as cancer targeting	383:431	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	4	theme	challenging	383:393	arg1	targeting					423:431	cancer targeting	416:431	cancer targeting	416:431	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	5	theme	screening	573:581	arg1	difficulty					559:568	the difficulty	555:568	the difficulty of screening	555:581	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	5	6	theme	mutant	1029:1034	arg1	aptamers					1036:1043	two optimal mutant aptamers	1017:1043	two optimal mutant aptamers	1017:1043	Combined experiments and simulations have identified two optimal mutant aptamers.
37384819	4	7	theme	flexible	932:939	arg1	structures					941:950	the flexible structures	928:950	the flexible structures of glycans	928:961	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	4	8	theme	glycans	809:815	arg1	example					798:804	a representative example	781:804	a representative example of glycans	781:815	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	7	9	theme	aptamers	1345:1352	arg1	application					1310:1320	application	1310:1320	application	1310:1320	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	7	9	theme	aptamers	1345:1352	arg1	development					1294:1304	more extensive in vitro development	1270:1304	more extensive in vitro development	1270:1304	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	2	10	from	scarcity	488:495	arg1	mechanisms					534:543	glycan-aptamer binding mechanisms	511:543	glycan-aptamer binding mechanisms	511:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	11	theme	high	447:450	arg1	flexibility					452:462	the high flexibility	443:462	the high flexibility of glycosidic bonds	443:482	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	6	12	theme	aptamer	1150:1156	arg1	pools					1158:1162	the initial aptamer pools	1138:1162	the initial aptamer pools	1138:1162	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	6	12	theme	aptamer	1150:1156	arg1	genes					1119:1123	the glycan-binding rRNA genes	1095:1123	the glycan-binding rRNA genes	1095:1123	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	5	13	theme	Combined	964:971	arg1	experiments					973:983	Combined experiments	964:983	Combined experiments	964:983	Combined experiments and simulations have identified two optimal mutant aptamers.
37384819	6	14	theme	potential	1071:1079	arg1	strategy					1081:1088	a potential strategy	1069:1088	a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening	1069:1194	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	0	15	theme	In	0:1	arg1	Selection					10:18	In Silico Selection	0:18	In Silico Selection	0:18	In Silico Selection and Validation of High-Affinity ssDNA Aptamers Targeting Paromomycin.
37384819	1	16	theme	disease	189:195	arg1	states					197:202	disease states	189:202	disease states	189:202	Glycans are promising for disease diagnosis since glycan biosynthesis is significantly affected by disease states, and glycosylation changes are probably more pronounced than protein expression during the transformation to the diseased condition.
37384819	2	17	from	studies	500:506	arg1	mechanisms					534:543	glycan-aptamer binding mechanisms	511:543	glycan-aptamer binding mechanisms	511:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	7	18	dep	in	1215:1216	arg1	silico					1218:1223	silico	1218:1223	silico	1218:1223	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	4	19	theme	representative	783:796	arg1	example					798:804	a representative example	781:804	a representative example of glycans	781:815	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	3	20	dep	glycans	632:638	arg1	aptamers					650:657	aptamers	650:657	aptamers	650:657	In this work, the model of interactions between glycans and ssDNA aptamers synthesized based on the sequence of rRNA genes was developed.
37384819	2	21	theme	bonds	478:482	arg1	scarcity					488:495	scarcity	488:495	scarcity of studies on glycan-aptamer binding mechanisms	488:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	21	theme	bonds	478:482	arg1	flexibility					452:462	the high flexibility	443:462	the high flexibility of glycosidic bonds	443:482	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	22	theme	Glycan-specific	337:351	arg1	aptamers					353:360	Glycan-specific aptamers	337:360	Glycan-specific aptamers	337:360	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	23	theme	cancer	416:421	arg1	targeting					423:431	cancer targeting	416:431	cancer targeting	416:431	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	24	theme	glycosidic	467:476	arg1	bonds					478:482	glycosidic bonds	467:482	glycosidic bonds	467:482	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	7	25	dep	extensive	1275:1283	arg1	in					1285:1286	in	1285:1286	in	1285:1286	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	5	26	theme	optimal	1021:1027	arg1	aptamers					1036:1043	two optimal mutant aptamers	1017:1043	two optimal mutant aptamers	1017:1043	Combined experiments and simulations have identified two optimal mutant aptamers.
37384819	7	27	dep	in	1285:1286	arg1	vitro					1288:1292	vitro	1288:1292	vitro	1288:1292	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	4	28	theme	simulation-based	726:741	arg1	approach					743:750	Our simulation-based approach	722:750	Our simulation-based approach	722:750	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	1	29	theme	glycosylation	209:221	arg1	changes					223:229	glycosylation changes	209:229	glycosylation changes	209:229	Glycans are promising for disease diagnosis since glycan biosynthesis is significantly affected by disease states, and glycosylation changes are probably more pronounced than protein expression during the transformation to the diseased condition.
37384819	7	30	theme	in	1215:1216	arg1	workflow					1225:1232	this in silico workflow	1210:1232	this in silico workflow	1210:1232	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	1	31	theme	diseased	317:324	arg1	condition					326:334	the diseased condition	313:334	the diseased condition	313:334	Glycans are promising for disease diagnosis since glycan biosynthesis is significantly affected by disease states, and glycosylation changes are probably more pronounced than protein expression during the transformation to the diseased condition.
37384819	4	32	theme	aptamers	873:880	arg1	structures					859:868	base-restricted stem structures	838:868	base-restricted stem structures of aptamers	838:880	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	2	33	theme	studies	500:506	arg1	scarcity					488:495	scarcity	488:495	scarcity of studies on glycan-aptamer binding mechanisms	488:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	33	theme	studies	500:506	arg1	flexibility					452:462	the high flexibility	443:462	the high flexibility of glycosidic bonds	443:482	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	7	34	dep	development	1294:1304	arg1	the					1266:1268	the	1266:1268	the	1266:1268	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	6	35	theme	rRNA	1114:1117	arg1	pools					1158:1162	the initial aptamer pools	1138:1162	the initial aptamer pools	1138:1162	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	6	35	theme	rRNA	1114:1117	arg1	genes					1119:1123	the glycan-binding rRNA genes	1095:1123	the glycan-binding rRNA genes	1095:1123	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	0	36	theme	ssDNA	52:56	arg1	Selection					10:18	In Silico Selection	0:18	In Silico Selection	0:18	In Silico Selection and Validation of High-Affinity ssDNA Aptamers Targeting Paromomycin.
37384819	0	36	theme	ssDNA	52:56	arg1	Validation					24:33	Validation	24:33	Validation	24:33	In Silico Selection and Validation of High-Affinity ssDNA Aptamers Targeting Paromomycin.
37384819	4	37	theme	glycans	955:961	arg1	structures					941:950	the flexible structures	928:950	the flexible structures of glycans	928:961	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	2	38	from	mechanisms	534:543	arg1	scarcity					488:495	scarcity	488:495	scarcity of studies on glycan-aptamer binding mechanisms	488:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	2	38	from	mechanisms	534:543	arg1	flexibility					452:462	the high flexibility	443:462	the high flexibility of glycosidic bonds	443:482	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	3	39	theme	interactions	611:622	arg1	model					602:606	the model	598:606	the model of interactions between glycans and ssDNA aptamers synthesized based on the sequence of rRNA genes	598:705	In this work, the model of interactions between glycans and ssDNA aptamers synthesized based on the sequence of rRNA genes was developed.
37384819	1	40	theme	disease	116:122	arg1	diagnosis					124:132	disease diagnosis	116:132	disease diagnosis	116:132	Glycans are promising for disease diagnosis since glycan biosynthesis is significantly affected by disease states, and glycosylation changes are probably more pronounced than protein expression during the transformation to the diseased condition.
37384819	0	41	theme	High-Affinity	38:50	arg1	ssDNA					52:56	High-Affinity ssDNA	38:56	High-Affinity ssDNA	38:56	In Silico Selection and Validation of High-Affinity ssDNA Aptamers Targeting Paromomycin.
37384819	4	42	theme	stem	854:857	arg1	structures					859:868	base-restricted stem structures	838:868	base-restricted stem structures of aptamers	838:880	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	4	43	theme	base-restricted	838:852	arg1	structures					859:868	base-restricted stem structures	838:868	base-restricted stem structures of aptamers	838:880	Our simulation-based approach revealed that paromomycin as a representative example of glycans is preferred to bind base-restricted stem structures of aptamers because they are more critical in stabilizing the flexible structures of glycans.
37384819	7	44	theme	ssDNA	1339:1343	arg1	aptamers					1345:1352	RNA-templated ssDNA aptamers	1325:1352	RNA-templated ssDNA aptamers targeting glycans	1325:1370	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
37384819	6	45	theme	glycan-binding	1099:1112	arg1	pools					1158:1162	the initial aptamer pools	1138:1162	the initial aptamer pools	1138:1162	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	6	45	theme	glycan-binding	1099:1112	arg1	genes					1119:1123	the glycan-binding rRNA genes	1095:1123	the glycan-binding rRNA genes	1095:1123	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	3	46	theme	rRNA	696:699	arg1	genes					701:705	rRNA genes	696:705	rRNA genes	696:705	In this work, the model of interactions between glycans and ssDNA aptamers synthesized based on the sequence of rRNA genes was developed.
37384819	1	47	theme	glycan	140:145	arg1	biosynthesis					147:158	glycan biosynthesis	140:158	glycan biosynthesis	140:158	Glycans are promising for disease diagnosis since glycan biosynthesis is significantly affected by disease states, and glycosylation changes are probably more pronounced than protein expression during the transformation to the diseased condition.
37384819	0	48	theme	Targeting	67:75	arg1	Paromomycin					77:87	Targeting Paromomycin	67:87	Targeting Paromomycin	67:87	In Silico Selection and Validation of High-Affinity ssDNA Aptamers Targeting Paromomycin.
37384819	3	49	theme	genes	701:705	arg1	sequence					684:691	the sequence	680:691	the sequence of rRNA genes	680:705	In this work, the model of interactions between glycans and ssDNA aptamers synthesized based on the sequence of rRNA genes was developed.
37384819	6	50	theme	aptamer	1178:1184	arg1	screening					1186:1194	aptamer screening	1178:1194	aptamer screening	1178:1194	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	6	51	theme	initial	1142:1148	arg1	pools					1158:1162	the initial aptamer pools	1138:1162	the initial aptamer pools	1138:1162	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	6	51	theme	initial	1142:1148	arg1	genes					1119:1123	the glycan-binding rRNA genes	1095:1123	the glycan-binding rRNA genes	1095:1123	Our work would provide a potential strategy that the glycan-binding rRNA genes could act as the initial aptamer pools to accelerate aptamer screening.
37384819	0	52	dep	In	0:1	arg1	Silico					3:8	Silico	3:8	Silico	3:8	In Silico Selection and Validation of High-Affinity ssDNA Aptamers Targeting Paromomycin.
37384819	2	53	from	flexibility	452:462	arg1	mechanisms					534:543	glycan-aptamer binding mechanisms	511:543	glycan-aptamer binding mechanisms	511:543	Glycan-specific aptamers can be developed for challenging applications such as cancer targeting; however, the high flexibility of glycosidic bonds and scarcity of studies on glycan-aptamer binding mechanisms increased the difficulty of screening.
37384819	7	54	theme	RNA-templated	1325:1337	arg1	aptamers					1345:1352	RNA-templated ssDNA aptamers	1325:1352	RNA-templated ssDNA aptamers targeting glycans	1325:1370	In addition, this in silico workflow would be potentially applied in the more extensive in vitro development and application of RNA-templated ssDNA aptamers targeting glycans.
36095241	5	0	theme	peptide-based	1174:1186	arg1	inhibitors					1188:1197	these peptide-based inhibitors	1168:1197	these peptide-based inhibitors	1168:1197	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	4	1	theme	inhibition	913:922	arg1	capacity					924:931	the inhibition capacity	909:931	the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334	909:981	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	3	2	attach	derived	509:515	arg1	RBD					522:524	RBD	522:524	RBD	522:524	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	2	attach	derived	509:515	arg2	peptide					492:498	an intrinsic O-glycosylated peptide P320-334	464:507	an intrinsic O-glycosylated peptide P320-334 derived from RBD	464:524	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	3	dep	sialyl-T	693:700	arg1	sT					703:704	sT	703:704	sT	703:704	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	0	4	theme	Inhibition	94:103	arg1	Functions					105:113	Their Inhibition Functions	88:113	Their Inhibition Functions	88:113	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.
36095241	5	5	theme	inhibitors	1188:1197	arg1	capacities					1154:1163	the inhibition capacities	1139:1163	the inhibition capacities	1139:1163	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	3	6	gly	glycopeptides	564:576	arg2	glycopeptides					564:576	homogeneous O-linked glycopeptides	543:576	homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	543:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	4	7	theme	sT-P320-334	971:981	arg1	capacity					924:931	the inhibition capacity	909:931	the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334	909:981	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	3	8	theme	Tn	589:590	arg1	structures					741:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	9	dep	sT	703:704	arg1	Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr					707:738	Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr	707:738	Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr	707:738	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	5	10	theme	novel	1220:1224	arg1	directions					1239:1248	novel optimization directions	1220:1248	novel optimization directions for the inhibitor design	1220:1273	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	3	11	theme	chemoenzymatic	779:792	arg1	strategies					794:803	chemoenzymatic strategies	779:803	chemoenzymatic strategies	779:803	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	4	12	theme	sT-P320-334	863:873	arg1	binding					852:858	the binding	848:858	the binding of sT-P320-334 to hACE2	848:882	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	5	13	theme	inhibition	1143:1152	arg1	capacities					1154:1163	the inhibition capacities	1139:1163	the inhibition capacities	1139:1163	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	4	14	theme	RBD-hACE2	941:949	arg1	binding					951:957	RBD-hACE2 binding	941:957	RBD-hACE2 binding	941:957	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	2	15	theme	inhibition	400:409	arg1	abilities					411:419	their inhibition abilities	394:419	their inhibition abilities	394:419	But how the O-glycosylation affects their inhibition abilities has not been intensively explored.
36095241	0	16	theme	Chemoenzymatic	0:13	arg1	Synthesis					15:23	Chemoenzymatic Synthesis	0:23	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.	0:114	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.
36095241	5	17	theme	optimization	1226:1237	arg1	directions					1239:1248	novel optimization directions	1220:1248	novel optimization directions for the inhibitor design	1220:1273	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	5	18	theme	short	1096:1100	arg1	structures					1111:1120	short O-glycan structures	1096:1120	short O-glycan structures	1096:1120	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	3	19	theme	T	614:614	arg1	structures					741:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	5	20	from	residue	1069:1075	arg1	terminal					1084:1091	the terminal	1080:1091	the terminal of short O-glycan structures	1080:1120	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	1	21	theme	spike	203:207	arg1	protein					213:219	spike (S) protein	203:219	spike (S) protein	203:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	0	22	theme	SARS-CoV-2	28:37	arg1	Glycopeptides					60:72	SARS-CoV-2 Homogeneous O-Linked Glycopeptides	28:72	SARS-CoV-2 Homogeneous O-Linked Glycopeptides	28:72	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.
36095241	1	23	theme	effective	278:286	arg1	strategies					288:297	the most effective strategies	269:297	the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2	269:355	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	2	24	gly	O-glycosylation	370:384	arg1	inhibition					400:409	their inhibition abilities	394:419	their inhibition abilities	394:419	But how the O-glycosylation affects their inhibition abilities has not been intensively explored.
36095241	3	25	dep	sialyl-Tn	645:653	arg1	Siaα2-6GalNAcα1-O-Ser/Thr					661:685	Siaα2-6GalNAcα1-O-Ser/Thr	661:685	Siaα2-6GalNAcα1-O-Ser/Thr	661:685	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	25	dep	sialyl-Tn	645:653	arg1	sTn					656:658	sTn	656:658	sTn	656:658	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	1	26	theme	strategies	288:297	arg1	strategies					288:297	the most effective strategies	269:297	the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2	269:355	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	26	theme	strategies	288:297	arg1	one					262:264	one	262:264	one	262:264	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	5	27	theme	O-glycan	1102:1109	arg1	structures					1111:1120	short O-glycan structures	1096:1120	short O-glycan structures	1096:1120	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	1	28	theme	conserved	134:142	arg1	peptides					144:151	highly conserved peptides	127:151	highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein	127:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	3	29	theme	homogeneous	543:553	arg1	glycopeptides					564:576	homogeneous O-linked glycopeptides	543:576	homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	543:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	0	30	theme	O-Linked	51:58	arg1	Glycopeptides					60:72	SARS-CoV-2 Homogeneous O-Linked Glycopeptides	28:72	SARS-CoV-2 Homogeneous O-Linked Glycopeptides	28:72	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.
36095241	5	31	theme	structures	1111:1120	arg1	terminal					1084:1091	the terminal	1080:1091	the terminal of short O-glycan structures	1080:1120	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	5	32	theme	sialic	1057:1062	arg1	residue					1069:1075	the sialic acid residue	1053:1075	the sialic acid residue on the terminal of short O-glycan structures	1053:1120	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	3	33	theme	intrinsic	467:475	arg1	peptide					492:498	an intrinsic O-glycosylated peptide P320-334	464:507	an intrinsic O-glycosylated peptide P320-334 derived from RBD	464:524	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	0	34	theme	Homogeneous	39:49	arg1	Glycopeptides					60:72	SARS-CoV-2 Homogeneous O-Linked Glycopeptides	28:72	SARS-CoV-2 Homogeneous O-Linked Glycopeptides	28:72	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.
36095241	3	35	contain	containing	578:587	arg1	glycopeptides					564:576	homogeneous O-linked glycopeptides	543:576	homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	543:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	35	contain	containing	578:587	arg2	structures					741:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	36	link	O-linked	555:562	arg1	glycopeptides					564:576	homogeneous O-linked glycopeptides	543:576	homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	543:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	1	37	dep	spike	203:207	arg1	S					210:210	S	210:210	S	210:210	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	38	theme	protein	213:219	arg1	RBD					195:197	RBD	195:197	RBD	195:197	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	38	theme	protein	213:219	arg1	domain					187:192	the receptor binding domain	166:192	the receptor binding domain (RBD) of spike (S) protein	166:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	38	theme	protein	213:219	arg1	protein					213:219	spike (S) protein	203:219	spike (S) protein	203:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	3	39	gly	O-glycosylated	477:490	arg1	peptide					492:498	an intrinsic O-glycosylated peptide P320-334	464:507	an intrinsic O-glycosylated peptide P320-334 derived from RBD	464:524	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	0	40	theme	Glycopeptides	60:72	arg1	Synthesis					15:23	Chemoenzymatic Synthesis	0:23	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.	0:114	Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions.
36095241	1	41	theme	coronavirus	334:344	arg1	SARS-CoV-2					346:355	the ever-mutating coronavirus SARS-CoV-2	316:355	the ever-mutating coronavirus SARS-CoV-2	316:355	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	42	theme	ever-mutating	320:332	arg1	SARS-CoV-2					346:355	the ever-mutating coronavirus SARS-CoV-2	316:355	the ever-mutating coronavirus SARS-CoV-2	316:355	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	4	43	theme	sTn-	962:965	arg1	capacity					924:931	the inhibition capacity	909:931	the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334	909:981	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	5	44	theme	acid	1064:1067	arg1	residue					1069:1075	the sialic acid residue	1053:1075	the sialic acid residue on the terminal of short O-glycan structures	1053:1120	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	4	45	dep	%	1024:1024	arg1	up					1011:1012	up	1011:1012	up	1011:1012	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	3	46	theme	sialyl-T	693:700	arg1	structures					741:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	4	47	theme	unglycosylated	824:837	arg1	peptide					839:845	the unglycosylated peptide	820:845	the unglycosylated peptide	820:845	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	5	48	theme	inhibitor	1258:1266	arg1	design					1268:1273	the inhibitor design	1254:1273	the inhibitor design	1254:1273	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	3	49	theme	O-linked	555:562	arg1	glycopeptides					564:576	homogeneous O-linked glycopeptides	543:576	homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	543:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	50	theme	O-glycosylated	477:490	arg1	peptide					492:498	an intrinsic O-glycosylated peptide P320-334	464:507	an intrinsic O-glycosylated peptide P320-334 derived from RBD	464:524	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	3	51	theme	sialyl-Tn	645:653	arg1	structures					741:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures	589:750	Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies.
36095241	5	52	dep	suggest	1045:1051	arg1	strengthen					1128:1137	strengthen	1128:1137	suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design	1045:1273	Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
36095241	1	53	theme	receptor	170:177	arg1	RBD					195:197	RBD	195:197	RBD	195:197	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	53	theme	receptor	170:177	arg1	domain					187:192	the receptor binding domain	166:192	the receptor binding domain (RBD) of spike (S) protein	166:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	53	theme	receptor	170:177	arg1	protein					213:219	spike (S) protein	203:219	spike (S) protein	203:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	54	theme	peptide-based	234:246	arg1	inhibitors					248:257	peptide-based inhibitors	234:257	peptide-based inhibitors	234:257	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	4	55	gly	unglycosylated	824:837	arg1	peptide					839:845	the unglycosylated peptide	820:845	the unglycosylated peptide	820:845	Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%.
36095241	1	56	attach	derived	153:159	arg2	peptides					144:151	highly conserved peptides	127:151	highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein	127:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	56	attach	derived	153:159	arg1	RBD					195:197	RBD	195:197	RBD	195:197	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	56	attach	derived	153:159	arg1	domain					187:192	the receptor binding domain	166:192	the receptor binding domain (RBD) of spike (S) protein	166:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	56	attach	derived	153:159	arg1	protein					213:219	spike (S) protein	203:219	spike (S) protein	203:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	57	theme	binding	179:185	arg1	RBD					195:197	RBD	195:197	RBD	195:197	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	57	theme	binding	179:185	arg1	domain					187:192	the receptor binding domain	166:192	the receptor binding domain (RBD) of spike (S) protein	166:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
36095241	1	57	theme	binding	179:185	arg1	protein					213:219	spike (S) protein	203:219	spike (S) protein	203:219	Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2.
35335137	12	0	theme	various	1685:1691	arg1	mechanisms					1693:1702	various mechanisms	1685:1702	various mechanisms	1685:1702	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	5	1	theme	plasma	598:603	arg1	N-glycans					613:621	plasma and IgG N-glycans	598:621	plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs	598:692	We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs.
35335137	10	2	theme	plasma	1257:1262	arg1	glycans					1264:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	11	3	theme	stages	1546:1551	arg1	use					1522:1524	the use	1518:1524	the use of disease severity stages in the analysis of more complex diseases	1518:1592	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	11	3	theme	stages	1546:1551	arg1	phenotypes					1503:1512	better-refined phenotypes	1488:1512	better-refined phenotypes	1488:1512	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	5	4	theme	IgG	609:611	arg1	N-glycans					613:621	plasma and IgG N-glycans	598:621	plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs	598:692	We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs.
35335137	13	5	theme	study	1843:1847	arg1	designs					1849:1855	more advanced and refined study designs	1817:1855	more advanced and refined study designs	1817:1855	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	2	6	theme	severity	299:306	arg1	spectrum					308:315	the disease severity spectrum	287:315	the disease severity spectrum	287:315	Therefore, we aimed to investigate the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum.
35335137	8	7	theme	interesting	871:881	arg1	differences					883:893	several interesting differences	863:893	several interesting differences across the analysed groups	863:920	We detected several interesting differences across the analysed groups, suggesting that N-glycans can be used as a biomarker for AMD.
35335137	11	8	theme	disease	1529:1535	arg1	stages					1546:1551	disease severity stages	1529:1551	disease severity stages	1529:1551	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	6	9	theme	detected	717:724	arg1	cases					726:730	106 (3.7%) detected cases	706:730	106 (3.7%) detected cases of AMD	706:737	There were 106 (3.7%) detected cases of AMD; 66 of them were bilateral.
35335137	12	10	theme	macular	1607:1613	arg1	degeneration					1615:1626	Age-related macular degeneration	1595:1626	Age-related macular degeneration progression	1595:1638	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	9	11	theme	odds	1123:1126	arg1	AMD					1109:1111	unilateral AMD	1098:1111	unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1098:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	11	theme	odds	1123:1126	arg1	ratio					1128:1132	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	11	12	from	phenotypes	1503:1512	arg1	analysis					1560:1567	the analysis	1556:1567	the analysis of more complex diseases	1556:1592	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	8	13	theme	analysed	906:913	arg1	groups					915:920	the analysed groups	902:920	the analysed groups	902:920	We detected several interesting differences across the analysed groups, suggesting that N-glycans can be used as a biomarker for AMD.
35335137	9	14	from	decrease	1031:1038	arg1	structures					1084:1093	the immunomodulatory bi-antennary glycan structures	1043:1093	the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1043:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	4	15	dep	drusen	559:564	arg1	iii					542:544	iii	542:544	iii	542:544	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	9	16	theme	confidence	1144:1153	arg1	interval					1155:1162	95% confidence interval 0.22-0.79	1140:1172	95% confidence interval 0.22-0.79	1140:1172	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	16	theme	confidence	1144:1153	arg1	0.43					1134:1137	0.43	1134:1137	0.43	1134:1137	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	13	17	theme	refined	1835:1841	arg1	designs					1849:1855	more advanced and refined study designs	1817:1855	more advanced and refined study designs	1817:1855	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	11	18	theme	aggregated	1373:1382	arg1	analysis					1384:1391	the aggregated analysis	1369:1391	the aggregated analysis	1369:1391	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	2	19	theme	N-glycosylation	264:278	arg1	changes					229:235	the changes	225:235	the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum	225:315	Therefore, we aimed to investigate the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum.
35335137	10	20	theme	substantial	1196:1206	arg1	increase					1208:1215	a substantial increase	1194:1215	a substantial increase in the pro-inflammatory tetra-antennary plasma glycans	1194:1270	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	12	21	theme	Age-related	1595:1605	arg1	degeneration					1615:1626	Age-related macular degeneration	1595:1626	Age-related macular degeneration progression	1595:1638	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	10	22	from	increase	1208:1215	arg1	glycans					1264:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	13	23	theme	case-control	1797:1808	arg1	study					1810:1814	a simple case-control study	1788:1814	a simple case-control study	1788:1814	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	9	24	from	structures	1084:1093	arg1	AMD					1109:1111	unilateral AMD	1098:1111	unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1098:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	24	from	structures	1084:1093	arg1	ratio					1128:1132	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	1	25	theme	research	172:179	arg1	studies					181:187	numerous research studies	163:187	numerous research studies	163:187	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	8	26	used	used	956:959	arg2	N-glycans					939:947	N-glycans	939:947	N-glycans	939:947	We detected several interesting differences across the analysed groups, suggesting that N-glycans can be used as a biomarker for AMD.
35335137	8	26	used	used	956:959	arg2	biomarker					966:974	a biomarker	964:974	a biomarker for AMD	964:982	We detected several interesting differences across the analysed groups, suggesting that N-glycans can be used as a biomarker for AMD.
35335137	4	27	theme	bilateral	505:513	arg1	groups					486:491	four groups	481:491	four groups	481:491	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	4	27	theme	bilateral	505:513	arg1	AMD					515:517	(i) bilateral AMD	501:517	(i) bilateral AMD	501:517	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	9	28	theme	unilateral	1098:1107	arg1	AMD					1109:1111	unilateral AMD	1098:1111	unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1098:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	28	theme	unilateral	1098:1107	arg1	ratio					1128:1132	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	5	29	theme	fundus	675:680	arg1	photographs					682:692	retinal fundus photographs	667:692	retinal fundus photographs	667:692	We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs.
35335137	13	30	theme	diseases	1910:1917	arg1	pathogenesis					1886:1897	the pathogenesis	1882:1897	the pathogenesis of complex diseases	1882:1917	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	7	31	theme	retinal	835:841	arg1	drusen					843:848	early-onset retinal drusen	823:848	early-onset retinal drusen	823:848	In addition, 45 (0.9%) subjects were recorded as having early-onset retinal drusen.
35335137	3	32	theme	Dalmatians	360:369	arg1	project					371:377	the 10.001 Dalmatians project	349:377	the 10.001 Dalmatians project	349:377	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	4	33	dep	AMD	536:538	arg1	ii					521:522	ii	521:522	ii	521:522	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	5	34	with	HPLC	635:638	arg1	photographs					682:692	retinal fundus photographs	667:692	retinal fundus photographs	667:692	We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs.
35335137	3	35	theme	isolated	401:408	arg1	islands					419:425	the isolated Croatian islands	397:425	the isolated Croatian islands of Vis and Korčula	397:444	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	3	36	theme	Korčula	438:444	arg1	islands					419:425	the isolated Croatian islands	397:425	the isolated Croatian islands of Vis and Korčula	397:444	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	0	37	theme	N-Glycosylation	0:14	arg1	Patterns					16:23	N-Glycosylation Patterns	0:23	N-Glycosylation Patterns across the Age-Related Macular Degeneration Spectrum.	0:77	N-Glycosylation Patterns across the Age-Related Macular Degeneration Spectrum.
35335137	1	38	theme	macular	111:117	arg1	AMD					133:135	AMD	133:135	AMD	133:135	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	1	38	theme	macular	111:117	arg1	degeneration					119:130	age-related macular degeneration	99:130	age-related macular degeneration (AMD)	99:136	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	4	39	theme	unilateral	525:534	arg1	AMD					536:538	(ii) unilateral AMD	520:538	(ii) unilateral AMD	520:538	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	4	39	theme	unilateral	525:534	arg1	groups					486:491	four groups	481:491	four groups	481:491	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	9	40	theme	Multivariate	985:996	arg1	analysis					998:1005	Multivariate analysis	985:1005	Multivariate analysis	985:1005	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	3	41	theme	Vis	430:432	arg1	islands					419:425	the isolated Croatian islands	397:425	the isolated Croatian islands of Vis and Korčula	397:444	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	0	42	theme	Age-Related	36:46	arg1	Degeneration					56:67	the Age-Related Macular Degeneration	32:67	the Age-Related Macular Degeneration Spectrum	32:76	N-Glycosylation Patterns across the Age-Related Macular Degeneration Spectrum.
35335137	4	43	dep	AMD	515:517	arg1	i					502:502	i	502:502	i	502:502	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	11	44	from	use	1522:1524	arg1	analysis					1560:1567	the analysis	1556:1567	the analysis of more complex diseases	1556:1592	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	10	45	theme	pro-inflammatory	1224:1239	arg1	glycans					1264:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	0	46	theme	Degeneration	56:67	arg1	Spectrum					69:76	the Age-Related Macular Degeneration Spectrum	32:76	the Age-Related Macular Degeneration Spectrum	32:76	N-Glycosylation Patterns across the Age-Related Macular Degeneration Spectrum.
35335137	13	47	theme	complex	1902:1908	arg1	diseases					1910:1917	complex diseases	1902:1917	complex diseases	1902:1917	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	11	48	theme	diseases	1585:1592	arg1	analysis					1560:1567	the analysis	1556:1567	the analysis of more complex diseases	1556:1592	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	9	49	theme	immunomodulatory	1047:1062	arg1	structures					1084:1093	the immunomodulatory bi-antennary glycan structures	1043:1093	the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1043:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	12	50	theme	mechanisms	1693:1702	arg1	interplay					1672:1680	the complex interplay	1660:1680	the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans	1660:1771	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	9	51	theme	glycan	1077:1082	arg1	structures					1084:1093	the immunomodulatory bi-antennary glycan structures	1043:1093	the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1043:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	8	52	theme	several	863:869	arg1	differences					883:893	several interesting differences	863:893	several interesting differences across the analysed groups	863:920	We detected several interesting differences across the analysed groups, suggesting that N-glycans can be used as a biomarker for AMD.
35335137	11	53	theme	single	1447:1452	arg1	category					1454:1461	a single category	1445:1461	a single category	1445:1461	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	6	54	theme	AMD	735:737	arg1	cases					726:730	106 (3.7%) detected cases	706:730	106 (3.7%) detected cases of AMD	706:737	There were 106 (3.7%) detected cases of AMD; 66 of them were bilateral.
35335137	6	55	theme	106	706:708	arg1	cases					726:730	106 (3.7%) detected cases	706:730	106 (3.7%) detected cases of AMD	706:737	There were 106 (3.7%) detected cases of AMD; 66 of them were bilateral.
35335137	12	56	theme	complex	1664:1670	arg1	interplay					1672:1680	the complex interplay	1660:1680	the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans	1660:1771	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	4	57	theme	early-onset	547:557	arg1	groups					486:491	four groups	481:491	four groups	481:491	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	4	57	theme	early-onset	547:557	arg1	drusen					559:564	(iii) early-onset drusen	541:564	(iii) early-onset drusen	541:564	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	11	58	theme	disease	1410:1416	arg1	stages					1418:1423	all three disease stages	1400:1423	all three disease stages	1400:1423	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	2	59	theme	disease	291:297	arg1	spectrum					308:315	the disease severity spectrum	287:315	the disease severity spectrum	287:315	Therefore, we aimed to investigate the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum.
35335137	12	60	theme	degeneration	1615:1626	arg1	progression					1628:1638	Age-related macular degeneration progression	1595:1638	Age-related macular degeneration progression	1595:1638	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	11	61	theme	severity	1537:1544	arg1	stages					1546:1551	disease severity stages	1529:1551	disease severity stages	1529:1551	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	9	62	theme	adjusted	1114:1121	arg1	AMD					1109:1111	unilateral AMD	1098:1111	unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1098:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	62	theme	adjusted	1114:1121	arg1	ratio					1128:1132	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)	1114:1173	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	13	63	theme	advanced	1822:1829	arg1	designs					1849:1855	more advanced and refined study designs	1817:1855	more advanced and refined study designs	1817:1855	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	3	64	from	project	371:377	arg1	subjects					335:342	2835 subjects	330:342	2835 subjects	330:342	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	2	65	theme	plasma	240:245	arg1	changes					229:235	the changes	225:235	the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum	225:315	Therefore, we aimed to investigate the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum.
35335137	9	66	theme	%	1142:1142	arg1	interval					1155:1162	95% confidence interval 0.22-0.79	1140:1172	95% confidence interval 0.22-0.79	1140:1172	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	66	theme	%	1142:1142	arg1	0.43					1134:1137	0.43	1134:1137	0.43	1134:1137	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	13	67	theme	simple	1790:1795	arg1	study					1810:1814	a simple case-control study	1788:1814	a simple case-control study	1788:1814	As opposed to a simple case-control study, more advanced and refined study designs are needed to understand the pathogenesis of complex diseases.
35335137	2	68	theme	IgG-specific	251:262	arg1	N-glycosylation					264:278	IgG-specific N-glycosylation	251:278	IgG-specific N-glycosylation	251:278	Therefore, we aimed to investigate the changes of plasma and IgG-specific N-glycosylation across the disease severity spectrum.
35335137	3	69	theme	10.001	353:358	arg1	project					371:377	the 10.001 Dalmatians project	349:377	the 10.001 Dalmatians project	349:377	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	1	70	theme	numerous	163:170	arg1	studies					181:187	numerous research studies	163:187	numerous research studies	163:187	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	9	71	dep	ratio	1128:1132	arg1	interval					1155:1162	95% confidence interval 0.22-0.79	1140:1172	95% confidence interval 0.22-0.79	1140:1172	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	9	71	dep	ratio	1128:1132	arg1	0.43					1134:1137	0.43	1134:1137	0.43	1134:1137	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	5	72	theme	retinal	667:673	arg1	photographs					682:692	retinal fundus photographs	667:692	retinal fundus photographs	667:692	We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs.
35335137	10	73	theme	bilateral	1275:1283	arg1	AMD					1285:1287	bilateral AMD	1275:1287	bilateral AMD (7.90 (2.94-20.95))	1275:1307	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	10	73	theme	bilateral	1275:1283	arg1	2.94-20.95					1296:1305	2.94-20.95	1296:1305	2.94-20.95	1296:1305	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	7	74	theme	early-onset	823:833	arg1	drusen					843:848	early-onset retinal drusen	823:848	early-onset retinal drusen	823:848	In addition, 45 (0.9%) subjects were recorded as having early-onset retinal drusen.
35335137	1	75	theme	age-related	99:109	arg1	AMD					133:135	AMD	133:135	AMD	133:135	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	1	75	theme	age-related	99:109	arg1	degeneration					119:130	age-related macular degeneration	99:130	age-related macular degeneration (AMD)	99:136	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	3	76	theme	Croatian	410:417	arg1	islands					419:425	the isolated Croatian islands	397:425	the isolated Croatian islands of Vis and Korčula	397:444	We examined 2835 subjects from the 10.001 Dalmatians project, originating from the isolated Croatian islands of Vis and Korčula.
35335137	1	77	theme	degeneration	119:130	arg1	pathogenesis					83:94	The pathogenesis	79:94	The pathogenesis of age-related macular degeneration (AMD)	79:136	The pathogenesis of age-related macular degeneration (AMD) remains elusive, despite numerous research studies.
35335137	5	78	with	association	650:660	arg1	photographs					682:692	retinal fundus photographs	667:692	retinal fundus photographs	667:692	We analysed plasma and IgG N-glycans measured by HPLC and their association with retinal fundus photographs.
35335137	0	79	theme	Macular	48:54	arg1	Degeneration					56:67	the Age-Related Macular Degeneration	32:67	the Age-Related Macular Degeneration Spectrum	32:76	N-Glycosylation Patterns across the Age-Related Macular Degeneration Spectrum.
35335137	12	80	theme	IgG	1759:1761	arg1	N-glycans					1763:1771	IgG N-glycans	1759:1771	IgG N-glycans	1759:1771	Age-related macular degeneration progression is characterised by the complex interplay of various mechanisms, some of which can be detected by measuring plasma and IgG N-glycans.
35335137	10	81	theme	tetra-antennary	1241:1255	arg1	glycans					1264:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	the pro-inflammatory tetra-antennary plasma glycans	1220:1270	We also detected a substantial increase in the pro-inflammatory tetra-antennary plasma glycans in bilateral AMD (7.90 (2.94-20.95)).
35335137	6	82	theme	them	746:749	arg1	them					746:749	them	746:749	them	746:749	There were 106 (3.7%) detected cases of AMD; 66 of them were bilateral.
35335137	6	82	theme	them	746:749	arg1	66					740:741	66	740:741	66	740:741	There were 106 (3.7%) detected cases of AMD; 66 of them were bilateral.
35335137	9	83	theme	significant	1019:1029	arg1	decrease					1031:1038	a significant decrease	1017:1038	a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1017:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35335137	11	84	theme	complex	1577:1583	arg1	diseases					1585:1592	more complex diseases	1572:1592	more complex diseases	1572:1592	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	11	85	theme	better-refined	1488:1501	arg1	phenotypes					1503:1512	better-refined phenotypes	1488:1512	better-refined phenotypes	1488:1512	Notably, some of these associations were not identified in the aggregated analysis, where all three disease stages were collapsed into a single category, suggesting the need for better-refined phenotypes and the use of disease severity stages in the analysis of more complex diseases.
35335137	4	86	theme	iv	572:573	arg1	groups					486:491	four groups	481:491	four groups	481:491	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	4	86	theme	iv	572:573	arg1	controls					576:583	(iv) controls	571:583	(iv) controls	571:583	All subjects were classified into four groups, namely (i) bilateral AMD, (ii) unilateral AMD, (iii) early-onset drusen, and (iv) controls.
35335137	9	87	theme	bi-antennary	1064:1075	arg1	structures					1084:1093	the immunomodulatory bi-antennary glycan structures	1043:1093	the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79))	1043:1174	Multivariate analysis suggested a significant decrease in the immunomodulatory bi-antennary glycan structures in unilateral AMD (adjusted odds ratio 0.43 (95% confidence interval 0.22-0.79)).
35715659	9	0	theme	tumor	1483:1487	arg1	regression					1489:1498	tumor regression	1483:1498	tumor regression	1483:1498	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	3	1	theme	cell	500:503	arg1	KATO-III					523:530	KATO-III	523:530	KATO-III	523:530	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	1	theme	cell	500:503	arg1	NUGC-4					512:517	NUGC-4	512:517	NUGC-4	512:517	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	1	theme	cell	500:503	arg1	lines					505:509	METHODS SRC cell lines	488:509	METHODS SRC cell lines (NUGC-4 and KATO-III)	488:531	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	10	2	theme	glycan	1567:1572	arg1	profiles					1574:1581	specific glycan profiles	1558:1581	specific glycan profiles	1558:1581	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	3	3	theme	SRC-specific	653:664	arg1	glycans					666:672	the SRC-specific glycans	649:672	the SRC-specific glycans	649:672	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	0	4	theme	Glycan	0:5	arg1	profile					18:24	Glycan expression profile	0:24	Glycan expression profile of signet ring cell gastric cancer cells	0:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	4	5	theme	high-affinity	814:826	arg1	lectins					828:834	high-affinity lectins	814:834	high-affinity lectins for SRC	814:842	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	11	6	theme	targeted	1664:1671	arg1	applicable					1711:1720	applicable	1711:1720	applicable	1711:1720	Additionally, we found a targeted therapy using rBC2LCN lectin might be applicable as an alternative treatment option for patients with SRC.
35715659	11	6	theme	targeted	1664:1671	arg1	therapy					1673:1679	a targeted therapy	1662:1679	a targeted therapy using rBC2LCN lectin	1662:1700	Additionally, we found a targeted therapy using rBC2LCN lectin might be applicable as an alternative treatment option for patients with SRC.
35715659	3	7	theme	NSRC	546:549	arg1	lines					557:561	non-SRC (NSRC) cell lines	537:561	non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45)	537:590	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	7	theme	NSRC	546:549	arg1	SNU-1					573:577	SNU-1	573:577	SNU-1	573:577	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	7	theme	NSRC	546:549	arg1	MKN-45					584:589	MKN-45	584:589	MKN-45	584:589	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	7	theme	NSRC	546:549	arg1	NCI-N87					564:570	NCI-N87	564:570	NCI-N87	564:570	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	6	8	theme	sialic	1090:1095	arg1	acids					1097:1101	α2-6-linked sialic acids	1078:1101	α2-6-linked sialic acids	1078:1101	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	6	8	theme	sialic	1090:1095	arg1	structure					1067:1075	the same glycan structure	1051:1075	the same glycan structure	1051:1075	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	7	9	dep	highest	1164:1170	arg1	followed					1208:1215	followed	1208:1215	followed by the BPL lectin (1.786-fold)	1208:1246	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	0	10	theme	drug	122:125	arg1	therapy					137:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	3	11	theme	non-SRC	537:543	arg1	lines					557:561	non-SRC (NSRC) cell lines	537:561	non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45)	537:590	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	11	theme	non-SRC	537:543	arg1	SNU-1					573:577	SNU-1	573:577	SNU-1	573:577	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	11	theme	non-SRC	537:543	arg1	MKN-45					584:589	MKN-45	584:589	MKN-45	584:589	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	11	theme	non-SRC	537:543	arg1	NCI-N87					564:570	NCI-N87	564:570	NCI-N87	564:570	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	10	12	link	α2-6-linked	1613:1623	arg1	acids					1632:1636	reduced α2-6-linked sialic acids	1605:1636	reduced α2-6-linked sialic acids	1605:1636	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	0	13	theme	therapy	137:143	arg1	profile					18:24	Glycan expression profile	0:24	Glycan expression profile of signet ring cell gastric cancer cells	0:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	0	13	theme	therapy	137:143	arg1	applicability					81:93	potential applicability	71:93	potential applicability of rBC2LCN-targeted lectin drug conjugate therapy	71:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	8	14	theme	NSRC	1330:1333	arg1	lines					1340:1344	the three NSRC cell lines	1320:1344	the three NSRC cell lines	1320:1344	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	3	15	theme	cell	552:555	arg1	lines					557:561	non-SRC (NSRC) cell lines	537:561	non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45)	537:590	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	15	theme	cell	552:555	arg1	SNU-1					573:577	SNU-1	573:577	SNU-1	573:577	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	15	theme	cell	552:555	arg1	MKN-45					584:589	MKN-45	584:589	MKN-45	584:589	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	15	theme	cell	552:555	arg1	NCI-N87					564:570	NCI-N87	564:570	NCI-N87	564:570	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	8	16	theme	lines	1340:1344	arg1	NCI-N87					1347:1353	NCI-N87	1347:1353	NCI-N87	1347:1353	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	8	16	theme	lines	1340:1344	arg1	one					1313:1315	one	1313:1315	one	1313:1315	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	8	16	theme	lines	1340:1344	arg1	lines					1340:1344	the three NSRC cell lines	1320:1344	the three NSRC cell lines	1320:1344	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	9	17	dep	rBC2LCN-PE38	1393:1404	arg1	rBC2LCN					1407:1413	rBC2LCN	1407:1413	rBC2LCN	1407:1413	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	9	17	dep	rBC2LCN-PE38	1393:1404	arg1	A					1441:1441	Pseudomonas exotoxin A	1420:1441	Pseudomonas exotoxin A	1420:1441	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	9	18	theme	exotoxin	1432:1439	arg1	A					1441:1441	Pseudomonas exotoxin A	1420:1441	Pseudomonas exotoxin A	1420:1441	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	0	19	theme	cancer	54:59	arg1	cells					61:65	signet ring cell gastric cancer cells	29:65	signet ring cell gastric cancer cells	29:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	1	20	theme	glycans	297:303	arg1	characteristics					258:272	the specific characteristics	245:272	the specific characteristics of cancer cell surface glycans and glycosylation	245:321	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	21	theme	Signet	157:162	arg1	SRC					185:187	SRC	185:187	SRC	185:187	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	21	theme	Signet	157:162	arg1	carcinoma					174:182	BACKGROUND Signet ring cell carcinoma	146:182	BACKGROUND Signet ring cell carcinoma (SRC)	146:188	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	21	theme	Signet	157:162	arg1	subtype					204:210	a distinct subtype	193:210	a distinct subtype of gastric cancer (GC)	193:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	2	22	theme	therapy	479:485	arg1	applicability					443:455	the potential applicability	429:455	the potential applicability of a glycan-targeting therapy	429:485	In this study, we investigated SRC-specific glycans using lectin microarray and evaluated the potential applicability of a glycan-targeting therapy.
35715659	1	23	theme	glycosylation	309:321	arg1	characteristics					258:272	the specific characteristics	245:272	the specific characteristics of cancer cell surface glycans and glycosylation	245:321	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	24	theme	cell	169:172	arg1	SRC					185:187	SRC	185:187	SRC	185:187	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	24	theme	cell	169:172	arg1	carcinoma					174:182	BACKGROUND Signet ring cell carcinoma	146:182	BACKGROUND Signet ring cell carcinoma (SRC)	146:188	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	24	theme	cell	169:172	arg1	subtype					204:210	a distinct subtype	193:210	a distinct subtype of gastric cancer (GC)	193:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	6	25	theme	Glycan-binding	951:964	arg1	motifs					966:971	Glycan-binding motifs	951:971	Glycan-binding motifs	951:971	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	10	26	theme	specific	1558:1565	arg1	profiles					1574:1581	specific glycan profiles	1558:1581	specific glycan profiles	1558:1581	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	7	27	from	ratio	1108:1112	arg1	SRC					1137:1139	SRC	1137:1139	SRC	1137:1139	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	8	28	theme	rBC2LCN	1249:1255	arg1	lectin					1257:1262	rBC2LCN lectin	1249:1262	rBC2LCN lectin	1249:1262	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	0	29	theme	rBC2LCN-targeted	98:113	arg1	therapy					137:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	10	30	dep	CONCLUSION	1535:1544	arg1	reported					1549:1556	reported	1549:1556	reported	1549:1556	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	11	31	theme	alternative	1728:1738	arg1	option					1750:1755	an alternative treatment option	1725:1755	an alternative treatment option for patients with SRC	1725:1777	Additionally, we found a targeted therapy using rBC2LCN lectin might be applicable as an alternative treatment option for patients with SRC.
35715659	7	32	theme	signal	1117:1122	arg1	intensity					1124:1132	signal intensity	1117:1132	signal intensity	1117:1132	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	9	33	theme	Pseudomonas	1420:1430	arg1	A					1441:1441	Pseudomonas exotoxin A	1420:1441	Pseudomonas exotoxin A	1420:1441	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	7	34	theme	BPL	1224:1226	arg1	1.786-fold					1236:1245	1.786-fold	1236:1245	1.786-fold	1236:1245	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	7	34	theme	BPL	1224:1226	arg1	lectin					1228:1233	the BPL lectin	1220:1233	the BPL lectin (1.786-fold)	1220:1246	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	4	35	theme	immunohistochemical	702:720	arg1	staining					729:736	immunohistochemical lectin staining	702:736	immunohistochemical lectin staining	702:736	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	2	36	theme	lectin	397:402	arg1	microarray					404:413	lectin microarray	397:413	lectin microarray	397:413	In this study, we investigated SRC-specific glycans using lectin microarray and evaluated the potential applicability of a glycan-targeting therapy.
35715659	1	37	theme	specific	249:256	arg1	characteristics					258:272	the specific characteristics	245:272	the specific characteristics of cancer cell surface glycans and glycosylation	245:321	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	5	38	theme	low-affinity	905:916	arg1	lectins					918:924	8 low-affinity lectins	903:924	8 low-affinity lectins	903:924	RESULTS Among the 96 lectins tested, 11 high-affinity and 8 low-affinity lectins were identified for SRC.
35715659	4	39	theme	drug	785:788	arg1	LDCs					802:805	LDCs	802:805	LDCs	802:805	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	4	39	theme	drug	785:788	arg1	conjugates					790:799	lectin drug conjugates	778:799	lectin drug conjugates (LDCs)	778:806	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	0	40	theme	signet	29:34	arg1	cells					61:65	signet ring cell gastric cancer cells	29:65	signet ring cell gastric cancer cells	29:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	8	41	theme	cell	1298:1301	arg1	lines					1303:1307	SRC cell lines	1294:1307	SRC cell lines	1294:1307	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	0	42	theme	cell	41:44	arg1	cells					61:65	signet ring cell gastric cancer cells	29:65	signet ring cell gastric cancer cells	29:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	1	43	theme	cell	284:287	arg1	glycans					297:303	cancer cell surface glycans	277:303	cancer cell surface glycans	277:303	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	9	44	theme	cytocidal	1452:1460	arg1	effects					1462:1468	cytocidal effects	1452:1468	cytocidal effects in vitro	1452:1477	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	3	45	theme	microarray	617:626	arg1	analysis					628:635	lectin microarray analysis	610:635	lectin microarray analysis	610:635	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	4	46	theme	anti-tumor	756:765	arg1	effects					767:773	the anti-tumor effects	752:773	the anti-tumor effects of lectin drug conjugates (LDCs)	752:806	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	10	47	theme	SRC	1586:1588	arg1	cells					1590:1594	SRC cells	1586:1594	SRC cells	1586:1594	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	6	48	theme	same	1055:1058	arg1	acids					1097:1101	α2-6-linked sialic acids	1078:1101	α2-6-linked sialic acids	1078:1101	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	6	48	theme	same	1055:1058	arg1	structure					1067:1075	the same glycan structure	1051:1075	the same glycan structure	1051:1075	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	1	49	theme	cancer	223:228	arg1	carcinoma					174:182	BACKGROUND Signet ring cell carcinoma	146:182	BACKGROUND Signet ring cell carcinoma (SRC)	146:188	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	49	theme	cancer	223:228	arg1	subtype					204:210	a distinct subtype	193:210	a distinct subtype of gastric cancer (GC)	193:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	9	50	dep	in	1503:1504	arg1	vivo					1506:1509	vivo	1506:1509	vivo	1506:1509	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	3	51	theme	SRC	496:498	arg1	KATO-III					523:530	KATO-III	523:530	KATO-III	523:530	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	51	theme	SRC	496:498	arg1	NUGC-4					512:517	NUGC-4	512:517	NUGC-4	512:517	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	51	theme	SRC	496:498	arg1	lines					505:509	METHODS SRC cell lines	488:509	METHODS SRC cell lines (NUGC-4 and KATO-III)	488:531	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	9	52	theme	xenograft	1517:1525	arg1	models					1527:1532	in vivo mouse xenograft models	1503:1532	in vivo mouse xenograft models	1503:1532	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	6	53	theme	low-affinity	1024:1035	arg1	lectins					1037:1043	5 (62.5%) low-affinity lectins	1014:1043	5 (62.5%) low-affinity lectins	1014:1043	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	9	54	theme	in	1503:1504	arg1	models					1527:1532	in vivo mouse xenograft models	1503:1532	in vivo mouse xenograft models	1503:1532	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	9	55	theme	LDC	1388:1390	arg1	rBC2LCN-PE38					1393:1404	rBC2LCN-PE38	1393:1404	rBC2LCN-PE38	1393:1404	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	9	55	theme	LDC	1388:1390	arg1	effects					1373:1379	The therapeutic effects	1357:1379	The therapeutic effects of the LDC	1357:1390	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	9	56	theme	mouse	1511:1515	arg1	models					1527:1532	in vivo mouse xenograft models	1503:1532	in vivo mouse xenograft models	1503:1532	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	3	57	dep	lines	557:561	arg1	lines					557:561	non-SRC (NSRC) cell lines	537:561	non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45)	537:590	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	57	dep	lines	557:561	arg1	SNU-1					573:577	SNU-1	573:577	SNU-1	573:577	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	57	dep	lines	557:561	arg1	MKN-45					584:589	MKN-45	584:589	MKN-45	584:589	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	57	dep	lines	557:561	arg1	NCI-N87					564:570	NCI-N87	564:570	NCI-N87	564:570	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	0	58	theme	conjugate	127:135	arg1	therapy					137:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	8	59	theme	SRC	1294:1296	arg1	lines					1303:1307	SRC cell lines	1294:1307	SRC cell lines	1294:1307	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	10	60	theme	α2-6-linked	1613:1623	arg1	acids					1632:1636	reduced α2-6-linked sialic acids	1605:1636	reduced α2-6-linked sialic acids	1605:1636	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	10	61	theme	sialic	1625:1630	arg1	acids					1632:1636	reduced α2-6-linked sialic acids	1605:1636	reduced α2-6-linked sialic acids	1605:1636	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	6	62	theme	α2-6-linked	1078:1088	arg1	acids					1097:1101	α2-6-linked sialic acids	1078:1101	α2-6-linked sialic acids	1078:1101	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	6	62	theme	α2-6-linked	1078:1088	arg1	structure					1067:1075	the same glycan structure	1051:1075	the same glycan structure	1051:1075	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	1	63	theme	distinct	195:202	arg1	carcinoma					174:182	BACKGROUND Signet ring cell carcinoma	146:182	BACKGROUND Signet ring cell carcinoma (SRC)	146:188	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	63	theme	distinct	195:202	arg1	subtype					204:210	a distinct subtype	193:210	a distinct subtype of gastric cancer (GC)	193:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	8	64	theme	cell	1335:1338	arg1	lines					1340:1344	the three NSRC cell lines	1320:1344	the three NSRC cell lines	1320:1344	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	11	65	with	patients	1761:1768	arg1	SRC					1775:1777	SRC	1775:1777	SRC	1775:1777	Additionally, we found a targeted therapy using rBC2LCN lectin might be applicable as an alternative treatment option for patients with SRC.
35715659	9	66	theme	therapeutic	1361:1371	arg1	rBC2LCN-PE38					1393:1404	rBC2LCN-PE38	1393:1404	rBC2LCN-PE38	1393:1404	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	9	66	theme	therapeutic	1361:1371	arg1	effects					1373:1379	The therapeutic effects	1357:1379	The therapeutic effects of the LDC	1357:1390	The therapeutic effects of the LDC, rBC2LCN-PE38 (rBC2LCN, and Pseudomonas exotoxin A), showed cytocidal effects in vitro and tumor regression in in vivo mouse xenograft models.
35715659	6	67	theme	high-affinity	987:999	arg1	lectins					1001:1007	the high-affinity lectins	983:1007	the high-affinity lectins	983:1007	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	6	68	theme	glycan	1060:1065	arg1	acids					1097:1101	α2-6-linked sialic acids	1078:1101	α2-6-linked sialic acids	1078:1101	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	6	68	theme	glycan	1060:1065	arg1	structure					1067:1075	the same glycan structure	1051:1075	the same glycan structure	1051:1075	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	0	69	theme	cells	61:65	arg1	profile					18:24	Glycan expression profile	0:24	Glycan expression profile of signet ring cell gastric cancer cells	0:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	0	69	theme	cells	61:65	arg1	applicability					81:93	potential applicability	71:93	potential applicability of rBC2LCN-targeted lectin drug conjugate therapy	71:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	1	70	theme	BACKGROUND	146:155	arg1	SRC					185:187	SRC	185:187	SRC	185:187	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	70	theme	BACKGROUND	146:155	arg1	carcinoma					174:182	BACKGROUND Signet ring cell carcinoma	146:182	BACKGROUND Signet ring cell carcinoma (SRC)	146:188	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	70	theme	BACKGROUND	146:155	arg1	subtype					204:210	a distinct subtype	193:210	a distinct subtype of gastric cancer (GC)	193:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	0	71	theme	potential	71:79	arg1	applicability					81:93	potential applicability	71:93	potential applicability of rBC2LCN-targeted lectin drug conjugate therapy	71:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	1	72	theme	ring	164:167	arg1	SRC					185:187	SRC	185:187	SRC	185:187	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	72	theme	ring	164:167	arg1	carcinoma					174:182	BACKGROUND Signet ring cell carcinoma	146:182	BACKGROUND Signet ring cell carcinoma (SRC)	146:188	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	72	theme	ring	164:167	arg1	subtype					204:210	a distinct subtype	193:210	a distinct subtype of gastric cancer (GC)	193:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	2	73	theme	glycan-targeting	462:477	arg1	therapy					479:485	a glycan-targeting therapy	460:485	a glycan-targeting therapy	460:485	In this study, we investigated SRC-specific glycans using lectin microarray and evaluated the potential applicability of a glycan-targeting therapy.
35715659	6	74	link	α2-6-linked	1078:1088	arg1	acids					1097:1101	α2-6-linked sialic acids	1078:1101	α2-6-linked sialic acids	1078:1101	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	6	74	link	α2-6-linked	1078:1088	arg1	structure					1067:1075	the same glycan structure	1051:1075	the same glycan structure	1051:1075	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	10	75	theme	reduced	1605:1611	arg1	acids					1632:1636	reduced α2-6-linked sialic acids	1605:1636	reduced α2-6-linked sialic acids	1605:1636	CONCLUSION We reported specific glycan profiles in SRC cells, showing reduced α2-6-linked sialic acids.
35715659	4	76	theme	lectin	722:727	arg1	staining					729:736	immunohistochemical lectin staining	702:736	immunohistochemical lectin staining	702:736	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	0	77	theme	lectin	115:120	arg1	therapy					137:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	rBC2LCN-targeted lectin drug conjugate therapy	98:143	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	7	78	theme	intensity	1124:1132	arg1	ratio					1108:1112	The ratio	1104:1112	The ratio of signal intensity in SRC to NSRC (SRC/NSRC)	1104:1158	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	7	78	theme	intensity	1124:1132	arg1	highest					1164:1170	highest	1164:1170	highest	1164:1170	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	0	79	theme	expression	7:16	arg1	profile					18:24	Glycan expression profile	0:24	Glycan expression profile of signet ring cell gastric cancer cells	0:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	11	80	theme	treatment	1740:1748	arg1	option					1750:1755	an alternative treatment option	1725:1755	an alternative treatment option for patients with SRC	1725:1777	Additionally, we found a targeted therapy using rBC2LCN lectin might be applicable as an alternative treatment option for patients with SRC.
35715659	3	81	dep	lines	505:509	arg1	KATO-III					523:530	KATO-III	523:530	KATO-III	523:530	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	81	dep	lines	505:509	arg1	NUGC-4					512:517	NUGC-4	512:517	NUGC-4	512:517	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	81	dep	lines	505:509	arg1	lines					505:509	METHODS SRC cell lines	488:509	METHODS SRC cell lines (NUGC-4 and KATO-III)	488:531	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	6	82	theme	5	1014:1014	arg1	lectins					1037:1043	5 (62.5%) low-affinity lectins	1014:1043	5 (62.5%) low-affinity lectins	1014:1043	Glycan-binding motifs varied in the high-affinity lectins, but 5 (62.5%) low-affinity lectins bound the same glycan structure, α2-6-linked sialic acids.
35715659	8	83	theme	high	1271:1274	arg1	affinity					1276:1283	high affinity	1271:1283	high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87)	1271:1354	rBC2LCN lectin showed high affinity for both SRC cell lines and one of the three NSRC cell lines (NCI-N87).
35715659	0	84	theme	ring	36:39	arg1	cells					61:65	signet ring cell gastric cancer cells	29:65	signet ring cell gastric cancer cells	29:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	4	85	theme	lectin	778:783	arg1	LDCs					802:805	LDCs	802:805	LDCs	802:805	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	4	85	theme	lectin	778:783	arg1	conjugates					790:799	lectin drug conjugates	778:799	lectin drug conjugates (LDCs)	778:806	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	2	86	theme	SRC-specific	370:381	arg1	glycans					383:389	SRC-specific glycans	370:389	SRC-specific glycans using lectin microarray	370:413	In this study, we investigated SRC-specific glycans using lectin microarray and evaluated the potential applicability of a glycan-targeting therapy.
35715659	0	87	theme	gastric	46:52	arg1	cells					61:65	signet ring cell gastric cancer cells	29:65	signet ring cell gastric cancer cells	29:65	Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN-targeted lectin drug conjugate therapy.
35715659	1	88	theme	cancer	277:282	arg1	glycans					297:303	cancer cell surface glycans	277:303	cancer cell surface glycans	277:303	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	2	89	theme	potential	433:441	arg1	applicability					443:455	the potential applicability	429:455	the potential applicability of a glycan-targeting therapy	429:485	In this study, we investigated SRC-specific glycans using lectin microarray and evaluated the potential applicability of a glycan-targeting therapy.
35715659	3	90	theme	lectin	610:615	arg1	analysis					628:635	lectin microarray analysis	610:635	lectin microarray analysis	610:635	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	4	91	theme	conjugates	790:799	arg1	effects					767:773	the anti-tumor effects	752:773	the anti-tumor effects of lectin drug conjugates (LDCs)	752:806	Additionally, we performed immunohistochemical lectin staining and evaluated the anti-tumor effects of lectin drug conjugates (LDCs) using high-affinity lectins for SRC.
35715659	3	92	theme	METHODS	488:494	arg1	KATO-III					523:530	KATO-III	523:530	KATO-III	523:530	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	92	theme	METHODS	488:494	arg1	NUGC-4					512:517	NUGC-4	512:517	NUGC-4	512:517	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	3	92	theme	METHODS	488:494	arg1	lines					505:509	METHODS SRC cell lines	488:509	METHODS SRC cell lines (NUGC-4 and KATO-III)	488:531	METHODS SRC cell lines (NUGC-4 and KATO-III) and non-SRC (NSRC) cell lines (NCI-N87, SNU-1, and MKN-45) were subjected to lectin microarray analysis to identify the SRC-specific glycans.
35715659	1	93	theme	surface	289:295	arg1	glycans					297:303	cancer cell surface glycans	277:303	cancer cell surface glycans	277:303	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	7	94	theme	rBC2LCN	1179:1185	arg1	lectin					1187:1192	the rBC2LCN lectin	1175:1192	the rBC2LCN lectin (1.930-fold)	1175:1205	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	7	94	theme	rBC2LCN	1179:1185	arg1	1.930-fold					1195:1204	1.930-fold	1195:1204	1.930-fold	1195:1204	The ratio of signal intensity in SRC to NSRC (SRC/NSRC) was highest in the rBC2LCN lectin (1.930-fold), followed by the BPL lectin (1.786-fold).
35715659	11	95	theme	rBC2LCN	1687:1693	arg1	lectin					1695:1700	rBC2LCN lectin	1687:1700	rBC2LCN lectin	1687:1700	Additionally, we found a targeted therapy using rBC2LCN lectin might be applicable as an alternative treatment option for patients with SRC.
35715659	1	96	theme	gastric	215:221	arg1	cancer					223:228	gastric cancer	215:228	gastric cancer (GC)	215:233	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35715659	1	96	theme	gastric	215:221	arg1	GC					231:232	GC	231:232	GC	231:232	BACKGROUND Signet ring cell carcinoma (SRC) is a distinct subtype of gastric cancer (GC); however, the specific characteristics of cancer cell surface glycans and glycosylation remain unclear.
35925863	4	0	theme	high-throughput	605:619	arg1	platform					658:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	8	1	from	changes	1260:1266	arg1	subclasses					1288:1297	different glycan subclasses	1271:1297	different glycan subclasses sharing certain structural features	1271:1333	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	12	2	theme	"	1936:1936	arg1	surveillance					1938:1949	"Long-COVID" surveillance	1925:1949	"Long-COVID" surveillance to capture the full spectrum of persistent symptoms	1925:2001	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	2	3	theme	COVID-19	304:311	arg1	pandemic					314:321	The corona virus disease-2019 (COVID-19) pandemic	273:321	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	273:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	4	4	theme	potential	703:711	arg1	alterations					750:760	potential COVID-19-associated serum N-glycomic alterations	703:760	potential COVID-19-associated serum N-glycomic alterations	703:760	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	10	5	theme	serum	1563:1567	arg1	variables					1578:1586	13 serum glycomic variables	1560:1586	13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls	1560:1661	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	2	6	theme	disease-2019	290:301	arg1	pandemic					314:321	The corona virus disease-2019 (COVID-19) pandemic	273:321	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	273:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	4	7	theme	serum	733:737	arg1	alterations					750:760	potential COVID-19-associated serum N-glycomic alterations	703:760	potential COVID-19-associated serum N-glycomic alterations	703:760	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	1	8	theme	biological	203:212	arg1	glycome					220:226	biological fluid glycome	203:226	biological fluid glycome	203:226	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	8	9	theme	glycan	1281:1286	arg1	subclasses					1288:1297	different glycan subclasses	1271:1297	different glycan subclasses sharing certain structural features	1271:1333	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	6	10	theme	higher	1048:1053	arg1	levels					1055:1060	significantly higher levels	1034:1060	significantly higher levels of glycans and variability	1034:1087	Although there were no specific glycan peaks exclusively present or absent in COVID-19 positive cohort, this cohort showed significantly higher levels of glycans and variability.
35925863	4	11	dep	high-throughput	605:619	arg1	high-sensitivity					622:637	high-sensitivity	622:637	high-sensitivity	622:637	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	8	12	theme	structural	1315:1324	arg1	features					1326:1333	certain structural features	1307:1333	certain structural features	1307:1333	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	7	13	theme	N-glycomic	1119:1128	arg1	profiles					1130:1137	the overall N-glycomic profiles	1107:1137	the overall N-glycomic profiles for healthy controls	1107:1158	On the contrary, the overall N-glycomic profiles for healthy controls were well-contained within a narrow range.
35925863	9	14	theme	hyperbranched	1360:1372	arg1	glycans					1394:1400	the hyperbranched and hypersialylated glycans	1356:1400	the hyperbranched and hypersialylated glycans	1356:1400	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	2	15	theme	corona	277:282	arg1	pandemic					314:321	The corona virus disease-2019 (COVID-19) pandemic	273:321	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	273:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	9	16	theme	hypersialylated	1378:1392	arg1	glycans					1394:1400	the hyperbranched and hypersialylated glycans	1356:1400	the hyperbranched and hypersialylated glycans	1356:1400	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	10	17	from	controls	1654:1661	arg1	positive					1632:1639	positive	1632:1639	positive	1632:1639	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	0	18	theme	COVID-19	80:87	arg1	surveillance					64:75	surveillance	64:75	surveillance of COVID-19	64:87	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19.
35925863	11	19	theme	serum	1669:1673	arg1	changes					1686:1692	Such serum N-glycomic changes	1664:1692	Such serum N-glycomic changes described herein	1664:1709	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	9	20	theme	derived	1412:1418	arg1	traits					1436:1441	their derived glycan subclass traits	1406:1441	their derived glycan subclass traits	1406:1441	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	10	21	theme	positive	1632:1639	arg1	COVID-19					1623:1630	the COVID-19	1619:1630	the COVID-19 positive from healthy controls	1619:1661	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	2	22	theme	human	436:440	arg1	health					442:447	global human health	429:447	global human health	429:447	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	9	23	theme	subclass	1427:1434	arg1	traits					1436:1441	their derived glycan subclass traits	1406:1441	their derived glycan subclass traits	1406:1441	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	11	24	gly	glycoproteins	1761:1773	arg1	glycoproteins					1761:1773	serum glycoproteins	1755:1773	serum glycoproteins	1755:1773	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	9	25	link	derived	1412:1418	arg1	traits					1436:1441	their derived glycan subclass traits	1406:1441	their derived glycan subclass traits	1406:1441	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	0	26	theme	Serum	0:4	arg1	profiling					17:25	Serum N-glycomic profiling	0:25	Serum N-glycomic profiling	0:25	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19.
35925863	3	27	theme	SARS-CoV-2	473:482	arg1	infection					484:492	SARS-CoV-2 infection	473:492	SARS-CoV-2 infection	473:492	However, the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile has been largely unexplored.
35925863	10	28	theme	healthy	1646:1652	arg1	controls					1654:1661	healthy controls	1646:1661	healthy controls	1646:1661	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	2	29	theme	global	429:434	arg1	health					442:447	global human health	429:447	global human health	429:447	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	6	30	theme	glycan	943:948	arg1	peaks					950:954	no specific glycan peaks	931:954	no specific glycan peaks	931:954	Although there were no specific glycan peaks exclusively present or absent in COVID-19 positive cohort, this cohort showed significantly higher levels of glycans and variability.
35925863	12	31	theme	symptoms	1994:2001	arg1	spectrum					1971:1978	the full spectrum	1962:1978	the full spectrum of persistent symptoms	1962:2001	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	10	32	theme	stochastic	1458:1467	arg1	embedding					1478:1486	T-distributed stochastic neighbor embedding	1444:1486	T-distributed stochastic neighbor embedding	1444:1486	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	3	33	theme	overall	501:507	arg1	profile					526:532	the overall serum N-glycomic profile	497:532	the overall serum N-glycomic profile	497:532	However, the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile has been largely unexplored.
35925863	5	34	theme	positive	881:888	arg1	fingerprints					856:867	the serum N-glycomic fingerprints	835:867	the serum N-glycomic fingerprints of COVID-19 positive and control cohorts	835:908	Use of this platform revealed both similarities and differences between the serum N-glycomic fingerprints of COVID-19 positive and control cohorts.
35925863	8	35	from	analysis	1227:1234	arg1	able					1245:1248	able	1245:1248	able	1245:1248	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	2	36	theme	respiratory	346:356	arg1	coronavirus					367:377	severe acute respiratory syndrome coronavirus 2	333:379	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	333:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	2	36	theme	respiratory	346:356	arg1	SARS-CoV-2					382:391	SARS-CoV-2	382:391	SARS-CoV-2	382:391	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	3	37	from	effect	463:468	arg1	profile					526:532	the overall serum N-glycomic profile	497:532	the overall serum N-glycomic profile	497:532	However, the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile has been largely unexplored.
35925863	12	38	theme	full	1966:1969	arg1	spectrum					1971:1978	the full spectrum	1962:1978	the full spectrum of persistent symptoms	1962:2001	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	4	39	theme	N-glycan	639:646	arg1	platform					658:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	10	40	theme	hierarchical	1492:1503	arg1	analysis					1524:1531	hierarchical heatmap clustering analysis	1492:1531	hierarchical heatmap clustering analysis	1492:1531	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	1	41	theme	disease	253:259	arg1	signatures					261:270	disease signatures	253:270	disease signatures	253:270	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	1	41	theme	disease	253:259	arg1	changes					192:198	changes	192:198	changes in biological fluid glycome	192:226	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	8	42	theme	glycomic	1218:1225	arg1	analysis					1227:1234	the serum glycomic analysis	1208:1234	the serum glycomic analysis	1208:1234	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	11	43	theme	COVID-19	1780:1787	arg1	infection					1789:1797	COVID-19 infection	1780:1797	COVID-19 infection	1780:1797	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	3	44	theme	N-glycomic	515:524	arg1	profile					526:532	the overall serum N-glycomic profile	497:532	the overall serum N-glycomic profile	497:532	However, the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile has been largely unexplored.
35925863	6	45	theme	positive	998:1005	arg1	cohort					1007:1012	COVID-19 positive cohort	989:1012	COVID-19 positive cohort	989:1012	Although there were no specific glycan peaks exclusively present or absent in COVID-19 positive cohort, this cohort showed significantly higher levels of glycans and variability.
35925863	4	46	theme	96-well-plate-based	585:603	arg1	platform					658:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	7	47	theme	narrow	1189:1194	arg1	range					1196:1200	a narrow range	1187:1200	a narrow range	1187:1200	On the contrary, the overall N-glycomic profiles for healthy controls were well-contained within a narrow range.
35925863	10	48	theme	clustering	1513:1522	arg1	analysis					1524:1531	hierarchical heatmap clustering analysis	1492:1531	hierarchical heatmap clustering analysis	1492:1531	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	5	49	dep	positive	881:888	arg1	cohorts					902:908	cohorts	902:908	cohorts	902:908	Use of this platform revealed both similarities and differences between the serum N-glycomic fingerprints of COVID-19 positive and control cohorts.
35925863	5	50	theme	N-glycomic	845:854	arg1	fingerprints					856:867	the serum N-glycomic fingerprints	835:867	the serum N-glycomic fingerprints of COVID-19 positive and control cohorts	835:908	Use of this platform revealed both similarities and differences between the serum N-glycomic fingerprints of COVID-19 positive and control cohorts.
35925863	2	51	theme	severe	333:338	arg1	coronavirus					367:377	severe acute respiratory syndrome coronavirus 2	333:379	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	333:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	2	51	theme	severe	333:338	arg1	SARS-CoV-2					382:391	SARS-CoV-2	382:391	SARS-CoV-2	382:391	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	6	52	theme	glycans	1065:1071	arg1	levels					1055:1060	significantly higher levels	1034:1060	significantly higher levels of glycans and variability	1034:1087	Although there were no specific glycan peaks exclusively present or absent in COVID-19 positive cohort, this cohort showed significantly higher levels of glycans and variability.
35925863	12	53	theme	Long-COVID	1926:1935	arg1	surveillance					1938:1949	"Long-COVID" surveillance	1925:1949	"Long-COVID" surveillance to capture the full spectrum of persistent symptoms	1925:2001	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	4	54	theme	COVID-19-associated	713:731	arg1	alterations					750:760	potential COVID-19-associated serum N-glycomic alterations	703:760	potential COVID-19-associated serum N-glycomic alterations	703:760	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	1	55	theme	fluid	214:218	arg1	glycome					220:226	biological fluid glycome	203:226	biological fluid glycome	203:226	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	8	56	theme	different	1271:1279	arg1	subclasses					1288:1297	different glycan subclasses	1271:1297	different glycan subclasses sharing certain structural features	1271:1333	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	3	57	theme	serum	509:513	arg1	profile					526:532	the overall serum N-glycomic profile	497:532	the overall serum N-glycomic profile	497:532	However, the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile has been largely unexplored.
35925863	7	58	theme	healthy	1143:1149	arg1	controls					1151:1158	healthy controls	1143:1158	healthy controls	1143:1158	On the contrary, the overall N-glycomic profiles for healthy controls were well-contained within a narrow range.
35925863	9	59	theme	significance	1339:1350	arg1	glycans					1394:1400	the hyperbranched and hypersialylated glycans	1356:1400	the hyperbranched and hypersialylated glycans	1356:1400	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	9	59	theme	significance	1339:1350	arg1	traits					1436:1441	their derived glycan subclass traits	1406:1441	their derived glycan subclass traits	1406:1441	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	8	60	theme	certain	1307:1313	arg1	features					1326:1333	certain structural features	1307:1333	certain structural features	1307:1333	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	9	61	gly	hypersialylated	1378:1392	arg1	glycans					1394:1400	the hyperbranched and hypersialylated glycans	1356:1400	the hyperbranched and hypersialylated glycans	1356:1400	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	7	62	theme	overall	1111:1117	arg1	profiles					1130:1137	the overall N-glycomic profiles	1107:1137	the overall N-glycomic profiles for healthy controls	1107:1158	On the contrary, the overall N-glycomic profiles for healthy controls were well-contained within a narrow range.
35925863	2	63	theme	virus	284:288	arg1	pandemic					314:321	The corona virus disease-2019 (COVID-19) pandemic	273:321	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	273:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	11	64	from	changes	1744:1750	arg1	glycoproteins					1761:1773	serum glycoproteins	1755:1773	serum glycoproteins	1755:1773	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	1	65	theme	aberrant	152:159	arg1	glycosylation					161:173	aberrant glycosylation	152:173	aberrant glycosylation	152:173	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	4	66	theme	N-glycomic	739:748	arg1	alterations					750:760	potential COVID-19-associated serum N-glycomic alterations	703:760	potential COVID-19-associated serum N-glycomic alterations	703:760	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	11	67	theme	N-glycomic	1675:1684	arg1	changes					1686:1692	Such serum N-glycomic changes	1664:1692	Such serum N-glycomic changes described herein	1664:1709	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	5	68	theme	serum	839:843	arg1	fingerprints					856:867	the serum N-glycomic fingerprints	835:867	the serum N-glycomic fingerprints of COVID-19 positive and control cohorts	835:908	Use of this platform revealed both similarities and differences between the serum N-glycomic fingerprints of COVID-19 positive and control cohorts.
35925863	1	69	from	changes	192:198	arg1	glycome					220:226	biological fluid glycome	203:226	biological fluid glycome	203:226	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	11	70	theme	Such	1664:1667	arg1	changes					1686:1692	Such serum N-glycomic changes	1664:1692	Such serum N-glycomic changes described herein	1664:1709	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	6	71	theme	variability	1077:1087	arg1	levels					1055:1060	significantly higher levels	1034:1060	significantly higher levels of glycans and variability	1034:1087	Although there were no specific glycan peaks exclusively present or absent in COVID-19 positive cohort, this cohort showed significantly higher levels of glycans and variability.
35925863	10	72	theme	glycomic	1569:1576	arg1	variables					1578:1586	13 serum glycomic variables	1560:1586	13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls	1560:1661	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	9	73	theme	glycan	1420:1425	arg1	traits					1436:1441	their derived glycan subclass traits	1406:1441	their derived glycan subclass traits	1406:1441	Of significance was the hyperbranched and hypersialylated glycans and their derived glycan subclass traits.
35925863	12	74	theme	serum	1825:1829	arg1	N-glycome					1831:1839	the serum N-glycome	1821:1839	mapping the serum N-glycome following SARS-CoV-2 infection	1813:1870	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	2	75	theme	significant	407:417	arg1	threat					419:424	a significant threat	405:424	a significant threat to global human health	405:447	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	0	76	theme	N-glycomic	6:15	arg1	profiling					17:25	Serum N-glycomic profiling	0:25	Serum N-glycomic profiling	0:25	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19.
35925863	1	77	theme	Disease	90:96	arg1	development					98:108	Disease development	90:108	Disease development	90:108	Disease development and progression are often associated with aberrant glycosylation, indicating that changes in biological fluid glycome may potentially serve as disease signatures.
35925863	5	78	theme	platform	775:782	arg1	Use					763:765	Use	763:765	Use of this platform	763:782	Use of this platform revealed both similarities and differences between the serum N-glycomic fingerprints of COVID-19 positive and control cohorts.
35925863	5	79	theme	control	894:900	arg1	fingerprints					856:867	the serum N-glycomic fingerprints	835:867	the serum N-glycomic fingerprints of COVID-19 positive and control cohorts	835:908	Use of this platform revealed both similarities and differences between the serum N-glycomic fingerprints of COVID-19 positive and control cohorts.
35925863	3	80	theme	infection	484:492	arg1	effect					463:468	the effect	459:468	the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile	459:532	However, the effect of SARS-CoV-2 infection on the overall serum N-glycomic profile has been largely unexplored.
35925863	0	81	theme	potential	39:47	arg1	signatures					49:58	potential signatures	39:58	potential signatures for surveillance of COVID-19	39:87	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19.
35925863	12	82	theme	mapping	1813:1819	arg1	N-glycome					1831:1839	the serum N-glycome	1821:1839	mapping the serum N-glycome following SARS-CoV-2 infection	1813:1870	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	11	83	theme	serum	1755:1759	arg1	glycoproteins					1761:1773	serum glycoproteins	1755:1773	serum glycoproteins	1755:1773	Such serum N-glycomic changes described herein may indicate or correlate to the changes in serum glycoproteins upon COVID-19 infection.
35925863	6	84	theme	specific	934:941	arg1	peaks					950:954	no specific glycan peaks	931:954	no specific glycan peaks	931:954	Although there were no specific glycan peaks exclusively present or absent in COVID-19 positive cohort, this cohort showed significantly higher levels of glycans and variability.
35925863	12	85	theme	persistent	1983:1992	arg1	symptoms					1994:2001	persistent symptoms	1983:2001	persistent symptoms	1983:2001	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
35925863	10	86	theme	T-distributed	1444:1456	arg1	embedding					1478:1486	T-distributed stochastic neighbor embedding	1444:1486	T-distributed stochastic neighbor embedding	1444:1486	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	2	87	theme	syndrome	358:365	arg1	coronavirus					367:377	severe acute respiratory syndrome coronavirus 2	333:379	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	333:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	2	87	theme	syndrome	358:365	arg1	SARS-CoV-2					382:391	SARS-CoV-2	382:391	SARS-CoV-2	382:391	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	8	88	theme	serum	1212:1216	arg1	analysis					1227:1234	the serum glycomic analysis	1208:1234	the serum glycomic analysis	1208:1234	From the serum glycomic analysis, we were able to deduce changes in different glycan subclasses sharing certain structural features.
35925863	4	89	theme	profiling	648:656	arg1	platform					658:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform	581:665	Here, we extended our 96-well-plate-based high-throughput, high-sensitivity N-glycan profiling platform further with the aim of elucidating potential COVID-19-associated serum N-glycomic alterations.
35925863	10	90	theme	heatmap	1505:1511	arg1	analysis					1524:1531	hierarchical heatmap clustering analysis	1492:1531	hierarchical heatmap clustering analysis	1492:1531	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	2	91	theme	acute	340:344	arg1	coronavirus					367:377	severe acute respiratory syndrome coronavirus 2	333:379	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	333:392	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	2	91	theme	acute	340:344	arg1	SARS-CoV-2					382:391	SARS-CoV-2	382:391	SARS-CoV-2	382:391	The corona virus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a significant threat to global human health.
35925863	10	92	theme	neighbor	1469:1476	arg1	embedding					1478:1486	T-distributed stochastic neighbor embedding	1444:1486	T-distributed stochastic neighbor embedding	1444:1486	T-distributed stochastic neighbor embedding and hierarchical heatmap clustering analysis were performed to identify 13 serum glycomic variables that potentially distinguished the COVID-19 positive from healthy controls.
35925863	12	93	theme	SARS-CoV-2	1851:1860	arg1	infection					1862:1870	SARS-CoV-2 infection	1851:1870	SARS-CoV-2 infection	1851:1870	Furthermore, mapping the serum N-glycome following SARS-CoV-2 infection may help us better understand the disease and enable "Long-COVID" surveillance to capture the full spectrum of persistent symptoms.
37194568	6	0	theme	labeled	1182:1188	arg1	analysis					1170:1177	the analysis	1166:1177	the analysis of labeled and derived glycans	1166:1208	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	2	1	theme	high-throughput	309:323	arg1	interpretation					354:367	high-throughput and reliable glycan spectral interpretation	309:367	high-throughput and reliable glycan spectral interpretation	309:367	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	4	2	theme	reliable	718:725	arg1	output					734:739	highly reliable result output	711:739	highly reliable result output	711:739	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	2	3	theme	tools	299:303	arg1	lack					283:286	the lack	279:286	the lack of generic tools for high-throughput and reliable glycan spectral interpretation	279:367	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	7	4	from	samples	1388:1394	arg1	characterization					1292:1307	generic characterization	1284:1307	generic characterization of various glycan types	1284:1331	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	4	from	samples	1388:1394	arg1	elucidation					1337:1347	elucidation	1337:1347	elucidation of component heterogeneity in glycomic samples	1337:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	6	5	theme	glycomic	1254:1261	arg1	studies					1263:1269	glycomic studies	1254:1269	glycomic studies	1254:1269	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	2	6	theme	spectral	345:352	arg1	interpretation					354:367	high-throughput and reliable glycan spectral interpretation	309:367	high-throughput and reliable glycan spectral interpretation	309:367	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	1	7	theme	compositional	211:223	arg1	exploration					240:250	the compositional and functional exploration	207:250	the compositional and functional exploration of glycosylation	207:267	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	2	8	theme	reliable	329:336	arg1	interpretation					354:367	high-throughput and reliable glycan spectral interpretation	309:367	high-throughput and reliable glycan spectral interpretation	309:367	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	1	9	theme	functional	229:238	arg1	exploration					240:250	the compositional and functional exploration	207:250	the compositional and functional exploration of glycosylation	207:267	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	7	10	from	characterization	1292:1307	arg1	samples					1388:1394	glycomic samples	1379:1394	glycomic samples	1379:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	6	11	theme	GlycoNote	1153:1161	arg1	application					1138:1148	An application	1135:1148	An application of GlycoNote to the analysis of labeled and derived glycans	1135:1208	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	4	12	with	method	669:674	arg1	decoy					691:695	iterative decoy	681:695	iterative decoy searching for highly reliable result output	681:739	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	5	13	theme	large-scale	898:908	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	13	theme	large-scale	898:908	arg1	datasets					919:926	several different large-scale glycomic datasets	880:926	several different large-scale glycomic datasets	880:926	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	13	theme	large-scale	898:908	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	13	theme	large-scale	898:908	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	13	theme	large-scale	898:908	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	6	14	theme	derived	1194:1200	arg1	glycans					1202:1208	derived glycans	1194:1208	derived glycans	1194:1208	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	4	15	theme	component	768:776	arg1	mode					787:790	an open-search component analysis mode	753:790	an open-search component analysis mode	753:790	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	5	16	theme	plant	1008:1012	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	7	17	from	elucidation	1337:1347	arg1	samples					1388:1394	glycomic samples	1379:1394	glycomic samples	1379:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	5	18	from	GlycoNote	867:875	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	18	from	GlycoNote	867:875	arg1	datasets					919:926	several different large-scale glycomic datasets	880:926	several different large-scale glycomic datasets	880:926	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	18	from	GlycoNote	867:875	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	18	from	GlycoNote	867:875	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	18	from	GlycoNote	867:875	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	19	theme	glycomic	910:917	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	19	theme	glycomic	910:917	arg1	datasets					919:926	several different large-scale glycomic datasets	880:926	several different large-scale glycomic datasets	880:926	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	19	theme	glycomic	910:917	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	19	theme	glycomic	910:917	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	19	theme	glycomic	910:917	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	0	20	theme	High-Throughput	80:94	arg1	Interpretation					125:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	1	21	theme	viable	187:192	arg1	strategy					194:201	a viable strategy	185:201	a viable strategy for the compositional and functional exploration of glycosylation	185:267	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	1	21	theme	viable	187:192	arg1	analysis					173:180	Mass spectrometry-based glycome analysis	141:180	Mass spectrometry-based glycome analysis	141:180	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	0	22	theme	Reliable	100:107	arg1	Interpretation					125:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	1	23	theme	glycome	165:171	arg1	strategy					194:201	a viable strategy	185:201	a viable strategy for the compositional and functional exploration of glycosylation	185:267	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	1	23	theme	glycome	165:171	arg1	analysis					173:180	Mass spectrometry-based glycome analysis	141:180	Mass spectrometry-based glycome analysis	141:180	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	0	24	theme	Spectral	116:123	arg1	Interpretation					125:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	4	25	theme	heterogeneity	796:808	arg1	analysis					810:817	heterogeneity analysis	796:817	heterogeneity analysis of monosaccharides and modifications	796:854	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	3	26	theme	reliable	460:467	arg1	tool					478:481	a generic and reliable glycomic tool	446:481	a generic and reliable glycomic tool	446:481	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	3	26	theme	reliable	460:467	arg1	GlycoNote					484:492	GlycoNote	484:492	GlycoNote	484:492	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	5	27	theme	different	888:896	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	27	theme	different	888:896	arg1	datasets					919:926	several different large-scale glycomic datasets	880:926	several different large-scale glycomic datasets	880:926	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	27	theme	different	888:896	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	27	theme	different	888:896	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	27	theme	different	888:896	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	7	28	theme	promising	1433:1441	arg1	GlycoNote					1418:1426	the freely available GlycoNote	1397:1426	the freely available GlycoNote	1397:1426	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	28	theme	promising	1433:1441	arg1	tool					1443:1446	a promising tool	1431:1446	a promising tool for facilitating glycomics in glycobiology research	1431:1498	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	4	29	theme	data	614:617	arg1	interpretation					562:575	interpretation	562:575	interpretation of tandem-mass spectrometry glycomic data from any sample source	562:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	0	30	theme	Iterative	15:23	arg1	Searching					31:39	Iterative Decoy Searching	15:39	Iterative Decoy Searching	15:39	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	5	31	theme	atypical	1035:1042	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	3	32	theme	generic	448:454	arg1	tool					478:481	a generic and reliable glycomic tool	446:481	a generic and reliable glycomic tool	446:481	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	3	32	theme	generic	448:454	arg1	GlycoNote					484:492	GlycoNote	484:492	GlycoNote	484:492	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	7	33	theme	available	1408:1416	arg1	GlycoNote					1418:1426	the freely available GlycoNote	1397:1426	the freely available GlycoNote	1397:1426	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	33	theme	available	1408:1416	arg1	tool					1443:1446	a promising tool	1431:1446	a promising tool for facilitating glycomics in glycobiology research	1431:1498	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	3	34	theme	glycome	525:531	arg1	analysis					533:540	comprehensive and precise glycome analysis	499:540	comprehensive and precise glycome analysis	499:540	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	0	35	theme	Open-Search	45:55	arg1	Analysis					67:74	Open-Search Component Analysis	45:74	Open-Search Component Analysis	45:74	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	4	36	theme	spectrometry	592:603	arg1	data					614:617	tandem-mass spectrometry glycomic data	580:617	tandem-mass spectrometry glycomic data from any sample source	580:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	0	37	with	GlycoNote	0:8	arg1	Analysis					67:74	Open-Search Component Analysis	45:74	Open-Search Component Analysis	45:74	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	0	37	with	GlycoNote	0:8	arg1	Searching					31:39	Iterative Decoy Searching	15:39	Iterative Decoy Searching	15:39	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	1	38	theme	glycosylation	255:267	arg1	exploration					240:250	the compositional and functional exploration	207:250	the compositional and functional exploration of glycosylation	207:267	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	6	39	theme	glycans	1202:1208	arg1	analysis					1170:1177	the analysis	1166:1177	the analysis of labeled and derived glycans	1166:1208	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	4	40	theme	novel	650:654	arg1	method					669:674	a novel target-decoy method	648:674	a novel target-decoy method with iterative decoy searching for highly reliable result output	648:739	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	2	41	theme	research	417:424	arg1	usability					395:403	the broad usability	385:403	the broad usability of glycomic research	385:424	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	5	42	theme	high	1099:1102	arg1	capacity					1104:1111	its high capacity	1095:1111	its high capacity	1095:1111	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	4	43	from	interpretation	562:575	arg1	source					635:640	any sample source	624:640	any sample source	624:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	5	44	from	elegans	1072:1078	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	44	from	elegans	1072:1078	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	44	from	elegans	1072:1078	arg1	O-glycome					975:983	O-glycome	975:983	O-glycome	975:983	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	44	from	elegans	1072:1078	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	44	from	elegans	1072:1078	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	7	45	theme	component	1352:1360	arg1	heterogeneity					1362:1374	component heterogeneity	1352:1374	component heterogeneity in glycomic samples	1352:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	46	from	heterogeneity	1362:1374	arg1	samples					1388:1394	glycomic samples	1379:1394	glycomic samples	1379:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	2	47	theme	broad	389:393	arg1	usability					395:403	the broad usability	385:403	the broad usability of glycomic research	385:424	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	5	48	theme	milk	945:948	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	7	49	theme	types	1327:1331	arg1	characterization					1292:1307	generic characterization	1284:1307	generic characterization of various glycan types	1284:1331	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	49	theme	types	1327:1331	arg1	elucidation					1337:1347	elucidation	1337:1347	elucidation of component heterogeneity in glycomic samples	1337:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	4	50	theme	result	727:732	arg1	output					734:739	highly reliable result output	711:739	highly reliable result output	711:739	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	2	51	theme	glycan	338:343	arg1	interpretation					354:367	high-throughput and reliable glycan spectral interpretation	309:367	high-throughput and reliable glycan spectral interpretation	309:367	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	5	52	theme	human	990:994	arg1	lines					1001:1005	human cell lines	990:1005	human cell lines	990:1005	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	4	53	theme	iterative	681:689	arg1	decoy					691:695	iterative decoy	681:695	iterative decoy searching for highly reliable result output	681:739	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	5	54	theme	cell	996:999	arg1	lines					1001:1005	human cell lines	990:1005	human cell lines	990:1005	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	4	55	theme	open-search	756:766	arg1	mode					787:790	an open-search component analysis mode	753:790	an open-search component analysis mode	753:790	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	2	56	theme	generic	291:297	arg1	tools					299:303	generic tools	291:303	generic tools for high-throughput and reliable glycan spectral interpretation	291:367	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
37194568	1	57	theme	spectrometry-based	146:163	arg1	strategy					194:201	a viable strategy	185:201	a viable strategy for the compositional and functional exploration of glycosylation	185:267	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	1	57	theme	spectrometry-based	146:163	arg1	analysis					173:180	Mass spectrometry-based glycome analysis	141:180	Mass spectrometry-based glycome analysis	141:180	Mass spectrometry-based glycome analysis is a viable strategy for the compositional and functional exploration of glycosylation.
37194568	7	58	theme	glycobiology	1478:1489	arg1	research					1491:1498	glycobiology research	1478:1498	glycobiology research	1478:1498	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	4	59	theme	analysis	778:785	arg1	mode					787:790	an open-search component analysis mode	753:790	an open-search component analysis mode	753:790	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	7	60	theme	various	1312:1318	arg1	types					1327:1331	various glycan types	1312:1331	various glycan types	1312:1331	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	61	theme	glycan	1320:1325	arg1	types					1327:1331	various glycan types	1312:1331	various glycan types	1312:1331	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	0	62	theme	Glycan	109:114	arg1	Interpretation					125:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	High-Throughput and Reliable Glycan Spectral Interpretation	80:138	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	6	63	theme	broad	1235:1239	arg1	usability					1241:1249	its broad usability	1231:1249	its broad usability in glycomic studies	1231:1269	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	4	64	theme	monosaccharides	822:836	arg1	analysis					810:817	heterogeneity analysis	796:817	heterogeneity analysis of monosaccharides and modifications	796:854	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	7	65	theme	generic	1284:1290	arg1	characterization					1292:1307	generic characterization	1284:1307	generic characterization of various glycan types	1284:1331	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	5	66	theme	Caenorhabditis	1057:1070	arg1	elegans					1072:1078	Caenorhabditis elegans	1057:1078	Caenorhabditis elegans	1057:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	7	67	from	glycomics	1465:1473	arg1	research					1491:1498	glycobiology research	1478:1498	glycobiology research	1478:1498	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	4	68	theme	modifications	842:854	arg1	analysis					810:817	heterogeneity analysis	796:817	heterogeneity analysis of monosaccharides and modifications	796:854	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	5	69	theme	several	880:886	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	69	theme	several	880:886	arg1	datasets					919:926	several different large-scale glycomic datasets	880:926	several different large-scale glycomic datasets	880:926	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	69	theme	several	880:886	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	69	theme	several	880:886	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	69	theme	several	880:886	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	6	70	from	usability	1241:1249	arg1	studies					1263:1269	glycomic studies	1254:1269	glycomic studies	1254:1269	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	3	71	theme	glycomic	469:476	arg1	tool					478:481	a generic and reliable glycomic tool	446:481	a generic and reliable glycomic tool	446:481	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	3	71	theme	glycomic	469:476	arg1	GlycoNote					484:492	GlycoNote	484:492	GlycoNote	484:492	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	0	72	theme	Decoy	25:29	arg1	Searching					31:39	Iterative Decoy Searching	15:39	Iterative Decoy Searching	15:39	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	5	73	from	lines	1001:1005	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	73	from	lines	1001:1005	arg1	polysaccharides					1014:1028	plant polysaccharides	1008:1028	plant polysaccharides	1008:1028	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	73	from	lines	1001:1005	arg1	O-glycome					975:983	O-glycome	975:983	O-glycome	975:983	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	73	from	lines	1001:1005	arg1	glycans					1044:1050	atypical glycans	1035:1050	atypical glycans from Caenorhabditis elegans	1035:1078	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	5	73	from	lines	1001:1005	arg1	N-					968:969	N-	968:969	N-	968:969	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	4	74	theme	sample	628:633	arg1	source					635:640	any sample source	624:640	any sample source	624:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	3	75	theme	comprehensive	499:511	arg1	analysis					533:540	comprehensive and precise glycome analysis	499:540	comprehensive and precise glycome analysis	499:540	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	4	76	theme	tandem-mass	580:590	arg1	spectrometry					592:603	tandem-mass spectrometry	580:603	tandem-mass spectrometry glycomic data from any sample source	580:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	4	77	from	source	635:640	arg1	data					614:617	tandem-mass spectrometry glycomic data	580:617	tandem-mass spectrometry glycomic data from any sample source	580:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	4	77	from	source	635:640	arg1	interpretation					562:575	interpretation	562:575	interpretation of tandem-mass spectrometry glycomic data from any sample source	562:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	0	78	theme	Component	57:65	arg1	Analysis					67:74	Open-Search Component Analysis	45:74	Open-Search Component Analysis	45:74	GlycoNote with Iterative Decoy Searching and Open-Search Component Analysis for High-Throughput and Reliable Glycan Spectral Interpretation.
37194568	5	79	theme	glycome	1117:1123	arg1	analysis					1125:1132	glycome analysis	1117:1132	glycome analysis	1117:1132	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	4	80	theme	glycomic	605:612	arg1	data					614:617	tandem-mass spectrometry glycomic data	580:617	tandem-mass spectrometry glycomic data from any sample source	580:640	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	7	81	theme	glycomic	1379:1386	arg1	samples					1388:1394	glycomic samples	1379:1394	glycomic samples	1379:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	4	82	theme	target-decoy	656:667	arg1	method					669:674	a novel target-decoy method	648:674	a novel target-decoy method with iterative decoy searching for highly reliable result output	648:739	GlycoNote supports interpretation of tandem-mass spectrometry glycomic data from any sample source, uses a novel target-decoy method with iterative decoy searching for highly reliable result output, and embeds an open-search component analysis mode for heterogeneity analysis of monosaccharides and modifications.
37194568	6	83	link	derived	1194:1200	arg1	glycans					1202:1208	derived glycans	1194:1208	derived glycans	1194:1208	An application of GlycoNote to the analysis of labeled and derived glycans further demonstrates its broad usability in glycomic studies.
37194568	3	84	theme	precise	517:523	arg1	analysis					533:540	comprehensive and precise glycome analysis	499:540	comprehensive and precise glycome analysis	499:540	Here, we developed a generic and reliable glycomic tool, GlycoNote, for comprehensive and precise glycome analysis.
37194568	5	85	theme	human	939:943	arg1	oligosaccharides					950:965	human milk oligosaccharides	939:965	human milk oligosaccharides	939:965	We tested GlycoNote on several different large-scale glycomic datasets, including human milk oligosaccharides, N- and O-glycome from human cell lines, plant polysaccharides, and atypical glycans from Caenorhabditis elegans, demonstrating its high capacity for glycome analysis.
37194568	7	86	theme	heterogeneity	1362:1374	arg1	characterization					1292:1307	generic characterization	1284:1307	generic characterization of various glycan types	1284:1331	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	7	86	theme	heterogeneity	1362:1374	arg1	elucidation					1337:1347	elucidation	1337:1347	elucidation of component heterogeneity in glycomic samples	1337:1394	By enabling generic characterization of various glycan types and elucidation of component heterogeneity in glycomic samples, the freely available GlycoNote is a promising tool for facilitating glycomics in glycobiology research.
37194568	2	87	theme	glycomic	408:415	arg1	research					417:424	glycomic research	408:424	glycomic research	408:424	However, the lack of generic tools for high-throughput and reliable glycan spectral interpretation largely hampers the broad usability of glycomic research.
36750571	2	0	theme	glycan	365:370	arg1	metabolism					372:381	glycan metabolism	365:381	glycan metabolism by human gut bacteria	365:403	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	1	1	theme	downstream	259:268	arg1	effects					270:276	downstream effects	259:276	downstream effects on the physiology and health of hosts	259:314	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	1	2	dep	physiology	285:294	arg1	the					281:283	the	281:283	the	281:283	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	1	3	theme	human	174:178	arg1	microbiota					184:193	the human gut microbiota	170:193	the human gut microbiota	170:193	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	9	4	theme	approaches	1375:1384	arg1	mechanism					1352:1360	the mechanism	1348:1360	the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition	1348:1453	Going forward, it could be used to provide insight into the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition.
36750571	0	5	theme	fluorescence-activated	99:120	arg1	sorting					127:133	fluorescence-activated cell sorting	99:133	fluorescence-activated cell sorting	99:133	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	7	6	theme	major	1090:1094	arg1	phyla					1096:1100	three major phyla	1084:1100	three major phyla	1084:1100	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	2	7	from	advances	332:339	arg1	understanding					348:360	our understanding	344:360	our understanding of glycan metabolism by human gut bacteria	344:403	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	1	8	dep	composition	140:150	arg1	The					136:138	The	136:138	The	136:138	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	4	9	theme	fluorescent	649:659	arg1	oligosaccharides					661:676	fluorescent oligosaccharides	649:676	fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS)	649:724	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	3	10	theme	healthy	547:553	arg1	volunteers					561:570	healthy human volunteers	547:570	healthy human volunteers that take up different glycans	547:601	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	3	11	theme	gut	529:531	arg1	bacteria					533:540	gut bacteria	529:540	gut bacteria	529:540	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	6	12	theme	species	978:984	arg1	ability					940:946	the ability	936:946	the ability of most, but not all, labeled species to consume the glycan of interest for growth	936:1029	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36750571	6	13	theme	In	907:908	arg1	validation					916:925	In vitro validation	907:925	In vitro validation	907:925	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36750571	5	14	theme	various	821:827	arg1	copri					854:858	Prevotella copri	843:858	Prevotella copri	843:858	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	14	theme	various	821:827	arg1	taxa					829:832	various taxa	821:832	various taxa	821:832	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	14	theme	various	821:827	arg1	wexlerae					897:904	Blautia wexlerae	889:904	Blautia wexlerae	889:904	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	14	theme	various	821:827	arg1	aerofaciens					873:883	Collinsella aerofaciens	861:883	Collinsella aerofaciens	861:883	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	9	15	used	used	1405:1408	arg2	glycans					1393:1399	glycans	1393:1399	glycans	1393:1399	Going forward, it could be used to provide insight into the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition.
36750571	1	16	theme	gut	180:182	arg1	microbiota					184:193	the human gut microbiota	170:193	the human gut microbiota	170:193	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	0	17	theme	cell	122:125	arg1	sorting					127:133	fluorescence-activated cell sorting	99:133	fluorescence-activated cell sorting	99:133	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	9	18	theme	prebiotic	1365:1373	arg1	approaches					1375:1384	prebiotic approaches	1365:1384	prebiotic approaches	1365:1384	Going forward, it could be used to provide insight into the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition.
36750571	1	19	theme	microbiota	184:193	arg1	composition					140:150	composition	140:150	composition	140:150	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	1	19	theme	microbiota	184:193	arg1	metabolism					156:165	metabolism	156:165	metabolism	156:165	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	0	20	theme	glycan	12:17	arg1	consumers					19:27	glycan consumers	12:27	glycan consumers	12:27	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	7	21	theme	glycan	1058:1063	arg1	consumers					1065:1073	glycan consumers	1058:1073	glycan consumers spanning three major phyla	1058:1100	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	2	22	theme	recent	325:330	arg1	advances					332:339	recent advances	325:339	recent advances in our understanding of glycan metabolism by human gut bacteria	325:403	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	7	23	theme	cells	1150:1154	arg1	cultures					1123:1130	cultures	1123:1130	cultures of sorted labeled cells	1123:1154	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	2	24	theme	gut	392:394	arg1	bacteria					396:403	human gut bacteria	386:403	human gut bacteria	386:403	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	6	25	theme	labeled	970:976	arg1	species					978:984	labeled species	970:984	labeled species	970:984	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36750571	3	26	theme	human	555:559	arg1	volunteers					561:570	healthy human volunteers	547:570	healthy human volunteers that take up different glycans	547:601	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	2	27	theme	human	386:390	arg1	bacteria					396:403	human gut bacteria	386:403	human gut bacteria	386:403	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	7	28	theme	sorted	1135:1140	arg1	cells					1150:1154	sorted labeled cells	1135:1154	sorted labeled cells	1135:1154	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	8	29	theme	gut	1278:1280	arg1	bacteria					1282:1289	gut bacteria	1278:1289	gut bacteria	1278:1289	By linking bacteria to the glycans they consume, this approach increases our basic understanding of glycan metabolism by gut bacteria.
36750571	8	30	dep	consume	1197:1203	arg1	they					1192:1195	they	1192:1195	they	1192:1195	By linking bacteria to the glycans they consume, this approach increases our basic understanding of glycan metabolism by gut bacteria.
36750571	2	31	attach	link	431:434	arg2	methods					420:426	methods	420:426	methods	420:426	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	2	31	attach	link	431:434	arg1	bacteria					463:470	their consuming bacteria	447:470	their consuming bacteria	447:470	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	3	32	attach	isolate	521:527	arg1	volunteers					561:570	healthy human volunteers	547:570	healthy human volunteers that take up different glycans	547:601	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	3	32	attach	isolate	521:527	arg2	assay					499:503	a functional assay	486:503	a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans	486:601	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	8	33	theme	basic	1234:1238	arg1	understanding					1240:1252	our basic understanding	1230:1252	our basic understanding of glycan metabolism	1230:1273	By linking bacteria to the glycans they consume, this approach increases our basic understanding of glycan metabolism by gut bacteria.
36750571	7	34	theme	labeled	1142:1148	arg1	cells					1150:1154	sorted labeled cells	1135:1154	sorted labeled cells	1135:1154	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	6	35	theme	all	965:967	arg1	ability					940:946	the ability	936:946	the ability of most, but not all, labeled species to consume the glycan of interest for growth	936:1029	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36750571	9	36	used	used	1319:1322	arg2	it					1307:1308	it	1307:1308	it	1307:1308	Going forward, it could be used to provide insight into the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition.
36750571	3	37	theme	functional	488:497	arg1	assay					499:503	a functional assay	486:503	a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans	486:601	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	0	38	theme	gut	38:40	arg1	samples					53:59	human gut microbiota samples	32:59	human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting	32:133	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	4	39	with	oligosaccharides	661:676	arg1	sorting					711:717	fluorescence-activated cell sorting	683:717	fluorescence-activated cell sorting (FACS)	683:724	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	4	39	with	oligosaccharides	661:676	arg1	FACS					720:723	FACS	720:723	FACS	720:723	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	1	40	theme	dietary	222:228	arg1	glycans					238:244	dietary complex glycans	222:244	dietary complex glycans	222:244	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	0	41	theme	human	32:36	arg1	samples					53:59	human gut microbiota samples	32:59	human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting	32:133	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	1	42	theme	hosts	310:314	arg1	health					300:305	health	300:305	health	300:305	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	1	42	theme	hosts	310:314	arg1	physiology					285:294	physiology	285:294	physiology	285:294	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	1	43	from	effects	270:276	arg1	health					300:305	health	300:305	health	300:305	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	1	43	from	effects	270:276	arg1	physiology					285:294	physiology	285:294	physiology	285:294	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	9	44	theme	microbiota	1432:1441	arg1	composition					1443:1453	the gut microbiota composition	1424:1453	the gut microbiota composition	1424:1453	Going forward, it could be used to provide insight into the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition.
36750571	1	45	theme	complex	230:236	arg1	glycans					238:244	dietary complex glycans	222:244	dietary complex glycans	222:244	The composition and metabolism of the human gut microbiota are strongly influenced by dietary complex glycans, which cause downstream effects on the physiology and health of hosts.
36750571	2	46	theme	consuming	453:461	arg1	bacteria					463:470	their consuming bacteria	447:470	their consuming bacteria	447:470	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	9	47	theme	gut	1428:1430	arg1	composition					1443:1453	the gut microbiota composition	1424:1453	the gut microbiota composition	1424:1453	Going forward, it could be used to provide insight into the mechanism of prebiotic approaches, where glycans are used to manipulate the gut microbiota composition.
36750571	8	48	theme	metabolism	1264:1273	arg1	understanding					1240:1252	our basic understanding	1230:1252	our basic understanding of glycan metabolism	1230:1273	By linking bacteria to the glycans they consume, this approach increases our basic understanding of glycan metabolism by gut bacteria.
36750571	0	49	theme	microbiota	42:51	arg1	samples					53:59	human gut microbiota samples	32:59	human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting	32:133	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	6	50	theme	most	951:954	arg1	ability					940:946	the ability	936:946	the ability of most, but not all, labeled species to consume the glycan of interest for growth	936:1029	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36750571	8	51	theme	glycan	1257:1262	arg1	metabolism					1264:1273	glycan metabolism	1257:1273	glycan metabolism	1257:1273	By linking bacteria to the glycans they consume, this approach increases our basic understanding of glycan metabolism by gut bacteria.
36750571	4	52	dep	amplicon	739:746	arg1	sequencing					748:757	sequencing	748:757	sequencing	748:757	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	7	53	attach	isolated	1109:1116	arg1	cultures					1123:1130	cultures	1123:1130	cultures of sorted labeled cells	1123:1154	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	7	53	attach	isolated	1109:1116	arg2	consumers					1065:1073	glycan consumers	1058:1073	glycan consumers spanning three major phyla	1058:1100	In parallel, we show that glycan consumers spanning three major phyla can be isolated from cultures of sorted labeled cells.
36750571	4	54	theme	fluorescence-activated	683:704	arg1	sorting					711:717	fluorescence-activated cell sorting	683:717	fluorescence-activated cell sorting (FACS)	683:724	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	4	54	theme	fluorescence-activated	683:704	arg1	FACS					720:723	FACS	720:723	FACS	720:723	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	6	55	theme	interest	1011:1018	arg1	glycan					1001:1006	the glycan	997:1006	the glycan of interest for growth	997:1029	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36750571	0	56	theme	metabolic	67:75	arg1	labeling					77:84	metabolic labeling	67:84	metabolic labeling coupled with fluorescence-activated cell sorting	67:133	Identifying glycan consumers in human gut microbiota samples using metabolic labeling coupled with fluorescence-activated cell sorting.
36750571	4	57	theme	metabolic	624:632	arg1	labeling					634:641	metabolic labeling	624:641	metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS)	624:724	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	3	58	theme	different	585:593	arg1	glycans					595:601	different glycans	585:601	different glycans	585:601	Here, we use a functional assay to identify and isolate gut bacteria from healthy human volunteers that take up different glycans.
36750571	4	59	theme	cell	706:709	arg1	sorting					711:717	fluorescence-activated cell sorting	683:717	fluorescence-activated cell sorting (FACS)	683:724	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	4	59	theme	cell	706:709	arg1	FACS					720:723	FACS	720:723	FACS	720:723	The method combines metabolic labeling using fluorescent oligosaccharides with fluorescence-activated cell sorting (FACS), followed by amplicon sequencing or culturomics.
36750571	8	60	theme	consume	1197:1203	arg1	glycans					1184:1190	the glycans	1180:1190	the glycans they consume	1180:1203	By linking bacteria to the glycans they consume, this approach increases our basic understanding of glycan metabolism by gut bacteria.
36750571	5	61	from	labeling	809:816	arg1	copri					854:858	Prevotella copri	843:858	Prevotella copri	843:858	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	61	from	labeling	809:816	arg1	taxa					829:832	various taxa	821:832	various taxa	821:832	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	61	from	labeling	809:816	arg1	wexlerae					897:904	Blautia wexlerae	889:904	Blautia wexlerae	889:904	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	61	from	labeling	809:816	arg1	aerofaciens					873:883	Collinsella aerofaciens	861:883	Collinsella aerofaciens	861:883	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	5	62	theme	metabolic	799:807	arg1	labeling					809:816	metabolic labeling	799:816	metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae	799:904	Our results demonstrate metabolic labeling in various taxa, such as Prevotella copri, Collinsella aerofaciens and Blautia wexlerae.
36750571	2	63	theme	metabolism	372:381	arg1	understanding					348:360	our understanding	344:360	our understanding of glycan metabolism by human gut bacteria	344:403	Despite recent advances in our understanding of glycan metabolism by human gut bacteria, we still need methods to link glycans to their consuming bacteria.
36750571	6	64	dep	In	907:908	arg1	vitro					910:914	vitro	910:914	vitro	910:914	In vitro validation confirms the ability of most, but not all, labeled species to consume the glycan of interest for growth.
36373229	6	0	theme	of	1137:1138	arg1	StcE					1163:1166	StcE	1163:1166	StcE	1163:1166	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	0	theme	of	1137:1138	arg1	inhibitor					1152:1160	secreted protease of C1 esterase inhibitor	1119:1160	secreted protease of C1 esterase inhibitor (StcE)	1119:1167	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	3	1	theme	structural	564:573	arg1	features					575:582	structural features	564:582	structural features of characterized O-glycoproteases	564:616	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	5	2	used	used	996:999	arg2	Search					845:850	O-Pair Search	838:850	O-Pair Search	838:850	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	5	2	used	used	996:999	arg2	platform					912:919	a recently developed O-glycopeptide-centric identification platform	853:919	a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization	853:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	2	3	located	found	403:407	arg2	those					397:401	those	397:401	those	397:401	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	3	located	found	403:407	arg1	domains					418:424	mucin domains	412:424	mucin domains	412:424	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	4	4	gly	O-glycopeptides	752:766	arg2	O-glycopeptides					752:766	O-glycopeptides	752:766	O-glycopeptides	752:766	One challenge of defining O-glycoprotease specificity restraints is the need to characterize O-glycopeptides with site-specific analysis of O-glycosites.
36373229	1	5	theme	specific	186:193	arg1	glycans					204:210	specific O-linked glycans	186:210	specific O-linked glycans	186:210	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	7	6	gly	O-glycopeptide	1567:1580	arg2	O-glycopeptide					1567:1580	O-glycopeptide	1567:1580	O-glycopeptide	1567:1580	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	2	7	gly	glycoproteins	324:336	arg1	glycoproteins					324:336	only glycoproteins	319:336	only glycoproteins	319:336	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	7	gly	glycoproteins	324:336	arg1	those					397:401	those	397:401	those	397:401	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	7	8	theme	search	1542:1547	arg1	times					1549:1553	lower search times	1536:1553	lower search times	1536:1553	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	8	9	gly	O-glycosylated	1826:1839	arg1	glycoproteins					1854:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	5	10	theme	O-glycoproteases	1049:1064	arg1	specificities					1024:1036	substrate specificities	1014:1036	substrate specificities of various O-glycoproteases	1014:1064	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	8	11	gly	glycoproteins	1854:1866	arg1	glycoproteins					1854:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	4	12	theme	specificity	701:711	arg1	restraints					713:722	O-glycoprotease specificity restraints	685:722	O-glycoprotease specificity restraints	685:722	One challenge of defining O-glycoprotease specificity restraints is the need to characterize O-glycopeptides with site-specific analysis of O-glycosites.
36373229	5	13	gly	O-glycopeptides	1096:1110	arg2	O-glycopeptides					1096:1110	O-glycopeptides	1096:1110	O-glycopeptides	1096:1110	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	4	14	gly	O-glycosites	799:810	arg2	O-glycosites					799:810	O-glycosites	799:810	O-glycosites	799:810	One challenge of defining O-glycoprotease specificity restraints is the need to characterize O-glycopeptides with site-specific analysis of O-glycosites.
36373229	3	15	theme	substrate	634:642	arg1	specificities					644:656	their substrate specificities	628:656	their substrate specificities	628:656	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	8	16	theme	mucin-domain	1841:1852	arg1	glycoproteins					1854:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	4	17	theme	O-glycoprotease	685:699	arg1	restraints					713:722	O-glycoprotease specificity restraints	685:722	O-glycoprotease specificity restraints	685:722	One challenge of defining O-glycoprotease specificity restraints is the need to characterize O-glycopeptides with site-specific analysis of O-glycosites.
36373229	6	18	theme	numerous	1274:1281	arg1	settings					1283:1290	numerous settings	1274:1290	numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs	1274:1445	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	5	19	theme	confident	953:961	arg1	localization					975:986	confident O-glycosite localization	953:986	confident O-glycosite localization	953:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	2	20	theme	only	319:322	arg1	glycoproteins					324:336	only glycoproteins	319:336	only glycoproteins	319:336	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	20	theme	only	319:322	arg1	those					397:401	those	397:401	those	397:401	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	21	from	O-glycoprotein	255:268	arg1	range					240:244	range	240:244	range	240:244	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	1	22	theme	O-linked	195:202	arg1	glycans					204:210	specific O-linked glycans	186:210	specific O-linked glycans	186:210	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	5	23	theme	developed	864:872	arg1	platform					912:919	a recently developed O-glycopeptide-centric identification platform	853:919	a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization	853:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	5	23	theme	developed	864:872	arg1	Search					845:850	O-Pair Search	838:850	O-Pair Search	838:850	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	6	24	theme	C1	1140:1141	arg1	StcE					1163:1166	StcE	1163:1166	StcE	1163:1166	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	24	theme	C1	1140:1141	arg1	inhibitor					1152:1160	secreted protease of C1 esterase inhibitor	1119:1160	secreted protease of C1 esterase inhibitor (StcE)	1119:1167	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	1	25	theme	emerging	94:101	arg1	O-Glycoproteases					70:85	O-Glycoproteases	70:85	O-Glycoproteases	70:85	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	1	25	theme	emerging	94:101	arg1	class					103:107	an emerging class	91:107	an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans	91:210	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	4	26	theme	site-specific	773:785	arg1	analysis					787:794	site-specific analysis	773:794	site-specific analysis of O-glycosites	773:810	One challenge of defining O-glycoprotease specificity restraints is the need to characterize O-glycopeptides with site-specific analysis of O-glycosites.
36373229	0	27	theme	O-glycoprotease	12:26	arg1	preferences					38:48	O-glycoprotease substrate preferences	12:48	O-glycoprotease substrate preferences	12:48	Deciphering O-glycoprotease substrate preferences with O-Pair Search.
36373229	8	28	theme	consensus	1634:1642	arg1	motif					1644:1648	a consensus motif	1632:1648	a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa)	1632:1719	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	1	29	link	O-linked	195:202	arg1	glycans					204:210	specific O-linked glycans	186:210	specific O-linked glycans	186:210	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	5	30	theme	O-glycopeptides	1096:1110	arg1	data					1088:1091	LC-MS/MS data	1079:1091	LC-MS/MS data of O-glycopeptides	1079:1110	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	4	31	theme	O-glycosites	799:810	arg1	analysis					787:794	site-specific analysis	773:794	site-specific analysis of O-glycosites	773:810	One challenge of defining O-glycoprotease specificity restraints is the need to characterize O-glycopeptides with site-specific analysis of O-glycosites.
36373229	5	32	theme	O-glycosite	963:973	arg1	localization					975:986	confident O-glycosite localization	953:986	confident O-glycosite localization	953:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	6	33	theme	esterase	1143:1150	arg1	StcE					1163:1166	StcE	1163:1166	StcE	1163:1166	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	33	theme	esterase	1143:1150	arg1	inhibitor					1152:1160	secreted protease of C1 esterase inhibitor	1119:1160	secreted protease of C1 esterase inhibitor (StcE)	1119:1167	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	34	gly	O-glycopeptide	1304:1317	arg2	O-glycopeptide					1304:1317	O-glycopeptide identification	1304:1332	O-glycopeptide identification	1304:1332	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	2	35	theme	sequence	372:379	arg1	motifs					381:386	specific O-glycosylated sequence motifs	348:386	specific O-glycosylated sequence motifs	348:386	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	36	dep	modifications	301:313	arg1	albeit					271:276	albeit	271:276	albeit	271:276	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	37	with	O-glycoprotein	255:268	arg1	modifications					301:313	specific O-glycan modifications	283:313	specific O-glycan modifications	283:313	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	8	38	theme	immunomodulating	1681:1696	arg1	IMPa					1715:1718	IMPa	1715:1718	IMPa	1715:1718	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	8	38	theme	immunomodulating	1681:1696	arg1	metalloprotease					1698:1712	the recently characterized immunomodulating metalloprotease	1654:1712	the recently characterized immunomodulating metalloprotease (IMPa)	1654:1719	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	8	39	theme	favorable	1773:1781	arg1	IMPa					1763:1766	IMPa	1763:1766	IMPa	1763:1766	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	8	39	theme	favorable	1773:1781	arg1	O-glycoprotease					1783:1797	a favorable O-glycoprotease	1771:1797	a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins	1771:1866	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	2	40	theme	O-glycosylated	357:370	arg1	motifs					381:386	specific O-glycosylated sequence motifs	348:386	specific O-glycosylated sequence motifs	348:386	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	7	41	used	used	1485:1488	arg2	motifs					1463:1468	These putative motifs	1448:1468	These putative motifs	1448:1468	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	3	42	theme	new	521:523	arg1	O-glycoproteases					525:540	new O-glycoproteases	521:540	new O-glycoproteases	521:540	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	0	43	theme	substrate	28:36	arg1	preferences					38:48	O-glycoprotease substrate preferences	12:48	O-glycoprotease substrate preferences	12:48	Deciphering O-glycoprotease substrate preferences with O-Pair Search.
36373229	6	44	theme	O-glycopeptide	1389:1402	arg1	data					1404:1407	O-glycopeptide data	1389:1407	O-glycopeptide data	1389:1407	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	3	45	theme	O-glycoproteases	601:616	arg1	features					575:582	structural features	564:582	structural features of characterized O-glycoproteases	564:616	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	2	46	theme	O-Glycoprotease	213:227	arg1	substrates					229:238	O-Glycoprotease substrates	213:238	O-Glycoprotease substrates	213:238	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	47	theme	specific	348:355	arg1	motifs					381:386	specific O-glycosylated sequence motifs	348:386	specific O-glycosylated sequence motifs	348:386	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	6	48	theme	non-specific	1347:1358	arg1	searches					1377:1384	non-specific and semi-tryptic searches	1347:1384	non-specific and semi-tryptic searches of O-glycopeptide data	1347:1407	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	0	49	theme	O-Pair	55:60	arg1	Search					62:67	O-Pair Search	55:67	O-Pair Search	55:67	Deciphering O-glycoprotease substrate preferences with O-Pair Search.
36373229	6	50	theme	protease	1128:1135	arg1	StcE					1163:1166	StcE	1163:1166	StcE	1163:1166	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	50	theme	protease	1128:1135	arg1	inhibitor					1152:1160	secreted protease of C1 esterase inhibitor	1119:1160	secreted protease of C1 esterase inhibitor (StcE)	1119:1167	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	5	51	theme	O-Pair	838:843	arg1	platform					912:919	a recently developed O-glycopeptide-centric identification platform	853:919	a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization	853:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	5	51	theme	O-Pair	838:843	arg1	Search					845:850	O-Pair Search	838:850	O-Pair Search	838:850	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	7	52	theme	new	1500:1502	arg1	settings					1522:1529	new protease cleavage settings	1500:1529	new protease cleavage settings that lower search times	1500:1553	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	5	53	gly	O-glycosite	963:973	arg2	O-glycosite					963:973	O-glycosite	963:973	O-glycosite	963:973	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	7	54	theme	lower	1536:1540	arg1	times					1549:1553	lower search times	1536:1553	lower search times	1536:1553	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	6	55	theme	O-endoprotease	1213:1226	arg1	OgpA					1228:1231	O-endoprotease OgpA	1213:1231	O-endoprotease OgpA	1213:1231	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	5	56	theme	rapid	934:938	arg1	searches					940:947	rapid searches	934:947	rapid searches	934:947	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	6	57	theme	secreted	1119:1126	arg1	StcE					1163:1166	StcE	1163:1166	StcE	1163:1166	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	57	theme	secreted	1119:1126	arg1	inhibitor					1152:1160	secreted protease of C1 esterase inhibitor	1119:1160	secreted protease of C1 esterase inhibitor (StcE)	1119:1167	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	1	58	gly	glycoproteins	144:156	arg1	glycoproteins					144:156	glycoproteins	144:156	glycoproteins	144:156	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	7	59	theme	protease	1504:1511	arg1	settings					1522:1529	new protease cleavage settings	1500:1529	new protease cleavage settings that lower search times	1500:1553	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	2	60	gly	O-glycoprotein	255:268	arg1	O-glycoprotein					255:268	any O-glycoprotein	251:268	any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains	251:424	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	8	61	theme	O-glycosylated	1826:1839	arg1	glycoproteins					1854:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	densely O-glycosylated mucin-domain glycoproteins	1818:1866	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	5	62	theme	identification	897:910	arg1	platform					912:919	a recently developed O-glycopeptide-centric identification platform	853:919	a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization	853:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	5	62	theme	identification	897:910	arg1	Search					845:850	O-Pair Search	838:850	O-Pair Search	838:850	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	3	63	theme	glycoproteomic	454:467	arg1	applications					469:480	multiple glycoproteomic applications	445:480	multiple glycoproteomic applications	445:480	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	6	64	theme	cleavage	1431:1438	arg1	motifs					1440:1445	candidate cleavage motifs	1421:1445	candidate cleavage motifs	1421:1445	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	5	65	theme	LC-MS/MS	1079:1086	arg1	data					1088:1091	LC-MS/MS data	1079:1091	LC-MS/MS data of O-glycopeptides	1079:1110	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	6	66	theme	data	1404:1407	arg1	searches					1377:1384	non-specific and semi-tryptic searches	1347:1384	non-specific and semi-tryptic searches of O-glycopeptide data	1347:1407	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	7	67	theme	O-glycopeptide	1567:1580	arg1	identifications					1582:1596	O-glycopeptide identifications	1567:1596	O-glycopeptide identifications	1567:1596	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	6	68	theme	candidate	1421:1429	arg1	motifs					1440:1445	candidate cleavage motifs	1421:1445	candidate cleavage motifs	1421:1445	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	6	69	theme	O-glycopeptide	1304:1317	arg1	identification					1319:1332	O-glycopeptide identification	1304:1332	O-glycopeptide identification	1304:1332	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	1	70	theme	enzymes	112:118	arg1	O-Glycoproteases					70:85	O-Glycoproteases	70:85	O-Glycoproteases	70:85	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	1	70	theme	enzymes	112:118	arg1	class					103:107	an emerging class	91:107	an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans	91:210	O-Glycoproteases are an emerging class of enzymes that selectively digest glycoproteins at positions decorated with specific O-linked glycans.
36373229	6	71	theme	semi-tryptic	1364:1375	arg1	searches					1377:1384	non-specific and semi-tryptic searches	1347:1384	non-specific and semi-tryptic searches of O-glycopeptide data	1347:1407	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	8	72	theme	characterized	1667:1679	arg1	IMPa					1715:1718	IMPa	1715:1718	IMPa	1715:1718	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	8	72	theme	characterized	1667:1679	arg1	metalloprotease					1698:1712	the recently characterized immunomodulating metalloprotease	1654:1712	the recently characterized immunomodulating metalloprotease (IMPa)	1654:1719	We use this platform to generate a consensus motif for the recently characterized immunomodulating metalloprotease (IMPa) from Pseudomonas aeruginosa and show that IMPa is a favorable O-glycoprotease for characterizing densely O-glycosylated mucin-domain glycoproteins.
36373229	3	73	dep	discover	512:519	arg1	both					507:510	both	507:510	both	507:510	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	6	74	gly	O-glycopeptide	1389:1402	arg2	O-glycopeptide					1389:1402	O-glycopeptide data	1389:1407	O-glycopeptide data	1389:1407	Using secreted protease of C1 esterase inhibitor (StcE) from enterohemorrhagic Escherichia coli and O-endoprotease OgpA from Akkermansia mucinophila, we explore numerous settings that effect O-glycopeptide identification and show how non-specific and semi-tryptic searches of O-glycopeptide data can produce candidate cleavage motifs.
36373229	3	75	theme	characterized	587:599	arg1	O-glycoproteases					601:616	characterized O-glycoproteases	587:616	characterized O-glycoproteases	587:616	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	5	76	theme	O-glycopeptide-centric	874:895	arg1	platform					912:919	a recently developed O-glycopeptide-centric identification platform	853:919	a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization	853:986	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	5	76	theme	O-glycopeptide-centric	874:895	arg1	Search					845:850	O-Pair Search	838:850	O-Pair Search	838:850	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	2	77	theme	O-glycan	292:299	arg1	modifications					301:313	specific O-glycan modifications	283:313	specific O-glycan modifications	283:313	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	7	78	theme	cleavage	1513:1520	arg1	settings					1522:1529	new protease cleavage settings	1500:1529	new protease cleavage settings that lower search times	1500:1553	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36373229	5	79	theme	various	1041:1047	arg1	O-glycoproteases					1049:1064	various O-glycoproteases	1041:1064	various O-glycoproteases	1041:1064	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	5	80	theme	substrate	1014:1022	arg1	specificities					1024:1036	substrate specificities	1014:1036	substrate specificities of various O-glycoproteases	1014:1064	Here, we demonstrate how O-Pair Search, a recently developed O-glycopeptide-centric identification platform that enables rapid searches and confident O-glycosite localization, can be used to determine substrate specificities of various O-glycoproteases de novo from LC-MS/MS data of O-glycopeptides.
36373229	3	81	theme	multiple	445:452	arg1	applications					469:480	multiple glycoproteomic applications	445:480	multiple glycoproteomic applications	445:480	Their utility for multiple glycoproteomic applications is driving the search to both discover new O-glycoproteases and to understand how structural features of characterized O-glycoproteases influence their substrate specificities.
36373229	2	82	theme	specific	283:290	arg1	modifications					301:313	specific O-glycan modifications	283:313	specific O-glycan modifications	283:313	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	2	83	theme	mucin	412:416	arg1	domains					418:424	mucin domains	412:424	mucin domains	412:424	O-Glycoprotease substrates range from any O-glycoprotein (albeit with specific O-glycan modifications) to only glycoproteins harboring specific O-glycosylated sequence motifs, such as those found in mucin domains.
36373229	7	84	theme	putative	1454:1461	arg1	motifs					1463:1468	These putative motifs	1448:1468	These putative motifs	1448:1468	These putative motifs can be further used to define new protease cleavage settings that lower search times and improve O-glycopeptide identifications.
36385894	7	0	theme	=	1497:1497	arg1	10-2					1507:1510	p adj = 4.818 × 10-2	1491:1510	p adj = 4.818 × 10-2	1491:1510	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	0	theme	=	1497:1497	arg1	pathways					1481:1488	immunoglobulin-mediated immune response pathways	1441:1488	immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2)	1441:1511	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	1	theme	dynamic	937:943	arg1	methods					965:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	2	theme	p	1318:1318	arg1	response					1308:1315	acute inflammatory response	1289:1315	acute inflammatory response (p adj = 6.404 × 10-5)	1289:1338	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	2	theme	p	1318:1318	arg1	×					1332:1332	p adj = 6.404 × 10-5	1318:1337	p adj = 6.404 × 10-5	1318:1337	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	1	3	theme	proteins	291:298	arg1	patterns					253:260	the glycosylation patterns	235:260	the glycosylation patterns of cell-surface and secreted proteins	235:298	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	4	4	theme	monitoring	954:963	arg1	methods					965:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	9	5	theme	N-glycans	1817:1825	arg1	glycans					1845:1851	specific N-glycans and site-specific glycans	1808:1851	specific N-glycans and site-specific glycans	1808:1851	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	4	6	theme	cohort	644:649	arg1	profiles					630:637	The N-glycan and glycoprotein profiles	600:637	profiles	630:637	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	8	7	theme	=	1598:1598	arg1	AUC					1593:1595	AUC	1593:1595	AUC	1593:1595	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	8	7	theme	=	1598:1598	arg1	curve					1586:1590	the curve	1582:1590	the curve (AUC) = 0.775; 95% CI: 0.617-0.931]	1582:1626	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	4	8	theme	triple	901:906	arg1	spectrometry					924:935	triple quadrupole mass spectrometry	901:935	triple quadrupole mass spectrometry	901:935	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	9	9	theme	site-specific	1831:1843	arg1	glycans					1845:1851	specific N-glycans and site-specific glycans	1808:1851	specific N-glycans and site-specific glycans	1808:1851	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	7	10	theme	=	1232:1232	arg1	proteins					1177:1184	proteins	1177:1184	proteins in complement	1177:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	10	theme	=	1232:1232	arg1	×					1240:1240	p adj = 6.418 × 10-4	1226:1245	p adj = 6.418 × 10-4	1226:1245	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	3	11	theme	cancer	583:588	arg1	patients					590:597	Philippine lung cancer patients	567:597	Philippine lung cancer patients	567:597	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	7	12	theme	immune	1465:1470	arg1	10-2					1507:1510	p adj = 4.818 × 10-2	1491:1510	p adj = 4.818 × 10-2	1491:1510	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	12	theme	immune	1465:1470	arg1	pathways					1481:1488	immunoglobulin-mediated immune response pathways	1441:1488	immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2)	1441:1511	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	13	theme	mass	919:922	arg1	spectrometry					924:935	triple quadrupole mass spectrometry	901:935	triple quadrupole mass spectrometry	901:935	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	14	theme	1.895	1422:1426	arg1	pathways					1404:1411	complement activation pathways	1382:1411	complement activation pathways (p adj = 1.895 × 10-2)	1382:1434	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	14	theme	1.895	1422:1426	arg1	10-2					1430:1433	p adj = 1.895 × 10-2	1414:1433	p adj = 1.895 × 10-2	1414:1433	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	15	theme	p	1226:1226	arg1	proteins					1177:1184	proteins	1177:1184	proteins in complement	1177:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	15	theme	p	1226:1226	arg1	×					1240:1240	p adj = 6.418 × 10-4	1226:1245	p adj = 6.418 × 10-4	1226:1245	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	1	16	theme	fundamental	212:222	arg1	changes					224:230	fundamental changes	212:230	fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression	212:342	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	4	17	dep	cohort	644:649	arg1	=					671:671	=	671:671	=	671:671	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	10	18	theme	glycoproteomic	2094:2107	arg1	methods					2109:2115	mass spectrometry-based glycomic and glycoproteomic methods	2057:2115	mass spectrometry-based glycomic and glycoproteomic methods	2057:2115	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	10	19	theme	first	1937:1941	arg1	glycan					1949:1954	the first serum glycan	1933:1954	the first serum glycan	1933:1954	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	1	20	gly	glycosylation	152:164	arg1	cancer					199:204	cancer	199:204	cancer	199:204	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	7	21	theme	p	1266:1266	arg1	immunity					1256:1263	innate immunity	1249:1263	innate immunity (p adj = 6.094 × 10-3)	1249:1286	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	21	theme	p	1266:1266	arg1	×					1280:1280	p adj = 6.094 × 10-3	1266:1285	p adj = 6.094 × 10-3	1266:1285	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	1	22	theme	glycosylation	239:251	arg1	patterns					253:260	the glycosylation patterns	235:260	the glycosylation patterns of cell-surface and secreted proteins	235:298	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	7	23	theme	activation	1393:1402	arg1	pathways					1404:1411	complement activation pathways	1382:1411	complement activation pathways (p adj = 1.895 × 10-2)	1382:1434	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	23	theme	activation	1393:1402	arg1	10-2					1430:1433	p adj = 1.895 × 10-2	1414:1433	p adj = 1.895 × 10-2	1414:1433	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	1	24	from	changes	224:230	arg1	patterns					253:260	the glycosylation patterns	235:260	the glycosylation patterns of cell-surface and secreted proteins	235:298	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	1	25	theme	Aberrant	143:150	arg1	glycosylation					152:164	Aberrant glycosylation	143:164	Aberrant glycosylation	143:164	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	10	26	theme	glycomic	2081:2088	arg1	methods					2109:2115	mass spectrometry-based glycomic and glycoproteomic methods	2057:2115	mass spectrometry-based glycomic and glycoproteomic methods	2057:2115	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	10	27	theme	glycopeptide	1960:1971	arg1	biomarkers					1973:1982	glycopeptide biomarkers	1960:1982	glycopeptide biomarkers of Philippine lung cancer patients	1960:2017	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	8	28	theme	higher	1705:1710	arg1	accuracies					1712:1721	higher accuracies	1705:1721	higher accuracies than N-glycans	1705:1736	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	5	29	theme	differential	1020:1031	arg1	abundances					1059:1068	differential N-glycan and glycopeptide abundances	1020:1068	differential N-glycan and glycopeptide abundances	1020:1068	Statistical analyses identified differential N-glycan and glycopeptide abundances.
36385894	0	30	theme	Cancer	62:67	arg1	Patients					69:76	Philippine Lung Cancer Patients	46:76	Philippine Lung Cancer Patients	46:76	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	0	31	theme	Glycopeptide	13:24	arg1	Biomarkers					32:41	Glycopeptide Serum Biomarkers	13:41	Glycopeptide Serum Biomarkers	13:41	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	6	32	theme	branched	1129:1136	arg1	structures					1138:1147	branched structures	1129:1147	branched structures	1129:1147	The N-glycans were mostly sialylated and sialofucosylated branched structures.
36385894	8	33	theme	N-glycans	1560:1568	arg1	[area					1570:1574	serum N-glycans [area	1554:1574	serum N-glycans [area	1554:1574	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	4	34	theme	cancer	709:714	arg1	patients					716:723	lung cancer patients	704:723	lung cancer patients	704:723	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	10	35	theme	lung	1998:2001	arg1	patients					2010:2017	Philippine lung cancer patients	1987:2017	Philippine lung cancer patients	1987:2017	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	7	36	theme	inflammatory	1295:1306	arg1	response					1308:1315	acute inflammatory response	1289:1315	acute inflammatory response (p adj = 6.404 × 10-5)	1289:1338	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	36	theme	inflammatory	1295:1306	arg1	×					1332:1332	p adj = 6.404 × 10-5	1318:1337	p adj = 6.404 × 10-5	1318:1337	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	0	37	from	N-Glycan	0:7	arg1	Patients					69:76	Philippine Lung Cancer Patients	46:76	Philippine Lung Cancer Patients	46:76	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	0	38	theme	Liquid	95:100	arg1	Spectrometry					129:140	Liquid Chromatography-Tandem Mass Spectrometry	95:140	Liquid Chromatography-Tandem Mass Spectrometry	95:140	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	8	39	dep	=	1598:1598	arg1	%					1609:1609	0.775; 95% CI: 0.617-0.931]	1600:1626	0.775; 95% CI: 0.617-0.931]	1600:1626	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	4	40	theme	serum	800:804	arg1	biomarkers					806:815	potential N-glycan and glycopeptide serum biomarkers	764:815	biomarkers	806:815	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	0	41	theme	Mass	124:127	arg1	Spectrometry					129:140	Liquid Chromatography-Tandem Mass Spectrometry	95:140	Liquid Chromatography-Tandem Mass Spectrometry	95:140	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	0	42	from	Biomarkers	32:41	arg1	Patients					69:76	Philippine Lung Cancer Patients	46:76	Philippine Lung Cancer Patients	46:76	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	7	43	theme	=	1365:1365	arg1	response					1349:1356	defense response	1341:1356	defense response (p adj = 2.082 × 10-4)	1341:1379	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	43	theme	=	1365:1365	arg1	×					1373:1373	p adj = 2.082 × 10-4	1359:1378	p adj = 2.082 × 10-4	1359:1378	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	8	44	dep	=	1651:1651	arg1	%					1662:1662	0.959; 95% CI: 0.85-1.0	1653:1675	0.959; 95% CI: 0.85-1.0	1653:1675	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	4	45	theme	potential	764:772	arg1	N-glycan					774:781	potential N-glycan and glycopeptide serum biomarkers	764:815	N-glycan	774:781	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	3	46	theme	first	499:503	arg1	time					505:508	the first time	495:508	the first time	495:508	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	7	47	theme	adj	1268:1270	arg1	immunity					1256:1263	innate immunity	1249:1263	innate immunity (p adj = 6.094 × 10-3)	1249:1286	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	47	theme	adj	1268:1270	arg1	×					1280:1280	p adj = 6.094 × 10-3	1266:1285	p adj = 6.094 × 10-3	1266:1285	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	8	48	contain	having	1698:1703	arg2	accuracies					1712:1721	higher accuracies	1705:1721	higher accuracies than N-glycans	1705:1736	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	8	48	contain	having	1698:1703	arg1	glycopeptides					1684:1696	glycopeptides	1684:1696	glycopeptides having higher accuracies than N-glycans	1684:1736	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	7	49	theme	p	1359:1359	arg1	response					1349:1356	defense response	1341:1356	defense response (p adj = 2.082 × 10-4)	1341:1379	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	49	theme	p	1359:1359	arg1	×					1373:1373	p adj = 2.082 × 10-4	1359:1378	p adj = 2.082 × 10-4	1359:1378	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	8	50	theme	serum	1554:1558	arg1	[area					1570:1574	serum N-glycans [area	1554:1574	serum N-glycans [area	1554:1574	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	4	51	theme	liquid	866:871	arg1	chromatography					873:886	ultra-high-performance liquid chromatography	843:886	ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry	843:935	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	2	52	theme	cancer	457:462	arg1	detection					464:472	cancer detection	457:472	cancer detection	457:472	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	2	53	gly	glycopeptide	371:382	arg2	glycopeptide					371:382	serum glycan and glycopeptide biomarkers	354:393	glycopeptide	371:382	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	6	54	gly	sialofucosylated	1112:1127	arg1	structures					1138:1147	branched structures	1129:1147	branched structures	1129:1147	The N-glycans were mostly sialylated and sialofucosylated branched structures.
36385894	0	55	theme	Philippine	46:55	arg1	Patients					69:76	Philippine Lung Cancer Patients	46:76	Philippine Lung Cancer Patients	46:76	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	9	56	theme	Philippine	1771:1780	arg1	sera					1802:1805	the Philippine lung cancer patient sera	1767:1805	the Philippine lung cancer patient sera	1767:1805	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	6	57	gly	sialylated	1097:1106	arg1	N-glycans					1075:1083	The N-glycans	1071:1083	The N-glycans	1071:1083	The N-glycans were mostly sialylated and sialofucosylated branched structures.
36385894	3	58	theme	potential	510:518	arg1	N-glycan					526:533	potential serum N-glycan and glycopeptide biomarkers	510:561	N-glycan	526:533	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	7	59	theme	4.818	1499:1503	arg1	10-2					1507:1510	p adj = 4.818 × 10-2	1491:1510	p adj = 4.818 × 10-2	1491:1510	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	59	theme	4.818	1499:1503	arg1	pathways					1481:1488	immunoglobulin-mediated immune response pathways	1441:1488	immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2)	1441:1511	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	10	60	gly	glycopeptide	1960:1971	arg2	glycopeptide					1960:1971	glycopeptide biomarkers	1960:1982	glycopeptide biomarkers of Philippine lung cancer patients	1960:2017	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	9	61	theme	cancer	1787:1792	arg1	sera					1802:1805	the Philippine lung cancer patient sera	1767:1805	the Philippine lung cancer patient sera	1767:1805	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	1	62	theme	cell-surface	265:276	arg1	patterns					253:260	the glycosylation patterns	235:260	the glycosylation patterns of cell-surface and secreted proteins	235:298	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	4	63	theme	=	654:654	arg1	n					652:652	n	652:652	n = 26 patients	652:666	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	64	theme	acute	1289:1293	arg1	response					1308:1315	acute inflammatory response	1289:1315	acute inflammatory response (p adj = 6.404 × 10-5)	1289:1338	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	64	theme	acute	1289:1293	arg1	×					1332:1332	p adj = 6.404 × 10-5	1318:1337	p adj = 6.404 × 10-5	1318:1337	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	3	65	theme	glycopeptide	539:550	arg1	biomarkers					552:561	potential serum N-glycan and glycopeptide biomarkers	510:561	biomarkers	552:561	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	1	66	theme	secreted	282:289	arg1	proteins					291:298	secreted proteins	282:298	secreted proteins	282:298	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	7	67	theme	adj	1320:1322	arg1	response					1308:1315	acute inflammatory response	1289:1315	acute inflammatory response (p adj = 6.404 × 10-5)	1289:1338	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	67	theme	adj	1320:1322	arg1	×					1332:1332	p adj = 6.404 × 10-5	1318:1337	p adj = 6.404 × 10-5	1318:1337	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	9	68	theme	specific	1808:1815	arg1	glycans					1845:1851	specific N-glycans and site-specific glycans	1808:1851	specific N-glycans and site-specific glycans	1808:1851	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	7	69	theme	response	1472:1479	arg1	10-2					1507:1510	p adj = 4.818 × 10-2	1491:1510	p adj = 4.818 × 10-2	1491:1510	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	69	theme	response	1472:1479	arg1	pathways					1481:1488	immunoglobulin-mediated immune response pathways	1441:1488	immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2)	1441:1511	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	70	theme	multiple	945:952	arg1	methods					965:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	71	from	cascades	1216:1223	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	72	theme	adj	1228:1230	arg1	proteins					1177:1184	proteins	1177:1184	proteins in complement	1177:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	72	theme	adj	1228:1230	arg1	×					1240:1240	p adj = 6.418 × 10-4	1226:1245	p adj = 6.418 × 10-4	1226:1245	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	3	73	theme	lung	578:581	arg1	patients					590:597	Philippine lung cancer patients	567:597	Philippine lung cancer patients	567:597	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	8	74	theme	=	1651:1651	arg1	AUC					1647:1649	AUC	1647:1649	AUC = 0.959; 95% CI: 0.85-1.0	1647:1675	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	7	75	theme	innate	1249:1254	arg1	immunity					1256:1263	innate immunity	1249:1263	innate immunity (p adj = 6.094 × 10-3)	1249:1286	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	75	theme	innate	1249:1254	arg1	×					1280:1280	p adj = 6.094 × 10-3	1266:1285	p adj = 6.094 × 10-3	1266:1285	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	76	theme	immunoglobulin-mediated	1441:1463	arg1	10-2					1507:1510	p adj = 4.818 × 10-2	1491:1510	p adj = 4.818 × 10-2	1491:1510	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	76	theme	immunoglobulin-mediated	1441:1463	arg1	pathways					1481:1488	immunoglobulin-mediated immune response pathways	1441:1488	immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2)	1441:1511	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	8	77	gly	glycopeptides	1632:1644	arg2	glycopeptides					1632:1644	glycopeptides	1632:1644	glycopeptides	1632:1644	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	10	78	theme	spectrometry-based	2062:2079	arg1	methods					2109:2115	mass spectrometry-based glycomic and glycoproteomic methods	2057:2115	mass spectrometry-based glycomic and glycoproteomic methods	2057:2115	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	4	79	theme	22	673:674	arg1	age-					676:679	age-	676:679	age-	676:679	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	1	80	gly	glycosylation	239:251	arg1	cell-surface					265:276	cell-surface	265:276	cell-surface	265:276	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	1	80	gly	glycosylation	239:251	arg1	proteins					291:298	secreted proteins	282:298	secreted proteins	282:298	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	2	81	theme	serum	354:358	arg1	such					348:351	such	348:351	such	348:351	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	2	81	theme	serum	354:358	arg1	glycan					360:365	serum glycan and glycopeptide biomarkers	354:393	glycan	360:365	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	2	81	theme	serum	354:358	arg1	biomarkers					384:393	serum glycan and glycopeptide biomarkers	354:393	biomarkers	384:393	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	4	82	theme	quadrupole	908:917	arg1	spectrometry					924:935	triple quadrupole mass spectrometry	901:935	triple quadrupole mass spectrometry	901:935	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	83	theme	×	1428:1428	arg1	pathways					1404:1411	complement activation pathways	1382:1411	complement activation pathways (p adj = 1.895 × 10-2)	1382:1434	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	83	theme	×	1428:1428	arg1	10-2					1430:1433	p adj = 1.895 × 10-2	1414:1433	p adj = 1.895 × 10-2	1414:1433	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	84	theme	coagulation	1204:1214	arg1	cascades					1216:1223	coagulation cascades	1204:1223	coagulation cascades	1204:1223	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	85	from	pathways	1481:1488	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	86	theme	=	1420:1420	arg1	pathways					1404:1411	complement activation pathways	1382:1411	complement activation pathways (p adj = 1.895 × 10-2)	1382:1434	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	86	theme	=	1420:1420	arg1	10-2					1430:1433	p adj = 1.895 × 10-2	1414:1433	p adj = 1.895 × 10-2	1414:1433	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	10	87	theme	methods	2109:2115	arg1	utility					2046:2052	the utility	2042:2052	the utility of mass spectrometry-based glycomic and glycoproteomic methods	2042:2115	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	10	88	theme	Philippine	1987:1996	arg1	patients					2010:2017	Philippine lung cancer patients	1987:2017	Philippine lung cancer patients	1987:2017	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	5	89	theme	Statistical	988:998	arg1	analyses					1000:1007	Statistical analyses	988:1007	Statistical analyses	988:1007	Statistical analyses identified differential N-glycan and glycopeptide abundances.
36385894	4	90	theme	patients	716:723	arg1	cohort					644:649	a cohort	642:649	a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients	642:723	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	4	91	dep	=	654:654	arg1	patients					659:666	26 patients	656:666	26 patients	656:666	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	4	92	gly	glycoprotein	617:628	arg1	glycoprotein					617:628	The N-glycan and glycoprotein profiles	600:637	glycoprotein	617:628	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	93	from	response	1308:1315	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	94	theme	complement	1382:1391	arg1	pathways					1404:1411	complement activation pathways	1382:1411	complement activation pathways (p adj = 1.895 × 10-2)	1382:1434	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	94	theme	complement	1382:1391	arg1	10-2					1430:1433	p adj = 1.895 × 10-2	1414:1433	p adj = 1.895 × 10-2	1414:1433	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	95	gly	glycopeptides	1154:1166	arg2	glycopeptides					1154:1166	The glycopeptides	1150:1166	The glycopeptides	1150:1166	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	10	96	theme	serum	1943:1947	arg1	glycan					1949:1954	the first serum glycan	1933:1954	the first serum glycan	1933:1954	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	4	97	gly	glycopeptide	787:798	arg2	glycopeptide					787:798	potential N-glycan and glycopeptide serum biomarkers	764:815	glycopeptide	787:798	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	8	98	gly	glycopeptides	1684:1696	arg2	glycopeptides					1684:1696	glycopeptides	1684:1696	glycopeptides having higher accuracies than N-glycans	1684:1736	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	7	99	from	immunity	1256:1263	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	100	theme	lung	704:707	arg1	patients					716:723	lung cancer patients	704:723	lung cancer patients	704:723	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	8	101	dep	curve	1586:1590	arg1	AUC					1647:1649	AUC	1647:1649	AUC = 0.959; 95% CI: 0.85-1.0	1647:1675	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	0	102	theme	Chromatography-Tandem	102:122	arg1	Spectrometry					129:140	Liquid Chromatography-Tandem Mass Spectrometry	95:140	Liquid Chromatography-Tandem Mass Spectrometry	95:140	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	8	103	theme	Biomarker	1514:1522	arg1	models					1524:1529	Biomarker models	1514:1529	Biomarker models	1514:1529	Biomarker models were constructed using serum N-glycans [area under the curve (AUC) = 0.775; 95% CI: 0.617-0.931] and glycopeptides (AUC = 0.959; 95% CI: 0.85-1.0), with glycopeptides having higher accuracies than N-glycans.
36385894	10	104	theme	patients	2010:2017	arg1	glycan					1949:1954	the first serum glycan	1933:1954	the first serum glycan	1933:1954	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	10	104	theme	patients	2010:2017	arg1	biomarkers					1973:1982	glycopeptide biomarkers	1960:1982	glycopeptide biomarkers of Philippine lung cancer patients	1960:2017	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	5	105	gly	glycopeptide	1046:1057	arg2	glycopeptide					1046:1057	glycopeptide	1046:1057	glycopeptide	1046:1057	Statistical analyses identified differential N-glycan and glycopeptide abundances.
36385894	4	106	theme	glycopeptide	787:798	arg1	biomarkers					806:815	potential N-glycan and glycopeptide serum biomarkers	764:815	biomarkers	806:815	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	7	107	theme	=	1272:1272	arg1	immunity					1256:1263	innate immunity	1249:1263	innate immunity (p adj = 6.094 × 10-3)	1249:1286	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	107	theme	=	1272:1272	arg1	×					1280:1280	p adj = 6.094 × 10-3	1266:1285	p adj = 6.094 × 10-3	1266:1285	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	5	108	theme	N-glycan	1033:1040	arg1	abundances					1059:1068	differential N-glycan and glycopeptide abundances	1020:1068	differential N-glycan and glycopeptide abundances	1020:1068	Statistical analyses identified differential N-glycan and glycopeptide abundances.
36385894	7	109	theme	adj	1361:1363	arg1	response					1349:1356	defense response	1341:1356	defense response (p adj = 2.082 × 10-4)	1341:1379	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	109	theme	adj	1361:1363	arg1	×					1373:1373	p adj = 2.082 × 10-4	1359:1378	p adj = 2.082 × 10-4	1359:1378	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	110	theme	N-glycan	604:611	arg1	profiles					630:637	The N-glycan and glycoprotein profiles	600:637	profiles	630:637	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	2	111	theme	mass	422:425	arg1	spectrometry					427:438	mass spectrometry	422:438	mass spectrometry	422:438	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	0	112	theme	Serum	26:30	arg1	Biomarkers					32:41	Glycopeptide Serum Biomarkers	13:41	Glycopeptide Serum Biomarkers	13:41	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	1	113	theme	cancer	325:330	arg1	progression					332:342	cancer progression	325:342	cancer progression	325:342	Aberrant glycosylation has been extensively reported in cancer, with fundamental changes in the glycosylation patterns of cell-surface and secreted proteins largely occurring during cancer progression.
36385894	5	114	theme	glycopeptide	1046:1057	arg1	abundances					1059:1068	differential N-glycan and glycopeptide abundances	1020:1068	differential N-glycan and glycopeptide abundances	1020:1068	Statistical analyses identified differential N-glycan and glycopeptide abundances.
36385894	7	115	from	pathways	1404:1411	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	116	theme	glycoprotein	617:628	arg1	profiles					630:637	The N-glycan and glycoprotein profiles	600:637	profiles	630:637	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	4	117	dep	=	671:671	arg1	n					669:669	n	669:669	n	669:669	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	4	117	dep	=	671:671	arg1	age-					676:679	age-	676:679	age-	676:679	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	4	117	dep	=	671:671	arg1	n					652:652	n	652:652	n = 26 patients	652:666	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	4	117	dep	=	671:671	arg1	gender-matched					685:698	gender-matched	685:698	gender-matched	685:698	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	10	118	theme	cancer	2003:2008	arg1	patients					2010:2017	Philippine lung cancer patients	1987:2017	Philippine lung cancer patients	1987:2017	This report represents the first serum glycan and glycopeptide biomarkers of Philippine lung cancer patients, further demonstrating the utility of mass spectrometry-based glycomic and glycoproteomic methods.
36385894	7	119	theme	defense	1341:1347	arg1	response					1349:1356	defense response	1341:1356	defense response (p adj = 2.082 × 10-4)	1341:1379	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	119	theme	defense	1341:1347	arg1	×					1373:1373	p adj = 2.082 × 10-4	1359:1378	p adj = 2.082 × 10-4	1359:1378	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	120	theme	ultra-high-performance	843:864	arg1	chromatography					873:886	ultra-high-performance liquid chromatography	843:886	ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry	843:935	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	0	121	theme	Lung	57:60	arg1	Patients					69:76	Philippine Lung Cancer Patients	46:76	Philippine Lung Cancer Patients	46:76	N-Glycan and Glycopeptide Serum Biomarkers in Philippine Lung Cancer Patients Identified Using Liquid Chromatography-Tandem Mass Spectrometry.
36385894	7	122	from	response	1349:1356	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	123	theme	chromatography	873:886	arg1	methods					965:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	2	124	theme	glycopeptide	371:382	arg1	such					348:351	such	348:351	such	348:351	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	2	124	theme	glycopeptide	371:382	arg1	glycan					360:365	serum glycan and glycopeptide biomarkers	354:393	glycan	360:365	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	2	124	theme	glycopeptide	371:382	arg1	biomarkers					384:393	serum glycan and glycopeptide biomarkers	354:393	biomarkers	384:393	As such, serum glycan and glycopeptide biomarkers have been discovered using mass spectrometry and proposed for cancer detection.
36385894	9	125	theme	lung	1782:1785	arg1	sera					1802:1805	the Philippine lung cancer patient sera	1767:1805	the Philippine lung cancer patient sera	1767:1805	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	3	126	gly	glycopeptide	539:550	arg2	glycopeptide					539:550	potential serum N-glycan and glycopeptide biomarkers	510:561	glycopeptide	539:550	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	3	127	theme	serum	520:524	arg1	N-glycan					526:533	potential serum N-glycan and glycopeptide biomarkers	510:561	N-glycan	526:533	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
36385894	7	128	theme	×	1505:1505	arg1	10-2					1507:1510	p adj = 4.818 × 10-2	1491:1510	p adj = 4.818 × 10-2	1491:1510	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	128	theme	×	1505:1505	arg1	pathways					1481:1488	immunoglobulin-mediated immune response pathways	1441:1488	immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2)	1441:1511	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	129	theme	=	1324:1324	arg1	response					1308:1315	acute inflammatory response	1289:1315	acute inflammatory response (p adj = 6.404 × 10-5)	1289:1338	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	7	129	theme	=	1324:1324	arg1	×					1332:1332	p adj = 6.404 × 10-5	1318:1337	p adj = 6.404 × 10-5	1318:1337	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	9	130	theme	patient	1794:1800	arg1	sera					1802:1805	the Philippine lung cancer patient sera	1767:1805	the Philippine lung cancer patient sera	1767:1805	The results suggest that in the Philippine lung cancer patient sera, specific N-glycans and site-specific glycans are differentially expressed between cases and controls.
36385894	7	131	from	proteins	1177:1184	arg1	complement					1189:1198	complement	1189:1198	complement	1189:1198	The glycopeptides involved proteins in complement and coagulation cascades (p adj = 6.418 × 10-4), innate immunity (p adj = 6.094 × 10-3), acute inflammatory response (p adj = 6.404 × 10-5), defense response (p adj = 2.082 × 10-4), complement activation pathways (p adj = 1.895 × 10-2), and immunoglobulin-mediated immune response pathways (p adj = 4.818 × 10-2).
36385894	4	132	theme	nano-QToF-MS/MS	823:837	arg1	methods					965:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods	823:971	The N-glycan and glycoprotein profiles of a cohort (n = 26 patients, n = 22 age- and gender-matched) of lung cancer patients were analyzed and compared to identify potential N-glycan and glycopeptide serum biomarkers using nano-QToF-MS/MS and ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry dynamic multiple monitoring methods, respectively.
36385894	3	133	theme	Philippine	567:576	arg1	patients					590:597	Philippine lung cancer patients	567:597	Philippine lung cancer patients	567:597	Here, we report for the first time potential serum N-glycan and glycopeptide biomarkers for Philippine lung cancer patients.
35987426	14	0	gly	glycoproteins	2206:2218	arg1	glycoproteins					2206:2218	glycoproteins	2206:2218	glycoproteins	2206:2218	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	7	1	theme	terminal	1046:1053	arg1	antigens					1126:1133	Tn antigens	1123:1133	Tn antigens	1123:1133	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	1	theme	terminal	1046:1053	arg1	II					1089:1090	GSA II	1085:1090	GSA II	1085:1090	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	1	theme	terminal	1046:1053	arg1	N-acetylglucosamine					1055:1073	terminal N-acetylglucosamine	1046:1073	terminal N-acetylglucosamine (GlcNAc) (GSA II)	1046:1091	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	1	theme	terminal	1046:1053	arg1	T-					1116:1117	T-	1116:1117	T-	1116:1117	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	1	theme	terminal	1046:1053	arg1	GlcNAc					1076:1081	GlcNAc	1076:1081	GlcNAc	1076:1081	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	1	theme	terminal	1046:1053	arg1	galactose					1094:1102	galactose	1094:1102	galactose (GSA I-B4)	1094:1113	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	13	2	theme	α1,3-linked	1941:1951	arg1	fucose					1953:1958	only α1,3-linked fucose	1936:1958	only α1,3-linked fucose	1936:1958	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	5	3	theme	Tissue	643:648	arg1	sections					650:657	Tissue sections	643:657	Tissue sections	643:657	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	6	4	theme	RESULTS	769:775	arg1	cells					783:787	RESULTS Basal cells	769:787	RESULTS Basal cells	769:787	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	7	5	theme	young	1011:1015	arg1	cells					1030:1034	The young intermediate cells	1007:1034	The young intermediate cells	1007:1034	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	4	6	from	stallions	632:640	arg1	bladders					607:614	urinary bladders	599:614	urinary bladders from four horse stallions	599:640	METHODS The study involved urinary bladders from four horse stallions.
35987426	1	7	theme	urinary	169:175	arg1	bladder					177:183	the urinary bladder	165:183	the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism	165:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	1	7	theme	urinary	169:175	arg1	barrier					212:218	a blood-urine barrier	198:218	a blood-urine barrier	198:218	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	6	8	theme	α2,6-linked	831:841	arg1	acid					850:853	α2,6-linked sialic acid	831:853	α2,6-linked sialic acid (SNA)	831:859	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	8	theme	α2,6-linked	831:841	arg1	SNA					856:858	SNA	856:858	SNA	856:858	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	9	with	sialoglycans	875:886	arg1	acids					900:904	sialic acids	893:904	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	893:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	3	10	theme	urothelium	535:544	arg1	pattern					498:504	the glycoprotein pattern	481:504	the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry	481:569	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	12	11	theme	glycans	1778:1784	arg1	secretion					1754:1762	intraluminal secretion	1741:1762	intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA)	1741:1845	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	8	12	link	O-linked	1219:1226	arg1	sialoglycans					1228:1239	O-linked sialoglycans	1219:1239	O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen)	1219:1277	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	3	13	theme	urinary	519:525	arg1	urothelium					535:544	the horse urinary bladder urothelium	509:544	the horse urinary bladder urothelium	509:544	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	11	14	theme	binding	1631:1637	arg1	KsDBA					1644:1648	KsDBA	1644:1648	KsDBA	1644:1648	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	11	14	theme	binding	1631:1637	arg1	DBA					1639:1641	GalNAc binding DBA	1624:1641	GalNAc binding DBA (KsDBA)	1624:1649	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	1	15	theme	blood-urine	200:210	arg1	bladder					177:183	the urinary bladder	165:183	the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism	165:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	1	15	theme	blood-urine	200:210	arg1	barrier					212:218	a blood-urine barrier	198:218	a blood-urine barrier	198:218	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	12	16	theme	intraluminal	1741:1752	arg1	secretion					1754:1762	intraluminal secretion	1741:1762	intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA)	1741:1845	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	3	17	theme	lectin	549:554	arg1	histochemistry					556:569	lectin histochemistry	549:569	lectin histochemistry	549:569	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	1	18	theme	multilayer	113:122	arg1	epithelium					124:133	a multilayer epithelium	111:133	a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism	111:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	1	18	theme	multilayer	113:122	arg1	Urothelium					97:106	BACKGROUND Urothelium	86:106	BACKGROUND Urothelium	86:106	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	6	19	theme	O-linked	866:873	arg1	sialoglycans					875:886	O-linked sialoglycans	866:886	O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	866:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	14	20	theme	urine	2179:2183	arg1	composition					2164:2174	the composition	2160:2174	the composition of urine	2160:2183	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	8	21	theme	intermediate	1158:1169	arg1	cells					1171:1175	The mature intermediate cells	1147:1175	The mature intermediate cells	1147:1175	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	11	22	theme	additional	1560:1569	arg1	acids					1608:1612	sialic acids	1601:1612	sialic acids	1601:1612	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	11	22	theme	additional	1560:1569	arg1	glycans					1571:1577	additional glycans	1560:1577	additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA)	1560:1649	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	11	22	theme	additional	1560:1569	arg1	antigen					1589:1595	T antigen	1587:1595	T antigen	1587:1595	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	13	23	theme	glycan	1895:1900	arg1	pattern					1902:1908	the most complex glycan pattern	1878:1908	the most complex glycan pattern in the urothelium	1878:1926	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	6	24	link	O-linked	866:873	arg1	sialoglycans					875:886	O-linked sialoglycans	866:886	O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	866:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	14	25	dep	CONCLUSIONS	1999:2009	arg1	showed					2022:2027	showed	2022:2027	showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins	2022:2218	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	8	26	theme	α1,2-linked	1324:1334	arg1	I					1348:1348	UEA I	1344:1348	UEA I	1344:1348	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	26	theme	α1,2-linked	1324:1334	arg1	fucose					1336:1341	α1,2-linked fucose	1324:1341	α1,2-linked fucose (UEA I)	1324:1349	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	14	27	theme	urothelium	2113:2122	arg1	layer					2100:2104	the basal to surface layer	2079:2104	the basal to surface layer of the urothelium	2079:2122	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	13	28	theme	luminal	1852:1858	arg1	surface					1860:1866	The luminal surface	1848:1866	The luminal surface	1848:1866	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	6	29	attach	linked	906:911	arg1	antigen					933:939	T antigen	931:939	T antigen	931:939	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	29	attach	linked	906:911	arg1	N-acetylgalactosamine					963:983	terminal N-acetylgalactosamine	954:983	terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	954:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	29	attach	linked	906:911	arg1	Galβl,3GalNAc					916:928	Galβl,3GalNAc	916:928	Galβl,3GalNAc (T antigen) (KsPNA)	916:948	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	29	attach	linked	906:911	arg1	KsPNA					943:947	KsPNA	943:947	KsPNA	943:947	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	29	attach	linked	906:911	arg2	acids					900:904	sialic acids	893:904	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	893:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	29	attach	linked	906:911	arg1	antigen					989:995	Tn antigen	986:995	Tn antigen	986:995	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	29	attach	linked	906:911	arg1	KsSBA					999:1003	KsSBA	999:1003	KsSBA	999:1003	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	1	30	theme	inner	148:152	arg1	surface					154:160	the inner surface	144:160	the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism	144:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	8	31	theme	high-mannose	1195:1206	arg1	N-glycans					1208:1216	additional high-mannose N-glycans	1184:1216	additional high-mannose N-glycans	1184:1216	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	11	32	theme	T	1587:1587	arg1	antigen					1589:1595	T antigen	1587:1595	T antigen	1587:1595	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	0	33	theme	urinary	69:75	arg1	bladder					77:83	horse urinary bladder	63:83	horse urinary bladder	63:83	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	8	34	link	α2,3-linked	1290:1300	arg1	MAL					1315:1317	MAL II	1315:1320	MAL II	1315:1320	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	34	link	α2,3-linked	1290:1300	arg1	acid					1309:1312	α2,6- and α2,3-linked sialic acid	1280:1312	α2,6- and α2,3-linked sialic acid (MAL II)	1280:1321	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	14	35	theme	surface	2092:2098	arg1	layer					2100:2104	the basal to surface layer	2079:2104	the basal to surface layer of the urothelium	2079:2122	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	7	36	theme	GSA	1105:1107	arg1	galactose					1094:1102	galactose	1094:1102	galactose (GSA I-B4)	1094:1113	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	36	theme	GSA	1105:1107	arg1	I-B4					1109:1112	GSA I-B4	1105:1112	GSA I-B4	1105:1112	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	37	theme	Tn	1123:1124	arg1	antigens					1126:1133	Tn antigens	1123:1133	Tn antigens	1123:1133	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	37	theme	Tn	1123:1124	arg1	N-acetylglucosamine					1055:1073	terminal N-acetylglucosamine	1046:1073	terminal N-acetylglucosamine (GlcNAc) (GSA II)	1046:1091	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	2	38	dep	serve	296:300	arg1	play					358:361	play	358:361	play a key role in the morphology and function of the multilayered epithelium	358:434	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	14	39	theme	basal	2083:2087	arg1	layer					2100:2104	the basal to surface layer	2079:2104	the basal to surface layer of the urothelium	2079:2122	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	10	40	theme	intermediate	1464:1475	arg1	cells					1477:1481	Few Con A positive intermediate cells	1445:1481	Few Con A positive intermediate cells	1445:1481	Few Con A positive intermediate cells were seen to cross the entire urothelium thickness.
35987426	12	41	theme	α1,3-linked	1680:1690	arg1	LTA					1700:1702	LTA	1700:1702	LTA	1700:1702	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	41	theme	α1,3-linked	1680:1690	arg1	fucose					1692:1697	α1,3-linked fucose	1680:1697	α1,3-linked fucose (LTA)	1680:1703	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	11	42	attach	linked	1614:1619	arg2	antigen					1589:1595	T antigen	1587:1595	T antigen	1587:1595	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	11	42	attach	linked	1614:1619	arg1	KsDBA					1644:1648	KsDBA	1644:1648	KsDBA	1644:1648	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	11	42	attach	linked	1614:1619	arg1	DBA					1639:1641	GalNAc binding DBA	1624:1641	GalNAc binding DBA (KsDBA)	1624:1649	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	2	43	theme	multilayered	412:423	arg1	epithelium					425:434	the multilayered epithelium	408:434	the multilayered epithelium	408:434	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	8	44	theme	sialyl-T	1242:1249	arg1	antigen					1251:1257	sialyl-T antigen	1242:1257	sialyl-T antigen	1242:1257	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	44	theme	sialyl-T	1242:1249	arg1	antigen					1270:1276	sialyl-Tn antigen	1260:1276	sialyl-Tn antigen	1260:1276	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	0	45	theme	Differential	0:11	arg1	expression					13:22	Differential expression	0:22	Differential expression of glycans in the urothelial layers of horse urinary bladder.	0:84	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	1	46	theme	BACKGROUND	86:95	arg1	epithelium					124:133	a multilayer epithelium	111:133	a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism	111:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	1	46	theme	BACKGROUND	86:95	arg1	Urothelium					97:106	BACKGROUND Urothelium	86:106	BACKGROUND Urothelium	86:106	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	7	47	theme	GSA	1085:1087	arg1	N-acetylglucosamine					1055:1073	terminal N-acetylglucosamine	1046:1073	terminal N-acetylglucosamine (GlcNAc) (GSA II)	1046:1091	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	47	theme	GSA	1085:1087	arg1	II					1089:1090	GSA II	1085:1090	GSA II	1085:1090	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	1	48	theme	whole	272:276	arg1	organism					278:285	the whole organism	268:285	the whole organism	268:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	12	49	theme	Few	1652:1654	arg1	cells					1664:1668	Few surface cells	1652:1668	Few surface cells	1652:1668	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	8	50	link	α1,2-linked	1324:1334	arg1	I					1348:1348	UEA I	1344:1348	UEA I	1344:1348	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	50	link	α1,2-linked	1324:1334	arg1	fucose					1336:1341	α1,2-linked fucose	1324:1341	α1,2-linked fucose (UEA I)	1324:1349	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	6	51	with	N-glycans	812:820	arg1	acids					900:904	sialic acids	893:904	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	893:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	3	52	theme	present	452:458	arg1	study					460:464	the present study	448:464	the present study	448:464	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	0	53	theme	urothelial	42:51	arg1	layers					53:58	the urothelial layers	38:58	the urothelial layers of horse urinary bladder	38:83	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	9	54	theme	overlying	1420:1428	arg1	layer					1438:1442	the overlying surface layer	1416:1442	the overlying surface layer	1416:1442	The latter residue marked the boundary with the overlying surface layer.
35987426	14	55	dep	layer	2100:2104	arg1	to					2089:2090	to	2089:2090	to	2089:2090	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	11	56	theme	surface	1539:1545	arg1	cells					1547:1551	The surface cells	1535:1551	The surface cells	1535:1551	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	6	57	theme	high-mannose	799:810	arg1	N-glycans					812:820	high-mannose N-glycans	799:820	high-mannose N-glycans (Con A)	799:828	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	57	theme	high-mannose	799:810	arg1	A					827:827	Con A	823:827	Con A	823:827	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	14	58	theme	glycan	2038:2043	arg1	pattern					2045:2051	the glycan pattern	2034:2051	the glycan pattern	2034:2051	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	6	59	theme	terminal	954:961	arg1	N-acetylgalactosamine					963:983	terminal N-acetylgalactosamine	954:983	terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	954:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	59	theme	terminal	954:961	arg1	antigen					989:995	Tn antigen	986:995	Tn antigen	986:995	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	59	theme	terminal	954:961	arg1	KsSBA					999:1003	KsSBA	999:1003	KsSBA	999:1003	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	8	60	theme	sialic	1302:1307	arg1	MAL					1315:1317	MAL II	1315:1320	MAL II	1315:1320	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	60	theme	sialic	1302:1307	arg1	acid					1309:1312	α2,6- and α2,3-linked sialic acid	1280:1312	α2,6- and α2,3-linked sialic acid (MAL II)	1280:1321	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	13	61	theme	demonstrated	1977:1988	arg1	glycans					1990:1996	the demonstrated glycans	1973:1996	the demonstrated glycans	1973:1996	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	12	62	theme	LFucα1,2	1814:1821	arg1	DBA					1842:1844	DBA	1842:1844	DBA	1842:1844	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	62	theme	LFucα1,2	1814:1821	arg1	Galβ1,3/4GlcNAcβ1					1823:1839	GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1	1803:1839	GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA)	1803:1845	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	2	63	theme	cells	343:347	arg1	differentiation					324:338	differentiation	324:338	differentiation	324:338	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	2	63	theme	cells	343:347	arg1	maturation					309:318	maturation	309:318	maturation	309:318	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	13	64	theme	only	1936:1939	arg1	fucose					1953:1958	only α1,3-linked fucose	1936:1958	only α1,3-linked fucose	1936:1958	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	6	65	with	acid	850:853	arg1	acids					900:904	sialic acids	893:904	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	893:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	7	66	theme	intermediate	1017:1028	arg1	cells					1030:1034	The young intermediate cells	1007:1034	The young intermediate cells	1007:1034	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	6	67	theme	Basal	777:781	arg1	cells					783:787	RESULTS Basal cells	769:787	RESULTS Basal cells	769:787	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	13	68	link	α1,3-linked	1941:1951	arg1	fucose					1953:1958	only α1,3-linked fucose	1936:1958	only α1,3-linked fucose	1936:1958	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	3	69	theme	glycoprotein	485:496	arg1	pattern					498:504	the glycoprotein pattern	481:504	the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry	481:569	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	12	70	theme	GalNAcα1,3	1803:1812	arg1	DBA					1842:1844	DBA	1842:1844	DBA	1842:1844	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	70	theme	GalNAcα1,3	1803:1812	arg1	Galβ1,3/4GlcNAcβ1					1823:1839	GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1	1803:1839	GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA)	1803:1845	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	6	71	theme	sialic	843:848	arg1	acid					850:853	α2,6-linked sialic acid	831:853	α2,6-linked sialic acid (SNA)	831:859	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	71	theme	sialic	843:848	arg1	SNA					856:858	SNA	856:858	SNA	856:858	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	4	72	theme	horse	626:630	arg1	stallions					632:640	four horse stallions	621:640	four horse stallions	621:640	METHODS The study involved urinary bladders from four horse stallions.
35987426	5	73	theme	sialidase	743:751	arg1	Ks					764:765	Ks	764:765	Ks	764:765	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	5	73	theme	sialidase	743:751	arg1	digestion					753:761	sialidase digestion	743:761	sialidase digestion (Ks)	743:766	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	3	74	theme	bladder	527:533	arg1	urothelium					535:544	the horse urinary bladder urothelium	509:544	the horse urinary bladder urothelium	509:544	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	1	75	theme	bladder	177:183	arg1	surface					154:160	the inner surface	144:160	the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism	144:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	3	76	theme	horse	513:517	arg1	urothelium					535:544	the horse urinary bladder urothelium	509:544	the horse urinary bladder urothelium	509:544	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	8	77	dep	sialoglycans	1228:1239	arg1	antigen					1251:1257	sialyl-T antigen	1242:1257	sialyl-T antigen	1242:1257	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	77	dep	sialoglycans	1228:1239	arg1	antigen					1270:1276	sialyl-Tn antigen	1260:1276	sialyl-Tn antigen	1260:1276	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	12	78	theme	mucin-type	1767:1776	arg1	glycans					1778:1784	mucin-type glycans	1767:1784	mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA)	1767:1845	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	8	79	theme	additional	1184:1193	arg1	N-glycans					1208:1216	additional high-mannose N-glycans	1184:1216	additional high-mannose N-glycans	1184:1216	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	4	80	theme	urinary	599:605	arg1	bladders					607:614	urinary bladders	599:614	urinary bladders from four horse stallions	599:640	METHODS The study involved urinary bladders from four horse stallions.
35987426	10	81	theme	Few	1445:1447	arg1	cells					1477:1481	Few Con A positive intermediate cells	1445:1481	Few Con A positive intermediate cells	1445:1481	Few Con A positive intermediate cells were seen to cross the entire urothelium thickness.
35987426	3	82	theme	study	460:464	arg1	aim					441:443	The aim	437:443	The aim of the present study	437:464	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	12	83	link	α1,3-linked	1680:1690	arg1	LTA					1700:1702	LTA	1700:1702	LTA	1700:1702	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	83	link	α1,3-linked	1680:1690	arg1	fucose					1692:1697	α1,3-linked fucose	1680:1697	α1,3-linked fucose (LTA)	1680:1703	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	84	theme	other	1719:1723	arg1	cells					1725:1729	some other cells	1714:1729	some other cells	1714:1729	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	6	85	theme	sialic	893:898	arg1	acids					900:904	sialic acids	893:904	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	893:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	5	86	with	combination	707:717	arg1	Ks					764:765	Ks	764:765	Ks	764:765	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	5	86	with	combination	707:717	arg1	saponification					724:737	saponification	724:737	saponification	724:737	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	5	86	with	combination	707:717	arg1	digestion					753:761	sialidase digestion	743:761	sialidase digestion (Ks)	743:766	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	14	87	theme	surface	2133:2139	arg1	cells					2141:2145	surface cells	2133:2145	surface cells	2133:2145	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	11	88	theme	GalNAc	1624:1629	arg1	KsDBA					1644:1648	KsDBA	1644:1648	KsDBA	1644:1648	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	11	88	theme	GalNAc	1624:1629	arg1	DBA					1639:1641	GalNAc binding DBA	1624:1641	GalNAc binding DBA (KsDBA)	1624:1649	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	13	89	theme	complex	1887:1893	arg1	pattern					1902:1908	the most complex glycan pattern	1878:1908	the most complex glycan pattern in the urothelium	1878:1926	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	8	90	theme	mature	1151:1156	arg1	cells					1171:1175	The mature intermediate cells	1147:1175	The mature intermediate cells	1147:1175	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	0	91	theme	horse	63:67	arg1	bladder					77:83	horse urinary bladder	63:83	horse urinary bladder	63:83	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	4	92	dep	METHODS	572:578	arg1	involved					590:597	involved	590:597	involved urinary bladders from four horse stallions	590:640	METHODS The study involved urinary bladders from four horse stallions.
35987426	8	93	theme	UEA	1344:1346	arg1	I					1348:1348	UEA I	1344:1348	UEA I	1344:1348	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	93	theme	UEA	1344:1346	arg1	fucose					1336:1341	α1,2-linked fucose	1324:1341	α1,2-linked fucose (UEA I)	1324:1349	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	0	94	theme	bladder	77:83	arg1	layers					53:58	the urothelial layers	38:58	the urothelial layers of horse urinary bladder	38:83	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	0	95	from	expression	13:22	arg1	layers					53:58	the urothelial layers	38:58	the urothelial layers of horse urinary bladder	38:83	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	3	96	gly	glycoprotein	485:496	arg1	glycoprotein					485:496	the glycoprotein pattern	481:504	the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry	481:569	The aim of the present study was to examine the glycoprotein pattern of the horse urinary bladder urothelium by lectin histochemistry.
35987426	5	97	theme	lectins	695:701	arg1	panel					679:683	a panel	677:683	a panel of eleven lectins	677:701	Tissue sections were stained with a panel of eleven lectins, in combination with saponification and sialidase digestion (Ks).
35987426	6	98	theme	T	931:931	arg1	antigen					933:939	T antigen	931:939	T antigen	931:939	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	98	theme	T	931:931	arg1	Galβl,3GalNAc					916:928	Galβl,3GalNAc	916:928	Galβl,3GalNAc (T antigen) (KsPNA)	916:948	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	8	99	theme	O-linked	1219:1226	arg1	sialoglycans					1228:1239	O-linked sialoglycans	1219:1239	O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen)	1219:1277	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	10	100	theme	positive	1455:1462	arg1	cells					1477:1481	Few Con A positive intermediate cells	1445:1481	Few Con A positive intermediate cells	1445:1481	Few Con A positive intermediate cells were seen to cross the entire urothelium thickness.
35987426	11	101	theme	sialic	1601:1606	arg1	acids					1608:1612	sialic acids	1601:1612	sialic acids	1601:1612	The surface cells showed additional glycans such as T antigen and sialic acids linked to GalNAc binding DBA (KsDBA).
35987426	9	102	theme	latter	1376:1381	arg1	residue					1383:1389	The latter residue	1372:1389	The latter residue	1372:1389	The latter residue marked the boundary with the overlying surface layer.
35987426	0	103	theme	glycans	27:33	arg1	expression					13:22	Differential expression	0:22	Differential expression of glycans in the urothelial layers of horse urinary bladder.	0:84	Differential expression of glycans in the urothelial layers of horse urinary bladder.
35987426	12	104	theme	surface	1656:1662	arg1	cells					1664:1668	Few surface cells	1652:1668	Few surface cells	1652:1668	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	6	105	theme	Tn	986:987	arg1	N-acetylgalactosamine					963:983	terminal N-acetylgalactosamine	954:983	terminal N-acetylgalactosamine (Tn antigen) (KsSBA)	954:1004	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	105	theme	Tn	986:987	arg1	antigen					989:995	Tn antigen	986:995	Tn antigen	986:995	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	106	link	α2,6-linked	831:841	arg1	acid					850:853	α2,6-linked sialic acid	831:853	α2,6-linked sialic acid (SNA)	831:859	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	106	link	α2,6-linked	831:841	arg1	SNA					856:858	SNA	856:858	SNA	856:858	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	1	107	theme	organism	278:285	arg1	wellbeing					255:263	the wellbeing	251:263	the wellbeing of the whole organism	251:285	BACKGROUND Urothelium is a multilayer epithelium covering the inner surface of the urinary bladder that acts as a blood-urine barrier and is involved in maintaining the wellbeing of the whole organism.
35987426	7	108	dep	T-	1116:1117	arg1	SBA					1141:1143	SBA	1141:1143	SBA	1141:1143	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	7	108	dep	T-	1116:1117	arg1	PNA					1136:1138	PNA	1136:1138	PNA	1136:1138	The young intermediate cells expressed terminal N-acetylglucosamine (GlcNAc) (GSA II), galactose (GSA I-B4), T- and Tn antigens (PNA, SBA).
35987426	8	109	theme	sialyl-Tn	1260:1268	arg1	antigen					1251:1257	sialyl-T antigen	1242:1257	sialyl-T antigen	1242:1257	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	109	theme	sialyl-Tn	1260:1268	arg1	antigen					1270:1276	sialyl-Tn antigen	1260:1276	sialyl-Tn antigen	1260:1276	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	6	110	theme	Con	823:825	arg1	N-glycans					812:820	high-mannose N-glycans	799:820	high-mannose N-glycans (Con A)	799:828	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	6	110	theme	Con	823:825	arg1	A					827:827	Con A	823:827	Con A	823:827	RESULTS Basal cells displayed high-mannose N-glycans (Con A), α2,6-linked sialic acid (SNA), and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA).
35987426	2	111	theme	epithelium	425:434	arg1	function					396:403	function	396:403	function	396:403	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	2	111	theme	epithelium	425:434	arg1	morphology					381:390	morphology	381:390	morphology	381:390	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	2	112	dep	morphology	381:390	arg1	the					377:379	the	377:379	the	377:379	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	10	113	theme	entire	1506:1511	arg1	urothelium					1513:1522	the entire urothelium	1502:1522	the entire urothelium	1502:1522	Few Con A positive intermediate cells were seen to cross the entire urothelium thickness.
35987426	9	114	theme	surface	1430:1436	arg1	layer					1438:1442	the overlying surface layer	1416:1442	the overlying surface layer	1416:1442	The latter residue marked the boundary with the overlying surface layer.
35987426	8	115	theme	α2,6-	1280:1284	arg1	MAL					1315:1317	MAL II	1315:1320	MAL II	1315:1320	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	115	theme	α2,6-	1280:1284	arg1	acid					1309:1312	α2,6- and α2,3-linked sialic acid	1280:1312	α2,6- and α2,3-linked sialic acid (MAL II)	1280:1321	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	14	116	theme	glycoproteins	2206:2218	arg1	secretion					2193:2201	the secretion	2189:2201	the secretion of glycoproteins	2189:2218	CONCLUSIONS This study showed that the glycan pattern becomes more complex from the basal to surface layer of the urothelium and that surface cells could modify the composition of urine via the secretion of glycoproteins.
35987426	2	117	theme	key	365:367	arg1	role					369:372	a key role	363:372	a key role	363:372	Glycans serve in the maturation and differentiation of cells and thus play a key role in the morphology and function of the multilayered epithelium.
35987426	13	118	from	pattern	1902:1908	arg1	urothelium					1917:1926	the urothelium	1913:1926	the urothelium	1913:1926	The luminal surface expressed the most complex glycan pattern in the urothelium because only α1,3-linked fucose lacked among the demonstrated glycans.
35987426	8	119	theme	α2,3-linked	1290:1300	arg1	MAL					1315:1317	MAL II	1315:1320	MAL II	1315:1320	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	8	119	theme	α2,3-linked	1290:1300	arg1	acid					1309:1312	α2,6- and α2,3-linked sialic acid	1280:1312	α2,6- and α2,3-linked sialic acid (MAL II)	1280:1321	The mature intermediate cells showed additional high-mannose N-glycans, O-linked sialoglycans (sialyl-T antigen, sialyl-Tn antigen), α2,6- and α2,3-linked sialic acid (MAL II), α1,2-linked fucose (UEA I), and GlcNAc (KsWGA).
35987426	12	120	contain	contained	1670:1678	arg2	LTA					1700:1702	LTA	1700:1702	LTA	1700:1702	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	120	contain	contained	1670:1678	arg1	cells					1664:1668	Few surface cells	1652:1668	Few surface cells	1652:1668	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
35987426	12	120	contain	contained	1670:1678	arg2	fucose					1692:1697	α1,3-linked fucose	1680:1697	α1,3-linked fucose (LTA)	1680:1703	Few surface cells contained α1,3-linked fucose (LTA), whereas some other cells displayed intraluminal secretion of mucin-type glycans terminating with GalNAcα1,3(LFucα1,2)Galβ1,3/4GlcNAcβ1 (DBA).
36746580	3	0	theme	label-free	699:708	arg1	glycoproteomics					710:724	label-free glycoproteomics	699:724	label-free glycoproteomics	699:724	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	2	1	theme	site-specific	336:348	arg1	N-glycosylation					350:364	the site-specific N-glycosylation	332:364	the site-specific N-glycosylation of human MFGM proteins	332:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	1	2	theme	neonatal	238:245	arg1	development					247:257	neonatal development	238:257	neonatal development	238:257	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	3	3	theme	glycoproteins	546:558	arg1	N-glycans					608:616	986 unique site-specific N-glycans	583:616	986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk	583:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	3	theme	glycoproteins	546:558	arg1	N-glycans					524:532	2617 unique site-specific N-glycans	498:532	2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum	498:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	4	gly	glycoproteins	630:642	arg1	glycoproteins					630:642	200 MFGM glycoproteins	621:642	200 MFGM glycoproteins in mature milk	621:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	5	theme	221	537:539	arg1	glycoproteins					546:558	221 MFGM glycoproteins	537:558	221 MFGM glycoproteins in human colostrum	537:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	1	6	theme	MFGM	172:175	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	5	7	gly	sialylated	989:998	arg1	structures					1010:1019	sialylated branching structures	989:1019	sialylated branching structures	989:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	0	8	theme	mature	126:131	arg1	milk					133:136	mature milk	126:136	mature milk	126:136	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	3	9	theme	unique	503:508	arg1	N-glycans					524:532	2617 unique site-specific N-glycans	498:532	2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum	498:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	8	10	theme	infant	1393:1398	arg1	formulas					1400:1407	infant formulas	1393:1407	infant formulas	1393:1407	The results of the study provide a background reference for the development of infant formulas.
36746580	0	11	theme	glycoproteomic	38:51	arg1	analysis					53:60	Quantitative label-free site-specific glycoproteomic analysis	0:60	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.	0:137	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	8	12	theme	study	1333:1337	arg1	results					1318:1324	The results	1314:1324	The results of the study	1314:1337	The results of the study provide a background reference for the development of infant formulas.
36746580	8	13	theme	formulas	1400:1407	arg1	development					1378:1388	the development	1374:1388	the development of infant formulas	1374:1407	The results of the study provide a background reference for the development of infant formulas.
36746580	3	14	theme	unique	587:592	arg1	N-glycans					608:616	986 unique site-specific N-glycans	583:616	986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk	583:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	15	theme	sialylated	989:998	arg1	structures					1010:1019	sialylated branching structures	989:1019	sialylated branching structures	989:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	3	16	theme	glycoproteins	630:642	arg1	N-glycans					608:616	986 unique site-specific N-glycans	583:616	986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk	583:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	16	theme	glycoproteins	630:642	arg1	N-glycans					524:532	2617 unique site-specific N-glycans	498:532	2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum	498:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	4	17	from	N-glycans	845:853	arg1	N-glycoproteins					861:875	25 N-glycoproteins	858:875	25 N-glycoproteins	858:875	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36746580	1	18	theme	Human	139:143	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	3	19	theme	human	563:567	arg1	colostrum					569:577	human colostrum	563:577	human colostrum	563:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	20	gly	glycoproteins	546:558	arg1	glycoproteins					546:558	221 MFGM glycoproteins	537:558	221 MFGM glycoproteins in human colostrum	537:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	0	21	theme	fat	74:76	arg1	protein					95:101	the milk fat globule membrane protein	65:101	the milk fat globule membrane protein	65:101	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	0	22	theme	site-specific	24:36	arg1	analysis					53:60	Quantitative label-free site-specific glycoproteomic analysis	0:60	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.	0:137	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	1	23	theme	fat	150:152	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	0	24	theme	membrane	86:93	arg1	protein					95:101	the milk fat globule membrane protein	65:101	the milk fat globule membrane protein	65:101	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	1	25	theme	membrane	162:169	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	3	26	from	glycoproteins	546:558	arg1	colostrum					569:577	human colostrum	563:577	human colostrum	563:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	27	theme	biological	1040:1049	arg1	processes					1051:1059	the biological processes	1036:1059	the biological processes of antigen processing and presentation	1036:1098	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	7	28	gly	glycoproteins	1299:1311	arg1	glycoproteins					1299:1311	human MFGM glycoproteins	1288:1311	human MFGM glycoproteins	1288:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	7	29	theme	glycoproteins	1299:1311	arg1	N-glycosylation					1269:1283	site-specific N-glycosylation	1255:1283	site-specific N-glycosylation of human MFGM glycoproteins	1255:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	6	30	theme	protein	1154:1160	arg1	patterns					1178:1185	human MFGM protein N-glycosylation patterns	1143:1185	human MFGM protein N-glycosylation patterns	1143:1185	This study reveals the dynamic changes in human MFGM protein N-glycosylation patterns during lactation.
36746580	0	31	from	analysis	53:60	arg1	colostrum					112:120	human colostrum	106:120	human colostrum	106:120	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	0	31	from	analysis	53:60	arg1	milk					133:136	mature milk	126:136	mature milk	126:136	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	0	32	theme	globule	78:84	arg1	protein					95:101	the milk fat globule membrane protein	65:101	the milk fat globule membrane protein	65:101	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	3	33	from	glycoproteins	630:642	arg1	milk					654:657	mature milk	647:657	mature milk	647:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	2	34	theme	proteins	380:387	arg1	N-glycosylation					350:364	the site-specific N-glycosylation	332:364	the site-specific N-glycosylation of human MFGM proteins	332:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	0	35	theme	Quantitative	0:11	arg1	analysis					53:60	Quantitative label-free site-specific glycoproteomic analysis	0:60	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.	0:137	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	1	36	theme	physiological	263:275	arg1	health					277:282	physiological health	263:282	physiological health	263:282	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	4	37	from	N-glycans	766:774	arg1	N-glycoproteins					782:796	10 N-glycoproteins	779:796	10 N-glycoproteins	779:796	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36746580	6	38	theme	human	1143:1147	arg1	patterns					1178:1185	human MFGM protein N-glycosylation patterns	1143:1185	human MFGM protein N-glycosylation patterns	1143:1185	This study reveals the dynamic changes in human MFGM protein N-glycosylation patterns during lactation.
36746580	7	39	theme	N-glycosylation	1269:1283	arg1	understanding					1238:1250	our understanding	1234:1250	our understanding of site-specific N-glycosylation of human MFGM glycoproteins	1234:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	1	40	theme	milk	145:148	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	7	41	theme	human	1288:1292	arg1	glycoproteins					1299:1311	human MFGM glycoproteins	1288:1311	human MFGM glycoproteins	1288:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	3	42	from	N-glycans	608:616	arg1	milk					654:657	mature milk	647:657	mature milk	647:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	42	from	N-glycans	608:616	arg1	colostrum					569:577	human colostrum	563:577	human colostrum	563:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	43	with	glycoproteins	923:935	arg1	Lewis					979:983	Lewis	979:983	Lewis	979:983	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	5	43	with	glycoproteins	923:935	arg1	structures					964:973	core-α1,6-fucosylated structures	942:973	core-α1,6-fucosylated structures	942:973	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	5	43	with	glycoproteins	923:935	arg1	structures					1010:1019	sialylated branching structures	989:1019	sialylated branching structures	989:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	3	44	theme	mature	647:652	arg1	milk					654:657	mature milk	647:657	mature milk	647:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	45	theme	intact	460:465	arg1	strategy					488:495	an intact glycopeptide-centred strategy	457:495	an intact glycopeptide-centred strategy	457:495	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	46	theme	processing	1072:1081	arg1	processes					1051:1059	the biological processes	1036:1059	the biological processes of antigen processing and presentation	1036:1098	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	7	47	gly	N-glycosylation	1269:1283	arg1	glycoproteins					1299:1311	human MFGM glycoproteins	1288:1311	human MFGM glycoproteins	1288:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	3	48	theme	site-specific	510:522	arg1	N-glycans					524:532	2617 unique site-specific N-glycans	498:532	2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum	498:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	49	theme	MFGM	918:921	arg1	glycoproteins					923:935	human MFGM glycoproteins	912:935	human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures	912:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	1	50	theme	essential	219:227	arg1	roles					229:233	essential roles	219:233	essential roles	219:233	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	5	51	theme	presentation	1087:1098	arg1	processes					1051:1059	the biological processes	1036:1059	the biological processes of antigen processing and presentation	1036:1098	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	2	52	from	changes	321:327	arg1	N-glycosylation					350:364	the site-specific N-glycosylation	332:364	the site-specific N-glycosylation of human MFGM proteins	332:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	3	53	theme	MFGM	541:544	arg1	glycoproteins					546:558	221 MFGM glycoproteins	537:558	221 MFGM glycoproteins in human colostrum	537:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	54	gly	glycoproteins	923:935	arg1	glycoproteins					923:935	human MFGM glycoproteins	912:935	human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures	912:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	3	55	from	milk	654:657	arg1	N-glycans					608:616	986 unique site-specific N-glycans	583:616	986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk	583:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	55	from	milk	654:657	arg1	N-glycans					524:532	2617 unique site-specific N-glycans	498:532	2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum	498:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	56	from	N-glycans	524:532	arg1	milk					654:657	mature milk	647:657	mature milk	647:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	56	from	N-glycans	524:532	arg1	colostrum					569:577	human colostrum	563:577	human colostrum	563:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	57	theme	human	912:916	arg1	glycoproteins					923:935	human MFGM glycoproteins	912:935	human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures	912:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	1	58	gly	N-glycosylated	198:211	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	8	59	theme	background	1349:1358	arg1	reference					1360:1368	a background reference	1347:1368	a background reference for the development of infant formulas	1347:1407	The results of the study provide a background reference for the development of infant formulas.
36746580	6	60	from	changes	1132:1138	arg1	patterns					1178:1185	human MFGM protein N-glycosylation patterns	1143:1185	human MFGM protein N-glycosylation patterns	1143:1185	This study reveals the dynamic changes in human MFGM protein N-glycosylation patterns during lactation.
36746580	3	61	theme	site-specific	594:606	arg1	N-glycans					608:616	986 unique site-specific N-glycans	583:616	986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk	583:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	62	gly	core-α1,6-fucosylated	942:962	arg1	structures					964:973	core-α1,6-fucosylated structures	942:973	core-α1,6-fucosylated structures	942:973	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	4	63	theme	milk	732:735	arg1	maturation					737:746	milk maturation	732:746	milk maturation	732:746	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36746580	3	64	theme	MFGM	625:628	arg1	glycoproteins					630:642	200 MFGM glycoproteins	621:642	200 MFGM glycoproteins in mature milk	621:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	5	65	theme	branching	1000:1008	arg1	structures					1010:1019	sialylated branching structures	989:1019	sialylated branching structures	989:1019	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	2	66	dep	profiles	298:305	arg1	the					294:296	the	294:296	the	294:296	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	3	67	from	colostrum	569:577	arg1	N-glycans					608:616	986 unique site-specific N-glycans	583:616	986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk	583:657	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	3	67	from	colostrum	569:577	arg1	N-glycans					524:532	2617 unique site-specific N-glycans	498:532	2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum	498:577	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	4	68	gly	N-glycoproteins	782:796	arg1	N-glycoproteins					782:796	10 N-glycoproteins	779:796	10 N-glycoproteins	779:796	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36746580	5	69	theme	core-α1,6-fucosylated	942:962	arg1	structures					964:973	core-α1,6-fucosylated structures	942:973	core-α1,6-fucosylated structures	942:973	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	0	70	theme	protein	95:101	arg1	analysis					53:60	Quantitative label-free site-specific glycoproteomic analysis	0:60	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.	0:137	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	1	71	theme	globule	154:160	arg1	proteins					178:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins	139:185	Human milk fat globule membrane (MFGM) proteins, which are N-glycosylated, play essential roles in neonatal development and physiological health.
36746580	0	72	theme	human	106:110	arg1	colostrum					112:120	human colostrum	106:120	human colostrum	106:120	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	2	73	from	profiles	298:305	arg1	N-glycosylation					350:364	the site-specific N-glycosylation	332:364	the site-specific N-glycosylation of human MFGM proteins	332:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	3	74	theme	glycopeptide-centred	467:486	arg1	strategy					488:495	an intact glycopeptide-centred strategy	457:495	an intact glycopeptide-centred strategy	457:495	Therefore, in this study, based on an intact glycopeptide-centred strategy, 2617 unique site-specific N-glycans of 221 MFGM glycoproteins in human colostrum and 986 unique site-specific N-glycans of 200 MFGM glycoproteins in mature milk were characterised and quantified using label-free glycoproteomics.
36746580	7	75	theme	MFGM	1294:1297	arg1	glycoproteins					1299:1311	human MFGM glycoproteins	1288:1311	human MFGM glycoproteins	1288:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	6	76	theme	N-glycosylation	1162:1176	arg1	patterns					1178:1185	human MFGM protein N-glycosylation patterns	1143:1185	human MFGM protein N-glycosylation patterns	1143:1185	This study reveals the dynamic changes in human MFGM protein N-glycosylation patterns during lactation.
36746580	0	77	theme	label-free	13:22	arg1	analysis					53:60	Quantitative label-free site-specific glycoproteomic analysis	0:60	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.	0:137	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	6	78	theme	MFGM	1149:1152	arg1	patterns					1178:1185	human MFGM protein N-glycosylation patterns	1143:1185	human MFGM protein N-glycosylation patterns	1143:1185	This study reveals the dynamic changes in human MFGM protein N-glycosylation patterns during lactation.
36746580	4	79	theme	site-specific	752:764	arg1	N-glycans					766:774	33 site-specific N-glycans	749:774	33 site-specific N-glycans on 10 N-glycoproteins	749:796	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36746580	2	80	theme	MFGM	375:378	arg1	proteins					380:387	human MFGM proteins	369:387	human MFGM proteins	369:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	7	81	theme	site-specific	1255:1267	arg1	N-glycosylation					1269:1283	site-specific N-glycosylation	1255:1283	site-specific N-glycosylation of human MFGM glycoproteins	1255:1311	Meanwhile, the study deepens our understanding of site-specific N-glycosylation of human MFGM glycoproteins.
36746580	4	82	gly	N-glycoproteins	861:875	arg1	N-glycoproteins					861:875	25 N-glycoproteins	858:875	25 N-glycoproteins	858:875	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36746580	2	83	theme	human	369:373	arg1	proteins					380:387	human MFGM proteins	369:387	human MFGM proteins	369:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	6	84	theme	dynamic	1124:1130	arg1	changes					1132:1138	the dynamic changes	1120:1138	the dynamic changes in human MFGM protein N-glycosylation patterns during lactation	1120:1202	This study reveals the dynamic changes in human MFGM protein N-glycosylation patterns during lactation.
36746580	2	85	gly	N-glycosylation	350:364	arg1	proteins					380:387	human MFGM proteins	369:387	human MFGM proteins	369:387	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	0	86	theme	milk	69:72	arg1	protein					95:101	the milk fat globule membrane protein	65:101	the milk fat globule membrane protein	65:101	Quantitative label-free site-specific glycoproteomic analysis of the milk fat globule membrane protein in human colostrum and mature milk.
36746580	5	87	theme	antigen	1064:1070	arg1	processing					1072:1081	antigen processing	1064:1081	antigen processing	1064:1081	Moreover, human MFGM glycoproteins with core-α1,6-fucosylated structures and Lewis and sialylated branching structures play a role in the biological processes of antigen processing and presentation.
36746580	2	88	theme	landscape	311:319	arg1	changes					321:327	landscape changes	311:327	landscape changes	311:327	However, the profiles and landscape changes in the site-specific N-glycosylation of human MFGM proteins during lactation remain unclear.
36746580	4	89	theme	site-specific	831:843	arg1	N-glycans					845:853	113 site-specific N-glycans	827:853	113 site-specific N-glycans on 25 N-glycoproteins	827:875	With milk maturation, 33 site-specific N-glycans on 10 N-glycoproteins increased significantly, and 113 site-specific N-glycans on 25 N-glycoproteins decreased significantly.
36252443	12	0	theme	biological	2124:2133	arg1	roles					2135:2139	glycoproteins' biological roles	2109:2139	glycoproteins' biological roles	2109:2139	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	11	1	theme	fifteen	1704:1710	arg1	compositions					1721:1732	Thirty-two and fifteen distinct compositions	1689:1732	compositions	1721:1732	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	2	2	theme	infant-associated	326:342	arg1	members					374:380	key members	370:380	key members of the breastfed infant's gut	370:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	2	2	theme	infant-associated	326:342	arg1	bifidobacteria					344:357	infant-associated bifidobacteria	326:357	infant-associated bifidobacteria	326:357	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	9	3	theme	native	1479:1484	arg1	glycoproteins					1486:1498	native glycoproteins	1479:1498	native glycoproteins	1479:1498	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	10	4	from	glycoproteins	1674:1686	arg1	F					1660:1660	PNGase F	1653:1660	PNGase F from native glycoproteins	1653:1686	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	10	5	theme	glycan	1623:1628	arg1	structures					1630:1639	glycan structures	1623:1639	glycan structures	1623:1639	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	7	6	theme	bovine	1159:1164	arg1	glycoproteins					1171:1183	bovine milk glycoproteins	1159:1183	bovine milk glycoproteins	1159:1183	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	5	7	theme	native	907:912	arg1	shape					914:918	the protein native shape	895:918	the protein native shape	895:918	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	9	8	theme	kinetic	1410:1416	arg1	evaluation					1418:1427	The kinetic evaluation	1406:1427	The kinetic evaluation	1406:1427	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	8	9	theme	EndoBI-1	1255:1262	arg1	activity					1243:1250	the activity	1239:1250	the activity of EndoBI-1	1239:1262	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	10	10	theme	PNGase	1653:1658	arg1	F					1660:1660	PNGase F	1653:1660	PNGase F from native glycoproteins	1653:1686	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	1	11	theme	living	236:241	arg1	organisms					243:251	living organisms	236:251	living organisms	236:251	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	12	12	theme	glycan	2016:2021	arg1	release					2023:2029	effective glycan release	2006:2029	effective glycan release	2006:2029	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	9	13	theme	glycan	1556:1561	arg1	release					1563:1569	0.012 mg/mL×min glycan release	1540:1569	0.012 mg/mL×min glycan release	1540:1569	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	9	14	gly	glycoproteins	1486:1498	arg1	glycoproteins					1486:1498	native glycoproteins	1479:1498	native glycoproteins	1479:1498	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	8	15	theme	peptide-N-glycosidase	1326:1346	arg1	F					1348:1348	the peptide-N-glycosidase F	1322:1348	the peptide-N-glycosidase F (PNGase F)	1322:1359	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	15	theme	peptide-N-glycosidase	1326:1346	arg1	F					1358:1358	PNGase F	1351:1358	PNGase F	1351:1358	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	15	theme	peptide-N-glycosidase	1326:1346	arg1	enzyme					1293:1298	a commercial enzyme	1280:1298	a commercial enzyme to release N-glycans	1280:1319	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	16	theme	commercial	1282:1291	arg1	F					1348:1348	the peptide-N-glycosidase F	1322:1348	the peptide-N-glycosidase F (PNGase F)	1322:1359	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	16	theme	commercial	1282:1291	arg1	enzyme					1293:1298	a commercial enzyme	1280:1298	a commercial enzyme to release N-glycans	1280:1319	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	2	17	theme	Released	254:261	arg1	substrates					311:320	growth substrates	304:320	growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut	304:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	2	17	theme	Released	254:261	arg1	N-glycans					263:271	Released N-glycans	254:271	Released N-glycans from milk glycoproteins	254:295	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	4	18	gly	deglycosylated	588:601	arg1	protein					603:609	the deglycosylated protein	584:609	the deglycosylated protein	584:609	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	5	19	theme	biological	961:970	arg1	roles					972:976	its biological roles	957:976	its biological roles	957:976	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	4	20	gly	glycoproteins	717:729	arg1	glycoproteins					717:729	glycoproteins	717:729	glycoproteins	717:729	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	7	21	theme	infantis	1059:1066	arg1	15697					1073:1077	infantis ATCC 15697	1059:1077	infantis ATCC 15697 (B. infantis)	1059:1091	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	5	22	theme	chemical	786:793	arg1	strategies					811:820	conventional enzymatic and chemical deglycosylation strategies	759:820	conventional enzymatic and chemical deglycosylation strategies to work efficiently	759:840	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	5	23	theme	further	931:937	arg1	investigations					939:952	further investigations	931:952	further investigations of its biological roles	931:976	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	4	24	theme	glycoproteins	717:729	arg1	activity					705:712	the biological activity	690:712	the biological activity of glycoproteins	690:729	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	11	25	theme	advanced	1838:1845	arg1	spectrometry					1852:1863	advanced mass spectrometry	1838:1863	advanced mass spectrometry	1838:1863	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	1	26	gly	glycoproteins	114:126	arg1	glycoproteins					114:126	Milk glycoproteins	109:126	Milk glycoproteins	109:126	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	8	27	gly	glycoproteins	1374:1386	arg1	glycoproteins					1374:1386	dairy glycoproteins	1368:1386	dairy glycoproteins	1368:1386	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	27	gly	glycoproteins	1374:1386	arg1	substrate					1395:1403	the substrate	1391:1403	the substrate	1391:1403	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	12	28	theme	native	1975:1980	arg1	form					1982:1985	the native form	1971:1985	the native form	1971:1985	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	1	29	theme	Milk	109:112	arg1	glycoproteins					114:126	Milk glycoproteins	109:126	Milk glycoproteins	109:126	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	12	30	theme	protein	1951:1957	arg1	backbone					1959:1966	their protein backbone	1945:1966	their protein backbone	1945:1966	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	0	31	theme	bifidogenic	11:21	arg1	N-glycans					23:31	bifidogenic N-glycans	11:31	bifidogenic N-glycans	11:31	Release of bifidogenic N-glycans from native bovine colostrum proteins by an endo-β-N-acetylglucosaminidase.
36252443	4	32	theme	deglycosylated	588:601	arg1	protein					603:609	the deglycosylated protein	584:609	the deglycosylated protein	584:609	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	6	33	from	longum	1045:1050	arg1	EndoBI-1					1014:1021	EndoBI-1	1014:1021	EndoBI-1	1014:1021	An endo-β-N-acetylglucosaminidase (EndoBI-1) from Bifidobacterium longum subsp.
36252443	6	33	from	longum	1045:1050	arg1	endo-β-N-acetylglucosaminidase					982:1011	An endo-β-N-acetylglucosaminidase	979:1011	An endo-β-N-acetylglucosaminidase (EndoBI-1) from Bifidobacterium longum	979:1050	An endo-β-N-acetylglucosaminidase (EndoBI-1) from Bifidobacterium longum subsp.
36252443	3	34	gly	glycoproteins	499:511	arg1	glycoproteins					499:511	glycoproteins	499:511	glycoproteins	499:511	To date, the mechanisms, and contributions of glycans to the biological activities of glycoproteins remain to be elucidated.
36252443	3	35	theme	biological	474:483	arg1	activities					485:494	the biological activities	470:494	the biological activities of glycoproteins	470:511	To date, the mechanisms, and contributions of glycans to the biological activities of glycoproteins remain to be elucidated.
36252443	9	36	from	activity	1467:1474	arg1	glycoproteins					1486:1498	native glycoproteins	1479:1498	native glycoproteins	1479:1498	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	12	37	theme	promising	1895:1903	arg1	enzyme					1905:1910	a promising enzyme	1893:1910	a promising enzyme	1893:1910	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	7	38	from	glycoproteins	1171:1183	arg1	N-glycans					1144:1152	N-glycans	1144:1152	N-glycans from bovine milk glycoproteins	1144:1183	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	12	39	gly	glycoproteins	2109:2121	arg1	glycoproteins					2109:2121	glycoproteins' biological roles	2109:2139	glycoproteins' biological roles	2109:2139	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	2	40	theme	breastfed	389:397	arg1	gut					408:410	the breastfed infant's gut	385:410	the breastfed infant's gut	385:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	0	41	theme	bovine	45:50	arg1	colostrum					52:60	native bovine colostrum	38:60	native bovine colostrum	38:60	Release of bifidogenic N-glycans from native bovine colostrum proteins by an endo-β-N-acetylglucosaminidase.
36252443	1	42	theme	various	133:139	arg1	roles					152:156	various biological roles	133:156	various biological roles	133:156	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	4	43	theme	released	563:570	arg1	glycans					572:578	the released glycans	559:578	the released glycans	559:578	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	11	44	attach	released	1739:1746	arg1	glycoproteins					1764:1776	the native glycoproteins	1753:1776	the native glycoproteins	1753:1776	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	11	44	attach	released	1739:1746	arg2	compositions					1721:1732	Thirty-two and fifteen distinct compositions	1689:1732	compositions	1721:1732	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	10	45	theme	broader	1606:1612	arg1	array					1614:1618	a broader array	1604:1618	a broader array of glycan structures	1604:1639	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	9	46	theme	higher	1460:1465	arg1	activity					1467:1474	higher activity	1460:1474	higher activity on native glycoproteins than PNGase F	1460:1512	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	11	47	theme	distinct	1712:1719	arg1	compositions					1721:1732	Thirty-two and fifteen distinct compositions	1689:1732	compositions	1721:1732	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	7	48	theme	milk	1166:1169	arg1	glycoproteins					1171:1183	bovine milk glycoproteins	1159:1183	bovine milk glycoproteins	1159:1183	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	8	49	theme	dairy	1368:1372	arg1	glycoproteins					1374:1386	dairy glycoproteins	1368:1386	dairy glycoproteins	1368:1386	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	49	theme	dairy	1368:1372	arg1	substrate					1395:1403	the substrate	1391:1403	the substrate	1391:1403	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	4	50	theme	native	620:625	arg1	form					649:652	their native (i.e., non-denatured) form	614:652	their native (i.e., non-denatured) form	614:652	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	10	51	theme	structures	1630:1639	arg1	array					1614:1618	a broader array	1604:1618	a broader array of glycan structures	1604:1639	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	11	52	theme	native	1757:1762	arg1	glycoproteins					1764:1776	the native glycoproteins	1753:1776	the native glycoproteins	1753:1776	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	1	53	theme	immune	216:221	arg1	responses					223:231	immune responses	216:231	immune responses	216:231	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	5	54	theme	protein	899:905	arg1	shape					914:918	the protein native shape	895:918	the protein native shape	895:918	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	4	55	theme	individual	663:672	arg1	contribution					674:685	the individual contribution	659:685	the individual contribution to the biological activity of glycoproteins	659:729	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	10	56	theme	native	1667:1672	arg1	glycoproteins					1674:1686	native glycoproteins	1667:1686	native glycoproteins	1667:1686	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	2	57	theme	key	370:372	arg1	members					374:380	key members	370:380	key members of the breastfed infant's gut	370:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	2	57	theme	key	370:372	arg1	bifidobacteria					344:357	infant-associated bifidobacteria	326:357	infant-associated bifidobacteria	326:357	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	9	58	theme	PNGase	1505:1510	arg1	F					1512:1512	PNGase F	1505:1512	PNGase F	1505:1512	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	2	59	gly	glycoproteins	283:295	arg1	glycoproteins					283:295	milk glycoproteins	278:295	milk glycoproteins	278:295	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	12	60	theme	subsequent	2051:2060	arg1	investigations					2062:2075	subsequent investigations	2051:2075	subsequent investigations	2051:2075	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	5	61	dep	strategies	811:820	arg1	work					825:828	work	825:828	to work efficiently	822:840	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	4	62	dep	native	620:625	arg1	non-denatured					634:646	non-denatured	634:646	non-denatured	634:646	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	2	63	theme	milk	278:281	arg1	glycoproteins					283:295	milk glycoproteins	278:295	milk glycoproteins	278:295	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	12	64	theme	effective	2006:2014	arg1	release					2023:2029	effective glycan release	2006:2029	effective glycan release	2006:2029	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	9	65	theme	0.012 mg/mL×min	1540:1554	arg1	release					1563:1569	0.012 mg/mL×min glycan release	1540:1569	0.012 mg/mL×min glycan release	1540:1569	The kinetic evaluation showed that EndoBI-1 displayed higher activity on native glycoproteins than PNGase F, with 0.036 mg/mL×min and 0.012 mg/mL×min glycan release, respectively.
36252443	12	66	from	release	1920:1926	arg1	form					1982:1985	the native form	1971:1985	the native form	1971:1985	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	4	67	dep	non-denatured	634:646	arg1	i.e.					628:631	i.e.	628:631	i.e.	628:631	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	2	68	theme	growth	304:309	arg1	substrates					311:320	growth substrates	304:320	growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut	304:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	2	68	theme	growth	304:309	arg1	N-glycans					263:271	Released N-glycans	254:271	Released N-glycans from milk glycoproteins	254:295	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	5	69	theme	roles	972:976	arg1	investigations					939:952	further investigations	931:952	further investigations of its biological roles	931:976	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	8	70	theme	PNGase	1351:1356	arg1	F					1348:1348	the peptide-N-glycosidase F	1322:1348	the peptide-N-glycosidase F (PNGase F)	1322:1359	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	8	70	theme	PNGase	1351:1356	arg1	F					1358:1358	PNGase F	1351:1358	PNGase F	1351:1358	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	7	71	theme	ATCC	1068:1071	arg1	15697					1073:1077	infantis ATCC 15697	1059:1077	infantis ATCC 15697 (B. infantis)	1059:1091	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	1	72	theme	antibacterial	168:180	arg1	activities					193:202	antibacterial, antiviral activities	168:202	activities	193:202	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	1	73	theme	biological	141:150	arg1	roles					152:156	various biological roles	133:156	various biological roles	133:156	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	4	74	theme	biological	694:703	arg1	activity					705:712	the biological activity	690:712	the biological activity of glycoproteins	690:729	Only by testing both the released glycans and the deglycosylated protein in their native (i.e., non-denatured) form, can the individual contribution to the biological activity of glycoproteins be elucidated.
36252443	5	75	theme	deglycosylation	795:809	arg1	strategies					811:820	conventional enzymatic and chemical deglycosylation strategies	759:820	conventional enzymatic and chemical deglycosylation strategies to work efficiently	759:840	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	1	76	theme	antiviral	183:191	arg1	activities					193:202	antibacterial, antiviral activities	168:202	activities	193:202	Milk glycoproteins play various biological roles including antibacterial, antiviral activities, modulating immune responses in living organisms.
36252443	11	77	gly	glycoproteins	1764:1776	arg1	glycoproteins					1764:1776	the native glycoproteins	1753:1776	the native glycoproteins	1753:1776	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	0	78	from	colostrum	52:60	arg1	Release					0:6	Release	0:6	Release of bifidogenic N-glycans from native bovine colostrum	0:60	Release of bifidogenic N-glycans from native bovine colostrum proteins by an endo-β-N-acetylglucosaminidase.
36252443	10	79	gly	glycoproteins	1674:1686	arg1	glycoproteins					1674:1686	native glycoproteins	1667:1686	native glycoproteins	1667:1686	EndoBI-1 released a broader array of glycan structures compared to PNGase F from native glycoproteins.
36252443	7	80	dep	15697	1073:1077	arg1	infantis					1083:1090	B. infantis	1080:1090	B. infantis	1080:1090	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	11	81	theme	mass	1847:1850	arg1	spectrometry					1852:1863	advanced mass spectrometry	1838:1863	advanced mass spectrometry	1838:1863	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	5	82	theme	conventional	759:770	arg1	strategies					811:820	conventional enzymatic and chemical deglycosylation strategies	759:820	conventional enzymatic and chemical deglycosylation strategies to work efficiently	759:840	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	5	83	theme	glycoprotein	843:854	arg1	denaturation					856:867	glycoprotein denaturation	843:867	glycoprotein denaturation	843:867	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	3	84	theme	glycans	459:465	arg1	mechanisms					426:435	the mechanisms	422:435	the mechanisms	422:435	To date, the mechanisms, and contributions of glycans to the biological activities of glycoproteins remain to be elucidated.
36252443	3	84	theme	glycans	459:465	arg1	contributions					442:454	contributions	442:454	contributions of glycans to the biological activities of glycoproteins	442:511	To date, the mechanisms, and contributions of glycans to the biological activities of glycoproteins remain to be elucidated.
36252443	0	85	theme	N-glycans	23:31	arg1	Release					0:6	Release	0:6	Release of bifidogenic N-glycans from native bovine colostrum	0:60	Release of bifidogenic N-glycans from native bovine colostrum proteins by an endo-β-N-acetylglucosaminidase.
36252443	8	86	dep	enzyme	1293:1298	arg1	release					1303:1309	release	1303:1309	to release N-glycans	1300:1319	In this study, the activity of EndoBI-1 was compared to a commercial enzyme to release N-glycans, the peptide-N-glycosidase F (PNGase F), using dairy glycoproteins as the substrate.
36252443	2	87	from	glycoproteins	283:295	arg1	substrates					311:320	growth substrates	304:320	growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut	304:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	2	87	from	glycoproteins	283:295	arg1	N-glycans					263:271	Released N-glycans	254:271	Released N-glycans from milk glycoproteins	254:295	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	3	88	theme	glycoproteins	499:511	arg1	activities					485:494	the biological activities	470:494	the biological activities of glycoproteins	470:511	To date, the mechanisms, and contributions of glycans to the biological activities of glycoproteins remain to be elucidated.
36252443	0	89	theme	native	38:43	arg1	colostrum					52:60	native bovine colostrum	38:60	native bovine colostrum	38:60	Release of bifidogenic N-glycans from native bovine colostrum proteins by an endo-β-N-acetylglucosaminidase.
36252443	12	90	theme	backbone	1959:1966	arg1	release					1920:1926	the release	1916:1926	the release of N-glycans and their protein backbone in the native form	1916:1985	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	7	91	gly	glycoproteins	1171:1183	arg1	glycoproteins					1171:1183	bovine milk glycoproteins	1159:1183	bovine milk glycoproteins	1159:1183	infantis ATCC 15697 (B. infantis) was characterized as having the ability to release N-glycans from bovine milk glycoproteins efficiently, without the denaturation.
36252443	5	92	gly	glycoprotein	843:854	arg1	glycoprotein					843:854	glycoprotein denaturation	843:867	glycoprotein denaturation	843:867	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	5	93	theme	enzymatic	772:780	arg1	strategies					811:820	conventional enzymatic and chemical deglycosylation strategies	759:820	conventional enzymatic and chemical deglycosylation strategies to work efficiently	759:840	However, for conventional enzymatic and chemical deglycosylation strategies to work efficiently, glycoprotein denaturation is required, which alters the protein native shape, hindering further investigations of its biological roles.
36252443	12	94	theme	N-glycans	1931:1939	arg1	release					1920:1926	the release	1916:1926	the release of N-glycans and their protein backbone in the native form	1916:1985	EndoBI-1 can be considered a promising enzyme for the release of N-glycans and their protein backbone in the native form, which will enable effective glycan release and will facilitate subsequent investigations to reveal their contribution to glycoproteins' biological roles.
36252443	11	95	theme	PNGase	1794:1799	arg1	F					1801:1801	PNGase F	1794:1801	PNGase F	1794:1801	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	11	96	theme	Thirty-two	1689:1698	arg1	compositions					1721:1732	Thirty-two and fifteen distinct compositions	1689:1732	compositions	1721:1732	Thirty-two and fifteen distinct compositions were released from the native glycoproteins by EndoBI-1 and PNGase F, respectively, as characterized by advanced mass spectrometry.
36252443	2	97	theme	gut	408:410	arg1	members					374:380	key members	370:380	key members of the breastfed infant's gut	370:410	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36252443	2	97	theme	gut	408:410	arg1	bifidobacteria					344:357	infant-associated bifidobacteria	326:357	infant-associated bifidobacteria	326:357	Released N-glycans from milk glycoproteins act as growth substrates for infant-associated bifidobacteria, which are key members of the breastfed infant's gut.
36179122	6	0	theme	structure-prediction	1197:1216	arg1	capabilities					1218:1229	the structure-prediction capabilities	1193:1229	the structure-prediction capabilities of two commonly used glycan force fields	1193:1270	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	6	1	theme	used	1247:1250	arg1	fields					1265:1270	two commonly used glycan force fields	1234:1270	two commonly used glycan force fields	1234:1270	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	7	2	theme	torsion	1448:1454	arg1	angles					1456:1461	ψ torsion angles	1446:1461	ψ torsion angles	1446:1461	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	0	3	theme	Space	77:81	arg1	Representation					13:26	Representation	13:26	Representation	13:26	Exploration, Representation, and Rationalization of the Conformational Phase Space of N-Glycans.
36179122	0	3	theme	Space	77:81	arg1	Rationalization					33:47	Rationalization	33:47	Rationalization	33:47	Exploration, Representation, and Rationalization of the Conformational Phase Space of N-Glycans.
36179122	0	3	theme	Space	77:81	arg1	Exploration					0:10	Exploration	0:10	Exploration	0:10	Exploration, Representation, and Rationalization of the Conformational Phase Space of N-Glycans.
36179122	3	4	theme	replica	573:579	arg1	exchange					581:588	replica exchange	573:588	replica exchange	573:588	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	7	5	theme	key	1428:1430	arg1	role					1432:1435	the key role	1424:1435	the key role of ω and ψ torsion angles in discriminating between different conformational states	1424:1519	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	5	6	from	effect	1068:1073	arg1	ensemble					1123:1130	the conformational ensemble	1104:1130	the conformational ensemble of selected high-mannose-type and complex glycans	1104:1180	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	3	7	theme	collective-variable	606:624	arg1	tempering					626:634	collective-variable tempering	606:634	collective-variable tempering	606:634	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	0	8	theme	N-Glycans	86:94	arg1	Space					77:81	the Conformational Phase Space	52:81	the Conformational Phase Space of N-Glycans	52:94	Exploration, Representation, and Rationalization of the Conformational Phase Space of N-Glycans.
36179122	5	9	dep	high-mannose-type	1144:1160	arg1	selected					1135:1142	selected	1135:1142	selected	1135:1142	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	5	10	theme	high-mannose-type	1144:1160	arg1	ensemble					1123:1130	the conformational ensemble	1104:1130	the conformational ensemble of selected high-mannose-type and complex glycans	1104:1180	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	7	11	theme	angles	1456:1461	arg1	role					1432:1435	the key role	1424:1435	the key role of ω and ψ torsion angles in discriminating between different conformational states	1424:1519	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	2	12	theme	torsional	336:344	arg1	flexibility					346:356	The torsional flexibility	332:356	The torsional flexibility of the glycosidic linkages	332:383	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	4	13	theme	conformational	848:861	arg1	maps					875:878	conformational free-energy maps	848:878	conformational free-energy maps	848:878	Several dimensionality-reduction algorithms are compared and employed to generate conformational free-energy maps in two dimensions.
36179122	3	14	theme	enhanced-sampling	538:554	arg1	scheme					556:561	a novel enhanced-sampling scheme	530:561	a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers,	530:691	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	1	15	from	relationships	164:176	arg1	<i>N</i>-glycans					181:196	<i>N</i>-glycans	181:196	<i>N</i>-glycans	181:196	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
36179122	6	16	theme	fields	1265:1270	arg1	capabilities					1218:1229	the structure-prediction capabilities	1193:1229	the structure-prediction capabilities of two commonly used glycan force fields	1193:1270	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	4	17	theme	Several	766:772	arg1	algorithms					799:808	Several dimensionality-reduction algorithms	766:808	Several dimensionality-reduction algorithms	766:808	Several dimensionality-reduction algorithms are compared and employed to generate conformational free-energy maps in two dimensions.
36179122	7	18	theme	intriguing	1536:1545	arg1	relevant					1644:1651	relevant	1644:1651	relevant	1644:1651	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	7	18	theme	intriguing	1536:1545	arg1	correlation					1547:1557	an intriguing correlation	1533:1557	an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant	1533:1651	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	2	19	dep	wide	417:420	arg1	rugged					423:428	rugged	423:428	rugged	423:428	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	7	20	theme	torsional	1571:1579	arg1	degrees					1600:1606	the torsional and ring-puckering degrees	1567:1606	the torsional and ring-puckering degrees of freedom	1567:1617	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	6	21	theme	constants	1382:1390	arg1	prediction					1305:1314	the theoretical prediction	1289:1314	the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants	1289:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	7	22	theme	ω	1440:1440	arg1	role					1432:1435	the key role	1424:1435	the key role of ω and ψ torsion angles in discriminating between different conformational states	1424:1519	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	2	23	theme	linkages	376:383	arg1	flexibility					346:356	The torsional flexibility	332:356	The torsional flexibility of the glycosidic linkages	332:383	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	2	23	theme	linkages	376:383	arg1	dynamics					398:405	the ring dynamics	389:405	the ring dynamics	389:405	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	7	24	theme	different	1489:1497	arg1	states					1514:1519	different conformational states	1489:1519	different conformational states	1489:1519	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	2	25	theme	free-energy	430:440	arg1	landscapes					442:451	wide, rugged free-energy landscapes	417:451	wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations	417:514	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	2	26	theme	dynamics	495:502	arg1	simulations					504:514	molecular dynamics simulations	485:514	molecular dynamics simulations	485:514	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	2	27	theme	glycosidic	365:374	arg1	linkages					376:383	the glycosidic linkages	361:383	the glycosidic linkages	361:383	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	4	28	theme	dimensionality-reduction	774:797	arg1	algorithms					799:808	Several dimensionality-reduction algorithms	766:808	Several dimensionality-reduction algorithms	766:808	Several dimensionality-reduction algorithms are compared and employed to generate conformational free-energy maps in two dimensions.
36179122	2	29	theme	molecular	485:493	arg1	simulations					504:514	molecular dynamics simulations	485:514	molecular dynamics simulations	485:514	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	6	30	theme	resonance	1361:1369	arg1	constants					1382:1390	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	5	31	theme	glycan	1001:1006	arg1	conformers					1008:1017	glycan conformers	1001:1017	glycan conformers	1001:1017	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	5	32	theme	conformational	1108:1121	arg1	ensemble					1123:1130	the conformational ensemble	1104:1130	the conformational ensemble of selected high-mannose-type and complex glycans	1104:1180	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	3	33	theme	<i>N</i>-glycan	738:752	arg1	conformers					754:763	solvated <i>N</i>-glycan conformers	729:763	solvated <i>N</i>-glycan conformers	729:763	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	6	34	theme	magnetic	1352:1359	arg1	resonance					1361:1369	nuclear magnetic resonance	1344:1369	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	6	35	theme	J-coupling	1371:1380	arg1	constants					1382:1390	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	2	36	theme	ring	393:396	arg1	dynamics					398:405	the ring dynamics	389:405	the ring dynamics	389:405	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	3	37	theme	conformers	754:763	arg1	distributions					712:724	converged distributions	702:724	converged distributions of solvated <i>N</i>-glycan conformers	702:763	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	3	38	theme	energy	676:681	arg1	barriers					683:690	all relevant energy barriers	663:690	all relevant energy barriers	663:690	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	6	39	theme	force	1259:1263	arg1	fields					1265:1270	two commonly used glycan force fields	1234:1270	two commonly used glycan force fields	1234:1270	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	5	40	theme	modeling	1024:1031	arg1	procedure					1033:1041	our modeling procedure	1020:1041	our modeling procedure	1020:1041	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	5	41	theme	developed	927:935	arg1	scheme					969:974	an originally developed conformation-based nomenclature scheme	913:974	an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers	913:1017	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	5	42	theme	chemical	1078:1085	arg1	substitutions					1087:1099	chemical substitutions	1078:1099	chemical substitutions	1078:1099	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	1	43	theme	multidimensional	242:257	arg1	compositional					259:271	their highly multidimensional compositional	229:271	their highly multidimensional compositional	229:271	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
36179122	5	44	theme	conformation-based	937:954	arg1	scheme					969:974	an originally developed conformation-based nomenclature scheme	913:974	an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers	913:1017	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	3	45	theme	solvated	729:736	arg1	conformers					754:763	solvated <i>N</i>-glycan conformers	729:763	solvated <i>N</i>-glycan conformers	729:763	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	7	46	theme	freedom	1611:1617	arg1	degrees					1600:1606	the torsional and ring-puckering degrees	1567:1606	the torsional and ring-puckering degrees of freedom	1567:1617	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	6	47	theme	available	1334:1342	arg1	constants					1382:1390	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	1	48	theme	fundamental	111:121	arg1	relevance					134:142	their fundamental biological relevance	105:142	their fundamental biological relevance	105:142	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
36179122	5	49	theme	nomenclature	956:967	arg1	scheme					969:974	an originally developed conformation-based nomenclature scheme	913:974	an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers	913:1017	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	3	50	theme	relevant	667:674	arg1	barriers					683:690	all relevant energy barriers	663:690	all relevant energy barriers	663:690	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	7	51	theme	conformational	1499:1512	arg1	states					1514:1519	different conformational states	1489:1519	different conformational states	1489:1519	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	1	52	theme	biological	123:132	arg1	relevance					134:142	their fundamental biological relevance	105:142	their fundamental biological relevance	105:142	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
36179122	5	53	theme	glycans	1174:1180	arg1	ensemble					1123:1130	the conformational ensemble	1104:1130	the conformational ensemble of selected high-mannose-type and complex glycans	1104:1180	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	3	54	theme	converged	702:710	arg1	distributions					712:724	converged distributions	702:724	converged distributions of solvated <i>N</i>-glycan conformers	702:763	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	4	55	theme	free-energy	863:873	arg1	maps					875:878	conformational free-energy maps	848:878	conformational free-energy maps	848:878	Several dimensionality-reduction algorithms are compared and employed to generate conformational free-energy maps in two dimensions.
36179122	5	56	theme	complex	1166:1172	arg1	glycans					1174:1180	selected high-mannose-type and complex glycans	1135:1180	glycans	1174:1180	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	3	57	theme	novel	532:536	arg1	scheme					556:561	a novel enhanced-sampling scheme	530:561	a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers,	530:691	We show that a novel enhanced-sampling scheme combining replica exchange with solute and collective-variable tempering, enabling transitions over all relevant energy barriers, delivers converged distributions of solvated <i>N</i>-glycan conformers.
36179122	6	58	theme	nuclear	1344:1350	arg1	resonance					1361:1369	nuclear magnetic resonance	1344:1369	experimentally available nuclear magnetic resonance J-coupling constants	1319:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	5	59	theme	substitutions	1087:1099	arg1	effect					1068:1073	the effect	1064:1073	the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans	1064:1180	Together with an originally developed conformation-based nomenclature scheme that uniquely identifies glycan conformers, our modeling procedure is applied to reveal the effect of chemical substitutions on the conformational ensemble of selected high-mannose-type and complex glycans.
36179122	0	60	theme	Phase	71:75	arg1	Space					77:81	the Conformational Phase Space	52:81	the Conformational Phase Space of N-Glycans	52:94	Exploration, Representation, and Rationalization of the Conformational Phase Space of N-Glycans.
36179122	6	61	theme	theoretical	1293:1303	arg1	prediction					1305:1314	the theoretical prediction	1289:1314	the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants	1289:1390	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	6	62	theme	glycan	1252:1257	arg1	fields					1265:1270	two commonly used glycan force fields	1234:1270	two commonly used glycan force fields	1234:1270	Moreover, the structure-prediction capabilities of two commonly used glycan force fields are assessed via the theoretical prediction of experimentally available nuclear magnetic resonance J-coupling constants.
36179122	1	63	theme	structure-property	145:162	arg1	relationships					164:176	structure-property relationships	145:176	structure-property relationships in <i>N</i>-glycans	145:196	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
36179122	7	64	theme	ψ	1446:1446	arg1	angles					1456:1461	ψ torsion angles	1446:1461	ψ torsion angles	1446:1461	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	1	65	theme	conformational	277:290	arg1	spaces					298:303	conformational phase spaces	277:303	conformational phase spaces	277:303	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
36179122	0	66	theme	Conformational	56:69	arg1	Space					77:81	the Conformational Phase Space	52:81	the Conformational Phase Space of N-Glycans	52:94	Exploration, Representation, and Rationalization of the Conformational Phase Space of N-Glycans.
36179122	7	67	theme	ring-puckering	1585:1598	arg1	degrees					1600:1606	the torsional and ring-puckering degrees	1567:1606	the torsional and ring-puckering degrees of freedom	1567:1617	The results especially confirm the key role of ω and ψ torsion angles in discriminating between different conformational states and suggest an intriguing correlation between the torsional and ring-puckering degrees of freedom that may be biologically relevant.
36179122	2	68	from	sample	475:480	arg1	simulations					504:514	molecular dynamics simulations	485:514	molecular dynamics simulations	485:514	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	2	69	theme	wide	417:420	arg1	landscapes					442:451	wide, rugged free-energy landscapes	417:451	wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations	417:514	The torsional flexibility of the glycosidic linkages and the ring dynamics result in wide, rugged free-energy landscapes that are difficult to sample in molecular dynamics simulations.
36179122	1	70	theme	phase	292:296	arg1	spaces					298:303	conformational phase spaces	277:303	conformational phase spaces	277:303	Despite their fundamental biological relevance, structure-property relationships in <i>N</i>-glycans are fundamentally lacking, and their highly multidimensional compositional and conformational phase spaces remain largely unexplored.
34978588	6	0	theme	glycan	890:895	arg1	p < 0.05					909:916	p < 0.05	909:916	p < 0.05	909:916	Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures (p < 0.05).
34978588	6	0	theme	glycan	890:895	arg1	structures					897:906	11 glycan structures	887:906	11 glycan structures (p < 0.05)	887:917	Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures (p < 0.05).
34978588	1	1	from	role	171:174	arg1	progression					196:206	oral cancer (OC) progression	179:206	oral cancer (OC) progression	179:206	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	2	2	theme	MALDI-MS-based	317:330	arg1	analysis					343:350	a MALDI-MS-based N-glycomic analysis	315:350	a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC	315:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	7	3	theme	cancer	1125:1130	arg1	signatures					1107:1116	targeted glycoproteomics signatures	1082:1116	targeted glycoproteomics signatures of the cancer	1082:1130	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	6	4	theme	N-glycomic	793:802	arg1	profiles					804:811	N-glycomic profiles	793:811	N-glycomic profiles from the serum	793:826	Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures (p < 0.05).
34978588	5	5	theme	early	721:725	arg1	stage					727:731	the early stage	717:731	the early stage of OC	717:737	Importantly, the increases in these glycans were significantly greater in the early stage of OC than those in the advanced stage of OC.
34978588	6	6	theme	significant	865:875	arg1	change					877:882	a significant change	863:882	a significant change of 11 glycan structures (p < 0.05)	863:917	Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures (p < 0.05).
34978588	7	7	theme	targeted	1082:1089	arg1	signatures					1107:1116	targeted glycoproteomics signatures	1082:1116	targeted glycoproteomics signatures of the cancer	1082:1130	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	2	8	theme	analysis	375:382	arg1	approach					384:391	multivariate data analysis approach	357:391	multivariate data analysis approach for exploration and classification of the patients with OC	357:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	5	9	theme	OC	736:737	arg1	stage					727:731	the early stage	717:731	the early stage of OC	717:737	Importantly, the increases in these glycans were significantly greater in the early stage of OC than those in the advanced stage of OC.
34978588	5	10	theme	advanced	757:764	arg1	stage					766:770	the advanced stage	753:770	the advanced stage of OC	753:776	Importantly, the increases in these glycans were significantly greater in the early stage of OC than those in the advanced stage of OC.
34978588	2	11	theme	data	370:373	arg1	approach					384:391	multivariate data analysis approach	357:391	multivariate data analysis approach for exploration and classification of the patients with OC	357:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	2	12	theme	patients	435:442	arg1	classification					413:426	classification	413:426	classification	413:426	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	2	12	theme	patients	435:442	arg1	exploration					397:407	exploration	397:407	exploration	397:407	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	3	13	theme	N-glycome	518:526	arg1	profiles					528:535	differential N-glycome profiles	505:535	differential N-glycome profiles	505:535	Various statistical analyses were used to determine differential N-glycome profiles.
34978588	4	14	theme	glycan	551:556	arg1	structures					558:567	8 glycan structures	549:567	8 glycan structures	549:567	There were 8 glycan structures significantly increased (p < 0.05) in all OC-derived microvesicles (MVs).
34978588	1	15	theme	Aberrant	89:96	arg1	N-glycosylation					106:120	Aberrant protein N-glycosylation	89:120	Aberrant protein N-glycosylation	89:120	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	2	16	theme	multivariate	357:368	arg1	approach					384:391	multivariate data analysis approach	357:391	multivariate data analysis approach for exploration and classification of the patients with OC	357:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	0	17	theme	N-Glycomic	0:9	arg1	profiling					11:19	N-Glycomic profiling	0:19	N-Glycomic profiling	0:19	N-Glycomic profiling reveals dysregulated glycans related to oral cancer using MALDI-MS.
34978588	1	18	theme	perfect	247:253	arg1	biomarker					255:263	a perfect biomarker	245:263	it a perfect biomarker for early-stage cancer	242:286	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	1	19	theme	protein	98:104	arg1	N-glycosylation					106:120	Aberrant protein N-glycosylation	89:120	Aberrant protein N-glycosylation	89:120	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	1	20	theme	oral	179:182	arg1	OC					192:193	OC	192:193	OC	192:193	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	1	20	theme	oral	179:182	arg1	cancer					184:189	oral cancer	179:189	oral cancer (OC) progression	179:206	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	0	21	theme	dysregulated	29:40	arg1	glycans					42:48	dysregulated glycans	29:48	dysregulated glycans related to oral cancer using MALDI-MS	29:86	N-Glycomic profiling reveals dysregulated glycans related to oral cancer using MALDI-MS.
34978588	7	22	theme	glycoproteomics	1091:1105	arg1	signatures					1107:1116	targeted glycoproteomics signatures	1082:1116	targeted glycoproteomics signatures of the cancer	1082:1130	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	1	23	theme	cancer	184:189	arg1	progression					196:206	oral cancer (OC) progression	179:206	oral cancer (OC) progression	179:206	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	7	24	theme	MV	986:987	arg1	profiling					1000:1008	MALDI-MS-based MV N-glycomic profiling	971:1008	MALDI-MS-based MV N-glycomic profiling	971:1008	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	3	25	theme	Various	453:459	arg1	analyses					473:480	Various statistical analyses	453:480	Various statistical analyses	453:480	Various statistical analyses were used to determine differential N-glycome profiles.
34978588	0	26	theme	related	50:56	arg1	glycans					42:48	dysregulated glycans	29:48	dysregulated glycans related to oral cancer using MALDI-MS	29:86	N-Glycomic profiling reveals dysregulated glycans related to oral cancer using MALDI-MS.
34978588	1	27	theme	early-stage	269:279	arg1	cancer					281:286	early-stage cancer	269:286	early-stage cancer	269:286	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	4	28	link	OC-derived	611:620	arg1	MVs					637:639	MVs	637:639	MVs	637:639	There were 8 glycan structures significantly increased (p < 0.05) in all OC-derived microvesicles (MVs).
34978588	4	28	link	OC-derived	611:620	arg1	microvesicles					622:634	all OC-derived microvesicles	607:634	all OC-derived microvesicles (MVs)	607:640	There were 8 glycan structures significantly increased (p < 0.05) in all OC-derived microvesicles (MVs).
34978588	7	29	theme	strong	1041:1046	arg1	potential					1048:1056	strong potential	1041:1056	strong potential for further identifying targeted glycoproteomics signatures of the cancer	1041:1130	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	7	30	theme	profiling	1000:1008	arg1	approach					959:966	the effectiveness approach	941:966	the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening	941:1024	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	0	31	theme	oral	61:64	arg1	cancer					66:71	oral cancer	61:71	oral cancer using MALDI-MS	61:86	N-Glycomic profiling reveals dysregulated glycans related to oral cancer using MALDI-MS.
34978588	5	32	from	increases	660:668	arg1	glycans					679:685	these glycans	673:685	these glycans	673:685	Importantly, the increases in these glycans were significantly greater in the early stage of OC than those in the advanced stage of OC.
34978588	4	33	dep	increased	583:591	arg1	p < 0.05					594:601	p < 0.05	594:601	p < 0.05	594:601	There were 8 glycan structures significantly increased (p < 0.05) in all OC-derived microvesicles (MVs).
34978588	3	34	used	used	487:490	arg2	analyses					473:480	Various statistical analyses	453:480	Various statistical analyses	453:480	Various statistical analyses were used to determine differential N-glycome profiles.
34978588	5	35	theme	OC	775:776	arg1	stage					766:770	the advanced stage	753:770	the advanced stage of OC	753:776	Importantly, the increases in these glycans were significantly greater in the early stage of OC than those in the advanced stage of OC.
34978588	1	36	dep	it	242:243	arg1	biomarker					255:263	a perfect biomarker	245:263	it a perfect biomarker for early-stage cancer	242:286	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	1	37	theme	malignancy	149:158	arg1	hallmarks					136:144	the hallmarks	132:144	the hallmarks of malignancy	132:158	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	2	38	with	patients	435:442	arg1	OC					449:450	OC	449:450	OC	449:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	7	39	theme	OC	1013:1014	arg1	screening					1016:1024	OC screening	1013:1024	OC screening	1013:1024	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	7	40	theme	N-glycomic	989:998	arg1	profiling					1000:1008	MALDI-MS-based MV N-glycomic profiling	971:1008	MALDI-MS-based MV N-glycomic profiling	971:1008	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	3	41	theme	statistical	461:471	arg1	analyses					473:480	Various statistical analyses	453:480	Various statistical analyses	453:480	Various statistical analyses were used to determine differential N-glycome profiles.
34978588	2	42	with	analysis	343:350	arg1	approach					384:391	multivariate data analysis approach	357:391	multivariate data analysis approach for exploration and classification of the patients with OC	357:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	1	43	theme	hallmarks	136:144	arg1	one					125:127	one	125:127	one	125:127	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	1	43	theme	hallmarks	136:144	arg1	hallmarks					136:144	the hallmarks	132:144	the hallmarks of malignancy	132:158	Aberrant protein N-glycosylation is one of the hallmarks of malignancy, while its role in oral cancer (OC) progression is still poorly understood making it a perfect biomarker for early-stage cancer.
34978588	7	44	theme	MALDI-MS-based	971:984	arg1	profiling					1000:1008	MALDI-MS-based MV N-glycomic profiling	971:1008	MALDI-MS-based MV N-glycomic profiling	971:1008	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	3	45	theme	differential	505:516	arg1	profiles					528:535	differential N-glycome profiles	505:535	differential N-glycome profiles	505:535	Various statistical analyses were used to determine differential N-glycome profiles.
34978588	7	46	from	approach	959:966	arg1	screening					1016:1024	OC screening	1013:1024	OC screening	1013:1024	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	6	47	from	serum	822:826	arg1	profiles					804:811	N-glycomic profiles	793:811	N-glycomic profiles from the serum	793:826	Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures (p < 0.05).
34978588	6	48	theme	structures	897:906	arg1	change					877:882	a significant change	863:882	a significant change of 11 glycan structures (p < 0.05)	863:917	Additionally, N-glycomic profiles from the serum were also performed, demonstrating a significant change of 11 glycan structures (p < 0.05).
34978588	7	49	theme	effectiveness	945:957	arg1	approach					959:966	the effectiveness approach	941:966	the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening	941:1024	Our data highlighted the effectiveness approach of MALDI-MS-based MV N-glycomic profiling on OC screening, and presented strong potential for further identifying targeted glycoproteomics signatures of the cancer.
34978588	2	50	theme	N-glycomic	332:341	arg1	analysis					343:350	a MALDI-MS-based N-glycomic analysis	315:350	a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC	315:450	In this work, we describe a MALDI-MS-based N-glycomic analysis with multivariate data analysis approach for exploration and classification of the patients with OC.
34978588	4	51	theme	OC-derived	611:620	arg1	MVs					637:639	MVs	637:639	MVs	637:639	There were 8 glycan structures significantly increased (p < 0.05) in all OC-derived microvesicles (MVs).
34978588	4	51	theme	OC-derived	611:620	arg1	microvesicles					622:634	all OC-derived microvesicles	607:634	all OC-derived microvesicles (MVs)	607:640	There were 8 glycan structures significantly increased (p < 0.05) in all OC-derived microvesicles (MVs).
37340602	0	0	theme	3D	85:86	arg1	Organization					112:123	3D Gastric Cancer Cellular Organization	85:123	3D Gastric Cancer Cellular Organization	85:123	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	3	1	theme	architecture	495:506	arg1	impact					476:481	the impact	472:481	the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs	472:562	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	1	2	theme	common	173:178	arg1	events					180:185	common events	173:185	common events in cancer	173:195	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	1	2	theme	common	173:178	arg1	Alterations					126:136	Alterations	126:136	Alterations of the glycosylation machinery	126:167	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	1	3	theme	tumor	256:260	arg1	cells					262:266	tumor cells	256:266	tumor cells	256:266	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	0	4	theme	Cancer	96:101	arg1	Organization					112:123	3D Gastric Cancer Cellular Organization	85:123	3D Gastric Cancer Cellular Organization	85:123	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	4	5	theme	3D	774:775	arg1	conditions					785:794	3D culture conditions	774:794	3D culture conditions	774:794	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	0	6	dep	Organization	112:123	arg1	Response					73:80	Response	73:80	Response	73:80	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	6	7	theme	EVs	1019:1021	arg1	proteome					994:1001	the proteome	990:1001	the proteome of the analyzed EVs	990:1021	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	0	8	theme	Gastric	88:94	arg1	Organization					112:123	3D Gastric Cancer Cellular Organization	85:123	3D Gastric Cancer Cellular Organization	85:123	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	4	9	theme	2D	755:756	arg1	monolayer					758:766	conventional 2D monolayer	742:766	conventional 2D monolayer	742:766	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	3	10	theme	glycans	547:553	arg1	packaging					525:533	the selective packaging	511:533	the selective packaging of cellular glycans into EVs	511:562	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	4	11	theme	releasing	708:716	arg1	EVs					718:720	producing and releasing EVs	694:720	producing and releasing EVs	694:720	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	7	12	theme	pathway	1161:1167	arg1	analysis					1169:1176	pathway analysis	1161:1176	pathway analysis	1161:1176	In addition, protein-protein interaction and pathway analysis reveal individual signatures on the EVs released by 2D- and 3D-cultured cells, suggesting distinct biological functions.
37340602	7	13	theme	protein-protein	1129:1143	arg1	interaction					1145:1155	protein-protein interaction	1129:1155	protein-protein interaction	1129:1155	In addition, protein-protein interaction and pathway analysis reveal individual signatures on the EVs released by 2D- and 3D-cultured cells, suggesting distinct biological functions.
37340602	6	14	theme	EV	1047:1048	arg1	packaging					1063:1071	an EV differential packaging	1044:1071	an EV differential packaging of specific proteins and glycans	1044:1104	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	9	15	theme	tumor	1415:1419	arg1	architecture					1430:1441	tumor cellular architecture	1415:1441	tumor cellular architecture	1415:1441	Overall, this data highlight the importance of tumor cellular architecture when assessing the cancer-EV cargo and its biological role.
37340602	2	16	theme	tumor-associated	389:404	arg1	glycans					406:412	several tumor-associated glycans	381:412	several tumor-associated glycans	381:412	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	0	17	theme	Cellular	103:110	arg1	Organization					112:123	3D Gastric Cancer Cellular Organization	85:123	3D Gastric Cancer Cellular Organization	85:123	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	3	18	from	impact	476:481	arg1	packaging					525:533	the selective packaging	511:533	the selective packaging of cellular glycans into EVs	511:562	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	0	19	theme	Differential	0:11	arg1	Protein					13:19	Differential Protein and Glycan Packaging	0:40	Protein	13:19	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	6	20	theme	differential	1050:1061	arg1	packaging					1063:1071	an EV differential packaging	1044:1071	an EV differential packaging of specific proteins and glycans	1044:1104	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	2	21	theme	several	381:387	arg1	glycans					406:412	several tumor-associated glycans	381:412	several tumor-associated glycans	381:412	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	6	22	theme	analyzed	1010:1017	arg1	EVs					1019:1021	the analyzed EVs	1006:1021	the analyzed EVs	1006:1021	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	7	23	theme	distinct	1268:1275	arg1	functions					1288:1296	distinct biological functions	1268:1296	distinct biological functions	1268:1296	In addition, protein-protein interaction and pathway analysis reveal individual signatures on the EVs released by 2D- and 3D-cultured cells, suggesting distinct biological functions.
37340602	2	24	theme	modulatory	305:314	arg1	role					316:319	a modulatory role	303:319	a modulatory role	303:319	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	4	25	theme	differential	651:662	arg1	glycosylation					664:676	differential glycosylation	651:676	differential glycosylation	651:676	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	2	26	theme	cancer	446:451	arg1	EVs					453:455	cancer EVs	446:455	cancer EVs	446:455	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	5	27	theme	specific	850:857	arg1	glycans					859:865	specific glycans	850:865	specific glycans	850:865	Furthermore, the proteomic content is identified and specific glycans are studied in the EVs produced by these cells, upon differential spatial organization.
37340602	5	28	theme	differential	920:931	arg1	organization					941:952	differential spatial organization	920:952	differential spatial organization	920:952	Furthermore, the proteomic content is identified and specific glycans are studied in the EVs produced by these cells, upon differential spatial organization.
37340602	0	29	theme	Glycan	25:30	arg1	Packaging					32:40	Differential Protein and Glycan Packaging	0:40	Packaging	32:40	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	9	30	theme	cellular	1421:1428	arg1	architecture					1430:1441	tumor cellular architecture	1415:1441	tumor cellular architecture	1415:1441	Overall, this data highlight the importance of tumor cellular architecture when assessing the cancer-EV cargo and its biological role.
37340602	4	31	theme	conventional	742:753	arg1	monolayer					758:766	conventional 2D monolayer	742:766	conventional 2D monolayer	742:766	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	9	32	theme	cancer-EV	1462:1470	arg1	cargo					1472:1476	the cancer-EV cargo	1458:1476	the cancer-EV cargo	1458:1476	Overall, this data highlight the importance of tumor cellular architecture when assessing the cancer-EV cargo and its biological role.
37340602	5	33	theme	proteomic	814:822	arg1	content					824:830	the proteomic content	810:830	the proteomic content	810:830	Furthermore, the proteomic content is identified and specific glycans are studied in the EVs produced by these cells, upon differential spatial organization.
37340602	2	34	dep	cancer	324:329	arg1	communication					331:343	communication	331:343	communication	331:343	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	6	35	theme	specific	1076:1083	arg1	proteins					1085:1092	specific proteins	1076:1092	specific proteins	1076:1092	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	7	36	theme	biological	1277:1286	arg1	functions					1288:1296	distinct biological functions	1268:1296	distinct biological functions	1268:1296	In addition, protein-protein interaction and pathway analysis reveal individual signatures on the EVs released by 2D- and 3D-cultured cells, suggesting distinct biological functions.
37340602	4	37	theme	producing	694:702	arg1	EVs					718:720	producing and releasing EVs	694:720	producing and releasing EVs	694:720	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	9	38	theme	biological	1486:1495	arg1	role					1497:1500	its biological role	1482:1500	its biological role	1482:1500	Overall, this data highlight the importance of tumor cellular architecture when assessing the cancer-EV cargo and its biological role.
37340602	6	39	theme	glycans	1098:1104	arg1	packaging					1063:1071	an EV differential packaging	1044:1071	an EV differential packaging of specific proteins and glycans	1044:1104	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	8	40	theme	protein	1305:1311	arg1	signatures					1313:1322	These protein signatures	1299:1322	These protein signatures	1299:1322	These protein signatures also show a correlation with clinical data.
37340602	4	41	theme	cancer	628:633	arg1	lines					640:644	gastric cancer cell lines	620:644	gastric cancer cell lines	620:644	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	4	42	theme	lines	640:644	arg1	capacity					608:615	the capacity	604:615	the capacity of gastric cancer cell lines with differential glycosylation	604:676	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	8	43	with	correlation	1336:1346	arg1	data					1362:1365	clinical data	1353:1365	clinical data	1353:1365	These protein signatures also show a correlation with clinical data.
37340602	4	44	theme	gastric	620:626	arg1	lines					640:644	gastric cancer cell lines	620:644	gastric cancer cell lines	620:644	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	9	45	theme	architecture	1430:1441	arg1	importance					1401:1410	the importance	1397:1410	the importance of tumor cellular architecture	1397:1441	Overall, this data highlight the importance of tumor cellular architecture when assessing the cancer-EV cargo and its biological role.
37340602	4	46	gly	glycosylation	664:676	arg1	capacity					608:615	the capacity	604:615	the capacity of gastric cancer cell lines with differential glycosylation	604:676	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	8	47	theme	clinical	1353:1360	arg1	data					1362:1365	clinical data	1353:1365	clinical data	1353:1365	These protein signatures also show a correlation with clinical data.
37340602	3	48	theme	3D	486:487	arg1	architecture					495:506	3D tumor architecture	486:506	3D tumor architecture	486:506	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	0	49	theme	Extracellular	47:59	arg1	Vesicles					61:68	Extracellular Vesicles	47:68	Extracellular Vesicles	47:68	Differential Protein and Glycan Packaging into Extracellular Vesicles in Response to 3D Gastric Cancer Cellular Organization.
37340602	7	50	theme	individual	1185:1194	arg1	signatures					1196:1205	individual signatures	1185:1205	individual signatures	1185:1205	In addition, protein-protein interaction and pathway analysis reveal individual signatures on the EVs released by 2D- and 3D-cultured cells, suggesting distinct biological functions.
37340602	3	51	theme	tumor	489:493	arg1	architecture					495:506	3D tumor architecture	486:506	3D tumor architecture	486:506	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	4	52	theme	culture	777:783	arg1	conditions					785:794	3D culture conditions	774:794	3D culture conditions	774:794	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	7	53	theme	3D-cultured	1238:1248	arg1	cells					1250:1254	3D-cultured cells	1238:1254	3D-cultured cells	1238:1254	In addition, protein-protein interaction and pathway analysis reveal individual signatures on the EVs released by 2D- and 3D-cultured cells, suggesting distinct biological functions.
37340602	5	54	theme	spatial	933:939	arg1	organization					941:952	differential spatial organization	920:952	differential spatial organization	920:952	Furthermore, the proteomic content is identified and specific glycans are studied in the EVs produced by these cells, upon differential spatial organization.
37340602	2	55	theme	Extracellular	269:281	arg1	EVs					293:295	EVs	293:295	EVs	293:295	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	2	55	theme	Extracellular	269:281	arg1	vesicles					283:290	Extracellular vesicles	269:290	Extracellular vesicles (EVs)	269:296	Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs.
37340602	3	56	theme	cellular	538:545	arg1	glycans					547:553	cellular glycans	538:553	cellular glycans	538:553	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	3	57	theme	selective	515:523	arg1	packaging					525:533	the selective packaging	511:533	the selective packaging of cellular glycans into EVs	511:562	Nevertheless, the impact of 3D tumor architecture in the selective packaging of cellular glycans into EVs has never been addressed.
37340602	1	58	theme	aberrant	226:233	arg1	structures					242:251	aberrant glycan structures	226:251	aberrant glycan structures	226:251	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	4	59	with	capacity	608:615	arg1	glycosylation					664:676	differential glycosylation	651:676	differential glycosylation	651:676	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	1	60	theme	glycosylation	145:157	arg1	machinery					159:167	the glycosylation machinery	141:167	the glycosylation machinery	141:167	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	4	61	theme	cell	635:638	arg1	lines					640:644	gastric cancer cell lines	620:644	gastric cancer cell lines	620:644	In this work, the capacity of gastric cancer cell lines with differential glycosylation is evaluated in producing and releasing EVs when cultured under conventional 2D monolayer or in 3D culture conditions.
37340602	1	62	theme	glycan	235:240	arg1	structures					242:251	aberrant glycan structures	226:251	aberrant glycan structures	226:251	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	6	63	theme	proteins	1085:1092	arg1	packaging					1063:1071	an EV differential packaging	1044:1071	an EV differential packaging of specific proteins and glycans	1044:1104	Here, it is observed that although the proteome of the analyzed EVs is mostly conserved, an EV differential packaging of specific proteins and glycans is found.
37340602	1	64	from	events	180:185	arg1	cancer					190:195	cancer	190:195	cancer	190:195	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	1	65	theme	machinery	159:167	arg1	events					180:185	common events	173:185	common events in cancer	173:195	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	1	65	theme	machinery	159:167	arg1	Alterations					126:136	Alterations	126:136	Alterations of the glycosylation machinery	126:167	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37340602	1	66	theme	structures	242:251	arg1	synthesis					213:221	the synthesis	209:221	the synthesis of aberrant glycan structures by tumor cells	209:266	Alterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells.
37186866	2	0	theme	plexin	483:488	arg1	receptors					490:498	plexin receptors	483:498	plexin receptors	483:498	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	5	1	theme	IPT	1212:1214	arg1	domains					1216:1222	IPT domains	1212:1222	IPT domains	1212:1222	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	6	2	theme	glycosylation	1383:1395	arg1	disorders					1370:1378	congenital disorders	1359:1378	congenital disorders of glycosylation	1359:1395	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	5	3	theme	domains	1216:1222	arg1	O-mannosylation					1193:1207	O-mannosylation	1193:1207	O-mannosylation of IPT domains	1193:1222	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	2	4	theme	transmembrane	605:617	arg1	families					677:684	transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	605:684	transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	605:684	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	4	5	theme	disease-causing	897:911	arg1	mutations					921:929	disease-causing TMEM260 mutations	897:929	disease-causing TMEM260 mutations	897:929	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	4	6	theme	receptor	1015:1022	arg1	defects					1035:1041	receptor maturation defects	1015:1041	receptor maturation defects	1015:1041	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	4	7	theme	IPT	957:959	arg1	domains					961:967	IPT domains	957:967	IPT domains	957:967	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	6	8	theme	growing	1342:1348	arg1	group					1350:1354	a growing group	1340:1354	a growing group of congenital disorders of glycosylation	1340:1395	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	6	8	theme	growing	1342:1348	arg1	disorders					1370:1378	congenital disorders	1359:1378	congenital disorders of glycosylation	1359:1395	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	2	9	theme	extracellular	304:316	arg1	IPT					364:366	IPT	364:366	IPT	364:366	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	9	theme	extracellular	304:316	arg1	plexin					334:339	plexin	334:339	plexin	334:339	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	9	theme	extracellular	304:316	arg1	factor					356:361	transcription factor	342:361	transcription factor	342:361	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	9	theme	extracellular	304:316	arg1	immunoglobulin					318:331	extracellular immunoglobulin	304:331	extracellular immunoglobulin	304:331	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	6	10	theme	congenital	1359:1368	arg1	disorders					1370:1378	congenital disorders	1359:1378	congenital disorders of glycosylation	1359:1395	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	2	11	theme	1-4 gene	668:675	arg1	families					677:684	transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	605:684	transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	605:684	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	12	theme	glycans	293:299	arg1	occurrence					269:278	wide occurrence	264:278	wide occurrence of O-mannose glycans	264:299	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	13	theme	factor	408:413	arg1	cMET					425:428	cMET	425:428	cMET	425:428	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	13	theme	factor	408:413	arg1	receptor					415:422	the hepatocyte growth factor receptor	386:422	the hepatocyte growth factor receptor (cMET)	386:429	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	4	14	theme	maturation	1024:1033	arg1	defects					1035:1041	receptor maturation defects	1015:1041	receptor maturation defects	1015:1041	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	3	15	dep	protein	804:810	arg1	O-mannosyltransferase					812:832	O-mannosyltransferase	812:832	an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains	790:874	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	2	16	theme	proteins	659:666	arg1	families					677:684	transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	605:684	transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	605:684	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	17	theme	O-mannose	283:291	arg1	glycans					293:299	O-mannose glycans	283:299	O-mannose glycans	283:299	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	18	theme	growth	401:406	arg1	cMET					425:428	cMET	425:428	cMET	425:428	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	18	theme	growth	401:406	arg1	receptor					415:422	the hepatocyte growth factor receptor	386:422	the hepatocyte growth factor receptor (cMET)	386:429	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	0	19	theme	SHDRA	4:8	arg1	O-mannosyltransferase					70:90	a protein-specific O-mannosyltransferase	51:90	a protein-specific O-mannosyltransferase	51:90	The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase.
37186866	0	19	theme	SHDRA	4:8	arg1	gene					30:33	The SHDRA syndrome-associated gene TMEM260	0:41	The SHDRA syndrome-associated gene TMEM260	0:41	The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase.
37186866	2	20	theme	repeat-containing	641:657	arg1	proteins					659:666	tetratricopeptide repeat-containing proteins	623:666	tetratricopeptide repeat-containing proteins	623:666	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	21	theme	hepatocyte	390:399	arg1	cMET					425:428	cMET	425:428	cMET	425:428	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	21	theme	hepatocyte	390:399	arg1	receptor					415:422	the hepatocyte growth factor receptor	386:422	the hepatocyte growth factor receptor (cMET)	386:429	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	22	theme	protein	455:461	arg1	RON					473:475	RON	473:475	RON	473:475	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	22	theme	protein	455:461	arg1	receptor					463:470	macrophage-stimulating protein receptor	432:470	macrophage-stimulating protein receptor (RON)	432:476	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	23	theme	tetratricopeptide	623:639	arg1	proteins					659:666	tetratricopeptide repeat-containing proteins	623:666	tetratricopeptide repeat-containing proteins	623:666	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	1	24	theme	TMEM260	110:116	arg1	gene					118:121	the TMEM260 gene	106:121	the TMEM260 gene	106:121	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	2	25	theme	macrophage-stimulating	432:453	arg1	RON					473:475	RON	473:475	RON	473:475	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	25	theme	macrophage-stimulating	432:453	arg1	receptor					463:470	macrophage-stimulating protein receptor	432:470	macrophage-stimulating protein receptor (RON)	432:476	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	26	theme	O-mannosylation	549:563	arg1	systems					565:571	two known protein O-mannosylation systems	531:571	two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	531:684	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	0	27	theme	syndrome-associated	10:28	arg1	O-mannosyltransferase					70:90	a protein-specific O-mannosyltransferase	51:90	a protein-specific O-mannosyltransferase	51:90	The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase.
37186866	0	27	theme	syndrome-associated	10:28	arg1	gene					30:33	The SHDRA syndrome-associated gene TMEM260	0:41	The SHDRA syndrome-associated gene TMEM260	0:41	The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase.
37186866	2	28	theme	protein	541:547	arg1	systems					565:571	two known protein O-mannosylation systems	531:571	two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	531:684	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	5	29	theme	O-mannosylation	1136:1150	arg1	pathway					1152:1158	the third protein-specific O-mannosylation pathway	1109:1158	the third protein-specific O-mannosylation pathway in mammals	1109:1169	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	2	30	theme	immunoglobulin	318:331	arg1	domains					369:375	extracellular immunoglobulin, plexin, transcription factor (IPT) domains	304:375	extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors	304:498	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	5	31	gly	O-mannosylation	1193:1207	arg1	domains					1216:1222	IPT domains	1212:1222	IPT domains	1212:1222	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	1	32	theme	encoded	208:214	arg1	protein					216:222	the encoded protein	204:222	the encoded protein	204:222	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	4	33	theme	cell	1069:1072	arg1	models					1074:1079	3D cell models	1066:1079	3D cell models	1066:1079	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	3	34	theme	TMEM260	769:775	arg1	gene					777:780	the TMEM260 gene	765:780	the TMEM260 gene	765:780	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	3	34	theme	TMEM260	769:775	arg1	protein					804:810	an ER-located protein	790:810	an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains	790:874	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	2	35	theme	known	535:539	arg1	systems					565:571	two known protein O-mannosylation systems	531:571	two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families	531:684	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	4	36	from	cells	998:1002	arg1	knockout					986:993	knockout	986:993	knockout	986:993	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	6	37	theme	disorders	1370:1378	arg1	group					1350:1354	a growing group	1340:1354	a growing group of congenital disorders of glycosylation	1340:1395	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	6	37	theme	disorders	1370:1378	arg1	disorders					1370:1378	congenital disorders	1359:1378	congenital disorders of glycosylation	1359:1395	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	1	38	theme	protein	216:222	arg1	function					192:199	the function	188:199	the function of the encoded protein	188:222	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	4	39	theme	3D	1066:1067	arg1	models					1074:1079	3D cell models	1066:1079	3D cell models	1066:1079	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	5	40	theme	critical	1231:1238	arg1	functions					1240:1248	critical functions	1231:1248	critical functions	1231:1248	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	5	41	from	pathway	1152:1158	arg1	mammals					1163:1169	mammals	1163:1169	mammals	1163:1169	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	5	42	theme	epithelial	1257:1266	arg1	morphogenesis					1268:1280	epithelial morphogenesis	1257:1280	epithelial morphogenesis	1257:1280	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	0	43	theme	protein-specific	53:68	arg1	O-mannosyltransferase					70:90	a protein-specific O-mannosyltransferase	51:90	a protein-specific O-mannosyltransferase	51:90	The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase.
37186866	0	43	theme	protein-specific	53:68	arg1	gene					30:33	The SHDRA syndrome-associated gene TMEM260	0:41	The SHDRA syndrome-associated gene TMEM260	0:41	The SHDRA syndrome-associated gene TMEM260 encodes a protein-specific O-mannosyltransferase.
37186866	4	44	from	knockout	986:993	arg1	cells					998:1002	cells	998:1002	cells	998:1002	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	4	45	theme	TMEM260	913:919	arg1	mutations					921:929	disease-causing TMEM260 mutations	897:929	disease-causing TMEM260 mutations	897:929	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	1	46	theme	structural	129:138	arg1	defects					146:152	structural heart defects	129:152	structural heart defects	129:152	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	4	47	theme	models	1074:1079	arg1	defects					1035:1041	receptor maturation defects	1015:1041	receptor maturation defects	1015:1041	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	4	47	theme	models	1074:1079	arg1	growth					1056:1061	abnormal growth	1047:1061	abnormal growth of 3D cell models	1047:1079	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	4	48	theme	domains	961:967	arg1	O-mannosylation					938:952	O-mannosylation	938:952	O-mannosylation of IPT domains	938:967	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	2	49	theme	domains	735:741	arg1	glycosylation					708:720	glycosylation	708:720	glycosylation of these IPT domains	708:741	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	1	50	theme	heart	140:144	arg1	defects					146:152	structural heart defects	129:152	structural heart defects	129:152	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	3	51	theme	ER-located	793:802	arg1	gene					777:780	the TMEM260 gene	765:780	the TMEM260 gene	765:780	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	3	51	theme	ER-located	793:802	arg1	protein					804:810	an ER-located protein	790:810	an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains	790:874	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	3	52	gly	glycosylates	851:862	arg1	domains					868:874	IPT domains	864:874	IPT domains	864:874	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	6	53	theme	glycosylation	1306:1318	arg1	pathway					1320:1326	a new glycosylation pathway	1300:1326	a new glycosylation pathway	1300:1326	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	2	54	theme	IPT	731:733	arg1	domains					735:741	these IPT domains	725:741	these IPT domains	725:741	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	5	55	theme	third	1113:1117	arg1	pathway					1152:1158	the third protein-specific O-mannosylation pathway	1109:1158	the third protein-specific O-mannosylation pathway in mammals	1109:1169	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	6	56	theme	new	1302:1304	arg1	pathway					1320:1326	a new glycosylation pathway	1300:1326	a new glycosylation pathway	1300:1326	Our findings add a new glycosylation pathway and gene to a growing group of congenital disorders of glycosylation.
37186866	2	57	theme	transcription	342:354	arg1	factor					356:361	transcription factor	342:361	transcription factor	342:361	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	57	theme	transcription	342:354	arg1	immunoglobulin					318:331	extracellular immunoglobulin	304:331	extracellular immunoglobulin	304:331	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	3	58	theme	IPT	864:866	arg1	domains					868:874	IPT domains	864:874	IPT domains	864:874	Here, we report that the TMEM260 gene encodes an ER-located protein O-mannosyltransferase that selectively glycosylates IPT domains.
37186866	4	59	theme	abnormal	1047:1054	arg1	growth					1056:1061	abnormal growth	1047:1061	abnormal growth of 3D cell models	1047:1079	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	5	60	theme	protein-specific	1119:1134	arg1	pathway					1152:1158	the third protein-specific O-mannosylation pathway	1109:1158	the third protein-specific O-mannosylation pathway in mammals	1109:1169	Thus, our study identifies the third protein-specific O-mannosylation pathway in mammals and demonstrates that O-mannosylation of IPT domains serves critical functions during epithelial morphogenesis.
37186866	2	61	theme	wide	264:267	arg1	occurrence					269:278	wide occurrence	264:278	wide occurrence of O-mannose glycans	264:299	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	1	62	theme	renal	158:162	arg1	anomalies					164:172	renal anomalies	158:172	renal anomalies syndrome	158:181	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	4	63	gly	O-mannosylation	938:952	arg1	domains					961:967	IPT domains	957:967	IPT domains	957:967	We demonstrate that disease-causing TMEM260 mutations impair O-mannosylation of IPT domains and that TMEM260 knockout in cells results in receptor maturation defects and abnormal growth of 3D cell models.
37186866	2	64	located	found	377:381	arg1	receptor					463:470	macrophage-stimulating protein receptor	432:470	macrophage-stimulating protein receptor (RON)	432:476	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	64	located	found	377:381	arg1	receptor					415:422	the hepatocyte growth factor receptor	386:422	the hepatocyte growth factor receptor (cMET)	386:429	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	64	located	found	377:381	arg1	receptors					490:498	plexin receptors	483:498	plexin receptors	483:498	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	64	located	found	377:381	arg2	domains					369:375	extracellular immunoglobulin, plexin, transcription factor (IPT) domains	304:375	extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors	304:498	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	64	located	found	377:381	arg1	cMET					425:428	cMET	425:428	cMET	425:428	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	2	64	located	found	377:381	arg1	RON					473:475	RON	473:475	RON	473:475	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
37186866	1	65	theme	anomalies	164:172	arg1	syndrome					174:181	renal anomalies syndrome	158:181	renal anomalies syndrome	158:181	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	1	66	from	Mutations	93:101	arg1	gene					118:121	the TMEM260 gene	106:121	the TMEM260 gene	106:121	Mutations in the TMEM260 gene cause structural heart defects and renal anomalies syndrome, but the function of the encoded protein remains unknown.
37186866	2	67	gly	glycosylation	708:720	arg1	domains					735:741	these IPT domains	725:741	these IPT domains	725:741	We previously reported wide occurrence of O-mannose glycans on extracellular immunoglobulin, plexin, transcription factor (IPT) domains found in the hepatocyte growth factor receptor (cMET), macrophage-stimulating protein receptor (RON), and plexin receptors, and further demonstrated that two known protein O-mannosylation systems orchestrated by the POMT1/2 and transmembrane and tetratricopeptide repeat-containing proteins 1-4 gene families were not required for glycosylation of these IPT domains.
36555411	5	0	with	structures	985:994	arg1	fucose					1011:1016	antennary fucose	1001:1016	antennary fucose	1001:1016	After the LCD period, there was also a significant rise in N-glycan structures with antennary fucose.
36555411	4	1	theme	notable	703:709	arg1	alterations					711:721	The most notable alterations	694:721	The most notable alterations of the plasma glycome	694:743	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	4	1	theme	notable	703:709	arg1	weeks					752:756	8 weeks	750:756	8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures	750:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	0	2	theme	Human	18:22	arg1	N-glycome					31:39	Human Plasma N-glycome	18:39	Human Plasma N-glycome	18:39	Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.
36555411	4	3	from	decrease	872:879	arg1	structures					905:914	high-branched glycan structures	884:914	high-branched glycan structures	884:914	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	1	4	theme	diseases	169:176	arg1	diabetes					189:196	diabetes	189:196	diabetes	189:196	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	4	theme	diseases	169:176	arg1	range					160:164	a wide range	153:164	a wide range of diseases, including diabetes, cardiovascular, and immunological disorders	153:241	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	4	theme	diseases	169:176	arg1	disorders					233:241	immunological disorders	219:241	immunological disorders	219:241	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	4	theme	diseases	169:176	arg1	cardiovascular					199:212	cardiovascular	199:212	cardiovascular	199:212	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	6	5	dep	effects	1113:1119	arg1	we					1121:1122	we	1121:1122	we	1121:1122	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	4	6	theme	high-branched	884:896	arg1	structures					905:914	high-branched glycan structures	884:914	high-branched glycan structures	884:914	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	5	7	theme	significant	956:966	arg1	rise					968:971	a significant rise	954:971	a significant rise in N-glycan structures with antennary fucose	954:1016	After the LCD period, there was also a significant rise in N-glycan structures with antennary fucose.
36555411	5	8	from	rise	968:971	arg1	structures					985:994	N-glycan structures	976:994	N-glycan structures with antennary fucose	976:1016	After the LCD period, there was also a significant rise in N-glycan structures with antennary fucose.
36555411	6	9	theme	LCD	1155:1157	arg1	period					1159:1164	the LCD period	1151:1164	the LCD period	1151:1164	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	3	10	theme	low-calorie	587:597	arg1	LCD					605:607	LCD	605:607	LCD	605:607	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	3	10	theme	low-calorie	587:597	arg1	diet					599:602	a low-calorie diet	585:602	a low-calorie diet (LCD)	585:608	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	2	11	theme	weight	307:312	arg1	loss					314:317	weight loss	307:317	weight loss	307:317	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	4	12	theme	glycome	737:743	arg1	alterations					711:721	The most notable alterations	694:721	The most notable alterations of the plasma glycome	694:743	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	4	12	theme	glycome	737:743	arg1	weeks					752:756	8 weeks	750:756	8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures	750:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	3	13	dep	subjected	572:580	arg1	followed					610:617	followed	610:617	followed by one of five different weight-maintenance diets in a period of 6 months	610:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	2	14	theme	due	300:302	arg1	alterations					288:298	plasma protein glycosylation alterations	259:298	plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets	259:357	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	6	15	theme	different	1081:1089	arg1	diets					1091:1095	different diets	1081:1095	different diets	1081:1095	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	2	16	from	participants	379:390	arg1	glycomes					365:372	1850 glycomes	360:372	1850 glycomes from participants of the Diogenes study	360:412	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	1	17	theme	Aberrant	96:103	arg1	glycosylation					120:132	Aberrant plasma protein glycosylation	96:132	Aberrant plasma protein glycosylation	96:132	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	3	18	from	diets	663:667	arg1	period					674:679	a period	672:679	a period of 6 months	672:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	6	19	theme	diets	1210:1214	arg1	period					1216:1221	the weight-maintenance diets period	1187:1221	the weight-maintenance diets period	1187:1221	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	3	20	theme	months	686:691	arg1	period					674:679	a period	672:679	a period of 6 months	672:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	2	21	theme	weight-maintenance	334:351	arg1	diets					353:357	successive weight-maintenance diets	323:357	successive weight-maintenance diets	323:357	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	2	22	theme	study	408:412	arg1	participants					379:390	participants	379:390	participants of the Diogenes study	379:412	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	0	23	theme	Plasma	24:29	arg1	N-glycome					31:39	Human Plasma N-glycome	18:39	Human Plasma N-glycome	18:39	Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.
36555411	4	24	theme	significant	799:809	arg1	increase					811:818	a significant increase	797:818	8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures	750:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	5	25	theme	antennary	1001:1009	arg1	fucose					1011:1016	antennary fucose	1001:1016	antennary fucose	1001:1016	After the LCD period, there was also a significant rise in N-glycan structures with antennary fucose.
36555411	2	26	theme	successive	323:332	arg1	diets					353:357	successive weight-maintenance diets	323:357	successive weight-maintenance diets	323:357	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	6	27	theme	significant	1053:1063	arg1	changes					1065:1071	significant changes	1053:1071	significant changes between different diets	1053:1095	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	1	28	theme	plasma	105:110	arg1	glycosylation					120:132	Aberrant plasma protein glycosylation	96:132	Aberrant plasma protein glycosylation	96:132	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	29	theme	wide	155:158	arg1	diabetes					189:196	diabetes	189:196	diabetes	189:196	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	29	theme	wide	155:158	arg1	range					160:164	a wide range	153:164	a wide range of diseases, including diabetes, cardiovascular, and immunological disorders	153:241	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	29	theme	wide	155:158	arg1	disorders					233:241	immunological disorders	219:241	immunological disorders	219:241	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	1	29	theme	wide	155:158	arg1	cardiovascular					199:212	cardiovascular	199:212	cardiovascular	199:212	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	3	30	theme	Diogenes	492:499	arg1	study					501:505	The Diogenes study	488:505	The Diogenes study	488:505	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	3	30	theme	Diogenes	492:499	arg1	study					539:543	a large dietary intervention study	510:543	a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months	510:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	6	31	theme	weight-maintenance	1191:1208	arg1	period					1216:1221	the weight-maintenance diets period	1187:1221	the weight-maintenance diets period	1187:1221	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	2	32	theme	Liquid	457:462	arg1	UHPLC					480:484	UHPLC	480:484	UHPLC	480:484	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	2	32	theme	Liquid	457:462	arg1	Chromatography					464:477	Ultra-High-Performance Liquid Chromatography	434:477	Ultra-High-Performance Liquid Chromatography (UHPLC)	434:485	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	0	33	theme	N-glycome	31:39	arg1	Susceptibility					0:13	Susceptibility	0:13	Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.	0:94	Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.
36555411	1	34	theme	immunological	219:231	arg1	disorders					233:241	immunological disorders	219:241	immunological disorders	219:241	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	4	35	theme	glycan	836:841	arg1	structures					843:852	low-branched glycan structures	823:852	low-branched glycan structures	823:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	6	36	theme	all	1109:1111	arg1	effects					1113:1119	almost all effects	1102:1119	almost all effects we observed immediately after the LCD period	1102:1164	Interestingly, we did not observe significant changes between different diets, and almost all effects we observed immediately after the LCD period were annulled during the weight-maintenance diets period.
36555411	3	37	theme	intervention	526:537	arg1	study					501:505	The Diogenes study	488:505	The Diogenes study	488:505	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	3	37	theme	intervention	526:537	arg1	study					539:543	a large dietary intervention study	510:543	a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months	510:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	4	38	theme	glycan	898:903	arg1	structures					905:914	high-branched glycan structures	884:914	high-branched glycan structures	884:914	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	4	39	theme	low-branched	823:834	arg1	structures					843:852	low-branched glycan structures	823:852	low-branched glycan structures	823:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	5	40	theme	LCD	927:929	arg1	period					931:936	the LCD period	923:936	the LCD period	923:936	After the LCD period, there was also a significant rise in N-glycan structures with antennary fucose.
36555411	3	41	theme	different	634:642	arg1	diets					663:667	one of five different weight-maintenance diets	622:667	one of five different weight-maintenance diets in a period of 6 months	622:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	4	42	theme	plasma	730:735	arg1	glycome					737:743	the plasma glycome	726:743	the plasma glycome	726:743	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	3	43	theme	weight-maintenance	644:661	arg1	diets					663:667	one of five different weight-maintenance diets	622:667	one of five different weight-maintenance diets in a period of 6 months	622:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	4	44	from	increase	811:818	arg1	structures					843:852	low-branched glycan structures	823:852	low-branched glycan structures	823:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	3	45	theme	large	512:516	arg1	study					501:505	The Diogenes study	488:505	The Diogenes study	488:505	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	3	45	theme	large	512:516	arg1	study					539:543	a large dietary intervention study	510:543	a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months	510:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	1	46	theme	protein	112:118	arg1	glycosylation					120:132	Aberrant plasma protein glycosylation	96:132	Aberrant plasma protein glycosylation	96:132	Aberrant plasma protein glycosylation is associated with a wide range of diseases, including diabetes, cardiovascular, and immunological disorders.
36555411	5	47	theme	N-glycan	976:983	arg1	structures					985:994	N-glycan structures	976:994	N-glycan structures with antennary fucose	976:1016	After the LCD period, there was also a significant rise in N-glycan structures with antennary fucose.
36555411	2	48	theme	glycosylation	274:286	arg1	alterations					288:298	plasma protein glycosylation alterations	259:298	plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets	259:357	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	3	49	theme	dietary	518:524	arg1	study					501:505	The Diogenes study	488:505	The Diogenes study	488:505	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	3	49	theme	dietary	518:524	arg1	study					539:543	a large dietary intervention study	510:543	a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months	510:691	The Diogenes study is a large dietary intervention study in which participants were subjected to a low-calorie diet (LCD) followed by one of five different weight-maintenance diets in a period of 6 months.
36555411	4	50	dep	weeks	752:756	arg1	increase					811:818	a significant increase	797:818	8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures	750:852	The most notable alterations of the plasma glycome were 8 weeks after the subjects engaged in the LCD; a significant increase in low-branched glycan structures, accompanied by a decrease in high-branched glycan structures.
36555411	0	51	theme	Weight-Maintenance	70:87	arg1	Diets					89:93	Different Weight-Maintenance Diets	60:93	Different Weight-Maintenance Diets	60:93	Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.
36555411	2	52	theme	Ultra-High-Performance	434:455	arg1	UHPLC					480:484	UHPLC	480:484	UHPLC	480:484	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	2	52	theme	Ultra-High-Performance	434:455	arg1	Chromatography					464:477	Ultra-High-Performance Liquid Chromatography	434:477	Ultra-High-Performance Liquid Chromatography (UHPLC)	434:485	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	2	53	theme	protein	266:272	arg1	alterations					288:298	plasma protein glycosylation alterations	259:298	plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets	259:357	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	2	54	theme	Diogenes	399:406	arg1	study					408:412	the Diogenes study	395:412	the Diogenes study	395:412	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
36555411	0	55	theme	Different	60:68	arg1	Diets					89:93	Different Weight-Maintenance Diets	60:93	Different Weight-Maintenance Diets	60:93	Susceptibility of Human Plasma N-glycome to Low-Calorie and Different Weight-Maintenance Diets.
36555411	2	56	theme	plasma	259:264	arg1	alterations					288:298	plasma protein glycosylation alterations	259:298	plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets	259:357	To investigate plasma protein glycosylation alterations due to weight loss and successive weight-maintenance diets, 1850 glycomes from participants of the Diogenes study were analyzed using Ultra-High-Performance Liquid Chromatography (UHPLC).
35931292	3	0	theme	present	289:295	arg1	study					297:301	The present study	285:301	The present study	285:301	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	6	1	theme	groups	963:968	arg1	introduction					935:946	the introduction	931:946	the introduction of hydrophilic groups	931:968	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	8	2	dep	in	1231:1232	arg1	vitro					1234:1238	vitro	1234:1238	vitro	1234:1238	In addition, glycosylation improved in vitro digestibility of hemoglobin by 41.15-69.09 %, which could be attributed to less β-sheet in secondary structures.
35931292	9	3	theme	protein	1553:1559	arg1	digestibility					1561:1573	the improved protein digestibility	1540:1573	the improved protein digestibility	1540:1573	Moreover, hemoglobin (324.38 ng/mg) exhibited better iron absorption than FeSO4 (121.63 ng/mg), with the value being further enhanced by glycosylation (442.73 ng/mg), which may be due to the improved protein digestibility and iron-chelating capacity.
35931292	4	4	theme	hemoglobin/chitosan	589:607	arg1	ratio					614:618	hemoglobin/chitosan mass ratio	589:618	hemoglobin/chitosan mass ratio of 4.3	589:625	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	6	5	theme	hydrophilic	951:961	arg1	groups					963:968	hydrophilic groups	951:968	hydrophilic groups	951:968	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	7	6	theme	antioxidant	1173:1183	arg1	activity					1185:1192	antioxidant activity	1173:1192	antioxidant activity	1173:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	7	theme	0.41-0.66 μM	1018:1029	arg1	protein					1041:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	7	theme	0.41-0.66 μM	1018:1029	arg1	products					1008:1015	glycosylated products	995:1015	glycosylated products (0.41-0.66 μM Trolox/mg protein)	995:1048	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	1	8	theme	common	156:161	arg1	deficiency					177:186	a common micronutrient deficiency	154:186	a common micronutrient deficiency	154:186	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	1	8	theme	common	156:161	arg1	anemia					138:143	Iron deficiency anemia	122:143	Iron deficiency anemia (IDA)	122:149	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	4	9	theme	Box-Behnken	443:453	arg1	design					455:460	Box-Behnken design	443:460	Box-Behnken design	443:460	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	0	10	theme	products	112:119	arg1	studies					50:56	Preparation, characterization and bioavailability studies	0:56	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.	0:120	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	9	11	theme	improved	1544:1551	arg1	digestibility					1561:1573	the improved protein digestibility	1540:1573	the improved protein digestibility	1540:1573	Moreover, hemoglobin (324.38 ng/mg) exhibited better iron absorption than FeSO4 (121.63 ng/mg), with the value being further enhanced by glycosylation (442.73 ng/mg), which may be due to the improved protein digestibility and iron-chelating capacity.
35931292	7	12	theme	brown	1153:1157	arg1	polymers					1159:1166	brown polymers	1153:1166	brown polymers with antioxidant activity	1153:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	13	theme	Trolox/mg	1031:1039	arg1	protein					1041:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	13	theme	Trolox/mg	1031:1039	arg1	products					1008:1015	glycosylated products	995:1015	glycosylated products (0.41-0.66 μM Trolox/mg protein)	995:1048	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	3	14	theme	physicochemical	365:379	arg1	structure					354:362	structure	354:362	structure	354:362	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	3	14	theme	physicochemical	365:379	arg1	characteristics					381:395	physicochemical characteristics	365:395	physicochemical characteristics	365:395	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	0	15	theme	glycosylated	99:110	arg1	products					112:119	its glycosylated products	95:119	its glycosylated products	95:119	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	4	16	theme	surface	475:481	arg1	methodology					483:493	response surface methodology	466:493	response surface methodology	466:493	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	5	17	theme	hemoglobin-chitosan	673:691	arg1	conjugates					693:702	hemoglobin-chitosan conjugates	673:702	hemoglobin-chitosan conjugates	673:702	The formation of hemoglobin-chitosan conjugates was verified by SDS-PAGE and fluorescence spectroscopy.
35931292	7	18	theme	products	1008:1015	arg1	capacity					983:990	Antioxidant capacity	971:990	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein)	971:1048	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	2	19	theme	high	257:260	arg1	content					262:268	its high content	253:268	its high content of hemoglobin	253:282	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	4	20	theme	mass	609:612	arg1	ratio					614:618	hemoglobin/chitosan mass ratio	589:618	hemoglobin/chitosan mass ratio of 4.3	589:625	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	8	21	theme	in	1231:1232	arg1	digestibility					1240:1252	in vitro digestibility	1231:1252	in vitro digestibility of hemoglobin	1231:1266	In addition, glycosylation improved in vitro digestibility of hemoglobin by 41.15-69.09 %, which could be attributed to less β-sheet in secondary structures.
35931292	4	22	theme	response	466:473	arg1	methodology					483:493	response surface methodology	466:493	response surface methodology	466:493	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	1	23	theme	micronutrient	163:175	arg1	deficiency					177:186	a common micronutrient deficiency	154:186	a common micronutrient deficiency	154:186	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	1	23	theme	micronutrient	163:175	arg1	anemia					138:143	Iron deficiency anemia	122:143	Iron deficiency anemia (IDA)	122:149	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	9	24	theme	iron	1406:1409	arg1	absorption					1411:1420	better iron absorption	1399:1420	better iron absorption	1399:1420	Moreover, hemoglobin (324.38 ng/mg) exhibited better iron absorption than FeSO4 (121.63 ng/mg), with the value being further enhanced by glycosylation (442.73 ng/mg), which may be due to the improved protein digestibility and iron-chelating capacity.
35931292	7	25	theme	glycosylated	995:1006	arg1	protein					1041:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	25	theme	glycosylated	995:1006	arg1	products					1008:1015	glycosylated products	995:1015	glycosylated products (0.41-0.66 μM Trolox/mg protein)	995:1048	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	0	26	gly	glycosylated	99:110	arg1	products					112:119	its glycosylated products	95:119	its glycosylated products	95:119	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	7	27	theme	0.06 μM	1102:1108	arg1	protein					1120:1126	0.06 μM Trolox/mg protein	1102:1126	0.06 μM Trolox/mg protein	1102:1126	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	27	theme	0.06 μM	1102:1108	arg1	protein					1093:1099	original protein	1084:1099	original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity	1084:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	0	28	theme	Preparation	0:10	arg1	studies					50:56	Preparation, characterization and bioavailability studies	0:56	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.	0:120	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	7	29	theme	Antioxidant	971:981	arg1	capacity					983:990	Antioxidant capacity	971:990	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein)	971:1048	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	8	30	from	β-sheet	1320:1326	arg1	structures					1341:1350	secondary structures	1331:1350	secondary structures	1331:1350	In addition, glycosylation improved in vitro digestibility of hemoglobin by 41.15-69.09 %, which could be attributed to less β-sheet in secondary structures.
35931292	3	31	theme	glycosylation	337:349	arg1	effects					326:332	the effects	322:332	the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin	322:434	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	2	32	theme	hemoglobin	273:282	arg1	content					262:268	its high content	253:268	its high content of hemoglobin	253:282	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	0	33	theme	characterization	13:28	arg1	studies					50:56	Preparation, characterization and bioavailability studies	0:56	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.	0:120	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	7	34	theme	Trolox/mg	1110:1118	arg1	protein					1120:1126	0.06 μM Trolox/mg protein	1102:1126	0.06 μM Trolox/mg protein	1102:1126	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	34	theme	Trolox/mg	1110:1118	arg1	protein					1093:1099	original protein	1084:1099	original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity	1084:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	35	theme	due	1129:1131	arg1	protein					1120:1126	0.06 μM Trolox/mg protein	1102:1126	0.06 μM Trolox/mg protein	1102:1126	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	35	theme	due	1129:1131	arg1	protein					1093:1099	original protein	1084:1099	original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity	1084:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	2	36	theme	Tegillarca	189:198	arg1	source					231:236	a good source	224:236	a good source of iron due to its high content of hemoglobin	224:282	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	2	36	theme	Tegillarca	189:198	arg1	granosa					200:206	Tegillarca granosa	189:206	Tegillarca granosa (T. granosa)	189:219	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	1	37	theme	Iron	122:125	arg1	IDA					146:148	IDA	146:148	IDA	146:148	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	1	37	theme	Iron	122:125	arg1	anemia					138:143	Iron deficiency anemia	122:143	Iron deficiency anemia (IDA)	122:149	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	1	37	theme	Iron	122:125	arg1	deficiency					177:186	a common micronutrient deficiency	154:186	a common micronutrient deficiency	154:186	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	8	38	theme	secondary	1331:1339	arg1	structures					1341:1350	secondary structures	1331:1350	secondary structures	1331:1350	In addition, glycosylation improved in vitro digestibility of hemoglobin by 41.15-69.09 %, which could be attributed to less β-sheet in secondary structures.
35931292	5	39	theme	fluorescence	733:744	arg1	spectroscopy					746:757	fluorescence spectroscopy	733:757	fluorescence spectroscopy	733:757	The formation of hemoglobin-chitosan conjugates was verified by SDS-PAGE and fluorescence spectroscopy.
35931292	2	40	theme	good	226:229	arg1	granosa					200:206	Tegillarca granosa	189:206	Tegillarca granosa (T. granosa)	189:219	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	2	40	theme	good	226:229	arg1	source					231:236	a good source	224:236	a good source of iron due to its high content of hemoglobin	224:282	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	9	41	theme	better	1399:1404	arg1	absorption					1411:1420	better iron absorption	1399:1420	better iron absorption	1399:1420	Moreover, hemoglobin (324.38 ng/mg) exhibited better iron absorption than FeSO4 (121.63 ng/mg), with the value being further enhanced by glycosylation (442.73 ng/mg), which may be due to the improved protein digestibility and iron-chelating capacity.
35931292	3	42	theme	hemoglobin	425:434	arg1	structure					354:362	structure	354:362	structure	354:362	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	3	42	theme	hemoglobin	425:434	arg1	characteristics					381:395	physicochemical characteristics	365:395	physicochemical characteristics	365:395	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	3	42	theme	hemoglobin	425:434	arg1	bioavailability					406:420	iron bioavailability	401:420	iron bioavailability of hemoglobin	401:434	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	0	43	theme	bioavailability	34:48	arg1	studies					50:56	Preparation, characterization and bioavailability studies	0:56	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.	0:120	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	3	44	from	effects	326:332	arg1	structure					354:362	structure	354:362	structure	354:362	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	3	44	from	effects	326:332	arg1	characteristics					381:395	physicochemical characteristics	365:395	physicochemical characteristics	365:395	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	3	44	from	effects	326:332	arg1	bioavailability					406:420	iron bioavailability	401:420	iron bioavailability of hemoglobin	401:434	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	8	45	theme	hemoglobin	1257:1266	arg1	digestibility					1240:1252	in vitro digestibility	1231:1252	in vitro digestibility of hemoglobin	1231:1266	In addition, glycosylation improved in vitro digestibility of hemoglobin by 41.15-69.09 %, which could be attributed to less β-sheet in secondary structures.
35931292	4	46	theme	15 min	648:653	arg1	61.8 °C					572:578	61.8 °C	572:578	61.8 °C	572:578	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	46	theme	15 min	648:653	arg1	time					640:643	reaction time	631:643	reaction time of 15 min	631:653	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	46	theme	15 min	648:653	arg1	ratio					614:618	hemoglobin/chitosan mass ratio	589:618	hemoglobin/chitosan mass ratio of 4.3	589:625	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	46	theme	15 min	648:653	arg1	pH 6.3					581:586	pH 6.3	581:586	pH 6.3	581:586	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	0	47	theme	Tegillarca	61:70	arg1	hemoglobin					80:89	Tegillarca granosa hemoglobin	61:89	Tegillarca granosa hemoglobin	61:89	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	4	48	theme	hemoglobin-chitosan	523:541	arg1	glycosylation					543:555	hemoglobin-chitosan glycosylation	523:555	hemoglobin-chitosan glycosylation	523:555	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	5	49	theme	conjugates	693:702	arg1	formation					660:668	The formation	656:668	The formation of hemoglobin-chitosan conjugates	656:702	The formation of hemoglobin-chitosan conjugates was verified by SDS-PAGE and fluorescence spectroscopy.
35931292	6	50	theme	water-holding	891:903	arg1	capacity					905:912	elevated water-holding capacity	882:912	elevated water-holding capacity	882:912	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	1	51	theme	deficiency	127:136	arg1	IDA					146:148	IDA	146:148	IDA	146:148	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	1	51	theme	deficiency	127:136	arg1	anemia					138:143	Iron deficiency anemia	122:143	Iron deficiency anemia (IDA)	122:149	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	1	51	theme	deficiency	127:136	arg1	deficiency					177:186	a common micronutrient deficiency	154:186	a common micronutrient deficiency	154:186	Iron deficiency anemia (IDA) is a common micronutrient deficiency.
35931292	4	52	theme	optimal	500:506	arg1	conditions					508:517	the optimal conditions	496:517	the optimal conditions for hemoglobin-chitosan glycosylation	496:555	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	6	53	theme	elevated	882:889	arg1	capacity					905:912	elevated water-holding capacity	882:912	elevated water-holding capacity	882:912	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	6	54	theme	hemoglobin	790:799	arg1	hydrophobicity					772:785	The surface hydrophobicity	760:785	The surface hydrophobicity of hemoglobin	760:799	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	6	55	theme	capacity	905:912	arg1	observations					866:877	the observations	862:877	the observations of elevated water-holding capacity	862:912	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	9	56	theme	iron-chelating	1579:1592	arg1	capacity					1594:1601	iron-chelating capacity	1579:1601	iron-chelating capacity	1579:1601	Moreover, hemoglobin (324.38 ng/mg) exhibited better iron absorption than FeSO4 (121.63 ng/mg), with the value being further enhanced by glycosylation (442.73 ng/mg), which may be due to the improved protein digestibility and iron-chelating capacity.
35931292	7	57	theme	original	1084:1091	arg1	protein					1120:1126	0.06 μM Trolox/mg protein	1102:1126	0.06 μM Trolox/mg protein	1102:1126	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	57	theme	original	1084:1091	arg1	protein					1093:1099	original protein	1084:1099	original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity	1084:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	4	58	dep	obtained	562:569	arg1	61.8 °C					572:578	61.8 °C	572:578	61.8 °C	572:578	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	58	dep	obtained	562:569	arg1	time					640:643	reaction time	631:643	reaction time of 15 min	631:653	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	58	dep	obtained	562:569	arg1	ratio					614:618	hemoglobin/chitosan mass ratio	589:618	hemoglobin/chitosan mass ratio of 4.3	589:625	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	58	dep	obtained	562:569	arg1	pH 6.3					581:586	pH 6.3	581:586	pH 6.3	581:586	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	59	theme	4.3	623:625	arg1	61.8 °C					572:578	61.8 °C	572:578	61.8 °C	572:578	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	59	theme	4.3	623:625	arg1	time					640:643	reaction time	631:643	reaction time of 15 min	631:653	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	59	theme	4.3	623:625	arg1	ratio					614:618	hemoglobin/chitosan mass ratio	589:618	hemoglobin/chitosan mass ratio of 4.3	589:625	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	4	59	theme	4.3	623:625	arg1	pH 6.3					581:586	pH 6.3	581:586	pH 6.3	581:586	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	2	60	theme	iron	241:244	arg1	granosa					200:206	Tegillarca granosa	189:206	Tegillarca granosa (T. granosa)	189:219	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	2	60	theme	iron	241:244	arg1	source					231:236	a good source	224:236	a good source of iron due to its high content of hemoglobin	224:282	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	7	61	with	polymers	1159:1166	arg1	activity					1185:1192	antioxidant activity	1173:1192	antioxidant activity	1173:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	2	62	dep	granosa	200:206	arg1	granosa					212:218	T. granosa	209:218	T. granosa	209:218	Tegillarca granosa (T. granosa) is a good source of iron due to its high content of hemoglobin.
35931292	0	63	theme	hemoglobin	80:89	arg1	studies					50:56	Preparation, characterization and bioavailability studies	0:56	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.	0:120	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	6	64	theme	surface	764:770	arg1	hydrophobicity					772:785	The surface hydrophobicity	760:785	The surface hydrophobicity of hemoglobin	760:799	The surface hydrophobicity of hemoglobin was reduced by 20.90-65.05 % after glycosylation, along with the observations of elevated water-holding capacity, likely owing to the introduction of hydrophilic groups.
35931292	4	65	theme	reaction	631:638	arg1	time					640:643	reaction time	631:643	reaction time of 15 min	631:653	Using Box-Behnken design and response surface methodology, the optimal conditions for hemoglobin-chitosan glycosylation were obtained: 61.8 °C, pH 6.3, hemoglobin/chitosan mass ratio of 4.3 and reaction time of 15 min.
35931292	0	66	theme	granosa	72:78	arg1	hemoglobin					80:89	Tegillarca granosa hemoglobin	61:89	Tegillarca granosa hemoglobin	61:89	Preparation, characterization and bioavailability studies of Tegillarca granosa hemoglobin and its glycosylated products.
35931292	3	67	theme	iron	401:404	arg1	structure					354:362	structure	354:362	structure	354:362	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	3	67	theme	iron	401:404	arg1	bioavailability					406:420	iron bioavailability	401:420	iron bioavailability of hemoglobin	401:434	The present study aimed to determine the effects of glycosylation on structure, physicochemical characteristics and iron bioavailability of hemoglobin.
35931292	7	68	gly	glycosylated	995:1006	arg1	protein					1041:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	0.41-0.66 μM Trolox/mg protein	1018:1047	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	68	gly	glycosylated	995:1006	arg1	products					1008:1015	glycosylated products	995:1015	glycosylated products (0.41-0.66 μM Trolox/mg protein)	995:1048	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
35931292	7	69	theme	polymers	1159:1166	arg1	formation					1140:1148	the formation	1136:1148	the formation of brown polymers with antioxidant activity	1136:1192	Antioxidant capacity of glycosylated products (0.41-0.66 μM Trolox/mg protein) was markedly greater than that of original protein (0.06 μM Trolox/mg protein) due to the formation of brown polymers with antioxidant activity.
36417860	3	0	theme	molecules	322:330	arg1	exposure					304:311	an extended exposure	292:311	an extended exposure of cargo molecules to Golgi enzymes	292:347	The resulting trafficking block leads to an extended exposure of cargo molecules to Golgi enzymes.
36417860	5	1	theme	subsequent	718:727	arg1	MGAT1					750:754	MGAT1	750:754	MGAT1	750:754	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	1	theme	subsequent	718:727	arg1	glycosyltransferase					729:747	the subsequent glycosyltransferase	714:747	the subsequent glycosyltransferase	714:747	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	6	2	theme	complex	989:995	arg1	glycans					997:1003	complex glycans	989:1003	complex glycans	989:1003	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	6	3	from	defects	850:856	arg1	cells					885:889	mannosidase I-deficient cells	861:889	mannosidase I-deficient cells	861:889	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	6	4	theme	I-deficient	873:883	arg1	cells					885:889	mannosidase I-deficient cells	861:889	mannosidase I-deficient cells	861:889	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	6	5	theme	MAN1A1	781:786	arg1	Expression					757:766	Expression	757:766	Expression of wild-type MAN1A1, but not its phosphomimetic mutant,	757:822	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	6	6	theme	mannosidase	861:871	arg1	cells					885:889	mannosidase I-deficient cells	861:889	mannosidase I-deficient cells	861:889	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	6	7	theme	wild-type	771:779	arg1	MAN1A1					781:786	wild-type MAN1A1	771:786	wild-type MAN1A1	771:786	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	3	8	theme	resulting	255:263	arg1	block					277:281	The resulting trafficking block	251:281	The resulting trafficking block	251:281	The resulting trafficking block leads to an extended exposure of cargo molecules to Golgi enzymes.
36417860	1	9	theme	accurate	161:168	arg1	glycosylation					170:182	accurate glycosylation	161:182	accurate glycosylation	161:182	N-glycans are processed mainly in the Golgi, and a well-organized Golgi structure is required for accurate glycosylation.
36417860	3	10	theme	trafficking	265:275	arg1	block					277:281	The resulting trafficking block	251:281	The resulting trafficking block	251:281	The resulting trafficking block leads to an extended exposure of cargo molecules to Golgi enzymes.
36417860	6	11	theme	glycosylation	836:848	arg1	defects					850:856	the glycosylation defects	832:856	the glycosylation defects in mannosidase I-deficient cells	832:889	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	5	12	theme	first	489:493	arg1	enzyme					495:500	the first enzyme	485:500	the first enzyme that cargo proteins encounter once arriving the Golgi	485:554	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	12	theme	first	489:493	arg1	IA					472:473	Golgi α-1,2-mannosidase IA	448:473	Golgi α-1,2-mannosidase IA (MAN1A1)	448:482	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	0	13	theme	Mitotic	0:6	arg1	phosphorylation					8:22	Mitotic phosphorylation	0:22	Mitotic phosphorylation	0:22	Mitotic phosphorylation inhibits the Golgi mannosidase MAN1A1.
36417860	4	14	theme	glycosylation	380:392	arg1	defects					394:400	glycosylation defects	380:400	glycosylation defects	380:400	It is unclear how cells avoid glycosylation defects during mitosis.
36417860	7	15	theme	cell	1090:1093	arg1	cycle					1095:1099	the cell cycle	1086:1099	the cell cycle	1086:1099	Our study reveals that glycosylation is regulated by cytosolic signaling during the cell cycle.
36417860	5	16	theme	α-1,2-mannosidase	454:470	arg1	enzyme					495:500	the first enzyme	485:500	the first enzyme that cargo proteins encounter once arriving the Golgi	485:554	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	16	theme	α-1,2-mannosidase	454:470	arg1	MAN1A1					476:481	MAN1A1	476:481	MAN1A1	476:481	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	16	theme	α-1,2-mannosidase	454:470	arg1	IA					472:473	Golgi α-1,2-mannosidase IA	448:473	Golgi α-1,2-mannosidase IA (MAN1A1)	448:482	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	7	17	theme	cytosolic	1059:1067	arg1	signaling					1069:1077	cytosolic signaling	1059:1077	cytosolic signaling	1059:1077	Our study reveals that glycosylation is regulated by cytosolic signaling during the cell cycle.
36417860	5	18	dep	proteins	513:520	arg1	encounter					522:530	encounter	522:530	cargo proteins encounter once arriving the Golgi	507:554	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	19	theme	glycan	665:670	arg1	isomers					672:678	glycan isomers	665:678	glycan isomers	665:678	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	0	20	theme	mannosidase	43:53	arg1	MAN1A1					55:60	the Golgi mannosidase MAN1A1	33:60	the Golgi mannosidase MAN1A1	33:60	Mitotic phosphorylation inhibits the Golgi mannosidase MAN1A1.
36417860	6	21	theme	mutant	944:949	arg1	expression					900:909	expression	900:909	expression of its phosphorylation-deficient mutant in mitosis	900:960	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	5	22	theme	isomers	672:678	arg1	production					651:660	the production	647:660	the production of glycan isomers	647:678	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	0	23	theme	Golgi	37:41	arg1	MAN1A1					55:60	the Golgi mannosidase MAN1A1	33:60	the Golgi mannosidase MAN1A1	33:60	Mitotic phosphorylation inhibits the Golgi mannosidase MAN1A1.
36417860	6	24	theme	phosphorylation-deficient	918:942	arg1	mutant					944:949	its phosphorylation-deficient mutant	914:949	its phosphorylation-deficient mutant	914:949	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	2	25	theme	severe	229:234	arg1	fragmentation					236:248	severe fragmentation	229:248	severe fragmentation	229:248	However, during mitosis the Golgi undergoes severe fragmentation.
36417860	6	26	theme	mutant	816:821	arg1	Expression					757:766	Expression	757:766	Expression of wild-type MAN1A1, but not its phosphomimetic mutant,	757:822	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	3	27	theme	cargo	316:320	arg1	molecules					322:330	cargo molecules	316:330	cargo molecules	316:330	The resulting trafficking block leads to an extended exposure of cargo molecules to Golgi enzymes.
36417860	6	28	theme	phosphomimetic	801:814	arg1	mutant					816:821	its phosphomimetic mutant	797:821	its phosphomimetic mutant	797:821	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	6	29	dep	rescues	824:830	arg1	whereas					892:898	whereas	892:898	whereas	892:898	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	3	30	theme	extended	295:302	arg1	exposure					304:311	an extended exposure	292:311	an extended exposure of cargo molecules to Golgi enzymes	292:347	The resulting trafficking block leads to an extended exposure of cargo molecules to Golgi enzymes.
36417860	5	31	with	interaction	697:707	arg1	MGAT1					750:754	MGAT1	750:754	MGAT1	750:754	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	31	with	interaction	697:707	arg1	glycosyltransferase					729:747	the subsequent glycosyltransferase	714:747	the subsequent glycosyltransferase	714:747	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	1	32	theme	well-organized	114:127	arg1	structure					135:143	a well-organized Golgi structure	112:143	a well-organized Golgi structure	112:143	N-glycans are processed mainly in the Golgi, and a well-organized Golgi structure is required for accurate glycosylation.
36417860	1	33	theme	Golgi	129:133	arg1	structure					135:143	a well-organized Golgi structure	112:143	a well-organized Golgi structure	112:143	N-glycans are processed mainly in the Golgi, and a well-organized Golgi structure is required for accurate glycosylation.
36417860	3	34	theme	Golgi	335:339	arg1	enzymes					341:347	Golgi enzymes	335:347	Golgi enzymes	335:347	The resulting trafficking block leads to an extended exposure of cargo molecules to Golgi enzymes.
36417860	5	35	theme	Golgi	448:452	arg1	enzyme					495:500	the first enzyme	485:500	the first enzyme that cargo proteins encounter once arriving the Golgi	485:554	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	35	theme	Golgi	448:452	arg1	MAN1A1					476:481	MAN1A1	476:481	MAN1A1	476:481	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	5	35	theme	Golgi	448:452	arg1	IA					472:473	Golgi α-1,2-mannosidase IA	448:473	Golgi α-1,2-mannosidase IA (MAN1A1)	448:482	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	6	36	from	expression	900:909	arg1	mitosis					954:960	mitosis	954:960	mitosis	954:960	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36417860	5	37	theme	cargo	507:511	arg1	proteins					513:520	cargo proteins	507:520	cargo proteins encounter once arriving the Golgi	507:554	In this study, we report that Golgi α-1,2-mannosidase IA (MAN1A1), the first enzyme that cargo proteins encounter once arriving the Golgi, is phosphorylated at serine 12 by CDK1 in mitosis, which attenuates its activity, affects the production of glycan isomers, and reduces its interaction with the subsequent glycosyltransferase, MGAT1.
36417860	6	38	theme	glycans	997:1003	arg1	formation					976:984	the formation	972:984	the formation of complex glycans	972:1003	Expression of wild-type MAN1A1, but not its phosphomimetic mutant, rescues the glycosylation defects in mannosidase I-deficient cells, whereas expression of its phosphorylation-deficient mutant in mitosis increases the formation of complex glycans.
36159782	4	0	theme	microgram	628:636	arg1	amounts					638:644	only low microgram amounts	619:644	only low microgram amounts of antibody and receptor	619:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	0	theme	microgram	628:636	arg1	receptor					662:669	receptor	662:669	receptor	662:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	0	theme	microgram	628:636	arg1	antibody					649:656	antibody	649:656	antibody	649:656	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	11	1	theme	FcγRIIa	1699:1705	arg1	receptor					1707:1714	the FcγRIIa receptor	1695:1714	the FcγRIIa receptor	1695:1714	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	7	2	theme	highest	1182:1188	arg1	affinity					1198:1205	The highest binding affinity	1178:1205	The highest binding affinity	1178:1205	The highest binding affinity was for the antibody carrying two complex-type glycans.
36159782	5	3	dep	mutated	877:883	arg1	Pro329-Gly					909:918	Pro329-Gly	909:918	Pro329-Gly	909:918	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	5	3	dep	mutated	877:883	arg1	Leu235Ala					897:905	Leu235Ala	897:905	Leu235Ala	897:905	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	5	3	dep	mutated	877:883	arg1	LALA-PG					921:927	LALA-PG	921:927	LALA-PG	921:927	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	12	4	theme	proposed	1804:1811	arg1	approach					1813:1820	the proposed approach	1800:1820	the proposed approach	1800:1820	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	4	5	theme	high	708:711	arg1	glycoforms					731:740	high and low-abundance glycoforms	708:740	high and low-abundance glycoforms	708:740	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	10	6	theme	FcγIIa	1621:1626	arg1	receptor					1628:1635	the FcγIIa receptor	1617:1635	the FcγIIa receptor	1617:1635	Fucosylation did not influence binding to the FcγIIa receptor.
36159782	11	7	theme	receptor	1707:1714	arg1	variants					1683:1690	the two variants	1675:1690	the two variants of the FcγRIIa receptor	1675:1714	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	1	8	theme	FcγRIIa	177:183	arg1	activation					185:194	FcγRIIa activation	177:194	FcγRIIa activation	177:194	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	8	9	theme	complex-type	1318:1329	arg1	glycans					1331:1337	complex-type glycans	1318:1337	complex-type glycans	1318:1337	Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
36159782	5	10	theme	IgG1	931:934	arg1	antibodies					936:945	mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies	877:945	mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	877:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	8	11	theme	Man5	1263:1266	arg1	glycans					1268:1274	Man5 glycans	1263:1274	Man5 glycans	1263:1274	Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
36159782	5	12	theme	clear	766:770	arg1	differences					772:782	clear differences	766:782	clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	766:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	2	13	theme	analytical	298:307	arg1	challenges					309:318	the major analytical challenges	288:318	the major analytical challenges requiring long enrichment or glycoengineering steps	288:370	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	12	14	from	species	1895:1901	arg1	mixtures					1906:1913	mixtures	1906:1913	mixtures promising a fast establishment of their structure-function relationships	1906:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	8	15	theme	decreased	1288:1296	arg1	binding					1298:1304	decreased binding	1288:1304	decreased binding compared to complex-type glycans	1288:1337	Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
36159782	12	16	from	mixtures	1906:1913	arg1	affinities					1862:1871	binding affinities	1854:1871	binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships	1854:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	6	17	theme	mutated	985:991	arg1	antibody					993:1000	The LALA-PG mutated antibody	973:1000	The LALA-PG mutated antibody	973:1000	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	3	18	theme	glycoengineering	579:594	arg1	need					571:574	the need	567:574	the need of glycoengineering	567:594	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	0	19	theme	binding	70:76	arg1	assessment					78:87	direct binding assessment	63:87	direct binding assessment of IgG and FcγRIIa	63:106	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	2	20	theme	glycoform	244:252	arg1	assessment					262:271	glycoform binding assessment	244:271	glycoform binding assessment	244:271	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	6	21	theme	non-specific	1064:1075	arg1	effects					1085:1091	potential non-specific binding effects	1054:1091	potential non-specific binding effects	1054:1091	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	6	22	dep	receptor	1034:1041	arg1	excluding					1044:1052	excluding	1044:1052	excluding potential non-specific binding effects	1044:1091	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	1	23	theme	glycoforms	163:172	arg1	impact					144:149	The impact	140:149	The impact of antibody glycoforms on FcγRIIa activation and immune responses	140:215	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	9	24	gly	sialylated	1555:1564	arg1	species					1566:1572	lower sialylated species	1549:1572	lower sialylated species	1549:1572	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	1	25	from	impact	144:149	arg1	activation					185:194	FcγRIIa activation	177:194	FcγRIIa activation	177:194	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	1	25	from	impact	144:149	arg1	responses					207:215	immune responses	200:215	immune responses	200:215	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	0	26	theme	Affinity	0:7	arg1	electrophoresis					19:33	Affinity capillary electrophoresis	0:33	Affinity capillary electrophoresis	0:33	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	12	27	theme	relationships	1974:1986	arg1	establishment					1932:1944	a fast establishment	1925:1944	a fast establishment of their structure-function relationships	1925:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	6	28	gly	non-glycosylated	1104:1119	arg1	IgG1					1121:1124	the non-glycosylated IgG1	1100:1124	the non-glycosylated IgG1	1100:1124	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	3	29	gly	glycoforms	525:534	arg1	antibody					516:523	different antibody glycoforms	506:534	different antibody glycoforms	506:534	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	9	30	theme	complex-type	1401:1412	arg1	glycans					1414:1420	complex-type glycans	1401:1420	complex-type glycans	1401:1420	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	6	31	theme	non-glycosylated	1104:1119	arg1	IgG1					1121:1124	the non-glycosylated IgG1	1100:1124	the non-glycosylated IgG1	1100:1124	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	3	32	theme	electrophoresis-mass	426:445	arg1	approach					460:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	0	33	theme	mass	37:40	arg1	spectrometry					42:53	mass spectrometry	37:53	mass spectrometry	37:53	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	3	34	theme	affinity	407:414	arg1	approach					460:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	11	35	dep	allotypes	1717:1725	arg1	allotypes					1717:1725	allotypes H131 and R131	1717:1739	allotypes H131 and R131	1717:1739	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	11	35	dep	allotypes	1717:1725	arg1	R131					1736:1739	R131	1736:1739	R131	1736:1739	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	11	35	dep	allotypes	1717:1725	arg1	H131					1727:1730	H131	1727:1730	H131	1727:1730	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	12	36	theme	species	1895:1901	arg1	affinities					1862:1871	binding affinities	1854:1871	binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships	1854:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	12	37	theme	antibody	1886:1893	arg1	species					1895:1901	different antibody species	1876:1901	different antibody species in mixtures promising a fast establishment of their structure-function relationships	1876:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	3	38	theme	antibody	516:523	arg1	glycoforms					525:534	different antibody glycoforms	506:534	different antibody glycoforms	506:534	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	9	39	theme	subtle	1448:1453	arg1	increase					1455:1462	a subtle increase	1446:1462	a subtle increase in binding to the FcγIIa receptor	1446:1496	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	9	40	from	increase	1455:1462	arg1	binding					1467:1473	binding	1467:1473	binding to the FcγIIa receptor	1467:1496	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	12	41	from	affinities	1862:1871	arg1	mixtures					1906:1913	mixtures	1906:1913	mixtures promising a fast establishment of their structure-function relationships	1906:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	4	42	theme	antibody	649:656	arg1	amounts					638:644	only low microgram amounts	619:644	only low microgram amounts of antibody and receptor	619:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	42	theme	antibody	649:656	arg1	receptor					662:669	receptor	662:669	receptor	662:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	42	theme	antibody	649:656	arg1	antibody					649:656	antibody	649:656	antibody	649:656	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	11	43	theme	comparable	1757:1766	arg1	selectivity					1778:1788	highly comparable glycoform selectivity	1750:1788	highly comparable glycoform selectivity	1750:1788	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	0	44	theme	direct	63:68	arg1	assessment					78:87	direct binding assessment	63:87	direct binding assessment of IgG and FcγRIIa	63:106	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	6	45	theme	LALA-PG	977:983	arg1	antibody					993:1000	The LALA-PG mutated antibody	973:1000	The LALA-PG mutated antibody	973:1000	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	12	46	theme	binding	1854:1860	arg1	affinities					1862:1871	binding affinities	1854:1871	binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships	1854:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	4	47	theme	receptor	662:669	arg1	amounts					638:644	only low microgram amounts	619:644	only low microgram amounts of antibody and receptor	619:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	47	theme	receptor	662:669	arg1	receptor					662:669	receptor	662:669	receptor	662:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	47	theme	receptor	662:669	arg1	antibody					649:656	antibody	649:656	antibody	649:656	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	5	48	theme	non-glycosylated	834:849	arg1	antibodies					851:860	doubly-, hemi-glycosylated and non-glycosylated antibodies	803:860	doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	803:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	3	49	theme	FcγIIa	543:548	arg1	receptor					550:557	the FcγIIa receptor	539:557	the FcγIIa receptor	539:557	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	5	50	from	differences	772:782	arg1	binging					787:793	binging	787:793	binging	787:793	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	4	51	theme	low	624:626	arg1	amounts					638:644	only low microgram amounts	619:644	only low microgram amounts of antibody and receptor	619:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	51	theme	low	624:626	arg1	receptor					662:669	receptor	662:669	receptor	662:669	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	4	51	theme	low	624:626	arg1	antibody					649:656	antibody	649:656	antibody	649:656	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	2	52	theme	major	292:296	arg1	challenges					309:318	the major analytical challenges	288:318	the major analytical challenges requiring long enrichment or glycoengineering steps	288:370	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	9	53	theme	FcγIIa	1482:1487	arg1	receptor					1489:1496	the FcγIIa receptor	1478:1496	the FcγIIa receptor	1478:1496	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	4	54	theme	low-abundance	717:729	arg1	glycoforms					731:740	high and low-abundance glycoforms	708:740	high and low-abundance glycoforms	708:740	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	2	55	theme	long	330:333	arg1	steps					366:370	long enrichment or glycoengineering steps	330:370	long enrichment or glycoengineering steps	330:370	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	6	56	theme	FcγIIa	1027:1032	arg1	receptor					1034:1041	FcγIIa receptor	1027:1041	the FcγIIa receptor (excluding potential non-specific binding effects)	1023:1092	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	11	57	dep	evaluated	1661:1669	arg1	allotypes					1717:1725	allotypes H131 and R131	1717:1739	allotypes H131 and R131	1717:1739	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	11	57	dep	evaluated	1661:1669	arg1	R131					1736:1739	R131	1736:1739	R131	1736:1739	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	11	57	dep	evaluated	1661:1669	arg1	H131					1727:1730	H131	1727:1730	H131	1727:1730	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	7	58	contain	carrying	1228:1235	arg1	antibody					1219:1226	the antibody	1215:1226	the antibody carrying two complex-type glycans	1215:1260	The highest binding affinity was for the antibody carrying two complex-type glycans.
36159782	7	58	contain	carrying	1228:1235	arg2	glycans					1254:1260	two complex-type glycans	1237:1260	two complex-type glycans	1237:1260	The highest binding affinity was for the antibody carrying two complex-type glycans.
36159782	2	59	theme	challenges	309:318	arg1	challenges					309:318	the major analytical challenges	288:318	the major analytical challenges requiring long enrichment or glycoengineering steps	288:370	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	2	59	theme	challenges	309:318	arg1	one					281:283	one	281:283	one	281:283	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	1	60	theme	immune	200:205	arg1	responses					207:215	immune responses	200:215	immune responses	200:215	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	5	61	theme	Fcγ	960:962	arg1	binding					964:970	Fcγ binding	960:970	Fcγ binding	960:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	8	62	contain	containing	1376:1385	arg2	Man5					1391:1394	two Man5	1387:1394	two Man5	1387:1394	Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
36159782	8	62	contain	containing	1376:1385	arg1	IgG					1372:1374	the IgG	1368:1374	the IgG containing two Man5	1368:1394	Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
36159782	8	63	theme	lowest	1349:1354	arg1	binding					1356:1362	the lowest binding	1345:1362	the lowest binding for the IgG containing two Man5	1345:1394	Man5 glycans resulted in decreased binding compared to complex-type glycans, with the lowest binding for the IgG containing two Man5.
36159782	1	64	gly	glycoforms	163:172	arg1	antibody					154:161	antibody glycoforms	154:172	antibody glycoforms	154:172	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	9	65	theme	sialylated	1555:1564	arg1	species					1566:1572	lower sialylated species	1549:1572	lower sialylated species	1549:1572	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	12	66	theme	different	1876:1884	arg1	species					1895:1901	different antibody species	1876:1901	different antibody species in mixtures promising a fast establishment of their structure-function relationships	1876:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	5	67	theme	hemi-glycosylated	812:828	arg1	antibodies					851:860	doubly-, hemi-glycosylated and non-glycosylated antibodies	803:860	doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	803:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	2	68	theme	binding	254:260	arg1	assessment					262:271	glycoform binding assessment	244:271	glycoform binding assessment	244:271	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	6	69	theme	binding	1077:1083	arg1	effects					1085:1091	potential non-specific binding effects	1054:1091	potential non-specific binding effects	1054:1091	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	4	70	theme	glycoforms	731:740	arg1	binding					697:703	the binding	693:703	the binding of high and low-abundance glycoforms	693:740	The approach required only low microgram amounts of antibody and receptor and enables assessing the binding of high and low-abundance glycoforms.
36159782	0	71	theme	IgG	92:94	arg1	assessment					78:87	direct binding assessment	63:87	direct binding assessment of IgG and FcγRIIa	63:106	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	1	72	theme	antibody	154:161	arg1	glycoforms					163:172	antibody glycoforms	154:172	antibody glycoforms	154:172	The impact of antibody glycoforms on FcγRIIa activation and immune responses is poorly understood.
36159782	6	73	theme	potential	1054:1062	arg1	effects					1085:1091	potential non-specific binding effects	1054:1091	potential non-specific binding effects	1054:1091	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	0	74	theme	glycoform-resolved	113:130	arg1	manner					132:137	a glycoform-resolved manner	111:137	a glycoform-resolved manner	111:137	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	0	75	theme	FcγRIIa	100:106	arg1	assessment					78:87	direct binding assessment	63:87	direct binding assessment of IgG and FcγRIIa	63:106	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
36159782	5	76	gly	hemi-glycosylated	812:828	arg1	antibodies					851:860	doubly-, hemi-glycosylated and non-glycosylated antibodies	803:860	doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	803:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	2	77	theme	enrichment	335:344	arg1	steps					366:370	long enrichment or glycoengineering steps	330:370	long enrichment or glycoengineering steps	330:370	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	5	78	theme	doubly-	803:809	arg1	antibodies					851:860	doubly-, hemi-glycosylated and non-glycosylated antibodies	803:860	doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	803:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	12	79	theme	structure-function	1955:1972	arg1	relationships					1974:1986	their structure-function relationships	1949:1986	their structure-function relationships	1949:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	6	80	theme	reduced	1144:1150	arg1	binding					1169:1175	a strongly reduced, but still minor binding	1133:1175	a strongly reduced, but still minor binding	1133:1175	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	5	81	gly	non-glycosylated	834:849	arg1	antibodies					851:860	doubly-, hemi-glycosylated and non-glycosylated antibodies	803:860	doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	803:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	7	82	theme	complex-type	1241:1252	arg1	glycans					1254:1260	two complex-type glycans	1237:1260	two complex-type glycans	1237:1260	The highest binding affinity was for the antibody carrying two complex-type glycans.
36159782	5	83	theme	mutated	877:883	arg1	antibodies					936:945	mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies	877:945	mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding	877:970	The approach indicated clear differences in binging between doubly-, hemi-glycosylated and non-glycosylated antibodies as well as for mutated (Leu234Ala, Leu235Ala - Pro329-Gly (LALA-PG)) IgG1 antibodies silenced for Fcγ binding.
36159782	12	84	theme	fast	1927:1930	arg1	establishment					1932:1944	a fast establishment	1925:1944	a fast establishment of their structure-function relationships	1925:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	3	85	theme	different	506:514	arg1	glycoforms					525:534	different antibody glycoforms	506:534	different antibody glycoforms	506:534	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	3	86	theme	spectrometry	447:458	arg1	approach					460:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	7	87	theme	binding	1190:1196	arg1	affinity					1198:1205	The highest binding affinity	1178:1205	The highest binding affinity	1178:1205	The highest binding affinity was for the antibody carrying two complex-type glycans.
36159782	12	88	theme	affinities	1862:1871	arg1	comparison					1840:1849	the direct comparison	1829:1849	the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships	1829:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	3	89	theme	capillary	416:424	arg1	approach					460:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	an affinity capillary electrophoresis-mass spectrometry approach	404:467	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	11	90	theme	glycoform	1768:1776	arg1	selectivity					1778:1788	highly comparable glycoform selectivity	1750:1788	highly comparable glycoform selectivity	1750:1788	Finally, the assay was evaluated for the two variants of the FcγRIIa receptor (allotypes H131 and R131) showing highly comparable glycoform selectivity.
36159782	2	91	theme	glycoengineering	349:364	arg1	steps					366:370	long enrichment or glycoengineering steps	330:370	long enrichment or glycoengineering steps	330:370	Yet, glycoform binding assessment remains one of the major analytical challenges requiring long enrichment or glycoengineering steps.
36159782	9	92	from	increase	1525:1532	arg1	binding					1537:1543	binding	1537:1543	binding	1537:1543	For complex-type glycans, galactosylation showed a subtle increase in binding to the FcγIIa receptor, and sialylation showed an increase in binding for lower sialylated species.
36159782	3	93	theme	glycoforms	525:534	arg1	binding					495:501	the binding	491:501	the binding of different antibody glycoforms to the FcγIIa receptor	491:557	Here, we developed and applied an affinity capillary electrophoresis-mass spectrometry approach to selectively assess the binding of different antibody glycoforms to the FcγIIa receptor without the need of glycoengineering.
36159782	12	94	theme	direct	1833:1838	arg1	comparison					1840:1849	the direct comparison	1829:1849	the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships	1829:1986	Overall, the proposed approach allows the direct comparison of binding affinities of different antibody species in mixtures promising a fast establishment of their structure-function relationships.
36159782	6	95	theme	minor	1163:1167	arg1	binding					1169:1175	a strongly reduced, but still minor binding	1133:1175	a strongly reduced, but still minor binding	1133:1175	The LALA-PG mutated antibody showed no binding to the FcγIIa receptor (excluding potential non-specific binding effects) while the non-glycosylated IgG1 showed a strongly reduced, but still minor binding.
36159782	0	96	theme	capillary	9:17	arg1	electrophoresis					19:33	Affinity capillary electrophoresis	0:33	Affinity capillary electrophoresis	0:33	Affinity capillary electrophoresis - mass spectrometry permits direct binding assessment of IgG and FcγRIIa in a glycoform-resolved manner.
35331917	12	0	theme	staining	1794:1801	arg1	's					1802:1803	standard staining's	1785:1803	standard staining's combined with imaging mass spectrometry	1785:1843	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	5	1	theme	N-glycome	657:665	arg1	profile					667:673	the N-glycome profile	653:673	the N-glycome profile in tissue	653:683	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	13	2	theme	spatial	1959:1965	arg1	distribution					1967:1978	the spatial distribution	1955:1978	the spatial distribution of abundances of released N-glycans	1955:2014	These results indicate that the spatial distribution of abundances of released N-glycans correlate with regions of tissue steatosis associated with NAFLD/NASH.
35331917	8	3	theme	high	1137:1140	arg1	diets					1150:1154	high caloric diets	1137:1154	high caloric diets	1137:1154	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	4	4	theme	liver	606:610	arg1	damage					612:617	specific liver damage	597:617	specific liver damage in NAFLD and NASH	597:635	Here, we hypothesized that these N-glycan modifications may be associated with specific liver damage in NAFLD and NASH.
35331917	9	5	theme	Clinical	1412:1419	arg1	stages					1447:1452	Clinical Research Network fibrosis stages	1412:1452	Clinical Research Network fibrosis stages	1412:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	10	6	theme	human	1552:1556	arg1	biopsies					1563:1570	human NASH biopsies	1552:1570	human NASH biopsies	1552:1570	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	0	7	theme	Imaging	0:6	arg1	Spectrometry					13:24	Imaging Mass Spectrometry	0:24	Imaging Mass Spectrometry	0:24	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	9	8	theme	Network	1430:1436	arg1	stages					1447:1452	Clinical Research Network fibrosis stages	1412:1452	Clinical Research Network fibrosis stages	1412:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	8	9	theme	N-glycan	1233:1240	arg1	structures					1242:1251	hybrid N-glycan structures	1226:1251	hybrid N-glycan structures	1226:1251	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	1	10	theme	progressive	218:228	arg1	form					230:233	the progressive form	214:233	the progressive form of nonalcoholic fatty liver disease (NAFLD)	214:277	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	10	theme	progressive	218:228	arg1	steatohepatitis					188:202	Nonalcoholic steatohepatitis	175:202	Nonalcoholic steatohepatitis (NASH)	175:209	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	8	11	theme	mannose	1192:1198	arg1	expression					1178:1187	increased expression	1168:1187	increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures	1168:1251	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	5	12	dep	in	756:757	arg1	situ					759:762	situ	759:762	situ	759:762	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	8	13	theme	control	1265:1271	arg1	livers					1279:1284	control mouse livers	1265:1284	control mouse livers	1265:1284	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	8	14	theme	complex/fucosylated	1201:1219	arg1	expression					1178:1187	increased expression	1168:1187	increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures	1168:1251	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	5	15	theme	imaging	686:692	arg1	spectrometry					699:710	imaging mass spectrometry	686:710	imaging mass spectrometry	686:710	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	11	16	located	localized	1661:1669	arg1	addition					1619:1626	addition	1619:1626	addition	1619:1626	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	11	16	located	localized	1661:1669	arg2	alterations					1644:1654	spatial glycan alterations	1629:1654	spatial glycan alterations	1629:1654	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	5	17	theme	mass	694:697	arg1	spectrometry					699:710	imaging mass spectrometry	686:710	imaging mass spectrometry	686:710	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	11	18	theme	fatty	1741:1745	arg1	areas					1747:1751	fibrotic and fatty areas	1728:1751	fibrotic and fatty areas	1728:1751	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	4	19	from	damage	612:617	arg1	NASH					632:635	NASH	632:635	NASH	632:635	Here, we hypothesized that these N-glycan modifications may be associated with specific liver damage in NAFLD and NASH.
35331917	4	19	from	damage	612:617	arg1	NAFLD					622:626	NAFLD	622:626	NAFLD	622:626	Here, we hypothesized that these N-glycan modifications may be associated with specific liver damage in NAFLD and NASH.
35331917	0	20	theme	Histopathological	97:113	arg1	Changes					115:121	Histopathological Changes	97:121	Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human	97:172	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	13	21	theme	steatosis	2049:2057	arg1	regions					2031:2037	regions	2031:2037	regions of tissue steatosis associated with NAFLD/NASH	2031:2084	These results indicate that the spatial distribution of abundances of released N-glycans correlate with regions of tissue steatosis associated with NAFLD/NASH.
35331917	11	22	from	changes	1705:1711	arg1	tissue					1716:1721	tissue	1716:1721	tissue	1716:1721	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	5	23	theme	quantitative	743:754	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	9	24	theme	animal	1303:1308	arg1	results					1310:1316	the animal results	1299:1316	the animal results	1299:1316	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	0	25	from	Alterations	34:44	arg1	Glycosylation					58:70	N-Linked Glycosylation	49:70	N-Linked Glycosylation	49:70	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	10	26	located	observed	1540:1547	arg1	biopsies					1563:1570	human NASH biopsies	1552:1570	human NASH biopsies	1552:1570	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	10	26	located	observed	1540:1547	arg2	alterations					1498:1508	the same glycan alterations	1482:1508	the same glycan alterations observed in mouse models	1482:1533	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	3	27	theme	Previous	425:432	arg1	research					434:441	Previous research	425:441	Previous research	425:441	Previous research demonstrated that serum N-glycan profiles can be altered in NASH patients.
35331917	5	28	theme	NAFLD/NASH	808:817	arg1	tissue					819:824	human NAFLD/NASH tissue	802:824	human NAFLD/NASH tissue	802:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	12	29	theme	modifications	1894:1906	arg1	origin					1875:1880	the origin	1871:1880	the origin of N-glycan modifications within the tissue	1871:1924	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	4	30	theme	N-glycan	551:558	arg1	modifications					560:572	these N-glycan modifications	545:572	these N-glycan modifications	545:572	Here, we hypothesized that these N-glycan modifications may be associated with specific liver damage in NAFLD and NASH.
35331917	10	31	theme	glycan	1491:1496	arg1	alterations					1498:1508	the same glycan alterations	1482:1508	the same glycan alterations observed in mouse models	1482:1533	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	9	32	theme	biopsy	1325:1330	arg1	specimens					1332:1340	liver biopsy specimens	1319:1340	liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages	1319:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	2	33	theme	hepatocellular	399:412	arg1	carcinoma					414:422	hepatocellular carcinoma	399:422	hepatocellular carcinoma	399:422	Further, NASH is a risk factor for cirrhosis and hepatocellular carcinoma.
35331917	3	34	theme	serum	461:465	arg1	profiles					476:483	serum N-glycan profiles	461:483	serum N-glycan profiles	461:483	Previous research demonstrated that serum N-glycan profiles can be altered in NASH patients.
35331917	5	35	from	profile	667:673	arg1	tissue					678:683	tissue	678:683	tissue	678:683	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	10	36	theme	mouse	1522:1526	arg1	models					1528:1533	mouse models	1522:1533	mouse models	1522:1533	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	11	37	theme	histopathological	1687:1703	arg1	changes					1705:1711	histopathological changes	1687:1711	histopathological changes in tissue like fibrotic and fatty areas	1687:1751	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	0	38	theme	N-Linked	49:56	arg1	Glycosylation					58:70	N-Linked Glycosylation	49:70	N-Linked Glycosylation	49:70	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	9	39	theme	human	1350:1354	arg1	patients					1367:1374	51 human NAFLD/NASH patients	1347:1374	51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages	1347:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	12	40	theme	mass	1827:1830	arg1	spectrometry					1832:1843	imaging mass spectrometry	1819:1843	imaging mass spectrometry	1819:1843	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	13	41	theme	tissue	2042:2047	arg1	steatosis					2049:2057	tissue steatosis	2042:2057	tissue steatosis associated with NAFLD/NASH	2042:2084	These results indicate that the spatial distribution of abundances of released N-glycans correlate with regions of tissue steatosis associated with NAFLD/NASH.
35331917	1	42	theme	nonalcoholic	238:249	arg1	NAFLD					272:276	NAFLD	272:276	NAFLD	272:276	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	42	theme	nonalcoholic	238:249	arg1	disease					263:269	nonalcoholic fatty liver disease	238:269	nonalcoholic fatty liver disease (NAFLD)	238:277	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	6	43	theme	murine	829:834	arg1	model					836:840	A murine model	827:840	A murine model	827:840	A murine model was used to induce NAFLD and NASH through ad libitum feeding with either a high-fat diet or a Western diet, respectively.
35331917	12	44	theme	standard	1785:1792	arg1	's					1802:1803	standard staining's	1785:1803	standard staining's combined with imaging mass spectrometry	1785:1843	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	13	45	theme	released	1997:2004	arg1	N-glycans					2006:2014	released N-glycans	1997:2014	released N-glycans	1997:2014	These results indicate that the spatial distribution of abundances of released N-glycans correlate with regions of tissue steatosis associated with NAFLD/NASH.
35331917	1	46	theme	liver	257:261	arg1	NAFLD					272:276	NAFLD	272:276	NAFLD	272:276	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	46	theme	liver	257:261	arg1	disease					263:269	nonalcoholic fatty liver disease	238:269	nonalcoholic fatty liver disease (NAFLD)	238:277	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	12	47	theme	's	1802:1803	arg1	use					1778:1780	the use	1774:1780	the use of standard staining's combined with imaging mass spectrometry	1774:1843	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	0	48	from	Steatohepatitis	139:153	arg1	Mouse					158:162	Mouse	158:162	Mouse	158:162	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	0	48	from	Steatohepatitis	139:153	arg1	Human					168:172	Human	168:172	Human	168:172	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	11	49	theme	glycan	1637:1642	arg1	alterations					1644:1654	spatial glycan alterations	1629:1654	spatial glycan alterations	1629:1654	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	7	50	theme	NAFLD/NASH	1070:1079	arg1	phenotypes					1081:1090	NAFLD/NASH phenotypes	1070:1090	NAFLD/NASH phenotypes	1070:1090	Mice fed a high-fat diet or Western diet developed inflammation, steatosis, and fibrosis, consistent with NAFLD/NASH phenotypes.
35331917	9	51	theme	NASH	1407:1410	arg1	range					1398:1402	the full range	1389:1402	the full range of NASH	1389:1410	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	6	52	theme	ad	884:885	arg1	libitum					887:893	ad libitum	884:893	ad libitum feeding with either a high-fat diet or a Western diet, respectively	884:961	A murine model was used to induce NAFLD and NASH through ad libitum feeding with either a high-fat diet or a Western diet, respectively.
35331917	4	53	theme	specific	597:604	arg1	damage					612:617	specific liver damage	597:617	specific liver damage in NAFLD and NASH	597:635	Here, we hypothesized that these N-glycan modifications may be associated with specific liver damage in NAFLD and NASH.
35331917	10	54	theme	NASH	1558:1561	arg1	biopsies					1563:1570	human NASH biopsies	1552:1570	human NASH biopsies	1552:1570	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	13	55	theme	abundances	1983:1992	arg1	distribution					1967:1978	the spatial distribution	1955:1978	the spatial distribution of abundances of released N-glycans	1955:2014	These results indicate that the spatial distribution of abundances of released N-glycans correlate with regions of tissue steatosis associated with NAFLD/NASH.
35331917	9	56	theme	Research	1421:1428	arg1	stages					1447:1452	Clinical Research Network fibrosis stages	1412:1452	Clinical Research Network fibrosis stages	1412:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	8	57	theme	caloric	1142:1148	arg1	diets					1150:1154	high caloric diets	1137:1154	high caloric diets	1137:1154	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	5	58	theme	glycan	773:778	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	5	59	link	N-linked	764:771	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	9	60	theme	fibrosis	1438:1445	arg1	stages					1447:1452	Clinical Research Network fibrosis stages	1412:1452	Clinical Research Network fibrosis stages	1412:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	8	61	theme	hybrid	1226:1231	arg1	structures					1242:1251	hybrid N-glycan structures	1226:1251	hybrid N-glycan structures	1226:1251	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	8	62	theme	increased	1168:1176	arg1	expression					1178:1187	increased expression	1168:1187	increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures	1168:1251	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	6	63	theme	Western	936:942	arg1	diet					944:947	a Western diet	934:947	a Western diet	934:947	A murine model was used to induce NAFLD and NASH through ad libitum feeding with either a high-fat diet or a Western diet, respectively.
35331917	8	64	theme	structures	1242:1251	arg1	expression					1178:1187	increased expression	1168:1187	increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures	1168:1251	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	5	65	used	used	716:719	arg2	spectrometry					699:710	imaging mass spectrometry	686:710	imaging mass spectrometry	686:710	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	9	66	dep	patients	1367:1374	arg1	representing					1376:1387	representing	1376:1387	representing the full range of NASH Clinical Research Network fibrosis stages	1376:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	10	67	theme	fibrosis	1606:1613	arg1	degree					1596:1601	the degree	1592:1601	the degree of fibrosis	1592:1613	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	12	68	theme	full	1855:1858	arg1	profile					1860:1866	a full profile	1853:1866	a full profile of the origin of N-glycan modifications within the tissue	1853:1924	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	6	69	theme	high-fat	917:924	arg1	diet					926:929	a high-fat diet	915:929	a high-fat diet	915:929	A murine model was used to induce NAFLD and NASH through ad libitum feeding with either a high-fat diet or a Western diet, respectively.
35331917	8	70	theme	mouse	1273:1277	arg1	livers					1279:1284	control mouse livers	1265:1284	control mouse livers	1265:1284	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	7	71	theme	Western	992:998	arg1	diet					1000:1003	Western diet	992:1003	Western diet	992:1003	Mice fed a high-fat diet or Western diet developed inflammation, steatosis, and fibrosis, consistent with NAFLD/NASH phenotypes.
35331917	7	72	theme	high-fat	975:982	arg1	diet					984:987	a high-fat diet	973:987	a high-fat diet	973:987	Mice fed a high-fat diet or Western diet developed inflammation, steatosis, and fibrosis, consistent with NAFLD/NASH phenotypes.
35331917	0	73	from	Changes	115:121	arg1	Steatohepatitis					139:153	Nonalcoholic Steatohepatitis	126:153	Nonalcoholic Steatohepatitis in Mouse and Human	126:172	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	10	74	located	observed	1510:1517	arg1	models					1528:1533	mouse models	1522:1533	mouse models	1522:1533	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	10	74	located	observed	1510:1517	arg2	alterations					1498:1508	the same glycan alterations	1482:1508	the same glycan alterations observed in mouse models	1482:1533	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	5	75	theme	in	756:757	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	5	76	theme	qualitative	727:737	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	5	77	theme	N-linked	764:771	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	1	78	theme	Nonalcoholic	175:186	arg1	form					230:233	the progressive form	214:233	the progressive form of nonalcoholic fatty liver disease (NAFLD)	214:277	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	78	theme	Nonalcoholic	175:186	arg1	NASH					205:208	NASH	205:208	NASH	205:208	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	78	theme	Nonalcoholic	175:186	arg1	steatohepatitis					188:202	Nonalcoholic steatohepatitis	175:202	Nonalcoholic steatohepatitis (NASH)	175:209	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	0	79	theme	Nonalcoholic	126:137	arg1	Steatohepatitis					139:153	Nonalcoholic Steatohepatitis	126:153	Nonalcoholic Steatohepatitis in Mouse and Human	126:172	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	12	80	theme	N-glycan	1885:1892	arg1	modifications					1894:1906	N-glycan modifications	1885:1906	N-glycan modifications within the tissue	1885:1924	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	0	81	theme	Mass	8:11	arg1	Spectrometry					13:24	Imaging Mass Spectrometry	0:24	Imaging Mass Spectrometry	0:24	Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human.
35331917	2	82	theme	risk	369:372	arg1	NASH					359:362	NASH	359:362	NASH	359:362	Further, NASH is a risk factor for cirrhosis and hepatocellular carcinoma.
35331917	2	82	theme	risk	369:372	arg1	factor					374:379	a risk factor	367:379	a risk factor for cirrhosis and hepatocellular carcinoma	367:422	Further, NASH is a risk factor for cirrhosis and hepatocellular carcinoma.
35331917	5	83	theme	tissue	819:824	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	9	84	theme	liver	1319:1323	arg1	specimens					1332:1340	liver biopsy specimens	1319:1340	liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages	1319:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	10	85	theme	same	1486:1489	arg1	alterations					1498:1508	the same glycan alterations	1482:1508	the same glycan alterations observed in mouse models	1482:1533	Importantly, the same glycan alterations observed in mouse models were observed in human NASH biopsies and correlated with the degree of fibrosis.
35331917	6	86	used	used	846:849	arg2	model					836:840	A murine model	827:840	A murine model	827:840	A murine model was used to induce NAFLD and NASH through ad libitum feeding with either a high-fat diet or a Western diet, respectively.
35331917	12	87	theme	origin	1875:1880	arg1	profile					1860:1866	a full profile	1853:1866	a full profile of the origin of N-glycan modifications within the tissue	1853:1924	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	3	88	theme	N-glycan	467:474	arg1	profiles					476:483	serum N-glycan profiles	461:483	serum N-glycan profiles	461:483	Previous research demonstrated that serum N-glycan profiles can be altered in NASH patients.
35331917	5	89	theme	mouse	792:796	arg1	analysis					780:787	a qualitative and quantitative in situ N-linked glycan analysis	725:787	a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue	725:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	1	90	theme	hepatocyte	317:326	arg1	injury					328:333	hepatocyte injury	317:333	hepatocyte injury	317:333	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	11	91	theme	fibrotic	1728:1735	arg1	areas					1747:1751	fibrotic and fatty areas	1728:1751	fibrotic and fatty areas	1728:1751	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	3	92	theme	NASH	503:506	arg1	patients					508:515	NASH patients	503:515	NASH patients	503:515	Previous research demonstrated that serum N-glycan profiles can be altered in NASH patients.
35331917	9	93	theme	NAFLD/NASH	1356:1365	arg1	patients					1367:1374	51 human NAFLD/NASH patients	1347:1374	51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages	1347:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	9	94	from	patients	1367:1374	arg1	specimens					1332:1340	liver biopsy specimens	1319:1340	liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages	1319:1452	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
35331917	12	95	theme	imaging	1819:1825	arg1	spectrometry					1832:1843	imaging mass spectrometry	1819:1843	imaging mass spectrometry	1819:1843	We demonstrate that the use of standard staining's combined with imaging mass spectrometry provide a full profile of the origin of N-glycan modifications within the tissue.
35331917	7	96	with	consistent	1054:1063	arg1	phenotypes					1081:1090	NAFLD/NASH phenotypes	1070:1090	NAFLD/NASH phenotypes	1070:1090	Mice fed a high-fat diet or Western diet developed inflammation, steatosis, and fibrosis, consistent with NAFLD/NASH phenotypes.
35331917	8	97	dep	resulted	1156:1163	arg1	compared					1253:1260	compared	1253:1260	compared to control mouse livers	1253:1284	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	1	98	theme	fatty	251:255	arg1	NAFLD					272:276	NAFLD	272:276	NAFLD	272:276	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	98	theme	fatty	251:255	arg1	disease					263:269	nonalcoholic fatty liver disease	238:269	nonalcoholic fatty liver disease (NAFLD)	238:277	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	8	99	theme	NAFLD/NASH	1106:1115	arg1	Induction					1093:1101	Induction	1093:1101	Induction of NAFLD/NASH for 18 months using high caloric diets	1093:1154	Induction of NAFLD/NASH for 18 months using high caloric diets resulted in increased expression of mannose, complex/fucosylated, and hybrid N-glycan structures compared to control mouse livers.
35331917	11	100	theme	spatial	1629:1635	arg1	alterations					1644:1654	spatial glycan alterations	1629:1654	spatial glycan alterations	1629:1654	In addition, spatial glycan alterations were localized specifically to histopathological changes in tissue like fibrotic and fatty areas.
35331917	1	101	theme	disease	263:269	arg1	form					230:233	the progressive form	214:233	the progressive form of nonalcoholic fatty liver disease (NAFLD)	214:277	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	1	101	theme	disease	263:269	arg1	steatohepatitis					188:202	Nonalcoholic steatohepatitis	175:202	Nonalcoholic steatohepatitis (NASH)	175:209	Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation, hepatocyte injury, and fibrosis.
35331917	13	102	theme	N-glycans	2006:2014	arg1	abundances					1983:1992	abundances	1983:1992	abundances of released N-glycans	1983:2014	These results indicate that the spatial distribution of abundances of released N-glycans correlate with regions of tissue steatosis associated with NAFLD/NASH.
35331917	5	103	theme	human	802:806	arg1	tissue					819:824	human NAFLD/NASH tissue	802:824	human NAFLD/NASH tissue	802:824	To investigate the N-glycome profile in tissue, imaging mass spectrometry was used for a qualitative and quantitative in situ N-linked glycan analysis of mouse and human NAFLD/NASH tissue.
35331917	9	104	theme	full	1393:1396	arg1	range					1398:1402	the full range	1389:1402	the full range of NASH	1389:1410	To validate the animal results, liver biopsy specimens from 51 human NAFLD/NASH patients representing the full range of NASH Clinical Research Network fibrosis stages were analyzed.
36766693	0	0	theme	Fibrinogen	72:81	arg1	Mannosylation					83:95	the Fibrinogen Mannosylation	68:95	the Fibrinogen Mannosylation	68:95	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	4	1	from	GNL	851:853	arg1	patients					858:865	patients	858:865	patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool	858:1103	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	5	2	attach	linked	1299:1304	arg1	lectin					1314:1319	this lectin	1309:1319	this lectin	1309:1319	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	5	2	attach	linked	1299:1304	arg2	events					1292:1297	events	1292:1297	events linked to this lectin	1292:1319	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	1	3	from	marker	170:175	arg1	patients					243:250	end-stage renal disease (ESRD) patients	212:250	end-stage renal disease (ESRD) patients on peritoneal dialysis	212:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	1	3	from	marker	170:175	arg1	dialysis					266:273	peritoneal dialysis	255:273	peritoneal dialysis	255:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	3	4	theme	univariate	466:475	arg1	analysis					492:499	a univariate Cox regression analysis	464:499	a univariate Cox regression analysis	464:499	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	2	5	from	predictors	424:433	arg1	patients					444:451	these patients	438:451	these patients	438:451	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	3	6	theme	mortality	791:799	arg1	predictors					801:810	mortality predictors	791:810	mortality predictors	791:810	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	7	theme	Cox	477:479	arg1	analysis					492:499	a univariate Cox regression analysis	464:499	a univariate Cox regression analysis	464:499	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	6	8	theme	exposed	1489:1495	arg1	residues					1505:1512	increasingly exposed mannose residues	1476:1512	increasingly exposed mannose residues	1476:1512	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	4	9	theme	prediction	1089:1098	arg1	factors					976:982	factors	976:982	factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool	976:1103	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	4	9	theme	prediction	1089:1098	arg1	tool					1100:1103	a prediction tool	1087:1103	a prediction tool	1087:1103	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	4	10	theme	N-glycan	939:946	arg1	structures					948:957	paucimannosidic/highly mannosidic N-glycan structures	905:957	paucimannosidic/highly mannosidic N-glycan structures	905:957	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	0	11	from	Prediction	0:9	arg1	Patients					27:34	Patients	27:34	Patients on Peritoneal Dialysis	27:57	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	0	11	from	Prediction	0:9	arg1	Dialysis					50:57	Peritoneal Dialysis	39:57	Peritoneal Dialysis	39:57	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	5	12	theme	entire	1274:1279	arg1	cascade					1281:1287	the entire cascade	1270:1287	the entire cascade of events linked to this lectin	1270:1319	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	3	13	theme	regression	481:490	arg1	analysis					492:499	a univariate Cox regression analysis	464:499	a univariate Cox regression analysis	464:499	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	5	14	theme	glycoproteins	1215:1227	arg1	reactivity					1188:1197	the reactivity	1184:1197	the reactivity of mannosylated glycoproteins with mannose-binding lectin	1184:1255	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	4	15	theme	mannosidic	928:937	arg1	structures					948:957	paucimannosidic/highly mannosidic N-glycan structures	905:957	paucimannosidic/highly mannosidic N-glycan structures	905:957	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	0	16	from	Dialysis	50:57	arg1	Prediction					0:9	Prediction	0:9	Prediction of Mortality in Patients on Peritoneal Dialysis	0:57	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	3	17	theme	urea	512:515	arg1	clearance					517:525	urea clearance	512:525	urea clearance	512:525	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	6	18	theme	unwanted	1536:1543	arg1	events					1545:1550	the unwanted events	1532:1550	the unwanted events	1532:1550	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	1	19	theme	peritoneal	255:264	arg1	dialysis					266:273	peritoneal dialysis	255:273	peritoneal dialysis	255:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	6	20	theme	mannose	1497:1503	arg1	residues					1505:1512	increasingly exposed mannose residues	1476:1512	increasingly exposed mannose residues	1476:1512	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	4	21	theme	Higher	813:818	arg1	intensity					827:835	Higher signal intensity	813:835	Higher signal intensity	813:835	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	2	22	theme	biochemical	378:388	arg1	parameters					390:399	other biochemical parameters	372:399	other biochemical parameters	372:399	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	3	23	from	ferritin	502:509	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	24	from	increase	569:576	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	1	25	theme	prognostic	159:168	arg1	marker					170:175	a prognostic marker	157:175	a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis	157:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	0	26	theme	Peritoneal	39:48	arg1	Dialysis					50:57	Peritoneal Dialysis	39:57	Peritoneal Dialysis	39:57	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	3	27	theme	potential	658:666	arg1	predictors					678:687	potential mortality predictors	658:687	potential mortality predictors	658:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	5	28	gly	mannosylated	1202:1213	arg1	glycoproteins					1215:1227	mannosylated glycoproteins	1202:1227	mannosylated glycoproteins	1202:1227	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	6	29	theme	cardiovascular	1360:1373	arg1	complications					1375:1387	cardiovascular complications	1360:1387	cardiovascular complications	1360:1387	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	0	30	from	Patients	27:34	arg1	Dialysis					50:57	Peritoneal Dialysis	39:57	Peritoneal Dialysis	39:57	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	1	31	from	dialysis	266:273	arg1	marker					170:175	a prognostic marker	157:175	a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis	157:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	5	32	with	reactivity	1188:1197	arg1	lectin					1250:1255	mannose-binding lectin	1234:1255	mannose-binding lectin	1234:1255	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	3	33	theme	residual	528:535	arg1	diuresis					537:544	residual diuresis	528:544	residual diuresis	528:544	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	4	34	theme	cardiovascular	1013:1026	arg1	events					1028:1033	unwanted cardiovascular events	1004:1033	unwanted cardiovascular events	1004:1033	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	3	35	theme	multivariate	705:716	arg1	analysis					733:740	additional multivariate Cox regression analysis	694:740	additional multivariate Cox regression analysis	694:740	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	4	36	theme	signal	820:825	arg1	intensity					827:835	Higher signal intensity	813:835	Higher signal intensity	813:835	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	6	37	with	fibrinogen	1460:1469	arg1	residues					1505:1512	increasingly exposed mannose residues	1476:1512	increasingly exposed mannose residues	1476:1512	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	1	38	theme	peritoneal	180:189	arg1	function					200:207	peritoneal membrane function	180:207	peritoneal membrane function	180:207	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	4	39	theme	all-cause	1039:1047	arg1	mortality					1049:1057	all-cause mortality	1039:1057	all-cause mortality	1039:1057	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	3	40	theme	Cox	718:720	arg1	analysis					733:740	additional multivariate Cox regression analysis	694:740	additional multivariate Cox regression analysis	694:740	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	41	theme	mortality	668:676	arg1	predictors					678:687	potential mortality predictors	658:687	potential mortality predictors	658:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	42	from	analysis	492:499	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	43	from	hyperglycemia	547:559	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	2	44	theme	parameters	390:399	arg1	ability					332:338	the ability	328:338	the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients	328:451	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	0	45	theme	Mortality	14:22	arg1	Prediction					0:9	Prediction	0:9	Prediction of Mortality in Patients on Peritoneal Dialysis	0:57	Prediction of Mortality in Patients on Peritoneal Dialysis Based on the Fibrinogen Mannosylation.
36766693	6	46	theme	plaques	1426:1432	arg1	complications					1375:1387	cardiovascular complications	1360:1387	cardiovascular complications	1360:1387	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	6	46	theme	plaques	1426:1432	arg1	formation					1397:1405	the formation	1393:1405	the formation of atherosclerotic plaques	1393:1432	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	2	47	theme	follow-up	284:292	arg1	period					294:299	a follow-up period	282:299	a follow-up period of 18 months	282:312	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	6	48	with	patients	1328:1335	arg1	ESRD					1342:1345	ESRD	1342:1345	ESRD	1342:1345	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	1	49	theme	function	200:207	arg1	marker					170:175	a prognostic marker	157:175	a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis	157:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	3	50	theme	additional	694:703	arg1	analysis					733:740	additional multivariate Cox regression analysis	694:740	additional multivariate Cox regression analysis	694:740	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	5	51	theme	mannose-binding	1234:1248	arg1	lectin					1250:1255	mannose-binding lectin	1234:1255	mannose-binding lectin	1234:1255	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	2	52	theme	lectins	352:358	arg1	ability					332:338	the ability	328:338	the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients	328:451	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	2	53	theme	other	372:376	arg1	parameters					390:399	other biochemical parameters	372:399	other biochemical parameters	372:399	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	5	54	theme	events	1292:1297	arg1	cascade					1281:1287	the entire cascade	1270:1287	the entire cascade of events linked to this lectin	1270:1319	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	5	55	theme	mannose	1144:1150	arg1	residues					1152:1159	mannose residues	1144:1159	mannose residues	1144:1159	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	1	56	from	patients	243:250	arg1	dialysis					266:273	peritoneal dialysis	255:273	peritoneal dialysis	255:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	3	57	theme	signal	585:590	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	1	58	theme	end-stage	212:220	arg1	ESRD					237:240	ESRD	237:240	ESRD	237:240	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	1	58	theme	end-stage	212:220	arg1	disease					228:234	end-stage renal disease	212:234	end-stage renal disease (ESRD) patients on peritoneal dialysis	212:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	4	59	theme	unwanted	1004:1011	arg1	events					1028:1033	unwanted cardiovascular events	1004:1033	unwanted cardiovascular events	1004:1033	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	1	60	theme	fibrinogen	122:131	arg1	fucosylation					133:144	fibrinogen fucosylation	122:144	fibrinogen fucosylation	122:144	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	5	61	theme	mannosylated	1202:1213	arg1	glycoproteins					1215:1227	mannosylated glycoproteins	1202:1227	mannosylated glycoproteins	1202:1227	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	2	62	theme	mortality	414:422	arg1	predictors					424:433	mortality predictors	414:433	mortality predictors in these patients	414:451	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	3	63	theme	regression	722:731	arg1	analysis					733:740	additional multivariate Cox regression analysis	694:740	additional multivariate Cox regression analysis	694:740	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	5	64	theme	Altered	1106:1112	arg1	structures					1121:1130	Altered glycan structures	1106:1130	Altered glycan structures composed of mannose residues	1106:1159	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	4	65	from	importance	891:900	arg1	fibrinogen					962:971	fibrinogen	962:971	fibrinogen	962:971	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	3	66	from	clearance	517:525	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	5	67	gly	glycoproteins	1215:1227	arg1	glycoproteins					1215:1227	mannosylated glycoproteins	1202:1227	mannosylated glycoproteins	1202:1227	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	1	68	theme	renal	222:226	arg1	ESRD					237:240	ESRD	237:240	ESRD	237:240	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	1	68	theme	renal	222:226	arg1	disease					228:234	end-stage renal disease	212:234	end-stage renal disease (ESRD) patients on peritoneal dialysis	212:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	3	69	theme	Galanthus	616:624	arg1	GNL					642:644	GNL	642:644	GNL	642:644	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	69	theme	Galanthus	616:624	arg1	lectin					634:639	Galanthus nivalis lectin	616:639	Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	616:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	2	70	theme	months	307:312	arg1	period					294:299	a follow-up period	282:299	a follow-up period of 18 months	282:312	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	1	71	theme	disease	228:234	arg1	patients					243:250	end-stage renal disease (ESRD) patients	212:250	end-stage renal disease (ESRD) patients on peritoneal dialysis	212:273	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	6	72	theme	atherosclerotic	1410:1424	arg1	plaques					1426:1432	atherosclerotic plaques	1410:1432	atherosclerotic plaques	1410:1432	Since patients with ESRD are prone to cardiovascular complications and the formation of atherosclerotic plaques, one can hypothesize that fibrinogen with increasingly exposed mannose residues may contribute to the unwanted events.
36766693	3	73	theme	nivalis	626:632	arg1	GNL					642:644	GNL	642:644	GNL	642:644	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	3	73	theme	nivalis	626:632	arg1	lectin					634:639	Galanthus nivalis lectin	616:639	Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	616:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	1	74	theme	membrane	191:198	arg1	function					200:207	peritoneal membrane function	180:207	peritoneal membrane function	180:207	As we already reported, fibrinogen fucosylation emerged as a prognostic marker of peritoneal membrane function in end-stage renal disease (ESRD) patients on peritoneal dialysis.
36766693	2	75	theme	employed	343:350	arg1	lectins					352:358	employed lectins	343:358	employed lectins	343:358	After a follow-up period of 18 months, we estimated the ability of employed lectins, as well as other biochemical parameters, to serve as mortality predictors in these patients.
36766693	3	76	from	diuresis	537:544	arg1	intensity					592:600	the signal intensity	581:600	the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors	581:687	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
36766693	4	77	dep	died	872:875	arg1	suggested					877:885	suggested	877:885	died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool	872:1103	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	5	78	theme	glycan	1114:1119	arg1	structures					1121:1130	Altered glycan structures	1106:1130	Altered glycan structures composed of mannose residues	1106:1159	Altered glycan structures composed of mannose residues are expected to affect the reactivity of mannosylated glycoproteins with mannose-binding lectin and possibly the entire cascade of events linked to this lectin.
36766693	4	79	theme	structures	948:957	arg1	importance					891:900	the importance	887:900	the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen	887:971	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	4	79	theme	structures	948:957	arg1	factors					976:982	factors	976:982	factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool	976:1103	Higher signal intensity obtained with GNL in patients that died suggested the importance of paucimannosidic/highly mannosidic N-glycan structures on fibrinogen as factors that are related to unwanted cardiovascular events and all-cause mortality and can possibly be seen as a prediction tool.
36766693	3	80	theme	glucose	758:764	arg1	concentration					766:778	glucose concentration	758:778	glucose concentration	758:778	Following a univariate Cox regression analysis, ferritin, urea clearance, residual diuresis, hyperglycemia, and an increase in the signal intensity obtained with Galanthus nivalis lectin (GNL) emerged as potential mortality predictors, but additional multivariate Cox regression analysis pointed only to glucose concentration and GNL as mortality predictors.
35219398	5	0	theme	CCM1	822:825	arg1	structure					786:794	the first crystal structure	768:794	the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	768:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	4	1	from	effect	665:670	arg1	formation					698:706	dimer formation	692:706	dimer formation calls its physiological relevance into question	692:754	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	6	2	theme	GFCC	1022:1025	arg1	dominant					1039:1046	dominant	1039:1046	dominant	1039:1046	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	6	2	theme	GFCC	1022:1025	arg1	dimer					1030:1034	the GFCC'C″ dimer	1018:1034	the GFCC'C″ dimer	1018:1034	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	5	3	theme	continuous-wave	897:911	arg1	resonance					974:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance	897:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	6	4	theme	structural	1104:1113	arg1	conservation					1115:1126	structural conservation	1104:1126	structural conservation	1104:1126	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	5	5	theme	electron-electron	924:940	arg1	resonance					974:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance	897:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	6	6	from	dominant	1039:1046	arg1	solution					1051:1058	solution	1051:1058	solution with different levels of glycosylation	1051:1097	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	5	7	from	solution	885:892	arg1	structure					786:794	the first crystal structure	768:794	the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	768:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	8	theme	resonance	974:982	arg1	spectroscopy					984:995	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	9	theme	paramagnetic	961:972	arg1	resonance					974:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance	897:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	2	10	theme	oligomeric	311:320	arg1	state					322:326	The physiological oligomeric state	293:326	The physiological oligomeric state and how it contributes to protein function	293:369	The physiological oligomeric state and how it contributes to protein function are central to understanding CEACAMs.
35219398	2	10	theme	oligomeric	311:320	arg1	central					375:381	central	375:381	central	375:381	The physiological oligomeric state and how it contributes to protein function are central to understanding CEACAMs.
35219398	6	11	theme	GFCC	1169:1172	arg1	dimer					1177:1181	the GFCC'C″ dimer	1165:1181	the GFCC'C″ dimer	1165:1181	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	3	12	theme	crystal	557:563	arg1	structures					565:574	crystal structures	557:574	crystal structures	557:574	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	5	13	from	characterization	865:880	arg1	solution					885:892	solution	885:892	solution	885:892	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	13	from	characterization	865:880	arg1	conformation					848:859	the GFCC'C″ dimer conformation	830:859	the GFCC'C″ dimer conformation	830:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	1	14	theme	Carcinoembryonic	78:93	arg1	molecules					113:121	Carcinoembryonic cellular adhesion molecules	78:121	Carcinoembryonic cellular adhesion molecules (CEACAMs)	78:131	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	14	theme	Carcinoembryonic	78:93	arg1	CEACAMs					124:130	CEACAMs	124:130	CEACAMs	124:130	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	5	15	theme	dimer	842:846	arg1	conformation					848:859	the GFCC'C″ dimer conformation	830:859	the GFCC'C″ dimer conformation	830:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	6	16	theme	glycosylation	1085:1097	arg1	levels					1075:1080	different levels	1065:1080	different levels of glycosylation	1065:1097	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	5	17	from	structure	786:794	arg1	solution					885:892	solution	885:892	solution	885:892	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	17	from	structure	786:794	arg1	conformation					848:859	the GFCC'C″ dimer conformation	830:859	the GFCC'C″ dimer conformation	830:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	1	18	theme	cellular	95:102	arg1	molecules					113:121	Carcinoembryonic cellular adhesion molecules	78:121	Carcinoembryonic cellular adhesion molecules (CEACAMs)	78:131	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	18	theme	cellular	95:102	arg1	CEACAMs					124:130	CEACAMs	124:130	CEACAMs	124:130	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	3	19	theme	different	452:460	arg1	C″					532:533	GFCC'C″	527:533	GFCC'C″	527:533	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	19	theme	different	452:460	arg1	ABED					518:521	ABED	518:521	ABED	518:521	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	19	theme	different	452:460	arg1	faces					511:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces	452:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	0	20	theme	CEACAM1	6:12	arg1	dimerization					23:34	Human CEACAM1 N-domain dimerization	0:34	Human CEACAM1 N-domain dimerization	0:34	Human CEACAM1 N-domain dimerization is independent from glycan modifications.
35219398	1	21	from	roles	147:151	arg1	proliferation					172:184	proliferation	172:184	proliferation	172:184	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	21	from	roles	147:151	arg1	survival					191:198	survival	191:198	survival	191:198	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	21	from	roles	147:151	arg1	signaling					161:169	cell signaling	156:169	cell signaling	156:169	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	22	theme	adhesion	104:111	arg1	molecules					113:121	Carcinoembryonic cellular adhesion molecules	78:121	Carcinoembryonic cellular adhesion molecules (CEACAMs)	78:131	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	22	theme	adhesion	104:111	arg1	CEACAMs					124:130	CEACAMs	124:130	CEACAMs	124:130	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	3	23	theme	dimer	422:426	arg1	conformations					428:440	Two putative dimer conformations	409:440	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	409:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	0	24	theme	Human	0:4	arg1	dimerization					23:34	Human CEACAM1 N-domain dimerization	0:34	Human CEACAM1 N-domain dimerization	0:34	Human CEACAM1 N-domain dimerization is independent from glycan modifications.
35219398	1	25	theme	-like	253:257	arg1	ectodomains					259:269	several immunoglobulin (Ig)-like ectodomains	226:269	several immunoglobulin (Ig)-like ectodomains glycosylated in vivo	226:290	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	4	26	theme	dimer	692:696	arg1	formation					698:706	dimer formation	692:706	dimer formation calls its physiological relevance into question	692:754	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	2	27	dep	state	322:326	arg1	contributes					339:349	contributes	339:349	contributes to protein function	339:369	The physiological oligomeric state and how it contributes to protein function are central to understanding CEACAMs.
35219398	5	28	from	conformation	848:859	arg1	structure					786:794	the first crystal structure	768:794	the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	768:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	4	29	gly	glycosylation	675:687	arg1	dimer					692:696	dimer formation	692:706	dimer formation calls its physiological relevance into question	692:754	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	5	30	theme	double	917:922	arg1	resonance					974:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance	897:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	31	theme	electron	952:959	arg1	resonance					974:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance	897:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	3	32	theme	Ig-like	481:487	arg1	CCM1					497:500	CCM1	497:500	CCM1	497:500	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	32	theme	Ig-like	481:487	arg1	domain					489:494	CEACAM1 N-terminal Ig-like domain	462:494	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	2	33	theme	physiological	297:309	arg1	state					322:326	The physiological oligomeric state	293:326	The physiological oligomeric state and how it contributes to protein function	293:369	The physiological oligomeric state and how it contributes to protein function are central to understanding CEACAMs.
35219398	2	33	theme	physiological	297:309	arg1	central					375:381	central	375:381	central	375:381	The physiological oligomeric state and how it contributes to protein function are central to understanding CEACAMs.
35219398	5	34	theme	resonance	942:950	arg1	resonance					974:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance	897:982	continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	897:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	4	35	theme	physiological	718:730	arg1	relevance					732:740	its physiological relevance	714:740	its physiological relevance	714:740	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	3	36	theme	domain	489:494	arg1	C″					532:533	GFCC'C″	527:533	GFCC'C″	527:533	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	36	theme	domain	489:494	arg1	ABED					518:521	ABED	518:521	ABED	518:521	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	36	theme	domain	489:494	arg1	faces					511:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces	452:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	37	dep	faces	511:515	arg1	C″					532:533	GFCC'C″	527:533	GFCC'C″	527:533	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	37	dep	faces	511:515	arg1	ABED					518:521	ABED	518:521	ABED	518:521	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	37	dep	faces	511:515	arg1	faces					511:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces	452:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	4	38	theme	solution	621:628	arg1	C″					582:583	GFCC'C″	577:583	GFCC'C″	577:583	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	4	38	theme	solution	621:628	arg1	dimer					630:634	the dominant CCM1 solution dimer	603:634	the dominant CCM1 solution dimer	603:634	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	6	39	with	solution	1051:1058	arg1	levels					1075:1080	different levels	1065:1080	different levels of glycosylation	1065:1097	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	6	40	theme	different	1065:1073	arg1	levels					1075:1080	different levels	1065:1080	different levels of glycosylation	1065:1097	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	3	41	theme	CEACAM1	462:468	arg1	CCM1					497:500	CCM1	497:500	CCM1	497:500	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	41	theme	CEACAM1	462:468	arg1	domain					489:494	CEACAM1 N-terminal Ig-like domain	462:494	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	42	theme	putative	413:420	arg1	conformations					428:440	Two putative dimer conformations	409:440	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	409:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	4	43	theme	glycosylation	675:687	arg1	effect					665:670	the effect	661:670	the effect of glycosylation on dimer formation calls its physiological relevance into question	661:754	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	5	44	theme	GFCC	834:837	arg1	conformation					848:859	the GFCC'C″ dimer conformation	830:859	the GFCC'C″ dimer conformation	830:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	3	45	theme	N-terminal	470:479	arg1	CCM1					497:500	CCM1	497:500	CCM1	497:500	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	45	theme	N-terminal	470:479	arg1	domain					489:494	CEACAM1 N-terminal Ig-like domain	462:494	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	0	46	theme	glycan	56:61	arg1	modifications					63:75	glycan modifications	56:75	glycan modifications	56:75	Human CEACAM1 N-domain dimerization is independent from glycan modifications.
35219398	0	47	from	modifications	63:75	arg1	independent					39:49	independent	39:49	independent	39:49	Human CEACAM1 N-domain dimerization is independent from glycan modifications.
35219398	5	48	gly	glycosylated	809:820	arg1	CCM1					822:825	minimally glycosylated CCM1	799:825	minimally glycosylated CCM1 in the GFCC'C″ dimer conformation	799:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	49	theme	crystal	778:784	arg1	structure					786:794	the first crystal structure	768:794	the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	768:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	4	50	dep	formation	698:706	arg1	calls					708:712	calls	708:712	calls	708:712	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	5	51	from	CCM1	822:825	arg1	solution					885:892	solution	885:892	solution	885:892	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	51	from	CCM1	822:825	arg1	conformation					848:859	the GFCC'C″ dimer conformation	830:859	the GFCC'C″ dimer conformation	830:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	3	52	theme	protein	503:509	arg1	C″					532:533	GFCC'C″	527:533	GFCC'C″	527:533	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	52	theme	protein	503:509	arg1	ABED					518:521	ABED	518:521	ABED	518:521	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	3	52	theme	protein	503:509	arg1	faces					511:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces	452:515	different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″)	452:534	Two putative dimer conformations involving different CEACAM1 N-terminal Ig-like domain (CCM1) protein faces (ABED and GFCC'C″) were identified from crystal structures.
35219398	6	53	from	solution	1051:1058	arg1	dominant					1039:1046	dominant	1039:1046	dominant	1039:1046	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	6	53	from	solution	1051:1058	arg1	dimer					1030:1034	the GFCC'C″ dimer	1018:1034	the GFCC'C″ dimer	1018:1034	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	1	54	gly	glycosylated	271:282	arg1	ectodomains					259:269	several immunoglobulin (Ig)-like ectodomains	226:269	several immunoglobulin (Ig)-like ectodomains glycosylated in vivo	226:290	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	1	55	theme	diverse	139:145	arg1	roles					147:151	diverse roles	139:151	diverse roles in cell signaling, proliferation, and survival	139:198	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	6	56	theme	C″	1174:1175	arg1	dimer					1177:1181	the GFCC'C″ dimer	1165:1181	the GFCC'C″ dimer	1165:1181	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	5	57	theme	glycosylated	809:820	arg1	CCM1					822:825	minimally glycosylated CCM1	799:825	minimally glycosylated CCM1 in the GFCC'C″ dimer conformation	799:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	1	58	theme	cell	156:159	arg1	signaling					161:169	cell signaling	156:169	cell signaling	156:169	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35219398	6	59	theme	co-evolved	1132:1141	arg1	residues					1143:1150	co-evolved residues	1132:1150	co-evolved residues	1132:1150	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	4	60	theme	CCM1	616:619	arg1	C″					582:583	GFCC'C″	577:583	GFCC'C″	577:583	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	4	60	theme	CCM1	616:619	arg1	dimer					630:634	the dominant CCM1 solution dimer	603:634	the dominant CCM1 solution dimer	603:634	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	4	61	theme	dominant	607:614	arg1	C″					582:583	GFCC'C″	577:583	GFCC'C″	577:583	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	4	61	theme	dominant	607:614	arg1	dimer					630:634	the dominant CCM1 solution dimer	603:634	the dominant CCM1 solution dimer	603:634	GFCC'C″ was identified as the dominant CCM1 solution dimer, but ambiguity regarding the effect of glycosylation on dimer formation calls its physiological relevance into question.
35219398	5	62	theme	characterization	865:880	arg1	structure					786:794	the first crystal structure	768:794	the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	768:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	5	63	theme	C″	839:840	arg1	conformation					848:859	the GFCC'C″ dimer conformation	830:859	the GFCC'C″ dimer conformation	830:859	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	6	64	theme	C″	1027:1028	arg1	dominant					1039:1046	dominant	1039:1046	dominant	1039:1046	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	6	64	theme	C″	1027:1028	arg1	dimer					1030:1034	the GFCC'C″ dimer	1018:1034	the GFCC'C″ dimer	1018:1034	Our results suggest the GFCC'C″ dimer is dominant in solution with different levels of glycosylation, and structural conservation and co-evolved residues support that the GFCC'C″ dimer is conserved across CEACAMs.
35219398	5	65	theme	first	772:776	arg1	structure					786:794	the first crystal structure	768:794	the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy	768:995	We present the first crystal structure of minimally glycosylated CCM1 in the GFCC'C″ dimer conformation and characterization in solution by continuous-wave and double electron-electron resonance electron paramagnetic resonance spectroscopy.
35219398	0	66	theme	N-domain	14:21	arg1	dimerization					23:34	Human CEACAM1 N-domain dimerization	0:34	Human CEACAM1 N-domain dimerization	0:34	Human CEACAM1 N-domain dimerization is independent from glycan modifications.
35219398	2	67	theme	protein	354:360	arg1	function					362:369	protein function	354:369	protein function	354:369	The physiological oligomeric state and how it contributes to protein function are central to understanding CEACAMs.
35219398	1	68	theme	several	226:232	arg1	ectodomains					259:269	several immunoglobulin (Ig)-like ectodomains	226:269	several immunoglobulin (Ig)-like ectodomains glycosylated in vivo	226:290	Carcinoembryonic cellular adhesion molecules (CEACAMs) serve diverse roles in cell signaling, proliferation, and survival and are made up of one or several immunoglobulin (Ig)-like ectodomains glycosylated in vivo.
35863585	2	0	with	health	423:428	arg1	potential					439:447	the potential	435:447	the potential for a therapeutic effect on intestinal diseases	435:495	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	4	1	theme	PEC + LPS	878:886	arg1	group					888:892	PEC + LPS group	878:892	PEC + LPS group	878:892	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	1	theme	PEC + LPS	878:886	arg1	groups					829:834	three groups	823:834	three groups: control group, LPS-challenged group, and PEC + LPS group	823:892	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	3	2	theme	protective	546:555	arg1	effect					557:562	the protective effect	542:562	the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model	542:698	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	1	3	theme	intestinal	294:303	arg1	inflammation					305:316	intestinal inflammation	294:316	intestinal inflammation	294:316	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	0	4	theme	intestinal	95:104	arg1	microbiota					106:115	intestinal microbiota	95:115	intestinal microbiota	95:115	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	11	5	theme	Spearman	1684:1691	arg1	correlation					1698:1708	Spearman rank correlation	1684:1708	Spearman rank correlation analysis	1684:1717	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	10	6	theme	gut	1515:1517	arg1	microbiota					1519:1528	the gut microbiota	1511:1528	the gut microbiota	1511:1528	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	12	7	theme	intestinal	2084:2093	arg1	injury					2095:2100	intestinal injury	2084:2100	intestinal injury	2084:2100	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	0	8	theme	lipopolysaccharide-challenged	120:148	arg1	piglets					150:156	lipopolysaccharide-challenged piglets	120:156	lipopolysaccharide-challenged piglets	120:156	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	11	9	theme	rank	1693:1696	arg1	correlation					1698:1708	Spearman rank correlation	1684:1708	Spearman rank correlation analysis	1684:1717	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	7	10	theme	inflammation	1126:1137	arg1	response					1139:1146	the LPS-induced inflammation response	1110:1146	the LPS-induced inflammation response	1110:1146	Pectin supplementation ameliorated the LPS-induced inflammation response and damage to the ileal morphology.
35863585	4	11	theme	age	790:792	arg1	d					785:785	21 d	782:785	Duroc × Landrace × Large White; barrows; 21 d of age	741:792	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	12	12	theme	growth	2127:2132	arg1	performance					2134:2144	the growth performance	2123:2144	the growth performance of piglets	2123:2155	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	11	13	theme	intestinal	1846:1855	arg1	glycosylation					1857:1869	intestinal glycosylation	1846:1869	intestinal glycosylation	1846:1869	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	9	14	theme	LPS	1335:1337	arg1	challenge					1339:1347	LPS challenge	1335:1347	LPS challenge	1335:1347	LPS challenge reduced the diversity of intestinal microbiota and enriched the relative abundance of Helicobacter.
35863585	7	15	theme	ileal	1166:1170	arg1	morphology					1172:1181	the ileal morphology	1162:1181	the ileal morphology	1162:1181	Pectin supplementation ameliorated the LPS-induced inflammation response and damage to the ileal morphology.
35863585	5	16	theme	experiment	963:972	arg1	d21					952:954	d21	952:954	d21	952:954	Piglets were administrated with LPS or saline on d14 and d21 of the experiment.
35863585	5	16	theme	experiment	963:972	arg1	d14					944:946	d14	944:946	d14	944:946	Piglets were administrated with LPS or saline on d14 and d21 of the experiment.
35863585	10	17	dep	bacteria	1561:1568	arg1	bacteria					1616:1623	-producing bacteria	1605:1623	-producing bacteria	1605:1623	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	8	18	theme	mucus	1314:1318	arg1	glycosylation					1320:1332	intestinal mucus glycosylation	1303:1332	intestinal mucus glycosylation	1303:1332	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	4	19	theme	LPS-challenged	852:865	arg1	group					867:871	LPS-challenged group	852:871	LPS-challenged group	852:871	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	19	theme	LPS-challenged	852:865	arg1	groups					829:834	three groups	823:834	three groups: control group, LPS-challenged group, and PEC + LPS group	823:892	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	6	20	theme	h	1050:1050	arg1	administration					1052:1065	3 h administration	1048:1065	3 h administration	1048:1065	All piglets were slaughtered and intestinal samples were collected after 3 h administration on d21.
35863585	4	21	theme	piglets	715:721	arg1	total					703:707	A total	701:707	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age)	701:793	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	8	22	theme	mRNA	1265:1268	arg1	expression					1270:1279	the mRNA expression	1261:1279	the mRNA expression of MUC2	1261:1287	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	7	23	theme	LPS-induced	1114:1124	arg1	response					1139:1146	the LPS-induced inflammation response	1110:1146	the LPS-induced inflammation response	1110:1146	Pectin supplementation ameliorated the LPS-induced inflammation response and damage to the ileal morphology.
35863585	3	24	theme	intestinal	582:591	arg1	injury					593:598	intestinal injury	582:598	intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model	582:698	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	10	25	theme	-producing	1605:1614	arg1	bacteria					1616:1623	-producing bacteria	1605:1623	-producing bacteria	1605:1623	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	10	26	theme	acetate	1662:1668	arg1	concentrations					1644:1657	the concentrations	1640:1657	the concentrations of acetate	1640:1668	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	10	27	theme	alpha	1465:1469	arg1	diversity					1471:1479	alpha diversity	1465:1479	alpha diversity	1465:1479	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	11	28	theme	potential	1737:1745	arg1	relationship					1747:1758	the potential relationship	1733:1758	the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets	1733:1880	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	1	29	theme	severe	220:225	arg1	infections					235:244	severe enteric infections	220:244	severe enteric infections	220:244	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	0	30	theme	Pectin	0:5	arg1	supplementation					7:21	Pectin supplementation	0:21	Pectin supplementation	0:21	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	1	31	theme	impaired	323:330	arg1	function					351:358	impaired intestinal barrier function	323:358	impaired intestinal barrier function	323:358	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	11	32	theme	intestinal	1794:1803	arg1	morphology					1805:1814	intestinal morphology	1794:1814	intestinal morphology	1794:1814	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	4	33	dep	White	766:770	arg1	barrows					773:779	barrows	773:779	Duroc × Landrace × Large White; barrows; 21 d of age	741:792	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	33	dep	White	766:770	arg1	d					785:785	21 d	782:785	Duroc × Landrace × Large White; barrows; 21 d of age	741:792	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	8	34	theme	MUC2	1284:1287	arg1	expression					1270:1279	the mRNA expression	1261:1279	the mRNA expression of MUC2	1261:1287	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	1	35	theme	enteric	227:233	arg1	infections					235:244	severe enteric infections	220:244	severe enteric infections	220:244	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	0	36	theme	intestinal	35:44	arg1	damage					74:79	intestinal epithelial barrier function damage	35:79	intestinal epithelial barrier function damage	35:79	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	1	37	theme	intestinal	332:341	arg1	function					351:358	impaired intestinal barrier function	323:358	impaired intestinal barrier function	323:358	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	12	38	theme	barrier	1968:1974	arg1	function					1976:1983	barrier function	1968:1983	barrier function	1968:1983	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	4	39	theme	control	837:843	arg1	groups					829:834	three groups	823:834	three groups: control group, LPS-challenged group, and PEC + LPS group	823:892	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	39	theme	control	837:843	arg1	group					845:849	control group	837:849	control group	837:849	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	8	40	theme	mucin	1227:1231	arg1	function					1241:1248	intestinal mucin barrier function	1216:1248	intestinal mucin barrier function	1216:1248	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	8	41	theme	intestinal	1216:1225	arg1	function					1241:1248	intestinal mucin barrier function	1216:1248	intestinal mucin barrier function	1216:1248	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	1	42	theme	barrier	343:349	arg1	function					351:358	impaired intestinal barrier function	323:358	impaired intestinal barrier function	323:358	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	7	43	theme	Pectin	1075:1080	arg1	supplementation					1082:1096	Pectin supplementation	1075:1096	Pectin supplementation	1075:1096	Pectin supplementation ameliorated the LPS-induced inflammation response and damage to the ileal morphology.
35863585	11	44	theme	intestinal	1768:1777	arg1	microbiota					1779:1788	intestinal microbiota	1768:1788	intestinal microbiota	1768:1788	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	3	45	theme	intraperitoneal	611:625	arg1	injection					627:635	intraperitoneal injection	611:635	intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS)	611:680	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	2	46	theme	therapeutic	455:465	arg1	effect					467:472	a therapeutic effect	453:472	a therapeutic effect on intestinal diseases	453:495	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	0	47	theme	barrier	57:63	arg1	damage					74:79	intestinal epithelial barrier function damage	35:79	intestinal epithelial barrier function damage	35:79	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	9	48	theme	microbiota	1385:1394	arg1	diversity					1361:1369	the diversity	1357:1369	the diversity of intestinal microbiota	1357:1394	LPS challenge reduced the diversity of intestinal microbiota and enriched the relative abundance of Helicobacter.
35863585	3	49	theme	lipopolysaccharide	657:674	arg1	injection					627:635	intraperitoneal injection	611:635	intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS)	611:680	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	6	50	theme	3	1048:1048	arg1	h					1050:1050	h	1050:1050	h	1050:1050	All piglets were slaughtered and intestinal samples were collected after 3 h administration on d21.
35863585	0	51	theme	epithelial	46:55	arg1	damage					74:79	intestinal epithelial barrier function damage	35:79	intestinal epithelial barrier function damage	35:79	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	12	52	theme	intestinal	1997:2006	arg1	composition					2019:2029	intestinal microbiota composition	1997:2029	intestinal microbiota composition	1997:2029	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	8	53	theme	barrier	1233:1239	arg1	function					1241:1248	intestinal mucin barrier function	1216:1248	intestinal mucin barrier function	1216:1248	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	3	54	theme	piglet	687:692	arg1	model					694:698	a piglet model	685:698	a piglet model	685:698	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	2	55	theme	intestinal	477:486	arg1	diseases					488:495	intestinal diseases	477:495	intestinal diseases	477:495	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	3	56	theme	21-d	502:505	arg1	study					507:511	One 21-d study	498:511	One 21-d study	498:511	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	12	57	theme	microbiota	2008:2017	arg1	composition					2019:2029	intestinal microbiota composition	1997:2029	intestinal microbiota composition	1997:2029	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	11	58	from	relationship	1747:1758	arg1	piglets					1874:1880	piglets	1874:1880	piglets	1874:1880	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	3	59	theme	Escherichia	640:650	arg1	lipopolysaccharide					657:674	Escherichia coli lipopolysaccharide	640:674	Escherichia coli lipopolysaccharide (LPS)	640:680	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	3	59	theme	Escherichia	640:650	arg1	LPS					677:679	LPS	677:679	LPS	677:679	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	11	60	theme	intestinal	1817:1826	arg1	inflammation					1828:1839	intestinal inflammation	1817:1839	intestinal inflammation	1817:1839	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	2	61	theme	prebiotic	377:385	arg1	Pectin					361:366	Pectin	361:366	Pectin (PEC)	361:372	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	2	61	theme	prebiotic	377:385	arg1	polysaccharide					387:400	a prebiotic polysaccharide	375:400	a prebiotic polysaccharide	375:400	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	0	62	theme	function	65:72	arg1	damage					74:79	intestinal epithelial barrier function damage	35:79	intestinal epithelial barrier function damage	35:79	Pectin supplementation ameliorates intestinal epithelial barrier function damage by modulating intestinal microbiota in lipopolysaccharide-challenged piglets.
35863585	10	63	theme	fatty	1586:1590	arg1	SCFAs					1599:1603	SCFAs	1599:1603	SCFAs	1599:1603	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	10	63	theme	fatty	1586:1590	arg1	acids					1592:1596	short-chain fatty acids	1574:1596	short-chain fatty acids (SCFAs)	1574:1604	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	3	64	theme	coli	652:655	arg1	lipopolysaccharide					657:674	Escherichia coli lipopolysaccharide	640:674	Escherichia coli lipopolysaccharide (LPS)	640:680	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	3	64	theme	coli	652:655	arg1	LPS					677:679	LPS	677:679	LPS	677:679	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	8	65	theme	intestinal	1303:1312	arg1	glycosylation					1320:1332	intestinal mucus glycosylation	1303:1332	intestinal mucus glycosylation	1303:1332	Meanwhile, pectin also improved intestinal mucin barrier function, increased the mRNA expression of MUC2, and improved intestinal mucus glycosylation.
35863585	9	66	theme	relative	1413:1420	arg1	abundance					1422:1430	the relative abundance	1409:1430	the relative abundance of Helicobacter	1409:1446	LPS challenge reduced the diversity of intestinal microbiota and enriched the relative abundance of Helicobacter.
35863585	10	67	theme	short-chain	1574:1584	arg1	SCFAs					1599:1603	SCFAs	1599:1603	SCFAs	1599:1603	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	10	67	theme	short-chain	1574:1584	arg1	acids					1592:1596	short-chain fatty acids	1574:1596	short-chain fatty acids (SCFAs)	1574:1604	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	4	68	dep	piglets	715:721	arg1	BW					737:738	6.77±0.92 kg BW	724:738	6.77±0.92 kg BW	724:738	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	9	69	theme	intestinal	1374:1383	arg1	microbiota					1385:1394	intestinal microbiota	1374:1394	intestinal microbiota	1374:1394	LPS challenge reduced the diversity of intestinal microbiota and enriched the relative abundance of Helicobacter.
35863585	1	70	theme	intestinal	261:270	arg1	dysbiosis					283:291	intestinal microbiota dysbiosis	261:291	intestinal microbiota dysbiosis	261:291	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	12	71	theme	intestinal	1943:1952	arg1	integrity					1954:1962	intestinal integrity	1943:1962	intestinal integrity	1943:1962	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	4	72	dep	BW	737:738	arg1	White					766:770	White	766:770	White	766:770	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	10	73	theme	microbiota	1519:1528	arg1	structure					1498:1506	the structure	1494:1506	the structure of the gut microbiota	1494:1528	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	3	74	theme	pectin	567:572	arg1	effect					557:562	the protective effect	542:562	the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model	542:698	One 21-d study was conducted to investigate the protective effect of pectin against intestinal injury induced by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS) in a piglet model.
35863585	1	75	theme	microbiota	272:281	arg1	dysbiosis					283:291	intestinal microbiota dysbiosis	261:291	intestinal microbiota dysbiosis	261:291	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	10	76	theme	anti-inflammatory	1543:1559	arg1	bacteria					1561:1568	anti-inflammatory bacteria	1543:1568	anti-inflammatory bacteria	1543:1568	Pectin restored alpha diversity and improved the structure of the gut microbiota by enriching anti-inflammatory bacteria and short-chain fatty acids (SCFAs)-producing bacteria, and increased the concentrations of acetate.
35863585	4	77	dep	groups	829:834	arg1	group					867:871	LPS-challenged group	852:871	LPS-challenged group	852:871	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	77	dep	groups	829:834	arg1	group					888:892	PEC + LPS group	878:892	PEC + LPS group	878:892	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	77	dep	groups	829:834	arg1	groups					829:834	three groups	823:834	three groups: control group, LPS-challenged group, and PEC + LPS group	823:892	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	4	77	dep	groups	829:834	arg1	group					845:849	control group	837:849	control group	837:849	A total of 24 piglets (6.77±0.92 kg BW; Duroc × Landrace × Large White; barrows; 21 d of age) were randomly assigned into three groups: control group, LPS-challenged group, and PEC + LPS group.
35863585	2	78	theme	intestinal	412:421	arg1	health					423:428	intestinal health	412:428	intestinal health with the potential for a therapeutic effect on intestinal diseases	412:495	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	9	79	theme	Helicobacter	1435:1446	arg1	abundance					1422:1430	the relative abundance	1409:1430	the relative abundance of Helicobacter	1409:1446	LPS challenge reduced the diversity of intestinal microbiota and enriched the relative abundance of Helicobacter.
35863585	12	80	theme	piglets	2149:2155	arg1	performance					2134:2144	the growth performance	2123:2144	the growth performance of piglets	2123:2155	Taken together, these results indicate that pectin enhances intestinal integrity and barrier function by altering intestinal microbiota composition and their metabolites, which subsequently alleviates intestinal injury and finally improves the growth performance of piglets.
35863585	11	81	theme	correlation	1698:1708	arg1	analysis					1710:1717	Spearman rank correlation analysis	1684:1717	Spearman rank correlation analysis	1684:1717	In addition, Spearman rank correlation analysis also revealed the potential relationship between intestinal microbiota and intestinal morphology, intestinal inflammation, and intestinal glycosylation in piglets.
35863585	2	82	from	effect	467:472	arg1	diseases					488:495	intestinal diseases	477:495	intestinal diseases	477:495	Pectin (PEC), a prebiotic polysaccharide, enhances intestinal health with the potential for a therapeutic effect on intestinal diseases.
35863585	1	83	theme	young	187:191	arg1	animals					193:199	young animals	187:199	young animals	187:199	During weaning, infants and young animals are susceptible to severe enteric infections, thus inducing intestinal microbiota dysbiosis, intestinal inflammation, and impaired intestinal barrier function.
35863585	6	84	theme	intestinal	1008:1017	arg1	samples					1019:1025	intestinal samples	1008:1025	intestinal samples	1008:1025	All piglets were slaughtered and intestinal samples were collected after 3 h administration on d21.
35506863	9	0	theme	aligned	1003:1009	arg1	hydrogel					1020:1027	aligned collagen hydrogel	1003:1027	aligned collagen hydrogel	1003:1027	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	14	1	theme	complex	1498:1504	arg1	glycans					1506:1512	complex glycans	1498:1512	complex glycans	1498:1512	In particular, loss of complex glycans in rat spinal cord may contribute to regeneration failure.
35506863	5	2	theme	regenerative	559:570	arg1	failure					572:578	regenerative failure	559:578	regenerative failure	559:578	The response compared regenerative success, regenerative failure, and treatment in an established nonregenerative mammalian system.
35506863	12	3	theme	large	1330:1334	arg1	increase					1336:1343	A large increase	1328:1343	A large increase in sialic acid	1328:1358	A large increase in sialic acid was observed in nonregenerative animals.
35506863	6	4	theme	rat	660:662	arg1	cord					671:674	a healthy rat spinal cord	650:674	a healthy rat spinal cord	650:674	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	0	5	theme	Nonregenerative	75:89	arg1	Models					91:96	Regenerative and Nonregenerative Models	58:96	Regenerative and Nonregenerative Models	58:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	5	6	theme	mammalian	629:637	arg1	system					639:644	an established nonregenerative mammalian system	598:644	an established nonregenerative mammalian system	598:644	The response compared regenerative success, regenerative failure, and treatment in an established nonregenerative mammalian system.
35506863	11	7	theme	necessary	1281:1289	arg1	foundation					1291:1300	a necessary foundation	1279:1300	a necessary foundation for additional branching	1279:1325	The addition of GlcNAc is required for processing complex-type glycans and is a necessary foundation for additional branching.
35506863	6	8	theme	healthy	652:658	arg1	cord					671:674	a healthy rat spinal cord	650:674	a healthy rat spinal cord	650:674	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	15	9	theme	glycosylation	1587:1599	arg1	response					1601:1608	the glycosylation response	1583:1608	the glycosylation response	1583:1608	Targeting the glycosylation response may be a promising strategy for future therapies.
35506863	10	10	from	levels	1134:1139	arg1	animals					1192:1198	premetamorphic animals	1177:1198	premetamorphic animals	1177:1198	In Xenopus, lectin histochemistry revealed increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals.
35506863	7	11	theme	oligomannose	873:884	arg1	structures					897:906	oligomannose and hybrid structures	873:906	structures	897:906	Following rat SCI, complex and outer-arm fucosylated glycans decreased while oligomannose and hybrid structures increased.
35506863	2	12	theme	regeneration	276:287	arg1	occurrence					262:271	the occurrence	258:271	the occurrence of regeneration	258:287	We hypothesize that glycosylation has a role in determining the occurrence of regeneration and that biomaterial treatment can influence this glycosylation response.
35506863	14	13	from	loss	1490:1493	arg1	cord					1528:1531	rat spinal cord	1517:1531	rat spinal cord	1517:1531	In particular, loss of complex glycans in rat spinal cord may contribute to regeneration failure.
35506863	6	14	theme	oligomannose	772:783	arg1	N-glycans					785:793	oligomannose N-glycans	772:793	oligomannose N-glycans	772:793	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	4	15	theme	aligned	488:494	arg1	hydrogel					505:512	an aligned collagen hydrogel	485:512	an aligned collagen hydrogel	485:512	Transected rats received an aligned collagen hydrogel.
35506863	0	16	from	Injury	48:53	arg1	Models					91:96	Regenerative and Nonregenerative Models	58:96	Regenerative and Nonregenerative Models	58:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	14	17	theme	regeneration	1551:1562	arg1	failure					1564:1570	regeneration failure	1551:1570	regeneration failure	1551:1570	In particular, loss of complex glycans in rat spinal cord may contribute to regeneration failure.
35506863	1	18	theme	tissue	159:164	arg1	integrity					166:174	tissue integrity	159:174	tissue integrity	159:174	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	9	19	theme	minimal	1035:1041	arg1	effect					1043:1048	a minimal effect	1033:1048	a minimal effect	1033:1048	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	3	20	from	response	397:404	arg1	rat					455:457	rat	455:457	rat	455:457	We investigated the glycosylation response to spinal cord transection in Xenopus laevis and rat.
35506863	3	20	from	response	397:404	arg1	laevis					444:449	Xenopus laevis	436:449	Xenopus laevis	436:449	We investigated the glycosylation response to spinal cord transection in Xenopus laevis and rat.
35506863	12	21	located	observed	1364:1371	arg2	increase					1336:1343	A large increase	1328:1343	A large increase in sialic acid	1328:1358	A large increase in sialic acid was observed in nonregenerative animals.
35506863	12	21	located	observed	1364:1371	arg1	animals					1392:1398	nonregenerative animals	1376:1398	nonregenerative animals	1376:1398	A large increase in sialic acid was observed in nonregenerative animals.
35506863	13	22	theme	regenerative	1453:1464	arg1	success					1466:1472	regenerative success	1453:1472	regenerative success	1453:1472	This work suggests that glycosylation may influence regenerative success.
35506863	9	23	theme	glycosylation	1057:1069	arg1	response					1071:1078	the glycosylation response	1053:1078	the glycosylation response	1053:1078	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	1	24	theme	integrity	166:174	arg1	loss					180:183	loss	180:183	loss of function	180:195	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	1	24	theme	integrity	166:174	arg1	disruption					145:154	disruption	145:154	disruption of tissue integrity	145:174	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	0	25	theme	Glycosylation	9:21	arg1	Responses					23:31	Distinct Glycosylation Responses	0:31	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models	0:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	4	26	theme	collagen	496:503	arg1	hydrogel					505:512	an aligned collagen hydrogel	485:512	an aligned collagen hydrogel	485:512	Transected rats received an aligned collagen hydrogel.
35506863	3	27	theme	Xenopus	436:442	arg1	laevis					444:449	Xenopus laevis	436:449	Xenopus laevis	436:449	We investigated the glycosylation response to spinal cord transection in Xenopus laevis and rat.
35506863	0	28	theme	Distinct	0:7	arg1	Responses					23:31	Distinct Glycosylation Responses	0:31	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models	0:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	5	29	theme	established	601:611	arg1	system					639:644	an established nonregenerative mammalian system	598:644	an established nonregenerative mammalian system	598:644	The response compared regenerative success, regenerative failure, and treatment in an established nonregenerative mammalian system.
35506863	1	30	theme	Traumatic	99:107	arg1	SCI					129:131	SCI	129:131	SCI	129:131	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	1	30	theme	Traumatic	99:107	arg1	injury					121:126	Traumatic spinal cord injury	99:126	Traumatic spinal cord injury (SCI)	99:132	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	5	31	theme	nonregenerative	613:627	arg1	system					639:644	an established nonregenerative mammalian system	598:644	an established nonregenerative mammalian system	598:644	The response compared regenerative success, regenerative failure, and treatment in an established nonregenerative mammalian system.
35506863	1	32	theme	spinal	109:114	arg1	SCI					129:131	SCI	129:131	SCI	129:131	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	1	32	theme	spinal	109:114	arg1	injury					121:126	Traumatic spinal cord injury	99:126	Traumatic spinal cord injury (SCI)	99:132	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	7	33	theme	hybrid	890:895	arg1	structures					897:906	oligomannose and hybrid structures	873:906	structures	897:906	Following rat SCI, complex and outer-arm fucosylated glycans decreased while oligomannose and hybrid structures increased.
35506863	2	34	theme	biomaterial	298:308	arg1	treatment					310:318	biomaterial treatment	298:318	biomaterial treatment	298:318	We hypothesize that glycosylation has a role in determining the occurrence of regeneration and that biomaterial treatment can influence this glycosylation response.
35506863	7	35	theme	outer-arm	827:835	arg1	glycans					849:855	complex and outer-arm fucosylated glycans	815:855	complex and outer-arm fucosylated glycans	815:855	Following rat SCI, complex and outer-arm fucosylated glycans decreased while oligomannose and hybrid structures increased.
35506863	14	36	theme	rat	1517:1519	arg1	cord					1528:1531	rat spinal cord	1517:1531	rat spinal cord	1517:1531	In particular, loss of complex glycans in rat spinal cord may contribute to regeneration failure.
35506863	4	37	theme	Transected	460:469	arg1	rats					471:474	Transected rats	460:474	Transected rats	460:474	Transected rats received an aligned collagen hydrogel.
35506863	1	38	theme	cord	116:119	arg1	SCI					129:131	SCI	129:131	SCI	129:131	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	1	38	theme	cord	116:119	arg1	injury					121:126	Traumatic spinal cord injury	99:126	Traumatic spinal cord injury (SCI)	99:132	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	14	39	theme	spinal	1521:1526	arg1	cord					1528:1531	rat spinal cord	1517:1531	rat spinal cord	1517:1531	In particular, loss of complex glycans in rat spinal cord may contribute to regeneration failure.
35506863	1	40	theme	function	188:195	arg1	loss					180:183	loss	180:183	loss of function	180:195	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	1	40	theme	function	188:195	arg1	disruption					145:154	disruption	145:154	disruption of tissue integrity	145:174	Traumatic spinal cord injury (SCI) results in disruption of tissue integrity and loss of function.
35506863	0	41	theme	Cord	43:46	arg1	Injury					48:53	Spinal Cord Injury	36:53	Spinal Cord Injury in Regenerative and Nonregenerative Models	36:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	7	42	theme	fucosylated	837:847	arg1	glycans					849:855	complex and outer-arm fucosylated glycans	815:855	complex and outer-arm fucosylated glycans	815:855	Following rat SCI, complex and outer-arm fucosylated glycans decreased while oligomannose and hybrid structures increased.
35506863	8	43	theme	Sialic	919:924	arg1	acid					926:929	Sialic acid	919:929	Sialic acid	919:929	Sialic acid was associated with microglia/macrophages following SCI.
35506863	11	44	theme	GlcNAc	1217:1222	arg1	addition					1205:1212	The addition	1201:1212	The addition of GlcNAc	1201:1222	The addition of GlcNAc is required for processing complex-type glycans and is a necessary foundation for additional branching.
35506863	6	45	theme	chromatography	701:714	arg1	N-glycoprofiling					723:738	ultraperformance liquid chromatography (UPLC) N-glycoprofiling	677:738	ultraperformance liquid chromatography (UPLC) N-glycoprofiling	677:738	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	12	46	theme	nonregenerative	1376:1390	arg1	animals					1392:1398	nonregenerative animals	1376:1398	nonregenerative animals	1376:1398	A large increase in sialic acid was observed in nonregenerative animals.
35506863	0	47	theme	Spinal	36:41	arg1	Injury					48:53	Spinal Cord Injury	36:53	Spinal Cord Injury in Regenerative and Nonregenerative Models	36:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	7	48	theme	complex	815:821	arg1	glycans					849:855	complex and outer-arm fucosylated glycans	815:855	complex and outer-arm fucosylated glycans	815:855	Following rat SCI, complex and outer-arm fucosylated glycans decreased while oligomannose and hybrid structures increased.
35506863	10	49	theme	lectin	1093:1098	arg1	histochemistry					1100:1113	lectin histochemistry	1093:1113	lectin histochemistry	1093:1113	In Xenopus, lectin histochemistry revealed increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals.
35506863	3	50	theme	spinal	409:414	arg1	transection					421:431	spinal cord transection	409:431	spinal cord transection	409:431	We investigated the glycosylation response to spinal cord transection in Xenopus laevis and rat.
35506863	10	51	theme	premetamorphic	1177:1190	arg1	animals					1192:1198	premetamorphic animals	1177:1198	premetamorphic animals	1177:1198	In Xenopus, lectin histochemistry revealed increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals.
35506863	14	52	theme	glycans	1506:1512	arg1	loss					1490:1493	loss	1490:1493	loss of complex glycans in rat spinal cord	1490:1531	In particular, loss of complex glycans in rat spinal cord may contribute to regeneration failure.
35506863	9	53	theme	collagen	1011:1018	arg1	hydrogel					1020:1027	aligned collagen hydrogel	1003:1027	aligned collagen hydrogel	1003:1027	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	2	54	theme	glycosylation	339:351	arg1	response					353:360	this glycosylation response	334:360	this glycosylation response	334:360	We hypothesize that glycosylation has a role in determining the occurrence of regeneration and that biomaterial treatment can influence this glycosylation response.
35506863	3	55	theme	cord	416:419	arg1	transection					421:431	spinal cord transection	409:431	spinal cord transection	409:431	We investigated the glycosylation response to spinal cord transection in Xenopus laevis and rat.
35506863	10	56	theme	N-acetyl-glucosamine	1144:1163	arg1	levels					1134:1139	increased levels	1124:1139	increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals	1124:1198	In Xenopus, lectin histochemistry revealed increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals.
35506863	6	57	theme	liquid	694:699	arg1	UPLC					717:720	UPLC	717:720	UPLC	717:720	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	6	57	theme	liquid	694:699	arg1	chromatography					701:714	ultraperformance liquid chromatography	677:714	ultraperformance liquid chromatography (UPLC) N-glycoprofiling	677:738	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	15	58	theme	future	1642:1647	arg1	therapies					1649:1657	future therapies	1642:1657	future therapies	1642:1657	Targeting the glycosylation response may be a promising strategy for future therapies.
35506863	11	59	theme	processing	1240:1249	arg1	glycans					1264:1270	processing complex-type glycans	1240:1270	processing complex-type glycans	1240:1270	The addition of GlcNAc is required for processing complex-type glycans and is a necessary foundation for additional branching.
35506863	12	60	from	increase	1336:1343	arg1	acid					1355:1358	sialic acid	1348:1358	sialic acid	1348:1358	A large increase in sialic acid was observed in nonregenerative animals.
35506863	6	61	theme	ultraperformance	677:692	arg1	UPLC					717:720	UPLC	717:720	UPLC	717:720	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	6	61	theme	ultraperformance	677:692	arg1	chromatography					701:714	ultraperformance liquid chromatography	677:714	ultraperformance liquid chromatography (UPLC) N-glycoprofiling	677:738	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	9	62	contain	had	1029:1031	arg2	effect					1043:1048	a minimal effect	1033:1048	a minimal effect	1033:1048	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	9	62	contain	had	1029:1031	arg1	Treatment					988:996	Treatment	988:996	Treatment with aligned collagen hydrogel	988:1027	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	15	63	theme	promising	1619:1627	arg1	strategy					1629:1636	a promising strategy	1617:1636	a promising strategy for future therapies	1617:1657	Targeting the glycosylation response may be a promising strategy for future therapies.
35506863	11	64	theme	complex-type	1251:1262	arg1	glycans					1264:1270	processing complex-type glycans	1240:1270	processing complex-type glycans	1240:1270	The addition of GlcNAc is required for processing complex-type glycans and is a necessary foundation for additional branching.
35506863	5	65	theme	regenerative	537:548	arg1	success					550:556	regenerative success	537:556	regenerative success	537:556	The response compared regenerative success, regenerative failure, and treatment in an established nonregenerative mammalian system.
35506863	12	66	theme	sialic	1348:1353	arg1	acid					1355:1358	sialic acid	1348:1358	sialic acid	1348:1358	A large increase in sialic acid was observed in nonregenerative animals.
35506863	11	67	theme	additional	1306:1315	arg1	branching					1317:1325	additional branching	1306:1325	additional branching	1306:1325	The addition of GlcNAc is required for processing complex-type glycans and is a necessary foundation for additional branching.
35506863	10	68	theme	increased	1124:1132	arg1	levels					1134:1139	increased levels	1124:1139	increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals	1124:1198	In Xenopus, lectin histochemistry revealed increased levels of N-acetyl-glucosamine (GlcNAc) in premetamorphic animals.
35506863	9	69	with	Treatment	988:996	arg1	hydrogel					1020:1027	aligned collagen hydrogel	1003:1027	aligned collagen hydrogel	1003:1027	Treatment with aligned collagen hydrogel had a minimal effect on the glycosylation response.
35506863	0	70	theme	Regenerative	58:69	arg1	Models					91:96	Regenerative and Nonregenerative Models	58:96	Regenerative and Nonregenerative Models	58:96	Distinct Glycosylation Responses to Spinal Cord Injury in Regenerative and Nonregenerative Models.
35506863	3	71	theme	glycosylation	383:395	arg1	response					397:404	the glycosylation response	379:404	the glycosylation response to spinal cord transection in Xenopus laevis and rat	379:457	We investigated the glycosylation response to spinal cord transection in Xenopus laevis and rat.
35506863	7	72	gly	fucosylated	837:847	arg1	glycans					849:855	complex and outer-arm fucosylated glycans	815:855	complex and outer-arm fucosylated glycans	815:855	Following rat SCI, complex and outer-arm fucosylated glycans decreased while oligomannose and hybrid structures increased.
35506863	6	73	theme	spinal	664:669	arg1	cord					671:674	a healthy rat spinal cord	650:674	a healthy rat spinal cord	650:674	In a healthy rat spinal cord, ultraperformance liquid chromatography (UPLC) N-glycoprofiling identified complex, hybrid, and oligomannose N-glycans.
35506863	2	74	contain	has	232:234	arg1	glycosylation					218:230	glycosylation	218:230	glycosylation	218:230	We hypothesize that glycosylation has a role in determining the occurrence of regeneration and that biomaterial treatment can influence this glycosylation response.
35506863	2	74	contain	has	232:234	arg2	role					238:241	a role	236:241	a role	236:241	We hypothesize that glycosylation has a role in determining the occurrence of regeneration and that biomaterial treatment can influence this glycosylation response.
36056620	6	0	theme	viral	1244:1248	arg1	sensitivity					1250:1260	viral sensitivity	1244:1260	viral sensitivity to nAb	1244:1267	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	9	1	theme	flexible	1618:1625	arg1	proteins					1636:1643	the structurally flexible envelope proteins	1601:1643	the structurally flexible envelope proteins	1601:1643	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	6	2	from	positions	1071:1079	arg1	N1					1100:1101	the N1	1096:1101	the N1	1096:1101	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	6	2	from	positions	1071:1079	arg1	motifs					1124:1129	N6 glycosylation motifs	1107:1129	N6 glycosylation motifs	1107:1129	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	2	3	theme	proteins	284:291	arg1	mechanism					302:310	a key mechanism	296:310	a key mechanism for such evasion	296:327	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	2	3	theme	proteins	284:291	arg1	glycosylation					252:264	N-linked glycosylation	243:264	N-linked glycosylation of viral envelope proteins	243:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	6	4	theme	adjacent	1146:1153	arg1	areas					1158:1162	adjacent E2 areas	1146:1162	adjacent E2 areas	1146:1162	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	6	5	theme	state	1222:1226	arg1	changes					1186:1192	changes	1186:1192	changes of the E1/E2 conformational state	1186:1226	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	2	6	theme	viral	269:273	arg1	proteins					284:291	viral envelope proteins	269:291	viral envelope proteins	269:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	4	7	theme	infected	621:628	arg1	patients					630:637	chronically infected patients	609:637	chronically infected patients without selective pressure by nAb in cell culture	609:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	6	8	theme	E1/E2	1201:1205	arg1	state					1222:1226	the E1/E2 conformational state	1197:1226	the E1/E2 conformational state	1197:1226	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	8	9	dep	CONCLUSIONS	1332:1342	arg1	show					1347:1350	show	1347:1350	show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy	1347:1472	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	1	10	theme	HCV	98:100	arg1	evasion					102:108	BACKGROUND AND AIMS HCV evasion	78:108	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb)	78:141	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	5	11	from	infection	985:993	arg1	protection					961:970	protection	961:970	protection from chronic infection	961:993	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	5	12	theme	polyclonal	793:802	arg1	viruses					826:832	polyclonal cell culture-passaged viruses	793:832	polyclonal cell culture-passaged viruses	793:832	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	1	13	theme	antibodies	126:135	arg1	evasion					102:108	BACKGROUND AND AIMS HCV evasion	78:108	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb)	78:141	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	8	14	theme	HCV	1418:1420	arg1	sensitivity					1422:1432	HCV sensitivity	1418:1432	HCV sensitivity to nAb	1418:1439	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	10	15	theme	cell	1765:1768	arg1	recombinants					1793:1804	highly fit cell culture infectious HCV recombinants	1754:1804	highly fit cell culture infectious HCV recombinants	1754:1804	Finally, this work resulted in a panel of highly fit cell culture infectious HCV recombinants.
36056620	5	16	theme	culture-passaged	809:824	arg1	viruses					826:832	polyclonal cell culture-passaged viruses	793:832	polyclonal cell culture-passaged viruses	793:832	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	9	17	theme	neutralizing	1689:1700	arg1	epitopes					1702:1709	important neutralizing epitopes	1679:1709	important neutralizing epitopes	1679:1709	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	6	18	theme	changes	1186:1192	arg1	532					1089:1091	532	1089:1091	532	1089:1091	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	6	18	theme	changes	1186:1192	arg1	regulators					1172:1181	key regulators	1168:1181	key regulators	1168:1181	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	6	18	theme	changes	1186:1192	arg1	positions					1071:1079	positions 418 and 532	1071:1091	positions	1071:1079	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	5	19	theme	conserved	883:891	arg1	epitopes					906:913	conserved neutralizing epitopes	883:913	conserved neutralizing epitopes	883:913	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	7	20	theme	occupancy	1321:1329	arg1	independent					1289:1299	independent	1289:1299	independent	1289:1299	These effects were independent of predicted glycan occupancy.
36056620	4	21	theme	cell	676:679	arg1	culture					681:687	cell culture	676:687	cell culture	676:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	10	22	theme	recombinants	1793:1804	arg1	panel					1745:1749	a panel	1743:1749	a panel of highly fit cell culture infectious HCV recombinants	1743:1804	Finally, this work resulted in a panel of highly fit cell culture infectious HCV recombinants.
36056620	5	23	theme	epitopes	906:913	arg1	exposure					871:878	exposure	871:878	exposure	871:878	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	5	23	theme	epitopes	906:913	arg1	fitness					859:865	highly increased fitness	842:865	highly increased fitness	842:865	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	6	24	theme	Further	996:1002	arg1	studies					1020:1026	Further reverse genetic studies	996:1026	Further reverse genetic studies of acquired E1/E2 substitutions	996:1058	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	7	25	theme	predicted	1304:1312	arg1	occupancy					1321:1329	predicted glycan occupancy	1304:1329	predicted glycan occupancy	1304:1329	These effects were independent of predicted glycan occupancy.
36056620	5	26	dep	regions	928:934	arg1	4					942:942	4	942:942	4	942:942	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	5	26	dep	regions	928:934	arg1	3					936:936	3	936:936	3	936:936	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	5	27	theme	original	708:715	arg1	viruses					717:723	the original viruses	704:723	the original viruses	704:723	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	10	28	theme	infectious	1778:1787	arg1	recombinants					1793:1804	highly fit cell culture infectious HCV recombinants	1754:1804	highly fit cell culture infectious HCV recombinants	1754:1804	Finally, this work resulted in a panel of highly fit cell culture infectious HCV recombinants.
36056620	8	29	link	N-linked	1356:1363	arg1	motifs					1379:1384	N-linked glycosylation motifs	1356:1384	N-linked glycosylation motifs	1356:1384	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	8	30	theme	occupancy	1464:1472	arg1	independent					1442:1452	independent	1442:1452	independent	1442:1452	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	2	31	link	N-linked	243:250	arg1	mechanism					302:310	a key mechanism	296:310	a key mechanism for such evasion	296:327	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	2	31	link	N-linked	243:250	arg1	glycosylation					252:264	N-linked glycosylation	243:264	N-linked glycosylation of viral envelope proteins	243:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	1	32	theme	viral	154:158	arg1	persistence					160:170	viral persistence	154:170	viral persistence	154:170	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	3	33	theme	vaccine	353:359	arg1	design					361:366	rational vaccine design	344:366	rational vaccine design	344:366	To facilitate rational vaccine design, we aimed to identify determinants of protection of conserved neutralizing epitopes.
36056620	9	34	theme	HCV	1518:1520	arg1	evasion					1526:1532	HCV nAb evasion	1518:1532	HCV nAb evasion	1518:1532	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	3	35	theme	neutralizing	430:441	arg1	epitopes					443:450	conserved neutralizing epitopes	420:450	conserved neutralizing epitopes	420:450	To facilitate rational vaccine design, we aimed to identify determinants of protection of conserved neutralizing epitopes.
36056620	9	36	theme	evasion	1526:1532	arg1	design					1555:1560	rational vaccine design	1538:1560	rational vaccine design	1538:1560	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	9	36	theme	evasion	1526:1532	arg1	understanding					1501:1513	the understanding	1497:1513	the understanding of HCV nAb evasion	1497:1532	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	4	37	theme	reverse	482:488	arg1	approach					503:510	a reverse evolutionary approach	480:510	a reverse evolutionary approach	480:510	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	5	38	theme	antigenic	918:926	arg1	regions					928:934	antigenic regions 3 and 4	918:942	antigenic regions 3 and 4	918:942	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	6	39	theme	E1/E2	1040:1044	arg1	substitutions					1046:1058	acquired E1/E2 substitutions	1031:1058	acquired E1/E2 substitutions	1031:1058	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	10	40	theme	HCV	1789:1791	arg1	recombinants					1793:1804	highly fit cell culture infectious HCV recombinants	1754:1804	highly fit cell culture infectious HCV recombinants	1754:1804	Finally, this work resulted in a panel of highly fit cell culture infectious HCV recombinants.
36056620	0	41	theme	novel	18:22	arg1	determinants					37:48	novel neutralizing determinants	18:48	novel neutralizing determinants for protection against HCV	18:75	Identification of novel neutralizing determinants for protection against HCV.
36056620	4	42	with	2a	542:543	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	42	with	2a	542:543	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	42	with	2a	542:543	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	8	43	theme	glycosylation	1365:1377	arg1	motifs					1379:1384	N-linked glycosylation motifs	1356:1384	N-linked glycosylation motifs	1356:1384	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	0	44	theme	determinants	37:48	arg1	Identification					0:13	Identification	0:13	Identification of novel neutralizing determinants for protection against HCV.	0:76	Identification of novel neutralizing determinants for protection against HCV.
36056620	6	45	theme	genetic	1012:1018	arg1	studies					1020:1026	Further reverse genetic studies	996:1026	Further reverse genetic studies of acquired E1/E2 substitutions	996:1058	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	4	46	theme	genotype	525:532	arg1	1a					534:535	genotype 1a	525:535	genotype 1a	525:535	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	9	47	theme	rational	1538:1545	arg1	design					1555:1560	rational vaccine design	1538:1560	rational vaccine design	1538:1560	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	8	48	theme	dramatic	1398:1405	arg1	changes					1407:1413	dramatic changes	1398:1413	dramatic changes	1398:1413	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	1	49	theme	needed	227:232	arg1	vaccine					234:240	an urgently needed vaccine	215:240	an urgently needed vaccine	215:240	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	5	50	theme	chronic	977:983	arg1	infection					985:993	chronic infection	977:993	chronic infection	977:993	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	4	51	with	3a	546:547	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	51	with	3a	546:547	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	51	with	3a	546:547	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	9	52	theme	envelope	1627:1634	arg1	proteins					1636:1643	the structurally flexible envelope proteins	1601:1643	the structurally flexible envelope proteins	1601:1643	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	6	53	theme	E2	1155:1156	arg1	areas					1158:1162	adjacent E2 areas	1146:1162	adjacent E2 areas	1146:1162	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	4	54	theme	4a	554:555	arg1	HCV					557:559	4a HCV	554:559	4a HCV	554:559	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	2	55	theme	envelope	275:282	arg1	proteins					284:291	viral envelope proteins	269:291	viral envelope proteins	269:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	2	56	gly	glycosylation	252:264	arg1	proteins					284:291	viral envelope proteins	269:291	viral envelope proteins	269:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	6	57	theme	conformational	1207:1220	arg1	state					1222:1226	the E1/E2 conformational state	1197:1226	the E1/E2 conformational state	1197:1226	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	4	58	with	1b	538:539	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	58	with	1b	538:539	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	58	with	1b	538:539	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	9	59	theme	open	1651:1654	arg1	conformation					1656:1667	an open conformation	1648:1667	an open conformation	1648:1667	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	6	60	gly	glycosylation	1110:1122	arg2	motifs					1124:1129	N6 glycosylation motifs	1107:1129	N6 glycosylation motifs	1107:1129	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	2	61	theme	key	298:300	arg1	glycosylation					252:264	N-linked glycosylation	243:264	N-linked glycosylation of viral envelope proteins	243:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	2	61	theme	key	298:300	arg1	mechanism					302:310	a key mechanism	296:310	a key mechanism for such evasion	296:327	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	6	62	theme	glycosylation	1110:1122	arg1	motifs					1124:1129	N6 glycosylation motifs	1107:1129	N6 glycosylation motifs	1107:1129	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	10	63	theme	culture	1770:1776	arg1	recombinants					1793:1804	highly fit cell culture infectious HCV recombinants	1754:1804	highly fit cell culture infectious HCV recombinants	1754:1804	Finally, this work resulted in a panel of highly fit cell culture infectious HCV recombinants.
36056620	5	64	theme	cell	804:807	arg1	viruses					826:832	polyclonal cell culture-passaged viruses	793:832	polyclonal cell culture-passaged viruses	793:832	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	9	65	theme	important	1679:1687	arg1	epitopes					1702:1709	important neutralizing epitopes	1679:1709	important neutralizing epitopes	1679:1709	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	10	66	theme	fit	1761:1763	arg1	recombinants					1793:1804	highly fit cell culture infectious HCV recombinants	1754:1804	highly fit cell culture infectious HCV recombinants	1754:1804	Finally, this work resulted in a panel of highly fit cell culture infectious HCV recombinants.
36056620	1	67	theme	neutralizing	113:124	arg1	nAb					138:140	nAb	138:140	nAb	138:140	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	1	67	theme	neutralizing	113:124	arg1	antibodies					126:135	neutralizing antibodies	113:135	neutralizing antibodies (nAb)	113:141	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	4	68	dep	proteins	575:582	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	68	dep	proteins	575:582	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	68	dep	proteins	575:582	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	69	with	HCV	557:559	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	69	with	HCV	557:559	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	69	with	HCV	557:559	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	5	70	theme	neutralizing	893:904	arg1	epitopes					906:913	conserved neutralizing epitopes	883:913	conserved neutralizing epitopes	883:913	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	4	71	with	1a	534:535	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	71	with	1a	534:535	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	71	with	1a	534:535	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	6	72	theme	reverse	1004:1010	arg1	studies					1020:1026	Further reverse genetic studies	996:1026	Further reverse genetic studies of acquired E1/E2 substitutions	996:1058	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	8	73	theme	glycan	1457:1462	arg1	occupancy					1464:1472	glycan occupancy	1457:1472	glycan occupancy	1457:1472	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	6	74	theme	key	1168:1170	arg1	532					1089:1091	532	1089:1091	532	1089:1091	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	6	74	theme	key	1168:1170	arg1	regulators					1172:1181	key regulators	1168:1181	key regulators	1168:1181	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	6	74	theme	key	1168:1170	arg1	positions					1071:1079	positions 418 and 532	1071:1091	positions	1071:1079	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	2	75	theme	N-linked	243:250	arg1	mechanism					302:310	a key mechanism	296:310	a key mechanism for such evasion	296:327	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	2	75	theme	N-linked	243:250	arg1	glycosylation					252:264	N-linked glycosylation	243:264	N-linked glycosylation of viral envelope proteins	243:291	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	5	76	theme	increased	849:857	arg1	fitness					859:865	highly increased fitness	842:865	highly increased fitness	842:865	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	7	77	theme	glycan	1314:1319	arg1	occupancy					1321:1329	predicted glycan occupancy	1304:1329	predicted glycan occupancy	1304:1329	These effects were independent of predicted glycan occupancy.
36056620	4	78	theme	selective	647:655	arg1	pressure					657:664	selective pressure	647:664	selective pressure by nAb in cell culture	647:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	5	79	from	exposure	871:878	arg1	regions					928:934	antigenic regions 3 and 4	918:942	antigenic regions 3 and 4	918:942	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	5	80	from	fitness	859:865	arg1	regions					928:934	antigenic regions 3 and 4	918:942	antigenic regions 3 and 4	918:942	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	1	81	theme	BACKGROUND	78:87	arg1	evasion					102:108	BACKGROUND AND AIMS HCV evasion	78:108	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb)	78:141	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	3	82	theme	rational	344:351	arg1	design					361:366	rational vaccine design	344:366	rational vaccine design	344:366	To facilitate rational vaccine design, we aimed to identify determinants of protection of conserved neutralizing epitopes.
36056620	4	83	theme	evolutionary	490:501	arg1	approach					503:510	a reverse evolutionary approach	480:510	a reverse evolutionary approach	480:510	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	3	84	theme	epitopes	443:450	arg1	protection					406:415	protection	406:415	protection of conserved neutralizing epitopes	406:450	To facilitate rational vaccine design, we aimed to identify determinants of protection of conserved neutralizing epitopes.
36056620	1	85	theme	AIMS	93:96	arg1	evasion					102:108	BACKGROUND AND AIMS HCV evasion	78:108	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb)	78:141	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
36056620	6	86	theme	substitutions	1046:1058	arg1	studies					1020:1026	Further reverse genetic studies	996:1026	Further reverse genetic studies of acquired E1/E2 substitutions	996:1058	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	3	87	theme	conserved	420:428	arg1	epitopes					443:450	conserved neutralizing epitopes	420:450	conserved neutralizing epitopes	420:450	To facilitate rational vaccine design, we aimed to identify determinants of protection of conserved neutralizing epitopes.
36056620	0	88	theme	neutralizing	24:35	arg1	determinants					37:48	novel neutralizing determinants	18:48	novel neutralizing determinants for protection against HCV	18:75	Identification of novel neutralizing determinants for protection against HCV.
36056620	9	89	theme	vaccine	1547:1553	arg1	design					1555:1560	rational vaccine design	1538:1560	rational vaccine design	1538:1560	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	6	90	theme	acquired	1031:1038	arg1	substitutions					1046:1058	acquired E1/E2 substitutions	1031:1058	acquired E1/E2 substitutions	1031:1058	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	9	91	theme	nAb	1522:1524	arg1	evasion					1526:1532	HCV nAb evasion	1518:1532	HCV nAb evasion	1518:1532	These findings aid in the understanding of HCV nAb evasion and rational vaccine design, as they can be exploited to stabilize the structurally flexible envelope proteins in an open conformation, exposing important neutralizing epitopes.
36056620	4	92	attach	derived	596:602	arg2	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	92	attach	derived	596:602	arg1	patients					630:637	chronically infected patients	609:637	chronically infected patients without selective pressure by nAb in cell culture	609:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	92	attach	derived	596:602	arg2	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	92	attach	derived	596:602	arg2	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	5	93	theme	HCV	726:728	arg1	recombinants					730:741	HCV recombinants	726:741	HCV recombinants	726:741	Compared with the original viruses, HCV recombinants, engineered to harbor substitutions identified in polyclonal cell culture-passaged viruses, showed highly increased fitness and exposure of conserved neutralizing epitopes in antigenic regions 3 and 4, associated with protection from chronic infection.
36056620	3	94	theme	protection	406:415	arg1	determinants					390:401	determinants	390:401	determinants of protection of conserved neutralizing epitopes	390:450	To facilitate rational vaccine design, we aimed to identify determinants of protection of conserved neutralizing epitopes.
36056620	8	95	theme	N-linked	1356:1363	arg1	motifs					1379:1384	N-linked glycosylation motifs	1356:1384	N-linked glycosylation motifs	1356:1384	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	6	96	theme	N6	1107:1108	arg1	motifs					1124:1129	N6 glycosylation motifs	1107:1129	N6 glycosylation motifs	1107:1129	Further reverse genetic studies of acquired E1/E2 substitutions identified positions 418 and 532 in the N1 and N6 glycosylation motifs, localizing to adjacent E2 areas, as key regulators of changes of the E1/E2 conformational state, which governed viral sensitivity to nAb.
36056620	4	97	theme	envelope	566:573	arg1	E2					592:593	E2	592:593	E2	592:593	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	97	theme	envelope	566:573	arg1	E1					585:586	E1	585:586	E1	585:586	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	4	97	theme	envelope	566:573	arg1	proteins					575:582	envelope proteins	566:582	envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture	566:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	2	98	theme	such	316:319	arg1	evasion					321:327	such evasion	316:327	such evasion	316:327	N-linked glycosylation of viral envelope proteins is a key mechanism for such evasion.
36056620	4	99	from	nAb	669:671	arg1	culture					681:687	cell culture	676:687	cell culture	676:687	APPROACH AND RESULTS Using a reverse evolutionary approach, we passaged genotype 1a, 1b, 2a, 3a, and 4a HCV with envelope proteins (E1 and E2) derived from chronically infected patients without selective pressure by nAb in cell culture.
36056620	8	100	gly	glycosylation	1365:1377	arg2	motifs					1379:1384	N-linked glycosylation motifs	1356:1384	N-linked glycosylation motifs	1356:1384	CONCLUSIONS We show how N-linked glycosylation motifs can trigger dramatic changes in HCV sensitivity to nAb, independent of glycan occupancy.
36056620	1	101	theme	vaccine	234:240	arg1	development					200:210	the development	196:210	the development of an urgently needed vaccine	196:240	BACKGROUND AND AIMS HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
35833795	4	0	theme	gas-phase	685:693	arg1	structures					695:704	multiple gas-phase structures	676:704	multiple gas-phase structures	676:704	HDX-IM-MS data indicated the presence of multiple gas-phase structures for each N-glycan including the isomers of A2G1.
35833795	5	1	from	collapse	859:866	arg1	phase					889:893	the gas phase	881:893	the gas phase	881:893	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	1	2	theme	atomic	157:162	arg1	composition					164:174	atomic composition	157:174	atomic composition	157:174	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	0	3	theme	Isomers	85:91	arg1	Elucidation					52:62	Structural Elucidation	41:62	Structural Elucidation of Branched N-Glycan Isomers	41:91	Exploring Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers.
35833795	5	4	theme	gas	885:887	arg1	phase					889:893	the gas phase	881:893	the gas phase	881:893	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	4	5	theme	multiple	676:683	arg1	structures					695:704	multiple gas-phase structures	676:704	multiple gas-phase structures	676:704	HDX-IM-MS data indicated the presence of multiple gas-phase structures for each N-glycan including the isomers of A2G1.
35833795	1	6	from	composition	164:174	arg1	identical					135:143	identical	135:143	identical	135:143	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	2	7	theme	elucidation	297:307	arg1	dimensions					272:281	additional dimensions	261:281	additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD)	261:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	3	8	theme	low	553:555	arg1	N-glycans					567:575	the low abundance N-glycans	549:575	the low abundance N-glycans	549:575	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	3	9	theme	abundance	557:565	arg1	N-glycans					567:575	the low abundance N-glycans	549:575	the low abundance N-glycans	549:575	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	2	10	theme	structural	286:295	arg1	elucidation					297:307	structural elucidation	286:307	structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD)	286:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	1	11	from	mass	148:151	arg1	identical					135:143	identical	135:143	identical	135:143	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	2	12	theme	hydrogen/deuterium	361:378	arg1	HDX					390:392	HDX	390:392	HDX	390:392	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	2	12	theme	hydrogen/deuterium	361:378	arg1	exchange					380:387	hydrogen/deuterium exchange	361:387	hydrogen/deuterium exchange (HDX)	361:393	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	5	13	theme	preferential	846:857	arg1	collapse					859:866	the preferential collapse	842:866	the preferential collapse of sugars in the gas phase	842:893	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	5	14	theme	collision	795:803	arg1	section					811:817	their collision cross section	789:817	their collision cross section	789:817	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	2	15	theme	electron	399:406	arg1	dissociation					416:427	electron capture dissociation	399:427	electron capture dissociation (ECD)	399:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	2	15	theme	electron	399:406	arg1	ECD					430:432	ECD	430:432	ECD	430:432	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	6	16	theme	IM-ECD	957:962	arg1	capable					977:983	capable	977:983	capable	977:983	The cyclic IM-ECD approach was capable of assigning and identifying each isomer to its IM peak.
35833795	6	16	theme	IM-ECD	957:962	arg1	approach					964:971	The cyclic IM-ECD approach	946:971	The cyclic IM-ECD approach	946:971	The cyclic IM-ECD approach was capable of assigning and identifying each isomer to its IM peak.
35833795	5	17	theme	A2G1	773:776	arg1	isomers					778:784	A2G1 isomers	773:784	A2G1 isomers	773:784	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	1	18	from	identical	135:143	arg1	mass					148:151	mass	148:151	mass	148:151	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	1	18	from	identical	135:143	arg1	composition					164:174	atomic composition	157:174	atomic composition	157:174	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	4	19	theme	HDX-IM-MS	635:643	arg1	data					645:648	HDX-IM-MS data	635:648	HDX-IM-MS data	635:648	HDX-IM-MS data indicated the presence of multiple gas-phase structures for each N-glycan including the isomers of A2G1.
35833795	0	20	theme	Gas-Phase	10:18	arg1	Methodologies					23:35	Gas-Phase MS Methodologies	10:35	Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers	10:91	Exploring Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers.
35833795	7	21	theme	unique	1046:1051	arg1	fragments					1064:1072	Two unique cross-ring fragments	1042:1072	Two unique cross-ring fragments	1042:1072	Two unique cross-ring fragments were identified for each isomer: m/z = 624.21 for α1-6 and m/z = 462.16 for α1-3.
35833795	1	22	theme	Structural	94:103	arg1	isomers					105:111	Structural isomers	94:111	Structural isomers of N-glycans that are identical in mass and atomic composition	94:174	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	1	23	theme	great	186:190	arg1	challenge					192:200	a great challenge	184:200	a great challenge to conventional mass spectrometry (MS)	184:239	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	5	24	theme	cross	805:809	arg1	section					811:817	their collision cross section	789:817	their collision cross section	789:817	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	6	25	theme	cyclic	950:955	arg1	capable					977:983	capable	977:983	capable	977:983	The cyclic IM-ECD approach was capable of assigning and identifying each isomer to its IM peak.
35833795	6	25	theme	cyclic	950:955	arg1	approach					964:971	The cyclic IM-ECD approach	946:971	The cyclic IM-ECD approach	946:971	The cyclic IM-ECD approach was capable of assigning and identifying each isomer to its IM peak.
35833795	7	26	theme	cross-ring	1053:1062	arg1	fragments					1064:1072	Two unique cross-ring fragments	1042:1072	Two unique cross-ring fragments	1042:1072	Two unique cross-ring fragments were identified for each isomer: m/z = 624.21 for α1-6 and m/z = 462.16 for α1-3.
35833795	2	27	theme	mobility	323:330	arg1	spectroscopy					337:348	ion mobility (IM) spectroscopy	319:348	ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD)	319:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	8	28	theme	first	1190:1194	arg1	peak					1199:1202	the first IM peak	1186:1202	the first IM peak	1186:1202	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	3	29	dep	isomers	601:607	arg1	α1-3					610:613	α1-3	610:613	α1-3	610:613	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	3	29	dep	isomers	601:607	arg1	α1-6					619:622	α1-6	619:622	α1-6	619:622	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	2	30	theme	ion	319:321	arg1	spectroscopy					337:348	ion mobility (IM) spectroscopy	319:348	ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD)	319:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	5	31	theme	ECD	927:929	arg1	fragmentation					931:943	further ECD fragmentation	919:943	further ECD fragmentation	919:943	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	8	32	theme	IM	1196:1197	arg1	peak					1199:1202	the first IM peak	1186:1202	the first IM peak	1186:1202	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	0	33	theme	MS	20:21	arg1	Methodologies					23:35	Gas-Phase MS Methodologies	10:35	Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers	10:91	Exploring Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers.
35833795	1	34	theme	N-glycans	116:124	arg1	isomers					105:111	Structural isomers	94:111	Structural isomers of N-glycans that are identical in mass and atomic composition	94:174	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	1	35	theme	conventional	205:216	arg1	MS					237:238	MS	237:238	MS	237:238	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	1	35	theme	conventional	205:216	arg1	spectrometry					223:234	conventional mass spectrometry	205:234	conventional mass spectrometry (MS)	205:239	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	0	36	theme	Structural	41:50	arg1	Elucidation					52:62	Structural Elucidation	41:62	Structural Elucidation of Branched N-Glycan Isomers	41:91	Exploring Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers.
35833795	3	37	theme	linkage-based	587:599	arg1	isomers					601:607	their linkage-based isomers	581:607	their linkage-based isomers (α1-3 and α1-6 for A2G1)	581:632	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	5	38	theme	sugars	871:876	arg1	collapse					859:866	the preferential collapse	842:866	the preferential collapse of sugars in the gas phase	842:893	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	1	39	theme	mass	218:221	arg1	MS					237:238	MS	237:238	MS	237:238	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	1	39	theme	mass	218:221	arg1	spectrometry					223:234	conventional mass spectrometry	205:234	conventional mass spectrometry (MS)	205:239	Structural isomers of N-glycans that are identical in mass and atomic composition provide a great challenge to conventional mass spectrometry (MS).
35833795	5	40	theme	isomers	778:784	arg1	Identification					755:768	Identification	755:768	Identification of A2G1 isomers by their collision cross section	755:817	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	4	41	theme	A2G1	749:752	arg1	isomers					738:744	the isomers	734:744	the isomers of A2G1	734:752	HDX-IM-MS data indicated the presence of multiple gas-phase structures for each N-glycan including the isomers of A2G1.
35833795	2	42	theme	capture	408:414	arg1	dissociation					416:427	electron capture dissociation	399:427	electron capture dissociation (ECD)	399:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	2	42	theme	capture	408:414	arg1	ECD					430:432	ECD	430:432	ECD	430:432	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	2	43	theme	A2	462:463	arg1	N-glycans					465:473	three main A2 N-glycans	451:473	three main A2 N-glycans	451:473	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	8	44	theme	IM	1281:1282	arg1	conformer					1306:1314	a more extended conformer	1290:1314	a more extended conformer	1290:1314	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	8	44	theme	IM	1281:1282	arg1	peak					1284:1287	the second IM peak	1270:1287	the second IM peak	1270:1287	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	8	45	theme	second	1274:1279	arg1	conformer					1306:1314	a more extended conformer	1290:1314	a more extended conformer	1290:1314	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	8	45	theme	second	1274:1279	arg1	peak					1284:1287	the second IM peak	1270:1287	the second IM peak	1270:1287	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	2	46	theme	main	457:460	arg1	N-glycans					465:473	three main A2 N-glycans	451:473	three main A2 N-glycans	451:473	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	8	47	theme	extended	1297:1304	arg1	conformer					1306:1314	a more extended conformer	1290:1314	a more extended conformer	1290:1314	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	8	47	theme	extended	1297:1304	arg1	peak					1284:1287	the second IM peak	1270:1287	the second IM peak	1270:1287	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	4	48	theme	structures	695:704	arg1	presence					664:671	the presence	660:671	the presence of multiple gas-phase structures for each N-glycan	660:722	HDX-IM-MS data indicated the presence of multiple gas-phase structures for each N-glycan including the isomers of A2G1.
35833795	2	49	theme	additional	261:270	arg1	dimensions					272:281	additional dimensions	261:281	additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD)	261:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	8	50	theme	compact	1223:1229	arg1	conformation					1231:1242	a more compact conformation	1216:1242	a more compact conformation	1216:1242	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	5	51	theme	further	919:925	arg1	fragmentation					931:943	further ECD fragmentation	919:943	further ECD fragmentation	919:943	Identification of A2G1 isomers by their collision cross section was complicated due to the preferential collapse of sugars in the gas phase, but it was possible by further ECD fragmentation.
35833795	6	52	theme	IM	1033:1034	arg1	peak					1036:1039	its IM peak	1029:1039	its IM peak	1029:1039	The cyclic IM-ECD approach was capable of assigning and identifying each isomer to its IM peak.
35833795	2	53	theme	IM	333:334	arg1	spectroscopy					337:348	ion mobility (IM) spectroscopy	319:348	ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD)	319:433	This study employs additional dimensions of structural elucidation including ion mobility (IM) spectroscopy coupled to hydrogen/deuterium exchange (HDX) and electron capture dissociation (ECD) to characterize three main A2 N-glycans and their conformers.
35833795	0	54	theme	N-Glycan	76:83	arg1	Isomers					85:91	Branched N-Glycan Isomers	67:91	Branched N-Glycan Isomers	67:91	Exploring Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers.
35833795	3	55	theme	IM-MS	509:513	arg1	experiments					515:525	IM-MS experiments	509:525	IM-MS experiments	509:525	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	8	56	theme	key	1171:1173	arg1	fragments					1175:1183	these key fragments	1165:1183	these key fragments	1165:1183	Based on these key fragments, the first IM peak, indicating a more compact conformation, was assigned to α1-3 and the second IM peak, a more extended conformer, was assigned to α1-6.
35833795	0	57	theme	Branched	67:74	arg1	Isomers					85:91	Branched N-Glycan Isomers	67:91	Branched N-Glycan Isomers	67:91	Exploring Gas-Phase MS Methodologies for Structural Elucidation of Branched N-Glycan Isomers.
35833795	3	58	theme	experiments	515:525	arg1	able					532:535	able	532:535	able	532:535	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
35833795	3	58	theme	experiments	515:525	arg1	series					499:504	A series	497:504	A series of IM-MS experiments	497:525	A series of IM-MS experiments were able to separate the low abundance N-glycans and their linkage-based isomers (α1-3 and α1-6 for A2G1).
36621331	2	0	theme	work	331:334	arg1	aim					319:321	the aim	315:321	the aim of this work	315:334	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	1	1	theme	solid	228:232	arg1	surfaces					234:241	solid surfaces	228:241	solid surfaces	228:241	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	0	2	theme	food	56:59	arg1	soil					61:64	a Burnt-on/Baked-on (BoBo) model food soil	23:64	a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy	23:140	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	3	3	theme	residues	669:676	arg1	cleaning					652:659	the enzymatic cleaning	638:659	the enzymatic cleaning of BoBo residues from surfaces	638:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	5	4	theme	xylan	968:972	arg1	enzymes					989:995	xylan depolymerising enzymes	968:995	xylan depolymerising enzymes	968:995	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	0	5	theme	Microarray	72:81	arg1	MAPP					102:105	MAPP	102:105	MAPP	102:105	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	0	5	theme	Microarray	72:81	arg1	Profiling					91:99	Microarray Polymer Profiling	72:99	Microarray Polymer Profiling (MAPP)	72:106	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	0	6	from	Analysis	0:7	arg1	soil					61:64	a Burnt-on/Baked-on (BoBo) model food soil	23:64	a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy	23:140	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	6	7	dep	complex	1193:1199	arg1	multi-component					1202:1216	multi-component	1202:1216	multi-component	1202:1216	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	4	8	theme	structural	776:785	arg1	modifications					787:799	extensive structural modifications	766:799	extensive structural modifications	766:799	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	6	9	dep	composition	1156:1166	arg1	the					1152:1154	the	1152:1154	the	1152:1154	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	4	10	theme	extensive	766:774	arg1	modifications					787:799	extensive structural modifications	766:799	extensive structural modifications	766:799	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	3	11	theme	Microarray	520:529	arg1	Profiling					539:547	Microarray Polymer Profiling	520:547	Microarray Polymer Profiling	520:547	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	5	12	theme	depolymerising	974:987	arg1	enzymes					989:995	xylan depolymerising enzymes	968:995	xylan depolymerising enzymes	968:995	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	5	13	from	inclusion	955:963	arg1	detergents					1022:1031	automatic dishwashing detergents	1000:1031	automatic dishwashing detergents	1000:1031	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	5	14	theme	recalcitrant	1057:1068	arg1	soils					1094:1098	recalcitrant, plant glycan-rich BoBo soils	1057:1098	soils	1094:1098	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	5	15	theme	high-throughput	908:922	arg1	screening					931:939	high-throughput enzyme screening	908:939	high-throughput enzyme screening	908:939	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	0	16	theme	Polymer	83:89	arg1	MAPP					102:105	MAPP	102:105	MAPP	102:105	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	0	16	theme	Polymer	83:89	arg1	Profiling					91:99	Microarray Polymer Profiling	72:99	Microarray Polymer Profiling (MAPP)	72:106	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	2	17	theme	food	443:446	arg1	soil					448:451	a Burnt-On/Baked-On (BoBo) model food soil	410:451	a Burnt-On/Baked-On (BoBo) model food soil	410:451	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	1	18	theme	food	154:157	arg1	materials					159:167	food materials	154:167	food materials	154:167	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	2	19	theme	enzyme	469:474	arg1	systems					476:482	enzyme systems	469:482	enzyme systems that may facilitate soil breakdown	469:517	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	5	20	theme	dishwashing	1010:1020	arg1	detergents					1022:1031	automatic dishwashing detergents	1000:1031	automatic dishwashing detergents	1000:1031	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	1	21	theme	materials	159:167	arg1	Burning					143:149	Burning	143:149	Burning of food materials during cooking	143:182	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	1	22	theme	residual	252:259	arg1	soils					266:270	residual food soils	252:270	residual food soils	252:270	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	2	23	theme	probe-based	289:299	arg1	technologies					301:312	molecular probe-based technologies	279:312	molecular probe-based technologies	279:312	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	1	24	theme	food	261:264	arg1	soils					266:270	residual food soils	252:270	residual food soils	252:270	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	5	25	theme	BoBo	1089:1092	arg1	soils					1094:1098	recalcitrant, plant glycan-rich BoBo soils	1057:1098	soils	1094:1098	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	4	26	theme	constituent	858:868	arg1	matrices					885:892	constituent polysaccharide matrices	858:892	constituent polysaccharide matrices	858:892	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	2	27	theme	molecular	279:287	arg1	technologies					301:312	molecular probe-based technologies	279:312	molecular probe-based technologies	279:312	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	2	28	theme	glycans	395:401	arg1	composition					357:367	composition	357:367	composition	357:367	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	2	28	theme	glycans	395:401	arg1	abundance					382:390	relative abundance	373:390	relative abundance	373:390	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	0	29	theme	glycans	12:18	arg1	Analysis					0:7	Analysis	0:7	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.	0:141	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	6	30	theme	removal	1172:1178	arg1	chemistry					1180:1188	removal chemistry	1172:1188	removal chemistry	1172:1188	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	6	31	theme	new	1135:1137	arg1	insight					1139:1145	new insight	1135:1145	new insight into the composition and removal chemistry of complex, multi-component food soils	1135:1227	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	0	32	theme	Burnt-on/Baked-on	25:41	arg1	soil					61:64	a Burnt-on/Baked-on (BoBo) model food soil	23:64	a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy	23:140	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	5	33	theme	enzymes	989:995	arg1	inclusion					955:963	inclusion	955:963	inclusion of xylan depolymerising enzymes in automatic dishwashing detergents	955:1031	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	6	34	theme	food	1218:1221	arg1	soils					1223:1227	complex, multi-component food soils	1193:1227	complex, multi-component food soils	1193:1227	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	2	35	theme	model	437:441	arg1	soil					448:451	a Burnt-On/Baked-On (BoBo) model food soil	410:451	a Burnt-On/Baked-On (BoBo) model food soil	410:451	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	2	36	theme	soil	504:507	arg1	breakdown					509:517	soil breakdown	504:517	soil breakdown	504:517	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	3	37	theme	target	616:621	arg1	mannan					606:611	mannan	606:611	mannan	606:611	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	37	theme	target	616:621	arg1	glucan					595:600	mixed-linkage glucan	581:600	mixed-linkage glucan	581:600	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	37	theme	target	616:621	arg1	substrates					623:632	target substrates	616:632	target substrates for the enzymatic cleaning of BoBo residues from surfaces	616:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	37	theme	target	616:621	arg1	arabinoxylan					567:578	arabinoxylan	567:578	arabinoxylan	567:578	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	37	theme	target	616:621	arg1	xylan					560:564	xylan	560:564	xylan	560:564	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	38	theme	mixed-linkage	581:593	arg1	arabinoxylan					567:578	arabinoxylan	567:578	arabinoxylan	567:578	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	38	theme	mixed-linkage	581:593	arg1	mannan					606:611	mannan	606:611	mannan	606:611	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	38	theme	mixed-linkage	581:593	arg1	substrates					623:632	target substrates	616:632	target substrates for the enzymatic cleaning of BoBo residues from surfaces	616:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	38	theme	mixed-linkage	581:593	arg1	glucan					595:600	mixed-linkage glucan	581:600	mixed-linkage glucan	581:600	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	38	theme	mixed-linkage	581:593	arg1	xylan					560:564	xylan	560:564	xylan	560:564	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	2	39	theme	relative	373:380	arg1	abundance					382:390	relative abundance	373:390	relative abundance	373:390	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36621331	0	40	theme	BoBo	44:47	arg1	soil					61:64	a Burnt-on/Baked-on (BoBo) model food soil	23:64	a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy	23:140	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	3	41	from	cleaning	652:659	arg1	surfaces					683:690	surfaces	683:690	surfaces	683:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	4	42	theme	polysaccharide	870:883	arg1	matrices					885:892	constituent polysaccharide matrices	858:892	constituent polysaccharide matrices	858:892	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	4	43	theme	immunofluorescence	702:719	arg1	microscopy					721:730	Indirect immunofluorescence microscopy	693:730	Indirect immunofluorescence microscopy	693:730	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	1	44	from	surfaces	234:241	arg1	removal					215:221	removal	215:221	removal from solid surfaces	215:241	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	1	44	from	surfaces	234:241	arg1	difficulty					201:210	the difficulty	197:210	the difficulty in removal from solid surfaces	197:241	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	0	45	theme	immunofluorescence	112:129	arg1	microscopy					131:140	immunofluorescence microscopy	112:140	immunofluorescence microscopy	112:140	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	4	46	theme	matrices	885:892	arg1	architecture					842:853	the three-dimensional architecture	820:853	the three-dimensional architecture of constituent polysaccharide matrices	820:892	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	4	47	theme	Indirect	693:700	arg1	microscopy					721:730	Indirect immunofluorescence microscopy	693:730	Indirect immunofluorescence microscopy	693:730	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	5	48	theme	soils	1094:1098	arg1	cleaning					1045:1052	cleaning	1045:1052	cleaning of recalcitrant, plant glycan-rich BoBo soils	1045:1098	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	1	49	from	difficulty	201:210	arg1	removal					215:221	removal	215:221	removal from solid surfaces	215:241	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	1	49	from	difficulty	201:210	arg1	surfaces					234:241	solid surfaces	228:241	solid surfaces	228:241	Burning of food materials during cooking can increase the difficulty in removal from solid surfaces, forming residual food soils.
36621331	3	50	theme	BoBo	664:667	arg1	residues					669:676	BoBo residues	664:676	BoBo residues from surfaces	664:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	5	51	theme	plant	1071:1075	arg1	soils					1094:1098	recalcitrant, plant glycan-rich BoBo soils	1057:1098	soils	1094:1098	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	4	52	theme	architecture	842:853	arg1	degradation					805:815	degradation	805:815	degradation of the three-dimensional architecture of constituent polysaccharide matrices	805:892	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	4	52	theme	architecture	842:853	arg1	modifications					787:799	extensive structural modifications	766:799	extensive structural modifications	766:799	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	3	53	theme	Polymer	531:537	arg1	Profiling					539:547	Microarray Polymer Profiling	520:547	Microarray Polymer Profiling	520:547	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	54	theme	enzymatic	642:650	arg1	cleaning					652:659	the enzymatic cleaning	638:659	the enzymatic cleaning of BoBo residues from surfaces	638:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	5	55	theme	glycan-rich	1077:1087	arg1	soils					1094:1098	recalcitrant, plant glycan-rich BoBo soils	1057:1098	soils	1094:1098	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	5	56	from	screening	931:939	arg1	Results					895:901	Results	895:901	Results from high-throughput enzyme screening	895:939	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	5	57	theme	automatic	1000:1008	arg1	detergents					1022:1031	automatic dishwashing detergents	1000:1031	automatic dishwashing detergents	1000:1031	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	6	58	theme	soils	1223:1227	arg1	composition					1156:1166	composition	1156:1166	composition	1156:1166	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	6	58	theme	soils	1223:1227	arg1	chemistry					1180:1188	removal chemistry	1172:1188	removal chemistry	1172:1188	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	0	59	theme	model	50:54	arg1	soil					61:64	a Burnt-on/Baked-on (BoBo) model food soil	23:64	a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy	23:140	Analysis of glycans in a Burnt-on/Baked-on (BoBo) model food soil using Microarray Polymer Profiling (MAPP) and immunofluorescence microscopy.
36621331	4	60	theme	three-dimensional	824:840	arg1	architecture					842:853	the three-dimensional architecture	820:853	the three-dimensional architecture of constituent polysaccharide matrices	820:892	Indirect immunofluorescence microscopy revealed that burning resulted in extensive structural modifications and degradation of the three-dimensional architecture of constituent polysaccharide matrices.
36621331	6	61	theme	complex	1193:1199	arg1	soils					1223:1227	complex, multi-component food soils	1193:1227	complex, multi-component food soils	1193:1227	Collectively, this study provides new insight into the composition and removal chemistry of complex, multi-component food soils.
36621331	5	62	theme	enzyme	924:929	arg1	screening					931:939	high-throughput enzyme screening	908:939	high-throughput enzyme screening	908:939	Results from high-throughput enzyme screening indicate that inclusion of xylan depolymerising enzymes in automatic dishwashing detergents may improve cleaning of recalcitrant, plant glycan-rich BoBo soils.
36621331	3	63	from	surfaces	683:690	arg1	cleaning					652:659	the enzymatic cleaning	638:659	the enzymatic cleaning of BoBo residues from surfaces	638:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	3	63	from	surfaces	683:690	arg1	residues					669:676	BoBo residues	664:676	BoBo residues from surfaces	664:690	Microarray Polymer Profiling identified xylan, arabinoxylan, mixed-linkage glucan and mannan as target substrates for the enzymatic cleaning of BoBo residues from surfaces.
36621331	2	64	dep	composition	357:367	arg1	the					353:355	the	353:355	the	353:355	Using molecular probe-based technologies, the aim of this work was to elucidate the composition and relative abundance of glycans within a Burnt-On/Baked-On (BoBo) model food soil and investigate enzyme systems that may facilitate soil breakdown.
36745435	0	0	theme	Arbf23	96:101	arg1	Motifs					104:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	4	1	theme	automated	695:703	arg1	AGA					722:724	AGA	722:724	AGA	722:724	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	4	1	theme	automated	695:703	arg1	assembly					712:719	automated glycan assembly	695:719	automated glycan assembly (AGA)	695:725	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	4	2	used	used	734:737	arg2	assembly					712:719	automated glycan assembly	695:719	automated glycan assembly (AGA)	695:725	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	4	2	used	used	734:737	arg2	AGA					722:724	AGA	722:724	AGA	722:724	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	1	3	theme	different	193:201	arg1	polysaccharides					203:217	different polysaccharides	193:217	different polysaccharides that helps to avert the innate immune response	193:264	Mycobacteria are covered in a thick layer of different polysaccharides that helps to avert the innate immune response.
36745435	3	4	from	residues	504:511	arg1	LAM					516:518	LAM	516:518	LAM	516:518	Arabinofuranose (Araf)residues in LAM and AG are connected either via α-1,2-trans linkages that are synthetically straightforward to install or the more challenging β-(1,2-cis) linkages.
36745435	3	4	from	residues	504:511	arg1	AG					524:525	AG	524:525	AG	524:525	Arabinofuranose (Araf)residues in LAM and AG are connected either via α-1,2-trans linkages that are synthetically straightforward to install or the more challenging β-(1,2-cis) linkages.
36745435	1	5	theme	polysaccharides	203:217	arg1	layer					184:188	a thick layer	176:188	a thick layer of different polysaccharides that helps to avert the innate immune response	176:264	Mycobacteria are covered in a thick layer of different polysaccharides that helps to avert the innate immune response.
36745435	0	6	theme	Glycan	10:15	arg1	Assembly					17:24	Automated Glycan Assembly	0:24	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside	0:63	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	4	7	theme	motif	890:894	arg1	assembly					795:802	the assembly	791:802	the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif	791:894	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	3	8	dep	challenging β-	635:648	arg1	1,2-cis					650:656	1,2-cis	650:656	1,2-cis	650:656	Arabinofuranose (Araf)residues in LAM and AG are connected either via α-1,2-trans linkages that are synthetically straightforward to install or the more challenging β-(1,2-cis) linkages.
36745435	0	9	theme	Automated	0:8	arg1	Assembly					17:24	Automated Glycan Assembly	0:24	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside	0:63	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	4	10	theme	glycan	705:710	arg1	AGA					722:724	AGA	722:724	AGA	722:724	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	4	10	theme	glycan	705:710	arg1	assembly					712:719	automated glycan assembly	695:719	automated glycan assembly (AGA)	695:725	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	2	11	theme	biological	464:473	arg1	roles					475:479	their structural and biological roles	443:479	their structural and biological roles	443:479	Lipoarabinomannan (LAM) and arabinogalactan (AG) are ubiquitously contained in these envelopes and rapid access to defined oligo- and polysaccharides is essential to elucidate their structural and biological roles.
36745435	3	12	theme	Araf	499:502	arg1	residues					504:511	Arabinofuranose (Araf)residues	482:511	Arabinofuranose (Araf)residues in LAM and AG	482:525	Arabinofuranose (Araf)residues in LAM and AG are connected either via α-1,2-trans linkages that are synthetically straightforward to install or the more challenging β-(1,2-cis) linkages.
36745435	0	13	theme	Hexaarabinofuranoside	43:63	arg1	Assembly					17:24	Automated Glycan Assembly	0:24	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside	0:63	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	0	13	theme	Hexaarabinofuranoside	43:63	arg1	Motifs					104:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	3	14	theme	challenging β-	635:648	arg1	linkages					659:666	the more challenging β-(1,2-cis) linkages	626:666	the more challenging β-(1,2-cis) linkages	626:666	Arabinofuranose (Araf)residues in LAM and AG are connected either via α-1,2-trans linkages that are synthetically straightforward to install or the more challenging β-(1,2-cis) linkages.
36745435	3	15	theme	Arabinofuranose	482:496	arg1	residues					504:511	Arabinofuranose (Araf)residues	482:511	Arabinofuranose (Araf)residues in LAM and AG	482:525	Arabinofuranose (Araf)residues in LAM and AG are connected either via α-1,2-trans linkages that are synthetically straightforward to install or the more challenging β-(1,2-cis) linkages.
36745435	0	16	theme	Mycobacterial	29:41	arg1	Hexaarabinofuranoside					43:63	Mycobacterial Hexaarabinofuranoside	29:63	Mycobacterial Hexaarabinofuranoside	29:63	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	1	17	theme	innate	243:248	arg1	response					257:264	the innate immune response	239:264	the innate immune response	239:264	Mycobacteria are covered in a thick layer of different polysaccharides that helps to avert the innate immune response.
36745435	0	18	theme	Docosasaccharide	69:84	arg1	Motifs					104:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	4	19	theme	arabinan	872:879	arg1	motif					890:894	a docosasaccharide arabinan (Araf23) motif	853:894	a docosasaccharide arabinan (Araf23) motif	853:894	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	2	20	theme	rapid	366:370	arg1	access					372:377	rapid access	366:377	rapid access to defined oligo- and polysaccharides	366:415	Lipoarabinomannan (LAM) and arabinogalactan (AG) are ubiquitously contained in these envelopes and rapid access to defined oligo- and polysaccharides is essential to elucidate their structural and biological roles.
36745435	4	21	theme	docosasaccharide	855:870	arg1	motif					890:894	a docosasaccharide arabinan (Araf23) motif	853:894	a docosasaccharide arabinan (Araf23) motif	853:894	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	4	22	theme	branched	816:823	arg1	hexasaccharide					834:847	a highly branched arabinan hexasaccharide	807:847	a highly branched arabinan hexasaccharide	807:847	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	1	23	theme	immune	250:255	arg1	response					257:264	the innate immune response	239:264	the innate immune response	239:264	Mycobacteria are covered in a thick layer of different polysaccharides that helps to avert the innate immune response.
36745435	1	24	theme	thick	178:182	arg1	layer					184:188	a thick layer	176:188	a thick layer of different polysaccharides that helps to avert the innate immune response	176:264	Mycobacteria are covered in a thick layer of different polysaccharides that helps to avert the innate immune response.
36745435	4	25	theme	hexasaccharide	834:847	arg1	assembly					795:802	the assembly	791:802	the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif	791:894	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	2	26	theme	structural	449:458	arg1	roles					475:479	their structural and biological roles	443:479	their structural and biological roles	443:479	Lipoarabinomannan (LAM) and arabinogalactan (AG) are ubiquitously contained in these envelopes and rapid access to defined oligo- and polysaccharides is essential to elucidate their structural and biological roles.
36745435	0	27	theme	Arabinan	86:93	arg1	Motifs					104:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Docosasaccharide Arabinan (Arbf23) Motifs	69:109	Automated Glycan Assembly of Mycobacterial Hexaarabinofuranoside and Docosasaccharide Arabinan (Arbf23) Motifs found on Mycobacterium tuberculosis.
36745435	4	28	theme	arabinan	825:832	arg1	hexasaccharide					834:847	a highly branched arabinan hexasaccharide	807:847	a highly branched arabinan hexasaccharide	807:847	Here, we demonstrate that automated glycan assembly (AGA) can be used to quickly prepare 1,2-cis-β-Araf as illustrated by the assembly of a highly branched arabinan hexasaccharide and a docosasaccharide arabinan (Araf23) motif.
36745435	2	29	theme	defined	382:388	arg1	oligo-					390:395	oligo-	390:395	oligo-	390:395	Lipoarabinomannan (LAM) and arabinogalactan (AG) are ubiquitously contained in these envelopes and rapid access to defined oligo- and polysaccharides is essential to elucidate their structural and biological roles.
36370046	6	0	from	understanding	762:774	arg1	SARS-CoV-2					794:803	SARS-CoV-2	794:803	SARS-CoV-2	794:803	Building an understanding of their roles in SARS-CoV-2 is important as we continue to develop effective medicines and vaccines to combat the disease.
36370046	7	1	gly	glycosylation	994:1006	arg1	RBD					1062:1064	RBD	1062:1064	RBD	1062:1064	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	7	1	gly	glycosylation	994:1006	arg1	domain					1054:1059	the spike protein receptor-binding domain	1019:1059	the spike protein receptor-binding domain (RBD)	1019:1065	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	1	2	theme	protein	254:260	arg1	surface					262:268	the protein surface	250:268	the protein surface	250:268	Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36370046	10	3	theme	spike	1613:1617	arg1	protein					1619:1625	the viral spike protein	1603:1625	the viral spike protein	1603:1625	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	5	4	theme	discrete	680:687	arg1	glycoforms					689:698	discrete glycoforms	680:698	discrete glycoforms	680:698	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	5	5	theme	experimental	647:658	arg1	data					660:663	experimental data	647:663	experimental data on the role of discrete glycoforms on the spike protein pathobiology	647:732	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	8	6	theme	potential	1217:1225	arg1	strategy					1227:1234	a potential strategy	1215:1234	a potential strategy for modulating the spike protein behaviors through glycoengineering	1215:1302	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	11	7	theme	molecular	1854:1862	arg1	biology					1864:1870	molecular biology	1854:1870	molecular biology	1854:1870	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	0	8	from	roles	81:85	arg1	affinity					107:114	receptor binding affinity	90:114	receptor binding affinity	90:114	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	9	9	theme	binding	1443:1449	arg1	affinity					1451:1458	the receptor binding affinity	1430:1458	the receptor binding affinity	1430:1458	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	7	10	theme	domain	1054:1059	arg1	profile					1008:1014	the glycosylation profile	990:1014	the glycosylation profile of the spike protein receptor-binding domain (RBD)	990:1065	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	8	11	theme	protein	1261:1267	arg1	behaviors					1269:1277	the spike protein behaviors	1251:1277	the spike protein behaviors	1251:1277	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	7	12	theme	protein	1029:1035	arg1	RBD					1062:1064	RBD	1062:1064	RBD	1062:1064	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	7	12	theme	protein	1029:1035	arg1	domain					1054:1059	the spike protein receptor-binding domain	1019:1059	the spike protein receptor-binding domain (RBD)	1019:1065	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	11	13	theme	fundamental	1788:1798	arg1	role					1800:1803	the fundamental role	1784:1803	the fundamental role of specific glycoforms on glycoconjugates across molecular biology	1784:1870	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	5	14	theme	spike	707:711	arg1	pathobiology					721:732	the spike protein pathobiology	703:732	the spike protein pathobiology	703:732	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	1	15	theme	SARS-CoV-2	132:141	arg1	protein					149:155	the SARS-CoV-2 spike protein	128:155	the SARS-CoV-2 spike protein	128:155	Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36370046	1	16	theme	protein	149:155	arg1	Glycans					117:123	Glycans	117:123	Glycans of the SARS-CoV-2 spike protein	117:155	Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36370046	10	17	theme	molecular	1481:1489	arg1	simulation					1500:1509	molecular dynamics simulation	1481:1509	molecular dynamics simulation	1481:1509	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	11	18	theme	glycoforms	1817:1826	arg1	role					1800:1803	the fundamental role	1784:1803	the fundamental role of specific glycoforms on glycoconjugates across molecular biology	1784:1870	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	9	19	theme	reported	1333:1340	arg1	S309					1370:1373	S309	1370:1373	S309	1370:1373	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	9	19	theme	reported	1333:1340	arg1	antibody					1360:1367	the reported anti-SARS-CoV-(2) antibody	1329:1367	the reported anti-SARS-CoV-(2) antibody	1329:1367	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	0	20	theme	receptor	90:97	arg1	affinity					107:114	receptor binding affinity	90:114	receptor binding affinity	90:114	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	9	21	from	impact	1392:1397	arg1	affinity					1451:1458	the receptor binding affinity	1430:1458	the receptor binding affinity	1430:1458	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	10	22	with	combination	1464:1474	arg1	simulation					1500:1509	molecular dynamics simulation	1481:1509	molecular dynamics simulation	1481:1509	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	10	23	theme	SARS-CoV-2	1688:1697	arg1	nature					1678:1683	the nature	1674:1683	the nature of SARS-CoV-2	1674:1697	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	0	24	theme	Structural	0:9	arg1	remodeling					11:20	Structural remodeling	0:20	Structural remodeling of SARS-CoV-2 spike protein glycans	0:56	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	5	25	from	data	660:663	arg1	role					672:675	the role	668:675	the role of discrete glycoforms on the spike protein pathobiology	668:732	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	8	26	theme	receptor	1088:1095	arg1	affinity					1105:1112	the receptor binding affinity	1084:1112	the receptor binding affinity	1084:1112	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	7	27	theme	glycoengineering	941:956	arg1	enzymes					958:964	glycoengineering enzymes	941:964	glycoengineering enzymes	941:964	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	4	28	theme	simulation	567:576	arg1	studies					578:584	Subsequent molecular simulation studies	546:584	Subsequent molecular simulation studies	546:584	Subsequent molecular simulation studies provided a knowledge basis of the glycan functions.
36370046	10	29	theme	regulatory	1534:1543	arg1	roles					1545:1549	the regulatory roles	1530:1549	the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2	1530:1697	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	3	30	theme	Analytical	465:474	arg1	reports					476:482	Analytical reports	465:482	Analytical reports	465:482	Analytical reports have described the glycan heterogeneity of the spike protein.
36370046	8	31	theme	affinity	1105:1112	arg1	Measurements					1068:1079	Measurements	1068:1079	Measurements of the receptor binding affinity	1068:1112	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	6	32	from	SARS-CoV-2	794:803	arg1	understanding					762:774	an understanding	759:774	an understanding of their roles in SARS-CoV-2	759:803	Building an understanding of their roles in SARS-CoV-2 is important as we continue to develop effective medicines and vaccines to combat the disease.
36370046	9	33	gly	glycoforms	1416:1425	arg1	RBD					1412:1414	different RBD glycoforms	1402:1425	different RBD glycoforms	1402:1425	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	0	34	theme	spike	36:40	arg1	glycans					50:56	SARS-CoV-2 spike protein glycans	25:56	SARS-CoV-2 spike protein glycans	25:56	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	8	35	theme	opposite	1123:1130	arg1	effects					1143:1149	opposite regulatory effects	1123:1149	opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering	1123:1302	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	11	36	theme	enzymatic	1719:1727	arg1	remodeling					1736:1745	enzymatic glycan remodeling	1719:1745	enzymatic glycan remodeling	1719:1745	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	6	37	theme	roles	785:789	arg1	understanding					762:774	an understanding	759:774	an understanding of their roles in SARS-CoV-2	759:803	Building an understanding of their roles in SARS-CoV-2 is important as we continue to develop effective medicines and vaccines to combat the disease.
36370046	0	38	theme	glycans	50:56	arg1	remodeling					11:20	Structural remodeling	0:20	Structural remodeling of SARS-CoV-2 spike protein glycans	0:56	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	4	39	theme	Subsequent	546:555	arg1	studies					578:584	Subsequent molecular simulation studies	546:584	Subsequent molecular simulation studies	546:584	Subsequent molecular simulation studies provided a knowledge basis of the glycan functions.
36370046	9	40	theme	RBD	1412:1414	arg1	glycoforms					1416:1425	different RBD glycoforms	1402:1425	different RBD glycoforms	1402:1425	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	6	41	from	roles	785:789	arg1	SARS-CoV-2					794:803	SARS-CoV-2	794:803	SARS-CoV-2	794:803	Building an understanding of their roles in SARS-CoV-2 is important as we continue to develop effective medicines and vaccines to combat the disease.
36370046	4	42	theme	glycan	620:625	arg1	functions					627:635	the glycan functions	616:635	the glycan functions	616:635	Subsequent molecular simulation studies provided a knowledge basis of the glycan functions.
36370046	7	43	theme	designed	916:923	arg1	combinations					925:936	designed combinations	916:936	designed combinations of glycoengineering enzymes	916:964	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	8	44	theme	glycans	1162:1168	arg1	effects					1143:1149	opposite regulatory effects	1123:1149	opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering	1123:1302	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	2	45	theme	principal	347:355	arg1	target					357:362	the principal target	343:362	the principal target for vaccine and therapeutic development	343:402	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	2	45	theme	principal	347:355	arg1	protein					326:332	The spike protein	316:332	The spike protein	316:332	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	9	46	theme	receptor	1434:1441	arg1	affinity					1451:1458	the receptor binding affinity	1430:1458	the receptor binding affinity	1430:1458	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	4	47	theme	knowledge	597:605	arg1	basis					607:611	a knowledge basis	595:611	a knowledge basis of the glycan functions	595:635	Subsequent molecular simulation studies provided a knowledge basis of the glycan functions.
36370046	10	48	theme	viral	1607:1611	arg1	protein					1619:1625	the viral spike protein	1603:1625	the viral spike protein	1603:1625	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	3	49	theme	protein	537:543	arg1	heterogeneity					510:522	the glycan heterogeneity	499:522	the glycan heterogeneity of the spike protein	499:543	Analytical reports have described the glycan heterogeneity of the spike protein.
36370046	1	50	theme	functional	180:189	arg1	roles					191:195	functional roles	180:195	functional roles	180:195	Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36370046	10	51	theme	host	1631:1634	arg1	receptor					1636:1643	host receptor	1631:1643	host receptor	1631:1643	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	5	52	theme	protein	713:719	arg1	pathobiology					721:732	the spike protein pathobiology	703:732	the spike protein pathobiology	703:732	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	1	53	theme	infection	204:212	arg1	processes					214:222	the infection processes	200:222	the infection processes	200:222	Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36370046	5	54	from	role	672:675	arg1	pathobiology					721:732	the spike protein pathobiology	703:732	the spike protein pathobiology	703:732	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	10	55	theme	new	1656:1658	arg1	insights					1660:1667	new insights	1656:1667	new insights into the nature of SARS-CoV-2	1656:1697	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	5	56	theme	glycoforms	689:698	arg1	role					672:675	the role	668:675	the role of discrete glycoforms on the spike protein pathobiology	668:732	However, experimental data on the role of discrete glycoforms on the spike protein pathobiology remains scarce.
36370046	8	57	theme	spike	1255:1259	arg1	behaviors					1269:1277	the spike protein behaviors	1251:1277	the spike protein behaviors	1251:1277	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	7	58	theme	receptor-binding	1037:1052	arg1	RBD					1062:1064	RBD	1062:1064	RBD	1062:1064	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	7	58	theme	receptor-binding	1037:1052	arg1	domain					1054:1059	the spike protein receptor-binding domain	1019:1059	the spike protein receptor-binding domain (RBD)	1019:1065	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	11	59	from	role	1800:1803	arg1	glycoconjugates					1831:1845	glycoconjugates	1831:1845	glycoconjugates across molecular biology	1831:1870	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	0	60	theme	regulatory	70:79	arg1	roles					81:85	the regulatory roles	66:85	the regulatory roles in receptor binding affinity	66:114	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	7	61	theme	spike	1023:1027	arg1	RBD					1062:1064	RBD	1062:1064	RBD	1062:1064	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	7	61	theme	spike	1023:1027	arg1	domain					1054:1059	the spike protein receptor-binding domain	1019:1059	the spike protein receptor-binding domain (RBD)	1019:1065	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	1	62	theme	spike	143:147	arg1	protein					149:155	the SARS-CoV-2 spike protein	128:155	the SARS-CoV-2 spike protein	128:155	Glycans of the SARS-CoV-2 spike protein are speculated to play functional roles in the infection processes as they extensively cover the protein surface and are highly conserved across the variants.
36370046	0	63	theme	binding	99:105	arg1	affinity					107:114	receptor binding affinity	90:114	receptor binding affinity	90:114	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	9	64	theme	anti-SARS-CoV-	1342:1355	arg1	S309					1370:1373	S309	1370:1373	S309	1370:1373	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	9	64	theme	anti-SARS-CoV-	1342:1355	arg1	antibody					1360:1367	the reported anti-SARS-CoV-(2) antibody	1329:1367	the reported anti-SARS-CoV-(2) antibody	1329:1367	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	7	65	theme	glycosylation	994:1006	arg1	profile					1008:1014	the glycosylation profile	990:1014	the glycosylation profile of the spike protein receptor-binding domain (RBD)	990:1065	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	11	66	theme	specific	1808:1815	arg1	glycoforms					1817:1826	specific glycoforms	1808:1826	specific glycoforms	1808:1826	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	3	67	gly	heterogeneity	510:522	arg1	protein					537:543	the spike protein	527:543	the spike protein	527:543	Analytical reports have described the glycan heterogeneity of the spike protein.
36370046	2	68	theme	therapeutic	380:390	arg1	development					392:402	therapeutic development	380:402	therapeutic development	380:402	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	8	69	theme	binding	1097:1103	arg1	affinity					1105:1112	the receptor binding affinity	1084:1112	the receptor binding affinity	1084:1112	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	2	70	theme	glycosylation	435:447	arg1	effects					420:426	the exact effects	410:426	the exact effects of its glycosylation	410:447	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	10	71	theme	dynamics	1491:1498	arg1	simulation					1500:1509	molecular dynamics simulation	1481:1509	molecular dynamics simulation	1481:1509	In combination with molecular dynamics simulation, this work reports the regulatory roles that glycosylation plays in the interaction between the viral spike protein and host receptor, providing new insights into the nature of SARS-CoV-2.
36370046	0	72	theme	SARS-CoV-2	25:34	arg1	glycans					50:56	SARS-CoV-2 spike protein glycans	25:56	SARS-CoV-2 spike protein glycans	25:56	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	7	73	theme	enzymes	958:964	arg1	combinations					925:936	designed combinations	916:936	designed combinations of glycoengineering enzymes	916:964	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	11	74	theme	glycan	1729:1734	arg1	remodeling					1736:1745	enzymatic glycan remodeling	1719:1745	enzymatic glycan remodeling	1719:1745	Beyond this study, enzymatic glycan remodeling offers the opportunity to understand the fundamental role of specific glycoforms on glycoconjugates across molecular biology.
36370046	2	75	theme	exact	414:418	arg1	effects					420:426	the exact effects	410:426	the exact effects of its glycosylation	410:447	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	0	76	theme	protein	42:48	arg1	glycans					50:56	SARS-CoV-2 spike protein glycans	25:56	SARS-CoV-2 spike protein glycans	25:56	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor binding affinity.
36370046	8	77	theme	regulatory	1132:1141	arg1	effects					1143:1149	opposite regulatory effects	1123:1149	opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering	1123:1302	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	7	78	used	used	911:914	arg2	we					908:909	we	908:909	we	908:909	Herein, we used designed combinations of glycoengineering enzymes to simplify and control the glycosylation profile of the spike protein receptor-binding domain (RBD).
36370046	4	79	theme	molecular	557:565	arg1	studies					578:584	Subsequent molecular simulation studies	546:584	Subsequent molecular simulation studies	546:584	Subsequent molecular simulation studies provided a knowledge basis of the glycan functions.
36370046	3	80	theme	glycan	503:508	arg1	heterogeneity					510:522	the glycan heterogeneity	499:522	the glycan heterogeneity of the spike protein	499:543	Analytical reports have described the glycan heterogeneity of the spike protein.
36370046	9	81	theme	different	1402:1410	arg1	glycoforms					1416:1425	different RBD glycoforms	1402:1425	different RBD glycoforms	1402:1425	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	8	82	theme	RBD	1158:1160	arg1	glycans					1162:1168	the RBD glycans	1154:1168	the RBD glycans	1154:1168	Measurements of the receptor binding affinity revealed opposite regulatory effects of the RBD glycans with and without sialylation, which presents a potential strategy for modulating the spike protein behaviors through glycoengineering.
36370046	4	83	theme	functions	627:635	arg1	basis					607:611	a knowledge basis	595:611	a knowledge basis of the glycan functions	595:635	Subsequent molecular simulation studies provided a knowledge basis of the glycan functions.
36370046	2	84	theme	spike	320:324	arg1	target					357:362	the principal target	343:362	the principal target for vaccine and therapeutic development	343:402	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	2	84	theme	spike	320:324	arg1	protein					326:332	The spike protein	316:332	The spike protein	316:332	The spike protein has been the principal target for vaccine and therapeutic development while the exact effects of its glycosylation remain elusive.
36370046	9	85	theme	glycoforms	1416:1425	arg1	impact					1392:1397	the impact	1388:1397	the impact of different RBD glycoforms on the receptor binding affinity	1388:1458	Moreover, we found that the reported anti-SARS-CoV-(2) antibody, S309, neutralizes the impact of different RBD glycoforms on the receptor binding affinity.
36370046	6	86	theme	effective	844:852	arg1	medicines					854:862	medicines	854:862	medicines	854:862	Building an understanding of their roles in SARS-CoV-2 is important as we continue to develop effective medicines and vaccines to combat the disease.
36370046	3	87	theme	spike	531:535	arg1	protein					537:543	the spike protein	527:543	the spike protein	527:543	Analytical reports have described the glycan heterogeneity of the spike protein.
35504880	6	0	theme	substrates	1007:1016	arg1	glycosylation					976:988	broad glycosylation	970:988	broad glycosylation of both acceptor substrates	970:1016	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	4	1	gly	glycopeptides	571:583	arg2	glycopeptides					571:583	the glycopeptides	567:583	the glycopeptides	567:583	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	1	2	theme	core	158:161	arg1	precursor					185:193	a common precursor	176:193	a common precursor for mucin-type O-glycans found in many glycoproteins	176:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	1	2	theme	core	158:161	arg1	structure					165:173	the core 1 structure	154:173	the core 1 structure	154:173	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	6	3	theme	acceptor	998:1005	arg1	substrates					1007:1016	both acceptor substrates	993:1016	both acceptor substrates	993:1016	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	6	4	gly	glycosylation	976:988	arg1	substrates					1007:1016	both acceptor substrates	993:1016	both acceptor substrates	993:1016	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	2	5	theme	catalysis	328:336	arg1	structure					262:270	the structure	258:270	the structure of C1GalT1	258:281	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	2	5	theme	catalysis	328:336	arg1	details					291:297	the details	287:297	the details of substrate recognition and catalysis	287:336	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	3	6	theme	SN2	537:539	arg1	mechanism					541:549	a SN2 mechanism	535:549	a SN2 mechanism	535:549	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	7	7	gly	glycosylation	1095:1107	arg1	substrates					1130:1139	multiple acceptor substrates	1112:1139	multiple acceptor substrates	1112:1139	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	4	8	theme	binding	693:699	arg1	parameters					701:710	optimal kinetic and binding parameters	673:710	optimal kinetic and binding parameters	673:710	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	4	9	theme	kinetic	681:687	arg1	parameters					701:710	optimal kinetic and binding parameters	673:710	optimal kinetic and binding parameters	673:710	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	7	10	theme	acceptor	1121:1128	arg1	substrates					1130:1139	multiple acceptor substrates	1112:1139	multiple acceptor substrates	1112:1139	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	3	11	theme	fold	511:514	arg1	C1GalT1					483:489	C1GalT1	483:489	C1GalT1	483:489	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	3	11	theme	fold	511:514	arg1	dimer					516:520	an obligate GT-A fold dimer	494:520	an obligate GT-A fold dimer that follows a SN2 mechanism	494:549	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	3	12	theme	C1GalT1	431:437	arg1	crystallography					412:426	X-ray crystallography	406:426	X-ray crystallography of C1GalT1 complexed to a glycopeptide	406:465	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	7	13	theme	mechanisms	1170:1179	arg1	mechanisms					1170:1179	mechanisms	1170:1179	mechanisms adopted by glycosyltransferases	1170:1211	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	7	13	theme	mechanisms	1170:1179	arg1	repertoire					1156:1165	the repertoire	1152:1165	the repertoire of mechanisms adopted by glycosyltransferases	1152:1211	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	7	14	theme	substrates	1130:1139	arg1	glycosylation					1095:1107	glycosylation	1095:1107	glycosylation of multiple acceptor substrates	1095:1139	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	3	15	theme	cellular	378:385	arg1	crystallography					412:426	X-ray crystallography	406:426	X-ray crystallography of C1GalT1 complexed to a glycopeptide	406:465	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	3	15	theme	cellular	378:385	arg1	studies					387:393	biophysical and cellular studies	362:393	biophysical and cellular studies	362:393	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	1	16	gly	glycoproteins	234:246	arg1	glycoproteins					234:246	many glycoproteins	229:246	many glycoproteins	229:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	0	17	theme	Structural	0:9	arg1	basis					11:15	Structural basis	0:15	Structural basis for the synthesis of the core 1 structure by C1GalT1	0:68	Structural basis for the synthesis of the core 1 structure by C1GalT1.
35504880	7	18	theme	multiple	1112:1119	arg1	substrates					1130:1139	multiple acceptor substrates	1112:1139	multiple acceptor substrates	1112:1139	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	4	19	theme	GalNAc	623:628	arg1	moiety					630:635	the GalNAc moiety	619:635	the GalNAc moiety	619:635	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	6	20	theme	broad	970:974	arg1	glycosylation					976:988	broad glycosylation	970:988	broad glycosylation of both acceptor substrates	970:1016	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	1	21	theme	common	178:183	arg1	precursor					185:193	a common precursor	176:193	a common precursor for mucin-type O-glycans found in many glycoproteins	176:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	1	21	theme	common	178:183	arg1	structure					165:173	the core 1 structure	154:173	the core 1 structure	154:173	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	3	22	theme	biophysical	362:372	arg1	crystallography					412:426	X-ray crystallography	406:426	X-ray crystallography of C1GalT1 complexed to a glycopeptide	406:465	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	3	22	theme	biophysical	362:372	arg1	studies					387:393	biophysical and cellular studies	362:393	biophysical and cellular studies	362:393	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	2	23	theme	C1GalT1	275:281	arg1	structure					262:270	the structure	258:270	the structure of C1GalT1	258:281	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	2	23	theme	C1GalT1	275:281	arg1	details					291:297	the details	287:297	the details of substrate recognition and catalysis	287:336	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	4	24	theme	peptide	647:653	arg1	sequence					655:662	the peptide sequence	643:662	the peptide sequence	643:662	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	2	25	theme	recognition	312:322	arg1	structure					262:270	the structure	258:270	the structure of C1GalT1	258:281	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	2	25	theme	recognition	312:322	arg1	details					291:297	the details	287:297	the details of substrate recognition and catalysis	287:336	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	1	26	located	found	220:224	arg2	O-glycans					210:218	mucin-type O-glycans	199:218	mucin-type O-glycans found in many glycoproteins	199:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	1	26	located	found	220:224	arg1	glycoproteins					234:246	many glycoproteins	229:246	many glycoproteins	229:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	3	27	theme	X-ray	406:410	arg1	crystallography					412:426	X-ray crystallography	406:426	X-ray crystallography of C1GalT1 complexed to a glycopeptide	406:465	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	4	28	theme	optimal	673:679	arg1	parameters					701:710	optimal kinetic and binding parameters	673:710	optimal kinetic and binding parameters	673:710	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	3	29	gly	glycopeptide	454:465	arg2	glycopeptide					454:465	a glycopeptide	452:465	a glycopeptide	452:465	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	1	30	theme	mucin-type	199:208	arg1	O-glycans					210:218	mucin-type O-glycans	199:218	mucin-type O-glycans found in many glycoproteins	199:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	0	31	theme	core	42:45	arg1	structure					49:57	the core 1 structure	38:57	the core 1 structure	38:57	Structural basis for the synthesis of the core 1 structure by C1GalT1.
35504880	6	32	theme	peptides	944:951	arg1	characteristic					913:926	characteristic	913:926	characteristic	913:926	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	1	33	theme	essential	85:93	arg1	glycosyltransferase					105:123	an essential inverting glycosyltransferase	82:123	an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins	82:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	1	33	theme	essential	85:93	arg1	C1GalT1					71:77	C1GalT1	71:77	C1GalT1	71:77	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	5	34	theme	high-energy	775:785	arg1	conformation					787:798	a high-energy conformation	773:798	a high-energy conformation of the α-GalNAc-Thr linkage, negligibly populated	773:848	Interestingly, to achieve glycosylation, C1GalT1 recognizes a high-energy conformation of the α-GalNAc-Thr linkage, negligibly populated in solution.
35504880	6	35	theme	α-GalNAc-Ser	931:942	arg1	peptides					944:951	α-GalNAc-Ser peptides	931:951	α-GalNAc-Ser peptides	931:951	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	7	36	theme	mechanistic	1062:1072	arg1	blueprint					1074:1082	a structural and mechanistic blueprint	1045:1082	a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates	1045:1139	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	1	37	theme	inverting	95:103	arg1	glycosyltransferase					105:123	an essential inverting glycosyltransferase	82:123	an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins	82:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	1	37	theme	inverting	95:103	arg1	C1GalT1					71:77	C1GalT1	71:77	C1GalT1	71:77	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	2	38	theme	substrate	302:310	arg1	recognition					312:322	substrate recognition	302:322	substrate recognition	302:322	To date, the structure of C1GalT1 and the details of substrate recognition and catalysis remain unknown.
35504880	7	39	theme	structural	1047:1056	arg1	blueprint					1074:1082	a structural and mechanistic blueprint	1045:1082	a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates	1045:1139	These findings illustrate a structural and mechanistic blueprint to explain glycosylation of multiple acceptor substrates, extending the repertoire of mechanisms adopted by glycosyltransferases.
35504880	1	40	theme	responsible	125:135	arg1	glycosyltransferase					105:123	an essential inverting glycosyltransferase	82:123	an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins	82:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	1	40	theme	responsible	125:135	arg1	C1GalT1					71:77	C1GalT1	71:77	C1GalT1	71:77	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
35504880	4	41	theme	glycopeptides	571:583	arg1	binding					556:562	The binding	552:562	The binding of the glycopeptides to the enzyme	552:597	The binding of the glycopeptides to the enzyme is mainly driven by the GalNAc moiety while the peptide sequence provides optimal kinetic and binding parameters.
35504880	0	42	theme	structure	49:57	arg1	synthesis					25:33	the synthesis	21:33	the synthesis of the core 1 structure by C1GalT1	21:68	Structural basis for the synthesis of the core 1 structure by C1GalT1.
35504880	5	43	theme	populated	840:848	arg1	linkage					820:826	the α-GalNAc-Thr linkage	803:826	the α-GalNAc-Thr linkage	803:826	Interestingly, to achieve glycosylation, C1GalT1 recognizes a high-energy conformation of the α-GalNAc-Thr linkage, negligibly populated in solution.
35504880	5	44	theme	linkage	820:826	arg1	conformation					787:798	a high-energy conformation	773:798	a high-energy conformation of the α-GalNAc-Thr linkage, negligibly populated	773:848	Interestingly, to achieve glycosylation, C1GalT1 recognizes a high-energy conformation of the α-GalNAc-Thr linkage, negligibly populated in solution.
35504880	3	45	theme	obligate	497:504	arg1	C1GalT1					483:489	C1GalT1	483:489	C1GalT1	483:489	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	3	45	theme	obligate	497:504	arg1	dimer					516:520	an obligate GT-A fold dimer	494:520	an obligate GT-A fold dimer that follows a SN2 mechanism	494:549	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	6	46	theme	characteristic	913:926	arg1	fragment					903:910	that fragment	898:910	that fragment	898:910	By imposing this 3D-arrangement on that fragment, characteristic of α-GalNAc-Ser peptides, C1GalT1 ensures broad glycosylation of both acceptor substrates.
35504880	5	47	theme	α-GalNAc-Thr	807:818	arg1	linkage					820:826	the α-GalNAc-Thr linkage	803:826	the α-GalNAc-Thr linkage	803:826	Interestingly, to achieve glycosylation, C1GalT1 recognizes a high-energy conformation of the α-GalNAc-Thr linkage, negligibly populated in solution.
35504880	3	48	theme	GT-A	506:509	arg1	C1GalT1					483:489	C1GalT1	483:489	C1GalT1	483:489	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	3	48	theme	GT-A	506:509	arg1	dimer					516:520	an obligate GT-A fold dimer	494:520	an obligate GT-A fold dimer that follows a SN2 mechanism	494:549	Through biophysical and cellular studies, including X-ray crystallography of C1GalT1 complexed to a glycopeptide, we report that C1GalT1 is an obligate GT-A fold dimer that follows a SN2 mechanism.
35504880	1	49	theme	many	229:232	arg1	glycoproteins					234:246	many glycoproteins	229:246	many glycoproteins	229:246	C1GalT1 is an essential inverting glycosyltransferase responsible for synthesizing the core 1 structure, a common precursor for mucin-type O-glycans found in many glycoproteins.
37294165	1	0	theme	secreted	220:227	arg1	biomarker					309:317	an interesting biomarker	294:317	an interesting biomarker for cancer cells	294:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	0	theme	secreted	220:227	arg1	protein					229:235	a secreted protein	218:235	a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells	218:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	0	theme	secreted	220:227	arg1	inhibitor					181:189	Serine protease inhibitor	165:189	Serine protease inhibitor Kazal type 13 (SPINK13)	165:213	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	0	theme	secreted	220:227	arg1	drug					285:288	a therapeutic drug	271:288	a therapeutic drug	271:288	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	6	1	theme	insertion	1111:1119	arg1	strategy					1121:1128	This insertion strategy	1106:1128	This insertion strategy	1106:1128	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
37294165	6	2	theme	glycosylated	1213:1224	arg1	thioacid					1237:1244	glycosylated asparagine thioacid	1213:1244	glycosylated asparagine thioacid	1213:1244	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
37294165	4	3	theme	fast-flow	803:811	arg1	method					818:823	a fast-flow SPPS method	801:823	a fast-flow SPPS method	801:823	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	7	4	theme	glycoprotein	1359:1370	arg1	time					1351:1354	the total synthetic time	1331:1354	the total synthetic time of glycoprotein	1331:1370	Because the two peptides used for this synthesis were prepared by a fast-flow SPPS, the total synthetic time of glycoprotein was considerably shortened.
37294165	3	5	theme	glycosylated	528:539	arg1	SPINK					541:545	glycosylated SPINK 13	528:548	glycosylated SPINK 13	528:548	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	1	6	theme	protease	172:179	arg1	protein					229:235	a secreted protein	218:235	a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells	218:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	6	theme	protease	172:179	arg1	inhibitor					181:189	Serine protease inhibitor	165:189	Serine protease inhibitor Kazal type 13 (SPINK13)	165:213	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	7	theme	Kazal	191:195	arg1	type					197:200	Kazal type 13	191:203	Serine protease inhibitor Kazal type 13 (SPINK13)	165:213	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	7	theme	Kazal	191:195	arg1	SPINK13					206:212	SPINK13	206:212	SPINK13	206:212	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	8	8	theme	synthetic	1405:1413	arg1	concept					1415:1421	This synthetic concept	1400:1421	This synthetic concept	1400:1421	This synthetic concept enables us to repetitively synthesize a target glycoprotein easily.
37294165	7	9	theme	total	1335:1339	arg1	time					1351:1354	the total synthetic time	1331:1354	the total synthetic time of glycoprotein	1331:1370	Because the two peptides used for this synthesis were prepared by a fast-flow SPPS, the total synthetic time of glycoprotein was considerably shortened.
37294165	0	10	theme	Glycan	114:119	arg1	Strategy					131:138	Glycan Insertion Strategy	114:138	Glycan Insertion Strategy	114:138	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	2	11	contain	has	354:356	arg2	Pro-Asn-Val-Thr					380:394	Pro-Asn-Val-Thr	380:394	Pro-Asn-Val-Thr	380:394	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	2	11	contain	has	354:356	arg2	sequence					370:377	a consensus sequence	358:377	a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation	358:415	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	2	11	contain	has	354:356	arg1	SPINK13					346:352	SPINK13	346:352	SPINK13	346:352	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	6	12	theme	SPINK13	1183:1189	arg1	polypeptide					1168:1178	the full-length polypeptide	1152:1178	the full-length polypeptide of SPINK13	1152:1189	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
37294165	3	13	gly	glycosylated	528:539	arg1	SPINK					541:545	glycosylated SPINK 13	528:548	glycosylated SPINK 13	528:548	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	10	14	theme	glycosylated	1601:1612	arg1	SPINK13					1614:1620	glycosylated SPINK13	1601:1620	glycosylated SPINK13	1601:1620	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	8	15	gly	glycoprotein	1470:1481	arg1	glycoprotein					1470:1481	a target glycoprotein	1461:1481	a target glycoprotein	1461:1481	This synthetic concept enables us to repetitively synthesize a target glycoprotein easily.
37294165	7	16	theme	fast-flow	1315:1323	arg1	SPPS					1325:1328	a fast-flow SPPS	1313:1328	a fast-flow SPPS	1313:1328	Because the two peptides used for this synthesis were prepared by a fast-flow SPPS, the total synthetic time of glycoprotein was considerably shortened.
37294165	9	17	theme	bond	1572:1575	arg1	map					1577:1579	disulfide bond map	1562:1579	disulfide bond map	1562:1579	Folding experiments afforded well-folded structure confirmed by CD and disulfide bond map.
37294165	0	18	theme	Fast-Flow	144:152	arg1	SPPS					159:162	Fast-Flow Fmoc SPPS	144:162	Fast-Flow Fmoc SPPS	144:162	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	0	19	with	Method	102:107	arg1	SPPS					159:162	Fast-Flow Fmoc SPPS	144:162	Fast-Flow Fmoc SPPS	144:162	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	0	19	with	Method	102:107	arg1	Strategy					131:138	Glycan Insertion Strategy	114:138	Glycan Insertion Strategy	114:138	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	8	20	theme	target	1463:1468	arg1	glycoprotein					1470:1481	a target glycoprotein	1461:1481	a target glycoprotein	1461:1481	This synthetic concept enables us to repetitively synthesize a target glycoprotein easily.
37294165	0	21	theme	SPINK13	69:75	arg1	Glycoform					78:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	1	22	theme	interesting	297:307	arg1	biomarker					309:317	an interesting biomarker	294:317	an interesting biomarker for cancer cells	294:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	22	theme	interesting	297:307	arg1	protein					229:235	a secreted protein	218:235	a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells	218:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	9	23	theme	well-folded	1520:1530	arg1	structure					1532:1540	well-folded structure	1520:1540	well-folded structure confirmed by CD and disulfide bond map	1520:1579	Folding experiments afforded well-folded structure confirmed by CD and disulfide bond map.
37294165	10	24	gly	non-glycosylated	1626:1641	arg1	SPINK13					1643:1649	non-glycosylated SPINK13	1626:1649	non-glycosylated SPINK13	1626:1649	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	0	25	theme	Glycoform	78:86	arg1	Synthesis					15:23	Rapid Chemical Synthesis	0:23	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.	0:163	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	4	26	theme	rapid	721:725	arg1	method					737:742	a rapid synthetic method	719:742	a rapid synthetic method combined with the chemical glycan insertion strategy	719:795	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	10	27	theme	cancer	1667:1672	arg1	cells					1674:1678	pancreatic cancer cells	1656:1678	pancreatic cancer cells	1656:1678	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	4	28	theme	N-glycosylated	685:698	arg1	form					700:703	the scarce N-glycosylated form	674:703	the scarce N-glycosylated form of SPINK13	674:714	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	0	29	theme	Rapid	0:4	arg1	Synthesis					15:23	Rapid Chemical Synthesis	0:23	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.	0:163	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	9	30	theme	disulfide	1562:1570	arg1	map					1577:1579	disulfide bond map	1562:1579	disulfide bond map	1562:1579	Folding experiments afforded well-folded structure confirmed by CD and disulfide bond map.
37294165	10	31	theme	non-glycosylated	1692:1707	arg1	SPINK-13					1709:1716	non-glycosylated SPINK-13	1692:1716	non-glycosylated SPINK-13	1692:1716	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	5	32	theme	asparagine	839:848	arg1	thioacid					850:857	Glycosylated asparagine thioacid	826:857	Glycosylated asparagine thioacid	826:857	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	2	33	theme	N-glycosylation	435:449	arg1	functions					459:467	its functions	455:467	its functions	455:467	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	2	33	theme	N-glycosylation	435:449	arg1	existence					422:430	the existence	418:430	the existence of N-glycosylation	418:449	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	2	33	theme	N-glycosylation	435:449	arg1	unclear					479:485	unclear	479:485	unclear	479:485	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	4	34	theme	chemical	762:769	arg1	strategy					788:795	the chemical glycan insertion strategy	758:795	the chemical glycan insertion strategy	758:795	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	0	35	theme	Serine	28:33	arg1	Glycoform					78:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	5	36	theme	-Val	980:983	arg1	junction					985:992	the sterically bulky Pro-Asn(N-glycan)-Val junction	942:992	the sterically bulky Pro-Asn(N-glycan)-Val junction	942:992	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	3	37	theme	cell	584:587	arg1	method					600:605	the cell expression method	580:605	the cell expression method	580:605	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	4	38	theme	insertion	778:786	arg1	strategy					788:795	the chemical glycan insertion strategy	758:795	the chemical glycan insertion strategy	758:795	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	0	39	theme	Inhibitor	44:52	arg1	Glycoform					78:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	1	40	theme	therapeutic	273:283	arg1	protein					229:235	a secreted protein	218:235	a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells	218:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	40	theme	therapeutic	273:283	arg1	drug					285:288	a therapeutic drug	271:288	a therapeutic drug	271:288	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	3	41	theme	chemical	611:618	arg1	synthesis					620:628	chemical synthesis	611:628	chemical synthesis	611:628	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	1	42	dep	inhibitor	181:189	arg1	type					197:200	Kazal type 13	191:203	Serine protease inhibitor Kazal type 13 (SPINK13)	165:213	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	42	dep	inhibitor	181:189	arg1	SPINK13					206:212	SPINK13	206:212	SPINK13	206:212	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	10	43	theme	glycosylated	1747:1758	arg1	SPINK13					1760:1766	glycosylated SPINK13	1747:1766	glycosylated SPINK13	1747:1766	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	7	44	gly	glycoprotein	1359:1370	arg1	glycoprotein					1359:1370	glycoprotein	1359:1370	glycoprotein	1359:1370	Because the two peptides used for this synthesis were prepared by a fast-flow SPPS, the total synthetic time of glycoprotein was considerably shortened.
37294165	10	45	gly	glycosylated	1747:1758	arg1	SPINK13					1760:1766	glycosylated SPINK13	1747:1766	glycosylated SPINK13	1747:1766	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	4	46	theme	SPPS	813:816	arg1	method					818:823	a fast-flow SPPS method	801:823	a fast-flow SPPS method	801:823	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	6	47	theme	asparagine	1226:1235	arg1	thioacid					1237:1244	glycosylated asparagine thioacid	1213:1244	glycosylated asparagine thioacid	1213:1244	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
37294165	1	48	theme	Serine	165:170	arg1	protein					229:235	a secreted protein	218:235	a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells	218:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	1	48	theme	Serine	165:170	arg1	inhibitor					181:189	Serine protease inhibitor	165:189	Serine protease inhibitor Kazal type 13 (SPINK13)	165:213	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	5	49	theme	capture	1082:1088	arg1	TCL					1100:1102	TCL	1100:1102	TCL	1100:1102	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	5	49	theme	capture	1082:1088	arg1	ligation					1090:1097	thioacid capture ligation	1073:1097	thioacid capture ligation (TCL)	1073:1103	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	5	50	dep	-Val	980:983	arg1	Pro-Asn					963:969	sterically bulky Pro-Asn	946:969	sterically bulky Pro-Asn	946:969	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	10	51	theme	Invasion	1582:1589	arg1	assays					1591:1596	Invasion assays	1582:1596	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells	1582:1678	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	10	52	theme	non-glycosylated	1626:1641	arg1	SPINK13					1643:1649	non-glycosylated SPINK13	1626:1649	non-glycosylated SPINK13	1626:1649	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	0	53	theme	Insertion	121:129	arg1	Strategy					131:138	Glycan Insertion Strategy	114:138	Glycan Insertion Strategy	114:138	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	10	54	gly	non-glycosylated	1692:1707	arg1	SPINK-13					1709:1716	non-glycosylated SPINK-13	1692:1716	non-glycosylated SPINK-13	1692:1716	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	5	55	theme	Glycosylated	826:837	arg1	thioacid					850:857	Glycosylated asparagine thioacid	826:857	Glycosylated asparagine thioacid	826:857	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	7	56	theme	synthetic	1341:1349	arg1	time					1351:1354	the total synthetic time	1331:1354	the total synthetic time of glycoprotein	1331:1370	Because the two peptides used for this synthesis were prepared by a fast-flow SPPS, the total synthetic time of glycoprotein was considerably shortened.
37294165	10	57	theme	SPINK13	1614:1620	arg1	assays					1591:1596	Invasion assays	1582:1596	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells	1582:1678	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	5	58	theme	disulfide	1044:1052	arg1	DDC					1064:1066	DDC	1064:1066	DDC	1064:1066	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	5	58	theme	disulfide	1044:1052	arg1	coupling					1054:1061	diacyl disulfide coupling	1037:1061	diacyl disulfide coupling (DDC)	1037:1067	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	3	59	theme	SPINK	541:545	arg1	preparation					513:523	the preparation	509:523	the preparation of glycosylated SPINK 13	509:548	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	6	60	gly	glycosylated	1213:1224	arg1	thioacid					1237:1244	glycosylated asparagine thioacid	1213:1244	glycosylated asparagine thioacid	1213:1244	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
37294165	4	61	theme	chemical	652:659	arg1	synthesis					661:669	the chemical synthesis	648:669	the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method	648:823	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	0	62	theme	Fmoc	154:157	arg1	SPPS					159:162	Fast-Flow Fmoc SPPS	144:162	Fast-Flow Fmoc SPPS	144:162	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	5	63	theme	coupling	1001:1008	arg1	reactions					1010:1018	two coupling reactions	997:1018	two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL)	997:1103	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	3	64	dep	this	503:506	arg1	addition					491:498	addition	491:498	addition	491:498	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	6	65	theme	full-length	1156:1166	arg1	polypeptide					1168:1178	the full-length polypeptide	1152:1178	the full-length polypeptide of SPINK13	1152:1189	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
37294165	9	66	theme	Folding	1491:1497	arg1	experiments					1499:1509	Folding experiments	1491:1509	Folding experiments	1491:1509	Folding experiments afforded well-folded structure confirmed by CD and disulfide bond map.
37294165	4	67	gly	N-glycosylated	685:698	arg1	form					700:703	the scarce N-glycosylated form	674:703	the scarce N-glycosylated form of SPINK13	674:714	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	4	67	gly	N-glycosylated	685:698	arg1	SPINK13					708:714	SPINK13	708:714	SPINK13	708:714	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	5	68	theme	thioacid	1073:1080	arg1	TCL					1100:1102	TCL	1100:1102	TCL	1100:1102	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	5	68	theme	thioacid	1073:1080	arg1	ligation					1090:1097	thioacid capture ligation	1073:1097	thioacid capture ligation (TCL)	1073:1103	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	10	69	gly	glycosylated	1601:1612	arg1	SPINK13					1614:1620	glycosylated SPINK13	1601:1620	glycosylated SPINK13	1601:1620	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	4	70	theme	SPINK13	708:714	arg1	form					700:703	the scarce N-glycosylated form	674:703	the scarce N-glycosylated form of SPINK13	674:714	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	0	71	theme	Combined	93:100	arg1	Method					102:107	a Combined Method	91:107	a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS	91:162	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	1	72	theme	cancer	323:328	arg1	cells					330:334	cancer cells	323:334	cancer cells	323:334	Serine protease inhibitor Kazal type 13 (SPINK13) is a secreted protein that has been recently studied as a therapeutic drug and an interesting biomarker for cancer cells.
37294165	10	73	theme	pancreatic	1656:1665	arg1	cells					1674:1678	pancreatic cancer cells	1656:1678	pancreatic cancer cells	1656:1678	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	0	74	theme	Chemical	6:13	arg1	Synthesis					15:23	Rapid Chemical Synthesis	0:23	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.	0:163	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	4	75	theme	scarce	678:683	arg1	form					700:703	the scarce N-glycosylated form	674:703	the scarce N-glycosylated form of SPINK13	674:714	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	10	76	theme	SPINK13	1643:1649	arg1	assays					1591:1596	Invasion assays	1582:1596	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells	1582:1678	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	5	77	theme	peptide	916:922	arg1	segments					924:931	two peptide segments	912:931	two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction	912:992	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	3	78	theme	expression	589:598	arg1	method					600:605	the cell expression method	580:605	the cell expression method	580:605	In addition to this, the preparation of glycosylated SPINK 13 has not been examined by both the cell expression method and chemical synthesis.
37294165	4	79	theme	form	700:703	arg1	synthesis					661:669	the chemical synthesis	648:669	the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method	648:823	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	0	80	theme	Protease	35:42	arg1	Glycoform					78:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	2	81	theme	consensus	360:368	arg1	sequence					370:377	a consensus sequence	358:377	a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation	358:415	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	2	81	theme	consensus	360:368	arg1	Pro-Asn-Val-Thr					380:394	Pro-Asn-Val-Thr	380:394	Pro-Asn-Val-Thr	380:394	Although SPINK13 has a consensus sequence (Pro-Asn-Val-Thr) for N-glycosylation, the existence of N-glycosylation and its functions are still unclear.
37294165	0	82	theme	Kazal-type	54:63	arg1	Glycoform					78:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform	28:86	Rapid Chemical Synthesis of Serine Protease Inhibitor Kazal-type 13 (SPINK13) Glycoform by a Combined Method with Glycan Insertion Strategy and Fast-Flow Fmoc SPPS.
37294165	4	83	theme	glycan	771:776	arg1	strategy					788:795	the chemical glycan insertion strategy	758:795	the chemical glycan insertion strategy	758:795	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	5	84	theme	diacyl	1037:1042	arg1	DDC					1064:1066	DDC	1064:1066	DDC	1064:1066	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	5	84	theme	diacyl	1037:1042	arg1	coupling					1054:1061	diacyl disulfide coupling	1037:1061	diacyl disulfide coupling (DDC)	1037:1067	Glycosylated asparagine thioacid was designed to chemoselectively be inserted between two peptide segments where is the sterically bulky Pro-Asn(N-glycan)-Val junction by two coupling reactions which consist of diacyl disulfide coupling (DDC) and thioacid capture ligation (TCL).
37294165	10	85	with	assays	1591:1596	arg1	cells					1674:1678	pancreatic cancer cells	1656:1678	pancreatic cancer cells	1656:1678	Invasion assays of glycosylated SPINK13 and non-glycosylated SPINK13 with pancreatic cancer cells showed that non-glycosylated SPINK-13 was more potent than that of glycosylated SPINK13.
37294165	4	86	theme	synthetic	727:735	arg1	method					737:742	a rapid synthetic method	719:742	a rapid synthetic method combined with the chemical glycan insertion strategy	719:795	Herein we report the chemical synthesis of the scarce N-glycosylated form of SPINK13 by a rapid synthetic method combined with the chemical glycan insertion strategy and a fast-flow SPPS method.
37294165	6	87	from	thioacid	1237:1244	arg1	steps					1202:1206	two steps	1198:1206	two steps from glycosylated asparagine thioacid	1198:1244	This insertion strategy successfully afforded the full-length polypeptide of SPINK13 within two steps from glycosylated asparagine thioacid.
36435935	8	0	gly	N-glycosylation	1142:1156	arg2	sites					1158:1162	closely spaced N-glycosylation sites	1127:1162	closely spaced N-glycosylation sites	1127:1162	This alternate priming allows OST to efficiently process closely spaced N-glycosylation sites.
36435935	1	1	theme	protein	167:173	arg1	glycosylation					175:187	N-linked protein glycosylation	158:187	N-linked protein glycosylation	158:187	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	0	2	theme	oligosaccharyltransferase	74:98	arg1	recognition					27:37	glycan recognition	20:37	glycan recognition	20:37	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase.
36435935	0	2	theme	oligosaccharyltransferase	74:98	arg1	priming					52:58	reaction priming	43:58	reaction priming	43:58	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase.
36435935	2	3	theme	reticulum	368:376	arg1	lumen					343:347	the lumen	339:347	the lumen of the endoplasmic reticulum	339:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	3	4	theme	Precise	379:385	arg1	recognition					387:397	Precise recognition	379:397	Precise recognition of the fully assembled glycan by OST	379:434	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	4	5	theme	molecular	533:541	arg1	unknown					588:594	unknown	588:594	unknown	588:594	However, the molecular basis of the OST-donor glycan interaction is unknown.
36435935	4	5	theme	molecular	533:541	arg1	basis					543:547	the molecular basis	529:547	the molecular basis of the OST-donor glycan interaction	529:583	However, the molecular basis of the OST-donor glycan interaction is unknown.
36435935	7	6	theme	subsequent	972:981	arg1	binding					983:989	subsequent binding	972:989	subsequent binding of the other substrate	972:1012	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	6	7	theme	non-catalytic	824:836	arg1	OST2					856:859	OST2	856:859	OST2	856:859	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	6	7	theme	non-catalytic	824:836	arg1	WBP1					847:850	WBP1	847:850	WBP1	847:850	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	6	7	theme	non-catalytic	824:836	arg1	subunits					838:845	the non-catalytic subunits WBP1 and OST2	820:859	the non-catalytic subunits WBP1 and OST2	820:859	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	2	8	theme	secretory	317:325	arg1	proteins					327:334	secretory proteins	317:334	secretory proteins in the lumen of the endoplasmic reticulum	317:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	1	9	theme	glycosylation	175:187	arg1	enzyme					148:153	the central enzyme	136:153	the central enzyme of N-linked protein glycosylation	136:187	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	1	9	theme	glycosylation	175:187	arg1	Oligosaccharyltransferase					101:125	Oligosaccharyltransferase	101:125	Oligosaccharyltransferase (OST)	101:131	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	5	10	theme	S.	635:636	arg1	OST					649:651	S. cerevisiae OST	635:651	S. cerevisiae OST	635:651	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	5	11	from	structures	621:630	arg1	states					676:681	distinct functional states	656:681	distinct functional states	656:681	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	5	12	theme	OST	649:651	arg1	structures					621:630	cryo-EM structures	613:630	cryo-EM structures of S. cerevisiae OST in distinct functional states	613:681	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	2	13	theme	acceptor	299:306	arg1	sites					308:312	acceptor sites	299:312	acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum	299:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	7	14	dep	binding	883:889	arg1	either					891:896	either	891:896	either	891:896	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	3	15	theme	assembled	412:420	arg1	glycan					422:427	the fully assembled glycan	402:427	the fully assembled glycan	402:427	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	3	16	theme	subsequent	457:466	arg1	steps					484:488	the subsequent quality control steps	453:488	the subsequent quality control steps of glycoprotein biosynthesis	453:517	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	7	17	theme	OST	961:963	arg1	states					951:956	distinct primed states	935:956	distinct primed states of OST	935:963	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	5	18	theme	distinct	656:663	arg1	states					676:681	distinct functional states	656:681	distinct functional states	656:681	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	7	19	theme	primed	944:949	arg1	states					951:956	distinct primed states	935:956	distinct primed states of OST	935:963	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	0	20	theme	Molecular	0:8	arg1	basis					10:14	Molecular basis	0:14	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase	0:98	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase.
36435935	5	21	theme	functional	665:674	arg1	states					676:681	distinct functional states	656:681	distinct functional states	656:681	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	7	22	theme	distinct	935:942	arg1	states					951:956	distinct primed states	935:956	distinct primed states of OST	935:963	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	8	23	theme	alternate	1075:1083	arg1	priming					1085:1091	This alternate priming	1070:1091	This alternate priming	1070:1091	This alternate priming allows OST to efficiently process closely spaced N-glycosylation sites.
36435935	6	24	theme	terminal	713:720	arg1	Glc3					732:735	Glc3	732:735	Glc3	732:735	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	6	24	theme	terminal	713:720	arg1	glucoses					722:729	the terminal glucoses	709:729	the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog	709:791	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	0	25	theme	glycan	20:25	arg1	recognition					27:37	glycan recognition	20:37	glycan recognition	20:37	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase.
36435935	4	26	theme	interaction	573:583	arg1	unknown					588:594	unknown	588:594	unknown	588:594	However, the molecular basis of the OST-donor glycan interaction is unknown.
36435935	4	26	theme	interaction	573:583	arg1	basis					543:547	the molecular basis	529:547	the molecular basis of the OST-donor glycan interaction	529:583	However, the molecular basis of the OST-donor glycan interaction is unknown.
36435935	5	27	theme	cryo-EM	613:619	arg1	structures					621:630	cryo-EM structures	613:630	cryo-EM structures of S. cerevisiae OST in distinct functional states	613:681	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	7	28	theme	other	998:1002	arg1	substrate					1004:1012	the other substrate	994:1012	the other substrate	994:1012	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	7	29	theme	substrate	1004:1012	arg1	binding					983:989	subsequent binding	972:989	subsequent binding of the other substrate	972:1012	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	3	30	gly	glycoprotein	493:504	arg1	glycoprotein					493:504	glycoprotein biosynthesis	493:517	glycoprotein biosynthesis	493:517	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	2	31	from	donor	290:294	arg1	transfer					207:214	the transfer	203:214	the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum	203:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	6	32	dep	subunits	838:845	arg1	OST2					856:859	OST2	856:859	OST2	856:859	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	6	32	dep	subunits	838:845	arg1	WBP1					847:850	WBP1	847:850	WBP1	847:850	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	6	32	dep	subunits	838:845	arg1	subunits					838:845	the non-catalytic subunits WBP1 and OST2	820:859	the non-catalytic subunits WBP1 and OST2	820:859	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	3	33	theme	quality	468:474	arg1	steps					484:488	the subsequent quality control steps	453:488	the subsequent quality control steps of glycoprotein biosynthesis	453:517	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	1	34	link	N-linked	158:165	arg1	glycosylation					175:187	N-linked protein glycosylation	158:187	N-linked protein glycosylation	158:187	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	7	35	theme	conformational	1023:1036	arg1	changes					1038:1044	conformational changes	1023:1044	conformational changes required for catalysis	1023:1067	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	3	36	theme	control	476:482	arg1	steps					484:488	the subsequent quality control steps	453:488	the subsequent quality control steps of glycoprotein biosynthesis	453:517	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	3	37	theme	glycan	422:427	arg1	recognition					387:397	Precise recognition	379:397	Precise recognition of the fully assembled glycan by OST	379:434	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	8	38	theme	spaced	1135:1140	arg1	sites					1158:1162	closely spaced N-glycosylation sites	1127:1162	closely spaced N-glycosylation sites	1127:1162	This alternate priming allows OST to efficiently process closely spaced N-glycosylation sites.
36435935	6	39	theme	analog	786:791	arg1	Glc3					732:735	Glc3	732:735	Glc3	732:735	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	6	39	theme	analog	786:791	arg1	glucoses					722:729	the terminal glucoses	709:729	the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog	709:791	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	2	40	theme	endoplasmic	356:366	arg1	reticulum					368:376	the endoplasmic reticulum	352:376	the endoplasmic reticulum	352:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	0	41	theme	reaction	43:50	arg1	priming					52:58	reaction priming	43:58	reaction priming	43:58	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase.
36435935	4	42	theme	glycan	566:571	arg1	interaction					573:583	the OST-donor glycan interaction	552:583	the OST-donor glycan interaction	552:583	However, the molecular basis of the OST-donor glycan interaction is unknown.
36435935	2	43	theme	pre-assembled	221:233	arg1	GlcNAc2Man9Glc3					243:257	GlcNAc2Man9Glc3	243:257	GlcNAc2Man9Glc3	243:257	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	2	43	theme	pre-assembled	221:233	arg1	glycan					235:240	a pre-assembled glycan	219:240	a pre-assembled glycan	219:240	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	2	44	theme	glycan	235:240	arg1	transfer					207:214	the transfer	203:214	the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum	203:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	6	45	theme	glycan	779:784	arg1	analog					786:791	a chemo-enzymatically generated donor glycan analog	741:791	a chemo-enzymatically generated donor glycan analog	741:791	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	5	46	dep	S.	635:636	arg1	cerevisiae					638:647	cerevisiae	638:647	cerevisiae	638:647	Here we present cryo-EM structures of S. cerevisiae OST in distinct functional states.
36435935	4	47	theme	OST-donor	556:564	arg1	interaction					573:583	the OST-donor glycan interaction	552:583	the OST-donor glycan interaction	552:583	However, the molecular basis of the OST-donor glycan interaction is unknown.
36435935	6	48	theme	donor	773:777	arg1	analog					786:791	a chemo-enzymatically generated donor glycan analog	741:791	a chemo-enzymatically generated donor glycan analog	741:791	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	1	49	theme	central	140:146	arg1	enzyme					148:153	the central enzyme	136:153	the central enzyme of N-linked protein glycosylation	136:187	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	1	49	theme	central	140:146	arg1	Oligosaccharyltransferase					101:125	Oligosaccharyltransferase	101:125	Oligosaccharyltransferase (OST)	101:131	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	8	50	theme	N-glycosylation	1142:1156	arg1	sites					1158:1162	closely spaced N-glycosylation sites	1127:1162	closely spaced N-glycosylation sites	1127:1162	This alternate priming allows OST to efficiently process closely spaced N-glycosylation sites.
36435935	2	51	theme	dolichyl-pyrophosphate	267:288	arg1	donor					290:294	a dolichyl-pyrophosphate donor	265:294	a dolichyl-pyrophosphate donor	265:294	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	6	52	theme	generated	763:771	arg1	analog					786:791	a chemo-enzymatically generated donor glycan analog	741:791	a chemo-enzymatically generated donor glycan analog	741:791	Our findings reveal that the terminal glucoses (Glc3) of a chemo-enzymatically generated donor glycan analog bind to a pocket formed by the non-catalytic subunits WBP1 and OST2.
36435935	3	53	theme	biosynthesis	506:517	arg1	steps					484:488	the subsequent quality control steps	453:488	the subsequent quality control steps of glycoprotein biosynthesis	453:517	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	7	54	theme	acceptor	907:914	arg1	substrate					916:924	donor or acceptor substrate	898:924	substrate	916:924	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	3	55	theme	glycoprotein	493:504	arg1	biosynthesis					506:517	glycoprotein biosynthesis	493:517	glycoprotein biosynthesis	493:517	Precise recognition of the fully assembled glycan by OST is essential for the subsequent quality control steps of glycoprotein biosynthesis.
36435935	0	56	theme	eukaryotic	63:72	arg1	oligosaccharyltransferase					74:98	eukaryotic oligosaccharyltransferase	63:98	eukaryotic oligosaccharyltransferase	63:98	Molecular basis for glycan recognition and reaction priming of eukaryotic oligosaccharyltransferase.
36435935	7	57	theme	donor	898:902	arg1	substrate					916:924	donor or acceptor substrate	898:924	substrate	916:924	We further find that binding either donor or acceptor substrate leads to distinct primed states of OST, where subsequent binding of the other substrate triggers conformational changes required for catalysis.
36435935	2	58	from	sites	308:312	arg1	proteins					327:334	secretory proteins	317:334	secretory proteins in the lumen of the endoplasmic reticulum	317:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
36435935	1	59	theme	N-linked	158:165	arg1	glycosylation					175:187	N-linked protein glycosylation	158:187	N-linked protein glycosylation	158:187	Oligosaccharyltransferase (OST) is the central enzyme of N-linked protein glycosylation.
36435935	2	60	from	proteins	327:334	arg1	lumen					343:347	the lumen	339:347	the lumen of the endoplasmic reticulum	339:376	It catalyzes the transfer of a pre-assembled glycan, GlcNAc2Man9Glc3, from a dolichyl-pyrophosphate donor to acceptor sites in secretory proteins in the lumen of the endoplasmic reticulum.
37009642	5	0	theme	benzoic	674:680	arg1	tag					689:691	a 2-amino benzoic (2-AA) tag	664:691	a 2-amino benzoic (2-AA) tag	664:691	The N-glycans were released and labeled with a 2-amino benzoic (2-AA) tag.
37009642	6	1	theme	labeled	728:734	arg1	N-glycans					736:744	the 2-AA labeled N-glycans	719:744	the 2-AA labeled N-glycans	719:744	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	12	2	theme	adjacent	1593:1600	arg1	tissues					1610:1616	adjacent control tissues	1593:1616	adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data	1593:1681	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	9	3	theme	machine-learning	1147:1162	arg1	models					1164:1169	machine-learning models	1147:1169	machine-learning models	1147:1169	The data were separated based on the physical characteristics of N-glycans and used to test in machine-learning models.
37009642	0	4	theme	spectrometry-based	70:87	arg1	N-glycomics					89:99	mass spectrometry-based N-glycomics	65:99	mass spectrometry-based N-glycomics	65:99	Prediction of gastric cancer by machine learning integrated with mass spectrometry-based N-glycomics.
37009642	4	5	theme	tissues	515:521	arg1	proteins					427:434	The (glyco-) proteins	414:434	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	414:521	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	12	6	theme	N-glycomic	1667:1676	arg1	data					1678:1681	mass spectrometry-based N-glycomic data	1643:1681	mass spectrometry-based N-glycomic data	1643:1681	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	8	7	theme	N-glycans	1015:1023	arg1	levels					992:997	significant expression levels	969:997	significant expression levels of 14 different N-glycans	969:1023	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	1	8	theme	effective	162:170	arg1	treatment					185:193	effective and targeted treatment	162:193	effective and targeted treatment	162:193	Early and accurate diagnosis of gastric cancer is vital for effective and targeted treatment.
37009642	7	9	theme	N-glycans	888:896	arg1	areas					866:870	The relative and analyte areas	841:870	The relative and analyte areas of the detected N-glycans	841:896	The relative and analyte areas of the detected N-glycans were extracted from the obtained data.
37009642	4	10	theme	deparaffinization	595:611	arg1	step					613:616	the conventional deparaffinization step	578:616	the conventional deparaffinization step	578:616	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	11	11	theme	whole	1439:1443	arg1	dataset					1469:1475	the whole N-glycans relative area dataset	1435:1475	the whole N-glycans relative area dataset	1435:1475	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	4	12	theme	control	507:513	arg1	tissues					515:521	formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	439:521	tissues	515:521	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	5	13	theme	2-AA	683:686	arg1	tag					689:691	a 2-amino benzoic (2-AA) tag	664:691	a 2-amino benzoic (2-AA) tag	664:691	The N-glycans were released and labeled with a 2-amino benzoic (2-AA) tag.
37009642	8	14	theme	different	1005:1013	arg1	N-glycans					1015:1023	14 different N-glycans	1002:1023	14 different N-glycans	1002:1023	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	3	15	theme	gastric	364:370	arg1	cancer					372:377	gastric cancer	364:377	gastric cancer	364:377	This study aimed to profile the N-glycans in gastric cancer tissues to predict gastric cancer using machine learning algorithms.
37009642	8	16	theme	Statistical	937:947	arg1	analyses					949:956	Statistical analyses	937:956	Statistical analyses	937:956	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	8	17	theme	gastric	1028:1034	arg1	tissues					1043:1049	gastric cancer tissues	1028:1049	gastric cancer tissues	1028:1049	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	6	18	theme	2-AA	723:726	arg1	N-glycans					736:744	the 2-AA labeled N-glycans	719:744	the 2-AA labeled N-glycans	719:744	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	8	19	theme	cancer	1036:1041	arg1	tissues					1043:1049	gastric cancer tissues	1028:1049	gastric cancer tissues	1028:1049	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	10	20	theme	correlation	1320:1330	arg1	coefficient					1332:1342	Matthews correlation coefficient	1311:1342	Matthews correlation coefficient	1311:1342	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	7	21	theme	detected	879:886	arg1	N-glycans					888:896	the detected N-glycans	875:896	the detected N-glycans	875:896	The relative and analyte areas of the detected N-glycans were extracted from the obtained data.
37009642	4	22	theme	cancer	487:492	arg1	proteins					427:434	The (glyco-) proteins	414:434	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	414:521	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	10	23	theme	appropriate	1240:1250	arg1	model					1252:1256	the most appropriate model	1231:1256	the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset	1231:1374	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	23	theme	appropriate	1240:1250	arg1	perceptron					1210:1219	the multilayer perceptron	1195:1219	the multilayer perceptron (MLP)	1195:1225	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	6	24	theme	N-glycan	804:811	arg1	structures					813:822	fifty-nine N-glycan structures	793:822	fifty-nine N-glycan structures	793:822	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	1	25	theme	targeted	176:183	arg1	treatment					185:193	effective and targeted treatment	162:193	effective and targeted treatment	162:193	Early and accurate diagnosis of gastric cancer is vital for effective and targeted treatment.
37009642	3	26	theme	machine	385:391	arg1	learning					393:400	machine learning	385:400	machine learning algorithms	385:411	This study aimed to profile the N-glycans in gastric cancer tissues to predict gastric cancer using machine learning algorithms.
37009642	4	27	theme	gastric	479:485	arg1	cancer					487:492	formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	439:521	cancer	487:492	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	6	28	theme	fifty-nine	793:802	arg1	structures					813:822	fifty-nine N-glycan structures	793:822	fifty-nine N-glycan structures	793:822	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	3	29	theme	learning	393:400	arg1	algorithms					402:411	machine learning algorithms	385:411	machine learning algorithms	385:411	This study aimed to profile the N-glycans in gastric cancer tissues to predict gastric cancer using machine learning algorithms.
37009642	10	30	with	model	1252:1256	arg1	accuracy					1301:1308	accuracy	1301:1308	accuracy	1301:1308	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	30	with	model	1252:1256	arg1	specificity					1288:1298	specificity	1288:1298	specificity	1288:1298	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	30	with	model	1252:1256	arg1	coefficient					1332:1342	Matthews correlation coefficient	1311:1342	Matthews correlation coefficient	1311:1342	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	30	with	model	1252:1256	arg1	sensitivity					1275:1285	sensitivity	1275:1285	sensitivity	1275:1285	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	30	with	model	1252:1256	arg1	scores					1352:1357	f1 scores	1349:1357	f1 scores	1349:1357	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	5	31	theme	2-amino	666:672	arg1	tag					689:691	a 2-amino benzoic (2-AA) tag	664:691	a 2-amino benzoic (2-AA) tag	664:691	The N-glycans were released and labeled with a 2-amino benzoic (2-AA) tag.
37009642	1	32	theme	Early	102:106	arg1	diagnosis					121:129	Early and accurate diagnosis	102:129	Early and accurate diagnosis of gastric cancer	102:147	Early and accurate diagnosis of gastric cancer is vital for effective and targeted treatment.
37009642	6	33	theme	MALDI-MS	698:705	arg1	analysis					707:714	The MALDI-MS analysis	694:714	The MALDI-MS analysis of the 2-AA labeled N-glycans	694:744	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	12	34	with	tissues	1610:1616	arg1	accuracy					1628:1635	high accuracy	1623:1635	high accuracy using mass spectrometry-based N-glycomic data	1623:1681	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	0	35	theme	cancer	22:27	arg1	Prediction					0:9	Prediction	0:9	Prediction of gastric cancer by machine learning	0:47	Prediction of gastric cancer by machine learning integrated with mass spectrometry-based N-glycomics.
37009642	10	36	theme	Matthews	1311:1318	arg1	coefficient					1332:1342	Matthews correlation coefficient	1311:1342	Matthews correlation coefficient	1311:1342	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	7	37	theme	analyte	858:864	arg1	areas					866:870	The relative and analyte areas	841:870	The relative and analyte areas of the detected N-glycans	841:896	The relative and analyte areas of the detected N-glycans were extracted from the obtained data.
37009642	9	38	used	used	1131:1134	arg2	data					1056:1059	The data	1052:1059	The data	1052:1059	The data were separated based on the physical characteristics of N-glycans and used to test in machine-learning models.
37009642	0	39	theme	gastric	14:20	arg1	cancer					22:27	gastric cancer	14:27	gastric cancer	14:27	Prediction of gastric cancer by machine learning integrated with mass spectrometry-based N-glycomics.
37009642	4	40	theme	conventional	582:593	arg1	step					613:616	the conventional deparaffinization step	578:616	the conventional deparaffinization step	578:616	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	8	41	theme	significant	969:979	arg1	levels					992:997	significant expression levels	969:997	significant expression levels of 14 different N-glycans	969:1023	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	1	42	theme	accurate	112:119	arg1	diagnosis					121:129	Early and accurate diagnosis	102:129	Early and accurate diagnosis of gastric cancer	102:147	Early and accurate diagnosis of gastric cancer is vital for effective and targeted treatment.
37009642	11	43	theme	relative	1455:1462	arg1	dataset					1469:1475	the whole N-glycans relative area dataset	1435:1475	the whole N-glycans relative area dataset	1435:1475	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	10	44	theme	f1	1349:1350	arg1	scores					1352:1357	f1 scores	1349:1357	f1 scores	1349:1357	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	0	45	theme	machine	32:38	arg1	learning					40:47	machine learning	32:47	machine learning	32:47	Prediction of gastric cancer by machine learning integrated with mass spectrometry-based N-glycomics.
37009642	9	46	theme	N-glycans	1117:1125	arg1	characteristics					1098:1112	the physical characteristics	1085:1112	the physical characteristics of N-glycans	1085:1125	The data were separated based on the physical characteristics of N-glycans and used to test in machine-learning models.
37009642	4	47	theme	formalin-fixed	439:452	arg1	cancer					487:492	formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	439:521	cancer	487:492	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	9	48	theme	physical	1089:1096	arg1	characteristics					1098:1112	the physical characteristics	1085:1112	the physical characteristics of N-glycans	1085:1125	The data were separated based on the physical characteristics of N-glycans and used to test in machine-learning models.
37009642	7	49	theme	relative	845:852	arg1	areas					866:870	The relative and analyte areas	841:870	The relative and analyte areas of the detected N-glycans	841:896	The relative and analyte areas of the detected N-glycans were extracted from the obtained data.
37009642	11	50	theme	N-glycans	1445:1453	arg1	dataset					1469:1475	the whole N-glycans relative area dataset	1435:1475	the whole N-glycans relative area dataset	1435:1475	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	11	51	theme	AUC	1486:1488	arg1	value					1490:1494	the AUC value	1482:1494	the AUC value	1482:1494	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	11	51	theme	AUC	1486:1488	arg1	0.98					1514:1517	0.98	1514:1517	0.98	1514:1517	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	10	52	theme	multilayer	1199:1208	arg1	MLP					1222:1224	MLP	1222:1224	MLP	1222:1224	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	52	theme	multilayer	1199:1208	arg1	perceptron					1210:1219	the multilayer perceptron	1195:1219	the multilayer perceptron (MLP)	1195:1225	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	10	52	theme	multilayer	1199:1208	arg1	model					1252:1256	the most appropriate model	1231:1256	the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset	1231:1374	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	4	53	dep	embedded	463:470	arg1	FFPE					473:476	FFPE	473:476	FFPE	473:476	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	12	54	theme	spectrometry-based	1648:1665	arg1	data					1678:1681	mass spectrometry-based N-glycomic data	1643:1681	mass spectrometry-based N-glycomic data	1643:1681	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	11	55	theme	highest	1381:1387	arg1	score					1398:1402	The highest accuracy score	1377:1402	The highest accuracy score (96.0 ± 1.3)	1377:1415	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	11	55	theme	highest	1381:1387	arg1	±					1410:1410	96.0 ± 1.3	1405:1414	96.0 ± 1.3	1405:1414	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	4	56	theme	embedded	463:470	arg1	cancer					487:492	formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	439:521	cancer	487:492	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	6	57	theme	ionization	772:781	arg1	mode					783:786	negative ionization mode	763:786	negative ionization mode	763:786	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	4	58	theme	chloroform/methanol	541:559	arg1	extraction					561:570	chloroform/methanol extraction	541:570	chloroform/methanol extraction	541:570	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	3	59	from	N-glycans	317:325	arg1	tissues					345:351	gastric cancer tissues	330:351	gastric cancer tissues	330:351	This study aimed to profile the N-glycans in gastric cancer tissues to predict gastric cancer using machine learning algorithms.
37009642	2	60	theme	glycosylation	213:225	arg1	profiles					227:234	glycosylation profiles	213:234	glycosylation profiles	213:234	It is known that glycosylation profiles differ in the cancer tissue development process.
37009642	6	61	theme	negative	763:770	arg1	mode					783:786	negative ionization mode	763:786	negative ionization mode	763:786	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	10	62	theme	highest	1267:1273	arg1	sensitivity					1275:1285	sensitivity	1275:1285	sensitivity	1275:1285	It was determined that the multilayer perceptron (MLP) was the most appropriate model with the highest sensitivity, specificity, accuracy, Matthews correlation coefficient, and f1 scores for each dataset.
37009642	4	63	theme	glyco-	419:424	arg1	proteins					427:434	The (glyco-) proteins	414:434	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	414:521	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	2	64	theme	development	264:274	arg1	process					276:282	the cancer tissue development process	246:282	the cancer tissue development process	246:282	It is known that glycosylation profiles differ in the cancer tissue development process.
37009642	1	65	theme	gastric	134:140	arg1	cancer					142:147	gastric cancer	134:147	gastric cancer	134:147	Early and accurate diagnosis of gastric cancer is vital for effective and targeted treatment.
37009642	12	66	theme	gastric	1542:1548	arg1	tissues					1557:1563	gastric cancer tissues	1542:1563	gastric cancer tissues	1542:1563	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	12	67	theme	control	1602:1608	arg1	tissues					1610:1616	adjacent control tissues	1593:1616	adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data	1593:1681	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	2	68	theme	tissue	257:262	arg1	process					276:282	the cancer tissue development process	246:282	the cancer tissue development process	246:282	It is known that glycosylation profiles differ in the cancer tissue development process.
37009642	11	69	theme	accuracy	1389:1396	arg1	score					1398:1402	The highest accuracy score	1377:1402	The highest accuracy score (96.0 ± 1.3)	1377:1415	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	11	69	theme	accuracy	1389:1396	arg1	±					1410:1410	96.0 ± 1.3	1405:1414	96.0 ± 1.3	1405:1414	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	1	70	theme	cancer	142:147	arg1	diagnosis					121:129	Early and accurate diagnosis	102:129	Early and accurate diagnosis of gastric cancer	102:147	Early and accurate diagnosis of gastric cancer is vital for effective and targeted treatment.
37009642	3	71	theme	gastric	330:336	arg1	tissues					345:351	gastric cancer tissues	330:351	gastric cancer tissues	330:351	This study aimed to profile the N-glycans in gastric cancer tissues to predict gastric cancer using machine learning algorithms.
37009642	2	72	theme	cancer	250:255	arg1	process					276:282	the cancer tissue development process	246:282	the cancer tissue development process	246:282	It is known that glycosylation profiles differ in the cancer tissue development process.
37009642	8	73	theme	expression	981:990	arg1	levels					992:997	significant expression levels	969:997	significant expression levels of 14 different N-glycans	969:1023	Statistical analyses identified significant expression levels of 14 different N-glycans in gastric cancer tissues.
37009642	12	74	theme	high	1623:1626	arg1	accuracy					1628:1635	high accuracy	1623:1635	high accuracy using mass spectrometry-based N-glycomic data	1623:1681	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
37009642	7	75	theme	obtained	922:929	arg1	data					931:934	the obtained data	918:934	the obtained data	918:934	The relative and analyte areas of the detected N-glycans were extracted from the obtained data.
37009642	3	76	theme	cancer	338:343	arg1	tissues					345:351	gastric cancer tissues	330:351	gastric cancer tissues	330:351	This study aimed to profile the N-glycans in gastric cancer tissues to predict gastric cancer using machine learning algorithms.
37009642	4	77	theme	adjacent	498:505	arg1	tissues					515:521	formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues	439:521	tissues	515:521	The (glyco-) proteins of formalin-fixed parafilm embedded (FFPE) gastric cancer and adjacent control tissues were extracted by chloroform/methanol extraction after the conventional deparaffinization step.
37009642	11	78	theme	area	1464:1467	arg1	dataset					1469:1475	the whole N-glycans relative area dataset	1435:1475	the whole N-glycans relative area dataset	1435:1475	The highest accuracy score (96.0 ± 1.3) was obtained from the whole N-glycans relative area dataset, and the AUC value was determined as 0.98.
37009642	6	79	theme	N-glycans	736:744	arg1	analysis					707:714	The MALDI-MS analysis	694:714	The MALDI-MS analysis of the 2-AA labeled N-glycans	694:744	The MALDI-MS analysis of the 2-AA labeled N-glycans was performed in negative ionization mode, and fifty-nine N-glycan structures were determined.
37009642	12	80	theme	cancer	1550:1555	arg1	tissues					1557:1563	gastric cancer tissues	1542:1563	gastric cancer tissues	1542:1563	It was concluded that gastric cancer tissues could be distinguished from adjacent control tissues with high accuracy using mass spectrometry-based N-glycomic data.
35013926	0	0	theme	Microbial	82:90	arg1	Glycans					92:98	Profiling Microbial Glycans	72:98	Profiling Microbial Glycans	72:98	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	5	1	theme	fluorescent	739:749	arg1	BanLec-eGFP					760:770	BanLec-eGFP	760:770	BanLec-eGFP	760:770	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	1	theme	fluorescent	739:749	arg1	protein					751:757	green fluorescent protein	733:757	green fluorescent protein (BanLec-eGFP)	733:771	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	6	2	theme	absence	946:952	arg1	terms					921:925	terms	921:925	terms of the presence or absence of binding	921:963	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	0	3	theme	Profiling	72:80	arg1	Glycans					92:98	Profiling Microbial Glycans	72:98	Profiling Microbial Glycans	72:98	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	5	4	theme	produced	637:644	arg1	lectin					646:651	recombinantly produced lectin	623:651	recombinantly produced lectin	623:651	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	6	5	theme	0.8	1037:1039	arg1	coefficient					1022:1032	high Pearson correlation coefficient	997:1032	high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120	997:1070	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	6	6	theme	presence	934:941	arg1	terms					921:925	terms	921:925	terms of the presence or absence of binding	921:963	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	6	7	theme	Parallel	854:861	arg1	testing					863:869	Parallel testing	854:869	Parallel testing	854:869	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	4	8	theme	flow	568:571	arg1	cytometry					573:581	flow cytometry	568:581	flow cytometry	568:581	To further test the validity of this methodology, here we compare it with flow cytometry.
35013926	5	9	theme	produced	711:718	arg1	chimera					720:726	this lectin's recombinantly produced chimera	683:726	this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120)	683:815	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	9	theme	produced	711:718	arg1	acuminata					663:671	Musa acuminata	658:671	Musa acuminata (BanLec)	658:680	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	3	10	link	enzyme-linked	423:435	arg1	ELLSA					459:463	ELLSA	459:463	ELLSA	459:463	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	3	10	link	enzyme-linked	423:435	arg1	assay					452:456	an enzyme-linked lectin sorbent assay	420:456	an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells	420:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	8	11	theme	useful	1286:1291	arg1	ELLSA					1265:1269	ELLSA	1265:1269	ELLSA	1265:1269	As such, ELLSA proved to be a useful tool for profiling microbial glycan structures or testing novel lectins.
35013926	8	11	theme	useful	1286:1291	arg1	tool					1293:1296	a useful tool	1284:1296	a useful tool for profiling microbial glycan structures or testing novel lectins	1284:1363	As such, ELLSA proved to be a useful tool for profiling microbial glycan structures or testing novel lectins.
35013926	1	12	theme	unique	179:184	arg1	probes					210:215	unique, self-sustaining glycan probes	179:215	unique, self-sustaining glycan probes	179:215	The surface of microorganisms is covered with carbohydrates, which makes them unique, self-sustaining glycan probes.
35013926	3	13	theme	sorbent	444:450	arg1	ELLSA					459:463	ELLSA	459:463	ELLSA	459:463	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	3	13	theme	sorbent	444:450	arg1	assay					452:456	an enzyme-linked lectin sorbent assay	420:456	an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells	420:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	5	14	dep	used	605:608	arg1	biotinylated					610:621	biotinylated	610:621	biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120),	610:816	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	14	dep	used	605:608	arg1	biotinylated					823:834	biotinylated	823:834	biotinylated	823:834	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	14	dep	used	605:608	arg1	labeled					845:851	labeled	845:851	labeled	845:851	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	7	15	theme	high-throughput	1164:1178	arg1	analysis					1180:1187	high-throughput analysis	1164:1187	high-throughput analysis	1164:1187	The ELLSA method demonstrated multiple advantages, such as reliability and convenience for high-throughput analysis; it also required less lectin and yielded more consistent results.
35013926	6	16	theme	correlation	1010:1020	arg1	coefficient					1022:1032	high Pearson correlation coefficient	997:1032	high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120	997:1070	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	3	17	theme	enzyme-linked	423:435	arg1	ELLSA					459:463	ELLSA	459:463	ELLSA	459:463	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	3	17	theme	enzyme-linked	423:435	arg1	assay					452:456	an enzyme-linked lectin sorbent assay	420:456	an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells	420:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	3	18	theme	lectin	437:442	arg1	ELLSA					459:463	ELLSA	459:463	ELLSA	459:463	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	3	18	theme	lectin	437:442	arg1	assay					452:456	an enzyme-linked lectin sorbent assay	420:456	an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells	420:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	3	19	theme	lectin-microorganism	356:375	arg1	interactions					377:388	lectin-microorganism interactions	356:388	lectin-microorganism interactions	356:388	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	8	20	theme	microbial	1312:1320	arg1	structures					1329:1338	microbial glycan structures	1312:1338	microbial glycan structures	1312:1338	As such, ELLSA proved to be a useful tool for profiling microbial glycan structures or testing novel lectins.
35013926	6	21	theme	high	997:1000	arg1	coefficient					1022:1032	high Pearson correlation coefficient	997:1032	high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120	997:1070	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	0	22	theme	Enzyme-Linked	14:26	arg1	Assay					43:47	Enzyme-Linked Lectin Sorbent Assay	14:47	Enzyme-Linked Lectin Sorbent Assay	14:47	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	8	23	theme	glycan	1322:1327	arg1	structures					1329:1338	microbial glycan structures	1312:1338	microbial glycan structures	1312:1338	As such, ELLSA proved to be a useful tool for profiling microbial glycan structures or testing novel lectins.
35013926	5	24	dep	labeled	845:851	arg1	FITC					840:843	FITC	840:843	FITC	840:843	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	6	25	theme	equivalent	878:887	arg1	results					889:895	equivalent results	878:895	equivalent results for the two methods	878:915	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	1	26	theme	glycan	203:208	arg1	probes					210:215	unique, self-sustaining glycan probes	179:215	unique, self-sustaining glycan probes	179:215	The surface of microorganisms is covered with carbohydrates, which makes them unique, self-sustaining glycan probes.
35013926	0	27	theme	Assay	43:47	arg1	Comparison					0:9	Comparison	0:9	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.	0:99	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	1	28	dep	unique	179:184	arg1	self-sustaining					187:201	self-sustaining	187:201	self-sustaining	187:201	The surface of microorganisms is covered with carbohydrates, which makes them unique, self-sustaining glycan probes.
35013926	6	29	theme	Pearson	1002:1008	arg1	coefficient					1022:1032	high Pearson correlation coefficient	997:1032	high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120	997:1070	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	7	30	theme	consistent	1236:1245	arg1	results					1247:1253	more consistent results	1231:1253	more consistent results	1231:1253	The ELLSA method demonstrated multiple advantages, such as reliability and convenience for high-throughput analysis; it also required less lectin and yielded more consistent results.
35013926	0	31	theme	Sorbent	35:41	arg1	Assay					43:47	Enzyme-Linked Lectin Sorbent Assay	14:47	Enzyme-Linked Lectin Sorbent Assay	14:47	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	5	32	dep	biotinylated	610:621	arg1	both					818:821	both	818:821	both	818:821	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	0	33	theme	Lectin	28:33	arg1	Assay					43:47	Enzyme-Linked Lectin Sorbent Assay	14:47	Enzyme-Linked Lectin Sorbent Assay	14:47	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	6	34	theme	signal	971:976	arg1	intensity					978:986	signal intensity	971:986	signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120	971:1070	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	0	35	theme	Flow	53:56	arg1	Cytometry					58:66	Flow Cytometry	53:66	Flow Cytometry	53:66	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	5	36	theme	Musa	658:661	arg1	chimera					720:726	this lectin's recombinantly produced chimera	683:726	this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120)	683:815	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	36	theme	Musa	658:661	arg1	BanLec					674:679	BanLec	674:679	BanLec	674:679	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	36	theme	Musa	658:661	arg1	acuminata					663:671	Musa acuminata	658:671	Musa acuminata (BanLec)	658:680	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	37	used	used	605:608	arg2	we					602:603	we	602:603	we	602:603	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	2	38	theme	novel	330:334	arg1	lectins					336:342	novel lectins	330:342	novel lectins	330:342	Lectins are able to bind to these probes, and this interaction can be exploited for selecting microorganisms or novel lectins.
35013926	7	39	theme	ELLSA	1077:1081	arg1	method					1083:1088	The ELLSA method	1073:1088	The ELLSA method	1073:1088	The ELLSA method demonstrated multiple advantages, such as reliability and convenience for high-throughput analysis; it also required less lectin and yielded more consistent results.
35013926	4	40	theme	methodology	531:541	arg1	validity					514:521	the validity	510:521	the validity of this methodology	510:541	To further test the validity of this methodology, here we compare it with flow cytometry.
35013926	5	41	from	communis	799:806	arg1	RCA120					809:814	RCA120	809:814	RCA120	809:814	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	41	from	communis	799:806	arg1	lectin					779:784	a lectin	777:784	a lectin from Ricinus communis (RCA120)	777:815	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	41	from	communis	799:806	arg1	BanLec-eGFP					760:770	BanLec-eGFP	760:770	BanLec-eGFP	760:770	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	41	from	communis	799:806	arg1	protein					751:757	green fluorescent protein	733:757	green fluorescent protein (BanLec-eGFP)	733:771	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	1	42	theme	microorganisms	116:129	arg1	surface					105:111	The surface	101:111	The surface of microorganisms	101:129	The surface of microorganisms is covered with carbohydrates, which makes them unique, self-sustaining glycan probes.
35013926	7	43	theme	multiple	1103:1110	arg1	advantages					1112:1121	multiple advantages	1103:1121	multiple advantages	1103:1121	The ELLSA method demonstrated multiple advantages, such as reliability and convenience for high-throughput analysis; it also required less lectin and yielded more consistent results.
35013926	7	43	theme	multiple	1103:1110	arg1	convenience					1148:1158	convenience	1148:1158	convenience	1148:1158	The ELLSA method demonstrated multiple advantages, such as reliability and convenience for high-throughput analysis; it also required less lectin and yielded more consistent results.
35013926	7	43	theme	multiple	1103:1110	arg1	reliability					1132:1142	reliability	1132:1142	reliability	1132:1142	The ELLSA method demonstrated multiple advantages, such as reliability and convenience for high-throughput analysis; it also required less lectin and yielded more consistent results.
35013926	5	44	theme	green	733:737	arg1	BanLec-eGFP					760:770	BanLec-eGFP	760:770	BanLec-eGFP	760:770	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	44	theme	green	733:737	arg1	protein					751:757	green fluorescent protein	733:757	green fluorescent protein (BanLec-eGFP)	733:771	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	3	45	theme	whole	471:475	arg1	cells					487:491	whole bacterial cells	471:491	whole bacterial cells	471:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	6	46	theme	0.95	1056:1059	arg1	coefficient					1022:1032	high Pearson correlation coefficient	997:1032	high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120	997:1070	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	3	47	with	assay	452:456	arg1	cells					487:491	whole bacterial cells	471:491	whole bacterial cells	471:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	8	48	theme	novel	1351:1355	arg1	lectins					1357:1363	novel lectins	1351:1363	novel lectins	1351:1363	As such, ELLSA proved to be a useful tool for profiling microbial glycan structures or testing novel lectins.
35013926	5	49	with	chimera	720:726	arg1	RCA120					809:814	RCA120	809:814	RCA120	809:814	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	49	with	chimera	720:726	arg1	lectin					779:784	a lectin	777:784	a lectin from Ricinus communis (RCA120)	777:815	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	49	with	chimera	720:726	arg1	BanLec-eGFP					760:770	BanLec-eGFP	760:770	BanLec-eGFP	760:770	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	5	49	with	chimera	720:726	arg1	protein					751:757	green fluorescent protein	733:757	green fluorescent protein (BanLec-eGFP)	733:771	For this purpose, we used biotinylated recombinantly produced lectin from Musa acuminata (BanLec), this lectin's recombinantly produced chimera with green fluorescent protein (BanLec-eGFP) and a lectin from Ricinus communis (RCA120), both biotinylated and FITC labeled.
35013926	3	50	theme	bacterial	477:485	arg1	cells					487:491	whole bacterial cells	471:491	whole bacterial cells	471:491	To examine lectin-microorganism interactions, we have previously developed an enzyme-linked lectin sorbent assay (ELLSA) with whole bacterial cells.
35013926	6	51	theme	binding	957:963	arg1	absence					946:952	absence	946:952	absence	946:952	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	6	51	theme	binding	957:963	arg1	presence					934:941	presence	934:941	presence	934:941	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35013926	0	52	theme	Cytometry	58:66	arg1	Comparison					0:9	Comparison	0:9	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.	0:99	Comparison of Enzyme-Linked Lectin Sorbent Assay and Flow Cytometry for Profiling Microbial Glycans.
35013926	6	53	dep	presence	934:941	arg1	the					930:932	the	930:932	the	930:932	Parallel testing showed equivalent results for the two methods, in terms of the presence or absence of binding, with signal intensity yielding high Pearson correlation coefficient of 0.8 for BanLec and 0.95 for RCA120.
35276597	4	0	theme	maturation	990:999	arg1	stages					1001:1006	two different maturation stages	976:1006	two different maturation stages	976:1006	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	3	1	theme	structural	650:659	arg1	changes					661:667	the structural changes	646:667	the structural changes of N-glycan	646:679	However, neither N-glycosylation nor the influence of fruit maturation on the structural changes of N-glycan have been fully characterized in detail.
35276597	5	2	from	N-glycosylation	1207:1221	arg1	rMIR					1226:1229	rMIR	1226:1229	rMIR	1226:1229	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	2	from	N-glycosylation	1207:1221	arg1	nMIR					1194:1197	nMIR	1194:1197	nMIR	1194:1197	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	8	3	theme	recombinant	1702:1712	arg1	protein					1714:1720	recombinant protein	1702:1720	recombinant protein expressed in tomato plants	1702:1747	This study demonstrated the potential of recombinant protein expressed in tomato plants and paves the way for the commercial use of rMIR.
35276597	3	4	gly	N-glycosylation	589:603	arg1	detail					714:719	detail	714:719	detail	714:719	However, neither N-glycosylation nor the influence of fruit maturation on the structural changes of N-glycan have been fully characterized in detail.
35276597	8	5	theme	tomato	1735:1740	arg1	plants					1742:1747	tomato plants	1735:1747	tomato plants	1735:1747	This study demonstrated the potential of recombinant protein expressed in tomato plants and paves the way for the commercial use of rMIR.
35276597	4	6	theme	nMIR	884:887	arg1	stages					874:879	the natural maturation stages	851:879	the natural maturation stages of nMIR and rMIR	851:896	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	5	7	gly	N-glycosylation	1042:1056	arg1	MIRs					1070:1073	MIRs	1070:1073	MIRs	1070:1073	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	8	theme	detailed	1013:1020	arg1	mapping					1030:1036	The detailed peptide mapping	1009:1036	The detailed peptide mapping	1009:1036	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	4	9	theme	rMIR	893:896	arg1	stages					874:879	the natural maturation stages	851:879	the natural maturation stages of nMIR and rMIR	851:896	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	5	10	from	differences	1153:1163	arg1	N-glycosylation					1207:1221	the N-glycosylation	1203:1221	the N-glycosylation in rMIR	1203:1229	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	10	from	differences	1153:1163	arg1	structure					1181:1189	the N-glycan structure	1168:1189	the N-glycan structure in nMIR	1168:1197	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	7	11	theme	N-glycan	1606:1613	arg1	modifications					1560:1572	post-translational modifications	1541:1572	post-translational modifications	1541:1572	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	11	theme	N-glycan	1606:1613	arg1	structures					1615:1624	N-glycan structures	1606:1624	N-glycan structures	1606:1624	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	2	12	theme	protein	535:541	arg1	modifications					543:555	their protein modifications	529:555	their protein modifications	529:555	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	4	13	theme	stages	874:879	arg1	N-glycosylation					832:846	the N-glycosylation	828:846	the N-glycosylation of the natural maturation stages of nMIR and rMIR	828:896	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	2	14	from	fruit	482:486	arg1	miraculin					459:467	native miraculin	452:467	native miraculin from miracle fruit (nMIR) and rMIR	452:502	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	5	15	from	structure	1181:1189	arg1	rMIR					1226:1229	rMIR	1226:1229	rMIR	1226:1229	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	15	from	structure	1181:1189	arg1	nMIR					1194:1197	nMIR	1194:1197	nMIR	1194:1197	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	8	16	theme	commercial	1775:1784	arg1	use					1786:1788	the commercial use	1771:1788	the commercial use of rMIR	1771:1796	This study demonstrated the potential of recombinant protein expressed in tomato plants and paves the way for the commercial use of rMIR.
35276597	4	17	theme	N-glycan	921:928	arg1	structures					930:939	the N-glycan structures	917:939	the N-glycan structures on MIRs prepared from the fruit	917:971	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	0	18	theme	native	63:68	arg1	miraculin					86:94	plant-derived native and recombinant miraculin	49:94	plant-derived native and recombinant miraculin	49:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	1	19	theme	unique	146:151	arg1	miraculin					178:186	miraculin	178:186	miraculin (MIR)	178:192	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	19	theme	unique	146:151	arg1	protein					169:175	a unique taste-modifying protein	144:175	a unique taste-modifying protein	144:175	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	7	20	theme	post-translational	1541:1558	arg1	modifications					1560:1572	post-translational modifications	1541:1572	post-translational modifications	1541:1572	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	20	theme	post-translational	1541:1558	arg1	N-glycosylation					1586:1600	N-glycosylation	1586:1600	N-glycosylation	1586:1600	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	20	theme	post-translational	1541:1558	arg1	structures					1615:1624	N-glycan structures	1606:1624	N-glycan structures	1606:1624	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	4	21	theme	maturation	863:872	arg1	stages					874:879	the natural maturation stages	851:879	the natural maturation stages of nMIR and rMIR	851:896	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	0	22	theme	recombinant	74:84	arg1	miraculin					86:94	plant-derived native and recombinant miraculin	49:94	plant-derived native and recombinant miraculin	49:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	4	23	from	focus	735:739	arg1	N-glycosylation					744:758	N-glycosylation	744:758	N-glycosylation	744:758	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	0	24	from	Effect	0:5	arg1	N-glycosylation					30:44	N-glycosylation	30:44	N-glycosylation of plant-derived native and recombinant miraculin	30:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	6	25	theme	MIRs	1303:1306	arg1	analysis					1291:1298	N-Glycan analysis	1282:1298	N-Glycan analysis of MIRs from the maturation stage of fruits	1282:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	5	26	theme	N-glycosylation	1042:1056	arg1	analysis					1058:1065	N-glycosylation analysis	1042:1065	N-glycosylation analysis of MIRs	1042:1073	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	27	theme	backbone	1272:1279	arg1	cleavage					1248:1255	the cleavage	1244:1255	the cleavage of the peptide backbone	1244:1279	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	2	28	theme	tomato	416:421	arg1	plants					423:428	tomato plants	416:428	tomato plants	416:428	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	2	29	theme	miracle	474:480	arg1	nMIR					489:492	nMIR	489:492	nMIR	489:492	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	2	29	theme	miracle	474:480	arg1	fruit					482:486	miracle fruit	474:486	miracle fruit (nMIR)	474:493	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	1	30	theme	novel	261:265	arg1	sweetener					279:287	a novel low-calorie sweetener	259:287	a novel low-calorie sweetener	259:287	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	30	theme	novel	261:265	arg1	potential					219:227	an attractive potential	205:227	an attractive potential for commercial application	205:254	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	31	theme	Miracle	97:103	arg1	fruit					105:109	Miracle fruit	97:109	Miracle fruit	97:109	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	31	theme	Miracle	97:103	arg1	dulcificum					123:132	Synsepalum dulcificum	112:132	Synsepalum dulcificum	112:132	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	4	32	theme	different	980:988	arg1	stages					1001:1006	two different maturation stages	976:1006	two different maturation stages	976:1006	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	2	33	from	modifications	543:555	arg1	identical					516:524	identical	516:524	identical	516:524	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	0	34	theme	fruit	10:14	arg1	maturation					16:25	fruit maturation	10:25	fruit maturation	10:25	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	7	35	theme	expressed	1493:1501	arg1	rMIRs					1503:1507	the heterogeneously expressed rMIRs	1473:1507	the heterogeneously expressed rMIRs	1473:1507	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	36	theme	maturation	1642:1651	arg1	stages					1653:1658	the maturation stages	1638:1658	the maturation stages	1638:1658	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	2	37	theme	MIR	391:393	arg1	production					402:411	recombinant MIR (rMIR) production	379:411	recombinant MIR (rMIR) production in tomato plants	379:428	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	7	38	from	characteristics	1522:1536	arg1	modifications					1560:1572	post-translational modifications	1541:1572	post-translational modifications	1541:1572	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	38	from	characteristics	1522:1536	arg1	N-glycosylation					1586:1600	N-glycosylation	1586:1600	N-glycosylation	1586:1600	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	38	from	characteristics	1522:1536	arg1	structures					1615:1624	N-glycan structures	1606:1624	N-glycan structures	1606:1624	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	39	contain	had	1509:1511	arg2	characteristics					1522:1536	the same characteristics	1513:1536	the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures	1513:1624	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	7	39	contain	had	1509:1511	arg1	rMIRs					1503:1507	the heterogeneously expressed rMIRs	1473:1507	the heterogeneously expressed rMIRs	1473:1507	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	4	40	theme	maturation	790:799	arg1	contribution					768:779	the contribution	764:779	the contribution of fruit maturation to N-glycan	764:811	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	4	40	theme	maturation	790:799	arg1	focus					735:739	a focus	733:739	a focus on N-glycosylation	733:758	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	6	41	theme	fruits	1337:1342	arg1	stage					1328:1332	the maturation stage	1313:1332	the maturation stage of fruits	1313:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	4	42	theme	natural	855:861	arg1	stages					874:879	the natural maturation stages	851:879	the natural maturation stages of nMIR and rMIR	851:896	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	6	43	from	stage	1437:1441	arg1	similar					1387:1393	similar	1387:1393	similar	1387:1393	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	5	44	theme	N-glycan	1172:1179	arg1	structure					1181:1189	the N-glycan structure	1168:1189	the N-glycan structure in nMIR	1168:1197	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	0	45	gly	N-glycosylation	30:44	arg1	miraculin					86:94	plant-derived native and recombinant miraculin	49:94	plant-derived native and recombinant miraculin	49:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	5	46	gly	N-glycosylation	1207:1221	arg1	rMIR					1226:1229	rMIR	1226:1229	rMIR	1226:1229	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	46	gly	N-glycosylation	1207:1221	arg1	nMIR					1194:1197	nMIR	1194:1197	nMIR	1194:1197	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	3	47	theme	N-glycan	672:679	arg1	changes					661:667	the structural changes	646:667	the structural changes of N-glycan	646:679	However, neither N-glycosylation nor the influence of fruit maturation on the structural changes of N-glycan have been fully characterized in detail.
35276597	2	48	with	identical	516:524	arg1	N-glycan					562:569	N-glycan	562:569	N-glycan	562:569	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	1	49	theme	commercial	233:242	arg1	application					244:254	commercial application	233:254	commercial application	233:254	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	2	50	from	identical	516:524	arg1	modifications					543:555	their protein modifications	529:555	their protein modifications	529:555	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	3	51	from	influence	613:621	arg1	changes					661:667	the structural changes	646:667	the structural changes of N-glycan	646:679	However, neither N-glycosylation nor the influence of fruit maturation on the structural changes of N-glycan have been fully characterized in detail.
35276597	0	52	link	plant-derived	49:61	arg1	miraculin					86:94	plant-derived native and recombinant miraculin	49:94	plant-derived native and recombinant miraculin	49:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	2	53	theme	stable	305:310	arg1	system					319:324	a stable supply system	303:324	a stable supply system for MIR	303:332	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	8	54	theme	protein	1714:1720	arg1	potential					1689:1697	the potential	1685:1697	the potential of recombinant protein expressed in tomato plants	1685:1747	This study demonstrated the potential of recombinant protein expressed in tomato plants and paves the way for the commercial use of rMIR.
35276597	4	55	gly	N-glycosylation	832:846	arg1	stages					874:879	the natural maturation stages	851:879	the natural maturation stages of nMIR and rMIR	851:896	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	6	56	theme	N-Glycan	1282:1289	arg1	analysis					1291:1298	N-Glycan analysis	1282:1298	N-Glycan analysis of MIRs from the maturation stage of fruits	1282:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	5	57	theme	peptide	1022:1028	arg1	mapping					1030:1036	The detailed peptide mapping	1009:1036	The detailed peptide mapping	1009:1036	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	4	58	from	contribution	768:779	arg1	N-glycosylation					744:758	N-glycosylation	744:758	N-glycosylation	744:758	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	5	59	contain	have	1103:1106	arg2	variants					1108:1115	variants	1108:1115	variants	1108:1115	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	59	contain	have	1103:1106	arg1	MIRs					1098:1101	MIRs	1098:1101	MIRs	1098:1101	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	2	60	from	production	402:411	arg1	plants					423:428	tomato plants	416:428	tomato plants	416:428	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	0	61	theme	miraculin	86:94	arg1	N-glycosylation					30:44	N-glycosylation	30:44	N-glycosylation of plant-derived native and recombinant miraculin	30:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	1	62	theme	taste-modifying	153:167	arg1	miraculin					178:186	miraculin	178:186	miraculin (MIR)	178:192	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	62	theme	taste-modifying	153:167	arg1	protein					169:175	a unique taste-modifying protein	144:175	a unique taste-modifying protein	144:175	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	7	63	theme	same	1517:1520	arg1	characteristics					1522:1536	the same characteristics	1513:1536	the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures	1513:1624	These results indicated that the heterogeneously expressed rMIRs had the same characteristics in post-translational modifications, especially N-glycosylation and N-glycan structures, throughout the maturation stages.
35276597	2	64	theme	native	452:457	arg1	miraculin					459:467	native miraculin	452:467	native miraculin from miracle fruit (nMIR) and rMIR	452:502	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	6	65	from	stage	1328:1332	arg1	MIRs					1303:1306	MIRs	1303:1306	MIRs from the maturation stage of fruits	1303:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	6	65	from	stage	1328:1332	arg1	analysis					1291:1298	N-Glycan analysis	1282:1298	N-Glycan analysis of MIRs from the maturation stage of fruits	1282:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	8	66	theme	rMIR	1793:1796	arg1	use					1786:1788	the commercial use	1771:1788	the commercial use of rMIR	1771:1796	This study demonstrated the potential of recombinant protein expressed in tomato plants and paves the way for the commercial use of rMIR.
35276597	5	67	theme	peptide	1264:1270	arg1	backbone					1272:1279	the peptide backbone	1260:1279	the peptide backbone	1260:1279	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	6	68	from	analysis	1291:1298	arg1	stage					1328:1332	the maturation stage	1313:1332	the maturation stage of fruits	1313:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	1	69	theme	attractive	208:217	arg1	potential					219:227	an attractive potential	205:227	an attractive potential for commercial application	205:254	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	69	theme	attractive	208:217	arg1	sweetener					279:287	a novel low-calorie sweetener	259:287	a novel low-calorie sweetener	259:287	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	5	70	theme	MIRs	1070:1073	arg1	mapping					1030:1036	The detailed peptide mapping	1009:1036	The detailed peptide mapping	1009:1036	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	5	70	theme	MIRs	1070:1073	arg1	analysis					1058:1065	N-glycosylation analysis	1042:1065	N-glycosylation analysis of MIRs	1042:1073	The detailed peptide mapping and N-glycosylation analysis of MIRs provided evidence that MIRs have variants, which were derived mainly from the differences in the N-glycan structure in nMIR and the N-glycosylation in rMIR and not from the cleavage of the peptide backbone.
35276597	3	71	theme	maturation	632:641	arg1	influence					613:621	the influence	609:621	the influence of fruit maturation on the structural changes of N-glycan	609:679	However, neither N-glycosylation nor the influence of fruit maturation on the structural changes of N-glycan have been fully characterized in detail.
35276597	0	72	theme	maturation	16:25	arg1	Effect					0:5	Effect	0:5	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.	0:95	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	1	73	theme	low-calorie	267:277	arg1	sweetener					279:287	a novel low-calorie sweetener	259:287	a novel low-calorie sweetener	259:287	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	73	theme	low-calorie	267:277	arg1	potential					219:227	an attractive potential	205:227	an attractive potential for commercial application	205:254	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	6	74	theme	N-glycan	1362:1369	arg1	structures					1371:1380	N-glycan structures	1362:1380	N-glycan structures	1362:1380	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	2	75	theme	recombinant	379:389	arg1	production					402:411	recombinant MIR (rMIR) production	379:411	recombinant MIR (rMIR) production in tomato plants	379:428	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	0	76	theme	plant-derived	49:61	arg1	miraculin					86:94	plant-derived native and recombinant miraculin	49:94	plant-derived native and recombinant miraculin	49:94	Effect of fruit maturation on N-glycosylation of plant-derived native and recombinant miraculin.
35276597	1	77	contain	has	201:203	arg2	sweetener					279:287	a novel low-calorie sweetener	259:287	a novel low-calorie sweetener	259:287	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	77	contain	has	201:203	arg2	potential					219:227	an attractive potential	205:227	an attractive potential for commercial application	205:254	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	77	contain	has	201:203	arg1	miraculin					178:186	miraculin	178:186	miraculin (MIR)	178:192	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	1	77	contain	has	201:203	arg1	protein					169:175	a unique taste-modifying protein	144:175	a unique taste-modifying protein	144:175	Miracle fruit, Synsepalum dulcificum, produces a unique taste-modifying protein, miraculin (MIR), which has an attractive potential for commercial application as a novel low-calorie sweetener.
35276597	4	78	theme	fruit	784:788	arg1	maturation					790:799	fruit maturation	784:799	fruit maturation	784:799	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	6	79	theme	maturation	1317:1326	arg1	stage					1328:1332	the maturation stage	1313:1332	the maturation stage of fruits	1313:1342	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	2	80	from	rMIR	499:502	arg1	miraculin					459:467	native miraculin	452:467	native miraculin from miracle fruit (nMIR) and rMIR	452:502	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	3	81	theme	fruit	626:630	arg1	maturation					632:641	fruit maturation	626:641	fruit maturation	626:641	However, neither N-glycosylation nor the influence of fruit maturation on the structural changes of N-glycan have been fully characterized in detail.
35276597	2	82	theme	supply	312:317	arg1	system					319:324	a stable supply system	303:324	a stable supply system for MIR	303:332	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
35276597	6	83	theme	maturation	1426:1435	arg1	stage					1437:1441	every maturation stage	1420:1441	every maturation stage	1420:1441	N-Glycan analysis of MIRs from the maturation stage of fruits demonstrated that N-glycan structures were similar among nMIRs and rMIRs at every maturation stage.
35276597	4	84	from	structures	930:939	arg1	MIRs					944:947	MIRs	944:947	MIRs prepared from the fruit	944:971	Here, with a focus on N-glycosylation and the contribution of fruit maturation to N-glycan, we reanalyzed the N-glycosylation of the natural maturation stages of nMIR and rMIR, and then compared the N-glycan structures on MIRs prepared from the fruit at two different maturation stages.
35276597	2	85	theme	previous	337:344	arg1	study					346:350	a previous study	335:350	a previous study	335:350	To establish a stable supply system for MIR, a previous study established a platform for recombinant MIR (rMIR) production in tomato plants and demonstrated that native miraculin from miracle fruit (nMIR) and rMIR were almost identical in their protein modifications with N-glycan.
36380917	0	0	theme	proteolytic	77:87	arg1	stability					89:97	proteolytic stability	77:97	proteolytic stability	77:97	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	3	1	with	analogues	504:512	arg1	N-glycan					539:546	sialyl complex-type N-glycan	519:546	sialyl complex-type N-glycan modified at Asn26 and Asn34	519:574	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	4	2	theme	persistent	953:962	arg1	capability					984:993	more rapid and more persistent glucose-stabilizing capability	933:993	more rapid and more persistent glucose-stabilizing capability	933:993	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	6	3	theme	pharmacological	1397:1411	arg1	properties					1413:1422	enhanced pharmacological properties	1388:1422	enhanced pharmacological properties	1388:1422	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	6	4	gly	glycopeptides/glycoproteins	1335:1361	arg1	glycopeptides/glycoproteins					1335:1361	therapeutic glycopeptides/glycoproteins	1323:1361	therapeutic glycopeptides/glycoproteins with N-glycan	1323:1375	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	3	5	theme	sialyl	519:524	arg1	N-glycan					539:546	sialyl complex-type N-glycan	519:546	sialyl complex-type N-glycan modified at Asn26 and Asn34	519:574	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	0	6	from	Identification	0:13	arg1	stability					89:97	proteolytic stability	77:97	proteolytic stability	77:97	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	0	6	from	Identification	0:13	arg1	activity					123:130	glucose-stabilizing activity	103:130	glucose-stabilizing activity	103:130	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	6	7	theme	enhanced	1388:1395	arg1	properties					1413:1422	enhanced pharmacological properties	1388:1422	enhanced pharmacological properties	1388:1422	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	3	8	theme	in	608:609	arg1	half-life					617:625	a 36.7- and 24.0-fold in vitro half-life	586:625	a 36.7- and 24.0-fold in vitro half-life	586:625	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	6	9	theme	therapeutic	1323:1333	arg1	glycopeptides/glycoproteins					1335:1361	therapeutic glycopeptides/glycoproteins	1323:1361	therapeutic glycopeptides/glycoproteins with N-glycan	1323:1375	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	4	10	theme	db/db	1014:1018	arg1	mice					1020:1023	type 2 diabetic db/db mice	998:1023	type 2 diabetic db/db mice	998:1023	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	5	11	theme	N-glycan	1159:1166	arg1	modification					1168:1179	N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides	1159:1262	modification	1168:1179	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	4	12	theme	rapid	938:942	arg1	capability					984:993	more rapid and more persistent glucose-stabilizing capability	933:993	more rapid and more persistent glucose-stabilizing capability	933:993	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	0	13	gly	sialylation	62:72	arg1	peptide					149:155	glucagon-like peptide 1	135:157	glucagon-like peptide 1	135:157	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	6	14	with	glycopeptides/glycoproteins	1335:1361	arg1	N-glycan					1368:1375	N-glycan	1368:1375	N-glycan	1368:1375	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	3	15	theme	GLP-1	498:502	arg1	analogues					504:512	The glycosylated GLP-1 analogues	481:512	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34	481:574	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	0	16	theme	glucose-stabilizing	103:121	arg1	activity					123:130	glucose-stabilizing activity	103:130	glucose-stabilizing activity	103:130	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	4	17	gly	glycosylated	795:806	arg1	analogues					814:822	both glycosylated GLP-1 analogues	790:822	both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan	790:871	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	3	18	theme	24.0-fold	598:606	arg1	half-life					617:625	a 36.7- and 24.0-fold in vitro half-life	586:625	a 36.7- and 24.0-fold in vitro half-life	586:625	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	4	19	theme	glucose-stabilizing	964:982	arg1	capability					984:993	more rapid and more persistent glucose-stabilizing capability	933:993	more rapid and more persistent glucose-stabilizing capability	933:993	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	1	20	with	glycosylation	310:322	arg1	N-glycan					366:373	homogeneous biantennary complex-type N-glycan	329:373	homogeneous biantennary complex-type N-glycan	329:373	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	4	21	theme	GLP-1	808:812	arg1	analogues					814:822	both glycosylated GLP-1 analogues	790:822	both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan	790:871	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	5	22	theme	modified	1246:1253	arg1	peptides					1255:1262	the modified peptides	1242:1262	the modified peptides	1242:1262	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	6	23	theme	glycopeptides/glycoproteins	1335:1361	arg1	design					1313:1318	future design	1306:1318	future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties	1306:1422	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	4	24	theme	glycosylated	795:806	arg1	analogues					814:822	both glycosylated GLP-1 analogues	790:822	both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan	790:871	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	2	25	theme	GLP-1	421:425	arg1	analogues					427:435	All the N-glycan-modified GLP-1 analogues	395:435	All the N-glycan-modified GLP-1 analogues	395:435	All the N-glycan-modified GLP-1 analogues preserved an unchanged secondary structure.
36380917	0	26	theme	effect	22:27	arg1	Identification					0:13	Identification	0:13	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.	0:199	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	1	27	theme	site-directed	286:298	arg1	glycosylation					310:322	site-directed enzymatic glycosylation	286:322	site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan	286:373	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	0	28	theme	glucagon-like	135:147	arg1	peptide					149:155	glucagon-like peptide 1	135:157	glucagon-like peptide 1	135:157	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	4	29	theme	blood	900:904	arg1	levels					914:919	lower maximum blood glucose levels	886:919	lower maximum blood glucose levels	886:919	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	5	30	theme	position	1085:1092	arg1	selection					1057:1065	the selection	1053:1065	the selection of an appropriate position (to avoid hindering the peptide-receptor binding)	1053:1142	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	5	30	theme	position	1085:1092	arg1	crucial					1147:1153	crucial	1147:1153	crucial	1147:1153	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	3	31	theme	complex-type	526:537	arg1	N-glycan					539:546	sialyl complex-type N-glycan	519:546	sialyl complex-type N-glycan modified at Asn26 and Asn34	519:574	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	1	32	theme	enzymatic	300:308	arg1	glycosylation					310:322	site-directed enzymatic glycosylation	286:322	site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan	286:373	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	0	33	theme	N-glycan	32:39	arg1	modification					41:52	N-glycan modification and its sialylation	32:72	modification	41:52	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	4	34	theme	diabetic	1005:1012	arg1	mice					1020:1023	type 2 diabetic db/db mice	998:1023	type 2 diabetic db/db mice	998:1023	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	5	35	dep	selection	1057:1065	arg1	avoid					1098:1102	avoid	1098:1102	to avoid hindering the peptide-receptor binding	1095:1141	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	4	36	theme	maximum	892:898	arg1	levels					914:919	lower maximum blood glucose levels	886:919	lower maximum blood glucose levels	886:919	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	3	37	theme	glycosylated	485:496	arg1	analogues					504:512	The glycosylated GLP-1 analogues	481:512	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34	481:574	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	2	38	theme	secondary	460:468	arg1	structure					470:478	an unchanged secondary structure	447:478	an unchanged secondary structure	447:478	All the N-glycan-modified GLP-1 analogues preserved an unchanged secondary structure.
36380917	5	39	theme	therapeutic	1216:1226	arg1	properties					1228:1237	the therapeutic properties	1212:1237	the therapeutic properties of the modified peptides	1212:1262	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	0	40	theme	peptide	149:155	arg1	stability					89:97	proteolytic stability	77:97	proteolytic stability	77:97	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	0	40	theme	peptide	149:155	arg1	activity					123:130	glucose-stabilizing activity	103:130	glucose-stabilizing activity	103:130	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	4	41	theme	lower	886:890	arg1	levels					914:919	lower maximum blood glucose levels	886:919	lower maximum blood glucose levels	886:919	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	2	42	theme	unchanged	450:458	arg1	structure					470:478	an unchanged secondary structure	447:478	an unchanged secondary structure	447:478	All the N-glycan-modified GLP-1 analogues preserved an unchanged secondary structure.
36380917	1	43	theme	homogeneous	329:339	arg1	N-glycan					366:373	homogeneous biantennary complex-type N-glycan	329:373	homogeneous biantennary complex-type N-glycan	329:373	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	0	44	theme	site-directed	162:174	arg1	glycosylation					186:198	site-directed enzymatic glycosylation	162:198	site-directed enzymatic glycosylation	162:198	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	5	45	theme	peptides	1255:1262	arg1	properties					1228:1237	the therapeutic properties	1212:1237	the therapeutic properties of the modified peptides	1212:1262	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	4	46	theme	glucose	906:912	arg1	levels					914:919	lower maximum blood glucose levels	886:919	lower maximum blood glucose levels	886:919	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	0	47	theme	modification	41:52	arg1	effect					22:27	the effect	18:27	the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1	18:157	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	1	48	theme	biantennary	341:351	arg1	N-glycan					366:373	homogeneous biantennary complex-type N-glycan	329:373	homogeneous biantennary complex-type N-glycan	329:373	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	4	49	theme	type	998:1001	arg1	mice					1020:1023	type 2 diabetic db/db mice	998:1023	type 2 diabetic db/db mice	998:1023	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	0	50	from	activity	123:130	arg1	Identification					0:13	Identification	0:13	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.	0:199	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	3	51	theme	dipeptidyl	660:669	arg1	peptidase-IV					671:682	dipeptidyl peptidase-IV	660:682	dipeptidyl peptidase-IV (DPP-IV)	660:691	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	3	51	theme	dipeptidyl	660:669	arg1	DPP-IV					685:690	DPP-IV	685:690	DPP-IV	685:690	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	4	52	theme	native	776:781	arg1	GLP-1					783:787	native GLP-1	776:787	native GLP-1	776:787	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	6	53	theme	future	1306:1311	arg1	design					1313:1318	future design	1306:1318	future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties	1306:1422	The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
36380917	1	54	theme	complex-type	353:364	arg1	N-glycan					366:373	homogeneous biantennary complex-type N-glycan	329:373	homogeneous biantennary complex-type N-glycan	329:373	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	3	55	theme	mouse	751:755	arg1	serum					757:761	mouse serum	751:761	mouse serum	751:761	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	4	56	theme	sialyl	857:862	arg1	N-glycan					864:871	sialyl N-glycan	857:871	sialyl N-glycan	857:871	Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice.
36380917	3	57	dep	in	608:609	arg1	vitro					611:615	vitro	611:615	vitro	611:615	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	0	58	theme	enzymatic	176:184	arg1	glycosylation					186:198	site-directed enzymatic glycosylation	162:198	site-directed enzymatic glycosylation	162:198	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	5	59	theme	peptide-receptor	1118:1133	arg1	binding					1135:1141	the peptide-receptor binding	1114:1141	the peptide-receptor binding	1114:1141	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	1	60	theme	long-acting	239:249	arg1	peptide					265:271	long-acting glucagon-like peptide 1	239:273	long-acting glucagon-like peptide 1 (GLP-1)	239:281	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	1	60	theme	long-acting	239:249	arg1	GLP-1					276:280	GLP-1	276:280	GLP-1	276:280	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	0	61	theme	sialylation	62:72	arg1	effect					22:27	the effect	18:27	the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1	18:157	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	0	62	from	stability	89:97	arg1	Identification					0:13	Identification	0:13	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.	0:199	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	3	63	gly	glycosylated	485:496	arg1	analogues					504:512	The glycosylated GLP-1 analogues	481:512	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34	481:574	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
36380917	2	64	theme	N-glycan-modified	403:419	arg1	analogues					427:435	All the N-glycan-modified GLP-1 analogues	395:435	All the N-glycan-modified GLP-1 analogues	395:435	All the N-glycan-modified GLP-1 analogues preserved an unchanged secondary structure.
36380917	1	65	theme	glucagon-like	251:263	arg1	peptide					265:271	long-acting glucagon-like peptide 1	239:273	long-acting glucagon-like peptide 1 (GLP-1)	239:281	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	1	65	theme	glucagon-like	251:263	arg1	GLP-1					276:280	GLP-1	276:280	GLP-1	276:280	In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed.
36380917	0	66	from	effect	22:27	arg1	stability					89:97	proteolytic stability	77:97	proteolytic stability	77:97	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	0	66	from	effect	22:27	arg1	activity					123:130	glucose-stabilizing activity	103:130	glucose-stabilizing activity	103:130	Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation.
36380917	5	67	theme	appropriate	1073:1083	arg1	position					1085:1092	an appropriate position	1070:1092	an appropriate position	1070:1092	Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides.
36380917	3	68	theme	36.7-	588:592	arg1	half-life					617:625	a 36.7- and 24.0-fold in vitro half-life	586:625	a 36.7- and 24.0-fold in vitro half-life	586:625	The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum.
35487177	2	0	theme	Tn	322:323	arg1	moiety					333:338	Tn antigen moiety	322:338	Tn antigen moiety containing α-N-acetylgalactosamine residue	322:381	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	1	1	theme	type	203:206	arg1	O-glycan					208:215	mucin type O-glycan	197:215	mucin type O-glycan	197:215	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	4	2	theme	sugar	891:895	arg1	chips					897:901	sugar chips	891:901	sugar chips coated with ligand conjugates	891:931	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	2	3	gly	glycosylation	411:423	arg1	imidate					508:514	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	imidate	508:514	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	3	gly	glycosylation	411:423	arg1	moiety					528:533	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	moiety	528:533	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	3	gly	glycosylation	411:423	arg1	spacer					564:569	a hydrophilic spacer	550:569	a hydrophilic spacer when immobilized on a gold-coated sensor chip	550:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	1	4	theme	mucin	133:137	arg1	glycan					147:152	mucin related glycan	133:152	mucin related glycan	133:152	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	1	5	theme	O-glycan	208:215	arg1	core					170:173	core 3	170:175	core 3	170:175	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	1	5	theme	O-glycan	208:215	arg1	structures					183:192	5 structures	181:192	5 structures of mucin type O-glycan	181:215	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	3	6	theme	N-acetylglucosamine	700:718	arg1	donors					740:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	5	7	theme	kinetic	1086:1092	arg1	kd = 5.8 × 10-3					1139:1153	kd = 5.8 × 10-3	1139:1153	kd = 5.8 × 10-3	1139:1153	The specific interaction was observed between the core 3 structure and Jacalin (JAC) and kinetic parameters were estimated as ka = 1.5 × 104, kd = 5.8 × 10-3, and KD = 3.8 × 10-7.
35487177	5	7	theme	kinetic	1086:1092	arg1	KD = 3.8 × 10-7					1160:1174	KD = 3.8 × 10-7	1160:1174	KD = 3.8 × 10-7	1160:1174	The specific interaction was observed between the core 3 structure and Jacalin (JAC) and kinetic parameters were estimated as ka = 1.5 × 104, kd = 5.8 × 10-3, and KD = 3.8 × 10-7.
35487177	5	7	theme	kinetic	1086:1092	arg1	ka = 1.5 × 104					1123:1136	ka = 1.5 × 104	1123:1136	ka = 1.5 × 104	1123:1136	The specific interaction was observed between the core 3 structure and Jacalin (JAC) and kinetic parameters were estimated as ka = 1.5 × 104, kd = 5.8 × 10-3, and KD = 3.8 × 10-7.
35487177	5	7	theme	kinetic	1086:1092	arg1	parameters					1094:1103	kinetic parameters	1086:1103	kinetic parameters	1086:1103	The specific interaction was observed between the core 3 structure and Jacalin (JAC) and kinetic parameters were estimated as ka = 1.5 × 104, kd = 5.8 × 10-3, and KD = 3.8 × 10-7.
35487177	0	8	theme	interaction	63:73	arg1	analysis					75:82	their interaction analysis	57:82	their interaction analysis with sugar chips	57:99	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	3	9	theme	ligand	798:803	arg1	conjugates					805:814	sugar-chain ligand conjugates	786:814	sugar-chain ligand conjugates	786:814	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	4	10	theme	surface	954:960	arg1	SPR					981:983	SPR	981:983	SPR	981:983	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	4	10	theme	surface	954:960	arg1	resonance					970:978	surface plasmon resonance	954:978	a surface plasmon resonance (SPR) biosensor	952:994	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	5	11	theme	core	1047:1050	arg1	structure					1054:1062	the core 3 structure	1043:1062	the core 3 structure	1043:1062	The specific interaction was observed between the core 3 structure and Jacalin (JAC) and kinetic parameters were estimated as ka = 1.5 × 104, kd = 5.8 × 10-3, and KD = 3.8 × 10-7.
35487177	0	12	theme	sugar	89:93	arg1	chips					95:99	sugar chips	89:99	sugar chips	89:99	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	2	13	theme	α-selective	399:409	arg1	glycosylation					411:423	α-selective glycosylation	399:423	α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip	399:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	4	14	theme	interaction	854:864	arg1	analysis					866:873	The interaction analysis	850:873	The interaction analysis of lectins with sugar chips coated with ligand conjugates	850:931	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	1	15	theme	related	139:145	arg1	glycan					147:152	mucin related glycan	133:152	mucin related glycan	133:152	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	4	16	theme	ligand	915:920	arg1	conjugates					922:931	ligand conjugates	915:931	ligand conjugates	915:931	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	1	17	with	interaction	248:258	arg1	lectins					265:271	lectins	265:271	lectins using sugar chip technology	265:299	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	1	18	theme	glycan	147:152	arg1	analysis					121:128	the functional analysis	106:128	the functional analysis of mucin related glycan	106:152	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	3	19	theme	sugar-chain	786:796	arg1	conjugates					805:814	sugar-chain ligand conjugates	786:814	sugar-chain ligand conjugates	786:814	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	2	20	theme	hydrophilic	552:562	arg1	imidate					508:514	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	imidate	508:514	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	20	theme	hydrophilic	552:562	arg1	moiety					528:533	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	moiety	528:533	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	20	theme	hydrophilic	552:562	arg1	spacer					564:569	a hydrophilic spacer	550:569	a hydrophilic spacer when immobilized on a gold-coated sensor chip	550:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	21	theme	α-N-acetylgalactosamine	351:373	arg1	residue					375:381	α-N-acetylgalactosamine residue	351:381	α-N-acetylgalactosamine residue	351:381	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	22	theme	imidate	508:514	arg1	glycosylation					411:423	α-selective glycosylation	399:423	α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip	399:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	0	23	with	analysis	75:82	arg1	chips					95:99	sugar chips	89:99	sugar chips	89:99	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	3	24	gly	glycosylation	671:683	arg1	donors					740:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	0	25	theme	type	19:22	arg1	core					24:27	mucin type core 3 and core 5 structures	13:51	core	24:27	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	1	26	theme	binding	240:246	arg1	interaction					248:258	their binding interaction	234:258	their binding interaction with lectins using sugar chip technology	234:299	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	0	27	theme	mucin	13:17	arg1	core					24:27	mucin type core 3 and core 5 structures	13:51	core	24:27	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	2	28	theme	sensor	605:610	arg1	chip					612:615	a gold-coated sensor chip	591:615	a gold-coated sensor chip	591:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	29	contain	containing	340:349	arg2	residue					375:381	α-N-acetylgalactosamine residue	351:381	α-N-acetylgalactosamine residue	351:381	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	29	contain	containing	340:349	arg1	moiety					333:338	Tn antigen moiety	322:338	Tn antigen moiety containing α-N-acetylgalactosamine residue	322:381	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	30	theme	moiety	333:338	arg1	construction					306:317	The construction	302:317	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue	302:381	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	31	theme	gold-coated	593:603	arg1	chip					612:615	a gold-coated sensor chip	591:615	a gold-coated sensor chip	591:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	0	32	theme	core	24:27	arg1	analysis					75:82	their interaction analysis	57:82	their interaction analysis with sugar chips	57:99	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	0	32	theme	core	24:27	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of mucin type core 3 and core 5 structures	0:51	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	4	33	with	lectins	878:884	arg1	chips					897:901	sugar chips	891:901	sugar chips coated with ligand conjugates	891:931	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	2	34	theme	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl	428:506	arg1	imidate					508:514	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	imidate	508:514	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	34	theme	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl	428:506	arg1	moiety					528:533	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	moiety	528:533	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	34	theme	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl	428:506	arg1	spacer					564:569	a hydrophilic spacer	550:569	a hydrophilic spacer when immobilized on a gold-coated sensor chip	550:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	0	35	theme	core	35:38	arg1	structures					42:51	mucin type core 3 and core 5 structures	13:51	structures	42:51	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	3	36	theme	appropriate	688:698	arg1	donors					740:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	3	37	theme	core	629:632	arg1	structures					636:645	Core 3 and core 5 structures	618:645	structures	636:645	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	2	38	theme	glucose	520:526	arg1	imidate					508:514	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	imidate	508:514	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	38	theme	glucose	520:526	arg1	moiety					528:533	2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety	428:533	moiety	528:533	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	2	38	theme	glucose	520:526	arg1	spacer					564:569	a hydrophilic spacer	550:569	a hydrophilic spacer when immobilized on a gold-coated sensor chip	550:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	1	39	theme	sugar	279:283	arg1	technology					290:299	sugar chip technology	279:299	sugar chip technology	279:299	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	4	40	theme	resonance	970:978	arg1	biosensor					986:994	a surface plasmon resonance (SPR) biosensor	952:994	a surface plasmon resonance (SPR) biosensor	952:994	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	4	41	theme	plasmon	962:968	arg1	SPR					981:983	SPR	981:983	SPR	981:983	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	4	41	theme	plasmon	962:968	arg1	resonance					970:978	surface plasmon resonance	954:978	a surface plasmon resonance (SPR) biosensor	952:994	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	1	42	theme	chip	285:288	arg1	technology					290:299	sugar chip technology	279:299	sugar chip technology	279:299	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	0	43	with	Synthesis	0:8	arg1	chips					95:99	sugar chips	89:99	sugar chips	89:99	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	3	44	theme	N-galactosamine	724:738	arg1	donors					740:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	appropriate N-acetylglucosamine and N-galactosamine donors	688:745	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	5	45	theme	specific	1001:1008	arg1	interaction					1010:1020	The specific interaction	997:1020	The specific interaction	997:1020	The specific interaction was observed between the core 3 structure and Jacalin (JAC) and kinetic parameters were estimated as ka = 1.5 × 104, kd = 5.8 × 10-3, and KD = 3.8 × 10-7.
35487177	0	46	theme	structures	42:51	arg1	analysis					75:82	their interaction analysis	57:82	their interaction analysis with sugar chips	57:99	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	0	46	theme	structures	42:51	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of mucin type core 3 and core 5 structures	0:51	Synthesis of mucin type core 3 and core 5 structures and their interaction analysis with sugar chips.
35487177	3	47	theme	donors	740:745	arg1	glycosylation					671:683	the glycosylation	667:683	the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors	667:745	Core 3 and core 5 structures were synthesized by the glycosylation of appropriate N-acetylglucosamine and N-galactosamine donors, respectively, and were converted into sugar-chain ligand conjugates according to the method reported.
35487177	1	48	theme	functional	110:119	arg1	analysis					121:128	the functional analysis	106:128	the functional analysis of mucin related glycan	106:152	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35487177	2	49	theme	moiety	528:533	arg1	glycosylation					411:423	α-selective glycosylation	399:423	α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip	399:615	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	4	50	theme	lectins	878:884	arg1	analysis					866:873	The interaction analysis	850:873	The interaction analysis of lectins with sugar chips coated with ligand conjugates	850:931	The interaction analysis of lectins with sugar chips coated with ligand conjugates was performed with a surface plasmon resonance (SPR) biosensor.
35487177	2	51	theme	antigen	325:331	arg1	moiety					333:338	Tn antigen moiety	322:338	Tn antigen moiety containing α-N-acetylgalactosamine residue	322:381	The construction of Tn antigen moiety containing α-N-acetylgalactosamine residue was achieved by α-selective glycosylation of 2-azido-6-tert-butyldiphenylsilyl-3,4-di-O-chloroacetyl-2-deoxy-galctopyranosyl imidate and glucose moiety, which acts as a hydrophilic spacer when immobilized on a gold-coated sensor chip.
35487177	1	52	theme	mucin	197:201	arg1	O-glycan					208:215	mucin type O-glycan	197:215	mucin type O-glycan	197:215	For the functional analysis of mucin related glycan, we synthesized core 3 and 5 structures of mucin type O-glycan and investigated their binding interaction with lectins using sugar chip technology.
35123071	2	0	theme	natural	458:464	arg1	killer					466:471	natural killer	458:471	natural killer cell-mediated cytotoxicity	458:498	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	2	1	from	trophoblasts	405:416	arg1	abundant					387:394	abundant	387:394	abundant	387:394	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	6	2	gly	glycoproteins	1039:1051	arg1	glycoproteins					1039:1051	41 glycoproteins	1036:1051	41 glycoproteins with 43 glycopeptides	1036:1073	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	6	3	with	glycoproteins	1039:1051	arg1	glycopeptides					1061:1073	43 glycopeptides	1058:1073	43 glycopeptides	1058:1073	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	1	4	theme	N-glycosylation	228:242	arg1	type					220:223	a special type	210:223	a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development	210:357	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	4	theme	N-glycosylation	228:242	arg1	N-acetylglucosamine					111:129	Bisecting N-acetylglucosamine	101:129	Bisecting N-acetylglucosamine (GlcNAc)	101:138	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	7	5	theme	modification	1294:1305	arg1	roles					1268:1272	the potential roles	1254:1272	the potential roles of bisecting GlcNAc modification in the human amniotic membrane	1254:1336	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	3	6	theme	last	642:645	arg1	membrane					612:619	the human amniotic membrane	593:619	the human amniotic membrane	593:619	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	3	6	theme	last	642:645	arg1	barrier					647:653	the last barrier	638:653	the last barrier for the fetus	638:667	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	4	7	theme	bisected	803:810	arg1	N-glycans					812:820	bisected N-glycans	803:820	bisected N-glycans	803:820	To test this hypothesis, glycomic analysis of the human amniotic membrane was performed, and bisected N-glycans were detected.
35123071	1	8	theme	core	164:167	arg1	residue					179:185	the core β-mannose residue	160:185	the core β-mannose residue	160:185	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	6	9	contain	possess	1089:1095	arg2	GlcNAc					1109:1114	a bisecting GlcNAc	1097:1114	a bisecting GlcNAc	1097:1114	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	6	9	contain	possess	1089:1095	arg1	total					1027:1031	A total	1025:1031	A total of 41 glycoproteins with 43 glycopeptides	1025:1073	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	7	10	from	suppression	1469:1479	arg1	placenta					1490:1497	human placenta	1484:1497	human placenta	1484:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	1	11	theme	cell	323:326	arg1	adhesion					328:335	cell adhesion	323:335	cell adhesion	323:335	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	6	12	theme	first	1206:1210	arg1	time					1212:1215	the first time	1202:1215	the first time	1202:1215	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	7	13	from	roles	1268:1272	arg1	membrane					1329:1336	the human amniotic membrane	1310:1336	the human amniotic membrane	1310:1336	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	6	14	theme	bisecting	1099:1107	arg1	GlcNAc					1109:1114	a bisecting GlcNAc	1097:1114	a bisecting GlcNAc	1097:1114	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	7	15	theme	functional	1364:1373	arg1	studies					1375:1381	functional studies	1364:1381	functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta	1364:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	6	16	gly	glycoproteins	1133:1145	arg1	glycoproteins					1133:1145	these glycoproteins	1127:1145	these glycoproteins	1127:1145	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	1	17	attach	linked	150:155	arg2	N-acetylglucosamine					111:129	Bisecting N-acetylglucosamine	101:129	Bisecting N-acetylglucosamine (GlcNAc)	101:138	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	17	attach	linked	150:155	arg2	GlcNAc					143:148	a GlcNAc	141:148	a GlcNAc linked to the core β-mannose residue via a β1,4 linkage	141:204	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	17	attach	linked	150:155	arg1	residue					179:185	the core β-mannose residue	160:185	the core β-mannose residue	160:185	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	17	attach	linked	150:155	arg3	linkage					198:204	a β1,4 linkage	191:204	a β1,4 linkage	191:204	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	5	18	theme	human	917:921	arg1	proteins					931:938	human missing proteins	917:938	human missing proteins	917:938	Furthermore, our proteomic data, which have been previously employed to explore human missing proteins, were analyzed and the presence of bisecting GlcNAc-modified peptides was confirmed.
35123071	7	19	gly	glycoproteins	1386:1398	arg1	glycoproteins					1386:1398	glycoproteins	1386:1398	glycoproteins with bisecting GlcNAc modifications	1386:1434	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	1	20	theme	β-mannose	169:177	arg1	residue					179:185	the core β-mannose residue	160:185	the core β-mannose residue	160:185	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	21	theme	fetal	341:345	arg1	development					347:357	fetal development	341:357	fetal development	341:357	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	6	22	theme	modification	1185:1196	arg1	type					1177:1180	this type	1172:1180	this type of modification for the first time	1172:1215	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	5	23	theme	missing	923:929	arg1	proteins					931:938	human missing proteins	917:938	human missing proteins	917:938	Furthermore, our proteomic data, which have been previously employed to explore human missing proteins, were analyzed and the presence of bisecting GlcNAc-modified peptides was confirmed.
35123071	7	24	theme	functional	1440:1449	arg1	studies					1451:1457	functional studies	1440:1457	functional studies on immune suppression in human placenta	1440:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	2	25	theme	N-glycan	365:372	arg1	structure					374:382	This N-glycan structure	360:382	This N-glycan structure	360:382	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	7	26	from	studies	1375:1381	arg1	glycoproteins					1386:1398	glycoproteins	1386:1398	glycoproteins with bisecting GlcNAc modifications	1386:1434	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	7	26	from	studies	1375:1381	arg1	studies					1451:1457	functional studies	1440:1457	functional studies on immune suppression in human placenta	1440:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	0	27	from	Modification	44:55	arg1	Membrane					69:76	Amniotic Membrane	60:76	Amniotic Membrane	60:76	Profiling the Bisecting N-acetylglucosamine Modification in Amniotic Membrane via Mass Spectrometry.
35123071	0	28	theme	Mass	82:85	arg1	Spectrometry					87:98	Mass Spectrometry	82:98	Mass Spectrometry	82:98	Profiling the Bisecting N-acetylglucosamine Modification in Amniotic Membrane via Mass Spectrometry.
35123071	1	29	theme	Bisecting	101:109	arg1	type					220:223	a special type	210:223	a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development	210:357	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	29	theme	Bisecting	101:109	arg1	N-acetylglucosamine					111:129	Bisecting N-acetylglucosamine	101:129	Bisecting N-acetylglucosamine (GlcNAc)	101:138	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	29	theme	Bisecting	101:109	arg1	GlcNAc					143:148	a GlcNAc	141:148	a GlcNAc linked to the core β-mannose residue via a β1,4 linkage	141:204	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	29	theme	Bisecting	101:109	arg1	GlcNAc					132:137	GlcNAc	132:137	GlcNAc	132:137	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	7	30	theme	bisecting	1405:1413	arg1	GlcNAc					1415:1420	bisecting GlcNAc	1405:1420	bisecting GlcNAc modifications	1405:1434	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	6	31	gly	glycopeptides	1061:1073	arg2	glycopeptides					1061:1073	43 glycopeptides	1058:1073	43 glycopeptides	1058:1073	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	7	32	from	glycoproteins	1386:1398	arg1	suppression					1469:1479	immune suppression	1462:1479	immune suppression in human placenta	1462:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	7	33	theme	GlcNAc	1287:1292	arg1	modification					1294:1305	bisecting GlcNAc modification	1277:1305	bisecting GlcNAc modification	1277:1305	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	0	34	theme	N-acetylglucosamine	24:42	arg1	Modification					44:55	the Bisecting N-acetylglucosamine Modification	10:55	the Bisecting N-acetylglucosamine Modification in Amniotic Membrane	10:76	Profiling the Bisecting N-acetylglucosamine Modification in Amniotic Membrane via Mass Spectrometry.
35123071	7	35	theme	human	1314:1318	arg1	membrane					1329:1336	the human amniotic membrane	1310:1336	the human amniotic membrane	1310:1336	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	2	36	theme	human	399:403	arg1	trophoblasts					405:416	human trophoblasts	399:416	human trophoblasts	399:416	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	0	37	theme	Bisecting	14:22	arg1	Modification					44:55	the Bisecting N-acetylglucosamine Modification	10:55	the Bisecting N-acetylglucosamine Modification in Amniotic Membrane	10:76	Profiling the Bisecting N-acetylglucosamine Modification in Amniotic Membrane via Mass Spectrometry.
35123071	7	38	theme	human	1484:1488	arg1	placenta					1490:1497	human placenta	1484:1497	human placenta	1484:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	3	39	theme	bisected-type	687:699	arg1	glycans					701:707	bisected-type glycans	687:707	bisected-type glycans	687:707	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	4	40	theme	human	760:764	arg1	membrane					775:782	the human amniotic membrane	756:782	the human amniotic membrane	756:782	To test this hypothesis, glycomic analysis of the human amniotic membrane was performed, and bisected N-glycans were detected.
35123071	7	41	theme	immune	1462:1467	arg1	suppression					1469:1479	immune suppression	1462:1479	immune suppression in human placenta	1462:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	7	42	theme	potential	1258:1266	arg1	roles					1268:1272	the potential roles	1254:1272	the potential roles of bisecting GlcNAc modification in the human amniotic membrane	1254:1336	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	3	43	theme	human	597:601	arg1	membrane					612:619	the human amniotic membrane	593:619	the human amniotic membrane	593:619	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	3	43	theme	human	597:601	arg1	barrier					647:653	the last barrier	638:653	the last barrier for the fetus	638:667	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	7	44	theme	amniotic	1320:1327	arg1	membrane					1329:1336	the human amniotic membrane	1310:1336	the human amniotic membrane	1310:1336	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	1	45	theme	various	285:291	arg1	development					347:357	fetal development	341:357	fetal development	341:357	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	45	theme	various	285:291	arg1	adhesion					328:335	cell adhesion	323:335	cell adhesion	323:335	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	45	theme	various	285:291	arg1	processes					304:312	various biological processes	285:312	various biological processes	285:312	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	3	46	theme	amniotic	603:610	arg1	membrane					612:619	the human amniotic membrane	593:619	the human amniotic membrane	593:619	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	3	46	theme	amniotic	603:610	arg1	barrier					647:653	the last barrier	638:653	the last barrier for the fetus	638:667	In this study, we hypothesized that the human amniotic membrane, which serves as the last barrier for the fetus, may also express bisected-type glycans.
35123071	4	47	theme	membrane	775:782	arg1	analysis					744:751	glycomic analysis	735:751	glycomic analysis of the human amniotic membrane	735:782	To test this hypothesis, glycomic analysis of the human amniotic membrane was performed, and bisected N-glycans were detected.
35123071	5	48	theme	proteomic	854:862	arg1	data					864:867	our proteomic data	850:867	our proteomic data	850:867	Furthermore, our proteomic data, which have been previously employed to explore human missing proteins, were analyzed and the presence of bisecting GlcNAc-modified peptides was confirmed.
35123071	0	49	theme	Amniotic	60:67	arg1	Membrane					69:76	Amniotic Membrane	60:76	Amniotic Membrane	60:76	Profiling the Bisecting N-acetylglucosamine Modification in Amniotic Membrane via Mass Spectrometry.
35123071	1	50	theme	biological	293:302	arg1	development					347:357	fetal development	341:357	fetal development	341:357	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	50	theme	biological	293:302	arg1	adhesion					328:335	cell adhesion	323:335	cell adhesion	323:335	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	50	theme	biological	293:302	arg1	processes					304:312	various biological processes	285:312	various biological processes	285:312	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	5	51	theme	bisecting	975:983	arg1	peptides					1001:1008	bisecting GlcNAc-modified peptides	975:1008	bisecting GlcNAc-modified peptides	975:1008	Furthermore, our proteomic data, which have been previously employed to explore human missing proteins, were analyzed and the presence of bisecting GlcNAc-modified peptides was confirmed.
35123071	4	52	theme	amniotic	766:773	arg1	membrane					775:782	the human amniotic membrane	756:782	the human amniotic membrane	756:782	To test this hypothesis, glycomic analysis of the human amniotic membrane was performed, and bisected N-glycans were detected.
35123071	5	53	theme	GlcNAc-modified	985:999	arg1	peptides					1001:1008	bisecting GlcNAc-modified peptides	975:1008	bisecting GlcNAc-modified peptides	975:1008	Furthermore, our proteomic data, which have been previously employed to explore human missing proteins, were analyzed and the presence of bisecting GlcNAc-modified peptides was confirmed.
35123071	4	54	theme	glycomic	735:742	arg1	analysis					744:751	glycomic analysis	735:751	glycomic analysis of the human amniotic membrane	735:782	To test this hypothesis, glycomic analysis of the human amniotic membrane was performed, and bisected N-glycans were detected.
35123071	7	55	theme	GlcNAc	1415:1420	arg1	modifications					1422:1434	bisecting GlcNAc modifications	1405:1434	bisecting GlcNAc modifications	1405:1434	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	7	56	from	studies	1451:1457	arg1	suppression					1469:1479	immune suppression	1462:1479	immune suppression in human placenta	1462:1497	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	7	57	with	studies	1451:1457	arg1	modifications					1422:1434	bisecting GlcNAc modifications	1405:1434	bisecting GlcNAc modifications	1405:1434	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	5	58	theme	peptides	1001:1008	arg1	presence					963:970	the presence	959:970	the presence of bisecting GlcNAc-modified peptides	959:1008	Furthermore, our proteomic data, which have been previously employed to explore human missing proteins, were analyzed and the presence of bisecting GlcNAc-modified peptides was confirmed.
35123071	6	59	theme	glycoproteins	1133:1145	arg1	glycoproteins					1133:1145	these glycoproteins	1127:1145	these glycoproteins	1127:1145	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	6	59	theme	glycoproteins	1133:1145	arg1	25					1121:1122	25	1121:1122	25	1121:1122	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
35123071	2	60	from	abundant	387:394	arg1	trophoblasts					405:416	human trophoblasts	399:416	human trophoblasts	399:416	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	7	61	with	glycoproteins	1386:1398	arg1	modifications					1422:1434	bisecting GlcNAc modifications	1405:1434	bisecting GlcNAc modifications	1405:1434	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	1	62	theme	special	212:218	arg1	type					220:223	a special type	210:223	a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development	210:357	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	1	62	theme	special	212:218	arg1	N-acetylglucosamine					111:129	Bisecting N-acetylglucosamine	101:129	Bisecting N-acetylglucosamine (GlcNAc)	101:138	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	2	63	theme	cell-mediated	473:485	arg1	cytotoxicity					487:498	natural killer cell-mediated cytotoxicity	458:498	natural killer cell-mediated cytotoxicity	458:498	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	1	64	theme	β1,4	193:196	arg1	linkage					198:204	a β1,4 linkage	191:204	a β1,4 linkage	191:204	Bisecting N-acetylglucosamine (GlcNAc), a GlcNAc linked to the core β-mannose residue via a β1,4 linkage, is a special type of N-glycosylation that has been reported to be involved in various biological processes, such as cell adhesion and fetal development.
35123071	2	65	theme	killer	466:471	arg1	cytotoxicity					487:498	natural killer cell-mediated cytotoxicity	458:498	natural killer cell-mediated cytotoxicity	458:498	This N-glycan structure is abundant in human trophoblasts, which is postulated to be resistant to natural killer cell-mediated cytotoxicity, enabling a mother to nourish a fetus without rejection.
35123071	7	66	theme	bisecting	1277:1285	arg1	GlcNAc					1287:1292	bisecting GlcNAc	1277:1292	bisecting GlcNAc modification	1277:1305	These results provide insights into the potential roles of bisecting GlcNAc modification in the human amniotic membrane, and can be beneficial to functional studies on glycoproteins with bisecting GlcNAc modifications and functional studies on immune suppression in human placenta.
35123071	6	67	theme	glycoproteins	1039:1051	arg1	total					1027:1031	A total	1025:1031	A total of 41 glycoproteins with 43 glycopeptides	1025:1073	A total of 41 glycoproteins with 43 glycopeptides were found to possess a bisecting GlcNAc, and 25 of these glycoproteins were reported to exhibit this type of modification for the first time.
36053804	3	0	theme	paucimannose	609:620	arg1	N-glycans					622:630	paucimannose N-glycans	609:630	paucimannose N-glycans	609:630	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	6	1	theme	control	1132:1138	arg1	insects					1148:1154	the control GFPRNAi insects	1128:1154	the control GFPRNAi insects	1128:1154	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	2	2	theme	RNA	315:317	arg1	interference					319:330	RNA interference	315:330	RNA interference (RNAi)	315:337	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	2	theme	RNA	315:317	arg1	RNAi					333:336	RNAi	333:336	RNAi	333:336	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	4	3	from	level	853:857	arg1	effects					822:828	the effects	818:828	the effects at the organ or tissue level and also immune effects	818:881	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	4	4	theme	pest	796:799	arg1	context					809:815	a pest control context	794:815	a pest control context	794:815	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	7	5	theme	midgut	1266:1271	arg1	cells					1253:1257	the epithelial cells	1238:1257	the epithelial cells of the midgut of ManIaRNAi insects	1238:1292	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	11	6	from	decrease	1847:1854	arg1	size					1867:1870	PM pore size	1859:1870	PM pore size	1859:1870	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	8	7	theme	midgut	1477:1482	arg1	cells					1484:1488	the midgut cells	1473:1488	the midgut cells	1473:1488	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	8	8	theme	ManIa	1540:1544	arg1	silencing					1527:1535	the silencing	1523:1535	the silencing of ManIa	1523:1544	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	4	9	theme	organismal	757:766	arg1	level					768:772	the organismal level	753:772	the organismal level	753:772	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	11	10	dep	pathogens	1913:1921	arg1	epithelium					1944:1953	the midgut epithelium	1933:1953	the midgut epithelium	1933:1953	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	10	11	theme	glycan	1752:1757	arg1	structures					1759:1768	these glycan structures	1746:1768	these glycan structures	1746:1768	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	12	12	from	drosomycin-like	2059:2073	arg1	insects					2088:2094	ManIaRNAi insects	2078:2094	ManIaRNAi insects	2078:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	1	13	theme	digestive	147:155	arg1	system					157:162	the digestive system	143:162	the digestive system	143:162	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	7	14	theme	insects	1286:1292	arg1	midgut					1266:1271	the midgut	1262:1271	the midgut of ManIaRNAi insects	1262:1292	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	13	15	dep	Mv	2357:2358	arg1	the					2353:2355	the	2353:2355	the	2353:2355	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	7	16	theme	epithelial	1242:1251	arg1	cells					1253:1257	the epithelial cells	1238:1257	the epithelial cells of the midgut of ManIaRNAi insects	1238:1292	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	3	17	theme	RNAi-mediated	490:502	arg1	silencing					504:512	RNAi-mediated silencing	490:512	RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans,	490:631	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	1	18	theme	peritrophic	169:179	arg1	role					135:138	its role	131:138	its role in the digestive system	131:162	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	1	18	theme	peritrophic	169:179	arg1	PM					191:192	PM	191:192	PM	191:192	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	1	18	theme	peritrophic	169:179	arg1	membrane					181:188	the peritrophic membrane	165:188	the peritrophic membrane (PM)	165:193	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	4	19	theme	organ	837:841	arg1	level					853:857	the organ or tissue level	833:857	level	853:857	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	12	20	from	insects	2088:2094	arg1	levels					2025:2030	transcription levels	2011:2030	transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects	2011:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	11	21	theme	potential	1903:1911	arg1	pathogens					1913:1921	potential pathogens	1903:1921	potential pathogens to access the midgut epithelium	1903:1953	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	7	22	theme	microvilli	1219:1228	arg1	observation					1196:1206	the observation	1192:1206	the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects	1192:1292	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	10	23	theme	immune	1806:1811	arg1	pathways					1813:1820	the immune pathways	1802:1820	the immune pathways	1802:1820	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	5	24	theme	knowledge	928:936	arg1	gap					938:940	this knowledge gap	923:940	this knowledge gap	923:940	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	14	25	theme	Chemical	2386:2393	arg1	Industry					2395:2402	Chemical Industry	2386:2402	Chemical Industry	2386:2402	© 2022 Society of Chemical Industry.
36053804	8	26	theme	midgut	1297:1302	arg1	study					1320:1324	A midgut and PM proteome study	1295:1324	A midgut and PM proteome study	1295:1324	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	6	27	theme	pore	1075:1078	arg1	phenotype					1034:1042	marked phenotype	1027:1042	marked phenotype	1027:1042	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	6	27	theme	pore	1075:1078	arg1	size					1080:1083	the PM pore size	1068:1083	the PM pore size	1068:1083	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	13	28	theme	PM	2282:2283	arg1	function					2266:2273	the function	2262:2273	the function of the PM as a physical barrier	2262:2305	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	4	29	from	context	809:815	arg1	interesting					779:789	interesting	779:789	interesting	779:789	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	4	30	theme	immune	868:873	arg1	effects					875:881	immune effects	868:881	the effects at the organ or tissue level and also immune effects	818:881	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	8	31	theme	PM	1308:1309	arg1	study					1320:1324	A midgut and PM proteome study	1295:1324	A midgut and PM proteome study	1295:1324	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	0	32	theme	Mannosidase-Ia	8:21	arg1	RNAi					0:3	RNAi	0:3	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.	0:103	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	9	33	theme	activity	1583:1590	arg1	loss					1569:1572	the loss	1565:1572	the loss of ManIa activity	1565:1590	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	1	34	from	role	135:138	arg1	system					157:162	the digestive system	143:162	the digestive system	143:162	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	4	35	theme	tissue	846:851	arg1	level					853:857	the organ or tissue level	833:857	level	853:857	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	8	36	theme	reverse	1330:1336	arg1	RT-qPCR					1392:1398	RT-qPCR	1392:1398	RT-qPCR	1392:1398	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	8	36	theme	reverse	1330:1336	arg1	reaction					1382:1389	reverse transcription quantitative polymerase chain reaction	1330:1389	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	12	37	theme	drosomycin-like	2059:2073	arg1	levels					2025:2030	transcription levels	2011:2030	transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects	2011:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	0	38	theme	midgut	72:77	arg1	membrane					95:102	the midgut and peritrophic membrane	68:102	the midgut and peritrophic membrane	68:102	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	6	39	theme	PM	1072:1073	arg1	phenotype					1034:1042	marked phenotype	1027:1042	marked phenotype	1027:1042	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	6	39	theme	PM	1072:1073	arg1	size					1080:1083	the PM pore size	1068:1083	the PM pore size	1068:1083	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	2	40	theme	model	441:445	arg1	insect					447:452	a model insect	439:452	a model insect for functional studies	439:475	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	8	41	theme	quantitative	1352:1363	arg1	RT-qPCR					1392:1398	RT-qPCR	1392:1398	RT-qPCR	1392:1398	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	8	41	theme	quantitative	1352:1363	arg1	reaction					1382:1389	reverse transcription quantitative polymerase chain reaction	1330:1389	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	12	42	theme	ManIaRNAi	2078:2086	arg1	insects					2088:2094	ManIaRNAi insects	2078:2094	ManIaRNAi insects	2078:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	2	43	theme	notorious	344:352	arg1	beetle					387:392	the Colorado potato beetle	367:392	the Colorado potato beetle (CPB, Leptinotarsa decemlineata)	367:425	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	43	theme	notorious	344:352	arg1	insect					359:364	the notorious pest insect	340:364	the notorious pest insect	340:364	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	0	44	theme	peritrophic	83:93	arg1	membrane					95:102	the midgut and peritrophic membrane	68:102	the midgut and peritrophic membrane	68:102	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	0	45	theme	Colorado	30:37	arg1	beetle					46:51	the Colorado potato beetle	26:51	the Colorado potato beetle	26:51	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	9	46	theme	N-glycans	1625:1633	arg1	accumulation					1596:1607	an accumulation	1593:1607	an accumulation of high-mannose N-glycans	1593:1633	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	8	47	theme	chain	1376:1380	arg1	RT-qPCR					1392:1398	RT-qPCR	1392:1398	RT-qPCR	1392:1398	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	8	47	theme	chain	1376:1380	arg1	reaction					1382:1389	reverse transcription quantitative polymerase chain reaction	1330:1389	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	3	48	from	larva	674:678	arg1	transition					658:667	the transition	654:667	the transition from larva to pupa and the metamorphosis into adult beetles	654:727	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	3	49	from	enzyme	547:552	arg1	transition					561:570	the transition	557:570	the transition from high-mannose glycan moieties to paucimannose N-glycans	557:630	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	3	49	from	enzyme	547:552	arg1	moieties					597:604	high-mannose glycan moieties	577:604	high-mannose glycan moieties	577:604	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	9	50	with	agreement	1550:1558	arg1	loss					1569:1572	the loss	1565:1572	the loss of ManIa activity	1565:1590	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	5	51	from	PM	986:987	arg1	insects					1007:1013	ManIa-silenced insects	992:1013	ManIa-silenced insects	992:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	2	52	dep	beetle	387:392	arg1	CPB					395:397	CPB	395:397	CPB	395:397	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	52	dep	beetle	387:392	arg1	decemlineata					413:424	Leptinotarsa decemlineata	400:424	Leptinotarsa decemlineata	400:424	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	53	theme	potato	380:385	arg1	beetle					387:392	the Colorado potato beetle	367:392	the Colorado potato beetle (CPB, Leptinotarsa decemlineata)	367:425	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	53	theme	potato	380:385	arg1	insect					359:364	the notorious pest insect	340:364	the notorious pest insect	340:364	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	12	54	theme	anti-fungal	2039:2049	arg1	drosomycin-like					2059:2073	the anti-fungal peptide drosomycin-like	2035:2073	the anti-fungal peptide drosomycin-like in ManIaRNAi insects	2035:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	13	55	from	size	2231:2234	arg1	midgut					2203:2208	the midgut	2199:2208	the midgut	2199:2208	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	13	55	from	size	2231:2234	arg1	PM					2243:2244	the PM	2239:2244	the PM	2239:2244	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	5	56	from	midgut	975:980	arg1	insects					1007:1013	ManIa-silenced insects	992:1013	ManIa-silenced insects	992:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	7	57	theme	smaller	1163:1169	arg1	pores					1171:1175	These smaller pores	1157:1175	These smaller pores	1157:1175	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	10	58	theme	pathogen-associated	1684:1702	arg1	activation					1788:1797	the activation	1784:1797	the activation of the immune pathways	1784:1820	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	10	58	theme	pathogen-associated	1684:1702	arg1	PAMP					1723:1726	PAMP	1723:1726	PAMP	1723:1726	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	10	58	theme	pathogen-associated	1684:1702	arg1	pattern					1714:1720	a pathogen-associated molecular pattern	1682:1720	a pathogen-associated molecular pattern (PAMP)	1682:1727	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	2	59	theme	Leptinotarsa	400:411	arg1	CPB					395:397	CPB	395:397	CPB	395:397	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	59	theme	Leptinotarsa	400:411	arg1	decemlineata					413:424	Leptinotarsa decemlineata	400:424	Leptinotarsa decemlineata	400:424	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	13	60	theme	smaller	2218:2224	arg1	size					2231:2234	the smaller pore size	2214:2234	the smaller pore size in the PM	2214:2244	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	12	61	theme	transcription	2011:2023	arg1	levels					2025:2030	transcription levels	2011:2030	transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects	2011:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	0	62	theme	potato	39:44	arg1	beetle					46:51	the Colorado potato beetle	26:51	the Colorado potato beetle	26:51	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	9	63	located	observed	1639:1646	arg2	accumulation					1596:1607	an accumulation	1593:1607	an accumulation of high-mannose N-glycans	1593:1633	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	9	63	located	observed	1639:1646	arg1	insects					1670:1676	the ManIa-silenced insects	1651:1676	the ManIa-silenced insects	1651:1676	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	9	63	located	observed	1639:1646	arg1	agreement					1550:1558	agreement	1550:1558	agreement with the loss of ManIa activity	1550:1590	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	5	64	dep	midgut	975:980	arg1	the					971:973	the	971:973	the	971:973	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	8	65	theme	marker	1430:1435	arg1	genes					1437:1441	marker genes	1430:1441	marker genes	1430:1441	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	3	66	theme	glycan	590:595	arg1	moieties					597:604	high-mannose glycan moieties	577:604	high-mannose glycan moieties	577:604	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	13	67	from	response	2187:2194	arg1	midgut					2203:2208	the midgut	2199:2208	the midgut	2199:2208	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	13	67	from	response	2187:2194	arg1	PM					2243:2244	the PM	2239:2244	the PM	2239:2244	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	13	68	theme	potential	2170:2178	arg1	response					2187:2194	The potential immune response	2166:2194	The potential immune response in the midgut	2166:2208	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	3	69	from	moieties	597:604	arg1	transition					561:570	the transition	557:570	the transition from high-mannose glycan moieties to paucimannose N-glycans	557:630	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	3	69	from	moieties	597:604	arg1	Mannosidase-Ia					517:530	Mannosidase-Ia	517:530	Mannosidase-Ia (ManIa)	517:538	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	3	69	from	moieties	597:604	arg1	enzyme					547:552	a key enzyme	541:552	a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans	541:630	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	6	70	theme	GFPRNAi	1140:1146	arg1	insects					1148:1154	the control GFPRNAi insects	1128:1154	the control GFPRNAi insects	1128:1154	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	1	71	theme	physical	206:213	arg1	barrier					215:221	a physical barrier	204:221	a physical barrier protecting the intestine from abrasion and against pathogens	204:282	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	11	72	theme	midgut	1937:1942	arg1	epithelium					1944:1953	the midgut epithelium	1933:1953	the midgut epithelium	1933:1953	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	11	73	theme	observed	1838:1845	arg1	response					1883:1890	a response	1881:1890	a response to prevent potential pathogens to access the midgut epithelium	1881:1953	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	11	73	theme	observed	1838:1845	arg1	decrease					1847:1854	The observed decrease	1834:1854	The observed decrease in PM pore size	1834:1870	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	6	74	theme	ManIaRNAi	1049:1057	arg1	phenotype					1034:1042	marked phenotype	1027:1042	marked phenotype	1027:1042	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	6	74	theme	ManIaRNAi	1049:1057	arg1	insects					1059:1065	the ManIaRNAi insects	1045:1065	the ManIaRNAi insects	1045:1065	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	10	75	theme	structures	1759:1768	arg1	presence					1734:1741	the presence	1730:1741	the presence of these glycan structures	1730:1768	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	7	76	theme	ManIaRNAi	1276:1284	arg1	insects					1286:1292	ManIaRNAi insects	1276:1292	ManIaRNAi insects	1276:1292	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	11	77	theme	pore	1862:1865	arg1	size					1867:1870	PM pore size	1859:1870	PM pore size	1859:1870	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	13	78	theme	immune	2180:2185	arg1	response					2187:2194	The potential immune response	2166:2194	The potential immune response in the midgut	2166:2208	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	6	79	theme	marked	1027:1032	arg1	phenotype					1034:1042	marked phenotype	1027:1042	marked phenotype	1027:1042	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	6	79	theme	marked	1027:1032	arg1	size					1080:1083	the PM pore size	1068:1083	the PM pore size	1068:1083	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	6	79	theme	marked	1027:1032	arg1	insects					1059:1065	the ManIaRNAi insects	1045:1065	the ManIaRNAi insects	1045:1065	RESULTS As marked phenotype, the ManIaRNAi insects, the PM pore size was found to be decreased when compared to the control GFPRNAi insects.
36053804	13	80	theme	physical	2290:2297	arg1	barrier					2299:2305	a physical barrier	2288:2305	a physical barrier	2288:2305	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	8	81	with	analysis	1401:1408	arg1	selection					1417:1425	a selection	1415:1425	a selection of marker genes	1415:1441	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	12	82	from	levels	2025:2030	arg1	insects					2088:2094	ManIaRNAi insects	2078:2094	ManIaRNAi insects	2078:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	2	83	theme	functional	458:467	arg1	studies					469:475	functional studies	458:475	functional studies	458:475	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	0	84	from	changes	57:63	arg1	membrane					95:102	the midgut and peritrophic membrane	68:102	the midgut and peritrophic membrane	68:102	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	10	85	theme	pathways	1813:1820	arg1	activation					1788:1797	the activation	1784:1797	the activation of the immune pathways	1784:1820	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	10	85	theme	pathways	1813:1820	arg1	pattern					1714:1720	a pathogen-associated molecular pattern	1682:1720	a pathogen-associated molecular pattern (PAMP)	1682:1727	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	3	86	theme	Mannosidase-Ia	517:530	arg1	silencing					504:512	RNAi-mediated silencing	490:512	RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans,	490:631	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	11	87	dep	CONCLUSION	1823:1832	arg1	response					1883:1890	a response	1881:1890	a response to prevent potential pathogens to access the midgut epithelium	1881:1953	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	11	87	dep	CONCLUSION	1823:1832	arg1	decrease					1847:1854	The observed decrease	1834:1854	The observed decrease in PM pore size	1834:1870	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	0	88	from	RNAi	0:3	arg1	changes					57:63	changes	57:63	changes in the midgut and peritrophic membrane	57:102	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	0	88	from	RNAi	0:3	arg1	beetle					46:51	the Colorado potato beetle	26:51	the Colorado potato beetle	26:51	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	4	89	theme	control	801:807	arg1	context					809:815	a pest control context	794:815	a pest control context	794:815	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	3	90	theme	key	543:545	arg1	Mannosidase-Ia					517:530	Mannosidase-Ia	517:530	Mannosidase-Ia (ManIa)	517:538	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	3	90	theme	key	543:545	arg1	enzyme					547:552	a key enzyme	541:552	a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans	541:630	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	8	91	theme	proteome	1311:1318	arg1	study					1320:1324	A midgut and PM proteome study	1295:1324	A midgut and PM proteome study	1295:1324	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	7	92	theme	thinner	1211:1217	arg1	Mv					1231:1232	Mv	1231:1232	Mv	1231:1232	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	7	92	theme	thinner	1211:1217	arg1	microvilli					1219:1228	thinner microvilli	1211:1228	thinner microvilli (Mv)	1211:1233	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	9	93	theme	ManIa	1577:1581	arg1	activity					1583:1590	ManIa activity	1577:1590	ManIa activity	1577:1590	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	3	94	theme	adult	715:719	arg1	beetles					721:727	adult beetles	715:727	adult beetles	715:727	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	5	95	theme	ManIa-silenced	992:1005	arg1	insects					1007:1013	ManIa-silenced insects	992:1013	ManIa-silenced insects	992:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	0	96	from	beetle	46:51	arg1	membrane					95:102	the midgut and peritrophic membrane	68:102	the midgut and peritrophic membrane	68:102	RNAi of Mannosidase-Ia in the Colorado potato beetle and changes in the midgut and peritrophic membrane.
36053804	8	97	theme	transcription	1338:1350	arg1	RT-qPCR					1392:1398	RT-qPCR	1392:1398	RT-qPCR	1392:1398	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	8	97	theme	transcription	1338:1350	arg1	reaction					1382:1389	reverse transcription quantitative polymerase chain reaction	1330:1389	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	5	98	from	analysis	959:966	arg1	insects					1007:1013	ManIa-silenced insects	992:1013	ManIa-silenced insects	992:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	4	99	from	interesting	779:789	arg1	context					809:815	a pest control context	794:815	a pest control context	794:815	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	11	100	theme	PM	1859:1860	arg1	size					1867:1870	PM pore size	1859:1870	PM pore size	1859:1870	CONCLUSION The observed decrease in PM pore size could be a response to prevent potential pathogens to access the midgut epithelium.
36053804	8	101	theme	polymerase	1365:1374	arg1	RT-qPCR					1392:1398	RT-qPCR	1392:1398	RT-qPCR	1392:1398	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	8	101	theme	polymerase	1365:1374	arg1	reaction					1382:1389	reverse transcription quantitative polymerase chain reaction	1330:1389	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	12	102	theme	peptide	2051:2057	arg1	drosomycin-like					2059:2073	the anti-fungal peptide drosomycin-like	2035:2073	the anti-fungal peptide drosomycin-like in ManIaRNAi insects	2035:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	4	103	from	level	768:772	arg1	effects					742:748	these effects	736:748	these effects at the organismal level	736:772	While these effects at the organismal level were interesting in a pest control context, the effects at the organ or tissue level and also immune effects have not been investigated yet.
36053804	7	104	from	observation	1196:1206	arg1	cells					1253:1257	the epithelial cells	1238:1257	the epithelial cells of the midgut of ManIaRNAi insects	1238:1292	These smaller pores are related to the observation of thinner microvilli (Mv) on the epithelial cells of the midgut of ManIaRNAi insects.
36053804	9	105	theme	high-mannose	1612:1623	arg1	N-glycans					1625:1633	high-mannose N-glycans	1612:1633	high-mannose N-glycans	1612:1633	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	8	106	theme	reaction	1382:1389	arg1	analysis					1401:1408	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis	1330:1408	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	5	107	theme	PM	986:987	arg1	analysis					959:966	an analysis	956:966	an analysis of the midgut and PM in ManIa-silenced insects	956:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	5	108	theme	midgut	975:980	arg1	analysis					959:966	an analysis	956:966	an analysis of the midgut and PM in ManIa-silenced insects	956:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	8	109	with	study	1320:1324	arg1	selection					1417:1425	a selection	1415:1425	a selection of marker genes	1415:1441	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	1	110	from	BACKGROUND	105:114	arg1	addition					119:126	addition	119:126	addition	119:126	BACKGROUND In addition to its role in the digestive system, the peritrophic membrane (PM) provides a physical barrier protecting the intestine from abrasion and against pathogens.
36053804	2	111	theme	Colorado	371:378	arg1	beetle					387:392	the Colorado potato beetle	367:392	the Colorado potato beetle (CPB, Leptinotarsa decemlineata)	367:425	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	111	theme	Colorado	371:378	arg1	insect					359:364	the notorious pest insect	340:364	the notorious pest insect	340:364	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	10	112	theme	molecular	1704:1712	arg1	activation					1788:1797	the activation	1784:1797	the activation of the immune pathways	1784:1820	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	10	112	theme	molecular	1704:1712	arg1	PAMP					1723:1726	PAMP	1723:1726	PAMP	1723:1726	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	10	112	theme	molecular	1704:1712	arg1	pattern					1714:1720	a pathogen-associated molecular pattern	1682:1720	a pathogen-associated molecular pattern (PAMP)	1682:1727	As a pathogen-associated molecular pattern (PAMP), the presence of these glycan structures could trigger the activation of the immune pathways.
36053804	5	113	from	insects	1007:1013	arg1	analysis					959:966	an analysis	956:966	an analysis of the midgut and PM in ManIa-silenced insects	956:1013	To fill this knowledge gap, we performed an analysis of the midgut and PM in ManIa-silenced insects.
36053804	9	114	theme	ManIa-silenced	1655:1668	arg1	insects					1670:1676	the ManIa-silenced insects	1651:1676	the ManIa-silenced insects	1651:1676	In agreement with the loss of ManIa activity, an accumulation of high-mannose N-glycans was observed in the ManIa-silenced insects.
36053804	12	115	theme	strong	1992:1997	arg1	increase					1999:2006	the strong increase	1988:2006	the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects	1988:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	2	116	theme	pest	354:357	arg1	beetle					387:392	the Colorado potato beetle	367:392	the Colorado potato beetle (CPB, Leptinotarsa decemlineata)	367:425	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	2	116	theme	pest	354:357	arg1	insect					359:364	the notorious pest insect	340:364	the notorious pest insect	340:364	Because of its sensitivity to RNA interference (RNAi), the notorious pest insect, the Colorado potato beetle (CPB, Leptinotarsa decemlineata), has become a model insect for functional studies.
36053804	13	117	theme	pore	2226:2229	arg1	size					2231:2234	the smaller pore size	2214:2234	the smaller pore size in the PM	2214:2244	The potential immune response in the midgut and the smaller pore size in the PM shed a light on the function of the PM as a physical barrier and provide evidence for the relation between the Mv and PM.
36053804	12	118	theme	further	2106:2112	arg1	research					2114:2121	further research	2106:2121	further research	2106:2121	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36053804	8	119	theme	genes	1437:1441	arg1	selection					1417:1425	a selection	1415:1425	a selection of marker genes	1415:1441	A midgut and PM proteome study and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis with a selection of marker genes was performed to characterize the midgut cells and understand their response to the silencing of ManIa.
36053804	3	120	theme	high-mannose	577:588	arg1	moieties					597:604	high-mannose glycan moieties	577:604	high-mannose glycan moieties	577:604	Previously, RNAi-mediated silencing of Mannosidase-Ia (ManIa), a key enzyme in the transition from high-mannose glycan moieties to paucimannose N-glycans, was shown to disrupt the transition from larva to pupa and the metamorphosis into adult beetles.
36053804	12	121	from	increase	1999:2006	arg1	levels					2025:2030	transcription levels	2011:2030	transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects	2011:2094	This hypothesis is supported by the strong increase in transcription levels of the anti-fungal peptide drosomycin-like in ManIaRNAi insects, although further research is required to elucidate this possibility.
36717059	6	0	from	levels	1039:1044	arg1	datasets					1106:1113	developmental RNA-seq datasets	1084:1113	developmental RNA-seq datasets	1084:1113	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	2	1	theme	liquid-	343:349	arg1	larvae					369:374	liquid- or plate-grown L4 larvae	343:374	liquid- or plate-grown L4 larvae	343:374	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	4	2	theme	α-galactosylation	678:694	arg1	terms					636:640	terms	636:640	terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose	636:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	3	3	theme	cultivation	489:499	arg1	mode					481:484	the mode	477:484	the stages as well as the mode of cultivation	455:499	Of the over 200 different annotatable N-glycan structures, variations between the stages as well as the mode of cultivation were observed.
36717059	3	3	theme	cultivation	489:499	arg1	stages					459:464	the stages	455:464	the stages as well as the mode of cultivation	455:499	Of the over 200 different annotatable N-glycan structures, variations between the stages as well as the mode of cultivation were observed.
36717059	4	4	theme	methylation	645:655	arg1	terms					636:640	terms	636:640	terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose	636:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	6	5	theme	genes	1219:1223	arg1	clusters					1174:1181	clusters	1174:1181	clusters of potential glycosylation-relevant genes	1174:1223	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	6	6	theme	glycosylation-relevant	1196:1217	arg1	genes					1219:1223	potential glycosylation-relevant genes	1186:1223	potential glycosylation-relevant genes	1186:1223	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	6	7	theme	co-ordinated	1147:1158	arg1	expression					1160:1169	co-ordinated expression	1147:1169	co-ordinated expression of clusters of potential glycosylation-relevant genes	1147:1223	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	6	8	theme	clusters	1174:1181	arg1	expression					1160:1169	co-ordinated expression	1147:1169	co-ordinated expression of clusters of potential glycosylation-relevant genes	1147:1223	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	6	9	theme	developmental	1084:1096	arg1	datasets					1106:1113	developmental RNA-seq datasets	1084:1113	developmental RNA-seq datasets	1084:1113	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	2	10	theme	MALDI-TOF-MS	268:279	arg1	approach					281:288	an off-line MALDI-TOF-MS approach	256:288	an off-line MALDI-TOF-MS approach	256:288	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	3	11	theme	annotatable	403:413	arg1	structures					424:433	the over 200 different annotatable N-glycan structures	380:433	the over 200 different annotatable N-glycan structures	380:433	Of the over 200 different annotatable N-glycan structures, variations between the stages as well as the mode of cultivation were observed.
36717059	1	12	theme	wide	174:177	arg1	range					179:183	a wide range	172:183	a wide range of developmental, genetic, proteomic and glycomic studies	172:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	3	13	theme	N-glycan	415:422	arg1	structures					424:433	the over 200 different annotatable N-glycan structures	380:433	the over 200 different annotatable N-glycan structures	380:433	Of the over 200 different annotatable N-glycan structures, variations between the stages as well as the mode of cultivation were observed.
36717059	2	14	theme	off-line	259:266	arg1	approach					281:288	an off-line MALDI-TOF-MS approach	256:288	an off-line MALDI-TOF-MS approach	256:288	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	1	15	theme	range	179:183	arg1	elegans					89:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	1	15	theme	range	179:183	arg1	object					162:167	the object	158:167	the object of a wide range of developmental, genetic, proteomic and glycomic studies	158:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	1	15	theme	range	179:183	arg1	organism					136:143	a frequently-employed genetic model organism	100:143	a frequently-employed genetic model organism	100:143	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	4	16	theme	α1,6-fucose	740:750	arg1	α-galactosylation					678:694	α-galactosylation	678:694	α-galactosylation of mannose	678:705	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	16	theme	α1,6-fucose	740:750	arg1	methylation					645:655	methylation	645:655	methylation of bisecting fucose	645:675	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	16	theme	α1,6-fucose	740:750	arg1	di-β-galactosylation					711:730	di-β-galactosylation	711:730	di-β-galactosylation of core α1,6-fucose	711:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	7	17	theme	simple	1299:1304	arg1	nematode					1306:1313	a simple nematode	1297:1313	a simple nematode	1297:1313	Thus, there are still questions to be answered in terms of how and why a simple nematode synthesizes such a diverse glycome.
36717059	2	18	theme	larvae	369:374	arg1	N-glycans					312:320	the N-glycans	308:320	the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae	308:374	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	6	19	theme	structures	994:1003	arg1	set					980:982	the set	976:982	the set of glycan structures	976:1003	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	6	19	theme	structures	994:1003	arg1	structures					994:1003	glycan structures	987:1003	glycan structures	987:1003	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	1	20	theme	frequently-employed	102:120	arg1	elegans					89:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	1	20	theme	frequently-employed	102:120	arg1	organism					136:143	a frequently-employed genetic model organism	100:143	a frequently-employed genetic model organism	100:143	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	2	21	theme	L4	366:367	arg1	larvae					369:374	liquid- or plate-grown L4 larvae	343:374	liquid- or plate-grown L4 larvae	343:374	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	4	22	theme	liquid-	584:590	arg1	larvae					608:613	the liquid- and plate-grown larvae	580:613	the liquid- and plate-grown larvae	580:613	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	23	theme	embryonal	526:534	arg1	N-glycome					536:544	the embryonal N-glycome	522:544	the embryonal N-glycome	522:544	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	1	24	theme	genetic	122:128	arg1	elegans					89:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	1	24	theme	genetic	122:128	arg1	organism					136:143	a frequently-employed genetic model organism	100:143	a frequently-employed genetic model organism	100:143	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	5	25	theme	embryonal	845:853	arg1	O-glycomes					855:864	especially the embryonal O-glycomes	830:864	especially the embryonal O-glycomes	830:864	Furthermore, we analysed the O-glycans by LC-ESI-MS following β-elimination; especially the embryonal O-glycomes included a set of phosphorylcholine-modified structures, previously not shown to exist in nematodes.
36717059	4	26	theme	core	735:738	arg1	α1,6-fucose					740:750	core α1,6-fucose	735:750	core α1,6-fucose	735:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	1	27	theme	model	130:134	arg1	elegans					89:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans	74:95	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	1	27	theme	model	130:134	arg1	organism					136:143	a frequently-employed genetic model organism	100:143	a frequently-employed genetic model organism	100:143	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	1	28	theme	genetic	203:209	arg1	studies					235:241	developmental, genetic, proteomic and glycomic studies	188:241	developmental, genetic, proteomic and glycomic studies	188:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	4	29	theme	mannose	699:705	arg1	α-galactosylation					678:694	α-galactosylation	678:694	α-galactosylation of mannose	678:705	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	29	theme	mannose	699:705	arg1	methylation					645:655	methylation	645:655	methylation of bisecting fucose	645:675	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	29	theme	mannose	699:705	arg1	di-β-galactosylation					711:730	di-β-galactosylation	711:730	di-β-galactosylation of core α1,6-fucose	711:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	1	30	theme	developmental	188:200	arg1	studies					235:241	developmental, genetic, proteomic and glycomic studies	188:241	developmental, genetic, proteomic and glycomic studies	188:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	5	31	theme	phosphorylcholine-modified	884:909	arg1	structures					911:920	phosphorylcholine-modified structures	884:920	phosphorylcholine-modified structures	884:920	Furthermore, we analysed the O-glycans by LC-ESI-MS following β-elimination; especially the embryonal O-glycomes included a set of phosphorylcholine-modified structures, previously not shown to exist in nematodes.
36717059	0	32	theme	N-glycome	29:37	arg1	complexity					11:20	complexity	11:20	complexity of the N-glycome	11:37	Increasing complexity of the N-glycome during Caenorhabditis development.
36717059	3	33	theme	different	393:401	arg1	structures					424:433	the over 200 different annotatable N-glycan structures	380:433	the over 200 different annotatable N-glycan structures	380:433	Of the over 200 different annotatable N-glycan structures, variations between the stages as well as the mode of cultivation were observed.
36717059	1	34	theme	proteomic	212:220	arg1	studies					235:241	developmental, genetic, proteomic and glycomic studies	188:241	developmental, genetic, proteomic and glycomic studies	188:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	4	35	theme	bisecting	660:668	arg1	fucose					670:675	bisecting fucose	660:675	bisecting fucose	660:675	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	6	36	theme	glycan	987:992	arg1	structures					994:1003	glycan structures	987:1003	glycan structures	987:1003	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	2	37	theme	embryos	331:337	arg1	N-glycans					312:320	the N-glycans	308:320	the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae	308:374	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	0	38	theme	Caenorhabditis	46:59	arg1	development					61:71	Caenorhabditis development	46:71	Caenorhabditis development	46:71	Increasing complexity of the N-glycome during Caenorhabditis development.
36717059	6	39	theme	potential	1186:1194	arg1	genes					1219:1223	potential glycosylation-relevant genes	1186:1223	potential glycosylation-relevant genes	1186:1223	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	2	40	theme	mixed	325:329	arg1	embryos					331:337	mixed embryos	325:337	mixed embryos	325:337	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	5	41	theme	structures	911:920	arg1	set					877:879	a set	875:879	a set	875:879	Furthermore, we analysed the O-glycans by LC-ESI-MS following β-elimination; especially the embryonal O-glycomes included a set of phosphorylcholine-modified structures, previously not shown to exist in nematodes.
36717059	5	41	theme	structures	911:920	arg1	structures					911:920	phosphorylcholine-modified structures	884:920	phosphorylcholine-modified structures	884:920	Furthermore, we analysed the O-glycans by LC-ESI-MS following β-elimination; especially the embryonal O-glycomes included a set of phosphorylcholine-modified structures, previously not shown to exist in nematodes.
36717059	6	42	theme	glycosyltransferase	1049:1067	arg1	transcripts					1069:1079	glycosyltransferase transcripts	1049:1079	glycosyltransferase transcripts	1049:1079	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	4	43	theme	di-β-galactosylation	711:730	arg1	terms					636:640	terms	636:640	terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose	636:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	1	44	theme	glycomic	226:233	arg1	studies					235:241	developmental, genetic, proteomic and glycomic studies	188:241	developmental, genetic, proteomic and glycomic studies	188:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	6	45	theme	transcripts	1069:1079	arg1	levels					1039:1044	levels	1039:1044	levels of glycosyltransferase transcripts in developmental RNA-seq datasets	1039:1113	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	6	46	theme	RNA-seq	1098:1104	arg1	datasets					1106:1113	developmental RNA-seq datasets	1084:1113	developmental RNA-seq datasets	1084:1113	However, the set of glycan structures cannot be clearly correlated with levels of glycosyltransferase transcripts in developmental RNA-seq datasets, but there is an indication for co-ordinated expression of clusters of potential glycosylation-relevant genes.
36717059	2	47	theme	plate-grown	354:364	arg1	larvae					369:374	liquid- or plate-grown L4 larvae	343:374	liquid- or plate-grown L4 larvae	343:374	Here, using an off-line MALDI-TOF-MS approach, we have analysed the N-glycans of mixed embryos and liquid- or plate-grown L4 larvae.
36717059	7	48	theme	diverse	1334:1340	arg1	glycome					1342:1348	such a diverse glycome	1327:1348	such a diverse glycome	1327:1348	Thus, there are still questions to be answered in terms of how and why a simple nematode synthesizes such a diverse glycome.
36717059	1	49	theme	studies	235:241	arg1	range					179:183	a wide range	172:183	a wide range of developmental, genetic, proteomic and glycomic studies	172:241	Caenorhabditis elegans is a frequently-employed genetic model organism and has been the object of a wide range of developmental, genetic, proteomic and glycomic studies.
36717059	7	50	dep	how	1285:1287	arg1	synthesizes					1315:1325	synthesizes	1315:1325	synthesizes such a diverse glycome	1315:1348	Thus, there are still questions to be answered in terms of how and why a simple nematode synthesizes such a diverse glycome.
36717059	4	51	theme	fucose	670:675	arg1	α-galactosylation					678:694	α-galactosylation	678:694	α-galactosylation of mannose	678:705	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	51	theme	fucose	670:675	arg1	methylation					645:655	methylation	645:655	methylation of bisecting fucose	645:675	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	51	theme	fucose	670:675	arg1	di-β-galactosylation					711:730	di-β-galactosylation	711:730	di-β-galactosylation of core α1,6-fucose	711:750	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36717059	4	52	theme	plate-grown	596:606	arg1	larvae					608:613	the liquid- and plate-grown larvae	580:613	the liquid- and plate-grown larvae	580:613	While the embryonal N-glycome appears less complicated overall, the liquid- and plate-grown larvae differ especially in terms of methylation of bisecting fucose, α-galactosylation of mannose and di-β-galactosylation of core α1,6-fucose.
36098998	1	0	theme	biological	260:269	arg1	material					271:278	biological material	260:278	biological material	260:278	Isomeric N-glycans often vastly differ in their biological activities, hence the need for methods that allow resolving and structurally characterizing them in biological material.
36098998	0	1	theme	Mass	82:85	arg1	Spectrometry					87:98	Mass Spectrometry	82:98	Mass Spectrometry	82:98	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis Coupled to Mass Spectrometry.
36098998	2	2	theme	capillary	329:337	arg1	electrophoresis					339:353	capillary electrophoresis	329:353	capillary electrophoresis	329:353	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	4	3	theme	human	660:664	arg1	plasma					666:671	human plasma	660:671	human plasma	660:671	In total, 208 N-glycans were characterized in human plasma, with 57 compositions showing multiple isomers.
36098998	0	4	theme	N-Glycan	0:7	arg1	Differentiation					16:30	N-Glycan Isomer Differentiation	0:30	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis	0:69	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis Coupled to Mass Spectrometry.
36098998	0	5	theme	Isomer	9:14	arg1	Differentiation					16:30	N-Glycan Isomer Differentiation	0:30	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis	0:69	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis Coupled to Mass Spectrometry.
36098998	4	6	theme	multiple	703:710	arg1	isomers					712:718	multiple isomers	703:718	multiple isomers	703:718	In total, 208 N-glycans were characterized in human plasma, with 57 compositions showing multiple isomers.
36098998	2	7	theme	high	464:467	arg1	sensitivity					469:479	high sensitivity	464:479	high sensitivity	464:479	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	1	8	theme	Isomeric	101:108	arg1	N-glycans					110:118	Isomeric N-glycans	101:118	Isomeric N-glycans	101:118	Isomeric N-glycans often vastly differ in their biological activities, hence the need for methods that allow resolving and structurally characterizing them in biological material.
36098998	2	9	theme	mass	384:387	arg1	spectrometry					389:400	(tandem) mass spectrometry	375:400	(tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity	375:479	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	3	10	theme	linked	593:598	arg1	acids					607:611	specifically linked sialic acids	580:611	specifically linked sialic acids	580:611	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	2	11	theme	isomeric	442:449	arg1	N-glycans					451:459	isomeric N-glycans	442:459	isomeric N-glycans	442:459	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	2	12	theme	N-glycans	451:459	arg1	characterization					422:437	structural characterization	411:437	structural characterization of isomeric N-glycans	411:459	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	3	13	theme	sialic	600:605	arg1	acids					607:611	specifically linked sialic acids	580:611	specifically linked sialic acids	580:611	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	3	14	theme	diagnostic	496:505	arg1	ratios					520:525	diagnostic fragment ion ratios	496:525	diagnostic fragment ion ratios	496:525	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	0	15	theme	Flow	40:43	arg1	Electrophoresis					55:69	Zero Flow Capillary Electrophoresis	35:69	Zero Flow Capillary Electrophoresis	35:69	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis Coupled to Mass Spectrometry.
36098998	2	16	with	combination	358:368	arg1	spectrometry					389:400	(tandem) mass spectrometry	375:400	(tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity	375:479	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	2	17	theme	structural	411:420	arg1	characterization					422:437	structural characterization	411:437	structural characterization of isomeric N-glycans	411:459	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	0	18	theme	Capillary	45:53	arg1	Electrophoresis					55:69	Zero Flow Capillary Electrophoresis	35:69	Zero Flow Capillary Electrophoresis	35:69	N-Glycan Isomer Differentiation by Zero Flow Capillary Electrophoresis Coupled to Mass Spectrometry.
36098998	3	19	contain	carrying	571:578	arg2	acids					607:611	specifically linked sialic acids	580:611	specifically linked sialic acids	580:611	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	3	19	contain	carrying	571:578	arg1	antenna					563:569	the antenna	559:569	the antenna carrying specifically linked sialic acids	559:611	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	3	20	theme	fragment	507:514	arg1	ratios					520:525	diagnostic fragment ion ratios	496:525	diagnostic fragment ion ratios	496:525	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	2	21	theme	flow	309:312	arg1	approach					314:321	a zero flow approach	302:321	a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity	302:479	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36098998	3	22	theme	ion	516:518	arg1	ratios					520:525	diagnostic fragment ion ratios	496:525	diagnostic fragment ion ratios	496:525	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	3	23	link	linked	593:598	arg1	acids					607:611	specifically linked sialic acids	580:611	specifically linked sialic acids	580:611	Additionally, diagnostic fragment ion ratios were identified, indicative for the antenna carrying specifically linked sialic acids.
36098998	1	24	theme	biological	149:158	arg1	activities					160:169	their biological activities	143:169	their biological activities	143:169	Isomeric N-glycans often vastly differ in their biological activities, hence the need for methods that allow resolving and structurally characterizing them in biological material.
36098998	2	25	theme	tandem	376:381	arg1	spectrometry					389:400	(tandem) mass spectrometry	375:400	(tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity	375:479	Here, we established a zero flow approach using capillary electrophoresis in combination with (tandem) mass spectrometry to allow structural characterization of isomeric N-glycans at high sensitivity.
36266970	11	0	theme	carbohydrate	1879:1890	arg1	conditions					1892:1901	carbohydrate conditions	1879:1901	carbohydrate conditions	1879:1901	Overall, these experiments extend our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions and the expression level of the enzyme.
36266970	9	1	theme	SusG	1483:1486	arg1	dynamics					1471:1478	the dynamics	1467:1478	the dynamics of SusG and Bt1760 but not Bt4668	1467:1512	Furthermore, we characterized enzyme diffusion in a mixture of glycans and found that noncognate polysaccharides modify the dynamics of SusG and Bt1760 but not Bt4668.
36266970	0	2	from	dynamics	16:23	arg1	bacteroides					52:62	bacteroides	52:62	bacteroides	52:62	Single-molecule dynamics of surface lipoproteins in bacteroides indicate similarities and cooperativity.
36266970	7	3	from	presence	1153:1160	arg1	immobile					1137:1144	immobile	1137:1144	immobile	1137:1144	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	7	4	theme	polysaccharide	1169:1182	arg1	presence					1153:1160	the presence	1149:1160	the presence of the polysaccharide	1149:1182	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	4	5	theme	molecular	571:579	arg1	mechanisms					581:590	the molecular mechanisms	567:590	the molecular mechanisms of the Sus system	567:608	Although the molecular mechanisms of the Sus system are known, how the Sus and Sus-like proteins cooperate remains elusive.
36266970	3	6	theme	Sus-like	355:362	arg1	system					364:369	Each Sus-like system	350:369	Each Sus-like system	350:369	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	10	7	theme	protein	1704:1710	arg1	interactions					1712:1723	nonspecific protein interactions	1692:1723	nonspecific protein interactions	1692:1723	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	8	8	from	experiments	1233:1243	arg1	oligosaccharides					1263:1278	oligosaccharides	1263:1278	oligosaccharides	1263:1278	Moreover, experiments in glucose versus oligosaccharides suggest that the enzyme dynamics depend on their expression level.
36266970	8	8	from	experiments	1233:1243	arg1	glucose					1248:1254	glucose	1248:1254	glucose	1248:1254	Moreover, experiments in glucose versus oligosaccharides suggest that the enzyme dynamics depend on their expression level.
36266970	9	9	theme	Bt1760	1492:1497	arg1	dynamics					1471:1478	the dynamics	1467:1478	the dynamics of SusG and Bt1760 but not Bt4668	1467:1512	Furthermore, we characterized enzyme diffusion in a mixture of glycans and found that noncognate polysaccharides modify the dynamics of SusG and Bt1760 but not Bt4668.
36266970	9	10	theme	enzyme	1377:1382	arg1	diffusion					1384:1392	enzyme diffusion	1377:1392	enzyme diffusion	1377:1392	Furthermore, we characterized enzyme diffusion in a mixture of glycans and found that noncognate polysaccharides modify the dynamics of SusG and Bt1760 but not Bt4668.
36266970	5	11	theme	super-resolution	722:737	arg1	microscopy					752:761	single-molecule and super-resolution fluorescence microscopy	702:761	microscopy	752:761	Previously, we used single-molecule and super-resolution fluorescence microscopy to show that SusG is mobile on the outer membrane and slows down in the presence of starch.
36266970	7	12	with	consistent	1185:1194	arg1	binding					1214:1220	carbohydrate binding	1201:1220	carbohydrate binding	1201:1220	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	3	13	theme	polymer	539:545	arg1	substrate					547:555	a specific (cognate) polymer substrate	518:555	a specific (cognate) polymer substrate	518:555	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	7	14	from	diffusion	1019:1027	arg1	presence					1062:1069	the presence	1058:1069	the presence of its cognate glycan	1058:1091	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	5	15	theme	fluorescence	739:750	arg1	microscopy					752:761	single-molecule and super-resolution fluorescence microscopy	702:761	microscopy	752:761	Previously, we used single-molecule and super-resolution fluorescence microscopy to show that SusG is mobile on the outer membrane and slows down in the presence of starch.
36266970	10	16	theme	nonspecific	1692:1702	arg1	interactions					1712:1723	nonspecific protein interactions	1692:1723	nonspecific protein interactions	1692:1723	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	7	17	theme	surface	1037:1043	arg1	hydrolase					1045:1053	each surface hydrolase	1032:1053	each surface hydrolase	1032:1053	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	10	18	theme	noncognate	1611:1620	arg1	polysaccharides					1622:1636	noncognate polysaccharides	1611:1636	noncognate polysaccharides	1611:1636	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	4	19	theme	Sus-like	637:644	arg1	proteins					646:653	the Sus and Sus-like proteins	625:653	the Sus and Sus-like proteins	625:653	Although the molecular mechanisms of the Sus system are known, how the Sus and Sus-like proteins cooperate remains elusive.
36266970	7	20	theme	cognate	1078:1084	arg1	glycan					1086:1091	its cognate glycan	1074:1091	its cognate glycan	1074:1091	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	10	21	theme	hydrolase	1645:1653	arg1	dynamics					1655:1662	hydrolase dynamics	1645:1662	hydrolase dynamics	1645:1662	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	7	22	theme	hydrolase	1045:1053	arg1	diffusion					1019:1027	the diffusion	1015:1027	the diffusion of each surface hydrolase in the presence of its cognate glycan	1015:1091	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	2	23	theme	glycan	274:279	arg1	uptake					281:286	glycan uptake	274:286	glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt)	274:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	1	24	theme	available	187:195	arg1	glycans					197:203	the available glycans	183:203	the available glycans	183:203	The gut microbiota comprises hundreds of species with a composition shaped by the available glycans.
36266970	5	25	theme	outer	798:802	arg1	membrane					804:811	the outer membrane	794:811	the outer membrane	794:811	Previously, we used single-molecule and super-resolution fluorescence microscopy to show that SusG is mobile on the outer membrane and slows down in the presence of starch.
36266970	10	26	theme	polysaccharide	1550:1563	arg1	mixtures					1565:1572	polysaccharide mixtures	1550:1572	polysaccharide mixtures	1550:1572	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	2	27	theme	bacterium	305:313	arg1	Bt					345:346	Bt	345:346	Bt	345:346	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	27	theme	bacterium	305:313	arg1	thetaiotaomicron					327:342	the human gut bacterium Bacteroides thetaiotaomicron	291:342	the human gut bacterium Bacteroides thetaiotaomicron (Bt)	291:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	28	theme	Bacteroides	315:325	arg1	Bt					345:346	Bt	345:346	Bt	345:346	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	28	theme	Bacteroides	315:325	arg1	thetaiotaomicron					327:342	the human gut bacterium Bacteroides thetaiotaomicron	291:342	the human gut bacterium Bacteroides thetaiotaomicron (Bt)	291:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	0	29	theme	Single-molecule	0:14	arg1	dynamics					16:23	Single-molecule dynamics	0:23	Single-molecule dynamics of surface lipoproteins in bacteroides	0:62	Single-molecule dynamics of surface lipoproteins in bacteroides indicate similarities and cooperativity.
36266970	1	30	theme	gut	109:111	arg1	microbiota					113:122	The gut microbiota	105:122	The gut microbiota	105:122	The gut microbiota comprises hundreds of species with a composition shaped by the available glycans.
36266970	11	31	theme	expression	1911:1920	arg1	level					1922:1926	the expression level	1907:1926	the expression level of the enzyme	1907:1940	Overall, these experiments extend our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions and the expression level of the enzyme.
36266970	0	32	theme	surface	28:34	arg1	lipoproteins					36:47	surface lipoproteins	28:47	surface lipoproteins	28:47	Single-molecule dynamics of surface lipoproteins in bacteroides indicate similarities and cooperativity.
36266970	2	33	theme	gut	301:303	arg1	Bt					345:346	Bt	345:346	Bt	345:346	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	33	theme	gut	301:303	arg1	thetaiotaomicron					327:342	the human gut bacterium Bacteroides thetaiotaomicron	291:342	the human gut bacterium Bacteroides thetaiotaomicron (Bt)	291:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	9	34	theme	glycans	1410:1416	arg1	mixture					1399:1405	a mixture	1397:1405	a mixture of glycans	1397:1416	Furthermore, we characterized enzyme diffusion in a mixture of glycans and found that noncognate polysaccharides modify the dynamics of SusG and Bt1760 but not Bt4668.
36266970	3	35	theme	outer-membrane	380:393	arg1	proteins					395:402	outer-membrane proteins	380:402	outer-membrane proteins	380:402	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	10	36	theme	downregulation	1729:1742	arg1	combination					1677:1687	some combination	1672:1687	some combination of nonspecific protein interactions and downregulation of the hydrolase	1672:1759	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	2	37	theme	human	295:299	arg1	Bt					345:346	Bt	345:346	Bt	345:346	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	37	theme	human	295:299	arg1	thetaiotaomicron					327:342	the human gut bacterium Bacteroides thetaiotaomicron	291:342	the human gut bacterium Bacteroides thetaiotaomicron (Bt)	291:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	10	38	theme	hydrolase	1751:1759	arg1	interactions					1712:1723	nonspecific protein interactions	1692:1723	nonspecific protein interactions	1692:1723	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	10	38	theme	hydrolase	1751:1759	arg1	downregulation					1729:1742	downregulation	1729:1742	downregulation of the hydrolase	1729:1759	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	3	39	theme	cell-surface	466:477	arg1	hydrolases					489:498	one or more cell-surface glycoside hydrolases	454:498	one or more cell-surface glycoside hydrolases	454:498	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	7	40	theme	glycan	1086:1091	arg1	presence					1062:1069	the presence	1058:1069	the presence of its cognate glycan	1058:1091	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	6	41	dep	hydrolases	904:913	arg1	SusG					916:919	SusG	916:919	SusG	916:919	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	6	41	dep	hydrolases	904:913	arg1	hydrolases					904:913	three glycoside hydrolases	888:913	three glycoside hydrolases	888:913	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	6	41	dep	hydrolases	904:913	arg1	Bt4668					922:927	Bt4668	922:927	Bt4668	922:927	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	6	41	dep	hydrolases	904:913	arg1	Bt1760					934:939	Bt1760	934:939	Bt1760	934:939	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	5	42	theme	single-molecule	702:716	arg1	microscopy					752:761	single-molecule and super-resolution fluorescence microscopy	702:761	microscopy	752:761	Previously, we used single-molecule and super-resolution fluorescence microscopy to show that SusG is mobile on the outer membrane and slows down in the presence of starch.
36266970	4	43	theme	Sus	629:631	arg1	proteins					646:653	the Sus and Sus-like proteins	625:653	the Sus and Sus-like proteins	625:653	Although the molecular mechanisms of the Sus system are known, how the Sus and Sus-like proteins cooperate remains elusive.
36266970	0	44	theme	lipoproteins	36:47	arg1	dynamics					16:23	Single-molecule dynamics	0:23	Single-molecule dynamics of surface lipoproteins in bacteroides	0:62	Single-molecule dynamics of surface lipoproteins in bacteroides indicate similarities and cooperativity.
36266970	11	45	theme	lipoprotein	1830:1840	arg1	dynamics					1842:1849	Sus-like lipoprotein dynamics	1821:1849	Sus-like lipoprotein dynamics	1821:1849	Overall, these experiments extend our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions and the expression level of the enzyme.
36266970	5	46	used	used	697:700	arg2	we					694:695	we	694:695	we	694:695	Previously, we used single-molecule and super-resolution fluorescence microscopy to show that SusG is mobile on the outer membrane and slows down in the presence of starch.
36266970	3	47	dep	periplasm	439:447	arg1	the					435:437	the	435:437	the	435:437	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	11	48	theme	enzyme	1935:1940	arg1	understanding					1800:1812	our understanding	1796:1812	our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions	1796:1901	Overall, these experiments extend our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions and the expression level of the enzyme.
36266970	11	48	theme	enzyme	1935:1940	arg1	level					1922:1926	the expression level	1907:1926	the expression level of the enzyme	1907:1940	Overall, these experiments extend our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions and the expression level of the enzyme.
36266970	10	49	theme	genetic	1578:1584	arg1	knockouts					1586:1594	genetic knockouts	1578:1594	genetic knockouts	1578:1594	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	7	50	from	immobile	1137:1144	arg1	presence					1153:1160	the presence	1149:1160	the presence of the polysaccharide	1149:1182	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	9	51	theme	noncognate	1433:1442	arg1	polysaccharides					1444:1458	noncognate polysaccharides	1433:1458	noncognate polysaccharides	1433:1458	Furthermore, we characterized enzyme diffusion in a mixture of glycans and found that noncognate polysaccharides modify the dynamics of SusG and Bt1760 but not Bt4668.
36266970	4	52	theme	Sus	599:601	arg1	system					603:608	the Sus system	595:608	the Sus system	595:608	Although the molecular mechanisms of the Sus system are known, how the Sus and Sus-like proteins cooperate remains elusive.
36266970	2	53	theme	utilization	230:240	arg1	Sus					250:252	Sus	250:252	Sus	250:252	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	53	theme	utilization	230:240	arg1	system					242:247	The well-studied starch utilization system	206:247	The well-studied starch utilization system (Sus)	206:253	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	53	theme	utilization	230:240	arg1	prototype					260:268	a prototype	258:268	a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt)	258:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	54	from	uptake	281:286	arg1	Bt					345:346	Bt	345:346	Bt	345:346	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	54	from	uptake	281:286	arg1	thetaiotaomicron					327:342	the human gut bacterium Bacteroides thetaiotaomicron	291:342	the human gut bacterium Bacteroides thetaiotaomicron (Bt)	291:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	6	55	theme	hydrolases	904:913	arg1	dynamics					876:883	the dynamics	872:883	the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively	872:995	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	9	56	theme	Bt4668	1507:1512	arg1	dynamics					1471:1478	the dynamics	1467:1478	the dynamics of SusG and Bt1760 but not Bt4668	1467:1512	Furthermore, we characterized enzyme diffusion in a mixture of glycans and found that noncognate polysaccharides modify the dynamics of SusG and Bt1760 but not Bt4668.
36266970	2	57	theme	starch	223:228	arg1	Sus					250:252	Sus	250:252	Sus	250:252	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	57	theme	starch	223:228	arg1	system					242:247	The well-studied starch utilization system	206:247	The well-studied starch utilization system (Sus)	206:253	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	57	theme	starch	223:228	arg1	prototype					260:268	a prototype	258:268	a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt)	258:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	1	58	theme	species	146:152	arg1	hundreds					134:141	hundreds	134:141	hundreds of species	134:152	The gut microbiota comprises hundreds of species with a composition shaped by the available glycans.
36266970	8	59	theme	enzyme	1297:1302	arg1	dynamics					1304:1311	the enzyme dynamics	1293:1311	the enzyme dynamics	1293:1311	Moreover, experiments in glucose versus oligosaccharides suggest that the enzyme dynamics depend on their expression level.
36266970	4	60	theme	system	603:608	arg1	mechanisms					581:590	the molecular mechanisms	567:590	the molecular mechanisms of the Sus system	567:608	Although the molecular mechanisms of the Sus system are known, how the Sus and Sus-like proteins cooperate remains elusive.
36266970	3	61	theme	cognate	530:536	arg1	substrate					547:555	a specific (cognate) polymer substrate	518:555	a specific (cognate) polymer substrate	518:555	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	2	62	theme	well-studied	210:221	arg1	Sus					250:252	Sus	250:252	Sus	250:252	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	62	theme	well-studied	210:221	arg1	system					242:247	The well-studied starch utilization system	206:247	The well-studied starch utilization system (Sus)	206:253	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	2	62	theme	well-studied	210:221	arg1	prototype					260:268	a prototype	258:268	a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt)	258:347	The well-studied starch utilization system (Sus) is a prototype for glycan uptake in the human gut bacterium Bacteroides thetaiotaomicron (Bt).
36266970	7	63	theme	carbohydrate	1201:1212	arg1	binding					1214:1220	carbohydrate binding	1201:1220	carbohydrate binding	1201:1220	We characterized the diffusion of each surface hydrolase in the presence of its cognate glycan and found that all three enzymes are mostly immobile in the presence of the polysaccharide, consistent with carbohydrate binding.
36266970	3	64	theme	glycoside	479:487	arg1	hydrolases					489:498	one or more cell-surface glycoside hydrolases	454:498	one or more cell-surface glycoside hydrolases	454:498	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
36266970	8	65	theme	expression	1329:1338	arg1	level					1340:1344	their expression level	1323:1344	their expression level	1323:1344	Moreover, experiments in glucose versus oligosaccharides suggest that the enzyme dynamics depend on their expression level.
36266970	10	66	theme	interactions	1712:1723	arg1	combination					1677:1687	some combination	1672:1687	some combination of nonspecific protein interactions and downregulation of the hydrolase	1672:1759	We investigated these systems with polysaccharide mixtures and genetic knockouts and found that noncognate polysaccharides modify hydrolase dynamics through some combination of nonspecific protein interactions and downregulation of the hydrolase.
36266970	5	67	theme	starch	847:852	arg1	presence					835:842	the presence	831:842	the presence of starch	831:852	Previously, we used single-molecule and super-resolution fluorescence microscopy to show that SusG is mobile on the outer membrane and slows down in the presence of starch.
36266970	11	68	theme	Sus-like	1821:1828	arg1	dynamics					1842:1849	Sus-like lipoprotein dynamics	1821:1849	Sus-like lipoprotein dynamics	1821:1849	Overall, these experiments extend our understanding of how Sus-like lipoprotein dynamics can be modified by changing carbohydrate conditions and the expression level of the enzyme.
36266970	6	69	theme	glycoside	894:902	arg1	SusG					916:919	SusG	916:919	SusG	916:919	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	6	69	theme	glycoside	894:902	arg1	hydrolases					904:913	three glycoside hydrolases	888:913	three glycoside hydrolases	888:913	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	6	69	theme	glycoside	894:902	arg1	Bt4668					922:927	Bt4668	922:927	Bt4668	922:927	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	6	69	theme	glycoside	894:902	arg1	Bt1760					934:939	Bt1760	934:939	Bt1760	934:939	Here, we compare the dynamics of three glycoside hydrolases: SusG, Bt4668, and Bt1760, which target starch, galactan, and levan, respectively.
36266970	3	70	theme	specific	520:527	arg1	substrate					547:555	a specific (cognate) polymer substrate	518:555	a specific (cognate) polymer substrate	518:555	Each Sus-like system includes outer-membrane proteins, which translocate glycan into the periplasm, and one or more cell-surface glycoside hydrolases, which break down a specific (cognate) polymer substrate.
35760821	5	0	theme	glycosylation	1227:1239	arg1	patterns					1241:1248	the observed HMO glycosylation patterns	1210:1248	the observed HMO glycosylation patterns	1210:1248	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	2	1	theme	free	558:561	arg1	lactose					563:569	free lactose	558:569	free lactose	558:569	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	6	2	theme	common	1308:1313	arg1	HMOs					1315:1318	the most common HMOs	1299:1318	the most common HMOs found in lactating mothers	1299:1345	The model also provides a synthesis chassis for the most common HMOs found in lactating mothers.
35760821	4	3	theme	uncharacterised	1006:1020	arg1	HMOs					1022:1025	several previously uncharacterised HMOs	987:1025	several previously uncharacterised HMOs	987:1025	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	1	4	theme	several	216:222	arg1	benefits					224:231	several benefits	216:231	several benefits	216:231	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	0	5	theme	key	69:71	arg1	enzymes					73:79	key enzymes	69:79	key enzymes of their biosynthesis	69:101	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	4	6	theme	monosaccharide	797:810	arg1	compositions					812:823	monosaccharide compositions	797:823	monosaccharide compositions	797:823	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	5	7	theme	knockouts	1049:1057	arg1	effect					1032:1037	The effect	1028:1037	The effect of enzyme knockouts	1028:1057	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	4	8	theme	compositions	812:823	arg1	comparison					783:792	A comparison	781:792	A comparison of monosaccharide compositions	781:823	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	3	9	theme	new	756:758	arg1	structures					769:778	5 new core HMO structures	754:778	5 new core HMO structures	754:778	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	4	10	theme	possible	890:897	arg1	intermediates					909:921	intermediates	909:921	intermediates between major subnetworks	909:947	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	4	10	theme	possible	890:897	arg1	groups					899:904	two possible groups	886:904	two possible groups of intermediates between major subnetworks	886:947	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	3	11	theme	HMOs	660:663	arg1	206					640:642	206	640:642	206	640:642	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	3	11	theme	HMOs	660:663	arg1	HMOs					660:663	226 distinct HMOs	647:663	226 distinct HMOs isolated from human milk	647:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	4	12	theme	major	931:935	arg1	subnetworks					937:947	major subnetworks	931:947	major subnetworks	931:947	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	3	13	theme	core	760:763	arg1	structures					769:778	5 new core HMO structures	754:778	5 new core HMO structures	754:778	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	1	14	from	pathogens	295:303	arg1	protection					259:268	protection	259:268	protection from viral and bacterial pathogens	259:303	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	15	theme	immune	322:327	arg1	system					329:334	the immune system	318:334	the immune system	318:334	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	6	16	theme	synthesis	1277:1285	arg1	chassis					1287:1293	a synthesis chassis	1275:1293	a synthesis chassis for the most common HMOs found in lactating mothers	1275:1345	The model also provides a synthesis chassis for the most common HMOs found in lactating mothers.
35760821	1	17	theme	third	148:152	arg1	component					168:176	the third most abundant component	144:176	the third most abundant component of human milk	144:190	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	0	18	theme	biosynthesis	90:101	arg1	enzymes					73:79	key enzymes	69:79	key enzymes of their biosynthesis	69:101	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	3	19	theme	HMO	765:767	arg1	structures					769:778	5 new core HMO structures	754:778	5 new core HMO structures	754:778	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	4	20	theme	intermediates	909:921	arg1	intermediates					909:921	intermediates	909:921	intermediates between major subnetworks	909:947	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	4	20	theme	intermediates	909:921	arg1	groups					899:904	two possible groups	886:904	two possible groups of intermediates between major subnetworks	886:947	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	3	21	theme	distinct	651:658	arg1	HMOs					660:663	226 distinct HMOs	647:663	226 distinct HMOs isolated from human milk	647:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	3	22	attach	isolated	665:672	arg1	milk					685:688	human milk	679:688	human milk	679:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	3	22	attach	isolated	665:672	arg2	HMOs					660:663	226 distinct HMOs	647:663	226 distinct HMOs isolated from human milk	647:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	1	23	theme	abundant	159:166	arg1	component					168:176	the third most abundant component	144:176	the third most abundant component of human milk	144:190	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	0	24	theme	In	0:1	arg1	analysis					10:17	In silico analysis	0:17	In silico analysis of the human milk oligosaccharide glycome	0:59	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	4	25	theme	possible	964:971	arg1	structures					973:982	possible structures	964:982	possible structures	964:982	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	2	26	link	GalNAc-linked	512:524	arg1	enzymes					540:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	2	27	theme	HMO	376:378	arg1	production					380:389	HMO production	376:389	HMO production during lactation	376:406	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	4	28	theme	several	987:993	arg1	HMOs					1022:1025	several previously uncharacterised HMOs	987:1025	several previously uncharacterised HMOs	987:1025	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	1	29	theme	human	181:185	arg1	milk					187:190	human milk	181:190	human milk	181:190	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	0	30	theme	human	26:30	arg1	glycome					53:59	the human milk oligosaccharide glycome	22:59	the human milk oligosaccharide glycome	22:59	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	3	31	theme	human	679:683	arg1	milk					685:688	human milk	679:688	human milk	679:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	1	32	dep	convey	209:214	arg1	training					306:313	training	306:313	training of the immune system	306:334	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	32	dep	convey	209:214	arg1	including					249:257	including	249:257	including protection from viral and bacterial pathogens	249:303	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	32	dep	convey	209:214	arg1	influencing					341:351	influencing	341:351	influencing the gut microbiome	341:370	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	33	theme	milk	187:190	arg1	component					168:176	the third most abundant component	144:176	the third most abundant component of human milk	144:190	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	3	34	theme	biosynthetic	708:719	arg1	network					730:736	a biosynthetic reaction network	706:736	a biosynthetic reaction network that identifies 5 new core HMO structures	706:778	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	5	35	theme	observed	1214:1221	arg1	patterns					1241:1248	the observed HMO glycosylation patterns	1210:1248	the observed HMO glycosylation patterns	1210:1248	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	5	36	theme	enzyme	1042:1047	arg1	knockouts					1049:1057	enzyme knockouts	1042:1057	enzyme knockouts	1042:1057	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	4	37	dep	able	857:860	arg1	assign					957:962	assign	957:962	to assign possible structures to several previously uncharacterised HMOs	954:1025	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	4	37	dep	able	857:860	arg1	discriminate					865:876	discriminate	865:876	to discriminate between two possible groups of intermediates between major subnetworks	862:947	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	4	37	dep	able	857:860	arg1	able					857:860	able	857:860	able	857:860	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	4	37	dep	able	857:860	arg1	model					847:851	the model	843:851	the model	843:851	A comparison of monosaccharide compositions demonstrated that the model was able to discriminate between two possible groups of intermediates between major subnetworks, and to assign possible structures to several previously uncharacterised HMOs.
35760821	2	38	theme	glycosylation	454:466	arg1	processes					468:476	other glycosylation processes	448:476	other glycosylation processes	448:476	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	0	39	theme	oligosaccharide	37:51	arg1	glycome					53:59	the human milk oligosaccharide glycome	22:59	the human milk oligosaccharide glycome	22:59	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	1	40	theme	viral	275:279	arg1	pathogens					295:303	viral and bacterial pathogens	275:303	viral and bacterial pathogens	275:303	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	2	41	theme	enzymes	540:546	arg1	model					492:496	a model	490:496	a model of mucin-type GalNAc-linked glycosylation enzymes	490:546	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	1	42	theme	gut	357:359	arg1	microbiome					361:370	the gut microbiome	353:370	the gut microbiome	353:370	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	43	theme	Human	104:108	arg1	oligosaccharides					115:130	Human milk oligosaccharides	104:130	Human milk oligosaccharides (HMOs)	104:137	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	43	theme	Human	104:108	arg1	HMOs					133:136	HMOs	133:136	HMOs	133:136	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	0	44	theme	milk	32:35	arg1	glycome					53:59	the human milk oligosaccharide glycome	22:59	the human milk oligosaccharide glycome	22:59	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	2	45	theme	glycosylation	526:538	arg1	enzymes					540:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	5	46	theme	key	1158:1160	arg1	activities					1169:1178	key enzyme activities	1158:1178	key enzyme activities involved in the generation of the observed HMO glycosylation patterns	1158:1248	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	5	46	theme	key	1158:1160	arg1	β-1,3-N-acetylglucosaminyltransferase					1117:1153	β-1,3-N-acetylglucosaminyltransferase	1117:1153	β-1,3-N-acetylglucosaminyltransferase	1117:1153	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	5	46	theme	key	1158:1160	arg1	β-1,4-galactosyltransferase					1085:1111	β-1,4-galactosyltransferase	1085:1111	β-1,4-galactosyltransferase	1085:1111	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	1	47	theme	milk	110:113	arg1	oligosaccharides					115:130	Human milk oligosaccharides	104:130	Human milk oligosaccharides (HMOs)	104:137	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	1	47	theme	milk	110:113	arg1	HMOs					133:136	HMOs	133:136	HMOs	133:136	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	6	48	located	found	1320:1324	arg1	mothers					1339:1345	lactating mothers	1329:1345	lactating mothers	1329:1345	The model also provides a synthesis chassis for the most common HMOs found in lactating mothers.
35760821	6	48	located	found	1320:1324	arg2	HMOs					1315:1318	the most common HMOs	1299:1318	the most common HMOs found in lactating mothers	1299:1345	The model also provides a synthesis chassis for the most common HMOs found in lactating mothers.
35760821	1	49	theme	bacterial	285:293	arg1	pathogens					295:303	viral and bacterial pathogens	275:303	viral and bacterial pathogens	275:303	Human milk oligosaccharides (HMOs) form the third most abundant component of human milk and are known to convey several benefits to the neonate, including protection from viral and bacterial pathogens, training of the immune system, and influencing the gut microbiome.
35760821	2	50	theme	GalNAc-linked	512:524	arg1	enzymes					540:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	5	51	theme	HMO	1223:1225	arg1	patterns					1241:1248	the observed HMO glycosylation patterns	1210:1248	the observed HMO glycosylation patterns	1210:1248	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	6	52	theme	lactating	1329:1337	arg1	mothers					1339:1345	lactating mothers	1329:1345	lactating mothers	1329:1345	The model also provides a synthesis chassis for the most common HMOs found in lactating mothers.
35760821	5	53	theme	patterns	1241:1248	arg1	generation					1196:1205	the generation	1192:1205	the generation of the observed HMO glycosylation patterns	1192:1248	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	2	54	theme	mucin-type	501:510	arg1	enzymes					540:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	mucin-type GalNAc-linked glycosylation enzymes	501:546	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	3	55	theme	enzyme	601:606	arg1	activities					608:617	11 enzyme activities	598:617	11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk	598:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	2	56	theme	other	448:452	arg1	processes					468:476	other glycosylation processes	448:476	other glycosylation processes	448:476	As HMO production during lactation is driven by enzymes that are common to other glycosylation processes, we adapted a model of mucin-type GalNAc-linked glycosylation enzymes to act on free lactose.
35760821	3	57	theme	activities	608:617	arg1	subset					588:593	a subset	586:593	a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk	586:688	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35760821	0	58	theme	glycome	53:59	arg1	analysis					10:17	In silico analysis	0:17	In silico analysis of the human milk oligosaccharide glycome	0:59	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	5	59	theme	enzyme	1162:1167	arg1	activities					1169:1178	key enzyme activities	1158:1178	key enzyme activities involved in the generation of the observed HMO glycosylation patterns	1158:1248	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	5	59	theme	enzyme	1162:1167	arg1	β-1,3-N-acetylglucosaminyltransferase					1117:1153	β-1,3-N-acetylglucosaminyltransferase	1117:1153	β-1,3-N-acetylglucosaminyltransferase	1117:1153	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	5	59	theme	enzyme	1162:1167	arg1	β-1,4-galactosyltransferase					1085:1111	β-1,4-galactosyltransferase	1085:1111	β-1,4-galactosyltransferase	1085:1111	The effect of enzyme knockouts is presented, identifying β-1,4-galactosyltransferase and β-1,3-N-acetylglucosaminyltransferase as key enzyme activities involved in the generation of the observed HMO glycosylation patterns.
35760821	0	60	dep	In	0:1	arg1	silico					3:8	silico	3:8	silico	3:8	In silico analysis of the human milk oligosaccharide glycome reveals key enzymes of their biosynthesis.
35760821	3	61	theme	reaction	721:728	arg1	network					730:736	a biosynthetic reaction network	706:736	a biosynthetic reaction network that identifies 5 new core HMO structures	706:778	We identified a subset of 11 enzyme activities that can account for 206 of 226 distinct HMOs isolated from human milk and constructed a biosynthetic reaction network that identifies 5 new core HMO structures.
35647713	0	0	theme	Native-Like	65:75	arg1	Trimer					86:91	an HIV Native-Like Envelope Trimer	58:91	an HIV Native-Like Envelope Trimer	58:91	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	5	1	theme	immune	818:823	arg1	potentiator					825:835	an immune potentiator	815:835	an immune potentiator	815:835	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	3	2	theme	small	516:520	arg1	potentiators					538:549	conjugate small molecule immune potentiators	506:549	conjugate small molecule immune potentiators to viral glycoprotein immunogens	506:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	6	3	theme	receptor	1074:1081	arg1	agonist					1087:1093	a Toll-like receptor 7/8 agonist	1062:1093	a Toll-like receptor 7/8 agonist	1062:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	0	4	theme	HIV	61:63	arg1	Trimer					86:91	an HIV Native-Like Envelope Trimer	58:91	an HIV Native-Like Envelope Trimer	58:91	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	3	5	theme	molecule	522:529	arg1	potentiators					538:549	conjugate small molecule immune potentiators	506:549	conjugate small molecule immune potentiators to viral glycoprotein immunogens	506:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	6	6	theme	Toll-like	1064:1072	arg1	agonist					1087:1093	a Toll-like receptor 7/8 agonist	1062:1093	a Toll-like receptor 7/8 agonist	1062:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	0	7	theme	Trimer	86:91	arg1	Glycans					47:53	Glycans	47:53	Glycans of an HIV Native-Like Envelope Trimer	47:91	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	3	8	theme	immune	531:536	arg1	potentiators					538:549	conjugate small molecule immune potentiators	506:549	conjugate small molecule immune potentiators to viral glycoprotein immunogens	506:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	3	9	theme	glycoprotein	560:571	arg1	immunogens					573:582	viral glycoprotein immunogens	554:582	viral glycoprotein immunogens	554:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	0	10	theme	Envelope	77:84	arg1	Trimer					86:91	an HIV Native-Like Envelope Trimer	58:91	an HIV Native-Like Envelope Trimer	58:91	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	5	11	theme	viral	969:973	arg1	glycoprotein					975:986	a viral glycoprotein	967:986	a viral glycoprotein	967:986	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	3	12	theme	methods	495:501	arg1	lack					487:490	a lack	485:490	a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens	485:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	0	13	theme	Neutralization	103:116	arg1	Epitopes					118:125	Neutralization Epitopes	103:125	Neutralization Epitopes	103:125	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	4	14	theme	covalent	693:700	arg1	attachment					702:711	the covalent attachment	689:711	the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins	689:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	2	15	theme	adjuvant	290:297	arg1	attachment					273:282	Covalent attachment	264:282	Covalent attachment of an adjuvant to an immunogen	264:313	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	5	16	theme	sialyltransferase-mediated	915:940	arg1	transfer					942:949	sialyltransferase-mediated transfer	915:949	sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein	915:986	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	5	17	theme	glycoprotein	975:986	arg1	N-glycans					954:962	N-glycans	954:962	N-glycans of a viral glycoprotein	954:986	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	7	18	theme	several	1158:1164	arg1	antibodies					1189:1198	several broadly neutralization antibodies	1158:1198	several broadly neutralization antibodies	1158:1198	The modification did not compromise Env-trimer recognition by several broadly neutralization antibodies.
35647713	3	19	theme	viral	554:558	arg1	immunogens					573:582	viral glycoprotein immunogens	554:582	viral glycoprotein immunogens	554:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	1	20	theme	broad	182:186	arg1	protection					188:197	broad protection	182:197	broad protection	182:197	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	5	21	theme	potentiator	825:835	arg1	attachment					801:810	the attachment	797:810	the attachment of an immune potentiator to CMP-Neu5AcN3	797:851	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	7	22	theme	broadly	1166:1172	arg1	antibodies					1189:1198	several broadly neutralization antibodies	1158:1198	several broadly neutralization antibodies	1158:1198	The modification did not compromise Env-trimer recognition by several broadly neutralization antibodies.
35647713	3	23	theme	epitope	605:611	arg1	integrity					613:621	epitope integrity	605:621	epitope integrity	605:621	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	4	24	theme	molecule	722:729	arg1	adjuvants					731:739	small molecule adjuvants	716:739	small molecule adjuvants	716:739	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	7	25	theme	Env-trimer	1132:1141	arg1	recognition					1143:1153	Env-trimer recognition	1132:1153	Env-trimer recognition by several broadly neutralization antibodies	1132:1198	The modification did not compromise Env-trimer recognition by several broadly neutralization antibodies.
35647713	4	26	theme	glycoproteins	770:782	arg1	glycans					753:759	N-linked glycans	744:759	N-linked glycans of viral glycoproteins	744:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	4	27	link	N-linked	744:751	arg1	glycans					753:759	N-linked glycans	744:759	N-linked glycans of viral glycoproteins	744:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	8	28	theme	modified	1259:1266	arg1	immunogen					1268:1276	the modified immunogen	1255:1276	the modified immunogen	1255:1276	Electron microscopy confirmed structural integrity of the modified immunogen.
35647713	2	29	theme	presenting	402:411	arg1	cells					413:417	antigen presenting cells	394:417	antigen presenting cells resulting in more efficient immune activation	394:463	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	0	30	theme	Toll-Like	17:25	arg1	Agonist					36:42	a Toll-Like Receptor Agonist	15:42	a Toll-Like Receptor Agonist	15:42	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	6	31	theme	envelope	1041:1048	arg1	trimer					1050:1055	a native-like HIV envelope trimer	1023:1055	a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist	1023:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	5	32	theme	azide-alkyne	872:883	arg1	1,3-cycloaddition					885:901	Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition	856:901	Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein	856:986	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	5	33	theme	-catalyzed	861:870	arg1	1,3-cycloaddition					885:901	Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition	856:901	Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein	856:986	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	6	34	theme	HIV	1037:1039	arg1	trimer					1050:1055	a native-like HIV envelope trimer	1023:1055	a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist	1023:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	4	35	theme	one-step	645:652	arg1	approach					676:683	a one-step enzymatic conjugation approach	643:683	a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins	643:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	4	36	attach	attachment	702:711	arg2	adjuvants					731:739	small molecule adjuvants	716:739	small molecule adjuvants	716:739	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	4	36	attach	attachment	702:711	arg1	glycans					753:759	N-linked glycans	744:759	N-linked glycans of viral glycoproteins	744:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	4	37	theme	N-linked	744:751	arg1	glycans					753:759	N-linked glycans	744:759	N-linked glycans of viral glycoproteins	744:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	2	38	theme	immune	447:452	arg1	activation					454:463	more efficient immune activation	432:463	more efficient immune activation	432:463	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	0	39	theme	Agonist	36:42	arg1	Conjugation					0:10	Conjugation	0:10	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer	0:91	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	6	40	theme	native-like	1025:1035	arg1	trimer					1050:1055	a native-like HIV envelope trimer	1023:1055	a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist	1023:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	4	41	gly	glycoproteins	770:782	arg1	glycoproteins					770:782	viral glycoproteins	764:782	viral glycoproteins	764:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	1	42	theme	immune	217:222	arg1	responses					224:232	immune responses	217:232	immune responses elicited by subunit vaccines	217:261	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	4	43	theme	small	716:720	arg1	adjuvants					731:739	small molecule adjuvants	716:739	small molecule adjuvants	716:739	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	2	44	theme	efficient	437:445	arg1	activation					454:463	more efficient immune activation	432:463	more efficient immune activation	432:463	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	0	45	theme	Receptor	27:34	arg1	Agonist					36:42	a Toll-Like Receptor Agonist	15:42	a Toll-Like Receptor Agonist	15:42	Conjugation of a Toll-Like Receptor Agonist to Glycans of an HIV Native-Like Envelope Trimer Preserves Neutralization Epitopes.
35647713	4	46	theme	conjugation	664:674	arg1	approach					676:683	a one-step enzymatic conjugation approach	643:683	a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins	643:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	1	47	theme	responses	224:232	arg1	protection					188:197	broad protection	182:197	broad protection	182:197	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	1	47	theme	responses	224:232	arg1	durability					203:212	durability	203:212	durability	203:212	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	6	48	with	trimer	1050:1055	arg1	agonist					1087:1093	a Toll-like receptor 7/8 agonist	1062:1093	a Toll-like receptor 7/8 agonist	1062:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	8	49	theme	structural	1231:1240	arg1	integrity					1242:1250	structural integrity	1231:1250	structural integrity of the modified immunogen	1231:1276	Electron microscopy confirmed structural integrity of the modified immunogen.
35647713	4	50	theme	viral	764:768	arg1	glycoproteins					770:782	viral glycoproteins	764:782	viral glycoproteins	764:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	8	51	theme	Electron	1201:1208	arg1	microscopy					1210:1219	Electron microscopy	1201:1219	Electron microscopy	1201:1219	Electron microscopy confirmed structural integrity of the modified immunogen.
35647713	3	52	theme	conjugate	506:514	arg1	potentiators					538:549	conjugate small molecule immune potentiators	506:549	conjugate small molecule immune potentiators to viral glycoprotein immunogens	506:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	5	53	gly	glycoprotein	975:986	arg1	glycoprotein					975:986	a viral glycoprotein	967:986	a viral glycoprotein	967:986	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	8	54	theme	immunogen	1268:1276	arg1	integrity					1242:1250	structural integrity	1231:1250	structural integrity of the modified immunogen	1231:1276	Electron microscopy confirmed structural integrity of the modified immunogen.
35647713	4	55	theme	adjuvants	731:739	arg1	attachment					702:711	the covalent attachment	689:711	the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins	689:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35647713	1	56	theme	Small	128:132	arg1	adjuvants					143:151	Small molecule adjuvants	128:151	Small molecule adjuvants	128:151	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	2	57	attach	attachment	273:282	arg2	adjuvant					290:297	adjuvant	290:297	adjuvant	290:297	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	2	57	attach	attachment	273:282	arg1	immunogen					305:313	an immunogen	302:313	an immunogen	302:313	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	1	58	theme	molecule	134:141	arg1	adjuvants					143:151	Small molecule adjuvants	128:151	Small molecule adjuvants	128:151	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	7	59	theme	neutralization	1174:1187	arg1	antibodies					1189:1198	several broadly neutralization antibodies	1158:1198	several broadly neutralization antibodies	1158:1198	The modification did not compromise Env-trimer recognition by several broadly neutralization antibodies.
35647713	2	60	theme	Covalent	264:271	arg1	attachment					273:282	Covalent attachment	264:282	Covalent attachment of an adjuvant to an immunogen	264:313	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	2	61	theme	antigen	394:400	arg1	cells					413:417	antigen presenting cells	394:417	antigen presenting cells resulting in more efficient immune activation	394:463	Covalent attachment of an adjuvant to an immunogen is particularly attractive because it simultaneously delivers both entities to antigen presenting cells resulting in more efficient immune activation.
35647713	1	62	theme	subunit	246:252	arg1	vaccines					254:261	subunit vaccines	246:261	subunit vaccines	246:261	Small molecule adjuvants are attractive for enhancing broad protection and durability of immune responses elicited by subunit vaccines.
35647713	6	63	theme	7/8	1083:1085	arg1	agonist					1087:1093	a Toll-like receptor 7/8 agonist	1062:1093	a Toll-like receptor 7/8 agonist	1062:1093	The method was employed to modify a native-like HIV envelope trimer with a Toll-like receptor 7/8 agonist.
35647713	5	64	attach	attachment	801:810	arg2	potentiator					825:835	an immune potentiator	815:835	an immune potentiator	815:835	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	5	64	attach	attachment	801:810	arg1	CMP-Neu5AcN3					840:851	CMP-Neu5AcN3	840:851	CMP-Neu5AcN3	840:851	It involves the attachment of an immune potentiator to CMP-Neu5AcN3 by Cu(I)-catalyzed azide-alkyne 1,3-cycloaddition followed by sialyltransferase-mediated transfer to N-glycans of a viral glycoprotein.
35647713	3	65	gly	glycoprotein	560:571	arg1	glycoprotein					560:571	viral glycoprotein immunogens	554:582	viral glycoprotein immunogens	554:582	There is, however, a lack of methods to conjugate small molecule immune potentiators to viral glycoprotein immunogens without compromising epitope integrity.
35647713	4	66	theme	enzymatic	654:662	arg1	approach					676:683	a one-step enzymatic conjugation approach	643:683	a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins	643:782	We describe herein a one-step enzymatic conjugation approach for the covalent attachment of small molecule adjuvants to N-linked glycans of viral glycoproteins.
35718154	0	0	theme	blow	103:106	arg1	spinning					108:115	multi-fluid mixing solution blow spinning	75:115	multi-fluid mixing solution blow spinning	75:115	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	3	1	theme	secondary	680:688	arg1	structure					690:698	the secondary structure	676:698	the secondary structure of the protein	676:713	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	7	2	theme	green	1244:1248	arg1	method					1264:1269	a green and efficient method	1242:1269	a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers	1242:1338	The present work provides a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers.
35718154	3	3	theme	cleaved	624:630	arg1	groups					616:621	the the-NH2 groups	604:621	the the-NH2 groups	604:621	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	3	3	theme	cleaved	624:630	arg1	units					638:642	cleaved sugar units	624:642	cleaved sugar units of polysaccharide	624:660	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	6	4	theme	nanofibers	1186:1195	arg1	applicability					1148:1160	the applicability	1144:1160	the applicability of the gelatin/pullulan nanofibers in food packaging	1144:1213	In addition, the glycation improved the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging.
35718154	5	5	theme	transmission	927:938	arg1	rates					940:944	the water vapor transmission rates	911:944	the water vapor transmission rates	911:944	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	6	6	theme	gelatin/pullulan	1169:1184	arg1	nanofibers					1186:1195	the gelatin/pullulan nanofibers	1165:1195	the gelatin/pullulan nanofibers	1165:1195	In addition, the glycation improved the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging.
35718154	1	7	theme	physical	289:296	arg1	properties					298:307	the physical properties	285:307	the physical properties	285:307	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	5	8	theme	glycation	830:838	arg1	120 h					821:825	120 h	821:825	120 h of glycation	821:838	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	7	9	theme	nanofibers	1329:1338	arg1	properties					1298:1307	the physical properties	1285:1307	the physical properties of gelatin/pullulan nanofibers	1285:1338	The present work provides a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers.
35718154	5	10	theme	water	845:849	arg1	angle					859:863	the water contact angle	841:863	the water contact angle of nanofibers	841:877	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	3	11	theme	protein	707:713	arg1	structure					690:698	the secondary structure	676:698	the secondary structure of the protein	676:713	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	7	12	theme	gelatin/pullulan	1312:1327	arg1	nanofibers					1329:1338	gelatin/pullulan nanofibers	1312:1338	gelatin/pullulan nanofibers	1312:1338	The present work provides a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers.
35718154	5	13	dep	79.1°	900:904	arg1	to					897:898	to	897:898	to	897:898	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	2	14	theme	36.0 	409:413	arg1	%					404:404	%	404:404	%	404:404	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	7	15	theme	present	1220:1226	arg1	work					1228:1231	The present work	1216:1231	The present work	1216:1231	The present work provides a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers.
35718154	2	16	theme	grafting	336:343	arg1	degree					345:350	the grafting degree	332:350	the grafting degree of the nanofibers	332:368	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	1	17	theme	gelatin/pullulan	197:212	arg1	nanofibers					224:233	gelatin/pullulan composite nanofibers	197:233	gelatin/pullulan composite nanofibers	197:233	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	5	18	theme	water	915:919	arg1	rates					940:944	the water vapor transmission rates	911:944	the water vapor transmission rates	911:944	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	1	19	theme	composite	214:222	arg1	nanofibers					224:233	gelatin/pullulan composite nanofibers	197:233	gelatin/pullulan composite nanofibers	197:233	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	0	20	theme	gelatin/pullulan	33:48	arg1	Characterization					0:15	Characterization	0:15	Characterization of glycosylated gelatin/pullulan	0:48	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	6	21	theme	food	1200:1203	arg1	packaging					1205:1213	food packaging	1200:1213	food packaging	1200:1213	In addition, the glycation improved the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging.
35718154	3	22	theme	FTIR	558:561	arg1	results					563:569	FTIR results	558:569	FTIR results	558:569	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	0	23	theme	glycosylated	20:31	arg1	gelatin/pullulan					33:48	glycosylated gelatin/pullulan	20:48	glycosylated gelatin/pullulan	20:48	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	2	24	theme	nanofibers	546:555	arg1	structure					529:537	the structure	525:537	the structure of the nanofibers	525:555	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	4	25	theme	thermal	743:749	arg1	stability					751:759	the thermal stability	739:759	the thermal stability	739:759	The glycation enhanced the thermal stability and improved the rigidity of the nanofibers.
35718154	6	26	from	applicability	1148:1160	arg1	packaging					1205:1213	food packaging	1200:1213	food packaging	1200:1213	In addition, the glycation improved the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging.
35718154	2	27	theme	glycation	423:431	arg1	time					433:436	the glycation time	419:436	the glycation time	419:436	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	6	28	theme	nanofibers	1116:1125	arg1	stability					1099:1107	the water stability	1089:1107	the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging	1089:1213	In addition, the glycation improved the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging.
35718154	3	29	theme	polysaccharide	647:660	arg1	groups					616:621	the the-NH2 groups	604:621	the the-NH2 groups	604:621	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	3	29	theme	polysaccharide	647:660	arg1	units					638:642	cleaved sugar units	624:642	cleaved sugar units of polysaccharide	624:660	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	7	30	theme	physical	1289:1296	arg1	properties					1298:1307	the physical properties	1285:1307	the physical properties of gelatin/pullulan nanofibers	1285:1338	The present work provides a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers.
35718154	3	31	theme	sugar	632:636	arg1	groups					616:621	the the-NH2 groups	604:621	the the-NH2 groups	604:621	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	3	31	theme	sugar	632:636	arg1	units					638:642	cleaved sugar units	624:642	cleaved sugar units of polysaccharide	624:660	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	5	32	theme	enhanced	1005:1012	arg1	hydrophobicity					1014:1027	the enhanced hydrophobicity	1001:1027	the enhanced hydrophobicity	1001:1027	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	0	33	theme	multi-fluid	75:85	arg1	spinning					108:115	multi-fluid mixing solution blow spinning	75:115	multi-fluid mixing solution blow spinning	75:115	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	5	34	theme	nanofibers	868:877	arg1	angle					859:863	the water contact angle	841:863	the water contact angle of nanofibers	841:877	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	2	35	theme	glycation	499:507	arg1	72 h					491:494	72 h	491:494	72 h of glycation	491:507	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	0	36	gly	glycosylated	20:31	arg1	gelatin/pullulan					33:48	glycosylated gelatin/pullulan	20:48	glycosylated gelatin/pullulan	20:48	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	2	37	theme	nanofibers	359:368	arg1	degree					345:350	the grafting degree	332:350	the grafting degree of the nanofibers	332:368	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	2	38	theme	morphology	457:466	arg1	results					468:474	the morphology results	453:474	the morphology results	453:474	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	5	39	theme	barrier	1033:1039	arg1	properties					1041:1050	barrier properties	1033:1050	barrier properties	1033:1050	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	0	40	dep	nanofibers	50:59	arg1	fabricated					61:70	fabricated	61:70	nanofibers fabricated by multi-fluid mixing solution blow spinning	50:115	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	1	41	theme	multi-fluid	132:142	arg1	spinning					165:172	multi-fluid mixing solution blow spinning	132:172	multi-fluid mixing solution blow spinning	132:172	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	7	42	theme	efficient	1254:1262	arg1	method					1264:1269	a green and efficient method	1242:1269	a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers	1242:1338	The present work provides a green and efficient method for improving the physical properties of gelatin/pullulan nanofibers.
35718154	1	43	theme	blow	160:163	arg1	spinning					165:172	multi-fluid mixing solution blow spinning	132:172	multi-fluid mixing solution blow spinning	132:172	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	1	44	theme	mixing	144:149	arg1	spinning					165:172	multi-fluid mixing solution blow spinning	132:172	multi-fluid mixing solution blow spinning	132:172	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	5	45	theme	vapor	921:925	arg1	rates					940:944	the water vapor transmission rates	911:944	the water vapor transmission rates	911:944	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	2	46	dep	%	404:404	arg1	to					406:407	to	406:407	to	406:407	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	1	47	theme	solution	151:158	arg1	spinning					165:172	multi-fluid mixing solution blow spinning	132:172	multi-fluid mixing solution blow spinning	132:172	In this work, multi-fluid mixing solution blow spinning was applied to develop gelatin/pullulan composite nanofibers, and then the nanofibers were glycated to enhance the physical properties.
35718154	0	48	theme	solution	94:101	arg1	spinning					108:115	multi-fluid mixing solution blow spinning	75:115	multi-fluid mixing solution blow spinning	75:115	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	3	49	theme	the-NH2	608:614	arg1	groups					616:621	the the-NH2 groups	604:621	the the-NH2 groups	604:621	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	3	49	theme	the-NH2	608:614	arg1	units					638:642	cleaved sugar units	624:642	cleaved sugar units of polysaccharide	624:660	FTIR results show that the glycation consumed the the-NH2 groups, cleaved sugar units of polysaccharide, and affected the secondary structure of the protein.
35718154	2	50	theme	17.5 	399:403	arg1	%					404:404	%	404:404	%	404:404	The results show that the grafting degree of the nanofibers increased significantly from 17.5 % to 36.0 % as the glycation time increased, and the morphology results indicated that 72 h of glycation did not destroy the structure of the nanofibers.
35718154	5	51	theme	contact	851:857	arg1	angle					859:863	the water contact angle	841:863	the water contact angle of nanofibers	841:877	Besides, after 120 h of glycation, the water contact angle of nanofibers increased from 0° to 79.1°, and the water vapor transmission rates decreased from 12.49 to 8.97 g mm/m2 h kPa, indicating the enhanced hydrophobicity and barrier properties.
35718154	0	52	theme	mixing	87:92	arg1	spinning					108:115	multi-fluid mixing solution blow spinning	75:115	multi-fluid mixing solution blow spinning	75:115	Characterization of glycosylated gelatin/pullulan nanofibers fabricated by multi-fluid mixing solution blow spinning.
35718154	4	53	theme	nanofibers	794:803	arg1	rigidity					778:785	the rigidity	774:785	the rigidity of the nanofibers	774:803	The glycation enhanced the thermal stability and improved the rigidity of the nanofibers.
35718154	6	54	theme	water	1093:1097	arg1	stability					1099:1107	the water stability	1089:1107	the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging	1089:1213	In addition, the glycation improved the water stability of the nanofibers, which increased the applicability of the gelatin/pullulan nanofibers in food packaging.
36206406	9	0	theme	drug	1805:1808	arg1	enzymes					1703:1709	The enzymes	1699:1709	The enzymes required for adhesin glycosylation rather than the adhesins themselves	1699:1780	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	9	0	theme	drug	1805:1808	arg1	targets					1810:1816	better drug targets	1798:1816	better drug targets for preventing or treating <i>H. pylori</i> infection	1798:1870	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	9	0	theme	drug	1805:1808	arg1	adhesins					1762:1769	the adhesins	1758:1769	The enzymes required for adhesin glycosylation rather than the adhesins themselves	1699:1780	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	7	1	theme	vitro</i>	1489:1497	arg1	model					1509:1513	the <i>in vitro</i> cell-line model	1479:1513	the <i>in vitro</i> cell-line model	1479:1513	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	4	2	theme	molecular	720:728	arg1	pattern					745:751	a two-step molecular weight upshift pattern	709:751	a two-step molecular weight upshift pattern	709:751	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	2	3	theme	gastric	381:387	arg1	mucosa					389:394	the gastric mucosa	377:394	the gastric mucosa	377:394	To reach a long-term colonization in the host stomach, <i>H. pylori</i> employs multiple outer membrane adhesins for binding to the gastric mucosa.
36206406	8	4	theme	adhesin	1645:1651	arg1	modification					1653:1664	adhesin modification	1645:1664	adhesin modification	1645:1664	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	4	5	from	adhesins	626:633	arg1	pylori</i>					662:671	<i>H. pylori</i>	656:671	<i>H. pylori</i>	656:671	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	5	6	theme	involved	1120:1127	arg1	enzymes					1129:1135	the involved enzymes	1116:1135	the involved enzymes for the adhesin glycosylation	1116:1165	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	7	7	theme	cell-line	1499:1507	arg1	model					1509:1513	the <i>in vitro</i> cell-line model	1479:1513	the <i>in vitro</i> cell-line model	1479:1513	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	4	8	theme	two-step	711:718	arg1	pattern					745:751	a two-step molecular weight upshift pattern	709:751	a two-step molecular weight upshift pattern	709:751	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	5	9	theme	LPS	1197:1199	arg1	biosynthesis					1201:1212	the LPS biosynthesis	1193:1212	the LPS biosynthesis	1193:1212	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	0	10	theme	membrane	104:111	arg1	adhesins					113:120	outer membrane adhesins	98:120	outer membrane adhesins	98:120	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	6	11	theme	protease	1270:1277	arg1	resistance					1279:1288	the protease resistance	1266:1288	the protease resistance	1266:1288	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36206406	7	12	theme	significant	1432:1442	arg1	reduction					1444:1452	a significant reduction	1430:1452	a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model	1430:1513	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	4	13	theme	key	622:624	arg1	AlpA/B					635:640	AlpA/B	635:640	AlpA/B	635:640	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	13	theme	key	622:624	arg1	adhesins					626:633	key adhesins AlpA/B and BabA/B	622:651	key adhesins AlpA/B and BabA/B in <i>H. pylori</i>	622:671	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	13	theme	key	622:624	arg1	BabA/B					646:651	BabA/B	646:651	BabA/B	646:651	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	0	14	theme	outer	98:102	arg1	adhesins					113:120	outer membrane adhesins	98:120	outer membrane adhesins	98:120	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	7	15	theme	bacterial	1457:1465	arg1	adhesion					1467:1474	bacterial adhesion	1457:1474	bacterial adhesion	1457:1474	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	4	16	theme	inner	779:783	arg1	membrane					785:792	the inner membrane	775:792	the inner membrane	775:792	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	3	17	theme	bacterial	581:589	arg1	adhesion					591:598	bacterial adhesion	581:598	bacterial adhesion	581:598	However, due to the redundancy of adhesins that complement the adhesive function of bacteria, targeting each individual adhesin alone usually achieves nonideal outcomes for preventing bacterial adhesion.
36206406	3	18	theme	individual	506:515	arg1	adhesin					517:523	each individual adhesin	501:523	each individual adhesin alone	501:529	However, due to the redundancy of adhesins that complement the adhesive function of bacteria, targeting each individual adhesin alone usually achieves nonideal outcomes for preventing bacterial adhesion.
36206406	5	19	dep	enzymes	1027:1033	arg1	WaaL					1050:1053	WaaL	1050:1053	WaaL	1050:1053	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	19	dep	enzymes	1027:1033	arg1	WecA					1035:1038	WecA	1035:1038	WecA	1035:1038	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	19	dep	enzymes	1027:1033	arg1	enzymes					1027:1033	ligation enzymes WecA, Wzk, and WaaL	1018:1053	ligation enzymes WecA, Wzk, and WaaL	1018:1053	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	19	dep	enzymes	1027:1033	arg1	Wzk					1041:1043	Wzk	1041:1043	Wzk	1041:1043	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	0	20	theme	adhesins	113:120	arg1	modification					82:93	the modification	78:93	the modification of outer membrane adhesins	78:120	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	5	21	theme	underlying	1090:1099	arg1	mechanisms					1101:1110	the underlying mechanisms	1086:1110	the underlying mechanisms	1086:1110	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	22	theme	LPS	991:993	arg1	assembly					1005:1012	the LPS O-antigen assembly	987:1012	the LPS O-antigen assembly	987:1012	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	1	23	theme	several	198:204	arg1	diseases					214:221	several gastric diseases	198:221	several gastric diseases including gastric cancer	198:246	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	1	23	theme	several	198:204	arg1	cancer					241:246	gastric cancer	233:246	gastric cancer	233:246	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	7	24	from	reduction	1444:1452	arg1	adhesion					1467:1474	bacterial adhesion	1457:1474	bacterial adhesion	1457:1474	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	7	24	from	reduction	1444:1452	arg1	model					1509:1513	the <i>in vitro</i> cell-line model	1479:1513	the <i>in vitro</i> cell-line model	1479:1513	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	9	25	theme	pylori</i>	1851:1860	arg1	infection					1862:1870	<i>H. pylori</i> infection	1845:1870	<i>H. pylori</i> infection	1845:1870	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	2	26	theme	membrane	344:351	arg1	adhesins					353:360	multiple outer membrane adhesins	329:360	multiple outer membrane adhesins	329:360	To reach a long-term colonization in the host stomach, <i>H. pylori</i> employs multiple outer membrane adhesins for binding to the gastric mucosa.
36206406	8	27	theme	LPS	1624:1626	arg1	biosynthesis					1628:1639	LPS biosynthesis	1624:1639	LPS biosynthesis for adhesin modification and its biological significance	1624:1696	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	1	28	theme	gastric	206:212	arg1	diseases					214:221	several gastric diseases	198:221	several gastric diseases including gastric cancer	198:246	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	1	28	theme	gastric	206:212	arg1	cancer					241:246	gastric cancer	233:246	gastric cancer	233:246	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	0	29	theme	<i>Helicobacter	0:14	arg1	pylori</i>					16:25	<i>Helicobacter pylori</i>	0:25	<i>Helicobacter pylori</i>	0:25	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	6	30	theme	glycosylation	1235:1247	arg1	Loss					1215:1218	Loss	1215:1218	Loss of the adhesin glycosylation	1215:1247	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36206406	2	31	theme	outer	338:342	arg1	adhesins					353:360	multiple outer membrane adhesins	329:360	multiple outer membrane adhesins	329:360	To reach a long-term colonization in the host stomach, <i>H. pylori</i> employs multiple outer membrane adhesins for binding to the gastric mucosa.
36206406	1	32	theme	diseases	214:221	arg1	development					183:193	the development	179:193	the development of several gastric diseases including gastric cancer	179:246	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	8	33	theme	H.	1552:1553	arg1	pylori</i>					1555:1564	<i>that H. pylori</i>	1544:1564	<i>that H. pylori</i>	1544:1564	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	9	34	theme	adhesin	1724:1730	arg1	glycosylation					1732:1744	adhesin glycosylation	1724:1744	adhesin glycosylation	1724:1744	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	2	35	theme	multiple	329:336	arg1	adhesins					353:360	multiple outer membrane adhesins	329:360	multiple outer membrane adhesins	329:360	To reach a long-term colonization in the host stomach, <i>H. pylori</i> employs multiple outer membrane adhesins for binding to the gastric mucosa.
36206406	4	36	theme	outer	829:833	arg1	membrane					835:842	the outer membrane	825:842	the outer membrane	825:842	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	3	37	theme	bacteria	481:488	arg1	function					469:476	the adhesive function	456:476	the adhesive function of bacteria	456:488	However, due to the redundancy of adhesins that complement the adhesive function of bacteria, targeting each individual adhesin alone usually achieves nonideal outcomes for preventing bacterial adhesion.
36206406	7	38	theme	LPS	1407:1409	arg1	biosynthesis					1411:1422	the LPS biosynthesis	1403:1422	the LPS biosynthesis	1403:1422	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	8	39	theme	current	1520:1526	arg1	findings					1528:1535	The current findings	1516:1535	The current findings	1516:1535	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	8	40	theme	biological	1674:1683	arg1	significance					1685:1696	its biological significance	1670:1696	its biological significance	1670:1696	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	4	41	mod	modified	677:684	arg1	AlpA/B					635:640	AlpA/B	635:640	AlpA/B	635:640	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	41	mod	modified	677:684	arg3	glycans					689:695	glycans	689:695	glycans	689:695	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	41	mod	modified	677:684	arg1	adhesins					626:633	key adhesins AlpA/B and BabA/B	622:651	key adhesins AlpA/B and BabA/B in <i>H. pylori</i>	622:671	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	41	mod	modified	677:684	arg1	BabA/B					646:651	BabA/B	646:651	BabA/B	646:651	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	1	42	theme	gastric	233:239	arg1	cancer					241:246	gastric cancer	233:246	gastric cancer	233:246	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	0	43	theme	protein	45:51	arg1	system					67:72	a general protein glycosylation system	35:72	a general protein glycosylation system for the modification of outer membrane adhesins	35:120	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	4	44	theme	weight	730:735	arg1	pattern					745:751	a two-step molecular weight upshift pattern	709:751	a two-step molecular weight upshift pattern	709:751	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	6	45	theme	adhesins	1322:1329	arg1	resistance					1279:1288	the protease resistance	1266:1288	the protease resistance	1266:1288	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36206406	6	45	theme	adhesins	1322:1329	arg1	stability					1298:1306	the stability	1294:1306	the stability of the tested adhesins	1294:1329	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36206406	2	46	theme	long-term	260:268	arg1	colonization					270:281	a long-term colonization	258:281	a long-term colonization	258:281	To reach a long-term colonization in the host stomach, <i>H. pylori</i> employs multiple outer membrane adhesins for binding to the gastric mucosa.
36206406	6	47	theme	adhesin	1227:1233	arg1	glycosylation					1235:1247	the adhesin glycosylation	1223:1247	the adhesin glycosylation	1223:1247	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36206406	0	48	theme	general	37:43	arg1	system					67:72	a general protein glycosylation system	35:72	a general protein glycosylation system for the modification of outer membrane adhesins	35:120	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	8	49	theme	protein	1584:1590	arg1	system					1606:1611	a general protein glycosylation system	1574:1611	a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance	1574:1696	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	3	50	theme	adhesins	431:438	arg1	redundancy					417:426	the redundancy	413:426	the redundancy of adhesins that complement the adhesive function of bacteria	413:488	However, due to the redundancy of adhesins that complement the adhesive function of bacteria, targeting each individual adhesin alone usually achieves nonideal outcomes for preventing bacterial adhesion.
36206406	5	51	theme	related	927:933	arg1	assembly					1005:1012	the LPS O-antigen assembly	987:1012	the LPS O-antigen assembly	987:1012	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	51	theme	related	927:933	arg1	enzymes					919:925	some enzymes	914:925	some enzymes	914:925	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	51	theme	related	927:933	arg1	enzymes					1027:1033	ligation enzymes WecA, Wzk, and WaaL	1018:1053	ligation enzymes WecA, Wzk, and WaaL	1018:1053	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	52	theme	upshift	864:870	arg1	pattern					872:878	this upshift pattern	859:878	this upshift pattern	859:878	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	8	53	theme	general	1576:1582	arg1	system					1606:1611	a general protein glycosylation system	1574:1611	a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance	1574:1696	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	9	54	theme	better	1798:1803	arg1	enzymes					1703:1709	The enzymes	1699:1709	The enzymes required for adhesin glycosylation rather than the adhesins themselves	1699:1780	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	9	54	theme	better	1798:1803	arg1	targets					1810:1816	better drug targets	1798:1816	better drug targets for preventing or treating <i>H. pylori</i> infection	1798:1870	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	9	54	theme	better	1798:1803	arg1	adhesins					1762:1769	the adhesins	1758:1769	The enzymes required for adhesin glycosylation rather than the adhesins themselves	1699:1780	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	8	55	theme	<i>that	1544:1550	arg1	pylori</i>					1555:1564	<i>that H. pylori</i>	1544:1564	<i>that H. pylori</i>	1544:1564	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	1	56	theme	<i>Helicobacter	123:137	arg1	infection					150:158	<i>Helicobacter pylori</i> infection	123:158	<i>Helicobacter pylori</i> infection	123:158	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	0	57	theme	glycosylation	53:65	arg1	system					67:72	a general protein glycosylation system	35:72	a general protein glycosylation system for the modification of outer membrane adhesins	35:120	<i>Helicobacter pylori</i> employs a general protein glycosylation system for the modification of outer membrane adhesins.
36206406	5	58	theme	adhesin	1145:1151	arg1	glycosylation					1153:1165	the adhesin glycosylation	1141:1165	the adhesin glycosylation	1141:1165	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	1	59	theme	pylori</i>	139:148	arg1	infection					150:158	<i>Helicobacter pylori</i> infection	123:158	<i>Helicobacter pylori</i> infection	123:158	<i>Helicobacter pylori</i> infection is associated with the development of several gastric diseases including gastric cancer.
36206406	7	60	from	mutations	1390:1398	arg1	biosynthesis					1411:1422	the LPS biosynthesis	1403:1422	the LPS biosynthesis	1403:1422	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	8	61	theme	glycosylation	1592:1604	arg1	system					1606:1611	a general protein glycosylation system	1574:1611	a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance	1574:1696	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	4	62	theme	upshift	737:743	arg1	pattern					745:751	a two-step molecular weight upshift pattern	709:751	a two-step molecular weight upshift pattern	709:751	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	63	theme	inner	807:811	arg1	membrane					813:820	the inner membrane	803:820	the inner membrane	803:820	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	2	64	theme	host	290:293	arg1	stomach					295:301	the host stomach	286:301	the host stomach	286:301	To reach a long-term colonization in the host stomach, <i>H. pylori</i> employs multiple outer membrane adhesins for binding to the gastric mucosa.
36206406	6	65	theme	tested	1315:1320	arg1	adhesins					1322:1329	the tested adhesins	1311:1329	the tested adhesins	1311:1329	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36206406	5	66	theme	enzymes	919:925	arg1	expression					900:909	the expression	896:909	the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL,	896:1054	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	67	theme	lipopolysaccharide	938:955	arg1	biosynthesis					963:974	lipopolysaccharide (LPS) biosynthesis	938:974	lipopolysaccharide (LPS) biosynthesis	938:974	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	9	68	theme	<i>H.	1845:1849	arg1	infection					1862:1870	<i>H. pylori</i> infection	1845:1870	<i>H. pylori</i> infection	1845:1870	The enzymes required for adhesin glycosylation rather than the adhesins themselves are potentially better drug targets for preventing or treating <i>H. pylori</i> infection.
36206406	8	69	theme	related	1613:1619	arg1	system					1606:1611	a general protein glycosylation system	1574:1611	a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance	1574:1696	The current findings reveal <i>that H. pylori</i> employs a general protein glycosylation system related to LPS biosynthesis for adhesin modification and its biological significance.
36206406	4	70	dep	adhesins	626:633	arg1	AlpA/B					635:640	AlpA/B	635:640	AlpA/B	635:640	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	70	dep	adhesins	626:633	arg1	adhesins					626:633	key adhesins AlpA/B and BabA/B	622:651	key adhesins AlpA/B and BabA/B in <i>H. pylori</i>	622:671	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	4	70	dep	adhesins	626:633	arg1	BabA/B					646:651	BabA/B	646:651	BabA/B	646:651	Here, we report that key adhesins AlpA/B and BabA/B in <i>H. pylori</i> are modified by glycans and display a two-step molecular weight upshift pattern from the cytoplasm to the inner membrane and from the inner membrane to the outer membrane.
36206406	3	71	theme	adhesive	460:467	arg1	function					469:476	the adhesive function	456:476	the adhesive function of bacteria	456:488	However, due to the redundancy of adhesins that complement the adhesive function of bacteria, targeting each individual adhesin alone usually achieves nonideal outcomes for preventing bacterial adhesion.
36206406	5	72	theme	O-antigen	995:1003	arg1	assembly					1005:1012	the LPS O-antigen assembly	987:1012	the LPS O-antigen assembly	987:1012	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	7	73	theme	<i>in	1483:1487	arg1	model					1509:1513	the <i>in vitro</i> cell-line model	1479:1513	the <i>in vitro</i> cell-line model	1479:1513	In addition, mutations in the LPS biosynthesis cause a significant reduction in bacterial adhesion in the <i>in vitro</i> cell-line model.
36206406	5	74	theme	ligation	1018:1025	arg1	WaaL					1050:1053	WaaL	1050:1053	WaaL	1050:1053	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	74	theme	ligation	1018:1025	arg1	WecA					1035:1038	WecA	1035:1038	WecA	1035:1038	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	74	theme	ligation	1018:1025	arg1	enzymes					1027:1033	ligation enzymes WecA, Wzk, and WaaL	1018:1053	ligation enzymes WecA, Wzk, and WaaL	1018:1053	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	5	74	theme	ligation	1018:1025	arg1	Wzk					1041:1043	Wzk	1041:1043	Wzk	1041:1043	Nevertheless, this upshift pattern is missing when the expression of some enzymes related to lipopolysaccharide (LPS) biosynthesis, including the LPS O-antigen assembly and ligation enzymes WecA, Wzk, and WaaL, is disrupted, indicating that the underlying mechanisms and the involved enzymes for the adhesin glycosylation are partially shared with the LPS biosynthesis.
36206406	3	75	theme	nonideal	548:555	arg1	outcomes					557:564	nonideal outcomes	548:564	nonideal outcomes for preventing bacterial adhesion	548:598	However, due to the redundancy of adhesins that complement the adhesive function of bacteria, targeting each individual adhesin alone usually achieves nonideal outcomes for preventing bacterial adhesion.
36206406	6	76	theme	adhesin-binding	1352:1366	arg1	ability					1368:1374	the adhesin-binding ability	1348:1374	the adhesin-binding ability	1348:1374	Loss of the adhesin glycosylation not only reduces the protease resistance and the stability of the tested adhesins but also changes the adhesin-binding ability.
36827096	8	0	theme	family	1108:1113	arg1	presence					1084:1091	the presence	1080:1091	the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis	1080:1169	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	1	1	theme	carbohydrate-binding	128:147	arg1	adhesion					209:216	adhesion	209:216	adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders	209:327	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	1	theme	carbohydrate-binding	128:147	arg1	proteins					149:156	carbohydrate-binding proteins	128:156	carbohydrate-binding proteins	128:156	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	8	2	from	presence	1084:1091	arg1	yessoensis					1160:1169	the bivalve G. yessoensis	1145:1169	the bivalve G. yessoensis	1145:1169	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	0	3	theme	Glycymeris	67:76	arg1	yessoensis					78:87	the Bivalve Glycymeris yessoensis	55:87	the Bivalve Glycymeris yessoensis	55:87	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	0	4	from	Cloning	10:16	arg1	yessoensis					78:87	the Bivalve Glycymeris yessoensis	55:87	the Bivalve Glycymeris yessoensis	55:87	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	1	5	theme	proteins	149:156	arg1	lectins					97:103	C-type lectins	90:103	C-type lectins (CTLs)	90:110	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	5	theme	proteins	149:156	arg1	family					118:123	a family	116:123	a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders	116:327	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	9	6	theme	sulfate	1374:1380	arg1	group					1382:1386	a sulfate group	1372:1386	a sulfate group	1372:1386	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	6	theme	sulfate	1374:1380	arg1	residues					1441:1448	fucose or N-acetylgalactosamine residues	1409:1448	residues	1441:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	8	7	theme	GYL-like	1118:1125	arg1	lectins					1134:1140	GYL-like C-type lectins	1118:1140	GYL-like C-type lectins	1118:1140	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	6	8	theme	long-form	869:877	arg1	structure					891:899	CTL-typical long-form double-loop structure	857:899	CTL-typical long-form double-loop structure	857:899	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	4	9	gly	glycoprotein	603:614	arg1	GYL					594:596	GYL	594:596	GYL	594:596	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	4	9	gly	glycoprotein	603:614	arg1	glycoprotein					603:614	a glycoprotein	601:614	a glycoprotein containing two N-glycosylation sites per subunit	601:663	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	2	10	with	acids	445:449	arg1	EPN					509:511	EPN	509:511	EPN	509:511	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	10	with	acids	445:449	arg1	motifs					521:526	WND motifs	517:526	WND motifs	517:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	1	11	theme	serum	249:253	arg1	glycoproteins					255:267	serum glycoproteins	249:267	serum glycoproteins	249:267	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	6	12	theme	CTL-typical	857:867	arg1	structure					891:899	CTL-typical long-form double-loop structure	857:899	CTL-typical long-form double-loop structure	857:899	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	1	13	theme	glycoproteins	255:267	arg1	reactions					295:303	innate immune system reactions	274:303	innate immune system reactions	274:303	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	13	theme	glycoproteins	255:267	arg1	cells					226:230	cells	226:230	cells	226:230	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	13	theme	glycoproteins	255:267	arg1	turnover					237:244	the turnover	233:244	the turnover of serum glycoproteins	233:267	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	2	14	theme	recognition	479:489	arg1	CRD					499:501	CRD	499:501	CRD	499:501	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	14	theme	recognition	479:489	arg1	domain					491:496	the C-type carbohydrate recognition domain	455:496	the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	455:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	14	theme	recognition	479:489	arg1	yessoensis					403:412	the bivalve Glycymeris yessoensis	380:412	the bivalve Glycymeris yessoensis (GYL)	380:418	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	6	15	theme	potential	805:813	arg1	structure					828:836	The potential CRD tertiary structure	801:836	The potential CRD tertiary structure of the GYL	801:847	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	8	16	theme	lectins	1134:1140	arg1	family					1108:1113	a multigene family	1096:1113	a multigene family of GYL-like C-type lectins	1096:1140	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	2	17	theme	carbohydrate	466:477	arg1	CRD					499:501	CRD	499:501	CRD	499:501	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	17	theme	carbohydrate	466:477	arg1	domain					491:496	the C-type carbohydrate recognition domain	455:496	the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	455:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	17	theme	carbohydrate	466:477	arg1	yessoensis					403:412	the bivalve Glycymeris yessoensis	380:412	the bivalve Glycymeris yessoensis (GYL)	380:418	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	6	18	theme	GYL	845:847	arg1	structure					828:836	The potential CRD tertiary structure	801:836	The potential CRD tertiary structure of the GYL	801:847	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	9	19	theme	microarray	1189:1198	arg1	approach					1200:1207	the glycan microarray approach	1178:1207	the glycan microarray approach	1178:1207	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	2	20	theme	lectin	368:373	arg1	cloning					357:363	the cDNA cloning	348:363	the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	348:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	8	21	theme	multigene	1098:1106	arg1	family					1108:1113	a multigene family	1096:1113	a multigene family of GYL-like C-type lectins	1096:1140	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	2	22	theme	C-type	459:464	arg1	CRD					499:501	CRD	499:501	CRD	499:501	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	22	theme	C-type	459:464	arg1	domain					491:496	the C-type carbohydrate recognition domain	455:496	the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	455:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	22	theme	C-type	459:464	arg1	yessoensis					403:412	the bivalve Glycymeris yessoensis	380:412	the bivalve Glycymeris yessoensis (GYL)	380:418	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	1	23	theme	multiple	171:178	arg1	events					191:196	multiple biological events	171:196	multiple biological events	171:196	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	0	24	theme	Molecular	0:8	arg1	Cloning					10:16	Molecular Cloning	0:16	Molecular Cloning	0:16	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	1	25	gly	glycoproteins	255:267	arg1	glycoproteins					255:267	serum glycoproteins	249:267	serum glycoproteins	249:267	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	26	theme	C-type	90:95	arg1	CTLs					106:109	CTLs	106:109	CTLs	106:109	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	26	theme	C-type	90:95	arg1	lectins					97:103	C-type lectins	90:103	C-type lectins (CTLs)	90:110	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	26	theme	C-type	90:95	arg1	family					118:123	a family	116:123	a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders	116:327	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	1	27	theme	biological	180:189	arg1	events					191:196	multiple biological events	171:196	multiple biological events	171:196	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	8	28	theme	G.	1157:1158	arg1	yessoensis					1160:1169	the bivalve G. yessoensis	1145:1169	the bivalve G. yessoensis	1145:1169	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	9	29	theme	residues	1441:1448	arg1	group					1400:1404	a methyl group	1391:1404	a methyl group of fucose or N-acetylgalactosamine residues	1391:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	29	theme	residues	1441:1448	arg1	group					1382:1386	a sulfate group	1372:1386	a sulfate group	1372:1386	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	29	theme	residues	1441:1448	arg1	residues					1441:1448	fucose or N-acetylgalactosamine residues	1409:1448	residues	1441:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	2	30	with	domain	491:496	arg1	EPN					509:511	EPN	509:511	EPN	509:511	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	30	with	domain	491:496	arg1	motifs					521:526	WND motifs	517:526	WND motifs	517:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	9	31	theme	additional	1345:1354	arg1	fragment					1356:1363	an additional fragment	1342:1363	an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues	1342:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	32	theme	fucose	1409:1414	arg1	residues					1441:1448	fucose or N-acetylgalactosamine residues	1409:1448	residues	1441:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	5	33	theme	3-O-methylated	767:780	arg1	6-deoxy-D-glucose					782:798	3-O-methylated 6-deoxy-D-glucose	767:798	3-O-methylated 6-deoxy-D-glucose	767:798	N-glycans are made up of xylose, mannose, D-glucosamine, 3-O-methylated galactose, D-quinovoses, and 3-O-methylated 6-deoxy-D-glucose.
36827096	1	34	theme	innate	274:279	arg1	reactions					295:303	innate immune system reactions	274:303	innate immune system reactions	274:303	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	7	35	theme	lectin	1036:1041	arg1	isoforms					1019:1026	eight isoforms	1013:1026	eight isoforms of this lectin	1013:1041	Additionally, when confirming the GYL sequence, eight isoforms of this lectin were identified.
36827096	0	36	from	yessoensis	78:87	arg1	Characteristics					22:36	Characteristics	22:36	Characteristics	22:36	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	0	36	from	yessoensis	78:87	arg1	Lectin					43:48	a Lectin	41:48	a Lectin from the Bivalve Glycymeris yessoensis	41:87	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	0	36	from	yessoensis	78:87	arg1	Cloning					10:16	Molecular Cloning	0:16	Molecular Cloning	0:16	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	8	37	attach	presence	1084:1091	arg2	family					1108:1113	a multigene family	1096:1113	a multigene family of GYL-like C-type lectins	1096:1140	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	8	37	attach	presence	1084:1091	arg1	yessoensis					1160:1169	the bivalve G. yessoensis	1145:1169	the bivalve G. yessoensis	1145:1169	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	2	38	theme	Glycymeris	392:401	arg1	acids					445:449	161 amino acids	435:449	161 amino acids	435:449	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	38	theme	Glycymeris	392:401	arg1	domain					491:496	the C-type carbohydrate recognition domain	455:496	the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	455:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	38	theme	Glycymeris	392:401	arg1	GYL					415:417	GYL	415:417	GYL	415:417	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	38	theme	Glycymeris	392:401	arg1	yessoensis					403:412	the bivalve Glycymeris yessoensis	380:412	the bivalve Glycymeris yessoensis (GYL)	380:418	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	39	theme	amino	439:443	arg1	acids					445:449	161 amino acids	435:449	161 amino acids	435:449	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	39	theme	amino	439:443	arg1	yessoensis					403:412	the bivalve Glycymeris yessoensis	380:412	the bivalve Glycymeris yessoensis (GYL)	380:418	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	1	40	theme	immune	281:286	arg1	reactions					295:303	innate immune system reactions	274:303	innate immune system reactions	274:303	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	9	41	theme	N-acetylgalactosamine	1419:1439	arg1	residues					1441:1448	fucose or N-acetylgalactosamine residues	1409:1448	residues	1441:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	3	42	theme	amino	541:545	arg1	sequence					552:559	The deduced amino acid sequence	529:559	The deduced amino acid sequence	529:559	The deduced amino acid sequence showed similarity to other CTLs.
36827096	2	43	theme	bivalve	384:390	arg1	acids					445:449	161 amino acids	435:449	161 amino acids	435:449	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	43	theme	bivalve	384:390	arg1	domain					491:496	the C-type carbohydrate recognition domain	455:496	the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	455:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	43	theme	bivalve	384:390	arg1	GYL					415:417	GYL	415:417	GYL	415:417	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	2	43	theme	bivalve	384:390	arg1	yessoensis					403:412	the bivalve Glycymeris yessoensis	380:412	the bivalve Glycymeris yessoensis (GYL)	380:418	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	4	44	theme	N-glycosylation	631:645	arg1	sites					647:651	two N-glycosylation sites	627:651	two N-glycosylation sites	627:651	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	1	45	theme	system	288:293	arg1	reactions					295:303	innate immune system reactions	274:303	innate immune system reactions	274:303	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	5	46	theme	3-O-methylated	723:736	arg1	galactose					738:746	3-O-methylated galactose	723:746	3-O-methylated galactose	723:746	N-glycans are made up of xylose, mannose, D-glucosamine, 3-O-methylated galactose, D-quinovoses, and 3-O-methylated 6-deoxy-D-glucose.
36827096	3	47	theme	other	582:586	arg1	CTLs					588:591	other CTLs	582:591	other CTLs	582:591	The deduced amino acid sequence showed similarity to other CTLs.
36827096	3	48	theme	acid	547:550	arg1	sequence					552:559	The deduced amino acid sequence	529:559	The deduced amino acid sequence	529:559	The deduced amino acid sequence showed similarity to other CTLs.
36827096	6	49	from	bases	945:949	arg1	bridges					930:936	three disulfide bridges	914:936	three disulfide bridges at the bases of the loops	914:962	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	8	50	theme	C-type	1127:1132	arg1	lectins					1134:1140	GYL-like C-type lectins	1118:1140	GYL-like C-type lectins	1118:1140	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	6	51	theme	disulfide	920:928	arg1	bridges					930:936	three disulfide bridges	914:936	three disulfide bridges at the bases of the loops	914:962	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	6	52	theme	CRD	815:817	arg1	structure					828:836	The potential CRD tertiary structure	801:836	The potential CRD tertiary structure of the GYL	801:847	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	7	53	theme	GYL	999:1001	arg1	sequence					1003:1010	the GYL sequence	995:1010	the GYL sequence	995:1010	Additionally, when confirming the GYL sequence, eight isoforms of this lectin were identified.
36827096	0	54	theme	Lectin	43:48	arg1	Characteristics					22:36	Characteristics	22:36	Characteristics	22:36	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	0	54	theme	Lectin	43:48	arg1	Cloning					10:16	Molecular Cloning	0:16	Molecular Cloning	0:16	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	9	55	theme	natural	1210:1216	arg1	ligands					1231:1237	natural carbohydrate ligands	1210:1237	natural carbohydrate ligands	1210:1237	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	4	56	gly	N-glycosylation	631:645	arg2	two					627:629	two	627:629	two	627:629	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	4	56	gly	N-glycosylation	631:645	arg2	sites					647:651	two N-glycosylation sites	627:651	two N-glycosylation sites	627:651	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	6	57	theme	double-loop	879:889	arg1	structure					891:899	CTL-typical long-form double-loop structure	857:899	CTL-typical long-form double-loop structure	857:899	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	3	58	theme	deduced	533:539	arg1	sequence					552:559	The deduced amino acid sequence	529:559	The deduced amino acid sequence	529:559	The deduced amino acid sequence showed similarity to other CTLs.
36827096	6	59	theme	tertiary	819:826	arg1	structure					828:836	The potential CRD tertiary structure	801:836	The potential CRD tertiary structure of the GYL	801:847	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	1	60	theme	prospective	308:318	arg1	invaders					320:327	prospective invaders	308:327	prospective invaders	308:327	C-type lectins (CTLs) are a family of carbohydrate-binding proteins that mediate multiple biological events, including adhesion between cells, the turnover of serum glycoproteins, and innate immune system reactions to prospective invaders.
36827096	2	61	theme	WND	517:519	arg1	motifs					521:526	WND motifs	517:526	WND motifs	517:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	4	62	contain	containing	616:625	arg1	GYL					594:596	GYL	594:596	GYL	594:596	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	4	62	contain	containing	616:625	arg1	glycoprotein					603:614	a glycoprotein	601:614	a glycoprotein containing two N-glycosylation sites per subunit	601:663	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	4	62	contain	containing	616:625	arg2	sites					647:651	two N-glycosylation sites	627:651	two N-glycosylation sites	627:651	GYL is a glycoprotein containing two N-glycosylation sites per subunit.
36827096	9	63	contain	containing	1331:1340	arg2	fragment					1356:1363	an additional fragment	1342:1363	an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues	1342:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	63	contain	containing	1331:1340	arg1	glycotope					1265:1273	the glycotope	1261:1273	the glycotope for GYL	1261:1281	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	63	contain	containing	1331:1340	arg1	obligatory					1320:1329	obligatory	1320:1329	obligatory	1320:1329	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	0	64	theme	Bivalve	59:65	arg1	yessoensis					78:87	the Bivalve Glycymeris yessoensis	55:87	the Bivalve Glycymeris yessoensis	55:87	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	9	65	theme	carbohydrate	1218:1229	arg1	ligands					1231:1237	natural carbohydrate ligands	1210:1237	natural carbohydrate ligands	1210:1237	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	66	theme	glycan	1182:1187	arg1	approach					1200:1207	the glycan microarray approach	1178:1207	the glycan microarray approach	1178:1207	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	2	67	theme	cDNA	352:355	arg1	cloning					357:363	the cDNA cloning	348:363	the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	348:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
36827096	9	68	theme	methyl	1393:1398	arg1	group					1400:1404	a methyl group	1391:1404	a methyl group of fucose or N-acetylgalactosamine residues	1391:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	9	68	theme	methyl	1393:1398	arg1	residues					1441:1448	fucose or N-acetylgalactosamine residues	1409:1448	residues	1441:1448	Using the glycan microarray approach, natural carbohydrate ligands were established, and the glycotope for GYL was reconstructed as "Galβ1-4GlcNAcβ obligatory containing an additional fragment", like a sulfate group or a methyl group of fucose or N-acetylgalactosamine residues.
36827096	6	69	theme	loops	958:962	arg1	bases					945:949	the bases	941:949	the bases of the loops	941:962	The potential CRD tertiary structure of the GYL adopted CTL-typical long-form double-loop structure and included three disulfide bridges at the bases of the loops.
36827096	0	70	from	Characteristics	22:36	arg1	yessoensis					78:87	the Bivalve Glycymeris yessoensis	55:87	the Bivalve Glycymeris yessoensis	55:87	Molecular Cloning and Characteristics of a Lectin from the Bivalve Glycymeris yessoensis.
36827096	8	71	theme	bivalve	1149:1155	arg1	yessoensis					1160:1169	the bivalve G. yessoensis	1145:1169	the bivalve G. yessoensis	1145:1169	This fact indicates the presence of a multigene family of GYL-like C-type lectins in the bivalve G. yessoensis.
36827096	2	72	from	yessoensis	403:412	arg1	cloning					357:363	the cDNA cloning	348:363	the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs	348:526	Here, we describe the cDNA cloning of lectin from the bivalve Glycymeris yessoensis (GYL), which encodes 161 amino acids and the C-type carbohydrate recognition domain (CRD) with EPN and WND motifs.
35717753	0	0	theme	mass	99:102	arg1	spectrometry					104:115	tandem mass spectrometry	92:115	tandem mass spectrometry	92:115	Multidimensional identification of disaccharide isomers based on non-covalent complexes and tandem mass spectrometry.
35717753	8	1	theme	subtle	1430:1435	arg1	differences					1448:1458	subtle structural differences	1430:1458	subtle structural differences in disaccharide isomers	1430:1482	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	3	2	theme	glycan	317:322	arg1	isomers					324:330	glycan isomers	317:330	glycan isomers	317:330	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	6	3	theme	note	1025:1028	arg1	method					1047:1052	the established method	1031:1052	the established method	1031:1052	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	6	3	theme	note	1025:1028	arg1	able					1057:1060	able	1057:1060	able	1057:1060	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	4	4	theme	L-His	563:567	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	4	theme	L-His	563:567	arg1	-H					569:570	(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine	553:718	-H	569:570	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	0	5	theme	tandem	92:97	arg1	spectrometry					104:115	tandem mass spectrometry	92:115	tandem mass spectrometry	92:115	Multidimensional identification of disaccharide isomers based on non-covalent complexes and tandem mass spectrometry.
35717753	4	6	theme	dimeric	539:545	arg1	ions					504:507	two novel complex ions	486:507	two novel complex ions	486:507	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	6	theme	dimeric	539:545	arg1	-H					569:570	(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine	553:718	-H	569:570	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	6	theme	dimeric	539:545	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	6	theme	dimeric	539:545	arg1	ions					618:621	the mononuclear copper-bound quaternary ions	578:621	the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]	578:643	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	6	7	theme	histidine-based	1181:1195	arg1	ions					1205:1208	histidine-based complex ions	1181:1208	histidine-based complex ions	1181:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	4	8	theme	copper-bound	526:537	arg1	ions					504:507	two novel complex ions	486:507	two novel complex ions	486:507	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	8	theme	copper-bound	526:537	arg1	-H					569:570	(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine	553:718	-H	569:570	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	8	theme	copper-bound	526:537	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	8	theme	copper-bound	526:537	arg1	ions					618:621	the mononuclear copper-bound quaternary ions	578:621	the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]	578:643	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	7	9	theme	disaccharide	1313:1324	arg1	isomers					1326:1332	two disaccharide isomers	1309:1332	two disaccharide isomers (lactose and sucrose)	1309:1354	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	7	9	theme	disaccharide	1313:1324	arg1	sucrose					1347:1353	sucrose	1347:1353	sucrose	1347:1353	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	7	9	theme	disaccharide	1313:1324	arg1	lactose					1335:1341	lactose	1335:1341	lactose	1335:1341	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	5	10	theme	three-dimensional	949:965	arg1	vector					967:972	a three-dimensional vector	947:972	a three-dimensional vector	947:972	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	5	11	theme	above	898:902	arg1	types					908:912	the above two types	894:912	the above two types of complex ions	894:928	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	7	12	dep	identification	1263:1276	arg1	the					1259:1261	the	1259:1261	the	1259:1261	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	3	13	theme	structures	383:392	arg1	complexity					363:372	the complexity	359:372	the complexity of their structures including their complex compositions, linkages, and anomeric configurations	359:468	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	4	14	theme	complex	496:502	arg1	ions					504:507	two novel complex ions	486:507	two novel complex ions	486:507	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	14	theme	complex	496:502	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	15	theme	relative	800:807	arg1	quantification					809:822	relative quantification	800:822	relative quantification	800:822	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	1	16	from	polymers	156:163	arg1	nature					168:173	nature	168:173	nature	168:173	Glycans are the most abundant organic polymers in nature.
35717753	5	17	theme	unique	861:866	arg1	patterns					882:889	the unique fragmentation patterns	857:889	the unique fragmentation patterns of the above two types of complex ions	857:928	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	4	18	theme	novel	490:494	arg1	ions					504:507	two novel complex ions	486:507	two novel complex ions	486:507	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	18	theme	novel	490:494	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	6	19	theme	ions	1205:1208	arg1	ions					1173:1176	linkage-specific fragment ions	1147:1176	linkage-specific fragment ions of histidine-based complex ions	1147:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	5	20	theme	types	908:912	arg1	patterns					882:889	the unique fragmentation patterns	857:889	the unique fragmentation patterns of the above two types of complex ions	857:928	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	7	21	theme	relative	1282:1289	arg1	quantification					1291:1304	relative quantification	1282:1304	relative quantification	1282:1304	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	6	22	theme	complex	1197:1203	arg1	ions					1205:1208	histidine-based complex ions	1181:1208	histidine-based complex ions	1181:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	6	23	theme	linkage	1086:1092	arg1	isomers					1094:1100	linkage isomers	1086:1100	linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions	1086:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	7	24	dep	isomers	1326:1332	arg1	isomers					1326:1332	two disaccharide isomers	1309:1332	two disaccharide isomers (lactose and sucrose)	1309:1354	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	7	24	dep	isomers	1326:1332	arg1	sucrose					1347:1353	sucrose	1347:1353	sucrose	1347:1353	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	7	24	dep	isomers	1326:1332	arg1	lactose					1335:1341	lactose	1335:1341	lactose	1335:1341	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	3	25	theme	complex	410:416	arg1	linkages					432:439	linkages	432:439	linkages	432:439	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	3	25	theme	complex	410:416	arg1	compositions					418:429	their complex compositions	404:429	their complex compositions	404:429	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	3	25	theme	complex	410:416	arg1	configurations					455:468	anomeric configurations	446:468	anomeric configurations	446:468	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	8	26	from	conclusion	1379:1388	arg1	sensitive					1417:1425	sensitive	1417:1425	sensitive	1417:1425	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	8	26	from	conclusion	1379:1388	arg1	method					1407:1412	the established method	1391:1412	the established method	1391:1412	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	4	27	theme	dissociation-based	762:779	arg1	identification					781:794	collision-induced dissociation-based identification	744:794	collision-induced dissociation-based identification	744:794	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	5	28	theme	fragmentation	868:880	arg1	patterns					882:889	the unique fragmentation patterns	857:889	the unique fragmentation patterns of the above two types of complex ions	857:928	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	8	29	theme	disaccharide	1463:1474	arg1	isomers					1476:1482	disaccharide isomers	1463:1482	disaccharide isomers	1463:1482	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	3	30	theme	anomeric	446:453	arg1	compositions					418:429	their complex compositions	404:429	their complex compositions	404:429	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	3	30	theme	anomeric	446:453	arg1	configurations					455:468	anomeric configurations	446:468	anomeric configurations	446:468	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	0	31	theme	Multidimensional	0:15	arg1	identification					17:30	Multidimensional identification	0:30	Multidimensional identification of disaccharide isomers	0:54	Multidimensional identification of disaccharide isomers based on non-covalent complexes and tandem mass spectrometry.
35717753	4	32	theme	collision-induced	744:760	arg1	identification					781:794	collision-induced dissociation-based identification	744:794	collision-induced dissociation-based identification	744:794	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	8	33	contain	has	1488:1490	arg1	sensitive					1417:1425	sensitive	1417:1425	sensitive	1417:1425	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	8	33	contain	has	1488:1490	arg2	potential					1496:1504	the potential to be used for the differentiation of various glycans	1492:1558	the potential to be used for the differentiation of various glycans	1492:1558	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	8	33	contain	has	1488:1490	arg1	method					1407:1412	the established method	1391:1412	the established method	1391:1412	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	0	34	theme	disaccharide	35:46	arg1	isomers					48:54	disaccharide isomers	35:54	disaccharide isomers	35:54	Multidimensional identification of disaccharide isomers based on non-covalent complexes and tandem mass spectrometry.
35717753	6	35	theme	mass	1120:1123	arg1	spectrometry					1125:1136	tandem mass spectrometry	1113:1136	tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions	1113:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	3	36	theme	spectrometry-based	280:297	arg1	identification					299:312	mass spectrometry-based identification	275:312	mass spectrometry-based identification of glycan isomers	275:330	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	7	37	from	quantification	1291:1304	arg1	beverages					1365:1373	dairy beverages	1359:1373	dairy beverages	1359:1373	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	4	38	theme	copper-bound	594:605	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	38	theme	copper-bound	594:605	arg1	ions					618:621	the mononuclear copper-bound quaternary ions	578:621	the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]	578:643	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	38	theme	copper-bound	594:605	arg1	Cu2+					625:628	Cu2+	625:628	Cu2+	625:628	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	38	theme	copper-bound	594:605	arg1	A					631:631	A	631:631	A	631:631	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	38	theme	copper-bound	594:605	arg1	L-Ser					634:638	L-Ser	634:638	L-Ser	634:638	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	6	39	theme	established	1035:1045	arg1	method					1047:1052	the established method	1031:1052	the established method	1031:1052	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	6	39	theme	established	1035:1045	arg1	able					1057:1060	able	1057:1060	able	1057:1060	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	6	40	theme	isomers	1094:1100	arg1	mixtures					1074:1081	mixtures	1074:1081	mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions	1074:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	4	41	theme	mononuclear	582:592	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	41	theme	mononuclear	582:592	arg1	ions					618:621	the mononuclear copper-bound quaternary ions	578:621	the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]	578:643	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	41	theme	mononuclear	582:592	arg1	Cu2+					625:628	Cu2+	625:628	Cu2+	625:628	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	41	theme	mononuclear	582:592	arg1	A					631:631	A	631:631	A	631:631	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	41	theme	mononuclear	582:592	arg1	L-Ser					634:638	L-Ser	634:638	L-Ser	634:638	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	42	theme	A	560:560	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	42	theme	A	560:560	arg1	-H					569:570	(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine	553:718	-H	569:570	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	6	43	theme	linkage-specific	1147:1162	arg1	ions					1173:1176	linkage-specific fragment ions	1147:1176	linkage-specific fragment ions of histidine-based complex ions	1147:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	0	44	theme	isomers	48:54	arg1	identification					17:30	Multidimensional identification	0:30	Multidimensional identification of disaccharide isomers	0:54	Multidimensional identification of disaccharide isomers based on non-covalent complexes and tandem mass spectrometry.
35717753	8	45	theme	established	1395:1405	arg1	sensitive					1417:1425	sensitive	1417:1425	sensitive	1417:1425	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	8	45	theme	established	1395:1405	arg1	method					1407:1412	the established method	1391:1412	the established method	1391:1412	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	6	46	theme	fragment	1164:1171	arg1	ions					1173:1176	linkage-specific fragment ions	1147:1176	linkage-specific fragment ions of histidine-based complex ions	1147:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	4	47	theme	quaternary	607:616	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	47	theme	quaternary	607:616	arg1	ions					618:621	the mononuclear copper-bound quaternary ions	578:621	the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]	578:643	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	47	theme	quaternary	607:616	arg1	Cu2+					625:628	Cu2+	625:628	Cu2+	625:628	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	47	theme	quaternary	607:616	arg1	A					631:631	A	631:631	A	631:631	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	47	theme	quaternary	607:616	arg1	L-Ser					634:638	L-Ser	634:638	L-Ser	634:638	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	0	48	theme	non-covalent	65:76	arg1	complexes					78:86	non-covalent complexes	65:86	non-covalent complexes	65:86	Multidimensional identification of disaccharide isomers based on non-covalent complexes and tandem mass spectrometry.
35717753	3	49	theme	isomers	324:330	arg1	identification					299:312	mass spectrometry-based identification	275:312	mass spectrometry-based identification of glycan isomers	275:330	However, mass spectrometry-based identification of glycan isomers remains challenging due to the complexity of their structures including their complex compositions, linkages, and anomeric configurations.
35717753	2	50	theme	wide	230:233	arg1	range					235:239	a wide range	228:239	a wide range of biological functions	228:263	They are essential to living organisms and regulate a wide range of biological functions.
35717753	8	51	from	differences	1448:1458	arg1	isomers					1476:1482	disaccharide isomers	1463:1482	disaccharide isomers	1463:1482	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	4	52	dep	identification	781:794	arg1	the					740:742	the	740:742	the	740:742	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	53	theme	Cu2+	554:557	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	53	theme	Cu2+	554:557	arg1	-H					569:570	(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine	553:718	-H	569:570	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	8	54	theme	structural	1437:1446	arg1	differences					1448:1458	subtle structural differences	1430:1458	subtle structural differences in disaccharide isomers	1430:1482	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	7	55	theme	isomers	1326:1332	arg1	identification					1263:1276	identification	1263:1276	identification	1263:1276	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	7	55	theme	isomers	1326:1332	arg1	quantification					1291:1304	relative quantification	1282:1304	relative quantification	1282:1304	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	6	56	theme	tandem	1113:1118	arg1	spectrometry					1125:1136	tandem mass spectrometry	1113:1136	tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions	1113:1208	Of note, the established method is able to identify mixtures of linkage isomers only using tandem mass spectrometry based on linkage-specific fragment ions of histidine-based complex ions.
35717753	4	57	theme	isomers	843:849	arg1	identification					781:794	collision-induced dissociation-based identification	744:794	collision-induced dissociation-based identification	744:794	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	57	theme	isomers	843:849	arg1	quantification					809:822	relative quantification	800:822	relative quantification	800:822	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	5	58	theme	complex	917:923	arg1	ions					925:928	complex ions	917:928	complex ions	917:928	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	7	59	theme	dairy	1359:1363	arg1	beverages					1365:1373	dairy beverages	1359:1373	dairy beverages	1359:1373	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	1	60	theme	abundant	139:146	arg1	Glycans					118:124	Glycans	118:124	Glycans	118:124	Glycans are the most abundant organic polymers in nature.
35717753	1	60	theme	abundant	139:146	arg1	polymers					156:163	the most abundant organic polymers	130:163	the most abundant organic polymers in nature	130:173	Glycans are the most abundant organic polymers in nature.
35717753	8	61	theme	various	1544:1550	arg1	glycans					1552:1558	various glycans	1544:1558	various glycans	1544:1558	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	4	62	theme	disaccharide	830:841	arg1	isomers					843:849	14 disaccharide isomers	827:849	14 disaccharide isomers	827:849	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	5	63	theme	ions	925:928	arg1	types					908:912	the above two types	894:912	the above two types of complex ions	894:928	When the unique fragmentation patterns of the above two types of complex ions were mapped into a three-dimensional vector, all the isomers were completely distinguished.
35717753	1	64	theme	organic	148:154	arg1	Glycans					118:124	Glycans	118:124	Glycans	118:124	Glycans are the most abundant organic polymers in nature.
35717753	1	64	theme	organic	148:154	arg1	polymers					156:163	the most abundant organic polymers	130:163	the most abundant organic polymers in nature	130:173	Glycans are the most abundant organic polymers in nature.
35717753	8	65	from	sensitive	1417:1425	arg1	conclusion					1379:1388	conclusion	1379:1388	conclusion	1379:1388	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35717753	2	66	theme	living	198:203	arg1	organisms					205:213	living organisms	198:213	living organisms	198:213	They are essential to living organisms and regulate a wide range of biological functions.
35717753	2	67	theme	functions	255:263	arg1	range					235:239	a wide range	228:239	a wide range of biological functions	228:263	They are essential to living organisms and regulate a wide range of biological functions.
35717753	4	68	theme	mononuclear	514:524	arg1	ions					504:507	two novel complex ions	486:507	two novel complex ions	486:507	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	68	theme	mononuclear	514:524	arg1	-H					569:570	(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine	553:718	-H	569:570	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	68	theme	mononuclear	514:524	arg1	ions					547:550	the mononuclear copper-bound dimeric ions	510:550	the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine)	510:719	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	4	68	theme	mononuclear	514:524	arg1	ions					618:621	the mononuclear copper-bound quaternary ions	578:621	the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]	578:643	In this study, two novel complex ions, the mononuclear copper-bound dimeric ions [(Cu2+)(A)(L-His)-H]+ and the mononuclear copper-bound quaternary ions [(Cu2+)(A)(L-Ser)3-H]+ (where A denotes a disaccharide, and L-Ser/His denotes l-serine/histidine), were designed for the collision-induced dissociation-based identification and relative quantification of 14 disaccharide isomers.
35717753	2	69	theme	biological	244:253	arg1	functions					255:263	biological functions	244:263	biological functions	244:263	They are essential to living organisms and regulate a wide range of biological functions.
35717753	7	70	from	identification	1263:1276	arg1	beverages					1365:1373	dairy beverages	1359:1373	dairy beverages	1359:1373	Finally, the method was successfully applied to the identification and relative quantification of two disaccharide isomers (lactose and sucrose) in dairy beverages.
35717753	8	71	theme	glycans	1552:1558	arg1	differentiation					1525:1539	the differentiation	1521:1539	the differentiation of various glycans	1521:1558	In conclusion, the established method is sensitive to subtle structural differences in disaccharide isomers and has the potential to be used for the differentiation of various glycans.
35934376	10	0	theme	DKD	2035:2037	arg1	diagnosis					2022:2030	the diagnosis	2018:2030	the diagnosis of DKD	2018:2037	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	4	1	theme	current	561:567	arg1	methods					588:594	the current N-glycan profiling methods	557:594	the current N-glycan profiling methods for DKD	557:602	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	8	2	theme	urine	1626:1630	arg1	samples					1632:1638	urine samples	1626:1638	urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD	1626:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	9	3	theme	DKD	1834:1836	arg1	patients					1838:1845	DKD patients	1834:1845	DKD patients	1834:1845	Compared to healthy controls, 3 N-glycans were up-regulated and 14 N-glycans were down-regulated in DKD patients.
35934376	4	4	theme	profiling	578:586	arg1	methods					588:594	the current N-glycan profiling methods	557:594	the current N-glycan profiling methods for DKD	557:602	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	10	5	theme	competitive	1880:1890	arg1	method					1912:1917	a competitive sample purification method	1878:1917	a competitive sample purification method for in-depth analysis of urinary N-glycome by MS	1878:1966	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	6	6	theme	good	1219:1222	arg1	efficiency					1224:1233	good efficiency	1219:1233	good efficiency of immobilization of proteins to resin	1219:1272	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	2	7	theme	filtration	292:301	arg1	eGFR					309:312	eGFR	309:312	eGFR	309:312	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	7	theme	filtration	292:301	arg1	rate					303:306	estimated glomerular filtration rate	271:306	estimated glomerular filtration rate (eGFR)	271:313	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	8	theme	estimated	271:279	arg1	eGFR					309:312	eGFR	309:312	eGFR	309:312	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	8	theme	estimated	271:279	arg1	rate					303:306	estimated glomerular filtration rate	271:306	estimated glomerular filtration rate (eGFR)	271:313	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	5	9	theme	Glycoprotein	856:867	arg1	Immobilization					869:882	Ultrafast Glycoprotein Immobilization	846:882	Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG)	846:915	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	6	10	theme	NHS-reactive	1111:1122	arg1	chemistry					1124:1132	NHS-reactive chemistry	1111:1132	NHS-reactive chemistry	1111:1132	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	4	11	theme	interaction	660:670	arg1	chromatography					672:685	lectin affinity enrichment or hydrophilic interaction chromatography	618:685	chromatography	672:685	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	10	12	theme	purification	1899:1910	arg1	method					1912:1917	a competitive sample purification method	1878:1917	a competitive sample purification method for in-depth analysis of urinary N-glycome by MS	1878:1966	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	6	13	theme	subsequent	1279:1288	arg1	steps					1298:1302	the subsequent washing steps	1275:1302	the subsequent washing steps	1275:1302	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	10	14	theme	urinary	1944:1950	arg1	N-glycome					1952:1960	urinary N-glycome	1944:1960	urinary N-glycome	1944:1960	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	5	15	theme	novel	803:807	arg1	method					831:836	a novel N-glycan purification method	801:836	a novel N-glycan purification method	801:836	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	1	16	theme	kidney-related	196:209	arg1	complication					211:222	a common and serious kidney-related complication	175:222	a common and serious kidney-related complication of diabetic mellitus	175:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	16	theme	kidney-related	196:209	arg1	disease					158:164	Diabetic kidney disease	142:164	Diabetic kidney disease (DKD)	142:170	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	7	17	theme	fmol	1555:1558	arg1	level					1560:1564	fmol level	1555:1564	fmol level	1555:1564	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	0	18	from	disease	59:65	arg1	profiling					9:17	In-depth profiling	0:17	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).	0:140	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	4	19	theme	optical	700:706	arg1	detection					708:716	optical detection	700:716	optical detection	700:716	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	8	20	theme	data	1702:1705	arg1	N-glycome					1714:1722	N-glycome	1714:1722	N-glycome from DKD	1714:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	8	20	theme	data	1702:1705	arg1	set					1707:1709	the largest data set	1690:1709	the largest data set of N-glycome from DKD	1690:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	5	21	theme	in-depth	922:929	arg1	profiling					931:939	in-depth profiling	922:939	in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS)	922:996	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	1	22	theme	kidney	151:156	arg1	DKD					167:169	DKD	167:169	DKD	167:169	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	22	theme	kidney	151:156	arg1	disease					158:164	Diabetic kidney disease	142:164	Diabetic kidney disease (DKD)	142:170	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	22	theme	kidney	151:156	arg1	complication					211:222	a common and serious kidney-related complication	175:222	a common and serious kidney-related complication of diabetic mellitus	175:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	0	23	theme	ultrafast	70:78	arg1	immobilization					93:106	ultrafast glycoprotein immobilization	70:106	ultrafast glycoprotein immobilization for glycan extraction (UltraGIG)	70:139	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	10	24	theme	new	1980:1982	arg1	insights					1984:1991	new insights	1980:1991	new insights into biomarker study for the diagnosis of DKD	1980:2037	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	0	25	theme	glycan	112:117	arg1	UltraGIG					131:138	UltraGIG	131:138	UltraGIG	131:138	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	0	25	theme	glycan	112:117	arg1	extraction					119:128	glycan extraction	112:128	glycan extraction (UltraGIG)	112:139	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	2	26	contain	have	361:364	arg2	limitations					366:376	limitations	366:376	limitations in the diagnosis of DKD due to the lack of specificity and sensitivity	366:447	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	26	contain	have	361:364	arg1	they					356:359	they	356:359	they	356:359	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	5	27	theme	mass	975:978	arg1	MS					994:995	MS	994:995	MS	994:995	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	5	27	theme	mass	975:978	arg1	spectrometry					980:991	mass spectrometry	975:991	mass spectrometry (MS)	975:996	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	0	28	from	N-glycome	30:38	arg1	disease					59:65	diabetic kidney disease	43:65	diabetic kidney disease	43:65	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	2	29	used	used	328:331	arg2	eGFR					309:312	eGFR	309:312	eGFR	309:312	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	29	used	used	328:331	arg2	albuminuria					255:265	albuminuria	255:265	albuminuria	255:265	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	29	used	used	328:331	arg2	rate					303:306	estimated glomerular filtration rate	271:306	estimated glomerular filtration rate (eGFR)	271:313	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	0	30	theme	In-depth	0:7	arg1	profiling					9:17	In-depth profiling	0:17	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).	0:140	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	4	31	theme	N-glycome	742:750	arg1	coverage					752:759	limited N-glycome coverage	734:759	limited N-glycome coverage in low throughput	734:777	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	3	32	theme	Urinary	450:456	arg1	N-glycans					458:466	Urinary N-glycans	450:466	Urinary N-glycans	450:466	Urinary N-glycans are emerging as novel biomarkers for predicting renal prognosis in DKD.
35934376	5	33	theme	N-glycan	809:816	arg1	method					831:836	a novel N-glycan purification method	801:836	a novel N-glycan purification method	801:836	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	5	34	theme	N-glycome	952:960	arg1	profiling					931:939	in-depth profiling	922:939	in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS)	922:996	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	1	35	theme	Diabetic	142:149	arg1	DKD					167:169	DKD	167:169	DKD	167:169	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	35	theme	Diabetic	142:149	arg1	disease					158:164	Diabetic kidney disease	142:164	Diabetic kidney disease (DKD)	142:170	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	35	theme	Diabetic	142:149	arg1	complication					211:222	a common and serious kidney-related complication	175:222	a common and serious kidney-related complication of diabetic mellitus	175:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	9	36	theme	healthy	1746:1752	arg1	controls					1754:1761	healthy controls	1746:1761	healthy controls	1746:1761	Compared to healthy controls, 3 N-glycans were up-regulated and 14 N-glycans were down-regulated in DKD patients.
35934376	2	37	theme	due	402:404	arg1	DKD					398:400	DKD	398:400	DKD due to the lack of specificity and sensitivity	398:447	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	0	38	theme	N-glycome	30:38	arg1	profiling					9:17	In-depth profiling	0:17	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).	0:140	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	7	39	theme	BSA	1474:1476	arg1	mixture					1455:1461	the mixture	1451:1461	the mixture of IgG and BSA at a 1:100 M ratio	1451:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	4	40	with	enrichment	634:643	arg1	detection					708:716	optical detection	700:716	optical detection	700:716	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	0	41	theme	diabetic	43:50	arg1	disease					59:65	diabetic kidney disease	43:65	diabetic kidney disease	43:65	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	7	42	dep	glycans	1416:1422	arg1	N-glycans					1436:1444	extracting N-glycans	1425:1444	extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio	1425:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	7	42	dep	glycans	1416:1422	arg1	loss					1510:1513	loss	1510:1513	loss	1510:1513	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	7	43	theme	IgG	1466:1468	arg1	mixture					1455:1461	the mixture	1451:1461	the mixture of IgG and BSA at a 1:100 M ratio	1451:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	6	44	dep	rapidly	1026:1032	arg1	40 min					1042:1047	40 min	1042:1047	40 min	1042:1047	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	8	45	theme	237 N-glycan	1579:1590	arg1	compositions					1592:1603	237 N-glycan compositions	1579:1603	237 N-glycan compositions	1579:1603	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	1	46	theme	diabetic	227:234	arg1	mellitus					236:243	diabetic mellitus	227:243	diabetic mellitus	227:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	6	47	theme	other	1327:1331	arg1	impurities					1333:1342	other impurities	1327:1342	other impurities	1327:1342	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	6	48	theme	immobilization	1238:1251	arg1	efficiency					1224:1233	good efficiency	1219:1233	good efficiency of immobilization of proteins to resin	1219:1272	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	7	49	theme	extracting	1425:1434	arg1	N-glycans					1436:1444	extracting N-glycans	1425:1444	extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio	1425:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	7	50	theme	good	1391:1394	arg1	selectivity					1396:1406	good selectivity	1391:1406	good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss	1391:1513	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	4	51	theme	N-glycan	569:576	arg1	methods					588:594	the current N-glycan profiling methods	557:594	the current N-glycan profiling methods for DKD	557:602	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	2	52	theme	glomerular	281:290	arg1	eGFR					309:312	eGFR	309:312	eGFR	309:312	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	2	52	theme	glomerular	281:290	arg1	rate					303:306	estimated glomerular filtration rate	271:306	estimated glomerular filtration rate (eGFR)	271:313	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	5	53	theme	Ultrafast	846:854	arg1	Immobilization					869:882	Ultrafast Glycoprotein Immobilization	846:882	Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG)	846:915	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	2	54	from	limitations	366:376	arg1	diagnosis					385:393	the diagnosis	381:393	the diagnosis of DKD due to the lack of specificity and sensitivity	381:447	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	4	55	theme	hydrophilic	648:658	arg1	chromatography					672:685	lectin affinity enrichment or hydrophilic interaction chromatography	618:685	chromatography	672:685	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	6	56	attach	released	1173:1180	arg2	N-glycans					1144:1152	N-glycans	1144:1152	N-glycans	1144:1152	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	6	56	attach	released	1173:1180	arg1	resin					1191:1195	the resin	1187:1195	the resin	1187:1195	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	6	57	theme	washing	1290:1296	arg1	steps					1298:1302	the subsequent washing steps	1275:1302	the subsequent washing steps	1275:1302	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	8	58	theme	healthy	1653:1659	arg1	controls					1661:1668	healthy controls	1653:1668	healthy controls	1653:1668	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	5	59	theme	purification	818:829	arg1	method					831:836	a novel N-glycan purification method	801:836	a novel N-glycan purification method	801:836	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	2	60	theme	diagnostic	333:342	arg1	biomarkers					344:353	diagnostic biomarkers	333:353	diagnostic biomarkers	333:353	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	1	61	theme	serious	188:194	arg1	complication					211:222	a common and serious kidney-related complication	175:222	a common and serious kidney-related complication of diabetic mellitus	175:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	61	theme	serious	188:194	arg1	disease					158:164	Diabetic kidney disease	142:164	Diabetic kidney disease (DKD)	142:170	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	8	62	from	set	1707:1709	arg1	DKD					1729:1731	DKD	1729:1731	DKD	1729:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	7	63	theme	detection	1530:1538	arg1	sensitivity					1540:1550	detection sensitivity	1530:1550	detection sensitivity	1530:1550	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	10	64	theme	in-depth	1923:1930	arg1	analysis					1932:1939	in-depth analysis	1923:1939	in-depth analysis of urinary N-glycome by MS	1923:1966	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	6	65	theme	proteins	1256:1263	arg1	immobilization					1238:1251	immobilization	1238:1251	immobilization of proteins to resin	1238:1272	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	8	66	theme	largest	1694:1700	arg1	N-glycome					1714:1722	N-glycome	1714:1722	N-glycome from DKD	1714:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	8	66	theme	largest	1694:1700	arg1	set					1707:1709	the largest data set	1690:1709	the largest data set of N-glycome from DKD	1690:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	7	67	dep	showed	1384:1389	arg1	minimized					1519:1527	minimized	1519:1527	showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized	1384:1527	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	7	67	dep	showed	1384:1389	arg1	sensitivity					1540:1550	detection sensitivity	1530:1550	detection sensitivity	1530:1550	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	8	68	from	DKD	1729:1731	arg1	N-glycome					1714:1722	N-glycome	1714:1722	N-glycome from DKD	1714:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	8	68	from	DKD	1729:1731	arg1	set					1707:1709	the largest data set	1690:1709	the largest data set of N-glycome from DKD	1690:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	1	69	theme	common	177:182	arg1	complication					211:222	a common and serious kidney-related complication	175:222	a common and serious kidney-related complication of diabetic mellitus	175:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	69	theme	common	177:182	arg1	disease					158:164	Diabetic kidney disease	142:164	Diabetic kidney disease (DKD)	142:170	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	5	70	theme	Glycan	888:893	arg1	UltraGIG					907:914	UltraGIG	907:914	UltraGIG	907:914	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	5	70	theme	Glycan	888:893	arg1	extraction					895:904	Glycan extraction	888:904	Glycan extraction (UltraGIG)	888:915	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	10	71	theme	N-glycome	1952:1960	arg1	analysis					1932:1939	in-depth analysis	1923:1939	in-depth analysis of urinary N-glycome by MS	1923:1966	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	0	72	theme	glycoprotein	80:91	arg1	immobilization					93:106	ultrafast glycoprotein immobilization	70:106	ultrafast glycoprotein immobilization for glycan extraction (UltraGIG)	70:139	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	8	73	theme	N-glycome	1714:1722	arg1	N-glycome					1714:1722	N-glycome	1714:1722	N-glycome from DKD	1714:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	8	73	theme	N-glycome	1714:1722	arg1	set					1707:1709	the largest data set	1690:1709	the largest data set of N-glycome from DKD	1690:1731	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	0	74	from	profiling	9:17	arg1	disease					59:65	diabetic kidney disease	43:65	diabetic kidney disease	43:65	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	8	75	with	samples	1632:1638	arg1	DKD					1645:1647	DKD	1645:1647	DKD	1645:1647	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	8	75	with	samples	1632:1638	arg1	controls					1661:1668	healthy controls	1653:1668	healthy controls	1653:1668	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	7	76	from	level	1560:1564	arg1	sensitivity					1540:1550	detection sensitivity	1530:1550	detection sensitivity	1530:1550	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	4	77	from	coverage	752:759	arg1	throughput					768:777	low throughput	764:777	low throughput	764:777	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	5	78	from	profiling	931:939	arg1	DKD					965:967	DKD	965:967	DKD using mass spectrometry (MS)	965:996	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	4	79	theme	low	764:766	arg1	throughput					768:777	low throughput	764:777	low throughput	764:777	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	10	80	theme	sample	1892:1897	arg1	method					1912:1917	a competitive sample purification method	1878:1917	a competitive sample purification method for in-depth analysis of urinary N-glycome by MS	1878:1966	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	2	81	theme	specificity	421:431	arg1	lack					413:416	the lack	409:416	the lack of specificity and sensitivity	409:447	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	0	82	theme	urinary	22:28	arg1	N-glycome					30:38	urinary N-glycome	22:38	urinary N-glycome in diabetic kidney disease	22:65	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	7	83	from	ratio	1491:1495	arg1	mixture					1455:1461	the mixture	1451:1461	the mixture of IgG and BSA at a 1:100 M ratio	1451:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	5	84	theme	urinary	944:950	arg1	N-glycome					952:960	urinary N-glycome	944:960	urinary N-glycome	944:960	Herein, we developed a novel N-glycan purification method, termed Ultrafast Glycoprotein Immobilization for Glycan extraction (UltraGIG), for in-depth profiling of urinary N-glycome in DKD using mass spectrometry (MS).
35934376	4	85	theme	limited	734:740	arg1	coverage					752:759	limited N-glycome coverage	734:759	limited N-glycome coverage in low throughput	734:777	However, most of the current N-glycan profiling methods for DKD were based on lectin affinity enrichment or hydrophilic interaction chromatography (HILIC) with optical detection, which provided limited N-glycome coverage in low throughput.
35934376	7	86	theme	1:100 M	1483:1489	arg1	ratio					1491:1495	a 1:100 M ratio	1481:1495	a 1:100 M ratio	1481:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	2	87	theme	DKD	398:400	arg1	diagnosis					385:393	the diagnosis	381:393	the diagnosis of DKD due to the lack of specificity and sensitivity	381:447	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	0	88	theme	kidney	52:57	arg1	disease					59:65	diabetic kidney disease	43:65	diabetic kidney disease	43:65	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	2	89	theme	sensitivity	437:447	arg1	lack					413:416	the lack	409:416	the lack of specificity and sensitivity	409:447	Although albuminuria and estimated glomerular filtration rate (eGFR) are commonly used diagnostic biomarkers, they have limitations in the diagnosis of DKD due to the lack of specificity and sensitivity.
35934376	3	90	theme	novel	484:488	arg1	biomarkers					490:499	novel biomarkers	484:499	novel biomarkers for predicting renal prognosis in DKD	484:537	Urinary N-glycans are emerging as novel biomarkers for predicting renal prognosis in DKD.
35934376	0	91	gly	glycoprotein	80:91	arg1	glycoprotein					80:91	ultrafast glycoprotein immobilization	70:106	ultrafast glycoprotein immobilization for glycan extraction (UltraGIG)	70:139	In-depth profiling of urinary N-glycome in diabetic kidney disease by ultrafast glycoprotein immobilization for glycan extraction (UltraGIG).
35934376	8	92	theme	compositions	1592:1603	arg1	total					1570:1574	A total	1568:1574	A total of 237 N-glycan compositions	1568:1603	A total of 237 N-glycan compositions were identified from urine samples with DKD and healthy controls, which representing the largest data set of N-glycome from DKD.
35934376	7	93	from	mixture	1455:1461	arg1	N-glycans					1436:1444	extracting N-glycans	1425:1444	extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio	1425:1495	The UltraGIG showed good selectivity towards glycans (extracting N-glycans from the mixture of IgG and BSA at a 1:100 M ratio) and samples loss was minimized (detection sensitivity at fmol level).
35934376	6	94	theme	high	1076:1079	arg1	%					1100:1100	over 98%	1093:1100	over 98%	1093:1100	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	6	94	theme	high	1076:1079	arg1	efficiency					1081:1090	high efficiency	1076:1090	high efficiency (over 98%)	1076:1101	In UltraGIG, proteins were rapidly (within 40 min) immobilized to resin with high efficiency (over 98%) through NHS-reactive chemistry, and then N-glycans were enzymatically released from the resin by PNGase F. Owing to good efficiency of immobilization of proteins to resin, the subsequent washing steps to remove proteins and other impurities could be easily performed.
35934376	10	95	theme	biomarker	1998:2006	arg1	study					2008:2012	biomarker study	1998:2012	biomarker study for the diagnosis of DKD	1998:2037	Collectively, UltraGIG offers a competitive sample purification method for in-depth analysis of urinary N-glycome by MS and provide new insights into biomarker study for the diagnosis of DKD.
35934376	3	96	theme	renal	516:520	arg1	prognosis					522:530	renal prognosis	516:530	renal prognosis	516:530	Urinary N-glycans are emerging as novel biomarkers for predicting renal prognosis in DKD.
35934376	1	97	theme	mellitus	236:243	arg1	complication					211:222	a common and serious kidney-related complication	175:222	a common and serious kidney-related complication of diabetic mellitus	175:243	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35934376	1	97	theme	mellitus	236:243	arg1	disease					158:164	Diabetic kidney disease	142:164	Diabetic kidney disease (DKD)	142:170	Diabetic kidney disease (DKD) is a common and serious kidney-related complication of diabetic mellitus.
35388686	3	0	from	analysis	722:729	arg1	digestion					765:773	proteolytic digestion	753:773	proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	753:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	1	1	theme	monosaccharide	277:290	arg1	patterns					300:307	monosaccharide linkage patterns	277:307	monosaccharide linkage patterns	277:307	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	2	2	theme	characterization	516:531	arg1	localization					480:491	the simultaneous localization	463:491	the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD	463:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	3	3	theme	glycopeptides	734:746	arg1	analysis					722:729	analysis	722:729	analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	722:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	4	from	HKU1	844:847	arg1	digestion					765:773	proteolytic digestion	753:773	proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	753:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	4	from	HKU1	844:847	arg1	proteins					815:822	recombinant human coronaviruse spike proteins	778:822	recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	778:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	1	5	theme	linkage	292:298	arg1	patterns					300:307	monosaccharide linkage patterns	277:307	monosaccharide linkage patterns	277:307	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	2	6	theme	linkages	581:588	arg1	latter					595:600	latter	595:600	latter	595:600	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	6	theme	linkages	581:588	arg1	glycosites					496:505	glycosites	496:505	glycosites	496:505	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	6	theme	linkages	581:588	arg1	characterization					516:531	full characterization	511:531	full characterization	511:531	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	7	theme	intersaccharide	565:579	arg1	linkages					581:588	intersaccharide linkages	565:588	intersaccharide linkages	565:588	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	3	8	theme	human	790:794	arg1	proteins					815:822	recombinant human coronaviruse spike proteins	778:822	recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	778:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	9	theme	coronaviruse	796:807	arg1	proteins					815:822	recombinant human coronaviruse spike proteins	778:822	recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	778:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	1	10	from	lability	318:325	arg1	patterns					300:307	monosaccharide linkage patterns	277:307	monosaccharide linkage patterns	277:307	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	2	11	theme	photodissociation	425:441	arg1	approach					450:457	an HCD-triggered-ultraviolet photodissociation (UVPD) approach	396:457	an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD	396:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	12	theme	compositions	548:559	arg1	latter					595:600	latter	595:600	latter	595:600	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	12	theme	compositions	548:559	arg1	glycosites					496:505	glycosites	496:505	glycosites	496:505	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	12	theme	compositions	548:559	arg1	characterization					516:531	full characterization	511:531	full characterization	511:531	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	13	theme	full	511:514	arg1	characterization					516:531	full characterization	511:531	full characterization	511:531	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	1	14	theme	vast	206:209	arg1	diversity					211:219	the vast diversity	202:219	the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein	202:371	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	3	15	theme	recombinant	778:788	arg1	proteins					815:822	recombinant human coronaviruse spike proteins	778:822	recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	778:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	2	16	theme	glycan	541:546	arg1	compositions					548:559	glycan compositions	541:559	glycan compositions	541:559	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	17	theme	simultaneous	467:478	arg1	localization					480:491	the simultaneous localization	463:491	the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD	463:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	3	18	from	SARS-CoV-2	829:838	arg1	digestion					765:773	proteolytic digestion	753:773	proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	753:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	18	from	SARS-CoV-2	829:838	arg1	proteins					815:822	recombinant human coronaviruse spike proteins	778:822	recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	778:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	0	19	theme	Spike	18:22	arg1	N-Glycosylation					32:46	Viral Spike Protein N-Glycosylation	12:46	Viral Spike Protein N-Glycosylation	12:46	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	1	20	theme	protein	123:129	arg1	glycosylation					131:143	protein glycosylation	123:143	protein glycosylation	123:143	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	1	21	theme	oligosaccharides	224:239	arg1	diversity					211:219	the vast diversity	202:219	the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein	202:371	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	0	22	theme	Viral	12:16	arg1	N-Glycosylation					32:46	Viral Spike Protein N-Glycosylation	12:46	Viral Spike Protein N-Glycosylation	12:46	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	3	23	theme	spike	809:813	arg1	proteins					815:822	recombinant human coronaviruse spike proteins	778:822	recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	778:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	24	theme	glycan	693:698	arg1	compositions					700:711	glycan compositions	693:711	glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	693:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	1	25	theme	glycosylation	131:143	arg1	Characterization					103:118	Characterization	103:118	Characterization of protein glycosylation by tandem mass spectrometry	103:171	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	2	26	theme	glycosites	496:505	arg1	localization					480:491	the simultaneous localization	463:491	the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD	463:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	0	27	theme	N-Glycosylation	32:46	arg1	Analysis					0:7	Analysis	0:7	Analysis of Viral Spike Protein N-Glycosylation	0:46	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	3	28	theme	proteins	815:822	arg1	digestion					765:773	proteolytic digestion	753:773	proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	753:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	2	29	theme	UVPD	444:447	arg1	approach					450:457	an HCD-triggered-ultraviolet photodissociation (UVPD) approach	396:457	an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD	396:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	0	30	theme	Protein	24:30	arg1	N-Glycosylation					32:46	Viral Spike Protein N-Glycosylation	12:46	Viral Spike Protein N-Glycosylation	12:46	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	4	31	link	N-linked	935:942	arg1	glycoforms					944:953	N-linked glycoforms	935:953	N-linked glycoforms with confidence	935:969	UVPD reveals unique intersaccharide linkage information and is leveraged to localize N-linked glycoforms with confidence.
35388686	0	32	theme	Ultraviolet	54:64	arg1	Spectrometry					89:100	Ultraviolet Photodissociation Mass Spectrometry	54:100	Ultraviolet Photodissociation Mass Spectrometry	54:100	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	1	33	theme	linkage	334:340	arg1	lability					318:325	the lability	314:325	the lability of the linkage between the glycan and protein	314:371	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	1	33	theme	linkage	334:340	arg1	variation					264:272	the variation	260:272	the variation in monosaccharide linkage patterns	260:307	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	1	33	theme	linkage	334:340	arg1	proteins					250:257	proteins	250:257	proteins	250:257	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	1	34	from	variation	264:272	arg1	patterns					300:307	monosaccharide linkage patterns	277:307	monosaccharide linkage patterns	277:307	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	1	35	from	proteins	250:257	arg1	patterns					300:307	monosaccharide linkage patterns	277:307	monosaccharide linkage patterns	277:307	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	3	36	from	digestion	765:773	arg1	HKU1					844:847	HKU1	844:847	HKU1	844:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	36	from	digestion	765:773	arg1	glycopeptides					734:746	glycopeptides	734:746	glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	734:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	36	from	digestion	765:773	arg1	SARS-CoV-2					829:838	SARS-CoV-2	829:838	SARS-CoV-2	829:838	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	36	from	digestion	765:773	arg1	analysis					722:729	analysis	722:729	analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	722:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	2	37	theme	cross-ring	624:633	arg1	cleavages					635:643	extensive cross-ring cleavages	614:643	extensive cross-ring cleavages enabled by UVPD	614:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	38	gly	glycosites	496:505	arg2	glycosites					496:505	glycosites	496:505	glycosites	496:505	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	38	gly	glycosites	496:505	arg2	latter					595:600	latter	595:600	latter	595:600	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	38	gly	glycosites	496:505	arg1	compositions					548:559	glycan compositions	541:559	glycan compositions	541:559	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	2	38	gly	glycosites	496:505	arg1	linkages					581:588	intersaccharide linkages	565:588	intersaccharide linkages	565:588	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	1	39	theme	tandem	148:153	arg1	spectrometry					160:171	tandem mass spectrometry	148:171	tandem mass spectrometry	148:171	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	3	40	gly	glycopeptides	734:746	arg2	glycopeptides					734:746	glycopeptides	734:746	glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	734:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	3	40	gly	glycopeptides	734:746	arg1	digestion					765:773	proteolytic digestion	753:773	proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	753:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	2	41	theme	extensive	614:622	arg1	cleavages					635:643	extensive cross-ring cleavages	614:643	extensive cross-ring cleavages enabled by UVPD	614:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	4	42	theme	unique	863:868	arg1	information					894:904	unique intersaccharide linkage information	863:904	unique intersaccharide linkage information	863:904	UVPD reveals unique intersaccharide linkage information and is leveraged to localize N-linked glycoforms with confidence.
35388686	1	43	theme	mass	155:158	arg1	spectrometry					160:171	tandem mass spectrometry	148:171	tandem mass spectrometry	148:171	Characterization of protein glycosylation by tandem mass spectrometry remains challenging owing to the vast diversity of oligosaccharides bound to proteins, the variation in monosaccharide linkage patterns, and the lability of the linkage between the glycan and protein.
35388686	0	44	theme	Mass	84:87	arg1	Spectrometry					89:100	Ultraviolet Photodissociation Mass Spectrometry	54:100	Ultraviolet Photodissociation Mass Spectrometry	54:100	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	4	45	theme	linkage	886:892	arg1	information					894:904	unique intersaccharide linkage information	863:904	unique intersaccharide linkage information	863:904	UVPD reveals unique intersaccharide linkage information and is leveraged to localize N-linked glycoforms with confidence.
35388686	2	46	theme	HCD-triggered-ultraviolet	399:423	arg1	approach					450:457	an HCD-triggered-ultraviolet photodissociation (UVPD) approach	396:457	an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD	396:659	Here, we have adapted an HCD-triggered-ultraviolet photodissociation (UVPD) approach for the simultaneous localization of glycosites and full characterization of both glycan compositions and intersaccharide linkages, the latter provided by extensive cross-ring cleavages enabled by UVPD.
35388686	0	47	theme	Photodissociation	66:82	arg1	Spectrometry					89:100	Ultraviolet Photodissociation Mass Spectrometry	54:100	Ultraviolet Photodissociation Mass Spectrometry	54:100	Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.
35388686	3	48	theme	proteolytic	753:763	arg1	digestion					765:773	proteolytic digestion	753:773	proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1	753:847	The method is applied to study glycan compositions based on analysis of glycopeptides from proteolytic digestion of recombinant human coronaviruse spike proteins from SARS-CoV-2 and HKU1.
35388686	4	49	theme	intersaccharide	870:884	arg1	information					894:904	unique intersaccharide linkage information	863:904	unique intersaccharide linkage information	863:904	UVPD reveals unique intersaccharide linkage information and is leveraged to localize N-linked glycoforms with confidence.
35388686	4	50	theme	N-linked	935:942	arg1	glycoforms					944:953	N-linked glycoforms	935:953	N-linked glycoforms with confidence	935:969	UVPD reveals unique intersaccharide linkage information and is leveraged to localize N-linked glycoforms with confidence.
35388686	4	51	with	glycoforms	944:953	arg1	confidence					960:969	confidence	960:969	confidence	960:969	UVPD reveals unique intersaccharide linkage information and is leveraged to localize N-linked glycoforms with confidence.
36233110	6	0	theme	immune	1310:1315	arg1	reactions					1317:1325	adverse immune reactions	1302:1325	adverse immune reactions	1302:1325	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	4	1	theme	N-glycosylation	923:937	arg1	sites					939:943	all five N-glycosylation sites	914:943	all five N-glycosylation sites	914:943	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	1	theme	N-glycosylation	923:937	arg1	group					973:977	a group	971:977	a group	971:977	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	2	2	theme	MSMS	339:342	arg1	mapping					344:350	Glycopeptide-based nano-LC MSMS mapping	312:350	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot	312:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	5	3	from	lots	1029:1032	arg1	sites					1088:1092	the two sites	1080:1092	the two sites of the VEGFR-2 domain	1080:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	3	from	lots	1029:1032	arg1	types					1048:1052	the glycan types	1037:1052	the glycan types	1037:1052	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	3	from	lots	1029:1032	arg1	domain					1109:1114	the VEGFR-2 domain	1097:1114	the VEGFR-2 domain	1097:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	6	4	theme	glycans	1275:1281	arg1	presence					1229:1236	The presence	1225:1236	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics,	1225:1351	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	1	5	theme	different	217:225	arg1	regions					227:233	three different regions	211:233	three different regions	211:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	2	6	theme	IgG	606:608	arg1	region					613:618	the human IgG Fc region	596:618	the human IgG Fc region	596:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	7	theme	samples	372:378	arg1	mapping					344:350	Glycopeptide-based nano-LC MSMS mapping	312:350	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot	312:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	7	8	theme	control	1629:1635	arg1	part					1613:1616	a part	1611:1616	a part of quality control	1611:1635	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	1	9	gly	glycosylation	150:162	arg1	samples					174:180	samples	174:180	samples of aflibercept obtained from three different regions	174:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	5	10	theme	VEGFR-2	1101:1107	arg1	domain					1109:1114	the VEGFR-2 domain	1097:1114	the VEGFR-2 domain	1097:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	3	11	theme	glycopeptide-mapping	632:651	arg1	results					653:659	the glycopeptide-mapping results	628:659	the glycopeptide-mapping results obtained from the three different aflibercept lots	628:710	Next, the glycopeptide-mapping results obtained from the three different aflibercept lots were compared to evaluate the similarity between the samples.
36233110	4	12	from	level	887:891	arg1	composition					842:852	glycan composition	835:852	glycan composition	835:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	6	13	theme	domain	1437:1442	arg1	site					1444:1447	the IgG Fc domain site	1426:1447	the IgG Fc domain site	1426:1447	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	1	14	theme	protein	142:148	arg1	states					164:169	the protein glycosylation states	138:169	the protein glycosylation states of samples of aflibercept obtained from three different regions	138:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	7	15	theme	applicable	1735:1744	arg1	outcome					1746:1752	a more applicable outcome	1728:1752	a more applicable outcome	1728:1752	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	6	16	theme	N-glycolylneuraminic	1241:1260	arg1	NeuGc					1268:1272	NeuGc	1268:1272	NeuGc	1268:1272	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	6	16	theme	N-glycolylneuraminic	1241:1260	arg1	acid					1262:1265	N-glycolylneuraminic acid	1241:1265	N-glycolylneuraminic acid (NeuGc) glycans	1241:1281	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	4	17	theme	aflibercept	780:790	arg1	lots					792:795	Three aflibercept lots	774:795	Three aflibercept lots	774:795	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	2	18	theme	Glycopeptide-based	312:329	arg1	mapping					344:350	Glycopeptide-based nano-LC MSMS mapping	312:350	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot	312:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	1	19	theme	states	164:169	arg1	evaluation					124:133	The evaluation	120:133	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions	120:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	6	20	theme	domains	1406:1412	arg1	domains					1406:1412	VEGFR1 and VEGFR2 domains	1388:1412	VEGFR1 and VEGFR2 domains	1388:1412	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	6	20	theme	domains	1406:1412	arg1	sites					1379:1383	the sites	1375:1383	the sites of VEGFR1 and VEGFR2 domains	1375:1412	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	0	21	theme	Microheterogeneity	21:38	arg1	Evaluation					40:49	Site-Specific Glycan Microheterogeneity Evaluation	0:49	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.	0:118	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	4	22	from	composition	842:852	arg1	branching					898:906	branching	898:906	branching	898:906	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	22	from	composition	842:852	arg1	level					868:872	fucosylation level	855:872	fucosylation level	855:872	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	22	from	composition	842:852	arg1	degree					811:816	a high degree	804:816	a high degree of similarity in glycan composition	804:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	22	from	composition	842:852	arg1	level					887:891	sialylation level	875:891	sialylation level	875:891	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	1	23	theme	samples	174:180	arg1	states					164:169	the protein glycosylation states	138:169	the protein glycosylation states of samples of aflibercept obtained from three different regions	138:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	7	24	gly	N-glycosylation	1553:1567	arg2	sites					1569:1573	multiple N-glycosylation sites	1544:1573	multiple N-glycosylation sites	1544:1573	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	2	25	from	sites	518:522	arg1	region					613:618	the human IgG Fc region	596:618	the human IgG Fc region	596:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	25	from	sites	518:522	arg1	region					572:577	the VEGFR-2 region	560:577	the VEGFR-2 region	560:577	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	25	from	sites	518:522	arg1	region					539:544	the VEGFR-1 region	527:544	the VEGFR-1 region	527:544	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	0	26	theme	LC-MSMS	103:109	arg1	Mapping					111:117	Glycopeptide-Based LC-MSMS Mapping	84:117	Glycopeptide-Based LC-MSMS Mapping	84:117	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	1	27	theme	aflibercept	185:195	arg1	samples					174:180	samples	174:180	samples of aflibercept obtained from three different regions	174:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	2	28	gly	N-glycosylation	491:505	arg2	sites					507:511	the five N-glycosylation sites	482:511	the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region)	482:619	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	28	gly	N-glycosylation	491:505	arg2	five					486:489	five	486:489	five	486:489	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	5	29	theme	noticeable	999:1008	arg1	variations					1010:1019	noticeable variations	999:1019	noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain	999:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	2	30	theme	VEGFR-1	531:537	arg1	region					539:544	the VEGFR-1 region	527:544	the VEGFR-1 region	527:544	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	0	31	theme	Site-Specific	0:12	arg1	Evaluation					40:49	Site-Specific Glycan Microheterogeneity Evaluation	0:49	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.	0:118	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	4	32	theme	high	806:809	arg1	degree					811:816	a high degree	804:816	a high degree of similarity in glycan composition	804:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	6	33	theme	IgG	1430:1432	arg1	site					1444:1447	the IgG Fc domain site	1426:1447	the IgG Fc domain site	1426:1447	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	7	34	theme	multiple	1544:1551	arg1	sites					1569:1573	multiple N-glycosylation sites	1544:1573	multiple N-glycosylation sites	1544:1573	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	2	35	dep	sites	507:511	arg1	sites					518:522	two sites	514:522	two sites in the VEGFR-1 region	514:544	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	35	dep	sites	507:511	arg1	site					588:591	one site	584:591	one site in the human IgG Fc region	584:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	35	dep	sites	507:511	arg1	sites					551:555	two sites	547:555	two sites in the VEGFR-2 region	547:577	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	7	36	theme	proteins	1524:1531	arg1	profiles					1505:1512	the glycosylation profiles	1487:1512	the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept	1487:1594	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	3	37	theme	different	685:693	arg1	lots					707:710	the three different aflibercept lots	675:710	the three different aflibercept lots	675:710	Next, the glycopeptide-mapping results obtained from the three different aflibercept lots were compared to evaluate the similarity between the samples.
36233110	0	38	theme	Fusion	66:71	arg1	Protein					73:79	Aflibercept Fusion Protein	54:79	Aflibercept Fusion Protein	54:79	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	1	39	theme	site-specific	252:264	arg1	profiling					301:309	site-specific N-linked glycan microheterogeneity profiling	252:309	site-specific N-linked glycan microheterogeneity profiling	252:309	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	7	40	theme	glycosylation	1491:1503	arg1	profiles					1505:1512	the glycosylation profiles	1487:1512	the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept	1487:1594	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	4	41	theme	fucosylation	855:866	arg1	level					868:872	fucosylation level	855:872	fucosylation level	855:872	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	6	42	located	detected	1363:1370	arg1	domains					1406:1412	VEGFR1 and VEGFR2 domains	1388:1412	VEGFR1 and VEGFR2 domains	1388:1412	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	6	42	located	detected	1363:1370	arg1	sites					1379:1383	the sites	1375:1383	the sites of VEGFR1 and VEGFR2 domains	1375:1412	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	6	42	located	detected	1363:1370	arg2	presence					1229:1236	The presence	1225:1236	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics,	1225:1351	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	1	43	theme	glycan	275:280	arg1	profiling					301:309	site-specific N-linked glycan microheterogeneity profiling	252:309	site-specific N-linked glycan microheterogeneity profiling	252:309	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	5	44	theme	glycan	1041:1046	arg1	types					1048:1052	the glycan types	1037:1052	the glycan types	1037:1052	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	2	45	theme	glycan	445:450	arg1	microheterogeneity					452:469	glycan microheterogeneity	445:469	glycan microheterogeneity	445:469	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	6	46	theme	adverse	1302:1308	arg1	reactions					1317:1325	adverse immune reactions	1302:1325	adverse immune reactions	1302:1325	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	2	47	theme	tryptic-digested	355:370	arg1	samples					372:378	tryptic-digested samples	355:378	tryptic-digested samples of each aflibercept lot	355:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	48	from	information	427:437	arg1	sites					507:511	the five N-glycosylation sites	482:511	the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region)	482:619	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	48	from	information	427:437	arg1	each					474:477	each	474:477	each	474:477	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	5	49	gly	N-glycosylation	1152:1166	arg2	sites					1168:1172	the five N-glycosylation sites	1143:1172	the five N-glycosylation sites	1143:1172	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	49	gly	N-glycosylation	1152:1166	arg2	five					1147:1150	five	1147:1150	five	1147:1150	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	2	50	theme	aflibercept	388:398	arg1	lot					400:402	each aflibercept lot	383:402	each aflibercept lot	383:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	1	51	link	N-linked	266:273	arg1	profiling					301:309	site-specific N-linked glycan microheterogeneity profiling	252:309	site-specific N-linked glycan microheterogeneity profiling	252:309	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	5	52	from	levels	1070:1075	arg1	sites					1088:1092	the two sites	1080:1092	the two sites of the VEGFR-2 domain	1080:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	52	from	levels	1070:1075	arg1	types					1048:1052	the glycan types	1037:1052	the glycan types	1037:1052	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	52	from	levels	1070:1075	arg1	domain					1109:1114	the VEGFR-2 domain	1097:1114	the VEGFR-2 domain	1097:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	7	53	contain	containing	1533:1542	arg2	sites					1569:1573	multiple N-glycosylation sites	1544:1573	multiple N-glycosylation sites	1544:1573	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	7	53	contain	containing	1533:1542	arg1	aflibercept					1584:1594	aflibercept	1584:1594	aflibercept	1584:1594	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	7	53	contain	containing	1533:1542	arg1	proteins					1524:1531	fusion proteins	1517:1531	fusion proteins	1517:1531	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	7	54	theme	quality	1621:1627	arg1	control					1629:1635	quality control	1621:1635	quality control	1621:1635	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	2	55	theme	human	600:604	arg1	region					613:618	the human IgG Fc region	596:618	the human IgG Fc region	596:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	4	56	gly	N-glycosylation	923:937	arg2	sites					939:943	all five N-glycosylation sites	914:943	all five N-glycosylation sites	914:943	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	56	gly	N-glycosylation	923:937	arg2	five					918:921	five	918:921	five	918:921	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	56	gly	N-glycosylation	923:937	arg2	group					973:977	a group	971:977	a group	971:977	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	5	57	theme	domain	1109:1114	arg1	sites					1088:1092	the two sites	1080:1092	the two sites of the VEGFR-2 domain	1080:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	57	theme	domain	1109:1114	arg1	domain					1109:1114	the VEGFR-2 domain	1097:1114	the VEGFR-2 domain	1097:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	6	58	theme	acid	1262:1265	arg1	glycans					1275:1281	N-glycolylneuraminic acid (NeuGc) glycans	1241:1281	N-glycolylneuraminic acid (NeuGc) glycans	1241:1281	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	6	59	theme	antibody	1330:1337	arg1	therapeutics					1339:1350	antibody therapeutics	1330:1350	antibody therapeutics	1330:1350	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	2	60	theme	nano-LC	331:337	arg1	mapping					344:350	Glycopeptide-based nano-LC MSMS mapping	312:350	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot	312:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	4	61	from	level	868:872	arg1	composition					842:852	glycan composition	835:852	glycan composition	835:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	1	62	theme	glycosylation	150:162	arg1	states					164:169	the protein glycosylation states	138:169	the protein glycosylation states of samples of aflibercept obtained from three different regions	138:233	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	2	63	theme	Fc	610:611	arg1	region					613:618	the human IgG Fc region	596:618	the human IgG Fc region	596:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	64	from	site	588:591	arg1	region					613:618	the human IgG Fc region	596:618	the human IgG Fc region	596:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	64	from	site	588:591	arg1	region					572:577	the VEGFR-2 region	560:577	the VEGFR-2 region	560:577	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	64	from	site	588:591	arg1	region					539:544	the VEGFR-1 region	527:544	the VEGFR-1 region	527:544	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	0	65	theme	Glycopeptide-Based	84:101	arg1	Mapping					111:117	Glycopeptide-Based LC-MSMS Mapping	84:117	Glycopeptide-Based LC-MSMS Mapping	84:117	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	5	66	located	observed	1121:1128	arg1	hand					993:996	the other hand	983:996	the other hand	983:996	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	66	located	observed	1121:1128	arg2	variations					1010:1019	noticeable variations	999:1019	noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain	999:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	7	67	gly	glycosylation	1491:1503	arg1	aflibercept					1584:1594	aflibercept	1584:1594	aflibercept	1584:1594	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	7	67	gly	glycosylation	1491:1503	arg1	proteins					1524:1531	fusion proteins	1517:1531	fusion proteins	1517:1531	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	2	68	theme	VEGFR-2	564:570	arg1	region					572:577	the VEGFR-2 region	560:577	the VEGFR-2 region	560:577	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	6	69	theme	VEGFR2	1399:1404	arg1	domains					1406:1412	VEGFR1 and VEGFR2 domains	1388:1412	VEGFR1 and VEGFR2 domains	1388:1412	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	6	70	theme	VEGFR1	1388:1393	arg1	domains					1406:1412	VEGFR1 and VEGFR2 domains	1388:1412	VEGFR1 and VEGFR2 domains	1388:1412	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	5	71	theme	N-glycosylation	1152:1166	arg1	sites					1168:1172	the five N-glycosylation sites	1143:1172	the five N-glycosylation sites	1143:1172	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	4	72	from	similarity	821:830	arg1	composition					842:852	glycan composition	835:852	glycan composition	835:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	73	from	branching	898:906	arg1	composition					842:852	glycan composition	835:852	glycan composition	835:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	74	from	degree	811:816	arg1	composition					842:852	glycan composition	835:852	glycan composition	835:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	2	75	from	sites	551:555	arg1	region					613:618	the human IgG Fc region	596:618	the human IgG Fc region	596:618	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	75	from	sites	551:555	arg1	region					572:577	the VEGFR-2 region	560:577	the VEGFR-2 region	560:577	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	2	75	from	sites	551:555	arg1	region					539:544	the VEGFR-1 region	527:544	the VEGFR-1 region	527:544	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	4	76	theme	similarity	821:830	arg1	branching					898:906	branching	898:906	branching	898:906	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	76	theme	similarity	821:830	arg1	level					868:872	fucosylation level	855:872	fucosylation level	855:872	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	76	theme	similarity	821:830	arg1	degree					811:816	a high degree	804:816	a high degree of similarity in glycan composition	804:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	4	76	theme	similarity	821:830	arg1	level					887:891	sialylation level	875:891	sialylation level	875:891	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	0	77	theme	Glycan	14:19	arg1	Evaluation					40:49	Site-Specific Glycan Microheterogeneity Evaluation	0:49	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.	0:118	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	7	78	theme	biosimilar	1687:1696	arg1	development					1698:1708	biosimilar development	1687:1708	biosimilar development	1687:1708	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	6	79	theme	Fc	1434:1435	arg1	site					1444:1447	the IgG Fc domain site	1426:1447	the IgG Fc domain site	1426:1447	The presence of N-glycolylneuraminic acid (NeuGc) glycans, which may mediate adverse immune reactions in antibody therapeutics, were also detected on the sites of VEGFR1 and VEGFR2 domains, but not on the IgG Fc domain site.
36233110	5	80	theme	glycopeptide-based	1198:1215	arg1	method					1217:1222	the glycopeptide-based method	1194:1222	the glycopeptide-based method	1194:1222	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	5	81	theme	other	987:991	arg1	hand					993:996	the other hand	983:996	the other hand	983:996	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	3	82	theme	aflibercept	695:705	arg1	lots					707:710	the three different aflibercept lots	675:710	the three different aflibercept lots	675:710	Next, the glycopeptide-mapping results obtained from the three different aflibercept lots were compared to evaluate the similarity between the samples.
36233110	0	83	theme	Aflibercept	54:64	arg1	Protein					73:79	Aflibercept Fusion Protein	54:79	Aflibercept Fusion Protein	54:79	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	7	84	theme	N-glycosylation	1553:1567	arg1	sites					1569:1573	multiple N-glycosylation sites	1544:1573	multiple N-glycosylation sites	1544:1573	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	2	85	theme	N-glycosylation	491:505	arg1	sites					507:511	the five N-glycosylation sites	482:511	the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region)	482:619	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	0	86	theme	Protein	73:79	arg1	Evaluation					40:49	Site-Specific Glycan Microheterogeneity Evaluation	0:49	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.	0:118	Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
36233110	5	87	theme	sialylation	1058:1068	arg1	levels					1070:1075	sialylation levels	1058:1075	sialylation levels on the two sites of the VEGFR-2 domain	1058:1114	On the other hand, noticeable variations between lots in the glycan types and sialylation levels on the two sites of the VEGFR-2 domain were observed when each of the five N-glycosylation sites were assessed using the glycopeptide-based method.
36233110	4	88	theme	sialylation	875:885	arg1	level					887:891	sialylation level	875:891	sialylation level	875:891	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	2	89	theme	site-specific	413:425	arg1	information					427:437	site-specific information	413:437	site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region)	413:619	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	7	90	theme	fusion	1517:1522	arg1	aflibercept					1584:1594	aflibercept	1584:1594	aflibercept	1584:1594	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	7	90	theme	fusion	1517:1522	arg1	proteins					1524:1531	fusion proteins	1517:1531	fusion proteins	1517:1531	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	4	91	theme	glycan	835:840	arg1	composition					842:852	glycan composition	835:852	glycan composition	835:852	Three aflibercept lots showed a high degree of similarity in glycan composition, fucosylation level, sialylation level, and branching, when all five N-glycosylation sites were assessed together as a group.
36233110	2	92	theme	lot	400:402	arg1	samples					372:378	tryptic-digested samples	355:378	tryptic-digested samples of each aflibercept lot	355:402	Glycopeptide-based nano-LC MSMS mapping of tryptic-digested samples of each aflibercept lot provided site-specific information about glycan microheterogeneity on each of the five N-glycosylation sites (two sites in the VEGFR-1 region, two sites in the VEGFR-2 region, and one site in the human IgG Fc region).
36233110	1	93	theme	N-linked	266:273	arg1	profiling					301:309	site-specific N-linked glycan microheterogeneity profiling	252:309	site-specific N-linked glycan microheterogeneity profiling	252:309	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36233110	7	94	theme	profiles	1505:1512	arg1	analyses					1475:1482	analyses	1475:1482	analyses	1475:1482	These results imply that analyses of the glycosylation profiles of fusion proteins containing multiple N-glycosylation sites, such as aflibercept, being done as a part of quality control for the therapeutics manufacturing process or for biosimilar development, can be done with a more applicable outcome by assessing each site separately.
36233110	1	95	theme	microheterogeneity	282:299	arg1	profiling					301:309	site-specific N-linked glycan microheterogeneity profiling	252:309	site-specific N-linked glycan microheterogeneity profiling	252:309	The evaluation of the protein glycosylation states of samples of aflibercept obtained from three different regions was conducted by site-specific N-linked glycan microheterogeneity profiling.
36266689	8	0	theme	diatom	1276:1281	arg1	tricornutum					1286:1296	diatom P. tricornutum	1276:1296	diatom P. tricornutum	1276:1296	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	8	1	theme	P.	1283:1284	arg1	tricornutum					1286:1296	diatom P. tricornutum	1276:1296	diatom P. tricornutum	1276:1296	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	7	2	theme	ERQC	994:997	arg1	pathway					999:1005	ERQC pathway	994:1005	ERQC pathway	994:1005	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	9	3	theme	related	1533:1539	arg1	mechanism					1541:1549	the related mechanism	1529:1549	the related mechanism	1529:1549	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	8	4	theme	N-glycans	1187:1195	arg1	identification					1169:1182	The identification	1165:1182	The identification of N-glycans, especially complex-type N-glycan structures	1165:1240	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	5	5	theme	neutral	741:747	arg1	lipid					749:753	neutral lipid	741:753	neutral lipid	741:753	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36266689	6	6	theme	ERQC	927:930	arg1	expression					913:922	the differential expression	896:922	the differential expression of ERQC and ERAD related genes	896:953	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	7	7	theme	genes	976:980	arg1	important					1118:1126	important	1118:1126	important	1118:1126	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	7	theme	genes	976:980	arg1	expression					1061:1070	the differential expression	1044:1070	the differential expression of genes related with ERAD mechanism	1044:1107	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	7	theme	genes	976:980	arg1	upregulation					960:971	The upregulation	956:971	The upregulation of genes involved in ERQC pathway	956:1005	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	7	theme	genes	976:980	arg1	activation					1012:1021	the activation	1008:1021	the activation of anti-oxidases	1008:1038	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	9	8	theme	mechanism	1541:1549	arg1	study					1520:1524	further in-depth study	1503:1524	further in-depth study of the related mechanism and the diatom expression system	1503:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	0	9	theme	N-glycan	138:145	arg1	structures					147:156	N-glycan structures	138:156	N-glycan structures	138:156	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	7	10	theme	genes	1075:1079	arg1	important					1118:1126	important	1118:1126	important	1118:1126	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	10	theme	genes	1075:1079	arg1	expression					1061:1070	the differential expression	1044:1070	the differential expression of genes related with ERAD mechanism	1044:1107	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	10	theme	genes	1075:1079	arg1	upregulation					960:971	The upregulation	956:971	The upregulation of genes involved in ERQC pathway	956:1005	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	10	theme	genes	1075:1079	arg1	activation					1012:1021	the activation	1008:1021	the activation of anti-oxidases	1008:1038	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	0	11	dep	N-glycoproteins	118:132	arg1	the					114:116	the	114:116	the	114:116	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	4	12	theme	cell	548:551	arg1	growth					553:558	cell growth	548:558	cell growth	548:558	The results showed that cell growth and photosynthesis were significantly inhibited in P. tricornutum under the tunicamycin stress.
36266689	9	13	theme	ERAD	1462:1465	arg1	models					1443:1448	models	1443:1448	models of ERQC and ERAD	1443:1465	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	7	14	theme	differential	1048:1059	arg1	expression					1061:1070	the differential expression	1044:1070	the differential expression of genes related with ERAD mechanism	1044:1107	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	14	theme	differential	1048:1059	arg1	important					1118:1126	important	1118:1126	important	1118:1126	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	2	15	theme	tunicamycin	346:356	arg1	effects					335:341	the physiological, transcriptomic, and N-glycomic effects	285:341	the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum	285:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	2	15	theme	tunicamycin	346:356	arg1	unknown					421:427	unknown	421:427	unknown	421:427	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	6	16	theme	differential	900:911	arg1	expression					913:922	the differential expression	896:922	the differential expression of ERQC and ERAD related genes	896:953	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	9	17	theme	ERQC	1453:1456	arg1	models					1443:1448	models	1443:1448	models of ERQC and ERAD	1443:1465	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	1	18	theme	first	224:228	arg1	step					230:233	the first step	220:233	the first step of protein N-glycosylation modification	220:273	Tunicamycin inhibits the first step of protein N-glycosylation modification.
36266689	8	19	from	function	1350:1357	arg1	proteins					1394:1401	proteins	1394:1401	proteins	1394:1401	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	0	20	gly	N-glycoproteins	118:132	arg1	N-glycoproteins					118:132	N-glycoproteins	118:132	N-glycoproteins	118:132	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	3	21	theme	stress	516:521	arg1	effects					493:499	the effects	489:499	the effects of tunicamycin stress	489:521	In this study, comprehensive approaches were used to study the effects of tunicamycin stress.
36266689	0	22	theme	reticulum-quality	12:28	arg1	pathway					38:44	Endoplasmic reticulum-quality control pathway	0:44	Endoplasmic reticulum-quality control pathway	0:44	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	5	23	theme	soluble	723:729	arg1	sugar					731:735	the soluble sugar	719:735	the soluble sugar	719:735	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36266689	5	24	theme	soluble	660:666	arg1	content					676:682	The soluble protein content	656:682	The soluble protein content	656:682	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36266689	2	25	theme	Phaeodactylum	385:397	arg1	tricornutum					399:409	important marine diatom Phaeodactylum tricornutum	361:409	important marine diatom Phaeodactylum tricornutum	361:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	8	26	theme	N-glycan	1222:1229	arg1	structures					1231:1240	complex-type N-glycan structures	1209:1240	especially complex-type N-glycan structures	1198:1240	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	8	26	theme	N-glycan	1222:1229	arg1	N-glycans					1187:1195	N-glycans	1187:1195	N-glycans	1187:1195	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	3	27	theme	comprehensive	445:457	arg1	approaches					459:468	comprehensive approaches	445:468	comprehensive approaches	445:468	In this study, comprehensive approaches were used to study the effects of tunicamycin stress.
36266689	0	28	theme	Endoplasmic	0:10	arg1	pathway					38:44	Endoplasmic reticulum-quality control pathway	0:44	Endoplasmic reticulum-quality control pathway	0:44	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	4	29	theme	tunicamycin	636:646	arg1	stress					648:653	the tunicamycin stress	632:653	the tunicamycin stress	632:653	The results showed that cell growth and photosynthesis were significantly inhibited in P. tricornutum under the tunicamycin stress.
36266689	5	30	theme	protein	668:674	arg1	content					676:682	The soluble protein content	656:682	The soluble protein content	656:682	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36266689	2	31	theme	diatom	378:383	arg1	tricornutum					399:409	important marine diatom Phaeodactylum tricornutum	361:409	important marine diatom Phaeodactylum tricornutum	361:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	1	32	theme	protein	238:244	arg1	modification					262:273	protein N-glycosylation modification	238:273	protein N-glycosylation modification	238:273	Tunicamycin inhibits the first step of protein N-glycosylation modification.
36266689	9	33	dep	working	1435:1441	arg1	provide					1472:1478	provide	1472:1478	will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system	1467:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	0	34	theme	diatom	165:170	arg1	tricornutum					186:196	the diatom Phaeodactylum tricornutum	161:196	the diatom Phaeodactylum tricornutum	161:196	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	6	35	theme	tunicamycin	872:882	arg1	stress					850:855	The stress	846:855	The stress of 0.3 μg ml-1 tunicamycin	846:882	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	2	36	theme	marine	371:376	arg1	tricornutum					399:409	important marine diatom Phaeodactylum tricornutum	361:409	important marine diatom Phaeodactylum tricornutum	361:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	1	37	theme	N-glycosylation	246:260	arg1	modification					262:273	protein N-glycosylation modification	238:273	protein N-glycosylation modification	238:273	Tunicamycin inhibits the first step of protein N-glycosylation modification.
36266689	0	38	theme	control	30:36	arg1	pathway					38:44	Endoplasmic reticulum-quality control pathway	0:44	Endoplasmic reticulum-quality control pathway	0:44	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	2	39	theme	N-glycomic	324:333	arg1	effects					335:341	the physiological, transcriptomic, and N-glycomic effects	285:341	the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum	285:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	2	39	theme	N-glycomic	324:333	arg1	unknown					421:427	unknown	421:427	unknown	421:427	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	0	40	from	N-glycoproteins	118:132	arg1	tricornutum					186:196	the diatom Phaeodactylum tricornutum	161:196	the diatom Phaeodactylum tricornutum	161:196	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	2	41	theme	important	361:369	arg1	tricornutum					399:409	important marine diatom Phaeodactylum tricornutum	361:409	important marine diatom Phaeodactylum tricornutum	361:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	6	42	dep	ERQC	927:930	arg1	genes					949:953	related genes	941:953	related genes	941:953	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	1	43	theme	modification	262:273	arg1	step					230:233	the first step	220:233	the first step of protein N-glycosylation modification	220:273	Tunicamycin inhibits the first step of protein N-glycosylation modification.
36266689	0	44	theme	endoplasmic	50:60	arg1	degradation					83:93	endoplasmic reticulum-associated degradation	50:93	endoplasmic reticulum-associated degradation	50:93	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	8	45	theme	complex-type	1209:1220	arg1	structures					1231:1240	complex-type N-glycan structures	1209:1240	especially complex-type N-glycan structures	1198:1240	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	8	45	theme	complex-type	1209:1220	arg1	N-glycans					1187:1195	N-glycans	1187:1195	N-glycans	1187:1195	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	5	46	theme	carbon	813:818	arg1	balance					802:808	the balance	798:808	the balance of carbon and nitrogen metabolisms	798:843	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36266689	3	47	theme	tunicamycin	504:514	arg1	stress					516:521	tunicamycin stress	504:521	tunicamycin stress	504:521	In this study, comprehensive approaches were used to study the effects of tunicamycin stress.
36266689	9	48	theme	solid	1482:1486	arg1	foundation					1488:1497	a solid foundation	1480:1497	a solid foundation for further in-depth study of the related mechanism and the diatom expression system	1480:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	0	49	theme	Phaeodactylum	172:184	arg1	tricornutum					186:196	the diatom Phaeodactylum tricornutum	161:196	the diatom Phaeodactylum tricornutum	161:196	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	2	50	theme	physiological	289:301	arg1	effects					335:341	the physiological, transcriptomic, and N-glycomic effects	285:341	the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum	285:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	2	50	theme	physiological	289:301	arg1	unknown					421:427	unknown	421:427	unknown	421:427	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	6	51	theme	0.3 μg ml-1	860:870	arg1	tunicamycin					872:882	0.3 μg ml-1 tunicamycin	860:882	0.3 μg ml-1 tunicamycin	860:882	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	9	52	theme	further	1503:1509	arg1	study					1520:1524	further in-depth study	1503:1524	further in-depth study of the related mechanism and the diatom expression system	1503:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	8	53	theme	N-glycosylation	1362:1376	arg1	modification					1378:1389	N-glycosylation modification	1362:1389	N-glycosylation modification	1362:1389	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	8	54	theme	tricornutum	1286:1296	arg1	database					1264:1271	the N-glycan database	1251:1271	the N-glycan database of diatom P. tricornutum	1251:1296	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	8	55	theme	N-glycan	1255:1262	arg1	database					1264:1271	the N-glycan database	1251:1271	the N-glycan database of diatom P. tricornutum	1251:1296	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	9	56	theme	diatom	1559:1564	arg1	system					1577:1582	the diatom expression system	1555:1582	the diatom expression system	1555:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	0	57	theme	reticulum-associated	62:81	arg1	degradation					83:93	endoplasmic reticulum-associated degradation	50:93	endoplasmic reticulum-associated degradation	50:93	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	3	58	used	used	475:478	arg2	approaches					459:468	comprehensive approaches	445:468	comprehensive approaches	445:468	In this study, comprehensive approaches were used to study the effects of tunicamycin stress.
36266689	6	59	theme	related	941:947	arg1	genes					949:953	related genes	941:953	related genes	941:953	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	7	60	theme	anti-oxidases	1026:1038	arg1	important					1118:1126	important	1118:1126	important	1118:1126	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	60	theme	anti-oxidases	1026:1038	arg1	expression					1061:1070	the differential expression	1044:1070	the differential expression of genes related with ERAD mechanism	1044:1107	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	60	theme	anti-oxidases	1026:1038	arg1	upregulation					960:971	The upregulation	956:971	The upregulation of genes involved in ERQC pathway	956:1005	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	7	60	theme	anti-oxidases	1026:1038	arg1	activation					1012:1021	the activation	1008:1021	the activation of anti-oxidases	1008:1038	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	0	61	from	structures	147:156	arg1	tricornutum					186:196	the diatom Phaeodactylum tricornutum	161:196	the diatom Phaeodactylum tricornutum	161:196	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	0	62	dep	pathway	38:44	arg1	mechanism					95:103	mechanism	95:103	mechanism	95:103	Endoplasmic reticulum-quality control pathway and endoplasmic reticulum-associated degradation mechanism regulate the N-glycoproteins and N-glycan structures in the diatom Phaeodactylum tricornutum.
36266689	2	63	from	effects	335:341	arg1	tricornutum					399:409	important marine diatom Phaeodactylum tricornutum	361:409	important marine diatom Phaeodactylum tricornutum	361:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	9	64	theme	expression	1566:1575	arg1	system					1577:1582	the diatom expression system	1555:1582	the diatom expression system	1555:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	6	65	theme	ERAD	936:939	arg1	expression					913:922	the differential expression	896:922	the differential expression of ERQC and ERAD related genes	896:953	The stress of 0.3 μg ml-1 tunicamycin resulted in the differential expression of ERQC and ERAD related genes.
36266689	8	66	theme	important	1311:1319	arg1	information					1321:1331	important information	1311:1331	important information for studying the function of N-glycosylation modification on proteins	1311:1401	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	7	67	theme	ERAD	1094:1097	arg1	mechanism					1099:1107	ERAD mechanism	1094:1107	ERAD mechanism	1094:1107	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	9	68	theme	system	1577:1582	arg1	study					1520:1524	further in-depth study	1503:1524	further in-depth study of the related mechanism and the diatom expression system	1503:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	7	69	from	homeostasis	1144:1154	arg1	cell					1159:1162	cell	1159:1162	cell	1159:1162	The upregulation of genes involved in ERQC pathway, the activation of anti-oxidases and the differential expression of genes related with ERAD mechanism might be important for maintaining homeostasis in cell.
36266689	8	70	theme	modification	1378:1389	arg1	function					1350:1357	the function	1346:1357	the function of N-glycosylation modification on proteins	1346:1401	The identification of N-glycans, especially complex-type N-glycan structures enriched the N-glycan database of diatom P. tricornutum and provided important information for studying the function of N-glycosylation modification on proteins.
36266689	5	71	dep	carbon	813:818	arg1	metabolisms					833:843	metabolisms	833:843	metabolisms	833:843	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36266689	2	72	theme	transcriptomic	304:317	arg1	effects					335:341	the physiological, transcriptomic, and N-glycomic effects	285:341	the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum	285:409	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	2	72	theme	transcriptomic	304:317	arg1	unknown					421:427	unknown	421:427	unknown	421:427	However, the physiological, transcriptomic, and N-glycomic effects of tunicamycin on important marine diatom Phaeodactylum tricornutum are still unknown.
36266689	9	73	theme	in-depth	1511:1518	arg1	study					1520:1524	further in-depth study	1503:1524	further in-depth study of the related mechanism and the diatom expression system	1503:1582	As a whole, our study proposed working models of ERQC and ERAD will provide a solid foundation for further in-depth study of the related mechanism and the diatom expression system.
36266689	5	74	theme	nitrogen	824:831	arg1	balance					802:808	the balance	798:808	the balance of carbon and nitrogen metabolisms	798:843	The soluble protein content was significantly decreased, while the soluble sugar and neutral lipid were dramatically increased to orchestrate the balance of carbon and nitrogen metabolisms.
36513905	8	0	theme	Glycan	1019:1024	arg1	identities					1026:1035	Glycan identities	1019:1035	Glycan identities	1019:1035	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	2	1	dep	properties	307:316	arg1	the					303:305	the	303:305	the	303:305	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	7	2	dep	CONCLUSION	916:925	arg1	analysis					931:938	FLD analysis	927:938	CONCLUSION FLD analysis	916:938	RESULTS AND CONCLUSION FLD analysis identified 18 and 19 glycan peaks in adalimumab and trastuzumab, respectively.
36513905	3	3	from	species	431:437	arg1	products					462:469	biotherapeutic drug products	442:469	biotherapeutic drug products	442:469	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	10	4	theme	low	1380:1382	arg1	glycans					1394:1400	many low abundance glycans	1375:1400	many low abundance glycans identified by PRM	1375:1418	Notably, many low abundance glycans identified by PRM included species that were not reported in other studies.
36513905	3	5	theme	specific	517:524	arg1	methods					526:532	more sensitive and specific methods	498:532	more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function	498:613	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	6	6	theme	MS	891:892	arg1	analysis					894:901	the MS analysis	887:901	the MS analysis	887:901	A parallel reaction monitoring (PRM) workflow was used for the MS analysis.
36513905	10	7	theme	many	1375:1378	arg1	glycans					1394:1400	many low abundance glycans	1375:1400	many low abundance glycans identified by PRM	1375:1418	Notably, many low abundance glycans identified by PRM included species that were not reported in other studies.
36513905	5	8	theme	mass	804:807	arg1	MS					823:824	MS	823:824	MS	823:824	Glycans were separated using HILIC and detected using either fluorescence (FLD) or mass spectrometry (MS).
36513905	5	8	theme	mass	804:807	arg1	spectrometry					809:820	mass spectrometry	804:820	mass spectrometry (MS)	804:825	Glycans were separated using HILIC and detected using either fluorescence (FLD) or mass spectrometry (MS).
36513905	3	9	theme	established	369:379	arg1	methods					381:387	established methods	369:387	established methods	369:387	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	3	10	theme	low	563:565	arg1	species					577:583	low abundance species	563:583	low abundance species which may impact mAb function	563:613	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	12	11	theme	glycan	1777:1782	arg1	analysis					1784:1791	glycan analysis	1777:1791	glycan analysis	1777:1791	The results established PRM as a precise, informative tool for glycan analysis and quantitation.
36513905	1	12	theme	PURPOSE	76:82	arg1	composition					91:101	PURPOSE Glycan composition	76:101	PURPOSE Glycan composition	76:101	PURPOSE Glycan composition can impact a biotherapeutic's safety and efficacy.
36513905	8	13	theme	glycan	1124:1129	arg1	species					1131:1137	co-eluting glycan species	1113:1137	co-eluting glycan species	1113:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	9	14	theme	glycan	1188:1193	arg1	species					1195:1201	38 and 39 glycan species	1178:1201	38 and 39 glycan species	1178:1201	PRM analysis quantified 38 and 39 glycan species in adalimumab and trastuzumab, respectively, and the increase in glycans that could be identified was due to superior sensitivity and selectivity compared to FLD.
36513905	1	15	theme	Glycan	84:89	arg1	composition					91:101	PURPOSE Glycan composition	76:101	PURPOSE Glycan composition	76:101	PURPOSE Glycan composition can impact a biotherapeutic's safety and efficacy.
36513905	12	16	theme	precise	1747:1753	arg1	tool					1768:1771	a precise, informative tool	1745:1771	a precise, informative tool for glycan analysis and quantitation	1745:1808	The results established PRM as a precise, informative tool for glycan analysis and quantitation.
36513905	12	16	theme	precise	1747:1753	arg1	PRM					1738:1740	PRM	1738:1740	PRM	1738:1740	The results established PRM as a precise, informative tool for glycan analysis and quantitation.
36513905	0	17	theme	Monitoring	55:64	arg1	LC-MS/MS					66:73	Parallel Reaction Monitoring LC-MS/MS	37:73	Parallel Reaction Monitoring LC-MS/MS	37:73	Comprehensive N-Glycan Mapping using Parallel Reaction Monitoring LC-MS/MS.
36513905	7	18	theme	FLD	927:929	arg1	analysis					931:938	FLD analysis	927:938	CONCLUSION FLD analysis	916:938	RESULTS AND CONCLUSION FLD analysis identified 18 and 19 glycan peaks in adalimumab and trastuzumab, respectively.
36513905	0	19	theme	N-Glycan	14:21	arg1	Mapping					23:29	Comprehensive N-Glycan Mapping	0:29	Comprehensive N-Glycan Mapping	0:29	Comprehensive N-Glycan Mapping using Parallel Reaction Monitoring LC-MS/MS.
36513905	3	20	theme	biotherapeutic	442:455	arg1	products					462:469	biotherapeutic drug products	442:469	biotherapeutic drug products	442:469	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	0	21	theme	Comprehensive	0:12	arg1	Mapping					23:29	Comprehensive N-Glycan Mapping	0:29	Comprehensive N-Glycan Mapping	0:29	Comprehensive N-Glycan Mapping using Parallel Reaction Monitoring LC-MS/MS.
36513905	9	22	theme	superior	1312:1319	arg1	sensitivity					1321:1331	superior sensitivity	1312:1331	superior sensitivity	1312:1331	PRM analysis quantified 38 and 39 glycan species in adalimumab and trastuzumab, respectively, and the increase in glycans that could be identified was due to superior sensitivity and selectivity compared to FLD.
36513905	6	23	theme	monitoring	848:857	arg1	workflow					865:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow was used for the MS analysis.
36513905	6	24	theme	reaction	839:846	arg1	workflow					865:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow was used for the MS analysis.
36513905	3	25	theme	drug	457:460	arg1	products					462:469	biotherapeutic drug products	442:469	biotherapeutic drug products	442:469	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	8	26	theme	high	1077:1080	arg1	number					1082:1087	a high number	1075:1087	a high number of FLD peaks containing co-eluting glycan species	1075:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	2	27	theme	attributes	221:230	arg1	abundance					191:199	the relative abundance	178:199	the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content	178:290	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	3	28	theme	abundance	567:575	arg1	species					577:583	low abundance species	563:583	low abundance species which may impact mAb function	563:613	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	11	29	theme	unique	1526:1531	arg1	features					1544:1551	unique structural features	1526:1551	unique structural features	1526:1551	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	11	30	theme	MS	1623:1624	arg1	acquisition					1626:1636	de-coupling MS acquisition	1611:1636	de-coupling MS acquisition	1611:1636	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	11	31	theme	additional	1503:1512	arg1	advantages					1514:1523	several additional advantages	1495:1523	several additional advantages	1495:1523	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	2	32	theme	relative	182:189	arg1	abundance					191:199	the relative abundance	178:199	the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content	178:290	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	0	33	theme	Reaction	46:53	arg1	LC-MS/MS					66:73	Parallel Reaction Monitoring LC-MS/MS	37:73	Parallel Reaction Monitoring LC-MS/MS	37:73	Comprehensive N-Glycan Mapping using Parallel Reaction Monitoring LC-MS/MS.
36513905	0	34	theme	Parallel	37:44	arg1	LC-MS/MS					66:73	Parallel Reaction Monitoring LC-MS/MS	37:73	Parallel Reaction Monitoring LC-MS/MS	37:73	Comprehensive N-Glycan Mapping using Parallel Reaction Monitoring LC-MS/MS.
36513905	10	35	theme	other	1463:1467	arg1	studies					1469:1475	other studies	1463:1475	other studies	1463:1475	Notably, many low abundance glycans identified by PRM included species that were not reported in other studies.
36513905	6	36	theme	PRM	860:862	arg1	workflow					865:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow was used for the MS analysis.
36513905	11	37	theme	collected	1583:1591	arg1	spectra					1599:1605	the collected MS/MS spectra	1579:1605	the collected MS/MS spectra	1579:1605	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	3	38	theme	major	418:422	arg1	species					431:437	major glycan species	418:437	major glycan species in biotherapeutic drug products	418:469	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	8	39	theme	peaks	1096:1100	arg1	number					1082:1087	a high number	1075:1087	a high number of FLD peaks containing co-eluting glycan species	1075:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	6	40	used	used	878:881	arg2	workflow					865:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow was used for the MS analysis.
36513905	4	41	attach	released	632:639	arg1	trastuzumab					671:681	trastuzumab	671:681	trastuzumab	671:681	METHODS Glycans released from two mAbs, adalimumab and trastuzumab, were derivatized with Rapifluor-MS™.
36513905	4	41	attach	released	632:639	arg2	Glycans					624:630	METHODS Glycans	616:630	METHODS Glycans released from two mAbs, adalimumab and trastuzumab,	616:682	METHODS Glycans released from two mAbs, adalimumab and trastuzumab, were derivatized with Rapifluor-MS™.
36513905	4	41	attach	released	632:639	arg1	adalimumab					656:665	adalimumab	656:665	adalimumab	656:665	METHODS Glycans released from two mAbs, adalimumab and trastuzumab, were derivatized with Rapifluor-MS™.
36513905	4	41	attach	released	632:639	arg1	mAbs					650:653	two mAbs	646:653	two mAbs	646:653	METHODS Glycans released from two mAbs, adalimumab and trastuzumab, were derivatized with Rapifluor-MS™.
36513905	11	42	theme	MS/MS	1593:1597	arg1	spectra					1599:1605	the collected MS/MS spectra	1579:1605	the collected MS/MS spectra	1579:1605	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	8	43	contain	containing	1102:1111	arg1	peaks					1096:1100	FLD peaks	1092:1100	FLD peaks containing co-eluting glycan species	1092:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	8	43	contain	containing	1102:1111	arg2	species					1131:1137	co-eluting glycan species	1113:1137	co-eluting glycan species	1113:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	3	44	theme	glycan	424:429	arg1	species					431:437	major glycan species	418:437	major glycan species in biotherapeutic drug products	418:469	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	8	45	theme	FLD	1092:1094	arg1	peaks					1096:1100	FLD peaks	1092:1100	FLD peaks containing co-eluting glycan species	1092:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	2	46	theme	glycan	214:219	arg1	attributes					221:230	different glycan attributes	204:230	different glycan attributes like afucosylation, galactosylation or high-mannose content	204:290	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	3	47	theme	mAb	602:604	arg1	function					606:613	mAb function	602:613	mAb function	602:613	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	3	48	theme	sensitive	503:511	arg1	methods					526:532	more sensitive and specific methods	498:532	more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function	498:613	While established methods can effectively characterize major glycan species in biotherapeutic drug products, there is still a need for more sensitive and specific methods that can effectively monitor low abundance species which may impact mAb function.
36513905	10	49	theme	abundance	1384:1392	arg1	glycans					1394:1400	many low abundance glycans	1375:1400	many low abundance glycans identified by PRM	1375:1418	Notably, many low abundance glycans identified by PRM included species that were not reported in other studies.
36513905	8	50	theme	co-eluting	1113:1122	arg1	species					1131:1137	co-eluting glycan species	1113:1137	co-eluting glycan species	1113:1137	Glycan identities were determined using MS-analysis and a high number of FLD peaks containing co-eluting glycan species were observed.
36513905	2	51	theme	different	204:212	arg1	attributes					221:230	different glycan attributes	204:230	different glycan attributes like afucosylation, galactosylation or high-mannose content	204:290	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	11	52	theme	structural	1533:1542	arg1	features					1544:1551	unique structural features	1526:1551	unique structural features	1526:1551	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	2	53	theme	antibody	347:354	arg1	functions					321:329	functions	321:329	functions	321:329	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	2	53	theme	antibody	347:354	arg1	properties					307:316	properties	307:316	properties	307:316	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	12	54	dep	precise	1747:1753	arg1	informative					1756:1766	informative	1756:1766	informative	1756:1766	The results established PRM as a precise, informative tool for glycan analysis and quantitation.
36513905	6	55	theme	parallel	830:837	arg1	workflow					865:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow	828:872	A parallel reaction monitoring (PRM) workflow was used for the MS analysis.
36513905	2	56	theme	high-mannose	271:282	arg1	content					284:290	high-mannose content	271:290	high-mannose content	271:290	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	11	57	theme	de-coupling	1611:1621	arg1	acquisition					1626:1636	de-coupling MS acquisition	1611:1636	de-coupling MS acquisition	1611:1636	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	2	58	theme	monoclonal	336:345	arg1	mAb					357:359	mAb	357:359	mAb	357:359	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	2	58	theme	monoclonal	336:345	arg1	antibody					347:354	monoclonal antibody	336:354	a monoclonal antibody (mAb)	334:360	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	4	59	theme	METHODS	616:622	arg1	Glycans					624:630	METHODS Glycans	616:630	METHODS Glycans released from two mAbs, adalimumab and trastuzumab,	616:682	METHODS Glycans released from two mAbs, adalimumab and trastuzumab, were derivatized with Rapifluor-MS™.
36513905	9	60	from	increase	1256:1263	arg1	glycans					1268:1274	glycans	1268:1274	glycans that could be identified	1268:1299	PRM analysis quantified 38 and 39 glycan species in adalimumab and trastuzumab, respectively, and the increase in glycans that could be identified was due to superior sensitivity and selectivity compared to FLD.
36513905	11	61	theme	methods	1685:1691	arg1	transfer					1673:1680	the transfer	1669:1680	the transfer of methods between instruments	1669:1711	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	9	62	theme	PRM	1154:1156	arg1	analysis					1158:1165	PRM analysis	1154:1165	PRM analysis	1154:1165	PRM analysis quantified 38 and 39 glycan species in adalimumab and trastuzumab, respectively, and the increase in glycans that could be identified was due to superior sensitivity and selectivity compared to FLD.
36513905	2	63	from	changes	167:173	arg1	abundance					191:199	the relative abundance	178:199	the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content	178:290	For example, changes in the relative abundance of different glycan attributes like afucosylation, galactosylation or high-mannose content can change the properties or functions of a monoclonal antibody (mAb).
36513905	11	64	theme	data	1642:1645	arg1	processing					1647:1656	data processing	1642:1656	data processing	1642:1656	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
36513905	7	65	theme	glycan	961:966	arg1	peaks					968:972	18 and 19 glycan peaks	951:972	18 and 19 glycan peaks	951:972	RESULTS AND CONCLUSION FLD analysis identified 18 and 19 glycan peaks in adalimumab and trastuzumab, respectively.
36513905	11	66	theme	several	1495:1501	arg1	advantages					1514:1523	several additional advantages	1495:1523	several additional advantages	1495:1523	PRM also offered several additional advantages; unique structural features could be identified using the collected MS/MS spectra and de-coupling MS acquisition and data processing simplified the transfer of methods between instruments.
35802124	0	0	theme	MALDI	91:95	arg1	MSI					97:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	5	1	theme	incubation	915:924	arg1	chamber					926:932	the incubation chamber	911:932	the incubation chamber	911:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	5	2	theme	salts	861:865	arg1	solutions					840:848	saturated solutions	830:848	saturated solutions of various salts that maintain constant relative humidity in the incubation chamber	830:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	1	3	theme	tissue	160:165	arg1	specimens					167:175	tissue specimens	160:175	tissue specimens	160:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	0	4	theme	N-Glycan	82:89	arg1	MSI					97:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	2	5	theme	N-glycans	339:347	arg1	imaging					328:334	Mass spectrometry imaging	310:334	Mass spectrometry imaging of N-glycans	310:347	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	6	6	theme	KNO3	1014:1017	arg1	solution					1002:1009	a saturated solution	990:1009	a saturated solution of KNO3 that maintains an 89% RH	990:1042	We showed that the best performance was achieved using a saturated solution of KNO3 that maintains an 89% RH.
35802124	7	7	theme	ion	1125:1127	arg1	delocalization					1129:1142	the minutest ion delocalization	1112:1142	the minutest ion delocalization	1112:1142	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	1	8	from	specimens	167:175	arg1	Investigation					102:114	Investigation	102:114	Investigation of the spatial distribution of N-glycans in tissue specimens	102:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	5	9	from	humidity	899:906	arg1	chamber					926:932	the incubation chamber	911:932	the incubation chamber	911:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	1	10	theme	altered	247:253	arg1	hallmark					277:284	a hallmark	275:284	a hallmark of disease progression	275:307	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	1	10	theme	altered	247:253	arg1	N-glycans					255:263	altered N-glycans	247:263	altered N-glycans	247:263	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	7	11	theme	microanatomical	1274:1288	arg1	compartments					1290:1301	distinct microanatomical compartments	1265:1301	distinct microanatomical compartments	1265:1301	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	0	12	from	Information	51:61	arg1	MSI					97:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	3	13	theme	released	573:580	arg1	N-glycans					582:590	released N-glycans	573:590	released N-glycans	573:590	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	3	14	theme	incubation	514:523	arg1	steps					525:529	Unstandardized and uncontrolled incubation steps	482:529	Unstandardized and uncontrolled incubation steps	482:529	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	3	15	theme	Unstandardized	482:495	arg1	steps					525:529	Unstandardized and uncontrolled incubation steps	482:529	Unstandardized and uncontrolled incubation steps	482:529	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	7	16	theme	μm	1175:1176	arg1	resolution					1186:1195	a 35 μm spatial resolution	1170:1195	a 35 μm spatial resolution	1170:1195	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	2	17	theme	efficient	414:422	arg1	release					432:438	efficient in situ release	414:438	efficient in situ release of N-glycans from their carrier proteins	414:479	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	3	18	theme	significant	543:553	arg1	delocalization					555:568	significant delocalization	543:568	significant delocalization of released N-glycans	543:590	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	2	19	theme	tissue	392:397	arg1	incubation					399:408	tissue incubation	392:408	tissue incubation	392:408	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	3	20	from	region	685:690	arg1	tissue					699:704	the tissue	695:704	the tissue	695:704	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	2	21	from	proteins	472:479	arg1	release					432:438	efficient in situ release	414:438	efficient in situ release of N-glycans from their carrier proteins	414:479	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	7	22	theme	minutest	1116:1123	arg1	delocalization					1129:1142	the minutest ion delocalization	1112:1142	the minutest ion delocalization	1112:1142	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	1	23	from	distribution	131:142	arg1	specimens					167:175	tissue specimens	160:175	tissue specimens	160:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	4	24	theme	N-glycans	795:803	arg1	MALDI-MSI					782:790	accurate and sensitive MALDI-MSI	759:790	accurate and sensitive MALDI-MSI of N-glycans	759:803	Herein, we optimized the incubation step to provide accurate and sensitive MALDI-MSI of N-glycans.
35802124	2	25	theme	N-glycans	443:451	arg1	release					432:438	efficient in situ release	414:438	efficient in situ release of N-glycans from their carrier proteins	414:479	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	7	26	theme	distinct	1220:1227	arg1	patterns					1237:1244	six distinct spatial patterns	1216:1244	six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section	1216:1340	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	7	27	theme	spatial	1229:1235	arg1	patterns					1237:1244	six distinct spatial patterns	1216:1244	six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section	1216:1340	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	4	28	theme	accurate	759:766	arg1	MALDI-MSI					782:790	accurate and sensitive MALDI-MSI	759:790	accurate and sensitive MALDI-MSI of N-glycans	759:803	Herein, we optimized the incubation step to provide accurate and sensitive MALDI-MSI of N-glycans.
35802124	7	29	theme	spatial	1178:1184	arg1	resolution					1186:1195	a 35 μm spatial resolution	1170:1195	a 35 μm spatial resolution	1170:1195	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	0	30	theme	Controlled	0:9	arg1	Humidity					11:18	Controlled Humidity	0:18	Controlled Humidity	0:18	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	5	31	theme	relative	890:897	arg1	humidity					899:906	constant relative humidity	881:906	constant relative humidity in the incubation chamber	881:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	2	32	theme	N-glycanase	367:377	arg1	spraying					379:386	peptide N-glycanase spraying	359:386	peptide N-glycanase spraying	359:386	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	3	33	theme	N-glycans	582:590	arg1	delocalization					555:568	significant delocalization	543:568	significant delocalization of released N-glycans	543:590	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	1	34	theme	powerful	194:201	arg1	tool					203:206	a powerful tool	192:206	a powerful tool in clinical research	192:227	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	5	35	theme	various	853:859	arg1	salts					861:865	various salts	853:865	various salts that maintain constant relative humidity in the incubation chamber	853:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	6	36	theme	saturated	992:1000	arg1	solution					1002:1009	a saturated solution	990:1009	a saturated solution of KNO3 that maintains an 89% RH	990:1042	We showed that the best performance was achieved using a saturated solution of KNO3 that maintains an 89% RH.
35802124	3	37	theme	microanatomical	669:683	arg1	region					685:690	a specific microanatomical region	658:690	a specific microanatomical region in the tissue	658:704	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	2	38	theme	peptide	359:365	arg1	spraying					379:386	peptide N-glycanase spraying	359:386	peptide N-glycanase spraying	359:386	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	0	39	theme	Spatial	36:42	arg1	Detail					44:49	Fine Spatial Detail	31:49	Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI	31:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	3	40	theme	uncontrolled	501:512	arg1	steps					525:529	Unstandardized and uncontrolled incubation steps	482:529	Unstandardized and uncontrolled incubation steps	482:529	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	7	41	theme	near	1069:1072	arg1	sensitivity					1082:1092	near maximal sensitivity	1069:1092	near maximal sensitivity	1069:1092	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	7	42	theme	nephrectomy	1315:1325	arg1	section					1334:1340	a kidney nephrectomy tissue section	1306:1340	a kidney nephrectomy tissue section	1306:1340	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	7	43	theme	kidney	1308:1313	arg1	section					1334:1340	a kidney nephrectomy tissue section	1306:1340	a kidney nephrectomy tissue section	1306:1340	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	0	44	theme	Fine	31:34	arg1	Detail					44:49	Fine Spatial Detail	31:49	Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI	31:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	2	45	theme	carrier	464:470	arg1	proteins					472:479	their carrier proteins	458:479	their carrier proteins	458:479	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	7	46	theme	maximal	1074:1080	arg1	sensitivity					1082:1092	near maximal sensitivity	1069:1092	near maximal sensitivity	1069:1092	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	1	47	theme	clinical	211:218	arg1	research					220:227	clinical research	211:227	clinical research	211:227	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	1	48	theme	disease	289:295	arg1	progression					297:307	disease progression	289:307	disease progression	289:307	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	3	49	theme	specific	660:667	arg1	region					685:690	a specific microanatomical region	658:690	a specific microanatomical region in the tissue	658:704	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	2	50	dep	in	424:425	arg1	situ					427:430	situ	427:430	situ	427:430	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	4	51	theme	incubation	732:741	arg1	step					743:746	the incubation step	728:746	the incubation step	728:746	Herein, we optimized the incubation step to provide accurate and sensitive MALDI-MSI of N-glycans.
35802124	0	52	theme	Detail	44:49	arg1	Information					51:61	Fine Spatial Detail Information	31:61	Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI	31:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	1	53	theme	progression	297:307	arg1	hallmark					277:284	a hallmark	275:284	a hallmark of disease progression	275:307	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	1	53	theme	progression	297:307	arg1	N-glycans					255:263	altered N-glycans	247:263	altered N-glycans	247:263	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	1	54	theme	spatial	123:129	arg1	distribution					131:142	the spatial distribution	119:142	the spatial distribution of N-glycans in tissue specimens	119:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	1	55	from	Investigation	102:114	arg1	specimens					167:175	tissue specimens	160:175	tissue specimens	160:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	7	56	theme	distinct	1265:1272	arg1	compartments					1290:1301	distinct microanatomical compartments	1265:1301	distinct microanatomical compartments	1265:1301	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	1	57	from	tool	203:206	arg1	research					220:227	clinical research	211:227	clinical research	211:227	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	1	58	theme	distribution	131:142	arg1	Investigation					102:114	Investigation	102:114	Investigation of the spatial distribution of N-glycans in tissue specimens	102:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	4	59	theme	sensitive	772:780	arg1	MALDI-MSI					782:790	accurate and sensitive MALDI-MSI	759:790	accurate and sensitive MALDI-MSI of N-glycans	759:803	Herein, we optimized the incubation step to provide accurate and sensitive MALDI-MSI of N-glycans.
35802124	2	60	theme	Mass	310:313	arg1	spectrometry					315:326	Mass spectrometry	310:326	Mass spectrometry imaging of N-glycans	310:347	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	2	61	theme	spectrometry	315:326	arg1	imaging					328:334	Mass spectrometry imaging	310:334	Mass spectrometry imaging of N-glycans	310:347	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	0	62	theme	Enzyme-Assisted	66:80	arg1	MSI					97:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Enzyme-Assisted N-Glycan MALDI MSI	66:99	Controlled Humidity Levels for Fine Spatial Detail Information in Enzyme-Assisted N-Glycan MALDI MSI.
35802124	5	63	theme	constant	881:888	arg1	humidity					899:906	constant relative humidity	881:906	constant relative humidity in the incubation chamber	881:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	3	64	theme	given	628:632	arg1	composition					643:653	given N-glycan composition	628:653	given N-glycan composition	628:653	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	2	65	theme	in	424:425	arg1	release					432:438	efficient in situ release	414:438	efficient in situ release of N-glycans from their carrier proteins	414:479	Mass spectrometry imaging of N-glycans relies on peptide N-glycanase spraying and tissue incubation for efficient in situ release of N-glycans from their carrier proteins.
35802124	1	66	theme	N-glycans	147:155	arg1	distribution					131:142	the spatial distribution	119:142	the spatial distribution of N-glycans in tissue specimens	119:175	Investigation of the spatial distribution of N-glycans in tissue specimens has emerged as a powerful tool in clinical research, in part, because altered N-glycans are often a hallmark of disease progression.
35802124	7	67	theme	tissue	1327:1332	arg1	section					1334:1340	a kidney nephrectomy tissue section	1306:1340	a kidney nephrectomy tissue section	1306:1340	Under these conditions, near maximal sensitivity was achieved with the minutest ion delocalization, which we demonstrated at a 35 μm spatial resolution, where we observed six distinct spatial patterns that colocalize to distinct microanatomical compartments in a kidney nephrectomy tissue section.
35802124	6	68	theme	%	1039:1039	arg1	RH					1041:1042	an 89% RH	1034:1042	an 89% RH	1034:1042	We showed that the best performance was achieved using a saturated solution of KNO3 that maintains an 89% RH.
35802124	6	69	theme	best	954:957	arg1	performance					959:969	the best performance	950:969	the best performance	950:969	We showed that the best performance was achieved using a saturated solution of KNO3 that maintains an 89% RH.
35802124	3	70	theme	N-glycan	634:641	arg1	composition					643:653	given N-glycan composition	628:653	given N-glycan composition	628:653	Unstandardized and uncontrolled incubation steps often cause significant delocalization of released N-glycans, resulting in the inability to link given N-glycan composition to a specific microanatomical region in the tissue.
35802124	5	71	theme	saturated	830:838	arg1	solutions					840:848	saturated solutions	830:848	saturated solutions of various salts that maintain constant relative humidity in the incubation chamber	830:932	Specifically, we tested saturated solutions of various salts that maintain constant relative humidity in the incubation chamber.
35802124	6	72	theme	89	1037:1038	arg1	%					1039:1039	%	1039:1039	%	1039:1039	We showed that the best performance was achieved using a saturated solution of KNO3 that maintains an 89% RH.
37336068	6	0	theme	antibodies	1192:1201	arg1	levels					1159:1164	high levels	1154:1164	high levels of specific anti-WTAs IgG antibodies	1154:1201	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	6	1	theme	β-1,4-GlcNAc	1287:1298	arg1	pattern					1313:1319	the β-1,4-GlcNAc modification pattern	1283:1319	chain length as well as the β-1,4-GlcNAc modification pattern	1259:1319	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	2	2	theme	anti-MRSA	323:331	arg1	vaccine					333:339	prophylactic or therapeutic anti-MRSA vaccine	295:339	prophylactic or therapeutic anti-MRSA vaccine	295:339	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	4	3	theme	ionic	727:731	arg1	strategy					784:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy	724:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach	724:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	6	4	theme	chain	1259:1263	arg1	length					1265:1270	chain length	1259:1270	chain length as well as the β-1,4-GlcNAc modification pattern	1259:1319	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	4	5	theme	GlcNAc	684:689	arg1	modification					691:702	GlcNAc modification	684:702	GlcNAc modification	684:702	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	2	6	theme	potential	346:354	arg1	approach					356:363	a potential approach	344:363	a potential approach to treat S. aureus infections and overcome the resistance crisis	344:428	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	2	6	theme	potential	346:354	arg1	Development					280:290	Development	280:290	Development of prophylactic or therapeutic anti-MRSA vaccine	280:339	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	1	7	theme	life-threating	237:250	arg1	infections					252:261	its life-threating infections	233:261	its life-threating infections to human health	233:277	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	5	8	theme	vaccine	912:918	arg1	WTAs					864:867	the obtained WTAs	851:867	the obtained WTAs	851:867	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	5	8	theme	vaccine	912:918	arg1	candidates					920:929	vaccine candidates	912:929	vaccine candidates	912:929	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	8	9	theme	OP-killing	1569:1578	arg1	activities					1580:1589	the most potent OP-killing activities	1553:1589	the most potent OP-killing activities to MSSA and MRSA cells	1553:1612	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	7	10	theme	production	1466:1475	arg1	titers					1438:1443	the highest titers	1426:1443	the highest titers of specific antibody production	1426:1475	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	8	11	dep	affinity	1540:1547	arg1	the					1504:1506	the	1504:1506	the	1504:1506	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	7	12	theme	specific	1448:1455	arg1	production					1466:1475	specific antibody production	1448:1475	specific antibody production	1448:1475	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	4	13	theme	oligosaccharide	750:764	arg1	strategy					784:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy	724:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach	724:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	0	14	theme	potential	76:84	arg1	vaccine					86:92	potential vaccine	76:92	potential vaccine against methicillin-resistant Staphylococcus aureus	76:144	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	7	15	theme	conjugate	1336:1344	arg1	T6					1346:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	1	16	theme	high	203:206	arg1	pathogen					217:224	a high priority pathogen	201:224	a high priority pathogen due to its life-threating infections to human health	201:277	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	1	16	theme	high	203:206	arg1	aureus					184:189	Staphylococcus aureus	169:189	Methicillin-resistant Staphylococcus aureus (MRSA)	147:196	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	6	17	theme	WTAs-TT	1079:1085	arg1	conjugates					1087:1096	the WTAs-TT conjugates	1075:1096	the WTAs-TT conjugates	1075:1096	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	7	18	theme	Heptamer	1322:1329	arg1	T6					1346:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	3	19	gly	glycosylated	444:455	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	19	gly	glycosylated	444:455	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	19	gly	glycosylated	444:455	arg1	WTAs					478:481	WTAs	478:481	WTAs	478:481	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	0	20	dep	Staphylococcus	124:137	arg1	aureus					139:144	aureus	139:144	aureus	139:144	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	6	21	theme	specific	1169:1176	arg1	antibodies					1192:1201	specific anti-WTAs IgG antibodies	1169:1201	specific anti-WTAs IgG antibodies	1169:1201	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	3	22	theme	glycosylated	444:455	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	22	theme	glycosylated	444:455	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	22	theme	glycosylated	444:455	arg1	WTAs					478:481	WTAs	478:481	WTAs	478:481	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	8	23	theme	T6	1482:1483	arg1	antisera					1485:1492	The T6 antisera	1478:1492	The T6 antisera	1478:1492	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	5	24	theme	tetanus	890:896	arg1	TT					905:906	TT	905:906	TT	905:906	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	5	24	theme	tetanus	890:896	arg1	toxin					898:902	tetanus toxin	890:902	tetanus toxin (TT)	890:907	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	9	25	theme	further	1702:1708	arg1	development					1710:1720	further development	1702:1720	further development against MRSA	1702:1733	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	7	26	theme	highest	1430:1436	arg1	titers					1438:1443	the highest titers	1426:1443	the highest titers of specific antibody production	1426:1475	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	4	27	theme	chromatography-free	816:834	arg1	approach					836:843	chromatography-free approach	816:843	chromatography-free approach	816:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	0	28	theme	structure-defined	13:29	arg1	acids					67:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids	13:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus	13:144	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	3	29	theme	β-lactam	565:572	arg1	resistance					574:583	β-lactam resistance	565:583	β-lactam resistance	565:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	8	30	theme	highest	1508:1514	arg1	affinity					1540:1547	recognition and binding affinity	1516:1547	affinity	1540:1547	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	0	31	theme	wall	53:56	arg1	acids					67:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids	13:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus	13:144	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	3	32	theme	teichoic	462:469	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	32	theme	teichoic	462:469	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	32	theme	teichoic	462:469	arg1	WTAs					478:481	WTAs	478:481	WTAs	478:481	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	33	theme	antigen	525:531	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	33	theme	antigen	525:531	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	0	34	theme	acids	67:71	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.	0:145	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	6	35	theme	WTAs	1234:1237	arg1	structure					1239:1247	the WTAs structure	1230:1247	the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern	1230:1319	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	6	36	theme	modification	1300:1311	arg1	pattern					1313:1319	the β-1,4-GlcNAc modification pattern	1283:1319	chain length as well as the β-1,4-GlcNAc modification pattern	1259:1319	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	2	37	theme	aureus	377:382	arg1	infections					384:393	S. aureus infections	374:393	S. aureus infections	374:393	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	4	38	from	strategy	784:791	arg1	efficiency					801:810	high efficiency	796:810	high efficiency	796:810	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	4	38	from	strategy	784:791	arg1	approach					836:843	chromatography-free approach	816:843	chromatography-free approach	816:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	1	39	theme	human	266:270	arg1	health					272:277	human health	266:277	human health	266:277	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	7	40	theme	modified	1386:1393	arg1	RboP					1395:1398	β-1,4-GlcNAc modified RboP	1373:1398	β-1,4-GlcNAc modified RboP	1373:1398	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	4	41	theme	chain	656:660	arg1	length					662:667	chain length	656:667	chain length	656:667	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	6	42	theme	IgG	1188:1190	arg1	antibodies					1192:1201	specific anti-WTAs IgG antibodies	1169:1201	specific anti-WTAs IgG antibodies	1169:1201	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	4	43	theme	β-1,4-GlcNAc-modified	619:639	arg1	WTAs					641:644	structure-defined β-1,4-GlcNAc-modified WTAs	601:644	structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification	601:702	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	2	44	theme	vaccine	333:339	arg1	approach					356:363	a potential approach	344:363	a potential approach to treat S. aureus infections and overcome the resistance crisis	344:428	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	2	44	theme	vaccine	333:339	arg1	Development					280:290	Development	280:290	Development of prophylactic or therapeutic anti-MRSA vaccine	280:339	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	1	45	theme	priority	208:215	arg1	pathogen					217:224	a high priority pathogen	201:224	a high priority pathogen due to its life-threating infections to human health	201:277	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	1	45	theme	priority	208:215	arg1	aureus					184:189	Staphylococcus aureus	169:189	Methicillin-resistant Staphylococcus aureus (MRSA)	147:196	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	1	46	theme	due	226:228	arg1	pathogen					217:224	a high priority pathogen	201:224	a high priority pathogen due to its life-threating infections to human health	201:277	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	1	46	theme	due	226:228	arg1	aureus					184:189	Staphylococcus aureus	169:189	Methicillin-resistant Staphylococcus aureus (MRSA)	147:196	Methicillin-resistant Staphylococcus aureus (MRSA) is a high priority pathogen due to its life-threating infections to human health.
37336068	3	47	attach	derived	484:490	arg2	WTAs					478:481	WTAs	478:481	WTAs	478:481	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	47	attach	derived	484:490	arg2	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	47	attach	derived	484:490	arg2	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	47	attach	derived	484:490	arg1	aureus					500:505	S. aureus	497:505	S. aureus	497:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	6	48	theme	immunological	1039:1051	arg1	studies					1053:1059	In vivo immunological studies	1031:1059	In vivo immunological studies	1031:1059	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	8	49	theme	potent	1562:1567	arg1	activities					1580:1589	the most potent OP-killing activities	1553:1589	the most potent OP-killing activities to MSSA and MRSA cells	1553:1612	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	5	50	theme	mouse	963:967	arg1	model					969:973	a mouse model	961:973	a mouse model to determine the structure-immunogenicity relationship	961:1028	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	9	51	theme	glycosylated	1657:1668	arg1	WTAs					1670:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	9	51	theme	glycosylated	1657:1668	arg1	antigens					1689:1696	promising antigens	1679:1696	promising antigens for further development against MRSA	1679:1733	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	6	52	theme	In	1031:1032	arg1	studies					1053:1059	In vivo immunological studies	1031:1059	In vivo immunological studies	1031:1059	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	6	53	dep	In	1031:1032	arg1	vivo					1034:1037	vivo	1034:1037	vivo	1034:1037	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	4	54	theme	modification	691:702	arg1	length					662:667	chain length	656:667	chain length	656:667	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	4	54	theme	modification	691:702	arg1	numbers					673:679	numbers	673:679	numbers of GlcNAc modification	673:702	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	4	55	theme	ILSOS	777:781	arg1	strategy					784:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy	724:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach	724:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	2	56	theme	therapeutic	311:321	arg1	vaccine					333:339	prophylactic or therapeutic anti-MRSA vaccine	295:339	prophylactic or therapeutic anti-MRSA vaccine	295:339	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	0	57	theme	teichoic	58:65	arg1	acids					67:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids	13:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus	13:144	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	6	58	theme	cell-dependent	1116:1129	arg1	responses					1131:1139	robust T cell-dependent responses	1107:1139	robust T cell-dependent responses	1107:1139	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	8	59	theme	MRSA	1603:1606	arg1	cells					1608:1612	MRSA cells	1603:1612	MRSA cells	1603:1612	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	2	60	theme	prophylactic	295:306	arg1	vaccine					333:339	prophylactic or therapeutic anti-MRSA vaccine	295:339	prophylactic or therapeutic anti-MRSA vaccine	295:339	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	6	61	theme	robust	1107:1112	arg1	responses					1131:1139	robust T cell-dependent responses	1107:1139	robust T cell-dependent responses	1107:1139	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	7	62	theme	antibody	1457:1464	arg1	production					1466:1475	specific antibody production	1448:1475	specific antibody production	1448:1475	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	4	63	theme	liquid-supported	733:748	arg1	strategy					784:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy	724:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach	724:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	7	64	theme	WTAs	1331:1334	arg1	T6					1346:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	7	65	contain	carrying	1350:1357	arg1	T6					1346:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6	1322:1347	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	7	65	contain	carrying	1350:1357	arg2	copy					1365:1368	three copy	1359:1368	three copy of β-1,4-GlcNAc modified RboP	1359:1398	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	9	66	theme	β-1,4-GlcNAc	1644:1655	arg1	WTAs					1670:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	9	66	theme	β-1,4-GlcNAc	1644:1655	arg1	antigens					1689:1696	promising antigens	1679:1696	promising antigens for further development against MRSA	1679:1733	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	4	67	theme	synthesis	766:774	arg1	strategy					784:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy	724:791	an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach	724:843	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	9	68	theme	promising	1679:1687	arg1	WTAs					1670:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	9	68	theme	promising	1679:1687	arg1	antigens					1689:1696	promising antigens	1679:1696	promising antigens for further development against MRSA	1679:1733	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	6	69	theme	anti-WTAs	1178:1186	arg1	antibodies					1192:1201	specific anti-WTAs IgG antibodies	1169:1201	specific anti-WTAs IgG antibodies	1169:1201	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	9	70	gly	glycosylated	1657:1668	arg1	WTAs					1670:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	β-1,4-GlcNAc glycosylated WTAs	1644:1673	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	9	70	gly	glycosylated	1657:1668	arg1	antigens					1689:1696	promising antigens	1679:1696	promising antigens for further development against MRSA	1679:1733	This study demonstrated that β-1,4-GlcNAc glycosylated WTAs are promising antigens for further development against MRSA.
37336068	5	71	theme	structure-immunogenicity	992:1015	arg1	relationship					1017:1028	the structure-immunogenicity relationship	988:1028	the structure-immunogenicity relationship	988:1028	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	3	72	theme	wall	457:460	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	72	theme	wall	457:460	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	72	theme	wall	457:460	arg1	WTAs					478:481	WTAs	478:481	WTAs	478:481	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	4	73	theme	high	796:799	arg1	efficiency					801:810	high efficiency	796:810	high efficiency	796:810	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	0	74	theme	β-1,4-GlcNAc-modified	31:51	arg1	acids					67:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids	13:71	structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus	13:144	Synthesis of structure-defined β-1,4-GlcNAc-modified wall teichoic acids as potential vaccine against methicillin-resistant Staphylococcus aureus.
37336068	6	75	theme	high	1154:1157	arg1	levels					1159:1164	high levels	1154:1164	high levels of specific anti-WTAs IgG antibodies	1154:1201	In vivo immunological studies revealed that the WTAs-TT conjugates provoked robust T cell-dependent responses and elicited high levels of specific anti-WTAs IgG antibodies production associated with the WTAs structure including chain length as well as the β-1,4-GlcNAc modification pattern.
37336068	3	76	theme	β-1,4-GlcNAc	431:442	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	76	theme	β-1,4-GlcNAc	431:442	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	76	theme	β-1,4-GlcNAc	431:442	arg1	WTAs					478:481	WTAs	478:481	WTAs	478:481	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	4	77	theme	structure-defined	601:617	arg1	WTAs					641:644	structure-defined β-1,4-GlcNAc-modified WTAs	601:644	structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification	601:702	In this study, structure-defined β-1,4-GlcNAc-modified WTAs varied in chain length and numbers of GlcNAc modification were synthesized by an ionic liquid-supported oligosaccharide synthesis (ILSOS) strategy in high efficiency and chromatography-free approach.
37336068	3	78	theme	new	513:515	arg1	acids					471:475	β-1,4-GlcNAc glycosylated wall teichoic acids	431:475	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus	431:505	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	3	78	theme	new	513:515	arg1	type					517:520	a new type	511:520	a new type of antigen that is closely associated with β-lactam resistance	511:583	β-1,4-GlcNAc glycosylated wall teichoic acids (WTAs) derived from S. aureus are a new type of antigen that is closely associated with β-lactam resistance.
37336068	5	79	theme	obtained	855:862	arg1	WTAs					864:867	the obtained WTAs	851:867	the obtained WTAs	851:867	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	5	79	theme	obtained	855:862	arg1	candidates					920:929	vaccine candidates	912:929	vaccine candidates	912:929	Then the obtained WTAs were conjugated with tetanus toxin (TT) as vaccine candidates and were further evaluated in a mouse model to determine the structure-immunogenicity relationship.
37336068	7	80	theme	RboP	1395:1398	arg1	copy					1365:1368	three copy	1359:1368	three copy of β-1,4-GlcNAc modified RboP	1359:1398	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	8	81	theme	recognition	1516:1526	arg1	affinity					1540:1547	recognition and binding affinity	1516:1547	affinity	1540:1547	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	7	82	theme	β-1,4-GlcNAc	1373:1384	arg1	RboP					1395:1398	β-1,4-GlcNAc modified RboP	1373:1398	β-1,4-GlcNAc modified RboP	1373:1398	Heptamer WTAs conjugate T6, carrying three copy of β-1,4-GlcNAc modified RboP, was identified to elicit the highest titers of specific antibody production.
37336068	8	83	theme	binding	1532:1538	arg1	affinity					1540:1547	recognition and binding affinity	1516:1547	affinity	1540:1547	The T6 antisera exhibited the highest recognition and binding affinity and the most potent OP-killing activities to MSSA and MRSA cells.
37336068	2	84	theme	S.	374:375	arg1	infections					384:393	S. aureus infections	374:393	S. aureus infections	374:393	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
37336068	2	85	theme	resistance	412:421	arg1	crisis					423:428	the resistance crisis	408:428	the resistance crisis	408:428	Development of prophylactic or therapeutic anti-MRSA vaccine is a potential approach to treat S. aureus infections and overcome the resistance crisis.
36650134	4	0	theme	dynamic	811:817	arg1	responses					835:843	predictable, specific, and dynamic transcriptional responses	784:843	predictable, specific, and dynamic transcriptional responses	784:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	2	1	theme	gut	411:413	arg1	composition					426:436	the gut microbiota composition	407:436	the gut microbiota composition	407:436	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	7	2	theme	intestinal	1273:1282	arg1	environment					1284:1294	the mammalian intestinal environment	1259:1294	the mammalian intestinal environment	1259:1294	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	4	3	theme	gut	675:677	arg1	proteins					714:721	specialized sensor proteins	695:721	specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses	695:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	4	3	theme	gut	675:677	arg1	microbes					679:686	gut microbes	675:686	gut microbes	675:686	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	7	4	dep	enhance	1230:1236	arg1	We					1183:1184	We	1183:1184	We	1183:1184	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	4	5	theme	specialized	695:705	arg1	proteins					714:721	specialized sensor proteins	695:721	specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses	695:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	4	5	theme	specialized	695:705	arg1	microbes					679:686	gut microbes	675:686	gut microbes	675:686	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	3	6	theme	glycomics	639:647	arg1	approaches					649:658	glycomics approaches	639:658	glycomics approaches	639:658	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	3	7	theme	structural	561:570	arg1	complexity					572:581	glycan structural complexity	554:581	glycan structural complexity	554:581	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	3	8	theme	substantial	613:623	arg1	challenges					625:634	substantial challenges	613:634	substantial challenges to glycomics approaches	613:658	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	1	9	theme	accessible	195:204	arg1	nutrients					206:214	differentially accessible nutrients	180:214	differentially accessible nutrients	180:214	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	1	10	theme	critical	84:91	arg1	functions					104:112	critical biological functions	84:112	critical biological functions	84:112	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	3	11	theme	microbial	518:526	arg1	substrates					528:537	individual microbial substrates	507:537	individual microbial substrates	507:537	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	0	12	theme	gut	11:13	arg1	microbes					15:22	gut microbes	11:22	gut microbes	11:22	Harnessing gut microbes for glycan detection and quantification.
36650134	1	13	theme	biological	93:102	arg1	functions					104:112	critical biological functions	84:112	critical biological functions	84:112	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	2	14	theme	metabolism	442:451	arg1	modulation					393:402	modulation	393:402	modulation of the gut microbiota composition and metabolism	393:451	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	7	15	theme	human	1350:1354	arg1	health					1356:1361	human health	1350:1361	human health	1350:1361	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	7	16	theme	host-microbial	1309:1322	arg1	interactions					1324:1335	host-microbial interactions	1309:1335	host-microbial interactions critical for human health	1309:1361	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	5	17	dep	presence	904:911	arg1	the					900:902	the	900:902	the	900:902	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	1	18	theme	distinct	219:226	arg1	subsets					238:244	distinct microbial subsets	219:244	distinct microbial subsets	219:244	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	5	19	theme	similar	946:952	arg1	glycans					981:987	compositionally similar, yet structurally distinct glycans	930:987	compositionally similar, yet structurally distinct glycans	930:987	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	6	20	theme	target	1096:1101	arg1	molecules					1103:1111	target molecules	1096:1111	target molecules for downstream characterization	1096:1143	We implement these tools to examine glycan mixtures, isolate target molecules for downstream characterization, and quantify the recovered products.
36650134	7	21	theme	mammalian	1263:1271	arg1	environment					1284:1294	the mammalian intestinal environment	1259:1294	the mammalian intestinal environment	1259:1294	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	5	22	dep	reporter	1014:1021	arg1	develop					1026:1032	develop	1026:1032	develop	1026:1032	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	1	23	theme	microbial	228:236	arg1	subsets					238:244	distinct microbial subsets	219:244	distinct microbial subsets	219:244	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	7	24	theme	critical	1337:1344	arg1	interactions					1324:1335	host-microbial interactions	1309:1335	host-microbial interactions critical for human health	1309:1361	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	2	25	theme	therapeutic	351:361	arg1	avenues					363:369	therapeutic avenues	351:369	therapeutic avenues	351:369	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	4	26	theme	unique	738:743	arg1	structures					752:761	unique glycan structures	738:761	unique glycan structures	738:761	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	3	27	theme	heterogeneous	473:485	arg1	mixtures					494:501	heterogeneous glycan mixtures	473:501	heterogeneous glycan mixtures	473:501	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	4	28	theme	transcriptional	819:833	arg1	responses					835:843	predictable, specific, and dynamic transcriptional responses	784:843	predictable, specific, and dynamic transcriptional responses	784:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	2	29	theme	glycan	277:282	arg1	substrates					284:293	identifying unique glycan substrates	258:293	identifying unique glycan substrates that support defined microbial populations	258:336	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	4	30	theme	predictable	784:794	arg1	responses					835:843	predictable, specific, and dynamic transcriptional responses	784:843	predictable, specific, and dynamic transcriptional responses	784:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	5	31	theme	distinct	972:979	arg1	glycans					981:987	compositionally similar, yet structurally distinct glycans	930:987	compositionally similar, yet structurally distinct glycans	930:987	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	0	32	theme	glycan	28:33	arg1	detection					35:43	glycan detection	28:43	glycan detection	28:43	Harnessing gut microbes for glycan detection and quantification.
36650134	3	33	theme	glycan	487:492	arg1	mixtures					494:501	heterogeneous glycan mixtures	473:501	heterogeneous glycan mixtures	473:501	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	2	34	theme	unique	270:275	arg1	substrates					284:293	identifying unique glycan substrates	258:293	identifying unique glycan substrates that support defined microbial populations	258:336	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	5	35	theme	glycans	981:987	arg1	abundance					917:925	abundance	917:925	abundance	917:925	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	5	35	theme	glycans	981:987	arg1	presence					904:911	presence	904:911	presence	904:911	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	7	36	theme	environment	1284:1294	arg1	understanding					1242:1254	our understanding	1238:1254	our understanding of the mammalian intestinal environment	1238:1294	We assert that this toolkit could dramatically enhance our understanding of the mammalian intestinal environment and identify host-microbial interactions critical for human health.
36650134	6	37	theme	glycan	1071:1076	arg1	mixtures					1078:1085	glycan mixtures	1071:1085	glycan mixtures	1071:1085	We implement these tools to examine glycan mixtures, isolate target molecules for downstream characterization, and quantify the recovered products.
36650134	3	38	theme	individual	507:516	arg1	substrates					528:537	individual microbial substrates	507:537	individual microbial substrates	507:537	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	2	39	theme	identifying	258:268	arg1	substrates					284:293	identifying unique glycan substrates	258:293	identifying unique glycan substrates that support defined microbial populations	258:336	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	4	40	theme	sensor	707:712	arg1	proteins					714:721	specialized sensor proteins	695:721	specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses	695:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	4	40	theme	sensor	707:712	arg1	microbes					679:686	gut microbes	675:686	gut microbes	675:686	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	1	41	theme	mammalian	130:138	arg1	composition					155:165	the mammalian gut microbiota composition	126:165	the mammalian gut microbiota composition	126:165	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	2	42	theme	defined	308:314	arg1	populations					326:336	defined microbial populations	308:336	defined microbial populations	308:336	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	4	43	theme	specific	797:804	arg1	responses					835:843	predictable, specific, and dynamic transcriptional responses	784:843	predictable, specific, and dynamic transcriptional responses	784:843	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	1	44	theme	gut	140:142	arg1	composition					155:165	the mammalian gut microbiota composition	126:165	the mammalian gut microbiota composition	126:165	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	5	45	theme	transcriptional	998:1012	arg1	reporter					1014:1021	a transcriptional reporter	996:1021	a transcriptional reporter we develop	996:1032	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	6	46	theme	recovered	1163:1171	arg1	products					1173:1180	the recovered products	1159:1180	the recovered products	1159:1180	We implement these tools to examine glycan mixtures, isolate target molecules for downstream characterization, and quantify the recovered products.
36650134	2	47	theme	microbial	316:324	arg1	populations					326:336	defined microbial populations	308:336	defined microbial populations	308:336	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	1	48	theme	microbiota	144:153	arg1	composition					155:165	the mammalian gut microbiota composition	126:165	the mammalian gut microbiota composition	126:165	Glycans facilitate critical biological functions and control the mammalian gut microbiota composition by supplying differentially accessible nutrients to distinct microbial subsets.
36650134	3	49	theme	glycan	554:559	arg1	complexity					572:581	glycan structural complexity	554:581	glycan structural complexity	554:581	However, examining heterogeneous glycan mixtures for individual microbial substrates is hindered by glycan structural complexity and diversity, which presents substantial challenges to glycomics approaches.
36650134	5	50	theme	microbial	868:876	arg1	machinery					878:886	this microbial machinery	863:886	this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans	863:987	Here, we harness this microbial machinery to indicate the presence and abundance of compositionally similar, yet structurally distinct glycans, using a transcriptional reporter we develop.
36650134	4	51	theme	glycan	745:750	arg1	structures					752:761	unique glycan structures	738:761	unique glycan structures	738:761	Fortuitously, gut microbes encode specialized sensor proteins that recognize unique glycan structures and in-turn activate predictable, specific, and dynamic transcriptional responses.
36650134	2	52	theme	composition	426:436	arg1	modulation					393:402	modulation	393:402	modulation of the gut microbiota composition and metabolism	393:451	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
36650134	6	53	theme	downstream	1117:1126	arg1	characterization					1128:1143	downstream characterization	1117:1143	downstream characterization	1117:1143	We implement these tools to examine glycan mixtures, isolate target molecules for downstream characterization, and quantify the recovered products.
36650134	2	54	theme	microbiota	415:424	arg1	composition					426:436	the gut microbiota composition	407:436	the gut microbiota composition	407:436	Therefore, identifying unique glycan substrates that support defined microbial populations could inform therapeutic avenues to treat diseases via modulation of the gut microbiota composition and metabolism.
35394422	0	0	theme	synthesis	75:83	arg1	enzymes					85:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	4	1	theme	Biochemical	609:619	arg1	characterization					621:636	Biochemical characterization	609:636	Biochemical characterization	609:636	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	0	2	theme	chitobiose	64:73	arg1	enzymes					85:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	2	3	theme	identical	302:310	arg1	structure					291:299	a lipid-linked chitobiose core structure	260:299	a lipid-linked chitobiose core structure	260:299	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	4	4	theme	-α-D-GlcNAc-diphosphodolichol	693:721	arg1	function					652:659	its function	648:659	its function	648:659	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	4	4	theme	-α-D-GlcNAc-diphosphodolichol	693:721	arg1	glycosyltransferase					723:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	0	5	theme	enzymes	85:91	arg1	homolog					29:35	an ancient archaeal homolog	9:35	an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes	9:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	0	5	theme	enzymes	85:91	arg1	Agl24					0:4	Agl24	0:4	Agl24	0:4	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	6	6	theme	eukaryotic	984:993	arg1	Alg14/13					995:1002	the eukaryotic Alg14/13	980:1002	the eukaryotic Alg14/13	980:1002	Furthermore, bioinformatics and structural modeling revealed similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively.
35394422	2	7	link	lipid-linked	262:273	arg1	structure					291:299	a lipid-linked chitobiose core structure	260:299	a lipid-linked chitobiose core structure	260:299	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	1	8	located	found	155:159	arg2	N-glycosylation					102:116	Protein N-glycosylation	94:116	Protein N-glycosylation	94:116	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	1	8	located	found	155:159	arg2	modification					142:153	a post-translational modification	121:153	a post-translational modification found in organisms of all domains of life	121:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	1	8	located	found	155:159	arg1	organisms					164:172	organisms	164:172	organisms of all domains of life	164:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	4	9	theme	inverting	667:675	arg1	function					652:659	its function	648:659	its function	648:659	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	4	9	theme	inverting	667:675	arg1	glycosyltransferase					723:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	2	10	theme	structure	291:299	arg1	synthesis					247:255	the synthesis	243:255	the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes	243:332	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	3	11	theme	thermostable	437:448	arg1	β-1,4-N-acetylglucosaminyltransferase					459:495	a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase	435:495	a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase	435:495	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	5	12	theme	eukaryotic	809:818	arg1	homologs					834:841	the eukaryotic and bacterial homologs	805:841	the eukaryotic and bacterial homologs	805:841	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	2	13	theme	core	286:289	arg1	structure					291:299	a lipid-linked chitobiose core structure	260:299	a lipid-linked chitobiose core structure	260:299	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	5	14	located	found	791:795	arg2	residue					782:788	a conserved histidine residue	760:788	a conserved histidine residue	760:788	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	5	14	located	found	791:795	arg1	homologs					834:841	the eukaryotic and bacterial homologs	805:841	the eukaryotic and bacterial homologs	805:841	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	1	15	theme	domains	181:187	arg1	organisms					164:172	organisms	164:172	organisms of all domains of life	164:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	6	16	theme	Agl24	971:975	arg1	similarities					955:966	similarities	955:966	similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively	955:1114	Furthermore, bioinformatics and structural modeling revealed similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively.
35394422	3	17	theme	chitobiose	592:601	arg1	core					603:606	the N-glycan chitobiose core	579:606	the N-glycan chitobiose core	579:606	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	3	18	theme	core	603:606	arg1	synthesis					566:574	the synthesis	562:574	the synthesis of the N-glycan chitobiose core	562:606	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	1	19	theme	life	192:195	arg1	life					192:195	life	192:195	life	192:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	1	19	theme	life	192:195	arg1	domains					181:187	all domains	177:187	all domains of life	177:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	0	20	theme	ancient	12:18	arg1	homolog					29:35	an ancient archaeal homolog	9:35	an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes	9:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	0	20	theme	ancient	12:18	arg1	Agl24					0:4	Agl24	0:4	Agl24	0:4	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	5	21	theme	histidine	772:780	arg1	residue					782:788	a conserved histidine residue	760:788	a conserved histidine residue	760:788	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	1	22	theme	Protein	94:100	arg1	modification					142:153	a post-translational modification	121:153	a post-translational modification found in organisms of all domains of life	121:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	1	22	theme	Protein	94:100	arg1	N-glycosylation					102:116	Protein N-glycosylation	94:116	Protein N-glycosylation	94:116	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	4	23	theme	β-D-GlcNAc-	677:687	arg1	function					652:659	its function	648:659	its function	648:659	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	4	23	theme	β-D-GlcNAc-	677:687	arg1	glycosyltransferase					723:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	5	24	theme	residue	782:788	arg1	Substitution					744:755	Substitution	744:755	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs,	744:842	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	3	25	theme	N-glycan	583:590	arg1	core					603:606	the N-glycan chitobiose core	579:606	the N-glycan chitobiose core	579:606	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	3	26	theme	archaeal	504:511	arg1	enzyme					527:532	archaeal glycosylation enzyme 24	504:535	archaeal glycosylation enzyme 24 (Agl24)	504:543	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	3	26	theme	archaeal	504:511	arg1	Agl24					538:542	Agl24	538:542	Agl24	538:542	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	7	27	theme	lateral	1219:1225	arg1	transfer					1227:1234	a lateral transfer	1217:1234	a lateral transfer	1217:1234	Phylogenetic analysis of Alg14/13 homologs indicates that they are ancient in Eukaryotes, either as a lateral transfer or inherited through eukaryogenesis.
35394422	7	28	from	ancient	1184:1190	arg1	Eukaryotes					1195:1204	Eukaryotes	1195:1204	Eukaryotes	1195:1204	Phylogenetic analysis of Alg14/13 homologs indicates that they are ancient in Eukaryotes, either as a lateral transfer or inherited through eukaryogenesis.
35394422	4	29	theme	1→4	689:691	arg1	function					652:659	its function	648:659	its function	648:659	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	4	29	theme	1→4	689:691	arg1	glycosyltransferase					723:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase	664:741	Biochemical characterization confirmed its function as an inverting β-D-GlcNAc-(1→4)-α-D-GlcNAc-diphosphodolichol glycosyltransferase.
35394422	3	30	theme	β-1,4-N-acetylglucosaminyltransferase	459:495	arg1	identification					417:430	the identification	413:430	the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core	413:606	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	0	31	theme	archaeal	20:27	arg1	homolog					29:35	an ancient archaeal homolog	9:35	an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes	9:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	0	31	theme	archaeal	20:27	arg1	Agl24					0:4	Agl24	0:4	Agl24	0:4	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	6	32	theme	bacterial	1034:1042	arg1	MurG					1044:1047	the bacterial MurG	1030:1047	the bacterial MurG	1030:1047	Furthermore, bioinformatics and structural modeling revealed similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively.
35394422	7	33	theme	Alg14/13	1142:1149	arg1	homologs					1151:1158	Alg14/13 homologs	1142:1158	Alg14/13 homologs	1142:1158	Phylogenetic analysis of Alg14/13 homologs indicates that they are ancient in Eukaryotes, either as a lateral transfer or inherited through eukaryogenesis.
35394422	5	34	theme	functional	861:870	arg1	importance					872:881	its functional importance	857:881	its functional importance for Agl24	857:891	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	7	35	from	Eukaryotes	1195:1204	arg1	ancient					1184:1190	ancient	1184:1190	ancient	1184:1190	Phylogenetic analysis of Alg14/13 homologs indicates that they are ancient in Eukaryotes, either as a lateral transfer or inherited through eukaryogenesis.
35394422	7	36	theme	Phylogenetic	1117:1128	arg1	analysis					1130:1137	Phylogenetic analysis	1117:1137	Phylogenetic analysis of Alg14/13 homologs	1117:1158	Phylogenetic analysis of Alg14/13 homologs indicates that they are ancient in Eukaryotes, either as a lateral transfer or inherited through eukaryogenesis.
35394422	5	37	theme	bacterial	824:832	arg1	homologs					834:841	the eukaryotic and bacterial homologs	805:841	the eukaryotic and bacterial homologs	805:841	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	7	38	theme	homologs	1151:1158	arg1	analysis					1130:1137	Phylogenetic analysis	1117:1137	Phylogenetic analysis of Alg14/13 homologs	1117:1158	Phylogenetic analysis of Alg14/13 homologs indicates that they are ancient in Eukaryotes, either as a lateral transfer or inherited through eukaryogenesis.
35394422	6	39	theme	structural	926:935	arg1	modeling					937:944	structural modeling	926:944	structural modeling	926:944	Furthermore, bioinformatics and structural modeling revealed similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively.
35394422	2	40	theme	crenarchaeal	202:213	arg1	N-glycosylation					215:229	The crenarchaeal N-glycosylation	198:229	The crenarchaeal N-glycosylation	198:229	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	2	41	theme	chitobiose	275:284	arg1	structure					291:299	a lipid-linked chitobiose core structure	260:299	a lipid-linked chitobiose core structure	260:299	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	1	42	theme	post-translational	123:140	arg1	modification					142:153	a post-translational modification	121:153	a post-translational modification found in organisms of all domains of life	121:195	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	1	42	theme	post-translational	123:140	arg1	N-glycosylation					102:116	Protein N-glycosylation	94:116	Protein N-glycosylation	94:116	Protein N-glycosylation is a post-translational modification found in organisms of all domains of life.
35394422	5	43	theme	conserved	762:770	arg1	residue					782:788	a conserved histidine residue	760:788	a conserved histidine residue	760:788	Substitution of a conserved histidine residue, found also in the eukaryotic and bacterial homologs, demonstrated its functional importance for Agl24.
35394422	2	44	theme	lipid-linked	262:273	arg1	structure					291:299	a lipid-linked chitobiose core structure	260:299	a lipid-linked chitobiose core structure	260:299	The crenarchaeal N-glycosylation begins with the synthesis of a lipid-linked chitobiose core structure, identical to that in Eukaryotes, although the enzyme catalyzing this reaction remains unknown.
35394422	3	45	theme	glycosylation	513:525	arg1	enzyme					527:532	archaeal glycosylation enzyme 24	504:535	archaeal glycosylation enzyme 24 (Agl24)	504:543	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	3	45	theme	glycosylation	513:525	arg1	Agl24					538:542	Agl24	538:542	Agl24	538:542	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	0	46	theme	N-glycan	55:62	arg1	enzymes					85:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	3	47	theme	archaeal	450:457	arg1	β-1,4-N-acetylglucosaminyltransferase					459:495	a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase	435:495	a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase	435:495	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
35394422	6	48	theme	similar	1085:1091	arg1	reaction					1093:1100	a similar reaction	1083:1100	a similar reaction	1083:1100	Furthermore, bioinformatics and structural modeling revealed similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively.
35394422	0	49	theme	eukaryotic	44:53	arg1	enzymes					85:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	the eukaryotic N-glycan chitobiose synthesis enzymes	40:91	Agl24 is an ancient archaeal homolog of the eukaryotic N-glycan chitobiose synthesis enzymes.
35394422	6	50	theme	distant	1010:1016	arg1	relation					1018:1025	a distant relation	1008:1025	a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively	1008:1114	Furthermore, bioinformatics and structural modeling revealed similarities of Agl24 to the eukaryotic Alg14/13 and a distant relation to the bacterial MurG, which are catalyzing the same or a similar reaction, respectively.
35394422	3	51	theme	responsible	546:556	arg1	β-1,4-N-acetylglucosaminyltransferase					459:495	a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase	435:495	a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase	435:495	Here, we report the identification of a thermostable archaeal β-1,4-N-acetylglucosaminyltransferase, named archaeal glycosylation enzyme 24 (Agl24), responsible for the synthesis of the N-glycan chitobiose core.
37005509	2	0	theme	Tsuji-Trost-type	427:442	arg1	methodology					458:468	ligand-controlled Tsuji-Trost-type glycosylation methodology	409:468	ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner	409:616	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	2	1	theme	α-	593:594	arg1	manner					611:616	an α- or β-selective manner	590:616	an α- or β-selective manner	590:616	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	2	2	theme	ligand-controlled	409:425	arg1	methodology					458:468	ligand-controlled Tsuji-Trost-type glycosylation methodology	409:468	ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner	409:616	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	0	3	theme	Ligands	142:148	arg1	Discovery					112:120	Discovery	112:120	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.	0:149	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	3	4	theme	native	707:712	arg1	glucosylceramides					714:730	native glucosylceramides	707:730	native glucosylceramides	707:730	Glucocerebrosidase GBA1 cleaves these synthetic pseudo-β-glucosylceramides similarly to native glucosylceramides.
37005509	1	5	theme	compact	300:306	arg1	group					337:341	a compact sp2-hybridized exo-methylene group	298:341	a compact sp2-hybridized exo-methylene group	298:341	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	0	6	theme	Mincle-Selective	125:140	arg1	Ligands					142:148	Mincle-Selective Ligands	125:148	Mincle-Selective Ligands	125:148	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	1	7	theme	sp2-hybridized	308:321	arg1	group					337:341	a compact sp2-hybridized exo-methylene group	298:341	a compact sp2-hybridized exo-methylene group	298:341	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	3	8	theme	synthetic	657:665	arg1	pseudo-β-glucosylceramides					667:692	these synthetic pseudo-β-glucosylceramides	651:692	these synthetic pseudo-β-glucosylceramides	651:692	Glucocerebrosidase GBA1 cleaves these synthetic pseudo-β-glucosylceramides similarly to native glucosylceramides.
37005509	1	9	theme	carbohydrate	223:234	arg1	structure					236:244	the carbohydrate structure	219:244	the carbohydrate structure	219:244	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	2	10	theme	glucosylceramide	559:574	arg1	analogues					576:584	glucosylceramide analogues	559:584	glucosylceramide analogues	559:584	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	1	11	theme	structure	236:244	arg1	position					207:214	the sp3-hybridized C2 position	185:214	the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group)	185:280	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	0	12	theme	Ligand-controlled	0:16	arg1	Synthesis					34:42	Ligand-controlled Stereoselective Synthesis	0:42	Ligand-controlled Stereoselective Synthesis	0:42	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	1	13	theme	exo-methylene	323:335	arg1	group					337:341	a compact sp2-hybridized exo-methylene group	298:341	a compact sp2-hybridized exo-methylene group	298:341	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	1	14	contain	have	359:362	arg2	activities					382:391	unique biological activities	364:391	unique biological activities	364:391	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	1	14	contain	have	359:362	arg1	analogues					166:174	Glycoconjugate analogues	151:174	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group	151:341	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	2	15	theme	2-exo-methylene	509:523	arg1	pseudo-glycoconjugates					525:546	these 2-exo-methylene pseudo-glycoconjugates	503:546	these 2-exo-methylene pseudo-glycoconjugates	503:546	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	2	15	theme	2-exo-methylene	509:523	arg1	analogues					576:584	glucosylceramide analogues	559:584	glucosylceramide analogues	559:584	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	2	16	theme	pseudo-glycoconjugates	525:546	arg1	pseudo-glycoconjugates					525:546	these 2-exo-methylene pseudo-glycoconjugates	503:546	these 2-exo-methylene pseudo-glycoconjugates	503:546	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	2	16	theme	pseudo-glycoconjugates	525:546	arg1	analogues					576:584	glucosylceramide analogues	559:584	glucosylceramide analogues	559:584	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	2	16	theme	pseudo-glycoconjugates	525:546	arg1	variety					492:498	a variety	490:498	a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues,	490:585	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	1	17	theme	Glycoconjugate	151:164	arg1	analogues					166:174	Glycoconjugate analogues	151:174	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group	151:341	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	4	18	theme	C-type	825:830	arg1	Mincle					840:845	Mincle	840:845	Mincle	840:845	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	4	18	theme	C-type	825:830	arg1	lectin					832:837	macrophage-inducible C-type lectin	804:837	macrophage-inducible C-type lectin (Mincle)	804:846	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	0	19	theme	Biological	48:57	arg1	Activities					59:68	Biological Activities	48:68	Biological Activities	48:68	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	1	20	theme	hydroxyl	266:273	arg1	group					275:279	a hydroxyl group	264:279	a hydroxyl group	264:279	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	0	21	theme	2-Exomethylene	73:86	arg1	Pseudo-glycoconjugates					88:109	2-Exomethylene Pseudo-glycoconjugates	73:109	2-Exomethylene Pseudo-glycoconjugates	73:109	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	2	22	theme	β-selective	599:609	arg1	manner					611:616	an α- or β-selective manner	590:616	an α- or β-selective manner	590:616	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	1	23	theme	unique	364:369	arg1	activities					382:391	unique biological activities	364:391	unique biological activities	364:391	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	4	24	theme	selective	770:778	arg1	activity					787:794	selective ligand activity	770:794	selective ligand activity towards macrophage-inducible C-type lectin (Mincle)	770:846	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	3	25	theme	Glucocerebrosidase	619:636	arg1	GBA1					638:641	Glucocerebrosidase GBA1	619:641	Glucocerebrosidase GBA1	619:641	Glucocerebrosidase GBA1 cleaves these synthetic pseudo-β-glucosylceramides similarly to native glucosylceramides.
37005509	1	26	theme	biological	371:380	arg1	activities					382:391	unique biological activities	364:391	unique biological activities	364:391	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	4	27	theme	native	860:865	arg1	glucosylceramides					867:883	native glucosylceramides	860:883	native glucosylceramides	860:883	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	0	28	dep	Synthesis	34:42	arg1	Discovery					112:120	Discovery	112:120	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.	0:149	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	1	29	theme	C2	204:205	arg1	position					207:214	the sp3-hybridized C2 position	185:214	the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group)	185:280	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	4	30	theme	ligand	780:785	arg1	activity					787:794	selective ligand activity	770:794	selective ligand activity towards macrophage-inducible C-type lectin (Mincle)	770:846	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	1	31	theme	sp3-hybridized	189:202	arg1	position					207:214	the sp3-hybridized C2 position	185:214	the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group)	185:280	Glycoconjugate analogues in which the sp3-hybridized C2 position of the carbohydrate structure (normally bearing a hydroxyl group) is converted to a compact sp2-hybridized exo-methylene group are expected to have unique biological activities.
37005509	4	32	theme	macrophage-inducible	804:823	arg1	Mincle					840:845	Mincle	840:845	Mincle	840:845	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	4	32	theme	macrophage-inducible	804:823	arg1	lectin					832:837	macrophage-inducible C-type lectin	804:837	macrophage-inducible C-type lectin (Mincle)	804:846	The pseudo-glucosylceramides exhibit selective ligand activity towards macrophage-inducible C-type lectin (Mincle), but unlike native glucosylceramides, are inactive towards CD1d.
37005509	0	33	theme	Pseudo-glycoconjugates	88:109	arg1	Synthesis					34:42	Ligand-controlled Stereoselective Synthesis	0:42	Ligand-controlled Stereoselective Synthesis	0:42	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	0	33	theme	Pseudo-glycoconjugates	88:109	arg1	Activities					59:68	Biological Activities	48:68	Biological Activities	48:68	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
37005509	2	34	theme	glycosylation	444:456	arg1	methodology					458:468	ligand-controlled Tsuji-Trost-type glycosylation methodology	409:468	ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner	409:616	We established ligand-controlled Tsuji-Trost-type glycosylation methodology to directly prepare a variety of these 2-exo-methylene pseudo-glycoconjugates, including glucosylceramide analogues, in an α- or β-selective manner.
37005509	0	35	theme	Stereoselective	18:32	arg1	Synthesis					34:42	Ligand-controlled Stereoselective Synthesis	0:42	Ligand-controlled Stereoselective Synthesis	0:42	Ligand-controlled Stereoselective Synthesis and Biological Activities of 2-Exomethylene Pseudo-glycoconjugates: Discovery of Mincle-Selective Ligands.
36437732	4	0	theme	EXPERIMENTAL	632:643	arg1	DESIGN					645:650	EXPERIMENTAL DESIGN	632:650	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls	632:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	6	1	theme	Global	907:912	arg1	level					914:918	Global level	907:918	Global level	907:918	Global level and specific subtypes of glycan structures were compared between patients and controls.
36437732	8	2	theme	glycans	1266:1272	arg1	glycans					1266:1272	35 individual glycans	1252:1272	35 individual glycans	1252:1272	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	8	2	theme	glycans	1266:1272	arg1	three					1243:1247	three	1243:1247	three	1243:1247	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	10	3	theme	thyroid	1635:1641	arg1	recurrence					1650:1659	thyroid cancer recurrence	1635:1659	thyroid cancer recurrence	1635:1659	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	7	4	dep	RESULTS	1008:1014	arg1	evaluated					1019:1027	evaluated	1019:1027	evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls	1019:1114	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	8	5	theme	significant	1281:1291	arg1	differences					1293:1303	significant differences	1281:1303	significant differences	1281:1303	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	12	6	theme	surveillance	1840:1851	arg1	tool					1853:1856	an effective surveillance tool	1827:1856	an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation	1827:1937	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	11	7	theme	N-glycomic	1715:1724	arg1	profile					1726:1732	CONCLUSIONS Altered N-glycomic profile	1695:1732	CONCLUSIONS Altered N-glycomic profile	1695:1732	CONCLUSIONS Altered N-glycomic profile was associated with thyroid cancer recurrence.
36437732	10	8	dep	AUC = 0.82	1662:1671	arg1	%					1679:1679	CI 95% = 0.64-0.99	1674:1691	CI 95% = 0.64-0.99	1674:1691	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	9	9	theme	biantennary	1354:1364	arg1	N-glycans					1383:1391	biosynthetically related biantennary core fucosylated N-glycans	1329:1391	biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose)	1329:1486	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	9	theme	biantennary	1354:1364	arg1	glycans					1316:1322	The three glycans	1306:1322	The three glycans	1306:1322	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	3	10	theme	recurrent	606:614	arg1	cancer					624:629	recurrent thyroid cancer	606:629	recurrent thyroid cancer	606:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	4	11	from	patients	690:697	arg1	samples					677:683	banked serum samples	664:683	banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls	664:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	4	12	theme	recurrent	704:712	arg1	cancer					722:727	recurrent thyroid cancer	704:727	recurrent thyroid cancer	704:727	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	9	13	theme	fucosylated	1371:1381	arg1	N-glycans					1383:1391	biosynthetically related biantennary core fucosylated N-glycans	1329:1391	biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose)	1329:1486	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	13	theme	fucosylated	1371:1381	arg1	glycans					1316:1322	The three glycans	1306:1322	The three glycans	1306:1322	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	10	14	theme	CI	1674:1675	arg1	%					1679:1679	CI 95% = 0.64-0.99	1674:1691	CI 95% = 0.64-0.99	1674:1691	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	7	15	theme	healthy	1099:1105	arg1	controls					1107:1114	15 healthy controls	1096:1114	15 healthy controls	1096:1114	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	1	16	theme	Thyroid	119:125	arg1	recurrence					134:143	PURPOSE Thyroid cancer recurrence	111:143	PURPOSE Thyroid cancer recurrence following curative thyroidectomy	111:176	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	4	17	theme	healthy	752:758	arg1	controls					760:767	healthy controls	752:767	healthy controls	752:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	0	18	theme	recurrence	52:61	arg1	profile					15:21	profile	15:21	profile	15:21	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	0	18	theme	recurrence	52:61	arg1	biomarker					39:47	a predictive biomarker	26:47	a predictive biomarker of recurrence in patients with differentiated thyroid cancer	26:108	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	7	19	theme	cancer	1074:1079	arg1	recurrence					1081:1090	cancer recurrence	1074:1090	cancer recurrence	1074:1090	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	1	20	theme	curative	155:162	arg1	thyroidectomy					164:176	curative thyroidectomy	155:176	curative thyroidectomy	155:176	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	7	21	from	patients	1060:1067	arg1	samples					1044:1050	28 independent samples	1029:1050	28 independent samples from 13 patients with cancer recurrence and 15 healthy controls	1029:1114	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	7	22	with	controls	1107:1114	arg1	recurrence					1081:1090	cancer recurrence	1074:1090	cancer recurrence	1074:1090	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	3	23	from	surveillance	590:601	arg1	cancer					624:629	recurrent thyroid cancer	606:629	recurrent thyroid cancer	606:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	0	24	theme	differentiated	80:93	arg1	cancer					103:108	differentiated thyroid cancer	80:108	differentiated thyroid cancer	80:108	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	8	25	theme	glycosylation	1136:1148	arg1	modifications					1196:1208	terminal glycan modifications	1180:1208	terminal glycan modifications	1180:1208	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	8	25	theme	glycosylation	1136:1148	arg1	features					1124:1131	Global features	1117:1131	Global features	1117:1131	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	8	25	theme	glycosylation	1136:1148	arg1	class					1170:1174	N-glycan class	1161:1174	N-glycan class	1161:1174	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	0	26	from	biomarker	39:47	arg1	patients					66:73	patients	66:73	patients with differentiated thyroid cancer	66:108	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	7	27	theme	independent	1032:1042	arg1	samples					1044:1050	28 independent samples	1029:1050	28 independent samples from 13 patients with cancer recurrence and 15 healthy controls	1029:1114	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	10	28	theme	reduced	1524:1530	arg1	galactosylation					1532:1546	reduced galactosylation	1524:1546	reduced galactosylation	1524:1546	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	2	29	theme	serum	402:406	arg1	glycosylation					408:420	serum glycosylation	402:420	serum glycosylation	402:420	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	9	30	dep	galactosylation	1427:1441	arg1	G2F					1458:1460	G2F	1458:1460	G2F	1458:1460	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	30	dep	galactosylation	1427:1441	arg1	G0F					1444:1446	G0F	1444:1446	G0F	1444:1446	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	30	dep	galactosylation	1427:1441	arg1	G1F					1449:1451	G1F	1449:1451	G1F	1449:1451	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	3	31	theme	potential	499:507	arg1	utility					509:515	the potential utility	495:515	the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer	495:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	8	32	theme	terminal	1180:1187	arg1	modifications					1196:1208	terminal glycan modifications	1180:1208	terminal glycan modifications	1180:1208	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	2	33	theme	cancer	433:438	arg1	surveillance					440:451	thyroid cancer surveillance	425:451	thyroid cancer surveillance	425:451	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	10	34	dep	G0F	1502:1504	arg1	G1F					1506:1508	G1F	1506:1508	G1F	1506:1508	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	6	35	theme	glycan	945:950	arg1	structures					952:961	glycan structures	945:961	glycan structures	945:961	Global level and specific subtypes of glycan structures were compared between patients and controls.
36437732	10	36	theme	healthy	1592:1598	arg1	p = 0.004					1610:1618	p = 0.004	1610:1618	p = 0.004	1610:1618	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	10	36	theme	healthy	1592:1598	arg1	controls					1600:1607	healthy controls	1592:1607	healthy controls (p = 0.004)	1592:1619	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	11	37	theme	thyroid	1754:1760	arg1	recurrence					1769:1778	thyroid cancer recurrence	1754:1778	thyroid cancer recurrence	1754:1778	CONCLUSIONS Altered N-glycomic profile was associated with thyroid cancer recurrence.
36437732	3	38	theme	serum	528:532	arg1	profile					543:549	altered serum glycomic profile	520:549	altered serum glycomic profile	520:549	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	5	39	theme	MALDI-TOF	878:886	arg1	spectrometry					893:904	MALDI-TOF mass spectrometry	878:904	MALDI-TOF mass spectrometry	878:904	N-glycans were enzymatically released from serum glycoproteins, labeled via permethylation, and analyzed by MALDI-TOF mass spectrometry.
36437732	12	40	theme	cancer	1903:1908	arg1	prognosis					1882:1890	prognosis	1882:1890	prognosis	1882:1890	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	12	40	theme	cancer	1903:1908	arg1	care					1873:1876	care	1873:1876	care	1873:1876	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	12	41	theme	thyroid	1895:1901	arg1	cancer					1903:1908	thyroid cancer	1895:1908	thyroid cancer	1895:1908	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	9	42	dep	G0F	1444:1446	arg1	F					1477:1477	F	1477:1477	F	1477:1477	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	42	dep	G0F	1444:1446	arg1	G					1463:1463	G	1463:1463	G	1463:1463	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	1	43	theme	current	236:242	arg1	strategies					257:266	current surveillance strategies	236:266	current surveillance strategies	236:266	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	12	44	theme	prospective	1916:1926	arg1	validation					1928:1937	prospective validation	1916:1937	prospective validation	1916:1937	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	2	45	gly	glycosylation	339:351	arg1	cancer					375:380	thyroid cancer	367:380	thyroid cancer	367:380	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	4	46	theme	serum	671:675	arg1	samples					677:683	banked serum samples	664:683	banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls	664:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	11	47	theme	Altered	1707:1713	arg1	profile					1726:1732	CONCLUSIONS Altered N-glycomic profile	1695:1732	CONCLUSIONS Altered N-glycomic profile	1695:1732	CONCLUSIONS Altered N-glycomic profile was associated with thyroid cancer recurrence.
36437732	3	48	theme	profile	543:549	arg1	utility					509:515	the potential utility	495:515	the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer	495:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	4	49	from	controls	760:767	arg1	samples					677:683	banked serum samples	664:683	banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls	664:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	12	50	theme	effective	1830:1838	arg1	tool					1853:1856	an effective surveillance tool	1827:1856	an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation	1827:1937	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	10	51	theme	cancer	1643:1648	arg1	recurrence					1650:1659	thyroid cancer recurrence	1635:1659	thyroid cancer recurrence	1635:1659	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	0	52	with	patients	66:73	arg1	cancer					103:108	differentiated thyroid cancer	80:108	differentiated thyroid cancer	80:108	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	3	53	theme	disease	582:588	arg1	surveillance					590:601	disease surveillance	582:601	disease surveillance in recurrent thyroid cancer	582:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	1	54	theme	early	287:291	arg1	detection					293:301	early detection	287:301	early detection	287:301	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	8	55	theme	individual	1255:1264	arg1	glycans					1266:1272	35 individual glycans	1252:1272	35 individual glycans	1252:1272	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	10	56	located	observed	1552:1559	arg2	ratio					1493:1497	The ratio	1489:1497	The ratio of G0F:G1F that captures reduced galactosylation	1489:1546	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	10	56	located	observed	1552:1559	arg1	samples					1573:1579	patients samples	1564:1579	patients samples	1564:1579	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	4	57	with	controls	760:767	arg1	cancer					722:727	recurrent thyroid cancer	704:727	recurrent thyroid cancer	704:727	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	2	58	theme	Prior	304:308	arg1	studies					310:316	Prior studies	304:316	Prior studies	304:316	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	4	59	theme	thyroid	714:720	arg1	cancer					722:727	recurrent thyroid cancer	704:727	recurrent thyroid cancer	704:727	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	3	60	theme	thyroid	616:622	arg1	cancer					624:629	recurrent thyroid cancer	606:629	recurrent thyroid cancer	606:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	1	61	theme	increased	197:205	arg1	morbidity					207:215	morbidity	207:215	morbidity	207:215	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	2	62	from	utility	391:397	arg1	surveillance					440:451	thyroid cancer surveillance	425:451	thyroid cancer surveillance	425:451	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	9	63	gly	fucosylated	1371:1381	arg1	N-glycans					1383:1391	biosynthetically related biantennary core fucosylated N-glycans	1329:1391	biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose)	1329:1486	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	63	gly	fucosylated	1371:1381	arg1	glycans					1316:1322	The three glycans	1306:1322	The three glycans	1306:1322	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	8	64	theme	Global	1117:1122	arg1	modifications					1196:1208	terminal glycan modifications	1180:1208	terminal glycan modifications	1180:1208	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	8	64	theme	Global	1117:1122	arg1	features					1124:1131	Global features	1117:1131	Global features	1117:1131	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	8	64	theme	Global	1117:1122	arg1	class					1170:1174	N-glycan class	1161:1174	N-glycan class	1161:1174	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	10	65	dep	predicted	1625:1633	arg1	AUC = 0.82					1662:1671	AUC = 0.82	1662:1671	AUC = 0.82	1662:1671	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	9	66	theme	related	1346:1352	arg1	N-glycans					1383:1391	biosynthetically related biantennary core fucosylated N-glycans	1329:1391	biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose)	1329:1486	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	66	theme	related	1346:1352	arg1	glycans					1316:1322	The three glycans	1306:1322	The three glycans	1306:1322	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	2	67	theme	tissue	332:337	arg1	glycosylation					339:351	tissue glycosylation	332:351	tissue glycosylation	332:351	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	7	68	from	controls	1107:1114	arg1	samples					1044:1050	28 independent samples	1029:1050	28 independent samples from 13 patients with cancer recurrence and 15 healthy controls	1029:1114	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	2	69	theme	thyroid	367:373	arg1	cancer					375:380	thyroid cancer	367:380	thyroid cancer	367:380	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	4	70	dep	DESIGN	645:650	arg1	employed					655:662	employed	655:662	employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls	655:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	1	71	theme	PURPOSE	111:117	arg1	recurrence					134:143	PURPOSE Thyroid cancer recurrence	111:143	PURPOSE Thyroid cancer recurrence following curative thyroidectomy	111:176	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	7	72	with	patients	1060:1067	arg1	recurrence					1081:1090	cancer recurrence	1074:1090	cancer recurrence	1074:1090	RESULTS We evaluated 28 independent samples from 13 patients with cancer recurrence and 15 healthy controls.
36437732	1	73	theme	cancer	127:132	arg1	recurrence					134:143	PURPOSE Thyroid cancer recurrence	111:143	PURPOSE Thyroid cancer recurrence following curative thyroidectomy	111:176	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	12	74	theme	serum-based	1786:1796	arg1	biomarker					1798:1806	This serum-based biomarker	1781:1806	This serum-based biomarker	1781:1806	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	5	75	theme	serum	813:817	arg1	glycoproteins					819:831	serum glycoproteins	813:831	serum glycoproteins	813:831	N-glycans were enzymatically released from serum glycoproteins, labeled via permethylation, and analyzed by MALDI-TOF mass spectrometry.
36437732	0	76	theme	thyroid	95:101	arg1	cancer					103:108	differentiated thyroid cancer	80:108	differentiated thyroid cancer	80:108	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	9	77	theme	galactosylation	1427:1441	arg1	degree					1417:1422	the degree	1413:1422	the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose)	1413:1486	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	10	78	theme	G0F	1502:1504	arg1	ratio					1493:1497	The ratio	1489:1497	The ratio of G0F:G1F that captures reduced galactosylation	1489:1546	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	12	79	dep	care	1873:1876	arg1	the					1869:1871	the	1869:1871	the	1869:1871	This serum-based biomarker would be useful as an effective surveillance tool to improve the care and prognosis of thyroid cancer after prospective validation.
36437732	8	80	theme	N-glycan	1161:1168	arg1	class					1170:1174	N-glycan class	1161:1174	N-glycan class	1161:1174	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	9	81	dep	G	1463:1463	arg1	fucose					1480:1485	fucose	1480:1485	fucose	1480:1485	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	81	dep	G	1463:1463	arg1	galactose					1466:1474	galactose	1466:1474	galactose	1466:1474	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	5	82	attach	released	799:806	arg1	glycoproteins					819:831	serum glycoproteins	813:831	serum glycoproteins	813:831	N-glycans were enzymatically released from serum glycoproteins, labeled via permethylation, and analyzed by MALDI-TOF mass spectrometry.
36437732	5	82	attach	released	799:806	arg2	N-glycans					770:778	N-glycans	770:778	N-glycans	770:778	N-glycans were enzymatically released from serum glycoproteins, labeled via permethylation, and analyzed by MALDI-TOF mass spectrometry.
36437732	2	83	theme	glycosylation	408:420	arg1	utility					391:397	the utility	387:397	the utility of serum glycosylation in thyroid cancer surveillance	387:451	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	5	84	theme	mass	888:891	arg1	spectrometry					893:904	MALDI-TOF mass spectrometry	878:904	MALDI-TOF mass spectrometry	878:904	N-glycans were enzymatically released from serum glycoproteins, labeled via permethylation, and analyzed by MALDI-TOF mass spectrometry.
36437732	9	85	theme	core	1366:1369	arg1	N-glycans					1383:1391	biosynthetically related biantennary core fucosylated N-glycans	1329:1391	biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose)	1329:1486	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	9	85	theme	core	1366:1369	arg1	glycans					1316:1322	The three glycans	1306:1322	The three glycans	1306:1322	The three glycans were biosynthetically related biantennary core fucosylated N-glycans that only varied by the degree of galactosylation (G0F, G1F, and G2F; G: galactose, F: fucose).
36437732	8	86	theme	glycan	1189:1194	arg1	modifications					1196:1208	terminal glycan modifications	1180:1208	terminal glycan modifications	1180:1208	Global features of glycosylation, including N-glycan class and terminal glycan modifications were similar between groups, but three of 35 individual glycans showed significant differences.
36437732	10	87	theme	patients	1564:1571	arg1	samples					1573:1579	patients samples	1564:1579	patients samples	1564:1579	The ratio of G0F:G1F that captures reduced galactosylation was observed in patients samples but not in healthy controls (p = 0.004) and predicted thyroid cancer recurrence (AUC = 0.82, CI 95% = 0.64-0.99).
36437732	11	88	theme	cancer	1762:1767	arg1	recurrence					1769:1778	thyroid cancer recurrence	1754:1778	thyroid cancer recurrence	1754:1778	CONCLUSIONS Altered N-glycomic profile was associated with thyroid cancer recurrence.
36437732	5	89	gly	glycoproteins	819:831	arg1	glycoproteins					819:831	serum glycoproteins	813:831	serum glycoproteins	813:831	N-glycans were enzymatically released from serum glycoproteins, labeled via permethylation, and analyzed by MALDI-TOF mass spectrometry.
36437732	0	90	theme	predictive	28:37	arg1	profile					15:21	profile	15:21	profile	15:21	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	0	90	theme	predictive	28:37	arg1	biomarker					39:47	a predictive biomarker	26:47	a predictive biomarker of recurrence in patients with differentiated thyroid cancer	26:108	Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
36437732	6	91	theme	structures	952:961	arg1	level					914:918	Global level	907:918	Global level	907:918	Global level and specific subtypes of glycan structures were compared between patients and controls.
36437732	6	91	theme	structures	952:961	arg1	subtypes					933:940	specific subtypes	924:940	specific subtypes	924:940	Global level and specific subtypes of glycan structures were compared between patients and controls.
36437732	2	92	theme	thyroid	425:431	arg1	surveillance					440:451	thyroid cancer surveillance	425:451	thyroid cancer surveillance	425:451	Prior studies indicate that tissue glycosylation is altered in thyroid cancer, but the utility of serum glycosylation in thyroid cancer surveillance remains unexplored.
36437732	3	93	theme	glycomic	534:541	arg1	profile					543:549	altered serum glycomic profile	520:549	altered serum glycomic profile	520:549	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	6	94	theme	specific	924:931	arg1	subtypes					933:940	specific subtypes	924:940	specific subtypes	924:940	Global level and specific subtypes of glycan structures were compared between patients and controls.
36437732	4	95	theme	banked	664:669	arg1	samples					677:683	banked serum samples	664:683	banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls	664:767	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	4	96	with	patients	690:697	arg1	cancer					722:727	recurrent thyroid cancer	704:727	recurrent thyroid cancer	704:727	EXPERIMENTAL DESIGN We employed banked serum samples from patients with recurrent thyroid cancer post thyroidectomy and healthy controls.
36437732	3	97	theme	altered	520:526	arg1	profile					543:549	altered serum glycomic profile	520:549	altered serum glycomic profile	520:549	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
36437732	1	98	theme	surveillance	244:255	arg1	strategies					257:266	current surveillance strategies	236:266	current surveillance strategies	236:266	PURPOSE Thyroid cancer recurrence following curative thyroidectomy is associated with increased morbidity and mortality, but current surveillance strategies are inadequate for early detection.
36437732	11	99	theme	CONCLUSIONS	1695:1705	arg1	profile					1726:1732	CONCLUSIONS Altered N-glycomic profile	1695:1732	CONCLUSIONS Altered N-glycomic profile	1695:1732	CONCLUSIONS Altered N-glycomic profile was associated with thyroid cancer recurrence.
36437732	3	100	theme	tumor-specific	556:569	arg1	target					571:576	a tumor-specific target	554:576	a tumor-specific target for disease surveillance in recurrent thyroid cancer	554:629	We therefore assessed the potential utility of altered serum glycomic profile as a tumor-specific target for disease surveillance in recurrent thyroid cancer.
35411940	8	0	theme	reticuloendothelial	1132:1150	arg1	test					1161:1164	a splenic reticuloendothelial function test	1122:1164	a splenic reticuloendothelial function test	1122:1164	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	8	0	theme	reticuloendothelial	1132:1150	arg1	HMGs					1104:1107	HMGs	1104:1107	HMGs	1104:1107	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	2	1	theme	cross-linked	316:327	arg1	proteins					329:336	cross-linked proteins	316:336	cross-linked proteins with N-linked high-mannose glycans (HMGs)	316:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	6	2	theme	structures	999:1008	arg1	mixture					973:979	a mixture	971:979	a mixture of Man5-9 GlcNAc2 structures	971:1008	Glycomic analysis by mass spectrometry identified a mixture of Man5-9 GlcNAc2 structures.
35411940	8	3	theme	splenic	1124:1130	arg1	test					1161:1164	a splenic reticuloendothelial function test	1122:1164	a splenic reticuloendothelial function test	1122:1164	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	8	3	theme	splenic	1124:1130	arg1	HMGs					1104:1107	HMGs	1104:1107	HMGs	1104:1107	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	8	4	from	levels	1179:1184	arg1	RBCs					1189:1192	RBCs	1189:1192	RBCs from patients with potential functional hyposplenism	1189:1245	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	1	5	theme	they	134:137	arg1	age					139:141	they age	134:141	they age	134:141	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	6	6	theme	GlcNAc2	991:997	arg1	structures					999:1008	Man5-9 GlcNAc2 structures	984:1008	Man5-9 GlcNAc2 structures	984:1008	Glycomic analysis by mass spectrometry identified a mixture of Man5-9 GlcNAc2 structures.
35411940	3	7	theme	phagocytic	522:531	arg1	cells					545:549	specialised phagocytic endothelial cells	510:549	specialised phagocytic endothelial cells	510:549	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	6	8	theme	Man5-9	984:989	arg1	structures					999:1008	Man5-9 GlcNAc2 structures	984:1008	Man5-9 GlcNAc2 structures	984:1008	Glycomic analysis by mass spectrometry identified a mixture of Man5-9 GlcNAc2 structures.
35411940	3	9	theme	endothelial	533:543	arg1	cells					545:549	specialised phagocytic endothelial cells	510:549	specialised phagocytic endothelial cells	510:549	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	2	10	link	cross-linked	316:327	arg1	proteins					329:336	cross-linked proteins	316:336	cross-linked proteins with N-linked high-mannose glycans (HMGs)	316:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	5	11	theme	large	894:898	arg1	aggregates					909:918	large membrane aggregates	894:918	large membrane aggregates	894:918	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	1	12	theme	Red	73:75	arg1	RBCs					90:93	RBCs	90:93	RBCs	90:93	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	1	12	theme	Red	73:75	arg1	cells					83:87	Red blood cells	73:87	Red blood cells (RBCs)	73:94	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	5	13	theme	high	856:859	arg1	levels					861:866	high levels	856:866	high levels	856:866	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	5	14	from	patients	782:789	arg1	RBCs					772:775	RBCs	772:775	RBCs from patients who had previously undergone splenectomy	772:830	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	1	15	from	membrane	108:115	arg1	spleen					124:129	the spleen	120:129	the spleen	120:129	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	1	16	theme	blood	77:81	arg1	RBCs					90:93	RBCs	90:93	RBCs	90:93	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	1	16	theme	blood	77:81	arg1	cells					83:87	Red blood cells	73:87	Red blood cells (RBCs)	73:94	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	8	17	theme	functional	1223:1232	arg1	hyposplenism					1234:1245	potential functional hyposplenism	1213:1245	potential functional hyposplenism	1213:1245	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	3	18	theme	diseases	629:636	arg1	characteristic					605:618	characteristic	605:618	characteristic	605:618	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	2	19	theme	oxidative	272:280	arg1	stress					282:287	oxidative stress	272:287	oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs)	272:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	2	20	theme	high-mannose	352:363	arg1	glycans					365:371	N-linked high-mannose glycans	343:371	N-linked high-mannose glycans (HMGs)	343:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	2	20	theme	high-mannose	352:363	arg1	HMGs					374:377	HMGs	374:377	HMGs	374:377	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	4	21	theme	membrane	709:716	arg1	removal					684:690	removal	684:690	removal of molecules and membrane in healthy individuals	684:739	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	2	22	theme	N-linked	343:350	arg1	glycans					365:371	N-linked high-mannose glycans	343:371	N-linked high-mannose glycans (HMGs)	343:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	2	22	theme	N-linked	343:350	arg1	HMGs					374:377	HMGs	374:377	HMGs	374:377	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	0	23	theme	membrane	27:34	arg1	Measurement					0:10	Measurement	0:10	Measurement of erythrocyte membrane	0:34	Measurement of erythrocyte membrane mannoses to assess splenic function.
35411940	3	24	theme	specialised	510:520	arg1	cells					545:549	specialised phagocytic endothelial cells	510:549	specialised phagocytic endothelial cells	510:549	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	0	25	theme	erythrocyte	15:25	arg1	membrane					27:34	erythrocyte membrane	15:34	erythrocyte membrane	15:34	Measurement of erythrocyte membrane mannoses to assess splenic function.
35411940	2	26	theme	Plasmodium	244:253	arg1	falciparum					255:264	Plasmodium falciparum	244:264	Plasmodium falciparum	244:264	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	5	27	theme	HMGs	764:767	arg1	expression					750:759	Surface expression	742:759	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy	742:830	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	5	28	theme	membrane	900:907	arg1	aggregates					909:918	large membrane aggregates	894:918	large membrane aggregates	894:918	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	2	29	link	N-linked	343:350	arg1	glycans					365:371	N-linked high-mannose glycans	343:371	N-linked high-mannose glycans (HMGs)	343:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	2	29	link	N-linked	343:350	arg1	HMGs					374:377	HMGs	374:377	HMGs	374:377	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	8	30	theme	high	1271:1274	arg1	levels					1276:1281	high levels	1271:1281	high levels that may indicate risk of complications	1271:1321	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	6	31	theme	mass	942:945	arg1	spectrometry					947:958	mass spectrometry	942:958	mass spectrometry	942:958	Glycomic analysis by mass spectrometry identified a mixture of Man5-9 GlcNAc2 structures.
35411940	3	32	theme	characteristic	605:618	arg1	haemolysis					594:603	the extravascular haemolysis	576:603	the extravascular haemolysis characteristic of these diseases	576:636	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	8	33	theme	complications	1309:1321	arg1	risk					1301:1304	risk	1301:1304	risk of complications	1301:1321	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	3	34	theme	mannose-binding	416:430	arg1	receptor					463:470	the mannose receptor	451:470	the mannose receptor (CD206)	451:478	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	3	34	theme	mannose-binding	416:430	arg1	lectins					432:438	mannose-binding lectins	416:438	mannose-binding lectins	416:438	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	0	35	theme	splenic	55:61	arg1	function					63:70	splenic function	55:70	splenic function	55:70	Measurement of erythrocyte membrane mannoses to assess splenic function.
35411940	7	36	theme	manual	1043:1048	arg1	r = 0.75-0.85					1062:1074	r = 0.75-0.85	1062:1074	r = 0.75-0.85	1062:1074	HMG levels correlated well with manual pit counts (r = 0.75-0.85).
35411940	7	36	theme	manual	1043:1048	arg1	counts					1054:1059	manual pit counts	1043:1059	manual pit counts (r = 0.75-0.85)	1043:1075	HMG levels correlated well with manual pit counts (r = 0.75-0.85).
35411940	8	37	from	patients	1199:1206	arg1	RBCs					1189:1192	RBCs	1189:1192	RBCs from patients with potential functional hyposplenism	1189:1245	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	3	38	theme	mannose	455:461	arg1	CD206					473:477	CD206	473:477	CD206	473:477	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	3	38	theme	mannose	455:461	arg1	receptor					463:470	the mannose receptor	451:470	the mannose receptor (CD206)	451:478	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	7	39	theme	pit	1050:1052	arg1	r = 0.75-0.85					1062:1074	r = 0.75-0.85	1062:1074	r = 0.75-0.85	1062:1074	HMG levels correlated well with manual pit counts (r = 0.75-0.85).
35411940	7	39	theme	pit	1050:1052	arg1	counts					1054:1059	manual pit counts	1043:1059	manual pit counts (r = 0.75-0.85)	1043:1075	HMG levels correlated well with manual pit counts (r = 0.75-0.85).
35411940	5	40	from	expression	750:759	arg1	RBCs					772:775	RBCs	772:775	RBCs from patients who had previously undergone splenectomy	772:830	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	1	41	theme	plasma	101:106	arg1	membrane					108:115	plasma membrane	101:115	plasma membrane in the spleen	101:129	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	6	42	theme	Glycomic	921:928	arg1	analysis					930:937	Glycomic analysis	921:937	Glycomic analysis by mass spectrometry	921:958	Glycomic analysis by mass spectrometry identified a mixture of Man5-9 GlcNAc2 structures.
35411940	3	43	theme	extravascular	580:592	arg1	haemolysis					594:603	the extravascular haemolysis	576:603	the extravascular haemolysis characteristic of these diseases	576:636	These glycans can be recognised by mannose-binding lectins, including the mannose receptor (CD206), expressed on macrophages and specialised phagocytic endothelial cells in the spleen to mediate the extravascular haemolysis characteristic of these diseases.
35411940	2	44	theme	cell	214:217	arg1	disease					219:225	Sickle cell disease	207:225	Sickle cell disease	207:225	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	7	45	theme	HMG	1011:1013	arg1	levels					1015:1020	HMG levels	1011:1020	HMG levels	1011:1020	HMG levels correlated well with manual pit counts (r = 0.75-0.85).
35411940	2	46	theme	Sickle	207:212	arg1	disease					219:225	Sickle cell disease	207:225	Sickle cell disease	207:225	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	4	47	theme	healthy	721:727	arg1	individuals					729:739	healthy individuals	721:739	healthy individuals	721:739	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	4	48	theme	molecules	695:703	arg1	removal					684:690	removal	684:690	removal of molecules and membrane in healthy individuals	684:739	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	8	49	theme	potential	1213:1221	arg1	hyposplenism					1234:1245	potential functional hyposplenism	1213:1245	potential functional hyposplenism	1213:1245	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	2	50	with	proteins	329:336	arg1	glycans					365:371	N-linked high-mannose glycans	343:371	N-linked high-mannose glycans (HMGs)	343:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	2	50	with	proteins	329:336	arg1	HMGs					374:377	HMGs	374:377	HMGs	374:377	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	1	51	dep	cells	152:156	arg1	the					148:150	the	148:150	the	148:150	Red blood cells (RBCs) lose plasma membrane in the spleen as they age, but the cells and molecules involved are yet to be identified.
35411940	4	52	from	removal	684:690	arg1	individuals					729:739	healthy individuals	721:739	healthy individuals	721:739	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	5	53	theme	Surface	742:748	arg1	expression					750:759	Surface expression	742:759	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy	742:830	Surface expression of HMGs on RBCs from patients who had previously undergone splenectomy was therefore assessed: high levels were indeed observable as large membrane aggregates.
35411940	4	54	attach	removal	684:690	arg2	membrane					709:716	membrane	709:716	membrane	709:716	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	4	54	attach	removal	684:690	arg2	molecules					695:703	molecules	695:703	molecules	695:703	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	4	54	attach	removal	684:690	arg3	individuals					729:739	healthy individuals	721:739	healthy individuals	721:739	We postulated this system might also mediate removal of molecules and membrane in healthy individuals.
35411940	8	55	with	patients	1199:1206	arg1	hyposplenism					1234:1245	potential functional hyposplenism	1213:1245	potential functional hyposplenism	1213:1245	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	2	56	theme	proteins	329:336	arg1	aggregates					302:311	aggregates	302:311	aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs)	302:378	Sickle cell disease and infection by Plasmodium falciparum cause oxidative stress that induces aggregates of cross-linked proteins with N-linked high-mannose glycans (HMGs).
35411940	8	57	theme	function	1152:1159	arg1	test					1161:1164	a splenic reticuloendothelial function test	1122:1164	a splenic reticuloendothelial function test	1122:1164	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
35411940	8	57	theme	function	1152:1159	arg1	HMGs					1104:1107	HMGs	1104:1107	HMGs	1104:1107	To assess further whether HMGs might act as a splenic reticuloendothelial function test, we measured levels on RBCs from patients with potential functional hyposplenism, some of whom exhibited high levels that may indicate risk of complications.
36361885	9	0	from	residues	1232:1239	arg1	List					1264:1267	the TAG List	1256:1267	the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1256:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	9	1	theme	TAG	1260:1262	arg1	List					1264:1267	the TAG List	1256:1267	the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1256:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	10	2	with	spectra	1467:1473	arg1	linearity					1480:1488	linearity	1480:1488	linearity at the level of R2 &gt	1480:1511	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	9	3	theme	previous	1370:1377	arg1	version					1379:1385	the previous version	1366:1385	the previous version of TAG	1366:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	3	4	theme	mass	330:333	arg1	spectrometry					335:346	mass spectrometry	330:346	mass spectrometry	330:346	Glycomics via mass spectrometry has focused on the composition of glycans, but informatics analysis has not kept pace with the development of instrumentation and measurement techniques.
36361885	10	5	theme	&gt	1509:1511	arg1	level					1497:1501	the level	1493:1501	the level of R2 &gt	1493:1511	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	10	6	from	level	1497:1501	arg1	linearity					1480:1488	linearity	1480:1488	linearity at the level of R2 &gt	1480:1511	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	9	7	from	redefinitions	1215:1227	arg1	List					1264:1267	the TAG List	1256:1267	the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1256:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	4	8	theme	Accelerating	523:534	arg1	TAG					547:549	TAG	547:549	TAG	547:549	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	4	8	theme	Accelerating	523:534	arg1	Glycomics					536:544	Toolbox Accelerating Glycomics	515:544	Toolbox Accelerating Glycomics (TAG)	515:550	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	5	9	dep	such	777:780	arg1	as					782:783	as	782:783	as	782:783	In the present work, we improved TAG for large-scale analysis such as cohort analysis of serum samples.
36361885	10	10	theme	large-scale	1700:1710	arg1	analyses					1712:1719	large-scale analyses	1700:1719	large-scale analyses	1700:1719	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	8	11	theme	calibration	1118:1128	arg1	curves					1130:1135	calibration curves	1118:1135	calibration curves	1118:1135	A routine to generate calibration curves has been implemented to explore quantitation.
36361885	7	12	theme	glycan	1083:1088	arg1	list					1090:1093	the glycan list	1079:1093	the glycan list	1079:1093	Glycans modified by SALSA and several structures discovered in recent years were added to the glycan list.
36361885	6	13	from	differences	891:901	arg1	α2,6-linkages					933:945	α2,6-linkages	933:945	α2,6-linkages	933:945	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	6	13	from	differences	891:901	arg1	linkages					906:913	linkages	906:913	linkages such as α2,3- and α2,6-linkages of sialic acids	906:961	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	6	13	from	differences	891:901	arg1	α2,3-					923:927	α2,3-	923:927	α2,3-	923:927	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	6	14	theme	acids	957:961	arg1	α2,6-linkages					933:945	α2,6-linkages	933:945	α2,6-linkages	933:945	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	6	14	theme	acids	957:961	arg1	α2,3-					923:927	α2,3-	923:927	α2,3-	923:927	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	0	15	theme	SALSA-Modified	103:116	arg1	Glycans					127:133	SALSA-Modified and Rare Glycans	103:133	SALSA-Modified and Rare Glycans	103:133	Toolbox Accelerating Glycomics (TAG): Improving Large-Scale Serum Glycomics and Refinement to Identify SALSA-Modified and Rare Glycans.
36361885	6	16	theme	SALSA	868:872	arg1	method					875:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	2	17	theme	structural	269:278	arg1	diversity					280:288	their broad structural diversity	257:288	their broad structural diversity	257:288	However, their broad structural diversity makes analysis difficult.
36361885	1	18	theme	cellular	177:184	arg1	differentiation					212:226	differentiation	212:226	differentiation	212:226	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	18	theme	cellular	177:184	arg1	processes					186:194	many fundamental cellular processes	160:194	many fundamental cellular processes such as growth, differentiation, and morphogenesis	160:245	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	18	theme	cellular	177:184	arg1	growth					204:209	growth	204:209	growth	204:209	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	18	theme	cellular	177:184	arg1	morphogenesis					233:245	morphogenesis	233:245	morphogenesis	233:245	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	19	theme	many	160:163	arg1	differentiation					212:226	differentiation	212:226	differentiation	212:226	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	19	theme	many	160:163	arg1	processes					186:194	many fundamental cellular processes	160:194	many fundamental cellular processes such as growth, differentiation, and morphogenesis	160:245	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	19	theme	many	160:163	arg1	growth					204:209	growth	204:209	growth	204:209	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	19	theme	many	160:163	arg1	morphogenesis					233:245	morphogenesis	233:245	morphogenesis	233:245	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	5	20	theme	present	722:728	arg1	work					730:733	the present work	718:733	the present work	718:733	In the present work, we improved TAG for large-scale analysis such as cohort analysis of serum samples.
36361885	2	21	theme	broad	263:267	arg1	diversity					280:288	their broad structural diversity	257:288	their broad structural diversity	257:288	However, their broad structural diversity makes analysis difficult.
36361885	1	22	theme	fundamental	165:175	arg1	differentiation					212:226	differentiation	212:226	differentiation	212:226	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	22	theme	fundamental	165:175	arg1	processes					186:194	many fundamental cellular processes	160:194	many fundamental cellular processes such as growth, differentiation, and morphogenesis	160:245	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	22	theme	fundamental	165:175	arg1	growth					204:209	growth	204:209	growth	204:209	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	1	22	theme	fundamental	165:175	arg1	morphogenesis					233:245	morphogenesis	233:245	morphogenesis	233:245	Glycans are involved in many fundamental cellular processes such as growth, differentiation, and morphogenesis.
36361885	6	23	theme	alkylamidation	852:865	arg1	method					875:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	9	24	from	glycans	1245:1251	arg1	List					1264:1267	the TAG List	1256:1267	the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1256:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	4	25	theme	sialic	655:660	arg1	modifications					667:679	sialic acid modifications	655:679	sialic acid modifications	655:679	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	10	26	theme	glycan	1536:1541	arg1	structures					1543:1552	81 estimated glycan structures	1523:1552	81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N	1523:1627	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	6	27	theme	sialic	950:955	arg1	acids					957:961	sialic acids	950:961	sialic acids	950:961	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	6	28	from	differences	968:978	arg1	mass					983:986	mass	983:986	mass	983:986	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	5	29	theme	cohort	785:790	arg1	analysis					792:799	cohort analysis	785:799	large-scale analysis such as cohort analysis of serum samples	756:816	In the present work, we improved TAG for large-scale analysis such as cohort analysis of serum samples.
36361885	0	30	theme	Rare	122:125	arg1	Glycans					127:133	SALSA-Modified and Rare Glycans	103:133	SALSA-Modified and Rare Glycans	103:133	Toolbox Accelerating Glycomics (TAG): Improving Large-Scale Serum Glycomics and Refinement to Identify SALSA-Modified and Rare Glycans.
36361885	10	31	theme	rare	1591:1594	arg1	glycans					1596:1602	rare glycans	1591:1602	rare glycans such as those with the N	1591:1627	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	10	31	theme	rare	1591:1594	arg1	those					1612:1616	those	1612:1616	those	1612:1616	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	5	32	theme	large-scale	756:766	arg1	analysis					768:775	large-scale analysis	756:775	large-scale analysis such as cohort analysis of serum samples	756:816	In the present work, we improved TAG for large-scale analysis such as cohort analysis of serum samples.
36361885	3	33	theme	instrumentation	458:472	arg1	development					443:453	the development	439:453	the development of instrumentation and measurement techniques	439:499	Glycomics via mass spectrometry has focused on the composition of glycans, but informatics analysis has not kept pace with the development of instrumentation and measurement techniques.
36361885	3	34	theme	glycans	382:388	arg1	composition					367:377	the composition	363:377	the composition of glycans	363:388	Glycomics via mass spectrometry has focused on the composition of glycans, but informatics analysis has not kept pace with the development of instrumentation and measurement techniques.
36361885	7	35	theme	recent	1052:1057	arg1	years					1059:1063	recent years	1052:1063	recent years	1052:1063	Glycans modified by SALSA and several structures discovered in recent years were added to the glycan list.
36361885	6	36	theme	linkage-specific	835:850	arg1	method					875:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	9	37	theme	TAG	1390:1392	arg1	version					1379:1385	the previous version	1366:1385	the previous version of TAG	1366:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	5	38	theme	serum	804:808	arg1	samples					810:816	serum samples	804:816	serum samples	804:816	In the present work, we improved TAG for large-scale analysis such as cohort analysis of serum samples.
36361885	9	39	from	List	1264:1267	arg1	redefinitions					1215:1227	redefinitions	1215:1227	redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1215:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	10	40	theme	N'-diacetyllactosediamine	1629:1653	arg1	structure					1655:1663	N'-diacetyllactosediamine structure	1629:1663	N'-diacetyllactosediamine structure	1629:1663	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	10	40	theme	N'-diacetyllactosediamine	1629:1653	arg1	sera					1455:1458	purchased sera	1445:1458	purchased sera	1445:1458	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	10	41	theme	sera	1455:1458	arg1	analysis					1433:1440	analysis	1433:1440	analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure	1433:1663	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	6	42	theme	acid	830:833	arg1	method					875:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	5	43	theme	samples	810:816	arg1	analysis					792:799	cohort analysis	785:799	large-scale analysis such as cohort analysis of serum samples	756:816	In the present work, we improved TAG for large-scale analysis such as cohort analysis of serum samples.
36361885	10	44	theme	purchased	1445:1453	arg1	structure					1655:1663	N'-diacetyllactosediamine structure	1629:1663	N'-diacetyllactosediamine structure	1629:1663	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	10	44	theme	purchased	1445:1453	arg1	sera					1455:1458	purchased sera	1445:1458	purchased sera	1445:1458	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	6	45	theme	sialic	823:828	arg1	method					875:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method	819:880	The sialic acid linkage-specific alkylamidation (SALSA) method converts differences in linkages such as α2,3- and α2,6-linkages of sialic acids into differences in mass.
36361885	10	46	theme	estimated	1526:1534	arg1	structures					1543:1552	81 estimated glycan structures	1523:1552	81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N	1523:1627	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	10	47	theme	R2	1506:1507	arg1	&gt					1509:1511	R2 &gt	1506:1511	R2 &gt	1506:1511	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	3	48	theme	informatics	395:405	arg1	analysis					407:414	informatics analysis	395:414	informatics analysis	395:414	Glycomics via mass spectrometry has focused on the composition of glycans, but informatics analysis has not kept pace with the development of instrumentation and measurement techniques.
36361885	10	49	dep	sera	1455:1458	arg1	0.8					1514:1516	0.8	1514:1516	0.8	1514:1516	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	7	50	theme	several	1019:1025	arg1	structures					1027:1036	several structures	1019:1036	several structures discovered in recent years	1019:1063	Glycans modified by SALSA and several structures discovered in recent years were added to the glycan list.
36361885	9	51	theme	residues	1232:1239	arg1	redefinitions					1215:1227	redefinitions	1215:1227	redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1215:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	4	52	theme	fast	686:689	arg1	processing					691:700	fast processing	686:700	fast processing	686:700	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	10	53	with	sera	1455:1458	arg1	linearity					1480:1488	linearity	1480:1488	linearity at the level of R2 &gt	1480:1511	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	4	54	dep	developed	505:513	arg1	added					577:581	added	577:581	can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications	570:679	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	4	54	dep	developed	505:513	arg1	possible					705:712	possible	705:712	possible	705:712	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	3	55	theme	measurement	478:488	arg1	techniques					490:499	measurement techniques	478:499	measurement techniques	478:499	Glycomics via mass spectrometry has focused on the composition of glycans, but informatics analysis has not kept pace with the development of instrumentation and measurement techniques.
36361885	4	56	theme	glycan	599:604	arg1	list					606:609	the glycan list	595:609	the glycan list that can be freely designed with labels and sialic acid modifications	595:679	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	10	57	theme	spectra	1467:1473	arg1	analysis					1433:1440	analysis	1433:1440	analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure	1433:1663	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	9	58	theme	glycans	1245:1251	arg1	redefinitions					1215:1227	redefinitions	1215:1227	redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG	1215:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	3	59	theme	techniques	490:499	arg1	development					443:453	the development	439:453	the development of instrumentation and measurement techniques	439:499	Glycomics via mass spectrometry has focused on the composition of glycans, but informatics analysis has not kept pace with the development of instrumentation and measurement techniques.
36361885	0	60	theme	Serum	60:64	arg1	Glycomics					66:74	Large-Scale Serum Glycomics	48:74	Large-Scale Serum Glycomics	48:74	Toolbox Accelerating Glycomics (TAG): Improving Large-Scale Serum Glycomics and Refinement to Identify SALSA-Modified and Rare Glycans.
36361885	10	61	theme	glycans	1596:1602	arg1	candidate					1578:1586	some candidate	1573:1586	some candidate of rare glycans such as those with the N	1573:1627	These functions were verified through analysis of purchased sera and 74 spectra with linearity at the level of R2 &gt; 0.8 with 81 estimated glycan structures obtained including some candidate of rare glycans such as those with the N,N'-diacetyllactosediamine structure, suggesting they can be applied to large-scale analyses.
36361885	0	62	theme	Large-Scale	48:58	arg1	Glycomics					66:74	Large-Scale Serum Glycomics	48:74	Large-Scale Serum Glycomics	48:74	Toolbox Accelerating Glycomics (TAG): Improving Large-Scale Serum Glycomics and Refinement to Identify SALSA-Modified and Rare Glycans.
36361885	4	63	theme	Toolbox	515:521	arg1	TAG					547:549	TAG	547:549	TAG	547:549	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	4	63	theme	Toolbox	515:521	arg1	Glycomics					536:544	Toolbox Accelerating Glycomics	515:544	Toolbox Accelerating Glycomics (TAG)	515:550	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
36361885	9	64	from	information	1284:1294	arg1	glycans					1299:1305	glycans	1299:1305	glycans that could not be attributed because it was not assumed in the previous version of TAG	1299:1392	These improvements are based on redefinitions of residues and glycans in the TAG List to incorporate information on glycans that could not be attributed because it was not assumed in the previous version of TAG.
36361885	4	65	theme	acid	662:665	arg1	modifications					667:679	sialic acid modifications	655:679	sialic acid modifications	655:679	We developed Toolbox Accelerating Glycomics (TAG), in which glycans can be added manually to the glycan list that can be freely designed with labels and sialic acid modifications, and fast processing is possible.
34972858	5	0	theme	streamlined	760:770	arg1	platform					792:799	an innovative streamlined 96-well-plate-based platform	746:799	an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation	746:937	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	4	1	theme	analysis	648:655	arg1	procedure					657:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	4	1	theme	analysis	648:655	arg1	time-consuming					670:683	time-consuming	670:683	time-consuming	670:683	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	1	2	gly	glycoproteins	193:205	arg1	glycoproteins					193:205	biotherapeutic glycoproteins	178:205	biotherapeutic glycoproteins	178:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	3	theme	product	285:291	arg1	efficacy					313:320	efficacy	313:320	efficacy	313:320	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	3	theme	product	285:291	arg1	safety					302:307	safety	302:307	safety	302:307	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	3	theme	product	285:291	arg1	quality					293:299	desired product quality	277:299	desired product quality	277:299	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	7	4	from	analysis	1255:1262	arg1	sources					1329:1335	various sources	1321:1335	various sources	1321:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	5	theme	human	1267:1271	arg1	serum					1273:1277	human serum	1267:1277	human serum	1267:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	11	6	theme	biomarker	2178:2186	arg1	discovery					2188:2196	disease biomarker discovery	2170:2196	disease biomarker discovery	2170:2196	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	5	7	theme	96-well-plate-based	772:790	arg1	platform					792:799	an innovative streamlined 96-well-plate-based platform	746:799	an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation	746:937	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	8	8	theme	fluorescence	1419:1430	arg1	detection					1432:1440	fluorescence detection separation and analysis	1419:1464	detection	1432:1440	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	1	9	theme	critical	212:219	arg1	attribute					229:237	a critical quality attribute	210:237	a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy	210:320	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	9	theme	critical	212:219	arg1	profile					167:173	The glycosylation profile	149:173	The glycosylation profile of biotherapeutic glycoproteins	149:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	8	10	theme	hydrophilic	1360:1370	arg1	HILIC					1407:1411	HILIC	1407:1411	HILIC	1407:1411	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	8	10	theme	hydrophilic	1360:1370	arg1	chromatography					1391:1404	preliminary hydrophilic interaction liquid chromatography	1348:1404	preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis	1348:1464	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	9	11	used	utilized	1802:1809	arg2	chromatography					1715:1728	Hydrophilic interaction ultra-performance liquid chromatography	1666:1728	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry	1666:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	9	12	theme	accurate	1840:1847	arg1	confirmation					1861:1872	accurate glycan mass confirmation	1840:1872	accurate glycan mass confirmation	1840:1872	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	7	13	theme	GU	1234:1235	arg1	database					1238:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database	1184:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources	1184:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	9	14	theme	ultra-performance	1690:1706	arg1	chromatography					1715:1728	Hydrophilic interaction ultra-performance liquid chromatography	1666:1728	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry	1666:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	8	15	theme	liquid	1384:1389	arg1	HILIC					1407:1411	HILIC	1407:1411	HILIC	1407:1411	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	8	15	theme	liquid	1384:1389	arg1	chromatography					1391:1404	preliminary hydrophilic interaction liquid chromatography	1348:1404	preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis	1348:1464	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	6	16	theme	glycan	1108:1113	arg1	profiling					1126:1134	expedited glycan structural profiling	1098:1134	expedited glycan structural profiling	1098:1134	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	8	17	theme	glycan	1647:1652	arg1	assignment					1654:1663	the glycan assignment	1643:1663	the glycan assignment	1643:1663	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	10	18	theme	GU	1908:1909	arg1	accurate					1923:1930	accurate	1923:1930	accurate	1923:1930	The constructed InstantPC glycan GU database is accurate and robust.
34972858	10	18	theme	GU	1908:1909	arg1	database					1911:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database is accurate and robust.
34972858	5	19	theme	high-throughput	831:845	arg1	profiling					872:880	high-throughput, high-sensitivity glycan profiling	831:880	high-throughput, high-sensitivity glycan profiling	831:880	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	7	20	theme	glycoproteins	1302:1314	arg1	analysis					1255:1262	analysis	1255:1262	analysis of human serum	1255:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	20	theme	glycoproteins	1302:1314	arg1	serum					1273:1277	human serum	1267:1277	human serum	1267:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	20	theme	glycoproteins	1302:1314	arg1	variety					1285:1291	a variety	1283:1291	a variety of other glycoproteins from various sources	1283:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	20	theme	glycoproteins	1302:1314	arg1	glycoproteins					1302:1314	other glycoproteins	1296:1314	other glycoproteins from various sources	1296:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	10	21	theme	InstantPC	1891:1899	arg1	accurate					1923:1930	accurate	1923:1930	accurate	1923:1930	The constructed InstantPC glycan GU database is accurate and robust.
34972858	10	21	theme	InstantPC	1891:1899	arg1	database					1911:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database is accurate and robust.
34972858	7	22	theme	glycan	1213:1218	arg1	database					1238:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database	1184:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources	1184:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	11	23	dep	high-throughput	2037:2051	arg1	high-sensitivity					2054:2069	high-sensitivity	2054:2069	high-sensitivity	2054:2069	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	4	24	with	time-consuming	670:683	arg1	reproducibility					711:725	poor reproducibility	706:725	poor reproducibility	706:725	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	8	25	theme	complex	1486:1492	arg1	profiles					1501:1508	complex glycan profiles	1486:1508	complex glycan profiles	1486:1508	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	11	26	theme	platform	2024:2031	arg1	application					1995:2005	the application	1991:2005	the application of the developed platform for high-throughput, high-sensitivity glycan profiling	1991:2086	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	7	27	theme	detailed	1186:1193	arg1	database					1238:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database	1184:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources	1184:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	9	28	theme	ionization	1756:1765	arg1	spectrometry					1772:1783	electrospray ionization mass spectrometry	1743:1783	electrospray ionization mass spectrometry	1743:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	8	29	with	chromatography	1391:1404	arg1	detection					1432:1440	fluorescence detection separation and analysis	1419:1464	detection	1432:1440	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	8	29	with	chromatography	1391:1404	arg1	analysis					1457:1464	analysis	1457:1464	analysis	1457:1464	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	5	30	theme	innovative	749:758	arg1	platform					792:799	an innovative streamlined 96-well-plate-based platform	746:799	an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation	746:937	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	5	31	dep	InstantPC	811:819	arg1	label					821:825	label	821:825	label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation	821:937	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	7	32	from	variety	1285:1291	arg1	sources					1329:1335	various sources	1321:1335	various sources	1321:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	1	33	theme	biotherapeutic	178:191	arg1	glycoproteins					193:205	biotherapeutic glycoproteins	178:205	biotherapeutic glycoproteins	178:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	8	34	theme	further	1528:1534	arg1	fractionation					1536:1548	further fractionation	1528:1548	further fractionation by weak anion exchange HILIC	1528:1577	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	11	35	theme	high-throughput	2037:2051	arg1	profiling					2078:2086	high-throughput, high-sensitivity glycan profiling	2037:2086	high-throughput, high-sensitivity glycan profiling	2037:2086	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	8	36	dep	detection	1432:1440	arg1	separation					1442:1451	separation	1442:1451	separation	1442:1451	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	7	37	from	sources	1329:1335	arg1	analysis					1255:1262	analysis	1255:1262	analysis of human serum	1255:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	37	from	sources	1329:1335	arg1	serum					1273:1277	human serum	1267:1277	human serum	1267:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	37	from	sources	1329:1335	arg1	variety					1285:1291	a variety	1283:1291	a variety of other glycoproteins from various sources	1283:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	37	from	sources	1329:1335	arg1	glycoproteins					1302:1314	other glycoproteins	1296:1314	other glycoproteins from various sources	1296:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	8	38	theme	anion	1558:1562	arg1	HILIC					1573:1577	weak anion exchange HILIC	1553:1577	weak anion exchange HILIC	1553:1577	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	0	39	dep	foundation	73:82	arg1	work					84:87	work	84:87	work	84:87	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	2	40	theme	disease	446:452	arg1	manifestation					454:466	disease manifestation	446:466	disease manifestation	446:466	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
34972858	6	41	theme	standards	1002:1010	arg1	availability					961:972	the limited availability	949:972	the limited availability of InstantPC-labeled glycan standards	949:1010	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	9	42	theme	mass	1856:1859	arg1	confirmation					1861:1872	accurate glycan mass confirmation	1840:1872	accurate glycan mass confirmation	1840:1872	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	4	43	theme	N-glycosylation	632:646	arg1	procedure					657:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	4	43	theme	N-glycosylation	632:646	arg1	time-consuming					670:683	time-consuming	670:683	time-consuming	670:683	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	9	44	theme	mass	1767:1770	arg1	spectrometry					1772:1783	electrospray ionization mass spectrometry	1743:1783	electrospray ionization mass spectrometry	1743:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	4	45	theme	conventional	596:607	arg1	procedure					657:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	4	45	theme	conventional	596:607	arg1	time-consuming					670:683	time-consuming	670:683	time-consuming	670:683	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	8	46	theme	exoglycosidase	1583:1596	arg1	digestion					1609:1617	exoglycosidase sequential digestion	1583:1617	exoglycosidase sequential digestion for cross-validation of the glycan assignment	1583:1663	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	7	47	theme	other	1296:1300	arg1	glycoproteins					1302:1314	other glycoproteins	1296:1314	other glycoproteins from various sources	1296:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	0	48	theme	glycan	41:46	arg1	database					61:68	an InstantPC-derivatized glycan glucose unit database	16:68	an InstantPC-derivatized glycan glucose unit database	16:68	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	6	49	theme	InstantPC-labeled	977:993	arg1	standards					1002:1010	InstantPC-labeled glycan standards	977:1010	InstantPC-labeled glycan standards	977:1010	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	2	50	theme	prominent	356:364	arg1	modifications					397:409	the most prominent and complex post-translational modifications	347:409	the most prominent and complex post-translational modifications	347:409	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
34972858	0	51	theme	unit	56:59	arg1	database					61:68	an InstantPC-derivatized glycan glucose unit database	16:68	an InstantPC-derivatized glycan glucose unit database	16:68	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	11	52	theme	biopharmaceutical	2137:2153	arg1	production					2155:2164	glycan-based biopharmaceutical production	2124:2164	glycan-based biopharmaceutical production	2124:2164	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	1	53	gly	glycosylation	153:165	arg1	glycoproteins					193:205	biotherapeutic glycoproteins	178:205	biotherapeutic glycoproteins	178:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	3	54	theme	disease	546:552	arg1	diagnostics					554:564	disease diagnostics	546:564	disease diagnostics	546:564	Changes in glycosylation may serve as a specific and sensitive biomarker for disease diagnostics and prognostics.
34972858	0	55	dep	Construction	0:11	arg1	foundation					73:82	A foundation work	71:87	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.	0:147	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	7	56	theme	serum	1273:1277	arg1	analysis					1255:1262	analysis	1255:1262	analysis of human serum	1255:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	56	theme	serum	1273:1277	arg1	serum					1273:1277	human serum	1267:1277	human serum	1267:1277	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	56	theme	serum	1273:1277	arg1	variety					1285:1291	a variety	1283:1291	a variety of other glycoproteins from various sources	1283:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	7	56	theme	serum	1273:1277	arg1	glycoproteins					1302:1314	other glycoproteins	1296:1314	other glycoproteins from various sources	1296:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	2	57	theme	complex	370:376	arg1	modifications					397:409	the most prominent and complex post-translational modifications	347:409	the most prominent and complex post-translational modifications	347:409	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
34972858	1	58	theme	desired	277:283	arg1	efficacy					313:320	efficacy	313:320	efficacy	313:320	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	58	theme	desired	277:283	arg1	safety					302:307	safety	302:307	safety	302:307	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	58	theme	desired	277:283	arg1	quality					293:299	desired product quality	277:299	desired product quality	277:299	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	6	59	dep	applicability	1043:1055	arg1	the					1039:1041	the	1039:1041	the	1039:1041	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	1	60	theme	glycoproteins	193:205	arg1	profile					167:173	The glycosylation profile	149:173	The glycosylation profile of biotherapeutic glycoproteins	149:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	60	theme	glycoproteins	193:205	arg1	attribute					229:237	a critical quality attribute	210:237	a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy	210:320	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	10	61	theme	constructed	1879:1889	arg1	accurate					1923:1930	accurate	1923:1930	accurate	1923:1930	The constructed InstantPC glycan GU database is accurate and robust.
34972858	10	61	theme	constructed	1879:1889	arg1	database					1911:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database is accurate and robust.
34972858	1	62	theme	quality	221:227	arg1	attribute					229:237	a critical quality attribute	210:237	a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy	210:320	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	62	theme	quality	221:227	arg1	profile					167:173	The glycosylation profile	149:173	The glycosylation profile of biotherapeutic glycoproteins	149:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	8	63	theme	preliminary	1348:1358	arg1	HILIC					1407:1411	HILIC	1407:1411	HILIC	1407:1411	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	8	63	theme	preliminary	1348:1358	arg1	chromatography					1391:1404	preliminary hydrophilic interaction liquid chromatography	1348:1404	preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis	1348:1464	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	6	64	theme	structural	1115:1124	arg1	profiling					1126:1134	expedited glycan structural profiling	1098:1134	expedited glycan structural profiling	1098:1134	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	8	65	theme	assignment	1654:1663	arg1	cross-validation					1623:1638	cross-validation	1623:1638	cross-validation of the glycan assignment	1623:1663	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	4	66	theme	poor	706:709	arg1	reproducibility					711:725	poor reproducibility	706:725	poor reproducibility	706:725	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	11	67	theme	disease	2170:2176	arg1	discovery					2188:2196	disease biomarker discovery	2170:2196	disease biomarker discovery	2170:2196	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	7	68	theme	glucose	1220:1226	arg1	database					1238:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database	1184:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources	1184:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	9	69	theme	Hydrophilic	1666:1676	arg1	chromatography					1715:1728	Hydrophilic interaction ultra-performance liquid chromatography	1666:1728	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry	1666:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	9	70	theme	liquid	1708:1713	arg1	chromatography					1715:1728	Hydrophilic interaction ultra-performance liquid chromatography	1666:1728	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry	1666:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	8	71	theme	interaction	1372:1382	arg1	HILIC					1407:1411	HILIC	1407:1411	HILIC	1407:1411	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	8	71	theme	interaction	1372:1382	arg1	chromatography					1391:1404	preliminary hydrophilic interaction liquid chromatography	1348:1404	preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis	1348:1464	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	6	72	theme	expedited	1098:1106	arg1	profiling					1126:1134	expedited glycan structural profiling	1098:1134	expedited glycan structural profiling	1098:1134	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	10	73	theme	glycan	1901:1906	arg1	accurate					1923:1930	accurate	1923:1930	accurate	1923:1930	The constructed InstantPC glycan GU database is accurate and robust.
34972858	10	73	theme	glycan	1901:1906	arg1	database					1911:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database	1875:1918	The constructed InstantPC glycan GU database is accurate and robust.
34972858	11	74	theme	glycan-based	2124:2135	arg1	production					2155:2164	glycan-based biopharmaceutical production	2124:2164	glycan-based biopharmaceutical production	2124:2164	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	7	75	theme	InstantPC-labeled	1195:1211	arg1	database					1238:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database	1184:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources	1184:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	6	76	theme	platform	1085:1092	arg1	transferability					1061:1075	transferability	1061:1075	transferability	1061:1075	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	6	76	theme	platform	1085:1092	arg1	applicability					1043:1055	applicability	1043:1055	applicability	1043:1055	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	9	77	theme	electrospray	1743:1754	arg1	spectrometry					1772:1783	electrospray ionization mass spectrometry	1743:1783	electrospray ionization mass spectrometry	1743:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	9	78	theme	interaction	1678:1688	arg1	chromatography					1715:1728	Hydrophilic interaction ultra-performance liquid chromatography	1666:1728	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry	1666:1783	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	1	79	theme	glycosylation	153:165	arg1	profile					167:173	The glycosylation profile	149:173	The glycosylation profile of biotherapeutic glycoproteins	149:205	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	1	79	theme	glycosylation	153:165	arg1	attribute					229:237	a critical quality attribute	210:237	a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy	210:320	The glycosylation profile of biotherapeutic glycoproteins is a critical quality attribute that is routinely monitored to ensure desired product quality, safety and efficacy.
34972858	5	80	dep	high-throughput	831:845	arg1	high-sensitivity					848:863	high-sensitivity	848:863	high-sensitivity	848:863	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	8	81	theme	glycan	1494:1499	arg1	profiles					1501:1508	complex glycan profiles	1486:1508	complex glycan profiles	1486:1508	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	11	82	theme	developed	2014:2022	arg1	platform					2024:2031	the developed platform	2010:2031	the developed platform	2010:2031	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	8	83	gly	glycoproteins	1467:1479	arg1	glycoproteins					1467:1479	glycoproteins	1467:1479	glycoproteins with complex glycan profiles	1467:1508	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	0	84	theme	glycomic	130:137	arg1	analysis					139:146	high-throughput and high-sensitivity glycomic analysis	93:146	high-throughput and high-sensitivity glycomic analysis	93:146	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	11	85	theme	glycan	2071:2076	arg1	profiling					2078:2086	high-throughput, high-sensitivity glycan profiling	2037:2086	high-throughput, high-sensitivity glycan profiling	2037:2086	It is believed that this database will enhance the application of the developed platform for high-throughput, high-sensitivity glycan profiling and that it will eventually advance glycan-based biopharmaceutical production and disease biomarker discovery.
34972858	0	86	theme	high-throughput	93:107	arg1	analysis					139:146	high-throughput and high-sensitivity glycomic analysis	93:146	high-throughput and high-sensitivity glycomic analysis	93:146	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	0	87	theme	high-sensitivity	113:128	arg1	analysis					139:146	high-throughput and high-sensitivity glycomic analysis	93:146	high-throughput and high-sensitivity glycomic analysis	93:146	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	9	88	theme	glycan	1815:1820	arg1	fragmentation					1822:1834	glycan fragmentation	1815:1834	glycan fragmentation	1815:1834	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	5	89	theme	glycan	865:870	arg1	profiling					872:880	high-throughput, high-sensitivity glycan profiling	831:880	high-throughput, high-sensitivity glycan profiling	831:880	We have evaluated an innovative streamlined 96-well-plate-based platform utilizing InstantPC label for high-throughput, high-sensitivity glycan profiling, which is user-friendly, robust and ready for automation.
34972858	7	90	theme	various	1321:1327	arg1	sources					1329:1335	various sources	1321:1335	various sources	1321:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	8	91	theme	weak	1553:1556	arg1	HILIC					1573:1577	weak anion exchange HILIC	1553:1577	weak anion exchange HILIC	1553:1577	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	0	92	theme	InstantPC-derivatized	19:39	arg1	database					61:68	an InstantPC-derivatized glycan glucose unit database	16:68	an InstantPC-derivatized glycan glucose unit database	16:68	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	9	93	theme	glycan	1849:1854	arg1	confirmation					1861:1872	accurate glycan mass confirmation	1840:1872	accurate glycan mass confirmation	1840:1872	Hydrophilic interaction ultra-performance liquid chromatography coupled with electrospray ionization mass spectrometry was subsequently utilized for glycan fragmentation and accurate glycan mass confirmation.
34972858	4	94	theme	2-aminobenzamide-based	609:630	arg1	procedure					657:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	the conventional 2-aminobenzamide-based N-glycosylation analysis procedure	592:665	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	4	94	theme	2-aminobenzamide-based	609:630	arg1	time-consuming					670:683	time-consuming	670:683	time-consuming	670:683	However, the conventional 2-aminobenzamide-based N-glycosylation analysis procedure is time-consuming and insensitive with poor reproducibility.
34972858	8	95	theme	exchange	1564:1571	arg1	HILIC					1573:1577	weak anion exchange HILIC	1553:1577	weak anion exchange HILIC	1553:1577	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	2	96	theme	modifications	397:409	arg1	modifications					397:409	the most prominent and complex post-translational modifications	347:409	the most prominent and complex post-translational modifications	347:409	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
34972858	2	96	theme	modifications	397:409	arg1	one					340:342	one	340:342	one	340:342	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
34972858	0	97	theme	glucose	48:54	arg1	database					61:68	an InstantPC-derivatized glycan glucose unit database	16:68	an InstantPC-derivatized glycan glucose unit database	16:68	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	6	98	theme	glycan	995:1000	arg1	standards					1002:1010	InstantPC-labeled glycan standards	977:1010	InstantPC-labeled glycan standards	977:1010	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	8	99	with	glycoproteins	1467:1479	arg1	profiles					1501:1508	complex glycan profiles	1486:1508	complex glycan profiles	1486:1508	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	2	100	theme	key	434:436	arg1	role					438:441	a key role	432:441	a key role	432:441	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
34972858	0	101	theme	database	61:68	arg1	Construction					0:11	Construction	0:11	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.	0:147	Construction of an InstantPC-derivatized glycan glucose unit database: A foundation work for high-throughput and high-sensitivity glycomic analysis.
34972858	7	102	theme	unit	1228:1231	arg1	database					1238:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database	1184:1245	a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources	1184:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	8	103	theme	sequential	1598:1607	arg1	digestion					1609:1617	exoglycosidase sequential digestion	1583:1617	exoglycosidase sequential digestion for cross-validation of the glycan assignment	1583:1663	Following preliminary hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection separation and analysis, glycoproteins with complex glycan profiles were subjected to further fractionation by weak anion exchange HILIC and exoglycosidase sequential digestion for cross-validation of the glycan assignment.
34972858	3	104	theme	sensitive	522:530	arg1	Changes					469:475	Changes	469:475	Changes in glycosylation	469:492	Changes in glycosylation may serve as a specific and sensitive biomarker for disease diagnostics and prognostics.
34972858	3	104	theme	sensitive	522:530	arg1	biomarker					532:540	a specific and sensitive biomarker	507:540	a specific and sensitive biomarker for disease diagnostics and prognostics	507:580	Changes in glycosylation may serve as a specific and sensitive biomarker for disease diagnostics and prognostics.
34972858	6	105	theme	limited	953:959	arg1	availability					961:972	the limited availability	949:972	the limited availability of InstantPC-labeled glycan standards	949:1010	However, the limited availability of InstantPC-labeled glycan standards has significantly hampered the applicability and transferability of this platform for expedited glycan structural profiling.
34972858	3	106	theme	specific	509:516	arg1	Changes					469:475	Changes	469:475	Changes in glycosylation	469:492	Changes in glycosylation may serve as a specific and sensitive biomarker for disease diagnostics and prognostics.
34972858	3	106	theme	specific	509:516	arg1	biomarker					532:540	a specific and sensitive biomarker	507:540	a specific and sensitive biomarker for disease diagnostics and prognostics	507:580	Changes in glycosylation may serve as a specific and sensitive biomarker for disease diagnostics and prognostics.
34972858	7	107	gly	glycoproteins	1302:1314	arg1	glycoproteins					1302:1314	other glycoproteins	1296:1314	other glycoproteins from various sources	1296:1335	To address this challenge, we have constructed a detailed InstantPC-labeled glycan glucose unit (GU) database through analysis of human serum and a variety of other glycoproteins from various sources.
34972858	3	108	from	Changes	469:475	arg1	glycosylation					480:492	glycosylation	480:492	glycosylation	480:492	Changes in glycosylation may serve as a specific and sensitive biomarker for disease diagnostics and prognostics.
34972858	2	109	theme	post-translational	378:395	arg1	modifications					397:409	the most prominent and complex post-translational modifications	347:409	the most prominent and complex post-translational modifications	347:409	Additionally, as one of the most prominent and complex post-translational modifications, glycosylation plays a key role in disease manifestation.
35049286	7	0	theme	expected	1513:1520	arg1	structures					1522:1531	the expected structures	1509:1531	the expected structures	1509:1531	Finally, a Rp of about 250 in ion mobility made it possible to detect the eighth and last of the expected structures.
35049286	3	1	theme	enzymatic	733:741	arg1	synthesis					769:777	enzymatic and chemoenzymatic glycan synthesis	733:777	enzymatic and chemoenzymatic glycan synthesis	733:777	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	6	2	theme	mobility	1359:1366	arg1	step					1347:1350	an additional step	1333:1350	an additional step of ion mobility at a resolving power (Rp) of approximately 100	1333:1413	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	2	3	theme	known	366:370	arg1	isomers					425:431	known monosaccharide composition feature multiple possible isomers	366:431	known monosaccharide composition feature multiple possible isomers	366:431	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	8	4	theme	products	1730:1737	arg1	regioisomers					1691:1702	seven regioisomers	1685:1702	seven regioisomers out of the eight possible products of enzymatic glucosylation	1685:1764	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	5	5	theme	ones	1290:1293	arg1	products					1228:1235	six reaction products	1215:1235	six reaction products of enzymatic glucosylation out of the eight possible ones	1215:1293	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	8	6	theme	enzymatic	1742:1750	arg1	glucosylation					1752:1764	enzymatic glucosylation	1742:1764	enzymatic glucosylation	1742:1764	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	3	7	theme	synthesis	769:777	arg1	development					718:728	the rapid development	708:728	the rapid development of enzymatic and chemoenzymatic glycan synthesis	708:777	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	6	8	theme	additional	1336:1345	arg1	step					1347:1350	an additional step	1333:1350	an additional step of ion mobility at a resolving power (Rp) of approximately 100	1333:1413	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	2	9	theme	feature	399:405	arg1	isomers					425:431	known monosaccharide composition feature multiple possible isomers	366:431	known monosaccharide composition feature multiple possible isomers	366:431	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	7	10	theme	ion	1446:1448	arg1	mobility					1450:1457	ion mobility	1446:1457	ion mobility	1446:1457	Finally, a Rp of about 250 in ion mobility made it possible to detect the eighth and last of the expected structures.
35049286	1	11	theme	particular	194:203	arg1	glycans					215:221	particular microbial glycans	194:221	particular microbial glycans	194:221	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	7	12	theme	250	1439:1441	arg1	Rp					1427:1428	a Rp	1425:1428	a Rp of about 250 in ion mobility	1425:1457	Finally, a Rp of about 250 in ion mobility made it possible to detect the eighth and last of the expected structures.
35049286	5	13	theme	media	1158:1162	arg1	analysis					1133:1140	A first analysis	1125:1140	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS	1125:1199	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	4	14	theme	type/group-specific	984:1002	arg1	bricks					1038:1043	type/group-specific Shigella flexneri pentasaccharide bricks	984:1043	type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	984:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	4	15	theme	mutants	924:930	arg1	ability					899:905	the ability	895:905	the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	895:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	8	16	with	MS	1578:1579	arg1	CTD					1639:1641	CTD	1639:1641	CTD	1639:1641	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	8	16	with	MS	1578:1579	arg1	dissociation					1625:1636	high activation energy charge transfer dissociation	1586:1636	high activation energy charge transfer dissociation (CTD)	1586:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	4	17	theme	sucrose-utilizing	935:951	arg1	α-transglucosylases					953:971	sucrose-utilizing α-transglucosylases	935:971	sucrose-utilizing α-transglucosylases	935:971	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	0	18	theme	Glycans	167:173	arg1	Structure					115:123	the Structure	111:123	the Structure of Complex Chemoenzymatically Synthesized Glycans	111:173	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	3	19	theme	glycans	680:686	arg1	determination					643:655	not only the correct determination	622:655	not only the correct determination of naturally occurring glycans	622:686	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	5	20	dep	ones	1290:1293	arg1	out					1264:1266	out	1264:1266	out	1264:1266	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	1	21	from	Carbohydrates	176:188	arg1	glycans					215:221	particular microbial glycans	194:221	particular microbial glycans	194:221	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	4	22	theme	lightly	1059:1065	arg1	substrate					1114:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	0	23	theme	High	74:77	arg1	Energy					79:84	High Energy	74:84	High Energy of Activation	74:98	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	4	24	theme	flexneri	1013:1020	arg1	bricks					1038:1043	type/group-specific Shigella flexneri pentasaccharide bricks	984:1043	type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	984:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	9	25	theme	IMS	1838:1840	arg1	potential					1793:1801	the potential	1789:1801	the potential of the recently described powerful IMS	1789:1840	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	6	26	theme	100	1411:1413	arg1	power					1383:1387	a resolving power	1371:1387	a resolving power (Rp) of approximately 100	1371:1413	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	6	26	theme	100	1411:1413	arg1	Rp					1390:1391	Rp	1390:1391	Rp	1390:1391	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	9	27	theme	precise	1869:1875	arg1	characterization					1888:1903	the precise structural characterization	1865:1903	the precise structural characterization of complex glycans	1865:1922	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	1	28	theme	biological	312:321	arg1	processes					323:331	numerous biological processes	303:331	numerous biological processes	303:331	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	2	29	theme	possible	416:423	arg1	isomers					425:431	known monosaccharide composition feature multiple possible isomers	366:431	known monosaccharide composition feature multiple possible isomers	366:431	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	0	30	theme	High-Resolution	15:29	arg1	Mobility					46:53	High-Resolution Multistage Ion Mobility	15:53	High-Resolution Multistage Ion Mobility	15:53	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	1	31	theme	numerous	303:310	arg1	processes					323:331	numerous biological processes	303:331	numerous biological processes	303:331	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	4	32	theme	non-natural	1077:1087	arg1	substrate					1114:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	8	33	theme	high	1586:1589	arg1	CTD					1639:1641	CTD	1639:1641	CTD	1639:1641	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	8	33	theme	high	1586:1589	arg1	dissociation					1625:1636	high activation energy charge transfer dissociation	1586:1636	high activation energy charge transfer dissociation (CTD)	1586:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	4	34	theme	mass	860:863	arg1	MS					879:880	MS	879:880	MS	879:880	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	4	34	theme	mass	860:863	arg1	spectrometry					865:876	mass spectrometry	860:876	mass spectrometry (MS)	860:881	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	0	35	theme	Ion	42:44	arg1	Mobility					46:53	High-Resolution Multistage Ion Mobility	15:53	High-Resolution Multistage Ion Mobility	15:53	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	9	36	theme	structural	1877:1886	arg1	characterization					1888:1903	the precise structural characterization	1865:1903	the precise structural characterization of complex glycans	1865:1922	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	4	37	theme	acceptor	1105:1112	arg1	substrate					1114:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	8	38	theme	energy	1602:1607	arg1	CTD					1639:1641	CTD	1639:1641	CTD	1639:1641	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	8	38	theme	energy	1602:1607	arg1	dissociation					1625:1636	high activation energy charge transfer dissociation	1586:1636	high activation energy charge transfer dissociation (CTD)	1586:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	2	39	dep	anomerism	456:464	arg1	the					452:454	the	452:454	the	452:454	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	3	40	theme	able	533:536	arg1	tools					527:531	Robust analytical tools	509:531	Robust analytical tools able to circumvent this extreme structural complexity	509:585	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	7	41	dep	eighth	1490:1495	arg1	the					1486:1488	the	1486:1488	the	1486:1488	Finally, a Rp of about 250 in ion mobility made it possible to detect the eighth and last of the expected structures.
35049286	5	42	theme	first	1127:1131	arg1	analysis					1133:1140	A first analysis	1125:1140	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS	1125:1199	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	9	43	theme	complex	1908:1914	arg1	glycans					1916:1922	complex glycans	1908:1922	complex glycans	1908:1922	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	8	44	theme	transfer	1616:1623	arg1	CTD					1639:1641	CTD	1639:1641	CTD	1639:1641	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	8	44	theme	transfer	1616:1623	arg1	dissociation					1625:1636	high activation energy charge transfer dissociation	1586:1636	high activation energy charge transfer dissociation (CTD)	1586:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	4	45	theme	complementary	826:838	arg1	strategies					840:849	complementary strategies	826:849	complementary strategies based on mass spectrometry (MS)	826:881	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	0	46	with	Combination	0:10	arg1	Energy					79:84	High Energy	74:84	High Energy of Activation	74:98	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	3	47	theme	analytical	516:525	arg1	tools					527:531	Robust analytical tools	509:531	Robust analytical tools able to circumvent this extreme structural complexity	509:585	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	7	48	theme	structures	1522:1531	arg1	eighth					1490:1495	eighth	1490:1495	eighth	1490:1495	Finally, a Rp of about 250 in ion mobility made it possible to detect the eighth and last of the expected structures.
35049286	3	49	theme	rapid	712:716	arg1	development					718:728	the rapid development	708:728	the rapid development of enzymatic and chemoenzymatic glycan synthesis	708:777	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	3	50	theme	extreme	557:563	arg1	complexity					576:585	this extreme structural complexity	552:585	this extreme structural complexity	552:585	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	1	51	theme	diverse	248:254	arg1	Carbohydrates					176:188	Carbohydrates	176:188	Carbohydrates	176:188	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	1	51	theme	diverse	248:254	arg1	biomolecules					256:267	highly structurally diverse biomolecules	228:267	highly structurally diverse biomolecules	228:267	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	2	52	theme	linkages	499:506	arg1	position					470:477	position	470:477	position	470:477	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	2	52	theme	linkages	499:506	arg1	anomerism					456:464	anomerism	456:464	anomerism	456:464	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	3	53	theme	glycan	762:767	arg1	synthesis					769:777	enzymatic and chemoenzymatic glycan synthesis	733:777	enzymatic and chemoenzymatic glycan synthesis	733:777	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	2	54	theme	monosaccharide	372:385	arg1	isomers					425:431	known monosaccharide composition feature multiple possible isomers	366:431	known monosaccharide composition feature multiple possible isomers	366:431	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	5	55	theme	possible	1281:1288	arg1	ones					1290:1293	the eight possible ones	1271:1293	the eight possible ones	1271:1293	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	6	56	theme	ion	1355:1357	arg1	mobility					1359:1366	ion mobility	1355:1366	ion mobility	1355:1366	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	8	57	theme	possible	1721:1728	arg1	products					1730:1737	the eight possible products	1711:1737	the eight possible products of enzymatic glucosylation	1711:1764	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	0	58	with	MS	66:67	arg1	Energy					79:84	High Energy	74:84	High Energy of Activation	74:98	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	2	59	theme	glycosidic	488:497	arg1	linkages					499:506	their glycosidic linkages	482:506	their glycosidic linkages	482:506	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	5	60	theme	enzymatic	1240:1248	arg1	glucosylation					1250:1262	enzymatic glucosylation	1240:1262	enzymatic glucosylation	1240:1262	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	2	61	theme	special	337:343	arg1	interest					345:352	special interest	337:352	special interest	337:352	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	8	62	theme	glucosylation	1752:1764	arg1	products					1730:1737	the eight possible products	1711:1737	the eight possible products of enzymatic glucosylation	1711:1764	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	1	63	theme	microbial	205:213	arg1	glycans					215:221	particular microbial glycans	194:221	particular microbial glycans	194:221	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
35049286	4	64	theme	α-transglucosylases	953:971	arg1	mutants					924:930	14 engineered mutants	910:930	14 engineered mutants of sucrose-utilizing α-transglucosylases	910:971	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	0	65	theme	Complex	128:134	arg1	Glycans					167:173	Complex Chemoenzymatically Synthesized Glycans	128:173	Complex Chemoenzymatically Synthesized Glycans	128:173	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	3	66	theme	correct	635:641	arg1	determination					643:655	not only the correct determination	622:655	not only the correct determination of naturally occurring glycans	622:686	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	8	67	dep	products	1730:1737	arg1	out					1704:1706	out	1704:1706	out	1704:1706	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	5	68	theme	glucosylation	1250:1262	arg1	products					1228:1235	six reaction products	1215:1235	six reaction products of enzymatic glucosylation out of the eight possible ones	1215:1293	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	9	69	theme	described	1819:1827	arg1	IMS					1838:1840	the recently described powerful IMS	1806:1840	the recently described powerful IMS	1806:1840	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	0	70	theme	Synthesized	155:165	arg1	Glycans					167:173	Complex Chemoenzymatically Synthesized Glycans	128:173	Complex Chemoenzymatically Synthesized Glycans	128:173	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	4	71	theme	engineered	913:922	arg1	mutants					924:930	14 engineered mutants	910:930	14 engineered mutants of sucrose-utilizing α-transglucosylases	910:971	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	6	72	theme	seventh	1298:1304	arg1	structure					1306:1314	A seventh structure	1296:1314	A seventh structure	1296:1314	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	6	73	theme	resolving	1373:1381	arg1	power					1383:1387	a resolving power	1371:1387	a resolving power (Rp) of approximately 100	1371:1413	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	6	73	theme	resolving	1373:1381	arg1	Rp					1390:1391	Rp	1390:1391	Rp	1390:1391	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	3	74	theme	occurring	670:678	arg1	glycans					680:686	naturally occurring glycans	660:686	naturally occurring glycans	660:686	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	5	75	theme	reaction	1149:1156	arg1	media					1158:1162	the reaction media	1145:1162	the reaction media	1145:1162	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	9	76	theme	powerful	1829:1836	arg1	IMS					1838:1840	the recently described powerful IMS	1806:1840	the recently described powerful IMS	1806:1840	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	3	77	dep	ensure	615:620	arg1	demand					605:610	demand	605:610	demand	605:610	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	4	78	theme	single	1052:1057	arg1	substrate					1114:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	0	79	theme	Activation	89:98	arg1	Energy					79:84	High Energy	74:84	High Energy of Activation	74:98	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	5	80	theme	reaction	1219:1226	arg1	products					1228:1235	six reaction products	1215:1235	six reaction products of enzymatic glucosylation out of the eight possible ones	1215:1293	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	4	81	theme	Shigella	1004:1011	arg1	flexneri					1013:1020	Shigella flexneri	1004:1020	type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	984:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	5	82	theme	high-accuracy	1184:1196	arg1	MS					1198:1199	high-accuracy MS	1184:1199	high-accuracy MS	1184:1199	A first analysis of the reaction media by UHPLC coupled to high-accuracy MS led to detect six reaction products of enzymatic glucosylation out of the eight possible ones.
35049286	4	83	theme	pentasaccharide	1022:1036	arg1	bricks					1038:1043	type/group-specific Shigella flexneri pentasaccharide bricks	984:1043	type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	984:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	8	84	theme	tandem	1571:1576	arg1	MS					1578:1579	tandem MS	1571:1579	tandem MS with high activation energy charge transfer dissociation (CTD)	1571:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	2	85	theme	isomers	425:431	arg1	glycans					355:361	glycans	355:361	glycans	355:361	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	2	86	theme	multiple	407:414	arg1	isomers					425:431	known monosaccharide composition feature multiple possible isomers	366:431	known monosaccharide composition feature multiple possible isomers	366:431	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	0	87	theme	Multistage	31:40	arg1	Mobility					46:53	High-Resolution Multistage Ion Mobility	15:53	High-Resolution Multistage Ion Mobility	15:53	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	7	88	from	Rp	1427:1428	arg1	mobility					1450:1457	ion mobility	1446:1457	ion mobility	1446:1457	Finally, a Rp of about 250 in ion mobility made it possible to detect the eighth and last of the expected structures.
35049286	8	89	theme	activation	1591:1600	arg1	CTD					1639:1641	CTD	1639:1641	CTD	1639:1641	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	8	89	theme	activation	1591:1600	arg1	dissociation					1625:1636	high activation energy charge transfer dissociation	1586:1636	high activation energy charge transfer dissociation (CTD)	1586:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	3	90	theme	Robust	509:514	arg1	tools					527:531	Robust analytical tools	509:531	Robust analytical tools able to circumvent this extreme structural complexity	509:585	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	0	91	theme	Mobility	46:53	arg1	Combination					0:10	Combination	0:10	Combination of High-Resolution Multistage Ion Mobility	0:53	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	0	91	theme	Mobility	46:53	arg1	MS					66:67	Tandem MS	59:67	Tandem MS with High Energy of Activation	59:98	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	4	92	from	substrate	1114:1122	arg1	bricks					1038:1043	type/group-specific Shigella flexneri pentasaccharide bricks	984:1043	type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	984:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	4	93	theme	protected	1067:1075	arg1	substrate					1114:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	8	94	theme	charge	1609:1614	arg1	CTD					1639:1641	CTD	1639:1641	CTD	1639:1641	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	8	94	theme	charge	1609:1614	arg1	dissociation					1625:1636	high activation energy charge transfer dissociation	1586:1636	high activation energy charge transfer dissociation (CTD)	1586:1642	Complementary to these measurements, tandem MS with high activation energy charge transfer dissociation (CTD) allowed us to unambiguously characterize seven regioisomers out of the eight possible products of enzymatic glucosylation.
35049286	0	95	theme	Tandem	59:64	arg1	MS					66:67	Tandem MS	59:67	Tandem MS with High Energy of Activation	59:98	Combination of High-Resolution Multistage Ion Mobility and Tandem MS with High Energy of Activation to Resolve the Structure of Complex Chemoenzymatically Synthesized Glycans.
35049286	4	96	theme	tetrasaccharide	1089:1103	arg1	substrate					1114:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	a single lightly protected non-natural tetrasaccharide acceptor substrate	1050:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	6	97	from	power	1383:1387	arg1	step					1347:1350	an additional step	1333:1350	an additional step of ion mobility at a resolving power (Rp) of approximately 100	1333:1413	A seventh structure was evidenced by an additional step of ion mobility at a resolving power (Rp) of approximately 100.
35049286	9	98	theme	glycans	1916:1922	arg1	characterization					1888:1903	the precise structural characterization	1865:1903	the precise structural characterization of complex glycans	1865:1922	This work illustrates the potential of the recently described powerful IMS and CTD-MS methods for the precise structural characterization of complex glycans.
35049286	2	99	theme	composition	387:397	arg1	isomers					425:431	known monosaccharide composition feature multiple possible isomers	366:431	known monosaccharide composition feature multiple possible isomers	366:431	Of special interest, glycans of known monosaccharide composition feature multiple possible isomers, differentiated by the anomerism and position of their glycosidic linkages.
35049286	3	100	theme	chemoenzymatic	747:760	arg1	synthesis					769:777	enzymatic and chemoenzymatic glycan synthesis	733:777	enzymatic and chemoenzymatic glycan synthesis	733:777	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	4	101	theme	strategies	840:849	arg1	use					819:821	the use	815:821	the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate	815:1122	In support to the later, we report the use of complementary strategies based on mass spectrometry (MS) to evaluate the ability of 14 engineered mutants of sucrose-utilizing α-transglucosylases to produce type/group-specific Shigella flexneri pentasaccharide bricks from a single lightly protected non-natural tetrasaccharide acceptor substrate.
35049286	3	102	theme	structural	565:574	arg1	complexity					576:585	this extreme structural complexity	552:585	this extreme structural complexity	552:585	Robust analytical tools able to circumvent this extreme structural complexity are increasing in demand to ensure not only the correct determination of naturally occurring glycans but also to support the rapid development of enzymatic and chemoenzymatic glycan synthesis.
35049286	1	103	theme	biomolecules	256:267	arg1	recognition					274:284	the recognition	270:284	the recognition	270:284	Carbohydrates, in particular microbial glycans, are highly structurally diverse biomolecules, the recognition of which governs numerous biological processes.
36324280	2	0	theme	procedure	465:473	arg1	lack					398:401	the lack	394:401	the lack of a fast, efficient, and robust high-throughput Hp isolation procedure	394:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	3	1	theme	interaction	694:704	arg1	chromatography					735:748	hydrophilic interaction ultrahigh-performance liquid chromatography	682:748	hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR)	682:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	2	2	theme	isolation	455:463	arg1	procedure					465:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	6	3	theme	quadrupole	1381:1390	arg1	time					1392:1395	electrospray ionization quadrupole time	1357:1395	electrospray ionization quadrupole time of flight mass spectrometry	1357:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	4	4	theme	Hp	887:888	arg1	enrichment					890:899	fast, efficient, and robust Hp enrichment	859:899	fast, efficient, and robust Hp enrichment	859:899	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	4	5	from	monolithic	812:821	arg1	format					845:850	a 96-well format	835:850	a 96-well format	835:850	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	3	6	from	plasma	567:572	arg1	enrichment					545:554	Hp enrichment	542:554	Hp enrichment from human plasma	542:572	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	6	7	theme	chromatographic	1267:1281	arg1	peaks					1283:1287	28 individual chromatographic peaks	1253:1287	28 individual chromatographic peaks	1253:1287	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	3	8	from	support	611:617	arg1	analysis					670:677	downstream Hp N-glycome analysis	646:677	downstream Hp N-glycome analysis	646:677	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	3	8	from	support	611:617	arg1	mode					637:640	immunoaffinity mode	622:640	immunoaffinity mode	622:640	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	6	9	theme	individual	1256:1265	arg1	peaks					1283:1287	28 individual chromatographic peaks	1253:1287	28 individual chromatographic peaks	1253:1287	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	1	10	with	protein	136:142	arg1	sites					197:201	four N-glycosylation sites	176:201	four N-glycosylation sites carrying mainly complex type N-glycans	176:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	5	11	theme	Hp	992:993	arg1	deglycosylation					995:1009	Hp deglycosylation	992:1009	Hp deglycosylation	992:1009	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	6	12	theme	HILIC-UHPLC-FLR	1195:1209	arg1	analysis					1211:1218	HILIC-UHPLC-FLR analysis	1195:1218	HILIC-UHPLC-FLR analysis	1195:1218	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	3	13	theme	high-throughput	515:529	arg1	method					531:536	a high-throughput method	513:536	a high-throughput method	513:536	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	2	14	theme	different	275:283	arg1	types					285:289	different types	275:289	different types of diseases	275:301	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	7	15	theme	developed	1430:1438	arg1	applicable					1519:1528	applicable	1519:1528	applicable	1519:1528	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	7	15	theme	developed	1430:1438	arg1	approach					1451:1458	The developed analytical approach	1426:1458	The developed analytical approach	1426:1458	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	7	16	theme	Hp	1493:1494	arg1	N-glycosylation					1496:1510	total Hp N-glycosylation	1487:1510	total Hp N-glycosylation	1487:1510	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	1	17	gly	N-glycosylation	181:195	arg2	sites					197:201	four N-glycosylation sites	176:201	four N-glycosylation sites carrying mainly complex type N-glycans	176:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	1	17	gly	N-glycosylation	181:195	arg2	four					176:179	four	176:179	four	176:179	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	6	18	theme	N-glycan	1299:1306	arg1	compositions					1308:1319	N-glycan compositions	1299:1319	N-glycan compositions	1299:1319	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	7	19	from	studies	1545:1551	arg1	applicable					1519:1528	applicable	1519:1528	applicable	1519:1528	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	7	19	from	studies	1545:1551	arg1	approach					1451:1458	The developed analytical approach	1426:1458	The developed analytical approach	1426:1458	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	3	20	theme	ultrahigh-performance	706:726	arg1	chromatography					735:748	hydrophilic interaction ultrahigh-performance liquid chromatography	682:748	hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR)	682:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	4	21	theme	efficient	865:873	arg1	enrichment					890:899	fast, efficient, and robust Hp enrichment	859:899	fast, efficient, and robust Hp enrichment	859:899	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	2	22	theme	efficient	414:422	arg1	procedure					465:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	0	23	theme	immunoaffinity	16:29	arg1	enrichment					31:40	High-throughput immunoaffinity enrichment	0:40	High-throughput immunoaffinity enrichment	0:40	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	3	24	theme	liquid	728:733	arg1	chromatography					735:748	hydrophilic interaction ultrahigh-performance liquid chromatography	682:748	hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR)	682:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	4	25	theme	robust	880:885	arg1	enrichment					890:899	fast, efficient, and robust Hp enrichment	859:899	fast, efficient, and robust Hp enrichment	859:899	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	3	26	theme	Hp	542:543	arg1	enrichment					545:554	Hp enrichment	542:554	Hp enrichment from human plasma	542:572	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	5	27	theme	N-glycome	943:951	arg1	analysis					953:960	The N-glycome analysis	939:960	The N-glycome analysis	939:960	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	0	28	theme	High-throughput	0:14	arg1	enrichment					31:40	High-throughput immunoaffinity enrichment	0:40	High-throughput immunoaffinity enrichment	0:40	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	5	29	theme	glycosylation	1093:1105	arg1	site					1107:1110	the specific glycosylation site	1080:1110	the specific glycosylation site	1080:1110	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	3	30	theme	Hp	657:658	arg1	analysis					670:677	downstream Hp N-glycome analysis	646:677	downstream Hp N-glycome analysis	646:677	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	7	31	theme	analytical	1440:1449	arg1	applicable					1519:1528	applicable	1519:1528	applicable	1519:1528	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	7	31	theme	analytical	1440:1449	arg1	approach					1451:1458	The developed analytical approach	1426:1458	The developed analytical approach	1426:1458	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	2	32	theme	analytical	360:369	arg1	challenges					371:380	analytical challenges	360:380	analytical challenges	360:380	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	7	33	theme	N-glycosylation	1496:1510	arg1	evaluation					1473:1482	fast evaluation	1468:1482	fast evaluation of total Hp N-glycosylation	1468:1510	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	6	34	theme	spectrometry	1412:1423	arg1	time					1392:1395	electrospray ionization quadrupole time	1357:1395	electrospray ionization quadrupole time of flight mass spectrometry	1357:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	4	35	theme	fast	859:862	arg1	enrichment					890:899	fast, efficient, and robust Hp enrichment	859:899	fast, efficient, and robust Hp enrichment	859:899	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	2	36	theme	diseases	294:301	arg1	types					285:289	different types	275:289	different types of diseases	275:301	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	2	37	theme	fast	408:411	arg1	procedure					465:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	3	38	theme	fluorescent	755:765	arg1	HILIC-UHPLC-FLR					778:792	HILIC-UHPLC-FLR	778:792	HILIC-UHPLC-FLR	778:792	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	3	38	theme	fluorescent	755:765	arg1	detection					767:775	fluorescent detection	755:775	fluorescent detection (HILIC-UHPLC-FLR)	755:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	6	39	theme	mass	1407:1410	arg1	spectrometry					1412:1423	flight mass spectrometry	1400:1423	flight mass spectrometry	1400:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	3	40	theme	immunoaffinity	622:635	arg1	mode					637:640	immunoaffinity mode	622:640	immunoaffinity mode	622:640	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	7	41	theme	total	1487:1491	arg1	N-glycosylation					1496:1510	total Hp N-glycosylation	1487:1510	total Hp N-glycosylation	1487:1510	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	2	42	theme	robust	429:434	arg1	procedure					465:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	1	43	theme	N-glycosylation	181:195	arg1	sites					197:201	four N-glycosylation sites	176:201	four N-glycosylation sites carrying mainly complex type N-glycans	176:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	2	44	theme	Hp	452:453	arg1	procedure					465:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	3	45	theme	monolithic	584:593	arg1	support					611:617	monolithic chromatographic support	584:617	monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis	584:677	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	6	46	theme	flight	1400:1405	arg1	spectrometry					1412:1423	flight mass spectrometry	1400:1423	flight mass spectrometry	1400:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	5	47	gly	glycosylation	1093:1105	arg2	site					1107:1110	the specific glycosylation site	1080:1110	the specific glycosylation site	1080:1110	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	7	48	theme	fast	1468:1471	arg1	evaluation					1473:1482	fast evaluation	1468:1482	fast evaluation of total Hp N-glycosylation	1468:1510	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	2	49	theme	high-throughput	436:450	arg1	procedure					465:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	a fast, efficient, and robust high-throughput Hp isolation procedure	406:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	5	50	theme	tested	1176:1181	arg1	conditions					1183:1192	tested conditions	1176:1192	tested conditions	1176:1192	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	0	51	theme	N-glycan	46:53	arg1	analysis					55:62	N-glycan analysis	46:62	N-glycan analysis of human plasma haptoglobin	46:90	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	5	52	theme	N-glycan	1056:1063	arg1	release					1065:1071	N-glycan release	1056:1071	N-glycan release	1056:1071	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	7	53	from	applicable	1519:1528	arg1	studies					1545:1551	large-scale studies	1533:1551	large-scale studies	1533:1551	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	0	54	theme	human	67:71	arg1	haptoglobin					80:90	human plasma haptoglobin	67:90	human plasma haptoglobin	67:90	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	4	55	theme	plasma	923:928	arg1	samples					930:936	diluted plasma samples	915:936	diluted plasma samples	915:936	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	5	56	theme	deglycosylation	995:1009	arg1	degree					982:987	a degree	980:987	a degree of Hp deglycosylation	980:1009	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	7	57	theme	large-scale	1533:1543	arg1	studies					1545:1551	large-scale studies	1533:1551	large-scale studies	1533:1551	The developed analytical approach enables fast evaluation of total Hp N-glycosylation and is applicable in large-scale studies.
36324280	6	58	theme	robust	1228:1233	arg1	quantification					1235:1248	robust quantification	1228:1248	robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry	1228:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	4	59	theme	diluted	915:921	arg1	samples					930:936	diluted plasma samples	915:936	diluted plasma samples	915:936	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	1	60	contain	carrying	203:210	arg2	N-glycans					232:240	mainly complex type N-glycans	212:240	mainly complex type N-glycans	212:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	1	60	contain	carrying	203:210	arg1	sites					197:201	four N-glycosylation sites	176:201	four N-glycosylation sites carrying mainly complex type N-glycans	176:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	3	61	theme	human	561:565	arg1	plasma					567:572	human plasma	561:572	human plasma	561:572	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	1	62	theme	positive	115:122	arg1	Haptoglobin					93:103	Haptoglobin	93:103	Haptoglobin (Hp)	93:108	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	1	62	theme	positive	115:122	arg1	protein					136:142	a positive acute phase protein	113:142	a positive acute phase protein	113:142	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	6	63	theme	peaks	1283:1287	arg1	quantification					1235:1248	robust quantification	1228:1248	robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry	1228:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	6	64	theme	ionization	1370:1379	arg1	time					1392:1395	electrospray ionization quadrupole time	1357:1395	electrospray ionization quadrupole time of flight mass spectrometry	1357:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	3	65	theme	N-glycome	660:668	arg1	analysis					670:677	downstream Hp N-glycome analysis	646:677	downstream Hp N-glycome analysis	646:677	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	2	66	dep	challenges	371:380	arg1	lack					398:401	the lack	394:401	the lack of a fast, efficient, and robust high-throughput Hp isolation procedure	394:473	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36324280	4	67	from	format	845:850	arg1	monolithic					812:821	monolithic	812:821	monolithic	812:821	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	1	68	theme	acute	124:128	arg1	Haptoglobin					93:103	Haptoglobin	93:103	Haptoglobin (Hp)	93:108	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	1	68	theme	acute	124:128	arg1	protein					136:142	a positive acute phase protein	113:142	a positive acute phase protein	113:142	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	3	69	theme	method	531:536	arg1	development					498:508	the development	494:508	the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR)	494:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	6	70	theme	electrospray	1357:1368	arg1	time					1392:1395	electrospray ionization quadrupole time	1357:1395	electrospray ionization quadrupole time of flight mass spectrometry	1357:1423	HILIC-UHPLC-FLR analysis enables robust quantification of 28 individual chromatographic peaks, in which N-glycan compositions were determined by UHPLC coupled to electrospray ionization quadrupole time of flight mass spectrometry.
36324280	5	71	theme	specific	1084:1091	arg1	site					1107:1110	the specific glycosylation site	1080:1110	the specific glycosylation site	1080:1110	The N-glycome analysis demonstrated that a degree of Hp deglycosylation differs depending on the conditions used for N-glycan release and on the specific glycosylation site, with Asn 241 being the most resistant to deglycosylation under tested conditions.
36324280	3	72	theme	chromatographic	595:609	arg1	support					611:617	monolithic chromatographic support	584:617	monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis	584:677	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	1	73	theme	phase	130:134	arg1	Haptoglobin					93:103	Haptoglobin	93:103	Haptoglobin (Hp)	93:108	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	1	73	theme	phase	130:134	arg1	protein					136:142	a positive acute phase protein	113:142	a positive acute phase protein	113:142	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	3	74	with	chromatography	735:748	arg1	HILIC-UHPLC-FLR					778:792	HILIC-UHPLC-FLR	778:792	HILIC-UHPLC-FLR	778:792	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	3	74	with	chromatography	735:748	arg1	detection					767:775	fluorescent detection	755:775	fluorescent detection (HILIC-UHPLC-FLR)	755:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	1	75	theme	complex	219:225	arg1	N-glycans					232:240	mainly complex type N-glycans	212:240	mainly complex type N-glycans	212:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	0	76	theme	haptoglobin	80:90	arg1	enrichment					31:40	High-throughput immunoaffinity enrichment	0:40	High-throughput immunoaffinity enrichment	0:40	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	0	76	theme	haptoglobin	80:90	arg1	analysis					55:62	N-glycan analysis	46:62	N-glycan analysis of human plasma haptoglobin	46:90	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	3	77	theme	downstream	646:655	arg1	analysis					670:677	downstream Hp N-glycome analysis	646:677	downstream Hp N-glycome analysis	646:677	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	4	78	theme	96-well	837:843	arg1	format					845:850	a 96-well format	835:850	a 96-well format	835:850	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	4	79	dep	monolithic	812:821	arg1	supports					823:830	supports	823:830	supports	823:830	Chromatographic monolithic supports in a 96-well format enable fast, efficient, and robust Hp enrichment directly from diluted plasma samples.
36324280	1	80	theme	type	227:230	arg1	N-glycans					232:240	mainly complex type N-glycans	212:240	mainly complex type N-glycans	212:240	Haptoglobin (Hp) is a positive acute phase protein, synthesized in the liver, with four N-glycosylation sites carrying mainly complex type N-glycans.
36324280	0	81	theme	plasma	73:78	arg1	haptoglobin					80:90	human plasma haptoglobin	67:90	human plasma haptoglobin	67:90	High-throughput immunoaffinity enrichment and N-glycan analysis of human plasma haptoglobin.
36324280	3	82	theme	hydrophilic	682:692	arg1	chromatography					735:748	hydrophilic interaction ultrahigh-performance liquid chromatography	682:748	hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR)	682:793	Here, we describe the development of a high-throughput method for Hp enrichment from human plasma, based on monolithic chromatographic support in immunoaffinity mode and downstream Hp N-glycome analysis by hydrophilic interaction ultrahigh-performance liquid chromatography with fluorescent detection (HILIC-UHPLC-FLR).
36324280	2	83	gly	glycosylation	247:259	arg1	types					285:289	different types	275:289	different types of diseases	275:301	Its glycosylation is altered in different types of diseases but still has not been extensively studied mainly due to analytical challenges, especially the lack of a fast, efficient, and robust high-throughput Hp isolation procedure.
36445784	4	0	theme	proteins	1009:1016	arg1	analysis					972:979	analysis	972:979	analysis of GPI-interacting membrane proteins	972:1016	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	3	1	theme	GPI	737:739	arg1	derivative					741:750	This bifunctional GPI derivative	719:750	This bifunctional GPI derivative	719:750	This bifunctional GPI derivative can cross-react with molecules in proximity upon photoactivation and be subsequently labeled with other molecular tags via click reaction.
36445784	4	2	dep	such	964:967	arg1	as					969:970	as	969:970	as	969:970	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	4	3	theme	valuable	917:924	arg1	probe					926:930	a valuable probe	915:930	a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins,	915:1017	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	4	3	theme	valuable	917:924	arg1	it					902:903	it	902:903	it	902:903	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	1	4	theme	anchors	243:249	arg1	structure					214:222	the highly conserved core structure	188:222	the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	188:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	4	5	theme	membrane	1000:1007	arg1	proteins					1009:1016	GPI-interacting membrane proteins	984:1016	GPI-interacting membrane proteins	984:1016	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	1	6	from	alkynes	316:322	arg1	glycan					331:336	the glycan	327:336	the glycan	327:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	7	theme	group	426:430	arg1	manipulation					432:443	group manipulation	426:443	group manipulation	426:443	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	8	theme	GPI	161:163	arg1	derivative					166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative	111:175	derivative	166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	2	9	from	groups	573:578	arg1	target					597:602	the synthetic target	583:602	the synthetic target	583:602	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	4	10	theme	biological	936:945	arg1	studies					947:953	biological studies	936:953	biological studies of GPIs	936:961	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	1	11	from	chain	296:300	arg1	glycan					331:336	the glycan	327:336	the glycan	327:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	3	12	theme	other	850:854	arg1	tags					866:869	other molecular tags	850:869	other molecular tags	850:869	This bifunctional GPI derivative can cross-react with molecules in proximity upon photoactivation and be subsequently labeled with other molecular tags via click reaction.
36445784	1	13	theme	photoactivable	258:271	arg1	diazirine					273:281	a photoactivable diazirine	256:281	a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	256:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	0	14	theme	Biology	102:108	arg1	Study					89:93	the Study	85:93	the Study of GPI Biology	85:108	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	1	15	theme	regioselective	449:462	arg1	phosphorylation					464:478	regioselective phosphorylation	449:478	regioselective phosphorylation	449:478	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	0	16	theme	GPI	98:100	arg1	Biology					102:108	GPI Biology	98:108	GPI Biology	98:108	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	3	17	theme	bifunctional	724:735	arg1	derivative					741:750	This bifunctional GPI derivative	719:750	This bifunctional GPI derivative	719:750	This bifunctional GPI derivative can cross-react with molecules in proximity upon photoactivation and be subsequently labeled with other molecular tags via click reaction.
36445784	1	18	theme	convergent	359:368	arg1	strategy					390:397	a convergent [3+2] glycosylation strategy	357:397	a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation	357:478	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	19	from	diazirine	273:281	arg1	chain					296:300	the lipid chain and clickable alkynes	286:322	chain	296:300	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	19	from	diazirine	273:281	arg1	alkynes					316:322	the lipid chain and clickable alkynes	286:322	alkynes	316:322	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	4	20	theme	GPI-interacting	984:998	arg1	proteins					1009:1016	GPI-interacting membrane proteins	984:1016	GPI-interacting membrane proteins	984:1016	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	4	21	theme	GPIs	958:961	arg1	studies					947:953	biological studies	936:953	biological studies of GPIs	936:961	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	0	22	theme	Bifunctionalized	15:30	arg1	GPI					62:64	GPI	62:64	GPI	62:64	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	0	22	theme	Bifunctionalized	15:30	arg1	Glycosylphosphatidylinositol					32:59	Bifunctionalized Glycosylphosphatidylinositol	15:59	a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology	13:108	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	2	23	from	target	597:602	arg1	presence					530:537	the presence	526:537	the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics	526:644	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	2	24	theme	functional	562:571	arg1	groups					573:578	several distinctive functional groups	542:578	several distinctive functional groups in the synthetic target, which complicated the protection tactics	542:644	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	2	25	theme	inherent	666:673	arg1	difficulties					675:686	the inherent difficulties	662:686	the inherent difficulties associated with GPI synthesis	662:716	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	3	26	theme	molecular	856:864	arg1	tags					866:869	other molecular tags	850:869	other molecular tags	850:869	This bifunctional GPI derivative can cross-react with molecules in proximity upon photoactivation and be subsequently labeled with other molecular tags via click reaction.
36445784	1	27	with	strategy	390:397	arg1	stage					409:413	late stage	404:413	late stage protecting group manipulation and regioselective phosphorylation	404:478	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	4	28	theme	functional	1051:1060	arg1	mechanisms					1062:1071	their functional mechanisms	1045:1071	their functional mechanisms	1045:1071	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	2	29	theme	distinctive	550:560	arg1	groups					573:578	several distinctive functional groups	542:578	several distinctive functional groups in the synthetic target, which complicated the protection tactics	542:644	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	1	30	theme	[3+2	370:373	arg1	strategy					390:397	a convergent [3+2] glycosylation strategy	357:397	a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation	357:478	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	31	theme	conserved	199:207	arg1	structure					214:222	the highly conserved core structure	188:222	the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	188:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	32	theme	lipid	290:294	arg1	chain					296:300	the lipid chain and clickable alkynes	286:322	chain	296:300	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	2	33	theme	several	542:548	arg1	groups					573:578	several distinctive functional groups	542:578	several distinctive functional groups in the synthetic target, which complicated the protection tactics	542:644	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	1	34	contain	containing	177:186	arg2	structure					214:222	the highly conserved core structure	188:222	the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	188:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	34	contain	containing	177:186	arg1	derivative					166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative	111:175	derivative	166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	35	theme	core	209:212	arg1	structure					214:222	the highly conserved core structure	188:222	the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	188:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	0	36	theme	Glycosylphosphatidylinositol	32:59	arg1	Anchor					67:72	a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor	13:72	a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology	13:108	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	2	37	theme	protection	627:636	arg1	tactics					638:644	the protection tactics	623:644	the protection tactics	623:644	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	1	38	theme	glycosylation	376:388	arg1	strategy					390:397	a convergent [3+2] glycosylation strategy	357:397	a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation	357:478	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	2	39	theme	synthetic	587:595	arg1	target					597:602	the synthetic target	583:602	the synthetic target	583:602	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	2	40	theme	synthesis	504:512	arg1	due					519:521	due	519:521	due	519:521	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	2	40	theme	synthesis	504:512	arg1	challenges					485:494	The challenges	481:494	The challenges of this synthesis	481:512	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	4	41	theme	gaining	1023:1029	arg1	insights					1031:1038	gaining insights	1023:1038	gaining insights into their functional mechanisms	1023:1071	Therefore, it should be a valuable probe for biological studies of GPIs, such as analysis of GPI-interacting membrane proteins, and gaining insights into their functional mechanisms.
36445784	1	42	theme	clickable	306:314	arg1	alkynes					316:322	the lipid chain and clickable alkynes	286:322	alkynes	316:322	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	43	with	anchors	243:249	arg1	diazirine					273:281	a photoactivable diazirine	256:281	a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	256:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	2	44	dep	difficulties	675:686	arg1	addition					650:657	addition	650:657	addition	650:657	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	1	45	theme	late	404:407	arg1	stage					409:413	late stage	404:413	late stage protecting group manipulation and regioselective phosphorylation	404:478	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	2	46	theme	GPI	704:706	arg1	synthesis					708:716	GPI synthesis	704:716	GPI synthesis	704:716	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	1	47	theme	new	113:115	arg1	derivative					166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative	111:175	derivative	166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	2	48	theme	groups	573:578	arg1	presence					530:537	the presence	526:537	the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics	526:644	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	2	49	from	presence	530:537	arg1	target					597:602	the synthetic target	583:602	the synthetic target	583:602	The challenges of this synthesis were due to the presence of several distinctive functional groups in the synthetic target, which complicated the protection tactics, in addition to the inherent difficulties associated with GPI synthesis.
36445784	3	50	theme	click	875:879	arg1	reaction					881:888	click reaction	875:888	click reaction	875:888	This bifunctional GPI derivative can cross-react with molecules in proximity upon photoactivation and be subsequently labeled with other molecular tags via click reaction.
36445784	0	51	theme	Useful	74:79	arg1	Anchor					67:72	a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor	13:72	a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology	13:108	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	3	52	from	molecules	773:781	arg1	proximity					786:794	proximity	786:794	proximity	786:794	This bifunctional GPI derivative can cross-react with molecules in proximity upon photoactivation and be subsequently labeled with other molecular tags via click reaction.
36445784	1	53	theme	bifunctional	118:129	arg1	derivative					166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative	111:175	derivative	166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	54	theme	natural	231:237	arg1	anchors					243:249	all natural GPI anchors	227:249	all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	227:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	0	55	theme	Anchor	67:72	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.	0:109	Synthesis of a Bifunctionalized Glycosylphosphatidylinositol (GPI) Anchor Useful for the Study of GPI Biology.
36445784	1	56	theme	glycosylphosphatidylinositol	131:158	arg1	derivative					166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative	111:175	derivative	166:175	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36445784	1	57	theme	GPI	239:241	arg1	anchors					243:249	all natural GPI anchors	227:249	all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan	227:336	A new, bifunctional glycosylphosphatidylinositol (GPI) derivative containing the highly conserved core structure of all natural GPI anchors with a photoactivable diazirine in the lipid chain and clickable alkynes in the glycan was synthesized by a convergent [3+2] glycosylation strategy with late stage protecting group manipulation and regioselective phosphorylation.
36511577	0	0	theme	Separation	91:100	arg1	Media					102:106	Spongy-like Separation Media	79:106	Spongy-like Separation Media	79:106	Classification of Extracellular Vesicles Based on Surface Glycan Structures by Spongy-like Separation Media.
36511577	9	1	theme	lectin-immobilized	1276:1293	arg1	SPMs					1295:1298	lectin-immobilized SPMs	1276:1298	lectin-immobilized SPMs	1276:1298	Finally, lectin-immobilized SPMs are employed to classify EVs based on the surface glycan structures and demonstrate different subpopulations by proteome profiling.
36511577	5	2	theme	novel	553:557	arg1	method					602:607	a novel lectin-based affinity chromatography (LAC) method	551:607	a novel lectin-based affinity chromatography (LAC) method	551:607	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	7	3	theme	binding	1074:1080	arg1	activity					1082:1089	the binding activity	1070:1089	the binding activity	1070:1089	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	0	4	theme	Spongy-like	79:89	arg1	Media					102:106	Spongy-like Separation Media	79:106	Spongy-like Separation Media	79:106	Classification of Extracellular Vesicles Based on Surface Glycan Structures by Spongy-like Separation Media.
36511577	4	5	theme	purification	413:424	arg1	methods					426:432	the same purification methods	404:432	the same purification methods	404:432	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	10	6	theme	contents	1495:1502	arg1	variation					1474:1482	the variation	1470:1482	the variation of protein contents in EVs	1470:1509	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	7	7	theme	Sambucus	965:972	arg1	agglutinin					986:995	Sambucus sieboldiana agglutinin	965:995	Sambucus sieboldiana agglutinin	965:995	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	7	7	theme	Sambucus	965:972	arg1	lectins					927:933	Two distinct lectins	914:933	Two distinct lectins with different specificities	914:962	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	7	8	theme	concanavalin	1001:1012	arg1	A					1014:1014	concanavalin A	1001:1014	concanavalin A	1001:1014	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	7	8	theme	concanavalin	1001:1012	arg1	lectins					927:933	Two distinct lectins	914:933	Two distinct lectins with different specificities	914:962	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	4	9	theme	same	408:411	arg1	methods					426:432	the same purification methods	404:432	the same purification methods	404:432	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	4	10	theme	objective	494:502	arg1	functions					515:523	objective biological functions	494:523	objective biological functions	494:523	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	5	11	theme	affinity	572:579	arg1	method					602:607	a novel lectin-based affinity chromatography (LAC) method	551:607	a novel lectin-based affinity chromatography (LAC) method	551:607	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	7	12	theme	sieboldiana	974:984	arg1	agglutinin					986:995	Sambucus sieboldiana agglutinin	965:995	Sambucus sieboldiana agglutinin	965:995	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	7	12	theme	sieboldiana	974:984	arg1	lectins					927:933	Two distinct lectins	914:933	Two distinct lectins with different specificities	914:962	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	8	13	theme	large	1191:1195	arg1	pores					1210:1214	the large flow-through pores	1187:1214	the large flow-through pores (>10 μm) of SPM	1187:1230	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	8	13	theme	large	1191:1195	arg1	μm					1221:1222	>10 μm	1217:1222	>10 μm	1217:1222	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	8	14	theme	typical	1246:1252	arg1	gel					1262:1264	a typical agarose gel	1244:1264	a typical agarose gel	1244:1264	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	3	15	contain	have	295:298	arg2	compositions					324:335	heterogeneous molecular compositions	300:335	heterogeneous molecular compositions	300:335	However, they have heterogeneous molecular compositions.
36511577	3	15	contain	have	295:298	arg1	they					290:293	they	290:293	they	290:293	However, they have heterogeneous molecular compositions.
36511577	10	16	theme	immobilized	1559:1569	arg1	media					1571:1575	lectin immobilized media	1552:1575	lectin immobilized media	1552:1575	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	6	17	theme	epoxy	900:904	arg1	groups					906:911	epoxy groups	900:911	epoxy groups	900:911	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	5	18	theme	glycan	640:645	arg1	structures					647:656	their glycan structures	634:656	their glycan structures	634:656	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	5	19	theme	LAC	597:599	arg1	method					602:607	a novel lectin-based affinity chromatography (LAC) method	551:607	a novel lectin-based affinity chromatography (LAC) method	551:607	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	1	20	theme	various	178:184	arg1	biomolecules					186:197	various biomolecules	178:197	various biomolecules	178:197	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	4	21	theme	biological	504:513	arg1	functions					515:523	objective biological functions	494:523	objective biological functions	494:523	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	8	22	theme	high	1102:1105	arg1	rates					1116:1120	high recovery rates	1102:1120	high recovery rates of liposomal nanoparticles as a model of EVs	1102:1165	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	6	23	theme	ethylene-co-glycidyl	784:803	arg1	poly					779:782	poly	779:782	poly(ethylene-co-glycidyl methacrylate) with continuous micropores	779:844	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	6	23	theme	ethylene-co-glycidyl	784:803	arg1	methacrylate					805:816	ethylene-co-glycidyl methacrylate	784:816	ethylene-co-glycidyl methacrylate	784:816	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	6	24	theme	monolithic	718:727	arg1	polymer					729:735	a spongy-like monolithic polymer	704:735	a spongy-like monolithic polymer (spongy monolith, SPM)	704:758	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	6	24	theme	monolithic	718:727	arg1	spongy					738:743	spongy monolith, SPM	738:757	spongy	738:743	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	6	25	with	reaction	886:893	arg1	groups					906:911	epoxy groups	900:911	epoxy groups	900:911	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	8	26	theme	flow-through	1197:1208	arg1	pores					1210:1214	the large flow-through pores	1187:1214	the large flow-through pores (>10 μm) of SPM	1187:1230	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	8	26	theme	flow-through	1197:1208	arg1	μm					1221:1222	>10 μm	1217:1222	>10 μm	1217:1222	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	6	27	theme	continuous	824:833	arg1	micropores					835:844	continuous micropores	824:844	continuous micropores	824:844	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	5	28	theme	method	602:607	arg1	potential					538:546	the potential	534:546	the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures	534:656	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	10	29	theme	glycans	1540:1546	arg1	difference					1518:1527	the difference	1514:1527	the difference of surface glycans	1514:1546	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	6	30	theme	spongy-like	706:716	arg1	polymer					729:735	a spongy-like monolithic polymer	704:735	a spongy-like monolithic polymer (spongy monolith, SPM)	704:758	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	6	30	theme	spongy-like	706:716	arg1	spongy					738:743	spongy monolith, SPM	738:757	spongy	738:743	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	0	31	theme	Vesicles	32:39	arg1	Classification					0:13	Classification	0:13	Classification of Extracellular Vesicles	0:39	Classification of Extracellular Vesicles Based on Surface Glycan Structures by Spongy-like Separation Media.
36511577	7	32	theme	different	940:948	arg1	specificities					950:962	different specificities	940:962	different specificities	940:962	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	1	33	theme	Extracellular	109:121	arg1	vesicles					156:163	lipid bilayer vesicles	142:163	lipid bilayer vesicles that enclose various biomolecules	142:197	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	1	33	theme	Extracellular	109:121	arg1	EVs					133:135	EVs	133:135	EVs	133:135	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	1	33	theme	Extracellular	109:121	arg1	vesicles					123:130	Extracellular vesicles	109:130	Extracellular vesicles (EVs)	109:136	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	0	34	theme	Extracellular	18:30	arg1	Vesicles					32:39	Extracellular Vesicles	18:39	Extracellular Vesicles	18:39	Classification of Extracellular Vesicles Based on Surface Glycan Structures by Spongy-like Separation Media.
36511577	5	35	theme	chromatography	581:594	arg1	method					602:607	a novel lectin-based affinity chromatography (LAC) method	551:607	a novel lectin-based affinity chromatography (LAC) method	551:607	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	4	36	theme	significant	457:467	arg1	which					446:450	which	446:450	which	446:450	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	4	36	theme	significant	457:467	arg1	obstacle					469:476	a significant obstacle	455:476	a significant obstacle for elucidating objective biological functions	455:523	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	4	37	from	cells	383:387	arg1	compositions					342:353	The compositions	338:353	The compositions of EVs from identical donor cells obtained using the same purification methods	338:432	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	8	38	theme	agarose	1254:1260	arg1	gel					1262:1264	a typical agarose gel	1244:1264	a typical agarose gel	1244:1264	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	7	39	with	lectins	927:933	arg1	specificities					950:962	different specificities	940:962	different specificities	940:962	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	8	40	theme	liposomal	1125:1133	arg1	nanoparticles					1135:1147	liposomal nanoparticles	1125:1147	liposomal nanoparticles as a model of EVs	1125:1165	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	6	41	theme	protein	878:884	arg1	reaction					886:893	an efficient in situ protein reaction	857:893	an efficient in situ protein reaction with epoxy groups	857:911	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	8	42	theme	recovery	1107:1114	arg1	rates					1116:1120	high recovery rates	1102:1120	high recovery rates of liposomal nanoparticles as a model of EVs	1102:1165	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	6	43	with	poly	779:782	arg1	micropores					835:844	continuous micropores	824:844	continuous micropores	824:844	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	9	44	theme	glycan	1350:1355	arg1	structures					1357:1366	the surface glycan structures	1338:1366	the surface glycan structures	1338:1366	Finally, lectin-immobilized SPMs are employed to classify EVs based on the surface glycan structures and demonstrate different subpopulations by proteome profiling.
36511577	10	45	theme	protein	1487:1493	arg1	contents					1495:1502	protein contents	1487:1502	protein contents	1487:1502	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	5	46	theme	lectin-based	559:570	arg1	method					602:607	a novel lectin-based affinity chromatography (LAC) method	551:607	a novel lectin-based affinity chromatography (LAC) method	551:607	Herein, the potential of a novel lectin-based affinity chromatography (LAC) method to classify EVs based on their glycan structures is demonstrated.
36511577	10	47	theme	lectin	1552:1557	arg1	media					1571:1575	lectin immobilized media	1552:1575	lectin immobilized media	1552:1575	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	0	48	theme	Glycan	58:63	arg1	Structures					65:74	Surface Glycan Structures	50:74	Surface Glycan Structures by Spongy-like Separation Media	50:106	Classification of Extracellular Vesicles Based on Surface Glycan Structures by Spongy-like Separation Media.
36511577	6	49	dep	in	870:871	arg1	situ					873:876	situ	873:876	situ	873:876	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	3	50	theme	molecular	314:322	arg1	compositions					324:335	heterogeneous molecular compositions	300:335	heterogeneous molecular compositions	300:335	However, they have heterogeneous molecular compositions.
36511577	6	51	theme	in	870:871	arg1	reaction					886:893	an efficient in situ protein reaction	857:893	an efficient in situ protein reaction with epoxy groups	857:911	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	4	52	theme	EVs	358:360	arg1	compositions					342:353	The compositions	338:353	The compositions of EVs from identical donor cells obtained using the same purification methods	338:432	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	0	53	theme	Surface	50:56	arg1	Structures					65:74	Surface Glycan Structures	50:74	Surface Glycan Structures by Spongy-like Separation Media	50:106	Classification of Extracellular Vesicles Based on Surface Glycan Structures by Spongy-like Separation Media.
36511577	8	54	theme	nanoparticles	1135:1147	arg1	rates					1116:1120	high recovery rates	1102:1120	high recovery rates of liposomal nanoparticles as a model of EVs	1102:1165	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	6	55	theme	efficient	860:868	arg1	reaction					886:893	an efficient in situ protein reaction	857:893	an efficient in situ protein reaction with epoxy groups	857:911	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	2	56	theme	sensitive	220:228	arg1	biomarkers					230:239	sensitive biomarkers	220:239	sensitive biomarkers	220:239	EVs hold promise as sensitive biomarkers to detect and monitor various diseases.
36511577	4	57	theme	donor	377:381	arg1	cells					383:387	identical donor cells	367:387	identical donor cells obtained using the same purification methods	367:432	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	10	58	theme	first	1444:1448	arg1	approach					1450:1457	the first approach	1440:1457	the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media	1440:1575	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	10	58	theme	first	1444:1448	arg1	This					1432:1435	This	1432:1435	This	1432:1435	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	6	59	theme	proposed	679:686	arg1	method					688:693	The proposed method	675:693	The proposed method	675:693	The proposed method utilizes a spongy-like monolithic polymer (spongy monolith, SPM), which consists of poly(ethylene-co-glycidyl methacrylate) with continuous micropores and allows an efficient in situ protein reaction with epoxy groups.
36511577	10	60	from	variation	1474:1482	arg1	EVs					1507:1509	EVs	1507:1509	EVs	1507:1509	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	9	61	theme	surface	1342:1348	arg1	structures					1357:1366	the surface glycan structures	1338:1366	the surface glycan structures	1338:1366	Finally, lectin-immobilized SPMs are employed to classify EVs based on the surface glycan structures and demonstrate different subpopulations by proteome profiling.
36511577	4	62	theme	identical	367:375	arg1	cells					383:387	identical donor cells	367:387	identical donor cells obtained using the same purification methods	367:432	The compositions of EVs from identical donor cells obtained using the same purification methods may differ, which is a significant obstacle for elucidating objective biological functions.
36511577	9	63	theme	different	1384:1392	arg1	subpopulations					1394:1407	different subpopulations	1384:1407	different subpopulations	1384:1407	Finally, lectin-immobilized SPMs are employed to classify EVs based on the surface glycan structures and demonstrate different subpopulations by proteome profiling.
36511577	3	64	theme	heterogeneous	300:312	arg1	compositions					324:335	heterogeneous molecular compositions	300:335	heterogeneous molecular compositions	300:335	However, they have heterogeneous molecular compositions.
36511577	2	65	theme	various	263:269	arg1	diseases					271:278	various diseases	263:278	various diseases	263:278	EVs hold promise as sensitive biomarkers to detect and monitor various diseases.
36511577	8	66	theme	EVs	1163:1165	arg1	model					1154:1158	a model	1152:1158	a model of EVs	1152:1165	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	1	67	theme	lipid	142:146	arg1	vesicles					156:163	lipid bilayer vesicles	142:163	lipid bilayer vesicles that enclose various biomolecules	142:197	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	1	67	theme	lipid	142:146	arg1	vesicles					123:130	Extracellular vesicles	109:130	Extracellular vesicles (EVs)	109:136	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	7	68	theme	distinct	918:925	arg1	agglutinin					986:995	Sambucus sieboldiana agglutinin	965:995	Sambucus sieboldiana agglutinin	965:995	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	7	68	theme	distinct	918:925	arg1	A					1014:1014	concanavalin A	1001:1014	concanavalin A	1001:1014	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	7	68	theme	distinct	918:925	arg1	lectins					927:933	Two distinct lectins	914:933	Two distinct lectins with different specificities	914:962	Two distinct lectins with different specificities, Sambucus sieboldiana agglutinin and concanavalin A, are effectively immobilized on SPM without impacting the binding activity.
36511577	10	69	theme	surface	1532:1538	arg1	glycans					1540:1546	surface glycans	1532:1546	surface glycans	1532:1546	This is the first approach to clarify the variation of protein contents in EVs by the difference of surface glycans via lectin immobilized media.
36511577	8	70	theme	SPM	1228:1230	arg1	pores					1210:1214	the large flow-through pores	1187:1214	the large flow-through pores (>10 μm) of SPM	1187:1230	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	8	70	theme	SPM	1228:1230	arg1	μm					1221:1222	>10 μm	1217:1222	>10 μm	1217:1222	Moreover, high recovery rates of liposomal nanoparticles as a model of EVs are achieved due to the large flow-through pores (>10 μm) of SPM compared to a typical agarose gel.
36511577	1	71	theme	bilayer	148:154	arg1	vesicles					156:163	lipid bilayer vesicles	142:163	lipid bilayer vesicles that enclose various biomolecules	142:197	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	1	71	theme	bilayer	148:154	arg1	vesicles					123:130	Extracellular vesicles	109:130	Extracellular vesicles (EVs)	109:136	Extracellular vesicles (EVs) are lipid bilayer vesicles that enclose various biomolecules.
36511577	9	72	theme	proteome	1412:1419	arg1	profiling					1421:1429	proteome profiling	1412:1429	proteome profiling	1412:1429	Finally, lectin-immobilized SPMs are employed to classify EVs based on the surface glycan structures and demonstrate different subpopulations by proteome profiling.
35285615	1	0	theme	entire	265:270	arg1	complement					272:281	the entire complement	261:281	the entire complement of proteoforms	261:296	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	4	1	theme	phenotype	1066:1074	arg1	2-1					1076:1078	phenotype 2-1	1066:1078	phenotype 2-1	1066:1078	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	3	2	theme	average	753:759	arg1	mass					761:764	the average mass	749:764	not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms	740:853	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	8	3	theme	triantennary	1954:1965	arg1	structures					1967:1976	the triantennary structures	1950:1976	the triantennary structures	1950:1976	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	3	4	theme	limited	586:592	arg1	reduction					601:609	limited charge reduction	586:609	limited charge reduction	586:609	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	5	5	theme	haptoglobin	1447:1457	arg1	subunits					1459:1466	metastable haptoglobin subunits	1436:1466	metastable haptoglobin subunits	1436:1466	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	4	6	theme	approach	876:883	arg1	Application					856:866	Application	856:866	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1)	856:960	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	4	7	theme	ionic	1142:1146	arg1	signals					1148:1154	their ionic signals	1136:1154	their ionic signals	1136:1154	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	3	8	theme	protein	773:779	arg1	range					799:803	the mass range	790:803	not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms	740:853	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	3	8	theme	protein	773:779	arg1	mass					761:764	the average mass	749:764	not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms	740:853	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	3	9	theme	electrospray	616:627	arg1	MS					646:647	electrospray ionization (ESI) MS	616:647	electrospray ionization (ESI) MS	616:647	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	7	10	theme	phenotypes	1719:1728	arg1	patterns					1690:1697	N-Glycosylation patterns	1674:1697	N-Glycosylation patterns of both haptoglobin phenotypes	1674:1728	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	8	11	theme	haptoglobin	1996:2006	arg1	2-1					2008:2010	haptoglobin 2-1	1996:2010	haptoglobin 2-1	1996:2010	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	3	12	theme	reduction	601:609	arg1	way					663:665	an elegant way	652:665	an elegant way to obtain meaningful information on most heterogeneous systems	652:728	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	3	12	theme	reduction	601:609	arg1	Incorporation					569:581	Incorporation	569:581	Incorporation of limited charge reduction into electrospray ionization (ESI) MS	569:647	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	1	13	theme	Intact-mass	130:140	arg1	measurements					142:153	Intact-mass measurements	130:153	Intact-mass measurements	130:153	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	3	14	theme	mass	794:797	arg1	range					799:803	the mass range	790:803	not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms	740:853	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	4	15	from	evidence	971:978	arg1	extent					1017:1022	their extent	1011:1022	their extent of glycosylation	1011:1039	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	6	16	theme	heavy	1660:1664	arg1	chains					1666:1671	the heavy chains	1656:1671	the heavy chains	1656:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	4	17	theme	phenotypes	922:931	arg1	characterization					888:903	characterization	888:903	characterization of two different phenotypes of haptoglobin (1-1 and 2-1)	888:960	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	6	18	from	patterns	1644:1651	arg1	wealth					1605:1610	a wealth	1603:1610	a wealth of information on glycosylation patterns of the heavy chains	1603:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	8	19	theme	higher	1933:1938	arg1	number					1940:1945	higher number	1933:1945	higher number of the triantennary structures	1933:1976	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	4	20	theme	haptoglobin	936:946	arg1	phenotypes					922:931	two different phenotypes	908:931	two different phenotypes of haptoglobin (1-1 and 2-1)	908:960	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	3	21	theme	elegant	655:661	arg1	way					663:665	an elegant way	652:665	an elegant way to obtain meaningful information on most heterogeneous systems	652:728	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	3	21	theme	elegant	655:661	arg1	Incorporation					569:581	Incorporation	569:581	Incorporation of limited charge reduction into electrospray ionization (ESI) MS	569:647	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	6	22	theme	glycosylation	1630:1642	arg1	patterns					1644:1651	glycosylation patterns	1630:1651	glycosylation patterns of the heavy chains	1630:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	7	23	theme	type	1806:1809	arg1	structures					1784:1793	bi- and triantennary structures	1763:1793	bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation	1763:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	4	24	theme	significant	985:995	arg1	difference					997:1006	a significant difference	983:1006	a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter)	983:1101	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	9	25	dep	applications	2391:2402	arg1	process					2361:2367	process	2361:2367	process	2361:2367	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	9	25	dep	applications	2391:2402	arg1	e.g.					2355:2358	e.g.	2355:2358	e.g.	2355:2358	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	9	26	theme	glycosylation	2061:2073	arg1	patterns					2075:2082	The glycosylation patterns	2057:2082	The glycosylation patterns deduced from the XP-RC/MS measurements	2057:2121	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	5	27	theme	online	1319:1324	arg1	detection					1329:1337	online MS detection	1319:1337	online MS detection	1319:1337	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	9	28	theme	protein	2322:2328	arg1	heterogeneity					2330:2342	protein heterogeneity	2322:2342	protein heterogeneity	2322:2342	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	5	29	with	chromatography	1291:1304	arg1	detection					1329:1337	online MS detection	1319:1337	online MS detection	1319:1337	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	6	30	theme	information	1615:1625	arg1	wealth					1605:1610	a wealth	1603:1610	a wealth of information on glycosylation patterns of the heavy chains	1603:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	5	31	theme	reactive	1282:1289	arg1	chromatography					1291:1304	cross-path reactive chromatography	1271:1304	cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits	1271:1466	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	5	31	theme	reactive	1282:1289	arg1	XP-RC					1307:1311	XP-RC	1307:1311	XP-RC	1307:1311	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	3	32	theme	proteoforms	843:853	arg1	complement					829:838	the entire complement	818:838	the entire complement of proteoforms	818:853	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	0	33	theme	Intact-Mass	77:87	arg1	Approaches					92:101	Orthogonal Intact-Mass MS Approaches	66:101	Orthogonal Intact-Mass MS Approaches	66:101	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	1	34	from	popular	181:187	arg1	MS					211:212	MS	211:212	MS	211:212	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	1	34	from	popular	181:187	arg1	spectrometry					197:208	mass spectrometry	192:208	mass spectrometry (MS)	192:213	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	7	35	theme	triantennary	1771:1782	arg1	structures					1784:1793	bi- and triantennary structures	1763:1793	bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation	1763:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	8	36	theme	haptoglobin	1909:1919	arg1	1-1					1921:1923	haptoglobin 1-1	1909:1923	haptoglobin 1-1	1909:1923	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	7	37	theme	bi-	1763:1765	arg1	structures					1784:1793	bi- and triantennary structures	1763:1793	bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation	1763:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	2	38	theme	straightforward	536:550	arg1	measurements					555:566	straightforward MS measurements	536:566	straightforward MS measurements	536:566	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	5	39	theme	chromatographic	1355:1369	arg1	separation					1371:1380	chromatographic separation	1355:1380	chromatographic separation	1355:1380	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	0	40	theme	Multivariate	107:118	arg1	Analysis					120:127	Multivariate Analysis	107:127	Multivariate Analysis	107:127	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	9	41	theme	latter	2251:2256	arg1	technique					2258:2266	the latter technique	2247:2266	the latter technique	2247:2266	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	2	42	theme	diversity	469:477	arg1	degrees					447:453	relatively modest degrees	429:453	relatively modest degrees of structural diversity	429:477	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	0	43	theme	Orthogonal	66:75	arg1	Approaches					92:101	Orthogonal Intact-Mass MS Approaches	66:101	Orthogonal Intact-Mass MS Approaches	66:101	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	9	44	theme	analytical	2369:2378	arg1	applications					2391:2402	analytical technology applications	2369:2402	analytical technology applications	2369:2402	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	0	45	theme	Rapid	0:4	arg1	Evaluation					6:15	Rapid Evaluation	0:15	Rapid Evaluation of the Extent of Haptoglobin Glycosylation	0:58	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	1	46	theme	proteoforms	286:296	arg1	complement					272:281	the entire complement	261:281	the entire complement of proteoforms	261:296	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	4	47	theme	glycan	1051:1056	arg1	load					1058:1061	the glycan load	1047:1061	the glycan load of phenotype 2-1 being notably lighter	1047:1100	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	2	48	theme	modest	440:445	arg1	degrees					447:453	relatively modest degrees	429:453	relatively modest degrees of structural diversity	429:477	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	5	49	theme	glycosylation	1197:1209	arg1	patterns					1211:1218	their glycosylation patterns	1191:1218	their glycosylation patterns	1191:1218	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	7	50	theme	fucosylation	1845:1856	arg1	level					1836:1840	significant level	1824:1840	significant level of fucosylation and sialylation	1824:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	2	51	theme	high	487:490	arg1	extent					492:497	the high extent	483:497	the high extent of heterogeneity	483:514	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	3	52	theme	meaningful	677:686	arg1	information					688:698	meaningful information	677:698	meaningful information on most heterogeneous systems	677:728	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	0	53	theme	Extent	24:29	arg1	Evaluation					6:15	Rapid Evaluation	0:15	Rapid Evaluation of the Extent of Haptoglobin Glycosylation	0:58	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	4	54	theme	glycosylation	1027:1039	arg1	extent					1017:1022	their extent	1011:1022	their extent of glycosylation	1011:1039	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	0	55	theme	Haptoglobin	34:44	arg1	Glycosylation					46:58	Haptoglobin Glycosylation	34:58	Haptoglobin Glycosylation	34:58	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	5	56	theme	detailed	1162:1169	arg1	characterization					1171:1186	More detailed characterization	1157:1186	More detailed characterization of their glycosylation patterns	1157:1218	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	6	57	located	present	1556:1562	arg2	modifications					1538:1550	no modifications	1535:1550	no modifications	1535:1550	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	6	57	located	present	1556:1562	arg1	chains					1583:1588	their light chains	1571:1588	their light chains	1571:1588	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	3	58	theme	heterogeneous	708:720	arg1	systems					722:728	most heterogeneous systems	703:728	most heterogeneous systems	703:728	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	5	59	theme	metastable	1436:1445	arg1	subunits					1459:1466	metastable haptoglobin subunits	1436:1466	metastable haptoglobin subunits	1436:1466	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	3	60	from	information	688:698	arg1	systems					722:728	most heterogeneous systems	703:728	most heterogeneous systems	703:728	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	2	61	theme	approach	376:383	arg1	applications					355:366	applications	355:366	applications of this approach	355:383	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	9	62	theme	charge	2213:2218	arg1	reduction					2220:2228	limited charge reduction	2205:2228	limited charge reduction	2205:2228	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	5	63	theme	disulfide	1408:1416	arg1	bonds					1418:1422	disulfide bonds	1408:1422	disulfide bonds	1408:1422	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	8	64	theme	structures	1967:1976	arg1	number					1940:1945	higher number	1933:1945	higher number of the triantennary structures	1933:1976	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	6	65	theme	haptoglobin	1498:1508	arg1	phenotypes					1510:1519	both haptoglobin phenotypes	1493:1519	both haptoglobin phenotypes	1493:1519	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	7	66	theme	sialylation	1862:1872	arg1	level					1836:1840	significant level	1824:1840	significant level of fucosylation and sialylation	1824:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	1	67	theme	mass	192:195	arg1	MS					211:212	MS	211:212	MS	211:212	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	1	67	theme	mass	192:195	arg1	spectrometry					197:208	mass spectrometry	192:208	mass spectrometry (MS)	192:213	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	6	68	gly	glycosylation	1630:1642	arg1	chains					1666:1671	the heavy chains	1656:1671	the heavy chains	1656:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	4	69	theme	signals	1148:1154	arg1	significant					1113:1123	significant	1113:1123	significant	1113:1123	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	4	70	from	extent	1017:1022	arg1	evidence					971:978	evidence	971:978	evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter)	971:1101	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	8	71	theme	fucosylation	2043:2054	arg1	extent					2033:2038	a higher extent	2024:2038	a higher extent of fucosylation	2024:2054	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	8	71	theme	fucosylation	2043:2054	arg1	2-1					2008:2010	haptoglobin 2-1	1996:2010	haptoglobin 2-1	1996:2010	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	9	72	with	agreement	2130:2138	arg1	conclusions					2149:2159	the conclusions	2145:2159	the conclusions of the intact-mass analysis supplemented by limited charge reduction	2145:2228	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	7	73	theme	haptoglobin	1707:1717	arg1	phenotypes					1719:1728	both haptoglobin phenotypes	1702:1728	both haptoglobin phenotypes	1702:1728	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	9	74	theme	intact-mass	2168:2178	arg1	analysis					2180:2187	the intact-mass analysis	2164:2187	the intact-mass analysis supplemented by limited charge reduction	2164:2228	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	3	75	theme	charge	594:599	arg1	reduction					601:609	limited charge reduction	586:609	limited charge reduction	586:609	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	6	76	theme	light	1577:1581	arg1	chains					1583:1588	their light chains	1571:1588	their light chains	1571:1588	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	3	77	theme	ESI	641:643	arg1	MS					646:647	electrospray ionization (ESI) MS	616:647	electrospray ionization (ESI) MS	616:647	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	1	78	theme	protein	221:227	arg1	characterization					229:244	protein characterization	221:244	protein characterization	221:244	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	7	79	theme	N-Glycosylation	1674:1688	arg1	patterns					1690:1697	N-Glycosylation patterns	1674:1697	N-Glycosylation patterns of both haptoglobin phenotypes	1674:1728	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	3	80	theme	ionization	629:638	arg1	MS					646:647	electrospray ionization (ESI) MS	616:647	electrospray ionization (ESI) MS	616:647	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	4	81	dep	significant	1113:1123	arg1	overlap					1125:1131	overlap	1125:1131	overlap	1125:1131	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	4	82	theme	different	912:920	arg1	phenotypes					922:931	two different phenotypes	908:931	two different phenotypes of haptoglobin (1-1 and 2-1)	908:960	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	7	83	with	consistent	1747:1756	arg1	structures					1784:1793	bi- and triantennary structures	1763:1793	bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation	1763:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	9	84	theme	analysis	2180:2187	arg1	conclusions					2149:2159	the conclusions	2145:2159	the conclusions of the intact-mass analysis supplemented by limited charge reduction	2145:2228	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	9	85	theme	fast	2303:2306	arg1	assessment					2308:2317	fast assessment	2303:2317	fast assessment of protein heterogeneity	2303:2342	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	8	86	theme	higher	2026:2031	arg1	extent					2033:2038	a higher extent	2024:2038	a higher extent of fucosylation	2024:2054	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	7	87	theme	significant	1824:1834	arg1	level					1836:1840	significant level	1824:1840	significant level of fucosylation and sialylation	1824:1872	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	3	88	theme	entire	822:827	arg1	complement					829:838	the entire complement	818:838	the entire complement of proteoforms	818:853	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	4	89	dep	haptoglobin	936:946	arg1	1-1					949:951	1-1	949:951	1-1	949:951	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	4	89	dep	haptoglobin	936:946	arg1	2-1					957:959	2-1	957:959	2-1	957:959	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	6	90	from	information	1615:1625	arg1	patterns					1644:1651	glycosylation patterns	1630:1651	glycosylation patterns of the heavy chains	1630:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	2	91	theme	heterogeneity	502:514	arg1	extent					492:497	the high extent	483:497	the high extent of heterogeneity	483:514	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	5	92	theme	cross-path	1271:1280	arg1	chromatography					1291:1304	cross-path reactive chromatography	1271:1304	cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits	1271:1466	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	5	92	theme	cross-path	1271:1280	arg1	XP-RC					1307:1311	XP-RC	1307:1311	XP-RC	1307:1311	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	9	93	theme	heterogeneity	2330:2342	arg1	assessment					2308:2317	fast assessment	2303:2317	fast assessment of protein heterogeneity	2303:2342	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	0	94	theme	MS	89:90	arg1	Approaches					92:101	Orthogonal Intact-Mass MS Approaches	66:101	Orthogonal Intact-Mass MS Approaches	66:101	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	1	95	from	spectrometry	197:208	arg1	popular					181:187	popular	181:187	popular	181:187	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	7	96	theme	complex	1798:1804	arg1	type					1806:1809	complex type	1798:1809	complex type	1798:1809	N-Glycosylation patterns of both haptoglobin phenotypes were found to be consistent with bi- and triantennary structures of complex type that exhibit significant level of fucosylation and sialylation.
35285615	4	97	theme	difference	997:1006	arg1	evidence					971:978	evidence	971:978	evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter)	971:1101	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	5	98	theme	chromatography	1291:1304	arg1	technique					1258:1266	the recently introduced technique	1234:1266	the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits	1234:1466	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	8	99	theme	multivariate	1884:1895	arg1	analysis					1897:1904	multivariate analysis	1884:1904	multivariate analysis of haptoglobin 1-1	1884:1923	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	2	100	theme	MS	552:553	arg1	measurements					555:566	straightforward MS measurements	536:566	straightforward MS measurements	536:566	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	9	101	theme	XP-RC/MS	2101:2108	arg1	measurements					2110:2121	the XP-RC/MS measurements	2097:2121	the XP-RC/MS measurements	2097:2121	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	6	102	from	wealth	1605:1610	arg1	patterns					1644:1651	glycosylation patterns	1630:1651	glycosylation patterns of the heavy chains	1630:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	5	103	theme	introduced	1247:1256	arg1	technique					1258:1266	the recently introduced technique	1234:1266	the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits	1234:1466	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	8	104	theme	1-1	1921:1923	arg1	analysis					1897:1904	multivariate analysis	1884:1904	multivariate analysis of haptoglobin 1-1	1884:1923	However, multivariate analysis of haptoglobin 1-1 reveals higher number of the triantennary structures, in comparison to haptoglobin 2-1, as well as a higher extent of fucosylation.
35285615	2	105	theme	structural	458:467	arg1	diversity					469:477	structural diversity	458:477	structural diversity	458:477	However, applications of this approach are currently limited to systems exhibiting relatively modest degrees of structural diversity, as the high extent of heterogeneity frequently prevents straightforward MS measurements.
35285615	5	106	theme	MS	1326:1327	arg1	detection					1329:1337	online MS detection	1319:1337	online MS detection	1319:1337	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	9	107	theme	technology	2380:2389	arg1	applications					2391:2402	analytical technology applications	2369:2402	analytical technology applications	2369:2402	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
35285615	6	108	theme	XP-RC	1484:1488	arg1	Application					1469:1479	Application	1469:1479	Application of XP-RC to both haptoglobin phenotypes	1469:1519	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	6	109	theme	chains	1666:1671	arg1	patterns					1644:1651	glycosylation patterns	1630:1651	glycosylation patterns of the heavy chains	1630:1671	Application of XP-RC to both haptoglobin phenotypes confirms that no modifications are present within their light chains and provides a wealth of information on glycosylation patterns of the heavy chains.
35285615	5	110	theme	patterns	1211:1218	arg1	characterization					1171:1186	More detailed characterization	1157:1186	More detailed characterization of their glycosylation patterns	1157:1218	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	5	111	theme	bonds	1418:1422	arg1	reduction					1395:1403	in-line reduction	1387:1403	in-line reduction of disulfide bonds	1387:1422	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	0	112	theme	Glycosylation	46:58	arg1	Extent					24:29	the Extent	20:29	the Extent of Haptoglobin Glycosylation	20:58	Rapid Evaluation of the Extent of Haptoglobin Glycosylation Using Orthogonal Intact-Mass MS Approaches and Multivariate Analysis.
35285615	4	113	with	difference	997:1006	arg1	load					1058:1061	the glycan load	1047:1061	the glycan load of phenotype 2-1 being notably lighter	1047:1100	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	3	114	theme	most	703:706	arg1	systems					722:728	most heterogeneous systems	703:728	most heterogeneous systems	703:728	Incorporation of limited charge reduction into electrospray ionization (ESI) MS is an elegant way to obtain meaningful information on most heterogeneous systems, yielding not only the average mass of the protein but also the mass range populated by the entire complement of proteoforms.
35285615	1	115	theme	short	334:338	arg1	time					340:343	a relatively short time	321:343	a relatively short time	321:343	Intact-mass measurements are becoming increasingly popular in mass spectrometry (MS) based protein characterization, as they allow the entire complement of proteoforms to be evaluated within a relatively short time.
35285615	5	116	theme	in-line	1387:1393	arg1	reduction					1395:1403	in-line reduction	1387:1403	in-line reduction of disulfide bonds	1387:1422	More detailed characterization of their glycosylation patterns is enabled by the recently introduced technique of cross-path reactive chromatography (XP-RC) with online MS detection, which combines chromatographic separation with in-line reduction of disulfide bonds to generate metastable haptoglobin subunits.
35285615	4	117	from	difference	997:1006	arg1	extent					1017:1022	their extent	1011:1022	their extent of glycosylation	1011:1039	Application of this approach to characterization of two different phenotypes of haptoglobin (1-1 and 2-1) provides evidence of a significant difference in their extent of glycosylation (with the glycan load of phenotype 2-1 being notably lighter) despite a significant overlap of their ionic signals.
35285615	9	118	theme	limited	2205:2211	arg1	reduction					2220:2228	limited charge reduction	2205:2228	limited charge reduction	2205:2228	The glycosylation patterns deduced from the XP-RC/MS measurements are in agreement with the conclusions of the intact-mass analysis supplemented by limited charge reduction, suggesting that the latter technique can be employed in situations when fast assessment of protein heterogeneity is needed (e.g., process analytical technology applications).
37094403	1	0	theme	cationic	160:167	arg1	CS					177:178	CS	177:178	CS	177:178	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	0	theme	cationic	160:167	arg1	starch					169:174	cationic starch	160:174	cationic starch (CS)	160:179	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	1	theme	alcohol	229:235	arg1	precipitation					237:249	alcohol precipitation	229:249	alcohol precipitation	229:249	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	2	2	theme	CS/XG	349:353	arg1	nanoparticles					355:367	CS/XG nanoparticles	349:367	CS/XG nanoparticles	349:367	Physicochemical properties, micromorphology, and emulsification properties of CS/XG nanoparticles were measured.
37094403	6	3	theme	emulsions	789:797	arg1	results					778:784	the rheological and stability results	748:784	results	778:784	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	2	4	theme	Physicochemical	271:285	arg1	properties					287:296	Physicochemical properties	271:296	Physicochemical properties	271:296	Physicochemical properties, micromorphology, and emulsification properties of CS/XG nanoparticles were measured.
37094403	2	5	theme	nanoparticles	355:367	arg1	properties					335:344	emulsification properties	320:344	emulsification properties	320:344	Physicochemical properties, micromorphology, and emulsification properties of CS/XG nanoparticles were measured.
37094403	2	5	theme	nanoparticles	355:367	arg1	micromorphology					299:313	micromorphology	299:313	micromorphology	299:313	Physicochemical properties, micromorphology, and emulsification properties of CS/XG nanoparticles were measured.
37094403	2	5	theme	nanoparticles	355:367	arg1	properties					287:296	Physicochemical properties	271:296	Physicochemical properties	271:296	Physicochemical properties, micromorphology, and emulsification properties of CS/XG nanoparticles were measured.
37094403	3	6	theme	nanoparticles	458:470	arg1	size					440:443	the diameter size	427:443	the diameter size of the CS/XG nanoparticles	427:470	SEM showed that after compositing with XG, the diameter size of the CS/XG nanoparticles was increased from about 50 nm to 150-300 nm.
37094403	3	7	theme	diameter	431:438	arg1	size					440:443	the diameter size	427:443	the diameter size of the CS/XG nanoparticles	427:470	SEM showed that after compositing with XG, the diameter size of the CS/XG nanoparticles was increased from about 50 nm to 150-300 nm.
37094403	6	8	theme	emulsions	880:888	arg1	properties					866:875	the rheological and stability properties	836:875	properties	866:875	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	7	9	theme	efficient	993:1001	arg1	method					1003:1008	an efficient method	990:1008	an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties	990:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	4	10	theme	CP/MAS	537:542	arg1	NMR					544:546	13C CP/MAS NMR	533:546	13C CP/MAS NMR	533:546	FT-IR, XRD and 13C CP/MAS NMR confirmed that XG was successfully complexed with CS.
37094403	0	11	theme	Preparation	0:10	arg1	properties					31:40	Preparation and emulsification properties	0:40	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.	0:96	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	1	12	theme	first	259:263	arg1	time					265:268	the first time	255:268	the first time	255:268	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	5	13	theme	visual	615:620	arg1	observation					622:632	the visual observation	611:632	the visual observation	611:632	Besides, the visual observation indicated emulsions stabilized by CS/XG nanoparticles had excellent storage and thermal properties.
37094403	7	14	theme	emulsifying	1070:1080	arg1	properties					1082:1091	efficient emulsifying properties	1060:1091	efficient emulsifying properties	1060:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	7	15	with	nanoparticles	1041:1053	arg1	properties					1082:1091	efficient emulsifying properties	1060:1091	efficient emulsifying properties	1060:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	4	16	theme	13C	533:535	arg1	NMR					544:546	13C CP/MAS NMR	533:546	13C CP/MAS NMR	533:546	FT-IR, XRD and 13C CP/MAS NMR confirmed that XG was successfully complexed with CS.
37094403	5	17	theme	excellent	692:700	arg1	storage					702:708	excellent storage and thermal properties	692:731	storage	702:708	Besides, the visual observation indicated emulsions stabilized by CS/XG nanoparticles had excellent storage and thermal properties.
37094403	3	18	dep	150-300 nm	506:515	arg1	to					503:504	to	503:504	to	503:504	SEM showed that after compositing with XG, the diameter size of the CS/XG nanoparticles was increased from about 50 nm to 150-300 nm.
37094403	3	19	theme	CS/XG	452:456	arg1	nanoparticles					458:470	the CS/XG nanoparticles	448:470	the CS/XG nanoparticles	448:470	SEM showed that after compositing with XG, the diameter size of the CS/XG nanoparticles was increased from about 50 nm to 150-300 nm.
37094403	0	20	theme	emulsification	16:29	arg1	properties					31:40	Preparation and emulsification properties	0:40	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.	0:96	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	1	21	theme	starch	169:174	arg1	gum					193:195	xanthan gum	185:195	xanthan gum (XG)	185:200	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	21	theme	starch	169:174	arg1	composite					147:155	the composite	143:155	the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation	143:249	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	21	theme	starch	169:174	arg1	starch					169:174	cationic starch	160:174	cationic starch (CS)	160:179	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	22	theme	gum	193:195	arg1	gum					193:195	xanthan gum	185:195	xanthan gum (XG)	185:200	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	22	theme	gum	193:195	arg1	composite					147:155	the composite	143:155	the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation	143:249	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	22	theme	gum	193:195	arg1	starch					169:174	cationic starch	160:174	cationic starch (CS)	160:179	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	0	23	theme	cationic	45:52	arg1	nanoparticles					83:95	cationic starch-xanthan gum composite nanoparticles	45:95	cationic starch-xanthan gum composite nanoparticles	45:95	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	6	24	theme	stability	856:864	arg1	properties					866:875	the rheological and stability properties	836:875	properties	866:875	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	5	25	theme	thermal	714:720	arg1	properties					722:731	excellent storage and thermal properties	692:731	properties	722:731	Besides, the visual observation indicated emulsions stabilized by CS/XG nanoparticles had excellent storage and thermal properties.
37094403	6	26	theme	stability	768:776	arg1	results					778:784	the rheological and stability results	748:784	results	778:784	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	0	27	theme	gum	69:71	arg1	nanoparticles					83:95	cationic starch-xanthan gum composite nanoparticles	45:95	cationic starch-xanthan gum composite nanoparticles	45:95	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	6	28	theme	environmental	935:947	arg1	responsiveness					949:962	environmental responsiveness	935:962	environmental responsiveness	935:962	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	7	29	theme	composite	1031:1039	arg1	nanoparticles					1041:1053	CS and GX composite nanoparticles	1021:1053	CS and GX composite nanoparticles with efficient emulsifying properties	1021:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	6	30	theme	rheological	840:850	arg1	properties					866:875	the rheological and stability properties	836:875	properties	866:875	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	7	31	theme	CS	1021:1022	arg1	nanoparticles					1041:1053	CS and GX composite nanoparticles	1021:1053	CS and GX composite nanoparticles with efficient emulsifying properties	1021:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	7	32	theme	efficient	1060:1068	arg1	properties					1082:1091	efficient emulsifying properties	1060:1091	efficient emulsifying properties	1060:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	0	33	theme	starch-xanthan	54:67	arg1	nanoparticles					83:95	cationic starch-xanthan gum composite nanoparticles	45:95	cationic starch-xanthan gum composite nanoparticles	45:95	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	5	34	theme	CS/XG	668:672	arg1	nanoparticles					674:686	CS/XG nanoparticles	668:686	CS/XG nanoparticles	668:686	Besides, the visual observation indicated emulsions stabilized by CS/XG nanoparticles had excellent storage and thermal properties.
37094403	6	35	theme	rheological	752:762	arg1	results					778:784	the rheological and stability results	748:784	results	778:784	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	2	36	theme	emulsification	320:333	arg1	properties					335:344	emulsification properties	320:344	emulsification properties	320:344	Physicochemical properties, micromorphology, and emulsification properties of CS/XG nanoparticles were measured.
37094403	7	37	theme	GX	1028:1029	arg1	nanoparticles					1041:1053	CS and GX composite nanoparticles	1021:1053	CS and GX composite nanoparticles with efficient emulsifying properties	1021:1091	Thus, this work provides an efficient method to prepare CS and GX composite nanoparticles with efficient emulsifying properties.
37094403	6	38	contain	had	931:933	arg1	emulsions					921:929	the prepared emulsions	908:929	the prepared emulsions	908:929	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	6	38	contain	had	931:933	arg2	responsiveness					949:962	environmental responsiveness	935:962	environmental responsiveness	935:962	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	0	39	theme	nanoparticles	83:95	arg1	properties					31:40	Preparation and emulsification properties	0:40	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.	0:96	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	1	40	theme	xanthan	185:191	arg1	gum					193:195	xanthan gum	185:195	xanthan gum (XG)	185:200	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	1	40	theme	xanthan	185:191	arg1	XG					198:199	XG	198:199	XG	198:199	In this work, nanoparticles were prepared by the composite of cationic starch (CS) and xanthan gum (XG) through gelatinization and alcohol precipitation for the first time.
37094403	6	41	contain	had	821:823	arg1	pH					809:810	pH	809:810	pH	809:810	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	6	41	contain	had	821:823	arg2	effects					825:831	effects	825:831	effects	825:831	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	6	41	contain	had	821:823	arg1	NaCl					816:819	NaCl	816:819	NaCl	816:819	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	0	42	theme	composite	73:81	arg1	nanoparticles					83:95	cationic starch-xanthan gum composite nanoparticles	45:95	cationic starch-xanthan gum composite nanoparticles	45:95	Preparation and emulsification properties of cationic starch-xanthan gum composite nanoparticles.
37094403	6	43	theme	prepared	912:919	arg1	emulsions					921:929	the prepared emulsions	908:929	the prepared emulsions	908:929	Additionally, the rheological and stability results of emulsions show that pH and NaCl had effects on the rheological and stability properties of emulsions, which means that the prepared emulsions had environmental responsiveness.
37094403	5	44	dep	indicated	634:642	arg1	had					688:690	had	688:690	indicated emulsions stabilized by CS/XG nanoparticles had excellent storage and thermal properties	634:731	Besides, the visual observation indicated emulsions stabilized by CS/XG nanoparticles had excellent storage and thermal properties.
37108903	4	0	theme	cell	994:997	arg1	content					1011:1017	a higher cell wall chitin content	985:1017	a higher cell wall chitin content	985:1017	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	3	1	theme	S.	664:665	arg1	globosa					667:673	S. globosa	664:673	S. globosa	664:673	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	5	2	theme	cell	1341:1344	arg1	wall					1346:1349	this fungal cell wall	1329:1349	this fungal cell wall	1329:1349	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	9	3	dep	composition	2184:2194	arg1	the					2170:2172	the	2170:2172	the	2170:2172	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	4	4	theme	chitin	1004:1009	arg1	content					1011:1017	a higher cell wall chitin content	985:1017	a higher cell wall chitin content	985:1017	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	9	5	theme	species	2234:2240	arg1	composition					2184:2194	cell wall composition	2174:2194	cell wall composition	2174:2194	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	9	5	theme	species	2234:2240	arg1	structure					2200:2208	structure	2200:2208	structure	2200:2208	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	4	6	theme	β-1,3-glucan	1063:1074	arg1	content					1076:1082	a higher β-1,3-glucan content	1054:1082	a higher β-1,3-glucan content	1054:1082	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	4	7	dep	found	1095:1099	arg1	exposed					1106:1112	exposed	1106:1112	was found most exposed at the cell surface	1091:1132	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	7	8	theme	cytokine	1894:1901	arg1	profiles					1903:1910	different cytokine profiles	1884:1910	different cytokine profiles	1884:1910	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	6	9	dep	S.	1449:1450	arg1	brasiliensis					1452:1463	S. brasiliensis and S. globosa	1449:1478	brasiliensis	1452:1463	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	6	9	dep	S.	1449:1450	arg1	globosa					1472:1478	globosa	1472:1478	globosa	1472:1478	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	8	10	theme	dectin-1	2083:2090	arg1	activation					2069:2078	the activation	2065:2078	the activation of dectin-1, mannose receptor, and TLR2, but not TLR4	2065:2132	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	1	11	theme	thermodimorphic	193:207	arg1	species					209:215	the thermodimorphic species	189:215	the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa	189:336	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	4	12	contain	have	980:983	arg2	content					1011:1017	a higher cell wall chitin content	985:1017	a higher cell wall chitin content	985:1017	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	4	12	contain	have	980:983	arg1	conidia					951:957	S. globosa conidia	940:957	S. globosa conidia	940:957	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	4	12	contain	have	980:983	arg1	cells					974:978	yeast-like cells	963:978	yeast-like cells	963:978	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	8	13	theme	mannose	2093:2099	arg1	receptor					2101:2108	mannose receptor	2093:2108	mannose receptor	2093:2108	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	7	14	dep	schenckii	1834:1842	arg1	species					1864:1870	species	1864:1870	species	1864:1870	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	7	14	dep	schenckii	1834:1842	arg1	the					1827:1829	the	1827:1829	the	1827:1829	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	1	15	theme	Sporothrix	224:233	arg1	clade					246:250	the Sporothrix pathogenic clade	220:250	the Sporothrix pathogenic clade	220:250	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	8	16	theme	TLR2	2115:2118	arg1	activation					2069:2078	the activation	2065:2078	the activation of dectin-1, mannose receptor, and TLR2, but not TLR4	2065:2132	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	6	17	theme	stimulation	1506:1516	arg1	profile					1518:1524	a similar cytokine stimulation profile	1487:1524	a similar cytokine stimulation profile	1487:1524	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	1	18	theme	animal	125:130	arg1	infection					139:147	human and animal fungal infection	115:147	human and animal fungal infection	115:147	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	4	19	theme	cell	1121:1124	arg1	surface					1126:1132	the cell surface	1117:1132	the cell surface	1117:1132	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	3	20	theme	cytokine	763:770	arg1	production					772:781	cytokine production	763:781	cytokine production	763:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	9	21	theme	human	2316:2320	arg1	PBMCs					2322:2326	human PBMCs	2316:2326	human PBMCs	2316:2326	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	6	22	theme	similar	1489:1495	arg1	profile					1518:1524	a similar cytokine stimulation profile	1487:1524	a similar cytokine stimulation profile	1487:1524	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	7	23	theme	S.	1634:1635	arg1	globosa					1637:1643	S. globosa	1634:1643	S. globosa were exposed at the surface or N- and O-glycans	1634:1691	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	6	24	theme	S.	1569:1570	arg1	globosa					1572:1578	S. globosa	1569:1578	S. globosa	1569:1578	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	5	25	theme	lower	1213:1217	arg1	levels					1219:1224	lower levels	1213:1224	lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans	1213:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	0	26	theme	Human	70:74	arg1	Cells					88:92	Human Mononuclear Cells	70:92	Human Mononuclear Cells	70:92	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells.
37108903	4	27	theme	S.	940:941	arg1	conidia					951:957	S. globosa conidia	940:957	S. globosa conidia	940:957	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	3	28	theme	peripheral	794:803	arg1	PBMCs					830:834	PBMCs	830:834	PBMCs	830:834	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	28	theme	peripheral	794:803	arg1	cells					823:827	human peripheral blood mononuclear cells	788:827	human peripheral blood mononuclear cells (PBMCs)	788:835	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	9	29	theme	species-specific	2343:2358	arg1	profiles					2369:2376	species-specific cytokine profiles	2343:2376	species-specific cytokine profiles	2343:2376	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	7	30	theme	cell	1610:1613	arg1	components					1620:1629	the inner cell wall components	1600:1629	the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans	1600:1691	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	9	31	from	structure	2200:2208	arg1	morphologies					2255:2266	the three morphologies	2245:2266	the three morphologies	2245:2266	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	3	32	theme	mononuclear	811:821	arg1	PBMCs					830:834	PBMCs	830:834	PBMCs	830:834	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	32	theme	mononuclear	811:821	arg1	cells					823:827	human peripheral blood mononuclear cells	788:827	human peripheral blood mononuclear cells (PBMCs)	788:835	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	2	33	theme	globosa	518:524	arg1	wall					531:534	S. globosa cell wall	515:534	S. globosa cell wall	515:534	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	5	34	theme	glycoconjugates	1257:1271	arg1	levels					1219:1224	lower levels	1213:1224	lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans	1213:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	6	35	theme	higher	1538:1543	arg1	stimulation					1545:1555	a higher stimulation	1536:1555	a higher stimulation of IL-10 by S. globosa	1536:1578	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	2	36	theme	Sporothrix	401:410	arg1	species					412:418	the Sporothrix species	397:418	the Sporothrix species	397:418	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	0	37	theme	Differential	0:11	arg1	Recognition					13:23	Differential Recognition	0:23	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells	0:92	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells.
37108903	4	38	theme	higher	987:992	arg1	content					1011:1017	a higher cell wall chitin content	985:1017	a higher cell wall chitin content	985:1017	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	1	39	dep	distributed	149:159	arg1	infection					139:147	human and animal fungal infection	115:147	human and animal fungal infection	115:147	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	1	40	theme	human	115:119	arg1	infection					139:147	human and animal fungal infection	115:147	human and animal fungal infection	115:147	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	7	41	from	profile	1731:1737	arg1	morphotypes					1768:1778	its three morphotypes	1758:1778	its three morphotypes	1758:1778	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	0	42	theme	Relevant	39:46	arg1	Species					59:65	Clinically Relevant Sporothrix Species	28:65	Clinically Relevant Sporothrix Species	28:65	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells.
37108903	1	43	theme	Sporothrix	319:328	arg1	globosa					330:336	Sporothrix globosa	319:336	Sporothrix globosa	319:336	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	4	44	contain	have	1049:1052	arg1	morphologies					1036:1047	all three morphologies	1026:1047	all three morphologies	1026:1047	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	4	44	contain	have	1049:1052	arg2	content					1076:1082	a higher β-1,3-glucan content	1054:1082	a higher β-1,3-glucan content	1054:1082	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	4	45	theme	yeast-like	963:972	arg1	cells					974:978	yeast-like cells	963:978	yeast-like cells	963:978	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	3	46	dep	morphologies	684:695	arg1	conidia					709:715	conidia	709:715	conidia	709:715	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	46	dep	morphologies	684:695	arg1	germlings					698:706	germlings	698:706	germlings	698:706	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	46	dep	morphologies	684:695	arg1	cells					733:737	yeast-like cells	722:737	yeast-like cells	722:737	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	47	from	differences	748:758	arg1	production					772:781	cytokine production	763:781	cytokine production	763:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	5	48	theme	O-linked	1295:1302	arg1	glycans					1304:1310	O-linked glycans	1295:1310	O-linked glycans	1295:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	9	49	theme	cell	2174:2177	arg1	composition					2184:2194	cell wall composition	2174:2194	cell wall composition	2174:2194	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	0	50	theme	Species	59:65	arg1	Recognition					13:23	Differential Recognition	0:23	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells	0:92	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells.
37108903	7	51	theme	production	1720:1729	arg1	profile					1731:1737	the cytokine production profile	1707:1737	the cytokine production profile of this species in its three morphotypes	1707:1778	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	5	52	link	O-linked	1295:1302	arg1	glycans					1304:1310	O-linked glycans	1295:1310	O-linked glycans	1295:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	2	53	theme	wall	348:351	arg1	composition					353:363	The cell wall composition	339:363	The cell wall composition	339:363	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	1	54	theme	pathogenic	235:244	arg1	clade					246:250	the Sporothrix pathogenic clade	220:250	the Sporothrix pathogenic clade	220:250	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	3	55	theme	wall	644:647	arg1	composition					649:659	the cell wall composition	635:659	the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production	635:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	4	56	theme	wall	999:1002	arg1	content					1011:1017	a higher cell wall chitin content	985:1017	a higher cell wall chitin content	985:1017	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	3	57	from	composition	649:659	arg1	differences					748:758	the differences	744:758	the differences in cytokine production	744:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	57	from	composition	649:659	arg1	morphologies					684:695	three morphologies	678:695	three morphologies (germlings, conidia, and yeast-like cells)	678:738	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	5	58	theme	N-	1288:1289	arg1	levels					1219:1224	lower levels	1213:1224	lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans	1213:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	2	59	theme	immune	373:378	arg1	response					380:387	the immune response	369:387	the immune response against the Sporothrix species	369:418	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	3	60	theme	globosa	667:673	arg1	composition					649:659	the cell wall composition	635:659	the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production	635:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	9	61	theme	Sporothrix	2223:2232	arg1	species					2234:2240	the three Sporothrix species	2213:2240	the three Sporothrix species	2213:2240	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	5	62	theme	species-specific	1355:1370	arg1	proportions					1372:1382	species-specific proportions	1355:1382	species-specific proportions	1355:1382	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	3	63	from	morphologies	684:695	arg1	production					772:781	cytokine production	763:781	cytokine production	763:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	8	64	located	found	1981:1985	arg1	addition					1964:1971	addition	1964:1971	addition	1964:1971	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	8	64	located	found	1981:1985	arg2	it					1974:1975	it	1974:1975	it	1974:1975	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	3	65	theme	yeast-like	722:731	arg1	cells					733:737	yeast-like cells	722:737	yeast-like cells	722:737	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	5	66	theme	fungal	1334:1339	arg1	wall					1346:1349	this fungal cell wall	1329:1349	this fungal cell wall	1329:1349	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	7	67	theme	different	1884:1892	arg1	profiles					1903:1910	different cytokine profiles	1884:1910	different cytokine profiles	1884:1910	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	2	68	theme	immune	544:549	arg1	response					551:558	the immune response	540:558	the immune response	540:558	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	4	69	theme	higher	1056:1061	arg1	content					1076:1082	a higher β-1,3-glucan content	1054:1082	a higher β-1,3-glucan content	1054:1082	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	8	70	theme	receptor	2101:2108	arg1	activation					2069:2078	the activation	2065:2078	the activation of dectin-1, mannose receptor, and TLR2, but not TLR4	2065:2132	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	5	71	theme	S.	1198:1199	arg1	globosa					1201:1207	S. globosa	1198:1207	S. globosa	1198:1207	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	6	72	theme	cytokine	1497:1504	arg1	profile					1518:1524	a similar cytokine stimulation profile	1487:1524	a similar cytokine stimulation profile	1487:1524	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	1	73	theme	fungal	132:137	arg1	infection					139:147	human and animal fungal infection	115:147	human and animal fungal infection	115:147	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	0	74	theme	Mononuclear	76:86	arg1	Cells					88:92	Human Mononuclear Cells	70:92	Human Mononuclear Cells	70:92	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells.
37108903	1	75	theme	distributed	149:159	arg1	worldwide					161:169	a human and animal fungal infection distributed worldwide	113:169	a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa	113:336	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	1	75	theme	distributed	149:159	arg1	Sporotrichosis					95:108	Sporotrichosis	95:108	Sporotrichosis	95:108	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	7	76	theme	globosa	1637:1643	arg1	components					1620:1629	the inner cell wall components	1600:1629	the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans	1600:1691	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	9	77	with	interaction	2299:2309	arg1	PBMCs					2322:2326	human PBMCs	2316:2326	human PBMCs	2316:2326	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	5	78	theme	components	1408:1417	arg1	organization					1388:1399	organization	1388:1399	organization of its components	1388:1417	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	5	78	theme	components	1408:1417	arg1	proportions					1372:1382	species-specific proportions	1355:1382	species-specific proportions	1355:1382	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	3	79	theme	blood	805:809	arg1	PBMCs					830:834	PBMCs	830:834	PBMCs	830:834	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	79	theme	blood	805:809	arg1	cells					823:827	human peripheral blood mononuclear cells	788:827	human peripheral blood mononuclear cells (PBMCs)	788:835	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	9	80	theme	cytokine	2360:2367	arg1	profiles					2369:2376	species-specific cytokine profiles	2343:2376	species-specific cytokine profiles	2343:2376	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	6	81	theme	IL-10	1560:1564	arg1	stimulation					1545:1555	a higher stimulation	1536:1555	a higher stimulation of IL-10 by S. globosa	1536:1578	When interacting with PBMCs, S. brasiliensis and S. globosa showed a similar cytokine stimulation profile, but with a higher stimulation of IL-10 by S. globosa.
37108903	7	82	theme	wall	1615:1618	arg1	components					1620:1629	the inner cell wall components	1600:1629	the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans	1600:1691	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	2	83	theme	cell	526:529	arg1	wall					531:534	S. globosa cell wall	515:534	S. globosa cell wall	515:534	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	5	84	theme	rhamnose-based	1242:1255	arg1	glycoconjugates					1257:1271	mannose- and rhamnose-based glycoconjugates	1229:1271	mannose- and rhamnose-based glycoconjugates	1229:1271	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	3	85	theme	human	788:792	arg1	PBMCs					830:834	PBMCs	830:834	PBMCs	830:834	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	3	85	theme	human	788:792	arg1	cells					823:827	human peripheral blood mononuclear cells	788:827	human peripheral blood mononuclear cells (PBMCs)	788:835	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	7	86	theme	inner	1604:1608	arg1	components					1620:1629	the inner cell wall components	1600:1629	the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans	1600:1691	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	2	87	theme	S.	515:516	arg1	wall					531:534	S. globosa cell wall	515:534	S. globosa cell wall	515:534	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	5	88	contain	has	1351:1353	arg1	wall					1346:1349	this fungal cell wall	1329:1349	this fungal cell wall	1329:1349	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	5	88	contain	has	1351:1353	arg2	organization					1388:1399	organization	1388:1399	organization of its components	1388:1417	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	5	88	contain	has	1351:1353	arg2	proportions					1372:1382	species-specific proportions	1355:1382	species-specific proportions	1355:1382	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	5	89	theme	mannose-	1229:1236	arg1	glycoconjugates					1257:1271	mannose- and rhamnose-based glycoconjugates	1229:1271	mannose- and rhamnose-based glycoconjugates	1229:1271	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	0	90	theme	Sporothrix	48:57	arg1	Species					59:65	Clinically Relevant Sporothrix Species	28:65	Clinically Relevant Sporothrix Species	28:65	Differential Recognition of Clinically Relevant Sporothrix Species by Human Mononuclear Cells.
37108903	2	91	dep	wall	531:534	arg1	the					511:513	the	511:513	the	511:513	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	4	92	theme	globosa	943:949	arg1	conidia					951:957	S. globosa conidia	940:957	S. globosa conidia	940:957	We found that S. globosa conidia and yeast-like cells have a higher cell wall chitin content, while all three morphologies have a higher β-1,3-glucan content, which was found most exposed at the cell surface when compared to S. schenckii and S. brasiliensis.
37108903	8	93	theme	anti-inflammatory	1996:2012	arg1	response					2014:2021	the anti-inflammatory response	1992:2021	the anti-inflammatory response stimulated by S. globosa	1992:2046	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	8	93	theme	anti-inflammatory	1996:2012	arg1	dependent					2052:2060	dependent	2052:2060	dependent	2052:2060	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
37108903	5	94	theme	glycans	1304:1310	arg1	levels					1219:1224	lower levels	1213:1224	lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans	1213:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	9	95	theme	wall	2179:2182	arg1	composition					2184:2194	cell wall composition	2174:2194	cell wall composition	2174:2194	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	7	96	theme	species	1747:1753	arg1	profile					1731:1737	the cytokine production profile	1707:1737	the cytokine production profile of this species in its three morphotypes	1707:1778	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	9	97	from	composition	2184:2194	arg1	morphologies					2255:2266	the three morphologies	2245:2266	the three morphologies	2245:2266	All of these results indicate that the cell wall composition and structure of the three Sporothrix species in the three morphologies are different, affecting their interaction with human PBMCs and generating species-specific cytokine profiles.
37108903	5	98	contain	has	1209:1211	arg1	globosa					1201:1207	S. globosa	1198:1207	S. globosa	1198:1207	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	5	98	contain	has	1209:1211	arg2	levels					1219:1224	lower levels	1213:1224	lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans	1213:1310	In addition, S. globosa has lower levels of mannose- and rhamnose-based glycoconjugates, as well as of N- and O-linked glycans, indicating that this fungal cell wall has species-specific proportions and organization of its components.
37108903	3	99	theme	cell	639:642	arg1	composition					649:659	the cell wall composition	635:659	the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production	635:781	Therefore, in this study, we aimed to analyze the cell wall composition of S. globosa in three morphologies (germlings, conidia, and yeast-like cells) and the differences in cytokine production when human peripheral blood mononuclear cells (PBMCs) interact with these morphotypes, using S. schenckii and S. brasiliensis as a comparison.
37108903	2	100	theme	cell	343:346	arg1	composition					353:363	The cell wall composition	339:363	The cell wall composition	339:363	The cell wall composition and the immune response against the Sporothrix species have been studied mainly in S. brasiliensis and S. schenckii, whilst little is known about the S. globosa cell wall and the immune response that its components trigger.
37108903	1	101	theme	clade	246:250	arg1	species					209:215	the thermodimorphic species	189:215	the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa	189:336	Sporotrichosis is a human and animal fungal infection distributed worldwide that is caused by the thermodimorphic species of the Sporothrix pathogenic clade, which includes Sporothrix brasiliensis, Sporothrix schenckii, and Sporothrix globosa.
37108903	7	102	theme	cytokine	1711:1718	arg1	profile					1731:1737	the cytokine production profile	1707:1737	the cytokine production profile of this species in its three morphotypes	1707:1778	Additionally, when the inner cell wall components of S. globosa were exposed at the surface or N- and O-glycans were removed, the cytokine production profile of this species in its three morphotypes did not significantly change, contrasting with the S. schenckii and S. brasiliensis species that showed different cytokine profiles depending on the treatment applied to the walls.
37108903	8	103	theme	S.	2037:2038	arg1	globosa					2040:2046	S. globosa	2037:2046	S. globosa	2037:2046	In addition, it was found that the anti-inflammatory response stimulated by S. globosa was dependent on the activation of dectin-1, mannose receptor, and TLR2, but not TLR4.
35802832	2	0	theme	regulatory	524:533	arg1	mechanisms					535:544	regulatory mechanisms	524:544	regulatory mechanisms	524:544	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	5	1	theme	disialylated	986:997	arg1	O-glycans					999:1007	disialylated O-glycans	986:1007	disialylated O-glycans	986:1007	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	1	2	theme	O-glycan	182:189	arg1	modifications					191:203	various O-glycan modifications	174:203	various O-glycan modifications	174:203	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	0	3	theme	O-Glycans	96:104	arg1	Analysis					30:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	0	3	theme	O-Glycans	96:104	arg1	Effects					60:66	Immunomodulatory Effects	43:66	Immunomodulatory Effects	43:66	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	4	4	from	O-glycans	796:804	arg1	milk					816:819	bovine milk	809:819	bovine milk	809:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	2	5	theme	casein	364:369	arg1	glycomacropeptide					371:387	casein glycomacropeptide	364:387	casein glycomacropeptide	364:387	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	6	6	theme	milk	1038:1041	arg1	sources					1043:1049	both milk sources	1033:1049	both milk sources	1033:1049	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	1	7	theme	glycopeptide	275:286	arg1	composition					256:266	the amino acid composition	241:266	the amino acid composition of the glycopeptide	241:286	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	6	8	from	sources	1043:1049	arg1	Glycomacropeptide					1010:1026	Glycomacropeptide	1010:1026	Glycomacropeptide from both milk sources	1010:1049	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	6	9	from	expression	1086:1095	arg1	cells					1136:1140	RAW264.7 cells	1127:1140	RAW264.7 cells	1127:1140	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	4	10	theme	total	772:776	arg1	O-glycans					796:804	total glycomacropeptide O-glycans	772:804	total glycomacropeptide O-glycans in bovine milk	772:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	7	11	theme	possible	1229:1236	arg1	use					1238:1240	the possible use	1225:1240	the possible use of casein glycomacropeptide as an immunomodulatory agent	1225:1297	This study demonstrates the possible use of casein glycomacropeptide as an immunomodulatory agent.
35802832	5	12	theme	higher	968:973	arg1	content					975:981	a higher content	966:981	a higher content of disialylated O-glycans	966:1007	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	2	13	theme	glycomacropeptide	371:387	arg1	O-glycans					351:359	O-glycans	351:359	O-glycans of casein glycomacropeptide from bovine and caprine whey powder	351:423	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	0	14	theme	Whey	128:131	arg1	Powder					133:138	Caprine Whey Powder	120:138	Caprine Whey Powder	120:138	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	0	15	from	Effects	60:66	arg1	Powder					133:138	Caprine Whey Powder	120:138	Caprine Whey Powder	120:138	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	0	15	from	Effects	60:66	arg1	Bovine					109:114	Bovine	109:114	Bovine	109:114	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	4	16	theme	caprine	842:848	arg1	milk					850:853	caprine milk	842:853	caprine milk	842:853	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	3	17	theme	total	572:576	arg1	content					578:584	O-Glycans' total content	561:584	O-Glycans' total content	561:584	O-Glycans' total content was 1.54 times higher in bovine than in caprine glycomacropeptide.
35802832	5	18	theme	Bovine	856:861	arg1	glycosylation					881:893	Bovine glycomacropeptide glycosylation	856:893	Bovine glycomacropeptide glycosylation	856:893	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	0	19	theme	Caprine	120:126	arg1	Powder					133:138	Caprine Whey Powder	120:138	Caprine Whey Powder	120:138	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	6	20	theme	RAW264.7	1127:1134	arg1	cells					1136:1140	RAW264.7 cells	1127:1140	RAW264.7 cells	1127:1140	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	1	21	gly	glycopeptide	275:286	arg2	glycopeptide					275:286	the glycopeptide	271:286	the glycopeptide	271:286	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	4	22	theme	glycomacropeptide	778:794	arg1	O-glycans					796:804	total glycomacropeptide O-glycans	772:804	total glycomacropeptide O-glycans in bovine milk	772:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	2	23	theme	whey	413:416	arg1	powder					418:423	caprine whey powder	405:423	caprine whey powder	405:423	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	0	24	theme	Mass	12:15	arg1	Analysis					30:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	1	25	contain	carries	166:172	arg2	modifications					191:203	various O-glycan modifications	174:203	various O-glycan modifications	174:203	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	1	25	contain	carries	166:172	arg1	glycomacropeptide					148:164	Casein glycomacropeptide	141:164	Casein glycomacropeptide	141:164	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	7	26	theme	casein	1245:1250	arg1	glycomacropeptide					1252:1268	casein glycomacropeptide	1245:1268	casein glycomacropeptide	1245:1268	This study demonstrates the possible use of casein glycomacropeptide as an immunomodulatory agent.
35802832	6	27	theme	immunomodulatory	1165:1180	arg1	pathway					1192:1198	the MAPK immunomodulatory signaling pathway	1156:1198	the MAPK immunomodulatory signaling pathway	1156:1198	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	2	28	theme	caprine	405:411	arg1	powder					418:423	caprine whey powder	405:423	caprine whey powder	405:423	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	0	29	theme	Comparative	0:10	arg1	Analysis					30:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	2	30	from	bovine	394:399	arg1	O-glycans					351:359	O-glycans	351:359	O-glycans of casein glycomacropeptide from bovine and caprine whey powder	351:423	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	6	31	theme	MAPK	1160:1163	arg1	pathway					1192:1198	the MAPK immunomodulatory signaling pathway	1156:1198	the MAPK immunomodulatory signaling pathway	1156:1198	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	6	32	theme	IL-1α	1100:1104	arg1	expression					1086:1095	the mRNA expression	1077:1095	the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells	1077:1140	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	6	33	theme	mRNA	1081:1084	arg1	expression					1086:1095	the mRNA expression	1077:1095	the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells	1077:1140	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	0	34	theme	Spectrometry	17:28	arg1	Analysis					30:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis	0:37	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	1	35	theme	different	303:311	arg1	activities					324:333	different biological activities	303:333	different biological activities	303:333	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	4	36	theme	O-glycans	796:804	arg1	%					767:767	nearly 50%	758:767	nearly 50% of total glycomacropeptide O-glycans in bovine milk	758:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	36	theme	O-glycans	796:804	arg1	O-glycans					796:804	total glycomacropeptide O-glycans	772:804	total glycomacropeptide O-glycans in bovine milk	772:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	6	37	theme	TNF-α	1107:1111	arg1	expression					1086:1095	the mRNA expression	1077:1095	the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells	1077:1140	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	7	38	theme	immunomodulatory	1276:1291	arg1	agent					1293:1297	an immunomodulatory agent	1273:1297	an immunomodulatory agent	1273:1297	This study demonstrates the possible use of casein glycomacropeptide as an immunomodulatory agent.
35802832	0	39	theme	Immunomodulatory	43:58	arg1	Effects					60:66	Immunomodulatory Effects	43:66	Immunomodulatory Effects	43:66	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	1	40	theme	biological	313:322	arg1	activities					324:333	different biological activities	303:333	different biological activities	303:333	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	3	41	theme	caprine	626:632	arg1	glycomacropeptide					634:650	caprine glycomacropeptide	626:650	caprine glycomacropeptide	626:650	O-Glycans' total content was 1.54 times higher in bovine than in caprine glycomacropeptide.
35802832	2	42	theme	immune	502:507	arg1	activities					509:518	their immune activities	496:518	their immune activities	496:518	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	5	43	gly	disialylated	986:997	arg1	O-glycans					999:1007	disialylated O-glycans	986:1007	disialylated O-glycans	986:1007	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	5	44	theme	cells	936:940	arg1	activity					915:922	the immune activity	904:922	the immune activity	904:922	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	4	45	from	%	837:837	arg1	milk					850:853	caprine milk	842:853	caprine milk	842:853	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	7	46	theme	glycomacropeptide	1252:1268	arg1	use					1238:1240	the possible use	1225:1240	the possible use of casein glycomacropeptide as an immunomodulatory agent	1225:1297	This study demonstrates the possible use of casein glycomacropeptide as an immunomodulatory agent.
35802832	4	47	dep	H	675:675	arg1	acid					738:741	N-acetylneuraminic acid	719:741	N-acetylneuraminic acid	719:741	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	5	48	theme	RAW264.7	927:934	arg1	cells					936:940	RAW264.7 cells	927:940	RAW264.7 cells	927:940	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	2	49	from	powder	418:423	arg1	O-glycans					351:359	O-glycans	351:359	O-glycans of casein glycomacropeptide from bovine and caprine whey powder	351:423	In this study, O-glycans of casein glycomacropeptide from bovine and caprine whey powder were qualitatively and quantitatively analyzed by LC-UV-ESI-MS/MS, and their immune activities and regulatory mechanisms were compared.
35802832	4	50	theme	N-acetylneuraminic	719:736	arg1	acid					738:741	N-acetylneuraminic acid	719:741	N-acetylneuraminic acid	719:741	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	5	51	attach	linked	956:961	arg1	content					975:981	a higher content	966:981	a higher content of disialylated O-glycans	966:1007	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	5	51	attach	linked	956:961	arg2	activity					915:922	the immune activity	904:922	the immune activity	904:922	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	4	52	from	%	767:767	arg1	milk					816:819	bovine milk	809:819	bovine milk	809:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	53	theme	bovine	809:814	arg1	milk					816:819	bovine milk	809:819	bovine milk	809:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	1	54	from	variations	227:236	arg1	composition					256:266	the amino acid composition	241:266	the amino acid composition of the glycopeptide	241:286	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	1	55	theme	Casein	141:146	arg1	glycomacropeptide					148:164	Casein glycomacropeptide	141:164	Casein glycomacropeptide	141:164	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	1	56	theme	amino	245:249	arg1	composition					256:266	the amino acid composition	241:266	the amino acid composition of the glycopeptide	241:286	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	6	57	theme	signaling	1182:1190	arg1	pathway					1192:1198	the MAPK immunomodulatory signaling pathway	1156:1198	the MAPK immunomodulatory signaling pathway	1156:1198	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	5	58	theme	O-glycans	999:1007	arg1	content					975:981	a higher content	966:981	a higher content of disialylated O-glycans	966:1007	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	5	59	theme	immune	908:913	arg1	activity					915:922	the immune activity	904:922	the immune activity	904:922	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	1	60	theme	acid	251:254	arg1	composition					256:266	the amino acid composition	241:266	the amino acid composition of the glycopeptide	241:286	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	0	61	theme	Glycomacropeptide	78:94	arg1	O-Glycans					96:104	Casein Glycomacropeptide O-Glycans	71:104	Casein Glycomacropeptide O-Glycans	71:104	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	4	62	from	milk	816:819	arg1	%					767:767	nearly 50%	758:767	nearly 50% of total glycomacropeptide O-glycans in bovine milk	758:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	62	from	milk	816:819	arg1	O-glycans					796:804	total glycomacropeptide O-glycans	772:804	total glycomacropeptide O-glycans in bovine milk	772:819	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	6	63	theme	IL-10	1118:1122	arg1	expression					1086:1095	the mRNA expression	1077:1095	the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells	1077:1140	Glycomacropeptide from both milk sources significantly upregulated the mRNA expression of IL-1α, TNF-α, and IL-10 in RAW264.7 cells and activated the MAPK immunomodulatory signaling pathway.
35802832	5	64	theme	glycomacropeptide	863:879	arg1	glycosylation					881:893	Bovine glycomacropeptide glycosylation	856:893	Bovine glycomacropeptide glycosylation	856:893	Bovine glycomacropeptide glycosylation promoted the immune activity of RAW264.7 cells, which may be linked to a higher content of disialylated O-glycans.
35802832	0	65	theme	Casein	71:76	arg1	O-Glycans					96:104	Casein Glycomacropeptide O-Glycans	71:104	Casein Glycomacropeptide O-Glycans	71:104	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	0	66	from	Analysis	30:37	arg1	Powder					133:138	Caprine Whey Powder	120:138	Caprine Whey Powder	120:138	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	0	66	from	Analysis	30:37	arg1	Bovine					109:114	Bovine	109:114	Bovine	109:114	Comparative Mass Spectrometry Analysis and Immunomodulatory Effects of Casein Glycomacropeptide O-Glycans in Bovine and Caprine Whey Powder.
35802832	1	67	theme	various	174:180	arg1	modifications					191:203	various O-glycan modifications	174:203	various O-glycan modifications	174:203	Casein glycomacropeptide carries various O-glycan modifications, which, together with variations in the amino acid composition of the glycopeptide, may result in different biological activities.
35802832	4	68	theme	glycoform	657:665	arg1	H					675:675	H	675:675	H	675:675	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	68	theme	glycoform	657:665	arg1	hexose					678:683	hexose	678:683	hexose	678:683	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	68	theme	glycoform	657:665	arg1	S					716:716	S	716:716	S	716:716	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	68	theme	glycoform	657:665	arg1	H1N1S2					667:672	The glycoform H1N1S2	653:672	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid)	653:742	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	68	theme	glycoform	657:665	arg1	N					686:686	N	686:686	N	686:686	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35802832	4	68	theme	glycoform	657:665	arg1	N-acetylgalactosamine					689:709	N-acetylgalactosamine	689:709	N-acetylgalactosamine	689:709	The glycoform H1N1S2 (H: hexose; N: N-acetylgalactosamine; and S: N-acetylneuraminic acid) accounted for nearly 50% of total glycomacropeptide O-glycans in bovine milk but less than 20% in caprine milk.
35477030	0	0	theme	related	189:195	arg1	pentasaccharide					173:187	the pentasaccharide	169:187	the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	169:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	1	theme	glycoside	305:313	arg1	form					287:290	the form	283:290	the form of its allyl glycoside	283:313	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	2	attach	isolated	212:219	arg1	tataricus					252:260	the medicinal plant Aster tataricus	226:260	the medicinal plant Aster tataricus L. f.	226:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	2	attach	isolated	212:219	arg2	saponin					204:210	the saponin	200:210	the saponin isolated from the medicinal plant Aster tataricus L. f.	200:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	3	dep	tataricus	252:260	arg1	f.					265:266	f.	265:266	f.	265:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	4	theme	type	84:87	arg1	saponins					89:96	the anti-inflammatory oleanane type saponins	53:96	the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	53:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	5	theme	pentasaccharide	173:187	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	6	theme	plant	240:244	arg1	tataricus					252:260	the medicinal plant Aster tataricus	226:260	the medicinal plant Aster tataricus L. f.	226:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	7	theme	medicinal	230:238	arg1	tataricus					252:260	the medicinal plant Aster tataricus	226:260	the medicinal plant Aster tataricus L. f.	226:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	3	8	theme	possible	872:879	arg1	formation					896:904	possible glycoconjugate formation	872:904	possible glycoconjugate formation	872:904	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	0	9	attach	isolated	98:105	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	9	attach	isolated	98:105	arg2	saponins					89:96	the anti-inflammatory oleanane type saponins	53:96	the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	53:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	3	10	theme	allyl	777:781	arg1	glycoside					783:791	its allyl glycoside	773:791	its allyl glycoside	773:791	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	1	11	theme	disaccharide	435:446	arg1	donor					448:452	the disaccharide donor	431:452	the disaccharide donor	431:452	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	3	12	theme	glycoconjugate	881:894	arg1	formation					896:904	possible glycoconjugate formation	872:904	possible glycoconjugate formation	872:904	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	0	13	theme	plant	122:126	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	3	14	theme	glycoside	783:791	arg1	form					765:768	the form	761:768	the form of its allyl glycoside	761:791	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	0	15	theme	Aster	246:250	arg1	tataricus					252:260	the medicinal plant Aster tataricus	226:260	the medicinal plant Aster tataricus L. f.	226:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	16	theme	medicinal	112:120	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	3	17	theme	formation	896:904	arg1	evaluation					835:844	further biological evaluation	816:844	further biological evaluation of the said structure and possible glycoconjugate formation as per need	816:916	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	1	18	theme	[3 + 2	361:366	arg1	strategy					385:392	a [3 + 2] block synthesis strategy	359:392	a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate	359:639	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	2	19	with	procedure	695:703	arg1	modification					717:728	little modification	710:728	little modification	710:728	The apiose moiety has been synthesized by literature procedure with little modification.
35477030	0	20	theme	Chemical	0:7	arg1	synthesis					9:17	Chemical synthesis	0:17	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	0:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	3	21	from	pentasaccharide	742:756	arg1	form					765:768	the form	761:768	the form of its allyl glycoside	761:791	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	1	22	theme	thioglycoside	594:606	arg1	trichloroacetimidate					620:639	the thioglycoside or glycosyl trichloroacetimidate	590:639	trichloroacetimidate	620:639	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	2	23	theme	apiose	646:651	arg1	moiety					653:658	The apiose moiety	642:658	The apiose moiety	642:658	The apiose moiety has been synthesized by literature procedure with little modification.
35477030	0	24	theme	tataricus	134:142	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	2	25	theme	literature	684:693	arg1	procedure					695:703	literature procedure	684:703	literature procedure with little modification	684:728	The apiose moiety has been synthesized by literature procedure with little modification.
35477030	2	26	theme	little	710:715	arg1	modification					717:728	little modification	710:728	little modification	710:728	The apiose moiety has been synthesized by literature procedure with little modification.
35477030	0	27	theme	Aster	128:132	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	1	28	theme	glycosyl	611:618	arg1	trichloroacetimidate					620:639	the thioglycoside or glycosyl trichloroacetimidate	590:639	trichloroacetimidate	620:639	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	1	29	dep	glycosylations	551:564	arg1	either					566:571	either	566:571	either	566:571	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	0	30	theme	related	42:48	arg1	pentasaccharide					26:40	the pentasaccharide	22:40	the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	22:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	31	theme	f.	147:148	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	1	32	theme	block	369:373	arg1	strategy					385:392	a [3 + 2] block synthesis strategy	359:392	a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate	359:639	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	1	33	theme	trichloroacetimidate	620:639	arg1	activation					576:585	activation	576:585	activation of the thioglycoside or glycosyl trichloroacetimidate	576:639	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	0	34	theme	pentasaccharide	26:40	arg1	synthesis					9:17	Chemical synthesis	0:17	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	0:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	1	35	theme	synthesis	375:383	arg1	strategy					385:392	a [3 + 2] block synthesis strategy	359:392	a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate	359:639	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	3	36	theme	further	816:822	arg1	evaluation					835:844	further biological evaluation	816:844	further biological evaluation of the said structure and possible glycoconjugate formation as per need	816:916	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	0	37	theme	Total	150:154	arg1	synthesis					156:164	medicinal plant Aster tataricus L. f. Total synthesis	112:164	medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	112:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	1	38	theme	semi-protected	496:509	arg1	monosaccharides					511:525	semi-protected monosaccharides	496:525	semi-protected monosaccharides	496:525	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	3	39	dep	structure	858:866	arg1	the					849:851	the	849:851	the	849:851	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	3	40	theme	biological	824:833	arg1	evaluation					835:844	further biological evaluation	816:844	further biological evaluation of the said structure and possible glycoconjugate formation as per need	816:916	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	3	41	theme	target	735:740	arg1	beneficial					801:810	beneficial	801:810	beneficial	801:810	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	3	41	theme	target	735:740	arg1	pentasaccharide					742:756	The target pentasaccharide	731:756	The target pentasaccharide in the form of its allyl glycoside	731:791	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	3	42	theme	structure	858:866	arg1	evaluation					835:844	further biological evaluation	816:844	further biological evaluation of the said structure and possible glycoconjugate formation as per need	816:916	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
35477030	1	43	theme	trisaccharide	404:416	arg1	acceptor					418:425	the trisaccharide acceptor	400:425	the trisaccharide acceptor	400:425	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	0	44	theme	allyl	299:303	arg1	glycoside					305:313	its allyl glycoside	295:313	its allyl glycoside	295:313	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	0	45	theme	oleanane	75:82	arg1	saponins					89:96	the anti-inflammatory oleanane type saponins	53:96	the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	53:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	1	46	theme	stereoselective	535:549	arg1	glycosylations					551:564	stereoselective glycosylations	535:564	stereoselective glycosylations	535:564	The synthesis is accomplished by following a [3 + 2] block synthesis strategy where the trisaccharide acceptor and the disaccharide donor are rationally designed and obtained from semi-protected monosaccharides through stereoselective glycosylations either by activation of the thioglycoside or glycosyl trichloroacetimidate.
35477030	0	47	theme	anti-inflammatory	57:73	arg1	saponins					89:96	the anti-inflammatory oleanane type saponins	53:96	the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f.	53:266	Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f. Total synthesis of the pentasaccharide related to the saponin isolated from the medicinal plant Aster tataricus L. f. is reported in the form of its allyl glycoside.
35477030	3	48	theme	said	853:856	arg1	structure					858:866	said structure	853:866	said structure	853:866	The target pentasaccharide in the form of its allyl glycoside will be beneficial for further biological evaluation of the said structure and possible glycoconjugate formation as per need.
36409896	1	0	gly	glycosylation	72:84	arg1	disease					171:177	disease	171:177	disease	171:177	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	1	0	gly	glycosylation	72:84	arg1	health					160:165	health	160:165	health	160:165	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	3	1	gly	glycoproteins	550:562	arg1	glycoproteins					550:562	off-target glycoproteins	539:562	off-target glycoproteins	539:562	Here, we describe a method to identify and characterize a class of nanobodies that can distinguish glycoforms without reactivity to off-target glycoproteins or glycans.
36409896	5	2	theme	IgG	920:922	arg1	profile					931:937	their IgG glycan profile	914:937	their IgG glycan profile	914:937	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	5	3	theme	glycan	924:929	arg1	profile					931:937	their IgG glycan profile	914:937	their IgG glycan profile	914:937	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	0	4	gly	glycoforms	52:61	arg1	IgG					45:47	IgG Fc glycoforms	45:61	IgG Fc glycoforms	45:61	Synthetic nanobodies as tools to distinguish IgG Fc glycoforms.
36409896	0	4	gly	glycoforms	52:61	arg1	Fc					49:50	IgG Fc glycoforms	45:61	IgG Fc glycoforms	45:61	Synthetic nanobodies as tools to distinguish IgG Fc glycoforms.
36409896	4	5	theme	G	619:619	arg1	glycoforms					630:639	immunoglobulin G (IgG) Fc glycoforms	604:639	immunoglobulin G (IgG) Fc glycoforms	604:639	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	5	6	theme	receptor	968:975	arg1	binding					977:983	IgG-Fcγ receptor binding	960:983	IgG-Fcγ receptor binding	960:983	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	4	7	theme	terminal	741:748	arg1	residues					762:769	terminal sialic acid residues	741:769	terminal sialic acid residues	741:769	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	4	8	theme	immunoglobulin	604:617	arg1	IgG					622:624	IgG	622:624	IgG	622:624	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	4	8	theme	immunoglobulin	604:617	arg1	G					619:619	immunoglobulin G	604:619	immunoglobulin G (IgG) Fc glycoforms	604:639	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	5	9	from	structure	1061:1069	arg1	cells					1081:1085	living cells	1074:1085	living cells	1074:1085	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	4	10	gly	glycoforms	630:639	arg1	IgG					622:624	IgG	622:624	IgG	622:624	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	4	10	gly	glycoforms	630:639	arg1	G					619:619	immunoglobulin G	604:619	immunoglobulin G (IgG) Fc glycoforms	604:639	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	4	10	gly	glycoforms	630:639	arg1	Fc					627:628	immunoglobulin G (IgG) Fc glycoforms	604:639	immunoglobulin G (IgG) Fc glycoforms	604:639	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	1	11	theme	Protein	64:70	arg1	glycosylation					72:84	Protein glycosylation	64:84	Protein glycosylation	64:84	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	1	11	theme	Protein	64:70	arg1	mediator					99:106	a crucial mediator	89:106	a crucial mediator of biological functions	89:130	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	5	12	theme	SARS-CoV-2	873:882	arg1	individuals					893:903	SARS-CoV-2 infected individuals	873:903	SARS-CoV-2 infected individuals	873:903	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	0	13	theme	IgG	45:47	arg1	glycoforms					52:61	IgG Fc glycoforms	45:61	IgG Fc glycoforms	45:61	Synthetic nanobodies as tools to distinguish IgG Fc glycoforms.
36409896	5	14	theme	IgG-Fcγ	960:966	arg1	binding					977:983	IgG-Fcγ receptor binding	960:983	IgG-Fcγ receptor binding	960:983	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	5	15	theme	infected	884:891	arg1	individuals					893:903	SARS-CoV-2 infected individuals	873:903	SARS-CoV-2 infected individuals	873:903	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	6	16	theme	reagents	1145:1152	arg1	development					1130:1140	the development	1126:1140	the development of reagents	1126:1152	Ultimately, we provide a strategy for the development of reagents to identify and manipulate IgG Fc glycoforms.
36409896	4	17	theme	acid	757:760	arg1	residues					762:769	terminal sialic acid residues	741:769	terminal sialic acid residues	741:769	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	2	18	theme	protein	398:404	arg1	isolation					374:382	isolation	374:382	isolation	374:382	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	2	18	theme	protein	398:404	arg1	purification					357:368	biochemical purification	345:368	biochemical purification	345:368	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	0	19	theme	Synthetic	0:8	arg1	nanobodies					10:19	Synthetic nanobodies	0:19	Synthetic nanobodies as tools	0:28	Synthetic nanobodies as tools to distinguish IgG Fc glycoforms.
36409896	2	20	theme	mass	308:311	arg1	spectrometry					313:324	mass spectrometry	308:324	mass spectrometry	308:324	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	2	21	theme	target	391:396	arg1	protein					398:404	the target protein	387:404	the target protein	387:404	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	5	22	theme	receptor	1039:1046	arg1	structure					1061:1069	the B cell receptor (BCR) glycan structure	1028:1069	the B cell receptor (BCR) glycan structure on living cells	1028:1085	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	1	23	theme	crucial	91:97	arg1	glycosylation					72:84	Protein glycosylation	64:84	Protein glycosylation	64:84	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	1	23	theme	crucial	91:97	arg1	mediator					99:106	a crucial mediator	89:106	a crucial mediator of biological functions	89:130	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	4	24	theme	sialic	750:755	arg1	residues					762:769	terminal sialic acid residues	741:769	terminal sialic acid residues	741:769	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	3	25	theme	off-target	539:548	arg1	glycoproteins					550:562	off-target glycoproteins	539:562	off-target glycoproteins	539:562	Here, we describe a method to identify and characterize a class of nanobodies that can distinguish glycoforms without reactivity to off-target glycoproteins or glycans.
36409896	5	26	theme	dengue	856:861	arg1	virus					863:867	dengue virus	856:867	dengue virus	856:867	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	2	27	theme	biochemical	345:355	arg1	purification					357:368	biochemical purification	345:368	biochemical purification	345:368	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	5	28	theme	standard	799:806	arg1	methods					820:826	standard biochemical methods	799:826	standard biochemical methods	799:826	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	5	29	theme	living	1074:1079	arg1	cells					1081:1085	living cells	1074:1085	living cells	1074:1085	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	5	30	theme	B	1032:1032	arg1	BCR					1049:1051	BCR	1049:1051	BCR	1049:1051	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	5	30	theme	B	1032:1032	arg1	receptor					1039:1046	B cell receptor	1032:1046	the B cell receptor (BCR) glycan structure on living cells	1028:1085	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	0	31	theme	Fc	49:50	arg1	glycoforms					52:61	IgG Fc glycoforms	45:61	IgG Fc glycoforms	45:61	Synthetic nanobodies as tools to distinguish IgG Fc glycoforms.
36409896	5	32	theme	cell	1034:1037	arg1	BCR					1049:1051	BCR	1049:1051	BCR	1049:1051	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	5	32	theme	cell	1034:1037	arg1	receptor					1039:1046	B cell receptor	1032:1046	the B cell receptor (BCR) glycan structure on living cells	1028:1085	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	2	33	gly	glycoforms	219:228	arg1	protein					211:217	complex protein glycoforms	203:228	complex protein glycoforms	203:228	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	2	34	theme	complex	203:209	arg1	glycoforms					219:228	complex protein glycoforms	203:228	complex protein glycoforms	203:228	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	2	35	theme	protein	211:217	arg1	glycoforms					219:228	complex protein glycoforms	203:228	complex protein glycoforms	203:228	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	1	36	theme	biological	111:120	arg1	functions					122:130	biological functions	111:130	biological functions	111:130	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	2	37	theme	lectin	257:262	arg1	tools					264:268	current lectin tools	249:268	current lectin tools	249:268	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	1	38	theme	functions	122:130	arg1	glycosylation					72:84	Protein glycosylation	64:84	Protein glycosylation	64:84	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	1	38	theme	functions	122:130	arg1	mediator					99:106	a crucial mediator	89:106	a crucial mediator of biological functions	89:130	Protein glycosylation is a crucial mediator of biological functions and is tightly regulated in health and disease.
36409896	2	39	theme	current	249:255	arg1	tools					264:268	current lectin tools	249:268	current lectin tools	249:268	However, interrogating complex protein glycoforms is challenging, as current lectin tools are limited by cross-reactivity while mass spectrometry typically requires biochemical purification and isolation of the target protein.
36409896	3	40	theme	nanobodies	474:483	arg1	class					465:469	a class	463:469	a class of nanobodies that can distinguish glycoforms without reactivity to off-target glycoproteins or glycans	463:573	Here, we describe a method to identify and characterize a class of nanobodies that can distinguish glycoforms without reactivity to off-target glycoproteins or glycans.
36409896	6	41	gly	glycoforms	1188:1197	arg1	IgG					1181:1183	IgG Fc glycoforms	1181:1197	IgG Fc glycoforms	1181:1197	Ultimately, we provide a strategy for the development of reagents to identify and manipulate IgG Fc glycoforms.
36409896	6	41	gly	glycoforms	1188:1197	arg1	Fc					1185:1186	IgG Fc glycoforms	1181:1197	IgG Fc glycoforms	1181:1197	Ultimately, we provide a strategy for the development of reagents to identify and manipulate IgG Fc glycoforms.
36409896	5	42	theme	glycan	1054:1059	arg1	structure					1061:1069	the B cell receptor (BCR) glycan structure	1028:1069	the B cell receptor (BCR) glycan structure on living cells	1028:1085	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	6	43	theme	Fc	1185:1186	arg1	glycoforms					1188:1197	IgG Fc glycoforms	1181:1197	IgG Fc glycoforms	1181:1197	Ultimately, we provide a strategy for the development of reagents to identify and manipulate IgG Fc glycoforms.
36409896	4	44	theme	Fc	627:628	arg1	glycoforms					630:639	immunoglobulin G (IgG) Fc glycoforms	604:639	immunoglobulin G (IgG) Fc glycoforms	604:639	We apply this technology to immunoglobulin G (IgG) Fc glycoforms and define nanobodies that specifically recognize either IgG lacking its core-fucose or IgG bearing terminal sialic acid residues.
36409896	5	45	theme	biochemical	808:818	arg1	methods					820:826	standard biochemical methods	799:826	standard biochemical methods	799:826	By adapting these tools to standard biochemical methods, we can clinically stratify dengue virus and SARS-CoV-2 infected individuals based on their IgG glycan profile, selectively disrupt IgG-Fcγ receptor binding both in vitro and in vivo, and interrogate the B cell receptor (BCR) glycan structure on living cells.
36409896	6	46	theme	IgG	1181:1183	arg1	glycoforms					1188:1197	IgG Fc glycoforms	1181:1197	IgG Fc glycoforms	1181:1197	Ultimately, we provide a strategy for the development of reagents to identify and manipulate IgG Fc glycoforms.
35247653	7	0	theme	intact	1294:1299	arg1	glycoprotein					1301:1312	intact glycoprotein	1294:1312	intact glycoprotein	1294:1312	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	5	1	theme	zone	950:953	arg1	electrophoresis					955:969	capillary zone electrophoresis	940:969	capillary zone electrophoresis with ultraviolet detection (CE-UV)	940:1004	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	3	2	theme	interaction	652:662	arg1	CapZIC-HILIC-MS					705:719	CapZIC-HILIC-MS	705:719	CapZIC-HILIC-MS	705:719	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	2	theme	interaction	652:662	arg1	spectrometry					691:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry	617:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	617:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	2	3	theme	neurodegenerative	364:380	arg1	diseases					382:389	neurodegenerative diseases	364:389	neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties	364:451	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	1	4	theme	acid	259:262	arg1	content					264:270	its low sialic acid content	244:270	its low sialic acid content	244:270	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	5	5	dep	composition	1022:1032	arg1	the					1018:1020	the	1018:1020	the	1018:1020	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	7	6	gly	glycoprotein	1301:1312	arg1	glycoprotein					1301:1312	intact glycoprotein	1294:1312	intact glycoprotein	1294:1312	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	4	7	theme	sialylated	748:757	arg1	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	8	theme	commercial	844:853	arg1	rhEPOs					855:860	other commercial rhEPOs	838:860	other commercial rhEPOs	838:860	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	2	9	from	protein	336:342	arg1	treatment					351:359	the treatment	347:359	the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties	347:451	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	5	10	theme	electrolyte	1059:1069	arg1	pH					1038:1039	pH	1038:1039	pH	1038:1039	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	5	10	theme	electrolyte	1059:1069	arg1	composition					1022:1032	composition	1022:1032	composition	1022:1032	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	2	11	theme	therapeutic	324:334	arg1	protein					336:342	therapeutic protein	324:342	therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties	324:451	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	5	12	with	electrophoresis	955:969	arg1	CE-UV					999:1003	CE-UV	999:1003	CE-UV	999:1003	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	5	12	with	electrophoresis	955:969	arg1	detection					988:996	ultraviolet detection	976:996	ultraviolet detection (CE-UV)	976:1004	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	7	13	theme	robust	1332:1337	arg1	platform					1363:1370	a robust and reliable analytical platform	1330:1370	a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases	1330:1490	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	4	14	theme	glycans	759:765	arg1	structures					785:794	less branched structures	771:794	less branched structures	771:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	14	theme	glycans	759:765	arg1	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	14	theme	glycans	759:765	arg1	amount					734:739	A superior amount	723:739	A superior amount of low sialylated glycans and less branched structures	723:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	7	15	from	biopharmaceutical	1444:1460	arg1	diseases					1483:1490	neurodegenerative diseases	1465:1490	neurodegenerative diseases	1465:1490	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	3	16	theme	N-glycans	515:523	arg1	characterization					481:496	an in-depth characterization	469:496	an in-depth characterization of NeuroEPO plus N-glycans	469:523	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	17	theme	NeuroEPO	501:508	arg1	characterization					481:496	an in-depth characterization	469:496	an in-depth characterization of NeuroEPO plus N-glycans	469:523	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	2	18	theme	rhEPO	284:288	arg1	product					290:296	This novel rhEPO product	273:296	This novel rhEPO product	273:296	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	6	19	theme	electrophoresis	1125:1139	arg1	method					1152:1157	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	5	20	theme	ultraviolet	976:986	arg1	CE-UV					999:1003	CE-UV	999:1003	CE-UV	999:1003	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	5	20	theme	ultraviolet	976:986	arg1	detection					988:996	ultraviolet detection	976:996	ultraviolet detection (CE-UV)	976:1004	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	2	21	theme	novel	278:282	arg1	product					290:296	This novel rhEPO product	273:296	This novel rhEPO product	273:296	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	1	22	theme	erythropoietic	184:197	arg1	activity					199:206	erythropoietic activity	184:206	erythropoietic activity	184:206	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	3	23	theme	isotope	551:557	arg1	/[13C6					565:570	a glycan isotope [12C6]/[13C6]	542:571	a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	542:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	7	24	theme	reliable	1343:1350	arg1	platform					1363:1370	a robust and reliable analytical platform	1330:1370	a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases	1330:1490	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	1	25	theme	NeuroEPO	97:104	arg1	plus					106:109	NeuroEPO plus	97:109	NeuroEPO plus	97:109	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	25	theme	NeuroEPO	97:104	arg1	erythropoietin					153:166	a recently developed recombinant human erythropoietin	114:166	a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity	114:206	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	5	26	theme	intact	870:875	arg1	glycoprotein					877:888	the intact glycoprotein	866:888	the intact glycoprotein level	866:894	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	4	27	theme	branched	776:783	arg1	structures					785:794	less branched structures	771:794	less branched structures	771:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	7	28	theme	neurodegenerative	1465:1481	arg1	diseases					1483:1490	neurodegenerative diseases	1465:1490	neurodegenerative diseases	1465:1490	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	6	29	theme	conventional	1232:1243	arg1	products					1258:1265	conventional acidic rhEPO products	1232:1265	conventional acidic rhEPO products	1232:1265	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	4	30	theme	superior	725:732	arg1	structures					785:794	less branched structures	771:794	less branched structures	771:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	30	theme	superior	725:732	arg1	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	30	theme	superior	725:732	arg1	amount					734:739	A superior amount	723:739	A superior amount of low sialylated glycans and less branched structures	723:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	0	31	theme	hyposialylated	23:36	arg1	erythropoietin					38:51	a novel hyposialylated erythropoietin	15:51	a novel hyposialylated erythropoietin	15:51	Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35247653	5	32	gly	glycoprotein	877:888	arg1	glycoprotein					877:888	the intact glycoprotein	866:888	the intact glycoprotein level	866:894	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	6	33	theme	rhEPO	1222:1226	arg1	analysis					1199:1206	the simultaneous analysis	1182:1206	the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products	1182:1265	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	1	34	theme	shorter	212:218	arg1	half-life					227:235	shorter plasma half-life	212:235	shorter plasma half-life due to its low sialic acid content	212:270	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	0	35	theme	novel	17:21	arg1	erythropoietin					38:51	a novel hyposialylated erythropoietin	15:51	a novel hyposialylated erythropoietin	15:51	Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35247653	3	36	theme	[12C6	559:563	arg1	/[13C6					565:570	a glycan isotope [12C6]/[13C6]	542:571	a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	542:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	37	theme	aniline	579:585	arg1	labeling					587:594	aniline labeling	579:594	aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	579:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	1	38	theme	plasma	220:225	arg1	half-life					227:235	shorter plasma half-life	212:235	shorter plasma half-life due to its low sialic acid content	212:270	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	6	39	theme	gel	1121:1123	arg1	electrophoresis					1125:1139	focusing polyacrylamide gel electrophoresis	1097:1139	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	6	39	theme	gel	1121:1123	arg1	IEF-PAGE					1142:1149	IEF-PAGE	1142:1149	IEF-PAGE	1142:1149	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	3	40	theme	capillary	617:625	arg1	CapZIC-HILIC-MS					705:719	CapZIC-HILIC-MS	705:719	CapZIC-HILIC-MS	705:719	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	40	theme	capillary	617:625	arg1	spectrometry					691:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry	617:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	617:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	5	41	theme	capillary	940:948	arg1	electrophoresis					955:969	capillary zone electrophoresis	940:969	capillary zone electrophoresis with ultraviolet detection (CE-UV)	940:1004	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	3	42	theme	in-depth	472:479	arg1	characterization					481:496	an in-depth characterization	469:496	an in-depth characterization of NeuroEPO plus N-glycans	469:523	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	4	43	theme	low	744:746	arg1	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	3	44	theme	zwitterionic	627:638	arg1	CapZIC-HILIC-MS					705:719	CapZIC-HILIC-MS	705:719	CapZIC-HILIC-MS	705:719	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	44	theme	zwitterionic	627:638	arg1	spectrometry					691:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry	617:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	617:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	2	45	theme	neurodegenerative	424:440	arg1	properties					442:451	its neuroprotective and neurodegenerative properties	400:451	its neuroprotective and neurodegenerative properties	400:451	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	4	46	located	detected	801:808	arg2	amount					734:739	A superior amount	723:739	A superior amount of low sialylated glycans and less branched structures	723:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	46	located	detected	801:808	arg1	compare					827:833	compare	827:833	compare	827:833	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	46	located	detected	801:808	arg1	NeuroEPO					813:820	NeuroEPO	813:820	NeuroEPO	813:820	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	46	located	detected	801:808	arg2	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	46	located	detected	801:808	arg2	structures					785:794	less branched structures	771:794	less branched structures	771:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	5	47	theme	glycoprotein	877:888	arg1	level					890:894	the intact glycoprotein level	866:894	the intact glycoprotein level	866:894	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	7	48	dep	glycomic	1281:1288	arg1	methods					1314:1320	methods	1314:1320	methods	1314:1320	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	0	49	theme	intact	56:61	arg1	glycoprotein					63:74	intact glycoprotein	56:74	intact glycoprotein	56:74	Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35247653	6	50	theme	products	1258:1265	arg1	analysis					1199:1206	the simultaneous analysis	1182:1206	the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products	1182:1265	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	7	51	theme	future	1419:1424	arg1	implementation					1426:1439	its future implementation	1415:1439	its future implementation as biopharmaceutical in neurodegenerative diseases	1415:1490	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	0	52	gly	hyposialylated	23:36	arg1	erythropoietin					38:51	a novel hyposialylated erythropoietin	15:51	a novel hyposialylated erythropoietin	15:51	Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35247653	1	53	theme	developed	125:133	arg1	plus					106:109	NeuroEPO plus	97:109	NeuroEPO plus	97:109	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	53	theme	developed	125:133	arg1	rhEPO					169:173	rhEPO	169:173	rhEPO	169:173	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	53	theme	developed	125:133	arg1	erythropoietin					153:166	a recently developed recombinant human erythropoietin	114:166	a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity	114:206	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	3	54	theme	labeling	587:594	arg1	strategy					596:603	aniline labeling strategy	579:603	aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	579:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	4	55	gly	sialylated	748:757	arg1	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	5	56	theme	separation	1048:1057	arg1	electrolyte					1059:1069	the separation electrolyte	1044:1069	the separation electrolyte	1044:1069	At the intact glycoprotein level, NeuroEPO plus glycoforms were separated by capillary zone electrophoresis with ultraviolet detection (CE-UV), optimizing the composition and pH of the separation electrolyte.
35247653	3	57	theme	liquid	664:669	arg1	CapZIC-HILIC-MS					705:719	CapZIC-HILIC-MS	705:719	CapZIC-HILIC-MS	705:719	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	57	theme	liquid	664:669	arg1	spectrometry					691:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry	617:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	617:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	6	58	theme	isoelectric	1085:1095	arg1	method					1152:1157	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	1	59	theme	recombinant	135:145	arg1	plus					106:109	NeuroEPO plus	97:109	NeuroEPO plus	97:109	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	59	theme	recombinant	135:145	arg1	rhEPO					169:173	rhEPO	169:173	rhEPO	169:173	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	59	theme	recombinant	135:145	arg1	erythropoietin					153:166	a recently developed recombinant human erythropoietin	114:166	a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity	114:206	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	6	60	theme	simultaneous	1186:1197	arg1	analysis					1199:1206	the simultaneous analysis	1182:1206	the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products	1182:1265	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	6	61	theme	focusing	1097:1104	arg1	electrophoresis					1125:1139	focusing polyacrylamide gel electrophoresis	1097:1139	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	6	61	theme	focusing	1097:1104	arg1	IEF-PAGE					1142:1149	IEF-PAGE	1142:1149	IEF-PAGE	1142:1149	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	4	62	theme	other	838:842	arg1	rhEPOs					855:860	other commercial rhEPOs	838:860	other commercial rhEPOs	838:860	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	3	63	theme	chromatography-mass	671:689	arg1	CapZIC-HILIC-MS					705:719	CapZIC-HILIC-MS	705:719	CapZIC-HILIC-MS	705:719	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	63	theme	chromatography-mass	671:689	arg1	spectrometry					691:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry	617:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	617:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	6	64	theme	rhEPO	1252:1256	arg1	products					1258:1265	conventional acidic rhEPO products	1232:1265	conventional acidic rhEPO products	1232:1265	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	1	65	theme	human	147:151	arg1	plus					106:109	NeuroEPO plus	97:109	NeuroEPO plus	97:109	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	65	theme	human	147:151	arg1	rhEPO					169:173	rhEPO	169:173	rhEPO	169:173	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	1	65	theme	human	147:151	arg1	erythropoietin					153:166	a recently developed recombinant human erythropoietin	114:166	a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity	114:206	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	4	66	theme	structures	785:794	arg1	structures					785:794	less branched structures	771:794	less branched structures	771:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	66	theme	structures	785:794	arg1	glycans					759:765	low sialylated glycans	744:765	low sialylated glycans	744:765	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	4	66	theme	structures	785:794	arg1	amount					734:739	A superior amount	723:739	A superior amount of low sialylated glycans and less branched structures	723:794	A superior amount of low sialylated glycans and less branched structures were detected in NeuroEPO plus compare to other commercial rhEPOs.
35247653	0	67	theme	glycan	80:85	arg1	analysis					87:94	glycan analysis	80:94	glycan analysis	80:94	Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35247653	6	68	theme	polyacrylamide	1106:1119	arg1	electrophoresis					1125:1139	focusing polyacrylamide gel electrophoresis	1097:1139	an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method	1082:1157	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	6	68	theme	polyacrylamide	1106:1119	arg1	IEF-PAGE					1142:1149	IEF-PAGE	1142:1149	IEF-PAGE	1142:1149	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	3	69	theme	hydrophilic	640:650	arg1	CapZIC-HILIC-MS					705:719	CapZIC-HILIC-MS	705:719	CapZIC-HILIC-MS	705:719	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	3	69	theme	hydrophilic	640:650	arg1	spectrometry					691:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry	617:702	capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	617:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	6	70	theme	acidic	1245:1250	arg1	products					1258:1265	conventional acidic rhEPO products	1232:1265	conventional acidic rhEPO products	1232:1265	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	3	71	theme	glycan	544:549	arg1	/[13C6					565:570	a glycan isotope [12C6]/[13C6]	542:571	a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS)	542:720	In this study, an in-depth characterization of NeuroEPO plus N-glycans was performed by a glycan isotope [12C6]/[13C6] coded aniline labeling strategy followed by capillary zwitterionic hydrophilic interaction liquid chromatography-mass spectrometry (CapZIC-HILIC-MS).
35247653	2	72	theme	neuroprotective	404:418	arg1	properties					442:451	its neuroprotective and neurodegenerative properties	400:451	its neuroprotective and neurodegenerative properties	400:451	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	1	73	theme	low	248:250	arg1	content					264:270	its low sialic acid content	244:270	its low sialic acid content	244:270	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
35247653	6	74	theme	basic	1216:1220	arg1	rhEPO					1222:1226	this basic rhEPO	1211:1226	this basic rhEPO	1211:1226	Moreover, an isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) method was also optimized for the simultaneous analysis of this basic rhEPO and conventional acidic rhEPO products.
35247653	0	75	gly	glycoprotein	63:74	arg1	glycoprotein					63:74	intact glycoprotein	56:74	intact glycoprotein	56:74	Characterizing a novel hyposialylated erythropoietin by intact glycoprotein and glycan analysis.
35247653	7	76	theme	analytical	1352:1361	arg1	platform					1363:1370	a robust and reliable analytical platform	1330:1370	a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases	1330:1490	The proposed glycomic and intact glycoprotein methods provide a robust and reliable analytical platform for NeuroEPO plus characterization and for its future implementation as biopharmaceutical in neurodegenerative diseases.
35247653	2	77	theme	diseases	382:389	arg1	treatment					351:359	the treatment	347:359	the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties	347:451	This novel rhEPO product is under investigation as therapeutic protein in the treatment of neurodegenerative diseases owing to its neuroprotective and neurodegenerative properties.
35247653	1	78	theme	sialic	252:257	arg1	content					264:270	its low sialic acid content	244:270	its low sialic acid content	244:270	NeuroEPO plus is a recently developed recombinant human erythropoietin (rhEPO) without erythropoietic activity and shorter plasma half-life due to its low sialic acid content.
36329887	12	0	theme	binding	2216:2222	arg1	capacity					2224:2231	binding capacity	2216:2231	binding capacity of the same receptor preparation to different FSH glycoforms	2216:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	3	1	theme	biological	674:683	arg1	activity					685:692	greater biological activity	666:692	greater biological activity	666:692	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	11	2	theme	gel	2022:2024	arg1	filtration					2026:2035	pituitary hFSH glycoform Superdex 75 gel filtration	1985:2035	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	7	3	theme	ESI-IM-CID	1487:1496	arg1	spectrometry					1504:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	7	4	theme	dissociation	1473:1484	arg1	spectrometry					1504:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	6	5	theme	FSH21	1267:1271	arg1	occupancy					1282:1290	greater FSH21 receptor occupancy	1259:1290	greater FSH21 receptor occupancy	1259:1290	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	1	6	theme	α/β	176:178	arg1	hormone					158:164	Follicle-stimulating hormone	137:164	Follicle-stimulating hormone (FSH)	137:170	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	6	theme	α/β	176:178	arg1	hormone					207:213	an α/β heterodimeric glycoprotein hormone	173:213	an α/β heterodimeric glycoprotein hormone	173:213	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	7	7	theme	ionization-ion	1431:1444	arg1	spectrometry					1504:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	1	8	theme	glycoprotein	194:205	arg1	hormone					158:164	Follicle-stimulating hormone	137:164	Follicle-stimulating hormone (FSH)	137:170	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	8	theme	glycoprotein	194:205	arg1	hormone					207:213	an α/β heterodimeric glycoprotein hormone	173:213	an α/β heterodimeric glycoprotein hormone	173:213	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	6	9	theme	Western	1148:1154	arg1	blots					1156:1160	Western blots	1148:1160	Western blots	1148:1160	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	4	10	gly	F1-deglycosylated	711:727	arg1	FSH					729:731	Endoglycosidase F1-deglycosylated FSH	695:731	Endoglycosidase F1-deglycosylated FSH	695:731	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	12	11	theme	preparation	2254:2264	arg1	capacity					2224:2231	binding capacity	2216:2231	binding capacity of the same receptor preparation to different FSH glycoforms	2216:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	11	12	theme	αAsn<sup>52</sup>	1933:1949	arg1	deglycosylation					1951:1965	Selective αAsn<sup>52</sup> deglycosylation	1923:1965	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1923:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	5	13	theme	remaining	1026:1034	arg1	sites					1051:1055	the remaining ligand-binding sites	1022:1055	the remaining ligand-binding sites	1022:1055	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	10	14	theme	additional	1906:1915	arg1	mass					1917:1920	the additional mass	1902:1920	the additional mass	1902:1920	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	0	15	from	Variation	113:121	arg1	Abundance					126:134	Abundance	126:134	Abundance	126:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	4	16	theme	F1-deglycosylated	711:727	arg1	FSH					729:731	Endoglycosidase F1-deglycosylated FSH	695:731	Endoglycosidase F1-deglycosylated FSH	695:731	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	6	17	theme	FSHR	1308:1311	arg1	model					1320:1324	the putative FSHR trimer model	1295:1324	the putative FSHR trimer model	1295:1324	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	6	18	theme	Asn<sup>52</sup>	1184:1199	arg1	glycans					1201:1207	Asn<sup>52</sup> glycans	1184:1207	Asn<sup>52</sup> glycans in these preparations	1184:1229	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	10	19	with	tri-antennary	1847:1859	arg1	repeats					1879:1885	lactosamine repeats	1867:1885	lactosamine repeats accounting for the additional mass	1867:1920	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	11	20	theme	tri-antennary	2097:2109	arg1	glycans					2111:2117	tri-antennary glycans	2097:2117	tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms	2097:2181	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	6	21	dep	small	1236:1240	arg1	enable					1252:1257	enable	1252:1257	to enable greater FSH21 receptor occupancy in the putative FSHR trimer model	1249:1324	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	0	22	theme	Glycan	69:74	arg1	Consistency					87:97	Major Glycan Structural Consistency	63:97	Major Glycan Structural Consistency	63:97	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	1	23	theme	N-glycans	335:343	arg1	N-glycans					335:343	two FSHβ subunit N-glycans	318:343	two FSHβ subunit N-glycans	318:343	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	23	theme	N-glycans	335:343	arg1	one					311:313	one	311:313	one	311:313	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	11	24	theme	molecular	2151:2159	arg1	weight					2161:2166	the lowest molecular weight	2140:2166	the lowest molecular weight FSH glycoforms	2140:2181	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	2	25	theme	21	480:481	arg1	kDa					483:485	kDa	483:485	kDa	483:485	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	1	26	dep	one	311:313	arg1	either					304:309	either	304:309	either	304:309	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	12	27	theme	same	2240:2243	arg1	preparation					2254:2264	the same receptor preparation	2236:2264	the same receptor preparation	2236:2264	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	6	28	from	glycans	1201:1207	arg1	preparations					1218:1229	these preparations	1212:1229	these preparations	1212:1229	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	8	29	theme	core-linked	1551:1561	arg1	fucose					1563:1568	core-linked fucose	1551:1568	core-linked fucose	1551:1568	FSHβ glycans typically possessed core-linked fucose and were roughly one third bi-antennary, one third tri-antennary and one third tetra-antennary.
36329887	5	30	theme	FSHα	890:893	arg1	Asn<sup>52</sup>					895:910	FSHα Asn<sup>52</sup>	890:910	FSHα Asn<sup>52</sup>	890:910	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	11	31	theme	FSH	2168:2170	arg1	glycoforms					2172:2181	FSH glycoforms	2168:2181	the lowest molecular weight FSH glycoforms	2140:2181	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	4	32	theme	extracellular	755:767	arg1	receptor					787:794	the FSH receptor	779:794	the FSH receptor crystallized as a trimeric complex	779:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	4	32	theme	extracellular	755:767	arg1	domain					769:774	the complete extracellular domain	742:774	the complete extracellular domain of the FSH receptor crystallized as a trimeric complex	742:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	0	33	theme	Minor	100:104	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	33	theme	Minor	100:104	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	12	34	gly	glycoforms	2283:2292	arg1	FSH					2279:2281	different FSH glycoforms	2269:2292	different FSH glycoforms	2269:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	12	35	from	organization	2309:2320	arg1	membranes					2350:2358	cell membranes	2345:2358	cell membranes	2345:2358	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	11	36	theme	ESI-IM-CID	2059:2068	arg1	spectrometry					2075:2086	ESI-IM-CID mass spectrometry	2059:2086	ESI-IM-CID mass spectrometry	2059:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	6	37	theme	most	1065:1068	arg1	preparations					1083:1094	the most active FSH21 preparations	1061:1094	the most active FSH21 preparations	1061:1094	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	2	38	gly	fully-glycosylated	381:398	arg1	variants					368:375	The two most abundant variants	346:375	The two most abundant variants	346:375	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	38	gly	fully-glycosylated	381:398	arg1	FSH24					400:404	fully-glycosylated FSH24	381:404	fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots)	381:449	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	12	39	theme	αAsn<sup>52</sup>	2377:2393	arg1	oligosaccharide					2395:2409	the αAsn<sup>52</sup> oligosaccharide	2373:2409	the αAsn<sup>52</sup> oligosaccharide	2373:2409	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	0	40	theme	Human	0:4	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	40	theme	Human	0:4	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	5	41	theme	central	940:946	arg1	pocket					948:953	the central pocket	936:953	the central pocket in this complex	936:969	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	7	42	theme	purified	1334:1341	arg1	oligosaccharides					1348:1363	Highly purified hFSH oligosaccharides	1327:1363	Highly purified hFSH oligosaccharides	1327:1363	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	11	43	theme	lowest	2144:2149	arg1	weight					2161:2166	the lowest molecular weight	2140:2166	the lowest molecular weight FSH glycoforms	2140:2181	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	9	44	theme	FSHα	1666:1669	arg1	oligosaccharides					1671:1686	FSHα oligosaccharides	1666:1686	FSHα oligosaccharides	1666:1686	FSHα oligosaccharides largely lacked core fucose and were bi- or tri-antennary.
36329887	2	45	theme	FSHβ	423:426	arg1	band					428:431	24 kDa FSHβ band	416:431	24 kDa FSHβ band in Western blots	416:448	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	0	46	theme	Glycoform	10:18	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	46	theme	Glycoform	10:18	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	10	47	theme	αAsn<sup>52</sup>	1752:1768	arg1	glycans					1770:1776	Those αAsn<sup>52</sup> glycans	1746:1776	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values	1746:1828	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	2	48	theme	24	416:417	arg1	kDa					419:421	kDa	419:421	kDa	419:421	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	0	49	theme	Asparagine<sup>52</sup>	30:52	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	49	theme	Asparagine<sup>52</sup>	30:52	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	12	50	theme	receptor	2333:2340	arg1	organization					2309:2320	the organization	2305:2320	the organization of the FSH receptor in cell membranes	2305:2358	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	12	50	theme	receptor	2333:2340	arg1	differences					2201:2211	the differences	2197:2211	the differences in binding capacity of the same receptor preparation to different FSH glycoforms	2197:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	3	51	theme	FSH	603:605	arg1	sites					615:619	more FSH binding sites	598:619	more FSH binding sites	598:619	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	11	52	gly	deglycosylation	1951:1965	arg1	fractions					2037:2045	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions	1970:2045	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	11	53	theme	glycoform	2000:2008	arg1	filtration					2026:2035	pituitary hFSH glycoform Superdex 75 gel filtration	1985:2035	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	1	54	theme	FSHβ	322:325	arg1	N-glycans					335:343	two FSHβ subunit N-glycans	318:343	two FSHβ subunit N-glycans	318:343	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	6	55	theme	α-subunit	1129:1137	arg1	bands					1139:1143	more rapidly migrating α-subunit bands	1106:1143	more rapidly migrating α-subunit bands in Western blots	1106:1160	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	8	56	contain	possessed	1541:1549	arg2	fucose					1563:1568	core-linked fucose	1551:1568	core-linked fucose	1551:1568	FSHβ glycans typically possessed core-linked fucose and were roughly one third bi-antennary, one third tri-antennary and one third tetra-antennary.
36329887	8	56	contain	possessed	1541:1549	arg1	glycans					1523:1529	FSHβ glycans	1518:1529	FSHβ glycans	1518:1529	FSHβ glycans typically possessed core-linked fucose and were roughly one third bi-antennary, one third tri-antennary and one third tetra-antennary.
36329887	3	57	theme	hypo-glycosylated	633:649	arg1	FSH21					651:655	hypo-glycosylated FSH21	633:655	hypo-glycosylated FSH21	633:655	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	4	58	theme	FSH	783:785	arg1	receptor					787:794	the FSH receptor	779:794	the FSH receptor crystallized as a trimeric complex	779:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	10	59	theme	glycan	1805:1810	arg1	values					1823:1828	tetra-antennary glycan <i>m/z</i> values	1789:1828	tetra-antennary glycan <i>m/z</i> values	1789:1828	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	5	60	theme	other	987:991	arg1	ligands					1001:1007	the other two FSH ligands	983:1007	the other two FSH ligands	983:1007	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	12	61	theme	cell	2345:2348	arg1	membranes					2350:2358	cell membranes	2345:2358	cell membranes	2345:2358	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	11	62	theme	filtration	2026:2035	arg1	fractions					2037:2045	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions	1970:2045	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	5	63	theme	FSH	997:999	arg1	ligands					1001:1007	the other two FSH ligands	983:1007	the other two FSH ligands	983:1007	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	2	64	dep	FSH24	400:404	arg1	based					407:411	based	407:411	based on 24 kDa FSHβ band in Western blots	407:448	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	6	65	theme	putative	1299:1306	arg1	model					1320:1324	the putative FSHR trimer model	1295:1324	the putative FSHR trimer model	1295:1324	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	2	66	theme	abundant	359:366	arg1	variants					368:375	The two most abundant variants	346:375	The two most abundant variants	346:375	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	66	theme	abundant	359:366	arg1	FSH24					400:404	fully-glycosylated FSH24	381:404	fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots)	381:449	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	67	from	band	428:431	arg1	blots					444:448	Western blots	436:448	Western blots	436:448	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	12	68	from	differences	2201:2211	arg1	capacity					2224:2231	binding capacity	2216:2231	binding capacity of the same receptor preparation to different FSH glycoforms	2216:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	6	69	theme	FSH21	1077:1081	arg1	preparations					1083:1094	the most active FSH21 preparations	1061:1094	the most active FSH21 preparations	1061:1094	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	1	70	gly	glycoprotein	194:205	arg1	glycoprotein					194:205	an α/β heterodimeric glycoprotein hormone	173:213	an α/β heterodimeric glycoprotein hormone	173:213	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	10	71	theme	lactosamine	1867:1877	arg1	repeats					1879:1885	lactosamine repeats	1867:1885	lactosamine repeats accounting for the additional mass	1867:1920	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	5	72	attach	attached	878:885	arg2	glycan					871:876	a single biantennary glycan	850:876	a single biantennary glycan attached to FSHα Asn<sup>52</sup>	850:910	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	5	72	attach	attached	878:885	arg1	Asn<sup>52</sup>					895:910	FSHα Asn<sup>52</sup>	890:910	FSHα Asn<sup>52</sup>	890:910	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	11	73	gly	glycoforms	2172:2181	arg1	FSH					2168:2170	FSH glycoforms	2168:2181	the lowest molecular weight FSH glycoforms	2140:2181	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	6	74	theme	receptor	1273:1280	arg1	occupancy					1282:1290	greater FSH21 receptor occupancy	1259:1290	greater FSH21 receptor occupancy	1259:1290	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	1	75	theme	heterodimeric	180:192	arg1	hormone					158:164	Follicle-stimulating hormone	137:164	Follicle-stimulating hormone (FSH)	137:170	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	75	theme	heterodimeric	180:192	arg1	hormone					207:213	an α/β heterodimeric glycoprotein hormone	173:213	an α/β heterodimeric glycoprotein hormone	173:213	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	7	76	theme	mass	1499:1502	arg1	spectrometry					1504:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	6	77	theme	greater	1259:1265	arg1	occupancy					1282:1290	greater FSH21 receptor occupancy	1259:1290	greater FSH21 receptor occupancy	1259:1290	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	5	78	theme	single	852:857	arg1	glycan					871:876	a single biantennary glycan	850:876	a single biantennary glycan attached to FSHα Asn<sup>52</sup>	850:910	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	7	79	theme	mobility-collision-induced	1446:1471	arg1	spectrometry					1504:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	11	80	theme	Selective	1923:1931	arg1	deglycosylation					1951:1965	Selective αAsn<sup>52</sup> deglycosylation	1923:1965	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1923:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	7	81	theme	electrospray	1418:1429	arg1	spectrometry					1504:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry	1418:1515	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	12	82	theme	FSH	2279:2281	arg1	glycoforms					2283:2292	different FSH glycoforms	2269:2292	different FSH glycoforms	2269:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	11	83	theme	Superdex	2010:2017	arg1	filtration					2026:2035	pituitary hFSH glycoform Superdex 75 gel filtration	1985:2035	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	5	84	theme	biantennary	859:869	arg1	glycan					871:876	a single biantennary glycan	850:876	a single biantennary glycan attached to FSHα Asn<sup>52</sup>	850:910	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	11	85	dep	weight	2161:2166	arg1	glycoforms					2172:2181	FSH glycoforms	2168:2181	the lowest molecular weight FSH glycoforms	2140:2181	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	8	86	theme	FSHβ	1518:1521	arg1	glycans					1523:1529	FSHβ glycans	1518:1529	FSHβ glycans	1518:1529	FSHβ glycans typically possessed core-linked fucose and were roughly one third bi-antennary, one third tri-antennary and one third tetra-antennary.
36329887	11	87	theme	representative	1970:1983	arg1	fractions					2037:2045	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions	1970:2045	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	1	88	dep	presence	281:288	arg1	the					277:279	the	277:279	the	277:279	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	12	89	theme	receptor	2245:2252	arg1	preparation					2254:2264	the same receptor preparation	2236:2264	the same receptor preparation	2236:2264	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	6	90	theme	trimer	1313:1318	arg1	model					1320:1324	the putative FSHR trimer model	1295:1324	the putative FSHR trimer model	1295:1324	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	5	91	theme	ligand-binding	1036:1049	arg1	sites					1051:1055	the remaining ligand-binding sites	1022:1055	the remaining ligand-binding sites	1022:1055	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	1	92	theme	Follicle-stimulating	137:156	arg1	FSH					167:169	FSH	167:169	FSH	167:169	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	92	theme	Follicle-stimulating	137:156	arg1	hormone					158:164	Follicle-stimulating hormone	137:164	Follicle-stimulating hormone (FSH)	137:170	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	92	theme	Follicle-stimulating	137:156	arg1	hormone					207:213	an α/β heterodimeric glycoprotein hormone	173:213	an α/β heterodimeric glycoprotein hormone	173:213	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	6	93	contain	possessed	1096:1104	arg2	bands					1139:1143	more rapidly migrating α-subunit bands	1106:1143	more rapidly migrating α-subunit bands in Western blots	1106:1160	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	6	93	contain	possessed	1096:1104	arg1	preparations					1083:1094	the most active FSH21 preparations	1061:1094	the most active FSH21 preparations	1061:1094	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	7	94	theme	FSH	1383:1385	arg1	subunit					1387:1393	each FSH subunit	1378:1393	each FSH subunit	1378:1393	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	4	95	theme	Endoglycosidase	695:709	arg1	FSH					729:731	Endoglycosidase F1-deglycosylated FSH	695:731	Endoglycosidase F1-deglycosylated FSH	695:731	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	11	96	theme	pituitary	1985:1993	arg1	filtration					2026:2035	pituitary hFSH glycoform Superdex 75 gel filtration	1985:2035	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	0	97	theme	Structural	76:85	arg1	Consistency					87:97	Major Glycan Structural Consistency	63:97	Major Glycan Structural Consistency	63:97	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	3	98	theme	FSH	574:576	arg1	receptor					578:585	the FSH receptor	570:585	the FSH receptor	570:585	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	2	99	theme	kDa	483:485	arg1	band					487:490	21 kDa band	480:490	21 kDa band	480:490	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	7	100	attach	derived	1365:1371	arg2	oligosaccharides					1348:1363	Highly purified hFSH oligosaccharides	1327:1363	Highly purified hFSH oligosaccharides	1327:1363	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	7	100	attach	derived	1365:1371	arg1	subunit					1387:1393	each FSH subunit	1378:1393	each FSH subunit	1378:1393	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	0	101	theme	Glycan	106:111	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	101	theme	Glycan	106:111	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	7	102	theme	hFSH	1343:1346	arg1	oligosaccharides					1348:1363	Highly purified hFSH oligosaccharides	1327:1363	Highly purified hFSH oligosaccharides	1327:1363	Highly purified hFSH oligosaccharides derived from each FSH subunit, were characterized by electrospray ionization-ion mobility-collision-induced dissociation (ESI-IM-CID) mass spectrometry.
36329887	2	103	dep	FSH21	473:477	arg1	lacks					493:497	lacks	493:497	lacks βAsn<sup>24</sup> glycans	493:523	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	104	theme	βAsn<sup>24</sup>	499:515	arg1	glycans					517:523	βAsn<sup>24</sup> glycans	499:523	βAsn<sup>24</sup> glycans	499:523	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	4	105	theme	complete	746:753	arg1	receptor					787:794	the FSH receptor	779:794	the FSH receptor crystallized as a trimeric complex	779:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	4	105	theme	complete	746:753	arg1	domain					769:774	the complete extracellular domain	742:774	the complete extracellular domain of the FSH receptor crystallized as a trimeric complex	742:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	11	106	theme	hFSH	1995:1998	arg1	filtration					2026:2035	pituitary hFSH glycoform Superdex 75 gel filtration	1985:2035	representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1970:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	6	107	theme	active	1070:1075	arg1	preparations					1083:1094	the most active FSH21 preparations	1061:1094	the most active FSH21 preparations	1061:1094	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	11	108	theme	mass	2070:2073	arg1	spectrometry					2075:2086	ESI-IM-CID mass spectrometry	2059:2086	ESI-IM-CID mass spectrometry	2059:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36329887	0	109	theme	FSH	6:8	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	109	theme	FSH	6:8	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	2	110	theme	Western	436:442	arg1	blots					444:448	Western blots	436:448	Western blots	436:448	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	111	theme	fully-glycosylated	381:398	arg1	variants					368:375	The two most abundant variants	346:375	The two most abundant variants	346:375	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	111	theme	fully-glycosylated	381:398	arg1	FSH24					400:404	fully-glycosylated FSH24	381:404	fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots)	381:449	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	0	112	theme	α-Subunit	20:28	arg1	Glycans					54:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans	0:60	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	112	theme	α-Subunit	20:28	arg1	Variation					113:121	Minor Glycan Variation	100:121	Minor Glycan Variation in Abundance	100:134	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	2	113	dep	lacks	493:497	arg1	band					487:490	21 kDa band	480:490	21 kDa band	480:490	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	8	114	link	core-linked	1551:1561	arg1	fucose					1563:1568	core-linked fucose	1551:1568	core-linked fucose	1551:1568	FSHβ glycans typically possessed core-linked fucose and were roughly one third bi-antennary, one third tri-antennary and one third tetra-antennary.
36329887	3	115	theme	binding	607:613	arg1	sites					615:619	more FSH binding sites	598:619	more FSH binding sites	598:619	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	2	116	theme	kDa	419:421	arg1	band					428:431	24 kDa FSHβ band	416:431	24 kDa FSHβ band in Western blots	416:448	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	1	117	theme	one	311:313	arg1	absence					293:299	absence	293:299	absence	293:299	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	1	117	theme	one	311:313	arg1	presence					281:288	presence	281:288	presence	281:288	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	2	118	gly	hypo-glycosylated	455:471	arg1	FSH21					473:477	hypo-glycosylated FSH21	455:477	hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans)	455:524	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	2	119	theme	hypo-glycosylated	455:471	arg1	FSH21					473:477	hypo-glycosylated FSH21	455:477	hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans)	455:524	The two most abundant variants are fully-glycosylated FSH24 (based on 24 kDa FSHβ band in Western blots) and hypo-glycosylated FSH21 (21 kDa band, lacks βAsn<sup>24</sup> glycans).
36329887	3	120	theme	more	598:601	arg1	sites					615:619	more FSH binding sites	598:619	more FSH binding sites	598:619	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	0	121	theme	Major	63:67	arg1	Consistency					87:97	Major Glycan Structural Consistency	63:97	Major Glycan Structural Consistency	63:97	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	0	122	dep	Glycans	54:60	arg1	Consistency					87:97	Major Glycan Structural Consistency	63:97	Major Glycan Structural Consistency	63:97	Human FSH Glycoform α-Subunit Asparagine<sup>52</sup> Glycans: Major Glycan Structural Consistency, Minor Glycan Variation in Abundance.
36329887	4	123	theme	trimeric	814:821	arg1	complex					823:829	a trimeric complex	812:829	a trimeric complex	812:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	6	124	from	bands	1139:1143	arg1	blots					1156:1160	Western blots	1148:1160	Western blots	1148:1160	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	10	125	theme	<i>m/z</i>	1812:1821	arg1	values					1823:1828	tetra-antennary glycan <i>m/z</i> values	1789:1828	tetra-antennary glycan <i>m/z</i> values	1789:1828	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	5	126	from	pocket	948:953	arg1	complex					963:969	this complex	958:969	this complex	958:969	It was noted that a single biantennary glycan attached to FSHα Asn<sup>52</sup> might preemptively fill the central pocket in this complex and prevent the other two FSH ligands from binding the remaining ligand-binding sites.
36329887	1	127	theme	subunit	327:333	arg1	N-glycans					335:343	two FSHβ subunit N-glycans	318:343	two FSHβ subunit N-glycans	318:343	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	9	128	theme	core	1703:1706	arg1	fucose					1708:1713	core fucose	1703:1713	core fucose	1703:1713	FSHα oligosaccharides largely lacked core fucose and were bi- or tri-antennary.
36329887	6	129	theme	migrating	1119:1127	arg1	bands					1139:1143	more rapidly migrating α-subunit bands	1106:1143	more rapidly migrating α-subunit bands in Western blots	1106:1160	As the most active FSH21 preparations possessed more rapidly migrating α-subunit bands in Western blots, we hypothesized that Asn<sup>52</sup> glycans in these preparations were small enough to enable greater FSH21 receptor occupancy in the putative FSHR trimer model.
36329887	3	130	gly	hypo-glycosylated	633:649	arg1	FSH21					651:655	hypo-glycosylated FSH21	633:655	hypo-glycosylated FSH21	633:655	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	12	131	theme	FSH	2329:2331	arg1	receptor					2333:2340	the FSH receptor	2325:2340	the FSH receptor	2325:2340	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	10	132	theme	tetra-antennary	1789:1803	arg1	values					1823:1828	tetra-antennary glycan <i>m/z</i> values	1789:1828	tetra-antennary glycan <i>m/z</i> values	1789:1828	Those αAsn<sup>52</sup> glycans exhibiting tetra-antennary glycan <i>m/z</i> values were found to be tri-antennary, with lactosamine repeats accounting for the additional mass.
36329887	1	133	theme	significant	241:251	arg1	variants					253:260	functionally significant variants	228:260	functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans	228:343	Follicle-stimulating hormone (FSH), an α/β heterodimeric glycoprotein hormone, consists of functionally significant variants resulting from the presence or absence of either one of two FSHβ subunit N-glycans.
36329887	12	134	theme	different	2269:2277	arg1	glycoforms					2283:2292	different FSH glycoforms	2269:2292	different FSH glycoforms	2269:2292	Accordingly, the differences in binding capacity of the same receptor preparation to different FSH glycoforms are likely the organization of the FSH receptor in cell membranes, rather than the αAsn<sup>52</sup> oligosaccharide.
36329887	3	135	theme	greater	666:672	arg1	activity					685:692	greater biological activity	666:692	greater biological activity	666:692	Due to its ability to bind more rapidly to the FSH receptor and occupy more FSH binding sites than FSH24, hypo-glycosylated FSH21 exhibits greater biological activity.
36329887	4	136	theme	receptor	787:794	arg1	receptor					787:794	the FSH receptor	779:794	the FSH receptor crystallized as a trimeric complex	779:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	4	136	theme	receptor	787:794	arg1	domain					769:774	the complete extracellular domain	742:774	the complete extracellular domain of the FSH receptor crystallized as a trimeric complex	742:829	Endoglycosidase F1-deglycosylated FSH bound to the complete extracellular domain of the FSH receptor crystallized as a trimeric complex.
36329887	11	137	theme	fractions	2037:2045	arg1	deglycosylation					1951:1965	Selective αAsn<sup>52</sup> deglycosylation	1923:1965	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry	1923:2086	Selective αAsn<sup>52</sup> deglycosylation of representative pituitary hFSH glycoform Superdex 75 gel filtration fractions followed by ESI-IM-CID mass spectrometry revealed tri-antennary glycans predominated even in the lowest molecular weight FSH glycoforms.
36121379	5	0	theme	glycan	755:760	arg1	fucosylation					799:810	fucosylation	799:810	fucosylation	799:810	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	0	theme	glycan	755:760	arg1	sialylation					783:793	sialylation	783:793	sialylation	783:793	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	0	theme	glycan	755:760	arg1	features					762:769	characteristic isomeric glycan features	731:769	characteristic isomeric glycan features such as the sialylation and fucosylation pattern	731:818	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	6	1	theme	glycan	911:916	arg1	analysis					918:925	glycan analysis	911:925	glycan analysis	911:925	However, while both LC-MS and IM-MS have clearly proven their individual capabilities for glycan analysis, attempts to combine both methods into a consistent workflow are lacking.
36121379	0	2	theme	Sialic	17:22	arg1	Isomers					29:35	Sialic Acid Isomers	17:35	Sialic Acid Isomers from Released N-Glycans	17:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	4	3	theme	MS-based	453:460	arg1	detection					462:470	MS-based detection	453:470	MS-based detection	453:470	However, MS-based detection often does not provide sufficient information to distinguish glycan isomers.
36121379	0	4	theme	Mobility	71:78	arg1	Spectrometry					80:91	Ion Mobility Spectrometry	67:91	Ion Mobility Spectrometry	67:91	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	4	5	theme	sufficient	495:504	arg1	information					506:516	sufficient information	495:516	sufficient information to distinguish glycan isomers	495:546	However, MS-based detection often does not provide sufficient information to distinguish glycan isomers.
36121379	7	6	attach	released	1135:1142	arg1	glycoprotein					1168:1179	human alpha-1-acid glycoprotein	1149:1179	human alpha-1-acid glycoprotein (hAGP)	1149:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	6	attach	released	1135:1142	arg1	hAGP					1182:1185	hAGP	1182:1185	hAGP	1182:1185	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	6	attach	released	1135:1142	arg2	structures					1124:1133	the glycan structures	1113:1133	the glycan structures released from human alpha-1-acid glycoprotein (hAGP)	1113:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	10	7	theme	sialic	1585:1590	arg1	acids					1592:1596	multiple sialic acids	1576:1596	multiple sialic acids within one LC-IM-MS run	1576:1620	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	0	8	from	Determination	0:12	arg1	N-Glycans					51:59	Released N-Glycans	42:59	Released N-Glycans	42:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	10	9	theme	glycan	1556:1561	arg1	isomers					1563:1569	glycan isomers	1556:1569	glycan isomers with multiple sialic acids within one LC-IM-MS run	1556:1620	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	2	10	theme	complex	281:287	arg1	regio-					289:294	a complex regio-	279:294	a complex regio-	279:294	They can exhibit highly diverse structures with multiple branched sites as well as a complex regio- and stereochemistry.
36121379	10	11	theme	multiple	1576:1583	arg1	acids					1592:1596	multiple sialic acids	1576:1596	multiple sialic acids within one LC-IM-MS run	1576:1620	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	0	12	from	N-Glycans	51:59	arg1	Determination					0:12	Determination	0:12	Determination of Sialic Acid Isomers from Released N-Glycans	0:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	0	12	from	N-Glycans	51:59	arg1	Isomers					29:35	Sialic Acid Isomers	17:35	Sialic Acid Isomers from Released N-Glycans	17:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	8	13	from	information	1281:1291	arg1	composition					1303:1313	glycan composition	1296:1313	glycan composition	1296:1313	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	6	14	theme	consistent	968:977	arg1	workflow					979:986	a consistent workflow	966:986	a consistent workflow are lacking	966:998	However, while both LC-MS and IM-MS have clearly proven their individual capabilities for glycan analysis, attempts to combine both methods into a consistent workflow are lacking.
36121379	10	15	theme	LC-IM-MS	1609:1616	arg1	run					1618:1620	one LC-IM-MS run	1605:1620	one LC-IM-MS run	1605:1620	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	10	16	with	isomers	1563:1569	arg1	acids					1592:1596	multiple sialic acids	1576:1596	multiple sialic acids within one LC-IM-MS run	1576:1620	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	1	17	theme	major	166:170	arg1	classes					172:178	the major classes	162:178	the major classes of biopolymers	162:193	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	7	18	theme	glycan	1117:1122	arg1	structures					1124:1133	the glycan structures	1113:1133	the glycan structures released from human alpha-1-acid glycoprotein (hAGP)	1113:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	3	19	from	chromatography	380:393	arg1	combination					403:413	combination	403:413	combination with mass spectrometry (MS)	403:441	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	5	20	dep	sialylation	783:793	arg1	the					779:781	the	779:781	the	779:781	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	20	dep	sialylation	783:793	arg1	pattern					812:818	pattern	812:818	pattern	812:818	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	1	21	from	nature	134:139	arg1	ubiquitous					120:129	ubiquitous	120:129	ubiquitous	120:129	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	3	22	with	combination	403:413	arg1	spectrometry					425:436	mass spectrometry	420:436	mass spectrometry (MS)	420:441	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	3	22	with	combination	403:413	arg1	MS					439:440	MS	439:440	MS	439:440	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	1	23	theme	classes	172:178	arg1	one					155:157	one	155:157	one	155:157	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	1	23	theme	classes	172:178	arg1	classes					172:178	the major classes	162:178	the major classes of biopolymers	162:193	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	7	24	theme	alpha-1-acid	1155:1166	arg1	hAGP					1182:1185	hAGP	1182:1185	hAGP	1182:1185	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	24	theme	alpha-1-acid	1155:1166	arg1	glycoprotein					1168:1179	human alpha-1-acid glycoprotein	1149:1179	human alpha-1-acid glycoprotein (hAGP)	1149:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	3	25	theme	common	319:324	arg1	way					326:328	A common way	317:328	A common way to analytically address this complexity	317:368	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	3	25	theme	common	319:324	arg1	chromatography					380:393	liquid chromatography	373:393	liquid chromatography (LC)	373:398	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	5	26	theme	characteristic	731:744	arg1	fucosylation					799:810	fucosylation	799:810	fucosylation	799:810	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	26	theme	characteristic	731:744	arg1	sialylation					783:793	sialylation	783:793	sialylation	783:793	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	26	theme	characteristic	731:744	arg1	features					762:769	characteristic isomeric glycan features	731:769	characteristic isomeric glycan features such as the sialylation and fucosylation pattern	731:818	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	10	27	theme	feature	1517:1523	arg1	mapping					1525:1531	This feature mapping	1512:1531	This feature mapping	1512:1531	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	8	28	theme	sialylated	1233:1242	arg1	glycans					1260:1266	highly sialylated multi-antennary glycans	1226:1266	highly sialylated multi-antennary glycans	1226:1266	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	1	29	from	ubiquitous	120:129	arg1	nature					134:139	nature	134:139	nature	134:139	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	1	30	theme	Complex	94:100	arg1	carbohydrates					102:114	Complex carbohydrates	94:114	Complex carbohydrates	94:114	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	3	31	theme	mass	420:423	arg1	spectrometry					425:436	mass spectrometry	420:436	mass spectrometry (MS)	420:441	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	3	31	theme	mass	420:423	arg1	MS					439:440	MS	439:440	MS	439:440	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	0	32	theme	Acid	24:27	arg1	Isomers					29:35	Sialic Acid Isomers	17:35	Sialic Acid Isomers from Released N-Glycans	17:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	5	33	theme	great	678:682	arg1	potential					684:692	great potential	678:692	great potential	678:692	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	8	34	theme	glycans	1260:1266	arg1	mixture					1215:1221	the crude mixture	1205:1221	the crude mixture of highly sialylated multi-antennary glycans	1205:1266	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	3	35	theme	liquid	373:378	arg1	chromatography					380:393	liquid chromatography	373:393	liquid chromatography (LC)	373:398	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	3	35	theme	liquid	373:378	arg1	way					326:328	A common way	317:328	A common way to analytically address this complexity	317:368	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	3	35	theme	liquid	373:378	arg1	LC					396:397	LC	396:397	LC	396:397	A common way to analytically address this complexity is liquid chromatography (LC) in combination with mass spectrometry (MS).
36121379	7	36	theme	liquid	1061:1066	arg1	HILIC					1084:1088	HILIC	1084:1088	HILIC	1084:1088	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	36	theme	liquid	1061:1066	arg1	chromatography					1068:1081	hydrophilic interaction liquid chromatography	1037:1081	hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP)	1037:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	6	37	dep	attempts	928:935	arg1	proven					870:875	proven	870:875	have clearly proven their individual capabilities for glycan analysis	857:925	However, while both LC-MS and IM-MS have clearly proven their individual capabilities for glycan analysis, attempts to combine both methods into a consistent workflow are lacking.
36121379	8	38	theme	α2,6-	1360:1364	arg1	isomers					1394:1400	α2,6- and α2,3-linked sialic acid isomers	1360:1400	α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments	1360:1434	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	8	39	theme	multi-antennary	1244:1258	arg1	glycans					1260:1266	highly sialylated multi-antennary glycans	1226:1266	highly sialylated multi-antennary glycans	1226:1266	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	8	40	theme	sialic	1382:1387	arg1	acid					1389:1392	α2,3-linked sialic acid	1370:1392	α2,3-linked sialic acid	1370:1392	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	1	41	theme	biopolymers	183:193	arg1	classes					172:178	the major classes	162:178	the major classes of biopolymers	162:193	Complex carbohydrates are ubiquitous in nature and represent one of the major classes of biopolymers.
36121379	10	42	theme	N-glycan	1674:1681	arg1	analysis					1683:1690	N-glycan analysis	1674:1690	N-glycan analysis	1674:1690	This feature mapping can confidently assign glycan isomers with multiple sialic acids within one LC-IM-MS run and is fully compatible with existing workflows for N-glycan analysis.
36121379	0	43	theme	Isomers	29:35	arg1	Determination					0:12	Determination	0:12	Determination of Sialic Acid Isomers from Released N-Glycans	0:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	6	44	theme	individual	883:892	arg1	capabilities					894:905	their individual capabilities	877:905	their individual capabilities	877:905	However, while both LC-MS and IM-MS have clearly proven their individual capabilities for glycan analysis, attempts to combine both methods into a consistent workflow are lacking.
36121379	7	45	theme	hydrophilic	1037:1047	arg1	HILIC					1084:1088	HILIC	1084:1088	HILIC	1084:1088	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	45	theme	hydrophilic	1037:1047	arg1	chromatography					1068:1081	hydrophilic interaction liquid chromatography	1037:1081	hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP)	1037:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	8	46	theme	α2,3-linked	1370:1380	arg1	acid					1389:1392	α2,3-linked sialic acid	1370:1392	α2,3-linked sialic acid	1370:1392	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	8	47	theme	crude	1209:1213	arg1	mixture					1215:1221	the crude mixture	1205:1221	the crude mixture of highly sialylated multi-antennary glycans	1205:1266	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	8	48	gly	sialylated	1233:1242	arg1	glycans					1260:1266	highly sialylated multi-antennary glycans	1226:1266	highly sialylated multi-antennary glycans	1226:1266	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	2	49	theme	diverse	220:226	arg1	structures					228:237	highly diverse structures	213:237	highly diverse structures	213:237	They can exhibit highly diverse structures with multiple branched sites as well as a complex regio- and stereochemistry.
36121379	7	50	with	chromatography	1068:1081	arg1	IM-MS					1096:1100	IM-MS	1096:1100	IM-MS	1096:1100	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	0	51	theme	Released	42:49	arg1	N-Glycans					51:59	Released N-Glycans	42:59	Released N-Glycans	42:59	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	4	52	theme	glycan	533:538	arg1	isomers					540:546	glycan isomers	533:546	glycan isomers	533:546	However, MS-based detection often does not provide sufficient information to distinguish glycan isomers.
36121379	7	53	theme	interaction	1049:1059	arg1	HILIC					1084:1088	HILIC	1084:1088	HILIC	1084:1088	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	53	theme	interaction	1049:1059	arg1	chromatography					1068:1081	hydrophilic interaction liquid chromatography	1037:1081	hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP)	1037:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	8	54	theme	acid	1389:1392	arg1	isomers					1394:1400	α2,6- and α2,3-linked sialic acid isomers	1360:1400	α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments	1360:1434	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	5	55	theme	Ion	549:551	arg1	IM-MS					581:585	IM-MS	581:585	IM-MS	581:585	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	55	theme	Ion	549:551	arg1	spectrometry					567:578	Ion mobility-mass spectrometry	549:578	Ion mobility-mass spectrometry (IM-MS)	549:586	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	8	56	theme	characteristic	1411:1424	arg1	fragments					1426:1434	characteristic fragments	1411:1434	characteristic fragments	1411:1434	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	7	57	gly	glycoprotein	1168:1179	arg1	hAGP					1182:1185	hAGP	1182:1185	hAGP	1182:1185	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	57	gly	glycoprotein	1168:1179	arg1	glycoprotein					1168:1179	human alpha-1-acid glycoprotein	1149:1179	human alpha-1-acid glycoprotein (hAGP)	1149:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	5	58	theme	mobility-mass	553:565	arg1	IM-MS					581:585	IM-MS	581:585	IM-MS	581:585	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	58	theme	mobility-mass	553:565	arg1	spectrometry					567:578	Ion mobility-mass spectrometry	549:578	Ion mobility-mass spectrometry (IM-MS)	549:586	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	8	59	theme	glycan	1296:1301	arg1	composition					1303:1313	glycan composition	1296:1313	glycan composition	1296:1313	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	9	60	theme	fucosylation	1498:1509	arg1	assignment					1476:1485	the assignment	1472:1485	the assignment of antenna fucosylation	1472:1509	Further, the technique can support the assignment of antenna fucosylation.
36121379	9	61	theme	antenna	1490:1496	arg1	fucosylation					1498:1509	antenna fucosylation	1490:1509	antenna fucosylation	1490:1509	Further, the technique can support the assignment of antenna fucosylation.
36121379	0	62	theme	Ion	67:69	arg1	Spectrometry					80:91	Ion Mobility Spectrometry	67:91	Ion Mobility Spectrometry	67:91	Determination of Sialic Acid Isomers from Released N-Glycans Using Ion Mobility Spectrometry.
36121379	2	63	theme	branched	253:260	arg1	sites					262:266	multiple branched sites	244:266	multiple branched sites as well as a complex regio- and stereochemistry	244:314	They can exhibit highly diverse structures with multiple branched sites as well as a complex regio- and stereochemistry.
36121379	8	64	used	used	1327:1330	arg2	IMS					1320:1322	IMS	1320:1322	IMS	1320:1322	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
36121379	5	65	theme	isomeric	746:753	arg1	fucosylation					799:810	fucosylation	799:810	fucosylation	799:810	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	65	theme	isomeric	746:753	arg1	sialylation					783:793	sialylation	783:793	sialylation	783:793	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	5	65	theme	isomeric	746:753	arg1	features					762:769	characteristic isomeric glycan features	731:769	characteristic isomeric glycan features such as the sialylation and fucosylation pattern	731:818	Ion mobility-mass spectrometry (IM-MS)─a technique that separates ions based on their size, charge, and shape─has recently shown great potential to solve this problem by identifying characteristic isomeric glycan features such as the sialylation and fucosylation pattern.
36121379	6	66	dep	workflow	979:986	arg1	lacking					992:998	lacking	992:998	are lacking	988:998	However, while both LC-MS and IM-MS have clearly proven their individual capabilities for glycan analysis, attempts to combine both methods into a consistent workflow are lacking.
36121379	2	67	theme	multiple	244:251	arg1	sites					262:266	multiple branched sites	244:266	multiple branched sites as well as a complex regio- and stereochemistry	244:314	They can exhibit highly diverse structures with multiple branched sites as well as a complex regio- and stereochemistry.
36121379	7	68	theme	human	1149:1153	arg1	hAGP					1182:1185	hAGP	1182:1185	hAGP	1182:1185	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	7	68	theme	human	1149:1153	arg1	glycoprotein					1168:1179	human alpha-1-acid glycoprotein	1149:1179	human alpha-1-acid glycoprotein (hAGP)	1149:1186	Here, we close this gap and combine hydrophilic interaction liquid chromatography (HILIC) with IM-MS to analyze the glycan structures released from human alpha-1-acid glycoprotein (hAGP).
36121379	8	69	link	α2,3-linked	1370:1380	arg1	acid					1389:1392	α2,3-linked sialic acid	1370:1392	α2,3-linked sialic acid	1370:1392	HILIC separates the crude mixture of highly sialylated multi-antennary glycans, MS provides information on glycan composition, and IMS is used to distinguish and quantify α2,6- and α2,3-linked sialic acid isomers based on characteristic fragments.
35597280	0	0	theme	amino	88:92	arg1	acids					94:98	nearby amino acids	81:98	nearby amino acids	81:98	O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
35597280	3	1	from	significance	679:690	arg1	TSRs					720:723	TSRs	720:723	TSRs	720:723	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	0	2	theme	nearby	81:86	arg1	acids					94:98	nearby amino acids	81:98	nearby amino acids	81:98	O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
35597280	3	3	theme	O-fucose	695:702	arg1	modification					704:715	O-fucose modification	695:715	O-fucose modification	695:715	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	8	4	theme	TSR3	1488:1491	arg1	domain					1493:1498	the TSR3 domain	1484:1498	the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1484:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	5	5	from	localized	895:903	arg1	addition					875:882	addition	875:882	addition	875:882	In addition, POFUT2 is localized to the endoplasmic reticulum (ER) and only modifies folded TSRs, stabilizing their structures.
35597280	8	6	theme	specific	1460:1467	arg1	acids					1475:1479	specific amino acids	1460:1479	specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1460:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	8	7	from	domain	1493:1498	arg1	thrombospondin-1					1503:1518	thrombospondin-1	1503:1518	thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1503:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	3	8	theme	modification	704:715	arg1	significance					679:690	the biological significance	664:690	the biological significance of O-fucose modification on TSRs	664:723	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	8	9	theme	dynamics	1336:1343	arg1	simulations					1350:1360	molecular dynamics (MD) simulations	1326:1360	molecular dynamics (MD) simulations	1326:1360	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	8	10	theme	Glucose-Fucose	1417:1430	arg1	disaccharide					1432:1443	the Glucose-Fucose disaccharide	1413:1443	the Glucose-Fucose disaccharide	1413:1443	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	9	11	theme	acids	1680:1684	arg1	mutation					1656:1663	mutation	1656:1663	mutation of these amino acids	1656:1684	We also show that mutation of these amino acids reduces the stabilizing effect of the sugars in vitro.
35597280	6	12	theme	quality	1139:1145	arg1	control					1147:1153	quality control	1139:1153	quality control	1139:1153	These observations suggest that POFUT2 is involved in an ER quality control mechanism for TSR folding and that B3GLCT also participates in quality control by providing additional stabilization to TSRs.
35597280	6	13	theme	additional	1168:1177	arg1	stabilization					1179:1191	additional stabilization	1168:1191	additional stabilization	1168:1191	These observations suggest that POFUT2 is involved in an ER quality control mechanism for TSR folding and that B3GLCT also participates in quality control by providing additional stabilization to TSRs.
35597280	2	14	with	disaccharide	503:514	arg1	addition					525:532	the addition	521:532	the addition of glucose	521:543	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	5	15	theme	folded	957:962	arg1	TSRs					964:967	folded TSRs	957:967	folded TSRs	957:967	In addition, POFUT2 is localized to the endoplasmic reticulum (ER) and only modifies folded TSRs, stabilizing their structures.
35597280	9	16	theme	amino	1674:1678	arg1	acids					1680:1684	these amino acids	1668:1684	these amino acids	1668:1684	We also show that mutation of these amino acids reduces the stabilizing effect of the sugars in vitro.
35597280	8	17	theme	MD	1346:1347	arg1	simulations					1350:1360	molecular dynamics (MD) simulations	1326:1360	molecular dynamics (MD) simulations	1326:1360	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	6	18	theme	ER	1057:1058	arg1	mechanism					1076:1084	an ER quality control mechanism	1054:1084	an ER quality control mechanism for TSR folding	1054:1100	These observations suggest that POFUT2 is involved in an ER quality control mechanism for TSR folding and that B3GLCT also participates in quality control by providing additional stabilization to TSRs.
35597280	6	19	theme	control	1068:1074	arg1	mechanism					1076:1084	an ER quality control mechanism	1054:1084	an ER quality control mechanism for TSR folding	1054:1100	These observations suggest that POFUT2 is involved in an ER quality control mechanism for TSR folding and that B3GLCT also participates in quality control by providing additional stabilization to TSRs.
35597280	8	20	from	acids	1475:1479	arg1	domain					1493:1498	the TSR3 domain	1484:1498	the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1484:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	4	21	theme	proteins	832:839	arg1	secretion					814:822	secretion	814:822	secretion of many proteins containing O-fucosylated TSRs	814:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	8	22	gly	O-fucosylation	1553:1566	arg2	site					1581:1584	the O-fucosylation modification site	1549:1584	the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1549:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	6	23	theme	quality	1060:1066	arg1	mechanism					1076:1084	an ER quality control mechanism	1054:1084	an ER quality control mechanism for TSR folding	1054:1100	These observations suggest that POFUT2 is involved in an ER quality control mechanism for TSR folding and that B3GLCT also participates in quality control by providing additional stabilization to TSRs.
35597280	2	24	theme	O-fucose	444:451	arg1	modification					453:464	the O-fucose modification	440:464	the O-fucose modification	440:464	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	0	25	from	motif	35:39	arg1	thrombospondin-1					44:59	thrombospondin-1	44:59	thrombospondin-1	44:59	O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
35597280	4	26	from	cells	756:760	arg1	Knockout					726:733	Knockout	726:733	Knockout	726:733	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	4	27	theme	HEK293T	748:754	arg1	cells					756:760	HEK293T cells	748:760	HEK293T cells	748:760	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	3	28	from	lethality	632:640	arg1	mice					645:648	mice	645:648	mice	645:648	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	1	29	theme	small	174:178	arg1	repeats					155:161	Thrombospondin type-1 repeats	133:161	Thrombospondin type-1 repeats (TSRs)	133:168	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	29	theme	small	174:178	arg1	motifs					188:193	small protein motifs	174:193	small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	174:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	8	30	theme	O-fucosylation	1553:1566	arg1	site					1581:1584	the O-fucosylation modification site	1549:1584	the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1549:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	4	31	theme	O-fucosylated	852:864	arg1	TSRs					866:869	O-fucosylated TSRs	852:869	O-fucosylated TSRs	852:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	2	32	theme	Protein	306:312	arg1	POFUT2					338:343	POFUT2	338:343	POFUT2	338:343	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	2	32	theme	Protein	306:312	arg1	O-fucosyltransferase					314:333	Protein O-fucosyltransferase 2	306:335	Protein O-fucosyltransferase 2 (POFUT2)	306:344	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	1	33	theme	protein	180:186	arg1	repeats					155:161	Thrombospondin type-1 repeats	133:161	Thrombospondin type-1 repeats (TSRs)	133:168	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	33	theme	protein	180:186	arg1	motifs					188:193	small protein motifs	174:193	small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	174:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	0	34	theme	TSR3	30:33	arg1	motif					35:39	the TSR3 motif	26:39	the TSR3 motif in thrombospondin-1	26:59	O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
35597280	9	35	theme	stabilizing	1698:1708	arg1	effect					1710:1715	the stabilizing effect	1694:1715	the stabilizing effect of the sugars in vitro	1694:1738	We also show that mutation of these amino acids reduces the stabilizing effect of the sugars in vitro.
35597280	8	36	theme	NMR	1395:1397	arg1	evidence					1399:1406	crystallographic and NMR evidence	1374:1406	evidence	1399:1406	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	10	37	dep	provide	1752:1758	arg1	participates					1834:1845	participates	1834:1845	participates in quality control mechanisms inside the ER	1834:1889	These data provide mechanistic details regarding the importance of O-fucosylation and how it participates in quality control mechanisms inside the ER.
35597280	4	38	theme	partial	798:804	arg1	loss					806:809	complete or partial loss	786:809	complete or partial loss of secretion of many proteins containing O-fucosylated TSRs	786:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	0	39	theme	disulfide	117:125	arg1	bond					127:130	a disulfide bond	115:130	a disulfide bond	115:130	O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
35597280	10	40	theme	mechanistic	1760:1770	arg1	details					1772:1778	mechanistic details	1760:1778	mechanistic details regarding the importance of O-fucosylation	1760:1821	These data provide mechanistic details regarding the importance of O-fucosylation and how it participates in quality control mechanisms inside the ER.
35597280	2	41	theme	consensus	416:424	arg1	sequence					426:433	the appropriate consensus sequence	400:433	the appropriate consensus sequence	400:433	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	1	42	theme	O-linked	289:296	arg1	fucose					298:303	an O-linked fucose	286:303	an O-linked fucose	286:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	10	43	theme	O-fucosylation	1808:1821	arg1	importance					1794:1803	the importance	1790:1803	the importance of O-fucosylation	1790:1821	These data provide mechanistic details regarding the importance of O-fucosylation and how it participates in quality control mechanisms inside the ER.
35597280	4	44	gly	O-fucosylated	852:864	arg1	TSRs					866:869	O-fucosylated TSRs	852:869	O-fucosylated TSRs	852:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	4	45	theme	secretion	814:822	arg1	loss					806:809	complete or partial loss	786:809	complete or partial loss of secretion of many proteins containing O-fucosylated TSRs	786:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	2	46	theme	O-fucose	372:379	arg1	addition					360:367	the addition	356:367	the addition of O-fucose to TSRs containing the appropriate consensus sequence	356:433	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	2	47	theme	appropriate	404:414	arg1	sequence					426:433	the appropriate consensus sequence	400:433	the appropriate consensus sequence	400:433	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	2	48	theme	glucose	537:543	arg1	addition					525:532	the addition	521:532	the addition of glucose	521:543	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	8	49	theme	amino	1469:1473	arg1	acids					1475:1479	specific amino acids	1460:1479	specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1460:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	8	50	theme	crystallographic	1374:1389	arg1	evidence					1399:1406	crystallographic and NMR evidence	1374:1406	evidence	1399:1406	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	1	51	theme	conserved	210:218	arg1	cysteines					220:228	six conserved cysteines	206:228	six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	206:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	10	52	theme	quality	1850:1856	arg1	mechanisms					1866:1875	quality control mechanisms	1850:1875	quality control mechanisms inside the ER	1850:1889	These data provide mechanistic details regarding the importance of O-fucosylation and how it participates in quality control mechanisms inside the ER.
35597280	9	53	theme	sugars	1724:1729	arg1	in vitro					1731:1738	the sugars in vitro	1720:1738	the sugars in vitro	1720:1738	We also show that mutation of these amino acids reduces the stabilizing effect of the sugars in vitro.
35597280	2	54	contain	containing	389:398	arg1	TSRs					384:387	TSRs	384:387	TSRs containing the appropriate consensus sequence	384:433	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	2	54	contain	containing	389:398	arg2	sequence					426:433	the appropriate consensus sequence	400:433	the appropriate consensus sequence	400:433	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	4	55	theme	many	827:830	arg1	proteins					832:839	many proteins	827:839	many proteins containing O-fucosylated TSRs	827:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	9	56	theme	in vitro	1731:1738	arg1	effect					1710:1715	the stabilizing effect	1694:1715	the stabilizing effect of the sugars in vitro	1694:1738	We also show that mutation of these amino acids reduces the stabilizing effect of the sugars in vitro.
35597280	8	57	theme	modification	1568:1579	arg1	site					1581:1584	the O-fucosylation modification site	1549:1584	the O-fucosylation modification site resulting in protection of a nearby disulfide bond	1549:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	3	58	theme	Pofut2	596:601	arg1	Elimination					581:591	Elimination	581:591	Elimination of Pofut2 in mice	581:609	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	5	59	theme	endoplasmic	912:922	arg1	ER					935:936	ER	935:936	ER	935:936	In addition, POFUT2 is localized to the endoplasmic reticulum (ER) and only modifies folded TSRs, stabilizing their structures.
35597280	5	59	theme	endoplasmic	912:922	arg1	reticulum					924:932	the endoplasmic reticulum	908:932	the endoplasmic reticulum (ER)	908:937	In addition, POFUT2 is localized to the endoplasmic reticulum (ER) and only modifies folded TSRs, stabilizing their structures.
35597280	4	60	contain	containing	841:850	arg1	proteins					832:839	many proteins	827:839	many proteins containing O-fucosylated TSRs	827:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	4	60	contain	containing	841:850	arg2	TSRs					866:869	O-fucosylated TSRs	852:869	O-fucosylated TSRs	852:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	10	61	theme	control	1858:1864	arg1	mechanisms					1866:1875	quality control mechanisms	1850:1875	quality control mechanisms inside the ER	1850:1889	These data provide mechanistic details regarding the importance of O-fucosylation and how it participates in quality control mechanisms inside the ER.
35597280	3	62	theme	embryonic	622:630	arg1	lethality					632:640	embryonic lethality	622:640	embryonic lethality in mice	622:648	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	4	63	theme	POFUT2	738:743	arg1	Knockout					726:733	Knockout	726:733	Knockout	726:733	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	8	64	theme	nearby	1615:1620	arg1	bond					1632:1635	a nearby disulfide bond	1613:1635	a nearby disulfide bond	1613:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	1	65	contain	containing	195:204	arg2	cysteines					220:228	six conserved cysteines	206:228	six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	206:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	65	contain	containing	195:204	arg1	motifs					188:193	small protein motifs	174:193	small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	174:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	65	contain	containing	195:204	arg1	repeats					155:161	Thrombospondin type-1 repeats	133:161	Thrombospondin type-1 repeats (TSRs)	133:168	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	4	66	theme	complete	786:793	arg1	loss					806:809	complete or partial loss	786:809	complete or partial loss of secretion of many proteins containing O-fucosylated TSRs	786:869	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	5	67	from	addition	875:882	arg1	localized					895:903	localized	895:903	localized	895:903	In addition, POFUT2 is localized to the endoplasmic reticulum (ER) and only modifies folded TSRs, stabilizing their structures.
35597280	1	68	theme	Thrombospondin	133:146	arg1	repeats					155:161	Thrombospondin type-1 repeats	133:161	Thrombospondin type-1 repeats (TSRs)	133:168	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	68	theme	Thrombospondin	133:146	arg1	motifs					188:193	small protein motifs	174:193	small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	174:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	68	theme	Thrombospondin	133:146	arg1	TSRs					164:167	TSRs	164:167	TSRs	164:167	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	4	69	from	Knockout	726:733	arg1	cells					756:760	HEK293T cells	748:760	HEK293T cells	748:760	Knockout of POFUT2 in HEK293T cells has been shown to cause complete or partial loss of secretion of many proteins containing O-fucosylated TSRs.
35597280	7	70	theme	sugars	1253:1258	arg1	addition					1235:1242	addition	1235:1242	addition of these sugars	1235:1258	However, the mechanisms by which addition of these sugars result in stabilization are poorly understood.
35597280	3	71	theme	biological	668:677	arg1	significance					679:690	the biological significance	664:690	the biological significance of O-fucose modification on TSRs	664:723	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	8	72	theme	molecular	1326:1334	arg1	simulations					1350:1360	molecular dynamics (MD) simulations	1326:1360	molecular dynamics (MD) simulations	1326:1360	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	1	73	link	O-linked	289:296	arg1	fucose					298:303	an O-linked fucose	286:303	an O-linked fucose	286:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	74	theme	type-1	148:153	arg1	repeats					155:161	Thrombospondin type-1 repeats	133:161	Thrombospondin type-1 repeats (TSRs)	133:168	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	74	theme	type-1	148:153	arg1	motifs					188:193	small protein motifs	174:193	small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose	174:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	74	theme	type-1	148:153	arg1	TSRs					164:167	TSRs	164:167	TSRs	164:167	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	3	75	from	Elimination	581:591	arg1	mice					606:609	mice	606:609	mice	606:609	Elimination of Pofut2 in mice results in embryonic lethality in mice, highlighting the biological significance of O-fucose modification on TSRs.
35597280	8	76	theme	bond	1632:1635	arg1	protection					1599:1608	protection	1599:1608	protection of a nearby disulfide bond	1599:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	2	77	theme	Glucose-Fucose	488:501	arg1	disaccharide					503:514	a Glucose-Fucose disaccharide	486:514	a Glucose-Fucose disaccharide with the addition of glucose	486:543	Protein O-fucosyltransferase 2 (POFUT2) catalyzes the addition of O-fucose to TSRs containing the appropriate consensus sequence, and the O-fucose modification can be elongated to a Glucose-Fucose disaccharide with the addition of glucose by β3-glucosyltransferase (B3GLCT).
35597280	1	78	mod	modified	272:279	arg3	fucose					298:303	an O-linked fucose	286:303	an O-linked fucose	286:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	1	78	mod	modified	272:279	arg1	bonds					254:258	three disulfide bonds	238:258	three disulfide bonds that can be modified with an O-linked fucose	238:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35597280	6	79	theme	TSR	1090:1092	arg1	folding					1094:1100	TSR folding	1090:1100	TSR folding	1090:1100	These observations suggest that POFUT2 is involved in an ER quality control mechanism for TSR folding and that B3GLCT also participates in quality control by providing additional stabilization to TSRs.
35597280	8	80	theme	disulfide	1622:1630	arg1	bond					1632:1635	a nearby disulfide bond	1613:1635	a nearby disulfide bond	1613:1635	Here, we conducted molecular dynamics (MD) simulations and provide crystallographic and NMR evidence that the Glucose-Fucose disaccharide interacts with specific amino acids in the TSR3 domain in thrombospondin-1 that are within proximity to the O-fucosylation modification site resulting in protection of a nearby disulfide bond.
35597280	1	81	theme	disulfide	244:252	arg1	bonds					254:258	three disulfide bonds	238:258	three disulfide bonds that can be modified with an O-linked fucose	238:303	Thrombospondin type-1 repeats (TSRs) are small protein motifs containing six conserved cysteines forming three disulfide bonds that can be modified with an O-linked fucose.
35414481	8	0	dep	predisposition	1053:1066	arg1	BRCA1/2					1083:1089	15 BRCA1/2	1080:1089	15 BRCA1/2	1080:1089	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	0	dep	predisposition	1053:1066	arg1	STK11					1094:1098	5 STK11	1092:1098	5 STK11	1092:1098	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	0	dep	predisposition	1053:1066	arg1	history					1123:1129	a family history	1114:1129	a family history of PDAC	1114:1137	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	0	dep	predisposition	1053:1066	arg1	CDKN2A					1072:1077	77 CDKN2A	1069:1077	77 CDKN2A	1069:1077	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	5	1	theme	spectrometry	656:667	arg1	analysis					669:676	Mass spectrometry analysis	651:676	Mass spectrometry analysis	651:676	Mass spectrometry analysis was performed to determine the total N-glycome for each consecutive sample.
35414481	6	2	theme	relative	856:863	arg1	abundances					865:874	relative abundances	856:874	relative abundances	856:874	Potentially discriminating N-glycans were selected based on our previous cross-sectional analysis and relative abundances were calculated for each glycosylation feature.
35414481	12	3	theme	%	1850:1850	arg1	specificity					1813:1823	a specificity	1811:1823	a specificity of 92%, sensitivity of 49% and accuracy of 90%	1811:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	4	4	theme	consecutive	594:604	arg1	samples					612:618	at least two consecutive serum samples	581:618	at least two consecutive serum samples	581:618	Those, of which at least two consecutive serum samples were available, were included.
35414481	11	5	theme	tri-	1537:1540	arg1	types					1598:1602	specific sialic linkage types	1574:1602	specific sialic linkage types	1574:1602	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	5	theme	tri-	1537:1540	arg1	structures					1562:1571	tri- and tetra-antennary structures	1537:1571	tri- and tetra-antennary structures	1537:1571	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	1	6	theme	early	267:271	arg1	detection					273:281	early detection	267:281	early detection based on solely imaging modalities	267:316	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	12	7	theme	accuracy	1856:1863	arg1	specificity					1813:1823	a specificity	1811:1823	a specificity of 92%, sensitivity of 49% and accuracy of 90%	1811:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	8	8	theme	increased	1188:1196	arg1	risk					1198:1201	>10-fold increased risk	1179:1201	>10-fold increased risk of developing PDAC	1179:1220	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	6	9	theme	previous	818:825	arg1	analysis					843:850	our previous cross-sectional analysis	814:850	our previous cross-sectional analysis	814:850	Potentially discriminating N-glycans were selected based on our previous cross-sectional analysis and relative abundances were calculated for each glycosylation feature.
35414481	3	10	theme	surveillance	542:553	arg1	programs					555:562	two surveillance programs	538:562	two surveillance programs	538:562	METHODS Individuals with a hereditary predisposition to develop PDAC were followed in two surveillance programs.
35414481	1	11	theme	pancreatic	184:193	arg1	PDAC					218:221	PDAC	218:221	PDAC	218:221	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	1	11	theme	pancreatic	184:193	arg1	adenocarcinoma					202:215	developing pancreatic ductal adenocarcinoma	173:215	developing pancreatic ductal adenocarcinoma (PDAC)	173:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	8	12	theme	PDAC	1134:1137	arg1	history					1123:1129	a family history	1114:1129	a family history of PDAC	1114:1137	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	7	13	dep	individuals	936:946	arg1	N = 119					962:968	"FPC-cohort" N = 119	949:968	"FPC-cohort" N = 119; Leiden cohort N = 46	949:990	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46) were included.
35414481	1	14	theme	adenocarcinoma	202:215	arg1	risk					165:168	risk	165:168	risk of developing pancreatic ductal adenocarcinoma (PDAC)	165:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	12	15	theme	of	1845:1846	arg1	%					1870:1870	90%	1868:1870	90%	1868:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	12	15	theme	of	1845:1846	arg1	%					1850:1850	sensitivity of 49%	1833:1850	sensitivity of 49%	1833:1850	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	8	16	theme	PDAC	1217:1220	arg1	risk					1198:1201	>10-fold increased risk	1179:1201	>10-fold increased risk of developing PDAC	1179:1220	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	3	17	with	Individuals	460:470	arg1	predisposition					490:503	a hereditary predisposition	477:503	a hereditary predisposition to develop PDAC	477:519	METHODS Individuals with a hereditary predisposition to develop PDAC were followed in two surveillance programs.
35414481	8	18	theme	genetic	1155:1161	arg1	predisposition					1163:1176	a known genetic predisposition	1147:1176	a known genetic predisposition (>10-fold increased risk of developing PDAC)	1147:1221	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	13	19	from	detection	1928:1936	arg1	program					1965:1971	a pancreas surveillance program	1941:1971	a pancreas surveillance program	1941:1971	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	11	20	dep	decreased	1613:1621	arg1	diantennary					1637:1647	diantennary	1637:1647	diantennary	1637:1647	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	20	dep	decreased	1613:1621	arg1	glycans					1662:1668	complex-type diantennary and bisected glycans	1624:1668	glycans	1662:1668	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	12	21	with	controls	1797:1804	arg1	specificity					1813:1823	a specificity	1811:1823	a specificity of 92%, sensitivity of 49% and accuracy of 90%	1811:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	1	22	theme	BACKGROUND	123:132	arg1	Surveillance					134:145	BACKGROUND Surveillance	123:145	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC)	123:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	13	23	theme	pancreas	1943:1950	arg1	program					1965:1971	a pancreas surveillance program	1941:1971	a pancreas surveillance program	1941:1971	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	0	24	theme	earlier	58:64	arg1	detection					66:74	earlier detection	58:74	earlier detection of pancreatic cancer	58:95	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	9	25	theme	samples	1273:1279	arg1	number					1255:1260	a median number	1246:1260	a median number of 3 serum samples (IQR 3)	1246:1287	From each individual, a median number of 3 serum samples (IQR 3) was collected.
35414481	13	26	theme	early	1922:1926	arg1	detection					1928:1936	early detection	1922:1936	early detection in a pancreas surveillance program	1922:1971	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	1	27	from	risk	165:168	arg1	Surveillance					134:145	BACKGROUND Surveillance	123:145	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC)	123:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	1	27	from	risk	165:168	arg1	individuals					150:160	individuals	150:160	individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC)	150:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	0	28	theme	cancer	90:95	arg1	detection					66:74	earlier detection	58:74	earlier detection of pancreatic cancer	58:95	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	13	29	theme	CONCLUSION	1873:1882	arg1	monitoring					1899:1908	CONCLUSION Serum N-glycan monitoring	1873:1908	CONCLUSION Serum N-glycan monitoring	1873:1908	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	0	30	theme	high-risk	100:108	arg1	individuals					110:120	high-risk individuals	100:120	high-risk individuals	100:120	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	13	31	theme	N-glycan	1890:1897	arg1	monitoring					1899:1908	CONCLUSION Serum N-glycan monitoring	1873:1908	CONCLUSION Serum N-glycan monitoring	1873:1908	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	1	32	from	Surveillance	134:145	arg1	risk					165:168	risk	165:168	risk of developing pancreatic ductal adenocarcinoma (PDAC)	165:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	0	33	theme	Longitudinal	0:11	arg1	changes					13:19	Longitudinal changes	0:19	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals	0:120	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	2	34	theme	high-risk	429:437	arg1	individuals					439:449	high-risk individuals	429:449	high-risk individuals	429:449	We aimed to identify changes in serum glycosylation levels over time to earlier detect PDAC in high-risk individuals.
35414481	4	35	theme	Those	565:569	arg1	available					625:633	available	625:633	available	625:633	Those, of which at least two consecutive serum samples were available, were included.
35414481	7	36	dep	N = 119	962:968	arg1	cohort					978:983	Leiden cohort N = 46	971:990	"FPC-cohort" N = 119; Leiden cohort N = 46	949:990	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46) were included.
35414481	11	37	dep	increased	1512:1520	arg1	decreased					1613:1621	decreased	1613:1621	decreased (complex-type diantennary and bisected glycans)	1613:1669	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	37	dep	increased	1512:1520	arg1	fucosylation					1523:1534	fucosylation	1523:1534	fucosylation	1523:1534	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	12	38	theme	fucosylated	1732:1742	arg1	glycans					1744:1750	tri-antennary fucosylated glycans	1718:1750	tri-antennary fucosylated glycans	1718:1750	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	11	39	theme	specific	1574:1581	arg1	types					1598:1602	specific sialic linkage types	1574:1602	specific sialic linkage types	1574:1602	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	39	theme	specific	1574:1581	arg1	structures					1562:1571	tri- and tetra-antennary structures	1537:1571	tri- and tetra-antennary structures	1537:1571	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	3	40	theme	METHODS	452:458	arg1	Individuals					460:470	METHODS Individuals	452:470	METHODS Individuals with a hereditary predisposition to develop PDAC	452:519	METHODS Individuals with a hereditary predisposition to develop PDAC were followed in two surveillance programs.
35414481	0	41	theme	protein	30:36	arg1	levels					47:52	serum protein N-Glycan levels	24:52	serum protein N-Glycan levels for earlier detection of pancreatic cancer	24:95	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	1	42	theme	imaging	299:305	arg1	modalities					307:316	solely imaging modalities	292:316	solely imaging modalities	292:316	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	6	43	theme	glycosylation	901:913	arg1	feature					915:921	each glycosylation feature	896:921	each glycosylation feature	896:921	Potentially discriminating N-glycans were selected based on our previous cross-sectional analysis and relative abundances were calculated for each glycosylation feature.
35414481	11	44	dep	fucosylation	1523:1534	arg1	types					1598:1602	specific sialic linkage types	1574:1602	specific sialic linkage types	1574:1602	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	44	dep	fucosylation	1523:1534	arg1	structures					1562:1571	tri- and tetra-antennary structures	1537:1571	tri- and tetra-antennary structures	1537:1571	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	10	45	theme	patients	1391:1398	arg1	nine					1371:1374	nine	1371:1374	nine	1371:1374	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	10	45	theme	patients	1391:1398	arg1	%					1379:1379	90%	1377:1379	90%	1377:1379	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	10	45	theme	patients	1391:1398	arg1	patients					1391:1398	these patients	1385:1398	these patients	1385:1398	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	0	46	theme	levels	47:52	arg1	changes					13:19	Longitudinal changes	0:19	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals	0:120	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	7	47	dep	RESULTS	924:930	arg1	individuals					936:946	165 individuals	932:946	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46)	924:991	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46) were included.
35414481	6	48	theme	discriminating	766:779	arg1	N-glycans					781:789	Potentially discriminating N-glycans	754:789	Potentially discriminating N-glycans	754:789	Potentially discriminating N-glycans were selected based on our previous cross-sectional analysis and relative abundances were calculated for each glycosylation feature.
35414481	3	49	theme	hereditary	479:488	arg1	predisposition					490:503	a hereditary predisposition	477:503	a hereditary predisposition to develop PDAC	477:519	METHODS Individuals with a hereditary predisposition to develop PDAC were followed in two surveillance programs.
35414481	4	50	theme	serum	606:610	arg1	samples					612:618	at least two consecutive serum samples	581:618	at least two consecutive serum samples	581:618	Those, of which at least two consecutive serum samples were available, were included.
35414481	10	51	theme	germline	1417:1424	arg1	mutation					1426:1433	a CDKN2A germline mutation	1408:1433	a CDKN2A germline mutation	1408:1433	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	11	52	theme	linkage	1590:1596	arg1	types					1598:1602	specific sialic linkage types	1574:1602	specific sialic linkage types	1574:1602	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	52	theme	linkage	1590:1596	arg1	structures					1562:1571	tri- and tetra-antennary structures	1537:1571	tri- and tetra-antennary structures	1537:1571	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	53	theme	glycosylation	1477:1489	arg1	characteristics					1491:1505	glycosylation characteristics	1477:1505	glycosylation characteristics	1477:1505	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	2	54	theme	serum	366:370	arg1	levels					386:391	serum glycosylation levels	366:391	serum glycosylation levels	366:391	We aimed to identify changes in serum glycosylation levels over time to earlier detect PDAC in high-risk individuals.
35414481	7	55	theme	FPC-cohort	950:959	arg1	N = 119					962:968	"FPC-cohort" N = 119	949:968	"FPC-cohort" N = 119; Leiden cohort N = 46	949:990	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46) were included.
35414481	2	56	from	PDAC	421:424	arg1	individuals					439:449	high-risk individuals	429:449	high-risk individuals	429:449	We aimed to identify changes in serum glycosylation levels over time to earlier detect PDAC in high-risk individuals.
35414481	5	57	theme	Mass	651:654	arg1	analysis					669:676	Mass spectrometry analysis	651:676	Mass spectrometry analysis	651:676	Mass spectrometry analysis was performed to determine the total N-glycome for each consecutive sample.
35414481	12	58	theme	%	1870:1870	arg1	accuracy					1856:1863	accuracy	1856:1863	accuracy	1856:1863	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	12	58	theme	%	1870:1870	arg1	%					1870:1870	90%	1868:1870	90%	1868:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	12	58	theme	%	1870:1870	arg1	%					1850:1850	sensitivity of 49%	1833:1850	sensitivity of 49%	1833:1850	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	12	58	theme	%	1870:1870	arg1	%					1830:1830	92%	1828:1830	92%	1828:1830	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	6	59	theme	cross-sectional	827:841	arg1	analysis					843:850	our previous cross-sectional analysis	814:850	our previous cross-sectional analysis	814:850	Potentially discriminating N-glycans were selected based on our previous cross-sectional analysis and relative abundances were calculated for each glycosylation feature.
35414481	1	60	theme	developing	173:182	arg1	PDAC					218:221	PDAC	218:221	PDAC	218:221	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	1	60	theme	developing	173:182	arg1	adenocarcinoma					202:215	developing pancreatic ductal adenocarcinoma	173:215	developing pancreatic ductal adenocarcinoma (PDAC)	173:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	8	61	theme	family	1116:1121	arg1	history					1123:1129	a family history	1114:1129	a family history of PDAC	1114:1137	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	2	62	from	changes	355:361	arg1	levels					386:391	serum glycosylation levels	366:391	serum glycosylation levels	366:391	We aimed to identify changes in serum glycosylation levels over time to earlier detect PDAC in high-risk individuals.
35414481	11	63	theme	PDAC	1439:1442	arg1	cases					1444:1448	PDAC cases	1439:1448	PDAC cases	1439:1448	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	1	64	theme	ductal	195:200	arg1	PDAC					218:221	PDAC	218:221	PDAC	218:221	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	1	64	theme	ductal	195:200	arg1	adenocarcinoma					202:215	developing pancreatic ductal adenocarcinoma	173:215	developing pancreatic ductal adenocarcinoma (PDAC)	173:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	12	65	theme	%	1830:1830	arg1	specificity					1813:1823	a specificity	1811:1823	a specificity of 92%, sensitivity of 49% and accuracy of 90%	1811:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	5	66	theme	total	709:713	arg1	N-glycome					715:723	the total N-glycome	705:723	the total N-glycome for each consecutive sample	705:751	Mass spectrometry analysis was performed to determine the total N-glycome for each consecutive sample.
35414481	12	67	theme	sensitivity	1833:1843	arg1	%					1870:1870	90%	1868:1870	90%	1868:1870	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	12	67	theme	sensitivity	1833:1843	arg1	%					1850:1850	sensitivity of 49%	1833:1850	sensitivity of 49%	1833:1850	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	8	68	theme	developing	1206:1215	arg1	PDAC					1217:1220	developing PDAC	1206:1220	developing PDAC	1206:1220	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	69	theme	known	1149:1153	arg1	predisposition					1163:1176	a known genetic predisposition	1147:1176	a known genetic predisposition (>10-fold increased risk of developing PDAC)	1147:1221	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	13	70	theme	surveillance	1952:1963	arg1	program					1965:1971	a pancreas surveillance program	1941:1971	a pancreas surveillance program	1941:1971	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	1	71	theme	individuals	150:160	arg1	Surveillance					134:145	BACKGROUND Surveillance	123:145	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC)	123:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	0	72	theme	pancreatic	79:88	arg1	cancer					90:95	pancreatic cancer	79:95	pancreatic cancer	79:95	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	0	73	from	changes	13:19	arg1	individuals					110:120	high-risk individuals	100:120	high-risk individuals	100:120	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	11	74	theme	bisected	1653:1660	arg1	glycans					1662:1668	complex-type diantennary and bisected glycans	1624:1668	glycans	1662:1668	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	5	75	theme	consecutive	734:744	arg1	sample					746:751	each consecutive sample	729:751	each consecutive sample	729:751	Mass spectrometry analysis was performed to determine the total N-glycome for each consecutive sample.
35414481	8	76	theme	genetic	1045:1051	arg1	predisposition					1053:1066	a genetic predisposition	1043:1066	a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11)	1043:1099	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	10	77	contain	carried	1400:1406	arg1	nine					1371:1374	nine	1371:1374	nine	1371:1374	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	10	77	contain	carried	1400:1406	arg1	%					1379:1379	90%	1377:1379	90%	1377:1379	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	10	77	contain	carried	1400:1406	arg2	mutation					1426:1433	a CDKN2A germline mutation	1408:1433	a CDKN2A germline mutation	1408:1433	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	10	77	contain	carried	1400:1406	arg1	patients					1391:1398	these patients	1385:1398	these patients	1385:1398	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	12	78	gly	fucosylated	1732:1742	arg1	glycans					1744:1750	tri-antennary fucosylated glycans	1718:1750	tri-antennary fucosylated glycans	1718:1750	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	9	79	theme	median	1248:1253	arg1	number					1255:1260	a median number	1246:1260	a median number of 3 serum samples (IQR 3)	1246:1287	From each individual, a median number of 3 serum samples (IQR 3) was collected.
35414481	10	80	theme	follow-up	1360:1368	arg1	months					1350:1355	35 months	1347:1355	35 months of follow-up	1347:1368	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35414481	13	81	theme	Serum	1884:1888	arg1	monitoring					1899:1908	CONCLUSION Serum N-glycan monitoring	1873:1908	CONCLUSION Serum N-glycan monitoring	1873:1908	CONCLUSION Serum N-glycan monitoring may support early detection in a pancreas surveillance program.
35414481	2	82	theme	glycosylation	372:384	arg1	levels					386:391	serum glycosylation levels	366:391	serum glycosylation levels	366:391	We aimed to identify changes in serum glycosylation levels over time to earlier detect PDAC in high-risk individuals.
35414481	0	83	theme	serum	24:28	arg1	levels					47:52	serum protein N-Glycan levels	24:52	serum protein N-Glycan levels for earlier detection of pancreatic cancer	24:95	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	9	84	theme	serum	1267:1271	arg1	samples					1273:1279	3 serum samples	1265:1279	3 serum samples (IQR 3)	1265:1287	From each individual, a median number of 3 serum samples (IQR 3) was collected.
35414481	9	84	theme	serum	1267:1271	arg1	IQR					1282:1284	IQR 3	1282:1286	IQR 3	1282:1286	From each individual, a median number of 3 serum samples (IQR 3) was collected.
35414481	7	85	theme	Leiden	971:976	arg1	cohort					978:983	Leiden cohort N = 46	971:990	"FPC-cohort" N = 119; Leiden cohort N = 46	949:990	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46) were included.
35414481	8	86	dep	predisposition	1163:1176	arg1	risk					1198:1201	>10-fold increased risk	1179:1201	>10-fold increased risk of developing PDAC	1179:1220	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	0	87	theme	N-Glycan	38:45	arg1	levels					47:52	serum protein N-Glycan levels	24:52	serum protein N-Glycan levels for earlier detection of pancreatic cancer	24:95	Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
35414481	11	88	theme	tetra-antennary	1546:1560	arg1	types					1598:1602	specific sialic linkage types	1574:1602	specific sialic linkage types	1574:1602	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	88	theme	tetra-antennary	1546:1560	arg1	structures					1562:1571	tri- and tetra-antennary structures	1537:1571	tri- and tetra-antennary structures	1537:1571	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	8	89	contain	had	1039:1041	arg2	68					1105:1106	68	1105:1106	68	1105:1106	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	89	contain	had	1039:1041	arg1	individuals					1027:1037	97 (59%) individuals	1018:1037	97 (59%) individuals	1018:1037	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	89	contain	had	1039:1041	arg1	%					1024:1024	59%	1022:1024	59%	1022:1024	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	89	contain	had	1039:1041	arg2	predisposition					1053:1066	a genetic predisposition	1043:1066	a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11)	1043:1099	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	8	89	contain	had	1039:1041	arg2	%					1111:1111	41%	1109:1111	41%	1109:1111	In total, 97 (59%) individuals had a genetic predisposition (77 CDKN2A, 15 BRCA1/2, 5 STK11) and 68 (41%) a family history of PDAC without a known genetic predisposition (>10-fold increased risk of developing PDAC).
35414481	12	90	theme	largest	1676:1682	arg1	change					1684:1689	The largest change	1672:1689	The largest change over time	1672:1699	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	1	91	contain	has	224:226	arg1	Surveillance					134:145	BACKGROUND Surveillance	123:145	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC)	123:222	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	1	91	contain	has	224:226	arg2	potential					232:240	the potential to improve survival	228:260	the potential to improve survival	228:260	BACKGROUND Surveillance of individuals at risk of developing pancreatic ductal adenocarcinoma (PDAC) has the potential to improve survival, yet early detection based on solely imaging modalities is challenging.
35414481	7	92	theme	"	960:960	arg1	N = 119					962:968	"FPC-cohort" N = 119	949:968	"FPC-cohort" N = 119; Leiden cohort N = 46	949:990	RESULTS 165 individuals ("FPC-cohort" N = 119; Leiden cohort N = 46) were included.
35414481	12	93	theme	tri-antennary	1718:1730	arg1	glycans					1744:1750	tri-antennary fucosylated glycans	1718:1750	tri-antennary fucosylated glycans	1718:1750	The largest change over time was observed for tri-antennary fucosylated glycans, which were able to differentiate cases from controls with a specificity of 92%, sensitivity of 49% and accuracy of 90%.
35414481	11	94	theme	sialic	1583:1588	arg1	types					1598:1602	specific sialic linkage types	1574:1602	specific sialic linkage types	1574:1602	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	11	94	theme	sialic	1583:1588	arg1	structures					1562:1571	tri- and tetra-antennary structures	1537:1571	tri- and tetra-antennary structures	1537:1571	In PDAC cases, compared to all controls, glycosylation characteristics were increased (fucosylation, tri- and tetra-antennary structures, specific sialic linkage types), others decreased (complex-type diantennary and bisected glycans).
35414481	10	95	theme	CDKN2A	1410:1415	arg1	mutation					1426:1433	a CDKN2A germline mutation	1408:1433	a CDKN2A germline mutation	1408:1433	Ten individuals (6%) developed PDAC during 35 months of follow-up; nine (90%) of these patients carried a CDKN2A germline mutation.
35779510	0	0	from	solubility	14:23	arg1	water					53:57	water	53:57	water	53:57	Improving the solubility of myofibrillar proteins in water by destroying and suppressing myosin molecular assembly via glycation.
35779510	7	1	theme	zeta-potential	951:964	arg1	results					1043:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	1	2	theme	self-assembling	154:168	arg1	myosin					142:147	Filamentous myosin	130:147	Filamentous myosin	130:147	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	1	2	theme	self-assembling	154:168	arg1	polymer					170:176	a self-assembling polymer	152:176	a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media	152:263	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	1	3	theme	strength	250:257	arg1	media					259:263	low ionic strength media	240:263	low ionic strength media	240:263	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	6	4	theme	main	884:887	arg1	unfolding					846:854	unfolding	846:854	unfolding of the MPs	846:865	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	6	4	theme	main	884:887	arg1	loss					815:818	the loss	811:818	the loss of α-helix structures	811:840	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	6	4	theme	main	884:887	arg1	reasons					889:895	the main reasons	880:895	the main reasons for MP solubilization	880:917	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	5	5	theme	dispersion	638:647	arg1	stability					649:657	dispersion stability	638:657	dispersion stability	638:657	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	0	6	theme	molecular	96:104	arg1	assembly					106:113	myosin molecular assembly	89:113	myosin molecular assembly	89:113	Improving the solubility of myofibrillar proteins in water by destroying and suppressing myosin molecular assembly via glycation.
35779510	0	7	theme	myosin	89:94	arg1	assembly					106:113	myosin molecular assembly	89:113	myosin molecular assembly	89:113	Improving the solubility of myofibrillar proteins in water by destroying and suppressing myosin molecular assembly via glycation.
35779510	7	8	theme	steric	1101:1106	arg1	hindrance					1108:1116	steric hindrance	1101:1116	steric hindrance	1101:1116	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	6	9	theme	structure	791:799	arg1	analyses					801:808	structure analyses	791:808	structure analyses	791:808	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	5	10	theme	uniform	722:728	arg1	P < 0.05					744:751	P < 0.05	744:751	P < 0.05	744:751	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	5	10	theme	uniform	722:728	arg1	distribution					730:741	more uniform distribution	717:741	more uniform distribution (P < 0.05)	717:752	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	7	11	theme	electrostatic	1074:1086	arg1	repulsion					1088:1096	electrostatic repulsion	1074:1096	electrostatic repulsion	1074:1096	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	6	12	theme	MPs	863:865	arg1	unfolding					846:854	unfolding	846:854	unfolding of the MPs	846:865	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	6	12	theme	MPs	863:865	arg1	loss					815:818	the loss	811:818	the loss of α-helix structures	811:840	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	6	12	theme	MPs	863:865	arg1	reasons					889:895	the main reasons	880:895	the main reasons for MP solubilization	880:917	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	7	13	theme	filamentous	1143:1153	arg1	aggregates					1162:1171	disintegrate existing filamentous myosin aggregates	1121:1171	disintegrate existing filamentous myosin aggregates	1121:1171	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	2	14	from	solubility	350:359	arg1	water					371:375	water	371:375	water	371:375	This study was aimed at investigating if glycation has the potential to improve the solubility of MPs in water.
35779510	7	15	theme	further	1185:1191	arg1	behavior					1207:1214	further self-assembly behavior	1185:1214	further self-assembly behavior	1185:1214	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	7	16	theme	self-assembly	1193:1205	arg1	behavior					1207:1214	further self-assembly behavior	1185:1214	further self-assembly behavior	1185:1214	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	5	17	theme	higher	616:621	arg1	solubility					623:632	a higher solubility	614:632	a higher solubility	614:632	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	6	18	dep	secondary	768:776	arg1	analyses					801:808	structure analyses	791:808	structure analyses	791:808	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	1	19	theme	myofibrillar	192:203	arg1	MPs					215:217	MPs	215:217	MPs	215:217	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	1	19	theme	myofibrillar	192:203	arg1	proteins					205:212	myofibrillar proteins	192:212	myofibrillar proteins (MPs)	192:218	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	7	20	theme	observation	1031:1041	arg1	results					1043:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	4	21	theme	amino	550:554	arg1	analyses					561:568	amino acid analyses	550:568	amino acid analyses	550:568	The conjugation was verified by SDS-PAGE, FT-IR and amino acid analyses.
35779510	3	22	from	37 °C	491:495	arg1	conditions					477:486	wet reaction conditions	464:486	wet reaction conditions at 37 °C	464:495	MPs were conjugated with monosaccharides, oligosaccharides, and polysaccharides under wet reaction conditions at 37 °C.
35779510	5	23	from	solubility	623:632	arg1	water					662:666	water	662:666	water	662:666	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	3	24	theme	wet	464:466	arg1	conditions					477:486	wet reaction conditions	464:486	wet reaction conditions at 37 °C	464:495	MPs were conjugated with monosaccharides, oligosaccharides, and polysaccharides under wet reaction conditions at 37 °C.
35779510	5	25	theme	smaller	691:697	arg1	size					708:711	smaller particle size	691:711	smaller particle size	691:711	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	3	26	theme	reaction	468:475	arg1	conditions					477:486	wet reaction conditions	464:486	wet reaction conditions at 37 °C	464:495	MPs were conjugated with monosaccharides, oligosaccharides, and polysaccharides under wet reaction conditions at 37 °C.
35779510	0	27	theme	proteins	41:48	arg1	solubility					14:23	the solubility	10:23	the solubility of myofibrillar proteins in water	10:57	Improving the solubility of myofibrillar proteins in water by destroying and suppressing myosin molecular assembly via glycation.
35779510	4	28	theme	acid	556:559	arg1	analyses					561:568	amino acid analyses	550:568	amino acid analyses	550:568	The conjugation was verified by SDS-PAGE, FT-IR and amino acid analyses.
35779510	5	29	theme	particle	699:706	arg1	size					708:711	smaller particle size	691:711	smaller particle size	691:711	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	0	30	theme	myofibrillar	28:39	arg1	proteins					41:48	myofibrillar proteins	28:48	myofibrillar proteins	28:48	Improving the solubility of myofibrillar proteins in water by destroying and suppressing myosin molecular assembly via glycation.
35779510	5	31	from	stability	649:657	arg1	water					662:666	water	662:666	water	662:666	MPs conjugated with dextran (DX) exhibited a higher solubility and dispersion stability in water, which corresponded to smaller particle size and more uniform distribution (P < 0.05).
35779510	7	32	theme	myosin	1155:1160	arg1	aggregates					1162:1171	disintegrate existing filamentous myosin aggregates	1121:1171	disintegrate existing filamentous myosin aggregates	1121:1171	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	7	33	theme	microscopy	991:1000	arg1	results					1043:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	7	34	theme	disintegrate	1121:1132	arg1	aggregates					1162:1171	disintegrate existing filamentous myosin aggregates	1121:1171	disintegrate existing filamentous myosin aggregates	1121:1171	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	7	35	theme	force	1014:1018	arg1	microscopy					1020:1029	atomic force microscopy	1007:1029	atomic force microscopy	1007:1029	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	6	36	theme	structures	831:840	arg1	unfolding					846:854	unfolding	846:854	unfolding of the MPs	846:865	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	6	36	theme	structures	831:840	arg1	loss					815:818	the loss	811:818	the loss of α-helix structures	811:840	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	6	36	theme	structures	831:840	arg1	reasons					889:895	the main reasons	880:895	the main reasons for MP solubilization	880:917	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	7	37	theme	existing	1134:1141	arg1	aggregates					1162:1171	disintegrate existing filamentous myosin aggregates	1121:1171	disintegrate existing filamentous myosin aggregates	1121:1171	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	6	38	theme	MP	901:902	arg1	solubilization					904:917	MP solubilization	901:917	MP solubilization	901:917	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	7	39	theme	microscopy	1020:1029	arg1	results					1043:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results	947:1049	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	6	40	theme	α-helix	823:829	arg1	structures					831:840	α-helix structures	823:840	α-helix structures	823:840	According to secondary and tertiary structure analyses, the loss of α-helix structures and unfolding of the MPs appear to be the main reasons for MP solubilization.
35779510	7	41	theme	laser	976:980	arg1	microscopy					991:1000	confocal laser scanning microscopy	967:1000	confocal laser scanning microscopy	967:1000	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	2	42	contain	has	317:319	arg1	glycation					307:315	glycation	307:315	glycation	307:315	This study was aimed at investigating if glycation has the potential to improve the solubility of MPs in water.
35779510	2	42	contain	has	317:319	arg2	potential					325:333	the potential to improve the solubility of MPs in water	321:375	the potential to improve the solubility of MPs in water	321:375	This study was aimed at investigating if glycation has the potential to improve the solubility of MPs in water.
35779510	7	43	theme	scanning	982:989	arg1	microscopy					991:1000	confocal laser scanning microscopy	967:1000	confocal laser scanning microscopy	967:1000	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	1	44	theme	Filamentous	130:140	arg1	myosin					142:147	Filamentous myosin	130:147	Filamentous myosin	130:147	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	1	44	theme	Filamentous	130:140	arg1	polymer					170:176	a self-assembling polymer	152:176	a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media	152:263	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	7	45	theme	atomic	1007:1012	arg1	microscopy					1020:1029	atomic force microscopy	1007:1029	atomic force microscopy	1007:1029	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	7	46	theme	confocal	967:974	arg1	microscopy					991:1000	confocal laser scanning microscopy	967:1000	confocal laser scanning microscopy	967:1000	Additionally, according to the zeta-potential, confocal laser scanning microscopy, and atomic force microscopy observation results, glycation can provide electrostatic repulsion or steric hindrance to disintegrate existing filamentous myosin aggregates and inhibit further self-assembly behavior.
35779510	2	47	theme	MPs	364:366	arg1	solubility					350:359	the solubility	346:359	the solubility of MPs in water	346:375	This study was aimed at investigating if glycation has the potential to improve the solubility of MPs in water.
35779510	1	48	theme	low	240:242	arg1	strength					250:257	low ionic strength	240:257	low ionic strength media	240:263	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35779510	1	49	theme	ionic	244:248	arg1	strength					250:257	low ionic strength	240:257	low ionic strength media	240:263	Filamentous myosin is a self-assembling polymer that prevents myofibrillar proteins (MPs) from functioning in low ionic strength media.
35545700	0	0	theme	specificity	82:92	arg1	communities					43:53	microbial communities	33:53	microbial communities	33:53	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	0	0	theme	specificity	82:92	arg1	function					60:67	a function	58:67	a function of substrate specificity through fluorescent labelling	58:122	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	4	1	theme	labelled	678:685	arg1	glycans					687:693	2-AB labelled glycans	673:693	2-AB labelled glycans of different monosaccharide composition	673:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	1	theme	labelled	678:685	arg1	degrees					736:742	degrees	736:742	degrees of acetylation and polymerization	736:776	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	6	2	theme	techniques	1070:1079	arg1	combination					1041:1051	this combination	1036:1051	this combination of complementary techniques	1036:1079	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	2	3	theme	powerful	346:353	arg1	route					355:359	a powerful route	344:359	a powerful route towards this target	344:379	To this aim fluorescent labelling of glycans may provide a powerful route towards this target.
35545700	1	4	theme	complexities	245:256	arg1	unravelling					226:236	the continued unravelling	212:236	the continued unravelling of the complexities in the human gut microbiome	212:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	0	5	theme	substrate	72:80	arg1	specificity					82:92	substrate specificity	72:92	substrate specificity	72:92	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	1	6	theme	metabolism	165:174	arg1	tool					192:195	an effective tool	179:195	an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome	179:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	1	6	theme	metabolism	165:174	arg1	study					129:133	The study	125:133	The study of specific glycan uptake and metabolism	125:174	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	4	7	theme	microbes	571:578	arg1	strain					531:536	single strain	524:536	single strain	524:536	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	7	theme	microbes	571:578	arg1	fermentations					554:566	co-cultured fermentations	542:566	co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus	542:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	0	8	theme	fluorescent	102:112	arg1	labelling					114:122	fluorescent labelling	102:122	fluorescent labelling	102:122	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	4	9	theme	common	589:594	arg1	human-gut					596:604	the common human-gut	585:604	the common human-gut derived Bacteroides genus	585:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	10	theme	polymerization	763:776	arg1	glycans					687:693	2-AB labelled glycans	673:693	2-AB labelled glycans of different monosaccharide composition	673:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	10	theme	polymerization	763:776	arg1	degrees					736:742	degrees	736:742	degrees of acetylation and polymerization	736:776	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	5	11	from	level	1017:1021	arg1	metabolism					944:953	the metabolism	940:953	the metabolism of labelled glycans in both supernatants and at a single cell level	940:1021	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	1	12	theme	human	265:269	arg1	microbiome					275:284	the human gut microbiome	261:284	the human gut microbiome	261:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	4	13	from	human-gut	596:604	arg1	microbes					571:578	microbes	571:578	microbes from the common human-gut derived Bacteroides genus	571:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	13	from	human-gut	596:604	arg1	strain					531:536	single strain	524:536	single strain	524:536	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	13	from	human-gut	596:604	arg1	fermentations					554:566	co-cultured fermentations	542:566	co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus	542:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	6	14	theme	substrate	1120:1128	arg1	specificity					1130:1140	substrate specificity	1120:1140	substrate specificity	1120:1140	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	5	15	theme	microscopy	862:871	arg1	techniques					892:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	5	16	theme	cytometry	882:890	arg1	techniques					892:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	5	17	theme	multifaceted	791:802	arg1	approach					804:811	a multifaceted approach	789:811	a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques	789:901	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	5	18	from	metabolism	944:953	arg1	supernatants					983:994	both supernatants	978:994	both supernatants	978:994	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	4	19	from	fermentations	554:566	arg1	human-gut					596:604	the common human-gut	585:604	the common human-gut derived Bacteroides genus	585:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	5	20	theme	chromatography	827:840	arg1	techniques					892:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	3	21	theme	glycans	510:516	arg1	degradation					486:496	microbial degradation	476:496	microbial degradation of labelled glycans	476:516	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	4	22	theme	co-cultured	542:552	arg1	fermentations					554:566	co-cultured fermentations	542:566	co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus	542:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	5	23	theme	labelled	958:965	arg1	glycans					967:973	labelled glycans	958:973	labelled glycans	958:973	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	1	24	theme	effective	182:190	arg1	tool					192:195	an effective tool	179:195	an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome	179:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	1	24	theme	effective	182:190	arg1	study					129:133	The study	125:133	The study of specific glycan uptake and metabolism	125:174	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	0	25	theme	Technical	0:8	arg1	pipeline					10:17	Technical pipeline	0:17	Technical pipeline	0:17	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	1	26	theme	gut	271:273	arg1	microbiome					275:284	the human gut microbiome	261:284	the human gut microbiome	261:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	1	27	from	microbiome	275:284	arg1	unravelling					226:236	the continued unravelling	212:236	the continued unravelling of the complexities in the human gut microbiome	212:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	2	28	theme	fluorescent	299:309	arg1	labelling					311:319	fluorescent labelling	299:319	fluorescent labelling of glycans	299:330	To this aim fluorescent labelling of glycans may provide a powerful route towards this target.
35545700	3	29	theme	fluorescent	413:423	arg1	2-AB					449:452	2-AB	449:452	2-AB	449:452	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	3	29	theme	fluorescent	413:423	arg1	2-aminobenzamide					431:446	2-aminobenzamide	431:446	the fluorescent label 2-aminobenzamide (2-AB)	409:453	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	5	30	theme	mass	843:846	arg1	spectrometry					848:859	mass spectrometry	843:859	mass spectrometry	843:859	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	6	31	theme	microbial	1171:1179	arg1	communities					1181:1191	microbial communities	1171:1191	microbial communities	1171:1191	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	5	32	theme	spectrometry	848:859	arg1	techniques					892:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	chromatography, mass spectrometry, microscopy and flow cytometry techniques	827:901	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	5	33	theme	glycans	967:973	arg1	metabolism					944:953	the metabolism	940:953	the metabolism of labelled glycans in both supernatants and at a single cell level	940:1021	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	4	34	theme	acetylation	747:757	arg1	glycans					687:693	2-AB labelled glycans	673:693	2-AB labelled glycans of different monosaccharide composition	673:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	34	theme	acetylation	747:757	arg1	degrees					736:742	degrees	736:742	degrees of acetylation and polymerization	736:776	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	3	35	theme	labelled	501:508	arg1	glycans					510:516	labelled glycans	501:516	labelled glycans	501:516	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	4	36	from	strain	531:536	arg1	human-gut					596:604	the common human-gut	585:604	the common human-gut derived Bacteroides genus	585:630	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	37	theme	different	698:706	arg1	composition					723:733	different monosaccharide composition	698:733	different monosaccharide composition	698:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	1	38	from	complexities	245:256	arg1	microbiome					275:284	the human gut microbiome	261:284	the human gut microbiome	261:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	6	39	theme	complementary	1056:1068	arg1	techniques					1070:1079	complementary techniques	1056:1079	complementary techniques	1056:1079	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	0	40	theme	microbial	33:41	arg1	communities					43:53	microbial communities	33:53	microbial communities	33:53	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	0	40	theme	microbial	33:41	arg1	function					60:67	a function	58:67	a function of substrate specificity through fluorescent labelling	58:122	Technical pipeline for screening microbial communities as a function of substrate specificity through fluorescent labelling.
35545700	5	41	theme	flow	877:880	arg1	cytometry					882:890	flow cytometry	877:890	flow cytometry	877:890	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	4	42	theme	monosaccharide	708:721	arg1	composition					723:733	different monosaccharide composition	698:733	different monosaccharide composition	698:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	3	43	dep	2-aminobenzamide	431:446	arg1	label					425:429	label	425:429	label	425:429	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	3	44	theme	microbial	476:484	arg1	degradation					486:496	microbial degradation	476:496	microbial degradation of labelled glycans	476:516	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	4	45	theme	single	524:529	arg1	strain					531:536	single strain	524:536	single strain	524:536	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	3	46	used	used	404:407	arg2	we					388:389	we	388:389	we	388:389	Here, we successfully used the fluorescent label 2-aminobenzamide (2-AB) to monitor and study microbial degradation of labelled glycans.
35545700	6	47	dep	role	1150:1153	arg1	plays					1158:1162	plays	1158:1162	plays within microbial communities	1158:1191	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	5	48	theme	single	1005:1010	arg1	level					1017:1021	a single cell level	1003:1021	a single cell level	1003:1021	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	4	49	theme	2-AB	673:676	arg1	glycans					687:693	2-AB labelled glycans	673:693	2-AB labelled glycans of different monosaccharide composition	673:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	49	theme	2-AB	673:676	arg1	degrees					736:742	degrees	736:742	degrees of acetylation and polymerization	736:776	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	2	50	theme	glycans	324:330	arg1	labelling					311:319	fluorescent labelling	299:319	fluorescent labelling of glycans	299:330	To this aim fluorescent labelling of glycans may provide a powerful route towards this target.
35545700	1	51	theme	continued	216:224	arg1	unravelling					226:236	the continued unravelling	212:236	the continued unravelling of the complexities in the human gut microbiome	212:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	1	52	from	unravelling	226:236	arg1	microbiome					275:284	the human gut microbiome	261:284	the human gut microbiome	261:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	5	53	theme	cell	1012:1015	arg1	level					1017:1021	a single cell level	1003:1021	a single cell level	1003:1021	Utilizing a multifaceted approach that combines chromatography, mass spectrometry, microscopy and flow cytometry techniques, it is possible to better understand the metabolism of labelled glycans in both supernatants and at a single cell level.
35545700	1	54	theme	specific	138:145	arg1	uptake					154:159	specific glycan uptake	138:159	specific glycan uptake	138:159	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	4	55	theme	composition	723:733	arg1	glycans					687:693	2-AB labelled glycans	673:693	2-AB labelled glycans of different monosaccharide composition	673:733	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	4	55	theme	composition	723:733	arg1	degrees					736:742	degrees	736:742	degrees of acetylation and polymerization	736:776	Both single strain and co-cultured fermentations of microbes from the common human-gut derived Bacteroides genus, are able to grow when supplemented with 2-AB labelled glycans of different monosaccharide composition, degrees of acetylation and polymerization.
35545700	6	56	theme	specificity	1130:1140	arg1	role					1150:1153	the role	1146:1153	the role it plays within microbial communities	1146:1191	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	6	56	theme	specificity	1130:1140	arg1	understanding					1103:1115	the understanding	1099:1115	the understanding of substrate specificity	1099:1140	We envisage this combination of complementary techniques will help further the understanding of substrate specificity and the role it plays within microbial communities.
35545700	1	57	theme	glycan	147:152	arg1	uptake					154:159	specific glycan uptake	138:159	specific glycan uptake	138:159	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	1	58	theme	uptake	154:159	arg1	tool					192:195	an effective tool	179:195	an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome	179:284	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
35545700	1	58	theme	uptake	154:159	arg1	study					129:133	The study	125:133	The study of specific glycan uptake and metabolism	125:174	The study of specific glycan uptake and metabolism is an effective tool in aiding with the continued unravelling of the complexities in the human gut microbiome.
36135182	6	0	contain	had	777:779	arg1	activator					752:760	the plasminogen activator	736:760	the plasminogen activator in the mutants	736:775	When the N398 site was eliminated, the plasminogen activator in the mutants had their activities reduced to ~40%.
36135182	6	0	contain	had	777:779	arg2	activities					787:796	their activities	781:796	their activities	781:796	When the N398 site was eliminated, the plasminogen activator in the mutants had their activities reduced to ~40%.
36135182	3	1	from	effect	419:424	arg1	activation					463:472	plasminogen activation	451:472	plasminogen activation	451:472	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	3	1	from	effect	419:424	arg1	sensitivity					482:492	fibrin sensitivity	475:492	fibrin sensitivity	475:492	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	3	2	theme	fibrin	475:480	arg1	activation					463:472	plasminogen activation	451:472	plasminogen activation	451:472	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	3	2	theme	fibrin	475:480	arg1	sensitivity					482:492	fibrin sensitivity	475:492	fibrin sensitivity	475:492	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	4	3	theme	logical	554:560	arg1	design					572:577	A logical structure design	552:577	A logical structure design	552:577	A logical structure design was performed in this study.
36135182	1	4	contain	has	114:116	arg1	α2					102:103	Bat plasminogen activators α2	75:103	Bat plasminogen activators α2 (DSPAα2)	75:112	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	4	contain	has	114:116	arg2	value					143:147	extremely high medicinal value	118:147	extremely high medicinal value	118:147	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	4	contain	has	114:116	arg2	protein					184:190	a powerful natural thrombolytic protein	152:190	a powerful natural thrombolytic protein	152:190	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	4	contain	has	114:116	arg1	DSPAα2					106:111	DSPAα2	106:111	DSPAα2	106:111	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	9	5	gly	N-glycosylation	1123:1137	arg1	DSPAα2					1175:1180	DSPAα2	1175:1180	DSPAα2	1175:1180	This study confirms that N-glycosylation affects the biochemical function of DSPAα2, which provides a reference for subsequent applications of DSPAα2.
36135182	9	6	theme	subsequent	1214:1223	arg1	applications					1225:1236	subsequent applications	1214:1236	subsequent applications of DSPAα2	1214:1246	This study confirms that N-glycosylation affects the biochemical function of DSPAα2, which provides a reference for subsequent applications of DSPAα2.
36135182	7	7	theme	N185	824:827	arg1	site					829:832	the N185 site	820:832	the N185 site	820:832	When the N185 site was inactivated, there was a weak decrease in the plasminogen activation of its mutant, while the fibrin sensitivity significantly decreased by ~10-fold.
36135182	3	8	theme	N-glycosylation	374:388	arg1	sites					390:394	the N-glycosylation sites	370:394	the N-glycosylation sites	370:394	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	2	9	theme	high-mannose-type	294:310	arg1	N-glycans					312:320	high-mannose-type N-glycans	294:320	high-mannose-type N-glycans	294:320	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	5	10	theme	double	636:641	arg1	mutant					643:648	one double mutant	632:648	one double mutant	632:648	Four single mutants and one double mutant were constructed and expressed in Pichia pastoris.
36135182	7	11	theme	plasminogen	884:894	arg1	activation					896:905	the plasminogen activation	880:905	the plasminogen activation of its mutant	880:919	When the N185 site was inactivated, there was a weak decrease in the plasminogen activation of its mutant, while the fibrin sensitivity significantly decreased by ~10-fold.
36135182	3	12	theme	physicochemical	514:528	arg1	properties					530:539	the physicochemical properties	510:539	the physicochemical properties of DSPAα2	510:549	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	2	13	theme	N-glycans	312:320	arg1	classes					283:289	its non-human classes	269:289	its non-human classes of high-mannose-type N-glycans	269:320	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	3	14	gly	N-glycosylation	374:388	arg2	sites					390:394	the N-glycosylation sites	370:394	the N-glycosylation sites	370:394	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	1	15	theme	Bat	75:77	arg1	α2					102:103	Bat plasminogen activators α2	75:103	Bat plasminogen activators α2 (DSPAα2)	75:112	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	15	theme	Bat	75:77	arg1	DSPAα2					106:111	DSPAα2	106:111	DSPAα2	106:111	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	16	theme	powerful	154:161	arg1	value					143:147	extremely high medicinal value	118:147	extremely high medicinal value	118:147	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	16	theme	powerful	154:161	arg1	protein					184:190	a powerful natural thrombolytic protein	152:190	a powerful natural thrombolytic protein	152:190	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	4	17	theme	structure	562:570	arg1	design					572:577	A logical structure design	552:577	A logical structure design	552:577	A logical structure design was performed in this study.
36135182	9	18	theme	DSPAα2	1175:1180	arg1	function					1163:1170	the biochemical function	1147:1170	the biochemical function	1147:1170	This study confirms that N-glycosylation affects the biochemical function of DSPAα2, which provides a reference for subsequent applications of DSPAα2.
36135182	1	19	theme	plasminogen	79:89	arg1	α2					102:103	Bat plasminogen activators α2	75:103	Bat plasminogen activators α2 (DSPAα2)	75:112	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	19	theme	plasminogen	79:89	arg1	DSPAα2					106:111	DSPAα2	106:111	DSPAα2	106:111	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	20	theme	natural	163:169	arg1	value					143:147	extremely high medicinal value	118:147	extremely high medicinal value	118:147	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	20	theme	natural	163:169	arg1	protein					184:190	a powerful natural thrombolytic protein	152:190	a powerful natural thrombolytic protein	152:190	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	0	21	theme	N-Glycosylation	10:24	arg1	Sites					26:30	Different N-Glycosylation Sites	0:30	Different N-Glycosylation Sites	0:30	Different N-Glycosylation Sites Reduce the Activity of Recombinant DSPAα2.
36135182	1	22	theme	activators	91:100	arg1	α2					102:103	Bat plasminogen activators α2	75:103	Bat plasminogen activators α2 (DSPAα2)	75:112	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	22	theme	activators	91:100	arg1	DSPAα2					106:111	DSPAα2	106:111	DSPAα2	106:111	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	23	theme	thrombolytic	171:182	arg1	value					143:147	extremely high medicinal value	118:147	extremely high medicinal value	118:147	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	23	theme	thrombolytic	171:182	arg1	protein					184:190	a powerful natural thrombolytic protein	152:190	a powerful natural thrombolytic protein	152:190	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	0	24	theme	Different	0:8	arg1	Sites					26:30	Different N-Glycosylation Sites	0:30	Different N-Glycosylation Sites	0:30	Different N-Glycosylation Sites Reduce the Activity of Recombinant DSPAα2.
36135182	5	25	theme	single	613:618	arg1	mutants					620:626	Four single mutants	608:626	Four single mutants	608:626	Four single mutants and one double mutant were constructed and expressed in Pichia pastoris.
36135182	6	26	theme	plasminogen	740:750	arg1	activator					752:760	the plasminogen activator	736:760	the plasminogen activator in the mutants	736:775	When the N398 site was eliminated, the plasminogen activator in the mutants had their activities reduced to ~40%.
36135182	7	27	theme	weak	863:866	arg1	decrease					868:875	a weak decrease	861:875	a weak decrease in the plasminogen activation of its mutant	861:919	When the N185 site was inactivated, there was a weak decrease in the plasminogen activation of its mutant, while the fibrin sensitivity significantly decreased by ~10-fold.
36135182	2	28	dep	has	219:221	arg1	N398					259:262	N398	259:262	N398	259:262	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	2	28	dep	has	219:221	arg1	N185					250:253	N185	250:253	N185	250:253	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	2	29	theme	non-human	273:281	arg1	classes					283:289	its non-human classes	269:289	its non-human classes of high-mannose-type N-glycans	269:320	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	3	30	theme	chain	442:446	arg1	effect					419:424	the effect	415:424	the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity	415:492	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	8	31	dep	resistance	1057:1066	arg1	the					1050:1052	the	1050:1052	the	1050:1052	Neither N-glycosylation nor deglycosylation mutations changed the pH resistance or heat resistance of DSPAα2.
36135182	5	32	theme	Pichia	684:689	arg1	pastoris					691:698	Pichia pastoris	684:698	Pichia pastoris	684:698	Four single mutants and one double mutant were constructed and expressed in Pichia pastoris.
36135182	2	33	theme	N-glycosylation	227:241	arg1	sites					243:247	two N-glycosylation sites	223:247	two N-glycosylation sites	223:247	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	2	34	gly	N-glycosylation	227:241	arg2	sites					243:247	two N-glycosylation sites	223:247	two N-glycosylation sites	223:247	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	2	34	gly	N-glycosylation	227:241	arg2	two					223:225	two	223:225	two	223:225	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	8	35	theme	pH	1054:1055	arg1	resistance					1057:1066	pH resistance	1054:1066	pH resistance	1054:1066	Neither N-glycosylation nor deglycosylation mutations changed the pH resistance or heat resistance of DSPAα2.
36135182	6	36	from	activator	752:760	arg1	mutants					769:775	the mutants	765:775	the mutants	765:775	When the N398 site was eliminated, the plasminogen activator in the mutants had their activities reduced to ~40%.
36135182	0	37	theme	Recombinant	55:65	arg1	DSPAα2					67:72	Recombinant DSPAα2	55:72	Recombinant DSPAα2	55:72	Different N-Glycosylation Sites Reduce the Activity of Recombinant DSPAα2.
36135182	8	38	theme	heat	1071:1074	arg1	resistance					1076:1085	heat resistance	1071:1085	heat resistance	1071:1085	Neither N-glycosylation nor deglycosylation mutations changed the pH resistance or heat resistance of DSPAα2.
36135182	8	39	theme	DSPAα2	1090:1095	arg1	resistance					1057:1066	pH resistance	1054:1066	pH resistance	1054:1066	Neither N-glycosylation nor deglycosylation mutations changed the pH resistance or heat resistance of DSPAα2.
36135182	8	39	theme	DSPAα2	1090:1095	arg1	resistance					1076:1085	heat resistance	1071:1085	heat resistance	1071:1085	Neither N-glycosylation nor deglycosylation mutations changed the pH resistance or heat resistance of DSPAα2.
36135182	2	40	theme	immune	332:337	arg1	responses					339:347	immune responses	332:347	immune responses	332:347	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	2	41	theme	wild-type	202:210	arg1	DSPAα2					212:217	wild-type DSPAα2	202:217	wild-type DSPAα2	202:217	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	7	42	theme	fibrin	932:937	arg1	sensitivity					939:949	the fibrin sensitivity	928:949	the fibrin sensitivity	928:949	When the N185 site was inactivated, there was a weak decrease in the plasminogen activation of its mutant, while the fibrin sensitivity significantly decreased by ~10-fold.
36135182	7	43	from	decrease	868:875	arg1	activation					896:905	the plasminogen activation	880:905	the plasminogen activation of its mutant	880:919	When the N185 site was inactivated, there was a weak decrease in the plasminogen activation of its mutant, while the fibrin sensitivity significantly decreased by ~10-fold.
36135182	3	44	theme	DSPAα2	544:549	arg1	properties					530:539	the physicochemical properties	510:539	the physicochemical properties of DSPAα2	510:549	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	9	45	theme	biochemical	1151:1161	arg1	function					1163:1170	the biochemical function	1147:1170	the biochemical function	1147:1170	This study confirms that N-glycosylation affects the biochemical function of DSPAα2, which provides a reference for subsequent applications of DSPAα2.
36135182	9	46	theme	DSPAα2	1241:1246	arg1	applications					1225:1236	subsequent applications	1214:1236	subsequent applications of DSPAα2	1214:1246	This study confirms that N-glycosylation affects the biochemical function of DSPAα2, which provides a reference for subsequent applications of DSPAα2.
36135182	1	47	theme	high	128:131	arg1	value					143:147	extremely high medicinal value	118:147	extremely high medicinal value	118:147	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	47	theme	high	128:131	arg1	protein					184:190	a powerful natural thrombolytic protein	152:190	a powerful natural thrombolytic protein	152:190	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	2	48	contain	has	219:221	arg1	DSPAα2					212:217	wild-type DSPAα2	202:217	wild-type DSPAα2	202:217	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	2	48	contain	has	219:221	arg2	sites					243:247	two N-glycosylation sites	223:247	two N-glycosylation sites	223:247	However, wild-type DSPAα2 has two N-glycosylation sites (N185 and N398) and its non-human classes of high-mannose-type N-glycans may cause immune responses in vivo.
36135182	8	49	theme	deglycosylation	1016:1030	arg1	mutations					1032:1040	deglycosylation mutations	1016:1040	deglycosylation mutations	1016:1040	Neither N-glycosylation nor deglycosylation mutations changed the pH resistance or heat resistance of DSPAα2.
36135182	3	50	theme	N-glycan	433:440	arg1	chain					442:446	its N-glycan chain	429:446	its N-glycan chain	429:446	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	1	51	theme	medicinal	133:141	arg1	value					143:147	extremely high medicinal value	118:147	extremely high medicinal value	118:147	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	1	51	theme	medicinal	133:141	arg1	protein					184:190	a powerful natural thrombolytic protein	152:190	a powerful natural thrombolytic protein	152:190	Bat plasminogen activators α2 (DSPAα2) has extremely high medicinal value as a powerful natural thrombolytic protein.
36135182	3	52	theme	plasminogen	451:461	arg1	activation					463:472	plasminogen activation	451:472	plasminogen activation	451:472	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	3	52	theme	plasminogen	451:461	arg1	sensitivity					482:492	fibrin sensitivity	475:492	fibrin sensitivity	475:492	By mutating the N-glycosylation sites, we aimed to study the effect of its N-glycan chain on plasminogen activation, fibrin sensitivity, and to observe the physicochemical properties of DSPAα2.
36135182	0	53	theme	DSPAα2	67:72	arg1	Activity					43:50	the Activity	39:50	the Activity of Recombinant DSPAα2	39:72	Different N-Glycosylation Sites Reduce the Activity of Recombinant DSPAα2.
36135182	7	54	theme	mutant	914:919	arg1	activation					896:905	the plasminogen activation	880:905	the plasminogen activation of its mutant	880:919	When the N185 site was inactivated, there was a weak decrease in the plasminogen activation of its mutant, while the fibrin sensitivity significantly decreased by ~10-fold.
35945033	9	0	theme	peptide	2184:2190	arg1	analysis					2200:2207	peptide mapping analysis	2184:2207	peptide mapping analysis	2184:2207	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	8	1	theme	mouse	1937:1941	arg1	serum					1943:1947	mouse serum	1937:1947	mouse serum	1937:1947	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	2	2	theme	vertebrate	410:419	arg1	N-glycosylation					429:443	vertebrate protein N-glycosylation	410:443	vertebrate protein N-glycosylation	410:443	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	1	3	theme	eukaryotic	299:308	arg1	origins					310:316	different eukaryotic origins	289:316	different eukaryotic origins	289:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	6	4	dep	Dyella	1603:1608	arg1	japonicum					1610:1618	Dyella japonicum	1603:1618	Dyella japonicum (Dj)	1603:1623	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	5	5	theme	enzymatic	1333:1341	arg1	properties					1343:1352	significantly improved enzymatic properties	1310:1352	significantly improved enzymatic properties	1310:1352	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	4	6	theme	deuterium	953:961	arg1	exchange					963:970	hydrogen deuterium exchange	944:970	hydrogen deuterium exchange mass spectrometry (HDX-MS)	944:997	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	1	7	gly	glycoproteins	224:236	arg1	glycoproteins					224:236	glycoproteins	224:236	glycoproteins	224:236	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	8	8	theme	Rc	1818:1819	arg1	versatility					1796:1806	The versatility	1792:1806	The versatility of PNGase Rc	1792:1819	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	4	9	theme	mass	972:975	arg1	HDX-MS					991:996	HDX-MS	991:996	HDX-MS	991:996	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	9	theme	mass	972:975	arg1	spectrometry					977:988	hydrogen deuterium exchange mass spectrometry	944:988	hydrogen deuterium exchange mass spectrometry (HDX-MS)	944:997	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	7	10	gly	glycoproteins	1678:1690	arg1	peroxidase					1704:1713	horseradish peroxidase	1692:1713	horseradish peroxidase	1692:1713	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	10	gly	glycoproteins	1678:1690	arg1	lactoferrin					1726:1736	bovine lactoferrin	1719:1736	bovine lactoferrin	1719:1736	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	10	gly	glycoproteins	1678:1690	arg1	glycoproteins					1678:1690	the glycoproteins horseradish peroxidase and bovine lactoferrin	1674:1736	the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h)	1674:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	3	11	theme	PNGases	855:861	arg1	lack					838:841	the lack	834:841	the lack of suitable PNGases	834:861	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	8	12	theme	nematode	1963:1970	arg1	elegans					1987:1993	the soil nematode Caenorhabditis elegans	1954:1993	the soil nematode Caenorhabditis elegans	1954:1993	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	9	13	dep	model	2068:2072	arg1	possess					2112:2118	possess	2112:2118	possess more disulfide bonds	2112:2139	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	7	14	theme	PNGase	1764:1769	arg1	Dj					1771:1772	PNGase Dj	1764:1772	PNGase Dj (10 min vs. 6 h)	1764:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	4	15	theme	enzymatic	1027:1035	arg1	release					1037:1043	a highly efficient enzymatic release	1008:1043	a highly efficient enzymatic release of N-glycans at low pH values	1008:1073	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	7	16	gly	deglycosylate	1660:1672	arg1	peroxidase					1704:1713	horseradish peroxidase	1692:1713	horseradish peroxidase	1692:1713	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	16	gly	deglycosylate	1660:1672	arg1	lactoferrin					1726:1736	bovine lactoferrin	1719:1736	bovine lactoferrin	1719:1736	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	16	gly	deglycosylate	1660:1672	arg1	glycoproteins					1678:1690	the glycoproteins horseradish peroxidase and bovine lactoferrin	1674:1736	the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h)	1674:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	0	17	theme	hydrogen	135:142	arg1	exchange					154:161	hydrogen deuterium exchange	135:161	hydrogen deuterium exchange	135:161	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	5	18	theme	unstudied	1178:1186	arg1	H+					1230:1231	PNGase H+	1223:1231	PNGase H+	1223:1231	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	18	theme	unstudied	1178:1186	arg1	N-glycanase					1210:1220	a previously unstudied superacidic bacterial N-glycanase	1165:1220	a previously unstudied superacidic bacterial N-glycanase (PNGase H+ )	1165:1233	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	7	19	theme	faster	1752:1757	arg1	peroxidase					1704:1713	horseradish peroxidase	1692:1713	horseradish peroxidase	1692:1713	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	19	theme	faster	1752:1757	arg1	lactoferrin					1726:1736	bovine lactoferrin	1719:1736	bovine lactoferrin	1719:1736	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	19	theme	faster	1752:1757	arg1	glycoproteins					1678:1690	the glycoproteins horseradish peroxidase and bovine lactoferrin	1674:1736	the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h)	1674:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	9	20	theme	disulfide	2021:2029	arg1	bonds					2031:2035	only two disulfide bonds	2012:2035	only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds)	2012:2140	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	9	21	theme	improved	2253:2260	arg1	yield					2285:2289	the improved recombinant expression yield	2249:2289	the improved recombinant expression yield of PNGase Rc	2249:2302	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	5	22	theme	bacterial	1200:1208	arg1	H+					1230:1231	PNGase H+	1223:1231	PNGase H+	1223:1231	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	22	theme	bacterial	1200:1208	arg1	N-glycanase					1210:1220	a previously unstudied superacidic bacterial N-glycanase	1165:1220	a previously unstudied superacidic bacterial N-glycanase (PNGase H+ )	1165:1233	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	0	23	theme	glycoproteins	193:205	arg1	exchange					154:161	hydrogen deuterium exchange	135:161	hydrogen deuterium exchange	135:161	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	0	23	theme	glycoproteins	193:205	arg1	analysis					98:105	rapid analysis	92:105	rapid analysis of eukaryotic N-glycans	92:129	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	9	24	theme	mapping	2192:2198	arg1	analysis					2200:2207	peptide mapping analysis	2184:2207	peptide mapping analysis	2184:2207	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	9	25	theme	expression	2274:2283	arg1	yield					2285:2289	the improved recombinant expression yield	2249:2289	the improved recombinant expression yield of PNGase Rc	2249:2302	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	0	26	theme	spectrometry	168:179	arg1	analysis					181:188	mass spectrometry analysis	163:188	mass spectrometry analysis	163:188	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	3	27	theme	limited	689:695	arg1	candidates					704:713	only limited PNGase candidates	684:713	only limited PNGase candidates	684:713	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	8	28	theme	diverse	1868:1874	arg1	array					1876:1880	a diverse array	1866:1880	a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans	1866:1993	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	9	29	theme	AlphaFold	2050:2058	arg1	model					2068:2072	the AlphaFold protein model	2046:2072	the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds)	2046:2140	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	6	30	theme	recombinant	1426:1436	arg1	Rc					1445:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	3	31	theme	N-glycans	733:741	arg1	analysis					743:750	N-glycans analysis	733:750	N-glycans analysis	733:750	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	1	32	from	analysis	212:219	arg1	origins					310:316	different eukaryotic origins	289:316	different eukaryotic origins	289:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	7	33	theme	horseradish	1692:1702	arg1	peroxidase					1704:1713	horseradish peroxidase	1692:1713	horseradish peroxidase	1692:1713	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	33	theme	horseradish	1692:1702	arg1	glycoproteins					1678:1690	the glycoproteins horseradish peroxidase and bovine lactoferrin	1674:1736	the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h)	1674:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	9	34	theme	protein	2060:2066	arg1	model					2068:2072	the AlphaFold protein model	2046:2072	the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds)	2046:2140	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	9	35	theme	Rc	2301:2302	arg1	yield					2285:2289	the improved recombinant expression yield	2249:2289	the improved recombinant expression yield of PNGase Rc	2249:2302	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	2	36	gly	glycoproteins	661:673	arg1	glycoproteins					661:673	glycoproteins	661:673	glycoproteins	661:673	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	37	theme	enzymatic	580:588	arg1	tools					590:594	indispensable enzymatic tools	566:594	indispensable enzymatic tools	566:594	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	37	theme	enzymatic	580:588	arg1	amidases					536:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases	478:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases)	478:553	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	5	38	theme	PNGase	1387:1392	arg1	variants					1397:1404	previously described PNGase H+ variants	1366:1404	previously described PNGase H+ variants	1366:1404	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	0	39	theme	rapid	92:96	arg1	analysis					98:105	rapid analysis	92:105	rapid analysis of eukaryotic N-glycans	92:129	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	8	40	theme	peach	1901:1905	arg1	fruit					1907:1911	peach fruit	1901:1911	peach fruit	1901:1911	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	0	41	gly	glycoproteins	193:205	arg1	glycoproteins					193:205	glycoproteins	193:205	glycoproteins	193:205	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	7	42	dep	Dj	1771:1772	arg1	10 min					1775:1780	10 min	1775:1780	10 min	1775:1780	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	42	dep	Dj	1771:1772	arg1	6 h					1786:1788	6 h	1786:1788	6 h	1786:1788	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	2	43	theme	asparagine-linked	609:625	arg1	N-glycans					645:653	N-glycans	645:653	N-glycans	645:653	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	43	theme	asparagine-linked	609:625	arg1	oligosaccharides					627:642	asparagine-linked oligosaccharides	609:642	asparagine-linked oligosaccharides (N-glycans) from glycoproteins	609:673	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	9	44	theme	other	2086:2090	arg1	PNGases					2104:2110	all other superacidic PNGases	2082:2110	all other superacidic PNGases	2082:2110	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	4	45	theme	chromatography-mass	884:902	arg1	LC-MS					918:922	LC-MS	918:922	LC-MS	918:922	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	45	theme	chromatography-mass	884:902	arg1	spectrometry					904:915	liquid chromatography-mass spectrometry	877:915	liquid chromatography-mass spectrometry (LC-MS) workflows	877:933	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	2	46	theme	bacterial	478:486	arg1	tools					590:594	indispensable enzymatic tools	566:594	indispensable enzymatic tools	566:594	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	46	theme	bacterial	478:486	arg1	PNGases					546:552	PNGases	546:552	PNGases	546:552	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	46	theme	bacterial	478:486	arg1	amidases					536:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases	478:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases)	478:553	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	0	47	theme	N-glycans	121:129	arg1	exchange					154:161	hydrogen deuterium exchange	135:161	hydrogen deuterium exchange	135:161	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	0	47	theme	N-glycans	121:129	arg1	analysis					98:105	rapid analysis	92:105	rapid analysis of eukaryotic N-glycans	92:129	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	8	48	theme	trumpet	1919:1925	arg1	mushroom					1927:1934	king trumpet mushroom	1914:1934	king trumpet mushroom	1914:1934	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	0	49	theme	PNGase	0:5	arg1	H + variant					7:17	PNGase H + variant	0:17	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.	0:206	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	1	50	theme	unbiased	326:333	arg1	workflows					357:365	unbiased and robust analytical workflows	326:365	unbiased and robust analytical workflows	326:365	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	6	51	from	Dyella	1603:1608	arg1	variant					1590:1596	the currently used PNGase H+ variant	1561:1596	the currently used PNGase H+ variant from Dyella japonicum (Dj)	1561:1623	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	6	52	theme	%	1537:1537	arg1	increase					1539:1546	~56% increase	1534:1546	~56% increase	1534:1546	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	6	52	theme	%	1537:1537	arg1	activity					1524:1531	higher specific activity	1508:1531	higher specific activity (~56% increase)	1508:1547	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	1	53	theme	robust	339:344	arg1	workflows					357:365	unbiased and robust analytical workflows	326:365	unbiased and robust analytical workflows	326:365	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	7	54	theme	Recombinant	1626:1636	arg1	Rc					1645:1646	Recombinant PNGase Rc	1626:1646	Recombinant PNGase Rc	1626:1646	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	4	55	theme	structural	1107:1116	arg1	analysis					1118:1125	the comprehensive structural analysis	1089:1125	the comprehensive structural analysis of glycoproteins	1089:1142	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	0	56	theme	improved	52:59	arg1	efficiency					77:86	improved deglycosylation efficiency	52:86	improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins	52:205	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	3	57	theme	plant	786:790	arg1	N-glycans					809:817	plant and invertebrate N-glycans	786:817	plant and invertebrate N-glycans	786:817	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	2	58	theme	functional	387:396	arg1	analysis					398:405	The structural and functional analysis	368:405	The structural and functional analysis of vertebrate protein N-glycosylation	368:443	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	5	59	contain	has	1306:1308	arg1	H+					1230:1231	PNGase H+	1223:1231	PNGase H+	1223:1231	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	59	contain	has	1306:1308	arg2	properties					1343:1352	significantly improved enzymatic properties	1310:1352	significantly improved enzymatic properties	1310:1352	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	59	contain	has	1306:1308	arg1	N-glycanase					1210:1220	a previously unstudied superacidic bacterial N-glycanase	1165:1220	a previously unstudied superacidic bacterial N-glycanase (PNGase H+ )	1165:1233	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	2	60	theme	peptide-N4-	488:498	arg1	tools					590:594	indispensable enzymatic tools	566:594	indispensable enzymatic tools	566:594	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	60	theme	peptide-N4-	488:498	arg1	PNGases					546:552	PNGases	546:552	PNGases	546:552	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	60	theme	peptide-N4-	488:498	arg1	amidases					536:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases	478:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases)	478:553	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	6	61	theme	PNGase	1580:1585	arg1	variant					1590:1596	the currently used PNGase H+ variant	1561:1596	the currently used PNGase H+ variant from Dyella japonicum (Dj)	1561:1623	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	1	62	theme	N-glycosylation	268:282	arg1	analysis					212:219	The analysis	208:219	The analysis of glycoproteins	208:236	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	1	62	theme	N-glycosylation	268:282	arg1	comparison					246:255	the comparison	242:255	the comparison of protein N-glycosylation from different eukaryotic origins	242:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	6	63	theme	soluble	1418:1424	arg1	Rc					1445:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	2	64	theme	protein	421:427	arg1	N-glycosylation					429:443	vertebrate protein N-glycosylation	410:443	vertebrate protein N-glycosylation	410:443	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	1	65	theme	different	289:297	arg1	origins					310:316	different eukaryotic origins	289:316	different eukaryotic origins	289:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	3	66	theme	invertebrate	796:807	arg1	N-glycans					809:817	plant and invertebrate N-glycans	786:817	plant and invertebrate N-glycans	786:817	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	6	67	theme	Active	1407:1412	arg1	Rc					1445:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	5	68	theme	improved	1324:1331	arg1	properties					1343:1352	significantly improved enzymatic properties	1310:1352	significantly improved enzymatic properties	1310:1352	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	8	69	theme	soil	1958:1961	arg1	elegans					1987:1993	the soil nematode Caenorhabditis elegans	1954:1993	the soil nematode Caenorhabditis elegans	1954:1993	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	6	70	theme	specific	1515:1522	arg1	increase					1539:1546	~56% increase	1534:1546	~56% increase	1534:1546	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	6	70	theme	specific	1515:1522	arg1	activity					1524:1531	higher specific activity	1508:1531	higher specific activity (~56% increase)	1508:1547	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	4	71	theme	hydrogen	944:951	arg1	exchange					963:970	hydrogen deuterium exchange	944:970	hydrogen deuterium exchange mass spectrometry (HDX-MS)	944:997	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	6	72	theme	higher	1467:1472	arg1	3.8-fold					1489:1496	3.8-fold	1489:1496	3.8-fold	1489:1496	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	6	72	theme	higher	1467:1472	arg1	level					1482:1486	a higher protein level	1465:1486	a higher protein level (3.8-fold)	1465:1497	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	8	73	theme	Caenorhabditis	1972:1985	arg1	elegans					1987:1993	the soil nematode Caenorhabditis elegans	1954:1993	the soil nematode Caenorhabditis elegans	1954:1993	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	9	74	theme	possible	2224:2231	arg1	explanation					2233:2243	a possible explanation	2222:2243	a possible explanation for the improved recombinant expression yield of PNGase Rc	2222:2302	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	2	75	theme	structural	372:381	arg1	analysis					398:405	The structural and functional analysis	368:405	The structural and functional analysis of vertebrate protein N-glycosylation	368:443	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	8	76	theme	PNGase	1811:1816	arg1	Rc					1818:1819	PNGase Rc	1811:1819	PNGase Rc	1811:1819	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	4	77	theme	exchange	963:970	arg1	HDX-MS					991:996	HDX-MS	991:996	HDX-MS	991:996	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	77	theme	exchange	963:970	arg1	spectrometry					977:988	hydrogen deuterium exchange mass spectrometry	944:988	hydrogen deuterium exchange mass spectrometry (HDX-MS)	944:997	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	0	78	theme	deuterium	144:152	arg1	exchange					154:161	hydrogen deuterium exchange	135:161	hydrogen deuterium exchange	135:161	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	1	79	theme	glycoproteins	224:236	arg1	analysis					212:219	The analysis	208:219	The analysis of glycoproteins	208:236	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	1	79	theme	glycoproteins	224:236	arg1	comparison					246:255	the comparison	242:255	the comparison of protein N-glycosylation from different eukaryotic origins	242:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	4	80	theme	efficient	1017:1025	arg1	release					1037:1043	a highly efficient enzymatic release	1008:1043	a highly efficient enzymatic release of N-glycans at low pH values	1008:1073	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	3	81	theme	suitable	846:853	arg1	PNGases					855:861	suitable PNGases	846:861	suitable PNGases	846:861	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	0	82	theme	mass	163:166	arg1	analysis					181:188	mass spectrometry analysis	163:188	mass spectrometry analysis	163:188	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	5	83	theme	superacidic	1188:1198	arg1	H+					1230:1231	PNGase H+	1223:1231	PNGase H+	1223:1231	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	83	theme	superacidic	1188:1198	arg1	N-glycanase					1210:1220	a previously unstudied superacidic bacterial N-glycanase	1165:1220	a previously unstudied superacidic bacterial N-glycanase (PNGase H+ )	1165:1233	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	3	84	theme	PNGase	697:702	arg1	candidates					704:713	only limited PNGase candidates	684:713	only limited PNGase candidates	684:713	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	7	85	theme	bovine	1719:1724	arg1	lactoferrin					1726:1736	bovine lactoferrin	1719:1736	bovine lactoferrin	1719:1736	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	85	theme	bovine	1719:1724	arg1	glycoproteins					1678:1690	the glycoproteins horseradish peroxidase and bovine lactoferrin	1674:1736	the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h)	1674:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	9	86	theme	bonds	2031:2035	arg1	presence					2000:2007	The presence	1996:2007	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds)	1996:2140	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	9	87	theme	recombinant	2262:2272	arg1	yield					2285:2289	the improved recombinant expression yield	2249:2289	the improved recombinant expression yield of PNGase Rc	2249:2302	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	1	88	from	comparison	246:255	arg1	origins					310:316	different eukaryotic origins	289:316	different eukaryotic origins	289:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	1	89	from	origins	310:316	arg1	analysis					212:219	The analysis	208:219	The analysis of glycoproteins	208:236	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	1	89	from	origins	310:316	arg1	N-glycosylation					268:282	protein N-glycosylation	260:282	protein N-glycosylation from different eukaryotic origins	260:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	1	89	from	origins	310:316	arg1	comparison					246:255	the comparison	242:255	the comparison of protein N-glycosylation from different eukaryotic origins	242:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	6	90	theme	PNGase	1438:1443	arg1	Rc					1445:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc	1407:1446	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	2	91	link	asparagine-linked	609:625	arg1	N-glycans					645:653	N-glycans	645:653	N-glycans	645:653	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	91	link	asparagine-linked	609:625	arg1	oligosaccharides					627:642	asparagine-linked oligosaccharides	609:642	asparagine-linked oligosaccharides (N-glycans) from glycoproteins	609:673	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	9	92	theme	PNGase	2294:2299	arg1	Rc					2301:2302	PNGase Rc	2294:2302	PNGase Rc	2294:2302	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	6	93	theme	higher	1508:1513	arg1	increase					1539:1546	~56% increase	1534:1546	~56% increase	1534:1546	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	6	93	theme	higher	1508:1513	arg1	activity					1524:1531	higher specific activity	1508:1531	higher specific activity (~56% increase)	1508:1547	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	0	94	from	Rudaea	24:29	arg1	H + variant					7:17	PNGase H + variant	0:17	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.	0:206	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	5	95	theme	described	1377:1385	arg1	variants					1397:1404	previously described PNGase H+ variants	1366:1404	previously described PNGase H+ variants	1366:1404	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	8	96	theme	samples	1885:1891	arg1	array					1876:1880	a diverse array	1866:1880	a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans	1866:1993	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	2	97	theme	indispensable	566:578	arg1	tools					590:594	indispensable enzymatic tools	566:594	indispensable enzymatic tools	566:594	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	97	theme	indispensable	566:578	arg1	amidases					536:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases	478:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases)	478:553	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	5	98	theme	H+	1394:1395	arg1	variants					1397:1404	previously described PNGase H+ variants	1366:1404	previously described PNGase H+ variants	1366:1404	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	9	99	contain	possess	2112:2118	arg1	PNGases					2104:2110	all other superacidic PNGases	2082:2110	all other superacidic PNGases	2082:2110	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	9	99	contain	possess	2112:2118	arg2	bonds					2135:2139	more disulfide bonds	2120:2139	more disulfide bonds	2120:2139	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	0	100	theme	eukaryotic	110:119	arg1	N-glycans					121:129	eukaryotic N-glycans	110:129	eukaryotic N-glycans	110:129	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	5	101	theme	soil	1256:1259	arg1	bacterium					1261:1269	the soil bacterium Rudaea cellulosilytica (Rc)	1252:1297	the soil bacterium Rudaea cellulosilytica (Rc)	1252:1297	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	4	102	theme	N-glycans	1048:1056	arg1	release					1037:1043	a highly efficient enzymatic release	1008:1043	a highly efficient enzymatic release of N-glycans at low pH values	1008:1073	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	5	103	theme	PNGase	1223:1228	arg1	H+					1230:1231	PNGase H+	1223:1231	PNGase H+	1223:1231	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	103	theme	PNGase	1223:1228	arg1	N-glycanase					1210:1220	a previously unstudied superacidic bacterial N-glycanase	1165:1220	a previously unstudied superacidic bacterial N-glycanase (PNGase H+ )	1165:1233	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	4	104	theme	low	1061:1063	arg1	values					1068:1073	low pH values	1061:1073	low pH values	1061:1073	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	5	105	dep	bacterium	1261:1269	arg1	cellulosilytica					1278:1292	Rudaea cellulosilytica	1271:1292	the soil bacterium Rudaea cellulosilytica (Rc)	1252:1297	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	105	dep	bacterium	1261:1269	arg1	Rc					1295:1296	Rc	1295:1296	Rc	1295:1296	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	9	106	theme	superacidic	2092:2102	arg1	PNGases					2104:2110	all other superacidic PNGases	2082:2110	all other superacidic PNGases	2082:2110	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	4	107	theme	liquid	877:882	arg1	LC-MS					918:922	LC-MS	918:922	LC-MS	918:922	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	107	theme	liquid	877:882	arg1	spectrometry					904:915	liquid chromatography-mass spectrometry	877:915	liquid chromatography-mass spectrometry (LC-MS) workflows	877:933	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	108	theme	pH	1065:1066	arg1	values					1068:1073	low pH values	1061:1073	low pH values	1061:1073	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	8	109	theme	king	1914:1917	arg1	mushroom					1927:1934	king trumpet mushroom	1914:1934	king trumpet mushroom	1914:1934	The versatility of PNGase Rc was demonstrated by releasing N-glycans from a diverse array of samples such as peach fruit, king trumpet mushroom, mouse serum, and the soil nematode Caenorhabditis elegans.
35945033	0	110	dep	analysis	98:105	arg1	analysis					181:188	mass spectrometry analysis	163:188	mass spectrometry analysis	163:188	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	4	111	theme	glycoproteins	1130:1142	arg1	analysis					1118:1125	the comprehensive structural analysis	1089:1125	the comprehensive structural analysis of glycoproteins	1089:1142	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	9	112	theme	intact	2167:2172	arg1	mass-					2174:2178	intact mass-	2167:2178	intact mass-	2167:2178	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	2	113	theme	asparagine	525:534	arg1	tools					590:594	indispensable enzymatic tools	566:594	indispensable enzymatic tools	566:594	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	113	theme	asparagine	525:534	arg1	PNGases					546:552	PNGases	546:552	PNGases	546:552	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	113	theme	asparagine	525:534	arg1	amidases					536:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases	478:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases)	478:553	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	9	114	theme	disulfide	2125:2133	arg1	bonds					2135:2139	more disulfide bonds	2120:2139	more disulfide bonds	2120:2139	The presence of only two disulfide bonds shown in the AlphaFold protein model (so far all other superacidic PNGases possess more disulfide bonds) could be corroborated by intact mass- and peptide mapping analysis and provides a possible explanation for the improved recombinant expression yield of PNGase Rc.
35945033	2	115	theme	N-acetyl-β-glucosaminyl	500:522	arg1	tools					590:594	indispensable enzymatic tools	566:594	indispensable enzymatic tools	566:594	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	115	theme	N-acetyl-β-glucosaminyl	500:522	arg1	PNGases					546:552	PNGases	546:552	PNGases	546:552	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	115	theme	N-acetyl-β-glucosaminyl	500:522	arg1	amidases					536:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases	478:543	bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases)	478:553	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	1	116	theme	analytical	346:355	arg1	workflows					357:365	unbiased and robust analytical workflows	326:365	unbiased and robust analytical workflows	326:365	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	7	117	theme	PNGase	1638:1643	arg1	Rc					1645:1646	Recombinant PNGase Rc	1626:1646	Recombinant PNGase Rc	1626:1646	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	4	118	gly	glycoproteins	1130:1142	arg1	glycoproteins					1130:1142	glycoproteins	1130:1142	glycoproteins	1130:1142	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	119	theme	comprehensive	1093:1105	arg1	analysis					1118:1125	the comprehensive structural analysis	1089:1125	the comprehensive structural analysis of glycoproteins	1089:1142	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	6	120	theme	protein	1474:1480	arg1	3.8-fold					1489:1496	3.8-fold	1489:1496	3.8-fold	1489:1496	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	6	120	theme	protein	1474:1480	arg1	level					1482:1486	a higher protein level	1465:1486	a higher protein level (3.8-fold)	1465:1497	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	0	121	theme	deglycosylation	61:75	arg1	efficiency					77:86	improved deglycosylation efficiency	52:86	improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins	52:205	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	5	122	theme	Rudaea	1271:1276	arg1	cellulosilytica					1278:1292	Rudaea cellulosilytica	1271:1292	the soil bacterium Rudaea cellulosilytica (Rc)	1252:1297	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	5	122	theme	Rudaea	1271:1276	arg1	Rc					1295:1296	Rc	1295:1296	Rc	1295:1296	Herein, we describe a previously unstudied superacidic bacterial N-glycanase (PNGase H+ ) originating from the soil bacterium Rudaea cellulosilytica (Rc), which has significantly improved enzymatic properties compared to previously described PNGase H+ variants.
35945033	0	123	with	H + variant	7:17	arg1	efficiency					77:86	improved deglycosylation efficiency	52:86	improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins	52:205	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	7	124	dep	glycoproteins	1678:1690	arg1	peroxidase					1704:1713	horseradish peroxidase	1692:1713	horseradish peroxidase	1692:1713	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	124	dep	glycoproteins	1678:1690	arg1	lactoferrin					1726:1736	bovine lactoferrin	1719:1736	bovine lactoferrin	1719:1736	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	7	124	dep	glycoproteins	1678:1690	arg1	glycoproteins					1678:1690	the glycoproteins horseradish peroxidase and bovine lactoferrin	1674:1736	the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h)	1674:1789	Recombinant PNGase Rc was able to deglycosylate the glycoproteins horseradish peroxidase and bovine lactoferrin significantly faster than PNGase Dj (10 min vs. 6 h).
35945033	0	125	dep	Rudaea	24:29	arg1	cellulosilytica					31:45	Rudaea cellulosilytica	24:45	Rudaea cellulosilytica	24:45	PNGase H + variant from Rudaea cellulosilytica with improved deglycosylation efficiency for rapid analysis of eukaryotic N-glycans and hydrogen deuterium exchange mass spectrometry analysis of glycoproteins.
35945033	4	126	theme	spectrometry	904:915	arg1	spectrometry					977:988	hydrogen deuterium exchange mass spectrometry	944:988	hydrogen deuterium exchange mass spectrometry (HDX-MS)	944:997	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	4	126	theme	spectrometry	904:915	arg1	workflows					925:933	liquid chromatography-mass spectrometry (LC-MS) workflows	877:933	liquid chromatography-mass spectrometry (LC-MS) workflows	877:933	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35945033	6	127	theme	H+	1587:1588	arg1	variant					1590:1596	the currently used PNGase H+ variant	1561:1596	the currently used PNGase H+ variant from Dyella japonicum (Dj)	1561:1623	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	1	128	theme	protein	260:266	arg1	N-glycosylation					268:282	protein N-glycosylation	260:282	protein N-glycosylation from different eukaryotic origins	260:316	The analysis of glycoproteins and the comparison of protein N-glycosylation from different eukaryotic origins require unbiased and robust analytical workflows.
35945033	2	129	from	glycoproteins	661:673	arg1	N-glycans					645:653	N-glycans	645:653	N-glycans	645:653	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	2	129	from	glycoproteins	661:673	arg1	oligosaccharides					627:642	asparagine-linked oligosaccharides	609:642	asparagine-linked oligosaccharides (N-glycans) from glycoproteins	609:673	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	3	130	theme	N-glycans	809:817	arg1	analysis					774:781	particularly the analysis	757:781	particularly the analysis of plant and invertebrate N-glycans	757:817	So far, only limited PNGase candidates are available for N-glycans analysis, and particularly the analysis of plant and invertebrate N-glycans is hampered by the lack of suitable PNGases.
35945033	2	131	theme	N-glycosylation	429:443	arg1	analysis					398:405	The structural and functional analysis	368:405	The structural and functional analysis of vertebrate protein N-glycosylation	368:443	The structural and functional analysis of vertebrate protein N-glycosylation currently depends extensively on bacterial peptide-N4-(N-acetyl-β-glucosaminyl) asparagine amidases (PNGases), which are indispensable enzymatic tools in releasing asparagine-linked oligosaccharides (N-glycans) from glycoproteins.
35945033	6	132	theme	used	1575:1578	arg1	variant					1590:1596	the currently used PNGase H+ variant	1561:1596	the currently used PNGase H+ variant from Dyella japonicum (Dj)	1561:1623	Active and soluble recombinant PNGase Rc was expressed at a higher protein level (3.8-fold) and with higher specific activity (~56% increase) compared to the currently used PNGase H+ variant from Dyella japonicum (Dj).
35945033	4	133	from	values	1068:1073	arg1	release					1037:1043	a highly efficient enzymatic release	1008:1043	a highly efficient enzymatic release of N-glycans at low pH values	1008:1073	Furthermore, liquid chromatography-mass spectrometry (LC-MS) workflows, such as hydrogen deuterium exchange mass spectrometry (HDX-MS), require a highly efficient enzymatic release of N-glycans at low pH values to facilitate the comprehensive structural analysis of glycoproteins.
35458202	2	0	theme	host	498:501	arg1	physiology					503:512	host physiology	498:512	host physiology	498:512	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	0	1	theme	Food	70:73	arg1	Encyclopedia					54:65	the Davis Food Glycopedia-A Glycan Encyclopedia	19:65	the Davis Food Glycopedia-A Glycan Encyclopedia of Food	19:73	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.
35458202	5	2	theme	hierarchical	1158:1169	arg1	analysis					1182:1189	hierarchical clustering analysis	1158:1189	hierarchical clustering analysis	1158:1189	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	5	3	theme	many	1093:1096	arg1	foods					1098:1102	many foods	1093:1102	many foods within the same group	1093:1124	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	2	4	dep	microbiome	483:492	arg1	the					475:477	the	475:477	the	475:477	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	5	5	theme	clustering	1171:1180	arg1	analysis					1182:1189	hierarchical clustering analysis	1158:1189	hierarchical clustering analysis	1158:1189	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	6	6	from	residues	1328:1335	arg1	rich					1296:1299	rich	1296:1299	rich	1296:1299	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	4	7	theme	Davis	953:957	arg1	database					998:1005	an open-access database	983:1005	an open-access database that provides quantitative structural information on the carbohydrates in food	983:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	7	theme	Davis	953:957	arg1	DFG					977:979	DFG	977:979	DFG	977:979	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	7	theme	Davis	953:957	arg1	"					974:974	Davis Food Glycopedia"	953:974	Davis Food Glycopedia" (DFG)	953:980	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	8	from	information	1045:1055	arg1	carbohydrates					1064:1076	the carbohydrates	1060:1076	the carbohydrates in food	1060:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	3	9	theme	detailed	536:543	arg1	catalogue					545:553	a detailed catalogue	534:553	a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	534:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	4	10	theme	Glycopedia	964:973	arg1	database					998:1005	an open-access database	983:1005	an open-access database that provides quantitative structural information on the carbohydrates in food	983:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	10	theme	Glycopedia	964:973	arg1	DFG					977:979	DFG	977:979	DFG	977:979	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	10	theme	Glycopedia	964:973	arg1	"					974:974	Davis Food Glycopedia"	953:974	Davis Food Glycopedia" (DFG)	953:980	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	11	theme	Food	959:962	arg1	database					998:1005	an open-access database	983:1005	an open-access database that provides quantitative structural information on the carbohydrates in food	983:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	11	theme	Food	959:962	arg1	DFG					977:979	DFG	977:979	DFG	977:979	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	11	theme	Food	959:962	arg1	"					974:974	Davis Food Glycopedia"	953:974	Davis Food Glycopedia" (DFG)	953:980	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	3	12	attach	present	570:576	arg1	foods					595:599	complementary foods	581:599	complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	581:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	3	12	attach	present	570:576	arg2	glycans					562:568	the glycans	558:568	the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	558:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	6	13	theme	prophylactic	1442:1453	arg1	diets					1470:1474	prophylactic or therapeutic diets	1442:1474	prophylactic or therapeutic diets	1442:1474	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	6	14	theme	rich	1296:1299	arg1	diets					1290:1294	diets	1290:1294	diets rich in specific monosaccharide residues	1290:1335	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	6	15	from	rich	1296:1299	arg1	residues					1328:1335	specific monosaccharide residues	1304:1335	specific monosaccharide residues	1304:1335	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	4	16	from	groups	762:767	arg1	compositions					713:724	The monosaccharide compositions	694:724	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more	694:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	1	17	theme	molecular	80:88	arg1	complexity					90:99	The molecular complexity	76:99	The molecular complexity of the carbohydrates consumed by humans	76:139	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	3	18	from	foods	595:599	arg1	present					570:576	present	570:576	present	570:576	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	6	19	theme	microbiome	1386:1395	arg1	modulation					1364:1373	a more targeted modulation	1348:1373	a more targeted modulation of the gut microbiome	1348:1395	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	6	20	dep	formulate	1280:1288	arg1	opening					1406:1412	opening	1406:1412	opening	1406:1412	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	4	21	theme	food	757:760	arg1	Beans					815:819	Beans	815:819	Beans	815:819	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Nuts					843:846	Nuts	843:846	Nuts	843:846	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	more					907:910	more	907:910	more	907:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Vegetables					787:796	Vegetables	787:796	Vegetables	787:796	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Seeds					849:853	Seeds	849:853	Seeds	849:853	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Peas					822:825	Peas	822:825	Peas	822:825	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	groups					762:767	diverse food groups	749:767	diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more	749:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Legumes					834:840	Other Legumes	828:840	Other Legumes	828:840	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Sugars					856:861	Sugars	856:861	Sugars	856:861	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Products					805:812	Grain Products	799:812	Grain Products	799:812	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Fruits					779:784	Fruits	779:784	Fruits	779:784	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	21	theme	food	757:760	arg1	Products					893:900	Animal Products	886:900	Animal Products	886:900	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	6	22	theme	monosaccharide	1313:1326	arg1	residues					1328:1335	specific monosaccharide residues	1304:1335	specific monosaccharide residues	1304:1335	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	3	23	theme	glycans	562:568	arg1	catalogue					545:553	a detailed catalogue	534:553	a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	534:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	3	24	theme	complementary	581:593	arg1	foods					595:599	complementary foods	581:599	complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	581:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	5	25	theme	similar	1136:1142	arg1	compositions					1144:1155	similar compositions	1136:1155	similar compositions	1136:1155	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	4	26	theme	Grain	799:803	arg1	Products					805:812	Grain Products	799:812	Grain Products	799:812	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	6	27	theme	gut	1382:1384	arg1	microbiome					1386:1395	the gut microbiome	1378:1395	the gut microbiome	1378:1395	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	3	28	theme	present	570:576	arg1	glycans					562:568	the glycans	558:568	the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	558:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	6	29	theme	diets	1470:1474	arg1	class					1433:1437	a new class	1427:1437	a new class of prophylactic or therapeutic diets	1427:1474	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	4	30	from	carbohydrates	1064:1076	arg1	food					1081:1084	food	1081:1084	food	1081:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	0	31	theme	Food	29:32	arg1	Encyclopedia					54:65	the Davis Food Glycopedia-A Glycan Encyclopedia	19:65	the Davis Food Glycopedia-A Glycan Encyclopedia of Food	19:73	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.
35458202	2	32	theme	such	336:339	arg1	information					341:351	such information	336:351	such information	336:351	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	5	33	contain	possessed	1126:1134	arg2	compositions					1144:1155	similar compositions	1136:1155	similar compositions	1136:1155	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	5	33	contain	possessed	1126:1134	arg1	foods					1098:1102	many foods	1093:1102	many foods within the same group	1093:1124	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	1	34	theme	analytical	194:203	arg1	methods					205:211	analytical methods	194:211	analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information	194:324	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	6	35	theme	therapeutic	1458:1468	arg1	diets					1470:1474	prophylactic or therapeutic diets	1442:1474	prophylactic or therapeutic diets	1442:1474	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	2	36	theme	glycan	412:417	arg1	structures					419:428	specific glycan structures	403:428	specific glycan structures	403:428	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	0	37	theme	Davis	23:27	arg1	Encyclopedia					54:65	the Davis Food Glycopedia-A Glycan Encyclopedia	19:65	the Davis Food Glycopedia-A Glycan Encyclopedia of Food	19:73	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.
35458202	1	38	theme	quantitative	290:301	arg1	information					314:324	quantitative structural information	290:324	quantitative structural information	290:324	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	2	39	theme	gut	479:481	arg1	microbiome					483:492	gut microbiome	479:492	gut microbiome	479:492	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	1	40	theme	methods	205:211	arg1	lack					186:189	a lack	184:189	a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information	184:324	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	0	41	theme	Glycan	47:52	arg1	Encyclopedia					54:65	the Davis Food Glycopedia-A Glycan Encyclopedia	19:65	the Davis Food Glycopedia-A Glycan Encyclopedia of Food	19:73	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.
35458202	1	42	theme	structural	303:312	arg1	information					314:324	quantitative structural information	290:324	quantitative structural information	290:324	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	6	43	used	used	1272:1275	arg2	Glycopedia					1254:1263	Such a Glycopedia	1247:1263	Such a Glycopedia	1247:1263	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	1	44	contain	possess	218:224	arg2	resolution					259:268	resolution	259:268	resolution	259:268	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	1	44	contain	possess	218:224	arg2	sensitivity					242:252	sensitivity	242:252	sensitivity	242:252	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	1	44	contain	possess	218:224	arg2	throughput					230:239	throughput	230:239	throughput	230:239	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	1	44	contain	possess	218:224	arg1	methods					205:211	analytical methods	194:211	analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information	194:324	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	4	45	theme	foods	738:742	arg1	compositions					713:724	The monosaccharide compositions	694:724	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more	694:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	0	46	theme	Glycopedia-A	34:45	arg1	Encyclopedia					54:65	the Davis Food Glycopedia-A Glycan Encyclopedia	19:65	the Davis Food Glycopedia-A Glycan Encyclopedia of Food	19:73	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.
35458202	6	47	theme	specific	1304:1311	arg1	residues					1328:1335	specific monosaccharide residues	1304:1335	specific monosaccharide residues	1304:1335	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	4	48	theme	Other	828:832	arg1	Legumes					834:840	Other Legumes	828:840	Other Legumes	828:840	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	2	49	with	interaction	458:468	arg1	physiology					503:512	host physiology	498:512	host physiology	498:512	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	2	49	with	interaction	458:468	arg1	microbiome					483:492	gut microbiome	479:492	gut microbiome	479:492	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	1	50	theme	carbohydrates	108:120	arg1	complexity					90:99	The molecular complexity	76:99	The molecular complexity of the carbohydrates consumed by humans	76:139	The molecular complexity of the carbohydrates consumed by humans has been deceptively oversimplified due to a lack of analytical methods that possess the throughput, sensitivity, and resolution required to provide quantitative structural information.
35458202	4	51	theme	quantitative	1021:1032	arg1	information					1045:1055	quantitative structural information	1021:1055	quantitative structural information on the carbohydrates in food	1021:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	5	52	theme	same	1115:1118	arg1	group					1120:1124	the same group	1111:1124	the same group	1111:1124	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
35458202	4	53	theme	Animal	886:891	arg1	Products					893:900	Animal Products	886:900	Animal Products	886:900	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	54	used	used	930:933	arg2	compositions					713:724	The monosaccharide compositions	694:724	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more	694:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Beans					815:819	Beans	815:819	Beans	815:819	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Nuts					843:846	Nuts	843:846	Nuts	843:846	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	more					907:910	more	907:910	more	907:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Vegetables					787:796	Vegetables	787:796	Vegetables	787:796	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Seeds					849:853	Seeds	849:853	Seeds	849:853	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Peas					822:825	Peas	822:825	Peas	822:825	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	groups					762:767	diverse food groups	749:767	diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more	749:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Legumes					834:840	Other Legumes	828:840	Other Legumes	828:840	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Sugars					856:861	Sugars	856:861	Sugars	856:861	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Products					805:812	Grain Products	799:812	Grain Products	799:812	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Fruits					779:784	Fruits	779:784	Fruits	779:784	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	55	theme	diverse	749:755	arg1	Products					893:900	Animal Products	886:900	Animal Products	886:900	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	3	56	from	present	570:576	arg1	foods					595:599	complementary foods	581:599	complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults	581:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	3	57	theme	American	677:684	arg1	adults					686:691	American adults	677:691	American adults	677:691	This work presents a detailed catalogue of the glycans present in complementary foods commonly consumed by toddlers during weaning and foods commonly consumed by American adults.
35458202	2	58	theme	specific	403:410	arg1	structures					419:428	specific glycan structures	403:428	specific glycan structures	403:428	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	6	59	theme	targeted	1355:1362	arg1	modulation					1364:1373	a more targeted modulation	1348:1373	a more targeted modulation of the gut microbiome	1348:1395	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	6	60	theme	new	1429:1431	arg1	class					1433:1437	a new class	1427:1437	a new class of prophylactic or therapeutic diets	1427:1474	Such a Glycopedia can be used to formulate diets rich in specific monosaccharide residues to provide a more targeted modulation of the gut microbiome, thereby opening the door for a new class of prophylactic or therapeutic diets.
35458202	2	61	theme	integral	368:375	arg1	part					377:380	an integral part	365:380	an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology	365:512	However, such information is becoming an integral part of understanding how specific glycan structures impact health through their interaction with the gut microbiome and host physiology.
35458202	4	62	theme	structural	1034:1043	arg1	information					1045:1055	quantitative structural information	1021:1055	quantitative structural information on the carbohydrates in food	1021:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	0	63	theme	Encyclopedia	54:65	arg1	Development					4:14	The Development	0:14	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.	0:74	The Development of the Davis Food Glycopedia-A Glycan Encyclopedia of Food.
35458202	4	64	theme	monosaccharide	698:711	arg1	compositions					713:724	The monosaccharide compositions	694:724	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more	694:910	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	65	theme	open-access	986:996	arg1	database					998:1005	an open-access database	983:1005	an open-access database that provides quantitative structural information on the carbohydrates in food	983:1084	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	4	65	theme	open-access	986:996	arg1	"					974:974	Davis Food Glycopedia"	953:974	Davis Food Glycopedia" (DFG)	953:980	The monosaccharide compositions of over 800 foods from diverse food groups including Fruits, Vegetables, Grain Products, Beans, Peas, Other Legumes, Nuts, Seeds; Sugars, Sweets and Beverages; Animal Products, and more were obtained and used to construct the "Davis Food Glycopedia" (DFG), an open-access database that provides quantitative structural information on the carbohydrates in food.
35458202	5	66	theme	different	1221:1229	arg1	groups					1231:1236	different groups	1221:1236	different groups as well	1221:1244	While many foods within the same group possessed similar compositions, hierarchical clustering analysis revealed similarities between different groups as well.
37216524	3	0	contain	have	358:361	arg2	activity					375:382	a decreased activity	363:382	a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans	363:539	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	3	0	contain	have	358:361	arg1	patients					349:356	The patients	345:356	The patients	345:356	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	4	1	theme	chaperone	605:613	arg1	Cosmc					615:619	its specific molecular chaperone Cosmc	582:619	its specific molecular chaperone Cosmc	582:619	The T-synthase function is dependent on its specific molecular chaperone Cosmc, which is encoded by X-chromosomal C1GALT1C1.
37216524	6	2	theme	acute	846:850	arg1	AKI					867:869	AKI	867:869	AKI	867:869	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	6	2	theme	acute	846:850	arg1	injury					859:864	acute kidney injury	846:864	acute kidney injury (AKI)	846:870	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	3	3	theme	extended	522:529	arg1	O-glycans					531:539	all extended O-glycans	518:539	all extended O-glycans	518:539	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	1	4	from	Mutations	65:73	arg1	genes					78:82	genes	78:82	genes encoding molecular chaperones	78:112	Mutations in genes encoding molecular chaperones can lead to chaperonopathies, but none have so far been identified causing congenital disorders of glycosylation.
37216524	5	5	theme	hemizygous	691:700	arg1	c.59C>A					710:716	the hemizygous variant c.59C>A	687:716	the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1	687:754	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
37216524	10	6	theme	activity	1434:1441	arg1	reduction					1398:1406	a large reduction	1390:1406	a large reduction	1390:1406	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	12	7	contain	have	1763:1766	arg2	levels					1773:1778	high levels	1768:1778	high levels of galactose-deficient IgA1 in sera	1768:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	12	7	contain	have	1763:1766	arg1	individuals					1751:1761	all four affected individuals	1733:1761	all four affected individuals	1733:1761	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	2	8	theme	novel	281:285	arg1	chaperonopathy					287:300	a novel chaperonopathy	279:300	a novel chaperonopathy	279:300	Here we identified two maternal half-brothers with a novel chaperonopathy, causing impaired protein O-glycosylation.
37216524	6	9	theme	uremic	902:907	arg1	syndrome					909:916	atypical hemolytic uremic syndrome	883:916	atypical hemolytic uremic syndrome	883:916	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	6	10	theme	short	809:813	arg1	stature					815:821	short stature	809:821	short stature	809:821	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	1	11	theme	congenital	189:198	arg1	disorders					200:208	congenital disorders	189:208	congenital disorders of glycosylation	189:225	Mutations in genes encoding molecular chaperones can lead to chaperonopathies, but none have so far been identified causing congenital disorders of glycosylation.
37216524	8	12	theme	male	1047:1050	arg1	patients					1052:1059	the male patients	1043:1059	the male patients	1043:1059	AKI in the male patients proved fully responsive to treatment with the complement inhibitor Eculizumab.
37216524	11	13	theme	cells	1628:1632	arg1	transfection					1589:1600	Transient transfection	1579:1600	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1	1579:1657	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	13	14	theme	O-glycan	1888:1895	arg1	chaperonopathy					1897:1910	a novel O-glycan chaperonopathy	1880:1910	a novel O-glycan chaperonopathy	1880:1910	These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
37216524	2	15	theme	impaired	311:318	arg1	O-glycosylation					328:342	impaired protein O-glycosylation	311:342	impaired protein O-glycosylation	311:342	Here we identified two maternal half-brothers with a novel chaperonopathy, causing impaired protein O-glycosylation.
37216524	10	16	from	amounts	1492:1498	arg1	glycoproteins					1564:1576	multiple glycoproteins	1555:1576	multiple glycoproteins	1555:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	8	17	with	treatment	1088:1096	arg1	Eculizumab					1128:1137	the complement inhibitor Eculizumab	1103:1137	the complement inhibitor Eculizumab	1103:1137	AKI in the male patients proved fully responsive to treatment with the complement inhibitor Eculizumab.
37216524	13	18	from	status	1951:1956	arg1	patients					1967:1974	these patients	1961:1974	these patients	1961:1974	These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
37216524	12	19	from	sera	1811:1814	arg1	levels					1773:1778	high levels	1768:1778	high levels of galactose-deficient IgA1 in sera	1768:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	10	20	from	Tn-antigen	1516:1525	arg1	glycoproteins					1564:1576	multiple glycoproteins	1555:1576	multiple glycoproteins	1555:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	2	21	theme	maternal	251:258	arg1	half-brothers					260:272	two maternal half-brothers	247:272	two maternal half-brothers with a novel chaperonopathy	247:300	Here we identified two maternal half-brothers with a novel chaperonopathy, causing impaired protein O-glycosylation.
37216524	12	22	theme	IgA1	1803:1806	arg1	levels					1773:1778	high levels	1768:1778	high levels of galactose-deficient IgA1 in sera	1768:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	10	23	theme	decreased	1317:1325	arg1	expression					1327:1336	its decreased expression	1313:1336	its decreased expression	1313:1336	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	7	24	theme	skewed	1004:1009	arg1	X-inactivation					1011:1024	skewed X-inactivation	1004:1024	skewed X-inactivation in blood	1004:1033	Their heterozygous mother and maternal grandmother show an attenuated phenotype with skewed X-inactivation in blood.
37216524	10	25	theme	varied	1485:1490	arg1	amounts					1492:1498	varied amounts	1485:1498	varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1485:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	25	theme	varied	1485:1490	arg1	Tn-antigen					1516:1525	pathological Tn-antigen	1503:1525	pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1503:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	25	theme	varied	1485:1490	arg1	GalNAcα1-O-Ser/Thr/Tyr					1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	11	26	theme	patient	1605:1611	arg1	cells					1628:1632	patient lymphoblastoid cells	1605:1632	patient lymphoblastoid cells	1605:1632	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	11	27	theme	Transient	1579:1587	arg1	transfection					1589:1600	Transient transfection	1579:1600	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1	1579:1657	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	12	28	theme	high	1768:1771	arg1	levels					1773:1778	high levels	1768:1778	high levels of galactose-deficient IgA1 in sera	1768:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	3	29	theme	decreased	365:373	arg1	activity					375:382	a decreased activity	363:382	a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans	363:539	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	10	30	theme	Tn-antigen	1516:1525	arg1	amounts					1492:1498	varied amounts	1485:1498	varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1485:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	30	theme	Tn-antigen	1516:1525	arg1	Tn-antigen					1516:1525	pathological Tn-antigen	1503:1525	pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1503:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	30	theme	Tn-antigen	1516:1525	arg1	GalNAcα1-O-Ser/Thr/Tyr					1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	0	31	theme	Germline	0:7	arg1	mutation					19:26	Germline C1GALT1C1 mutation	0:26	Germline C1GALT1C1 mutation	0:26	Germline C1GALT1C1 mutation causes a multisystem chaperonopathy.
37216524	12	32	from	IgA1	1803:1806	arg1	sera					1811:1814	sera	1811:1814	sera	1811:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	10	33	theme	tissue-specific	1359:1373	arg1	manner					1375:1380	a cell or tissue-specific manner	1349:1380	manner	1375:1380	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	3	34	theme	O-glycan	476:483	arg1	structure					490:498	a ubiquitous O-glycan core structure	463:498	a ubiquitous O-glycan core structure	463:498	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	8	35	theme	inhibitor	1118:1126	arg1	Eculizumab					1128:1137	the complement inhibitor Eculizumab	1103:1137	the complement inhibitor Eculizumab	1103:1137	AKI in the male patients proved fully responsive to treatment with the complement inhibitor Eculizumab.
37216524	6	36	theme	hemolytic	892:900	arg1	syndrome					909:916	atypical hemolytic uremic syndrome	883:916	atypical hemolytic uremic syndrome	883:916	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	10	37	theme	cell	1351:1354	arg1	manner					1375:1380	a cell or tissue-specific manner	1349:1380	manner	1375:1380	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	9	38	theme	transmembrane	1180:1192	arg1	domain					1194:1199	the transmembrane domain	1176:1199	the transmembrane domain of Cosmc	1176:1208	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	9	38	theme	transmembrane	1180:1192	arg1	Cosmc					1204:1208	Cosmc	1204:1208	Cosmc	1204:1208	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	6	39	theme	developmental	770:782	arg1	delay					784:788	developmental delay	770:788	developmental delay	770:788	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	7	40	theme	maternal	949:956	arg1	grandmother					958:968	maternal grandmother	949:968	maternal grandmother	949:968	Their heterozygous mother and maternal grandmother show an attenuated phenotype with skewed X-inactivation in blood.
37216524	13	41	theme	altered	1927:1933	arg1	status					1951:1956	the altered O-glycosylation status	1923:1956	the altered O-glycosylation status in these patients	1923:1974	These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
37216524	10	42	theme	T-synthase	1411:1420	arg1	protein					1422:1428	T-synthase protein	1411:1428	T-synthase protein	1411:1428	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	4	43	theme	molecular	595:603	arg1	Cosmc					615:619	its specific molecular chaperone Cosmc	582:619	its specific molecular chaperone Cosmc	582:619	The T-synthase function is dependent on its specific molecular chaperone Cosmc, which is encoded by X-chromosomal C1GALT1C1.
37216524	9	44	theme	reduced	1237:1243	arg1	expression					1245:1254	dramatically reduced expression	1224:1254	dramatically reduced expression of the Cosmc protein	1224:1275	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	11	45	theme	glycosylation	1696:1708	arg1	defect					1710:1715	the T-synthase and glycosylation defect	1677:1715	the T-synthase and glycosylation defect	1677:1715	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	12	46	from	levels	1773:1778	arg1	sera					1811:1814	sera	1811:1814	sera	1811:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	11	47	theme	lymphoblastoid	1613:1626	arg1	cells					1628:1632	patient lymphoblastoid cells	1605:1632	patient lymphoblastoid cells	1605:1632	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	9	48	theme	Cosmc	1263:1267	arg1	protein					1269:1275	the Cosmc protein	1259:1275	the Cosmc protein	1259:1275	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	13	49	theme	novel	1882:1886	arg1	chaperonopathy					1897:1910	a novel O-glycan chaperonopathy	1880:1910	a novel O-glycan chaperonopathy	1880:1910	These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
37216524	9	50	theme	protein	1269:1275	arg1	expression					1245:1254	dramatically reduced expression	1224:1254	dramatically reduced expression of the Cosmc protein	1224:1275	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	2	51	theme	protein	320:326	arg1	O-glycosylation					328:342	impaired protein O-glycosylation	311:342	impaired protein O-glycosylation	311:342	Here we identified two maternal half-brothers with a novel chaperonopathy, causing impaired protein O-glycosylation.
37216524	4	52	theme	X-chromosomal	642:654	arg1	C1GALT1C1					656:664	X-chromosomal C1GALT1C1	642:664	X-chromosomal C1GALT1C1	642:664	The T-synthase function is dependent on its specific molecular chaperone Cosmc, which is encoded by X-chromosomal C1GALT1C1.
37216524	1	53	theme	glycosylation	213:225	arg1	disorders					200:208	congenital disorders	189:208	congenital disorders of glycosylation	189:225	Mutations in genes encoding molecular chaperones can lead to chaperonopathies, but none have so far been identified causing congenital disorders of glycosylation.
37216524	2	54	with	half-brothers	260:272	arg1	chaperonopathy					287:300	a novel chaperonopathy	279:300	a novel chaperonopathy	279:300	Here we identified two maternal half-brothers with a novel chaperonopathy, causing impaired protein O-glycosylation.
37216524	11	55	theme	wild-type	1639:1647	arg1	C1GALT1C1					1649:1657	wild-type C1GALT1C1	1639:1657	wild-type C1GALT1C1	1639:1657	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	13	56	theme	A20D-Cosmc	1852:1861	arg1	mutation					1863:1870	the A20D-Cosmc mutation	1848:1870	the A20D-Cosmc mutation	1848:1870	These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
37216524	5	57	theme	variant	702:708	arg1	c.59C>A					710:716	the hemizygous variant c.59C>A	687:716	the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1	687:754	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
37216524	11	58	theme	T-synthase	1681:1690	arg1	defect					1710:1715	the T-synthase and glycosylation defect	1677:1715	the T-synthase and glycosylation defect	1677:1715	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	10	59	gly	glycoproteins	1564:1576	arg1	glycoproteins					1564:1576	multiple glycoproteins	1555:1576	multiple glycoproteins	1555:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	60	from	glycoproteins	1564:1576	arg1	amounts					1492:1498	varied amounts	1485:1498	varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1485:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	60	from	glycoproteins	1564:1576	arg1	Tn-antigen					1516:1525	pathological Tn-antigen	1503:1525	pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1503:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	60	from	glycoproteins	1564:1576	arg1	GalNAcα1-O-Ser/Thr/Tyr					1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	5	61	dep	p.Ala20Asp	719:728	arg1	A20D-Cosmc					731:740	A20D-Cosmc	731:740	p.Ala20Asp; A20D-Cosmc	719:740	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
37216524	12	62	theme	galactose-deficient	1783:1801	arg1	IgA1					1803:1806	galactose-deficient IgA1	1783:1806	galactose-deficient IgA1 in sera	1783:1814	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	11	63	with	transfection	1589:1600	arg1	C1GALT1C1					1649:1657	wild-type C1GALT1C1	1639:1657	wild-type C1GALT1C1	1639:1657	Transient transfection of patient lymphoblastoid cells with wild-type C1GALT1C1 partially rescued the T-synthase and glycosylation defect.
37216524	10	64	theme	amounts	1492:1498	arg1	expression					1471:1480	expression	1471:1480	expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1471:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	7	65	from	X-inactivation	1011:1024	arg1	blood					1029:1033	blood	1029:1033	blood	1029:1033	Their heterozygous mother and maternal grandmother show an attenuated phenotype with skewed X-inactivation in blood.
37216524	3	66	theme	T-synthase	387:396	arg1	activity					375:382	a decreased activity	363:382	a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans	363:539	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	5	67	dep	c.59C>A	710:716	arg1	p.Ala20Asp					719:728	p.Ala20Asp	719:728	p.Ala20Asp; A20D-Cosmc	719:740	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
37216524	0	68	theme	C1GALT1C1	9:17	arg1	mutation					19:26	Germline C1GALT1C1 mutation	0:26	Germline C1GALT1C1 mutation	0:26	Germline C1GALT1C1 mutation causes a multisystem chaperonopathy.
37216524	8	69	theme	complement	1107:1116	arg1	Eculizumab					1128:1137	the complement inhibitor Eculizumab	1103:1137	the complement inhibitor Eculizumab	1103:1137	AKI in the male patients proved fully responsive to treatment with the complement inhibitor Eculizumab.
37216524	7	70	theme	attenuated	978:987	arg1	phenotype					989:997	an attenuated phenotype	975:997	an attenuated phenotype with skewed X-inactivation in blood	975:1033	Their heterozygous mother and maternal grandmother show an attenuated phenotype with skewed X-inactivation in blood.
37216524	1	71	theme	molecular	93:101	arg1	chaperones					103:112	molecular chaperones	93:112	molecular chaperones	93:112	Mutations in genes encoding molecular chaperones can lead to chaperonopathies, but none have so far been identified causing congenital disorders of glycosylation.
37216524	10	72	theme	pathological	1503:1514	arg1	Tn-antigen					1516:1525	pathological Tn-antigen	1503:1525	pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins	1503:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	10	72	theme	pathological	1503:1514	arg1	GalNAcα1-O-Ser/Thr/Tyr					1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	GalNAcα1-O-Ser/Thr/Tyr	1528:1549	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	9	73	theme	germline	1145:1152	arg1	variant					1154:1160	This germline variant	1140:1160	This germline variant	1140:1160	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	9	74	theme	Cosmc	1204:1208	arg1	domain					1194:1199	the transmembrane domain	1176:1199	the transmembrane domain of Cosmc	1176:1208	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	9	74	theme	Cosmc	1204:1208	arg1	Cosmc					1204:1208	Cosmc	1204:1208	Cosmc	1204:1208	This germline variant occurs within the transmembrane domain of Cosmc, resulting in dramatically reduced expression of the Cosmc protein.
37216524	4	75	theme	specific	586:593	arg1	Cosmc					615:619	its specific molecular chaperone Cosmc	582:619	its specific molecular chaperone Cosmc	582:619	The T-synthase function is dependent on its specific molecular chaperone Cosmc, which is encoded by X-chromosomal C1GALT1C1.
37216524	10	76	theme	multiple	1555:1562	arg1	glycoproteins					1564:1576	multiple glycoproteins	1555:1576	multiple glycoproteins	1555:1576	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	3	77	theme	core	485:488	arg1	structure					490:498	a ubiquitous O-glycan core structure	463:498	a ubiquitous O-glycan core structure	463:498	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	0	78	theme	multisystem	37:47	arg1	chaperonopathy					49:62	a multisystem chaperonopathy	35:62	a multisystem chaperonopathy	35:62	Germline C1GALT1C1 mutation causes a multisystem chaperonopathy.
37216524	6	79	theme	atypical	883:890	arg1	syndrome					909:916	atypical hemolytic uremic syndrome	883:916	atypical hemolytic uremic syndrome	883:916	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	12	80	theme	affected	1742:1749	arg1	individuals					1751:1761	all four affected individuals	1733:1761	all four affected individuals	1733:1761	Interestingly, all four affected individuals have high levels of galactose-deficient IgA1 in sera.
37216524	4	81	theme	T-synthase	546:555	arg1	function					557:564	The T-synthase function	542:564	The T-synthase function	542:564	The T-synthase function is dependent on its specific molecular chaperone Cosmc, which is encoded by X-chromosomal C1GALT1C1.
37216524	4	81	theme	T-synthase	546:555	arg1	dependent					569:577	dependent	569:577	dependent	569:577	The T-synthase function is dependent on its specific molecular chaperone Cosmc, which is encoded by X-chromosomal C1GALT1C1.
37216524	10	82	theme	large	1392:1396	arg1	reduction					1398:1406	a large reduction	1390:1406	a large reduction	1390:1406	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	3	83	theme	ubiquitous	465:474	arg1	structure					490:498	a ubiquitous O-glycan core structure	463:498	a ubiquitous O-glycan core structure	463:498	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	7	84	with	phenotype	989:997	arg1	X-inactivation					1011:1024	skewed X-inactivation	1004:1024	skewed X-inactivation in blood	1004:1033	Their heterozygous mother and maternal grandmother show an attenuated phenotype with skewed X-inactivation in blood.
37216524	3	85	dep	T-antigen	452:460	arg1	the					448:450	the	448:450	the	448:450	The patients have a decreased activity of T-synthase (C1GALT1), an enzyme that exclusively synthesizes the T-antigen, a ubiquitous O-glycan core structure and precursor for all extended O-glycans.
37216524	8	86	from	AKI	1036:1038	arg1	patients					1052:1059	the male patients	1043:1059	the male patients	1043:1059	AKI in the male patients proved fully responsive to treatment with the complement inhibitor Eculizumab.
37216524	10	87	theme	protein	1422:1428	arg1	reduction					1398:1406	a large reduction	1390:1406	a large reduction	1390:1406	Although A20D-Cosmc is functional, its decreased expression, though in a cell or tissue-specific manner, causes a large reduction of T-synthase protein and activity, which accordingly leads to expression of varied amounts of pathological Tn-antigen (GalNAcα1-O-Ser/Thr/Tyr) on multiple glycoproteins.
37216524	7	88	theme	heterozygous	925:936	arg1	mother					938:943	Their heterozygous mother	919:943	Their heterozygous mother	919:943	Their heterozygous mother and maternal grandmother show an attenuated phenotype with skewed X-inactivation in blood.
37216524	6	89	theme	kidney	852:857	arg1	AKI					867:869	AKI	867:869	AKI	867:869	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	6	89	theme	kidney	852:857	arg1	injury					859:864	acute kidney injury	846:864	acute kidney injury (AKI)	846:870	They exhibit developmental delay, immunodeficiency, short stature, thrombocytopenia, and acute kidney injury (AKI) resembling atypical hemolytic uremic syndrome.
37216524	5	90	contain	carry	681:685	arg2	c.59C>A					710:716	the hemizygous variant c.59C>A	687:716	the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1	687:754	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
37216524	5	90	contain	carry	681:685	arg1	patients					672:679	Both patients	667:679	Both patients	667:679	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
37216524	13	91	theme	O-glycosylation	1935:1949	arg1	status					1951:1956	the altered O-glycosylation status	1923:1956	the altered O-glycosylation status in these patients	1923:1974	These results demonstrate that the A20D-Cosmc mutation defines a novel O-glycan chaperonopathy and causes the altered O-glycosylation status in these patients.
37216524	5	92	from	c.59C>A	710:716	arg1	C1GALT1C1					746:754	C1GALT1C1	746:754	C1GALT1C1	746:754	Both patients carry the hemizygous variant c.59C>A (p.Ala20Asp; A20D-Cosmc) in C1GALT1C1.
36809652	7	0	from	VEGFR2	1309:1314	arg1	signaling					1349:1357	MAPK signaling	1344:1357	MAPK signaling	1344:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	4	1	theme	protein	759:765	arg1	MAPK					775:778	MAPK	775:778	MAPK	775:778	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	1	theme	protein	759:765	arg1	kinase					767:772	mitogen-activated protein kinase	741:772	mitogen-activated protein kinase (MAPK) signaling	741:789	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	0	2	theme	human	118:122	arg1	cells					151:155	human umbilical vein endothelial cells	118:155	human umbilical vein endothelial cells	118:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	0	3	theme	endothelial	139:149	arg1	cells					151:155	human umbilical vein endothelial cells	118:155	human umbilical vein endothelial cells	118:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	5	4	theme	endothelial	1020:1030	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	4	theme	endothelial	1020:1030	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	8	5	link	-linked	1528:1534	arg1	O-glycans					1536:1544	apo(a)-linked O-glycans	1522:1544	apo(a)-linked O-glycans	1522:1544	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	5	6	from	migration	966:974	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	6	from	migration	966:974	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	7	from	potential	854:862	arg1	Lp					904:905	Lp	904:905	Lp(a)	904:908	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	7	from	potential	854:862	arg1	a					907:907	a	907:907	a	907:907	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	1	8	theme	polymorphic	197:207	arg1	O-glycoprotein					209:222	a highly polymorphic O-glycoprotein	188:222	a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)]	188:276	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	1	8	theme	polymorphic	197:207	arg1	[apo					176:179	Apolipoprotein(a) [apo	158:179	Apolipoprotein(a) [apo(a)]	158:183	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	7	9	from	proteins	1332:1339	arg1	signaling					1349:1357	MAPK signaling	1344:1357	MAPK signaling	1344:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	10	gly	de-O-glycosylated	1460:1476	arg1	a					1482:1482	a	1482:1482	a	1482:1482	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	10	gly	de-O-glycosylated	1460:1476	arg1	apo					1478:1480	de-O-glycosylated apo	1460:1480	de-O-glycosylated apo(a)	1460:1483	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	6	11	dep	in	1121:1122	arg1	vitro					1124:1128	vitro	1124:1128	vitro	1124:1128	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	9	12	theme	activity	1921:1928	arg1	inhibition					1888:1897	apo(a) O-glycans-mediated inhibition	1862:1897	apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1	1862:1942	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	8	13	theme	angiogenic	1663:1672	arg1	pathway					1684:1690	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway	1618:1690	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells	1618:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	5	14	from	structures	880:889	arg1	Lp					904:905	Lp	904:905	Lp(a)	904:908	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	14	from	structures	880:889	arg1	a					907:907	a	907:907	a	907:907	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	1	15	theme	Apolipoprotein	158:171	arg1	O-glycoprotein					209:222	a highly polymorphic O-glycoprotein	188:222	a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)]	188:276	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	1	15	theme	Apolipoprotein	158:171	arg1	a					181:181	a	181:181	a	181:181	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	1	15	theme	Apolipoprotein	158:171	arg1	[apo					176:179	Apolipoprotein(a) [apo	158:179	Apolipoprotein(a) [apo(a)]	158:183	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	7	16	theme	intact	1413:1418	arg1	structures					1429:1438	intact O-glycan structures	1413:1438	intact O-glycan structures	1413:1438	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	9	17	theme	galectin-1	1933:1942	arg1	activity					1921:1928	the pro-angiogenic activity	1902:1928	the pro-angiogenic activity of galectin-1	1902:1942	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	0	18	theme	pro-angiogenic	77:90	arg1	activity					92:99	the pro-angiogenic activity	73:99	the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells	73:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	7	19	from	levels	1280:1285	arg1	signaling					1349:1357	MAPK signaling	1344:1357	MAPK signaling	1344:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	9	20	theme	plasma	1724:1729	arg1	a					1734:1734	a	1734:1734	a	1734:1734	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	20	theme	plasma	1724:1729	arg1	Lp					1731:1732	plasma Lp	1724:1732	higher plasma Lp(a) level in women	1717:1750	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	5	21	dep	demonstrated	837:848	arg1	Using					792:796	Using	792:796	Using apo(a)	792:803	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	6	22	theme	interaction	1146:1156	arg1	studies					1158:1164	in vitro protein-protein interaction studies	1121:1164	in vitro protein-protein interaction studies	1121:1164	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	3	23	theme	pathophysiological	471:488	arg1	significance					490:501	the pathophysiological significance	467:501	the pathophysiological significance of apo(a)-galectin-1 binding	467:530	But the pathophysiological significance of apo(a)-galectin-1 binding is not yet been revealed.
36809652	7	24	from	galectin-1	1290:1299	arg1	signaling					1349:1357	MAPK signaling	1344:1357	MAPK signaling	1344:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	0	25	theme	vein	134:137	arg1	cells					151:155	human umbilical vein endothelial cells	118:155	human umbilical vein endothelial cells	118:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	4	26	theme	galectin-1	592:601	arg1	binding					581:587	Carbohydrate-dependent binding	558:587	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells	558:670	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	5	27	theme	apo	894:896	arg1	structures					880:889	the O-glycan structures	867:889	the O-glycan structures of apo(a) in Lp(a)	867:908	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	2	28	theme	placental	435:443	arg1	tissues					454:460	placental vascular tissues	435:460	placental vascular tissues	435:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	8	29	theme	pathway	1684:1690	arg1	inhibition					1604:1613	the inhibition	1600:1613	the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells	1600:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	9	30	theme	underlying	1962:1971	arg1	mechanism					1983:1991	the underlying molecular mechanism	1958:1991	the underlying molecular mechanism of pathogenesis of Lp(a)	1958:2016	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	0	31	theme	umbilical	124:132	arg1	cells					151:155	human umbilical vein endothelial cells	118:155	human umbilical vein endothelial cells	118:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	2	32	theme	galectin-1	357:366	arg1	structures					292:301	The O-glycan structures	279:301	The O-glycan structures of apo(a) subunit of Lp(a)	279:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	32	theme	galectin-1	357:366	arg1	ligands					346:352	strong ligands	339:352	strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	339:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	9	33	theme	mechanism	1983:1991	arg1	mechanism					1983:1991	the underlying molecular mechanism	1958:1991	the underlying molecular mechanism of pathogenesis of Lp(a)	1958:2016	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	33	theme	mechanism	1983:1991	arg1	one					1951:1953	one	1951:1953	one	1951:1953	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	6	34	theme	superior	1193:1200	arg1	apo					1181:1183	apo	1181:1183	apo(a)	1181:1186	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	6	34	theme	superior	1193:1200	arg1	ligand					1202:1207	a superior ligand	1191:1207	a superior ligand to NRP-1 for galectin-1 binding	1191:1239	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	1	35	theme	a	267:267	arg1	[Lp					270:272	lipoprotein(a) [Lp	255:272	lipoprotein(a) [Lp(a)]	255:276	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	1	35	theme	a	267:267	arg1	a					274:274	a	274:274	a	274:274	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	8	36	theme	-linked	1528:1534	arg1	O-glycans					1536:1544	apo(a)-linked O-glycans	1522:1544	apo(a)-linked O-glycans	1522:1544	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	9	37	theme	pathogenesis	1996:2007	arg1	mechanism					1983:1991	the underlying molecular mechanism	1958:1991	the underlying molecular mechanism of pathogenesis of Lp(a)	1958:2016	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	0	38	theme	lipoprotein	47:57	arg1	subunit					30:36	apo(a) subunit	23:36	apo(a) subunit of human lipoprotein(a)	23:60	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	9	39	from	one	1951:1953	arg1	pre-eclampsia					2021:2033	pre-eclampsia	2021:2033	pre-eclampsia	2021:2033	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	40	theme	pregnancy-associated	1802:1821	arg1	complication					1832:1843	a pregnancy-associated vascular complication	1800:1843	a pregnancy-associated vascular complication	1800:1843	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	40	theme	pregnancy-associated	1802:1821	arg1	pre-eclamsia					1786:1797	pre-eclamsia	1786:1797	pre-eclamsia	1786:1797	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	2	41	theme	binding	381:387	arg1	galectin-1					357:366	galectin-1	357:366	galectin-1	357:366	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	41	theme	binding	381:387	arg1	lectin					404:409	an O-glycan binding pro-angiogenic lectin	369:409	an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	369:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	9	42	theme	independent	1758:1768	arg1	factor					1775:1780	an independent risk factor	1755:1780	an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication	1755:1843	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	42	theme	independent	1758:1768	arg1	level					1737:1741	higher plasma Lp(a) level	1717:1741	higher plasma Lp(a) level in women	1717:1750	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	5	43	theme	chick	1080:1084	arg1	membrane					1102:1109	chick chorioallantoic membrane	1080:1109	chick chorioallantoic membrane	1080:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	9	44	theme	Lp	2012:2013	arg1	pathogenesis					1996:2007	pathogenesis	1996:2007	pathogenesis of Lp(a)	1996:2016	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	8	45	theme	signaling	1674:1682	arg1	pathway					1684:1690	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway	1618:1690	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells	1618:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	7	46	with	apo	1401:1403	arg1	structures					1429:1438	intact O-glycan structures	1413:1438	intact O-glycan structures	1413:1438	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	47	theme	de-O-glycosylated	1460:1476	arg1	a					1482:1482	a	1482:1482	a	1482:1482	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	47	theme	de-O-glycosylated	1460:1476	arg1	apo					1478:1480	de-O-glycosylated apo	1460:1480	de-O-glycosylated apo(a)	1460:1483	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	4	48	theme	endothelial	654:664	arg1	cells					666:670	endothelial cells	654:670	endothelial cells	654:670	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	5	49	from	Lp	904:905	arg1	potential					854:862	the potential	850:862	the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane	850:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	0	50	theme	a	27:27	arg1	subunit					30:36	apo(a) subunit	23:36	apo(a) subunit of human lipoprotein(a)	23:60	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	8	51	theme	galectin-1	1569:1578	arg1	binding					1558:1564	the binding	1554:1564	the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells	1554:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	5	52	theme	umbilical	1005:1013	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	52	theme	umbilical	1005:1013	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	7	53	theme	protein	1272:1278	arg1	levels					1280:1285	the protein levels	1268:1285	the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling	1268:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	2	54	theme	O-glycan	283:290	arg1	structures					292:301	The O-glycan structures	279:301	The O-glycan structures of apo(a) subunit of Lp(a)	279:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	54	theme	O-glycan	283:290	arg1	ligands					346:352	strong ligands	339:352	strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	339:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	0	55	theme	O-glycan	0:7	arg1	structures					9:18	O-glycan structures	0:18	O-glycan structures in apo(a) subunit of human lipoprotein(a)	0:60	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	9	56	theme	vascular	1823:1830	arg1	complication					1832:1843	a pregnancy-associated vascular complication	1800:1843	a pregnancy-associated vascular complication	1800:1843	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	56	theme	vascular	1823:1830	arg1	pre-eclamsia					1786:1797	pre-eclamsia	1786:1797	pre-eclamsia	1786:1797	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	5	57	theme	human	999:1003	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	57	theme	human	999:1003	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	7	58	from	signaling	1349:1357	arg1	levels					1280:1285	the protein levels	1268:1285	the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling	1268:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	59	theme	proteins	1332:1339	arg1	levels					1280:1285	the protein levels	1268:1285	the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling	1268:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	60	theme	O-glycan	1420:1427	arg1	structures					1429:1438	intact O-glycan structures	1413:1438	intact O-glycan structures	1413:1438	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	3	61	theme	binding	524:530	arg1	significance					490:501	the pathophysiological significance	467:501	the pathophysiological significance of apo(a)-galectin-1 binding	467:530	But the pathophysiological significance of apo(a)-galectin-1 binding is not yet been revealed.
36809652	4	62	theme	factor	710:715	arg1	receptor					717:724	vascular endothelial growth factor receptor 2	682:726	vascular endothelial growth factor receptor 2 (VEGFR2)	682:735	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	62	theme	factor	710:715	arg1	VEGFR2					729:734	VEGFR2	729:734	VEGFR2	729:734	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	5	63	from	proliferation	951:963	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	63	from	proliferation	951:963	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	64	theme	O-glycan	871:878	arg1	structures					880:889	the O-glycan structures	867:889	the O-glycan structures of apo(a) in Lp(a)	867:908	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	1	65	theme	lipoprotein	255:265	arg1	[Lp					270:272	lipoprotein(a) [Lp	255:272	lipoprotein(a) [Lp(a)]	255:276	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	1	65	theme	lipoprotein	255:265	arg1	a					274:274	a	274:274	a	274:274	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	7	66	theme	VEGFR2	1309:1314	arg1	levels					1280:1285	the protein levels	1268:1285	the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling	1268:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	7	67	theme	NRP-1	1302:1306	arg1	levels					1280:1285	the protein levels	1268:1285	the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling	1268:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	4	68	theme	endothelial	691:701	arg1	receptor					717:724	vascular endothelial growth factor receptor 2	682:726	vascular endothelial growth factor receptor 2 (VEGFR2)	682:735	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	68	theme	endothelial	691:701	arg1	VEGFR2					729:734	VEGFR2	729:734	VEGFR2	729:734	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	7	69	theme	galectin-1	1290:1299	arg1	levels					1280:1285	the protein levels	1268:1285	the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling	1268:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	8	70	from	pathway	1684:1690	arg1	cells					1707:1711	endothelial cells	1695:1711	endothelial cells	1695:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	5	71	theme	vein	1015:1018	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	71	theme	vein	1015:1018	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	4	72	theme	mitogen-activated	741:757	arg1	MAPK					775:778	MAPK	775:778	MAPK	775:778	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	72	theme	mitogen-activated	741:757	arg1	kinase					767:772	mitogen-activated protein kinase	741:772	mitogen-activated protein kinase (MAPK) signaling	741:789	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	9	73	theme	O-glycans-mediated	1869:1886	arg1	inhibition					1888:1897	apo(a) O-glycans-mediated inhibition	1862:1897	apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1	1862:1942	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	4	74	theme	kinase	767:772	arg1	signaling					781:789	mitogen-activated protein kinase (MAPK) signaling	741:789	mitogen-activated protein kinase (MAPK) signaling	741:789	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	8	75	theme	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated	1618:1661	arg1	pathway					1684:1690	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway	1618:1690	galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells	1618:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	5	76	from	neovascularization	1058:1075	arg1	membrane					1102:1109	chick chorioallantoic membrane	1080:1109	chick chorioallantoic membrane	1080:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	9	77	theme	pro-angiogenic	1906:1919	arg1	activity					1921:1928	the pro-angiogenic activity	1902:1928	the pro-angiogenic activity of galectin-1	1902:1942	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	5	78	from	tube-formation	981:994	arg1	cells					1032:1036	human umbilical vein endothelial cells	999:1036	human umbilical vein endothelial cells (HUVECs)	999:1045	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	78	from	tube-formation	981:994	arg1	HUVECs					1039:1044	HUVECs	1039:1044	HUVECs	1039:1044	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	9	79	theme	higher	1717:1722	arg1	factor					1775:1780	an independent risk factor	1755:1780	an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication	1755:1843	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	79	theme	higher	1717:1722	arg1	level					1737:1741	higher plasma Lp(a) level	1717:1741	higher plasma Lp(a) level in women	1717:1750	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	0	80	theme	galectin-1	104:113	arg1	activity					92:99	the pro-angiogenic activity	73:99	the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells	73:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	7	81	theme	apo	1401:1403	arg1	presence					1389:1396	the presence	1385:1396	the presence of apo(a) with intact O-glycan structures	1385:1438	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	2	82	theme	pro-angiogenic	389:402	arg1	galectin-1					357:366	galectin-1	357:366	galectin-1	357:366	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	82	theme	pro-angiogenic	389:402	arg1	lectin					404:409	an O-glycan binding pro-angiogenic lectin	369:409	an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	369:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	9	83	theme	Lp	1731:1732	arg1	factor					1775:1780	an independent risk factor	1755:1780	an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication	1755:1843	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	83	theme	Lp	1731:1732	arg1	level					1737:1741	higher plasma Lp(a) level	1717:1741	higher plasma Lp(a) level in women	1717:1750	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	6	84	theme	protein-protein	1130:1144	arg1	studies					1158:1164	in vitro protein-protein interaction studies	1121:1164	in vitro protein-protein interaction studies	1121:1164	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	1	85	gly	O-glycoprotein	209:222	arg1	O-glycoprotein					209:222	a highly polymorphic O-glycoprotein	188:222	a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)]	188:276	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	1	85	gly	O-glycoprotein	209:222	arg1	[apo					176:179	Apolipoprotein(a) [apo	158:179	Apolipoprotein(a) [apo(a)]	158:183	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	2	86	theme	vascular	445:452	arg1	tissues					454:460	placental vascular tissues	435:460	placental vascular tissues	435:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	5	87	theme	chorioallantoic	1086:1100	arg1	membrane					1102:1109	chick chorioallantoic membrane	1080:1109	chick chorioallantoic membrane	1080:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	6	88	theme	in	1121:1122	arg1	studies					1158:1164	in vitro protein-protein interaction studies	1121:1164	in vitro protein-protein interaction studies	1121:1164	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	9	89	theme	molecular	1973:1981	arg1	mechanism					1983:1991	the underlying molecular mechanism	1958:1991	the underlying molecular mechanism of pathogenesis of Lp(a)	1958:2016	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	0	90	theme	human	41:45	arg1	lipoprotein					47:57	human lipoprotein	41:57	human lipoprotein(a)	41:60	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	0	90	theme	human	41:45	arg1	a					59:59	a	59:59	a	59:59	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	8	91	from	cells	1707:1711	arg1	inhibition					1604:1613	the inhibition	1600:1613	the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells	1600:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	2	92	theme	strong	339:344	arg1	structures					292:301	The O-glycan structures	279:301	The O-glycan structures of apo(a) subunit of Lp(a)	279:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	92	theme	strong	339:344	arg1	ligands					346:352	strong ligands	339:352	strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	339:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	0	93	from	structures	9:18	arg1	subunit					30:36	apo(a) subunit	23:36	apo(a) subunit of human lipoprotein(a)	23:60	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	4	94	theme	Carbohydrate-dependent	558:579	arg1	binding					581:587	Carbohydrate-dependent binding	558:587	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells	558:670	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	95	gly	O-glycoprotein	614:627	arg1	neuropilin-1					630:641	neuropilin-1	630:641	neuropilin-1 (NRP-1)	630:649	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	95	gly	O-glycoprotein	614:627	arg1	O-glycoprotein					614:627	another O-glycoprotein	606:627	another O-glycoprotein	606:627	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	5	96	theme	human	820:824	arg1	plasma					826:831	human plasma	820:831	human plasma	820:831	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	7	97	theme	MAPK	1344:1347	arg1	signaling					1349:1357	MAPK signaling	1344:1357	MAPK signaling	1344:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	2	98	theme	O-glycan	372:379	arg1	galectin-1					357:366	galectin-1	357:366	galectin-1	357:366	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	98	theme	O-glycan	372:379	arg1	lectin					404:409	an O-glycan binding pro-angiogenic lectin	369:409	an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	369:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	9	99	theme	risk	1770:1773	arg1	factor					1775:1780	an independent risk factor	1755:1780	an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication	1755:1843	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	9	99	theme	risk	1770:1773	arg1	level					1737:1741	higher plasma Lp(a) level	1717:1741	higher plasma Lp(a) level in women	1717:1750	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	5	100	theme	angiogenic	921:930	arg1	tube-formation					981:994	tube-formation	981:994	tube-formation	981:994	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	100	theme	angiogenic	921:930	arg1	migration					966:974	migration	966:974	migration	966:974	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	100	theme	angiogenic	921:930	arg1	properties					932:941	angiogenic properties	921:941	angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane	921:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	5	100	theme	angiogenic	921:930	arg1	proliferation					951:963	proliferation	951:963	proliferation	951:963	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	9	101	from	level	1737:1741	arg1	women					1746:1750	women	1746:1750	women	1746:1750	As higher plasma Lp(a) level in women is an independent risk factor for pre-eclamsia, a pregnancy-associated vascular complication, we propose that apo(a) O-glycans-mediated inhibition of the pro-angiogenic activity of galectin-1 may be one of the underlying molecular mechanism of pathogenesis of Lp(a) in pre-eclampsia.
36809652	2	102	theme	Lp	324:325	arg1	subunit					313:319	apo(a) subunit	306:319	apo(a) subunit of Lp(a)	306:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	8	103	from	inhibition	1604:1613	arg1	cells					1707:1711	endothelial cells	1695:1711	endothelial cells	1695:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	0	104	theme	apo	23:25	arg1	subunit					30:36	apo(a) subunit	23:36	apo(a) subunit of human lipoprotein(a)	23:60	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	2	105	theme	subunit	313:319	arg1	structures					292:301	The O-glycan structures	279:301	The O-glycan structures of apo(a) subunit of Lp(a)	279:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	2	105	theme	subunit	313:319	arg1	ligands					346:352	strong ligands	339:352	strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues	339:460	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	0	106	from	cells	151:155	arg1	activity					92:99	the pro-angiogenic activity	73:99	the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells	73:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	3	107	theme	-galectin-1	512:522	arg1	binding					524:530	apo(a)-galectin-1 binding	506:530	apo(a)-galectin-1 binding	506:530	But the pathophysiological significance of apo(a)-galectin-1 binding is not yet been revealed.
36809652	2	108	theme	a	310:310	arg1	subunit					313:319	apo(a) subunit	306:319	apo(a) subunit of Lp(a)	306:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	6	109	theme	galectin-1	1222:1231	arg1	binding					1233:1239	galectin-1 binding	1222:1239	galectin-1 binding	1222:1239	Further, in vitro protein-protein interaction studies have confirmed apo(a) as a superior ligand to NRP-1 for galectin-1 binding.
36809652	1	110	theme	human	239:243	arg1	plasma					245:250	human plasma	239:250	human plasma	239:250	Apolipoprotein(a) [apo(a)] is a highly polymorphic O-glycoprotein circulating in human plasma as lipoprotein(a) [Lp(a)].
36809652	4	111	theme	growth	703:708	arg1	receptor					717:724	vascular endothelial growth factor receptor 2	682:726	vascular endothelial growth factor receptor 2 (VEGFR2)	682:735	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	111	theme	growth	703:708	arg1	VEGFR2					729:734	VEGFR2	729:734	VEGFR2	729:734	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	2	112	theme	apo	306:308	arg1	subunit					313:319	apo(a) subunit	306:319	apo(a) subunit of Lp(a)	306:328	The O-glycan structures of apo(a) subunit of Lp(a) serve as strong ligands of galectin-1, an O-glycan binding pro-angiogenic lectin abundantly expressed in placental vascular tissues.
36809652	5	113	from	properties	932:941	arg1	membrane					1102:1109	chick chorioallantoic membrane	1080:1109	chick chorioallantoic membrane	1080:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	7	114	theme	downstream	1321:1330	arg1	proteins					1332:1339	downstream proteins	1321:1339	downstream proteins	1321:1339	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	5	115	theme	structures	880:889	arg1	potential					854:862	the potential	850:862	the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane	850:1109	Using apo(a), isolated from human plasma, we demonstrated the potential of the O-glycan structures of apo(a) in Lp(a) to inhibit angiogenic properties such as proliferation, migration, and tube-formation in human umbilical vein endothelial cells (HUVECs) as well as neovascularization in chick chorioallantoic membrane.
36809652	8	116	theme	endothelial	1695:1705	arg1	cells					1707:1711	endothelial cells	1695:1711	endothelial cells	1695:1711	In conclusion, our study shows that apo(a)-linked O-glycans prevent the binding of galectin-1 to NRP-1 leading to the inhibition of galectin-1/neuropilin-1/VEGFR2/MAPK-mediated angiogenic signaling pathway in endothelial cells.
36809652	0	117	from	galectin-1	104:113	arg1	cells					151:155	human umbilical vein endothelial cells	118:155	human umbilical vein endothelial cells	118:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	7	118	from	NRP-1	1302:1306	arg1	signaling					1349:1357	MAPK signaling	1344:1357	MAPK signaling	1344:1357	We also demonstrated that the protein levels of galectin-1, NRP-1, VEGFR2, and downstream proteins in MAPK signaling were reduced in HUVECs in the presence of apo(a) with intact O-glycan structures compared to that of de-O-glycosylated apo(a).
36809652	0	119	from	activity	92:99	arg1	cells					151:155	human umbilical vein endothelial cells	118:155	human umbilical vein endothelial cells	118:155	O-glycan structures in apo(a) subunit of human lipoprotein(a) suppresses the pro-angiogenic activity of galectin-1 on human umbilical vein endothelial cells.
36809652	4	120	theme	vascular	682:689	arg1	receptor					717:724	vascular endothelial growth factor receptor 2	682:726	vascular endothelial growth factor receptor 2 (VEGFR2)	682:735	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	120	theme	vascular	682:689	arg1	VEGFR2					729:734	VEGFR2	729:734	VEGFR2	729:734	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36809652	4	121	from	binding	581:587	arg1	cells					666:670	endothelial cells	654:670	endothelial cells	654:670	Carbohydrate-dependent binding of galectin-1 to another O-glycoprotein, neuropilin-1 (NRP-1) on endothelial cells activates vascular endothelial growth factor receptor 2 (VEGFR2) and mitogen-activated protein kinase (MAPK) signaling.
36399685	6	0	theme	genotype-glycophenotype	1043:1065	arg1	link					1067:1070	a genotype-glycophenotype link	1041:1070	a genotype-glycophenotype link between an arrested glycoprotein	1041:1103	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36399685	7	1	theme	biological	1229:1238	arg1	properties					1256:1265	advantageous biological and biophysical properties	1216:1265	advantageous biological and biophysical properties	1216:1265	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	0	2	from	Stalling	9:16	arg1	Extracts					57:64	Cell-Free Extracts	47:64	Cell-Free Extracts	47:64	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.
36399685	1	3	theme	proteins	154:161	arg1	selection					118:126	selection	118:126	selection	118:126	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	1	3	theme	proteins	154:161	arg1	evolution					141:149	directed evolution	132:149	directed evolution	132:149	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	5	4	theme	ribosome	820:827	arg1	stalling					829:836	ribosome stalling	820:836	ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures	820:933	This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures.
36399685	4	5	gly	N-glycoprotein	742:755	arg1	N-glycoprotein					742:755	cell-free N-glycoprotein synthesis	732:765	cell-free N-glycoprotein synthesis	732:765	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	6	6	gly	glycoprotein	1092:1103	arg1	glycoprotein					1092:1103	an arrested glycoprotein	1080:1103	an arrested glycoprotein	1080:1103	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36399685	1	7	theme	Ribosome	67:74	arg1	display					76:82	Ribosome display	67:82	Ribosome display	67:82	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	1	7	theme	Ribosome	67:74	arg1	method					107:112	a powerful in vitro method	87:112	a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries	87:200	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	4	8	theme	translation	696:706	arg1	arrest					708:713	SecM-mediated translation arrest	682:713	SecM-mediated translation arrest	682:713	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	7	9	with	selection	1168:1176	arg1	properties					1256:1265	advantageous biological and biophysical properties	1216:1265	advantageous biological and biophysical properties	1216:1265	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	7	10	with	evolution	1182:1190	arg1	properties					1256:1265	advantageous biological and biophysical properties	1216:1265	advantageous biological and biophysical properties	1216:1265	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	4	11	theme	cell-free	732:740	arg1	synthesis					757:765	cell-free N-glycoprotein synthesis	732:765	cell-free N-glycoprotein synthesis	732:765	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	0	12	theme	Cell-Free	47:55	arg1	Extracts					57:64	Cell-Free Extracts	47:64	Cell-Free Extracts	47:64	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.
36399685	3	13	link	asparagine-linked	445:461	arg1	glycoproteins					474:486	asparagine-linked (N-linked) glycoproteins	445:486	asparagine-linked (N-linked) glycoproteins	445:486	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	3	14	theme	N-linked	464:471	arg1	glycoproteins					474:486	asparagine-linked (N-linked) glycoproteins	445:486	asparagine-linked (N-linked) glycoproteins	445:486	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	6	15	theme	message	1117:1123	arg1	evidence					1029:1036	evidence	1029:1036	evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message	1029:1123	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36399685	1	16	theme	combinatorial	178:190	arg1	libraries					192:200	combinatorial libraries	178:200	combinatorial libraries	178:200	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	0	17	theme	Ribosome	0:7	arg1	Stalling					9:16	Ribosome Stalling	0:16	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.	0:65	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.
36399685	4	18	theme	ribosome-nascent	611:626	arg1	glycoRNC					635:642	glycoRNC	635:642	glycoRNC	635:642	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	4	18	theme	ribosome-nascent	611:626	arg1	chain					628:632	ribosome-nascent chain	611:632	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	3	19	link	N-linked	464:471	arg1	glycoproteins					474:486	asparagine-linked (N-linked) glycoproteins	445:486	asparagine-linked (N-linked) glycoproteins	445:486	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	1	20	theme	powerful	89:96	arg1	display					76:82	Ribosome display	67:82	Ribosome display	67:82	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	1	20	theme	powerful	89:96	arg1	method					107:112	a powerful in vitro method	87:112	a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries	87:200	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	3	21	theme	asparagine-linked	445:461	arg1	glycoproteins					474:486	asparagine-linked (N-linked) glycoproteins	445:486	asparagine-linked (N-linked) glycoproteins	445:486	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	3	22	theme	complementary	367:379	arg1	methods					381:387	complementary methods	367:387	complementary methods	367:387	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	4	23	theme	glycosylated	598:609	arg1	complexes					645:653	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	7	24	theme	advantageous	1216:1227	arg1	properties					1256:1265	advantageous biological and biophysical properties	1216:1265	advantageous biological and biophysical properties	1216:1265	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	1	25	theme	in	98:99	arg1	display					76:82	Ribosome display	67:82	Ribosome display	67:82	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	1	25	theme	in	98:99	arg1	method					107:112	a powerful in vitro method	87:112	a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries	87:200	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	3	26	theme	methods	381:387	arg1	set					360:362	a set	358:362	a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation	358:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	3	26	theme	methods	381:387	arg1	methods					381:387	complementary methods	367:387	complementary methods	367:387	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	5	27	theme	first-in-kind	795:807	arg1	method					809:814	a first-in-kind method	793:814	a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures	793:933	This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures.
36399685	3	28	theme	glycostructural	543:557	arg1	interrogation					559:571	downstream functional and glycostructural interrogation	517:571	downstream functional and glycostructural interrogation	517:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	1	29	theme	directed	132:139	arg1	evolution					141:149	directed evolution	132:149	directed evolution	132:149	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	4	30	theme	chain	628:632	arg1	complexes					645:653	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	7	31	theme	N-glycoproteins	1195:1209	arg1	evolution					1182:1190	evolution	1182:1190	evolution	1182:1190	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	7	31	theme	N-glycoproteins	1195:1209	arg1	selection					1168:1176	selection	1168:1176	selection	1168:1176	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	4	32	theme	N-glycoprotein	742:755	arg1	synthesis					757:765	cell-free N-glycoprotein synthesis	732:765	cell-free N-glycoprotein synthesis	732:765	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	0	33	theme	Glycoproteins	30:42	arg1	Stalling					9:16	Ribosome Stalling	0:16	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.	0:65	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.
36399685	0	34	theme	N-Linked	21:28	arg1	Glycoproteins					30:42	N-Linked Glycoproteins	21:42	N-Linked Glycoproteins	21:42	Ribosome Stalling of N-Linked Glycoproteins in Cell-Free Extracts.
36399685	4	35	gly	glycosylated	598:609	arg1	complexes					645:653	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	glycosylated ribosome-nascent chain (glycoRNC) complexes	598:653	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	5	36	theme	target	841:846	arg1	proteins					848:855	target proteins	841:855	target proteins modified efficiently and site-specifically with different N-glycan structures	841:933	This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures.
36399685	3	37	theme	stalled	403:409	arg1	complexes					420:428	stalled ribosome complexes	403:428	stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation	403:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	6	38	theme	arrested	1083:1090	arg1	glycoprotein					1092:1103	an arrested glycoprotein	1080:1103	an arrested glycoprotein	1080:1103	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36399685	5	39	theme	N-glycan	915:922	arg1	structures					924:933	different N-glycan structures	905:933	different N-glycan structures	905:933	This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures.
36399685	6	40	theme	RNA	1113:1115	arg1	message					1117:1123	its RNA message	1109:1123	its RNA message	1109:1123	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36399685	3	41	gly	glycoproteins	474:486	arg1	glycoproteins					474:486	asparagine-linked (N-linked) glycoproteins	445:486	asparagine-linked (N-linked) glycoproteins	445:486	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	3	42	theme	downstream	517:526	arg1	interrogation					559:571	downstream functional and glycostructural interrogation	517:571	downstream functional and glycostructural interrogation	517:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	3	43	theme	ribosome	411:418	arg1	complexes					420:428	stalled ribosome complexes	403:428	stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation	403:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	7	44	gly	N-glycoproteins	1195:1209	arg1	N-glycoproteins					1195:1209	N-glycoproteins	1195:1209	N-glycoproteins	1195:1209	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	6	45	theme	encoding	967:974	arg1	mRNAs					976:980	encoding mRNAs	967:980	encoding mRNAs	967:980	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36399685	3	46	theme	functional	528:537	arg1	interrogation					559:571	downstream functional and glycostructural interrogation	517:571	downstream functional and glycostructural interrogation	517:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	3	47	theme	amenable	505:512	arg1	conformations					491:503	conformations	491:503	conformations amenable to downstream functional and glycostructural interrogation	491:571	To address this gap, we developed a set of complementary methods for producing stalled ribosome complexes that displayed asparagine-linked (N-linked) glycoproteins in conformations amenable to downstream functional and glycostructural interrogation.
36399685	2	48	theme	post-translational	257:274	arg1	glycosylation					298:310	glycosylation	298:310	glycosylation	298:310	However, the ability to display proteins with complex post-translational modifications such as glycosylation is limited.
36399685	2	48	theme	post-translational	257:274	arg1	modifications					276:288	complex post-translational modifications	249:288	complex post-translational modifications such as glycosylation	249:310	However, the ability to display proteins with complex post-translational modifications such as glycosylation is limited.
36399685	7	49	theme	biophysical	1244:1254	arg1	properties					1256:1265	advantageous biological and biophysical properties	1216:1265	advantageous biological and biophysical properties	1216:1265	We anticipate that our method will enable selection and evolution of N-glycoproteins with advantageous biological and biophysical properties.
36399685	5	50	theme	proteins	848:855	arg1	stalling					829:836	ribosome stalling	820:836	ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures	820:933	This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures.
36399685	2	51	theme	complex	249:255	arg1	glycosylation					298:310	glycosylation	298:310	glycosylation	298:310	However, the ability to display proteins with complex post-translational modifications such as glycosylation is limited.
36399685	2	51	theme	complex	249:255	arg1	modifications					276:288	complex post-translational modifications	249:288	complex post-translational modifications such as glycosylation	249:310	However, the ability to display proteins with complex post-translational modifications such as glycosylation is limited.
36399685	1	52	dep	in	98:99	arg1	vitro					101:105	vitro	101:105	vitro	101:105	Ribosome display is a powerful in vitro method for selection and directed evolution of proteins expressed from combinatorial libraries.
36399685	4	53	theme	SecM-mediated	682:694	arg1	arrest					708:713	SecM-mediated translation arrest	682:713	SecM-mediated translation arrest	682:713	The ability to generate glycosylated ribosome-nascent chain (glycoRNC) complexes was enabled by integrating SecM-mediated translation arrest with methods for cell-free N-glycoprotein synthesis.
36399685	5	54	theme	different	905:913	arg1	structures					924:933	different N-glycan structures	905:933	different N-glycan structures	905:933	This integration enabled a first-in-kind method for ribosome stalling of target proteins modified efficiently and site-specifically with different N-glycan structures.
36399685	6	55	theme	link	1067:1070	arg1	evidence					1029:1036	evidence	1029:1036	evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message	1029:1123	Moreover, the observation that encoding mRNAs remained stably attached to ribosomes provides evidence of a genotype-glycophenotype link between an arrested glycoprotein and its RNA message.
36044591	6	0	theme	varying	1085:1091	arg1	properties					1101:1110	varying binding properties	1085:1110	varying binding properties	1085:1110	Fluorescence-based microplate screening of carbohydrate binding showed that these compounds exhibit varying binding properties depending on their structures.
36044591	8	1	theme	glycan	1357:1362	arg1	system					1381:1386	an exciting glycan binding liposome system	1345:1386	an exciting glycan binding liposome system for targeted delivery	1345:1408	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	8	1	theme	glycan	1357:1362	arg1	BBALs					1330:1334	multivalent BBALs	1318:1334	multivalent BBALs	1318:1334	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	4	2	theme	cell	782:785	arg1	recognition					795:805	cell surface recognition	782:805	cell surface recognition based on carbohydrate binding interactions	782:848	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	6	3	theme	carbohydrate	1028:1039	arg1	binding					1041:1047	carbohydrate binding	1028:1047	carbohydrate binding	1028:1047	Fluorescence-based microplate screening of carbohydrate binding showed that these compounds exhibit varying binding properties depending on their structures.
36044591	6	4	theme	binding	1093:1099	arg1	properties					1101:1110	varying binding properties	1085:1110	varying binding properties	1085:1110	Fluorescence-based microplate screening of carbohydrate binding showed that these compounds exhibit varying binding properties depending on their structures.
36044591	5	5	theme	variable	908:915	arg1	linkers					917:923	variable linkers	908:923	variable linkers	908:923	In order to vary properties, multiple BBALs (1 a-d) with variable linkers in between the binding units were designed and synthesized.
36044591	5	6	theme	binding	940:946	arg1	units					948:952	the binding units	936:952	the binding units	936:952	In order to vary properties, multiple BBALs (1 a-d) with variable linkers in between the binding units were designed and synthesized.
36044591	7	7	theme	fluorescence	1157:1168	arg1	experiments					1181:1191	fluorescence microscopy experiments	1157:1191	fluorescence microscopy experiments	1157:1191	Additionally, fluorescence microscopy experiments indicated enhancements in cellular association when BBALs were incorporated within liposomes.
36044591	3	8	theme	glycan	520:525	arg1	overabundance					527:539	glycan overabundance	520:539	glycan overabundance	520:539	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	9	theme	glycosylation	554:566	arg1	patterns					568:575	aberrant glycosylation patterns	545:575	aberrant glycosylation patterns	545:575	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	9	theme	glycosylation	554:566	arg1	feature					590:596	a common feature	581:596	a common feature of diseased cells	581:614	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	4	10	theme	acid	681:684	arg1	BBALs					694:698	BBALs	694:698	BBALs	694:698	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	4	10	theme	acid	681:684	arg1	lipids					686:691	bis-boronic acid lipids	669:691	bis-boronic acid lipids (BBALs)	669:699	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	3	11	theme	common	583:588	arg1	patterns					568:575	aberrant glycosylation patterns	545:575	aberrant glycosylation patterns	545:575	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	11	theme	common	583:588	arg1	feature					590:596	a common feature	581:596	a common feature of diseased cells	581:614	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	7	12	theme	microscopy	1170:1179	arg1	experiments					1181:1191	fluorescence microscopy experiments	1157:1191	fluorescence microscopy experiments	1157:1191	Additionally, fluorescence microscopy experiments indicated enhancements in cellular association when BBALs were incorporated within liposomes.
36044591	6	13	theme	microplate	1004:1013	arg1	screening					1015:1023	Fluorescence-based microplate screening	985:1023	Fluorescence-based microplate screening of carbohydrate binding	985:1047	Fluorescence-based microplate screening of carbohydrate binding showed that these compounds exhibit varying binding properties depending on their structures.
36044591	5	14	from	BBALs	889:893	arg1	units					948:952	the binding units	936:952	the binding units	936:952	In order to vary properties, multiple BBALs (1 a-d) with variable linkers in between the binding units were designed and synthesized.
36044591	4	15	theme	selective	741:749	arg1	sensing					762:768	selective saccharide sensing	741:768	selective saccharide sensing	741:768	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	4	16	theme	surface	787:793	arg1	recognition					795:805	cell surface recognition	782:805	cell surface recognition based on carbohydrate binding interactions	782:848	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	1	17	theme	pharmacokinetic	180:194	arg1	properties					196:205	the pharmacokinetic properties	176:205	the pharmacokinetic properties of a wide range of drugs and diagnostic agents	176:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	0	18	theme	Bis-Boronic	0:10	arg1	Acid					12:15	Bis-Boronic Acid	0:15	Bis-Boronic Acid	0:15	Bis-Boronic Acid Liposomes for Carbohydrate Recognition and Cellular Delivery.
36044591	4	19	theme	bis-boronic	669:679	arg1	BBALs					694:698	BBALs	694:698	BBALs	694:698	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	4	19	theme	bis-boronic	669:679	arg1	lipids					686:691	bis-boronic acid lipids	669:691	bis-boronic acid lipids (BBALs)	669:699	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	1	20	theme	effective	93:101	arg1	Liposomes					79:87	Liposomes	79:87	Liposomes	79:87	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	1	20	theme	effective	93:101	arg1	nanocarriers					115:126	effective therapeutic nanocarriers	93:126	effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents	93:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	3	21	theme	Cell	389:392	arg1	glycans					403:409	Cell membrane glycans	389:409	Cell membrane glycans	389:409	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	6	22	theme	Fluorescence-based	985:1002	arg1	screening					1015:1023	Fluorescence-based microplate screening	985:1023	Fluorescence-based microplate screening of carbohydrate binding	985:1047	Fluorescence-based microplate screening of carbohydrate binding showed that these compounds exhibit varying binding properties depending on their structures.
36044591	1	23	theme	therapeutic	103:113	arg1	Liposomes					79:87	Liposomes	79:87	Liposomes	79:87	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	1	23	theme	therapeutic	103:113	arg1	nanocarriers					115:126	effective therapeutic nanocarriers	93:126	effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents	93:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	8	24	theme	exciting	1348:1355	arg1	system					1381:1386	an exciting glycan binding liposome system	1345:1386	an exciting glycan binding liposome system for targeted delivery	1345:1408	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	8	24	theme	exciting	1348:1355	arg1	BBALs					1330:1334	multivalent BBALs	1318:1334	multivalent BBALs	1318:1334	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	4	25	theme	carbohydrate	816:827	arg1	interactions					837:848	carbohydrate binding interactions	816:848	carbohydrate binding interactions	816:848	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	2	26	theme	liposomal	305:313	arg1	delivery					320:327	liposomal drug delivery	305:327	liposomal drug delivery	305:327	A primary area in which improvement is needed for liposomal drug delivery is to maximize the delivery of these nanocarriers to cells.
36044591	1	27	theme	wide	212:215	arg1	range					217:221	a wide range	210:221	a wide range of drugs and diagnostic agents	210:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	2	28	theme	drug	315:318	arg1	delivery					320:327	liposomal drug delivery	305:327	liposomal drug delivery	305:327	A primary area in which improvement is needed for liposomal drug delivery is to maximize the delivery of these nanocarriers to cells.
36044591	1	29	theme	due	128:130	arg1	Liposomes					79:87	Liposomes	79:87	Liposomes	79:87	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	1	29	theme	due	128:130	arg1	nanocarriers					115:126	effective therapeutic nanocarriers	93:126	effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents	93:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	1	30	theme	range	217:221	arg1	properties					196:205	the pharmacokinetic properties	176:205	the pharmacokinetic properties of a wide range of drugs and diagnostic agents	176:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	7	31	theme	cellular	1219:1226	arg1	association					1228:1238	cellular association	1219:1238	cellular association	1219:1238	Additionally, fluorescence microscopy experiments indicated enhancements in cellular association when BBALs were incorporated within liposomes.
36044591	3	32	theme	cells	610:614	arg1	patterns					568:575	aberrant glycosylation patterns	545:575	aberrant glycosylation patterns	545:575	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	32	theme	cells	610:614	arg1	feature					590:596	a common feature	581:596	a common feature of diseased cells	581:614	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	8	33	theme	liposome	1372:1379	arg1	system					1381:1386	an exciting glycan binding liposome system	1345:1386	an exciting glycan binding liposome system for targeted delivery	1345:1408	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	8	33	theme	liposome	1372:1379	arg1	BBALs					1330:1334	multivalent BBALs	1318:1334	multivalent BBALs	1318:1334	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	0	34	theme	Carbohydrate	31:42	arg1	Recognition					44:54	Carbohydrate Recognition	31:54	Carbohydrate Recognition	31:54	Bis-Boronic Acid Liposomes for Carbohydrate Recognition and Cellular Delivery.
36044591	3	35	theme	exciting	419:426	arg1	targets					428:434	exciting targets	419:434	exciting targets for liposomal delivery	419:457	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	4	36	theme	binding	829:835	arg1	interactions					837:848	carbohydrate binding interactions	816:848	carbohydrate binding interactions	816:848	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	1	37	theme	drugs	226:230	arg1	range					217:221	a wide range	210:221	a wide range of drugs and diagnostic agents	210:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	3	38	theme	membrane	394:401	arg1	glycans					403:409	Cell membrane glycans	389:409	Cell membrane glycans	389:409	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	5	39	with	BBALs	889:893	arg1	linkers					917:923	variable linkers	908:923	variable linkers	908:923	In order to vary properties, multiple BBALs (1 a-d) with variable linkers in between the binding units were designed and synthesized.
36044591	3	40	theme	liposomal	440:448	arg1	delivery					450:457	liposomal delivery	440:457	liposomal delivery	440:457	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	41	theme	diseased	601:608	arg1	cells					610:614	diseased cells	601:614	diseased cells	601:614	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	42	theme	cell	501:504	arg1	membranes					506:514	cell membranes	501:514	cell membranes	501:514	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	43	theme	aberrant	545:552	arg1	patterns					568:575	aberrant glycosylation patterns	545:575	aberrant glycosylation patterns	545:575	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	3	43	theme	aberrant	545:552	arg1	feature					590:596	a common feature	581:596	a common feature of diseased cells	581:614	Cell membrane glycans provide exciting targets for liposomal delivery since they are often densely clustered on cell membranes and glycan overabundance and aberrant glycosylation patterns are a common feature of diseased cells.
36044591	4	44	theme	saccharide	751:760	arg1	sensing					762:768	selective saccharide sensing	741:768	selective saccharide sensing	741:768	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	8	45	theme	targeted	1392:1399	arg1	delivery					1401:1408	targeted delivery	1392:1408	targeted delivery	1392:1408	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	8	46	theme	multivalent	1318:1328	arg1	BBALs					1330:1334	multivalent BBALs	1318:1334	multivalent BBALs	1318:1334	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	8	46	theme	multivalent	1318:1328	arg1	system					1381:1386	an exciting glycan binding liposome system	1345:1386	an exciting glycan binding liposome system for targeted delivery	1345:1408	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	1	47	theme	diagnostic	236:245	arg1	agents					247:252	diagnostic agents	236:252	diagnostic agents	236:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	8	48	theme	binding	1364:1370	arg1	system					1381:1386	an exciting glycan binding liposome system	1345:1386	an exciting glycan binding liposome system for targeted delivery	1345:1408	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	8	48	theme	binding	1364:1370	arg1	BBALs					1330:1334	multivalent BBALs	1318:1334	multivalent BBALs	1318:1334	These results demonstrate that multivalent BBALs serve as an exciting glycan binding liposome system for targeted delivery.
36044591	2	49	theme	primary	257:263	arg1	area					265:268	A primary area	255:268	A primary area in which improvement is needed for liposomal drug delivery	255:327	A primary area in which improvement is needed for liposomal drug delivery is to maximize the delivery of these nanocarriers to cells.
36044591	4	50	theme	liposome	637:644	arg1	platform					646:653	a liposome platform	635:653	a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions	635:848	Herein, we report a liposome platform incorporating bis-boronic acid lipids (BBALs) to increase valency in order to achieve selective saccharide sensing and enhance cell surface recognition based on carbohydrate binding interactions.
36044591	2	51	theme	nanocarriers	366:377	arg1	delivery					348:355	the delivery	344:355	the delivery of these nanocarriers to cells	344:386	A primary area in which improvement is needed for liposomal drug delivery is to maximize the delivery of these nanocarriers to cells.
36044591	5	52	theme	multiple	880:887	arg1	1 a-d					896:900	1 a-d	896:900	1 a-d	896:900	In order to vary properties, multiple BBALs (1 a-d) with variable linkers in between the binding units were designed and synthesized.
36044591	5	52	theme	multiple	880:887	arg1	BBALs					889:893	multiple BBALs	880:893	multiple BBALs (1 a-d) with variable linkers in between the binding units	880:952	In order to vary properties, multiple BBALs (1 a-d) with variable linkers in between the binding units were designed and synthesized.
36044591	1	53	theme	agents	247:252	arg1	range					217:221	a wide range	210:221	a wide range of drugs and diagnostic agents	210:252	Liposomes are effective therapeutic nanocarriers due to their ability to encapsulate and enhance the pharmacokinetic properties of a wide range of drugs and diagnostic agents.
36044591	0	54	theme	Cellular	60:67	arg1	Delivery					69:76	Cellular Delivery	60:76	Cellular Delivery	60:76	Bis-Boronic Acid Liposomes for Carbohydrate Recognition and Cellular Delivery.
36044591	6	55	theme	binding	1041:1047	arg1	screening					1015:1023	Fluorescence-based microplate screening	985:1023	Fluorescence-based microplate screening of carbohydrate binding	985:1047	Fluorescence-based microplate screening of carbohydrate binding showed that these compounds exhibit varying binding properties depending on their structures.
35281276	6	0	with	line	592:595	arg1	cytokines					667:675	cytokines	667:675	cytokines (IL-4 and TNF-α)	667:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	0	with	line	592:595	arg1	wells					657:661	fibronectin (FN) coated wells	633:661	fibronectin (FN) coated wells	633:661	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	0	with	line	592:595	arg1	TNF-α					687:691	TNF-α	687:691	TNF-α	687:691	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	0	with	line	592:595	arg1	IL-4					678:681	IL-4	678:681	IL-4	678:681	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	3	1	theme	cellular	266:273	arg1	receptors					275:283	Many cellular receptors	261:283	Many cellular receptors	261:283	Many cellular receptors are glycosylated, and their activity can be modulated through changes in glycan structure.
35281276	6	2	theme	cultured	576:583	arg1	line					592:595	a cultured T cell line	574:595	a cultured T cell line (Jurkat)	574:604	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	2	theme	cultured	576:583	arg1	assay					622:626	a transwell assay	610:626	a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α)	610:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	2	theme	cultured	576:583	arg1	chemoattractants					697:712	chemoattractants	697:712	chemoattractants in the bottom chamber	697:734	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	2	theme	cultured	576:583	arg1	Jurkat					598:603	Jurkat	598:603	Jurkat	598:603	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	3	theme	bottom	721:726	arg1	chamber					728:734	the bottom chamber	717:734	the bottom chamber	717:734	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	1	4	theme	immune	142:147	arg1	response					149:156	the immune response	138:156	the immune response	138:156	Cell migration to a site of inflammation is an important step of the immune response.
35281276	9	5	theme	NEU	964:966	arg1	targets					1079:1085	targets	1079:1085	targets for anti-inflammatory strategies	1079:1118	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	5	theme	NEU	964:966	arg1	NEU4					995:998	NEU4	995:998	NEU4	995:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	5	theme	NEU	964:966	arg1	NEU1					979:982	NEU1	979:982	NEU1	979:982	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	5	theme	NEU	964:966	arg1	NEU3					985:988	NEU3	985:988	NEU3	985:988	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	5	theme	NEU	964:966	arg1	regulators					1020:1029	positive regulators	1011:1029	positive regulators of transmigration	1011:1047	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	5	theme	NEU	964:966	arg1	isoenzymes					968:977	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	4	6	dep	folding	426:432	arg1	the					422:424	the	422:424	the	422:424	Furthermore, glycosylation can be critical to the folding and trafficking of receptors.
35281276	9	7	theme	positive	1011:1018	arg1	regulators					1020:1029	positive regulators	1011:1029	positive regulators of transmigration	1011:1047	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	7	theme	positive	1011:1018	arg1	isoenzymes					968:977	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	2	8	theme	cell	255:258	arg1	machinery					238:246	the signal processing machinery	216:246	the signal processing machinery of the cell	216:258	This process is coordinated by cytokines, receptors, and the signal processing machinery of the cell.
35281276	2	8	theme	cell	255:258	arg1	receptors					201:209	receptors	201:209	receptors	201:209	This process is coordinated by cytokines, receptors, and the signal processing machinery of the cell.
35281276	2	8	theme	cell	255:258	arg1	cytokines					190:198	cytokines	190:198	cytokines	190:198	This process is coordinated by cytokines, receptors, and the signal processing machinery of the cell.
35281276	3	9	from	changes	347:353	arg1	structure					365:373	glycan structure	358:373	glycan structure	358:373	Many cellular receptors are glycosylated, and their activity can be modulated through changes in glycan structure.
35281276	8	10	theme	pharmacological	871:885	arg1	inhibition					887:896	pharmacological inhibition	871:896	pharmacological inhibition of these enzymes	871:913	Furthermore, we found that pharmacological inhibition of these enzymes inhibited transmigration.
35281276	1	11	theme	Cell	73:76	arg1	migration					78:86	Cell migration	73:86	Cell migration to a site of inflammation	73:112	Cell migration to a site of inflammation is an important step of the immune response.
35281276	1	11	theme	Cell	73:76	arg1	step					130:133	an important step	117:133	an important step of the immune response	117:156	Cell migration to a site of inflammation is an important step of the immune response.
35281276	6	12	theme	fibronectin	633:643	arg1	wells					657:661	fibronectin (FN) coated wells	633:661	fibronectin (FN) coated wells	633:661	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	1	13	theme	response	149:156	arg1	migration					78:86	Cell migration	73:86	Cell migration to a site of inflammation	73:112	Cell migration to a site of inflammation is an important step of the immune response.
35281276	1	13	theme	response	149:156	arg1	step					130:133	an important step	117:133	an important step of the immune response	117:156	Cell migration to a site of inflammation is an important step of the immune response.
35281276	5	14	theme	enzymes	533:539	arg1	role					498:501	the role	494:501	the role of native human neuraminidase enzymes (NEU) in transmigration	494:563	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	5	15	from	role	498:501	arg1	transmigration					550:563	transmigration	550:563	transmigration	550:563	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	4	16	theme	receptors	453:461	arg1	trafficking					438:448	trafficking	438:448	trafficking	438:448	Furthermore, glycosylation can be critical to the folding and trafficking of receptors.
35281276	4	16	theme	receptors	453:461	arg1	folding					426:432	folding	426:432	folding	426:432	Furthermore, glycosylation can be critical to the folding and trafficking of receptors.
35281276	9	17	dep	isoenzymes	968:977	arg1	NEU3					985:988	NEU3	985:988	NEU3	985:988	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	17	dep	isoenzymes	968:977	arg1	NEU4					995:998	NEU4	995:998	NEU4	995:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	17	dep	isoenzymes	968:977	arg1	NEU1					979:982	NEU1	979:982	NEU1	979:982	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	17	dep	isoenzymes	968:977	arg1	isoenzymes					968:977	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	18	theme	human	958:962	arg1	targets					1079:1085	targets	1079:1085	targets for anti-inflammatory strategies	1079:1118	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	18	theme	human	958:962	arg1	NEU4					995:998	NEU4	995:998	NEU4	995:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	18	theme	human	958:962	arg1	NEU1					979:982	NEU1	979:982	NEU1	979:982	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	18	theme	human	958:962	arg1	NEU3					985:988	NEU3	985:988	NEU3	985:988	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	18	theme	human	958:962	arg1	regulators					1020:1029	positive regulators	1011:1029	positive regulators of transmigration	1011:1047	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	18	theme	human	958:962	arg1	isoenzymes					968:977	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	3	19	theme	glycan	358:363	arg1	structure					365:373	glycan structure	358:373	glycan structure	358:373	Many cellular receptors are glycosylated, and their activity can be modulated through changes in glycan structure.
35281276	6	20	theme	transwell	612:620	arg1	line					592:595	a cultured T cell line	574:595	a cultured T cell line (Jurkat)	574:604	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	20	theme	transwell	612:620	arg1	chemoattractants					697:712	chemoattractants	697:712	chemoattractants in the bottom chamber	697:734	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	20	theme	transwell	612:620	arg1	assay					622:626	a transwell assay	610:626	a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α)	610:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	0	21	theme	Neuraminidase	20:32	arg1	Enzymes					34:40	Human Neuraminidase Enzymes	14:40	Human Neuraminidase Enzymes	14:40	Inhibitors of Human Neuraminidase Enzymes Block Transmigration in vitro.
35281276	8	22	theme	enzymes	907:913	arg1	inhibition					887:896	pharmacological inhibition	871:896	pharmacological inhibition of these enzymes	871:913	Furthermore, we found that pharmacological inhibition of these enzymes inhibited transmigration.
35281276	6	23	dep	cytokines	667:675	arg1	cytokines					667:675	cytokines	667:675	cytokines (IL-4 and TNF-α)	667:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	23	dep	cytokines	667:675	arg1	TNF-α					687:691	TNF-α	687:691	TNF-α	687:691	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	23	dep	cytokines	667:675	arg1	IL-4					678:681	IL-4	678:681	IL-4	678:681	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	0	24	theme	Human	14:18	arg1	Enzymes					34:40	Human Neuraminidase Enzymes	14:40	Human Neuraminidase Enzymes	14:40	Inhibitors of Human Neuraminidase Enzymes Block Transmigration in vitro.
35281276	6	25	with	assay	622:626	arg1	cytokines					667:675	cytokines	667:675	cytokines (IL-4 and TNF-α)	667:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	25	with	assay	622:626	arg1	wells					657:661	fibronectin (FN) coated wells	633:661	fibronectin (FN) coated wells	633:661	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	25	with	assay	622:626	arg1	TNF-α					687:691	TNF-α	687:691	TNF-α	687:691	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	25	with	assay	622:626	arg1	IL-4					678:681	IL-4	678:681	IL-4	678:681	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	26	used	used	569:572	arg2	We					566:567	We	566:567	We	566:567	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	0	27	theme	Enzymes	34:40	arg1	Inhibitors					0:9	Inhibitors	0:9	Inhibitors of Human Neuraminidase Enzymes	0:40	Inhibitors of Human Neuraminidase Enzymes Block Transmigration in vitro.
35281276	5	28	theme	native	506:511	arg1	NEU					542:544	NEU	542:544	NEU	542:544	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	5	28	theme	native	506:511	arg1	enzymes					533:539	native human neuraminidase enzymes	506:539	native human neuraminidase enzymes (NEU)	506:545	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	1	29	theme	inflammation	101:112	arg1	inflammation					101:112	inflammation	101:112	inflammation	101:112	Cell migration to a site of inflammation is an important step of the immune response.
35281276	1	29	theme	inflammation	101:112	arg1	site					93:96	a site	91:96	a site of inflammation	91:112	Cell migration to a site of inflammation is an important step of the immune response.
35281276	5	30	theme	human	513:517	arg1	NEU					542:544	NEU	542:544	NEU	542:544	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	5	30	theme	human	513:517	arg1	enzymes					533:539	native human neuraminidase enzymes	506:539	native human neuraminidase enzymes (NEU)	506:545	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	3	31	theme	Many	261:264	arg1	receptors					275:283	Many cellular receptors	261:283	Many cellular receptors	261:283	Many cellular receptors are glycosylated, and their activity can be modulated through changes in glycan structure.
35281276	7	32	theme	siRNA	827:831	arg1	knockdown					833:841	an siRNA knockdown	824:841	an siRNA knockdown	824:841	We observed that NEU1, NEU3, and NEU4 were positive regulators of transmigration using an siRNA knockdown.
35281276	5	33	theme	neuraminidase	519:531	arg1	NEU					542:544	NEU	542:544	NEU	542:544	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	5	33	theme	neuraminidase	519:531	arg1	enzymes					533:539	native human neuraminidase enzymes	506:539	native human neuraminidase enzymes (NEU)	506:545	In this work, we investigated the role of native human neuraminidase enzymes (NEU) in transmigration.
35281276	9	34	theme	anti-inflammatory	1091:1107	arg1	strategies					1109:1118	anti-inflammatory strategies	1091:1118	anti-inflammatory strategies	1091:1118	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	7	35	theme	transmigration	803:816	arg1	regulators					789:798	positive regulators	780:798	positive regulators of transmigration	780:816	We observed that NEU1, NEU3, and NEU4 were positive regulators of transmigration using an siRNA knockdown.
35281276	3	36	gly	glycosylated	289:300	arg1	receptors					275:283	Many cellular receptors	261:283	Many cellular receptors	261:283	Many cellular receptors are glycosylated, and their activity can be modulated through changes in glycan structure.
35281276	2	37	theme	processing	227:236	arg1	machinery					238:246	the signal processing machinery	216:246	the signal processing machinery of the cell	216:258	This process is coordinated by cytokines, receptors, and the signal processing machinery of the cell.
35281276	9	38	theme	transmigration	1034:1047	arg1	regulators					1020:1029	positive regulators	1011:1029	positive regulators of transmigration	1011:1047	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	9	38	theme	transmigration	1034:1047	arg1	isoenzymes					968:977	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	human NEU isoenzymes NEU1, NEU3, and NEU4	958:998	We conclude that human NEU isoenzymes NEU1, NEU3, and NEU4 can act as positive regulators of transmigration and should be investigated as targets for anti-inflammatory strategies.
35281276	1	39	theme	important	120:128	arg1	migration					78:86	Cell migration	73:86	Cell migration to a site of inflammation	73:112	Cell migration to a site of inflammation is an important step of the immune response.
35281276	1	39	theme	important	120:128	arg1	step					130:133	an important step	117:133	an important step of the immune response	117:156	Cell migration to a site of inflammation is an important step of the immune response.
35281276	7	40	theme	positive	780:787	arg1	regulators					789:798	positive regulators	780:798	positive regulators of transmigration	780:816	We observed that NEU1, NEU3, and NEU4 were positive regulators of transmigration using an siRNA knockdown.
35281276	2	41	theme	signal	220:225	arg1	machinery					238:246	the signal processing machinery	216:246	the signal processing machinery of the cell	216:258	This process is coordinated by cytokines, receptors, and the signal processing machinery of the cell.
35281276	6	42	theme	coated	650:655	arg1	wells					657:661	fibronectin (FN) coated wells	633:661	fibronectin (FN) coated wells	633:661	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	43	theme	cell	587:590	arg1	line					592:595	a cultured T cell line	574:595	a cultured T cell line (Jurkat)	574:604	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	43	theme	cell	587:590	arg1	assay					622:626	a transwell assay	610:626	a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α)	610:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	43	theme	cell	587:590	arg1	chemoattractants					697:712	chemoattractants	697:712	chemoattractants in the bottom chamber	697:734	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	43	theme	cell	587:590	arg1	Jurkat					598:603	Jurkat	598:603	Jurkat	598:603	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	44	from	chemoattractants	697:712	arg1	chamber					728:734	the bottom chamber	717:734	the bottom chamber	717:734	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	45	theme	T	585:585	arg1	line					592:595	a cultured T cell line	574:595	a cultured T cell line (Jurkat)	574:604	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	45	theme	T	585:585	arg1	assay					622:626	a transwell assay	610:626	a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α)	610:692	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	45	theme	T	585:585	arg1	chemoattractants					697:712	chemoattractants	697:712	chemoattractants in the bottom chamber	697:734	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
35281276	6	45	theme	T	585:585	arg1	Jurkat					598:603	Jurkat	598:603	Jurkat	598:603	We used a cultured T cell line (Jurkat) and a transwell assay with fibronectin (FN) coated wells and cytokines (IL-4 and TNF-α) as chemoattractants in the bottom chamber.
36631484	8	0	theme	post-production	1755:1769	arg1	profiling					1778:1786	more detailed post-production glycan profiling	1741:1786	more detailed post-production glycan profiling	1741:1786	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	9	1	theme	protein	2241:2247	arg1	GlycoPrint					2272:2281	GlycoPrint	2272:2281	GlycoPrint	2272:2281	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	9	1	theme	protein	2241:2247	arg1	pattern					2263:2269	the protein glycosylation pattern	2237:2269	the protein glycosylation pattern (GlycoPrint)	2237:2282	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	6	2	theme	binding	1368:1374	arg1	reagents					1376:1383	high-specificity glycan binding reagents	1344:1383	high-specificity glycan binding reagents	1344:1383	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	2	3	theme	pharmacological	357:371	arg1	safety					373:378	pharmacological safety	357:378	pharmacological safety	357:378	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	9	4	gly	glycoproteins	2351:2363	arg1	glycoproteins					2351:2363	model glycoproteins	2345:2363	model glycoproteins	2345:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	6	5	theme	glycoprotein	1237:1248	arg1	engineering					1250:1260	glycoprotein engineering	1237:1260	glycoprotein engineering	1237:1260	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	6	6	theme	high-specificity	1344:1359	arg1	reagents					1376:1383	high-specificity glycan binding reagents	1344:1383	high-specificity glycan binding reagents	1344:1383	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	3	7	theme	batch-to-batch	547:560	arg1	consistency					562:572	batch-to-batch consistency	547:572	batch-to-batch consistency	547:572	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	2	8	contain	have	269:272	arg1	Variations					229:238	Variations	229:238	Variations in protein glycosylation	229:263	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	2	8	contain	have	269:272	arg2	effects					283:289	dramatic effects	274:289	dramatic effects	274:289	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	7	9	theme	orthogonal	1570:1579	arg1	features					1595:1602	multiple orthogonal glycosylation features	1561:1602	multiple orthogonal glycosylation features	1561:1602	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	7	10	theme	multiplex	1513:1521	arg1	array					1534:1538	a multiplex suspension array	1511:1538	a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation	1511:1652	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	8	11	theme	research	1986:1993	arg1	bench					1995:1999	the research bench	1982:1999	the research bench	1982:1999	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	2	12	theme	dramatic	274:281	arg1	effects					283:289	dramatic effects	274:289	dramatic effects	274:289	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	8	13	theme	cost-effective	1848:1861	arg1	method					1882:1887	a cost-effective, rapid, yet robust method	1846:1887	a cost-effective, rapid, yet robust method for use at-line	1846:1903	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	8	13	theme	cost-effective	1848:1861	arg1	technology					1927:1936	a process analytic technology	1908:1936	a process analytic technology	1908:1936	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	8	14	theme	rapid	1864:1868	arg1	method					1882:1887	a cost-effective, rapid, yet robust method	1846:1887	a cost-effective, rapid, yet robust method for use at-line	1846:1903	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	8	14	theme	rapid	1864:1868	arg1	technology					1927:1936	a process analytic technology	1908:1936	a process analytic technology	1908:1936	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	9	15	theme	GlycoSense	2176:2185	arg1	method					2187:2192	the GlycoSense method	2172:2192	the GlycoSense method	2172:2192	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	7	16	theme	optical	1471:1477	arg1	properties					1479:1488	distinct optical properties	1462:1488	distinct optical properties	1462:1488	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	9	17	theme	in	2295:2296	arg1	modification					2314:2325	the in vitro enzymatic modification	2291:2325	the in vitro enzymatic modification of the glycans in model glycoproteins	2291:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	6	18	theme	fluorescent	1297:1307	arg1	microspheres					1309:1320	fluorescent microspheres	1297:1320	fluorescent microspheres	1297:1320	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	6	19	gly	glycoprotein	1237:1248	arg1	glycoprotein					1237:1248	glycoprotein engineering	1237:1260	glycoprotein engineering	1237:1260	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	9	20	theme	enzymatic	2304:2312	arg1	modification					2314:2325	the in vitro enzymatic modification	2291:2325	the in vitro enzymatic modification of the glycans in model glycoproteins	2291:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	8	21	theme	detailed	1746:1753	arg1	profiling					1778:1786	more detailed post-production glycan profiling	1741:1786	more detailed post-production glycan profiling	1741:1786	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	1	22	theme	biological	206:215	arg1	activities					217:226	biological activities	206:226	biological activities	206:226	The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities.
36631484	7	23	theme	distinct	1462:1469	arg1	properties					1479:1488	distinct optical properties	1462:1488	distinct optical properties	1462:1488	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	9	24	from	glycoproteins	2351:2363	arg1	modification					2314:2325	the in vitro enzymatic modification	2291:2325	the in vitro enzymatic modification of the glycans in model glycoproteins	2291:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	8	25	theme	use	1893:1895	arg1	at-line					1897:1903	use at-line	1893:1903	use at-line	1893:1903	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	1	26	theme	proteins	126:133	arg1	majority					104:111	The majority	100:111	The majority of mammalian proteins	100:133	The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities.
36631484	7	27	theme	microspheres	1444:1455	arg1	range					1414:1418	a range	1412:1418	a range of carbohydrate-sensing microspheres with distinct optical properties	1412:1488	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	9	28	theme	well-defined	2089:2100	arg1	glycosylation					2102:2114	well-defined glycosylation	2089:2114	well-defined glycosylation	2089:2114	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	6	29	dep	employs	1268:1274	arg1	coupled					1333:1339	coupled	1333:1339	coupled to high-specificity glycan binding reagents	1333:1383	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	9	30	theme	glycans	2334:2340	arg1	modification					2314:2325	the in vitro enzymatic modification	2291:2325	the in vitro enzymatic modification of the glycans in model glycoproteins	2291:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	4	31	theme	pharmaceutical	735:748	arg1	rejection					756:764	pharmaceutical batch rejection	735:764	pharmaceutical batch rejection	735:764	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	9	32	theme	model	2345:2349	arg1	glycoproteins					2351:2363	model glycoproteins	2345:2363	model glycoproteins	2345:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	9	33	from	changes	2226:2232	arg1	GlycoPrint					2272:2281	GlycoPrint	2272:2281	GlycoPrint	2272:2281	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	9	33	from	changes	2226:2232	arg1	pattern					2263:2269	the protein glycosylation pattern	2237:2269	the protein glycosylation pattern (GlycoPrint)	2237:2282	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	2	34	theme	protein	243:249	arg1	glycosylation					251:263	protein glycosylation	243:263	protein glycosylation	243:263	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	8	35	theme	process	1910:1916	arg1	technology					1927:1936	a process analytic technology	1908:1936	a process analytic technology	1908:1936	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	8	35	theme	process	1910:1916	arg1	method					1882:1887	a cost-effective, rapid, yet robust method	1846:1887	a cost-effective, rapid, yet robust method for use at-line	1846:1903	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	5	36	theme	expertise	933:941	arg1	level					924:928	a high level	917:928	a high level of expertise	917:941	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	5	37	dep	time-consuming	948:961	arg1	performed					1114:1122	performed	1114:1122	are generally performed only post-production	1100:1143	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	9	38	gly	glycosylation	2102:2114	arg1	glycoproteins					2070:2082	glycoproteins	2070:2082	glycoproteins with well-defined glycosylation	2070:2114	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	3	39	theme	therapeutic	442:452	arg1	biologicals					454:464	therapeutic biologicals	442:464	therapeutic biologicals	442:464	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	0	40	theme	in	73:74	arg1	glycoengineering					82:97	in vitro glycoengineering	73:97	in vitro glycoengineering	73:97	Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
36631484	4	41	theme	rejection	756:764	arg1	causes					725:730	the leading causes	713:730	the leading causes of pharmaceutical batch rejection	713:764	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	8	42	theme	biopharmaceutical	1949:1965	arg1	workflow					1967:1974	a biopharmaceutical workflow	1947:1974	a biopharmaceutical workflow	1947:1974	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	9	43	theme	method	2187:2192	arg1	capabilities					2156:2167	the capabilities	2152:2167	the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins	2152:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	3	44	theme	critical	471:478	arg1	CQA					499:501	CQA	499:501	CQA	499:501	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	3	44	theme	critical	471:478	arg1	attribute					488:496	a critical quality attribute	469:496	a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency	469:572	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	3	44	theme	critical	471:478	arg1	glycosylation					425:437	The glycosylation	421:437	The glycosylation of therapeutic biologicals	421:464	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	7	45	theme	GlycoSense	1393:1402	arg1	method					1404:1409	our GlycoSense method	1389:1409	our GlycoSense method	1389:1409	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	5	46	theme	glycosylation	810:822	arg1	characterization					782:797	the characterization	778:797	the characterization of protein glycosylation	778:822	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	8	47	theme	GlycoSense	1696:1705	arg1	method					1707:1712	The GlycoSense method	1692:1712	The GlycoSense method	1692:1712	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	0	48	theme	protein	44:50	arg1	glycosylation					52:64	protein glycosylation	44:64	protein glycosylation	44:64	Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
36631484	5	49	theme	in	1070:1071	arg1	modification					1086:1097	in vitro glycan modification	1070:1097	in vitro glycan modification	1070:1097	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	6	50	theme	simplified	1163:1172	arg1	approach					1174:1181	a simplified approach	1161:1181	a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents	1161:1383	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	2	51	theme	effector	338:345	arg1	function					347:354	antibody effector function	329:354	antibody effector function	329:354	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	9	52	dep	in	2032:2033	arg1	vitro					2035:2039	vitro	2035:2039	vitro	2035:2039	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	1	53	theme	activities	217:226	arg1	range					197:201	a wide range	190:201	a wide range of biological activities	190:226	The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities.
36631484	6	54	theme	glycosylation	1207:1219	arg1	features					1221:1228	glycosylation features	1207:1228	glycosylation features	1207:1228	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	0	55	dep	detection	16:24	arg1	the					12:14	the	12:14	the	12:14	Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
36631484	9	56	dep	in	2295:2296	arg1	vitro					2298:2302	vitro	2298:2302	vitro	2298:2302	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	5	57	theme	biologics	1039:1047	arg1	production					1049:1058	in-process biologics production	1028:1058	in-process biologics production	1028:1058	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	7	58	theme	glycosylation	1581:1593	arg1	features					1595:1602	multiple orthogonal glycosylation features	1561:1602	multiple orthogonal glycosylation features	1561:1602	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	4	59	theme	many	584:587	arg1	factors					589:595	many factors	584:595	many factors	584:595	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	9	60	theme	glycosylation	2249:2261	arg1	GlycoPrint					2272:2281	GlycoPrint	2272:2281	GlycoPrint	2272:2281	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	9	60	theme	glycosylation	2249:2261	arg1	pattern					2263:2269	the protein glycosylation pattern	2237:2269	the protein glycosylation pattern (GlycoPrint)	2237:2282	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	6	61	theme	glycan	1361:1366	arg1	reagents					1376:1383	high-specificity glycan binding reagents	1344:1383	high-specificity glycan binding reagents	1344:1383	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	2	62	theme	protein	294:300	arg1	stability					302:310	protein stability	294:310	protein stability	294:310	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	7	63	theme	multiple	1561:1568	arg1	features					1595:1602	multiple orthogonal glycosylation features	1561:1602	multiple orthogonal glycosylation features	1561:1602	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	7	64	theme	capable	1540:1546	arg1	array					1534:1538	a multiplex suspension array	1511:1538	a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation	1511:1652	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	9	65	theme	growing	2006:2012	arg1	interest					2014:2021	The growing interest	2002:2021	The growing interest	2002:2021	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	8	66	theme	glycan	1771:1776	arg1	profiling					1778:1786	more detailed post-production glycan profiling	1741:1786	more detailed post-production glycan profiling	1741:1786	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	4	67	from	variations	675:684	arg1	glycosylation					689:701	glycosylation	689:701	glycosylation	689:701	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	7	68	theme	suspension	1523:1532	arg1	array					1534:1538	a multiplex suspension array	1511:1538	a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation	1511:1652	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	9	69	from	modification	2314:2325	arg1	glycoproteins					2351:2363	model glycoproteins	2345:2363	model glycoproteins	2345:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	5	70	dep	in	1070:1071	arg1	vitro					1073:1077	vitro	1073:1077	vitro	1073:1077	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	4	71	gly	glycoprotein	646:657	arg1	glycoprotein					646:657	glycoprotein production	646:668	glycoprotein production	646:668	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	9	72	theme	in	2032:2033	arg1	glycoengineering					2041:2056	in vitro glycoengineering	2032:2056	in vitro glycoengineering	2032:2056	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	1	73	theme	wide	192:195	arg1	range					197:201	a wide range	190:201	a wide range of biological activities	190:226	The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities.
36631484	4	74	theme	glycans	631:637	arg1	composition					612:622	the composition	608:622	the composition of the glycans during glycoprotein production	608:668	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	1	75	gly	glycosylated	139:150	arg1	majority					104:111	The majority	100:111	The majority of mammalian proteins	100:133	The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities.
36631484	5	76	theme	mass	884:887	arg1	spectrometry					889:900	mass spectrometry	884:900	mass spectrometry	884:900	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	4	77	theme	glycoprotein	646:657	arg1	production					659:668	glycoprotein production	646:668	glycoprotein production	646:668	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	5	78	theme	only	1124:1127	arg1	post-production					1129:1143	only post-production	1124:1143	only post-production	1124:1143	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	8	79	theme	robust	1875:1880	arg1	method					1882:1887	a cost-effective, rapid, yet robust method	1846:1887	a cost-effective, rapid, yet robust method for use at-line	1846:1903	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	8	79	theme	robust	1875:1880	arg1	technology					1927:1936	a process analytic technology	1908:1936	a process analytic technology	1908:1936	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	1	80	theme	mammalian	116:124	arg1	proteins					126:133	mammalian proteins	116:133	mammalian proteins	116:133	The majority of mammalian proteins are glycosylated, with the glycans serving to modulate a wide range of biological activities.
36631484	6	81	theme	flow	1276:1279	arg1	cytometry					1281:1289	flow cytometry	1276:1289	flow cytometry using fluorescent microspheres	1276:1320	Here we report a simplified approach to assist in monitoring glycosylation features during glycoprotein engineering, that employs flow cytometry using fluorescent microspheres chemically coupled to high-specificity glycan binding reagents.
36631484	4	82	theme	leading	717:723	arg1	causes					725:730	the leading causes	713:730	the leading causes of pharmaceutical batch rejection	713:764	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	9	83	from	glycans	2334:2340	arg1	glycoproteins					2351:2363	model glycoproteins	2345:2363	model glycoproteins	2345:2363	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	5	84	theme	glycan	1079:1084	arg1	modification					1086:1097	in vitro glycan modification	1070:1097	in vitro glycan modification	1070:1097	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	9	85	gly	glycoproteins	2070:2082	arg1	glycoproteins					2070:2082	glycoproteins	2070:2082	glycoproteins with well-defined glycosylation	2070:2114	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	5	86	theme	high	919:922	arg1	level					924:928	a high level	917:928	a high level of expertise	917:941	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	7	87	theme	carbohydrate-sensing	1423:1442	arg1	microspheres					1444:1455	carbohydrate-sensing microspheres	1423:1455	carbohydrate-sensing microspheres with distinct optical properties	1423:1488	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	7	88	with	microspheres	1444:1455	arg1	properties					1479:1488	distinct optical properties	1462:1488	distinct optical properties	1462:1488	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	8	89	theme	analytic	1918:1925	arg1	technology					1927:1936	a process analytic technology	1908:1936	a process analytic technology	1908:1936	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	8	89	theme	analytic	1918:1925	arg1	method					1882:1887	a cost-effective, rapid, yet robust method	1846:1887	a cost-effective, rapid, yet robust method for use at-line	1846:1903	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	7	90	theme	glycan	1676:1681	arg1	release					1683:1689	glycan release	1676:1689	glycan release	1676:1689	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	9	91	with	glycoproteins	2070:2082	arg1	glycosylation					2102:2114	well-defined glycosylation	2089:2114	well-defined glycosylation	2089:2114	The growing interest in using in vitro glycoengineering to generate glycoproteins with well-defined glycosylation, provides motivation to demonstrate the capabilities of the GlycoSense method, which we apply here to monitor changes in the protein glycosylation pattern (GlycoPrint) during the in vitro enzymatic modification of the glycans in model glycoproteins.
36631484	3	92	theme	biologicals	454:464	arg1	glycosylation					425:437	The glycosylation	421:437	The glycosylation of therapeutic biologicals	421:464	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	3	92	theme	biologicals	454:464	arg1	attribute					488:496	a critical quality attribute	469:496	a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency	469:572	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	2	93	from	Variations	229:238	arg1	glycosylation					251:263	protein glycosylation	243:263	protein glycosylation	243:263	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	8	94	dep	providing	1836:1844	arg1	PAT					1939:1941	PAT	1939:1941	PAT	1939:1941	The GlycoSense method is not intended to replace more detailed post-production glycan profiling, but instead, to complement them by potentially providing a cost-effective, rapid, yet robust method for use at-line as a process analytic technology (PAT) in a biopharmaceutical workflow or at the research bench.
36631484	4	95	theme	batch	750:754	arg1	rejection					756:764	pharmaceutical batch rejection	735:764	pharmaceutical batch rejection	735:764	Notably, many factors can affect the composition of the glycans during glycoprotein production, and variations in glycosylation are among the leading causes of pharmaceutical batch rejection.
36631484	0	96	dep	in	73:74	arg1	vitro					76:80	vitro	76:80	vitro	76:80	Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
36631484	3	97	theme	quality	480:486	arg1	CQA					499:501	CQA	499:501	CQA	499:501	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	3	97	theme	quality	480:486	arg1	attribute					488:496	a critical quality attribute	469:496	a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency	469:572	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	3	97	theme	quality	480:486	arg1	glycosylation					425:437	The glycosylation	421:437	The glycosylation of therapeutic biologicals	421:464	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36631484	5	98	theme	protein	802:808	arg1	glycosylation					810:822	protein glycosylation	802:822	protein glycosylation	802:822	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	2	99	theme	serum	404:408	arg1	half-life					410:418	serum half-life	404:418	serum half-life	404:418	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	0	100	theme	glycosylation	52:64	arg1	detection					16:24	detection	16:24	detection	16:24	Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
36631484	0	100	theme	glycosylation	52:64	arg1	monitoring					30:39	monitoring	30:39	monitoring	30:39	Simplifying the detection and monitoring of protein glycosylation during in vitro glycoengineering.
36631484	2	101	theme	antibody	329:336	arg1	function					347:354	antibody effector function	329:354	antibody effector function	329:354	Variations in protein glycosylation can have dramatic effects on protein stability, immunogenicity, antibody effector function, pharmacological safety and potency, as well as serum half-life.
36631484	7	102	theme	commonplace	1626:1636	arg1	instrumentation					1638:1652	commonplace instrumentation	1626:1652	commonplace instrumentation	1626:1652	In our GlycoSense method, a range of carbohydrate-sensing microspheres with distinct optical properties may be combined into a multiplex suspension array capable of detecting multiple orthogonal glycosylation features simultaneously, using commonplace instrumentation, without the need for glycan release.
36631484	5	103	theme	in-process	1028:1037	arg1	production					1049:1058	in-process biologics production	1028:1058	in-process biologics production	1028:1058	Currently, the characterization of protein glycosylation relies heavily on methods that employ chromatography and/or mass spectrometry, which require a high level of expertise, are time-consuming and costly and, because they are challenging to implement during in-process biologics production or during in vitro glycan modification, are generally performed only post-production.
36631484	3	104	gly	glycosylation	425:437	arg1	biologicals					454:464	therapeutic biologicals	442:464	therapeutic biologicals	442:464	The glycosylation of therapeutic biologicals is a critical quality attribute (CQA) that must be carefully monitored to ensure batch-to-batch consistency.
36192063	4	0	theme	model	675:679	arg1	system					681:686	a model system	673:686	a model system	673:686	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	10	1	theme	N-glycosylation	1859:1873	arg1	types					1850:1854	many types	1845:1854	many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine	1845:2004	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	3	2	theme	mass	627:630	arg1	TMT					638:640	TMT	638:640	TMT	638:640	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	3	2	theme	mass	627:630	arg1	tags					632:635	multiplex tandem mass tags	610:635	multiplex tandem mass tags (TMT)	610:641	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	9	3	theme	Intact	1733:1738	arg1	N-glycoproteins					1740:1754	Intact N-glycoproteins	1733:1754	Intact N-glycoproteins with α2,6-sialylation	1733:1776	Intact N-glycoproteins with α2,6-sialylation were associated with coronavirus disease-(COVID)-19.
36192063	10	4	from	family	2083:2088	arg1	N-glycoproteins					2047:2061	intact N-glycoproteins	2040:2061	intact N-glycoproteins from immunoglobulin family	2040:2088	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	8	5	with	N-glycopeptides	1553:1567	arg1	residues					1603:1610	linkage-specific sialic acid residues	1574:1610	linkage-specific sialic acid residues	1574:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	3	6	theme	tandem	620:625	arg1	TMT					638:640	TMT	638:640	TMT	638:640	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	3	6	theme	tandem	620:625	arg1	tags					632:635	multiplex tandem mass tags	610:635	multiplex tandem mass tags (TMT)	610:641	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	0	7	theme	Sialic	0:5	arg1	acid					7:10	Sialic acid	0:10	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
36192063	2	8	theme	aberrant	391:398	arg1	sialylation					400:410	aberrant sialylation	391:410	aberrant sialylation	391:410	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	4	9	theme	relative	732:739	arg1	tissues					724:730	cancer tissues	717:730	cancer tissues relative to adjacent non-tumor tissues	717:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	6	10	gly	N-glycoproteins	1380:1394	arg1	N-glycoproteins					1380:1394	254 intact N-glycoproteins	1369:1394	254 intact N-glycoproteins	1369:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	5	11	theme	ionization-tandem	1006:1022	arg1	RPLC-nanoESI-MS/MS					1043:1060	RPLC-nanoESI-MS/MS	1043:1060	RPLC-nanoESI-MS/MS	1043:1060	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	11	theme	ionization-tandem	1006:1022	arg1	spectrometry					1029:1040	liquid chromatography-nano-electron spray ionization-tandem mass spectrometry	964:1040	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	9	12	gly	α2,6-sialylation	1761:1776	arg1	N-glycoproteins					1740:1754	Intact N-glycoproteins	1733:1754	Intact N-glycoproteins with α2,6-sialylation	1733:1776	Intact N-glycoproteins with α2,6-sialylation were associated with coronavirus disease-(COVID)-19.
36192063	4	13	theme	adjacent	744:751	arg1	tissues					763:769	adjacent non-tumor tissues	744:769	adjacent non-tumor tissues	744:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	5	14	with	level	1191:1195	arg1	N-glycosite					1216:1226	N-glycosite	1216:1226	N-glycosite	1216:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	14	with	level	1191:1195	arg1	structure					1202:1210	structure	1202:1210	structure	1202:1210	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	15	theme	liquid	964:969	arg1	RPLC-nanoESI-MS/MS					1043:1060	RPLC-nanoESI-MS/MS	1043:1060	RPLC-nanoESI-MS/MS	1043:1060	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	15	theme	liquid	964:969	arg1	spectrometry					1029:1040	liquid chromatography-nano-electron spray ionization-tandem mass spectrometry	964:1040	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	16	theme	spectrometry	1029:1040	arg1	analysis					1063:1070	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis	949:1070	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	8	17	theme	linkage-specific	1574:1589	arg1	residues					1603:1610	linkage-specific sialic acid residues	1574:1610	linkage-specific sialic acid residues	1574:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	10	18	theme	terminal	1967:1974	arg1	N-acetylglucosamine					1986:2004	terminal bisecting N-acetylglucosamine	1967:2004	terminal bisecting N-acetylglucosamine	1967:2004	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	5	19	theme	N-glycosylation	1117:1131	arg1	characterization					1097:1112	comprehensive characterization	1083:1112	comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	1083:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	8	20	theme	acid	1598:1601	arg1	residues					1603:1610	linkage-specific sialic acid residues	1574:1610	linkage-specific sialic acid residues	1574:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	4	21	gly	N-glycopeptide	803:816	arg2	N-glycopeptide					803:816	the intact N-glycopeptide level	792:822	the intact N-glycopeptide level with N-glycosite information	792:851	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	10	22	theme	immunoglobulin	2068:2081	arg1	family					2083:2088	immunoglobulin family	2068:2088	immunoglobulin family	2068:2088	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	8	23	with	29 N-glycans	1642:1653	arg1	acids					1679:1683	α2,6-linked sialic acids	1660:1683	α2,6-linked sialic acids	1660:1683	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	8	23	with	29 N-glycans	1642:1653	arg1	55 N-glycans					1689:1700	55 N-glycans	1689:1700	55 N-glycans with α2,3-linked sialic acids	1689:1730	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	5	24	theme	chromatography-nano-electron	971:998	arg1	RPLC-nanoESI-MS/MS					1043:1060	RPLC-nanoESI-MS/MS	1043:1060	RPLC-nanoESI-MS/MS	1043:1060	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	24	theme	chromatography-nano-electron	971:998	arg1	spectrometry					1029:1040	liquid chromatography-nano-electron spray ionization-tandem mass spectrometry	964:1040	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	4	25	theme	N-glycopeptide	803:816	arg1	level					818:822	the intact N-glycopeptide level	792:822	the intact N-glycopeptide level with N-glycosite information	792:851	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	8	26	with	55 N-glycans	1689:1700	arg1	acids					1726:1730	α2,3-linked sialic acids	1707:1730	α2,3-linked sialic acids	1707:1730	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	5	27	theme	sialic	906:911	arg1	acid					913:916	sialic acid	906:916	sialic acid alkylamidation	906:931	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	8	28	with	acids	1679:1683	arg1	acids					1726:1730	α2,3-linked sialic acids	1707:1730	α2,3-linked sialic acids	1707:1730	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	5	29	theme	TMT-labeled	854:864	arg1	N-glycopeptides					873:887	TMT-labeled intact N-glycopeptides	854:887	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation	854:931	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	3	30	dep	alkylamidation	591:604	arg1	-labeling					642:650	-labeling	642:650	-labeling	642:650	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	8	31	theme	sialic	1591:1596	arg1	residues					1603:1610	linkage-specific sialic acid residues	1574:1610	linkage-specific sialic acid residues	1574:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	8	32	theme	α2,6-linked	1660:1670	arg1	acids					1679:1683	α2,6-linked sialic acids	1660:1683	α2,6-linked sialic acids	1660:1683	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	3	33	theme	sialic	515:520	arg1	N-glycoproteomics					557:573	sialic acid linkage-specific quantitative N-glycoproteomics	515:573	sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling	515:650	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	5	34	theme	reversed-phase	949:962	arg1	analysis					1063:1070	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis	949:1070	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	35	theme	sialic	1150:1155	arg1	acid					1157:1160	sialic acid	1150:1160	sialic acid at the intact N-glycopeptide level with structure and N-glycosite	1150:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	2	36	gly	N-glycopeptides	447:461	arg2	N-glycopeptides					447:461	intact N-glycopeptides level	440:467	intact N-glycopeptides level	440:467	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	5	37	gly	N-glycopeptides	873:887	arg2	N-glycopeptides					873:887	TMT-labeled intact N-glycopeptides	854:887	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation	854:931	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	3	38	theme	N-glycoproteomics	557:573	arg1	study					506:510	our study	502:510	our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling	502:650	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	0	39	theme	linkage-specific	12:27	arg1	N-glycoproteomics					42:58	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
36192063	1	40	theme	many	152:155	arg1	processes					168:176	many biological processes	152:176	many biological processes	152:176	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	6	41	theme	intact	1249:1254	arg1	N-glycopeptides					1256:1270	6384 intact N-glycopeptides	1244:1270	6384 intact N-glycopeptides without sialylation	1244:1290	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	8	42	theme	α2,3-linked	1707:1717	arg1	acids					1726:1730	α2,3-linked sialic acids	1707:1730	α2,3-linked sialic acids	1707:1730	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	3	43	theme	linkage-specific	527:542	arg1	N-glycoproteomics					557:573	sialic acid linkage-specific quantitative N-glycoproteomics	515:573	sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling	515:650	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	5	44	gly	N-glycosite	1216:1226	arg2	N-glycosite					1216:1226	N-glycosite	1216:1226	N-glycosite	1216:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	0	45	theme	selective	66:74	arg1	alkylamidation					76:89	selective alkylamidation	66:89	selective alkylamidation	66:89	Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
36192063	2	46	theme	quantitative	307:318	arg1	N-glycoproteomics					320:336	Mass spectrometry-based quantitative N-glycoproteomics	283:336	Mass spectrometry-based quantitative N-glycoproteomics	283:336	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	10	47	theme	many	1845:1848	arg1	types					1850:1854	many types	1845:1854	many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine	1845:2004	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	7	48	gly	N-glycoproteins	1426:1440	arg1	glycosyltransferases					1499:1518	glycosyltransferases	1499:1518	glycosyltransferases	1499:1518	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36192063	7	48	gly	N-glycoproteins	1426:1440	arg1	N-glycoproteins					1426:1440	Eight intact N-glycoproteins	1413:1440	Eight intact N-glycoproteins responsible for N-glycan biosynthesis	1413:1478	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36192063	3	49	theme	selective	581:589	arg1	alkylamidation					591:604	selective alkylamidation	581:604	selective alkylamidation	581:604	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	6	50	theme	intact	1341:1346	arg1	N-glycopeptides					1348:1362	521 differentially expressed intact N-glycopeptides	1312:1362	521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins	1312:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	4	51	theme	differential	689:700	arg1	sialylation					702:712	differential sialylation	689:712	differential sialylation in cancer tissues relative to adjacent non-tumor tissues	689:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	10	52	theme	intact	2040:2045	arg1	N-glycoproteins					2047:2061	intact N-glycoproteins	2040:2061	intact N-glycoproteins from immunoglobulin family	2040:2088	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	7	53	theme	responsible	1442:1452	arg1	glycosyltransferases					1499:1518	glycosyltransferases	1499:1518	glycosyltransferases	1499:1518	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36192063	7	53	theme	responsible	1442:1452	arg1	N-glycoproteins					1426:1440	Eight intact N-glycoproteins	1413:1440	Eight intact N-glycoproteins responsible for N-glycan biosynthesis	1413:1478	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36192063	2	54	theme	intact	440:445	arg1	level					463:467	intact N-glycopeptides level	440:467	intact N-glycopeptides level	440:467	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	5	55	from	level	1191:1195	arg1	acid					1157:1160	sialic acid	1150:1160	sialic acid at the intact N-glycopeptide level with structure and N-glycosite	1150:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	10	56	theme	branch	1925:1930	arg1	fucosylation					1932:1943	core and/or branch fucosylation	1913:1943	fucosylation	1932:1943	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	4	57	with	level	818:822	arg1	information					841:851	N-glycosite information	829:851	N-glycosite information	829:851	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	2	58	theme	quantitative	366:377	arg1	analysis					379:386	quantitative analysis	366:386	quantitative analysis of aberrant sialylation	366:410	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	10	59	theme	core	1913:1916	arg1	fucosylation					1932:1943	core and/or branch fucosylation	1913:1943	fucosylation	1932:1943	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	1	60	theme	aberrant	212:219	arg1	sialylation					221:231	aberrant sialylation	212:231	aberrant sialylation	212:231	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	4	61	theme	non-tumor	753:761	arg1	tissues					763:769	adjacent non-tumor tissues	744:769	adjacent non-tumor tissues	744:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	2	62	theme	sialylation	400:410	arg1	analysis					379:386	quantitative analysis	366:386	quantitative analysis of aberrant sialylation	366:410	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	8	63	link	α2,6-linked	1660:1670	arg1	acids					1679:1683	α2,6-linked sialic acids	1660:1683	α2,6-linked sialic acids	1660:1683	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	2	64	from	level	463:467	arg1	method					430:435	multiplexing method	417:435	multiplexing method at intact N-glycopeptides level	417:467	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	5	65	theme	spray	1000:1004	arg1	RPLC-nanoESI-MS/MS					1043:1060	RPLC-nanoESI-MS/MS	1043:1060	RPLC-nanoESI-MS/MS	1043:1060	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	65	theme	spray	1000:1004	arg1	spectrometry					1029:1040	liquid chromatography-nano-electron spray ionization-tandem mass spectrometry	964:1040	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	6	66	theme	intact	1373:1378	arg1	N-glycoproteins					1380:1394	254 intact N-glycoproteins	1369:1394	254 intact N-glycoproteins	1369:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	2	67	theme	multiplexing	417:428	arg1	method					430:435	multiplexing method	417:435	multiplexing method at intact N-glycopeptides level	417:467	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	4	68	gly	N-glycosite	829:839	arg2	N-glycosite					829:839	N-glycosite	829:839	N-glycosite	829:839	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	2	69	theme	spectrometry-based	288:305	arg1	N-glycoproteomics					320:336	Mass spectrometry-based quantitative N-glycoproteomics	283:336	Mass spectrometry-based quantitative N-glycoproteomics	283:336	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	5	70	theme	mass	1024:1027	arg1	RPLC-nanoESI-MS/MS					1043:1060	RPLC-nanoESI-MS/MS	1043:1060	RPLC-nanoESI-MS/MS	1043:1060	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	70	theme	mass	1024:1027	arg1	spectrometry					1029:1040	liquid chromatography-nano-electron spray ionization-tandem mass spectrometry	964:1040	reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	949:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	8	71	theme	intact	1546:1551	arg1	N-glycopeptides					1553:1567	307 sialylated intact N-glycopeptides	1531:1567	307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues	1531:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	10	72	theme	bisecting	1976:1984	arg1	N-acetylglucosamine					1986:2004	terminal bisecting N-acetylglucosamine	1967:2004	terminal bisecting N-acetylglucosamine	1967:2004	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	10	73	gly	N-glycoproteins	2047:2061	arg1	N-glycoproteins					2047:2061	intact N-glycoproteins	2040:2061	intact N-glycoproteins from immunoglobulin family	2040:2088	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	1	74	theme	biological	157:166	arg1	processes					168:176	many biological processes	152:176	many biological processes	152:176	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	8	75	gly	sialylated	1535:1544	arg1	N-glycopeptides					1553:1567	307 sialylated intact N-glycopeptides	1531:1567	307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues	1531:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	4	76	theme	N-glycosite	829:839	arg1	information					841:851	N-glycosite information	829:851	N-glycosite information	829:851	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	0	77	theme	multiplex	95:103	arg1	TMT-labeling					105:116	multiplex TMT-labeling	95:116	multiplex TMT-labeling	95:116	Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
36192063	8	78	gly	N-glycopeptides	1553:1567	arg2	N-glycopeptides					1553:1567	307 sialylated intact N-glycopeptides	1531:1567	307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues	1531:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	8	79	theme	sialylated	1535:1544	arg1	N-glycopeptides					1553:1567	307 sialylated intact N-glycopeptides	1531:1567	307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues	1531:1610	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	1	80	theme	linkage-specific	183:198	arg1	manner					200:205	a linkage-specific manner	181:205	a linkage-specific manner	181:205	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	8	81	link	α2,3-linked	1707:1717	arg1	acids					1726:1730	α2,3-linked sialic acids	1707:1730	α2,3-linked sialic acids	1707:1730	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	4	82	from	sialylation	702:712	arg1	tissues					724:730	cancer tissues	717:730	cancer tissues relative to adjacent non-tumor tissues	717:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	5	83	theme	comprehensive	1083:1095	arg1	characterization					1097:1112	comprehensive characterization	1083:1112	comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite	1083:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	84	gly	N-glycopeptide	1176:1189	arg2	N-glycopeptide					1176:1189	the intact N-glycopeptide level	1165:1195	the intact N-glycopeptide level with structure and N-glycosite	1165:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	4	85	theme	intact	796:801	arg1	level					818:822	the intact N-glycopeptide level	792:822	the intact N-glycopeptide level with N-glycosite information	792:851	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	7	86	theme	N-glycan	1458:1465	arg1	biosynthesis					1467:1478	N-glycan biosynthesis	1458:1478	N-glycan biosynthesis	1458:1478	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36192063	4	87	gly	sialylation	702:712	arg1	tissues					724:730	cancer tissues	717:730	cancer tissues relative to adjacent non-tumor tissues	717:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	4	87	gly	sialylation	702:712	arg1	level					818:822	the intact N-glycopeptide level	792:822	the intact N-glycopeptide level with N-glycosite information	792:851	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	5	88	theme	intact	1169:1174	arg1	level					1191:1195	the intact N-glycopeptide level	1165:1195	the intact N-glycopeptide level with structure and N-glycosite	1165:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	5	89	theme	intact	866:871	arg1	N-glycopeptides					873:887	TMT-labeled intact N-glycopeptides	854:887	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation	854:931	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	9	90	theme	disease-	1811:1818	arg1	-19					1826:1828	coronavirus disease-(COVID)-19	1799:1828	coronavirus disease-(COVID)-19	1799:1828	Intact N-glycoproteins with α2,6-sialylation were associated with coronavirus disease-(COVID)-19.
36192063	5	91	theme	N-glycopeptide	1176:1189	arg1	level					1191:1195	the intact N-glycopeptide level	1165:1195	the intact N-glycopeptide level with structure and N-glycosite	1165:1226	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	3	92	theme	acid	522:525	arg1	N-glycoproteomics					557:573	sialic acid linkage-specific quantitative N-glycoproteomics	515:573	sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling	515:650	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	0	93	theme	acid	7:10	arg1	N-glycoproteomics					42:58	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
36192063	1	94	theme	Protein	119:125	arg1	sialylation					127:137	Protein sialylation	119:137	Protein sialylation	119:137	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	4	95	theme	lung	658:661	arg1	cancer					663:668	lung cancer	658:668	lung cancer as a model system	658:686	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	6	96	gly	N-glycopeptides	1348:1362	arg2	N-glycopeptides					1348:1362	521 differentially expressed intact N-glycopeptides	1312:1362	521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins	1312:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	6	96	gly	N-glycopeptides	1348:1362	arg1	N-glycoproteins					1380:1394	254 intact N-glycoproteins	1369:1394	254 intact N-glycoproteins	1369:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	8	97	theme	sialic	1672:1677	arg1	acids					1679:1683	α2,6-linked sialic acids	1660:1683	α2,6-linked sialic acids	1660:1683	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	6	98	from	N-glycoproteins	1380:1394	arg1	N-glycopeptides					1348:1362	521 differentially expressed intact N-glycopeptides	1312:1362	521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins	1312:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	0	99	theme	quantitative	29:40	arg1	N-glycoproteomics					42:58	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics	0:58	Sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex TMT-labeling.
36192063	6	100	gly	N-glycopeptides	1256:1270	arg2	N-glycopeptides					1256:1270	6384 intact N-glycopeptides	1244:1270	6384 intact N-glycopeptides without sialylation	1244:1290	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	5	101	theme	acid	913:916	arg1	alkylamidation					918:931	sialic acid alkylamidation	906:931	sialic acid alkylamidation	906:931	TMT-labeled intact N-glycopeptides with and without sialic acid alkylamidation were subject to reversed-phase liquid chromatography-nano-electron spray ionization-tandem mass spectrometry (RPLC-nanoESI-MS/MS) analysis to provide comprehensive characterization of N-glycosylation with and without sialic acid at the intact N-glycopeptide level with structure and N-glycosite.
36192063	1	102	theme	many	258:261	arg1	diseases					273:280	many malignant diseases	258:280	many malignant diseases	258:280	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	9	103	with	N-glycoproteins	1740:1754	arg1	α2,6-sialylation					1761:1776	α2,6-sialylation	1761:1776	α2,6-sialylation	1761:1776	Intact N-glycoproteins with α2,6-sialylation were associated with coronavirus disease-(COVID)-19.
36192063	3	104	theme	quantitative	544:555	arg1	N-glycoproteomics					557:573	sialic acid linkage-specific quantitative N-glycoproteomics	515:573	sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling	515:650	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	8	105	theme	sialic	1719:1724	arg1	acids					1726:1730	α2,3-linked sialic acids	1707:1730	α2,3-linked sialic acids	1707:1730	In total, 307 sialylated intact N-glycopeptides with linkage-specific sialic acid residues were identified together with 29 N-glycans with α2,6-linked sialic acids and 55 N-glycans with α2,3-linked sialic acids.
36192063	3	106	theme	multiplex	610:618	arg1	TMT					638:640	TMT	638:640	TMT	638:640	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	3	106	theme	multiplex	610:618	arg1	tags					632:635	multiplex tandem mass tags	610:635	multiplex tandem mass tags (TMT)	610:641	Here we report our study of sialic acid linkage-specific quantitative N-glycoproteomics using selective alkylamidation and multiplex tandem mass tags (TMT)-labeling.
36192063	9	107	dep	disease-	1811:1818	arg1	COVID					1820:1824	COVID	1820:1824	COVID	1820:1824	Intact N-glycoproteins with α2,6-sialylation were associated with coronavirus disease-(COVID)-19.
36192063	2	108	theme	N-glycopeptides	447:461	arg1	level					463:467	intact N-glycopeptides level	440:467	intact N-glycopeptides level	440:467	Mass spectrometry-based quantitative N-glycoproteomics has been widely adopted for quantitative analysis of aberrant sialylation, yet multiplexing method at intact N-glycopeptides level is still lacking.
36192063	1	109	theme	malignant	263:271	arg1	diseases					273:280	many malignant diseases	258:280	many malignant diseases	258:280	Protein sialylation participates many biological processes in a linkage-specific manner, and aberrant sialylation has been associated with many malignant diseases.
36192063	6	110	theme	expressed	1331:1339	arg1	N-glycopeptides					1348:1362	521 differentially expressed intact N-glycopeptides	1312:1362	521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins	1312:1394	In this study, 6384 intact N-glycopeptides without sialylation were identified and 521 differentially expressed intact N-glycopeptides from 254 intact N-glycoproteins were quantified.
36192063	4	111	theme	cancer	717:722	arg1	tissues					724:730	cancer tissues	717:730	cancer tissues relative to adjacent non-tumor tissues	717:769	With lung cancer as a model system, differential sialylation in cancer tissues relative to adjacent non-tumor tissues was characterized at the intact N-glycopeptide level with N-glycosite information.
36192063	10	112	theme	terminal	1885:1892	arg1	N-galactosylation					1894:1910	terminal N-galactosylation	1885:1910	terminal N-galactosylation	1885:1910	Additionally, many types of N-glycosylation including terminal N-galactosylation, core and/or branch fucosylation, α2,6-sialylation and terminal bisecting N-acetylglucosamine were identified and quantified in intact N-glycoproteins from immunoglobulin family.
36192063	9	113	gly	N-glycoproteins	1740:1754	arg1	N-glycoproteins					1740:1754	Intact N-glycoproteins	1733:1754	Intact N-glycoproteins with α2,6-sialylation	1733:1776	Intact N-glycoproteins with α2,6-sialylation were associated with coronavirus disease-(COVID)-19.
36192063	7	114	theme	intact	1419:1424	arg1	glycosyltransferases					1499:1518	glycosyltransferases	1499:1518	glycosyltransferases	1499:1518	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36192063	7	114	theme	intact	1419:1424	arg1	N-glycoproteins					1426:1440	Eight intact N-glycoproteins	1413:1440	Eight intact N-glycoproteins responsible for N-glycan biosynthesis	1413:1478	Eight intact N-glycoproteins responsible for N-glycan biosynthesis were identified as glycosyltransferases.
36669592	0	0	theme	line	98:101	arg1	signatures					25:34	O-glycomic and proteomic signatures	0:34	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line	0:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	5	1	theme	proteomic	856:864	arg1	approach					866:873	a quantitative proteomic approach	841:873	a quantitative proteomic approach	841:873	Moreover, a quantitative proteomic approach was used to decipher changes in the cell proteome.
36669592	6	2	theme	differentiated	954:967	arg1	cells					989:993	the fully differentiated butyrate-stimulated cells	944:993	the fully differentiated butyrate-stimulated cells	944:993	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	4	3	theme	tandem	786:791	arg1	spectrometry					798:809	electrospray ionization tandem mass spectrometry	762:809	electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	762:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	3	theme	tandem	786:791	arg1	PGC-nanoLC-MS/MS					812:827	PGC-nanoLC-MS/MS	812:827	PGC-nanoLC-MS/MS	812:827	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	0	4	theme	cell	93:96	arg1	line					98:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	8	5	from	patterns	1332:1339	arg1	gut					1348:1350	the gut	1344:1350	the gut	1344:1350	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	6	6	gly	sialylated	1039:1048	arg1	structures					1059:1068	sialylated O-glycan structures	1039:1068	sialylated O-glycan structures	1039:1068	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	4	7	theme	ionization	775:784	arg1	spectrometry					798:809	electrospray ionization tandem mass spectrometry	762:809	electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	762:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	7	theme	ionization	775:784	arg1	PGC-nanoLC-MS/MS					812:827	PGC-nanoLC-MS/MS	812:827	PGC-nanoLC-MS/MS	812:827	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	8	theme	epithelial	629:638	arg1	differentiation					640:654	butyrate-induced epithelial differentiation	612:654	butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2	612:689	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	8	9	theme	future	1278:1283	arg1	endeavors					1285:1293	future endeavors	1278:1293	future endeavors	1278:1293	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	7	10	theme	O-glycome	1227:1235	arg1	changes					1237:1243	the observed O-glycome changes	1214:1243	the observed O-glycome changes	1214:1243	By performing an integrative approach, we generated hypotheses about the origin of the observed O-glycome changes.
36669592	2	11	theme	energy	323:328	arg1	source					330:335	the preferred energy source	309:335	the preferred energy source of intestinal epithelial cells, capable of inducing differentiation	309:403	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	8	12	theme	patterns	1483:1490	arg1	role					1469:1472	the functional role	1454:1472	bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1420:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	12	theme	patterns	1483:1490	arg1	glycosidases					1430:1441	bacterial glycosidases	1420:1441	bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1420:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	7	13	theme	changes	1237:1243	arg1	origin					1204:1209	the origin	1200:1209	the origin of the observed O-glycome changes	1200:1243	By performing an integrative approach, we generated hypotheses about the origin of the observed O-glycome changes.
36669592	8	14	from	action	1410:1415	arg1	dysbiosis					1511:1519	dysbiosis	1511:1519	dysbiosis at the gut-microbiota interface	1511:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	14	from	action	1410:1415	arg1	homeostasis					1495:1505	homeostasis	1495:1505	homeostasis	1495:1505	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	2	15	theme	preferred	313:321	arg1	source					330:335	the preferred energy source	309:335	the preferred energy source of intestinal epithelial cells, capable of inducing differentiation	309:403	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	2	16	theme	cells	362:366	arg1	source					330:335	the preferred energy source	309:335	the preferred energy source of intestinal epithelial cells, capable of inducing differentiation	309:403	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	8	17	theme	dynamic	1308:1314	arg1	patterns					1332:1339	the dynamic O-glycosylation patterns	1304:1339	the dynamic O-glycosylation patterns in the gut	1304:1350	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	3	18	theme	proteins	476:483	arg1	glycosylation					504:516	protein glycosylation	496:516	the expression of specific proteins as well as protein glycosylation	449:516	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	3	18	theme	proteins	476:483	arg1	expression					453:462	the expression	449:462	the expression of specific proteins as well as protein glycosylation	449:516	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	5	19	from	changes	896:902	arg1	proteome					916:923	the cell proteome	907:923	the cell proteome	907:923	Moreover, a quantitative proteomic approach was used to decipher changes in the cell proteome.
36669592	7	20	theme	observed	1218:1225	arg1	changes					1237:1243	the observed O-glycome changes	1214:1243	the observed O-glycome changes	1214:1243	By performing an integrative approach, we generated hypotheses about the origin of the observed O-glycome changes.
36669592	0	21	dep	differentiation	103:117	arg1	signatures					25:34	O-glycomic and proteomic signatures	0:34	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line	0:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	2	22	from	effects	268:274	arg1	homeostasis					290:300	intestinal homeostasis	279:300	intestinal homeostasis	279:300	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	1	23	theme	human	196:200	arg1	host					202:205	the human host	192:205	the human host	192:205	Gut microbiota of the gastrointestinal tract provide health benefits to the human host via bacterial metabolites.
36669592	6	24	theme	structures	1059:1068	arg1	expression					1025:1034	a higher expression	1016:1034	a higher expression of sialylated O-glycan structures	1016:1068	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	8	25	dep	pave	1261:1264	arg1	either					1353:1358	either	1353:1358	either	1353:1358	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	2	26	theme	epithelial	351:360	arg1	cells					362:366	intestinal epithelial cells	340:366	intestinal epithelial cells	340:366	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	0	27	theme	O-glycomic	0:9	arg1	signatures					25:34	O-glycomic and proteomic signatures	0:34	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line	0:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	2	28	theme	intestinal	340:349	arg1	cells					362:366	intestinal epithelial cells	340:366	intestinal epithelial cells	340:366	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	3	29	theme	specific	467:474	arg1	proteins					476:483	specific proteins	467:483	specific proteins	467:483	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	8	30	theme	O-glycosylation	1316:1330	arg1	patterns					1332:1339	the dynamic O-glycosylation patterns	1304:1339	the dynamic O-glycosylation patterns in the gut	1304:1350	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	31	theme	bacterial	1420:1428	arg1	glycosidases					1430:1441	bacterial glycosidases	1420:1441	bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1420:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	32	from	homeostasis	1495:1505	arg1	action					1410:1415	the action	1406:1415	the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1406:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	1	33	theme	Gut	120:122	arg1	microbiota					124:133	Gut microbiota	120:133	Gut microbiota of the gastrointestinal tract	120:163	Gut microbiota of the gastrointestinal tract provide health benefits to the human host via bacterial metabolites.
36669592	1	34	theme	bacterial	211:219	arg1	metabolites					221:231	bacterial metabolites	211:231	bacterial metabolites	211:231	Gut microbiota of the gastrointestinal tract provide health benefits to the human host via bacterial metabolites.
36669592	0	35	theme	proteomic	15:23	arg1	signatures					25:34	O-glycomic and proteomic signatures	0:34	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line	0:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	4	36	theme	butyrate-induced	612:627	arg1	differentiation					640:654	butyrate-induced epithelial differentiation	612:654	butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2	612:689	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	7	37	theme	integrative	1148:1158	arg1	approach					1160:1167	an integrative approach	1145:1167	an integrative approach	1145:1167	By performing an integrative approach, we generated hypotheses about the origin of the observed O-glycome changes.
36669592	4	38	with	chromatography	742:755	arg1	spectrometry					798:809	electrospray ionization tandem mass spectrometry	762:809	electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	762:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	38	with	chromatography	742:755	arg1	PGC-nanoLC-MS/MS					812:827	PGC-nanoLC-MS/MS	812:827	PGC-nanoLC-MS/MS	812:827	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	8	39	from	interface	1543:1551	arg1	role					1469:1472	the functional role	1454:1472	bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1420:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	39	from	interface	1543:1551	arg1	dysbiosis					1511:1519	dysbiosis	1511:1519	dysbiosis at the gut-microbiota interface	1511:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	39	from	interface	1543:1551	arg1	glycosidases					1430:1441	bacterial glycosidases	1420:1441	bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1420:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	39	from	interface	1543:1551	arg1	homeostasis					1495:1505	homeostasis	1495:1505	homeostasis	1495:1505	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	40	theme	cellular	1373:1380	arg1	biosynthesis					1382:1393	cellular biosynthesis	1373:1393	cellular biosynthesis	1373:1393	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	0	41	theme	spontaneous	39:49	arg1	line					98:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	4	42	theme	mass	793:796	arg1	spectrometry					798:809	electrospray ionization tandem mass spectrometry	762:809	electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	762:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	42	theme	mass	793:796	arg1	PGC-nanoLC-MS/MS					812:827	PGC-nanoLC-MS/MS	812:827	PGC-nanoLC-MS/MS	812:827	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	5	43	used	used	879:882	arg2	approach					866:873	a quantitative proteomic approach	841:873	a quantitative proteomic approach	841:873	Moreover, a quantitative proteomic approach was used to decipher changes in the cell proteome.
36669592	3	44	gly	glycosylation	504:516	arg1	proteins					476:483	specific proteins	467:483	specific proteins	467:483	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	4	45	theme	nano-liquid	730:740	arg1	chromatography					742:755	porous graphitized carbon nano-liquid chromatography	704:755	porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	704:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	46	theme	porous	704:709	arg1	chromatography					742:755	porous graphitized carbon nano-liquid chromatography	704:755	porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	704:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	47	theme	carbon	723:728	arg1	chromatography					742:755	porous graphitized carbon nano-liquid chromatography	704:755	porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	704:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	48	theme	mucin	570:574	arg1	O-glycans					576:584	specific mucin O-glycans	561:584	specific mucin O-glycans	561:584	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	6	49	dep	characterized	999:1011	arg1	whereas					1071:1077	whereas	1071:1077	whereas	1071:1077	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	2	50	theme	beneficial	257:266	arg1	effects					268:274	beneficial effects	257:274	beneficial effects on intestinal homeostasis	257:300	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	0	51	theme	butyrate-stimulated	55:73	arg1	line					98:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	4	52	theme	specific	561:568	arg1	O-glycans					576:584	specific mucin O-glycans	561:584	specific mucin O-glycans	561:584	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	8	53	theme	functional	1458:1467	arg1	role					1469:1472	the functional role	1454:1472	bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1420:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	5	54	theme	quantitative	843:854	arg1	approach					866:873	a quantitative proteomic approach	841:873	a quantitative proteomic approach	841:873	Moreover, a quantitative proteomic approach was used to decipher changes in the cell proteome.
36669592	6	55	theme	butyrate-stimulated	969:987	arg1	cells					989:993	the fully differentiated butyrate-stimulated cells	944:993	the fully differentiated butyrate-stimulated cells	944:993	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	8	56	theme	glycosidases	1430:1441	arg1	action					1410:1415	the action	1406:1415	the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1406:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	4	57	theme	intestinal	663:672	arg1	CaCo-2					684:689	the intestinal cell line CaCo-2	659:689	the intestinal cell line CaCo-2	659:689	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	6	58	theme	higher	1018:1023	arg1	expression					1025:1034	a higher expression	1016:1034	a higher expression of sialylated O-glycan structures	1016:1068	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	2	59	theme	Bacterial	234:242	arg1	butyrate					244:251	Bacterial butyrate	234:251	Bacterial butyrate	234:251	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	2	60	theme	capable	369:375	arg1	cells					362:366	intestinal epithelial cells	340:366	intestinal epithelial cells	340:366	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	8	61	from	glycosidases	1430:1441	arg1	interface					1543:1551	the gut-microbiota interface	1524:1551	the gut-microbiota interface	1524:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	61	from	glycosidases	1430:1441	arg1	dysbiosis					1511:1519	dysbiosis	1511:1519	dysbiosis at the gut-microbiota interface	1511:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	61	from	glycosidases	1430:1441	arg1	homeostasis					1495:1505	homeostasis	1495:1505	homeostasis	1495:1505	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	6	62	theme	O-glycan	1050:1057	arg1	structures					1059:1068	sialylated O-glycan structures	1039:1068	sialylated O-glycan structures	1039:1068	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	1	63	theme	gastrointestinal	142:157	arg1	tract					159:163	the gastrointestinal tract	138:163	the gastrointestinal tract	138:163	Gut microbiota of the gastrointestinal tract provide health benefits to the human host via bacterial metabolites.
36669592	8	64	from	role	1469:1472	arg1	interface					1543:1551	the gut-microbiota interface	1524:1551	the gut-microbiota interface	1524:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	64	from	role	1469:1472	arg1	dysbiosis					1511:1519	dysbiosis	1511:1519	dysbiosis at the gut-microbiota interface	1511:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	64	from	role	1469:1472	arg1	homeostasis					1495:1505	homeostasis	1495:1505	homeostasis	1495:1505	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	4	65	theme	cell	674:677	arg1	CaCo-2					684:689	the intestinal cell line CaCo-2	659:689	the intestinal cell line CaCo-2	659:689	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	8	66	theme	role	1469:1472	arg1	action					1410:1415	the action	1406:1415	the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1406:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	8	67	theme	gut-microbiota	1528:1541	arg1	interface					1543:1551	the gut-microbiota interface	1524:1551	the gut-microbiota interface	1524:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	1	68	theme	tract	159:163	arg1	microbiota					124:133	Gut microbiota	120:133	Gut microbiota of the gastrointestinal tract	120:163	Gut microbiota of the gastrointestinal tract provide health benefits to the human host via bacterial metabolites.
36669592	2	69	contain	has	253:255	arg1	butyrate					244:251	Bacterial butyrate	234:251	Bacterial butyrate	234:251	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	2	69	contain	has	253:255	arg2	effects					268:274	beneficial effects	257:274	beneficial effects on intestinal homeostasis	257:300	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	0	70	theme	cancer	86:91	arg1	line					98:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	2	71	theme	intestinal	279:288	arg1	homeostasis					290:300	intestinal homeostasis	279:300	intestinal homeostasis	279:300	Bacterial butyrate has beneficial effects on intestinal homeostasis and is the preferred energy source of intestinal epithelial cells, capable of inducing differentiation.
36669592	3	72	theme	protein	496:502	arg1	glycosylation					504:516	protein glycosylation	496:516	the expression of specific proteins as well as protein glycosylation	449:516	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	4	73	theme	electrospray	762:773	arg1	spectrometry					798:809	electrospray ionization tandem mass spectrometry	762:809	electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	762:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	73	theme	electrospray	762:773	arg1	PGC-nanoLC-MS/MS					812:827	PGC-nanoLC-MS/MS	812:827	PGC-nanoLC-MS/MS	812:827	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	74	theme	graphitized	711:721	arg1	chromatography					742:755	porous graphitized carbon nano-liquid chromatography	704:755	porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS)	704:828	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	4	75	theme	CaCo-2	684:689	arg1	differentiation					640:654	butyrate-induced epithelial differentiation	612:654	butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2	612:689	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36669592	0	76	theme	colorectal	75:84	arg1	line					98:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	spontaneous and butyrate-stimulated colorectal cancer cell line	39:101	O-glycomic and proteomic signatures of spontaneous and butyrate-stimulated colorectal cancer cell line differentiation.
36669592	3	77	from	changes	438:444	arg1	expression					453:462	the expression	449:462	the expression of specific proteins as well as protein glycosylation	449:516	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	3	77	from	changes	438:444	arg1	glycosylation					504:516	protein glycosylation	496:516	the expression of specific proteins as well as protein glycosylation	449:516	It was previously observed that changes in the expression of specific proteins as well as protein glycosylation occur with differentiation.
36669592	5	78	theme	cell	911:914	arg1	proteome					916:923	the cell proteome	907:923	the cell proteome	907:923	Moreover, a quantitative proteomic approach was used to decipher changes in the cell proteome.
36669592	8	79	from	dysbiosis	1511:1519	arg1	action					1410:1415	the action	1406:1415	the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface	1406:1551	These insights pave the way for future endeavors to study the dynamic O-glycosylation patterns in the gut, either produced via cellular biosynthesis or through the action of bacterial glycosidases as well as the functional role of these patterns in homeostasis and dysbiosis at the gut-microbiota interface.
36669592	1	80	theme	health	173:178	arg1	benefits					180:187	health benefits	173:187	health benefits	173:187	Gut microbiota of the gastrointestinal tract provide health benefits to the human host via bacterial metabolites.
36669592	6	81	theme	sialylated	1039:1048	arg1	structures					1059:1068	sialylated O-glycan structures	1039:1068	sialylated O-glycan structures	1039:1068	It was found that the fully differentiated butyrate-stimulated cells are characterized by a higher expression of sialylated O-glycan structures, whereas fucosylation is downregulated with differentiation.
36669592	4	82	theme	line	679:682	arg1	CaCo-2					684:689	the intestinal cell line CaCo-2	659:689	the intestinal cell line CaCo-2	659:689	In this study, specific mucin O-glycans were identified that mark butyrate-induced epithelial differentiation of the intestinal cell line CaCo-2, by applying porous graphitized carbon nano-liquid chromatography with electrospray ionization tandem mass spectrometry (PGC-nanoLC-MS/MS).
36652139	0	0	theme	Commercial	88:97	arg1	Preparations					99:110	PMSG Commercial Preparations	83:110	PMSG Commercial Preparations	83:110	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	3	1	theme	RP-HPLC-purified	699:714	arg1	PMSG					716:719	a RP-HPLC-purified PMSG	697:719	a RP-HPLC-purified PMSG	697:719	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	1	2	theme	glycoprotein	154:165	arg1	gonadotropin					130:141	Equine chorionic gonadotropin	113:141	Equine chorionic gonadotropin (eCG)	113:147	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	2	theme	glycoprotein	154:165	arg1	hormone					167:173	a glycoprotein hormone	152:173	a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock	152:303	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	0	3	theme	PMSG	83:86	arg1	Preparations					99:110	PMSG Commercial Preparations	83:110	PMSG Commercial Preparations	83:110	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	9	4	theme	recombinant	1326:1336	arg1	hormones					1338:1345	the purified recombinant hormones	1313:1345	the purified recombinant hormones	1313:1345	Slight differences between the purified recombinant hormones were found.
36652139	8	5	theme	F	1225:1225	arg1	treatment					1227:1235	PNGase F treatment	1218:1235	PNGase F treatment	1218:1235	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	4	6	theme	reCG	792:795	arg1	characteristics					773:787	the structural and functional characteristics	743:787	the structural and functional characteristics of reCG	743:795	To gain insight into the structural and functional characteristics of reCG, a bioinformatics analysis was performed.
36652139	13	7	theme	glycan	1796:1801	arg1	moieties					1803:1810	the glycan moieties	1792:1810	the glycan moieties	1792:1810	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	4	8	theme	functional	762:771	arg1	characteristics					773:787	the structural and functional characteristics	743:787	the structural and functional characteristics of reCG	743:795	To gain insight into the structural and functional characteristics of reCG, a bioinformatics analysis was performed.
36652139	11	9	from	differences	1578:1588	arg1	potency					1610:1616	their biological potency	1593:1616	their biological potency	1593:1616	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
36652139	6	10	theme	order	1010:1014	arg1	structures					1016:1025	Higher order structures	1003:1025	Higher order structures	1003:1025	Higher order structures were studied by fluorescence spectroscopy and SEC-HPLC.
36652139	8	11	theme	PNGase	1218:1223	arg1	treatment					1227:1235	PNGase F treatment	1218:1235	PNGase F treatment	1218:1235	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	13	12	theme	moieties	1803:1810	arg1	importance					1778:1787	the importance	1774:1787	the importance of the glycan moieties on eCG conformation and hence in its biological activity	1774:1867	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	2	13	from	available	344:352	arg1	market					361:366	the market	357:366	the market for veterinary use	357:385	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	3	14	theme	suspension	529:538	arg1	cells					547:551	suspension CHO-K1 cells	529:551	suspension CHO-K1 cells	529:551	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	11	15	theme	PMSG	1533:1536	arg1	preparations					1517:1528	two commercial preparations	1502:1528	two commercial preparations of PMSG	1502:1536	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
36652139	1	16	theme	reproductive	267:278	arg1	performance					280:290	the reproductive performance	263:290	the reproductive performance in livestock	263:303	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	5	17	theme	exhaustive	842:851	arg1	characterization					853:868	An exhaustive characterization	839:868	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC	839:986	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	0	18	with	Studies	70:76	arg1	Preparations					99:110	PMSG Commercial Preparations	83:110	PMSG Commercial Preparations	83:110	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	8	19	theme	weak	1260:1263	arg1	exchange-HPLC					1271:1283	weak anion exchange-HPLC	1260:1283	weak anion exchange-HPLC	1260:1283	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	6	20	theme	Higher	1003:1008	arg1	structures					1016:1025	Higher order structures	1003:1025	Higher order structures	1003:1025	Higher order structures were studied by fluorescence spectroscopy and SEC-HPLC.
36652139	12	21	contain	having	1656:1661	arg1	importance					1642:1651	the importance	1638:1651	the importance of having a standardized production process, as	1638:1699	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	12	21	contain	having	1656:1661	arg2	process					1689:1695	a standardized production process	1663:1695	a standardized production process	1663:1695	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	0	22	theme	Physicochemical	0:14	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.	0:111	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	2	23	theme	gonadotropin	455:466	arg1	preparations					419:430	partially purified preparations	400:430	partially purified preparations of pregnant mare serum gonadotropin (PMSG)	400:473	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	1	24	from	performance	280:290	arg1	livestock					295:303	livestock	295:303	livestock	295:303	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	11	25	theme	sialic	1474:1479	arg1	content					1486:1492	sialic acid content	1474:1492	sialic acid content	1474:1492	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
36652139	13	26	theme	denaturing	1881:1890	arg1	processes					1892:1900	denaturing processes	1881:1900	denaturing processes such as aggregation	1881:1920	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	13	26	theme	denaturing	1881:1890	arg1	aggregation					1910:1920	aggregation	1910:1920	aggregation	1910:1920	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	13	27	from	importance	1778:1787	arg1	conformation					1819:1830	eCG conformation	1815:1830	eCG conformation	1815:1830	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	13	27	from	importance	1778:1787	arg1	activity					1860:1867	its biological activity	1845:1867	its biological activity	1845:1867	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	2	28	theme	serum	449:453	arg1	PMSG					469:472	PMSG	469:472	PMSG	469:472	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	2	28	theme	serum	449:453	arg1	gonadotropin					455:466	pregnant mare serum gonadotropin	435:466	pregnant mare serum gonadotropin (PMSG)	435:473	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	11	29	theme	acid	1481:1484	arg1	content					1486:1492	sialic acid content	1474:1492	sialic acid content	1474:1492	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
36652139	9	30	theme	Slight	1286:1291	arg1	differences					1293:1303	Slight differences	1286:1303	Slight differences between the purified recombinant hormones	1286:1345	Slight differences between the purified recombinant hormones were found.
36652139	12	31	theme	recombinant	1713:1723	arg1	bioprocess					1733:1742	a recombinant protein bioprocess	1711:1742	a recombinant protein bioprocess	1711:1742	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	1	32	theme	timed	190:194	arg1	protocols					242:250	timed artificial ovulation (TAI) and superovulation protocols	190:250	timed artificial ovulation (TAI) and superovulation protocols	190:250	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	2	33	theme	mare	444:447	arg1	PMSG					469:472	PMSG	469:472	PMSG	469:472	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	2	33	theme	mare	444:447	arg1	gonadotropin					455:466	pregnant mare serum gonadotropin	435:466	pregnant mare serum gonadotropin (PMSG)	435:473	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	10	34	theme	recombinant	1368:1378	arg1	molecules					1380:1388	recombinant molecules	1368:1388	recombinant molecules	1368:1388	However, recombinant molecules and PMSG exhibited variations in the glycosylation pattern.
36652139	13	35	theme	biological	1849:1858	arg1	activity					1860:1867	its biological activity	1845:1867	its biological activity	1845:1867	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	2	36	from	market	361:366	arg1	available					344:352	available	344:352	available	344:352	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	1	37	theme	Equine	113:118	arg1	eCG					144:146	eCG	144:146	eCG	144:146	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	37	theme	Equine	113:118	arg1	gonadotropin					130:141	Equine chorionic gonadotropin	113:141	Equine chorionic gonadotropin (eCG)	113:147	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	37	theme	Equine	113:118	arg1	hormone					167:173	a glycoprotein hormone	152:173	a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock	152:303	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	38	theme	artificial	196:205	arg1	ovulation					207:215	artificial ovulation	196:215	artificial ovulation (TAI)	196:221	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	38	theme	artificial	196:205	arg1	TAI					218:220	TAI	218:220	TAI	218:220	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	2	39	theme	pregnant	435:442	arg1	PMSG					469:472	PMSG	469:472	PMSG	469:472	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	2	39	theme	pregnant	435:442	arg1	gonadotropin					455:466	pregnant mare serum gonadotropin	435:466	pregnant mare serum gonadotropin (PMSG)	435:473	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	10	40	from	variations	1409:1418	arg1	pattern					1441:1447	the glycosylation pattern	1423:1447	the glycosylation pattern	1423:1447	However, recombinant molecules and PMSG exhibited variations in the glycosylation pattern.
36652139	12	41	dep	show	1633:1636	arg1	occurs					1701:1706	occurs	1701:1706	show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess	1633:1742	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	1	42	theme	chorionic	120:128	arg1	eCG					144:146	eCG	144:146	eCG	144:146	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	42	theme	chorionic	120:128	arg1	gonadotropin					130:141	Equine chorionic gonadotropin	113:141	Equine chorionic gonadotropin (eCG)	113:147	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	42	theme	chorionic	120:128	arg1	hormone					167:173	a glycoprotein hormone	152:173	a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock	152:303	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	1	43	theme	ovulation	207:215	arg1	protocols					242:250	timed artificial ovulation (TAI) and superovulation protocols	190:250	timed artificial ovulation (TAI) and superovulation protocols	190:250	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	0	44	theme	eCG	50:52	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.	0:111	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	5	45	theme	nicked	936:941	arg1	forms					943:947	nicked forms	936:947	nicked forms	936:947	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	5	45	theme	nicked	936:941	arg1	degree					913:918	the purity degree	902:918	the purity degree	902:918	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	8	46	theme	Glycosylation	1139:1151	arg1	analysis					1153:1160	Glycosylation analysis	1139:1160	Glycosylation analysis	1139:1160	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	3	47	theme	chromatographic	586:600	arg1	-HPLC					672:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	47	theme	chromatographic	586:600	arg1	methods					602:608	different chromatographic methods	576:608	different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC)	576:677	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	2	48	theme	veterinary	372:381	arg1	use					383:385	veterinary use	372:385	veterinary use	372:385	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	2	49	theme	purified	410:417	arg1	preparations					419:430	partially purified preparations	400:430	partially purified preparations of pregnant mare serum gonadotropin (PMSG)	400:473	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	0	50	theme	Recombinant	38:48	arg1	eCG					50:52	a Recombinant eCG	36:52	a Recombinant eCG	36:52	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	12	51	theme	standardized	1665:1676	arg1	process					1689:1695	a standardized production process	1663:1695	a standardized production process	1663:1695	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	13	52	theme	eCG	1815:1817	arg1	conformation					1819:1830	eCG conformation	1815:1830	eCG conformation	1815:1830	Besides, our results reflect the importance of the glycan moieties on eCG conformation and hence in its biological activity, preventing denaturing processes such as aggregation.
36652139	9	53	theme	purified	1317:1324	arg1	hormones					1338:1345	the purified recombinant hormones	1313:1345	the purified recombinant hormones	1313:1345	Slight differences between the purified recombinant hormones were found.
36652139	8	54	theme	anion	1265:1269	arg1	exchange-HPLC					1271:1283	weak anion exchange-HPLC	1260:1283	weak anion exchange-HPLC	1260:1283	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	4	55	theme	structural	747:756	arg1	characteristics					773:787	the structural and functional characteristics	743:787	the structural and functional characteristics of reCG	743:795	To gain insight into the structural and functional characteristics of reCG, a bioinformatics analysis was performed.
36652139	0	56	theme	Comparative	58:68	arg1	Studies					70:76	Comparative Studies	58:76	Comparative Studies	58:76	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	3	57	theme	recombinant	494:504	arg1	eCG					506:508	a bioactive recombinant eCG	482:508	a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells	482:551	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	57	theme	recombinant	494:504	arg1	reCG					511:514	reCG	511:514	reCG	511:514	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	58	theme	reverse-phase	654:666	arg1	-HPLC					672:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	58	theme	reverse-phase	654:666	arg1	methods					602:608	different chromatographic methods	576:608	different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC)	576:677	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	10	59	theme	glycosylation	1427:1439	arg1	pattern					1441:1447	the glycosylation pattern	1423:1447	the glycosylation pattern	1423:1447	However, recombinant molecules and PMSG exhibited variations in the glycosylation pattern.
36652139	2	60	theme	available	344:352	arg1	products					335:342	the only eCG products	322:342	the only eCG products available in the market for veterinary use	322:385	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	7	61	theme	Isoforms	1083:1090	arg1	profile					1092:1098	Isoforms profile	1083:1098	Isoforms profile	1083:1098	Isoforms profile were analyzed by isoelectric focusing.
36652139	11	62	from	differences	1459:1469	arg1	content					1486:1492	sialic acid content	1474:1492	sialic acid content	1474:1492	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
36652139	3	63	theme	different	576:584	arg1	-HPLC					672:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	63	theme	different	576:584	arg1	methods					602:608	different chromatographic methods	576:608	different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC)	576:677	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	64	theme	bioactive	484:492	arg1	eCG					506:508	a bioactive recombinant eCG	482:508	a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells	482:551	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	64	theme	bioactive	484:492	arg1	reCG					511:514	reCG	511:514	reCG	511:514	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	12	65	theme	production	1678:1687	arg1	process					1689:1695	a standardized production process	1663:1695	a standardized production process	1663:1695	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	3	66	theme	interaction	623:633	arg1	chromatography					635:648	hydrophobic interaction chromatography	611:648	hydrophobic interaction chromatography	611:648	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	2	67	theme	eCG	331:333	arg1	products					335:342	the only eCG products	322:342	the only eCG products available in the market for veterinary use	322:385	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	3	68	theme	CHO-K1	540:545	arg1	cells					547:551	suspension CHO-K1 cells	529:551	suspension CHO-K1 cells	529:551	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	1	69	gly	glycoprotein	154:165	arg1	glycoprotein					154:165	a glycoprotein hormone	152:173	a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock	152:303	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	3	70	theme	chromatography	635:648	arg1	-HPLC					672:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	hydrophobic interaction chromatography and reverse-phase (RP)-HPLC	611:676	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	3	70	theme	chromatography	635:648	arg1	methods					602:608	different chromatographic methods	576:608	different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC)	576:677	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	12	71	theme	protein	1725:1731	arg1	bioprocess					1733:1742	a recombinant protein bioprocess	1711:1742	a recombinant protein bioprocess	1711:1742	These results show the importance of having a standardized production process, as occurs in a recombinant protein bioprocess.
36652139	2	72	theme	only	326:329	arg1	products					335:342	the only eCG products	322:342	the only eCG products available in the market for veterinary use	322:385	Until recently, the only eCG products available in the market for veterinary use consisted in partially purified preparations of pregnant mare serum gonadotropin (PMSG).
36652139	8	73	theme	pulsed	1184:1189	arg1	detection					1204:1212	pulsed amperometric detection	1184:1212	pulsed amperometric detection	1184:1212	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	6	74	theme	fluorescence	1043:1054	arg1	spectroscopy					1056:1067	fluorescence spectroscopy	1043:1067	fluorescence spectroscopy	1043:1067	Higher order structures were studied by fluorescence spectroscopy and SEC-HPLC.
36652139	8	75	theme	amperometric	1191:1202	arg1	detection					1204:1212	pulsed amperometric detection	1184:1212	pulsed amperometric detection	1184:1212	Glycosylation analysis was performed through pulsed amperometric detection and PNGase F treatment following SDS-PAGE and weak anion exchange-HPLC.
36652139	4	76	theme	bioinformatics	800:813	arg1	analysis					815:822	a bioinformatics analysis	798:822	a bioinformatics analysis	798:822	To gain insight into the structural and functional characteristics of reCG, a bioinformatics analysis was performed.
36652139	5	77	theme	purity	906:911	arg1	aggregates					921:930	aggregates	921:930	aggregates	921:930	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	5	77	theme	purity	906:911	arg1	forms					943:947	nicked forms	936:947	nicked forms	936:947	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	5	77	theme	purity	906:911	arg1	degree					913:918	the purity degree	902:918	the purity degree	902:918	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	1	78	theme	superovulation	227:240	arg1	protocols					242:250	timed artificial ovulation (TAI) and superovulation protocols	190:250	timed artificial ovulation (TAI) and superovulation protocols	190:250	Equine chorionic gonadotropin (eCG) is a glycoprotein hormone widely used in timed artificial ovulation (TAI) and superovulation protocols to improve the reproductive performance in livestock.
36652139	0	79	theme	Studies	70:76	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.	0:111	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	3	80	theme	hydrophobic	611:621	arg1	chromatography					635:648	hydrophobic interaction chromatography	611:648	hydrophobic interaction chromatography	611:648	Here, a bioactive recombinant eCG (reCG) produced in suspension CHO-K1 cells was purified employing different chromatographic methods (hydrophobic interaction chromatography and reverse-phase (RP)-HPLC) and compared with a RP-HPLC-purified PMSG.
36652139	0	81	with	eCG	50:52	arg1	Preparations					99:110	PMSG Commercial Preparations	83:110	PMSG Commercial Preparations	83:110	Physicochemical Characterization of a Recombinant eCG and Comparative Studies with PMSG Commercial Preparations.
36652139	5	82	theme	degree	913:918	arg1	determination					885:897	the determination	881:897	the determination of the purity degree, aggregates and nicked forms	881:947	An exhaustive characterization comprising the determination of the purity degree, aggregates and nicked forms through SDS-PAGE, RP-HPLC and SEC-HPLC was performed.
36652139	11	83	theme	biological	1599:1608	arg1	potency					1610:1616	their biological potency	1593:1616	their biological potency	1593:1616	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
36652139	11	84	theme	commercial	1506:1515	arg1	preparations					1517:1528	two commercial preparations	1502:1528	two commercial preparations of PMSG	1502:1536	In fact, differences in sialic acid content between two commercial preparations of PMSG were also obtained, which could lead to differences in their biological potency.
37357420	7	0	from	database	1001:1008	arg1	libraries					974:982	the natural compound libraries	953:982	the natural compound libraries from the COCONUT database	953:1008	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	3	1	theme	anticancer	635:644	arg1	drugs					646:650	anticancer drugs	635:650	anticancer drugs	635:650	The role that the upregulated FUT6 plays in the progression of tumor to malignancy, with reduced survival rates, makes it a potential target for anticancer drugs.
37357420	7	2	theme	best	1060:1063	arg1	model					1090:1094	best affinity toward the FUT6 model	1060:1094	best affinity toward the FUT6 model	1060:1094	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	2	3	dep	attributed	325:334	arg1	FUT6					381:384	FUT6	381:384	FUT6	381:384	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	1	4	gly	fucosylated	174:184	arg1	glycan					199:204	a fucosylated cell-surface glycan	172:204	a fucosylated cell-surface glycan that is normally involved in cell-cell interactions	172:256	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	1	4	gly	fucosylated	174:184	arg1	antigen					161:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	10	5	theme	MD	1515:1516	arg1	simulations					1518:1528	the MD simulations	1511:1528	the MD simulations	1511:1528	Analysis of the MD simulations showed that the identified NPs establish stable contacts with FUT6 under dynamics conditions.
37357420	11	6	theme	FUT6	1737:1740	arg1	inhibitors					1752:1761	experimentally tested FUT6 synthetic inhibitors	1715:1761	experimentally tested FUT6 synthetic inhibitors	1715:1761	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	7	7	theme	natural	1032:1038	arg1	products					1040:1047	potential natural products	1022:1047	potential natural products (NPs)	1022:1053	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	7	7	theme	natural	1032:1038	arg1	NPs					1050:1052	NPs	1050:1052	NPs	1050:1052	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	1	8	theme	cell-surface	186:197	arg1	glycan					199:204	a fucosylated cell-surface glycan	172:204	a fucosylated cell-surface glycan that is normally involved in cell-cell interactions	172:256	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	1	8	theme	cell-surface	186:197	arg1	antigen					161:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	2	9	theme	surface	299:305	arg1	glycans					307:313	cell surface glycans	294:313	cell surface glycans	294:313	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	9	10	theme	dynamics	1397:1404	arg1	simulations					1411:1421	molecular dynamics (MD) simulations	1387:1421	molecular dynamics (MD) simulations	1387:1421	We also performed molecular dynamics (MD) simulations for the FUT6 complexes with identified NPs, to investigate their stability.
37357420	6	11	theme	human	907:911	arg1	FUT6					913:916	human FUT6	907:916	human FUT6 using AlphaFold	907:932	We first modeled the three-dimensional structure of human FUT6 using AlphaFold.
37357420	8	12	theme	interaction	1201:1211	arg1	patterns					1213:1220	interaction patterns	1201:1220	interaction patterns	1201:1220	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	7	13	theme	natural	957:963	arg1	libraries					974:982	the natural compound libraries	953:982	the natural compound libraries from the COCONUT database	953:1008	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	9	14	theme	MD	1407:1408	arg1	simulations					1411:1421	molecular dynamics (MD) simulations	1387:1421	molecular dynamics (MD) simulations	1387:1421	We also performed molecular dynamics (MD) simulations for the FUT6 complexes with identified NPs, to investigate their stability.
37357420	7	15	theme	COCONUT	993:999	arg1	database					1001:1008	the COCONUT database	989:1008	the COCONUT database	989:1008	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	3	16	theme	tumor	553:557	arg1	progression					538:548	the progression	534:548	the progression of tumor to malignancy	534:571	The role that the upregulated FUT6 plays in the progression of tumor to malignancy, with reduced survival rates, makes it a potential target for anticancer drugs.
37357420	1	17	theme	Sialyl	138:143	arg1	sLex					154:157	sLex	154:157	sLex	154:157	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	1	17	theme	Sialyl	138:143	arg1	X					151:151	Sialyl Lewis X	138:151	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	3	18	theme	survival	587:594	arg1	rates					596:600	reduced survival rates	579:600	reduced survival rates	579:600	The role that the upregulated FUT6 plays in the progression of tumor to malignancy, with reduced survival rates, makes it a potential target for anticancer drugs.
37357420	1	19	theme	X	151:151	arg1	glycan					199:204	a fucosylated cell-surface glycan	172:204	a fucosylated cell-surface glycan that is normally involved in cell-cell interactions	172:256	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	1	19	theme	X	151:151	arg1	antigen					161:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	2	20	theme	oral	476:479	arg1	cancers					481:487	human colorectal, lung, prostate, and oral cancers	438:487	cancers	481:487	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	11	21	theme	screened	1652:1659	arg1	compounds					1661:1669	the three screened compounds	1642:1669	the three screened compounds	1642:1669	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	3	22	theme	upregulated	508:518	arg1	FUT6					520:523	the upregulated FUT6	504:523	the upregulated FUT6	504:523	The role that the upregulated FUT6 plays in the progression of tumor to malignancy, with reduced survival rates, makes it a potential target for anticancer drugs.
37357420	5	23	theme	potential	828:836	arg1	inhibitors					843:852	potential FUT6 inhibitors	828:852	potential FUT6 inhibitors	828:852	In this study, we used in silico techniques to identify potential FUT6 inhibitors.
37357420	0	24	theme	promising	84:92	arg1	inhibitors					102:111	promising natural inhibitors	84:111	promising natural inhibitors of fucosyltransferase 6	84:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	12	25	theme	toward FUT6	1872:1882	arg1	inhibition					1884:1893	future experimental validation toward FUT6 inhibition	1841:1893	future experimental validation toward FUT6 inhibition	1841:1893	This envisages good prospects for future experimental validation toward FUT6 inhibition.
37357420	9	26	theme	identified	1451:1460	arg1	NPs					1462:1464	identified NPs	1451:1464	identified NPs	1451:1464	We also performed molecular dynamics (MD) simulations for the FUT6 complexes with identified NPs, to investigate their stability.
37357420	8	27	link	derived	1351:1357	arg1	compound					1359:1366	a GDP-triazole derived compound	1336:1366	a GDP-triazole derived compound	1336:1366	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	2	28	theme	enhanced	263:270	arg1	expression					272:281	The enhanced expression	259:281	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6),	259:386	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	11	29	theme	promising	1681:1689	arg1	alternatives					1699:1710	promising natural alternatives	1681:1710	promising natural alternatives to experimentally tested FUT6 synthetic inhibitors	1681:1761	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	0	30	theme	inhibitors	102:111	arg1	uncovering					70:79	In silico uncovering	60:79	targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6	35:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	8	31	theme	FUT6	1289:1292	arg1	inhibitors					1294:1303	two experimentally tested FUT6 inhibitors	1263:1303	two experimentally tested FUT6 inhibitors	1263:1303	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	0	32	theme	fucosyltransferase	116:133	arg1	inhibitors					102:111	promising natural inhibitors	84:111	promising natural inhibitors of fucosyltransferase 6	84:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	2	33	theme	human	438:442	arg1	prostate					462:469	human colorectal, lung, prostate, and oral cancers	438:487	prostate	462:469	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	4	34	theme	structures	693:702	arg1	lack					672:675	the lack	668:675	the lack of experimental structures for FUT6	668:711	Unfortunately, the lack of experimental structures for FUT6 has hampered the design and development of its inhibitors.
37357420	12	35	theme	experimental	1848:1859	arg1	inhibition					1884:1893	future experimental validation toward FUT6 inhibition	1841:1893	future experimental validation toward FUT6 inhibition	1841:1893	This envisages good prospects for future experimental validation toward FUT6 inhibition.
37357420	10	36	theme	dynamics	1603:1610	arg1	conditions					1612:1621	dynamics conditions	1603:1621	dynamics conditions	1603:1621	Analysis of the MD simulations showed that the identified NPs establish stable contacts with FUT6 under dynamics conditions.
37357420	0	37	theme	targeted	35:42	arg1	discovery					49:57	targeted drug discovery	35:57	targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6	35:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	2	38	from	expression	272:281	arg1	glycans					307:313	cell surface glycans	294:313	cell surface glycans	294:313	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	4	39	dep	design	730:735	arg1	the					726:728	the	726:728	the	726:728	Unfortunately, the lack of experimental structures for FUT6 has hampered the design and development of its inhibitors.
37357420	8	40	theme	fucose	1315:1320	arg1	mimetic-1					1322:1330	fucose mimetic-1	1315:1330	fucose mimetic-1	1315:1330	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	12	41	theme	good	1822:1825	arg1	prospects					1827:1835	good prospects	1822:1835	good prospects for future experimental validation toward FUT6 inhibition	1822:1893	This envisages good prospects for future experimental validation toward FUT6 inhibition.
37357420	0	42	dep	In	60:61	arg1	silico					63:68	silico	63:68	silico	63:68	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	5	43	dep	in	795:796	arg1	silico					798:803	silico	798:803	silico	798:803	In this study, we used in silico techniques to identify potential FUT6 inhibitors.
37357420	0	44	theme	In	60:61	arg1	uncovering					70:79	In silico uncovering	60:79	targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6	35:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	2	45	dep	prostate	462:469	arg1	lung					456:459	human colorectal, lung, prostate, and oral cancers	438:487	lung	456:459	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	8	46	dep	those	1239:1243	arg1	we					1245:1246	we	1245:1246	we	1245:1246	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	8	47	theme	GDP-triazole	1338:1349	arg1	compound					1359:1366	a GDP-triazole derived compound	1336:1366	a GDP-triazole derived compound	1336:1366	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	11	48	theme	comparable	1778:1787	arg1	affinity					1797:1804	expected comparable binding affinity	1769:1804	expected comparable binding affinity	1769:1804	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	3	49	theme	potential	614:622	arg1	target					624:629	a potential target	612:629	a potential target for anticancer drugs	612:650	The role that the upregulated FUT6 plays in the progression of tumor to malignancy, with reduced survival rates, makes it a potential target for anticancer drugs.
37357420	1	50	theme	cell-cell	235:243	arg1	interactions					245:256	cell-cell interactions	235:256	cell-cell interactions	235:256	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	10	51	with	contacts	1578:1585	arg1	FUT6					1592:1595	FUT6	1592:1595	FUT6	1592:1595	Analysis of the MD simulations showed that the identified NPs establish stable contacts with FUT6 under dynamics conditions.
37357420	2	52	theme	cell	294:297	arg1	glycans					307:313	cell surface glycans	294:313	cell surface glycans	294:313	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	2	53	theme	sLex	286:289	arg1	expression					272:281	The enhanced expression	259:281	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6),	259:386	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	5	54	theme	in	795:796	arg1	techniques					805:814	in silico techniques	795:814	in silico techniques	795:814	In this study, we used in silico techniques to identify potential FUT6 inhibitors.
37357420	7	55	theme	toward the	1074:1083	arg1	model					1090:1094	best affinity toward the FUT6 model	1060:1094	best affinity toward the FUT6 model	1060:1094	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	10	56	theme	simulations	1518:1528	arg1	Analysis					1499:1506	Analysis	1499:1506	Analysis of the MD simulations	1499:1528	Analysis of the MD simulations showed that the identified NPs establish stable contacts with FUT6 under dynamics conditions.
37357420	7	57	theme	potential	1022:1030	arg1	products					1040:1047	potential natural products	1022:1047	potential natural products (NPs)	1022:1053	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	7	57	theme	potential	1022:1030	arg1	NPs					1050:1052	NPs	1050:1052	NPs	1050:1052	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	1	58	theme	fucosylated	174:184	arg1	glycan					199:204	a fucosylated cell-surface glycan	172:204	a fucosylated cell-surface glycan that is normally involved in cell-cell interactions	172:256	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	1	58	theme	fucosylated	174:184	arg1	antigen					161:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	11	59	theme	synthetic	1742:1750	arg1	inhibitors					1752:1761	experimentally tested FUT6 synthetic inhibitors	1715:1761	experimentally tested FUT6 synthetic inhibitors	1715:1761	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	0	60	dep	discovery	49:57	arg1	uncovering					70:79	In silico uncovering	60:79	targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6	35:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	9	61	theme	molecular	1387:1395	arg1	simulations					1411:1421	molecular dynamics (MD) simulations	1387:1421	molecular dynamics (MD) simulations	1387:1421	We also performed molecular dynamics (MD) simulations for the FUT6 complexes with identified NPs, to investigate their stability.
37357420	8	62	theme	simulations	1118:1128	arg1	NPs					1151:1153	three NPs	1145:1153	three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound	1145:1366	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	8	62	theme	simulations	1118:1128	arg1	result					1102:1107	a result	1100:1107	a result of these simulations	1100:1128	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	6	63	theme	FUT6	913:916	arg1	structure					894:902	the three-dimensional structure	872:902	the three-dimensional structure of human FUT6 using AlphaFold	872:932	We first modeled the three-dimensional structure of human FUT6 using AlphaFold.
37357420	8	64	theme	binding	1178:1184	arg1	affinities					1186:1195	binding affinities	1178:1195	binding affinities	1178:1195	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	10	65	theme	identified	1546:1555	arg1	NPs					1557:1559	the identified NPs	1542:1559	the identified NPs	1542:1559	Analysis of the MD simulations showed that the identified NPs establish stable contacts with FUT6 under dynamics conditions.
37357420	11	66	theme	tested	1730:1735	arg1	inhibitors					1752:1761	experimentally tested FUT6 synthetic inhibitors	1715:1761	experimentally tested FUT6 synthetic inhibitors	1715:1761	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	11	67	theme	expected	1769:1776	arg1	affinity					1797:1804	expected comparable binding affinity	1769:1804	expected comparable binding affinity	1769:1804	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	7	68	theme	compound	965:972	arg1	libraries					974:982	the natural compound libraries	953:982	the natural compound libraries from the COCONUT database	953:1008	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	6	69	theme	three-dimensional	876:892	arg1	structure					894:902	the three-dimensional structure	872:902	the three-dimensional structure of human FUT6 using AlphaFold	872:932	We first modeled the three-dimensional structure of human FUT6 using AlphaFold.
37357420	3	70	theme	reduced	579:585	arg1	rates					596:600	reduced survival rates	579:600	reduced survival rates	579:600	The role that the upregulated FUT6 plays in the progression of tumor to malignancy, with reduced survival rates, makes it a potential target for anticancer drugs.
37357420	1	71	theme	Lewis	145:149	arg1	sLex					154:157	sLex	154:157	sLex	154:157	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	1	71	theme	Lewis	145:149	arg1	X					151:151	Sialyl Lewis X	138:151	Sialyl Lewis X (sLex ) antigen	138:167	Sialyl Lewis X (sLex ) antigen is a fucosylated cell-surface glycan that is normally involved in cell-cell interactions.
37357420	8	72	theme	similar	1228:1234	arg1	affinities					1186:1195	binding affinities	1178:1195	binding affinities	1178:1195	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	9	73	theme	FUT6	1431:1434	arg1	complexes					1436:1444	the FUT6 complexes	1427:1444	the FUT6 complexes with identified NPs	1427:1464	We also performed molecular dynamics (MD) simulations for the FUT6 complexes with identified NPs, to investigate their stability.
37357420	0	74	theme	natural	94:100	arg1	inhibitors					102:111	promising natural inhibitors	84:111	promising natural inhibitors of fucosyltransferase 6	84:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	5	75	theme	FUT6	838:841	arg1	inhibitors					843:852	potential FUT6 inhibitors	828:852	potential FUT6 inhibitors	828:852	In this study, we used in silico techniques to identify potential FUT6 inhibitors.
37357420	9	76	with	complexes	1436:1444	arg1	NPs					1462:1464	identified NPs	1451:1464	identified NPs	1451:1464	We also performed molecular dynamics (MD) simulations for the FUT6 complexes with identified NPs, to investigate their stability.
37357420	11	77	theme	natural	1691:1697	arg1	alternatives					1699:1710	promising natural alternatives	1681:1710	promising natural alternatives to experimentally tested FUT6 synthetic inhibitors	1681:1761	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	12	78	theme	future	1841:1846	arg1	inhibition					1884:1893	future experimental validation toward FUT6 inhibition	1841:1893	future experimental validation toward FUT6 inhibition	1841:1893	This envisages good prospects for future experimental validation toward FUT6 inhibition.
37357420	8	79	theme	tested	1282:1287	arg1	inhibitors					1294:1303	two experimentally tested FUT6 inhibitors	1263:1303	two experimentally tested FUT6 inhibitors	1263:1303	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	10	80	theme	stable	1571:1576	arg1	contacts					1578:1585	stable contacts	1571:1585	stable contacts with FUT6	1571:1595	Analysis of the MD simulations showed that the identified NPs establish stable contacts with FUT6 under dynamics conditions.
37357420	12	81	theme	validation	1861:1870	arg1	inhibition					1884:1893	future experimental validation toward FUT6 inhibition	1841:1893	future experimental validation toward FUT6 inhibition	1841:1893	This envisages good prospects for future experimental validation toward FUT6 inhibition.
37357420	4	82	theme	experimental	680:691	arg1	structures					693:702	experimental structures	680:702	experimental structures	680:702	Unfortunately, the lack of experimental structures for FUT6 has hampered the design and development of its inhibitors.
37357420	0	83	theme	drug	44:47	arg1	discovery					49:57	targeted drug discovery	35:57	targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6	35:135	Toward α-1,3/4 fucosyltransferases targeted drug discovery: In silico uncovering of promising natural inhibitors of fucosyltransferase 6.
37357420	7	84	theme	FUT6	1085:1088	arg1	model					1090:1094	best affinity toward the FUT6 model	1060:1094	best affinity toward the FUT6 model	1060:1094	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	4	85	theme	inhibitors	760:769	arg1	development					741:751	development	741:751	development	741:751	Unfortunately, the lack of experimental structures for FUT6 has hampered the design and development of its inhibitors.
37357420	4	85	theme	inhibitors	760:769	arg1	design					730:735	design	730:735	design	730:735	Unfortunately, the lack of experimental structures for FUT6 has hampered the design and development of its inhibitors.
37357420	7	86	theme	affinity	1065:1072	arg1	model					1090:1094	best affinity toward the FUT6 model	1060:1094	best affinity toward the FUT6 model	1060:1094	Then, we screened the natural compound libraries from the COCONUT database to sort out potential natural products (NPs) with best affinity toward the FUT6 model.
37357420	2	87	theme	colorectal	444:453	arg1	prostate					462:469	human colorectal, lung, prostate, and oral cancers	438:487	prostate	462:469	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
37357420	5	88	used	used	790:793	arg2	we					787:788	we	787:788	we	787:788	In this study, we used in silico techniques to identify potential FUT6 inhibitors.
37357420	11	89	theme	binding	1789:1795	arg1	affinity					1797:1804	expected comparable binding affinity	1769:1804	expected comparable binding affinity	1769:1804	On these grounds, the three screened compounds appear as promising natural alternatives to experimentally tested FUT6 synthetic inhibitors, with expected comparable binding affinity.
37357420	8	90	theme	derived	1351:1357	arg1	compound					1359:1366	a GDP-triazole derived compound	1336:1366	a GDP-triazole derived compound	1336:1366	As a result of these simulations, we identified three NPs for which we predicted binding affinities and interaction patterns quite similar to those we calculated for two experimentally tested FUT6 inhibitors, that is, fucose mimetic-1 and a GDP-triazole derived compound.
37357420	2	91	theme	fucosyltransferase	359:376	arg1	upregulation					343:354	the upregulation	339:354	the upregulation of fucosyltransferase 6	339:378	The enhanced expression of sLex on cell surface glycans, which is attributed to the upregulation of fucosyltransferase 6 (FUT6), has been implicated in facilitating metastasis in human colorectal, lung, prostate, and oral cancers.
35247773	6	0	theme	SDC-based	1074:1082	arg1	nanogels					1084:1091	the SDC-based nanogels	1070:1091	the SDC-based nanogels possessed a potential to be used as desirable nanocarriers for encapsulating hydrophobic bioactive compounds	1070:1200	Results demonstrated the SDC-based nanogels possessed a potential to be used as desirable nanocarriers for encapsulating hydrophobic bioactive compounds.
35247773	3	1	theme	emulsifying	669:679	arg1	properties					681:690	emulsifying properties	669:690	emulsifying properties	669:690	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	1	2	theme	Maillard	179:186	arg1	reaction					188:195	the Maillard reaction	175:195	the Maillard reaction combined with protein self-assembly in this study	175:245	Soybean protein isolate (SPI)-dextran conjugate-based nanogels were prepared via the Maillard reaction combined with protein self-assembly in this study.
35247773	4	3	theme	pH	756:757	arg1	Effects					720:726	Effects	720:726	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index	720:819	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	3	4	theme	loosened	525:532	arg1	conformation					543:554	loosened tertiary conformation	525:554	loosened tertiary conformation	525:554	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	2	5	theme	mass	299:302	arg1	1:1.75					311:316	1:1.75	311:316	1:1.75	311:316	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	2	5	theme	mass	299:302	arg1	ratio					304:308	SPI/dextran mass ratio	287:308	SPI/dextran mass ratio (1:1.75)	287:317	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	5	6	from	translucent	870:880	arg1	solution					893:900	aqueous solution	885:900	aqueous solution	885:900	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	2	7	theme	SPI/dextran	287:297	arg1	1:1.75					311:316	1:1.75	311:316	1:1.75	311:316	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	2	7	theme	SPI/dextran	287:297	arg1	ratio					304:308	SPI/dextran mass ratio	287:308	SPI/dextran mass ratio (1:1.75)	287:317	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	5	8	theme	SDC-based	846:854	arg1	translucent					870:880	translucent	870:880	translucent	870:880	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	5	8	theme	SDC-based	846:854	arg1	nanogels					856:863	The SDC-based nanogels	842:863	The SDC-based nanogels	842:863	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	5	9	theme	aqueous	885:891	arg1	solution					893:900	aqueous solution	885:900	aqueous solution	885:900	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	5	10	theme	∼104.4 nm	962:970	arg1	Dh					956:957	a Dh	954:957	a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage	954:1046	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	3	11	theme	native	708:713	arg1	SPI					715:717	the native SPI	704:717	the native SPI	704:717	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	12	from	changes	453:459	arg1	composition					472:482	protein composition	464:482	protein composition	464:482	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	5	13	theme	spherical	918:926	arg1	structure					939:947	a spherical core-shell structure	916:947	a spherical core-shell structure	916:947	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	2	14	theme	SPI-dextran	362:372	arg1	conjugate					374:382	SPI-dextran conjugate	362:382	SPI-dextran conjugate (SDC)	362:388	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	2	14	theme	SPI-dextran	362:372	arg1	SDC					385:387	SDC	385:387	SDC	385:387	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	5	15	from	solution	893:900	arg1	translucent					870:880	translucent	870:880	translucent	870:880	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	5	15	from	solution	893:900	arg1	nanogels					856:863	The SDC-based nanogels	842:863	The SDC-based nanogels	842:863	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	5	16	theme	core-shell	928:937	arg1	structure					939:947	a spherical core-shell structure	916:947	a spherical core-shell structure	916:947	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	1	17	theme	protein	211:217	arg1	self-assembly					219:231	protein self-assembly	211:231	protein self-assembly in this study	211:245	Soybean protein isolate (SPI)-dextran conjugate-based nanogels were prepared via the Maillard reaction combined with protein self-assembly in this study.
35247773	4	18	theme	time	785:788	arg1	Effects					720:726	Effects	720:726	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index	720:819	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	5	19	theme	good	978:981	arg1	stability					983:991	a good stability	976:991	a good stability against thermal treatment, ionic strength, and storage	976:1046	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	4	20	from	Effects	720:726	arg1	Dh					793:794	Dh	793:794	Dh	793:794	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	4	20	from	Effects	720:726	arg1	polydispersity					800:813	polydispersity	800:813	polydispersity	800:813	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	3	21	theme	tertiary	534:541	arg1	conformation					543:554	loosened tertiary conformation	525:554	loosened tertiary conformation	525:554	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	6	22	theme	desirable	1129:1137	arg1	nanocarriers					1139:1150	desirable nanocarriers	1129:1150	desirable nanocarriers for encapsulating hydrophobic bioactive compounds	1129:1200	Results demonstrated the SDC-based nanogels possessed a potential to be used as desirable nanocarriers for encapsulating hydrophobic bioactive compounds.
35247773	4	23	theme	heating	760:766	arg1	temperature					768:778	heating temperature	760:778	heating temperature	760:778	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	6	24	theme	bioactive	1182:1190	arg1	compounds					1192:1200	hydrophobic bioactive compounds	1170:1200	hydrophobic bioactive compounds	1170:1200	Results demonstrated the SDC-based nanogels possessed a potential to be used as desirable nanocarriers for encapsulating hydrophobic bioactive compounds.
35247773	4	25	theme	conjugate	731:739	arg1	concentration					741:753	conjugate concentration	731:753	conjugate concentration	731:753	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	0	26	theme	protein	44:50	arg1	characterization					16:31	characterization	16:31	characterization	16:31	Preparation and characterization of soybean protein isolate-dextran conjugate-based nanogels.
35247773	0	26	theme	protein	44:50	arg1	Preparation					0:10	Preparation	0:10	Preparation	0:10	Preparation and characterization of soybean protein isolate-dextran conjugate-based nanogels.
35247773	3	27	theme	protein	464:470	arg1	composition					472:482	protein composition	464:482	protein composition	464:482	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	28	theme	zeta	640:643	arg1	potential					645:653	zeta potential	640:653	zeta potential	640:653	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	2	29	theme	molecular	260:268	arg1	40 kDa					278:283	40 kDa	278:283	40 kDa	278:283	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	2	29	theme	molecular	260:268	arg1	weight					270:275	The dextran molecular weight	248:275	The dextran molecular weight (40 kDa)	248:284	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	4	30	dep	Dh	793:794	arg1	index					815:819	index	815:819	index	815:819	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	0	31	theme	soybean	36:42	arg1	protein					44:50	soybean protein	36:50	soybean protein	36:50	Preparation and characterization of soybean protein isolate-dextran conjugate-based nanogels.
35247773	2	32	theme	dextran	252:258	arg1	40 kDa					278:283	40 kDa	278:283	40 kDa	278:283	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	2	32	theme	dextran	252:258	arg1	weight					270:275	The dextran molecular weight	248:275	The dextran molecular weight (40 kDa)	248:284	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	0	33	theme	conjugate-based	68:82	arg1	nanogels					84:91	conjugate-based nanogels	68:91	conjugate-based nanogels	68:91	Preparation and characterization of soybean protein isolate-dextran conjugate-based nanogels.
35247773	3	34	theme	surface	565:571	arg1	hydrophobicity					573:586	surface hydrophobicity	565:586	surface hydrophobicity	565:586	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	1	35	theme	-dextran	123:130	arg1	nanogels					148:155	Soybean protein isolate (SPI)-dextran conjugate-based nanogels	94:155	Soybean protein isolate (SPI)-dextran conjugate-based nanogels	94:155	Soybean protein isolate (SPI)-dextran conjugate-based nanogels were prepared via the Maillard reaction combined with protein self-assembly in this study.
35247773	6	36	theme	hydrophobic	1170:1180	arg1	compounds					1192:1200	hydrophobic bioactive compounds	1170:1200	hydrophobic bioactive compounds	1170:1200	Results demonstrated the SDC-based nanogels possessed a potential to be used as desirable nanocarriers for encapsulating hydrophobic bioactive compounds.
35247773	5	37	theme	ionic	1020:1024	arg1	strength					1026:1033	ionic strength	1020:1033	ionic strength	1020:1033	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	1	38	from	self-assembly	219:231	arg1	study					241:245	this study	236:245	this study	236:245	Soybean protein isolate (SPI)-dextran conjugate-based nanogels were prepared via the Maillard reaction combined with protein self-assembly in this study.
35247773	1	39	theme	conjugate-based	132:146	arg1	nanogels					148:155	Soybean protein isolate (SPI)-dextran conjugate-based nanogels	94:155	Soybean protein isolate (SPI)-dextran conjugate-based nanogels	94:155	Soybean protein isolate (SPI)-dextran conjugate-based nanogels were prepared via the Maillard reaction combined with protein self-assembly in this study.
35247773	5	40	theme	stability	983:991	arg1	Dh					956:957	a Dh	954:957	a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage	954:1046	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	5	41	theme	thermal	1001:1007	arg1	treatment					1009:1017	thermal treatment	1001:1017	thermal treatment	1001:1017	The SDC-based nanogels were translucent in aqueous solution and exhibited a spherical core-shell structure with a Dh of ∼104.4 nm and a good stability against thermal treatment, ionic strength, and storage.
35247773	2	42	theme	incubation	324:333	arg1	time					335:338	incubation time	324:338	incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC)	324:388	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	2	42	theme	incubation	324:333	arg1	d					345:345	3.3 d	341:345	3.3 d	341:345	The dextran molecular weight (40 kDa), SPI/dextran mass ratio (1:1.75), and incubation time (3.3 d) for preparing SPI-dextran conjugate (SDC) were firstly optimized.
35247773	4	43	theme	concentration	741:753	arg1	Effects					720:726	Effects	720:726	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index	720:819	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	4	44	theme	temperature	768:778	arg1	Effects					720:726	Effects	720:726	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index	720:819	Effects of conjugate concentration, pH, heating temperature, and time on Dh and polydispersity index were also evaluated.
35247773	3	45	theme	Z-average	599:607	arg1	Dh					632:633	Dh	632:633	Dh	632:633	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	45	theme	Z-average	599:607	arg1	diameter					622:629	Z-average hydrodynamic diameter	599:629	Z-average hydrodynamic diameter (Dh)	599:634	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	46	theme	infrared	488:495	arg1	bands					508:512	infrared absorption bands	488:512	infrared absorption bands	488:512	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	47	theme	hydrodynamic	609:620	arg1	Dh					632:633	Dh	632:633	Dh	632:633	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	47	theme	hydrodynamic	609:620	arg1	diameter					622:629	Z-average hydrodynamic diameter	599:629	Z-average hydrodynamic diameter (Dh)	599:634	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	48	theme	absorption	497:506	arg1	bands					508:512	infrared absorption bands	488:512	infrared absorption bands	488:512	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
35247773	3	49	from	bands	508:512	arg1	composition					472:482	protein composition	464:482	protein composition	464:482	The SDC was confirmed by analyzing the changes in protein composition and infrared absorption bands and showed loosened tertiary conformation, reduced surface hydrophobicity, decreased Z-average hydrodynamic diameter (Dh) and zeta potential, and improved emulsifying properties compared to the native SPI.
37216558	8	0	theme	commensal	1075:1083	arg1	vestibularis					1057:1068	S. vestibularis	1054:1068	S. vestibularis	1054:1068	S. vestibularis is a commensal bacterium widely distributed in healthy individuals.
37216558	8	0	theme	commensal	1075:1083	arg1	bacterium					1085:1093	a commensal bacterium	1073:1093	a commensal bacterium widely distributed in healthy individuals	1073:1135	S. vestibularis is a commensal bacterium widely distributed in healthy individuals.
37216558	12	1	theme	ternary	1571:1577	arg1	formation					1587:1595	ternary complex formation	1571:1595	ternary complex formation that can promote microbe clustering	1571:1631	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	12	2	theme	super-resolution	1534:1549	arg1	microscopy					1551:1560	super-resolution microscopy	1534:1560	super-resolution microscopy	1534:1560	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	11	3	theme	salivary	1459:1466	arg1	MUC7					1474:1477	the salivary mucin MUC7	1455:1477	the salivary mucin MUC7	1455:1477	The mGAP probes also revealed that ZG16B interacts with the salivary mucin MUC7.
37216558	5	4	theme	oral	641:644	arg1	microbes					646:653	oral microbes	641:653	oral microbes	641:653	We postulated that ZG16B would bind microbial glycans to mediate recognition of oral microbes.
37216558	12	5	theme	vestibularis	1495:1506	arg1	MUC7					1512:1515	MUC7	1512:1515	MUC7	1512:1515	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	12	5	theme	vestibularis	1495:1506	arg1	Analysis					1480:1487	Analysis	1480:1487	Analysis of S. vestibularis	1480:1506	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	0	6	theme	host-microbe	75:86	arg1	interactions					88:99	host-microbe interactions	75:99	host-microbe interactions with oral commensals	75:120	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	6	7	theme	probe	710:714	arg1	strategy					723:730	a microbial glycan analysis probe (mGAP) strategy	682:730	a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality	682:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	7	8	theme	Streptococcus	1026:1038	arg1	vestibularis					1040:1051	Streptococcus vestibularis	1026:1051	Streptococcus vestibularis	1026:1051	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	2	9	from	gene	288:291	arg1	glands					311:316	human salivary glands	296:316	human salivary glands	296:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	13	10	theme	commensal	1745:1753	arg1	microbes					1755:1762	commensal microbes	1745:1762	commensal microbes	1745:1762	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	5	11	theme	microbial	597:605	arg1	glycans					607:613	microbial glycans	597:613	microbial glycans	597:613	We postulated that ZG16B would bind microbial glycans to mediate recognition of oral microbes.
37216558	11	12	theme	mucin	1468:1472	arg1	MUC7					1474:1477	the salivary mucin MUC7	1455:1477	the salivary mucin MUC7	1455:1477	The mGAP probes also revealed that ZG16B interacts with the salivary mucin MUC7.
37216558	12	13	theme	microbe	1614:1620	arg1	clustering					1622:1631	microbe clustering	1614:1631	microbe clustering	1614:1631	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	3	14	theme	interaction	426:436	arg1	partners					438:445	its interaction partners	422:445	its interaction partners in the oral microbiome	422:468	Despite the abundance of this protein, its interaction partners in the oral microbiome are unknown.
37216558	3	15	theme	protein	413:419	arg1	abundance					395:403	the abundance	391:403	the abundance of this protein	391:419	Despite the abundance of this protein, its interaction partners in the oral microbiome are unknown.
37216558	6	16	theme	reporter	802:809	arg1	functionality					811:823	fluorescent or biotin reporter functionality	780:823	fluorescent or biotin reporter functionality	780:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	8	17	theme	healthy	1117:1123	arg1	individuals					1125:1135	healthy individuals	1117:1135	healthy individuals	1117:1135	S. vestibularis is a commensal bacterium widely distributed in healthy individuals.
37216558	1	18	theme	human	158:162	arg1	health					164:169	health	164:169	health	164:169	The oral microbiome is critical to human health and disease, yet the role that host salivary proteins play in maintaining oral health is unclear.
37216558	0	19	theme	oral	6:9	arg1	probe					59:63	a cell wall polysaccharide probe	32:63	a cell wall polysaccharide probe	32:63	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	0	19	theme	oral	6:9	arg1	ZG16B					18:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	6	20	theme	biotin	795:800	arg1	functionality					811:823	fluorescent or biotin reporter functionality	780:823	fluorescent or biotin reporter functionality	780:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	0	21	with	interactions	88:99	arg1	commensals					111:120	oral commensals	106:120	oral commensals	106:120	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	2	22	theme	expressed	278:286	arg1	protein					353:359	the lectin zymogen granule protein	326:359	the lectin zymogen granule protein 16 homolog B (ZG16B)	326:380	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	22	theme	expressed	278:286	arg1	gene					288:291	A highly expressed gene	269:291	A highly expressed gene in human salivary glands	269:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	3	23	theme	oral	454:457	arg1	microbiome					459:468	the oral microbiome	450:468	the oral microbiome	450:468	Despite the abundance of this protein, its interaction partners in the oral microbiome are unknown.
37216558	2	24	theme	granule	345:351	arg1	protein					353:359	the lectin zymogen granule protein	326:359	the lectin zymogen granule protein 16 homolog B (ZG16B)	326:380	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	24	theme	granule	345:351	arg1	gene					288:291	A highly expressed gene	269:291	A highly expressed gene in human salivary glands	269:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	24	theme	granule	345:351	arg1	ZG16B					375:379	ZG16B	375:379	ZG16B	375:379	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	0	25	theme	Human	0:4	arg1	probe					59:63	a cell wall polysaccharide probe	32:63	a cell wall polysaccharide probe	32:63	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	0	25	theme	Human	0:4	arg1	ZG16B					18:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	1	26	theme	oral	245:248	arg1	health					250:255	oral health	245:255	oral health	245:255	The oral microbiome is critical to human health and disease, yet the role that host salivary proteins play in maintaining oral health is unclear.
37216558	12	27	with	MUC7	1512:1515	arg1	ZG16B					1522:1526	ZG16B	1522:1526	ZG16B	1522:1526	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	6	28	theme	analysis	701:708	arg1	strategy					723:730	a microbial glycan analysis probe (mGAP) strategy	682:730	a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality	682:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	7	29	theme	plaque	860:865	arg1	isolates					867:874	dental plaque isolates	853:874	dental plaque isolates	853:874	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	11	30	theme	mGAP	1403:1406	arg1	probes					1408:1413	The mGAP probes	1399:1413	The mGAP probes	1399:1413	The mGAP probes also revealed that ZG16B interacts with the salivary mucin MUC7.
37216558	2	31	theme	zymogen	337:343	arg1	protein					353:359	the lectin zymogen granule protein	326:359	the lectin zymogen granule protein 16 homolog B (ZG16B)	326:380	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	31	theme	zymogen	337:343	arg1	gene					288:291	A highly expressed gene	269:291	A highly expressed gene in human salivary glands	269:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	31	theme	zymogen	337:343	arg1	ZG16B					375:379	ZG16B	375:379	ZG16B	375:379	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	13	32	theme	microbiome	1721:1730	arg1	balance					1701:1707	the compositional balance	1683:1707	the compositional balance of the oral microbiome	1683:1730	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	7	33	theme	dental	853:858	arg1	isolates					867:874	dental plaque isolates	853:874	dental plaque isolates	853:874	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	10	34	theme	S.	1372:1373	arg1	abundance					1388:1396	S. vestibularis abundance	1372:1396	S. vestibularis abundance	1372:1396	ZG16B slows the growth of S. vestibularis with no cytotoxicity, suggesting that it regulates S. vestibularis abundance.
37216558	3	35	from	partners	438:445	arg1	microbiome					459:468	the oral microbiome	450:468	the oral microbiome	450:468	Despite the abundance of this protein, its interaction partners in the oral microbiome are unknown.
37216558	4	36	contain	possesses	489:497	arg2	fold					508:511	a lectin fold	499:511	a lectin fold	499:511	ZG16B possesses a lectin fold, but whether it binds carbohydrates is unclear.
37216558	4	36	contain	possesses	489:497	arg1	ZG16B					483:487	ZG16B	483:487	ZG16B	483:487	ZG16B possesses a lectin fold, but whether it binds carbohydrates is unclear.
37216558	12	37	theme	complex	1579:1585	arg1	formation					1587:1595	ternary complex formation	1571:1595	ternary complex formation that can promote microbe clustering	1571:1631	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	0	38	theme	lectin	11:16	arg1	probe					59:63	a cell wall polysaccharide probe	32:63	a cell wall polysaccharide probe	32:63	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	0	38	theme	lectin	11:16	arg1	ZG16B					18:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	7	39	theme	Gemella	982:988	arg1	haemolysans					990:1000	Gemella haemolysans	982:1000	Gemella haemolysans	982:1000	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	0	40	theme	oral	106:109	arg1	commensals					111:120	oral commensals	106:120	oral commensals	106:120	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	13	41	theme	clearance	1815:1823	arg1	mechanism					1825:1833	a mucin-assisted clearance mechanism	1798:1833	a mucin-assisted clearance mechanism	1798:1833	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	1	42	theme	oral	127:130	arg1	microbiome					132:141	The oral microbiome	123:141	The oral microbiome	123:141	The oral microbiome is critical to human health and disease, yet the role that host salivary proteins play in maintaining oral health is unclear.
37216558	1	42	theme	oral	127:130	arg1	critical					146:153	critical	146:153	critical	146:153	The oral microbiome is critical to human health and disease, yet the role that host salivary proteins play in maintaining oral health is unclear.
37216558	10	43	dep	S.	1372:1373	arg1	vestibularis					1375:1386	vestibularis	1375:1386	vestibularis	1375:1386	ZG16B slows the growth of S. vestibularis with no cytotoxicity, suggesting that it regulates S. vestibularis abundance.
37216558	4	44	theme	lectin	501:506	arg1	fold					508:511	a lectin fold	499:511	a lectin fold	499:511	ZG16B possesses a lectin fold, but whether it binds carbohydrates is unclear.
37216558	5	45	theme	microbes	646:653	arg1	recognition					626:636	recognition	626:636	recognition of oral microbes	626:653	We postulated that ZG16B would bind microbial glycans to mediate recognition of oral microbes.
37216558	6	46	theme	fluorescent	780:790	arg1	functionality					811:823	fluorescent or biotin reporter functionality	780:823	fluorescent or biotin reporter functionality	780:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	13	47	theme	compositional	1687:1699	arg1	balance					1701:1707	the compositional balance	1683:1707	the compositional balance of the oral microbiome	1683:1730	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	9	48	theme	cell	1181:1184	arg1	polysaccharides					1191:1205	the cell wall polysaccharides	1177:1205	the cell wall polysaccharides attached to the peptidoglycan	1177:1235	ZG16B binds to S. vestibularis through the cell wall polysaccharides attached to the peptidoglycan, indicating that the protein is a lectin.
37216558	6	49	theme	microbial	684:692	arg1	strategy					723:730	a microbial glycan analysis probe (mGAP) strategy	682:730	a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality	682:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	2	50	theme	homolog	364:370	arg1	B					372:372	16 homolog B	361:372	the lectin zymogen granule protein 16 homolog B (ZG16B)	326:380	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	0	51	theme	cell	34:37	arg1	probe					59:63	a cell wall polysaccharide probe	32:63	a cell wall polysaccharide probe	32:63	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	0	51	theme	cell	34:37	arg1	ZG16B					18:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	12	52	with	Analysis	1480:1487	arg1	ZG16B					1522:1526	ZG16B	1522:1526	ZG16B	1522:1526	Analysis of S. vestibularis and MUC7 with ZG16B using super-resolution microscopy supports ternary complex formation that can promote microbe clustering.
37216558	9	53	theme	wall	1186:1189	arg1	polysaccharides					1191:1205	the cell wall polysaccharides	1177:1205	the cell wall polysaccharides attached to the peptidoglycan	1177:1235	ZG16B binds to S. vestibularis through the cell wall polysaccharides attached to the peptidoglycan, indicating that the protein is a lectin.
37216558	2	54	theme	salivary	302:309	arg1	glands					311:316	human salivary glands	296:316	human salivary glands	296:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	13	55	dep	growth	1785:1790	arg1	using					1792:1796	using	1792:1796	using a mucin-assisted clearance mechanism	1792:1833	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	6	56	theme	recombinant	757:767	arg1	protein					769:775	the recombinant protein	753:775	the recombinant protein	753:775	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	2	57	theme	human	296:300	arg1	glands					311:316	human salivary glands	296:316	human salivary glands	296:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	10	58	theme	vestibularis	1308:1319	arg1	growth					1295:1300	the growth	1291:1300	the growth of S. vestibularis with no cytotoxicity	1291:1340	ZG16B slows the growth of S. vestibularis with no cytotoxicity, suggesting that it regulates S. vestibularis abundance.
37216558	6	59	theme	glycan	694:699	arg1	strategy					723:730	a microbial glycan analysis probe (mGAP) strategy	682:730	a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality	682:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	13	60	theme	oral	1716:1719	arg1	microbiome					1721:1730	the oral microbiome	1712:1730	the oral microbiome	1712:1730	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	7	61	theme	oral	936:939	arg1	microbes					941:948	oral microbes	936:948	oral microbes	936:948	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	7	62	theme	Streptococcus	961:973	arg1	mitis					975:979	Streptococcus mitis	961:979	Streptococcus mitis	961:979	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	7	63	theme	microbes	941:948	arg1	set					929:931	a limited set	919:931	a limited set	919:931	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	7	63	theme	microbes	941:948	arg1	microbes					941:948	oral microbes	936:948	oral microbes	936:948	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	7	64	theme	limited	921:927	arg1	set					929:931	a limited set	919:931	a limited set	919:931	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	7	64	theme	limited	921:927	arg1	microbes					941:948	oral microbes	936:948	oral microbes	936:948	Applying the ZG16B-mGAP to dental plaque isolates revealed that ZG16B predominantly binds to a limited set of oral microbes, including Streptococcus mitis, Gemella haemolysans, and, most prominently, Streptococcus vestibularis.
37216558	13	65	theme	mucin-assisted	1800:1813	arg1	mechanism					1825:1833	a mucin-assisted clearance mechanism	1798:1833	a mucin-assisted clearance mechanism	1798:1833	Together, our data suggest that ZG16B influences the compositional balance of the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism.
37216558	6	66	theme	mGAP	717:720	arg1	strategy					723:730	a microbial glycan analysis probe (mGAP) strategy	682:730	a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality	682:823	To this end, we developed a microbial glycan analysis probe (mGAP) strategy based on conjugating the recombinant protein to fluorescent or biotin reporter functionality.
37216558	0	67	theme	polysaccharide	44:57	arg1	probe					59:63	a cell wall polysaccharide probe	32:63	a cell wall polysaccharide probe	32:63	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	0	67	theme	polysaccharide	44:57	arg1	ZG16B					18:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	2	68	theme	lectin	330:335	arg1	protein					353:359	the lectin zymogen granule protein	326:359	the lectin zymogen granule protein 16 homolog B (ZG16B)	326:380	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	68	theme	lectin	330:335	arg1	gene					288:291	A highly expressed gene	269:291	A highly expressed gene in human salivary glands	269:316	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	2	68	theme	lectin	330:335	arg1	ZG16B					375:379	ZG16B	375:379	ZG16B	375:379	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	1	69	theme	host	202:205	arg1	proteins					216:223	host salivary proteins	202:223	host salivary proteins	202:223	The oral microbiome is critical to human health and disease, yet the role that host salivary proteins play in maintaining oral health is unclear.
37216558	0	70	theme	wall	39:42	arg1	probe					59:63	a cell wall polysaccharide probe	32:63	a cell wall polysaccharide probe	32:63	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	0	70	theme	wall	39:42	arg1	ZG16B					18:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B	0:22	Human oral lectin ZG16B acts as a cell wall polysaccharide probe to decode host-microbe interactions with oral commensals.
37216558	2	71	dep	protein	353:359	arg1	B					372:372	16 homolog B	361:372	the lectin zymogen granule protein 16 homolog B (ZG16B)	326:380	A highly expressed gene in human salivary glands encodes the lectin zymogen granule protein 16 homolog B (ZG16B).
37216558	9	72	attach	attached	1207:1214	arg1	peptidoglycan					1223:1235	the peptidoglycan	1219:1235	the peptidoglycan	1219:1235	ZG16B binds to S. vestibularis through the cell wall polysaccharides attached to the peptidoglycan, indicating that the protein is a lectin.
37216558	9	72	attach	attached	1207:1214	arg2	polysaccharides					1191:1205	the cell wall polysaccharides	1177:1205	the cell wall polysaccharides attached to the peptidoglycan	1177:1235	ZG16B binds to S. vestibularis through the cell wall polysaccharides attached to the peptidoglycan, indicating that the protein is a lectin.
37216558	1	73	theme	salivary	207:214	arg1	proteins					216:223	host salivary proteins	202:223	host salivary proteins	202:223	The oral microbiome is critical to human health and disease, yet the role that host salivary proteins play in maintaining oral health is unclear.
35621956	5	0	theme	Mef2	751:754	arg1	fucoidanase					756:766	The Mef2 fucoidanase	747:766	The Mef2 fucoidanase	747:766	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	6	1	theme	U/μM	1270:1273	arg1	activity					1227:1234	an activity	1224:1234	an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM	1224:1273	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	2	2	used	utilized	315:322	arg2	Endo-fucoidanases					216:232	Endo-fucoidanases	216:232	Endo-fucoidanases	216:232	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	6	3	theme	10-3	1265:1268	arg1	U/μM					1270:1273	3.6 × 10-3 U/μM	1259:1273	3.6 × 10-3 U/μM	1259:1273	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	6	4	theme	different	1195:1203	arg1	fucoidans					1205:1213	two structurally different fucoidans	1178:1213	two structurally different fucoidans	1178:1213	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	2	5	theme	fucoidans	405:413	arg1	details					394:400	new structural details	379:400	new structural details of fucoidans	379:413	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	8	6	theme	novel	1580:1584	arg1	α					1586:1586	novel α	1580:1586	novel α	1580:1586	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	0	7	theme	latissima	93:101	arg1	Fucoidans					103:111	Saccharina latissima Fucoidans	82:111	Saccharina latissima Fucoidans	82:111	The Endo-α(1,3)-Fucoidanase Mef2 Releases Uniquely Branched Oligosaccharides from Saccharina latissima Fucoidans.
35621956	6	8	dep	transform	1055:1063	arg1	infrared					1065:1072	infrared	1065:1072	transform infrared spectroscopy (FTIR)	1055:1092	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	8	9	link	-linked	1539:1545	arg1	residues					1555:1562	α(1,3)-linked fucosyl residues	1533:1562	α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima	1533:1673	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	6	10	dep	Fourier	1047:1053	arg1	transform					1055:1063	transform	1055:1063	transform infrared spectroscopy (FTIR)	1055:1092	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	2	11	theme	tailor-make	327:337	arg1	oligosaccharides					348:363	tailor-make fucoidan oligosaccharides	327:363	tailor-make fucoidan oligosaccharides	327:363	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	5	12	dep	50	857:858	arg1	to					854:855	to	854:855	to	854:855	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	0	13	theme	Saccharina	82:91	arg1	Fucoidans					103:111	Saccharina latissima Fucoidans	82:111	Saccharina latissima Fucoidans	82:111	The Endo-α(1,3)-Fucoidanase Mef2 Releases Uniquely Branched Oligosaccharides from Saccharina latissima Fucoidans.
35621956	2	14	theme	new	379:381	arg1	details					394:400	new structural details	379:400	new structural details of fucoidans	379:413	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	4	15	theme	enZyme	723:728	arg1	CAZy					740:743	CAZy	740:743	CAZy	740:743	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	4	15	theme	enZyme	723:728	arg1	database					730:737	the Carbohydrate Active enZyme database	699:737	the Carbohydrate Active enZyme database (CAZy)	699:744	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	3	16	theme	Muricauda	505:513	arg1	eckloniae					515:523	the marine bacterium Muricauda eckloniae	484:523	the marine bacterium Muricauda eckloniae	484:523	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	5	17	dep	44	926:927	arg1	to					923:924	to	923:924	to	923:924	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	5	18	from	°C	929:930	arg1	temperature					903:913	the melting temperature	891:913	the melting temperature from 38 to 44 °C	891:930	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	8	19	theme	-linked	1592:1598	arg1	branches					1608:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	4	20	from	family	677:682	arg1	CAZy					740:743	CAZy	740:743	CAZy	740:743	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	4	20	from	family	677:682	arg1	database					730:737	the Carbohydrate Active enZyme database	699:737	the Carbohydrate Active enZyme database (CAZy)	699:744	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	4	21	theme	hydrolase	667:675	arg1	family					677:682	the glycosyl hydrolase family 107 (GH107)	654:694	the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy)	654:744	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	4	22	theme	primary	604:610	arg1	sequence					612:619	the primary sequence	600:619	the primary sequence	600:619	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	1	23	located	found	189:193	arg1	macroalgae					204:213	brown macroalgae	198:213	brown macroalgae	198:213	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	1	23	located	found	189:193	arg2	Fucoidans					114:122	Fucoidans	114:122	Fucoidans	114:122	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	1	23	located	found	189:193	arg2	fucosyl-polysaccharides					155:177	complex bioactive sulfated fucosyl-polysaccharides	128:177	complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae	128:213	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	6	24	theme	Mef2	1170:1173	arg1	activity					1130:1137	the enzymatic activity	1116:1137	the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively	1116:1347	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	3	25	theme	Mef2	546:549	arg1	protein					551:557	the Mef2 protein	542:557	the Mef2 protein	542:557	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	1	26	theme	brown	198:202	arg1	macroalgae					204:213	brown macroalgae	198:213	brown macroalgae	198:213	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	5	27	dep	°C.	860:862	arg1	50					857:858	50	857:858	50	857:858	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	6	28	used	used	1098:1101	arg2	Fourier					1047:1053	Fourier	1047:1053	Fourier transform infrared spectroscopy (FTIR)	1047:1092	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	3	29	theme	endo-α	434:439	arg1	1,3					441:443	1,3	441:443	1,3	441:443	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	3	29	theme	endo-α	434:439	arg1	-fucoidanase					445:456	an endo-α(1,3)-fucoidanase	431:456	an endo-α(1,3)-fucoidanase	431:456	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	4	30	theme	Active	716:721	arg1	CAZy					740:743	CAZy	740:743	CAZy	740:743	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	4	30	theme	Active	716:721	arg1	database					730:737	the Carbohydrate Active enZyme database	699:737	the Carbohydrate Active enZyme database (CAZy)	699:744	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	3	31	from	eckloniae	515:523	arg1	Mef2					473:476	Mef2	473:476	Mef2	473:476	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	3	31	from	eckloniae	515:523	arg1	gene					467:470	gene	467:470	gene	467:470	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	5	32	theme	Mef2	985:988	arg1	activity					973:980	optimal activity	965:980	optimal activity of Mef2	965:988	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	8	33	theme	fucosyl	1600:1606	arg1	branches					1608:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	6	34	theme	Mef2	1020:1023	arg1	specificity					1005:1015	The substrate specificity	991:1015	The substrate specificity of Mef2	991:1023	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	6	35	theme	10-3	1245:1248	arg1	U/μM					1250:1253	1.2 × 10-3 U/μM	1239:1253	1.2 × 10-3 U/μM	1239:1253	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	8	36	dep	-linked	1592:1598	arg1	α					1586:1586	novel α	1580:1586	novel α	1580:1586	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	5	37	dep	temperatures	838:849	arg1	shown					873:877	shown	873:877	was shown to increase the melting temperature from 38 to 44 °C	869:930	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	5	37	dep	temperatures	838:849	arg1	required					952:959	required	952:959	was furthermore required for optimal activity of Mef2	936:988	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	6	38	theme	substrate	995:1003	arg1	specificity					1005:1015	The substrate specificity	991:1015	The substrate specificity of Mef2	991:1023	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	5	39	theme	melting	895:901	arg1	temperature					903:913	the melting temperature	891:913	the melting temperature from 38 to 44 °C	891:930	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	8	40	theme	fucoidan	1463:1470	arg1	oligosaccharides					1472:1487	The fucoidan oligosaccharides	1459:1487	The fucoidan oligosaccharides released by Mef2	1459:1504	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	6	41	theme	×	1243:1243	arg1	U/μM					1250:1253	1.2 × 10-3 U/μM	1239:1253	1.2 × 10-3 U/μM	1239:1253	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	6	42	from	latissima	1325:1333	arg1	fucoidans					1278:1286	fucoidans	1278:1286	fucoidans from Fucus evanescens and Saccharina latissima, respectively	1278:1347	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	2	43	theme	fucoidan	339:346	arg1	oligosaccharides					348:363	tailor-make fucoidan oligosaccharides	327:363	tailor-make fucoidan oligosaccharides	327:363	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	3	44	theme	marine	488:493	arg1	eckloniae					515:523	the marine bacterium Muricauda eckloniae	484:523	the marine bacterium Muricauda eckloniae	484:523	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	0	45	theme	-Fucoidanase	15:26	arg1	Mef2					28:31	The Endo-α(1,3)-Fucoidanase Mef2	0:31	The Endo-α(1,3)-Fucoidanase Mef2	0:31	The Endo-α(1,3)-Fucoidanase Mef2 Releases Uniquely Branched Oligosaccharides from Saccharina latissima Fucoidans.
35621956	6	46	theme	1.2	1239:1241	arg1	×					1243:1243	×	1243:1243	×	1243:1243	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	2	47	theme	linkages	282:289	arg1	hydrolysis					256:265	the specific hydrolysis	243:265	the specific hydrolysis of α-L-fucosyl linkages	243:289	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	8	48	theme	fucosyl	1547:1553	arg1	residues					1555:1562	α(1,3)-linked fucosyl residues	1533:1562	α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima	1533:1673	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	5	49	theme	maximal	775:781	arg1	activity					783:790	maximal activity	775:790	maximal activity	775:790	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	2	50	theme	α-L-fucosyl	270:280	arg1	linkages					282:289	α-L-fucosyl linkages	270:289	α-L-fucosyl linkages	270:289	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	6	51	theme	U/μM	1250:1253	arg1	activity					1227:1234	an activity	1224:1234	an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM	1224:1273	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	7	52	theme	described	1398:1406	arg1	fucoidanase					1408:1418	the first described fucoidanase	1388:1418	the first described fucoidanase active on fucoidans from S. latissima	1388:1456	Interestingly, Mef2 was identified as the first described fucoidanase active on fucoidans from S. latissima.
35621956	7	52	theme	described	1398:1406	arg1	Mef2					1365:1368	Mef2	1365:1368	Mef2	1365:1368	Interestingly, Mef2 was identified as the first described fucoidanase active on fucoidans from S. latissima.
35621956	6	53	theme	×	1263:1263	arg1	U/μM					1270:1273	3.6 × 10-3 U/μM	1259:1273	3.6 × 10-3 U/μM	1259:1273	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	8	54	with	residues	1555:1562	arg1	branches					1608:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	6	55	theme	enzyme	1153:1158	arg1	U/μM					1161:1164	μM enzyme: U/μM	1150:1164	μM enzyme: U/μM	1150:1164	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	5	56	dep	Ca2+	864:867	arg1	°C.					860:862	°C.	860:862	°C.	860:862	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	4	57	theme	Carbohydrate	703:714	arg1	CAZy					740:743	CAZy	740:743	CAZy	740:743	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	4	57	theme	Carbohydrate	703:714	arg1	database					730:737	the Carbohydrate Active enZyme database	699:737	the Carbohydrate Active enZyme database (CAZy)	699:744	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	3	58	theme	bacterium	495:503	arg1	eckloniae					515:523	the marine bacterium Muricauda eckloniae	484:523	the marine bacterium Muricauda eckloniae	484:523	In this study, an endo-α(1,3)-fucoidanase encoding gene, Mef2, from the marine bacterium Muricauda eckloniae, was cloned, and the Mef2 protein was functionally characterized.
35621956	2	59	theme	specific	247:254	arg1	hydrolysis					256:265	the specific hydrolysis	243:265	the specific hydrolysis of α-L-fucosyl linkages	243:289	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	6	60	dep	activity	1130:1137	arg1	Units					1140:1144	Units	1140:1144	Units per μM enzyme: U/μM	1140:1164	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	8	61	theme	-linked	1539:1545	arg1	residues					1555:1562	α(1,3)-linked fucosyl residues	1533:1562	α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima	1533:1673	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	7	62	theme	active	1420:1425	arg1	fucoidanase					1408:1418	the first described fucoidanase	1388:1418	the first described fucoidanase active on fucoidans from S. latissima	1388:1456	Interestingly, Mef2 was identified as the first described fucoidanase active on fucoidans from S. latissima.
35621956	7	62	theme	active	1420:1425	arg1	Mef2					1365:1368	Mef2	1365:1368	Mef2	1365:1368	Interestingly, Mef2 was identified as the first described fucoidanase active on fucoidans from S. latissima.
35621956	5	63	theme	optimal	965:971	arg1	activity					973:980	optimal activity	965:980	optimal activity of Mef2	965:988	The Mef2 fucoidanase showed maximal activity at pH 8 and 35 °C, although it could tolerate temperatures up to 50 °C. Ca2+ was shown to increase the melting temperature from 38 to 44 °C and was furthermore required for optimal activity of Mef2.
35621956	1	64	theme	complex	128:134	arg1	fucosyl-polysaccharides					155:177	complex bioactive sulfated fucosyl-polysaccharides	128:177	complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae	128:213	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	1	64	theme	complex	128:134	arg1	Fucoidans					114:122	Fucoidans	114:122	Fucoidans	114:122	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	8	65	link	-linked	1592:1598	arg1	branches					1608:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	8	66	from	latissima	1665:1673	arg1	fucoidans					1647:1655	fucoidans	1647:1655	fucoidans from S. latissima	1647:1673	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	6	67	theme	enzymatic	1120:1128	arg1	activity					1130:1137	the enzymatic activity	1116:1137	the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively	1116:1347	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	1	68	theme	bioactive	136:144	arg1	fucosyl-polysaccharides					155:177	complex bioactive sulfated fucosyl-polysaccharides	128:177	complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae	128:213	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	1	68	theme	bioactive	136:144	arg1	Fucoidans					114:122	Fucoidans	114:122	Fucoidans	114:122	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	6	69	from	activity	1130:1137	arg1	fucoidans					1205:1213	two structurally different fucoidans	1178:1213	two structurally different fucoidans	1178:1213	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	2	70	theme	structural	383:392	arg1	details					394:400	new structural details	379:400	new structural details of fucoidans	379:413	Endo-fucoidanases catalyze the specific hydrolysis of α-L-fucosyl linkages in fucoidans and can be utilized to tailor-make fucoidan oligosaccharides and elucidate new structural details of fucoidans.
35621956	0	71	theme	Branched	51:58	arg1	Oligosaccharides					60:75	Uniquely Branched Oligosaccharides	42:75	Uniquely Branched Oligosaccharides	42:75	The Endo-α(1,3)-Fucoidanase Mef2 Releases Uniquely Branched Oligosaccharides from Saccharina latissima Fucoidans.
35621956	6	72	from	evanescens	1299:1308	arg1	fucoidans					1278:1286	fucoidans	1278:1286	fucoidans from Fucus evanescens and Saccharina latissima, respectively	1278:1347	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35621956	8	73	theme	residues	1555:1562	arg1	backbone					1521:1528	a backbone	1519:1528	a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima	1519:1673	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	1	74	theme	sulfated	146:153	arg1	fucosyl-polysaccharides					155:177	complex bioactive sulfated fucosyl-polysaccharides	128:177	complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae	128:213	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	1	74	theme	sulfated	146:153	arg1	Fucoidans					114:122	Fucoidans	114:122	Fucoidans	114:122	Fucoidans are complex bioactive sulfated fucosyl-polysaccharides primarily found in brown macroalgae.
35621956	4	75	theme	glycosyl	658:665	arg1	family					677:682	the glycosyl hydrolase family 107 (GH107)	654:694	the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy)	654:744	Based on the primary sequence, Mef2 was suggested to belong to the glycosyl hydrolase family 107 (GH107) in the Carbohydrate Active enZyme database (CAZy).
35621956	7	76	from	latissima	1448:1456	arg1	fucoidans					1430:1438	fucoidans	1430:1438	fucoidans from S. latissima	1430:1456	Interestingly, Mef2 was identified as the first described fucoidanase active on fucoidans from S. latissima.
35621956	8	77	theme	unique	1569:1574	arg1	branches					1608:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	unique and novel α(1,4)-linked fucosyl branches	1569:1615	The fucoidan oligosaccharides released by Mef2 consisted of a backbone of α(1,3)-linked fucosyl residues with unique and novel α(1,4)-linked fucosyl branches, not previously identified in fucoidans from S. latissima.
35621956	6	78	theme	3.6	1259:1261	arg1	×					1263:1263	×	1263:1263	×	1263:1263	The substrate specificity of Mef2 was investigated, and Fourier transform infrared spectroscopy (FTIR) was used to determine the enzymatic activity (Units per μM enzyme: U/μM) of Mef2 on two structurally different fucoidans, showing an activity of 1.2 × 10-3 U/μM and 3.6 × 10-3 U/μM on fucoidans from Fucus evanescens and Saccharina latissima, respectively.
35427438	7	0	dep	LLC	864:866	arg1	Periodicals					852:862	Periodicals	852:862	Periodicals	852:862	© 2022 Wiley Periodicals LLC.
35427438	8	1	theme	Basic	1081:1085	arg1	Protocol					1087:1094	Cas9 nuclease Basic Protocol 3	1067:1096	Cas9 nuclease Basic Protocol 3	1067:1096	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	6	2	theme	glycobiology	764:775	arg1	This					737:740	This	737:740	This	737:740	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	6	2	theme	glycobiology	764:775	arg1	strategy					777:784	a powerful systems glycobiology strategy	745:784	a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes	745:836	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	2	3	theme	arbitrary	385:393	arg1	types					400:404	arbitrary cell types	385:404	arbitrary cell types	385:404	This article describes a method for utilizing a freely available GlycoGene CRISPR library to knock out any gene participating in human glycosylation in arbitrary cell types.
35427438	4	4	theme	various	591:597	arg1	reagents					615:622	various lectin/antibody reagents	591:622	various lectin/antibody reagents	591:622	The cell library can be screened using various lectin/antibody reagents.
35427438	0	5	theme	CRISPR	76:81	arg1	Library					83:89	the GlycoGene CRISPR Library	62:89	the GlycoGene CRISPR Library	62:89	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	8	6	theme	GlycoGene	922:930	arg1	Protocol					961:968	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	7	theme	related	1276:1282	arg1	NGS					1294:1296	related multiplex NGS	1276:1296	related multiplex NGS	1276:1296	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	8	theme	NGS	1200:1202	arg1	Protocol					1210:1217	NGS Basic Protocol 4	1200:1219	NGS Basic Protocol 4	1200:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	9	theme	lentivirus	1007:1016	arg1	pool					1018:1021	a GlycoGene CRISPR lentivirus pool	988:1021	a GlycoGene CRISPR lentivirus pool	988:1021	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	10	theme	Basic	869:873	arg1	Protocol					875:882	Basic Protocol 1	869:884	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	5	11	theme	glycan	682:687	arg1	relationships					722:734	glycan structure-glycogene-glycopathway relationships	682:734	glycan structure-glycogene-glycopathway relationships	682:734	It can also be applied in functional assays to establish glycan structure-glycogene-glycopathway relationships.
35427438	8	12	theme	cell	1039:1042	arg1	line					1044:1047	an isogenic cell line	1027:1047	an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4	1027:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	6	13	theme	systems	756:762	arg1	This					737:740	This	737:740	This	737:740	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	6	13	theme	systems	756:762	arg1	strategy					777:784	a powerful systems glycobiology strategy	745:784	a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes	745:836	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	4	14	theme	lectin/antibody	599:613	arg1	reagents					615:622	various lectin/antibody reagents	591:622	various lectin/antibody reagents	591:622	The cell library can be screened using various lectin/antibody reagents.
35427438	3	15	contain	contains	491:498	arg2	sgRNA					512:516	one or more sgRNA	500:516	one or more sgRNA	500:516	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	15	contain	contains	491:498	arg1	cell					486:489	each cell	481:489	each cell	481:489	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	8	16	theme	NGS	1294:1296	arg1	Protocol					1321:1328	Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5	1222:1330	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	17	theme	isogenic	1030:1037	arg1	line					1044:1047	an isogenic cell line	1027:1047	an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4	1027:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	2	18	theme	CRISPR	308:313	arg1	library					315:321	a freely available GlycoGene CRISPR library	279:321	a freely available GlycoGene CRISPR library	279:321	This article describes a method for utilizing a freely available GlycoGene CRISPR library to knock out any gene participating in human glycosylation in arbitrary cell types.
35427438	3	19	theme	CRISPR	445:450	arg1	library					466:472	a stable GlycoGene CRISPR knockout cell library	426:472	a stable GlycoGene CRISPR knockout cell library	426:472	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	19	theme	CRISPR	445:450	arg1	product					415:421	The end product	407:421	The end product	407:421	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	20	theme	cell	461:464	arg1	library					466:472	a stable GlycoGene CRISPR knockout cell library	426:472	a stable GlycoGene CRISPR knockout cell library	426:472	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	20	theme	cell	461:464	arg1	product					415:421	The end product	407:421	The end product	407:421	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	8	21	theme	non-binding	1254:1264	arg1	cells					1266:1270	lectin-binding or non-binding cells	1236:1270	lectin-binding or non-binding cells	1236:1270	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	3	22	theme	stable	428:433	arg1	library					466:472	a stable GlycoGene CRISPR knockout cell library	426:472	a stable GlycoGene CRISPR knockout cell library	426:472	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	22	theme	stable	428:433	arg1	product					415:421	The end product	407:421	The end product	407:421	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	2	23	theme	GlycoGene	298:306	arg1	library					315:321	a freely available GlycoGene CRISPR library	279:321	a freely available GlycoGene CRISPR library	279:321	This article describes a method for utilizing a freely available GlycoGene CRISPR library to knock out any gene participating in human glycosylation in arbitrary cell types.
35427438	8	24	theme	plasmid	939:945	arg1	Protocol					961:968	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	25	theme	Protocol	961:968	arg1	Scale-up					887:894	Scale-up	887:894	Scale-up	887:894	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	25	theme	Protocol	961:968	arg1	validation					904:913	NGS validation	900:913	NGS validation	900:913	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	0	26	theme	Genetic	8:14	arg1	Screens					16:22	Forward Genetic Screens	0:22	Forward Genetic Screens of Human Glycosylation Pathways	0:54	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	3	27	theme	corresponding	528:540	arg1	function					542:549	corresponding function	528:549	corresponding function	528:549	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	8	28	theme	line	1044:1047	arg1	Preparation					973:983	Preparation	973:983	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	29	theme	multiplex	1284:1292	arg1	NGS					1294:1296	related multiplex NGS	1276:1296	related multiplex NGS	1276:1296	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	30	theme	CRISPR	932:937	arg1	Protocol					961:968	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	31	theme	specific	202:209	arg1	processes					222:230	specific biological processes	202:230	specific biological processes	202:230	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	0	32	theme	Forward	0:6	arg1	Screens					16:22	Forward Genetic Screens	0:22	Forward Genetic Screens of Human Glycosylation Pathways	0:54	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	8	33	dep	Protocol	875:882	arg1	Scale-up					887:894	Scale-up	887:894	Scale-up	887:894	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	33	dep	Protocol	875:882	arg1	validation					904:913	NGS validation	900:913	NGS validation	900:913	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	33	dep	Protocol	875:882	arg1	Preparation					973:983	Preparation	973:983	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	33	dep	Protocol	875:882	arg1	analysis					1356:1363	Bioinformatics pathway analysis	1333:1363	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	33	dep	Protocol	875:882	arg1	Protocol					1321:1328	Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5	1222:1330	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	5	34	theme	functional	651:660	arg1	assays					662:667	functional assays	651:667	functional assays	651:667	It can also be applied in functional assays to establish glycan structure-glycogene-glycopathway relationships.
35427438	8	35	theme	Cas9	1067:1070	arg1	Protocol					1087:1094	Cas9 nuclease Basic Protocol 3	1067:1096	Cas9 nuclease Basic Protocol 3	1067:1096	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	36	theme	CRISPR-Cas9-based	92:108	arg1	screens					126:132	CRISPR-Cas9-based forward genetic screens	92:132	CRISPR-Cas9-based forward genetic screens	92:132	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	8	37	theme	Basic	955:959	arg1	Protocol					961:968	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	38	theme	biological	211:220	arg1	processes					222:230	specific biological processes	202:230	specific biological processes	202:230	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	8	39	theme	cell	1133:1136	arg1	library					1138:1144	a GlycoGene CRISPR cell library	1114:1144	a GlycoGene CRISPR cell library	1114:1144	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	40	theme	Basic	1204:1208	arg1	Protocol					1210:1217	NGS Basic Protocol 4	1200:1219	NGS Basic Protocol 4	1200:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	41	theme	CRISPR	1126:1131	arg1	library					1138:1144	a GlycoGene CRISPR cell library	1114:1144	a GlycoGene CRISPR cell library	1114:1144	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	42	theme	forward	110:116	arg1	screens					126:132	CRISPR-Cas9-based forward genetic screens	92:132	CRISPR-Cas9-based forward genetic screens	92:132	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	8	43	theme	library	947:953	arg1	Protocol					961:968	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	the GlycoGene CRISPR plasmid library Basic Protocol 2	918:970	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	44	theme	acquisition	1303:1313	arg1	Protocol					1321:1328	Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5	1222:1330	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	45	theme	Enrichment	1222:1231	arg1	Protocol					1321:1328	Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5	1222:1330	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	46	theme	GlycoGene	1116:1124	arg1	library					1138:1144	a GlycoGene CRISPR cell library	1114:1144	a GlycoGene CRISPR cell library	1114:1144	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	47	theme	genetic	118:124	arg1	screens					126:132	CRISPR-Cas9-based forward genetic screens	92:132	CRISPR-Cas9-based forward genetic screens	92:132	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	0	48	theme	Glycosylation	33:45	arg1	Pathways					47:54	Human Glycosylation Pathways	27:54	Human Glycosylation Pathways	27:54	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	6	49	theme	powerful	747:754	arg1	This					737:740	This	737:740	This	737:740	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	6	49	theme	powerful	747:754	arg1	strategy					777:784	a powerful systems glycobiology strategy	745:784	a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes	745:836	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	8	50	theme	library	1138:1144	arg1	Protocol					1087:1094	Cas9 nuclease Basic Protocol 3	1067:1096	Cas9 nuclease Basic Protocol 3	1067:1096	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	50	theme	library	1138:1144	arg1	self-inactivation					1147:1163	self-inactivation	1147:1163	self-inactivation of Cas9	1147:1171	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	50	theme	library	1138:1144	arg1	validation					1186:1195	library validation	1178:1195	library validation by NGS Basic Protocol 4	1178:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	50	theme	library	1138:1144	arg1	Preparation					1099:1109	Preparation	1099:1109	Preparation of a GlycoGene CRISPR cell library	1099:1144	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	3	51	theme	knockout	452:459	arg1	library					466:472	a stable GlycoGene CRISPR knockout cell library	426:472	a stable GlycoGene CRISPR knockout cell library	426:472	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	51	theme	knockout	452:459	arg1	product					415:421	The end product	407:421	The end product	407:421	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	0	52	theme	Human	27:31	arg1	Pathways					47:54	Human Glycosylation Pathways	27:54	Human Glycosylation Pathways	27:54	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	3	53	theme	GlycoGene	435:443	arg1	library					466:472	a stable GlycoGene CRISPR knockout cell library	426:472	a stable GlycoGene CRISPR knockout cell library	426:472	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	53	theme	GlycoGene	435:443	arg1	product					415:421	The end product	407:421	The end product	407:421	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	8	54	theme	library	1178:1184	arg1	validation					1186:1195	library validation	1178:1195	library validation by NGS Basic Protocol 4	1178:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	55	theme	Bioinformatics	1333:1346	arg1	analysis					1356:1363	Bioinformatics pathway analysis	1333:1363	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	56	theme	cells	1266:1270	arg1	Enrichment					1222:1231	Enrichment	1222:1231	Enrichment of lectin-binding or non-binding cells	1222:1270	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	56	theme	cells	1266:1270	arg1	NGS					1294:1296	related multiplex NGS	1276:1296	related multiplex NGS	1276:1296	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	5	57	theme	structure-glycogene-glycopathway	689:720	arg1	relationships					722:734	glycan structure-glycogene-glycopathway relationships	682:734	glycan structure-glycogene-glycopathway relationships	682:734	It can also be applied in functional assays to establish glycan structure-glycogene-glycopathway relationships.
35427438	0	58	theme	Pathways	47:54	arg1	Screens					16:22	Forward Genetic Screens	0:22	Forward Genetic Screens of Human Glycosylation Pathways	0:54	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	4	59	theme	cell	556:559	arg1	library					561:567	The cell library	552:567	The cell library	552:567	The cell library can be screened using various lectin/antibody reagents.
35427438	8	60	dep	Enrichment	1222:1231	arg1	data					1298:1301	data	1298:1301	data	1298:1301	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	2	61	theme	human	362:366	arg1	glycosylation					368:380	human glycosylation	362:380	human glycosylation	362:380	This article describes a method for utilizing a freely available GlycoGene CRISPR library to knock out any gene participating in human glycosylation in arbitrary cell types.
35427438	8	62	theme	Cas9	1168:1171	arg1	Protocol					1087:1094	Cas9 nuclease Basic Protocol 3	1067:1096	Cas9 nuclease Basic Protocol 3	1067:1096	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	62	theme	Cas9	1168:1171	arg1	self-inactivation					1147:1163	self-inactivation	1147:1163	self-inactivation of Cas9	1147:1171	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	62	theme	Cas9	1168:1171	arg1	validation					1186:1195	library validation	1178:1195	library validation by NGS Basic Protocol 4	1178:1219	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	62	theme	Cas9	1168:1171	arg1	Preparation					1099:1109	Preparation	1099:1109	Preparation of a GlycoGene CRISPR cell library	1099:1144	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	2	63	theme	available	288:296	arg1	library					315:321	a freely available GlycoGene CRISPR library	279:321	a freely available GlycoGene CRISPR library	279:321	This article describes a method for utilizing a freely available GlycoGene CRISPR library to knock out any gene participating in human glycosylation in arbitrary cell types.
35427438	6	64	theme	glycosylation	801:813	arg1	pathways					815:822	glycosylation pathways	801:822	glycosylation pathways	801:822	This is a powerful systems glycobiology strategy for dissecting glycosylation pathways and processes.
35427438	8	65	theme	pathway	1348:1354	arg1	analysis					1356:1363	Bioinformatics pathway analysis	1333:1363	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	66	theme	CRISPR	1000:1005	arg1	pool					1018:1021	a GlycoGene CRISPR lentivirus pool	988:1021	a GlycoGene CRISPR lentivirus pool	988:1021	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	67	theme	powerful	146:153	arg1	platform					165:172	a powerful discovery platform	144:172	a powerful discovery platform to uncover genes regulating specific biological processes	144:230	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	8	68	theme	lectin-binding	1236:1249	arg1	cells					1266:1270	lectin-binding or non-binding cells	1236:1270	lectin-binding or non-binding cells	1236:1270	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	0	69	theme	GlycoGene	66:74	arg1	Library					83:89	the GlycoGene CRISPR Library	62:89	the GlycoGene CRISPR Library	62:89	Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.
35427438	8	70	theme	Basic	1315:1319	arg1	Protocol					1321:1328	Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5	1222:1330	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	71	theme	GlycoGene	990:998	arg1	pool					1018:1021	a GlycoGene CRISPR lentivirus pool	988:1021	a GlycoGene CRISPR lentivirus pool	988:1021	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	1	72	theme	discovery	155:163	arg1	platform					165:172	a powerful discovery platform	144:172	a powerful discovery platform to uncover genes regulating specific biological processes	144:230	CRISPR-Cas9-based forward genetic screens represent a powerful discovery platform to uncover genes regulating specific biological processes.
35427438	3	73	theme	end	411:413	arg1	library					466:472	a stable GlycoGene CRISPR knockout cell library	426:472	a stable GlycoGene CRISPR knockout cell library	426:472	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	3	73	theme	end	411:413	arg1	product					415:421	The end product	407:421	The end product	407:421	The end product is a stable GlycoGene CRISPR knockout cell library, where each cell contains one or more sgRNA and lacks corresponding function.
35427438	8	74	theme	nuclease	1072:1079	arg1	Protocol					1087:1094	Cas9 nuclease Basic Protocol 3	1067:1096	Cas9 nuclease Basic Protocol 3	1067:1096	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	8	75	theme	pool	1018:1021	arg1	Preparation					973:983	Preparation	973:983	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.	869:1364	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35427438	2	76	theme	cell	395:398	arg1	types					400:404	arbitrary cell types	385:404	arbitrary cell types	385:404	This article describes a method for utilizing a freely available GlycoGene CRISPR library to knock out any gene participating in human glycosylation in arbitrary cell types.
35427438	8	77	theme	NGS	900:902	arg1	validation					904:913	NGS validation	900:913	NGS validation	900:913	Basic Protocol 1: Scale-up and NGS validation of the GlycoGene CRISPR plasmid library Basic Protocol 2: Preparation of a GlycoGene CRISPR lentivirus pool and an isogenic cell line stably expressing Cas9 nuclease Basic Protocol 3: Preparation of a GlycoGene CRISPR cell library, self-inactivation of Cas9, and library validation by NGS Basic Protocol 4: Enrichment of lectin-binding or non-binding cells and related multiplex NGS data acquisition Basic Protocol 5: Bioinformatics pathway analysis.
35656823	4	0	theme	synthetic	490:498	arg1	pathway					500:506	a synthetic pathway	488:506	a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively	488:723	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	4	1	theme	amylose	590:596	arg1	blocks					566:571	methylated and acetylated building blocks	531:571	methylated and acetylated building blocks of cellulose and amylose	531:596	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	6	2	dep	oligo-	1068:1073	arg1	block					1093:1097	block	1093:1097	block	1093:1097	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	4	3	theme	regioselective	606:619	arg1	modification					621:632	the regioselective modification	602:632	the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively	602:723	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	6	4	used	used	963:966	arg2	donors					924:929	The regioselectively modified glycosyl donors	885:929	The regioselectively modified glycosyl donors	885:929	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	6	4	used	used	963:966	arg2	acceptors					935:943	acceptors	935:943	acceptors	935:943	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	2	5	theme	supramolecular	293:306	arg1	structures					308:317	the different supramolecular structures	279:317	the different supramolecular structures of the two α- and β-configured blocks	279:355	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	6	6	theme	-configured	1030:1040	arg1	oligo-					1068:1073	an α(1 → 4)-configured and a β(1 → 4)-configured oligo-	1019:1073	an α(1 → 4)-configured and a β(1 → 4)-configured oligo-	1019:1073	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	5	7	theme	opposite	758:765	arg1	blocks					786:791	the opposite α- or β-configured blocks	754:791	the opposite α- or β-configured blocks	754:791	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	5	8	with	acceptors	739:747	arg1	blocks					786:791	the opposite α- or β-configured blocks	754:791	the opposite α- or β-configured blocks	754:791	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	1	9	theme	All-glucose	77:87	arg1	copolysaccharides					95:111	All-glucose block copolysaccharides	77:111	All-glucose block copolysaccharides with alternated α- and β-configured blocks	77:154	All-glucose block copolysaccharides with alternated α- and β-configured blocks do not exist in nature.
35656823	5	10	theme	α-	767:768	arg1	blocks					786:791	the opposite α- or β-configured blocks	754:791	the opposite α- or β-configured blocks	754:791	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	1	11	theme	block	89:93	arg1	copolysaccharides					95:111	All-glucose block copolysaccharides	77:111	All-glucose block copolysaccharides with alternated α- and β-configured blocks	77:154	All-glucose block copolysaccharides with alternated α- and β-configured blocks do not exist in nature.
35656823	3	12	theme	non-derivatized	433:447	arg1	polysaccharide					461:474	a non-derivatized all-glucose polysaccharide	431:474	a non-derivatized all-glucose polysaccharide	431:474	This would be helical for starch and linear for cellulose in the case of a non-derivatized all-glucose polysaccharide.
35656823	4	13	theme	cellulose	576:584	arg1	blocks					566:571	methylated and acetylated building blocks	531:571	methylated and acetylated building blocks of cellulose and amylose	531:596	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	2	14	theme	α-	330:331	arg1	blocks					350:355	the two α- and β-configured blocks	322:355	the two α- and β-configured blocks	322:355	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	6	15	theme	-configured	1056:1066	arg1	oligo-					1068:1073	an α(1 → 4)-configured and a β(1 → 4)-configured oligo-	1019:1073	an α(1 → 4)-configured and a β(1 → 4)-configured oligo-	1019:1073	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	5	16	theme	permethylated	841:853	arg1	amylose					855:861	permethylated amylose	841:861	permethylated amylose as well as cellulose	841:882	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	4	17	theme	glycosyl	681:688	arg1	acceptors					690:698	glycosyl acceptors	681:698	glycosyl acceptors	681:698	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	1	18	with	copolysaccharides	95:111	arg1	blocks					149:154	alternated α- and β-configured blocks	118:154	alternated α- and β-configured blocks	118:154	All-glucose block copolysaccharides with alternated α- and β-configured blocks do not exist in nature.
35656823	4	19	theme	blocks	566:571	arg1	preparation					516:526	the preparation	512:526	the preparation of methylated and acetylated building blocks of cellulose and amylose	512:596	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	1	20	theme	alternated	118:127	arg1	blocks					149:154	alternated α- and β-configured blocks	118:154	alternated α- and β-configured blocks	118:154	All-glucose block copolysaccharides with alternated α- and β-configured blocks do not exist in nature.
35656823	4	21	from	end	667:669	arg1	modification					621:632	the regioselective modification	602:632	the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively	602:723	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	4	22	theme	reducing	658:665	arg1	end					667:669	the non-reducing and reducing end	637:669	end	667:669	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	2	23	theme	different	283:291	arg1	structures					308:317	the different supramolecular structures	279:317	the different supramolecular structures of the two α- and β-configured blocks	279:355	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	6	24	theme	glycosyl	915:922	arg1	donors					924:929	The regioselectively modified glycosyl donors	885:929	The regioselectively modified glycosyl donors	885:929	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	1	25	theme	α-	129:130	arg1	blocks					149:154	alternated α- and β-configured blocks	118:154	alternated α- and β-configured blocks	118:154	All-glucose block copolysaccharides with alternated α- and β-configured blocks do not exist in nature.
35656823	5	26	theme	amylose	855:861	arg1	methanolysis					825:836	acid-catalyzed methanolysis	810:836	acid-catalyzed methanolysis of permethylated amylose as well as cellulose	810:882	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	0	27	theme	Acetylated	44:53	arg1	Cellulose					55:63	Cellulose	55:63	Cellulose	55:63	Block Copolysaccharides from Methylated and Acetylated Cellulose and Starch.
35656823	2	28	theme	blocks	350:355	arg1	structures					308:317	the different supramolecular structures	279:317	the different supramolecular structures of the two α- and β-configured blocks	279:355	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	5	29	theme	glycosyl	730:737	arg1	acceptors					739:747	The glycosyl acceptors	726:747	The glycosyl acceptors with the opposite α- or β-configured blocks	726:791	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	5	30	theme	cellulose	874:882	arg1	methanolysis					825:836	acid-catalyzed methanolysis	810:836	acid-catalyzed methanolysis of permethylated amylose as well as cellulose	810:882	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	3	31	theme	all-glucose	449:459	arg1	polysaccharide					461:474	a non-derivatized all-glucose polysaccharide	431:474	a non-derivatized all-glucose polysaccharide	431:474	This would be helical for starch and linear for cellulose in the case of a non-derivatized all-glucose polysaccharide.
35656823	6	32	theme	copolysaccharides	996:1012	arg1	preparation					975:985	the preparation	971:985	the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block	971:1097	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	2	33	theme	Such	180:183	arg1	polysaccharides					185:199	Such polysaccharides	180:199	Such polysaccharides	180:199	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	0	34	theme	Methylated	29:38	arg1	Cellulose					55:63	Cellulose	55:63	Cellulose	55:63	Block Copolysaccharides from Methylated and Acetylated Cellulose and Starch.
35656823	3	35	theme	polysaccharide	461:474	arg1	case					423:426	the case	419:426	the case of a non-derivatized all-glucose polysaccharide	419:474	This would be helical for starch and linear for cellulose in the case of a non-derivatized all-glucose polysaccharide.
35656823	5	36	theme	acid-catalyzed	810:823	arg1	methanolysis					825:836	acid-catalyzed methanolysis	810:836	acid-catalyzed methanolysis of permethylated amylose as well as cellulose	810:882	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	4	37	theme	methylated	531:540	arg1	blocks					566:571	methylated and acetylated building blocks	531:571	methylated and acetylated building blocks of cellulose and amylose	531:596	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	3	38	from	helical	372:378	arg1	case					423:426	the case	419:426	the case of a non-derivatized all-glucose polysaccharide	419:474	This would be helical for starch and linear for cellulose in the case of a non-derivatized all-glucose polysaccharide.
35656823	4	39	theme	building	557:564	arg1	blocks					566:571	methylated and acetylated building blocks	531:571	methylated and acetylated building blocks of cellulose and amylose	531:596	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	1	40	theme	β-configured	136:147	arg1	blocks					149:154	alternated α- and β-configured blocks	118:154	alternated α- and β-configured blocks	118:154	All-glucose block copolysaccharides with alternated α- and β-configured blocks do not exist in nature.
35656823	4	41	theme	acetylated	546:555	arg1	blocks					566:571	methylated and acetylated building blocks	531:571	methylated and acetylated building blocks of cellulose and amylose	531:596	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	2	42	theme	β-configured	337:348	arg1	blocks					350:355	the two α- and β-configured blocks	322:355	the two α- and β-configured blocks	322:355	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	6	43	with	copolysaccharides	996:1012	arg1	polysaccharide					1078:1091	polysaccharide	1078:1091	polysaccharide	1078:1091	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	6	43	with	copolysaccharides	996:1012	arg1	oligo-					1068:1073	an α(1 → 4)-configured and a β(1 → 4)-configured oligo-	1019:1073	an α(1 → 4)-configured and a β(1 → 4)-configured oligo-	1019:1073	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	3	44	from	case	423:426	arg1	helical					372:378	helical	372:378	helical	372:378	This would be helical for starch and linear for cellulose in the case of a non-derivatized all-glucose polysaccharide.
35656823	6	45	theme	modified	906:913	arg1	donors					924:929	The regioselectively modified glycosyl donors	885:929	The regioselectively modified glycosyl donors	885:929	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35656823	4	46	theme	non-reducing	641:652	arg1	end					667:669	the non-reducing and reducing end	637:669	end	667:669	We propose a synthetic pathway for the preparation of methylated and acetylated building blocks of cellulose and amylose for the regioselective modification at the non-reducing and reducing end to act as glycosyl acceptors and donors, respectively.
35656823	5	47	theme	β-configured	773:784	arg1	blocks					786:791	the opposite α- or β-configured blocks	754:791	the opposite α- or β-configured blocks	754:791	The glycosyl acceptors with the opposite α- or β-configured blocks were prepared by acid-catalyzed methanolysis of permethylated amylose as well as cellulose.
35656823	2	48	theme	interesting	249:259	arg1	properties					261:270	very interesting properties	244:270	very interesting properties	244:270	Such polysaccharides, and materials made thereof, might exhibit very interesting properties due to the different supramolecular structures of the two α- and β-configured blocks.
35656823	6	49	theme	block	990:994	arg1	copolysaccharides					996:1012	block copolysaccharides	990:1012	block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block	990:1097	The regioselectively modified glycosyl donors and acceptors were successfully used in the preparation of block copolysaccharides with an α(1 → 4)-configured and a β(1 → 4)-configured oligo- or polysaccharide block, respectively.
35577189	0	0	theme	bioactive	111:119	arg1	packaging					121:129	bioactive packaging	111:129	bioactive packaging	111:129	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	1	1	theme	molecular	175:183	arg1	weight					185:190	a molecular weight	173:190	a molecular weight of 51.8 kDa	173:202	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	5	2	theme	AMP	863:865	arg1	addition					846:853	the addition	842:853	the addition of CMP, AMP, and cAMP	842:875	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	5	3	theme	vapor	903:907	arg1	ability					929:935	the light, water vapor, and oxygen barrier ability	886:935	the light, water vapor, and oxygen barrier ability	886:935	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	4	4	theme	complex	824:830	arg1	films					813:817	films	813:817	films more complex	813:830	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	4	5	dep	microscope	633:642	arg1	results					723:729	results	723:729	results	723:729	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	2	6	theme	%	309:309	arg1	sulfate					311:317	5.31% sulfate	305:317	5.31% sulfate	305:317	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	5	7	theme	cAMP	872:875	arg1	addition					846:853	the addition	842:853	the addition of CMP, AMP, and cAMP	842:875	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	3	8	dep	molecules	495:503	arg1	monophosphate					593:605	cyclic adenosine monophosphate	576:605	cyclic adenosine monophosphate (cAMP)	576:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	8	dep	molecules	495:503	arg1	cytidine-5'-monophosphate					505:529	cytidine-5'-monophosphate	505:529	cytidine-5'-monophosphate (CMP)	505:535	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	8	dep	molecules	495:503	arg1	AMP					566:568	AMP	566:568	AMP	566:568	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	8	dep	molecules	495:503	arg1	CMP					532:534	CMP	532:534	CMP	532:534	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	8	dep	molecules	495:503	arg1	cAMP					608:611	cAMP	608:611	cAMP	608:611	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	8	dep	molecules	495:503	arg1	adenosine-5'-monophosphate					538:563	adenosine-5'-monophosphate	538:563	adenosine-5'-monophosphate (AMP)	538:569	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	8	dep	molecules	495:503	arg1	molecules					495:503	the small biological molecules	474:503	the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP)	474:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	2	9	theme	5.31	305:308	arg1	%					309:309	%	309:309	%	309:309	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	7	10	theme	polysaccharide	1309:1322	arg1	film					1324:1327	a functional edible polysaccharide film	1289:1327	a functional edible polysaccharide film applied in food industries	1289:1354	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	7	10	theme	polysaccharide	1309:1322	arg1	value					1271:1275	the potential value	1257:1275	the potential value of cAMPF	1257:1284	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	4	11	theme	FTIR	679:682	arg1	spectrum					685:692	(FTIR) spectrum	678:692	(FTIR) spectrum	678:692	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	5	12	theme	light	890:894	arg1	ability					929:935	the light, water vapor, and oxygen barrier ability	886:935	the light, water vapor, and oxygen barrier ability	886:935	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	2	13	dep	suggested	281:289	arg1	contained					295:303	contained	295:303	contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose	295:350	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	2	13	dep	suggested	281:289	arg1	composed					367:374	composed	367:374	was mainly composed of galactose	356:387	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	5	14	theme	Gram-negative	1015:1027	arg1	bacteria					1043:1050	Gram-negative and -positive bacteria	1015:1050	Gram-negative and -positive bacteria	1015:1050	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	4	15	theme	film	782:785	arg1	substrates					787:796	the film substrates	778:796	the film substrates	778:796	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	3	16	used	used	436:439	arg2	matrix					424:429	a biopolymer matrix	411:429	a biopolymer matrix	411:429	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	16	used	used	436:439	arg2	GAP					403:405	GAP	403:405	GAP	403:405	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	6	17	from	4 °C	1193:1196	arg1	preservation					1177:1188	preservation	1177:1188	preservation at 4 °C	1177:1196	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	6	17	from	4 °C	1193:1196	arg1	packaging					1163:1171	fish packaging	1158:1171	fish packaging	1158:1171	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	0	18	theme	Gelidium	14:21	arg1	films					59:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	1	19	with	polysaccharide	146:159	arg1	weight					185:190	a molecular weight	173:190	a molecular weight of 51.8 kDa	173:202	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	2	20	theme	%	328:328	arg1	3,6-anhydro-galactose					330:350	17.33% 3,6-anhydro-galactose	323:350	17.33% 3,6-anhydro-galactose	323:350	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	1	21	theme	51.8 kDa	195:202	arg1	weight					185:190	a molecular weight	173:190	a molecular weight of 51.8 kDa	173:202	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	0	22	theme	Antibacterial	0:12	arg1	films					59:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	7	23	theme	food	1340:1343	arg1	industries					1345:1354	food industries	1340:1354	food industries	1340:1354	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	6	24	theme	fish	1158:1161	arg1	packaging					1163:1171	fish packaging	1158:1171	fish packaging	1158:1171	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	2	25	theme	17.33	323:327	arg1	%					328:328	%	328:328	%	328:328	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	0	26	theme	polysaccharide-based	31:50	arg1	films					59:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	7	27	theme	cAMPF	1280:1284	arg1	value					1271:1275	the potential value	1257:1275	the potential value of cAMPF	1257:1284	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	7	27	theme	cAMPF	1280:1284	arg1	film					1324:1327	a functional edible polysaccharide film	1289:1327	a functional edible polysaccharide film applied in food industries	1289:1354	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	5	28	theme	surface	938:944	arg1	wettability					946:956	surface wettability	938:956	surface wettability	938:956	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	3	29	theme	composite	453:461	arg1	films					463:467	the composite films	449:467	the composite films	449:467	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	0	30	theme	amansii	23:29	arg1	films					59:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	1	31	theme	homogeneous	134:144	arg1	GAP					162:164	GAP	162:164	GAP	162:164	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	1	31	theme	homogeneous	134:144	arg1	polysaccharide					146:159	A homogeneous polysaccharide	132:159	A homogeneous polysaccharide (GAP)	132:165	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	4	32	theme	electron	624:631	arg1	SEM					645:647	SEM	645:647	SEM	645:647	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	4	32	theme	electron	624:631	arg1	microscope					633:642	Scanning electron microscope	615:642	Scanning electron microscope (SEM)	615:648	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	3	33	theme	biopolymer	413:422	arg1	GAP					403:405	GAP	403:405	GAP	403:405	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	33	theme	biopolymer	413:422	arg1	matrix					424:429	a biopolymer matrix	411:429	a biopolymer matrix	411:429	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	5	34	theme	oxygen	914:919	arg1	ability					929:935	the light, water vapor, and oxygen barrier ability	886:935	the light, water vapor, and oxygen barrier ability	886:935	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	0	35	theme	edible	52:57	arg1	films					59:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films	0:63	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	7	36	theme	functional	1291:1300	arg1	film					1324:1327	a functional edible polysaccharide film	1289:1327	a functional edible polysaccharide film applied in food industries	1289:1354	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	7	36	theme	functional	1291:1300	arg1	value					1271:1275	the potential value	1257:1275	the potential value of cAMPF	1257:1284	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	4	37	theme	Scanning	615:622	arg1	SEM					645:647	SEM	645:647	SEM	645:647	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	4	37	theme	Scanning	615:622	arg1	microscope					633:642	Scanning electron microscope	615:642	Scanning electron microscope (SEM)	615:648	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	1	38	theme	edible	223:228	arg1	amansii					251:257	edible red seaweed Gelidium amansii	223:257	edible red seaweed Gelidium amansii	223:257	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	0	39	theme	cyclic	76:81	arg1	monophosphate					93:105	cyclic adenosine monophosphate	76:105	cyclic adenosine monophosphate for bioactive packaging	76:129	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	7	40	theme	potential	1261:1269	arg1	value					1271:1275	the potential value	1257:1275	the potential value of cAMPF	1257:1284	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	7	40	theme	potential	1261:1269	arg1	film					1324:1327	a functional edible polysaccharide film	1289:1327	a functional edible polysaccharide film applied in food industries	1289:1354	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	5	41	theme	antimicrobial	984:996	arg1	activity					998:1005	antimicrobial activity	984:1005	antimicrobial activity against Gram-negative and -positive bacteria	984:1050	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	3	42	theme	cyclic	576:581	arg1	monophosphate					593:605	cyclic adenosine monophosphate	576:605	cyclic adenosine monophosphate (cAMP)	576:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	42	theme	cyclic	576:581	arg1	molecules					495:503	the small biological molecules	474:503	the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP)	474:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	42	theme	cyclic	576:581	arg1	cAMP					608:611	cAMP	608:611	cAMP	608:611	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	43	theme	small	478:482	arg1	monophosphate					593:605	cyclic adenosine monophosphate	576:605	cyclic adenosine monophosphate (cAMP)	576:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	43	theme	small	478:482	arg1	cytidine-5'-monophosphate					505:529	cytidine-5'-monophosphate	505:529	cytidine-5'-monophosphate (CMP)	505:535	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	43	theme	small	478:482	arg1	adenosine-5'-monophosphate					538:563	adenosine-5'-monophosphate	538:563	adenosine-5'-monophosphate (AMP)	538:569	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	43	theme	small	478:482	arg1	molecules					495:503	the small biological molecules	474:503	the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP)	474:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	6	44	theme	shelf	1220:1224	arg1	life					1226:1229	the fish shelf life	1211:1229	the fish shelf life	1211:1229	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	1	45	attach	isolated	209:216	arg2	polysaccharide					146:159	A homogeneous polysaccharide	132:159	A homogeneous polysaccharide (GAP)	132:165	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	1	45	attach	isolated	209:216	arg1	amansii					251:257	edible red seaweed Gelidium amansii	223:257	edible red seaweed Gelidium amansii	223:257	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	1	45	attach	isolated	209:216	arg2	GAP					162:164	GAP	162:164	GAP	162:164	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	3	46	theme	adenosine	583:591	arg1	monophosphate					593:605	cyclic adenosine monophosphate	576:605	cyclic adenosine monophosphate (cAMP)	576:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	46	theme	adenosine	583:591	arg1	molecules					495:503	the small biological molecules	474:503	the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP)	474:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	46	theme	adenosine	583:591	arg1	cAMP					608:611	cAMP	608:611	cAMP	608:611	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	47	theme	biological	484:493	arg1	monophosphate					593:605	cyclic adenosine monophosphate	576:605	cyclic adenosine monophosphate (cAMP)	576:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	47	theme	biological	484:493	arg1	cytidine-5'-monophosphate					505:529	cytidine-5'-monophosphate	505:529	cytidine-5'-monophosphate (CMP)	505:535	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	47	theme	biological	484:493	arg1	adenosine-5'-monophosphate					538:563	adenosine-5'-monophosphate	538:563	adenosine-5'-monophosphate (AMP)	538:569	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	3	47	theme	biological	484:493	arg1	molecules					495:503	the small biological molecules	474:503	the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP)	474:612	Furthermore, GAP, as a biopolymer matrix, was used to form the composite films with the small biological molecules cytidine-5'-monophosphate (CMP), adenosine-5'-monophosphate (AMP), and cyclic adenosine monophosphate (cAMP).
35577189	6	48	theme	fish	1215:1218	arg1	life					1226:1229	the fish shelf life	1211:1229	the fish shelf life	1211:1229	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	5	49	theme	water	897:901	arg1	vapor					903:907	water vapor	897:907	water vapor	897:907	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	4	50	dep	transform	659:667	arg1	infrared					669:676	infrared	669:676	transform infrared (FTIR) spectrum	659:692	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	5	51	theme	barrier	921:927	arg1	ability					929:935	the light, water vapor, and oxygen barrier ability	886:935	the light, water vapor, and oxygen barrier ability	886:935	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	4	52	theme	X-ray	699:703	arg1	XRD					718:720	XRD	718:720	XRD	718:720	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	4	52	theme	X-ray	699:703	arg1	diffraction					705:715	X-ray diffraction	699:715	X-ray diffraction (XRD)	699:721	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	6	53	theme	GAP-based	1062:1070	arg1	films					1072:1076	GAP-based films	1062:1076	GAP-based films composited with cAMP (cAMPF)	1062:1105	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	1	54	theme	red	230:232	arg1	amansii					251:257	edible red seaweed Gelidium amansii	223:257	edible red seaweed Gelidium amansii	223:257	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	5	55	theme	CMP	858:860	arg1	addition					846:853	the addition	842:853	the addition of CMP, AMP, and cAMP	842:875	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	4	56	dep	Fourier	651:657	arg1	transform					659:667	transform	659:667	transform infrared (FTIR) spectrum	659:692	Scanning electron microscope (SEM), Fourier transform infrared (FTIR) spectrum, and X-ray diffraction (XRD) results showed that CMP, AMP, and cAMP interacted with the film substrates and might made films more complex.
35577189	1	57	theme	seaweed	234:240	arg1	amansii					251:257	edible red seaweed Gelidium amansii	223:257	edible red seaweed Gelidium amansii	223:257	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	5	58	theme	mechanical	959:968	arg1	strength					970:977	mechanical strength	959:977	mechanical strength	959:977	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	2	59	theme	Composition	260:270	arg1	analysis					272:279	Composition analysis	260:279	Composition analysis	260:279	Composition analysis suggested GAP contained 5.31% sulfate and 17.33% 3,6-anhydro-galactose and was mainly composed of galactose.
35577189	1	60	theme	Gelidium	242:249	arg1	amansii					251:257	edible red seaweed Gelidium amansii	223:257	edible red seaweed Gelidium amansii	223:257	A homogeneous polysaccharide (GAP), with a molecular weight of 51.8 kDa, was isolated from edible red seaweed Gelidium amansii.
35577189	0	61	theme	adenosine	83:91	arg1	monophosphate					93:105	cyclic adenosine monophosphate	76:105	cyclic adenosine monophosphate for bioactive packaging	76:129	Antibacterial Gelidium amansii polysaccharide-based edible films containing cyclic adenosine monophosphate for bioactive packaging.
35577189	5	62	theme	-positive	1033:1041	arg1	bacteria					1043:1050	Gram-negative and -positive bacteria	1015:1050	Gram-negative and -positive bacteria	1015:1050	Notably, the addition of CMP, AMP, and cAMP promoted the light, water vapor, and oxygen barrier ability, surface wettability, mechanical strength, and antimicrobial activity against Gram-negative and -positive bacteria.
35577189	6	63	theme	best	1121:1124	arg1	characteristics					1126:1140	the best characteristics	1117:1140	the best characteristics were applied to fish packaging and preservation at 4 °C	1117:1196	Finally, GAP-based films composited with cAMP (cAMPF) exhibited the best characteristics were applied to fish packaging and preservation at 4 °C and extended the fish shelf life.
35577189	7	64	theme	edible	1302:1307	arg1	film					1324:1327	a functional edible polysaccharide film	1289:1327	a functional edible polysaccharide film applied in food industries	1289:1354	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
35577189	7	64	theme	edible	1302:1307	arg1	value					1271:1275	the potential value	1257:1275	the potential value of cAMPF	1257:1284	All these data suggested the potential value of cAMPF as a functional edible polysaccharide film applied in food industries.
37348475	2	0	theme	green	362:366	arg1	tags					429:432	tags	429:432	tags	429:432	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	0	theme	green	362:366	arg1	NtAGP1					313:318	NtAGP1	313:318	NtAGP1	313:318	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	0	theme	green	362:366	arg1	protein					380:386	green fluorescent protein	362:386	green fluorescent protein (GFP)	362:392	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	0	theme	green	362:366	arg1	sporamin					411:418	sweet potato sporamin	398:418	sweet potato sporamin (SPO)	398:424	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	0	theme	green	362:366	arg1	model					351:355	a model	349:355	a model	349:355	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	0	theme	green	362:366	arg1	GFP					389:391	GFP	389:391	GFP	389:391	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	3	1	theme	large	602:606	arg1	smear					608:612	large smear	602:612	large smear on SDS-polyacrylamide gel	602:638	The NtAGP1 fusion proteins migrated as large smear on SDS-polyacrylamide gel and these proteins also localized preferentially to the plasma membrane.
37348475	1	2	theme	-anchoring	288:297	arg1	signal					299:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	0	3	theme	arabinogalactan	119:133	arg1	precursor					143:151	a classical arabinogalactan protein precursor	107:151	a classical arabinogalactan protein precursor	107:151	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	5	4	theme	structures	917:926	arg1	SPO-AGPΔC					971:979	the secreted SPO-AGPΔC	958:979	the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP	958:1031	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	5	4	theme	structures	917:926	arg1	Comparison					892:901	Comparison	892:901	Comparison of the glycan structures of the microsomal SPO-AGP	892:952	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	0	5	theme	classical	109:117	arg1	precursor					143:151	a classical arabinogalactan protein precursor	107:151	a classical arabinogalactan protein precursor	107:151	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	3	6	theme	plasma	696:701	arg1	membrane					703:710	the plasma membrane	692:710	the plasma membrane	692:710	The NtAGP1 fusion proteins migrated as large smear on SDS-polyacrylamide gel and these proteins also localized preferentially to the plasma membrane.
37348475	2	7	theme	BY-2	551:554	arg1	cells					556:560	tobacco BY-2 cells	543:560	tobacco BY-2 cells	543:560	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	0	8	gly	glycosylation	90:102	arg1	cells					169:173	tobacco BY-2 cells	156:173	tobacco BY-2 cells	156:173	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	0	8	gly	glycosylation	90:102	arg1	precursor					143:151	a classical arabinogalactan protein precursor	107:151	a classical arabinogalactan protein precursor	107:151	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	0	9	theme	precursor	143:151	arg1	transport					66:74	proper transport	59:74	proper transport	59:74	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	0	9	theme	precursor	143:151	arg1	glycosylation					90:102	extensive glycosylation	80:102	extensive glycosylation	80:102	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	0	10	from	transport	66:74	arg1	cells					169:173	tobacco BY-2 cells	156:173	tobacco BY-2 cells	156:173	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	5	11	theme	microsomal	935:944	arg1	SPO-AGP					946:952	the microsomal SPO-AGP	931:952	the microsomal SPO-AGP	931:952	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	1	12	theme	plant	195:199	arg1	proteins					216:223	plant arabinogalctan proteins	195:223	plant arabinogalctan proteins (AGPs)	195:230	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	1	12	theme	plant	195:199	arg1	AGPs					226:229	AGPs	226:229	AGPs	226:229	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	0	13	theme	protein	135:141	arg1	precursor					143:151	a classical arabinogalactan protein precursor	107:151	a classical arabinogalactan protein precursor	107:151	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	4	14	theme	AGPΔC	737:741	arg1	fusions					726:732	fusions	726:732	fusions of AGPΔC with GFP- and SPO	726:759	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	1	15	theme	arabinogalctan	201:214	arg1	proteins					216:223	plant arabinogalctan proteins	195:223	plant arabinogalctan proteins (AGPs)	195:230	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	1	15	theme	arabinogalctan	201:214	arg1	AGPs					226:229	AGPs	226:229	AGPs	226:229	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	5	16	theme	proteins	1079:1086	arg1	different					1092:1100	different	1092:1100	different	1092:1100	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	5	16	theme	proteins	1079:1086	arg1	structures					1059:1068	the glycan structures	1048:1068	the glycan structures of these proteins	1048:1086	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	6	17	gly	glycosylation	1191:1203	arg1	precursor					1216:1224	the AGP precursor	1208:1224	the AGP precursor	1208:1224	These observations indicate that GPI-anchoring is required for the proper transport and glycosylation of the AGP precursor.
37348475	6	18	theme	AGP	1212:1214	arg1	precursor					1216:1224	the AGP precursor	1208:1224	the AGP precursor	1208:1224	These observations indicate that GPI-anchoring is required for the proper transport and glycosylation of the AGP precursor.
37348475	1	19	theme	proteins	216:223	arg1	precursors					181:190	Many precursors	176:190	Many precursors of plant arabinogalctan proteins (AGPs)	176:230	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	4	20	dep	secreted	801:808	arg1	whereas					811:817	whereas	811:817	whereas	811:817	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	5	21	theme	glycan	1052:1057	arg1	different					1092:1100	different	1092:1100	different	1092:1100	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	5	21	theme	glycan	1052:1057	arg1	structures					1059:1068	the glycan structures	1048:1068	the glycan structures of these proteins	1048:1086	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	5	22	theme	SPO-AGP	946:952	arg1	structures					917:926	the glycan structures	906:926	the glycan structures of the microsomal SPO-AGP	906:952	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	5	23	theme	secreted	962:969	arg1	SPO-AGPΔC					971:979	the secreted SPO-AGPΔC	958:979	the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP	958:1031	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	0	24	theme	tobacco	156:162	arg1	cells					169:173	tobacco BY-2 cells	156:173	tobacco BY-2 cells	156:173	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	2	25	theme	tobacco	333:339	arg1	AGP					341:343	a classical tobacco AGP	321:343	a classical tobacco AGP	321:343	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	25	theme	tobacco	333:339	arg1	NtAGP1					313:318	NtAGP1	313:318	NtAGP1	313:318	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	26	theme	classical	323:331	arg1	AGP					341:343	a classical tobacco AGP	321:343	a classical tobacco AGP	321:343	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	26	theme	classical	323:331	arg1	NtAGP1					313:318	NtAGP1	313:318	NtAGP1	313:318	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	0	27	theme	proper	59:64	arg1	transport					66:74	proper transport	59:74	proper transport	59:74	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	4	28	with	fusions	726:732	arg1	SPO					757:759	SPO	757:759	SPO	757:759	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	4	28	with	fusions	726:732	arg1	GFP-					748:751	GFP-	748:751	GFP-	748:751	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	2	29	theme	GPI-anchoring	511:523	arg1	signal					525:530	GPI-anchoring signal	511:530	GPI-anchoring signal	511:530	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	30	from	localization	451:462	arg1	cells					556:560	tobacco BY-2 cells	543:560	tobacco BY-2 cells	543:560	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	6	31	theme	precursor	1216:1224	arg1	glycosylation					1191:1203	glycosylation	1191:1203	glycosylation	1191:1203	These observations indicate that GPI-anchoring is required for the proper transport and glycosylation of the AGP precursor.
37348475	6	31	theme	precursor	1216:1224	arg1	transport					1177:1185	transport	1177:1185	transport	1177:1185	These observations indicate that GPI-anchoring is required for the proper transport and glycosylation of the AGP precursor.
37348475	2	32	theme	potato	404:409	arg1	SPO					421:423	SPO	421:423	SPO	421:423	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	32	theme	potato	404:409	arg1	tags					429:432	tags	429:432	tags	429:432	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	32	theme	potato	404:409	arg1	NtAGP1					313:318	NtAGP1	313:318	NtAGP1	313:318	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	32	theme	potato	404:409	arg1	protein					380:386	green fluorescent protein	362:386	green fluorescent protein (GFP)	362:392	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	32	theme	potato	404:409	arg1	sporamin					411:418	sweet potato sporamin	398:418	sweet potato sporamin (SPO)	398:424	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	32	theme	potato	404:409	arg1	model					351:355	a model	349:355	a model	349:355	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	3	33	from	smear	608:612	arg1	gel					636:638	SDS-polyacrylamide gel	617:638	SDS-polyacrylamide gel	617:638	The NtAGP1 fusion proteins migrated as large smear on SDS-polyacrylamide gel and these proteins also localized preferentially to the plasma membrane.
37348475	0	34	theme	BY-2	164:167	arg1	cells					169:173	tobacco BY-2 cells	156:173	tobacco BY-2 cells	156:173	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	0	35	from	glycosylation	90:102	arg1	cells					169:173	tobacco BY-2 cells	156:173	tobacco BY-2 cells	156:173	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	0	36	dep	transport	66:74	arg1	the					55:57	the	55:57	the	55:57	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	2	37	theme	sweet	398:402	arg1	SPO					421:423	SPO	421:423	SPO	421:423	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	37	theme	sweet	398:402	arg1	tags					429:432	tags	429:432	tags	429:432	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	37	theme	sweet	398:402	arg1	NtAGP1					313:318	NtAGP1	313:318	NtAGP1	313:318	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	37	theme	sweet	398:402	arg1	protein					380:386	green fluorescent protein	362:386	green fluorescent protein (GFP)	362:392	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	37	theme	sweet	398:402	arg1	sporamin					411:418	sweet potato sporamin	398:418	sweet potato sporamin (SPO)	398:424	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	37	theme	sweet	398:402	arg1	model					351:355	a model	349:355	a model	349:355	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	38	theme	mutant	496:501	arg1	modification					468:479	modification	468:479	modification	468:479	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	38	theme	mutant	496:501	arg1	localization					451:462	localization	451:462	localization	451:462	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	39	theme	tobacco	543:549	arg1	cells					556:560	tobacco BY-2 cells	543:560	tobacco BY-2 cells	543:560	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	40	from	modification	468:479	arg1	cells					556:560	tobacco BY-2 cells	543:560	tobacco BY-2 cells	543:560	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	6	41	dep	transport	1177:1185	arg1	the					1166:1168	the	1166:1168	the	1166:1168	These observations indicate that GPI-anchoring is required for the proper transport and glycosylation of the AGP precursor.
37348475	5	42	theme	glycan	910:915	arg1	structures					917:926	the glycan structures	906:926	the glycan structures of the microsomal SPO-AGP	906:952	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	2	43	dep	localization	451:462	arg1	the					447:449	the	447:449	the	447:449	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	5	44	theme	glycan	1010:1015	arg1	epitopes					1017:1024	the glycan epitopes	1006:1024	the glycan epitopes of AGP	1006:1031	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	6	45	theme	proper	1170:1175	arg1	transport					1177:1185	transport	1177:1185	transport	1177:1185	These observations indicate that GPI-anchoring is required for the proper transport and glycosylation of the AGP precursor.
37348475	1	46	contain	contains	232:239	arg2	signal					299:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	1	46	contain	contains	232:239	arg1	precursors					181:190	Many precursors	176:190	Many precursors of plant arabinogalctan proteins (AGPs)	176:230	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	4	47	theme	several	769:775	arg1	forms					777:781	several forms	769:781	several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles	769:889	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	2	48	theme	AGP	484:486	arg1	modification					468:479	modification	468:479	modification	468:479	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	48	theme	AGP	484:486	arg1	localization					451:462	localization	451:462	localization	451:462	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	1	49	theme	C-terminal	243:252	arg1	signal					299:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	4	50	theme	endomembrane	848:859	arg1	vacuoles					882:889	vacuoles	882:889	vacuoles	882:889	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	4	50	theme	endomembrane	848:859	arg1	organelles					861:870	the endomembrane organelles	844:870	the endomembrane organelles including vacuoles	844:889	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	3	51	theme	SDS-polyacrylamide	617:634	arg1	gel					636:638	SDS-polyacrylamide gel	617:638	SDS-polyacrylamide gel	617:638	The NtAGP1 fusion proteins migrated as large smear on SDS-polyacrylamide gel and these proteins also localized preferentially to the plasma membrane.
37348475	2	52	theme	fluorescent	368:378	arg1	tags					429:432	tags	429:432	tags	429:432	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	52	theme	fluorescent	368:378	arg1	NtAGP1					313:318	NtAGP1	313:318	NtAGP1	313:318	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	52	theme	fluorescent	368:378	arg1	protein					380:386	green fluorescent protein	362:386	green fluorescent protein (GFP)	362:392	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	52	theme	fluorescent	368:378	arg1	sporamin					411:418	sweet potato sporamin	398:418	sweet potato sporamin (SPO)	398:424	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	52	theme	fluorescent	368:378	arg1	model					351:355	a model	349:355	a model	349:355	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	2	52	theme	fluorescent	368:378	arg1	GFP					389:391	GFP	389:391	GFP	389:391	Using NtAGP1, a classical tobacco AGP, as a model, and green fluorescent protein (GFP) and sweet potato sporamin (SPO) as tags, we analyzed the localization and modification of AGP and its mutant without GPI-anchoring signal (AGPΔC) in tobacco BY-2 cells.
37348475	1	53	theme	glycosylphosphatidylinositol	254:281	arg1	signal					299:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	5	54	theme	AGP	1029:1031	arg1	epitopes					1017:1024	the glycan epitopes	1006:1024	the glycan epitopes of AGP	1006:1031	Comparison of the glycan structures of the microsomal SPO-AGP and the secreted SPO-AGPΔC using antibodies against the glycan epitopes of AGP indicated that the glycan structures of these proteins are different.
37348475	3	55	theme	NtAGP1	567:572	arg1	proteins					581:588	The NtAGP1 fusion proteins	563:588	The NtAGP1 fusion proteins	563:588	The NtAGP1 fusion proteins migrated as large smear on SDS-polyacrylamide gel and these proteins also localized preferentially to the plasma membrane.
37348475	4	56	dep	forms	777:781	arg1	secreted					801:808	secreted	801:808	were secreted	796:808	In contrast, fusions of AGPΔC with GFP- and SPO yielded several forms: The largest were secreted, whereas others were recovered in the endomembrane organelles including vacuoles.
37348475	0	57	theme	extensive	80:88	arg1	glycosylation					90:102	extensive glycosylation	80:102	extensive glycosylation	80:102	Glycosylphosphatidylinositol-anchoring is required for the proper transport and extensive glycosylation of a classical arabinogalactan protein precursor in tobacco BY-2 cells.
37348475	3	58	theme	fusion	574:579	arg1	proteins					581:588	The NtAGP1 fusion proteins	563:588	The NtAGP1 fusion proteins	563:588	The NtAGP1 fusion proteins migrated as large smear on SDS-polyacrylamide gel and these proteins also localized preferentially to the plasma membrane.
37348475	1	59	theme	Many	176:179	arg1	precursors					181:190	Many precursors	176:190	Many precursors of plant arabinogalctan proteins (AGPs)	176:230	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
37348475	1	60	theme	GPI	284:286	arg1	signal					299:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal	241:304	Many precursors of plant arabinogalctan proteins (AGPs) contains a C-terminal glycosylphosphatidylinositol (GPI)-anchoring signal.
36350770	5	0	theme	polysaccharide	1154:1167	arg1	shape					1141:1145	the helical shape	1129:1145	the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity	1129:1241	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	4	1	theme	neutral	806:812	arg1	conditions					814:823	neutral conditions	806:823	neutral conditions	806:823	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	1	2	theme	labile	269:274	arg1	esters					285:290	labile O-acetyl esters	269:290	labile O-acetyl esters	269:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	5	3	with	structure	904:912	arg1	esters					930:935	the acetyl esters	919:935	the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues	919:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	1	4	theme	serotype	180:187	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	4	theme	serotype	180:187	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	5	theme	O-acetyl	276:283	arg1	esters					285:290	labile O-acetyl esters	269:290	labile O-acetyl esters	269:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	2	6	theme	α-galacturonic	386:399	arg1	acids					401:405	α-galacturonic acids	386:405	α-galacturonic acids	386:405	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	3	7	theme	deprotection	572:583	arg1	scheme					585:590	a careful deprotection scheme	562:590	a careful deprotection scheme to prevent migration and hydrolysis	562:626	The lability of the O-acetyl esters imposed a careful deprotection scheme to prevent migration and hydrolysis.
36350770	5	8	theme	close	978:982	arg1	proximity					984:992	close proximity	978:992	close proximity of the neighboring AAT residues	978:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	5	9	theme	AAT	1013:1015	arg1	residues					1017:1024	the neighboring AAT residues	997:1024	the neighboring AAT residues	997:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	2	10	theme	target	297:302	arg1	oligosaccharides					304:319	The target oligosaccharides	293:319	The target oligosaccharides	293:319	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	5	11	theme	acetyl	923:928	arg1	esters					930:935	the acetyl esters	919:935	the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues	919:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	4	12	theme	NMR	697:699	arg1	spectroscopy					701:712	NMR spectroscopy	697:712	NMR spectroscopy	697:712	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	2	13	theme	stereoselective	458:472	arg1	manner					474:479	a highly stereoselective manner	449:479	a highly stereoselective manner using trisaccharide building blocks	449:515	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	0	14	theme	Zwitterionic	10:21	arg1	Oligosaccharides					55:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides	0:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides	0:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	4	15	theme	pD	681:682	arg1	values					684:689	various pD values	673:689	various pD values using NMR spectroscopy	673:712	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	4	16	theme	esters	773:778	arg1	hydrolysis					742:751	hydrolysis	742:751	hydrolysis	742:751	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	4	16	theme	esters	773:778	arg1	migration					728:736	migration	728:736	migration	728:736	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	1	17	theme	Sp1	192:194	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	17	theme	Sp1	192:194	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	0	18	theme	Synthetic	0:8	arg1	Oligosaccharides					55:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides	0:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides	0:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	2	19	theme	α-2,4-diamino-2,4,6-trideoxy	337:364	arg1	AAT					377:379	AAT	377:379	AAT	377:379	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	2	19	theme	α-2,4-diamino-2,4,6-trideoxy	337:364	arg1	galactose					366:374	rare α-2,4-diamino-2,4,6-trideoxy galactose	332:374	rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT)	332:380	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	5	20	theme	conformational	1044:1057	arg1	restrictions					1059:1070	conformational restrictions	1044:1070	conformational restrictions	1044:1070	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	2	21	theme	rare	332:335	arg1	AAT					377:379	AAT	377:379	AAT	377:379	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	2	21	theme	rare	332:335	arg1	galactose					366:374	rare α-2,4-diamino-2,4,6-trideoxy galactose	332:374	rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT)	332:380	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	2	22	dep	level	439:443	arg1	up					423:424	up	423:424	up	423:424	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	1	23	theme	oligosaccharide	197:211	arg1	synthesis					138:146	the first total synthesis	122:146	the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	122:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	4	24	theme	C-3-O-acetyl	760:771	arg1	esters					773:778	the C-3-O-acetyl esters	756:778	the C-3-O-acetyl esters	756:778	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	5	25	theme	unique	1216:1221	arg1	activity					1234:1241	its unique biological activity	1212:1241	its unique biological activity	1212:1241	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	5	26	theme	residues	1017:1024	arg1	proximity					984:992	close proximity	978:992	close proximity of the neighboring AAT residues	978:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	1	27	dep	Streptococcus	155:167	arg1	pneumoniae					169:178	pneumoniae	169:178	pneumoniae	169:178	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	5	28	theme	right-handed	883:894	arg1	structure					904:912	a right-handed helical structure	881:912	a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues	881:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	5	29	theme	biological	1223:1232	arg1	activity					1234:1241	its unique biological activity	1212:1241	its unique biological activity	1212:1241	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	5	30	theme	neighboring	1001:1011	arg1	residues					1017:1024	the neighboring AAT residues	997:1024	the neighboring AAT residues	997:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	1	31	contain	carrying	260:267	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	31	contain	carrying	260:267	arg2	esters					285:290	labile O-acetyl esters	269:290	labile O-acetyl esters	269:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	31	contain	carrying	260:267	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	5	32	theme	helical	896:902	arg1	structure					904:912	a right-handed helical structure	881:912	a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues	881:1024	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	2	33	theme	building	501:508	arg1	blocks					510:515	trisaccharide building blocks	487:515	trisaccharide building blocks	487:515	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	0	34	theme	Type	48:51	arg1	Oligosaccharides					55:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides	0:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides	0:70	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	1	35	theme	unique	216:221	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	35	theme	unique	216:221	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	2	36	theme	trisaccharide	487:499	arg1	blocks					510:515	trisaccharide building blocks	487:515	trisaccharide building blocks	487:515	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	5	37	theme	helical	1133:1139	arg1	shape					1141:1145	the helical shape	1129:1145	the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity	1129:1241	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	5	38	theme	AATα1-4GalA	1079:1089	arg1	linkages					1108:1115	the AATα1-4GalA(3OAc) glycosidic linkages	1075:1115	the AATα1-4GalA(3OAc) glycosidic linkages	1075:1115	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	1	39	theme	first	126:130	arg1	synthesis					138:146	the first total synthesis	122:146	the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	122:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	5	40	theme	3OAc	1091:1094	arg1	linkages					1108:1115	the AATα1-4GalA(3OAc) glycosidic linkages	1075:1115	the AATα1-4GalA(3OAc) glycosidic linkages	1075:1115	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	3	41	theme	O-acetyl	538:545	arg1	esters					547:552	the O-acetyl esters	534:552	the O-acetyl esters	534:552	The lability of the O-acetyl esters imposed a careful deprotection scheme to prevent migration and hydrolysis.
36350770	1	42	theme	total	132:136	arg1	synthesis					138:146	the first total synthesis	122:146	the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	122:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	5	43	theme	helix	969:973	arg1	periphery					952:960	the periphery	948:960	the periphery of the helix	948:973	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	1	44	theme	zwitterionic	223:234	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	44	theme	zwitterionic	223:234	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	3	45	theme	careful	564:570	arg1	scheme					585:590	a careful deprotection scheme	562:590	a careful deprotection scheme to prevent migration and hydrolysis	562:626	The lability of the O-acetyl esters imposed a careful deprotection scheme to prevent migration and hydrolysis.
36350770	5	46	theme	glycosidic	1097:1106	arg1	linkages					1108:1115	the AATα1-4GalA(3OAc) glycosidic linkages	1075:1115	the AATα1-4GalA(3OAc) glycosidic linkages	1075:1115	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	0	47	dep	Streptococcus	23:35	arg1	pneumoniae					37:46	pneumoniae	37:46	pneumoniae	37:46	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	1	48	theme	capsular	236:243	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	48	theme	capsular	236:243	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	0	49	theme	O-Acetyl	88:95	arg1	Esters					97:102	Labile O-Acetyl Esters	81:102	Labile O-Acetyl Esters	81:102	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	2	50	theme	9-mer	433:437	arg1	level					439:443	the 9-mer level	429:443	the 9-mer level	429:443	The target oligosaccharides, featuring rare α-2,4-diamino-2,4,6-trideoxy galactose (AAT) and α-galacturonic acids, were assembled up to the 9-mer level, in a highly stereoselective manner using trisaccharide building blocks.
36350770	0	51	dep	Zwitterionic	10:21	arg1	Streptococcus					23:35	Streptococcus	23:35	Streptococcus	23:35	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	4	52	theme	various	673:679	arg1	values					684:689	various pD values	673:689	various pD values using NMR spectroscopy	673:712	The migration was investigated in detail at various pD values using NMR spectroscopy, to show that migration and hydrolysis of the C-3-O-acetyl esters readily takes place under neutral conditions.
36350770	3	53	theme	esters	547:552	arg1	lability					522:529	The lability	518:529	The lability of the O-acetyl esters	518:552	The lability of the O-acetyl esters imposed a careful deprotection scheme to prevent migration and hydrolysis.
36350770	0	54	theme	Labile	81:86	arg1	Esters					97:102	Labile O-Acetyl Esters	81:102	Labile O-Acetyl Esters	81:102	Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters.
36350770	5	55	theme	Structural	826:835	arg1	investigation					837:849	Structural investigation	826:849	Structural investigation	826:849	Structural investigation showed the oligomers to adopt a right-handed helical structure with the acetyl esters exposed on the periphery of the helix in close proximity of the neighboring AAT residues, thereby imposing conformational restrictions on the AATα1-4GalA(3OAc) glycosidic linkages, supporting the helical shape of the polysaccharide, that has been proposed to be critical for its unique biological activity.
36350770	1	56	theme	Streptococcus	155:167	arg1	polysaccharide					245:258	a unique zwitterionic capsular polysaccharide	214:258	a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters	214:290	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36350770	1	56	theme	Streptococcus	155:167	arg1	oligosaccharide					197:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide	151:211	We herein report the first total synthesis of the Streptococcus pneumoniae serotype 1 (Sp1) oligosaccharide, a unique zwitterionic capsular polysaccharide carrying labile O-acetyl esters.
36399934	8	0	theme	Glu1B	1164:1168	arg1	activity					1122:1129	The high specific activity	1104:1129	The high specific activity of the recombinant β-glucosidase Glu1B	1104:1168	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	10	1	theme	cellulose	1816:1824	arg1	hydrolysis					1802:1811	the enzymatic hydrolysis	1788:1811	the enzymatic hydrolysis of cellulose	1788:1824	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	8	2	from	presence	1194:1201	arg1	Gln455					1240:1245	Gln455	1240:1245	Gln455	1240:1245	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	2	from	presence	1194:1201	arg1	aglycone					1252:1259	aglycone	1252:1259	aglycone (Thr193 and Hys252)	1252:1279	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	2	from	presence	1194:1201	arg1	glycone					1231:1237	the glycone	1227:1237	the glycone (Gln455)	1227:1246	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	9	3	from	residues	1495:1502	arg1	site					1518:1521	the active site	1507:1521	the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1507:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	6	4	dep	%	949:949	arg1	80					946:947	80	946:947	80	946:947	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	10	5	theme	biomass	1866:1872	arg1	saccharification					1830:1845	saccharification	1830:1845	saccharification of lignocellulosic biomass	1830:1872	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	10	6	theme	P.	1666:1667	arg1	system					1689:1694	the P. pastoris expression system	1662:1694	the P. pastoris expression system	1662:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	8	7	from	glycone	1231:1237	arg1	presence					1194:1201	the presence	1190:1201	the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites	1190:1386	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	6	8	theme	residual	907:914	arg1	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	9	9	from	presence	1463:1470	arg1	site					1518:1521	the active site	1507:1521	the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1507:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	4	10	theme	P.	711:712	arg1	strain					732:737	the P. pastoris KM71BGlu strain	707:737	the P. pastoris KM71BGlu strain	707:737	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	2	11	theme	biomass	352:358	arg1	saccharification					316:331	the saccharification	312:331	the saccharification of lignocellulosic biomass	312:358	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	1	12	theme	terminal	212:219	arg1	residues					221:228	non-reducing terminal residues	199:228	non-reducing terminal residues in β-D-glucosides	199:246	β-glucosidases (E.C. 3.2.1.21) are enzymes that hydrolyze β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides, with the release of glucose.
36399934	8	13	theme	residues	1215:1222	arg1	presence					1194:1201	the presence	1190:1201	the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites	1190:1386	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	6	14	theme	431-597 U/mg	991:1002	arg1	protein					1004:1010	431-597 U/mg protein	991:1010	431-597 U/mg protein	991:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	10	15	from	properties	1610:1619	arg1	system					1689:1694	the P. pastoris expression system	1662:1694	the P. pastoris expression system	1662:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	4	16	theme	induction	680:688	arg1	36 h					663:666	36 h	663:666	36 h of methanol induction in shake flasks	663:704	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	10	17	theme	expression	1678:1687	arg1	system					1689:1694	the P. pastoris expression system	1662:1694	the P. pastoris expression system	1662:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	4	18	theme	shake	693:697	arg1	flasks					699:704	shake flasks	693:704	shake flasks	693:704	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	8	19	from	aglycone	1252:1259	arg1	presence					1194:1201	the presence	1190:1201	the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites	1190:1386	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	20	theme	binding	1281:1287	arg1	sites					1289:1293	binding sites	1281:1293	binding sites	1281:1293	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	1	21	from	residues	221:228	arg1	bonds					188:192	β-1,4-glycosidic bonds	171:192	β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides	171:246	β-glucosidases (E.C. 3.2.1.21) are enzymes that hydrolyze β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides, with the release of glucose.
36399934	1	21	from	residues	221:228	arg1	β-D-glucosides					233:246	β-D-glucosides	233:246	β-D-glucosides	233:246	β-glucosidases (E.C. 3.2.1.21) are enzymes that hydrolyze β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides, with the release of glucose.
36399934	6	22	contain	had	851:853	arg2	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	22	contain	had	851:853	arg1	product					843:849	The recombinant product	827:849	The recombinant product	827:849	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	22	contain	had	851:853	arg2	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	22	contain	had	851:853	arg2	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	22	contain	had	851:853	arg2	Ki					1019:1020	a Ki	1017:1020	a Ki for glucose of 166 mM	1017:1042	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	22	contain	had	851:853	arg2	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	4	23	theme	KM71BGlu	723:730	arg1	strain					732:737	the P. pastoris KM71BGlu strain	707:737	the P. pastoris KM71BGlu strain	707:737	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	5	24	theme	N-glycosylated	791:804	arg1	Glu1B					820:824	N-glycosylated β-glucosidase Glu1B	791:824	N-glycosylated β-glucosidase Glu1B	791:824	26 mg/L) of N-glycosylated β-glucosidase Glu1B.
36399934	9	25	theme	specific	1475:1482	arg1	residues					1495:1502	specific gatekeeper residues	1475:1502	specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1475:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	10	26	from	system	1689:1694	arg1	properties					1610:1619	its biochemical properties	1594:1619	its biochemical properties	1594:1619	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	10	26	from	system	1689:1694	arg1	possibility					1629:1639	the possibility	1625:1639	the possibility of its production in the P. pastoris expression system	1625:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	8	27	theme	residues	1314:1321	arg1	presence					1194:1201	the presence	1190:1201	the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites	1190:1386	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	10	28	dep	P.	1666:1667	arg1	pastoris					1669:1676	pastoris	1669:1676	pastoris	1669:1676	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	5	29	theme	Glu1B	820:824	arg1	26 mg/L					779:785	26 mg/L)	779:786	26 mg/L) of N-glycosylated β-glucosidase Glu1B	779:824	26 mg/L) of N-glycosylated β-glucosidase Glu1B.
36399934	1	30	theme	β-1,4-glycosidic	171:186	arg1	bonds					188:192	β-1,4-glycosidic bonds	171:192	β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides	171:246	β-glucosidases (E.C. 3.2.1.21) are enzymes that hydrolyze β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides, with the release of glucose.
36399934	5	31	gly	N-glycosylated	791:804	arg1	Glu1B					820:824	N-glycosylated β-glucosidase Glu1B	791:824	N-glycosylated β-glucosidase Glu1B	791:824	26 mg/L) of N-glycosylated β-glucosidase Glu1B.
36399934	3	32	theme	Coptotermes	577:587	arg1	formosanus					589:598	the termite Coptotermes formosanus	565:598	the termite Coptotermes formosanus	565:598	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	2	33	theme	low	365:367	arg1	efficiency					369:378	low efficiency	365:378	low efficiency in hydrolyzing cellobiose	365:404	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	0	34	theme	Biochemical	0:10	arg1	characterization					12:27	Biochemical characterization	0:27	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus	0:82	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	0	35	dep	Coptotermes	61:71	arg1	formosanus					73:82	Coptotermes formosanus	61:82	Coptotermes formosanus	61:82	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	0	36	theme	β-glucosidase	36:48	arg1	Glu1B					50:54	the β-glucosidase Glu1B	32:54	the β-glucosidase Glu1B from Coptotermes formosanus	32:82	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	4	37	from	36 h	663:666	arg1	flasks					699:704	shake flasks	693:704	shake flasks	693:704	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	2	38	theme	hydrolyzing	383:393	arg1	cellobiose					395:404	hydrolyzing cellobiose	383:404	hydrolyzing cellobiose	383:404	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	8	39	theme	high	1108:1111	arg1	activity					1122:1129	The high specific activity	1104:1129	The high specific activity of the recombinant β-glucosidase Glu1B	1104:1168	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	6	40	theme	optimum	877:883	arg1	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	8	41	dep	along	1296:1300	arg1	with					1302:1305	with	1302:1305	with	1302:1305	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	42	theme	sites	1382:1386	arg1	sites					1382:1386	these two sites	1372:1386	these two sites	1372:1386	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	42	theme	sites	1382:1386	arg1	residues					1360:1367	residues	1360:1367	residues of these two sites	1360:1386	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	3	43	theme	Pichia	501:506	arg1	pastoris					508:515	Pichia pastoris	501:515	Pichia pastoris strains	501:523	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	6	44	theme	5.0	872:874	arg1	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	44	theme	5.0	872:874	arg1	Ki					1019:1020	a Ki	1017:1020	a Ki for glucose of 166 mM	1017:1042	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	44	theme	5.0	872:874	arg1	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	44	theme	5.0	872:874	arg1	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	44	theme	5.0	872:874	arg1	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	10	45	theme	production	1648:1657	arg1	properties					1610:1619	its biochemical properties	1594:1619	its biochemical properties	1594:1619	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	10	45	theme	production	1648:1657	arg1	possibility					1629:1639	the possibility	1625:1639	the possibility of its production in the P. pastoris expression system	1625:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	8	46	from	residues	1215:1222	arg1	Gln455					1240:1245	Gln455	1240:1245	Gln455	1240:1245	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	46	from	residues	1215:1222	arg1	aglycone					1252:1259	aglycone	1252:1259	aglycone (Thr193 and Hys252)	1252:1279	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	46	from	residues	1215:1222	arg1	glycone					1231:1237	the glycone	1227:1237	the glycone (Gln455)	1227:1246	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	5	47	theme	β-glucosidase	806:818	arg1	Glu1B					820:824	N-glycosylated β-glucosidase Glu1B	791:824	N-glycosylated β-glucosidase Glu1B	791:824	26 mg/L) of N-glycosylated β-glucosidase Glu1B.
36399934	1	48	theme	glucose	269:275	arg1	release					258:264	the release	254:264	the release of glucose	254:275	β-glucosidases (E.C. 3.2.1.21) are enzymes that hydrolyze β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides, with the release of glucose.
36399934	8	49	theme	β-glucosidase	1150:1162	arg1	Glu1B					1164:1168	the recombinant β-glucosidase Glu1B	1134:1168	the recombinant β-glucosidase Glu1B	1134:1168	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	2	50	from	efficiency	369:378	arg1	cellobiose					395:404	hydrolyzing cellobiose	383:404	hydrolyzing cellobiose	383:404	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	10	51	from	possibility	1629:1639	arg1	system					1689:1694	the P. pastoris expression system	1662:1694	the P. pastoris expression system	1662:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	6	52	theme	optimum	858:864	arg1	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	3	53	theme	termite	569:575	arg1	formosanus					589:598	the termite Coptotermes formosanus	565:598	the termite Coptotermes formosanus	565:598	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	10	54	from	supplement	1774:1783	arg1	hydrolysis					1802:1811	the enzymatic hydrolysis	1788:1811	the enzymatic hydrolysis of cellulose	1788:1824	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	6	55	from	40 °C	928:932	arg1	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	55	from	40 °C	928:932	arg1	Ki					1019:1020	a Ki	1017:1020	a Ki for glucose of 166 mM	1017:1042	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	55	from	40 °C	928:932	arg1	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	55	from	40 °C	928:932	arg1	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	55	from	40 °C	928:932	arg1	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	10	56	theme	lignocellulosic	1850:1864	arg1	biomass					1866:1872	lignocellulosic biomass	1850:1872	lignocellulosic biomass	1850:1872	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	6	57	theme	recombinant	831:841	arg1	product					843:849	The recombinant product	827:849	The recombinant product	827:849	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	1	58	theme	non-reducing	199:210	arg1	residues					221:228	non-reducing terminal residues	199:228	non-reducing terminal residues in β-D-glucosides	199:246	β-glucosidases (E.C. 3.2.1.21) are enzymes that hydrolyze β-1,4-glycosidic bonds from non-reducing terminal residues in β-D-glucosides, with the release of glucose.
36399934	6	59	theme	protein	1004:1010	arg1	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	59	theme	protein	1004:1010	arg1	Ki					1019:1020	a Ki	1017:1020	a Ki for glucose of 166 mM	1017:1042	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	59	theme	protein	1004:1010	arg1	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	59	theme	protein	1004:1010	arg1	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	59	theme	protein	1004:1010	arg1	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	10	60	from	production	1648:1657	arg1	system					1689:1694	the P. pastoris expression system	1662:1694	the P. pastoris expression system	1662:1694	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	2	61	theme	lignocellulosic	336:350	arg1	biomass					352:358	lignocellulosic biomass	336:358	lignocellulosic biomass	336:358	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	8	62	theme	specific	1206:1213	arg1	residues					1215:1222	specific residues	1206:1222	specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites	1206:1293	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	9	63	theme	residues	1495:1502	arg1	presence					1463:1470	the presence	1459:1470	the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1459:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	4	64	theme	methanol	671:678	arg1	induction					680:688	methanol induction	671:688	methanol induction	671:688	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	3	65	theme	recombinant	637:647	arg1	enzyme					649:654	the recombinant enzyme	633:654	the recombinant enzyme	633:654	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	7	66	theme	protein	1049:1055	arg1	structure					1057:1065	The protein structure	1045:1065	The protein structure	1045:1065	The protein structure was stabilized by Mn2+ and glycerol.
36399934	6	67	theme	specific	952:959	arg1	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	9	68	dep	site	1518:1521	arg1	Ser369					1548:1553	Ser369	1548:1553	Ser369	1548:1553	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	9	68	dep	site	1518:1521	arg1	Arg451					1576:1581	Arg451	1576:1581	Arg451	1576:1581	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	9	68	dep	site	1518:1521	arg1	Gln360					1532:1537	Gln360	1532:1537	Gln360	1532:1537	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	9	68	dep	site	1518:1521	arg1	Ser370					1556:1561	Ser370	1556:1561	Ser370	1556:1561	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	9	68	dep	site	1518:1521	arg1	Leu450					1564:1569	Leu450	1564:1569	Leu450	1564:1569	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	9	68	dep	site	1518:1521	arg1	Ala368					1540:1545	Ala368	1540:1545	Ala368	1540:1545	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	3	69	from	formosanus	589:598	arg1	Glu1B					554:558	the β-glucosidase Glu1B	536:558	the β-glucosidase Glu1B from the termite Coptotermes formosanus	536:598	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	6	70	theme	166 mM	1037:1042	arg1	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	70	theme	166 mM	1037:1042	arg1	Ki					1019:1020	a Ki	1017:1020	a Ki for glucose of 166 mM	1017:1042	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	70	theme	166 mM	1037:1042	arg1	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	70	theme	166 mM	1037:1042	arg1	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	70	theme	166 mM	1037:1042	arg1	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	0	71	theme	Pichia	96:101	arg1	pastoris					103:110	Pichia pastoris	96:110	Pichia pastoris	96:110	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	9	72	theme	gatekeeper	1484:1493	arg1	residues					1495:1502	specific gatekeeper residues	1475:1502	specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1475:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	9	73	from	site	1518:1521	arg1	presence					1463:1470	the presence	1459:1470	the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1459:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	0	74	from	characterization	12:27	arg1	Coptotermes					61:71	Coptotermes	61:71	Coptotermes	61:71	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	8	75	theme	linker	1307:1312	arg1	Ile251					1332:1337	Ile251	1332:1337	Ile251	1332:1337	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	75	theme	linker	1307:1312	arg1	Phe333					1344:1349	Phe333	1344:1349	Phe333	1344:1349	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	75	theme	linker	1307:1312	arg1	Leu192					1324:1329	Leu192	1324:1329	Leu192	1324:1329	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	75	theme	linker	1307:1312	arg1	residues					1314:1321	linker residues	1307:1321	linker residues (Leu192, Ile251, and Phe333)	1307:1350	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	0	76	from	Coptotermes	61:71	arg1	Glu1B					50:54	the β-glucosidase Glu1B	32:54	the β-glucosidase Glu1B from Coptotermes formosanus	32:82	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	0	76	from	Coptotermes	61:71	arg1	characterization					12:27	Biochemical characterization	0:27	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus	0:82	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	10	77	theme	biochemical	1598:1608	arg1	properties					1610:1619	its biochemical properties	1594:1619	its biochemical properties	1594:1619	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	10	78	dep	β-glucosidase	1701:1713	arg1	described					1728:1736	described	1728:1736	described in this work	1728:1749	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	10	78	dep	β-glucosidase	1701:1713	arg1	produced					1715:1722	produced	1715:1722	produced	1715:1722	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	9	79	theme	active	1511:1516	arg1	site					1518:1521	the active site	1507:1521	the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451)	1507:1582	Moreover, the resistance to inhibition by glucose was correlated with the presence of specific gatekeeper residues in the active site (Met204, Gln360, Ala368, Ser369, Ser370, Leu450, and Arg451).
36399934	8	80	dep	aglycone	1252:1259	arg1	Thr193					1262:1267	Thr193	1262:1267	Thr193	1262:1267	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	80	dep	aglycone	1252:1259	arg1	Hys252					1273:1278	Hys252	1273:1278	Hys252	1273:1278	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	81	dep	glycone	1231:1237	arg1	sites					1289:1293	binding sites	1281:1293	binding sites	1281:1293	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	3	82	theme	β-glucosidase	540:552	arg1	Glu1B					554:558	the β-glucosidase Glu1B	536:558	the β-glucosidase Glu1B from the termite Coptotermes formosanus	536:598	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	0	83	theme	Glu1B	50:54	arg1	characterization					12:27	Biochemical characterization	0:27	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus	0:82	Biochemical characterization of the β-glucosidase Glu1B from Coptotermes formosanus produced in Pichia pastoris.
36399934	6	84	theme	50 °C	900:904	arg1	activity					961:968	specific activity	952:968	specific activity toward cellobiose of 431-597 U/mg protein	952:1010	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	84	theme	50 °C	900:904	arg1	Ki					1019:1020	a Ki	1017:1020	a Ki for glucose of 166 mM	1017:1042	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	84	theme	50 °C	900:904	arg1	activity					916:923	residual activity	907:923	residual activity at 40 °C higher than 80 %	907:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	84	theme	50 °C	900:904	arg1	temperature					885:895	optimum temperature	877:895	optimum temperature of 50 °C	877:904	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	6	84	theme	50 °C	900:904	arg1	pH					866:867	an optimum pH	855:867	an optimum pH of 5.0	855:874	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	8	85	dep	residues	1314:1321	arg1	Ile251					1332:1337	Ile251	1332:1337	Ile251	1332:1337	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	85	dep	residues	1314:1321	arg1	Phe333					1344:1349	Phe333	1344:1349	Phe333	1344:1349	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	85	dep	residues	1314:1321	arg1	Leu192					1324:1329	Leu192	1324:1329	Leu192	1324:1329	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	85	dep	residues	1314:1321	arg1	residues					1314:1321	linker residues	1307:1321	linker residues (Leu192, Ile251, and Phe333)	1307:1350	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	8	86	theme	specific	1113:1120	arg1	activity					1122:1129	The high specific activity	1104:1129	The high specific activity of the recombinant β-glucosidase Glu1B	1104:1168	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36399934	10	87	theme	enzymatic	1792:1800	arg1	hydrolysis					1802:1811	the enzymatic hydrolysis	1788:1811	the enzymatic hydrolysis of cellulose	1788:1824	Based on its biochemical properties and the possibility of its production in the P. pastoris expression system, the β-glucosidase produced and described in this work could be suitable as a supplement in the enzymatic hydrolysis of cellulose for saccharification of lignocellulosic biomass.
36399934	2	88	contain	have	360:363	arg1	β-glucosidases					278:291	β-glucosidases	278:291	β-glucosidases currently used for the saccharification of lignocellulosic biomass	278:358	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	2	88	contain	have	360:363	arg2	efficiency					369:378	low efficiency	365:378	low efficiency in hydrolyzing cellobiose	365:404	β-glucosidases currently used for the saccharification of lignocellulosic biomass have low efficiency in hydrolyzing cellobiose and are inhibited by glucose, contrary to what would be desirable.
36399934	4	89	dep	P.	711:712	arg1	pastoris					714:721	pastoris	714:721	pastoris	714:721	After 36 h of methanol induction in shake flasks, the P. pastoris KM71BGlu strain produced and secreted 4.1 U/mL (approx.
36399934	6	90	dep	activity	916:923	arg1	%					949:949	%	949:949	%	949:949	The recombinant product had an optimum pH of 5.0, optimum temperature of 50 °C, residual activity at 40 °C higher than 80 %, specific activity toward cellobiose of 431-597 U/mg protein, and a Ki for glucose of 166 mM.
36399934	3	91	theme	pastoris	508:515	arg1	strains					517:523	Pichia pastoris strains	501:523	Pichia pastoris strains	501:523	In this work, we engineered Pichia pastoris strains to produce the β-glucosidase Glu1B from the termite Coptotermes formosanus, and biochemically characterized the recombinant enzyme.
36399934	8	92	theme	recombinant	1138:1148	arg1	Glu1B					1164:1168	the recombinant β-glucosidase Glu1B	1134:1168	the recombinant β-glucosidase Glu1B	1134:1168	The high specific activity of the recombinant β-glucosidase Glu1B was correlated with the presence of specific residues in the glycone (Gln455) and aglycone (Thr193 and Hys252) binding sites, along with linker residues (Leu192, Ile251, and Phe333) between residues of these two sites.
36534501	3	0	theme	report	457:462	arg1	aim					438:440	The aim	434:440	The aim of the present report	434:462	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	9	1	theme	glycan	1385:1390	arg1	chains					1392:1397	glycan chains	1385:1397	glycan chains	1385:1397	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	10	2	theme	activity	1540:1547	arg1	inhibition					1519:1528	inhibition	1519:1528	inhibition of MMP-14 activity	1519:1547	Altogether, the results demonstrated that each SLRP exhibited inhibition of MMP-14 activity.
36534501	4	3	theme	interacting	809:819	arg1	acids					793:797	the specific amino acids	774:797	the specific amino acids of MMP-14 interacting with each of the four SLRPs	774:847	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	2	4	theme	antitumor	312:320	arg1	activity					322:329	antitumor activity	312:329	antitumor activity	312:329	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	11	5	theme	core	1649:1652	arg1	conformation					1662:1673	the core protein conformation	1645:1673	the core protein conformation	1645:1673	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	6	6	theme	number	990:995	arg1	impact					976:981	The impact	972:981	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14	972:1080	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	2	7	contain	possess	304:310	arg2	activity					322:329	antitumor activity	312:329	antitumor activity	312:329	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	7	contain	possess	304:310	arg1	Lumican					226:232	Lumican	226:232	Lumican	226:232	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	7	contain	possess	304:310	arg1	member					237:242	a member	235:242	a member of the SLRPs family	235:262	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	7	contain	possess	304:310	arg1	peptides					281:288	its derived peptides	269:288	its derived peptides	269:288	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	9	8	with	interaction	1402:1412	arg1	MMP-14					1419:1424	MMP-14	1419:1424	MMP-14	1419:1424	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	5	9	theme	inhibition	940:949	arg1	constants					927:935	the constants	923:935	the constants of inhibition (Ki)	923:954	The inhibition of each SLRP (100 nM) on MMP-14 activity was measured and the constants of inhibition (Ki) were evaluated.
36534501	3	10	theme	three-dimensional	497:513	arg1	modeling					520:527	in silico three-dimensional (3D) modeling	487:527	in silico three-dimensional (3D) modeling	487:527	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	6	11	theme	lumican	1043:1049	arg1	structures					1015:1024	structures	1015:1024	structures	1015:1024	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	6	11	theme	lumican	1043:1049	arg1	dynamics					1031:1038	dynamics	1031:1038	dynamics	1031:1038	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	6	11	theme	lumican	1043:1049	arg1	chains					1007:1012	glycan chains	1000:1012	glycan chains	1000:1012	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	0	12	dep	in	91:92	arg1	silico					94:99	silico	94:99	silico	94:99	Differential MMP-14 targeting by biglycan, decorin, fibromodulin, and lumican unraveled by in silico approach.
36534501	10	13	theme	MMP-14	1533:1538	arg1	activity					1540:1547	MMP-14 activity	1533:1547	MMP-14 activity	1533:1547	Altogether, the results demonstrated that each SLRP exhibited inhibition of MMP-14 activity.
36534501	2	14	theme	family	257:262	arg1	Lumican					226:232	Lumican	226:232	Lumican	226:232	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	14	theme	family	257:262	arg1	member					237:242	a member	235:242	a member of the SLRPs family	235:262	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	14	theme	family	257:262	arg1	peptides					281:288	its derived peptides	269:288	its derived peptides	269:288	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	3	15	dep	three-dimensional	497:513	arg1	3D					516:517	3D	516:517	3D	516:517	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	11	16	theme	MMP-14	1589:1594	arg1	related					1625:1631	related	1625:1631	related	1625:1631	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	11	16	theme	MMP-14	1589:1594	arg1	targeting					1576:1584	the differential targeting	1559:1584	the differential targeting of MMP-14 by the SLRPs	1559:1607	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	11	17	theme	differential	1563:1574	arg1	related					1625:1631	related	1625:1631	related	1625:1631	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	11	17	theme	differential	1563:1574	arg1	targeting					1576:1584	the differential targeting	1559:1584	the differential targeting of MMP-14 by the SLRPs	1559:1607	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	9	18	from	effect	1440:1445	arg1	interaction					1402:1412	interaction	1402:1412	interaction with MMP-14	1402:1424	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	2	19	theme	MMP-14	384:389	arg1	MMP-14					384:389	MMP-14	384:389	MMP-14	384:389	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	19	theme	MMP-14	384:389	arg1	domain					374:379	the catalytic domain	360:379	the catalytic domain of MMP-14 leading to the inhibition of its activity	360:431	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	20	theme	SLRPs	251:255	arg1	family					257:262	the SLRPs family	247:262	the SLRPs family	247:262	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	4	21	theme	docking	727:733	arg1	experiments					735:745	Molecular docking experiments	717:745	Molecular docking experiments	717:745	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	2	22	theme	catalytic	364:372	arg1	MMP-14					384:389	MMP-14	384:389	MMP-14	384:389	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	2	22	theme	catalytic	364:372	arg1	domain					374:379	the catalytic domain	360:379	the catalytic domain of MMP-14 leading to the inhibition of its activity	360:431	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	0	23	theme	in	91:92	arg1	approach					101:108	in silico approach	91:108	in silico approach	91:108	Differential MMP-14 targeting by biglycan, decorin, fibromodulin, and lumican unraveled by in silico approach.
36534501	4	24	theme	amino	787:791	arg1	acids					793:797	the specific amino acids	774:797	the specific amino acids of MMP-14 interacting with each of the four SLRPs	774:847	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	3	25	theme	in	487:488	arg1	modeling					520:527	in silico three-dimensional (3D) modeling	487:527	in silico three-dimensional (3D) modeling	487:527	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	1	26	theme	major	156:160	arg1	regulators					162:171	major regulators	156:171	major regulators of extracellular matrix assembly and cell signaling	156:223	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	26	theme	major	156:160	arg1	proteoglycans					130:142	Small leucine-rich proteoglycans	111:142	Small leucine-rich proteoglycans (SLRPs)	111:150	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	0	27	theme	MMP-14	13:18	arg1	targeting					20:28	Differential MMP-14 targeting	0:28	Differential MMP-14 targeting by biglycan, decorin, fibromodulin, and lumican	0:76	Differential MMP-14 targeting by biglycan, decorin, fibromodulin, and lumican unraveled by in silico approach.
36534501	6	28	with	interaction	1058:1068	arg1	MMP-14					1075:1080	MMP-14	1075:1080	MMP-14	1075:1080	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	4	29	theme	MMP-14	802:807	arg1	interacting					809:819	MMP-14 interacting	802:819	MMP-14 interacting with each of the four SLRPs	802:847	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	5	30	theme	SLRP	873:876	arg1	inhibition					854:863	The inhibition	850:863	The inhibition of each SLRP (100 nM) on MMP-14 activity	850:904	The inhibition of each SLRP (100 nM) on MMP-14 activity was measured and the constants of inhibition (Ki) were evaluated.
36534501	6	31	from	impact	976:981	arg1	interaction					1058:1068	the interaction	1054:1068	the interaction with MMP-14	1054:1080	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	0	32	theme	Differential	0:11	arg1	targeting					20:28	Differential MMP-14 targeting	0:28	Differential MMP-14 targeting by biglycan, decorin, fibromodulin, and lumican	0:76	Differential MMP-14 targeting by biglycan, decorin, fibromodulin, and lumican unraveled by in silico approach.
36534501	9	33	theme	SLRPs	1450:1454	arg1	effect					1440:1445	shielding effect	1430:1445	shielding effect of SLRPs	1430:1454	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	9	33	theme	SLRPs	1450:1454	arg1	role					1377:1380	the role	1373:1380	the role of glycan chains in interaction with MMP-14	1373:1424	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	9	34	from	role	1377:1380	arg1	interaction					1402:1412	interaction	1402:1412	interaction with MMP-14	1402:1424	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	2	35	theme	derived	273:279	arg1	peptides					281:288	its derived peptides	269:288	its derived peptides	269:288	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	5	36	theme	each	868:871	arg1	SLRP					873:876	each SLRP	868:876	each SLRP (100 nM)	868:885	The inhibition of each SLRP (100 nM) on MMP-14 activity was measured and the constants of inhibition (Ki) were evaluated.
36534501	5	36	theme	each	868:871	arg1	nM					883:884	100 nM	879:884	100 nM	879:884	The inhibition of each SLRP (100 nM) on MMP-14 activity was measured and the constants of inhibition (Ki) were evaluated.
36534501	6	37	theme	dynamics	1031:1038	arg1	number					990:995	the number	986:995	the number of glycan chains, structures, and dynamics of lumican	986:1049	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	5	38	from	inhibition	854:863	arg1	activity					897:904	MMP-14 activity	890:904	MMP-14 activity	890:904	The inhibition of each SLRP (100 nM) on MMP-14 activity was measured and the constants of inhibition (Ki) were evaluated.
36534501	1	39	theme	extracellular	176:188	arg1	assembly					197:204	extracellular matrix assembly	176:204	extracellular matrix assembly	176:204	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	6	40	theme	chains	1007:1012	arg1	number					990:995	the number	986:995	the number of glycan chains, structures, and dynamics of lumican	986:1049	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	11	41	theme	protein	1654:1660	arg1	conformation					1662:1673	the core protein conformation	1645:1673	the core protein conformation	1645:1673	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	4	42	theme	Molecular	717:725	arg1	experiments					735:745	Molecular docking experiments	717:745	Molecular docking experiments	717:745	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	3	43	theme	core	590:593	arg1	protein					595:601	their core protein	584:601	their core protein	584:601	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	7	44	theme	docking	1140:1146	arg1	analysis					1148:1155	Molecular docking analysis	1130:1155	Molecular docking analysis	1130:1155	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	1	45	theme	matrix	190:195	arg1	assembly					197:204	extracellular matrix assembly	176:204	extracellular matrix assembly	176:204	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	3	46	dep	in	487:488	arg1	silico					490:495	silico	490:495	silico	490:495	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	6	47	theme	dynamics	1108:1115	arg1	simulations					1117:1127	molecular dynamics simulations	1098:1127	molecular dynamics simulations	1098:1127	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	6	48	theme	structures	1015:1024	arg1	number					990:995	the number	986:995	the number of glycan chains, structures, and dynamics of lumican	986:1049	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	7	49	theme	domain	1264:1269	arg1	regions					1239:1245	different regions	1229:1245	different regions of the catalytic domain of MMP-14	1229:1279	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	4	50	with	interacting	809:819	arg1	SLRPs					843:847	the four SLRPs	834:847	the four SLRPs	834:847	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	4	50	with	interacting	809:819	arg1	each					826:829	each	826:829	each	826:829	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	1	51	theme	assembly	197:204	arg1	regulators					162:171	major regulators	156:171	major regulators of extracellular matrix assembly and cell signaling	156:223	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	51	theme	assembly	197:204	arg1	proteoglycans					130:142	Small leucine-rich proteoglycans	111:142	Small leucine-rich proteoglycans (SLRPs)	111:150	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	3	52	dep	capacity	660:667	arg1	regulate					694:701	regulate	694:701	to regulate its activity	691:714	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	3	52	dep	capacity	660:667	arg1	bind					672:675	bind	672:675	to bind to MMP-14	669:685	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	7	53	theme	catalytic	1254:1262	arg1	MMP-14					1274:1279	MMP-14	1274:1279	MMP-14	1274:1279	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	7	53	theme	catalytic	1254:1262	arg1	domain					1264:1269	the catalytic domain	1250:1269	the catalytic domain of MMP-14	1250:1279	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	2	54	theme	activity	424:431	arg1	inhibition					406:415	the inhibition	402:415	the inhibition of its activity	402:431	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	11	55	theme	glycan	1691:1696	arg1	structures					1704:1713	the glycan chain structures	1687:1713	the glycan chain structures	1687:1713	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36534501	4	56	theme	specific	778:785	arg1	acids					793:797	the specific amino acids	774:797	the specific amino acids of MMP-14 interacting with each of the four SLRPs	774:847	Molecular docking experiments were performed to identify the specific amino acids of MMP-14 interacting with each of the four SLRPs.
36534501	9	57	theme	chains	1392:1397	arg1	effect					1440:1445	shielding effect	1430:1445	shielding effect of SLRPs	1430:1454	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	9	57	theme	chains	1392:1397	arg1	role					1377:1380	the role	1373:1380	the role of glycan chains in interaction with MMP-14	1373:1424	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	3	58	theme	specific	613:620	arg1	chains					637:642	their specific polysaccharide chains	607:642	their specific polysaccharide chains	607:642	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	6	59	theme	molecular	1098:1106	arg1	simulations					1117:1127	molecular dynamics simulations	1098:1127	molecular dynamics simulations	1098:1127	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	3	60	theme	present	449:455	arg1	report					457:462	the present report	445:462	the present report	445:462	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	2	61	link	derived	273:279	arg1	peptides					281:288	its derived peptides	269:288	its derived peptides	269:288	Lumican, a member of the SLRPs family, and its derived peptides were shown to possess antitumor activity by interacting directly with the catalytic domain of MMP-14 leading to the inhibition of its activity.
36534501	3	62	theme	polysaccharide	622:635	arg1	chains					637:642	their specific polysaccharide chains	607:642	their specific polysaccharide chains	607:642	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	1	63	theme	Small	111:115	arg1	regulators					162:171	major regulators	156:171	major regulators of extracellular matrix assembly and cell signaling	156:223	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	63	theme	Small	111:115	arg1	SLRPs					145:149	SLRPs	145:149	SLRPs	145:149	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	63	theme	Small	111:115	arg1	proteoglycans					130:142	Small leucine-rich proteoglycans	111:142	Small leucine-rich proteoglycans (SLRPs)	111:150	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	7	64	theme	MMP-14	1274:1279	arg1	MMP-14					1274:1279	MMP-14	1274:1279	MMP-14	1274:1279	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	7	64	theme	MMP-14	1274:1279	arg1	domain					1264:1269	the catalytic domain	1250:1269	the catalytic domain of MMP-14	1250:1279	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	1	65	theme	cell	210:213	arg1	signaling					215:223	cell signaling	210:223	cell signaling	210:223	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	3	66	theme	SLRPs	568:572	arg1	structure					533:541	structure	533:541	structure	533:541	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	3	66	theme	SLRPs	568:572	arg1	dynamics					551:558	the dynamics	547:558	the dynamics	547:558	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	1	67	theme	leucine-rich	117:128	arg1	regulators					162:171	major regulators	156:171	major regulators of extracellular matrix assembly and cell signaling	156:223	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	67	theme	leucine-rich	117:128	arg1	SLRPs					145:149	SLRPs	145:149	SLRPs	145:149	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	67	theme	leucine-rich	117:128	arg1	proteoglycans					130:142	Small leucine-rich proteoglycans	111:142	Small leucine-rich proteoglycans (SLRPs)	111:150	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	7	68	theme	concave	1208:1214	arg1	face					1216:1219	their concave face	1202:1219	their concave face	1202:1219	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	1	69	theme	signaling	215:223	arg1	regulators					162:171	major regulators	156:171	major regulators of extracellular matrix assembly and cell signaling	156:223	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	1	69	theme	signaling	215:223	arg1	proteoglycans					130:142	Small leucine-rich proteoglycans	111:142	Small leucine-rich proteoglycans (SLRPs)	111:150	Small leucine-rich proteoglycans (SLRPs) are major regulators of extracellular matrix assembly and cell signaling.
36534501	5	70	theme	MMP-14	890:895	arg1	activity					897:904	MMP-14 activity	890:904	MMP-14 activity	890:904	The inhibition of each SLRP (100 nM) on MMP-14 activity was measured and the constants of inhibition (Ki) were evaluated.
36534501	8	71	theme	MMP-14	1321:1326	arg1	activity					1328:1335	the MMP-14 activity	1317:1335	the MMP-14 activity	1317:1335	Each SLRPs inhibited significantly the MMP-14 activity.
36534501	9	72	theme	molecular	1347:1355	arg1	dynamics					1357:1364	molecular dynamics	1347:1364	molecular dynamics	1347:1364	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	6	73	theme	glycan	1000:1005	arg1	chains					1007:1012	glycan chains	1000:1012	glycan chains	1000:1012	The impact of the number of glycan chains, structures, and dynamics of lumican on the interaction with MMP-14 was assessed by molecular dynamics simulations.
36534501	3	74	dep	structure	533:541	arg1	the					529:531	the	529:531	the	529:531	The aim of the present report was to characterize by in silico three-dimensional (3D) modeling the structure and the dynamics of four SLRPs including their core protein and their specific polysaccharide chains to assess their capacity to bind to MMP-14 and to regulate its activity.
36534501	9	75	theme	shielding	1430:1438	arg1	effect					1440:1445	shielding effect	1430:1445	shielding effect of SLRPs	1430:1454	Finally, molecular dynamics showed the role of glycan chains in interaction with MMP-14 and shielding effect of SLRPs.
36534501	7	76	theme	different	1229:1237	arg1	regions					1239:1245	different regions	1229:1245	different regions of the catalytic domain of MMP-14	1229:1279	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	7	77	theme	Molecular	1130:1138	arg1	analysis					1148:1155	Molecular docking analysis	1130:1155	Molecular docking analysis	1130:1155	Molecular docking analysis showed that all SLRPs bind to MMP-14 through their concave face, but in different regions of the catalytic domain of MMP-14.
36534501	11	78	theme	chain	1698:1702	arg1	structures					1704:1713	the glycan chain structures	1687:1713	the glycan chain structures	1687:1713	However, the differential targeting of MMP-14 by the SLRPs was shown to be related not only to the core protein conformation but also to the glycan chain structures and dynamics.
36289103	8	0	theme	similar	1191:1197	arg1	levels					1199:1204	similar levels	1191:1204	similar levels of α2-6 and α2-3 sialylated N-glycans	1191:1242	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	4	1	theme	HNSCC-specific	584:597	arg1	glycome					599:605	HNSCC-specific glycome	584:605	HNSCC-specific glycome	584:605	Nevertheless, HNSCC-specific glycome is to date largely unknown.
36289103	12	2	contain	carrying	1688:1695	arg2	residues					1709:1716	core-fucose residues	1697:1716	core-fucose residues	1697:1716	Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry.
36289103	12	2	contain	carrying	1688:1695	arg1	N-glycans					1678:1686	oligomannose N-glycans	1665:1686	oligomannose N-glycans carrying core-fucose residues	1665:1716	Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry.
36289103	6	3	theme	Oligomannose-type	860:876	arg1	N-glycans					878:886	Oligomannose-type N-glycans	860:886	Oligomannose-type N-glycans	860:886	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	3	theme	Oligomannose-type	860:876	arg1	features					909:916	the predominant features	893:916	the predominant features	893:916	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	5	4	theme	HNSCC	669:673	arg1	lines					680:684	six established HNSCC cell lines	653:684	six established HNSCC cell lines	653:684	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	10	5	theme	fucose-type	1445:1455	arg1	N-glycans					1457:1465	Almost all fucose-type N-glycans	1434:1465	Almost all fucose-type N-glycans	1434:1465	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	3	6	theme	as	546:547	arg1	targets					561:567	as therapeutic targets	546:567	as therapeutic targets	546:567	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	6	theme	as	546:547	arg1	promise					494:500	promise	494:500	promise	494:500	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	1	7	theme	squamous	274:281	arg1	HNSCC					299:303	HNSCC	299:303	HNSCC	299:303	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	7	theme	squamous	274:281	arg1	carcinoma					288:296	squamous cell carcinoma	274:296	squamous cell carcinoma (HNSCC)	274:304	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	8	8	theme	sialylated	1223:1232	arg1	N-glycans					1234:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	6	9	theme	cell	931:934	arg1	%					959:959	57.5-70%	952:959	57.5-70%	952:959	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	9	theme	cell	931:934	arg1	lines					936:940	all HNSCC cell lines	921:940	all HNSCC cell lines analysed (57.5-70%)	921:960	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	10	from	features	909:916	arg1	%					959:959	57.5-70%	952:959	57.5-70%	952:959	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	10	from	features	909:916	arg1	lines					936:940	all HNSCC cell lines	921:940	all HNSCC cell lines analysed (57.5-70%)	921:960	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	1	11	theme	cell	185:188	arg1	surfaces					190:197	cell surfaces	185:197	cell surfaces	185:197	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	13	12	theme	glycosylation	1854:1866	arg1	features					1868:1875	diverse and specific glycosylation features	1833:1875	diverse and specific glycosylation features	1833:1875	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	5	13	theme	qualitative	701:711	arg1	N-glycome					735:743	the qualitative and semi-quantitative N-glycome	697:743	the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry	697:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	12	14	theme	oligomannose	1665:1676	arg1	N-glycans					1678:1686	oligomannose N-glycans	1665:1686	oligomannose N-glycans carrying core-fucose residues	1665:1716	Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry.
36289103	5	15	theme	semi-quantitative	717:733	arg1	N-glycome					735:743	the qualitative and semi-quantitative N-glycome	697:743	the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry	697:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	9	16	theme	cell	1299:1302	arg1	lines					1304:1308	HPV-positive cell lines	1286:1308	HPV-positive cell lines	1286:1308	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	1	17	from	surfaces	190:197	arg1	changes					174:180	glycosylation changes	160:180	glycosylation changes at cell surfaces	160:197	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	18	theme	common	104:109	arg1	Glycosylation					78:90	Glycosylation	78:90	Glycosylation	78:90	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	18	theme	common	104:109	arg1	modification					130:141	the most common post-translational modification	95:141	the most common post-translational modification of proteins	95:153	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	5	19	theme	liquid	777:782	arg1	chromatography					784:797	porous graphitized carbon liquid chromatography	751:797	porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry	751:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	7	20	theme	line-dependent	1023:1036	arg1	differences					1038:1048	considerable cell line-dependent differences	1005:1048	considerable cell line-dependent differences ranging from 24 to 35%	1005:1071	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	1	21	theme	proteins	146:153	arg1	Glycosylation					78:90	Glycosylation	78:90	Glycosylation	78:90	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	21	theme	proteins	146:153	arg1	modification					130:141	the most common post-translational modification	95:141	the most common post-translational modification of proteins	95:153	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	8	22	theme	most	1141:1144	arg1	lines					1157:1161	most HNSCC cell lines	1141:1161	most HNSCC cell lines	1141:1161	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	8	23	from	dominant	1125:1132	arg1	cells					1179:1183	SCC-9 cells	1173:1183	SCC-9 cells	1173:1183	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	8	24	gly	sialylated	1099:1108	arg1	N-glycans					1110:1118	α2-6 linked sialylated N-glycans	1087:1118	α2-6 linked sialylated N-glycans	1087:1118	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	9	25	theme	phosphorylated	1337:1350	arg1	N-glycans					1365:1373	phosphorylated oligomannose N-glycans	1337:1373	phosphorylated oligomannose N-glycans	1337:1373	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	7	26	theme	considerable	1005:1016	arg1	differences					1038:1048	considerable cell line-dependent differences	1005:1048	considerable cell line-dependent differences ranging from 24 to 35%	1005:1071	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	13	27	theme	systematic	1788:1797	arg1	mapping					1799:1805	This first systematic mapping	1777:1805	This first systematic mapping of the N-glycome	1777:1822	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	9	28	theme	N-glycans	1365:1373	arg1	levels					1327:1332	higher levels	1320:1332	higher levels	1320:1332	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	7	29	theme	N-glycans	988:996	arg1	levels					967:972	The levels	963:972	The levels of sialylated N-glycans	963:996	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	10	30	theme	Lewis-type	1529:1538	arg1	fucosylation					1540:1551	Lewis-type fucosylation	1529:1551	Lewis-type fucosylation identified	1529:1562	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	5	31	theme	graphitized	758:768	arg1	chromatography					784:797	porous graphitized carbon liquid chromatography	751:797	porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry	751:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	8	32	theme	linked	1092:1097	arg1	N-glycans					1110:1118	α2-6 linked sialylated N-glycans	1087:1118	α2-6 linked sialylated N-glycans	1087:1118	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	13	33	theme	diagnostic	1956:1965	arg1	relevance					1967:1975	their possible diagnostic relevance	1941:1975	their possible diagnostic relevance	1941:1975	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	0	34	theme	Head	0:3	arg1	traits					31:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	0	34	theme	Head	0:3	arg1	line					47:50	cell line	42:50	cell line	42:50	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	1	35	theme	cell	283:286	arg1	HNSCC					299:303	HNSCC	299:303	HNSCC	299:303	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	35	theme	cell	283:286	arg1	carcinoma					288:296	squamous cell carcinoma	274:296	squamous cell carcinoma (HNSCC)	274:304	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	12	36	theme	core-fucose	1697:1707	arg1	residues					1709:1716	core-fucose residues	1697:1716	core-fucose residues	1697:1716	Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry.
36289103	2	37	theme	late	404:407	arg1	diagnosis					409:417	late diagnosis	404:417	late diagnosis	404:417	In HNSCC, 5-year survival remains poor, averaging around 50% globally: this is partly related to late diagnosis.
36289103	5	38	theme	ionisation	823:832	arg1	spectrometry					846:857	electrospray ionisation tandem mass spectrometry	810:857	electrospray ionisation tandem mass spectrometry	810:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	3	39	theme	glycosylation	437:449	arg1	signatures					451:460	Specific protein glycosylation signatures	420:460	Specific protein glycosylation signatures on malignant keratinocytes	420:487	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	0	40	theme	neck	9:12	arg1	traits					31:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	0	40	theme	neck	9:12	arg1	line					47:50	cell line	42:50	cell line	42:50	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	6	41	theme	HNSCC	925:929	arg1	%					959:959	57.5-70%	952:959	57.5-70%	952:959	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	41	theme	HNSCC	925:929	arg1	lines					936:940	all HNSCC cell lines	921:940	all HNSCC cell lines analysed (57.5-70%)	921:960	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	0	42	dep	line	47:50	arg1	status-dependent					60:75	status-dependent	60:75	status-dependent	60:75	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	3	43	theme	Specific	420:427	arg1	signatures					451:460	Specific protein glycosylation signatures	420:460	Specific protein glycosylation signatures on malignant keratinocytes	420:487	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	0	44	theme	N-glycome	21:29	arg1	traits					31:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	0	44	theme	N-glycome	21:29	arg1	line					47:50	cell line	42:50	cell line	42:50	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	9	45	theme	lysosomal	1414:1422	arg1	pathways					1424:1431	lysosomal pathways	1414:1431	lysosomal pathways	1414:1431	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	5	46	theme	electrospray	810:821	arg1	spectrometry					846:857	electrospray ionisation tandem mass spectrometry	810:857	electrospray ionisation tandem mass spectrometry	810:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	8	47	from	cells	1179:1183	arg1	dominant					1125:1132	dominant	1125:1132	dominant	1125:1132	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	5	48	theme	tandem	834:839	arg1	spectrometry					846:857	electrospray ionisation tandem mass spectrometry	810:857	electrospray ionisation tandem mass spectrometry	810:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	8	49	theme	cell	1152:1155	arg1	lines					1157:1161	most HNSCC cell lines	1141:1161	most HNSCC cell lines	1141:1161	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	6	50	theme	predominant	897:907	arg1	N-glycans					878:886	Oligomannose-type N-glycans	860:886	Oligomannose-type N-glycans	860:886	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	50	theme	predominant	897:907	arg1	features					909:916	the predominant features	893:916	the predominant features	893:916	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	3	51	from	signatures	451:460	arg1	keratinocytes					475:487	malignant keratinocytes	465:487	malignant keratinocytes	465:487	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	2	52	theme	5-year	317:322	arg1	survival					324:331	5-year survival	317:331	5-year survival	317:331	In HNSCC, 5-year survival remains poor, averaging around 50% globally: this is partly related to late diagnosis.
36289103	12	53	theme	mass	1758:1761	arg1	spectrometry					1763:1774	tandem mass spectrometry	1751:1774	tandem mass spectrometry	1751:1774	Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry.
36289103	3	54	theme	diagnostic	505:514	arg1	biomarkers					531:540	diagnostic and prognostic biomarkers	505:540	diagnostic and prognostic biomarkers	505:540	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	54	theme	diagnostic	505:514	arg1	promise					494:500	promise	494:500	promise	494:500	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	13	55	theme	possible	1947:1954	arg1	relevance					1967:1975	their possible diagnostic relevance	1941:1975	their possible diagnostic relevance	1941:1975	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	8	56	theme	SCC-9	1173:1177	arg1	cells					1179:1183	SCC-9 cells	1173:1183	SCC-9 cells	1173:1183	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	6	57	dep	analysed	942:949	arg1	%					959:959	57.5-70%	952:959	57.5-70%	952:959	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	6	57	dep	analysed	942:949	arg1	lines					936:940	all HNSCC cell lines	921:940	all HNSCC cell lines analysed (57.5-70%)	921:960	Oligomannose-type N-glycans were the predominant features in all HNSCC cell lines analysed (57.5-70%).
36289103	5	58	theme	established	657:667	arg1	lines					680:684	six established HNSCC cell lines	653:684	six established HNSCC cell lines	653:684	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	8	59	gly	sialylated	1223:1232	arg1	N-glycans					1234:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	8	60	link	linked	1092:1097	arg1	N-glycans					1110:1118	α2-6 linked sialylated N-glycans	1087:1118	α2-6 linked sialylated N-glycans	1087:1118	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	9	61	contain	contained	1310:1318	arg1	lines					1304:1308	HPV-positive cell lines	1286:1308	HPV-positive cell lines	1286:1308	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	9	61	contain	contained	1310:1318	arg2	levels					1327:1332	higher levels	1320:1332	higher levels	1320:1332	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	3	62	theme	prognostic	520:529	arg1	biomarkers					531:540	diagnostic and prognostic biomarkers	505:540	diagnostic and prognostic biomarkers	505:540	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	62	theme	prognostic	520:529	arg1	promise					494:500	promise	494:500	promise	494:500	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	1	63	theme	glycosylation	160:172	arg1	changes					174:180	glycosylation changes	160:180	glycosylation changes at cell surfaces	160:197	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	8	64	theme	α2-6	1209:1212	arg1	N-glycans					1234:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	13	65	theme	diverse	1833:1839	arg1	features					1868:1875	diverse and specific glycosylation features	1833:1875	diverse and specific glycosylation features	1833:1875	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	11	66	theme	low	1630:1632	arg1	levels					1634:1639	low levels	1630:1639	low levels	1630:1639	We also observed paucimannose-type N-glycans (2-5.5%), though in low levels.
36289103	8	67	theme	α2-3	1218:1221	arg1	N-glycans					1234:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	α2-6 and α2-3 sialylated N-glycans	1209:1242	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	13	68	theme	specific	1845:1852	arg1	features					1868:1875	diverse and specific glycosylation features	1833:1875	diverse and specific glycosylation features	1833:1875	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	10	69	theme	core-fucose	1475:1485	arg1	residues					1487:1494	core-fucose residues	1475:1494	core-fucose residues	1475:1494	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	3	70	theme	therapeutic	549:559	arg1	targets					561:567	as therapeutic targets	546:567	as therapeutic targets	546:567	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	70	theme	therapeutic	549:559	arg1	promise					494:500	promise	494:500	promise	494:500	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	8	71	theme	N-glycans	1234:1242	arg1	levels					1199:1204	similar levels	1191:1204	similar levels of α2-6 and α2-3 sialylated N-glycans	1191:1242	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	13	72	theme	N-glycome	1814:1822	arg1	mapping					1799:1805	This first systematic mapping	1777:1805	This first systematic mapping of the N-glycome	1777:1822	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	5	73	theme	cell	675:678	arg1	lines					680:684	six established HNSCC cell lines	653:684	six established HNSCC cell lines	653:684	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	9	74	theme	HPV-positive	1286:1297	arg1	lines					1304:1308	HPV-positive cell lines	1286:1308	HPV-positive cell lines	1286:1308	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	1	75	theme	post-translational	111:128	arg1	Glycosylation					78:90	Glycosylation	78:90	Glycosylation	78:90	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	75	theme	post-translational	111:128	arg1	modification					130:141	the most common post-translational modification	95:141	the most common post-translational modification of proteins	95:153	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	76	dep	head	260:263	arg1	HNSCC					299:303	HNSCC	299:303	HNSCC	299:303	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	1	76	dep	head	260:263	arg1	carcinoma					288:296	squamous cell carcinoma	274:296	squamous cell carcinoma (HNSCC)	274:304	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	5	77	theme	carbon	770:775	arg1	chromatography					784:797	porous graphitized carbon liquid chromatography	751:797	porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry	751:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	9	78	theme	higher	1320:1325	arg1	levels					1327:1332	higher levels	1320:1332	higher levels	1320:1332	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	11	79	theme	paucimannose-type	1582:1598	arg1	%					1616:1616	2-5.5%	1611:1616	2-5.5%	1611:1616	We also observed paucimannose-type N-glycans (2-5.5%), though in low levels.
36289103	11	79	theme	paucimannose-type	1582:1598	arg1	N-glycans					1600:1608	paucimannose-type N-glycans	1582:1608	paucimannose-type N-glycans (2-5.5%)	1582:1617	We also observed paucimannose-type N-glycans (2-5.5%), though in low levels.
36289103	12	80	theme	tandem	1751:1756	arg1	spectrometry					1763:1774	tandem mass spectrometry	1751:1774	tandem mass spectrometry	1751:1774	Finally, we identified oligomannose N-glycans carrying core-fucose residues and confirmed their structure by tandem mass spectrometry.
36289103	13	81	theme	first	1782:1786	arg1	mapping					1799:1805	This first systematic mapping	1777:1805	This first systematic mapping of the N-glycome	1777:1822	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	9	82	theme	oligomannose	1352:1363	arg1	N-glycans					1365:1373	phosphorylated oligomannose N-glycans	1337:1373	phosphorylated oligomannose N-glycans	1337:1373	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	8	83	theme	α2-6	1087:1090	arg1	N-glycans					1110:1118	α2-6 linked sialylated N-glycans	1087:1118	α2-6 linked sialylated N-glycans	1087:1118	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	7	84	theme	cell	1018:1021	arg1	differences					1038:1048	considerable cell line-dependent differences	1005:1048	considerable cell line-dependent differences ranging from 24 to 35%	1005:1071	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	10	85	theme	minor	1506:1510	arg1	levels					1512:1517	just minor levels	1501:1517	just minor levels (< 4%) of Lewis-type fucosylation identified	1501:1562	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	10	85	theme	minor	1506:1510	arg1	%					1523:1523	< 4%	1520:1523	< 4%	1520:1523	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	5	86	theme	porous	751:756	arg1	chromatography					784:797	porous graphitized carbon liquid chromatography	751:797	porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry	751:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	8	87	theme	sialylated	1099:1108	arg1	N-glycans					1110:1118	α2-6 linked sialylated N-glycans	1087:1118	α2-6 linked sialylated N-glycans	1087:1118	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	3	88	contain	have	489:492	arg2	targets					561:567	as therapeutic targets	546:567	as therapeutic targets	546:567	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	88	contain	have	489:492	arg2	promise					494:500	promise	494:500	promise	494:500	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	88	contain	have	489:492	arg2	biomarkers					531:540	diagnostic and prognostic biomarkers	505:540	diagnostic and prognostic biomarkers	505:540	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	3	88	contain	have	489:492	arg1	signatures					451:460	Specific protein glycosylation signatures	420:460	Specific protein glycosylation signatures on malignant keratinocytes	420:487	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	7	89	dep	35	1069:1070	arg1	to					1066:1067	to	1066:1067	to	1066:1067	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	5	90	theme	mass	841:844	arg1	spectrometry					846:857	electrospray ionisation tandem mass spectrometry	810:857	electrospray ionisation tandem mass spectrometry	810:857	Herein, we tested six established HNSCC cell lines to capture the qualitative and semi-quantitative N-glycome using porous graphitized carbon liquid chromatography coupled to electrospray ionisation tandem mass spectrometry.
36289103	7	91	theme	sialylated	977:986	arg1	N-glycans					988:996	sialylated N-glycans	977:996	sialylated N-glycans	977:996	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	13	92	theme	further	1906:1912	arg1	studies					1914:1920	further studies	1906:1920	further studies aimed at assessing their possible diagnostic relevance	1906:1975	This first systematic mapping of the N-glycome revealed diverse and specific glycosylation features in HNSCC, paving the way for further studies aimed at assessing their possible diagnostic relevance.
36289103	0	93	theme	cancer	14:19	arg1	traits					31:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	0	93	theme	cancer	14:19	arg1	line					47:50	cell line	42:50	cell line	42:50	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	8	94	theme	HNSCC	1146:1150	arg1	lines					1157:1161	most HNSCC cell lines	1141:1161	most HNSCC cell lines	1141:1161	Importantly, α2-6 linked sialylated N-glycans were dominant across most HNSCC cell lines except in SCC-9 cells where similar levels of α2-6 and α2-3 sialylated N-glycans were observed.
36289103	10	95	theme	fucosylation	1540:1551	arg1	levels					1512:1517	just minor levels	1501:1517	just minor levels (< 4%) of Lewis-type fucosylation identified	1501:1562	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	10	95	theme	fucosylation	1540:1551	arg1	%					1523:1523	< 4%	1520:1523	< 4%	1520:1523	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	3	96	theme	protein	429:435	arg1	signatures					451:460	Specific protein glycosylation signatures	420:460	Specific protein glycosylation signatures on malignant keratinocytes	420:487	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	0	97	theme	cell	42:45	arg1	traits					31:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits	0:36	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	0	97	theme	cell	42:45	arg1	line					47:50	cell line	42:50	cell line	42:50	Head and neck cancer N-glycome traits are cell line and HPV status-dependent.
36289103	9	98	theme	pathways	1424:1431	arg1	upregulation					1398:1409	an upregulation	1395:1409	an upregulation of lysosomal pathways	1395:1431	Furthermore, we found that HPV-positive cell lines contained higher levels of phosphorylated oligomannose N-glycans, which hint towards an upregulation of lysosomal pathways.
36289103	7	99	gly	sialylated	977:986	arg1	N-glycans					988:996	sialylated N-glycans	977:996	sialylated N-glycans	977:996	The levels of sialylated N-glycans showed considerable cell line-dependent differences ranging from 24 to 35%.
36289103	3	100	theme	malignant	465:473	arg1	keratinocytes					475:487	malignant keratinocytes	465:487	malignant keratinocytes	465:487	Specific protein glycosylation signatures on malignant keratinocytes have promise as diagnostic and prognostic biomarkers and as therapeutic targets.
36289103	1	101	theme	malignant	230:238	arg1	epithelia					240:248	malignant epithelia	230:248	malignant epithelia including head and neck squamous cell carcinoma (HNSCC)	230:304	Glycosylation is the most common post-translational modification of proteins, and glycosylation changes at cell surfaces are frequently associated with malignant epithelia including head and neck squamous cell carcinoma (HNSCC).
36289103	10	102	contain	carried	1467:1473	arg1	N-glycans					1457:1465	Almost all fucose-type N-glycans	1434:1465	Almost all fucose-type N-glycans	1434:1465	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36289103	10	102	contain	carried	1467:1473	arg2	residues					1487:1494	core-fucose residues	1475:1494	core-fucose residues	1475:1494	Almost all fucose-type N-glycans carried core-fucose residues with just minor levels (< 4%) of Lewis-type fucosylation identified.
36856664	5	0	theme	glycans	906:912	arg1	labeling					857:864	metabolic labeling	847:864	metabolic labeling	847:864	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	5	0	theme	glycans	906:912	arg1	detection					870:878	detection	870:878	detection	870:878	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	7	1	theme	inositol	1154:1161	arg1	analogues					1171:1179	synthetic azido inositol (InoAz) analogues	1138:1179	synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria	1138:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	9	2	with	combination	1437:1447	arg1	chemistry					1468:1476	bioorthogonal chemistry	1454:1476	bioorthogonal chemistry	1454:1476	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	7	3	theme	intact	1241:1246	arg1	mycobacteria					1248:1259	intact mycobacteria	1241:1259	intact mycobacteria	1241:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	9	4	from	biosynthesis	1543:1554	arg1	organisms					1606:1614	diverse mycobacterial organisms	1584:1614	diverse mycobacterial organisms	1584:1614	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	7	5	theme	azido	1148:1152	arg1	analogues					1171:1179	synthetic azido inositol (InoAz) analogues	1138:1179	synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria	1138:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	7	6	from	LAM	1234:1236	arg1	mycobacteria					1248:1259	intact mycobacteria	1241:1259	intact mycobacteria	1241:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	9	7	theme	bioorthogonal	1454:1466	arg1	chemistry					1468:1476	bioorthogonal chemistry	1454:1476	bioorthogonal chemistry	1454:1476	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	2	8	theme	envelope	365:372	arg1	composition					310:320	composition	310:320	composition	310:320	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	2	8	theme	envelope	365:372	arg1	Central					274:280	Central	274:280	Central	274:280	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	2	8	theme	envelope	365:372	arg1	organization					326:337	organization	326:337	organization	326:337	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	9	9	theme	InoAz	1420:1424	arg1	probes					1426:1431	InoAz probes	1420:1431	InoAz probes	1420:1431	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	9	10	theme	PIM	1526:1528	arg1	biosynthesis					1543:1554	PIM, LM, and LAM biosynthesis	1526:1554	PIM, LM, and LAM biosynthesis	1526:1554	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	7	11	theme	synthetic	1138:1146	arg1	analogues					1171:1179	synthetic azido inositol (InoAz) analogues	1138:1179	synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria	1138:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	9	12	theme	diverse	1584:1590	arg1	organisms					1606:1614	diverse mycobacterial organisms	1584:1614	diverse mycobacterial organisms	1584:1614	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	3	13	theme	phosphatidylinositol	564:583	arg1	PIM					596:598	PIM	596:598	PIM	596:598	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	13	theme	phosphatidylinositol	564:583	arg1	mannoside					585:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside	517:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM)	517:599	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	9	14	theme	LAM	1539:1541	arg1	biosynthesis					1543:1554	PIM, LM, and LAM biosynthesis	1526:1554	PIM, LM, and LAM biosynthesis	1526:1554	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	0	15	theme	Inositol	93:100	arg1	Importer					102:109	an Inositol Importer	90:109	an Inositol Importer in Mycobacteria	90:125	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	4	16	theme	LAM	763:765	arg1	aspects					739:745	many aspects	734:745	many aspects of PIM, LM, and LAM construction	734:778	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	4	16	theme	LAM	763:765	arg1	dynamics					784:791	dynamics	784:791	dynamics	784:791	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	3	17	theme	mannoside	585:593	arg1	core					509:512	the structural core	494:512	the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM)	494:660	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	2	18	dep	composition	310:320	arg1	the					306:308	the	306:308	the	306:308	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	5	19	theme	metabolic	847:855	arg1	labeling					857:864	metabolic labeling	847:864	metabolic labeling	847:864	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	1	20	from	Mycobacterium	152:164	arg1	Bacteria					128:135	Bacteria	128:135	Bacteria from the genus Mycobacterium	128:164	Bacteria from the genus Mycobacterium include pathogens that cause serious diseases in humans and remain as difficult infectious agents to treat.
36856664	3	21	theme	envelope	543:550	arg1	PIM					596:598	PIM	596:598	PIM	596:598	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	21	theme	envelope	543:550	arg1	mannoside					585:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside	517:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM)	517:599	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	22	theme	essential	433:441	arg1	Inositol					418:425	Inositol	418:425	Inositol	418:425	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	22	theme	essential	433:441	arg1	metabolite					443:452	an essential metabolite	430:452	an essential metabolite for mycobacteria	430:469	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	6	23	theme	acid-containing	1072:1086	arg1	glycolipids					1088:1098	mycolic acid-containing glycolipids	1064:1098	mycolic acid-containing glycolipids	1064:1098	However, these tools have been limited to peptidoglycan, arabinogalactan, and mycolic acid-containing glycolipids.
36856664	7	24	theme	InoAz	1164:1168	arg1	analogues					1171:1179	synthetic azido inositol (InoAz) analogues	1138:1179	synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria	1138:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	3	25	theme	glycolipids	552:562	arg1	PIM					596:598	PIM	596:598	PIM	596:598	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	25	theme	glycolipids	552:562	arg1	mannoside					585:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside	517:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM)	517:599	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	26	theme	structural	498:507	arg1	core					509:512	the structural core	494:512	the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM)	494:660	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	2	27	theme	complex	401:407	arg1	glycans					409:415	unique and complex glycans	390:415	unique and complex glycans	390:415	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	0	28	theme	Inositol	6:13	arg1	Probes					15:20	Azido Inositol Probes	0:20	Azido Inositol Probes	0:20	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	4	29	theme	LM	755:756	arg1	aspects					739:745	many aspects	734:745	many aspects of PIM, LM, and LAM construction	734:778	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	4	29	theme	LM	755:756	arg1	dynamics					784:791	dynamics	784:791	dynamics	784:791	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	1	30	theme	serious	195:201	arg1	diseases					203:210	serious diseases	195:210	serious diseases in humans	195:220	Bacteria from the genus Mycobacterium include pathogens that cause serious diseases in humans and remain as difficult infectious agents to treat.
36856664	0	31	theme	Azido	0:4	arg1	Probes					15:20	Azido Inositol Probes	0:20	Azido Inositol Probes	0:20	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	2	32	theme	unique	390:395	arg1	glycans					409:415	unique and complex glycans	390:415	unique and complex glycans	390:415	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	9	33	theme	mycobacterial	1592:1604	arg1	organisms					1606:1614	diverse mycobacterial organisms	1584:1614	diverse mycobacterial organisms	1584:1614	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	8	34	theme	Mycobacterium	1361:1373	arg1	smegmatis					1375:1383	Mycobacterium smegmatis	1361:1383	Mycobacterium smegmatis	1361:1383	Additionally, we leverage an InoAz probe to discover an inositol importer and catabolic pathway in Mycobacterium smegmatis.
36856664	9	35	theme	LM	1531:1532	arg1	biosynthesis					1543:1554	PIM, LM, and LAM biosynthesis	1526:1554	PIM, LM, and LAM biosynthesis	1526:1554	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	9	36	from	dynamics	1572:1579	arg1	organisms					1606:1614	diverse mycobacterial organisms	1584:1614	diverse mycobacterial organisms	1584:1614	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	3	37	theme	immunomodulatory	521:536	arg1	PIM					596:598	PIM	596:598	PIM	596:598	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	37	theme	immunomodulatory	521:536	arg1	mannoside					585:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside	517:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM)	517:599	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	7	38	theme	analogues	1171:1179	arg1	development					1123:1133	the development	1119:1133	the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria	1119:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	4	39	theme	many	734:737	arg1	aspects					739:745	many aspects	734:745	many aspects of PIM, LM, and LAM construction	734:778	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	9	40	theme	valuable	1494:1501	arg1	tool					1503:1506	a valuable tool	1492:1506	a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms	1492:1614	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	7	41	from	PIMs	1220:1223	arg1	mycobacteria					1248:1259	intact mycobacteria	1241:1259	intact mycobacteria	1241:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	5	42	theme	mycobacterial	892:904	arg1	glycans					906:912	specific mycobacterial glycans	883:912	specific mycobacterial glycans	883:912	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	6	43	theme	mycolic	1064:1070	arg1	glycolipids					1088:1098	mycolic acid-containing glycolipids	1064:1098	mycolic acid-containing glycolipids	1064:1098	However, these tools have been limited to peptidoglycan, arabinogalactan, and mycolic acid-containing glycolipids.
36856664	0	44	theme	Metabolic	29:37	arg1	Labeling					39:46	Metabolic Labeling	29:46	Metabolic Labeling of Inositol-Containing Glycans	29:77	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	5	45	theme	specific	883:890	arg1	glycans					906:912	specific mycobacterial glycans	883:912	specific mycobacterial glycans	883:912	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	0	46	theme	Inositol-Containing	51:69	arg1	Glycans					71:77	Inositol-Containing Glycans	51:77	Inositol-Containing Glycans	51:77	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	4	47	theme	mycobacterial	691:703	arg1	physiology					705:714	mycobacterial physiology	691:714	mycobacterial physiology	691:714	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	7	48	from	LM	1226:1227	arg1	mycobacteria					1248:1259	intact mycobacteria	1241:1259	intact mycobacteria	1241:1259	Herein, we report the development of synthetic azido inositol (InoAz) analogues as probes that can metabolically label PIMs, LM, and LAM in intact mycobacteria.
36856664	3	49	theme	PIM-anchored	605:616	arg1	LM					630:631	LM	630:631	LM	630:631	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	49	theme	PIM-anchored	605:616	arg1	lipomannan					618:627	PIM-anchored lipomannan	605:627	PIM-anchored lipomannan (LM)	605:632	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	2	50	theme	cell	360:363	arg1	envelope					365:372	the mycobacterial cell envelope	342:372	the mycobacterial cell envelope	342:372	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	3	51	theme	lipomannan	618:627	arg1	core					509:512	the structural core	494:512	the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM)	494:660	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	2	52	theme	mycobacterial	346:358	arg1	envelope					365:372	the mycobacterial cell envelope	342:372	the mycobacterial cell envelope	342:372	Central to these challenges are the composition and organization of the mycobacterial cell envelope, which includes unique and complex glycans.
36856664	3	53	from	presence	482:489	arg1	core					509:512	the structural core	494:512	the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM)	494:660	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	4	54	theme	PIM	750:752	arg1	aspects					739:745	many aspects	734:745	many aspects of PIM, LM, and LAM construction	734:778	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	4	54	theme	PIM	750:752	arg1	dynamics					784:791	dynamics	784:791	dynamics	784:791	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	4	55	dep	PIM	750:752	arg1	construction					767:778	construction	767:778	construction	767:778	Despite their importance to mycobacterial physiology and pathogenesis, many aspects of PIM, LM, and LAM construction and dynamics remain poorly understood.
36856664	5	56	theme	cell	949:952	arg1	assembly					963:970	cell envelope assembly	949:970	cell envelope assembly	949:970	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	0	57	from	Importer	102:109	arg1	Mycobacteria					114:125	Mycobacteria	114:125	Mycobacteria	114:125	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	8	58	theme	inositol	1318:1325	arg1	importer					1327:1334	an inositol importer	1315:1334	an inositol importer	1315:1334	Additionally, we leverage an InoAz probe to discover an inositol importer and catabolic pathway in Mycobacterium smegmatis.
36856664	5	59	theme	envelope	954:961	arg1	assembly					963:970	cell envelope assembly	949:970	cell envelope assembly	949:970	Recently, probes that allow metabolic labeling and detection of specific mycobacterial glycans have been developed to investigate cell envelope assembly and dynamics.
36856664	8	60	theme	catabolic	1340:1348	arg1	pathway					1350:1356	catabolic pathway	1340:1356	catabolic pathway	1340:1356	Additionally, we leverage an InoAz probe to discover an inositol importer and catabolic pathway in Mycobacterium smegmatis.
36856664	1	61	theme	difficult	236:244	arg1	agents					257:262	difficult infectious agents	236:262	difficult infectious agents	236:262	Bacteria from the genus Mycobacterium include pathogens that cause serious diseases in humans and remain as difficult infectious agents to treat.
36856664	1	62	from	diseases	203:210	arg1	humans					215:220	humans	215:220	humans	215:220	Bacteria from the genus Mycobacterium include pathogens that cause serious diseases in humans and remain as difficult infectious agents to treat.
36856664	1	63	theme	genus	146:150	arg1	Mycobacterium					152:164	the genus Mycobacterium	142:164	the genus Mycobacterium	142:164	Bacteria from the genus Mycobacterium include pathogens that cause serious diseases in humans and remain as difficult infectious agents to treat.
36856664	9	64	from	transport	1557:1565	arg1	organisms					1606:1614	diverse mycobacterial organisms	1584:1614	diverse mycobacterial organisms	1584:1614	We anticipate that in the future, InoAz probes, in combination with bioorthogonal chemistry, will provide a valuable tool for investigating PIM, LM, and LAM biosynthesis, transport, and dynamics in diverse mycobacterial organisms.
36856664	1	65	theme	infectious	246:255	arg1	agents					257:262	difficult infectious agents	236:262	difficult infectious agents	236:262	Bacteria from the genus Mycobacterium include pathogens that cause serious diseases in humans and remain as difficult infectious agents to treat.
36856664	0	66	theme	Glycans	71:77	arg1	Labeling					39:46	Metabolic Labeling	29:46	Metabolic Labeling of Inositol-Containing Glycans	29:77	Azido Inositol Probes Enable Metabolic Labeling of Inositol-Containing Glycans and Reveal an Inositol Importer in Mycobacteria.
36856664	3	67	theme	cell	538:541	arg1	PIM					596:598	PIM	596:598	PIM	596:598	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	3	67	theme	cell	538:541	arg1	mannoside					585:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside	517:593	the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM)	517:599	Inositol is an essential metabolite for mycobacteria due to its presence in the structural core of the immunomodulatory cell envelope glycolipids phosphatidylinositol mannoside (PIM) and PIM-anchored lipomannan (LM) and lipoarabinomannan (LAM).
36856664	8	68	theme	InoAz	1291:1295	arg1	probe					1297:1301	an InoAz probe	1288:1301	an InoAz probe to discover an inositol importer and catabolic pathway in Mycobacterium smegmatis	1288:1383	Additionally, we leverage an InoAz probe to discover an inositol importer and catabolic pathway in Mycobacterium smegmatis.
35293727	7	0	theme	decay	1277:1281	arg1	Protein					1300:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	1	theme	MALDI-in-source	1261:1275	arg1	Protein					1300:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	8	2	from	absence	1555:1561	arg1	samples					1579:1585	the samples	1575:1585	the samples	1575:1585	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	10	3	theme	sample	1814:1819	arg1	amounts					1821:1827	minute sample amounts	1807:1827	minute sample amounts	1807:1827	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	6	4	theme	terminal	909:916	arg1	sequencing					918:927	protein terminal sequencing	901:927	protein terminal sequencing	901:927	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	2	5	theme	carrier	337:343	arg1	proteins					345:352	specific carrier proteins	328:352	specific carrier proteins	328:352	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	7	6	from	O6A	1158:1160	arg1	serotypes					1144:1152	E. coli serotypes O2	1136:1155	E. coli serotypes O2	1136:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	10	7	theme	minute	1807:1812	arg1	amounts					1821:1827	minute sample amounts	1807:1827	minute sample amounts	1807:1827	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	10	8	theme	bacterial	1973:1981	arg1	vaccines					1998:2005	bacterial glycoconjugate vaccines	1973:2005	bacterial glycoconjugate vaccines	1973:2005	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	4	9	theme	recombinant	513:523	arg1	vaccines					540:547	recombinant glycoconjugate vaccines	513:547	recombinant glycoconjugate vaccines	513:547	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	7	10	theme	detoxified	1193:1202	arg1	A					1213:1213	the genetically detoxified exotoxin A	1177:1213	the genetically detoxified exotoxin A	1177:1213	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	10	11	theme	features	1961:1968	arg1	corroboration					1929:1941	fast corroboration	1924:1941	fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development	1924:2046	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	1	12	theme	Bacterial	125:133	arg1	vaccines					150:157	Bacterial glycoconjugate vaccines	125:157	Bacterial glycoconjugate vaccines	125:157	Bacterial glycoconjugate vaccines have a major role in preventing microbial infections.
35293727	10	13	theme	early-	2014:2019	arg1	development					2036:2046	early- and late-stage development	2014:2046	early- and late-stage development	2014:2046	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	0	14	theme	coli	60:63	arg1	Vaccines					65:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	10	15	theme	vaccines	1998:2005	arg1	features					1961:1968	key structural features	1946:1968	key structural features of bacterial glycoconjugate vaccines	1946:2005	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	7	16	theme	coli	1139:1142	arg1	serotypes					1144:1152	E. coli serotypes O2	1136:1155	E. coli serotypes O2	1136:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	4	17	theme	structural	561:570	arg1	heterogeneity					572:584	a high structural heterogeneity	554:584	a high structural heterogeneity	554:584	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	5	18	theme	such	686:689	arg1	characterization					691:706	such characterization	686:706	such characterization	686:706	Since development and quality control processes rely on such characterization, novel strategies are needed for faster and informative analysis.
35293727	9	19	theme	O-antigen	1689:1697	arg1	fragments					1703:1711	O-antigen ISD fragments	1689:1711	O-antigen ISD fragments	1689:1711	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	8	20	theme	fragments	1660:1668	arg1	detection					1631:1639	the detection	1627:1639	the detection of sodiated glycan fragments	1627:1668	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	0	21	theme	Decay	93:97	arg1	Spectrometry					111:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	7	22	theme	O-antigen	1105:1113	arg1	polysaccharides					1115:1129	the O-antigen polysaccharides	1101:1129	the O-antigen polysaccharides from E. coli serotypes O2	1101:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	9	23	theme	fragments	1703:1711	arg1	analysis					1677:1684	MS/MS analysis	1671:1684	MS/MS analysis of O-antigen ISD fragments	1671:1711	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	8	24	theme	fragments	1532:1540	arg1	analysis					1512:1519	The analysis	1508:1519	The analysis of protein fragments	1508:1540	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	6	25	theme	novel	793:797	arg1	approach					799:806	a novel approach	791:806	a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines	791:1021	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	0	26	theme	Mass	106:109	arg1	Spectrometry					111:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	0	27	theme	Glycoengineered	31:45	arg1	Vaccines					65:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	5	28	theme	control	660:666	arg1	processes					668:676	quality control processes	652:676	quality control processes	652:676	Since development and quality control processes rely on such characterization, novel strategies are needed for faster and informative analysis.
35293727	3	29	theme	multiple	469:476	arg1	sites					492:496	multiple glycosylation sites	469:496	multiple glycosylation sites	469:496	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	7	30	theme	ISD	1319:1321	arg1	ions					1332:1335	glycan ISD fragment ions	1312:1335	glycan ISD fragment ions	1312:1335	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	0	31	theme	Protein	11:17	arg1	Analysis					19:26	Protein Analysis	11:26	Protein Analysis	11:26	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	6	32	theme	vaccines	1014:1021	arg1	units					980:984	the oligosaccharide repeat units	953:984	the oligosaccharide repeat units of bacterial glycoconjugate vaccines	953:1021	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	9	33	theme	specific	1742:1749	arg1	signatures					1763:1772	specific repeat unit signatures	1742:1772	specific repeat unit signatures	1742:1772	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	7	34	theme	MS.	1296:1298	arg1	Protein					1300:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	6	35	theme	bacterial	989:997	arg1	vaccines					1014:1021	bacterial glycoconjugate vaccines	989:1021	bacterial glycoconjugate vaccines	989:1021	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	9	36	theme	unit	1758:1761	arg1	signatures					1763:1772	specific repeat unit signatures	1742:1772	specific repeat unit signatures	1742:1772	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	3	37	theme	carrier	443:449	arg1	proteins					451:458	carrier proteins	443:458	carrier proteins	443:458	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	10	38	theme	late-stage	2025:2034	arg1	development					2036:2046	early- and late-stage development	2014:2046	early- and late-stage development	2014:2046	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	6	39	theme	mass	870:873	arg1	analysis					888:895	ultrahigh-resolution mass spectrometry analysis	849:895	ultrahigh-resolution mass spectrometry analysis	849:895	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	0	40	theme	Bacterial	47:55	arg1	Vaccines					65:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	6	41	theme	units	980:984	arg1	characterization					933:948	characterization	933:948	characterization	933:948	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	6	41	theme	units	980:984	arg1	sequencing					918:927	protein terminal sequencing	901:927	protein terminal sequencing	901:927	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	4	42	theme	challenging	617:627	arg1	characterization					600:615	their characterization challenging	594:627	their characterization challenging	594:627	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	2	43	theme	bacterial	225:233	arg1	polysaccharides					262:276	O-antigen polysaccharides	252:276	O-antigen polysaccharides	252:276	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	2	43	theme	bacterial	225:233	arg1	glycans					235:241	Immunogenic bacterial glycans	213:241	Immunogenic bacterial glycans	213:241	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	10	44	theme	derivatizations	1857:1871	arg1	use					1841:1843	the use	1837:1843	the use of chemical derivatizations	1837:1871	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	6	45	theme	oligosaccharide	957:971	arg1	units					980:984	the oligosaccharide repeat units	953:984	the oligosaccharide repeat units of bacterial glycoconjugate vaccines	953:1021	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	3	46	gly	glycosylation	478:490	arg2	sites					492:496	multiple glycosylation sites	469:496	multiple glycosylation sites	469:496	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	6	47	theme	sample	826:831	arg1	preparation					833:843	minimal sample preparation	818:843	minimal sample preparation	818:843	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	10	48	theme	hands-on	1897:1904	arg1	time					1906:1909	minimal hands-on time	1889:1909	minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development	1889:2046	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	0	49	theme	E.	57:58	arg1	Vaccines					65:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycoengineered Bacterial E. coli Vaccines	31:72	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	7	50	theme	acid	1450:1453	arg1	1,5-diaminonaphtalene					1369:1389	1,5-diaminonaphtalene	1369:1389	1,5-diaminonaphtalene	1369:1389	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	50	theme	acid	1450:1453	arg1	matrix					1486:1491	a MALDI matrix	1478:1491	a MALDI matrix	1478:1491	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	50	theme	acid	1450:1453	arg1	super-DHB					1464:1472	super-DHB	1464:1472	super-DHB	1464:1472	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	50	theme	acid	1450:1453	arg1	mixture					1455:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture	1395:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB)	1395:1473	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	5	51	theme	faster	741:746	arg1	analysis					764:771	faster and informative analysis	741:771	faster and informative analysis	741:771	Since development and quality control processes rely on such characterization, novel strategies are needed for faster and informative analysis.
35293727	7	52	theme	vaccine	1045:1051	arg1	candidates					1053:1062	Three glycoconjugate vaccine candidates	1024:1062	Three glycoconjugate vaccine candidates	1024:1062	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	8	53	theme	sodiated	1644:1651	arg1	fragments					1660:1668	sodiated glycan fragments	1644:1668	sodiated glycan fragments	1644:1668	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	7	54	theme	2,5-dihydroxybenzoic	1397:1416	arg1	1,5-diaminonaphtalene					1369:1389	1,5-diaminonaphtalene	1369:1389	1,5-diaminonaphtalene	1369:1389	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	54	theme	2,5-dihydroxybenzoic	1397:1416	arg1	matrix					1486:1491	a MALDI matrix	1478:1491	a MALDI matrix	1478:1491	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	54	theme	2,5-dihydroxybenzoic	1397:1416	arg1	super-DHB					1464:1472	super-DHB	1464:1472	super-DHB	1464:1472	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	54	theme	2,5-dihydroxybenzoic	1397:1416	arg1	mixture					1455:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture	1395:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB)	1395:1473	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	5	55	theme	informative	752:762	arg1	analysis					764:771	faster and informative analysis	741:771	faster and informative analysis	741:771	Since development and quality control processes rely on such characterization, novel strategies are needed for faster and informative analysis.
35293727	10	56	theme	fast	1924:1927	arg1	corroboration					1929:1941	fast corroboration	1924:1941	fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development	1924:2046	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	3	57	contain	have	464:467	arg1	proteins					451:458	carrier proteins	443:458	carrier proteins	443:458	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	3	57	contain	have	464:467	arg2	sites					492:496	multiple glycosylation sites	469:496	multiple glycosylation sites	469:496	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	7	58	from	serotypes	1144:1152	arg1	polysaccharides					1115:1129	the O-antigen polysaccharides	1101:1129	the O-antigen polysaccharides from E. coli serotypes O2	1101:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	58	from	serotypes	1144:1152	arg1	bioconjugation					1083:1096	the bioconjugation	1079:1096	the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2	1079:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	58	from	serotypes	1144:1152	arg1	O6A					1158:1160	O6A	1158:1160	O6A	1158:1160	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	58	from	serotypes	1144:1152	arg1	O25B					1167:1170	O25B	1167:1170	O25B	1167:1170	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	1	59	contain	have	159:162	arg2	role					172:175	a major role	164:175	a major role	164:175	Bacterial glycoconjugate vaccines have a major role in preventing microbial infections.
35293727	1	59	contain	have	159:162	arg1	vaccines					150:157	Bacterial glycoconjugate vaccines	125:157	Bacterial glycoconjugate vaccines	125:157	Bacterial glycoconjugate vaccines have a major role in preventing microbial infections.
35293727	6	60	theme	protein	901:907	arg1	sequencing					918:927	protein terminal sequencing	901:927	protein terminal sequencing	901:927	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	10	61	theme	structural	1950:1959	arg1	features					1961:1968	key structural features	1946:1968	key structural features of bacterial glycoconjugate vaccines	1946:2005	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	1	62	theme	microbial	191:199	arg1	infections					201:210	microbial infections	191:210	microbial infections	191:210	Bacterial glycoconjugate vaccines have a major role in preventing microbial infections.
35293727	2	63	theme	specific	328:335	arg1	proteins					345:352	specific carrier proteins	328:352	specific carrier proteins	328:352	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	10	64	theme	key	1946:1948	arg1	features					1961:1968	key structural features	1946:1968	key structural features of bacterial glycoconjugate vaccines	1946:2005	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	8	65	theme	salt	1610:1613	arg1	key					1619:1621	key	1619:1621	key	1619:1621	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	8	65	theme	salt	1610:1613	arg1	presence					1598:1605	the presence	1594:1605	the presence of salt	1594:1613	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	7	66	theme	exotoxin	1204:1211	arg1	A					1213:1213	the genetically detoxified exotoxin A	1177:1213	the genetically detoxified exotoxin A	1177:1213	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	2	67	theme	O-antigen	252:260	arg1	polysaccharides					262:276	O-antigen polysaccharides	252:276	O-antigen polysaccharides	252:276	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	4	68	theme	glycoconjugate	525:538	arg1	vaccines					540:547	recombinant glycoconjugate vaccines	513:547	recombinant glycoconjugate vaccines	513:547	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	7	69	from	O25B	1167:1170	arg1	serotypes					1144:1152	E. coli serotypes O2	1136:1155	E. coli serotypes O2	1136:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	10	70	theme	developed	1779:1787	arg1	strategy					1789:1796	The developed strategy	1775:1796	The developed strategy	1775:1796	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	7	71	from	bioconjugation	1083:1096	arg1	serotypes					1144:1152	E. coli serotypes O2	1136:1155	E. coli serotypes O2	1136:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	5	72	theme	quality	652:658	arg1	processes					668:676	quality control processes	652:676	quality control processes	652:676	Since development and quality control processes rely on such characterization, novel strategies are needed for faster and informative analysis.
35293727	1	73	theme	glycoconjugate	135:148	arg1	vaccines					150:157	Bacterial glycoconjugate vaccines	125:157	Bacterial glycoconjugate vaccines	125:157	Bacterial glycoconjugate vaccines have a major role in preventing microbial infections.
35293727	0	74	theme	Vaccines	65:72	arg1	Glycan					0:5	Glycan	0:5	Glycan	0:5	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	0	74	theme	Vaccines	65:72	arg1	Analysis					19:26	Protein Analysis	11:26	Protein Analysis	11:26	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	9	75	theme	MS/MS	1671:1675	arg1	analysis					1677:1684	MS/MS analysis	1671:1684	MS/MS analysis of O-antigen ISD fragments	1671:1711	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	8	76	theme	glycan	1653:1658	arg1	fragments					1660:1668	sodiated glycan fragments	1644:1668	sodiated glycan fragments	1644:1668	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	0	77	theme	MALDI-in-Source	77:91	arg1	Spectrometry					111:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	1	78	theme	major	166:170	arg1	role					172:175	a major role	164:175	a major role	164:175	Bacterial glycoconjugate vaccines have a major role in preventing microbial infections.
35293727	0	79	theme	FT-ICR	99:104	arg1	Spectrometry					111:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	MALDI-in-Source Decay FT-ICR Mass Spectrometry	77:122	Glycan and Protein Analysis of Glycoengineered Bacterial E. coli Vaccines by MALDI-in-Source Decay FT-ICR Mass Spectrometry.
35293727	7	80	theme	E.	1136:1137	arg1	serotypes					1144:1152	E. coli serotypes O2	1136:1155	E. coli serotypes O2	1136:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	9	81	theme	ISD	1699:1701	arg1	fragments					1703:1711	O-antigen ISD fragments	1689:1711	O-antigen ISD fragments	1689:1711	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	10	82	theme	chemical	1848:1855	arg1	derivatizations					1857:1871	chemical derivatizations	1848:1871	chemical derivatizations	1848:1871	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	7	83	theme	fragment	1323:1330	arg1	ions					1332:1335	glycan ISD fragment ions	1312:1335	glycan ISD fragment ions	1312:1335	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	5	84	theme	novel	709:713	arg1	strategies					715:724	novel strategies	709:724	novel strategies	709:724	Since development and quality control processes rely on such characterization, novel strategies are needed for faster and informative analysis.
35293727	3	85	theme	O-Antigen	385:393	arg1	polysaccharides					395:409	O-Antigen polysaccharides	385:409	O-Antigen polysaccharides	385:409	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	3	85	theme	O-Antigen	385:393	arg1	polydisperse					425:436	polydisperse	425:436	polydisperse	425:436	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	4	86	theme	high	556:559	arg1	heterogeneity					572:584	a high structural heterogeneity	554:584	a high structural heterogeneity	554:584	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	8	87	theme	protein	1524:1530	arg1	fragments					1532:1540	protein fragments	1524:1540	protein fragments	1524:1540	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	7	88	theme	glycan	1312:1317	arg1	ions					1332:1335	glycan ISD fragment ions	1312:1335	glycan ISD fragment ions	1312:1335	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	3	89	theme	glycosylation	478:490	arg1	sites					492:496	multiple glycosylation sites	469:496	multiple glycosylation sites	469:496	O-Antigen polysaccharides are typically polydisperse, and carrier proteins can have multiple glycosylation sites.
35293727	7	90	theme	polysaccharides	1115:1129	arg1	bioconjugation					1083:1096	the bioconjugation	1079:1096	the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2	1079:1155	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	90	theme	polysaccharides	1115:1129	arg1	O6A					1158:1160	O6A	1158:1160	O6A	1158:1160	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	90	theme	polysaccharides	1115:1129	arg1	O25B					1167:1170	O25B	1167:1170	O25B	1167:1170	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	10	91	theme	glycoconjugate	1983:1996	arg1	vaccines					1998:2005	bacterial glycoconjugate vaccines	1973:2005	bacterial glycoconjugate vaccines	1973:2005	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	7	92	theme	MALDI	1480:1484	arg1	matrix					1486:1491	a MALDI matrix	1478:1491	a MALDI matrix	1478:1491	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	92	theme	MALDI	1480:1484	arg1	1,5-diaminonaphtalene					1369:1389	1,5-diaminonaphtalene	1369:1389	1,5-diaminonaphtalene	1369:1389	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	92	theme	MALDI	1480:1484	arg1	mixture					1455:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture	1395:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB)	1395:1473	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	93	theme	FT-ICR	1289:1294	arg1	Protein					1300:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	6	94	theme	glycoconjugate	999:1012	arg1	vaccines					1014:1021	bacterial glycoconjugate vaccines	989:1021	bacterial glycoconjugate vaccines	989:1021	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	9	95	theme	repeat	1751:1756	arg1	signatures					1763:1772	specific repeat unit signatures	1742:1772	specific repeat unit signatures	1742:1772	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	8	96	theme	salts	1566:1570	arg1	absence					1555:1561	the absence	1551:1561	the absence of salts in the samples	1551:1585	The analysis of protein fragments required the absence of salts in the samples, while the presence of salt was key for the detection of sodiated glycan fragments.
35293727	6	97	theme	spectrometry	875:886	arg1	analysis					888:895	ultrahigh-resolution mass spectrometry analysis	849:895	ultrahigh-resolution mass spectrometry analysis	849:895	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	7	98	theme	ISD	1284:1286	arg1	Protein					1300:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	MALDI-in-source decay (ISD) FT-ICR MS. Protein	1261:1306	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	9	99	theme	signatures	1763:1772	arg1	detection					1729:1737	the detection	1725:1737	the detection of specific repeat unit signatures	1725:1772	MS/MS analysis of O-antigen ISD fragments allowed for the detection of specific repeat unit signatures.
35293727	6	100	theme	ultrahigh-resolution	849:868	arg1	analysis					888:895	ultrahigh-resolution mass spectrometry analysis	849:895	ultrahigh-resolution mass spectrometry analysis	849:895	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	2	101	theme	effective	365:373	arg1	vaccines					375:382	effective vaccines	365:382	effective vaccines	365:382	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	6	102	theme	repeat	973:978	arg1	units					980:984	the oligosaccharide repeat units	953:984	the oligosaccharide repeat units of bacterial glycoconjugate vaccines	953:1021	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	2	103	theme	Immunogenic	213:223	arg1	polysaccharides					262:276	O-antigen polysaccharides	252:276	O-antigen polysaccharides	252:276	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	2	103	theme	Immunogenic	213:223	arg1	glycans					235:241	Immunogenic bacterial glycans	213:241	Immunogenic bacterial glycans	213:241	Immunogenic bacterial glycans, such as O-antigen polysaccharides, can be recombinantly expressed and combined with specific carrier proteins to produce effective vaccines.
35293727	4	104	contain	have	549:552	arg1	vaccines					540:547	recombinant glycoconjugate vaccines	513:547	recombinant glycoconjugate vaccines	513:547	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	4	104	contain	have	549:552	arg2	heterogeneity					572:584	a high structural heterogeneity	554:584	a high structural heterogeneity	554:584	Consequently, recombinant glycoconjugate vaccines have a high structural heterogeneity, making their characterization challenging.
35293727	7	105	theme	acid/2-hydroxy-5-methoxybenzoic	1418:1448	arg1	1,5-diaminonaphtalene					1369:1389	1,5-diaminonaphtalene	1369:1389	1,5-diaminonaphtalene	1369:1389	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	105	theme	acid/2-hydroxy-5-methoxybenzoic	1418:1448	arg1	matrix					1486:1491	a MALDI matrix	1478:1491	a MALDI matrix	1478:1491	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	105	theme	acid/2-hydroxy-5-methoxybenzoic	1418:1448	arg1	super-DHB					1464:1472	super-DHB	1464:1472	super-DHB	1464:1472	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	7	105	theme	acid/2-hydroxy-5-methoxybenzoic	1418:1448	arg1	mixture					1455:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture	1395:1461	a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB)	1395:1473	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
35293727	6	106	theme	minimal	818:824	arg1	preparation					833:843	minimal sample preparation	818:843	minimal sample preparation	818:843	Here, we present a novel approach employing minimal sample preparation and ultrahigh-resolution mass spectrometry analysis for protein terminal sequencing and characterization of the oligosaccharide repeat units of bacterial glycoconjugate vaccines.
35293727	10	107	theme	minimal	1889:1895	arg1	time					1906:1909	minimal hands-on time	1889:1909	minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development	1889:2046	The developed strategy requires minute sample amounts, avoids the use of chemical derivatizations, and comes with minimal hands-on time allowing for fast corroboration of key structural features of bacterial glycoconjugate vaccines during early- and late-stage development.
35293727	7	108	theme	glycoconjugate	1030:1043	arg1	candidates					1053:1062	Three glycoconjugate vaccine candidates	1024:1062	Three glycoconjugate vaccine candidates	1024:1062	Three glycoconjugate vaccine candidates, obtained from the bioconjugation of the O-antigen polysaccharides from E. coli serotypes O2, O6A, and O25B with the genetically detoxified exotoxin A from Pseudomonas aeruginosa, were analyzed by MALDI-in-source decay (ISD) FT-ICR MS. Protein and glycan ISD fragment ions were selectively detected using 1,5-diaminonaphtalene and a 2,5-dihydroxybenzoic acid/2-hydroxy-5-methoxybenzoic acid mixture (super-DHB) as a MALDI matrix, respectively.
36430846	9	0	theme	endothelial	1433:1443	arg1	cells					1451:1455	endothelial HUVEC cells	1433:1455	endothelial HUVEC cells	1433:1455	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	4	1	theme	glycosylation	499:511	arg1	profiles					513:520	glycosylation profiles	499:520	glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry	499:683	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	6	2	theme	cells	906:910	arg1	status					876:881	the glycosylation status	858:881	the glycosylation status of the T-24 and HCV-29 cells	858:910	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	6	2	theme	cells	906:910	arg1	responsible					915:925	responsible	915:925	responsible	915:925	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	10	3	attach	present	1566:1572	arg2	cells					1560:1564	various cells	1552:1564	various cells present in the tumor microenvironment	1552:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	10	3	attach	present	1566:1572	arg1	microenvironment					1587:1602	the tumor microenvironment	1577:1602	the tumor microenvironment	1577:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	4	4	theme	cells	595:599	arg1	profiles					513:520	glycosylation profiles	499:520	glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry	499:683	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	0	5	theme	Cancer	85:90	arg1	Cells					92:96	Bladder Cancer Cells	77:96	Bladder Cancer Cells	77:96	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	4	6	theme	T-24	525:528	arg1	cells					556:560	T-24 urothelial bladder cancer cells	525:560	T-24 urothelial bladder cancer cells	525:560	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	8	7	theme	function	1343:1350	arg1	modulation					1314:1323	modulation	1314:1323	modulation of recipient cell function	1314:1350	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	1	8	theme	therapeutic	159:169	arg1	challenge					171:179	a therapeutic challenge	157:179	a therapeutic challenge	157:179	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	4	9	theme	epithelial	584:593	arg1	cells					595:599	HCV-29 normal ureter epithelial cells	563:599	HCV-29 normal ureter epithelial cells	563:599	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	8	10	theme	aforementioned	1212:1225	arg1	effects					1227:1233	the aforementioned effects	1208:1233	the aforementioned effects	1208:1233	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	9	11	theme	T-24-derived	1365:1376	arg1	ectosomes					1378:1386	T-24-derived ectosomes	1365:1386	T-24-derived ectosomes	1365:1386	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	9	12	theme	HUVEC	1445:1449	arg1	cells					1451:1455	endothelial HUVEC cells	1433:1455	endothelial HUVEC cells	1433:1455	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	5	13	theme	β-1,6-branched	774:787	arg1	glycans					789:795	β-1,6-branched glycans	774:795	β-1,6-branched glycans	774:795	Ectosomes displayed distinct total and surface glycosylation profiles with abundance of β-1,6-branched glycans and sialilated structures.
36430846	4	14	gly	glycosylation	499:511	arg1	cells					556:560	T-24 urothelial bladder cancer cells	525:560	T-24 urothelial bladder cancer cells	525:560	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	4	14	gly	glycosylation	499:511	arg1	cells					595:599	HCV-29 normal ureter epithelial cells	563:599	HCV-29 normal ureter epithelial cells	563:599	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	4	14	gly	glycosylation	499:511	arg1	ectosomes					606:614	ectosomes	606:614	ectosomes	606:614	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	6	15	theme	cells	1011:1015	arg1	migration					988:996	migration	988:996	migration	988:996	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	6	15	theme	cells	1011:1015	arg1	proliferation					970:982	proliferation	970:982	proliferation	970:982	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	5	16	theme	sialilated	801:810	arg1	structures					812:821	sialilated structures	801:821	sialilated structures	801:821	Ectosomes displayed distinct total and surface glycosylation profiles with abundance of β-1,6-branched glycans and sialilated structures.
36430846	4	17	theme	study	478:482	arg1	aim					466:468	the aim	462:468	the aim of this study	462:482	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	10	18	theme	cells	1560:1564	arg1	function					1540:1547	the function	1536:1547	the function of various cells present in the tumor microenvironment	1536:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	2	19	theme	extracellular	290:302	arg1	vesicles					304:311	extracellular vesicles	290:311	extracellular vesicles	290:311	Several studies showed that extracellular vesicles promote angiogenesis, migration and metastasis, and inhibit apoptosis in bladder cancer.
36430846	10	20	theme	various	1552:1558	arg1	cells					1560:1564	various cells	1552:1564	various cells present in the tumor microenvironment	1552:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	10	21	theme	present	1566:1572	arg1	cells					1560:1564	various cells	1552:1564	various cells present in the tumor microenvironment	1552:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	4	22	theme	ectosomes	606:614	arg1	profiles					513:520	glycosylation profiles	499:520	glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry	499:683	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	9	23	theme	cells	1451:1455	arg1	motility					1421:1428	motility	1421:1428	motility	1421:1428	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	9	23	theme	cells	1451:1455	arg1	viability					1407:1415	viability	1407:1415	viability	1407:1415	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	0	24	from	Presence	31:38	arg1	Ectosomes					102:110	Ectosomes	102:110	Ectosomes	102:110	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	0	24	from	Presence	31:38	arg1	Cells					92:96	Bladder Cancer Cells	77:96	Bladder Cancer Cells	77:96	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	2	25	from	apoptosis	373:381	arg1	cancer					394:399	bladder cancer	386:399	bladder cancer	386:399	Several studies showed that extracellular vesicles promote angiogenesis, migration and metastasis, and inhibit apoptosis in bladder cancer.
36430846	6	26	gly	glycosylation	862:874	arg1	cells					906:910	the T-24 and HCV-29 cells	886:910	cells	906:910	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	0	27	theme	Lectin-Based	0:11	arg1	Study					13:17	Lectin-Based Study	0:17	Lectin-Based Study	0:17	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	4	28	theme	HCV-29	563:568	arg1	cells					595:599	HCV-29 normal ureter epithelial cells	563:599	HCV-29 normal ureter epithelial cells	563:599	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	7	29	theme	HCV-29	1141:1146	arg1	cells					1148:1152	HCV-29 cells	1141:1152	HCV-29 cells	1141:1152	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	4	30	theme	flow	670:673	arg1	cytometry					675:683	flow cytometry	670:683	flow cytometry	670:683	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	10	31	theme	tumor	1581:1585	arg1	microenvironment					1587:1602	the tumor microenvironment	1577:1602	the tumor microenvironment	1577:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	9	32	link	T-24-derived	1365:1376	arg1	ectosomes					1378:1386	T-24-derived ectosomes	1365:1386	T-24-derived ectosomes	1365:1386	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	8	33	theme	recipient	1328:1336	arg1	function					1343:1350	recipient cell function	1328:1350	recipient cell function	1328:1350	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	8	34	theme	DMJ-treated	1189:1199	arg1	cells					1201:1205	DMJ-treated cells	1189:1205	DMJ-treated cells	1189:1205	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	4	35	theme	ureter	577:582	arg1	cells					595:599	HCV-29 normal ureter epithelial cells	563:599	HCV-29 normal ureter epithelial cells	563:599	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	6	36	theme	HCV-29	899:904	arg1	cells					906:910	the T-24 and HCV-29 cells	886:910	cells	906:910	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	1	37	theme	Bladder	113:119	arg1	cancer					121:126	Bladder cancer	113:126	Bladder cancer	113:126	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	1	37	theme	Bladder	113:119	arg1	malignancy					133:142	a malignancy	131:142	a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression	131:259	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	7	38	dep	Stronger	1018:1025	arg1	promigratory					1048:1059	promigratory	1048:1059	promigratory	1048:1059	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	7	38	dep	Stronger	1018:1025	arg1	proproliferative					1027:1042	proproliferative	1027:1042	proproliferative	1027:1042	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	4	39	theme	cell	633:636	arg1	lines					638:642	both cell lines	628:642	both cell lines using lectin blotting and flow cytometry	628:683	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	5	40	theme	structures	812:821	arg1	abundance					761:769	abundance	761:769	abundance of β-1,6-branched glycans and sialilated structures	761:821	Ectosomes displayed distinct total and surface glycosylation profiles with abundance of β-1,6-branched glycans and sialilated structures.
36430846	4	41	theme	normal	570:575	arg1	cells					595:599	HCV-29 normal ureter epithelial cells	563:599	HCV-29 normal ureter epithelial cells	563:599	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	5	42	theme	surface	725:731	arg1	profiles					747:754	distinct total and surface glycosylation profiles	706:754	profiles	747:754	Ectosomes displayed distinct total and surface glycosylation profiles with abundance of β-1,6-branched glycans and sialilated structures.
36430846	4	43	theme	lectin	650:655	arg1	blotting					657:664	lectin blotting	650:664	lectin blotting	650:664	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	1	44	theme	new	216:218	arg1	biomarkers					220:229	new biomarkers	216:229	new biomarkers	216:229	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	3	45	theme	glycosylation	434:446	arg1	status					448:453	their glycosylation status	428:453	their glycosylation status	428:453	This effect may depend on their glycosylation status.
36430846	4	46	theme	bladder	541:547	arg1	cells					556:560	T-24 urothelial bladder cancer cells	525:560	T-24 urothelial bladder cancer cells	525:560	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	5	47	theme	glycosylation	733:745	arg1	profiles					747:754	distinct total and surface glycosylation profiles	706:754	profiles	747:754	Ectosomes displayed distinct total and surface glycosylation profiles with abundance of β-1,6-branched glycans and sialilated structures.
36430846	6	48	theme	T-24	890:893	arg1	cells					906:910	the T-24 and HCV-29 cells	886:910	cells	906:910	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	1	49	theme	biomarkers	220:229	arg1	identification					198:211	the identification	194:211	the identification of new biomarkers and mechanisms of progression	194:259	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	0	50	theme	Glycoepitopes	60:72	arg1	Presence					31:38	the Presence	27:38	the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes	27:110	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	4	51	theme	urothelial	530:539	arg1	cells					556:560	T-24 urothelial bladder cancer cells	525:560	T-24 urothelial bladder cancer cells	525:560	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	7	52	link	T-24-derived	1073:1084	arg1	ectosomes					1086:1094	T-24-derived ectosomes	1073:1094	T-24-derived ectosomes	1073:1094	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	0	53	theme	Disease-Relevant	43:58	arg1	Glycoepitopes					60:72	Disease-Relevant Glycoepitopes	43:72	Disease-Relevant Glycoepitopes	43:72	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	4	54	theme	cells	556:560	arg1	profiles					513:520	glycosylation profiles	499:520	glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry	499:683	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	9	55	theme	fibroblasts	1466:1476	arg1	motility					1421:1428	motility	1421:1428	motility	1421:1428	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	9	55	theme	fibroblasts	1466:1476	arg1	viability					1407:1415	viability	1407:1415	viability	1407:1415	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	7	56	located	observed	1100:1107	arg1	comparison					1112:1121	comparison	1112:1121	comparison to ectosomes from HCV-29 cells	1112:1152	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	7	56	located	observed	1100:1107	arg2	activity					1061:1068	Stronger proproliferative and promigratory activity	1018:1068	Stronger proproliferative and promigratory activity of T-24-derived ectosomes	1018:1094	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	10	57	from	microenvironment	1587:1602	arg1	present					1566:1572	present	1566:1572	present	1566:1572	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	6	58	dep	proliferation	970:982	arg1	the					966:968	the	966:968	the	966:968	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	9	59	dep	viability	1407:1415	arg1	the					1403:1405	the	1403:1405	the	1403:1405	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	4	60	theme	cancer	549:554	arg1	cells					556:560	T-24 urothelial bladder cancer cells	525:560	T-24 urothelial bladder cancer cells	525:560	Thus, the aim of this study was to compare glycosylation profiles of T-24 urothelial bladder cancer cells, HCV-29 normal ureter epithelial cells, and ectosomes released by both cell lines using lectin blotting and flow cytometry.
36430846	7	61	theme	T-24-derived	1073:1084	arg1	ectosomes					1086:1094	T-24-derived ectosomes	1073:1094	T-24-derived ectosomes	1073:1094	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	9	62	theme	Hs27	1461:1464	arg1	fibroblasts					1466:1476	Hs27 fibroblasts	1461:1476	Hs27 fibroblasts	1461:1476	HCV-29- and T-24-derived ectosomes also increased the viability and motility of endothelial HUVEC cells and Hs27 fibroblasts.
36430846	7	63	theme	ectosomes	1086:1094	arg1	activity					1061:1068	Stronger proproliferative and promigratory activity	1018:1068	Stronger proproliferative and promigratory activity of T-24-derived ectosomes	1018:1094	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	6	64	theme	glycosylation	862:874	arg1	status					876:881	the glycosylation status	858:881	the glycosylation status of the T-24 and HCV-29 cells	858:910	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	6	64	theme	glycosylation	862:874	arg1	responsible					915:925	responsible	915:925	responsible	915:925	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	7	65	theme	Stronger	1018:1025	arg1	activity					1061:1068	Stronger proproliferative and promigratory activity	1018:1068	Stronger proproliferative and promigratory activity of T-24-derived ectosomes	1018:1094	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	1	66	theme	mechanisms	235:244	arg1	identification					198:211	the identification	194:211	the identification of new biomarkers and mechanisms of progression	194:259	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	0	67	theme	Bladder	77:83	arg1	Cells					92:96	Bladder Cancer Cells	77:96	Bladder Cancer Cells	77:96	Lectin-Based Study Reveals the Presence of Disease-Relevant Glycoepitopes in Bladder Cancer Cells and Ectosomes.
36430846	8	68	theme	cell	1338:1341	arg1	function					1343:1350	recipient cell function	1328:1350	recipient cell function	1328:1350	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	2	69	theme	Several	262:268	arg1	studies					270:276	Several studies	262:276	Several studies	262:276	Several studies showed that extracellular vesicles promote angiogenesis, migration and metastasis, and inhibit apoptosis in bladder cancer.
36430846	10	70	from	present	1566:1572	arg1	microenvironment					1587:1602	the tumor microenvironment	1577:1602	the tumor microenvironment	1577:1602	This supports the hypothesis that ectosomes can modulate the function of various cells present in the tumor microenvironment.
36430846	8	71	attach	isolated	1175:1182	arg1	cells					1201:1205	DMJ-treated cells	1189:1205	DMJ-treated cells	1189:1205	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	8	71	attach	isolated	1175:1182	arg2	ectosomes					1160:1168	ectosomes	1160:1168	ectosomes	1160:1168	When ectosomes were isolated from DMJ-treated cells, the aforementioned effects were diminished, suggesting that glycans carried by ectosomes were involved in modulation of recipient cell function.
36430846	5	72	theme	glycans	789:795	arg1	abundance					761:769	abundance	761:769	abundance of β-1,6-branched glycans and sialilated structures	761:821	Ectosomes displayed distinct total and surface glycosylation profiles with abundance of β-1,6-branched glycans and sialilated structures.
36430846	6	73	theme	recipient	1001:1009	arg1	cells					1011:1015	recipient cells	1001:1015	recipient cells	1001:1015	Then, it was investigated whether the glycosylation status of the T-24 and HCV-29 cells is responsible for the effect exerted by ectosomes on the proliferation and migration of recipient cells.
36430846	2	74	theme	bladder	386:392	arg1	cancer					394:399	bladder cancer	386:399	bladder cancer	386:399	Several studies showed that extracellular vesicles promote angiogenesis, migration and metastasis, and inhibit apoptosis in bladder cancer.
36430846	7	75	from	cells	1148:1152	arg1	ectosomes					1126:1134	ectosomes	1126:1134	ectosomes from HCV-29 cells	1126:1152	Stronger proproliferative and promigratory activity of T-24-derived ectosomes was observed in comparison to ectosomes from HCV-29 cells.
36430846	1	76	theme	progression	249:259	arg1	mechanisms					235:244	mechanisms	235:244	mechanisms of progression	235:259	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
36430846	1	76	theme	progression	249:259	arg1	biomarkers					220:229	new biomarkers	216:229	new biomarkers	216:229	Bladder cancer is a malignancy that remains a therapeutic challenge and requires the identification of new biomarkers and mechanisms of progression.
35532124	7	0	located	observed	1258:1265	arg2	state					1242:1246	an intermediate state	1226:1246	an intermediate state	1226:1246	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	7	0	located	observed	1258:1265	arg2	state					1216:1220	its native state	1205:1220	its native state	1205:1220	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	7	0	located	observed	1258:1265	arg1	unfolding					1283:1291	urea-induced unfolding	1270:1291	urea-induced unfolding	1270:1291	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	5	1	theme	O-glycan	813:820	arg1	moieties					822:829	their polypeptide and O-glycan moieties	791:829	moieties	822:829	Here, we study how these linkers, and their polypeptide and O-glycan moieties, regulate A1 affinity by measuring affinity, kinetics, thermodynamics, hydrogen deuterium exchange (HDX), and unfolding by temperature and urea.
35532124	1	2	theme	protein	229:235	arg1	VWF					260:262	VWF	260:262	VWF	260:262	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	2	theme	protein	229:235	arg1	factor					252:257	the ultralong protein von Willebrand factor	215:257	the ultralong protein von Willebrand factor (VWF)	215:263	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	7	3	theme	specific	1123:1130	arg1	regions					1132:1138	specific regions	1123:1138	specific regions of A1	1123:1144	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	1	4	theme	platelet	297:304	arg1	plug					306:309	a platelet plug	295:309	a platelet plug	295:309	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	5	theme	arterial	151:158	arg1	circulation					160:170	the arterial circulation	147:170	the arterial circulation	147:170	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	6	theme	von	237:239	arg1	VWF					260:262	VWF	260:262	VWF	260:262	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	6	theme	von	237:239	arg1	factor					252:257	the ultralong protein von Willebrand factor	215:257	the ultralong protein von Willebrand factor (VWF)	215:263	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	3	7	theme	A1	405:406	arg1	core					408:411	The A1 core	401:411	The A1 core	401:411	The A1 core is protected from force-induced unfolding by a long-range disulfide that links cysteines near its N- and C-termini.
35532124	5	8	theme	deuterium	911:919	arg1	exchange					921:928	hydrogen deuterium exchange	902:928	hydrogen deuterium exchange (HDX)	902:934	Here, we study how these linkers, and their polypeptide and O-glycan moieties, regulate A1 affinity by measuring affinity, kinetics, thermodynamics, hydrogen deuterium exchange (HDX), and unfolding by temperature and urea.
35532124	5	8	theme	deuterium	911:919	arg1	HDX					931:933	HDX	931:933	HDX	931:933	Here, we study how these linkers, and their polypeptide and O-glycan moieties, regulate A1 affinity by measuring affinity, kinetics, thermodynamics, hydrogen deuterium exchange (HDX), and unfolding by temperature and urea.
35532124	1	9	theme	Willebrand	241:250	arg1	VWF					260:262	VWF	260:262	VWF	260:262	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	9	theme	Willebrand	241:250	arg1	factor					252:257	the ultralong protein von Willebrand factor	215:257	the ultralong protein von Willebrand factor (VWF)	215:263	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	10	from	Hemostasis	133:142	arg1	circulation					160:170	the arterial circulation	147:170	the arterial circulation	147:170	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	6	11	theme	A1	996:997	arg1	affinity					999:1006	A1 affinity	996:1006	A1 affinity	996:1006	The N-linker lowers A1 affinity 40-fold with a stronger contribution from its O-glycan than polypeptide moiety.
35532124	1	12	theme	factor	252:257	arg1	domain					205:210	the A1 domain	198:210	the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug	198:309	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	12	theme	factor	252:257	arg1	factor					252:257	the ultralong protein von Willebrand factor	215:257	the ultralong protein von Willebrand factor (VWF)	215:263	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	0	13	theme	O-glycosylated	101:114	arg1	N-					116:117	its O-glycosylated N-	97:117	its O-glycosylated N-	97:117	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	8	14	theme	significant	1388:1398	arg1	effect					1400:1405	no significant effect	1385:1405	no significant effect	1385:1405	The C-linker also decreases affinity of A1 for GPIbα, but in contrast to the N-linker, has no significant effect on HDX or A1 stability.
35532124	9	15	theme	intermediate	1521:1532	arg1	state					1534:1538	the intermediate state	1517:1538	the intermediate state	1517:1538	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	7	16	theme	native	1209:1214	arg1	state					1216:1220	its native state	1205:1220	its native state	1205:1220	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	4	17	theme	tensile	611:617	arg1	force					619:623	tensile force	611:623	tensile force to A1	611:629	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1, are reported to regulate A1 activation for binding to GPIb, but the mechanism is controversial and incompletely defined.
35532124	4	18	theme	O-glycosylated	533:546	arg1	linkers					548:554	The O-glycosylated linkers	529:554	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1,	529:630	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1, are reported to regulate A1 activation for binding to GPIb, but the mechanism is controversial and incompletely defined.
35532124	6	19	theme	polypeptide	1068:1078	arg1	moiety					1080:1085	polypeptide moiety	1068:1085	polypeptide moiety	1068:1085	The N-linker lowers A1 affinity 40-fold with a stronger contribution from its O-glycan than polypeptide moiety.
35532124	7	20	theme	intermediate	1229:1240	arg1	state					1242:1246	an intermediate state	1226:1246	an intermediate state	1226:1246	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	0	21	theme	Willebrand	4:13	arg1	factor					15:20	Von Willebrand factor	0:20	Von Willebrand factor	0:20	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	9	22	with	consistent	1486:1495	arg1	model					1506:1510	the model	1502:1510	the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker	1502:1662	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	2	23	theme	tensile	331:337	arg1	force					339:343	tensile force	331:343	tensile force on VWF concatemers imparted by hydrodynamic drag force	331:398	A1 is activated by tensile force on VWF concatemers imparted by hydrodynamic drag force.
35532124	0	24	theme	Von	0:2	arg1	factor					15:20	Von Willebrand factor	0:20	Von Willebrand factor	0:20	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	8	25	theme	A1	1417:1418	arg1	stability					1420:1428	A1 stability	1417:1428	A1 stability	1417:1428	The C-linker also decreases affinity of A1 for GPIbα, but in contrast to the N-linker, has no significant effect on HDX or A1 stability.
35532124	9	26	theme	high	1544:1547	arg1	affinity					1549:1556	high affinity	1544:1556	high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker	1544:1662	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	4	27	gly	O-glycosylated	533:546	arg1	linkers					548:554	The O-glycosylated linkers	529:554	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1,	529:630	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1, are reported to regulate A1 activation for binding to GPIb, but the mechanism is controversial and incompletely defined.
35532124	9	28	theme	different	1437:1445	arg1	models					1447:1452	different models	1437:1452	different models for A1 activation	1437:1470	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	8	29	contain	has	1381:1383	arg1	C-linker					1298:1305	The C-linker	1294:1305	The C-linker	1294:1305	The C-linker also decreases affinity of A1 for GPIbα, but in contrast to the N-linker, has no significant effect on HDX or A1 stability.
35532124	8	29	contain	has	1381:1383	arg2	effect					1400:1405	no significant effect	1385:1405	no significant effect	1385:1405	The C-linker also decreases affinity of A1 for GPIbα, but in contrast to the N-linker, has no significant effect on HDX or A1 stability.
35532124	2	30	theme	drag	389:392	arg1	force					394:398	hydrodynamic drag force	376:398	hydrodynamic drag force	376:398	A1 is activated by tensile force on VWF concatemers imparted by hydrodynamic drag force.
35532124	9	31	theme	A1	1458:1459	arg1	activation					1461:1470	A1 activation	1458:1470	A1 activation	1458:1470	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	2	32	theme	hydrodynamic	376:387	arg1	force					394:398	hydrodynamic drag force	376:398	hydrodynamic drag force	376:398	A1 is activated by tensile force on VWF concatemers imparted by hydrodynamic drag force.
35532124	0	33	gly	O-glycosylated	101:114	arg1	N-					116:117	its O-glycosylated N-	97:117	its O-glycosylated N-	97:117	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	4	34	theme	neighboring	575:585	arg1	domains					587:593	its neighboring domains	571:593	its neighboring domains	571:593	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1, are reported to regulate A1 activation for binding to GPIb, but the mechanism is controversial and incompletely defined.
35532124	7	35	theme	energy	1186:1191	arg1	gap					1193:1195	the energy gap	1182:1195	the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding	1182:1291	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	7	36	theme	urea-induced	1270:1281	arg1	unfolding					1283:1291	urea-induced unfolding	1270:1291	urea-induced unfolding	1270:1291	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	6	37	from	O-glycan	1054:1061	arg1	contribution					1032:1043	a stronger contribution	1021:1043	a stronger contribution from its O-glycan than polypeptide moiety	1021:1085	The N-linker lowers A1 affinity 40-fold with a stronger contribution from its O-glycan than polypeptide moiety.
35532124	0	38	theme	domain	25:30	arg1	stability					32:40	A1 domain stability	22:40	A1 domain stability	22:40	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	0	39	theme	A1	22:23	arg1	stability					32:40	A1 domain stability	22:40	A1 domain stability	22:40	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	1	40	theme	A1	202:203	arg1	domain					205:210	the A1 domain	198:210	the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug	198:309	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	40	theme	A1	202:203	arg1	factor					252:257	the ultralong protein von Willebrand factor	215:257	the ultralong protein von Willebrand factor (VWF)	215:263	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	7	41	from	HDX	1116:1118	arg1	regions					1132:1138	specific regions	1123:1138	specific regions of A1	1123:1144	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	3	42	theme	force-induced	431:443	arg1	unfolding					445:453	force-induced unfolding	431:453	force-induced unfolding	431:453	The A1 core is protected from force-induced unfolding by a long-range disulfide that links cysteines near its N- and C-termini.
35532124	6	43	theme	stronger	1023:1030	arg1	contribution					1032:1043	a stronger contribution	1021:1043	a stronger contribution from its O-glycan than polypeptide moiety	1021:1085	The N-linker lowers A1 affinity 40-fold with a stronger contribution from its O-glycan than polypeptide moiety.
35532124	8	44	dep	N-linker	1371:1378	arg1	contrast					1355:1362	contrast	1355:1362	contrast	1355:1362	The C-linker also decreases affinity of A1 for GPIbα, but in contrast to the N-linker, has no significant effect on HDX or A1 stability.
35532124	5	45	theme	hydrogen	902:909	arg1	exchange					921:928	hydrogen deuterium exchange	902:928	hydrogen deuterium exchange (HDX)	902:934	Here, we study how these linkers, and their polypeptide and O-glycan moieties, regulate A1 affinity by measuring affinity, kinetics, thermodynamics, hydrogen deuterium exchange (HDX), and unfolding by temperature and urea.
35532124	5	45	theme	hydrogen	902:909	arg1	HDX					931:933	HDX	931:933	HDX	931:933	Here, we study how these linkers, and their polypeptide and O-glycan moieties, regulate A1 affinity by measuring affinity, kinetics, thermodynamics, hydrogen deuterium exchange (HDX), and unfolding by temperature and urea.
35532124	2	46	from	force	339:343	arg1	concatemers					352:362	VWF concatemers	348:362	VWF concatemers imparted by hydrodynamic drag force	348:398	A1 is activated by tensile force on VWF concatemers imparted by hydrodynamic drag force.
35532124	5	47	theme	A1	841:842	arg1	affinity					844:851	A1 affinity	841:851	A1 affinity	841:851	Here, we study how these linkers, and their polypeptide and O-glycan moieties, regulate A1 affinity by measuring affinity, kinetics, thermodynamics, hydrogen deuterium exchange (HDX), and unfolding by temperature and urea.
35532124	1	48	theme	domain	205:210	arg1	binding					187:193	binding	187:193	binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug	187:309	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	0	49	dep	factor	15:20	arg1	stability					32:40	A1 domain stability	22:40	A1 domain stability	22:40	Von Willebrand factor A1 domain stability and affinity for GPIbα are differentially regulated by its O-glycosylated N- and C-linker.
35532124	4	50	theme	A1	657:658	arg1	activation					660:669	A1 activation	657:669	A1 activation	657:669	The O-glycosylated linkers between A1 and its neighboring domains, which transmit tensile force to A1, are reported to regulate A1 activation for binding to GPIb, but the mechanism is controversial and incompletely defined.
35532124	9	51	theme	tensile	1589:1595	arg1	force					1597:1601	tensile force	1589:1601	tensile force	1589:1601	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	2	52	theme	VWF	348:350	arg1	concatemers					352:362	VWF concatemers	348:362	VWF concatemers imparted by hydrodynamic drag force	348:398	A1 is activated by tensile force on VWF concatemers imparted by hydrodynamic drag force.
35532124	8	53	theme	A1	1334:1335	arg1	affinity					1322:1329	affinity	1322:1329	affinity of A1 for GPIbα	1322:1345	The C-linker also decreases affinity of A1 for GPIbα, but in contrast to the N-linker, has no significant effect on HDX or A1 stability.
35532124	3	54	theme	long-range	460:469	arg1	disulfide					471:479	a long-range disulfide	458:479	a long-range disulfide that links cysteines near its N- and C-termini	458:526	The A1 core is protected from force-induced unfolding by a long-range disulfide that links cysteines near its N- and C-termini.
35532124	9	55	contain	has	1540:1542	arg1	state					1534:1538	the intermediate state	1517:1538	the intermediate state	1517:1538	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	9	55	contain	has	1540:1542	arg2	model					1506:1510	the model	1502:1510	the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker	1502:1662	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	9	55	contain	has	1540:1542	arg2	affinity					1549:1556	high affinity	1544:1556	high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker	1544:1662	Among different models for A1 activation, our data are consistent with the model that the intermediate state has high affinity for GPIbα, which is induced by tensile force physiologically and regulated allosterically by the N-linker.
35532124	7	56	theme	thermal	1160:1166	arg1	stability					1168:1176	thermal stability	1160:1176	thermal stability	1160:1176	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	7	57	theme	A1	1143:1144	arg1	regions					1132:1138	specific regions	1123:1138	specific regions of A1	1123:1144	The N-linker also decreases HDX in specific regions of A1 and increases thermal stability and the energy gap between its native state and an intermediate state, which is observed in urea-induced unfolding.
35532124	1	58	theme	ultralong	219:227	arg1	VWF					260:262	VWF	260:262	VWF	260:262	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35532124	1	58	theme	ultralong	219:227	arg1	factor					252:257	the ultralong protein von Willebrand factor	215:257	the ultralong protein von Willebrand factor (VWF)	215:263	Hemostasis in the arterial circulation is mediated by binding of the A1 domain of the ultralong protein von Willebrand factor (VWF) to GPIbα on platelets to form a platelet plug.
35309324	8	0	theme	significance	1372:1383	arg1	understanding					1351:1363	our understanding	1347:1363	our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab	1347:1440	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	8	1	with	interaction	1414:1424	arg1	cemiplimab					1431:1440	cemiplimab	1431:1440	cemiplimab	1431:1440	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	3	2	from	effects	477:483	arg1	interactions					516:527	the interactions	512:527	the interactions with cemiplimab	512:543	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	1	3	theme	powerful	223:230	arg1	therapy					124:130	Immune checkpoint therapy	106:130	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1)	106:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	3	theme	powerful	223:230	arg1	treatment					241:249	a powerful clinical treatment	221:249	a powerful clinical treatment for tumors	221:260	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	4	4	theme	heavy	643:647	arg1	chain					649:653	its heavy chain	639:653	its heavy chain	639:653	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	5	5	from	glycan	876:881	arg1	loop					893:896	the BC loop	886:896	the BC loop of PD-1	886:904	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	1	6	theme	clinical	232:239	arg1	therapy					124:130	Immune checkpoint therapy	106:130	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1)	106:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	6	theme	clinical	232:239	arg1	treatment					241:249	a powerful clinical treatment	221:249	a powerful clinical treatment for tumors	221:260	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	2	7	from	approved	299:306	arg1	2018					311:314	2018	311:314	2018	311:314	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	4	8	theme	complex	583:589	arg1	structure					550:558	The structure	546:558	The structure of the cemiplimab/PD-1 complex	546:589	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	4	9	theme	predominant	694:704	arg1	region					706:711	the predominant region	690:711	the predominant region to compete with the binding of PD-L1 to PD-1	690:756	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	4	9	theme	predominant	694:704	arg1	chain					674:678	the light chain	664:678	the light chain	664:678	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	3	10	from	PD-1	464:467	arg1	interactions					516:527	the interactions	512:527	the interactions with cemiplimab	512:543	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	3	11	theme	PD-1	488:491	arg1	N-glycosylation					493:507	PD-1 N-glycosylation	488:507	PD-1 N-glycosylation	488:507	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	8	12	from	understanding	1351:1363	arg1	interaction					1414:1424	the interaction	1410:1424	the interaction with cemiplimab	1410:1440	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	8	13	from	interaction	1414:1424	arg1	understanding					1351:1363	our understanding	1347:1363	our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab	1347:1440	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	5	14	theme	interaction	763:773	arg1	network					775:781	The interaction network	759:781	The interaction network of cemiplimab to PD-1	759:803	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	2	15	from	2018	311:314	arg1	approved					299:306	approved	299:306	approved	299:306	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	6	16	theme	blocking	1086:1093	arg1	efficiency					1095:1104	the PD-1/PD-L1 blocking efficiency	1071:1104	the PD-1/PD-L1 blocking efficiency of cemiplimab	1071:1118	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	6	17	theme	binding	962:968	arg1	affinity					970:977	The binding affinity	958:977	The binding affinity of cemiplimab with PD-1	958:1001	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	5	18	theme	cemiplimab	786:795	arg1	network					775:781	The interaction network	759:781	The interaction network of cemiplimab to PD-1	759:803	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	5	19	theme	BC	890:891	arg1	loop					893:896	the BC loop	886:896	the BC loop of PD-1	886:904	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	5	20	with	interaction	929:939	arg1	cemiplimab					946:955	cemiplimab	946:955	cemiplimab	946:955	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	0	21	theme	N58-Glycosylation-Dependent	5:31	arg1	Binding					33:39	PD-1 N58-Glycosylation-Dependent Binding	0:39	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody	0:62	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	2	22	theme	IgG4	285:288	arg1	Cemiplimab					263:272	Cemiplimab	263:272	Cemiplimab	263:272	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	2	22	theme	IgG4	285:288	arg1	antibody					290:297	a human IgG4 antibody	277:297	a human IgG4 antibody approved in 2018	277:314	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	1	23	theme	Immune	106:111	arg1	treatment					241:249	a powerful clinical treatment	221:249	a powerful clinical treatment for tumors	221:260	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	23	theme	Immune	106:111	arg1	ICT					133:135	ICT	133:135	ICT	133:135	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	23	theme	Immune	106:111	arg1	therapy					124:130	Immune checkpoint therapy	106:130	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1)	106:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	6	24	theme	cemiplimab	982:991	arg1	affinity					970:977	The binding affinity	958:977	The binding affinity of cemiplimab with PD-1	958:1001	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	1	25	theme	programmed	179:188	arg1	protein					201:207	programmed cell death protein 1	179:209	programmed cell death protein 1 (PD-1)	179:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	25	theme	programmed	179:188	arg1	PD-1					212:215	PD-1	212:215	PD-1	212:215	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	0	26	theme	PD-1	0:3	arg1	Binding					33:39	PD-1 N58-Glycosylation-Dependent Binding	0:39	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody	0:62	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	1	27	theme	checkpoint	113:122	arg1	treatment					241:249	a powerful clinical treatment	221:249	a powerful clinical treatment for tumors	221:260	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	27	theme	checkpoint	113:122	arg1	ICT					133:135	ICT	133:135	ICT	133:135	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	27	theme	checkpoint	113:122	arg1	therapy					124:130	Immune checkpoint therapy	106:130	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1)	106:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	8	28	from	significance	1372:1383	arg1	interaction					1414:1424	the interaction	1410:1424	the interaction with cemiplimab	1410:1440	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	1	29	theme	cell	190:193	arg1	protein					201:207	programmed cell death protein 1	179:209	programmed cell death protein 1 (PD-1)	179:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	29	theme	cell	190:193	arg1	PD-1					212:215	PD-1	212:215	PD-1	212:215	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	7	30	gly	glycosylation	1286:1298	arg1	PD-1					1303:1306	PD-1	1303:1306	PD-1	1303:1306	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	7	31	theme	N58	1282:1284	arg1	glycosylation					1286:1298	the N58 glycosylation	1278:1298	the N58 glycosylation of PD-1	1278:1306	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	8	32	theme	glycosylation	1393:1405	arg1	significance					1372:1383	the significance	1368:1383	the significance of PD-1 glycosylation in the interaction with cemiplimab	1368:1440	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	2	33	theme	human	279:283	arg1	Cemiplimab					263:272	Cemiplimab	263:272	Cemiplimab	263:272	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	2	33	theme	human	279:283	arg1	antibody					290:297	a human IgG4 antibody	277:297	a human IgG4 antibody approved in 2018	277:314	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	1	34	theme	death	195:199	arg1	protein					201:207	programmed cell death protein 1	179:209	programmed cell death protein 1 (PD-1)	179:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	34	theme	death	195:199	arg1	PD-1					212:215	PD-1	212:215	PD-1	212:215	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	2	35	theme	cell	387:390	arg1	carcinoma					392:400	locally advanced basal cell carcinoma	364:400	locally advanced basal cell carcinoma	364:400	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	8	36	theme	PD-1	1388:1391	arg1	glycosylation					1393:1405	PD-1 glycosylation	1388:1405	PD-1 glycosylation	1388:1405	Taken together, these findings expand our understanding of the significance of PD-1 glycosylation in the interaction with cemiplimab.
35309324	5	37	theme	N58	872:874	arg1	glycan					876:881	the N58 glycan	868:881	the N58 glycan on the BC loop of PD-1	868:904	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	2	38	theme	advanced	372:379	arg1	carcinoma					392:400	locally advanced basal cell carcinoma	364:400	locally advanced basal cell carcinoma	364:400	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	0	39	theme	Antibody	55:62	arg1	Binding					33:39	PD-1 N58-Glycosylation-Dependent Binding	0:39	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody	0:62	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	5	40	theme	PD-1-binding	845:856	arg1	camrelizumab					823:834	camrelizumab	823:834	camrelizumab (another PD-1-binding MAb)	823:861	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	5	40	theme	PD-1-binding	845:856	arg1	MAb					858:860	another PD-1-binding MAb	837:860	another PD-1-binding MAb	837:860	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	6	41	theme	N58-glycosylation-deficient	1155:1181	arg1	PD-1					1183:1186	the N58-glycosylation-deficient PD-1	1151:1186	the N58-glycosylation-deficient PD-1	1151:1186	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	7	42	theme	cemiplimab	1259:1268	arg1	blocking					1238:1245	blocking	1238:1245	blocking	1238:1245	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	7	42	theme	cemiplimab	1259:1268	arg1	binding					1226:1232	binding	1226:1232	binding	1226:1232	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	0	43	theme	Monoclonal	44:53	arg1	Antibody					55:62	Monoclonal Antibody	44:62	Monoclonal Antibody	44:62	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	0	44	dep	Cemiplimab	64:73	arg1	Binding					33:39	PD-1 N58-Glycosylation-Dependent Binding	0:39	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody	0:62	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	1	45	with	therapy	124:130	arg1	antibody					156:163	a monoclonal antibody	143:163	a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1)	143:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	45	with	therapy	124:130	arg1	MAb					166:168	MAb	166:168	MAb	166:168	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	6	46	with	affinity	970:977	arg1	PD-1					998:1001	PD-1	998:1001	PD-1	998:1001	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	6	47	theme	N58-glycan-deficient	1036:1055	arg1	PD-1					1057:1060	N58-glycan-deficient PD-1	1036:1060	N58-glycan-deficient PD-1	1036:1060	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	3	48	theme	cemiplimab	444:453	arg1	structure					431:439	the crystal structure	419:439	the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab	419:543	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	6	49	theme	cemiplimab	1109:1118	arg1	efficiency					1095:1104	the PD-1/PD-L1 blocking efficiency	1071:1104	the PD-1/PD-L1 blocking efficiency of cemiplimab	1071:1118	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	7	50	dep	binding	1226:1232	arg1	efficacy					1247:1254	efficacy	1247:1254	efficacy	1247:1254	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	7	50	dep	binding	1226:1232	arg1	the					1222:1224	the	1222:1224	the	1222:1224	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	4	51	theme	PD-L1	744:748	arg1	binding					733:739	the binding	729:739	the binding of PD-L1 to PD-1	729:756	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	3	52	theme	crystal	423:429	arg1	structure					431:439	the crystal structure	419:439	the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab	419:543	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	3	53	theme	N-glycosylation	493:507	arg1	PD-1					464:467	PD-1	464:467	PD-1	464:467	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	3	53	theme	N-glycosylation	493:507	arg1	effects					477:483	the effects	473:483	the effects of PD-1 N-glycosylation on the interactions with cemiplimab	473:543	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	6	54	theme	PD-1/PD-L1	1075:1084	arg1	efficiency					1095:1104	the PD-1/PD-L1 blocking efficiency	1071:1104	the PD-1/PD-L1 blocking efficiency of cemiplimab	1071:1118	The binding affinity of cemiplimab with PD-1 was substantially decreased with N58-glycan-deficient PD-1, whereas the PD-1/PD-L1 blocking efficiency of cemiplimab was attenuated upon binding to the N58-glycosylation-deficient PD-1.
35309324	7	55	theme	PD-1	1303:1306	arg1	glycosylation					1286:1298	the N58 glycosylation	1278:1298	the N58 glycosylation of PD-1	1278:1306	These results indicate that both the binding and blocking efficacy of cemiplimab require the N58 glycosylation of PD-1.
35309324	2	56	theme	approved	299:306	arg1	Cemiplimab					263:272	Cemiplimab	263:272	Cemiplimab	263:272	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	2	56	theme	approved	299:306	arg1	antibody					290:297	a human IgG4 antibody	277:297	a human IgG4 antibody approved in 2018	277:314	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	4	57	theme	light	668:672	arg1	region					706:711	the predominant region	690:711	the predominant region to compete with the binding of PD-L1 to PD-1	690:756	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	4	57	theme	light	668:672	arg1	chain					674:678	the light chain	664:678	the light chain	664:678	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	0	58	theme	Checkpoint	86:95	arg1	Therapy					97:103	Immune Checkpoint Therapy	79:103	Immune Checkpoint Therapy	79:103	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	5	59	theme	PD-1	901:904	arg1	loop					893:896	the BC loop	886:896	the BC loop of PD-1	886:904	The interaction network of cemiplimab to PD-1 resembles that of camrelizumab (another PD-1-binding MAb), and the N58 glycan on the BC loop of PD-1 may be involved in the interaction with cemiplimab.
35309324	2	60	theme	basal	381:385	arg1	carcinoma					392:400	locally advanced basal cell carcinoma	364:400	locally advanced basal cell carcinoma	364:400	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
35309324	1	61	theme	monoclonal	145:154	arg1	antibody					156:163	a monoclonal antibody	143:163	a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1)	143:216	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	1	61	theme	monoclonal	145:154	arg1	MAb					166:168	MAb	166:168	MAb	166:168	Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors.
35309324	4	62	theme	cemiplimab/PD-1	567:581	arg1	complex					583:589	the cemiplimab/PD-1 complex	563:589	the cemiplimab/PD-1 complex	563:589	The structure of the cemiplimab/PD-1 complex shows that cemiplimab mainly binds to PD-1 with its heavy chain, whereas the light chain serves as the predominant region to compete with the binding of PD-L1 to PD-1.
35309324	0	63	theme	Immune	79:84	arg1	Therapy					97:103	Immune Checkpoint Therapy	79:103	Immune Checkpoint Therapy	79:103	PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy.
35309324	3	64	with	interactions	516:527	arg1	cemiplimab					534:543	cemiplimab	534:543	cemiplimab	534:543	Here, we report the crystal structure of cemiplimab bound to PD-1 and the effects of PD-1 N-glycosylation on the interactions with cemiplimab.
35309324	2	65	theme	first	327:331	arg1	MAb					333:335	the first MAb	323:335	the first MAb proven to be effective for locally advanced basal cell carcinoma	323:400	Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma.
36528711	6	0	theme	Fc	957:958	arg1	peptide					960:966	the Fc peptide	953:966	the Fc peptide	953:966	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	4	1	theme	IgG1	630:633	arg1	substrate					638:646	their IgG1 Fc substrate	624:646	their IgG1 Fc substrate	624:646	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	1	2	theme	pathogenic	162:171	arg1	bacteria					173:180	pathogenic bacteria	162:180	pathogenic bacteria	162:180	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	2	3	theme	IgG	375:377	arg1	deglycosylation					350:364	deglycosylation	350:364	deglycosylation	350:364	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	2	3	theme	IgG	375:377	arg1	cleavage					337:344	cleavage	337:344	cleavage	337:344	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	1	4	theme	IgG	118:120	arg1	antibodies					122:131	IgG antibodies	118:131	IgG antibodies	118:131	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	4	5	with	complex	611:617	arg1	substrate					638:646	their IgG1 Fc substrate	624:646	their IgG1 Fc substrate	624:646	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	4	6	theme	Fc	635:636	arg1	substrate					638:646	their IgG1 Fc substrate	624:646	their IgG1 Fc substrate	624:646	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	2	7	theme	human	369:373	arg1	IgG					375:377	human IgG	369:377	human IgG	369:377	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	2	8	theme	glycosidase	290:300	arg1	EndoS					302:306	the glycosidase EndoS	286:306	the glycosidase EndoS	286:306	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	4	9	theme	preferential	702:713	arg1	crystallisation					718:732	preferential Fc crystallisation	702:732	preferential Fc crystallisation	702:732	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	5	10	theme	antibody	803:810	arg1	hinge					812:816	the antibody hinge	799:816	the antibody hinge	799:816	The IdeS protease displays extensive Fc recognition and encases the antibody hinge.
36528711	3	11	theme	kidney	434:439	arg1	transplantation					441:455	kidney transplantation	434:455	kidney transplantation	434:455	IdeS has received clinical approval for kidney transplantation in hypersensitised individuals, while EndoS has found application in engineering antibody glycosylation.
36528711	3	12	theme	clinical	412:419	arg1	approval					421:428	clinical approval	412:428	clinical approval for kidney transplantation	412:455	IdeS has received clinical approval for kidney transplantation in hypersensitised individuals, while EndoS has found application in engineering antibody glycosylation.
36528711	0	13	theme	substrate	10:18	arg1	recognition					20:30	Extensive substrate recognition	0:30	Extensive substrate recognition by the streptococcal antibody-degrading enzymes	0:78	Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS.
36528711	6	14	theme	hydrolase	842:850	arg1	domain					852:857	the glycan hydrolase domain	831:857	the glycan hydrolase domain in EndoS	831:866	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	1	15	theme	Enzymatic	96:104	arg1	cleavage					106:113	Enzymatic cleavage	96:113	Enzymatic cleavage of IgG antibodies	96:131	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	1	15	theme	Enzymatic	96:104	arg1	strategy					145:152	a common strategy	136:152	a common strategy used by pathogenic bacteria to ablate immune effector function	136:215	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	6	16	theme	additional	927:936	arg1	recognition					938:948	additional recognition	927:948	additional recognition of the Fc peptide	927:966	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	0	17	theme	Extensive	0:8	arg1	recognition					20:30	Extensive substrate recognition	0:30	Extensive substrate recognition by the streptococcal antibody-degrading enzymes	0:78	Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS.
36528711	6	18	theme	glycan	835:840	arg1	domain					852:857	the glycan hydrolase domain	831:857	the glycan hydrolase domain in EndoS	831:866	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	3	19	theme	hypersensitised	460:474	arg1	individuals					476:486	hypersensitised individuals	460:486	hypersensitised individuals	460:486	IdeS has received clinical approval for kidney transplantation in hypersensitised individuals, while EndoS has found application in engineering antibody glycosylation.
36528711	4	20	theme	enzymes	600:606	arg1	structures					581:590	crystal structures	573:590	crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation	573:732	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	7	21	theme	bacterial	1095:1103	arg1	enzymes					1105:1111	bacterial enzymes	1095:1111	bacterial enzymes	1095:1111	In this work, we reveal the molecular basis of antibody recognition by bacterial enzymes, providing a template for the development of next-generation enzymes.
36528711	1	22	theme	effector	199:206	arg1	function					208:215	immune effector function	192:215	immune effector function	192:215	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	6	23	theme	carbohydrate	995:1006	arg1	module					1016:1021	the so-called carbohydrate binding module	981:1021	the so-called carbohydrate binding module	981:1021	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	5	24	theme	extensive	762:770	arg1	recognition					775:785	extensive Fc recognition	762:785	extensive Fc recognition	762:785	The IdeS protease displays extensive Fc recognition and encases the antibody hinge.
36528711	0	25	dep	IdeS	80:83	arg1	recognition					20:30	Extensive substrate recognition	0:30	Extensive substrate recognition by the streptococcal antibody-degrading enzymes	0:78	Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS.
36528711	2	26	dep	Streptococcus	222:234	arg1	pyogenes					236:243	pyogenes	236:243	pyogenes	236:243	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	0	27	theme	streptococcal	39:51	arg1	enzymes					72:78	the streptococcal antibody-degrading enzymes	35:78	the streptococcal antibody-degrading enzymes	35:78	Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS.
36528711	6	28	theme	so-called	985:993	arg1	module					1016:1021	the so-called carbohydrate binding module	981:1021	the so-called carbohydrate binding module	981:1021	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	5	29	theme	Fc	772:773	arg1	recognition					775:785	extensive Fc recognition	762:785	extensive Fc recognition	762:785	The IdeS protease displays extensive Fc recognition and encases the antibody hinge.
36528711	6	30	theme	"	905:905	arg1	conformation					907:918	a "flipped-out" conformation	891:918	a "flipped-out" conformation	891:918	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	1	31	theme	immune	192:197	arg1	function					208:215	immune effector function	192:215	immune effector function	192:215	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	6	32	from	domain	852:857	arg1	EndoS					862:866	EndoS	862:866	EndoS	862:866	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	6	33	theme	flipped-out	894:904	arg1	conformation					907:918	a "flipped-out" conformation	891:918	a "flipped-out" conformation	891:918	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	4	34	from	structures	581:590	arg1	complex					611:617	complex	611:617	complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation	611:732	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	4	35	theme	crystal	573:579	arg1	structures					581:590	crystal structures	573:590	crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation	573:732	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	6	36	theme	binding	1008:1014	arg1	module					1016:1021	the so-called carbohydrate binding module	981:1021	the so-called carbohydrate binding module	981:1021	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	7	37	theme	molecular	1052:1060	arg1	basis					1062:1066	the molecular basis	1048:1066	the molecular basis of antibody recognition	1048:1090	In this work, we reveal the molecular basis of antibody recognition by bacterial enzymes, providing a template for the development of next-generation enzymes.
36528711	1	38	theme	antibodies	122:131	arg1	cleavage					106:113	Enzymatic cleavage	96:113	Enzymatic cleavage of IgG antibodies	96:131	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	1	38	theme	antibodies	122:131	arg1	strategy					145:152	a common strategy	136:152	a common strategy used by pathogenic bacteria to ablate immune effector function	136:215	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	0	39	theme	antibody-degrading	53:70	arg1	enzymes					72:78	the streptococcal antibody-degrading enzymes	35:78	the streptococcal antibody-degrading enzymes	35:78	Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS.
36528711	7	40	theme	antibody	1071:1078	arg1	recognition					1080:1090	antibody recognition	1071:1090	antibody recognition	1071:1090	In this work, we reveal the molecular basis of antibody recognition by bacterial enzymes, providing a template for the development of next-generation enzymes.
36528711	2	41	theme	Streptococcus	222:234	arg1	bacterium					245:253	The Streptococcus pyogenes bacterium	218:253	The Streptococcus pyogenes bacterium	218:253	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	3	42	theme	antibody	538:545	arg1	glycosylation					547:559	antibody glycosylation	538:559	antibody glycosylation	538:559	IdeS has received clinical approval for kidney transplantation in hypersensitised individuals, while EndoS has found application in engineering antibody glycosylation.
36528711	5	43	theme	IdeS	739:742	arg1	protease					744:751	The IdeS protease	735:751	The IdeS protease	735:751	The IdeS protease displays extensive Fc recognition and encases the antibody hinge.
36528711	4	44	theme	Fc	715:716	arg1	crystallisation					718:732	preferential Fc crystallisation	702:732	preferential Fc crystallisation	702:732	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	7	45	theme	enzymes	1174:1180	arg1	development					1143:1153	the development	1139:1153	the development of next-generation enzymes	1139:1180	In this work, we reveal the molecular basis of antibody recognition by bacterial enzymes, providing a template for the development of next-generation enzymes.
36528711	2	46	gly	deglycosylation	350:364	arg1	IgG					375:377	human IgG	369:377	human IgG	369:377	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	1	47	theme	common	138:143	arg1	cleavage					106:113	Enzymatic cleavage	96:113	Enzymatic cleavage of IgG antibodies	96:131	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	1	47	theme	common	138:143	arg1	strategy					145:152	a common strategy	136:152	a common strategy used by pathogenic bacteria to ablate immune effector function	136:215	Enzymatic cleavage of IgG antibodies is a common strategy used by pathogenic bacteria to ablate immune effector function.
36528711	6	48	theme	Fc	878:879	arg1	glycan					881:886	the Fc glycan	874:886	the Fc glycan	874:886	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	2	49	theme	protease	268:275	arg1	IdeS					277:280	the protease IdeS	264:280	the protease IdeS	264:280	The Streptococcus pyogenes bacterium secretes the protease IdeS and the glycosidase EndoS, which specifically catalyse cleavage and deglycosylation of human IgG, respectively.
36528711	4	50	theme	Fc	674:675	arg1	engineering					677:687	Fc engineering	674:687	Fc engineering	674:687	We present crystal structures of both enzymes in complex with their IgG1 Fc substrate, which was achieved using Fc engineering to disfavour preferential Fc crystallisation.
36528711	7	51	theme	next-generation	1158:1172	arg1	enzymes					1174:1180	next-generation enzymes	1158:1180	next-generation enzymes	1158:1180	In this work, we reveal the molecular basis of antibody recognition by bacterial enzymes, providing a template for the development of next-generation enzymes.
36528711	6	52	theme	peptide	960:966	arg1	recognition					938:948	additional recognition	927:948	additional recognition of the Fc peptide	927:966	Conversely, the glycan hydrolase domain in EndoS traps the Fc glycan in a "flipped-out" conformation, while additional recognition of the Fc peptide is driven by the so-called carbohydrate binding module.
36528711	7	53	theme	recognition	1080:1090	arg1	basis					1062:1066	the molecular basis	1048:1066	the molecular basis of antibody recognition	1048:1090	In this work, we reveal the molecular basis of antibody recognition by bacterial enzymes, providing a template for the development of next-generation enzymes.
36005851	3	0	from	synthesis	410:418	arg1	residues					497:504	two protected glucose residues	475:504	two protected glucose residues	475:504	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	0	from	synthesis	410:418	arg1	glycosylations					533:546	several chemoselective glycosylations	510:546	several chemoselective glycosylations involving thioglycoside donors	510:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	1	1	from	Canetti	179:185	arg1	glycans					139:145	lipooligosaccharide (LOS) glycans	113:145	lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti	113:185	A route for preparing lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti was developed and applied to the most complex of these structures, LOS II.
36005851	2	2	theme	nonasaccharide	290:303	arg1	synthesis					266:274	The synthesis	262:274	The synthesis of the target nonasaccharide	262:303	The synthesis of the target nonasaccharide was achieved via a convergent [3+3+3] approach.
36005851	2	3	theme	target	283:288	arg1	nonasaccharide					290:303	the target nonasaccharide	279:303	the target nonasaccharide	279:303	The synthesis of the target nonasaccharide was achieved via a convergent [3+3+3] approach.
36005851	3	4	theme	glucose	489:495	arg1	residues					497:504	two protected glucose residues	475:504	two protected glucose residues	475:504	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	5	theme	trehalose	453:461	arg1	moiety					463:468	an asymmetrically substituted trehalose moiety	423:468	an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	423:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	6	theme	Key	353:355	arg1	features					357:364	Key features	353:364	Key features of the strategy	353:380	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	7	from	residues	497:504	arg1	synthesis					410:418	the stereoselective synthesis	390:418	the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	390:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	7	from	residues	497:504	arg1	moiety					463:468	an asymmetrically substituted trehalose moiety	423:468	an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	423:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	8	theme	moiety	463:468	arg1	synthesis					410:418	the stereoselective synthesis	390:418	the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	390:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	9	theme	substituted	441:451	arg1	moiety					463:468	an asymmetrically substituted trehalose moiety	423:468	an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	423:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	0	10	theme	Mycobacterium	17:29	arg1	Nonasaccharide					75:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide.
36005851	1	11	theme	lipooligosaccharide	113:131	arg1	glycans					139:145	lipooligosaccharide (LOS) glycans	113:145	lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti	113:185	A route for preparing lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti was developed and applied to the most complex of these structures, LOS II.
36005851	3	12	from	glycosylations	533:546	arg1	synthesis					410:418	the stereoselective synthesis	390:418	the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	390:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	12	from	glycosylations	533:546	arg1	moiety					463:468	an asymmetrically substituted trehalose moiety	423:468	an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	423:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	13	theme	protected	479:487	arg1	residues					497:504	two protected glucose residues	475:504	two protected glucose residues	475:504	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	14	theme	strategy	373:380	arg1	features					357:364	Key features	353:364	Key features of the strategy	353:380	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	1	15	theme	most	220:223	arg1	LOS					254:256	LOS II	254:259	LOS II	254:259	A route for preparing lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti was developed and applied to the most complex of these structures, LOS II.
36005851	1	15	theme	most	220:223	arg1	complex					225:231	the most complex	216:231	the most complex of these structures	216:251	A route for preparing lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti was developed and applied to the most complex of these structures, LOS II.
36005851	0	16	theme	Canetti	44:50	arg1	Nonasaccharide					75:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide.
36005851	0	17	theme	tuberculosis	31:42	arg1	Nonasaccharide					75:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide.
36005851	3	18	theme	stereoselective	394:408	arg1	synthesis					410:418	the stereoselective synthesis	390:418	the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors	390:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	3	19	theme	several	510:516	arg1	glycosylations					533:546	several chemoselective glycosylations	510:546	several chemoselective glycosylations involving thioglycoside donors	510:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	0	20	theme	Lipooligosaccharide	52:70	arg1	Nonasaccharide					75:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide	13:88	Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide.
36005851	3	21	theme	chemoselective	518:531	arg1	glycosylations					533:546	several chemoselective glycosylations	510:546	several chemoselective glycosylations involving thioglycoside donors	510:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	2	22	theme	[3+3+3	335:340	arg1	approach					343:350	a convergent [3+3+3] approach	322:350	a convergent [3+3+3] approach	322:350	The synthesis of the target nonasaccharide was achieved via a convergent [3+3+3] approach.
36005851	2	23	theme	convergent	324:333	arg1	approach					343:350	a convergent [3+3+3] approach	322:350	a convergent [3+3+3] approach	322:350	The synthesis of the target nonasaccharide was achieved via a convergent [3+3+3] approach.
36005851	1	24	theme	structures	242:251	arg1	LOS					254:256	LOS II	254:259	LOS II	254:259	A route for preparing lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti was developed and applied to the most complex of these structures, LOS II.
36005851	1	24	theme	structures	242:251	arg1	complex					225:231	the most complex	216:231	the most complex of these structures	216:251	A route for preparing lipooligosaccharide (LOS) glycans from Mycobacterium tuberculosis Canetti was developed and applied to the most complex of these structures, LOS II.
36005851	3	25	theme	thioglycoside	558:570	arg1	donors					572:577	thioglycoside donors	558:577	thioglycoside donors	558:577	Key features of the strategy include the stereoselective synthesis of an asymmetrically substituted trehalose moiety from two protected glucose residues and several chemoselective glycosylations involving thioglycoside donors.
36005851	0	26	theme	Nonasaccharide	75:88	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide.	0:89	Synthesis of the Mycobacterium tuberculosis Canetti Lipooligosaccharide II Nonasaccharide.
36775128	0	0	theme	TSP	72:74	arg1	family					84:89	the TSP protein family	68:89	the TSP protein family	68:89	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	0	1	from	abundance	14:22	arg1	parvum					110:115	Cryptosporidium parvum	94:115	Cryptosporidium parvum	94:115	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	5	2	theme	protein	760:766	arg1	level					768:772	the protein level	756:772	the protein level	756:772	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	1	3	theme	zoonotic	146:153	arg1	parasite					168:175	a zoonotic apicomplexan parasite	144:175	a zoonotic apicomplexan parasite	144:175	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	3	theme	zoonotic	146:153	arg1	parvum					134:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	3	theme	zoonotic	146:153	arg1	worldwide					217:225	diarrheal disease worldwide	199:225	diarrheal disease worldwide	199:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	6	4	theme	ZIC-HILIC	918:926	arg1	techniques					939:948	antibody-enabled and ZIC-HILIC enrichment techniques	897:948	antibody-enabled and ZIC-HILIC enrichment techniques	897:948	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	4	5	theme	orthologous	516:526	arg1	proteins					550:557	12 orthologous TSR domain-containing proteins	513:557	12 orthologous TSR domain-containing proteins known as CpTSP1-12	513:576	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36775128	8	6	attach	present	1532:1538	arg1	meronts					1564:1570	meronts	1564:1570	meronts	1564:1570	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	6	attach	present	1532:1538	arg1	sporozoites					1548:1558	sporozoites	1548:1558	sporozoites	1548:1558	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	6	attach	present	1532:1538	arg2	it					1393:1394	it	1393:1394	it	1393:1394	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	1	7	theme	apicomplexan	155:166	arg1	parasite					168:175	a zoonotic apicomplexan parasite	144:175	a zoonotic apicomplexan parasite	144:175	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	7	theme	apicomplexan	155:166	arg1	parvum					134:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	7	theme	apicomplexan	155:166	arg1	worldwide					217:225	diarrheal disease worldwide	199:225	diarrheal disease worldwide	199:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	0	8	theme	family	84:89	arg1	abundance					14:22	abundance	14:22	abundance	14:22	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	0	8	theme	family	84:89	arg1	profile					39:45	glycosylation profile	25:45	glycosylation profile	25:45	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	0	8	theme	family	84:89	arg1	Conservation					0:11	Conservation	0:11	Conservation	0:11	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	0	8	theme	family	84:89	arg1	localization					52:63	localization	52:63	localization	52:63	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	0	9	from	Conservation	0:11	arg1	parvum					110:115	Cryptosporidium parvum	94:115	Cryptosporidium parvum	94:115	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	9	10	theme	new	1589:1591	arg1	light					1593:1597	new light	1589:1597	new light	1589:1597	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	9	11	theme	vaccines	1728:1735	arg1	biology					1697:1703	parasite biology	1688:1703	parasite biology	1688:1703	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	9	11	theme	vaccines	1728:1735	arg1	development					1713:1723	the development	1709:1723	the development of vaccines against cryptosporidiosis	1709:1761	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	8	12	theme	adhesins	1515:1522	arg1	reminiscent					1461:1471	reminiscent	1461:1471	reminiscent	1461:1471	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	0	13	theme	protein	76:82	arg1	family					84:89	the TSP protein family	68:89	the TSP protein family	68:89	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	8	14	dep	sporozoites	1548:1558	arg1	both					1540:1543	both	1540:1543	both	1540:1543	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	9	15	theme	proteins	1639:1646	arg1	family					1619:1624	an under-studied family	1602:1624	an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis	1602:1761	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	8	16	from	sporozoites	1548:1558	arg1	present					1532:1538	present	1532:1538	present	1532:1538	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	0	17	theme	Cryptosporidium	94:108	arg1	parvum					110:115	Cryptosporidium parvum	94:115	Cryptosporidium parvum	94:115	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	9	18	theme	parasite	1688:1695	arg1	biology					1697:1703	parasite biology	1688:1703	parasite biology	1688:1703	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	6	19	link	N-linked	1016:1023	arg1	glycans					1025:1031	N-linked glycans	1016:1031	N-linked glycans	1016:1031	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	6	20	gly	glycosylation	835:847	arg1	proteins					865:872	these proteins	859:872	these proteins	859:872	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	7	21	theme	C.	1288:1289	arg1	sporozoites					1298:1308	C. parvum sporozoites	1288:1308	C. parvum sporozoites	1288:1308	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	0	22	from	profile	39:45	arg1	parvum					110:115	Cryptosporidium parvum	94:115	Cryptosporidium parvum	94:115	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	7	23	theme	CpTSP	1129:1133	arg1	family					1143:1148	the CpTSP protein family	1125:1148	the CpTSP protein family within C. parvum	1125:1165	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	7	24	theme	parvum	1291:1296	arg1	sporozoites					1298:1308	C. parvum sporozoites	1288:1308	C. parvum sporozoites	1288:1308	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	7	25	theme	C.	1157:1158	arg1	parvum					1160:1165	C. parvum	1157:1165	C. parvum	1157:1165	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	9	26	theme	under-studied	1605:1617	arg1	family					1619:1624	an under-studied family	1602:1624	an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis	1602:1761	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	3	27	theme	conserved	426:434	arg1	adhesin					436:442	a conserved adhesin	424:442	a conserved adhesin possessing a thrombospondin repeat (TSR) domain	424:490	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	8	28	theme	other	1476:1480	arg1	adhesins					1515:1522	other apicomplexan motility-associated adhesins	1476:1522	other apicomplexan motility-associated adhesins	1476:1522	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	29	theme	cell	1412:1415	arg1	surface					1417:1423	the cell surface	1408:1423	the cell surface	1408:1423	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	1	30	theme	common	183:188	arg1	cause					190:194	a common cause	181:194	a common cause of diarrheal disease worldwide	181:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	3	31	theme	approved	365:372	arg1	vaccine					374:380	the only approved vaccine	356:380	the only approved vaccine against any apicomplexan parasite	356:414	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	7	32	theme	sporozoites	1298:1308	arg1	pathway					1277:1283	the secretory pathway	1263:1283	the secretory pathway of C. parvum sporozoites	1263:1308	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	5	33	theme	protein	710:716	arg1	family					718:723	the CpTSP protein family	700:723	the CpTSP protein family	700:723	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	4	34	theme	C.	493:494	arg1	parvum					496:501	C. parvum	493:501	C. parvum	493:501	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36775128	2	35	theme	important	297:305	arg1	goal					307:310	an important goal	294:310	an important goal for tackling cryptosporidiosis	294:341	The development of vaccines to prevent or limit infection remains an important goal for tackling cryptosporidiosis.
36775128	8	36	located	present	1532:1538	arg1	meronts					1564:1570	meronts	1564:1570	meronts	1564:1570	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	36	located	present	1532:1538	arg1	sporozoites					1548:1558	sporozoites	1548:1558	sporozoites	1548:1558	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	36	located	present	1532:1538	arg2	it					1393:1394	it	1393:1394	it	1393:1394	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	37	theme	motility-associated	1495:1513	arg1	adhesins					1515:1522	other apicomplexan motility-associated adhesins	1476:1522	other apicomplexan motility-associated adhesins	1476:1522	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	5	38	theme	family	718:723	arg1	conservation					684:695	conservation	684:695	conservation	684:695	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	5	38	theme	family	718:723	arg1	abundance					743:751	their abundance	737:751	their abundance at the protein level	737:772	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	5	38	theme	family	718:723	arg1	architecture					667:678	architecture	667:678	architecture	667:678	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	6	39	theme	proteins	865:872	arg1	states					849:854	the glycosylation states	831:854	the glycosylation states of these proteins	831:872	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	4	40	contain	possesses	503:511	arg1	parvum					496:501	C. parvum	493:501	C. parvum	493:501	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36775128	4	40	contain	possesses	503:511	arg2	proteins					550:557	12 orthologous TSR domain-containing proteins	513:557	12 orthologous TSR domain-containing proteins known as CpTSP1-12	513:576	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36775128	8	41	theme	reminiscent	1461:1471	arg1	pattern					1453:1459	a pattern	1451:1459	a pattern reminiscent of other apicomplexan motility-associated adhesins	1451:1522	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	7	42	theme	secretory	1267:1275	arg1	pathway					1277:1283	the secretory pathway	1263:1283	the secretory pathway of C. parvum sporozoites	1263:1308	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	6	43	mod	modified	990:997	arg3	glycans					1025:1031	N-linked glycans	1016:1031	N-linked glycans	1016:1031	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	6	43	mod	modified	990:997	arg3	O-					1008:1009	O-	1008:1009	O-	1008:1009	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	6	43	mod	modified	990:997	arg3	C-					1004:1005	C-	1004:1005	C-	1004:1005	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	6	43	mod	modified	990:997	arg1	proteins					977:984	these proteins	971:984	these proteins	971:984	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	8	44	theme	apicomplexan	1482:1493	arg1	adhesins					1515:1522	other apicomplexan motility-associated adhesins	1476:1522	other apicomplexan motility-associated adhesins	1476:1522	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	9	45	theme	parvum	1632:1637	arg1	proteins					1639:1646	C. parvum proteins	1629:1646	C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis	1629:1761	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	1	46	theme	diarrheal	199:207	arg1	worldwide					217:225	diarrheal disease worldwide	199:225	diarrheal disease worldwide	199:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	7	47	link	C-linked	1090:1097	arg1	mannose					1099:1105	the C-linked mannose	1086:1105	the C-linked mannose that is unique to the CpTSP protein family within C. parvum	1086:1165	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	7	47	link	C-linked	1090:1097	arg1	unique					1115:1120	unique	1115:1120	unique	1115:1120	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	3	48	theme	thrombospondin	457:470	arg1	repeat					472:477	thrombospondin repeat	457:477	a thrombospondin repeat (TSR) domain	455:490	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	3	48	theme	thrombospondin	457:470	arg1	TSR					480:482	TSR	480:482	TSR	480:482	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	0	49	theme	glycosylation	25:37	arg1	profile					39:45	glycosylation profile	25:45	glycosylation profile	25:45	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	4	50	theme	domain-containing	532:548	arg1	proteins					550:557	12 orthologous TSR domain-containing proteins	513:557	12 orthologous TSR domain-containing proteins known as CpTSP1-12	513:576	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36775128	7	51	theme	protein	1135:1141	arg1	family					1143:1148	the CpTSP protein family	1125:1148	the CpTSP protein family within C. parvum	1125:1165	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	5	52	theme	lifecycle	809:817	arg1	stage					796:800	the sporozoite stage	781:800	the sporozoite stage of the lifecycle	781:817	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	1	53	theme	disease	209:215	arg1	worldwide					217:225	diarrheal disease worldwide	199:225	diarrheal disease worldwide	199:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	3	54	theme	apicomplexan	394:405	arg1	parasite					407:414	any apicomplexan parasite	390:414	any apicomplexan parasite	390:414	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	4	55	theme	TSR	528:530	arg1	proteins					550:557	12 orthologous TSR domain-containing proteins	513:557	12 orthologous TSR domain-containing proteins known as CpTSP1-12	513:576	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36775128	0	56	from	localization	52:63	arg1	parvum					110:115	Cryptosporidium parvum	94:115	Cryptosporidium parvum	94:115	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	3	57	theme	repeat	472:477	arg1	domain					485:490	a thrombospondin repeat (TSR) domain	455:490	a thrombospondin repeat (TSR) domain	455:490	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	6	58	theme	antibody-enabled	897:912	arg1	techniques					939:948	antibody-enabled and ZIC-HILIC enrichment techniques	897:948	antibody-enabled and ZIC-HILIC enrichment techniques	897:948	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	7	59	theme	expansion	1040:1048	arg1	microscopy					1050:1059	expansion microscopy	1040:1059	expansion microscopy	1040:1059	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	6	60	theme	glycosylation	835:847	arg1	states					849:854	the glycosylation states	831:854	the glycosylation states of these proteins	831:872	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	7	61	theme	C-linked	1090:1097	arg1	mannose					1099:1105	the C-linked mannose	1086:1105	the C-linked mannose that is unique to the CpTSP protein family within C. parvum	1086:1165	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	7	61	theme	C-linked	1090:1097	arg1	unique					1115:1120	unique	1115:1120	unique	1115:1120	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	6	62	theme	techniques	939:948	arg1	combination					882:892	a combination	880:892	a combination of antibody-enabled and ZIC-HILIC enrichment techniques	880:948	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	8	63	from	meronts	1564:1570	arg1	present					1532:1538	present	1532:1538	present	1532:1538	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	5	64	from	level	768:772	arg1	conservation					684:695	conservation	684:695	conservation	684:695	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	5	64	from	level	768:772	arg1	abundance					743:751	their abundance	737:751	their abundance at the protein level	737:772	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	5	64	from	level	768:772	arg1	architecture					667:678	architecture	667:678	architecture	667:678	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	0	65	gly	glycosylation	25:37	arg1	family					84:89	the TSP protein family	68:89	the TSP protein family	68:89	Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
36775128	1	66	theme	Cryptosporidium	118:132	arg1	parasite					168:175	a zoonotic apicomplexan parasite	144:175	a zoonotic apicomplexan parasite	144:175	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	66	theme	Cryptosporidium	118:132	arg1	parvum					134:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	66	theme	Cryptosporidium	118:132	arg1	worldwide					217:225	diarrheal disease worldwide	199:225	diarrheal disease worldwide	199:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	8	67	theme	polyclonal	1335:1344	arg1	antibody					1346:1353	a polyclonal antibody	1333:1353	a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts	1333:1570	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	1	68	theme	worldwide	217:225	arg1	parasite					168:175	a zoonotic apicomplexan parasite	144:175	a zoonotic apicomplexan parasite	144:175	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	68	theme	worldwide	217:225	arg1	parvum					134:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum	118:139	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	68	theme	worldwide	217:225	arg1	worldwide					217:225	diarrheal disease worldwide	199:225	diarrheal disease worldwide	199:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	1	68	theme	worldwide	217:225	arg1	cause					190:194	a common cause	181:194	a common cause of diarrheal disease worldwide	181:225	Cryptosporidium parvum is a zoonotic apicomplexan parasite and a common cause of diarrheal disease worldwide.
36775128	5	69	theme	CpTSP	704:708	arg1	family					718:723	the CpTSP protein family	700:723	the CpTSP protein family	700:723	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	8	70	from	present	1532:1538	arg1	meronts					1564:1570	meronts	1564:1570	meronts	1564:1570	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	70	from	present	1532:1538	arg1	sporozoites					1548:1558	sporozoites	1548:1558	sporozoites	1548:1558	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	7	71	located	found	1200:1204	arg2	proteins					1187:1194	these proteins	1181:1194	these proteins	1181:1194	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	7	71	located	found	1200:1204	arg1	surface					1223:1229	the cell surface	1214:1229	the cell surface	1214:1229	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	7	72	theme	cell	1218:1221	arg1	surface					1223:1229	the cell surface	1214:1229	the cell surface	1214:1229	Using expansion microscopy, and an antibody against the C-linked mannose that is unique to the CpTSP protein family within C. parvum, we show that these proteins are found both on the cell surface and in structures that resemble the secretory pathway of C. parvum sporozoites.
36775128	3	73	contain	possessing	444:453	arg1	adhesin					436:442	a conserved adhesin	424:442	a conserved adhesin possessing a thrombospondin repeat (TSR) domain	424:490	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	3	73	contain	possessing	444:453	arg2	domain					485:490	a thrombospondin repeat (TSR) domain	455:490	a thrombospondin repeat (TSR) domain	455:490	At present, the only approved vaccine against any apicomplexan parasite targets a conserved adhesin possessing a thrombospondin repeat (TSR) domain.
36775128	2	74	theme	vaccines	247:254	arg1	development					232:242	The development	228:242	The development of vaccines to prevent or limit infection	228:284	The development of vaccines to prevent or limit infection remains an important goal for tackling cryptosporidiosis.
36775128	8	75	located	found	1399:1403	arg1	pattern					1453:1459	a pattern	1451:1459	a pattern reminiscent of other apicomplexan motility-associated adhesins	1451:1522	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	75	located	found	1399:1403	arg2	it					1393:1394	it	1393:1394	it	1393:1394	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	8	75	located	found	1399:1403	arg1	surface					1417:1423	the cell surface	1408:1423	the cell surface	1408:1423	Finally, we generated a polyclonal antibody against CpTSP1 (TRAP-C1) to show that it is found at the cell surface and within micronemes, in a pattern reminiscent of other apicomplexan motility-associated adhesins, and is present both in sporozoites and meronts.
36775128	5	76	theme	sporozoite	785:794	arg1	stage					796:800	the sporozoite stage	781:800	the sporozoite stage of the lifecycle	781:817	Here, we explore the architecture and conservation of the CpTSP protein family, as well as their abundance at the protein level within the sporozoite stage of the lifecycle.
36775128	6	77	theme	enrichment	928:937	arg1	techniques					939:948	antibody-enabled and ZIC-HILIC enrichment techniques	897:948	antibody-enabled and ZIC-HILIC enrichment techniques	897:948	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	6	78	theme	N-linked	1016:1023	arg1	glycans					1025:1031	N-linked glycans	1016:1031	N-linked glycans	1016:1031	We examine the glycosylation states of these proteins using a combination of antibody-enabled and ZIC-HILIC enrichment techniques, to demonstrate that these proteins are modified with C-, O-, and N-linked glycans.
36775128	9	79	theme	C.	1629:1630	arg1	proteins					1639:1646	C. parvum proteins	1629:1646	C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis	1629:1761	This work sheds new light on an under-studied family of C. parvum proteins that are likely to be important to both parasite biology and the development of vaccines against cryptosporidiosis.
36775128	4	80	theme	important	626:634	arg1	antigens					636:643	these potentially important antigens	608:643	these potentially important antigens	608:643	C. parvum possesses 12 orthologous TSR domain-containing proteins known as CpTSP1-12, though little is known about these potentially important antigens.
36725259	6	0	theme	spectra	894:900	arg1	analysis					902:909	infrared spectra analysis	885:909	infrared spectra analysis	885:909	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	6	1	contain	had	940:942	arg2	characteristics					970:984	typical infrared spectral characteristics	944:984	typical infrared spectral characteristics of polysaccharides	944:1003	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	6	1	contain	had	940:942	arg1	LBPs					935:938	the five LBPs	926:938	the five LBPs	926:938	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	11	2	theme	inhibitory	1674:1683	arg1	higher					1725:1730	higher	1725:1730	higher	1725:1730	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	2	theme	inhibitory	1674:1683	arg1	rate					1685:1688	the inhibitory rate	1670:1688	the inhibitory rate of LBP-4 on α-amylase	1670:1710	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	1	3	theme	different	240:248	arg1	methods					261:267	different extraction methods	240:267	different extraction methods	240:267	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	7	4	theme	analysis	1072:1079	arg1	results					1010:1016	The results	1006:1016	The results of nuclear magnetic resonance characteristic spectrum analysis	1006:1079	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	11	5	theme	LBP-4	1693:1697	arg1	higher					1725:1730	higher	1725:1730	higher	1725:1730	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	5	theme	LBP-4	1693:1697	arg1	rate					1685:1688	the inhibitory rate	1670:1688	the inhibitory rate of LBP-4 on α-amylase	1670:1710	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	3	6	theme	%	522:522	arg1	content					505:511	The total polysaccharide content	480:511	The total polysaccharide content	480:511	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	6	theme	%	522:522	arg1	%					527:527	81.95%±1.6%	517:527	81.95%±1.6%	517:527	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	6	7	theme	spectral	961:968	arg1	characteristics					970:984	typical infrared spectral characteristics	944:984	typical infrared spectral characteristics of polysaccharides	944:1003	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	10	8	theme	lipid	1417:1421	arg1	rate					1443:1446	the highest lipid oxidation clearance rate	1405:1446	the highest lipid oxidation clearance rate	1405:1446	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	3	9	theme	protein	611:617	arg1	content					619:625	the protein content	607:625	the protein content	607:625	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	9	theme	protein	611:617	arg1	%					641:641	0.06%±0.03%	631:641	0.06%±0.03%	631:641	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	6	10	theme	typical	944:950	arg1	characteristics					970:984	typical infrared spectral characteristics	944:984	typical infrared spectral characteristics of polysaccharides	944:1003	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	3	11	theme	total	484:488	arg1	content					505:511	The total polysaccharide content	480:511	The total polysaccharide content	480:511	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	11	theme	total	484:488	arg1	%					527:527	81.95%±1.6%	517:527	81.95%±1.6%	517:527	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	0	12	from	activities	81:90	arg1	barbarum					123:130	Lycium barbarum	116:130	Lycium barbarum	116:130	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	3	13	dep	%	584:584	arg1	%					599:599	24.81%±0.46%	588:599	24.81%±0.46%	588:599	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	11	14	theme	control	1758:1764	arg1	group					1766:1770	the positive control group	1745:1770	the positive control group	1745:1770	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	9	15	theme	activities	1283:1292	arg1	screening					1294:1302	activities screening	1283:1302	activities screening	1283:1302	The results of activities screening suggested that the biological activities of the five LBPs were significantly different.
36725259	4	16	theme	LBPs	703:706	arg1	compositions					678:689	The monosaccharide compositions	659:689	The monosaccharide compositions of the five LBPs	659:706	The monosaccharide compositions of the five LBPs were basically same, mainly including glucose, xylose, and galactose.
36725259	4	16	theme	LBPs	703:706	arg1	same					723:726	same	723:726	same	723:726	The monosaccharide compositions of the five LBPs were basically same, mainly including glucose, xylose, and galactose.
36725259	8	17	theme	polysaccharides	1251:1265	arg1	activities					1237:1246	the activities	1233:1246	the activities of polysaccharides	1233:1265	Meanwhile, there were triple helix structures in LBP-2, LBP-3, and LBP-4, which enhanced the activities of polysaccharides.
36725259	10	18	theme	clearance	1433:1441	arg1	rate					1443:1446	the highest lipid oxidation clearance rate	1405:1446	the highest lipid oxidation clearance rate	1405:1446	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	7	19	theme	nuclear	1021:1027	arg1	resonance					1038:1046	nuclear magnetic resonance	1021:1046	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	5	20	theme	different	844:852	arg1	monosaccharide					854:867	different monosaccharide	844:867	different monosaccharide	844:867	However, there was significant difference in the content ratio of different monosaccharide.
36725259	3	21	theme	acid	557:560	arg1	content					562:568	the uronic acid content	546:568	the uronic acid content	546:568	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	21	theme	acid	557:560	arg1	%					584:584	8.26%±0.46%	574:584	8.26%±0.46%	574:584	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	1	22	from	barbarum	182:189	arg1	polysaccharides					154:168	five polysaccharides	149:168	five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5)	149:208	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	3	23	dep	%	527:527	arg1	%					542:542	92.96%±0.76%	531:542	92.96%±0.76%	531:542	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	13	24	dep	development	1947:1957	arg1	the					1935:1937	the	1935:1937	the	1935:1937	This study provides references for the precise development and utilization of LBPs.
36725259	7	25	theme	spectrum	1063:1070	arg1	analysis					1072:1079	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	12	26	theme	inhibitory	1839:1848	arg1	activity					1850:1857	stronger inhibitory activity	1830:1857	stronger inhibitory activity	1830:1857	LBP-2 showed stronger inhibitory activity against α-glucosidase and hyaluronidase.
36725259	3	27	theme	%	649:649	arg1	%					655:655	1.35%±0.13%	645:655	1.35%±0.13%	645:655	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	7	28	theme	resonance	1038:1046	arg1	analysis					1072:1079	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	1	29	theme	biological	332:341	arg1	activities					343:352	biological activities	332:352	biological activities	332:352	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	0	30	from	[Effects	0:7	arg1	activities					81:90	biological activities	70:90	biological activities	70:90	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	0	30	from	[Effects	0:7	arg1	compositions					53:64	chemical compositions	44:64	chemical compositions	44:64	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	0	31	theme	polysaccharides	95:109	arg1	activities					81:90	biological activities	70:90	biological activities	70:90	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	0	31	theme	polysaccharides	95:109	arg1	compositions					53:64	chemical compositions	44:64	chemical compositions	44:64	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	9	32	theme	LBPs	1357:1360	arg1	activities					1334:1343	the biological activities	1319:1343	the biological activities of the five LBPs	1319:1360	The results of activities screening suggested that the biological activities of the five LBPs were significantly different.
36725259	9	32	theme	LBPs	1357:1360	arg1	different					1381:1389	different	1381:1389	different	1381:1389	The results of activities screening suggested that the biological activities of the five LBPs were significantly different.
36725259	11	33	dep	g·L~	1807:1810	arg1	-1					1812:1813	-1	1812:1813	-1	1812:1813	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	8	34	theme	helix	1173:1177	arg1	structures					1179:1188	triple helix structures	1166:1188	triple helix structures	1166:1188	Meanwhile, there were triple helix structures in LBP-2, LBP-3, and LBP-4, which enhanced the activities of polysaccharides.
36725259	0	35	theme	biological	70:79	arg1	activities					81:90	biological activities	70:90	biological activities	70:90	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	10	36	theme	antioxidant	1457:1467	arg1	activity					1469:1476	its antioxidant activity	1453:1476	its antioxidant activity	1453:1476	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	0	37	theme	different	12:20	arg1	methods					33:39	different extraction methods	12:39	different extraction methods	12:39	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	2	38	theme	composition	401:411	arg1	analysis					413:420	chemical composition analysis	392:420	chemical composition analysis	392:420	The results of chemical composition analysis showed that alkaloids were not detected in the five LBPs.
36725259	0	39	theme	methods	33:39	arg1	[Effects					0:7	[Effects	0:7	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum	0:130	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	0	40	theme	chemical	44:51	arg1	compositions					53:64	chemical compositions	44:64	chemical compositions	44:64	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	1	41	theme	structural	300:309	arg1	characteristics					311:325	structural characteristics	300:325	structural characteristics	300:325	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	5	42	theme	content	827:833	arg1	ratio					835:839	the content ratio	823:839	the content ratio of different monosaccharide	823:867	However, there was significant difference in the content ratio of different monosaccharide.
36725259	11	43	theme	other	1649:1653	arg1	fractions					1655:1663	other fractions	1649:1663	other fractions	1649:1663	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	5	44	theme	significant	797:807	arg1	difference					809:818	significant difference	797:818	significant difference	797:818	However, there was significant difference in the content ratio of different monosaccharide.
36725259	6	45	theme	analysis	902:909	arg1	results					874:880	The results	870:880	The results of infrared spectra analysis	870:909	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	3	46	theme	%	593:593	arg1	%					599:599	24.81%±0.46%	588:599	24.81%±0.46%	588:599	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	47	theme	polysaccharide	490:503	arg1	content					505:511	The total polysaccharide content	480:511	The total polysaccharide content	480:511	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	47	theme	polysaccharide	490:503	arg1	%					527:527	81.95%±1.6%	517:527	81.95%±1.6%	517:527	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	13	48	theme	precise	1939:1945	arg1	development					1947:1957	precise development	1939:1957	precise development	1939:1957	This study provides references for the precise development and utilization of LBPs.
36725259	4	49	theme	monosaccharide	663:676	arg1	compositions					678:689	The monosaccharide compositions	659:689	The monosaccharide compositions of the five LBPs	659:706	The monosaccharide compositions of the five LBPs were basically same, mainly including glucose, xylose, and galactose.
36725259	4	49	theme	monosaccharide	663:676	arg1	same					723:726	same	723:726	same	723:726	The monosaccharide compositions of the five LBPs were basically same, mainly including glucose, xylose, and galactose.
36725259	6	50	theme	infrared	885:892	arg1	analysis					902:909	infrared spectra analysis	885:909	infrared spectra analysis	885:909	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	8	51	from	structures	1179:1188	arg1	LBP-3					1200:1204	LBP-3	1200:1204	LBP-3	1200:1204	Meanwhile, there were triple helix structures in LBP-2, LBP-3, and LBP-4, which enhanced the activities of polysaccharides.
36725259	8	51	from	structures	1179:1188	arg1	LBP-4					1211:1215	LBP-4	1211:1215	LBP-4	1211:1215	Meanwhile, there were triple helix structures in LBP-2, LBP-3, and LBP-4, which enhanced the activities of polysaccharides.
36725259	8	51	from	structures	1179:1188	arg1	LBP-2					1193:1197	LBP-2	1193:1197	LBP-2	1193:1197	Meanwhile, there were triple helix structures in LBP-2, LBP-3, and LBP-4, which enhanced the activities of polysaccharides.
36725259	1	52	theme	extraction	250:259	arg1	methods					261:267	different extraction methods	240:267	different extraction methods	240:267	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	2	53	located	detected	453:460	arg1	LBPs					474:477	the five LBPs	465:477	the five LBPs	465:477	The results of chemical composition analysis showed that alkaloids were not detected in the five LBPs.
36725259	2	53	located	detected	453:460	arg2	alkaloids					434:442	alkaloids	434:442	alkaloids	434:442	The results of chemical composition analysis showed that alkaloids were not detected in the five LBPs.
36725259	6	54	theme	polysaccharides	989:1003	arg1	characteristics					970:984	typical infrared spectral characteristics	944:984	typical infrared spectral characteristics of polysaccharides	944:1003	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	11	55	theme	activation	1582:1591	arg1	rate					1593:1596	its activation rate	1578:1596	its activation rate of alcohol dehydrogenase	1578:1621	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	10	56	theme	oxidation	1423:1431	arg1	rate					1443:1446	the highest lipid oxidation clearance rate	1405:1446	the highest lipid oxidation clearance rate	1405:1446	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	11	57	theme	dehydrogenase	1609:1621	arg1	rate					1593:1596	its activation rate	1578:1596	its activation rate of alcohol dehydrogenase	1578:1621	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	57	theme	dehydrogenase	1609:1621	arg1	better					1628:1633	better	1628:1633	better	1628:1633	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	57	theme	dehydrogenase	1609:1621	arg1	rate					1547:1550	The inhibitory rate	1532:1550	The inhibitory rate of LBP-4 on α-amylase	1532:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	6	58	theme	infrared	952:959	arg1	characteristics					970:984	typical infrared spectral characteristics	944:984	typical infrared spectral characteristics of polysaccharides	944:1003	The results of infrared spectra analysis indicated that the five LBPs had typical infrared spectral characteristics of polysaccharides.
36725259	10	59	theme	highest	1409:1415	arg1	rate					1443:1446	the highest lipid oxidation clearance rate	1405:1446	the highest lipid oxidation clearance rate	1405:1446	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	11	60	theme	alcohol	1601:1607	arg1	dehydrogenase					1609:1621	alcohol dehydrogenase	1601:1621	alcohol dehydrogenase	1601:1621	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	3	61	dep	%	641:641	arg1	%					655:655	1.35%±0.13%	645:655	1.35%±0.13%	645:655	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	11	62	theme	positive	1749:1756	arg1	group					1766:1770	the positive control group	1745:1770	the positive control group	1745:1770	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	63	from	rate	1593:1596	arg1	α-amylase					1564:1572	α-amylase	1564:1572	α-amylase	1564:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	3	64	theme	%	635:635	arg1	content					619:625	the protein content	607:625	the protein content	607:625	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	64	theme	%	635:635	arg1	%					641:641	0.06%±0.03%	631:641	0.06%±0.03%	631:641	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	65	theme	%	536:536	arg1	%					542:542	92.96%±0.76%	531:542	92.96%±0.76%	531:542	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	9	66	theme	screening	1294:1302	arg1	results					1272:1278	The results	1268:1278	The results of activities screening	1268:1302	The results of activities screening suggested that the biological activities of the five LBPs were significantly different.
36725259	11	67	from	LBP-4	1555:1559	arg1	α-amylase					1564:1572	α-amylase	1564:1572	α-amylase	1564:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	0	68	from	barbarum	123:130	arg1	activities					81:90	biological activities	70:90	biological activities	70:90	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	0	68	from	barbarum	123:130	arg1	polysaccharides					95:109	polysaccharides	95:109	polysaccharides from Lycium barbarum	95:130	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	0	68	from	barbarum	123:130	arg1	compositions					53:64	chemical compositions	44:64	chemical compositions	44:64	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	3	69	theme	uronic	550:555	arg1	content					562:568	the uronic acid content	546:568	the uronic acid content	546:568	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	69	theme	uronic	550:555	arg1	%					584:584	8.26%±0.46%	574:584	8.26%±0.46%	574:584	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	11	70	from	α-amylase	1564:1572	arg1	rate					1593:1596	its activation rate	1578:1596	its activation rate of alcohol dehydrogenase	1578:1621	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	70	from	α-amylase	1564:1572	arg1	better					1628:1633	better	1628:1633	better	1628:1633	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	70	from	α-amylase	1564:1572	arg1	rate					1547:1550	The inhibitory rate	1532:1550	The inhibitory rate of LBP-4 on α-amylase	1532:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	71	from	LBP-4	1693:1697	arg1	α-amylase					1702:1710	α-amylase	1702:1710	α-amylase	1702:1710	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	10	72	theme	positive	1508:1515	arg1	group					1525:1529	the positive control group	1504:1529	the positive control group	1504:1529	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	7	73	theme	characteristic	1048:1061	arg1	analysis					1072:1079	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	5	74	theme	monosaccharide	854:867	arg1	ratio					835:839	the content ratio	823:839	the content ratio of different monosaccharide	823:867	However, there was significant difference in the content ratio of different monosaccharide.
36725259	9	75	theme	biological	1323:1332	arg1	activities					1334:1343	the biological activities	1319:1343	the biological activities of the five LBPs	1319:1360	The results of activities screening suggested that the biological activities of the five LBPs were significantly different.
36725259	9	75	theme	biological	1323:1332	arg1	different					1381:1389	different	1381:1389	different	1381:1389	The results of activities screening suggested that the biological activities of the five LBPs were significantly different.
36725259	11	76	from	α-amylase	1702:1710	arg1	higher					1725:1730	higher	1725:1730	higher	1725:1730	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	76	from	α-amylase	1702:1710	arg1	rate					1685:1688	the inhibitory rate	1670:1688	the inhibitory rate of LBP-4 on α-amylase	1670:1710	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	77	theme	LBP-4	1555:1559	arg1	rate					1593:1596	its activation rate	1578:1596	its activation rate of alcohol dehydrogenase	1578:1621	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	77	theme	LBP-4	1555:1559	arg1	better					1628:1633	better	1628:1633	better	1628:1633	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	77	theme	LBP-4	1555:1559	arg1	rate					1547:1550	The inhibitory rate	1532:1550	The inhibitory rate of LBP-4 on α-amylase	1532:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	7	78	theme	magnetic	1029:1036	arg1	resonance					1038:1046	nuclear magnetic resonance	1021:1046	nuclear magnetic resonance characteristic spectrum analysis	1021:1079	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	11	79	from	rate	1547:1550	arg1	α-amylase					1564:1572	α-amylase	1564:1572	α-amylase	1564:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	12	80	theme	stronger	1830:1837	arg1	activity					1850:1857	stronger inhibitory activity	1830:1857	stronger inhibitory activity	1830:1857	LBP-2 showed stronger inhibitory activity against α-glucosidase and hyaluronidase.
36725259	0	81	from	compositions	53:64	arg1	barbarum					123:130	Lycium barbarum	116:130	Lycium barbarum	116:130	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	11	82	from	rate	1685:1688	arg1	α-amylase					1702:1710	α-amylase	1702:1710	α-amylase	1702:1710	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	1	83	theme	LBPs	357:360	arg1	activities					343:352	biological activities	332:352	biological activities	332:352	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	1	83	theme	LBPs	357:360	arg1	composition					287:297	the chemical composition	274:297	the chemical composition	274:297	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	1	83	theme	LBPs	357:360	arg1	characteristics					311:325	structural characteristics	300:325	structural characteristics	300:325	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	8	84	theme	triple	1166:1171	arg1	structures					1179:1188	triple helix structures	1166:1188	triple helix structures	1166:1188	Meanwhile, there were triple helix structures in LBP-2, LBP-3, and LBP-4, which enhanced the activities of polysaccharides.
36725259	7	85	contain	had	1109:1111	arg1	LBPs					1104:1107	the five LBPs	1095:1107	the five LBPs	1095:1107	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	7	85	contain	had	1109:1111	arg2	configurations					1117:1130	two configurations	1113:1130	two configurations of α and β	1113:1141	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	7	86	theme	β	1141:1141	arg1	configurations					1117:1130	two configurations	1113:1130	two configurations of α and β	1113:1141	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	0	87	theme	extraction	22:31	arg1	methods					33:39	different extraction methods	12:39	different extraction methods	12:39	[Effects of different extraction methods on chemical compositions and biological activities of polysaccharides from Lycium barbarum].
36725259	7	88	theme	α	1135:1135	arg1	configurations					1117:1130	two configurations	1113:1130	two configurations of α and β	1113:1141	The results of nuclear magnetic resonance characteristic spectrum analysis revealed that the five LBPs had two configurations of α and β.
36725259	2	89	theme	analysis	413:420	arg1	results					381:387	The results	377:387	The results of chemical composition analysis	377:420	The results of chemical composition analysis showed that alkaloids were not detected in the five LBPs.
36725259	1	90	theme	chemical	278:285	arg1	composition					287:297	the chemical composition	274:297	the chemical composition	274:297	In this study, five polysaccharides from Lycium barbarum(LBPs)(LBP-1-LBP-5) were selectively extracted by different extraction methods, and the chemical composition, structural characteristics, and biological activities of LBPs were explored.
36725259	2	91	theme	chemical	392:399	arg1	analysis					413:420	chemical composition analysis	392:420	chemical composition analysis	392:420	The results of chemical composition analysis showed that alkaloids were not detected in the five LBPs.
36725259	11	92	theme	inhibitory	1536:1545	arg1	better					1628:1633	better	1628:1633	better	1628:1633	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	92	theme	inhibitory	1536:1545	arg1	rate					1547:1550	The inhibitory rate	1532:1550	The inhibitory rate of LBP-4 on α-amylase	1532:1572	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	10	93	theme	control	1517:1523	arg1	group					1525:1529	the positive control group	1504:1529	the positive control group	1504:1529	LBP-3 showed the highest lipid oxidation clearance rate, and its antioxidant activity was equivalent to that of the positive control group.
36725259	3	94	theme	%	578:578	arg1	content					562:568	the uronic acid content	546:568	the uronic acid content	546:568	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	3	94	theme	%	578:578	arg1	%					584:584	8.26%±0.46%	574:584	8.26%±0.46%	574:584	The total polysaccharide content was(81.95%±1.6%)-(92.96%±0.76%), the uronic acid content was(8.26%±0.46%)-(24.81%±0.46%), and the protein content was(0.06%±0.03%)-(1.35%±0.13%).
36725259	11	95	theme	mass	1781:1784	arg1	concentration					1786:1798	the mass concentration	1777:1798	the mass concentration	1777:1798	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	11	95	theme	mass	1781:1784	arg1	g·L~					1807:1810	10 g·L~	1804:1810	10 g·L~	1804:1810	The inhibitory rate of LBP-4 on α-amylase and its activation rate of alcohol dehydrogenase were better than those of other fractions, and the inhibitory rate of LBP-4 on α-amylase was slightly higher than that of the positive control group when the mass concentration was 10 g·L~(-1).
36725259	13	96	theme	LBPs	1978:1981	arg1	utilization					1963:1973	utilization	1963:1973	utilization	1963:1973	This study provides references for the precise development and utilization of LBPs.
36725259	13	96	theme	LBPs	1978:1981	arg1	development					1947:1957	precise development	1939:1957	precise development	1939:1957	This study provides references for the precise development and utilization of LBPs.
35752336	0	0	theme	infected	111:118	arg1	healing					142:148	infected and susceptible wound healing	111:148	infected and susceptible wound healing	111:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	6	1	theme	good	1025:1028	arg1	biocompatibility					1030:1045	good biocompatibility	1025:1045	good biocompatibility	1025:1045	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	7	2	theme	great	1259:1263	arg1	potential					1265:1273	great potential	1259:1273	great potential to promote infected and susceptible wound healing	1259:1323	Therefore, the multifunctional composited microneedles show great potential to promote infected and susceptible wound healing.
35752336	3	3	theme	microneedles	559:570	arg1	structure					546:554	the porous structure	535:554	the porous structure of microneedles	535:570	In our design system, the porous structure of microneedles gradually disappeared, and the mechanical properties were significantly improved after multiple fillings.
35752336	6	4	theme	free	1122:1125	arg1	radicals					1127:1134	scavenging excessive free radicals	1101:1134	scavenging excessive free radicals	1101:1134	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	6	4	theme	free	1122:1125	arg1	biofilms					1091:1098	the bacterial biofilms	1077:1098	the bacterial biofilms	1077:1098	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	6	5	theme	scavenging	1101:1110	arg1	radicals					1127:1134	scavenging excessive free radicals	1101:1134	scavenging excessive free radicals	1101:1134	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	6	5	theme	scavenging	1101:1110	arg1	biofilms					1091:1098	the bacterial biofilms	1077:1098	the bacterial biofilms	1077:1098	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	1	6	theme	infected	293:300	arg1	healing					308:314	the infected wound healing	289:314	the infected wound healing process	289:322	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	0	7	theme	susceptible	124:134	arg1	healing					142:148	infected and susceptible wound healing	111:148	infected and susceptible wound healing	111:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	7	8	theme	multifunctional	1214:1228	arg1	microneedles					1241:1252	the multifunctional composited microneedles	1210:1252	the multifunctional composited microneedles	1210:1252	Therefore, the multifunctional composited microneedles show great potential to promote infected and susceptible wound healing.
35752336	3	9	theme	mechanical	603:612	arg1	properties					614:623	the mechanical properties	599:623	the mechanical properties	599:623	In our design system, the porous structure of microneedles gradually disappeared, and the mechanical properties were significantly improved after multiple fillings.
35752336	1	10	theme	wound	302:306	arg1	healing					308:314	the infected wound healing	289:314	the infected wound healing process	289:322	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	4	11	theme	antibacterial	780:792	arg1	effects					794:800	antibacterial effects	780:800	antibacterial effects	780:800	Ag+ is reduced in-situ to silver nanoparticles by the abundant polyphenols of tannic acid, displaying antibacterial effects both in vitro and vivo, even for methicillin resistant Staphylococcus aureus.
35752336	1	12	theme	healing	308:314	arg1	process					316:322	the infected wound healing process	289:322	the infected wound healing process	289:322	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	7	13	theme	wound	1311:1315	arg1	healing					1317:1323	infected and susceptible wound healing	1286:1323	infected and susceptible wound healing	1286:1323	Therefore, the multifunctional composited microneedles show great potential to promote infected and susceptible wound healing.
35752336	4	14	theme	silver	704:709	arg1	nanoparticles					711:723	silver nanoparticles	704:723	silver nanoparticles	704:723	Ag+ is reduced in-situ to silver nanoparticles by the abundant polyphenols of tannic acid, displaying antibacterial effects both in vitro and vivo, even for methicillin resistant Staphylococcus aureus.
35752336	5	15	theme	piercing	953:960	arg1	biofilm					962:968	piercing biofilm	953:968	piercing biofilm	953:968	The addition of Bletilla striata polysaccharide increased the ability of piercing biofilm and promoted wound healing.
35752336	0	16	theme	wound	136:140	arg1	healing					142:148	infected and susceptible wound healing	111:148	infected and susceptible wound healing	111:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	7	17	theme	infected	1286:1293	arg1	healing					1317:1323	infected and susceptible wound healing	1286:1323	infected and susceptible wound healing	1286:1323	Therefore, the multifunctional composited microneedles show great potential to promote infected and susceptible wound healing.
35752336	2	18	theme	composited	378:387	arg1	microneedles					389:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	4	19	theme	abundant	732:739	arg1	polyphenols					741:751	the abundant polyphenols	728:751	the abundant polyphenols of tannic acid	728:766	Ag+ is reduced in-situ to silver nanoparticles by the abundant polyphenols of tannic acid, displaying antibacterial effects both in vitro and vivo, even for methicillin resistant Staphylococcus aureus.
35752336	0	20	theme	synthesis	8:16	arg1	silver					18:23	In-situ synthesis silver	0:23	In-situ synthesis silver	0:23	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	2	21	theme	polysaccharide	363:376	arg1	microneedles					389:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	4	22	theme	tannic	756:761	arg1	acid					763:766	tannic acid	756:766	tannic acid	756:766	Ag+ is reduced in-situ to silver nanoparticles by the abundant polyphenols of tannic acid, displaying antibacterial effects both in vitro and vivo, even for methicillin resistant Staphylococcus aureus.
35752336	0	23	theme	In-situ	0:6	arg1	silver					18:23	In-situ synthesis silver	0:23	In-situ synthesis silver	0:23	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	2	24	theme	striata	355:361	arg1	microneedles					389:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	6	25	theme	wound	1184:1188	arg1	healing					1190:1196	wound healing	1184:1196	wound healing	1184:1196	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	5	26	theme	striata	905:911	arg1	polysaccharide					913:926	Bletilla striata polysaccharide	896:926	Bletilla striata polysaccharide	896:926	The addition of Bletilla striata polysaccharide increased the ability of piercing biofilm and promoted wound healing.
35752336	5	27	theme	Bletilla	896:903	arg1	polysaccharide					913:926	Bletilla striata polysaccharide	896:926	Bletilla striata polysaccharide	896:926	The addition of Bletilla striata polysaccharide increased the ability of piercing biofilm and promoted wound healing.
35752336	2	28	theme	Chitosan/Bletilla	337:353	arg1	microneedles					389:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	the Chitosan/Bletilla striata polysaccharide composited microneedles	333:400	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	1	29	theme	bacterial	226:234	arg1	obstruction					244:254	bacterial biofilm obstruction	226:254	bacterial biofilm obstruction	226:254	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	2	30	theme	step	492:495	arg1	centrifugation					497:510	step centrifugation	492:510	step centrifugation	492:510	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	1	31	theme	biofilm	236:242	arg1	obstruction					244:254	bacterial biofilm obstruction	226:254	bacterial biofilm obstruction	226:254	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	0	32	theme	chitosan/Bletilla	42:58	arg1	microneedles					94:105	chitosan/Bletilla striata polysaccharide composited microneedles	42:105	chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing	42:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	2	33	theme	striata	461:467	arg1	polysaccharide					469:482	Bletilla striata polysaccharide	452:482	Bletilla striata polysaccharide	452:482	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	6	34	theme	inflammatory	1148:1159	arg1	factors					1161:1167	inflammatory factors	1148:1167	inflammatory factors	1148:1167	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	5	35	theme	biofilm	962:968	arg1	ability					942:948	the ability	938:948	the ability of piercing biofilm	938:968	The addition of Bletilla striata polysaccharide increased the ability of piercing biofilm and promoted wound healing.
35752336	6	36	theme	excessive	1112:1120	arg1	radicals					1127:1134	scavenging excessive free radicals	1101:1134	scavenging excessive free radicals	1101:1134	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	6	36	theme	excessive	1112:1120	arg1	biofilms					1091:1098	the bacterial biofilms	1077:1098	the bacterial biofilms	1077:1098	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	7	37	theme	susceptible	1299:1309	arg1	healing					1317:1323	infected and susceptible wound healing	1286:1323	infected and susceptible wound healing	1286:1323	Therefore, the multifunctional composited microneedles show great potential to promote infected and susceptible wound healing.
35752336	1	38	from	obstruction	244:254	arg1	process					316:322	the infected wound healing process	289:322	the infected wound healing process	289:322	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	2	39	theme	Bletilla	452:459	arg1	polysaccharide					469:482	Bletilla striata polysaccharide	452:482	Bletilla striata polysaccharide	452:482	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	0	40	theme	polysaccharide	68:81	arg1	microneedles					94:105	chitosan/Bletilla striata polysaccharide composited microneedles	42:105	chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing	42:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	5	41	theme	wound	983:987	arg1	healing					989:995	wound healing	983:995	wound healing	983:995	The addition of Bletilla striata polysaccharide increased the ability of piercing biofilm and promoted wound healing.
35752336	1	42	from	resistance	275:284	arg1	process					316:322	the infected wound healing process	289:322	the infected wound healing process	289:322	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	6	43	theme	bacterial	1081:1089	arg1	radicals					1127:1134	scavenging excessive free radicals	1101:1134	scavenging excessive free radicals	1101:1134	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	6	43	theme	bacterial	1081:1089	arg1	biofilms					1091:1098	the bacterial biofilms	1077:1098	the bacterial biofilms	1077:1098	The microneedles exhibited good biocompatibility and with function of piercing the bacterial biofilms, scavenging excessive free radicals, inhibiting inflammatory factors, and promoting wound healing.
35752336	3	44	theme	multiple	659:666	arg1	fillings					668:675	multiple fillings	659:675	multiple fillings	659:675	In our design system, the porous structure of microneedles gradually disappeared, and the mechanical properties were significantly improved after multiple fillings.
35752336	0	45	theme	striata	60:66	arg1	microneedles					94:105	chitosan/Bletilla striata polysaccharide composited microneedles	42:105	chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing	42:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	7	46	theme	composited	1230:1239	arg1	microneedles					1241:1252	the multifunctional composited microneedles	1210:1252	the multifunctional composited microneedles	1210:1252	Therefore, the multifunctional composited microneedles show great potential to promote infected and susceptible wound healing.
35752336	1	47	theme	novel	153:157	arg1	strategy					173:180	A novel antibacterial strategy	151:180	A novel antibacterial strategy	151:180	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	1	48	theme	bacterial	260:268	arg1	resistance					275:284	bacterial drug resistance	260:284	bacterial drug resistance	260:284	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	1	49	theme	antibacterial	159:171	arg1	strategy					173:180	A novel antibacterial strategy	151:180	A novel antibacterial strategy	151:180	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	1	50	theme	drug	270:273	arg1	resistance					275:284	bacterial drug resistance	260:284	bacterial drug resistance	260:284	A novel antibacterial strategy is urgently required to develop for solving bacterial biofilm obstruction and bacterial drug resistance in the infected wound healing process.
35752336	3	51	theme	design	520:525	arg1	system					527:532	our design system	516:532	our design system	516:532	In our design system, the porous structure of microneedles gradually disappeared, and the mechanical properties were significantly improved after multiple fillings.
35752336	2	52	theme	tannic	429:434	arg1	acid					436:439	tannic acid	429:439	tannic acid	429:439	Herein, the Chitosan/Bletilla striata polysaccharide composited microneedles were prepared by chitosan, tannic acid, AgNO3 and Bletilla striata polysaccharide through step centrifugation.
35752336	3	53	theme	porous	539:544	arg1	structure					546:554	the porous structure	535:554	the porous structure of microneedles	535:570	In our design system, the porous structure of microneedles gradually disappeared, and the mechanical properties were significantly improved after multiple fillings.
35752336	0	54	theme	composited	83:92	arg1	microneedles					94:105	chitosan/Bletilla striata polysaccharide composited microneedles	42:105	chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing	42:148	In-situ synthesis silver nanoparticles in chitosan/Bletilla striata polysaccharide composited microneedles for infected and susceptible wound healing.
35752336	5	55	theme	polysaccharide	913:926	arg1	addition					884:891	The addition	880:891	The addition of Bletilla striata polysaccharide	880:926	The addition of Bletilla striata polysaccharide increased the ability of piercing biofilm and promoted wound healing.
35752336	4	56	theme	acid	763:766	arg1	polyphenols					741:751	the abundant polyphenols	728:751	the abundant polyphenols of tannic acid	728:766	Ag+ is reduced in-situ to silver nanoparticles by the abundant polyphenols of tannic acid, displaying antibacterial effects both in vitro and vivo, even for methicillin resistant Staphylococcus aureus.
35877740	4	0	theme	-β-d-Xylp-	670:679	arg1	-β-d-GlcAp-					691:701	→4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-	647:701	-β-d-GlcAp-	691:701	UCP mainly consisted of →4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-(1→ residues.
35877740	9	1	theme	cyclophosphamide-induced	1241:1264	arg1	damage					1266:1271	the cyclophosphamide-induced damage	1237:1271	the cyclophosphamide-induced damage to the spleen and thymus	1237:1296	The results showed that UCP markedly increased the spleen and thymus indexes and ameliorated the cyclophosphamide-induced damage to the spleen and thymus.
35877740	0	2	theme	Polysaccharide	61:74	arg1	Activity					17:24	Immunomodulatory Activity	0:24	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga	0:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	0	3	from	Activity	17:24	arg1	Alga					112:115	the Green Alga	102:115	the Green Alga	102:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	5	4	dep	-l-Rhap-	774:781	arg1	→4					771:772	→4	771:772	→4	771:772	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	5	4	dep	-l-Rhap-	774:781	arg1	C-2					790:792	C-2	790:792	C-2	790:792	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	5	4	dep	-l-Rhap-	774:781	arg1	1→					811:812	-β-d-Xylp-(1→	800:812	→4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→	771:812	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	5	4	dep	-l-Rhap-	774:781	arg1	1→					783:784	1→	783:784	1→	783:784	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	10	5	theme	blood	1338:1342	arg1	cells					1344:1348	white blood cells	1332:1348	white blood cells	1332:1348	UCP could increase the levels of white blood cells, lymphocytes, and platelets, and improve the hematopoietic inhibition caused by cyclophosphamide.
35877740	1	6	theme	large	159:163	arg1	polysaccharides					176:190	polysaccharides	176:190	polysaccharides	176:190	Algae accumulate large amounts of polysaccharides in their cell walls or intercellular regions.
35877740	1	6	theme	large	159:163	arg1	amounts					165:171	large amounts	159:171	large amounts of polysaccharides	159:190	Algae accumulate large amounts of polysaccharides in their cell walls or intercellular regions.
35877740	8	7	from	activity	1037:1044	arg1	vivo					1056:1059	vivo	1056:1059	vivo	1056:1059	The immunomodulatory activity of UCP in vivo was further investigated using immunosuppressive mice induced by cyclophosphamide.
35877740	3	8	theme	sulfated	358:365	arg1	UCP					383:385	UCP	383:385	UCP	383:385	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	3	8	theme	sulfated	358:365	arg1	polysaccharide					367:380	a sulfated polysaccharide	356:380	a sulfated polysaccharide	356:380	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	10	9	theme	lymphocytes	1351:1361	arg1	levels					1322:1327	the levels	1318:1327	the levels of white blood cells, lymphocytes, and platelets	1318:1376	UCP could increase the levels of white blood cells, lymphocytes, and platelets, and improve the hematopoietic inhibition caused by cyclophosphamide.
35877740	10	10	theme	platelets	1368:1376	arg1	levels					1322:1327	the levels	1318:1327	the levels of white blood cells, lymphocytes, and platelets	1318:1376	UCP could increase the levels of white blood cells, lymphocytes, and platelets, and improve the hematopoietic inhibition caused by cyclophosphamide.
35877740	0	11	with	Polysaccharide	61:74	arg1	Structure					87:95	Novel Structure	81:95	Novel Structure	81:95	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	2	12	contain	possess	265:271	arg2	potential					278:286	high potential	273:286	high potential	273:286	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	2	12	contain	possess	265:271	arg1	Polysaccharides					238:252	Polysaccharides	238:252	Polysaccharides from algae	238:263	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	2	12	contain	possess	265:271	arg2	candidates					301:310	promising candidates	291:310	promising candidates for marine drug development	291:338	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	0	13	theme	Novel	81:85	arg1	Structure					87:95	Novel Structure	81:95	Novel Structure	81:95	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	6	14	theme	Partial	815:821	arg1	glycosylation					823:835	Partial glycosylation	815:835	Partial glycosylation	815:835	Partial glycosylation was at C-2 of →4)-α-l-Rhap-(1→ residues.
35877740	2	15	theme	promising	291:299	arg1	potential					278:286	high potential	273:286	high potential	273:286	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	2	15	theme	promising	291:299	arg1	candidates					301:310	promising candidates	291:310	promising candidates for marine drug development	291:338	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	8	16	theme	immunosuppressive	1092:1108	arg1	mice					1110:1113	immunosuppressive mice	1092:1113	immunosuppressive mice induced by cyclophosphamide	1092:1141	The immunomodulatory activity of UCP in vivo was further investigated using immunosuppressive mice induced by cyclophosphamide.
35877740	7	17	theme	phagocytosis	1002:1013	arg1	assays					952:957	the assays	948:957	the assays of lymphocyte proliferation and macrophage phagocytosis	948:1013	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	12	18	theme	sulfated	1585:1592	arg1	polysaccharide					1594:1607	a novel sulfated polysaccharide	1577:1607	a novel sulfated polysaccharide	1577:1607	The data demonstrated that UCP is a novel sulfated polysaccharide and may be a promising immunomodulatory agent.
35877740	12	18	theme	sulfated	1585:1592	arg1	UCP					1570:1572	UCP	1570:1572	UCP	1570:1572	The data demonstrated that UCP is a novel sulfated polysaccharide and may be a promising immunomodulatory agent.
35877740	10	19	theme	hematopoietic	1395:1407	arg1	inhibition					1409:1418	the hematopoietic inhibition	1391:1418	the hematopoietic inhibition caused by cyclophosphamide	1391:1445	UCP could increase the levels of white blood cells, lymphocytes, and platelets, and improve the hematopoietic inhibition caused by cyclophosphamide.
35877740	7	20	theme	proliferation	973:985	arg1	assays					952:957	the assays	948:957	the assays of lymphocyte proliferation and macrophage phagocytosis	948:1013	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	7	21	theme	potent	894:899	arg1	effect					918:923	a potent immunomodulatory effect	892:923	a potent immunomodulatory effect	892:923	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	12	22	theme	novel	1579:1583	arg1	polysaccharide					1594:1607	a novel sulfated polysaccharide	1577:1607	a novel sulfated polysaccharide	1577:1607	The data demonstrated that UCP is a novel sulfated polysaccharide and may be a promising immunomodulatory agent.
35877740	12	22	theme	novel	1579:1583	arg1	UCP					1570:1572	UCP	1570:1572	UCP	1570:1572	The data demonstrated that UCP is a novel sulfated polysaccharide and may be a promising immunomodulatory agent.
35877740	5	23	theme	→4	797:798	arg1	C-2					790:792	C-2	790:792	C-2	790:792	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	5	23	theme	→4	797:798	arg1	1→					783:784	1→	783:784	1→	783:784	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	5	24	theme	Sulfate	716:722	arg1	groups					730:735	Sulfate ester groups	716:735	Sulfate ester groups	716:735	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	4	25	dep	-β-d-GlcAp-	691:701	arg1	→4					688:689	→4	688:689	→4	688:689	UCP mainly consisted of →4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-(1→ residues.
35877740	4	25	dep	-β-d-GlcAp-	691:701	arg1	1→					681:682	1→	681:682	1→	681:682	UCP mainly consisted of →4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-(1→ residues.
35877740	1	26	theme	polysaccharides	176:190	arg1	polysaccharides					176:190	polysaccharides	176:190	polysaccharides	176:190	Algae accumulate large amounts of polysaccharides in their cell walls or intercellular regions.
35877740	1	26	theme	polysaccharides	176:190	arg1	amounts					165:171	large amounts	159:171	large amounts of polysaccharides	159:190	Algae accumulate large amounts of polysaccharides in their cell walls or intercellular regions.
35877740	0	27	theme	Immunomodulatory	0:15	arg1	Activity					17:24	Immunomodulatory Activity	0:24	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga	0:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	3	28	dep	Ulva	408:411	arg1	conglobata					413:422	conglobata	413:422	conglobata	413:422	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	2	29	theme	drug	323:326	arg1	development					328:338	marine drug development	316:338	marine drug development	316:338	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	2	30	from	algae	259:263	arg1	Polysaccharides					238:252	Polysaccharides	238:252	Polysaccharides from algae	238:263	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	5	31	theme	-β-d-Xylp-	800:809	arg1	1→					811:812	-β-d-Xylp-(1→	800:812	→4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→	771:812	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	6	32	theme	residues	868:875	arg1	C-2					844:846	C-2	844:846	C-2 of →4)-α-l-Rhap-(1→ residues	844:875	Partial glycosylation was at C-2 of →4)-α-l-Rhap-(1→ residues.
35877740	7	33	theme	lymphocyte	962:971	arg1	proliferation					973:985	lymphocyte proliferation	962:985	lymphocyte proliferation	962:985	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	10	34	theme	cells	1344:1348	arg1	levels					1322:1327	the levels	1318:1327	the levels of white blood cells, lymphocytes, and platelets	1318:1376	UCP could increase the levels of white blood cells, lymphocytes, and platelets, and improve the hematopoietic inhibition caused by cyclophosphamide.
35877740	2	35	theme	marine	316:321	arg1	development					328:338	marine drug development	316:338	marine drug development	316:338	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	7	36	dep	possessed	882:890	arg1	evaluated					935:943	evaluated	935:943	evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis	935:1013	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	5	37	theme	-l-Rhap-	774:781	arg1	C-3					764:766	C-3	764:766	C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→	764:812	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
35877740	6	38	theme	1→	865:866	arg1	residues					868:875	→4)-α-l-Rhap-(1→ residues	851:875	→4)-α-l-Rhap-(1→ residues	851:875	Partial glycosylation was at C-2 of →4)-α-l-Rhap-(1→ residues.
35877740	0	39	theme	Green	106:110	arg1	Alga					112:115	the Green Alga	102:115	the Green Alga	102:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	7	40	contain	possessed	882:890	arg1	UCP					878:880	UCP	878:880	UCP	878:880	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	7	40	contain	possessed	882:890	arg2	effect					918:923	a potent immunomodulatory effect	892:923	a potent immunomodulatory effect	892:923	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	1	41	theme	cell	201:204	arg1	walls					206:210	their cell walls	195:210	their cell walls	195:210	Algae accumulate large amounts of polysaccharides in their cell walls or intercellular regions.
35877740	3	42	theme	alga	403:406	arg1	Kjellman					424:431	the green alga Ulva conglobata Kjellman	393:431	the green alga Ulva conglobata Kjellman	393:431	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	3	43	theme	spectroscopic	600:612	arg1	methods					614:620	chemical and spectroscopic methods	587:620	chemical and spectroscopic methods	587:620	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	4	44	theme	-α/β-l-Rhap-	650:661	arg1	-β-d-GlcAp-					691:701	→4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-	647:701	-β-d-GlcAp-	691:701	UCP mainly consisted of →4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-(1→ residues.
35877740	3	45	theme	Ulva	408:411	arg1	Kjellman					424:431	the green alga Ulva conglobata Kjellman	393:431	the green alga Ulva conglobata Kjellman	393:431	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	6	46	theme	-α-l-Rhap-	854:863	arg1	residues					868:875	→4)-α-l-Rhap-(1→ residues	851:875	→4)-α-l-Rhap-(1→ residues	851:875	Partial glycosylation was at C-2 of →4)-α-l-Rhap-(1→ residues.
35877740	3	47	theme	methods	614:620	arg1	combination					572:582	a combination	570:582	a combination of chemical and spectroscopic methods	570:620	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	3	48	theme	water	449:453	arg1	extraction					455:464	water extraction	449:464	water extraction	449:464	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	8	49	theme	immunomodulatory	1020:1035	arg1	activity					1037:1044	The immunomodulatory activity	1016:1044	The immunomodulatory activity of UCP in vivo	1016:1059	The immunomodulatory activity of UCP in vivo was further investigated using immunosuppressive mice induced by cyclophosphamide.
35877740	8	50	theme	UCP	1049:1051	arg1	activity					1037:1044	The immunomodulatory activity	1016:1044	The immunomodulatory activity of UCP in vivo	1016:1059	The immunomodulatory activity of UCP in vivo was further investigated using immunosuppressive mice induced by cyclophosphamide.
35877740	3	51	theme	chemical	587:594	arg1	methods					614:620	chemical and spectroscopic methods	587:620	chemical and spectroscopic methods	587:620	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	11	52	theme	IgE	1529:1531	arg1	secretions					1489:1498	the secretions	1485:1498	the secretions of the immunoglobulin (Ig)G, IgE, and IgM	1485:1540	Moreover, UCP significantly promoted the secretions of the immunoglobulin (Ig)G, IgE, and IgM.
35877740	3	53	theme	green	397:401	arg1	Kjellman					424:431	the green alga Ulva conglobata Kjellman	393:431	the green alga Ulva conglobata Kjellman	393:431	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	4	54	dep	consisted	634:642	arg1	residues					706:713	1→ residues	703:713	1→ residues	703:713	UCP mainly consisted of →4)-α/β-l-Rhap-(1→, →4)-β-d-Xylp-(1→ and →4)-β-d-GlcAp-(1→ residues.
35877740	7	55	theme	immunomodulatory	901:916	arg1	effect					918:923	a potent immunomodulatory effect	892:923	a potent immunomodulatory effect	892:923	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	3	56	theme	size-exclusion	487:500	arg1	chromatography					502:515	size-exclusion chromatography	487:515	size-exclusion chromatography	487:515	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	11	57	theme	immunoglobulin	1507:1520	arg1	G					1526:1526	the immunoglobulin (Ig)G	1503:1526	the immunoglobulin (Ig)G	1503:1526	Moreover, UCP significantly promoted the secretions of the immunoglobulin (Ig)G, IgE, and IgM.
35877740	9	58	theme	spleen	1195:1200	arg1	indexes					1213:1219	the spleen and thymus indexes	1191:1219	the spleen and thymus indexes	1191:1219	The results showed that UCP markedly increased the spleen and thymus indexes and ameliorated the cyclophosphamide-induced damage to the spleen and thymus.
35877740	2	59	theme	high	273:276	arg1	potential					278:286	high potential	273:286	high potential	273:286	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	2	59	theme	high	273:276	arg1	candidates					301:310	promising candidates	291:310	promising candidates for marine drug development	291:338	Polysaccharides from algae possess high potential as promising candidates for marine drug development.
35877740	10	60	theme	white	1332:1336	arg1	cells					1344:1348	white blood cells	1332:1348	white blood cells	1332:1348	UCP could increase the levels of white blood cells, lymphocytes, and platelets, and improve the hematopoietic inhibition caused by cyclophosphamide.
35877740	1	61	theme	intercellular	215:227	arg1	regions					229:235	intercellular regions	215:235	intercellular regions	215:235	Algae accumulate large amounts of polysaccharides in their cell walls or intercellular regions.
35877740	11	62	theme	G	1526:1526	arg1	secretions					1489:1498	the secretions	1485:1498	the secretions of the immunoglobulin (Ig)G, IgE, and IgM	1485:1540	Moreover, UCP significantly promoted the secretions of the immunoglobulin (Ig)G, IgE, and IgM.
35877740	11	63	theme	IgM	1538:1540	arg1	secretions					1489:1498	the secretions	1485:1498	the secretions of the immunoglobulin (Ig)G, IgE, and IgM	1485:1540	Moreover, UCP significantly promoted the secretions of the immunoglobulin (Ig)G, IgE, and IgM.
35877740	12	64	theme	immunomodulatory	1632:1647	arg1	agent					1649:1653	a promising immunomodulatory agent	1620:1653	a promising immunomodulatory agent	1620:1653	The data demonstrated that UCP is a novel sulfated polysaccharide and may be a promising immunomodulatory agent.
35877740	7	65	theme	macrophage	991:1000	arg1	phagocytosis					1002:1013	macrophage phagocytosis	991:1013	macrophage phagocytosis	991:1013	UCP possessed a potent immunomodulatory effect in vitro, evaluated by the assays of lymphocyte proliferation and macrophage phagocytosis.
35877740	0	66	theme	Sulfated	52:59	arg1	Polysaccharide					61:74	a Sulfated Polysaccharide	50:74	a Sulfated Polysaccharide with Novel Structure from the Green Alga	50:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	9	67	theme	thymus	1206:1211	arg1	indexes					1213:1219	the spleen and thymus indexes	1191:1219	the spleen and thymus indexes	1191:1219	The results showed that UCP markedly increased the spleen and thymus indexes and ameliorated the cyclophosphamide-induced damage to the spleen and thymus.
35877740	3	68	dep	extraction	455:464	arg1	purification					517:528	purification	517:528	purification	517:528	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	3	69	from	Kjellman	424:431	arg1	UCP					383:385	UCP	383:385	UCP	383:385	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	3	69	from	Kjellman	424:431	arg1	polysaccharide					367:380	a sulfated polysaccharide	356:380	a sulfated polysaccharide	356:380	In this study, a sulfated polysaccharide, UCP, from the green alga Ulva conglobata Kjellman was obtained by water extraction, anion-exchange, and size-exclusion chromatography purification, and its structure was characterized by a combination of chemical and spectroscopic methods.
35877740	0	70	dep	Kjellman	132:139	arg1	Activity					17:24	Immunomodulatory Activity	0:24	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga	0:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	12	71	theme	promising	1622:1630	arg1	agent					1649:1653	a promising immunomodulatory agent	1620:1653	a promising immunomodulatory agent	1620:1653	The data demonstrated that UCP is a novel sulfated polysaccharide and may be a promising immunomodulatory agent.
35877740	0	72	from	Alga	112:115	arg1	Polysaccharide					61:74	a Sulfated Polysaccharide	50:74	a Sulfated Polysaccharide with Novel Structure from the Green Alga	50:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	0	72	from	Alga	112:115	arg1	Activity					17:24	Immunomodulatory Activity	0:24	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga	0:115	Immunomodulatory Activity In Vitro and In Vivo of a Sulfated Polysaccharide with Novel Structure from the Green Alga Ulvaconglobata Kjellman.
35877740	5	73	theme	ester	724:728	arg1	groups					730:735	Sulfate ester groups	716:735	Sulfate ester groups	716:735	Sulfate ester groups were substituted mainly at C-3 of →4)-l-Rhap-(1→ and C-2 of →4)-β-d-Xylp-(1→.
36388954	2	0	dep	reticulum	501:509	arg1	Golgi					515:519	the Golgi	511:519	the Golgi	511:519	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	1	1	theme	cells	176:180	arg1	processing					88:97	Glycoprotein processing	75:97	Glycoprotein processing along a complex highly compartmentalized pathway	75:146	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36388954	1	1	theme	cells	176:180	arg1	hallmark					153:160	a hallmark	151:160	a hallmark of eukaryotic cells	151:180	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36388954	3	2	gly	glycoprotein	738:749	arg1	glycoprotein					738:749	the glycoprotein	734:749	the glycoprotein	734:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	4	3	theme	secretory	825:833	arg1	pathway					835:841	the cellular secretory pathway	812:841	the cellular secretory pathway	812:841	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	3	4	theme	site-specific	573:585	arg1	processing					596:605	site-specific N-glycan processing	573:605	site-specific N-glycan processing	573:605	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	1	5	theme	Glycoprotein	75:86	arg1	processing					88:97	Glycoprotein processing	75:97	Glycoprotein processing along a complex highly compartmentalized pathway	75:146	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36388954	1	5	theme	Glycoprotein	75:86	arg1	hallmark					153:160	a hallmark	151:160	a hallmark of eukaryotic cells	151:180	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36388954	4	6	theme	protein	904:910	arg1	complexity					877:886	an increased glycan complexity	857:886	an increased glycan complexity of the secreted protein	857:910	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	2	7	theme	N-glycosylation	296:310	arg1	sites					312:316	five distinct N-glycosylation sites	282:316	five distinct N-glycosylation sites	282:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	8	theme	reactions	419:427	arg1	set					401:403	a complex set	391:403	a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	391:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	8	theme	reactions	419:427	arg1	reactions					419:427	processing reactions	408:427	processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	408:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	9	gly	N-glycosylation	296:310	arg2	five					282:285	five	282:285	five	282:285	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	9	gly	N-glycosylation	296:310	arg2	sites					312:316	five distinct N-glycosylation sites	282:316	five distinct N-glycosylation sites	282:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	4	10	theme	increased	860:868	arg1	complexity					877:886	an increased glycan complexity	857:886	an increased glycan complexity of the secreted protein	857:910	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	2	11	theme	distinct	287:294	arg1	sites					312:316	five distinct N-glycosylation sites	282:316	five distinct N-glycosylation sites	282:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	12	theme	processing	408:417	arg1	reactions					419:427	processing reactions	408:427	processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	408:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	0	13	theme	network	14:20	arg1	mapping					22:28	Glycosylation network mapping	0:28	Glycosylation network mapping	0:28	Glycosylation network mapping and site-specific glycan maturation in vivo.
36388954	0	14	theme	Glycosylation	0:12	arg1	mapping					22:28	Glycosylation network mapping	0:28	Glycosylation network mapping	0:28	Glycosylation network mapping and site-specific glycan maturation in vivo.
36388954	2	15	theme	mathematical	332:343	arg1	model					345:349	a mathematical model	330:349	a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	330:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	4	16	theme	different	792:800	arg1	routes					802:807	different routes	792:807	different routes of the cellular secretory pathway	792:841	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	3	17	theme	phosphorylated	625:638	arg1	structures					647:656	phosphorylated glycan structures	625:656	phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein	625:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	3	18	theme	N-glycan	587:594	arg1	processing					596:605	site-specific N-glycan processing	573:605	site-specific N-glycan processing	573:605	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	2	19	theme	intracellular	450:462	arg1	reticulum					501:509	the endoplasmic reticulum the Golgi, or the lysosome	485:536	reticulum	501:509	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	19	theme	intracellular	450:462	arg1	compartments					464:475	defined intracellular compartments	442:475	defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	442:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	19	theme	intracellular	450:462	arg1	lysosome					529:536	the lysosome	525:536	the lysosome	525:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	1	20	theme	complex	107:113	arg1	pathway					140:146	a complex highly compartmentalized pathway	105:146	a complex highly compartmentalized pathway	105:146	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36388954	1	21	theme	compartmentalized	122:138	arg1	pathway					140:146	a complex highly compartmentalized pathway	105:146	a complex highly compartmentalized pathway	105:146	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36388954	3	22	theme	responsible	693:703	arg1	pathway					685:691	the mannose-6-phosphate pathway	661:691	the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein	661:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	2	23	theme	defined	442:448	arg1	reticulum					501:509	the endoplasmic reticulum the Golgi, or the lysosome	485:536	reticulum	501:509	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	23	theme	defined	442:448	arg1	compartments					464:475	defined intracellular compartments	442:475	defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	442:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	23	theme	defined	442:448	arg1	lysosome					529:536	the lysosome	525:536	the lysosome	525:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	0	24	theme	glycan	48:53	arg1	maturation					55:64	site-specific glycan maturation	34:64	site-specific glycan maturation	34:64	Glycosylation network mapping and site-specific glycan maturation in vivo.
36388954	4	25	theme	model	769:773	arg1	protein					775:781	our model protein	765:781	our model protein	765:781	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	3	26	theme	lysosomal	713:721	arg1	sorting					723:729	the lysosomal sorting	709:729	the lysosomal sorting of the glycoprotein	709:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	3	27	theme	glycan	640:645	arg1	structures					647:656	phosphorylated glycan structures	625:656	phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein	625:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	0	28	theme	site-specific	34:46	arg1	maturation					55:64	site-specific glycan maturation	34:64	site-specific glycan maturation	34:64	Glycosylation network mapping and site-specific glycan maturation in vivo.
36388954	2	29	with	protein	269:275	arg1	sites					312:316	five distinct N-glycosylation sites	282:316	five distinct N-glycosylation sites	282:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	30	located	localized	429:437	arg1	reticulum					501:509	the endoplasmic reticulum the Golgi, or the lysosome	485:536	reticulum	501:509	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	30	located	localized	429:437	arg1	compartments					464:475	defined intracellular compartments	442:475	defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	442:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	30	located	localized	429:437	arg1	lysosome					529:536	the lysosome	525:536	the lysosome	525:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	30	located	localized	429:437	arg2	reactions					419:427	processing reactions	408:427	processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	408:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	4	31	theme	glycan	870:875	arg1	complexity					877:886	an increased glycan complexity	857:886	an increased glycan complexity of the secreted protein	857:910	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	4	32	theme	cellular	816:823	arg1	pathway					835:841	the cellular secretory pathway	812:841	the cellular secretory pathway	812:841	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	2	33	theme	processing	247:256	arg1	kinetics					199:206	the kinetics	195:206	the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites	195:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	34	theme	pathway	368:374	arg1	model					345:349	a mathematical model	330:349	a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	330:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	35	theme	endoplasmic	489:499	arg1	reticulum					501:509	the endoplasmic reticulum the Golgi, or the lysosome	485:536	reticulum	501:509	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	4	36	theme	secreted	895:902	arg1	protein					904:910	the secreted protein	891:910	the secreted protein	891:910	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	2	37	theme	glycan	240:245	arg1	processing					247:256	intracellular, site-specific glycan processing	211:256	intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites	211:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	38	theme	secretory	358:366	arg1	pathway					368:374	the secretory pathway	354:374	the secretory pathway	354:374	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	3	39	theme	glycoprotein	738:749	arg1	sorting					723:729	the lysosomal sorting	709:729	the lysosomal sorting of the glycoprotein	709:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	3	40	theme	mannose-6-phosphate	665:683	arg1	pathway					685:691	the mannose-6-phosphate pathway	661:691	the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein	661:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	2	41	dep	intracellular	211:223	arg1	site-specific					226:238	site-specific	226:238	site-specific	226:238	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	4	42	theme	pathway	835:841	arg1	routes					802:807	different routes	792:807	different routes of the cellular secretory pathway	792:841	Importantly, our model protein can take different routes of the cellular secretory pathway, resulting in an increased glycan complexity of the secreted protein.
36388954	2	43	theme	intracellular	211:223	arg1	processing					247:256	intracellular, site-specific glycan processing	211:256	intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites	211:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	3	44	theme	pathway	685:691	arg1	structures					647:656	phosphorylated glycan structures	625:656	phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein	625:749	The model was able to accommodate site-specific N-glycan processing and we identified phosphorylated glycan structures of the mannose-6-phosphate pathway responsible for the lysosomal sorting of the glycoprotein.
36388954	2	45	theme	protein	269:275	arg1	processing					247:256	intracellular, site-specific glycan processing	211:256	intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites	211:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	46	theme	complex	393:399	arg1	set					401:403	a complex set	391:403	a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	391:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	46	theme	complex	393:399	arg1	reactions					419:427	processing reactions	408:427	processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome	408:536	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	2	47	theme	model	263:267	arg1	protein					269:275	a model protein	261:275	a model protein with five distinct N-glycosylation sites	261:316	We followed the kinetics of intracellular, site-specific glycan processing of a model protein with five distinct N-glycosylation sites and deduced a mathematical model of the secretory pathway that describes a complex set of processing reactions localized in defined intracellular compartments such as the endoplasmic reticulum the Golgi, or the lysosome.
36388954	1	48	theme	eukaryotic	165:174	arg1	cells					176:180	eukaryotic cells	165:180	eukaryotic cells	165:180	Glycoprotein processing along a complex highly compartmentalized pathway is a hallmark of eukaryotic cells.
36914840	6	0	theme	significant	1091:1101	arg1	differences					1103:1113	no significant differences	1088:1113	no significant differences within the glycoforms quantified across subclasses	1088:1164	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	3	1	theme	medium-throughput	500:516	arg1	analysis					547:554	the medium-throughput subclass-specific nano-LC-MS analysis	496:554	the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice	496:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	1	2	theme	milk	133:136	arg1	IgG					156:158	IgG	156:158	IgG	156:158	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	1	2	theme	milk	133:136	arg1	G					153:153	Breast milk immunoglobulin G	126:153	Breast milk immunoglobulin G (IgG)	126:159	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	4	3	from	model	678:682	arg1	offspring					762:770	the offspring	758:770	the offspring	758:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	7	4	theme	glycoforms	1431:1440	arg1	abundance					1399:1407	the increased relative abundance	1376:1407	the increased relative abundance of the IgG3-G2 and S1 glycoforms	1376:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	5	from	glycopatterns	653:665	arg1	model					678:682	a mouse model	670:682	a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring	670:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	3	6	theme	small	577:581	arg1	volumes					588:594	small milk volumes	577:594	small milk volumes of lactating mice	577:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	0	7	from	model	79:83	arg1	Fc-linked					28:36	Fc-linked	28:36	Fc-linked	28:36	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	7	8	theme	glycoforms	1350:1359	arg1	abundance					1312:1320	the decreased relative abundance	1289:1320	the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms	1289:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	1	9	from	transfer	192:199	arg1	life					230:233	early life	224:233	early life	224:233	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	5	10	gly	glycosylation	893:905	arg1	day					1007:1009	postnatal day 15	997:1012	postnatal day 15	997:1012	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	5	10	gly	glycosylation	893:905	arg1	serum					945:949	maternal serum	936:949	maternal serum	936:949	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	5	10	gly	glycosylation	893:905	arg1	milk					968:971	maternal breast milk	952:971	maternal breast milk	952:971	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	5	10	gly	glycosylation	893:905	arg1	serum					988:992	offspring serum	978:992	offspring serum	978:992	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	7	11	from	changes	1228:1234	arg1	serum					1273:1277	IgG-Fc glycosylation in offspring serum	1239:1277	IgG-Fc glycosylation in offspring serum	1239:1277	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	3	12	theme	lactating	599:607	arg1	mice					609:612	lactating mice	599:612	lactating mice	599:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	1	13	theme	Breast	126:131	arg1	IgG					156:158	IgG	156:158	IgG	156:158	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	1	13	theme	Breast	126:131	arg1	G					153:153	Breast milk immunoglobulin G	126:153	Breast milk immunoglobulin G (IgG)	126:159	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	8	14	theme	integrative	1491:1501	arg1	multi-omics-					1503:1514	the emerging integrative multi-omics-	1478:1514	the emerging integrative multi-omics-	1478:1514	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	7	15	theme	increased	1380:1388	arg1	abundance					1399:1407	the increased relative abundance	1376:1407	the increased relative abundance of the IgG3-G2 and S1 glycoforms	1376:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	16	theme	asthma	733:738	arg1	susceptibility					740:753	increased asthma susceptibility	723:753	increased asthma susceptibility in the offspring	723:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	1	17	theme	immunoglobulin	138:151	arg1	IgG					156:158	IgG	156:158	IgG	156:158	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	1	17	theme	immunoglobulin	138:151	arg1	G					153:153	Breast milk immunoglobulin G	126:153	Breast milk immunoglobulin G (IgG)	126:159	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	6	18	theme	IgG	1019:1021	arg1	profiles					1037:1044	The IgG glycosylation profiles	1015:1044	The IgG glycosylation profiles of mouse maternal milk and serum	1015:1077	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	7	19	theme	IgG1F-G1	1329:1336	arg1	glycoforms					1350:1359	the IgG1F-G1 and IgG3-G0 glycoforms	1325:1359	the IgG1F-G1 and IgG3-G0 glycoforms	1325:1359	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	20	theme	antibiotic	687:696	arg1	use					698:700	antibiotic use	687:700	antibiotic use during pregnancy	687:717	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	7	21	theme	offspring	1263:1271	arg1	serum					1273:1277	IgG-Fc glycosylation in offspring serum	1239:1277	IgG-Fc glycosylation in offspring serum	1239:1277	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	5	22	theme	gestation	844:852	arg1	days					854:857	gestation days 8-17 and IgG1F, IgG2	844:878	gestation days 8-17 and IgG1F, IgG2	844:878	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	8	23	theme	milk	1539:1542	arg1	analyses					1544:1551	glycomics-oriented milk analyses	1520:1551	glycomics-oriented milk analyses	1520:1551	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	5	24	theme	Pregnant	787:794	arg1	mice					803:806	Pregnant BALB/c mice	787:806	Pregnant BALB/c mice	787:806	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	8	25	dep	multi-omics-	1503:1514	arg1	both					1553:1556	both	1553:1556	both	1553:1556	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	0	26	theme	vancomycin	88:97	arg1	exposure					99:106	vancomycin exposure	88:106	vancomycin exposure during pregnancy	88:123	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	8	27	theme	rodent	1561:1566	arg1	models					1568:1573	rodent models	1561:1573	rodent models	1561:1573	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	2	28	theme	milk	385:388	arg1	glycosylation					397:409	breast milk IgG-Fc glycosylation	378:409	breast milk IgG-Fc glycosylation in mouse models	378:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	0	29	theme	N-glycosylation	38:52	arg1	analysis					65:72	N-glycosylation nano-LC-MS analysis	38:72	N-glycosylation nano-LC-MS analysis	38:72	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	4	30	from	offspring	762:770	arg1	model					678:682	a mouse model	670:682	a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring	670:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	6	31	theme	serum	1073:1077	arg1	profiles					1037:1044	The IgG glycosylation profiles	1015:1044	The IgG glycosylation profiles of mouse maternal milk and serum	1015:1077	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	0	32	from	Fc-linked	28:36	arg1	model					79:83	a model	77:83	a model of vancomycin exposure during pregnancy	77:123	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	0	33	theme	Mouse	0:4	arg1	G					26:26	Mouse milk immunoglobulin G	0:26	Mouse milk immunoglobulin G	0:26	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	5	34	theme	maternal	952:959	arg1	milk					968:971	maternal breast milk	952:971	maternal breast milk	952:971	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	6	35	theme	milk	1064:1067	arg1	profiles					1037:1044	The IgG glycosylation profiles	1015:1044	The IgG glycosylation profiles of mouse maternal milk and serum	1015:1077	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	2	36	theme	mouse	414:418	arg1	models					420:425	mouse models	414:425	mouse models	414:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	0	37	theme	immunoglobulin	11:24	arg1	G					26:26	Mouse milk immunoglobulin G	0:26	Mouse milk immunoglobulin G	0:26	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	1	38	theme	immune	263:268	arg1	system					270:275	the neonatal immune system	250:275	the neonatal immune system	250:275	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	6	39	theme	mouse	1049:1053	arg1	milk					1064:1067	mouse maternal milk and serum	1049:1077	milk	1064:1067	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	0	40	theme	nano-LC-MS	54:63	arg1	analysis					65:72	N-glycosylation nano-LC-MS analysis	38:72	N-glycosylation nano-LC-MS analysis	38:72	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	1	41	theme	effector	303:310	arg1	functions					312:320	N-glycan-mediated effector functions	285:320	N-glycan-mediated effector functions	285:320	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	8	42	theme	mother-infant	1623:1635	arg1	interactions					1651:1662	mother-infant immunological interactions	1623:1662	mother-infant immunological interactions	1623:1662	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	1	43	theme	passive	204:210	arg1	immunity					212:219	passive immunity	204:219	passive immunity	204:219	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	5	44	theme	postnatal	997:1005	arg1	day					1007:1009	postnatal day 15	997:1012	postnatal day 15	997:1012	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	2	45	from	glycosylation	397:409	arg1	models					420:425	mouse models	414:425	mouse models	414:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	7	46	theme	decreased	1293:1301	arg1	abundance					1312:1320	the decreased relative abundance	1289:1320	the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms	1289:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	8	47	theme	interactions	1651:1662	arg1	understanding					1606:1618	a better understanding	1597:1618	a better understanding of mother-infant immunological interactions	1597:1662	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	5	48	dep	days	854:857	arg1	IgG2					875:878	IgG2	875:878	IgG2	875:878	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	5	48	dep	days	854:857	arg1	8-17					859:862	8-17	859:862	8-17	859:862	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	6	49	gly	glycosylation	1023:1035	arg1	serum					1073:1077	mouse maternal milk and serum	1049:1077	serum	1073:1077	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	6	49	gly	glycosylation	1023:1035	arg1	milk					1064:1067	mouse maternal milk and serum	1049:1077	milk	1064:1067	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	3	50	theme	subclass-specific	518:534	arg1	analysis					547:554	the medium-throughput subclass-specific nano-LC-MS analysis	496:554	the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice	496:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	7	51	gly	glycoforms	1431:1440	arg1	S1					1428:1429	the IgG3-G2 and S1 glycoforms	1412:1440	S1	1428:1429	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	7	51	gly	glycoforms	1431:1440	arg1	IgG3-G2					1416:1422	the IgG3-G2 and S1 glycoforms	1412:1440	IgG3-G2	1416:1422	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	52	theme	established	624:634	arg1	methods					636:642	the established methods	620:642	the established methods	620:642	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	4	53	from	use	698:700	arg1	offspring					762:770	the offspring	758:770	the offspring	758:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	3	54	theme	IgG	559:561	arg1	analysis					547:554	the medium-throughput subclass-specific nano-LC-MS analysis	496:554	the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice	496:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	0	55	attach	Fc-linked	28:36	arg3	model					79:83	a model	77:83	a model of vancomycin exposure during pregnancy	77:123	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	7	56	theme	IgG-Fc	1239:1244	arg1	serum					1273:1277	IgG-Fc glycosylation in offspring serum	1239:1277	IgG-Fc glycosylation in offspring serum	1239:1277	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	3	57	theme	milk	583:586	arg1	volumes					588:594	small milk volumes	577:594	small milk volumes of lactating mice	577:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	1	58	theme	important	170:178	arg1	role					180:183	an important role	167:183	an important role	167:183	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	4	59	theme	mouse	672:676	arg1	model					678:682	a mouse model	670:682	a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring	670:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	7	60	theme	S1	1428:1429	arg1	glycoforms					1431:1440	the IgG3-G2 and S1 glycoforms	1412:1440	glycoforms	1431:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	3	61	theme	mice	609:612	arg1	volumes					588:594	small milk volumes	577:594	small milk volumes of lactating mice	577:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	8	62	theme	emerging	1482:1489	arg1	multi-omics-					1503:1514	the emerging integrative multi-omics-	1478:1514	the emerging integrative multi-omics-	1478:1514	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	7	63	theme	IgG3-G2	1416:1422	arg1	glycoforms					1431:1440	the IgG3-G2 and S1 glycoforms	1412:1440	glycoforms	1431:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	64	theme	IgG	649:651	arg1	glycopatterns					653:665	the IgG glycopatterns	645:665	the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring	645:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	5	65	theme	maternal	936:943	arg1	serum					945:949	maternal serum	936:949	maternal serum	936:949	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	6	66	theme	glycosylation	1023:1035	arg1	profiles					1037:1044	The IgG glycosylation profiles	1015:1044	The IgG glycosylation profiles of mouse maternal milk and serum	1015:1077	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	8	67	theme	glycomics-oriented	1520:1537	arg1	analyses					1544:1551	glycomics-oriented milk analyses	1520:1551	glycomics-oriented milk analyses	1520:1551	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	7	68	theme	relative	1390:1397	arg1	abundance					1399:1407	the increased relative abundance	1376:1407	the increased relative abundance of the IgG3-G2 and S1 glycoforms	1376:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	69	theme	increased	723:731	arg1	susceptibility					740:753	increased asthma susceptibility	723:753	increased asthma susceptibility in the offspring	723:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	7	70	theme	glycosylation in	1246:1261	arg1	serum					1273:1277	IgG-Fc glycosylation in offspring serum	1239:1277	IgG-Fc glycosylation in offspring serum	1239:1277	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	5	71	theme	IgG3-Fc	885:891	arg1	glycosylation					893:905	IgG3-Fc glycosylation	885:905	IgG3-Fc glycosylation	885:905	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	4	72	theme	use	698:700	arg1	model					678:682	a mouse model	670:682	a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring	670:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	0	73	theme	exposure	99:106	arg1	model					79:83	a model	77:83	a model of vancomycin exposure during pregnancy	77:123	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	2	74	gly	glycosylation	397:409	arg1	models					420:425	mouse models	414:425	mouse models	414:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	5	75	theme	offspring	978:986	arg1	serum					988:992	offspring serum	978:992	offspring serum	978:992	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	8	76	theme	human	1579:1583	arg1	cohorts					1585:1591	human cohorts	1579:1591	human cohorts	1579:1591	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	2	77	theme	breast	378:383	arg1	glycosylation					397:409	breast milk IgG-Fc glycosylation	378:409	breast milk IgG-Fc glycosylation in mouse models	378:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	0	78	theme	milk	6:9	arg1	G					26:26	Mouse milk immunoglobulin G	0:26	Mouse milk immunoglobulin G	0:26	Mouse milk immunoglobulin G Fc-linked N-glycosylation nano-LC-MS analysis in a model of vancomycin exposure during pregnancy.
36914840	7	79	theme	IgG3-G0	1342:1348	arg1	glycoforms					1350:1359	the IgG1F-G1 and IgG3-G0 glycoforms	1325:1359	the IgG1F-G1 and IgG3-G0 glycoforms	1325:1359	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	4	80	theme	susceptibility	740:753	arg1	model					678:682	a mouse model	670:682	a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring	670:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	7	81	theme	vancomycin	1176:1185	arg1	use					1187:1189	vancomycin use	1176:1189	vancomycin use during pregnancy	1176:1206	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	1	82	theme	neonatal	254:261	arg1	system					270:275	the neonatal immune system	250:275	the neonatal immune system	250:275	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	4	83	from	susceptibility	740:753	arg1	offspring					762:770	the offspring	758:770	the offspring	758:770	With the established methods, the IgG glycopatterns in a mouse model of antibiotic use during pregnancy and increased asthma susceptibility in the offspring were analyzed.
36914840	5	84	theme	breast	961:966	arg1	milk					968:971	maternal breast milk	952:971	maternal breast milk	952:971	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	6	85	theme	maternal	1055:1062	arg1	milk					1064:1067	mouse maternal milk and serum	1049:1077	milk	1064:1067	The IgG glycosylation profiles of mouse maternal milk and serum revealed no significant differences within the glycoforms quantified across subclasses.
36914840	8	86	theme	better	1599:1604	arg1	understanding					1606:1618	a better understanding	1597:1618	a better understanding of mother-infant immunological interactions	1597:1662	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	2	87	theme	available	357:365	arg1	protocols					347:355	no protocols	344:355	no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models	344:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	5	88	theme	BALB/c	796:801	arg1	mice					803:806	Pregnant BALB/c mice	787:806	Pregnant BALB/c mice	787:806	Pregnant BALB/c mice were treated with vancomycin during gestation days 8-17 and IgG1F, IgG2, and IgG3-Fc glycosylation was subsequently analyzed in maternal serum, maternal breast milk, and offspring serum on postnatal day 15.
36914840	2	89	theme	IgG-Fc	390:395	arg1	glycosylation					397:409	breast milk IgG-Fc glycosylation	378:409	breast milk IgG-Fc glycosylation in mouse models	378:425	Currently, there are no protocols available to analyze breast milk IgG-Fc glycosylation in mouse models.
36914840	1	90	theme	N-glycan-mediated	285:301	arg1	functions					312:320	N-glycan-mediated effector functions	285:320	N-glycan-mediated effector functions	285:320	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	7	91	theme	relative	1303:1310	arg1	abundance					1312:1320	the decreased relative abundance	1289:1320	the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms	1289:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	8	92	theme	immunological	1637:1649	arg1	interactions					1651:1662	mother-infant immunological interactions	1623:1662	mother-infant immunological interactions	1623:1662	The workflow presented will aid in the emerging integrative multi-omics- and glycomics-oriented milk analyses both in rodent models and human cohorts for a better understanding of mother-infant immunological interactions.
36914840	7	93	dep	associated	1212:1221	arg1	shown					1280:1284	shown	1280:1284	shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms	1280:1440	However, vancomycin use during pregnancy was associated with changes in IgG-Fc glycosylation in offspring serum, shown by the decreased relative abundance of the IgG1F-G1 and IgG3-G0 glycoforms, together with the increased relative abundance of the IgG3-G2 and S1 glycoforms.
36914840	3	94	theme	glycoproteomic	468:481	arg1	workflow					483:490	a glycoproteomic workflow	466:490	a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice	466:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	1	95	theme	immunity	212:219	arg1	transfer					192:199	the transfer	188:199	the transfer of passive immunity in early life	188:233	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36914840	3	96	theme	nano-LC-MS	536:545	arg1	analysis					547:554	the medium-throughput subclass-specific nano-LC-MS analysis	496:554	the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice	496:612	Therefore, we developed and validated a glycoproteomic workflow for the medium-throughput subclass-specific nano-LC-MS analysis of IgG enriched from small milk volumes of lactating mice.
36914840	1	97	theme	early	224:228	arg1	life					230:233	early life	224:233	early life	224:233	Breast milk immunoglobulin G (IgG) plays an important role in the transfer of passive immunity in early life and in shaping the neonatal immune system through N-glycan-mediated effector functions.
36968546	6	0	theme	living	959:964	arg1	cell					966:969	the living cell	955:969	the living cell	955:969	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	1	from	Thr678	945:950	arg1	cell					966:969	the living cell	955:969	the living cell	955:969	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	8	2	theme	sialylated	1277:1286	arg1	trisaccharide					1288:1300	a sialylated trisaccharide	1275:1300	a sialylated trisaccharide	1275:1300	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	5	3	from	glycans	685:691	arg1	Thr678					696:701	Thr678	696:701	Thr678 of SARS-CoV-2 spike	696:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	6	4	theme	glycosyltransferase	891:909	arg1	GalNAc-T1					911:919	the glycosyltransferase GalNAc-T1	887:919	the glycosyltransferase GalNAc-T1	887:919	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	7	5	theme	sole	1070:1073	arg1	incorporation					1075:1087	the sole incorporation	1066:1087	the sole incorporation of N-acetylgalactosamine	1066:1112	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	0	6	theme	Mutational	96:105	arg1	Trajectory					107:116	the Mutational Trajectory	92:116	the Mutational Trajectory in Variants of Concern	92:139	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.
36968546	7	7	from	impact	1122:1127	arg1	O-glycopeptides					1157:1171	synthetic O-glycopeptides	1147:1171	synthetic O-glycopeptides	1147:1171	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	6	8	dep	VOCs	1020:1023	arg1	Alpha					1025:1029	Alpha	1025:1029	Alpha	1025:1029	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	8	dep	VOCs	1020:1023	arg1	VOCs					1020:1023	the VOCs Alpha, Delta, and Omicron	1016:1049	the VOCs Alpha, Delta, and Omicron	1016:1049	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	8	dep	VOCs	1020:1023	arg1	Delta					1032:1036	Delta	1032:1036	Delta	1032:1036	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	8	dep	VOCs	1020:1023	arg1	Omicron					1043:1049	Omicron	1043:1049	Omicron	1043:1049	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	4	9	theme	proteolytic	558:568	arg1	processing					570:579	proteolytic processing	558:579	proteolytic processing	558:579	Glycans near the cleavage site have raised questions about proteolytic processing and the consequences of variant-borne mutations.
36968546	5	10	theme	spike	717:721	arg1	Thr678					696:701	Thr678	696:701	Thr678 of SARS-CoV-2 spike	696:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	6	11	from	mutations	1003:1011	arg1	Alpha					1025:1029	Alpha	1025:1029	Alpha	1025:1029	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	11	from	mutations	1003:1011	arg1	VOCs					1020:1023	the VOCs Alpha, Delta, and Omicron	1016:1049	the VOCs Alpha, Delta, and Omicron	1016:1049	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	11	from	mutations	1003:1011	arg1	Delta					1032:1036	Delta	1032:1036	Delta	1032:1036	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	11	from	mutations	1003:1011	arg1	Omicron					1043:1049	Omicron	1043:1049	Omicron	1043:1049	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	12	gly	glycosylation	928:940	arg1	Thr678					945:950	Thr678	945:950	Thr678 in the living cell	945:969	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	6	12	gly	glycosylation	928:940	arg1	event					975:979	an event	972:979	an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron	972:1049	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	9	13	theme	VOC	1533:1535	arg1	evolution					1537:1545	VOC evolution	1533:1545	VOC evolution	1533:1545	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	1	14	theme	major	255:259	arg1	emergence					146:154	The emergence	142:154	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike	142:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	1	14	theme	major	255:259	arg1	factor					261:266	a major factor	253:266	a major factor for human viral transmission	253:295	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	8	15	theme	negative	1308:1315	arg1	impact					1317:1322	a negative impact	1306:1322	a negative impact	1306:1322	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	1	16	theme	polybasic	161:169	arg1	motif					180:184	a polybasic cleavage motif	159:184	a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike	159:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	5	17	theme	furin	733:737	arg1	cleavage					751:758	furin and TMPRSS2 cleavage	733:758	furin and TMPRSS2 cleavage	733:758	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	6	18	theme	direct	866:871	arg1	evidence					873:880	direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron	866:1049	direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron	866:1049	We provide direct evidence that the glycosyltransferase GalNAc-T1 primes glycosylation at Thr678 in the living cell, an event that is suppressed by mutations in the VOCs Alpha, Delta, and Omicron.
36968546	5	19	theme	likely	798:803	arg1	glycosylation					779:791	O-linked glycosylation	770:791	O-linked glycosylation	770:791	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	19	theme	likely	798:803	arg1	force					813:817	a likely driving force	796:817	a likely driving force for the emergence of VOC mutations	796:852	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	1	20	theme	cleavage	171:178	arg1	motif					180:184	a polybasic cleavage motif	159:184	a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike	159:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	8	21	gly	sialylated	1277:1286	arg1	trisaccharide					1288:1300	a sialylated trisaccharide	1275:1300	a sialylated trisaccharide	1275:1300	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	7	22	dep	65	1238:1239	arg1	to					1235:1236	to	1235:1236	to	1235:1236	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	7	23	theme	sialic	1194:1199	arg1	acid					1201:1204	sialic acid	1194:1204	sialic acid	1194:1204	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	1	24	theme	motif	180:184	arg1	emergence					146:154	The emergence	142:154	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike	142:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	1	24	theme	motif	180:184	arg1	factor					261:266	a major factor	253:266	a major factor for human viral transmission	253:295	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	0	25	theme	O-Linked	0:7	arg1	Sialoglycans					9:20	O-Linked Sialoglycans	0:20	O-Linked Sialoglycans	0:20	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.
36968546	4	26	theme	cleavage	516:523	arg1	site					525:528	the cleavage site	512:528	the cleavage site	512:528	Glycans near the cleavage site have raised questions about proteolytic processing and the consequences of variant-borne mutations.
36968546	5	27	theme	mutations	844:852	arg1	emergence					827:835	the emergence	823:835	the emergence of VOC mutations	823:852	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	8	28	contain	had	1302:1304	arg2	impact					1317:1322	a negative impact	1306:1322	a negative impact	1306:1322	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	8	28	contain	had	1302:1304	arg1	O-glycosylation					1254:1268	O-glycosylation	1254:1268	O-glycosylation with a sialylated trisaccharide	1254:1300	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	5	29	theme	driving	805:811	arg1	glycosylation					779:791	O-linked glycosylation	770:791	O-linked glycosylation	770:791	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	29	theme	driving	805:811	arg1	force					813:817	a likely driving force	796:817	a likely driving force for the emergence of VOC mutations	796:852	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	4	30	theme	variant-borne	605:617	arg1	mutations					619:627	variant-borne mutations	605:627	variant-borne mutations	605:627	Glycans near the cleavage site have raised questions about proteolytic processing and the consequences of variant-borne mutations.
36968546	1	31	theme	human	272:276	arg1	transmission					284:295	human viral transmission	272:295	human viral transmission	272:295	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	8	32	theme	TMPRSS2	1327:1333	arg1	cleavage					1335:1342	TMPRSS2 cleavage	1327:1342	TMPRSS2 cleavage	1327:1342	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	9	33	theme	substantial	1503:1513	arg1	disruption					1468:1477	disruption	1468:1477	disruption of O-glycosylation	1468:1496	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	9	33	theme	substantial	1503:1513	arg1	force					1523:1527	a substantial driving force	1501:1527	a substantial driving force for VOC evolution	1501:1545	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	1	34	theme	protease	194:201	arg1	furin					203:207	the protease furin	190:207	the protease furin in SARS-CoV-2 spike	190:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	1	35	theme	viral	278:282	arg1	transmission					284:295	human viral transmission	272:295	human viral transmission	272:295	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	7	36	theme	synthetic	1147:1155	arg1	O-glycopeptides					1157:1171	synthetic O-glycopeptides	1147:1171	synthetic O-glycopeptides	1147:1171	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	9	37	theme	major	1418:1422	arg1	O-glycosylation					1397:1411	O-glycosylation	1397:1411	O-glycosylation	1397:1411	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	9	37	theme	major	1418:1422	arg1	determinant					1424:1434	a major determinant	1416:1434	a major determinant of spike maturation	1416:1454	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	7	38	theme	N-acetylgalactosamine	1092:1112	arg1	incorporation					1075:1087	the sole incorporation	1066:1087	the sole incorporation of N-acetylgalactosamine	1066:1112	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	5	39	theme	VOC	840:842	arg1	mutations					844:852	VOC mutations	840:852	VOC mutations	840:852	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	0	40	theme	Concern	133:139	arg1	Variants					121:128	Variants	121:128	Variants of Concern	121:139	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.
36968546	9	41	theme	maturation	1445:1454	arg1	O-glycosylation					1397:1411	O-glycosylation	1397:1411	O-glycosylation	1397:1411	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	9	41	theme	maturation	1445:1454	arg1	determinant					1424:1434	a major determinant	1416:1434	a major determinant of spike maturation	1416:1454	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	7	42	theme	furin	1129:1133	arg1	activity					1135:1142	furin activity	1129:1142	furin activity	1129:1142	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	1	43	from	furin	203:207	arg1	spike					223:227	SARS-CoV-2 spike	212:227	SARS-CoV-2 spike	212:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	4	44	theme	mutations	619:627	arg1	questions					542:550	questions	542:550	questions about proteolytic processing	542:579	Glycans near the cleavage site have raised questions about proteolytic processing and the consequences of variant-borne mutations.
36968546	4	44	theme	mutations	619:627	arg1	consequences					589:600	the consequences	585:600	the consequences of variant-borne mutations	585:627	Glycans near the cleavage site have raised questions about proteolytic processing and the consequences of variant-borne mutations.
36968546	0	45	theme	Spike	61:65	arg1	Proteolysis					35:45	the Proteolysis	31:45	the Proteolysis of SARS-CoV-2 Spike	31:65	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.
36968546	5	46	theme	SARS-CoV-2	706:715	arg1	spike					717:721	SARS-CoV-2 spike	706:721	SARS-CoV-2 spike	706:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	7	47	gly	O-glycopeptides	1157:1171	arg2	O-glycopeptides					1157:1171	synthetic O-glycopeptides	1147:1171	synthetic O-glycopeptides	1147:1171	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	9	48	theme	spike	1439:1443	arg1	maturation					1445:1454	spike maturation	1439:1454	spike maturation	1439:1454	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	3	49	from	variants	421:428	arg1	spikes					403:408	spikes	403:408	spikes from these variants	403:428	Besides furin, spikes from these variants appear to rely on other proteases for maturation, including TMPRSS2.
36968546	3	50	theme	other	448:452	arg1	TMPRSS2					490:496	TMPRSS2	490:496	TMPRSS2	490:496	Besides furin, spikes from these variants appear to rely on other proteases for maturation, including TMPRSS2.
36968546	3	50	theme	other	448:452	arg1	proteases					454:462	other proteases	448:462	other proteases	448:462	Besides furin, spikes from these variants appear to rely on other proteases for maturation, including TMPRSS2.
36968546	0	51	theme	SARS-CoV-2	50:59	arg1	Spike					61:65	SARS-CoV-2 Spike	50:65	SARS-CoV-2 Spike	50:65	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.
36968546	5	52	theme	sialic	653:658	arg1	glycans					685:691	sialic acid-containing O-linked glycans	653:691	sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike	653:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	53	link	O-linked	770:777	arg1	glycosylation					779:791	O-linked glycosylation	770:791	O-linked glycosylation	770:791	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	53	link	O-linked	770:777	arg1	force					813:817	a likely driving force	796:817	a likely driving force for the emergence of VOC mutations	796:852	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	54	link	O-linked	676:683	arg1	glycans					685:691	sialic acid-containing O-linked glycans	653:691	sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike	653:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	55	theme	acid-containing	660:674	arg1	glycans					685:691	sialic acid-containing O-linked glycans	653:691	sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike	653:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	0	56	from	Trajectory	107:116	arg1	Variants					121:128	Variants	121:128	Variants of Concern	121:139	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern.
36968546	1	57	theme	SARS-CoV-2	212:221	arg1	spike					223:227	SARS-CoV-2 spike	212:227	SARS-CoV-2 spike	212:227	The emergence of a polybasic cleavage motif for the protease furin in SARS-CoV-2 spike has been established as a major factor for human viral transmission.
36968546	5	58	theme	O-linked	676:683	arg1	glycans					685:691	sialic acid-containing O-linked glycans	653:691	sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike	653:721	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	9	59	theme	driving	1515:1521	arg1	disruption					1468:1477	disruption	1468:1477	disruption of O-glycosylation	1468:1496	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	9	59	theme	driving	1515:1521	arg1	force					1523:1527	a substantial driving force	1501:1527	a substantial driving force for VOC evolution	1501:1545	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	2	60	theme	N-terminal	309:318	arg1	region					302:307	The region	298:307	The region N-terminal to that motif	298:332	The region N-terminal to that motif is extensively mutated in variants of concern (VOCs).
36968546	7	61	theme	acid	1201:1204	arg1	presence					1182:1189	the presence	1178:1189	the presence of sialic acid	1178:1204	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	8	62	with	O-glycosylation	1254:1268	arg1	trisaccharide					1288:1300	a sialylated trisaccharide	1275:1300	a sialylated trisaccharide	1275:1300	Similarly, O-glycosylation with a sialylated trisaccharide had a negative impact on TMPRSS2 cleavage.
36968546	9	63	theme	O-glycosylation	1482:1496	arg1	disruption					1468:1477	disruption	1468:1477	disruption of O-glycosylation	1468:1496	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	9	63	theme	O-glycosylation	1482:1496	arg1	force					1523:1527	a substantial driving force	1501:1527	a substantial driving force for VOC evolution	1501:1545	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36968546	7	64	theme	furin	1218:1222	arg1	rate					1224:1227	the furin rate	1214:1227	the furin rate	1214:1227	We found that the sole incorporation of N-acetylgalactosamine did not impact furin activity in synthetic O-glycopeptides, but the presence of sialic acid reduced the furin rate by up to 65%.
36968546	2	65	theme	concern	372:378	arg1	variants					360:367	variants	360:367	variants of concern (VOCs)	360:385	The region N-terminal to that motif is extensively mutated in variants of concern (VOCs).
36968546	5	66	theme	TMPRSS2	743:749	arg1	cleavage					751:758	furin and TMPRSS2 cleavage	733:758	furin and TMPRSS2 cleavage	733:758	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	67	theme	O-linked	770:777	arg1	glycosylation					779:791	O-linked glycosylation	770:791	O-linked glycosylation	770:791	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	5	67	theme	O-linked	770:777	arg1	force					813:817	a likely driving force	796:817	a likely driving force for the emergence of VOC mutations	796:852	Here, we identify that sialic acid-containing O-linked glycans on Thr678 of SARS-CoV-2 spike influence furin and TMPRSS2 cleavage and posit O-linked glycosylation as a likely driving force for the emergence of VOC mutations.
36968546	9	68	theme	chemistry-centered	1352:1369	arg1	approach					1371:1378	a chemistry-centered approach	1350:1378	a chemistry-centered approach	1350:1378	With a chemistry-centered approach, we substantiate O-glycosylation as a major determinant of spike maturation and propose disruption of O-glycosylation as a substantial driving force for VOC evolution.
36444039	3	0	theme	protein	338:344	arg1	glycosylation					346:358	protein glycosylation	338:358	protein glycosylation	338:358	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	3	1	dep	method	299:304	arg1	obtain					423:428	obtain	423:428	to obtain dextran aldehydes	420:446	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	6	2	theme	glycosylated	736:747	arg1	products					749:756	dextran glycosylated products	728:756	dextran glycosylated products	728:756	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	8	3	theme	modification	1158:1169	arg1	methods					1171:1177	protein modification methods	1150:1177	protein modification methods	1150:1177	The polysaccharide aldehyde showed great potential for expanding protein modification methods to promote its industrialization.
36444039	3	4	theme	glycosylation	346:358	arg1	efficiency					324:333	the efficiency	320:333	the efficiency of protein glycosylation	320:358	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	4	5	theme	dextran	538:544	arg1	aldehyde					546:553	dextran aldehyde	538:553	dextran aldehyde with higher aldehyde group content and reduced molecular weight	538:617	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	4	6	theme	Increased	463:471	arg1	ratio					479:483	Increased molar ratio	463:483	Increased molar ratio between periodate and glucose unit in dextran	463:529	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	6	7	theme	glycosylated	844:855	arg1	products					857:864	dextran aldehyde glycosylated products	827:864	dextran aldehyde glycosylated products	827:864	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	4	8	theme	molecular	602:610	arg1	weight					612:617	reduced molecular weight	594:617	reduced molecular weight	594:617	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	3	9	theme	dextran	386:392	arg1	oxidation					394:402	dextran oxidation	386:402	dextran oxidation	386:402	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	7	10	theme	sodium	964:969	arg1	caseinate					971:979	Dextran aldehyde-modified sodium caseinate	938:979	Dextran aldehyde-modified sodium caseinate	938:979	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	6	11	theme	aldehyde	835:842	arg1	products					857:864	dextran aldehyde glycosylated products	827:864	dextran aldehyde glycosylated products	827:864	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	4	12	with	aldehyde	546:553	arg1	content					582:588	higher aldehyde group content	560:588	higher aldehyde group content	560:588	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	4	12	with	aldehyde	546:553	arg1	weight					612:617	reduced molecular weight	594:617	reduced molecular weight	594:617	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	3	13	theme	oxidation	394:402	arg1	degrees					375:381	different degrees	365:381	different degrees of dextran oxidation	365:402	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	4	14	theme	glucose	507:513	arg1	unit					515:518	glucose unit	507:518	glucose unit	507:518	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	6	15	theme	dextran	827:833	arg1	aldehyde					835:842	dextran aldehyde	827:842	dextran aldehyde glycosylated products	827:864	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	6	16	theme	dextran	728:734	arg1	products					749:756	dextran glycosylated products	728:756	dextran glycosylated products	728:756	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	5	17	theme	increased	638:646	arg1	oxidation					648:656	an increased oxidation	635:656	an increased oxidation	635:656	This is due to an increased oxidation, which increases the degree of glycosylation by 43.22%.
36444039	1	18	theme	functional	174:183	arg1	properties					185:194	the functional properties	170:194	the functional properties of proteins	170:206	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	7	19	theme	salt	1055:1058	arg1	ions					1060:1063	salt ions	1055:1063	salt ions	1055:1063	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	7	20	theme	aldehyde-modified	946:962	arg1	caseinate					971:979	Dextran aldehyde-modified sodium caseinate	938:979	Dextran aldehyde-modified sodium caseinate	938:979	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	6	21	theme	foaming	807:813	arg1	capacity					815:822	foaming capacity	807:822	foaming capacity	807:822	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	6	22	theme	poor	917:920	arg1	stability					927:935	poor foam stability	917:935	poor foam stability	917:935	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	0	23	theme	Structural	0:9	arg1	properties					26:35	Structural and functional properties	0:35	Structural and functional properties of sodium	0:45	Structural and functional properties of sodium caseinate glycosylated by dextran aldehyde.
36444039	8	24	theme	polysaccharide	1089:1102	arg1	aldehyde					1104:1111	The polysaccharide aldehyde	1085:1111	The polysaccharide aldehyde	1085:1111	The polysaccharide aldehyde showed great potential for expanding protein modification methods to promote its industrialization.
36444039	1	25	theme	proteins	199:206	arg1	properties					185:194	the functional properties	170:194	the functional properties of proteins	170:206	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	4	26	theme	group	576:580	arg1	content					582:588	higher aldehyde group content	560:588	higher aldehyde group content	560:588	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	7	27	theme	Dextran	938:944	arg1	caseinate					971:979	Dextran aldehyde-modified sodium caseinate	938:979	Dextran aldehyde-modified sodium caseinate	938:979	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	7	28	theme	lower	991:995	arg1	digestibility					997:1009	lower digestibility	991:1009	lower digestibility	991:1009	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	0	29	theme	functional	15:24	arg1	properties					26:35	Structural and functional properties	0:35	Structural and functional properties of sodium	0:45	Structural and functional properties of sodium caseinate glycosylated by dextran aldehyde.
36444039	4	30	theme	reduced	594:600	arg1	weight					612:617	reduced molecular weight	594:617	reduced molecular weight	594:617	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	8	31	theme	great	1120:1124	arg1	potential					1126:1134	great potential	1120:1134	great potential for expanding protein modification methods to promote its industrialization	1120:1210	The polysaccharide aldehyde showed great potential for expanding protein modification methods to promote its industrialization.
36444039	1	32	theme	effective	111:119	arg1	method					121:126	an effective method	108:126	an effective method of protein modification which can improve the functional properties of proteins	108:206	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	1	32	theme	effective	111:119	arg1	Glycosylation					91:103	Glycosylation	91:103	Glycosylation	91:103	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	6	33	theme	foam	922:925	arg1	stability					927:935	poor foam stability	917:935	poor foam stability	917:935	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	0	34	theme	sodium	40:45	arg1	properties					26:35	Structural and functional properties	0:35	Structural and functional properties of sodium	0:45	Structural and functional properties of sodium caseinate glycosylated by dextran aldehyde.
36444039	4	35	from	ratio	479:483	arg1	dextran					523:529	dextran	523:529	dextran	523:529	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	4	36	theme	molar	473:477	arg1	ratio					479:483	Increased molar ratio	463:483	Increased molar ratio between periodate and glucose unit in dextran	463:529	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	3	37	with	method	299:304	arg1	periodate					409:417	periodate	409:417	periodate	409:417	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	0	38	dep	caseinate	47:55	arg1	glycosylated					57:68	glycosylated	57:68	caseinate glycosylated by dextran aldehyde	47:88	Structural and functional properties of sodium caseinate glycosylated by dextran aldehyde.
36444039	6	39	theme	stability	785:793	arg1	indices					795:801	stability indices	785:801	stability indices	785:801	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	6	40	gly	glycosylated	844:855	arg1	products					857:864	dextran aldehyde glycosylated products	827:864	dextran aldehyde glycosylated products	827:864	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	5	41	theme	glycosylation	689:701	arg1	degree					679:684	the degree	675:684	the degree of glycosylation	675:701	This is due to an increased oxidation, which increases the degree of glycosylation by 43.22%.
36444039	3	42	theme	dextran	430:436	arg1	aldehydes					438:446	dextran aldehydes	430:446	dextran aldehydes	430:446	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36444039	4	43	theme	aldehyde	567:574	arg1	content					582:588	higher aldehyde group content	560:588	higher aldehyde group content	560:588	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	8	44	theme	protein	1150:1156	arg1	methods					1171:1177	protein modification methods	1150:1177	protein modification methods	1150:1177	The polysaccharide aldehyde showed great potential for expanding protein modification methods to promote its industrialization.
36444039	2	45	theme	glycosylation	229:241	arg1	methods					243:249	Traditional protein glycosylation methods	209:249	Traditional protein glycosylation methods	209:249	Traditional protein glycosylation methods are typically limited by slow reaction rates.
36444039	4	46	theme	higher	560:565	arg1	content					582:588	higher aldehyde group content	560:588	higher aldehyde group content	560:588	Increased molar ratio between periodate and glucose unit in dextran led to dextran aldehyde with higher aldehyde group content and reduced molecular weight.
36444039	2	47	theme	protein	221:227	arg1	methods					243:249	Traditional protein glycosylation methods	209:249	Traditional protein glycosylation methods	209:249	Traditional protein glycosylation methods are typically limited by slow reaction rates.
36444039	6	48	theme	emulsifying	763:773	arg1	activity					775:782	the emulsifying activity	759:782	the emulsifying activity	759:782	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	1	49	theme	protein	131:137	arg1	modification					139:150	protein modification	131:150	protein modification	131:150	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	7	50	theme	heat	1069:1072	arg1	treatment					1074:1082	heat treatment	1069:1082	heat treatment	1069:1082	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	2	51	theme	Traditional	209:219	arg1	methods					243:249	Traditional protein glycosylation methods	209:249	Traditional protein glycosylation methods	209:249	Traditional protein glycosylation methods are typically limited by slow reaction rates.
36444039	2	52	theme	reaction	281:288	arg1	rates					290:294	slow reaction rates	276:294	slow reaction rates	276:294	Traditional protein glycosylation methods are typically limited by slow reaction rates.
36444039	1	53	theme	modification	139:150	arg1	method					121:126	an effective method	108:126	an effective method of protein modification which can improve the functional properties of proteins	108:206	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	1	53	theme	modification	139:150	arg1	Glycosylation					91:103	Glycosylation	91:103	Glycosylation	91:103	Glycosylation is an effective method of protein modification which can improve the functional properties of proteins.
36444039	0	54	theme	dextran	73:79	arg1	aldehyde					81:88	dextran aldehyde	73:88	dextran aldehyde	73:88	Structural and functional properties of sodium caseinate glycosylated by dextran aldehyde.
36444039	6	55	theme	products	857:864	arg1	activity					775:782	the emulsifying activity	759:782	the emulsifying activity	759:782	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	6	55	theme	products	857:864	arg1	indices					795:801	stability indices	785:801	stability indices	785:801	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	6	55	theme	products	857:864	arg1	capacity					815:822	foaming capacity	807:822	foaming capacity	807:822	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	2	56	theme	slow	276:279	arg1	rates					290:294	slow reaction rates	276:294	slow reaction rates	276:294	Traditional protein glycosylation methods are typically limited by slow reaction rates.
36444039	7	57	theme	better	1030:1035	arg1	stability					1037:1045	better stability	1030:1045	better stability against salt ions and heat treatment	1030:1082	Dextran aldehyde-modified sodium caseinate presented lower digestibility and could maintain better stability against salt ions and heat treatment.
36444039	6	58	gly	glycosylated	736:747	arg1	products					749:756	dextran glycosylated products	728:756	dextran glycosylated products	728:756	Compared with dextran glycosylated products, the emulsifying activity, stability indices and foaming capacity of dextran aldehyde glycosylated products increased by 30.8, 301 and 50%, respectively, with poor foam stability.
36444039	3	59	theme	different	365:373	arg1	degrees					375:381	different degrees	365:381	different degrees of dextran oxidation	365:402	A method for improving the efficiency of protein glycosylation from different degrees of dextran oxidation with periodate, to obtain dextran aldehydes, is presented.
36216861	4	0	theme	cytokine	1027:1034	arg1	concentration					1036:1048	pro-inflammatory cytokine concentration	1010:1048	pro-inflammatory cytokine concentration	1010:1048	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	2	1	from	abundant	429:436	arg1	paucimannose					441:452	paucimannose	441:452	paucimannose	441:452	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	1	from	abundant	429:436	arg1	glycans					471:477	high mannose glycans	458:477	high mannose glycans	458:477	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	2	with	glycans	471:477	arg1	antennae					534:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	3	with	glycans	560:566	arg1	antennae					534:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	1	4	theme	physiological	238:250	arg1	events					252:257	physiological events	238:257	physiological events associated with reproductive health	238:293	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	2	5	theme	complex	480:486	arg1	glycans					488:494	complex glycans	480:494	complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae	480:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	6	with	glycans	488:494	arg1	antennae					534:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	7	theme	rich	359:362	arg1	N-glycome					376:384	an extremely rich and complex N-glycome	346:384	an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation	346:610	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	5	8	theme	reproductive	1147:1158	arg1	health					1160:1165	reproductive health	1147:1165	reproductive health	1147:1165	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	4	9	theme	higher	958:963	arg1	fucosylation					965:976	higher fucosylation	958:976	higher fucosylation	958:976	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	2	10	from	paucimannose	441:452	arg1	abundant					429:436	abundant	429:436	abundant	429:436	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	11	theme	LacNAc	526:531	arg1	antennae					534:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	3	12	theme	pregnancy	741:749	arg1	outcome					751:757	pregnancy outcome	741:757	pregnancy outcome	741:757	N-glycosylation profiles were observed to differ in relation to pregnancy status, microbial composition, immune activation, and pregnancy outcome.
36216861	4	13	from	women	781:785	arg1	CVF					772:774	CVF	772:774	CVF from women experiencing term birth	772:809	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	5	14	theme	glycans	1136:1142	arg1	potential					1249:1257	their potential	1243:1257	their potential for preventative therapy	1243:1282	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	5	14	theme	glycans	1136:1142	arg1	role					1113:1116	the role	1109:1116	the role of cervicovaginal glycans in reproductive health	1109:1165	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	5	14	theme	glycans	1136:1142	arg1	contribution					1174:1185	their contribution	1168:1185	their contribution to the mechanism of microbial driven preterm birth	1168:1236	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	1	15	theme	rich	190:193	arg1	fluid					206:210	glycan rich biological fluid	183:210	glycan rich biological fluid	183:210	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	4	16	theme	term	800:803	arg1	birth					805:809	term birth	800:809	term birth	800:809	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	2	17	theme	pregnant	396:403	arg1	women					422:426	pregnant and non-pregnant women	396:426	pregnant and non-pregnant women	396:426	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	18	theme	N-Acetyllactosamine	505:523	arg1	antennae					534:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	4	19	theme	preterm	856:862	arg1	birth					864:868	preterm birth	856:868	preterm birth	856:868	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	2	20	from	glycans	471:477	arg1	abundant					429:436	abundant	429:436	abundant	429:436	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	4	21	theme	lower	877:881	arg1	sialylation					883:893	lower sialylation	877:893	lower sialylation	877:893	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	5	22	theme	microbial	1207:1215	arg1	birth					1232:1236	microbial driven preterm birth	1207:1236	microbial driven preterm birth	1207:1236	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	2	23	dep	reveal	339:344	arg1	Using					296:300	Using	296:300	Using a comprehensive glycomic strategy	296:334	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	1	24	theme	important	169:177	arg1	fluid					130:134	Human cervicovaginal fluid	109:134	Human cervicovaginal fluid (CVF)	109:140	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	24	theme	important	169:177	arg1	complex					147:153	a complex	145:153	a complex	145:153	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	25	theme	reproductive	275:286	arg1	health					288:293	reproductive health	275:293	reproductive health	275:293	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	2	26	from	N-glycome	376:384	arg1	CVF					389:391	CVF	389:391	CVF	389:391	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	27	theme	glycomic	318:325	arg1	strategy					327:334	a comprehensive glycomic strategy	302:334	a comprehensive glycomic strategy	302:334	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	0	28	theme	fluid	34:38	arg1	N-glycosylation					0:14	N-glycosylation	0:14	N-glycosylation of cervicovaginal fluid	0:38	N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.
36216861	5	29	theme	driven	1217:1222	arg1	birth					1232:1236	microbial driven preterm birth	1207:1236	microbial driven preterm birth	1207:1236	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	2	30	theme	Poly-LacNAc	548:558	arg1	glycans					560:566	Poly-LacNAc glycans	548:566	Poly-LacNAc glycans	548:566	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	31	theme	comprehensive	304:316	arg1	strategy					327:334	a comprehensive glycomic strategy	302:334	a comprehensive glycomic strategy	302:334	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	1	32	theme	glycan	183:188	arg1	fluid					206:210	glycan rich biological fluid	183:210	glycan rich biological fluid	183:210	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	0	33	theme	cervicovaginal	19:32	arg1	fluid					34:38	cervicovaginal fluid	19:38	cervicovaginal fluid	19:38	N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.
36216861	5	34	theme	preterm	1224:1230	arg1	birth					1232:1236	microbial driven preterm birth	1207:1236	microbial driven preterm birth	1207:1236	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	5	35	from	potential	1249:1257	arg1	health					1160:1165	reproductive health	1147:1165	reproductive health	1147:1165	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	5	36	from	contribution	1174:1185	arg1	health					1160:1165	reproductive health	1147:1165	reproductive health	1147:1165	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	1	37	theme	Human	109:113	arg1	CVF					137:139	CVF	137:139	CVF	137:139	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	37	theme	Human	109:113	arg1	fluid					130:134	Human cervicovaginal fluid	109:134	Human cervicovaginal fluid (CVF)	109:140	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	37	theme	Human	109:113	arg1	complex					147:153	a complex	145:153	a complex	145:153	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	2	38	theme	women	422:426	arg1	N-glycome					376:384	an extremely rich and complex N-glycome	346:384	an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation	346:610	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	0	39	theme	microbial	49:57	arg1	community					59:67	microbial community	49:67	microbial community	49:67	N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.
36216861	5	40	theme	birth	1232:1236	arg1	mechanism					1194:1202	the mechanism	1190:1202	the mechanism of microbial driven preterm birth	1190:1236	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	2	41	theme	non-pregnant	409:420	arg1	women					422:426	pregnant and non-pregnant women	396:426	pregnant and non-pregnant women	396:426	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	0	42	gly	N-glycosylation	0:14	arg1	fluid					34:38	cervicovaginal fluid	19:38	cervicovaginal fluid	19:38	N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.
36216861	1	43	theme	biological	195:204	arg1	fluid					206:210	glycan rich biological fluid	183:210	glycan rich biological fluid	183:210	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	4	44	theme	pro-inflammatory	1010:1025	arg1	concentration					1036:1048	pro-inflammatory cytokine concentration	1010:1048	pro-inflammatory cytokine concentration	1010:1048	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	4	45	theme	microbiome	942:951	arg1	presence					920:927	the presence	916:927	the presence of a diverse microbiome	916:951	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	3	46	theme	N-glycosylation	613:627	arg1	profiles					629:636	N-glycosylation profiles	613:636	N-glycosylation profiles	613:636	N-glycosylation profiles were observed to differ in relation to pregnancy status, microbial composition, immune activation, and pregnancy outcome.
36216861	2	47	theme	mannose	463:469	arg1	glycans					471:477	high mannose glycans	458:477	high mannose glycans	458:477	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	5	48	from	role	1113:1116	arg1	health					1160:1165	reproductive health	1147:1165	reproductive health	1147:1165	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	5	49	theme	cervicovaginal	1121:1134	arg1	glycans					1136:1142	cervicovaginal glycans	1121:1142	cervicovaginal glycans	1121:1142	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	1	50	dep	fundamental	213:223	arg1	complex					147:153	a complex	145:153	a complex	145:153	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	50	dep	fundamental	213:223	arg1	fluid					130:134	Human cervicovaginal fluid	109:134	Human cervicovaginal fluid (CVF)	109:140	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	50	dep	fundamental	213:223	arg1	fluid					206:210	glycan rich biological fluid	183:210	glycan rich biological fluid	183:210	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	51	theme	cervicovaginal	115:128	arg1	CVF					137:139	CVF	137:139	CVF	137:139	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	51	theme	cervicovaginal	115:128	arg1	fluid					130:134	Human cervicovaginal fluid	109:134	Human cervicovaginal fluid (CVF)	109:140	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	1	51	theme	cervicovaginal	115:128	arg1	complex					147:153	a complex	145:153	a complex	145:153	Human cervicovaginal fluid (CVF) is a complex, functionally important and glycan rich biological fluid, fundamental in mediating physiological events associated with reproductive health.
36216861	2	52	theme	high	458:461	arg1	glycans					471:477	high mannose glycans	458:477	high mannose glycans	458:477	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	4	53	theme	diverse	934:940	arg1	microbiome					942:951	a diverse microbiome	932:951	a diverse microbiome	932:951	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	5	54	theme	first	1069:1073	arg1	study					1056:1060	This study	1051:1060	This study	1051:1060	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	5	54	theme	first	1069:1073	arg1	step					1075:1078	the first step	1065:1078	the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy	1065:1282	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	3	55	theme	microbial	695:703	arg1	composition					705:715	microbial composition	695:715	microbial composition	695:715	N-glycosylation profiles were observed to differ in relation to pregnancy status, microbial composition, immune activation, and pregnancy outcome.
36216861	2	56	with	paucimannose	441:452	arg1	antennae					534:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	2-4 N-Acetyllactosamine (LacNAc) antennae	501:541	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	4	57	from	women	821:825	arg1	CVF					812:814	CVF	812:814	CVF from women who subsequently experienced preterm birth	812:868	Compared to CVF from women experiencing term birth, CVF from women who subsequently experienced preterm birth showed lower sialylation, which correlated to the presence of a diverse microbiome, and higher fucosylation, which correlated positively to pro-inflammatory cytokine concentration.
36216861	3	58	theme	pregnancy	677:685	arg1	status					687:692	pregnancy status	677:692	pregnancy status	677:692	N-glycosylation profiles were observed to differ in relation to pregnancy status, microbial composition, immune activation, and pregnancy outcome.
36216861	5	59	theme	preventative	1263:1274	arg1	therapy					1276:1282	preventative therapy	1263:1282	preventative therapy	1263:1282	This study is the first step towards better understanding the role of cervicovaginal glycans in reproductive health, their contribution to the mechanism of microbial driven preterm birth, and their potential for preventative therapy.
36216861	0	60	theme	immune	70:75	arg1	activity					77:84	immune activity	70:84	immune activity	70:84	N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.
36216861	3	61	theme	immune	718:723	arg1	activation					725:734	immune activation	718:734	immune activation	718:734	N-glycosylation profiles were observed to differ in relation to pregnancy status, microbial composition, immune activation, and pregnancy outcome.
36216861	2	62	theme	abundant	429:436	arg1	women					422:426	pregnant and non-pregnant women	396:426	pregnant and non-pregnant women	396:426	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	2	63	theme	complex	368:374	arg1	N-glycome					376:384	an extremely rich and complex N-glycome	346:384	an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation	346:610	Using a comprehensive glycomic strategy we reveal an extremely rich and complex N-glycome in CVF of pregnant and non-pregnant women, abundant in paucimannose and high mannose glycans, complex glycans with 2-4 N-Acetyllactosamine (LacNAc) antennae, and Poly-LacNAc glycans decorated with fucosylation and sialylation.
36216861	0	64	theme	pregnancy	91:99	arg1	status					101:106	pregnancy status	91:106	pregnancy status	91:106	N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.
36758646	0	0	theme	Nilaparvata	97:107	arg1	lugens					109:114	the hemimetabolous insect Nilaparvata lugens	71:114	the hemimetabolous insect Nilaparvata lugens	71:114	α-1,6-fucosyltransferase plays a critical role during embryogenesis of the hemimetabolous insect Nilaparvata lugens.
36758646	8	1	from	differences	1161:1171	arg1	abundance					1180:1188	the abundance	1176:1188	the abundance of proteins	1176:1200	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	1	2	theme	post-translational	168:185	arg1	modifications					187:199	the most important post-translational modifications	149:199	the most important post-translational modifications	149:199	Protein glycosylation is one of the most important post-translational modifications, modulating the properties of proteins.
36758646	9	3	theme	N.	1416:1417	arg1	lugens					1419:1424	N. lugens	1416:1424	N. lugens during embryonic development	1416:1453	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	0	4	theme	insect	90:95	arg1	lugens					109:114	the hemimetabolous insect Nilaparvata lugens	71:114	the hemimetabolous insect Nilaparvata lugens	71:114	α-1,6-fucosyltransferase plays a critical role during embryogenesis of the hemimetabolous insect Nilaparvata lugens.
36758646	6	5	theme	parental	824:831	arg1	RNAi					833:836	parental RNAi	824:836	parental RNAi of FucT6	824:845	However, parental RNAi of FucT6 led to full failure in the hatching of eggs, and this effect was maternally mediated.
36758646	1	6	theme	modifications	187:199	arg1	one					142:144	one	142:144	one	142:144	Protein glycosylation is one of the most important post-translational modifications, modulating the properties of proteins.
36758646	1	6	theme	modifications	187:199	arg1	modifications					187:199	the most important post-translational modifications	149:199	the most important post-translational modifications	149:199	Protein glycosylation is one of the most important post-translational modifications, modulating the properties of proteins.
36758646	5	7	from	silencing	761:769	arg1	adults					783:788	adults	783:788	adults	783:788	In this study, RNAi-mediated gene silencing of FucT6 in adults did not cause lethality.
36758646	2	8	theme	N-glycans	371:379	arg1	structure					358:366	the core structure	349:366	the core structure of N-glycans on glycoproteins	349:396	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	7	9	theme	expression	953:962	arg1	levels					964:969	gene expression levels	948:969	gene expression levels of FucT6 in the eggs	948:990	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	9	10	gly	glycoproteins	1385:1397	arg1	glycoproteins					1385:1397	glycoproteins	1385:1397	glycoproteins	1385:1397	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	3	11	theme	process	574:580	arg1	failure					551:557	a failure	549:557	a failure of the ecdysis process	549:580	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	0	12	theme	lugens	109:114	arg1	embryogenesis					54:66	embryogenesis	54:66	embryogenesis of the hemimetabolous insect Nilaparvata lugens	54:114	α-1,6-fucosyltransferase plays a critical role during embryogenesis of the hemimetabolous insect Nilaparvata lugens.
36758646	6	13	theme	eggs	886:889	arg1	hatching					874:881	the hatching	870:881	the hatching of eggs	870:889	However, parental RNAi of FucT6 led to full failure in the hatching of eggs, and this effect was maternally mediated.
36758646	8	14	from	role	1275:1278	arg1	development					1331:1341	embryonal development	1321:1341	embryonal development	1321:1341	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	8	15	theme	embryonal	1321:1329	arg1	development					1331:1341	embryonal development	1321:1341	embryonal development	1321:1341	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	9	16	theme	N-glycosylation	1509:1523	arg1	role					1501:1504	the role	1497:1504	the role of N-glycosylation in embryogenesis in insects	1497:1551	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	4	17	theme	N.	716:717	arg1	lugens					719:724	N. lugens	716:724	N. lugens	716:724	These results suggested the requirement of FucT6 during nymphal development in N. lugens.
36758646	3	18	theme	third-instar	500:511	arg1	nymphs					513:518	the third-instar nymphs	496:518	the third-instar nymphs of Nilaparvata lugens	496:540	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	2	19	from	structure	358:366	arg1	glycoproteins					384:396	glycoproteins	384:396	glycoproteins	384:396	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	9	20	theme	embryonic	1433:1441	arg1	development					1443:1453	embryonic development	1433:1453	embryonic development	1433:1453	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	7	21	from	FucT6	974:978	arg1	eggs					987:990	the eggs	983:990	the eggs	983:990	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	4	22	theme	FucT6	680:684	arg1	requirement					665:675	the requirement	661:675	the requirement of FucT6	661:684	These results suggested the requirement of FucT6 during nymphal development in N. lugens.
36758646	8	23	theme	Proteome	1124:1131	arg1	analysis					1133:1140	Proteome analysis	1124:1140	Proteome analysis	1124:1140	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	2	24	theme	important	292:300	arg1	α-1,6-fucosyltransferase					253:276	α-1,6-fucosyltransferase	253:276	α-1,6-fucosyltransferase (FucT6)	253:284	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	2	24	theme	important	292:300	arg1	enzyme					302:307	an important enzyme	289:307	an important enzyme	289:307	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	5	25	theme	gene	756:759	arg1	silencing					761:769	RNAi-mediated gene silencing	742:769	RNAi-mediated gene silencing of FucT6 in adults	742:788	In this study, RNAi-mediated gene silencing of FucT6 in adults did not cause lethality.
36758646	8	26	theme	significant	1149:1159	arg1	differences					1161:1171	significant differences	1149:1171	significant differences in the abundance of proteins between different embryonal developmental stages	1149:1249	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	4	27	theme	nymphal	693:699	arg1	development					701:711	nymphal development	693:711	nymphal development in N. lugens	693:724	These results suggested the requirement of FucT6 during nymphal development in N. lugens.
36758646	8	28	theme	different	1210:1218	arg1	stages					1244:1249	different embryonal developmental stages	1210:1249	different embryonal developmental stages	1210:1249	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	3	29	theme	nymphal	589:595	arg1	development					597:607	nymphal development	589:607	nymphal development	589:607	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	3	30	theme	previous	444:451	arg1	study					453:457	our previous study	440:457	our previous study	440:457	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	0	31	theme	critical	33:40	arg1	role					42:45	a critical role	31:45	a critical role	31:45	α-1,6-fucosyltransferase plays a critical role during embryogenesis of the hemimetabolous insect Nilaparvata lugens.
36758646	2	32	gly	glycoproteins	384:396	arg1	glycoproteins					384:396	glycoproteins	384:396	glycoproteins	384:396	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	9	33	from	role	1501:1504	arg1	embryogenesis					1528:1540	embryogenesis	1528:1540	embryogenesis in insects	1528:1551	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	3	34	theme	ecdysis	566:572	arg1	process					574:580	the ecdysis process	562:580	the ecdysis process	562:580	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	7	35	theme	gene	948:951	arg1	levels					964:969	gene expression levels	948:969	gene expression levels of FucT6 in the eggs	948:990	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	9	36	theme	new	1479:1481	arg1	insights					1483:1490	new insights	1479:1490	new insights into the role of N-glycosylation in embryogenesis in insects	1479:1551	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	6	37	from	failure	859:865	arg1	hatching					874:881	the hatching	870:881	the hatching of eggs	870:889	However, parental RNAi of FucT6 led to full failure in the hatching of eggs, and this effect was maternally mediated.
36758646	2	38	theme	glycosylation	316:328	arg1	pathway					330:336	the glycosylation pathway	312:336	the glycosylation pathway	312:336	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	1	39	theme	proteins	231:238	arg1	properties					217:226	the properties	213:226	the properties of proteins	213:238	Protein glycosylation is one of the most important post-translational modifications, modulating the properties of proteins.
36758646	7	40	from	eggs	987:990	arg1	levels					964:969	gene expression levels	948:969	gene expression levels of FucT6 in the eggs	948:990	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	8	41	theme	N-fucosylation	1303:1316	arg1	role					1275:1278	the crucial role	1263:1278	the crucial role of FucT6 mediated core N-fucosylation in embryonal development	1263:1341	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	9	42	from	embryogenesis	1528:1540	arg1	insects					1545:1551	insects	1545:1551	insects	1545:1551	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	3	43	theme	RNAi-mediated	460:472	arg1	silencing					474:482	RNAi-mediated silencing	460:482	RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens	460:540	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	8	44	theme	embryonal	1220:1228	arg1	stages					1244:1249	different embryonal developmental stages	1210:1249	different embryonal developmental stages	1210:1249	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	2	45	theme	residue	428:434	arg1	addition					407:414	the addition	403:414	the addition of a fucose residue	403:434	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	7	46	from	levels	964:969	arg1	eggs					987:990	the eggs	983:990	the eggs	983:990	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	6	47	theme	full	854:857	arg1	failure					859:865	full failure	854:865	full failure in the hatching of eggs	854:889	However, parental RNAi of FucT6 led to full failure in the hatching of eggs, and this effect was maternally mediated.
36758646	7	48	theme	egg	1119:1121	arg1	side					1107:1110	the anterior side	1094:1110	the anterior side of the egg	1094:1121	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	2	49	theme	fucose	421:426	arg1	residue					428:434	a fucose residue	419:434	a fucose residue	419:434	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	7	50	theme	anterior	1098:1105	arg1	side					1107:1110	the anterior side	1094:1110	the anterior side of the egg	1094:1121	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	9	51	theme	correct	1355:1361	arg1	α-1,6-fucosylation					1363:1380	correct α-1,6-fucosylation	1355:1380	correct α-1,6-fucosylation of glycoproteins	1355:1397	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	3	52	from	silencing	474:482	arg1	nymphs					513:518	the third-instar nymphs	496:518	the third-instar nymphs of Nilaparvata lugens	496:540	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	3	53	theme	FucT6	487:491	arg1	silencing					474:482	RNAi-mediated silencing	460:482	RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens	460:540	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	9	54	gly	α-1,6-fucosylation	1363:1380	arg1	glycoproteins					1385:1397	glycoproteins	1385:1397	glycoproteins	1385:1397	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	9	54	gly	α-1,6-fucosylation	1363:1380	arg1	N.					1416:1417	N. lugens	1416:1424	N. lugens during embryonic development	1416:1453	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	3	55	theme	Nilaparvata	523:533	arg1	lugens					535:540	Nilaparvata lugens	523:540	Nilaparvata lugens	523:540	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	8	56	theme	crucial	1267:1273	arg1	role					1275:1278	the crucial role	1263:1278	the crucial role of FucT6 mediated core N-fucosylation in embryonal development	1263:1341	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	2	57	from	enzyme	302:307	arg1	pathway					330:336	the glycosylation pathway	312:336	the glycosylation pathway	312:336	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	2	57	from	enzyme	302:307	arg1	insects					244:250	insects	244:250	insects	244:250	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	6	58	theme	FucT6	841:845	arg1	RNAi					833:836	parental RNAi	824:836	parental RNAi of FucT6	824:845	However, parental RNAi of FucT6 led to full failure in the hatching of eggs, and this effect was maternally mediated.
36758646	8	59	theme	developmental	1230:1242	arg1	stages					1244:1249	different embryonal developmental stages	1210:1249	different embryonal developmental stages	1210:1249	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	2	60	theme	core	353:356	arg1	structure					358:366	the core structure	349:366	the core structure of N-glycans on glycoproteins	349:396	In insects, α-1,6-fucosyltransferase (FucT6) is an important enzyme in the glycosylation pathway, modifying the core structure of N-glycans on glycoproteins with the addition of a fucose residue.
36758646	1	61	theme	Protein	117:123	arg1	glycosylation					125:137	Protein glycosylation	117:137	Protein glycosylation	117:137	Protein glycosylation is one of the most important post-translational modifications, modulating the properties of proteins.
36758646	9	62	theme	glycoproteins	1385:1397	arg1	α-1,6-fucosylation					1363:1380	correct α-1,6-fucosylation	1355:1380	correct α-1,6-fucosylation of glycoproteins	1355:1397	Therefore, correct α-1,6-fucosylation of glycoproteins is important for N. lugens during embryonic development and this study provides new insights into the role of N-glycosylation in embryogenesis in insects.
36758646	7	63	theme	katatrepsis	1006:1016	arg1	event					1018:1022	the katatrepsis event	1002:1022	the katatrepsis event	1002:1022	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	8	64	theme	core	1298:1301	arg1	N-fucosylation					1303:1316	FucT6 mediated core N-fucosylation	1283:1316	FucT6 mediated core N-fucosylation	1283:1316	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	7	65	theme	FucT6	974:978	arg1	levels					964:969	gene expression levels	948:969	gene expression levels of FucT6 in the eggs	948:990	Interestingly, gene expression levels of FucT6 in the eggs peaked at the katatrepsis event, where the embryo rotates 180° resulting in the head pointing towards the anterior side of the egg.
36758646	8	66	theme	mediated	1289:1296	arg1	N-fucosylation					1303:1316	FucT6 mediated core N-fucosylation	1283:1316	FucT6 mediated core N-fucosylation	1283:1316	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	8	67	theme	proteins	1193:1200	arg1	abundance					1180:1188	the abundance	1176:1188	the abundance of proteins	1176:1200	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	8	68	theme	FucT6	1283:1287	arg1	N-fucosylation					1303:1316	FucT6 mediated core N-fucosylation	1283:1316	FucT6 mediated core N-fucosylation	1283:1316	Proteome analysis showed significant differences in the abundance of proteins between different embryonal developmental stages, suggesting the crucial role of FucT6 mediated core N-fucosylation in embryonal development.
36758646	0	69	theme	hemimetabolous	75:88	arg1	lugens					109:114	the hemimetabolous insect Nilaparvata lugens	71:114	the hemimetabolous insect Nilaparvata lugens	71:114	α-1,6-fucosyltransferase plays a critical role during embryogenesis of the hemimetabolous insect Nilaparvata lugens.
36758646	4	70	from	development	701:711	arg1	lugens					719:724	N. lugens	716:724	N. lugens	716:724	These results suggested the requirement of FucT6 during nymphal development in N. lugens.
36758646	3	71	theme	high	621:624	arg1	mortality					626:634	high mortality	621:634	high mortality	621:634	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	3	72	theme	lugens	535:540	arg1	nymphs					513:518	the third-instar nymphs	496:518	the third-instar nymphs of Nilaparvata lugens	496:540	In our previous study, RNAi-mediated silencing of FucT6 in the third-instar nymphs of Nilaparvata lugens caused a failure of the ecdysis process during nymphal development, leading to high mortality.
36758646	5	73	theme	FucT6	774:778	arg1	silencing					761:769	RNAi-mediated gene silencing	742:769	RNAi-mediated gene silencing of FucT6 in adults	742:788	In this study, RNAi-mediated gene silencing of FucT6 in adults did not cause lethality.
36758646	1	74	theme	important	158:166	arg1	modifications					187:199	the most important post-translational modifications	149:199	the most important post-translational modifications	149:199	Protein glycosylation is one of the most important post-translational modifications, modulating the properties of proteins.
36758646	5	75	theme	RNAi-mediated	742:754	arg1	silencing					761:769	RNAi-mediated gene silencing	742:769	RNAi-mediated gene silencing of FucT6 in adults	742:788	In this study, RNAi-mediated gene silencing of FucT6 in adults did not cause lethality.
36694402	5	0	theme	%	807:807	arg1	CI					830:831	95% confidence interval (CI)	805:832	95% confidence interval (CI)	805:832	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	4	1	theme	logistic	545:552	arg1	regression					554:563	Multivariable logistic regression	531:563	Multivariable logistic regression	531:563	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	6	2	theme	IBD	903:905	arg1	patients					907:914	54 IBD patients	900:914	54 IBD patients	900:914	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	5	3	theme	confidence	809:818	arg1	CI					830:831	95% confidence interval (CI)	805:832	95% confidence interval (CI)	805:832	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	3	4	link	derived	492:498	arg1	traits					507:512	24 derived glycan traits	489:512	24 derived glycan traits	489:512	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	5	5	theme	hazard	661:666	arg1	models					668:673	Cox proportional hazard models	644:673	Cox proportional hazard models	644:673	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	6	6	theme	replication	878:888	arg1	cohort					890:895	an independent replication cohort	863:895	an independent replication cohort of 54 IBD patients	863:914	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	3	7	theme	glycan	373:378	arg1	peaks					380:384	Forty-seven individual glycan peaks	350:384	Forty-seven individual glycan peaks	350:384	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	4	8	link	derived	608:614	arg1	traits					623:628	derived glycan traits	608:628	derived glycan traits	608:628	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	2	9	theme	discovery	296:304	arg1	cohort					306:311	a discovery cohort	294:311	a discovery cohort of 244 newly diagnosed IBD patients	294:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	3	10	theme	performance	417:427	arg1	chromatography					436:449	ultra-high performance liquid chromatography	406:449	ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated	406:528	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	2	11	theme	diagnosed	326:334	arg1	patients					340:347	244 newly diagnosed IBD patients	316:347	244 newly diagnosed IBD patients	316:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	3	12	theme	Forty-seven	350:360	arg1	peaks					380:384	Forty-seven individual glycan peaks	350:384	Forty-seven individual glycan peaks	350:384	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	3	13	theme	individual	362:371	arg1	peaks					380:384	Forty-seven individual glycan peaks	350:384	Forty-seven individual glycan peaks	350:384	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	0	14	from	Escalation	46:55	arg1	Disease					79:85	Inflammatory Bowel Disease	60:85	Inflammatory Bowel Disease	60:85	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
36694402	3	15	theme	ultra-high	406:415	arg1	chromatography					436:449	ultra-high performance liquid chromatography	406:449	ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated	406:528	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	0	16	theme	N-Glycomic	6:15	arg1	Biomarkers					17:26	Serum N-Glycomic Biomarkers	0:26	Serum N-Glycomic Biomarkers	0:26	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
36694402	4	17	theme	traits	623:628	arg1	associations					592:603	associations	592:603	associations of derived glycan traits with disease	592:641	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	5	18	theme	treatment	696:704	arg1	escalation					706:715	treatment escalation	696:715	treatment escalation from first-line treatment to biologics or surgery	696:765	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	0	19	theme	Serum	0:4	arg1	Biomarkers					17:26	Serum N-Glycomic Biomarkers	0:26	Serum N-Glycomic Biomarkers	0:26	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
36694402	4	20	theme	glycan	616:621	arg1	traits					623:628	derived glycan traits	608:628	derived glycan traits	608:628	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	5	21	theme	Cox	644:646	arg1	models					668:673	Cox proportional hazard models	644:673	Cox proportional hazard models	644:673	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	4	22	with	associations	592:603	arg1	disease					635:641	disease	635:641	disease	635:641	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	5	23	used	used	680:683	arg2	models					668:673	Cox proportional hazard models	644:673	Cox proportional hazard models	644:673	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	5	24	theme	first-line	722:731	arg1	treatment					733:741	first-line treatment	722:741	first-line treatment	722:741	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	4	25	theme	derived	608:614	arg1	traits					623:628	derived glycan traits	608:628	derived glycan traits	608:628	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	5	26	theme	hazard	768:773	arg1	p=1.1×10-12					792:802	p=1.1×10-12	792:802	p=1.1×10-12	792:802	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	5	26	theme	hazard	768:773	arg1	HR					782:783	hazard ratio (HR) 25.9	768:789	hazard ratio (HR) 25.9	768:789	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	1	27	from	diagnosis	136:144	arg1	decision-making					117:131	clinical decision-making	108:131	clinical decision-making at diagnosis of inflammatory bowel disease (IBD)	108:180	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	1	28	theme	clinical	108:115	arg1	decision-making					117:131	clinical decision-making	108:131	clinical decision-making at diagnosis of inflammatory bowel disease (IBD)	108:180	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	3	29	theme	glycan	500:505	arg1	traits					507:512	24 derived glycan traits	489:512	24 derived glycan traits	489:512	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	5	30	theme	ratio	775:779	arg1	p=1.1×10-12					792:802	p=1.1×10-12	792:802	p=1.1×10-12	792:802	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	5	30	theme	ratio	775:779	arg1	HR					782:783	hazard ratio (HR) 25.9	768:789	hazard ratio (HR) 25.9	768:789	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	6	31	theme	5.1	932:934	arg1	HR					926:927	a HR	924:927	a HR of 5.1	924:934	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	5	32	theme	interval	820:827	arg1	CI					830:831	95% confidence interval (CI)	805:832	95% confidence interval (CI)	805:832	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	2	33	theme	patients	340:347	arg1	cohort					306:311	a discovery cohort	294:311	a discovery cohort of 244 newly diagnosed IBD patients	294:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	6	34	dep	p=1.1×10-5	937:946	arg1	%					951:951	95% CI	949:954	95% CI	949:954	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	6	34	dep	p=1.1×10-5	937:946	arg1	2.54-10.1					957:965	2.54-10.1	957:965	2.54-10.1	957:965	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	0	35	theme	Treatment	36:44	arg1	Escalation					46:55	Treatment Escalation	36:55	Treatment Escalation in Inflammatory Bowel Disease	36:85	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
36694402	5	36	from	treatment	733:741	arg1	escalation					706:715	treatment escalation	696:715	treatment escalation from first-line treatment to biologics or surgery	696:765	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	2	37	theme	N-glycomic	237:246	arg1	biomarker					248:256	a composite serum N-glycomic biomarker	219:256	a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients	219:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	3	38	theme	derived	492:498	arg1	traits					507:512	24 derived glycan traits	489:512	24 derived glycan traits	489:512	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	0	39	theme	Inflammatory	60:71	arg1	Disease					79:85	Inflammatory Bowel Disease	60:85	Inflammatory Bowel Disease	60:85	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
36694402	7	40	theme	biomarkers	1034:1043	arg1	capacity					1007:1014	the prognostic capacity	992:1014	the prognostic capacity of serum N-glycan biomarkers	992:1043	These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.
36694402	5	41	dep	HR	782:783	arg1	CI					830:831	95% confidence interval (CI)	805:832	95% confidence interval (CI)	805:832	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	5	41	dep	HR	782:783	arg1	8.52-78.78					835:844	8.52-78.78	835:844	8.52-78.78	835:844	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	2	42	theme	serum	231:235	arg1	biomarker					248:256	a composite serum N-glycomic biomarker	219:256	a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients	219:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	4	43	theme	Multivariable	531:543	arg1	regression					554:563	Multivariable logistic regression	531:563	Multivariable logistic regression	531:563	Multivariable logistic regression was performed to determine associations of derived glycan traits with disease.
36694402	3	44	theme	liquid	429:434	arg1	chromatography					436:449	ultra-high performance liquid chromatography	406:449	ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated	406:528	Forty-seven individual glycan peaks were analysed using ultra-high performance liquid chromatography identifying 105 glycoforms from which 24 derived glycan traits were calculated.
36694402	6	45	theme	independent	866:876	arg1	cohort					890:895	an independent replication cohort	863:895	an independent replication cohort of 54 IBD patients	863:914	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	2	46	theme	composite	221:229	arg1	biomarker					248:256	a composite serum N-glycomic biomarker	219:256	a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients	219:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	1	47	dep	Biomarkers	88:97	arg1	guide					102:106	guide	102:106	to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD)	99:180	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	7	48	from	medicine	1087:1094	arg1	IBD					1099:1101	IBD	1099:1101	IBD	1099:1101	These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.
36694402	5	49	theme	proportional	648:659	arg1	models					668:673	Cox proportional hazard models	644:673	Cox proportional hazard models	644:673	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	7	50	theme	serum	1019:1023	arg1	biomarkers					1034:1043	serum N-glycan biomarkers	1019:1043	serum N-glycan biomarkers	1019:1043	These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.
36694402	2	51	theme	disease	276:282	arg1	course					284:289	future disease course	269:289	future disease course	269:289	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	7	52	theme	prognostic	996:1005	arg1	capacity					1007:1014	the prognostic capacity	992:1014	the prognostic capacity of serum N-glycan biomarkers	992:1043	These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.
36694402	2	53	theme	IBD	336:338	arg1	patients					340:347	244 newly diagnosed IBD patients	316:347	244 newly diagnosed IBD patients	316:347	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	7	54	theme	N-glycan	1025:1032	arg1	biomarkers					1034:1043	serum N-glycan biomarkers	1019:1043	serum N-glycan biomarkers	1019:1043	These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.
36694402	2	55	theme	future	269:274	arg1	course					284:289	future disease course	269:289	future disease course	269:289	We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
36694402	5	56	dep	predict	688:694	arg1	p=1.1×10-12					792:802	p=1.1×10-12	792:802	p=1.1×10-12	792:802	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	5	56	dep	predict	688:694	arg1	HR					782:783	hazard ratio (HR) 25.9	768:789	hazard ratio (HR) 25.9	768:789	Cox proportional hazard models were used to predict treatment escalation from first-line treatment to biologics or surgery (hazard ratio (HR) 25.9, p=1.1×10-12; 95% confidence interval (CI), 8.52-78.78).
36694402	1	57	theme	inflammatory	149:160	arg1	disease					168:174	inflammatory bowel disease	149:174	inflammatory bowel disease (IBD)	149:180	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	1	57	theme	inflammatory	149:160	arg1	IBD					177:179	IBD	177:179	IBD	177:179	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	7	58	theme	personalized	1074:1085	arg1	medicine					1087:1094	personalized medicine	1074:1094	personalized medicine in IBD	1074:1101	These data demonstrate the prognostic capacity of serum N-glycan biomarkers and represent a step towards personalized medicine in IBD.
36694402	6	59	theme	patients	907:914	arg1	cohort					890:895	an independent replication cohort	863:895	an independent replication cohort of 54 IBD patients	863:914	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36694402	1	60	theme	bowel	162:166	arg1	disease					168:174	inflammatory bowel disease	149:174	inflammatory bowel disease (IBD)	149:180	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	1	60	theme	bowel	162:166	arg1	IBD					177:179	IBD	177:179	IBD	177:179	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	0	61	theme	Bowel	73:77	arg1	Disease					79:85	Inflammatory Bowel Disease	60:85	Inflammatory Bowel Disease	60:85	Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease.
36694402	1	62	theme	disease	168:174	arg1	diagnosis					136:144	diagnosis	136:144	diagnosis of inflammatory bowel disease (IBD)	136:180	Biomarkers to guide clinical decision-making at diagnosis of inflammatory bowel disease (IBD) are urgently needed.
36694402	6	63	dep	yielded	916:922	arg1	p=1.1×10-5					937:946	p=1.1×10-5	937:946	p=1.1×10-5	937:946	Application to an independent replication cohort of 54 IBD patients yielded a HR of 5.1 (p=1.1×10-5; 95% CI, 2.54-10.1).
36739718	0	0	from	comparison	21:30	arg1	aspera					116:121	aspera	116:121	aspera	116:121	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	0	from	comparison	21:30	arg1	Cyathula					79:86	Cyathula	79:86	Cyathula	79:86	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	7	1	theme	blood	1386:1390	arg1	stasis					1392:1397	blood stasis	1386:1397	blood stasis	1386:1397	AB is partial to immunomodulation while CO is partial to removing blood stasis.
36739718	2	2	from	abundant	397:404	arg1	drugs					415:419	these drugs	409:419	these drugs	409:419	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	1	3	theme	Achyranthes	169:179	arg1	AB					192:193	AB	192:193	AB	192:193	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	3	theme	Achyranthes	169:179	arg1	bidentata					181:189	Achyranthes bidentata	169:189	Achyranthes bidentata (AB)	169:194	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	3	4	theme	AB	663:664	arg1	batches					652:658	22 batches	649:658	22 batches of AB, CO and AA	649:675	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	9	5	from	understanding	1616:1628	arg1	profiles					1637:1644	the profiles	1633:1644	the profiles of polysaccharides from AB, CO and AA	1633:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	4	6	theme	acid	922:925	arg1	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	6	theme	acid	922:925	arg1	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	1	7	theme	due	318:320	arg1	practice					309:316	clinical practice	300:316	clinical practice due to their similar chemical components and functions	300:371	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	4	8	theme	CO	801:802	arg1	Polysaccharides					778:792	Polysaccharides	778:792	Polysaccharides of AB, CO and AA	778:809	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	2	9	theme	them	607:610	arg1	control					596:602	the quality control	584:602	the quality control of them	584:610	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	1	10	theme	bidentata	181:189	arg1	drugs					265:269	different drugs	255:269	different drugs	255:269	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	10	theme	bidentata	181:189	arg1	roots					160:164	the roots	156:164	the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA)	156:249	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	5	11	theme	6-D-fructosidic	1182:1196	arg1	linkages					1198:1205	6-D-fructosidic linkages	1182:1205	6-D-fructosidic linkages	1182:1205	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	5	11	theme	6-D-fructosidic	1182:1196	arg1	fructans					1153:1160	fructans	1153:1160	fructans with β-2,1 and β-2	1153:1179	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	0	12	from	Characterization	0:15	arg1	aspera					116:121	aspera	116:121	aspera	116:121	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	12	from	Characterization	0:15	arg1	Cyathula					79:86	Cyathula	79:86	Cyathula	79:86	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	9	13	theme	polysaccharides	1649:1663	arg1	profiles					1637:1644	the profiles	1633:1644	the profiles of polysaccharides from AB, CO and AA	1633:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	4	14	theme	key	988:990	arg1	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	14	theme	key	988:990	arg1	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	15	theme	fructose	882:889	arg1	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	15	theme	fructose	882:889	arg1	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	2	16	from	comparison	435:444	arg1	AA					481:482	AA	481:482	AA	481:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	16	from	comparison	435:444	arg1	CO					474:475	CO	474:475	CO	474:475	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	16	from	comparison	435:444	arg1	AB					470:471	AB	470:471	AB	470:471	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	17	theme	identical	542:550	arg1	functions					552:560	their similar but not identical functions	520:560	their similar but not identical functions	520:560	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	4	18	contain	had	811:813	arg1	Polysaccharides					778:792	Polysaccharides	778:792	Polysaccharides of AB, CO and AA	778:809	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	18	contain	had	811:813	arg2	compositions					838:849	similar monosaccharide compositions	815:849	similar monosaccharide compositions	815:849	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	3	19	theme	saccharide	758:767	arg1	mapping					769:775	saccharide mapping	758:775	saccharide mapping	758:775	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	4	20	theme	acid	903:906	arg1	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	20	theme	acid	903:906	arg1	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	1	21	theme	similar	331:337	arg1	components					348:357	similar chemical components	331:357	similar chemical components	331:357	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	2	22	theme	quality	588:594	arg1	control					596:602	the quality control	584:602	the quality control of them	584:610	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	8	23	theme	drugs	1580:1584	arg1	differentia					1553:1563	the efficacy differentia	1540:1563	the efficacy differentia of these three drugs	1540:1584	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	4	24	theme	glucuronic	892:901	arg1	acid					903:906	glucuronic acid	892:906	glucuronic acid	892:906	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	1	25	theme	chemical	339:346	arg1	components					348:357	similar chemical components	331:357	similar chemical components	331:357	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	8	26	theme	substance	1447:1455	arg1	Fructans					1400:1407	Fructans	1400:1407	Fructans	1400:1407	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	26	theme	substance	1447:1455	arg1	pectins					1413:1419	pectins	1413:1419	pectins	1413:1419	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	26	theme	substance	1447:1455	arg1	basis					1457:1461	the similar bioactive substance basis	1425:1461	the similar bioactive substance basis of AB, CO and AA	1425:1478	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	3	27	from	batches	652:658	arg1	polysaccharides					628:642	polysaccharides	628:642	polysaccharides from 22 batches of AB, CO and AA	628:675	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	5	28	theme	weight	1044:1049	arg1	distribution					1051:1062	molecular weight distribution	1034:1062	molecular weight distribution	1034:1062	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	3	29	theme	AA	674:675	arg1	batches					652:658	22 batches	649:658	22 batches of AB, CO and AA	649:675	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	4	30	theme	similar	815:821	arg1	compositions					838:849	similar monosaccharide compositions	815:849	similar monosaccharide compositions	815:849	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	5	31	theme	saccharide	1068:1077	arg1	mapping					1079:1085	saccharide mapping	1068:1085	saccharide mapping	1068:1085	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	1	32	theme	different	255:263	arg1	drugs					265:269	different drugs	255:269	different drugs	255:269	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	32	theme	different	255:263	arg1	roots					160:164	the roots	156:164	the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA)	156:249	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	4	33	theme	AB	797:798	arg1	Polysaccharides					778:792	Polysaccharides	778:792	Polysaccharides of AB, CO and AA	778:809	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	5	34	from	AB	1115:1116	arg1	polysaccharides					1094:1108	polysaccharides	1094:1108	polysaccharides from AB	1094:1116	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	5	35	from	mapping	1079:1085	arg1	Results					1021:1027	Results	1021:1027	Results from molecular weight distribution and saccharide mapping	1021:1085	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	8	36	theme	AB	1466:1467	arg1	Fructans					1400:1407	Fructans	1400:1407	Fructans	1400:1407	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	36	theme	AB	1466:1467	arg1	pectins					1413:1419	pectins	1413:1419	pectins	1413:1419	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	36	theme	AB	1466:1467	arg1	basis					1457:1461	the similar bioactive substance basis	1425:1461	the similar bioactive substance basis of AB, CO and AA	1425:1478	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	4	37	theme	relative	861:868	arg1	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	37	theme	relative	861:868	arg1	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	0	38	dep	Cyathula	79:86	arg1	officinalis					88:98	officinalis	88:98	officinalis	88:98	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	5	39	theme	polymerization	1228:1241	arg1	degree					1218:1223	their degree	1212:1223	their degree of polymerization	1212:1241	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	1	40	theme	Cyathula	197:204	arg1	officinalis					206:216	Cyathula officinalis	197:216	Cyathula officinalis (CO)	197:221	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	40	theme	Cyathula	197:204	arg1	CO					219:220	CO	219:220	CO	219:220	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	3	41	theme	CO	667:668	arg1	batches					652:658	22 batches	649:658	22 batches of AB, CO and AA	649:675	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	9	42	theme	better	1609:1614	arg1	understanding					1616:1628	a better understanding	1607:1628	a better understanding on the profiles of polysaccharides from AB, CO and AA	1607:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	2	43	from	AB	470:471	arg1	comparison					435:444	a systematic comparison	422:444	a systematic comparison of polysaccharides from AB, CO and AA	422:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	43	from	AB	470:471	arg1	necessary					496:504	necessary	496:504	necessary	496:504	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	43	from	AB	470:471	arg1	polysaccharides					449:463	polysaccharides	449:463	polysaccharides from AB, CO and AA	449:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	0	44	dep	mapping	138:144	arg1	comparison					21:30	comparison	21:30	comparison	21:30	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	44	dep	mapping	138:144	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	1	45	theme	officinalis	206:216	arg1	drugs					265:269	different drugs	255:269	different drugs	255:269	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	45	theme	officinalis	206:216	arg1	roots					160:164	the roots	156:164	the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA)	156:249	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	2	46	theme	polysaccharides	449:463	arg1	comparison					435:444	a systematic comparison	422:444	a systematic comparison of polysaccharides from AB, CO and AA	422:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	46	theme	polysaccharides	449:463	arg1	necessary					496:504	necessary	496:504	necessary	496:504	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	8	47	theme	CO	1470:1471	arg1	Fructans					1400:1407	Fructans	1400:1407	Fructans	1400:1407	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	47	theme	CO	1470:1471	arg1	pectins					1413:1419	pectins	1413:1419	pectins	1413:1419	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	47	theme	CO	1470:1471	arg1	basis					1457:1461	the similar bioactive substance basis	1425:1461	the similar bioactive substance basis of AB, CO and AA	1425:1478	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	0	48	theme	polysaccharides	35:49	arg1	comparison					21:30	comparison	21:30	comparison	21:30	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	48	theme	polysaccharides	35:49	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	3	49	theme	monosaccharide	696:709	arg1	composition					711:721	monosaccharide composition	696:721	monosaccharide composition	696:721	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	4	50	theme	glucose	931:937	arg1	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	50	theme	glucose	931:937	arg1	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	0	51	from	Cyathula	79:86	arg1	comparison					21:30	comparison	21:30	comparison	21:30	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	51	from	Cyathula	79:86	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	51	from	Cyathula	79:86	arg1	polysaccharides					35:49	polysaccharides	35:49	polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera	35:121	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	9	52	theme	clinical	1707:1714	arg1	usage					1716:1720	their clinical usage	1701:1720	their clinical usage	1701:1720	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	5	53	from	distribution	1051:1062	arg1	Results					1021:1027	Results	1021:1027	Results from molecular weight distribution and saccharide mapping	1021:1085	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	8	54	theme	AA	1477:1478	arg1	Fructans					1400:1407	Fructans	1400:1407	Fructans	1400:1407	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	54	theme	AA	1477:1478	arg1	pectins					1413:1419	pectins	1413:1419	pectins	1413:1419	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	54	theme	AA	1477:1478	arg1	basis					1457:1461	the similar bioactive substance basis	1425:1461	the similar bioactive substance basis of AB, CO and AA	1425:1478	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	4	55	theme	monosaccharide	823:836	arg1	compositions					838:849	similar monosaccharide compositions	815:849	similar monosaccharide compositions	815:849	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	9	56	from	AA	1681:1682	arg1	profiles					1637:1644	the profiles	1633:1644	the profiles of polysaccharides from AB, CO and AA	1633:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	56	from	AA	1681:1682	arg1	polysaccharides					1649:1663	polysaccharides	1649:1663	polysaccharides from AB, CO and AA	1649:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	5	57	theme	molecular	1034:1042	arg1	distribution					1051:1062	molecular weight distribution	1034:1062	molecular weight distribution	1034:1062	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	2	58	theme	systematic	424:433	arg1	comparison					435:444	a systematic comparison	422:444	a systematic comparison of polysaccharides from AB, CO and AA	422:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	58	theme	systematic	424:433	arg1	necessary					496:504	necessary	496:504	necessary	496:504	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	8	59	theme	structural	1494:1503	arg1	difference					1505:1514	their structural difference	1488:1514	their structural difference	1488:1514	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	2	60	from	drugs	415:419	arg1	abundant					397:404	abundant	397:404	abundant	397:404	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	61	from	AA	481:482	arg1	comparison					435:444	a systematic comparison	422:444	a systematic comparison of polysaccharides from AB, CO and AA	422:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	61	from	AA	481:482	arg1	necessary					496:504	necessary	496:504	necessary	496:504	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	61	from	AA	481:482	arg1	polysaccharides					449:463	polysaccharides	449:463	polysaccharides from AB, CO and AA	449:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	62	from	CO	474:475	arg1	comparison					435:444	a systematic comparison	422:444	a systematic comparison of polysaccharides from AB, CO and AA	422:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	62	from	CO	474:475	arg1	necessary					496:504	necessary	496:504	necessary	496:504	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	2	62	from	CO	474:475	arg1	polysaccharides					449:463	polysaccharides	449:463	polysaccharides from AB, CO and AA	449:482	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	9	63	dep	provides	1598:1605	arg1	facilitating					1726:1737	facilitating	1726:1737	facilitating their quality control	1726:1759	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	63	dep	provides	1598:1605	arg1	guiding					1693:1699	guiding	1693:1699	guiding their clinical usage	1693:1720	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	2	64	theme	similar	526:532	arg1	functions					552:560	their similar but not identical functions	520:560	their similar but not identical functions	520:560	As polysaccharides are abundant in these drugs, a systematic comparison of polysaccharides from AB, CO and AA is not only necessary to understand their similar but not identical functions, but also helpful for the quality control of them.
36739718	9	65	from	CO	1674:1675	arg1	profiles					1637:1644	the profiles	1633:1644	the profiles of polysaccharides from AB, CO and AA	1633:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	65	from	CO	1674:1675	arg1	polysaccharides					1649:1663	polysaccharides	1649:1663	polysaccharides from AB, CO and AA	1649:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	66	theme	quality	1745:1751	arg1	control					1753:1759	their quality control	1739:1759	their quality control	1739:1759	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	8	67	theme	efficacy	1544:1551	arg1	differentia					1553:1563	the efficacy differentia	1540:1563	the efficacy differentia of these three drugs	1540:1584	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	4	68	used	used	980:983	arg2	contents					870:877	their relative contents	855:877	their relative contents of fructose, glucuronic acid, galacturonic acid and glucose	855:937	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	68	used	used	980:983	arg2	markers					992:998	key markers	988:998	key markers	988:998	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	3	69	theme	weight	734:739	arg1	distribution					741:752	molecular weight distribution	724:752	molecular weight distribution	724:752	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	8	70	theme	bioactive	1437:1445	arg1	Fructans					1400:1407	Fructans	1400:1407	Fructans	1400:1407	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	70	theme	bioactive	1437:1445	arg1	pectins					1413:1419	pectins	1413:1419	pectins	1413:1419	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	70	theme	bioactive	1437:1445	arg1	basis					1457:1461	the similar bioactive substance basis	1425:1461	the similar bioactive substance basis of AB, CO and AA	1425:1478	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	0	71	from	aspera	116:121	arg1	comparison					21:30	comparison	21:30	comparison	21:30	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	71	from	aspera	116:121	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	0	71	from	aspera	116:121	arg1	polysaccharides					35:49	polysaccharides	35:49	polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera	35:121	Characterization and comparison of polysaccharides from Achyranthes bidentata, Cyathula officinalis and Achyranthes aspera by saccharides mapping.
36739718	4	72	theme	AA	808:809	arg1	Polysaccharides					778:792	Polysaccharides	778:792	Polysaccharides of AB, CO and AA	778:809	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	4	73	theme	galacturonic	909:920	arg1	acid					922:925	galacturonic acid	909:925	galacturonic acid	909:925	Polysaccharides of AB, CO and AA had similar monosaccharide compositions but their relative contents of fructose, glucuronic acid, galacturonic acid and glucose were significant different, and could be used as key markers to distinguish them.
36739718	9	74	from	AB	1670:1671	arg1	profiles					1637:1644	the profiles	1633:1644	the profiles of polysaccharides from AB, CO and AA	1633:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	74	from	AB	1670:1671	arg1	polysaccharides					1649:1663	polysaccharides	1649:1663	polysaccharides from AB, CO and AA	1649:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	75	from	profiles	1637:1644	arg1	AA					1681:1682	AA	1681:1682	AA	1681:1682	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	75	from	profiles	1637:1644	arg1	CO					1674:1675	CO	1674:1675	CO	1674:1675	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	9	75	from	profiles	1637:1644	arg1	AB					1670:1671	AB	1670:1671	AB	1670:1671	This study provides a better understanding on the profiles of polysaccharides from AB, CO and AA, further guiding their clinical usage and facilitating their quality control.
36739718	1	76	theme	Achyranthes	227:237	arg1	AA					247:248	AA	247:248	AA	247:248	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	76	theme	Achyranthes	227:237	arg1	aspera					239:244	Achyranthes aspera	227:244	Achyranthes aspera (AA)	227:249	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	77	theme	clinical	300:307	arg1	practice					309:316	clinical practice	300:316	clinical practice due to their similar chemical components and functions	300:371	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	3	78	theme	molecular	724:732	arg1	distribution					741:752	molecular weight distribution	724:752	molecular weight distribution	724:752	In this study, polysaccharides from 22 batches of AB, CO and AA were compared with monosaccharide composition, molecular weight distribution and saccharide mapping.
36739718	5	79	with	fructans	1153:1160	arg1	β-2					1177:1179	β-2	1177:1179	β-2	1177:1179	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	5	79	with	fructans	1153:1160	arg1	β-2,1					1167:1171	β-2,1	1167:1171	β-2,1	1167:1171	Results from molecular weight distribution and saccharide mapping showed polysaccharides from AB, CO and AA were mainly composed of fructans with β-2,1 and β-2, 6-D-fructosidic linkages, but their degree of polymerization were different.
36739718	8	80	theme	similar	1429:1435	arg1	Fructans					1400:1407	Fructans	1400:1407	Fructans	1400:1407	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	80	theme	similar	1429:1435	arg1	pectins					1413:1419	pectins	1413:1419	pectins	1413:1419	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	8	80	theme	similar	1429:1435	arg1	basis					1457:1461	the similar bioactive substance basis	1425:1461	the similar bioactive substance basis of AB, CO and AA	1425:1478	Fructans and pectins are the similar bioactive substance basis of AB, CO and AA whereas their structural difference might be contributed to the efficacy differentia of these three drugs.
36739718	1	81	theme	aspera	239:244	arg1	drugs					265:269	different drugs	255:269	different drugs	255:269	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
36739718	1	81	theme	aspera	239:244	arg1	roots					160:164	the roots	156:164	the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA)	156:249	Although the roots of Achyranthes bidentata (AB), Cyathula officinalis (CO) and Achyranthes aspera (AA) are different drugs, they are always confused in clinical practice due to their similar chemical components and functions.
37267309	2	0	theme	BcsA	353:356	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	7	1	theme	ovoid-like	1125:1134	arg1	structure					1136:1144	a two-domain transmembrane ovoid-like structure	1098:1144	a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1098:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	11	2	theme	responses	2017:2025	arg1	range					1999:2003	similar range	1991:2003	similar range of adaptive responses	1991:2025	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	11	3	theme	adaptive	2008:2015	arg1	responses					2017:2025	adaptive responses	2008:2025	adaptive responses	2008:2025	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	7	4	with	protein	1161:1167	arg1	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	7	5	theme	two-domain	1100:1109	arg1	structure					1136:1144	a two-domain transmembrane ovoid-like structure	1098:1144	a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1098:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	5	6	theme	opportunistic	782:794	arg1	strains					807:813	phytopathogenic and human opportunistic pathogenic strains	756:813	phytopathogenic and human opportunistic pathogenic strains	756:813	We identified 112 Orphans among soil and plant-associated pseudomonads as well as in phytopathogenic and human opportunistic pathogenic strains.
37267309	6	7	theme	proteins	864:871	arg1	distribution					825:836	The wide distribution	816:836	The wide distribution of these highly conserved proteins	816:871	The wide distribution of these highly conserved proteins suggest they form a novel family of synthases producing a different polysaccharide.
37267309	2	8	theme	bacterial	305:313	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	1	9	theme	cell	207:210	arg1	coating					220:226	cell surface coating	207:226	cell surface coating	207:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	2	10	theme	Orphan	297:302	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	11	11	theme	induced	1889:1895	arg1	suppression					1906:1916	induced systemic suppression	1889:1916	induced systemic suppression	1889:1916	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	1	12	from	biofilms	264:271	arg1	coating					220:226	cell surface coating	207:226	cell surface coating	207:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	5	13	theme	pathogenic	796:805	arg1	strains					807:813	phytopathogenic and human opportunistic pathogenic strains	756:813	phytopathogenic and human opportunistic pathogenic strains	756:813	We identified 112 Orphans among soil and plant-associated pseudomonads as well as in phytopathogenic and human opportunistic pathogenic strains.
37267309	7	14	theme	secondary	1009:1017	arg1	structure					1019:1027	secondary structure	1009:1027	secondary structure	1009:1027	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	1	15	theme	surface	229:235	arg1	interactions					246:257	surface and host interactions	229:257	interactions	246:257	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	8	16	theme	cyclic-β-	1452:1460	arg1	-glucan					1466:1472	cyclic-β-(1,3)-glucan (CβG)	1452:1478	cyclic-β-(1,3)-glucan (CβG)	1452:1478	We suggest the GT2 domain synthesises β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG).
37267309	11	17	theme	cyclic	1817:1822	arg1	glucans					1824:1830	cyclic glucans	1817:1830	cyclic glucans	1817:1830	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	6	18	theme	synthases	909:917	arg1	family					899:904	a novel family	891:904	a novel family of synthases producing a different polysaccharide	891:954	The wide distribution of these highly conserved proteins suggest they form a novel family of synthases producing a different polysaccharide.
37267309	8	19	theme	GT2	1331:1333	arg1	domain					1335:1340	the GT2 domain	1327:1340	the GT2 domain	1327:1340	We suggest the GT2 domain synthesises β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG).
37267309	11	20	theme	similar	1991:1997	arg1	range					1999:2003	similar range	1991:2003	similar range of adaptive responses	1991:2025	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	0	21	theme	novel	81:85	arg1	family					87:92	a novel family	79:92	a novel family of pseudomonad cyclic-β-glucan synthases	79:133	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	7	22	theme	In	957:958	arg1	analysis					967:974	In silico analysis	957:974	In silico analysis	957:974	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	10	23	dep	PaPAK	1674:1678	arg1	known					1704:1708	known	1704:1708	known as NdvB	1704:1716	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	9	24	theme	enzymatic	1523:1531	arg1	characterisation					1533:1548	enzymatic characterisation	1523:1548	enzymatic characterisation	1523:1548	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	10	25	theme	PaPAK	1674:1678	arg1	mutants					1730:1736	PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants	1674:1736	PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants	1674:1736	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	2	26	theme	model	386:390	arg1	PA01					420:423	P. aeruginosa PA01	406:423	P. aeruginosa PA01	406:423	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	26	theme	model	386:390	arg1	SBW25					441:445	P. fluorescens SBW25	426:445	P. fluorescens SBW25	426:445	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	26	theme	model	386:390	arg1	pv					481:482	P. syringae pv	469:482	P. syringae pv	469:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	26	theme	model	386:390	arg1	pseudomonads					392:403	four model pseudomonads	381:403	four model pseudomonads	381:403	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	26	theme	model	386:390	arg1	putida					451:456	putida	451:456	putida	451:456	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	7	27	theme	GH17	1214:1217	arg1	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	4	28	dep	structural	641:650	arg1	folds					652:656	folds	652:656	folds	652:656	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	2	29	theme	fluorescens	429:439	arg1	pseudomonads					392:403	four model pseudomonads	381:403	four model pseudomonads	381:403	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	29	theme	fluorescens	429:439	arg1	SBW25					441:445	P. fluorescens SBW25	426:445	P. fluorescens SBW25	426:445	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	5	30	theme	plant-associated	712:727	arg1	pseudomonads					729:740	soil and plant-associated pseudomonads	703:740	pseudomonads	729:740	We identified 112 Orphans among soil and plant-associated pseudomonads as well as in phytopathogenic and human opportunistic pathogenic strains.
37267309	7	31	dep	structure	1019:1027	arg1	predictions					1042:1052	predictions	1042:1052	predictions	1042:1052	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	11	32	theme	systemic	1897:1904	arg1	suppression					1906:1916	induced systemic suppression	1889:1916	induced systemic suppression	1889:1916	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	0	33	theme	Bioinformatics	0:13	arg1	characterization					15:30	Bioinformatics characterization	0:30	Bioinformatics characterization of BcsA-like orphan proteins	0:59	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	9	34	theme	molecular	1561:1569	arg1	simulations					1571:1581	recent molecular simulations	1554:1581	recent molecular simulations	1554:1581	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	2	35	theme	-like	358:362	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	7	36	theme	periplasmic	1176:1186	arg1	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	6	37	theme	conserved	854:862	arg1	proteins					864:871	these highly conserved proteins	841:871	these highly conserved proteins	841:871	The wide distribution of these highly conserved proteins suggest they form a novel family of synthases producing a different polysaccharide.
37267309	4	38	theme	Orphan	539:544	arg1	proteins					555:562	the Orphan and BcsA proteins	535:562	the Orphan and BcsA proteins	535:562	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	7	39	theme	hydrolase	1197:1205	arg1	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	0	40	theme	orphan	45:50	arg1	proteins					52:59	BcsA-like orphan proteins	35:59	BcsA-like orphan proteins	35:59	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	9	41	theme	PaPA01	1590:1595	arg1	characterisation					1533:1548	enzymatic characterisation	1523:1548	enzymatic characterisation	1523:1548	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	9	41	theme	PaPA01	1590:1595	arg1	simulations					1571:1581	recent molecular simulations	1554:1581	recent molecular simulations	1554:1581	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	7	42	theme	Orphan	1154:1159	arg1	protein					1161:1167	the Orphan protein	1150:1167	the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1150:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	4	43	dep	identity	594:601	arg1	%					583:583	%	583:583	%	583:583	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	2	44	theme	catalytic	334:342	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	45	dep	P.	469:470	arg1	syringae					472:479	syringae	472:479	syringae	472:479	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	9	46	theme	domains	1615:1621	arg1	characterisation					1533:1548	enzymatic characterisation	1523:1548	enzymatic characterisation	1523:1548	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	9	46	theme	domains	1615:1621	arg1	simulations					1571:1581	recent molecular simulations	1554:1581	recent molecular simulations	1554:1581	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	7	47	theme	GT2	1304:1306	arg1	domain					1308:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	4	48	contain	have	627:630	arg1	they					614:617	they	614:617	they	614:617	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	4	48	contain	have	627:630	arg2	structural					641:650	structural	641:650	structural	641:650	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	4	48	contain	have	627:630	arg2	function					661:668	function	661:668	function	661:668	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	10	49	theme	transposon	1719:1728	arg1	mutants					1730:1736	PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants	1674:1736	PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants	1674:1736	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	7	50	theme	family	1207:1212	arg1	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	7	51	theme	glycosyltransferase	1277:1295	arg1	domain					1308:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	11	52	theme	plant	1869:1873	arg1	infection					1875:1883	plant infection	1869:1883	plant infection	1869:1883	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	6	53	theme	novel	893:897	arg1	family					899:904	a novel family	891:904	a novel family of synthases producing a different polysaccharide	891:954	The wide distribution of these highly conserved proteins suggest they form a novel family of synthases producing a different polysaccharide.
37267309	4	54	theme	BcsA	550:553	arg1	proteins					555:562	the Orphan and BcsA proteins	535:562	the Orphan and BcsA proteins	535:562	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	7	55	theme	transmembrane	1111:1123	arg1	structure					1136:1144	a two-domain transmembrane ovoid-like structure	1098:1144	a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1098:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	10	56	theme	CβG	1743:1745	arg1	production					1747:1756	CβG production	1743:1756	CβG production	1743:1756	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	10	57	theme	antibiotic	1781:1790	arg1	resistance					1792:1801	biofilm-associated antibiotic resistance	1762:1801	biofilm-associated antibiotic resistance	1762:1801	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	1	58	theme	functional	187:196	arg1	roles					198:202	functional roles	187:202	functional roles in cell surface coating	187:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	2	59	theme	cellulose	315:323	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	7	60	theme	structural	1067:1076	arg1	modelling					1078:1086	protein structural modelling	1059:1086	protein structural modelling	1059:1086	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	9	61	theme	PpKT2440	1601:1608	arg1	domains					1615:1621	the PaPA01 and PpKT2440 GH17 domains	1586:1621	domains	1615:1621	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	1	62	theme	surface	212:218	arg1	coating					220:226	cell surface coating	207:226	cell surface coating	207:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	10	63	theme	biofilm-associated	1762:1779	arg1	resistance					1792:1801	biofilm-associated antibiotic resistance	1762:1801	biofilm-associated antibiotic resistance	1762:1801	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	6	64	theme	different	931:939	arg1	polysaccharide					941:954	a different polysaccharide	929:954	a different polysaccharide	929:954	The wide distribution of these highly conserved proteins suggest they form a novel family of synthases producing a different polysaccharide.
37267309	7	65	attach	linked	1226:1231	arg3	region					1253:1258	a transmembrane region	1237:1258	a transmembrane region	1237:1258	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	7	65	attach	linked	1226:1231	arg1	domain					1308:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	7	65	attach	linked	1226:1231	arg2	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	1	66	from	interactions	246:257	arg1	coating					220:226	cell surface coating	207:226	cell surface coating	207:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	11	67	theme	novel	1949:1953	arg1	family					1955:1960	this novel family	1944:1960	this novel family of CβG synthases	1944:1977	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	4	68	dep	%	583:583	arg1	41					581:582	41	581:582	41	581:582	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	2	69	located	found	372:376	arg1	PA01					420:423	P. aeruginosa PA01	406:423	P. aeruginosa PA01	406:423	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	69	located	found	372:376	arg1	pseudomonads					392:403	four model pseudomonads	381:403	four model pseudomonads	381:403	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	69	located	found	372:376	arg1	SBW25					441:445	P. fluorescens SBW25	426:445	P. fluorescens SBW25	426:445	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	69	located	found	372:376	arg2	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	69	located	found	372:376	arg1	pv					481:482	P. syringae pv	469:482	P. syringae pv	469:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	69	located	found	372:376	arg1	putida					451:456	putida	451:456	putida	451:456	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	7	70	dep	In	957:958	arg1	silico					960:965	silico	960:965	silico	960:965	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	10	71	theme	Orphan	1691:1696	arg1	mutants					1730:1736	PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants	1674:1736	PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants	1674:1736	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	7	72	theme	transmembrane	1239:1251	arg1	region					1253:1258	a transmembrane region	1237:1258	a transmembrane region	1237:1258	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	11	73	theme	synthases	1969:1977	arg1	family					1955:1960	this novel family	1944:1960	this novel family of CβG synthases	1944:1977	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	7	74	theme	sequence	987:994	arg1	comparisons					996:1006	sequence comparisons	987:1006	sequence comparisons	987:1006	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	9	75	theme	structural	1485:1494	arg1	models					1496:1501	Our structural models	1481:1501	Our structural models	1481:1501	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	2	76	theme	P.	469:470	arg1	pseudomonads					392:403	four model pseudomonads	381:403	four model pseudomonads	381:403	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	76	theme	P.	469:470	arg1	pv					481:482	P. syringae pv	469:482	P. syringae pv	469:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	1	77	with	polysaccharides	166:180	arg1	interactions					246:257	surface and host interactions	229:257	interactions	246:257	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	1	77	with	polysaccharides	166:180	arg1	biofilms					264:271	biofilms	264:271	biofilms	264:271	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	1	77	with	polysaccharides	166:180	arg1	roles					198:202	functional roles	187:202	functional roles in cell surface coating	187:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	1	78	from	roles	198:202	arg1	coating					220:226	cell surface coating	207:226	cell surface coating	207:226	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	1	79	theme	polysaccharides	166:180	arg1	polysaccharides					166:180	polysaccharides	166:180	polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms	166:271	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	1	79	theme	polysaccharides	166:180	arg1	variety					155:161	a variety	153:161	a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms	153:271	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	9	80	with	consistent	1507:1516	arg1	characterisation					1533:1548	enzymatic characterisation	1523:1548	enzymatic characterisation	1523:1548	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	9	80	with	consistent	1507:1516	arg1	simulations					1571:1581	recent molecular simulations	1554:1581	recent molecular simulations	1554:1581	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	8	81	theme	β-	1354:1355	arg1	-glucan					1361:1367	β-(1,3)-glucan	1354:1367	β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG)	1354:1478	We suggest the GT2 domain synthesises β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG).
37267309	0	82	theme	pseudomonad	97:107	arg1	synthases					125:133	pseudomonad cyclic-β-glucan synthases	97:133	pseudomonad cyclic-β-glucan synthases	97:133	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	10	83	dep	known	1704:1708	arg1	also					1699:1702	also	1699:1702	also	1699:1702	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	8	84	theme	1,3	1357:1359	arg1	-glucan					1361:1367	β-(1,3)-glucan	1354:1367	β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG)	1354:1478	We suggest the GT2 domain synthesises β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG).
37267309	10	85	theme	PaPA14	1684:1689	arg1	Orphan					1691:1696	PaPA14 Orphan	1684:1696	PaPA14 Orphan	1684:1696	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	0	86	theme	synthases	125:133	arg1	family					87:92	a novel family	79:92	a novel family of pseudomonad cyclic-β-glucan synthases	79:133	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	5	87	theme	soil	703:706	arg1	pseudomonads					729:740	soil and plant-associated pseudomonads	703:740	pseudomonads	729:740	We identified 112 Orphans among soil and plant-associated pseudomonads as well as in phytopathogenic and human opportunistic pathogenic strains.
37267309	5	88	theme	human	776:780	arg1	strains					807:813	phytopathogenic and human opportunistic pathogenic strains	756:813	phytopathogenic and human opportunistic pathogenic strains	756:813	We identified 112 Orphans among soil and plant-associated pseudomonads as well as in phytopathogenic and human opportunistic pathogenic strains.
37267309	9	89	theme	recent	1554:1559	arg1	simulations					1571:1581	recent molecular simulations	1554:1581	recent molecular simulations	1554:1581	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	2	90	theme	P.	426:427	arg1	pseudomonads					392:403	four model pseudomonads	381:403	four model pseudomonads	381:403	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	90	theme	P.	426:427	arg1	SBW25					441:445	P. fluorescens SBW25	426:445	P. fluorescens SBW25	426:445	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	0	91	theme	BcsA-like	35:43	arg1	proteins					52:59	BcsA-like orphan proteins	35:59	BcsA-like orphan proteins	35:59	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	8	92	dep	-glucan	1466:1472	arg1	1,3					1462:1464	1,3	1462:1464	1,3	1462:1464	We suggest the GT2 domain synthesises β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG).
37267309	2	93	theme	P.	406:407	arg1	PA01					420:423	P. aeruginosa PA01	406:423	P. aeruginosa PA01	406:423	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	93	theme	P.	406:407	arg1	pseudomonads					392:403	four model pseudomonads	381:403	four model pseudomonads	381:403	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	0	94	theme	proteins	52:59	arg1	characterization					15:30	Bioinformatics characterization	0:30	Bioinformatics characterization of BcsA-like orphan proteins	0:59	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	10	95	theme	functional	1643:1652	arg1	explanation					1654:1664	a functional explanation	1641:1664	a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance	1641:1801	It also provides a functional explanation linking PaPAK and PaPA14 Orphan (also known as NdvB) transposon mutants with CβG production and biofilm-associated antibiotic resistance.
37267309	4	96	theme	Pairwise	500:507	arg1	alignments					509:518	Pairwise alignments	500:518	Pairwise alignments	500:518	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	8	97	theme	GH17	1396:1399	arg1	domain					1401:1406	the GH17 domain	1392:1406	the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG)	1392:1478	We suggest the GT2 domain synthesises β-(1,3)-glucan that is transferred to the GH17 domain where it is cleaved and cyclised to produce cyclic-β-(1,3)-glucan (CβG).
37267309	0	98	theme	cyclic-β-glucan	109:123	arg1	synthases					125:133	pseudomonad cyclic-β-glucan synthases	97:133	pseudomonad cyclic-β-glucan synthases	97:133	Bioinformatics characterization of BcsA-like orphan proteins suggest they form a novel family of pseudomonad cyclic-β-glucan synthases.
37267309	5	99	theme	phytopathogenic	756:770	arg1	strains					807:813	phytopathogenic and human opportunistic pathogenic strains	756:813	phytopathogenic and human opportunistic pathogenic strains	756:813	We identified 112 Orphans among soil and plant-associated pseudomonads as well as in phytopathogenic and human opportunistic pathogenic strains.
37267309	7	100	theme	protein	1059:1065	arg1	modelling					1078:1086	protein structural modelling	1059:1086	protein structural modelling	1059:1086	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	2	101	dep	P.	406:407	arg1	aeruginosa					409:418	aeruginosa	409:418	aeruginosa	409:418	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	2	102	theme	subunit	344:350	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	6	103	theme	wide	820:823	arg1	distribution					825:836	The wide distribution	816:836	The wide distribution of these highly conserved proteins	816:871	The wide distribution of these highly conserved proteins suggest they form a novel family of synthases producing a different polysaccharide.
37267309	9	104	theme	GH17	1610:1613	arg1	domains					1615:1621	the PaPA01 and PpKT2440 GH17 domains	1586:1621	domains	1615:1621	Our structural models are consistent with enzymatic characterisation and recent molecular simulations of the PaPA01 and PpKT2440 GH17 domains.
37267309	11	105	theme	CβG	1965:1967	arg1	synthases					1969:1977	CβG synthases	1965:1977	CβG synthases	1965:1977	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	7	106	theme	family	1297:1302	arg1	domain					1308:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	2	107	theme	synthase	325:332	arg1	protein					364:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein	293:370	an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv	293:482	We have identified an 'Orphan' bacterial cellulose synthase catalytic subunit (BcsA)-like protein found in four model pseudomonads, P. aeruginosa PA01, P. fluorescens SBW25, P. putida KT2440 and P. syringae pv.
37267309	1	108	theme	host	241:244	arg1	interactions					246:257	surface and host interactions	229:257	interactions	246:257	Bacteria produce a variety of polysaccharides with functional roles in cell surface coating, surface and host interactions, and biofilms.
37267309	11	109	dep	suggest	1936:1942	arg1	provide					1983:1989	provide	1983:1989	suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads	1936:2042	Importantly, cyclic glucans are also involved in osmoregulation, plant infection and induced systemic suppression, and our findings suggest this novel family of CβG synthases may provide similar range of adaptive responses for pseudomonads.
37267309	7	110	theme	cytoplasmic	1265:1275	arg1	domain					1308:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	a cytoplasmic glycosyltransferase family GT2 domain	1263:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
37267309	4	111	theme	sequence	585:592	arg1	identity					594:601	less than 41% sequence identity	571:601	less than 41% sequence identity	571:601	Pairwise alignments indicated that the Orphan and BcsA proteins shared less than 41% sequence identity suggesting they may not have the same structural folds or function.
37267309	7	112	theme	glycosyl	1188:1195	arg1	domain					1219:1224	a periplasmic glycosyl hydrolase family GH17 domain	1174:1224	a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain	1174:1313	In silico analysis, including sequence comparisons, secondary structure and topology predictions, and protein structural modelling, revealed a two-domain transmembrane ovoid-like structure for the Orphan protein with a periplasmic glycosyl hydrolase family GH17 domain linked via a transmembrane region to a cytoplasmic glycosyltransferase family GT2 domain.
35921896	5	0	theme	cellular	702:709	arg1	responses					718:726	cellular immune responses	702:726	cellular immune responses	702:726	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	3	1	theme	genetic	537:543	arg1	polymorphism					545:556	a genetic polymorphism	535:556	a genetic polymorphism	535:556	Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism.
35921896	6	2	theme	-glycans	955:962	arg1	composition					909:919	composition	909:919	composition of the CD16a asparagine-linked (N)-glycans	909:962	Another relevant variable shown to affect affinity is composition of the CD16a asparagine-linked (N)-glycans.
35921896	6	3	theme	relevant	863:870	arg1	variable					872:879	Another relevant variable	855:879	Another relevant variable shown to affect affinity	855:904	Another relevant variable shown to affect affinity is composition of the CD16a asparagine-linked (N)-glycans.
35921896	2	4	theme	γ	279:279	arg1	receptor					281:288	Fc γ receptor	276:288	Fc γ receptor IIIa/CD16a	276:299	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	6	5	theme	N	953:953	arg1	-glycans					955:962	the CD16a asparagine-linked (N)-glycans	924:962	the CD16a asparagine-linked (N)-glycans	924:962	Another relevant variable shown to affect affinity is composition of the CD16a asparagine-linked (N)-glycans.
35921896	6	6	theme	asparagine-linked	934:950	arg1	-glycans					955:962	the CD16a asparagine-linked (N)-glycans	924:962	the CD16a asparagine-linked (N)-glycans	924:962	Another relevant variable shown to affect affinity is composition of the CD16a asparagine-linked (N)-glycans.
35921896	9	7	theme	N162	1269:1272	arg1	glycan					1274:1279	the N162 glycan	1265:1279	the N162 glycan	1265:1279	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	2	8	theme	natural	310:316	arg1	cells					325:329	natural killer cells	310:329	natural killer cells	310:329	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	0	9	theme	destabilized	111:122	arg1	interface					141:149	a destabilized antibody-binding interface	109:149	a destabilized antibody-binding interface	109:149	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	5	10	theme	CD16a	775:779	arg1	engagement					781:790	CD16a engagement	775:790	CD16a engagement	775:790	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	9	11	theme	binding	1291:1297	arg1	event					1299:1303	the binding event	1287:1303	the binding event	1287:1303	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	1	12	theme	cellular	211:218	arg1	responses					227:235	healing cellular immune responses	203:235	healing cellular immune responses	203:235	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	12	13	theme	glycan	1620:1625	arg1	resonances					1627:1636	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	resonances	1627:1636	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	5	14	theme	clinical	732:739	arg1	efficacy					741:748	clinical efficacy	732:748	clinical efficacy of antibodies relying on CD16a engagement	732:790	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	14	15	with	F158	1812:1815	arg1	heterogeneity					1857:1869	increased interface conformational heterogeneity	1822:1869	increased interface conformational heterogeneity	1822:1869	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	12	16	theme	backbone	1596:1603	arg1	amide					1605:1609	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	amide	1605:1609	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	11	17	theme	dissociation	1515:1526	arg1	rate					1528:1531	the dissociation rate	1511:1531	the dissociation rate	1511:1531	Surprisingly, we found N-glycan composition had a smaller effect on the dissociation rate.
35921896	7	18	theme	F158	1030:1033	arg1	affinity					1035:1042	CD16a F158 affinity	1024:1042	CD16a F158 affinity	1024:1042	It is currently not known how N-glycan composition affects CD16a F158 affinity.
35921896	8	19	theme	N-glycan	1137:1144	arg1	composition					1146:1156	N-glycan composition	1137:1156	N-glycan composition	1137:1156	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	1	20	theme	γ	173:173	arg1	FcγRs					186:190	FcγRs	186:190	FcγRs	186:190	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	1	20	theme	γ	173:173	arg1	receptors					175:183	Fc γ receptors	170:183	Fc γ receptors (FcγRs)	170:191	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	9	21	theme	binding	1238:1244	arg1	kinetics					1246:1253	binding kinetics	1238:1253	binding kinetics	1238:1253	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	9	22	theme	N162	1351:1354	arg1	glycan					1356:1361	the N162 glycan	1347:1361	the N162 glycan increased the speed of binding	1347:1392	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	7	23	theme	N-glycan	995:1002	arg1	composition					1004:1014	N-glycan composition	995:1014	N-glycan composition	995:1014	It is currently not known how N-glycan composition affects CD16a F158 affinity.
35921896	12	24	theme	CD16a	1585:1589	arg1	amide					1605:1609	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	amide	1605:1609	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	3	25	theme	resulting	498:506	arg1	response					515:522	the resulting immune response	494:522	the resulting immune response	494:522	Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism.
35921896	3	26	theme	CD16a	458:462	arg1	strength					481:488	CD16a antibody-binding strength	458:488	CD16a antibody-binding strength	458:488	Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism.
35921896	8	27	dep	V158	1190:1193	arg1	affinity					1212:1219	binding affinity	1204:1219	binding affinity	1204:1219	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	11	28	theme	N-glycan	1466:1473	arg1	composition					1475:1485	N-glycan composition	1466:1485	N-glycan composition	1466:1485	Surprisingly, we found N-glycan composition had a smaller effect on the dissociation rate.
35921896	14	29	theme	binding-competent	1899:1915	arg1	forms					1917:1921	binding-competent forms	1899:1921	binding-competent forms available and decreasing affinity	1899:1955	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	10	30	theme	binding	1419:1425	arg1	rate					1427:1430	a slower binding rate	1410:1430	a slower binding rate than V158	1410:1440	F158 displayed a slower binding rate than V158.
35921896	0	31	theme	Fc	19:20	arg1	allotype					43:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	9	32	theme	binding	1386:1392	arg1	speed					1377:1381	the speed	1373:1381	the speed of binding	1373:1392	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	6	33	theme	CD16a	928:932	arg1	-glycans					955:962	the CD16a asparagine-linked (N)-glycans	924:962	the CD16a asparagine-linked (N)-glycans	924:962	Another relevant variable shown to affect affinity is composition of the CD16a asparagine-linked (N)-glycans.
35921896	11	34	theme	smaller	1493:1499	arg1	effect					1501:1506	a smaller effect	1491:1506	a smaller effect	1491:1506	Surprisingly, we found N-glycan composition had a smaller effect on the dissociation rate.
35921896	0	35	theme	receptor	24:31	arg1	allotype					43:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	5	36	theme	CD16a	838:842	arg1	structure					844:852	CD16a structure	838:852	CD16a structure	838:852	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	12	37	theme	conformational	1553:1566	arg1	heterogeneity					1568:1580	conformational heterogeneity	1553:1580	conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy	1553:1659	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	13	38	theme	chemical	1682:1689	arg1	perturbations					1697:1709	chemical shift perturbations	1682:1709	chemical shift perturbations between V158 and F158	1682:1731	Residues exhibiting chemical shift perturbations between V158 and F158 mapped to the antibody-binding interface.
35921896	2	39	theme	target	342:347	arg1	tissues					349:355	target tissues	342:355	target tissues with cytotoxic proteins	342:379	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	0	40	theme	F158	38:41	arg1	allotype					43:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	4	41	theme	CD16a	575:579	arg1	allotype					586:593	The predominant CD16a F158 allotype	559:593	The predominant CD16a F158 allotype	559:593	The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype.
35921896	3	42	theme	immune	508:513	arg1	response					515:522	the resulting immune response	494:522	the resulting immune response	494:522	Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism.
35921896	14	43	theme	interface	1832:1840	arg1	heterogeneity					1857:1869	increased interface conformational heterogeneity	1822:1869	increased interface conformational heterogeneity	1822:1869	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	13	44	theme	antibody-binding	1747:1762	arg1	interface					1764:1772	the antibody-binding interface	1743:1772	the antibody-binding interface	1743:1772	Residues exhibiting chemical shift perturbations between V158 and F158 mapped to the antibody-binding interface.
35921896	4	45	theme	V158	652:655	arg1	allotype					657:664	the less common V158 allotype	636:664	the less common V158 allotype	636:664	The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype.
35921896	14	46	theme	CD16a	1806:1810	arg1	F158					1812:1815	CD16a F158	1806:1815	CD16a F158 with increased interface conformational heterogeneity	1806:1869	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	4	47	theme	less	617:620	arg1	affinity					622:629	less affinity	617:629	less affinity than the less common V158 allotype	617:664	The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype.
35921896	5	48	theme	immune	711:716	arg1	responses					718:726	cellular immune responses	702:726	cellular immune responses	702:726	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	2	49	theme	receptor	281:288	arg1	IIIa/CD16a					290:299	Fc γ receptor IIIa/CD16a	276:299	Fc γ receptor IIIa/CD16a	276:299	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	1	50	theme	target	260:265	arg1	antigen					267:273	a target antigen	258:273	a target antigen	258:273	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	8	51	theme	binding	1204:1210	arg1	affinity					1212:1219	binding affinity	1204:1219	binding affinity	1204:1219	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	14	52	theme	available	1923:1931	arg1	forms					1917:1921	binding-competent forms	1899:1921	binding-competent forms available and decreasing affinity	1899:1955	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	9	53	theme	kinetics	1246:1253	arg1	analysis					1226:1233	Our analysis	1222:1233	Our analysis of binding kinetics	1222:1253	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	2	54	theme	Fc	276:277	arg1	receptor					281:288	Fc γ receptor	276:288	Fc γ receptor IIIa/CD16a	276:299	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	2	55	theme	killer	318:323	arg1	cells					325:329	natural killer cells	310:329	natural killer cells	310:329	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	8	56	theme	N-glycan	1065:1072	arg1	composition					1074:1084	N-glycan composition	1065:1084	N-glycan composition	1065:1084	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	0	57	theme	antibody-binding	124:139	arg1	interface					141:149	a destabilized antibody-binding interface	109:149	a destabilized antibody-binding interface	109:149	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	14	58	theme	forms	1917:1921	arg1	population					1885:1894	the population	1881:1894	the population of binding-competent forms available and decreasing affinity	1881:1955	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	1	59	theme	healing	203:209	arg1	responses					227:235	healing cellular immune responses	203:235	healing cellular immune responses	203:235	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	12	60	theme	resonances	1627:1636	arg1	heterogeneity					1568:1580	conformational heterogeneity	1553:1580	conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy	1553:1659	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	11	61	dep	found	1460:1464	arg1	had					1487:1489	had	1487:1489	found N-glycan composition had a smaller effect on the dissociation rate	1460:1531	Surprisingly, we found N-glycan composition had a smaller effect on the dissociation rate.
35921896	12	62	theme	NMR	1644:1646	arg1	spectroscopy					1648:1659	NMR spectroscopy	1644:1659	NMR spectroscopy	1644:1659	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	5	63	theme	antibodies	753:762	arg1	efficacy					741:748	clinical efficacy	732:748	clinical efficacy of antibodies relying on CD16a engagement	732:790	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	5	63	theme	antibodies	753:762	arg1	responses					718:726	cellular immune responses	702:726	cellular immune responses	702:726	This polymorphism likewise affects cellular immune responses and clinical efficacy of antibodies relying on CD16a engagement, though it remains unclear how V/F158 affects CD16a structure.
35921896	12	64	gly	heterogeneity	1568:1580	arg1	amide					1605:1609	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	amide	1605:1609	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	12	64	gly	heterogeneity	1568:1580	arg1	resonances					1627:1636	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	resonances	1627:1636	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	12	65	theme	amide	1605:1609	arg1	heterogeneity					1568:1580	conformational heterogeneity	1553:1580	conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy	1553:1659	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	14	66	theme	decreasing	1937:1946	arg1	forms					1917:1921	binding-competent forms	1899:1921	binding-competent forms available and decreasing affinity	1899:1955	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	12	67	theme	N162	1615:1618	arg1	resonances					1627:1636	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	resonances	1627:1636	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	1	68	theme	immune	220:225	arg1	responses					227:235	healing cellular immune responses	203:235	healing cellular immune responses	203:235	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	0	69	theme	N-glycan	75:82	arg1	composition					84:94	N-glycan composition	75:94	N-glycan composition	75:94	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	1	70	theme	Fc	170:171	arg1	FcγRs					186:190	FcγRs	186:190	FcγRs	186:190	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	1	70	theme	Fc	170:171	arg1	receptors					175:183	Fc γ receptors	170:183	Fc γ receptors (FcγRs)	170:191	Antibodies engage Fc γ receptors (FcγRs) to elicit healing cellular immune responses following binding to a target antigen.
35921896	8	71	from	differences	1175:1185	arg1	F158					1199:1202	F158	1199:1202	F158	1199:1202	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	8	71	from	differences	1175:1185	arg1	V158					1190:1193	V158	1190:1193	V158	1190:1193	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	7	72	theme	CD16a	1024:1028	arg1	affinity					1035:1042	CD16a F158 affinity	1024:1042	CD16a F158 affinity	1024:1042	It is currently not known how N-glycan composition affects CD16a F158 affinity.
35921896	12	73	theme	F158	1591:1594	arg1	amide					1605:1609	CD16a F158 backbone amide and N162 glycan resonances	1585:1636	amide	1605:1609	We also identified conformational heterogeneity of CD16a F158 backbone amide and N162 glycan resonances using NMR spectroscopy.
35921896	8	74	theme	F158	1107:1110	arg1	allotypes					1112:1120	F158 allotypes	1107:1120	F158 allotypes	1107:1120	Here, we determined N-glycan composition affects the V158 and F158 allotypes similarly, and N-glycan composition does not explain differences in V158 and F158 binding affinity.
35921896	3	75	theme	antibody-binding	464:479	arg1	strength					481:488	CD16a antibody-binding strength	458:488	CD16a antibody-binding strength	458:488	Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism.
35921896	0	76	theme	weaker-binding	4:17	arg1	allotype					43:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	0	77	theme	γ	22:22	arg1	allotype					43:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	6	78	link	asparagine-linked	934:950	arg1	-glycans					955:962	the CD16a asparagine-linked (N)-glycans	924:962	the CD16a asparagine-linked (N)-glycans	924:962	Another relevant variable shown to affect affinity is composition of the CD16a asparagine-linked (N)-glycans.
35921896	0	79	theme	IIIa	33:36	arg1	allotype					43:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype	0:50	The weaker-binding Fc γ receptor IIIa F158 allotype retains sensitivity to N-glycan composition and exhibits a destabilized antibody-binding interface.
35921896	3	80	theme	Multiple	432:439	arg1	variables					441:449	Multiple variables	432:449	Multiple variables	432:449	Multiple variables affect CD16a antibody-binding strength and the resulting immune response, including a genetic polymorphism.
35921896	4	81	theme	predominant	563:573	arg1	allotype					586:593	The predominant CD16a F158 allotype	559:593	The predominant CD16a F158 allotype	559:593	The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype.
35921896	4	82	theme	F158	581:584	arg1	allotype					586:593	The predominant CD16a F158 allotype	559:593	The predominant CD16a F158 allotype	559:593	The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype.
35921896	13	83	theme	shift	1691:1695	arg1	perturbations					1697:1709	chemical shift perturbations	1682:1709	chemical shift perturbations between V158 and F158	1682:1731	Residues exhibiting chemical shift perturbations between V158 and F158 mapped to the antibody-binding interface.
35921896	14	84	theme	conformational	1842:1855	arg1	heterogeneity					1857:1869	increased interface conformational heterogeneity	1822:1869	increased interface conformational heterogeneity	1822:1869	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	2	85	with	tissues	349:355	arg1	proteins					372:379	cytotoxic proteins	362:379	cytotoxic proteins	362:379	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
35921896	4	86	theme	common	645:650	arg1	allotype					657:664	the less common V158 allotype	636:664	the less common V158 allotype	636:664	The predominant CD16a F158 allotype binds antibodies with less affinity than the less common V158 allotype.
35921896	10	87	theme	slower	1412:1417	arg1	rate					1427:1430	a slower binding rate	1410:1430	a slower binding rate than V158	1410:1440	F158 displayed a slower binding rate than V158.
35921896	14	88	theme	increased	1822:1830	arg1	heterogeneity					1857:1869	increased interface conformational heterogeneity	1822:1869	increased interface conformational heterogeneity	1822:1869	These data support a model for CD16a F158 with increased interface conformational heterogeneity, reducing the population of binding-competent forms available and decreasing affinity.
35921896	9	89	dep	slows	1281:1285	arg1	removing					1338:1345	removing	1338:1345	removing the N162 glycan increased the speed of binding	1338:1392	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	9	89	dep	slows	1281:1285	arg1	shortening					1310:1319	shortening	1310:1319	shortening the N-glycans	1310:1333	Our analysis of binding kinetics indicated the N162 glycan slows the binding event, and shortening the N-glycans or removing the N162 glycan increased the speed of binding.
35921896	2	90	theme	cytotoxic	362:370	arg1	proteins					372:379	cytotoxic proteins	362:379	cytotoxic proteins	362:379	Fc γ receptor IIIa/CD16a triggers natural killer cells to destroy target tissues with cytotoxic proteins and enhances phagocytosis mediated by macrophages.
36206692	7	0	theme	RPLC-ESI-MRM-MS	1385:1399	arg1	method					1401:1406	RPLC-ESI-MRM-MS method	1385:1406	RPLC-ESI-MRM-MS method	1385:1406	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	2	1	theme	resistant	652:660	arg1	column					677:682	a high-pressure resistant reversed-phase column	636:682	a high-pressure resistant reversed-phase column	636:682	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	7	2	theme	established	1342:1352	arg1	acetylation					1361:1371	the established direct acetylation	1338:1371	the established direct acetylation as followed RPLC-ESI-MRM-MS method	1338:1406	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	2	3	theme	Ara	522:524	arg1	aldoses					498:504	8 aldoses	496:504	8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc)	496:548	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	3	theme	Ara	522:524	arg1	Rha					537:539	Ara, Xyl, Rib, Rha	522:539	Rha	537:539	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	0	4	from	acetylation	7:17	arg1	fungi					77:81	fungi	77:81	fungi	77:81	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	0	4	from	acetylation	7:17	arg1	plants					66:71	edible plants	59:71	edible plants	59:71	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	2	5	theme	alditols	569:576	arg1	determination					479:491	simultaneous determination	466:491	simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA)	466:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	6	theme	acids	611:615	arg1	determination					479:491	simultaneous determination	466:491	simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA)	466:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	7	theme	mass	412:415	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	7	theme	mass	412:415	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	8	dep	acids	611:615	arg1	GlcA					618:621	GlcA	618:621	GlcA	618:621	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	8	dep	acids	611:615	arg1	acids					611:615	2 uronic acids	602:615	2 uronic acids (GlcA and GalA)	602:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	8	dep	acids	611:615	arg1	GalA					627:630	GalA	627:630	GalA	627:630	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	5	9	theme	co-elution	1125:1134	arg1	problem					1136:1142	co-elution problem	1125:1142	co-elution problem of Fru and Man	1125:1157	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	0	10	theme	reverse	89:95	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	2	11	theme	uronic	604:609	arg1	GlcA					618:621	GlcA	618:621	GlcA	618:621	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	11	theme	uronic	604:609	arg1	acids					611:615	2 uronic acids	602:615	2 uronic acids (GlcA and GalA)	602:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	11	theme	uronic	604:609	arg1	GalA					627:630	GalA	627:630	GalA	627:630	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	3	12	theme	β-	916:917	arg1	isomers					919:925	the ɑ- and β- isomers	905:925	the ɑ- and β- isomers merged together	905:941	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	7	13	theme	complex	1463:1469	arg1	polysaccharides					1471:1485	complex polysaccharides	1463:1485	complex polysaccharides from edible plants and fungi	1463:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	3	14	used	used	762:765	arg2	DMSO					753:756	no DMSO	750:756	no DMSO	750:756	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	3	15	theme	single	851:856	arg1	peak					874:877	a single chromatographic peak	849:877	a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together	849:941	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	7	16	theme	polysaccharides	1471:1485	arg1	analysis					1451:1458	compositional analysis	1437:1458	compositional analysis of complex polysaccharides from edible plants and fungi	1437:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	0	17	theme	liquid	103:108	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	5	18	theme	ketose	1226:1231	arg1	occurrence					1170:1179	occurrence	1170:1179	occurrence of a specific Q3 ion for aldoses rather than ketose	1170:1231	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	4	19	theme	other	976:980	arg1	carbohydrates					985:997	all the other 11 carbohydrates	968:997	all the other 11 carbohydrates	968:997	Except for Fru and Man, all the other 11 carbohydrates were base-line separated in a 1.7 µm CYANO column.
36206692	3	20	theme	chromatographic	858:872	arg1	peak					874:877	a single chromatographic peak	849:877	a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together	849:941	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	0	21	theme	phase	97:101	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	2	22	dep	aldoses	498:504	arg1	aldoses					498:504	8 aldoses	496:504	8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc)	496:548	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	22	dep	aldoses	498:504	arg1	Rha					537:539	Ara, Xyl, Rib, Rha	522:539	Rha	537:539	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	22	dep	aldoses	498:504	arg1	Glc					507:509	Glc	507:509	Glc	507:509	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	22	dep	aldoses	498:504	arg1	Fuc					545:547	Fuc	545:547	Fuc	545:547	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	22	dep	aldoses	498:504	arg1	Gal					512:514	Gal	512:514	Gal	512:514	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	22	dep	aldoses	498:504	arg1	Man					517:519	Man	517:519	Man	517:519	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	4	23	dep	separated	1014:1022	arg1	base-line					1004:1012	base-line	1004:1012	base-line	1004:1012	Except for Fru and Man, all the other 11 carbohydrates were base-line separated in a 1.7 µm CYANO column.
36206692	2	24	theme	acetylation	291:301	arg1	strategy					303:310	a direct acetylation strategy	282:310	a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	282:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	7	25	from	plants	1499:1504	arg1	analysis					1451:1458	compositional analysis	1437:1458	compositional analysis of complex polysaccharides from edible plants and fungi	1437:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	7	25	from	plants	1499:1504	arg1	polysaccharides					1471:1485	complex polysaccharides	1463:1485	complex polysaccharides from edible plants and fungi	1463:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	7	26	from	analysis	1451:1458	arg1	fungi					1510:1514	fungi	1510:1514	fungi	1510:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	7	26	from	analysis	1451:1458	arg1	plants					1499:1504	edible plants	1492:1504	edible plants	1492:1504	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	6	27	theme	Fluoro-Phenyl	1270:1282	arg1	column					1284:1289	a 1.7 µm Fluoro-Phenyl column	1261:1289	a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man	1261:1327	The result was verified on a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man.
36206692	2	28	theme	electrospray	363:374	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	28	theme	electrospray	363:374	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	7	29	theme	direct	1354:1359	arg1	acetylation					1361:1371	the established direct acetylation	1338:1371	the established direct acetylation as followed RPLC-ESI-MRM-MS method	1338:1406	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	0	30	theme	Direct	0:5	arg1	acetylation					7:17	Direct acetylation	0:17	Direct acetylation for full analysis of polysaccharides in edible plants and fungi	0:81	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	7	31	dep	acetylation	1361:1371	arg1	followed					1376:1383	followed	1376:1383	followed RPLC-ESI-MRM-MS method	1376:1406	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	2	32	theme	chromatography	348:361	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	32	theme	chromatography	348:361	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	3	33	theme	RPLC	882:885	arg1	conditions					887:896	RPLC conditions	882:896	RPLC conditions	882:896	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	0	34	theme	full	23:26	arg1	analysis					28:35	full analysis	23:35	full analysis of polysaccharides	23:54	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	0	35	theme	reaction	134:141	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	2	36	theme	liquid	341:346	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	36	theme	liquid	341:346	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	37	theme	aldoses	498:504	arg1	determination					479:491	simultaneous determination	466:491	simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA)	466:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	7	38	theme	edible	1492:1497	arg1	plants					1499:1504	edible plants	1492:1504	edible plants	1492:1504	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	0	39	theme	chromatography-multiple	110:132	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	2	40	theme	reversed-phase	326:339	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	40	theme	reversed-phase	326:339	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	4	41	theme	CYANO	1036:1040	arg1	column					1042:1047	a 1.7 µm CYANO column	1027:1047	a 1.7 µm CYANO column	1027:1047	Except for Fru and Man, all the other 11 carbohydrates were base-line separated in a 1.7 µm CYANO column.
36206692	6	42	theme	Fru	1317:1319	arg1	separation					1303:1312	a full separation	1296:1312	a full separation of Fru and Man	1296:1327	The result was verified on a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man.
36206692	0	43	theme	mass	154:157	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	3	44	from	peak	874:877	arg1	conditions					887:896	RPLC conditions	882:896	RPLC conditions	882:896	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	4	45	theme	1.7 µm	1029:1034	arg1	column					1042:1047	a 1.7 µm CYANO column	1027:1047	a 1.7 µm CYANO column	1027:1047	Except for Fru and Man, all the other 11 carbohydrates were base-line separated in a 1.7 µm CYANO column.
36206692	1	46	theme	monosaccharide	232:245	arg1	composition					247:257	monosaccharide composition	232:257	monosaccharide composition method	232:264	It is vitally important to characterize polysaccharides by monosaccharide composition method.
36206692	5	47	theme	correction	1061:1070	arg1	method					1079:1084	correction factor method	1061:1084	correction factor method	1061:1084	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	0	48	theme	monitoring	143:152	arg1	spectrometry					159:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry	89:170	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	6	49	theme	Man	1325:1327	arg1	separation					1303:1312	a full separation	1296:1312	a full separation of Fru and Man	1296:1327	The result was verified on a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man.
36206692	2	50	theme	high-pressure	638:650	arg1	column					677:682	a high-pressure resistant reversed-phase column	636:682	a high-pressure resistant reversed-phase column	636:682	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	1	51	theme	composition	247:257	arg1	method					259:264	monosaccharide composition method	232:264	monosaccharide composition method	232:264	It is vitally important to characterize polysaccharides by monosaccharide composition method.
36206692	5	52	theme	factor	1072:1077	arg1	method					1079:1084	correction factor method	1061:1084	correction factor method	1061:1084	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	6	53	theme	1.7 µm	1263:1268	arg1	column					1284:1289	a 1.7 µm Fluoro-Phenyl column	1261:1289	a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man	1261:1327	The result was verified on a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man.
36206692	7	54	theme	compositional	1437:1449	arg1	analysis					1451:1458	compositional analysis	1437:1458	compositional analysis of complex polysaccharides from edible plants and fungi	1437:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	3	55	theme	ɑ-	909:910	arg1	isomers					919:925	the ɑ- and β- isomers	905:925	the ɑ- and β- isomers merged together	905:941	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	2	56	theme	monitoring	401:410	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	56	theme	monitoring	401:410	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	0	57	theme	polysaccharides	40:54	arg1	analysis					28:35	full analysis	23:35	full analysis of polysaccharides	23:54	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	3	58	theme	due	898:900	arg1	peak					874:877	a single chromatographic peak	849:877	a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together	849:941	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	2	59	theme	reaction	392:399	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	59	theme	reaction	392:399	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	5	60	theme	specific	1186:1193	arg1	ion					1198:1200	a specific Q3 ion	1184:1200	a specific Q3 ion for aldoses rather than ketose	1184:1231	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	3	61	theme	direct	718:723	arg1	acetylation					725:735	direct acetylation	718:735	direct acetylation	718:735	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	7	62	from	fungi	1510:1514	arg1	analysis					1451:1458	compositional analysis	1437:1458	compositional analysis of complex polysaccharides from edible plants and fungi	1437:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	7	62	from	fungi	1510:1514	arg1	polysaccharides					1471:1485	complex polysaccharides	1463:1485	complex polysaccharides from edible plants and fungi	1463:1514	Herein, the established direct acetylation as followed RPLC-ESI-MRM-MS method was successfully applied for compositional analysis of complex polysaccharides from edible plants and fungi.
36206692	2	63	theme	direct	284:289	arg1	strategy					303:310	a direct acetylation strategy	282:310	a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	282:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	64	theme	multiple	383:390	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	64	theme	multiple	383:390	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	3	65	theme	configurations	800:813	arg1	transformation					782:795	the transformation	778:795	the transformation of configurations	778:813	Employing 1-MeIm as catalyst for direct acetylation, even though no DMSO was used to inhibit the transformation of configurations, each carbohydrate still produced a single chromatographic peak in RPLC conditions due to the ɑ- and β- isomers merged together.
36206692	5	66	theme	Fru	1147:1149	arg1	problem					1136:1142	co-elution problem	1125:1142	co-elution problem of Fru and Man	1125:1157	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	2	67	theme	ketose	553:558	arg1	determination					479:491	simultaneous determination	466:491	simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA)	466:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	6	68	with	column	1284:1289	arg1	separation					1303:1312	a full separation	1296:1312	a full separation of Fru and Man	1296:1327	The result was verified on a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man.
36206692	2	69	dep	Rha	537:539	arg1	Xyl					527:529	Ara, Xyl, Rib, Rha	522:539	Xyl	527:529	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	69	dep	Rha	537:539	arg1	Rib					532:534	Ara, Xyl, Rib, Rha	522:539	Rib	532:534	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	70	theme	tandem	376:381	arg1	spectrometry					417:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry	326:428	reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS)	326:446	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	70	theme	tandem	376:381	arg1	RPLC-ESI-MRM-MS					431:445	RPLC-ESI-MRM-MS	431:445	RPLC-ESI-MRM-MS	431:445	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	5	71	theme	ion	1198:1200	arg1	occurrence					1170:1179	occurrence	1170:1179	occurrence of a specific Q3 ion for aldoses rather than ketose	1170:1231	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	2	72	theme	simultaneous	466:477	arg1	determination					479:491	simultaneous determination	466:491	simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA)	466:631	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	6	73	theme	full	1298:1301	arg1	separation					1303:1312	a full separation	1296:1312	a full separation of Fru and Man	1296:1327	The result was verified on a 1.7 µm Fluoro-Phenyl column with a full separation of Fru and Man.
36206692	5	74	theme	Q3	1195:1196	arg1	ion					1198:1200	a specific Q3 ion	1184:1200	a specific Q3 ion for aldoses rather than ketose	1184:1231	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	5	75	theme	Man	1155:1157	arg1	problem					1136:1142	co-elution problem	1125:1142	co-elution problem of Fru and Man	1125:1157	Therefore, correction factor method is further proposed to perfectly solve co-elution problem of Fru and Man because of occurrence of a specific Q3 ion for aldoses rather than ketose.
36206692	0	76	theme	edible	59:64	arg1	plants					66:71	edible plants	59:71	edible plants	59:71	Direct acetylation for full analysis of polysaccharides in edible plants and fungi using reverse phase liquid chromatography-multiple reaction monitoring mass spectrometry.
36206692	2	77	dep	alditols	569:576	arg1	alditols					569:576	2 alditols	567:576	2 alditols (Glc-ol and Man-ol)	567:596	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	77	dep	alditols	569:576	arg1	Man-ol					590:595	Man-ol	590:595	Man-ol	590:595	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	77	dep	alditols	569:576	arg1	Glc-ol					579:584	Glc-ol	579:584	Glc-ol	579:584	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36206692	2	78	theme	reversed-phase	662:675	arg1	column					677:682	a high-pressure resistant reversed-phase column	636:682	a high-pressure resistant reversed-phase column	636:682	In this study, a direct acetylation strategy combined with reversed-phase liquid chromatography electrospray tandem multiple reaction monitoring mass spectrometry (RPLC-ESI-MRM-MS) was developed for simultaneous determination of 8 aldoses (Glc, Gal, Man, Ara, Xyl, Rib, Rha and Fuc), a ketose (Fru), 2 alditols (Glc-ol and Man-ol) and 2 uronic acids (GlcA and GalA) on a high-pressure resistant reversed-phase column.
36239281	3	0	theme	heptasaccharide	799:813	arg1	heparin					791:797	an unmodified heparin heptasaccharide	777:813	an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	777:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	4	1	theme	diverse	1017:1023	arg1	molecules					1036:1044	diverse HS/heparin molecules	1017:1044	diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents	1017:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	1	2	theme	heparan	173:179	arg1	HS					190:191	HS	190:191	HS	190:191	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	1	2	theme	heparan	173:179	arg1	sulfate					181:187	heparan sulfate	173:187	heparan sulfate (HS)	173:192	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	1	3	theme	sulfate	181:187	arg1	pathway					150:156	the biosynthetic pathway	133:156	the biosynthetic pathway of heparin and heparan sulfate (HS)	133:192	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	1	4	from	activity	322:329	arg1	yields					347:352	good overall yields	334:352	good overall yields	334:352	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	1	5	theme	well-defined	255:266	arg1	oligosaccharides					276:291	structurally well-defined heparin oligosaccharides	242:291	structurally well-defined heparin oligosaccharides	242:291	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	4	6	theme	structural	1070:1079	arg1	features					1081:1088	completely natural structural features	1051:1088	completely natural structural features as promising therapeutic agents	1051:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	3	7	theme	unmodified	780:789	arg1	heparin					791:797	an unmodified heparin heptasaccharide	777:813	an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	777:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	1	8	theme	heparin	268:274	arg1	oligosaccharides					276:291	structurally well-defined heparin oligosaccharides	242:291	structurally well-defined heparin oligosaccharides	242:291	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	4	9	theme	promising	1093:1101	arg1	agents					1115:1120	promising therapeutic agents	1093:1120	promising therapeutic agents	1093:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	3	10	theme	heparin	791:797	arg1	synthesis					764:772	the highly efficient synthesis	743:772	the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	743:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	4	11	theme	generic	957:963	arg1	strategy					965:972	This successful generic strategy	941:972	This successful generic strategy	941:972	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	2	12	theme	glycosyl	427:434	arg1	convenient					500:509	convenient	500:509	convenient	500:509	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	12	theme	glycosyl	427:434	arg1	acceptor					436:443	an unnatural glycosyl acceptor	414:443	an unnatural glycosyl acceptor	414:443	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	12	theme	glycosyl	427:434	arg1	glucuronide					467:477	<i>p</i>-nitrophenyl glucuronide	446:477	<i>p</i>-nitrophenyl glucuronide (GlcA-PNP)	446:488	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	4	13	theme	successful	946:955	arg1	strategy					965:972	This successful generic strategy	941:972	This successful generic strategy	941:972	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	2	14	theme	unnatural	417:425	arg1	convenient					500:509	convenient	500:509	convenient	500:509	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	14	theme	unnatural	417:425	arg1	acceptor					436:443	an unnatural glycosyl acceptor	414:443	an unnatural glycosyl acceptor	414:443	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	14	theme	unnatural	417:425	arg1	glucuronide					467:477	<i>p</i>-nitrophenyl glucuronide	446:477	<i>p</i>-nitrophenyl glucuronide (GlcA-PNP)	446:488	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	0	15	theme	chemoenzymatic	7:20	arg1	synthesis					22:30	Facile chemoenzymatic synthesis	0:30	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin	0:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	1	16	theme	chemoenzymatic	98:111	arg1	approach					113:120	A chemoenzymatic approach	96:120	A chemoenzymatic approach	96:120	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	4	17	with	molecules	1036:1044	arg1	features					1081:1088	completely natural structural features	1051:1088	completely natural structural features as promising therapeutic agents	1051:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	0	18	theme	Facile	0:5	arg1	synthesis					22:30	Facile chemoenzymatic synthesis	0:30	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin	0:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	1	19	theme	oligosaccharides	276:291	arg1	series					232:237	a series	230:237	a series of structurally well-defined heparin oligosaccharides	230:291	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	3	20	theme	potent	834:839	arg1	vitro</i>					870:878	potent anticoagulant activity <i>in vitro</i>	834:878	potent anticoagulant activity <i>in vitro</i>	834:878	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	2	21	theme	undesirable	595:605	arg1	characteristics					617:631	undesirable structure characteristics	595:631	undesirable structure characteristics	595:631	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	1	22	theme	excellent	298:306	arg1	activity					322:329	excellent anticoagulant activity	298:329	excellent anticoagulant activity in good overall yields	298:352	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	4	23	theme	molecules	1036:1044	arg1	synthesis					1004:1012	the scalable synthesis	991:1012	the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents	991:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	3	24	theme	specific	703:710	arg1	cleavage					712:719	the specific cleavage	699:719	the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	699:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	2	25	theme	chemoenzymatic	367:380	arg1	synthesis					382:390	The current chemoenzymatic synthesis	355:390	The current chemoenzymatic synthesis	355:390	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	26	theme	<i>p</i>-nitrophenyl	446:465	arg1	GlcA-PNP					480:487	GlcA-PNP	480:487	GlcA-PNP	480:487	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	26	theme	<i>p</i>-nitrophenyl	446:465	arg1	acceptor					436:443	an unnatural glycosyl acceptor	414:443	an unnatural glycosyl acceptor	414:443	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	2	26	theme	<i>p</i>-nitrophenyl	446:465	arg1	glucuronide					467:477	<i>p</i>-nitrophenyl glucuronide	446:477	<i>p</i>-nitrophenyl glucuronide (GlcA-PNP)	446:488	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	0	27	theme	anticoagulant	46:58	arg1	heparin					87:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	1	28	theme	anticoagulant	308:320	arg1	activity					322:329	excellent anticoagulant activity	298:329	excellent anticoagulant activity in good overall yields	298:352	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	4	29	theme	natural	1062:1068	arg1	features					1081:1088	completely natural structural features	1051:1088	completely natural structural features as promising therapeutic agents	1051:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	0	30	theme	unmodified	35:44	arg1	heparin					87:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	3	31	theme	<i>in	864:868	arg1	vitro</i>					870:878	potent anticoagulant activity <i>in vitro</i>	834:878	potent anticoagulant activity <i>in vitro</i>	834:878	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	2	32	theme	heparin	572:578	arg1	molecules					580:588	heparin molecules	572:588	heparin molecules with undesirable structure characteristics	572:631	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	3	33	theme	anticoagulant	841:853	arg1	vitro</i>					870:878	potent anticoagulant activity <i>in vitro</i>	834:878	potent anticoagulant activity <i>in vitro</i>	834:878	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	3	34	theme	activity	855:862	arg1	vitro</i>					870:878	potent anticoagulant activity <i>in vitro</i>	834:878	potent anticoagulant activity <i>in vitro</i>	834:878	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	0	35	theme	molecular	70:78	arg1	heparin					87:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	4	36	theme	scalable	995:1002	arg1	synthesis					1004:1012	the scalable synthesis	991:1012	the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents	991:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	4	37	theme	therapeutic	1103:1113	arg1	agents					1115:1120	promising therapeutic agents	1093:1120	promising therapeutic agents	1093:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	2	38	theme	current	359:365	arg1	synthesis					382:390	The current chemoenzymatic synthesis	355:390	The current chemoenzymatic synthesis	355:390	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	0	39	theme	ultra-low	60:68	arg1	heparin					87:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	1	40	theme	good	334:337	arg1	yields					347:352	good overall yields	334:352	good overall yields	334:352	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	2	41	dep	detection	515:523	arg1	recovery					525:532	recovery	525:532	recovery	525:532	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	1	42	theme	biosynthetic	137:148	arg1	pathway					150:156	the biosynthetic pathway	133:156	the biosynthetic pathway of heparin and heparan sulfate (HS)	133:192	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	2	43	with	molecules	580:588	arg1	characteristics					617:631	undesirable structure characteristics	595:631	undesirable structure characteristics	595:631	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	1	44	theme	overall	339:345	arg1	yields					347:352	good overall yields	334:352	good overall yields	334:352	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	4	45	theme	HS/heparin	1025:1034	arg1	molecules					1036:1044	diverse HS/heparin molecules	1017:1044	diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents	1017:1120	This successful generic strategy is applicable to the scalable synthesis of diverse HS/heparin molecules with completely natural structural features as promising therapeutic agents.
36239281	3	46	theme	pharmacokinetic	897:911	arg1	profiles					913:920	commensurate pharmacokinetic profiles	884:920	commensurate pharmacokinetic profiles	884:920	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	2	47	theme	structure	607:615	arg1	characteristics					617:631	undesirable structure characteristics	595:631	undesirable structure characteristics	595:631	The current chemoenzymatic synthesis typically begins with an unnatural glycosyl acceptor, <i>p</i>-nitrophenyl glucuronide (GlcA-PNP), which is convenient for detection recovery and purification, although it affords heparin molecules with undesirable structure characteristics.
36239281	3	48	theme	assisted	687:694	arg1	strategy					678:685	a facile chemoenzymatic strategy	654:685	a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	654:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	0	49	theme	heparin	87:93	arg1	synthesis					22:30	Facile chemoenzymatic synthesis	0:30	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin	0:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	3	50	theme	heparinase	724:733	arg1	cleavage					712:719	the specific cleavage	699:719	the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	699:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	3	51	theme	facile	656:661	arg1	strategy					678:685	a facile chemoenzymatic strategy	654:685	a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	654:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	1	52	theme	heparin	161:167	arg1	pathway					150:156	the biosynthetic pathway	133:156	the biosynthetic pathway of heparin and heparan sulfate (HS)	133:192	A chemoenzymatic approach, mimicking the biosynthetic pathway of heparin and heparan sulfate (HS), has been well developed to prepare a series of structurally well-defined heparin oligosaccharides with excellent anticoagulant activity in good overall yields.
36239281	0	53	theme	weight	80:85	arg1	heparin					87:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	unmodified anticoagulant ultra-low molecular weight heparin	35:93	Facile chemoenzymatic synthesis of unmodified anticoagulant ultra-low molecular weight heparin.
36239281	3	54	theme	efficient	754:762	arg1	synthesis					764:772	the highly efficient synthesis	743:772	the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	743:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	3	55	theme	chemoenzymatic	663:676	arg1	strategy					678:685	a facile chemoenzymatic strategy	654:685	a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux	654:938	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
36239281	3	56	theme	commensurate	884:895	arg1	profiles					913:920	commensurate pharmacokinetic profiles	884:920	commensurate pharmacokinetic profiles	884:920	Herein, we describe a facile chemoenzymatic strategy assisted by the specific cleavage of heparinase III for the highly efficient synthesis of an unmodified heparin heptasaccharide which demonstrated potent anticoagulant activity <i>in vitro</i> and commensurate pharmacokinetic profiles with fondaparinux.
37310804	0	0	theme	Fragments	94:102	arg1	Synthesis					6:14	Total Synthesis	0:14	Total Synthesis	0:14	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	0	0	theme	Fragments	94:102	arg1	Studies					31:37	Structural Studies	20:37	Structural Studies	20:37	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	2	1	theme	well-defined	487:498	arg1	fragments					504:512	well-defined ZPS fragments	487:512	well-defined ZPS fragments	487:512	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	6	2	theme	larger	1324:1329	arg1	polysaccharides					1337:1351	larger PS A1 polysaccharides	1324:1351	larger PS A1 polysaccharides	1324:1351	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	3	3	dep	12	664:665	arg1	to					661:662	to	661:662	to	661:662	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	0	4	theme	A1	91:92	arg1	Fragments					94:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	5	5	theme	functionalization	1148:1164	arg1	handle					1166:1171	an orthogonal alkyne functionalization handle	1127:1171	an orthogonal alkyne functionalization handle	1127:1171	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	7	6	theme	detailed	1527:1534	arg1	studies					1548:1554	detailed interaction studies	1527:1554	detailed interaction studies with binding proteins	1527:1576	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	7	7	from	level	1655:1659	arg1	action					1601:1606	action	1601:1606	action of these unique oligosaccharides at the atomic level	1601:1659	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	7	7	from	level	1655:1659	arg1	mode					1593:1596	the mode	1589:1596	the mode of action of these unique oligosaccharides at the atomic level	1589:1659	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	7	8	theme	action	1601:1606	arg1	mode					1593:1596	the mode	1589:1596	the mode of action of these unique oligosaccharides at the atomic level	1589:1659	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	2	9	theme	sufficient	530:539	arg1	quantity					541:548	sufficient quantity	530:548	sufficient quantity	530:548	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	3	10	theme	repeating	703:711	arg1	units					713:717	three repeating units	697:717	three repeating units	697:717	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	4	11	theme	apt	887:889	arg1	nucleophile					891:901	an apt nucleophile	884:901	an apt nucleophile	884:901	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	11	theme	apt	887:889	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	6	12	theme	bent	1262:1265	arg1	structure					1267:1275	a bent structure	1260:1275	a bent structure	1260:1275	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	7	13	theme	fragments	1458:1466	arg1	availability					1438:1449	The availability	1434:1449	The availability of the fragments	1434:1466	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	7	13	theme	fragments	1458:1466	arg1	insight					1476:1482	the insight	1472:1482	the insight into their secondary structure	1472:1513	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	1	14	theme	MHC-II	279:284	arg1	molecules					286:294	MHC-II molecules	279:294	MHC-II molecules	279:294	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	6	15	theme	left-handed	1302:1312	arg1	helix					1314:1318	a left-handed helix	1300:1318	a left-handed helix for larger PS A1 polysaccharides	1300:1351	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	2	16	dep	remains	320:326	arg1	required					518:525	required	518:525	are required in sufficient quantity and quality	514:560	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	2	16	dep	remains	320:326	arg1	bind					374:377	bind	374:377	bind to these receptors	374:396	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	6	17	theme	amino	1392:1396	arg1	groups					1398:1403	the key positively charged amino groups	1365:1403	the key positively charged amino groups	1365:1403	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	1	18	contain	carrying	172:179	arg2	carboxylates					241:252	negatively charged carboxylates	222:252	negatively charged carboxylates	222:252	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	1	18	contain	carrying	172:179	arg1	polysaccharides					118:132	Zwitterionic polysaccharides	105:132	Zwitterionic polysaccharides (ZPSs)	105:139	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	1	18	contain	carrying	172:179	arg2	groups					211:216	positively charged amine groups	186:216	positively charged amine groups	186:216	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	1	18	contain	carrying	172:179	arg1	carbohydrates					157:169	exceptional carbohydrates	145:169	exceptional carbohydrates	145:169	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	4	19	theme	C-3	784:786	arg1	Key					720:722	Key	720:722	Key	720:722	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	19	theme	C-3	784:786	arg1	incorporation					765:777	the incorporation	761:777	the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	761:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	6	20	theme	charged	1384:1390	arg1	groups					1398:1403	the key positively charged amino groups	1365:1403	the key positively charged amino groups	1365:1403	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	5	21	theme	alkyne	1141:1146	arg1	handle					1166:1171	an orthogonal alkyne functionalization handle	1127:1171	an orthogonal alkyne functionalization handle	1127:1171	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	7	22	with	studies	1548:1554	arg1	proteins					1569:1576	binding proteins	1561:1576	binding proteins	1561:1576	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	1	23	theme	charged	197:203	arg1	groups					211:216	positively charged amine groups	186:216	positively charged amine groups	186:216	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	5	24	theme	unique	1014:1019	arg1	strategy					1038:1045	a unique protecting group strategy	1012:1045	a unique protecting group strategy	1012:1045	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	1	25	theme	amine	205:209	arg1	groups					211:216	positively charged amine groups	186:216	positively charged amine groups	186:216	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	0	26	theme	Total	0:4	arg1	Synthesis					6:14	Total Synthesis	0:14	Total Synthesis	0:14	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	1	27	theme	Zwitterionic	105:116	arg1	ZPSs					135:138	ZPSs	135:138	ZPSs	135:138	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	1	27	theme	Zwitterionic	105:116	arg1	polysaccharides					118:132	Zwitterionic polysaccharides	105:132	Zwitterionic polysaccharides (ZPSs)	105:139	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	1	27	theme	Zwitterionic	105:116	arg1	carbohydrates					157:169	exceptional carbohydrates	145:169	exceptional carbohydrates	145:169	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	0	28	theme	Structural	20:29	arg1	Studies					31:37	Structural Studies	20:37	Structural Studies	20:37	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	4	29	theme	ring-inverted	812:824	arg1	nucleophile					891:901	an apt nucleophile	884:901	an apt nucleophile	884:901	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	29	theme	ring-inverted	812:824	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	29	theme	ring-inverted	812:824	arg1	C-3					784:786	a C-3	782:786	a C-3	782:786	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	29	theme	ring-inverted	812:824	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	30	theme	stereoselective	916:930	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	30	theme	stereoselective	916:930	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	31	theme	building	841:848	arg1	nucleophile					891:901	an apt nucleophile	884:901	an apt nucleophile	884:901	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	31	theme	building	841:848	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	31	theme	building	841:848	arg1	C-3					784:786	a C-3	782:786	a C-3	782:786	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	31	theme	building	841:848	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	5	32	theme	stereoselective	952:966	arg1	route					978:982	Our stereoselective synthesis route	948:982	Our stereoselective synthesis route	948:982	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	4	33	theme	galactosamine	827:839	arg1	nucleophile					891:901	an apt nucleophile	884:901	an apt nucleophile	884:901	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	33	theme	galactosamine	827:839	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	33	theme	galactosamine	827:839	arg1	C-3					784:786	a C-3	782:786	a C-3	782:786	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	33	theme	galactosamine	827:839	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	2	34	theme	structural	421:430	arg1	features					432:439	the structural features	417:439	the structural features responsible for this "peptide-like" behavior	417:484	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	6	35	theme	structural	1183:1192	arg1	studies					1194:1200	Detailed structural studies	1174:1200	Detailed structural studies	1174:1200	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	1	36	theme	T	308:308	arg1	cells					310:314	T cells	308:314	T cells	308:314	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	6	37	theme	key	1369:1371	arg1	groups					1398:1403	the key positively charged amino groups	1365:1403	the key positively charged amino groups	1365:1403	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	5	38	theme	synthesis	968:976	arg1	route					978:982	Our stereoselective synthesis route	948:982	Our stereoselective synthesis route	948:982	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	2	39	theme	peptide-like	463:474	arg1	behavior					477:484	this "peptide-like" behavior	457:484	this "peptide-like" behavior	457:484	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	5	40	theme	handle	1166:1171	arg1	incorporation					1110:1122	the incorporation	1106:1122	the incorporation of an orthogonal alkyne functionalization handle	1106:1171	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	0	41	dep	Bacteroides	55:65	arg1	fragilis					67:74	fragilis	67:74	fragilis	67:74	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	1	42	theme	charged	233:239	arg1	carboxylates					241:252	negatively charged carboxylates	222:252	negatively charged carboxylates	222:252	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	2	43	theme	"	475:475	arg1	behavior					477:484	this "peptide-like" behavior	457:484	this "peptide-like" behavior	457:484	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	7	44	theme	atomic	1648:1653	arg1	level					1655:1659	the atomic level	1644:1659	the atomic level	1644:1659	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	4	45	theme	glycosyl	932:939	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	45	theme	glycosyl	932:939	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	3	46	theme	fragments	635:643	arg1	synthesis					595:603	the first total synthesis	579:603	the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides	579:681	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	2	47	theme	responsible	441:451	arg1	features					432:439	the structural features	417:439	the structural features responsible for this "peptide-like" behavior	417:484	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	5	48	theme	group	1032:1036	arg1	strategy					1038:1045	a unique protecting group strategy	1012:1045	a unique protecting group strategy	1012:1045	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	0	49	theme	Bacteroides	55:65	arg1	Fragments					94:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	5	50	theme	base-labile	1057:1067	arg1	groups					1080:1085	base-labile protecting groups	1057:1085	base-labile protecting groups	1057:1085	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	3	51	theme	first	583:587	arg1	synthesis					595:603	the first total synthesis	579:603	the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides	579:681	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	7	52	from	mode	1593:1596	arg1	level					1655:1659	the atomic level	1644:1659	the atomic level	1644:1659	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	0	53	theme	Zwitterionic	42:53	arg1	Fragments					94:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	3	54	theme	total	589:593	arg1	synthesis					595:603	the first total synthesis	579:603	the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides	579:681	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	7	55	theme	binding	1561:1567	arg1	proteins					1569:1576	binding proteins	1561:1576	binding proteins	1561:1576	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	6	56	theme	assembled	1225:1233	arg1	oligosaccharides					1235:1250	the assembled oligosaccharides	1221:1250	the assembled oligosaccharides	1221:1250	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	6	57	theme	A1	1334:1335	arg1	polysaccharides					1337:1351	larger PS A1 polysaccharides	1324:1351	larger PS A1 polysaccharides	1324:1351	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	4	58	theme	C-6-silylidene-bridged	788:809	arg1	nucleophile					891:901	an apt nucleophile	884:901	an apt nucleophile	884:901	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	58	theme	C-6-silylidene-bridged	788:809	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	58	theme	C-6-silylidene-bridged	788:809	arg1	C-3					784:786	a C-3	782:786	a C-3	782:786	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	58	theme	C-6-silylidene-bridged	788:809	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	3	59	theme	PS	629:630	arg1	fragments					635:643	Bacteroides fragilis PS A1 fragments	608:643	Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides	608:681	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	4	60	theme	"	825:825	arg1	nucleophile					891:901	an apt nucleophile	884:901	an apt nucleophile	884:901	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	60	theme	"	825:825	arg1	donor					941:945	a stereoselective glycosyl donor	914:945	a stereoselective glycosyl donor	914:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	60	theme	"	825:825	arg1	C-3					784:786	a C-3	782:786	a C-3	782:786	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	60	theme	"	825:825	arg1	block					850:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block	788:854	C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor	788:945	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	4	61	theme	successful	731:740	arg1	syntheses					742:750	our successful syntheses	727:750	our successful syntheses	727:750	Key to our successful syntheses has been the incorporation of a C-3,C-6-silylidene-bridged "ring-inverted" galactosamine building block that was designed to act as an apt nucleophile as well as a stereoselective glycosyl donor.
37310804	6	62	theme	Detailed	1174:1181	arg1	studies					1194:1200	Detailed structural studies	1174:1200	Detailed structural studies	1174:1200	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	7	63	theme	unique	1617:1622	arg1	oligosaccharides					1624:1639	these unique oligosaccharides	1611:1639	these unique oligosaccharides	1611:1639	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	6	64	theme	PS	1331:1332	arg1	polysaccharides					1337:1351	larger PS A1 polysaccharides	1324:1351	larger PS A1 polysaccharides	1324:1351	Detailed structural studies have revealed that the assembled oligosaccharides take up a bent structure, which translates into a left-handed helix for larger PS A1 polysaccharides, presenting the key positively charged amino groups to the outside of the helix.
37310804	5	65	theme	protecting	1069:1078	arg1	groups					1080:1085	base-labile protecting groups	1057:1085	base-labile protecting groups	1057:1085	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	3	66	theme	A1	632:633	arg1	fragments					635:643	Bacteroides fragilis PS A1 fragments	608:643	Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides	608:681	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	1	67	theme	exceptional	145:155	arg1	polysaccharides					118:132	Zwitterionic polysaccharides	105:132	Zwitterionic polysaccharides (ZPSs)	105:139	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	1	67	theme	exceptional	145:155	arg1	carbohydrates					157:169	exceptional carbohydrates	145:169	exceptional carbohydrates	145:169	Zwitterionic polysaccharides (ZPSs) are exceptional carbohydrates, carrying both positively charged amine groups and negatively charged carboxylates, that can be loaded onto MHC-II molecules to activate T cells.
37310804	7	68	theme	oligosaccharides	1624:1639	arg1	action					1601:1606	action	1601:1606	action of these unique oligosaccharides at the atomic level	1601:1659	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	0	69	theme	Polysaccharide	76:89	arg1	Fragments					94:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments	42:102	Total Synthesis and Structural Studies of Zwitterionic Bacteroides fragilis Polysaccharide A1 Fragments.
37310804	7	70	theme	interaction	1536:1546	arg1	studies					1548:1554	detailed interaction studies	1527:1554	detailed interaction studies with binding proteins	1527:1576	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	3	71	theme	Bacteroides	608:618	arg1	fragments					635:643	Bacteroides fragilis PS A1 fragments	608:643	Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides	608:681	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	3	72	dep	Bacteroides	608:618	arg1	fragilis					620:627	fragilis	620:627	fragilis	620:627	We here present the first total synthesis of Bacteroides fragilis PS A1 fragments encompassing up to 12 monosaccharides, representing three repeating units.
37310804	7	73	theme	secondary	1495:1503	arg1	structure					1505:1513	their secondary structure	1489:1513	their secondary structure	1489:1513	The availability of the fragments and the insight into their secondary structure will enable detailed interaction studies with binding proteins to unravel the mode of action of these unique oligosaccharides at the atomic level.
37310804	2	74	theme	ZPS	500:502	arg1	fragments					504:512	well-defined ZPS fragments	487:512	well-defined ZPS fragments	487:512	It remains enigmatic, however, how these polysaccharides bind to these receptors, and to understand the structural features responsible for this "peptide-like" behavior, well-defined ZPS fragments are required in sufficient quantity and quality.
37310804	5	75	theme	orthogonal	1130:1139	arg1	handle					1166:1171	an orthogonal alkyne functionalization handle	1127:1171	an orthogonal alkyne functionalization handle	1127:1171	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37310804	5	76	theme	protecting	1021:1030	arg1	strategy					1038:1045	a unique protecting group strategy	1012:1045	a unique protecting group strategy	1012:1045	Our stereoselective synthesis route is further characterized by a unique protecting group strategy, built on base-labile protecting groups, which has allowed the incorporation of an orthogonal alkyne functionalization handle.
37292769	6	0	theme	glycan	861:866	arg1	moiety					868:873	the glycan moiety	857:873	the glycan moiety	857:873	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	3	1	theme	biological	551:560	arg1	systems					562:568	biological systems	551:568	biological systems	551:568	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	9	2	theme	fragments	1509:1517	arg1	occurrence					1487:1496	the occurrence	1483:1496	the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell	1483:1620	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	8	3	theme	terminal	1248:1255	arg1	GlcNAc					1257:1262	the reducing terminal GlcNAc	1235:1262	the reducing terminal GlcNAc	1235:1262	These standards were isotopically labelled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by oligomannose core moiety and fragments generated from outer antennary structures.
37292769	2	4	gly	glycopeptide	267:278	arg2	glycopeptide					267:278	isobaric glycopeptide structures	258:289	isobaric glycopeptide structures	258:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	7	5	theme	isotope-labelled	1148:1163	arg1	standards					1178:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	Here, we investigated fragmentation specificity using synthetic stable isotope-labelled glycopeptide standards.
37292769	2	6	theme	isobaric	258:265	arg1	structures					280:289	isobaric glycopeptide structures	258:289	isobaric glycopeptide structures	258:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	8	7	theme	core	1328:1331	arg1	moiety					1333:1338	oligomannose core moiety	1315:1338	oligomannose core moiety	1315:1338	These standards were isotopically labelled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by oligomannose core moiety and fragments generated from outer antennary structures.
37292769	7	8	theme	synthetic	1131:1139	arg1	standards					1178:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	Here, we investigated fragmentation specificity using synthetic stable isotope-labelled glycopeptide standards.
37292769	9	9	theme	glyco	1541:1545	arg1	rearrangement					1552:1564	glyco unit rearrangement	1541:1564	glyco unit rearrangement	1541:1564	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	10	10	theme	minimal	1669:1675	arg1	threshold					1687:1695	a minimal intensity threshold	1667:1695	a minimal intensity threshold for these fragments	1667:1715	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent the misidentification of structure-specific fragments in glycoproteomics analysis.
37292769	11	11	theme	glycoproteomics	1899:1913	arg1	measurements					1915:1926	more accurate and reliable glycoproteomics measurements	1872:1926	more accurate and reliable glycoproteomics measurements	1872:1926	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	9	12	theme	mannose	1569:1575	arg1	fragmentation					1582:1594	mannose core fragmentation	1569:1594	mannose core fragmentation	1569:1594	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	6	13	theme	specific	978:985	arg1	moieties					994:1001	specific glycan moieties	978:1001	specific glycan moieties	978:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	8	14	theme	outer	1369:1373	arg1	structures					1385:1394	outer antennary structures	1369:1394	outer antennary structures	1369:1394	These standards were isotopically labelled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by oligomannose core moiety and fragments generated from outer antennary structures.
37292769	4	15	theme	structural	662:671	arg1	elucidation					673:683	structural elucidation	662:683	structural elucidation	662:683	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	11	16	from	quest	1862:1866	arg1	forward					1847:1853	forward	1847:1853	forward	1847:1853	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	1	17	theme	crucial	113:119	arg1	insights					121:128	crucial insights	113:128	crucial insights into the intricate world of glycosylation analysis	113:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37292769	5	18	theme	different	778:786	arg1	stabilities					788:798	different stabilities	778:798	different stabilities	778:798	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37292769	9	19	dep	false	1439:1443	arg1	positive					1445:1452	positive	1445:1452	positive	1445:1452	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	4	20	theme	qualitative	701:711	arg1	purposes					713:720	qualitative purposes	701:720	qualitative purposes	701:720	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	1	21	theme	intricate	139:147	arg1	world					149:153	the intricate world	135:153	the intricate world of glycosylation analysis	135:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37292769	5	22	theme	glycan	745:750	arg1	units					752:756	glycan units	745:756	glycan units	745:756	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37292769	2	23	theme	structures	280:289	arg1	analysis					246:253	the qualitative and quantitative analysis	213:253	the qualitative and quantitative analysis of isobaric glycopeptide structures	213:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	10	24	theme	structure-specific	1753:1770	arg1	fragments					1772:1780	structure-specific fragments	1753:1780	structure-specific fragments	1753:1780	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent the misidentification of structure-specific fragments in glycoproteomics analysis.
37292769	0	25	from	ions	17:20	arg1	analysis					69:76	site-specific glycoproteomics analysis	39:76	site-specific glycoproteomics analysis	39:76	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	0	25	from	ions	17:20	arg1	structure					25:33	structure	25:33	structure	25:33	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	0	26	theme	"	6:6	arg1	ions					17:20	Ghost" fragment ions	1:20	Ghost" fragment ions in structure and site-specific glycoproteomics analysis	1:76	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	6	27	theme	oxonium	911:917	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	6	27	theme	oxonium	911:917	arg1	ions					919:922	oxonium ions	911:922	oxonium ions	911:922	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	3	28	theme	complex	406:412	arg1	structures					421:430	these complex glycan structures	400:430	these complex glycan structures	400:430	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	5	29	theme	fragmentation	814:826	arg1	conditions					828:837	CID/HCD fragmentation conditions	806:837	CID/HCD fragmentation conditions	806:837	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37292769	10	30	from	misidentification	1732:1748	arg1	analysis					1801:1808	glycoproteomics analysis	1785:1808	glycoproteomics analysis	1785:1808	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent the misidentification of structure-specific fragments in glycoproteomics analysis.
37292769	0	31	theme	site-specific	39:51	arg1	analysis					69:76	site-specific glycoproteomics analysis	39:76	site-specific glycoproteomics analysis	39:76	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	6	32	theme	molecular	888:896	arg1	weight					898:903	low molecular weight	884:903	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	11	33	theme	forward	1847:1853	arg1	step					1842:1845	a crucial step	1832:1845	a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements	1832:1926	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	2	34	theme	hurdles	324:330	arg1	hurdles					324:330	the most daunting hurdles	306:330	the most daunting hurdles in the field of glycoproteomics	306:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	2	34	theme	hurdles	324:330	arg1	one					299:301	one	299:301	one	299:301	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	3	35	theme	glycoproteins	534:546	arg1	role					526:529	the role	522:529	the role of glycoproteins in biological systems	522:568	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	11	36	theme	crucial	1834:1840	arg1	step					1842:1845	a crucial step	1832:1845	a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements	1832:1926	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	6	37	theme	structure-specific	945:962	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	6	37	theme	structure-specific	945:962	arg1	signature					964:972	a structure-specific signature	943:972	a structure-specific signature for specific glycan moieties	943:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	12	38	theme	Graphical	1929:1937	arg1	abstract					1939:1946	Graphical abstract	1929:1946	Graphical abstract	1929:1946	Graphical abstract
37292769	4	39	theme	collision	618:626	arg1	CE					636:637	CE	636:637	CE	636:637	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	4	39	theme	collision	618:626	arg1	energy					628:633	collision energy	618:633	collision energy (CE)	618:638	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	2	40	from	hurdles	324:330	arg1	field					339:343	the field	335:343	the field of glycoproteomics	335:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	4	41	theme	recent	577:582	arg1	publications					584:595	A few recent publications	571:595	A few recent publications	571:595	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	7	42	theme	glycopeptide	1165:1176	arg1	standards					1178:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	Here, we investigated fragmentation specificity using synthetic stable isotope-labelled glycopeptide standards.
37292769	9	43	theme	"	1507:1507	arg1	fragments					1509:1517	"Ghost" fragments	1501:1517	"Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell	1501:1620	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	3	44	gly	glycoproteins	534:546	arg1	glycoproteins					534:546	glycoproteins	534:546	glycoproteins	534:546	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	7	45	theme	stable	1141:1146	arg1	standards					1178:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	Here, we investigated fragmentation specificity using synthetic stable isotope-labelled glycopeptide standards.
37292769	3	46	from	role	526:529	arg1	systems					562:568	biological systems	551:568	biological systems	551:568	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	2	47	theme	glycopeptide	267:278	arg1	structures					280:289	isobaric glycopeptide structures	258:289	isobaric glycopeptide structures	258:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	1	48	theme	glycosylation	158:170	arg1	analysis					172:179	glycosylation analysis	158:179	glycosylation analysis	158:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37292769	8	49	theme	reducing	1239:1246	arg1	GlcNAc					1257:1262	the reducing terminal GlcNAc	1235:1262	the reducing terminal GlcNAc	1235:1262	These standards were isotopically labelled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by oligomannose core moiety and fragments generated from outer antennary structures.
37292769	9	50	theme	single	1534:1539	arg1	rearrangement					1552:1564	glyco unit rearrangement	1541:1564	glyco unit rearrangement	1541:1564	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	8	51	theme	oligomannose	1315:1326	arg1	moiety					1333:1338	oligomannose core moiety	1315:1338	oligomannose core moiety	1315:1338	These standards were isotopically labelled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by oligomannose core moiety and fragments generated from outer antennary structures.
37292769	10	52	theme	intensity	1677:1685	arg1	threshold					1687:1695	a minimal intensity threshold	1667:1695	a minimal intensity threshold for these fragments	1667:1715	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent the misidentification of structure-specific fragments in glycoproteomics analysis.
37292769	7	53	theme	fragmentation	1099:1111	arg1	specificity					1113:1123	fragmentation specificity	1099:1123	fragmentation specificity	1099:1123	Here, we investigated fragmentation specificity using synthetic stable isotope-labelled glycopeptide standards.
37292769	9	54	theme	unit	1547:1550	arg1	rearrangement					1552:1564	glyco unit rearrangement	1541:1564	glyco unit rearrangement	1541:1564	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	5	55	theme	Different	723:731	arg1	linkages					733:740	Different linkages	723:740	Different linkages of glycan units	723:756	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37292769	2	56	theme	qualitative	217:227	arg1	analysis					246:253	the qualitative and quantitative analysis	213:253	the qualitative and quantitative analysis of isobaric glycopeptide structures	213:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	1	57	theme	analysis	172:179	arg1	world					149:153	the intricate world	135:153	the intricate world of glycosylation analysis	135:179	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37292769	6	58	theme	glycan	987:992	arg1	moieties					994:1001	specific glycan moieties	978:1001	specific glycan moieties	978:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	7	59	gly	glycopeptide	1165:1176	arg2	glycopeptide					1165:1176	synthetic stable isotope-labelled glycopeptide standards	1131:1186	synthetic stable isotope-labelled glycopeptide standards	1131:1186	Here, we investigated fragmentation specificity using synthetic stable isotope-labelled glycopeptide standards.
37292769	9	60	theme	core	1577:1580	arg1	fragmentation					1582:1594	mannose core fragmentation	1569:1594	mannose core fragmentation	1569:1594	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	8	61	theme	antennary	1375:1383	arg1	structures					1385:1394	outer antennary structures	1369:1394	outer antennary structures	1369:1394	These standards were isotopically labelled at the reducing terminal GlcNAc, which allowed us to resolve fragments produced by oligomannose core moiety and fragments generated from outer antennary structures.
37292769	0	62	theme	glycoproteomics	53:67	arg1	analysis					69:76	site-specific glycoproteomics analysis	39:76	site-specific glycoproteomics analysis	39:76	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	2	63	theme	quantitative	233:244	arg1	analysis					246:253	the qualitative and quantitative analysis	213:253	the qualitative and quantitative analysis of isobaric glycopeptide structures	213:289	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	9	64	theme	collision	1607:1615	arg1	cell					1617:1620	the collision cell	1603:1620	the collision cell	1603:1620	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	6	65	theme	fragments	1034:1042	arg1	specificity					1013:1023	specificity	1013:1023	specificity of these fragments	1013:1042	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	11	66	from	forward	1847:1853	arg1	quest					1862:1866	the quest	1858:1866	the quest for more accurate and reliable glycoproteomics measurements	1858:1926	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	11	67	theme	reliable	1890:1897	arg1	measurements					1915:1926	more accurate and reliable glycoproteomics measurements	1872:1926	more accurate and reliable glycoproteomics measurements	1872:1926	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	11	68	theme	accurate	1877:1884	arg1	measurements					1915:1926	more accurate and reliable glycoproteomics measurements	1872:1926	more accurate and reliable glycoproteomics measurements	1872:1926	Our findings provide a crucial step forward in the quest for more accurate and reliable glycoproteomics measurements.
37292769	5	69	theme	units	752:756	arg1	linkages					733:740	Different linkages	723:740	Different linkages of glycan units	723:756	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37292769	3	70	theme	significant	440:450	arg1	challenge					452:460	a significant challenge	438:460	a significant challenge	438:460	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	0	71	theme	Ghost	1:5	arg1	ions					17:20	Ghost" fragment ions	1:20	Ghost" fragment ions in structure and site-specific glycoproteomics analysis	1:76	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	1	72	theme	Mass	79:82	arg1	spectrometry					84:95	Mass spectrometry	79:95	Mass spectrometry (MS)	79:100	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37292769	1	72	theme	Mass	79:82	arg1	MS					98:99	MS	98:99	MS	98:99	Mass spectrometry (MS) can unlock crucial insights into the intricate world of glycosylation analysis.
37292769	0	73	theme	fragment	8:15	arg1	ions					17:20	Ghost" fragment ions	1:20	Ghost" fragment ions in structure and site-specific glycoproteomics analysis	1:76	"Ghost" fragment ions in structure and site-specific glycoproteomics analysis.
37292769	4	74	theme	few	573:575	arg1	publications					584:595	A few recent publications	571:595	A few recent publications	571:595	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	10	75	theme	glycoproteomics	1785:1799	arg1	analysis					1801:1808	glycoproteomics analysis	1785:1808	glycoproteomics analysis	1785:1808	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent the misidentification of structure-specific fragments in glycoproteomics analysis.
37292769	5	76	theme	CID/HCD	806:812	arg1	conditions					828:837	CID/HCD fragmentation conditions	806:837	CID/HCD fragmentation conditions	806:837	Different linkages of glycan units usually demonstrate different stabilities under CID/HCD fragmentation conditions.
37292769	9	77	theme	false	1439:1443	arg1	assignments					1464:1474	false positive structure assignments	1439:1474	false positive structure assignments	1439:1474	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	3	78	theme	glycan	414:419	arg1	structures					421:430	these complex glycan structures	400:430	these complex glycan structures	400:430	The ability to distinguish between these complex glycan structures poses a significant challenge, hindering our ability to accurately measure and understand the role of glycoproteins in biological systems.
37292769	10	79	theme	fragments	1772:1780	arg1	misidentification					1732:1748	the misidentification	1728:1748	the misidentification of structure-specific fragments in glycoproteomics analysis	1728:1808	To mitigate this issue, we have established a minimal intensity threshold for these fragments to prevent the misidentification of structure-specific fragments in glycoproteomics analysis.
37292769	9	80	theme	structure	1454:1462	arg1	assignments					1464:1474	false positive structure assignments	1439:1474	false positive structure assignments	1439:1474	Our research identified the potential for false positive structure assignments due to the occurrence of "Ghost" fragments resulting from single glyco unit rearrangement or mannose core fragmentation within the collision cell.
37292769	6	81	theme	weight	898:903	arg1	ions					905:908	low molecular weight ions	884:908	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	6	81	theme	weight	898:903	arg1	signature					964:972	a structure-specific signature	943:972	a structure-specific signature for specific glycan moieties	943:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	6	81	theme	weight	898:903	arg1	ions					919:922	oxonium ions	911:922	oxonium ions	911:922	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	2	82	theme	immense	194:200	arg1	potential					202:210	its immense potential	190:210	its immense potential	190:210	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	6	83	theme	low	884:886	arg1	weight					898:903	low molecular weight	884:903	low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties	884:1001	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	2	84	theme	daunting	315:322	arg1	hurdles					324:330	the most daunting hurdles	306:330	the most daunting hurdles in the field of glycoproteomics	306:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
37292769	6	85	theme	moiety	868:873	arg1	Fragmentation					840:852	Fragmentation	840:852	Fragmentation of the glycan moiety	840:873	Fragmentation of the glycan moiety produces low molecular weight ions (oxonium ions) that can serve as a structure-specific signature for specific glycan moieties, however, specificity of these fragments has never been examined closely.
37292769	4	86	theme	energy	628:633	arg1	use					611:613	the use	607:613	the use of collision energy (CE) modulation to improve structural elucidation	607:683	A few recent publications described the use of collision energy (CE) modulation to improve structural elucidation, especially for qualitative purposes.
37292769	2	87	theme	glycoproteomics	348:362	arg1	field					339:343	the field	335:343	the field of glycoproteomics	335:362	Despite its immense potential, the qualitative and quantitative analysis of isobaric glycopeptide structures remains one of the most daunting hurdles in the field of glycoproteomics.
36912209	0	0	theme	gut	81:83	arg1	microbiota					85:94	the human gut microbiota	71:94	the human gut microbiota	71:94	Carbohydrate esterases involved in deacetylation of food components by the human gut microbiota.
36912209	8	1	theme	substrate	1594:1602	arg1	specificity					1604:1614	more broad substrate specificity	1583:1614	more broad substrate specificity	1583:1614	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	9	2	theme	acetylesterases	1691:1705	arg1	regioselectivity					1671:1686	regioselectivity	1671:1686	regioselectivity	1671:1686	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	9	2	theme	acetylesterases	1691:1705	arg1	functions					1657:1665	functions	1657:1665	functions	1657:1665	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	9	3	theme	human	1811:1815	arg1	gut					1817:1819	the human gut	1807:1819	the human gut	1807:1819	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	1	4	theme	food	167:170	arg1	stuffs					172:177	food stuffs	167:177	food stuffs as well	167:185	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	0	5	theme	human	75:79	arg1	microbiota					85:94	the human gut microbiota	71:94	the human gut microbiota	71:94	Carbohydrate esterases involved in deacetylation of food components by the human gut microbiota.
36912209	7	6	contain	have	1305:1308	arg2	mechanism					1329:1337	a common acid-base mechanism	1310:1337	a common acid-base mechanism	1310:1337	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	7	6	contain	have	1305:1308	arg1	acetylesterases					1289:1303	these acetylesterases	1283:1303	these acetylesterases	1283:1303	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	7	6	contain	have	1305:1308	arg1	most					1275:1278	most	1275:1278	most	1275:1278	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	4	7	theme	advanced	739:746	arg1	machinery					758:766	a more advanced degrading machinery	732:766	a more advanced degrading machinery for microbes	732:779	Of particular note, O-acetylations increase the overall complexity of a polymer, thus requiring a more advanced degrading machinery for microbes to utilize it.
36912209	9	8	theme	developing	1834:1843	arg1	applications					1845:1856	developing applications	1834:1856	developing applications of these enzymes	1834:1873	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	8	9	theme	carbohydrate	1539:1550	arg1	carbohydrate					1539:1550	the carbohydrate	1535:1550	the carbohydrate	1535:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	8	9	theme	carbohydrate	1539:1550	arg1	residue					1524:1530	the glycosyl residue	1511:1530	the glycosyl residue of the carbohydrate	1511:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	1	10	from	stuffs	172:177	arg1	widespread					153:162	widespread	153:162	widespread	153:162	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	3	11	theme	polysaccharide	608:621	arg1	degradation					623:633	polysaccharide degradation	608:633	polysaccharide degradation	608:633	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	8	12	theme	other	1559:1563	arg1	members					1565:1571	other members	1559:1571	other members that have more broad substrate specificity	1559:1614	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	5	13	theme	food	1020:1023	arg1	preparations					1038:1049	food and beverage preparations	1020:1049	food and beverage preparations	1020:1049	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	1	14	from	widespread	153:162	arg1	stuffs					172:177	food stuffs	167:177	food stuffs as well	167:185	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	4	15	theme	degrading	748:756	arg1	machinery					758:766	a more advanced degrading machinery	732:766	a more advanced degrading machinery for microbes	732:779	Of particular note, O-acetylations increase the overall complexity of a polymer, thus requiring a more advanced degrading machinery for microbes to utilize it.
36912209	4	16	theme	particular	639:648	arg1	note					650:653	particular note	639:653	particular note	639:653	Of particular note, O-acetylations increase the overall complexity of a polymer, thus requiring a more advanced degrading machinery for microbes to utilize it.
36912209	5	17	theme	microbial	975:983	arg1	origin					985:990	microbial origin	975:990	microbial origin	975:990	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	9	18	theme	fundamental	1727:1737	arg1	understanding					1751:1763	fundamental mechanistic understanding	1727:1763	fundamental mechanistic understanding	1727:1763	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	4	19	theme	overall	684:690	arg1	complexity					692:701	the overall complexity	680:701	the overall complexity of a polymer	680:714	Of particular note, O-acetylations increase the overall complexity of a polymer, thus requiring a more advanced degrading machinery for microbes to utilize it.
36912209	3	20	theme	glycosyl	568:575	arg1	hydrolases					577:586	glycosyl hydrolases	568:586	glycosyl hydrolases	568:586	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	5	21	theme	food	941:944	arg1	stabilizers					960:970	stabilizers	960:970	stabilizers of microbial origin	960:990	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	21	theme	food	941:944	arg1	ingredients					947:957	ingredients	947:957	ingredients	947:957	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	21	theme	food	941:944	arg1	acetylesterases					822:836	acetylesterases	822:836	acetylesterases from the gut microbiota that deacetylate various food polysaccharides	822:906	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	21	theme	food	941:944	arg1	components					927:936	natural components	919:936	natural components of food	919:944	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	9	22	theme	mechanistic	1739:1749	arg1	understanding					1751:1763	fundamental mechanistic understanding	1727:1763	fundamental mechanistic understanding	1727:1763	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	2	23	theme	gut	278:280	arg1	environment					282:292	the gut environment	274:292	the gut environment	274:292	These modifications meet the gut environment and are removed from their carbohydrate substrates by the resident microbiota.
36912209	4	24	theme	polymer	708:714	arg1	complexity					692:701	the overall complexity	680:701	the overall complexity of a polymer	680:714	Of particular note, O-acetylations increase the overall complexity of a polymer, thus requiring a more advanced degrading machinery for microbes to utilize it.
36912209	9	25	theme	enzymes	1867:1873	arg1	applications					1845:1856	developing applications	1834:1856	developing applications of these enzymes	1834:1873	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	2	26	theme	carbohydrate	321:332	arg1	substrates					334:343	their carbohydrate substrates	315:343	their carbohydrate substrates	315:343	These modifications meet the gut environment and are removed from their carbohydrate substrates by the resident microbiota.
36912209	3	27	theme	polysaccharides	447:461	arg1	properties					480:489	polysaccharides physico-chemical properties	447:489	polysaccharides physico-chemical properties such as viscosity	447:507	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	3	27	theme	polysaccharides	447:461	arg1	viscosity					499:507	viscosity	499:507	viscosity	499:507	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	0	28	theme	Carbohydrate	0:11	arg1	esterases					13:21	Carbohydrate esterases	0:21	Carbohydrate esterases	0:21	Carbohydrate esterases involved in deacetylation of food components by the human gut microbiota.
36912209	9	29	theme	Current	1617:1623	arg1	research					1625:1632	Current research	1617:1632	Current research aimed at unveiling the functions and regioselectivity of acetylesterases	1617:1705	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	6	30	from	families	1106:1113	arg1	database					1127:1134	the CAZy database	1118:1134	the CAZy database	1118:1134	These enzymes include members belonging to at least 8 families in the CAZy database, as well as a large number of biochemically characterized esterases that have not been classified yet.
36912209	6	31	theme	esterases	1194:1202	arg1	members					1074:1080	members	1074:1080	members belonging to at least 8 families in the CAZy database	1074:1134	These enzymes include members belonging to at least 8 families in the CAZy database, as well as a large number of biochemically characterized esterases that have not been classified yet.
36912209	6	31	theme	esterases	1194:1202	arg1	number					1156:1161	a large number	1148:1161	a large number of biochemically characterized esterases that have not been classified yet	1148:1236	These enzymes include members belonging to at least 8 families in the CAZy database, as well as a large number of biochemically characterized esterases that have not been classified yet.
36912209	8	32	from	position	1479:1486	arg1	carbohydrate					1539:1550	the carbohydrate	1535:1550	the carbohydrate	1535:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	8	32	from	position	1479:1486	arg1	residue					1524:1530	the glycosyl residue	1511:1530	the glycosyl residue of the carbohydrate	1511:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	3	33	theme	physico-chemical	463:478	arg1	properties					480:489	polysaccharides physico-chemical properties	447:489	polysaccharides physico-chemical properties such as viscosity	447:507	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	3	33	theme	physico-chemical	463:478	arg1	viscosity					499:507	viscosity	499:507	viscosity	499:507	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	5	34	theme	food	887:890	arg1	polysaccharides					892:906	various food polysaccharides	879:906	various food polysaccharides	879:906	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	35	theme	various	879:885	arg1	polysaccharides					892:906	various food polysaccharides	879:906	various food polysaccharides	879:906	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	7	36	dep	structural	1257:1266	arg1	folds					1268:1272	folds	1268:1272	folds	1268:1272	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	1	37	theme	Non-carbohydrate	97:112	arg1	acetylations					136:147	acetylations	136:147	acetylations	136:147	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	1	37	theme	Non-carbohydrate	97:112	arg1	modifications					114:126	Non-carbohydrate modifications	97:126	Non-carbohydrate modifications such as acetylations	97:147	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	3	38	theme	abundant	388:395	arg1	modifications					397:409	the most abundant modifications	379:409	the most abundant modifications	379:409	Among the most abundant modifications are O-acetylations, contributing to polysaccharides physico-chemical properties such as viscosity and gelling ability, as well as reducing accessibility for glycosyl hydrolases, and thus hindering polysaccharide degradation.
36912209	2	39	attach	removed	302:308	arg2	modifications					255:267	These modifications	249:267	These modifications	249:267	These modifications meet the gut environment and are removed from their carbohydrate substrates by the resident microbiota.
36912209	2	39	attach	removed	302:308	arg1	substrates					334:343	their carbohydrate substrates	315:343	their carbohydrate substrates	315:343	These modifications meet the gut environment and are removed from their carbohydrate substrates by the resident microbiota.
36912209	9	40	theme	dietary	1772:1778	arg1	components					1780:1789	dietary components	1772:1789	dietary components	1772:1789	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	5	41	theme	microbes	1007:1014	arg1	part					999:1002	part	999:1002	part of microbes for food and beverage preparations	999:1049	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	1	42	theme	important	200:208	arg1	roles					210:214	important roles	200:214	important roles	200:214	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	9	43	theme	industrial	1896:1905	arg1	products					1907:1914	novel industrial products	1890:1914	novel industrial products	1890:1914	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	8	44	theme	broad	1588:1592	arg1	specificity					1604:1614	more broad substrate specificity	1583:1614	more broad substrate specificity	1583:1614	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	7	45	theme	hydrolase	1362:1370	arg1	superfamily					1372:1382	the SGNH hydrolase superfamily	1353:1382	the SGNH hydrolase superfamily	1353:1382	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	9	46	dep	functions	1657:1665	arg1	the					1653:1655	the	1653:1655	the	1653:1655	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	5	47	theme	gut	847:849	arg1	microbiota					851:860	the gut microbiota	843:860	the gut microbiota that deacetylate various food polysaccharides	843:906	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	8	48	theme	group	1502:1506	arg1	position					1479:1486	the position	1475:1486	the position of the acetyl group on the glycosyl residue of the carbohydrate	1475:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	5	49	theme	natural	919:925	arg1	stabilizers					960:970	stabilizers	960:970	stabilizers of microbial origin	960:990	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	49	theme	natural	919:925	arg1	ingredients					947:957	ingredients	947:957	ingredients	947:957	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	49	theme	natural	919:925	arg1	acetylesterases					822:836	acetylesterases	822:836	acetylesterases from the gut microbiota that deacetylate various food polysaccharides	822:906	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	49	theme	natural	919:925	arg1	components					927:936	natural components	919:936	natural components of food	919:944	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	0	50	theme	components	57:66	arg1	deacetylation					35:47	deacetylation	35:47	deacetylation of food components by the human gut microbiota	35:94	Carbohydrate esterases involved in deacetylation of food components by the human gut microbiota.
36912209	8	51	theme	acetyl	1495:1500	arg1	group					1502:1506	the acetyl group	1491:1506	the acetyl group	1491:1506	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	8	52	theme	acetylesterases	1410:1424	arg1	examples					1398:1405	examples	1398:1405	examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate	1398:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	2	53	theme	resident	352:359	arg1	microbiota					361:370	the resident microbiota	348:370	the resident microbiota	348:370	These modifications meet the gut environment and are removed from their carbohydrate substrates by the resident microbiota.
36912209	0	54	theme	food	52:55	arg1	components					57:66	food components	52:66	food components	52:66	Carbohydrate esterases involved in deacetylation of food components by the human gut microbiota.
36912209	7	55	theme	acid-base	1319:1327	arg1	mechanism					1329:1337	a common acid-base mechanism	1310:1337	a common acid-base mechanism	1310:1337	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	5	56	theme	origin	985:990	arg1	stabilizers					960:970	stabilizers	960:970	stabilizers of microbial origin	960:990	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	56	theme	origin	985:990	arg1	components					927:936	natural components	919:936	natural components of food	919:944	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	6	57	theme	large	1150:1154	arg1	number					1156:1161	a large number	1148:1161	a large number of biochemically characterized esterases that have not been classified yet	1148:1236	These enzymes include members belonging to at least 8 families in the CAZy database, as well as a large number of biochemically characterized esterases that have not been classified yet.
36912209	6	58	theme	characterized	1180:1192	arg1	esterases					1194:1202	biochemically characterized esterases	1166:1202	biochemically characterized esterases that have not been classified yet	1166:1236	These enzymes include members belonging to at least 8 families in the CAZy database, as well as a large number of biochemically characterized esterases that have not been classified yet.
36912209	1	59	theme	diverse	219:225	arg1	processes					238:246	diverse biological processes	219:246	diverse biological processes	219:246	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	5	60	theme	beverage	1029:1036	arg1	preparations					1038:1049	food and beverage preparations	1020:1049	food and beverage preparations	1020:1049	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	7	61	theme	common	1312:1317	arg1	mechanism					1329:1337	a common acid-base mechanism	1310:1337	a common acid-base mechanism	1310:1337	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	7	62	theme	SGNH	1357:1360	arg1	superfamily					1372:1382	the SGNH hydrolase superfamily	1353:1382	the SGNH hydrolase superfamily	1353:1382	Despite different structural folds, most of these acetylesterases have a common acid-base mechanism and belong to the SGNH hydrolase superfamily.
36912209	1	63	theme	biological	227:236	arg1	processes					238:246	diverse biological processes	219:246	diverse biological processes	219:246	Non-carbohydrate modifications such as acetylations are widespread in food stuffs as well as they play important roles in diverse biological processes.
36912209	8	64	theme	glycosyl	1515:1522	arg1	carbohydrate					1539:1550	the carbohydrate	1535:1550	the carbohydrate	1535:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	8	64	theme	glycosyl	1515:1522	arg1	residue					1524:1530	the glycosyl residue	1511:1530	the glycosyl residue of the carbohydrate	1511:1550	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	9	65	used	utilized	1795:1802	arg2	components					1780:1789	dietary components	1772:1789	dietary components	1772:1789	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	6	66	theme	CAZy	1122:1125	arg1	database					1127:1134	the CAZy database	1118:1134	the CAZy database	1118:1134	These enzymes include members belonging to at least 8 families in the CAZy database, as well as a large number of biochemically characterized esterases that have not been classified yet.
36912209	5	67	from	microbiota	851:860	arg1	acetylesterases					822:836	acetylesterases	822:836	acetylesterases from the gut microbiota that deacetylate various food polysaccharides	822:906	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	5	67	from	microbiota	851:860	arg1	components					927:936	natural components	919:936	natural components of food	919:944	This minireview describes acetylesterases from the gut microbiota that deacetylate various food polysaccharides, either as natural components of food, ingredients, stabilizers of microbial origin, or as part of microbes for food and beverage preparations.
36912209	9	68	theme	novel	1890:1894	arg1	products					1907:1914	novel industrial products	1890:1914	novel industrial products	1890:1914	Current research aimed at unveiling the functions and regioselectivity of acetylesterases will help providing fundamental mechanistic understanding on how dietary components are utilized in the human gut and will aid developing applications of these enzymes to manufacture novel industrial products.
36912209	8	69	contain	have	1578:1581	arg1	members					1565:1571	other members	1559:1571	other members that have more broad substrate specificity	1559:1614	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36912209	8	69	contain	have	1578:1581	arg2	specificity					1604:1614	more broad substrate specificity	1583:1614	more broad substrate specificity	1583:1614	We highlight examples of acetylesterases that are highly specific to one substrate and to the position of the acetyl group on the glycosyl residue of the carbohydrate, while other members that have more broad substrate specificity.
36131913	4	0	theme	polymorphism	860:871	arg1	relationships					828:840	structure-function relationships	809:840	structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII	809:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	5	1	dep	composition	1029:1039	arg1	both					1041:1044	both	1041:1044	both	1041:1044	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	4	2	theme	Mm	876:877	arg1	FcγRIII					879:885	Mm FcγRIII	876:885	Mm FcγRIII	876:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	6	3	theme	affinity	1148:1155	arg1	variant					1157:1163	the higher affinity variant	1137:1163	the higher affinity variant	1137:1163	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	7	4	theme	glycan-glycan	1337:1349	arg1	interactions					1351:1362	glycan-glycan interactions	1337:1362	glycan-glycan interactions	1337:1362	Instead, this side chain appears to modulate glycan-glycan interactions at the Fc/FcγRIII interface.
36131913	0	5	theme	Rhesus	135:140	arg1	macaques					142:149	Rhesus macaques	135:149	Rhesus macaques	135:149	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	5	6	theme	the	1060:1062	arg1	receptor					1064:1071	the Fc and the receptor	1049:1071	receptor	1064:1071	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	8	7	theme	glycan	1417:1422	arg1	composition					1424:1434	glycan composition	1417:1434	glycan composition	1417:1434	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	1	8	theme	vaccine	241:247	arg1	efficacy					249:256	vaccine efficacy	241:256	vaccine efficacy	241:256	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	9	9	theme	better	1685:1690	arg1	interpretation					1692:1705	the better interpretation	1681:1705	the better interpretation of nonhuman primate studies	1681:1733	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	6	10	theme	binding	1273:1279	arg1	interface					1281:1289	the binding interface	1269:1289	the binding interface	1269:1289	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	4	11	from	relationships	828:840	arg1	FcγRIII					879:885	Mm FcγRIII	876:885	Mm FcγRIII	876:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	2	12	theme	Fc	589:590	arg1	functions					601:609	Fc effector functions	589:609	Fc effector functions	589:609	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	0	13	from	function	123:130	arg1	macaques					142:149	Rhesus macaques	135:149	Rhesus macaques	135:149	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	5	14	theme	Fc	1053:1054	arg1	receptor					1064:1071	the Fc and the receptor	1049:1071	receptor	1064:1071	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	5	15	theme	variants	939:946	arg1	affinity					915:922	the affinity	911:922	the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses	911:991	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	7	16	theme	side	1306:1309	arg1	chain					1311:1315	this side chain	1301:1315	this side chain	1301:1315	Instead, this side chain appears to modulate glycan-glycan interactions at the Fc/FcγRIII interface.
36131913	1	17	theme	effector	164:171	arg1	functions					173:181	Fc mediated effector functions	152:181	Fc mediated effector functions of antibodies	152:195	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	9	18	theme	primate	1719:1725	arg1	studies					1727:1733	nonhuman primate studies	1710:1733	nonhuman primate studies	1710:1733	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	8	19	dep	becomes	1588:1594	arg1	such					1497:1500	such	1497:1500	such	1497:1500	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	0	20	theme	CD16-dependent	99:112	arg1	function					123:130	CD16-dependent effector function	99:130	CD16-dependent effector function in Rhesus macaques	99:149	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	3	21	dep	Ile158	764:769	arg1	variants					782:789	variants	782:789	variants	782:789	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	5	22	theme	macaque	970:976	arg1	subclasses					982:991	the macaque IgG subclasses	966:991	the macaque IgG subclasses	966:991	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	4	23	from	polymorphism	860:871	arg1	FcγRIII					879:885	Mm FcγRIII	876:885	Mm FcγRIII	876:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	3	24	with	FcγRIIIa	750:757	arg1	Val158					775:780	Val158	775:780	Val158	775:780	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	24	with	FcγRIIIa	750:757	arg1	Ile158					764:769	Ile158	764:769	Ile158	764:769	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	5	25	theme	Mm	951:952	arg1	FcγRIII					954:960	Mm FcγRIII	951:960	Mm FcγRIII	951:960	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	9	26	theme	human	1771:1775	arg1	cells					1786:1790	human effector cells	1771:1790	human effector cells carrying different FcγRIIIa alleles	1771:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	8	27	theme	oligomannose	1512:1523	arg1	glycans					1530:1536	oligomannose type glycans	1512:1536	oligomannose type glycans	1512:1536	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	0	28	theme	interspecies	23:34	arg1	differences					36:46	human-macaque interspecies differences	9:46	human-macaque interspecies differences in Fc-effector functions	9:71	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	2	29	theme	immune	495:500	arg1	system					502:507	their adaptive immune system	480:507	their adaptive immune system	480:507	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	3	30	theme	affinity	662:669	arg1	receptor					679:686	one low affinity FcγRIII receptor	654:686	one low affinity FcγRIII receptor	654:686	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	30	theme	affinity	662:669	arg1	CD16					689:692	CD16	689:692	CD16	689:692	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	2	31	dep	identity	422:429	arg1	%					411:411	%	411:411	%	411:411	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	5	32	theme	glycan	1022:1027	arg1	composition					1029:1039	glycan composition	1022:1039	glycan composition	1022:1039	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	9	33	theme	different	1801:1809	arg1	alleles					1820:1826	different FcγRIIIa alleles	1801:1826	different FcγRIIIa alleles	1801:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	2	34	theme	Macaca	369:374	arg1	Mm					385:386	Mm	385:386	Mm	385:386	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	2	34	theme	Macaca	369:374	arg1	macaques					359:366	Rhesus macaques	352:366	Rhesus macaques	352:366	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	2	34	theme	Macaca	369:374	arg1	mulatta					376:382	Macaca mulatta	369:382	Macaca mulatta (Mm)	369:387	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	6	35	theme	Phe/Val158	1100:1109	arg1	polymorphism					1111:1122	the human Phe/Val158 polymorphism	1090:1122	the human Phe/Val158 polymorphism in FcγRIIIa	1090:1134	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	2	36	dep	%	411:411	arg1	93					409:410	93	409:410	93	409:410	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	1	37	theme	assessing	262:270	arg1	functions					278:286	those functions	272:286	assessing those functions in animal models	262:303	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	0	38	dep	Decoding	0:7	arg1	basis					89:93	The structural basis	74:93	The structural basis for CD16-dependent effector function in Rhesus macaques	74:149	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	1	39	theme	animal	291:296	arg1	models					298:303	animal models	291:303	animal models	291:303	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	2	40	with	identity	422:429	arg1	humans					436:441	humans	436:441	humans	436:441	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	5	41	from	changes	1011:1017	arg1	composition					1029:1039	glycan composition	1022:1039	glycan composition	1022:1039	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	1	42	theme	antibodies	186:195	arg1	functions					173:181	Fc mediated effector functions	152:181	Fc mediated effector functions of antibodies	152:195	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	4	43	theme	Ile/Val158	849:858	arg1	polymorphism					860:871	the Ile/Val158 polymorphism	845:871	the Ile/Val158 polymorphism in Mm FcγRIII	845:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	8	44	from	glycans	1547:1553	arg1	Asn162					1573:1578	Asn162	1573:1578	Asn162	1573:1578	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	8	44	from	glycans	1547:1553	arg1	Asn45					1563:1567	Asn45	1563:1567	Asn45	1563:1567	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	8	45	with	variant	1600:1606	arg1	affinity					1620:1627	higher affinity	1613:1627	higher affinity to Fc	1613:1633	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	1	46	theme	important	202:210	arg1	roles					212:216	important roles	202:216	important roles	202:216	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	8	47	theme	Val158	1482:1487	arg1	variant					1489:1495	the Val158 variant	1478:1495	the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc	1478:1633	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	6	48	theme	higher	1141:1146	arg1	affinity					1148:1155	the higher affinity	1137:1155	the higher affinity variant	1137:1163	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	3	49	from	position	726:733	arg1	polymorphism					710:721	a polymorphism	708:721	a polymorphism at position 158	708:737	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	8	50	from	changes	1406:1412	arg1	composition					1424:1434	glycan composition	1417:1434	glycan composition	1417:1434	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	8	50	from	changes	1406:1412	arg1	receptor					1443:1450	the receptor	1439:1450	the receptor	1439:1450	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	3	51	dep	humans	627:632	arg1	contrast					615:622	contrast	615:622	contrast	615:622	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	7	52	theme	Fc/FcγRIII	1371:1380	arg1	interface					1382:1390	the Fc/FcγRIII interface	1367:1390	the Fc/FcγRIII interface	1367:1390	Instead, this side chain appears to modulate glycan-glycan interactions at the Fc/FcγRIII interface.
36131913	3	53	contain	have	649:652	arg2	CD16					689:692	CD16	689:692	CD16	689:692	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	53	contain	have	649:652	arg2	receptor					679:686	one low affinity FcγRIII receptor	654:686	one low affinity FcγRIII receptor	654:686	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	53	contain	have	649:652	arg1	macaques					635:642	macaques	635:642	macaques only	635:647	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	54	theme	human	744:748	arg1	FcγRIIIa					750:757	human FcγRIIIa	744:757	human FcγRIIIa with Ile158 and Val158 variants	744:789	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	1	55	from	functions	278:286	arg1	models					298:303	animal models	291:303	animal models	291:303	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	2	56	theme	effector	592:599	arg1	functions					601:609	Fc effector functions	589:609	Fc effector functions	589:609	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	6	57	theme	side	1209:1212	arg1	chain					1214:1218	the larger, more hydrophobic side chain	1180:1218	the larger, more hydrophobic side chain	1180:1218	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	6	57	theme	side	1209:1212	arg1	Ile					1221:1223	Ile	1221:1223	Ile	1221:1223	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	6	58	dep	larger	1184:1189	arg1	hydrophobic					1197:1207	hydrophobic	1197:1207	hydrophobic	1197:1207	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	5	59	theme	allelic	931:937	arg1	variants					939:946	the allelic variants	927:946	the allelic variants of Mm FcγRIII	927:960	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	8	60	theme	greater	1459:1465	arg1	effect					1467:1472	a greater effect	1457:1472	a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc	1457:1633	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	0	61	theme	structural	78:87	arg1	basis					89:93	The structural basis	74:93	The structural basis for CD16-dependent effector function in Rhesus macaques	74:149	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	9	62	contain	carrying	1792:1799	arg2	alleles					1820:1826	different FcγRIIIa alleles	1801:1826	different FcγRIIIa alleles	1801:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	9	62	contain	carrying	1792:1799	arg1	cells					1786:1790	human effector cells	1771:1790	human effector cells carrying different FcγRIIIa alleles	1771:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	1	63	theme	mediated	155:162	arg1	functions					173:181	Fc mediated effector functions	152:181	Fc mediated effector functions of antibodies	152:195	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	9	64	theme	nonhuman	1710:1717	arg1	studies					1727:1733	nonhuman primate studies	1710:1733	nonhuman primate studies	1710:1733	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	0	65	from	differences	36:46	arg1	functions					63:71	Fc-effector functions	51:71	Fc-effector functions	51:71	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	6	66	theme	larger	1184:1189	arg1	chain					1214:1218	the larger, more hydrophobic side chain	1180:1218	the larger, more hydrophobic side chain	1180:1218	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	6	66	theme	larger	1184:1189	arg1	Ile					1221:1223	Ile	1221:1223	Ile	1221:1223	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	9	67	theme	studies	1727:1733	arg1	interpretation					1692:1705	the better interpretation	1681:1705	the better interpretation of nonhuman primate studies	1681:1733	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	2	68	from	differences	465:475	arg1	system					502:507	their adaptive immune system	480:507	their adaptive immune system	480:507	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	0	69	theme	effector	114:121	arg1	function					123:130	CD16-dependent effector function	99:130	CD16-dependent effector function in Rhesus macaques	99:149	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	4	70	from	FcγRIII	879:885	arg1	relationships					828:840	structure-function relationships	809:840	structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII	809:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	2	71	theme	Rhesus	352:357	arg1	macaques					359:366	Rhesus macaques	352:366	Rhesus macaques	352:366	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	2	71	theme	Rhesus	352:357	arg1	mulatta					376:382	Macaca mulatta	369:382	Macaca mulatta (Mm)	369:387	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	5	72	theme	IgG	978:980	arg1	subclasses					982:991	the macaque IgG subclasses	966:991	the macaque IgG subclasses	966:991	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	0	73	theme	human-macaque	9:21	arg1	differences					36:46	human-macaque interspecies differences	9:46	human-macaque interspecies differences in Fc-effector functions	9:71	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	2	74	theme	important	455:463	arg1	differences					465:475	important differences	455:475	important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions	455:609	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	8	75	theme	type	1525:1528	arg1	glycans					1530:1536	oligomannose type glycans	1512:1536	oligomannose type glycans	1512:1536	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	5	76	theme	FcγRIII	954:960	arg1	variants					939:946	the allelic variants	927:946	the allelic variants of Mm FcγRIII	927:960	Our data indicate that the affinity of the allelic variants of Mm FcγRIII for the macaque IgG subclasses vary greatly with changes in glycan composition both on the Fc and the receptor.
36131913	9	77	theme	effector	1777:1784	arg1	cells					1786:1790	human effector cells	1771:1790	human effector cells carrying different FcγRIIIa alleles	1771:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	3	78	theme	low	658:660	arg1	receptor					679:686	one low affinity FcγRIII receptor	654:686	one low affinity FcγRIII receptor	654:686	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	78	theme	low	658:660	arg1	CD16					689:692	CD16	689:692	CD16	689:692	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	0	79	theme	Fc-effector	51:61	arg1	functions					63:71	Fc-effector functions	51:71	Fc-effector functions	51:71	Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
36131913	2	80	theme	adaptive	486:493	arg1	system					502:507	their adaptive immune system	480:507	their adaptive immune system	480:507	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	4	81	theme	structure-function	809:826	arg1	relationships					828:840	structure-function relationships	809:840	structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII	809:885	Here we describe structure-function relationships of the Ile/Val158 polymorphism in Mm FcγRIII.
36131913	6	82	from	polymorphism	1111:1122	arg1	FcγRIIIa					1127:1134	FcγRIIIa	1127:1134	FcγRIIIa	1127:1134	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	2	83	theme	sequence	413:420	arg1	identity					422:429	approximately 93% sequence identity	395:429	approximately 93% sequence identity with humans	395:441	Rhesus macaques, Macaca mulatta (Mm) share approximately 93% sequence identity with humans but display important differences in their adaptive immune system that complicates their use in validating therapeutics and vaccines that rely on Fc effector functions.
36131913	1	84	theme	species	331:337	arg1	differences					339:349	species differences	331:349	species differences	331:349	Fc mediated effector functions of antibodies play important roles in immunotherapies and vaccine efficacy but assessing those functions in animal models can be challenging due to species differences.
36131913	9	85	theme	FcγRIIIa	1811:1818	arg1	alleles					1820:1826	different FcγRIIIa alleles	1801:1826	different FcγRIIIa alleles	1801:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	8	86	theme	higher	1613:1618	arg1	affinity					1620:1627	higher affinity	1613:1627	higher affinity to Fc	1613:1633	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	3	87	theme	FcγRIII	671:677	arg1	receptor					679:686	one low affinity FcγRIII receptor	654:686	one low affinity FcγRIII receptor	654:686	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	3	87	theme	FcγRIII	671:677	arg1	CD16					689:692	CD16	689:692	CD16	689:692	In contrast to humans, macaques only have one low affinity FcγRIII receptor, CD16, which shares a polymorphism at position 158 with human FcγRIIIa with Ile158 and Val158 variants.
36131913	9	88	contain	have	1650:1653	arg2	implications					1655:1666	implications	1655:1666	implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles	1655:1826	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	9	88	contain	have	1650:1653	arg1	results					1642:1648	These results	1636:1648	These results	1636:1648	These results have implications not only for the better interpretation of nonhuman primate studies but also for studies performed with human effector cells carrying different FcγRIIIa alleles.
36131913	6	89	theme	human	1094:1098	arg1	polymorphism					1111:1122	the human Phe/Val158 polymorphism	1090:1122	the human Phe/Val158 polymorphism in FcγRIIIa	1090:1134	However, unlike the human Phe/Val158 polymorphism in FcγRIIIa, the higher affinity variant corresponds to the larger, more hydrophobic side chain, Ile, even though it is not directly involved in the binding interface.
36131913	8	90	contain	have	1452:1455	arg2	effect					1467:1472	a greater effect	1457:1472	a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc	1457:1633	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	8	90	contain	have	1452:1455	arg1	changes					1406:1412	changes	1406:1412	changes in glycan composition on the receptor	1406:1450	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36131913	8	91	dep	variant	1489:1495	arg1	becomes					1588:1594	becomes	1588:1594	becomes the variant with higher affinity to Fc	1588:1633	Furthermore, changes in glycan composition on the receptor have a greater effect for the Val158 variant such that with oligomannose type glycans and with glycans only on Asn45 and Asn162, Val158 becomes the variant with higher affinity to Fc.
36604058	0	0	theme	signalling	103:112	arg1	pathway					114:120	TGF-β/Smads-SIRT1 signalling pathway	85:120	TGF-β/Smads-SIRT1 signalling pathway	85:120	Target acquisition of anti-aging manno-oligosaccharide that triggers ECM process via TGF-β/Smads-SIRT1 signalling pathway.
36604058	6	1	theme	first	925:929	arg1	This					913:916	This	913:916	This	913:916	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	6	1	theme	first	925:929	arg1	study					931:935	the first study	921:935	the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging	921:1040	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	6	2	from	method	1021:1026	arg1	aging					1036:1040	skin aging	1031:1040	skin aging	1031:1040	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	4	3	theme	human	708:712	arg1	skin					714:717	human skin	708:717	human skin	708:717	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	0	4	theme	TGF-β/Smads-SIRT1	85:101	arg1	pathway					114:120	TGF-β/Smads-SIRT1 signalling pathway	85:120	TGF-β/Smads-SIRT1 signalling pathway	85:120	Target acquisition of anti-aging manno-oligosaccharide that triggers ECM process via TGF-β/Smads-SIRT1 signalling pathway.
36604058	1	5	theme	physiological	167:179	arg1	processes					198:206	physiological and pathological processes	167:206	physiological and pathological processes	167:206	Glycans play a crucial role in a variety of physiological and pathological processes.
36604058	4	6	from	effects	697:703	arg1	skin					714:717	human skin	708:717	human skin	708:717	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	6	7	theme	aging	1087:1091	arg1	problem					1093:1099	the skin aging problem	1078:1099	the skin aging problem	1078:1099	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	3	8	theme	skin	499:502	arg1	process					510:516	the skin aging process	495:516	the skin aging process	495:516	The exogenous addition of structurally defined glycans is of great importance for delaying the skin aging process.
36604058	2	9	theme	glycans	295:301	arg1	structure					282:290	structure	282:290	structure	282:290	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	9	theme	glycans	295:301	arg1	length					243:248	the sugar chain length	227:248	the sugar chain length	227:248	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	9	theme	glycans	295:301	arg1	composition					266:276	monosaccharide composition	251:276	monosaccharide composition	251:276	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	10	from	changes	333:339	arg1	glycogens					344:352	glycogens	344:352	glycogens in skin cells	344:366	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	4	11	theme	human	754:758	arg1	studies					769:775	human clinical studies	754:775	human clinical studies	754:775	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	6	12	theme	degradation	988:998	arg1	effects					970:976	the beneficial effects	955:976	the beneficial effects of glycan degradation	955:998	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	6	13	theme	skin	1031:1034	arg1	aging					1036:1040	skin aging	1031:1040	skin aging	1031:1040	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	2	14	theme	potential	374:382	arg1	changes					333:339	the changes	329:339	the changes in glycogens in skin cells	329:366	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	14	theme	potential	374:382	arg1	biomarker					384:392	a potential biomarker	372:392	a potential biomarker of aging	372:401	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	15	from	glycogens	344:352	arg1	cells					362:366	skin cells	357:366	skin cells	357:366	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	6	16	theme	skin	1082:1085	arg1	problem					1093:1099	the skin aging problem	1078:1099	the skin aging problem	1078:1099	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	1	17	theme	pathological	185:196	arg1	processes					198:206	physiological and pathological processes	167:206	physiological and pathological processes	167:206	Glycans play a crucial role in a variety of physiological and pathological processes.
36604058	6	18	theme	beneficial	959:968	arg1	effects					970:976	the beneficial effects	955:976	the beneficial effects of glycan degradation	955:998	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	6	19	theme	glycan	981:986	arg1	degradation					988:998	glycan degradation	981:998	glycan degradation	981:998	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	1	20	theme	processes	198:206	arg1	processes					198:206	physiological and pathological processes	167:206	physiological and pathological processes	167:206	Glycans play a crucial role in a variety of physiological and pathological processes.
36604058	1	20	theme	processes	198:206	arg1	variety					156:162	a variety	154:162	a variety of physiological and pathological processes	154:206	Glycans play a crucial role in a variety of physiological and pathological processes.
36604058	4	21	theme	functional	534:543	arg1	glycan					545:550	a functional glycan	532:550	a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale	532:613	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	4	22	theme	clinical	760:767	arg1	studies					769:775	human clinical studies	754:775	human clinical studies	754:775	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	3	23	theme	exogenous	408:416	arg1	addition					418:425	The exogenous addition	404:425	The exogenous addition of structurally defined glycans	404:457	The exogenous addition of structurally defined glycans is of great importance for delaying the skin aging process.
36604058	0	24	theme	anti-aging	22:31	arg1	manno-oligosaccharide					33:53	anti-aging manno-oligosaccharide	22:53	anti-aging manno-oligosaccharide	22:53	Target acquisition of anti-aging manno-oligosaccharide that triggers ECM process via TGF-β/Smads-SIRT1 signalling pathway.
36604058	3	25	theme	glycans	451:457	arg1	addition					418:425	The exogenous addition	404:425	The exogenous addition of structurally defined glycans	404:457	The exogenous addition of structurally defined glycans is of great importance for delaying the skin aging process.
36604058	5	26	theme	anti-aging	817:826	arg1	effects					828:834	anti-aging effects	817:834	anti-aging effects	817:834	Further studies show that DOMOS exerts anti-aging effects by triggering the ECM process through a TGF-β/Smad-SIRT1 signalling pathway.
36604058	2	27	theme	aging	397:401	arg1	changes					333:339	the changes	329:339	the changes in glycogens in skin cells	329:366	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	27	theme	aging	397:401	arg1	biomarker					384:392	a potential biomarker	372:392	a potential biomarker of aging	372:401	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	5	28	theme	Further	778:784	arg1	studies					786:792	Further studies	778:792	Further studies	778:792	Further studies show that DOMOS exerts anti-aging effects by triggering the ECM process through a TGF-β/Smad-SIRT1 signalling pathway.
36604058	2	29	dep	change	303:308	arg1	changes					333:339	the changes	329:339	the changes in glycogens in skin cells	329:366	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	29	dep	change	303:308	arg1	biomarker					384:392	a potential biomarker	372:392	a potential biomarker of aging	372:401	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	2	30	theme	chain	237:241	arg1	length					243:248	the sugar chain length	227:248	the sugar chain length	227:248	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	5	31	theme	TGF-β/Smad-SIRT1	876:891	arg1	pathway					904:910	a TGF-β/Smad-SIRT1 signalling pathway	874:910	a TGF-β/Smad-SIRT1 signalling pathway	874:910	Further studies show that DOMOS exerts anti-aging effects by triggering the ECM process through a TGF-β/Smad-SIRT1 signalling pathway.
36604058	4	32	theme	efficient	638:646	arg1	depolymerization					658:673	efficient enzymatic depolymerization	638:673	efficient enzymatic depolymerization	638:673	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	0	33	theme	manno-oligosaccharide	33:53	arg1	acquisition					7:17	acquisition	7:17	acquisition of anti-aging manno-oligosaccharide that triggers ECM process via TGF-β/Smads-SIRT1 signalling pathway	7:120	Target acquisition of anti-aging manno-oligosaccharide that triggers ECM process via TGF-β/Smads-SIRT1 signalling pathway.
36604058	2	34	theme	sugar	231:235	arg1	length					243:248	the sugar chain length	227:248	the sugar chain length	227:248	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	3	35	theme	defined	443:449	arg1	glycans					451:457	structurally defined glycans	430:457	structurally defined glycans	430:457	The exogenous addition of structurally defined glycans is of great importance for delaying the skin aging process.
36604058	0	36	theme	ECM	69:71	arg1	process					73:79	ECM process	69:79	ECM process	69:79	Target acquisition of anti-aging manno-oligosaccharide that triggers ECM process via TGF-β/Smads-SIRT1 signalling pathway.
36604058	5	37	theme	signalling	893:902	arg1	pathway					904:910	a TGF-β/Smad-SIRT1 signalling pathway	874:910	a TGF-β/Smad-SIRT1 signalling pathway	874:910	Further studies show that DOMOS exerts anti-aging effects by triggering the ECM process through a TGF-β/Smad-SIRT1 signalling pathway.
36604058	6	38	theme	all-new	1058:1064	arg1	solution					1066:1073	an all-new solution	1055:1073	an all-new solution to the skin aging problem that people are most concerned about	1055:1136	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36604058	2	39	theme	skin	221:224	arg1	terms					212:216	terms	212:216	terms of skin	212:224	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	1	40	theme	crucial	138:144	arg1	role					146:149	a crucial role	136:149	a crucial role	136:149	Glycans play a crucial role in a variety of physiological and pathological processes.
36604058	4	41	theme	anti-aging	686:695	arg1	effects					697:703	anti-aging effects	686:703	anti-aging effects on human skin	686:717	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	4	42	theme	Dendrobium	593:602	arg1	officinale					604:613	Dendrobium officinale	593:613	Dendrobium officinale	593:613	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	2	43	theme	monosaccharide	251:264	arg1	composition					266:276	monosaccharide composition	251:276	monosaccharide composition	251:276	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	3	44	theme	great	465:469	arg1	importance					471:480	great importance	465:480	great importance	465:480	The exogenous addition of structurally defined glycans is of great importance for delaying the skin aging process.
36604058	5	45	theme	ECM	854:856	arg1	process					858:864	the ECM process	850:864	the ECM process	850:864	Further studies show that DOMOS exerts anti-aging effects by triggering the ECM process through a TGF-β/Smad-SIRT1 signalling pathway.
36604058	2	46	theme	skin	357:360	arg1	cells					362:366	skin cells	357:366	skin cells	357:366	In terms of skin, the sugar chain length, monosaccharide composition and structure of glycans change with age, and thus the changes in glycogens in skin cells are a potential biomarker of aging.
36604058	4	47	theme	enzymatic	648:656	arg1	depolymerization					658:673	efficient enzymatic depolymerization	638:673	efficient enzymatic depolymerization	638:673	Fortunately, a functional glycan named manno-oligosaccharide (DOMOS) from Dendrobium officinale was obtained herein by efficient enzymatic depolymerization and exerts anti-aging effects on human skin in vitro and in vivo together with human clinical studies.
36604058	3	48	theme	aging	504:508	arg1	process					510:516	the skin aging process	495:516	the skin aging process	495:516	The exogenous addition of structurally defined glycans is of great importance for delaying the skin aging process.
36604058	6	49	theme	specific	1012:1019	arg1	method					1021:1026	a highly specific method	1003:1026	a highly specific method on skin aging	1003:1040	This is the first study to concentrate on the beneficial effects of glycan degradation by a highly specific method on skin aging and provides an all-new solution to the skin aging problem that people are most concerned about.
36500422	8	0	theme	β-type	1205:1210	arg1	structures					1231:1240	different α- and β-type glycosidic linkage structures	1188:1240	different α- and β-type glycosidic linkage structures	1188:1240	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	3	1	theme	different	499:507	arg1	wines					509:513	different wines	499:513	different wines	499:513	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36500422	1	2	theme	sensory	237:243	arg1	properties					245:254	the sensory properties	233:254	the sensory properties of the wine	233:266	It has been reported that polysaccharides in wine can interact with tannins and other wine components and modify the sensory properties of the wine.
36500422	8	3	theme	linkage	1223:1229	arg1	structures					1231:1240	different α- and β-type glycosidic linkage structures	1188:1240	different α- and β-type glycosidic linkage structures	1188:1240	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	12	4	from	KDa	1707:1709	arg1	comparison					1631:1640	comparison	1631:1640	comparison	1631:1640	In comparison, all of the polysaccharides in the PNWP-L fraction were below 25 KDa, with a majority distributed approximately 6 kDa (95.1%).
36500422	10	5	theme	molecular	1493:1501	arg1	sizes					1503:1507	molecular sizes	1493:1507	molecular sizes from 25 kDa	1493:1519	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	13	6	theme	composition	1781:1791	arg1	analysis					1793:1800	GC-MS sugar composition analysis	1769:1800	GC-MS sugar composition analysis	1769:1800	GC-MS sugar composition analysis showed that PNWP-L was mainly composed of galacturonic acid, rhamnose, galactose, and arabinose, while PNWP-H was mainly composed of mannose, arabinose, and galactose.
36500422	7	7	theme	glycosidic	1145:1154	arg1	linkages					1156:1163	α- and β-type glycosidic linkages	1131:1163	α- and β-type glycosidic linkages	1131:1163	The FT-IR analysis showed that PNWPs were acidic polysaccharides with α- and β-type glycosidic linkages.
36500422	9	8	theme	stretching	1293:1302	arg1	vibrations					1304:1313	stronger antisymmetric and symmetric stretching vibrations	1256:1313	stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids	1256:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	5	9	theme	gas	921:923	arg1	GC-MS					959:963	GC-MS	959:963	GC-MS	959:963	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	5	9	theme	gas	921:923	arg1	spectrometry					945:956	gas chromatography-mass spectrometry	921:956	gas chromatography-mass spectrometry (GC-MS)	921:964	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	9	10	from	acid	1387:1390	arg1	PNWP-L					1395:1400	PNWP-L	1395:1400	PNWP-L	1395:1400	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	6	11	theme	different	1013:1021	arg1	properties					1032:1041	different chemical properties	1013:1041	different chemical properties	1013:1041	The results showed that PNWP-L and PNWP-H had different chemical properties and compositions.
36500422	5	12	theme	laser	854:858	arg1	spectrometry					903:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	9	13	theme	anions	1330:1335	arg1	vibrations					1304:1313	stronger antisymmetric and symmetric stretching vibrations	1256:1313	stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids	1256:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	5	14	theme	mass	898:901	arg1	spectrometry					903:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	13	15	theme	GC-MS	1769:1773	arg1	analysis					1793:1800	GC-MS sugar composition analysis	1769:1800	GC-MS sugar composition analysis	1769:1800	GC-MS sugar composition analysis showed that PNWP-L was mainly composed of galacturonic acid, rhamnose, galactose, and arabinose, while PNWP-H was mainly composed of mannose, arabinose, and galactose.
36500422	11	16	located	found	1598:1602	arg1	fraction					1618:1625	the PNWP-H fraction	1607:1625	the PNWP-H fraction	1607:1625	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	11	16	located	found	1598:1602	arg2	percentage					1546:1555	Only a small percentage	1533:1555	Only a small percentage of smaller molecular polysaccharides	1533:1592	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	7	17	theme	acidic	1103:1108	arg1	polysaccharides					1110:1124	acidic polysaccharides	1103:1124	acidic polysaccharides with α- and β-type glycosidic linkages	1103:1163	The FT-IR analysis showed that PNWPs were acidic polysaccharides with α- and β-type glycosidic linkages.
36500422	9	18	theme	uronic	1340:1345	arg1	acids					1347:1351	uronic acids	1340:1351	uronic acids	1340:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	10	19	theme	fraction	1480:1487	arg1	fraction					1480:1487	the PNWP-H fraction	1469:1487	the PNWP-H fraction	1469:1487	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	10	19	theme	fraction	1480:1487	arg1	%					1464:1464	over 72%	1457:1464	over 72% of the PNWP-H fraction	1457:1487	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	0	20	from	Wines	91:95	arg1	Characterization					11:26	Characterization	11:26	Characterization	11:26	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	0	20	from	Wines	91:95	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	0	20	from	Wines	91:95	arg1	Analysis					47:54	Compositional Analysis	33:54	Compositional Analysis	33:54	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	0	21	theme	Polysaccharides	59:73	arg1	Characterization					11:26	Characterization	11:26	Characterization	11:26	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	0	21	theme	Polysaccharides	59:73	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	0	21	theme	Polysaccharides	59:73	arg1	Analysis					47:54	Compositional Analysis	33:54	Compositional Analysis	33:54	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	11	22	theme	polysaccharides	1578:1592	arg1	percentage					1546:1555	Only a small percentage	1533:1555	Only a small percentage of smaller molecular polysaccharides	1533:1592	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	15	23	theme	rich	2230:2233	arg1	mannoproteins					2196:2208	mannoproteins	2196:2208	mannoproteins	2196:2208	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	15	24	from	rich	2230:2233	arg1	galactose					2252:2260	galactose	2252:2260	galactose (PRAG)	2252:2267	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	15	24	from	rich	2230:2233	arg1	arabinose					2238:2246	arabinose	2238:2246	arabinose	2238:2246	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	15	24	from	rich	2230:2233	arg1	PRAG					2263:2266	PRAG	2263:2266	PRAG	2263:2266	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	11	25	theme	smaller	1560:1566	arg1	polysaccharides					1578:1592	smaller molecular polysaccharides	1560:1592	smaller molecular polysaccharides	1560:1592	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	15	26	from	arabinose	2238:2246	arg1	rich					2230:2233	rich	2230:2233	rich	2230:2233	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	0	27	theme	Compositional	33:45	arg1	Analysis					47:54	Compositional Analysis	33:54	Compositional Analysis	33:54	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	15	28	from	galactose	2252:2260	arg1	rich					2230:2233	rich	2230:2233	rich	2230:2233	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	16	29	theme	Further	2270:2276	arg1	research					2278:2285	Further research	2270:2285	Further research	2270:2285	Further research is needed to understand the impacts of these fractions on wine organoleptic properties.
36500422	14	30	theme	sugar	2006:2010	arg1	analysis					2024:2031	sugar composition analysis	2006:2031	sugar composition analysis	2006:2031	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	14	31	theme	rich	2122:2125	arg1	rhamnogalacturonans					2082:2100	rhamnogalacturonans	2082:2100	rhamnogalacturonans	2082:2100	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	2	32	theme	varied	404:409	arg1	composition					411:421	varied composition	404:421	varied composition	404:421	Unfortunately, the contribution of polysaccharides to wine quality is poorly understood, mainly due to their complicated structure and varied composition.
36500422	5	33	theme	exclusion	797:805	arg1	chromatography					807:820	size exclusion chromatography	792:820	size exclusion chromatography	792:820	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	14	34	from	rich	2122:2125	arg1	PRAG					2155:2158	PRAG	2155:2158	PRAG	2155:2158	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	14	34	from	rich	2122:2125	arg1	galactose					2144:2152	galactose	2144:2152	galactose (PRAG)	2144:2159	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	14	34	from	rich	2122:2125	arg1	arabinose					2130:2138	arabinose	2130:2138	arabinose	2130:2138	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	14	35	theme	molecular	1974:1982	arg1	distribution					1989:2000	The molecular size distribution	1970:2000	The molecular size distribution	1970:2000	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	10	36	theme	exclusion	1412:1420	arg1	chromatography					1422:1435	size exclusion chromatography	1407:1435	The size exclusion chromatography results	1403:1443	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	3	37	theme	molecular	457:465	arg1	structure					467:475	molecular structure	457:475	molecular structure	457:475	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36500422	1	38	theme	wine	206:209	arg1	components					211:220	other wine components	200:220	other wine components	200:220	It has been reported that polysaccharides in wine can interact with tannins and other wine components and modify the sensory properties of the wine.
36500422	4	39	theme	pinot	587:591	arg1	wine					598:601	pinot noir wine	587:601	pinot noir wine	587:601	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	8	40	theme	different	1188:1196	arg1	structures					1231:1240	different α- and β-type glycosidic linkage structures	1188:1240	different α- and β-type glycosidic linkage structures	1188:1240	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	0	41	dep	Isolation	0:8	arg1	Study					113:117	An Exploratory Study	98:117	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.	0:118	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	13	42	theme	galacturonic	1844:1855	arg1	acid					1857:1860	galacturonic acid	1844:1860	galacturonic acid	1844:1860	GC-MS sugar composition analysis showed that PNWP-L was mainly composed of galacturonic acid, rhamnose, galactose, and arabinose, while PNWP-H was mainly composed of mannose, arabinose, and galactose.
36500422	16	43	theme	fractions	2332:2340	arg1	impacts					2315:2321	the impacts	2311:2321	the impacts of these fractions on wine organoleptic properties	2311:2372	Further research is needed to understand the impacts of these fractions on wine organoleptic properties.
36500422	3	44	from	structure	467:475	arg1	wines					509:513	different wines	499:513	different wines	499:513	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36500422	10	45	contain	had	1489:1491	arg2	sizes					1503:1507	molecular sizes	1493:1507	molecular sizes from 25 kDa	1493:1519	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	10	45	contain	had	1489:1491	arg1	%					1464:1464	over 72%	1457:1464	over 72% of the PNWP-H fraction	1457:1487	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	10	45	contain	had	1489:1491	arg1	fraction					1480:1487	the PNWP-H fraction	1469:1487	the PNWP-H fraction	1469:1487	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	8	46	theme	glycosidic	1212:1221	arg1	structures					1231:1240	different α- and β-type glycosidic linkage structures	1188:1240	different α- and β-type glycosidic linkage structures	1188:1240	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	14	47	from	arabinose	2130:2138	arg1	rich					2122:2125	rich	2122:2125	rich	2122:2125	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	9	48	theme	antisymmetric	1265:1277	arg1	vibrations					1304:1313	stronger antisymmetric and symmetric stretching vibrations	1256:1313	stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids	1256:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	14	49	from	galactose	2144:2152	arg1	rich					2122:2125	rich	2122:2125	rich	2122:2125	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	13	50	theme	sugar	1775:1779	arg1	analysis					1793:1800	GC-MS sugar composition analysis	1769:1800	GC-MS sugar composition analysis	1769:1800	GC-MS sugar composition analysis showed that PNWP-L was mainly composed of galacturonic acid, rhamnose, galactose, and arabinose, while PNWP-H was mainly composed of mannose, arabinose, and galactose.
36500422	7	51	theme	β-type	1138:1143	arg1	linkages					1156:1163	α- and β-type glycosidic linkages	1131:1163	α- and β-type glycosidic linkages	1131:1163	The FT-IR analysis showed that PNWPs were acidic polysaccharides with α- and β-type glycosidic linkages.
36500422	9	52	theme	symmetric	1283:1291	arg1	vibrations					1304:1313	stronger antisymmetric and symmetric stretching vibrations	1256:1313	stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids	1256:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	6	53	theme	chemical	1023:1030	arg1	properties					1032:1041	different chemical properties	1013:1041	different chemical properties	1013:1041	The results showed that PNWP-L and PNWP-H had different chemical properties and compositions.
36500422	11	54	theme	PNWP-H	1611:1616	arg1	fraction					1618:1625	the PNWP-H fraction	1607:1625	the PNWP-H fraction	1607:1625	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	7	55	theme	α-	1131:1132	arg1	linkages					1156:1163	α- and β-type glycosidic linkages	1131:1163	α- and β-type glycosidic linkages	1131:1163	The FT-IR analysis showed that PNWPs were acidic polysaccharides with α- and β-type glycosidic linkages.
36500422	10	56	theme	PNWP-H	1473:1478	arg1	fraction					1480:1487	the PNWP-H fraction	1469:1487	the PNWP-H fraction	1469:1487	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	5	57	theme	matrix-assisted	838:852	arg1	spectrometry					903:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	10	58	from	kDa	1517:1519	arg1	sizes					1503:1507	molecular sizes	1493:1507	molecular sizes from 25 kDa	1493:1519	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	3	59	from	composition	441:451	arg1	wines					509:513	different wines	499:513	different wines	499:513	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36500422	8	60	contain	had	1184:1186	arg2	structures					1231:1240	different α- and β-type glycosidic linkage structures	1188:1240	different α- and β-type glycosidic linkage structures	1188:1240	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	8	60	contain	had	1184:1186	arg1	PNWP-H					1177:1182	PNWP-H	1177:1182	PNWP-H	1177:1182	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	8	60	contain	had	1184:1186	arg1	PNWP-L					1166:1171	PNWP-L	1166:1171	PNWP-L	1166:1171	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	2	61	theme	wine	323:326	arg1	quality					328:334	wine quality	323:334	wine quality	323:334	Unfortunately, the contribution of polysaccharides to wine quality is poorly understood, mainly due to their complicated structure and varied composition.
36500422	9	62	theme	carboxylate	1318:1328	arg1	anions					1330:1335	carboxylate anions	1318:1335	carboxylate anions of uronic acids	1318:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	5	63	theme	desorption/ionization-high-resolution	860:896	arg1	spectrometry					903:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	matrix-assisted laser desorption/ionization-high-resolution mass spectrometry	838:914	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	11	64	theme	small	1540:1544	arg1	percentage					1546:1555	Only a small percentage	1533:1555	Only a small percentage of smaller molecular polysaccharides	1533:1592	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	9	65	theme	acids	1347:1351	arg1	anions					1330:1335	carboxylate anions	1318:1335	carboxylate anions of uronic acids	1318:1351	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	7	66	theme	FT-IR	1065:1069	arg1	analysis					1071:1078	The FT-IR analysis	1061:1078	The FT-IR analysis	1061:1078	The FT-IR analysis showed that PNWPs were acidic polysaccharides with α- and β-type glycosidic linkages.
36500422	9	67	dep	antisymmetric	1265:1277	arg1	stronger					1256:1263	stronger	1256:1263	stronger	1256:1263	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	4	68	theme	membrane-based	705:718	arg1	ultrafiltration					720:734	membrane-based ultrafiltration	705:734	membrane-based ultrafiltration	705:734	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	16	69	theme	wine	2345:2348	arg1	properties					2363:2372	wine organoleptic properties	2345:2372	wine organoleptic properties	2345:2372	Further research is needed to understand the impacts of these fractions on wine organoleptic properties.
36500422	4	70	attach	isolated	573:580	arg2	polysaccharides					552:566	the polysaccharides	548:566	the polysaccharides	548:566	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	4	70	attach	isolated	573:580	arg1	wine					598:601	pinot noir wine	587:601	pinot noir wine	587:601	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	5	71	theme	chromatography-mass	925:943	arg1	GC-MS					959:963	GC-MS	959:963	GC-MS	959:963	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	5	71	theme	chromatography-mass	925:943	arg1	spectrometry					945:956	gas chromatography-mass spectrometry	921:956	gas chromatography-mass spectrometry (GC-MS)	921:964	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	15	72	from	mannoproteins	2196:2208	arg1	comparison					2165:2174	comparison	2165:2174	comparison	2165:2174	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	4	73	theme	low-molecular-weight	659:678	arg1	fractions					689:697	high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions	624:697	fractions	689:697	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	11	74	theme	molecular	1568:1576	arg1	polysaccharides					1578:1592	smaller molecular polysaccharides	1560:1592	smaller molecular polysaccharides	1560:1592	Only a small percentage of smaller molecular polysaccharides was found in the PNWP-H fraction.
36500422	15	75	from	polysaccharides	2214:2228	arg1	comparison					2165:2174	comparison	2165:2174	comparison	2165:2174	In comparison, PNWP-H were mostly mannoproteins and polysaccharides rich in arabinose and galactose (PRAG).
36500422	4	76	theme	PNWP-L	681:686	arg1	fractions					689:697	high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions	624:697	fractions	689:697	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	16	77	theme	organoleptic	2350:2361	arg1	properties					2363:2372	wine organoleptic properties	2345:2372	wine organoleptic properties	2345:2372	Further research is needed to understand the impacts of these fractions on wine organoleptic properties.
36500422	9	78	theme	uronic	1380:1385	arg1	acid					1387:1390	more uronic acid	1375:1390	more uronic acid in PNWP-L	1375:1400	FT-IR showed stronger antisymmetric and symmetric stretching vibrations of carboxylate anions of uronic acids in PNWP-L, suggesting more uronic acid in PNWP-L.
36500422	1	79	from	polysaccharides	146:160	arg1	wine					165:168	wine	165:168	wine	165:168	It has been reported that polysaccharides in wine can interact with tannins and other wine components and modify the sensory properties of the wine.
36500422	0	80	theme	Exploratory	101:111	arg1	Study					113:117	An Exploratory Study	98:117	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.	0:118	Isolation, Characterization, and Compositional Analysis of Polysaccharides from Pinot Noir Wines: An Exploratory Study.
36500422	16	81	from	impacts	2315:2321	arg1	properties					2363:2372	wine organoleptic properties	2345:2372	wine organoleptic properties	2345:2372	Further research is needed to understand the impacts of these fractions on wine organoleptic properties.
36500422	5	82	theme	polysaccharide	742:755	arg1	fraction					757:764	Each polysaccharide fraction	737:764	Each polysaccharide fraction	737:764	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	14	83	theme	composition	2012:2022	arg1	analysis					2024:2031	sugar composition analysis	2006:2031	sugar composition analysis	2006:2031	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	1	84	theme	wine	263:266	arg1	properties					245:254	the sensory properties	233:254	the sensory properties of the wine	233:266	It has been reported that polysaccharides in wine can interact with tannins and other wine components and modify the sensory properties of the wine.
36500422	12	85	theme	PNWP-L	1677:1682	arg1	fraction					1684:1691	the PNWP-L fraction	1673:1691	the PNWP-L fraction	1673:1691	In comparison, all of the polysaccharides in the PNWP-L fraction were below 25 KDa, with a majority distributed approximately 6 kDa (95.1%).
36500422	7	86	with	polysaccharides	1110:1124	arg1	linkages					1156:1163	α- and β-type glycosidic linkages	1131:1163	α- and β-type glycosidic linkages	1131:1163	The FT-IR analysis showed that PNWPs were acidic polysaccharides with α- and β-type glycosidic linkages.
36500422	5	87	theme	size	792:795	arg1	chromatography					807:820	size exclusion chromatography	792:820	size exclusion chromatography	792:820	Each polysaccharide fraction was further studied using size exclusion chromatography, UV-Vis, FT-IR, matrix-assisted laser desorption/ionization-high-resolution mass spectrometry, and gas chromatography-mass spectrometry (GC-MS).
36500422	12	88	from	polysaccharides	1654:1668	arg1	fraction					1684:1691	the PNWP-L fraction	1673:1691	the PNWP-L fraction	1673:1691	In comparison, all of the polysaccharides in the PNWP-L fraction were below 25 KDa, with a majority distributed approximately 6 kDa (95.1%).
36500422	14	89	theme	size	1984:1987	arg1	distribution					1989:2000	The molecular size distribution	1970:2000	The molecular size distribution	1970:2000	The molecular size distribution and sugar composition analysis suggested that the PNWP-L primarily consisted of rhamnogalacturonans and polysaccharides rich in arabinose and galactose (PRAG).
36500422	6	90	contain	had	1009:1011	arg1	PNWP-L					991:996	PNWP-L	991:996	PNWP-L	991:996	The results showed that PNWP-L and PNWP-H had different chemical properties and compositions.
36500422	6	90	contain	had	1009:1011	arg2	properties					1032:1041	different chemical properties	1013:1041	different chemical properties	1013:1041	The results showed that PNWP-L and PNWP-H had different chemical properties and compositions.
36500422	6	90	contain	had	1009:1011	arg1	PNWP-H					1002:1007	PNWP-H	1002:1007	PNWP-H	1002:1007	The results showed that PNWP-L and PNWP-H had different chemical properties and compositions.
36500422	6	90	contain	had	1009:1011	arg2	compositions					1047:1058	compositions	1047:1058	compositions	1047:1058	The results showed that PNWP-L and PNWP-H had different chemical properties and compositions.
36500422	10	91	theme	chromatography	1422:1435	arg1	results					1437:1443	The size exclusion chromatography results	1403:1443	The size exclusion chromatography results	1403:1443	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	2	92	theme	complicated	378:388	arg1	structure					390:398	complicated structure	378:398	complicated structure	378:398	Unfortunately, the contribution of polysaccharides to wine quality is poorly understood, mainly due to their complicated structure and varied composition.
36500422	12	93	with	KDa	1707:1709	arg1	majority					1719:1726	a majority	1717:1726	a majority distributed approximately 6 kDa (95.1%)	1717:1766	In comparison, all of the polysaccharides in the PNWP-L fraction were below 25 KDa, with a majority distributed approximately 6 kDa (95.1%).
36500422	10	94	theme	size	1407:1410	arg1	chromatography					1422:1435	size exclusion chromatography	1407:1435	The size exclusion chromatography results	1403:1443	The size exclusion chromatography results showed that over 72% of the PNWP-H fraction had molecular sizes from 25 kDa to 670 kDa.
36500422	3	95	theme	polysaccharides	480:494	arg1	composition					441:451	composition	441:451	composition	441:451	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36500422	3	95	theme	polysaccharides	480:494	arg1	structure					467:475	molecular structure	457:475	molecular structure	457:475	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36500422	4	96	theme	noir	593:596	arg1	wine					598:601	pinot noir wine	587:601	pinot noir wine	587:601	In this study, the polysaccharides were isolated from pinot noir wine, then separated into high-molecular-weight (PNWP-H) and low-molecular-weight (PNWP-L) fractions using membrane-based ultrafiltration.
36500422	2	97	theme	polysaccharides	304:318	arg1	contribution					288:299	the contribution	284:299	the contribution of polysaccharides to wine quality	284:334	Unfortunately, the contribution of polysaccharides to wine quality is poorly understood, mainly due to their complicated structure and varied composition.
36500422	8	98	theme	α-	1198:1199	arg1	structures					1231:1240	different α- and β-type glycosidic linkage structures	1188:1240	different α- and β-type glycosidic linkage structures	1188:1240	PNWP-L and PNWP-H had different α- and β-type glycosidic linkage structures.
36500422	1	99	theme	other	200:204	arg1	components					211:220	other wine components	200:220	other wine components	200:220	It has been reported that polysaccharides in wine can interact with tannins and other wine components and modify the sensory properties of the wine.
36500422	3	100	dep	composition	441:451	arg1	the					437:439	the	437:439	the	437:439	In addition, the composition and molecular structure of polysaccharides in different wines can vary greatly.
36610622	0	0	theme	conventional	83:94	arg1	sludge					106:111	conventional activated sludge	83:111	conventional activated sludge (CAS)	83:117	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	0	0	theme	conventional	83:94	arg1	CAS					114:116	CAS	114:116	CAS	114:116	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	10	1	from	reason	1338:1343	arg1	applications					1377:1388	applications	1377:1388	applications	1377:1388	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	1	2	theme	value	138:142	arg1	polymers					182:189	alginate-like extracellular polymers	154:189	alginate-like extracellular polymers (ALE)	154:195	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	2	theme	value	138:142	arg1	material					144:151	a highly added value material	123:151	a highly added value material	123:151	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	3	theme	polymeric	233:241	arg1	substances					243:252	extracellular polymeric substances	219:252	extracellular polymeric substances (EPS)	219:258	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	3	theme	polymeric	233:241	arg1	EPS					255:257	EPS	255:257	EPS	255:257	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	6	4	theme	natural	695:701	arg1	alginate					703:710	natural alginate	695:710	natural alginate	695:710	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	2	5	theme	conventional	305:316	arg1	CAS					336:338	CAS	336:338	CAS	336:338	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	5	theme	conventional	305:316	arg1	sludge					328:333	conventional activated sludge	305:333	conventional activated sludge (CAS)	305:339	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	3	6	from	huge	455:458	arg1	amount					476:481	its absolute amount	463:481	its absolute amount	463:481	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	11	7	from	CAS	1490:1492	arg1	blocks					1471:1476	three blocks	1465:1476	three blocks of ALE from CAS	1465:1492	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	11	8	theme	ALE	1573:1575	arg1	blocks					1563:1568	the compositional blocks	1545:1568	the compositional blocks of ALE from AGS	1545:1584	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	3	9	theme	absolute	467:474	arg1	amount					476:481	its absolute amount	463:481	its absolute amount	463:481	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	0	10	theme	activated	96:104	arg1	sludge					106:111	conventional activated sludge	83:111	conventional activated sludge (CAS)	83:117	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	0	10	theme	activated	96:104	arg1	CAS					114:116	CAS	114:116	CAS	114:116	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	9	11	theme	MML	1208:1210	arg1	higher					1236:1241	higher	1236:1241	higher	1236:1241	And the GGL and MML blocks in CAS were much higher than AGS, by more than 1/2.
36610622	9	11	theme	MML	1208:1210	arg1	blocks					1212:1217	And the GGL and MML blocks	1192:1217	blocks	1212:1217	And the GGL and MML blocks in CAS were much higher than AGS, by more than 1/2.
36610622	10	12	from	AGS	1312:1314	arg1	reason					1338:1343	the reason	1334:1343	the reason forming different properties	1334:1372	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	12	from	AGS	1312:1314	arg1	ALE					1305:1307	ALE	1305:1307	ALE	1305:1307	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	12	from	AGS	1312:1314	arg1	blocks					1295:1300	Different compositional blocks	1271:1300	Different compositional blocks of ALE in AGS and CAS	1271:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	9	13	from	blocks	1212:1217	arg1	CAS					1222:1224	CAS	1222:1224	CAS	1222:1224	And the GGL and MML blocks in CAS were much higher than AGS, by more than 1/2.
36610622	2	14	theme	activated	318:326	arg1	CAS					336:338	CAS	336:338	CAS	336:338	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	14	theme	activated	318:326	arg1	sludge					328:333	conventional activated sludge	305:333	conventional activated sludge (CAS)	305:339	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	4	15	theme	ALE	497:499	arg1	property					501:508	the ALE property	493:508	the ALE property of CAS	493:515	Although the ALE property of CAS was identified not so good as that from AGS, the mechanisms remains unclear.
36610622	10	16	theme	compositional	1281:1293	arg1	reason					1338:1343	the reason	1334:1343	the reason forming different properties	1334:1372	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	16	theme	compositional	1281:1293	arg1	blocks					1295:1300	Different compositional blocks	1271:1300	Different compositional blocks of ALE in AGS and CAS	1271:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	17	from	blocks	1295:1300	arg1	CAS					1320:1322	CAS	1320:1322	CAS	1320:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	17	from	blocks	1295:1300	arg1	AGS					1312:1314	AGS	1312:1314	AGS	1312:1314	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	7	18	from	%	1032:1032	arg1	weight					1063:1068	weight	1063:1068	weight	1063:1068	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	11	19	theme	compositional	1549:1561	arg1	blocks					1563:1568	the compositional blocks	1545:1568	the compositional blocks of ALE from AGS	1545:1584	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	5	20	theme	ALE	677:679	arg1	blocks					667:672	the chemically compositional blocks	638:672	the chemically compositional blocks of ALE	638:679	For this reason, it is necessary to unravel the chemically compositional blocks of ALE.
36610622	5	21	theme	compositional	653:665	arg1	blocks					667:672	the chemically compositional blocks	638:672	the chemically compositional blocks of ALE	638:679	For this reason, it is necessary to unravel the chemically compositional blocks of ALE.
36610622	3	22	dep	sludge	430:435	arg1	WAS					438:440	WAS	438:440	WAS	438:440	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	8	23	from	blocks	1129:1134	arg1	CAS					1139:1141	CAS	1139:1141	CAS	1139:1141	Moreover, the GGL blocks in CAS were obviously lower than AGS, up to by 3/1-2/1.
36610622	1	24	theme	alginate-like	154:166	arg1	polymers					182:189	alginate-like extracellular polymers	154:189	alginate-like extracellular polymers (ALE)	154:195	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	24	theme	alginate-like	154:166	arg1	material					144:151	a highly added value material	123:151	a highly added value material	123:151	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	0	25	theme	compositional	11:23	arg1	blocks					25:30	compositional blocks	11:30	compositional blocks of alginate-like extracellular polymers (ALE)	11:76	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	6	26	theme	compositional	745:757	arg1	GML					772:774	GML	772:774	GML	772:774	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	26	theme	compositional	745:757	arg1	GGL					767:769	GGL	767:769	GGL	767:769	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	26	theme	compositional	745:757	arg1	blocks					759:764	three compositional blocks	739:764	three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate)	739:832	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	26	theme	compositional	745:757	arg1	MML					780:782	MML	780:782	MML	780:782	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	10	27	theme	Different	1271:1279	arg1	reason					1338:1343	the reason	1334:1343	the reason forming different properties	1334:1372	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	27	theme	Different	1271:1279	arg1	blocks					1295:1300	Different compositional blocks	1271:1300	Different compositional blocks of ALE in AGS and CAS	1271:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	1	28	theme	extracellular	168:180	arg1	polymers					182:189	alginate-like extracellular polymers	154:189	alginate-like extracellular polymers (ALE)	154:195	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	28	theme	extracellular	168:180	arg1	material					144:151	a highly added value material	123:151	a highly added value material	123:151	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	6	29	dep	blocks	759:764	arg1	GML					772:774	GML	772:774	GML	772:774	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	29	dep	blocks	759:764	arg1	GGL					767:769	GGL	767:769	GGL	767:769	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	29	dep	blocks	759:764	arg1	blocks					759:764	three compositional blocks	739:764	three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate)	739:832	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	29	dep	blocks	759:764	arg1	MML					780:782	MML	780:782	MML	780:782	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	7	30	from	%	1044:1044	arg1	weight					1063:1068	weight	1063:1068	weight	1063:1068	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	6	31	theme	other	851:855	arg1	protein					880:886	protein	880:886	protein (PN)	880:891	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	31	theme	other	851:855	arg1	compositions					857:868	other compositions	851:868	other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA)	851:945	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	10	32	theme	different	1353:1361	arg1	properties					1363:1372	different properties	1353:1372	different properties	1353:1372	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	2	33	theme	ALE	375:377	arg1	ALE					375:377	ALE	375:377	ALE	375:377	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	33	theme	ALE	375:377	arg1	amount					365:370	a certain amount	355:370	a certain amount of ALE	355:377	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	1	34	theme	aerobic	265:271	arg1	AGS					290:292	AGS	290:292	AGS	290:292	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	34	theme	aerobic	265:271	arg1	sludge					282:287	aerobic granular sludge	265:287	aerobic granular sludge (AGS)	265:293	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	8	35	theme	GGL	1125:1127	arg1	lower					1158:1162	lower	1158:1162	lower	1158:1162	Moreover, the GGL blocks in CAS were obviously lower than AGS, up to by 3/1-2/1.
36610622	8	35	theme	GGL	1125:1127	arg1	blocks					1129:1134	the GGL blocks	1121:1134	the GGL blocks in CAS	1121:1141	Moreover, the GGL blocks in CAS were obviously lower than AGS, up to by 3/1-2/1.
36610622	3	36	used	used	397:400	arg2	CAS					383:385	CAS	383:385	CAS	383:385	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	0	37	theme	extracellular	49:61	arg1	polymers					63:70	alginate-like extracellular polymers	35:70	alginate-like extracellular polymers (ALE)	35:76	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	1	38	theme	granular	273:280	arg1	AGS					290:292	AGS	290:292	AGS	290:292	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	38	theme	granular	273:280	arg1	sludge					282:287	aerobic granular sludge	265:287	aerobic granular sludge (AGS)	265:293	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	11	39	theme	potential	1512:1520	arg1	applications					1522:1533	its potential applications	1508:1533	its potential applications	1508:1533	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	2	40	theme	certain	357:363	arg1	ALE					375:377	ALE	375:377	ALE	375:377	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	40	theme	certain	357:363	arg1	amount					365:370	a certain amount	355:370	a certain amount of ALE	355:377	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	0	41	theme	alginate-like	35:47	arg1	polymers					63:70	alginate-like extracellular polymers	35:70	alginate-like extracellular polymers (ALE)	35:76	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	6	42	dep	separated	724:732	arg1	associated					835:844	associated	835:844	associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA)	835:945	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	10	43	theme	ALE	1305:1307	arg1	reason					1338:1343	the reason	1334:1343	the reason forming different properties	1334:1372	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	43	theme	ALE	1305:1307	arg1	blocks					1295:1300	Different compositional blocks	1271:1300	Different compositional blocks of ALE in AGS and CAS	1271:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	0	44	dep	polymers	63:70	arg1	ALE					73:75	ALE	73:75	ALE	73:75	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	8	45	dep	to	1177:1178	arg1	up					1174:1175	up	1174:1175	up	1174:1175	Moreover, the GGL blocks in CAS were obviously lower than AGS, up to by 3/1-2/1.
36610622	11	46	from	AGS	1582:1584	arg1	ALE					1573:1575	ALE	1573:1575	ALE	1573:1575	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	11	46	from	AGS	1582:1584	arg1	blocks					1563:1568	the compositional blocks	1545:1568	the compositional blocks of ALE from AGS	1545:1584	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	2	47	contain	contains	346:353	arg2	amount					365:370	a certain amount	355:370	a certain amount of ALE	355:377	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	47	contain	contains	346:353	arg1	sludge					328:333	conventional activated sludge	305:333	conventional activated sludge (CAS)	305:339	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	47	contain	contains	346:353	arg2	CAS					336:338	CAS	336:338	CAS	336:338	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	47	contain	contains	346:353	arg1	fact					299:302	fact	299:302	fact	299:302	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	47	contain	contains	346:353	arg2	ALE					375:377	ALE	375:377	ALE	375:377	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	47	contain	contains	346:353	arg1	CAS					336:338	CAS	336:338	CAS	336:338	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	2	47	contain	contains	346:353	arg2	sludge					328:333	conventional activated sludge	305:333	conventional activated sludge (CAS)	305:339	In fact, conventional activated sludge (CAS) also contains a certain amount of ALE.
36610622	7	48	from	%	1058:1058	arg1	weight					1063:1068	weight	1063:1068	weight	1063:1068	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	3	49	theme	activated	420:428	arg1	sludge					430:435	waste activated sludge	414:435	waste activated sludge (WAS) from CAS	414:450	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	0	50	theme	polymers	63:70	arg1	blocks					25:30	compositional blocks	11:30	compositional blocks of alginate-like extracellular polymers (ALE)	11:76	Extracting compositional blocks of alginate-like extracellular polymers (ALE) from conventional activated sludge (CAS).
36610622	11	51	theme	ALE	1481:1483	arg1	blocks					1471:1476	three blocks	1465:1476	three blocks of ALE from CAS	1465:1492	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	9	52	theme	GGL	1200:1202	arg1	higher					1236:1241	higher	1236:1241	higher	1236:1241	And the GGL and MML blocks in CAS were much higher than AGS, by more than 1/2.
36610622	9	52	theme	GGL	1200:1202	arg1	blocks					1212:1217	And the GGL and MML blocks	1192:1217	blocks	1212:1217	And the GGL and MML blocks in CAS were much higher than AGS, by more than 1/2.
36610622	7	53	theme	previous	1095:1102	arg1	study					1104:1108	the previous study	1091:1108	the previous study	1091:1108	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	1	54	dep	polymers	182:189	arg1	ALE					192:194	ALE	192:194	ALE	192:194	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	6	55	theme	humic	931:935	arg1	protein					880:886	protein	880:886	protein (PN)	880:891	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	55	theme	humic	931:935	arg1	HA					943:944	HA	943:944	HA	943:944	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	55	theme	humic	931:935	arg1	acid					937:940	humic acid	931:940	humic acid (HA)	931:945	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	4	56	theme	CAS	513:515	arg1	property					501:508	the ALE property	493:508	the ALE property of CAS	493:515	Although the ALE property of CAS was identified not so good as that from AGS, the mechanisms remains unclear.
36610622	7	57	dep	extracted	980:988	arg1	%					1032:1032	GGL = 54 %	1023:1032	GGL = 54 %	1023:1032	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	7	57	dep	extracted	980:988	arg1	%					1044:1044	GML = 42 %	1035:1044	GML = 42 %	1035:1044	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	7	57	dep	extracted	980:988	arg1	%					1058:1058	MML = 4 %	1050:1058	MML = 4 %	1050:1058	With real WAS from CAS, ALE was extracted and three blocks were separated: GGL = 54 %, GML = 42 % and MML = 4 % in weight, which is similar to the previous study.
36610622	3	58	theme	waste	414:418	arg1	sludge					430:435	waste activated sludge	414:435	waste activated sludge (WAS) from CAS	414:450	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	3	59	from	amount	476:481	arg1	huge					455:458	huge	455:458	huge	455:458	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	10	60	from	ALE	1305:1307	arg1	CAS					1320:1322	CAS	1320:1322	CAS	1320:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	60	from	ALE	1305:1307	arg1	AGS					1312:1314	AGS	1312:1314	AGS	1312:1314	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	11	61	theme	further	1410:1416	arg1	study					1418:1422	a further study	1408:1422	a further study	1408:1422	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	11	62	from	blocks	1563:1568	arg1	AGS					1582:1584	AGS	1582:1584	AGS	1582:1584	For this reason, a further study will be initiated to dispense/reorganize three blocks of ALE from CAS for expanding its potential applications, based on the compositional blocks of ALE from AGS.
36610622	10	63	from	CAS	1320:1322	arg1	reason					1338:1343	the reason	1334:1343	the reason forming different properties	1334:1372	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	63	from	CAS	1320:1322	arg1	ALE					1305:1307	ALE	1305:1307	ALE	1305:1307	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	10	63	from	CAS	1320:1322	arg1	blocks					1295:1300	Different compositional blocks	1271:1300	Different compositional blocks of ALE in AGS and CAS	1271:1322	Different compositional blocks of ALE in AGS and CAS should be the reason forming different properties in applications.
36610622	6	64	contain	containing	796:805	arg1	units					790:794	units	790:794	units containing guluronate or mannuronate	790:831	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	64	contain	containing	796:805	arg2	mannuronate					821:831	mannuronate	821:831	mannuronate	821:831	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	6	64	contain	containing	796:805	arg2	guluronate					807:816	guluronate	807:816	guluronate	807:816	Referring to natural alginate, ALE can be separated into three compositional blocks: GGL, GML and MML (like units containing guluronate or mannuronate), associated with other compositions including protein (PN), polysaccharide (PS), phosphorus (P), humic acid (HA).
36610622	1	65	theme	added	132:136	arg1	polymers					182:189	alginate-like extracellular polymers	154:189	alginate-like extracellular polymers (ALE)	154:195	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	65	theme	added	132:136	arg1	material					144:151	a highly added value material	123:151	a highly added value material	123:151	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	3	66	from	CAS	448:450	arg1	sludge					430:435	waste activated sludge	414:435	waste activated sludge (WAS) from CAS	414:450	As CAS is widely used everywhere, waste activated sludge (WAS) from CAS is huge in its absolute amount.
36610622	1	67	theme	extracellular	219:231	arg1	substances					243:252	extracellular polymeric substances	219:252	extracellular polymeric substances (EPS)	219:258	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
36610622	1	67	theme	extracellular	219:231	arg1	EPS					255:257	EPS	255:257	EPS	255:257	As a highly added value material, alginate-like extracellular polymers (ALE) can be extracted from extracellular polymeric substances (EPS) from aerobic granular sludge (AGS).
37178884	4	0	theme	50 	972:974	arg1	%					980:980	50 %-50 %	972:980	50 %-50 %	972:980	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	0	theme	50 	972:974	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	1	1	theme	biocomposite	381:392	arg1	aerogels					394:401	biocomposite aerogels	381:401	biocomposite aerogels	381:401	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	5	2	theme	Porosity	1082:1089	arg1	values					1091:1096	Porosity values	1082:1096	Porosity values for NC-Chitosan (NC/CH) based aerogels	1082:1135	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	3	3	theme	main	654:657	arg1	aim					659:661	the main aim	650:661	the main aim of this study	650:675	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	8	4	theme	size	1680:1683	arg1	pores					1685:1689	different size pores	1670:1689	different size pores	1670:1689	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	1	5	theme	groups	271:276	arg1	amounts					238:244	different amounts	228:244	different amounts of aldehyde and carboxyl groups	228:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	5	theme	groups	271:276	arg1	aldehyde					249:256	aldehyde	249:256	aldehyde	249:256	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	5	theme	groups	271:276	arg1	groups					271:276	carboxyl groups	262:276	carboxyl groups	262:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	2	6	theme	fraction	576:583	arg1	effect					544:549	the effect	540:549	the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties	540:629	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	6	7	theme	0.01 g/cm3	1350:1359	arg1	range					1341:1345	the range	1337:1345	the range of 0.01 g/cm3 for both NC-CH and NC-GL composites	1337:1395	In addition, densities were determined in the range of 0.01 g/cm3 for both NC-CH and NC-GL composites, but higher values were obtained in ranged between 0.01 and 0.03 g/cm3 for NC-AL samples.
37178884	3	8	theme	study	671:675	arg1	aim					659:661	the main aim	650:661	the main aim of this study	650:675	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	8	9	theme	surface	1706:1712	arg1	topography					1714:1723	homogenous surface topography	1695:1723	homogenous surface topography	1695:1723	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	5	10	theme	%	1258:1258	arg1	values					1238:1243	values	1238:1243	values of 99.2-99.8 % and 98.47 to 99.7 %, respectively	1238:1292	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	1	11	theme	nanofibrillated	187:201	arg1	NFCs					215:218	NFCs	215:218	NFCs	215:218	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	11	theme	nanofibrillated	187:201	arg1	celluloses					203:212	nanofibrillated celluloses	187:212	nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups	187:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	0	12	theme	added	128:132	arg1	composites					134:143	chitosan, gelatin, alginate added composites	100:143	chitosan, gelatin, alginate added composites	100:143	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	9	13	theme	tests	1755:1759	arg1	materials					1768:1776	these materials	1762:1776	these materials	1762:1776	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	13	theme	tests	1755:1759	arg1	result					1731:1736	a result	1729:1736	a result of the specified tests	1729:1759	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	3	14	theme	materials	786:794	arg1	characteristics					746:760	the basic characteristics	736:760	the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix	736:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	8	15	contain	have	1635:1638	arg1	materials					1625:1633	all materials	1621:1633	all materials	1621:1633	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	8	15	contain	have	1635:1638	arg2	structure					1655:1663	a porous micro structure	1640:1663	a porous micro structure with different size pores and homogenous surface topography	1640:1723	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	9	16	used	used	1785:1788	arg2	result					1731:1736	a result	1729:1736	a result of the specified tests	1729:1759	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	16	used	used	1785:1788	arg2	materials					1768:1776	these materials	1762:1776	these materials	1762:1776	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	1	17	theme	mixing	356:361	arg1	ratios					363:368	different mixing ratios	346:368	different mixing ratios	346:368	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	18	contain	having	221:226	arg2	groups					271:276	carboxyl groups	262:276	carboxyl groups	262:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	18	contain	having	221:226	arg1	NFCs					215:218	NFCs	215:218	NFCs	215:218	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	18	contain	having	221:226	arg2	aldehyde					249:256	aldehyde	249:256	aldehyde	249:256	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	18	contain	having	221:226	arg1	celluloses					203:212	nanofibrillated celluloses	187:212	nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups	187:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	18	contain	having	221:226	arg2	amounts					238:244	different amounts	228:244	different amounts of aldehyde and carboxyl groups	228:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	5	19	dep	99.7 	1273:1277	arg1	to					1270:1271	to	1270:1271	to	1270:1271	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	2	20	theme	biopolymers	513:523	arg1	addition					483:490	the addition	479:490	the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties	479:629	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	3	21	from	amount	833:838	arg1	matrix					848:853	main matrix	843:853	main matrix	843:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	4	22	theme	lyophilization	1056:1069	arg1	procedure					1071:1079	the fundamentally easy lyophilization procedure	1033:1079	the fundamentally easy lyophilization procedure	1033:1079	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	8	23	theme	SEM	1598:1600	arg1	images					1602:1607	SEM images	1598:1607	SEM images	1598:1607	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	6	24	dep	composites	1386:1395	arg1	NC-GL					1380:1384	NC-GL	1380:1384	NC-GL	1380:1384	In addition, densities were determined in the range of 0.01 g/cm3 for both NC-CH and NC-GL composites, but higher values were obtained in ranged between 0.01 and 0.03 g/cm3 for NC-AL samples.
37178884	6	24	dep	composites	1386:1395	arg1	both					1365:1368	both	1365:1368	both	1365:1368	In addition, densities were determined in the range of 0.01 g/cm3 for both NC-CH and NC-GL composites, but higher values were obtained in ranged between 0.01 and 0.03 g/cm3 for NC-AL samples.
37178884	4	25	theme	%	920:920	arg1	concentration					922:934	1 % concentration	918:934	1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %)	918:999	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	0	26	theme	main	76:79	arg1	characteristics					81:95	main characteristics	76:95	main characteristics	76:95	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	7	27	theme	decreasing	1527:1536	arg1	trend					1538:1542	a decreasing trend	1525:1542	a decreasing trend with the addition of biopolymers into NC composition	1525:1595	The crystallinity index values showed a decreasing trend with the addition of biopolymers into NC composition.
37178884	9	28	theme	many	1793:1796	arg1	applications					1819:1830	many different industrial applications	1793:1830	many different industrial applications	1793:1830	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	28	theme	many	1793:1796	arg1	collectors					1846:1855	dust collectors	1841:1855	dust collectors	1841:1855	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	4	29	theme	NC-biopolymer	888:900	arg1	compositions					902:913	homogenous NC-biopolymer compositions	877:913	homogenous NC-biopolymer compositions	877:913	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	7	30	with	trend	1538:1542	arg1	addition					1553:1560	the addition	1549:1560	the addition of biopolymers into NC composition	1549:1595	The crystallinity index values showed a decreasing trend with the addition of biopolymers into NC composition.
37178884	2	31	theme	main	592:595	arg1	NC					604:605	the main matrix NC	588:605	the main matrix NC	588:605	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	3	32	dep	materials	786:794	arg1	addition					796:803	addition	796:803	addition	796:803	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	3	33	theme	main	843:846	arg1	matrix					848:853	main matrix	843:853	main matrix	843:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	3	34	theme	NFC-biopolymer	765:778	arg1	materials					786:794	NFC-biopolymer based materials	765:794	NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix	765:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	8	35	theme	porous	1642:1647	arg1	structure					1655:1663	a porous micro structure	1640:1663	a porous micro structure with different size pores and homogenous surface topography	1640:1723	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	3	36	theme	amount	833:838	arg1	efficiency					808:817	efficiency	808:817	efficiency of biopolymer amount in main matrix	808:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	2	37	theme	composite	610:618	arg1	properties					620:629	composite properties	610:629	composite properties	610:629	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	0	38	theme	Different	0:8	arg1	carboxyl-aldehyde					20:36	carboxyl-aldehyde	20:36	carboxyl-aldehyde	20:36	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	0	38	theme	Different	0:8	arg1	amount					10:15	Different amount	0:15	Different amount of carboxyl-aldehyde	0:36	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	2	39	theme	NC	604:605	arg1	fraction					576:583	carboxyl and aldehyde fraction	554:583	fraction	576:583	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	2	40	from	effect	544:549	arg1	properties					620:629	composite properties	610:629	composite properties	610:629	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	9	41	theme	liquid	1858:1863	arg1	adsorbers					1865:1873	liquid adsorbers	1858:1873	liquid adsorbers	1858:1873	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	41	theme	liquid	1858:1863	arg1	collectors					1846:1855	dust collectors	1841:1855	dust collectors	1841:1855	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	4	42	theme	varied	941:946	arg1	proportions					948:958	varied proportions	941:958	varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %)	941:999	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	43	theme	75 	961:963	arg1	%					991:991	25 %-75 %	983:991	25 %-75 %	983:991	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	43	theme	75 	961:963	arg1	%					980:980	50 %-50 %	972:980	50 %-50 %	972:980	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	43	theme	75 	961:963	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	43	theme	75 	961:963	arg1	%					998:998	100 %	994:998	100 %	994:998	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	44	theme	25 	983:985	arg1	%					991:991	25 %-75 %	983:991	25 %-75 %	983:991	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	44	theme	25 	983:985	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	45	theme	%	975:975	arg1	%					980:980	50 %-50 %	972:980	50 %-50 %	972:980	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	45	theme	%	975:975	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	9	46	theme	medical	1912:1918	arg1	materials					1920:1928	medical materials	1912:1928	medical materials	1912:1928	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	8	47	theme	different	1670:1678	arg1	pores					1685:1689	different size pores	1670:1689	different size pores	1670:1689	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	1	48	theme	aldehyde	249:256	arg1	amounts					238:244	different amounts	228:244	different amounts of aldehyde and carboxyl groups	228:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	48	theme	aldehyde	249:256	arg1	aldehyde					249:256	aldehyde	249:256	aldehyde	249:256	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	48	theme	aldehyde	249:256	arg1	groups					271:276	carboxyl groups	262:276	carboxyl groups	262:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	5	49	dep	99.84 	1157:1162	arg1	to					1154:1155	to	1154:1155	to	1154:1155	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	8	50	with	structure	1655:1663	arg1	pores					1685:1689	different size pores	1670:1689	different size pores	1670:1689	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	8	50	with	structure	1655:1663	arg1	topography					1714:1723	homogenous surface topography	1695:1723	homogenous surface topography	1695:1723	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	4	51	dep	proportions	948:958	arg1	%					991:991	25 %-75 %	983:991	25 %-75 %	983:991	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	51	dep	proportions	948:958	arg1	%					980:980	50 %-50 %	972:980	50 %-50 %	972:980	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	51	dep	proportions	948:958	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	51	dep	proportions	948:958	arg1	%					998:998	100 %	994:998	100 %	994:998	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	1	52	theme	carboxyl	262:269	arg1	groups					271:276	carboxyl groups	262:276	carboxyl groups	262:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	3	53	from	efficiency	808:817	arg1	matrix					848:853	main matrix	843:853	main matrix	843:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	8	54	theme	homogenous	1695:1704	arg1	topography					1714:1723	homogenous surface topography	1695:1723	homogenous surface topography	1695:1723	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	5	55	theme	%	1278:1278	arg1	values					1238:1243	values	1238:1243	values of 99.2-99.8 % and 98.47 to 99.7 %, respectively	1238:1292	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	1	56	theme	different	168:176	arg1	types					178:182	two different types	164:182	two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups	164:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	2	57	theme	aldehyde	567:574	arg1	fraction					576:583	carboxyl and aldehyde fraction	554:583	fraction	576:583	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	7	58	theme	NC	1582:1583	arg1	composition					1585:1595	NC composition	1582:1595	NC composition	1582:1595	The crystallinity index values showed a decreasing trend with the addition of biopolymers into NC composition.
37178884	2	59	theme	carboxyl	554:561	arg1	fraction					576:583	carboxyl and aldehyde fraction	554:583	fraction	576:583	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	6	60	dep	both	1365:1368	arg1	NC-CH					1370:1374	NC-CH	1370:1374	NC-CH	1370:1374	In addition, densities were determined in the range of 0.01 g/cm3 for both NC-CH and NC-GL composites, but higher values were obtained in ranged between 0.01 and 0.03 g/cm3 for NC-AL samples.
37178884	5	61	from	%	1163:1163	arg1	range					1137:1141	range	1137:1141	range	1137:1141	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	7	62	theme	biopolymers	1565:1575	arg1	addition					1553:1560	the addition	1549:1560	the addition of biopolymers into NC composition	1549:1595	The crystallinity index values showed a decreasing trend with the addition of biopolymers into NC composition.
37178884	0	63	theme	composites	134:143	arg1	cellulose					62:70	nanofibril cellulose	51:70	nanofibril cellulose	51:70	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	0	63	theme	composites	134:143	arg1	characteristics					81:95	main characteristics	76:95	main characteristics	76:95	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	9	64	theme	different	1798:1806	arg1	applications					1819:1830	many different industrial applications	1793:1830	many different industrial applications	1793:1830	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	64	theme	different	1798:1806	arg1	collectors					1846:1855	dust collectors	1841:1855	dust collectors	1841:1855	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	1	65	theme	celluloses	203:212	arg1	types					178:182	two different types	164:182	two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups	164:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	2	66	theme	NC	495:496	arg1	addition					483:490	the addition	479:490	the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties	479:629	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	9	67	theme	specified	1745:1753	arg1	tests					1755:1759	the specified tests	1741:1759	the specified tests	1741:1759	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	4	68	theme	easy	1051:1054	arg1	procedure					1071:1079	the fundamentally easy lyophilization procedure	1033:1079	the fundamentally easy lyophilization procedure	1033:1079	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	3	69	theme	carboxyl	700:707	arg1	groups					722:727	carboxyl and aldehyde groups	700:727	groups	722:727	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	1	70	theme	different	346:354	arg1	ratios					363:368	different mixing ratios	346:368	different mixing ratios	346:368	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	6	71	theme	higher	1402:1407	arg1	values					1409:1414	higher values	1402:1414	higher values	1402:1414	In addition, densities were determined in the range of 0.01 g/cm3 for both NC-CH and NC-GL composites, but higher values were obtained in ranged between 0.01 and 0.03 g/cm3 for NC-AL samples.
37178884	9	72	theme	industrial	1808:1817	arg1	applications					1819:1830	many different industrial applications	1793:1830	many different industrial applications	1793:1830	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	72	theme	industrial	1808:1817	arg1	collectors					1846:1855	dust collectors	1841:1855	dust collectors	1841:1855	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	2	73	theme	mentioning	502:511	arg1	biopolymers					513:523	mentioning biopolymers	502:523	mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties	502:629	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	6	74	theme	NC-AL	1472:1476	arg1	samples					1478:1484	NC-AL samples	1472:1484	NC-AL samples	1472:1484	In addition, densities were determined in the range of 0.01 g/cm3 for both NC-CH and NC-GL composites, but higher values were obtained in ranged between 0.01 and 0.03 g/cm3 for NC-AL samples.
37178884	3	75	theme	based	780:784	arg1	materials					786:794	NFC-biopolymer based materials	765:794	NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix	765:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	4	76	theme	1 	918:919	arg1	%					920:920	%	920:920	%	920:920	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	3	77	from	matrix	848:853	arg1	efficiency					808:817	efficiency	808:817	efficiency of biopolymer amount in main matrix	808:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	5	78	theme	based	1122:1126	arg1	aerogels					1128:1135	NC-Chitosan (NC/CH) based aerogels	1102:1135	NC-Chitosan (NC/CH) based aerogels	1102:1135	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	3	79	theme	aldehyde	713:720	arg1	groups					722:727	carboxyl and aldehyde groups	700:727	groups	722:727	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	0	80	theme	chitosan	100:107	arg1	composites					134:143	chitosan, gelatin, alginate added composites	100:143	chitosan, gelatin, alginate added composites	100:143	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	3	81	theme	biopolymer	822:831	arg1	amount					833:838	biopolymer amount	822:838	biopolymer amount in main matrix	822:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	2	82	theme	matrix	597:602	arg1	NC					604:605	the main matrix NC	588:605	the main matrix NC	588:605	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	4	83	theme	homogenous	877:886	arg1	compositions					902:913	homogenous NC-biopolymer compositions	877:913	homogenous NC-biopolymer compositions	877:913	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	3	84	theme	basic	740:744	arg1	characteristics					746:760	the basic characteristics	736:760	the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix	736:853	For this purpose, the main aim of this study was to investigate how carboxyl and aldehyde groups affect the basic characteristics of NFC-biopolymer based materials addition to efficiency of biopolymer amount in main matrix.
37178884	7	85	theme	index	1505:1509	arg1	values					1511:1516	The crystallinity index values	1487:1516	The crystallinity index values	1487:1516	The crystallinity index values showed a decreasing trend with the addition of biopolymers into NC composition.
37178884	2	86	from	study	425:429	arg1	literature					438:447	the literature	434:447	the literature	434:447	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	7	87	theme	crystallinity	1491:1503	arg1	values					1511:1516	The crystallinity index values	1487:1516	The crystallinity index values	1487:1516	The crystallinity index values showed a decreasing trend with the addition of biopolymers into NC composition.
37178884	4	88	theme	%	964:964	arg1	%					991:991	25 %-75 %	983:991	25 %-75 %	983:991	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	88	theme	%	964:964	arg1	%					980:980	50 %-50 %	972:980	50 %-50 %	972:980	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	88	theme	%	964:964	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	88	theme	%	964:964	arg1	%					998:998	100 %	994:998	100 %	994:998	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	9	89	theme	dust	1841:1844	arg1	adsorbers					1865:1873	liquid adsorbers	1858:1873	liquid adsorbers	1858:1873	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	89	theme	dust	1841:1844	arg1	material					1885:1892	specific material	1876:1892	specific material for packaging and medical materials	1876:1928	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	89	theme	dust	1841:1844	arg1	collectors					1846:1855	dust collectors	1841:1855	dust collectors	1841:1855	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	0	90	theme	carboxyl-aldehyde	20:36	arg1	carboxyl-aldehyde					20:36	carboxyl-aldehyde	20:36	carboxyl-aldehyde	20:36	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	0	90	theme	carboxyl-aldehyde	20:36	arg1	amount					10:15	Different amount	0:15	Different amount of carboxyl-aldehyde	0:36	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	8	91	theme	micro	1649:1653	arg1	structure					1655:1663	a porous micro structure	1640:1663	a porous micro structure with different size pores and homogenous surface topography	1640:1723	SEM images showed that all materials have a porous micro structure with different size pores and homogenous surface topography.
37178884	0	92	theme	nanofibril	51:60	arg1	cellulose					62:70	nanofibril cellulose	51:70	nanofibril cellulose	51:70	Different amount of carboxyl-aldehyde fractionated nanofibril cellulose and main characteristics of chitosan, gelatin, alginate added composites.
37178884	2	93	theme	related	417:423	arg1	study					425:429	no related study	414:429	no related study in the literature	414:447	There was no related study in the literature about producing aerogels with the addition of NC and mentioning biopolymers in addition to the effect of carboxyl and aldehyde fraction of the main matrix NC on composite properties.
37178884	1	94	dep	alginate	327:334	arg1	AL					337:338	AL	337:338	AL	337:338	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	4	95	with	concentration	922:934	arg1	proportions					948:958	varied proportions	941:958	varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %)	941:999	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	9	96	theme	specific	1876:1883	arg1	material					1885:1892	specific material	1876:1892	specific material for packaging and medical materials	1876:1928	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	9	96	theme	specific	1876:1883	arg1	collectors					1846:1855	dust collectors	1841:1855	dust collectors	1841:1855	As a result of the specified tests, these materials can be used in many different industrial applications, such as dust collectors, liquid adsorbers, specific material for packaging and medical materials.
37178884	5	97	contain	have	1233:1236	arg1	those					1174:1178	those	1174:1178	those	1174:1178	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	5	97	contain	have	1233:1236	arg2	values					1238:1243	values	1238:1243	values of 99.2-99.8 % and 98.47 to 99.7 %, respectively	1238:1292	Porosity values for NC-Chitosan (NC/CH) based aerogels range from 97.85 to 99.84 %, whereas those made from NC-Gelatin (NC/GL) and NC-Alginate (NC-AL) have values of 99.2-99.8 % and 98.47 to 99.7 %, respectively.
37178884	1	98	theme	different	228:236	arg1	amounts					238:244	different amounts	228:244	different amounts of aldehyde and carboxyl groups	228:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	98	theme	different	228:236	arg1	aldehyde					249:256	aldehyde	249:256	aldehyde	249:256	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	1	98	theme	different	228:236	arg1	groups					271:276	carboxyl groups	262:276	carboxyl groups	262:276	In this research, two different types of nanofibrillated celluloses (NFCs) having different amounts of aldehyde and carboxyl groups were mixed with chitosan (CH), gelatin (GL), and alginate (AL) with different mixing ratios to produce biocomposite aerogels.
37178884	4	99	theme	%	986:986	arg1	%					991:991	25 %-75 %	983:991	25 %-75 %	983:991	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
37178884	4	99	theme	%	986:986	arg1	%					969:969	75 %-25 %	961:969	75 %-25 %	961:969	Even after preparing homogenous NC-biopolymer compositions at 1 % concentration with varied proportions (75 %-25 %, 50 %-50 %, 25 %-75 %, 100 %), aerogels were still made using the fundamentally easy lyophilization procedure.
36709835	0	0	theme	Remicade®	86:94	arg1	Functionality					37:49	Functionality	37:49	Functionality	37:49	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	0	0	theme	Remicade®	86:94	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization	0:31	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	8	1	contain	had	1212:1214	arg2	pM					1254:1255	1.9 ± 0.1 pM	1244:1255	1.9 ± 0.1 pM	1244:1255	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	8	1	contain	had	1212:1214	arg1	Humira®					1204:1210	Humira®	1204:1210	Humira®	1204:1210	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	8	1	contain	had	1212:1214	arg2	EC50					1238:1241	a significantly lower EC50	1216:1241	a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA	1216:1305	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	1	2	theme	FDA-approved	138:149	arg1	biopharmaceuticals					161:178	FDA-approved anti-TNFα biopharmaceuticals	138:178	FDA-approved anti-TNFα biopharmaceuticals	138:178	FDA-approved anti-TNFα biopharmaceuticals are successful in treating a range of autoimmune diseases.
36709835	9	3	from	potent	1438:1443	arg1	assay					1464:1468	the bioreporter assay	1448:1468	the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM)	1448:1579	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	7	4	theme	effector	1153:1160	arg1	function					1162:1169	effector function	1153:1169	effector function	1153:1169	For the functional studies we tested TNFα binding via ELISA, FcγRIIIa binding via AlphaLISA and effector function using an ADCC bioreporter assay.
36709835	7	5	theme	functional	1065:1074	arg1	studies					1076:1082	the functional studies	1061:1082	the functional studies	1061:1082	For the functional studies we tested TNFα binding via ELISA, FcγRIIIa binding via AlphaLISA and effector function using an ADCC bioreporter assay.
36709835	5	6	theme	±	899:899	arg1	%					904:904	15.5 ± 1.3%	894:904	15.5 ± 1.3%	894:904	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	6	theme	±	899:899	arg1	glycans					885:891	afucosylated glycans	872:891	afucosylated glycans (15.5 ± 1.3%)	872:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	3	7	theme	functional	502:511	arg1	differences					513:523	structural and functional differences	487:523	structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®)	487:603	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	9	8	theme	nM	1504:1505	arg1	value					1483:1487	an EC50 value	1475:1487	an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM)	1475:1579	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	10	9	theme	shared	1671:1676	arg1	mechanisms					1678:1687	shared mechanisms	1671:1687	shared mechanisms of action	1671:1697	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	10	10	theme	single	1718:1723	arg1	laboratory					1725:1734	a single laboratory	1716:1734	a single laboratory	1716:1734	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	6	11	gly	afucosylated	1021:1032	arg1	glycans					1048:1054	afucosylated, high-mannose glycans	1021:1054	glycans	1048:1054	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	3	12	theme	anti-TNFα	550:558	arg1	Aria®					598:602	Aria®	598:602	Aria®	598:602	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	12	theme	anti-TNFα	550:558	arg1	Humira®					566:572	Humira®	566:572	Humira®	566:572	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	12	theme	anti-TNFα	550:558	arg1	mAbs					560:563	three full-length anti-TNFα mAbs	532:563	three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®)	532:603	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	12	theme	anti-TNFα	550:558	arg1	Remicade®					575:583	Remicade®	575:583	Remicade®	575:583	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	2	13	from	outcomes	306:313	arg1	identical					279:287	identical	279:287	identical	279:287	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	3	14	from	implications	630:641	arg1	efficacy					680:687	the products' efficacy	666:687	the products' efficacy	666:687	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	10	15	theme	conditions	1757:1766	arg1	set					1750:1752	one set	1746:1752	one set of conditions	1746:1766	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	10	15	theme	conditions	1757:1766	arg1	conditions					1757:1766	conditions	1757:1766	conditions	1757:1766	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	5	16	gly	afucosylated	872:883	arg1	%					904:904	15.5 ± 1.3%	894:904	15.5 ± 1.3%	894:904	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	16	gly	afucosylated	872:883	arg1	glycans					885:891	afucosylated glycans	872:891	afucosylated glycans (15.5 ± 1.3%)	872:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	7	17	theme	ADCC	1180:1183	arg1	assay					1197:1201	an ADCC bioreporter assay	1177:1201	an ADCC bioreporter assay	1177:1201	For the functional studies we tested TNFα binding via ELISA, FcγRIIIa binding via AlphaLISA and effector function using an ADCC bioreporter assay.
36709835	2	18	theme	product-specific	345:360	arg1	differences					362:372	product-specific differences	345:372	product-specific differences stemming from protein structural differences, doses and routes of administration	345:453	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	7	19	theme	bioreporter	1185:1195	arg1	assay					1197:1201	an ADCC bioreporter assay	1177:1201	an ADCC bioreporter assay	1177:1201	For the functional studies we tested TNFα binding via ELISA, FcγRIIIa binding via AlphaLISA and effector function using an ADCC bioreporter assay.
36709835	9	20	from	assay	1464:1468	arg1	potent					1438:1443	potent	1438:1443	potent	1438:1443	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	9	20	from	assay	1464:1468	arg1	Humira®					1412:1418	Humira®	1412:1418	Humira®	1412:1418	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	5	21	theme	28	949:950	arg1	glycans					940:946	unique glycans	933:946	unique glycans	933:946	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	22	theme	afucosylated	872:883	arg1	%					904:904	15.5 ± 1.3%	894:904	15.5 ± 1.3%	894:904	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	22	theme	afucosylated	872:883	arg1	glycans					885:891	afucosylated glycans	872:891	afucosylated glycans (15.5 ± 1.3%)	872:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	3	23	theme	full-length	538:548	arg1	Aria®					598:602	Aria®	598:602	Aria®	598:602	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	23	theme	full-length	538:548	arg1	Humira®					566:572	Humira®	566:572	Humira®	566:572	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	23	theme	full-length	538:548	arg1	mAbs					560:563	three full-length anti-TNFα mAbs	532:563	three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®)	532:603	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	23	theme	full-length	538:548	arg1	Remicade®					575:583	Remicade®	575:583	Remicade®	575:583	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	6	24	theme	afucosylated	1021:1032	arg1	glycans					1048:1054	afucosylated, high-mannose glycans	1021:1054	glycans	1048:1054	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	2	25	theme	structural	396:405	arg1	doses					420:424	doses	420:424	doses	420:424	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	2	25	theme	structural	396:405	arg1	differences					407:417	protein structural differences	388:417	protein structural differences	388:417	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	2	25	theme	structural	396:405	arg1	routes					430:435	routes	430:435	routes	430:435	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	5	26	theme	largest	915:921	arg1	number					923:928	the largest number	911:928	the largest number of unique glycans, 28	911:950	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	2	27	theme	protein	388:394	arg1	doses					420:424	doses	420:424	doses	420:424	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	2	27	theme	protein	388:394	arg1	differences					407:417	protein structural differences	388:417	protein structural differences	388:417	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	2	27	theme	protein	388:394	arg1	routes					430:435	routes	430:435	routes	430:435	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	0	28	theme	Physicochemical	0:14	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization	0:31	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	8	29	theme	binding	1361:1367	arg1	affinity					1369:1376	higher TNFα and FcγRIIIa binding affinity	1336:1376	higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®	1336:1409	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	5	30	contain	had	845:847	arg1	Remicade®					835:843	Remicade®	835:843	Remicade®	835:843	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	30	contain	had	845:847	arg2	percent					861:867	the highest percent	849:867	the highest percent of afucosylated glycans (15.5 ± 1.3%)	849:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	30	contain	had	845:847	arg2	number					923:928	the largest number	911:928	the largest number of unique glycans, 28	911:950	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	31	theme	glycans	885:891	arg1	number					923:928	the largest number	911:928	the largest number of unique glycans, 28	911:950	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	31	theme	glycans	885:891	arg1	percent					861:867	the highest percent	849:867	the highest percent of afucosylated glycans (15.5 ± 1.3%)	849:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	2	32	theme	administration	440:453	arg1	doses					420:424	doses	420:424	doses	420:424	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	2	32	theme	administration	440:453	arg1	differences					407:417	protein structural differences	388:417	protein structural differences	388:417	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	2	32	theme	administration	440:453	arg1	routes					430:435	routes	430:435	routes	430:435	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	9	33	theme	±	1497:1497	arg1	nM					1504:1505	0.55 ± 0.03 nM	1492:1505	0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM)	1492:1579	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	0	34	theme	Aria®	120:124	arg1	Functionality					37:49	Functionality	37:49	Functionality	37:49	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	0	34	theme	Aria®	120:124	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization	0:31	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	2	35	theme	patient	298:304	arg1	outcomes					306:313	their patient outcomes	292:313	their patient outcomes	292:313	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	10	36	theme	action	1692:1697	arg1	mechanisms					1678:1687	shared mechanisms	1671:1687	shared mechanisms of action	1671:1697	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	1	37	theme	anti-TNFα	151:159	arg1	biopharmaceuticals					161:178	FDA-approved anti-TNFα biopharmaceuticals	138:178	FDA-approved anti-TNFα biopharmaceuticals	138:178	FDA-approved anti-TNFα biopharmaceuticals are successful in treating a range of autoimmune diseases.
36709835	6	38	theme	glycans	1048:1054	arg1	glycans					1048:1054	afucosylated, high-mannose glycans	1021:1054	glycans	1048:1054	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	6	38	theme	glycans	1048:1054	arg1	%					1016:1016	0.8%	1013:1016	0.8% of afucosylated, high-mannose glycans	1013:1054	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	8	39	theme	±	1283:1283	arg1	nM					1289:1290	10.5 ± 1.1 nM	1278:1290	10.5 ± 1.1 nM	1278:1290	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	8	39	theme	±	1283:1283	arg1	IC50					1272:1275	IC50	1272:1275	IC50 (10.5 ± 1.1 nM)	1272:1291	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	4	40	theme	structural	694:703	arg1	characterization					705:720	structural characterization	694:720	structural characterization	694:720	For structural characterization, we quantified N-glycans using mass spectrometry and fluorescence labeling.
36709835	3	41	theme	such	646:649	arg1	differences					651:661	such differences	646:661	such differences	646:661	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	10	42	theme	functional	1630:1639	arg1	differences					1641:1651	functional differences	1630:1651	functional differences between mAbs with shared mechanisms of action	1630:1697	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	8	43	contain	has	1332:1334	arg2	affinity					1369:1376	higher TNFα and FcγRIIIa binding affinity	1336:1376	higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®	1336:1409	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	8	43	contain	has	1332:1334	arg1	Humira®					1324:1330	Humira®	1324:1330	Humira®	1324:1330	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	7	44	theme	TNFα	1094:1097	arg1	binding					1099:1105	TNFα binding	1094:1105	TNFα binding	1094:1105	For the functional studies we tested TNFα binding via ELISA, FcγRIIIa binding via AlphaLISA and effector function using an ADCC bioreporter assay.
36709835	8	45	theme	TNFα	1343:1346	arg1	affinity					1369:1376	higher TNFα and FcγRIIIa binding affinity	1336:1376	higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®	1336:1409	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	8	46	theme	0.1	1250:1252	arg1	±					1248:1248	±	1248:1248	±	1248:1248	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	5	47	theme	highest	853:859	arg1	percent					861:867	the highest percent	849:867	the highest percent of afucosylated glycans (15.5 ± 1.3%)	849:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	8	48	theme	lower	1232:1236	arg1	EC50					1238:1241	a significantly lower EC50	1216:1241	a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA	1216:1305	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	8	48	theme	lower	1232:1236	arg1	pM					1254:1255	1.9 ± 0.1 pM	1244:1255	1.9 ± 0.1 pM	1244:1255	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	9	49	with	assay	1464:1468	arg1	value					1483:1487	an EC50 value	1475:1487	an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM)	1475:1579	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	8	50	theme	higher	1336:1341	arg1	affinity					1369:1376	higher TNFα and FcγRIIIa binding affinity	1336:1376	higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®	1336:1409	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	9	51	theme	EC50	1478:1481	arg1	value					1483:1487	an EC50 value	1475:1487	an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM)	1475:1579	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	8	52	theme	1.9	1244:1246	arg1	±					1248:1248	±	1248:1248	±	1248:1248	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	0	53	theme	Humira®	65:71	arg1	Functionality					37:49	Functionality	37:49	Functionality	37:49	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	0	53	theme	Humira®	65:71	arg1	Characterization					16:31	Physicochemical Characterization	0:31	Physicochemical Characterization	0:31	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	8	54	theme	FcγRIIIa	1352:1359	arg1	affinity					1369:1376	higher TNFα and FcγRIIIa binding affinity	1336:1376	higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®	1336:1409	Humira® had a significantly lower EC50 (1.9 ± 0.1 pM) for ELISA and IC50 (10.5 ± 1.1 nM) for AlphaLISA, suggesting that Humira® has higher TNFα and FcγRIIIa binding affinity than Remicade® and Simponi Aria®.
36709835	3	55	theme	structural	487:496	arg1	differences					513:523	structural and functional differences	487:523	structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®)	487:603	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	10	56	with	mAbs	1661:1664	arg1	mechanisms					1678:1687	shared mechanisms	1671:1687	shared mechanisms of action	1671:1697	This comparison is significant as it highlights functional differences between mAbs with shared mechanisms of action when examined in a single laboratory and under one set of conditions.
36709835	9	57	theme	0.67	1565:1568	arg1	±					1570:1570	±	1570:1570	±	1570:1570	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	2	58	theme	anti-TNFα	256:264	arg1	products					266:273	not all anti-TNFα products	248:273	not all anti-TNFα products	248:273	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	4	59	theme	mass	753:756	arg1	spectrometry					758:769	mass spectrometry	753:769	mass spectrometry	753:769	For structural characterization, we quantified N-glycans using mass spectrometry and fluorescence labeling.
36709835	1	60	theme	autoimmune	218:227	arg1	diseases					229:236	autoimmune diseases	218:236	autoimmune diseases	218:236	FDA-approved anti-TNFα biopharmaceuticals are successful in treating a range of autoimmune diseases.
36709835	4	61	theme	fluorescence	775:786	arg1	labeling					788:795	fluorescence labeling	775:795	fluorescence labeling	775:795	For structural characterization, we quantified N-glycans using mass spectrometry and fluorescence labeling.
36709835	3	62	theme	differences	651:661	arg1	implications					630:641	the implications	626:641	the implications of such differences on the products' efficacy	626:687	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	5	63	theme	glycans	940:946	arg1	number					923:928	the largest number	911:928	the largest number of unique glycans, 28	911:950	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	5	63	theme	glycans	940:946	arg1	percent					861:867	the highest percent	849:867	the highest percent of afucosylated glycans (15.5 ± 1.3%)	849:905	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	3	64	dep	mAbs	560:563	arg1	Humira®					566:572	Humira®	566:572	Humira®	566:572	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	64	dep	mAbs	560:563	arg1	mAbs					560:563	three full-length anti-TNFα mAbs	532:563	three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®)	532:603	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	64	dep	mAbs	560:563	arg1	Aria®					598:602	Aria®	598:602	Aria®	598:602	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	3	64	dep	mAbs	560:563	arg1	Remicade®					575:583	Remicade®	575:583	Remicade®	575:583	In this work, we focus only on structural and functional differences across three full-length anti-TNFα mAbs (Humira®, Remicade®, and Simponi Aria®) to better understand the implications of such differences on the products' efficacy.
36709835	1	65	theme	diseases	229:236	arg1	range					209:213	a range	207:213	a range of autoimmune diseases	207:236	FDA-approved anti-TNFα biopharmaceuticals are successful in treating a range of autoimmune diseases.
36709835	9	66	theme	0.03	1572:1575	arg1	±					1570:1570	±	1570:1570	±	1570:1570	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	6	67	contain	had	967:969	arg2	glycans					989:995	the fewest unique glycans	971:995	the fewest unique glycans	971:995	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	6	67	contain	had	967:969	arg1	Humira®					959:965	Humira®	959:965	Humira®	959:965	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	0	68	dep	Characterization	16:31	arg1	Comparison					51:60	Comparison	51:60	Comparison	51:60	Physicochemical Characterization and Functionality Comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria®(golimumab).
36709835	5	69	theme	unique	933:938	arg1	glycans					940:946	unique glycans	933:946	unique glycans	933:946	From these studies, we observed that Remicade® had the highest percent of afucosylated glycans (15.5 ± 1.3%) and the largest number of unique glycans, 28.
36709835	2	70	from	identical	279:287	arg1	outcomes					306:313	their patient outcomes	292:313	their patient outcomes	292:313	However, not all anti-TNFα products are identical in their patient outcomes, suggesting that there may be product-specific differences stemming from protein structural differences, doses and routes of administration.
36709835	6	71	theme	unique	982:987	arg1	glycans					989:995	the fewest unique glycans	971:995	the fewest unique glycans	971:995	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	9	72	theme	bioreporter	1452:1462	arg1	assay					1464:1468	the bioreporter assay	1448:1468	the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM)	1448:1579	Humira® was also the most potent in the bioreporter assay with an EC50 value of 0.55 ± 0.03 nM compared to Remicade® (0.64 ± 0.04 nM) and Simponi Aria® (0.67 ± 0.03 nM).
36709835	6	73	theme	high-mannose	1035:1046	arg1	glycans					1048:1054	afucosylated, high-mannose glycans	1021:1054	glycans	1048:1054	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36709835	6	74	theme	fewest	975:980	arg1	glycans					989:995	the fewest unique glycans	971:995	the fewest unique glycans	971:995	While Humira® had the fewest unique glycans, 15, and 11.4 ± 0.8% of afucosylated, high-mannose glycans.
36210615	6	0	theme	human	1759:1763	arg1	envenomation					1765:1776	human envenomation	1759:1776	human envenomation	1759:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	3	1	theme	proteolytic	689:699	arg1	activity					701:708	venom proteolytic activity	683:708	venom proteolytic activity	683:708	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	5	2	theme	sialic	1362:1367	arg1	acid					1369:1372	sialic acid	1362:1372	sialic acid	1362:1372	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	1	3	theme	proteomes	250:258	arg1	diversification					225:239	the diversification	221:239	the diversification of venom proteomes	221:258	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	6	4	theme	relevant	1747:1754	arg1	proteases					1737:1745	venom proteases	1731:1745	venom proteases relevant in human envenomation	1731:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	3	5	theme	abundant	514:521	arg1	proteases					500:508	serine proteases	493:508	serine proteases	493:508	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	5	theme	abundant	514:521	arg1	components					523:532	abundant components	514:532	abundant components of Bothrops venoms and essential in the envenomation process	514:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	5	theme	abundant	514:521	arg1	metalloproteases					472:487	metalloproteases	472:487	metalloproteases	472:487	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	6	6	from	relevant	1747:1754	arg1	envenomation					1765:1776	human envenomation	1759:1776	human envenomation	1759:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	2	7	theme	sialic	442:447	arg1	acid					449:452	sialic acid	442:452	sialic acid	442:452	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	3	8	from	components	523:532	arg1	process					587:593	the envenomation process	570:593	the envenomation process	570:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	2	9	theme	Bothrops	298:305	arg1	venoms					307:312	Bothrops venoms	298:312	Bothrops venoms	298:312	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	6	10	from	envenomation	1765:1776	arg1	relevant					1747:1754	relevant	1747:1754	relevant	1747:1754	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	4	11	theme	gelatinolytic	908:920	arg1	activity					922:929	the gelatinolytic activity	904:929	the gelatinolytic activity of all venoms	904:943	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	12	theme	venoms	1064:1069	arg1	plasma					1050:1055	human plasma	1044:1055	human plasma of all venoms	1044:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	13	with	interaction	1206:1216	arg1	substrates					1250:1259	their protein substrates	1236:1259	their protein substrates	1236:1259	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	3	14	theme	envenomation	574:585	arg1	process					587:593	the envenomation process	570:593	the envenomation process	570:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	6	15	theme	first	1619:1623	arg1	time					1625:1628	the first time	1615:1628	the first time	1615:1628	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	5	16	from	N-glycans	1431:1439	arg1	essential					1418:1426	essential	1418:1426	essential	1418:1426	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	4	17	theme	venoms	885:890	arg1	zymography					866:875	zymography	866:875	zymography of most venoms	866:890	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	18	theme	proteins	1124:1131	arg1	profile					1106:1112	the proteolysis profile	1090:1112	the proteolysis profile of plasma proteins	1090:1131	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	19	dep	decreased	951:959	arg1	ii					947:948	ii	947:948	ii	947:948	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	5	20	from	essential	1418:1426	arg1	N-glycans					1431:1439	N-glycans	1431:1439	N-glycans of serine proteases acting on small substrates	1431:1486	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	5	21	theme	acid	1369:1372	arg1	removal					1351:1357	removal	1351:1357	removal of sialic acid	1351:1372	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	4	22	theme	B. jararaca	1136:1146	arg1	venom					1148:1152	B. jararaca venom	1136:1152	B. jararaca venom	1136:1152	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	6	23	theme	venom	1590:1594	arg1	proteases					1596:1604	Bothrops venom proteases	1581:1604	Bothrops venom proteases	1581:1604	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	4	24	theme	proteolysis	1094:1104	arg1	profile					1106:1112	the proteolysis profile	1090:1112	the proteolysis profile of plasma proteins	1090:1131	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	3	25	theme	several	627:633	arg1	sites					649:653	several glycosylation sites	627:653	several glycosylation sites	627:653	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	26	from	activity	1032:1039	arg1	fibrinogen					1004:1013	fibrinogen	1004:1013	fibrinogen	1004:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	6	27	dep	expand	1515:1520	arg1	point					1630:1634	point	1630:1634	point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation	1630:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	6	28	theme	chains	1670:1675	arg1	importance					1643:1652	the importance	1639:1652	the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation	1639:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	0	29	theme	snake	62:66	arg1	proteases					74:82	snake venom proteases	62:82	snake venom proteases	62:82	Sialic acid-containing glycans play a role in the activity of snake venom proteases.
36210615	6	30	theme	Bothrops	1581:1588	arg1	proteases					1596:1604	Bothrops venom proteases	1581:1604	Bothrops venom proteases	1581:1604	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	4	31	theme	venoms	938:943	arg1	activity					922:929	the gelatinolytic activity	904:929	the gelatinolytic activity of all venoms	904:943	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	0	32	theme	proteases	74:82	arg1	activity					50:57	the activity	46:57	the activity of snake venom proteases	46:82	Sialic acid-containing glycans play a role in the activity of snake venom proteases.
36210615	6	33	theme	subproteomes	1565:1576	arg1	variability					1546:1556	the variability	1542:1556	the variability of the subproteomes of Bothrops venom proteases	1542:1604	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	2	34	theme	hybrid/complex	382:395	arg1	N-glycans					397:405	most hybrid/complex N-glycans	377:405	most hybrid/complex N-glycans identified in these venoms	377:432	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	0	35	theme	Sialic	0:5	arg1	glycans					23:29	Sialic acid-containing glycans	0:29	Sialic acid-containing glycans	0:29	Sialic acid-containing glycans play a role in the activity of snake venom proteases.
36210615	6	36	contain	containing	1677:1686	arg1	chains					1670:1675	carbohydrate chains	1657:1675	carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation	1657:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	6	36	contain	containing	1677:1686	arg2	acid					1695:1698	sialic acid	1688:1698	sialic acid	1688:1698	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	4	37	theme	sialic	754:759	arg1	acid					761:764	sialic acid	754:764	sialic acid by treatment of nine Bothrops venoms with neuraminidase	754:820	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	38	dep	altered	826:832	arg1	decreased					951:959	decreased	951:959	(ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms	946:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	38	dep	altered	826:832	arg1	i					823:823	i	823:823	i	823:823	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	3	39	dep	Bothrops	537:544	arg1	venoms					546:551	venoms	546:551	venoms	546:551	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	6	40	theme	enzymatic	1707:1715	arg1	activities					1717:1726	the enzymatic activities	1703:1726	the enzymatic activities of venom proteases relevant in human envenomation	1703:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	4	41	from	activity	977:984	arg1	fibrinogen					1004:1013	fibrinogen	1004:1013	fibrinogen	1004:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	42	theme	plasma	1050:1055	arg1	activity					1032:1039	the clotting activity	1019:1039	the clotting activity of human plasma of all venoms	1019:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	42	theme	plasma	1050:1055	arg1	activity					977:984	the proteolytic activity	961:984	the proteolytic activity of some venoms on fibrinogen	961:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	6	43	theme	sialic	1688:1693	arg1	acid					1695:1698	sialic acid	1688:1698	sialic acid	1688:1698	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	5	44	theme	proteases	1451:1459	arg1	N-glycans					1431:1439	N-glycans	1431:1439	N-glycans of serine proteases acting on small substrates	1431:1486	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	3	45	theme	venom	683:687	arg1	activity					701:708	venom proteolytic activity	683:708	venom proteolytic activity	683:708	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	46	theme	Bothrops	787:794	arg1	venoms					796:801	nine Bothrops venoms	782:801	nine Bothrops venoms	782:801	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	1	47	theme	venom	130:134	arg1	proteins					136:143	snake venom proteins	124:143	snake venom proteins	124:143	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	3	48	contain	contain	619:625	arg2	sites					649:653	several glycosylation sites	627:653	several glycosylation sites	627:653	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	48	contain	contain	619:625	arg1	enzymes					611:617	these enzymes	605:617	these enzymes	605:617	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	49	theme	acid	675:678	arg1	role					660:663	the role	656:663	the role of sialic acid in venom proteolytic activity	656:708	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	5	50	theme	venom	1290:1294	arg1	activity					1307:1314	venom amidolytic activity	1290:1314	venom amidolytic activity	1290:1314	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	4	51	theme	clotting	1023:1030	arg1	activity					1032:1039	the clotting activity	1019:1039	the clotting activity of human plasma of all venoms	1019:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	5	52	theme	activity	1307:1314	arg1	profile					1279:1285	the profile	1275:1285	the profile of venom amidolytic activity on Bz-Arg-pNA	1275:1328	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	2	53	theme	glycoprotein	346:357	arg1	content					359:365	their glycoprotein content	340:365	their glycoprotein content	340:365	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	1	54	theme	venom	244:248	arg1	proteomes					250:258	venom proteomes	244:258	venom proteomes	244:258	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	4	55	theme	gelatinolysis	849:861	arg1	pattern					838:844	the pattern	834:844	the pattern of gelatinolysis in zymography of most venoms	834:890	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	2	56	contain	contain	434:440	arg2	acid					449:452	sialic acid	442:452	sialic acid	442:452	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	2	56	contain	contain	434:440	arg1	N-glycans					397:405	most hybrid/complex N-glycans	377:405	most hybrid/complex N-glycans identified in these venoms	377:432	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	3	57	theme	essential	557:565	arg1	proteases					500:508	serine proteases	493:508	serine proteases	493:508	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	57	theme	essential	557:565	arg1	components					523:532	abundant components	514:532	abundant components of Bothrops venoms and essential in the envenomation process	514:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	57	theme	essential	557:565	arg1	metalloproteases					472:487	metalloproteases	472:487	metalloproteases	472:487	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	6	58	theme	proteases	1737:1745	arg1	activities					1717:1726	the enzymatic activities	1703:1726	the enzymatic activities of venom proteases relevant in human envenomation	1703:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	3	59	from	role	660:663	arg1	activity					701:708	venom proteolytic activity	683:708	venom proteolytic activity	683:708	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	60	theme	protein	1242:1248	arg1	substrates					1250:1259	their protein substrates	1236:1259	their protein substrates	1236:1259	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	3	61	gly	glycosylation	635:647	arg2	sites					649:653	several glycosylation sites	627:653	several glycosylation sites	627:653	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	62	with	treatment	769:777	arg1	neuraminidase					808:820	neuraminidase	808:820	neuraminidase	808:820	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	1	63	theme	post-translational	169:186	arg1	modification					188:199	a post-translational modification	167:199	a post-translational modification that contributes to the diversification of venom proteomes	167:258	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	1	63	theme	post-translational	169:186	arg1	glycosylation					150:162	glycosylation	150:162	glycosylation	150:162	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	4	64	theme	most	880:883	arg1	venoms					885:890	most venoms	880:890	most venoms	880:890	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	3	65	theme	glycosylation	635:647	arg1	sites					649:653	several glycosylation sites	627:653	several glycosylation sites	627:653	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	6	66	theme	proteases	1596:1604	arg1	subproteomes					1565:1576	the subproteomes	1561:1576	the subproteomes of Bothrops venom proteases	1561:1604	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	5	67	from	profile	1279:1285	arg1	Bz-Arg-pNA					1319:1328	Bz-Arg-pNA	1319:1328	Bz-Arg-pNA	1319:1328	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	3	68	from	process	587:593	arg1	essential					557:565	essential	557:565	essential	557:565	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	68	from	process	587:593	arg1	components					523:532	abundant components	514:532	abundant components of Bothrops venoms and essential in the envenomation process	514:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	68	from	process	587:593	arg1	proteases					500:508	serine proteases	493:508	serine proteases	493:508	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	68	from	process	587:593	arg1	metalloproteases					472:487	metalloproteases	472:487	metalloproteases	472:487	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	69	dep	altered	1082:1088	arg1	iii					1077:1079	iii	1077:1079	iii	1077:1079	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	1	70	theme	snake	124:128	arg1	proteins					136:143	snake venom proteins	124:143	snake venom proteins	124:143	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	4	71	theme	plasma	1117:1122	arg1	proteins					1124:1131	plasma proteins	1117:1131	plasma proteins	1117:1131	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	0	72	theme	venom	68:72	arg1	proteases					74:82	snake venom proteases	62:82	snake venom proteases	62:82	Sialic acid-containing glycans play a role in the activity of snake venom proteases.
36210615	1	73	theme	proteins	136:143	arg1	feature					113:119	a feature	111:119	a feature of snake venom proteins	111:143	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	1	73	theme	proteins	136:143	arg1	modification					188:199	a post-translational modification	167:199	a post-translational modification that contributes to the diversification of venom proteomes	167:258	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	1	73	theme	proteins	136:143	arg1	glycosylation					150:162	glycosylation	150:162	glycosylation	150:162	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	1	73	theme	proteins	136:143	arg1	variability					96:106	Structural variability	85:106	Structural variability	85:106	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	6	74	theme	carbohydrate	1657:1668	arg1	chains					1670:1675	carbohydrate chains	1657:1675	carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation	1657:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	3	75	from	essential	557:565	arg1	process					587:593	the envenomation process	570:593	the envenomation process	570:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	76	theme	acid	761:764	arg1	removal					743:749	removal	743:749	removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase	743:820	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	77	from	pattern	838:844	arg1	zymography					866:875	zymography	866:875	zymography of most venoms	866:890	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	2	78	theme	most	377:380	arg1	N-glycans					397:405	most hybrid/complex N-glycans	377:405	most hybrid/complex N-glycans identified in these venoms	377:432	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	0	79	theme	acid-containing	7:21	arg1	glycans					23:29	Sialic acid-containing glycans	0:29	Sialic acid-containing glycans	0:29	Sialic acid-containing glycans play a role in the activity of snake venom proteases.
36210615	4	80	theme	venoms	994:999	arg1	activity					1032:1039	the clotting activity	1019:1039	the clotting activity of human plasma of all venoms	1019:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	80	theme	venoms	994:999	arg1	activity					977:984	the proteolytic activity	961:984	the proteolytic activity of some venoms on fibrinogen	961:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	6	81	theme	venom	1731:1735	arg1	proteases					1737:1745	venom proteases	1731:1745	venom proteases relevant in human envenomation	1731:1776	In summary, these results expand the knowledge about the variability of the subproteomes of Bothrops venom proteases, and for the first time point to the importance of carbohydrate chains containing sialic acid in the enzymatic activities of venom proteases relevant in human envenomation.
36210615	4	82	theme	sialic	1171:1176	arg1	acid					1178:1181	sialic acid	1171:1181	sialic acid	1171:1181	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	83	from	fibrinogen	1004:1013	arg1	activity					1032:1039	the clotting activity	1019:1039	the clotting activity of human plasma of all venoms	1019:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	83	from	fibrinogen	1004:1013	arg1	activity					977:984	the proteolytic activity	961:984	the proteolytic activity of some venoms on fibrinogen	961:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	1	84	theme	Structural	85:94	arg1	feature					113:119	a feature	111:119	a feature of snake venom proteins	111:143	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	1	84	theme	Structural	85:94	arg1	variability					96:106	Structural variability	85:106	Structural variability	85:106	Structural variability is a feature of snake venom proteins, and glycosylation is a post-translational modification that contributes to the diversification of venom proteomes.
36210615	5	85	theme	small	1471:1475	arg1	substrates					1477:1486	small substrates	1471:1486	small substrates	1471:1486	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	4	86	theme	proteases	1221:1229	arg1	interaction					1206:1216	the interaction	1202:1216	the interaction of proteases with their protein substrates	1202:1259	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	87	from	venoms	994:999	arg1	fibrinogen					1004:1013	fibrinogen	1004:1013	fibrinogen	1004:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	4	88	theme	proteolytic	965:975	arg1	activity					977:984	the proteolytic activity	961:984	the proteolytic activity of some venoms on fibrinogen	961:1013	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	2	89	gly	glycoprotein	346:357	arg1	glycoprotein					346:357	their glycoprotein content	340:365	their glycoprotein content	340:365	Studies by our group have shown that Bothrops venoms are distinctly defined by their glycoprotein content, and that most hybrid/complex N-glycans identified in these venoms contain sialic acid.
36210615	5	90	theme	serine	1444:1449	arg1	proteases					1451:1459	serine proteases	1444:1459	serine proteases acting on small substrates	1444:1486	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	4	91	theme	human	1044:1048	arg1	plasma					1050:1055	human plasma	1044:1055	human plasma of all venoms	1044:1069	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	3	92	theme	sialic	668:673	arg1	acid					675:678	sialic acid	668:678	sialic acid	668:678	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	93	theme	serine	493:498	arg1	proteases					500:508	serine proteases	493:508	serine proteases	493:508	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	93	theme	serine	493:498	arg1	components					523:532	abundant components	514:532	abundant components of Bothrops venoms and essential in the envenomation process	514:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	93	theme	serine	493:498	arg1	metalloproteases					472:487	metalloproteases	472:487	metalloproteases	472:487	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	4	94	theme	venoms	796:801	arg1	treatment					769:777	treatment	769:777	treatment of nine Bothrops venoms with neuraminidase	769:820	Here we show that removal of sialic acid by treatment of nine Bothrops venoms with neuraminidase (i) altered the pattern of gelatinolysis in zymography of most venoms and reduced the gelatinolytic activity of all venoms, (ii) decreased the proteolytic activity of some venoms on fibrinogen and the clotting activity of human plasma of all venoms, and (iii) altered the proteolysis profile of plasma proteins by B. jararaca venom, suggesting that sialic acid may play a role in the interaction of proteases with their protein substrates.
36210615	5	95	theme	amidolytic	1296:1305	arg1	activity					1307:1314	venom amidolytic activity	1290:1314	venom amidolytic activity	1290:1314	In contrast, the profile of venom amidolytic activity on Bz-Arg-pNA did not change after removal of sialic acid, indicating that this monosaccharide is not essential in N-glycans of serine proteases acting on small substrates.
36210615	3	96	theme	Bothrops	537:544	arg1	proteases					500:508	serine proteases	493:508	serine proteases	493:508	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	96	theme	Bothrops	537:544	arg1	components					523:532	abundant components	514:532	abundant components of Bothrops venoms and essential in the envenomation process	514:593	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36210615	3	96	theme	Bothrops	537:544	arg1	metalloproteases					472:487	metalloproteases	472:487	metalloproteases	472:487	Considering that metalloproteases and serine proteases are abundant components of Bothrops venoms and essential in the envenomation process, and that these enzymes contain several glycosylation sites, the role of sialic acid in venom proteolytic activity was evaluated.
36682649	1	0	theme	Poly	452:455	arg1	surface					441:447	the surface	437:447	the surface of Poly (L-lactic acid) (PLA)	437:477	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	6	1	theme	excellent	1494:1502	arg1	abilities					1540:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	6	1	theme	excellent	1494:1502	arg1	cells					1487:1491	L929 fibroblast cells	1471:1491	L929 fibroblast cells	1471:1491	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	1	2	theme	carboxymethylcellulose	282:303	arg1	sodium					305:310	carboxymethylcellulose sodium	282:310	carboxymethylcellulose sodium	282:310	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	1	3	theme	L-lactic	458:465	arg1	Poly					452:455	Poly	452:455	Poly (L-lactic acid) (PLA)	452:477	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	1	3	theme	L-lactic	458:465	arg1	acid					467:470	L-lactic acid	458:470	L-lactic acid	458:470	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	2	4	theme	SCMC	647:650	arg1	bioactivity					632:642	bioactivity	632:642	bioactivity	632:642	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	2	4	theme	SCMC	647:650	arg1	structure					618:626	preliminary structure	606:626	preliminary structure	606:626	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	2	5	with	structure	618:626	arg1	degree					667:672	different degree	657:672	different degree of sulfation	657:685	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	3	6	theme	surface	759:765	arg1	compositions					776:787	The surface chemical compositions	755:787	The surface chemical compositions	755:787	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	2	7	with	bioactivity	632:642	arg1	degree					667:672	different degree	657:672	different degree of sulfation	657:685	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	7	8	theme	clinical	1753:1760	arg1	applications					1762:1773	future clinical applications	1746:1773	future clinical applications	1746:1773	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	0	9	theme	l-lactic	134:141	arg1	poly					128:131	poly	128:131	poly (l-lactic acid) film for cardiovascular implant applications	128:192	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	0	9	theme	l-lactic	134:141	arg1	acid					143:146	l-lactic acid	134:146	l-lactic acid	134:146	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	5	10	theme	film	1111:1114	arg1	term					1067:1070	term	1067:1070	term of (SCMC/CS)15 multilayer-modified PLA film	1067:1114	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	1	11	theme	heparin-like	210:221	arg1	polysaccharides					223:237	heparin-like polysaccharides	210:237	heparin-like polysaccharides	210:237	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	5	12	theme	thromboplastin	1227:1240	arg1	time					1242:1245	the activated partial thromboplastin time	1205:1245	the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s	1205:1300	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	6	13	theme	L929	1471:1474	arg1	abilities					1540:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	6	13	theme	L929	1471:1474	arg1	cells					1487:1491	L929 fibroblast cells	1471:1491	L929 fibroblast cells	1471:1491	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	2	14	dep	structure	618:626	arg1	The					602:604	The	602:604	The	602:604	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	7	15	theme	promising	1723:1731	arg1	potential					1733:1741	promising potential	1723:1741	promising potential	1723:1741	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	3	16	theme	photoelectron	885:897	arg1	spectrometer					899:910	X-ray photoelectron spectrometer	879:910	X-ray photoelectron spectrometer	879:910	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	5	17	dep	prolonged	1247:1255	arg1	exceed					1289:1294	exceed	1289:1294	prolonged by 11.9 times and thrombin time exceed 300 s	1247:1300	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	3	18	theme	SCMC/CS	822:828	arg1	films					854:858	SCMC/CS multilayer-modified PLA films	822:858	SCMC/CS multilayer-modified PLA films	822:858	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	0	19	theme	implant	173:179	arg1	applications					181:192	cardiovascular implant applications	158:192	cardiovascular implant applications	158:192	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	5	20	theme	multilayer-modified	1087:1105	arg1	film					1111:1114	(SCMC/CS)15 multilayer-modified PLA film	1075:1114	(SCMC/CS)15 multilayer-modified PLA film	1075:1114	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	5	21	theme	hemolysis	1330:1338	arg1	rate					1340:1343	hemolysis rate	1330:1343	hemolysis rate	1330:1343	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	7	22	theme	antibacterial	1689:1701	arg1	properties					1703:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	4	23	theme	multilayer-modified	1018:1036	arg1	films					1042:1046	SCMC/CS multilayer-modified PLA films	1010:1046	SCMC/CS multilayer-modified PLA films	1010:1046	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films were performed.
36682649	6	24	theme	modified	1416:1423	arg1	films					1429:1433	this modified PLA films	1411:1433	this modified PLA films	1411:1433	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	1	25	theme	carboxymethylcellulose	364:385	arg1	CS					415:416	CS	415:416	CS	415:416	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	1	25	theme	carboxymethylcellulose	364:385	arg1	SCMC					395:398	SCMC	395:398	SCMC	395:398	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	1	25	theme	carboxymethylcellulose	364:385	arg1	sodium					387:392	sulfated carboxymethylcellulose sodium	355:392	sulfated carboxymethylcellulose sodium (SCMC)	355:399	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	3	26	theme	electron	922:929	arg1	microscopy					931:940	scanning electron microscopy	913:940	scanning electron microscopy	913:940	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	7	27	theme	anti-inflammatory	1667:1683	arg1	properties					1703:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	4	28	theme	films	1042:1046	arg1	tests					1001:1005	anticoagulation tests	985:1005	anticoagulation tests of SCMC/CS multilayer-modified PLA films	985:1046	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films were performed.
36682649	2	29	theme	best	724:727	arg1	performance					729:739	best performance	724:739	best performance	724:739	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	7	30	theme	cytocompatibility	1648:1664	arg1	properties					1703:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	4	31	theme	anticoagulation	985:999	arg1	tests					1001:1005	anticoagulation tests	985:1005	anticoagulation tests of SCMC/CS multilayer-modified PLA films	985:1046	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films were performed.
36682649	3	32	theme	PLA	850:852	arg1	films					854:858	SCMC/CS multilayer-modified PLA films	822:858	SCMC/CS multilayer-modified PLA films	822:858	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	3	33	theme	contact	952:958	arg1	meter					966:970	water contact angle meter	946:970	water contact angle meter	946:970	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	7	34	theme	hemocompatibility	1629:1645	arg1	properties					1703:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	1	35	theme	blood-contact	535:547	arg1	application					549:559	the potential blood-contact application	521:559	the potential blood-contact application such as bioresorbable vascular scaffold	521:599	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	0	36	theme	poly	128:131	arg1	film					149:152	poly (l-lactic acid) film	128:152	poly (l-lactic acid) film for cardiovascular implant applications	128:192	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	5	37	theme	plate	1144:1148	arg1	adhesion					1150:1157	plate adhesion	1144:1157	plate adhesion	1144:1157	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	7	38	contain	have	1718:1721	arg2	potential					1733:1741	promising potential	1723:1741	promising potential	1723:1741	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	7	38	contain	have	1718:1721	arg1	films					1618:1622	the multifunctional SCMC/CS multilayer-modified PLA films	1566:1622	the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1566:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	1	39	theme	biobased	326:333	arg1	bilayer					335:341	a fully biobased bilayer	318:341	a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS)	318:417	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	5	40	theme	unmodified	1381:1390	arg1	film					1396:1399	unmodified PLA film	1381:1399	unmodified PLA film	1381:1399	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	6	41	theme	fibroblast	1476:1485	arg1	abilities					1540:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	6	41	theme	fibroblast	1476:1485	arg1	cells					1487:1491	L929 fibroblast cells	1471:1491	L929 fibroblast cells	1471:1491	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	2	42	theme	sulfation	677:685	arg1	degree					667:672	different degree	657:672	different degree of sulfation	657:685	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	1	43	theme	bioresorbable	569:581	arg1	scaffold					592:599	bioresorbable vascular scaffold	569:599	bioresorbable vascular scaffold	569:599	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	2	44	with	SCMC	714:717	arg1	performance					729:739	best performance	724:739	best performance	724:739	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	7	45	theme	PLA	1614:1616	arg1	films					1618:1622	the multifunctional SCMC/CS multilayer-modified PLA films	1566:1622	the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1566:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	6	46	theme	good	1445:1448	arg1	cytocompatibility					1450:1466	good cytocompatibility	1445:1466	good cytocompatibility	1445:1466	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	0	47	theme	multilayers	31:41	arg1	Preparation					0:10	Preparation	0:10	Preparation of fully bio-based multilayers	0:41	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	7	48	theme	SCMC/CS	1586:1592	arg1	films					1618:1622	the multifunctional SCMC/CS multilayer-modified PLA films	1566:1622	the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1566:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	0	49	theme	carboxymethylcellulose	68:89	arg1	sodium					91:96	heparin-like carboxymethylcellulose sodium	55:96	heparin-like carboxymethylcellulose sodium	55:96	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	1	50	theme	layer-by-layer	487:500	arg1	assembly					508:515	layer-by-layer (LBL) assembly	487:515	layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold	487:599	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	5	51	theme	SCMC/CS	1076:1082	arg1	film					1111:1114	(SCMC/CS)15 multilayer-modified PLA film	1075:1114	(SCMC/CS)15 multilayer-modified PLA film	1075:1114	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	5	52	dep	reduced	1359:1365	arg1	compared					1367:1374	compared	1367:1374	reduced compared with unmodified PLA film	1359:1399	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	1	53	theme	LBL	503:505	arg1	assembly					508:515	layer-by-layer (LBL) assembly	487:515	layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold	487:599	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	6	54	theme	antibacterial	1526:1538	arg1	abilities					1540:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	6	54	theme	antibacterial	1526:1538	arg1	cells					1487:1491	L929 fibroblast cells	1471:1491	L929 fibroblast cells	1471:1491	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	6	55	theme	anti-inflammatory	1504:1520	arg1	abilities					1540:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	excellent anti-inflammatory and antibacterial abilities	1494:1548	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	6	55	theme	anti-inflammatory	1504:1520	arg1	cells					1487:1491	L929 fibroblast cells	1471:1491	L929 fibroblast cells	1471:1491	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	5	56	theme	partial	1219:1225	arg1	time					1242:1245	the activated partial thromboplastin time	1205:1245	the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s	1205:1300	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	2	57	theme	preliminary	606:616	arg1	structure					618:626	preliminary structure	606:626	preliminary structure	606:626	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	1	58	theme	sodium	305:310	arg1	sulfation					269:277	sulfation	269:277	sulfation of carboxymethylcellulose sodium	269:310	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	7	59	theme	future	1746:1751	arg1	applications					1762:1773	future clinical applications	1746:1773	future clinical applications	1746:1773	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	3	60	theme	chemical	767:774	arg1	compositions					776:787	The surface chemical compositions	755:787	The surface chemical compositions	755:787	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	7	61	with	films	1618:1622	arg1	properties					1703:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1629:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	0	62	theme	cardiovascular	158:171	arg1	applications					181:192	cardiovascular implant applications	158:192	cardiovascular implant applications	158:192	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	5	63	theme	protein	1121:1127	arg1	adsorption					1129:1138	the protein adsorption	1117:1138	the protein adsorption	1117:1138	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	5	64	theme	contact	1307:1313	arg1	activation					1315:1324	the contact activation	1303:1324	the contact activation	1303:1324	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	3	65	theme	multilayer-modified	830:848	arg1	films					854:858	SCMC/CS multilayer-modified PLA films	822:858	SCMC/CS multilayer-modified PLA films	822:858	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	6	66	theme	PLA	1425:1427	arg1	films					1429:1433	this modified PLA films	1411:1433	this modified PLA films	1411:1433	Besides, this modified PLA films performed good cytocompatibility to L929 fibroblast cells, excellent anti-inflammatory and antibacterial abilities.
36682649	5	67	theme	PLA	1107:1109	arg1	film					1111:1114	(SCMC/CS)15 multilayer-modified PLA film	1075:1114	(SCMC/CS)15 multilayer-modified PLA film	1075:1114	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	3	68	theme	X-ray	879:883	arg1	spectrometer					899:910	X-ray photoelectron spectrometer	879:910	X-ray photoelectron spectrometer	879:910	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	4	69	theme	SCMC/CS	1010:1016	arg1	films					1042:1046	SCMC/CS multilayer-modified PLA films	1010:1046	SCMC/CS multilayer-modified PLA films	1010:1046	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films were performed.
36682649	5	70	theme	thrombin	1275:1282	arg1	time					1284:1287	thrombin time	1275:1287	thrombin time	1275:1287	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	4	71	theme	PLA	1038:1040	arg1	films					1042:1046	SCMC/CS multilayer-modified PLA films	1010:1046	SCMC/CS multilayer-modified PLA films	1010:1046	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films were performed.
36682649	3	72	theme	scanning	913:920	arg1	microscopy					931:940	scanning electron microscopy	913:940	scanning electron microscopy	913:940	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	2	73	theme	different	657:665	arg1	degree					667:672	different degree	657:672	different degree of sulfation	657:685	The preliminary structure and bioactivity of SCMC with different degree of sulfation were investigated, and the SCMC with best performance was selected.
36682649	1	74	theme	potential	525:533	arg1	application					549:559	the potential blood-contact application	521:559	the potential blood-contact application such as bioresorbable vascular scaffold	521:599	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	3	75	theme	films	854:858	arg1	wettability					807:817	wettability	807:817	wettability of SCMC/CS multilayer-modified PLA films	807:858	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	3	75	theme	films	854:858	arg1	morphologies					790:801	morphologies	790:801	morphologies	790:801	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	3	75	theme	films	854:858	arg1	compositions					776:787	The surface chemical compositions	755:787	The surface chemical compositions	755:787	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	3	76	theme	angle	960:964	arg1	meter					966:970	water contact angle meter	946:970	water contact angle meter	946:970	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	4	77	theme	tests	1001:1005	arg1	series					975:980	A series	973:980	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films	973:1046	A series of anticoagulation tests of SCMC/CS multilayer-modified PLA films were performed.
36682649	3	78	theme	water	946:950	arg1	meter					966:970	water contact angle meter	946:970	water contact angle meter	946:970	The surface chemical compositions, morphologies and wettability of SCMC/CS multilayer-modified PLA films were researched by X-ray photoelectron spectrometer, scanning electron microscopy and water contact angle meter.
36682649	0	79	theme	bio-based	21:29	arg1	multilayers					31:41	fully bio-based multilayers	15:41	fully bio-based multilayers	15:41	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	1	80	theme	vascular	583:590	arg1	scaffold					592:599	bioresorbable vascular scaffold	569:599	bioresorbable vascular scaffold	569:599	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	5	81	theme	activated	1209:1217	arg1	time					1242:1245	the activated partial thromboplastin time	1205:1245	the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s	1205:1300	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
36682649	0	82	theme	heparin-like	55:66	arg1	sodium					91:96	heparin-like carboxymethylcellulose sodium	55:96	heparin-like carboxymethylcellulose sodium	55:96	Preparation of fully bio-based multilayers composed of heparin-like carboxymethylcellulose sodium and chitosan to functionalize poly (l-lactic acid) film for cardiovascular implant applications.
36682649	7	83	theme	multilayer-modified	1594:1612	arg1	films					1618:1622	the multifunctional SCMC/CS multilayer-modified PLA films	1566:1622	the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1566:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	1	84	theme	sulfated	355:362	arg1	CS					415:416	CS	415:416	CS	415:416	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	1	84	theme	sulfated	355:362	arg1	SCMC					395:398	SCMC	395:398	SCMC	395:398	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	1	84	theme	sulfated	355:362	arg1	sodium					387:392	sulfated carboxymethylcellulose sodium	355:392	sulfated carboxymethylcellulose sodium (SCMC)	355:399	In this study, heparin-like polysaccharides were successfully produced by sulfation of carboxymethylcellulose sodium, then a fully biobased bilayer composed of sulfated carboxymethylcellulose sodium (SCMC) and chitosan (CS) was composited on the surface of Poly (L-lactic acid) (PLA) through layer-by-layer (LBL) assembly for the potential blood-contact application such as bioresorbable vascular scaffold.
36682649	7	85	theme	multifunctional	1570:1584	arg1	films					1618:1622	the multifunctional SCMC/CS multilayer-modified PLA films	1566:1622	the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties	1566:1712	In conclusion, the multifunctional SCMC/CS multilayer-modified PLA films with hemocompatibility, cytocompatibility, anti-inflammatory and antibacterial properties may have promising potential in future clinical applications.
36682649	5	86	theme	PLA	1392:1394	arg1	film					1396:1399	unmodified PLA film	1381:1399	unmodified PLA film	1381:1399	In term of (SCMC/CS)15 multilayer-modified PLA film, the protein adsorption and plate adhesion decreased by 44.6 % and 71.5 %, respectively, the activated partial thromboplastin time prolonged by 11.9 times and thrombin time exceed 300 s, the contact activation and hemolysis rate significantly reduced compared with unmodified PLA film.
35653809	2	0	theme	polysaccharides	485:499	arg1	analysis					473:480	the compositional analysis	455:480	the compositional analysis of polysaccharides	455:499	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	4	1	theme	information	843:853	arg1	information					843:853	information	843:853	information of monosaccharide contents in Atractylodes polysaccharides	843:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	4	1	theme	information	843:853	arg1	amount					833:838	maximum amount	825:838	maximum amount of information of monosaccharide contents in Atractylodes polysaccharides	825:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	3	2	theme	regressions	719:729	arg1	combination					691:701	a combination	689:701	a combination of multivariate regressions	689:729	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	7	3	theme	high	1471:1474	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	3	theme	high	1471:1474	arg1	safety					1489:1494	high experimental safety	1471:1494	high experimental safety	1471:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	1	4	theme	nature	168:173	arg1	polysaccharides					175:189	nature polysaccharides	168:189	nature polysaccharides	168:189	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	6	5	dep	ability	1198:1204	arg1	RPD > 3					1220:1226	RPD > 3	1220:1226	RPD > 3	1220:1226	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	6	5	dep	ability	1198:1204	arg1	R2 ≥ 0.9					1207:1214	R2 ≥ 0.9	1207:1214	R2 ≥ 0.9	1207:1214	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	7	6	theme	new	1295:1297	arg1	possibility					1299:1309	a new possibility	1293:1309	a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1293:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	0	7	theme	case	98:101	arg1	study					103:107	A case study	96:107	A case study of Atractylodes polysaccharides	96:139	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	7	8	theme	compositions	1374:1385	arg1	determination					1334:1346	the nondestructive determination	1315:1346	the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1315:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	6	9	theme	good	1182:1185	arg1	ability					1198:1204	good prediction ability	1182:1204	good prediction ability (R2 ≥ 0.9 and RPD > 3)	1182:1227	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	1	10	theme	larger	256:261	arg1	property					272:279	larger polarity property	256:279	larger polarity property	256:279	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	6	11	contain	have	1172:1175	arg1	models					1165:1170	All the most optimal prediction models	1133:1170	All the most optimal prediction models	1133:1170	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	6	11	contain	have	1172:1175	arg2	no					1233:1234	no	1233:1234	no	1233:1234	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	6	11	contain	have	1172:1175	arg2	ability					1198:1204	good prediction ability	1182:1204	good prediction ability (R2 ≥ 0.9 and RPD > 3)	1182:1227	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	2	12	used	used	369:372	arg2	spectroscopy					313:324	infrared spectroscopy	304:324	infrared spectroscopy	304:324	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	2	12	used	used	369:372	arg2	modeling					350:357	multiple regression modeling	330:357	multiple regression modeling	330:357	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	4	13	theme	processing	767:776	arg1	pretreatments					778:790	different data processing pretreatments	752:790	different data processing pretreatments	752:790	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	3	14	from	ketose	630:635	arg1	polysaccharides					670:684	Atractylodes polysaccharides	657:684	Atractylodes polysaccharides	657:684	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	1	15	theme	polarity	263:270	arg1	property					272:279	larger polarity property	256:279	larger polarity property	256:279	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	3	16	theme	total	528:532	arg1	reflectance-fourier					534:552	attenuated total reflectance-fourier	517:552	attenuated total reflectance-fourier transform infrared spectroscopy	517:584	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	7	17	theme	complex	1351:1357	arg1	compositions					1374:1385	complex monosaccharide compositions	1351:1385	complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1351:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	1	18	theme	polysaccharides	175:189	arg1	evaluation					154:163	The quality evaluation	142:163	The quality evaluation of nature polysaccharides	142:189	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	1	18	theme	polysaccharides	175:189	arg1	nut					202:204	a tough nut	194:204	a tough nut to crack	194:213	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	7	19	from	time	1435:1438	arg1	compositions					1374:1385	complex monosaccharide compositions	1351:1385	complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1351:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	5	20	used	used	986:989	arg2	points					949:954	different smoothing points	929:954	different smoothing points	929:954	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	5	20	used	used	986:989	arg2	MSC					978:980	MSC	978:980	MSC	978:980	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	5	20	used	used	986:989	arg2	SNV					970:972	SNV	970:972	SNV	970:972	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	5	20	used	used	986:989	arg2	derivatives					957:967	derivatives	957:967	derivatives	957:967	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	6	21	theme	prediction	1187:1196	arg1	ability					1198:1204	good prediction ability	1182:1204	good prediction ability (R2 ≥ 0.9 and RPD > 3)	1182:1227	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	4	22	theme	maximum	825:831	arg1	information					843:853	information	843:853	information of monosaccharide contents in Atractylodes polysaccharides	843:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	4	22	theme	maximum	825:831	arg1	amount					833:838	maximum amount	825:838	maximum amount of information of monosaccharide contents in Atractylodes polysaccharides	825:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	5	23	theme	different	929:937	arg1	points					949:954	different smoothing points	929:954	different smoothing points	929:954	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	0	24	theme	nondestructive	2:15	arg1	solution					17:24	A nondestructive solution	0:24	A nondestructive solution	0:24	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	3	25	from	acids	648:652	arg1	polysaccharides					670:684	Atractylodes polysaccharides	657:684	Atractylodes polysaccharides	657:684	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	5	26	theme	smoothing	939:947	arg1	points					949:954	different smoothing points	929:954	different smoothing points	929:954	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	2	27	theme	infrared	304:311	arg1	spectroscopy					313:324	infrared spectroscopy	304:324	infrared spectroscopy	304:324	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	2	28	theme	quantitative	378:389	arg1	examinations					391:402	quantitative examinations	378:402	quantitative examinations in multiple fields	378:421	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	7	29	theme	low	1441:1443	arg1	requirement					1455:1465	low equipment requirement	1441:1465	low equipment requirement	1441:1465	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	29	theme	low	1441:1443	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	30	theme	natural	1390:1396	arg1	polysaccharides					1398:1412	natural polysaccharides	1390:1412	natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1390:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	0	31	theme	polysaccharides	125:139	arg1	study					103:107	A case study	96:107	A case study of Atractylodes polysaccharides	96:139	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	4	32	theme	Atractylodes	885:896	arg1	polysaccharides					898:912	Atractylodes polysaccharides	885:912	Atractylodes polysaccharides	885:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	4	33	theme	resulting	797:805	arg1	spectrum					807:814	the resulting spectrum	793:814	the resulting spectrum	793:814	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	6	34	theme	prediction	1154:1163	arg1	models					1165:1170	All the most optimal prediction models	1133:1170	All the most optimal prediction models	1133:1170	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	0	35	theme	Atractylodes	112:123	arg1	polysaccharides					125:139	Atractylodes polysaccharides	112:139	Atractylodes polysaccharides	112:139	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	5	36	theme	spectrum	1011:1018	arg1	processing					1020:1029	the pre-modeling spectrum processing	994:1029	the pre-modeling spectrum processing	994:1029	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	3	37	from	aldoses	621:627	arg1	polysaccharides					670:684	Atractylodes polysaccharides	657:684	Atractylodes polysaccharides	657:684	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	6	38	theme	optimal	1146:1152	arg1	models					1165:1170	All the most optimal prediction models	1133:1170	All the most optimal prediction models	1133:1170	All the most optimal prediction models have both good prediction ability (R2 ≥ 0.9 and RPD > 3) and no over fitting (RMSEP/RMSEC < 3).
35653809	7	39	theme	nondestructive	1319:1332	arg1	determination					1334:1346	the nondestructive determination	1315:1346	the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1315:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	3	40	dep	reflectance-fourier	534:552	arg1	transform					554:562	transform	554:562	transform infrared spectroscopy	554:584	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	7	41	from	polysaccharides	1398:1412	arg1	requirement					1455:1465	low equipment requirement	1441:1465	low equipment requirement	1441:1465	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	41	from	polysaccharides	1398:1412	arg1	safety					1489:1494	high experimental safety	1471:1494	high experimental safety	1471:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	41	from	polysaccharides	1398:1412	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	5	42	used	used	1052:1055	arg2	screening					1039:1047	VIP screening	1035:1047	VIP screening	1035:1047	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	1	43	theme	tough	196:200	arg1	evaluation					154:163	The quality evaluation	142:163	The quality evaluation of nature polysaccharides	142:189	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	1	43	theme	tough	196:200	arg1	nut					202:204	a tough nut	194:204	a tough nut to crack	194:213	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	2	44	theme	multiple	407:414	arg1	fields					416:421	multiple fields	407:421	multiple fields	407:421	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	2	45	theme	compositional	459:471	arg1	analysis					473:480	the compositional analysis	455:480	the compositional analysis of polysaccharides	455:499	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	5	46	theme	model	1126:1130	arg1	calculation					1107:1117	the calculation	1103:1117	the calculation of the model	1103:1130	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	4	47	theme	contents	873:880	arg1	information					843:853	information	843:853	information of monosaccharide contents in Atractylodes polysaccharides	843:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	2	48	from	examinations	391:402	arg1	fields					416:421	multiple fields	407:421	multiple fields	407:421	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	3	49	used	used	589:592	arg2	reflectance-fourier					534:552	attenuated total reflectance-fourier	517:552	attenuated total reflectance-fourier transform infrared spectroscopy	517:584	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	0	50	theme	ATR-FTIR	57:64	arg1	regressions					83:93	ATR-FTIR and multivariate regressions	57:93	ATR-FTIR and multivariate regressions	57:93	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	3	51	theme	Atractylodes	657:668	arg1	polysaccharides					670:684	Atractylodes polysaccharides	657:684	Atractylodes polysaccharides	657:684	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	7	52	theme	short	1419:1423	arg1	requirement					1455:1465	low equipment requirement	1441:1465	low equipment requirement	1441:1465	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	52	theme	short	1419:1423	arg1	safety					1489:1494	high experimental safety	1471:1494	high experimental safety	1471:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	52	theme	short	1419:1423	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	4	53	theme	different	752:760	arg1	pretreatments					778:790	different data processing pretreatments	752:790	different data processing pretreatments	752:790	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	7	54	theme	monosaccharide	1359:1372	arg1	compositions					1374:1385	complex monosaccharide compositions	1351:1385	complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1351:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	5	55	theme	variables	1081:1089	arg1	number					1071:1076	the number	1067:1076	the number of variables to simplify the calculation of the model	1067:1130	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	0	56	dep	quantify	29:36	arg1	study					103:107	A case study	96:107	A case study of Atractylodes polysaccharides	96:139	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	2	57	theme	regression	339:348	arg1	modeling					350:357	multiple regression modeling	330:357	multiple regression modeling	330:357	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	4	58	contain	contains	816:823	arg2	amount					833:838	maximum amount	825:838	maximum amount of information of monosaccharide contents in Atractylodes polysaccharides	825:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	4	58	contain	contains	816:823	arg2	information					843:853	information	843:853	information of monosaccharide contents in Atractylodes polysaccharides	843:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	4	58	contain	contains	816:823	arg1	spectrum					807:814	the resulting spectrum	793:814	the resulting spectrum	793:814	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	3	59	theme	multivariate	706:717	arg1	regressions					719:729	multivariate regressions	706:729	multivariate regressions	706:729	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	3	60	theme	uronic	641:646	arg1	acids					648:652	uronic acids	641:652	uronic acids	641:652	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	4	61	from	contents	873:880	arg1	polysaccharides					898:912	Atractylodes polysaccharides	885:912	Atractylodes polysaccharides	885:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	2	62	theme	multiple	330:337	arg1	modeling					350:357	multiple regression modeling	330:357	multiple regression modeling	330:357	It is well-known that infrared spectroscopy and multiple regression modeling have been used for quantitative examinations in multiple fields, but it has not been applied to the compositional analysis of polysaccharides.
35653809	5	63	theme	pre-modeling	998:1009	arg1	processing					1020:1029	the pre-modeling spectrum processing	994:1029	the pre-modeling spectrum processing	994:1029	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	7	64	theme	equipment	1445:1453	arg1	requirement					1455:1465	low equipment requirement	1441:1465	low equipment requirement	1441:1465	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	64	theme	equipment	1445:1453	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	65	theme	experimental	1476:1487	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	65	theme	experimental	1476:1487	arg1	safety					1489:1494	high experimental safety	1471:1494	high experimental safety	1471:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	4	66	from	polysaccharides	898:912	arg1	information					843:853	information	843:853	information of monosaccharide contents in Atractylodes polysaccharides	843:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	4	67	theme	data	762:765	arg1	pretreatments					778:790	different data processing pretreatments	752:790	different data processing pretreatments	752:790	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	3	68	dep	transform	554:562	arg1	infrared					564:571	infrared	564:571	transform infrared spectroscopy	554:584	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	0	69	theme	multivariate	70:81	arg1	regressions					83:93	ATR-FTIR and multivariate regressions	57:93	ATR-FTIR and multivariate regressions	57:93	A nondestructive solution to quantify monosaccharides by ATR-FTIR and multivariate regressions: A case study of Atractylodes polysaccharides.
35653809	5	70	theme	VIP	1035:1037	arg1	screening					1039:1047	VIP screening	1035:1047	VIP screening	1035:1047	In this case, different smoothing points, derivatives, SNV and MSC are used in the pre-modeling spectrum processing and VIP screening is used to reduce the number of variables to simplify the calculation of the model.
35653809	4	71	theme	monosaccharide	858:871	arg1	contents					873:880	monosaccharide contents	858:880	monosaccharide contents in Atractylodes polysaccharides	858:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	7	72	from	compositions	1374:1385	arg1	requirement					1455:1465	low equipment requirement	1441:1465	low equipment requirement	1441:1465	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	72	from	compositions	1374:1385	arg1	safety					1489:1494	high experimental safety	1471:1494	high experimental safety	1471:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	72	from	compositions	1374:1385	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	1	73	theme	quality	146:152	arg1	evaluation					154:163	The quality evaluation	142:163	The quality evaluation of nature polysaccharides	142:189	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	1	73	theme	quality	146:152	arg1	nut					202:204	a tough nut	194:204	a tough nut to crack	194:213	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	1	74	theme	high	230:233	arg1	distributions					238:250	its high Mw distributions	226:250	its high Mw distributions	226:250	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
35653809	7	75	theme	polysaccharides	1398:1412	arg1	compositions					1374:1385	complex monosaccharide compositions	1351:1385	complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety	1351:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	4	76	from	information	843:853	arg1	polysaccharides					898:912	Atractylodes polysaccharides	885:912	Atractylodes polysaccharides	885:912	After experience of different data processing pretreatments, the resulting spectrum contains maximum amount of information of monosaccharide contents in Atractylodes polysaccharides.
35653809	3	77	theme	attenuated	517:526	arg1	reflectance-fourier					534:552	attenuated total reflectance-fourier	517:552	attenuated total reflectance-fourier transform infrared spectroscopy	517:584	In this study, attenuated total reflectance-fourier transform infrared spectroscopy is used to simultaneously quantify aldoses, ketose and uronic acids in Atractylodes polysaccharides by a combination of multivariate regressions.
35653809	7	78	theme	detection	1425:1433	arg1	requirement					1455:1465	low equipment requirement	1441:1465	low equipment requirement	1441:1465	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	78	theme	detection	1425:1433	arg1	safety					1489:1494	high experimental safety	1471:1494	high experimental safety	1471:1494	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	7	78	theme	detection	1425:1433	arg1	time					1435:1438	a short detection time	1417:1438	a short detection time	1417:1438	This strategy has opened a new possibility for the nondestructive determination of complex monosaccharide compositions of natural polysaccharides in a short detection time, low equipment requirement and high experimental safety.
35653809	1	79	theme	Mw	235:236	arg1	distributions					238:250	its high Mw distributions	226:250	its high Mw distributions	226:250	The quality evaluation of nature polysaccharides is a tough nut to crack because of its high Mw distributions and larger polarity property.
36262345	7	0	theme	diminished	1182:1191	arg1	sensitivity					1193:1203	diminished sensitivity	1182:1203	diminished sensitivity compared to positive mode	1182:1229	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	3	1	theme	Released	477:484	arg1	's					492:493	Released glycan's	477:493	Released glycan's	477:493	Released glycan's are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling.
36262345	1	2	theme	glycan	239:244	arg1	techniques					255:264	glycan analysis techniques	239:264	glycan analysis techniques	239:264	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	2	3	theme	free	275:278	arg1	's					286:287	free glycan's	275:287	free glycan's	275:287	Because free glycan's lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis.
36262345	12	4	from	mode	2184:2187	arg1	response					2127:2134	the final ESI response	2113:2134	the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves	2113:2214	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	9	5	attach	released	1557:1564	arg2	N-glycans					1547:1555	N-glycans	1547:1555	N-glycans released from IgG sample	1547:1580	N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS.
36262345	9	5	attach	released	1557:1564	arg1	sample					1575:1580	IgG sample	1571:1580	IgG sample	1571:1580	N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS.
36262345	10	6	theme	labels	1717:1722	arg1	performance					1724:1734	studied labels performance	1709:1734	studied labels performance	1709:1734	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	5	7	theme	's	821:822	arg1	ionization					801:810	ionization	801:810	ionization	801:810	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	5	7	theme	's	821:822	arg1	fluorescence					784:795	fluorescence	784:795	fluorescence	784:795	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	5	7	theme	's	821:822	arg1	need					832:835	the need to quantify these contributions to improve glycan analysis methods	828:902	the need to quantify these contributions to improve glycan analysis methods	828:902	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	4	8	theme	ionization	640:649	arg1	efficiency					651:660	ionization efficiency	640:660	ionization efficiency	640:660	Some fluorescent labels can also promote ionization efficiency, thus facilitating MS detection.
36262345	2	9	theme	chromophore	294:304	arg1	properties					321:330	chromophore or fluorophore properties	294:330	chromophore or fluorophore properties	294:330	Because free glycan's lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis.
36262345	12	10	from	ionization	2158:2167	arg1	mode					2184:2187	negative MS mode	2172:2187	negative MS mode	2172:2187	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	13	11	theme	fluorophores	2272:2283	arg1	development					2257:2267	development	2257:2267	development	2257:2267	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	13	11	theme	fluorophores	2272:2283	arg1	research					2244:2251	further research	2236:2251	further research	2236:2251	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	6	12	theme	glycan	1083:1088	arg1	structures					1090:1099	detailed glycan structures	1074:1099	detailed glycan structures	1074:1099	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	3	13	theme	fluorescent	527:537	arg1	tag					539:541	a fluorescent tag	525:541	a fluorescent tag	525:541	Released glycan's are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling.
36262345	11	14	contain	having	1899:1904	arg1	labels					1892:1897	more hydrophobic labels	1875:1897	more hydrophobic labels having bigger signal intensities in one laboratory	1875:1948	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	11	14	contain	having	1899:1904	arg2	intensities					1920:1930	bigger signal intensities	1906:1930	bigger signal intensities	1906:1930	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	11	15	theme	other	1984:1988	arg1	laboratory					1990:1999	the other laboratory	1980:1999	the other laboratory	1980:1999	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	11	16	theme	signal	1913:1918	arg1	intensities					1920:1930	bigger signal intensities	1906:1930	bigger signal intensities	1906:1930	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	3	17	theme	LC	585:586	arg1	profiling					588:596	LC profiling	585:596	LC profiling	585:596	Released glycan's are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling.
36262345	7	18	theme	high-throughput	1310:1324	arg1	analysis					1326:1333	successful high-throughput analysis	1299:1333	successful high-throughput analysis	1299:1333	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	12	19	theme	MS	2024:2025	arg1	parameters					2027:2036	MS parameters	2024:2036	MS parameters	2024:2036	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	10	20	theme	mobile	1806:1811	arg1	4.4					1823:1825	4.4	1823:1825	4.4	1823:1825	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	10	20	theme	mobile	1806:1811	arg1	pH					1819:1820	two mobile phase pH	1802:1820	two mobile phase pH (4.4 and 7.4)	1802:1834	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	10	20	theme	mobile	1806:1811	arg1	7.4					1831:1833	7.4	1831:1833	7.4	1831:1833	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	5	21	theme	glycan	880:885	arg1	methods					896:902	glycan analysis methods	880:902	glycan analysis methods	880:902	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	2	22	theme	analysis	467:474	arg1	sensitivity					448:458	the sensitivity	444:458	the sensitivity of the analysis	444:474	Because free glycan's lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis.
36262345	8	23	theme	hydrophobicity	1456:1469	arg1	influence					1437:1445	the influence	1433:1445	the influence of label hydrophobicity and presence of a negative charge on glycan ionization	1433:1524	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	1	24	from	role	146:149	arg1	protein					171:177	protein	171:177	protein functioning	171:189	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	8	25	theme	presence	1475:1482	arg1	influence					1437:1445	the influence	1433:1445	the influence of label hydrophobicity and presence of a negative charge on glycan ionization	1433:1524	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	0	26	theme	MS	62:63	arg1	mode					65:68	negative MS mode	53:68	negative MS mode	53:68	In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.
36262345	1	27	theme	essential	136:144	arg1	role					146:149	essential role	136:149	essential role of glycosylation in protein functioning	136:189	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	6	28	theme	MS	942:943	arg1	mode					945:948	negative MS mode	933:948	negative MS mode	933:948	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	12	29	theme	negative	2172:2179	arg1	mode					2184:2187	negative MS mode	2172:2187	negative MS mode	2172:2187	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	7	30	theme	mode	1154:1157	arg1	MS					1159:1160	negative mode MS	1145:1160	negative mode MS	1145:1160	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	1	31	theme	past	118:121	arg1	decades					127:133	the past few decades	114:133	the past few decades	114:133	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	8	32	theme	charge	1498:1503	arg1	presence					1475:1482	presence	1475:1482	presence	1475:1482	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	8	32	theme	charge	1498:1503	arg1	hydrophobicity					1456:1469	hydrophobicity	1456:1469	hydrophobicity	1456:1469	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	11	33	theme	hydrophobic	1880:1890	arg1	labels					1892:1897	more hydrophobic labels	1875:1897	more hydrophobic labels having bigger signal intensities in one laboratory	1875:1948	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	13	34	from	suitable	2298:2305	arg1	mode					2362:2365	the negative MS mode	2346:2365	the negative MS mode	2346:2365	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	0	35	theme	N-glycan	90:97	arg1	analysis					99:106	high-throughput N-glycan analysis	74:106	high-throughput N-glycan analysis	74:106	In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.
36262345	6	36	theme	MS	1020:1021	arg1	mode					1023:1026	positive MS mode	1011:1026	positive MS mode	1011:1026	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	8	37	theme	glycan	1508:1513	arg1	ionization					1515:1524	glycan ionization	1508:1524	glycan ionization	1508:1524	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	8	38	from	influence	1437:1445	arg1	ionization					1515:1524	glycan ionization	1508:1524	glycan ionization	1508:1524	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	7	39	theme	glycan	1128:1133	arg1	labels					1135:1140	traditional glycan labels	1116:1140	traditional glycan labels in negative mode MS	1116:1160	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	12	40	theme	ionization	2158:2167	arg1	response					2127:2134	the final ESI response	2113:2134	the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves	2113:2214	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	13	41	theme	MS	2359:2360	arg1	mode					2362:2365	the negative MS mode	2346:2365	the negative MS mode	2346:2365	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	7	42	theme	appropriate	1257:1267	arg1	selection					1244:1252	selection	1244:1252	selection of appropriate label even more important for successful high-throughput analysis	1244:1333	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	8	43	theme	MS	1538:1539	arg1	mode					1541:1544	negative MS mode	1529:1544	negative MS mode	1529:1544	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	12	44	theme	final	2117:2121	arg1	response					2127:2134	the final ESI response	2113:2134	the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves	2113:2214	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	0	45	dep	fluorescent	31:41	arg1	label					43:47	label	43:47	label for negative MS mode for high-throughput N-glycan analysis	43:106	In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.
36262345	8	46	theme	different	1376:1384	arg1	properties					1401:1410	different chemo-physical properties	1376:1410	different chemo-physical properties	1376:1410	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	0	47	theme	fluorescent	31:41	arg1	pursuit					5:11	a pursuit	3:11	a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis	3:106	In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.
36262345	8	48	theme	properties	1401:1410	arg1	labels					1366:1371	eleven fluorescent labels	1347:1371	eleven fluorescent labels of different chemo-physical properties	1347:1410	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	13	49	theme	high-throughput	2311:2325	arg1	analysis					2334:2341	high-throughput glycan analysis	2311:2341	high-throughput glycan analysis	2311:2341	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	10	50	theme	studied	1709:1715	arg1	performance					1724:1734	studied labels performance	1709:1734	studied labels performance	1709:1734	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	7	51	dep	appropriate	1257:1267	arg1	label					1269:1273	label	1269:1273	label even more important for successful high-throughput analysis	1269:1333	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	9	52	theme	labels	1618:1623	arg1	one					1600:1602	one	1600:1602	one	1600:1602	N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS.
36262345	9	52	theme	labels	1618:1623	arg1	labels					1618:1623	the eleven labels	1607:1623	the eleven labels	1607:1623	N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS.
36262345	2	53	theme	glycan	280:285	arg1	's					286:287	free glycan's	275:287	free glycan's	275:287	Because free glycan's lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis.
36262345	1	54	theme	analysis	246:253	arg1	techniques					255:264	glycan analysis techniques	239:264	glycan analysis techniques	239:264	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	10	55	theme	performance	1724:1734	arg1	evaluation					1695:1704	evaluation	1695:1704	evaluation of studied labels performance more objective	1695:1749	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	5	56	theme	glycan	815:820	arg1	's					821:822	glycan's	815:822	glycan's	815:822	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	12	57	contain	have	2086:2089	arg1	parameters					2027:2036	MS parameters	2024:2036	MS parameters	2024:2036	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	12	57	contain	have	2086:2089	arg1	configuration					2052:2064	intrinsic configuration	2042:2064	intrinsic configuration	2042:2064	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	12	57	contain	have	2086:2089	arg2	effect					2103:2108	even bigger effect	2091:2108	even bigger effect	2091:2108	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	10	58	theme	objective	1741:1749	arg1	evaluation					1695:1704	evaluation	1695:1704	evaluation of studied labels performance more objective	1695:1749	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	1	59	theme	glycosylation	154:166	arg1	role					146:149	essential role	136:149	essential role of glycosylation in protein functioning	136:189	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	6	60	theme	structures	1090:1099	arg1	elucidation					1059:1069	a less ambiguous elucidation	1042:1069	a less ambiguous elucidation of detailed glycan structures	1042:1099	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	12	61	theme	spectrometer	2073:2084	arg1	parameters					2027:2036	MS parameters	2024:2036	MS parameters	2024:2036	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	12	61	theme	spectrometer	2073:2084	arg1	configuration					2052:2064	intrinsic configuration	2042:2064	intrinsic configuration	2042:2064	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	11	62	theme	such	1966:1969	arg1	trend					1971:1975	no such trend	1963:1975	no such trend	1963:1975	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	7	63	from	labels	1135:1140	arg1	MS					1159:1160	negative mode MS	1145:1160	negative mode MS	1145:1160	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	6	64	theme	detailed	1074:1081	arg1	structures					1090:1099	detailed glycan structures	1074:1099	detailed glycan structures	1074:1099	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	11	65	theme	bigger	1906:1911	arg1	intensities					1920:1930	bigger signal intensities	1906:1930	bigger signal intensities	1906:1930	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	13	66	theme	further	2236:2242	arg1	research					2244:2251	further research	2236:2251	further research	2236:2251	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	4	67	theme	fluorescent	604:614	arg1	labels					616:621	Some fluorescent labels	599:621	Some fluorescent labels	599:621	Some fluorescent labels can also promote ionization efficiency, thus facilitating MS detection.
36262345	7	68	theme	negative	1145:1152	arg1	mode					1154:1157	negative mode	1145:1157	negative mode MS	1145:1160	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	11	69	theme	labels	1892:1897	arg1	trend					1866:1870	a notable trend	1856:1870	a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory	1856:1948	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	4	70	theme	MS	681:682	arg1	detection					684:692	MS detection	681:692	MS detection	681:692	Some fluorescent labels can also promote ionization efficiency, thus facilitating MS detection.
36262345	12	71	theme	bigger	2096:2101	arg1	effect					2103:2108	even bigger effect	2091:2108	even bigger effect	2091:2108	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	10	72	theme	phase	1813:1817	arg1	4.4					1823:1825	4.4	1823:1825	4.4	1823:1825	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	10	72	theme	phase	1813:1817	arg1	pH					1819:1820	two mobile phase pH	1802:1820	two mobile phase pH (4.4 and 7.4)	1802:1834	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	10	72	theme	phase	1813:1817	arg1	7.4					1831:1833	7.4	1831:1833	7.4	1831:1833	To make evaluation of studied labels performance more objective, analysis was performed in two laboratories and at two mobile phase pH (4.4 and 7.4).
36262345	7	73	theme	positive	1217:1224	arg1	mode					1226:1229	positive mode	1217:1229	positive mode	1217:1229	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	0	74	theme	negative	53:60	arg1	mode					65:68	negative MS mode	53:68	negative MS mode	53:68	In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.
36262345	1	75	theme	few	123:125	arg1	decades					127:133	the past few decades	114:133	the past few decades	114:133	Over the past few decades, essential role of glycosylation in protein functioning has become widely recognized, rapidly advancing glycan analysis techniques.
36262345	7	76	theme	successful	1299:1308	arg1	analysis					1326:1333	successful high-throughput analysis	1299:1333	successful high-throughput analysis	1299:1333	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	8	77	theme	negative	1489:1496	arg1	charge					1498:1503	a negative charge	1487:1503	a negative charge	1487:1503	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	13	78	from	mode	2362:2365	arg1	suitable					2298:2305	suitable	2298:2305	suitable	2298:2305	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	0	79	theme	high-throughput	74:88	arg1	analysis					99:106	high-throughput N-glycan analysis	74:106	high-throughput N-glycan analysis	74:106	In a pursuit of optimal glycan fluorescent label for negative MS mode for high-throughput N-glycan analysis.
36262345	6	80	theme	negative	933:940	arg1	mode					945:948	negative MS mode	933:948	negative MS mode	933:948	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	3	81	from	detection	572:580	arg1	profiling					588:596	LC profiling	585:596	LC profiling	585:596	Released glycan's are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling.
36262345	12	82	theme	MS	2181:2182	arg1	mode					2184:2187	negative MS mode	2172:2187	negative MS mode	2172:2187	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	11	83	theme	notable	1858:1864	arg1	trend					1866:1870	a notable trend	1856:1870	a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory	1856:1948	Although there was a notable trend of more hydrophobic labels having bigger signal intensities in one laboratory, we observed no such trend in the other laboratory.
36262345	7	84	theme	traditional	1116:1126	arg1	labels					1135:1140	traditional glycan labels	1116:1140	traditional glycan labels in negative mode MS	1116:1160	Additionally, traditional glycan labels in negative mode MS usually result with diminished sensitivity compared to positive mode, thus making selection of appropriate label even more important for successful high-throughput analysis.
36262345	5	85	theme	analysis	887:894	arg1	methods					896:902	glycan analysis methods	880:902	glycan analysis methods	880:902	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	6	86	theme	positive	1011:1018	arg1	mode					1023:1026	positive MS mode	1011:1026	positive MS mode	1011:1026	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	8	87	theme	negative	1529:1536	arg1	mode					1541:1544	negative MS mode	1529:1544	negative MS mode	1529:1544	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	8	88	dep	hydrophobicity	1456:1469	arg1	label					1450:1454	label	1450:1454	label	1450:1454	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	13	89	theme	negative	2350:2357	arg1	mode					2362:2365	the negative MS mode	2346:2365	the negative MS mode	2346:2365	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	12	90	theme	labeled-glycan	2143:2156	arg1	ionization					2158:2167	the labeled-glycan ionization	2139:2167	the labeled-glycan ionization in negative MS mode that the labels themselves	2139:2214	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	3	91	theme	glycan	486:491	arg1	's					492:493	Released glycan's	477:493	Released glycan's	477:493	Released glycan's are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling.
36262345	5	92	theme	design	731:736	arg1	fluorophores					738:749	design fluorophores	731:749	design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods	731:902	For this reason, there is a need to design fluorophores that will contribute more to the fluorescence and ionization of glycan's and the need to quantify these contributions to improve glycan analysis methods.
36262345	9	93	theme	IgG	1571:1573	arg1	sample					1575:1580	IgG sample	1571:1580	IgG sample	1571:1580	N-glycans released from IgG sample were labeled with one of the eleven labels, purified with HILIC-SPE and analyzed with HILIC-UPLC-FLR-MS.
36262345	8	94	theme	fluorescent	1354:1364	arg1	labels					1366:1371	eleven fluorescent labels	1347:1371	eleven fluorescent labels of different chemo-physical properties	1347:1410	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	13	95	theme	glycan	2327:2332	arg1	analysis					2334:2341	high-throughput glycan analysis	2311:2341	high-throughput glycan analysis	2311:2341	With this in mind, further research and development of fluorophores that will be suitable for high-throughput glycan analysis in the negative MS mode are proposed.
36262345	12	96	theme	ESI	2123:2125	arg1	response					2127:2134	the final ESI response	2113:2134	the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves	2113:2214	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	12	97	from	response	2127:2134	arg1	mode					2184:2187	negative MS mode	2172:2187	negative MS mode	2172:2187	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
36262345	3	98	theme	optical	564:570	arg1	detection					572:580	their optical detection	558:580	their optical detection in LC profiling	558:596	Released glycan's are usually derivatized using a fluorescent tag, which enables their optical detection in LC profiling.
36262345	6	99	theme	ambiguous	1049:1057	arg1	elucidation					1059:1069	a less ambiguous elucidation	1042:1069	a less ambiguous elucidation of detailed glycan structures	1042:1099	In this paper we focused on negative MS mode as these methods are more informative than methods involving positive MS mode, allowing for a less ambiguous elucidation of detailed glycan structures.
36262345	8	100	theme	chemo-physical	1386:1399	arg1	properties					1401:1410	different chemo-physical properties	1376:1410	different chemo-physical properties	1376:1410	Therefore, eleven fluorescent labels of different chemo-physical properties were chosen to study the influence of label hydrophobicity and presence of a negative charge on glycan ionization in negative MS mode.
36262345	2	101	theme	fluorophore	309:319	arg1	properties					321:330	chromophore or fluorophore properties	294:330	chromophore or fluorophore properties	294:330	Because free glycan's lack chromophore or fluorophore properties, and do not ionize well, they are often derivatized to facilitate their separation or detection, and to enhance the sensitivity of the analysis.
36262345	12	102	theme	intrinsic	2042:2050	arg1	configuration					2052:2064	intrinsic configuration	2042:2064	intrinsic configuration	2042:2064	The results show that MS parameters and intrinsic configuration of the spectrometer have even bigger effect on the final ESI response of the labeled-glycan ionization in negative MS mode that the labels themselves.
35667459	0	0	theme	Dictyosphaerium	101:115	arg1	chlorelloides					117:129	green microalgae Dictyosphaerium chlorelloides	84:129	green microalgae Dictyosphaerium chlorelloides	84:129	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	7	1	theme	1 → 2	1240:1244	arg1	chain					1262:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	7	2	theme	1,3-linked	1155:1164	arg1	units					1175:1179	1,3-linked β-D-Galp units	1155:1179	1,3-linked β-D-Galp units	1155:1179	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	1	3	theme	monosaccharide	300:313	arg1	composition					315:325	monosaccharide composition	300:325	monosaccharide composition	300:325	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	0	4	theme	microalgae	90:99	arg1	chlorelloides					117:129	green microalgae Dictyosphaerium chlorelloides	84:129	green microalgae Dictyosphaerium chlorelloides	84:129	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	7	5	theme	β-D-Galp	1166:1173	arg1	units					1175:1179	1,3-linked β-D-Galp units	1155:1179	1,3-linked β-D-Galp units	1155:1179	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	2	6	theme	different	436:444	arg1	extent					446:451	different extent	436:451	different extent by mannose and glucose	436:474	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	7	7	theme	6-OMe-α-D-Galp-	1223:1237	arg1	chain					1262:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	3	8	theme	branched	584:591	arg1	rhamnogalactans					593:607	highly branched rhamnogalactans	577:607	highly branched rhamnogalactans	577:607	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	9	from	rhamnogalactans	593:607	arg1	quantity					613:620	the quantity	609:620	the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked)	609:727	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	9	from	rhamnogalactans	593:607	arg1	equal					740:744	equal	740:744	equal	740:744	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	5	10	dep	residues	961:968	arg1	3-O-methyl					999:1008	3-O-methyl	999:1008	3-O-methyl	999:1008	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	10	dep	residues	961:968	arg1	2,3-O-dimethyl					983:996	2,3-O-dimethyl	983:996	2,3-O-dimethyl	983:996	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	10	dep	residues	961:968	arg1	2-O-methyl					971:980	2-O-methyl	971:980	2-O-methyl	971:980	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	10	dep	residues	961:968	arg1	6-O-methyl					1014:1023	6-O-methyl	1014:1023	6-O-methyl	1014:1023	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	1	11	theme	molecular	331:339	arg1	distribution					348:359	molecular weight distribution	331:359	molecular weight distribution	331:359	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	7	12	theme	other	1269:1273	arg1	chain					1262:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	5	13	theme	terminal	874:881	arg1	mannose					883:889	terminal mannose	874:889	terminal mannose	874:889	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	14	theme	galactose	951:959	arg1	residues					961:968	galactose residues	951:968	galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	951:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	1	15	theme	D.	224:225	arg1	chlorelloides					227:239	D. chlorelloides	224:239	D. chlorelloides	224:239	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	5	16	theme	O-methylated	923:934	arg1	derivatives					936:946	O-methylated derivatives	923:946	O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	923:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	6	17	theme	individual	1030:1039	arg1	fractions					1041:1049	individual fractions	1030:1049	individual fractions	1030:1049	In individual fractions their content and type varied.
35667459	5	18	theme	EPS	857:859	arg1	EPS					857:859	EPS	857:859	EPS	857:859	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	18	theme	EPS	857:859	arg1	backbone					845:852	a rhamnogalactan backbone	828:852	a rhamnogalactan backbone of EPS	828:859	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	18	theme	EPS	857:859	arg1	lot					916:918	a lot	914:918	a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	914:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	18	theme	EPS	857:859	arg1	derivatives					936:946	O-methylated derivatives	923:946	O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	923:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	3	19	from	equal	740:744	arg1	rhamnogalactans					593:607	highly branched rhamnogalactans	577:607	highly branched rhamnogalactans	577:607	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	7	20	theme	-α-L-Araf	1247:1255	arg1	chain					1262:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	0	21	theme	Structural	0:9	arg1	features					11:18	Structural features	0:18	Structural features of biologically active extracellular polysaccharide	0:70	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	1	22	theme	weight	341:346	arg1	distribution					348:359	molecular weight distribution	331:359	molecular weight distribution	331:359	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	4	23	from	linkages	773:780	arg1	dominant					804:811	dominant	804:811	dominant	804:811	From various α-L-rhamnose linkages the 1,2,4-linkage was dominant.
35667459	4	23	from	linkages	773:780	arg1	1,2,4-linkage					786:798	the 1,2,4-linkage	782:798	the 1,2,4-linkage	782:798	From various α-L-rhamnose linkages the 1,2,4-linkage was dominant.
35667459	3	24	theme	linear	625:630	arg1	units					687:691	linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units	625:691	linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked)	625:727	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	5	25	theme	residues	961:968	arg1	derivatives					936:946	O-methylated derivatives	923:946	O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	923:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	2	26	theme	compositional	374:386	arg1	analyses					388:395	Their sugar compositional analyses	362:395	Their sugar compositional analyses	362:395	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	4	27	theme	α-L-rhamnose	760:771	arg1	linkages					773:780	various α-L-rhamnose linkages	752:780	various α-L-rhamnose linkages	752:780	From various α-L-rhamnose linkages the 1,2,4-linkage was dominant.
35667459	7	28	theme	arabinogalactan	1102:1116	arg1	study					1089:1093	Detail study	1082:1093	Detail study of the arabinogalactan	1082:1116	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	3	29	theme	units	687:691	arg1	quantity					613:620	the quantity	609:620	the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked)	609:727	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	29	theme	units	687:691	arg1	equal					740:744	equal	740:744	equal	740:744	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	2	30	theme	sugar	368:372	arg1	analyses					388:395	Their sugar compositional analyses	362:395	Their sugar compositional analyses	362:395	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	3	31	dep	linear	625:630	arg1	1,6-linked					648:657	1,6-linked	648:657	1,6-linked	648:657	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	31	dep	linear	625:630	arg1	1,4-					639:642	1,4-	639:642	1,4-	639:642	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	31	dep	linear	625:630	arg1	1,3-					633:636	1,3-	633:636	1,3-	633:636	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	2	32	theme	EPS	491:493	arg1	rhamnogalactans					404:418	rhamnogalactans	404:418	rhamnogalactans	404:418	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	2	32	theme	EPS	491:493	arg1	component					495:503	a dominant EPS component	480:503	a dominant EPS component in all fractions (91 %)	480:527	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	0	33	theme	extracellular	43:55	arg1	polysaccharide					57:70	biologically active extracellular polysaccharide	23:70	biologically active extracellular polysaccharide	23:70	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	5	34	theme	mannose	883:889	arg1	units					903:907	terminal mannose and glucose units	874:907	terminal mannose and glucose units	874:907	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	2	35	theme	dominant	482:489	arg1	rhamnogalactans					404:418	rhamnogalactans	404:418	rhamnogalactans	404:418	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	2	35	theme	dominant	482:489	arg1	component					495:503	a dominant EPS component	480:503	a dominant EPS component in all fractions (91 %)	480:527	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	0	36	theme	active	36:41	arg1	polysaccharide					57:70	biologically active extracellular polysaccharide	23:70	biologically active extracellular polysaccharide	23:70	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	3	37	theme	branched	664:671	arg1	units					687:691	linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units	625:691	linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked)	625:727	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	5	38	theme	rhamnogalactan	830:843	arg1	backbone					845:852	a rhamnogalactan backbone	828:852	a rhamnogalactan backbone of EPS	828:859	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	3	39	theme	β-D-galactose	673:685	arg1	units					687:691	linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units	625:691	linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked)	625:727	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	2	40	contain	containing	540:549	arg1	one					536:538	one	536:538	one	536:538	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	2	40	contain	containing	540:549	arg2	%					570:570	7 %	568:570	7 %	568:570	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	2	40	contain	containing	540:549	arg2	arabinogalactan					551:565	arabinogalactan	551:565	arabinogalactan (7 %)	551:571	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	5	41	theme	derivatives	936:946	arg1	EPS					857:859	EPS	857:859	EPS	857:859	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	41	theme	derivatives	936:946	arg1	backbone					845:852	a rhamnogalactan backbone	828:852	a rhamnogalactan backbone of EPS	828:859	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	41	theme	derivatives	936:946	arg1	lot					916:918	a lot	914:918	a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	914:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	5	41	theme	derivatives	936:946	arg1	derivatives					936:946	O-methylated derivatives	923:946	O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl)	923:1024	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	0	42	theme	polysaccharide	57:70	arg1	features					11:18	Structural features	0:18	Structural features of biologically active extracellular polysaccharide	0:70	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	7	43	theme	Detail	1082:1087	arg1	study					1089:1093	Detail study	1082:1093	Detail study of the arabinogalactan	1082:1116	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	7	44	link	1,3-linked	1155:1164	arg1	units					1175:1179	1,3-linked β-D-Galp units	1155:1179	1,3-linked β-D-Galp units	1155:1179	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	4	45	theme	various	752:758	arg1	linkages					773:780	various α-L-rhamnose linkages	752:780	various α-L-rhamnose linkages	752:780	From various α-L-rhamnose linkages the 1,2,4-linkage was dominant.
35667459	1	46	theme	Ion-exchange	132:143	arg1	chromatography					145:158	Ion-exchange chromatography	132:158	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides	132:239	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	5	47	theme	glucose	895:901	arg1	units					903:907	terminal mannose and glucose units	874:907	terminal mannose and glucose units	874:907	Data indicate a rhamnogalactan backbone of EPS, branched by terminal mannose and glucose units, and a lot of O-methylated derivatives of galactose residues (2-O-methyl, 2,3-O-dimethyl, 3-O-methyl and 6-O-methyl).
35667459	1	48	theme	active	180:185	arg1	biopolymer					201:210	the biologically active extracellular biopolymer	163:210	the biologically active extracellular biopolymer produced by D. chlorelloides	163:239	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	1	49	theme	protein	283:289	arg1	content					291:297	protein content	283:297	protein content	283:297	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	0	50	theme	green	84:88	arg1	chlorelloides					117:129	green microalgae Dictyosphaerium chlorelloides	84:129	green microalgae Dictyosphaerium chlorelloides	84:129	Structural features of biologically active extracellular polysaccharide produced by green microalgae Dictyosphaerium chlorelloides.
35667459	1	51	theme	extracellular	187:199	arg1	biopolymer					201:210	the biologically active extracellular biopolymer	163:210	the biologically active extracellular biopolymer produced by D. chlorelloides	163:239	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
35667459	3	52	dep	units	687:691	arg1	1,3,4,6-linked					713:726	1,3,4,6-linked	713:726	1,3,4,6-linked	713:726	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	52	dep	units	687:691	arg1	1,4,6-					702:707	1,4,6-	702:707	1,4,6-	702:707	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	3	52	dep	units	687:691	arg1	1,3,6-					694:699	1,3,6-	694:699	1,3,6-	694:699	In highly branched rhamnogalactans the quantity of linear (1,3-; 1,4- and 1,6-linked) and branched β-D-galactose units (1,3,6-, 1,4,6- and 1,3,4,6-linked) was nearly equal.
35667459	7	53	theme	side	1257:1260	arg1	chain					1262:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain	1223:1266	Detail study of the arabinogalactan showed that its backbone consists of 1,3-linked β-D-Galp units; some of them are branched through O-4 by 6-OMe-α-D-Galp- (1 → 2) -α-L-Araf side chain, other through O-6 by 3-OMe-β-D-Galp, 6-OMe-β-D-Galp, β-D-Galp and β-D-Galf.
35667459	2	54	from	component	495:503	arg1	fractions					512:520	all fractions	508:520	all fractions (91 %)	508:527	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	2	54	from	component	495:503	arg1	%					526:526	91 %	523:526	91 %	523:526	Their sugar compositional analyses showed rhamnogalactans, substituted to different extent by mannose and glucose, as a dominant EPS component in all fractions (91 %) except one containing arabinogalactan (7 %).
35667459	1	55	theme	biopolymer	201:210	arg1	chromatography					145:158	Ion-exchange chromatography	132:158	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides	132:239	Ion-exchange chromatography of the biologically active extracellular biopolymer produced by D. chlorelloides yielded ten fractions differing in yield, protein content, monosaccharide composition and molecular weight distribution.
36796554	0	0	with	polysaccharide	41:54	arg1	system					79:84	intestinal immune system	61:84	intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture	61:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	2	1	theme	culture	409:415	arg1	PLME					426:429	PLME	426:429	PLME	426:429	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	2	1	theme	culture	409:415	arg1	extract					417:423	Phellinus linteus mycelial-containing whole culture extract	365:423	Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation	365:464	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	9	2	theme	broth	1758:1762	arg1	postbiotics					1764:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	8	3	theme	acidic	1437:1442	arg1	polysaccharide					1444:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	8	3	theme	acidic	1437:1442	arg1	PLME-CP-III-1					1376:1388	PLME-CP-III-1	1376:1388	PLME-CP-III-1	1376:1388	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	2	4	theme	whole	403:407	arg1	PLME					426:429	PLME	426:429	PLME	426:429	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	2	4	theme	whole	403:407	arg1	extract					417:423	Phellinus linteus mycelial-containing whole culture extract	365:423	Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation	365:464	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	3	5	from	ingredients	586:596	arg1	PLME					601:604	PLME	601:604	PLME	601:604	Here, we aimed to isolate and structurally elucidate the active ingredients in PLME by activity-guided fractionation.
36796554	9	6	theme	acidic	1686:1691	arg1	polysaccharide					1693:1706	acidic polysaccharide	1686:1706	acidic polysaccharide	1686:1706	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	5	7	theme	anion-exchange	1023:1036	arg1	chromatography					1045:1058	anion-exchange column chromatography	1023:1058	anion-exchange column chromatography	1023:1058	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	4	8	theme	immunostimulatory	655:671	arg1	activity					673:680	The intestinal immunostimulatory activity	640:680	The intestinal immunostimulatory activity	640:680	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	9	theme	patch	809:813	arg1	cells					820:824	C3H-HeN mouse-derived Peyer's patch (PP) cells	779:824	C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions	779:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	9	10	theme	system	1668:1673	arg1	characteristics					1623:1637	the structural characteristics	1608:1637	the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics	1608:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	5	11	theme	column	1038:1043	arg1	chromatography					1045:1058	anion-exchange column chromatography	1023:1058	anion-exchange column chromatography	1023:1058	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	4	12	link	mouse-derived	787:799	arg1	cells					820:824	C3H-HeN mouse-derived Peyer's patch (PP) cells	779:824	C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions	779:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	13	from	activity	735:742	arg1	cells					820:824	C3H-HeN mouse-derived Peyer's patch (PP) cells	779:824	C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions	779:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	14	theme	intestinal	644:653	arg1	activity					673:680	The intestinal immunostimulatory activity	640:680	The intestinal immunostimulatory activity	640:680	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	15	theme	C3H-HeN	779:785	arg1	cells					820:824	C3H-HeN mouse-derived Peyer's patch (PP) cells	779:824	C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions	779:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	6	16	theme	BM	1061:1062	arg1	proliferation					1069:1081	BM cell proliferation	1061:1081	BM cell proliferation	1061:1081	BM cell proliferation and cytokine production of PLME-CP-III were significantly improved compared to those of PLME-CP.
36796554	6	17	theme	PLME-CP-III	1110:1120	arg1	proliferation					1069:1081	BM cell proliferation	1061:1081	BM cell proliferation	1061:1081	BM cell proliferation and cytokine production of PLME-CP-III were significantly improved compared to those of PLME-CP.
36796554	6	17	theme	PLME-CP-III	1110:1120	arg1	production					1096:1105	cytokine production	1087:1105	cytokine production of PLME-CP-III	1087:1120	BM cell proliferation and cytokine production of PLME-CP-III were significantly improved compared to those of PLME-CP.
36796554	8	18	theme	weight	1308:1313	arg1	distribution					1315:1326	the molecular weight distribution	1294:1326	the molecular weight distribution	1294:1326	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	4	19	theme	cell	716:719	arg1	activity					735:742	bone marrow (BM) cell proliferation activity	699:742	bone marrow (BM) cell proliferation activity	699:742	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	2	20	theme	system	503:508	arg1	activation					510:519	immune system activation	496:519	immune system activation	496:519	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	8	21	theme	novel	1408:1412	arg1	polysaccharide					1444:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	8	21	theme	novel	1408:1412	arg1	PLME-CP-III-1					1376:1388	PLME-CP-III-1	1376:1388	PLME-CP-III-1	1376:1388	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	3	22	theme	active	579:584	arg1	ingredients					586:596	the active ingredients	575:596	the active ingredients in PLME	575:604	Here, we aimed to isolate and structurally elucidate the active ingredients in PLME by activity-guided fractionation.
36796554	8	23	theme	glycosyl	1349:1356	arg1	analyses					1366:1373	glycosyl linkage analyses	1349:1373	glycosyl linkage analyses	1349:1373	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	2	24	theme	immune	496:501	arg1	activation					510:519	immune system activation	496:519	immune system activation	496:519	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	9	25	theme	whole	1744:1748	arg1	postbiotics					1764:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	3	26	theme	activity-guided	609:623	arg1	fractionation					625:637	activity-guided fractionation	609:637	activity-guided fractionation	609:637	Here, we aimed to isolate and structurally elucidate the active ingredients in PLME by activity-guided fractionation.
36796554	5	27	theme	ethanol	933:939	arg1	precipitation					941:953	ethanol precipitation	933:953	ethanol precipitation	933:953	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	5	28	theme	crude	879:883	arg1	PLME-CP					901:907	PLME-CP	901:907	PLME-CP	901:907	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	5	28	theme	crude	879:883	arg1	polysaccharide					885:898	The initially crude polysaccharide	865:898	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation	865:953	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	7	29	theme	filtration	1258:1267	arg1	chromatography					1269:1282	gel filtration chromatography	1254:1282	gel filtration chromatography	1254:1282	PLME-CP-III was then fractionated into PLME-CP-III-1 and PLME-CP-III-2 by gel filtration chromatography.
36796554	8	30	theme	linkage	1358:1364	arg1	analyses					1366:1373	glycosyl linkage analyses	1349:1373	glycosyl linkage analyses	1349:1373	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	2	31	theme	potential	348:356	arg1	use					358:360	the potential use	344:360	the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation	344:519	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	4	32	theme	proliferation	721:733	arg1	activity					735:742	bone marrow (BM) cell proliferation activity	699:742	bone marrow (BM) cell proliferation activity	699:742	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	0	33	theme	acid-rich	31:39	arg1	polysaccharide					41:54	galacturonic acid-rich polysaccharide	18:54	galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture	18:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	9	34	theme	immune	1661:1666	arg1	system					1668:1673	a novel intestinal immune system	1642:1673	a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics	1642:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	8	35	theme	galacturonic	1414:1425	arg1	polysaccharide					1444:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	8	35	theme	galacturonic	1414:1425	arg1	PLME-CP-III-1					1376:1388	PLME-CP-III-1	1376:1388	PLME-CP-III-1	1376:1388	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	5	36	theme	PLME-CP-0	1001:1009	arg1	fractions					990:998	four fractions	985:998	four fractions (PLME-CP-0 to -III)	985:1018	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	5	36	theme	PLME-CP-0	1001:1009	arg1	-III					1014:1017	PLME-CP-0 to -III	1001:1017	PLME-CP-0 to -III	1001:1017	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	5	37	dep	-III	1014:1017	arg1	to					1011:1012	to	1011:1012	to	1011:1012	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	9	38	theme	first	1582:1586	arg1	This					1570:1573	This	1570:1573	This	1570:1573	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	9	38	theme	first	1582:1586	arg1	study					1588:1592	the first study	1578:1592	the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics	1578:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	4	39	theme	marrow	704:709	arg1	activity					735:742	bone marrow (BM) cell proliferation activity	699:742	bone marrow (BM) cell proliferation activity	699:742	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	0	40	theme	galacturonic	18:29	arg1	polysaccharide					41:54	galacturonic acid-rich polysaccharide	18:54	galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture	18:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	9	41	theme	mycelium-containing	1724:1742	arg1	postbiotics					1764:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	6	42	theme	cytokine	1087:1094	arg1	production					1096:1105	cytokine production	1087:1105	cytokine production of PLME-CP-III	1087:1120	BM cell proliferation and cytokine production of PLME-CP-III were significantly improved compared to those of PLME-CP.
36796554	4	43	theme	cytokine	756:763	arg1	production					765:774	related cytokine production	748:774	related cytokine production	748:774	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	44	theme	bone	699:702	arg1	BM					712:713	BM	712:713	BM	712:713	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	44	theme	bone	699:702	arg1	marrow					704:709	bone marrow	699:709	bone marrow (BM) cell proliferation activity	699:742	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	7	45	theme	gel	1254:1256	arg1	chromatography					1269:1282	gel filtration chromatography	1254:1282	gel filtration chromatography	1254:1282	PLME-CP-III was then fractionated into PLME-CP-III-1 and PLME-CP-III-2 by gel filtration chromatography.
36796554	9	46	theme	culture	1750:1756	arg1	postbiotics					1764:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	0	47	theme	linteus	154:160	arg1	culture					181:187	Phellinus linteus mycelial submerged culture	144:187	Phellinus linteus mycelial submerged culture	144:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	8	48	theme	intestinal	1531:1540	arg1	activity					1560:1567	PP-mediated intestinal immunostimulatory activity	1519:1567	PP-mediated intestinal immunostimulatory activity	1519:1567	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	0	49	theme	polysaccharide	41:54	arg1	Identification					0:13	Identification	0:13	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.	0:188	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	0	50	theme	Phellinus	144:152	arg1	culture					181:187	Phellinus linteus mycelial submerged culture	144:187	Phellinus linteus mycelial submerged culture	144:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	1	51	dep	development	207:217	arg1	the					203:205	the	203:205	the	203:205	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	5	52	theme	PLME	913:916	arg1	PLME-CP					901:907	PLME-CP	901:907	PLME-CP	901:907	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	5	52	theme	PLME	913:916	arg1	polysaccharide					885:898	The initially crude polysaccharide	865:898	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation	865:953	The initially crude polysaccharide (PLME-CP) of PLME prepared using ethanol precipitation was further fractionated into four fractions (PLME-CP-0 to -III) by anion-exchange column chromatography.
36796554	1	53	theme	industrial	238:247	arg1	applications					249:260	industrial applications	238:260	industrial applications of medicinal mushrooms as postbiotics	238:298	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	0	54	theme	immune	72:77	arg1	system					79:84	intestinal immune system	61:84	intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture	61:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	0	55	theme	submerged	171:179	arg1	culture					181:187	Phellinus linteus mycelial submerged culture	144:187	Phellinus linteus mycelial submerged culture	144:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	9	56	theme	intestinal	1650:1659	arg1	system					1668:1673	a novel intestinal immune system	1642:1673	a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics	1642:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	8	57	theme	important	1488:1496	arg1	role					1498:1501	an important role	1485:1501	an important role	1485:1501	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	2	58	theme	mycelial-containing	383:401	arg1	PLME					426:429	PLME	426:429	PLME	426:429	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	2	58	theme	mycelial-containing	383:401	arg1	extract					417:423	Phellinus linteus mycelial-containing whole culture extract	365:423	Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation	365:464	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	0	59	theme	intestinal	61:70	arg1	system					79:84	intestinal immune system	61:84	intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture	61:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	0	60	theme	mycelial	162:169	arg1	culture					181:187	Phellinus linteus mycelial submerged culture	144:187	Phellinus linteus mycelial submerged culture	144:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	9	61	theme	P.	1713:1714	arg1	postbiotics					1764:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	8	62	theme	immunostimulatory	1542:1558	arg1	activity					1560:1567	PP-mediated intestinal immunostimulatory activity	1519:1567	PP-mediated intestinal immunostimulatory activity	1519:1567	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	9	63	theme	novel	1644:1648	arg1	system					1668:1673	a novel intestinal immune system	1642:1673	a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics	1642:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	2	64	theme	linteus	375:381	arg1	PLME					426:429	PLME	426:429	PLME	426:429	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	2	64	theme	linteus	375:381	arg1	extract					417:423	Phellinus linteus mycelial-containing whole culture extract	365:423	Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation	365:464	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	9	65	theme	linteus	1716:1722	arg1	postbiotics					1764:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	P. linteus mycelium-containing whole culture broth postbiotics	1713:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	8	66	theme	molecular	1298:1306	arg1	distribution					1315:1326	the molecular weight distribution	1294:1326	the molecular weight distribution	1294:1326	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	8	67	theme	PP-mediated	1519:1529	arg1	activity					1560:1567	PP-mediated intestinal immunostimulatory activity	1519:1567	PP-mediated intestinal immunostimulatory activity	1519:1567	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	2	68	theme	Phellinus	365:373	arg1	PLME					426:429	PLME	426:429	PLME	426:429	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	2	68	theme	Phellinus	365:373	arg1	extract					417:423	Phellinus linteus mycelial-containing whole culture extract	365:423	Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation	365:464	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	1	69	theme	applications	249:260	arg1	exploration					223:233	exploration	223:233	exploration	223:233	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	1	69	theme	applications	249:260	arg1	development					207:217	development	207:217	development	207:217	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	0	70	theme	culture	181:187	arg1	postbiotics					129:139	postbiotics	129:139	postbiotics of Phellinus linteus mycelial submerged culture	129:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	4	71	theme	polysaccharide	839:852	arg1	fractions					854:862	polysaccharide fractions	839:862	polysaccharide fractions	839:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	4	72	theme	mouse-derived	787:799	arg1	cells					820:824	C3H-HeN mouse-derived Peyer's patch (PP) cells	779:824	C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions	779:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	8	73	theme	acid-rich	1427:1435	arg1	polysaccharide					1444:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	a novel galacturonic acid-rich acidic polysaccharide	1406:1457	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	8	73	theme	acid-rich	1427:1435	arg1	PLME-CP-III-1					1376:1388	PLME-CP-III-1	1376:1388	PLME-CP-III-1	1376:1388	Based on the molecular weight distribution, monosaccharide, and glycosyl linkage analyses, PLME-CP-III-1 was revealed as a novel galacturonic acid-rich acidic polysaccharide and further shown to play an important role in facilitating PP-mediated intestinal immunostimulatory activity.
36796554	2	74	theme	submerged	444:452	arg1	cultivation					454:464	submerged cultivation	444:464	submerged cultivation	444:464	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	9	75	theme	structural	1612:1621	arg1	characteristics					1623:1637	the structural characteristics	1608:1637	the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics	1608:1774	This is the first study demonstrating the structural characteristics of a novel intestinal immune system modulating acidic polysaccharide from P. linteus mycelium-containing whole culture broth postbiotics.
36796554	4	76	theme	related	748:754	arg1	production					765:774	related cytokine production	748:774	related cytokine production	748:774	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	1	77	theme	medicinal	265:273	arg1	mushrooms					275:283	medicinal mushrooms	265:283	medicinal mushrooms as postbiotics	265:298	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	6	78	theme	cell	1064:1067	arg1	proliferation					1069:1081	BM cell proliferation	1061:1081	BM cell proliferation	1061:1081	BM cell proliferation and cytokine production of PLME-CP-III were significantly improved compared to those of PLME-CP.
36796554	0	79	from	postbiotics	129:139	arg1	patch					118:122	Peyer's patch	110:122	Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture	110:187	Identification of galacturonic acid-rich polysaccharide with intestinal immune system modulating activity via Peyer's patch from postbiotics of Phellinus linteus mycelial submerged culture.
36796554	1	80	from	Interests	190:198	arg1	exploration					223:233	exploration	223:233	exploration	223:233	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	1	80	from	Interests	190:198	arg1	development					207:217	development	207:217	development	207:217	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36796554	2	81	theme	extract	417:423	arg1	use					358:360	the potential use	344:360	the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation	344:519	We recently reported the potential use of Phellinus linteus mycelial-containing whole culture extract (PLME) prepared by submerged cultivation as a postbiotic that promotes immune system activation.
36796554	4	82	from	production	765:774	arg1	cells					820:824	C3H-HeN mouse-derived Peyer's patch (PP) cells	779:824	C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions	779:862	The intestinal immunostimulatory activity was evaluated by bone marrow (BM) cell proliferation activity and related cytokine production in C3H-HeN mouse-derived Peyer's patch (PP) cells treated with polysaccharide fractions.
36796554	1	83	theme	mushrooms	275:283	arg1	applications					249:260	industrial applications	238:260	industrial applications of medicinal mushrooms as postbiotics	238:298	Interests in the development and exploration of industrial applications of medicinal mushrooms as postbiotics have lately increased.
36794810	0	0	theme	monosaccharide	97:110	arg1	analysis					126:133	full monosaccharide compositional analysis	92:133	full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	92:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	1	1	theme	few	379:381	arg1	reports					383:389	few reports	379:389	few reports	379:389	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	4	2	theme	systematic	1069:1078	arg1	optimization					1080:1091	a systematic optimization	1067:1091	a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on	1067:1207	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	3	3	theme	water	885:889	arg1	solubility					891:900	water solubility	885:900	water solubility	885:900	Each carbohydrate herein is simultaneously labeled as 1-pheny-3-methyl-5-pyrazolone and acetyl-derivative via pre-column derivatizations for aiming to increase ultraviolet absorption sensitivity and decrease water solubility.
36794810	0	4	theme	full	92:95	arg1	analysis					126:133	full monosaccharide compositional analysis	92:133	full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	92:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	3	5	theme	ultraviolet	837:847	arg1	sensitivity					860:870	ultraviolet absorption sensitivity	837:870	ultraviolet absorption sensitivity	837:870	Each carbohydrate herein is simultaneously labeled as 1-pheny-3-methyl-5-pyrazolone and acetyl-derivative via pre-column derivatizations for aiming to increase ultraviolet absorption sensitivity and decrease water solubility.
36794810	5	6	theme	mobile	1242:1247	arg1	phase					1249:1253	mobile phase	1242:1253	mobile phase	1242:1253	Compared with carbon dioxide as mobile phase, the addition of binary modifier increases the resolution of analytes.
36794810	4	7	theme	on	1206:1207	arg1	optimization					1080:1091	a systematic optimization	1067:1091	a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on	1067:1207	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	3	8	theme	absorption	849:858	arg1	sensitivity					860:870	ultraviolet absorption sensitivity	837:870	ultraviolet absorption sensitivity	837:870	Each carbohydrate herein is simultaneously labeled as 1-pheny-3-methyl-5-pyrazolone and acetyl-derivative via pre-column derivatizations for aiming to increase ultraviolet absorption sensitivity and decrease water solubility.
36794810	4	9	dep	and	1199:1201	arg1	so					1203:1204	so	1203:1204	so	1203:1204	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	8	10	theme	monosaccharide	1641:1654	arg1	analysis					1670:1677	monosaccharide compositional analysis	1641:1677	monosaccharide compositional analysis of natural polysaccharides	1641:1704	To sum up, a new alternative approach is provided for monosaccharide compositional analysis of natural polysaccharides.
36794810	4	11	theme	organic	1158:1164	arg1	parameters					1114:1123	multiple relevant parameters	1096:1123	multiple relevant parameters	1096:1123	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	11	theme	organic	1158:1164	arg1	modifiers					1166:1174	organic modifiers	1158:1174	organic modifiers	1158:1174	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	0	12	theme	compositional	112:124	arg1	analysis					126:133	full monosaccharide compositional analysis	92:133	full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	92:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	5	13	theme	binary	1272:1277	arg1	modifier					1279:1286	binary modifier	1272:1286	binary modifier	1272:1286	Compared with carbon dioxide as mobile phase, the addition of binary modifier increases the resolution of analytes.
36794810	4	14	theme	parameters	1114:1123	arg1	optimization					1080:1091	a systematic optimization	1067:1091	a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on	1067:1207	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	1	15	theme	analytical	327:336	arg1	fields					338:343	analytical fields	327:343	analytical fields in recent years	327:359	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	0	16	theme	polysaccharides	138:152	arg1	analysis					126:133	full monosaccharide compositional analysis	92:133	full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	92:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	5	17	theme	modifier	1279:1286	arg1	addition					1260:1267	the addition	1256:1267	the addition of binary modifier	1256:1286	Compared with carbon dioxide as mobile phase, the addition of binary modifier increases the resolution of analytes.
36794810	4	18	theme	array	1049:1053	arg1	detector					1055:1062	photo-diode array detector	1037:1062	photo-diode array detector	1037:1062	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	8	19	theme	polysaccharides	1690:1704	arg1	analysis					1670:1677	monosaccharide compositional analysis	1641:1677	monosaccharide compositional analysis of natural polysaccharides	1641:1704	To sum up, a new alternative approach is provided for monosaccharide compositional analysis of natural polysaccharides.
36794810	7	20	theme	chinensis	1569:1577	arg1	fruits					1579:1584	Schisandra chinensis fruits	1558:1584	Schisandra chinensis fruits	1558:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	2	21	theme	supercritical	522:534	arg1	technology					557:566	an ultra-high performance supercritical fluid chromatography technology	496:566	an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier	496:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	1	22	theme	monosaccharide	409:422	arg1	analysis					438:445	monosaccharide compositional analysis	409:445	monosaccharide compositional analysis of macromolecule polysaccharides	409:478	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	4	23	theme	photo-diode	1037:1047	arg1	detector					1055:1062	photo-diode array detector	1037:1062	photo-diode array detector	1037:1062	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	2	24	theme	performance	510:520	arg1	technology					557:566	an ultra-high performance supercritical fluid chromatography technology	496:566	an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier	496:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	4	25	theme	stationary	1139:1148	arg1	parameters					1114:1123	multiple relevant parameters	1096:1123	multiple relevant parameters	1096:1123	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	25	theme	stationary	1139:1148	arg1	phases					1150:1155	column stationary phases	1132:1155	column stationary phases	1132:1155	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	7	26	theme	Schisandra	1558:1567	arg1	fruits					1579:1584	Schisandra chinensis fruits	1558:1584	Schisandra chinensis fruits	1558:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	0	27	theme	alternative	3:13	arg1	strategy					15:22	An alternative strategy	0:22	An alternative strategy	0:22	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	1	28	theme	compositional	424:436	arg1	analysis					438:445	monosaccharide compositional analysis	409:445	monosaccharide compositional analysis of macromolecule polysaccharides	409:478	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	1	29	from	fields	338:343	arg1	years					355:359	recent years	348:359	recent years	348:359	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	4	30	theme	common	906:911	arg1	monosaccharides					913:927	10 common monosaccharides	903:927	10 common monosaccharides	903:927	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	31	dep	parameters	1114:1123	arg1	e.g.					1126:1129	multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates	1096:1197	e.g.	1126:1129	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	8	32	theme	new	1600:1602	arg1	approach					1616:1623	a new alternative approach	1598:1623	a new alternative approach	1598:1623	To sum up, a new alternative approach is provided for monosaccharide compositional analysis of natural polysaccharides.
36794810	2	33	theme	ultra-high	499:508	arg1	technology					557:566	an ultra-high performance supercritical fluid chromatography technology	496:566	an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier	496:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	2	34	used	used	603:606	arg2	technology					557:566	an ultra-high performance supercritical fluid chromatography technology	496:566	an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier	496:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	1	35	dep	green	193:197	arg1	characteristics					224:238	characteristics	224:238	characteristics	224:238	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	7	36	theme	heteropolysaccharides	1531:1551	arg1	analysis					1519:1526	full monosaccharide compositional analysis	1485:1526	full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits	1485:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	6	37	theme	consumption	1380:1390	arg1	advantages					1360:1369	the advantages	1356:1369	the advantages of small consumption for organic solvent, safety and environmental-friendly	1356:1445	Additionally, this method has the advantages of small consumption for organic solvent, safety and environmental-friendly.
36794810	0	38	theme	Schisandra	157:166	arg1	fruits					178:183	Schisandra chinensis fruits	157:183	Schisandra chinensis fruits	157:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	8	39	theme	alternative	1604:1614	arg1	approach					1616:1623	a new alternative approach	1598:1623	a new alternative approach	1598:1623	To sum up, a new alternative approach is provided for monosaccharide compositional analysis of natural polysaccharides.
36794810	7	40	theme	compositional	1505:1517	arg1	analysis					1519:1526	full monosaccharide compositional analysis	1485:1526	full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits	1485:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	1	41	theme	recent	348:353	arg1	years					355:359	recent years	348:359	recent years	348:359	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	8	42	theme	compositional	1656:1668	arg1	analysis					1670:1677	monosaccharide compositional analysis	1641:1677	monosaccharide compositional analysis of natural polysaccharides	1641:1704	To sum up, a new alternative approach is provided for monosaccharide compositional analysis of natural polysaccharides.
36794810	3	43	theme	pre-column	787:796	arg1	derivatizations					798:812	pre-column derivatizations	787:812	pre-column derivatizations for aiming to increase ultraviolet absorption sensitivity and decrease water solubility	787:900	Each carbohydrate herein is simultaneously labeled as 1-pheny-3-methyl-5-pyrazolone and acetyl-derivative via pre-column derivatizations for aiming to increase ultraviolet absorption sensitivity and decrease water solubility.
36794810	2	44	theme	chromatography	542:555	arg1	technology					557:566	an ultra-high performance supercritical fluid chromatography technology	496:566	an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier	496:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	1	45	theme	ultra-high	245:254	arg1	chromatography					288:301	the ultra-high performance supercritical fluid chromatography	241:301	the ultra-high performance supercritical fluid chromatography	241:301	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	0	46	theme	performance	41:51	arg1	chromatography					73:86	ultra-high performance supercritical fluid chromatography	30:86	ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	30:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	7	47	from	fruits	1579:1584	arg1	heteropolysaccharides					1531:1551	heteropolysaccharides	1531:1551	heteropolysaccharides from Schisandra chinensis fruits	1531:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	7	47	from	fruits	1579:1584	arg1	analysis					1519:1526	full monosaccharide compositional analysis	1485:1526	full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits	1485:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	2	48	theme	monosaccharide	621:634	arg1	compositions					636:647	monosaccharide compositions	621:647	monosaccharide compositions of natural polysaccharides	621:674	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	7	49	theme	full	1485:1488	arg1	analysis					1519:1526	full monosaccharide compositional analysis	1485:1526	full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits	1485:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	4	50	theme	column	1132:1137	arg1	parameters					1114:1123	multiple relevant parameters	1096:1123	multiple relevant parameters	1096:1123	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	50	theme	column	1132:1137	arg1	phases					1150:1155	column stationary phases	1132:1155	column stationary phases	1132:1155	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	1	51	theme	performance	256:266	arg1	chromatography					288:301	the ultra-high performance supercritical fluid chromatography	241:301	the ultra-high performance supercritical fluid chromatography	241:301	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	0	52	theme	ultra-high	30:39	arg1	chromatography					73:86	ultra-high performance supercritical fluid chromatography	30:86	ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	30:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	0	53	theme	chinensis	168:176	arg1	fruits					178:183	Schisandra chinensis fruits	157:183	Schisandra chinensis fruits	157:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	1	54	used	used	319:322	arg2	chromatography					288:301	the ultra-high performance supercritical fluid chromatography	241:301	the ultra-high performance supercritical fluid chromatography	241:301	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	4	55	theme	fluid	1002:1006	arg1	chromatography					1008:1021	ultra-high performance supercritical fluid chromatography	965:1021	ultra-high performance supercritical fluid chromatography combined with photo-diode array detector	965:1062	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	1	56	theme	supercritical	268:280	arg1	chromatography					288:301	the ultra-high performance supercritical fluid chromatography	241:301	the ultra-high performance supercritical fluid chromatography	241:301	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	0	57	theme	fluid	67:71	arg1	chromatography					73:86	ultra-high performance supercritical fluid chromatography	30:86	ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	30:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	4	58	theme	relevant	1105:1112	arg1	parameters					1114:1123	multiple relevant parameters	1096:1123	multiple relevant parameters	1096:1123	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	58	theme	relevant	1105:1112	arg1	additives					1177:1185	additives	1177:1185	additives	1177:1185	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	58	theme	relevant	1105:1112	arg1	phases					1150:1155	column stationary phases	1132:1155	column stationary phases	1132:1155	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	58	theme	relevant	1105:1112	arg1	modifiers					1166:1174	organic modifiers	1158:1174	organic modifiers	1158:1174	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	58	theme	relevant	1105:1112	arg1	rates					1193:1197	flow rates	1188:1197	flow rates	1188:1197	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	1	59	theme	polysaccharides	464:478	arg1	analysis					438:445	monosaccharide compositional analysis	409:445	monosaccharide compositional analysis of macromolecule polysaccharides	409:478	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	5	60	theme	analytes	1316:1323	arg1	resolution					1302:1311	the resolution	1298:1311	the resolution of analytes	1298:1323	Compared with carbon dioxide as mobile phase, the addition of binary modifier increases the resolution of analytes.
36794810	0	61	theme	supercritical	53:65	arg1	chromatography					73:86	ultra-high performance supercritical fluid chromatography	30:86	ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	30:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	4	62	theme	multiple	1096:1103	arg1	parameters					1114:1123	multiple relevant parameters	1096:1123	multiple relevant parameters	1096:1123	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	62	theme	multiple	1096:1103	arg1	additives					1177:1185	additives	1177:1185	additives	1177:1185	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	62	theme	multiple	1096:1103	arg1	phases					1150:1155	column stationary phases	1132:1155	column stationary phases	1132:1155	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	62	theme	multiple	1096:1103	arg1	modifiers					1166:1174	organic modifiers	1158:1174	organic modifiers	1158:1174	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	62	theme	multiple	1096:1103	arg1	rates					1193:1197	flow rates	1188:1197	flow rates	1188:1197	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	0	63	from	polysaccharides	138:152	arg1	fruits					178:183	Schisandra chinensis fruits	157:183	Schisandra chinensis fruits	157:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	5	64	theme	carbon	1224:1229	arg1	dioxide					1231:1237	carbon dioxide	1224:1237	carbon dioxide as mobile phase	1224:1253	Compared with carbon dioxide as mobile phase, the addition of binary modifier increases the resolution of analytes.
36794810	1	65	theme	macromolecule	450:462	arg1	polysaccharides					464:478	macromolecule polysaccharides	450:478	macromolecule polysaccharides	450:478	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	6	66	theme	small	1374:1378	arg1	consumption					1380:1390	small consumption	1374:1390	small consumption	1374:1390	Additionally, this method has the advantages of small consumption for organic solvent, safety and environmental-friendly.
36794810	2	67	theme	polysaccharides	660:674	arg1	compositions					636:647	monosaccharide compositions	621:647	monosaccharide compositions of natural polysaccharides	621:674	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	6	68	theme	organic	1396:1402	arg1	solvent					1404:1410	organic solvent	1396:1410	organic solvent	1396:1410	Additionally, this method has the advantages of small consumption for organic solvent, safety and environmental-friendly.
36794810	4	69	theme	ultra-high	965:974	arg1	chromatography					1008:1021	ultra-high performance supercritical fluid chromatography	965:1021	ultra-high performance supercritical fluid chromatography combined with photo-diode array detector	965:1062	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	7	70	from	analysis	1519:1526	arg1	fruits					1579:1584	Schisandra chinensis fruits	1558:1584	Schisandra chinensis fruits	1558:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	1	71	theme	fluid	282:286	arg1	chromatography					288:301	the ultra-high performance supercritical fluid chromatography	241:301	the ultra-high performance supercritical fluid chromatography	241:301	Due to green and environment-friendly characteristics, the ultra-high performance supercritical fluid chromatography has been widely used in analytical fields in recent years, but until to now few reports are available for monosaccharide compositional analysis of macromolecule polysaccharides.
36794810	2	72	theme	natural	652:658	arg1	polysaccharides					660:674	natural polysaccharides	652:674	natural polysaccharides	652:674	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	0	73	from	analysis	126:133	arg1	fruits					178:183	Schisandra chinensis fruits	157:183	Schisandra chinensis fruits	157:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36794810	2	74	theme	unusual	576:582	arg1	modifier					591:598	an unusual binary modifier	573:598	an unusual binary modifier	573:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	6	75	contain	has	1352:1354	arg2	advantages					1360:1369	the advantages	1356:1369	the advantages of small consumption for organic solvent, safety and environmental-friendly	1356:1445	Additionally, this method has the advantages of small consumption for organic solvent, safety and environmental-friendly.
36794810	6	75	contain	has	1352:1354	arg1	method					1345:1350	this method	1340:1350	this method	1340:1350	Additionally, this method has the advantages of small consumption for organic solvent, safety and environmental-friendly.
36794810	2	76	theme	binary	584:589	arg1	modifier					591:598	an unusual binary modifier	573:598	an unusual binary modifier	573:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	7	77	theme	monosaccharide	1490:1503	arg1	analysis					1519:1526	full monosaccharide compositional analysis	1485:1526	full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits	1485:1584	It has been successfully applied for full monosaccharide compositional analysis of heteropolysaccharides from Schisandra chinensis fruits.
36794810	4	78	theme	supercritical	988:1000	arg1	chromatography					1008:1021	ultra-high performance supercritical fluid chromatography	965:1021	ultra-high performance supercritical fluid chromatography combined with photo-diode array detector	965:1062	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	8	79	theme	natural	1682:1688	arg1	polysaccharides					1690:1704	natural polysaccharides	1682:1704	natural polysaccharides	1682:1704	To sum up, a new alternative approach is provided for monosaccharide compositional analysis of natural polysaccharides.
36794810	2	80	theme	fluid	536:540	arg1	technology					557:566	an ultra-high performance supercritical fluid chromatography technology	496:566	an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier	496:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	4	81	theme	flow	1188:1191	arg1	parameters					1114:1123	multiple relevant parameters	1096:1123	multiple relevant parameters	1096:1123	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	81	theme	flow	1188:1191	arg1	rates					1193:1197	flow rates	1188:1197	flow rates	1188:1197	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	4	82	theme	performance	976:986	arg1	chromatography					1008:1021	ultra-high performance supercritical fluid chromatography	965:1021	ultra-high performance supercritical fluid chromatography combined with photo-diode array detector	965:1062	10 common monosaccharides are fully separated and detected on ultra-high performance supercritical fluid chromatography combined with photo-diode array detector by a systematic optimization of multiple relevant parameters, e.g., column stationary phases, organic modifiers, additives, flow rates and so on.
36794810	2	83	with	technology	557:566	arg1	modifier					591:598	an unusual binary modifier	573:598	an unusual binary modifier	573:598	In this study, an ultra-high performance supercritical fluid chromatography technology with an unusual binary modifier is used to determine monosaccharide compositions of natural polysaccharides.
36794810	0	84	from	fruits	178:183	arg1	analysis					126:133	full monosaccharide compositional analysis	92:133	full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits	92:183	An alternative strategy based ultra-high performance supercritical fluid chromatography for full monosaccharide compositional analysis of polysaccharides in Schisandra chinensis fruits.
36126575	1	0	theme	fractionation	160:172	arg1	protocol					174:181	a sequential fractionation protocol	147:181	a sequential fractionation protocol (cold and hot aqueous and alkaline extractions)	147:229	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	4	1	dep	present	876:882	arg1	β-glucan					841:848	a recalcitrant β-glucan	826:848	a recalcitrant β-glucan in G. frondosa	826:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	1	dep	present	876:882	arg1	present					876:882	present	876:882	present	876:882	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	1	dep	present	876:882	arg1	%					904:904	7.38%	900:904	7.38%	900:904	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	0	2	from	differences	14:24	arg1	mushrooms					72:80	three relevant mushrooms	57:80	three relevant mushrooms	57:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	2	3	theme	aqueous	606:612	arg1	extracts					614:621	Room temperature aqueous extracts	589:621	Room temperature aqueous extracts	589:621	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	0	4	theme	extraction	112:121	arg1	protocol					123:130	a sequential extraction protocol	99:130	a sequential extraction protocol	99:130	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	2	5	theme	temperature	594:604	arg1	extracts					614:621	Room temperature aqueous extracts	589:621	Room temperature aqueous extracts	589:621	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	5	6	theme	β-glucan	925:932	arg1	populations					934:944	β-glucan populations	925:944	β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue	925:1089	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	1	7	theme	gross	268:272	arg1	analysis					302:309	monosaccharide analysis	287:309	monosaccharide analysis	287:309	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	7	theme	gross	268:272	arg1	analysis					258:265	detailed compositional analysis	235:265	detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA)	235:321	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	7	theme	gross	268:272	arg1	FTIR					312:315	FTIR	312:315	FTIR	312:315	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	7	theme	gross	268:272	arg1	composition					274:284	gross composition	268:284	gross composition	268:284	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	0	8	theme	sequential	101:110	arg1	protocol					123:130	a sequential extraction protocol	99:130	a sequential extraction protocol	99:130	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	1	9	theme	relevant	344:351	arg1	mushrooms					353:361	three relevant mushrooms	338:361	three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus)	338:452	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	2	10	theme	Room	589:592	arg1	extracts					614:621	Room temperature aqueous extracts	589:621	Room temperature aqueous extracts	589:621	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	1	11	theme	β-glucan	537:544	arg1	extraction					546:555	β-glucan extraction	537:555	β-glucan extraction	537:555	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	4	12	from	β-glucan	841:848	arg1	frondosa					856:863	G. frondosa	853:863	G. frondosa	853:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	13	theme	recalcitrant	828:839	arg1	β-glucan					841:848	a recalcitrant β-glucan	826:848	a recalcitrant β-glucan in G. frondosa	826:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	13	theme	recalcitrant	828:839	arg1	present					876:882	present	876:882	present	876:882	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	13	theme	recalcitrant	828:839	arg1	%					904:904	7.38%	900:904	7.38%	900:904	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	6	14	theme	rational	1125:1132	arg1	design					1134:1139	the rational design	1121:1139	the rational design of extraction processes aiming to valorise mushroom biomass	1121:1199	This work sets the basis for the rational design of extraction processes aiming to valorise mushroom biomass.
36126575	1	15	dep	extracted	498:506	arg1	affected					560:567	affected	560:567	is affected by mushroom source	557:586	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	3	16	theme	β-glucan	712:719	arg1	content					721:727	β-glucan content	712:727	β-glucan content	712:727	β-glucan content was highest in P. ostreatus and was concentrated in the more soluble fractions.
36126575	2	17	theme	overall	638:644	arg1	%					661:661	56.3-82%	654:661	56.3-82%	654:661	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	2	17	theme	overall	638:644	arg1	yields					646:651	highest overall yields	630:651	highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols	630:709	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	2	18	theme	highest	630:636	arg1	%					661:661	56.3-82%	654:661	56.3-82%	654:661	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	2	18	theme	highest	630:636	arg1	yields					646:651	highest overall yields	630:651	highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols	630:709	Room temperature aqueous extracts showed highest overall yields (56.3-82%) consisting of proteins, sugars and polyphenols.
36126575	0	19	theme	Compositional	0:12	arg1	differences					14:24	Compositional differences	0:24	Compositional differences of β-glucan-rich extracts from three relevant mushrooms	0:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	6	20	theme	processes	1155:1163	arg1	design					1134:1139	the rational design	1121:1139	the rational design of extraction processes aiming to valorise mushroom biomass	1121:1199	This work sets the basis for the rational design of extraction processes aiming to valorise mushroom biomass.
36126575	5	21	theme	higher	1046:1051	arg1	purity					1060:1065	higher chitin purity	1046:1065	higher chitin purity (47.78%)	1046:1074	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	21	theme	higher	1046:1051	arg1	%					1073:1073	47.78%	1068:1073	47.78%	1068:1073	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	21	theme	higher	1046:1051	arg1	extracts					985:992	aqueous and alkaline extracts	964:992	extracts	985:992	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	1	22	dep	protocol	174:181	arg1	cold					184:187	cold	184:187	cold	184:187	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	22	dep	protocol	174:181	arg1	aqueous					197:203	aqueous	197:203	aqueous	197:203	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	4	23	attach	present	876:882	arg2	present					876:882	present	876:882	present	876:882	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	23	attach	present	876:882	arg1	residue					891:897	the residue	887:897	the residue	887:897	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	23	attach	present	876:882	arg1	contrary					816:823	the contrary	812:823	the contrary	812:823	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	23	attach	present	876:882	arg2	%					904:904	7.38%	900:904	7.38%	900:904	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	23	attach	present	876:882	arg2	β-glucan					841:848	a recalcitrant β-glucan	826:848	a recalcitrant β-glucan in G. frondosa	826:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	24	theme	G.	853:854	arg1	frondosa					856:863	G. frondosa	853:863	G. frondosa	853:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	0	25	theme	β-glucan-rich	29:41	arg1	extracts					43:50	β-glucan-rich extracts	29:50	β-glucan-rich extracts from three relevant mushrooms	29:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	1	26	theme	monosaccharide	287:300	arg1	analysis					302:309	monosaccharide analysis	287:309	monosaccharide analysis	287:309	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	26	theme	monosaccharide	287:300	arg1	composition					274:284	gross composition	268:284	gross composition	268:284	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	6	27	theme	valorise	1175:1182	arg1	biomass					1193:1199	valorise mushroom biomass	1175:1199	valorise mushroom biomass	1175:1199	This work sets the basis for the rational design of extraction processes aiming to valorise mushroom biomass.
36126575	5	28	theme	non-glucan	1015:1024	arg1	polysaccharides					1026:1040	non-glucan polysaccharides	1015:1040	non-glucan polysaccharides	1015:1040	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	1	29	theme	mushroom	572:579	arg1	source					581:586	mushroom source	572:586	mushroom source	572:586	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	30	from	mushrooms	353:361	arg1	terms					366:370	terms	366:370	terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus)	366:452	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	5	31	theme	L.	908:909	arg1	edodes					911:916	L. edodes	908:916	L. edodes	908:916	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	32	theme	chitin	1053:1058	arg1	purity					1060:1065	higher chitin purity	1046:1065	higher chitin purity (47.78%)	1046:1074	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	32	theme	chitin	1053:1058	arg1	%					1073:1073	47.78%	1068:1073	47.78%	1068:1073	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	32	theme	chitin	1053:1058	arg1	extracts					985:992	aqueous and alkaline extracts	964:992	extracts	985:992	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	4	33	located	present	876:882	arg2	present					876:882	present	876:882	present	876:882	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	33	located	present	876:882	arg1	residue					891:897	the residue	887:897	the residue	887:897	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	33	located	present	876:882	arg1	contrary					816:823	the contrary	812:823	the contrary	812:823	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	33	located	present	876:882	arg2	%					904:904	7.38%	900:904	7.38%	900:904	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	33	located	present	876:882	arg2	β-glucan					841:848	a recalcitrant β-glucan	826:848	a recalcitrant β-glucan in G. frondosa	826:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	1	34	theme	global	375:380	arg1	production					382:391	global production	375:391	global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus)	375:452	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	35	theme	alkaline	209:216	arg1	extractions					218:228	alkaline extractions	209:228	alkaline extractions	209:228	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	0	36	theme	extracts	43:50	arg1	differences					14:24	Compositional differences	0:24	Compositional differences of β-glucan-rich extracts from three relevant mushrooms	0:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	1	37	theme	production	382:391	arg1	terms					366:370	terms	366:370	terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus)	366:452	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	5	38	theme	higher	995:1000	arg1	extracts					985:992	aqueous and alkaline extracts	964:992	extracts	985:992	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	38	theme	higher	995:1000	arg1	abundance					1002:1010	higher abundance	995:1010	higher abundance of non-glucan polysaccharides	995:1040	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	0	39	theme	relevant	63:70	arg1	mushrooms					72:80	three relevant mushrooms	57:80	three relevant mushrooms	57:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	0	40	from	mushrooms	72:80	arg1	differences					14:24	Compositional differences	0:24	Compositional differences of β-glucan-rich extracts from three relevant mushrooms	0:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	0	40	from	mushrooms	72:80	arg1	extracts					43:50	β-glucan-rich extracts	29:50	β-glucan-rich extracts from three relevant mushrooms	29:80	Compositional differences of β-glucan-rich extracts from three relevant mushrooms obtained through a sequential extraction protocol.
36126575	6	41	theme	mushroom	1184:1191	arg1	biomass					1193:1199	valorise mushroom biomass	1175:1199	valorise mushroom biomass	1175:1199	This work sets the basis for the rational design of extraction processes aiming to valorise mushroom biomass.
36126575	4	42	from	residue	891:897	arg1	β-glucan					841:848	a recalcitrant β-glucan	826:848	a recalcitrant β-glucan in G. frondosa	826:863	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	42	from	residue	891:897	arg1	present					876:882	present	876:882	present	876:882	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	4	42	from	residue	891:897	arg1	%					904:904	7.38%	900:904	7.38%	900:904	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	5	43	theme	polysaccharides	1026:1040	arg1	purity					1060:1065	higher chitin purity	1046:1065	higher chitin purity (47.78%)	1046:1074	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	43	theme	polysaccharides	1026:1040	arg1	%					1073:1073	47.78%	1068:1073	47.78%	1068:1073	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	43	theme	polysaccharides	1026:1040	arg1	extracts					985:992	aqueous and alkaline extracts	964:992	extracts	985:992	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	43	theme	polysaccharides	1026:1040	arg1	abundance					1002:1010	higher abundance	995:1010	higher abundance of non-glucan polysaccharides	995:1040	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	1	44	dep	Pleurotus	433:441	arg1	ostreatus					443:451	ostreatus	443:451	ostreatus	443:451	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	6	45	theme	extraction	1144:1153	arg1	processes					1155:1163	extraction processes	1144:1163	extraction processes aiming to valorise mushroom biomass	1144:1199	This work sets the basis for the rational design of extraction processes aiming to valorise mushroom biomass.
36126575	1	46	dep	composition	274:284	arg1	TGA					318:320	TGA	318:320	TGA	318:320	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	5	47	theme	aqueous	964:970	arg1	purity					1060:1065	higher chitin purity	1046:1065	higher chitin purity (47.78%)	1046:1074	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	47	theme	aqueous	964:970	arg1	extracts					985:992	aqueous and alkaline extracts	964:992	extracts	985:992	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	47	theme	aqueous	964:970	arg1	abundance					1002:1010	higher abundance	995:1010	higher abundance of non-glucan polysaccharides	995:1040	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	1	48	dep	production	382:391	arg1	Pleurotus					433:441	Pleurotus	433:441	Pleurotus	433:441	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	48	dep	production	382:391	arg1	frondosa					402:409	Grifola frondosa	394:409	Grifola frondosa	394:409	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	48	dep	production	382:391	arg1	edodes					422:427	Lentinula edodes	412:427	Lentinula edodes	412:427	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	4	49	from	present	876:882	arg1	residue					891:897	the residue	887:897	the residue	887:897	On the contrary, a recalcitrant β-glucan in G. frondosa was mainly present in the residue (7.38%).
36126575	5	50	theme	alkaline	976:983	arg1	purity					1060:1065	higher chitin purity	1046:1065	higher chitin purity (47.78%)	1046:1074	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	50	theme	alkaline	976:983	arg1	extracts					985:992	aqueous and alkaline extracts	964:992	extracts	985:992	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	5	50	theme	alkaline	976:983	arg1	abundance					1002:1010	higher abundance	995:1010	higher abundance of non-glucan polysaccharides	995:1040	L. edodes showed β-glucan populations distributed along aqueous and alkaline extracts, higher abundance of non-glucan polysaccharides and higher chitin purity (47.78%) in the residue.
36126575	1	51	theme	detailed	235:242	arg1	analysis					258:265	detailed compositional analysis	235:265	detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA)	235:321	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	51	theme	detailed	235:242	arg1	composition					274:284	gross composition	268:284	gross composition	268:284	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	3	52	theme	soluble	790:796	arg1	fractions					798:806	the more soluble fractions	781:806	the more soluble fractions	781:806	β-glucan content was highest in P. ostreatus and was concentrated in the more soluble fractions.
36126575	1	53	theme	sequential	149:158	arg1	protocol					174:181	a sequential fractionation protocol	147:181	a sequential fractionation protocol (cold and hot aqueous and alkaline extractions)	147:229	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	54	theme	compositional	244:256	arg1	analysis					258:265	detailed compositional analysis	235:265	detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA)	235:321	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
36126575	1	54	theme	compositional	244:256	arg1	composition					274:284	gross composition	268:284	gross composition	268:284	In this work, a sequential fractionation protocol (cold and hot aqueous and alkaline extractions) and detailed compositional analysis (gross composition, monosaccharide analysis, FTIR, TGA) was applied to three relevant mushrooms in terms of global production (Grifola frondosa, Lentinula edodes and Pleurotus ostreatus) aiming to understand what is preferentially extracted during fractionation and how β-glucan extraction is affected by mushroom source.
37266972	12	0	theme	IgG	1499:1501	arg1	glycovariants					1503:1515	IgG glycovariants	1499:1515	IgG glycovariants	1499:1515	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	4	1	theme	ectopic	590:596	arg1	expression					598:607	ectopic expression	590:607	ectopic expression of genes involved in the N-glycosylation pathway	590:656	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	6	2	theme	glycoprotein	823:834	arg1	B					836:836	glycoprotein B	823:836	glycoprotein B	823:836	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	11	3	dep	in	1387:1388	arg1	vitro					1390:1394	vitro	1390:1394	vitro	1390:1394	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	13	4	theme	BY-2	1697:1700	arg1	cells					1702:1706	BY-2 cells	1697:1706	BY-2 cells	1697:1706	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	11	5	theme	expected	1464:1471	arg1	glycoforms					1473:1482	the expected glycoforms	1460:1482	the expected glycoforms	1460:1482	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	2	6	theme	residues	300:307	arg1	presence					278:285	the presence	274:285	the presence of non-human residues	274:307	However, N-glycosylation, which increases heterogeneity and raises safety concerns due to the presence of non-human residues, is usually not controlled.
37266972	10	7	theme	extensive	1229:1237	arg1	deglycosylation					1239:1253	extensive deglycosylation	1229:1253	extensive deglycosylation	1229:1253	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	6	8	theme	high	897:900	arg1	N-glycans					910:918	only high mannose N-glycans	892:918	only high mannose N-glycans	892:918	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	9	9	from	site	1193:1196	arg1	%					1150:1150	More than 90%	1138:1150	More than 90% of the N-glycans at the conserved Asn297 site	1138:1196	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	9	9	from	site	1193:1196	arg1	N-glycans					1159:1167	the N-glycans	1155:1167	the N-glycans	1155:1167	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	13	10	theme	deglycosylated	1655:1668	arg1	proteins					1685:1692	deglycosylated pharmaceutical proteins	1655:1692	deglycosylated pharmaceutical proteins	1655:1692	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	12	11	from	impact	1577:1582	arg1	stability					1630:1638	the thermal stability	1618:1638	the thermal stability	1618:1638	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	8	12	theme	N-glycosylation	1043:1057	arg1	profile					1059:1065	The N-glycosylation profile	1039:1065	The N-glycosylation profile of the secreted antibody	1039:1090	The N-glycosylation profile of the secreted antibody was determined by mass spectrometry analysis.
37266972	13	13	from	Production	1641:1650	arg1	cells					1702:1706	BY-2 cells	1697:1706	BY-2 cells	1697:1706	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	5	14	theme	lines	706:710	arg1	generation					682:691	the generation	678:691	the generation of BY-2 cell lines producing deglycosylated proteins	678:744	Here, we report on the generation of BY-2 cell lines producing deglycosylated proteins.
37266972	13	15	theme	proteins	1685:1692	arg1	Production					1641:1650	Production	1641:1650	Production of deglycosylated pharmaceutical proteins in BY-2 cells	1641:1706	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	5	16	theme	deglycosylated	722:735	arg1	proteins					737:744	deglycosylated proteins	722:744	deglycosylated proteins	722:744	Here, we report on the generation of BY-2 cell lines producing deglycosylated proteins.
37266972	10	17	gly	glycoprotein	1258:1269	arg1	glycoprotein					1258:1269	glycoprotein B	1258:1271	glycoprotein B	1258:1271	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	6	18	gly	glycoprotein	823:834	arg1	glycoprotein					823:834	glycoprotein B	823:836	glycoprotein B	823:836	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	11	19	theme	mobility	1406:1413	arg1	assay					1421:1425	in vitro enzymatic mobility shift assay	1387:1425	in vitro enzymatic mobility shift assay	1387:1425	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	10	20	gly	deglycosylation	1239:1253	arg1	B					1271:1271	glycoprotein B	1258:1271	glycoprotein B	1258:1271	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	10	21	gly	18 N-glycosylation	1290:1307	arg2	sites					1309:1313	18 N-glycosylation sites	1290:1313	18 N-glycosylation sites	1290:1313	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	5	22	gly	deglycosylated	722:735	arg1	proteins					737:744	deglycosylated proteins	722:744	deglycosylated proteins	722:744	Here, we report on the generation of BY-2 cell lines producing deglycosylated proteins.
37266972	5	23	theme	BY-2	696:699	arg1	lines					706:710	BY-2 cell lines	696:710	BY-2 cell lines producing deglycosylated proteins	696:744	Here, we report on the generation of BY-2 cell lines producing deglycosylated proteins.
37266972	7	24	theme	N-acetylglucosamine	1009:1027	arg1	residues					1029:1036	single, asparagine-linked, N-acetylglucosamine residues	982:1036	single, asparagine-linked, N-acetylglucosamine residues	982:1036	Endoglycosidase T cleaves high mannose N-glycans to generate single, asparagine-linked, N-acetylglucosamine residues.
37266972	12	25	theme	thermal	1622:1628	arg1	stability					1630:1638	the thermal stability	1618:1638	the thermal stability	1618:1638	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	10	26	theme	B	1271:1271	arg1	deglycosylation					1239:1253	extensive deglycosylation	1229:1253	extensive deglycosylation	1229:1253	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	0	27	theme	BY-2	64:67	arg1	cells					69:73	tobacco BY-2 cells	56:73	tobacco BY-2 cells	56:73	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	2	28	theme	due	267:269	arg1	safety					251:256	safety concerns	251:265	safety concerns due to the presence of non-human residues	251:307	However, N-glycosylation, which increases heterogeneity and raises safety concerns due to the presence of non-human residues, is usually not controlled.
37266972	1	29	theme	multiple	155:162	arg1	systems					175:181	multiple expression systems	155:181	multiple expression systems	155:181	Production of recombinant pharmaceutical glycoproteins has been carried out in multiple expression systems.
37266972	0	30	from	deglycosylation	8:22	arg1	cells					69:73	tobacco BY-2 cells	56:73	tobacco BY-2 cells	56:73	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	11	31	theme	N-glycan	1330:1337	arg1	composition					1339:1349	N-glycan composition	1330:1349	N-glycan composition of gB glycovariants	1330:1369	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	7	32	theme	single	982:987	arg1	residues					1029:1036	single, asparagine-linked, N-acetylglucosamine residues	982:1036	single, asparagine-linked, N-acetylglucosamine residues	982:1036	Endoglycosidase T cleaves high mannose N-glycans to generate single, asparagine-linked, N-acetylglucosamine residues.
37266972	12	33	theme	N-glycosylation	1591:1605	arg1	pattern					1607:1613	the N-glycosylation pattern	1587:1613	the N-glycosylation pattern	1587:1613	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	3	34	theme	N-glycans	369:377	arg1	presence					341:348	presence	341:348	presence	341:348	The presence and composition of N-glycans are also susceptible to affect protein stability, function and immunogenicity.
37266972	3	34	theme	N-glycans	369:377	arg1	composition					354:364	composition	354:364	composition	354:364	The presence and composition of N-glycans are also susceptible to affect protein stability, function and immunogenicity.
37266972	4	35	theme	Bright	534:539	arg1	lines					562:566	Bright Yellow-2 (BY-2) cell lines	534:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	10	36	theme	18 N-glycosylation	1290:1307	arg1	sites					1309:1313	18 N-glycosylation sites	1290:1313	18 N-glycosylation sites	1290:1313	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	8	37	theme	secreted	1074:1081	arg1	antibody					1083:1090	the secreted antibody	1070:1090	the secreted antibody	1070:1090	The N-glycosylation profile of the secreted antibody was determined by mass spectrometry analysis.
37266972	11	38	theme	glycovariants	1357:1369	arg1	composition					1339:1349	N-glycan composition	1330:1349	N-glycan composition of gB glycovariants	1330:1369	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	7	39	theme	mannose	952:958	arg1	N-glycans					960:968	high mannose N-glycans	947:968	high mannose N-glycans	947:968	Endoglycosidase T cleaves high mannose N-glycans to generate single, asparagine-linked, N-acetylglucosamine residues.
37266972	0	40	theme	In	0:1	arg1	deglycosylation					8:22	In vivo deglycosylation	0:22	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells	0:73	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	1	41	theme	recombinant	90:100	arg1	glycoproteins					117:129	recombinant pharmaceutical glycoproteins	90:129	recombinant pharmaceutical glycoproteins	90:129	Production of recombinant pharmaceutical glycoproteins has been carried out in multiple expression systems.
37266972	12	42	theme	significant	1565:1575	arg1	impact					1577:1582	a significant impact	1563:1582	a significant impact of the N-glycosylation pattern on the thermal stability	1563:1638	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	13	43	theme	BY-2	1743:1746	arg1	lines					1753:1757	glycoengineered BY-2 cell lines	1727:1757	glycoengineered BY-2 cell lines	1727:1757	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	8	44	theme	spectrometry	1115:1126	arg1	analysis					1128:1135	mass spectrometry analysis	1110:1135	mass spectrometry analysis	1110:1135	The N-glycosylation profile of the secreted antibody was determined by mass spectrometry analysis.
37266972	1	45	theme	glycoproteins	117:129	arg1	Production					76:85	Production	76:85	Production of recombinant pharmaceutical glycoproteins	76:129	Production of recombinant pharmaceutical glycoproteins has been carried out in multiple expression systems.
37266972	3	46	dep	presence	341:348	arg1	The					337:339	The	337:339	The	337:339	The presence and composition of N-glycans are also susceptible to affect protein stability, function and immunogenicity.
37266972	11	47	with	consistent	1444:1453	arg1	glycoforms					1473:1482	the expected glycoforms	1460:1482	the expected glycoforms	1460:1482	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	0	48	theme	recombinant	27:37	arg1	glycoproteins					39:51	recombinant glycoproteins	27:51	recombinant glycoproteins	27:51	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	6	49	theme	BY-2	866:869	arg1	lines					876:880	BY-2 cell lines	866:880	BY-2 cell lines producing only high mannose N-glycans	866:918	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	3	50	theme	protein	410:416	arg1	stability					418:426	protein stability	410:426	protein stability	410:426	The presence and composition of N-glycans are also susceptible to affect protein stability, function and immunogenicity.
37266972	6	51	theme	endoglycosidase	760:774	arg1	T					776:776	endoglycosidase T	760:776	endoglycosidase T	760:776	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	4	52	dep	tabacum	526:532	arg1	lines					562:566	Bright Yellow-2 (BY-2) cell lines	534:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	6	53	theme	cytomegalovirus	847:861	arg1	G					818:818	immunoglobulin G	803:818	immunoglobulin G	803:818	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	6	53	theme	cytomegalovirus	847:861	arg1	B					836:836	glycoprotein B	823:836	glycoprotein B	823:836	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	0	54	gly	glycoproteins	39:51	arg1	glycoproteins					39:51	recombinant glycoproteins	27:51	recombinant glycoproteins	27:51	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	4	55	theme	genes	612:616	arg1	expression					598:607	ectopic expression	590:607	ectopic expression of genes involved in the N-glycosylation pathway	590:656	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	4	55	theme	genes	612:616	arg1	knock					576:580	knock	576:580	knock out	576:584	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	9	56	theme	Asn297	1186:1191	arg1	site					1193:1196	the conserved Asn297 site	1172:1196	the conserved Asn297 site	1172:1196	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	12	57	theme	glycovariants	1503:1515	arg1	Comparison					1485:1494	Comparison	1485:1494	Comparison of IgG glycovariants by differential scanning fluorimetry	1485:1552	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	0	58	dep	In	0:1	arg1	vivo					3:6	vivo	3:6	vivo	3:6	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	10	59	theme	glycoprotein	1258:1269	arg1	B					1271:1271	glycoprotein B	1258:1271	glycoprotein B	1258:1271	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	4	60	theme	Nicotiana	516:524	arg1	tabacum					526:532	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	12	61	theme	differential	1520:1531	arg1	fluorimetry					1542:1552	differential scanning fluorimetry	1520:1552	differential scanning fluorimetry	1520:1552	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	6	62	theme	mannose	902:908	arg1	N-glycans					910:918	only high mannose N-glycans	892:918	only high mannose N-glycans	892:918	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	9	63	theme	N-glycans	1159:1167	arg1	%					1150:1150	More than 90%	1138:1150	More than 90% of the N-glycans at the conserved Asn297 site	1138:1196	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	9	63	theme	N-glycans	1159:1167	arg1	N-glycans					1159:1167	the N-glycans	1155:1167	the N-glycans	1155:1167	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	6	64	theme	immunoglobulin	803:816	arg1	G					818:818	immunoglobulin G	803:818	immunoglobulin G	803:818	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	2	65	theme	non-human	290:298	arg1	residues					300:307	non-human residues	290:307	non-human residues	290:307	However, N-glycosylation, which increases heterogeneity and raises safety concerns due to the presence of non-human residues, is usually not controlled.
37266972	11	66	theme	in	1387:1388	arg1	assay					1421:1425	in vitro enzymatic mobility shift assay	1387:1425	in vitro enzymatic mobility shift assay	1387:1425	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	9	67	gly	deglycosylated	1203:1216	arg1	%					1150:1150	More than 90%	1138:1150	More than 90% of the N-glycans at the conserved Asn297 site	1138:1196	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	9	67	gly	deglycosylated	1203:1216	arg1	N-glycans					1159:1167	the N-glycans	1155:1167	the N-glycans	1155:1167	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	6	68	dep	G	818:818	arg1	an					800:801	an	800:801	an	800:801	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	5	69	theme	cell	701:704	arg1	lines					706:710	BY-2 cell lines	696:710	BY-2 cell lines producing deglycosylated proteins	696:744	Here, we report on the generation of BY-2 cell lines producing deglycosylated proteins.
37266972	13	70	theme	pharmaceutical	1670:1683	arg1	proteins					1685:1692	deglycosylated pharmaceutical proteins	1655:1692	deglycosylated pharmaceutical proteins	1655:1692	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	4	71	theme	N-glycosylation	634:648	arg1	pathway					650:656	the N-glycosylation pathway	630:656	the N-glycosylation pathway	630:656	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	11	72	theme	shift	1415:1419	arg1	assay					1421:1425	in vitro enzymatic mobility shift assay	1387:1425	in vitro enzymatic mobility shift assay	1387:1425	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	13	73	gly	deglycosylated	1655:1668	arg1	proteins					1685:1692	deglycosylated pharmaceutical proteins	1655:1692	deglycosylated pharmaceutical proteins	1655:1692	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	2	74	dep	safety	251:256	arg1	concerns					258:265	concerns	258:265	concerns	258:265	However, N-glycosylation, which increases heterogeneity and raises safety concerns due to the presence of non-human residues, is usually not controlled.
37266972	11	75	theme	enzymatic	1396:1404	arg1	assay					1421:1425	in vitro enzymatic mobility shift assay	1387:1425	in vitro enzymatic mobility shift assay	1387:1425	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	10	76	contain	possesses	1280:1288	arg1	deglycosylation					1239:1253	extensive deglycosylation	1229:1253	extensive deglycosylation	1229:1253	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	10	76	contain	possesses	1280:1288	arg2	sites					1309:1313	18 N-glycosylation sites	1290:1313	18 N-glycosylation sites	1290:1313	Likewise, extensive deglycosylation of glycoprotein B, which possesses 18 N-glycosylation sites, was observed.
37266972	13	77	theme	lines	1753:1757	arg1	lines					1753:1757	glycoengineered BY-2 cell lines	1727:1757	glycoengineered BY-2 cell lines	1727:1757	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	13	77	theme	lines	1753:1757	arg1	set					1720:1722	the set	1716:1722	the set of glycoengineered BY-2 cell lines	1716:1757	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	6	78	theme	human	841:845	arg1	cytomegalovirus					847:861	human cytomegalovirus	841:861	human cytomegalovirus	841:861	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	7	79	dep	single	982:987	arg1	asparagine-linked					990:1006	asparagine-linked	990:1006	asparagine-linked	990:1006	Endoglycosidase T cleaves high mannose N-glycans to generate single, asparagine-linked, N-acetylglucosamine residues.
37266972	1	80	theme	expression	164:173	arg1	systems					175:181	multiple expression systems	155:181	multiple expression systems	155:181	Production of recombinant pharmaceutical glycoproteins has been carried out in multiple expression systems.
37266972	12	81	theme	pattern	1607:1613	arg1	impact					1577:1582	a significant impact	1563:1582	a significant impact of the N-glycosylation pattern on the thermal stability	1563:1638	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	4	82	theme	Yellow-2	541:548	arg1	lines					562:566	Bright Yellow-2 (BY-2) cell lines	534:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	8	83	theme	antibody	1083:1090	arg1	profile					1059:1065	The N-glycosylation profile	1039:1065	The N-glycosylation profile of the secreted antibody	1039:1090	The N-glycosylation profile of the secreted antibody was determined by mass spectrometry analysis.
37266972	1	84	gly	glycoproteins	117:129	arg1	glycoproteins					117:129	recombinant pharmaceutical glycoproteins	90:129	recombinant pharmaceutical glycoproteins	90:129	Production of recombinant pharmaceutical glycoproteins has been carried out in multiple expression systems.
37266972	4	85	theme	glycoengineered	500:514	arg1	tabacum					526:532	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	8	86	theme	mass	1110:1113	arg1	analysis					1128:1135	mass spectrometry analysis	1110:1135	mass spectrometry analysis	1110:1135	The N-glycosylation profile of the secreted antibody was determined by mass spectrometry analysis.
37266972	11	87	theme	gB	1354:1355	arg1	glycovariants					1357:1369	gB glycovariants	1354:1369	gB glycovariants	1354:1369	N-glycan composition of gB glycovariants was assessed by in vitro enzymatic mobility shift assay and proven to be consistent with the expected glycoforms.
37266972	7	88	theme	high	947:950	arg1	N-glycans					960:968	high mannose N-glycans	947:968	high mannose N-glycans	947:968	Endoglycosidase T cleaves high mannose N-glycans to generate single, asparagine-linked, N-acetylglucosamine residues.
37266972	1	89	theme	pharmaceutical	102:115	arg1	glycoproteins					117:129	recombinant pharmaceutical glycoproteins	90:129	recombinant pharmaceutical glycoproteins	90:129	Production of recombinant pharmaceutical glycoproteins has been carried out in multiple expression systems.
37266972	13	90	theme	cell	1748:1751	arg1	lines					1753:1757	glycoengineered BY-2 cell lines	1727:1757	glycoengineered BY-2 cell lines	1727:1757	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	0	91	theme	glycoproteins	39:51	arg1	deglycosylation					8:22	In vivo deglycosylation	0:22	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells	0:73	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	6	92	theme	cell	871:874	arg1	lines					876:880	BY-2 cell lines	866:880	BY-2 cell lines producing only high mannose N-glycans	866:918	To this end, endoglycosidase T was co-expressed with an immunoglobulin G or glycoprotein B of human cytomegalovirus in BY-2 cell lines producing only high mannose N-glycans.
37266972	4	93	theme	BY-2	551:554	arg1	lines					562:566	Bright Yellow-2 (BY-2) cell lines	534:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	0	94	theme	tobacco	56:62	arg1	cells					69:73	tobacco BY-2 cells	56:73	tobacco BY-2 cells	56:73	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	0	95	gly	deglycosylation	8:22	arg1	glycoproteins					39:51	recombinant glycoproteins	27:51	recombinant glycoproteins	27:51	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	0	95	gly	deglycosylation	8:22	arg1	cells					69:73	tobacco BY-2 cells	56:73	tobacco BY-2 cells	56:73	In vivo deglycosylation of recombinant glycoproteins in tobacco BY-2 cells.
37266972	4	96	theme	cell	557:560	arg1	lines					562:566	Bright Yellow-2 (BY-2) cell lines	534:566	glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines	500:566	To tackle these issues, we are developing glycoengineered Nicotiana tabacum Bright Yellow-2 (BY-2) cell lines through knock out and ectopic expression of genes involved in the N-glycosylation pathway.
37266972	7	97	theme	Endoglycosidase	921:935	arg1	T					937:937	Endoglycosidase T	921:937	Endoglycosidase T	921:937	Endoglycosidase T cleaves high mannose N-glycans to generate single, asparagine-linked, N-acetylglucosamine residues.
37266972	12	98	theme	scanning	1533:1540	arg1	fluorimetry					1542:1552	differential scanning fluorimetry	1520:1552	differential scanning fluorimetry	1520:1552	Comparison of IgG glycovariants by differential scanning fluorimetry revealed a significant impact of the N-glycosylation pattern on the thermal stability.
37266972	13	99	theme	glycoengineered	1727:1741	arg1	lines					1753:1757	glycoengineered BY-2 cell lines	1727:1757	glycoengineered BY-2 cell lines	1727:1757	Production of deglycosylated pharmaceutical proteins in BY-2 cells expands the set of glycoengineered BY-2 cell lines.
37266972	9	100	theme	conserved	1176:1184	arg1	site					1193:1196	the conserved Asn297 site	1172:1196	the conserved Asn297 site	1172:1196	More than 90% of the N-glycans at the conserved Asn297 site were deglycosylated.
37266972	8	101	gly	N-glycosylation	1043:1057	arg1	antibody					1083:1090	the secreted antibody	1070:1090	the secreted antibody	1070:1090	The N-glycosylation profile of the secreted antibody was determined by mass spectrometry analysis.
36482940	2	0	theme	obtained	625:632	arg1	datasets					638:645	the obtained raw datasets	621:645	the obtained raw datasets	621:645	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	1	theme	discovery	702:710	arg1	rate					712:715	the spectrum-level false discovery rate	677:715	the spectrum-level false discovery rate ≤1%	677:719	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	1	2	gly	N-glycosylation	190:204	arg1	cells					230:234	ovarian cancer SKOV3 cells	209:234	ovarian cancer SKOV3 cells	209:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	6	3	theme	biochemical	1594:1604	arg1	methods					1606:1612	biochemical methods	1594:1612	biochemical methods	1594:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	4	4	theme	p-value	1133:1139	arg1	≤					1141:1141	p-value ≤ 0.05	1133:1146	p-value ≤ 0.05	1133:1146	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	3	5	theme	glycopeptide	729:740	arg1	matches					751:757	13,822 glycopeptide spectral matches	722:757	13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information	722:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	6	6	theme	reaction	1570:1577	arg1	monitoring					1579:1588	multiple reaction monitoring	1561:1588	multiple reaction monitoring	1561:1588	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	1	7	theme	cancer	217:222	arg1	cells					230:234	ovarian cancer SKOV3 cells	209:234	ovarian cancer SKOV3 cells	209:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	1	8	theme	cells	230:234	arg1	N-glycosylation					190:204	differential cell-surface N-glycosylation	164:204	differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells	164:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	3	9	gly	3,733 N-glycosites	876:893	arg2	3,733 N-glycosites					876:893	3,733 N-glycosites	876:893	3,733 N-glycosites	876:893	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	10	theme	quantitative	598:609	arg1	search					611:616	qualitative and quantitative search	582:616	qualitative and quantitative search on the obtained raw datasets	582:645	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	11	gly	glycopeptide	729:740	arg2	glycopeptide					729:740	13,822 glycopeptide spectral matches	722:757	13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information	722:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	1	12	theme	structure-specific	105:122	arg1	study					155:159	Site- and structure-specific quantitative N-glycoproteomics study	95:159	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.	84:305	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	2	13	theme	qualitative	582:592	arg1	search					611:616	qualitative and quantitative search	582:616	qualitative and quantitative search on the obtained raw datasets	582:645	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	14	theme	N-glycoproteomics	137:153	arg1	study					155:159	Site- and structure-specific quantitative N-glycoproteomics study	95:159	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.	84:305	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	3	15	theme	3,754 N-glycan	899:912	arg1	structures					923:932	3,754 N-glycan sequence structures	899:932	3,754 N-glycan sequence structures	899:932	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	16	theme	structure-specific	498:515	arg1	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	17	theme	N-glycan	828:835	arg1	information					847:857	N-glycan structure information	828:857	N-glycan structure information	828:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	6	18	theme	biomarker	1506:1514	arg1	candidates					1516:1525	putative N-glycoprotein biomarker candidates	1482:1525	putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods	1482:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	3	19	theme	site-determining	952:967	arg1	ions					1003:1006	site-determining and structure-diagnostic fragment ions	952:1006	site-determining and structure-diagnostic fragment ions	952:1006	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	20	theme	site-	488:492	arg1	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	21	gly	N-glycosite	812:822	arg2	N-glycosite					812:822	comprehensive N-glycosite	798:822	comprehensive N-glycosite	798:822	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	5	22	theme	cancer	1331:1336	arg1	cells					1344:1348	ovarian cancer SKOV3 cells	1323:1348	ovarian cancer SKOV3 cells	1323:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	0	23	theme	cell	72:75	arg1	lines					77:81	SKOV3 versus IOSE80 cell lines	52:81	SKOV3 versus IOSE80 cell lines	52:81	Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines.
36482940	1	24	theme	cell-surface	177:188	arg1	N-glycosylation					190:204	differential cell-surface N-glycosylation	164:204	differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells	164:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	2	25	theme	engine	546:551	arg1	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	26	used	used	384:387	arg2	HCD					332:334	HCD	332:334	HCD with stepped normalized collision energies	332:377	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	26	used	used	384:387	arg2	C18-RPLC-MS/MS					316:329	C18-RPLC-MS/MS	316:329	C18-RPLC-MS/MS (HCD with stepped normalized collision energies)	316:378	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	5	27	theme	cells	1344:1348	arg1	N-glycosylation					1304:1318	Differential cell-surface N-glycosylation	1278:1318	Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells	1278:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	2	28	used	used	566:569	arg2	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	29	theme	N-glycopeptide	524:537	arg1	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	5	30	gly	N-glycosylation	1304:1318	arg1	cells					1344:1348	ovarian cancer SKOV3 cells	1323:1348	ovarian cancer SKOV3 cells	1323:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	5	31	theme	structure-specific	1414:1431	arg1	N-glycoproteomics					1433:1449	site- and structure-specific N-glycoproteomics	1404:1449	site- and structure-specific N-glycoproteomics	1404:1449	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	2	32	gly	N-glycopeptide	524:537	arg2	N-glycopeptide					524:537	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	33	theme	structure-diagnostic	973:992	arg1	ions					1003:1006	site-determining and structure-diagnostic fragment ions	952:1006	site-determining and structure-diagnostic fragment ions	952:1006	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	4	34	theme	fold	1111:1114	arg1	change					1116:1121	fold change ≥1.5	1111:1126	fold change ≥1.5	1111:1126	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	0	35	theme	Comparative	0:10	arg1	glycoproteomics					12:26	Comparative glycoproteomics	0:26	Comparative glycoproteomics	0:26	Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines.
36482940	2	36	from	search	611:616	arg1	datasets					638:645	the obtained raw datasets	621:645	the obtained raw datasets	621:645	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	6	37	theme	putative	1482:1489	arg1	candidates					1516:1525	putative N-glycoprotein biomarker candidates	1482:1525	putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods	1482:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	2	38	theme	intact	428:433	arg1	N-glycopeptides					435:449	labeled intact N-glycopeptides	420:449	labeled intact N-glycopeptides from SKOV3 and IOSE80 cells	420:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	39	theme	Site-	95:99	arg1	study					155:159	Site- and structure-specific quantitative N-glycoproteomics study	95:159	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.	84:305	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	5	40	theme	site-	1404:1408	arg1	N-glycoproteomics					1433:1449	site- and structure-specific N-glycoproteomics	1404:1449	site- and structure-specific N-glycoproteomics	1404:1449	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	6	41	theme	validation	1538:1547	arg1	study					1549:1553	future validation study	1531:1553	future validation study using multiple reaction monitoring and biochemical methods	1531:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	3	42	theme	false	696:700	arg1	rate					712:715	the spectrum-level false discovery rate	677:715	the spectrum-level false discovery rate ≤1%	677:719	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	43	theme	collision	360:368	arg1	energies					370:377	stepped normalized collision energies	341:377	stepped normalized collision energies	341:377	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	44	theme	non-cancerous	245:257	arg1	cells					285:289	the non-cancerous ovarian epithelial IOSE80 cells	241:289	the non-cancerous ovarian epithelial IOSE80 cells as the control	241:304	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	1	45	theme	epithelial	267:276	arg1	cells					285:289	the non-cancerous ovarian epithelial IOSE80 cells	241:289	the non-cancerous ovarian epithelial IOSE80 cells as the control	241:304	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	6	46	theme	future	1531:1536	arg1	study					1549:1553	future validation study	1531:1553	future validation study using multiple reaction monitoring and biochemical methods	1531:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	6	47	gly	N-glycoprotein	1491:1504	arg1	N-glycoprotein					1491:1504	putative N-glycoprotein biomarker candidates	1482:1525	putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods	1482:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	6	48	theme	N-glycoprotein	1491:1504	arg1	candidates					1516:1525	putative N-glycoprotein biomarker candidates	1482:1525	putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods	1482:1612	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	3	49	theme	rate	712:715	arg1	control					666:672	the control	662:672	the control of the spectrum-level false discovery rate ≤1%	662:719	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	4	50	theme	IOSE80	1186:1191	arg1	cells					1193:1197	IOSE80 cells	1186:1197	IOSE80 cells	1186:1197	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	3	51	theme	spectral	742:749	arg1	matches					751:757	13,822 glycopeptide spectral matches	722:757	13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information	722:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	1	52	theme	N-glycosylation	190:204	arg1	study					155:159	Site- and structure-specific quantitative N-glycoproteomics study	95:159	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.	84:305	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	3	53	theme	13,822	722:727	arg1	matches					751:757	13,822 glycopeptide spectral matches	722:757	13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information	722:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	54	theme	stepped	341:347	arg1	energies					370:377	stepped normalized collision energies	341:377	stepped normalized collision energies	341:377	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	55	theme	ovarian	209:215	arg1	cells					230:234	ovarian cancer SKOV3 cells	209:234	ovarian cancer SKOV3 cells	209:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	2	56	theme	raw	634:636	arg1	datasets					638:645	the obtained raw datasets	621:645	the obtained raw datasets	621:645	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	4	57	theme	SKOV3	1162:1166	arg1	cells					1168:1172	SKOV3 cells	1162:1172	SKOV3 cells relative to IOSE80 cells	1162:1197	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	1	58	theme	SKOV3	224:228	arg1	cells					230:234	ovarian cancer SKOV3 cells	209:234	ovarian cancer SKOV3 cells	209:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	4	59	theme	relative	1174:1181	arg1	cells					1168:1172	SKOV3 cells	1162:1172	SKOV3 cells relative to IOSE80 cells	1162:1197	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	4	60	from	DEPGs	1153:1157	arg1	cells					1168:1172	SKOV3 cells	1162:1172	SKOV3 cells relative to IOSE80 cells	1162:1197	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	3	61	theme	comprehensive	798:810	arg1	N-glycosite					812:822	comprehensive N-glycosite	798:822	comprehensive N-glycosite	798:822	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	1	62	theme	quantitative	124:135	arg1	study					155:159	Site- and structure-specific quantitative N-glycoproteomics study	95:159	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.	84:305	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	0	63	theme	IOSE80	65:70	arg1	lines					77:81	SKOV3 versus IOSE80 cell lines	52:81	SKOV3 versus IOSE80 cell lines	52:81	Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines.
36482940	3	64	theme	sequence	914:921	arg1	structures					923:932	3,754 N-glycan sequence structures	899:932	3,754 N-glycan sequence structures	899:932	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	5	65	theme	Differential	1278:1289	arg1	N-glycosylation					1304:1318	Differential cell-surface N-glycosylation	1278:1318	Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells	1278:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	5	66	theme	ovarian	1323:1329	arg1	cells					1344:1348	ovarian cancer SKOV3 cells	1323:1348	ovarian cancer SKOV3 cells	1323:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	3	67	theme	structure	837:845	arg1	information					847:857	N-glycan structure information	828:857	N-glycan structure information	828:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	0	68	theme	lines	77:81	arg1	surface					41:47	the surface	37:47	the surface of SKOV3 versus IOSE80 cell lines	37:81	Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines.
36482940	1	69	theme	differential	164:175	arg1	N-glycosylation					190:204	differential cell-surface N-glycosylation	164:204	differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells	164:234	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	2	70	from	cells	473:477	arg1	N-glycopeptides					435:449	labeled intact N-glycopeptides	420:449	labeled intact N-glycopeptides from SKOV3 and IOSE80 cells	420:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	70	from	cells	473:477	arg1	mixture					409:415	the 1: 1 mixture	400:415	the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells	400:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	71	with	HCD	332:334	arg1	energies					370:377	stepped normalized collision energies	341:377	stepped normalized collision energies	341:377	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	72	dep	Objective	84:92	arg1	study					155:159	Site- and structure-specific quantitative N-glycoproteomics study	95:159	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.	84:305	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	5	73	theme	SKOV3	1338:1342	arg1	cells					1344:1348	ovarian cancer SKOV3 cells	1323:1348	ovarian cancer SKOV3 cells	1323:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	1	74	with	study	155:159	arg1	cells					285:289	the non-cancerous ovarian epithelial IOSE80 cells	241:289	the non-cancerous ovarian epithelial IOSE80 cells as the control	241:304	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	2	75	theme	search	539:544	arg1	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	76	gly	2,918 N-glycoproteins	771:791	arg1	2,918 N-glycoproteins					771:791	2,918 N-glycoproteins	771:791	2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information	771:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	6	77	theme	discovery	1457:1465	arg1	study					1467:1471	This discovery study	1452:1471	This discovery study	1452:1471	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	2	78	theme	intact	517:522	arg1	GPSeeker					553:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	the site- and structure-specific intact N-glycopeptide search engine GPSeeker	484:560	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	79	theme	ovarian	259:265	arg1	cells					285:289	the non-cancerous ovarian epithelial IOSE80 cells	241:289	the non-cancerous ovarian epithelial IOSE80 cells as the control	241:304	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36482940	4	80	theme	less	1046:1049	arg1	control					1032:1038	the control	1028:1038	the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05	1028:1146	With the control of no less than two observations among the three technical replicates, fold change ≥1.5, and p-value ≤ 0.05, 746 DEPGs in SKOV3 cells relative to IOSE80 cells were quantified, where 421 were upregulated and 325 downregulated.
36482940	3	81	theme	fragment	994:1001	arg1	ions					1003:1006	site-determining and structure-diagnostic fragment ions	952:1006	site-determining and structure-diagnostic fragment ions	952:1006	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	82	theme	SKOV3	456:460	arg1	cells					473:477	SKOV3 and IOSE80 cells	456:477	cells	473:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	5	83	theme	isotopic	1382:1389	arg1	labeling					1391:1398	isotopic labeling	1382:1398	isotopic labeling	1382:1398	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	6	84	theme	multiple	1561:1568	arg1	monitoring					1579:1588	multiple reaction monitoring	1561:1588	multiple reaction monitoring	1561:1588	This discovery study provides putative N-glycoprotein biomarker candidates for future validation study using multiple reaction monitoring and biochemical methods.
36482940	3	85	dep	rate	712:715	arg1	%					719:719	≤1%	717:719	the spectrum-level false discovery rate ≤1%	677:719	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	3	86	with	2,918 N-glycoproteins	771:791	arg1	information					847:857	N-glycan structure information	828:857	N-glycan structure information	828:857	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	3	86	with	2,918 N-glycoproteins	771:791	arg1	N-glycosite					812:822	comprehensive N-glycosite	798:822	comprehensive N-glycosite	798:822	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	87	theme	N-glycopeptides	435:449	arg1	mixture					409:415	the 1: 1 mixture	400:415	the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells	400:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	88	theme	labeled	420:426	arg1	N-glycopeptides					435:449	labeled intact N-glycopeptides	420:449	labeled intact N-glycopeptides from SKOV3 and IOSE80 cells	420:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	0	89	theme	SKOV3	52:56	arg1	lines					77:81	SKOV3 versus IOSE80 cell lines	52:81	SKOV3 versus IOSE80 cell lines	52:81	Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines.
36482940	2	90	theme	IOSE80	466:471	arg1	cells					473:477	SKOV3 and IOSE80 cells	456:477	cells	473:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	3	91	theme	spectrum-level	681:694	arg1	rate					712:715	the spectrum-level false discovery rate	677:715	the spectrum-level false discovery rate ≤1%	677:719	Results: With the control of the spectrum-level false discovery rate ≤1%, 13,822 glycopeptide spectral matches coming from 2,918 N-glycoproteins with comprehensive N-glycosite and N-glycan structure information were identified; 3,733 N-glycosites and 3,754 N-glycan sequence structures were confirmed by site-determining and structure-diagnostic fragment ions, respectively.
36482940	2	92	theme	normalized	349:358	arg1	energies					370:377	stepped normalized collision energies	341:377	stepped normalized collision energies	341:377	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	5	93	theme	cell-surface	1291:1302	arg1	N-glycosylation					1304:1318	Differential cell-surface N-glycosylation	1278:1318	Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells	1278:1348	Conclusion: Differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells were quantitatively analyzed by isotopic labeling and site- and structure-specific N-glycoproteomics.
36482940	2	94	gly	N-glycopeptides	435:449	arg2	N-glycopeptides					435:449	labeled intact N-glycopeptides	420:449	labeled intact N-glycopeptides from SKOV3 and IOSE80 cells	420:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	94	gly	N-glycopeptides	435:449	arg1	cells					473:477	SKOV3 and IOSE80 cells	456:477	cells	473:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	2	95	from	mixture	409:415	arg1	cells					473:477	SKOV3 and IOSE80 cells	456:477	cells	473:477	Methods: C18-RPLC-MS/MS (HCD with stepped normalized collision energies) was used to analyze the 1: 1 mixture of labeled intact N-glycopeptides from SKOV3 and IOSE80 cells, and the site- and structure-specific intact N-glycopeptide search engine GPSeeker was used to conduct qualitative and quantitative search on the obtained raw datasets.
36482940	1	96	theme	IOSE80	278:283	arg1	cells					285:289	the non-cancerous ovarian epithelial IOSE80 cells	241:289	the non-cancerous ovarian epithelial IOSE80 cells as the control	241:304	Objective: Site- and structure-specific quantitative N-glycoproteomics study of differential cell-surface N-glycosylation of ovarian cancer SKOV3 cells with the non-cancerous ovarian epithelial IOSE80 cells as the control.
36198365	0	0	theme	film	77:80	arg1	adhesion					55:62	interfacial adhesion	43:62	interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites	43:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	4	1	from	resins	589:594	arg1	cellulose					599:607	cellulose film	599:612	cellulose film	599:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	5	2	theme	excellent	746:754	arg1	adhesion					768:775	excellent interfacial adhesion	746:775	excellent interfacial adhesion	746:775	The VDE-DDM resin exhibited excellent interfacial adhesion with cellulose than VDE-IPDA and DGEBA-DDM resins.
36198365	9	3	theme	VDE-DDM	1304:1310	arg1	resin					1312:1316	the VDE-DDM resin	1300:1316	the VDE-DDM resin	1300:1316	Furthermore, the phosphorus moiety of the VDE-DDM resin endows flame retardancy to the VDE-DDM/TJF composite during combustion.
36198365	4	4	theme	adhesion	561:568	arg1	feasibility					570:580	the interfacial adhesion feasibility	545:580	the interfacial adhesion feasibility of VDE resins on cellulose film	545:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	0	5	theme	cellulose	67:75	arg1	film					77:80	cellulose film	67:80	cellulose film	67:80	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	10	6	theme	VDE-DDM/TJF	1437:1447	arg1	composite					1449:1457	bio-based VDE-DDM/TJF composite	1427:1457	bio-based VDE-DDM/TJF composite	1427:1457	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	0	7	link	derived	20:26	arg1	resin					34:38	bio-based derived epoxy resin	10:38	bio-based derived epoxy resin	10:38	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	8	8	theme	commercial	1213:1222	arg1	resin					1230:1234	the commercial epoxy resin	1209:1234	the commercial epoxy resin composite, DGEBA-DDM/TJF	1209:1259	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	4	9	theme	interfacial	549:559	arg1	feasibility					570:580	the interfacial adhesion feasibility	545:580	the interfacial adhesion feasibility of VDE resins on cellulose film	545:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	0	10	theme	applicability	86:98	arg1	adhesion					55:62	interfacial adhesion	43:62	interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites	43:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	0	11	from	Effect	0:5	arg1	adhesion					55:62	interfacial adhesion	43:62	interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites	43:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	8	12	theme	VDE-DDM/TJF	1151:1161	arg1	higher					1197:1202	higher	1197:1202	higher	1197:1202	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	8	12	theme	VDE-DDM/TJF	1151:1161	arg1	strength					1184:1191	The bio-based VDE-DDM/TJF composite's flexural strength	1137:1191	The bio-based VDE-DDM/TJF composite's flexural strength	1137:1191	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	2	13	theme	curing	300:305	arg1	methane					344:350	4,4´-diaminodiphenyl methane	323:350	4,4´-diaminodiphenyl methane (DDM)	323:356	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	13	theme	curing	300:305	arg1	agents					307:312	curing agents	300:312	curing agents	300:312	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	13	theme	curing	300:305	arg1	diamine					373:379	isophorone diamine	362:379	isophorone diamine	362:379	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	4	14	theme	single-lap	638:647	arg1	examination					661:671	the single-lap shear joint examination	634:671	the single-lap shear joint examination	634:671	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	6	15	theme	2.9 ± 0.3 GPa	966:978	arg1	stability					909:917	thermal stability	901:917	thermal stability of 241.0 °C at Td5%	901:937	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	6	15	theme	2.9 ± 0.3 GPa	966:978	arg1	strength					873:880	a tensile strength	863:880	a tensile strength of 86.0 ± 6.5 MPa	863:898	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	6	15	theme	2.9 ± 0.3 GPa	966:978	arg1	modulus					955:961	an elastic modulus	944:961	an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin	944:1027	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	4	16	from	feasibility	570:580	arg1	cellulose					599:607	cellulose film	599:612	cellulose film	599:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	6	17	theme	thermal	901:907	arg1	stability					909:917	thermal stability	901:917	thermal stability of 241.0 °C at Td5%	901:937	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	0	18	theme	natural	108:114	arg1	composites					138:147	natural jute fiber-reinforced composites	108:147	natural jute fiber-reinforced composites	108:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	6	19	theme	86.0 ± 6.5 MPa	885:898	arg1	stability					909:917	thermal stability	901:917	thermal stability of 241.0 °C at Td5%	901:937	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	6	19	theme	86.0 ± 6.5 MPa	885:898	arg1	strength					873:880	a tensile strength	863:880	a tensile strength of 86.0 ± 6.5 MPa	863:898	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	6	19	theme	86.0 ± 6.5 MPa	885:898	arg1	modulus					955:961	an elastic modulus	944:961	an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin	944:1027	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	8	20	theme	bio-based	1141:1149	arg1	higher					1197:1202	higher	1197:1202	higher	1197:1202	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	8	20	theme	bio-based	1141:1149	arg1	strength					1184:1191	The bio-based VDE-DDM/TJF composite's flexural strength	1137:1191	The bio-based VDE-DDM/TJF composite's flexural strength	1137:1191	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	8	21	theme	composite	1236:1244	arg1	resin					1230:1234	the commercial epoxy resin	1209:1234	the commercial epoxy resin composite, DGEBA-DDM/TJF	1209:1259	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	10	22	theme	structural	1508:1517	arg1	applications					1519:1530	environment-friendly and high-performance structural applications	1466:1530	environment-friendly and high-performance structural applications	1466:1530	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	4	23	theme	joint	655:659	arg1	examination					661:671	the single-lap shear joint examination	634:671	the single-lap shear joint examination	634:671	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	1	24	theme	bio-based	171:179	arg1	resin					210:214	a bio-based vanillin-derived epoxy (VDE) resin	169:214	a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites	169:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	5	25	theme	VDE-DDM	722:728	arg1	resin					730:734	The VDE-DDM resin	718:734	The VDE-DDM resin	718:734	The VDE-DDM resin exhibited excellent interfacial adhesion with cellulose than VDE-IPDA and DGEBA-DDM resins.
36198365	9	26	theme	phosphorus	1279:1288	arg1	moiety					1290:1295	the phosphorus moiety	1275:1295	the phosphorus moiety of the VDE-DDM resin	1275:1316	Furthermore, the phosphorus moiety of the VDE-DDM resin endows flame retardancy to the VDE-DDM/TJF composite during combustion.
36198365	3	27	theme	VDE	406:408	arg1	resins					410:415	The prepared VDE resins	393:415	The prepared VDE resins with various curing parameters	393:446	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	7	28	theme	developed	1043:1051	arg1	resin					1061:1065	the developed VDE-DDM resin	1039:1065	the developed VDE-DDM resin	1039:1065	Besides, the developed VDE-DDM resin was used to fabricate treated-jute fiber (TJF)-reinforced composites.
36198365	3	29	theme	water	515:519	arg1	angle					529:533	water contact angle	515:533	water contact angle	515:533	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	4	30	theme	resins	589:594	arg1	feasibility					570:580	the interfacial adhesion feasibility	545:580	the interfacial adhesion feasibility of VDE resins on cellulose film	545:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	1	31	theme	vanillin-derived	181:196	arg1	resin					210:214	a bio-based vanillin-derived epoxy (VDE) resin	169:214	a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites	169:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	5	32	theme	VDE-IPDA	797:804	arg1	resins					820:825	VDE-IPDA and DGEBA-DDM resins	797:825	VDE-IPDA and DGEBA-DDM resins	797:825	The VDE-DDM resin exhibited excellent interfacial adhesion with cellulose than VDE-IPDA and DGEBA-DDM resins.
36198365	5	33	theme	interfacial	756:766	arg1	adhesion					768:775	excellent interfacial adhesion	746:775	excellent interfacial adhesion	746:775	The VDE-DDM resin exhibited excellent interfacial adhesion with cellulose than VDE-IPDA and DGEBA-DDM resins.
36198365	7	34	theme	VDE-DDM	1053:1059	arg1	resin					1061:1065	the developed VDE-DDM resin	1039:1065	the developed VDE-DDM resin	1039:1065	Besides, the developed VDE-DDM resin was used to fabricate treated-jute fiber (TJF)-reinforced composites.
36198365	10	35	theme	appealing	1403:1411	arg1	properties					1413:1422	the appealing properties	1399:1422	the appealing properties of bio-based VDE-DDM/TJF composite	1399:1457	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	3	36	dep	test	492:495	arg1	tensile					484:490	FTIR, NMR, tensile test	473:495	tensile	484:490	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	3	36	dep	test	492:495	arg1	NMR					479:481	FTIR, NMR, tensile test	473:495	NMR	479:481	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	10	37	theme	composite	1449:1457	arg1	properties					1413:1422	the appealing properties	1399:1422	the appealing properties of bio-based VDE-DDM/TJF composite	1399:1457	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	1	38	theme	epoxy	198:202	arg1	resin					210:214	a bio-based vanillin-derived epoxy (VDE) resin	169:214	a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites	169:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	7	39	used	used	1071:1074	arg2	resin					1061:1065	the developed VDE-DDM resin	1039:1065	the developed VDE-DDM resin	1039:1065	Besides, the developed VDE-DDM resin was used to fabricate treated-jute fiber (TJF)-reinforced composites.
36198365	9	40	theme	resin	1312:1316	arg1	moiety					1290:1295	the phosphorus moiety	1275:1295	the phosphorus moiety of the VDE-DDM resin	1275:1316	Furthermore, the phosphorus moiety of the VDE-DDM resin endows flame retardancy to the VDE-DDM/TJF composite during combustion.
36198365	1	41	link	vanillin-derived	181:196	arg1	resin					210:214	a bio-based vanillin-derived epoxy (VDE) resin	169:214	a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites	169:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	10	42	theme	high-performance	1491:1506	arg1	applications					1519:1530	environment-friendly and high-performance structural applications	1466:1530	environment-friendly and high-performance structural applications	1466:1530	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	3	43	theme	various	422:428	arg1	parameters					437:446	various curing parameters	422:446	various curing parameters	422:446	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	0	44	theme	derived	20:26	arg1	resin					34:38	bio-based derived epoxy resin	10:38	bio-based derived epoxy resin	10:38	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	6	45	theme	elastic	947:953	arg1	modulus					955:961	an elastic modulus	944:961	an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin	944:1027	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	0	46	theme	fiber-reinforced	121:136	arg1	composites					138:147	natural jute fiber-reinforced composites	108:147	natural jute fiber-reinforced composites	108:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	8	47	theme	flexural	1175:1182	arg1	higher					1197:1202	higher	1197:1202	higher	1197:1202	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	8	47	theme	flexural	1175:1182	arg1	strength					1184:1191	The bio-based VDE-DDM/TJF composite's flexural strength	1137:1191	The bio-based VDE-DDM/TJF composite's flexural strength	1137:1191	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	8	48	dep	composite	1236:1244	arg1	DGEBA-DDM/TJF					1247:1259	DGEBA-DDM/TJF	1247:1259	DGEBA-DDM/TJF	1247:1259	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	1	49	theme	VDE	205:207	arg1	resin					210:214	a bio-based vanillin-derived epoxy (VDE) resin	169:214	a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites	169:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	0	50	theme	bio-based	10:18	arg1	resin					34:38	bio-based derived epoxy resin	10:38	bio-based derived epoxy resin	10:38	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	4	51	theme	VDE	585:587	arg1	resins					589:594	VDE resins	585:594	VDE resins on cellulose film	585:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	0	52	theme	jute	116:119	arg1	composites					138:147	natural jute fiber-reinforced composites	108:147	natural jute fiber-reinforced composites	108:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	6	53	theme	tensile	865:871	arg1	strength					873:880	a tensile strength	863:880	a tensile strength of 86.0 ± 6.5 MPa	863:898	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	3	54	theme	FTIR	473:476	arg1	test					492:495	FTIR, NMR, tensile test	473:495	test	492:495	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	0	55	theme	resin	34:38	arg1	Effect					0:5	Effect	0:5	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.	0:148	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	4	56	theme	shear	649:653	arg1	examination					661:671	the single-lap shear joint examination	634:671	the single-lap shear joint examination	634:671	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	6	57	theme	epoxy	1017:1021	arg1	resin					1023:1027	the commercial epoxy resin	1002:1027	the commercial epoxy resin	1002:1027	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	0	58	theme	epoxy	28:32	arg1	resin					34:38	bio-based derived epoxy resin	10:38	bio-based derived epoxy resin	10:38	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	7	59	theme	-reinforced	1113:1123	arg1	composites					1125:1134	treated-jute fiber (TJF)-reinforced composites	1089:1134	treated-jute fiber (TJF)-reinforced composites	1089:1134	Besides, the developed VDE-DDM resin was used to fabricate treated-jute fiber (TJF)-reinforced composites.
36198365	5	60	theme	DGEBA-DDM	810:818	arg1	resins					820:825	VDE-IPDA and DGEBA-DDM resins	797:825	VDE-IPDA and DGEBA-DDM resins	797:825	The VDE-DDM resin exhibited excellent interfacial adhesion with cellulose than VDE-IPDA and DGEBA-DDM resins.
36198365	6	61	theme	commercial	1006:1015	arg1	resin					1023:1027	the commercial epoxy resin	1002:1027	the commercial epoxy resin	1002:1027	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	0	62	theme	interfacial	43:53	arg1	adhesion					55:62	interfacial adhesion	43:62	interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites	43:147	Effect of bio-based derived epoxy resin on interfacial adhesion of cellulose film and applicability towards natural jute fiber-reinforced composites.
36198365	6	63	theme	%	937:937	arg1	stability					909:917	thermal stability	901:917	thermal stability of 241.0 °C at Td5%	901:937	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	6	63	theme	%	937:937	arg1	strength					873:880	a tensile strength	863:880	a tensile strength of 86.0 ± 6.5 MPa	863:898	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	6	63	theme	%	937:937	arg1	modulus					955:961	an elastic modulus	944:961	an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin	944:1027	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	3	64	theme	curing	430:435	arg1	parameters					437:446	various curing parameters	422:446	various curing parameters	422:446	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	8	65	theme	epoxy	1224:1228	arg1	resin					1230:1234	the commercial epoxy resin	1209:1234	the commercial epoxy resin composite, DGEBA-DDM/TJF	1209:1259	The bio-based VDE-DDM/TJF composite's flexural strength was higher than the commercial epoxy resin composite, DGEBA-DDM/TJF.
36198365	4	66	theme	commercial	693:702	arg1	DGEBA					711:715	DGEBA	711:715	DGEBA	711:715	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	4	66	theme	commercial	693:702	arg1	epoxy					704:708	a commercial epoxy	691:708	a commercial epoxy	691:708	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	3	67	theme	prepared	397:404	arg1	resins					410:415	The prepared VDE resins	393:415	The prepared VDE resins with various curing parameters	393:446	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	9	68	theme	VDE-DDM/TJF	1349:1359	arg1	composite					1361:1369	the VDE-DDM/TJF composite	1345:1369	the VDE-DDM/TJF composite	1345:1369	Furthermore, the phosphorus moiety of the VDE-DDM resin endows flame retardancy to the VDE-DDM/TJF composite during combustion.
36198365	6	69	theme	VDE-DDM	838:844	arg1	thermoset					846:854	The cured VDE-DDM thermoset	828:854	The cured VDE-DDM thermoset	828:854	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	10	70	theme	bio-based	1427:1435	arg1	composite					1449:1457	bio-based VDE-DDM/TJF composite	1427:1457	bio-based VDE-DDM/TJF composite	1427:1457	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	10	71	theme	environment-friendly	1466:1485	arg1	applications					1519:1530	environment-friendly and high-performance structural applications	1466:1530	environment-friendly and high-performance structural applications	1466:1530	Overall, the appealing properties of bio-based VDE-DDM/TJF composite render environment-friendly and high-performance structural applications.
36198365	6	72	theme	cured	832:836	arg1	thermoset					846:854	The cured VDE-DDM thermoset	828:854	The cured VDE-DDM thermoset	828:854	The cured VDE-DDM thermoset showed a tensile strength of 86.0 ± 6.5 MPa, thermal stability of 241.0 °C at Td5%, and an elastic modulus of 2.9 ± 0.3 GPa, which is better than the commercial epoxy resin.
36198365	9	73	theme	flame	1325:1329	arg1	retardancy					1331:1340	flame retardancy	1325:1340	flame retardancy	1325:1340	Furthermore, the phosphorus moiety of the VDE-DDM resin endows flame retardancy to the VDE-DDM/TJF composite during combustion.
36198365	1	74	theme	bio-based	220:228	arg1	composites					255:264	bio-based natural fiber-reinforced composites	220:264	bio-based natural fiber-reinforced composites	220:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	3	75	with	resins	410:415	arg1	parameters					437:446	various curing parameters	422:446	various curing parameters	422:446	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	3	76	theme	contact	521:527	arg1	angle					529:533	water contact angle	515:533	water contact angle	515:533	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	2	77	theme	4,4´-diaminodiphenyl	323:342	arg1	DDM					353:355	DDM	353:355	DDM	353:355	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	77	theme	4,4´-diaminodiphenyl	323:342	arg1	methane					344:350	4,4´-diaminodiphenyl methane	323:350	4,4´-diaminodiphenyl methane (DDM)	323:356	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	77	theme	4,4´-diaminodiphenyl	323:342	arg1	agents					307:312	curing agents	300:312	curing agents	300:312	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	1	78	theme	natural	230:236	arg1	composites					255:264	bio-based natural fiber-reinforced composites	220:264	bio-based natural fiber-reinforced composites	220:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	4	79	from	cellulose	599:607	arg1	feasibility					570:580	the interfacial adhesion feasibility	545:580	the interfacial adhesion feasibility of VDE resins on cellulose film	545:612	Further, the interfacial adhesion feasibility of VDE resins on cellulose film was studied through the single-lap shear joint examination and compared with a commercial epoxy, DGEBA.
36198365	2	80	theme	VDE	267:269	arg1	monomer					271:277	VDE monomer	267:277	VDE monomer	267:277	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	3	81	theme	bending	498:504	arg1	test					506:509	bending test	498:509	bending test	498:509	The prepared VDE resins with various curing parameters were characterized using FTIR, NMR, tensile test, bending test and water contact angle.
36198365	1	82	theme	fiber-reinforced	238:253	arg1	composites					255:264	bio-based natural fiber-reinforced composites	220:264	bio-based natural fiber-reinforced composites	220:264	This paper reports a bio-based vanillin-derived epoxy (VDE) resin for bio-based natural fiber-reinforced composites.
36198365	2	83	used	used	387:390	arg2	diamine					373:379	isophorone diamine	362:379	isophorone diamine	362:379	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	83	used	used	387:390	arg2	agents					307:312	curing agents	300:312	curing agents	300:312	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	83	used	used	387:390	arg2	methane					344:350	4,4´-diaminodiphenyl methane	323:350	4,4´-diaminodiphenyl methane (DDM)	323:356	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	84	theme	isophorone	362:371	arg1	agents					307:312	curing agents	300:312	curing agents	300:312	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
36198365	2	84	theme	isophorone	362:371	arg1	diamine					373:379	isophorone diamine	362:379	isophorone diamine	362:379	VDE monomer was synthesized, and curing agents, namely, 4,4´-diaminodiphenyl methane (DDM) and isophorone diamine, were used.
35693943	8	0	theme	MnCl2	1161:1165	arg1	supplementation					1167:1181	MnCl2 supplementation	1161:1181	MnCl2 supplementation	1161:1181	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	6	1	theme	other	919:923	arg1	types					953:957	all the other Golgi-related glycosylation types	911:957	all the other Golgi-related glycosylation types	911:957	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	10	2	theme	MnCl2	1564:1568	arg1	impact					1545:1550	the differential impact	1528:1550	the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency	1528:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	10	3	theme	glycosylation	1607:1619	arg1	defects					1621:1627	the Golgi glycosylation defects	1597:1627	the Golgi glycosylation defects caused by TMEM165 deficiency	1597:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	2	4	theme	complex	297:303	arg1	diversity					305:313	a complex diversity	295:313	a complex diversity of glycan structures	295:334	In eukaryotes, many glycosylation pathways occur simultaneously onto proteins and lipids for generating a complex diversity of glycan structures.
35693943	5	5	theme	promising	756:764	arg1	therapy					734:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	5	5	theme	promising	756:764	arg1	treatment					775:783	a promising tailored treatment	754:783	a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients	754:840	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	1	6	theme	life	185:188	arg1	life					185:188	life	185:188	life	185:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	1	6	theme	life	185:188	arg1	domains					174:180	all domains	170:180	all domains of life	170:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	8	7	theme	TMEM165-deficient	1212:1228	arg1	cells					1230:1234	TMEM165-deficient cells	1212:1234	TMEM165-deficient cells	1212:1234	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	11	8	from	effects	1870:1876	arg1	types					1919:1923	the other Golgi-related glycosylation types	1881:1923	the other Golgi-related glycosylation types	1881:1923	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	10	9	theme	TMEM165	1639:1645	arg1	deficiency					1647:1656	TMEM165 deficiency	1639:1656	TMEM165 deficiency	1639:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	2	10	theme	structures	325:334	arg1	diversity					305:313	a complex diversity	295:313	a complex diversity of glycan structures	295:334	In eukaryotes, many glycosylation pathways occur simultaneously onto proteins and lipids for generating a complex diversity of glycan structures.
35693943	7	11	theme	Golgi	1092:1096	arg1	homeostasis					1115:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	Our previous results established a link between TMEM165 deficiency and altered Golgi manganese (Mn2+) homeostasis.
35693943	11	12	theme	Golgi-related	1891:1903	arg1	types					1919:1923	the other Golgi-related glycosylation types	1881:1923	the other Golgi-related glycosylation types	1881:1923	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	0	13	from	Defects	75:81	arg1	Deficiency					94:103	TMEM165 Deficiency	86:103	TMEM165 Deficiency	86:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	8	14	theme	N-glycosylation	1323:1337	arg1	defects					1339:1345	the observed N-glycosylation defects	1310:1345	the observed N-glycosylation defects	1310:1345	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	7	15	theme	TMEM165	1061:1067	arg1	deficiency					1069:1078	TMEM165 deficiency	1061:1078	TMEM165 deficiency	1061:1078	Our previous results established a link between TMEM165 deficiency and altered Golgi manganese (Mn2+) homeostasis.
35693943	6	16	theme	glycosylation	939:951	arg1	types					953:957	all the other Golgi-related glycosylation types	911:957	all the other Golgi-related glycosylation types	911:957	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	1	17	theme	cellular	150:157	arg1	Glycosylation					106:118	Glycosylation	106:118	Glycosylation	106:118	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	1	17	theme	cellular	150:157	arg1	process					159:165	a ubiquitous and universal cellular process	123:165	a ubiquitous and universal cellular process in all domains of life	123:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	11	18	theme	D-Gal	1795:1799	arg1	supplementation					1801:1815	D-Gal supplementation	1795:1815	D-Gal supplementation	1795:1815	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	4	19	used	used	640:643	arg2	administration					556:569	oral administration	551:569	oral administration of specific monosaccharides to bypass the metabolic defects	551:629	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	0	20	theme	TMEM165	86:92	arg1	Deficiency					94:103	TMEM165 Deficiency	86:103	TMEM165 Deficiency	86:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	6	21	theme	defect	1005:1010	arg1	singularity					985:995	the singularity	981:995	the singularity of this defect	981:1010	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	11	22	link	N-linked	1834:1841	arg1	glycosylation					1843:1855	the N-linked glycosylation	1830:1855	the N-linked glycosylation	1830:1855	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	1	23	from	process	159:165	arg1	life					185:188	life	185:188	life	185:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	1	23	from	process	159:165	arg1	domains					174:180	all domains	170:180	all domains of life	170:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	3	24	theme	genetic	355:361	arg1	diseases					363:370	severe genetic diseases	348:370	severe genetic diseases called Congenital Disorders of Glycosylation (CDG)	348:421	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	3	25	theme	Glycosylation	403:415	arg1	Disorders					390:398	Congenital Disorders	379:398	Congenital Disorders of Glycosylation (CDG)	379:421	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	10	26	theme	present	1498:1504	arg1	study					1506:1510	the present study	1494:1510	the present study	1494:1510	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	0	27	theme	Differential	0:11	arg1	Effects					13:19	Differential Effects	0:19	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency	0:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	9	28	theme	other	1366:1370	arg1	synthesis					1459:1467	glycosaminoglycan (GAG) synthesis	1435:1467	glycosaminoglycan (GAG) synthesis	1435:1467	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	28	theme	other	1366:1370	arg1	types					1392:1396	the other Golgi glycosylation types	1362:1396	the other Golgi glycosylation types	1362:1396	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	28	theme	other	1366:1370	arg1	O-glycosylation					1415:1429	O-glycosylation	1415:1429	O-glycosylation	1415:1429	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	4	29	theme	oral	551:554	arg1	administration					556:569	oral administration	551:569	oral administration of specific monosaccharides to bypass the metabolic defects	551:629	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	10	30	theme	differential	1532:1543	arg1	impact					1545:1550	the differential impact	1528:1550	the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency	1528:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	3	31	theme	functional	478:487	arg1	relevance					489:497	the functional relevance	474:497	the functional relevance of these processes	474:516	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	9	32	theme	glycosylation	1378:1390	arg1	synthesis					1459:1467	glycosaminoglycan (GAG) synthesis	1435:1467	glycosaminoglycan (GAG) synthesis	1435:1467	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	32	theme	glycosylation	1378:1390	arg1	types					1392:1396	the other Golgi glycosylation types	1362:1396	the other Golgi glycosylation types	1362:1396	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	32	theme	glycosylation	1378:1390	arg1	O-glycosylation					1415:1429	O-glycosylation	1415:1429	O-glycosylation	1415:1429	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	0	33	theme	Supplementation	36:50	arg1	Effects					13:19	Differential Effects	0:19	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency	0:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	11	34	dep	N-	1721:1722	arg1	the					1717:1719	the	1717:1719	the	1717:1719	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	6	35	dep	deficiency	851:860	arg1	only					866:869	only	866:869	only	866:869	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	3	36	theme	processes	508:516	arg1	relevance					489:497	the functional relevance	474:497	the functional relevance of these processes	474:516	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	5	37	theme	specific	789:796	arg1	CDG					798:800	specific CDG	789:800	specific CDG	789:800	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	8	38	from	N-glycosylation	1193:1207	arg1	cells					1230:1234	TMEM165-deficient cells	1212:1234	TMEM165-deficient cells	1212:1234	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	2	39	theme	many	206:209	arg1	pathways					225:232	many glycosylation pathways	206:232	many glycosylation pathways	206:232	In eukaryotes, many glycosylation pathways occur simultaneously onto proteins and lipids for generating a complex diversity of glycan structures.
35693943	4	40	theme	metabolic	613:621	arg1	defects					623:629	the metabolic defects	609:629	the metabolic defects	609:629	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	11	41	theme	TMEM165-deficient	1770:1786	arg1	cells					1788:1792	TMEM165-deficient cells	1770:1792	TMEM165-deficient cells	1770:1792	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	8	42	theme	fascinating	1140:1150	arg1	power					1152:1156	the fascinating power	1136:1156	the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells	1136:1234	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	6	43	theme	Golgi-related	925:937	arg1	types					953:957	all the other Golgi-related glycosylation types	911:957	all the other Golgi-related glycosylation types	911:957	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	10	44	theme	supplementation	1570:1584	arg1	effects					1586:1592	supplementation effects	1570:1592	supplementation effects	1570:1592	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	8	45	gly	N-glycosylation	1193:1207	arg1	cells					1230:1234	TMEM165-deficient cells	1212:1234	TMEM165-deficient cells	1212:1234	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	4	46	theme	monosaccharides	583:597	arg1	administration					556:569	oral administration	551:569	oral administration of specific monosaccharides to bypass the metabolic defects	551:629	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	8	47	theme	supplementation	1167:1181	arg1	power					1152:1156	the fascinating power	1136:1156	the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells	1136:1234	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	10	48	theme	Golgi	1601:1605	arg1	defects					1621:1627	the Golgi glycosylation defects	1597:1627	the Golgi glycosylation defects caused by TMEM165 deficiency	1597:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	7	49	theme	Mn2+	1109:1112	arg1	homeostasis					1115:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	Our previous results established a link between TMEM165 deficiency and altered Golgi manganese (Mn2+) homeostasis.
35693943	0	50	theme	Golgi	55:59	arg1	Defects					75:81	Golgi Glycosylation Defects	55:81	Golgi Glycosylation Defects in TMEM165 Deficiency	55:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	6	51	theme	N-glycosylation	883:897	arg1	process					899:905	the N-glycosylation process	879:905	the N-glycosylation process	879:905	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	10	52	dep	D-Gal	1555:1559	arg1	effects					1586:1592	supplementation effects	1570:1592	supplementation effects	1570:1592	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	7	53	theme	manganese	1098:1106	arg1	homeostasis					1115:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	Our previous results established a link between TMEM165 deficiency and altered Golgi manganese (Mn2+) homeostasis.
35693943	6	54	theme	TMEM165	843:849	arg1	deficiency					851:860	TMEM165 deficiency	843:860	TMEM165 deficiency	843:860	TMEM165 deficiency not only affects the N-glycosylation process but all the other Golgi-related glycosylation types, then contributing to the singularity of this defect.
35693943	7	55	theme	altered	1084:1090	arg1	homeostasis					1115:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	altered Golgi manganese (Mn2+) homeostasis	1084:1125	Our previous results established a link between TMEM165 deficiency and altered Golgi manganese (Mn2+) homeostasis.
35693943	2	56	theme	glycan	318:323	arg1	structures					325:334	glycan structures	318:334	glycan structures	318:334	In eukaryotes, many glycosylation pathways occur simultaneously onto proteins and lipids for generating a complex diversity of glycan structures.
35693943	5	57	theme	TMEM165-CDG	821:831	arg1	patients					833:840	TMEM165-CDG patients	821:840	TMEM165-CDG patients	821:840	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	9	58	from	effect	1352:1357	arg1	synthesis					1459:1467	glycosaminoglycan (GAG) synthesis	1435:1467	glycosaminoglycan (GAG) synthesis	1435:1467	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	58	from	effect	1352:1357	arg1	types					1392:1396	the other Golgi glycosylation types	1362:1396	the other Golgi glycosylation types	1362:1396	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	58	from	effect	1352:1357	arg1	O-glycosylation					1415:1429	O-glycosylation	1415:1429	O-glycosylation	1415:1429	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	5	59	theme	D-Galactose	716:726	arg1	therapy					734:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	5	59	theme	D-Galactose	716:726	arg1	treatment					775:783	a promising tailored treatment	754:783	a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients	754:840	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	8	60	theme	D-Gal	1237:1241	arg1	supplementation					1243:1257	D-Gal supplementation	1237:1257	D-Gal supplementation	1237:1257	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	10	61	from	impact	1545:1550	arg1	defects					1621:1627	the Golgi glycosylation defects	1597:1627	the Golgi glycosylation defects caused by TMEM165 deficiency	1597:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	11	62	theme	glycosylation	1905:1917	arg1	types					1919:1923	the other Golgi-related glycosylation types	1881:1923	the other Golgi-related glycosylation types	1881:1923	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	1	63	theme	ubiquitous	125:134	arg1	Glycosylation					106:118	Glycosylation	106:118	Glycosylation	106:118	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	1	63	theme	ubiquitous	125:134	arg1	process					159:165	a ubiquitous and universal cellular process	123:165	a ubiquitous and universal cellular process in all domains of life	123:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	8	64	theme	observed	1314:1321	arg1	defects					1339:1345	the observed N-glycosylation defects	1310:1345	the observed N-glycosylation defects	1310:1345	Besides the fascinating power of MnCl2 supplementation to rescue N-glycosylation in TMEM165-deficient cells, D-Gal supplementation has also been shown to be promising in suppressing the observed N-glycosylation defects.
35693943	11	65	theme	other	1885:1889	arg1	types					1919:1923	the other Golgi-related glycosylation types	1881:1923	the other Golgi-related glycosylation types	1881:1923	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	7	66	theme	previous	1017:1024	arg1	results					1026:1032	Our previous results	1013:1032	Our previous results	1013:1032	Our previous results established a link between TMEM165 deficiency and altered Golgi manganese (Mn2+) homeostasis.
35693943	1	67	theme	universal	140:148	arg1	Glycosylation					106:118	Glycosylation	106:118	Glycosylation	106:118	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	1	67	theme	universal	140:148	arg1	process					159:165	a ubiquitous and universal cellular process	123:165	a ubiquitous and universal cellular process in all domains of life	123:188	Glycosylation is a ubiquitous and universal cellular process in all domains of life.
35693943	3	68	theme	severe	348:353	arg1	diseases					363:370	severe genetic diseases	348:370	severe genetic diseases called Congenital Disorders of Glycosylation (CDG)	348:421	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	4	69	theme	real	522:525	arg1	cure					527:530	No real cure	519:530	No real cure	519:530	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	4	70	theme	simplest	679:686	arg1	treatments					699:708	the simplest and safest treatments	675:708	treatments	699:708	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	12	71	theme	MnCl2	1984:1988	arg1	use					1977:1979	the use	1973:1979	the use of MnCl2 for TMEM165-CDG therapy	1973:2012	According to these results, we would recommend the use of MnCl2 for TMEM165-CDG therapy.
35693943	5	72	theme	Oral	711:714	arg1	therapy					734:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	5	72	theme	Oral	711:714	arg1	treatment					775:783	a promising tailored treatment	754:783	a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients	754:840	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	0	73	from	Effects	13:19	arg1	Defects					75:81	Golgi Glycosylation Defects	55:81	Golgi Glycosylation Defects in TMEM165 Deficiency	55:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	4	74	theme	safest	692:697	arg1	treatments					699:708	the simplest and safest treatments	675:708	treatments	699:708	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	5	75	theme	Gal	729:731	arg1	therapy					734:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	5	75	theme	Gal	729:731	arg1	treatment					775:783	a promising tailored treatment	754:783	a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients	754:840	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	12	76	theme	TMEM165-CDG	1994:2004	arg1	therapy					2006:2012	TMEM165-CDG therapy	1994:2012	TMEM165-CDG therapy	1994:2012	According to these results, we would recommend the use of MnCl2 for TMEM165-CDG therapy.
35693943	3	77	theme	Congenital	379:388	arg1	Disorders					390:398	Congenital Disorders	379:398	Congenital Disorders of Glycosylation (CDG)	379:421	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	11	78	theme	N-linked	1834:1841	arg1	glycosylation					1843:1855	the N-linked glycosylation	1830:1855	the N-linked glycosylation	1830:1855	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	11	79	from	glycosylations	1752:1765	arg1	cells					1788:1792	TMEM165-deficient cells	1770:1792	TMEM165-deficient cells	1770:1792	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	3	80	theme	glycosylation	439:451	arg1	defects					453:459	glycosylation defects	439:459	glycosylation defects	439:459	In humans, severe genetic diseases called Congenital Disorders of Glycosylation (CDG), resulting from glycosylation defects, demonstrate the functional relevance of these processes.
35693943	0	81	theme	D-Galactose	24:34	arg1	Supplementation					36:50	D-Galactose Supplementation	24:50	D-Galactose Supplementation	24:50	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	9	82	theme	Golgi	1372:1376	arg1	synthesis					1459:1467	glycosaminoglycan (GAG) synthesis	1435:1467	glycosaminoglycan (GAG) synthesis	1435:1467	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	82	theme	Golgi	1372:1376	arg1	types					1392:1396	the other Golgi glycosylation types	1362:1396	the other Golgi glycosylation types	1362:1396	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	82	theme	Golgi	1372:1376	arg1	O-glycosylation					1415:1429	O-glycosylation	1415:1429	O-glycosylation	1415:1429	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	4	83	theme	specific	574:581	arg1	monosaccharides					583:597	specific monosaccharides	574:597	specific monosaccharides	574:597	No real cure exists so far, but oral administration of specific monosaccharides to bypass the metabolic defects has been used in few CDG, then constituting the simplest and safest treatments.
35693943	11	84	theme	GAG	1748:1750	arg1	glycosylations					1752:1765	GAG glycosylations	1748:1765	the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells	1717:1792	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	5	85	theme	tailored	766:773	arg1	therapy					734:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy	711:740	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	5	85	theme	tailored	766:773	arg1	treatment					775:783	a promising tailored treatment	754:783	a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients	754:840	Oral D-Galactose (Gal) therapy was seen as a promising tailored treatment for specific CDG and peculiarly for TMEM165-CDG patients.
35693943	0	86	theme	Glycosylation	61:73	arg1	Defects					75:81	Golgi Glycosylation Defects	55:81	Golgi Glycosylation Defects in TMEM165 Deficiency	55:103	Differential Effects of D-Galactose Supplementation on Golgi Glycosylation Defects in TMEM165 Deficiency.
35693943	10	87	theme	D-Gal	1555:1559	arg1	impact					1545:1550	the differential impact	1528:1550	the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency	1528:1656	In the present study, we demonstrate the differential impact of D-Gal or MnCl2 supplementation effects on the Golgi glycosylation defects caused by TMEM165 deficiency.
35693943	2	88	theme	glycosylation	211:223	arg1	pathways					225:232	many glycosylation pathways	206:232	many glycosylation pathways	206:232	In eukaryotes, many glycosylation pathways occur simultaneously onto proteins and lipids for generating a complex diversity of glycan structures.
35693943	11	89	theme	MnCl2	1667:1671	arg1	supplementation					1673:1687	MnCl2 supplementation	1667:1687	MnCl2 supplementation	1667:1687	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
35693943	9	90	theme	glycosaminoglycan	1435:1451	arg1	synthesis					1459:1467	glycosaminoglycan (GAG) synthesis	1435:1467	glycosaminoglycan (GAG) synthesis	1435:1467	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	9	90	theme	glycosaminoglycan	1435:1451	arg1	types					1392:1396	the other Golgi glycosylation types	1362:1396	the other Golgi glycosylation types	1362:1396	Its effect on the other Golgi glycosylation types, most especially O-glycosylation and glycosaminoglycan (GAG) synthesis, was however unknown.
35693943	11	91	from	N-	1721:1722	arg1	cells					1788:1792	TMEM165-deficient cells	1770:1792	TMEM165-deficient cells	1770:1792	Whereas MnCl2 supplementation unambiguously fully rescues the N- and O-linked as well as GAG glycosylations in TMEM165-deficient cells, D-Gal supplementation only rescues the N-linked glycosylation, without any effects on the other Golgi-related glycosylation types.
37398169	2	0	theme	structures	338:347	arg1	distribution					316:327	the spatial distribution	304:327	the spatial distribution of these structures	304:347	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
37398169	6	1	theme	protein	1047:1053	arg1	modifications					1055:1067	these critical protein modifications	1032:1067	these critical protein modifications	1032:1067	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	6	2	theme	brain	1103:1107	arg1	disease					1088:1094	disease	1088:1094	disease	1088:1094	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	6	2	theme	brain	1103:1107	arg1	development					1072:1082	development	1072:1082	development	1072:1082	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	5	3	theme	cerebellum	932:941	arg1	layer					919:923	the synapse-rich molecular layer	892:923	the synapse-rich molecular layer of the cerebellum	892:941	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	1	4	theme	critical	159:166	arg1	role					168:171	a critical role	157:171	a critical role	157:171	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	4	5	theme	high-mannose-type	593:609	arg1	N-glycans					611:619	high-mannose-type N-glycans	593:619	high-mannose-type N-glycans	593:619	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	1	6	link	N-linked	69:76	arg1	glycosylation					78:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	6	link	N-linked	69:76	arg1	modification					108:119	a ubiquitous modification	95:119	a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain	95:216	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	5	7	dep	showed	845:850	arg1	partitioned					857:867	partitioned	857:867	partitioned labeling	857:876	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	8	theme	specific	768:775	arg1	motifs					777:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	8	theme	specific	768:775	arg1	fucose					816:821	fucose	816:821	fucose	816:821	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	8	theme	specific	768:775	arg1	GlcNAc					837:842	bisecting GlcNAc	827:842	bisecting GlcNAc	827:842	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	1	9	theme	Protein	61:67	arg1	glycosylation					78:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	9	theme	Protein	61:67	arg1	modification					108:119	a ubiquitous modification	95:119	a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain	95:216	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	3	10	theme	mouse	564:568	arg1	brain					570:574	the mouse brain	560:574	the mouse brain	560:574	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	1	11	theme	N-linked	69:76	arg1	glycosylation					78:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	11	theme	N-linked	69:76	arg1	modification					108:119	a ubiquitous modification	95:119	a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain	95:216	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	5	12	theme	molecular	909:917	arg1	layer					919:923	the synapse-rich molecular layer	892:923	the synapse-rich molecular layer of the cerebellum	892:941	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	4	13	located	observed	720:727	arg1	magnification					737:749	high magnification	732:749	high magnification	732:749	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	4	13	located	observed	720:727	arg2	structures					709:718	some punctate structures	695:718	some punctate structures observed on high magnification	695:749	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	4	14	theme	abundant	631:638	arg1	Lectins					577:583	Lectins	577:583	Lectins binding high-mannose-type N-glycans	577:619	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	4	14	theme	abundant	631:638	arg1	class					640:644	the most abundant class	622:644	the most abundant class of brain N-glycans	622:663	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	3	15	theme	differing	447:455	arg1	specificities					457:469	differing specificities	447:469	differing specificities to various classes of N-glycans	447:501	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	0	16	from	distribution	32:43	arg1	brain					54:58	mouse brain	48:58	mouse brain	48:58	N-glycans show distinct spatial distribution in mouse brain.
37398169	4	17	theme	diffuse	673:679	arg1	staining					681:688	diffuse staining	673:688	diffuse staining with some punctate structures observed on high magnification	673:749	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	3	18	theme	binding	426:432	arg1	lectins					434:440	carbohydrate binding lectins	413:440	carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls	413:526	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	6	19	theme	critical	1038:1045	arg1	modifications					1055:1067	these critical protein modifications	1032:1067	these critical protein modifications	1032:1067	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	5	20	theme	synapse-rich	896:907	arg1	layer					919:923	the synapse-rich molecular layer	892:923	the synapse-rich molecular layer of the cerebellum	892:941	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	0	21	theme	spatial	24:30	arg1	distribution					32:43	distinct spatial distribution	15:43	distinct spatial distribution in mouse brain	15:58	N-glycans show distinct spatial distribution in mouse brain.
37398169	6	22	theme	future	1014:1019	arg1	studies					1021:1027	future studies	1014:1027	future studies of these critical protein modifications	1014:1067	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	1	23	theme	ubiquitous	97:106	arg1	glycosylation					78:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation	61:90	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	23	theme	ubiquitous	97:106	arg1	modification					108:119	a ubiquitous modification	95:119	a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain	95:216	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	3	24	theme	various	474:480	arg1	classes					482:488	various classes	474:488	various classes of N-glycans	474:501	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	0	25	theme	distinct	15:22	arg1	distribution					32:43	distinct spatial distribution	15:43	distinct spatial distribution in mouse brain	15:58	N-glycans show distinct spatial distribution in mouse brain.
37398169	2	26	theme	tight	269:273	arg1	regulation					275:284	tight regulation	269:284	tight regulation in the brain	269:297	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
37398169	4	27	theme	brain	649:653	arg1	N-glycans					655:663	brain N-glycans	649:663	brain N-glycans	649:663	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	4	28	theme	high	732:735	arg1	magnification					737:749	high magnification	732:749	high magnification	732:749	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	3	29	theme	carbohydrate	413:424	arg1	lectins					434:440	carbohydrate binding lectins	413:440	carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls	413:526	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	5	30	theme	Lectins	752:758	arg1	motifs					777:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	30	theme	Lectins	752:758	arg1	fucose					816:821	fucose	816:821	fucose	816:821	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	30	theme	Lectins	752:758	arg1	GlcNAc					837:842	bisecting GlcNAc	827:842	bisecting GlcNAc	827:842	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	4	31	with	staining	681:688	arg1	structures					709:718	some punctate structures	695:718	some punctate structures observed on high magnification	695:749	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	1	32	dep	development	180:190	arg1	the					176:178	the	176:178	the	176:178	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	5	33	theme	bisecting	827:835	arg1	GlcNAc					837:842	bisecting GlcNAc	827:842	bisecting GlcNAc	827:842	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	34	theme	binding	760:766	arg1	motifs					777:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	34	theme	binding	760:766	arg1	fucose					816:821	fucose	816:821	fucose	816:821	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	34	theme	binding	760:766	arg1	GlcNAc					837:842	bisecting GlcNAc	827:842	bisecting GlcNAc	827:842	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	0	35	theme	mouse	48:52	arg1	brain					54:58	mouse brain	48:58	mouse brain	48:58	N-glycans show distinct spatial distribution in mouse brain.
37398169	3	36	theme	brain	570:574	arg1	regions					549:555	multiple regions	540:555	multiple regions of the mouse brain	540:574	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	3	37	with	lectins	434:440	arg1	specificities					457:469	differing specificities	447:469	differing specificities to various classes of N-glycans	447:501	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	3	37	with	lectins	434:440	arg1	controls					519:526	appropriate controls	507:526	appropriate controls	507:526	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	3	38	theme	appropriate	507:517	arg1	controls					519:526	appropriate controls	507:526	appropriate controls	507:526	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	6	39	theme	N-glycans	978:986	arg1	distribution					962:973	the distribution	958:973	the distribution of N-glycans across the brain	958:1003	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	4	40	theme	punctate	700:707	arg1	structures					709:718	some punctate structures	695:718	some punctate structures observed on high magnification	695:749	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	1	41	theme	secretory	128:136	arg1	pathway					138:144	the secretory pathway	124:144	the secretory pathway	124:144	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	42	from	modification	108:119	arg1	pathway					138:144	the secretory pathway	124:144	the secretory pathway	124:144	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	43	theme	brain	212:216	arg1	function					196:203	function	196:203	function	196:203	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	1	43	theme	brain	212:216	arg1	development					180:190	development	180:190	development	180:190	Protein N-linked glycosylation is a ubiquitous modification in the secretory pathway that plays a critical role in the development and function of the brain.
37398169	3	44	theme	N-glycans	493:501	arg1	classes					482:488	various classes	474:488	various classes of N-glycans	474:501	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	2	45	theme	spatial	308:314	arg1	distribution					316:327	the spatial distribution	304:327	the spatial distribution of these structures	304:347	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
37398169	5	46	theme	complex	787:793	arg1	N-glycans					795:803	complex N-glycans	787:803	complex N-glycans	787:803	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	2	47	theme	distinct	236:243	arg1	composition					245:255	a distinct composition	234:255	a distinct composition	234:255	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
37398169	4	48	theme	N-glycans	655:663	arg1	Lectins					577:583	Lectins	577:583	Lectins binding high-mannose-type N-glycans	577:619	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	4	48	theme	N-glycans	655:663	arg1	class					640:644	the most abundant class	622:644	the most abundant class of brain N-glycans	622:663	Lectins binding high-mannose-type N-glycans, the most abundant class of brain N-glycans, showed diffuse staining with some punctate structures observed on high magnification.
37398169	2	49	from	regulation	275:284	arg1	brain					293:297	the brain	289:297	the brain	289:297	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
37398169	5	50	theme	N-glycans	795:803	arg1	motifs					777:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs	752:782	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	50	theme	N-glycans	795:803	arg1	fucose					816:821	fucose	816:821	fucose	816:821	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	5	50	theme	N-glycans	795:803	arg1	GlcNAc					837:842	bisecting GlcNAc	827:842	bisecting GlcNAc	827:842	Lectins binding specific motifs of complex N-glycans, including fucose and bisecting GlcNAc, showed more partitioned labeling, including to the synapse-rich molecular layer of the cerebellum.
37398169	6	51	theme	modifications	1055:1067	arg1	studies					1021:1027	future studies	1014:1027	future studies of these critical protein modifications	1014:1067	Understanding the distribution of N-glycans across the brain will aid future studies of these critical protein modifications in development and disease of the brain.
37398169	3	52	theme	multiple	540:547	arg1	regions					549:555	multiple regions	540:555	multiple regions of the mouse brain	540:574	Here, we systematically employed carbohydrate binding lectins with differing specificities to various classes of N-glycans and appropriate controls to identify multiple regions of the mouse brain.
37398169	2	53	contain	have	229:232	arg1	N-glycans					219:227	N-glycans	219:227	N-glycans	219:227	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
37398169	2	53	contain	have	229:232	arg2	composition					245:255	a distinct composition	234:255	a distinct composition	234:255	N-glycans have a distinct composition and undergo tight regulation in the brain, but the spatial distribution of these structures remains relatively unexplored.
35415843	7	0	dep	research	1556:1563	arg1	the					1552:1554	the	1552:1554	the	1552:1554	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	3	1	theme	weight	733:738	arg1	distributions					740:752	molecular weight distributions	723:752	molecular weight distributions	723:752	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	1	2	theme	gradient	181:188	arg1	method					212:217	gradient ethanol precipitation method	181:217	gradient ethanol precipitation method	181:217	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	1	3	theme	VL8	302:304	arg1	polysaccharides					259:273	the extracellular polysaccharides	241:273	the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS)	241:314	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	0	4	from	characterization	11:26	arg1	paracasei					108:116	Lactobacillus paracasei	94:116	Lactobacillus paracasei	94:116	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	1	5	theme	ethanol	190:196	arg1	method					212:217	gradient ethanol precipitation method	181:217	gradient ethanol precipitation method	181:217	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	3	6	theme	ethanol	655:661	arg1	concentration					663:675	ethanol concentration	655:675	ethanol concentration	655:675	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	7	7	from	application	1656:1666	arg1	development					1682:1692	the future development	1671:1692	the future development of food industry	1671:1709	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	3	8	theme	chemical	700:707	arg1	compositions					709:720	their chemical compositions	694:720	their chemical compositions	694:720	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	4	9	theme	better	915:920	arg1	activities					939:948	better immunomodulatory activities	915:948	better immunomodulatory activities	915:948	Among the three polysaccharide fractions, VL8-EPS50 displayed better immunomodulatory activities compared with VL8-EPS30 and VL8-EPS70.
35415843	3	10	theme	molecular	542:550	arg1	heteropolysaccharides					568:588	high molecular weight sulfated heteropolysaccharides	537:588	high molecular weight sulfated heteropolysaccharides	537:588	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	7	11	theme	materials	1475:1483	arg1	source					1461:1466	the source	1457:1466	the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry	1457:1709	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	7	12	theme	theoretical	1530:1540	arg1	basis					1542:1546	some theoretical basis	1525:1546	some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria	1525:1636	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	5	13	theme	immunomodulatory	1018:1033	arg1	effects					1035:1041	immunomodulatory effects	1018:1041	immunomodulatory effects	1018:1041	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	3	14	theme	weight	552:557	arg1	heteropolysaccharides					568:588	high molecular weight sulfated heteropolysaccharides	537:588	high molecular weight sulfated heteropolysaccharides	537:588	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	0	15	theme	ethanol	143:149	arg1	precipitation					151:163	gradient ethanol precipitation	134:163	gradient ethanol precipitation	134:163	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	1	16	theme	precipitation	198:210	arg1	method					212:217	gradient ethanol precipitation method	181:217	gradient ethanol precipitation method	181:217	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	0	17	theme	gradient	134:141	arg1	precipitation					151:163	gradient ethanol precipitation	134:163	gradient ethanol precipitation	134:163	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	3	18	theme	molecular	723:731	arg1	distributions					740:752	molecular weight distributions	723:752	molecular weight distributions	723:752	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	3	19	theme	high	537:540	arg1	heteropolysaccharides					568:588	high molecular weight sulfated heteropolysaccharides	537:588	high molecular weight sulfated heteropolysaccharides	537:588	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	3	20	contain	had	677:679	arg1	alteration					641:650	the alteration	637:650	the alteration of ethanol concentration	637:675	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	3	20	contain	had	677:679	arg2	effect					684:689	an effect	681:689	an effect	681:689	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	3	21	theme	concentration	663:675	arg1	alteration					641:650	the alteration	637:650	the alteration of ethanol concentration	637:675	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	0	22	from	effects	49:55	arg1	paracasei					108:116	Lactobacillus paracasei	94:116	Lactobacillus paracasei	94:116	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	6	23	theme	immunomodulatory	1311:1326	arg1	activity					1328:1335	their immunomodulatory activity	1305:1335	their immunomodulatory activity	1305:1335	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	0	24	dep	VL8	118:120	arg1	obtained					122:129	obtained	122:129	VL8 obtained by gradient ethanol precipitation	118:163	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	6	25	theme	in	1380:1381	arg1	activity					1405:1412	in vivo immunomodulatory activity	1380:1412	in vivo immunomodulatory activity	1380:1412	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	2	26	theme	ethanol	436:442	arg1	concentrations					444:457	different ethanol concentrations	426:457	different ethanol concentrations (30%, 50%, and 70%, v/v)	426:482	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	26	theme	ethanol	436:442	arg1	%					462:462	30%	460:462	30%	460:462	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	26	theme	ethanol	436:442	arg1	%					467:467	50%	465:467	50%	465:467	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	26	theme	ethanol	436:442	arg1	%					476:476	70%	474:476	70%	474:476	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	0	27	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	6	28	used	used	1371:1374	arg2	VL8-EPS50					1342:1350	VL8-EPS50	1342:1350	VL8-EPS50	1342:1350	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	4	29	theme	polysaccharide	869:882	arg1	fractions					884:892	the three polysaccharide fractions	859:892	the three polysaccharide fractions	859:892	Among the three polysaccharide fractions, VL8-EPS50 displayed better immunomodulatory activities compared with VL8-EPS30 and VL8-EPS70.
35415843	7	30	theme	functional	1489:1498	arg1	foods					1500:1504	functional foods	1489:1504	functional foods	1489:1504	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	2	31	theme	different	426:434	arg1	concentrations					444:457	different ethanol concentrations	426:457	different ethanol concentrations (30%, 50%, and 70%, v/v)	426:482	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	31	theme	different	426:434	arg1	%					462:462	30%	460:462	30%	460:462	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	31	theme	different	426:434	arg1	%					467:467	50%	465:467	50%	465:467	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	31	theme	different	426:434	arg1	%					476:476	70%	474:476	70%	474:476	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	0	32	theme	immunomodulatory	32:47	arg1	effects					49:55	immunomodulatory effects	32:55	immunomodulatory effects	32:55	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	5	33	theme	phagocytic	1060:1069	arg1	activity					1071:1078	the phagocytic activity	1056:1078	the phagocytic activity of RAW264.7 cells	1056:1096	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	3	34	theme	sulfated	559:566	arg1	heteropolysaccharides					568:588	high molecular weight sulfated heteropolysaccharides	537:588	high molecular weight sulfated heteropolysaccharides	537:588	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	7	35	dep	Application	1425:1435	arg1	opens					1448:1452	opens	1448:1452	opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry	1448:1709	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	6	36	dep	in	1380:1381	arg1	vivo					1383:1386	vivo	1383:1386	vivo	1383:1386	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	3	37	theme	monosaccharide	755:768	arg1	composition					770:780	monosaccharide composition	755:780	monosaccharide composition	755:780	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	1	38	dep	Lactobacillus	278:290	arg1	paracasei					292:300	paracasei	292:300	paracasei	292:300	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	2	39	theme	physicochemical	329:343	arg1	properties					345:354	physicochemical properties	329:354	physicochemical properties	329:354	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	5	40	dep	thermal	1175:1181	arg1	stronger					1166:1173	stronger	1166:1173	stronger	1166:1173	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	7	41	theme	acid	1624:1627	arg1	bacteria					1629:1636	lactic acid bacteria	1617:1636	lactic acid bacteria	1617:1636	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	0	42	from	paracasei	108:116	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	0	42	from	paracasei	108:116	arg1	effects					49:55	immunomodulatory effects	32:55	immunomodulatory effects	32:55	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	0	42	from	paracasei	108:116	arg1	polysaccharide					74:87	extracellular polysaccharide	60:87	extracellular polysaccharide from Lactobacillus paracasei	60:116	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	2	43	dep	%	462:462	arg1	v/v					479:481	v/v	479:481	v/v	479:481	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	7	44	theme	industry	1702:1709	arg1	development					1682:1692	the future development	1671:1692	the future development of food industry	1671:1709	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	6	45	theme	immunomodulatory	1388:1403	arg1	activity					1405:1412	in vivo immunomodulatory activity	1380:1412	in vivo immunomodulatory activity	1380:1412	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	5	46	theme	nitric	1137:1142	arg1	oxide					1144:1148	more nitric oxide	1132:1148	more nitric oxide	1132:1148	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	5	47	theme	RAW264.7	1083:1090	arg1	cells					1092:1096	RAW264.7 cells	1083:1096	RAW264.7 cells	1083:1096	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	1	48	theme	extracellular	245:257	arg1	polysaccharides					259:273	the extracellular polysaccharides	241:273	the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS)	241:314	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	0	49	theme	polysaccharide	74:87	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	0	49	theme	polysaccharide	74:87	arg1	effects					49:55	immunomodulatory effects	32:55	immunomodulatory effects	32:55	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	7	50	theme	lactic	1617:1622	arg1	bacteria					1629:1636	lactic acid bacteria	1617:1636	lactic acid bacteria	1617:1636	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	5	51	theme	oxide	1144:1148	arg1	secretion					1119:1127	their secretion	1113:1127	their secretion of more nitric oxide	1113:1148	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	5	52	theme	cells	1092:1096	arg1	activity					1071:1078	the phagocytic activity	1056:1078	the phagocytic activity of RAW264.7 cells	1056:1096	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	2	53	theme	VL8-EPS	389:395	arg1	yields					321:326	The yields	317:326	The yields	317:326	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	53	theme	VL8-EPS	389:395	arg1	properties					345:354	physicochemical properties	329:354	physicochemical properties	329:354	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	2	53	theme	VL8-EPS	389:395	arg1	effects					378:384	immunomodulatory effects	361:384	immunomodulatory effects	361:384	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	0	54	theme	extracellular	60:72	arg1	polysaccharide					74:87	extracellular polysaccharide	60:87	extracellular polysaccharide from Lactobacillus paracasei	60:116	Structural characterization and immunomodulatory effects of extracellular polysaccharide from Lactobacillus paracasei VL8 obtained by gradient ethanol precipitation.
35415843	3	55	theme	surface	787:793	arg1	structure					795:803	surface structure	787:803	surface structure	787:803	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35415843	4	56	theme	immunomodulatory	922:937	arg1	activities					939:948	better immunomodulatory activities	915:948	better immunomodulatory activities	915:948	Among the three polysaccharide fractions, VL8-EPS50 displayed better immunomodulatory activities compared with VL8-EPS30 and VL8-EPS70.
35415843	7	57	theme	extracellular	1584:1596	arg1	polysaccharides					1598:1612	extracellular polysaccharides	1584:1612	extracellular polysaccharides of lactic acid bacteria	1584:1636	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	7	58	theme	bacteria	1629:1636	arg1	polysaccharides					1598:1612	extracellular polysaccharides	1584:1612	extracellular polysaccharides of lactic acid bacteria	1584:1636	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	7	59	theme	food	1697:1700	arg1	industry					1702:1709	food industry	1697:1709	food industry	1697:1709	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	7	60	theme	polysaccharides	1598:1612	arg1	development					1569:1579	development	1569:1579	development	1569:1579	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	7	60	theme	polysaccharides	1598:1612	arg1	research					1556:1563	research	1556:1563	research	1556:1563	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	6	61	theme	structural	1255:1264	arg1	characteristics					1266:1280	the structural characteristics	1251:1280	the structural characteristics of polysaccharides	1251:1299	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	6	62	theme	polysaccharides	1285:1299	arg1	activity					1328:1335	their immunomodulatory activity	1305:1335	their immunomodulatory activity	1305:1335	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	6	62	theme	polysaccharides	1285:1299	arg1	characteristics					1266:1280	the structural characteristics	1251:1280	the structural characteristics of polysaccharides	1251:1299	In summary, there was a correlation between the structural characteristics of polysaccharides and their immunomodulatory activity, and VL8-EPS50 was preferentially used for in vivo immunomodulatory activity.
35415843	7	63	theme	raw	1471:1473	arg1	materials					1475:1483	raw materials	1471:1483	raw materials	1471:1483	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	7	64	theme	future	1675:1680	arg1	development					1682:1692	the future development	1671:1692	the future development of food industry	1671:1709	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	5	65	theme	more	1132:1135	arg1	oxide					1144:1148	more nitric oxide	1132:1148	more nitric oxide	1132:1148	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	2	66	theme	immunomodulatory	361:376	arg1	effects					378:384	immunomodulatory effects	361:384	immunomodulatory effects	361:384	The yields, physicochemical properties, and immunomodulatory effects of VL8-EPS obtained by precipitation at different ethanol concentrations (30%, 50%, and 70%, v/v) were compared.
35415843	5	67	theme	solution	1187:1194	arg1	stability					1196:1204	stronger thermal and solution stability	1166:1204	stability	1196:1204	VL8-EPS50 was found to exert immunomodulatory effects by enhancing the phagocytic activity of RAW264.7 cells and to promote their secretion of more nitric oxide; it also showed stronger thermal and solution stability.
35415843	7	68	theme	Practical	1415:1423	arg1	Application					1425:1435	Practical Application	1415:1435	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.	1415:1710	Practical Application This study opens up the source of raw materials for functional foods, which can provide some theoretical basis for the research and development of extracellular polysaccharides of lactic acid bacteria and promote their application in the future development of food industry.
35415843	1	69	theme	Lactobacillus	278:290	arg1	VL8-EPS					307:313	VL8-EPS	307:313	VL8-EPS	307:313	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	1	69	theme	Lactobacillus	278:290	arg1	VL8					302:304	Lactobacillus paracasei VL8	278:304	Lactobacillus paracasei VL8 (VL8-EPS)	278:314	In this study, gradient ethanol precipitation method was applied to obtain the extracellular polysaccharides of Lactobacillus paracasei VL8 (VL8-EPS).
35415843	3	70	theme	primary	816:822	arg1	structure					824:832	the primary structure	812:832	the primary structure	812:832	The results showed that VL8-EPSs were high molecular weight sulfated heteropolysaccharides, composed mainly of glucose and galactose, and the alteration of ethanol concentration had an effect on their chemical compositions, molecular weight distributions, monosaccharide composition, and surface structure, while the primary structure remained the same.
35939326	7	0	theme	high	1110:1113	arg1	hindrance					1122:1130	The high steric hindrance	1106:1130	The high steric hindrance induced by the high carbon sugars and trinacriform architecture	1106:1194	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	8	1	dep	α-	1425:1426	arg1	→					1430:1430	1 → 6	1428:1432	1 → 6	1428:1432	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	5	2	dep	match	766:770	arg1	The					762:764	The	762:764	The	762:764	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	7	3	theme	convergent	1335:1344	arg1	strategies					1346:1355	convergent strategies	1335:1355	a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies	1260:1355	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	1	4	theme	gastric	275:281	arg1	mucosa					283:288	the gastric mucosa	271:288	the gastric mucosa of more than half of the world's population	271:332	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	9	5	theme	core	1561:1564	arg1	epitope					1584:1590	the inner core trisaccharide key epitope	1551:1590	the inner core trisaccharide key epitope	1551:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	0	6	with	Evaluation	134:143	arg1	Serum					156:160	Human Serum	150:160	Human Serum	150:160	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	9	7	theme	key	1580:1582	arg1	epitope					1584:1590	the inner core trisaccharide key epitope	1551:1590	the inner core trisaccharide key epitope	1551:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	5	8	theme	glycosyl	797:804	arg1	donor					806:810	the glycosyl donor	793:810	the glycosyl donor	793:810	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	3	9	theme	candidate	562:570	arg1	structure					481:489	The conserved core structure	462:489	The conserved core structure of H. pylori lipopolysaccharide (LPS)	462:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	9	theme	candidate	562:570	arg1	structure					572:580	a promising candidate structure	550:580	a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes	550:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	9	10	theme	IgG	1614:1616	arg1	recognition					1618:1628	IgG recognition	1614:1628	IgG recognition	1614:1628	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	8	11	theme	antigenicity	1361:1372	arg1	evaluation					1374:1383	An antigenicity evaluation	1358:1383	An antigenicity evaluation using glycan microarrays	1358:1408	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	5	12	theme	judicious	881:889	arg1	choice					891:896	a judicious choice	879:896	a judicious choice of orthogonal protection strategies and glycosylation conditions	879:961	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	6	13	theme	participation	993:1005	arg1	combination					966:976	A combination	964:976	A combination of acyl remote participation and solvent effects	964:1025	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	0	14	theme	Undecasaccharide	58:73	arg1	Synthesis					9:17	Chemical Synthesis	0:17	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.	0:161	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	5	15	theme	hydroxyl	845:852	arg1	groups					854:859	the inert hydroxyl groups	835:859	the inert hydroxyl groups	835:859	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	6	16	theme	acyl	981:984	arg1	participation					993:1005	acyl remote participation	981:1005	acyl remote participation	981:1005	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	0	17	theme	Helicobacter	78:89	arg1	Lipopolysaccharide					98:115	Helicobacter pylori Lipopolysaccharide	78:115	Helicobacter pylori Lipopolysaccharide	78:115	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	8	18	theme	α-	1425:1426	arg1	trisaccharide					1442:1454	an α-(1 → 6)-glucan trisaccharide	1422:1454	an α-(1 → 6)-glucan trisaccharide	1422:1454	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	4	19	theme	LPS	732:734	arg1	undecasaccharide					702:717	the core undecasaccharide	693:717	the core undecasaccharide of H. pylori LPS	693:734	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	3	20	dep	H.	494:495	arg1	pylori					497:502	H. pylori lipopolysaccharide (LPS)	494:527	H. pylori lipopolysaccharide (LPS)	494:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	20	dep	H.	494:495	arg1	LPS					524:526	LPS	524:526	LPS	524:526	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	20	dep	H.	494:495	arg1	lipopolysaccharide					504:521	lipopolysaccharide	504:521	H. pylori lipopolysaccharide (LPS)	494:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	0	21	theme	Lipopolysaccharide	98:115	arg1	Undecasaccharide					58:73	the Highly Sterically Hindered Core Undecasaccharide	22:73	the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum	22:160	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	2	22	dep	H.	365:366	arg1	pylori					368:373	H. pylori	365:373	H. pylori	365:373	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	2	23	theme	high	382:385	arg1	risk					387:390	a high risk	380:390	a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer	380:459	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	0	24	theme	Antigenicity	121:132	arg1	Evaluation					134:143	Antigenicity Evaluation	121:143	Antigenicity Evaluation with Human Serum	121:160	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	5	25	theme	conditions	952:961	arg1	choice					891:896	a judicious choice	879:896	a judicious choice of orthogonal protection strategies and glycosylation conditions	879:961	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	6	26	theme	selective	1048:1056	arg1	formation					1058:1066	selective formation	1048:1066	selective formation of the five 1,2-cis-glucosidic bonds	1048:1103	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	4	27	theme	undecasaccharide	702:717	arg1	synthesis					680:688	a total synthesis	672:688	a total synthesis of the core undecasaccharide of H. pylori LPS	672:734	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	4	27	theme	undecasaccharide	702:717	arg1	antigens					752:759	its subunit antigens	740:759	its subunit antigens	740:759	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	0	28	theme	Chemical	0:7	arg1	Synthesis					9:17	Chemical Synthesis	0:17	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.	0:161	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	0	29	dep	Helicobacter	78:89	arg1	pylori					91:96	pylori	91:96	pylori	91:96	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	8	30	theme	-glucan	1434:1440	arg1	trisaccharide					1442:1454	an α-(1 → 6)-glucan trisaccharide	1422:1454	an α-(1 → 6)-glucan trisaccharide	1422:1454	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	4	31	theme	H.	722:723	arg1	LPS					732:734	H. pylori LPS	722:734	H. pylori LPS	722:734	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	2	32	theme	chronic	403:409	arg1	gastritis					411:419	chronic gastritis	403:419	chronic gastritis	403:419	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	7	33	theme	high	1147:1150	arg1	sugars					1159:1164	the high carbon sugars	1143:1164	the high carbon sugars	1143:1164	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	1	34	theme	more	293:296	arg1	half					303:306	more than half	293:306	more than half of the world's population	293:332	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	5	35	theme	protection	912:921	arg1	strategies					923:932	orthogonal protection strategies	901:932	orthogonal protection strategies	901:932	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	1	36	theme	Helicobacter	163:174	arg1	pylori					176:181	Helicobacter pylori	163:181	Helicobacter pylori	163:181	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	2	37	theme	gastric	446:452	arg1	cancer					454:459	even gastric cancer	441:459	even gastric cancer	441:459	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	1	38	theme	half	303:306	arg1	mucosa					283:288	the gastric mucosa	271:288	the gastric mucosa of more than half of the world's population	271:332	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	6	39	theme	solvent	1011:1017	arg1	effects					1019:1025	solvent effects	1011:1025	solvent effects	1011:1025	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	3	40	theme	glycoconjugate	603:616	arg1	vaccine					618:624	a glycoconjugate vaccine	601:624	a glycoconjugate vaccine targeting multiple serotypes	601:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	0	41	theme	Hindered	44:51	arg1	Undecasaccharide					58:73	the Highly Sterically Hindered Core Undecasaccharide	22:73	the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum	22:160	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	7	42	theme	assembly	1282:1289	arg1	[2					1291:1292	a finely tuned linear assembly [2	1260:1292	a finely tuned linear assembly [2	1260:1292	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	1	43	theme	Health	234:239	arg1	Department					220:229	the Department	216:229	the Department of Health and Human Services	216:258	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	7	44	theme	tuned	1269:1273	arg1	[2					1291:1292	a finely tuned linear assembly [2	1260:1292	a finely tuned linear assembly [2	1260:1292	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	1	45	theme	Human	245:249	arg1	Services					251:258	Human Services	245:258	Human Services	245:258	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	0	46	theme	Core	53:56	arg1	Undecasaccharide					58:73	the Highly Sterically Hindered Core Undecasaccharide	22:73	the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum	22:160	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	9	47	theme	phosphate	1532:1540	arg1	important					1600:1608	important	1600:1608	important	1600:1608	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	9	47	theme	phosphate	1532:1540	arg1	group					1542:1546	The phosphate group	1528:1546	The phosphate group of the inner core trisaccharide key epitope	1528:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	9	47	theme	phosphate	1532:1540	arg1	epitope					1584:1590	the inner core trisaccharide key epitope	1551:1590	the inner core trisaccharide key epitope	1551:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	8	48	theme	H.	1499:1500	arg1	patients					1518:1525	H. pylori-infected patients	1499:1525	H. pylori-infected patients	1499:1525	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	3	49	theme	core	476:479	arg1	structure					481:489	The conserved core structure	462:489	The conserved core structure of H. pylori lipopolysaccharide (LPS)	462:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	49	theme	core	476:479	arg1	structure					572:580	a promising candidate structure	550:580	a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes	550:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	8	50	theme	patients	1518:1525	arg1	sera					1491:1494	sera	1491:1494	sera of H. pylori-infected patients	1491:1525	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	10	51	theme	important	1653:1661	arg1	findings					1637:1644	These findings	1631:1644	These findings	1631:1644	These findings are an important step toward designing carbohydrate-based vaccines against H. pylori.
35939326	10	51	theme	important	1653:1661	arg1	step					1663:1666	an important step	1650:1666	an important step toward designing carbohydrate-based vaccines against H. pylori	1650:1729	These findings are an important step toward designing carbohydrate-based vaccines against H. pylori.
35939326	9	52	theme	inner	1555:1559	arg1	epitope					1584:1590	the inner core trisaccharide key epitope	1551:1590	the inner core trisaccharide key epitope	1551:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	9	53	theme	trisaccharide	1566:1578	arg1	epitope					1584:1590	the inner core trisaccharide key epitope	1551:1590	the inner core trisaccharide key epitope	1551:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	10	54	theme	carbohydrate-based	1685:1702	arg1	vaccines					1704:1711	carbohydrate-based vaccines	1685:1711	carbohydrate-based vaccines against H. pylori	1685:1729	These findings are an important step toward designing carbohydrate-based vaccines against H. pylori.
35939326	1	55	theme	human	196:200	arg1	carcinogen					202:211	a human carcinogen	194:211	a human carcinogen	194:211	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	9	56	theme	epitope	1584:1590	arg1	important					1600:1608	important	1600:1608	important	1600:1608	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	9	56	theme	epitope	1584:1590	arg1	group					1542:1546	The phosphate group	1528:1546	The phosphate group of the inner core trisaccharide key epitope	1528:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	9	56	theme	epitope	1584:1590	arg1	epitope					1584:1590	the inner core trisaccharide key epitope	1551:1590	the inner core trisaccharide key epitope	1551:1590	The phosphate group of the inner core trisaccharide key epitope is very important for IgG recognition.
35939326	0	57	theme	Human	150:154	arg1	Serum					156:160	Human Serum	150:160	Human Serum	150:160	Chemical Synthesis of the Highly Sterically Hindered Core Undecasaccharide of Helicobacter pylori Lipopolysaccharide for Antigenicity Evaluation with Human Serum.
35939326	2	58	contain	have	375:378	arg2	risk					387:390	a high risk	380:390	a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer	380:459	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	2	58	contain	have	375:378	arg1	individuals					339:349	The individuals	335:349	The individuals infected with H. pylori	335:373	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	3	59	theme	promising	552:560	arg1	structure					481:489	The conserved core structure	462:489	The conserved core structure of H. pylori lipopolysaccharide (LPS)	462:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	59	theme	promising	552:560	arg1	structure					572:580	a promising candidate structure	550:580	a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes	550:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	8	60	theme	glycan	1391:1396	arg1	microarrays					1398:1408	glycan microarrays	1391:1408	glycan microarrays	1391:1408	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	4	61	theme	total	674:678	arg1	synthesis					680:688	a total synthesis	672:688	a total synthesis of the core undecasaccharide of H. pylori LPS	672:734	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	7	62	theme	core	1214:1217	arg1	undecasaccharide					1219:1234	the core undecasaccharide	1210:1234	the core undecasaccharide	1210:1234	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	5	63	theme	inert	839:843	arg1	groups					854:859	the inert hydroxyl groups	835:859	the inert hydroxyl groups	835:859	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	6	64	theme	remote	986:991	arg1	participation					993:1005	acyl remote participation	981:1005	acyl remote participation	981:1005	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	1	65	theme	population	323:332	arg1	half					303:306	more than half	293:306	more than half of the world's population	293:332	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	5	66	theme	strategies	923:932	arg1	choice					891:896	a judicious choice	879:896	a judicious choice of orthogonal protection strategies and glycosylation conditions	879:961	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	4	67	theme	pylori	725:730	arg1	LPS					732:734	H. pylori LPS	722:734	H. pylori LPS	722:734	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	6	68	theme	bonds	1099:1103	arg1	formation					1058:1066	selective formation	1048:1066	selective formation of the five 1,2-cis-glucosidic bonds	1048:1103	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	5	69	theme	glycosylation	938:950	arg1	conditions					952:961	glycosylation conditions	938:961	glycosylation conditions	938:961	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	7	70	theme	carbon	1152:1157	arg1	sugars					1159:1164	the high carbon sugars	1143:1164	the high carbon sugars	1143:1164	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	2	71	theme	peptic	422:427	arg1	ulcers					429:434	peptic ulcers	422:434	peptic ulcers	422:434	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	4	72	theme	core	697:700	arg1	undecasaccharide					702:717	the core undecasaccharide	693:717	the core undecasaccharide of H. pylori LPS	693:734	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	5	73	theme	orthogonal	901:910	arg1	strategies					923:932	orthogonal protection strategies	901:932	orthogonal protection strategies	901:932	The match and mismatch between the glycosyl donor and acceptor caused by the inert hydroxyl groups were addressed by a judicious choice of orthogonal protection strategies and glycosylation conditions.
35939326	3	74	theme	vaccine	618:624	arg1	development					586:596	development	586:596	development of a glycoconjugate vaccine targeting multiple serotypes	586:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	1	75	theme	than	298:301	arg1	half					303:306	more than half	293:306	more than half of the world's population	293:332	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
35939326	7	76	dep	+	1299:1299	arg1	3					1302:1302	3	1302:1302	3	1302:1302	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	7	76	dep	+	1299:1299	arg1	1					1307:1307	1	1307:1307	1	1307:1307	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	6	77	theme	effects	1019:1025	arg1	combination					966:976	A combination	964:976	A combination of acyl remote participation and solvent effects	964:1025	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	2	78	theme	even	441:444	arg1	cancer					454:459	even gastric cancer	441:459	even gastric cancer	441:459	The individuals infected with H. pylori have a high risk to develop chronic gastritis, peptic ulcers, and even gastric cancer.
35939326	8	79	theme	IgG	1473:1475	arg1	antibodies					1477:1486	IgG antibodies	1473:1486	IgG antibodies	1473:1486	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	7	80	theme	trinacriform	1170:1181	arg1	architecture					1183:1194	trinacriform architecture	1170:1194	trinacriform architecture	1170:1194	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	7	81	theme	steric	1115:1120	arg1	hindrance					1122:1130	The high steric hindrance	1106:1130	The high steric hindrance induced by the high carbon sugars and trinacriform architecture	1106:1194	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	7	82	theme	linear	1275:1280	arg1	[2					1291:1292	a finely tuned linear assembly [2	1260:1292	a finely tuned linear assembly [2	1260:1292	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	3	83	theme	conserved	466:474	arg1	structure					481:489	The conserved core structure	462:489	The conserved core structure of H. pylori lipopolysaccharide (LPS)	462:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	83	theme	conserved	466:474	arg1	structure					572:580	a promising candidate structure	550:580	a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes	550:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	7	84	dep	[2	1291:1292	arg1	+					1299:1299	+	1299:1299	+	1299:1299	The high steric hindrance induced by the high carbon sugars and trinacriform architecture required that the core undecasaccharide was synthesized through a finely tuned linear assembly [2 + (1 + (3 + (1 + (1 + 3))))] rather than convergent strategies.
35939326	3	85	theme	multiple	636:643	arg1	serotypes					645:653	multiple serotypes	636:653	multiple serotypes	636:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	4	86	theme	subunit	744:750	arg1	antigens					752:759	its subunit antigens	740:759	its subunit antigens	740:759	Here, we report a total synthesis of the core undecasaccharide of H. pylori LPS and its subunit antigens.
35939326	6	87	theme	1,2-cis-glucosidic	1080:1097	arg1	bonds					1099:1103	the five 1,2-cis-glucosidic bonds	1071:1103	the five 1,2-cis-glucosidic bonds	1071:1103	A combination of acyl remote participation and solvent effects has been applied for selective formation of the five 1,2-cis-glucosidic bonds.
35939326	8	88	theme	pylori-infected	1502:1516	arg1	patients					1518:1525	H. pylori-infected patients	1499:1525	H. pylori-infected patients	1499:1525	An antigenicity evaluation using glycan microarrays showed that an α-(1 → 6)-glucan trisaccharide is recognized by IgG antibodies in sera of H. pylori-infected patients.
35939326	3	89	theme	H.	494:495	arg1	structure					481:489	The conserved core structure	462:489	The conserved core structure of H. pylori lipopolysaccharide (LPS)	462:527	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	3	89	theme	H.	494:495	arg1	structure					572:580	a promising candidate structure	550:580	a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes	550:653	The conserved core structure of H. pylori lipopolysaccharide (LPS) has been regarded as a promising candidate structure for development of a glycoconjugate vaccine targeting multiple serotypes.
35939326	1	90	theme	Services	251:258	arg1	Department					220:229	the Department	216:229	the Department of Health and Human Services	216:258	Helicobacter pylori, listed as a human carcinogen by the Department of Health and Human Services, colonizes the gastric mucosa of more than half of the world's population.
36903897	1	0	theme	glycoprotein	197:208	arg1	superfamily					217:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	Arabinogalactan-proteins (AGPs) are members of the hydroxyproline-rich glycoprotein (HRGP) superfamily.
36903897	0	1	theme	Suspension	105:114	arg1	Cultures					116:123	Arabidopsis Cell Suspension Cultures	88:123	Arabidopsis Cell Suspension Cultures	88:123	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	2	2	theme	side	412:415	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	6	3	dep	type	1361:1364	arg1	features					1383:1390	AG functional features	1369:1390	type II AG functional features	1361:1390	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	5	4	theme	glucuronosylation	1097:1113	arg1	level					1088:1092	a much lower level	1075:1092	a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture	1075:1173	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	3	5	theme	enhanced	592:599	arg1	protein					619:625	enhanced green fluorescent protein	592:625	enhanced green fluorescent protein	592:625	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	5	theme	enhanced	592:599	arg1	32-EGFP					583:589	(Ser-Hyp)32-EGFP	574:589	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	6	theme	green	601:605	arg1	protein					619:625	enhanced green fluorescent protein	592:625	enhanced green fluorescent protein	592:625	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	6	theme	green	601:605	arg1	32-EGFP					583:589	(Ser-Hyp)32-EGFP	574:589	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	6	7	from	presence	1215:1222	arg1	systems					1291:1297	the two systems	1283:1297	the two systems	1283:1297	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	3	8	theme	fluorescent	607:617	arg1	protein					619:625	enhanced green fluorescent protein	592:625	enhanced green fluorescent protein	592:625	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	8	theme	fluorescent	607:617	arg1	32-EGFP					583:589	(Ser-Hyp)32-EGFP	574:589	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	2	9	theme	galactan	328:335	arg1	backbone					337:344	a β-1,3-linked galactan backbone	313:344	a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	313:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	6	10	theme	glycosyl	1236:1243	arg1	transferases					1245:1256	distinct glycosyl transferases	1227:1256	distinct glycosyl transferases for AGP glycosylation	1227:1278	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	5	11	theme	Arabidopsis	1002:1012	arg1	culture					1025:1031	Arabidopsis suspension culture	1002:1031	Arabidopsis suspension culture	1002:1031	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	3	12	with	work	528:531	arg1	Hyp-O-polysaccharides					538:558	Hyp-O-polysaccharides	538:558	Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	538:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	2	13	theme	β-1,3-linked	315:326	arg1	backbone					337:344	a β-1,3-linked galactan backbone	313:344	a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	313:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	1	14	theme	HRGP	211:214	arg1	superfamily					217:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	Arabinogalactan-proteins (AGPs) are members of the hydroxyproline-rich glycoprotein (HRGP) superfamily.
36903897	3	15	attach	isolated	766:773	arg2	AGPs					761:764	AGPs	761:764	AGPs isolated from tobacco	761:786	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	15	attach	isolated	766:773	arg1	tobacco					780:786	tobacco	780:786	tobacco	780:786	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	6	16	theme	AG	1369:1370	arg1	features					1383:1390	AG functional features	1369:1390	type II AG functional features	1361:1390	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	4	17	from	presence	825:832	arg1	backbone					867:874	the galactan backbone	854:874	the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture	854:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	0	18	theme	Arabinogalactan	0:14	arg1	Structures					16:25	Arabinogalactan Structures	0:25	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule	0:73	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	4	19	theme	suspension	947:956	arg1	culture					958:964	tobacco suspension culture	939:964	tobacco suspension culture	939:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	5	20	theme	terminal-rhamnosyl	1038:1055	arg1	residues					1057:1064	terminal-rhamnosyl residues	1038:1064	terminal-rhamnosyl residues	1038:1064	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	1	21	theme	superfamily	217:227	arg1	members					162:168	members	162:168	members of the hydroxyproline-rich glycoprotein (HRGP) superfamily	162:227	Arabinogalactan-proteins (AGPs) are members of the hydroxyproline-rich glycoprotein (HRGP) superfamily.
36903897	1	21	theme	superfamily	217:227	arg1	Arabinogalactan-proteins					126:149	Arabinogalactan-proteins	126:149	Arabinogalactan-proteins (AGPs)	126:156	Arabinogalactan-proteins (AGPs) are members of the hydroxyproline-rich glycoprotein (HRGP) superfamily.
36903897	2	22	theme	fucosyl	500:506	arg1	residues					508:515	fucosyl residues	500:515	fucosyl residues	500:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	2	23	link	β-1,3-linked	315:326	arg1	backbone					337:344	a β-1,3-linked galactan backbone	313:344	a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	313:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	4	24	theme	tobacco	939:945	arg1	culture					958:964	tobacco suspension culture	939:964	tobacco suspension culture	939:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	2	25	theme	galactosyl	362:371	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	3	26	with	consistent	711:720	arg1	features					749:756	the common structural features	727:756	the common structural features of AGPs isolated from tobacco	727:786	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	0	27	theme	Repetitive	30:39	arg1	Glycomodule					63:73	Repetitive Serine-Hydroxyproline Glycomodule	30:73	Repetitive Serine-Hydroxyproline Glycomodule	30:73	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	5	28	theme	tobacco	1148:1154	arg1	culture					1167:1173	tobacco suspension culture	1148:1173	tobacco suspension culture	1148:1173	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	2	29	theme	6-O-linked	351:360	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	3	30	theme	fusion	628:633	arg1	glycoproteins					635:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins	574:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	31	theme	32-EGFP	583:589	arg1	glycoproteins					635:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins	574:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	5	32	contain	have	1070:1073	arg2	level					1088:1092	a much lower level	1075:1092	a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture	1075:1173	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	5	32	contain	have	1070:1073	arg1	AGPs					984:987	the AGPs	980:987	the AGPs expressed in Arabidopsis suspension culture	980:1031	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	0	33	theme	Glycomodule	63:73	arg1	Structures					16:25	Arabinogalactan Structures	0:25	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule	0:73	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	4	34	theme	β-1,6-linkage	837:849	arg1	presence					825:832	the presence	821:832	the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture	821:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	3	35	theme	common	731:736	arg1	features					749:756	the common structural features	727:756	the common structural features of AGPs isolated from tobacco	727:786	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	4	36	theme	AGP	901:903	arg1	glycoproteins					912:924	AGP fusion glycoproteins	901:924	AGP fusion glycoproteins expressed in tobacco suspension culture	901:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	0	37	theme	Serine-Hydroxyproline	41:61	arg1	Glycomodule					63:73	Repetitive Serine-Hydroxyproline Glycomodule	30:73	Repetitive Serine-Hydroxyproline Glycomodule	30:73	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	2	38	link	6-O-linked	351:360	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	3	39	theme	transgenic	666:675	arg1	culture					700:706	transgenic Arabidopsis suspension culture	666:706	transgenic Arabidopsis suspension culture	666:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	6	40	theme	functional	1372:1381	arg1	features					1383:1390	AG functional features	1369:1390	type II AG functional features	1361:1390	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	3	41	gly	glycoproteins	635:647	arg1	glycoproteins					635:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins	574:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	6	42	attach	presence	1215:1222	arg2	transferases					1245:1256	distinct glycosyl transferases	1227:1256	distinct glycosyl transferases for AGP glycosylation	1227:1278	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	6	42	attach	presence	1215:1222	arg1	systems					1291:1297	the two systems	1283:1297	the two systems	1283:1297	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	6	43	theme	AG	1343:1344	arg1	structures					1346:1355	minimum AG structures	1335:1355	minimum AG structures	1335:1355	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	6	44	theme	distinct	1227:1234	arg1	transferases					1245:1256	distinct glycosyl transferases	1227:1256	distinct glycosyl transferases for AGP glycosylation	1227:1278	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	2	45	theme	1,6-galactan	399:410	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	4	46	gly	glycoproteins	912:924	arg1	glycoproteins					912:924	AGP fusion glycoproteins	901:924	AGP fusion glycoproteins expressed in tobacco suspension culture	901:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	5	47	theme	suspension	1156:1165	arg1	culture					1167:1173	tobacco suspension culture	1148:1173	tobacco suspension culture	1148:1173	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	4	48	theme	fusion	905:910	arg1	glycoproteins					912:924	AGP fusion glycoproteins	901:924	AGP fusion glycoproteins expressed in tobacco suspension culture	901:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	5	49	theme	suspension	1014:1023	arg1	culture					1025:1031	Arabidopsis suspension culture	1002:1031	Arabidopsis suspension culture	1002:1031	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	6	50	theme	minimum	1335:1341	arg1	structures					1346:1355	minimum AG structures	1335:1355	minimum AG structures	1335:1355	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	4	51	attach	presence	825:832	arg2	β-1,6-linkage					837:849	β-1,6-linkage	837:849	β-1,6-linkage	837:849	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	4	51	attach	presence	825:832	arg1	backbone					867:874	the galactan backbone	854:874	the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture	854:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	3	52	theme	AGPs	761:764	arg1	features					749:756	the common structural features	727:756	the common structural features of AGPs isolated from tobacco	727:786	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	6	53	theme	structures	1346:1355	arg1	existence					1322:1330	the existence	1318:1330	the existence of minimum AG structures for type II AG functional features	1318:1390	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	6	54	theme	transferases	1245:1256	arg1	presence					1215:1222	the presence	1211:1222	the presence of distinct glycosyl transferases for AGP glycosylation in the two systems	1211:1297	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	2	55	gly	glycosylated	247:258	arg1	They					230:233	They	230:233	They	230:233	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	1	56	gly	glycoprotein	197:208	arg1	glycoprotein					197:208	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	Arabinogalactan-proteins (AGPs) are members of the hydroxyproline-rich glycoprotein (HRGP) superfamily.
36903897	3	57	theme	structural	738:747	arg1	features					749:756	the common structural features	727:756	the common structural features of AGPs isolated from tobacco	727:786	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	4	58	theme	galactan	858:865	arg1	backbone					867:874	the galactan backbone	854:874	the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture	854:964	In addition, this work confirms the presence of β-1,6-linkage on the galactan backbone identified previously in AGP fusion glycoproteins expressed in tobacco suspension culture.
36903897	3	59	attach	isolated	560:567	arg1	glycoproteins					635:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins	574:647	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	59	attach	isolated	560:567	arg2	Hyp-O-polysaccharides					538:558	Hyp-O-polysaccharides	538:558	Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	538:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	2	60	theme	oligo-1,6-galactosyl	374:393	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	6	61	theme	AGP	1262:1264	arg1	glycosylation					1266:1278	AGP glycosylation	1262:1278	AGP glycosylation	1262:1278	These differences not only suggest the presence of distinct glycosyl transferases for AGP glycosylation in the two systems, but also indicate the existence of minimum AG structures for type II AG functional features.
36903897	0	62	theme	Cell	100:103	arg1	Cultures					116:123	Arabidopsis Cell Suspension Cultures	88:123	Arabidopsis Cell Suspension Cultures	88:123	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	5	63	theme	lower	1082:1086	arg1	level					1088:1092	a much lower level	1075:1092	a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture	1075:1173	Furthermore, the AGPs expressed in Arabidopsis suspension culture lack terminal-rhamnosyl residues and have a much lower level of glucuronosylation compared with those expressed in tobacco suspension culture.
36903897	3	64	theme	Arabidopsis	677:687	arg1	culture					700:706	transgenic Arabidopsis suspension culture	666:706	transgenic Arabidopsis suspension culture	666:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	65	theme	Ser-Hyp	575:581	arg1	protein					619:625	enhanced green fluorescent protein	592:625	enhanced green fluorescent protein	592:625	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	3	65	theme	Ser-Hyp	575:581	arg1	32-EGFP					583:589	(Ser-Hyp)32-EGFP	574:589	(Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture	574:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	2	66	with	backbone	337:344	arg1	chains					417:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains	351:422	6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues	351:515	They are heavily glycosylated with arabinogalactans, which are usually composed of a β-1,3-linked galactan backbone with 6-O-linked galactosyl, oligo-1,6-galactosyl, or 1,6-galactan side chains that are further decorated with arabinosyl, glucuronosyl, rhamnosyl, and/or fucosyl residues.
36903897	0	67	theme	Arabidopsis	88:98	arg1	Cultures					116:123	Arabidopsis Cell Suspension Cultures	88:123	Arabidopsis Cell Suspension Cultures	88:123	Arabinogalactan Structures of Repetitive Serine-Hydroxyproline Glycomodule Expressed by Arabidopsis Cell Suspension Cultures.
36903897	3	68	theme	suspension	689:698	arg1	culture					700:706	transgenic Arabidopsis suspension culture	666:706	transgenic Arabidopsis suspension culture	666:706	Here, our work with Hyp-O-polysaccharides isolated from (Ser-Hyp)32-EGFP (enhanced green fluorescent protein) fusion glycoproteins overexpressed in transgenic Arabidopsis suspension culture is consistent with the common structural features of AGPs isolated from tobacco.
36903897	1	69	theme	hydroxyproline-rich	177:195	arg1	superfamily					217:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	the hydroxyproline-rich glycoprotein (HRGP) superfamily	173:227	Arabinogalactan-proteins (AGPs) are members of the hydroxyproline-rich glycoprotein (HRGP) superfamily.
35597209	0	0	theme	meningitidis	300:311	arg1	polysaccharides					271:285	capsular polysaccharides	262:285	capsular polysaccharides of Neisseria meningitidis serotype A	262:322	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	1	theme	Neisseria	290:298	arg1	meningitidis					300:311	Neisseria meningitidis serotype A	290:322	Neisseria meningitidis serotype A	290:322	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	2	dep	meningitidis	300:311	arg1	A					322:322	serotype A	313:322	Neisseria meningitidis serotype A	290:322	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	1	3	theme	trichloroacetyl	439:453	arg1	group					455:459	the trichloroacetyl group	435:459	the trichloroacetyl group	435:459	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	1	4	theme	reaction	534:541	arg1	intermediates					543:555	the reaction intermediates	530:555	the reaction intermediates	530:555	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	0	5	dep	meningitidis	140:151	arg1	serotype					153:160	serotype	153:160	Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	130:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	1	6	theme	group	455:459	arg1	introduction					419:430	The introduction	415:430	The introduction of the trichloroacetyl group into the amino group of mannosamine	415:495	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	0	7	theme	capsular	262:269	arg1	polysaccharides					271:285	capsular polysaccharides	262:285	capsular polysaccharides of Neisseria meningitidis serotype A	262:322	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	8	theme	serotype	313:320	arg1	A					322:322	serotype A	313:322	Neisseria meningitidis serotype A	290:322	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	2	9	theme	disaccharide	574:585	arg1	derivatives					608:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives	558:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives	558:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives were obtained and isolated.
35597209	0	10	theme	Solid-phase	0:10	arg1	synthesis					12:20	Solid-phase synthesis	0:20	Solid-phase synthesis	0:20	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	11	theme	N-trichloroacetyl	25:41	arg1	units					77:81	N-trichloroacetyl mannosamine 1-phosphate repeating units	25:81	N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	25:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	12	theme	N-Trichloroacetyl	165:181	arg1	analogs					183:189	N-Trichloroacetyl analogs	165:189	N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	165:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	1	13	theme	intermediates	543:555	arg1	stabilization					513:525	the stabilization	509:525	the stabilization of the reaction intermediates	509:555	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	3	14	theme	first	660:664	arg1	example					666:672	the first example	656:672	the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages	656:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	3	14	theme	first	660:664	arg1	This					648:651	This	648:651	This	648:651	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	1	15	theme	amino	470:474	arg1	mannosamine					485:495	mannosamine	485:495	mannosamine	485:495	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	1	15	theme	amino	470:474	arg1	group					476:480	the amino group	466:480	the amino group of mannosamine	466:495	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	3	16	contain	having	755:760	arg2	linkages					790:797	no less than four phosphate linkages	762:797	no less than four phosphate linkages	762:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	3	16	contain	having	755:760	arg1	structure					745:753	the N-acylated mannosamine 1-phosphate structure	706:753	the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages	706:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	0	17	theme	1-phosphate	55:65	arg1	units					77:81	N-trichloroacetyl mannosamine 1-phosphate repeating units	25:81	N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	25:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	18	theme	mannosamine	43:53	arg1	units					77:81	N-trichloroacetyl mannosamine 1-phosphate repeating units	25:81	N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	25:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	19	theme	solid-phase	356:366	arg1	synthesis					368:376	solid-phase synthesis	356:376	solid-phase synthesis using an oxazaphospholidine monomer	356:412	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	20	theme	units	77:81	arg1	synthesis					12:20	Solid-phase synthesis	0:20	Solid-phase synthesis	0:20	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	21	theme	1-phosphate	214:224	arg1	analogs					183:189	N-Trichloroacetyl analogs	165:189	N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	165:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	1	22	theme	mannosamine	485:495	arg1	mannosamine					485:495	mannosamine	485:495	mannosamine	485:495	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	1	22	theme	mannosamine	485:495	arg1	group					476:480	the amino group	466:480	the amino group of mannosamine	466:495	The introduction of the trichloroacetyl group into the amino group of mannosamine resulted in the stabilization of the reaction intermediates.
35597209	0	23	theme	repeating	67:75	arg1	units					77:81	N-trichloroacetyl mannosamine 1-phosphate repeating units	25:81	N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	25:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	24	theme	N-acetylmannosamine	194:212	arg1	1-phosphate					214:224	N-acetylmannosamine 1-phosphate	194:224	N-acetylmannosamine 1-phosphate repeating units	194:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	3	25	theme	1-phosphate	733:743	arg1	structure					745:753	the N-acylated mannosamine 1-phosphate structure	706:753	the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages	706:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	0	26	attach	derived	117:123	arg1	meningitidis					140:151	Neisseria meningitidis	130:151	Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	130:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	26	attach	derived	117:123	arg2	polysaccharide					102:115	capsular polysaccharide	93:115	capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	93:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	3	27	theme	structure	745:753	arg1	synthesis					693:701	the synthesis	689:701	the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages	689:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	0	28	theme	oxazaphospholidine	387:404	arg1	monomer					406:412	an oxazaphospholidine monomer	384:412	an oxazaphospholidine monomer	384:412	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	2	29	theme	tetrasaccharide	592:606	arg1	derivatives					608:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives	558:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives	558:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives were obtained and isolated.
35597209	0	30	theme	capsular	93:100	arg1	polysaccharide					102:115	capsular polysaccharide	93:115	capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units	93:240	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	3	31	theme	phosphate	780:788	arg1	linkages					790:797	no less than four phosphate linkages	762:797	no less than four phosphate linkages	762:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	3	32	theme	N-acylated	710:719	arg1	structure					745:753	the N-acylated mannosamine 1-phosphate structure	706:753	the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages	706:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	0	33	located	found	253:257	arg1	polysaccharides					271:285	capsular polysaccharides	262:285	capsular polysaccharides of Neisseria meningitidis serotype A	262:322	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	0	33	located	found	253:257	arg2	synthesis					12:20	Solid-phase synthesis	0:20	Solid-phase synthesis	0:20	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
35597209	2	34	theme	Monosaccharide	558:571	arg1	derivatives					608:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives	558:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives	558:618	Monosaccharide, disaccharide, and tetrasaccharide derivatives were obtained and isolated.
35597209	3	35	theme	mannosamine	721:731	arg1	structure					745:753	the N-acylated mannosamine 1-phosphate structure	706:753	the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages	706:797	This is the first example to demonstrate the synthesis of the N-acylated mannosamine 1-phosphate structure having no less than four phosphate linkages.
35597209	0	36	dep	analogs	183:189	arg1	A.					162:163	A.	162:163	A.	162:163	Solid-phase synthesis of N-trichloroacetyl mannosamine 1-phosphate repeating units mimicking capsular polysaccharide derived from Neisseria meningitidis serotype A. N-Trichloroacetyl analogs of N-acetylmannosamine 1-phosphate repeating units, which are found in capsular polysaccharides of Neisseria meningitidis serotype A, were successfully obtained via solid-phase synthesis using an oxazaphospholidine monomer.
36461247	0	0	theme	skin	101:104	arg1	walls					111:115	blueberry skin cell walls	91:115	blueberry skin cell walls	91:115	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	2	1	theme	comprehensive	523:535	arg1	CoMPP					567:571	CoMPP	567:571	CoMPP	567:571	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	1	theme	comprehensive	523:535	arg1	profiling					556:564	comprehensive microarray polymer profiling	523:564	comprehensive microarray polymer profiling (CoMPP)	523:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	5	2	theme	soluble	826:832	arg1	fraction					834:841	the KOH soluble fraction	818:841	the KOH soluble fraction	818:841	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	4	3	theme	dominant	756:763	arg1	fraction					742:749	the KOH soluble fraction	726:749	the KOH soluble fraction	726:749	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	4	3	theme	dominant	756:763	arg1	fraction					765:772	a dominant fraction	754:772	a dominant fraction in fermented blueberry skin	754:800	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	0	4	theme	blueberry	91:99	arg1	walls					111:115	blueberry skin cell walls	91:115	blueberry skin cell walls	91:115	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	1	5	theme	rare	174:177	arg1	reports					179:185	rare reports	174:185	rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production	174:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	6	6	dep	substances	1102:1111	arg1	such					1114:1117	such	1114:1117	such	1114:1117	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	3	7	theme	cross-corroborating	579:597	arg1	data					599:602	The cross-corroborating data	575:602	The cross-corroborating data	575:602	The cross-corroborating data revealed that blueberry skin cell wall is particularly rich in xyloglucan.
36461247	6	8	theme	beneficial	1091:1100	arg1	substances					1102:1111	extract beneficial substances	1083:1111	extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing	1083:1190	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	0	9	theme	cell	106:109	arg1	walls					111:115	blueberry skin cell walls	91:115	blueberry skin cell walls	91:115	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	4	10	theme	Chemical	679:686	arg1	analysis					702:709	Chemical fractionation analysis	679:709	Chemical fractionation analysis	679:709	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	3	11	from	rich	659:662	arg1	xyloglucan					667:676	xyloglucan	667:676	xyloglucan	667:676	The cross-corroborating data revealed that blueberry skin cell wall is particularly rich in xyloglucan.
36461247	1	12	theme	wine	291:294	arg1	production					296:305	wine production	291:305	wine production	291:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	0	13	from	changes	61:67	arg1	walls					111:115	blueberry skin cell walls	91:115	blueberry skin cell walls	91:115	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	2	14	theme	wall	435:438	arg1	techniques					449:458	cell wall analysis techniques	430:458	cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP)	430:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	14	theme	wall	435:438	arg1	spectroscopy					480:491	infra-red spectroscopy	470:491	infra-red spectroscopy	470:491	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	14	theme	wall	435:438	arg1	analysis					509:516	monosaccharide analysis	494:516	monosaccharide analysis	494:516	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	14	theme	wall	435:438	arg1	profiling					556:564	comprehensive microarray polymer profiling	523:564	comprehensive microarray polymer profiling (CoMPP)	523:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	5	15	theme	enzyme-resistant	942:957	arg1	polymers					966:973	some enzyme-resistant pectin polymers	937:973	some enzyme-resistant pectin polymers	937:973	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	6	16	theme	extract	1083:1089	arg1	substances					1102:1111	extract beneficial substances	1083:1111	extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing	1083:1190	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	6	17	theme	strategies	1069:1078	arg1	development					1044:1054	the development	1040:1054	the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing	1040:1190	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	2	18	theme	infra-red	470:478	arg1	spectroscopy					480:491	infra-red spectroscopy	470:491	infra-red spectroscopy	470:491	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	3	19	from	xyloglucan	667:676	arg1	rich					659:662	rich	659:662	rich	659:662	The cross-corroborating data revealed that blueberry skin cell wall is particularly rich in xyloglucan.
36461247	5	20	theme	KOH	822:824	arg1	fraction					834:841	the KOH soluble fraction	818:841	the KOH soluble fraction	818:841	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	2	21	theme	compositional	327:339	arg1	changes					341:347	the compositional changes	323:347	the compositional changes occurring in blueberry skin during fermentation	323:395	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	6	22	theme	berry	1160:1164	arg1	tissues					1166:1172	berry tissues	1160:1172	berry tissues	1160:1172	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	4	23	theme	soluble	734:740	arg1	fraction					742:749	the KOH soluble fraction	726:749	the KOH soluble fraction	726:749	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	4	23	theme	soluble	734:740	arg1	fraction					765:772	a dominant fraction	754:772	a dominant fraction in fermented blueberry skin	754:800	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	0	24	theme	Combined	0:7	arg1	high-throughput					9:23	Combined high-throughput and fractionation approaches	0:52	high-throughput	9:23	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	3	25	theme	skin	628:631	arg1	wall					638:641	blueberry skin cell wall	618:641	blueberry skin cell wall	618:641	The cross-corroborating data revealed that blueberry skin cell wall is particularly rich in xyloglucan.
36461247	4	26	theme	KOH	730:732	arg1	fraction					742:749	the KOH soluble fraction	726:749	the KOH soluble fraction	726:749	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	4	26	theme	KOH	730:732	arg1	fraction					765:772	a dominant fraction	754:772	a dominant fraction in fermented blueberry skin	754:800	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	0	27	theme	fractionation	29:41	arg1	approaches					43:52	Combined high-throughput and fractionation approaches	0:52	approaches	43:52	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	5	28	theme	pectin	887:892	arg1	chains					901:906	pectin branch chains	887:906	pectin branch chains	887:906	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	0	29	theme	wine	141:144	arg1	production					146:155	wine production	141:155	wine production	141:155	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	6	30	from	tissues	1166:1172	arg1	substances					1102:1111	extract beneficial substances	1083:1111	extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing	1083:1190	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	2	31	theme	analysis	440:447	arg1	techniques					449:458	cell wall analysis techniques	430:458	cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP)	430:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	31	theme	analysis	440:447	arg1	spectroscopy					480:491	infra-red spectroscopy	470:491	infra-red spectroscopy	470:491	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	31	theme	analysis	440:447	arg1	analysis					509:516	monosaccharide analysis	494:516	monosaccharide analysis	494:516	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	31	theme	analysis	440:447	arg1	profiling					556:564	comprehensive microarray polymer profiling	523:564	comprehensive microarray polymer profiling (CoMPP)	523:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	32	theme	techniques	449:458	arg1	combination					415:425	a combination	413:425	a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP)	413:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	6	33	theme	effective	1059:1067	arg1	strategies					1069:1078	effective strategies	1059:1078	effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing	1059:1190	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	1	34	theme	polymers	222:229	arg1	structure/composition					197:217	the structure/composition	193:217	the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production	193:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	5	35	theme	tight	920:924	arg1	binding					926:932	tight binding	920:932	tight binding of some enzyme-resistant pectin polymers to hemicellulose	920:990	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	5	36	theme	pectin	959:964	arg1	polymers					966:973	some enzyme-resistant pectin polymers	937:973	some enzyme-resistant pectin polymers	937:973	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	2	37	theme	cell	430:433	arg1	techniques					449:458	cell wall analysis techniques	430:458	cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP)	430:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	37	theme	cell	430:433	arg1	spectroscopy					480:491	infra-red spectroscopy	470:491	infra-red spectroscopy	470:491	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	37	theme	cell	430:433	arg1	analysis					509:516	monosaccharide analysis	494:516	monosaccharide analysis	494:516	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	37	theme	cell	430:433	arg1	profiling					556:564	comprehensive microarray polymer profiling	523:564	comprehensive microarray polymer profiling (CoMPP)	523:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	5	38	theme	abundant	853:860	arg1	epitopes					862:869	abundant epitopes	853:869	abundant epitopes associated with pectin branch chains	853:906	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	5	39	theme	branch	894:899	arg1	chains					901:906	pectin branch chains	887:906	pectin branch chains	887:906	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	1	40	theme	blueberry	234:242	arg1	skin					244:247	blueberry skin	234:247	blueberry skin	234:247	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	2	41	theme	monosaccharide	494:507	arg1	analysis					509:516	monosaccharide analysis	494:516	monosaccharide analysis	494:516	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	0	42	theme	polysaccharides	72:86	arg1	changes					61:67	changes	61:67	changes of polysaccharides in blueberry skin cell walls	61:115	Combined high-throughput and fractionation approaches reveal changes of polysaccharides in blueberry skin cell walls during fermentation for wine production.
36461247	3	43	theme	cell	633:636	arg1	wall					638:641	blueberry skin cell wall	618:641	blueberry skin cell wall	618:641	The cross-corroborating data revealed that blueberry skin cell wall is particularly rich in xyloglucan.
36461247	2	44	theme	blueberry	362:370	arg1	skin					372:375	blueberry skin	362:375	blueberry skin	362:375	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	1	45	from	changes	259:265	arg1	structure/composition					197:217	the structure/composition	193:217	the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production	193:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	3	46	theme	blueberry	618:626	arg1	wall					638:641	blueberry skin cell wall	618:641	blueberry skin cell wall	618:641	The cross-corroborating data revealed that blueberry skin cell wall is particularly rich in xyloglucan.
36461247	1	47	from	skin	244:247	arg1	structure/composition					197:217	the structure/composition	193:217	the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production	193:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	1	48	from	polymers	222:229	arg1	skin					244:247	blueberry skin	234:247	blueberry skin	234:247	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	1	48	from	polymers	222:229	arg1	changes					259:265	their changes	253:265	their changes during fermentation for wine production	253:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	4	49	theme	blueberry	787:795	arg1	skin					797:800	fermented blueberry skin	777:800	fermented blueberry skin	777:800	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	4	50	theme	fermented	777:785	arg1	skin					797:800	fermented blueberry skin	777:800	fermented blueberry skin	777:800	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	2	51	theme	polymer	548:554	arg1	CoMPP					567:571	CoMPP	567:571	CoMPP	567:571	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	51	theme	polymer	548:554	arg1	profiling					556:564	comprehensive microarray polymer profiling	523:564	comprehensive microarray polymer profiling (CoMPP)	523:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	5	52	contain	contained	843:851	arg2	epitopes					862:869	abundant epitopes	853:869	abundant epitopes associated with pectin branch chains	853:906	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	5	52	contain	contained	843:851	arg1	fraction					834:841	the KOH soluble fraction	818:841	the KOH soluble fraction	818:841	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	1	53	from	structure/composition	197:217	arg1	skin					244:247	blueberry skin	234:247	blueberry skin	234:247	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	1	53	from	structure/composition	197:217	arg1	changes					259:265	their changes	253:265	their changes during fermentation for wine production	253:305	There have been rare reports about the structure/composition of polymers in blueberry skin and their changes during fermentation for wine production.
36461247	5	54	theme	polymers	966:973	arg1	binding					926:932	tight binding	920:932	tight binding of some enzyme-resistant pectin polymers to hemicellulose	920:990	Interestingly, the KOH soluble fraction contained abundant epitopes associated with pectin branch chains, indicating tight binding of some enzyme-resistant pectin polymers to hemicellulose.
36461247	4	55	from	fraction	765:772	arg1	skin					797:800	fermented blueberry skin	777:800	fermented blueberry skin	777:800	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
36461247	2	56	theme	microarray	537:546	arg1	CoMPP					567:571	CoMPP	567:571	CoMPP	567:571	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	2	56	theme	microarray	537:546	arg1	profiling					556:564	comprehensive microarray polymer profiling	523:564	comprehensive microarray polymer profiling (CoMPP)	523:572	In this study, the compositional changes occurring in blueberry skin during fermentation were tracked by a combination of cell wall analysis techniques including infra-red spectroscopy, monosaccharide analysis, and comprehensive microarray polymer profiling (CoMPP).
36461247	6	57	theme	important	1013:1021	arg1	implications					1023:1034	important implications	1013:1034	important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing	1013:1190	This study provides important implications for the development of effective strategies to extract beneficial substances (such as aromatics, tannins and pigments) from berry tissues during processing.
36461247	4	58	theme	fractionation	688:700	arg1	analysis					702:709	Chemical fractionation analysis	679:709	Chemical fractionation analysis	679:709	Chemical fractionation analysis indicated that the KOH soluble fraction is a dominant fraction in fermented blueberry skin.
37085078	0	0	theme	wall	92:95	arg1	polysaccharide					97:110	cell wall polysaccharide	87:110	cell wall polysaccharide from Kluyveromyces marxianus	87:139	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	1	from	characterization	20:35	arg1	marxianus					131:139	Kluyveromyces marxianus	117:139	Kluyveromyces marxianus	117:139	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	8	2	theme	amino	1530:1534	arg1	acid					1536:1539	amino acid	1530:1539	amino acid	1530:1539	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	0	3	theme	cell	87:90	arg1	polysaccharide					97:110	cell wall polysaccharide	87:110	cell wall polysaccharide from Kluyveromyces marxianus	87:139	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	6	4	theme	intestine	1214:1222	arg1	Bacteroidetes					1224:1236	intestine Bacteroidetes	1214:1236	intestine Bacteroidetes	1214:1236	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	1	5	dep	marxianus	236:244	arg1	MC-MPS					255:260	MC-MPS	255:260	MC-MPS	255:260	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	1	5	dep	marxianus	236:244	arg1	G-MPS					267:271	G-MPS	267:271	G-MPS	267:271	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	1	5	dep	marxianus	236:244	arg1	LZ-MPS					247:252	LZ-MPS	247:252	LZ-MPS	247:252	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	1	6	theme	yeast	176:180	arg1	MPS					193:195	MPS	193:195	MPS	193:195	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	1	6	theme	yeast	176:180	arg1	α-mannans					182:190	the three yeast α-mannans	166:190	the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS)	166:272	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	4	7	theme	human	764:768	arg1	microbiota					774:783	human gut microbiota	764:783	human gut microbiota	764:783	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	2	8	dep	characterization	347:362	arg1	the					323:325	the	323:325	the	323:325	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	4	9	theme	molecular	642:650	arg1	weight					652:657	the molecular weight	638:657	the molecular weight	638:657	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	0	10	theme	polysaccharide	97:110	arg1	characterization					20:35	Advanced structural characterization	0:35	Advanced structural characterization	0:35	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	10	theme	polysaccharide	97:110	arg1	properties					73:82	in vitro fermentation prebiotic properties	41:82	in vitro fermentation prebiotic properties	41:82	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	8	11	theme	human	1440:1444	arg1	microbiota					1450:1459	the human gut microbiota	1436:1459	the human gut microbiota	1436:1459	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	3	12	theme	MPS	533:535	arg1	molecules					510:518	the polysaccharide molecules	491:518	the polysaccharide molecules of the three MPS	491:535	According to the results of this study, the polysaccharide molecules of the three MPS were aggregated in solution, supporting their branched chain structure.
37085078	5	13	theme	acids	839:843	arg1	Meanwhile					786:794	Meanwhile	786:794	Meanwhile	786:794	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	13	theme	acids	839:843	arg1	production					801:810	the production	797:810	the production of total short-chain fatty acids (SCFAs) of the three MPS	797:868	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	4	14	theme	fermentation	669:680	arg1	pH					663:664	pH	663:664	pH	663:664	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	4	14	theme	fermentation	669:680	arg1	weight					652:657	the molecular weight	638:657	the molecular weight	638:657	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	6	15	theme	microbiota	1058:1067	arg1	composition					1033:1043	the composition	1029:1043	the composition of human gut microbiota	1029:1067	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	5	16	theme	total	815:819	arg1	SCFAs					846:850	SCFAs	846:850	SCFAs	846:850	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	16	theme	total	815:819	arg1	acids					839:843	total short-chain fatty acids	815:843	total short-chain fatty acids (SCFAs) of the three MPS	815:868	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	4	17	theme	in	615:616	arg1	fermentation					624:635	in vitro fermentation	615:635	in vitro fermentation	615:635	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	2	18	theme	fecal	387:391	arg1	behavior					406:413	the in vitro human fecal fermentation behavior	368:413	the in vitro human fecal fermentation behavior	368:413	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	5	19	theme	MPS	866:868	arg1	SCFAs					846:850	SCFAs	846:850	SCFAs	846:850	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	19	theme	MPS	866:868	arg1	acids					839:843	total short-chain fatty acids	815:843	total short-chain fatty acids (SCFAs) of the three MPS	815:868	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	6	20	theme	human	1048:1052	arg1	microbiota					1058:1067	human gut microbiota	1048:1067	human gut microbiota	1048:1067	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	2	21	theme	human	381:385	arg1	behavior					406:413	the in vitro human fecal fermentation behavior	368:413	the in vitro human fecal fermentation behavior	368:413	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	0	22	theme	structural	9:18	arg1	characterization					20:35	Advanced structural characterization	0:35	Advanced structural characterization	0:35	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	8	23	theme	gut	1446:1448	arg1	microbiota					1450:1459	the human gut microbiota	1436:1459	the human gut microbiota	1436:1459	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	7	24	theme	metabolism	1251:1260	arg1	terms					1242:1246	terms	1242:1246	terms of metabolism	1242:1260	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	0	25	theme	Advanced	0:7	arg1	characterization					20:35	Advanced structural characterization	0:35	Advanced structural characterization	0:35	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	6	26	theme	MPS	1175:1177	arg1	bioactivities					1148:1160	the bioactivities	1144:1160	the bioactivities of the three MPS	1144:1177	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	7	27	theme	glycan	1331:1336	arg1	biosynthesis					1338:1349	glycan biosynthesis	1331:1349	glycan biosynthesis	1331:1349	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	2	28	theme	in	372:373	arg1	behavior					406:413	the in vitro human fecal fermentation behavior	368:413	the in vitro human fecal fermentation behavior	368:413	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	2	29	theme	MPS	428:430	arg1	characterization					347:362	advanced structural characterization	327:362	advanced structural characterization	327:362	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	2	29	theme	MPS	428:430	arg1	behavior					406:413	the in vitro human fecal fermentation behavior	368:413	the in vitro human fecal fermentation behavior	368:413	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	4	30	dep	in	615:616	arg1	vitro					618:622	vitro	618:622	vitro	618:622	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	5	31	theme	propionic	913:921	arg1	acid					923:926	propionic acid	913:926	propionic acid	913:926	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	32	theme	acid	923:926	arg1	45.55					932:936	45.55	932:936	45.55	932:936	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	32	theme	acid	923:926	arg1	production					899:908	the production	895:908	the production of propionic acid	895:926	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	6	33	theme	Bacteroidetes	1113:1125	arg1	proliferation					1096:1108	the proliferation	1092:1108	the proliferation of Bacteroidetes	1092:1125	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	2	34	theme	structural	336:345	arg1	characterization					347:362	advanced structural characterization	327:362	advanced structural characterization	327:362	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	1	35	theme	various	203:209	arg1	sources					211:217	various sources	203:217	various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS)	203:272	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	6	36	theme	gut	1054:1056	arg1	microbiota					1058:1067	human gut microbiota	1048:1067	human gut microbiota	1048:1067	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	8	37	from	metabolisms	1503:1513	arg1	glycan					1545:1550	glycan	1545:1550	glycan	1545:1550	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	8	37	from	metabolisms	1503:1513	arg1	acid					1536:1539	amino acid	1530:1539	amino acid	1530:1539	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	7	38	theme	amino	1304:1308	arg1	metabolism					1315:1324	amino acid metabolism	1304:1324	amino acid metabolism	1304:1324	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	5	39	theme	short-chain	821:831	arg1	SCFAs					846:850	SCFAs	846:850	SCFAs	846:850	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	39	theme	short-chain	821:831	arg1	acids					839:843	total short-chain fatty acids	815:843	total short-chain fatty acids (SCFAs) of the three MPS	815:868	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	0	40	theme	in	41:42	arg1	properties					73:82	in vitro fermentation prebiotic properties	41:82	in vitro fermentation prebiotic properties	41:82	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	8	41	theme	SCFAs	1484:1488	arg1	level					1475:1479	the level	1471:1479	the level of SCFAs	1471:1488	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	3	42	theme	branched	583:590	arg1	structure					598:606	their branched chain structure	577:606	their branched chain structure	577:606	According to the results of this study, the polysaccharide molecules of the three MPS were aggregated in solution, supporting their branched chain structure.
37085078	1	43	from	sources	211:217	arg1	MPS					193:195	MPS	193:195	MPS	193:195	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	1	43	from	sources	211:217	arg1	α-mannans					182:190	the three yeast α-mannans	166:190	the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS)	166:272	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	2	44	theme	fermentation	393:404	arg1	behavior					406:413	the in vitro human fecal fermentation behavior	368:413	the in vitro human fecal fermentation behavior	368:413	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	0	45	theme	prebiotic	63:71	arg1	properties					73:82	in vitro fermentation prebiotic properties	41:82	in vitro fermentation prebiotic properties	41:82	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	46	from	properties	73:82	arg1	marxianus					131:139	Kluyveromyces marxianus	117:139	Kluyveromyces marxianus	117:139	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	6	47	contain	have	1003:1006	arg2	ability					1012:1018	the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes	1008:1125	the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes	1008:1125	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	6	47	contain	have	1003:1006	arg1	MPS					999:1001	the three MPS	989:1001	the three MPS	989:1001	In particular, the three MPS have the ability to alter the composition of human gut microbiota, especially to promote the proliferation of Bacteroidetes, suggesting that the bioactivities of the three MPS can be significantly influenced by intestine Bacteroidetes.
37085078	7	48	theme	bacteria	1369:1376	arg1	cofactors					1283:1291	cofactors	1283:1291	cofactors	1283:1291	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	7	48	theme	bacteria	1369:1376	arg1	metabolism					1315:1324	amino acid metabolism	1304:1324	amino acid metabolism	1304:1324	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	7	48	theme	bacteria	1369:1376	arg1	metabolism					1355:1364	metabolism	1355:1364	metabolism	1355:1364	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	7	48	theme	bacteria	1369:1376	arg1	biosynthesis					1338:1349	glycan biosynthesis	1331:1349	glycan biosynthesis	1331:1349	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	7	48	theme	bacteria	1369:1376	arg1	vitamins					1294:1301	vitamins	1294:1301	vitamins	1294:1301	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	2	49	theme	advanced	327:334	arg1	characterization					347:362	advanced structural characterization	327:362	advanced structural characterization	327:362	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	0	50	theme	fermentation	50:61	arg1	properties					73:82	in vitro fermentation prebiotic properties	41:82	in vitro fermentation prebiotic properties	41:82	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	51	from	marxianus	131:139	arg1	characterization					20:35	Advanced structural characterization	0:35	Advanced structural characterization	0:35	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	51	from	marxianus	131:139	arg1	properties					73:82	in vitro fermentation prebiotic properties	41:82	in vitro fermentation prebiotic properties	41:82	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	51	from	marxianus	131:139	arg1	polysaccharide					97:110	cell wall polysaccharide	87:110	cell wall polysaccharide from Kluyveromyces marxianus	87:139	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	0	52	dep	in	41:42	arg1	vitro					44:48	vitro	44:48	vitro	44:48	Advanced structural characterization and in vitro fermentation prebiotic properties of cell wall polysaccharide from Kluyveromyces marxianus.
37085078	3	53	theme	study	484:488	arg1	results					468:474	the results	464:474	the results of this study	464:488	According to the results of this study, the polysaccharide molecules of the three MPS were aggregated in solution, supporting their branched chain structure.
37085078	4	54	used	utilized	752:759	arg2	MPS					739:741	the three MPS	729:741	the three MPS	729:741	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	4	55	theme	gut	770:772	arg1	microbiota					774:783	human gut microbiota	764:783	human gut microbiota	764:783	After in vitro fermentation, the molecular weight and pH of fermentation broth decreased significantly, indicating that the three MPS could be utilized by human gut microbiota.
37085078	7	56	theme	acid	1310:1313	arg1	metabolism					1315:1324	amino acid metabolism	1304:1324	amino acid metabolism	1304:1324	In terms of metabolism, all MPS can promote cofactors, vitamins, amino acid metabolism, and glycan biosynthesis and metabolism of bacteria.
37085078	1	57	theme	previous	150:157	arg1	study					159:163	previous study	150:163	previous study	150:163	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	2	58	dep	in	372:373	arg1	vitro					375:379	vitro	375:379	vitro	375:379	In this study, the advanced structural characterization and the in vitro human fecal fermentation behavior of the three MPS were investigated.
37085078	1	59	theme	marxianus	236:244	arg1	sources					211:217	various sources	203:217	various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS)	203:272	Through previous study, the three yeast α-mannans (MPS) from various sources of Kluyveromyces marxianus (LZ-MPS, MC-MPS, and G-MPS) were preliminarily characterized.
37085078	5	60	theme	fatty	833:837	arg1	SCFAs					846:850	SCFAs	846:850	SCFAs	846:850	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	5	60	theme	fatty	833:837	arg1	acids					839:843	total short-chain fatty acids	815:843	total short-chain fatty acids (SCFAs) of the three MPS	815:868	Meanwhile, the production of total short-chain fatty acids (SCFAs) of the three MPS was promoted, especially the production of propionic acid was 45.55, 38.23, and 38.87 mM, respectively.
37085078	3	61	theme	chain	592:596	arg1	structure					598:606	their branched chain structure	577:606	their branched chain structure	577:606	According to the results of this study, the polysaccharide molecules of the three MPS were aggregated in solution, supporting their branched chain structure.
37085078	3	62	theme	polysaccharide	495:508	arg1	molecules					510:518	the polysaccharide molecules	491:518	the polysaccharide molecules of the three MPS	491:535	According to the results of this study, the polysaccharide molecules of the three MPS were aggregated in solution, supporting their branched chain structure.
37085078	8	63	theme	bacteria	1518:1525	arg1	metabolisms					1503:1513	the metabolisms	1499:1513	the metabolisms of bacteria on amino acid and glycan	1499:1550	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
37085078	8	64	theme	intestinal	1569:1578	arg1	health					1580:1585	the intestinal health	1565:1585	the intestinal health	1565:1585	In consequence, the three MPS were confirmed to regulate the human gut microbiota, increase the level of SCFAs, promote the metabolisms of bacteria on amino acid and glycan, and improve the intestinal health.
36436850	1	0	theme	polysaccharides	332:346	arg1	network					348:354	the polysaccharides network	328:354	the polysaccharides network of plant cell walls	328:374	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	4	1	theme	structure	729:737	arg1	changes					696:702	The changes	692:702	The changes of cellulose crystalline structure and assembly pattern of cellulose	692:771	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	1	2	theme	hemicelluloses	152:165	arg1	contributions					135:147	the contributions	131:147	the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks	131:229	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	2	3	theme	cellulose	493:501	arg1	crystallization					474:488	the crystallization	470:488	the crystallization of cellulose	470:501	Both polysaccharides could induce the change of diameters of cellulose ribbons and influence the crystallization of cellulose.
36436850	5	4	theme	profound	910:917	arg1	insight					919:925	a profound insight	908:925	a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials	908:1087	The results provide a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials.
36436850	3	5	theme	X-ray	525:529	arg1	SAXS					543:546	SAXS	543:546	SAXS	543:546	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	3	5	theme	X-ray	525:529	arg1	scattering					531:540	small-angle X-ray scattering	513:540	small-angle X-ray scattering (SAXS)	513:547	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	0	6	theme	networks	101:108	arg1	properties					77:86	mechanical properties	66:86	mechanical properties	66:86	Insights into the contributions of hemicelluloses to assembly and mechanical properties of cellulose networks.
36436850	0	6	theme	networks	101:108	arg1	assembly					53:60	assembly	53:60	assembly	53:60	Insights into the contributions of hemicelluloses to assembly and mechanical properties of cellulose networks.
36436850	4	7	theme	tensile	798:804	arg1	strength					806:813	lower tensile strength	792:813	lower tensile strength	792:813	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	0	8	theme	cellulose	91:99	arg1	networks					101:108	cellulose networks	91:108	cellulose networks	91:108	Insights into the contributions of hemicelluloses to assembly and mechanical properties of cellulose networks.
36436850	1	9	theme	plant	359:363	arg1	walls					370:374	plant cell walls	359:374	plant cell walls	359:374	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	4	10	theme	lower	792:796	arg1	strength					806:813	lower tensile strength	792:813	lower tensile strength	792:813	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	3	11	theme	small-angle	513:523	arg1	SAXS					543:546	SAXS	543:546	SAXS	543:546	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	3	11	theme	small-angle	513:523	arg1	scattering					531:540	small-angle X-ray scattering	513:540	small-angle X-ray scattering (SAXS)	513:547	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	1	12	theme	cell	365:368	arg1	walls					370:374	plant cell walls	359:374	plant cell walls	359:374	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	1	13	theme	walls	370:374	arg1	network					348:354	the polysaccharides network	328:354	the polysaccharides network of plant cell walls	328:374	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	1	14	contain	containing	272:281	arg2	glucomannan					293:303	glucomannan	293:303	glucomannan	293:303	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	1	14	contain	containing	272:281	arg2	xylan					283:287	xylan	283:287	xylan	283:287	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	1	14	contain	containing	272:281	arg1	composites					261:270	the bacterial cellulose (BC) composites	232:270	the bacterial cellulose (BC) composites containing xylan and glucomannan	232:303	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	2	15	theme	ribbons	448:454	arg1	diameters					425:433	diameters	425:433	diameters of cellulose ribbons	425:454	Both polysaccharides could induce the change of diameters of cellulose ribbons and influence the crystallization of cellulose.
36436850	4	16	theme	cellulose	763:771	arg1	structure					729:737	cellulose crystalline structure	707:737	cellulose crystalline structure	707:737	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	16	theme	cellulose	763:771	arg1	pattern					752:758	assembly pattern	743:758	assembly pattern of cellulose	743:771	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	1	17	theme	mechanical	187:196	arg1	properties					198:207	mechanical properties	187:207	mechanical properties	187:207	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	2	18	theme	cellulose	438:446	arg1	ribbons					448:454	cellulose ribbons	438:454	cellulose ribbons	438:454	Both polysaccharides could induce the change of diameters of cellulose ribbons and influence the crystallization of cellulose.
36436850	3	19	theme	microfibrils	599:610	arg1	assembly					587:594	the assembly	583:594	the assembly of microfibrils into cellulose ribbons	583:633	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	5	20	theme	networks	982:989	arg1	relationships					955:967	the structure-property relationships	932:967	the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials	932:1087	The results provide a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials.
36436850	2	21	theme	diameters	425:433	arg1	change					415:420	the change	411:420	the change of diameters of cellulose ribbons	411:454	Both polysaccharides could induce the change of diameters of cellulose ribbons and influence the crystallization of cellulose.
36436850	5	22	theme	cellulose	972:980	arg1	networks					982:989	cellulose networks	972:989	cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials	972:1087	The results provide a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials.
36436850	4	23	theme	crystalline	717:727	arg1	structure					729:737	cellulose crystalline structure	707:737	cellulose crystalline structure	707:737	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	0	24	theme	hemicelluloses	35:48	arg1	contributions					18:30	the contributions	14:30	the contributions of hemicelluloses to assembly and mechanical properties of cellulose networks	14:108	Insights into the contributions of hemicelluloses to assembly and mechanical properties of cellulose networks.
36436850	5	25	theme	biomaterials	1076:1087	arg1	development					1051:1061	the development	1047:1061	the development of cellulose biomaterials	1047:1087	The results provide a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials.
36436850	1	26	theme	cellulose	212:220	arg1	networks					222:229	cellulose networks	212:229	cellulose networks	212:229	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	3	27	theme	cellulose	617:625	arg1	ribbons					627:633	cellulose ribbons	617:633	cellulose ribbons	617:633	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	1	28	theme	networks	222:229	arg1	assembly					174:181	assembly	174:181	assembly	174:181	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	1	28	theme	networks	222:229	arg1	properties					198:207	mechanical properties	187:207	mechanical properties	187:207	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	4	29	theme	BC	849:850	arg1	composites					852:861	the BC composites	845:861	the BC composites	845:861	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	30	theme	composites	852:861	arg1	break					836:840	higher strain at break	819:840	higher strain at break	819:840	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	30	theme	composites	852:861	arg1	strength					806:813	lower tensile strength	792:813	lower tensile strength	792:813	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	31	theme	assembly	743:750	arg1	pattern					752:758	assembly pattern	743:758	assembly pattern of cellulose	743:771	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	5	32	theme	cellulose	1066:1074	arg1	biomaterials					1076:1087	cellulose biomaterials	1066:1087	cellulose biomaterials	1066:1087	The results provide a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials.
36436850	1	33	dep	assembly	174:181	arg1	the					170:172	the	170:172	the	170:172	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	4	34	theme	strain	826:831	arg1	break					836:840	higher strain at break	819:840	higher strain at break	819:840	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	5	35	theme	structure-property	936:953	arg1	relationships					955:967	the structure-property relationships	932:967	the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials	932:1087	The results provide a profound insight into the structure-property relationships of cellulose networks affected by hemicelluloses, which could be conducive to the development of cellulose biomaterials.
36436850	3	36	theme	microfibrils	678:689	arg1	packing					667:673	the packing	663:673	the packing of microfibrils	663:689	Besides, small-angle X-ray scattering (SAXS) demonstrated that xylan inhibited the assembly of microfibrils into cellulose ribbons, while glucomannan promoted the packing of microfibrils.
36436850	4	37	theme	higher	819:824	arg1	break					836:840	higher strain at break	819:840	higher strain at break	819:840	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	38	from	break	836:840	arg1	at					833:834	higher strain at break	819:840	higher strain at break	819:840	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	38	from	break	836:840	arg1	strain					826:831	higher strain at break	819:840	higher strain at break	819:840	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	39	theme	pattern	752:758	arg1	changes					696:702	The changes	692:702	The changes of cellulose crystalline structure and assembly pattern of cellulose	692:771	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	0	40	theme	mechanical	66:75	arg1	properties					77:86	mechanical properties	66:86	mechanical properties	66:86	Insights into the contributions of hemicelluloses to assembly and mechanical properties of cellulose networks.
36436850	4	41	theme	cellulose	707:715	arg1	structure					729:737	cellulose crystalline structure	707:737	cellulose crystalline structure	707:737	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	1	42	theme	bacterial	236:244	arg1	BC					257:258	BC	257:258	BC	257:258	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	1	42	theme	bacterial	236:244	arg1	cellulose					246:254	bacterial cellulose	236:254	the bacterial cellulose (BC) composites containing xylan and glucomannan	232:303	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36436850	4	43	theme	at	833:834	arg1	break					836:840	higher strain at break	819:840	higher strain at break	819:840	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	4	44	dep	strength	806:813	arg1	the					788:790	the	788:790	the	788:790	The changes of cellulose crystalline structure and assembly pattern of cellulose contributed to the lower tensile strength and higher strain at break of the BC composites as compared with the BC.
36436850	1	45	theme	cellulose	246:254	arg1	composites					261:270	the bacterial cellulose (BC) composites	232:270	the bacterial cellulose (BC) composites containing xylan and glucomannan	232:303	In order to explore the contributions of hemicelluloses to the assembly and mechanical properties of cellulose networks, the bacterial cellulose (BC) composites containing xylan and glucomannan were prepared to mimic the polysaccharides network of plant cell walls.
36035814	1	0	theme	many	157:160	arg1	processes					173:181	many biological processes	157:181	many biological processes	157:181	Protein-O-glycosylation has been shown to be essential for many biological processes.
36035814	0	1	theme	Core	75:78	arg1	O-Glycan-Array					82:95	a Core 1 O-Glycan-Array	73:95	a Core 1 O-Glycan-Array	73:95	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.
36035814	5	2	theme	chemical	957:964	arg1	sydnone-aglycon					888:902	This sydnone-aglycon	883:902	This sydnone-aglycon	883:902	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	5	2	theme	chemical	957:964	arg1	tool					966:969	a valuable chemical tool	946:969	a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships	946:1081	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	1	3	theme	biological	162:171	arg1	processes					173:181	many biological processes	157:181	many biological processes	157:181	Protein-O-glycosylation has been shown to be essential for many biological processes.
36035814	5	4	theme	valuable	948:955	arg1	sydnone-aglycon					888:902	This sydnone-aglycon	883:902	This sydnone-aglycon	883:902	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	5	4	theme	valuable	948:955	arg1	tool					966:969	a valuable chemical tool	946:969	a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships	946:1081	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	0	5	theme	O-Glycan-Array	82:95	arg1	Preparation					58:68	the Facile Preparation	47:68	the Facile Preparation of a Core 1 O-Glycan-Array	47:95	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.
36035814	3	6	from	aglycon	378:384	arg1	synthesis					426:434	their synthesis	420:434	their synthesis	420:434	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	5	7	theme	structure-activity	1050:1067	arg1	relationships					1069:1081	O-glycan structure-activity relationships	1041:1081	O-glycan structure-activity relationships	1041:1081	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	4	8	theme	bioorthogonal	716:728	arg1	reaction					781:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	4	9	theme	cycloaddition	761:773	arg1	reaction					781:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	0	10	theme	Facile	51:56	arg1	Preparation					58:68	the Facile Preparation	47:68	the Facile Preparation of a Core 1 O-Glycan-Array	47:95	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.
36035814	3	11	theme	small	543:547	arg1	library					549:555	a small library	541:555	a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis	541:622	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	0	12	theme	Clickable	2:10	arg1	Sydnone-Aglycone					26:41	A Clickable Bioorthogonal Sydnone-Aglycone	0:41	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.	0:96	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.
36035814	4	13	theme	O-glycan	696:703	arg1	array					705:709	an O-glycan array	693:709	an O-glycan array	693:709	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	3	14	theme	O-glycans	586:594	arg1	library					549:555	a small library	541:555	a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis	541:622	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	3	15	with	compatible	448:457	arg1	glycosylations					501:514	enzymatic glycosylations	491:514	enzymatic glycosylations	491:514	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	3	15	with	compatible	448:457	arg1	chemistry					477:485	carbohydrate chemistry	464:485	carbohydrate chemistry	464:485	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	5	16	theme	limited	992:998	arg1	technologies					1000:1011	the limited technologies	988:1011	the limited technologies available for investigating O-glycan structure-activity relationships	988:1081	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	3	17	theme	sydnone-containing	560:577	arg1	O-glycans					586:594	sydnone-containing core 1 O-glycans	560:594	sydnone-containing core 1 O-glycans	560:594	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	3	18	theme	carbohydrate	464:475	arg1	chemistry					477:485	carbohydrate chemistry	464:485	carbohydrate chemistry	464:485	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	0	19	theme	Bioorthogonal	12:24	arg1	Sydnone-Aglycone					26:41	A Clickable Bioorthogonal Sydnone-Aglycone	0:41	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.	0:96	A Clickable Bioorthogonal Sydnone-Aglycone for the Facile Preparation of a Core 1 O-Glycan-Array.
36035814	5	20	theme	available	1013:1021	arg1	technologies					1000:1011	the limited technologies	988:1011	the limited technologies available for investigating O-glycan structure-activity relationships	988:1081	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	3	21	theme	core	579:582	arg1	O-glycans					586:594	sydnone-containing core 1 O-glycans	560:594	sydnone-containing core 1 O-glycans	560:594	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	4	22	theme	interactions	869:880	arg1	screening					840:848	the high-throughput screening	820:848	the high-throughput screening of O-glycan-lectin interactions	820:880	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	4	23	theme	facile	671:676	arg1	preparation					678:688	the facile preparation	667:688	the facile preparation of an O-glycan array	667:709	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	4	24	theme	O-glycan-lectin	853:867	arg1	interactions					869:880	O-glycan-lectin interactions	853:880	O-glycan-lectin interactions	853:880	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	2	25	theme	O-glycan	236:243	arg1	structures					245:254	O-glycan structures	236:254	O-glycan structures	236:254	However, determining the exact relationship between O-glycan structures and their biological activity remains challenging.
36035814	4	26	theme	sydnone-alkyne	746:759	arg1	reaction					781:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	3	27	theme	early-on	408:415	arg1	O-glycans					398:406	core 1 O-glycans early-on	391:415	core 1 O-glycans early-on	391:415	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	3	28	theme	chemoenzymatic	599:612	arg1	synthesis					614:622	chemoenzymatic synthesis	599:622	chemoenzymatic synthesis	599:622	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	4	29	theme	strain-promoted	730:744	arg1	reaction					781:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	4	30	used	utilized	807:814	arg2	sydnone-aglycon					629:643	The sydnone-aglycon	625:643	The sydnone-aglycon	625:643	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	2	31	theme	exact	209:213	arg1	relationship					215:226	the exact relationship	205:226	the exact relationship between O-glycan structures and their biological activity	205:284	However, determining the exact relationship between O-glycan structures and their biological activity remains challenging.
36035814	4	32	theme	high-throughput	824:838	arg1	screening					840:848	the high-throughput screening	820:848	the high-throughput screening of O-glycan-lectin interactions	820:880	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	4	33	theme	array	705:709	arg1	preparation					678:688	the facile preparation	667:688	the facile preparation of an O-glycan array	667:709	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	4	34	theme	click	775:779	arg1	reaction					781:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction	716:788	The sydnone-aglycon was then employed for the facile preparation of an O-glycan array, via bioorthogonal strain-promoted sydnone-alkyne cycloaddition click reaction, and in turn was utilized for the high-throughput screening of O-glycan-lectin interactions.
36035814	5	35	theme	O-glycan	1041:1048	arg1	relationships					1069:1081	O-glycan structure-activity relationships	1041:1081	O-glycan structure-activity relationships	1041:1081	This sydnone-aglycon, particularly adapted for O-glycomics, is a valuable chemical tool that complements the limited technologies available for investigating O-glycan structure-activity relationships.
36035814	3	36	theme	enzymatic	491:499	arg1	glycosylations					501:514	enzymatic glycosylations	491:514	enzymatic glycosylations	491:514	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
36035814	2	37	theme	biological	266:275	arg1	activity					277:284	their biological activity	260:284	their biological activity	260:284	However, determining the exact relationship between O-glycan structures and their biological activity remains challenging.
36035814	3	38	theme	core	391:394	arg1	O-glycans					398:406	core 1 O-glycans early-on	391:415	core 1 O-glycans early-on	391:415	Here we report that, unlike azides, sydnones can be incorporated as an aglycon into core 1 O-glycans early-on in their synthesis since it is compatible with carbohydrate chemistry and enzymatic glycosylations, allowing us to generate a small library of sydnone-containing core 1 O-glycans by chemoenzymatic synthesis.
35191914	1	0	theme	body-derived	177:188	arg1	AAPs					207:210	AAPs	207:210	AAPs	207:210	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	0	theme	body-derived	177:188	arg1	polysaccharides					190:204	fruiting body-derived polysaccharides	168:204	Auricularia auricula fruiting body-derived polysaccharides (AAPs)	147:211	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	0	1	theme	polysaccharides	73:87	arg1	ability					62:68	antioxidant stress ability	43:68	antioxidant stress ability	43:68	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	0	1	theme	polysaccharides	73:87	arg1	composition					27:37	chemical composition	18:37	chemical composition	18:37	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	5	2	theme	elegans	877:883	arg1	lifespan					852:859	the lifespan	848:859	the lifespan of wild-type C. elegans	848:883	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	2	3	from	influences	329:338	arg1	activity					416:423	antioxidant activity	404:423	antioxidant activity in vitro and in vivo	404:444	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	2	3	from	influences	329:338	arg1	compositions					387:398	the chemical compositions	374:398	the chemical compositions	374:398	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	3	4	contain	possessed	527:535	arg2	kDa					618:620	406.77 kDa	611:620	406.77 kDa	611:620	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	4	contain	possessed	527:535	arg2	content					561:567	the highest uronic acid content	537:567	the highest uronic acid content (33.53%)	537:576	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	4	contain	possessed	527:535	arg1	AAPs					513:516	freeze-dried AAPs	500:516	freeze-dried AAPs (AAPs-F)	500:525	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	4	contain	possessed	527:535	arg2	%					575:575	33.53%	570:575	33.53%	570:575	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	4	contain	possessed	527:535	arg2	weight					603:608	the lowest molecular weight	582:608	the lowest molecular weight (406.77 kDa)	582:621	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	4	contain	possessed	527:535	arg1	AAPs-F					519:524	AAPs-F	519:524	AAPs-F	519:524	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	4	5	theme	potent	660:665	arg1	abilities					679:687	the most potent antioxidant abilities	651:687	the most potent antioxidant abilities	651:687	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	3	6	theme	acid	556:559	arg1	content					561:567	the highest uronic acid content	537:567	the highest uronic acid content (33.53%)	537:576	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	6	theme	acid	556:559	arg1	%					575:575	33.53%	570:575	33.53%	570:575	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	5	7	theme	p	945:945	arg1	viologen					935:942	methyl viologen	928:942	methyl viologen (p < 0.05)	928:953	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	5	7	theme	p	945:945	arg1	<					947:947	p < 0.05	945:952	p < 0.05	945:952	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	3	8	theme	freeze-dried	500:511	arg1	AAPs					513:516	freeze-dried AAPs	500:516	freeze-dried AAPs (AAPs-F)	500:525	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	8	theme	freeze-dried	500:511	arg1	AAPs-F					519:524	AAPs-F	519:524	AAPs-F	519:524	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	0	9	theme	different	121:129	arg1	methods					138:144	different drying methods	121:144	different drying methods	121:144	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	5	10	theme	oxidative	891:899	arg1	stress					901:906	oxidative stress	891:906	oxidative stress induced by H2O2 and methyl viologen (p < 0.05)	891:953	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	3	11	theme	highest	541:547	arg1	content					561:567	the highest uronic acid content	537:567	the highest uronic acid content (33.53%)	537:576	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	11	theme	highest	541:547	arg1	%					575:575	33.53%	570:575	33.53%	570:575	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	4	12	theme	chelating	784:792	arg1	capacity					794:801	metal ion chelating capacity	774:801	metal ion chelating capacity	774:801	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	5	13	theme	significant	1093:1103	arg1	role					1105:1108	a significant role	1091:1108	a significant role	1091:1108	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	6	14	theme	preferred	1208:1216	arg1	freeze-drying					1172:1184	freeze-drying	1172:1184	freeze-drying	1172:1184	Hence, freeze-drying was determined as the preferred procedure for obtaining high-quality AAPs.
35191914	6	14	theme	preferred	1208:1216	arg1	procedure					1218:1226	the preferred procedure	1204:1226	the preferred procedure for obtaining high-quality AAPs	1204:1258	Hence, freeze-drying was determined as the preferred procedure for obtaining high-quality AAPs.
35191914	3	15	theme	uronic	549:554	arg1	content					561:567	the highest uronic acid content	537:567	the highest uronic acid content (33.53%)	537:576	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	15	theme	uronic	549:554	arg1	%					575:575	33.53%	570:575	33.53%	570:575	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	5	16	theme	expression	979:988	arg1	levels					990:995	the mRNA expression levels	970:995	the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold)	970:1079	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	0	17	from	composition	27:37	arg1	auricula					106:113	Auricularia auricula	94:113	Auricularia auricula	94:113	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	4	18	theme	DPPH˙	719:723	arg1	abilities					736:744	DPPH˙ scavenging abilities	719:744	DPPH˙ scavenging abilities	719:744	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	2	19	theme	antioxidant	404:414	arg1	activity					416:423	antioxidant activity	404:423	antioxidant activity in vitro and in vivo	404:444	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	1	20	dep	polysaccharides	190:204	arg1	auricula					159:166	Auricularia auricula fruiting body-derived polysaccharides (AAPs)	147:211	Auricularia auricula fruiting body-derived polysaccharides (AAPs)	147:211	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	2	21	theme	AAPs	449:452	arg1	activity					416:423	antioxidant activity	404:423	antioxidant activity in vitro and in vivo	404:444	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	2	21	theme	AAPs	449:452	arg1	compositions					387:398	the chemical compositions	374:398	the chemical compositions	374:398	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	2	22	theme	chemical	378:385	arg1	compositions					387:398	the chemical compositions	374:398	the chemical compositions	374:398	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	1	23	link	body-derived	177:188	arg1	AAPs					207:210	AAPs	207:210	AAPs	207:210	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	23	link	body-derived	177:188	arg1	polysaccharides					190:204	fruiting body-derived polysaccharides	168:204	Auricularia auricula fruiting body-derived polysaccharides (AAPs)	147:211	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	5	24	theme	methyl	928:933	arg1	viologen					935:942	methyl viologen	928:942	methyl viologen (p < 0.05)	928:953	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	5	24	theme	methyl	928:933	arg1	<					947:947	p < 0.05	945:952	p < 0.05	945:952	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	5	25	theme	mRNA	974:977	arg1	levels					990:995	the mRNA expression levels	970:995	the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold)	970:1079	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	0	26	theme	drying	131:136	arg1	methods					138:144	different drying methods	121:144	different drying methods	121:144	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	4	27	theme	scavenging	725:734	arg1	abilities					736:744	DPPH˙ scavenging abilities	719:744	DPPH˙ scavenging abilities	719:744	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	3	28	theme	lowest	586:591	arg1	weight					603:608	the lowest molecular weight	582:608	the lowest molecular weight (406.77 kDa)	582:621	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	28	theme	lowest	586:591	arg1	kDa					618:620	406.77 kDa	611:620	406.77 kDa	611:620	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	1	29	theme	different	230:238	arg1	microwave-drying					307:322	microwave-drying	307:322	microwave-drying	307:322	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	29	theme	different	230:238	arg1	procedures					247:256	different drying procedures	230:256	different drying procedures	230:256	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	29	theme	different	230:238	arg1	freeze-					294:300	freeze-	294:300	freeze-	294:300	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	29	theme	different	230:238	arg1	air-					273:276	air-	273:276	air-	273:276	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	29	theme	different	230:238	arg1	infrared-					283:291	infrared-	283:291	infrared-	283:291	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	0	30	theme	composition	27:37	arg1	Comparison					0:9	Comparison	0:9	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.	0:145	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	5	31	theme	sod-3	1020:1024	arg1	levels					990:995	the mRNA expression levels	970:995	the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold)	970:1079	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	0	32	theme	chemical	18:25	arg1	composition					27:37	chemical composition	18:37	chemical composition	18:37	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	1	33	theme	drying	240:245	arg1	microwave-drying					307:322	microwave-drying	307:322	microwave-drying	307:322	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	33	theme	drying	240:245	arg1	procedures					247:256	different drying procedures	230:256	different drying procedures	230:256	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	33	theme	drying	240:245	arg1	freeze-					294:300	freeze-	294:300	freeze-	294:300	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	33	theme	drying	240:245	arg1	air-					273:276	air-	273:276	air-	273:276	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	33	theme	drying	240:245	arg1	infrared-					283:291	infrared-	283:291	infrared-	283:291	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	0	34	theme	stress	55:60	arg1	ability					62:68	antioxidant stress ability	43:68	antioxidant stress ability	43:68	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	0	35	from	ability	62:68	arg1	auricula					106:113	Auricularia auricula	94:113	Auricularia auricula	94:113	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	2	36	theme	procedures	360:369	arg1	influences					329:338	The influences	325:338	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs	325:452	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	0	37	theme	antioxidant	43:53	arg1	ability					62:68	antioxidant stress ability	43:68	antioxidant stress ability	43:68	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	5	38	theme	sir-2.1	1061:1067	arg1	levels					990:995	the mRNA expression levels	970:995	the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold)	970:1079	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	6	39	theme	high-quality	1242:1253	arg1	AAPs					1255:1258	high-quality AAPs	1242:1258	high-quality AAPs	1242:1258	Hence, freeze-drying was determined as the preferred procedure for obtaining high-quality AAPs.
35191914	5	40	theme	daf-16	1000:1005	arg1	levels					990:995	the mRNA expression levels	970:995	the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold)	970:1079	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	0	41	dep	composition	27:37	arg1	the					14:16	the	14:16	the	14:16	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	2	42	theme	drying	353:358	arg1	procedures					360:369	different drying procedures	343:369	different drying procedures	343:369	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	5	43	theme	p	1154:1154	arg1	apoptosis					1143:1151	apoptosis	1143:1151	apoptosis (p < 0.05)	1143:1162	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	5	43	theme	p	1154:1154	arg1	<					1156:1156	p < 0.05	1154:1161	p < 0.05	1154:1161	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	3	44	theme	molecular	593:601	arg1	weight					603:608	the lowest molecular weight	582:608	the lowest molecular weight (406.77 kDa)	582:621	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	3	44	theme	molecular	593:601	arg1	kDa					618:620	406.77 kDa	611:620	406.77 kDa	611:620	The results indicated that freeze-dried AAPs (AAPs-F) possessed the highest uronic acid content (33.53%) and the lowest molecular weight (406.77 kDa).
35191914	2	45	theme	different	343:351	arg1	procedures					360:369	different drying procedures	343:369	different drying procedures	343:369	The influences of different drying procedures on the chemical compositions and antioxidant activity in vitro and in vivo of AAPs were investigated.
35191914	4	46	theme	reducing	754:761	arg1	power					763:767	ferric reducing power	747:767	ferric reducing power	747:767	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	0	47	from	auricula	106:113	arg1	polysaccharides					73:87	polysaccharides	73:87	polysaccharides from Auricularia auricula	73:113	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	0	47	from	auricula	106:113	arg1	ability					62:68	antioxidant stress ability	43:68	antioxidant stress ability	43:68	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	0	47	from	auricula	106:113	arg1	composition					27:37	chemical composition	18:37	chemical composition	18:37	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	4	48	theme	ferric	747:752	arg1	power					763:767	ferric reducing power	747:767	ferric reducing power	747:767	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	1	49	theme	Auricularia	147:157	arg1	AAPs					207:210	AAPs	207:210	AAPs	207:210	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	49	theme	Auricularia	147:157	arg1	polysaccharides					190:204	fruiting body-derived polysaccharides	168:204	Auricularia auricula fruiting body-derived polysaccharides (AAPs)	147:211	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	4	50	theme	ion	780:782	arg1	capacity					794:801	metal ion chelating capacity	774:801	metal ion chelating capacity	774:801	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	4	51	theme	antioxidant	667:677	arg1	abilities					679:687	the most potent antioxidant abilities	651:687	the most potent antioxidant abilities	651:687	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	0	52	theme	ability	62:68	arg1	Comparison					0:9	Comparison	0:9	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.	0:145	Comparison of the chemical composition and antioxidant stress ability of polysaccharides from Auricularia auricula under different drying methods.
35191914	5	53	theme	skn-1	1039:1043	arg1	levels					990:995	the mRNA expression levels	970:995	the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold)	970:1079	Besides, AAPs-F could significantly prolong the lifespan of wild-type C. elegans under oxidative stress induced by H2O2 and methyl viologen (p < 0.05) and upregulate the mRNA expression levels of daf-16 (>2.7 fold), sod-3 (>9.2 fold), skn-1 (>4.5 fold) and sir-2.1 (>1.9 fold), and play a significant role in protecting C. elegans against apoptosis (p < 0.05).
35191914	4	54	theme	metal	774:778	arg1	capacity					794:801	metal ion chelating capacity	774:801	metal ion chelating capacity	774:801	Moreover, AAPs-F exhibited the most potent antioxidant abilities in vitro, including ABTS+ and DPPH˙ scavenging abilities, ferric reducing power, and metal ion chelating capacity.
35191914	1	55	theme	fruiting	168:175	arg1	AAPs					207:210	AAPs	207:210	AAPs	207:210	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
35191914	1	55	theme	fruiting	168:175	arg1	polysaccharides					190:204	fruiting body-derived polysaccharides	168:204	Auricularia auricula fruiting body-derived polysaccharides (AAPs)	147:211	Auricularia auricula fruiting body-derived polysaccharides (AAPs) were dried using different drying procedures, including hot air-, far infrared-, freeze-, and microwave-drying.
36585837	9	0	from	sites	1311:1315	arg1	glycoproteins					1324:1336	220 glycoproteins	1320:1336	220 glycoproteins in sow milk	1320:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	6	1	theme	chromatography	864:877	arg1	LC-MS/MS					905:912	LC-MS/MS	905:912	LC-MS/MS	905:912	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	6	1	theme	chromatography	864:877	arg1	mass-spectrometry					886:902	label-free liquid chromatography tandem mass-spectrometry	846:902	label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS)	846:913	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	9	2	dep	sites	1311:1315	arg1	and					1245:1247	and	1245:1247	and	1245:1247	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	7	3	dep	Sus	963:965	arg1	database					982:989	Uniport database	974:989	Sus scrofa Uniport database to identify proteins and measure their relative abundances	963:1048	MaxQuant software was used to align spectra to Sus scrofa Uniport database to identify proteins and measure their relative abundances.
36585837	7	4	theme	MaxQuant	916:923	arg1	software					925:932	MaxQuant software	916:932	MaxQuant software	916:932	MaxQuant software was used to align spectra to Sus scrofa Uniport database to identify proteins and measure their relative abundances.
36585837	4	5	theme	-linked	431:437	arg1	proteins					452:459	N -linked glycosylated proteins	429:459	N -linked glycosylated proteins	429:459	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	13	6	theme	neonate	1796:1802	arg1	development					1804:1814	neonate development	1796:1814	neonate development	1796:1814	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	10	7	theme	sites	1463:1467	arg1	number					1439:1444	number	1439:1444	number of glycosylation sites (1 to 14)	1439:1477	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	11	8	theme	polymeric	1568:1576	arg1	PIGR					1562:1565	PIGR	1562:1565	PIGR (polymeric immunoglobulin receptor)	1562:1601	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	11	8	theme	polymeric	1568:1576	arg1	receptor					1593:1600	polymeric immunoglobulin receptor	1568:1600	polymeric immunoglobulin receptor	1568:1600	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	6	9	gly	glycopeptides	815:827	arg2	glycopeptides					815:827	Purified glycopeptides	806:827	Purified glycopeptides	806:827	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	3	10	theme	sugar	291:295	arg1	moieties					297:304	sugar moieties	291:304	sugar moieties	291:304	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	4	11	theme	milk	481:484	arg1	samples					486:492	homogenate swine milk samples	464:492	homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively	464:652	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	9	12	gly	glycoproteins	1324:1336	arg1	glycoproteins					1324:1336	220 glycoproteins	1320:1336	220 glycoproteins in sow milk	1320:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	13	13	theme	glycosylated	1766:1777	arg1	protection					1825:1834	protection	1825:1834	protection against pathogens	1825:1852	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	13	13	theme	glycosylated	1766:1777	arg1	proteins					1784:1791	glycosylated milk proteins	1766:1791	glycosylated milk proteins	1766:1791	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	5	14	theme	PNGase	754:759	arg1	F					751:751	Peptide N-glycosidase F	729:751	Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites	729:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	5	14	theme	PNGase	754:759	arg1	F					761:761	PNGase F	754:761	PNGase F	754:761	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	13	15	theme	proteins	1784:1791	arg1	relevance					1753:1761	the relevance	1749:1761	the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens	1749:1852	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	11	16	theme	immunoglobulin	1578:1591	arg1	PIGR					1562:1565	PIGR	1562:1565	PIGR (polymeric immunoglobulin receptor)	1562:1601	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	11	16	theme	immunoglobulin	1578:1591	arg1	receptor					1593:1600	polymeric immunoglobulin receptor	1568:1600	polymeric immunoglobulin receptor	1568:1600	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	5	17	theme	Peptide	729:735	arg1	F					751:751	Peptide N-glycosidase F	729:751	Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites	729:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	5	17	theme	Peptide	729:735	arg1	F					761:761	PNGase F	754:761	PNGase F	754:761	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	9	18	theme	220	1320:1322	arg1	glycoproteins					1324:1336	220 glycoproteins	1320:1336	220 glycoproteins in sow milk	1320:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	1	19	theme	neonate	125:131	arg1	development					133:143	neonate development	125:143	neonate development	125:143	Milk proteins serve as nutrition and affect neonate development and immunity through their bioactivity.
36585837	4	20	theme	homogenate	464:473	arg1	samples					486:492	homogenate swine milk samples	464:492	homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively	464:652	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	4	21	theme	transitional	611:622	arg1	milk					635:638	transitional and mature milk	611:638	transitional and mature milk	611:638	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	7	22	theme	relative	1030:1037	arg1	abundances					1039:1048	their relative abundances	1024:1048	their relative abundances	1024:1048	MaxQuant software was used to align spectra to Sus scrofa Uniport database to identify proteins and measure their relative abundances.
36585837	9	23	dep	glycosylation	1272:1284	arg1	P>0.75					1287:1292	P>0.75	1287:1292	P>0.75 for deamidation	1287:1308	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	4	24	gly	glycosylated	439:450	arg1	proteins					452:459	N -linked glycosylated proteins	429:459	N -linked glycosylated proteins	429:459	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	3	25	theme	glycans	338:344	arg1	attachment					324:333	attachment	324:333	attachment of glycans to asparagine indicated as N-link glycosylation	324:392	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	0	26	theme	lactation	70:78	arg1	course					60:65	the course	56:65	the course of lactation	56:78	Characterization of sow milk N-liked glycoproteome over the course of lactation.
36585837	6	27	theme	label-free	846:855	arg1	LC-MS/MS					905:912	LC-MS/MS	905:912	LC-MS/MS	905:912	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	6	27	theme	label-free	846:855	arg1	mass-spectrometry					886:902	label-free liquid chromatography tandem mass-spectrometry	846:902	label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS)	846:913	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	5	28	gly	glycosylation	785:797	arg2	sites					799:803	N-linked glycosylation sites	776:803	N-linked glycosylation sites	776:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	13	29	from	development	1804:1814	arg1	relevance					1753:1761	the relevance	1749:1761	the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens	1749:1852	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	8	30	theme	abundant	1125:1132	arg1	glycoproteins					1096:1108	glycoproteins	1096:1108	glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05)	1096:1192	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	7	31	theme	Uniport	974:980	arg1	database					982:989	Uniport database	974:989	Sus scrofa Uniport database to identify proteins and measure their relative abundances	963:1048	MaxQuant software was used to align spectra to Sus scrofa Uniport database to identify proteins and measure their relative abundances.
36585837	10	32	gly	glycosylation	1449:1461	arg2	sites					1463:1467	glycosylation sites	1449:1467	glycosylation sites (1 to 14)	1449:1477	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	10	32	gly	glycosylation	1449:1461	arg2	14					1475:1476	14	1475:1476	14	1475:1476	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	3	33	attach	attachment	324:333	arg1	asparagine					349:358	asparagine	349:358	asparagine indicated as N-link glycosylation	349:392	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	3	33	attach	attachment	324:333	arg2	glycans					338:344	glycans	338:344	glycans	338:344	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	10	34	theme	transitional	1532:1543	arg1	milk					1556:1559	transitional and mature milk	1532:1559	transitional and mature milk	1532:1559	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	10	34	theme	transitional	1532:1543	arg1	colostrum					1521:1529	colostrum	1521:1529	colostrum	1521:1529	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	0	35	theme	sow	20:22	arg1	N-liked					29:35	sow milk N-liked	20:35	sow milk N-liked	20:35	Characterization of sow milk N-liked glycoproteome over the course of lactation.
36585837	8	36	theme	transitional	1153:1164	arg1	colostrum					1142:1150	colostrum	1142:1150	colostrum	1142:1150	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	8	36	theme	transitional	1153:1164	arg1	milk					1177:1180	transitional and mature milk	1153:1180	transitional and mature milk (FDR <0.05)	1153:1192	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	8	36	theme	transitional	1153:1164	arg1	<0.05					1187:1191	FDR <0.05	1183:1191	FDR <0.05	1183:1191	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	0	37	theme	N-liked	29:35	arg1	Characterization					0:15	Characterization	0:15	Characterization of sow milk N-liked	0:35	Characterization of sow milk N-liked glycoproteome over the course of lactation.
36585837	4	38	dep	represent	542:550	arg1	represent					601:609	represent	601:609	represent	601:609	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	8	39	theme	mature	1170:1175	arg1	colostrum					1142:1150	colostrum	1142:1150	colostrum	1142:1150	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	8	39	theme	mature	1170:1175	arg1	milk					1177:1180	transitional and mature milk	1153:1180	transitional and mature milk (FDR <0.05)	1153:1192	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	8	39	theme	mature	1170:1175	arg1	<0.05					1187:1191	FDR <0.05	1183:1191	FDR <0.05	1183:1191	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	5	40	theme	glycosylation	785:797	arg1	sites					799:803	N-linked glycosylation sites	776:803	N-linked glycosylation sites	776:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	9	41	theme	Shotgun	1195:1201	arg1	analysis					1212:1219	Shotgun proteome analysis	1195:1219	Shotgun proteome analysis	1195:1219	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	11	42	with	protein	1629:1635	arg1	sites					1645:1649	14 sites	1642:1649	14 sites identified	1642:1660	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	10	43	theme	mature	1549:1554	arg1	milk					1556:1559	transitional and mature milk	1532:1559	transitional and mature milk	1532:1559	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	10	43	theme	mature	1549:1554	arg1	colostrum					1521:1529	colostrum	1521:1529	colostrum	1521:1529	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	2	44	theme	proteins	221:228	arg1	modifications					204:216	Post-translational modifications	185:216	Post-translational modifications of proteins	185:228	Post-translational modifications of proteins affect their bioactivity.
36585837	11	45	theme	glycosylated	1616:1627	arg1	protein					1629:1635	the most glycosylated protein	1607:1635	the most glycosylated protein with 14 sites identified	1607:1660	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	11	45	theme	glycosylated	1616:1627	arg1	PIGR					1562:1565	PIGR	1562:1565	PIGR (polymeric immunoglobulin receptor)	1562:1601	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	4	46	link	-linked	431:437	arg1	proteins					452:459	N -linked glycosylated proteins	429:459	N -linked glycosylated proteins	429:459	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	7	47	used	used	938:941	arg2	software					925:932	MaxQuant software	916:932	MaxQuant software	916:932	MaxQuant software was used to align spectra to Sus scrofa Uniport database to identify proteins and measure their relative abundances.
36585837	3	48	attach	attachment	277:286	arg1	proteins					309:316	proteins	309:316	proteins	309:316	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	3	48	attach	attachment	277:286	arg2	moieties					297:304	sugar moieties	291:304	sugar moieties	291:304	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	10	49	theme	production	1414:1423	arg1	phases					1393:1398	all three phases	1383:1398	all three phases of swine milk production	1383:1423	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	9	50	from	glycoproteins	1324:1336	arg1	milk					1345:1348	sow milk	1341:1348	sow milk	1341:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	10	51	theme	swine	1403:1407	arg1	production					1414:1423	swine milk production	1403:1423	swine milk production	1403:1423	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	13	52	from	proteins	1784:1791	arg1	development					1804:1814	neonate development	1796:1814	neonate development	1796:1814	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	5	53	theme	lectin-based	688:699	arg1	extraction					701:710	lectin-based extraction	688:710	lectin-based extraction	688:710	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	6	54	theme	liquid	857:862	arg1	LC-MS/MS					905:912	LC-MS/MS	905:912	LC-MS/MS	905:912	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	6	54	theme	liquid	857:862	arg1	mass-spectrometry					886:902	label-free liquid chromatography tandem mass-spectrometry	846:902	label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS)	846:913	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	4	55	theme	glycosylated	439:450	arg1	proteins					452:459	N -linked glycosylated proteins	429:459	N -linked glycosylated proteins	429:459	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	13	56	gly	glycosylated	1766:1777	arg1	protection					1825:1834	protection	1825:1834	protection against pathogens	1825:1852	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	13	56	gly	glycosylated	1766:1777	arg1	proteins					1784:1791	glycosylated milk proteins	1766:1791	glycosylated milk proteins	1766:1791	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	8	57	theme	t-test	1069:1074	arg1	analysis					1076:1083	Welch's t-test analysis	1061:1083	Welch's t-test analysis	1061:1083	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	5	58	theme	N-glycosidase	737:749	arg1	F					751:751	Peptide N-glycosidase F	729:751	Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites	729:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	5	58	theme	N-glycosidase	737:749	arg1	F					761:761	PNGase F	754:761	PNGase F	754:761	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	6	59	theme	Purified	806:813	arg1	glycopeptides					815:827	Purified glycopeptides	806:827	Purified glycopeptides	806:827	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	5	60	link	N-linked	776:783	arg1	sites					799:803	N-linked glycosylation sites	776:803	N-linked glycosylation sites	776:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	3	61	theme	moieties	297:304	arg1	Glycosylation					256:268	Glycosylation	256:268	Glycosylation	256:268	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	3	61	theme	moieties	297:304	arg1	attachment					277:286	the attachment	273:286	the attachment of sugar moieties to proteins	273:316	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	13	62	theme	milk	1779:1782	arg1	protection					1825:1834	protection	1825:1834	protection against pathogens	1825:1852	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	13	62	theme	milk	1779:1782	arg1	proteins					1784:1791	glycosylated milk proteins	1766:1791	glycosylated milk proteins	1766:1791	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	10	63	theme	glycosylation	1449:1461	arg1	sites					1463:1467	glycosylation sites	1449:1467	glycosylation sites (1 to 14)	1449:1477	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	10	63	theme	glycosylation	1449:1461	arg1	14					1475:1476	14	1475:1476	14	1475:1476	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	4	64	theme	swine	475:479	arg1	samples					486:492	homogenate swine milk samples	464:492	homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively	464:652	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	8	65	gly	glycoproteins	1096:1108	arg1	glycoproteins					1096:1108	glycoproteins	1096:1108	glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05)	1096:1192	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	5	66	theme	N-linked	776:783	arg1	sites					799:803	N-linked glycosylation sites	776:803	N-linked glycosylation sites	776:803	Glycopeptides were isolated with lectin-based extraction and treated with Peptide N-glycosidase F (PNGase F) to identify N-linked glycosylation sites.
36585837	9	67	theme	sow	1341:1343	arg1	milk					1345:1348	sow milk	1341:1348	sow milk	1341:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	3	68	theme	N-link	373:378	arg1	glycosylation					380:392	N-link glycosylation	373:392	N-link glycosylation	373:392	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	1	69	theme	Milk	81:84	arg1	proteins					86:93	Milk proteins	81:93	Milk proteins	81:93	Milk proteins serve as nutrition and affect neonate development and immunity through their bioactivity.
36585837	12	70	theme	mucin	1704:1708	arg1	proteins					1710:1717	mucin proteins	1704:1717	mucin proteins	1704:1717	Also highly glycosylated were casein and mucin proteins.
36585837	9	71	link	N-linked	1236:1243	arg1	sites					1311:1315	545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites	1232:1315	545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk	1232:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	0	72	theme	milk	24:27	arg1	N-liked					29:35	sow milk N-liked	20:35	sow milk N-liked	20:35	Characterization of sow milk N-liked glycoproteome over the course of lactation.
36585837	9	73	dep	and	1245:1247	arg1	Q					1260:1260	Q	1260:1260	Q	1260:1260	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	9	73	dep	and	1245:1247	arg1	glutamine					1249:1257	glutamine	1249:1257	glutamine	1249:1257	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	9	73	dep	and	1245:1247	arg1	glycosylation					1272:1284	glycosylation	1272:1284	glycosylation (P>0.75 for deamidation)	1272:1309	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	9	73	dep	and	1245:1247	arg1	-linked					1263:1269	-linked	1263:1269	-linked	1263:1269	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	9	74	theme	545	1232:1234	arg1	sites					1311:1315	545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites	1232:1315	545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk	1232:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	2	75	theme	Post-translational	185:202	arg1	modifications					204:216	Post-translational modifications	185:216	Post-translational modifications of proteins	185:228	Post-translational modifications of proteins affect their bioactivity.
36585837	10	76	dep	14	1475:1476	arg1	to					1472:1473	to	1472:1473	to	1472:1473	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36585837	11	77	gly	glycosylated	1616:1627	arg1	protein					1629:1635	the most glycosylated protein	1607:1635	the most glycosylated protein with 14 sites identified	1607:1660	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	11	77	gly	glycosylated	1616:1627	arg1	PIGR					1562:1565	PIGR	1562:1565	PIGR (polymeric immunoglobulin receptor)	1562:1601	PIGR (polymeric immunoglobulin receptor) was the most glycosylated protein with 14 sites identified.
36585837	13	78	from	relevance	1753:1761	arg1	development					1804:1814	neonate development	1796:1814	neonate development	1796:1814	These data are described and the relevance of glycosylated milk proteins in neonate development, such as protection against pathogens is discussed.
36585837	8	79	theme	FDR	1183:1185	arg1	milk					1177:1180	transitional and mature milk	1153:1180	transitional and mature milk (FDR <0.05)	1153:1192	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	8	79	theme	FDR	1183:1185	arg1	<0.05					1187:1191	FDR <0.05	1183:1191	FDR <0.05	1183:1191	ANOVA and Welch's t-test analysis identified glycoproteins differentially abundant between colostrum, transitional and mature milk (FDR <0.05).
36585837	9	80	theme	proteome	1203:1210	arg1	analysis					1212:1219	Shotgun proteome analysis	1195:1219	Shotgun proteome analysis	1195:1219	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	3	81	with	attachment	277:286	arg1	attachment					324:333	attachment	324:333	attachment of glycans to asparagine indicated as N-link glycosylation	324:392	Glycosylation is the attachment of sugar moieties to proteins, with attachment of glycans to asparagine indicated as N-link glycosylation.
36585837	9	82	theme	N-linked	1236:1243	arg1	sites					1311:1315	545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites	1232:1315	545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk	1232:1348	Shotgun proteome analysis identified 545 N-linked and glutamine, Q, -linked, glycosylation (P>0.75 for deamidation) sites on 220 glycoproteins in sow milk.
36585837	4	83	theme	mature	628:633	arg1	milk					635:638	transitional and mature milk	611:638	transitional and mature milk	611:638	Our objective was to characterize N -linked glycosylated proteins in homogenate swine milk samples collected from sows (n=5/6) during farrowing to represent colostrum, and on day 3 and 14 post-farrowing to represent transitional and mature milk, respectively.
36585837	6	84	theme	tandem	879:884	arg1	LC-MS/MS					905:912	LC-MS/MS	905:912	LC-MS/MS	905:912	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	6	84	theme	tandem	879:884	arg1	mass-spectrometry					886:902	label-free liquid chromatography tandem mass-spectrometry	846:902	label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS)	846:913	Purified glycopeptides were analysed by label-free liquid chromatography tandem mass-spectrometry (LC-MS/MS).
36585837	10	85	theme	milk	1409:1412	arg1	production					1414:1423	swine milk production	1403:1423	swine milk production	1403:1423	Glycoproteins were found across all three phases of swine milk production and varied by number of glycosylation sites (1 to 14) and in abundance and distribution between colostrum, transitional and mature milk.
36805683	7	0	theme	better	1172:1177	arg1	predictor					1179:1187	a better predictor	1170:1187	a better predictor of response than clinical variables alone	1170:1229	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	4	1	theme	effective	584:592	arg1	response					612:619	an effective antitumour immune response	581:619	an effective antitumour immune response	581:619	Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response.
36805683	5	2	theme	advanced	789:796	arg1	melanoma					798:805	advanced melanoma	789:805	advanced melanoma from two European countries	789:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	8	3	from	changes	1249:1255	arg1	glycosylation					1274:1286	serum protein glycosylation	1260:1286	serum protein glycosylation	1260:1286	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	8	4	theme	therapies	1506:1514	arg1	patients					1471:1478	patients	1471:1478	patients	1471:1478	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	8	4	theme	therapies	1506:1514	arg1	design					1488:1493	the design	1484:1493	the design of adjunct therapies aiming at improving immune response	1484:1550	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	5	5	theme	proteins	740:747	arg1	N-glycome					715:723	the N-glycome	711:723	the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries	711:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	4	6	theme	aberrant	505:512	arg1	glycosylation					514:526	aberrant glycosylation	505:526	aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response	505:619	Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response.
36805683	5	7	theme	response	675:682	arg1	glyco-markers					658:670	novel glyco-markers	652:670	novel glyco-markers of response and survival	652:695	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	7	8	theme	higher	1012:1017	arg1	abundancy					1019:1027	higher abundancy	1012:1027	higher abundancy of low-branched structures containing lower abundances of antennary fucose	1012:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	8	9	theme	new	1433:1435	arg1	avenues					1437:1443	new avenues	1433:1443	new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response	1433:1550	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	4	10	theme	immune	605:610	arg1	response					612:619	an effective antitumour immune response	581:619	an effective antitumour immune response	581:619	Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response.
36805683	7	11	contain	containing	1056:1065	arg1	structures					1045:1054	low-branched structures	1032:1054	low-branched structures containing lower abundances of antennary fucose	1032:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	7	11	contain	containing	1056:1065	arg2	abundances					1073:1082	lower abundances	1067:1082	lower abundances of antennary fucose	1067:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	2	12	theme	survival	281:288	arg1	biomarker					268:276	no reliable biomarker	256:276	no reliable biomarker of survival or response	256:300	However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs.
36805683	4	13	theme	antitumour	594:603	arg1	response					612:619	an effective antitumour immune response	581:619	an effective antitumour immune response	581:619	Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response.
36805683	7	14	theme	response	1192:1199	arg1	survival					1157:1164	survival	1157:1164	survival	1157:1164	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	7	14	theme	response	1192:1199	arg1	predictor					1179:1187	a better predictor	1170:1187	a better predictor of response than clinical variables alone	1170:1229	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	0	15	from	response	37:44	arg1	patients					102:109	patients	102:109	patients with advanced melanoma	102:132	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	7	16	theme	N-glycome	964:972	arg1	profile					974:980	a pre-treatment N-glycome profile	948:980	a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose	948:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	0	17	theme	serum	6:10	arg1	N-glycans					12:20	Total serum N-glycans	0:20	Total serum N-glycans	0:20	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	0	18	with	patients	102:109	arg1	melanoma					125:132	advanced melanoma	116:132	advanced melanoma	116:132	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	0	19	theme	Total	0:4	arg1	N-glycans					12:20	Total serum N-glycans	0:20	Total serum N-glycans	0:20	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	7	20	theme	clinical	1206:1213	arg1	variables					1215:1223	clinical variables	1206:1223	clinical variables alone	1206:1229	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	5	21	theme	novel	652:656	arg1	glyco-markers					658:670	novel glyco-markers	652:670	novel glyco-markers of response and survival	652:695	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	8	22	theme	serum	1260:1264	arg1	glycosylation					1274:1286	serum protein glycosylation	1260:1286	serum protein glycosylation	1260:1286	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	7	23	theme	pre-treatment	950:962	arg1	profile					974:980	a pre-treatment N-glycome profile	948:980	a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose	948:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	8	24	theme	melanoma	1340:1347	arg1	behaviour					1349:1357	a pro-metastatic melanoma behaviour	1323:1357	a pro-metastatic melanoma behaviour	1323:1357	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	0	25	theme	advanced	116:123	arg1	melanoma					125:132	advanced melanoma	116:132	advanced melanoma	116:132	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	8	26	theme	adjunct	1498:1504	arg1	therapies					1506:1514	adjunct therapies	1498:1514	adjunct therapies aiming at improving immune response	1498:1550	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	2	27	theme	response	293:300	arg1	biomarker					268:276	no reliable biomarker	256:276	no reliable biomarker of survival or response	256:300	However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs.
36805683	8	28	theme	pro-metastatic	1325:1338	arg1	behaviour					1349:1357	a pro-metastatic melanoma behaviour	1323:1357	a pro-metastatic melanoma behaviour	1323:1357	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	5	29	theme	total	728:732	arg1	proteins					740:747	total serum proteins	728:747	total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries	728:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	8	30	theme	immune	1536:1541	arg1	response					1543:1550	immune response	1536:1550	immune response	1536:1550	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	5	31	theme	ICI-naive	765:773	arg1	patients					775:782	88 ICI-naive patients	762:782	88 ICI-naive patients with advanced melanoma from two European countries	762:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	5	32	theme	serum	734:738	arg1	proteins					740:747	total serum proteins	728:747	total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries	728:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	1	33	theme	melanoma	219:226	arg1	treatment					206:214	the treatment	202:214	the treatment of melanoma and other cancers	202:244	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	0	34	theme	immune	49:54	arg1	therapy					78:84	immune checkpoint inhibition therapy	49:84	immune checkpoint inhibition therapy	49:84	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	7	35	dep	RESULTS	892:898	arg1	We					900:901	We	900:901	We	900:901	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	5	36	theme	survival	688:695	arg1	glyco-markers					658:670	novel glyco-markers	652:670	novel glyco-markers of response and survival	652:695	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	6	37	theme	ICI	877:879	arg1	treatment					881:889	ICI treatment	877:889	ICI treatment	877:889	Samples were collected before and during ICI treatment.
36805683	3	38	dep	proteins	430:437	arg1	functions					465:473	functions	465:473	functions	465:473	Glycosylation affects proteins and lipids' structure and functions.
36805683	3	38	dep	proteins	430:437	arg1	structure					451:459	structure	451:459	structure	451:459	Glycosylation affects proteins and lipids' structure and functions.
36805683	5	39	from	countries	825:833	arg1	melanoma					798:805	advanced melanoma	789:805	advanced melanoma from two European countries	789:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	5	40	theme	European	816:823	arg1	countries					825:833	two European countries	812:833	two European countries	812:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	8	41	theme	protein	1266:1272	arg1	glycosylation					1274:1286	serum protein glycosylation	1260:1286	serum protein glycosylation	1260:1286	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	5	42	dep	METHODS	622:628	arg1	aim					633:635	aim	633:635	aim	633:635	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	7	43	theme	antennary	1087:1095	arg1	fucose					1097:1102	antennary fucose	1087:1102	antennary fucose	1087:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	2	44	with	patients	343:350	arg1	melanoma					357:364	melanoma	357:364	melanoma	357:364	However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs.
36805683	2	45	theme	reliable	259:266	arg1	biomarker					268:276	no reliable biomarker	256:276	no reliable biomarker of survival or response	256:300	However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs.
36805683	7	46	theme	lower	1067:1071	arg1	abundances					1073:1082	lower abundances	1067:1082	lower abundances of antennary fucose	1067:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	7	47	theme	fucose	1097:1102	arg1	abundances					1073:1082	lower abundances	1067:1082	lower abundances of antennary fucose	1067:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	8	48	theme	patients	1471:1478	arg1	stratification					1453:1466	the stratification	1449:1466	the stratification of patients and the design of adjunct therapies aiming at improving immune response	1449:1550	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	7	49	theme	low-branched	1032:1043	arg1	structures					1045:1054	low-branched structures	1032:1054	low-branched structures containing lower abundances of antennary fucose	1032:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	1	50	theme	BACKGROUND	135:144	arg1	ICIs					176:179	ICIs	176:179	ICIs	176:179	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	1	50	theme	BACKGROUND	135:144	arg1	inhibitors					164:173	BACKGROUND Immune checkpoint inhibitors	135:173	BACKGROUND Immune checkpoint inhibitors (ICIs)	135:180	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	1	51	theme	other	232:236	arg1	cancers					238:244	other cancers	232:244	other cancers	232:244	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	0	52	theme	inhibition	67:76	arg1	therapy					78:84	immune checkpoint inhibition therapy	49:84	immune checkpoint inhibition therapy	49:84	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	0	53	from	survival	90:97	arg1	patients					102:109	patients	102:109	patients with advanced melanoma	102:132	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	8	54	theme	design	1488:1493	arg1	stratification					1453:1466	the stratification	1449:1466	the stratification of patients and the design of adjunct therapies aiming at improving immune response	1449:1550	CONCLUSION While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
36805683	7	55	theme	structures	1045:1054	arg1	abundancy					1019:1027	higher abundancy	1012:1027	higher abundancy of low-branched structures containing lower abundances of antennary fucose	1012:1102	RESULTS We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone.
36805683	1	56	theme	Immune	146:151	arg1	ICIs					176:179	ICIs	176:179	ICIs	176:179	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	1	56	theme	Immune	146:151	arg1	inhibitors					164:173	BACKGROUND Immune checkpoint inhibitors	135:173	BACKGROUND Immune checkpoint inhibitors (ICIs)	135:180	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	1	57	theme	cancers	238:244	arg1	treatment					206:214	the treatment	202:214	the treatment of melanoma and other cancers	202:244	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	0	58	theme	checkpoint	56:65	arg1	therapy					78:84	immune checkpoint inhibition therapy	49:84	immune checkpoint inhibition therapy	49:84	Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
36805683	5	59	with	patients	775:782	arg1	melanoma					798:805	advanced melanoma	789:805	advanced melanoma from two European countries	789:833	METHODS We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries.
36805683	1	60	theme	checkpoint	153:162	arg1	ICIs					176:179	ICIs	176:179	ICIs	176:179	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
36805683	1	60	theme	checkpoint	153:162	arg1	inhibitors					164:173	BACKGROUND Immune checkpoint inhibitors	135:173	BACKGROUND Immune checkpoint inhibitors (ICIs)	135:180	BACKGROUND Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers.
34939096	2	0	theme	glycoengineering	380:395	arg1	approaches					397:406	enhanced in vitro glycoengineering approaches	362:406	enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes	362:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	1	1	theme	recombinant	284:294	arg1	production					296:305	the recombinant production	280:305	the recombinant production of monoclonal antibodies (mAbs)	280:337	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	6	2	theme	mode	1317:1320	arg1	approach					1322:1329	an optimized two-step mixed mode approach	1289:1329	an optimized two-step mixed mode approach	1289:1329	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	6	3	theme	IgG1	1404:1407	arg1	mAb					1409:1411	the IgG1 mAb	1400:1411	the IgG1 mAb	1400:1411	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	7	4	theme	%	1643:1643	arg1	sialylation					1657:1667	61% biantennary sialylation	1641:1667	61% biantennary sialylation	1641:1667	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	6	5	theme	two-step	1302:1309	arg1	approach					1322:1329	an optimized two-step mixed mode approach	1289:1329	an optimized two-step mixed mode approach	1289:1329	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	4	6	theme	affinity	981:988	arg1	chromatography					990:1003	affinity chromatography	981:1003	affinity chromatography using Protein A or KappaSelect	981:1034	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	3	7	theme	in	675:676	arg1	protocols					701:709	different in vitro glycoengineering protocols	665:709	different in vitro glycoengineering protocols (two-step vs. one-step)	665:733	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	7	8	theme	α2,6-sialyltransferase	1558:1579	arg1	reaction					1546:1553	in-solution reaction	1534:1553	in-solution reaction of α2,6-sialyltransferase	1534:1579	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	5	9	dep	in	1139:1140	arg1	vitro					1142:1146	vitro	1142:1146	vitro	1142:1146	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	5	10	theme	culture	1199:1205	arg1	harvest					1207:1213	cell culture harvest	1194:1213	cell culture harvest	1194:1213	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	5	11	from	glycoengineering	1148:1163	arg1	column					1168:1173	column	1168:1173	column	1168:1173	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	4	12	theme	efficient	1063:1071	arg1	galactosylation					1073:1087	more efficient galactosylation	1058:1087	more efficient galactosylation	1058:1087	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	6	13	theme	in	1371:1372	arg1	glycoengineering					1380:1395	in vitro glycoengineering	1371:1395	in vitro glycoengineering of the IgG1 mAb	1371:1411	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	2	14	theme	sialylation	517:527	arg1	efficiency					483:492	the efficiency	479:492	the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes	479:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	4	15	theme	mAb	822:824	arg1	amounts					826:832	mAb amounts	822:832	mAb amounts ranging from 1 mg to 1 g.	822:858	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	3	16	theme	glycoengineering	684:699	arg1	protocols					701:709	different in vitro glycoengineering protocols	665:709	different in vitro glycoengineering protocols (two-step vs. one-step)	665:733	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	9	17	theme	easy-to-handle	1916:1929	arg1	workflow					1931:1938	an optimized easy-to-handle workflow	1903:1938	an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production	1903:2023	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	7	18	theme	β1,4-galactosyltransferase	1493:1518	arg1	harvest					1459:1465	harvest	1459:1465	harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase	1459:1579	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	6	19	theme	overall	1422:1428	arg1	process					1444:1450	the overall manufacturing process	1418:1450	the overall manufacturing process	1418:1450	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	7	20	theme	%	1607:1607	arg1	galactosylation					1621:1635	100% biantennary galactosylation	1604:1635	100% biantennary galactosylation	1604:1635	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	2	21	theme	common	586:591	arg1	processes					610:618	common mAb purification processes	586:618	common mAb purification processes	586:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	4	22	theme	reactions	791:799	arg1	Scalability					772:782	Scalability	772:782	Scalability of the reactions	772:799	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	1	23	theme	specific	169:176	arg1	modification					178:189	specific modification	169:189	specific modification	169:189	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	4	24	theme	mAbs	1122:1125	arg1	sialylation					1093:1103	sialylation	1093:1103	sialylation	1093:1103	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	4	24	theme	mAbs	1122:1125	arg1	galactosylation					1073:1087	more efficient galactosylation	1058:1087	more efficient galactosylation	1058:1087	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	6	25	dep	in	1371:1372	arg1	vitro					1374:1378	vitro	1374:1378	vitro	1374:1378	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	2	26	with	efficiency	483:492	arg1	aim					538:540	the aim to implement in vitro glycoengineering into common mAb purification processes	534:618	the aim to implement in vitro glycoengineering into common mAb purification processes	534:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	3	27	dep	in	675:676	arg1	vitro					678:682	vitro	678:682	vitro	678:682	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	0	28	theme	industrial	99:108	arg1	production					110:119	industrial production	99:119	industrial production	99:119	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	6	29	theme	mixed	1311:1315	arg1	approach					1322:1329	an optimized two-step mixed mode approach	1289:1329	an optimized two-step mixed mode approach	1289:1329	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	2	30	theme	purification	597:608	arg1	processes					610:618	common mAb purification processes	586:618	common mAb purification processes	586:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	7	31	theme	on-column	1471:1479	arg1	reaction					1481:1488	on-column reaction	1471:1488	on-column reaction	1471:1488	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	1	32	theme	monoclonal	310:319	arg1	mAbs					333:336	mAbs	333:336	mAbs	333:336	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	1	32	theme	monoclonal	310:319	arg1	antibodies					321:330	monoclonal antibodies	310:330	monoclonal antibodies (mAbs)	310:337	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	9	33	theme	mAb	2010:2012	arg1	production					2014:2023	industrial mAb production	1999:2023	industrial mAb production	1999:2023	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	2	34	theme	galactosylation	497:511	arg1	efficiency					483:492	the efficiency	479:492	the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes	479:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	0	35	theme	in	18:19	arg1	glycoengineering					27:42	in vitro glycoengineering	18:42	in vitro glycoengineering of monoclonal antibodies	18:67	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	1	36	theme	In	122:123	arg1	method					220:225	appropriate method	208:225	appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs)	208:337	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	1	36	theme	In	122:123	arg1	glycoengineering					131:146	In vitro glycoengineering	122:146	In vitro glycoengineering using exoenzymes for specific modification	122:189	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	2	37	theme	in	555:556	arg1	glycoengineering					564:579	in vitro glycoengineering	555:579	in vitro glycoengineering into common mAb purification processes	555:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	3	38	theme	overall	753:759	arg1	procedure					761:769	the overall procedure	749:769	the overall procedure	749:769	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	0	39	theme	glycoengineering	27:42	arg1	Implementation					0:13	Implementation	0:13	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production	0:119	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	9	40	dep	in	1864:1865	arg1	vitro					1867:1871	vitro	1867:1871	vitro	1867:1871	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	0	41	theme	monoclonal	47:56	arg1	antibodies					58:67	monoclonal antibodies	47:67	monoclonal antibodies	47:67	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	4	42	theme	β1,4-galactosyltransferase	891:916	arg1	reactions					878:886	the reactions	874:886	the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase	874:943	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	2	43	theme	enhanced	362:369	arg1	approaches					397:406	enhanced in vitro glycoengineering approaches	362:406	enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes	362:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	7	44	theme	100	1604:1606	arg1	%					1607:1607	%	1607:1607	%	1607:1607	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	5	45	theme	Performing	1128:1137	arg1	glycoengineering					1148:1163	Performing in vitro glycoengineering	1128:1163	Performing in vitro glycoengineering on column	1128:1173	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	8	46	theme	further	1772:1778	arg1	reactions					1780:1788	further reactions	1772:1788	further reactions	1772:1788	Moreover, the enzymes applied in in vitro glycoengineering could be separated, recycled and reused in further reactions to improve economic efficiency.
34939096	4	47	theme	α2,6-sialyltransferase	922:943	arg1	reactions					878:886	the reactions	874:886	the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase	874:943	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	8	48	dep	in	1703:1704	arg1	vitro					1706:1710	vitro	1706:1710	vitro	1706:1710	Moreover, the enzymes applied in in vitro glycoengineering could be separated, recycled and reused in further reactions to improve economic efficiency.
34939096	7	49	theme	biantennary	1645:1655	arg1	sialylation					1657:1667	61% biantennary sialylation	1641:1667	61% biantennary sialylation	1641:1667	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	8	50	theme	economic	1801:1808	arg1	efficiency					1810:1819	economic efficiency	1801:1819	economic efficiency	1801:1819	Moreover, the enzymes applied in in vitro glycoengineering could be separated, recycled and reused in further reactions to improve economic efficiency.
34939096	6	51	theme	mAb	1409:1411	arg1	glycoengineering					1380:1395	in vitro glycoengineering	1371:1395	in vitro glycoengineering of the IgG1 mAb	1371:1411	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	7	52	theme	61	1641:1642	arg1	%					1643:1643	%	1643:1643	%	1643:1643	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	4	53	theme	Protein	1011:1017	arg1	A					1019:1019	Protein A	1011:1019	Protein A	1011:1019	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	7	54	theme	biantennary	1609:1619	arg1	galactosylation					1621:1635	100% biantennary galactosylation	1604:1635	100% biantennary galactosylation	1604:1635	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	3	55	theme	Feasibility	621:631	arg1	studies					633:639	Feasibility studies	621:639	Feasibility studies	621:639	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	1	56	theme	appropriate	208:218	arg1	method					220:225	appropriate method	208:225	appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs)	208:337	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	1	56	theme	appropriate	208:218	arg1	glycoengineering					131:146	In vitro glycoengineering	122:146	In vitro glycoengineering using exoenzymes for specific modification	122:189	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	6	57	theme	optimized	1292:1300	arg1	approach					1322:1329	an optimized two-step mixed mode approach	1289:1329	an optimized two-step mixed mode approach	1289:1329	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	3	58	theme	different	665:673	arg1	protocols					701:709	different in vitro glycoengineering protocols	665:709	different in vitro glycoengineering protocols (two-step vs. one-step)	665:733	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	3	59	dep	protocols	701:709	arg1	one-step					725:732	one-step	725:732	one-step	725:732	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	3	59	dep	protocols	701:709	arg1	two-step					712:719	two-step	712:719	two-step	712:719	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	9	60	theme	in	1864:1865	arg1	glycoengineering					1873:1888	in vitro glycoengineering	1864:1888	in vitro glycoengineering	1864:1888	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	4	61	dep	work	959:962	arg1	providing					1048:1056	providing	1048:1056	providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs	1048:1125	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	5	62	theme	harvest	1207:1213	arg1	use					1187:1189	the use	1183:1189	the use of cell culture harvest that yielded results comparable to those of purified bulk	1183:1271	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	3	63	theme	protocols	701:709	arg1	potential					652:660	the potential	648:660	the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure	648:769	Feasibility studies tested the potential of different in vitro glycoengineering protocols (two-step vs. one-step) to facilitate the overall procedure.
34939096	1	64	theme	sugar	237:241	arg1	moieties					243:250	sugar moieties	237:250	sugar moieties of glycan structures	237:271	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	9	65	theme	optimized	1906:1914	arg1	workflow					1931:1938	an optimized easy-to-handle workflow	1903:1938	an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production	1903:2023	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	7	66	theme	in-solution	1534:1544	arg1	reaction					1546:1553	in-solution reaction	1534:1553	in-solution reaction of α2,6-sialyltransferase	1534:1579	Using harvest for on-column reaction of β1,4-galactosyltransferase combined with in-solution reaction of α2,6-sialyltransferase, this approach yielded 100% biantennary galactosylation and 61% biantennary sialylation.
34939096	6	67	theme	manufacturing	1430:1442	arg1	process					1444:1450	the overall manufacturing process	1418:1450	the overall manufacturing process	1418:1450	Based thereon, an optimized two-step mixed mode approach was found most appropriate to integrate in vitro glycoengineering of the IgG1 mAb into the overall manufacturing process.
34939096	0	68	theme	downstream	74:83	arg1	processing					85:94	downstream processing	74:94	downstream processing of industrial production	74:119	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	5	69	theme	cell	1194:1197	arg1	harvest					1207:1213	cell culture harvest	1194:1213	cell culture harvest	1194:1213	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	4	70	theme	IgG1	1108:1111	arg1	mAbs					1122:1125	IgG1 and IgG4 mAbs	1108:1125	IgG1 and IgG4 mAbs	1108:1125	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	1	71	dep	In	122:123	arg1	vitro					125:129	vitro	125:129	vitro	125:129	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	5	72	theme	purified	1259:1266	arg1	bulk					1268:1271	purified bulk	1259:1271	purified bulk	1259:1271	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	4	73	theme	IgG4	1117:1120	arg1	mAbs					1122:1125	IgG1 and IgG4 mAbs	1108:1125	IgG1 and IgG4 mAbs	1108:1125	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	0	74	theme	production	110:119	arg1	processing					85:94	downstream processing	74:94	downstream processing of industrial production	74:119	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	0	75	dep	in	18:19	arg1	vitro					21:25	vitro	21:25	vitro	21:25	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	2	76	dep	in	555:556	arg1	vitro					558:562	vitro	558:562	vitro	558:562	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	8	77	theme	in	1703:1704	arg1	glycoengineering					1712:1727	in vitro glycoengineering	1703:1727	in vitro glycoengineering	1703:1727	Moreover, the enzymes applied in in vitro glycoengineering could be separated, recycled and reused in further reactions to improve economic efficiency.
34939096	5	78	theme	comparable	1236:1245	arg1	results					1228:1234	results	1228:1234	results comparable to those of purified bulk	1228:1271	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
34939096	2	79	theme	mAb	593:595	arg1	processes					610:618	common mAb purification processes	586:618	common mAb purification processes	586:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	9	80	theme	downstream	1974:1983	arg1	processing					1985:1994	the downstream processing	1970:1994	the downstream processing of industrial mAb production	1970:2023	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	9	81	theme	industrial	1999:2008	arg1	production					2014:2023	industrial mAb production	1999:2023	industrial mAb production	1999:2023	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	1	82	theme	antibodies	321:330	arg1	production					296:305	the recombinant production	280:305	the recombinant production of monoclonal antibodies (mAbs)	280:337	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	4	83	gly	sialylation	1093:1103	arg1	mAbs					1122:1125	IgG1 and IgG4 mAbs	1108:1125	IgG1 and IgG4 mAbs	1108:1125	Scalability of the reactions was demonstrated for mAb amounts ranging from 1 mg to 1 g. Additionally, the reactions of β1,4-galactosyltransferase and α2,6-sialyltransferase were shown to work on column during affinity chromatography using Protein A or KappaSelect, the latter providing more efficient galactosylation and sialylation of IgG1 and IgG4 mAbs.
34939096	9	84	theme	production	2014:2023	arg1	processing					1985:1994	the downstream processing	1970:1994	the downstream processing of industrial mAb production	1970:2023	Overall, the study provides a toolbox for in vitro glycoengineering and presents an optimized easy-to-handle workflow to implement this method into the downstream processing of industrial mAb production.
34939096	2	85	dep	in	371:372	arg1	vitro					374:378	vitro	374:378	vitro	374:378	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	1	86	theme	structures	262:271	arg1	moieties					243:250	sugar moieties	237:250	sugar moieties of glycan structures	237:271	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	0	87	theme	antibodies	58:67	arg1	glycoengineering					27:42	in vitro glycoengineering	18:42	in vitro glycoengineering of monoclonal antibodies	18:67	Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
34939096	2	88	theme	in	371:372	arg1	approaches					397:406	enhanced in vitro glycoengineering approaches	362:406	enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes	362:618	This report describes enhanced in vitro glycoengineering approaches using β1,4-galactosyltransferase and α2,6-sialyltransferase to improve the efficiency of galactosylation and sialylation with the aim to implement in vitro glycoengineering into common mAb purification processes.
34939096	1	89	theme	glycan	255:260	arg1	structures					262:271	glycan structures	255:271	glycan structures	255:271	In vitro glycoengineering using exoenzymes for specific modification is recognized as appropriate method to tailor sugar moieties of glycan structures during the recombinant production of monoclonal antibodies (mAbs).
34939096	5	90	theme	in	1139:1140	arg1	glycoengineering					1148:1163	Performing in vitro glycoengineering	1128:1163	Performing in vitro glycoengineering on column	1128:1173	Performing in vitro glycoengineering on column enabled the use of cell culture harvest that yielded results comparable to those of purified bulk.
35698379	0	0	theme	polyurethane-cellulose	85:106	arg1	composites					108:117	polyurethane-cellulose composites	85:117	polyurethane-cellulose composites	85:117	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	6	1	theme	future	1136:1141	arg1	composites					1153:1162	future cellulose composites	1136:1162	future cellulose composites	1136:1162	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	6	2	theme	compositions	1026:1037	arg1	effect					995:1000	the effect	991:1000	the effect of cellulose additives, compositions, and processes on PU/cellulose composites	991:1079	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	5	3	from	54.95 MPa	923:931	arg1	composites					943:952	PU/CNF composites	936:952	PU/CNF composites	936:952	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	0	4	from	Effect	0:5	arg1	properties					71:80	mechanical properties	60:80	mechanical properties of polyurethane-cellulose composites	60:117	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	3	5	theme	enhanced	552:559	arg1	modulus					569:575	enhanced Young's modulus	552:575	enhanced Young's modulus of composites from 0.04 to 6.94 MPa	552:611	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	6	6	theme	additives	1015:1023	arg1	effect					995:1000	the effect	991:1000	the effect of cellulose additives, compositions, and processes on PU/cellulose composites	991:1079	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	0	7	theme	composites	108:117	arg1	properties					71:80	mechanical properties	60:80	mechanical properties of polyurethane-cellulose composites	60:117	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	6	8	theme	cellulose	1005:1013	arg1	additives					1015:1023	cellulose additives	1005:1023	cellulose additives	1005:1023	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	5	9	theme	PU/CNF	936:941	arg1	composites					943:952	PU/CNF composites	936:952	PU/CNF composites	936:952	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	4	10	from	interference	682:693	arg1	microstructure					705:718	the PU microstructure	698:718	the PU microstructure	698:718	The CNF is heterogeneously distributed in PU/CNF composites without interference on the PU microstructure and slightly increased modulus to 0.24 MPa.
35698379	4	10	from	interference	682:693	arg1	modulus					743:749	slightly increased modulus	724:749	slightly increased modulus to 0.24 MPa	724:761	The CNF is heterogeneously distributed in PU/CNF composites without interference on the PU microstructure and slightly increased modulus to 0.24 MPa.
35698379	5	11	theme	electrospinning	796:810	arg1	process					812:818	the electrospinning process	792:818	the electrospinning process	792:818	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	2	12	theme	drop-casting	444:455	arg1	process					476:482	either drop-casting or electrospinning process	437:482	either drop-casting or electrospinning process	437:482	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	3	13	theme	microphase	526:535	arg1	separation					537:546	microphase separation	526:546	microphase separation	526:546	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	6	14	theme	comprehensive	1094:1106	arg1	understanding					1108:1120	a comprehensive understanding	1092:1120	a comprehensive understanding for designing future cellulose composites	1092:1162	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	1	15	theme	different	205:213	arg1	impacts					215:221	different impacts	205:221	different impacts on the morphologies and properties of composites	205:270	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	5	16	theme	PU/EC	841:845	arg1	composites					847:856	the PU/EC composites	837:856	the PU/EC composites	837:856	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	3	17	theme	composites	580:589	arg1	modulus					569:575	enhanced Young's modulus	552:575	enhanced Young's modulus of composites from 0.04 to 6.94 MPa	552:611	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	3	17	theme	composites	580:589	arg1	separation					537:546	microphase separation	526:546	microphase separation	526:546	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	3	18	dep	6.94 MPa	604:611	arg1	to					601:602	to	601:602	to	601:602	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	0	19	theme	compositions	20:31	arg1	Effect					0:5	Effect	0:5	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.	0:118	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	2	20	theme	composites	326:335	arg1	properties					312:321	properties	312:321	properties	312:321	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	20	theme	composites	326:335	arg1	morphologies					295:306	morphologies	295:306	morphologies	295:306	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	0	21	theme	cellulose	10:18	arg1	compositions					20:31	cellulose compositions	10:31	cellulose compositions	10:31	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	2	22	dep	morphologies	295:306	arg1	the					291:293	the	291:293	the	291:293	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	0	23	theme	fabrication	37:47	arg1	methods					49:55	fabrication methods	37:55	fabrication methods	37:55	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	2	24	with	polyurethane	349:360	arg1	nanofiber					413:421	cellulose nanofiber	403:421	cellulose nanofiber (CNF)	403:427	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	24	with	polyurethane	349:360	arg1	CNF					424:426	CNF	424:426	CNF	424:426	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	24	with	polyurethane	349:360	arg1	EC					396:397	EC	396:397	EC	396:397	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	24	with	polyurethane	349:360	arg1	cellulose					385:393	ethyl cellulose	379:393	ethyl cellulose (EC)	379:398	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	3	25	from	6.94 MPa	604:611	arg1	modulus					569:575	enhanced Young's modulus	552:575	enhanced Young's modulus of composites from 0.04 to 6.94 MPa	552:611	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	3	25	from	6.94 MPa	604:611	arg1	separation					537:546	microphase separation	526:546	microphase separation	526:546	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	3	25	from	6.94 MPa	604:611	arg1	composites					580:589	composites	580:589	composites from 0.04 to 6.94 MPa	580:611	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	4	26	theme	PU/CNF	656:661	arg1	composites					663:672	PU/CNF composites	656:672	PU/CNF composites without interference on the PU microstructure and slightly increased modulus to 0.24 MPa	656:761	The CNF is heterogeneously distributed in PU/CNF composites without interference on the PU microstructure and slightly increased modulus to 0.24 MPa.
35698379	4	27	theme	PU	702:703	arg1	microstructure					705:718	the PU microstructure	698:718	the PU microstructure	698:718	The CNF is heterogeneously distributed in PU/CNF composites without interference on the PU microstructure and slightly increased modulus to 0.24 MPa.
35698379	5	28	theme	process	812:818	arg1	force					783:787	the shearing force	770:787	the shearing force of the electrospinning process	770:818	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	6	29	from	effect	995:1000	arg1	composites					1070:1079	PU/cellulose composites	1057:1079	PU/cellulose composites	1057:1079	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	2	30	theme	cellulose	403:411	arg1	nanofiber					413:421	cellulose nanofiber	403:421	cellulose nanofiber (CNF)	403:427	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	30	theme	cellulose	403:411	arg1	CNF					424:426	CNF	424:426	CNF	424:426	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	31	theme	electrospinning	460:474	arg1	process					476:482	either drop-casting or electrospinning process	437:482	either drop-casting or electrospinning process	437:482	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	5	32	theme	Young	904:908	arg1	modulus					912:918	Young's modulus	904:918	Young's modulus	904:918	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	6	33	theme	PU/cellulose	1057:1068	arg1	composites					1070:1079	PU/cellulose composites	1057:1079	PU/cellulose composites	1057:1079	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	6	34	theme	cellulose	1143:1151	arg1	composites					1153:1162	future cellulose composites	1136:1162	future cellulose composites	1136:1162	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	4	35	theme	increased	733:741	arg1	modulus					743:749	slightly increased modulus	724:749	slightly increased modulus to 0.24 MPa	724:761	The CNF is heterogeneously distributed in PU/CNF composites without interference on the PU microstructure and slightly increased modulus to 0.24 MPa.
35698379	0	36	theme	methods	49:55	arg1	Effect					0:5	Effect	0:5	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.	0:118	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	1	37	theme	cellulose-based	133:147	arg1	materials					167:175	cellulose-based polymer composite materials	133:175	cellulose-based polymer composite materials	133:175	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	38	dep	morphologies	230:241	arg1	the					226:228	the	226:228	the	226:228	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	39	theme	polymer	149:155	arg1	materials					167:175	cellulose-based polymer composite materials	133:175	cellulose-based polymer composite materials	133:175	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	3	40	from	modulus	569:575	arg1	6.94 MPa					604:611	6.94 MPa	604:611	6.94 MPa	604:611	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35698379	1	41	theme	composite	157:165	arg1	materials					167:175	cellulose-based polymer composite materials	133:175	cellulose-based polymer composite materials	133:175	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	6	42	theme	processes	1044:1052	arg1	effect					995:1000	the effect	991:1000	the effect of cellulose additives, compositions, and processes on PU/cellulose composites	991:1079	A model is established to summarize the effect of cellulose additives, compositions, and processes on PU/cellulose composites, providing a comprehensive understanding for designing future cellulose composites.
35698379	5	43	theme	shearing	774:781	arg1	force					783:787	the shearing force	770:787	the shearing force of the electrospinning process	770:818	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	5	44	theme	PU	883:884	arg1	crystallinity					886:898	PU crystallinity	883:898	PU crystallinity	883:898	While the shearing force of the electrospinning process slightly affects the PU/EC composites, it drastically enhances PU crystallinity and Young's modulus to 54.95 MPa in PU/CNF composites.
35698379	1	45	from	impacts	215:221	arg1	properties					247:256	properties	247:256	properties	247:256	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	45	from	impacts	215:221	arg1	morphologies					230:241	morphologies	230:241	morphologies	230:241	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	46	theme	materials	167:175	arg1	materials					167:175	cellulose-based polymer composite materials	133:175	cellulose-based polymer composite materials	133:175	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	46	theme	materials	167:175	arg1	variety					122:128	A variety	120:128	A variety of cellulose-based polymer composite materials	120:175	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	47	theme	composites	261:270	arg1	properties					247:256	properties	247:256	properties	247:256	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	1	47	theme	composites	261:270	arg1	morphologies					230:241	morphologies	230:241	morphologies	230:241	A variety of cellulose-based polymer composite materials has been developed and show different impacts on the morphologies and properties of composites.
35698379	0	48	theme	mechanical	60:69	arg1	properties					71:80	mechanical properties	60:80	mechanical properties of polyurethane-cellulose composites	60:117	Effect of cellulose compositions and fabrication methods on mechanical properties of polyurethane-cellulose composites.
35698379	2	49	theme	ethyl	379:383	arg1	EC					396:397	EC	396:397	EC	396:397	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	2	49	theme	ethyl	379:383	arg1	cellulose					385:393	ethyl cellulose	379:393	ethyl cellulose (EC)	379:398	Herein, we report the morphologies and properties of composites by blending polyurethane (PU) with either ethyl cellulose (EC) or cellulose nanofiber (CNF) through either drop-casting or electrospinning process.
35698379	3	50	from	separation	537:546	arg1	6.94 MPa					604:611	6.94 MPa	604:611	6.94 MPa	604:611	EC is homogenously mixed with PU without microphase separation and enhanced Young's modulus of composites from 0.04 to 6.94 MPa.
35628150	5	0	theme	hydrophobic	594:604	arg1	molecules					606:614	hydrophobic molecules	594:614	hydrophobic molecules	594:614	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	3	1	theme	obtained	362:369	arg1	co-polymer					371:380	The obtained co-polymer	358:380	The obtained co-polymer	358:380	The obtained co-polymer was crosslinked with genipin and composited with graphene oxide.
35628150	4	2	theme	FTIR	447:450	arg1	spectra					452:458	FTIR spectra	447:458	FTIR spectra	447:458	FTIR spectra highlighted the modification and multi-components interaction.
35628150	1	3	theme	fatty	200:204	arg1	co-polymer					234:243	fatty acid-coupled polysaccharide co-polymer	200:243	fatty acid-coupled polysaccharide co-polymer	200:243	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	1	3	theme	fatty	200:204	arg1	phase					263:267	the continuous phase	248:267	the continuous phase	248:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	9	4	with	substrates	1189:1198	arg1	architecture					1219:1230	heterogeneous architecture	1205:1230	heterogeneous architecture	1205:1230	The robust and stable substrates with heterogeneous architecture we developed show promise in biomedical applications.
35628150	2	5	theme	palmitic	332:339	arg1	acid					352:355	palmitic and lauric acid	332:355	palmitic and lauric acid	332:355	The matrix was synthesized by N, O-acylation of chitosan with palmitic and lauric acid.
35628150	9	6	theme	heterogeneous	1205:1217	arg1	architecture					1219:1230	heterogeneous architecture	1205:1230	heterogeneous architecture	1205:1230	The robust and stable substrates with heterogeneous architecture we developed show promise in biomedical applications.
35628150	7	7	with	blocks	891:896	arg1	oxide					912:916	graphene oxide	903:916	graphene oxide	903:916	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	7	8	theme	in	942:943	arg1	tests					973:977	in vitro enzymatic degradation tests	942:977	in vitro enzymatic degradation tests	942:977	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	5	9	theme	angle	545:549	arg1	tests					551:555	contact angle tests	537:555	contact angle tests	537:555	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	9	10	theme	biomedical	1261:1270	arg1	applications					1272:1283	biomedical applications	1261:1283	biomedical applications	1261:1283	The robust and stable substrates with heterogeneous architecture we developed show promise in biomedical applications.
35628150	8	11	theme	In	997:998	arg1	tests					1057:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	8	12	theme	adsorption	1106:1115	arg1	test					1117:1120	the protein adsorption test	1094:1120	the protein adsorption test	1094:1120	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	2	13	theme	chitosan	318:325	arg1	N					300:300	N	300:300	N	300:300	The matrix was synthesized by N, O-acylation of chitosan with palmitic and lauric acid.
35628150	2	13	theme	chitosan	318:325	arg1	O-acylation					303:313	O-acylation	303:313	O-acylation of chitosan with palmitic and lauric acid	303:355	The matrix was synthesized by N, O-acylation of chitosan with palmitic and lauric acid.
35628150	6	14	theme	acid	814:817	arg1	self-organization					819:835	chitosan/fatty acid self-organization	799:835	chitosan/fatty acid self-organization	799:835	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	1	15	theme	acid-coupled	206:217	arg1	co-polymer					234:243	fatty acid-coupled polysaccharide co-polymer	200:243	fatty acid-coupled polysaccharide co-polymer	200:243	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	1	15	theme	acid-coupled	206:217	arg1	phase					263:267	the continuous phase	248:267	the continuous phase	248:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	5	16	theme	core-shell	697:706	arg1	structuration					723:735	a core-shell macromolecular structuration	695:735	a core-shell macromolecular structuration	695:735	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	5	17	theme	surface	638:644	arg1	roughness					646:654	surface roughness	638:654	surface roughness	638:654	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	0	18	theme	Chitosan-Based	0:13	arg1	Materials					15:23	Chitosan-Based Materials	0:23	Chitosan-Based Materials	0:23	Chitosan-Based Materials Featuring Multiscale Anisotropy for Wider Tissue Engineering Applications.
35628150	6	19	theme	chitosan/fatty	799:812	arg1	self-organization					819:835	chitosan/fatty acid self-organization	799:835	chitosan/fatty acid self-organization	799:835	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	1	20	theme	polysaccharide	219:232	arg1	co-polymer					234:243	fatty acid-coupled polysaccharide co-polymer	200:243	fatty acid-coupled polysaccharide co-polymer	200:243	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	1	20	theme	polysaccharide	219:232	arg1	phase					263:267	the continuous phase	248:267	the continuous phase	248:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	3	21	theme	graphene	431:438	arg1	oxide					440:444	graphene oxide	431:444	graphene oxide	431:444	The obtained co-polymer was crosslinked with genipin and composited with graphene oxide.
35628150	8	22	theme	viability	1006:1014	arg1	tests					1057:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	5	23	theme	macromolecular	708:721	arg1	structuration					723:735	a core-shell macromolecular structuration	695:735	a core-shell macromolecular structuration	695:735	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	1	24	with	composites	127:136	arg1	variability					182:192	increased morphological and structural variability	143:192	increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase	143:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	8	25	dep	In	997:998	arg1	vitro					1000:1004	vitro	1000:1004	vitro	1000:1004	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	1	26	theme	graphene	112:119	arg1	composites					127:136	graphene oxide composites	112:136	graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase	112:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	6	27	theme	due	792:794	arg1	gradient					783:790	a notable durotaxis gradient	763:790	a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment	763:864	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	0	28	theme	Multiscale	35:44	arg1	Anisotropy					46:55	Multiscale Anisotropy	35:55	Multiscale Anisotropy for Wider Tissue Engineering Applications	35:97	Chitosan-Based Materials Featuring Multiscale Anisotropy for Wider Tissue Engineering Applications.
35628150	7	29	theme	enzymatic	951:959	arg1	tests					973:977	in vitro enzymatic degradation tests	942:977	in vitro enzymatic degradation tests	942:977	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	1	30	theme	oxide	121:125	arg1	composites					127:136	graphene oxide composites	112:136	graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase	112:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	7	31	theme	degradation	961:971	arg1	tests					973:977	in vitro enzymatic degradation tests	942:977	in vitro enzymatic degradation tests	942:977	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	8	32	theme	promising	1071:1079	arg1	results					1081:1087	promising results	1071:1087	promising results	1071:1087	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	9	33	dep	substrates	1189:1198	arg1	developed					1235:1243	developed	1235:1243	developed	1235:1243	The robust and stable substrates with heterogeneous architecture we developed show promise in biomedical applications.
35628150	6	34	theme	notable	765:771	arg1	gradient					783:790	a notable durotaxis gradient	763:790	a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment	763:864	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	6	35	theme	durotaxis	773:781	arg1	gradient					783:790	a notable durotaxis gradient	763:790	a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment	763:864	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	1	36	theme	continuous	252:261	arg1	co-polymer					234:243	fatty acid-coupled polysaccharide co-polymer	200:243	fatty acid-coupled polysaccharide co-polymer	200:243	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	1	36	theme	continuous	252:261	arg1	phase					263:267	the continuous phase	248:267	the continuous phase	248:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	8	37	theme	protein	1098:1104	arg1	test					1117:1120	the protein adsorption test	1094:1120	the protein adsorption test	1094:1120	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	5	38	theme	contact	537:543	arg1	tests					551:555	contact angle tests	537:555	contact angle tests	537:555	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	7	39	theme	graphene	903:910	arg1	oxide					912:916	graphene oxide	903:916	graphene oxide	903:916	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	5	40	theme	molecules	606:614	arg1	conjugation					579:589	the conjugation	575:589	the conjugation of hydrophobic molecules to chitosan	575:626	DLS, SEM, and contact angle tests demonstrated that the conjugation of hydrophobic molecules to chitosan increased surface roughness and hydrophilicity, since it triggered a core-shell macromolecular structuration.
35628150	0	41	theme	Tissue	67:72	arg1	Applications					86:97	Wider Tissue Engineering Applications	61:97	Wider Tissue Engineering Applications	61:97	Chitosan-Based Materials Featuring Multiscale Anisotropy for Wider Tissue Engineering Applications.
35628150	8	42	theme	inflammatory	1035:1046	arg1	response					1048:1055	inflammatory response	1035:1055	inflammatory response	1035:1055	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	0	43	theme	Wider	61:65	arg1	Applications					86:97	Wider Tissue Engineering Applications	61:97	Wider Tissue Engineering Applications	61:97	Chitosan-Based Materials Featuring Multiscale Anisotropy for Wider Tissue Engineering Applications.
35628150	2	44	with	O-acylation	303:313	arg1	acid					352:355	palmitic and lauric acid	332:355	palmitic and lauric acid	332:355	The matrix was synthesized by N, O-acylation of chitosan with palmitic and lauric acid.
35628150	4	45	theme	modification	476:487	arg1	interaction					510:520	the modification and multi-components interaction	472:520	the modification and multi-components interaction	472:520	FTIR spectra highlighted the modification and multi-components interaction.
35628150	8	46	theme	cytotoxicity	1017:1028	arg1	tests					1057:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	1	47	theme	increased	143:151	arg1	variability					182:192	increased morphological and structural variability	143:192	increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase	143:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	8	48	theme	antifouling	1145:1155	arg1	efficacy					1157:1164	potential antifouling efficacy	1135:1164	potential antifouling efficacy	1135:1164	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	8	49	theme	potential	1135:1143	arg1	efficacy					1157:1164	potential antifouling efficacy	1135:1164	potential antifouling efficacy	1135:1164	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	1	50	theme	morphological	153:165	arg1	variability					182:192	increased morphological and structural variability	143:192	increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase	143:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	2	51	theme	lauric	345:350	arg1	acid					352:355	palmitic and lauric acid	332:355	palmitic and lauric acid	332:355	The matrix was synthesized by N, O-acylation of chitosan with palmitic and lauric acid.
35628150	7	52	theme	composited	871:880	arg1	blocks					891:896	The composited building blocks	867:896	The composited building blocks with graphene oxide	867:916	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	7	52	theme	composited	871:880	arg1	stable					928:933	stable	928:933	stable	928:933	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	4	53	theme	multi-components	493:508	arg1	interaction					510:520	the modification and multi-components interaction	472:520	the modification and multi-components interaction	472:520	FTIR spectra highlighted the modification and multi-components interaction.
35628150	8	54	theme	response	1048:1055	arg1	tests					1057:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests	997:1061	In vitro viability, cytotoxicity, and inflammatory response tests yielded promising results, and the protein adsorption test demonstrated potential antifouling efficacy.
35628150	7	55	dep	in	942:943	arg1	vitro					945:949	vitro	945:949	vitro	945:949	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	9	56	theme	robust	1171:1176	arg1	substrates					1189:1198	The robust and stable substrates	1167:1198	The robust and stable substrates with heterogeneous architecture we developed	1167:1243	The robust and stable substrates with heterogeneous architecture we developed show promise in biomedical applications.
35628150	7	57	theme	building	882:889	arg1	blocks					891:896	The composited building blocks	867:896	The composited building blocks with graphene oxide	867:916	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	7	57	theme	building	882:889	arg1	stable					928:933	stable	928:933	stable	928:933	The composited building blocks with graphene oxide were more stable during in vitro enzymatic degradation tests and swelled less.
35628150	6	58	theme	sheet	850:854	arg1	embedment					856:864	graphene sheet embedment	841:864	graphene sheet embedment	841:864	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	1	59	theme	structural	171:180	arg1	variability					182:192	increased morphological and structural variability	143:192	increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase	143:267	We designed graphene oxide composites with increased morphological and structural variability using fatty acid-coupled polysaccharide co-polymer as the continuous phase.
35628150	0	60	theme	Engineering	74:84	arg1	Applications					86:97	Wider Tissue Engineering Applications	61:97	Wider Tissue Engineering Applications	61:97	Chitosan-Based Materials Featuring Multiscale Anisotropy for Wider Tissue Engineering Applications.
35628150	6	61	theme	graphene	841:848	arg1	embedment					856:864	graphene sheet embedment	841:864	graphene sheet embedment	841:864	Nanoindentation revealed a notable durotaxis gradient due to chitosan/fatty acid self-organization and graphene sheet embedment.
35628150	9	62	theme	stable	1182:1187	arg1	substrates					1189:1198	The robust and stable substrates	1167:1198	The robust and stable substrates with heterogeneous architecture we developed	1167:1243	The robust and stable substrates with heterogeneous architecture we developed show promise in biomedical applications.
36181372	9	0	theme	Rituximab	1291:1299	arg1	kinetics					1279:1286	unfavorable binding kinetics	1259:1286	unfavorable binding kinetics of Rituximab and FcγRIIIA	1259:1312	The glucose stress conditions did not result in unfavorable binding kinetics of Rituximab and FcγRIIIA.
36181372	2	1	theme	drugs	366:370	arg1	attributes					346:355	the functional attributes	331:355	the functional attributes of these drugs	331:370	Several orthogonal strategies are employed to characterize the functional attributes of these drugs.
36181372	7	2	theme	glycoform	989:997	arg1	peaks					1007:1011	the three Rituximab glycoform mixture peaks	969:1011	the three Rituximab glycoform mixture peaks	969:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	10	3	theme	dissociation	1319:1330	arg1	similar					1413:1419	similar	1413:1419	similar	1413:1419	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	10	3	theme	dissociation	1319:1330	arg1	constants					1337:1345	The dissociation rate constants	1315:1345	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F,	1315:1406	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	8	4	theme	chromatographic	1101:1115	arg1	profiles					1125:1132	the chromatographic elution profiles	1097:1132	the chromatographic elution profiles	1097:1132	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	6	5	theme	receptor	916:923	arg1	protein					925:931	the receptor protein	912:931	the receptor protein	912:931	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	10	6	theme	plasmon	1476:1482	arg1	resonance					1484:1492	surface plasmon resonance	1468:1492	surface plasmon resonance	1468:1492	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	1	7	theme	pre-clinical	230:241	arg1	investigations					256:269	pre-clinical and clinical investigations	230:269	pre-clinical and clinical investigations	230:269	Analytical and functional characterization of batches of biologics/biosimilar products are imperative towards qualifying them for pre-clinical and clinical investigations.
36181372	1	8	theme	clinical	247:254	arg1	investigations					256:269	pre-clinical and clinical investigations	230:269	pre-clinical and clinical investigations	230:269	Analytical and functional characterization of batches of biologics/biosimilar products are imperative towards qualifying them for pre-clinical and clinical investigations.
36181372	12	9	theme	glucose	1736:1742	arg1	stress					1744:1749	glucose stress	1736:1749	glucose stress	1736:1749	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	9	10	theme	glucose	1215:1221	arg1	conditions					1230:1239	The glucose stress conditions	1211:1239	The glucose stress conditions	1211:1239	The glucose stress conditions did not result in unfavorable binding kinetics of Rituximab and FcγRIIIA.
36181372	7	11	attach	present	958:964	arg2	glycans					950:956	The predominant glycans	934:956	The predominant glycans present in the three Rituximab glycoform mixture peaks	934:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	7	11	attach	present	958:964	arg1	peaks					1007:1011	the three Rituximab glycoform mixture peaks	969:1011	the three Rituximab glycoform mixture peaks	969:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	7	11	attach	present	958:964	arg2	G0F					1018:1020	G0F	1018:1020	G0F	1018:1020	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	4	12	theme	unit	525:528	arg1	operations					530:539	the crucial unit operations	513:539	the crucial unit operations	513:539	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	14	13	theme	Such	1854:1857	arg1	tools					1935:1939	potential process analytical technology (PAT) tools	1889:1939	potential process analytical technology (PAT) tools in the biosimilar development process	1889:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	13	theme	Such	1854:1857	arg1	approaches					1859:1868	Such approaches	1854:1868	Such approaches	1854:1868	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	12	14	theme	effector	1702:1709	arg1	activity					1711:1718	the effector activity	1698:1718	the effector activity	1698:1718	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	14	15	theme	development	1959:1969	arg1	process					1971:1977	the biosimilar development process	1944:1977	the biosimilar development process	1944:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	1	16	theme	biologics/biosimilar	157:176	arg1	products					178:185	biologics/biosimilar products	157:185	biologics/biosimilar products	157:185	Analytical and functional characterization of batches of biologics/biosimilar products are imperative towards qualifying them for pre-clinical and clinical investigations.
36181372	8	17	attach	derived	1084:1090	arg2	constants					1069:1077	Dissociation rate constants	1051:1077	Dissociation rate constants	1051:1077	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	8	17	attach	derived	1084:1090	arg1	profiles					1125:1132	the chromatographic elution profiles	1097:1132	the chromatographic elution profiles	1097:1132	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	10	18	theme	mixture	1364:1370	arg1	similar					1413:1419	similar	1413:1419	similar	1413:1419	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	10	18	theme	mixture	1364:1370	arg1	constants					1337:1345	The dissociation rate constants	1315:1345	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F,	1315:1406	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	12	19	dep	ex	1630:1631	arg1	vivo					1633:1636	vivo	1633:1636	vivo	1633:1636	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	2	20	theme	functional	335:344	arg1	attributes					346:355	the functional attributes	331:355	the functional attributes of these drugs	331:370	Several orthogonal strategies are employed to characterize the functional attributes of these drugs.
36181372	10	21	theme	dissociation	1428:1439	arg1	constants					1446:1454	the dissociation rate constants	1424:1454	the dissociation rate constants obtained by surface plasmon resonance	1424:1492	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	3	22	theme	techniques	406:415	arg1	feasible					471:478	feasible	471:478	feasible	471:478	However, the use of conventional techniques for online monitoring of functional attributes is not feasible.
36181372	3	22	theme	techniques	406:415	arg1	use					386:388	the use	382:388	the use of conventional techniques for online monitoring of functional attributes	382:462	However, the use of conventional techniques for online monitoring of functional attributes is not feasible.
36181372	0	23	theme	rituximab	89:97	arg1	characterization					69:84	conventional functional characterization	45:84	conventional functional characterization of rituximab	45:97	FcγRIIIA affinity chromatography complements conventional functional characterization of rituximab.
36181372	6	24	theme	FcγRIIIA	745:752	arg1	chromatography					763:776	FcγRIIIA affinity chromatography	745:776	FcγRIIIA affinity chromatography	745:776	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	8	25	theme	profiling	1146:1154	arg1	method					1156:1161	the peak profiling method	1137:1161	the peak profiling method	1137:1161	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	5	26	theme	independent	686:696	arg1	characterization					722:737	an independent quantitative functional characterization	683:737	an independent quantitative functional characterization tool	683:742	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	7	27	from	peaks	1007:1011	arg1	present					958:964	present	958:964	present	958:964	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	5	28	theme	functional	711:720	arg1	characterization					722:737	an independent quantitative functional characterization	683:737	an independent quantitative functional characterization tool	683:742	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	3	29	theme	online	421:426	arg1	monitoring					428:437	online monitoring	421:437	online monitoring of functional attributes	421:462	However, the use of conventional techniques for online monitoring of functional attributes is not feasible.
36181372	4	30	theme	downstream	552:561	arg1	processing					563:572	the downstream processing	548:572	the downstream processing of biopharmaceuticals	548:594	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	5	31	theme	affinity	656:663	arg1	chromatography					665:678	FcγRIIIA affinity chromatography	647:678	FcγRIIIA affinity chromatography	647:678	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	13	32	theme	single	1837:1842	arg1	analysis					1844:1851	a single analysis	1835:1851	a single analysis	1835:1851	Thus, FcγRIIIA affinity chromatography permitted three independent assessments via a single analysis.
36181372	6	33	theme	mixtures	829:836	arg1	elution					798:804	sequential elution	787:804	sequential elution of Rituximab glycoform mixtures	787:836	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	0	34	theme	FcγRIIIA	0:7	arg1	chromatography					18:31	FcγRIIIA affinity chromatography	0:31	FcγRIIIA affinity chromatography	0:31	FcγRIIIA affinity chromatography complements conventional functional characterization of rituximab.
36181372	3	35	theme	attributes	453:462	arg1	monitoring					428:437	online monitoring	421:437	online monitoring of functional attributes	421:462	However, the use of conventional techniques for online monitoring of functional attributes is not feasible.
36181372	9	36	theme	stress	1223:1228	arg1	conditions					1230:1239	The glucose stress conditions	1211:1239	The glucose stress conditions	1211:1239	The glucose stress conditions did not result in unfavorable binding kinetics of Rituximab and FcγRIIIA.
36181372	14	37	theme	biosimilar	1948:1957	arg1	process					1971:1977	the biosimilar development process	1944:1977	the biosimilar development process	1944:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	8	38	theme	stress	1192:1197	arg1	conditions					1199:1208	the control and glucose stress conditions	1168:1208	conditions	1199:1208	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	12	39	theme	ADCC	1638:1641	arg1	assay					1652:1656	the ex vivo ADCC reporter assay	1626:1656	the ex vivo ADCC reporter assay	1626:1656	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	1	40	theme	batches	146:152	arg1	Analytical					100:109	Analytical	100:109	Analytical	100:109	Analytical and functional characterization of batches of biologics/biosimilar products are imperative towards qualifying them for pre-clinical and clinical investigations.
36181372	13	41	theme	independent	1807:1817	arg1	assessments					1819:1829	three independent assessments	1801:1829	three independent assessments	1801:1829	Thus, FcγRIIIA affinity chromatography permitted three independent assessments via a single analysis.
36181372	11	42	theme	ADCC	1602:1605	arg1	activity					1607:1614	the ADCC activity	1598:1614	the ADCC activity	1598:1614	Moreover, the glycosylation profiles obtained from chromatographic estimation can be corroborated with the ADCC activity.
36181372	0	43	theme	conventional	45:56	arg1	characterization					69:84	conventional functional characterization	45:84	conventional functional characterization of rituximab	45:97	FcγRIIIA affinity chromatography complements conventional functional characterization of rituximab.
36181372	14	44	from	tools	1935:1939	arg1	process					1971:1977	the biosimilar development process	1944:1977	the biosimilar development process	1944:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	8	45	theme	Dissociation	1051:1062	arg1	constants					1069:1077	Dissociation rate constants	1051:1077	Dissociation rate constants	1051:1077	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	13	46	theme	affinity	1767:1774	arg1	chromatography					1776:1789	FcγRIIIA affinity chromatography	1758:1789	FcγRIIIA affinity chromatography	1758:1789	Thus, FcγRIIIA affinity chromatography permitted three independent assessments via a single analysis.
36181372	2	47	theme	Several	272:278	arg1	strategies					291:300	Several orthogonal strategies	272:300	Several orthogonal strategies	272:300	Several orthogonal strategies are employed to characterize the functional attributes of these drugs.
36181372	9	48	theme	unfavorable	1259:1269	arg1	kinetics					1279:1286	unfavorable binding kinetics	1259:1286	unfavorable binding kinetics of Rituximab and FcγRIIIA	1259:1312	The glucose stress conditions did not result in unfavorable binding kinetics of Rituximab and FcγRIIIA.
36181372	12	49	theme	ex	1630:1631	arg1	assay					1652:1656	the ex vivo ADCC reporter assay	1626:1656	the ex vivo ADCC reporter assay	1626:1656	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	11	50	theme	glycosylation	1509:1521	arg1	profiles					1523:1530	the glycosylation profiles	1505:1530	the glycosylation profiles obtained from chromatographic estimation	1505:1571	Moreover, the glycosylation profiles obtained from chromatographic estimation can be corroborated with the ADCC activity.
36181372	14	51	theme	analytical	1907:1916	arg1	PAT					1930:1932	PAT	1930:1932	PAT	1930:1932	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	51	theme	analytical	1907:1916	arg1	technology					1918:1927	potential process analytical technology	1889:1927	potential process analytical technology (PAT) tools in the biosimilar development process	1889:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	6	52	theme	varying	848:854	arg1	levels					856:861	varying levels	848:861	varying levels of galactosylation	848:880	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	14	53	theme	potential	1889:1897	arg1	PAT					1930:1932	PAT	1930:1932	PAT	1930:1932	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	53	theme	potential	1889:1897	arg1	technology					1918:1927	potential process analytical technology	1889:1927	potential process analytical technology (PAT) tools in the biosimilar development process	1889:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	4	54	theme	Liquid	481:486	arg1	chromatography					488:501	Liquid chromatography	481:501	Liquid chromatography	481:501	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	11	55	theme	chromatographic	1546:1560	arg1	estimation					1562:1571	chromatographic estimation	1546:1571	chromatographic estimation	1546:1571	Moreover, the glycosylation profiles obtained from chromatographic estimation can be corroborated with the ADCC activity.
36181372	9	56	theme	FcγRIIIA	1305:1312	arg1	kinetics					1279:1286	unfavorable binding kinetics	1259:1286	unfavorable binding kinetics of Rituximab and FcγRIIIA	1259:1312	The glucose stress conditions did not result in unfavorable binding kinetics of Rituximab and FcγRIIIA.
36181372	10	57	theme	rate	1332:1335	arg1	similar					1413:1419	similar	1413:1419	similar	1413:1419	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	10	57	theme	rate	1332:1335	arg1	constants					1337:1345	The dissociation rate constants	1315:1345	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F,	1315:1406	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	8	58	theme	elution	1117:1123	arg1	profiles					1125:1132	the chromatographic elution profiles	1097:1132	the chromatographic elution profiles	1097:1132	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	7	59	theme	mixture	999:1005	arg1	peaks					1007:1011	the three Rituximab glycoform mixture peaks	969:1011	the three Rituximab glycoform mixture peaks	969:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	7	60	theme	Rituximab	979:987	arg1	peaks					1007:1011	the three Rituximab glycoform mixture peaks	969:1011	the three Rituximab glycoform mixture peaks	969:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	8	61	theme	peak	1141:1144	arg1	method					1156:1161	the peak profiling method	1137:1161	the peak profiling method	1137:1161	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	4	62	theme	operations	530:539	arg1	operations					530:539	the crucial unit operations	513:539	the crucial unit operations	513:539	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	4	62	theme	operations	530:539	arg1	one					506:508	one	506:508	one	506:508	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	7	63	theme	present	958:964	arg1	G0F					1018:1020	G0F	1018:1020	G0F	1018:1020	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	7	63	theme	present	958:964	arg1	glycans					950:956	The predominant glycans	934:956	The predominant glycans present in the three Rituximab glycoform mixture peaks	934:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	6	64	theme	sequential	787:796	arg1	elution					798:804	sequential elution	787:804	sequential elution of Rituximab glycoform mixtures	787:836	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	5	65	theme	FcγRIIIA	647:654	arg1	chromatography					665:678	FcγRIIIA affinity chromatography	647:678	FcγRIIIA affinity chromatography	647:678	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	1	66	theme	products	178:185	arg1	batches					146:152	batches	146:152	batches of biologics/biosimilar products	146:185	Analytical and functional characterization of batches of biologics/biosimilar products are imperative towards qualifying them for pre-clinical and clinical investigations.
36181372	4	67	theme	crucial	517:523	arg1	operations					530:539	the crucial unit operations	513:539	the crucial unit operations	513:539	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	10	68	theme	glycoform	1354:1362	arg1	mixture					1364:1370	the glycoform mixture 2	1350:1372	the glycoform mixture 2	1350:1372	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	10	69	theme	rate	1441:1444	arg1	constants					1446:1454	the dissociation rate constants	1424:1454	the dissociation rate constants obtained by surface plasmon resonance	1424:1492	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	6	70	theme	affinity	754:761	arg1	chromatography					763:776	FcγRIIIA affinity chromatography	745:776	FcγRIIIA affinity chromatography	745:776	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	6	71	theme	Rituximab	809:817	arg1	mixtures					829:836	Rituximab glycoform mixtures	809:836	Rituximab glycoform mixtures	809:836	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	3	72	theme	conventional	393:404	arg1	techniques					406:415	conventional techniques	393:415	conventional techniques	393:415	However, the use of conventional techniques for online monitoring of functional attributes is not feasible.
36181372	12	73	from	increase	1686:1693	arg1	activity					1711:1718	the effector activity	1698:1718	the effector activity	1698:1718	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	5	74	theme	quantitative	698:709	arg1	characterization					722:737	an independent quantitative functional characterization	683:737	an independent quantitative functional characterization tool	683:742	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	3	75	theme	functional	442:451	arg1	attributes					453:462	functional attributes	442:462	functional attributes	442:462	However, the use of conventional techniques for online monitoring of functional attributes is not feasible.
36181372	5	76	theme	characterization	722:737	arg1	tool					739:742	an independent quantitative functional characterization tool	683:742	an independent quantitative functional characterization tool	683:742	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	4	77	theme	biopharmaceuticals	577:594	arg1	processing					563:572	the downstream processing	548:572	the downstream processing of biopharmaceuticals	548:594	Liquid chromatography is one of the crucial unit operations during the downstream processing of biopharmaceuticals.
36181372	0	78	theme	affinity	9:16	arg1	chromatography					18:31	FcγRIIIA affinity chromatography	0:31	FcγRIIIA affinity chromatography	0:31	FcγRIIIA affinity chromatography complements conventional functional characterization of rituximab.
36181372	8	79	theme	glucose	1184:1190	arg1	conditions					1199:1208	the control and glucose stress conditions	1168:1208	conditions	1199:1208	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	5	80	theme	chromatography	665:678	arg1	utility					636:642	the utility	632:642	the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool	632:742	In this work, we have demonstrated the utility of FcγRIIIA affinity chromatography as an independent quantitative functional characterization tool.
36181372	1	81	theme	functional	115:124	arg1	characterization					126:141	functional characterization	115:141	functional characterization	115:141	Analytical and functional characterization of batches of biologics/biosimilar products are imperative towards qualifying them for pre-clinical and clinical investigations.
36181372	6	82	theme	glycoform	819:827	arg1	mixtures					829:836	Rituximab glycoform mixtures	809:836	Rituximab glycoform mixtures	809:836	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	7	83	theme	predominant	938:948	arg1	G0F					1018:1020	G0F	1018:1020	G0F	1018:1020	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	7	83	theme	predominant	938:948	arg1	glycans					950:956	The predominant glycans	934:956	The predominant glycans present in the three Rituximab glycoform mixture peaks	934:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	0	84	theme	functional	58:67	arg1	characterization					69:84	conventional functional characterization	45:84	conventional functional characterization of rituximab	45:97	FcγRIIIA affinity chromatography complements conventional functional characterization of rituximab.
36181372	7	85	from	present	958:964	arg1	peaks					1007:1011	the three Rituximab glycoform mixture peaks	969:1011	the three Rituximab glycoform mixture peaks	969:1011	The predominant glycans present in the three Rituximab glycoform mixture peaks were G0F, G1F, and G2F, respectively.
36181372	10	86	theme	surface	1468:1474	arg1	resonance					1484:1492	surface plasmon resonance	1468:1492	surface plasmon resonance	1468:1492	The dissociation rate constants of the glycoform mixture 2, predominantly consisting of G1F, were similar to the dissociation rate constants obtained by surface plasmon resonance.
36181372	12	87	theme	reporter	1643:1650	arg1	assay					1652:1656	the ex vivo ADCC reporter assay	1626:1656	the ex vivo ADCC reporter assay	1626:1656	However, the ex vivo ADCC reporter assay indicated that there was an increase in the effector activity with increasing glucose stress.
36181372	6	88	theme	galactosylation	866:880	arg1	levels					856:861	varying levels	848:861	varying levels of galactosylation	848:880	FcγRIIIA affinity chromatography aided in sequential elution of Rituximab glycoform mixtures, based on varying levels of galactosylation, and thereby the affinity for the receptor protein.
36181372	13	89	theme	FcγRIIIA	1758:1765	arg1	chromatography					1776:1789	FcγRIIIA affinity chromatography	1758:1789	FcγRIIIA affinity chromatography	1758:1789	Thus, FcγRIIIA affinity chromatography permitted three independent assessments via a single analysis.
36181372	2	90	theme	orthogonal	280:289	arg1	strategies					291:300	Several orthogonal strategies	272:300	Several orthogonal strategies	272:300	Several orthogonal strategies are employed to characterize the functional attributes of these drugs.
36181372	9	91	theme	binding	1271:1277	arg1	kinetics					1279:1286	unfavorable binding kinetics	1259:1286	unfavorable binding kinetics of Rituximab and FcγRIIIA	1259:1312	The glucose stress conditions did not result in unfavorable binding kinetics of Rituximab and FcγRIIIA.
36181372	14	92	theme	technology	1918:1927	arg1	tools					1935:1939	potential process analytical technology (PAT) tools	1889:1939	potential process analytical technology (PAT) tools in the biosimilar development process	1889:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	92	theme	technology	1918:1927	arg1	approaches					1859:1868	Such approaches	1854:1868	Such approaches	1854:1868	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	8	93	theme	rate	1064:1067	arg1	constants					1069:1077	Dissociation rate constants	1051:1077	Dissociation rate constants	1051:1077	Dissociation rate constants were derived from the chromatographic elution profiles by the peak profiling method, for the control and glucose stress conditions.
36181372	14	94	used	utilized	1877:1884	arg2	approaches					1859:1868	Such approaches	1854:1868	Such approaches	1854:1868	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	94	used	utilized	1877:1884	arg2	tools					1935:1939	potential process analytical technology (PAT) tools	1889:1939	potential process analytical technology (PAT) tools in the biosimilar development process	1889:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	95	theme	process	1899:1905	arg1	PAT					1930:1932	PAT	1930:1932	PAT	1930:1932	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36181372	14	95	theme	process	1899:1905	arg1	technology					1918:1927	potential process analytical technology	1889:1927	potential process analytical technology (PAT) tools in the biosimilar development process	1889:1977	Such approaches can be utilized as potential process analytical technology (PAT) tools in the biosimilar development process.
36280670	0	0	theme	glycans	93:99	arg1	remodeling					79:88	efficient cell-free remodeling	59:88	efficient cell-free remodeling of glycans	59:99	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans.
36280670	5	1	theme	structure-function	1166:1183	arg1	studies					1185:1191	structure-function studies	1166:1191	structure-function studies	1166:1191	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	5	2	theme	complex	1257:1263	arg1	glycomolecules					1265:1278	complex glycomolecules	1257:1278	complex glycomolecules	1257:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	5	3	theme	GTs	1136:1138	arg1	quantities					1092:1101	large quantities	1086:1101	large quantities	1086:1101	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	4	4	theme	glycans	893:899	arg1	remodeling					850:859	structural remodeling	839:859	structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab	839:972	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	1	5	theme	new	183:185	arg1	ones					187:190	prototype entirely new ones	164:190	prototype entirely new ones	164:190	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	3	6	theme	human	716:720	arg1	origin					722:727	human origin	716:727	human origin	716:727	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	5	7	theme	biomedical	1223:1232	arg1	applications					1234:1245	biochemical and biomedical applications	1207:1245	biochemical and biomedical applications involving complex glycomolecules	1207:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	5	8	theme	effective	1040:1048	arg1	route					1077:1081	an effective and versatile biosynthetic route	1037:1081	an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules	1037:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	5	9	theme	redesigning	1012:1022	arg1	GTs					1024:1026	rationally redesigning GTs	1001:1026	rationally redesigning GTs	1001:1026	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	3	10	theme	used	754:757	arg1	platforms					770:778	several commonly used expression platforms	737:778	several commonly used expression platforms	737:778	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	4	11	theme	free	869:872	arg1	glycans					893:899	both free and protein-linked glycans	864:899	both free and protein-linked glycans	864:899	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	5	12	dep	diverse	1106:1112	arg1	active					1129:1134	active	1129:1134	active	1129:1134	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	0	13	theme	universal	2:10	arg1	pipeline					37:44	A universal glycoenzyme biosynthesis pipeline	0:44	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans	0:99	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans.
36280670	3	14	theme	several	737:743	arg1	platforms					770:778	several commonly used expression platforms	737:778	several commonly used expression platforms	737:778	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	4	15	theme	protein-linked	878:891	arg1	glycans					893:899	both free and protein-linked glycans	864:899	both free and protein-linked glycans	864:899	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	5	16	from	use	1159:1161	arg1	applications					1234:1245	biochemical and biomedical applications	1207:1245	biochemical and biomedical applications involving complex glycomolecules	1207:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	5	16	from	use	1159:1161	arg1	studies					1185:1191	structure-function studies	1166:1191	structure-function studies	1166:1191	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	3	17	theme	GTs	694:696	arg1	production					656:665	facile production	649:665	facile production	649:665	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	0	18	theme	biosynthesis	24:35	arg1	pipeline					37:44	A universal glycoenzyme biosynthesis pipeline	0:44	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans	0:99	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans.
36280670	1	19	theme	membrane	291:298	arg1	proteins					300:307	membrane proteins	291:307	membrane proteins that fail to express in heterologous hosts	291:350	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	1	19	theme	membrane	291:298	arg1	many					273:276	many	273:276	many	273:276	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	1	19	theme	membrane	291:298	arg1	glycoenzymes					259:270	functional glycoenzymes	248:270	functional glycoenzymes	248:270	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	2	20	with	cytoplasm	528:536	arg1	retention					559:567	retention	559:567	retention of biological activity	559:590	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	5	21	theme	biosynthetic	1064:1075	arg1	route					1077:1081	an effective and versatile biosynthetic route	1037:1081	an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules	1037:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	3	22	theme	origin	722:727	arg1	production					656:665	facile production	649:665	facile production	649:665	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	0	23	theme	glycoenzyme	12:22	arg1	pipeline					37:44	A universal glycoenzyme biosynthesis pipeline	0:44	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans	0:99	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans.
36280670	3	24	theme	expression	759:768	arg1	platforms					770:778	several commonly used expression platforms	737:778	several commonly used expression platforms	737:778	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	4	25	theme	therapeutic	950:960	arg1	trastuzumab					962:972	the monoclonal antibody therapeutic trastuzumab	926:972	the monoclonal antibody therapeutic trastuzumab	926:972	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	4	26	link	protein-linked	878:891	arg1	glycans					893:899	both free and protein-linked glycans	864:899	both free and protein-linked glycans	864:899	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	2	27	theme	cells	548:552	arg1	cytoplasm					528:536	the cytoplasm	524:536	the cytoplasm of living cells with retention of biological activity	524:590	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	4	28	theme	structural	839:848	arg1	remodeling					850:859	structural remodeling	839:859	structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab	839:972	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	2	29	theme	living	541:546	arg1	cells					548:552	living cells	541:552	living cells	541:552	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	3	30	theme	facile	649:654	arg1	production					656:665	facile production	649:665	facile production	649:665	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	1	31	theme	limited	224:230	arg1	availability					232:243	the limited availability	220:243	the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts	220:350	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	0	32	theme	efficient	59:67	arg1	remodeling					79:88	efficient cell-free remodeling	59:88	efficient cell-free remodeling of glycans	59:99	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans.
36280670	0	33	theme	cell-free	69:77	arg1	remodeling					79:88	efficient cell-free remodeling	59:88	efficient cell-free remodeling of glycans	59:99	A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans.
36280670	4	34	theme	antibody	941:948	arg1	trastuzumab					962:972	the monoclonal antibody therapeutic trastuzumab	926:972	the monoclonal antibody therapeutic trastuzumab	926:972	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	2	35	theme	activity	583:590	arg1	retention					559:567	retention	559:567	retention of biological activity	559:590	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	5	36	theme	large	1086:1090	arg1	quantities					1092:1101	large quantities	1086:1101	large quantities	1086:1101	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	1	37	theme	natural	130:136	arg1	pathways					152:159	natural glycosylation pathways	130:159	natural glycosylation pathways	130:159	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	5	38	theme	biochemical	1207:1217	arg1	applications					1234:1245	biochemical and biomedical applications	1207:1245	biochemical and biomedical applications involving complex glycomolecules	1207:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	2	39	theme	biological	572:581	arg1	activity					583:590	biological activity	572:590	biological activity	572:590	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	4	40	theme	enzymes	819:825	arg1	subset					789:794	a subset	787:794	a subset of these water-soluble enzymes	787:825	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	3	41	theme	approach	632:639	arg1	universality					612:623	the universality	608:623	the universality of the approach	608:639	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	1	42	theme	glycosylation	138:150	arg1	pathways					152:159	natural glycosylation pathways	130:159	natural glycosylation pathways	130:159	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	4	43	theme	monoclonal	930:939	arg1	trastuzumab					962:972	the monoclonal antibody therapeutic trastuzumab	926:972	the monoclonal antibody therapeutic trastuzumab	926:972	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	3	44	theme	difficult-to-express	673:692	arg1	GTs					694:696	98 difficult-to-express GTs	670:696	98 difficult-to-express GTs	670:696	We demonstrate the universality of the approach through facile production of 98 difficult-to-express GTs, predominantly of human origin, across several commonly used expression platforms.
36280670	4	45	theme	water-soluble	805:817	arg1	enzymes					819:825	these water-soluble enzymes	799:825	these water-soluble enzymes	799:825	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	1	46	theme	prototype	164:172	arg1	ones					187:190	prototype entirely new ones	164:190	prototype entirely new ones	164:190	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	5	47	theme	diverse	1106:1112	arg1	GTs					1136:1138	diverse, enzymatically active GTs	1106:1138	diverse, enzymatically active GTs	1106:1138	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	2	48	theme	membrane-bound	411:424	arg1	glycosyltransferases					426:445	membrane-bound glycosyltransferases	411:445	membrane-bound glycosyltransferases (GTs)	411:451	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	2	48	theme	membrane-bound	411:424	arg1	GTs					448:450	GTs	448:450	GTs	448:450	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	4	49	located	found	917:921	arg1	trastuzumab					962:972	the monoclonal antibody therapeutic trastuzumab	926:972	the monoclonal antibody therapeutic trastuzumab	926:972	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	4	49	located	found	917:921	arg2	those					911:915	those	911:915	those	911:915	Using a subset of these water-soluble enzymes, we perform structural remodeling of both free and protein-linked glycans including those found on the monoclonal antibody therapeutic trastuzumab.
36280670	1	50	theme	functional	248:257	arg1	glycoenzymes					259:270	functional glycoenzymes	248:270	functional glycoenzymes	248:270	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	2	51	theme	high	509:512	arg1	levels					514:519	high levels	509:519	high levels	509:519	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	1	52	theme	heterologous	333:344	arg1	hosts					346:350	heterologous hosts	333:350	heterologous hosts	333:350	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	5	53	theme	versatile	1054:1062	arg1	route					1077:1081	an effective and versatile biosynthetic route	1037:1081	an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules	1037:1278	Overall, our strategy for rationally redesigning GTs provides an effective and versatile biosynthetic route to large quantities of diverse, enzymatically active GTs, which should find use in structure-function studies as well as in biochemical and biomedical applications involving complex glycomolecules.
36280670	2	54	theme	soluble	464:470	arg1	biocatalysts					472:483	water soluble biocatalysts	458:483	water soluble biocatalysts	458:483	Here, we describe a strategy for topologically converting membrane-bound glycosyltransferases (GTs) into water soluble biocatalysts, which are expressed at high levels in the cytoplasm of living cells with retention of biological activity.
36280670	1	55	theme	glycoenzymes	259:270	arg1	proteins					300:307	membrane proteins	291:307	membrane proteins that fail to express in heterologous hosts	291:350	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	1	55	theme	glycoenzymes	259:270	arg1	many					273:276	many	273:276	many	273:276	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	1	55	theme	glycoenzymes	259:270	arg1	availability					232:243	the limited availability	220:243	the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts	220:350	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
36280670	1	55	theme	glycoenzymes	259:270	arg1	glycoenzymes					259:270	functional glycoenzymes	248:270	functional glycoenzymes	248:270	The ability to reconstitute natural glycosylation pathways or prototype entirely new ones from scratch is hampered by the limited availability of functional glycoenzymes, many of which are membrane proteins that fail to express in heterologous hosts.
35894177	0	0	theme	Green	79:83	arg1	Microalgae					85:94	Nordic Green Microalgae	72:94	Nordic Green Microalgae	72:94	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	5	1	dep	pluvialis	662:670	arg1	B2-2					641:644	B2-2	641:644	B2-2	641:644	(B2-2), Haematococcus pluvialis, and Coelastrella sp.
35894177	5	1	dep	pluvialis	662:670	arg1	sp					690:691	sp	690:691	sp	690:691	(B2-2), Haematococcus pluvialis, and Coelastrella sp.
35894177	2	2	theme	harvesting	358:367	arg1	bottlenecks					313:323	clear bottlenecks	307:323	clear bottlenecks	307:323	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	2	2	theme	harvesting	358:367	arg1	steps					369:373	the cell disruption and cell harvesting steps	329:373	the cell disruption and cell harvesting steps	329:373	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	7	3	theme	cell	845:848	arg1	walls					850:854	the cell walls	841:854	the cell walls	841:854	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	1	4	theme	components	244:253	arg1	properties					210:219	the promising and diverse properties	184:219	the promising and diverse properties of their intracellular components	184:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	0	5	theme	Nordic	72:77	arg1	Microalgae					85:94	Nordic Green Microalgae	72:94	Nordic Green Microalgae	72:94	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	4	6	dep	explore	510:516	arg1	sp					636:637	Scenedesmus sp	624:637	Scenedesmus sp	624:637	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	4	6	dep	explore	510:516	arg1	13-1					617:620	13-1	617:620	13-1	617:620	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	4	6	dep	explore	510:516	arg1	vulgaris					607:614	Chlorella vulgaris	597:614	Chlorella vulgaris (13-1)	597:621	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	6	7	theme	growth	761:766	arg1	phases					768:773	logarithmic and stationary growth phases	734:773	logarithmic and stationary growth phases	734:773	(3-4)) and their changes in relation to logarithmic and stationary growth phases.
35894177	2	8	theme	cell	353:356	arg1	harvesting					358:367	cell harvesting	353:367	cell harvesting	353:367	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	11	9	theme	other	1405:1409	arg1	strains					1424:1430	the other three Nordic strains	1401:1430	the other three Nordic strains using trimethylsilyl derivatization	1401:1466	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	4	10	theme	study	497:501	arg1	aim					485:487	The aim	481:487	The aim of this study	481:501	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	10	11	theme	sp	1350:1351	arg1	composition					1319:1329	sugar and protein composition	1301:1329	composition	1319:1329	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	6	12	theme	stationary	750:759	arg1	phases					768:773	logarithmic and stationary growth phases	734:773	logarithmic and stationary growth phases	734:773	(3-4)) and their changes in relation to logarithmic and stationary growth phases.
35894177	4	13	theme	microalgal	577:586	arg1	strains					588:594	four Nordic microalgal strains	565:594	four Nordic microalgal strains	565:594	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	0	14	theme	Microalgae	85:94	arg1	Wall					38:41	the Cell Wall Structure and Composition	29:67	the Cell Wall Structure and Composition of Nordic Green Microalgae	29:94	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	3	15	from	Challenges	376:385	arg1	both					390:393	both	390:393	both	390:393	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	3	15	from	Challenges	376:385	arg1	processes					404:412	these processes	398:412	these processes	398:412	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	10	16	located	observed	1289:1296	arg2	differences					1272:1282	Very prominent differences	1257:1282	Very prominent differences	1257:1282	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	10	16	located	observed	1289:1296	arg1	composition					1319:1329	sugar and protein composition	1301:1329	composition	1319:1329	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	11	17	theme	cell	1387:1390	arg1	walls					1392:1396	the cell walls	1383:1396	the cell walls of the other three Nordic strains using trimethylsilyl derivatization	1383:1466	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	4	18	theme	Nordic	570:575	arg1	strains					588:594	four Nordic microalgal strains	565:594	four Nordic microalgal strains	565:594	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	11	19	theme	strains	1424:1430	arg1	walls					1392:1396	the cell walls	1383:1396	the cell walls of the other three Nordic strains using trimethylsilyl derivatization	1383:1466	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	3	20	theme	cell	470:473	arg1	wall					475:478	the microalgal cell wall	455:478	the microalgal cell wall	455:478	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	6	21	dep	3-4	695:697	arg1	changes					711:717	their changes	705:717	their changes in relation to logarithmic and stationary growth phases	705:773	(3-4)) and their changes in relation to logarithmic and stationary growth phases.
35894177	1	22	theme	biofuel	158:164	arg1	industries					166:175	food, pharmaceutical, and biofuel industries	132:175	food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components	132:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	11	23	theme	cell	1361:1364	arg1	wall					1366:1369	(B2-2) cell wall	1354:1369	(B2-2) cell wall	1354:1369	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	8	24	theme	cryogenic	946:954	arg1	spectroscopy					976:987	cryogenic X-ray photoelectron spectroscopy	946:987	cryogenic X-ray photoelectron spectroscopy	946:987	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	2	25	theme	biotechnological	267:282	arg1	applications					284:295	current biotechnological applications	259:295	current biotechnological applications	259:295	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	4	26	theme	Scenedesmus	624:634	arg1	sp					636:637	Scenedesmus sp	624:637	Scenedesmus sp	624:637	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	4	26	theme	Scenedesmus	624:634	arg1	vulgaris					607:614	Chlorella vulgaris	597:614	Chlorella vulgaris (13-1)	597:621	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	8	27	theme	cell	1086:1089	arg1	wall					1091:1094	the microalgal cell wall	1071:1094	the microalgal cell wall	1071:1094	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	7	28	theme	imaging	809:815	arg1	microscopy					798:807	Transmission electron microscopy imaging	776:815	Transmission electron microscopy imaging	776:815	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	1	29	theme	due	177:179	arg1	industries					166:175	food, pharmaceutical, and biofuel industries	132:175	food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components	132:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	0	30	theme	Detailed	0:7	arg1	Characterization					9:24	Detailed Characterization	0:24	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.	0:95	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	9	31	theme	infrared	1127:1134	arg1	spectroscopy					1136:1147	infrared spectroscopy	1127:1147	infrared spectroscopy	1127:1147	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	8	32	from	lipid	1004:1008	arg1	cultures					1099:1106	cultures	1099:1106	cultures	1099:1106	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	7	33	theme	structural	871:880	arg1	layers					932:937	layers	932:937	layers	932:937	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	7	33	theme	structural	871:880	arg1	elements					882:889	structural elements	871:889	structural elements such as spines, microfibrillar hairs, or layers	871:937	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	7	33	theme	structural	871:880	arg1	spines					899:904	spines	899:904	spines	899:904	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	7	33	theme	structural	871:880	arg1	hairs					922:926	microfibrillar hairs	907:926	microfibrillar hairs	907:926	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	7	34	theme	Transmission	776:787	arg1	microscopy					798:807	Transmission electron microscopy imaging	776:815	Transmission electron microscopy imaging	776:815	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	8	35	theme	photoelectron	962:974	arg1	spectroscopy					976:987	cryogenic X-ray photoelectron spectroscopy	946:987	cryogenic X-ray photoelectron spectroscopy	946:987	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	4	36	theme	wall	527:530	arg1	compositions					532:543	the cell wall compositions	518:543	the cell wall compositions	518:543	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	8	37	theme	polysaccharide	1024:1037	arg1	content					1039:1045	polysaccharide content	1024:1045	polysaccharide content	1024:1045	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	2	38	from	steps	369:373	arg1	applications					284:295	current biotechnological applications	259:295	current biotechnological applications	259:295	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	2	39	theme	clear	307:311	arg1	steps					369:373	the cell disruption and cell harvesting steps	329:373	the cell disruption and cell harvesting steps	329:373	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	2	39	theme	clear	307:311	arg1	bottlenecks					313:323	clear bottlenecks	307:323	clear bottlenecks	307:323	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	7	40	theme	electron	789:796	arg1	microscopy					798:807	Transmission electron microscopy imaging	776:815	Transmission electron microscopy imaging	776:815	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	3	41	theme	microalgal	459:468	arg1	wall					475:478	the microalgal cell wall	455:478	the microalgal cell wall	455:478	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	9	42	theme	growth	1177:1182	arg1	phases					1184:1189	growth phases	1177:1189	growth phases within the polysaccharide and protein fractions of the cell wall	1177:1254	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	10	43	theme	sugar	1301:1305	arg1	composition					1319:1329	sugar and protein composition	1301:1329	composition	1319:1329	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	1	44	theme	promising	188:196	arg1	properties					210:219	the promising and diverse properties	184:219	the promising and diverse properties of their intracellular components	184:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	0	45	theme	Wall	38:41	arg1	Characterization					9:24	Detailed Characterization	0:24	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.	0:95	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	9	46	dep	transform	1117:1125	arg1	highlighted					1149:1159	highlighted	1149:1159	transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall	1117:1254	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	10	47	theme	prominent	1262:1270	arg1	differences					1272:1282	Very prominent differences	1257:1282	Very prominent differences	1257:1282	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	0	48	theme	Cell	33:36	arg1	Wall					38:41	the Cell Wall Structure and Composition	29:67	the Cell Wall Structure and Composition of Nordic Green Microalgae	29:94	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	9	49	theme	polysaccharide	1202:1215	arg1	fractions					1229:1237	the polysaccharide and protein fractions	1198:1237	fractions	1229:1237	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	8	50	theme	X-ray	956:960	arg1	spectroscopy					976:987	cryogenic X-ray photoelectron spectroscopy	946:987	cryogenic X-ray photoelectron spectroscopy	946:987	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	10	51	theme	protein	1311:1317	arg1	composition					1319:1329	sugar and protein composition	1301:1329	composition	1319:1329	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	1	52	theme	diverse	202:208	arg1	properties					210:219	the promising and diverse properties	184:219	the promising and diverse properties of their intracellular components	184:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	8	53	from	protein	1011:1017	arg1	cultures					1099:1106	cultures	1099:1106	cultures	1099:1106	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	8	54	theme	outer	1054:1058	arg1	surface					1060:1066	the outer surface	1050:1066	the outer surface of the microalgal cell wall	1050:1094	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	0	55	dep	Wall	38:41	arg1	Composition					57:67	Composition	57:67	Composition	57:67	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	0	55	dep	Wall	38:41	arg1	Structure					43:51	Structure	43:51	Structure	43:51	Detailed Characterization of the Cell Wall Structure and Composition of Nordic Green Microalgae.
35894177	4	56	theme	strains	588:594	arg1	compositions					532:543	the cell wall compositions	518:543	the cell wall compositions	518:543	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	4	56	theme	strains	588:594	arg1	morphologies					549:560	morphologies	549:560	morphologies	549:560	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	4	57	theme	cell	522:525	arg1	compositions					532:543	the cell wall compositions	518:543	the cell wall compositions	518:543	The aim of this study was to explore the cell wall compositions and morphologies of four Nordic microalgal strains (Chlorella vulgaris (13-1), Scenedesmus sp.
35894177	11	58	theme	Nordic	1417:1422	arg1	strains					1424:1430	the other three Nordic strains	1401:1430	the other three Nordic strains using trimethylsilyl derivatization	1401:1466	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	9	59	theme	protein	1221:1227	arg1	fractions					1229:1237	the polysaccharide and protein fractions	1198:1237	fractions	1229:1237	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	9	60	theme	wall	1251:1254	arg1	fractions					1229:1237	the polysaccharide and protein fractions	1198:1237	fractions	1229:1237	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	2	61	theme	disruption	338:347	arg1	bottlenecks					313:323	clear bottlenecks	307:323	clear bottlenecks	307:323	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	2	61	theme	disruption	338:347	arg1	steps					369:373	the cell disruption and cell harvesting steps	329:373	the cell disruption and cell harvesting steps	329:373	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	6	62	from	changes	711:717	arg1	relation					722:729	relation	722:729	relation to logarithmic and stationary growth phases	722:773	(3-4)) and their changes in relation to logarithmic and stationary growth phases.
35894177	3	63	attach	linked	427:432	arg2	Challenges					376:385	Challenges	376:385	Challenges in both of these processes	376:412	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	3	63	attach	linked	427:432	arg1	properties					441:450	the properties	437:450	the properties of the microalgal cell wall	437:478	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	2	64	theme	current	259:265	arg1	applications					284:295	current biotechnological applications	259:295	current biotechnological applications	259:295	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	8	65	from	content	1039:1045	arg1	cultures					1099:1106	cultures	1099:1106	cultures	1099:1106	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	2	66	theme	cell	333:336	arg1	disruption					338:347	cell disruption	333:347	cell disruption	333:347	In current biotechnological applications, however, clear bottlenecks are the cell disruption and cell harvesting steps.
35894177	1	67	theme	Green	97:101	arg1	microalgae					103:112	Green microalgae	97:112	Green microalgae	97:112	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	8	68	theme	surface	1060:1066	arg1	content					1039:1045	polysaccharide content	1024:1045	polysaccharide content	1024:1045	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	8	68	theme	surface	1060:1066	arg1	protein					1011:1017	protein	1011:1017	protein	1011:1017	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	8	68	theme	surface	1060:1066	arg1	lipid					1004:1008	lipid	1004:1008	lipid	1004:1008	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	10	69	theme	Scenedesmus	1338:1348	arg1	sp					1350:1351	the Scenedesmus sp	1334:1351	the Scenedesmus sp	1334:1351	Very prominent differences were observed in sugar and protein composition of the Scenedesmus sp.
35894177	1	70	theme	food	132:135	arg1	industries					166:175	food, pharmaceutical, and biofuel industries	132:175	food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components	132:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	6	71	theme	logarithmic	734:744	arg1	phases					768:773	logarithmic and stationary growth phases	734:773	logarithmic and stationary growth phases	734:773	(3-4)) and their changes in relation to logarithmic and stationary growth phases.
35894177	3	72	theme	wall	475:478	arg1	properties					441:450	the properties	437:450	the properties of the microalgal cell wall	437:478	Challenges in both of these processes are directly linked to the properties of the microalgal cell wall.
35894177	8	73	theme	microalgal	1075:1084	arg1	wall					1091:1094	the microalgal cell wall	1071:1094	the microalgal cell wall	1071:1094	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	7	74	theme	microfibrillar	907:920	arg1	hairs					922:926	microfibrillar hairs	907:926	microfibrillar hairs	907:926	Transmission electron microscopy imaging enabled us to visualize the cell walls and to observe structural elements such as spines, microfibrillar hairs, or layers.
35894177	11	75	theme	trimethylsilyl	1438:1451	arg1	derivatization					1453:1466	trimethylsilyl derivatization	1438:1466	trimethylsilyl derivatization	1438:1466	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	11	76	theme	B2-2	1355:1358	arg1	wall					1366:1369	(B2-2) cell wall	1354:1369	(B2-2) cell wall	1354:1369	(B2-2) cell wall compared to the cell walls of the other three Nordic strains using trimethylsilyl derivatization.
35894177	9	77	theme	cell	1246:1249	arg1	wall					1251:1254	the cell wall	1242:1254	the cell wall	1242:1254	Fourier transform infrared spectroscopy highlighted changes between growth phases within the polysaccharide and protein fractions of the cell wall.
35894177	8	78	theme	wall	1091:1094	arg1	surface					1060:1066	the outer surface	1050:1066	the outer surface of the microalgal cell wall	1050:1094	Using cryogenic X-ray photoelectron spectroscopy, we quantified lipid, protein, and polysaccharide content of the outer surface of the microalgal cell wall in cultures.
35894177	1	79	theme	pharmaceutical	138:151	arg1	industries					166:175	food, pharmaceutical, and biofuel industries	132:175	food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components	132:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
35894177	1	80	theme	intracellular	230:242	arg1	components					244:253	their intracellular components	224:253	their intracellular components	224:253	Green microalgae are attractive to food, pharmaceutical, and biofuel industries due to the promising and diverse properties of their intracellular components.
36370510	0	0	theme	devonianum	92:101	arg1	types					72:76	two types	68:76	two types of Dendrobium devonianum with different appearance	68:127	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	2	1	theme	PDP	326:328	arg1	skin					331:334	green (GDP) and purple (PDP) skin	302:334	skin	331:334	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	6	2	theme	extraction	953:962	arg1	lower					981:985	lower	981:985	lower	981:985	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	2	theme	extraction	953:962	arg1	yield					964:968	the extraction yield	949:968	the extraction yield of GDP	949:975	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	0	3	theme	Dendrobium	81:90	arg1	devonianum					92:101	Dendrobium devonianum	81:101	Dendrobium devonianum	81:101	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	1	4	theme	Dendrobium	175:184	arg1	species					164:170	a precious species	153:170	a precious species of Dendrobium	153:184	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	1	4	theme	Dendrobium	175:184	arg1	devonianum					141:150	Dendrobium devonianum	130:150	Dendrobium devonianum	130:150	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	1	5	theme	purple-skinned	239:252	arg1	appearance					254:263	its purple-skinned appearance	235:263	its purple-skinned appearance	235:263	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	0	6	theme	different	108:116	arg1	appearance					118:127	different appearance	108:127	different appearance	108:127	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	0	7	from	Characterization	0:15	arg1	types					72:76	two types	68:76	two types of Dendrobium devonianum with different appearance	68:127	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	2	8	from	GDP	309:311	arg1	polysaccharides					281:295	polysaccharides	281:295	polysaccharides from green (GDP) and purple (PDP) skin D. devonianum	281:348	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	5	9	theme	potentiation	908:919	arg1	activity					921:928	stronger immunological potentiation activity	885:928	stronger immunological potentiation activity	885:928	Especially, GDP showed stronger immunological potentiation activity in vitro.
36370510	4	10	theme	β-1,4-Manp	634:643	arg1	linkages					622:629	glycosidic linkages	611:629	glycosidic linkages of β-1,4-Manp and β-1,4-Glcp	611:658	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	11	theme	compositional	734:746	arg1	monosaccharides					748:762	compositional monosaccharides	734:762	compositional monosaccharides of mannose to glucose ratio	734:790	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	11	theme	compositional	734:746	arg1	1.00					800:803	1.00	800:803	1.00	800:803	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	11	theme	compositional	734:746	arg1	1.00					820:823	1.00	820:823	1.00	820:823	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	3	12	theme	immunological	493:505	arg1	activities					507:516	immunological activities	493:516	immunological activities	493:516	Their difference in physicochemical properties and immunological activities were investigated and compared.
36370510	1	13	theme	Dendrobium	130:139	arg1	species					164:170	a precious species	153:170	a precious species of Dendrobium	153:184	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	1	13	theme	Dendrobium	130:139	arg1	devonianum					141:150	Dendrobium devonianum	130:150	Dendrobium devonianum	130:150	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	2	14	theme	assisted	378:385	arg1	extraction					387:396	homogenate assisted extraction	367:396	homogenate assisted extraction	367:396	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	4	15	theme	mannose	767:773	arg1	ratio					786:790	mannose to glucose ratio	767:790	mannose to glucose ratio	767:790	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	6	16	theme	good	1136:1139	arg1	alternative					1141:1151	a good alternative	1134:1151	a good alternative of purple one	1134:1165	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	16	theme	good	1136:1139	arg1	devonianum					1113:1122	green skin D. devonianum	1099:1122	green skin D. devonianum	1099:1122	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	17	theme	skin	1105:1108	arg1	alternative					1141:1151	a good alternative	1134:1151	a good alternative of purple one	1134:1165	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	17	theme	skin	1105:1108	arg1	devonianum					1113:1122	green skin D. devonianum	1099:1122	green skin D. devonianum	1099:1122	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	4	18	dep	ratio	786:790	arg1	to					775:776	to	775:776	to	775:776	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	6	19	theme	green	1099:1103	arg1	alternative					1141:1151	a good alternative	1134:1151	a good alternative of purple one	1134:1165	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	19	theme	green	1099:1103	arg1	devonianum					1113:1122	green skin D. devonianum	1099:1122	green skin D. devonianum	1099:1122	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	2	20	from	skin	331:334	arg1	polysaccharides					281:295	polysaccharides	281:295	polysaccharides from green (GDP) and purple (PDP) skin D. devonianum	281:348	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	2	21	theme	green	302:306	arg1	GDP					309:311	green (GDP) and purple (PDP) skin	302:334	GDP	309:311	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	4	22	theme	molecular	671:679	arg1	3.563 × 105					711:721	3.563 × 105	711:721	3.563 × 105	711:721	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	22	theme	molecular	671:679	arg1	2.044 × 105					690:700	2.044 × 105	690:700	2.044 × 105	690:700	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	22	theme	molecular	671:679	arg1	weights					681:687	their molecular weights	665:687	their molecular weights	665:687	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	2	23	theme	ethanol	399:405	arg1	precipitation					407:419	ethanol precipitation	399:419	ethanol precipitation	399:419	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	7	24	dep	cultivation	1233:1243	arg1	the					1229:1231	the	1229:1231	the	1229:1231	These findings are helpful to provide evidence for improving the cultivation and production of D. devonianum.
36370510	0	25	with	types	72:76	arg1	appearance					118:127	different appearance	108:127	different appearance	108:127	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	5	26	theme	stronger	885:892	arg1	activity					921:928	stronger immunological potentiation activity	885:928	stronger immunological potentiation activity	885:928	Especially, GDP showed stronger immunological potentiation activity in vitro.
36370510	0	27	theme	immunological	21:33	arg1	activity					35:42	immunological activity	21:42	immunological activity	21:42	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	6	28	theme	D.	1110:1111	arg1	alternative					1141:1151	a good alternative	1134:1151	a good alternative of purple one	1134:1165	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	28	theme	D.	1110:1111	arg1	devonianum					1113:1122	green skin D. devonianum	1099:1122	green skin D. devonianum	1099:1122	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	5	29	theme	immunological	894:906	arg1	activity					921:928	stronger immunological potentiation activity	885:928	stronger immunological potentiation activity	885:928	Especially, GDP showed stronger immunological potentiation activity in vitro.
36370510	1	30	theme	Zi-pi	203:207	arg1	"					215:215	"Zi-pi Shi-hu"	202:215	"Zi-pi Shi-hu" in Chinese	202:226	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	0	31	theme	polysaccharides	47:61	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	0	31	theme	polysaccharides	47:61	arg1	activity					35:42	immunological activity	21:42	immunological activity	21:42	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	1	32	theme	Shi-hu	209:214	arg1	"					215:215	"Zi-pi Shi-hu"	202:215	"Zi-pi Shi-hu" in Chinese	202:226	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	2	33	theme	homogenate	367:376	arg1	extraction					387:396	homogenate assisted extraction	367:396	homogenate assisted extraction	367:396	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	7	34	theme	D.	1263:1264	arg1	devonianum					1266:1275	D. devonianum	1263:1275	D. devonianum	1263:1275	These findings are helpful to provide evidence for improving the cultivation and production of D. devonianum.
36370510	4	35	theme	β-1,4-Glcp	649:658	arg1	linkages					622:629	glycosidic linkages	611:629	glycosidic linkages of β-1,4-Manp and β-1,4-Glcp	611:658	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	0	36	from	types	72:76	arg1	polysaccharides					47:61	polysaccharides	47:61	polysaccharides from two types of Dendrobium devonianum with different appearance	47:127	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	0	36	from	types	72:76	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	0	36	from	types	72:76	arg1	activity					35:42	immunological activity	21:42	immunological activity	21:42	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	6	37	theme	purple	1156:1161	arg1	alternative					1141:1151	a good alternative	1134:1151	a good alternative of purple one	1134:1165	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	37	theme	purple	1156:1161	arg1	devonianum					1113:1122	green skin D. devonianum	1099:1122	green skin D. devonianum	1099:1122	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	1	38	from	"	215:215	arg1	Chinese					220:226	Chinese	220:226	Chinese	220:226	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	2	39	theme	purple	318:323	arg1	skin					331:334	green (GDP) and purple (PDP) skin	302:334	skin	331:334	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	2	40	dep	polysaccharides	281:295	arg1	D.					336:337	D.	336:337	D.	336:337	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	4	41	theme	glucose	778:784	arg1	ratio					786:790	mannose to glucose ratio	767:790	mannose to glucose ratio	767:790	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	3	42	from	difference	448:457	arg1	properties					478:487	physicochemical properties	462:487	physicochemical properties	462:487	Their difference in physicochemical properties and immunological activities were investigated and compared.
36370510	3	42	from	difference	448:457	arg1	activities					507:516	immunological activities	493:516	immunological activities	493:516	Their difference in physicochemical properties and immunological activities were investigated and compared.
36370510	6	43	theme	immunological	1052:1064	arg1	activity					1066:1073	immunological activity	1052:1073	immunological activity of its polysaccharides	1052:1096	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	44	theme	polysaccharides	1082:1096	arg1	production					1021:1030	the production	1017:1030	the production of raw material	1017:1046	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	44	theme	polysaccharides	1082:1096	arg1	activity					1066:1073	immunological activity	1052:1073	immunological activity of its polysaccharides	1052:1096	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	4	45	theme	glycosidic	611:620	arg1	linkages					622:629	glycosidic linkages	611:629	glycosidic linkages of β-1,4-Manp and β-1,4-Glcp	611:658	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	2	46	dep	D.	336:337	arg1	devonianum					339:348	D. devonianum	336:348	polysaccharides from green (GDP) and purple (PDP) skin D. devonianum	281:348	In this study, polysaccharides from green (GDP) and purple (PDP) skin D. devonianum were isolated by homogenate assisted extraction, ethanol precipitation and ultrafiltration.
36370510	3	47	theme	physicochemical	462:476	arg1	properties					478:487	physicochemical properties	462:487	physicochemical properties	462:487	Their difference in physicochemical properties and immunological activities were investigated and compared.
36370510	6	48	theme	GDP	973:975	arg1	lower					981:985	lower	981:985	lower	981:985	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	48	theme	GDP	973:975	arg1	yield					964:968	the extraction yield	949:968	the extraction yield of GDP	949:975	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	4	49	contain	contained	601:609	arg1	PDP					590:592	PDP	590:592	PDP	590:592	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	49	contain	contained	601:609	arg1	GDP					582:584	GDP	582:584	GDP	582:584	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	49	contain	contained	601:609	arg2	linkages					622:629	glycosidic linkages	611:629	glycosidic linkages of β-1,4-Manp and β-1,4-Glcp	611:658	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	1	50	theme	precious	155:162	arg1	species					164:170	a precious species	153:170	a precious species of Dendrobium	153:184	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	1	50	theme	precious	155:162	arg1	devonianum					141:150	Dendrobium devonianum	130:150	Dendrobium devonianum	130:150	Dendrobium devonianum, a precious species of Dendrobium, is also called "Zi-pi Shi-hu" in Chinese due to its purple-skinned appearance.
36370510	7	51	theme	devonianum	1266:1275	arg1	cultivation					1233:1243	cultivation	1233:1243	cultivation	1233:1243	These findings are helpful to provide evidence for improving the cultivation and production of D. devonianum.
36370510	7	51	theme	devonianum	1266:1275	arg1	production					1249:1258	production	1249:1258	production	1249:1258	These findings are helpful to provide evidence for improving the cultivation and production of D. devonianum.
36370510	6	52	theme	material	1039:1046	arg1	production					1021:1030	the production	1017:1030	the production of raw material	1017:1046	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	6	52	theme	material	1039:1046	arg1	activity					1066:1073	immunological activity	1052:1073	immunological activity of its polysaccharides	1052:1096	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36370510	0	53	from	activity	35:42	arg1	types					72:76	two types	68:76	two types of Dendrobium devonianum with different appearance	68:127	Characterization and immunological activity of polysaccharides from two types of Dendrobium devonianum with different appearance.
36370510	4	54	theme	ratio	786:790	arg1	3.563 × 105					711:721	3.563 × 105	711:721	3.563 × 105	711:721	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	54	theme	ratio	786:790	arg1	monosaccharides					748:762	compositional monosaccharides	734:762	compositional monosaccharides of mannose to glucose ratio	734:790	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	54	theme	ratio	786:790	arg1	2.044 × 105					690:700	2.044 × 105	690:700	2.044 × 105	690:700	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	54	theme	ratio	786:790	arg1	1.00					800:803	1.00	800:803	1.00	800:803	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	54	theme	ratio	786:790	arg1	1.00					820:823	1.00	820:823	1.00	820:823	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	4	54	theme	ratio	786:790	arg1	weights					681:687	their molecular weights	665:687	their molecular weights	665:687	The results suggested that both GDP and PDP mainly contained glycosidic linkages of β-1,4-Manp and β-1,4-Glcp, but their molecular weights, 2.044 × 105 (GDP) vs 3.563 × 105 (PDP), and compositional monosaccharides of mannose to glucose ratio, 16.46: 1.00 (GDP) vs 7.61: 1.00 (PDP), were significantly different.
36370510	6	55	theme	raw	1035:1037	arg1	material					1039:1046	raw material	1035:1046	raw material	1035:1046	Although the extraction yield of GDP was lower than that of PDP, considering the production of raw material and immunological activity of its polysaccharides, green skin D. devonianum should be a good alternative of purple one.
36791391	5	0	theme	non-reducing	730:741	arg1	end					743:745	the non-reducing end	726:745	the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization	726:812	The xylo-oligosaccharide donors were protected at the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization.
36791391	7	1	theme	Arabidopsis	1193:1203	arg1	thaliana					1205:1212	Arabidopsis thaliana	1193:1212	Arabidopsis thaliana	1193:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	1	2	theme	oligosaccharide	159:173	arg1	samples					175:181	pure oligosaccharide samples	154:181	pure oligosaccharide samples that closely represent structural features of cell wall glycans	154:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	7	3	theme	xylan	1013:1017	arg1	XOAT1					1037:1041	the xylan acetyltransferase XOAT1	1009:1041	the xylan acetyltransferase XOAT1 from Arabidopsis thaliana	1009:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	4	4	dep	dodecasaccharides	584:600	arg1	up					578:579	up	578:579	up	578:579	Herein, the synthesis of xylan oligosaccharides up to dodecasaccharides is reported, with glycosynthase-mediated coupling reactions as key steps.
36791391	1	5	theme	samples	175:181	arg1	lack					146:149	a lack	144:149	a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans	144:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	8	6	theme	glucuronosyl	1329:1340	arg1	substituent					1342:1352	a single glucuronosyl substituent	1320:1352	a single glucuronosyl substituent	1320:1352	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	4	7	theme	oligosaccharides	561:576	arg1	synthesis					542:550	the synthesis	538:550	the synthesis of xylan oligosaccharides up to dodecasaccharides	538:600	Herein, the synthesis of xylan oligosaccharides up to dodecasaccharides is reported, with glycosynthase-mediated coupling reactions as key steps.
36791391	6	8	theme	oligosaccharides	906:921	arg1	end					888:890	the reducing end xylose	875:897	the reducing end xylose of the oligosaccharides	875:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	8	9	theme	single	1322:1327	arg1	substituent					1342:1352	a single glucuronosyl substituent	1320:1352	a single glucuronosyl substituent	1320:1352	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	6	10	from	end	888:890	arg1	substituent					860:870	an unnatural 3-O-methylether substituent	831:870	an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides	831:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	6	10	from	end	888:890	arg1	Installation					815:826	Installation	815:826	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides	815:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	5	11	theme	xylo-oligosaccharide	680:699	arg1	donors					701:706	The xylo-oligosaccharide donors	676:706	The xylo-oligosaccharide donors	676:706	The xylo-oligosaccharide donors were protected at the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization.
36791391	4	12	theme	key	665:667	arg1	steps					669:673	key steps	665:673	key steps	665:673	Herein, the synthesis of xylan oligosaccharides up to dodecasaccharides is reported, with glycosynthase-mediated coupling reactions as key steps.
36791391	8	13	theme	acceptors	1481:1489	arg1	value					1461:1465	the value	1457:1465	the value of long-chain acceptors for assaying biosynthetic glycosyltransferases	1457:1536	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	1	14	theme	Plant	95:99	arg1	research					101:108	Plant research	95:108	Plant research	95:108	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	7	15	theme	enzymatic	986:994	arg1	activity					996:1003	enzymatic activity	986:1003	enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	986:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	8	16	theme	dodecasaccharide	1416:1431	arg1	acceptor					1433:1440	the dodecasaccharide acceptor	1412:1440	the dodecasaccharide acceptor	1412:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	7	17	from	thaliana	1205:1212	arg1	XOAT1					1037:1041	the xylan acetyltransferase XOAT1	1009:1041	the xylan acetyltransferase XOAT1 from Arabidopsis thaliana	1009:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	17	from	thaliana	1205:1212	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	17	from	thaliana	1205:1212	arg1	GUX3					1183:1186	the xylan glucuronosyltransferase GUX3	1149:1186	the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	1149:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	6	18	theme	xylose	892:897	arg1	end					888:890	the reducing end xylose	875:897	the reducing end xylose of the oligosaccharides	875:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	7	19	theme	Biochemical	954:964	arg1	assays					966:971	Biochemical assays	954:971	Biochemical assays	954:971	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	20	from	switchgrass	1132:1142	arg1	XOAT1					1037:1041	the xylan acetyltransferase XOAT1	1009:1041	the xylan acetyltransferase XOAT1 from Arabidopsis thaliana	1009:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	20	from	switchgrass	1132:1142	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	20	from	switchgrass	1132:1142	arg1	GUX3					1183:1186	the xylan glucuronosyltransferase GUX3	1149:1186	the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	1149:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	21	theme	XAT3	1105:1108	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	22	theme	arabinofuranosyl-transferase	1076:1103	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	3	23	theme	a-glycosyl	467:476	arg1	fluorides					478:486	a-glycosyl fluorides	467:486	a-glycosyl fluorides	467:486	These enzymes enable the ligation of oligosaccharide donors, when activated for example as a-glycosyl fluorides, with suitable acceptor oligosaccharides.
36791391	0	24	theme	Chemo-enzymatic	0:14	arg1	synthesis					16:24	Chemo-enzymatic synthesis	0:24	Chemo-enzymatic synthesis of long-chain oligosaccharides for studying xylan-modifying enzymes	0:92	Chemo-enzymatic synthesis of long-chain oligosaccharides for studying xylan-modifying enzymes.
36791391	6	25	theme	good	931:934	arg1	solubility					942:951	good water solubility	931:951	good water solubility	931:951	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	6	26	theme	reducing	879:886	arg1	end					888:890	the reducing end xylose	875:897	the reducing end xylose of the oligosaccharides	875:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	1	27	theme	structural	206:215	arg1	features					217:224	structural features	206:224	structural features of cell wall glycans	206:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	0	28	theme	long-chain	29:38	arg1	oligosaccharides					40:55	long-chain oligosaccharides	29:55	long-chain oligosaccharides	29:55	Chemo-enzymatic synthesis of long-chain oligosaccharides for studying xylan-modifying enzymes.
36791391	2	29	theme	chemo-enzymatic	328:342	arg1	alternative					251:261	An alternative	248:261	An alternative to purely chemical synthesis to access these oligosaccharides	248:323	An alternative to purely chemical synthesis to access these oligosaccharides is chemo-enzymatic synthesis using glycosynthases.
36791391	2	29	theme	chemo-enzymatic	328:342	arg1	synthesis					344:352	chemo-enzymatic synthesis	328:352	chemo-enzymatic synthesis using glycosynthases	328:373	An alternative to purely chemical synthesis to access these oligosaccharides is chemo-enzymatic synthesis using glycosynthases.
36791391	3	30	theme	donors	429:434	arg1	ligation					401:408	the ligation	397:408	the ligation of oligosaccharide donors	397:434	These enzymes enable the ligation of oligosaccharide donors, when activated for example as a-glycosyl fluorides, with suitable acceptor oligosaccharides.
36791391	4	31	theme	coupling	643:650	arg1	reactions					652:660	glycosynthase-mediated coupling reactions	620:660	glycosynthase-mediated coupling reactions as key steps	620:673	Herein, the synthesis of xylan oligosaccharides up to dodecasaccharides is reported, with glycosynthase-mediated coupling reactions as key steps.
36791391	8	32	theme	glucuronosyltransferase	1230:1252	arg1	GUX3					1254:1257	the glucuronosyltransferase GUX3	1226:1257	the glucuronosyltransferase GUX3	1226:1257	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	1	33	theme	several	125:131	arg1	aspects					133:139	several aspects	125:139	several aspects	125:139	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	6	34	from	Installation	815:826	arg1	end					888:890	the reducing end xylose	875:897	the reducing end xylose of the oligosaccharides	875:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	8	35	theme	xylose	1393:1398	arg1	acceptor					1433:1440	the dodecasaccharide acceptor	1412:1440	the dodecasaccharide acceptor	1412:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	8	35	theme	xylose	1393:1398	arg1	residues					1400:1407	the central xylose residues	1381:1407	the central xylose residues of the dodecasaccharide acceptor	1381:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	4	36	theme	glycosynthase-mediated	620:641	arg1	reactions					652:660	glycosynthase-mediated coupling reactions	620:660	glycosynthase-mediated coupling reactions as key steps	620:673	Herein, the synthesis of xylan oligosaccharides up to dodecasaccharides is reported, with glycosynthase-mediated coupling reactions as key steps.
36791391	8	37	theme	MALDI-MS/MS	1260:1270	arg1	analysis					1272:1279	MALDI-MS/MS analysis	1260:1279	MALDI-MS/MS analysis of the reaction product	1260:1303	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	1	38	theme	cell	229:232	arg1	glycans					239:245	cell wall glycans	229:245	cell wall glycans	229:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	8	39	theme	acceptor	1433:1440	arg1	acceptor					1433:1440	the dodecasaccharide acceptor	1412:1440	the dodecasaccharide acceptor	1412:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	8	39	theme	acceptor	1433:1440	arg1	residues					1400:1407	the central xylose residues	1381:1407	the central xylose residues of the dodecasaccharide acceptor	1381:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	3	40	theme	suitable	494:501	arg1	oligosaccharides					512:527	suitable acceptor oligosaccharides	494:527	suitable acceptor oligosaccharides	494:527	These enzymes enable the ligation of oligosaccharide donors, when activated for example as a-glycosyl fluorides, with suitable acceptor oligosaccharides.
36791391	0	41	theme	oligosaccharides	40:55	arg1	synthesis					16:24	Chemo-enzymatic synthesis	0:24	Chemo-enzymatic synthesis of long-chain oligosaccharides for studying xylan-modifying enzymes	0:92	Chemo-enzymatic synthesis of long-chain oligosaccharides for studying xylan-modifying enzymes.
36791391	8	42	theme	central	1385:1391	arg1	acceptor					1433:1440	the dodecasaccharide acceptor	1412:1440	the dodecasaccharide acceptor	1412:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	8	42	theme	central	1385:1391	arg1	residues					1400:1407	the central xylose residues	1381:1407	the central xylose residues of the dodecasaccharide acceptor	1381:1440	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	3	43	theme	oligosaccharide	413:427	arg1	donors					429:434	oligosaccharide donors	413:434	oligosaccharide donors	413:434	These enzymes enable the ligation of oligosaccharide donors, when activated for example as a-glycosyl fluorides, with suitable acceptor oligosaccharides.
36791391	7	44	theme	glucuronosyltransferase	1159:1181	arg1	GUX3					1183:1186	the xylan glucuronosyltransferase GUX3	1149:1186	the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	1149:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	3	45	theme	acceptor	503:510	arg1	oligosaccharides					512:527	suitable acceptor oligosaccharides	494:527	suitable acceptor oligosaccharides	494:527	These enzymes enable the ligation of oligosaccharide donors, when activated for example as a-glycosyl fluorides, with suitable acceptor oligosaccharides.
36791391	0	46	theme	xylan-modifying	70:84	arg1	enzymes					86:92	xylan-modifying enzymes	70:92	xylan-modifying enzymes	70:92	Chemo-enzymatic synthesis of long-chain oligosaccharides for studying xylan-modifying enzymes.
36791391	5	47	theme	4-O-tetrahydropyranyl	754:774	arg1	THP					777:779	THP	777:779	THP	777:779	The xylo-oligosaccharide donors were protected at the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization.
36791391	5	47	theme	4-O-tetrahydropyranyl	754:774	arg1	group					782:786	a 4-O-tetrahydropyranyl (THP) group	752:786	a 4-O-tetrahydropyranyl (THP) group to prevent polymerization	752:812	The xylo-oligosaccharide donors were protected at the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization.
36791391	6	48	theme	substituent	860:870	arg1	Installation					815:826	Installation	815:826	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides	815:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	7	49	from	thaliana	1060:1067	arg1	XOAT1					1037:1041	the xylan acetyltransferase XOAT1	1009:1041	the xylan acetyltransferase XOAT1 from Arabidopsis thaliana	1009:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	49	from	thaliana	1060:1067	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	49	from	thaliana	1060:1067	arg1	GUX3					1183:1186	the xylan glucuronosyltransferase GUX3	1149:1186	the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	1149:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	3	50	with	fluorides	478:486	arg1	oligosaccharides					512:527	suitable acceptor oligosaccharides	494:527	suitable acceptor oligosaccharides	494:527	These enzymes enable the ligation of oligosaccharide donors, when activated for example as a-glycosyl fluorides, with suitable acceptor oligosaccharides.
36791391	6	51	theme	3-O-methylether	844:858	arg1	substituent					860:870	an unnatural 3-O-methylether substituent	831:870	an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides	831:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	8	52	theme	long-chain	1470:1479	arg1	acceptors					1481:1489	long-chain acceptors	1470:1489	long-chain acceptors	1470:1489	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	8	53	theme	reaction	1288:1295	arg1	product					1297:1303	the reaction product	1284:1303	the reaction product	1284:1303	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	7	54	theme	xylan	1070:1074	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	6	55	theme	unnatural	834:842	arg1	substituent					860:870	an unnatural 3-O-methylether substituent	831:870	an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides	831:921	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	5	56	with	end	743:745	arg1	THP					777:779	THP	777:779	THP	777:779	The xylo-oligosaccharide donors were protected at the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization.
36791391	5	56	with	end	743:745	arg1	group					782:786	a 4-O-tetrahydropyranyl (THP) group	752:786	a 4-O-tetrahydropyranyl (THP) group to prevent polymerization	752:812	The xylo-oligosaccharide donors were protected at the non-reducing end with a 4-O-tetrahydropyranyl (THP) group to prevent polymerization.
36791391	7	57	theme	Arabidopsis	1048:1058	arg1	thaliana					1060:1067	Arabidopsis thaliana	1048:1067	Arabidopsis thaliana	1048:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	1	58	theme	glycans	239:245	arg1	features					217:224	structural features	206:224	structural features of cell wall glycans	206:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	7	59	theme	xylan	1153:1157	arg1	GUX3					1183:1186	the xylan glucuronosyltransferase GUX3	1149:1186	the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	1149:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	6	60	theme	water	936:940	arg1	solubility					942:951	good water solubility	931:951	good water solubility	931:951	Installation of an unnatural 3-O-methylether substituent at the reducing end xylose of the oligosaccharides ensured good water solubility.
36791391	2	61	theme	chemical	273:280	arg1	synthesis					282:290	purely chemical synthesis	266:290	purely chemical synthesis	266:290	An alternative to purely chemical synthesis to access these oligosaccharides is chemo-enzymatic synthesis using glycosynthases.
36791391	8	62	theme	biosynthetic	1504:1515	arg1	glycosyltransferases					1517:1536	biosynthetic glycosyltransferases	1504:1536	biosynthetic glycosyltransferases	1504:1536	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	7	63	theme	acetyltransferase	1019:1035	arg1	XOAT1					1037:1041	the xylan acetyltransferase XOAT1	1009:1041	the xylan acetyltransferase XOAT1 from Arabidopsis thaliana	1009:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	1	64	theme	wall	234:237	arg1	glycans					239:245	cell wall glycans	229:245	cell wall glycans	229:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
36791391	2	65	dep	access	295:300	arg1	oligosaccharides					308:323	these oligosaccharides	302:323	these oligosaccharides	302:323	An alternative to purely chemical synthesis to access these oligosaccharides is chemo-enzymatic synthesis using glycosynthases.
36791391	7	66	from	rice	1123:1126	arg1	XOAT1					1037:1041	the xylan acetyltransferase XOAT1	1009:1041	the xylan acetyltransferase XOAT1 from Arabidopsis thaliana	1009:1067	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	66	from	rice	1123:1126	arg1	enzymes					1110:1116	xylan arabinofuranosyl-transferase XAT3 enzymes	1070:1116	xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass	1070:1142	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	7	66	from	rice	1123:1126	arg1	GUX3					1183:1186	the xylan glucuronosyltransferase GUX3	1149:1186	the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana	1149:1212	Biochemical assays demonstrated enzymatic activity for the xylan acetyltransferase XOAT1 from Arabidopsis thaliana, xylan arabinofuranosyl-transferase XAT3 enzymes from rice and switchgrass, and the xylan glucuronosyltransferase GUX3 from Arabidopsis thaliana.
36791391	8	67	theme	product	1297:1303	arg1	analysis					1272:1279	MALDI-MS/MS analysis	1260:1279	MALDI-MS/MS analysis of the reaction product	1260:1303	In case of the glucuronosyltransferase GUX3, MALDI-MS/MS analysis of the reaction product suggested that a single glucuronosyl substituent was installed primarily at the central xylose residues of the dodecasaccharide acceptor, demonstrating the value of long-chain acceptors for assaying biosynthetic glycosyltransferases.
36791391	4	68	theme	xylan	555:559	arg1	oligosaccharides					561:576	xylan oligosaccharides	555:576	xylan oligosaccharides	555:576	Herein, the synthesis of xylan oligosaccharides up to dodecasaccharides is reported, with glycosynthase-mediated coupling reactions as key steps.
36791391	1	69	theme	pure	154:157	arg1	samples					175:181	pure oligosaccharide samples	154:181	pure oligosaccharide samples that closely represent structural features of cell wall glycans	154:245	Plant research is hampered in several aspects by a lack of pure oligosaccharide samples that closely represent structural features of cell wall glycans.
35882856	1	0	theme	s	306:306	arg1	knowledge					279:287	knowledge	279:287	knowledge of host receptor(s)	279:307	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	7	1	theme	large	1122:1126	arg1	toxins					1140:1145	large clostridial toxins	1122:1145	large clostridial toxins	1122:1145	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	7	2	theme	fucosylation	1027:1038	arg1	importance					993:1002	the importance	989:1002	the importance of TMPRSS2 and surface fucosylation in TcsH actions	989:1054	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	2	3	theme	host	444:447	arg1	TMPRSS2					433:439	TMPRSS2	433:439	TMPRSS2	433:439	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	3	theme	host	444:447	arg1	factors					449:455	host factors	444:455	host factors contributing to the binding and entry of TcsH	444:501	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	3	theme	host	444:447	arg1	fucosylation					416:427	cell surface fucosylation	403:427	cell surface fucosylation	403:427	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	7	4	theme	clostridial	1128:1138	arg1	toxins					1140:1145	large clostridial toxins	1122:1145	large clostridial toxins	1122:1145	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	6	5	theme	systematic	915:924	arg1	toxicity					926:933	TcsH-induced systematic toxicity	902:933	TcsH-induced systematic toxicity	902:933	By using Tmprss2‒/‒ mice, we show that Tmprss2 is important for TcsH-induced systematic toxicity and colonic epithelial lesions.
35882856	3	6	theme	Genetic	504:510	arg1	deletion					512:519	Genetic deletion	504:519	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells	504:587	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	2	7	with	screens	359:365	arg1	TcsH					383:386	TcsH	383:386	TcsH	383:386	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	7	8	theme	host	1090:1093	arg1	mechanisms					1107:1116	host recognition mechanisms	1090:1116	host recognition mechanisms for large clostridial toxins	1090:1145	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	2	9	theme	CRISPR/Cas9	347:357	arg1	screens					359:365	two genome-wide CRISPR/Cas9 screens	331:365	two genome-wide CRISPR/Cas9 screens parallelly with TcsH	331:386	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	7	10	theme	recognition	1095:1105	arg1	mechanisms					1107:1116	host recognition mechanisms	1090:1116	host recognition mechanisms for large clostridial toxins	1090:1145	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	0	11	theme	Paeniclostridium	0:15	arg1	toxin					39:43	Paeniclostridium sordellii hemorrhagic toxin	0:43	Paeniclostridium sordellii hemorrhagic toxin	0:43	Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.
35882856	2	12	theme	genome-wide	335:345	arg1	screens					359:365	two genome-wide CRISPR/Cas9 screens	331:365	two genome-wide CRISPR/Cas9 screens parallelly with TcsH	331:386	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	13	theme	surface	408:414	arg1	TMPRSS2					433:439	TMPRSS2	433:439	TMPRSS2	433:439	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	13	theme	surface	408:414	arg1	factors					449:455	host factors	444:455	host factors contributing to the binding and entry of TcsH	444:501	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	13	theme	surface	408:414	arg1	fucosylation					416:427	cell surface fucosylation	403:427	cell surface fucosylation	403:427	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	14	contain	carried	319:325	arg2	TMPRSS2					433:439	TMPRSS2	433:439	TMPRSS2	433:439	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	14	contain	carried	319:325	arg1	we					316:317	we	316:317	we	316:317	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	14	contain	carried	319:325	arg2	fucosylation					416:427	cell surface fucosylation	403:427	cell surface fucosylation	403:427	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	14	contain	carried	319:325	arg2	factors					449:455	host factors	444:455	host factors contributing to the binding and entry of TcsH	444:501	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	1	15	theme	Hemorrhagic	99:109	arg1	toxin					111:115	Hemorrhagic toxin	99:115	Hemorrhagic toxin (TcsH)	99:122	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	1	15	theme	Hemorrhagic	99:109	arg1	exotoxin					140:147	an important exotoxin	127:147	an important exotoxin produced by Paeniclostridium sordellii	127:186	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	1	15	theme	Hemorrhagic	99:109	arg1	TcsH					118:121	TcsH	118:121	TcsH	118:121	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	7	16	theme	TcsH	1043:1046	arg1	actions					1048:1054	TcsH actions	1043:1054	TcsH actions	1043:1054	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	2	17	theme	cell	403:406	arg1	TMPRSS2					433:439	TMPRSS2	433:439	TMPRSS2	433:439	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	17	theme	cell	403:406	arg1	factors					449:455	host factors	444:455	host factors contributing to the binding and entry of TcsH	444:501	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	17	theme	cell	403:406	arg1	fucosylation					416:427	cell surface fucosylation	403:427	cell surface fucosylation	403:427	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	6	18	theme	TcsH-induced	902:913	arg1	toxicity					926:933	TcsH-induced systematic toxicity	902:933	TcsH-induced systematic toxicity	902:933	By using Tmprss2‒/‒ mice, we show that Tmprss2 is important for TcsH-induced systematic toxicity and colonic epithelial lesions.
35882856	3	19	theme	fucosylation	531:542	arg1	enzymes					557:563	fucosylation biosynthesis enzymes	531:563	fucosylation biosynthesis enzymes	531:563	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	4	20	theme	TcsH	710:713	arg1	binding/entry					693:705	the binding/entry	689:705	the binding/entry of TcsH	689:713	Interestingly, TMPRSS2 and fucosylated glycans can mediate the binding/entry of TcsH independently, thus serving as redundant receptors.
35882856	2	21	dep	binding	477:483	arg1	the					473:475	the	473:475	the	473:475	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	1	22	theme	exact	197:201	arg1	role					203:206	the exact role	193:206	the exact role of TcsH in the pathogenesis	193:234	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	0	23	theme	hemorrhagic	27:37	arg1	toxin					39:43	Paeniclostridium sordellii hemorrhagic toxin	0:43	Paeniclostridium sordellii hemorrhagic toxin	0:43	Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.
35882856	6	24	theme	epithelial	947:956	arg1	lesions					958:964	colonic epithelial lesions	939:964	colonic epithelial lesions	939:964	By using Tmprss2‒/‒ mice, we show that Tmprss2 is important for TcsH-induced systematic toxicity and colonic epithelial lesions.
35882856	3	25	theme	TcsH	611:614	arg1	intoxication					616:627	TcsH intoxication	611:627	TcsH intoxication	611:627	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	5	26	theme	CROPs	824:828	arg1	domain					830:835	its CROPs domain	820:835	its CROPs domain	820:835	Both TMPRSS2 and fucosylation recognize TcsH through its CROPs domain.
35882856	6	27	theme	colonic	939:945	arg1	lesions					958:964	colonic epithelial lesions	939:964	colonic epithelial lesions	939:964	By using Tmprss2‒/‒ mice, we show that Tmprss2 is important for TcsH-induced systematic toxicity and colonic epithelial lesions.
35882856	2	28	theme	TcsH	498:501	arg1	binding					477:483	binding	477:483	binding	477:483	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	2	28	theme	TcsH	498:501	arg1	entry					489:493	entry	489:493	entry	489:493	Here, we carried out two genome-wide CRISPR/Cas9 screens parallelly with TcsH and identified cell surface fucosylation and TMPRSS2 as host factors contributing to the binding and entry of TcsH.
35882856	6	29	theme	Tmprss2‒/‒	847:856	arg1	mice					858:861	Tmprss2‒/‒ mice	847:861	Tmprss2‒/‒ mice	847:861	By using Tmprss2‒/‒ mice, we show that Tmprss2 is important for TcsH-induced systematic toxicity and colonic epithelial lesions.
35882856	1	30	theme	knowledge	279:287	arg1	lack					271:274	the lack	267:274	the lack of knowledge of host receptor(s)	267:307	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	3	31	theme	TMPRSS2	568:574	arg1	deletion					512:519	Genetic deletion	504:519	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells	504:587	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	7	32	theme	TMPRSS2	1007:1013	arg1	importance					993:1002	the importance	989:1002	the importance of TMPRSS2 and surface fucosylation in TcsH actions	989:1054	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	1	33	theme	TcsH	211:214	arg1	role					203:206	the exact role	193:206	the exact role of TcsH in the pathogenesis	193:234	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	3	34	theme	biosynthesis	544:555	arg1	enzymes					557:563	fucosylation biosynthesis enzymes	531:563	fucosylation biosynthesis enzymes	531:563	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	1	35	theme	host	292:295	arg1	s					306:306	host receptor(s)	292:307	host receptor(s)	292:307	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	4	36	gly	fucosylated	657:667	arg1	glycans					669:675	fucosylated glycans	657:675	fucosylated glycans	657:675	Interestingly, TMPRSS2 and fucosylated glycans can mediate the binding/entry of TcsH independently, thus serving as redundant receptors.
35882856	3	37	theme	enzymes	557:563	arg1	deletion					512:519	Genetic deletion	504:519	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells	504:587	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	3	38	from	deletion	512:519	arg1	cells					583:587	the cells	579:587	the cells	579:587	Genetic deletion of either fucosylation biosynthesis enzymes or TMPRSS2 in the cells confers resistance to TcsH intoxication.
35882856	1	39	theme	receptor	297:304	arg1	s					306:306	host receptor(s)	292:307	host receptor(s)	292:307	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	7	40	theme	surface	1019:1025	arg1	fucosylation					1027:1038	surface fucosylation	1019:1038	surface fucosylation	1019:1038	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	1	41	from	role	203:206	arg1	pathogenesis					223:234	the pathogenesis	219:234	the pathogenesis	219:234	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	4	42	theme	redundant	746:754	arg1	receptors					756:764	redundant receptors	746:764	redundant receptors	746:764	Interestingly, TMPRSS2 and fucosylated glycans can mediate the binding/entry of TcsH independently, thus serving as redundant receptors.
35882856	1	43	theme	important	130:138	arg1	toxin					111:115	Hemorrhagic toxin	99:115	Hemorrhagic toxin (TcsH)	99:122	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	1	43	theme	important	130:138	arg1	exotoxin					140:147	an important exotoxin	127:147	an important exotoxin produced by Paeniclostridium sordellii	127:186	Hemorrhagic toxin (TcsH) is an important exotoxin produced by Paeniclostridium sordellii, but the exact role of TcsH in the pathogenesis remains unclear, partly due to the lack of knowledge of host receptor(s).
35882856	0	44	theme	epithelial	79:88	arg1	lesions					90:96	colonic epithelial lesions	71:96	colonic epithelial lesions	71:96	Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.
35882856	7	45	from	importance	993:1002	arg1	actions					1048:1054	TcsH actions	1043:1054	TcsH actions	1043:1054	These findings reveal the importance of TMPRSS2 and surface fucosylation in TcsH actions and further provide insights into host recognition mechanisms for large clostridial toxins.
35882856	4	46	theme	fucosylated	657:667	arg1	glycans					669:675	fucosylated glycans	657:675	fucosylated glycans	657:675	Interestingly, TMPRSS2 and fucosylated glycans can mediate the binding/entry of TcsH independently, thus serving as redundant receptors.
35882856	0	47	theme	colonic	71:77	arg1	lesions					90:96	colonic epithelial lesions	71:96	colonic epithelial lesions	71:96	Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.
35882856	0	48	dep	Paeniclostridium	0:15	arg1	sordellii					17:25	sordellii	17:25	sordellii	17:25	Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions.
36239409	5	0	theme	tetrasaccharide	1139:1153	arg1	structure					1122:1130	The structure	1118:1130	The structure of the tetrasaccharide repeating unit of the O-antigen	1118:1185	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	1	theme	1H,1H-TOCSY	658:668	arg1	spectra					674:680	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	spectra	674:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	2	from	cluster	457:463	arg1	combination					399:409	a combination	397:409	a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	397:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	2	3	theme	chain-length	248:259	arg1	distribution					261:272	A nonrandom modal chain-length distribution	230:272	A nonrandom modal chain-length distribution	230:272	A nonrandom modal chain-length distribution was observed for the lipopolysaccharide, a pattern which is typical when long O-specific polysaccharides are expressed.
36239409	5	4	dep	E.	1393:1394	arg1	coli					1396:1399	coli	1396:1399	coli	1396:1399	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	4	5	theme	mannosyl	1078:1085	arg1	unit					1112:1115	the repeating unit	1098:1115	the repeating unit	1098:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	5	theme	mannosyl	1078:1085	arg1	residue					1087:1093	the 3-O-substituted mannosyl residue	1058:1093	the 3-O-substituted mannosyl residue of the repeating unit	1058:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	5	6	theme	biological	1298:1307	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	6	theme	biological	1298:1307	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	7	theme	coupling	576:583	arg1	constants					585:593	NMR coupling constants	572:593	NMR coupling constants of anomeric protons	572:613	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	4	8	theme	O-acetyl	856:863	arg1	groups					865:870	O-acetyl groups	856:870	O-acetyl groups	856:870	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	6	9	theme	baltica	1486:1492	arg1	NN015840T					1501:1509	Cellulophaga baltica strain NN015840T	1473:1509	Cellulophaga baltica strain NN015840T	1473:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	3	10	theme	program	808:814	arg1	CASPER					816:821	the computer program CASPER	795:821	the computer program CASPER	795:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	2	11	theme	modal	242:246	arg1	distribution					261:272	A nonrandom modal chain-length distribution	230:272	A nonrandom modal chain-length distribution	230:272	A nonrandom modal chain-length distribution was observed for the lipopolysaccharide, a pattern which is typical when long O-specific polysaccharides are expressed.
36239409	5	12	theme	-β-d-Manp-	1203:1212	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	12	theme	-β-d-Manp-	1203:1212	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	13	theme	polymer	757:763	arg1	structure					727:735	the structure	723:735	the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER	723:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	14	theme	protons	607:613	arg1	constants					585:593	NMR coupling constants	572:593	NMR coupling constants of anomeric protons	572:613	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	5	15	theme	1→3	1214:1216	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	15	theme	1→3	1214:1216	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	0	16	theme	O93	59:61	arg1	structure					29:37	the O-antigen structure	15:37	the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes	15:108	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	6	17	theme	O-specific	1442:1451	arg1	polysaccharide					1453:1466	the acidic O-specific polysaccharide	1431:1466	the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T	1431:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	4	18	theme	repeating	1102:1110	arg1	unit					1112:1115	the repeating unit	1098:1115	the repeating unit	1098:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	0	19	theme	characterization	67:82	arg1	structure					29:37	the O-antigen structure	15:37	the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes	15:108	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	3	20	from	combination	399:409	arg1	cluster					457:463	the gene cluster	448:463	the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	448:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	6	21	theme	E.	1549:1550	arg1	O93					1557:1559	E. coli O93	1549:1559	E. coli O93	1549:1559	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	1	22	theme	international	151:163	arg1	strain					175:180	the international reference strain	147:180	the international reference strain Escherichia coli	147:197	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	4	23	theme	2D	911:912	arg1	experiments					918:928	2D NMR experiments	911:928	2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit	911:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	6	24	theme	mannosyl	1617:1624	arg1	residue					1626:1632	the O-acetylated mannosyl residue	1600:1632	the O-acetylated mannosyl residue	1600:1632	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	3	25	from	structure	727:735	arg1	fashion					781:787	an automated fashion	768:787	an automated fashion using the computer program CASPER	768:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	5	26	theme	structural	1338:1347	arg1	elements					1349:1356	structural elements	1338:1356	structural elements	1338:1356	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	27	theme	-β-d-GlcpA-	1239:1249	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	27	theme	-β-d-GlcpA-	1239:1249	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	0	28	theme	genes	104:108	arg1	characterization					67:82	characterization	67:82	characterization	67:82	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	0	28	theme	genes	104:108	arg1	O93					59:61	O93	59:61	O93	59:61	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	6	29	from	O93	1557:1559	arg1	O-antigen					1534:1542	the O-antigen	1530:1542	the O-antigen from E. coli O93	1530:1559	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	4	30	contain	carries	848:854	arg1	polysaccharide					828:841	The polysaccharide	824:841	The polysaccharide	824:841	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	30	contain	carries	848:854	arg2	groups					865:870	O-acetyl groups	856:870	O-acetyl groups	856:870	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	31	contain	carry	1031:1035	arg1	~¼					1020:1021	~¼	1020:1021	~¼	1020:1021	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	31	contain	carry	1031:1035	arg2	s					1052:1052	O-acetyl group(s)	1037:1053	O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit	1037:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	5	32	theme	-β-d-Manp2Ac6Ac-	1218:1233	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	32	theme	-β-d-Manp2Ac6Ac-	1218:1233	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	6	33	theme	polysaccharide	1453:1466	arg1	structure					1418:1426	The structure	1414:1426	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T	1414:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	6	34	dep	E.	1549:1550	arg1	coli					1552:1555	coli	1552:1555	coli	1552:1555	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	4	35	theme	population	953:962	arg1	~½					943:944	~½	943:944	~½ of the population	943:962	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	3	36	from	fashion	781:787	arg1	structure					727:735	the structure	723:735	the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER	723:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	1	37	dep	Escherichia	182:192	arg1	coli					194:197	coli	194:197	coli	194:197	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	5	38	theme	1→4	1235:1237	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	38	theme	1→4	1235:1237	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	39	theme	information	433:443	arg1	combination					399:409	a combination	397:409	a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	397:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	0	40	theme	structure	29:37	arg1	Elucidation					0:10	Elucidation	0:10	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.	0:109	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	0	41	dep	Escherichia	42:52	arg1	coli					54:57	coli	54:57	coli	54:57	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	0	42	theme	Escherichia	42:52	arg1	O93					59:61	O93	59:61	O93	59:61	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	3	43	from	polymer	757:763	arg1	fashion					781:787	an automated fashion	768:787	an automated fashion using the computer program CASPER	768:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	44	theme	1H	640:641	arg1	13C-HSQC					644:651	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	13C-HSQC	644:651	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	45	theme	glycosyl	527:534	arg1	transferases					536:547	glycosyl transferases	527:547	glycosyl transferases	527:547	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	4	46	theme	group	1046:1050	arg1	s					1052:1052	O-acetyl group(s)	1037:1053	O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit	1037:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	3	47	theme	unassigned	626:635	arg1	13C-HSQC					644:651	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	13C-HSQC	644:651	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	48	theme	putative	506:513	arg1	function					515:522	putative function	506:522	putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	506:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	5	49	theme	O-antigen	1177:1185	arg1	unit					1165:1168	unit	1165:1168	unit of the O-antigen	1165:1185	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	50	theme	carbohydrate	744:755	arg1	polymer					757:763	the carbohydrate polymer	740:763	the carbohydrate polymer in an automated fashion using the computer program CASPER	740:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	6	51	theme	acidic	1435:1440	arg1	polysaccharide					1453:1466	the acidic O-specific polysaccharide	1431:1466	the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T	1431:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	4	52	theme	3-O-substituted	1062:1076	arg1	unit					1112:1115	the repeating unit	1098:1115	the repeating unit	1098:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	52	theme	3-O-substituted	1062:1076	arg1	residue					1087:1093	the 3-O-substituted mannosyl residue	1058:1093	the 3-O-substituted mannosyl residue of the repeating unit	1058:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	3	53	from	function	515:522	arg1	transferases					536:547	glycosyl transferases	527:547	glycosyl transferases	527:547	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	53	from	function	515:522	arg1	magnitude					559:567	the magnitude	555:567	(ii) the magnitude of NMR coupling constants of anomeric protons	550:613	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	53	from	function	515:522	arg1	13C-HSQC					644:651	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	13C-HSQC	644:651	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	1	54	theme	reference	165:173	arg1	strain					175:180	the international reference strain	147:180	the international reference strain Escherichia coli	147:197	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	3	55	theme	NMR	670:672	arg1	spectra					674:680	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	spectra	674:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	1	56	theme	Escherichia	182:192	arg1	strain					175:180	the international reference strain	147:180	the international reference strain Escherichia coli	147:197	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	5	57	theme	repeating	1309:1317	arg1	-α-d-GlcpNAc-					1255:1267	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	→2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→	1200:1270	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	5	57	theme	repeating	1309:1317	arg1	unit					1319:1322	the biological repeating unit	1294:1322	the biological repeating unit	1294:1322	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	2	58	theme	O-specific	352:361	arg1	polysaccharides					363:377	long O-specific polysaccharides	347:377	long O-specific polysaccharides	347:377	A nonrandom modal chain-length distribution was observed for the lipopolysaccharide, a pattern which is typical when long O-specific polysaccharides are expressed.
36239409	3	59	theme	NMR	572:574	arg1	constants					585:593	NMR coupling constants	572:593	NMR coupling constants of anomeric protons	572:613	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	4	60	from	s	1052:1052	arg1	unit					1112:1115	the repeating unit	1098:1115	the repeating unit	1098:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	60	from	s	1052:1052	arg1	residue					1087:1093	the 3-O-substituted mannosyl residue	1058:1093	the 3-O-substituted mannosyl residue of the repeating unit	1058:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	6	61	theme	O-acetyl	1576:1583	arg1	group					1585:1589	the O-acetyl group	1572:1589	the O-acetyl group at O6 of the O-acetylated mannosyl residue	1572:1632	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	6	62	theme	strain	1494:1499	arg1	NN015840T					1501:1509	Cellulophaga baltica strain NN015840T	1473:1509	Cellulophaga baltica strain NN015840T	1473:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	5	63	theme	E.	1393:1394	arg1	K84					1401:1403	E. coli K84	1393:1403	E. coli K84	1393:1403	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	64	theme	anomeric	598:605	arg1	protons					607:613	anomeric protons	598:613	anomeric protons	598:613	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	6	65	theme	Cellulophaga	1473:1484	arg1	NN015840T					1501:1509	Cellulophaga baltica strain NN015840T	1473:1509	Cellulophaga baltica strain NN015840T	1473:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	6	66	from	NN015840T	1501:1509	arg1	polysaccharide					1453:1466	the acidic O-specific polysaccharide	1431:1466	the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T	1431:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	6	66	from	NN015840T	1501:1509	arg1	structure					1418:1426	The structure	1414:1426	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T	1414:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	5	67	from	K50	1409:1411	arg1	polysaccharides					1372:1386	capsular polysaccharides	1363:1386	capsular polysaccharides from E. coli K84 and K50	1363:1411	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	3	68	theme	constants	585:593	arg1	transferases					536:547	glycosyl transferases	527:547	glycosyl transferases	527:547	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	68	theme	constants	585:593	arg1	magnitude					559:567	the magnitude	555:567	(ii) the magnitude of NMR coupling constants of anomeric protons	550:613	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	68	theme	constants	585:593	arg1	spectra					674:680	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	spectra	674:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	68	theme	constants	585:593	arg1	13C-HSQC					644:651	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	13C-HSQC	644:651	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	69	dep	magnitude	559:567	arg1	ii					551:552	ii	551:552	ii	551:552	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	1	70	theme	O-antigen	132:140	arg1	structure					115:123	The structure	111:123	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16	111:207	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	3	71	theme	computer	799:806	arg1	program					808:814	the computer program	795:814	the computer program CASPER	795:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	5	72	from	K84	1401:1403	arg1	polysaccharides					1372:1386	capsular polysaccharides	1363:1386	capsular polysaccharides from E. coli K84 and K50	1363:1411	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	4	73	theme	unit	1112:1115	arg1	unit					1112:1115	the repeating unit	1098:1115	the repeating unit	1098:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	4	73	theme	unit	1112:1115	arg1	residue					1087:1093	the 3-O-substituted mannosyl residue	1058:1093	the 3-O-substituted mannosyl residue of the repeating unit	1058:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	2	74	theme	nonrandom	232:240	arg1	distribution					261:272	A nonrandom modal chain-length distribution	230:272	A nonrandom modal chain-length distribution	230:272	A nonrandom modal chain-length distribution was observed for the lipopolysaccharide, a pattern which is typical when long O-specific polysaccharides are expressed.
36239409	1	75	from	strain	175:180	arg1	structure					115:123	The structure	111:123	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16	111:207	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	1	75	from	strain	175:180	arg1	O-antigen					132:140	the O-antigen	128:140	the O-antigen from the international reference strain Escherichia coli	128:197	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	6	76	theme	residue	1626:1632	arg1	O6					1594:1595	O6	1594:1595	O6 of the O-acetylated mannosyl residue	1594:1632	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	0	77	theme	biosynthetic	91:102	arg1	genes					104:108	its biosynthetic genes	87:108	its biosynthetic genes	87:108	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	6	78	from	structure	1418:1426	arg1	NN015840T					1501:1509	Cellulophaga baltica strain NN015840T	1473:1509	Cellulophaga baltica strain NN015840T	1473:1509	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	6	79	from	O6	1594:1595	arg1	group					1585:1589	the O-acetyl group	1572:1589	the O-acetyl group at O6 of the O-acetylated mannosyl residue	1572:1632	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	6	80	theme	O-acetylated	1604:1615	arg1	residue					1626:1632	the O-acetylated mannosyl residue	1600:1632	the O-acetylated mannosyl residue	1600:1632	The structure of the acidic O-specific polysaccharide from Cellulophaga baltica strain NN015840T differs to that of the O-antigen from E. coli O93 by lacking the O-acetyl group at O6 of the O-acetylated mannosyl residue.
36239409	3	81	theme	automated	771:779	arg1	fashion					781:787	an automated fashion	768:787	an automated fashion using the computer program CASPER	768:821	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	4	82	theme	NMR	914:916	arg1	experiments					918:928	2D NMR experiments	911:928	2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit	911:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	1	83	dep	structure	115:123	arg1	H16					205:207	H16	205:207	H16	205:207	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	1	83	dep	structure	115:123	arg1	O93					199:201	O93	199:201	O93	199:201	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	3	84	theme	bioinformatics	418:431	arg1	information					433:443	(i) bioinformatics information	414:443	(i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	414:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	5	85	theme	capsular	1363:1370	arg1	polysaccharides					1372:1386	capsular polysaccharides	1363:1386	capsular polysaccharides from E. coli K84 and K50	1363:1411	The structure of the tetrasaccharide repeating unit of the O-antigen is given by: →2)-β-d-Manp-(1→3)-β-d-Manp2Ac6Ac-(1→4)-β-d-GlcpA-(1→3)-α-d-GlcpNAc-(1→, which should also be the biological repeating unit and it shares structural elements with capsular polysaccharides from E. coli K84 and K50.
36239409	0	86	theme	O-antigen	19:27	arg1	structure					29:37	the O-antigen structure	15:37	the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes	15:108	Elucidation of the O-antigen structure of Escherichia coli O93 and characterization of its biosynthetic genes.
36239409	3	87	dep	13C-HSQC	644:651	arg1	iii					621:623	iii	621:623	iii	621:623	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	1	88	from	structure	115:123	arg1	strain					175:180	the international reference strain	147:180	the international reference strain Escherichia coli	147:197	The structure of the O-antigen from the international reference strain Escherichia coli O93:-:H16 has been determined.
36239409	3	89	theme	gene	452:455	arg1	cluster					457:463	the gene cluster	448:463	the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	448:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	90	from	information	433:443	arg1	cluster					457:463	the gene cluster	448:463	the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	448:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	91	theme	2D	637:638	arg1	13C-HSQC					644:651	(iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	620:680	13C-HSQC	644:651	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	92	theme	O-antigen	476:484	arg1	synthesis					486:494	O-antigen synthesis	476:494	O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	476:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	93	dep	information	433:443	arg1	i					415:415	i	415:415	i	415:415	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	3	94	theme	related	465:471	arg1	cluster					457:463	the gene cluster	448:463	the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra	448:680	By a combination of (i) bioinformatics information on the gene cluster related to O-antigen synthesis including putative function on glycosyl transferases, (ii) the magnitude of NMR coupling constants of anomeric protons, and (iii) unassigned 2D 1H, 13C-HSQC, and 1H,1H-TOCSY NMR spectra it was possible to efficiently elucidate the structure of the carbohydrate polymer in an automated fashion using the computer program CASPER.
36239409	4	95	theme	O-acetyl	1037:1044	arg1	s					1052:1052	O-acetyl group(s)	1037:1053	O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit	1037:1115	The polysaccharide also carries O-acetyl groups and their locations were determined by 2D NMR experiments showing that ~½ of the population was 2,6-di-O-acetylated, ~¼ was 2-O-acetylated, whereas ~¼ did not carry O-acetyl group(s) in the 3-O-substituted mannosyl residue of the repeating unit.
36239409	2	96	theme	long	347:350	arg1	polysaccharides					363:377	long O-specific polysaccharides	347:377	long O-specific polysaccharides	347:377	A nonrandom modal chain-length distribution was observed for the lipopolysaccharide, a pattern which is typical when long O-specific polysaccharides are expressed.
37069671	7	0	theme	dissolved	1113:1121	arg1	α-glucans					1056:1064	α-glucans	1056:1064	α-glucans	1056:1064	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	0	theme	dissolved	1113:1121	arg1	β-glucans					1023:1031	β-glucans	1023:1031	β-glucans (diatom laminarin)	1023:1050	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	0	theme	dissolved	1113:1121	arg1	substrates					1138:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	6	1	theme	clades	861:866	arg1	MAGs					835:838	50 particularly active MAGs	812:838	50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders	812:907	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	3	2	theme	prime	530:534	arg1	importance					536:545	prime importance	530:545	prime importance	530:545	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	2	3	theme	planktonic	289:298	arg1	bacteria					300:307	planktonic bacteria	289:307	planktonic bacteria	289:307	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	7	4	theme	Saccharide	910:919	arg1	measurements					921:932	Saccharide measurements	910:932	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data	910:1010	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	8	5	from	peak	1298:1301	arg1	flagellate					1306:1315	flagellate	1306:1315	flagellate	1306:1315	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	8	5	from	peak	1298:1301	arg1	nadir					1325:1329	the nadir	1321:1329	the nadir in bacterial total cell counts	1321:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	2	6	theme	clades	279:284	arg1	blooms					257:262	successive blooms	246:262	successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale	246:382	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	8	7	theme	bloom	1270:1274	arg1	phase					1276:1280	the second bloom phase	1259:1280	the second bloom phase	1259:1280	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	6	8	theme	active	828:833	arg1	MAGs					835:838	50 particularly active MAGs	812:838	50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders	812:907	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	4	9	theme	90-day	636:641	arg1	period					643:648	a 90-day period	634:648	a 90-day period	634:648	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	10	10	theme	phytoplankton	1880:1892	arg1	blooms					1894:1899	phytoplankton blooms	1880:1899	phytoplankton blooms	1880:1899	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	9	11	theme	bacterioplankton	1553:1568	arg1	members					1570:1576	abundant bacterioplankton members	1544:1576	abundant bacterioplankton members	1544:1576	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	8	12	theme	cell	1350:1353	arg1	counts					1355:1360	bacterial total cell counts	1334:1360	bacterial total cell counts	1334:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	5	13	theme	genomes	751:757	arg1	reconstruction					708:721	reconstruction	708:721	reconstruction of 251 metagenome-assembled genomes (MAGs)	708:764	Bacterioplankton metagenomes from 30 time points allowed reconstruction of 251 metagenome-assembled genomes (MAGs).
37069671	4	14	dep	spring	596:601	arg1	bloom					603:607	bloom	603:607	bloom	603:607	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	7	15	theme	prominent	1078:1086	arg1	α-glucans					1056:1064	α-glucans	1056:1064	α-glucans	1056:1064	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	15	theme	prominent	1078:1086	arg1	β-glucans					1023:1031	β-glucans	1023:1031	β-glucans (diatom laminarin)	1023:1050	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	15	theme	prominent	1078:1086	arg1	substrates					1138:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	10	16	contain	have	1812:1815	arg2	influence					1831:1839	a significant influence	1817:1839	a significant influence	1817:1839	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	10	16	contain	have	1812:1815	arg1	recycling					1727:1735	recycling	1727:1735	recycling of bacterial glycans as a result of increased bacterial cell mortality	1727:1806	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	10	17	theme	glycans	1713:1719	arg1	release					1696:1702	the release	1692:1702	the release of algal glycans	1692:1719	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	7	18	theme	polysaccharide	1123:1136	arg1	α-glucans					1056:1064	α-glucans	1056:1064	α-glucans	1056:1064	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	18	theme	polysaccharide	1123:1136	arg1	β-glucans					1023:1031	β-glucans	1023:1031	β-glucans (diatom laminarin)	1023:1050	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	18	theme	polysaccharide	1123:1136	arg1	substrates					1138:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	19	theme	metabolized	1101:1111	arg1	α-glucans					1056:1064	α-glucans	1056:1064	α-glucans	1056:1064	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	19	theme	metabolized	1101:1111	arg1	β-glucans					1023:1031	β-glucans	1023:1031	β-glucans (diatom laminarin)	1023:1050	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	19	theme	metabolized	1101:1111	arg1	substrates					1138:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	the most prominent and actively metabolized dissolved polysaccharide substrates	1069:1147	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	1	20	theme	BACKGROUND	142:151	arg1	Blooms					153:158	BACKGROUND Blooms	142:158	BACKGROUND Blooms of marine microalgae	142:179	BACKGROUND Blooms of marine microalgae play a pivotal role in global carbon cycling.
37069671	0	21	theme	abundant	62:69	arg1	clades					88:93	abundant bacterioplankton clades	62:93	abundant bacterioplankton clades	62:93	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	11	22	dep	Abstract	1908:1915	arg1	Video					1902:1906	Video	1902:1906	Video	1902:1906	Video Abstract.
37069671	2	23	theme	successive	246:255	arg1	blooms					257:262	successive blooms	246:262	successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale	246:382	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	0	24	theme	clades	88:93	arg1	composition					47:57	the community composition	33:57	the community composition of abundant bacterioplankton clades	33:93	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	7	25	theme	diatom	1034:1039	arg1	β-glucans					1023:1031	β-glucans	1023:1031	β-glucans (diatom laminarin)	1023:1050	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	25	theme	diatom	1034:1039	arg1	laminarin					1041:1049	diatom laminarin	1034:1049	diatom laminarin	1034:1049	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	0	26	dep	phytoplankton	121:133	arg1	bloom					135:139	bloom	135:139	bloom	135:139	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	9	27	theme	polysaccharide	1641:1654	arg1	niches					1656:1661	similar polysaccharide niches	1633:1661	similar polysaccharide niches	1633:1661	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	0	28	theme	Sea	110:112	arg1	phytoplankton					121:133	a North Sea spring phytoplankton bloom	102:139	a North Sea spring phytoplankton bloom	102:139	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	10	29	theme	bacterial	1740:1748	arg1	glycans					1750:1756	bacterial glycans	1740:1756	bacterial glycans	1740:1756	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	0	30	theme	Dissolved	0:8	arg1	glycans					18:24	Dissolved storage glycans	0:24	Dissolved storage glycans	0:24	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	9	31	from	composition	1404:1414	arg1	polysaccharides					1477:1491	particular abundant storage polysaccharides	1449:1491	particular abundant storage polysaccharides	1449:1491	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	10	32	theme	increased	1773:1781	arg1	mortality					1798:1806	increased bacterial cell mortality	1773:1806	increased bacterial cell mortality	1773:1806	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	3	33	theme	distinct	421:428	arg1	polysaccharides					430:444	distinct polysaccharides	421:444	distinct polysaccharides	421:444	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	9	34	theme	polysaccharides	1429:1443	arg1	composition					1404:1414	composition	1404:1414	composition	1404:1414	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	34	theme	polysaccharides	1429:1443	arg1	polysaccharides					1429:1443	dissolved polysaccharides	1419:1443	dissolved polysaccharides	1419:1443	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	34	theme	polysaccharides	1429:1443	arg1	amounts					1392:1398	amounts	1392:1398	amounts	1392:1398	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	35	dep	amounts	1392:1398	arg1	the					1388:1390	the	1388:1390	the	1388:1390	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	6	36	theme	polysaccharide	884:897	arg1	degraders					899:907	many polysaccharide degraders	879:907	many polysaccharide degraders	879:907	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	6	37	theme	Corresponding	767:779	arg1	metatranscriptomes					781:798	Corresponding metatranscriptomes	767:798	Corresponding metatranscriptomes	767:798	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	2	38	theme	algal	352:356	arg1	biomass					358:364	algal biomass	352:364	algal biomass	352:364	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	4	39	from	spring	596:601	arg1	Bight					623:627	the German Bight	612:627	the German Bight	612:627	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	3	40	theme	importance	536:545	arg1	process					519:525	a process	517:525	a process of prime importance	517:545	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	3	40	theme	importance	536:545	arg1	decomposition					465:477	the microbial decomposition	451:477	the microbial decomposition of these polysaccharides	451:502	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	8	41	theme	PUL	1216:1218	arg1	expression					1220:1229	α-glucan PUL expression	1207:1229	α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts	1207:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	5	42	theme	Bacterioplankton	651:666	arg1	metagenomes					668:678	Bacterioplankton metagenomes	651:678	Bacterioplankton metagenomes from 30 time points	651:698	Bacterioplankton metagenomes from 30 time points allowed reconstruction of 251 metagenome-assembled genomes (MAGs).
37069671	2	43	theme	global	371:376	arg1	scale					378:382	a global scale	369:382	a global scale	369:382	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	7	44	theme	polysaccharide	958:971	arg1	loci					985:988	polysaccharide utilization loci	958:988	polysaccharide utilization loci (PUL)	958:994	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	44	theme	polysaccharide	958:971	arg1	PUL					991:993	PUL	991:993	PUL	991:993	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	4	45	theme	biphasic	587:594	arg1	spring					596:601	a complete biphasic spring bloom	576:607	a complete biphasic spring bloom in the German Bight	576:627	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	6	46	theme	abundant	852:859	arg1	degraders					899:907	many polysaccharide degraders	879:907	many polysaccharide degraders	879:907	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	6	46	theme	abundant	852:859	arg1	clades					861:866	the most abundant clades	843:866	the most abundant clades	843:866	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	2	47	theme	bacteria	300:307	arg1	clades					279:284	specialized clades	267:284	specialized clades of planktonic bacteria	267:307	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	9	48	theme	pronounced	1501:1510	arg1	influence					1512:1520	a pronounced influence	1499:1520	a pronounced influence	1499:1520	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	10	49	theme	bacterioplankton	1844:1859	arg1	composition					1861:1871	bacterioplankton composition	1844:1871	bacterioplankton composition during phytoplankton blooms	1844:1899	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	8	50	theme	second	1263:1268	arg1	phase					1276:1280	the second bloom phase	1259:1280	the second bloom phase	1259:1280	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	10	51	theme	algal	1707:1711	arg1	glycans					1713:1719	algal glycans	1707:1719	algal glycans	1707:1719	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	1	52	theme	pivotal	188:194	arg1	role					196:199	a pivotal role	186:199	a pivotal role	186:199	BACKGROUND Blooms of marine microalgae play a pivotal role in global carbon cycling.
37069671	9	53	from	amounts	1392:1398	arg1	polysaccharides					1477:1491	particular abundant storage polysaccharides	1449:1491	particular abundant storage polysaccharides	1449:1491	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	7	54	dep	bacterial	948:956	arg1	loci					985:988	polysaccharide utilization loci	958:988	polysaccharide utilization loci (PUL)	958:994	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	54	dep	bacterial	948:956	arg1	PUL					991:993	PUL	991:993	PUL	991:993	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	9	55	contain	have	1494:1497	arg2	influence					1512:1520	a pronounced influence	1499:1520	a pronounced influence	1499:1520	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	55	contain	have	1494:1497	arg1	composition					1404:1414	composition	1404:1414	composition	1404:1414	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	55	contain	have	1494:1497	arg1	polysaccharides					1429:1443	dissolved polysaccharides	1419:1443	dissolved polysaccharides	1419:1443	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	55	contain	have	1494:1497	arg1	amounts					1392:1398	amounts	1392:1398	amounts	1392:1398	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	9	56	theme	abundant	1544:1551	arg1	members					1570:1576	abundant bacterioplankton members	1544:1576	abundant bacterioplankton members	1544:1576	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	8	57	theme	phase	1276:1280	arg1	beginning					1246:1254	the beginning	1242:1254	the beginning of the second bloom phase	1242:1280	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	1	58	theme	microalgae	170:179	arg1	Blooms					153:158	BACKGROUND Blooms	142:158	BACKGROUND Blooms of marine microalgae	142:179	BACKGROUND Blooms of marine microalgae play a pivotal role in global carbon cycling.
37069671	10	59	theme	mortality	1798:1806	arg1	result					1763:1768	a result	1761:1768	a result of increased bacterial cell mortality	1761:1806	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	5	60	theme	metagenome-assembled	730:749	arg1	MAGs					760:763	MAGs	760:763	MAGs	760:763	Bacterioplankton metagenomes from 30 time points allowed reconstruction of 251 metagenome-assembled genomes (MAGs).
37069671	5	60	theme	metagenome-assembled	730:749	arg1	genomes					751:757	251 metagenome-assembled genomes	726:757	251 metagenome-assembled genomes (MAGs)	726:764	Bacterioplankton metagenomes from 30 time points allowed reconstruction of 251 metagenome-assembled genomes (MAGs).
37069671	9	61	theme	members	1570:1576	arg1	composition					1529:1539	the composition	1525:1539	the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches	1525:1661	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	8	62	theme	total	1344:1348	arg1	counts					1355:1360	bacterial total cell counts	1334:1360	bacterial total cell counts	1334:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	5	63	theme	time	688:691	arg1	points					693:698	30 time points	685:698	30 time points	685:698	Bacterioplankton metagenomes from 30 time points allowed reconstruction of 251 metagenome-assembled genomes (MAGs).
37069671	2	64	theme	Such	227:230	arg1	blooms					232:237	Such blooms	227:237	Such blooms	227:237	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	9	65	theme	phytoplankton	1585:1597	arg1	blooms					1599:1604	phytoplankton blooms	1585:1604	phytoplankton blooms	1585:1604	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	2	66	theme	specialized	267:277	arg1	clades					279:284	specialized clades	267:284	specialized clades of planktonic bacteria	267:307	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	8	67	from	flagellate	1306:1315	arg1	counts					1355:1360	bacterial total cell counts	1334:1360	bacterial total cell counts	1334:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	10	68	theme	cell	1793:1796	arg1	mortality					1798:1806	increased bacterial cell mortality	1773:1806	increased bacterial cell mortality	1773:1806	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	0	69	theme	bacterioplankton	71:86	arg1	clades					88:93	abundant bacterioplankton clades	62:93	abundant bacterioplankton clades	62:93	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	8	70	theme	bacterial	1334:1342	arg1	counts					1355:1360	bacterial total cell counts	1334:1360	bacterial total cell counts	1334:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	9	71	theme	abundant	1460:1467	arg1	polysaccharides					1477:1491	particular abundant storage polysaccharides	1449:1491	particular abundant storage polysaccharides	1449:1491	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	1	72	theme	marine	163:168	arg1	microalgae					170:179	marine microalgae	163:179	marine microalgae	163:179	BACKGROUND Blooms of marine microalgae play a pivotal role in global carbon cycling.
37069671	0	73	theme	North	104:108	arg1	phytoplankton					121:133	a North Sea spring phytoplankton bloom	102:139	a North Sea spring phytoplankton bloom	102:139	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	4	74	dep	RESULTS	548:554	arg1	sampled					568:574	sampled	568:574	sampled a complete biphasic spring bloom in the German Bight over a 90-day period	568:648	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	9	75	theme	similar	1633:1639	arg1	niches					1656:1661	similar polysaccharide niches	1633:1661	similar polysaccharide niches	1633:1661	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	0	76	theme	spring	114:119	arg1	phytoplankton					121:133	a North Sea spring phytoplankton bloom	102:139	a North Sea spring phytoplankton bloom	102:139	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	1	77	theme	global	204:209	arg1	cycling					218:224	global carbon cycling	204:224	global carbon cycling	204:224	BACKGROUND Blooms of marine microalgae play a pivotal role in global carbon cycling.
37069671	3	78	theme	microbial	455:463	arg1	process					519:525	a process	517:525	a process of prime importance	517:545	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	3	78	theme	microbial	455:463	arg1	decomposition					465:477	the microbial decomposition	451:477	the microbial decomposition of these polysaccharides	451:502	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	0	79	theme	storage	10:16	arg1	glycans					18:24	Dissolved storage glycans	0:24	Dissolved storage glycans	0:24	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	9	80	dep	CONCLUSIONS	1363:1373	arg1	show					1378:1381	show	1378:1381	show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches	1378:1661	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	7	81	theme	expression	996:1005	arg1	data					1007:1010	bacterial polysaccharide utilization loci (PUL) expression data	948:1010	bacterial polysaccharide utilization loci (PUL) expression data	948:1010	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	4	82	theme	complete	578:585	arg1	spring					596:601	a complete biphasic spring bloom	576:607	a complete biphasic spring bloom in the German Bight	576:627	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	3	83	theme	polysaccharides	488:502	arg1	process					519:525	a process	517:525	a process of prime importance	517:545	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	3	83	theme	polysaccharides	488:502	arg1	decomposition					465:477	the microbial decomposition	451:477	the microbial decomposition of these polysaccharides	451:502	This biomass is largely composed of distinct polysaccharides, and the microbial decomposition of these polysaccharides is therefore a process of prime importance.
37069671	0	84	theme	community	37:45	arg1	composition					47:57	the community composition	33:57	the community composition of abundant bacterioplankton clades	33:93	Dissolved storage glycans shaped the community composition of abundant bacterioplankton clades during a North Sea spring phytoplankton bloom.
37069671	9	85	theme	dissolved	1419:1427	arg1	polysaccharides					1429:1443	dissolved polysaccharides	1419:1443	dissolved polysaccharides	1419:1443	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	1	86	theme	carbon	211:216	arg1	cycling					218:224	global carbon cycling	204:224	global carbon cycling	204:224	BACKGROUND Blooms of marine microalgae play a pivotal role in global carbon cycling.
37069671	2	87	theme	biomass	358:364	arg1	gigatons					340:347	gigatons	340:347	gigatons of algal biomass	340:364	Such blooms entail successive blooms of specialized clades of planktonic bacteria that collectively remineralize gigatons of algal biomass on a global scale.
37069671	9	88	theme	particular	1449:1458	arg1	polysaccharides					1477:1491	particular abundant storage polysaccharides	1449:1491	particular abundant storage polysaccharides	1449:1491	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	8	89	theme	α-glucan	1207:1214	arg1	expression					1220:1229	α-glucan PUL expression	1207:1229	α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts	1207:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	6	90	theme	many	879:882	arg1	degraders					899:907	many polysaccharide degraders	879:907	many polysaccharide degraders	879:907	Corresponding metatranscriptomes highlighted 50 particularly active MAGs of the most abundant clades, including many polysaccharide degraders.
37069671	4	91	theme	German	616:621	arg1	Bight					623:627	the German Bight	612:627	the German Bight	612:627	RESULTS In 2020, we sampled a complete biphasic spring bloom in the German Bight over a 90-day period.
37069671	8	92	from	nadir	1325:1329	arg1	counts					1355:1360	bacterial total cell counts	1334:1360	bacterial total cell counts	1334:1360	Both substrates were consumed throughout the bloom, with α-glucan PUL expression peaking at the beginning of the second bloom phase shortly after a peak in flagellate and the nadir in bacterial total cell counts.
37069671	10	93	theme	bacterial	1783:1791	arg1	mortality					1798:1806	increased bacterial cell mortality	1773:1806	increased bacterial cell mortality	1773:1806	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	7	94	theme	utilization	973:983	arg1	loci					985:988	polysaccharide utilization loci	958:988	polysaccharide utilization loci (PUL)	958:994	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	7	94	theme	utilization	973:983	arg1	PUL					991:993	PUL	991:993	PUL	991:993	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	9	95	theme	storage	1469:1475	arg1	polysaccharides					1477:1491	particular abundant storage polysaccharides	1449:1491	particular abundant storage polysaccharides	1449:1491	CONCLUSIONS We show that the amounts and composition of dissolved polysaccharides, in particular abundant storage polysaccharides, have a pronounced influence on the composition of abundant bacterioplankton members during phytoplankton blooms, some of which compete for similar polysaccharide niches.
37069671	10	96	theme	glycans	1750:1756	arg1	recycling					1727:1735	recycling	1727:1735	recycling of bacterial glycans as a result of increased bacterial cell mortality	1727:1806	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	10	97	theme	significant	1819:1829	arg1	influence					1831:1839	a significant influence	1817:1839	a significant influence	1817:1839	We hypothesize that besides the release of algal glycans, also recycling of bacterial glycans as a result of increased bacterial cell mortality can have a significant influence on bacterioplankton composition during phytoplankton blooms.
37069671	7	98	theme	bacterial	948:956	arg1	data					1007:1010	bacterial polysaccharide utilization loci (PUL) expression data	948:1010	bacterial polysaccharide utilization loci (PUL) expression data	948:1010	Saccharide measurements together with bacterial polysaccharide utilization loci (PUL) expression data identified β-glucans (diatom laminarin) and α-glucans as the most prominent and actively metabolized dissolved polysaccharide substrates.
37069671	5	99	from	points	693:698	arg1	metagenomes					668:678	Bacterioplankton metagenomes	651:678	Bacterioplankton metagenomes from 30 time points	651:698	Bacterioplankton metagenomes from 30 time points allowed reconstruction of 251 metagenome-assembled genomes (MAGs).
36288283	0	0	theme	Lassa	72:76	arg1	virus					78:82	Lassa virus	72:82	Lassa virus	72:82	A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.
36288283	4	1	theme	biochemical	459:469	arg1	analyses					471:478	biochemical analyses	459:478	biochemical analyses	459:478	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	9	2	theme	rational	1364:1371	arg1	design					1373:1378	the rational design	1360:1378	the rational design of therapeutic modalities against LF and related infectious diseases	1360:1447	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	1	3	theme	ultimate	147:154	arg1	therapeutics					103:114	potent therapeutics	96:114	potent therapeutics	96:114	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	3	theme	ultimate	147:154	arg1	vaccines					130:137	effective vaccines	120:137	effective vaccines	120:137	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	3	theme	ultimate	147:154	arg1	goals					156:160	the ultimate goals	143:160	the ultimate goals in controlling infectious diseases	143:195	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	4	4	theme	broadly	571:577	arg1	antibodies					590:599	three broadly protective antibodies	565:599	three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections	565:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	6	5	theme	specific	946:953	arg1	glycans					955:961	specific glycans	946:961	specific glycans comprising the extensive glycan shield of GPC	946:1007	These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC.
36288283	4	6	theme	high-resolution	484:498	arg1	microscopy					514:523	high-resolution cryo-electron microscopy	484:523	high-resolution cryo-electron microscopy structures	484:534	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	2	7	theme	effective	306:314	arg1	antivirals					316:325	effective antivirals	306:325	effective antivirals	306:325	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	1	8	theme	potent	96:101	arg1	therapeutics					103:114	potent therapeutics	96:114	potent therapeutics	96:114	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	8	theme	potent	96:101	arg1	vaccines					130:137	effective vaccines	120:137	effective vaccines	120:137	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	8	theme	potent	96:101	arg1	goals					156:160	the ultimate goals	143:160	the ultimate goals in controlling infectious diseases	143:195	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	4	9	theme	antibodies	590:599	arg1	cocktail					553:560	a therapeutic cocktail	539:560	a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections	539:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	0	10	theme	virus	78:82	arg1	glycan					55:60	the dense glycan shield	45:67	the dense glycan shield of Lassa virus	45:82	A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.
36288283	4	11	theme	multiple	690:697	arg1	infections					704:713	multiple LASV infections	690:713	multiple LASV infections	690:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	9	12	theme	LF	1414:1415	arg1	diseases					1440:1447	LF and related infectious diseases	1414:1447	LF and related infectious diseases	1414:1447	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	4	13	theme	protective	579:588	arg1	antibodies					590:599	three broadly protective antibodies	565:599	three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections	565:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	8	14	theme	vaccine	1221:1227	arg1	discovery					1229:1237	vaccine discovery	1221:1237	vaccine discovery	1221:1237	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	4	15	gly	glycoprotein	622:633	arg1	glycoprotein					622:633	the LASV glycoprotein complex	613:641	the LASV glycoprotein complex (GPC)	613:647	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	1	16	theme	infectious	177:186	arg1	diseases					188:195	infectious diseases	177:195	infectious diseases	177:195	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	2	17	theme	fever	250:254	arg1	pathogen					232:239	the causative pathogen	218:239	the causative pathogen of Lassa fever (LF)	218:259	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	2	17	theme	fever	250:254	arg1	virus					204:208	Lassa virus	198:208	Lassa virus (LASV)	198:215	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	9	18	theme	rare	1297:1300	arg1	antibodies					1321:1330	rare, broad, and potent antibodies	1297:1330	rare, broad, and potent antibodies	1297:1330	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	9	19	theme	modalities	1395:1404	arg1	design					1373:1378	the rational design	1360:1378	the rational design of therapeutic modalities against LF and related infectious diseases	1360:1447	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	8	20	theme	suitable	1175:1182	arg1	antigen					1167:1173	a next-generation GPC antigen	1145:1173	a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery	1145:1237	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	2	21	theme	LASV	347:350	arg1	infection					352:360	LASV infection	347:360	LASV infection	347:360	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	5	22	theme	high	847:850	arg1	potency					852:858	high potency	847:858	high potency	847:858	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	4	23	theme	therapeutic	541:551	arg1	cocktail					553:560	a therapeutic cocktail	539:560	a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections	539:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	7	24	theme	GPC	1089:1091	arg1	trimerization					1093:1105	proper GPC trimerization	1082:1105	proper GPC trimerization	1082:1105	Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization.
36288283	8	25	theme	future	1188:1193	arg1	antibody					1208:1215	future neutralizing antibody	1188:1215	future neutralizing antibody	1188:1215	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	3	26	theme	neutralizing	394:405	arg1	antibodies					407:416	neutralizing antibodies	394:416	neutralizing antibodies against LASV	394:429	Furthermore, neutralizing antibodies against LASV are rare.
36288283	0	27	theme	protective	14:23	arg1	antibodies					25:34	protective antibodies	14:34	protective antibodies	14:34	A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.
36288283	6	28	theme	GPC	1005:1007	arg1	glycan					988:993	the extensive glycan shield	974:1000	the extensive glycan shield of GPC	974:1007	These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC.
36288283	9	29	theme	protective	1272:1281	arg1	mechanisms					1283:1292	protective mechanisms	1272:1292	protective mechanisms of rare, broad, and potent antibodies	1272:1330	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	1	30	theme	Developing	85:94	arg1	therapeutics					103:114	potent therapeutics	96:114	potent therapeutics	96:114	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	30	theme	Developing	85:94	arg1	vaccines					130:137	effective vaccines	120:137	effective vaccines	120:137	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	30	theme	Developing	85:94	arg1	goals					156:160	the ultimate goals	143:160	the ultimate goals in controlling infectious diseases	143:195	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	5	31	theme	broad	861:865	arg1	range					867:871	broad range	861:871	broad range	861:871	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	9	32	theme	therapeutic	1383:1393	arg1	modalities					1395:1404	therapeutic modalities	1383:1404	therapeutic modalities against LF and related infectious diseases	1383:1447	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	0	33	dep	glycan	55:60	arg1	shield					62:67	shield	62:67	shield	62:67	A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.
36288283	4	34	theme	glycoprotein	622:633	arg1	GPC					644:646	GPC	644:646	GPC	644:646	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	4	34	theme	glycoprotein	622:633	arg1	complex					635:641	the LASV glycoprotein complex	613:641	the LASV glycoprotein complex (GPC)	613:647	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	5	35	theme	complementary	796:808	arg1	mechanisms					825:834	complementary neutralization mechanisms	796:834	complementary neutralization mechanisms	796:834	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	4	36	theme	cocktail	553:560	arg1	structures					525:534	high-resolution cryo-electron microscopy structures	484:534	high-resolution cryo-electron microscopy structures	484:534	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	4	36	theme	cocktail	553:560	arg1	analyses					471:478	biochemical analyses	459:478	biochemical analyses	459:478	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	7	37	theme	proper	1082:1087	arg1	trimerization					1093:1105	proper GPC trimerization	1082:1105	proper GPC trimerization	1082:1105	Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization.
36288283	0	38	theme	antibodies	25:34	arg1	cocktail					2:9	A cocktail	0:9	A cocktail of protective antibodies	0:34	A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.
36288283	4	39	theme	microscopy	514:523	arg1	structures					525:534	high-resolution cryo-electron microscopy structures	484:534	high-resolution cryo-electron microscopy structures	484:534	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	5	40	theme	neutralization	810:823	arg1	mechanisms					825:834	complementary neutralization mechanisms	796:834	complementary neutralization mechanisms	796:834	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	6	41	dep	glycan	988:993	arg1	shield					995:1000	shield	995:1000	shield	995:1000	These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC.
36288283	0	42	theme	dense	49:53	arg1	glycan					55:60	the dense glycan shield	45:67	the dense glycan shield of Lassa virus	45:82	A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus.
36288283	4	43	theme	cryo-electron	500:512	arg1	microscopy					514:523	high-resolution cryo-electron microscopy	484:523	high-resolution cryo-electron microscopy structures	484:534	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	8	44	theme	antigen	1167:1173	arg1	engineering					1130:1140	engineering	1130:1140	engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery	1130:1237	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	7	45	theme	native	1057:1062	arg1	cleavage					1068:1075	native GPC cleavage	1057:1075	native GPC cleavage	1057:1075	Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization.
36288283	4	46	theme	infections	704:713	arg1	survivors					677:685	survivors	677:685	survivors of multiple LASV infections	677:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	5	47	theme	Structural	716:725	arg1	analyses					743:750	Structural and mechanistic analyses	716:750	Structural and mechanistic analyses	716:750	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	9	48	theme	broad	1303:1307	arg1	antibodies					1321:1330	rare, broad, and potent antibodies	1297:1330	rare, broad, and potent antibodies	1297:1330	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	7	49	theme	mammalian	1032:1040	arg1	glycosylation					1042:1054	mammalian glycosylation	1032:1054	mammalian glycosylation	1032:1054	Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization.
36288283	4	50	theme	LASV	699:702	arg1	infections					704:713	multiple LASV infections	690:713	multiple LASV infections	690:713	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	9	51	theme	related	1421:1427	arg1	diseases					1440:1447	LF and related infectious diseases	1414:1447	LF and related infectious diseases	1414:1447	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	7	52	theme	GPC	1064:1066	arg1	cleavage					1068:1075	native GPC cleavage	1057:1075	native GPC cleavage	1057:1075	Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization.
36288283	8	53	theme	neutralizing	1195:1206	arg1	antibody					1208:1215	future neutralizing antibody	1188:1215	future neutralizing antibody	1188:1215	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	2	54	theme	Lassa	244:248	arg1	LF					257:258	LF	257:258	LF	257:258	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	2	54	theme	Lassa	244:248	arg1	fever					250:254	Lassa fever	244:254	Lassa fever (LF)	244:259	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	1	55	theme	effective	120:128	arg1	therapeutics					103:114	potent therapeutics	96:114	potent therapeutics	96:114	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	55	theme	effective	120:128	arg1	vaccines					130:137	effective vaccines	120:137	effective vaccines	120:137	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	1	55	theme	effective	120:128	arg1	goals					156:160	the ultimate goals	143:160	the ultimate goals in controlling infectious diseases	143:195	Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases.
36288283	9	56	theme	infectious	1429:1438	arg1	diseases					1440:1447	LF and related infectious diseases	1414:1447	LF and related infectious diseases	1414:1447	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	8	57	theme	next-generation	1147:1161	arg1	antigen					1167:1173	a next-generation GPC antigen	1145:1173	a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery	1145:1237	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	2	58	theme	Lassa	198:202	arg1	pathogen					232:239	the causative pathogen	218:239	the causative pathogen of Lassa fever (LF)	218:259	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	2	58	theme	Lassa	198:202	arg1	LASV					211:214	LASV	211:214	LASV	211:214	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	2	58	theme	Lassa	198:202	arg1	virus					204:208	Lassa virus	198:208	Lassa virus (LASV)	198:215	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	8	59	theme	GPC	1163:1165	arg1	antigen					1167:1173	a next-generation GPC antigen	1145:1173	a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery	1145:1237	These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery.
36288283	2	60	theme	thousands	282:290	arg1	hundreds					270:277	hundreds	270:277	hundreds of thousands	270:290	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	5	61	theme	compatible	759:768	arg1	epitopes					783:790	compatible neutralizing epitopes	759:790	compatible neutralizing epitopes	759:790	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	9	62	theme	potent	1314:1319	arg1	antibodies					1321:1330	rare, broad, and potent antibodies	1297:1330	rare, broad, and potent antibodies	1297:1330	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	4	63	theme	LASV	617:620	arg1	GPC					644:646	GPC	644:646	GPC	644:646	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	4	63	theme	LASV	617:620	arg1	complex					635:641	the LASV glycoprotein complex	613:641	the LASV glycoprotein complex (GPC)	613:647	Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections.
36288283	5	64	theme	neutralizing	770:781	arg1	epitopes					783:790	compatible neutralizing epitopes	759:790	compatible neutralizing epitopes	759:790	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
36288283	9	65	theme	antibodies	1321:1330	arg1	mechanisms					1283:1292	protective mechanisms	1272:1292	protective mechanisms of rare, broad, and potent antibodies	1272:1330	Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.
36288283	2	66	theme	causative	222:230	arg1	pathogen					232:239	the causative pathogen	218:239	the causative pathogen of Lassa fever (LF)	218:259	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	2	66	theme	causative	222:230	arg1	virus					204:208	Lassa virus	198:208	Lassa virus (LASV)	198:215	Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking.
36288283	6	67	theme	extensive	978:986	arg1	glycan					988:993	the extensive glycan shield	974:1000	the extensive glycan shield of GPC	974:1007	These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC.
36288283	5	68	theme	mechanistic	731:741	arg1	analyses					743:750	Structural and mechanistic analyses	716:750	Structural and mechanistic analyses	716:750	Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape.
37146275	6	0	theme	patients	1383:1390	arg1	serum					1374:1378	the serum	1370:1378	the serum of patients with cervical cancer	1370:1411	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	3	1	from	introduction	775:786	arg1	surface					822:828	the surface	818:828	the surface of silica	818:838	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	5	2	theme	size	1265:1268	arg1	1:8000					1289:1294	1:8000	1289:1294	1:8000	1289:1294	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	2	theme	size	1265:1268	arg1	effects					1280:1286	size exclusion effects	1265:1286	size exclusion effects (1:8000)	1265:1295	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	1	3	theme	structures	284:293	arg1	abnormalities					236:248	abnormalities	236:248	abnormalities of glycosylation sites and glycan structures	236:293	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	2	4	theme	glycoproteins/peptides	427:448	arg1	analysis					411:418	the analysis	407:418	the analysis of the glycoproteins/peptides	407:448	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	3	5	theme	surface	664:670	arg1	exposure					680:687	the surface silicon exposure	660:687	the surface silicon exposure (79.6%)	660:695	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	3	5	theme	surface	664:670	arg1	%					694:694	79.6%	690:694	79.6%	690:694	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	5	6	theme	exclusion	1270:1278	arg1	1:8000					1289:1294	1:8000	1289:1294	1:8000	1289:1294	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	6	theme	exclusion	1270:1278	arg1	effects					1280:1286	size exclusion effects	1265:1286	size exclusion effects (1:8000)	1265:1295	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	6	7	theme	glycosylation	1422:1434	arg1	site					1436:1439	the glycosylation site	1418:1439	the glycosylation site	1418:1439	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	0	8	theme	Efficient	108:116	arg1	Identification					118:131	the Efficient Identification	104:131	the Efficient Identification of Intact N-Glycopeptides	104:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	5	9	theme	remarkable	1228:1237	arg1	1:8000					1252:1257	1:8000	1252:1257	1:8000	1252:1257	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	9	theme	remarkable	1228:1237	arg1	selectivity					1239:1249	remarkable selectivity	1228:1249	remarkable selectivity (1:8000)	1228:1258	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	1	10	gly	glycosylation	253:265	arg2	sites					267:271	glycosylation sites	253:271	glycosylation sites	253:271	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	4	11	theme	intrinsic	1005:1013	arg1	surface					1015:1021	the intrinsic surface	1001:1021	the intrinsic surface of the material	1001:1037	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	6	12	theme	cancer	1573:1578	arg1	diagnosis					1580:1588	cervical cancer diagnosis	1564:1588	cervical cancer diagnosis	1564:1588	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	3	13	theme	silanol	726:732	arg1	amount					702:707	the amount	698:707	the amount of surface polar silanol	698:732	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	3	13	theme	silanol	726:732	arg1	silanol					726:732	surface polar silanol	712:732	surface polar silanol	712:732	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	5	14	theme	hydrophilic	1096:1106	arg1	material					1108:1115	This microscopically highly hydrophilic material	1068:1115	This microscopically highly hydrophilic material	1068:1115	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	6	15	theme	practical	1539:1547	arg1	application					1549:1559	a broad practical application	1531:1559	a broad practical application in cervical cancer diagnosis	1531:1588	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	1	16	theme	various	304:310	arg1	diseases					320:327	various serious diseases	304:327	various serious diseases such as cancer	304:342	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	1	16	theme	various	304:310	arg1	cancer					337:342	cancer	337:342	cancer	337:342	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	3	17	theme	silica	833:838	arg1	surface					822:828	the surface	818:828	the surface of silica	818:838	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	5	18	theme	enrichment	1133:1142	arg1	ability					1144:1150	excellent enrichment ability	1123:1150	excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000)	1123:1295	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	4	19	theme	microscopic	845:855	arg1	hydrophilicity					857:870	The microscopic hydrophilicity	841:870	The microscopic hydrophilicity	841:870	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	5	20	gly	glycopeptides	1156:1168	arg2	selectivity					1239:1249	remarkable selectivity	1228:1249	remarkable selectivity (1:8000)	1228:1258	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	20	gly	glycopeptides	1156:1168	arg2	effects					1280:1286	size exclusion effects	1265:1286	size exclusion effects (1:8000)	1265:1295	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	20	gly	glycopeptides	1156:1168	arg2	limits					1203:1208	extremely low detection limits	1179:1208	extremely low detection limits (0.01 fmol μL-1)	1179:1225	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	20	gly	glycopeptides	1156:1168	arg2	glycopeptides					1156:1168	glycopeptides	1156:1168	glycopeptides	1156:1168	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	1	21	theme	life	200:203	arg1	activities					205:214	the life activities	196:214	the life activities of organisms	196:227	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	4	22	theme	water	981:985	arg1	molecules					987:995	water molecules	981:995	water molecules	981:995	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	3	23	theme	surface	712:718	arg1	silanol					726:732	surface polar silanol	712:732	surface polar silanol	712:732	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	2	24	theme	material	516:523	arg1	factor					541:546	an important factor	528:546	an important factor for the separation and enrichment performance	528:592	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	2	24	theme	material	516:523	arg1	hydrophilicity					494:507	the surface hydrophilicity	482:507	the surface hydrophilicity of the material	482:523	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	4	25	theme	molecules	987:995	arg1	interaction					966:976	the interaction	962:976	the interaction of water molecules	962:995	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	4	25	theme	molecules	987:995	arg1	surface					1015:1021	the intrinsic surface	1001:1021	the intrinsic surface of the material	1001:1037	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	2	26	theme	surface	486:492	arg1	factor					541:546	an important factor	528:546	an important factor for the separation and enrichment performance	528:592	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	2	26	theme	surface	486:492	arg1	hydrophilicity					494:507	the surface hydrophilicity	482:507	the surface hydrophilicity of the material	482:523	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	3	27	theme	polar	720:724	arg1	silanol					726:732	surface polar silanol	712:732	surface polar silanol	712:732	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	6	28	theme	cervical	1397:1404	arg1	cancer					1406:1411	cervical cancer	1397:1411	cervical cancer	1397:1411	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	6	29	theme	intact	1326:1331	arg1	N-glycopeptides					1333:1347	677 quantifiable intact N-glycopeptides	1309:1347	677 quantifiable intact N-glycopeptides	1309:1347	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	1	30	theme	serious	312:318	arg1	diseases					320:327	various serious diseases	304:327	various serious diseases such as cancer	304:342	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	1	30	theme	serious	312:318	arg1	cancer					337:342	cancer	337:342	cancer	337:342	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	6	31	theme	N-glycopeptides	1333:1347	arg1	total					1300:1304	A total	1298:1304	A total of 677 quantifiable intact N-glycopeptides	1298:1347	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	1	32	theme	organisms	219:227	arg1	activities					205:214	the life activities	196:214	the life activities of organisms	196:227	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	0	33	theme	N-Glycopeptides	143:157	arg1	Identification					118:131	the Efficient Identification	104:131	the Efficient Identification of Intact N-Glycopeptides	104:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	6	34	gly	glycosylation	1422:1434	arg2	site					1436:1439	the glycosylation site	1418:1439	the glycosylation site	1418:1439	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	6	35	gly	N-glycopeptides	1333:1347	arg2	N-glycopeptides					1333:1347	677 quantifiable intact N-glycopeptides	1309:1347	677 quantifiable intact N-glycopeptides	1309:1347	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	0	36	theme	Microscopic	15:25	arg1	Nanocomposites					59:72	Microscopic Highly Hydrophilic Silica-Based Nanocomposites	15:72	Microscopic Highly Hydrophilic Silica-Based Nanocomposites	15:72	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	5	37	theme	fmol	1216:1219	arg1	limits					1203:1208	extremely low detection limits	1179:1208	extremely low detection limits (0.01 fmol μL-1)	1179:1225	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	37	theme	fmol	1216:1219	arg1	μL-1					1221:1224	0.01 fmol μL-1	1211:1224	0.01 fmol μL-1	1211:1224	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	0	38	theme	Intact	136:141	arg1	N-Glycopeptides					143:157	Intact N-Glycopeptides	136:157	Intact N-Glycopeptides	136:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	3	39	theme	silicon	672:678	arg1	exposure					680:687	the surface silicon exposure	660:687	the surface silicon exposure (79.6%)	660:695	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	3	39	theme	silicon	672:678	arg1	%					694:694	79.6%	690:694	79.6%	690:694	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	3	40	theme	present	602:608	arg1	work					610:613	the present work	598:613	the present work	598:613	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	6	41	theme	novel	1507:1511	arg1	material					1513:1520	this novel material	1502:1520	this novel material	1502:1520	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	0	42	theme	Silica-Based	46:57	arg1	Nanocomposites					59:72	Microscopic Highly Hydrophilic Silica-Based Nanocomposites	15:72	Microscopic Highly Hydrophilic Silica-Based Nanocomposites	15:72	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	3	43	theme	exposure	680:687	arg1	increase					648:655	an obvious increase	637:655	an obvious increase of the surface silicon exposure (79.6%)	637:695	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	1	44	gly	Glycosylation	160:172	arg1	proteins					177:184	proteins	177:184	proteins	177:184	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	0	45	from	Exposure	92:99	arg1	Identification					118:131	the Efficient Identification	104:131	the Efficient Identification of Intact N-Glycopeptides	104:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	6	46	theme	glycan	1445:1450	arg1	structure					1452:1460	glycan structure	1445:1460	glycan structure	1445:1460	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	6	47	theme	quantifiable	1313:1324	arg1	N-glycopeptides					1333:1347	677 quantifiable intact N-glycopeptides	1309:1347	677 quantifiable intact N-glycopeptides	1309:1347	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	2	48	theme	mass	453:456	arg1	spectrometry					458:469	mass spectrometry	453:469	mass spectrometry	453:469	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	0	49	theme	Hydrophilic	34:44	arg1	Nanocomposites					59:72	Microscopic Highly Hydrophilic Silica-Based Nanocomposites	15:72	Microscopic Highly Hydrophilic Silica-Based Nanocomposites	15:72	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	4	50	theme	material	1030:1037	arg1	interaction					966:976	the interaction	962:976	the interaction of water molecules	962:995	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	4	50	theme	material	1030:1037	arg1	surface					1015:1021	the intrinsic surface	1001:1021	the intrinsic surface of the material	1001:1037	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	2	51	theme	enrichment	571:580	arg1	performance					582:592	enrichment performance	571:592	enrichment performance	571:592	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	6	52	with	patients	1383:1390	arg1	cancer					1406:1411	cervical cancer	1397:1411	cervical cancer	1397:1411	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	6	53	theme	broad	1533:1537	arg1	application					1549:1559	a broad practical application	1531:1559	a broad practical application in cervical cancer diagnosis	1531:1588	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	3	54	theme	active	795:800	arg1	groups					808:813	the active amino groups	791:813	the active amino groups	791:813	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	4	55	theme	physical-adsorption	904:922	arg1	measurements					924:935	water physical-adsorption measurements	898:935	water physical-adsorption measurements	898:935	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	2	56	theme	important	531:539	arg1	factor					541:546	an important factor	528:546	an important factor for the separation and enrichment performance	528:592	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	2	56	theme	important	531:539	arg1	hydrophilicity					494:507	the surface hydrophilicity	482:507	the surface hydrophilicity of the material	482:523	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	0	57	theme	Nanocomposites	59:72	arg1	Application					0:10	Application	0:10	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.	0:158	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	5	58	theme	detection	1193:1201	arg1	limits					1203:1208	extremely low detection limits	1179:1208	extremely low detection limits (0.01 fmol μL-1)	1179:1225	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	58	theme	detection	1193:1201	arg1	μL-1					1221:1224	0.01 fmol μL-1	1211:1224	0.01 fmol μL-1	1211:1224	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	4	59	theme	water	898:902	arg1	measurements					924:935	water physical-adsorption measurements	898:935	water physical-adsorption measurements	898:935	The microscopic hydrophilicity, which is determined with water physical-adsorption measurements and can directly reflect the interaction of water molecules and the intrinsic surface of the material, maximally increases by 44%.
37146275	5	60	theme	excellent	1123:1131	arg1	ability					1144:1150	excellent enrichment ability	1123:1150	excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000)	1123:1295	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	3	61	theme	obvious	640:646	arg1	increase					648:655	an obvious increase	637:655	an obvious increase of the surface silicon exposure (79.6%)	637:695	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	3	62	theme	increase	648:655	arg1	premise					626:632	the premise	622:632	the premise of an obvious increase of the surface silicon exposure (79.6%)	622:695	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	0	63	with	Application	0:10	arg1	Exposure					92:99	High Surface Exposure	79:99	High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides	79:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	2	64	theme	enrichment	362:371	arg1	procedure					373:381	enrichment procedure	362:381	enrichment procedure	362:381	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	1	65	theme	glycosylation	253:265	arg1	sites					267:271	glycosylation sites	253:271	glycosylation sites	253:271	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	2	66	dep	separation	556:565	arg1	the					552:554	the	552:554	the	552:554	A separation and enrichment procedure is necessary to realize the analysis of the glycoproteins/peptides by mass spectrometry, for which the surface hydrophilicity of the material is an important factor for the separation and enrichment performance.
37146275	6	67	from	application	1549:1559	arg1	diagnosis					1580:1588	cervical cancer diagnosis	1564:1588	cervical cancer diagnosis	1564:1588	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	1	68	theme	sites	267:271	arg1	abnormalities					236:248	abnormalities	236:248	abnormalities of glycosylation sites and glycan structures	236:293	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	0	69	theme	Surface	84:90	arg1	Exposure					92:99	High Surface Exposure	79:99	High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides	79:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	6	70	theme	cervical	1564:1571	arg1	diagnosis					1580:1588	cervical cancer diagnosis	1564:1588	cervical cancer diagnosis	1564:1588	A total of 677 quantifiable intact N-glycopeptides were identified from the serum of patients with cervical cancer, and the glycosylation site and glycan structure were analyzed in depth, indicating that this novel material can show a broad practical application in cervical cancer diagnosis.
37146275	3	71	theme	amino	802:806	arg1	groups					808:813	the active amino groups	791:813	the active amino groups	791:813	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	0	72	theme	High	79:82	arg1	Exposure					92:99	High Surface Exposure	79:99	High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides	79:157	Application of Microscopic Highly Hydrophilic Silica-Based Nanocomposites with High Surface Exposure in the Efficient Identification of Intact N-Glycopeptides.
37146275	5	73	theme	low	1189:1191	arg1	limits					1203:1208	extremely low detection limits	1179:1208	extremely low detection limits (0.01 fmol μL-1)	1179:1225	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	5	73	theme	low	1189:1191	arg1	μL-1					1221:1224	0.01 fmol μL-1	1211:1224	0.01 fmol μL-1	1211:1224	This microscopically highly hydrophilic material shows excellent enrichment ability for glycopeptides, such as extremely low detection limits (0.01 fmol μL-1), remarkable selectivity (1:8000), and size exclusion effects (1:8000).
37146275	3	74	theme	groups	808:813	arg1	introduction					775:786	the introduction	771:786	the introduction of the active amino groups on the surface of silica	771:838	In the present work, under the premise of an obvious increase of the surface silicon exposure (79.6%), the amount of surface polar silanol is remarkably generated accompanying the introduction of the active amino groups on the surface of silica.
37146275	1	75	theme	proteins	177:184	arg1	Glycosylation					160:172	Glycosylation	160:172	Glycosylation of proteins	160:184	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
37146275	1	76	theme	glycan	277:282	arg1	structures					284:293	glycan structures	277:293	glycan structures	277:293	Glycosylation of proteins regulates the life activities of organisms, while abnormalities of glycosylation sites and glycan structures occur in various serious diseases such as cancer.
36611938	5	0	theme	zebrafish	642:650	arg1	cells					662:666	zebrafish and C2C12 cells	642:666	cells	662:666	We aimed to elucidate the function of Fut8 in skeletal muscle using zebrafish and C2C12 cells for evaluation.
36611938	4	1	theme	spinal	488:493	arg1	deformity					495:503	spinal deformity	488:503	spinal deformity	488:503	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	8	2	theme	cell	1108:1111	arg1	differentiation					1113:1127	cell differentiation	1108:1127	cell differentiation	1108:1127	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	9	3	from	myofusion	1342:1350	arg1	particular					1355:1364	particular	1355:1364	particular	1355:1364	These results indicate that Fut8 is an important factor in myogenesis, and myofusion in particular.
36611938	5	4	from	function	600:607	arg1	muscle					629:634	skeletal muscle	620:634	skeletal muscle using zebrafish and C2C12 cells for evaluation	620:681	We aimed to elucidate the function of Fut8 in skeletal muscle using zebrafish and C2C12 cells for evaluation.
36611938	5	5	theme	C2C12	656:660	arg1	cells					662:666	zebrafish and C2C12 cells	642:666	cells	662:666	We aimed to elucidate the function of Fut8 in skeletal muscle using zebrafish and C2C12 cells for evaluation.
36611938	7	6	theme	Mutant	862:867	arg1	juveniles					869:877	Mutant juveniles	862:877	Mutant juveniles	862:877	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	6	7	theme	fut8a	706:710	arg1	morphants					712:720	most fut8a morphants	701:720	most fut8a morphants	701:720	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	8	8	with	treatment	1023:1031	arg1	2FF					1069:1071	2FF	1069:1071	2FF	1069:1071	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	8	with	treatment	1023:1031	arg1	2-fluorofucose					1053:1066	2-fluorofucose	1053:1066	2-fluorofucose (2FF)	1053:1072	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	8	with	treatment	1023:1031	arg1	inhibitor					1090:1098	a fucosylation inhibitor	1075:1098	a fucosylation inhibitor	1075:1098	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	9	theme	C2C12	1036:1040	arg1	cells					1042:1046	C2C12 cells	1036:1046	C2C12 cells	1036:1046	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	5	10	theme	Fut8	612:615	arg1	function					600:607	the function	596:607	the function of Fut8 in skeletal muscle using zebrafish and C2C12 cells for evaluation	596:681	We aimed to elucidate the function of Fut8 in skeletal muscle using zebrafish and C2C12 cells for evaluation.
36611938	6	11	theme	most	701:704	arg1	morphants					712:720	most fut8a morphants	701:720	most fut8a morphants	701:720	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	8	12	theme	myogenic	1211:1218	arg1	genes					1227:1231	other myogenic fusion genes	1205:1231	other myogenic fusion genes	1205:1231	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	5	13	theme	skeletal	620:627	arg1	muscle					629:634	skeletal muscle	620:634	skeletal muscle using zebrafish and C2C12 cells for evaluation	620:681	We aimed to elucidate the function of Fut8 in skeletal muscle using zebrafish and C2C12 cells for evaluation.
36611938	6	14	theme	earlier	768:774	arg1	stages					790:795	earlier developmental stages	768:795	earlier developmental stages	768:795	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	1	15	theme	important	87:95	arg1	Glycosylation					67:79	Glycosylation	67:79	Glycosylation	67:79	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	1	15	theme	important	87:95	arg1	mechanism					97:105	an important mechanism	84:105	an important mechanism regulating various biological processes, including intercellular signaling and adhesion	84:193	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	8	16	theme	other	1205:1209	arg1	genes					1227:1231	other myogenic fusion genes	1205:1231	other myogenic fusion genes	1205:1231	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	17	theme	myogenic	1168:1175	arg1	genes					1177:1181	myogenic genes	1168:1181	myogenic genes	1168:1181	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	17	theme	myogenic	1168:1175	arg1	genes					1227:1231	other myogenic fusion genes	1205:1231	other myogenic fusion genes	1205:1231	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	17	theme	myogenic	1168:1175	arg1	Myomaker					1192:1199	Myomaker	1192:1199	Myomaker	1192:1199	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	0	18	from	Myogenesis	42:51	arg1	Zebrafish					56:64	Zebrafish	56:64	Zebrafish	56:64	α-1,6-Fucosyltransferase Is Essential for Myogenesis in Zebrafish.
36611938	7	19	theme	myocepta	919:926	arg1	structures					942:951	abnormal myocepta and sarcomere structures	910:951	abnormal myocepta and sarcomere structures	910:951	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	8	20	theme	cells	1042:1046	arg1	treatment					1023:1031	treatment	1023:1031	treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation	1023:1127	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	9	21	from	factor	1316:1321	arg1	myogenesis					1326:1335	myogenesis	1326:1335	myogenesis	1326:1335	These results indicate that Fut8 is an important factor in myogenesis, and myofusion in particular.
36611938	9	21	from	factor	1316:1321	arg1	myofusion					1342:1350	myofusion	1342:1350	myofusion	1342:1350	These results indicate that Fut8 is an important factor in myogenesis, and myofusion in particular.
36611938	8	22	theme	fusion	1220:1225	arg1	genes					1227:1231	other myogenic fusion genes	1205:1231	other myogenic fusion genes	1205:1231	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	9	23	theme	important	1306:1314	arg1	factor					1316:1321	an important factor	1303:1321	an important factor	1303:1321	These results indicate that Fut8 is an important factor in myogenesis, and myofusion in particular.
36611938	9	23	theme	important	1306:1314	arg1	Fut8					1295:1298	Fut8	1295:1298	Fut8	1295:1298	These results indicate that Fut8 is an important factor in myogenesis, and myofusion in particular.
36611938	6	24	theme	developmental	776:788	arg1	stages					790:795	earlier developmental stages	768:795	earlier developmental stages	768:795	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	1	25	theme	various	118:124	arg1	processes					137:145	various biological processes	118:145	various biological processes	118:145	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	1	25	theme	various	118:124	arg1	adhesion					186:193	adhesion	186:193	adhesion	186:193	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	1	25	theme	various	118:124	arg1	signaling					172:180	intercellular signaling	158:180	intercellular signaling	158:180	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	8	26	theme	genes	1177:1181	arg1	expression					1154:1163	the expression	1150:1163	the expression of myogenic genes, such as Myomaker and other myogenic fusion genes,	1150:1232	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	4	27	theme	various	462:468	arg1	retardation					516:526	growth retardation	509:526	growth retardation	509:526	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	4	27	theme	various	462:468	arg1	deformity					495:503	spinal deformity	488:503	spinal deformity	488:503	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	4	27	theme	various	462:468	arg1	symptoms					470:477	various symptoms	462:477	various symptoms	462:477	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	1	28	theme	biological	126:135	arg1	processes					137:145	various biological processes	118:145	various biological processes	118:145	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	1	28	theme	biological	126:135	arg1	adhesion					186:193	adhesion	186:193	adhesion	186:193	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	1	28	theme	biological	126:135	arg1	signaling					172:180	intercellular signaling	158:180	intercellular signaling	158:180	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	7	29	theme	sarcomere	932:940	arg1	structures					942:951	abnormal myocepta and sarcomere structures	910:951	abnormal myocepta and sarcomere structures	910:951	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	8	30	theme	myotube	1248:1254	arg1	formation					1256:1264	myotube formation	1248:1264	myotube formation	1248:1264	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	4	31	from	effects	533:539	arg1	muscles					553:559	skeletal muscles	544:559	skeletal muscles	544:559	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	6	32	theme	oligonucleotides	838:853	arg1	concentrations					809:822	low concentrations	805:822	low concentrations of morpholino oligonucleotides (MOs)	805:859	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	2	33	theme	enzymes	251:257	arg1	family					241:246	a family	239:246	a family of enzymes that determine the terminal structure of glycans	239:306	α-1,6-fucosyltransferase (Fut8) belongs to a family of enzymes that determine the terminal structure of glycans.
36611938	4	34	theme	skeletal	544:551	arg1	muscles					553:559	skeletal muscles	544:559	skeletal muscles	544:559	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	3	35	theme	Caenorhabditis	339:352	arg1	elegans					354:360	Caenorhabditis elegans	339:360	Caenorhabditis elegans to humans	339:370	Fut8 is widely conserved from Caenorhabditis elegans to humans, and its mutants have been reported in humans, mice, and zebrafish.
36611938	6	36	theme	morpholino	827:836	arg1	MOs					856:858	MOs	856:858	MOs	856:858	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	6	36	theme	morpholino	827:836	arg1	oligonucleotides					838:853	morpholino oligonucleotides	827:853	morpholino oligonucleotides (MOs)	827:859	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	7	37	contain	had	884:886	arg1	juveniles					869:877	Mutant juveniles	862:877	Mutant juveniles	862:877	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	7	37	contain	had	884:886	arg2	sizes					899:903	small body sizes	888:903	small body sizes	888:903	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	7	37	contain	had	884:886	arg2	structures					942:951	abnormal myocepta and sarcomere structures	910:951	abnormal myocepta and sarcomere structures	910:951	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	7	38	theme	important	982:990	arg1	roles					992:996	important roles	982:996	important roles	982:996	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	9	39	from	myogenesis	1326:1335	arg1	particular					1355:1364	particular	1355:1364	particular	1355:1364	These results indicate that Fut8 is an important factor in myogenesis, and myofusion in particular.
36611938	7	40	theme	body	894:897	arg1	sizes					899:903	small body sizes	888:903	small body sizes	888:903	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	7	41	theme	abnormal	910:917	arg1	structures					942:951	abnormal myocepta and sarcomere structures	910:951	abnormal myocepta and sarcomere structures	910:951	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	6	42	theme	days	732:735	arg1	post-fertilization					737:754	2 days post-fertilization	730:754	2 days post-fertilization (dpf)	730:760	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	6	42	theme	days	732:735	arg1	dpf					757:759	dpf	757:759	dpf	757:759	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	2	43	theme	glycans	300:306	arg1	structure					287:295	the terminal structure	274:295	the terminal structure of glycans	274:306	α-1,6-fucosyltransferase (Fut8) belongs to a family of enzymes that determine the terminal structure of glycans.
36611938	1	44	theme	intercellular	158:170	arg1	signaling					172:180	intercellular signaling	158:180	intercellular signaling	158:180	Glycosylation is an important mechanism regulating various biological processes, including intercellular signaling and adhesion.
36611938	6	45	theme	low	805:807	arg1	concentrations					809:822	low concentrations	805:822	low concentrations of morpholino oligonucleotides (MOs)	805:859	We observed that most fut8a morphants died at 2 days post-fertilization (dpf) or in earlier developmental stages even at low concentrations of morpholino oligonucleotides (MOs).
36611938	2	46	theme	terminal	278:285	arg1	structure					287:295	the terminal structure	274:295	the terminal structure of glycans	274:306	α-1,6-fucosyltransferase (Fut8) belongs to a family of enzymes that determine the terminal structure of glycans.
36611938	7	47	theme	small	888:892	arg1	sizes					899:903	small body sizes	888:903	small body sizes	888:903	Mutant juveniles also had small body sizes, and abnormal myocepta and sarcomere structures, suggesting that Fut8a plays important roles in myogenesis.
36611938	4	48	theme	growth	509:514	arg1	retardation					516:526	growth retardation	509:526	growth retardation	509:526	Although mutants show various symptoms, such as spinal deformity and growth retardation, its effects on skeletal muscles are unknown.
36611938	8	49	theme	fucosylation	1077:1088	arg1	2-fluorofucose					1053:1066	2-fluorofucose	1053:1066	2-fluorofucose (2FF)	1053:1072	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36611938	8	49	theme	fucosylation	1077:1088	arg1	inhibitor					1090:1098	a fucosylation inhibitor	1075:1098	a fucosylation inhibitor	1075:1098	Moreover, treatment of C2C12 cells with 2-fluorofucose (2FF), a fucosylation inhibitor, during cell differentiation dramatically reduced the expression of myogenic genes, such as Myomaker and other myogenic fusion genes, and inhibited myotube formation.
36943879	0	0	theme	human	81:85	arg1	cells					110:114	human respiratory epithelial cells	81:114	human respiratory epithelial cells	81:114	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	6	1	theme	surface	659:665	arg1	charge					667:672	the surface charge	655:672	the surface charge	655:672	Contrary to the paradigm, the surface charge does not appreciably affect epithelial cell binding.
36943879	4	2	theme	capsular	418:425	arg1	CPSs					444:447	CPSs	444:447	CPSs	444:447	Here, we constructed isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae.
36943879	4	2	theme	capsular	418:425	arg1	polysaccharides					427:441	capsular polysaccharides	418:441	capsular polysaccharides (CPSs)	418:448	Here, we constructed isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae.
36943879	0	3	theme	epithelial	99:108	arg1	cells					110:114	human respiratory epithelial cells	81:114	human respiratory epithelial cells	81:114	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	0	4	from	Influence	0:8	arg1	colonization					37:48	the colonization	33:48	the colonization of Streptococcus pneumoniae on human respiratory epithelial cells	33:114	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	8	5	theme	monocyte	1017:1024	arg1	MCP-1					1052:1056	MCP-1	1052:1056	MCP-1	1052:1056	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	8	5	theme	monocyte	1017:1024	arg1	chemoattractantprotein-1					1026:1049	monocyte chemoattractantprotein-1	1017:1049	monocyte chemoattractantprotein-1 (MCP-1)	1017:1057	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	0	6	theme	respiratory	87:97	arg1	cells					110:114	human respiratory epithelial cells	81:114	human respiratory epithelial cells	81:114	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	7	7	from	presence	825:832	arg1	CPS					863:865	CPS	863:865	CPS	863:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	9	8	from	colonization	1242:1253	arg1	airway					1281:1286	the human airway	1271:1286	the human airway	1271:1286	Together, our results reveal glycomotifs of surface polysaccharides that are likely to be important for colonization and survival in the human airway.
36943879	7	9	theme	respiratory	759:769	arg1	cells					771:775	respiratory cells	759:775	respiratory cells	759:775	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	0	10	from	colonization	37:48	arg1	cells					110:114	human respiratory epithelial cells	81:114	human respiratory epithelial cells	81:114	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	4	11	theme	polysaccharides	427:441	arg1	types					409:413	84 types	406:413	84 types of capsular polysaccharides (CPSs)	406:448	Here, we constructed isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae.
36943879	5	12	theme	bronchial	601:609	arg1	cells					622:626	primary human nasal and bronchial epithelial cells	577:626	primary human nasal and bronchial epithelial cells	577:626	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
36943879	8	13	theme	pneumococcal	877:888	arg1	colonization					890:901	pneumococcal colonization	877:901	pneumococcal colonization	877:901	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	7	14	from	glycomotifs	848:858	arg1	CPS					863:865	CPS	863:865	CPS	863:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	5	15	theme	epithelial	611:620	arg1	cells					622:626	primary human nasal and bronchial epithelial cells	577:626	primary human nasal and bronchial epithelial cells	577:626	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
36943879	8	16	theme	interleukin	932:942	arg1	production					918:927	the production	914:927	the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells	914:1083	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	7	17	theme	glycomotifs	848:858	arg1	number					789:794	the number	785:794	the number of rhamnose residues	785:815	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	7	17	theme	glycomotifs	848:858	arg1	presence					825:832	the presence	821:832	the presence of human-like glycomotifs in CPS	821:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	8	18	theme	epithelial	1068:1077	arg1	cells					1079:1083	nasal epithelial cells	1062:1083	nasal epithelial cells	1062:1083	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	0	19	theme	structure	20:28	arg1	Influence					0:8	Influence	0:8	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.	0:115	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	8	20	theme	nasal	1062:1066	arg1	cells					1079:1083	nasal epithelial cells	1062:1083	nasal epithelial cells	1062:1083	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	8	21	theme	chemoattractantprotein-1	1026:1049	arg1	production					918:927	the production	914:927	the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells	914:1083	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	0	22	theme	glycan	13:18	arg1	structure					20:28	glycan structure	13:28	glycan structure	13:28	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	5	23	theme	nasal	591:595	arg1	cells					622:626	primary human nasal and bronchial epithelial cells	577:626	primary human nasal and bronchial epithelial cells	577:626	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
36943879	2	24	theme	key	181:183	arg1	functions					194:202	key cellular functions	181:202	key cellular functions such as immunomodulation and cell-cell recognition	181:253	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	2	24	theme	key	181:183	arg1	immunomodulation					212:227	immunomodulation	212:227	immunomodulation	212:227	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	2	24	theme	key	181:183	arg1	recognition					243:253	cell-cell recognition	233:253	cell-cell recognition	233:253	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	6	25	theme	cell	713:716	arg1	binding					718:724	epithelial cell binding	702:724	epithelial cell binding	702:724	Contrary to the paradigm, the surface charge does not appreciably affect epithelial cell binding.
36943879	7	26	theme	human-like	837:846	arg1	glycomotifs					848:858	human-like glycomotifs	837:858	human-like glycomotifs in CPS	837:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	9	27	theme	human	1275:1279	arg1	airway					1281:1286	the human airway	1271:1286	the human airway	1271:1286	Together, our results reveal glycomotifs of surface polysaccharides that are likely to be important for colonization and survival in the human airway.
36943879	7	28	from	CPS	863:865	arg1	number					789:794	the number	785:794	the number of rhamnose residues	785:815	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	7	28	from	CPS	863:865	arg1	presence					825:832	the presence	821:832	the presence of human-like glycomotifs in CPS	821:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	6	29	theme	epithelial	702:711	arg1	binding					718:724	epithelial cell binding	702:724	epithelial cell binding	702:724	Contrary to the paradigm, the surface charge does not appreciably affect epithelial cell binding.
36943879	9	30	theme	surface	1182:1188	arg1	polysaccharides					1190:1204	surface polysaccharides	1182:1204	surface polysaccharides	1182:1204	Together, our results reveal glycomotifs of surface polysaccharides that are likely to be important for colonization and survival in the human airway.
36943879	2	31	theme	cell-cell	233:241	arg1	recognition					243:253	cell-cell recognition	233:253	cell-cell recognition	233:253	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	5	32	theme	primary	577:583	arg1	cells					622:626	primary human nasal and bronchial epithelial cells	577:626	primary human nasal and bronchial epithelial cells	577:626	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
36943879	5	33	theme	human	585:589	arg1	cells					622:626	primary human nasal and bronchial epithelial cells	577:626	primary human nasal and bronchial epithelial cells	577:626	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
36943879	9	34	from	survival	1259:1266	arg1	airway					1281:1286	the human airway	1271:1286	the human airway	1271:1286	Together, our results reveal glycomotifs of surface polysaccharides that are likely to be important for colonization and survival in the human airway.
36943879	7	35	theme	residues	808:815	arg1	number					789:794	the number	785:794	the number of rhamnose residues	785:815	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	7	35	theme	residues	808:815	arg1	presence					825:832	the presence	821:832	the presence of human-like glycomotifs in CPS	821:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	7	36	from	number	789:794	arg1	CPS					863:865	CPS	863:865	CPS	863:865	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	8	37	from	production	918:927	arg1	cells					1079:1083	nasal epithelial cells	1062:1083	nasal epithelial cells	1062:1083	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	4	38	theme	capsule-switch	373:386	arg1	mutants					388:394	isogenic capsule-switch mutants	364:394	isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae	364:476	Here, we constructed isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae.
36943879	1	39	theme	all	127:129	arg1	cells					138:142	Virtually all living cells	117:142	Virtually all living cells	117:142	Virtually all living cells are encased in glycans.
36943879	8	40	theme	granulocyte-macrophage	954:975	arg1	factor					996:1001	granulocyte-macrophage colony-stimulating factor	954:1001	granulocyte-macrophage colony-stimulating factor (GM-CSF)	954:1010	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	8	40	theme	granulocyte-macrophage	954:975	arg1	GM-CSF					1004:1009	GM-CSF	1004:1009	GM-CSF	1004:1009	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	4	41	theme	isogenic	364:371	arg1	mutants					388:394	isogenic capsule-switch mutants	364:394	isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae	364:476	Here, we constructed isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae.
36943879	1	42	theme	living	131:136	arg1	cells					138:142	Virtually all living cells	117:142	Virtually all living cells	117:142	Virtually all living cells are encased in glycans.
36943879	8	43	theme	factor	996:1001	arg1	production					918:927	the production	914:927	the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells	914:1083	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	4	44	theme	Streptococcus	453:465	arg1	pneumoniae					467:476	Streptococcus pneumoniae	453:476	Streptococcus pneumoniae	453:476	Here, we constructed isogenic capsule-switch mutants harboring 84 types of capsular polysaccharides (CPSs) in Streptococcus pneumoniae.
36943879	8	45	theme	colony-stimulating	977:994	arg1	factor					996:1001	granulocyte-macrophage colony-stimulating factor	954:1001	granulocyte-macrophage colony-stimulating factor (GM-CSF)	954:1010	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	8	45	theme	colony-stimulating	977:994	arg1	GM-CSF					1004:1009	GM-CSF	1004:1009	GM-CSF	1004:1009	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	9	46	theme	polysaccharides	1190:1204	arg1	glycomotifs					1167:1177	glycomotifs	1167:1177	glycomotifs of surface polysaccharides that are likely to be important for colonization and survival in the human airway	1167:1286	Together, our results reveal glycomotifs of surface polysaccharides that are likely to be important for colonization and survival in the human airway.
36943879	7	47	theme	rhamnose	799:806	arg1	residues					808:815	rhamnose residues	799:815	rhamnose residues	799:815	Factors that affect adhesion to respiratory cells include the number of rhamnose residues and the presence of human-like glycomotifs in CPS.
36943879	0	48	theme	pneumoniae	67:76	arg1	colonization					37:48	the colonization	33:48	the colonization of Streptococcus pneumoniae on human respiratory epithelial cells	33:114	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	2	49	theme	cellular	185:192	arg1	functions					194:202	key cellular functions	181:202	key cellular functions such as immunomodulation and cell-cell recognition	181:253	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	2	49	theme	cellular	185:192	arg1	immunomodulation					212:227	immunomodulation	212:227	immunomodulation	212:227	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	2	49	theme	cellular	185:192	arg1	recognition					243:253	cell-cell recognition	233:253	cell-cell recognition	233:253	They perform key cellular functions such as immunomodulation and cell-cell recognition.
36943879	5	50	theme	related	561:567	arg1	CPSs					569:572	structurally related CPSs	548:572	structurally related CPSs	548:572	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
36943879	0	51	theme	Streptococcus	53:65	arg1	pneumoniae					67:76	Streptococcus pneumoniae	53:76	Streptococcus pneumoniae	53:76	Influence of glycan structure on the colonization of Streptococcus pneumoniae on human respiratory epithelial cells.
36943879	8	52	dep	stimulated	903:912	arg1	appears					1097:1103	appears	1097:1103	appears to be dependent on the serotype	1097:1135	Besides, pneumococcal colonization stimulated the production of interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF), and monocyte chemoattractantprotein-1 (MCP-1) in nasal epithelial cells, which also appears to be dependent on the serotype.
36943879	5	53	theme	CPSs	569:572	arg1	affinity					536:543	the affinity	532:543	the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells	532:626	This collection enables us to systematically measure the affinity of structurally related CPSs to primary human nasal and bronchial epithelial cells.
35917858	4	0	from	%	823:823	arg1	existence					832:840	the existence	828:840	the existence of cross-linked lignin	828:863	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	7	1	theme	product	1216:1222	arg1	prediction					1224:1233	product prediction	1216:1233	product prediction	1216:1233	Excellent correlations between structural cross-link and lignocellulose pyrolytome could facilitate product prediction and process design.
35917858	2	2	theme	CM-Sep	384:389	arg1	method					392:397	carboxymethylation-separation (CM-Sep) method	353:397	carboxymethylation-separation (CM-Sep) method	353:397	In this study, the structural cross-link between lignin and polysaccharides in lignocellulose was quantitatively estimated with carboxymethylation-separation (CM-Sep) method, and its influence on lignocellulose pyrolysis was systematically investigated.
35917858	3	3	theme	derivatives	586:596	arg1	production					546:555	the production	542:555	the production of small molecules and furan derivatives	542:596	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	0	4	theme	fast	90:93	arg1	pyrolysis					95:103	fast pyrolysis	90:103	fast pyrolysis of lignocellulose	90:121	Revealing the key role of structural cross-link between lignin and polysaccharides during fast pyrolysis of lignocellulose.
35917858	6	5	theme	ring	1032:1035	arg1	scission					1037:1044	boosted glycosyl ring scission	1015:1044	boosted glycosyl ring scission	1015:1044	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	0	6	theme	lignocellulose	108:121	arg1	pyrolysis					95:103	fast pyrolysis	90:103	fast pyrolysis of lignocellulose	90:121	Revealing the key role of structural cross-link between lignin and polysaccharides during fast pyrolysis of lignocellulose.
35917858	5	7	theme	cross-linked	893:904	arg1	lignin					906:911	cross-linked lignin	893:911	cross-linked lignin	893:911	Furthermore, the impact of cross-linked lignin was revealed to be significantly distinguished from free lignin.
35917858	5	8	theme	lignin	906:911	arg1	impact					883:888	the impact	879:888	the impact of cross-linked lignin	879:911	Furthermore, the impact of cross-linked lignin was revealed to be significantly distinguished from free lignin.
35917858	1	9	theme	native	165:170	arg1	form					181:184	the native existing form	161:184	the native existing form of major components in lignocellulose	161:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	1	9	theme	native	165:170	arg1	complex					144:150	Lignin-carbohydrate complex	124:150	Lignin-carbohydrate complex (LCC)	124:156	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	7	10	theme	lignocellulose	1173:1186	arg1	pyrolytome					1188:1197	lignocellulose pyrolytome	1173:1197	lignocellulose pyrolytome	1173:1197	Excellent correlations between structural cross-link and lignocellulose pyrolytome could facilitate product prediction and process design.
35917858	3	11	theme	furan	580:584	arg1	derivatives					586:596	furan derivatives	580:596	furan derivatives	580:596	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	1	12	theme	existing	172:179	arg1	form					181:184	the native existing form	161:184	the native existing form of major components in lignocellulose	161:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	1	12	theme	existing	172:179	arg1	complex					144:150	Lignin-carbohydrate complex	124:150	Lignin-carbohydrate complex (LCC)	124:156	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	7	13	theme	structural	1147:1156	arg1	cross-link					1158:1167	structural cross-link	1147:1167	structural cross-link	1147:1167	Excellent correlations between structural cross-link and lignocellulose pyrolytome could facilitate product prediction and process design.
35917858	4	14	link	cross-linked	845:856	arg1	lignin					858:863	cross-linked lignin	845:863	cross-linked lignin	845:863	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	6	15	theme	glycosyl	1023:1030	arg1	scission					1037:1044	boosted glycosyl ring scission	1015:1044	boosted glycosyl ring scission	1015:1044	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	3	16	link	cross-linked	483:494	arg1	lignin					496:501	The cross-linked lignin	479:501	The cross-linked lignin	479:501	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	4	17	theme	pyrolytic	764:772	arg1	products					774:781	pyrolytic products	764:781	pyrolytic products	764:781	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	6	18	theme	boosted	1015:1021	arg1	scission					1037:1044	boosted glycosyl ring scission	1015:1044	boosted glycosyl ring scission	1015:1044	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	4	19	theme	lignin	858:863	arg1	existence					832:840	the existence	828:840	the existence of cross-linked lignin	828:863	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	4	20	theme	levoglucosan	788:799	arg1	yield					801:805	levoglucosan yield	788:805	levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin	788:863	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	4	21	theme	cross-linked	845:856	arg1	lignin					858:863	cross-linked lignin	845:863	cross-linked lignin	845:863	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	1	22	theme	major	189:193	arg1	components					195:204	major components	189:204	major components in lignocellulose	189:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	0	23	theme	key	14:16	arg1	role					18:21	the key role	10:21	the key role of structural cross-link between lignin and polysaccharides	10:81	Revealing the key role of structural cross-link between lignin and polysaccharides during fast pyrolysis of lignocellulose.
35917858	2	24	from	cross-link	255:264	arg1	lignocellulose					304:317	lignocellulose	304:317	lignocellulose	304:317	In this study, the structural cross-link between lignin and polysaccharides in lignocellulose was quantitatively estimated with carboxymethylation-separation (CM-Sep) method, and its influence on lignocellulose pyrolysis was systematically investigated.
35917858	1	25	theme	components	195:204	arg1	form					181:184	the native existing form	161:184	the native existing form of major components in lignocellulose	161:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	1	25	theme	components	195:204	arg1	complex					144:150	Lignin-carbohydrate complex	124:150	Lignin-carbohydrate complex (LCC)	124:156	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	0	26	theme	structural	26:35	arg1	cross-link					37:46	structural cross-link	26:46	structural cross-link	26:46	Revealing the key role of structural cross-link between lignin and polysaccharides during fast pyrolysis of lignocellulose.
35917858	2	27	theme	carboxymethylation-separation	353:381	arg1	method					392:397	carboxymethylation-separation (CM-Sep) method	353:397	carboxymethylation-separation (CM-Sep) method	353:397	In this study, the structural cross-link between lignin and polysaccharides in lignocellulose was quantitatively estimated with carboxymethylation-separation (CM-Sep) method, and its influence on lignocellulose pyrolysis was systematically investigated.
35917858	3	28	theme	sugars	653:658	arg1	generation					629:638	the generation	625:638	the generation of anhydrous sugars	625:658	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	6	29	theme	end	997:999	arg1	formation					1001:1009	Impeded glycosidic end formation	978:1009	Impeded glycosidic end formation	978:1009	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	7	30	theme	Excellent	1116:1124	arg1	correlations					1126:1137	Excellent correlations	1116:1137	Excellent correlations between structural cross-link and lignocellulose pyrolytome	1116:1197	Excellent correlations between structural cross-link and lignocellulose pyrolytome could facilitate product prediction and process design.
35917858	6	31	theme	lignin	1057:1062	arg1	fragmentation					1064:1076	lignin fragmentation	1057:1076	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation	978:1076	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	2	32	theme	lignocellulose	421:434	arg1	pyrolysis					436:444	lignocellulose pyrolysis	421:444	lignocellulose pyrolysis	421:444	In this study, the structural cross-link between lignin and polysaccharides in lignocellulose was quantitatively estimated with carboxymethylation-separation (CM-Sep) method, and its influence on lignocellulose pyrolysis was systematically investigated.
35917858	6	33	theme	glycosidic	986:995	arg1	formation					1001:1009	Impeded glycosidic end formation	978:1009	Impeded glycosidic end formation	978:1009	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	1	34	from	lignocellulose	209:222	arg1	form					181:184	the native existing form	161:184	the native existing form of major components in lignocellulose	161:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	1	34	from	lignocellulose	209:222	arg1	complex					144:150	Lignin-carbohydrate complex	124:150	Lignin-carbohydrate complex (LCC)	124:156	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	0	35	theme	cross-link	37:46	arg1	role					18:21	the key role	10:21	the key role of structural cross-link between lignin and polysaccharides	10:81	Revealing the key role of structural cross-link between lignin and polysaccharides during fast pyrolysis of lignocellulose.
35917858	6	36	theme	Impeded	978:984	arg1	formation					1001:1009	Impeded glycosidic end formation	978:1009	Impeded glycosidic end formation	978:1009	Impeded glycosidic end formation and boosted glycosyl ring scission as well as lignin fragmentation were responsible for the distinction.
35917858	3	37	theme	anhydrous	643:651	arg1	sugars					653:658	anhydrous sugars	643:658	anhydrous sugars	643:658	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	1	38	theme	Lignin-carbohydrate	124:142	arg1	complex					144:150	Lignin-carbohydrate complex	124:150	Lignin-carbohydrate complex (LCC)	124:156	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	1	38	theme	Lignin-carbohydrate	124:142	arg1	form					181:184	the native existing form	161:184	the native existing form of major components in lignocellulose	161:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	1	38	theme	Lignin-carbohydrate	124:142	arg1	LCC					153:155	LCC	153:155	LCC	153:155	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	5	39	link	cross-linked	893:904	arg1	lignin					906:911	cross-linked lignin	893:911	cross-linked lignin	893:911	Furthermore, the impact of cross-linked lignin was revealed to be significantly distinguished from free lignin.
35917858	1	40	from	components	195:204	arg1	lignocellulose					209:222	lignocellulose	209:222	lignocellulose	209:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	5	41	theme	free	965:968	arg1	lignin					970:975	free lignin	965:975	free lignin	965:975	Furthermore, the impact of cross-linked lignin was revealed to be significantly distinguished from free lignin.
35917858	4	42	from	%	759:759	arg1	products					774:781	pyrolytic products	764:781	pyrolytic products	764:781	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	2	43	from	influence	408:416	arg1	pyrolysis					436:444	lignocellulose pyrolysis	421:444	lignocellulose pyrolysis	421:444	In this study, the structural cross-link between lignin and polysaccharides in lignocellulose was quantitatively estimated with carboxymethylation-separation (CM-Sep) method, and its influence on lignocellulose pyrolysis was systematically investigated.
35917858	2	44	theme	structural	244:253	arg1	cross-link					255:264	the structural cross-link	240:264	the structural cross-link between lignin and polysaccharides in lignocellulose	240:317	In this study, the structural cross-link between lignin and polysaccharides in lignocellulose was quantitatively estimated with carboxymethylation-separation (CM-Sep) method, and its influence on lignocellulose pyrolysis was systematically investigated.
35917858	1	45	from	form	181:184	arg1	lignocellulose					209:222	lignocellulose	209:222	lignocellulose	209:222	Lignin-carbohydrate complex (LCC) is the native existing form of major components in lignocellulose.
35917858	4	46	theme	anhydrous	723:731	arg1	sugars					733:738	anhydrous sugars	723:738	anhydrous sugars	723:738	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	3	47	theme	small	560:564	arg1	molecules					566:574	small molecules	560:574	small molecules	560:574	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	3	48	theme	cross-linked	483:494	arg1	lignin					496:501	The cross-linked lignin	479:501	The cross-linked lignin	479:501	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	4	49	theme	molecules	678:686	arg1	Content					661:667	Content	661:667	Content of small molecules	661:686	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35917858	3	50	theme	molecules	566:574	arg1	production					546:555	the production	542:555	the production of small molecules and furan derivatives	542:596	The cross-linked lignin was found to positively correlate with the production of small molecules and furan derivatives while negatively affecting the generation of anhydrous sugars.
35917858	4	51	theme	small	672:676	arg1	molecules					678:686	small molecules	672:686	small molecules	672:686	Content of small molecules was increased by 97% while that of anhydrous sugars was decreased by 47% in pyrolytic products with levoglucosan yield lowered by 54 wt% in the existence of cross-linked lignin.
35778274	7	0	theme	veins	1252:1256	arg1	injuries					1221:1228	lethal and sublethal injuries	1200:1228	lethal and sublethal injuries of femoral artery and veins	1200:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	2	1	theme	modified	357:364	arg1	chitosan					366:373	chitosan	366:373	chitosan	366:373	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	9	2	with	comparison	1664:1673	arg1	hemostats					1698:1706	common commercial hemostats	1680:1706	common commercial hemostats	1680:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	10	3	theme	CONCLUSION	1709:1718	arg1	use					1733:1735	CONCLUSION Simultaneous use	1709:1735	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material	1709:1840	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	5	4	theme	product	797:803	arg1	properties					779:788	The properties	775:788	The properties of the product	775:803	The properties of the product were surveyed by Fourier-transform infrared spectroscopy and compared with Arista-AH and Celox as commercial counterparts.
35778274	4	5	theme	Iranian	682:688	arg1	Organization					712:723	Iranian Intellectual Property Organization	682:723	Iranian Intellectual Property Organization	682:723	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	4	5	theme	Iranian	682:688	arg1	100865					674:679	Patent No. 100865	663:679	Patent No. 100865	663:679	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	6	6	theme	blood	979:983	arg1	RBCs					992:995	RBCs	992:995	RBCs	992:995	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	6	6	theme	blood	979:983	arg1	cells					985:989	red blood cells	975:989	red blood cells (RBCs)	975:996	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	10	7	theme	groups	1812:1817	arg1	use					1733:1735	CONCLUSION Simultaneous use	1709:1735	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material	1709:1840	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	5	8	theme	Fourier-transform	822:838	arg1	spectroscopy					849:860	Fourier-transform infrared spectroscopy	822:860	Fourier-transform infrared spectroscopy	822:860	The properties of the product were surveyed by Fourier-transform infrared spectroscopy and compared with Arista-AH and Celox as commercial counterparts.
35778274	4	9	theme	Patent	663:668	arg1	Organization					712:723	Iranian Intellectual Property Organization	682:723	Iranian Intellectual Property Organization	682:723	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	4	9	theme	Patent	663:668	arg1	100865					674:679	Patent No. 100865	663:679	Patent No. 100865	663:679	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	7	10	theme	Zealand	1175:1181	arg1	rabbits					1189:1195	24 healthy 6-month-old male New Zealand white rabbits	1143:1195	24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins	1143:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	8	11	theme	fundamental	1319:1329	arg1	development					1331:1341	a fundamental development	1317:1341	a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes	1317:1512	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	1	12	theme	Blood	139:143	arg1	formation					150:158	BACKGROUND Blood clot formation	128:158	BACKGROUND Blood clot formation	128:158	BACKGROUND Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding.
35778274	9	13	from	models	1624:1629	arg1	comparison					1664:1673	comparison	1664:1673	comparison with common commercial hemostats	1664:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	4	14	theme	Property	703:710	arg1	Organization					712:723	Iranian Intellectual Property Organization	682:723	Iranian Intellectual Property Organization	682:723	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	4	14	theme	Property	703:710	arg1	100865					674:679	Patent No. 100865	663:679	Patent No. 100865	663:679	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	0	15	theme	emergency	77:85	arg1	control					96:102	emergency bleeding control	77:102	emergency bleeding control	77:102	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	2	16	contain	containing	335:344	arg2	starch					379:384	starch	379:384	starch	379:384	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	2	16	contain	containing	335:344	arg2	chitosan					366:373	chitosan	366:373	chitosan	366:373	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	2	16	contain	containing	335:344	arg1	composite					325:333	a novel hemostatic composite	306:333	a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control	306:415	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	5	17	theme	commercial	903:912	arg1	counterparts					914:925	commercial counterparts	903:925	commercial counterparts	903:925	The properties of the product were surveyed by Fourier-transform infrared spectroscopy and compared with Arista-AH and Celox as commercial counterparts.
35778274	10	18	from	bleeding	1883:1890	arg1	conditions					1905:1914	emergency conditions	1895:1914	emergency conditions	1895:1914	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	8	19	theme	swelling	1388:1395	arg1	properties					1397:1406	swelling properties	1388:1406	swelling properties	1388:1406	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	9	20	theme	composite	1609:1617	arg1	application					1590:1600	the application	1586:1600	the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats	1586:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	3	21	theme	hemostatic	448:457	arg1	powder					459:464	this novel hemostatic powder	437:464	this novel hemostatic powder	437:464	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	0	22	theme	powder	48:53	arg1	efficacy					11:18	Hemostatic efficacy	0:18	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.	0:126	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	8	23	dep	RESULTS	1273:1279	arg1	Modification					1281:1292	Modification	1281:1292	Modification	1281:1292	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	23	dep	RESULTS	1273:1279	arg1	RESULTS					1273:1279	RESULTS Modification and composition	1273:1308	RESULTS Modification and composition	1273:1308	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	23	dep	RESULTS	1273:1279	arg1	composition					1298:1308	composition	1298:1308	composition	1298:1308	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	2	24	theme	emergency	390:398	arg1	control					409:415	emergency bleeding control	390:415	emergency bleeding control	390:415	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	0	25	theme	Hemostatic	0:9	arg1	efficacy					11:18	Hemostatic efficacy	0:18	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.	0:126	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	7	26	theme	white	1183:1187	arg1	rabbits					1189:1195	24 healthy 6-month-old male New Zealand white rabbits	1143:1195	24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins	1143:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	10	27	theme	water-absorbing	1740:1754	arg1	compounds					1756:1764	water-absorbing compounds	1740:1764	water-absorbing compounds	1740:1764	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	0	28	theme	polysaccharide	33:46	arg1	powder					48:53	composite polysaccharide powder	23:53	composite polysaccharide powder (starch-chitosan)	23:71	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	0	28	theme	polysaccharide	33:46	arg1	starch-chitosan					56:70	starch-chitosan	56:70	starch-chitosan	56:70	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	7	29	theme	New	1171:1173	arg1	rabbits					1189:1195	24 healthy 6-month-old male New Zealand white rabbits	1143:1195	24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins	1143:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	9	30	theme	injury	1654:1659	arg1	models					1624:1629	2 models	1622:1629	2 models of venous and arterial injury in comparison with common commercial hemostats	1622:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	9	31	from	superiority	1531:1541	arg1	efficiency					1555:1564	clotting efficiency	1546:1564	clotting efficiency	1546:1564	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	6	32	theme	biodegradability	1030:1045	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	10	33	theme	functional	1801:1810	arg1	groups					1812:1817	introducing positively charged functional groups	1770:1817	introducing positively charged functional groups	1770:1817	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	7	34	theme	6-month-old	1154:1164	arg1	rabbits					1189:1195	24 healthy 6-month-old male New Zealand white rabbits	1143:1195	24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins	1143:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	3	35	theme	available	497:505	arg1	AH					528:529	commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats	484:567	AH	528:529	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	3	36	theme	Celox	552:556	arg1	hemostats					559:567	commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats	484:567	hemostats	559:567	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	9	37	theme	common	1680:1685	arg1	hemostats					1698:1706	common commercial hemostats	1680:1706	common commercial hemostats	1680:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	8	38	theme	electrostatic	1473:1485	arg1	attributes					1503:1512	improved electrostatic and hydrophilic attributes	1464:1512	improved electrostatic and hydrophilic attributes	1464:1512	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	7	39	theme	lethal	1200:1205	arg1	injuries					1221:1228	lethal and sublethal injuries	1200:1228	lethal and sublethal injuries of femoral artery and veins	1200:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	9	40	from	application	1590:1600	arg1	models					1624:1629	2 models	1622:1629	2 models of venous and arterial injury in comparison with common commercial hemostats	1622:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	10	41	theme	considerable	1851:1862	arg1	control					1864:1870	a considerable control	1849:1870	a considerable control of femoral bleeding in emergency conditions	1849:1914	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	10	42	theme	bleeding	1883:1890	arg1	control					1864:1870	a considerable control	1849:1870	a considerable control of femoral bleeding in emergency conditions	1849:1914	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	7	43	theme	Hemostatic	1106:1115	arg1	efficacy					1117:1124	Hemostatic efficacy	1106:1124	Hemostatic efficacy	1106:1124	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	4	44	theme	No.	670:672	arg1	Organization					712:723	Iranian Intellectual Property Organization	682:723	Iranian Intellectual Property Organization	682:723	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	4	44	theme	No.	670:672	arg1	100865					674:679	Patent No. 100865	663:679	Patent No. 100865	663:679	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	7	45	theme	femoral	1233:1239	arg1	artery					1241:1246	femoral artery	1233:1246	femoral artery	1233:1246	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	2	46	theme	novel	308:312	arg1	composite					325:333	a novel hemostatic composite	306:333	a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control	306:415	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	6	47	theme	cells	985:989	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	10	48	theme	introducing	1770:1780	arg1	groups					1812:1817	introducing positively charged functional groups	1770:1817	introducing positively charged functional groups	1770:1817	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	1	49	from	bleeding	249:256	arg1	risk					223:226	the risk	219:226	the risk of death from severe bleeding	219:256	BACKGROUND Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding.
35778274	1	50	theme	blood	195:199	arg1	loss					201:204	blood loss	195:204	blood loss	195:204	BACKGROUND Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding.
35778274	6	51	theme	red	975:977	arg1	RBCs					992:995	RBCs	992:995	RBCs	992:995	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	6	51	theme	red	975:977	arg1	cells					985:989	red blood cells	975:989	red blood cells (RBCs)	975:996	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	8	52	theme	hydrophilic	1491:1501	arg1	attributes					1503:1512	improved electrostatic and hydrophilic attributes	1464:1512	improved electrostatic and hydrophilic attributes	1464:1512	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	10	53	theme	charged	1793:1799	arg1	groups					1812:1817	introducing positively charged functional groups	1770:1817	introducing positively charged functional groups	1770:1817	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	5	54	theme	infrared	840:847	arg1	spectroscopy					849:860	Fourier-transform infrared spectroscopy	822:860	Fourier-transform infrared spectroscopy	822:860	The properties of the product were surveyed by Fourier-transform infrared spectroscopy and compared with Arista-AH and Celox as commercial counterparts.
35778274	6	55	theme	platelet	962:969	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	10	56	theme	emergency	1895:1903	arg1	conditions					1905:1914	emergency conditions	1895:1914	emergency conditions	1895:1914	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	9	57	theme	clotting	1546:1553	arg1	efficiency					1555:1564	clotting efficiency	1546:1564	clotting efficiency	1546:1564	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	10	58	theme	hemostatic	1822:1831	arg1	material					1833:1840	hemostatic material	1822:1840	hemostatic material	1822:1840	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	6	59	theme	hemolysis	951:959	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	11	60	theme	introduced	1921:1930	arg1	biodegradable					1946:1958	biodegradable	1946:1958	biodegradable	1946:1958	The introduced composite was biodegradable and biocompatible and prompts RBC aggregation and platelet adhesion.
35778274	11	60	theme	introduced	1921:1930	arg1	composite					1932:1940	The introduced composite	1917:1940	The introduced composite	1917:1940	The introduced composite was biodegradable and biocompatible and prompts RBC aggregation and platelet adhesion.
35778274	1	61	theme	BACKGROUND	128:137	arg1	formation					150:158	BACKGROUND Blood clot formation	128:158	BACKGROUND Blood clot formation	128:158	BACKGROUND Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding.
35778274	2	62	theme	composite	325:333	arg1	characteristics					287:301	the characteristics	283:301	the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control	283:415	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	7	63	theme	artery	1241:1246	arg1	injuries					1221:1228	lethal and sublethal injuries	1200:1228	lethal and sublethal injuries of femoral artery and veins	1200:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	1	64	theme	clot	145:148	arg1	formation					150:158	BACKGROUND Blood clot formation	128:158	BACKGROUND Blood clot formation	128:158	BACKGROUND Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding.
35778274	6	65	theme	biocompatibility	1008:1023	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	4	66	theme	Intellectual	690:701	arg1	Organization					712:723	Iranian Intellectual Property Organization	682:723	Iranian Intellectual Property Organization	682:723	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	4	66	theme	Intellectual	690:701	arg1	100865					674:679	Patent No. 100865	663:679	Patent No. 100865	663:679	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	0	67	theme	bleeding	87:94	arg1	control					96:102	emergency bleeding control	77:102	emergency bleeding control	77:102	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	11	68	theme	RBC	1990:1992	arg1	aggregation					1994:2004	RBC aggregation	1990:2004	RBC aggregation	1990:2004	The introduced composite was biodegradable and biocompatible and prompts RBC aggregation and platelet adhesion.
35778274	10	69	from	control	1864:1870	arg1	conditions					1905:1914	emergency conditions	1895:1914	emergency conditions	1895:1914	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	6	70	theme	adhesion	998:1005	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	10	71	theme	Simultaneous	1720:1731	arg1	use					1733:1735	CONCLUSION Simultaneous use	1709:1735	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material	1709:1840	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	8	72	theme	physicochemical	1346:1360	arg1	properties					1397:1406	swelling properties	1388:1406	swelling properties	1388:1406	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	72	theme	physicochemical	1346:1360	arg1	absorption					1415:1424	water absorption	1409:1424	water absorption	1409:1424	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	72	theme	physicochemical	1346:1360	arg1	adhesion					1448:1455	platelet and RBC adhesion	1431:1455	adhesion	1448:1455	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	72	theme	physicochemical	1346:1360	arg1	characteristics					1362:1376	physicochemical characteristics	1346:1376	physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes	1346:1512	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	7	73	theme	sublethal	1211:1219	arg1	injuries					1221:1228	lethal and sublethal injuries	1200:1228	lethal and sublethal injuries of femoral artery and veins	1200:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	3	74	theme	starch-based	507:518	arg1	AH					528:529	commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats	484:567	AH	528:529	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	0	75	theme	animal	108:113	arg1	model study					115:125	An animal model study	105:125	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.	0:126	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	9	76	theme	significant	1519:1529	arg1	superiority					1531:1541	The significant superiority	1515:1541	The significant superiority in clotting efficiency	1515:1564	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	6	77	theme	in vitro	1088:1095	arg1	studies					1097:1103	in vitro studies	1088:1103	in vitro studies	1088:1103	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	7	78	from	rabbits	1189:1195	arg1	injuries					1221:1228	lethal and sublethal injuries	1200:1228	lethal and sublethal injuries of femoral artery and veins	1200:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	2	79	theme	bleeding	400:407	arg1	control					409:415	emergency bleeding control	390:415	emergency bleeding control	390:415	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	11	80	theme	platelet	2010:2017	arg1	adhesion					2019:2026	platelet adhesion	2010:2026	platelet adhesion	2010:2026	The introduced composite was biodegradable and biocompatible and prompts RBC aggregation and platelet adhesion.
35778274	10	81	from	conditions	1905:1914	arg1	control					1864:1870	a considerable control	1849:1870	a considerable control of femoral bleeding in emergency conditions	1849:1914	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	10	81	from	conditions	1905:1914	arg1	bleeding					1883:1890	bleeding	1883:1890	bleeding	1883:1890	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	8	82	theme	water	1409:1413	arg1	absorption					1415:1424	water absorption	1409:1424	water absorption	1409:1424	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	3	83	theme	novel	442:446	arg1	powder					459:464	this novel hemostatic powder	437:464	this novel hemostatic powder	437:464	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	0	84	theme	composite	23:31	arg1	powder					48:53	composite polysaccharide powder	23:53	composite polysaccharide powder (starch-chitosan)	23:71	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	0	84	theme	composite	23:31	arg1	starch-chitosan					56:70	starch-chitosan	56:70	starch-chitosan	56:70	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	0	85	dep	efficacy	11:18	arg1	model study					115:125	An animal model study	105:125	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.	0:126	Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
35778274	8	86	from	development	1331:1341	arg1	properties					1397:1406	swelling properties	1388:1406	swelling properties	1388:1406	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	86	from	development	1331:1341	arg1	absorption					1415:1424	water absorption	1409:1424	water absorption	1409:1424	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	86	from	development	1331:1341	arg1	adhesion					1448:1455	platelet and RBC adhesion	1431:1455	adhesion	1448:1455	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	8	86	from	development	1331:1341	arg1	characteristics					1362:1376	physicochemical characteristics	1346:1376	physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes	1346:1512	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	9	87	theme	venous	1634:1639	arg1	injury					1654:1659	venous and arterial injury	1634:1659	venous and arterial injury in comparison with common commercial hemostats	1634:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	9	88	from	comparison	1664:1673	arg1	models					1624:1629	2 models	1622:1629	2 models of venous and arterial injury in comparison with common commercial hemostats	1622:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	4	89	theme	composite	589:597	arg1	METHODS					570:576	METHODS	570:576	METHODS Hemostatic composite	570:597	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	10	90	theme	compounds	1756:1764	arg1	use					1733:1735	CONCLUSION Simultaneous use	1709:1735	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material	1709:1840	CONCLUSION Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions.
35778274	7	91	theme	male	1166:1169	arg1	rabbits					1189:1195	24 healthy 6-month-old male New Zealand white rabbits	1143:1195	24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins	1143:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	9	92	theme	arterial	1645:1652	arg1	injury					1654:1659	venous and arterial injury	1634:1659	venous and arterial injury in comparison with common commercial hemostats	1634:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	9	93	from	injury	1654:1659	arg1	comparison					1664:1673	comparison	1664:1673	comparison with common commercial hemostats	1664:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	8	94	theme	platelet	1431:1438	arg1	adhesion					1448:1455	platelet and RBC adhesion	1431:1455	adhesion	1448:1455	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	7	95	theme	healthy	1146:1152	arg1	rabbits					1189:1195	24 healthy 6-month-old male New Zealand white rabbits	1143:1195	24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins	1143:1256	Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
35778274	4	96	dep	authors	654:660	arg1	Organization					712:723	Iranian Intellectual Property Organization	682:723	Iranian Intellectual Property Organization	682:723	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	4	96	dep	authors	654:660	arg1	100865					674:679	Patent No. 100865	663:679	Patent No. 100865	663:679	METHODS Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran).
35778274	6	97	theme	cytocompatibility	932:948	arg1	attributes					1047:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes	928:1056	The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies.
35778274	8	98	theme	RBC	1444:1446	arg1	adhesion					1448:1455	platelet and RBC adhesion	1431:1455	adhesion	1448:1455	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	3	99	theme	Arista	521:526	arg1	AH					528:529	commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats	484:567	AH	528:529	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	2	100	theme	hemostatic	314:323	arg1	composite					325:333	a novel hemostatic composite	306:333	a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control	306:415	This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control.
35778274	9	101	theme	commercial	1687:1696	arg1	hemostats					1698:1706	common commercial hemostats	1680:1706	common commercial hemostats	1680:1706	The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
35778274	3	102	theme	powder	459:464	arg1	performance					422:432	The performance	418:432	The performance of this novel hemostatic powder	418:464	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	8	103	theme	improved	1464:1471	arg1	attributes					1503:1512	improved electrostatic and hydrophilic attributes	1464:1512	improved electrostatic and hydrophilic attributes	1464:1512	RESULTS Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes.
35778274	3	104	theme	chitosan-based	536:549	arg1	hemostats					559:567	commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats	484:567	hemostats	559:567	The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
35778274	1	105	theme	death	231:235	arg1	risk					223:226	the risk	219:226	the risk of death from severe bleeding	219:256	BACKGROUND Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding.
36754227	7	0	theme	SV2	1833:1835	arg1	glycosylation					1816:1828	a full glycosylation	1809:1828	a full glycosylation of SV2	1809:1835	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	7	0	theme	SV2	1833:1835	arg1	environment					1793:1803	a biologically relevant membrane environment	1760:1803	a biologically relevant membrane environment	1760:1803	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	2	1	from	position	339:346	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	1	from	position	339:346	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	1	from	position	339:346	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	1	from	position	339:346	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	1	from	position	339:346	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	1	from	position	339:346	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	1	from	position	339:346	arg1	LD-SV2C					305:311	LD-SV2C	305:311	LD-SV2C	305:311	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	2	from	position	252:259	arg1	LD-SV2A					218:224	LD-SV2A	218:224	LD-SV2A	218:224	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	4	3	theme	BoNT/A1	804:810	arg1	surface					793:799	the surface	789:799	the surface of BoNT/A1	789:810	The absence of an N-glycan homologous to N480g in LD-SV2A leads to a decrease of the binding of N573g to the surface of BoNT/A1.
36754227	3	4	theme	second	567:572	arg1	N-glycan					574:581	the second N-glycan	563:581	the second N-glycan	563:581	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	4	5	theme	homologous	711:720	arg1	N-glycan					702:709	an N-glycan	699:709	an N-glycan homologous to N480g	699:729	The absence of an N-glycan homologous to N480g in LD-SV2A leads to a decrease of the binding of N573g to the surface of BoNT/A1.
36754227	6	6	from	ganglioside	1351:1361	arg1	surface					1370:1376	the surface	1366:1376	the surface of BoNT/A1	1366:1387	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	2	7	gly	glycosylation	235:247	arg2	N573g					267:271	N573g	267:271	N573g	267:271	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	7	gly	glycosylation	235:247	arg2	position					252:259	position N573	252:264	position N573 (N573g)	252:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	7	gly	glycosylation	235:247	arg1	position					252:259	position N573	252:264	position N573 (N573g)	252:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	7	gly	glycosylation	235:247	arg1	N573g					267:271	N573g	267:271	N573g	267:271	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	5	8	theme	neurotoxin	955:964	arg1	affinity					939:946	the high affinity	930:946	the high affinity of the neurotoxin for binding LD-SV2C	930:984	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	2	9	gly	glycosylation	322:334	arg2	position					339:346	position N559	339:351	position N559 (N559g)	339:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	9	gly	glycosylation	322:334	arg1	position					339:346	position N559	339:351	position N559 (N559g)	339:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	9	gly	glycosylation	322:334	arg1	N559g					354:358	N559g	354:358	N559g	354:358	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	9	gly	glycosylation	322:334	arg2	N559g					354:358	N559g	354:358	N559g	354:358	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	5	10	theme	BoNT/A1	1221:1227	arg1	binding					1210:1216	the binding	1206:1216	the binding of BoNT/A1	1206:1227	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	11	theme	residues	1159:1166	arg1	presence					1134:1141	the presence	1130:1141	the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1130:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	0	12	theme	SV2C	78:81	arg1	receptors					83:91	SV2C receptors	78:91	SV2C receptors	78:91	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	7	13	gly	glycosylation	1816:1828	arg1	SV2					1833:1835	SV2	1833:1835	SV2	1833:1835	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	3	14	from	N-glycan	426:433	arg1	SV2C					484:487	SV2C	484:487	SV2C (LD-SV2C)	484:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	3	14	from	N-glycan	426:433	arg1	domain					474:479	the luminal domain	462:479	the luminal domain of SV2C (LD-SV2C)	462:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	2	15	theme	glycosylation	235:247	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	15	theme	glycosylation	235:247	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	15	theme	glycosylation	235:247	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	15	theme	glycosylation	235:247	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	15	theme	glycosylation	235:247	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	15	theme	glycosylation	235:247	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	3	16	theme	LD-SV2C	675:681	arg1	LD-SV2C					675:681	LD-SV2C	675:681	LD-SV2C	675:681	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	3	16	theme	LD-SV2C	675:681	arg1	residues					663:670	residues	663:670	residues of LD-SV2C	663:681	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	2	17	theme	luminal	281:287	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	17	theme	luminal	281:287	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	17	theme	luminal	281:287	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	17	theme	luminal	281:287	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	17	theme	luminal	281:287	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	7	18	theme	crystallographic	1723:1738	arg1	data					1740:1743	crystallographic data	1723:1743	crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2	1723:1835	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	1	19	theme	potent	140:145	arg1	poison					155:160	the most potent natural poison	131:160	the most potent natural poison in human	131:169	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	1	19	theme	potent	140:145	arg1	A1					115:116	Botulinum neurotoxin A1	94:116	Botulinum neurotoxin A1 (BoNT/A1)	94:126	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	5	20	theme	F557-F562	1029:1037	arg1	part					1039:1042	its F557-F562 part	1025:1042	its F557-F562 part	1025:1042	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	7	21	theme	mutational	1659:1668	arg1	studies					1670:1676	mutational studies	1659:1676	mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2	1659:1835	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	6	22	theme	binding	1317:1323	arg1	site					1325:1328	the well-known ganglioside binding site	1290:1328	the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1	1290:1387	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	1	23	theme	natural	147:153	arg1	poison					155:160	the most potent natural poison	131:160	the most potent natural poison in human	131:169	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	1	23	theme	natural	147:153	arg1	A1					115:116	Botulinum neurotoxin A1	94:116	Botulinum neurotoxin A1 (BoNT/A1)	94:126	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	4	24	from	absence	688:694	arg1	LD-SV2A					734:740	LD-SV2A	734:740	LD-SV2A	734:740	The absence of an N-glycan homologous to N480g in LD-SV2A leads to a decrease of the binding of N573g to the surface of BoNT/A1.
36754227	4	25	theme	N-glycan	702:709	arg1	absence					688:694	The absence	684:694	The absence of an N-glycan homologous to N480g in LD-SV2A	684:740	The absence of an N-glycan homologous to N480g in LD-SV2A leads to a decrease of the binding of N573g to the surface of BoNT/A1.
36754227	2	26	from	domain	289:294	arg1	position					339:346	position N559	339:351	position N559 (N559g)	339:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	26	from	domain	289:294	arg1	N559g					354:358	N559g	354:358	N559g	354:358	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	26	from	domain	289:294	arg1	position					252:259	position N573	252:264	position N573 (N573g)	252:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	26	from	domain	289:294	arg1	N573g					267:271	N573g	267:271	N573g	267:271	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	27	from	domain	202:207	arg1	position					339:346	position N559	339:351	position N559 (N559g)	339:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	27	from	domain	202:207	arg1	N559g					354:358	N559g	354:358	N559g	354:358	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	27	from	domain	202:207	arg1	position					252:259	position N573	252:264	position N573 (N573g)	252:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	27	from	domain	202:207	arg1	N573g					267:271	N573g	267:271	N573g	267:271	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	6	28	theme	ganglioside	1305:1315	arg1	site					1325:1328	the well-known ganglioside binding site	1290:1328	the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1	1290:1387	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	0	29	theme	Structural	0:9	arg1	basis					11:15	Structural basis	0:15	Structural basis of botulinum neurotoxin serotype A1	0:51	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	5	30	theme	LD-SV2A	895:901	arg1	interactions					843:854	the intermolecular interactions	824:854	the intermolecular interactions between BoNT/A	824:869	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	30	theme	LD-SV2A	895:901	arg1	part					887:890	the protein part	875:890	the protein part of LD-SV2A or LD-SV2C	875:912	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	6	31	theme	BoNT/A1	1381:1387	arg1	surface					1370:1376	the surface	1366:1376	the surface of BoNT/A1	1366:1387	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	3	32	theme	luminal	466:472	arg1	SV2C					484:487	SV2C	484:487	SV2C (LD-SV2C)	484:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	3	32	theme	luminal	466:472	arg1	domain					474:479	the luminal domain	462:479	the luminal domain of SV2C (LD-SV2C)	462:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	6	33	theme	well-known	1294:1303	arg1	site					1325:1328	the well-known ganglioside binding site	1290:1328	the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1	1290:1387	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	6	34	theme	sequence	1470:1477	arg1	1253-HQFNNIAK-1260					1479:1496	the sequence 1253-HQFNNIAK-1260	1466:1496	the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides	1466:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	0	35	theme	botulinum	20:28	arg1	neurotoxin					30:39	botulinum neurotoxin	20:39	botulinum neurotoxin serotype A1	20:51	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	6	36	theme	high	1572:1575	arg1	affinity					1577:1584	a high affinity	1570:1584	a high affinity to interact with gangliosides	1570:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	3	37	with	contacts	523:530	arg1	N-glycan					574:581	the second N-glycan	563:581	the second N-glycan	563:581	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	7	38	theme	membrane	1784:1791	arg1	environment					1793:1803	a biologically relevant membrane environment	1760:1803	a biologically relevant membrane environment	1760:1803	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	1	39	theme	Botulinum	94:102	arg1	poison					155:160	the most potent natural poison	131:160	the most potent natural poison in human	131:169	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	1	39	theme	Botulinum	94:102	arg1	BoNT/A1					119:125	BoNT/A1	119:125	BoNT/A1	119:125	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	1	39	theme	Botulinum	94:102	arg1	A1					115:116	Botulinum neurotoxin A1	94:116	Botulinum neurotoxin A1 (BoNT/A1)	94:126	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	6	40	contain	has	1566:1568	arg2	affinity					1577:1584	a high affinity	1570:1584	a high affinity to interact with gangliosides	1570:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	6	40	contain	has	1566:1568	arg1	1253-HQFNNIAK-1260					1479:1496	the sequence 1253-HQFNNIAK-1260	1466:1496	the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides	1466:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	0	41	theme	serotype	41:48	arg1	A1					50:51	botulinum neurotoxin serotype A1	20:51	botulinum neurotoxin serotype A1	20:51	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	3	42	dep	position	586:593	arg1	N559g					600:604	N559g	600:604	N559g	600:604	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	3	42	dep	position	586:593	arg1	559					595:597	559	595:597	position 559 (N559g)	586:605	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	4	43	theme	binding	769:775	arg1	decrease					753:760	a decrease	751:760	a decrease of the binding of N573g to the surface of BoNT/A1	751:810	The absence of an N-glycan homologous to N480g in LD-SV2A leads to a decrease of the binding of N573g to the surface of BoNT/A1.
36754227	5	44	theme	LD-SV2C	906:912	arg1	interactions					843:854	the intermolecular interactions	824:854	the intermolecular interactions between BoNT/A	824:869	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	44	theme	LD-SV2C	906:912	arg1	part					887:890	the protein part	875:890	the protein part of LD-SV2A or LD-SV2C	875:912	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	3	45	theme	SV2C	484:487	arg1	SV2C					484:487	SV2C	484:487	SV2C (LD-SV2C)	484:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	3	45	theme	SV2C	484:487	arg1	domain					474:479	the luminal domain	462:479	the luminal domain of SV2C (LD-SV2C)	462:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	6	46	theme	ganglioside	1430:1440	arg1	loop					1450:1453	the ganglioside binding loop	1426:1453	the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides	1426:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	0	47	theme	neurotoxin	30:39	arg1	A1					50:51	botulinum neurotoxin serotype A1	20:51	botulinum neurotoxin serotype A1	20:51	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	7	48	theme	relevant	1775:1782	arg1	environment					1793:1803	a biologically relevant membrane environment	1760:1803	a biologically relevant membrane environment	1760:1803	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	5	49	theme	better	1004:1009	arg1	compaction					1011:1020	a better compaction	1002:1020	a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1002:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	2	50	theme	glycosylation	322:334	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	50	theme	glycosylation	322:334	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	50	theme	glycosylation	322:334	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	50	theme	glycosylation	322:334	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	50	theme	glycosylation	322:334	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	50	theme	glycosylation	322:334	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	51	theme	neural	369:374	arg1	membrane					376:383	neural membrane	369:383	neural membrane	369:383	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	4	52	theme	N573g	780:784	arg1	binding					769:775	the binding	765:775	the binding of N573g to the surface of BoNT/A1	765:810	The absence of an N-glycan homologous to N480g in LD-SV2A leads to a decrease of the binding of N573g to the surface of BoNT/A1.
36754227	5	53	from	position	1171:1178	arg1	residues					1159:1166	two aromatic residues	1146:1166	two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1146:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	53	from	position	1171:1178	arg1	presence					1134:1141	the presence	1130:1141	the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1130:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	2	54	theme	luminal	194:200	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	54	theme	luminal	194:200	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	54	theme	luminal	194:200	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	54	theme	luminal	194:200	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	54	theme	luminal	194:200	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	6	55	theme	binding	1442:1448	arg1	loop					1450:1453	the ganglioside binding loop	1426:1453	the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides	1426:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	1	56	theme	neurotoxin	104:113	arg1	poison					155:160	the most potent natural poison	131:160	the most potent natural poison in human	131:169	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	1	56	theme	neurotoxin	104:113	arg1	BoNT/A1					119:125	BoNT/A1	119:125	BoNT/A1	119:125	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	1	56	theme	neurotoxin	104:113	arg1	A1					115:116	Botulinum neurotoxin A1	94:116	Botulinum neurotoxin A1 (BoNT/A1)	94:126	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	0	57	theme	A1	50:51	arg1	basis					11:15	Structural basis	0:15	Structural basis of botulinum neurotoxin serotype A1	0:51	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	5	58	theme	high	934:937	arg1	affinity					939:946	the high affinity	930:946	the high affinity of the neurotoxin for binding LD-SV2C	930:984	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	59	theme	protein	879:885	arg1	part					887:890	the protein part	875:890	the protein part of LD-SV2A or LD-SV2C	875:912	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	6	60	dep	structure	1406:1414	arg1	coined					1419:1424	coined	1419:1424	coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides	1419:1614	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	5	61	theme	CH-pi	1247:1251	arg1	interaction					1253:1263	CH-pi interaction	1247:1263	CH-pi interaction	1247:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	62	from	564	1188:1190	arg1	residues					1159:1166	two aromatic residues	1146:1166	two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1146:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	62	from	564	1188:1190	arg1	presence					1134:1141	the presence	1130:1141	the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1130:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	63	theme	part	1039:1042	arg1	compaction					1011:1020	a better compaction	1002:1020	a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1002:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	3	64	theme	neurotoxin	539:548	arg1	surface					550:556	the neurotoxin surface	535:556	the neurotoxin surface	535:556	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	5	65	from	presence	1134:1141	arg1	position					1171:1178	position 563 and 564	1171:1190	position	1171:1178	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	65	from	presence	1134:1141	arg1	564					1188:1190	564	1188:1190	564	1188:1190	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	1	66	from	poison	155:160	arg1	human					165:169	human	165:169	human	165:169	Botulinum neurotoxin A1 (BoNT/A1) is the most potent natural poison in human.
36754227	3	67	theme	computational	390:402	arg1	data					404:407	Our computational data	386:407	Our computational data	386:407	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	0	68	theme	human	64:68	arg1	SV2A					70:73	human SV2A	64:73	human SV2A	64:73	Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
36754227	3	69	theme	surface	550:556	arg1	contacts					523:530	the contacts	519:530	the contacts of the neurotoxin surface with the second N-glycan	519:581	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	5	70	theme	intermolecular	828:841	arg1	interactions					843:854	the intermolecular interactions	824:854	the intermolecular interactions between BoNT/A	824:869	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	5	71	theme	π-π	1058:1060	arg1	network					1062:1068	a π-π network	1056:1068	a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1056:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	7	72	theme	full	1811:1814	arg1	glycosylation					1816:1828	a full glycosylation	1809:1828	a full glycosylation of SV2	1809:1835	These data solved the puzzle generated by mutational studies that could be only partially understood with crystallographic data that lack both a biologically relevant membrane environment and a full glycosylation of SV2.
36754227	6	73	theme	BoNT/A	1539:1544	arg1	subtypes					1527:1534	all subtypes	1523:1534	all subtypes of BoNT/A	1523:1544	Finally, in addition to the well-known ganglioside binding site which accommodates a ganglioside on the surface of BoNT/A1, we identified a structure we coined the ganglioside binding loop defined by the sequence 1253-HQFNNIAK-1260 that is conserved across all subtypes of BoNT/A and is predicted to has a high affinity to interact with gangliosides.
36754227	2	74	theme	SV2A	212:215	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	74	theme	SV2A	212:215	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	74	theme	SV2A	212:215	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	74	theme	SV2A	212:215	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	74	theme	SV2A	212:215	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	74	theme	SV2A	212:215	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	5	75	theme	aromatic	1150:1157	arg1	residues					1159:1166	two aromatic residues	1146:1166	two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction	1146:1263	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36754227	2	76	theme	SV2C	299:302	arg1	domain					289:294	the luminal domain	277:294	the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g)	277:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	76	theme	SV2C	299:302	arg1	domain					202:207	the luminal domain	190:207	the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g)	190:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	76	theme	SV2C	299:302	arg1	SV2C					299:302	SV2C	299:302	SV2C (LD-SV2C)	299:312	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	76	theme	SV2C	299:302	arg1	glycosylation					322:334	its glycosylation	318:334	its glycosylation at position N559 (N559g)	318:359	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	76	theme	SV2C	299:302	arg1	glycosylation					235:247	its glycosylation	231:247	its glycosylation at position N573 (N573g)	231:272	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	2	76	theme	SV2C	299:302	arg1	SV2A					212:215	SV2A	212:215	SV2A (LD-SV2A)	212:225	BoNT/A1 recognize the luminal domain of SV2A (LD-SV2A) and its glycosylation at position N573 (N573g) or the luminal domain of SV2C (LD-SV2C) and its glycosylation at position N559 (N559g) to bind neural membrane.
36754227	3	77	from	position	438:445	arg1	N-glycan					426:433	the N-glycan	422:433	the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C)	422:497	Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C.
36754227	5	78	theme	binding	970:976	arg1	LD-SV2C					978:984	binding LD-SV2C	970:984	binding LD-SV2C	970:984	Concerning the intermolecular interactions between BoNT/A and the protein part of LD-SV2A or LD-SV2C, we showed that the high affinity of the neurotoxin for binding LD-SV2C are mediated by a better compaction of its F557-F562 part provided by a π-π network mediated by residues F547, F552, F557 and F562 coupled with the presence of two aromatic residues at position 563 and 564 that optimize the binding of BoNT/A1 via cation-pi and CH-pi interaction.
36596110	9	0	theme	medical	1365:1371	arg1	industries					1382:1391	the medical and food industries	1361:1391	the medical and food industries	1361:1391	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	7	1	theme	antioxidant	1058:1068	arg1	function					1070:1077	better antioxidant function	1051:1077	better antioxidant function	1051:1077	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	3	2	theme	protective	543:552	arg1	activity					554:561	liver protective activity	537:561	liver protective activity	537:561	Furthermore, their physicochemical structures, antioxidant and liver protective activity were investigated and compared.
36596110	0	3	theme	different	98:106	arg1	cultivars					108:116	different cultivars	98:116	different cultivars	98:116	Physicochemical characteristics and biological activities of grape polysaccharides collected from different cultivars.
36596110	6	4	theme	polysaccharides	925:939	arg1	activities					905:914	the antioxidant activities	889:914	the antioxidant activities of these polysaccharides	889:939	And the antioxidant activities of these polysaccharides were screened by free radical scavenging test.
36596110	5	5	theme	monosaccharide	806:819	arg1	compositions					821:832	monosaccharide compositions	806:832	monosaccharide compositions	806:832	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	9	6	theme	food	1377:1380	arg1	industries					1382:1391	the medical and food industries	1361:1391	the medical and food industries	1361:1391	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	8	7	contain	have	1160:1163	arg1	polysaccharides					1131:1145	the polysaccharides	1127:1145	the polysaccharides of BC and BF	1127:1158	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	8	7	contain	have	1160:1163	arg2	effect					1178:1183	a protective effect	1165:1183	a protective effect against myocardial I/R injury in mice	1165:1221	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	9	8	contain	have	1330:1333	arg2	applications					1345:1356	potential applications	1335:1356	potential applications	1335:1356	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	9	8	contain	have	1330:1333	arg1	grapes					1323:1328	BC and BF grapes	1313:1328	BC and BF grapes	1313:1328	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	8	9	from	effect	1178:1183	arg1	mice					1218:1221	mice	1218:1221	mice	1218:1221	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	5	10	theme	compositions	821:832	arg1	features					860:867	surface morphological features	838:867	surface morphological features	838:867	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	5	10	theme	compositions	821:832	arg1	weights					781:787	their molecular weights	765:787	their molecular weights	765:787	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	5	10	theme	compositions	821:832	arg1	ratios					796:801	molar ratios	790:801	molar ratios of monosaccharide compositions	790:832	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	8	11	dep	in	1093:1094	arg1	vivo					1096:1099	vivo	1096:1099	vivo	1096:1099	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	4	12	theme	monosaccharide	643:656	arg1	compositions					658:669	monosaccharide compositions	643:669	monosaccharide compositions	643:669	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	8	13	theme	I/R	1204:1206	arg1	injury					1208:1213	myocardial I/R injury	1193:1213	myocardial I/R injury	1193:1213	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	8	14	theme	mitochondrial	1272:1284	arg1	generation					1290:1299	mitochondrial ROS generation	1272:1299	mitochondrial ROS generation	1272:1299	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	5	15	theme	surface	838:844	arg1	features					860:867	surface morphological features	838:867	surface morphological features	838:867	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	6	16	theme	antioxidant	893:903	arg1	activities					905:914	the antioxidant activities	889:914	the antioxidant activities of these polysaccharides	889:939	And the antioxidant activities of these polysaccharides were screened by free radical scavenging test.
36596110	9	17	theme	BF	1320:1321	arg1	grapes					1323:1328	BC and BF grapes	1313:1328	BC and BF grapes	1313:1328	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	2	18	theme	ultrasonic	413:422	arg1	power					424:428	ultrasonic power	413:428	ultrasonic power	413:428	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	8	19	theme	BC	1150:1151	arg1	polysaccharides					1131:1145	the polysaccharides	1127:1145	the polysaccharides of BC and BF	1127:1158	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	7	20	dep	Beichun	989:995	arg1	polysaccharides					1025:1039	polysaccharides	1025:1039	polysaccharides	1025:1039	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	0	21	theme	Physicochemical	0:14	arg1	characteristics					16:30	Physicochemical characteristics	0:30	Physicochemical characteristics	0:30	Physicochemical characteristics and biological activities of grape polysaccharides collected from different cultivars.
36596110	7	22	theme	Benni	1008:1012	arg1	fuji					1014:1017	Benni fuji	1008:1017	'Benni fuji' (BF)	1007:1023	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	7	22	theme	Benni	1008:1012	arg1	BF					1021:1022	BF	1021:1022	BF	1021:1022	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	8	23	theme	in	1093:1094	arg1	evaluation					1101:1110	the in vivo evaluation	1089:1110	the in vivo evaluation	1089:1110	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	0	24	theme	biological	36:45	arg1	activities					47:56	biological activities	36:56	biological activities	36:56	Physicochemical characteristics and biological activities of grape polysaccharides collected from different cultivars.
36596110	8	25	theme	myocardial	1237:1246	arg1	necroptosis					1248:1258	myocardial necroptosis	1237:1258	myocardial necroptosis mediated by mitochondrial ROS generation	1237:1299	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	8	26	theme	BF	1157:1158	arg1	polysaccharides					1131:1145	the polysaccharides	1127:1145	the polysaccharides of BC and BF	1127:1158	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	2	27	theme	surface	326:332	arg1	RSM					347:349	RSM	347:349	RSM	347:349	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	27	theme	surface	326:332	arg1	methodology					334:344	response surface methodology	317:344	response surface methodology (RSM)	317:350	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	3	28	theme	physicochemical	493:507	arg1	structures					509:518	their physicochemical structures	487:518	their physicochemical structures	487:518	Furthermore, their physicochemical structures, antioxidant and liver protective activity were investigated and compared.
36596110	2	29	theme	liquid-to-solid	451:465	arg1	ratio					467:471	liquid-to-solid ratio	451:471	liquid-to-solid ratio	451:471	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	4	30	theme	functional	621:630	arg1	similar					742:748	similar	742:748	similar	742:748	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	4	30	theme	functional	621:630	arg1	groups					632:637	the functional groups	617:637	the functional groups	617:637	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	4	30	theme	functional	621:630	arg1	polysaccharides					686:700	these grape polysaccharides	674:700	these grape polysaccharides collected from different varieties	674:735	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	5	31	theme	molar	790:794	arg1	ratios					796:801	molar ratios	790:801	molar ratios of monosaccharide compositions	790:832	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	9	32	theme	BC	1313:1314	arg1	grapes					1323:1328	BC and BF grapes	1313:1328	BC and BF grapes	1313:1328	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	2	33	theme	response	317:324	arg1	RSM					347:349	RSM	347:349	RSM	347:349	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	33	theme	response	317:324	arg1	methodology					334:344	response surface methodology	317:344	response surface methodology (RSM)	317:350	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	1	34	theme	ultrasound-assisted	217:235	arg1	extraction					237:246	an efficient ultrasound-assisted extraction	204:246	an efficient ultrasound-assisted extraction	204:246	In this study, four wine grape polysaccharides were extracted and optimized by using an efficient ultrasound-assisted extraction.
36596110	2	35	theme	ultrasonic	431:440	arg1	time					442:445	ultrasonic time	431:445	ultrasonic time	431:445	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	6	36	theme	scavenging	971:980	arg1	test					982:985	free radical scavenging test	958:985	free radical scavenging test	958:985	And the antioxidant activities of these polysaccharides were screened by free radical scavenging test.
36596110	8	37	theme	ROS	1286:1288	arg1	generation					1290:1299	mitochondrial ROS generation	1272:1299	mitochondrial ROS generation	1272:1299	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	4	38	theme	different	717:725	arg1	varieties					727:735	different varieties	717:735	different varieties	717:735	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	0	39	theme	polysaccharides	67:81	arg1	characteristics					16:30	Physicochemical characteristics	0:30	Physicochemical characteristics	0:30	Physicochemical characteristics and biological activities of grape polysaccharides collected from different cultivars.
36596110	0	39	theme	polysaccharides	67:81	arg1	activities					47:56	biological activities	36:56	biological activities	36:56	Physicochemical characteristics and biological activities of grape polysaccharides collected from different cultivars.
36596110	6	40	theme	radical	963:969	arg1	test					982:985	free radical scavenging test	958:985	free radical scavenging test	958:985	And the antioxidant activities of these polysaccharides were screened by free radical scavenging test.
36596110	2	41	theme	three-level	251:261	arg1	BBD					297:299	BBD	297:299	BBD	297:299	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	41	theme	three-level	251:261	arg1	Design					289:294	A three-level, three-factor Box Behnken Design	249:294	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM)	249:350	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	8	42	theme	myocardial	1193:1202	arg1	injury					1208:1213	myocardial I/R injury	1193:1213	myocardial I/R injury	1193:1213	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	0	43	theme	grape	61:65	arg1	polysaccharides					67:81	grape polysaccharides	61:81	grape polysaccharides	61:81	Physicochemical characteristics and biological activities of grape polysaccharides collected from different cultivars.
36596110	8	44	theme	protective	1167:1176	arg1	effect					1178:1183	a protective effect	1165:1183	a protective effect against myocardial I/R injury in mice	1165:1221	Further, the in vivo evaluation indicated that the polysaccharides of BC and BF have a protective effect against myocardial I/R injury in mice by inhibiting myocardial necroptosis mediated by mitochondrial ROS generation.
36596110	6	45	theme	free	958:961	arg1	test					982:985	free radical scavenging test	958:985	free radical scavenging test	958:985	And the antioxidant activities of these polysaccharides were screened by free radical scavenging test.
36596110	3	46	theme	liver	537:541	arg1	activity					554:561	liver protective activity	537:561	liver protective activity	537:561	Furthermore, their physicochemical structures, antioxidant and liver protective activity were investigated and compared.
36596110	5	47	theme	molecular	771:779	arg1	weights					781:787	their molecular weights	765:787	their molecular weights	765:787	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	9	48	theme	potential	1335:1343	arg1	applications					1345:1356	potential applications	1335:1356	potential applications	1335:1356	Therefore, BC and BF grapes have potential applications in the medical and food industries.
36596110	1	49	theme	wine	139:142	arg1	polysaccharides					150:164	four wine grape polysaccharides	134:164	four wine grape polysaccharides	134:164	In this study, four wine grape polysaccharides were extracted and optimized by using an efficient ultrasound-assisted extraction.
36596110	1	50	theme	grape	144:148	arg1	polysaccharides					150:164	four wine grape polysaccharides	134:164	four wine grape polysaccharides	134:164	In this study, four wine grape polysaccharides were extracted and optimized by using an efficient ultrasound-assisted extraction.
36596110	5	51	theme	morphological	846:858	arg1	features					860:867	surface morphological features	838:867	surface morphological features	838:867	Nevertheless, their molecular weights, molar ratios of monosaccharide compositions and surface morphological features were different.
36596110	1	52	theme	efficient	207:215	arg1	extraction					237:246	an efficient ultrasound-assisted extraction	204:246	an efficient ultrasound-assisted extraction	204:246	In this study, four wine grape polysaccharides were extracted and optimized by using an efficient ultrasound-assisted extraction.
36596110	2	53	theme	Behnken	281:287	arg1	BBD					297:299	BBD	297:299	BBD	297:299	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	53	theme	Behnken	281:287	arg1	Design					289:294	A three-level, three-factor Box Behnken Design	249:294	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM)	249:350	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	54	dep	three-level	251:261	arg1	three-factor					264:275	three-factor	264:275	three-factor	264:275	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	55	theme	extraction	381:390	arg1	conditions					392:401	the extraction conditions	377:401	the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio	377:471	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	55	theme	extraction	381:390	arg1	power					424:428	ultrasonic power	413:428	ultrasonic power	413:428	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	55	theme	extraction	381:390	arg1	time					442:445	ultrasonic time	431:445	ultrasonic time	431:445	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	55	theme	extraction	381:390	arg1	ratio					467:471	liquid-to-solid ratio	451:471	liquid-to-solid ratio	451:471	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	4	56	theme	polysaccharides	686:700	arg1	similar					742:748	similar	742:748	similar	742:748	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	4	56	theme	polysaccharides	686:700	arg1	groups					632:637	the functional groups	617:637	the functional groups	617:637	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	4	56	theme	polysaccharides	686:700	arg1	compositions					658:669	monosaccharide compositions	643:669	monosaccharide compositions	643:669	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	4	56	theme	polysaccharides	686:700	arg1	polysaccharides					686:700	these grape polysaccharides	674:700	these grape polysaccharides collected from different varieties	674:735	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36596110	7	57	contain	possessed	1041:1049	arg1	BF					1021:1022	BF	1021:1022	BF	1021:1022	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	7	57	contain	possessed	1041:1049	arg1	fuji					1014:1017	Benni fuji	1008:1017	'Benni fuji' (BF)	1007:1023	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	7	57	contain	possessed	1041:1049	arg1	Beichun					989:995	'Beichun'	988:996	'Beichun' (BC)	988:1001	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	7	57	contain	possessed	1041:1049	arg1	BC					999:1000	BC	999:1000	BC	999:1000	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	7	57	contain	possessed	1041:1049	arg2	function					1070:1077	better antioxidant function	1051:1077	better antioxidant function	1051:1077	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	2	58	theme	Box	277:279	arg1	BBD					297:299	BBD	297:299	BBD	297:299	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	2	58	theme	Box	277:279	arg1	Design					289:294	A three-level, three-factor Box Behnken Design	249:294	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM)	249:350	A three-level, three-factor Box Behnken Design (BBD) combining with response surface methodology (RSM) was employed to optimize the extraction conditions including ultrasonic power, ultrasonic time and liquid-to-solid ratio.
36596110	7	59	theme	better	1051:1056	arg1	function					1070:1077	better antioxidant function	1051:1077	better antioxidant function	1051:1077	'Beichun' (BC) and 'Benni fuji' (BF) polysaccharides possessed better antioxidant function.
36596110	4	60	theme	grape	680:684	arg1	polysaccharides					686:700	these grape polysaccharides	674:700	these grape polysaccharides collected from different varieties	674:735	Results revealed that the functional groups and monosaccharide compositions of these grape polysaccharides collected from different varieties were similar.
36087978	4	0	theme	delignified	541:551	arg1	templet					558:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	6	1	theme	advanced	1143:1150	arg1	material					1169:1176	advanced transparent wood material	1143:1176	advanced transparent wood material from the point-of-view of wood chemical composition	1143:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	6	2	theme	new	1106:1108	arg1	insights					1110:1117	new insights	1106:1117	new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition	1106:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	5	3	theme	1.65 MJ/m3	957:966	arg1	strength					918:925	tensile strength	910:925	tensile strength of 165.3 MPa	910:938	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	3	theme	1.65 MJ/m3	957:966	arg1	toughness					944:952	toughness	944:952	toughness of 1.65 MJ/m3	944:966	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	4	from	defects	1018:1024	arg1	matrix					1051:1056	the matrix	1047:1056	the matrix	1047:1056	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	3	5	theme	high	377:380	arg1	content					396:402	high hemicellulose content	377:402	high hemicellulose content (~23 wt%)	377:412	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	3	5	theme	high	377:380	arg1	%					411:411	~23 wt%	405:411	~23 wt%	405:411	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	5	6	theme	resultant	724:732	arg1	composite					763:771	the resultant hemicellulose-rich wood/PMMA composite	720:771	the resultant hemicellulose-rich wood/PMMA composite	720:771	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	7	theme	defects	1018:1024	arg1	absence					991:997	the absence	987:997	the absence of microstructural defects and heterogeneity in the matrix	987:1056	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	8	theme	microstructural	1002:1016	arg1	defects					1018:1024	microstructural defects	1002:1024	microstructural defects	1002:1024	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	3	9	theme	hemicellulose	382:394	arg1	content					396:402	high hemicellulose content	377:402	high hemicellulose content (~23 wt%)	377:412	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	3	9	theme	hemicellulose	382:394	arg1	%					411:411	~23 wt%	405:411	~23 wt%	405:411	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	6	10	theme	chemical	1209:1216	arg1	composition					1218:1228	wood chemical composition	1204:1228	wood chemical composition	1204:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	5	11	theme	hemicellulose-rich	734:751	arg1	composite					763:771	the resultant hemicellulose-rich wood/PMMA composite	720:771	the resultant hemicellulose-rich wood/PMMA composite	720:771	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	6	12	from	fabrication	1128:1138	arg1	point-of-view					1187:1199	the point-of-view	1183:1199	the point-of-view of wood chemical composition	1183:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	5	13	theme	optical	850:856	arg1	transmittance					795:807	high optical transmittance	782:807	high optical transmittance (~85 %)	782:815	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	13	theme	optical	850:856	arg1	stability					858:866	acceptable optical stability	839:866	acceptable optical stability	839:866	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	14	theme	mechanical	889:898	arg1	strength					900:907	excellent mechanical strength	879:907	high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3)	782:967	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	4	15	theme	polymer	683:689	arg1	space-filling					691:703	petroleum-based polymer space-filling	667:703	petroleum-based polymer space-filling	667:703	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	5	16	theme	heterogeneity	1030:1042	arg1	absence					991:997	the absence	987:997	the absence of microstructural defects and heterogeneity in the matrix	987:1056	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	17	theme	tensile	910:916	arg1	strength					918:925	tensile strength	910:925	tensile strength of 165.3 MPa	910:938	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	18	theme	medium	818:823	arg1	transmittance					795:807	high optical transmittance	782:807	high optical transmittance (~85 %)	782:815	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	18	theme	medium	818:823	arg1	haze					825:828	medium haze	818:828	medium haze (~72 %)	818:836	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	18	theme	medium	818:823	arg1	%					835:835	~72 %	831:835	~72 %	831:835	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	4	19	theme	hemicellulose-rich	522:539	arg1	templet					558:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	2	20	theme	wood/polymer	283:294	arg1	wood					272:275	transparent wood	260:275	transparent wood (i.e. wood/polymer composite)	260:305	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	20	theme	wood/polymer	283:294	arg1	composite					296:304	i.e. wood/polymer composite	278:304	i.e. wood/polymer composite	278:304	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	0	21	theme	transparent	19:29	arg1	wood					31:34	Hemicellulose-rich transparent wood	0:34	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.	0:78	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.
36087978	6	22	theme	composition	1218:1228	arg1	point-of-view					1187:1199	the point-of-view	1183:1199	the point-of-view of wood chemical composition	1183:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	1	23	theme	vital	102:106	arg1	role					108:111	a vital role	100:111	a vital role	100:111	Hemicellulose plays a vital role in nature wood matrix.
36087978	5	24	from	matrix	1051:1056	arg1	absence					991:997	the absence	987:997	the absence of microstructural defects and heterogeneity in the matrix	987:1056	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	3	25	theme	supramolecular	443:456	arg1	structure					458:466	well-preserved cellulose supramolecular structure	418:466	well-preserved cellulose supramolecular structure	418:466	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	0	26	theme	Hemicellulose-rich	0:17	arg1	wood					31:34	Hemicellulose-rich transparent wood	0:34	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.	0:78	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.
36087978	2	27	theme	structural	320:329	arg1	wood					272:275	transparent wood	260:275	transparent wood (i.e. wood/polymer composite)	260:305	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	27	theme	structural	320:329	arg1	material					331:338	an emerging structural material	308:338	an emerging structural material	308:338	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	5	28	theme	165.3 MPa	930:938	arg1	strength					918:925	tensile strength	910:925	tensile strength of 165.3 MPa	910:938	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	28	theme	165.3 MPa	930:938	arg1	toughness					944:952	toughness	944:952	toughness of 1.65 MJ/m3	944:966	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	29	theme	optical	787:793	arg1	transmittance					795:807	high optical transmittance	782:807	high optical transmittance (~85 %)	782:815	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	29	theme	optical	787:793	arg1	%					814:814	~85 %	810:814	~85 %	810:814	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	29	theme	optical	787:793	arg1	stability					858:866	acceptable optical stability	839:866	acceptable optical stability	839:866	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	29	theme	optical	787:793	arg1	haze					825:828	medium haze	818:828	medium haze (~72 %)	818:836	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	2	30	theme	emerging	311:318	arg1	wood					272:275	transparent wood	260:275	transparent wood (i.e. wood/polymer composite)	260:305	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	30	theme	emerging	311:318	arg1	material					331:338	an emerging structural material	308:338	an emerging structural material	308:338	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	3	31	theme	peracetic	487:495	arg1	process					508:514	a peracetic acid-based process	485:514	a peracetic acid-based process	485:514	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	4	32	from	structure	600:608	arg1	lumen					638:642	lumen	638:642	lumen	638:642	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	32	from	structure	600:608	arg1	lamella					655:661	middle lamella	648:661	middle lamella	648:661	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	2	33	theme	hemicellulose	183:195	arg1	significance					167:178	the significance	163:178	the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material	163:338	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	1	34	theme	nature	116:121	arg1	matrix					128:133	nature wood matrix	116:133	nature wood matrix	116:133	Hemicellulose plays a vital role in nature wood matrix.
36087978	3	35	theme	acid-based	497:506	arg1	process					508:514	a peracetic acid-based process	485:514	a peracetic acid-based process	485:514	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	3	36	theme	well-preserved	418:431	arg1	structure					458:466	well-preserved cellulose supramolecular structure	418:466	well-preserved cellulose supramolecular structure	418:466	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	4	37	theme	sufficient	614:623	arg1	space					625:629	sufficient space	614:629	sufficient space	614:629	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	38	dep	lumen	638:642	arg1	the					634:636	the	634:636	the	634:636	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	3	39	with	templet	364:370	arg1	content					396:402	high hemicellulose content	377:402	high hemicellulose content (~23 wt%)	377:412	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	3	39	with	templet	364:370	arg1	%					411:411	~23 wt%	405:411	~23 wt%	405:411	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	3	39	with	templet	364:370	arg1	structure					458:466	well-preserved cellulose supramolecular structure	418:466	well-preserved cellulose supramolecular structure	418:466	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	3	40	theme	cellulose	433:441	arg1	structure					458:466	well-preserved cellulose supramolecular structure	418:466	well-preserved cellulose supramolecular structure	418:466	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	4	41	theme	intact	583:588	arg1	structure					600:608	nearly intact cell wall structure	576:608	nearly intact cell wall structure	576:608	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	42	theme	petroleum-based	667:681	arg1	space-filling					691:703	petroleum-based polymer space-filling	667:703	petroleum-based polymer space-filling	667:703	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	5	43	theme	acceptable	839:848	arg1	transmittance					795:807	high optical transmittance	782:807	high optical transmittance (~85 %)	782:815	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	43	theme	acceptable	839:848	arg1	stability					858:866	acceptable optical stability	839:866	acceptable optical stability	839:866	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	44	theme	wood/PMMA	753:761	arg1	composite					763:771	the resultant hemicellulose-rich wood/PMMA composite	720:771	the resultant hemicellulose-rich wood/PMMA composite	720:771	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	2	45	theme	macroscopic	234:244	arg1	properties					246:255	macroscopic properties	234:255	macroscopic properties	234:255	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	1	46	theme	wood	123:126	arg1	matrix					128:133	nature wood matrix	116:133	nature wood matrix	116:133	Hemicellulose plays a vital role in nature wood matrix.
36087978	0	47	theme	macroscopic	56:66	arg1	properties					68:77	macroscopic properties	56:77	macroscopic properties	56:77	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.
36087978	4	48	theme	wall	595:598	arg1	structure					600:608	nearly intact cell wall structure	576:608	nearly intact cell wall structure	576:608	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	49	from	space	625:629	arg1	lumen					638:642	lumen	638:642	lumen	638:642	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	49	from	space	625:629	arg1	lamella					655:661	middle lamella	648:661	middle lamella	648:661	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	6	50	from	point-of-view	1187:1199	arg1	material					1169:1176	advanced transparent wood material	1143:1176	advanced transparent wood material from the point-of-view of wood chemical composition	1143:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	6	50	from	point-of-view	1187:1199	arg1	fabrication					1128:1138	the fabrication	1124:1138	the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition	1124:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	4	51	theme	cell	590:593	arg1	structure					600:608	nearly intact cell wall structure	576:608	nearly intact cell wall structure	576:608	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	5	52	dep	strength	900:907	arg1	strength					918:925	tensile strength	910:925	tensile strength of 165.3 MPa	910:938	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	52	dep	strength	900:907	arg1	toughness					944:952	toughness	944:952	toughness of 1.65 MJ/m3	944:966	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	2	53	theme	i.e.	278:281	arg1	wood					272:275	transparent wood	260:275	transparent wood (i.e. wood/polymer composite)	260:305	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	53	theme	i.e.	278:281	arg1	composite					296:304	i.e. wood/polymer composite	278:304	i.e. wood/polymer composite	278:304	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	6	54	theme	wood	1204:1207	arg1	composition					1218:1228	wood chemical composition	1204:1228	wood chemical composition	1204:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	5	55	theme	high	782:785	arg1	transmittance					795:807	high optical transmittance	782:807	high optical transmittance (~85 %)	782:815	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	55	theme	high	782:785	arg1	%					814:814	~85 %	810:814	~85 %	810:814	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	55	theme	high	782:785	arg1	stability					858:866	acceptable optical stability	839:866	acceptable optical stability	839:866	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	5	55	theme	high	782:785	arg1	haze					825:828	medium haze	818:828	medium haze (~72 %)	818:836	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	0	56	dep	wood	31:34	arg1	Microstructure					37:50	Microstructure	37:50	Microstructure	37:50	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.
36087978	0	56	dep	wood	31:34	arg1	properties					68:77	macroscopic properties	56:77	macroscopic properties	56:77	Hemicellulose-rich transparent wood: Microstructure and macroscopic properties.
36087978	6	57	theme	material	1169:1176	arg1	fabrication					1128:1138	the fabrication	1124:1138	the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition	1124:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	4	58	theme	middle	648:653	arg1	lamella					655:661	middle lamella	648:661	middle lamella	648:661	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	3	59	theme	delignified	343:353	arg1	templet					364:370	A delignified basswood templet	341:370	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure	341:466	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	6	60	theme	transparent	1152:1162	arg1	material					1169:1176	advanced transparent wood material	1143:1176	advanced transparent wood material from the point-of-view of wood chemical composition	1143:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	2	61	theme	wood	272:275	arg1	properties					246:255	macroscopic properties	234:255	macroscopic properties	234:255	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	61	theme	wood	272:275	arg1	microstructure					215:228	microstructure	215:228	microstructure	215:228	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	5	62	theme	excellent	879:887	arg1	strength					900:907	excellent mechanical strength	879:907	high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3)	782:967	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	6	63	theme	wood	1164:1167	arg1	material					1169:1176	advanced transparent wood material	1143:1176	advanced transparent wood material from the point-of-view of wood chemical composition	1143:1228	It is anticipated that our study would provide new insights into the fabrication of advanced transparent wood material from the point-of-view of wood chemical composition.
36087978	5	64	from	absence	991:997	arg1	matrix					1051:1056	the matrix	1047:1056	the matrix	1047:1056	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36087978	2	65	dep	microstructure	215:228	arg1	the					211:213	the	211:213	the	211:213	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	3	66	theme	basswood	355:362	arg1	templet					364:370	A delignified basswood templet	341:370	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure	341:466	A delignified basswood templet with high hemicellulose content (~23 wt%) and well-preserved cellulose supramolecular structure was prepared via a peracetic acid-based process.
36087978	4	67	theme	wood	553:556	arg1	templet					558:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	2	68	theme	transparent	260:270	arg1	wood					272:275	transparent wood	260:275	transparent wood (i.e. wood/polymer composite)	260:305	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	68	theme	transparent	260:270	arg1	composite					296:304	i.e. wood/polymer composite	278:304	i.e. wood/polymer composite	278:304	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	2	68	theme	transparent	260:270	arg1	material					331:338	an emerging structural material	308:338	an emerging structural material	308:338	Here, we first demonstrate the significance of hemicellulose for improving the microstructure and macroscopic properties of transparent wood (i.e. wood/polymer composite), an emerging structural material.
36087978	4	69	contain	possesses	566:574	arg2	space					625:629	sufficient space	614:629	sufficient space	614:629	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	69	contain	possesses	566:574	arg1	templet					558:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet	517:564	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	4	69	contain	possesses	566:574	arg2	structure					600:608	nearly intact cell wall structure	576:608	nearly intact cell wall structure	576:608	This hemicellulose-rich delignified wood templet possesses nearly intact cell wall structure and sufficient space in the lumen and middle lamella for petroleum-based polymer space-filling.
36087978	5	70	from	heterogeneity	1030:1042	arg1	matrix					1051:1056	the matrix	1047:1056	the matrix	1047:1056	Consequently, the resultant hemicellulose-rich wood/PMMA composite exhibits high optical transmittance (~85 %), medium haze (~72 %), acceptable optical stability as well as excellent mechanical strength (tensile strength of 165.3 MPa and toughness of 1.65 MJ/m3), benefitting from the absence of microstructural defects and heterogeneity in the matrix.
36907309	0	0	from	banana	21:26	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides from banana (Musa spp.)	0:38	Polysaccharides from banana (Musa spp.)
36907309	9	1	theme	blossoms	1111:1118	arg1	application					1089:1099	the potential application	1075:1099	the potential application of banana blossoms in functional foods	1075:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	9	2	theme	functional	1123:1132	arg1	foods					1134:1138	functional foods	1123:1138	functional foods	1123:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	8	3	theme	functional	976:985	arg1	brownies					929:936	chocolate brownies	919:936	chocolate brownies	919:936	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	8	3	theme	functional	976:985	arg1	foods					987:991	functional foods	976:991	functional foods for diabetic patients	976:1013	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	8	4	theme	AGEs	911:914	arg1	levels					901:906	the levels	897:906	the levels of AGEs	897:914	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	3	5	theme	immune	180:185	arg1	system					187:192	the immune system	176:192	the immune system	176:192	(banana) is consumed globally as a healthy fruit and improves the immune system.
36907309	3	5	theme	immune	180:185	arg1	fruit					157:161	a healthy fruit	147:161	a healthy fruit	147:161	(banana) is consumed globally as a healthy fruit and improves the immune system.
36907309	7	6	theme	products	823:830	arg1	inhibitor					783:791	inhibitor	783:791	inhibitor of advanced glycosylation end products (AGEs)	783:837	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	6	theme	products	823:830	arg1	MSBP11					635:640	MSBP11	635:640	MSBP11	635:640	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	6	theme	products	823:830	arg1	antioxidant					767:777	a potential natural antioxidant	747:777	a potential natural antioxidant	747:777	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	7	theme	end	819:821	arg1	AGEs					833:836	AGEs	833:836	AGEs	833:836	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	7	theme	end	819:821	arg1	products					823:830	advanced glycosylation end products	796:830	advanced glycosylation end products (AGEs)	796:837	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	8	8	theme	chocolate	919:927	arg1	brownies					929:936	chocolate brownies	919:936	chocolate brownies	919:936	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	8	8	theme	chocolate	919:927	arg1	foods					987:991	functional foods	976:991	functional foods for diabetic patients	976:1013	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	1	9	theme	Isolation	50:58	arg1	effects					95:101	Isolation, identification and anti-glycation effects	50:101	Isolation, identification and anti-glycation effects	50:101	blossoms: Isolation, identification and anti-glycation effects.
36907309	4	10	theme	rich	249:252	arg1	blossoms					202:209	Banana blossoms	195:209	Banana blossoms	195:209	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	10	theme	rich	249:252	arg1	by-product					217:226	a by-product	215:226	a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds	215:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	11	from	substances	264:273	arg1	rich					249:252	rich	249:252	rich	249:252	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	7	12	theme	anti-glycation	675:688	arg1	activities					690:699	potent antioxidant and anti-glycation activities	652:699	potent antioxidant and anti-glycation activities	652:699	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	6	13	with	polysaccharide	516:529	arg1	mass					548:551	a molecular mass	536:551	a molecular mass of ~214.43 kDa	536:566	MSBP11 is a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa and composed of arabinose and galactose at a ratio of 0.303:0.697.
36907309	7	14	theme	glycosylation	805:817	arg1	AGEs					833:836	AGEs	833:836	AGEs	833:836	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	14	theme	glycosylation	805:817	arg1	products					823:830	advanced glycosylation end products	796:830	advanced glycosylation end products (AGEs)	796:837	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	9	15	from	blossoms	1111:1118	arg1	foods					1134:1138	functional foods	1123:1138	functional foods	1123:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	6	16	theme	~214.43 kDa	556:566	arg1	mass					548:551	a molecular mass	536:551	a molecular mass of ~214.43 kDa	536:566	MSBP11 is a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa and composed of arabinose and galactose at a ratio of 0.303:0.697.
36907309	1	17	theme	identification	61:74	arg1	effects					95:101	Isolation, identification and anti-glycation effects	50:101	Isolation, identification and anti-glycation effects	50:101	blossoms: Isolation, identification and anti-glycation effects.
36907309	4	18	theme	active	257:262	arg1	polysaccharides					283:297	polysaccharides	283:297	polysaccharides	283:297	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	18	theme	active	257:262	arg1	compounds					312:320	phenolic compounds	303:320	phenolic compounds	303:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	18	theme	active	257:262	arg1	substances					264:273	active substances	257:273	active substances such as polysaccharides and phenolic compounds	257:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	9	19	from	application	1089:1099	arg1	foods					1134:1138	functional foods	1123:1138	functional foods	1123:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	7	20	theme	natural	759:765	arg1	MSBP11					635:640	MSBP11	635:640	MSBP11	635:640	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	20	theme	natural	759:765	arg1	antioxidant					767:777	a potential natural antioxidant	747:777	a potential natural antioxidant	747:777	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	8	21	theme	diabetic	997:1004	arg1	patients					1006:1013	diabetic patients	997:1013	diabetic patients	997:1013	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	3	22	theme	healthy	149:155	arg1	system					187:192	the immune system	176:192	the immune system	176:192	(banana) is consumed globally as a healthy fruit and improves the immune system.
36907309	3	22	theme	healthy	149:155	arg1	fruit					157:161	a healthy fruit	147:161	a healthy fruit	147:161	(banana) is consumed globally as a healthy fruit and improves the immune system.
36907309	4	23	from	rich	249:252	arg1	polysaccharides					283:297	polysaccharides	283:297	polysaccharides	283:297	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	23	from	rich	249:252	arg1	compounds					312:320	phenolic compounds	303:320	phenolic compounds	303:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	23	from	rich	249:252	arg1	substances					264:273	active substances	257:273	active substances such as polysaccharides and phenolic compounds	257:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	1	24	theme	anti-glycation	80:93	arg1	effects					95:101	Isolation, identification and anti-glycation effects	50:101	Isolation, identification and anti-glycation effects	50:101	blossoms: Isolation, identification and anti-glycation effects.
36907309	6	25	theme	0.303:0.697	622:632	arg1	ratio					613:617	a ratio	611:617	a ratio of 0.303:0.697	611:632	MSBP11 is a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa and composed of arabinose and galactose at a ratio of 0.303:0.697.
36907309	6	26	theme	molecular	538:546	arg1	mass					548:551	a molecular mass	536:551	a molecular mass of ~214.43 kDa	536:566	MSBP11 is a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa and composed of arabinose and galactose at a ratio of 0.303:0.697.
36907309	7	27	theme	potent	652:657	arg1	activities					690:699	potent antioxidant and anti-glycation activities	652:699	potent antioxidant and anti-glycation activities	652:699	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	8	28	theme	banana	853:858	arg1	blossoms					860:867	banana blossoms	853:867	banana blossoms	853:867	In addition, banana blossoms have been shown to decrease the levels of AGEs in chocolate brownies, which might possibly be developed as functional foods for diabetic patients.
36907309	4	29	theme	harvesting	238:247	arg1	blossoms					202:209	Banana blossoms	195:209	Banana blossoms	195:209	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	29	theme	harvesting	238:247	arg1	by-product					217:226	a by-product	215:226	a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds	215:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	7	30	theme	potential	749:757	arg1	MSBP11					635:640	MSBP11	635:640	MSBP11	635:640	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	30	theme	potential	749:757	arg1	antioxidant					767:777	a potential natural antioxidant	747:777	a potential natural antioxidant	747:777	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	31	theme	antioxidant	659:669	arg1	activities					690:699	potent antioxidant and anti-glycation activities	652:699	potent antioxidant and anti-glycation activities	652:699	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	4	32	theme	banana	231:236	arg1	harvesting					238:247	banana harvesting	231:247	banana harvesting	231:247	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	0	33	theme	Musa	29:32	arg1	spp					34:36	Musa spp	29:36	Musa spp.	29:37	Polysaccharides from banana (Musa spp.)
36907309	4	34	theme	phenolic	303:310	arg1	compounds					312:320	phenolic compounds	303:320	phenolic compounds	303:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	6	35	theme	homogeneous	504:514	arg1	polysaccharide					516:529	a neutral homogeneous polysaccharide	494:529	a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa	494:566	MSBP11 is a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa and composed of arabinose and galactose at a ratio of 0.303:0.697.
36907309	9	36	theme	scientific	1038:1047	arg1	basis					1049:1053	a scientific basis	1036:1053	a scientific basis to further research the potential application of banana blossoms in functional foods	1036:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	3	37	dep	consumed	126:133	arg1	banana					115:120	banana	115:120	banana	115:120	(banana) is consumed globally as a healthy fruit and improves the immune system.
36907309	9	38	theme	potential	1079:1087	arg1	application					1089:1099	the potential application	1075:1099	the potential application of banana blossoms in functional foods	1075:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	4	39	theme	Banana	195:200	arg1	blossoms					202:209	Banana blossoms	195:209	Banana blossoms	195:209	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	4	39	theme	Banana	195:200	arg1	by-product					217:226	a by-product	215:226	a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds	215:320	Banana blossoms are a by-product of banana harvesting rich in active substances such as polysaccharides and phenolic compounds; however, these blossoms are typically discarded as waste.
36907309	0	40	dep	banana	21:26	arg1	spp					34:36	Musa spp	29:36	Musa spp.	29:37	Polysaccharides from banana (Musa spp.)
36907309	7	41	theme	advanced	796:803	arg1	AGEs					833:836	AGEs	833:836	AGEs	833:836	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	41	theme	advanced	796:803	arg1	products					823:830	advanced glycosylation end products	796:830	advanced glycosylation end products (AGEs)	796:837	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	6	42	theme	neutral	496:502	arg1	polysaccharide					516:529	a neutral homogeneous polysaccharide	494:529	a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa	494:566	MSBP11 is a neutral homogeneous polysaccharide with a molecular mass of ~214.43 kDa and composed of arabinose and galactose at a ratio of 0.303:0.697.
36907309	7	43	used	used	739:742	arg2	antioxidant					767:777	a potential natural antioxidant	747:777	a potential natural antioxidant	747:777	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	43	used	used	739:742	arg2	MSBP11					635:640	MSBP11	635:640	MSBP11	635:640	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	7	43	used	used	739:742	arg2	inhibitor					783:791	inhibitor	783:791	inhibitor of advanced glycosylation end products (AGEs)	783:837	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36907309	5	44	theme	banana	467:472	arg1	blossoms					474:481	banana blossoms	467:481	banana blossoms	467:481	In this report, a polysaccharide, MSBP11, was extracted, purified and identified from banana blossoms.
36907309	9	45	from	foods	1134:1138	arg1	application					1089:1099	the potential application	1075:1099	the potential application of banana blossoms in functional foods	1075:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	9	46	theme	banana	1104:1109	arg1	blossoms					1111:1118	banana blossoms	1104:1118	banana blossoms in functional foods	1104:1138	This study provides a scientific basis to further research the potential application of banana blossoms in functional foods.
36907309	1	47	dep	effects	95:101	arg1	blossoms					40:47	blossoms	40:47	blossoms	40:47	blossoms: Isolation, identification and anti-glycation effects.
36907309	7	48	theme	dose-dependent	706:719	arg1	manner					721:726	a dose-dependent manner	704:726	a dose-dependent manner	704:726	MSBP11 exhibited potent antioxidant and anti-glycation activities in a dose-dependent manner and can be used as a potential natural antioxidant and inhibitor of advanced glycosylation end products (AGEs).
36358951	5	0	theme	%	904:904	arg1	sponges					906:912	ACS-2.5% sponges	897:912	ACS-2.5% sponges	897:912	ACS-2.5% sponges facilitated wound closure and promoted angiogenesis and re-epithelialization in the dermis.
36358951	2	1	theme	Sargassum	444:452	arg1	polysaccharides					463:477	Sargassum pallidum polysaccharides	444:477	Sargassum pallidum polysaccharides	444:477	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	6	2	theme	polysaccharides	1092:1106	arg1	polysaccharides					1092:1106	Sargassum pallidum polysaccharides	1073:1106	Sargassum pallidum polysaccharides	1073:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	6	2	theme	polysaccharides	1092:1106	arg1	amount					1063:1068	a certain amount	1053:1068	a certain amount of Sargassum pallidum polysaccharides	1053:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	0	3	theme	Wounds	121:126	arg1	Healing					95:101	the Healing	91:101	the Healing of Full-Thickness Wounds	91:126	Bio-Multifunctional Sponges Containing Alginate/Chitosan/Sargassum Polysaccharides Promote the Healing of Full-Thickness Wounds.
36358951	3	4	with	sponges	591:597	arg1	concentrations					614:627	different concentrations	604:627	different concentrations of Sargassum pallidum polysaccharides	604:665	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides were obtained and termed AC, ACS-1%, ACS-2.5%, and ACS-5%.
36358951	6	5	theme	pallidum	1083:1090	arg1	polysaccharides					1092:1106	Sargassum pallidum polysaccharides	1073:1106	Sargassum pallidum polysaccharides	1073:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	1	6	theme	wound	161:165	arg1	dressings					167:175	bio-multifunctional wound dressings	141:175	bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features	141:259	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	6	7	theme	Sargassum	1073:1081	arg1	polysaccharides					1092:1106	Sargassum pallidum polysaccharides	1073:1106	Sargassum pallidum polysaccharides	1073:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	1	8	dep	hemostatic	189:198	arg1	features					252:259	features	252:259	features	252:259	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	1	9	theme	clinical	333:340	arg1	applications					342:353	clinical applications	333:353	clinical applications	333:353	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	4	10	theme	water	787:791	arg1	porosity					772:779	porosity	772:779	porosity	772:779	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	10	theme	water	787:791	arg1	rate					812:815	high water vapor transmission rate	782:815	high water vapor transmission rate	782:815	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	3	11	theme	pallidum	642:649	arg1	polysaccharides					651:665	Sargassum pallidum polysaccharides	632:665	Sargassum pallidum polysaccharides	632:665	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides were obtained and termed AC, ACS-1%, ACS-2.5%, and ACS-5%.
36358951	3	12	theme	polysaccharides	651:665	arg1	concentrations					614:627	different concentrations	604:627	different concentrations of Sargassum pallidum polysaccharides	604:665	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides were obtained and termed AC, ACS-1%, ACS-2.5%, and ACS-5%.
36358951	1	13	with	dressings	167:175	arg1	angiogenesis					239:250	angiogenesis	239:250	angiogenesis	239:250	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	1	13	with	dressings	167:175	arg1	antibacterial					201:213	antibacterial	201:213	antibacterial	201:213	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	1	13	with	dressings	167:175	arg1	hemostatic					189:198	hemostatic	189:198	hemostatic	189:198	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	1	13	with	dressings	167:175	arg1	anti-inflammatory					216:232	anti-inflammatory	216:232	anti-inflammatory	216:232	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	4	14	theme	water	823:827	arg1	porosity					772:779	porosity	772:779	porosity	772:779	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	14	theme	water	823:827	arg1	absorption					829:838	high water absorption	818:838	high water absorption	818:838	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	2	15	theme	electrostatic	487:499	arg1	interactions					501:512	electrostatic interactions	487:512	electrostatic interactions	487:512	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	0	16	theme	Bio-Multifunctional	0:18	arg1	Sponges					20:26	Bio-Multifunctional Sponges	0:26	Bio-Multifunctional Sponges Containing Alginate/Chitosan/Sargassum Polysaccharides	0:81	Bio-Multifunctional Sponges Containing Alginate/Chitosan/Sargassum Polysaccharides Promote the Healing of Full-Thickness Wounds.
36358951	4	17	theme	vapor	793:797	arg1	porosity					772:779	porosity	772:779	porosity	772:779	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	17	theme	vapor	793:797	arg1	rate					812:815	high water vapor transmission rate	782:815	high water vapor transmission rate	782:815	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	2	18	dep	coupling	408:415	arg1	alginate					417:424	alginate	417:424	alginate	417:424	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	4	19	theme	%	744:744	arg1	sponges					746:752	ACS-1% and ACS-2.5% sponges	726:752	ACS-1% and ACS-2.5% sponges	726:752	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	0	20	theme	Alginate/Chitosan/Sargassum	39:65	arg1	Polysaccharides					67:81	Alginate/Chitosan/Sargassum Polysaccharides	39:81	Alginate/Chitosan/Sargassum Polysaccharides	39:81	Bio-Multifunctional Sponges Containing Alginate/Chitosan/Sargassum Polysaccharides Promote the Healing of Full-Thickness Wounds.
36358951	6	21	theme	certain	1055:1061	arg1	polysaccharides					1092:1106	Sargassum pallidum polysaccharides	1073:1106	Sargassum pallidum polysaccharides	1073:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	6	21	theme	certain	1055:1061	arg1	amount					1063:1068	a certain amount	1053:1068	a certain amount of Sargassum pallidum polysaccharides	1053:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	2	22	theme	composite	387:395	arg1	sponges					397:403	bio-multifunctional composite sponges	367:403	bio-multifunctional composite sponges	367:403	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	2	23	theme	Ca2+	528:531	arg1	crosslinking					534:545	calcium ion (Ca2+) crosslinking	515:545	calcium ion (Ca2+) crosslinking	515:545	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	2	24	theme	bio-multifunctional	367:385	arg1	sponges					397:403	bio-multifunctional composite sponges	367:403	bio-multifunctional composite sponges	367:403	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	6	25	theme	full-thickness	1143:1156	arg1	wounds					1163:1168	full-thickness skin wounds	1143:1168	full-thickness skin wounds	1143:1168	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	3	26	theme	different	604:612	arg1	concentrations					614:627	different concentrations	604:627	different concentrations of Sargassum pallidum polysaccharides	604:665	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides were obtained and termed AC, ACS-1%, ACS-2.5%, and ACS-5%.
36358951	2	27	with	coupling	408:415	arg1	polysaccharides					463:477	Sargassum pallidum polysaccharides	444:477	Sargassum pallidum polysaccharides	444:477	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	6	28	contain	containing	1042:1051	arg2	amount					1063:1068	a certain amount	1053:1068	a certain amount of Sargassum pallidum polysaccharides	1053:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	6	28	contain	containing	1042:1051	arg1	sponges					1034:1040	ACS sponges	1030:1040	ACS sponges containing a certain amount of Sargassum pallidum polysaccharides	1030:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	6	28	contain	containing	1042:1051	arg2	polysaccharides					1092:1106	Sargassum pallidum polysaccharides	1073:1106	Sargassum pallidum polysaccharides	1073:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	6	29	theme	wounds	1163:1168	arg1	treatment					1130:1138	treatment	1130:1138	treatment of full-thickness skin wounds	1130:1168	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	2	30	theme	ion	523:525	arg1	crosslinking					534:545	calcium ion (Ca2+) crosslinking	515:545	calcium ion (Ca2+) crosslinking	515:545	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	2	31	with	chitosan	430:437	arg1	polysaccharides					463:477	Sargassum pallidum polysaccharides	444:477	Sargassum pallidum polysaccharides	444:477	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	4	32	theme	antibacterial	872:884	arg1	abilities					886:894	good hemostatic and antibacterial abilities	852:894	porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities	772:894	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	2	33	theme	calcium	515:521	arg1	crosslinking					534:545	calcium ion (Ca2+) crosslinking	515:545	calcium ion (Ca2+) crosslinking	515:545	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
36358951	6	34	theme	ACS	1030:1032	arg1	sponges					1034:1040	ACS sponges	1030:1040	ACS sponges containing a certain amount of Sargassum pallidum polysaccharides	1030:1106	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	4	35	theme	%	731:731	arg1	sponges					746:752	ACS-1% and ACS-2.5% sponges	726:752	ACS-1% and ACS-2.5% sponges	726:752	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	1	36	theme	dressings	167:175	arg1	Creation					129:136	Creation	129:136	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds	129:311	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	4	37	theme	high	782:785	arg1	porosity					772:779	porosity	772:779	porosity	772:779	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	37	theme	high	782:785	arg1	rate					812:815	high water vapor transmission rate	782:815	high water vapor transmission rate	782:815	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	38	theme	good	852:855	arg1	abilities					886:894	good hemostatic and antibacterial abilities	852:894	porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities	772:894	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	39	theme	transmission	799:810	arg1	porosity					772:779	porosity	772:779	porosity	772:779	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	39	theme	transmission	799:810	arg1	rate					812:815	high water vapor transmission rate	782:815	high water vapor transmission rate	782:815	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	1	40	theme	bio-multifunctional	141:159	arg1	dressings					167:175	bio-multifunctional wound dressings	141:175	bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features	141:259	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	6	41	theme	skin	1158:1161	arg1	wounds					1163:1168	full-thickness skin wounds	1143:1168	full-thickness skin wounds	1143:1168	These data suggest that ACS sponges containing a certain amount of Sargassum pallidum polysaccharides could be employed for treatment of full-thickness skin wounds.
36358951	4	42	theme	high	818:821	arg1	porosity					772:779	porosity	772:779	porosity	772:779	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	4	42	theme	high	818:821	arg1	absorption					829:838	high water absorption	818:838	high water absorption	818:838	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	3	43	theme	Sargassum	632:640	arg1	polysaccharides					651:665	Sargassum pallidum polysaccharides	632:665	Sargassum pallidum polysaccharides	632:665	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides were obtained and termed AC, ACS-1%, ACS-2.5%, and ACS-5%.
36358951	1	44	theme	full-thickness	291:304	arg1	wounds					306:311	full-thickness wounds	291:311	full-thickness wounds	291:311	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	0	45	theme	Full-Thickness	106:119	arg1	Wounds					121:126	Full-Thickness Wounds	106:126	Full-Thickness Wounds	106:126	Bio-Multifunctional Sponges Containing Alginate/Chitosan/Sargassum Polysaccharides Promote the Healing of Full-Thickness Wounds.
36358951	5	46	theme	wound	926:930	arg1	closure					932:938	wound closure	926:938	wound closure	926:938	ACS-2.5% sponges facilitated wound closure and promoted angiogenesis and re-epithelialization in the dermis.
36358951	3	47	theme	Alginate/chitosan	568:584	arg1	sponges					591:597	Alginate/chitosan (AC) sponges	568:597	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides	568:665	Alginate/chitosan (AC) sponges with different concentrations of Sargassum pallidum polysaccharides were obtained and termed AC, ACS-1%, ACS-2.5%, and ACS-5%.
36358951	1	48	theme	wounds	306:311	arg1	healing					280:286	the healing	276:286	the healing of full-thickness wounds	276:311	Creation of bio-multifunctional wound dressings with potent hemostatic, antibacterial, anti-inflammatory, and angiogenesis features for bolstering the healing of full-thickness wounds is sought after for clinical applications.
36358951	4	49	theme	hemostatic	857:866	arg1	abilities					886:894	good hemostatic and antibacterial abilities	852:894	porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities	772:894	ACS-1% and ACS-2.5% sponges exhibited uniform porosity, high water vapor transmission rate, high water absorption, as well as good hemostatic and antibacterial abilities.
36358951	2	50	theme	pallidum	454:461	arg1	polysaccharides					463:477	Sargassum pallidum polysaccharides	444:477	Sargassum pallidum polysaccharides	444:477	We created bio-multifunctional composite sponges by coupling alginate and chitosan with Sargassum pallidum polysaccharides through electrostatic interactions, calcium ion (Ca2+) crosslinking, and lyophilization.
35878444	1	0	theme	Se	153:154	arg1	incorporation					156:168	a covalent Se incorporation	142:168	a covalent Se incorporation	142:168	polysaccharides in response to a covalent Se incorporation.
35878444	6	1	with	YPS	1086:1088	arg1	immuno-stimulation					1103:1120	greater immuno-stimulation	1095:1120	greater immuno-stimulation	1095:1120	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	5	2	theme	splenic	959:965	arg1	lymphocytes					967:977	CD4+ splenic lymphocytes	954:977	CD4+ splenic lymphocytes	954:977	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	3	3	with	SeYPS-2	529:535	arg1	contents					556:563	respective Se contents	542:563	respective Se contents of 719 and 1585 mg/kg	542:585	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	6	4	theme	greater	1095:1101	arg1	immuno-stimulation					1103:1120	greater immuno-stimulation	1095:1120	greater immuno-stimulation	1095:1120	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	3	5	theme	mucilage	376:383	arg1	YPS					402:404	YPS	402:404	YPS	402:404	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	5	theme	mucilage	376:383	arg1	polysaccharides					385:399	the soluble yam mucilage polysaccharides	360:399	the soluble yam mucilage polysaccharides (YPS)	360:405	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	5	6	theme	lymphocytes	967:977	arg1	contents					894:901	the elevated contents	881:901	the elevated contents of serum immunoglobins	881:924	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	6	theme	lymphocytes	967:977	arg1	percentage					940:949	increased percentage	930:949	increased percentage of CD4+ splenic lymphocytes	930:977	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	3	7	theme	1585 mg/kg	576:585	arg1	contents					556:563	respective Se contents	542:563	respective Se contents of 719 and 1585 mg/kg	542:585	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	4	8	theme	GC-MS	608:612	arg1	analysis					614:621	GC-MS analysis	608:621	GC-MS analysis	608:621	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	3	9	theme	719	568:570	arg1	contents					556:563	respective Se contents	542:563	respective Se contents of 719 and 1585 mg/kg	542:585	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	5	10	theme	increased	930:938	arg1	percentage					940:949	increased percentage	930:949	increased percentage of CD4+ splenic lymphocytes	930:977	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	3	11	theme	soluble	364:370	arg1	YPS					402:404	YPS	402:404	YPS	402:404	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	11	theme	soluble	364:370	arg1	polysaccharides					385:399	the soluble yam mucilage polysaccharides	360:399	the soluble yam mucilage polysaccharides (YPS)	360:405	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	4	12	theme	compositional	645:657	arg1	features					659:666	the compositional features	641:666	the compositional features of SeYPS-1 and SeYPS-2	641:689	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	4	12	theme	compositional	645:657	arg1	similar					696:702	similar	696:702	similar	696:702	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	3	13	theme	Se	553:554	arg1	contents					556:563	respective Se contents	542:563	respective Se contents of 719 and 1585 mg/kg	542:585	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	6	14	theme	endowed	1078:1084	arg1	YPS					1086:1088	endowed YPS	1078:1088	endowed YPS with greater immuno-stimulation	1078:1120	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	4	15	theme	SeYPS-2	683:689	arg1	features					659:666	the compositional features	641:666	the compositional features of SeYPS-1 and SeYPS-2	641:689	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	4	15	theme	SeYPS-2	683:689	arg1	similar					696:702	similar	696:702	similar	696:702	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	3	16	theme	yam	372:374	arg1	YPS					402:404	YPS	402:404	YPS	402:404	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	16	theme	yam	372:374	arg1	polysaccharides					385:399	the soluble yam mucilage polysaccharides	360:399	the soluble yam mucilage polysaccharides (YPS)	360:405	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	6	17	from	composition	1043:1053	arg1	mice					1129:1132	the mice	1125:1132	the mice	1125:1132	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	6	18	theme	YPS	1086:1088	arg1	composition					1043:1053	the composition	1039:1053	the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice	1039:1132	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	5	19	theme	BALB/c	821:826	arg1	mice					828:831	the BALB/c mice	817:831	the BALB/c mice	817:831	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	20	theme	selenylated	772:782	arg1	products					784:791	the selenylated products	768:791	the selenylated products	768:791	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	20	theme	selenylated	772:782	arg1	SeYPS-2					805:811	SeYPS-2	805:811	SeYPS-2	805:811	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	6	21	theme	selenylation	1162:1173	arg1	extent					1152:1157	the higher extent	1141:1157	the higher extent of selenylation	1141:1173	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	2	22	dep	in	284:285	arg1	vivo					287:290	vivo	287:290	vivo	287:290	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	2	22	dep	in	284:285	arg1	immuno-stimulatory					292:309	immuno-stimulatory	292:309	immuno-stimulatory	292:309	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	0	23	theme	Monosaccharide	0:13	arg1	Thunb					103:107	Thunb	103:107	Thunb	103:107	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	0	23	theme	Monosaccharide	0:13	arg1	composition					15:25	Monosaccharide composition	0:25	Monosaccharide composition	0:25	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	3	24	with	SeYPS-1	517:523	arg1	contents					556:563	respective Se contents	542:563	respective Se contents of 719 and 1585 mg/kg	542:585	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	1	25	dep	incorporation	156:168	arg1	response					130:137	response	130:137	response	130:137	polysaccharides in response to a covalent Se incorporation.
35878444	3	26	theme	HNO3-Na2SeO3	444:455	arg1	system					457:462	the HNO3-Na2SeO3 system	440:462	the HNO3-Na2SeO3 system	440:462	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	0	27	theme	in	31:32	arg1	potential					58:66	in vivo immuno-stimulatory potential	31:66	in vivo immuno-stimulatory potential of soluble yam	31:81	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	6	28	theme	immuno-stimulatory	1203:1220	arg1	potential					1222:1230	a much enhanced immuno-stimulatory potential	1187:1230	a much enhanced immuno-stimulatory potential of SeYPS-2	1187:1241	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	6	29	theme	SeYPS-2	1235:1241	arg1	potential					1222:1230	a much enhanced immuno-stimulatory potential	1187:1230	a much enhanced immuno-stimulatory potential of SeYPS-2	1187:1241	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	2	30	theme	polysaccharides	328:342	arg1	potential					311:319	in vivo immuno-stimulatory potential	284:319	in vivo immuno-stimulatory potential of yam polysaccharides	284:342	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	2	30	theme	polysaccharides	328:342	arg1	features					271:278	compositional features	257:278	compositional features	257:278	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	3	31	theme	selenylated	473:483	arg1	SeYPS-2					529:535	SeYPS-2	529:535	SeYPS-2	529:535	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	31	theme	selenylated	473:483	arg1	products					500:507	two selenylated polysaccharide products	469:507	two selenylated polysaccharide products	469:507	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	31	theme	selenylated	473:483	arg1	SeYPS-1					517:523	SeYPS-1	517:523	SeYPS-1	517:523	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	2	32	theme	yam	324:326	arg1	polysaccharides					328:342	yam polysaccharides	324:342	yam polysaccharides	324:342	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	3	33	theme	polysaccharide	485:498	arg1	SeYPS-2					529:535	SeYPS-2	529:535	SeYPS-2	529:535	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	33	theme	polysaccharide	485:498	arg1	products					500:507	two selenylated polysaccharide products	469:507	two selenylated polysaccharide products	469:507	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	3	33	theme	polysaccharide	485:498	arg1	SeYPS-1					517:523	SeYPS-1	517:523	SeYPS-1	517:523	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	2	34	theme	present	175:181	arg1	study					183:187	The present study	171:187	The present study	171:187	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	4	35	theme	SeYPS-1	671:677	arg1	features					659:666	the compositional features	641:666	the compositional features of SeYPS-1 and SeYPS-2	641:689	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	4	35	theme	SeYPS-1	671:677	arg1	similar					696:702	similar	696:702	similar	696:702	GC-MS analysis demonstrated that the compositional features of SeYPS-1 and SeYPS-2 were similar to those of YPS.
35878444	5	36	theme	immuno-stimulatory	736:753	arg1	Meanwhile					721:729	Meanwhile	721:729	Meanwhile	721:729	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	36	theme	immuno-stimulatory	736:753	arg1	potential					755:763	the immuno-stimulatory potential	732:763	the immuno-stimulatory potential of the selenylated products, especially SeYPS-2	732:811	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	37	theme	products	784:791	arg1	Meanwhile					721:729	Meanwhile	721:729	Meanwhile	721:729	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	37	theme	products	784:791	arg1	potential					755:763	the immuno-stimulatory potential	732:763	the immuno-stimulatory potential of the selenylated products, especially SeYPS-2	732:811	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	38	theme	serum	906:910	arg1	immunoglobins					912:924	serum immunoglobins	906:924	serum immunoglobins	906:924	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	2	39	theme	selenylation	218:229	arg1	modification					231:242	selenylation modification	218:242	selenylation modification	218:242	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	5	40	theme	immunoglobins	912:924	arg1	contents					894:901	the elevated contents	881:901	the elevated contents of serum immunoglobins	881:924	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	5	40	theme	immunoglobins	912:924	arg1	percentage					940:949	increased percentage	930:949	increased percentage of CD4+ splenic lymphocytes	930:977	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	6	41	theme	enhanced	1194:1201	arg1	potential					1222:1230	a much enhanced immuno-stimulatory potential	1187:1230	a much enhanced immuno-stimulatory potential of SeYPS-2	1187:1241	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	0	42	dep	in	31:32	arg1	immuno-stimulatory					39:56	immuno-stimulatory	39:56	immuno-stimulatory	39:56	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	0	42	dep	in	31:32	arg1	vivo					34:37	vivo	34:37	vivo	34:37	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	2	43	theme	in	284:285	arg1	potential					311:319	in vivo immuno-stimulatory potential	284:319	in vivo immuno-stimulatory potential of yam polysaccharides	284:342	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	5	44	theme	CD4+	954:957	arg1	lymphocytes					967:977	CD4+ splenic lymphocytes	954:977	CD4+ splenic lymphocytes	954:977	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	3	45	theme	respective	542:551	arg1	contents					556:563	respective Se contents	542:563	respective Se contents of 719 and 1585 mg/kg	542:585	In this study, the soluble yam mucilage polysaccharides (YPS) were prepared and selenylated in the HNO3-Na2SeO3 system, and two selenylated polysaccharide products, namely SeYPS-1 and SeYPS-2 with respective Se contents of 719 and 1585 mg/kg, were thus obtained.
35878444	0	46	theme	yam	79:81	arg1	Thunb					103:107	Thunb	103:107	Thunb	103:107	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	0	46	theme	yam	79:81	arg1	potential					58:66	in vivo immuno-stimulatory potential	31:66	in vivo immuno-stimulatory potential of soluble yam	31:81	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	0	46	theme	yam	79:81	arg1	composition					15:25	Monosaccharide composition	0:25	Monosaccharide composition	0:25	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	5	47	dep	higher	843:848	arg1	reflected					868:876	reflected	868:876	reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes	868:977	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	6	48	theme	monosaccharides	1058:1072	arg1	composition					1043:1053	the composition	1039:1053	the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice	1039:1132	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	5	49	theme	elevated	885:892	arg1	contents					894:901	the elevated contents	881:901	the elevated contents of serum immunoglobins	881:924	Meanwhile, the immuno-stimulatory potential of the selenylated products, especially SeYPS-2, in the BALB/c mice model was higher than that of YPS, reflected by the elevated contents of serum immunoglobins and increased percentage of CD4+ splenic lymphocytes.
35878444	0	50	theme	soluble	71:77	arg1	yam					79:81	soluble yam	71:81	soluble yam	71:81	Monosaccharide composition and in vivo immuno-stimulatory potential of soluble yam (Dioscorea opposita Thunb.)
35878444	6	51	theme	higher	1145:1150	arg1	extent					1152:1157	the higher extent	1141:1157	the higher extent of selenylation	1141:1173	It was thus confirmed that the selenylation did not change the composition of monosaccharides but endowed YPS with greater immuno-stimulation in the mice, while the higher extent of selenylation also caused a much enhanced immuno-stimulatory potential of SeYPS-2.
35878444	2	52	theme	compositional	257:269	arg1	features					271:278	compositional features	257:278	compositional features	257:278	The present study aimed to investigate whether selenylation modification could affect compositional features and in vivo immuno-stimulatory potential of yam polysaccharides.
35878444	1	53	theme	covalent	144:151	arg1	incorporation					156:168	a covalent Se incorporation	142:168	a covalent Se incorporation	142:168	polysaccharides in response to a covalent Se incorporation.
37398203	9	0	theme	N	1530:1530	arg1	site					1547:1550	This novel N -glycosylation site	1519:1550	This novel N -glycosylation site (absent in the germline sequence)	1519:1584	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	9	0	theme	N	1530:1530	arg1	result					1591:1596	a result	1589:1596	a result of a single mutation giving rise to an NDT motif in the antibody sequence	1589:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	2	1	theme	antibodies	354:363	arg1	production					340:349	production	340:349	production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine	340:427	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	10	2	theme	light	1929:1933	arg1	chain					1935:1939	the light chain	1925:1939	the light chain (λ and κ)	1925:1949	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	4	3	theme	ensemble	590:597	arg1	fraction					573:580	a significant fraction	559:580	a significant fraction of this ensemble	559:597	Intact-mass MS measurements indicate that a significant fraction of this ensemble is comprised of antibodies representing a limited number of clones.
37398203	10	4	theme	anti-PF4	1813:1820	arg1	ensemble					1831:1838	the anti-PF4 antibody ensemble	1809:1838	the anti-PF4 antibody ensemble	1809:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	5	5	theme	MS	667:668	arg1	analysis					670:677	MS analysis	667:677	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain)	667:780	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	4	6	theme	clones	659:664	arg1	number					649:654	a limited number	639:654	a limited number of clones	639:664	Intact-mass MS measurements indicate that a significant fraction of this ensemble is comprised of antibodies representing a limited number of clones.
37398203	0	7	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pathogenic antibody	0:51	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	5	8	theme	component	821:829	arg1	nature					806:811	the monoclonal nature	791:811	the monoclonal nature of this component of the anti-PF4 antibodies repertoire	791:867	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	1	9	theme	dangerous	205:213	arg1	thrombocytopenia					157:172	Vaccine-induced immune thrombotic thrombocytopenia	123:172	Vaccine-induced immune thrombotic thrombocytopenia (VITT)	123:179	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	9	theme	dangerous	205:213	arg1	effect					220:225	a rare but extremely dangerous side effect	184:225	a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines	184:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	6	10	theme	chain	1104:1108	arg1	sequence					1075:1082	the amino acid sequence	1060:1082	the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment)	1060:1179	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	10	11	theme	ensemble	1831:1838	arg1	component					1796:1804	the polyclonal component	1781:1804	the polyclonal component of the anti-PF4 antibody ensemble	1781:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	2	12	theme	VITT	306:309	arg1	pathology					311:319	VITT pathology	306:319	VITT pathology	306:319	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	5	13	theme	monoclonal	795:804	arg1	nature					806:811	the monoclonal nature	791:811	the monoclonal nature of this component of the anti-PF4 antibodies repertoire	791:867	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	5	14	theme	light	712:716	arg1	chain					718:722	the light chain	708:722	the light chain	708:722	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	8	15	theme	peptide	1379:1385	arg1	routine					1395:1401	the peptide mapping routine	1375:1401	the peptide mapping routine	1375:1401	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	6	16	theme	short	1155:1159	arg1	segment					1172:1178	a short N-terminal segment	1153:1178	a short N-terminal segment	1153:1178	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	1	17	theme	thrombotic	146:155	arg1	thrombocytopenia					157:172	Vaccine-induced immune thrombotic thrombocytopenia	123:172	Vaccine-induced immune thrombotic thrombocytopenia (VITT)	123:179	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	17	theme	thrombotic	146:155	arg1	effect					220:225	a rare but extremely dangerous side effect	184:225	a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines	184:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	17	theme	thrombotic	146:155	arg1	VITT					175:178	VITT	175:178	VITT	175:178	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	5	18	theme	antibody	688:695	arg1	fragments					697:705	large antibody fragments	682:705	large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain)	682:780	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	9	19	theme	mutation	1610:1617	arg1	site					1547:1550	This novel N -glycosylation site	1519:1550	This novel N -glycosylation site (absent in the germline sequence)	1519:1584	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	9	19	theme	mutation	1610:1617	arg1	result					1591:1596	a result	1589:1596	a result of a single mutation giving rise to an NDT motif in the antibody sequence	1589:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	6	20	theme	chain	1136:1140	arg1	%					1121:1121	98%	1119:1121	98% of the heavy chain (excluding a short N-terminal segment)	1119:1179	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	6	20	theme	chain	1136:1140	arg1	chain					1136:1140	the heavy chain	1126:1140	the heavy chain (excluding a short N-terminal segment)	1126:1179	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	10	21	theme	subclasses	1876:1885	arg1	presence					1855:1862	the presence	1851:1862	the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ)	1851:1949	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	0	22	theme	immune	80:85	arg1	thrombocytopenia					98:113	vaccine-induced immune thrombotic thrombocytopenia	64:113	vaccine-induced immune thrombotic thrombocytopenia (VITT)	64:120	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	0	22	theme	immune	80:85	arg1	VITT					116:119	VITT	116:119	VITT	116:119	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	10	23	theme	Peptide	1673:1679	arg1	mapping					1681:1687	Peptide mapping	1673:1687	Peptide mapping	1673:1687	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	5	24	theme	antibodies	847:856	arg1	repertoire					858:867	the anti-PF4 antibodies repertoire	834:867	the anti-PF4 antibodies repertoire	834:867	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	6	25	theme	Peptide	965:971	arg1	mapping					973:979	Peptide mapping	965:979	Peptide mapping using two complementary proteases	965:1013	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	5	26	dep	fragments	697:705	arg1	chain					718:722	the light chain	708:722	the light chain	708:722	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	5	26	dep	fragments	697:705	arg1	fragments					752:760	the Fc/2 and Fd fragments	736:760	fragments	752:760	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	1	27	theme	Vaccine-induced	123:137	arg1	thrombocytopenia					157:172	Vaccine-induced immune thrombotic thrombocytopenia	123:172	Vaccine-induced immune thrombotic thrombocytopenia (VITT)	123:179	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	27	theme	Vaccine-induced	123:137	arg1	effect					220:225	a rare but extremely dangerous side effect	184:225	a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines	184:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	27	theme	Vaccine-induced	123:137	arg1	VITT					175:178	VITT	175:178	VITT	175:178	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	5	28	theme	biantennary	921:931	arg1	N-glycan					933:940	a fully mature complex biantennary N-glycan	898:940	a fully mature complex biantennary N-glycan	898:940	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	11	29	theme	VITT	2068:2071	arg1	pathogenesis					2073:2084	VITT pathogenesis	2068:2084	VITT pathogenesis	2068:2084	The structural information reported in this work will be indispensable for understanding the molecular mechanism of VITT pathogenesis.
37398203	0	30	theme	antibody	44:51	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pathogenic antibody	0:51	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	5	31	theme	chain	775:779	arg1	chain					718:722	the light chain	708:722	the light chain	708:722	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	5	31	theme	chain	775:779	arg1	fragments					752:760	the Fc/2 and Fd fragments	736:760	fragments	752:760	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	1	32	theme	-vectored	277:285	arg1	vaccines					296:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	6	33	used	used	1042:1045	arg2	mapping					973:979	Peptide mapping	965:979	Peptide mapping using two complementary proteases	965:1013	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	6	33	used	used	1042:1045	arg2	analysis					1028:1035	LC-MS/MS analysis	1019:1035	LC-MS/MS analysis	1019:1035	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	7	34	theme	IgG2	1253:1256	arg1	subclass					1258:1265	IgG2 subclass	1253:1265	IgG2 subclass	1253:1265	The sequence analysis allows the monoclonal antibody to be assigned to IgG2 subclass and verify that the light chain belongs to the λ-type.
37398203	2	35	theme	endogenous	408:417	arg1	chemokine					419:427	an endogenous chemokine	405:427	an endogenous chemokine	405:427	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	2	35	theme	endogenous	408:417	arg1	factor					389:394	platelet factor 4	380:396	platelet factor 4 (PF4)	380:402	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	8	36	from	-glycan	1416:1422	arg1	region					1435:1440	the Fab region	1427:1440	the Fab region of the antibody to be localized to the framework 3 region of the V H domain	1427:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	9	37	from	motif	1641:1645	arg1	sequence					1663:1670	the antibody sequence	1650:1670	the antibody sequence	1650:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	5	38	theme	mature	906:911	arg1	N-glycan					933:940	a fully mature complex biantennary N-glycan	898:940	a fully mature complex biantennary N-glycan	898:940	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	0	39	theme	pathogenic	33:42	arg1	antibody					44:51	a pathogenic antibody	31:51	a pathogenic antibody	31:51	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	6	40	theme	complementary	991:1003	arg1	proteases					1005:1013	two complementary proteases	987:1013	two complementary proteases	987:1013	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	8	41	theme	framework	1481:1489	arg1	region					1493:1498	the framework 3 region	1477:1498	the framework 3 region of the V H domain	1477:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	11	42	theme	structural	1956:1965	arg1	indispensable					2009:2021	indispensable	2009:2021	indispensable	2009:2021	The structural information reported in this work will be indispensable for understanding the molecular mechanism of VITT pathogenesis.
37398203	11	42	theme	structural	1956:1965	arg1	information					1967:1977	The structural information	1952:1977	The structural information reported in this work	1952:1999	The structural information reported in this work will be indispensable for understanding the molecular mechanism of VITT pathogenesis.
37398203	7	43	theme	monoclonal	1215:1224	arg1	antibody					1226:1233	the monoclonal antibody	1211:1233	the monoclonal antibody	1211:1233	The sequence analysis allows the monoclonal antibody to be assigned to IgG2 subclass and verify that the light chain belongs to the λ-type.
37398203	4	44	theme	MS	529:530	arg1	measurements					532:543	Intact-mass MS measurements	517:543	Intact-mass MS measurements	517:543	Intact-mass MS measurements indicate that a significant fraction of this ensemble is comprised of antibodies representing a limited number of clones.
37398203	10	45	theme	proteolytic	1746:1756	arg1	fragments					1758:1766	lower-abundance proteolytic fragments	1730:1766	lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble	1730:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	8	46	theme	de-	1349:1351	arg1	-glycosylation					1355:1368	enzymatic de- N -glycosylation	1339:1368	enzymatic de- N -glycosylation	1339:1368	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	5	47	theme	Fd	953:954	arg1	segment					956:962	its Fd segment	949:962	its Fd segment	949:962	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	10	48	theme	types	1916:1920	arg1	presence					1855:1862	the presence	1851:1862	the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ)	1851:1949	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	8	49	theme	-glycosylation	1355:1368	arg1	Incorporation					1322:1334	Incorporation	1322:1334	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine	1322:1401	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	2	50	theme	platelet	380:387	arg1	factor					389:394	platelet factor 4	380:396	platelet factor 4 (PF4)	380:402	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	2	50	theme	platelet	380:387	arg1	PF4					399:401	PF4	399:401	PF4	399:401	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	2	50	theme	platelet	380:387	arg1	chemokine					419:427	an endogenous chemokine	405:427	an endogenous chemokine	405:427	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	9	51	theme	novel	1524:1528	arg1	site					1547:1550	This novel N -glycosylation site	1519:1550	This novel N -glycosylation site (absent in the germline sequence)	1519:1584	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	9	51	theme	novel	1524:1528	arg1	result					1591:1596	a result	1589:1596	a result of a single mutation giving rise to an NDT motif in the antibody sequence	1589:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	7	52	theme	sequence	1186:1193	arg1	analysis					1195:1202	The sequence analysis	1182:1202	The sequence analysis	1182:1202	The sequence analysis allows the monoclonal antibody to be assigned to IgG2 subclass and verify that the light chain belongs to the λ-type.
37398203	8	53	theme	V	1507:1507	arg1	domain					1511:1516	the V H domain	1503:1516	the V H domain	1503:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	3	54	theme	VITT	495:498	arg1	patient					500:506	a VITT patient's	493:508	a VITT patient's blood	493:514	In this work we characterize anti-PF4 antibodies obtained from a VITT patient's blood.
37398203	1	55	theme	adenoviral	262:271	arg1	vaccines					296:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	9	56	theme	-glycosylation	1532:1545	arg1	site					1547:1550	This novel N -glycosylation site	1519:1550	This novel N -glycosylation site (absent in the germline sequence)	1519:1584	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	9	56	theme	-glycosylation	1532:1545	arg1	result					1591:1596	a result	1589:1596	a result of a single mutation giving rise to an NDT motif in the antibody sequence	1589:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	10	57	dep	chain	1935:1939	arg1	κ					1948:1948	κ	1948:1948	κ	1948:1948	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	10	57	dep	chain	1935:1939	arg1	λ					1942:1942	λ	1942:1942	λ	1942:1942	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	10	58	theme	chain	1935:1939	arg1	subclasses					1876:1885	all four subclasses	1867:1885	all four subclasses (IgG1 through IgG4)	1867:1905	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	10	58	theme	chain	1935:1939	arg1	types					1916:1920	both types	1911:1920	both types of the light chain (λ and κ)	1911:1949	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	8	59	theme	domain	1511:1516	arg1	region					1493:1498	the framework 3 region	1477:1498	the framework 3 region of the V H domain	1477:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	1	60	theme	Ad	274:275	arg1	vaccines					296:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	61	theme	rare	186:189	arg1	thrombocytopenia					157:172	Vaccine-induced immune thrombotic thrombocytopenia	123:172	Vaccine-induced immune thrombotic thrombocytopenia (VITT)	123:179	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	61	theme	rare	186:189	arg1	effect					220:225	a rare but extremely dangerous side effect	184:225	a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines	184:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	2	62	attach	linked	330:335	arg1	production					340:349	production	340:349	production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine	340:427	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	2	62	attach	linked	330:335	arg2	pathology					311:319	VITT pathology	306:319	VITT pathology	306:319	VITT pathology had been linked to production of antibodies that recognize platelet factor 4 (PF4), an endogenous chemokine.
37398203	9	63	theme	germline	1567:1574	arg1	sequence					1576:1583	the germline sequence	1563:1583	the germline sequence	1563:1583	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	5	64	theme	fragments	697:705	arg1	analysis					670:677	MS analysis	667:677	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain)	667:780	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	1	65	theme	side	215:218	arg1	thrombocytopenia					157:172	Vaccine-induced immune thrombotic thrombocytopenia	123:172	Vaccine-induced immune thrombotic thrombocytopenia (VITT)	123:179	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	65	theme	side	215:218	arg1	effect					220:225	a rare but extremely dangerous side effect	184:225	a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines	184:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	9	66	from	absent	1553:1558	arg1	sequence					1576:1583	the germline sequence	1563:1583	the germline sequence	1563:1583	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	6	67	theme	light	1098:1102	arg1	chain					1104:1108	the entire light chain	1087:1108	the entire light chain	1087:1108	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	10	68	theme	antibody	1822:1829	arg1	ensemble					1831:1838	the anti-PF4 antibody ensemble	1809:1838	the anti-PF4 antibody ensemble	1809:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	8	69	theme	mapping	1387:1393	arg1	routine					1395:1401	the peptide mapping routine	1375:1401	the peptide mapping routine	1375:1401	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	6	70	theme	N-terminal	1161:1170	arg1	segment					1172:1178	a short N-terminal segment	1153:1178	a short N-terminal segment	1153:1178	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	4	71	theme	limited	641:647	arg1	number					649:654	a limited number	639:654	a limited number of clones	639:664	Intact-mass MS measurements indicate that a significant fraction of this ensemble is comprised of antibodies representing a limited number of clones.
37398203	1	72	theme	immune	139:144	arg1	thrombocytopenia					157:172	Vaccine-induced immune thrombotic thrombocytopenia	123:172	Vaccine-induced immune thrombotic thrombocytopenia (VITT)	123:179	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	72	theme	immune	139:144	arg1	effect					220:225	a rare but extremely dangerous side effect	184:225	a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines	184:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	1	72	theme	immune	139:144	arg1	VITT					175:178	VITT	175:178	VITT	175:178	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	10	73	dep	subclasses	1876:1885	arg1	IgG1					1888:1891	IgG1	1888:1891	IgG1 through IgG4	1888:1904	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	5	74	theme	large	682:686	arg1	fragments					697:705	large antibody fragments	682:705	large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain)	682:780	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	9	75	theme	single	1603:1608	arg1	mutation					1610:1617	a single mutation	1601:1617	a single mutation giving rise to an NDT motif in the antibody sequence	1601:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	8	76	theme	N	1414:1414	arg1	-glycan					1416:1422	the N -glycan	1410:1422	the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain	1410:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	7	77	theme	light	1287:1291	arg1	chain					1293:1297	the light chain	1283:1297	the light chain	1283:1297	The sequence analysis allows the monoclonal antibody to be assigned to IgG2 subclass and verify that the light chain belongs to the λ-type.
37398203	0	78	theme	thrombotic	87:96	arg1	thrombocytopenia					98:113	vaccine-induced immune thrombotic thrombocytopenia	64:113	vaccine-induced immune thrombotic thrombocytopenia (VITT)	64:120	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	0	78	theme	thrombotic	87:96	arg1	VITT					116:119	VITT	116:119	VITT	116:119	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	5	79	theme	anti-PF4	838:845	arg1	repertoire					858:867	the anti-PF4 antibodies repertoire	834:867	the anti-PF4 antibodies repertoire	834:867	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	6	80	theme	heavy	1130:1134	arg1	chain					1136:1140	the heavy chain	1126:1140	the heavy chain (excluding a short N-terminal segment)	1126:1179	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	5	81	theme	Fc/2	740:743	arg1	fragments					752:760	the Fc/2 and Fd fragments	736:760	fragments	752:760	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	5	82	theme	repertoire	858:867	arg1	component					821:829	this component	816:829	this component of the anti-PF4 antibodies repertoire	816:867	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	11	83	theme	molecular	2045:2053	arg1	mechanism					2055:2063	the molecular mechanism	2041:2063	the molecular mechanism of VITT pathogenesis	2041:2084	The structural information reported in this work will be indispensable for understanding the molecular mechanism of VITT pathogenesis.
37398203	8	84	theme	Fab	1431:1433	arg1	region					1435:1440	the Fab region	1427:1440	the Fab region of the antibody to be localized to the framework 3 region of the V H domain	1427:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	5	85	theme	complex	913:919	arg1	N-glycan					933:940	a fully mature complex biantennary N-glycan	898:940	a fully mature complex biantennary N-glycan	898:940	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	9	86	from	sequence	1576:1583	arg1	absent					1553:1558	absent	1553:1558	absent	1553:1558	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	9	87	theme	NDT	1637:1639	arg1	motif					1641:1645	an NDT motif	1634:1645	an NDT motif in the antibody sequence	1634:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	5	88	theme	N-glycan	933:940	arg1	presence					886:893	the presence	882:893	the presence of a fully mature complex biantennary N-glycan within its Fd segment	882:962	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	11	89	theme	pathogenesis	2073:2084	arg1	mechanism					2055:2063	the molecular mechanism	2041:2063	the molecular mechanism of VITT pathogenesis	2041:2084	The structural information reported in this work will be indispensable for understanding the molecular mechanism of VITT pathogenesis.
37398203	8	90	theme	antibody	1449:1456	arg1	region					1435:1440	the Fab region	1427:1440	the Fab region of the antibody to be localized to the framework 3 region of the V H domain	1427:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	5	91	theme	heavy	769:773	arg1	chain					775:779	the heavy chain	765:779	the heavy chain	765:779	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	9	92	theme	antibody	1654:1661	arg1	sequence					1663:1670	the antibody sequence	1650:1670	the antibody sequence	1650:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	1	93	theme	COVID-19	287:294	arg1	vaccines					296:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
37398203	6	94	theme	LC-MS/MS	1019:1026	arg1	analysis					1028:1035	LC-MS/MS analysis	1019:1035	LC-MS/MS analysis	1019:1035	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	4	95	theme	significant	561:571	arg1	fraction					573:580	a significant fraction	559:580	a significant fraction of this ensemble	559:597	Intact-mass MS measurements indicate that a significant fraction of this ensemble is comprised of antibodies representing a limited number of clones.
37398203	10	96	theme	information	1715:1725	arg1	wealth					1705:1710	a wealth	1703:1710	a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble	1703:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	10	97	attach	derived	1768:1774	arg2	fragments					1758:1766	lower-abundance proteolytic fragments	1730:1766	lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble	1730:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	10	97	attach	derived	1768:1774	arg1	component					1796:1804	the polyclonal component	1781:1804	the polyclonal component of the anti-PF4 antibody ensemble	1781:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	3	98	theme	anti-PF4	459:466	arg1	antibodies					468:477	anti-PF4 antibodies	459:477	anti-PF4 antibodies obtained from a VITT patient's blood	459:514	In this work we characterize anti-PF4 antibodies obtained from a VITT patient's blood.
37398203	5	99	theme	Fd	749:750	arg1	fragments					752:760	the Fc/2 and Fd fragments	736:760	fragments	752:760	MS analysis of large antibody fragments (the light chain, as well as the Fc/2 and Fd fragments of the heavy chain) confirms the monoclonal nature of this component of the anti-PF4 antibodies repertoire, and reveals the presence of a fully mature complex biantennary N-glycan within its Fd segment.
37398203	4	100	theme	Intact-mass	517:527	arg1	measurements					532:543	Intact-mass MS measurements	517:543	Intact-mass MS measurements	517:543	Intact-mass MS measurements indicate that a significant fraction of this ensemble is comprised of antibodies representing a limited number of clones.
37398203	0	101	theme	vaccine-induced	64:78	arg1	thrombocytopenia					98:113	vaccine-induced immune thrombotic thrombocytopenia	64:113	vaccine-induced immune thrombotic thrombocytopenia (VITT)	64:120	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	0	101	theme	vaccine-induced	64:78	arg1	VITT					116:119	VITT	116:119	VITT	116:119	Structural characterization of a pathogenic antibody underlying vaccine-induced immune thrombotic thrombocytopenia (VITT).
37398203	6	102	theme	entire	1091:1096	arg1	chain					1104:1108	the entire light chain	1087:1108	the entire light chain	1087:1108	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	9	103	gly	-glycosylation	1532:1545	arg2	result					1591:1596	a result	1589:1596	a result of a single mutation giving rise to an NDT motif in the antibody sequence	1589:1670	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	9	103	gly	-glycosylation	1532:1545	arg2	site					1547:1550	This novel N -glycosylation site	1519:1550	This novel N -glycosylation site (absent in the germline sequence)	1519:1584	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	10	104	theme	lower-abundance	1730:1744	arg1	fragments					1758:1766	lower-abundance proteolytic fragments	1730:1766	lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble	1730:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	8	105	theme	enzymatic	1339:1347	arg1	-glycosylation					1355:1368	enzymatic de- N -glycosylation	1339:1368	enzymatic de- N -glycosylation	1339:1368	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	6	106	theme	amino	1064:1068	arg1	sequence					1075:1082	the amino acid sequence	1060:1082	the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment)	1060:1179	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	10	107	from	wealth	1705:1710	arg1	fragments					1758:1766	lower-abundance proteolytic fragments	1730:1766	lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble	1730:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	6	108	theme	acid	1070:1073	arg1	sequence					1075:1082	the amino acid sequence	1060:1082	the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment)	1060:1179	Peptide mapping using two complementary proteases and LC-MS/MS analysis were used to determine the amino acid sequence of the entire light chain and over 98% of the heavy chain (excluding a short N-terminal segment).
37398203	8	109	theme	H	1509:1509	arg1	domain					1511:1516	the V H domain	1503:1516	the V H domain	1503:1516	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	10	110	theme	polyclonal	1785:1794	arg1	component					1796:1804	the polyclonal component	1781:1804	the polyclonal component of the anti-PF4 antibody ensemble	1781:1838	Peptide mapping also provides a wealth of information on lower-abundance proteolytic fragments derived from the polyclonal component of the anti-PF4 antibody ensemble, revealing the presence of all four subclasses (IgG1 through IgG4) and both types of the light chain (λ and κ).
37398203	8	111	theme	N	1353:1353	arg1	-glycosylation					1355:1368	enzymatic de- N -glycosylation	1339:1368	enzymatic de- N -glycosylation	1339:1368	Incorporation of enzymatic de- N -glycosylation into the peptide mapping routine allows the N -glycan in the Fab region of the antibody to be localized to the framework 3 region of the V H domain.
37398203	9	112	dep	site	1547:1550	arg1	absent					1553:1558	absent	1553:1558	absent	1553:1558	This novel N -glycosylation site (absent in the germline sequence) is a result of a single mutation giving rise to an NDT motif in the antibody sequence.
37398203	1	113	theme	several	254:260	arg1	vaccines					296:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	several adenoviral (Ad)-vectored COVID-19 vaccines	254:303	Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but extremely dangerous side effect that has been reported for several adenoviral (Ad)-vectored COVID-19 vaccines.
36399503	3	0	theme	redesigned	887:896	arg1	loci					1037:1040	polysaccharide utilization loci	1010:1040	polysaccharide utilization loci	1010:1040	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	0	theme	redesigned	887:896	arg1	page					902:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page	472:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions	472:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	4	1	theme	glycan	1323:1328	arg1	substrates					1330:1339	glycan substrates	1323:1339	glycan substrates predicted for CGCs from microbiomes	1323:1375	In summary, this updated dbCAN-seq database highlights glycan substrates predicted for CGCs from microbiomes.
36399503	2	2	theme	numerous	344:351	arg1	MAGs					383:386	MAGs	383:386	MAGs	383:386	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	2	2	theme	numerous	344:351	arg1	genomes					374:380	numerous metagenome assembled genomes	344:380	numerous metagenome assembled genomes (MAGs)	344:387	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	3	3	theme	CGC	898:900	arg1	loci					1037:1040	polysaccharide utilization loci	1010:1040	polysaccharide utilization loci	1010:1040	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	3	theme	CGC	898:900	arg1	page					902:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page	472:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions	472:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	4	theme	substrate	855:863	arg1	assignments					865:875	substrate assignments	855:875	substrate assignments	855:875	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	5	theme	forest	247:252	arg1	guts					221:224	animal guts	214:224	animal guts	214:224	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	5	theme	forest	247:252	arg1	floors					254:259	forest floors	247:259	forest floors	247:259	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	5	6	theme	prediction	1419:1428	arg1	function					1430:1437	the substrate prediction function	1405:1437	the substrate prediction function in our dbCAN2 web server	1405:1462	Future work will implement the substrate prediction function in our dbCAN2 web server.
36399503	3	7	dep	environments	652:663	arg1	gut					612:614	human gut	606:614	human gut	606:614	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	7	dep	environments	652:663	arg1	oral					623:626	oral	623:626	oral	623:626	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	7	dep	environments	652:663	arg1	rumen					633:637	cow rumen	629:637	cow rumen	629:637	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	7	dep	environments	652:663	arg1	marine					644:649	marine	644:649	marine	644:649	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	7	dep	environments	652:663	arg1	environments					652:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	8	theme	novel	730:734	arg1	search					767:772	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	search	767:772	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	8	theme	novel	730:734	arg1	majority					794:801	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	majority	794:801	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	8	theme	novel	730:734	arg1	approaches					736:745	two novel approaches	726:745	two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting)	726:809	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	9	theme	447	696:698	arg1	CGCs					709:712	41 447 (24.54%) CGCs	693:712	41 447 (24.54%) CGCs	693:712	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	2	10	theme	microbiome	295:304	arg1	sequencing					306:315	microbiome sequencing	295:315	microbiome sequencing	295:315	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	0	11	from	substrates	43:52	arg1	microbiomes					57:67	microbiomes	57:67	microbiomes	57:67	dbCAN-seq update: CAZyme gene clusters and substrates in microbiomes.
36399503	3	12	dep	include	464:470	arg1	iv					1125:1126	iv	1125:1126	iv	1125:1126	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	12	dep	include	464:470	arg1	organize					1150:1157	organize	1150:1157	to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page	1147:1265	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	13	dep	inferred	714:721	arg1	approaches					820:829	the two approaches	812:829	the two approaches agreed on 4183 CGCs for substrate assignments	812:875	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	13	dep	inferred	714:721	arg1	iii					880:882	iii	880:882	iii	880:882	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	14	theme	new	486:488	arg1	data					490:493	the following new data	472:493	the following new data	472:493	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	4	15	theme	dbCAN-seq	1293:1301	arg1	database					1303:1310	this updated dbCAN-seq database	1280:1310	this updated dbCAN-seq database	1280:1310	In summary, this updated dbCAN-seq database highlights glycan substrates predicted for CGCs from microbiomes.
36399503	3	16	from	MAGs	581:584	arg1	CGCs					565:568	CGCs	565:568	CGCs	565:568	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	16	from	MAGs	581:584	arg1	CAZymes					522:528	(i) ∼498 000 CAZymes	509:528	(i) ∼498 000 CAZymes	509:528	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	16	from	MAGs	581:584	arg1	clusters					555:562	∼169 000 CAZyme gene clusters	534:562	∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments	534:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	17	theme	predicted	1102:1110	arg1	substrates					1112:1121	the predicted substrates	1098:1121	the predicted substrates	1098:1121	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	18	theme	subfamily	1071:1079	arg1	table					1081:1085	the eCAMI subfamily table	1061:1085	the eCAMI subfamily table	1061:1085	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	0	19	from	clusters	30:37	arg1	microbiomes					57:67	microbiomes	57:67	microbiomes	57:67	dbCAN-seq update: CAZyme gene clusters and substrates in microbiomes.
36399503	3	20	theme	dbCAN-seq	410:418	arg1	database					420:427	our dbCAN-seq database	406:427	our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq)	406:459	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	20	theme	dbCAN-seq	410:418	arg1	https					430:434	https	430:434	https	430:434	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	21	theme	Carbohydrate	70:81	arg1	EnZymes					90:96	Carbohydrate Active EnZymes	70:96	Carbohydrate Active EnZymes (CAZymes)	70:106	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	21	theme	Carbohydrate	70:81	arg1	CAZymes					99:105	CAZymes	99:105	CAZymes	99:105	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	22	theme	dbCAN-PUL	748:756	arg1	search					767:772	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	search	767:772	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	22	theme	dbCAN-PUL	748:756	arg1	approaches					736:745	two novel approaches	726:745	two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting)	726:809	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	23	dep	features	499:506	arg1	CGCs					565:568	CGCs	565:568	CGCs	565:568	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	23	dep	features	499:506	arg1	CAZymes					522:528	(i) ∼498 000 CAZymes	509:528	(i) ∼498 000 CAZymes	509:528	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	23	dep	features	499:506	arg1	substrates					678:687	(ii) Glycan substrates	666:687	features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates	499:687	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	23	dep	features	499:506	arg1	clusters					555:562	∼169 000 CAZyme gene clusters	534:562	∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments	534:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	24	dep	CAZymes	522:528	arg1	i					510:510	i	510:510	i	510:510	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	25	theme	cow	629:631	arg1	environments					652:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	25	theme	cow	629:631	arg1	rumen					633:637	cow rumen	629:637	cow rumen	629:637	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	26	theme	Active	83:88	arg1	EnZymes					90:96	Carbohydrate Active EnZymes	70:96	Carbohydrate Active EnZymes (CAZymes)	70:106	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	26	theme	Active	83:88	arg1	CAZymes					99:105	CAZymes	99:105	CAZymes	99:105	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	27	theme	homology	758:765	arg1	search					767:772	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	search	767:772	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	27	theme	homology	758:765	arg1	approaches					736:745	two novel approaches	726:745	two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting)	726:809	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	28	theme	carbohydrate	175:186	arg1	guts					221:224	animal guts	214:224	animal guts	214:224	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	28	theme	carbohydrate	175:186	arg1	environments					193:204	carbohydrate rich environments	175:204	carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments	175:280	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	29	theme	batch	1247:1251	arg1	page					1262:1265	A batch download page	1245:1265	A batch download page	1245:1265	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	30	dep	approaches	736:745	arg1	search					767:772	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	search	767:772	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	30	dep	approaches	736:745	arg1	approaches					736:745	two novel approaches	726:745	two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting)	726:809	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	30	dep	approaches	736:745	arg1	majority					794:801	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	majority	794:801	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	31	theme	CGC	1181:1183	arg1	access					1185:1190	easy CGC access	1176:1190	easy CGC access	1176:1190	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	32	theme	rich	188:191	arg1	guts					221:224	animal guts	214:224	animal guts	214:224	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	32	theme	rich	188:191	arg1	environments					193:204	carbohydrate rich environments	175:204	carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments	175:280	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	33	theme	polysaccharide	1010:1023	arg1	loci					1037:1040	polysaccharide utilization loci	1010:1040	polysaccharide utilization loci	1010:1040	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	33	theme	polysaccharide	1010:1023	arg1	page					902:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page	472:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions	472:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	34	theme	ocean	266:270	arg1	sediments					272:280	ocean sediments	266:280	ocean sediments	266:280	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	34	theme	ocean	266:270	arg1	guts					221:224	animal guts	214:224	animal guts	214:224	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	35	theme	∼498	513:516	arg1	CAZymes					522:528	(i) ∼498 000 CAZymes	509:528	(i) ∼498 000 CAZymes	509:528	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	4	36	from	microbiomes	1365:1375	arg1	CGCs					1355:1358	CGCs	1355:1358	CGCs from microbiomes	1355:1375	In summary, this updated dbCAN-seq database highlights glycan substrates predicted for CGCs from microbiomes.
36399503	3	37	theme	utilization	1025:1035	arg1	loci					1037:1040	polysaccharide utilization loci	1010:1040	polysaccharide utilization loci	1010:1040	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	37	theme	utilization	1025:1035	arg1	page					902:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page	472:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions	472:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	38	theme	eCAMI	1065:1069	arg1	table					1081:1085	the eCAMI subfamily table	1061:1085	the eCAMI subfamily table	1061:1085	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	39	theme	CGC	943:945	arg1	compositions					952:963	CGC gene compositions	943:963	CGC gene compositions	943:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	40	theme	000	518:520	arg1	CAZymes					522:528	(i) ∼498 000 CAZymes	509:528	(i) ∼498 000 CAZymes	509:528	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	41	theme	eCAMI	778:782	arg1	approaches					736:745	two novel approaches	726:745	two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting)	726:809	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	41	theme	eCAMI	778:782	arg1	majority					794:801	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	majority	794:801	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	42	theme	statistics	1131:1140	arg1	page					1142:1145	A statistics page	1129:1145	A statistics page	1129:1145	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	43	dep	page	902:905	arg1	inferred					714:721	inferred	714:721	inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments)	714:876	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	43	dep	page	902:905	arg1	PUL					1005:1007	PUL	1005:1007	PUL	1005:1007	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	43	dep	page	902:905	arg1	include					910:916	include	910:916	to include the graphical display of CGC gene compositions	907:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	5	44	theme	web	1453:1455	arg1	server					1457:1462	our dbCAN2 web server	1442:1462	our dbCAN2 web server	1442:1462	Future work will implement the substrate prediction function in our dbCAN2 web server.
36399503	3	45	theme	graphical	922:930	arg1	display					932:938	the graphical display	918:938	the graphical display of CGC gene compositions	918:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	46	dep	substrates	678:687	arg1	ii					667:668	ii	667:668	ii	667:668	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	47	theme	CAZyme	543:548	arg1	CGCs					565:568	CGCs	565:568	CGCs	565:568	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	47	theme	CAZyme	543:548	arg1	clusters					555:562	∼169 000 CAZyme gene clusters	534:562	∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments	534:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	48	theme	subfamily	784:792	arg1	approaches					736:745	two novel approaches	726:745	two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting)	726:809	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	48	theme	subfamily	784:792	arg1	majority					794:801	dbCAN-PUL homology search and eCAMI subfamily majority	748:801	majority	794:801	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	0	49	theme	gene	25:28	arg1	clusters					30:37	CAZyme gene clusters	18:37	CAZyme gene clusters	18:37	dbCAN-seq update: CAZyme gene clusters and substrates in microbiomes.
36399503	5	50	theme	Future	1378:1383	arg1	work					1385:1388	Future work	1378:1388	Future work	1378:1388	Future work will implement the substrate prediction function in our dbCAN2 web server.
36399503	0	51	theme	CAZyme	18:23	arg1	clusters					30:37	CAZyme gene clusters	18:37	CAZyme gene clusters	18:37	dbCAN-seq update: CAZyme gene clusters and substrates in microbiomes.
36399503	1	52	theme	animal	214:219	arg1	sediments					272:280	ocean sediments	266:280	ocean sediments	266:280	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	52	theme	animal	214:219	arg1	guts					221:224	animal guts	214:224	animal guts	214:224	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	52	theme	animal	214:219	arg1	soils					240:244	agricultural soils	227:244	agricultural soils	227:244	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	52	theme	animal	214:219	arg1	floors					254:259	forest floors	247:259	forest floors	247:259	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	53	theme	environments	652:663	arg1	MAGs					581:584	9421 MAGs	576:584	9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments	576:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	54	dep	according	1192:1200	arg1	page					1262:1265	A batch download page	1245:1265	A batch download page	1245:1265	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	4	55	theme	updated	1285:1291	arg1	database					1303:1310	this updated dbCAN-seq database	1280:1310	this updated dbCAN-seq database	1280:1310	In summary, this updated dbCAN-seq database highlights glycan substrates predicted for CGCs from microbiomes.
36399503	3	56	theme	dbCAN-PUL	1046:1054	arg1	loci					1037:1040	polysaccharide utilization loci	1010:1040	polysaccharide utilization loci	1010:1040	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	56	theme	dbCAN-PUL	1046:1054	arg1	subject					997:1003	subject	997:1003	subject	997:1003	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	56	theme	dbCAN-PUL	1046:1054	arg1	alignment					970:978	the alignment	966:978	the alignment of query CGC	966:991	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	56	theme	dbCAN-PUL	1046:1054	arg1	page					902:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page	472:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions	472:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	5	57	theme	substrate	1409:1417	arg1	function					1430:1437	the substrate prediction function	1405:1437	the substrate prediction function in our dbCAN2 web server	1405:1462	Future work will implement the substrate prediction function in our dbCAN2 web server.
36399503	3	58	theme	download	1253:1260	arg1	page					1262:1265	A batch download page	1245:1265	A batch download page	1245:1265	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	59	theme	000	539:541	arg1	CGCs					565:568	CGCs	565:568	CGCs	565:568	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	59	theme	000	539:541	arg1	clusters					555:562	∼169 000 CAZyme gene clusters	534:562	∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments	534:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	5	60	from	function	1430:1437	arg1	server					1457:1462	our dbCAN2 web server	1442:1462	our dbCAN2 web server	1442:1462	Future work will implement the substrate prediction function in our dbCAN2 web server.
36399503	3	61	theme	following	476:484	arg1	data					490:493	the following new data	472:493	the following new data	472:493	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	62	theme	gene	947:950	arg1	compositions					952:963	CGC gene compositions	943:963	CGC gene compositions	943:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	63	theme	human	606:610	arg1	gut					612:614	human gut	606:614	human gut	606:614	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	63	theme	human	606:610	arg1	environments					652:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	64	dep	https	430:434	arg1	//bcb.unl.edu/dbCAN_seq					436:458	//bcb.unl.edu/dbCAN_seq	436:458	//bcb.unl.edu/dbCAN_seq	436:458	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	65	theme	gene	550:553	arg1	CGCs					565:568	CGCs	565:568	CGCs	565:568	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	65	theme	gene	550:553	arg1	clusters					555:562	∼169 000 CAZyme gene clusters	534:562	∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments	534:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	66	theme	compositions	952:963	arg1	display					932:938	the graphical display	918:938	the graphical display of CGC gene compositions	918:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	67	theme	microbial	140:148	arg1	communities					150:160	microbial communities	140:160	microbial communities	140:160	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	68	theme	query	983:987	arg1	CGC					989:991	query CGC	983:991	query CGC	983:991	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	69	theme	ecological	594:603	arg1	gut					612:614	human gut	606:614	human gut	606:614	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	69	theme	ecological	594:603	arg1	environments					652:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	four ecological (human gut, human oral, cow rumen, and marine) environments	589:663	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	69	theme	ecological	594:603	arg1	rumen					633:637	cow rumen	629:637	cow rumen	629:637	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	69	theme	ecological	594:603	arg1	marine					644:649	marine	644:649	marine	644:649	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	2	70	theme	assembled	364:372	arg1	MAGs					383:386	MAGs	383:386	MAGs	383:386	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	2	70	theme	assembled	364:372	arg1	genomes					374:380	numerous metagenome assembled genomes	344:380	numerous metagenome assembled genomes (MAGs)	344:387	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	3	71	theme	Glycan	671:676	arg1	substrates					678:687	(ii) Glycan substrates	666:687	features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates	499:687	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	1	72	theme	agricultural	227:238	arg1	guts					221:224	animal guts	214:224	animal guts	214:224	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	1	72	theme	agricultural	227:238	arg1	soils					240:244	agricultural soils	227:244	agricultural soils	227:244	Carbohydrate Active EnZymes (CAZymes) are significantly important for microbial communities to thrive in carbohydrate rich environments such as animal guts, agricultural soils, forest floors, and ocean sediments.
36399503	3	73	theme	CGC	989:991	arg1	loci					1037:1040	polysaccharide utilization loci	1010:1040	polysaccharide utilization loci	1010:1040	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	73	theme	CGC	989:991	arg1	subject					997:1003	subject	997:1003	subject	997:1003	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	73	theme	CGC	989:991	arg1	alignment					970:978	the alignment	966:978	the alignment of query CGC	966:991	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	73	theme	CGC	989:991	arg1	page					902:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page	472:905	the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions	472:963	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	3	74	theme	taxonomic	1220:1228	arg1	phyla					1230:1234	taxonomic phyla	1220:1234	taxonomic phyla	1220:1234	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
36399503	2	75	theme	metagenome	353:362	arg1	MAGs					383:386	MAGs	383:386	MAGs	383:386	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	2	75	theme	metagenome	353:362	arg1	genomes					374:380	numerous metagenome assembled genomes	344:380	numerous metagenome assembled genomes (MAGs)	344:387	Since 2017, microbiome sequencing and assembly have produced numerous metagenome assembled genomes (MAGs).
36399503	5	76	theme	dbCAN2	1446:1451	arg1	server					1457:1462	our dbCAN2 web server	1442:1462	our dbCAN2 web server	1442:1462	Future work will implement the substrate prediction function in our dbCAN2 web server.
36399503	3	77	theme	easy	1176:1179	arg1	access					1185:1190	easy CGC access	1176:1190	easy CGC access	1176:1190	We have updated our dbCAN-seq database (https://bcb.unl.edu/dbCAN_seq) to include the following new data and features: (i) ∼498 000 CAZymes and ∼169 000 CAZyme gene clusters (CGCs) from 9421 MAGs of four ecological (human gut, human oral, cow rumen, and marine) environments; (ii) Glycan substrates for 41 447 (24.54%) CGCs inferred by two novel approaches (dbCAN-PUL homology search and eCAMI subfamily majority voting) (the two approaches agreed on 4183 CGCs for substrate assignments); (iii) A redesigned CGC page to include the graphical display of CGC gene compositions, the alignment of query CGC and subject PUL (polysaccharide utilization loci) of dbCAN-PUL, and the eCAMI subfamily table to support the predicted substrates; (iv) A statistics page to organize all the data for easy CGC access according to substrates and taxonomic phyla; and (v) A batch download page.
35598016	7	0	theme	algeriensis	1442:1452	arg1	repertoire					1425:1434	the first targeting CAZymes repertoire	1397:1434	the first targeting CAZymes repertoire of C. algeriensis	1397:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	0	theme	algeriensis	1442:1452	arg1	algeriensis					1442:1452	C. algeriensis	1439:1452	C. algeriensis	1439:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	0	theme	algeriensis	1442:1452	arg1	study					1388:1392	This study	1383:1392	This study	1383:1392	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	5	1	theme	carbohydrate	940:951	arg1	esterases					953:961	carbohydrate esterases	940:961	carbohydrate esterases	940:961	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	1	2	theme	genome	252:257	arg1	sequencing					259:268	whole genome sequencing	246:268	whole genome sequencing	246:268	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	7	3	theme	high	1482:1485	arg1	potential					1487:1495	the high potential	1478:1495	the high potential of identified enzymes for plant biomass degradation and their biotechnological applications	1478:1587	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	3	4	dep	generation	645:654	arg1	performed					697:705	performed	697:705	was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	693:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	5	with	contigs	752:758	arg1	length					808:813	a total length	800:813	a total length of 2,535,023 bp	800:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	5	with	contigs	752:758	arg1	content					779:785	an average GC content	765:785	an average GC content of 44.9%	765:794	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	0	6	theme	Caldicoprobacter	89:104	arg1	TH7C1T					118:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	6	7	from	analysis	1219:1226	arg1	genome					1265:1270	C. algeriensis genome	1250:1270	C. algeriensis genome	1250:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	5	8	theme	encoding	1114:1121	arg1	genes					1123:1127	CAZyme encoding genes	1107:1127	CAZyme encoding genes	1107:1127	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	2	9	theme	study	287:291	arg1	aim					275:277	The aim	271:277	The aim of this study	271:291	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	0	10	theme	thermophilic	76:87	arg1	TH7C1T					118:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	3	11	theme	GC	776:777	arg1	content					779:785	an average GC content	765:785	an average GC content of 44.9%	765:794	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	7	12	theme	biotechnological	1559:1574	arg1	applications					1576:1587	their biotechnological applications	1553:1587	their biotechnological applications	1553:1587	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	5	13	theme	oligosaccharide	1030:1044	arg1	transporters					1046:1057	oligosaccharide transporters	1030:1057	oligosaccharide transporters	1030:1057	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	3	14	theme	anaerobic	527:535	arg1	bacterium					537:545	a thermophilic anaerobic bacterium	512:545	a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	512:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	14	theme	anaerobic	527:535	arg1	TH7C1T					502:507	TH7C1T	502:507	TH7C1T	502:507	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	0	15	theme	TH7C1T	118:123	arg1	repertoire					58:67	repertoire	58:67	repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T	58:123	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	0	15	theme	TH7C1T	118:123	arg1	TH7C1T					118:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	7	16	theme	identified	1500:1509	arg1	enzymes					1511:1517	identified enzymes	1500:1517	identified enzymes for plant biomass degradation and their biotechnological applications	1500:1587	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	6	17	from	genome	1265:1270	arg1	analysis					1219:1226	analysis	1219:1226	analysis of CAZomes content in C. algeriensis genome	1219:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	5	18	dep	found	999:1003	arg1	linked					1005:1010	linked	1005:1010	linked to genes encoding oligosaccharide transporters and transcriptional regulators	1005:1088	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	0	19	theme	algeriensis	106:116	arg1	TH7C1T					118:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	the thermophilic Caldicoprobacter algeriensis TH7C1T	72:123	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	7	20	theme	plant	1523:1527	arg1	degradation					1537:1547	plant biomass degradation	1523:1547	plant biomass degradation	1523:1547	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	3	21	theme	average	768:774	arg1	content					779:785	an average GC content	765:785	an average GC content of 44.9%	765:794	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	2	22	theme	protein	309:315	arg1	CAZymes					342:348	CAZymes	342:348	CAZymes	342:348	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	2	22	theme	protein	309:315	arg1	genes					326:330	protein encoding genes	309:330	protein encoding genes including CAZymes	309:348	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	5	23	theme	Many	913:916	arg1	hydrolases					928:937	Many glycoside hydrolases	913:937	Many glycoside hydrolases	913:937	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	0	24	theme	Genome	0:5	arg1	sequence					7:14	Genome sequence	0:14	Genome sequence	0:14	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	3	25	theme	%	794:794	arg1	length					808:813	a total length	800:813	a total length of 2,535,023 bp	800:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	25	theme	%	794:794	arg1	content					779:785	an average GC content	765:785	an average GC content of 44.9%	765:794	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	26	theme	55 °C	623:627	arg1	temperatures					607:618	the temperatures	603:618	the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	603:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	2	27	theme	glycans-degrading	373:389	arg1	machinery					391:399	glycans-degrading machinery	373:399	glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain	373:462	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	0	28	theme	Carbohydrate	20:31	arg1	Enzymes					40:46	Carbohydrate Active Enzymes	20:46	Carbohydrate Active Enzymes (CAZymes)	20:56	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	0	28	theme	Carbohydrate	20:31	arg1	CAZymes					49:55	CAZymes	49:55	CAZymes	49:55	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	7	29	theme	biomass	1529:1535	arg1	degradation					1537:1547	plant biomass degradation	1523:1547	plant biomass degradation	1523:1547	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	4	30	theme	protein-coding	863:876	arg1	genes					878:882	2425 protein-coding genes	858:882	2425 protein-coding genes	858:882	Genome annotation reveals 2425 protein-coding genes with 97 ORFs coding CAZymes.
35598016	0	31	dep	repertoire	58:67	arg1	Enzymes					40:46	Carbohydrate Active Enzymes	20:46	Carbohydrate Active Enzymes (CAZymes)	20:56	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	0	31	dep	repertoire	58:67	arg1	sequence					7:14	Genome sequence	0:14	Genome sequence	0:14	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	0	31	dep	repertoire	58:67	arg1	CAZymes					49:55	CAZymes	49:55	CAZymes	49:55	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	6	32	theme	specific	1350:1357	arg1	substrates					1359:1368	specific substrates	1350:1368	specific substrates	1350:1368	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	2	33	theme	TH7C1T	450:455	arg1	strain					457:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	6	34	theme	C.	1250:1251	arg1	genome					1265:1270	C. algeriensis genome	1250:1270	C. algeriensis genome	1250:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	6	35	from	content	1239:1245	arg1	genome					1265:1270	C. algeriensis genome	1250:1270	C. algeriensis genome	1250:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	6	36	theme	gene	1291:1294	arg1	clusters					1296:1303	33 CAZyme gene clusters	1281:1303	33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates	1281:1368	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	6	37	theme	content	1239:1245	arg1	analysis					1219:1226	analysis	1219:1226	analysis of CAZomes content in C. algeriensis genome	1219:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	2	38	theme	algeriensis	438:448	arg1	strain					457:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	7	39	theme	CAZymes	1417:1423	arg1	repertoire					1425:1434	the first targeting CAZymes repertoire	1397:1434	the first targeting CAZymes repertoire of C. algeriensis	1397:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	39	theme	CAZymes	1417:1423	arg1	algeriensis					1442:1452	C. algeriensis	1439:1452	C. algeriensis	1439:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	39	theme	CAZymes	1417:1423	arg1	study					1388:1392	This study	1383:1392	This study	1383:1392	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	5	40	theme	glycosyltransferases	967:986	arg1	genes					988:992	glycosyltransferases genes	967:992	glycosyltransferases genes	967:992	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	7	41	theme	targeting	1407:1415	arg1	repertoire					1425:1434	the first targeting CAZymes repertoire	1397:1434	the first targeting CAZymes repertoire of C. algeriensis	1397:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	41	theme	targeting	1407:1415	arg1	algeriensis					1442:1452	C. algeriensis	1439:1452	C. algeriensis	1439:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	41	theme	targeting	1407:1415	arg1	study					1388:1392	This study	1383:1392	This study	1383:1392	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	3	42	theme	Next	640:643	arg1	generation					645:654	75 °C. Next generation	633:654	75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	633:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	1	43	theme	biology	189:195	arg1	field					180:184	the field	176:184	the field of biology for the discovery of potential CAZymes including whole genome sequencing	176:268	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	2	44	theme	Caldicoprobacter	421:436	arg1	strain					457:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	0	45	theme	Active	33:38	arg1	Enzymes					40:46	Carbohydrate Active Enzymes	20:46	Carbohydrate Active Enzymes (CAZymes)	20:56	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	0	45	theme	Active	33:38	arg1	CAZymes					49:55	CAZymes	49:55	CAZymes	49:55	Genome sequence and Carbohydrate Active Enzymes (CAZymes) repertoire of the thermophilic Caldicoprobacter algeriensis TH7C1T.
35598016	5	46	attach	linked	1005:1010	arg2	hydrolases					928:937	Many glycoside hydrolases	913:937	Many glycoside hydrolases	913:937	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	5	46	attach	linked	1005:1010	arg1	genes					1015:1019	genes	1015:1019	genes encoding oligosaccharide transporters and transcriptional regulators	1015:1088	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	5	46	attach	linked	1005:1010	arg2	esterases					953:961	carbohydrate esterases	940:961	carbohydrate esterases	940:961	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	5	46	attach	linked	1005:1010	arg2	genes					988:992	glycosyltransferases genes	967:992	glycosyltransferases genes	967:992	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	7	47	theme	enzymes	1511:1517	arg1	potential					1487:1495	the high potential	1478:1495	the high potential of identified enzymes for plant biomass degradation and their biotechnological applications	1478:1587	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	5	48	theme	polysaccharides	1167:1181	arg1	degradation					1183:1193	polysaccharides degradation	1167:1193	polysaccharides degradation	1167:1193	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	3	49	theme	generation	645:654	arg1	temperatures					607:618	the temperatures	603:618	the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	603:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	2	50	from	machinery	391:399	arg1	strain					457:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	2	51	theme	thermophilic	408:419	arg1	strain					457:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	the thermophilic Caldicoprobacter algeriensis TH7C1T strain	404:462	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	3	52	dep	RESULTS	465:471	arg1	bacterium					537:545	a thermophilic anaerobic bacterium	512:545	a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	512:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	52	dep	RESULTS	465:471	arg1	TH7C1T					502:507	TH7C1T	502:507	TH7C1T	502:507	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	6	53	theme	CAZomes	1231:1237	arg1	content					1239:1245	CAZomes content	1231:1245	CAZomes content in C. algeriensis genome	1231:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	7	54	dep	CONCLUSIONS	1371:1381	arg1	repertoire					1425:1434	the first targeting CAZymes repertoire	1397:1434	the first targeting CAZymes repertoire of C. algeriensis	1397:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	54	dep	CONCLUSIONS	1371:1381	arg1	algeriensis					1442:1452	C. algeriensis	1439:1452	C. algeriensis	1439:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	54	dep	CONCLUSIONS	1371:1381	arg1	study					1388:1392	This study	1383:1392	This study	1383:1392	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	3	55	theme	thermophilic	514:525	arg1	bacterium					537:545	a thermophilic anaerobic bacterium	512:545	a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	512:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	55	theme	thermophilic	514:525	arg1	TH7C1T					502:507	TH7C1T	502:507	TH7C1T	502:507	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	56	theme	75 °C.	633:638	arg1	generation					645:654	75 °C. Next generation	633:654	75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	633:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	1	57	theme	BACKGROUND	126:135	arg1	approaches					143:152	BACKGROUND Omics approaches	126:152	BACKGROUND Omics approaches	126:152	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	6	58	theme	enzyme	1320:1325	arg1	combinations					1327:1338	new enzyme combinations	1316:1338	new enzyme combinations targeting specific substrates	1316:1368	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	3	59	theme	total	802:806	arg1	length					808:813	a total length	800:813	a total length of 2,535,023 bp	800:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	5	60	theme	transcriptional	1063:1077	arg1	regulators					1079:1088	transcriptional regulators	1063:1088	transcriptional regulators	1063:1088	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	3	61	theme	Illumina	673:680	arg1	technology					682:691	Illumina technology	673:691	Illumina technology	673:691	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	5	62	theme	CAZyme	1107:1112	arg1	genes					1123:1127	CAZyme encoding genes	1107:1127	CAZyme encoding genes	1107:1127	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	1	63	theme	Omics	137:141	arg1	approaches					143:152	BACKGROUND Omics approaches	126:152	BACKGROUND Omics approaches	126:152	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	5	64	theme	glycoside	918:926	arg1	hydrolases					928:937	Many glycoside hydrolases	913:937	Many glycoside hydrolases	913:937	Many glycoside hydrolases, carbohydrate esterases and glycosyltransferases genes were found linked to genes encoding oligosaccharide transporters and transcriptional regulators; suggesting that CAZyme encoding genes are organized in clusters involved in polysaccharides degradation and transport.
35598016	1	65	theme	potential	218:226	arg1	sequencing					259:268	whole genome sequencing	246:268	whole genome sequencing	246:268	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	1	65	theme	potential	218:226	arg1	CAZymes					228:234	potential CAZymes	218:234	potential CAZymes including whole genome sequencing	218:268	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	3	66	theme	C.	714:715	arg1	strain					729:734	the C. algeriensis strain	710:734	the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	710:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	6	67	theme	CAZyme	1284:1289	arg1	clusters					1296:1303	33 CAZyme gene clusters	1281:1303	33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates	1281:1368	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	2	68	theme	encoding	317:324	arg1	CAZymes					342:348	CAZymes	342:348	CAZymes	342:348	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	2	68	theme	encoding	317:324	arg1	genes					326:330	protein encoding genes	309:330	protein encoding genes including CAZymes	309:348	The aim of this study was to identify protein encoding genes including CAZymes in order to understand glycans-degrading machinery in the thermophilic Caldicoprobacter algeriensis TH7C1T strain.
35598016	1	69	theme	CAZymes	228:234	arg1	discovery					205:213	the discovery	201:213	the discovery of potential CAZymes including whole genome sequencing	201:268	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
35598016	3	70	theme	algeriensis	717:727	arg1	strain					729:734	the C. algeriensis strain	710:734	the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp	710:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	6	71	theme	algeriensis	1253:1263	arg1	genome					1265:1270	C. algeriensis genome	1250:1270	C. algeriensis genome	1250:1270	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	3	72	theme	2,535,023 bp	818:829	arg1	length					808:813	a total length	800:813	a total length of 2,535,023 bp	800:829	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	3	72	theme	2,535,023 bp	818:829	arg1	content					779:785	an average GC content	765:785	an average GC content of 44.9%	765:794	RESULTS Caldicoprobacter algeriensis TH7C1T is a thermophilic anaerobic bacterium belonging to the Firmicutes phylum, which grows between the temperatures of 55 °C and 75 °C. Next generation sequencing using Illumina technology was performed on the C. algeriensis strain resulting in 45 contigs with an average GC content of 44.9% and a total length of 2,535,023 bp.
35598016	4	73	theme	Genome	832:837	arg1	annotation					839:848	Genome annotation	832:848	Genome annotation	832:848	Genome annotation reveals 2425 protein-coding genes with 97 ORFs coding CAZymes.
35598016	6	74	theme	new	1316:1318	arg1	combinations					1327:1338	new enzyme combinations	1316:1338	new enzyme combinations targeting specific substrates	1316:1368	In depth analysis of CAZomes content in C. algeriensis genome unveiled 33 CAZyme gene clusters uncovering new enzyme combinations targeting specific substrates.
35598016	7	75	theme	first	1401:1405	arg1	repertoire					1425:1434	the first targeting CAZymes repertoire	1397:1434	the first targeting CAZymes repertoire of C. algeriensis	1397:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	75	theme	first	1401:1405	arg1	algeriensis					1442:1452	C. algeriensis	1439:1452	C. algeriensis	1439:1452	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	7	75	theme	first	1401:1405	arg1	study					1388:1392	This study	1383:1392	This study	1383:1392	CONCLUSIONS This study is the first targeting CAZymes repertoire of C. algeriensis, it provides insight to the high potential of identified enzymes for plant biomass degradation and their biotechnological applications.
35598016	1	76	theme	whole	246:250	arg1	sequencing					259:268	whole genome sequencing	246:268	whole genome sequencing	246:268	BACKGROUND Omics approaches are widely applied in the field of biology for the discovery of potential CAZymes including whole genome sequencing.
36454453	5	0	from	proliferation	1551:1563	arg1	production					1505:1514	LPS-induced reactive oxygen species (ROS) production	1463:1514	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	0	from	proliferation	1551:1563	arg1	production					1389:1398	lipopolysaccharide (LPS)-induced prostaglandin production	1342:1398	lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1342:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	0	from	proliferation	1551:1563	arg1	H2O2-					1453:1457	H2O2-	1453:1457	H2O2-	1453:1457	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	6	1	theme	LPS-induced	1642:1652	arg1	ROS					1654:1656	LPS-induced ROS	1642:1656	LPS-induced ROS	1642:1656	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	5	2	theme	inhibitory	1425:1434	arg1	activities					1436:1445	(iii) inhibitory activities	1419:1445	(iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1419:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	3	3	theme	hot	497:499	arg1	water					501:505	hot water	497:505	hot water	497:505	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	4	theme	1H-1H	677:681	arg1	TOCSY					683:687	1H-1H TOCSY	677:687	1H-1H TOCSY	677:687	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	5	theme	exchange	526:533	arg1	chromatography					535:548	anion exchange chromatography	520:548	anion exchange chromatography	520:548	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	6	from	activity	1330:1337	arg1	production					1505:1514	LPS-induced reactive oxygen species (ROS) production	1463:1514	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	6	from	activity	1330:1337	arg1	production					1389:1398	lipopolysaccharide (LPS)-induced prostaglandin production	1342:1398	lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1342:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	6	from	activity	1330:1337	arg1	H2O2-					1453:1457	H2O2-	1453:1457	H2O2-	1453:1457	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	7	theme	branched	1021:1028	arg1	polysaccharide					1030:1043	a branched polysaccharide	1019:1043	a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa	1019:1196	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	2	8	theme	Recent	244:249	arg1	researches					251:260	Recent researches	244:260	Recent researches	244:260	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	5	9	theme	LPS-induced	1463:1473	arg1	ROS					1500:1502	ROS	1500:1502	ROS	1500:1502	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	9	theme	LPS-induced	1463:1473	arg1	species					1491:1497	LPS-induced reactive oxygen species	1463:1497	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	10	theme	oxygen	1484:1489	arg1	ROS					1500:1502	ROS	1500:1502	ROS	1500:1502	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	10	theme	oxygen	1484:1489	arg1	species					1491:1497	LPS-induced reactive oxygen species	1463:1497	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	11	dep	polysaccharide	1030:1043	arg1	branched					1117:1124	branched	1117:1124	branched occasionally at 6-positions	1117:1152	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	11	dep	polysaccharide	1030:1043	arg1	composed					1057:1064	composed	1057:1064	composed	1057:1064	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	11	dep	polysaccharide	1030:1043	arg1	having					1159:1164	having	1159:1164	having a molecular weight of ~ 570 kDa	1159:1196	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	3	12	theme	gas	747:749	arg1	spectrometry					771:782	gas chromatography-mass spectrometry	747:782	gas chromatography-mass spectrometry	747:782	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	13	from	production	1389:1398	arg1	cells					1412:1416	RAW264.7 cells	1403:1416	RAW264.7 cells	1403:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	0	14	from	hiantina	91:98	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	0	14	from	hiantina	91:98	arg1	activity					43:50	biological activity	32:50	biological activity	32:50	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	0	14	from	hiantina	91:98	arg1	α-glucan					58:65	an α-glucan	55:65	an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818)	55:114	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	3	15	theme	1H-13C	703:708	arg1	HSQC					710:713	1H-13C HSQC	703:713	1H-13C HSQC	703:713	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	16	theme	performance	794:804	arg1	HPSEC					837:841	HPSEC	837:841	HPSEC	837:841	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	16	theme	performance	794:804	arg1	chromatography					821:834	high performance size exclusion chromatography	789:834	high performance size exclusion chromatography (HPSEC)	789:842	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	0	17	theme	mollusk	76:82	arg1	hiantina					91:98	the mollusk Marcia hiantina	72:98	the mollusk Marcia hiantina (Lamarck, 1818)	72:114	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	3	18	theme	HSQC-NOESY	726:735	arg1	spectra					737:743	1H-13C HSQC-NOESY spectra	719:743	1H-13C HSQC-NOESY spectra	719:743	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	19	dep	lines	1289:1293	arg1	HaCaT					1306:1310	HaCaT	1306:1310	HaCaT	1306:1310	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	19	dep	lines	1289:1293	arg1	HT-29					1317:1321	HT-29	1317:1321	HT-29	1317:1321	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	19	dep	lines	1289:1293	arg1	RAW264.7					1296:1303	RAW264.7	1296:1303	RAW264.7	1296:1303	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	19	dep	lines	1289:1293	arg1	lines					1289:1293	three cell lines	1278:1293	three cell lines (RAW264.7, HaCaT, and HT-29)	1278:1322	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	20	theme	monosaccharide	868:881	arg1	composition					883:893	monosaccharide composition	868:893	monosaccharide composition	868:893	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	2	21	theme	wide	348:351	arg1	antitumor					425:433	antitumor	425:433	antitumor	425:433	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	21	theme	wide	348:351	arg1	immunomodulatory					404:419	immunomodulatory	404:419	immunomodulatory	404:419	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	21	theme	wide	348:351	arg1	antioxidant					391:401	antioxidant	391:401	antioxidant	391:401	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	21	theme	wide	348:351	arg1	range					353:357	a wide range	346:357	a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities	346:444	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	0	22	dep	hiantina	91:98	arg1	1818					110:113	1818	110:113	1818	110:113	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	0	22	dep	hiantina	91:98	arg1	Lamarck					101:107	Lamarck	101:107	Lamarck	101:107	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	3	23	theme	exclusion	811:819	arg1	HPSEC					837:841	HPSEC	837:841	HPSEC	837:841	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	23	theme	exclusion	811:819	arg1	chromatography					821:834	high performance size exclusion chromatography	789:834	high performance size exclusion chromatography (HPSEC)	789:842	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	4	24	theme	light	953:957	arg1	MALS					971:974	MALS	971:974	MALS	971:974	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	24	theme	light	953:957	arg1	scattering					959:968	multi-angle light scattering	941:968	multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	941:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	0	25	from	activity	43:50	arg1	hiantina					91:98	the mollusk Marcia hiantina	72:98	the mollusk Marcia hiantina (Lamarck, 1818)	72:114	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	0	26	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	1	27	theme	tropical	218:225	arg1	regions					235:241	the tropical coastal regions	214:241	the tropical coastal regions	214:241	Marcia hiantina (Mollusca, Bivalvia) (Lamarck, 1818), is an edible clam mainly distributed along the tropical coastal regions.
36454453	5	28	dep	viability	1265:1273	arg1	i					1262:1262	i	1262:1262	i	1262:1262	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	1	29	dep	hiantina	124:131	arg1	Lamarck					155:161	Lamarck	155:161	Lamarck	155:161	Marcia hiantina (Mollusca, Bivalvia) (Lamarck, 1818), is an edible clam mainly distributed along the tropical coastal regions.
36454453	2	30	theme	actions	373:379	arg1	antitumor					425:433	antitumor	425:433	antitumor	425:433	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	30	theme	actions	373:379	arg1	immunomodulatory					404:419	immunomodulatory	404:419	immunomodulatory	404:419	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	30	theme	actions	373:379	arg1	antioxidant					391:401	antioxidant	391:401	antioxidant	391:401	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	30	theme	actions	373:379	arg1	range					353:357	a wide range	346:357	a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities	346:444	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	3	31	theme	multiple	607:614	arg1	NMR					644:646	NMR	644:646	NMR	644:646	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	31	theme	multiple	607:614	arg1	resonance					633:641	multiple nuclear magnetic resonance	607:641	multiple nuclear magnetic resonance (NMR) methods	607:655	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	32	theme	HMC3	1519:1522	arg1	cells					1524:1528	HMC3 cells	1519:1528	HMC3 cells	1519:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	33	from	backbone	1107:1114	arg1	4-linked					1091:1098	4-linked	1091:1098	4-linked	1091:1098	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	5	34	theme	cell	1284:1287	arg1	HaCaT					1306:1310	HaCaT	1306:1310	HaCaT	1306:1310	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	34	theme	cell	1284:1287	arg1	HT-29					1317:1321	HT-29	1317:1321	HT-29	1317:1321	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	34	theme	cell	1284:1287	arg1	RAW264.7					1296:1303	RAW264.7	1296:1303	RAW264.7	1296:1303	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	34	theme	cell	1284:1287	arg1	lines					1289:1293	three cell lines	1278:1293	three cell lines (RAW264.7, HaCaT, and HT-29)	1278:1322	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	35	from	HPSEC	921:925	arg1	analysis					849:856	The analysis	845:856	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	845:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	5	36	from	production	1505:1514	arg1	cells					1524:1528	HMC3 cells	1519:1528	HMC3 cells	1519:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	37	theme	α-glycan	1000:1007	arg1	MALS					971:974	MALS	971:974	MALS	971:974	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	37	theme	α-glycan	1000:1007	arg1	scattering					959:968	multi-angle light scattering	941:968	multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	941:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	5	38	theme	prostaglandin	1375:1387	arg1	production					1389:1398	lipopolysaccharide (LPS)-induced prostaglandin production	1342:1398	lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1342:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	39	theme	molecular	1168:1176	arg1	weight					1178:1183	a molecular weight	1166:1183	a molecular weight of ~ 570 kDa	1166:1196	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	40	from	analyses	908:915	arg1	analysis					849:856	The analysis	845:856	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	845:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	5	41	from	activities	1436:1445	arg1	production					1505:1514	LPS-induced reactive oxygen species (ROS) production	1463:1514	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	41	from	activities	1436:1445	arg1	production					1389:1398	lipopolysaccharide (LPS)-induced prostaglandin production	1342:1398	lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1342:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	41	from	activities	1436:1445	arg1	H2O2-					1453:1457	H2O2-	1453:1457	H2O2-	1453:1457	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	6	42	theme	cell	1670:1673	arg1	activity					1689:1696	potent cell proliferative activity	1663:1696	potent cell proliferative activity	1663:1696	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	3	43	theme	magnetic	624:631	arg1	NMR					644:646	NMR	644:646	NMR	644:646	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	43	theme	magnetic	624:631	arg1	resonance					633:641	multiple nuclear magnetic resonance	607:641	multiple nuclear magnetic resonance (NMR) methods	607:655	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	1	44	theme	edible	177:182	arg1	clam					184:187	an edible clam	174:187	an edible clam mainly distributed along the tropical coastal regions	174:241	Marcia hiantina (Mollusca, Bivalvia) (Lamarck, 1818), is an edible clam mainly distributed along the tropical coastal regions.
36454453	1	44	theme	edible	177:182	arg1	hiantina					124:131	hiantina	124:131	hiantina	124:131	Marcia hiantina (Mollusca, Bivalvia) (Lamarck, 1818), is an edible clam mainly distributed along the tropical coastal regions.
36454453	5	45	theme	cell	1546:1549	arg1	assays					1253:1258	four cell-based assays	1237:1258	four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation	1237:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	45	theme	cell	1546:1549	arg1	proliferation					1551:1563	(iv) HaCaT cell proliferation	1535:1563	(iv) HaCaT cell proliferation	1535:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	46	theme	M.	980:981	arg1	α-glycan					1000:1007	M. hiantina-derived α-glycan	980:1007	M. hiantina-derived α-glycan	980:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	6	47	theme	ROS	1654:1656	arg1	activity					1689:1696	potent cell proliferative activity	1663:1696	potent cell proliferative activity	1663:1696	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	6	47	theme	ROS	1654:1656	arg1	cytotoxicity					1592:1603	no cytotoxicity	1589:1603	no cytotoxicity	1589:1603	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	6	47	theme	ROS	1654:1656	arg1	inhibition					1613:1622	potent inhibition	1606:1622	potent inhibition of both H2O2- and LPS-induced ROS	1606:1656	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	4	48	from	NMR	863:865	arg1	analysis					849:856	The analysis	845:856	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	845:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	3	49	theme	1H-1H	665:669	arg1	COSY					671:674	1H-1H COSY	665:674	1H-1H COSY	665:674	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	4	50	link	hiantina-derived	983:998	arg1	α-glycan					1000:1007	M. hiantina-derived α-glycan	980:1007	M. hiantina-derived α-glycan	980:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	51	attach	4-linked	1091:1098	arg3	backbone					1107:1114	its backbone	1103:1114	its backbone	1103:1114	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	5	52	theme	species	1491:1497	arg1	production					1505:1514	LPS-induced reactive oxygen species (ROS) production	1463:1514	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	3	53	theme	anion	520:524	arg1	chromatography					535:548	anion exchange chromatography	520:548	anion exchange chromatography	520:548	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	54	dep	activity	1330:1337	arg1	ii					1326:1327	ii	1326:1327	ii	1326:1327	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	55	theme	reactive	1475:1482	arg1	ROS					1500:1502	ROS	1500:1502	ROS	1500:1502	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	55	theme	reactive	1475:1482	arg1	species					1491:1497	LPS-induced reactive oxygen species	1463:1497	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	3	56	theme	1H-1H	690:694	arg1	NOESY					696:700	1H-1H NOESY	690:700	1H-1H NOESY	690:700	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	57	theme	mollusk	1203:1209	arg1	α-glucan					1211:1218	The mollusk α-glucan	1199:1218	The mollusk α-glucan	1199:1218	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	3	58	theme	1H-13C	719:724	arg1	spectra					737:743	1H-13C HSQC-NOESY spectra	719:743	1H-13C HSQC-NOESY spectra	719:743	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	59	theme	chromatography-mass	751:769	arg1	spectrometry					771:782	gas chromatography-mass spectrometry	747:782	gas chromatography-mass spectrometry	747:782	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	0	60	theme	Marcia	84:89	arg1	hiantina					91:98	the mollusk Marcia hiantina	72:98	the mollusk Marcia hiantina (Lamarck, 1818)	72:114	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	3	61	theme	size	806:809	arg1	HPSEC					837:841	HPSEC	837:841	HPSEC	837:841	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	61	theme	size	806:809	arg1	chromatography					821:834	high performance size exclusion chromatography	789:834	high performance size exclusion chromatography (HPSEC)	789:842	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	4	62	theme	methylation	896:906	arg1	analyses					908:915	methylation analyses	896:915	methylation analyses	896:915	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	0	63	from	characterization	11:26	arg1	hiantina					91:98	the mollusk Marcia hiantina	72:98	the mollusk Marcia hiantina (Lamarck, 1818)	72:114	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	3	64	theme	nuclear	616:622	arg1	NMR					644:646	NMR	644:646	NMR	644:646	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	64	theme	nuclear	616:622	arg1	resonance					633:641	multiple nuclear magnetic resonance	607:641	multiple nuclear magnetic resonance (NMR) methods	607:655	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	2	65	contain	possess	295:301	arg2	polysaccharides					324:338	polysaccharides	324:338	polysaccharides	324:338	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	65	contain	possess	295:301	arg1	clams					285:289	clams	285:289	clams	285:289	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	65	contain	possess	295:301	arg2	compounds					303:311	compounds	303:311	compounds	303:311	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	3	66	theme	high	789:792	arg1	HPSEC					837:841	HPSEC	837:841	HPSEC	837:841	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	66	theme	high	789:792	arg1	chromatography					821:834	high performance size exclusion chromatography	789:834	high performance size exclusion chromatography (HPSEC)	789:842	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	67	theme	cell-based	1242:1251	arg1	viability					1265:1273	(i) viability	1261:1273	(i) viability of three cell lines (RAW264.7, HaCaT, and HT-29)	1261:1322	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	67	theme	cell-based	1242:1251	arg1	assays					1253:1258	four cell-based assays	1237:1258	four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation	1237:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	67	theme	cell-based	1242:1251	arg1	activity					1330:1337	(ii) activity	1325:1337	(ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1325:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	67	theme	cell-based	1242:1251	arg1	proliferation					1551:1563	(iv) HaCaT cell proliferation	1535:1563	(iv) HaCaT cell proliferation	1535:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	2	68	dep	antioxidant	391:401	arg1	activities					435:444	activities	435:444	activities	435:444	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	5	69	from	viability	1265:1273	arg1	production					1505:1514	LPS-induced reactive oxygen species (ROS) production	1463:1514	LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1463:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	69	from	viability	1265:1273	arg1	production					1389:1398	lipopolysaccharide (LPS)-induced prostaglandin production	1342:1398	lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1342:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	69	from	viability	1265:1273	arg1	H2O2-					1453:1457	H2O2-	1453:1457	H2O2-	1453:1457	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	3	70	dep	isolated	468:475	arg1	purified					508:515	purified	508:515	purified by anion exchange chromatography	508:548	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	4	71	theme	multi-angle	941:951	arg1	MALS					971:974	MALS	971:974	MALS	971:974	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	4	71	theme	multi-angle	941:951	arg1	scattering					959:968	multi-angle light scattering	941:968	multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	941:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	6	72	theme	H2O2-	1632:1636	arg1	activity					1689:1696	potent cell proliferative activity	1663:1696	potent cell proliferative activity	1663:1696	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	6	72	theme	H2O2-	1632:1636	arg1	cytotoxicity					1592:1603	no cytotoxicity	1589:1603	no cytotoxicity	1589:1603	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	6	72	theme	H2O2-	1632:1636	arg1	inhibition					1613:1622	potent inhibition	1606:1622	potent inhibition of both H2O2- and LPS-induced ROS	1606:1656	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	0	73	theme	biological	32:41	arg1	activity					43:50	biological activity	32:50	biological activity	32:50	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	1	74	theme	coastal	227:233	arg1	regions					235:241	the tropical coastal regions	214:241	the tropical coastal regions	214:241	Marcia hiantina (Mollusca, Bivalvia) (Lamarck, 1818), is an edible clam mainly distributed along the tropical coastal regions.
36454453	5	75	theme	RAW264.7	1403:1410	arg1	cells					1412:1416	RAW264.7 cells	1403:1416	RAW264.7 cells	1403:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	2	76	theme	biological	362:371	arg1	antitumor					425:433	antitumor	425:433	antitumor	425:433	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	76	theme	biological	362:371	arg1	immunomodulatory					404:419	immunomodulatory	404:419	immunomodulatory	404:419	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	76	theme	biological	362:371	arg1	antioxidant					391:401	antioxidant	391:401	antioxidant	391:401	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	2	76	theme	biological	362:371	arg1	actions					373:379	biological actions	362:379	biological actions including antioxidant, immunomodulatory and antitumor activities	362:444	Recent researches have demonstrated that clams can possess compounds, including polysaccharides, with a wide range of biological actions including antioxidant, immunomodulatory and antitumor activities.
36454453	5	77	dep	activities	1436:1445	arg1	iii					1420:1422	iii	1420:1422	iii	1420:1422	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	6	78	theme	potent	1606:1611	arg1	inhibition					1613:1622	potent inhibition	1606:1622	potent inhibition of both H2O2- and LPS-induced ROS	1606:1656	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	0	79	theme	α-glucan	58:65	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	0	79	theme	α-glucan	58:65	arg1	activity					43:50	biological activity	32:50	biological activity	32:50	Structural characterization and biological activity of an α-glucan from the mollusk Marcia hiantina (Lamarck, 1818).
36454453	3	80	dep	1H	661:662	arg1	spectra					737:743	1H-13C HSQC-NOESY spectra	719:743	1H-13C HSQC-NOESY spectra	719:743	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	80	dep	1H	661:662	arg1	COSY					671:674	1H-1H COSY	665:674	1H-1H COSY	665:674	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	80	dep	1H	661:662	arg1	TOCSY					683:687	1H-1H TOCSY	677:687	1H-1H TOCSY	677:687	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	80	dep	1H	661:662	arg1	NOESY					696:700	1H-1H NOESY	690:700	1H-1H NOESY	690:700	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	80	dep	1H	661:662	arg1	HSQC					710:713	1H-13C HSQC	703:713	1H-13C HSQC	703:713	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	81	theme	-induced	1366:1373	arg1	production					1389:1398	lipopolysaccharide (LPS)-induced prostaglandin production	1342:1398	lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1342:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	3	82	theme	resonance	633:641	arg1	methods					649:655	multiple nuclear magnetic resonance (NMR) methods	607:655	multiple nuclear magnetic resonance (NMR) methods	607:655	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	83	theme	lines	1289:1293	arg1	viability					1265:1273	(i) viability	1261:1273	(i) viability of three cell lines (RAW264.7, HaCaT, and HT-29)	1261:1322	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	83	theme	lines	1289:1293	arg1	assays					1253:1258	four cell-based assays	1237:1258	four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation	1237:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	83	theme	lines	1289:1293	arg1	activity					1330:1337	(ii) activity	1325:1337	(ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1325:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	83	theme	lines	1289:1293	arg1	proliferation					1551:1563	(iv) HaCaT cell proliferation	1535:1563	(iv) HaCaT cell proliferation	1535:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	83	theme	lines	1289:1293	arg1	activities					1436:1445	(iii) inhibitory activities	1419:1445	(iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1419:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	84	from	H2O2-	1453:1457	arg1	cells					1524:1528	HMC3 cells	1519:1528	HMC3 cells	1519:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	85	from	4-linked	1091:1098	arg1	backbone					1107:1114	its backbone	1103:1114	its backbone	1103:1114	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	5	86	dep	assays	1253:1258	arg1	viability					1265:1273	(i) viability	1261:1273	(i) viability of three cell lines (RAW264.7, HaCaT, and HT-29)	1261:1322	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	86	dep	assays	1253:1258	arg1	activity					1330:1337	(ii) activity	1325:1337	(ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells	1325:1416	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	86	dep	assays	1253:1258	arg1	proliferation					1551:1563	(iv) HaCaT cell proliferation	1535:1563	(iv) HaCaT cell proliferation	1535:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	86	dep	assays	1253:1258	arg1	activities					1436:1445	(iii) inhibitory activities	1419:1445	(iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells	1419:1528	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	86	dep	assays	1253:1258	arg1	assays					1253:1258	four cell-based assays	1237:1258	four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation	1237:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	87	theme	hiantina-derived	983:998	arg1	α-glycan					1000:1007	M. hiantina-derived α-glycan	980:1007	M. hiantina-derived α-glycan	980:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	6	88	theme	proliferative	1675:1687	arg1	activity					1689:1696	potent cell proliferative activity	1663:1696	potent cell proliferative activity	1663:1696	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	4	89	theme	~ 570 kDa	1188:1196	arg1	weight					1178:1183	a molecular weight	1166:1183	a molecular weight of ~ 570 kDa	1166:1196	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
36454453	3	90	dep	combination	592:602	arg1	1H					661:662	1D 1H	658:662	1D 1H	658:662	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	6	91	theme	potent	1663:1668	arg1	activity					1689:1696	potent cell proliferative activity	1663:1696	potent cell proliferative activity	1663:1696	Results have indicated no cytotoxicity, potent inhibition of both H2O2- and LPS-induced ROS, and potent cell proliferative activity.
36454453	3	92	theme	methods	649:655	arg1	spectrometry					771:782	gas chromatography-mass spectrometry	747:782	gas chromatography-mass spectrometry	747:782	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	92	theme	methods	649:655	arg1	HPSEC					837:841	HPSEC	837:841	HPSEC	837:841	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	92	theme	methods	649:655	arg1	combination					592:602	a combination	590:602	a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra)	590:744	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	3	92	theme	methods	649:655	arg1	chromatography					821:834	high performance size exclusion chromatography	789:834	high performance size exclusion chromatography (HPSEC)	789:842	Here an α-glucan was isolated from M. hiantina by hot water, purified by anion exchange chromatography, and its structure was characterized by a combination of multiple nuclear magnetic resonance (NMR) methods (1D 1H, 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C HSQC-NOESY spectra), gas chromatography-mass spectrometry, and high performance size exclusion chromatography (HPSEC).
36454453	5	93	theme	HaCaT	1540:1544	arg1	assays					1253:1258	four cell-based assays	1237:1258	four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation	1237:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	5	93	theme	HaCaT	1540:1544	arg1	proliferation					1551:1563	(iv) HaCaT cell proliferation	1535:1563	(iv) HaCaT cell proliferation	1535:1563	The mollusk α-glucan was subjected to four cell-based assays: (i) viability of three cell lines (RAW264.7, HaCaT, and HT-29), (ii) activity on lipopolysaccharide (LPS)-induced prostaglandin production in RAW264.7 cells, (iii) inhibitory activities of in H2O2- and LPS-induced reactive oxygen species (ROS) production in HMC3 cells, and (iv) HaCaT cell proliferation.
36454453	4	94	from	composition	883:893	arg1	analysis					849:856	The analysis	845:856	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan	845:1007	The analysis from NMR, monosaccharide composition, methylation analyses and HPSEC combined with multi-angle light scattering (MALS) of M. hiantina-derived α-glycan confirmed a branched polysaccharide exclusively composed of glucose (Glc), mostly 4-linked in its backbone, branched occasionally at 6-positions, and having a molecular weight of ~ 570 kDa.
35425970	4	0	theme	female	621:626	arg1	monkeys					644:650	female and male rhesus monkeys	621:650	female and male rhesus monkeys	621:650	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	4	1	theme	male	632:635	arg1	monkeys					644:650	female and male rhesus monkeys	621:650	female and male rhesus monkeys	621:650	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	7	2	theme	E	905:905	arg1	types					914:918	The E and iE types	901:918	types	914:918	The E and iE types were specifically distributed not only in the tracheal tissue but also in gastrointestinal tissues.
35425970	2	3	theme	compositions	326:337	arg1	understanding					305:317	an understanding	302:317	an understanding of the compositions of GAGs in their tissues	302:362	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	3	theme	compositions	326:337	arg1	important					367:375	important	367:375	important	367:375	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	4	from	primate	270:276	arg1	research					292:299	biomedical research	281:299	biomedical research	281:299	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	6	5	theme	present	858:864	arg1	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	5	theme	present	858:864	arg1	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	0	6	from	analysis	14:21	arg1	mulatta					81:87	Macaca mulatta	74:87	Macaca mulatta	74:87	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	0	6	from	analysis	14:21	arg1	monkeys					65:71	rhesus monkeys	58:71	rhesus monkeys (Macaca mulatta)	58:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	6	7	theme	C	892:892	arg1	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	7	theme	C	892:892	arg1	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	2	8	from	research	292:299	arg1	primate					270:276	primate	270:276	primate	270:276	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	4	9	theme	sulfate	535:541	arg1	chain					577:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	1	10	located	found	121:125	arg2	GAGs					111:114	GAGs	111:114	GAGs	111:114	Glycosaminoglycans (GAGs) are found in various tissues and are involved in many physiological functions.
35425970	1	10	located	found	121:125	arg1	tissues					138:144	various tissues	130:144	various tissues	130:144	Glycosaminoglycans (GAGs) are found in various tissues and are involved in many physiological functions.
35425970	1	10	located	found	121:125	arg2	Glycosaminoglycans					91:108	Glycosaminoglycans	91:108	Glycosaminoglycans (GAGs)	91:115	Glycosaminoglycans (GAGs) are found in various tissues and are involved in many physiological functions.
35425970	6	11	theme	CS/DS	833:837	arg1	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	11	theme	CS/DS	833:837	arg1	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	12	theme	disaccharide	839:850	arg1	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	12	theme	disaccharide	839:850	arg1	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	0	13	from	monkeys	65:71	arg1	analysis					14:21	Compositional analysis	0:21	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta)	0:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	6	14	from	present	858:864	arg1	tissues					873:879	the tissues	869:879	the tissues	869:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	3	15	theme	rhesus	504:509	arg1	monkey					511:516	the rhesus monkey	500:516	the rhesus monkey	500:516	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	6	16	theme	major	827:831	arg1	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	16	theme	major	827:831	arg1	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	5	17	theme	CS/DS	778:782	arg1	chain					791:795	the CS/DS hybrid chain	774:795	the CS/DS hybrid chain	774:795	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	3	18	theme	study	394:398	arg1	aim					382:384	The aim	378:384	The aim of this study	378:398	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	2	19	from	compositions	326:337	arg1	tissues					356:362	their tissues	350:362	their tissues	350:362	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	5	20	theme	sulfation	753:761	arg1	pattern					763:769	the sulfation pattern	749:769	the sulfation pattern of the CS/DS hybrid chain	749:795	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	0	21	from	sulfate	47:53	arg1	mulatta					81:87	Macaca mulatta	74:87	Macaca mulatta	74:87	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	0	21	from	sulfate	47:53	arg1	monkeys					65:71	rhesus monkeys	58:71	rhesus monkeys (Macaca mulatta)	58:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	1	22	theme	many	166:169	arg1	functions					185:193	many physiological functions	166:193	many physiological functions	166:193	Glycosaminoglycans (GAGs) are found in various tissues and are involved in many physiological functions.
35425970	0	23	theme	Compositional	0:12	arg1	analysis					14:21	Compositional analysis	0:21	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta)	0:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	7	24	theme	gastrointestinal	994:1009	arg1	tissues					1011:1017	gastrointestinal tissues	994:1017	gastrointestinal tissues	994:1017	The E and iE types were specifically distributed not only in the tracheal tissue but also in gastrointestinal tissues.
35425970	2	25	from	GAGs	342:345	arg1	tissues					356:362	their tissues	350:362	their tissues	350:362	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	26	theme	biomedical	281:290	arg1	research					292:299	biomedical research	281:299	biomedical research	281:299	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	1	27	theme	physiological	171:183	arg1	functions					185:193	many physiological functions	166:193	many physiological functions	166:193	Glycosaminoglycans (GAGs) are found in various tissues and are involved in many physiological functions.
35425970	0	28	theme	chondroitin/dermatan	26:45	arg1	sulfate					47:53	chondroitin/dermatan sulfate	26:53	chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta)	26:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	5	29	dep	chondroitinases	711:725	arg1	chondroitinases					711:725	chondroitinases ABC and ACI	711:737	chondroitinases ABC and ACI	711:737	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	5	29	dep	chondroitinases	711:725	arg1	ACI					735:737	ACI	735:737	ACI	735:737	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	5	29	dep	chondroitinases	711:725	arg1	ABC					727:729	ABC	727:729	ABC	727:729	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	3	30	theme	monkey	511:516	arg1	tissues					489:495	several tissues	481:495	several tissues of the rhesus monkey	481:516	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	4	31	theme	hybrid	570:575	arg1	chain					577:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	7	32	theme	iE	911:912	arg1	types					914:918	The E and iE types	901:918	types	914:918	The E and iE types were specifically distributed not only in the tracheal tissue but also in gastrointestinal tissues.
35425970	4	33	theme	chondroitin	523:533	arg1	CS					544:545	CS	544:545	CS	544:545	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	4	33	theme	chondroitin	523:533	arg1	sulfate					535:541	chondroitin sulfate	523:541	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	1	34	theme	various	130:136	arg1	tissues					138:144	various tissues	130:144	various tissues	130:144	Glycosaminoglycans (GAGs) are found in various tissues and are involved in many physiological functions.
35425970	3	35	theme	disaccharides	454:466	arg1	pattern					443:449	sulfation pattern	433:449	sulfation pattern	433:449	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	3	35	theme	disaccharides	454:466	arg1	content					421:427	content	421:427	content	421:427	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	7	36	theme	tracheal	966:973	arg1	tissue					975:980	the tracheal tissue	962:980	the tracheal tissue	962:980	The E and iE types were specifically distributed not only in the tracheal tissue but also in gastrointestinal tissues.
35425970	2	37	used	used	256:259	arg2	mulatta					228:234	Macaca mulatta	221:234	Macaca mulatta	221:234	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	37	used	used	256:259	arg2	monkey					213:218	the rhesus monkey	202:218	the rhesus monkey (Macaca mulatta)	202:235	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	38	theme	Macaca	221:226	arg1	monkey					213:218	the rhesus monkey	202:218	the rhesus monkey (Macaca mulatta)	202:235	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	38	theme	Macaca	221:226	arg1	mulatta					228:234	Macaca mulatta	221:234	Macaca mulatta	221:234	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	4	39	theme	several	602:608	arg1	tissues					610:616	several tissues	602:616	several tissues of female and male rhesus monkeys	602:650	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	5	40	theme	hybrid	784:789	arg1	chain					791:795	the CS/DS hybrid chain	774:795	the CS/DS hybrid chain	774:795	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	0	41	theme	sulfate	47:53	arg1	analysis					14:21	Compositional analysis	0:21	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta)	0:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	6	42	theme	A	886:886	arg1	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	42	theme	A	886:886	arg1	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	5	43	theme	Compositional	653:665	arg1	analysis					667:674	Compositional analysis	653:674	Compositional analysis	653:674	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	5	44	theme	chain	791:795	arg1	pattern					763:769	the sulfation pattern	749:769	the sulfation pattern of the CS/DS hybrid chain	749:795	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	6	45	from	tissues	873:879	arg1	present					858:864	present	858:864	present	858:864	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	4	46	theme	monkeys	644:650	arg1	tissues					610:616	several tissues	602:616	several tissues of female and male rhesus monkeys	602:650	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	0	47	theme	rhesus	58:63	arg1	mulatta					81:87	Macaca mulatta	74:87	Macaca mulatta	74:87	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	0	47	theme	rhesus	58:63	arg1	monkeys					65:71	rhesus monkeys	58:71	rhesus monkeys (Macaca mulatta)	58:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	2	48	theme	rhesus	206:211	arg1	monkey					213:218	the rhesus monkey	202:218	the rhesus monkey (Macaca mulatta)	202:235	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	2	48	theme	rhesus	206:211	arg1	mulatta					228:234	Macaca mulatta	221:234	Macaca mulatta	221:234	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	4	49	theme	rhesus	637:642	arg1	monkeys					644:650	female and male rhesus monkeys	621:650	female and male rhesus monkeys	621:650	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	2	50	from	tissues	356:362	arg1	compositions					326:337	the compositions	322:337	the compositions of GAGs in their tissues	322:362	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	4	51	theme	sulfate	557:563	arg1	chain					577:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	3	52	theme	sulfation	433:441	arg1	pattern					443:449	sulfation pattern	433:449	sulfation pattern	433:449	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	4	53	theme	/dermatan	547:555	arg1	chain					577:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	0	54	theme	Macaca	74:79	arg1	mulatta					81:87	Macaca mulatta	74:87	Macaca mulatta	74:87	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	0	54	theme	Macaca	74:79	arg1	monkeys					65:71	rhesus monkeys	58:71	rhesus monkeys (Macaca mulatta)	58:88	Compositional analysis of chondroitin/dermatan sulfate in rhesus monkeys (Macaca mulatta).
35425970	5	55	with	digestion	696:704	arg1	chondroitinases					711:725	chondroitinases ABC and ACI	711:737	chondroitinases ABC and ACI	711:737	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	5	55	with	digestion	696:704	arg1	ACI					735:737	ACI	735:737	ACI	735:737	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	5	55	with	digestion	696:704	arg1	ABC					727:729	ABC	727:729	ABC	727:729	Compositional analysis was performed after digestion with chondroitinases ABC and ACI to reveal the sulfation pattern of the CS/DS hybrid chain.
35425970	6	56	attach	present	858:864	arg2	units					852:856	the major CS/DS disaccharide units	823:856	the major CS/DS disaccharide units present in the tissues	823:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	56	attach	present	858:864	arg2	types					894:898	A and C types	886:898	A and C types	886:898	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	6	56	attach	present	858:864	arg1	tissues					873:879	the tissues	869:879	the tissues	869:879	This study revealed that the major CS/DS disaccharide units present in the tissues were A and C types.
35425970	2	57	theme	GAGs	342:345	arg1	compositions					326:337	the compositions	322:337	the compositions of GAGs in their tissues	322:362	Since the rhesus monkey (Macaca mulatta) is the most widely used nonhuman primate in biomedical research, an understanding of the compositions of GAGs in their tissues is important.
35425970	4	58	theme	DS	566:567	arg1	chain					577:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain	519:581	The chondroitin sulfate (CS)/dermatan sulfate (DS) hybrid chain was extracted from several tissues of female and male rhesus monkeys.
35425970	3	59	dep	content	421:427	arg1	the					417:419	the	417:419	the	417:419	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
35425970	3	60	theme	several	481:487	arg1	tissues					489:495	several tissues	481:495	several tissues of the rhesus monkey	481:516	The aim of this study was to determine the content and sulfation pattern of disaccharides contained in several tissues of the rhesus monkey.
36813234	7	0	theme	NF-κB	1189:1193	arg1	pathway					1195:1201	the NF-κB pathway	1185:1201	the NF-κB pathway	1185:1201	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	5	1	gly	P-glycoprotein	826:839	arg1	P-glycoprotein					826:839	P-glycoprotein	826:839	P-glycoprotein (P-gp)	826:846	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	5	1	gly	P-glycoprotein	826:839	arg1	P-gp					842:845	P-gp	842:845	P-gp	842:845	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	6	2	theme	GnT-III	1023:1029	arg1	overexpression					1005:1018	the overexpression	1001:1018	the overexpression of GnT-III in K562/ADR cells	1001:1047	These upregulations were sufficiently suppressed by the overexpression of GnT-III in K562/ADR cells.
36813234	1	3	theme	resistance	179:188	arg1	phenomenon					155:164	The phenomenon	151:164	The phenomenon of multidrug resistance (MDR)	151:194	The phenomenon of multidrug resistance (MDR) is called chemoresistance with respect to the treatment of cancer, and it continues to be a major challenge.
36813234	7	4	theme	pathway	1195:1201	arg1	chemoresistance					1113:1127	chemoresistance	1113:1127	chemoresistance for doxorubicin and dasatinib	1113:1157	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	4	theme	pathway	1195:1201	arg1	activation					1171:1180	activation	1171:1180	activation of the NF-κB pathway	1171:1201	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	5	theme	GnT-III	1082:1088	arg1	expression					1068:1077	the expression	1064:1077	the expression of GnT-III	1064:1088	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	11	6	theme	TNFR2-NF/κB	1908:1918	arg1	pathway					1930:1936	the TNFR2-NF/κB signaling pathway	1904:1936	the TNFR2-NF/κB signaling pathway	1904:1936	Taken together, these results clearly show that GnT-III negatively regulates chemoresistance via the suppression of P-gp expression, which is regulated by the TNFR2-NF/κB signaling pathway.
36813234	4	7	from	levels	754:759	arg1	cells					776:780	parent K562 cells	764:780	parent K562 cells	764:780	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	4	8	theme	bisected	669:676	arg1	N-glycans					678:686	bisected N-glycans	669:686	bisected N-glycans	669:686	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	2	9	from	role	309:312	arg1	chemoresistance					336:350	chemoresistance	336:350	chemoresistance	336:350	The role of N-glycosylation in chemoresistance, however, remains poorly understood.
36813234	4	10	theme	RT-PCR	547:552	arg1	analysis					554:561	RT-PCR analysis	547:561	RT-PCR analysis	547:561	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	0	11	gly	P-glycoprotein	74:87	arg1	P-glycoprotein					74:87	P-glycoprotein expression	74:98	P-glycoprotein expression	74:98	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	9	12	theme	GnT-III	1496:1502	arg1	lack					1488:1491	The lack	1484:1491	The lack of GnT-III	1484:1502	The lack of GnT-III strongly induced TNFR2's auto-trimerization without ligand stimulation, which was rescued by the overexpression of GnT-III in K562/ADR cells.
36813234	4	13	dep	decreased	707:715	arg1	compared					736:743	compared	736:743	compared with the levels in parent K562 cells	736:780	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	7	14	theme	cell	1352:1355	arg1	surface					1357:1363	the cell surface	1348:1363	the cell surface	1348:1363	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	4	15	theme	N-glycans	678:686	arg1	levels					590:595	the expression levels	575:595	the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans,	575:687	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	5	16	theme	NF-κB	885:889	arg1	regulator					874:882	its intracellular key regulator	852:882	its intracellular key regulator	852:882	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	5	16	theme	NF-κB	885:889	arg1	signaling					891:899	NF-κB signaling	885:899	NF-κB signaling	885:899	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	0	17	theme	signaling	132:140	arg1	pathway					142:148	the TNFR2-NF-κB signaling pathway	116:148	the TNFR2-NF-κB signaling pathway	116:148	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	5	18	theme	expression	800:809	arg1	levels					811:816	the expression levels	796:816	the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling,	796:900	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	5	19	theme	K562/ADR	933:940	arg1	cells					942:946	K562/ADR cells	933:946	K562/ADR cells	933:946	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	7	20	theme	distinct	1270:1277	arg1	glycoproteins					1279:1291	two structurally distinct glycoproteins	1253:1291	two structurally distinct glycoproteins	1253:1291	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	20	theme	distinct	1270:1277	arg1	receptor					1298:1305	TNF receptor 1	1294:1307	TNF receptor 1 (TNFR1)	1294:1315	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	20	theme	distinct	1270:1277	arg1	receptor					1325:1332	TNF receptor 2	1321:1334	TNF receptor 2 (TNFR2)	1321:1342	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	4	21	theme	mRNA	646:649	arg1	levels					590:595	the expression levels	575:595	the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans,	575:687	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	0	22	theme	TNFR2-NF-κB	120:130	arg1	pathway					142:148	the TNFR2-NF-κB signaling pathway	116:148	the TNFR2-NF-κB signaling pathway	116:148	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	3	23	theme	adriamycin	434:443	arg1	resistance					445:454	adriamycin resistance	434:454	adriamycin resistance in K562 cells, which are also known as K562/ADR cells	434:508	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	7	24	gly	glycoproteins	1279:1291	arg1	glycoproteins					1279:1291	two structurally distinct glycoproteins	1253:1291	two structurally distinct glycoproteins	1253:1291	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	24	gly	glycoproteins	1279:1291	arg1	receptor					1298:1305	TNF receptor 1	1294:1307	TNF receptor 1 (TNFR1)	1294:1315	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	24	gly	glycoproteins	1279:1291	arg1	receptor					1325:1332	TNF receptor 2	1321:1334	TNF receptor 2 (TNFR2)	1321:1342	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	6	25	from	overexpression	1005:1018	arg1	cells					1043:1047	K562/ADR cells	1034:1047	K562/ADR cells	1034:1047	These upregulations were sufficiently suppressed by the overexpression of GnT-III in K562/ADR cells.
36813234	4	26	theme	K562/ADR	720:727	arg1	cells					729:733	K562/ADR cells	720:733	K562/ADR cells	720:733	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	3	27	theme	traditional	412:422	arg1	model					424:428	a traditional model	410:428	a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells	410:508	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	8	28	theme	bisected	1464:1471	arg1	N-glycans					1473:1481	bisected N-glycans	1464:1481	bisected N-glycans	1464:1481	Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
36813234	6	29	theme	K562/ADR	1034:1041	arg1	cells					1043:1047	K562/ADR cells	1034:1047	K562/ADR cells	1034:1047	These upregulations were sufficiently suppressed by the overexpression of GnT-III in K562/ADR cells.
36813234	4	30	theme	mass	524:527	arg1	spectrometry					529:540	mass spectrometry	524:540	mass spectrometry	524:540	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	9	31	theme	GnT-III	1619:1625	arg1	overexpression					1601:1614	the overexpression	1597:1614	the overexpression of GnT-III in K562/ADR cells	1597:1643	The lack of GnT-III strongly induced TNFR2's auto-trimerization without ligand stimulation, which was rescued by the overexpression of GnT-III in K562/ADR cells.
36813234	3	32	theme	K562	459:462	arg1	cells					504:508	K562/ADR cells	495:508	K562/ADR cells	495:508	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	3	32	theme	K562	459:462	arg1	cells					464:468	K562 cells	459:468	K562 cells	459:468	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	0	33	theme	GnT-III	14:20	arg1	Expression					0:9	Expression	0:9	Expression of GnT-III	0:20	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	0	34	theme	pathway	142:148	arg1	Involvement					101:111	Involvement	101:111	Involvement of the TNFR2-NF-κB signaling pathway	101:148	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	5	35	theme	intracellular	856:868	arg1	regulator					874:882	its intracellular key regulator	852:882	its intracellular key regulator	852:882	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	5	35	theme	intracellular	856:868	arg1	signaling					891:899	NF-κB signaling	885:899	NF-κB signaling	885:899	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	10	36	theme	TNFR2	1677:1681	arg1	deficiency					1663:1672	the deficiency	1659:1672	the deficiency of TNFR2	1659:1681	Furthermore, the deficiency of TNFR2 suppressed P-gp expression while it increased GnT-III expression.
36813234	4	37	theme	N-acetylglucosaminyltransferase	600:630	arg1	mRNA					646:649	N-acetylglucosaminyltransferase III (GnT-III) mRNA	600:649	N-acetylglucosaminyltransferase III (GnT-III) mRNA	600:649	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	1	38	theme	major	288:292	arg1	it					267:268	it	267:268	it	267:268	The phenomenon of multidrug resistance (MDR) is called chemoresistance with respect to the treatment of cancer, and it continues to be a major challenge.
36813234	1	38	theme	major	288:292	arg1	challenge					294:302	a major challenge	286:302	a major challenge	286:302	The phenomenon of multidrug resistance (MDR) is called chemoresistance with respect to the treatment of cancer, and it continues to be a major challenge.
36813234	9	39	theme	K562/ADR	1630:1637	arg1	cells					1639:1643	K562/ADR cells	1630:1643	K562/ADR cells	1630:1643	The lack of GnT-III strongly induced TNFR2's auto-trimerization without ligand stimulation, which was rescued by the overexpression of GnT-III in K562/ADR cells.
36813234	7	40	theme	TNF	1321:1323	arg1	TNFR2					1337:1341	TNFR2	1337:1341	TNFR2	1337:1341	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	40	theme	TNF	1321:1323	arg1	glycoproteins					1279:1291	two structurally distinct glycoproteins	1253:1291	two structurally distinct glycoproteins	1253:1291	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	40	theme	TNF	1321:1323	arg1	receptor					1325:1332	TNF receptor 2	1321:1334	TNF receptor 2 (TNFR2)	1321:1342	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	11	41	theme	P-gp	1865:1868	arg1	expression					1870:1879	P-gp expression	1865:1879	P-gp expression	1865:1879	Taken together, these results clearly show that GnT-III negatively regulates chemoresistance via the suppression of P-gp expression, which is regulated by the TNFR2-NF/κB signaling pathway.
36813234	4	42	theme	Lectin	511:516	arg1	blot					518:521	Lectin blot	511:521	Lectin blot	511:521	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	3	43	from	resistance	445:454	arg1	cells					504:508	K562/ADR cells	495:508	K562/ADR cells	495:508	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	3	43	from	resistance	445:454	arg1	cells					464:468	K562 cells	459:468	K562 cells	459:468	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	11	44	theme	expression	1870:1879	arg1	suppression					1850:1860	the suppression	1846:1860	the suppression	1846:1860	Taken together, these results clearly show that GnT-III negatively regulates chemoresistance via the suppression of P-gp expression, which is regulated by the TNFR2-NF/κB signaling pathway.
36813234	7	45	theme	tumor	1206:1210	arg1	factor					1221:1226	tumor necrosis factor α	1206:1228	tumor necrosis factor α (TNFα)	1206:1235	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	45	theme	tumor	1206:1210	arg1	TNFα					1231:1234	TNFα	1231:1234	TNFα	1231:1234	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	10	46	theme	GnT-III	1729:1735	arg1	expression					1737:1746	GnT-III expression	1729:1746	GnT-III expression	1729:1746	Furthermore, the deficiency of TNFR2 suppressed P-gp expression while it increased GnT-III expression.
36813234	5	47	theme	key	870:872	arg1	regulator					874:882	its intracellular key regulator	852:882	its intracellular key regulator	852:882	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	5	47	theme	key	870:872	arg1	signaling					891:899	NF-κB signaling	885:899	NF-κB signaling	885:899	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	8	48	theme	immunoprecipitation	1385:1403	arg1	analysis					1405:1412	our immunoprecipitation analysis	1381:1412	our immunoprecipitation analysis	1381:1412	Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
36813234	7	49	theme	TNF	1294:1296	arg1	glycoproteins					1279:1291	two structurally distinct glycoproteins	1253:1291	two structurally distinct glycoproteins	1253:1291	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	49	theme	TNF	1294:1296	arg1	receptor					1298:1305	TNF receptor 1	1294:1307	TNF receptor 1 (TNFR1)	1294:1315	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	49	theme	TNF	1294:1296	arg1	TNFR1					1310:1314	TNFR1	1310:1314	TNFR1	1310:1314	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	5	50	theme	regulator	874:882	arg1	levels					811:816	the expression levels	796:816	the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling,	796:900	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	10	51	theme	P-gp	1694:1697	arg1	expression					1699:1708	P-gp expression	1694:1708	P-gp expression	1694:1708	Furthermore, the deficiency of TNFR2 suppressed P-gp expression while it increased GnT-III expression.
36813234	11	52	theme	signaling	1920:1928	arg1	pathway					1930:1936	the TNFR2-NF/κB signaling pathway	1904:1936	the TNFR2-NF/κB signaling pathway	1904:1936	Taken together, these results clearly show that GnT-III negatively regulates chemoresistance via the suppression of P-gp expression, which is regulated by the TNFR2-NF/κB signaling pathway.
36813234	4	53	theme	parent	764:769	arg1	cells					776:780	parent K562 cells	764:780	parent K562 cells	764:780	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	0	54	dep	decreases	22:30	arg1	Involvement					101:111	Involvement	101:111	Involvement of the TNFR2-NF-κB signaling pathway	101:148	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	2	55	theme	N-glycosylation	317:331	arg1	role					309:312	The role	305:312	The role of N-glycosylation in chemoresistance	305:350	The role of N-glycosylation in chemoresistance, however, remains poorly understood.
36813234	4	56	theme	expression	579:588	arg1	levels					590:595	the expression levels	575:595	the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans,	575:687	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	4	57	theme	products	659:666	arg1	levels					590:595	the expression levels	575:595	the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans,	575:687	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	9	58	theme	ligand	1556:1561	arg1	stimulation					1563:1573	ligand stimulation	1556:1573	ligand stimulation	1556:1573	The lack of GnT-III strongly induced TNFR2's auto-trimerization without ligand stimulation, which was rescued by the overexpression of GnT-III in K562/ADR cells.
36813234	9	59	from	overexpression	1601:1614	arg1	cells					1639:1643	K562/ADR cells	1630:1643	K562/ADR cells	1630:1643	The lack of GnT-III strongly induced TNFR2's auto-trimerization without ligand stimulation, which was rescued by the overexpression of GnT-III in K562/ADR cells.
36813234	3	60	theme	K562/ADR	495:502	arg1	cells					464:468	K562 cells	459:468	K562 cells	459:468	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	3	60	theme	K562/ADR	495:502	arg1	cells					504:508	K562/ADR cells	495:508	K562/ADR cells	495:508	Here, we established a traditional model for adriamycin resistance in K562 cells, which are also known as K562/ADR cells.
36813234	5	61	theme	P-glycoprotein	826:839	arg1	levels					811:816	the expression levels	796:816	the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling,	796:900	By contrast, the expression levels of both P-glycoprotein (P-gp) and its intracellular key regulator, NF-κB signaling, are significantly increased in K562/ADR cells.
36813234	0	62	theme	P-glycoprotein	74:87	arg1	expression					89:98	P-glycoprotein expression	74:98	P-glycoprotein expression	74:98	Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.
36813234	4	63	theme	K562	771:774	arg1	cells					776:780	parent K562 cells	764:780	parent K562 cells	764:780	Lectin blot, mass spectrometry, and RT-PCR analysis showed that the expression levels of N-acetylglucosaminyltransferase III (GnT-III) mRNA and its products, bisected N-glycans, are significantly decreased in K562/ADR cells, compared with the levels in parent K562 cells.
36813234	8	64	contain	contains	1455:1462	arg1	TNFR2					1433:1437	TNFR2	1433:1437	TNFR2	1433:1437	Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
36813234	8	64	contain	contains	1455:1462	arg1	TNFR1					1448:1452	TNFR1	1448:1452	TNFR1	1448:1452	Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
36813234	8	64	contain	contains	1455:1462	arg2	N-glycans					1473:1481	bisected N-glycans	1464:1481	bisected N-glycans	1464:1481	Interestingly, our immunoprecipitation analysis revealed that only TNFR2, but not TNFR1, contains bisected N-glycans.
36813234	1	65	theme	multidrug	169:177	arg1	MDR					191:193	MDR	191:193	MDR	191:193	The phenomenon of multidrug resistance (MDR) is called chemoresistance with respect to the treatment of cancer, and it continues to be a major challenge.
36813234	1	65	theme	multidrug	169:177	arg1	resistance					179:188	multidrug resistance	169:188	multidrug resistance (MDR)	169:194	The phenomenon of multidrug resistance (MDR) is called chemoresistance with respect to the treatment of cancer, and it continues to be a major challenge.
36813234	7	66	theme	necrosis	1212:1219	arg1	factor					1221:1226	tumor necrosis factor α	1206:1228	tumor necrosis factor α (TNFα)	1206:1235	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	7	66	theme	necrosis	1212:1219	arg1	TNFα					1231:1234	TNFα	1231:1234	TNFα	1231:1234	We found that the expression of GnT-III consistently decreased chemoresistance for doxorubicin and dasatinib, as well as activation of the NF-κB pathway by tumor necrosis factor α (TNFα), which binds to two structurally distinct glycoproteins, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2), on the cell surface.
36813234	1	67	theme	cancer	255:260	arg1	treatment					242:250	the treatment	238:250	the treatment of cancer	238:260	The phenomenon of multidrug resistance (MDR) is called chemoresistance with respect to the treatment of cancer, and it continues to be a major challenge.
35775947	0	0	theme	Galp	59:62	arg1	Glycomimetic					70:81	Glycomimetic	70:81	Glycomimetic of the Epitope Recognized by Lytic Antibodies	70:127	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	0	0	theme	Galp	59:62	arg1	Unit					64:67	the S-Galp(α1 → 3)Galp Unit	41:67	the S-Galp(α1 → 3)Galp Unit	41:67	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	4	1	theme	lytic	1012:1016	arg1	antibodies					1018:1027	lytic antibodies	1012:1027	lytic antibodies	1012:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	3	2	theme	synthetic	751:759	arg1	structures					761:770	the synthetic structures	747:770	the synthetic structures as well as the structural-related glycomimetics	747:818	To study the interaction between both activities, it is important to count the synthetic structures as well as the structural-related glycomimetics.
35775947	5	3	theme	common	1046:1051	arg1	precursor					1061:1069	a common lactose precursor	1044:1069	a common lactose precursor	1044:1069	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	1	4	theme	sialic	285:290	arg1	acid					292:295	sialic acid	285:295	sialic acid from the host glycoconjugates	285:325	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	5	5	theme	double	1112:1117	arg1	inversion					1119:1127	double inversion	1112:1127	double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors	1112:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	5	6	theme	lactose	1053:1059	arg1	precursor					1061:1069	a common lactose precursor	1044:1069	a common lactose precursor	1044:1069	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	1	7	theme	acid	292:295	arg1	transfer					273:280	the transfer	269:280	the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite	269:375	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	8	theme	Chagas	216:221	arg1	disease					223:229	Chagas disease	216:229	Chagas disease	216:229	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	5	9	theme	residue	1167:1173	arg1	configuration					1136:1148	the configuration	1132:1148	the configuration of the galactose residue that was further glycosylated using different activated donors	1132:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	6	10	theme	exchange	1371:1378	arg1	chromatography					1380:1393	high-performance anion exchange chromatography	1348:1393	high-performance anion exchange chromatography	1348:1393	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	1	11	theme	disease	223:229	arg1	cruzi					196:200	Trypanosoma cruzi	184:200	Trypanosoma cruzi	184:200	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	11	theme	disease	223:229	arg1	agent					207:211	the agent	203:211	the agent of Chagas disease	203:229	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	12	theme	lytic	397:401	arg1	antibodies					403:412	lytic antibodies	397:412	lytic antibodies	397:412	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	4	13	theme	-β-Galp	952:958	arg1	motif					960:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	13	theme	-β-Galp	952:958	arg1	analog					976:981	the thio analog	967:981	the thio analog of the epitope recognized by lytic antibodies	967:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	1	14	theme	important	134:142	arg1	activities					144:153	Two important activities	130:153	Two important activities	130:153	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	15	theme	host	306:309	arg1	glycoconjugates					311:325	the host glycoconjugates	302:325	the host glycoconjugates	302:325	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	6	16	theme	acid	1291:1294	arg1	acceptors					1271:1279	good acceptors	1266:1279	good acceptors of sialic acid	1266:1294	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	1	17	theme	antibodies	403:412	arg1	presence					385:392	the presence	381:392	the presence of lytic antibodies	381:412	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	5	18	theme	sulfur	1076:1081	arg1	function					1083:1090	the sulfur function	1072:1090	the sulfur function	1072:1090	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	4	19	theme	epitope	990:996	arg1	motif					960:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	19	theme	epitope	990:996	arg1	analog					976:981	the thio analog	967:981	the thio analog of the epitope recognized by lytic antibodies	967:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	20	theme	isomeric	894:901	arg1	tetrasaccharides					903:918	two isomeric tetrasaccharides	890:918	two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies	890:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	21	contain	containing	920:929	arg2	motif					960:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	21	contain	containing	920:929	arg1	tetrasaccharides					903:918	two isomeric tetrasaccharides	890:918	two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies	890:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	21	contain	containing	920:929	arg2	analog					976:981	the thio analog	967:981	the thio analog of the epitope recognized by lytic antibodies	967:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	2	22	theme	galactose	614:622	arg1	residues					624:631	the galactose residues	610:631	the galactose residues	610:631	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	1	23	from	glycoconjugates	311:325	arg1	transfer					273:280	the transfer	269:280	the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite	269:375	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	23	from	glycoconjugates	311:325	arg1	acid					292:295	sialic acid	285:295	sialic acid from the host glycoconjugates	285:325	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	24	dep	-β-Galp	449:455	arg1	3					447:447	3	447:447	3	447:447	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	0	25	theme	Epitope	90:96	arg1	Glycomimetic					70:81	Glycomimetic	70:81	Glycomimetic of the Epitope Recognized by Lytic Antibodies	70:127	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	0	25	theme	Epitope	90:96	arg1	Unit					64:67	the S-Galp(α1 → 3)Galp Unit	41:67	the S-Galp(α1 → 3)Galp Unit	41:67	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	1	26	theme	epitope	428:434	arg1	-β-Galp					449:455	1 → 3)-β-Galp(1 → 4	443:461	1 → 3)-β-Galp(1 → 4	443:461	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	26	theme	epitope	428:434	arg1	-α-GlcNAcp					463:472	the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp	424:472	the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp	424:472	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	2	27	theme	parasite	530:537	arg1	mucins					539:544	the parasite mucins	526:544	the parasite mucins	526:544	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	2	28	theme	β-Galp	650:655	arg1	configuration					657:669	the β-Galp configuration	646:669	the β-Galp configuration	646:669	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	6	29	theme	good	1266:1269	arg1	acceptors					1271:1279	good acceptors	1266:1279	good acceptors of sialic acid	1266:1294	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	0	30	theme	Oligosaccharides	13:28	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of Oligosaccharides	0:28	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	5	31	theme	configuration	1136:1148	arg1	inversion					1119:1127	double inversion	1112:1127	double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors	1112:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	3	32	theme	structural-related	787:804	arg1	glycomimetics					806:818	the structural-related glycomimetics	783:818	the synthetic structures as well as the structural-related glycomimetics	747:818	To study the interaction between both activities, it is important to count the synthetic structures as well as the structural-related glycomimetics.
35775947	4	33	theme	thio	971:974	arg1	motif					960:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	33	theme	thio	971:974	arg1	analog					976:981	the thio analog	967:981	the thio analog of the epitope recognized by lytic antibodies	967:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	0	34	theme	S-Galp	45:50	arg1	Glycomimetic					70:81	Glycomimetic	70:81	Glycomimetic of the Epitope Recognized by Lytic Antibodies	70:127	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	0	34	theme	S-Galp	45:50	arg1	Unit					64:67	the S-Galp(α1 → 3)Galp Unit	41:67	the S-Galp(α1 → 3)Galp Unit	41:67	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	2	35	located	present	515:521	arg2	structure					490:498	This antigenic structure	475:498	This antigenic structure	475:498	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	2	35	located	present	515:521	arg1	mucins					539:544	the parasite mucins	526:544	the parasite mucins	526:544	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	6	36	theme	sialic	1284:1289	arg1	acid					1291:1294	sialic acid	1284:1294	sialic acid	1284:1294	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	2	37	from	present	515:521	arg1	mucins					539:544	the parasite mucins	526:544	the parasite mucins	526:544	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	1	38	theme	mucin-like	334:343	arg1	glycoproteins					345:357	the mucin-like glycoproteins	330:357	the mucin-like glycoproteins from the parasite	330:375	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	39	theme	α-Galp	436:441	arg1	-β-Galp					449:455	1 → 3)-β-Galp(1 → 4	443:461	1 → 3)-β-Galp(1 → 4	443:461	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	39	theme	α-Galp	436:441	arg1	-α-GlcNAcp					463:472	the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp	424:472	the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp	424:472	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	0	40	theme	α1	52:53	arg1	S-Galp					45:50	S-Galp	45:50	the S-Galp(α1 → 3)Galp Unit	41:67	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	0	40	theme	α1	52:53	arg1	→					55:55	α1 → 3	52:57	α1 → 3	52:57	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	2	41	theme	antigenic	480:488	arg1	structure					490:498	This antigenic structure	475:498	This antigenic structure	475:498	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	2	42	from	mucins	539:544	arg1	present					515:521	present	515:521	present	515:521	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	4	43	theme	trisaccharide	872:884	arg1	synthesis					857:865	the synthesis	853:865	the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies	853:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	0	44	theme	Lytic	112:116	arg1	Antibodies					118:127	Lytic Antibodies	112:127	Lytic Antibodies	112:127	Synthesis of Oligosaccharides Containing the S-Galp(α1 → 3)Galp Unit, Glycomimetic of the Epitope Recognized by Lytic Antibodies.
35775947	5	45	gly	glycosylated	1192:1203	arg1	residue					1167:1173	the galactose residue	1153:1173	the galactose residue that was further glycosylated using different activated donors	1153:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	6	46	theme	anion	1365:1369	arg1	chromatography					1380:1393	high-performance anion exchange chromatography	1348:1393	high-performance anion exchange chromatography	1348:1393	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	6	47	from	acceptors	1271:1279	arg1	reaction					1303:1310	the reaction	1299:1310	the reaction catalyzed by TcTS	1299:1328	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	1	48	theme	→	445:445	arg1	-β-Galp					449:455	1 → 3)-β-Galp(1 → 4	443:461	1 → 3)-β-Galp(1 → 4	443:461	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	48	theme	→	445:445	arg1	-α-GlcNAcp					463:472	the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp	424:472	the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp	424:472	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	6	49	theme	high-performance	1348:1363	arg1	chromatography					1380:1393	high-performance anion exchange chromatography	1348:1393	high-performance anion exchange chromatography	1348:1393	Both tetrasaccharides were good acceptors of sialic acid in the reaction catalyzed by TcTS, as determined by high-performance anion exchange chromatography.
35775947	1	50	theme	Trypanosoma	184:194	arg1	cruzi					196:200	Trypanosoma cruzi	184:200	Trypanosoma cruzi	184:200	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	50	theme	Trypanosoma	184:194	arg1	agent					207:211	the agent	203:211	the agent of Chagas disease	203:229	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	2	51	theme	trans-sialidase	585:599	arg1	substrates					571:580	substrates	571:580	substrates of trans-sialidase	571:599	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	5	52	theme	different	1211:1219	arg1	donors					1231:1236	different activated donors	1211:1236	different activated donors	1211:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	5	53	theme	galactose	1157:1165	arg1	residue					1167:1173	the galactose residue	1153:1173	the galactose residue that was further glycosylated using different activated donors	1153:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	1	54	gly	glycoproteins	345:357	arg1	glycoproteins					345:357	the mucin-like glycoproteins	330:357	the mucin-like glycoproteins from the parasite	330:375	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	55	theme	cruzi	196:200	arg1	surface					173:179	the surface	169:179	the surface of Trypanosoma cruzi, the agent of Chagas disease	169:229	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	1	56	from	parasite	368:375	arg1	glycoproteins					345:357	the mucin-like glycoproteins	330:357	the mucin-like glycoproteins from the parasite	330:375	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	5	57	theme	activated	1221:1229	arg1	donors					1231:1236	different activated donors	1211:1236	different activated donors	1211:1236	Starting with a common lactose precursor, the sulfur function was incorporated by double inversion of the configuration of the galactose residue that was further glycosylated using different activated donors.
35775947	2	58	attach	present	515:521	arg2	structure					490:498	This antigenic structure	475:498	This antigenic structure	475:498	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	2	58	attach	present	515:521	arg1	mucins					539:544	the parasite mucins	526:544	the parasite mucins	526:544	This antigenic structure is known to be present in the parasite mucins; however, in order to be substrates of trans-sialidase, some of the galactose residues should be in the β-Galp configuration.
35775947	1	59	from	transfer	273:280	arg1	glycoconjugates					311:325	the host glycoconjugates	302:325	the host glycoconjugates	302:325	Two important activities take place in the surface of Trypanosoma cruzi, the agent of Chagas disease: the trans-sialidase (TcTS) catalyzes the transfer of sialic acid from the host glycoconjugates to the mucin-like glycoproteins from the parasite and the presence of lytic antibodies recognize the epitope α-Galp(1 → 3)-β-Galp(1 → 4)-α-GlcNAcp.
35775947	4	60	theme	tetrasaccharides	903:918	arg1	synthesis					857:865	the synthesis	853:865	the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies	853:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	61	theme	1-S-α-Galp	935:944	arg1	motif					960:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	the 1-S-α-Galp(1 → 3)-β-Galp motif	931:964	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35775947	4	61	theme	1-S-α-Galp	935:944	arg1	analog					976:981	the thio analog	967:981	the thio analog of the epitope recognized by lytic antibodies	967:1027	With this purpose, we addressed the synthesis of a trisaccharide and two isomeric tetrasaccharides containing the 1-S-α-Galp(1 → 3)-β-Galp motif, the thio analog of the epitope recognized by lytic antibodies.
35405095	7	0	theme	O-glycan-binding	1147:1162	arg1	residues					1164:1171	O-glycan-binding residues	1147:1171	O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family	1147:1254	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	4	1	theme	enzymatic	692:700	arg1	machinery					702:710	the enzymatic machinery	688:710	the enzymatic machinery used by this microbe to process mucins in the gut	688:760	Although A. muciniphila is known to rely on mucins as a carbon and nitrogen source, the enzymatic machinery used by this microbe to process mucins in the gut is not yet fully characterized.
35405095	6	2	from	component	1051:1059	arg1	gut					1077:1079	the gut	1073:1079	the gut	1073:1079	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	1	3	theme	human	189:193	arg1	gut					195:197	the human gut	185:197	the human gut	185:197	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	8	4	theme	cleavage	1295:1302	arg1	motif					1304:1308	the substrate cleavage motif	1281:1308	the substrate cleavage motif	1281:1308	We further rationalized the substrate cleavage motif using molecular modeling to identify nonconserved glycan-interacting residues.
35405095	0	5	theme	substrate	102:110	arg1	preferences					112:122	substrate preferences	102:122	substrate preferences	102:122	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila alters substrate preferences.
35405095	1	6	located	found	176:180	arg2	muciniphila					137:147	Akkermansia muciniphila	125:147	Akkermansia muciniphila	125:147	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	1	6	located	found	176:180	arg2	microbe					168:174	a mucin-degrading microbe	150:174	a mucin-degrading microbe found in the human gut	150:197	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	1	6	located	found	176:180	arg1	gut					195:197	the human gut	185:197	the human gut	185:197	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	6	7	theme	major	1037:1041	arg1	component					1051:1059	the major protein component	1033:1059	the major protein component of mucus in the gut	1033:1079	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	6	7	theme	major	1037:1041	arg1	MUC2					1026:1029	purified mucin 2 (MUC2)	1008:1030	purified mucin 2 (MUC2)	1008:1030	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	8	8	theme	nonconserved	1347:1358	arg1	residues					1379:1386	nonconserved glycan-interacting residues	1347:1386	nonconserved glycan-interacting residues	1347:1386	We further rationalized the substrate cleavage motif using molecular modeling to identify nonconserved glycan-interacting residues.
35405095	3	9	theme	competitive	521:531	arg1	advantage					533:541	a competitive advantage	519:541	a competitive advantage in the sustained colonization of niche mucosal environments	519:601	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	10	theme	sustained	550:558	arg1	colonization					560:571	the sustained colonization	546:571	the sustained colonization of niche mucosal environments	546:601	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	5	11	theme	core	939:942	arg1	O-glycans					946:954	truncated core 1 O-glycans	929:954	truncated core 1 O-glycans	929:954	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	9	12	theme	recognition	1567:1577	arg1	determinants					1542:1553	the structural determinants	1527:1553	the structural determinants of O-glycan recognition	1527:1577	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	2	13	attach	derived	357:363	arg2	accessibility					316:328	accessibility	316:328	accessibility	316:328	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	2	13	attach	derived	357:363	arg1	diet					370:373	diet	370:373	diet	370:373	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	2	13	attach	derived	357:363	arg2	presence					303:310	presence	303:310	presence	303:310	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	2	13	attach	derived	357:363	arg1	glycoproteins					383:395	host glycoproteins	378:395	host glycoproteins	378:395	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	6	14	theme	protein	1043:1049	arg1	component					1051:1059	the major protein component	1033:1059	the major protein component of mucus in the gut	1033:1079	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	6	14	theme	protein	1043:1049	arg1	MUC2					1026:1029	purified mucin 2 (MUC2)	1008:1030	purified mucin 2 (MUC2)	1008:1030	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	5	15	theme	adjacent	902:909	arg1	residues					911:918	adjacent residues	902:918	adjacent residues carrying truncated core 1 O-glycans	902:954	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	7	16	theme	1.9 Å	1120:1124	arg1	AM0627					1112:1117	AM0627	1112:1117	AM0627 (1.9 Å resolution)	1112:1136	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	7	16	theme	1.9 Å	1120:1124	arg1	resolution					1126:1135	1.9 Å resolution	1120:1135	1.9 Å resolution	1120:1135	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	5	17	theme	mucin-selective	816:830	arg1	Amuc_0627					849:857	the mucin-selective metalloprotease, Amuc_0627 (AM0627)	812:866	Amuc_0627	849:857	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	3	18	from	advantage	533:541	arg1	colonization					560:571	the sustained colonization	546:571	the sustained colonization of niche mucosal environments	546:601	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	4	19	theme	nitrogen	671:678	arg1	source					680:685	a carbon and nitrogen source	658:685	source	680:685	Although A. muciniphila is known to rely on mucins as a carbon and nitrogen source, the enzymatic machinery used by this microbe to process mucins in the gut is not yet fully characterized.
35405095	7	20	theme	X-ray	1085:1089	arg1	structure					1099:1107	An X-ray crystal structure	1082:1107	An X-ray crystal structure of AM0627 (1.9 Å resolution)	1082:1136	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	8	21	theme	molecular	1316:1324	arg1	modeling					1326:1333	molecular modeling	1316:1333	molecular modeling	1316:1333	We further rationalized the substrate cleavage motif using molecular modeling to identify nonconserved glycan-interacting residues.
35405095	7	22	theme	AM0627	1112:1117	arg1	structure					1099:1107	An X-ray crystal structure	1082:1107	An X-ray crystal structure of AM0627 (1.9 Å resolution)	1082:1136	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	9	23	theme	O-glycan	1558:1565	arg1	recognition					1567:1577	O-glycan recognition	1558:1577	O-glycan recognition	1558:1577	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	3	24	theme	mucosal	582:588	arg1	environments					590:601	niche mucosal environments	576:601	niche mucosal environments	576:601	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	25	theme	host	436:439	arg1	mucins					441:446	host mucins	436:446	host mucins	436:446	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	25	theme	host	436:439	arg1	class					451:455	a class	449:455	a class of proteins carrying densely O-glycosylated domains	449:507	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	0	26	theme	Structure-guided	0:15	arg1	mutagenesis					17:27	Structure-guided mutagenesis	0:27	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila	0:93	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila alters substrate preferences.
35405095	1	27	theme	Akkermansia	125:135	arg1	microbe					168:174	a mucin-degrading microbe	150:174	a mucin-degrading microbe found in the human gut	150:197	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	1	27	theme	Akkermansia	125:135	arg1	muciniphila					137:147	Akkermansia muciniphila	125:147	Akkermansia muciniphila	125:147	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	9	28	theme	altered	1448:1454	arg1	preferences					1466:1476	altered substrate preferences	1448:1476	altered substrate preferences down to the glycan level	1448:1501	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	5	29	theme	metalloprotease	832:846	arg1	Amuc_0627					849:857	the mucin-selective metalloprotease, Amuc_0627 (AM0627)	812:866	Amuc_0627	849:857	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	9	30	theme	residues	1427:1434	arg1	mutagenesis					1406:1416	mutagenesis	1406:1416	mutagenesis of these residues	1406:1434	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	3	31	gly	O-glycosylated	486:499	arg1	domains					501:507	densely O-glycosylated domains	478:507	densely O-glycosylated domains	478:507	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	32	theme	proteins	460:467	arg1	mucins					441:446	host mucins	436:446	host mucins	436:446	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	32	theme	proteins	460:467	arg1	class					451:455	a class	449:455	a class of proteins carrying densely O-glycosylated domains	449:507	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	33	theme	environments	590:601	arg1	colonization					560:571	the sustained colonization	546:571	the sustained colonization of niche mucosal environments	546:601	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	2	34	gly	glycoproteins	383:395	arg1	glycoproteins					383:395	host glycoproteins	378:395	host glycoproteins	378:395	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	3	35	theme	niche	576:580	arg1	environments					590:601	niche mucosal environments	576:601	niche mucosal environments	576:601	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	5	36	contain	carrying	920:927	arg1	residues					911:918	adjacent residues	902:918	adjacent residues carrying truncated core 1 O-glycans	902:954	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	5	36	contain	carrying	920:927	arg2	O-glycans					946:954	truncated core 1 O-glycans	929:954	truncated core 1 O-glycans	929:954	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	1	37	theme	positive	225:232	arg1	outcomes					241:248	positive health outcomes	225:248	positive health outcomes	225:248	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	0	38	theme	metalloprotease	50:64	arg1	mutagenesis					17:27	Structure-guided mutagenesis	0:27	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila	0:93	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila alters substrate preferences.
35405095	7	39	theme	same	1244:1247	arg1	family					1249:1254	the same family	1240:1254	the same family	1240:1254	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	9	40	theme	glycan	1490:1495	arg1	level					1497:1501	the glycan level	1486:1501	the glycan level	1486:1501	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	4	41	theme	carbon	660:665	arg1	source					680:685	a carbon and nitrogen source	658:685	source	680:685	Although A. muciniphila is known to rely on mucins as a carbon and nitrogen source, the enzymatic machinery used by this microbe to process mucins in the gut is not yet fully characterized.
35405095	1	42	theme	health	234:239	arg1	outcomes					241:248	positive health outcomes	225:248	positive health outcomes	225:248	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	0	43	theme	mucin-selective	34:48	arg1	metalloprotease					50:64	a mucin-selective metalloprotease	32:64	a mucin-selective metalloprotease	32:64	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila alters substrate preferences.
35405095	7	44	theme	crystal	1091:1097	arg1	structure					1099:1107	An X-ray crystal structure	1082:1107	An X-ray crystal structure of AM0627 (1.9 Å resolution)	1082:1136	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	3	45	contain	carrying	469:476	arg1	proteins					460:467	proteins	460:467	proteins carrying densely O-glycosylated domains	460:507	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	3	45	contain	carrying	469:476	arg2	domains					501:507	densely O-glycosylated domains	478:507	densely O-glycosylated domains	478:507	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	7	46	from	family	1249:1254	arg1	enzymes					1227:1233	structurally characterized enzymes	1200:1233	structurally characterized enzymes from the same family	1200:1254	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	6	47	theme	purified	1008:1015	arg1	component					1051:1059	the major protein component	1033:1059	the major protein component of mucus in the gut	1033:1079	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	6	47	theme	purified	1008:1015	arg1	MUC2					1026:1029	purified mucin 2 (MUC2)	1008:1030	purified mucin 2 (MUC2)	1008:1030	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	0	48	from	muciniphila	83:93	arg1	mutagenesis					17:27	Structure-guided mutagenesis	0:27	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila	0:93	Structure-guided mutagenesis of a mucin-selective metalloprotease from Akkermansia muciniphila alters substrate preferences.
35405095	9	49	theme	down	1478:1481	arg1	preferences					1466:1476	altered substrate preferences	1448:1476	altered substrate preferences down to the glycan level	1448:1501	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	5	50	theme	truncated	929:937	arg1	O-glycans					946:954	truncated core 1 O-glycans	929:954	truncated core 1 O-glycans	929:954	Here, we focus on the mucin-selective metalloprotease, Amuc_0627 (AM0627), which is known to cleave between adjacent residues carrying truncated core 1 O-glycans.
35405095	8	51	theme	substrate	1285:1293	arg1	motif					1304:1308	the substrate cleavage motif	1281:1308	the substrate cleavage motif	1281:1308	We further rationalized the substrate cleavage motif using molecular modeling to identify nonconserved glycan-interacting residues.
35405095	1	52	theme	mucin-degrading	152:166	arg1	microbe					168:174	a mucin-degrading microbe	150:174	a mucin-degrading microbe found in the human gut	150:197	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	1	52	theme	mucin-degrading	152:166	arg1	muciniphila					137:147	Akkermansia muciniphila	125:147	Akkermansia muciniphila	125:147	Akkermansia muciniphila, a mucin-degrading microbe found in the human gut, is often associated with positive health outcomes.
35405095	7	53	theme	characterized	1213:1225	arg1	enzymes					1227:1233	structurally characterized enzymes	1200:1233	structurally characterized enzymes from the same family	1200:1254	An X-ray crystal structure of AM0627 (1.9 Å resolution) revealed O-glycan-binding residues that are conserved between structurally characterized enzymes from the same family.
35405095	2	54	theme	nutrients	333:341	arg1	accessibility					316:328	accessibility	316:328	accessibility	316:328	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	2	54	theme	nutrients	333:341	arg1	presence					303:310	presence	303:310	presence	303:310	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	6	55	theme	mucus	1064:1068	arg1	component					1051:1059	the major protein component	1033:1059	the major protein component of mucus in the gut	1033:1079	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	6	55	theme	mucus	1064:1068	arg1	MUC2					1026:1029	purified mucin 2 (MUC2)	1008:1030	purified mucin 2 (MUC2)	1008:1030	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	9	56	theme	structural	1531:1540	arg1	determinants					1542:1553	the structural determinants	1527:1553	the structural determinants of O-glycan recognition	1527:1577	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	3	57	theme	O-glycosylated	486:499	arg1	domains					501:507	densely O-glycosylated domains	478:507	densely O-glycosylated domains	478:507	In particular, the ability to degrade host mucins, a class of proteins carrying densely O-glycosylated domains, provides a competitive advantage in the sustained colonization of niche mucosal environments.
35405095	4	58	dep	microbe	725:731	arg1	process					736:742	process	736:742	to process mucins in the gut	733:760	Although A. muciniphila is known to rely on mucins as a carbon and nitrogen source, the enzymatic machinery used by this microbe to process mucins in the gut is not yet fully characterized.
35405095	8	59	theme	glycan-interacting	1360:1377	arg1	residues					1379:1386	nonconserved glycan-interacting residues	1347:1386	nonconserved glycan-interacting residues	1347:1386	We further rationalized the substrate cleavage motif using molecular modeling to identify nonconserved glycan-interacting residues.
35405095	9	60	theme	substrate	1456:1464	arg1	preferences					1466:1476	altered substrate preferences	1448:1476	altered substrate preferences down to the glycan level	1448:1501	We conclude that mutagenesis of these residues resulted in altered substrate preferences down to the glycan level, providing insight into the structural determinants of O-glycan recognition.
35405095	2	61	dep	presence	303:310	arg1	the					299:301	the	299:301	the	299:301	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	2	62	theme	A. muciniphila	268:281	arg1	abundance					255:263	The abundance	251:263	The abundance of A. muciniphila	251:281	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	2	63	theme	host	378:381	arg1	glycoproteins					383:395	host glycoproteins	378:395	host glycoproteins	378:395	The abundance of A. muciniphila is modulated by the presence and accessibility of nutrients, which can be derived from diet or host glycoproteins.
35405095	6	64	theme	mucin	1017:1021	arg1	component					1051:1059	the major protein component	1033:1059	the major protein component of mucus in the gut	1033:1079	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
35405095	6	64	theme	mucin	1017:1021	arg1	MUC2					1026:1029	purified mucin 2 (MUC2)	1008:1030	purified mucin 2 (MUC2)	1008:1030	We showed that this enzyme is capable of degrading purified mucin 2 (MUC2), the major protein component of mucus in the gut.
34626374	2	0	theme	several	501:507	arg1	strategies					533:542	several stable isotope labeling strategies	501:542	several stable isotope labeling strategies	501:542	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	0	1	from	Profiling	26:34	arg1	Preparations					77:88	Two Different Preparations	63:88	Two Different Preparations	63:88	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	0	2	theme	PMP	93:95	arg1	Labeling					116:123	PMP and Deuterated PMP Labeling	93:123	PMP and Deuterated PMP Labeling	93:123	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	1	3	theme	growth	331:336	arg1	factors					338:344	growth factors	331:344	growth factors	331:344	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	3	4	used	used	644:647	arg2	PMP					613:615	PMP	613:615	PMP	613:615	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	4	used	used	644:647	arg2	1-phenyl-3-methyl-5-pyrazolone					581:610	1-phenyl-3-methyl-5-pyrazolone	581:610	1-phenyl-3-methyl-5-pyrazolone (PMP)	581:616	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	4	used	used	644:647	arg2	d5-PMP					633:638	deuterated d5-PMP	622:638	deuterated d5-PMP	622:638	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	1	5	theme	metabolic	253:261	arg1	enzymes					263:269	the biosynthetic and metabolic enzymes	232:269	the biosynthetic and metabolic enzymes	232:269	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	0	6	theme	PMP	112:114	arg1	Labeling					116:123	PMP and Deuterated PMP Labeling	93:123	PMP and Deuterated PMP Labeling	93:123	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	0	7	theme	Deuterated	101:110	arg1	Labeling					116:123	PMP and Deuterated PMP Labeling	93:123	PMP and Deuterated PMP Labeling	93:123	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	1	8	dep	such	312:315	arg1	as					317:318	as	317:318	as	317:318	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	1	9	theme	nutritional	347:357	arg1	factors					359:365	nutritional factors	347:365	nutritional factors	347:365	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	1	10	theme	same	175:178	arg1	cells					187:191	the same animal cells	171:191	the same animal cells	171:191	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	2	11	theme	labeling	524:531	arg1	strategies					533:542	several stable isotope labeling strategies	501:542	several stable isotope labeling strategies	501:542	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	2	12	from	preparations	487:498	arg1	comparison					428:437	direct quantitative comparison	408:437	direct quantitative comparison of disaccharide compositions from different GAG preparations	408:498	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	2	13	theme	disaccharide	442:453	arg1	compositions					455:466	disaccharide compositions	442:466	disaccharide compositions	442:466	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	1	14	theme	animal	180:185	arg1	cells					187:191	the same animal cells	171:191	the same animal cells	171:191	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	0	15	theme	Disaccharide	13:24	arg1	Profiling					26:34	Quantitative Disaccharide Profiling	0:34	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.	0:124	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	0	16	theme	Quantitative	0:11	arg1	Profiling					26:34	Quantitative Disaccharide Profiling	0:34	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.	0:124	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	3	17	theme	mass	791:794	arg1	MS					810:811	MS	810:811	MS	810:811	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	17	theme	mass	791:794	arg1	spectrometry					796:807	mass spectrometry	791:807	mass spectrometry (MS)	791:812	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	2	18	theme	quantitative	415:426	arg1	comparison					428:437	direct quantitative comparison	408:437	direct quantitative comparison of disaccharide compositions from different GAG preparations	408:498	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	1	19	theme	other	283:287	arg1	factors					303:309	other environmental factors	283:309	other environmental factors	283:309	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	2	20	theme	different	473:481	arg1	preparations					487:498	different GAG preparations	473:498	different GAG preparations	473:498	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	2	21	theme	direct	408:413	arg1	comparison					428:437	direct quantitative comparison	408:437	direct quantitative comparison of disaccharide compositions from different GAG preparations	408:498	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	1	22	theme	environmental	289:301	arg1	factors					303:309	other environmental factors	283:309	other environmental factors	283:309	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	1	23	theme	isolation	372:380	arg1	procedures					382:391	isolation procedures	372:391	isolation procedures	372:391	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	0	24	theme	Glycosaminoglycans	39:56	arg1	Profiling					26:34	Quantitative Disaccharide Profiling	0:34	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.	0:124	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	2	25	theme	GAG	483:485	arg1	preparations					487:498	different GAG preparations	473:498	different GAG preparations	473:498	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	3	26	theme	differential	653:664	arg1	labeling					679:686	differential disaccharide labeling	653:686	differential disaccharide labeling	653:686	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	27	theme	deuterated	622:631	arg1	d5-PMP					633:638	deuterated d5-PMP	622:638	deuterated d5-PMP	622:638	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	0	28	theme	Different	67:75	arg1	Preparations					77:88	Two Different Preparations	63:88	Two Different Preparations	63:88	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	0	29	from	Preparations	77:88	arg1	Profiling					26:34	Quantitative Disaccharide Profiling	0:34	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.	0:124	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	0	29	from	Preparations	77:88	arg1	Glycosaminoglycans					39:56	Glycosaminoglycans	39:56	Glycosaminoglycans from Two Different Preparations	39:88	Quantitative Disaccharide Profiling of Glycosaminoglycans from Two Different Preparations by PMP and Deuterated PMP Labeling.
34626374	3	30	theme	liquid	749:754	arg1	chromatography					756:769	high performance liquid chromatography	732:769	high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS)	732:812	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	30	theme	liquid	749:754	arg1	HPLC					772:775	HPLC	772:775	HPLC	772:775	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	1	31	theme	Glycosaminoglycan	126:142	arg1	structures					155:164	Glycosaminoglycan (GAG) fine structures	126:164	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues	126:203	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	3	32	theme	chondroitin	705:715	arg1	sulfate					717:723	chondroitin sulfate	705:723	chondroitin sulfate GAG	705:727	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	1	33	from	tissues	197:203	arg1	structures					155:164	Glycosaminoglycan (GAG) fine structures	126:164	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues	126:203	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	3	34	theme	GAG	725:727	arg1	labeling					679:686	differential disaccharide labeling	653:686	differential disaccharide labeling	653:686	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	34	theme	GAG	725:727	arg1	profiling					692:700	profiling	692:700	profiling	692:700	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	35	theme	sulfate	717:723	arg1	GAG					725:727	chondroitin sulfate GAG	705:727	chondroitin sulfate GAG	705:727	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	36	theme	disaccharide	666:677	arg1	labeling					679:686	differential disaccharide labeling	653:686	differential disaccharide labeling	653:686	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	1	37	from	cells	187:191	arg1	structures					155:164	Glycosaminoglycan (GAG) fine structures	126:164	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues	126:203	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	2	38	theme	isotope	516:522	arg1	labeling					524:531	stable isotope labeling	509:531	several stable isotope labeling strategies	501:542	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	1	39	theme	fine	150:153	arg1	structures					155:164	Glycosaminoglycan (GAG) fine structures	126:164	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues	126:203	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
34626374	2	40	theme	stable	509:514	arg1	labeling					524:531	stable isotope labeling	509:531	several stable isotope labeling strategies	501:542	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	3	41	theme	high	732:735	arg1	chromatography					756:769	high performance liquid chromatography	732:769	high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS)	732:812	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	41	theme	high	732:735	arg1	HPLC					772:775	HPLC	772:775	HPLC	772:775	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	42	theme	performance	737:747	arg1	chromatography					756:769	high performance liquid chromatography	732:769	high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS)	732:812	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	3	42	theme	performance	737:747	arg1	HPLC					772:775	HPLC	772:775	HPLC	772:775	In this report, 1-phenyl-3-methyl-5-pyrazolone (PMP) and deuterated d5-PMP are used for differential disaccharide labeling and profiling of chondroitin sulfate GAG by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626374	2	43	theme	compositions	455:466	arg1	comparison					428:437	direct quantitative comparison	408:437	direct quantitative comparison of disaccharide compositions from different GAG preparations	408:498	To facilitate direct quantitative comparison of disaccharide compositions from different GAG preparations, several stable isotope labeling strategies have been developed.
34626374	1	44	theme	biosynthetic	236:247	arg1	enzymes					263:269	the biosynthetic and metabolic enzymes	232:269	the biosynthetic and metabolic enzymes	232:269	Glycosaminoglycan (GAG) fine structures from the same animal cells and tissues are controlled not only by the biosynthetic and metabolic enzymes but also by other environmental factors, such as chemicals, growth factors, nutritional factors, and isolation procedures.
37018915	5	0	theme	In	677:678	arg1	results					685:691	In vivo results	677:691	In vivo results	677:691	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	4	1	theme	cellular	610:617	arg1	uptake					619:624	better cellular uptake	603:624	better cellular uptake	603:624	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	6	2	theme	APC	907:909	arg1	uptakes					911:917	APC uptakes	907:917	APC uptakes	907:917	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	1	3	theme	infectious	162:171	arg1	diseases					173:180	infectious diseases	162:180	infectious diseases	162:180	Oral vaccine is a non-invasive, ideal way to protect communities from infectious diseases.
37018915	4	4	theme	better	603:608	arg1	uptake					619:624	better cellular uptake	603:624	better cellular uptake	603:624	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	5	5	theme	mucosal	791:797	arg1	responses					806:814	strong systemic and mucosal immune responses	771:814	strong systemic and mucosal immune responses	771:814	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	5	6	theme	immune	799:804	arg1	responses					806:814	strong systemic and mucosal immune responses	771:814	strong systemic and mucosal immune responses	771:814	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	2	7	theme	cellular	292:299	arg1	uptake					301:306	its cellular uptake	288:306	its cellular uptake by immune cells	288:322	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	3	8	theme	alginate/chitosan-coated	346:369	arg1	Alg-Chi-CNC					394:404	Alg-Chi-CNC	394:404	Alg-Chi-CNC	394:404	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	3	8	theme	alginate/chitosan-coated	346:369	arg1	nanocrystal					381:391	alginate/chitosan-coated cellulose nanocrystal	346:391	alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC)	346:405	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	6	9	theme	significant	973:983	arg1	differences					985:995	significant differences	973:995	significant differences	973:995	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	6	10	theme	mucus	886:890	arg1	permeation					892:901	mucus permeation	886:901	mucus permeation	886:901	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	3	11	theme	ovalbumin	462:470	arg1	delivery					478:485	ovalbumin (OVA) delivery	462:485	ovalbumin (OVA) delivery in the intestine	462:502	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	3	12	theme	cellulose	371:379	arg1	Alg-Chi-CNC					394:404	Alg-Chi-CNC	394:404	Alg-Chi-CNC	394:404	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	3	12	theme	cellulose	371:379	arg1	nanocrystal					381:391	alginate/chitosan-coated cellulose nanocrystal	346:391	alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC)	346:405	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	4	13	theme	In	505:506	arg1	permeation					522:531	In vitro mucosal permeation	505:531	In vitro mucosal permeation	505:531	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	1	14	theme	Oral	92:95	arg1	way					130:132	a non-invasive, ideal way	108:132	a non-invasive, ideal way to protect communities from infectious diseases	108:180	Oral vaccine is a non-invasive, ideal way to protect communities from infectious diseases.
37018915	1	14	theme	Oral	92:95	arg1	vaccine					97:103	Oral vaccine	92:103	Oral vaccine	92:103	Oral vaccine is a non-invasive, ideal way to protect communities from infectious diseases.
37018915	6	15	theme	composites	866:875	arg1	features					828:835	the features	824:835	the features of functional nano-cellulose composites	824:875	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	0	16	theme	Engineering	0:10	arg1	nano-cellulose					12:25	Engineering nano-cellulose	0:25	Engineering nano-cellulose	0:25	Engineering nano-cellulose bio-composites to improve protein delivery for oral vaccination.
37018915	4	17	dep	In	505:506	arg1	vitro					508:512	vitro	508:512	vitro	508:512	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	6	18	theme	nano-cellulose	851:864	arg1	composites					866:875	functional nano-cellulose composites	840:875	functional nano-cellulose composites	840:875	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	5	19	dep	In	677:678	arg1	vivo					680:683	vivo	680:683	vivo	680:683	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	6	20	theme	functional	840:849	arg1	composites					866:875	functional nano-cellulose composites	840:875	functional nano-cellulose composites	840:875	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	2	21	theme	immune	311:316	arg1	cells					318:322	immune cells	311:322	immune cells	311:322	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	5	22	theme	strong	771:776	arg1	responses					806:814	strong systemic and mucosal immune responses	771:814	strong systemic and mucosal immune responses	771:814	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	2	23	theme	vaccine	193:199	arg1	systems					210:216	Effective vaccine delivery systems	183:216	Effective vaccine delivery systems	183:216	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	1	24	theme	non-invasive	110:121	arg1	way					130:132	a non-invasive, ideal way	108:132	a non-invasive, ideal way to protect communities from infectious diseases	108:180	Oral vaccine is a non-invasive, ideal way to protect communities from infectious diseases.
37018915	1	24	theme	non-invasive	110:121	arg1	vaccine					97:103	Oral vaccine	92:103	Oral vaccine	92:103	Oral vaccine is a non-invasive, ideal way to protect communities from infectious diseases.
37018915	0	25	theme	protein	53:59	arg1	delivery					61:68	protein delivery	53:68	protein delivery	53:68	Engineering nano-cellulose bio-composites to improve protein delivery for oral vaccination.
37018915	6	26	dep	in	920:921	arg1	vivo					923:926	vivo	923:926	vivo	923:926	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	5	27	theme	systemic	778:785	arg1	responses					806:814	strong systemic and mucosal immune responses	771:814	strong systemic and mucosal immune responses	771:814	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	2	28	theme	Effective	183:191	arg1	systems					210:216	Effective vaccine delivery systems	183:216	Effective vaccine delivery systems	183:216	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	6	29	theme	intestine	1032:1040	arg1	complexity					1008:1017	the complexity	1004:1017	the complexity of the small intestine	1004:1040	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	6	30	theme	immune	941:946	arg1	responses					948:956	in vivo specific-OVA immune responses	920:956	in vivo specific-OVA immune responses	920:956	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	2	31	theme	vaccine	242:248	arg1	absorption					250:259	vaccine absorption	242:259	vaccine absorption	242:259	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	6	32	theme	small	1026:1030	arg1	intestine					1032:1040	the small intestine	1022:1040	the small intestine	1022:1040	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	6	33	theme	specific-OVA	928:939	arg1	responses					948:956	in vivo specific-OVA immune responses	920:956	in vivo specific-OVA immune responses	920:956	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	5	34	theme	nanocellulose	732:744	arg1	nanocomposites					746:759	alginate/chitosan-coated nanocellulose nanocomposites	707:759	alginate/chitosan-coated nanocellulose nanocomposites	707:759	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	5	35	theme	alginate/chitosan-coated	707:730	arg1	nanocomposites					746:759	alginate/chitosan-coated nanocellulose nanocomposites	707:759	alginate/chitosan-coated nanocellulose nanocomposites	707:759	In vivo results revealed that alginate/chitosan-coated nanocellulose nanocomposites generated strong systemic and mucosal immune responses.
37018915	3	36	from	delivery	478:485	arg1	intestine					494:502	the intestine	490:502	the intestine	490:502	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	4	37	theme	cellular	551:558	arg1	uptake					560:565	cellular uptake	551:565	cellular uptake	551:565	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	3	38	dep	nanocrystal	381:391	arg1	nanocomposites					436:449	nanocomposites	436:449	nanocomposites	436:449	Here, we constructed alginate/chitosan-coated cellulose nanocrystal (Alg-Chi-CNC) and nanofibril (Alg-Chi-CNF) nanocomposites to enhance ovalbumin (OVA) delivery in the intestine.
37018915	6	39	theme	in	920:921	arg1	responses					948:956	in vivo specific-OVA immune responses	920:956	in vivo specific-OVA immune responses	920:956	Though the features of functional nano-cellulose composites affected mucus permeation and APC uptakes, in vivo specific-OVA immune responses have not shown significant differences due to the complexity of the small intestine.
37018915	2	40	theme	small	268:272	arg1	intestine					274:282	the small intestine	264:282	the small intestine	264:282	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	4	41	theme	epithelial	629:638	arg1	APCs					670:673	APCs	670:673	APCs	670:673	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	4	41	theme	epithelial	629:638	arg1	cells					663:667	epithelial and antigen-presenting cells	629:667	epithelial and antigen-presenting cells (APCs)	629:674	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	2	42	theme	delivery	201:208	arg1	systems					210:216	Effective vaccine delivery systems	183:216	Effective vaccine delivery systems	183:216	Effective vaccine delivery systems are required to enhance vaccine absorption in the small intestine and its cellular uptake by immune cells.
37018915	0	43	theme	oral	74:77	arg1	vaccination					79:89	oral vaccination	74:89	oral vaccination	74:89	Engineering nano-cellulose bio-composites to improve protein delivery for oral vaccination.
37018915	4	44	theme	mucosal	514:520	arg1	permeation					522:531	In vitro mucosal permeation	505:531	In vitro mucosal permeation	505:531	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	1	45	dep	non-invasive	110:121	arg1	ideal					124:128	ideal	124:128	ideal	124:128	Oral vaccine is a non-invasive, ideal way to protect communities from infectious diseases.
37018915	4	46	theme	antigen-presenting	644:661	arg1	APCs					670:673	APCs	670:673	APCs	670:673	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
37018915	4	46	theme	antigen-presenting	644:661	arg1	cells					663:667	epithelial and antigen-presenting cells	629:667	epithelial and antigen-presenting cells (APCs)	629:674	In vitro mucosal permeation and diffusion and cellular uptake demonstrated that Chi-CNC exhibited better cellular uptake in epithelial and antigen-presenting cells (APCs).
35323459	4	0	dep	release	787:793	arg1	the					783:785	the	783:785	the	783:785	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	0	1	theme	Enzyme	80:85	arg1	Treatment					87:95	Enzyme Treatment	80:95	Enzyme Treatment	80:95	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	1	2	theme	eicosapentaenoic	167:182	arg1	EPA					190:192	EPA	190:192	EPA	190:192	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	1	2	theme	eicosapentaenoic	167:182	arg1	acid					184:187	eicosapentaenoic acid	167:187	eicosapentaenoic acid (EPA)	167:193	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	1	2	theme	eicosapentaenoic	167:182	arg1	acid					258:261	an essential and economically important polyunsaturated fatty acid	196:261	an essential and economically important polyunsaturated fatty acid	196:261	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	0	3	theme	EPA-Rich	100:107	arg1	Lipids					109:114	EPA-Rich Lipids	100:114	EPA-Rich Lipids	100:114	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	0	4	from	Effects	0:6	arg1	Lipids					109:114	EPA-Rich Lipids	100:114	EPA-Rich Lipids	100:114	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	0	5	dep	Extraction	116:125	arg1	Effects					0:6	Effects	0:6	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids	0:114	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	3	6	theme	promising	547:555	arg1	sources					568:574	the most promising microalgal sources	538:574	the most promising microalgal sources of EPA	538:581	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	3	7	theme	ethanol-based	393:405	arg1	rate					418:421	the ethanol-based extraction rate	389:421	the ethanol-based extraction rate	389:421	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	6	8	theme	lipid	1185:1189	arg1	yields					1191:1196	lipid yields	1185:1196	lipid yields	1185:1196	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	6	9	theme	enzymatic	1139:1147	arg1	treatment					1149:1157	enzymatic treatment	1139:1157	enzymatic treatment to alter this	1139:1171	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	5	10	theme	Scanning	852:859	arg1	microscopy					870:879	Scanning electron microscopy	852:879	Scanning electron microscopy	852:879	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	5	11	theme	cell	893:896	arg1	morphology					898:907	cell morphology	893:907	cell morphology	893:907	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	1	12	theme	acid	184:187	arg1	extraction					153:162	the extraction	149:162	the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid,	149:262	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	6	13	theme	hemicellulose	1110:1122	arg1	structure					1124:1132	cell-wall hemicellulose structure	1100:1132	cell-wall hemicellulose structure	1100:1132	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	6	14	attach	linked	1090:1095	arg1	structure					1124:1132	cell-wall hemicellulose structure	1100:1132	cell-wall hemicellulose structure	1100:1132	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	6	14	attach	linked	1090:1095	arg2	yields					1067:1072	Nannochloropsis lipid yields	1045:1072	Nannochloropsis lipid yields	1045:1072	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	6	14	attach	linked	1090:1095	arg3	conclusion					1033:1042	conclusion	1033:1042	conclusion	1033:1042	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	6	15	theme	cell-wall	1100:1108	arg1	structure					1124:1132	cell-wall hemicellulose structure	1100:1132	cell-wall hemicellulose structure	1100:1132	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	3	16	theme	microalgal	557:566	arg1	sources					568:574	the most promising microalgal sources	538:574	the most promising microalgal sources of EPA	538:581	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	4	17	theme	EPA	665:667	arg1	content					669:675	lipid EPA content	659:675	lipid EPA content	659:675	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	3	18	theme	sources	568:574	arg1	Nannochloropsis					514:528	powdered Nannochloropsis	505:528	powdered Nannochloropsis	505:528	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	3	18	theme	sources	568:574	arg1	one					531:533	one	531:533	one	531:533	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	3	18	theme	sources	568:574	arg1	sources					568:574	the most promising microalgal sources	538:574	the most promising microalgal sources of EPA	538:581	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	4	19	theme	lipid	659:663	arg1	content					669:675	lipid EPA content	659:675	lipid EPA content	659:675	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	5	20	theme	electron	861:868	arg1	microscopy					870:879	Scanning electron microscopy	852:879	Scanning electron microscopy	852:879	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	4	21	theme	amorphous	705:713	arg1	hemicellulose					715:727	the amorphous hemicellulose	701:727	the amorphous hemicellulose	701:727	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	2	22	theme	extraction	302:311	arg1	rates					313:317	lipid extraction rates	296:317	lipid extraction rates using food-grade solvents such as ethanol	296:359	However, lipid extraction rates using food-grade solvents such as ethanol are usually low.
35323459	5	23	theme	boundaries	973:982	arg1	loss					960:963	loss	960:963	loss of cell boundaries	960:982	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	5	23	theme	boundaries	973:982	arg1	rupture					951:957	cell-wall rupture	941:957	cell-wall rupture	941:957	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	5	23	theme	boundaries	973:982	arg1	release					993:999	the release	989:999	the release of intracellular substances	989:1027	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	0	24	theme	Structural	11:20	arg1	Changes					40:46	Structural and Compositional Changes	11:46	Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment	11:95	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	5	25	theme	cell	968:971	arg1	boundaries					973:982	cell boundaries	968:982	cell boundaries	968:982	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	2	26	theme	lipid	296:300	arg1	rates					313:317	lipid extraction rates	296:317	lipid extraction rates using food-grade solvents such as ethanol	296:359	However, lipid extraction rates using food-grade solvents such as ethanol are usually low.
35323459	4	27	theme	lipid	632:636	arg1	yields					638:643	lipid yields	632:643	lipid yields	632:643	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	0	28	theme	Changes	40:46	arg1	Effects					0:6	Effects	0:6	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids	0:114	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	5	29	theme	cell-wall	941:949	arg1	rupture					951:957	cell-wall rupture	941:957	cell-wall rupture	941:957	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	3	30	theme	relevant	445:452	arg1	mechanisms					454:463	the relevant mechanisms	441:463	the relevant mechanisms	441:463	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	1	31	theme	essential	199:207	arg1	acid					184:187	eicosapentaenoic acid	167:187	eicosapentaenoic acid (EPA)	167:193	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	1	31	theme	essential	199:207	arg1	acid					258:261	an essential and economically important polyunsaturated fatty acid	196:261	an essential and economically important polyunsaturated fatty acid	196:261	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	0	32	theme	Compositional	26:38	arg1	Changes					40:46	Structural and Compositional Changes	11:46	Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment	11:95	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	3	33	used	used	469:472	arg2	we					466:467	we	466:467	we	466:467	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	6	34	theme	lipid	1061:1065	arg1	yields					1067:1072	Nannochloropsis lipid yields	1045:1072	Nannochloropsis lipid yields	1045:1072	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	0	35	theme	Nanochloropsis	51:64	arg1	oceania					66:72	Nanochloropsis oceania	51:72	Nanochloropsis oceania	51:72	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	4	36	theme	lysodiacylglyceryltrimethylhomoserine	813:849	arg1	extraction					799:808	extraction	799:808	extraction	799:808	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	4	36	theme	lysodiacylglyceryltrimethylhomoserine	813:849	arg1	release					787:793	release	787:793	release	787:793	Cellulase and laccase synergistically increased lipid yields by 69.31% and lipid EPA content by 42.63%, by degrading the amorphous hemicellulose and cellulose, improving crystallinity, and promoting the release and extraction of lysodiacylglyceryltrimethylhomoserine.
35323459	3	37	theme	extraction	407:416	arg1	rate					418:421	the ethanol-based extraction rate	389:421	the ethanol-based extraction rate	389:421	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	3	38	theme	EPA	579:581	arg1	sources					568:574	the most promising microalgal sources	538:574	the most promising microalgal sources of EPA	538:581	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	1	39	theme	Improved	128:135	arg1	methods					137:143	Improved methods	128:143	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid,	128:262	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	6	40	dep	treatment	1149:1157	arg1	alter					1162:1166	alter	1162:1166	to alter this	1159:1171	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	3	41	theme	most	542:545	arg1	sources					568:574	the most promising microalgal sources	538:574	the most promising microalgal sources of EPA	538:581	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	6	42	theme	Nannochloropsis	1045:1059	arg1	yields					1067:1072	Nannochloropsis lipid yields	1045:1072	Nannochloropsis lipid yields	1045:1072	In conclusion, Nannochloropsis lipid yields may be directly linked to cell-wall hemicellulose structure, and enzymatic treatment to alter this may improve lipid yields.
35323459	5	43	theme	intracellular	1004:1016	arg1	substances					1018:1027	intracellular substances	1004:1027	intracellular substances	1004:1027	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	2	44	theme	food-grade	325:334	arg1	solvents					336:343	food-grade solvents	325:343	food-grade solvents such as ethanol	325:359	However, lipid extraction rates using food-grade solvents such as ethanol are usually low.
35323459	2	44	theme	food-grade	325:334	arg1	ethanol					353:359	ethanol	353:359	ethanol	353:359	However, lipid extraction rates using food-grade solvents such as ethanol are usually low.
35323459	1	45	theme	important	226:234	arg1	acid					184:187	eicosapentaenoic acid	167:187	eicosapentaenoic acid (EPA)	167:193	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	1	45	theme	important	226:234	arg1	acid					258:261	an essential and economically important polyunsaturated fatty acid	196:261	an essential and economically important polyunsaturated fatty acid	196:261	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	5	46	theme	substances	1018:1027	arg1	loss					960:963	loss	960:963	loss of cell boundaries	960:982	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	5	46	theme	substances	1018:1027	arg1	rupture					951:957	cell-wall rupture	941:957	cell-wall rupture	941:957	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	5	46	theme	substances	1018:1027	arg1	release					993:999	the release	989:999	the release of intracellular substances	989:1027	Scanning electron microscopy showed that cell morphology was substantially altered, with cell-wall rupture, loss of cell boundaries, and the release of intracellular substances.
35323459	3	47	theme	powdered	505:512	arg1	sources					568:574	the most promising microalgal sources	538:574	the most promising microalgal sources of EPA	538:581	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	3	47	theme	powdered	505:512	arg1	one					531:533	one	531:533	one	531:533	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	3	47	theme	powdered	505:512	arg1	Nannochloropsis					514:528	powdered Nannochloropsis	505:528	powdered Nannochloropsis	505:528	To improve the ethanol-based extraction rate, and to elucidate the relevant mechanisms, we used cellulase and laccase to treat powdered Nannochloropsis, one of the most promising microalgal sources of EPA.
35323459	1	48	theme	polyunsaturated	236:250	arg1	acid					184:187	eicosapentaenoic acid	167:187	eicosapentaenoic acid (EPA)	167:193	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	1	48	theme	polyunsaturated	236:250	arg1	acid					258:261	an essential and economically important polyunsaturated fatty acid	196:261	an essential and economically important polyunsaturated fatty acid	196:261	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	0	49	theme	oceania	66:72	arg1	Changes					40:46	Structural and Compositional Changes	11:46	Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment	11:95	Effects of Structural and Compositional Changes of Nanochloropsis oceania after Enzyme Treatment on EPA-Rich Lipids Extraction.
35323459	1	50	theme	fatty	252:256	arg1	acid					184:187	eicosapentaenoic acid	167:187	eicosapentaenoic acid (EPA)	167:193	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
35323459	1	50	theme	fatty	252:256	arg1	acid					258:261	an essential and economically important polyunsaturated fatty acid	196:261	an essential and economically important polyunsaturated fatty acid	196:261	Improved methods for the extraction of eicosapentaenoic acid (EPA), an essential and economically important polyunsaturated fatty acid, are urgently required.
36054821	0	0	theme	truncorum	103:111	arg1	polysaccharides/exopolysaccharides					32:65	the crude polysaccharides/exopolysaccharides	22:65	the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum	22:111	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum.
36054821	4	1	theme	origin	667:672	arg1	cells					652:656	HepG2 cancer cells	639:656	HepG2 cancer cells of human origin (three-way ANOVA)	639:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	3	2	dep	Coprinus	520:527	arg1	comatus					529:535	comatus	529:535	comatus	529:535	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	2	3	theme	filtrate	333:340	arg1	impact					286:291	the impact	282:291	the impact of submerged cultivated mycelia (M) and filtrate (F)	282:344	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	5	4	from	450 µg/mL	885:893	arg1	%					880:880	≈60%	877:880	≈60% at 450 µg/mL	877:893	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	6	5	theme	regression	918:927	arg1	analysis					936:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	5	6	dep	PSH/ePSH	831:838	arg1	needed					840:845	needed	840:845	PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL)	831:894	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	6	7	theme	square	911:916	arg1	analysis					936:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	3	8	theme	Coprinus	520:527	arg1	species					563:569	edible Coprinus comatus and Coprinellus truncorum species	513:569	edible Coprinus comatus and Coprinellus truncorum species	513:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	3	9	theme	F	508:508	arg1	activity					417:424	the cytotoxic activity	403:424	the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species	403:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	6	10	theme	least	905:909	arg1	analysis					936:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	4	11	theme	human	661:665	arg1	origin					667:672	human origin	661:672	human origin (three-way ANOVA)	661:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	4	11	theme	human	661:665	arg1	ANOVA					685:689	three-way ANOVA	675:689	three-way ANOVA	675:689	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	3	12	theme	exopolysaccharides	452:469	arg1	activity					417:424	the cytotoxic activity	403:424	the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species	403:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	6	13	theme	phenolic	969:976	arg1	composition					978:988	specific phenolic composition	960:988	specific phenolic composition of the PSH/ePSH	960:1004	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	3	14	theme	cultivated	491:500	arg1	M					502:502	submerged cultivated M	481:502	submerged cultivated M	481:502	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	1	15	theme	phenolic	173:180	arg1	PC					193:194	PC	193:194	PC	193:194	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	1	15	theme	phenolic	173:180	arg1	compounds					182:190	phenolic compounds	173:190	phenolic compounds (PC)	173:195	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	3	16	theme	M	502:502	arg1	activity					417:424	the cytotoxic activity	403:424	the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species	403:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	1	17	theme	compounds	182:190	arg1	Fungi					114:118	Fungi	114:118	Fungi	114:118	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	1	17	theme	compounds	182:190	arg1	source					137:142	an important source	124:142	an important source of polysaccharides (PSH) and phenolic compounds (PC)	124:195	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	5	18	theme	cell	768:771	arg1	viability					773:781	cell viability	768:781	cell viability	768:781	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	2	19	theme	mycelia	317:323	arg1	impact					286:291	the impact	282:291	the impact of submerged cultivated mycelia (M) and filtrate (F)	282:344	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	4	20	theme	cancer	645:650	arg1	cells					652:656	HepG2 cancer cells	639:656	HepG2 cancer cells of human origin (three-way ANOVA)	639:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	0	21	theme	Cytotoxic	0:8	arg1	activity					10:17	Cytotoxic activity	0:17	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum	0:111	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum.
36054821	6	22	theme	Partial	897:903	arg1	analysis					936:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	2	23	theme	cultivated	306:315	arg1	M					326:326	M	326:326	M	326:326	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	2	23	theme	cultivated	306:315	arg1	mycelia					317:323	submerged cultivated mycelia	296:323	submerged cultivated mycelia (M)	296:327	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	4	24	theme	HepG2	639:643	arg1	cells					652:656	HepG2 cancer cells	639:656	HepG2 cancer cells of human origin (three-way ANOVA)	639:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	6	25	theme	PSH/ePSH	997:1004	arg1	composition					978:988	specific phenolic composition	960:988	specific phenolic composition of the PSH/ePSH	960:1004	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	2	26	theme	submerged	296:304	arg1	M					326:326	M	326:326	M	326:326	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	2	26	theme	submerged	296:304	arg1	mycelia					317:323	submerged cultivated mycelia	296:323	submerged cultivated mycelia (M)	296:327	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	3	27	theme	isolated	429:436	arg1	PSH					444:446	isolated crude PSH and exopolysaccharides	429:469	PSH	444:446	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	3	27	theme	isolated	429:436	arg1	ePSH					472:475	ePSH	472:475	ePSH	472:475	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	5	28	dep	needed	840:845	arg1	72 h					847:850	72 h	847:850	PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL)	831:894	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	29	dep	efficient	728:736	arg1	%					787:787	≈50%	784:787	≈50% at 450 µg/mL	784:800	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	29	dep	efficient	728:736	arg1	PSH/ePSH					710:717	The C. truncorum PSH/ePSH	693:717	The C. truncorum PSH/ePSH	693:717	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	29	dep	efficient	728:736	arg1	efficient					728:736	efficient	728:736	efficient	728:736	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	3	30	theme	edible	513:518	arg1	species					563:569	edible Coprinus comatus and Coprinellus truncorum species	513:569	edible Coprinus comatus and Coprinellus truncorum species	513:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	3	31	theme	crude	438:442	arg1	PSH					444:446	isolated crude PSH and exopolysaccharides	429:469	PSH	444:446	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	3	31	theme	crude	438:442	arg1	ePSH					472:475	ePSH	472:475	ePSH	472:475	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	0	32	theme	polysaccharides/exopolysaccharides	32:65	arg1	activity					10:17	Cytotoxic activity	0:17	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum	0:111	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum.
36054821	6	33	theme	specific	960:967	arg1	composition					978:988	specific phenolic composition	960:988	specific phenolic composition of the PSH/ePSH	960:1004	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	2	34	theme	beneficial	236:245	arg1	effects					247:253	the beneficial effects	232:253	the beneficial effects of fungal consumption	232:275	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	4	35	theme	cytotoxic	612:620	arg1	activity					622:629	significant cytotoxic activity	600:629	significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA)	600:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	0	36	theme	crude	26:30	arg1	polysaccharides/exopolysaccharides					32:65	the crude polysaccharides/exopolysaccharides	22:65	the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum	22:111	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum.
36054821	5	37	theme	maximal	747:753	arg1	reduction					755:763	maximal reduction	747:763	maximal reduction in cell viability	747:781	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	3	38	theme	species	563:569	arg1	F					508:508	F	508:508	F	508:508	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	3	38	theme	species	563:569	arg1	M					502:502	submerged cultivated M	481:502	submerged cultivated M	481:502	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	5	39	from	450 µg/mL	792:800	arg1	%					787:787	≈50%	784:787	≈50% at 450 µg/mL	784:800	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	39	from	450 µg/mL	792:800	arg1	PSH/ePSH					710:717	The C. truncorum PSH/ePSH	693:717	The C. truncorum PSH/ePSH	693:717	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	39	from	450 µg/mL	792:800	arg1	efficient					728:736	efficient	728:736	efficient	728:736	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	4	40	theme	significant	600:610	arg1	activity					622:629	significant cytotoxic activity	600:629	significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA)	600:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	3	41	dep	Coprinellus	541:551	arg1	truncorum					553:561	truncorum	553:561	truncorum	553:561	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	5	42	dep	C.	697:698	arg1	truncorum					700:708	truncorum	700:708	truncorum	700:708	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	6	43	from	difference	1035:1044	arg1	activity					1055:1062	their activity	1049:1062	their activity	1049:1062	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
36054821	1	44	theme	important	127:135	arg1	Fungi					114:118	Fungi	114:118	Fungi	114:118	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	1	44	theme	important	127:135	arg1	source					137:142	an important source	124:142	an important source of polysaccharides (PSH) and phenolic compounds (PC)	124:195	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	3	45	theme	Coprinellus	541:551	arg1	species					563:569	edible Coprinus comatus and Coprinellus truncorum species	513:569	edible Coprinus comatus and Coprinellus truncorum species	513:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	4	46	theme	three-way	675:683	arg1	origin					667:672	human origin	661:672	human origin (three-way ANOVA)	661:690	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	4	46	theme	three-way	675:683	arg1	ANOVA					685:689	three-way ANOVA	675:689	three-way ANOVA	675:689	Both PSH and ePSH exhibited significant cytotoxic activity towards HepG2 cancer cells of human origin (three-way ANOVA).
36054821	2	47	theme	Numerous	198:205	arg1	studies					207:213	Numerous studies	198:213	Numerous studies	198:213	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	2	48	theme	consumption	265:275	arg1	effects					247:253	the beneficial effects	232:253	the beneficial effects of fungal consumption	232:275	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	3	49	theme	PSH	444:446	arg1	activity					417:424	the cytotoxic activity	403:424	the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species	403:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	5	50	theme	C.	697:698	arg1	%					787:787	≈50%	784:787	≈50% at 450 µg/mL	784:800	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	50	theme	C.	697:698	arg1	PSH/ePSH					710:717	The C. truncorum PSH/ePSH	693:717	The C. truncorum PSH/ePSH	693:717	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	50	theme	C.	697:698	arg1	efficient					728:736	efficient	728:736	efficient	728:736	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	5	51	dep	reach	855:859	arg1	%					880:880	≈60%	877:880	≈60% at 450 µg/mL	877:893	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	2	52	theme	fungal	258:263	arg1	consumption					265:275	fungal consumption	258:275	fungal consumption	258:275	Numerous studies have highlighted the beneficial effects of fungal consumption, but the impact of submerged cultivated mycelia (M) and filtrate (F) has not been fully investigated.
36054821	1	53	theme	polysaccharides	147:161	arg1	Fungi					114:118	Fungi	114:118	Fungi	114:118	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	1	53	theme	polysaccharides	147:161	arg1	source					137:142	an important source	124:142	an important source of polysaccharides (PSH) and phenolic compounds (PC)	124:195	Fungi are an important source of polysaccharides (PSH) and phenolic compounds (PC).
36054821	5	54	theme	similar	861:867	arg1	effect					869:874	similar effect	861:874	similar effect	861:874	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	3	55	theme	cytotoxic	407:415	arg1	activity					417:424	the cytotoxic activity	403:424	the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species	403:569	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	0	56	theme	comatus	79:85	arg1	polysaccharides/exopolysaccharides					32:65	the crude polysaccharides/exopolysaccharides	22:65	the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum	22:111	Cytotoxic activity of the crude polysaccharides/exopolysaccharides of Coprinus comatus and Coprinellus truncorum.
36054821	5	57	from	reduction	755:763	arg1	viability					773:781	cell viability	768:781	cell viability	768:781	The C. truncorum PSH/ePSH was more efficient inducing maximal reduction in cell viability (≈50% at 450 µg/mL) after 24 h while C. comatus PSH/ePSH needed 72 h to reach similar effect (≈60% at 450 µg/mL).
36054821	3	58	theme	submerged	481:489	arg1	M					502:502	submerged cultivated M	481:502	submerged cultivated M	481:502	We aimed to investigate the cytotoxic activity of isolated crude PSH and exopolysaccharides (ePSH) of submerged cultivated M and F of edible Coprinus comatus and Coprinellus truncorum species.
36054821	6	59	theme	PLSR	930:933	arg1	analysis					936:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis	897:943	Partial least square regression (PLSR) analysis indicated that specific phenolic composition of the PSH/ePSH could be responsible for the difference in their activity.
37049647	7	0	theme	functional	1279:1288	arg1	foods					1290:1294	functional foods	1279:1294	functional foods	1279:1294	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	4	1	theme	molecular	699:707	arg1	weight					709:714	molecular weight	699:714	molecular weight	699:714	The results show that Se-enriched treatment significantly changed the polysaccharides' chemical composition, molecular weight, and sugar chain configuration.
37049647	6	2	dep	enhance	934:940	arg1	activate					1002:1009	activate	1002:1009	activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1002:1099	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	0	3	theme	esculenta	111:119	arg1	Pers					126:129	Morchella esculenta (L.) Pers	101:129	Morchella esculenta (L.) Pers	101:129	Microanalysis Characterization and Immunomodulatory Effect for Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers.
37049647	7	4	theme	selenium-enriched	1174:1190	arg1	polysaccharide					1198:1211	selenium-enriched Morel polysaccharide	1174:1211	selenium-enriched Morel polysaccharide	1174:1211	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	2	5	from	abundant	312:319	arg1	Morel					276:280	Morel	276:280	Morel	276:280	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	2	6	theme	various	330:336	arg1	bioactivities					338:350	various bioactivities	330:350	various bioactivities	330:350	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	6	7	theme	immune	1017:1022	arg1	response					1024:1031	their immune response	1011:1031	their immune response	1011:1031	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	2	8	contain	have	325:328	arg1	polysaccharides					283:297	polysaccharides	283:297	polysaccharides	283:297	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	2	8	contain	have	325:328	arg2	bioactivities					338:350	various bioactivities	330:350	various bioactivities	330:350	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	2	8	contain	have	325:328	arg1	abundant					312:319	abundant	312:319	abundant	312:319	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	1	9	theme	many	246:249	arg1	substances					261:270	many bioactive substances	246:270	many bioactive substances	246:270	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	0	10	theme	L.	122:123	arg1	Pers					126:129	Morchella esculenta (L.) Pers	101:129	Morchella esculenta (L.) Pers	101:129	Microanalysis Characterization and Immunomodulatory Effect for Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers.
37049647	1	11	theme	bioactive	251:259	arg1	substances					261:270	many bioactive substances	246:270	many bioactive substances	246:270	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	6	12	theme	immunomodulatory	1122:1137	arg1	function					1139:1146	an immunomodulatory function	1119:1146	an immunomodulatory function	1119:1146	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	3	13	theme	novel	378:382	arg1	MPS					412:414	MPS	412:414	MPS	412:414	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	3	13	theme	novel	378:382	arg1	Se-MPS					401:406	Se-MPS	401:406	Se-MPS	401:406	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	3	13	theme	novel	378:382	arg1	polysaccharides					384:398	two novel polysaccharides	374:398	two novel polysaccharides	374:398	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	7	14	from	potential	1234:1242	arg1	foods					1290:1294	functional foods	1279:1294	functional foods	1279:1294	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	7	14	from	potential	1234:1242	arg1	medicines					1299:1307	medicines	1299:1307	medicines	1299:1307	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	5	15	theme	Se-enriched	765:775	arg1	treatment					777:785	the Se-enriched treatment	761:785	the Se-enriched treatment	761:785	In addition, the Se-enriched treatment also improved the polysaccharides' fragmentation and thermal stability.
37049647	7	16	contain	have	1224:1227	arg2	potential					1234:1242	more potential	1229:1242	more potential for development and utilization in functional foods or medicines	1229:1307	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	7	16	contain	have	1224:1227	arg1	polysaccharide					1198:1211	selenium-enriched Morel polysaccharide	1174:1211	selenium-enriched Morel polysaccharide	1174:1211	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	3	17	theme	structural	531:540	arg1	properties					563:572	their structural and immunomodulatory properties	525:572	their structural and immunomodulatory properties	525:572	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	4	18	theme	chain	727:731	arg1	configuration					733:745	sugar chain configuration	721:745	sugar chain configuration	721:745	The results show that Se-enriched treatment significantly changed the polysaccharides' chemical composition, molecular weight, and sugar chain configuration.
37049647	6	19	theme	Morel	884:888	arg1	Se-MPS					906:911	Se-MPS	906:911	Se-MPS	906:911	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	6	19	theme	Morel	884:888	arg1	polysaccharide					890:903	Se-enriched Morel polysaccharide	872:903	Se-enriched Morel polysaccharide (Se-MPS)	872:912	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	0	20	theme	Immunomodulatory	35:50	arg1	Effect					52:57	Immunomodulatory Effect	35:57	Immunomodulatory Effect	35:57	Microanalysis Characterization and Immunomodulatory Effect for Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers.
37049647	4	21	theme	Se-enriched	612:622	arg1	treatment					624:632	Se-enriched treatment	612:632	Se-enriched treatment	612:632	The results show that Se-enriched treatment significantly changed the polysaccharides' chemical composition, molecular weight, and sugar chain configuration.
37049647	3	22	theme	present	360:366	arg1	work					368:371	the present work	356:371	the present work	356:371	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	7	23	theme	ordinary	1314:1321	arg1	polysaccharide					1329:1342	ordinary Morel polysaccharide	1314:1342	ordinary Morel polysaccharide	1314:1342	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	7	24	theme	Morel	1323:1327	arg1	polysaccharide					1329:1342	ordinary Morel polysaccharide	1314:1342	ordinary Morel polysaccharide	1314:1342	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	6	25	theme	signaling	1083:1091	arg1	pathway					1093:1099	the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1048:1099	the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1048:1099	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	1	26	theme	medicinal	191:199	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	26	theme	medicinal	191:199	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	6	27	theme	TLR4-TRAF6-MAPKs-NF-κB	1052:1073	arg1	pathway					1093:1099	the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1048:1099	the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1048:1099	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	6	28	theme	cells	979:983	arg1	phagocytosis					942:953	phagocytosis	942:953	phagocytosis of RAW 264.7 macrophage cells	942:983	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	6	29	theme	Se-enriched	872:882	arg1	Se-MPS					906:911	Se-MPS	906:911	Se-MPS	906:911	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	6	29	theme	Se-enriched	872:882	arg1	polysaccharide					890:903	Se-enriched Morel polysaccharide	872:903	Se-enriched Morel polysaccharide (Se-MPS)	872:912	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	6	30	theme	cascade	1075:1081	arg1	pathway					1093:1099	the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1048:1099	the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway	1048:1099	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	7	31	theme	Morel	1192:1196	arg1	polysaccharide					1198:1211	selenium-enriched Morel polysaccharide	1174:1211	selenium-enriched Morel polysaccharide	1174:1211	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	6	32	theme	macrophage	968:977	arg1	cells					979:983	RAW 264.7 macrophage cells	958:983	RAW 264.7 macrophage cells	958:983	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	3	33	theme	immunomodulatory	546:561	arg1	properties					563:572	their structural and immunomodulatory properties	525:572	their structural and immunomodulatory properties	525:572	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	1	34	theme	Morchella	132:140	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	34	theme	Morchella	132:140	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	0	35	theme	Selenium-Enriched	63:79	arg1	Polysaccharide					81:94	Selenium-Enriched Polysaccharide	63:94	Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers	63:129	Microanalysis Characterization and Immunomodulatory Effect for Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers.
37049647	1	36	theme	esculenta	142:150	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	36	theme	esculenta	142:150	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	6	37	theme	RAW	958:960	arg1	cells					979:983	RAW 264.7 macrophage cells	958:983	RAW 264.7 macrophage cells	958:983	Importantly, Se-enriched Morel polysaccharide (Se-MPS) could significantly enhance phagocytosis of RAW 264.7 macrophage cells and, remarkably, activate their immune response via activating the TLR4-TRAF6-MAPKs-NF-κB cascade signaling pathway, finally exerting an immunomodulatory function.
37049647	0	38	from	Pers	126:129	arg1	Polysaccharide					81:94	Selenium-Enriched Polysaccharide	63:94	Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers	63:129	Microanalysis Characterization and Immunomodulatory Effect for Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers.
37049647	4	39	theme	chemical	677:684	arg1	composition					686:696	the polysaccharides' chemical composition	656:696	the polysaccharides' chemical composition	656:696	The results show that Se-enriched treatment significantly changed the polysaccharides' chemical composition, molecular weight, and sugar chain configuration.
37049647	4	40	theme	sugar	721:725	arg1	configuration					733:745	sugar chain configuration	721:745	sugar chain configuration	721:745	The results show that Se-enriched treatment significantly changed the polysaccharides' chemical composition, molecular weight, and sugar chain configuration.
37049647	1	41	theme	edible	205:210	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	41	theme	edible	205:210	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	42	theme	L.	153:154	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	42	theme	L.	153:154	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	2	43	from	Morel	276:280	arg1	polysaccharides					283:297	polysaccharides	283:297	polysaccharides	283:297	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	2	43	from	Morel	276:280	arg1	abundant					312:319	abundant	312:319	abundant	312:319	In Morel, polysaccharides are the most abundant and have various bioactivities.
37049647	1	44	theme	homologous	212:221	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	44	theme	homologous	212:221	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	0	45	theme	Morchella	101:109	arg1	Pers					126:129	Morchella esculenta (L.) Pers	101:129	Morchella esculenta (L.) Pers	101:129	Microanalysis Characterization and Immunomodulatory Effect for Selenium-Enriched Polysaccharide from Morchella esculenta (L.) Pers.
37049647	1	46	contain	contains	237:244	arg1	fungus					223:228	a medicinal and edible homologous fungus	189:228	a medicinal and edible homologous fungus	189:228	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	46	contain	contains	237:244	arg2	substances					261:270	many bioactive substances	246:270	many bioactive substances	246:270	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	1	46	contain	contains	237:244	arg1	Pers.					157:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers.	132:161	Morchella esculenta (L.) Pers., referred to as Morel, is a medicinal and edible homologous fungus, which contains many bioactive substances.
37049647	5	47	theme	thermal	840:846	arg1	stability					848:856	thermal stability	840:856	thermal stability	840:856	In addition, the Se-enriched treatment also improved the polysaccharides' fragmentation and thermal stability.
37049647	3	48	theme	common	485:490	arg1	mycelia					498:504	selenium-enriched (Se-enriched) and common Morel mycelia	449:504	mycelia	498:504	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
37049647	7	49	theme	more	1229:1232	arg1	potential					1234:1242	more potential	1229:1242	more potential for development and utilization in functional foods or medicines	1229:1307	Based on these findings, selenium-enriched Morel polysaccharide appears to have more potential for development and utilization in functional foods or medicines than ordinary Morel polysaccharide.
37049647	3	50	theme	Morel	492:496	arg1	mycelia					498:504	selenium-enriched (Se-enriched) and common Morel mycelia	449:504	mycelia	498:504	In the present work, two novel polysaccharides, Se-MPS and MPS, were prepared and purified from selenium-enriched (Se-enriched) and common Morel mycelia, respectively, and their structural and immunomodulatory properties were evaluated.
36080143	0	0	theme	Composites	77:86	arg1	Manufacturing					60:72	Additive Manufacturing	51:72	Additive Manufacturing of Composites Using Digital Light Processing	51:117	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	4	1	theme	mechanical	838:847	arg1	performance					849:859	mechanical performance	838:859	mechanical performance	838:859	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
36080143	7	2	from	effect	1229:1234	arg1	terms					1239:1243	terms	1239:1243	terms of stiffness improvement	1239:1268	However, the largest reinforcing effect in terms of stiffness improvement was obtained with starch.
36080143	0	3	theme	Light	102:106	arg1	Processing					108:117	Digital Light Processing	94:117	Digital Light Processing	94:117	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	3	4	theme	3D-printed	654:663	arg1	composites					665:674	the 3D-printed composites	650:674	the 3D-printed composites	650:674	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	8	5	theme	strongest	1346:1354	arg1	dependence					1356:1365	the strongest dependence	1342:1365	the strongest dependence of heat capacity on operating temperature	1342:1407	Additionally, starchy composites demonstrated the strongest dependence of heat capacity on operating temperature.
36080143	0	6	theme	Digital	94:100	arg1	Processing					108:117	Digital Light Processing	94:117	Digital Light Processing	94:117	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	3	7	theme	infrared	696:703	arg1	spectroscopy					705:716	infrared spectroscopy	696:716	infrared spectroscopy	696:716	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	4	8	theme	thermal	817:823	arg1	behavior					825:832	thermal behavior	817:832	thermal behavior	817:832	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
36080143	2	9	theme	hemp	497:500	arg1	fibers					502:507	hemp fibers	497:507	hemp fibers	497:507	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	5	10	theme	3D-printed	1103:1112	arg1	composites					1114:1123	the 3D-printed composites	1099:1123	the 3D-printed composites	1099:1123	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	2	11	theme	formulation	591:601	arg1	third					578:582	third	578:582	third	578:582	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	3	12	dep	morphology	608:617	arg1	The					604:606	The	604:606	The	604:606	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	5	13	theme	composites	1114:1123	arg1	performance					1084:1094	the mechanical performance	1069:1094	the mechanical performance of the 3D-printed composites	1069:1123	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	7	14	theme	largest	1209:1215	arg1	effect					1229:1234	the largest reinforcing effect	1205:1234	the largest reinforcing effect in terms of stiffness improvement	1205:1268	However, the largest reinforcing effect in terms of stiffness improvement was obtained with starch.
36080143	2	15	theme	composites	314:323	arg1	synthesis					290:298	The synthesis	286:298	The synthesis of 3D-printed composites	286:323	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	1	16	theme	hemp	273:276	arg1	fibers					278:283	hemp fibers	273:283	hemp fibers	273:283	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	2	17	theme	3D-printed	303:312	arg1	composites					314:323	3D-printed composites	303:323	3D-printed composites	303:323	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	2	18	theme	material	377:384	arg1	combinations					386:397	various material combinations	369:397	various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers	369:507	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	0	19	theme	Starchy	15:21	arg1	Material					38:45	a Starchy Photosensitive Material	13:45	a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing	13:117	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	8	20	theme	heat	1370:1373	arg1	capacity					1375:1382	heat capacity	1370:1382	heat capacity	1370:1382	Additionally, starchy composites demonstrated the strongest dependence of heat capacity on operating temperature.
36080143	4	21	theme	scanning	906:913	arg1	calorimetry					915:925	differential scanning calorimetry	893:925	differential scanning calorimetry	893:925	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
36080143	6	22	theme	hemp	1139:1142	arg1	fiber					1144:1148	hemp fiber or starch	1139:1158	fiber	1144:1148	In addition, hemp fiber or starch did not alter the tensile strength.
36080143	1	23	theme	digital	135:141	arg1	DLP					161:163	DLP	161:163	DLP	161:163	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	1	23	theme	digital	135:141	arg1	processing					149:158	digital light processing	135:158	digital light processing (DLP)	135:164	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	0	24	theme	Material	38:45	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.	0:118	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	3	25	theme	laser	719:723	arg1	granulometry					725:736	laser granulometry	719:736	laser granulometry	719:736	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	2	26	theme	weight	519:524	arg1	content					526:532	the weight content	515:532	the weight content for each reinforcing phase reaching up to a third of the formulation	515:601	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	2	27	theme	photosensitive	417:430	arg1	resin					432:436	pure photosensitive resin	412:436	pure photosensitive resin	412:436	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	1	28	theme	3D-printed	186:195	arg1	materials					207:215	3D-printed composite materials	186:215	3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers	186:283	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	0	29	theme	Photosensitive	23:36	arg1	Material					38:45	a Starchy Photosensitive Material	13:45	a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing	13:117	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	5	30	theme	mechanical	1073:1082	arg1	performance					1084:1094	the mechanical performance	1069:1094	the mechanical performance of the 3D-printed composites	1069:1123	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	3	31	theme	optical	762:768	arg1	microscopy					792:801	optical and scanning electron microscopy	762:801	microscopy	792:801	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	1	32	theme	composite	197:205	arg1	materials					207:215	3D-printed composite materials	186:215	3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers	186:283	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	0	33	theme	Additive	51:58	arg1	Manufacturing					60:72	Additive Manufacturing	51:72	Additive Manufacturing of Composites Using Digital Light Processing	51:117	Synthesis of a Starchy Photosensitive Material for Additive Manufacturing of Composites Using Digital Light Processing.
36080143	8	34	theme	capacity	1375:1382	arg1	dependence					1356:1365	the strongest dependence	1342:1365	the strongest dependence of heat capacity on operating temperature	1342:1407	Additionally, starchy composites demonstrated the strongest dependence of heat capacity on operating temperature.
36080143	7	35	theme	reinforcing	1217:1227	arg1	effect					1229:1234	the largest reinforcing effect	1205:1234	the largest reinforcing effect in terms of stiffness improvement	1205:1268	However, the largest reinforcing effect in terms of stiffness improvement was obtained with starch.
36080143	1	36	contain	containing	217:226	arg1	materials					207:215	3D-printed composite materials	186:215	3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers	186:283	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	1	36	contain	containing	217:226	arg2	resin					243:247	photosensitive resin	228:247	photosensitive resin blended with starch and hemp fibers	228:283	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	4	37	theme	differential	893:904	arg1	calorimetry					915:925	differential scanning calorimetry	893:925	differential scanning calorimetry	893:925	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
36080143	2	38	theme	phases	460:465	arg1	mixture					443:449	a mixture	441:449	a mixture	441:449	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	3	39	theme	X-ray	739:743	arg1	diffraction					745:755	X-ray diffraction	739:755	X-ray diffraction	739:755	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	2	40	theme	reinforcing	543:553	arg1	phase					555:559	each reinforcing phase	538:559	each reinforcing phase reaching up to a third of the formulation	538:601	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	5	41	theme	leading	1040:1046	arg1	factor					1048:1053	a leading factor	1038:1053	a leading factor for improving the mechanical performance of the 3D-printed composites	1038:1123	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	5	41	theme	leading	1040:1046	arg1	step					1030:1033	the post-curing step	1014:1033	the post-curing step	1014:1033	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	1	42	used	used	170:173	arg2	DLP					161:163	DLP	161:163	DLP	161:163	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	1	42	used	used	170:173	arg2	processing					149:158	digital light processing	135:158	digital light processing (DLP)	135:164	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	5	43	theme	post-curing	1018:1028	arg1	factor					1048:1053	a leading factor	1038:1053	a leading factor for improving the mechanical performance of the 3D-printed composites	1038:1123	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	5	43	theme	post-curing	1018:1028	arg1	step					1030:1033	the post-curing step	1014:1033	the post-curing step	1014:1033	The results showed that the post-curing step is a leading factor for improving the mechanical performance of the 3D-printed composites.
36080143	7	44	theme	stiffness	1248:1256	arg1	improvement					1258:1268	stiffness improvement	1248:1268	stiffness improvement	1248:1268	However, the largest reinforcing effect in terms of stiffness improvement was obtained with starch.
36080143	3	45	theme	scanning	774:781	arg1	microscopy					792:801	optical and scanning electron microscopy	762:801	microscopy	792:801	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	8	46	theme	starchy	1310:1316	arg1	composites					1318:1327	starchy composites	1310:1327	starchy composites	1310:1327	Additionally, starchy composites demonstrated the strongest dependence of heat capacity on operating temperature.
36080143	7	47	theme	improvement	1258:1268	arg1	terms					1239:1243	terms	1239:1243	terms of stiffness improvement	1239:1268	However, the largest reinforcing effect in terms of stiffness improvement was obtained with starch.
36080143	3	48	theme	electron	783:790	arg1	microscopy					792:801	optical and scanning electron microscopy	762:801	microscopy	792:801	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	4	49	theme	optical	973:979	arg1	imaging					981:987	high-speed optical imaging	962:987	high-speed optical imaging	962:987	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
36080143	2	50	theme	pure	412:415	arg1	resin					432:436	pure photosensitive resin	412:436	pure photosensitive resin	412:436	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	2	51	theme	various	369:375	arg1	combinations					386:397	various material combinations	369:397	various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers	369:507	The synthesis of 3D-printed composites was performed without heating, according to various material combinations ranging from pure photosensitive resin to a mixture of three phases, including resin, starch, and hemp fibers, with the weight content for each reinforcing phase reaching up to a third of the formulation.
36080143	1	52	theme	photosensitive	228:241	arg1	resin					243:247	photosensitive resin	228:247	photosensitive resin blended with starch and hemp fibers	228:283	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	4	53	theme	high-speed	962:971	arg1	imaging					981:987	high-speed optical imaging	962:987	high-speed optical imaging	962:987	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
36080143	3	54	theme	composites	665:674	arg1	composition					620:630	composition	620:630	composition	620:630	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	3	54	theme	composites	665:674	arg1	structure					637:645	structure	637:645	structure	637:645	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	3	54	theme	composites	665:674	arg1	morphology					608:617	morphology	608:617	morphology	608:617	The morphology, composition, and structure of the 3D-printed composites were assessed using infrared spectroscopy, laser granulometry, X-ray diffraction, and optical and scanning electron microscopy.
36080143	6	55	theme	tensile	1178:1184	arg1	strength					1186:1193	the tensile strength	1174:1193	the tensile strength	1174:1193	In addition, hemp fiber or starch did not alter the tensile strength.
36080143	1	56	theme	light	143:147	arg1	DLP					161:163	DLP	161:163	DLP	161:163	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	1	56	theme	light	143:147	arg1	processing					149:158	digital light processing	135:158	digital light processing (DLP)	135:164	In this study, digital light processing (DLP) was used to achieve 3D-printed composite materials containing photosensitive resin blended with starch and hemp fibers.
36080143	4	57	theme	tensile	932:938	arg1	testing					940:946	tensile testing	932:946	tensile testing	932:946	In addition, thermal behavior and mechanical performance were studied using calorimetry, differential scanning calorimetry, and tensile testing combined with high-speed optical imaging.
35780071	3	0	theme	fucoidan-degrading	350:367	arg1	fucoidanases					378:389	fucoidanases	378:389	fucoidanases	378:389	The structure-function relationship of fucoidans remains unclear but can be studied using fucoidan-degrading enzymes (fucoidanases).
35780071	3	0	theme	fucoidan-degrading	350:367	arg1	enzymes					369:375	fucoidan-degrading enzymes	350:375	fucoidan-degrading enzymes (fucoidanases)	350:390	The structure-function relationship of fucoidans remains unclear but can be studied using fucoidan-degrading enzymes (fucoidanases).
35780071	11	1	theme	fucoidanases	1344:1355	arg1	types					1335:1339	two different types	1321:1339	two different types of fucoidanases	1321:1355	Our findings indicate that one microbial strain can harbor genes encoding two different types of fucoidanases.
35780071	5	2	theme	microbial	453:461	arg1	strain					463:468	a microbial strain	451:468	a microbial strain that can grow on fucoidan from Cladosiphon okamuranus as the sole carbon source	451:548	SW as a microbial strain that can grow on fucoidan from Cladosiphon okamuranus as the sole carbon source.
35780071	2	3	theme	hetero-sulfated	110:124	arg1	Fucoidans					96:104	Fucoidans	96:104	Fucoidans	96:104	Fucoidans are hetero-sulfated polysaccharides that are widely distributed in brown algae and have been extensively studied for their various biological activities.
35780071	2	3	theme	hetero-sulfated	110:124	arg1	polysaccharides					126:140	hetero-sulfated polysaccharides	110:140	hetero-sulfated polysaccharides that are widely distributed in brown algae and have been extensively studied for their various biological activities	110:257	Fucoidans are hetero-sulfated polysaccharides that are widely distributed in brown algae and have been extensively studied for their various biological activities.
35780071	4	4	theme	Flavobacterium	426:439	arg1	sp					441:442	Flavobacterium sp	426:442	Flavobacterium sp	426:442	Here, we isolated and identified Flavobacterium sp.
35780071	6	5	theme	Genomic	551:557	arg1	analysis					559:566	Genomic analysis	551:566	Genomic analysis of this strain	551:581	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	2	6	theme	brown	173:177	arg1	algae					179:183	brown algae	173:183	brown algae	173:183	Fucoidans are hetero-sulfated polysaccharides that are widely distributed in brown algae and have been extensively studied for their various biological activities.
35780071	11	7	theme	microbial	1278:1286	arg1	strain					1288:1293	one microbial strain	1274:1293	one microbial strain	1274:1293	Our findings indicate that one microbial strain can harbor genes encoding two different types of fucoidanases.
35780071	6	8	theme	Psychromonas	710:721	arg1	sp					723:724	Psychromonas sp	710:724	Psychromonas sp	710:724	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	9	9	dep	C. okamuranus	924:936	arg1	fucoidans					959:967	degraded fucoidans	950:967	degraded fucoidans	950:967	Swfct catalyzed the degradation of deacetylated fucoidan from C. okamuranus, and Swfcn2 degraded fucoidans from Saccharina sculpera and Macrocystis pyrifera.
35780071	5	10	theme	sole	531:534	arg1	source					543:548	the sole carbon source	527:548	the sole carbon source	527:548	SW as a microbial strain that can grow on fucoidan from Cladosiphon okamuranus as the sole carbon source.
35780071	5	11	theme	carbon	536:541	arg1	source					543:548	the sole carbon source	527:548	the sole carbon source	527:548	SW as a microbial strain that can grow on fucoidan from Cladosiphon okamuranus as the sole carbon source.
35780071	9	12	theme	deacetylated	897:908	arg1	fucoidan					910:917	deacetylated fucoidan	897:917	deacetylated fucoidan	897:917	Swfct catalyzed the degradation of deacetylated fucoidan from C. okamuranus, and Swfcn2 degraded fucoidans from Saccharina sculpera and Macrocystis pyrifera.
35780071	10	13	theme	Swfcn2	1173:1178	arg1	properties					1159:1168	the enzyme properties	1148:1168	the enzyme properties of Swfcn2	1148:1178	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	3	14	theme	structure-function	264:281	arg1	relationship					283:294	The structure-function relationship	260:294	The structure-function relationship of fucoidans	260:307	The structure-function relationship of fucoidans remains unclear but can be studied using fucoidan-degrading enzymes (fucoidanases).
35780071	6	15	from	Luteolibacter	672:684	arg1	fct114					660:665	fct114	660:665	fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp	660:724	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	0	16	theme	fucoidanase	24:34	arg1	genes					36:40	different fucoidanase genes	14:40	different fucoidanase genes	14:40	Occurrence of different fucoidanase genes in Flavobacterium sp.
35780071	6	17	theme	genes	612:616	arg1	presence					596:603	the presence	592:603	the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp	592:724	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	10	18	theme	enzyme	1152:1157	arg1	properties					1159:1168	the enzyme properties	1148:1168	the enzyme properties of Swfcn2	1148:1178	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	3	19	theme	fucoidans	299:307	arg1	relationship					283:294	The structure-function relationship	260:294	The structure-function relationship of fucoidans	260:307	The structure-function relationship of fucoidans remains unclear but can be studied using fucoidan-degrading enzymes (fucoidanases).
35780071	10	20	theme	general	1024:1030	arg1	properties					1032:1041	The general properties	1020:1041	The general properties of Swfct	1020:1050	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	0	21	theme	genes	36:40	arg1	Occurrence					0:9	Occurrence	0:9	Occurrence of different fucoidanase genes in Flavobacterium sp.	0:62	Occurrence of different fucoidanase genes in Flavobacterium sp.
35780071	10	22	theme	carbohydrate-polyacrylamide	1198:1224	arg1	electrophoresis					1230:1244	carbohydrate-polyacrylamide gel electrophoresis	1198:1244	carbohydrate-polyacrylamide gel electrophoresis	1198:1244	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	9	23	theme	fucoidan	910:917	arg1	degradation					882:892	the degradation	878:892	the degradation of deacetylated fucoidan	878:917	Swfct catalyzed the degradation of deacetylated fucoidan from C. okamuranus, and Swfcn2 degraded fucoidans from Saccharina sculpera and Macrocystis pyrifera.
35780071	9	24	theme	degraded	950:957	arg1	fucoidans					959:967	degraded fucoidans	950:967	degraded fucoidans	950:967	Swfct catalyzed the degradation of deacetylated fucoidan from C. okamuranus, and Swfcn2 degraded fucoidans from Saccharina sculpera and Macrocystis pyrifera.
35780071	2	25	theme	biological	237:246	arg1	activities					248:257	their various biological activities	223:257	their various biological activities	223:257	Fucoidans are hetero-sulfated polysaccharides that are widely distributed in brown algae and have been extensively studied for their various biological activities.
35780071	0	26	theme	Flavobacterium	45:58	arg1	sp					60:61	Flavobacterium sp	45:61	Flavobacterium sp	45:61	Occurrence of different fucoidanase genes in Flavobacterium sp.
35780071	11	27	theme	different	1325:1333	arg1	types					1335:1339	two different types	1321:1339	two different types of fucoidanases	1321:1355	Our findings indicate that one microbial strain can harbor genes encoding two different types of fucoidanases.
35780071	10	28	theme	ends	1103:1106	arg1	amounts					1083:1089	the amounts	1079:1089	the amounts of reducing ends produced by the enzymatic reaction	1079:1141	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	10	28	theme	ends	1103:1106	arg1	ends					1103:1106	reducing ends	1094:1106	reducing ends produced by the enzymatic reaction	1094:1141	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	2	29	theme	various	229:235	arg1	activities					248:257	their various biological activities	223:257	their various biological activities	223:257	Fucoidans are hetero-sulfated polysaccharides that are widely distributed in brown algae and have been extensively studied for their various biological activities.
35780071	8	30	theme	gene	751:754	arg1	products					756:763	The gene products	747:763	The gene products	747:763	The gene products were produced in Escherichia coli and showed significantly different specificities for fucoidan.
35780071	10	31	theme	reducing	1094:1101	arg1	ends					1103:1106	reducing ends	1094:1106	reducing ends produced by the enzymatic reaction	1094:1141	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	6	32	dep	Luteolibacter	672:684	arg1	H18					692:694	H18	692:694	H18	692:694	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	6	32	dep	Luteolibacter	672:684	arg1	algae					686:690	Luteolibacter algae H18 and fcnA from Psychromonas sp	672:724	Luteolibacter algae H18 and fcnA from Psychromonas sp	672:724	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	6	32	dep	Luteolibacter	672:684	arg1	fcnA					700:703	fcnA	700:703	fcnA	700:703	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	8	33	theme	different	824:832	arg1	specificities					834:846	significantly different specificities	810:846	significantly different specificities	810:846	The gene products were produced in Escherichia coli and showed significantly different specificities for fucoidan.
35780071	10	34	theme	Swfct	1046:1050	arg1	properties					1032:1041	The general properties	1020:1041	The general properties of Swfct	1020:1050	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	5	35	dep	Cladosiphon	501:511	arg1	okamuranus					513:522	Cladosiphon okamuranus	501:522	Cladosiphon okamuranus	501:522	SW as a microbial strain that can grow on fucoidan from Cladosiphon okamuranus as the sole carbon source.
35780071	1	36	dep	SW	64:65	arg1	characterization					78:93	characterization	78:93	characterization	78:93	SW and enzyme characterization.
35780071	6	37	theme	strain	576:581	arg1	analysis					559:566	Genomic analysis	551:566	Genomic analysis of this strain	551:581	Genomic analysis of this strain revealed the presence of two genes, swfct and swfcn2, that are homologous to fct114 from Luteolibacter algae H18 and fcnA from Psychromonas sp.
35780071	10	38	theme	enzymatic	1124:1132	arg1	reaction					1134:1141	the enzymatic reaction	1120:1141	the enzymatic reaction	1120:1141	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
35780071	0	39	theme	different	14:22	arg1	genes					36:40	different fucoidanase genes	14:40	different fucoidanase genes	14:40	Occurrence of different fucoidanase genes in Flavobacterium sp.
35780071	0	40	from	Occurrence	0:9	arg1	sp					60:61	Flavobacterium sp	45:61	Flavobacterium sp	45:61	Occurrence of different fucoidanase genes in Flavobacterium sp.
35780071	10	41	theme	gel	1226:1228	arg1	electrophoresis					1230:1244	carbohydrate-polyacrylamide gel electrophoresis	1198:1244	carbohydrate-polyacrylamide gel electrophoresis	1198:1244	The general properties of Swfct were examined by measuring the amounts of reducing ends produced by the enzymatic reaction, and the enzyme properties of Swfcn2 were evaluated by carbohydrate-polyacrylamide gel electrophoresis.
36055406	0	0	theme	N-terminal	78:87	arg1	sequence					96:103	N-terminal signal sequence	78:103	N-terminal signal sequence	78:103	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	2	1	theme	mature	466:471	arg1	part					481:484	mature protein part	466:484	mature protein part	466:484	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	4	2	theme	KO	798:799	arg1	cells					801:805	KO cells	798:805	KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway	798:915	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	6	3	dep	pathways	1293:1300	arg1	GET					1289:1291	GET	1289:1291	GET	1289:1291	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	9	4	theme	selective	1742:1750	arg1	route					1761:1765	the selective ER entry route	1738:1765	the selective ER entry route	1738:1765	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	4	5	from	GET	897:899	arg1	defective					807:815	defective	807:815	defective	807:815	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	4	6	theme	SND	905:907	arg1	pathway					909:915	SND pathway	905:915	SND pathway	905:915	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	2	7	contain	contain	422:428	arg2	part					481:484	mature protein part	466:484	mature protein part	466:484	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	7	contain	contain	422:428	arg2	sequence					451:458	an N-terminal signal sequence	430:458	an N-terminal signal sequence (SS)	430:463	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	7	contain	contain	422:428	arg2	sequence					517:524	C-terminal GPI-attachment sequence	491:524	C-terminal GPI-attachment sequence (GPI-AS)	491:533	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	7	contain	contain	422:428	arg2	SS					461:462	SS	461:462	SS	461:462	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	7	contain	contain	422:428	arg1	GPI-APs					358:364	GPI-APs	358:364	GPI-APs	358:364	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	7	contain	contain	422:428	arg2	GPI-AS					527:532	GPI-AS	527:532	GPI-AS	527:532	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	7	contain	contain	422:428	arg1	preproproteins					400:413	preproproteins	400:413	preproproteins	400:413	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	5	8	dep	pathways	1056:1063	arg1	GET					1052:1054	GET	1052:1054	GET	1052:1054	We found GPI-AP CD59 largely depends on the SND pathway for ER entry, whereas prion protein (Prion) and LY6K depend on both Sec62 and GET pathways.
36055406	5	9	theme	ER	978:979	arg1	entry					981:985	ER entry	978:985	ER entry	978:985	We found GPI-AP CD59 largely depends on the SND pathway for ER entry, whereas prion protein (Prion) and LY6K depend on both Sec62 and GET pathways.
36055406	2	10	theme	GPI-attachment	502:515	arg1	GPI-AS					527:532	GPI-AS	527:532	GPI-AS	527:532	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	10	theme	GPI-attachment	502:515	arg1	sequence					517:524	C-terminal GPI-attachment sequence	491:524	C-terminal GPI-attachment sequence (GPI-AS)	491:533	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	3	11	theme	various	644:650	arg1	GPI-APs					652:658	various GPI-APs	644:658	various GPI-APs	644:658	However, how various GPI-APs are translocated into the ER lumen in mammalian cells is unclear.
36055406	2	12	theme	ER	562:563	arg1	lumen					565:569	the ER lumen	558:569	the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs	558:628	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	6	13	theme	LY6K	1091:1094	arg1	constructs					1096:1105	chimeric Prion and LY6K constructs	1072:1105	constructs	1096:1105	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	9	14	theme	entry	1755:1759	arg1	route					1761:1765	the selective ER entry route	1738:1765	the selective ER entry route	1738:1765	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	4	15	from	Sec62	890:894	arg1	defective					807:815	defective	807:815	defective	807:815	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	0	16	theme	signal	89:94	arg1	sequence					96:103	N-terminal signal sequence	78:103	N-terminal signal sequence	78:103	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	5	17	theme	prion	996:1000	arg1	Prion					1011:1015	Prion	1011:1015	Prion	1011:1015	We found GPI-AP CD59 largely depends on the SND pathway for ER entry, whereas prion protein (Prion) and LY6K depend on both Sec62 and GET pathways.
36055406	5	17	theme	prion	996:1000	arg1	protein					1002:1008	prion protein	996:1008	prion protein (Prion)	996:1016	We found GPI-AP CD59 largely depends on the SND pathway for ER entry, whereas prion protein (Prion) and LY6K depend on both Sec62 and GET pathways.
36055406	4	18	theme	cells	801:805	arg1	panel					789:793	a panel	787:793	a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway	787:915	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	7	19	theme	entry	1334:1338	arg1	route					1340:1344	the ER entry route	1327:1344	the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59	1327:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	0	20	theme	C-terminal	109:118	arg1	sequence					135:142	C-terminal GPI-attachment sequence	109:142	C-terminal GPI-attachment sequence	109:142	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	3	21	theme	ER	686:687	arg1	lumen					689:693	the ER lumen	682:693	the ER lumen in mammalian cells	682:712	However, how various GPI-APs are translocated into the ER lumen in mammalian cells is unclear.
36055406	3	22	from	lumen	689:693	arg1	cells					708:712	mammalian cells	698:712	mammalian cells	698:712	However, how various GPI-APs are translocated into the ER lumen in mammalian cells is unclear.
36055406	1	23	from	proteins	163:170	arg1	pathway					189:195	the secretory pathway	175:195	the secretory pathway	175:195	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	9	24	theme	GPI-APs	1720:1726	arg1	sequences					1707:1715	C-terminal sequences	1696:1715	C-terminal sequences of GPI-APs	1696:1726	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	1	25	theme	secretory	179:187	arg1	pathway					189:195	the secretory pathway	175:195	the secretory pathway	175:195	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	9	26	theme	C-terminal	1696:1705	arg1	sequences					1707:1715	C-terminal sequences	1696:1715	C-terminal sequences of GPI-APs	1696:1726	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	4	27	theme	GPI-APs	773:779	arg1	pathways					761:768	the ER entry pathways	748:768	the ER entry pathways of GPI-APs	748:779	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	0	28	theme	ER	0:1	arg1	pathway					9:15	ER entry pathway	0:15	ER entry pathway	0:15	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	2	29	theme	signal	444:449	arg1	SS					461:462	SS	461:462	SS	461:462	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	29	theme	signal	444:449	arg1	sequence					451:458	an N-terminal signal sequence	430:458	an N-terminal signal sequence (SS)	430:463	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	6	30	theme	SS	1131:1132	arg1	GPI-AS					1148:1153	the N-terminal SS or C-terminal GPI-AS	1116:1153	the N-terminal SS or C-terminal GPI-AS	1116:1153	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	7	31	with	constructs	1364:1373	arg1	GPI-ASs					1395:1401	the C-terminal GPI-ASs	1380:1401	the C-terminal GPI-ASs replaced with that of CD59	1380:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	7	32	theme	Prion	1358:1362	arg1	constructs					1364:1373	chimeric Prion constructs	1349:1373	chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59	1349:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	2	33	theme	N-terminal	433:442	arg1	SS					461:462	SS	461:462	SS	461:462	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	33	theme	N-terminal	433:442	arg1	sequence					451:458	an N-terminal signal sequence	430:458	an N-terminal signal sequence (SS)	430:463	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	3	34	theme	mammalian	698:706	arg1	cells					708:712	mammalian cells	698:712	mammalian cells	698:712	However, how various GPI-APs are translocated into the ER lumen in mammalian cells is unclear.
36055406	6	35	theme	N-terminal	1120:1129	arg1	GPI-AS					1148:1153	the N-terminal SS or C-terminal GPI-AS	1116:1153	the N-terminal SS or C-terminal GPI-AS	1116:1153	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	6	36	theme	C-terminal	1137:1146	arg1	GPI-AS					1148:1153	the N-terminal SS or C-terminal GPI-AS	1116:1153	the N-terminal SS or C-terminal GPI-AS	1116:1153	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	8	37	theme	acid	1597:1600	arg1	change					1602:1607	any amino acid change	1587:1607	any amino acid change in the mature protein part	1587:1634	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	6	38	theme	GPI-ASs	1238:1244	arg1	hydrophobicity					1208:1221	the hydrophobicity	1204:1221	the hydrophobicity of the SSs and GPI-ASs	1204:1244	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	4	39	theme	ER	865:866	arg1	pathway-namely					874:887	each signal recognition particle-independent ER entry pathway-namely	820:887	each signal recognition particle-independent ER entry pathway-namely	820:887	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	2	40	theme	mature	615:620	arg1	GPI-APs					622:628	mature GPI-APs	615:628	mature GPI-APs	615:628	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	0	41	theme	GPI-attachment	120:133	arg1	sequence					135:142	C-terminal GPI-attachment sequence	109:142	C-terminal GPI-attachment sequence	109:142	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	4	42	from	pathway-namely	874:887	arg1	defective					807:815	defective	807:815	defective	807:815	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	9	43	theme	maturation	1803:1812	arg1	processes					1814:1822	subsequent maturation processes	1792:1822	subsequent maturation processes of GPI-APs	1792:1833	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	9	44	theme	subsequent	1792:1801	arg1	processes					1814:1822	subsequent maturation processes	1792:1822	subsequent maturation processes of GPI-APs	1792:1833	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	7	45	theme	C-terminal	1384:1393	arg1	GPI-ASs					1395:1401	the C-terminal GPI-ASs	1380:1401	the C-terminal GPI-ASs replaced with that of CD59	1380:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	4	46	from	pathway	909:915	arg1	defective					807:815	defective	807:815	defective	807:815	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	4	47	theme	entry	755:759	arg1	pathways					761:768	the ER entry pathways	748:768	the ER entry pathways of GPI-APs	748:779	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	6	48	theme	chimeric	1072:1079	arg1	Prion					1081:1085	chimeric Prion and LY6K constructs	1072:1105	Prion	1081:1085	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	4	49	theme	entry	868:872	arg1	pathway-namely					874:887	each signal recognition particle-independent ER entry pathway-namely	820:887	each signal recognition particle-independent ER entry pathway-namely	820:887	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	4	50	theme	ER	752:753	arg1	pathways					761:768	the ER entry pathways	748:768	the ER entry pathways of GPI-APs	748:779	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	8	51	theme	mature	1616:1621	arg1	part					1631:1634	the mature protein part	1612:1634	the mature protein part	1612:1634	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	7	52	theme	SND	1449:1451	arg1	pathway					1453:1459	the SND pathway	1445:1459	the SND pathway	1445:1459	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	0	53	theme	proteins	51:58	arg1	pathway					9:15	ER entry pathway	0:15	ER entry pathway	0:15	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	0	53	theme	proteins	51:58	arg1	glycosylation					21:33	glycosylation	21:33	glycosylation of GPI-anchored proteins	21:58	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	6	54	theme	SSs	1230:1232	arg1	hydrophobicity					1208:1221	the hydrophobicity	1204:1221	the hydrophobicity of the SSs and GPI-ASs	1204:1244	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	0	55	theme	GPI-anchored	38:49	arg1	proteins					51:58	GPI-anchored proteins	38:58	GPI-anchored proteins	38:58	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	4	56	from	defective	807:815	arg1	GET					897:899	GET	897:899	GET	897:899	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	4	56	from	defective	807:815	arg1	pathway-namely					874:887	each signal recognition particle-independent ER entry pathway-namely	820:887	each signal recognition particle-independent ER entry pathway-namely	820:887	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	4	56	from	defective	807:815	arg1	Sec62					890:894	Sec62	890:894	Sec62	890:894	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	4	56	from	defective	807:815	arg1	pathway					909:915	SND pathway	905:915	SND pathway	905:915	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	6	57	from	dependence	1265:1274	arg1	Sec62					1279:1283	Sec62	1279:1283	Sec62	1279:1283	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	6	57	from	dependence	1265:1274	arg1	pathways					1293:1300	GET pathways	1289:1300	GET pathways	1289:1300	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	7	58	theme	constructs	1364:1373	arg1	route					1340:1344	the ER entry route	1327:1344	the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59	1327:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	9	59	theme	GPI-APs	1827:1833	arg1	processes					1814:1822	subsequent maturation processes	1792:1822	subsequent maturation processes of GPI-APs	1792:1833	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	4	60	theme	defective	807:815	arg1	cells					801:805	KO cells	798:805	KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway	798:915	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	6	61	dep	SSs	1230:1232	arg1	the					1226:1228	the	1226:1228	the	1226:1228	Using chimeric Prion and LY6K constructs in which the N-terminal SS or C-terminal GPI-AS was replaced with that of CD59, we revealed that the hydrophobicity of the SSs and GPI-ASs contributes to the dependence on Sec62 and GET pathways, respectively.
36055406	1	62	theme	endoplasmic	324:334	arg1	ER					347:348	ER	347:348	ER	347:348	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	1	62	theme	endoplasmic	324:334	arg1	reticulum					336:344	the endoplasmic reticulum	320:344	the endoplasmic reticulum (ER) lumen	320:355	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	4	63	theme	recognition	832:842	arg1	pathway-namely					874:887	each signal recognition particle-independent ER entry pathway-namely	820:887	each signal recognition particle-independent ER entry pathway-namely	820:887	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	5	64	theme	SND	962:964	arg1	pathway					966:972	the SND pathway	958:972	the SND pathway for ER entry	958:985	We found GPI-AP CD59 largely depends on the SND pathway for ER entry, whereas prion protein (Prion) and LY6K depend on both Sec62 and GET pathways.
36055406	0	65	gly	glycosylation	21:33	arg1	proteins					51:58	GPI-anchored proteins	38:58	GPI-anchored proteins	38:58	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	8	66	theme	protein	1623:1629	arg1	part					1631:1634	the mature protein part	1612:1634	the mature protein part	1612:1634	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	7	67	theme	ER	1331:1332	arg1	route					1340:1344	the ER entry route	1327:1344	the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59	1327:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	1	68	theme	-anchored	242:250	arg1	GPI-APs					262:268	GPI-APs	262:268	GPI-APs	262:268	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	1	68	theme	-anchored	242:250	arg1	proteins					252:259	glycosylphosphatidylinositol (GPI)-anchored proteins	208:259	glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs)	208:269	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	4	69	theme	signal	825:830	arg1	pathway-namely					874:887	each signal recognition particle-independent ER entry pathway-namely	820:887	each signal recognition particle-independent ER entry pathway-namely	820:887	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	8	70	from	change	1602:1607	arg1	part					1631:1634	the mature protein part	1612:1634	the mature protein part	1612:1634	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	8	71	theme	amino	1591:1595	arg1	change					1602:1607	any amino acid change	1587:1607	any amino acid change in the mature protein part	1587:1634	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	8	72	theme	oligosaccharyltransferase	1509:1533	arg1	isoforms					1535:1542	isoforms	1535:1542	isoforms	1535:1542	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	4	73	theme	particle-independent	844:863	arg1	pathway-namely					874:887	each signal recognition particle-independent ER entry pathway-namely	820:887	each signal recognition particle-independent ER entry pathway-namely	820:887	Here, we investigated the ER entry pathways of GPI-APs using a panel of KO cells defective in each signal recognition particle-independent ER entry pathway-namely, Sec62, GET, or SND pathway.
36055406	7	74	theme	chimeric	1349:1356	arg1	constructs					1364:1373	chimeric Prion constructs	1349:1373	chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59	1349:1428	Moreover, the ER entry route of chimeric Prion constructs with the C-terminal GPI-ASs replaced with that of CD59 was changed to the SND pathway.
36055406	9	75	theme	ER	1752:1753	arg1	route					1761:1765	the selective ER entry route	1738:1765	the selective ER entry route	1738:1765	Taking these findings together, this study revealed N- and C-terminal sequences of GPI-APs determine the selective ER entry route, which in turn regulates subsequent maturation processes of GPI-APs.
36055406	1	76	theme	synthesized	151:161	arg1	proteins					163:170	Newly synthesized proteins	145:170	Newly synthesized proteins	145:170	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	1	76	theme	synthesized	151:161	arg1	proteins					252:259	glycosylphosphatidylinositol (GPI)-anchored proteins	208:259	glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs)	208:269	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	2	77	theme	protein	473:479	arg1	part					481:484	mature protein part	466:484	mature protein part	466:484	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	1	78	theme	reticulum	336:344	arg1	lumen					351:355	the endoplasmic reticulum (ER) lumen	320:355	the endoplasmic reticulum (ER) lumen	320:355	Newly synthesized proteins in the secretory pathway, including glycosylphosphatidylinositol (GPI)-anchored proteins (GPI-APs), need to be correctly targeted and imported into the endoplasmic reticulum (ER) lumen.
36055406	5	79	theme	GPI-AP	927:932	arg1	CD59					934:937	GPI-AP CD59	927:937	GPI-AP CD59	927:937	We found GPI-AP CD59 largely depends on the SND pathway for ER entry, whereas prion protein (Prion) and LY6K depend on both Sec62 and GET pathways.
36055406	0	80	theme	entry	3:7	arg1	pathway					9:15	ER entry pathway	0:15	ER entry pathway	0:15	ER entry pathway and glycosylation of GPI-anchored proteins are determined by N-terminal signal sequence and C-terminal GPI-attachment sequence.
36055406	8	81	theme	GPI	1484:1486	arg1	structures					1488:1497	their GPI structures	1478:1497	their GPI structures and which oligosaccharyltransferase isoforms modify the constructs	1478:1564	Simultaneously, their GPI structures and which oligosaccharyltransferase isoforms modify the constructs were altered without any amino acid change in the mature protein part.
36055406	2	82	theme	C-terminal	491:500	arg1	GPI-AS					527:532	GPI-AS	527:532	GPI-AS	527:532	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
36055406	2	82	theme	C-terminal	491:500	arg1	sequence					517:524	C-terminal GPI-attachment sequence	491:524	C-terminal GPI-attachment sequence (GPI-AS)	491:533	GPI-APs are synthesized in the cytosol as preproproteins, which contain an N-terminal signal sequence (SS), mature protein part, and C-terminal GPI-attachment sequence (GPI-AS), and translocated into the ER lumen where SS and GPI-AS are removed, generating mature GPI-APs.
35889308	6	0	theme	several	961:967	arg1	mushrooms					979:987	several medicinal mushrooms	961:987	several medicinal mushrooms	961:987	We synthesized SeNCs on the basis of the extracellular polysaccharides of several medicinal mushrooms.
35889308	4	1	theme	low	598:600	arg1	impact					616:621	low environmental impact	598:621	low environmental impact	598:621	Biopolymers have attained great attention with perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties, being abundantly available, renewable, and eco-friendly.
35889308	6	2	theme	polysaccharides	942:956	arg1	basis					915:919	the basis	911:919	the basis of the extracellular polysaccharides of several medicinal mushrooms	911:987	We synthesized SeNCs on the basis of the extracellular polysaccharides of several medicinal mushrooms.
35889308	13	3	theme	root	1852:1855	arg1	biomass					1857:1863	the potato root biomass	1841:1863	the potato root biomass	1841:1863	Bio-composites based on Pleurotus ostreatus promoted increase in the potato root biomass in the Lugovskoi cultivar by up to 79% versus the control.
35889308	1	4	theme	selenium	241:248	arg1	nanocomposites					211:224	polymer nanocomposites	203:224	polymer nanocomposites (NCs)	203:230	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	4	theme	selenium	241:248	arg1	SeNCs					274:278	SeNCs	274:278	SeNCs	274:278	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	4	theme	selenium	241:248	arg1	nanocomposites					258:271	selenium polymer nanocomposites	241:271	selenium polymer nanocomposites (SeNCs)	241:279	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	2	5	from	nanofiller	307:316	arg1	NCs					321:323	NCs	321:323	NCs	321:323	Selenium as an inorganic nanofiller in NCs has been extensively studied for its biological activity.
35889308	8	6	theme	negative	1300:1307	arg1	effect					1309:1314	negative effect	1300:1314	negative effect on biomass of the vegetative part	1300:1348	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	14	7	theme	bio-composites	1985:1998	arg1	ability					1945:1951	The phytostimulating ability	1924:1951	The phytostimulating ability of mushroom-based Se-containing bio-composites	1924:1998	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	14	8	theme	mushroom-based	1956:1969	arg1	bio-composites					1985:1998	mushroom-based Se-containing bio-composites	1956:1998	mushroom-based Se-containing bio-composites	1956:1998	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	8	9	theme	height	1266:1271	arg1	number					1239:1244	the number	1235:1244	the number of leaves and plant height	1235:1271	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	8	10	theme	vegetative	1334:1343	arg1	part					1345:1348	the vegetative part	1330:1348	the vegetative part	1330:1348	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	16	11	theme	SeNCs	2390:2394	arg1	applications					2374:2385	possible applications	2365:2385	possible applications of SeNCs	2365:2394	Thus, by combining myco-nanotechnology with the intrinsic biological activity of selenium, an unexpectedly efficient tool for possible applications of SeNCs could be identified.
35889308	14	12	dep	together	2001:2008	arg1	with					2010:2013	with	2010:2013	with	2010:2013	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	1	13	theme	polymer	203:209	arg1	NCs					227:229	NCs	227:229	NCs	227:229	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	13	theme	polymer	203:209	arg1	nanocomposites					211:224	polymer nanocomposites	203:224	polymer nanocomposites (NCs)	203:230	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	13	theme	polymer	203:209	arg1	nanocomposites					258:271	selenium polymer nanocomposites	241:271	selenium polymer nanocomposites (SeNCs)	241:279	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	7	14	theme	potato	1102:1107	arg1	Lugovskoi					1136:1144	Lugovskoi	1136:1144	Lugovskoi	1136:1144	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	14	theme	potato	1102:1107	arg1	Lukyanovsky					1120:1130	Lukyanovsky	1120:1130	Lukyanovsky	1120:1130	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	14	theme	potato	1102:1107	arg1	cultivars					1109:1117	two potato cultivars	1098:1117	two potato cultivars: Lukyanovsky and Lugovskoi	1098:1144	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	6	15	theme	mushrooms	979:987	arg1	polysaccharides					942:956	the extracellular polysaccharides	924:956	the extracellular polysaccharides of several medicinal mushrooms	924:987	We synthesized SeNCs on the basis of the extracellular polysaccharides of several medicinal mushrooms.
35889308	5	16	from	mushrooms	790:798	arg1	polysaccharides					724:738	polysaccharides	724:738	polysaccharides	724:738	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	5	16	from	mushrooms	790:798	arg1	beta-glucans					751:762	including beta-glucans	741:762	including beta-glucans from edible and medicinal mushrooms	741:798	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	7	17	theme	plant	1047:1051	arg1	growth					1053:1058	potato plant growth	1040:1058	potato plant growth	1040:1058	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	11	18	theme	potato	1557:1562	arg1	biomass					1575:1581	the potato vegetative biomass	1553:1581	the potato vegetative biomass	1553:1581	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303 experienced an increase in the potato vegetative biomass by up to 55% versus the control.
35889308	0	19	theme	Plant	66:70	arg1	Growth					72:77	Potato Plant Growth	59:77	Potato Plant Growth	59:77	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	12	20	theme	Clavibacter	1745:1755	arg1	sepedonicus					1757:1767	the potato ring rot causative agent Clavibacter sepedonicus	1709:1767	the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1709:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	12	20	theme	Clavibacter	1745:1755	arg1	Cms					1770:1772	Cms	1770:1772	Cms	1770:1772	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	16	21	theme	biological	2297:2306	arg1	activity					2308:2315	the intrinsic biological activity	2283:2315	the intrinsic biological activity of selenium	2283:2327	Thus, by combining myco-nanotechnology with the intrinsic biological activity of selenium, an unexpectedly efficient tool for possible applications of SeNCs could be identified.
35889308	5	22	theme	edible	769:774	arg1	mushrooms					790:798	edible and medicinal mushrooms	769:798	mushrooms	790:798	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	14	23	theme	action	2099:2104	arg1	mode					2091:2094	the bifunctional mode	2074:2094	the bifunctional mode of action of these Se-biopreparations	2074:2132	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	12	24	theme	ring	1720:1723	arg1	sepedonicus					1757:1767	the potato ring rot causative agent Clavibacter sepedonicus	1709:1767	the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1709:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	12	24	theme	ring	1720:1723	arg1	Cms					1770:1772	Cms	1770:1772	Cms	1770:1772	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	2	25	theme	biological	362:371	arg1	activity					373:380	its biological activity	358:380	its biological activity	358:380	Selenium as an inorganic nanofiller in NCs has been extensively studied for its biological activity.
35889308	5	26	theme	medicinal	780:788	arg1	mushrooms					790:798	edible and medicinal mushrooms	769:798	mushrooms	790:798	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	9	27	theme	tubers	1375:1380	arg1	Treatment					1351:1359	Treatment	1351:1359	Treatment of the potato tubers with SeNC from Gr	1351:1398	Treatment of the potato tubers with SeNC from Gr.
35889308	12	28	theme	causative	1729:1737	arg1	sepedonicus					1757:1767	the potato ring rot causative agent Clavibacter sepedonicus	1709:1767	the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1709:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	12	28	theme	causative	1729:1737	arg1	Cms					1770:1772	Cms	1770:1772	Cms	1770:1772	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	11	29	theme	Ganoderma	1500:1508	arg1	lucidum					1510:1516	Ganoderma lucidum SIE1303	1500:1524	Ganoderma lucidum SIE1303	1500:1524	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303 experienced an increase in the potato vegetative biomass by up to 55% versus the control.
35889308	3	30	theme	safe	401:404	arg1	approaches					421:430	More ecologically safe and beneficial approaches	383:430	More ecologically safe and beneficial approaches to obtain Se-based products	383:458	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	3	30	theme	safe	401:404	arg1	challenge					476:484	the current challenge	464:484	the current challenge	464:484	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	0	31	theme	Mushroom-Derived	0:15	arg1	Selenium					23:30	Mushroom-Derived Novel Selenium	0:30	Mushroom-Derived Novel Selenium	0:30	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	1	32	theme	polymer	250:256	arg1	nanocomposites					211:224	polymer nanocomposites	203:224	polymer nanocomposites (NCs)	203:230	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	32	theme	polymer	250:256	arg1	SeNCs					274:278	SeNCs	274:278	SeNCs	274:278	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	32	theme	polymer	250:256	arg1	nanocomposites					258:271	selenium polymer nanocomposites	241:271	selenium polymer nanocomposites (SeNCs)	241:279	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	4	33	theme	multifunctional	546:560	arg1	NCs					583:585	perspective multifunctional and high-performance NCs	534:585	perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties	534:644	Biopolymers have attained great attention with perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties, being abundantly available, renewable, and eco-friendly.
35889308	11	34	dep	55	1592:1593	arg1	to					1589:1590	to	1589:1590	to	1589:1590	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303 experienced an increase in the potato vegetative biomass by up to 55% versus the control.
35889308	3	35	theme	Se-based	442:449	arg1	products					451:458	Se-based products	442:458	Se-based products	442:458	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	8	36	from	effect	1225:1230	arg1	number					1239:1244	the number	1235:1244	the number of leaves and plant height	1235:1271	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	8	36	from	effect	1225:1230	arg1	cultivars					1281:1289	both cultivars	1276:1289	both cultivars	1276:1289	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	4	37	theme	high-performance	566:581	arg1	NCs					583:585	perspective multifunctional and high-performance NCs	534:585	perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties	534:644	Biopolymers have attained great attention with perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties, being abundantly available, renewable, and eco-friendly.
35889308	16	38	theme	possible	2365:2372	arg1	applications					2374:2385	possible applications	2365:2385	possible applications of SeNCs	2365:2394	Thus, by combining myco-nanotechnology with the intrinsic biological activity of selenium, an unexpectedly efficient tool for possible applications of SeNCs could be identified.
35889308	4	39	theme	great	513:517	arg1	attention					519:527	great attention	513:527	great attention	513:527	Biopolymers have attained great attention with perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties, being abundantly available, renewable, and eco-friendly.
35889308	3	40	theme	current	468:474	arg1	approaches					421:430	More ecologically safe and beneficial approaches	383:430	More ecologically safe and beneficial approaches to obtain Se-based products	383:458	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	3	40	theme	current	468:474	arg1	challenge					476:484	the current challenge	464:484	the current challenge	464:484	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	3	41	dep	approaches	421:430	arg1	obtain					435:440	obtain	435:440	to obtain Se-based products	432:458	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	14	42	theme	Se-biopreparations	2115:2132	arg1	action					2099:2104	action	2099:2104	action of these Se-biopreparations	2099:2132	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	2	43	theme	inorganic	297:305	arg1	nanofiller					307:316	an inorganic nanofiller	294:316	an inorganic nanofiller in NCs	294:323	Selenium as an inorganic nanofiller in NCs has been extensively studied for its biological activity.
35889308	13	44	dep	79	1900:1901	arg1	to					1897:1898	to	1897:1898	to	1897:1898	Bio-composites based on Pleurotus ostreatus promoted increase in the potato root biomass in the Lugovskoi cultivar by up to 79% versus the control.
35889308	7	45	dep	cultivars	1109:1117	arg1	Lugovskoi					1136:1144	Lugovskoi	1136:1144	Lugovskoi	1136:1144	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	45	dep	cultivars	1109:1117	arg1	Lukyanovsky					1120:1130	Lukyanovsky	1120:1130	Lukyanovsky	1120:1130	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	45	dep	cultivars	1109:1117	arg1	cultivars					1109:1117	two potato cultivars	1098:1117	two potato cultivars: Lukyanovsky and Lugovskoi	1098:1144	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	6	46	theme	medicinal	969:977	arg1	mushrooms					979:987	several medicinal mushrooms	961:987	several medicinal mushrooms	961:987	We synthesized SeNCs on the basis of the extracellular polysaccharides of several medicinal mushrooms.
35889308	16	47	theme	intrinsic	2287:2295	arg1	activity					2308:2315	the intrinsic biological activity	2283:2315	the intrinsic biological activity of selenium	2283:2327	Thus, by combining myco-nanotechnology with the intrinsic biological activity of selenium, an unexpectedly efficient tool for possible applications of SeNCs could be identified.
35889308	8	48	theme	positive	1216:1223	arg1	effect					1225:1230	the strongest positive effect	1202:1230	the strongest positive effect on the number of leaves and plant height in both cultivars	1202:1289	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	13	49	theme	potato	1845:1850	arg1	biomass					1857:1863	the potato root biomass	1841:1863	the potato root biomass	1841:1863	Bio-composites based on Pleurotus ostreatus promoted increase in the potato root biomass in the Lugovskoi cultivar by up to 79% versus the control.
35889308	6	50	theme	extracellular	928:940	arg1	polysaccharides					942:956	the extracellular polysaccharides	924:956	the extracellular polysaccharides of several medicinal mushrooms	924:987	We synthesized SeNCs on the basis of the extracellular polysaccharides of several medicinal mushrooms.
35889308	4	51	theme	environmental	602:614	arg1	impact					616:621	low environmental impact	598:621	low environmental impact	598:621	Biopolymers have attained great attention with perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties, being abundantly available, renewable, and eco-friendly.
35889308	16	52	theme	selenium	2320:2327	arg1	activity					2308:2315	the intrinsic biological activity	2283:2315	the intrinsic biological activity of selenium	2283:2327	Thus, by combining myco-nanotechnology with the intrinsic biological activity of selenium, an unexpectedly efficient tool for possible applications of SeNCs could be identified.
35889308	10	53	theme	germ	1440:1443	arg1	length					1445:1450	germ length	1440:1450	germ length	1440:1450	umbellata also significantly increased germ length.
35889308	14	54	theme	Se-containing	1971:1983	arg1	bio-composites					1985:1998	mushroom-based Se-containing bio-composites	1956:1998	mushroom-based Se-containing bio-composites	1956:1998	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	1	55	theme	polymer	174:180	arg1	matrices					182:189	polymer matrices	174:189	polymer matrices	174:189	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	8	56	theme	leaves	1249:1254	arg1	number					1239:1244	the number	1235:1244	the number of leaves and plant height	1235:1271	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	5	57	theme	innovative	865:874	arg1	potential					876:884	innovative potential	865:884	innovative potential	865:884	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	8	58	theme	plant	1260:1264	arg1	height					1266:1271	plant height	1260:1271	plant height	1260:1271	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	5	59	dep	bioactive	805:813	arg1	biodegradable					831:843	biodegradable	831:843	biodegradable	831:843	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	5	59	dep	bioactive	805:813	arg1	biocompatible					816:828	biocompatible	816:828	biocompatible	816:828	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	5	60	theme	including	741:749	arg1	polysaccharides					724:738	polysaccharides	724:738	polysaccharides	724:738	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	5	60	theme	including	741:749	arg1	beta-glucans					751:762	including beta-glucans	741:762	including beta-glucans from edible and medicinal mushrooms	741:798	Composites based on polysaccharides, including beta-glucans from edible and medicinal mushrooms, are bioactive, biocompatible, biodegradable, and have exhibited innovative potential.
35889308	14	61	theme	phytostimulating	1928:1943	arg1	ability					1945:1951	The phytostimulating ability	1924:1951	The phytostimulating ability of mushroom-based Se-containing bio-composites	1924:1998	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	13	62	theme	Pleurotus	1800:1808	arg1	ostreatus					1810:1818	Pleurotus ostreatus	1800:1818	Pleurotus ostreatus	1800:1818	Bio-composites based on Pleurotus ostreatus promoted increase in the potato root biomass in the Lugovskoi cultivar by up to 79% versus the control.
35889308	8	63	from	effect	1309:1314	arg1	biomass					1319:1325	biomass	1319:1325	biomass of the vegetative part	1319:1348	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	8	64	theme	part	1345:1348	arg1	biomass					1319:1325	biomass	1319:1325	biomass of the vegetative part	1319:1348	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	11	65	theme	vegetative	1564:1573	arg1	biomass					1575:1581	the potato vegetative biomass	1553:1581	the potato vegetative biomass	1553:1581	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303 experienced an increase in the potato vegetative biomass by up to 55% versus the control.
35889308	15	66	theme	growth	2182:2187	arg1	enhancement					2189:2199	growth enhancement	2182:2199	growth enhancement	2182:2199	The application of stimulatory green SeNCs for growth enhancement could be used to increase crop yield.
35889308	7	67	theme	tuber	1064:1068	arg1	germination					1070:1080	tuber germination	1064:1080	tuber germination	1064:1080	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	1	68	theme	nanosized	134:142	arg1	Se					154:155	Se	154:155	Se	154:155	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	1	68	theme	nanosized	134:142	arg1	selenium					144:151	nanosized selenium	134:151	nanosized selenium (Se)	134:156	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	7	69	from	influence	994:1002	arg1	growth					1053:1058	potato plant growth	1040:1058	potato plant growth	1040:1058	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	69	from	influence	994:1002	arg1	germination					1070:1080	tuber germination	1064:1080	tuber germination	1064:1080	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	69	from	influence	994:1002	arg1	mushrooms					1027:1035	mushrooms	1027:1035	mushrooms	1027:1035	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	9	70	with	Treatment	1351:1359	arg1	SeNC					1387:1390	SeNC	1387:1390	SeNC	1387:1390	Treatment of the potato tubers with SeNC from Gr.
35889308	0	71	theme	Tuber	83:87	arg1	Germination					89:99	Tuber Germination	83:99	Tuber Germination	83:99	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	7	72	theme	potato	1040:1045	arg1	growth					1053:1058	potato plant growth	1040:1058	potato plant growth	1040:1058	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	12	73	theme	agent	1739:1743	arg1	sepedonicus					1757:1767	the potato ring rot causative agent Clavibacter sepedonicus	1709:1767	the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1709:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	12	73	theme	agent	1739:1743	arg1	Cms					1770:1772	Cms	1770:1772	Cms	1770:1772	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	7	74	from	mushrooms	1027:1035	arg1	bio-composites					1007:1020	bio-composites	1007:1020	bio-composites from mushrooms	1007:1035	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	7	74	from	mushrooms	1027:1035	arg1	influence					994:1002	The influence	990:1002	The influence of bio-composites from mushrooms on potato plant growth and tuber germination	990:1080	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	15	75	theme	stimulatory	2154:2164	arg1	SeNCs					2172:2176	stimulatory green SeNCs	2154:2176	stimulatory green SeNCs for growth enhancement	2154:2199	The application of stimulatory green SeNCs for growth enhancement could be used to increase crop yield.
35889308	15	76	theme	green	2166:2170	arg1	SeNCs					2172:2176	stimulatory green SeNCs	2154:2176	stimulatory green SeNCs for growth enhancement	2154:2199	The application of stimulatory green SeNCs for growth enhancement could be used to increase crop yield.
35889308	9	77	theme	potato	1368:1373	arg1	tubers					1375:1380	the potato tubers	1364:1380	the potato tubers	1364:1380	Treatment of the potato tubers with SeNC from Gr.
35889308	7	78	theme	bio-composites	1007:1020	arg1	influence					994:1002	The influence	990:1002	The influence of bio-composites from mushrooms on potato plant growth and tuber germination	990:1080	The influence of bio-composites from mushrooms on potato plant growth and tuber germination were studied in two potato cultivars: Lukyanovsky and Lugovskoi.
35889308	12	79	theme	potato	1713:1718	arg1	sepedonicus					1757:1767	the potato ring rot causative agent Clavibacter sepedonicus	1709:1767	the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1709:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	12	79	theme	potato	1713:1718	arg1	Cms					1770:1772	Cms	1770:1772	Cms	1770:1772	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	0	80	from	Effects	48:54	arg1	Growth					72:77	Potato Plant Growth	59:77	Potato Plant Growth	59:77	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	0	80	from	Effects	48:54	arg1	Germination					89:99	Tuber Germination	83:99	Tuber Germination	83:99	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	16	81	theme	efficient	2346:2354	arg1	tool					2356:2359	an unexpectedly efficient tool	2330:2359	an unexpectedly efficient tool for possible applications of SeNCs	2330:2394	Thus, by combining myco-nanotechnology with the intrinsic biological activity of selenium, an unexpectedly efficient tool for possible applications of SeNCs could be identified.
35889308	0	82	theme	Novel	17:21	arg1	Selenium					23:30	Mushroom-Derived Novel Selenium	0:30	Mushroom-Derived Novel Selenium	0:30	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	13	83	from	increase	1829:1836	arg1	biomass					1857:1863	the potato root biomass	1841:1863	the potato root biomass	1841:1863	Bio-composites based on Pleurotus ostreatus promoted increase in the potato root biomass in the Lugovskoi cultivar by up to 79% versus the control.
35889308	14	84	theme	bifunctional	2078:2089	arg1	mode					2091:2094	the bifunctional mode	2074:2094	the bifunctional mode of action of these Se-biopreparations	2074:2132	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	12	85	theme	rot	1725:1727	arg1	sepedonicus					1757:1767	the potato ring rot causative agent Clavibacter sepedonicus	1709:1767	the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1709:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	12	85	theme	rot	1725:1727	arg1	Cms					1770:1772	Cms	1770:1772	Cms	1770:1772	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	1	86	theme	Multicomponent	102:115	arg1	materials					117:125	Multicomponent materials	102:125	Multicomponent materials	102:125	Multicomponent materials, where nanosized selenium (Se) is dispersed in polymer matrices, present as polymer nanocomposites (NCs), namely, selenium polymer nanocomposites (SeNCs).
35889308	12	87	theme	biofilm	1688:1694	arg1	formation					1696:1704	biofilm formation	1688:1704	biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms)	1688:1773	We found earlier that this bio-composite was the most efficient against biofilm formation by the potato ring rot causative agent Clavibacter sepedonicus (Cms).
35889308	3	88	theme	beneficial	410:419	arg1	approaches					421:430	More ecologically safe and beneficial approaches	383:430	More ecologically safe and beneficial approaches to obtain Se-based products	383:458	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	3	88	theme	beneficial	410:419	arg1	challenge					476:484	the current challenge	464:484	the current challenge	464:484	More ecologically safe and beneficial approaches to obtain Se-based products are the current challenge.
35889308	0	89	theme	Potato	59:64	arg1	Growth					72:77	Potato Plant Growth	59:77	Potato Plant Growth	59:77	Mushroom-Derived Novel Selenium Nanocomposites' Effects on Potato Plant Growth and Tuber Germination.
35889308	8	90	theme	Grifola	1171:1177	arg1	umbellata					1179:1187	Grifola umbellata	1171:1187	Grifola umbellata	1171:1187	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	11	91	theme	Potato	1453:1458	arg1	plants					1460:1465	Potato plants	1453:1465	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303	1453:1524	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303 experienced an increase in the potato vegetative biomass by up to 55% versus the control.
35889308	11	92	from	increase	1541:1548	arg1	biomass					1575:1581	the potato vegetative biomass	1553:1581	the potato vegetative biomass	1553:1581	Potato plants exposed to Se-bio-composite from Ganoderma lucidum SIE1303 experienced an increase in the potato vegetative biomass by up to 55% versus the control.
35889308	14	93	theme	anti-phytopathogenic	2021:2040	arg1	activity					2042:2049	their anti-phytopathogenic activity	2015:2049	their anti-phytopathogenic activity	2015:2049	The phytostimulating ability of mushroom-based Se-containing bio-composites, together with their anti-phytopathogenic activity, testifies in favor of the bifunctional mode of action of these Se-biopreparations.
35889308	4	94	theme	unique	628:633	arg1	properties					635:644	unique properties	628:644	unique properties	628:644	Biopolymers have attained great attention with perspective multifunctional and high-performance NCs exhibiting low environmental impact with unique properties, being abundantly available, renewable, and eco-friendly.
35889308	15	95	used	used	2210:2213	arg2	application					2139:2149	The application	2135:2149	The application of stimulatory green SeNCs for growth enhancement	2135:2199	The application of stimulatory green SeNCs for growth enhancement could be used to increase crop yield.
35889308	8	96	theme	strongest	1206:1214	arg1	effect					1225:1230	the strongest positive effect	1202:1230	the strongest positive effect on the number of leaves and plant height in both cultivars	1202:1289	Bio-composites based on Grifola umbellata demonstrated the strongest positive effect on the number of leaves and plant height in both cultivars, without negative effect on biomass of the vegetative part.
35889308	15	97	theme	crop	2227:2230	arg1	yield					2232:2236	crop yield	2227:2236	crop yield	2227:2236	The application of stimulatory green SeNCs for growth enhancement could be used to increase crop yield.
35889308	15	98	theme	SeNCs	2172:2176	arg1	application					2139:2149	The application	2135:2149	The application of stimulatory green SeNCs for growth enhancement	2135:2199	The application of stimulatory green SeNCs for growth enhancement could be used to increase crop yield.
35889308	13	99	theme	Lugovskoi	1872:1880	arg1	cultivar					1882:1889	the Lugovskoi cultivar	1868:1889	the Lugovskoi cultivar	1868:1889	Bio-composites based on Pleurotus ostreatus promoted increase in the potato root biomass in the Lugovskoi cultivar by up to 79% versus the control.
36933625	9	0	theme	functional	1207:1216	arg1	criteria					1233:1240	functional and structural criteria	1207:1240	functional and structural criteria of characterized enzymes	1207:1265	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	9	0	theme	functional	1207:1216	arg1	organization					1193:1204	module organization	1186:1204	module organization	1186:1204	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	8	1	theme	activities	992:1001	arg1	Assessment					964:973	Assessment	964:973	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone	964:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	2	2	theme	insects	367:373	arg1	exoskeleton					352:362	the exoskeleton	348:362	the exoskeleton of insects and crustaceans	348:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	5	3	theme	colloidal	643:651	arg1	chitin					653:658	colloidal chitin	643:658	in some cases colloidal chitin	629:658	Synthetic substrates and in some cases colloidal chitin were used to characterize activities.
36933625	9	4	theme	structural	1222:1231	arg1	criteria					1233:1240	functional and structural criteria	1207:1240	functional and structural criteria of characterized enzymes	1207:1265	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	9	4	theme	structural	1222:1231	arg1	organization					1193:1204	module organization	1186:1204	module organization	1186:1204	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	5	5	from	chitin	653:658	arg1	cases					637:641	some cases	632:641	some cases	632:641	Synthetic substrates and in some cases colloidal chitin were used to characterize activities.
36933625	13	6	theme	waste	1854:1858	arg1	valorization					1827:1838	valorization	1827:1838	valorization of industrial waste	1827:1858	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	1	7	theme	glycosyl	196:203	arg1	hydrolases					205:214	glycosyl hydrolases	196:214	glycosyl hydrolases	196:214	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	8	8	theme	enzymatic	982:990	arg1	activities					992:1001	the enzymatic activities	978:1001	the enzymatic activities	978:1001	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	9	9	theme	enzymes	1259:1265	arg1	criteria					1233:1240	functional and structural criteria	1207:1240	functional and structural criteria of characterized enzymes	1207:1265	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	9	9	theme	enzymes	1259:1265	arg1	organization					1193:1204	module organization	1186:1204	module organization	1186:1204	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	2	10	theme	structural	293:302	arg1	component					304:312	an important structural component	280:312	an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans	280:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	10	theme	structural	293:302	arg1	chitin					272:277	chitin	272:277	chitin	272:277	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	7	11	theme	domain	856:861	arg1	structure					814:822	the TIM barrel structure	799:822	the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition	799:961	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	12	12	theme	GENERAL	1640:1646	arg1	enzymes					1672:1678	GENERAL SIGNIFICANCE Myxomycete enzymes	1640:1678	GENERAL SIGNIFICANCE Myxomycete enzymes	1640:1678	GENERAL SIGNIFICANCE Myxomycete enzymes are currently poorly characterized and constitute a potential source for new catalysts.
36933625	3	13	from	search	434:439	arg1	transcriptomes					444:457	transcriptomes	444:457	transcriptomes	444:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	12	14	theme	Myxomycete	1661:1670	arg1	enzymes					1672:1678	GENERAL SIGNIFICANCE Myxomycete enzymes	1640:1678	GENERAL SIGNIFICANCE Myxomycete enzymes	1640:1678	GENERAL SIGNIFICANCE Myxomycete enzymes are currently poorly characterized and constitute a potential source for new catalysts.
36933625	13	15	contain	have	1799:1802	arg2	potential					1813:1821	a strong potential	1804:1821	a strong potential for valorization of industrial waste	1804:1858	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	13	15	contain	have	1799:1802	arg1	hydrolases					1788:1797	glycosyl hydrolases	1779:1797	glycosyl hydrolases	1779:1797	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	2	16	theme	GH18	246:249	arg1	family					251:256	the GH18 family	242:256	the GH18 family	242:256	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	17	from	component	304:312	arg1	fungi					335:339	fungi	335:339	fungi	335:339	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	17	from	component	304:312	arg1	exoskeleton					352:362	the exoskeleton	348:362	the exoskeleton of insects and crustaceans	348:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	10	18	theme	polycephalum	1302:1313	arg1	sequences					1315:1323	Physarum polycephalum sequences	1293:1323	Physarum polycephalum sequences encompassing a chitinase like GH18 signature	1293:1368	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	0	19	theme	myxomycete	64:73	arg1	polycephalum					84:95	the myxomycete Physarum polycephalum	60:95	the myxomycete Physarum polycephalum	60:95	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	8	20	theme	CBM14	1040:1044	arg1	clone					1072:1076	the most active clone	1056:1076	the most active clone	1056:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	8	20	theme	CBM14	1040:1044	arg1	domain					1046:1051	the C-terminal CBM14 domain	1025:1051	the C-terminal CBM14 domain of the most active clone	1025:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	0	21	from	Characterization	0:15	arg1	polycephalum					84:95	the myxomycete Physarum polycephalum	60:95	the myxomycete Physarum polycephalum	60:95	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	0	21	from	Characterization	0:15	arg1	family					50:55	the GH18 gene family	36:55	the GH18 gene family	36:55	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	10	22	theme	binding	1545:1551	arg1	domains					1553:1559	additional sugar binding domains	1528:1559	additional sugar binding domains	1528:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	2	23	theme	crustaceans	379:389	arg1	exoskeleton					352:362	the exoskeleton	348:362	the exoskeleton of insects and crustaceans	348:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	10	24	theme	additional	1528:1537	arg1	domains					1553:1559	additional sugar binding domains	1528:1559	additional sugar binding domains	1528:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	3	25	theme	sequence	415:422	arg1	search					434:439	METHODS Low stringency sequence signature search	392:439	METHODS Low stringency sequence signature search in transcriptomes	392:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	7	26	theme	chitinase	836:844	arg1	domain					856:861	the GH18 chitinase catalytic domain	827:861	the GH18 chitinase catalytic domain	827:861	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	8	27	theme	clone	1072:1076	arg1	clone					1072:1076	the most active clone	1056:1076	the most active clone	1056:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	8	27	theme	clone	1072:1076	arg1	domain					1046:1051	the C-terminal CBM14 domain	1025:1051	the C-terminal CBM14 domain of the most active clone	1025:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	2	28	from	family	251:256	arg1	enzymes					229:235	enzymes	229:235	enzymes from the GH18 family	229:256	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	6	29	dep	sorted	741:746	arg1	functional					720:729	functional	720:729	functional	720:729	RESULTS Catalytically functional hits were sorted and their predicted structures compared.
36933625	6	29	dep	sorted	741:746	arg1	RESULTS					698:704	RESULTS	698:704	RESULTS	698:704	RESULTS Catalytically functional hits were sorted and their predicted structures compared.
36933625	0	30	theme	chitinases	20:29	arg1	Characterization					0:15	Characterization	0:15	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.	0:96	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	1	31	theme	Physarum	109:116	arg1	myxomycete					157:166	myxomycete	157:166	myxomycete	157:166	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	1	31	theme	Physarum	109:116	arg1	polycephalum					118:129	BACKGROUND Physarum polycephalum	98:129	BACKGROUND Physarum polycephalum	98:129	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	12	32	theme	potential	1732:1740	arg1	source					1742:1747	a potential source	1730:1747	a potential source for new catalysts	1730:1765	GENERAL SIGNIFICANCE Myxomycete enzymes are currently poorly characterized and constitute a potential source for new catalysts.
36933625	3	33	theme	Low	400:402	arg1	search					434:439	METHODS Low stringency sequence signature search	392:439	METHODS Low stringency sequence signature search in transcriptomes	392:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	0	34	theme	gene	45:48	arg1	family					50:55	the GH18 gene family	36:55	the GH18 gene family	36:55	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	7	35	theme	TIM	803:805	arg1	structure					814:822	the TIM barrel structure	799:822	the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition	799:961	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	10	36	theme	insertion	1482:1490	arg1	domain					1492:1497	a chitin insertion domain	1473:1497	a chitin insertion domain	1473:1497	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	10	37	theme	modular	1378:1384	arg1	structure					1386:1394	a modular structure	1376:1394	a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains	1376:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	2	38	theme	walls	326:330	arg1	component					304:312	an important structural component	280:312	an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans	280:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	38	theme	walls	326:330	arg1	chitin					272:277	chitin	272:277	chitin	272:277	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	10	39	theme	catalytic	1431:1439	arg1	barrels					1445:1451	a structurally conserved catalytic TIM barrels	1406:1451	a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains	1406:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	8	40	theme	chitinase	1140:1148	arg1	activity					1150:1157	the chitinase activity	1136:1157	the chitinase activity	1136:1157	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	9	41	theme	module	1186:1191	arg1	criteria					1233:1240	functional and structural criteria	1207:1240	functional and structural criteria of characterized enzymes	1207:1265	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	9	41	theme	module	1186:1191	arg1	organization					1193:1204	module organization	1186:1204	module organization	1186:1204	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	2	42	from	walls	326:330	arg1	fungi					335:339	fungi	335:339	fungi	335:339	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	42	from	walls	326:330	arg1	exoskeleton					352:362	the exoskeleton	348:362	the exoskeleton of insects and crustaceans	348:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	43	theme	important	283:291	arg1	component					304:312	an important structural component	280:312	an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans	280:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	43	theme	important	283:291	arg1	chitin					272:277	chitin	272:277	chitin	272:277	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	44	from	fungi	335:339	arg1	component					304:312	an important structural component	280:312	an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans	280:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	44	from	fungi	335:339	arg1	chitin					272:277	chitin	272:277	chitin	272:277	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	13	45	theme	therapeutic	1874:1884	arg1	field					1886:1890	therapeutic field	1874:1890	therapeutic field	1874:1890	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	11	46	theme	clear	1582:1586	arg1	role					1588:1591	a clear role	1580:1591	a clear role	1580:1591	One of them plays a clear role in enhancing activities toward natural chitin.
36933625	1	47	theme	large	181:185	arg1	range					187:191	a large range	179:191	a large range of glycosyl hydrolases	179:214	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	5	48	used	used	665:668	arg2	substrates					614:623	Synthetic substrates	604:623	Synthetic substrates	604:623	Synthetic substrates and in some cases colloidal chitin were used to characterize activities.
36933625	5	48	used	used	665:668	arg2	chitin					653:658	colloidal chitin	643:658	in some cases colloidal chitin	629:658	Synthetic substrates and in some cases colloidal chitin were used to characterize activities.
36933625	13	49	theme	industrial	1843:1852	arg1	waste					1854:1858	industrial waste	1843:1858	industrial waste	1843:1858	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	10	50	theme	chitin	1475:1480	arg1	domain					1492:1497	a chitin insertion domain	1473:1497	a chitin insertion domain	1473:1497	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	7	51	theme	binding	884:890	arg1	CBM50					908:912	CBM50	908:912	CBM50	908:912	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	7	51	theme	binding	884:890	arg1	motifs					892:897	binding motifs	884:897	binding motifs	884:897	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	7	51	theme	binding	884:890	arg1	CBM18					915:919	CBM18	915:919	CBM18	915:919	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	7	51	theme	binding	884:890	arg1	CBM14					926:930	CBM14	926:930	CBM14	926:930	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	8	52	theme	C-terminal	1029:1038	arg1	clone					1072:1076	the most active clone	1056:1076	the most active clone	1056:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	8	52	theme	C-terminal	1029:1038	arg1	domain					1046:1051	the C-terminal CBM14 domain	1025:1051	the C-terminal CBM14 domain of the most active clone	1025:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	2	53	from	exoskeleton	352:362	arg1	component					304:312	an important structural component	280:312	an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans	280:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	2	53	from	exoskeleton	352:362	arg1	chitin					272:277	chitin	272:277	chitin	272:277	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	9	54	theme	characterized	1245:1257	arg1	enzymes					1259:1265	characterized enzymes	1245:1265	characterized enzymes	1245:1265	A classification based on module organization, functional and structural criteria of characterized enzymes was proposed.
36933625	1	55	theme	hydrolases	205:214	arg1	range					187:191	a large range	179:191	a large range of glycosyl hydrolases	179:214	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	11	56	theme	them	1569:1572	arg1	One					1562:1564	One	1562:1564	One	1562:1564	One of them plays a clear role in enhancing activities toward natural chitin.
36933625	11	56	theme	them	1569:1572	arg1	them					1569:1572	them	1569:1572	them	1569:1572	One of them plays a clear role in enhancing activities toward natural chitin.
36933625	12	57	theme	SIGNIFICANCE	1648:1659	arg1	enzymes					1672:1678	GENERAL SIGNIFICANCE Myxomycete enzymes	1640:1678	GENERAL SIGNIFICANCE Myxomycete enzymes	1640:1678	GENERAL SIGNIFICANCE Myxomycete enzymes are currently poorly characterized and constitute a potential source for new catalysts.
36933625	11	58	theme	natural	1624:1630	arg1	chitin					1632:1637	natural chitin	1624:1637	natural chitin	1624:1637	One of them plays a clear role in enhancing activities toward natural chitin.
36933625	0	59	theme	Physarum	75:82	arg1	polycephalum					84:95	the myxomycete Physarum polycephalum	60:95	the myxomycete Physarum polycephalum	60:95	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	8	60	theme	domain	1046:1051	arg1	deletion					1013:1020	deletion	1013:1020	deletion of the C-terminal CBM14 domain of the most active clone	1013:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	5	61	from	substrates	614:623	arg1	cases					637:641	some cases	632:641	some cases	632:641	Synthetic substrates and in some cases colloidal chitin were used to characterize activities.
36933625	4	62	theme	Identified	518:527	arg1	sequences					529:537	Identified sequences	518:537	Identified sequences	518:537	Identified sequences were expressed in E. coli and corresponding structures modelled.
36933625	10	63	theme	Physarum	1293:1300	arg1	polycephalum					1302:1313	Physarum polycephalum	1293:1313	Physarum polycephalum sequences encompassing a chitinase like GH18 signature	1293:1368	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	10	64	dep	CONCLUSIONS	1281:1291	arg1	share					1370:1374	share	1370:1374	share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains	1370:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	0	65	from	family	50:55	arg1	chitinases					20:29	chitinases	20:29	chitinases from the GH18 gene family	20:55	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	0	65	from	family	50:55	arg1	Characterization					0:15	Characterization	0:15	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.	0:96	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	13	66	theme	strong	1806:1811	arg1	potential					1813:1821	a strong potential	1804:1821	a strong potential for valorization of industrial waste	1804:1858	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	2	67	theme	cell	321:324	arg1	walls					326:330	the cell walls	317:330	the cell walls in fungi and in the exoskeleton of insects and crustaceans	317:389	Among them, enzymes from the GH18 family can hydrolyze chitin, an important structural component of the cell walls in fungi and in the exoskeleton of insects and crustaceans.
36933625	8	68	theme	active	1065:1070	arg1	clone					1072:1076	the most active clone	1056:1076	the most active clone	1056:1076	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	10	69	theme	sugar	1539:1543	arg1	domains					1553:1559	additional sugar binding domains	1528:1559	additional sugar binding domains	1528:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	7	70	theme	sugar	945:949	arg1	recognition					951:961	sugar recognition	945:961	sugar recognition	945:961	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	12	71	theme	new	1753:1755	arg1	catalysts					1757:1765	new catalysts	1753:1765	new catalysts	1753:1765	GENERAL SIGNIFICANCE Myxomycete enzymes are currently poorly characterized and constitute a potential source for new catalysts.
36933625	13	72	theme	glycosyl	1779:1786	arg1	hydrolases					1788:1797	glycosyl hydrolases	1779:1797	glycosyl hydrolases	1779:1797	Among them glycosyl hydrolases have a strong potential for valorization of industrial waste as well as in therapeutic field.
36933625	3	73	theme	signature	424:432	arg1	search					434:439	METHODS Low stringency sequence signature search	392:439	METHODS Low stringency sequence signature search in transcriptomes	392:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	7	74	theme	catalytic	846:854	arg1	domain					856:861	the GH18 chitinase catalytic domain	827:861	the GH18 chitinase catalytic domain	827:861	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	8	75	theme	significant	1090:1100	arg1	contribution					1102:1113	a significant contribution	1088:1113	a significant contribution of this extension to the chitinase activity	1088:1157	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	5	76	theme	Synthetic	604:612	arg1	substrates					614:623	Synthetic substrates	604:623	Synthetic substrates	604:623	Synthetic substrates and in some cases colloidal chitin were used to characterize activities.
36933625	1	77	theme	BACKGROUND	98:107	arg1	myxomycete					157:166	myxomycete	157:166	myxomycete	157:166	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	1	77	theme	BACKGROUND	98:107	arg1	polycephalum					118:129	BACKGROUND Physarum polycephalum	98:129	BACKGROUND Physarum polycephalum	98:129	BACKGROUND Physarum polycephalum is an unusual macroscopic myxomycete expressing a large range of glycosyl hydrolases.
36933625	4	78	theme	corresponding	569:581	arg1	structures					583:592	corresponding structures	569:592	corresponding structures	569:592	Identified sequences were expressed in E. coli and corresponding structures modelled.
36933625	3	79	used	used	463:466	arg2	search					434:439	METHODS Low stringency sequence signature search	392:439	METHODS Low stringency sequence signature search in transcriptomes	392:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	0	80	theme	GH18	40:43	arg1	family					50:55	the GH18 gene family	36:55	the GH18 gene family	36:55	Characterization of chitinases from the GH18 gene family in the myxomycete Physarum polycephalum.
36933625	7	81	theme	GH18	831:834	arg1	domain					856:861	the GH18 chitinase catalytic domain	827:861	the GH18 chitinase catalytic domain	827:861	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	3	82	theme	stringency	404:413	arg1	search					434:439	METHODS Low stringency sequence signature search	392:439	METHODS Low stringency sequence signature search in transcriptomes	392:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	8	83	theme	extension	1123:1131	arg1	contribution					1102:1113	a significant contribution	1088:1113	a significant contribution of this extension to the chitinase activity	1088:1157	Assessment of the enzymatic activities following deletion of the C-terminal CBM14 domain of the most active clone evidenced a significant contribution of this extension to the chitinase activity.
36933625	3	84	theme	METHODS	392:398	arg1	search					434:439	METHODS Low stringency sequence signature search	392:439	METHODS Low stringency sequence signature search in transcriptomes	392:457	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	3	85	theme	related	495:501	arg1	sequences					485:493	GH18 sequences	480:493	GH18 sequences related to chitinases	480:515	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	7	86	theme	barrel	807:812	arg1	structure					814:822	the TIM barrel structure	799:822	the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition	799:961	All share the TIM barrel structure of the GH18 chitinase catalytic domain, optionally fused to binding motifs, such as CBM50, CBM18, and CBM14, involved in sugar recognition.
36933625	6	87	theme	predicted	758:766	arg1	structures					768:777	their predicted structures	752:777	their predicted structures	752:777	RESULTS Catalytically functional hits were sorted and their predicted structures compared.
36933625	10	88	theme	TIM	1441:1443	arg1	barrels					1445:1451	a structurally conserved catalytic TIM barrels	1406:1451	a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains	1406:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
36933625	3	89	theme	GH18	480:483	arg1	sequences					485:493	GH18 sequences	480:493	GH18 sequences related to chitinases	480:515	METHODS Low stringency sequence signature search in transcriptomes was used to identify GH18 sequences related to chitinases.
36933625	10	90	theme	conserved	1421:1429	arg1	barrels					1445:1451	a structurally conserved catalytic TIM barrels	1406:1451	a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains	1406:1559	CONCLUSIONS Physarum polycephalum sequences encompassing a chitinase like GH18 signature share a modular structure involving a structurally conserved catalytic TIM barrels decorated or not by a chitin insertion domain and optionally surrounded by additional sugar binding domains.
35904207	5	0	theme	impedance	882:890	arg1	spectroscopy					892:903	electrochemical impedance spectroscopy	866:903	electrochemical impedance spectroscopy	866:903	These tetrasaccharides were electrochemically grafted onto glassy carbon electrodes and their response to heavy metal ions was monitored by electrochemical impedance spectroscopy.
35904207	6	1	theme	uronic	1009:1014	arg1	type					1021:1024	the uronic acid type	1005:1024	the uronic acid type	1005:1024	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	5	2	theme	glassy	785:790	arg1	electrodes					799:808	glassy carbon electrodes	785:808	glassy carbon electrodes	785:808	These tetrasaccharides were electrochemically grafted onto glassy carbon electrodes and their response to heavy metal ions was monitored by electrochemical impedance spectroscopy.
35904207	6	3	theme	pattern	1044:1050	arg1	combination					990:1000	a combination	988:1000	a combination of the uronic acid type and the sulfation pattern	988:1050	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	3	4	dep	glycans	434:440	arg1	motifs					453:458	structural motifs	442:458	the glycans structural motifs	430:458	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	6	5	theme	Hg	940:941	arg1	binding					929:935	the binding	925:935	the binding of Hg(II), Cd(II), and Pb(II)	925:965	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	6	6	theme	Cd	948:949	arg1	binding					929:935	the binding	925:935	the binding of Hg(II), Cd(II), and Pb(II)	925:965	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	4	7	theme	analogs	654:660	arg1	library					600:606	a small library	592:606	a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions	592:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	5	8	theme	metal	838:842	arg1	ions					844:847	heavy metal ions	832:847	heavy metal ions	832:847	These tetrasaccharides were electrochemically grafted onto glassy carbon electrodes and their response to heavy metal ions was monitored by electrochemical impedance spectroscopy.
35904207	4	9	theme	sulfation	677:685	arg1	patterns					687:694	different sulfation patterns	667:694	different sulfation patterns	667:694	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	3	10	used	used	391:394	arg2	techniques					375:384	electrochemical and surface characterization techniques	330:384	electrochemical and surface characterization techniques	330:384	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	4	11	theme	different	667:675	arg1	patterns					687:694	different sulfation patterns	667:694	different sulfation patterns	667:694	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	6	12	theme	Pb	960:961	arg1	binding					929:935	the binding	925:935	the binding of Hg(II), Cd(II), and Pb(II)	925:965	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	1	13	theme	Heparan	89:95	arg1	glycosaminoglycans					105:122	Heparan sulfate glycosaminoglycans	89:122	Heparan sulfate glycosaminoglycans	89:122	Heparan sulfate glycosaminoglycans provides extracellular matrix defense against heavy metals cytotoxicity.
35904207	3	14	theme	sulfation	494:502	arg1	regiochemistry					504:517	sulfation regiochemistry	494:517	sulfation regiochemistry	494:517	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	4	15	theme	divergent	550:558	arg1	strategy					560:567	A divergent strategy	548:567	A divergent strategy	548:567	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	1	16	theme	sulfate	97:103	arg1	glycosaminoglycans					105:122	Heparan sulfate glycosaminoglycans	89:122	Heparan sulfate glycosaminoglycans	89:122	Heparan sulfate glycosaminoglycans provides extracellular matrix defense against heavy metals cytotoxicity.
35904207	0	17	theme	Heparan	10:16	arg1	Ions					38:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions Interaction Using Electrochemical Techniques.
35904207	5	18	theme	carbon	792:797	arg1	electrodes					799:808	glassy carbon electrodes	785:808	glassy carbon electrodes	785:808	These tetrasaccharides were electrochemically grafted onto glassy carbon electrodes and their response to heavy metal ions was monitored by electrochemical impedance spectroscopy.
35904207	0	19	theme	Profiling	0:8	arg1	Ions					38:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions Interaction Using Electrochemical Techniques.
35904207	6	20	theme	type	1021:1024	arg1	combination					990:1000	a combination	988:1000	a combination of the uronic acid type and the sulfation pattern	988:1050	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	6	21	theme	Key	906:908	arg1	differences					910:920	Key differences	906:920	Key differences in the binding of Hg(II), Cd(II), and Pb(II)	906:965	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	0	22	theme	Metal	32:36	arg1	Ions					38:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions Interaction Using Electrochemical Techniques.
35904207	6	23	theme	acid	1016:1019	arg1	type					1021:1024	the uronic acid type	1005:1024	the uronic acid type	1005:1024	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	1	24	theme	extracellular	133:145	arg1	defense					154:160	extracellular matrix defense	133:160	extracellular matrix defense against heavy metals cytotoxicity	133:194	Heparan sulfate glycosaminoglycans provides extracellular matrix defense against heavy metals cytotoxicity.
35904207	3	25	theme	metal	528:532	arg1	ions					534:537	heavy metal ions	522:537	heavy metal ions binding	522:545	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	0	26	theme	Sulfate-Heavy	18:30	arg1	Ions					38:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions	0:41	Profiling Heparan Sulfate-Heavy Metal Ions Interaction Using Electrochemical Techniques.
35904207	4	27	theme	tetrasaccharides	637:652	arg1	analogs					654:660	structurally well-defined tetrasaccharides analogs	611:660	structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions	611:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	1	28	theme	matrix	147:152	arg1	defense					154:160	extracellular matrix defense	133:160	extracellular matrix defense against heavy metals cytotoxicity	133:194	Heparan sulfate glycosaminoglycans provides extracellular matrix defense against heavy metals cytotoxicity.
35904207	3	29	theme	ions	534:537	arg1	binding					539:545	heavy metal ions binding	522:545	heavy metal ions binding	522:545	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	3	30	theme	acid	468:471	arg1	stereochemistry					473:487	uronic acid stereochemistry	461:487	uronic acid stereochemistry	461:487	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	4	31	theme	well-defined	624:635	arg1	analogs					654:660	structurally well-defined tetrasaccharides analogs	611:660	structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions	611:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	5	32	theme	heavy	832:836	arg1	ions					844:847	heavy metal ions	832:847	heavy metal ions	832:847	These tetrasaccharides were electrochemically grafted onto glassy carbon electrodes and their response to heavy metal ions was monitored by electrochemical impedance spectroscopy.
35904207	2	33	theme	glycan	221:226	arg1	sequences					228:236	the precise glycan sequences	209:236	the precise glycan sequences that bind a particular heavy metal ion	209:275	Identifying the precise glycan sequences that bind a particular heavy metal ion is a key for understanding those interactions.
35904207	3	34	theme	heavy	522:526	arg1	ions					534:537	heavy metal ions	522:537	heavy metal ions binding	522:545	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	0	35	theme	Electrochemical	61:75	arg1	Techniques					77:86	Electrochemical Techniques	61:86	Electrochemical Techniques	61:86	Profiling Heparan Sulfate-Heavy Metal Ions Interaction Using Electrochemical Techniques.
35904207	3	36	theme	surface	350:356	arg1	characterization					358:373	surface characterization	350:373	surface characterization	350:373	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	2	37	theme	precise	213:219	arg1	sequences					228:236	the precise glycan sequences	209:236	the precise glycan sequences that bind a particular heavy metal ion	209:275	Identifying the precise glycan sequences that bind a particular heavy metal ion is a key for understanding those interactions.
35904207	3	38	theme	uronic	461:466	arg1	stereochemistry					473:487	uronic acid stereochemistry	461:487	uronic acid stereochemistry	461:487	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	3	39	theme	characterization	358:373	arg1	techniques					375:384	electrochemical and surface characterization techniques	330:384	electrochemical and surface characterization techniques	330:384	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	2	40	theme	heavy	261:265	arg1	ion					273:275	a particular heavy metal ion	248:275	a particular heavy metal ion	248:275	Identifying the precise glycan sequences that bind a particular heavy metal ion is a key for understanding those interactions.
35904207	2	41	theme	metal	267:271	arg1	ion					273:275	a particular heavy metal ion	248:275	a particular heavy metal ion	248:275	Identifying the precise glycan sequences that bind a particular heavy metal ion is a key for understanding those interactions.
35904207	4	42	theme	small	594:598	arg1	library					600:606	a small library	592:606	a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions	592:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	3	43	theme	electrochemical	330:344	arg1	techniques					375:384	electrochemical and surface characterization techniques	330:384	electrochemical and surface characterization techniques	330:384	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	2	44	theme	particular	250:259	arg1	ion					273:275	a particular heavy metal ion	248:275	a particular heavy metal ion	248:275	Identifying the precise glycan sequences that bind a particular heavy metal ion is a key for understanding those interactions.
35904207	1	45	theme	heavy	170:174	arg1	metals					176:181	heavy metals	170:181	heavy metals cytotoxicity	170:194	Heparan sulfate glycosaminoglycans provides extracellular matrix defense against heavy metals cytotoxicity.
35904207	1	46	theme	metals	176:181	arg1	cytotoxicity					183:194	heavy metals cytotoxicity	170:194	heavy metals cytotoxicity	170:194	Heparan sulfate glycosaminoglycans provides extracellular matrix defense against heavy metals cytotoxicity.
35904207	6	47	from	differences	910:920	arg1	binding					929:935	the binding	925:935	the binding of Hg(II), Cd(II), and Pb(II)	925:965	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	6	48	theme	sulfation	1034:1042	arg1	pattern					1044:1050	the sulfation pattern	1030:1050	the sulfation pattern	1030:1050	Key differences in the binding of Hg(II), Cd(II), and Pb(II) were associated with a combination of the uronic acid type and the sulfation pattern.
35904207	4	49	theme	acid	707:710	arg1	compositions					712:723	uronic acid compositions	700:723	uronic acid compositions	700:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	5	50	theme	electrochemical	866:880	arg1	spectroscopy					892:903	electrochemical impedance spectroscopy	866:903	electrochemical impedance spectroscopy	866:903	These tetrasaccharides were electrochemically grafted onto glassy carbon electrodes and their response to heavy metal ions was monitored by electrochemical impedance spectroscopy.
35904207	4	51	with	analogs	654:660	arg1	compositions					712:723	uronic acid compositions	700:723	uronic acid compositions	700:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	4	51	with	analogs	654:660	arg1	patterns					687:694	different sulfation patterns	667:694	different sulfation patterns	667:694	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
35904207	3	52	theme	structural	442:451	arg1	motifs					453:458	structural motifs	442:458	the glycans structural motifs	430:458	Here, electrochemical and surface characterization techniques were used to elucidate the relation between the glycans structural motifs, uronic acid stereochemistry, and sulfation regiochemistry to heavy metal ions binding.
35904207	4	53	theme	uronic	700:705	arg1	compositions					712:723	uronic acid compositions	700:723	uronic acid compositions	700:723	A divergent strategy was employed to access a small library of structurally well-defined tetrasaccharides analogs with different sulfation patterns and uronic acid compositions.
36988338	6	0	theme	proteins	921:928	arg1	groups					907:912	the hydrophobic groups	891:912	the hydrophobic groups of the proteins in TPC	891:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	6	0	theme	proteins	921:928	arg1	proteins					921:928	the proteins	917:928	the proteins in TPC	917:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	7	1	theme	protein	1044:1050	arg1	results					1063:1069	The rheology and interfacial protein adsorption results	1015:1069	The rheology and interfacial protein adsorption results	1015:1069	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	8	2	theme	proteins	1332:1339	arg1	mode					1304:1307	the binding mode	1292:1307	the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion	1292:1414	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	0	3	theme	interfacial	78:88	arg1	stability					90:98	the interfacial stability	74:98	the interfacial stability in nanoemulsions	74:115	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	0	4	from	properties	11:20	arg1	nanoemulsions					103:115	nanoemulsions	103:115	nanoemulsions	103:115	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	10	5	from	binding	1693:1699	arg1	TPC					1736:1738	TPC	1736:1738	TPC	1736:1738	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
36988338	9	6	theme	proteins	1481:1488	arg1	groups					1467:1472	the hydrophilic groups	1451:1472	the hydrophilic groups of the proteins	1451:1488	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	9	6	theme	proteins	1481:1488	arg1	proteins					1481:1488	the proteins	1477:1488	the proteins	1477:1488	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	5	7	theme	proteins	737:744	arg1	proteins					737:744	proteins	737:744	proteins	737:744	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	5	7	theme	proteins	737:744	arg1	polysaccharides					717:731	polysaccharides	717:731	polysaccharides	717:731	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	5	7	theme	proteins	737:744	arg1	groups					707:712	the functional groups	692:712	the functional groups of polysaccharides and proteins	692:744	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	2	8	theme	antioxidant	286:296	arg1	effects					298:304	antioxidant effects	286:304	antioxidant effects	286:304	Due to its benefits in enhancing human immunity and antioxidant effects, TPC is widely used in culinary products.
36988338	3	9	theme	binding	352:358	arg1	mode					360:363	The binding mode	348:363	The binding mode of polysaccharides and proteins in TPC	348:402	The binding mode of polysaccharides and proteins in TPC, however, hasn't been well studied, it may be closely related to their functional properties, especially emulsification.
36988338	3	10	from	mode	360:363	arg1	TPC					400:402	TPC	400:402	TPC	400:402	The binding mode of polysaccharides and proteins in TPC, however, hasn't been well studied, it may be closely related to their functional properties, especially emulsification.
36988338	7	11	theme	oil-water	1118:1126	arg1	interface					1128:1136	the oil-water interface	1114:1136	the oil-water interface	1114:1136	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	9	12	theme	covalent	1523:1530	arg1	interactions					1532:1543	covalent interactions	1523:1543	covalent interactions	1523:1543	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	4	13	theme	monosaccharide	559:572	arg1	compositions					574:585	monosaccharide compositions	559:585	monosaccharide compositions of TPC	559:592	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	6	14	from	groups	907:912	arg1	TPC					933:935	TPC	933:935	TPC	933:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	2	15	theme	culinary	329:336	arg1	products					338:345	culinary products	329:345	culinary products	329:345	Due to its benefits in enhancing human immunity and antioxidant effects, TPC is widely used in culinary products.
36988338	9	16	theme	hydrophobic	1664:1674	arg1	core					1676:1679	a hydrophobic core	1662:1679	a hydrophobic core	1662:1679	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	8	17	theme	phase	1358:1362	arg1	behavior					1364:1371	their phase behavior	1352:1371	their phase behavior	1352:1371	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	4	18	theme	gel	652:654	arg1	chromatography					667:680	high-performance gel permeation chromatography	635:680	high-performance gel permeation chromatography	635:680	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	4	19	dep	RESULTS	525:531	arg1	determined					598:607	determined	598:607	was determined by ion chromatography and high-performance gel permeation chromatography	594:680	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	2	20	theme	human	267:271	arg1	immunity					273:280	human immunity	267:280	human immunity	267:280	Due to its benefits in enhancing human immunity and antioxidant effects, TPC is widely used in culinary products.
36988338	1	21	theme	occurring	179:187	arg1	conjugate					148:156	BACKGROUND Tea Polysaccharide conjugate	118:156	BACKGROUND Tea Polysaccharide conjugate (TPC)	118:162	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	21	theme	occurring	179:187	arg1	substance					196:204	a naturally occurring active substance	167:204	a naturally occurring active substance that is extracted from tea	167:231	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	3	22	theme	polysaccharides	368:382	arg1	mode					360:363	The binding mode	348:363	The binding mode of polysaccharides and proteins in TPC	348:402	The binding mode of polysaccharides and proteins in TPC, however, hasn't been well studied, it may be closely related to their functional properties, especially emulsification.
36988338	6	23	from	proteins	921:928	arg1	TPC					933:935	TPC	933:935	TPC	933:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	7	24	theme	emulsion	1221:1228	arg1	stability					1204:1212	the stability	1200:1212	the stability of the emulsion	1200:1228	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	2	25	used	used	321:324	arg2	TPC					307:309	TPC	307:309	TPC	307:309	Due to its benefits in enhancing human immunity and antioxidant effects, TPC is widely used in culinary products.
36988338	6	26	theme	hydrophobic	895:905	arg1	groups					907:912	the hydrophobic groups	891:912	the hydrophobic groups of the proteins in TPC	891:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	6	26	theme	hydrophobic	895:905	arg1	proteins					921:928	the proteins	917:928	the proteins in TPC	917:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	1	27	theme	active	189:194	arg1	conjugate					148:156	BACKGROUND Tea Polysaccharide conjugate	118:156	BACKGROUND Tea Polysaccharide conjugate (TPC)	118:162	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	27	theme	active	189:194	arg1	substance					196:204	a naturally occurring active substance	167:204	a naturally occurring active substance that is extracted from tea	167:231	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	0	28	theme	Structural	0:9	arg1	properties					11:20	Structural properties	0:20	Structural properties of Phoenix Oolong tea polysaccharide conjugates	0:68	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	7	29	theme	viscoelastic	1093:1104	arg1	film					1106:1109	a viscoelastic film	1091:1109	a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets	1091:1179	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	10	30	theme	unique	1686:1691	arg1	binding					1693:1699	The unique binding	1682:1699	The unique binding of polysaccharides and proteins in TPC	1682:1738	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
36988338	4	31	theme	permeation	656:665	arg1	chromatography					667:680	high-performance gel permeation chromatography	635:680	high-performance gel permeation chromatography	635:680	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	0	32	theme	Phoenix	25:31	arg1	conjugates					59:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	5	33	theme	proteins	803:810	arg1	presence					791:798	the presence	787:798	the presence of proteins	787:810	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	4	34	theme	ion	612:614	arg1	chromatography					616:629	ion chromatography	612:629	ion chromatography	612:629	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	7	35	theme	droplets	1172:1179	arg1	aggregation					1153:1163	the aggregation	1149:1163	the aggregation of oil droplets	1149:1179	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	4	36	theme	molecular	537:545	arg1	weights					547:553	The molecular weights	533:553	The molecular weights	533:553	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	0	37	from	stability	90:98	arg1	nanoemulsions					103:115	nanoemulsions	103:115	nanoemulsions	103:115	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	1	38	theme	BACKGROUND	118:127	arg1	conjugate					148:156	BACKGROUND Tea Polysaccharide conjugate	118:156	BACKGROUND Tea Polysaccharide conjugate (TPC)	118:162	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	38	theme	BACKGROUND	118:127	arg1	substance					196:204	a naturally occurring active substance	167:204	a naturally occurring active substance that is extracted from tea	167:231	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	38	theme	BACKGROUND	118:127	arg1	TPC					159:161	TPC	159:161	TPC	159:161	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	10	39	theme	proteins	1724:1731	arg1	binding					1693:1699	The unique binding	1682:1699	The unique binding of polysaccharides and proteins in TPC	1682:1738	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
36988338	8	40	theme	emulsifying	1261:1271	arg1	properties					1273:1282	these structural and emulsifying properties	1240:1282	these structural and emulsifying properties of TPC	1240:1289	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	0	41	theme	tea	40:42	arg1	conjugates					59:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	6	42	theme	polysaccharide	953:966	arg1	chains					968:973	polysaccharide chains	953:973	polysaccharide chains	953:973	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	5	43	theme	polysaccharides	717:731	arg1	proteins					737:744	proteins	737:744	proteins	737:744	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	5	43	theme	polysaccharides	717:731	arg1	polysaccharides					717:731	polysaccharides	717:731	polysaccharides	717:731	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	5	43	theme	polysaccharides	717:731	arg1	groups					707:712	the functional groups	692:712	the functional groups of polysaccharides and proteins	692:744	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	8	44	theme	TPC	1287:1289	arg1	properties					1273:1282	these structural and emulsifying properties	1240:1282	these structural and emulsifying properties of TPC	1240:1289	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	8	45	theme	structural	1246:1255	arg1	properties					1273:1282	these structural and emulsifying properties	1240:1282	these structural and emulsifying properties of TPC	1240:1289	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	5	46	theme	UV	849:850	arg1	spectroscopy					852:863	UV spectroscopy	849:863	UV spectroscopy	849:863	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	0	47	theme	Oolong	33:38	arg1	conjugates					59:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	9	48	attach	linked	1494:1499	arg2	proteins					1481:1488	the proteins	1477:1488	the proteins	1477:1488	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	9	48	attach	linked	1494:1499	arg3	CONCLUSION					1432:1441	CONCLUSION	1432:1441	CONCLUSION	1432:1441	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	9	48	attach	linked	1494:1499	arg2	groups					1467:1472	the hydrophilic groups	1451:1472	the hydrophilic groups of the proteins	1451:1488	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	9	48	attach	linked	1494:1499	arg1	polysaccharides					1504:1518	polysaccharides	1504:1518	polysaccharides	1504:1518	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	9	48	attach	linked	1494:1499	arg3	interactions					1532:1543	covalent interactions	1523:1543	covalent interactions	1523:1543	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	7	49	theme	oil	1168:1170	arg1	droplets					1172:1179	oil droplets	1168:1179	oil droplets	1168:1179	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	7	50	theme	rheology	1019:1026	arg1	results					1063:1069	The rheology and interfacial protein adsorption results	1015:1069	The rheology and interfacial protein adsorption results	1015:1069	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	0	51	theme	conjugates	59:68	arg1	stability					90:98	the interfacial stability	74:98	the interfacial stability in nanoemulsions	74:115	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	0	51	theme	conjugates	59:68	arg1	properties					11:20	Structural properties	0:20	Structural properties of Phoenix Oolong tea polysaccharide conjugates	0:68	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	9	52	with	chains	1611:1616	arg1	help					1627:1630	help	1627:1630	help	1627:1630	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	7	53	theme	adsorption	1052:1061	arg1	results					1063:1069	The rheology and interfacial protein adsorption results	1015:1069	The rheology and interfacial protein adsorption results	1015:1069	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	10	54	theme	stable	1850:1855	arg1	emulsions					1857:1865	stable emulsions	1850:1865	stable emulsions	1850:1865	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
36988338	8	55	theme	emulsion	1407:1414	arg1	interface					1390:1398	the oil-water interface	1376:1398	the oil-water interface of the emulsion	1376:1414	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	1	56	theme	Tea	129:131	arg1	conjugate					148:156	BACKGROUND Tea Polysaccharide conjugate	118:156	BACKGROUND Tea Polysaccharide conjugate (TPC)	118:162	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	56	theme	Tea	129:131	arg1	substance					196:204	a naturally occurring active substance	167:204	a naturally occurring active substance that is extracted from tea	167:231	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	56	theme	Tea	129:131	arg1	TPC					159:161	TPC	159:161	TPC	159:161	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	0	57	theme	polysaccharide	44:57	arg1	conjugates					59:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Phoenix Oolong tea polysaccharide conjugates	25:68	Structural properties of Phoenix Oolong tea polysaccharide conjugates and the interfacial stability in nanoemulsions.
36988338	7	58	from	interface	1128:1136	arg1	film					1106:1109	a viscoelastic film	1091:1109	a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets	1091:1179	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	6	59	from	TPC	933:935	arg1	groups					907:912	the hydrophobic groups	891:912	the hydrophobic groups of the proteins in TPC	891:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	6	59	from	TPC	933:935	arg1	proteins					921:928	the proteins	917:928	the proteins in TPC	917:935	It was hypothesized that the hydrophobic groups of the proteins in TPC were wrapped by polysaccharide chains, thus making the proteins undetectable.
36988338	1	60	theme	Polysaccharide	133:146	arg1	conjugate					148:156	BACKGROUND Tea Polysaccharide conjugate	118:156	BACKGROUND Tea Polysaccharide conjugate (TPC)	118:162	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	60	theme	Polysaccharide	133:146	arg1	substance					196:204	a naturally occurring active substance	167:204	a naturally occurring active substance that is extracted from tea	167:231	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	1	60	theme	Polysaccharide	133:146	arg1	TPC					159:161	TPC	159:161	TPC	159:161	BACKGROUND Tea Polysaccharide conjugate (TPC) is a naturally occurring active substance that is extracted from tea.
36988338	10	61	theme	oil-water	1821:1829	arg1	interface					1831:1839	the oil-water interface	1817:1839	the oil-water interface	1817:1839	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
36988338	7	62	theme	interfacial	1032:1042	arg1	protein					1044:1050	interfacial protein	1032:1050	interfacial protein	1032:1050	The rheology and interfacial protein adsorption results show that TPC forms a viscoelastic film at the oil-water interface to prevent the aggregation of oil droplets, thereby enhancing the stability of the emulsion.
36988338	9	63	dep	CONCLUSION	1432:1441	arg1	TPC					1446:1448	TPC	1446:1448	TPC	1446:1448	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	10	64	theme	amphiphilic	1753:1763	arg1	properties					1765:1774	its amphiphilic properties	1749:1774	its amphiphilic properties	1749:1774	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
36988338	9	65	theme	polysaccharide	1596:1609	arg1	chains					1611:1616	the polysaccharide chains	1592:1616	the polysaccharide chains with the help of hydrophobic forces	1592:1652	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	8	66	theme	oil-water	1380:1388	arg1	interface					1390:1398	the oil-water interface	1376:1398	the oil-water interface of the emulsion	1376:1414	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	4	67	theme	TPC	590:592	arg1	weights					547:553	The molecular weights	533:553	The molecular weights	533:553	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	4	67	theme	TPC	590:592	arg1	compositions					574:585	monosaccharide compositions	559:585	monosaccharide compositions of TPC	559:592	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	5	68	theme	functional	696:705	arg1	proteins					737:744	proteins	737:744	proteins	737:744	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	5	68	theme	functional	696:705	arg1	polysaccharides					717:731	polysaccharides	717:731	polysaccharides	717:731	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	5	68	theme	functional	696:705	arg1	groups					707:712	the functional groups	692:712	the functional groups of polysaccharides and proteins	692:744	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	9	69	theme	hydrophobic	1556:1566	arg1	groups					1568:1573	the hydrophobic groups	1552:1573	the hydrophobic groups	1552:1573	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	8	70	from	interface	1390:1398	arg1	mode					1304:1307	the binding mode	1292:1307	the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion	1292:1414	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	8	71	theme	binding	1296:1302	arg1	mode					1304:1307	the binding mode	1292:1307	the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion	1292:1414	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	5	72	theme	infrared	764:771	arg1	spectroscopy					773:784	infrared spectroscopy	764:784	infrared spectroscopy	764:784	Although the functional groups of polysaccharides and proteins were confirmed by infrared spectroscopy; the presence of proteins couldn't be detected by SDS-PAGE and UV spectroscopy.
36988338	9	73	theme	hydrophilic	1455:1465	arg1	groups					1467:1472	the hydrophilic groups	1451:1472	the hydrophilic groups of the proteins	1451:1488	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	9	73	theme	hydrophilic	1455:1465	arg1	proteins					1481:1488	the proteins	1477:1488	the proteins	1477:1488	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	8	74	theme	polysaccharides	1312:1326	arg1	mode					1304:1307	the binding mode	1292:1307	the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion	1292:1414	Based on these structural and emulsifying properties of TPC, the binding mode of polysaccharides and proteins along with their phase behavior at the oil-water interface of the emulsion was speculated.
36988338	4	75	theme	high-performance	635:650	arg1	chromatography					667:680	high-performance gel permeation chromatography	635:680	high-performance gel permeation chromatography	635:680	RESULTS The molecular weights and monosaccharide compositions of TPC was determined by ion chromatography and high-performance gel permeation chromatography.
36988338	3	76	theme	proteins	388:395	arg1	mode					360:363	The binding mode	348:363	The binding mode of polysaccharides and proteins in TPC	348:402	The binding mode of polysaccharides and proteins in TPC, however, hasn't been well studied, it may be closely related to their functional properties, especially emulsification.
36988338	9	77	theme	hydrophobic	1635:1645	arg1	forces					1647:1652	hydrophobic forces	1635:1652	hydrophobic forces	1635:1652	CONCLUSION In TPC, the hydrophilic groups of the proteins are linked to polysaccharides by covalent interactions, where the hydrophobic groups are wrapped with the polysaccharide chains with the help of hydrophobic forces to form a hydrophobic core.
36988338	3	78	theme	functional	475:484	arg1	properties					486:495	their functional properties	469:495	their functional properties	469:495	The binding mode of polysaccharides and proteins in TPC, however, hasn't been well studied, it may be closely related to their functional properties, especially emulsification.
36988338	3	78	theme	functional	475:484	arg1	emulsification					509:522	emulsification	509:522	emulsification	509:522	The binding mode of polysaccharides and proteins in TPC, however, hasn't been well studied, it may be closely related to their functional properties, especially emulsification.
36988338	10	79	theme	polysaccharides	1704:1718	arg1	binding					1693:1699	The unique binding	1682:1699	The unique binding of polysaccharides and proteins in TPC	1682:1738	The unique binding of polysaccharides and proteins in TPC enhances its amphiphilic properties, which can be effectively distributed at the oil-water interface and form stable emulsions.
35487082	6	0	theme	different	913:921	arg1	microstructures					923:937	different microstructures	913:937	different microstructures	913:937	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	1	1	theme	Barley	158:163	arg1	BGPs					188:191	BGPs	188:191	BGPs	188:191	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	1	theme	Barley	158:163	arg1	polysaccharides					171:185	Barley grass polysaccharides	158:185	Barley grass polysaccharides (BGPs)	158:192	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	2	theme	barley	242:247	arg1	grass					270:274	barley (Hordeum vulgare L.) grass	242:274	barley (Hordeum vulgare L.) grass (BG)	242:279	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	2	theme	barley	242:247	arg1	BG					277:278	BG	277:278	BG	277:278	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	2	theme	barley	242:247	arg1	vulgare					258:264	Hordeum vulgare L.	250:267	Hordeum vulgare L.	250:267	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	0	3	theme	barley	96:101	arg1	grass					124:128	barley (Hordeum vulgare L.) grass	96:128	barley (Hordeum vulgare L.) grass	96:128	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	7	4	theme	immunological	1124:1136	arg1	activity					1138:1145	immunological activity	1124:1145	immunological activity	1124:1145	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	1	5	theme	grass	165:169	arg1	BGPs					188:191	BGPs	188:191	BGPs	188:191	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	5	theme	grass	165:169	arg1	polysaccharides					171:185	Barley grass polysaccharides	158:185	Barley grass polysaccharides (BGPs)	158:192	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	6	theme	Hordeum	250:256	arg1	grass					270:274	barley (Hordeum vulgare L.) grass	242:274	barley (Hordeum vulgare L.) grass (BG)	242:279	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	1	6	theme	Hordeum	250:256	arg1	vulgare					258:264	Hordeum vulgare L.	250:267	Hordeum vulgare L.	250:267	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	0	7	theme	Hordeum	104:110	arg1	barley					96:101	barley	96:101	barley (Hordeum vulgare L.) grass	96:128	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	7	theme	Hordeum	104:110	arg1	vulgare					112:118	Hordeum vulgare L.	104:121	Hordeum vulgare L.	104:121	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	6	8	theme	structural	882:891	arg1	characteristics					893:907	similar preliminary structural characteristics	862:907	similar preliminary structural characteristics	862:907	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	3	9	theme	stem	483:486	arg1	elongation					488:497	stem elongation	483:497	stem elongation	483:497	In this study, seven BGPs were extracted from BG, which was harvested at three different growth stages (e.g., seedling, tillering, and stem elongation), by alkaline-extraction method.
35487082	7	10	theme	other	1152:1156	arg1	BGPs					1158:1161	other BGPs	1152:1161	other BGPs	1152:1161	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	2	11	theme	health	331:336	arg1	benefits					338:345	health benefits	331:345	health benefits	331:345	They exhibit favorable biological activities and health benefits.
35487082	0	12	from	stages	150:155	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.	0:156	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	13	from	activities	61:70	arg1	grass					124:128	barley (Hordeum vulgare L.) grass	96:128	barley (Hordeum vulgare L.) grass	96:128	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	7	14	theme	acid	1097:1100	arg1	activity					1110:1117	cholic acid binding activity	1090:1117	cholic acid binding activity	1090:1117	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	8	15	theme	harvest	1253:1259	arg1	time					1261:1264	the preferable harvest time	1238:1264	the preferable harvest time for preparing highly bioactive BGPs	1238:1300	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	8	15	theme	harvest	1253:1259	arg1	stage					1222:1226	the seedling stage	1209:1226	the seedling stage of BG	1209:1232	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	0	16	dep	vulgare	112:118	arg1	L.					120:121	Hordeum vulgare L.	104:121	Hordeum vulgare L.	104:121	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	6	17	theme	similar	862:868	arg1	characteristics					893:907	similar preliminary structural characteristics	862:907	similar preliminary structural characteristics	862:907	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	5	18	theme	molecular	757:765	arg1	weights					767:773	molecular weights	757:773	molecular weights	757:773	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	4	19	theme	physicochemical	538:552	arg1	properties					554:563	Their physicochemical properties	532:563	Their physicochemical properties	532:563	Their physicochemical properties, structural characteristics, and biological activities were investigated and compared.
35487082	8	20	theme	BG	1231:1232	arg1	time					1261:1264	the preferable harvest time	1238:1264	the preferable harvest time for preparing highly bioactive BGPs	1238:1300	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	8	20	theme	BG	1231:1232	arg1	stage					1222:1226	the seedling stage	1209:1226	the seedling stage of BG	1209:1232	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	6	21	theme	preliminary	870:880	arg1	characteristics					893:907	similar preliminary structural characteristics	862:907	similar preliminary structural characteristics	862:907	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	8	22	theme	preferable	1242:1251	arg1	time					1261:1264	the preferable harvest time	1238:1264	the preferable harvest time for preparing highly bioactive BGPs	1238:1300	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	8	22	theme	preferable	1242:1251	arg1	stage					1222:1226	the seedling stage	1209:1226	the seedling stage of BG	1209:1232	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	5	23	theme	extraction	682:691	arg1	yields					693:698	the extraction yields	678:698	the extraction yields	678:698	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	7	24	theme	cholic	1090:1095	arg1	acid					1097:1100	cholic acid	1090:1100	cholic acid binding activity	1090:1117	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	0	25	theme	characteristics	30:44	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.	0:156	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	5	26	theme	BGPs	788:791	arg1	compositions					710:721	chemical compositions	701:721	chemical compositions	701:721	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	5	26	theme	BGPs	788:791	arg1	constituents					739:750	monosaccharide constituents	724:750	monosaccharide constituents	724:750	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	5	26	theme	BGPs	788:791	arg1	weights					767:773	molecular weights	757:773	molecular weights	757:773	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	5	26	theme	BGPs	788:791	arg1	yields					693:698	the extraction yields	678:698	the extraction yields	678:698	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	7	27	theme	antioxidant	1066:1076	arg1	potentials					1078:1087	vitro antioxidant potentials	1060:1087	vitro antioxidant potentials	1060:1087	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	3	28	dep	seedling	458:465	arg1	e.g.					452:455	e.g.	452:455	e.g.	452:455	In this study, seven BGPs were extracted from BG, which was harvested at three different growth stages (e.g., seedling, tillering, and stem elongation), by alkaline-extraction method.
35487082	5	29	theme	different	805:813	arg1	stages					822:827	different growth stages	805:827	different growth stages	805:827	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	0	30	theme	physicochemical	14:28	arg1	characteristics					30:44	physicochemical characteristics	14:44	physicochemical characteristics	14:44	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	1	31	theme	grass	270:274	arg1	constituents					226:237	the major bioactive constituents	206:237	the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG)	206:279	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	5	32	theme	growth	815:820	arg1	stages					822:827	different growth stages	805:827	different growth stages	805:827	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	0	33	theme	biological	50:59	arg1	activities					61:70	biological activities	50:70	biological activities	50:70	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	34	theme	growth	143:148	arg1	stages					150:155	different growth stages	133:155	different growth stages	133:155	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	4	35	theme	biological	598:607	arg1	activities					609:618	biological activities	598:618	biological activities	598:618	Their physicochemical properties, structural characteristics, and biological activities were investigated and compared.
35487082	0	36	theme	different	133:141	arg1	stages					150:155	different growth stages	133:155	different growth stages	133:155	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	5	37	theme	chemical	701:708	arg1	compositions					710:721	chemical compositions	701:721	chemical compositions	701:721	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	8	38	theme	bioactive	1287:1295	arg1	BGPs					1297:1300	highly bioactive BGPs	1280:1300	highly bioactive BGPs	1280:1300	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	8	39	theme	seedling	1213:1220	arg1	time					1261:1264	the preferable harvest time	1238:1264	the preferable harvest time for preparing highly bioactive BGPs	1238:1300	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	8	39	theme	seedling	1213:1220	arg1	stage					1222:1226	the seedling stage	1209:1226	the seedling stage of BG	1209:1232	Therefore, these results indicated that that the seedling stage of BG was the preferable harvest time for preparing highly bioactive BGPs.
35487082	3	40	theme	alkaline-extraction	504:522	arg1	method					524:529	alkaline-extraction method	504:529	alkaline-extraction method	504:529	In this study, seven BGPs were extracted from BG, which was harvested at three different growth stages (e.g., seedling, tillering, and stem elongation), by alkaline-extraction method.
35487082	7	41	theme	vitro	1060:1064	arg1	potentials					1078:1087	vitro antioxidant potentials	1060:1087	vitro antioxidant potentials	1060:1087	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	0	42	theme	activities	61:70	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.	0:156	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	6	43	theme	thermal	943:949	arg1	properties					951:960	thermal properties	943:960	thermal properties	943:960	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	3	44	theme	different	427:435	arg1	stages					444:449	three different growth stages	421:449	three different growth stages (e.g., seedling, tillering, and stem elongation)	421:498	In this study, seven BGPs were extracted from BG, which was harvested at three different growth stages (e.g., seedling, tillering, and stem elongation), by alkaline-extraction method.
35487082	7	45	theme	binding	1102:1108	arg1	activity					1110:1117	cholic acid binding activity	1090:1117	cholic acid binding activity	1090:1117	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	2	46	theme	biological	305:314	arg1	activities					316:325	favorable biological activities	295:325	favorable biological activities	295:325	They exhibit favorable biological activities and health benefits.
35487082	7	47	theme	seedling	1023:1030	arg1	stage					1032:1036	the seedling stage	1019:1036	the seedling stage	1019:1036	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	1	48	dep	vulgare	258:264	arg1	L.					266:267	L.	266:267	L.	266:267	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	2	49	theme	favorable	295:303	arg1	activities					316:325	favorable biological activities	295:325	favorable biological activities	295:325	They exhibit favorable biological activities and health benefits.
35487082	1	50	theme	major	210:214	arg1	constituents					226:237	the major bioactive constituents	206:237	the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG)	206:279	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	3	51	theme	growth	437:442	arg1	stages					444:449	three different growth stages	421:449	three different growth stages (e.g., seedling, tillering, and stem elongation)	421:498	In this study, seven BGPs were extracted from BG, which was harvested at three different growth stages (e.g., seedling, tillering, and stem elongation), by alkaline-extraction method.
35487082	1	52	theme	bioactive	216:224	arg1	constituents					226:237	the major bioactive constituents	206:237	the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG)	206:279	Barley grass polysaccharides (BGPs) are some of the major bioactive constituents of barley (Hordeum vulgare L.) grass (BG).
35487082	5	53	theme	monosaccharide	724:737	arg1	constituents					739:750	monosaccharide constituents	724:750	monosaccharide constituents	724:750	Results demonstrated that the extraction yields, chemical compositions, monosaccharide constituents, and molecular weights of the seven BGPs obtained at different growth stages varied obviously.
35487082	6	54	contain	had	858:860	arg2	microstructures					923:937	different microstructures	913:937	different microstructures	913:937	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	6	54	contain	had	858:860	arg2	characteristics					893:907	similar preliminary structural characteristics	862:907	similar preliminary structural characteristics	862:907	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	6	54	contain	had	858:860	arg1	BGPs					853:856	These BGPs	847:856	These BGPs	847:856	These BGPs had similar preliminary structural characteristics but different microstructures and thermal properties.
35487082	7	55	dep	BGPs	980:983	arg1	BGP-Z21					998:1004	BGP-Z21	998:1004	BGP-Z21	998:1004	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	7	55	dep	BGPs	980:983	arg1	BGP-Z12					986:992	BGP-Z12	986:992	BGP-Z12	986:992	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	7	55	dep	BGPs	980:983	arg1	BGPs					980:983	the BGPs	976:983	the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage	976:1036	Furthermore, the BGPs (BGP-Z12 and BGP-Z21) obtained at the seedling stage possessed stronger in vitro antioxidant potentials, cholic acid binding activity, and immunological activity than other BGPs.
35487082	4	56	theme	structural	566:575	arg1	characteristics					577:591	structural characteristics	566:591	structural characteristics	566:591	Their physicochemical properties, structural characteristics, and biological activities were investigated and compared.
35487082	0	57	theme	polysaccharides	75:89	arg1	characteristics					30:44	physicochemical characteristics	14:44	physicochemical characteristics	14:44	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	57	theme	polysaccharides	75:89	arg1	activities					61:70	biological activities	50:70	biological activities	50:70	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	58	from	characteristics	30:44	arg1	grass					124:128	barley (Hordeum vulgare L.) grass	96:128	barley (Hordeum vulgare L.) grass	96:128	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	59	from	grass	124:128	arg1	polysaccharides					75:89	polysaccharides	75:89	polysaccharides from barley (Hordeum vulgare L.) grass	75:128	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	59	from	grass	124:128	arg1	characteristics					30:44	physicochemical characteristics	14:44	physicochemical characteristics	14:44	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
35487082	0	59	from	grass	124:128	arg1	activities					61:70	biological activities	50:70	biological activities	50:70	Comparison of physicochemical characteristics and biological activities of polysaccharides from barley (Hordeum vulgare L.) grass at different growth stages.
36211377	5	0	theme	800	800:802	arg1	kcal/d					804:809	800 kcal/d	800:809	800 kcal/d	800:809	In this study, participants followed a low-calorie diet (LCD) providing 800 kcal/d for 8 weeks, followed by one of five weight-maintenance diets over a 6-month period.
36211377	1	1	theme	G	183:183	arg1	glycosylation					191:203	immunoglobulin G (IgG) glycosylation	168:203	immunoglobulin G (IgG) glycosylation	168:203	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	8	2	theme	diet	1274:1277	arg1	type					1279:1282	the diet type	1270:1282	the diet type	1270:1282	Those changes were present regardless of the diet type, and we did not observe significant changes between different diets.
36211377	7	3	theme	bisecting	1158:1166	arg1	GlcNAc					1168:1173	bisecting GlcNAc	1158:1173	bisecting GlcNAc	1158:1173	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	6	4	dep	present	953:959	arg1	increase					1070:1077	the increase	1066:1077	the increase of sialylated N glycans	1066:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	4	dep	present	953:959	arg1	decrease					1034:1041	a statistically significant decrease	1006:1041	a statistically significant decrease of agalactosylated	1006:1060	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	4	dep	present	953:959	arg1	present					953:959	present	953:959	present	953:959	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	4	dep	present	953:959	arg1	alteration					917:926	The most significant alteration	896:926	The most significant alteration of the IgG N-glycome	896:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	5	theme	agalactosylated	1046:1060	arg1	increase					1070:1077	the increase	1066:1077	the increase of sialylated N glycans	1066:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	5	theme	agalactosylated	1046:1060	arg1	decrease					1034:1041	a statistically significant decrease	1006:1041	a statistically significant decrease of agalactosylated	1006:1060	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	5	theme	agalactosylated	1046:1060	arg1	present					953:959	present	953:959	present	953:959	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	5	theme	agalactosylated	1046:1060	arg1	alteration					917:926	The most significant alteration	896:926	The most significant alteration of the IgG N-glycome	896:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	2	6	theme	high	347:350	arg1	BMI					369:371	BMI	369:371	BMI	369:371	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	2	6	theme	high	347:350	arg1	index					362:366	a high body mass index	345:366	a high body mass index (BMI)	345:372	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	6	7	theme	IgG	935:937	arg1	N-glycome					939:947	the IgG N-glycome	931:947	the IgG N-glycome	931:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	0	8	from	Effects	0:6	arg1	composition					77:87	IgG glycome composition	65:87	IgG glycome composition	65:87	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	7	9	from	decrease	1183:1190	arg1	glycans					1145:1151	glycans	1145:1151	glycans with bisecting GlcNAc	1145:1173	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	7	9	from	decrease	1183:1190	arg1	glycans					1206:1212	sialylated glycans	1195:1212	sialylated glycans	1195:1212	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	6	10	theme	N	1093:1093	arg1	glycans					1095:1101	sialylated N glycans	1082:1101	sialylated N glycans	1082:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	11	theme	N-glycome	939:947	arg1	alteration					917:926	The most significant alteration	896:926	The most significant alteration of the IgG N-glycome	896:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	11	theme	N-glycome	939:947	arg1	decrease					1034:1041	a statistically significant decrease	1006:1041	a statistically significant decrease of agalactosylated	1006:1060	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	11	theme	N-glycome	939:947	arg1	present					953:959	present	953:959	present	953:959	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	11	theme	N-glycome	939:947	arg1	increase					1070:1077	the increase	1066:1077	the increase of sialylated N glycans	1066:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	1	12	gly	glycosylation	191:203	arg1	way					210:212	a way to produce more proinflammatory antibodies	208:255	a way to produce more proinflammatory antibodies	208:255	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	2	13	theme	body	352:355	arg1	BMI					369:371	BMI	369:371	BMI	369:371	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	2	13	theme	body	352:355	arg1	index					362:366	a high body mass index	345:366	a high body mass index (BMI)	345:372	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	4	14	theme	IgG	559:561	arg1	glycosylation					563:575	IgG glycosylation	559:575	IgG glycosylation	559:575	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	1	15	theme	adaptive	133:140	arg1	system					149:154	the adaptive immune system	129:154	the adaptive immune system	129:154	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	6	16	theme	significant	1022:1032	arg1	alteration					917:926	The most significant alteration	896:926	The most significant alteration of the IgG N-glycome	896:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	16	theme	significant	1022:1032	arg1	decrease					1034:1041	a statistically significant decrease	1006:1041	a statistically significant decrease of agalactosylated	1006:1060	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	16	theme	significant	1022:1032	arg1	present					953:959	present	953:959	present	953:959	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	16	theme	significant	1022:1032	arg1	increase					1070:1077	the increase	1066:1077	the increase of sialylated N glycans	1066:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	9	17	theme	glycome	1468:1474	arg1	composition					1476:1486	their IgG glycome composition	1458:1486	their IgG glycome composition	1458:1486	However, it should be noted that in all five diet groups, there were individuals who prominently altered their IgG glycome composition in either proinflammatory or anti-inflammatory directions.
36211377	3	18	theme	IgG	408:410	arg1	susceptibility					422:435	the IgG N-glycome susceptibility	404:435	the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss	404:513	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	4	19	from	changes	548:554	arg1	glycosylation					563:575	IgG glycosylation	559:575	IgG glycosylation	559:575	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	6	20	gly	sialylated	1082:1091	arg1	glycans					1095:1101	sialylated N glycans	1082:1101	sialylated N glycans	1082:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	3	21	theme	N-glycome	412:420	arg1	susceptibility					422:435	the IgG N-glycome susceptibility	404:435	the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss	404:513	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	3	22	theme	weight	503:508	arg1	loss					510:513	the initial weight loss	491:513	the initial weight loss	491:513	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	1	23	theme	Obesity-induced	90:104	arg1	inflammation					106:117	Obesity-induced inflammation	90:117	Obesity-induced inflammation	90:117	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	7	24	located	observed	1219:1226	arg1	period					1121:1126	the follow-up period	1107:1126	the follow-up period	1107:1126	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	7	24	located	observed	1219:1226	arg2	decrease					1183:1190	the decrease	1179:1190	the decrease in sialylated glycans	1179:1212	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	7	24	located	observed	1219:1226	arg2	increase					1133:1140	the increase	1129:1140	the increase in glycans with bisecting GlcNAc	1129:1173	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	4	25	theme	dietary	691:697	arg1	study					721:725	a dietary intervention Diogenes study	689:725	a dietary intervention Diogenes study	689:725	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	4	26	theme	Diogenes	712:719	arg1	study					721:725	a dietary intervention Diogenes study	689:725	a dietary intervention Diogenes study	689:725	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	7	27	gly	sialylated	1195:1204	arg1	glycans					1206:1212	sialylated glycans	1195:1212	sialylated glycans	1195:1212	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	5	28	theme	6-month	880:886	arg1	period					888:893	a 6-month period	878:893	a 6-month period	878:893	In this study, participants followed a low-calorie diet (LCD) providing 800 kcal/d for 8 weeks, followed by one of five weight-maintenance diets over a 6-month period.
36211377	6	29	theme	glycans	1095:1101	arg1	increase					1070:1077	the increase	1066:1077	the increase of sialylated N glycans	1066:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	29	theme	glycans	1095:1101	arg1	decrease					1034:1041	a statistically significant decrease	1006:1041	a statistically significant decrease of agalactosylated	1006:1060	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	29	theme	glycans	1095:1101	arg1	present					953:959	present	953:959	present	953:959	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	29	theme	glycans	1095:1101	arg1	alteration					917:926	The most significant alteration	896:926	The most significant alteration of the IgG N-glycome	896:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	3	30	theme	different	440:448	arg1	regimes					458:464	different dietary regimes	440:464	different dietary regimes	440:464	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	0	31	theme	low-calorie	11:21	arg1	Effects					0:6	Effects	0:6	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition	0:87	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	5	32	theme	weight-maintenance	848:865	arg1	diets					867:871	one of five weight-maintenance diets	836:871	one of five weight-maintenance diets	836:871	In this study, participants followed a low-calorie diet (LCD) providing 800 kcal/d for 8 weeks, followed by one of five weight-maintenance diets over a 6-month period.
36211377	3	33	theme	dietary	450:456	arg1	regimes					458:464	different dietary regimes	440:464	different dietary regimes	440:464	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	0	34	theme	weight-maintenance	37:54	arg1	diets					56:60	different weight-maintenance diets	27:60	different weight-maintenance diets	27:60	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	6	35	theme	significant	905:915	arg1	alteration					917:926	The most significant alteration	896:926	The most significant alteration of the IgG N-glycome	896:947	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	35	theme	significant	905:915	arg1	decrease					1034:1041	a statistically significant decrease	1006:1041	a statistically significant decrease of agalactosylated	1006:1060	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	35	theme	significant	905:915	arg1	present					953:959	present	953:959	present	953:959	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	6	35	theme	significant	905:915	arg1	increase					1070:1077	the increase	1066:1077	the increase of sialylated N glycans	1066:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	9	36	theme	proinflammatory	1498:1512	arg1	directions					1535:1544	either proinflammatory or anti-inflammatory directions	1491:1544	either proinflammatory or anti-inflammatory directions	1491:1544	However, it should be noted that in all five diet groups, there were individuals who prominently altered their IgG glycome composition in either proinflammatory or anti-inflammatory directions.
36211377	7	37	from	increase	1133:1140	arg1	glycans					1145:1151	glycans	1145:1151	glycans with bisecting GlcNAc	1145:1173	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	7	37	from	increase	1133:1140	arg1	glycans					1206:1212	sialylated glycans	1195:1212	sialylated glycans	1195:1212	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	9	38	theme	anti-inflammatory	1517:1533	arg1	directions					1535:1544	either proinflammatory or anti-inflammatory directions	1491:1544	either proinflammatory or anti-inflammatory directions	1491:1544	However, it should be noted that in all five diet groups, there were individuals who prominently altered their IgG glycome composition in either proinflammatory or anti-inflammatory directions.
36211377	0	39	theme	different	27:35	arg1	diets					56:60	different weight-maintenance diets	27:60	different weight-maintenance diets	27:60	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	9	40	theme	diet	1398:1401	arg1	groups					1403:1408	all five diet groups	1389:1408	all five diet groups	1389:1408	However, it should be noted that in all five diet groups, there were individuals who prominently altered their IgG glycome composition in either proinflammatory or anti-inflammatory directions.
36211377	8	41	theme	different	1336:1344	arg1	diets					1346:1350	different diets	1336:1350	different diets	1336:1350	Those changes were present regardless of the diet type, and we did not observe significant changes between different diets.
36211377	2	42	theme	central	378:384	arg1	adiposity					386:394	central adiposity	378:394	central adiposity	378:394	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	5	43	theme	low-calorie	767:777	arg1	LCD					785:787	LCD	785:787	LCD	785:787	In this study, participants followed a low-calorie diet (LCD) providing 800 kcal/d for 8 weeks, followed by one of five weight-maintenance diets over a 6-month period.
36211377	5	43	theme	low-calorie	767:777	arg1	diet					779:782	a low-calorie diet	765:782	a low-calorie diet (LCD) providing 800 kcal/d for 8 weeks	765:821	In this study, participants followed a low-calorie diet (LCD) providing 800 kcal/d for 8 weeks, followed by one of five weight-maintenance diets over a 6-month period.
36211377	3	44	theme	weight	470:475	arg1	control					477:483	weight control	470:483	weight control after the initial weight loss	470:513	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	0	45	theme	diets	56:60	arg1	Effects					0:6	Effects	0:6	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition	0:87	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	7	46	with	glycans	1145:1151	arg1	GlcNAc					1168:1173	bisecting GlcNAc	1158:1173	bisecting GlcNAc	1158:1173	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	1	47	theme	immune	142:147	arg1	system					149:154	the adaptive immune system	129:154	the adaptive immune system	129:154	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	7	48	theme	sialylated	1195:1204	arg1	glycans					1206:1212	sialylated glycans	1195:1212	sialylated glycans	1195:1212	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	4	49	theme	IgG	659:661	arg1	glycomes					663:670	1,850 IgG glycomes	653:670	1,850 IgG glycomes from subjects in a dietary intervention Diogenes study	653:725	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	4	50	theme	intervention	699:710	arg1	study					721:725	a dietary intervention Diogenes study	689:725	a dietary intervention Diogenes study	689:725	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	8	51	theme	significant	1308:1318	arg1	changes					1320:1326	significant changes	1308:1326	significant changes	1308:1326	Those changes were present regardless of the diet type, and we did not observe significant changes between different diets.
36211377	1	52	theme	immunoglobulin	168:181	arg1	IgG					186:188	IgG	186:188	IgG	186:188	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	1	52	theme	immunoglobulin	168:181	arg1	G					183:183	immunoglobulin G	168:183	immunoglobulin G (IgG) glycosylation	168:203	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	6	53	theme	sialylated	1082:1091	arg1	glycans					1095:1101	sialylated N glycans	1082:1101	sialylated N glycans	1082:1101	The most significant alteration of the IgG N-glycome was present 8 weeks after the subjects underwent an LCD, a statistically significant decrease of agalactosylated and the increase of sialylated N glycans.
36211377	1	54	theme	proinflammatory	230:244	arg1	antibodies					246:255	more proinflammatory antibodies	225:255	more proinflammatory antibodies	225:255	Obesity-induced inflammation activates the adaptive immune system by altering immunoglobulin G (IgG) glycosylation in a way to produce more proinflammatory antibodies.
36211377	0	55	theme	glycome	69:75	arg1	composition					77:87	IgG glycome composition	65:87	IgG glycome composition	65:87	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	4	56	theme	weight-maintenance	615:632	arg1	diets					634:638	subsequent weight-maintenance diets	604:638	subsequent weight-maintenance diets	604:638	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	2	57	theme	IgG	262:264	arg1	glycome					266:272	The IgG glycome	258:272	The IgG glycome	258:272	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	4	58	theme	subsequent	604:613	arg1	diets					634:638	subsequent weight-maintenance diets	604:638	subsequent weight-maintenance diets	604:638	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	3	59	theme	initial	495:501	arg1	loss					510:513	the initial weight loss	491:513	the initial weight loss	491:513	Still, the IgG N-glycome susceptibility to different dietary regimes for weight control after the initial weight loss has not been studied.
36211377	9	60	theme	IgG	1464:1466	arg1	composition					1476:1486	their IgG glycome composition	1458:1486	their IgG glycome composition	1458:1486	However, it should be noted that in all five diet groups, there were individuals who prominently altered their IgG glycome composition in either proinflammatory or anti-inflammatory directions.
36211377	0	61	theme	IgG	65:67	arg1	composition					77:87	IgG glycome composition	65:87	IgG glycome composition	65:87	Effects of low-calorie and different weight-maintenance diets on IgG glycome composition.
36211377	7	62	theme	follow-up	1111:1119	arg1	period					1121:1126	the follow-up period	1107:1126	the follow-up period	1107:1126	In the follow-up period, the increase in glycans with bisecting GlcNAc and the decrease in sialylated glycans were observed.
36211377	2	63	theme	mass	357:360	arg1	BMI					369:371	BMI	369:371	BMI	369:371	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	2	63	theme	mass	357:360	arg1	index					362:366	a high body mass index	345:366	a high body mass index (BMI)	345:372	The IgG glycome has already been well studied, and its alterations are correlated with a high body mass index (BMI) and central adiposity.
36211377	4	64	from	subjects	677:684	arg1	glycomes					663:670	1,850 IgG glycomes	653:670	1,850 IgG glycomes from subjects in a dietary intervention Diogenes study	653:725	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	4	64	from	subjects	677:684	arg1	study					721:725	a dietary intervention Diogenes study	689:725	a dietary intervention Diogenes study	689:725	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36211377	4	65	theme	weight	588:593	arg1	loss					595:598	weight loss	588:598	weight loss	588:598	To explore changes in IgG glycosylation induced by weight loss and subsequent weight-maintenance diets, we analyzed 1,850 IgG glycomes from subjects in a dietary intervention Diogenes study.
36199167	6	0	theme	HS	935:936	arg1	trends					947:952	natural HS activity trends	927:952	natural HS activity trends	927:952	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	5	1	theme	native	853:858	arg1	linkages					869:876	native glycosyl linkages	853:876	native glycosyl linkages	853:876	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	6	2	theme	exciting	1031:1038	arg1	tool					1040:1043	an exciting tool	1028:1043	an exciting tool to facilitate the understanding of HS biology	1028:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	2	theme	exciting	1031:1038	arg1	pseudo-oligosaccharides					995:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	0	3	theme	"	70:70	arg1	Library					25:31	a Library	23:31	a Library of Heparan Sulfate-Like "Head-to-Tail"	23:70	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	6	4	theme	biology	1083:1089	arg1	understanding					1063:1075	the understanding	1059:1075	the understanding of HS biology	1059:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	3	5	theme	head-to-tail	515:526	arg1	fashion					529:535	a "head-to-tail" fashion	512:535	a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module	512:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	6	theme	module	625:630	arg1	end					604:606	the non-reducing end	587:606	the non-reducing end of a neighboring module	587:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	7	theme	reducing	546:553	arg1	end					555:557	the reducing end	542:557	the reducing end of a disaccharide module	542:582	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	8	from	end	555:557	arg1	fashion					529:535	a "head-to-tail" fashion	512:535	a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module	512:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	5	9	theme	fibroblast	748:757	arg1	factor					766:771	fibroblast growth factor 2	748:773	fibroblast growth factor 2 (FGF-2)	748:781	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	5	9	theme	fibroblast	748:757	arg1	FGF-2					776:780	FGF-2	776:780	FGF-2	776:780	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	5	10	theme	growth	759:764	arg1	factor					766:771	fibroblast growth factor 2	748:773	fibroblast growth factor 2 (FGF-2)	748:781	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	5	10	theme	growth	759:764	arg1	FGF-2					776:780	FGF-2	776:780	FGF-2	776:780	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	5	11	theme	glycosyl	860:867	arg1	linkages					869:876	native glycosyl linkages	853:876	native glycosyl linkages	853:876	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	3	12	theme	pseudo-hexasaccharide	443:463	arg1	library					465:471	a HS-like pseudo-hexasaccharide library	433:471	a HS-like pseudo-hexasaccharide library	433:471	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	13	theme	biological	365:374	arg1	studies					376:382	biological studies	365:382	biological studies	365:382	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	5	14	theme	HS	825:826	arg1	oligosaccharides					828:843	HS oligosaccharides	825:843	HS oligosaccharides bearing native glycosyl linkages	825:876	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	6	15	theme	new	971:973	arg1	tool					1040:1043	an exciting tool	1028:1043	an exciting tool to facilitate the understanding of HS biology	1028:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	15	theme	new	971:973	arg1	pseudo-oligosaccharides					995:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	3	16	theme	disaccharide	564:575	arg1	module					577:582	a disaccharide module	562:582	a disaccharide module	562:582	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	1	17	theme	important	165:173	arg1	roles					175:179	important roles	165:179	important roles	165:179	Heparan sulfate (HS) plays important roles in many biological processes.
36199167	0	18	theme	Expedient	0:8	arg1	Synthesis					10:18	Expedient Synthesis	0:18	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail"	0:70	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	4	19	theme	HS-like	663:669	arg1	pseudo-hexasaccharides					671:692	27 HS-like pseudo-hexasaccharides	660:692	27 HS-like pseudo-hexasaccharides	660:692	Combinatorial syntheses of 27 HS-like pseudo-hexasaccharides were achieved.
36199167	3	20	theme	module	577:582	arg1	end					555:557	the reducing end	542:557	the reducing end of a disaccharide module	542:582	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	21	theme	HS-like	435:441	arg1	library					465:471	a HS-like pseudo-hexasaccharide library	433:471	a HS-like pseudo-hexasaccharide library	433:471	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	6	22	theme	linked	988:993	arg1	tool					1040:1043	an exciting tool	1028:1043	an exciting tool to facilitate the understanding of HS biology	1028:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	22	theme	linked	988:993	arg1	pseudo-oligosaccharides					995:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	0	23	theme	Relationship	116:127	arg1	Studies					129:135	Activity Relationship Studies	107:135	Activity Relationship Studies	107:135	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	3	24	theme	HS	480:481	arg1	disaccharides					483:495	HS disaccharides	480:495	HS disaccharides	480:495	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	25	theme	new	387:389	arg1	strategy					391:398	a new strategy	385:398	a new strategy	385:398	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	6	26	theme	head-to-tail	975:986	arg1	tool					1040:1043	an exciting tool	1028:1043	an exciting tool to facilitate the understanding of HS biology	1028:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	26	theme	head-to-tail	975:986	arg1	pseudo-oligosaccharides					995:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	0	27	theme	Activity	107:114	arg1	Studies					129:135	Activity Relationship Studies	107:135	Activity Relationship Studies	107:135	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	6	28	theme	synthesis	891:899	arg1	ability					909:915	the ability	905:915	the ability to mirror natural HS activity trends	905:952	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	28	theme	synthesis	891:899	arg1	ease					883:886	The ease	879:886	The ease of synthesis	879:899	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	2	29	theme	thorough	286:293	arg1	understanding					295:307	the thorough understanding	282:307	the thorough understanding of their structure-activity relationship	282:348	The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship.
36199167	1	30	theme	many	184:187	arg1	processes					200:208	many biological processes	184:208	many biological processes	184:208	Heparan sulfate (HS) plays important roles in many biological processes.
36199167	3	31	theme	neighboring	613:623	arg1	module					625:630	a neighboring module	611:630	a neighboring module	611:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	5	32	theme	compounds	727:735	arg1	class					718:722	This new class	709:722	This new class of compounds	709:735	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	3	33	theme	non-reducing	591:602	arg1	end					604:606	the non-reducing end	587:606	the non-reducing end of a neighboring module	587:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	4	34	theme	pseudo-hexasaccharides	671:692	arg1	syntheses					647:655	Combinatorial syntheses	633:655	Combinatorial syntheses of 27 HS-like pseudo-hexasaccharides	633:692	Combinatorial syntheses of 27 HS-like pseudo-hexasaccharides were achieved.
36199167	1	35	theme	biological	189:198	arg1	processes					200:208	many biological processes	184:208	many biological processes	184:208	Heparan sulfate (HS) plays important roles in many biological processes.
36199167	0	36	theme	Library	25:31	arg1	Synthesis					10:18	Expedient Synthesis	0:18	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail"	0:70	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	5	37	theme	similar	788:794	arg1	trends					815:820	similar structure-activity trends	788:820	similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages	788:876	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	2	38	theme	inherent	215:222	arg1	complexity					224:233	The inherent complexity	211:233	The inherent complexity of naturally existing HS	211:258	The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship.
36199167	6	39	theme	HS	1080:1081	arg1	biology					1083:1089	HS biology	1080:1089	HS biology	1080:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	0	40	theme	Sulfate-Like	44:55	arg1	"					70:70	Heparan Sulfate-Like "Head-to-Tail"	36:70	Heparan Sulfate-Like "Head-to-Tail"	36:70	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	0	41	theme	Heparan	36:42	arg1	"					70:70	Heparan Sulfate-Like "Head-to-Tail"	36:70	Heparan Sulfate-Like "Head-to-Tail"	36:70	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	6	42	theme	natural	927:933	arg1	trends					947:952	natural HS activity trends	927:952	natural HS activity trends	927:952	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	43	link	linked	988:993	arg1	tool					1040:1043	an exciting tool	1028:1043	an exciting tool to facilitate the understanding of HS biology	1028:1089	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	6	43	link	linked	988:993	arg1	pseudo-oligosaccharides					995:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	the new head-to-tail linked pseudo-oligosaccharides	967:1017	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	1	44	theme	Heparan	138:144	arg1	sulfate					146:152	Heparan sulfate	138:152	Heparan sulfate (HS)	138:157	Heparan sulfate (HS) plays important roles in many biological processes.
36199167	1	44	theme	Heparan	138:144	arg1	HS					155:156	HS	155:156	HS	155:156	Heparan sulfate (HS) plays important roles in many biological processes.
36199167	2	45	theme	HS	257:258	arg1	complexity					224:233	The inherent complexity	211:233	The inherent complexity of naturally existing HS	211:258	The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship.
36199167	2	46	theme	relationship	337:348	arg1	understanding					295:307	the thorough understanding	282:307	the thorough understanding of their structure-activity relationship	282:348	The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship.
36199167	5	47	theme	new	714:716	arg1	class					718:722	This new class	709:722	This new class of compounds	709:735	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	2	48	theme	existing	248:255	arg1	HS					257:258	naturally existing HS	238:258	naturally existing HS	238:258	The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship.
36199167	2	49	theme	structure-activity	318:335	arg1	relationship					337:348	their structure-activity relationship	312:348	their structure-activity relationship	312:348	The inherent complexity of naturally existing HS has severely hindered the thorough understanding of their structure-activity relationship.
36199167	0	50	theme	Head-to-Tail	58:69	arg1	"					70:70	Heparan Sulfate-Like "Head-to-Tail"	36:70	Heparan Sulfate-Like "Head-to-Tail"	36:70	Expedient Synthesis of a Library of Heparan Sulfate-Like "Head-to-Tail" Linked Multimers for Structure and Activity Relationship Studies.
36199167	4	51	theme	Combinatorial	633:645	arg1	syntheses					647:655	Combinatorial syntheses	633:655	Combinatorial syntheses of 27 HS-like pseudo-hexasaccharides	633:692	Combinatorial syntheses of 27 HS-like pseudo-hexasaccharides were achieved.
36199167	3	52	theme	"	527:527	arg1	fashion					529:535	a "head-to-tail" fashion	512:535	a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module	512:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	5	53	theme	structure-activity	796:813	arg1	trends					815:820	similar structure-activity trends	788:820	similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages	788:876	This new class of compounds bound with fibroblast growth factor 2 (FGF-2) with similar structure-activity trends as HS oligosaccharides bearing native glycosyl linkages.
36199167	6	54	theme	activity	938:945	arg1	trends					947:952	natural HS activity trends	927:952	natural HS activity trends	927:952	The ease of synthesis and the ability to mirror natural HS activity trends suggest that the new head-to-tail linked pseudo-oligosaccharides could be an exciting tool to facilitate the understanding of HS biology.
36199167	3	55	attach	linked	502:507	arg2	disaccharides					483:495	HS disaccharides	480:495	HS disaccharides	480:495	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36199167	3	55	attach	linked	502:507	arg3	fashion					529:535	a "head-to-tail" fashion	512:535	a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module	512:630	To facilitate biological studies, a new strategy has been developed to synthesize a HS-like pseudo-hexasaccharide library, where HS disaccharides were linked in a "head-to-tail" fashion from the reducing end of a disaccharide module to the non-reducing end of a neighboring module.
36306900	10	0	theme	active	1487:1492	arg1	material					1494:1501	an active material	1484:1501	an active material	1484:1501	Therefore, we produced, characterized, and applied an active material with potential application in fresh food packaging.
36306900	1	1	theme	commercial	320:329	arg1	polysaccharides					352:366	commercial κ-carrageenan/starch polysaccharides	320:366	commercial κ-carrageenan/starch polysaccharides	320:366	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	3	2	theme	X-ray	537:541	arg1	patterns					543:550	The X-ray patterns	533:550	The X-ray patterns	533:550	The X-ray patterns displayed diffraction peaks characteristics of the crystallographic plane of ZnONPs.
36306900	7	3	from	%	1037:1037	arg1	ZnONPs					1025:1030	ZnONPs	1025:1030	ZnONPs at 2 %	1025:1037	Still, ZnONPs at 2 % produce a hydrophobic surface, justified by lower moisture content, water solubility, and higher WCA.
36306900	6	4	theme	low	986:988	arg1	transparency					990:1001	low transparency	986:1001	low transparency	986:1001	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	4	theme	low	986:988	arg1	opacity					977:983	opacity	977:983	opacity (low transparency)	977:1002	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	1	5	theme	κ-carrageenan/starch	331:350	arg1	polysaccharides					352:366	commercial κ-carrageenan/starch polysaccharides	320:366	commercial κ-carrageenan/starch polysaccharides	320:366	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	9	6	theme	shelf	1421:1425	arg1	life					1427:1430	its shelf life	1417:1430	its shelf life	1417:1430	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	1	7	theme	casting	431:437	arg1	method					439:444	casting method	431:444	casting method	431:444	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	1	8	theme	food	165:168	arg1	packaging					170:178	food packaging	165:178	food packaging composed of non-renewable sources	165:212	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	9	9	from	coating	1338:1344	arg1	strawberries					1355:1366	fresh strawberries	1349:1366	fresh strawberries	1349:1366	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	10	10	theme	food	1539:1542	arg1	packaging					1544:1552	fresh food packaging	1533:1552	fresh food packaging	1533:1552	Therefore, we produced, characterized, and applied an active material with potential application in fresh food packaging.
36306900	7	11	theme	lower	1083:1087	arg1	content					1098:1104	lower moisture content	1083:1104	lower moisture content	1083:1104	Still, ZnONPs at 2 % produce a hydrophobic surface, justified by lower moisture content, water solubility, and higher WCA.
36306900	1	12	theme	new	253:255	arg1	biodegradable					277:289	biodegradable	277:289	biodegradable	277:289	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	1	12	theme	new	253:255	arg1	film					271:274	a new antimicrobial film	251:274	a new antimicrobial film	251:274	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	10	13	theme	fresh	1533:1537	arg1	packaging					1544:1552	fresh food packaging	1533:1552	fresh food packaging	1533:1552	Therefore, we produced, characterized, and applied an active material with potential application in fresh food packaging.
36306900	7	14	theme	moisture	1089:1096	arg1	content					1098:1104	lower moisture content	1083:1104	lower moisture content	1083:1104	Still, ZnONPs at 2 % produce a hydrophobic surface, justified by lower moisture content, water solubility, and higher WCA.
36306900	1	15	theme	antimicrobial	257:269	arg1	biodegradable					277:289	biodegradable	277:289	biodegradable	277:289	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	1	15	theme	antimicrobial	257:269	arg1	film					271:274	a new antimicrobial film	251:274	a new antimicrobial film	251:274	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	4	16	theme	peak	749:752	arg1	shift					754:758	endothermic peak shift	737:758	endothermic peak shift	737:758	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	1	17	theme	zinc	375:378	arg1	oxide					380:384	zinc oxide	375:384	zinc oxide nanoparticles (ZnONPs) for the first time	375:426	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	3	18	theme	peaks	574:578	arg1	characteristics					580:594	diffraction peaks characteristics	562:594	diffraction peaks characteristics of the crystallographic plane of ZnONPs	562:634	The X-ray patterns displayed diffraction peaks characteristics of the crystallographic plane of ZnONPs.
36306900	8	19	theme	coli	1219:1222	arg1	microorganisms					1275:1288	Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms	1207:1288	Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms	1207:1288	The ZnONPs promoted UV barrier and antimicrobial activity against Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms.
36306900	9	20	theme	fruit	1400:1404	arg1	coating					1338:1344	a coating	1336:1344	a coating on fresh strawberries	1336:1366	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	9	20	theme	fruit	1400:1404	arg1	material					1312:1319	the new active material	1297:1319	the new active material	1297:1319	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	9	20	theme	fruit	1400:1404	arg1	ripening					1384:1391	the ripening	1380:1391	the ripening of the fruit	1380:1404	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	1	21	theme	oxide	380:384	arg1	ZnONPs					401:406	ZnONPs	401:406	ZnONPs	401:406	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	1	21	theme	oxide	380:384	arg1	nanoparticles					386:398	zinc oxide nanoparticles	375:398	zinc oxide nanoparticles (ZnONPs) for the first time	375:426	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	8	22	theme	antimicrobial	1176:1188	arg1	activity					1190:1197	antimicrobial activity	1176:1197	antimicrobial activity	1176:1197	The ZnONPs promoted UV barrier and antimicrobial activity against Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms.
36306900	2	23	theme	Different	447:455	arg1	formulations					457:468	Different formulations	447:468	Different formulations of κ-carrageenan/starch/ZnONPs	447:499	Different formulations of κ-carrageenan/starch/ZnONPs were extensively characterized.
36306900	9	24	theme	active	1305:1310	arg1	coating					1338:1344	a coating	1336:1344	a coating on fresh strawberries	1336:1366	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	9	24	theme	active	1305:1310	arg1	material					1312:1319	the new active material	1297:1319	the new active material	1297:1319	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	9	24	theme	active	1305:1310	arg1	ripening					1384:1391	the ripening	1380:1391	the ripening of the fruit	1380:1404	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	6	25	theme	mechanical	898:907	arg1	properties					909:918	mechanical properties	898:918	mechanical properties (higher elongation at rupture and tensile strength)	898:970	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	25	theme	mechanical	898:907	arg1	SEM					859:861	SEM	859:861	SEM (cracks remotion of film surface)	859:895	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	26	theme	higher	921:926	arg1	elongation					928:937	higher elongation	921:937	higher elongation at rupture and tensile strength	921:969	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	27	dep	SEM	859:861	arg1	remotion					871:878	cracks remotion	864:878	cracks remotion of film surface	864:894	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	3	28	theme	ZnONPs	629:634	arg1	plane					620:624	the crystallographic plane	599:624	the crystallographic plane of ZnONPs	599:634	The X-ray patterns displayed diffraction peaks characteristics of the crystallographic plane of ZnONPs.
36306900	4	29	from	signals	703:709	arg1	shift					754:758	endothermic peak shift	737:758	endothermic peak shift	737:758	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	4	29	from	signals	703:709	arg1	spectrums					723:731	FTIR spectrums	718:731	FTIR spectrums	718:731	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	1	30	theme	non-renewable	192:204	arg1	sources					206:212	non-renewable sources	192:212	non-renewable sources	192:212	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	7	31	theme	higher	1129:1134	arg1	WCA					1136:1138	higher WCA	1129:1138	higher WCA	1129:1138	Still, ZnONPs at 2 % produce a hydrophobic surface, justified by lower moisture content, water solubility, and higher WCA.
36306900	3	32	theme	crystallographic	603:618	arg1	plane					620:624	the crystallographic plane	599:624	the crystallographic plane of ZnONPs	599:634	The X-ray patterns displayed diffraction peaks characteristics of the crystallographic plane of ZnONPs.
36306900	8	33	theme	UV	1161:1162	arg1	barrier					1164:1170	UV barrier	1161:1170	UV barrier	1161:1170	The ZnONPs promoted UV barrier and antimicrobial activity against Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms.
36306900	7	34	theme	hydrophobic	1049:1059	arg1	surface					1061:1067	a hydrophobic surface	1047:1067	a hydrophobic surface	1047:1067	Still, ZnONPs at 2 % produce a hydrophobic surface, justified by lower moisture content, water solubility, and higher WCA.
36306900	6	35	theme	surface	888:894	arg1	remotion					871:878	cracks remotion	864:878	cracks remotion of film surface	864:894	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	3	36	theme	plane	620:624	arg1	characteristics					580:594	diffraction peaks characteristics	562:594	diffraction peaks characteristics of the crystallographic plane of ZnONPs	562:634	The X-ray patterns displayed diffraction peaks characteristics of the crystallographic plane of ZnONPs.
36306900	8	37	theme	Typhimurium	1236:1246	arg1	microorganisms					1275:1288	Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms	1207:1288	Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms	1207:1288	The ZnONPs promoted UV barrier and antimicrobial activity against Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms.
36306900	0	38	theme	films	43:47	arg1	application					21:31	application	21:31	application	21:31	Characterization and application of active films based on commercial polysaccharides incorporating ZnONPs.
36306900	0	38	theme	films	43:47	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and application of active films based on commercial polysaccharides incorporating ZnONPs.
36306900	6	39	theme	film	883:886	arg1	surface					888:894	film surface	883:894	film surface	883:894	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	4	40	theme	FTIR	718:721	arg1	spectrums					723:731	FTIR spectrums	718:731	FTIR spectrums	718:731	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	2	41	theme	κ-carrageenan/starch/ZnONPs	473:499	arg1	formulations					457:468	Different formulations	447:468	Different formulations of κ-carrageenan/starch/ZnONPs	447:499	Different formulations of κ-carrageenan/starch/ZnONPs were extensively characterized.
36306900	0	42	theme	active	36:41	arg1	films					43:47	active films	36:47	active films	36:47	Characterization and application of active films based on commercial polysaccharides incorporating ZnONPs.
36306900	6	43	dep	properties	909:918	arg1	elongation					928:937	higher elongation	921:937	higher elongation at rupture and tensile strength	921:969	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	4	44	theme	specific	694:701	arg1	signals					703:709	specific signals	694:709	specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition	694:780	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	7	45	theme	water	1107:1111	arg1	solubility					1113:1122	water solubility	1107:1122	water solubility	1107:1122	Still, ZnONPs at 2 % produce a hydrophobic surface, justified by lower moisture content, water solubility, and higher WCA.
36306900	1	46	theme	UV	300:301	arg1	barrier					303:309	UV barrier	300:309	UV barrier based on commercial κ-carrageenan/starch polysaccharides	300:366	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	9	47	theme	new	1301:1303	arg1	coating					1338:1344	a coating	1336:1344	a coating on fresh strawberries	1336:1366	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	9	47	theme	new	1301:1303	arg1	material					1312:1319	the new active material	1297:1319	the new active material	1297:1319	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	9	47	theme	new	1301:1303	arg1	ripening					1384:1391	the ripening	1380:1391	the ripening of the fruit	1380:1404	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	4	48	theme	ZnONPs	766:771	arg1	addition					773:780	ZnONPs addition	766:780	ZnONPs addition	766:780	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	5	49	theme	resistant	823:831	arg1	material					833:840	a more resistant material	816:840	a more resistant material	816:840	The ZnONPs (1.5 and 2 %) produce a more resistant material.
36306900	6	50	from	rupture	942:948	arg1	elongation					928:937	higher elongation	921:937	higher elongation at rupture and tensile strength	921:969	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	51	theme	cracks	864:869	arg1	remotion					871:878	cracks remotion	864:878	cracks remotion of film surface	864:894	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	10	52	from	application	1518:1528	arg1	packaging					1544:1552	fresh food packaging	1533:1552	fresh food packaging	1533:1552	Therefore, we produced, characterized, and applied an active material with potential application in fresh food packaging.
36306900	8	53	theme	aureus	1268:1273	arg1	microorganisms					1275:1288	Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms	1207:1288	Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms	1207:1288	The ZnONPs promoted UV barrier and antimicrobial activity against Escherichia coli, Salmonella Typhimurium, and Staphylococcus aureus microorganisms.
36306900	9	54	theme	fresh	1349:1353	arg1	strawberries					1355:1366	fresh strawberries	1349:1366	fresh strawberries	1349:1366	Thus, the new active material was applied as a coating on fresh strawberries and delayed the ripening of the fruit, extending its shelf life.
36306900	6	55	from	strength	962:969	arg1	elongation					928:937	higher elongation	921:937	higher elongation at rupture and tensile strength	921:969	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	1	56	theme	first	417:421	arg1	time					423:426	the first time	413:426	the first time	413:426	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	4	57	dep	spectrums	723:731	arg1	the					714:716	the	714:716	the	714:716	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	1	58	theme	environmental	126:138	arg1	problems					140:147	the environmental problems	122:147	the environmental problems caused by using food packaging composed of non-renewable sources	122:212	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	4	59	theme	material	658:665	arg1	composite					667:675	the material composite	654:675	the material composite	654:675	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	6	60	theme	SEM	859:861	arg1	transparency					990:1001	low transparency	986:1001	low transparency	986:1001	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	60	theme	SEM	859:861	arg1	opacity					977:983	opacity	977:983	opacity (low transparency)	977:1002	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	6	60	theme	SEM	859:861	arg1	analysis					847:854	The analysis	843:854	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength),	843:971	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	1	61	theme	problems	140:147	arg1	face					114:117	the face	110:117	the face of the environmental problems caused by using food packaging composed of non-renewable sources	110:212	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	10	62	theme	potential	1508:1516	arg1	application					1518:1528	potential application	1508:1528	potential application in fresh food packaging	1508:1552	Therefore, we produced, characterized, and applied an active material with potential application in fresh food packaging.
36306900	4	63	theme	endothermic	737:747	arg1	shift					754:758	endothermic peak shift	737:758	endothermic peak shift	737:758	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36306900	1	64	theme	study	231:235	arg1	aim					219:221	the aim	215:221	the aim of this study	215:235	In the face of the environmental problems caused by using food packaging composed of non-renewable sources, the aim of this study was producing a new antimicrobial film, biodegradable and with UV barrier based on commercial κ-carrageenan/starch polysaccharides loaded zinc oxide nanoparticles (ZnONPs) for the first time by casting method.
36306900	0	65	theme	commercial	58:67	arg1	polysaccharides					69:83	commercial polysaccharides	58:83	commercial polysaccharides incorporating ZnONPs	58:104	Characterization and application of active films based on commercial polysaccharides incorporating ZnONPs.
36306900	3	66	theme	diffraction	562:572	arg1	characteristics					580:594	diffraction peaks characteristics	562:594	diffraction peaks characteristics of the crystallographic plane of ZnONPs	562:634	The X-ray patterns displayed diffraction peaks characteristics of the crystallographic plane of ZnONPs.
36306900	6	67	theme	tensile	954:960	arg1	strength					962:969	tensile strength	954:969	tensile strength	954:969	The analysis of SEM (cracks remotion of film surface), mechanical properties (higher elongation at rupture and tensile strength), and opacity (low transparency) confirm this.
36306900	4	68	theme	composite	667:675	arg1	formation					641:649	The formation	637:649	The formation of the material composite	637:675	The formation of the material composite was confirmed by specific signals in the FTIR spectrums and endothermic peak shift after ZnONPs addition.
36959936	9	0	theme	lower	1797:1801	arg1	loads					1809:1813	lower viral loads	1797:1813	lower viral loads	1797:1813	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	7	1	theme	culture-derived	1334:1348	arg1	protein					1350:1356	the mammalian cell culture-derived protein	1315:1356	the mammalian cell culture-derived protein	1315:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	4	2	theme	NXS/T	596:600	arg1	Generation™					602:612	NXS/T Generation™	596:612	NXS/T Generation™	596:612	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	2	theme	NXS/T	596:600	arg1	host					559:562	an integrated host and glyco-engineering approach	545:593	host	559:562	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	7	3	theme	plant-derived	1202:1214	arg1	material					1216:1223	the plant-derived material	1198:1223	the plant-derived material	1198:1223	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	2	4	theme	mammalian	266:274	arg1	cells					276:280	mammalian cells	266:280	mammalian cells	266:280	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	10	5	dep	structure	2041:2049	arg1	the					2017:2019	the	2017:2019	the	2017:2019	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	10	6	theme	cell-culture-derived	1898:1917	arg1	protein					1919:1925	the mammalian cell-culture-derived protein	1884:1925	the mammalian cell-culture-derived protein	1884:1925	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	1	7	theme	production	163:172	arg1	platform					174:181	a cheap, safe and scalable production platform	136:181	a cheap, safe and scalable production platform	136:181	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	1	7	theme	production	163:172	arg1	farming					95:101	Molecular farming	85:101	Molecular farming of vaccines	85:113	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	9	8	theme	weight	1835:1840	arg1	loss					1842:1845	weight loss	1835:1845	weight loss	1835:1845	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	5	9	theme	cell-produced	923:935	arg1	antigen					937:943	the equivalent mammalian cell-produced antigen	898:943	the equivalent mammalian cell-produced antigen	898:943	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	9	10	from	loss	1842:1845	arg1	loads					1809:1813	lower viral loads	1797:1813	lower viral loads	1797:1813	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	9	10	from	loss	1842:1845	arg1	pathology					1786:1794	reduced lung pathology	1773:1794	reduced lung pathology	1773:1794	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	9	10	from	loss	1842:1845	arg1	protection					1819:1828	protection	1819:1828	protection from weight loss	1819:1845	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	7	11	link	culture-derived	1334:1348	arg1	protein					1350:1356	the mammalian cell culture-derived protein	1315:1356	the mammalian cell culture-derived protein	1315:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	4	12	theme	spike	649:653	arg1	trimer					655:660	a SARS-CoV-2 prefusion spike trimer	626:660	a SARS-CoV-2 prefusion spike trimer	626:660	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	12	theme	spike	649:653	arg1	antigen					698:704	a model antigen	690:704	a model antigen from an emerging virus	690:727	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	8	13	theme	comparator	1568:1577	arg1	antigen					1589:1595	the comparator mammalian antigen	1564:1595	the comparator mammalian antigen	1564:1595	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	8	14	theme	neutralizing	1394:1405	arg1	antibodies					1407:1416	neutralizing antibodies	1394:1416	neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants	1394:1490	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	7	15	theme	Complex-type	1144:1155	arg1	glycans					1157:1163	Complex-type glycans	1144:1163	Complex-type glycans	1144:1163	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	6	16	theme	under-processed	992:1006	arg1	N-glycans					1021:1029	under-processed oligomannose N-glycans	992:1029	under-processed oligomannose N-glycans	992:1029	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	9	17	theme	reduced	1658:1664	arg1	loads					1672:1676	reduced viral loads	1658:1676	reduced viral loads	1658:1676	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	7	18	theme	cell	1329:1332	arg1	protein					1350:1356	the mammalian cell culture-derived protein	1315:1356	the mammalian cell culture-derived protein	1315:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	0	19	theme	SARS-CoV-2	17:26	arg1	protein					34:40	A plant-produced SARS-CoV-2 spike protein	0:40	A plant-produced SARS-CoV-2 spike protein	0:40	A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.
36959936	8	20	theme	heterologous	1453:1464	arg1	variants					1483:1490	heterologous Delta SARS-CoV-2 variants	1453:1490	heterologous Delta SARS-CoV-2 variants	1453:1490	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	8	21	theme	SARS-CoV-2	1472:1481	arg1	variants					1483:1490	heterologous Delta SARS-CoV-2 variants	1453:1490	heterologous Delta SARS-CoV-2 variants	1453:1490	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	5	22	theme	exclusion-purified	739:756	arg1	protein					758:764	The size exclusion-purified protein	730:764	The size exclusion-purified protein	730:764	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	5	23	from	antigen	937:943	arg1	indistinguishable					875:891	indistinguishable	875:891	indistinguishable	875:891	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	2	24	from	differences	205:215	arg1	machinery					243:251	the plant biosynthetic machinery	220:251	the plant biosynthetic machinery	220:251	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	7	25	link	plant-derived	1202:1214	arg1	material					1216:1223	the plant-derived material	1198:1223	the plant-derived material	1198:1223	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	1	26	theme	Molecular	85:93	arg1	platform					174:181	a cheap, safe and scalable production platform	136:181	a cheap, safe and scalable production platform	136:181	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	1	26	theme	Molecular	85:93	arg1	farming					95:101	Molecular farming	85:101	Molecular farming of vaccines	85:113	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	7	27	theme	mature	1269:1274	arg1	glycans					1285:1291	the predominantly mature, complex glycans	1251:1291	the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein	1251:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	9	28	theme	SARS-CoV-2	1738:1747	arg1	disease					1749:1755	SARS-CoV-2 disease	1738:1755	SARS-CoV-2 disease	1738:1755	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	9	29	from	disease	1749:1755	arg1	protection					1722:1731	significant protection	1710:1731	significant protection from SARS-CoV-2 disease	1710:1755	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	9	29	from	disease	1749:1755	arg1	challenge					1688:1696	challenge	1688:1696	challenge	1688:1696	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	6	30	theme	cell	1130:1133	arg1	culture					1135:1141	mammalian cell culture	1120:1141	mammalian cell culture	1120:1141	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	3	31	theme	key	406:408	arg1	modifications					429:441	key post-translational modifications	406:441	key post-translational modifications	406:441	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	4	32	theme	glyco-engineering	568:584	arg1	approach					586:593	an integrated host and glyco-engineering approach	545:593	approach	586:593	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	5	33	theme	characteristic	778:791	arg1	structure					803:811	a characteristic prefusion structure	776:811	a characteristic prefusion structure	776:811	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	2	34	theme	glycoproteins	322:334	arg1	production					302:311	the production	298:311	the production of viral glycoproteins	298:334	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	5	35	theme	transmission	828:839	arg1	microscopy					850:859	transmission electron microscopy	828:859	transmission electron microscopy	828:859	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	2	36	theme	plant	224:228	arg1	machinery					243:251	the plant biosynthetic machinery	220:251	the plant biosynthetic machinery	220:251	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	9	37	theme	lung	1781:1784	arg1	pathology					1786:1794	reduced lung pathology	1773:1794	reduced lung pathology	1773:1794	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	10	38	theme	mammalian	1888:1896	arg1	protein					1919:1925	the mammalian cell-culture-derived protein	1884:1925	the mammalian cell-culture-derived protein	1884:1925	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	5	39	theme	equivalent	902:911	arg1	antigen					937:943	the equivalent mammalian cell-produced antigen	898:943	the equivalent mammalian cell-produced antigen	898:943	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	9	40	theme	viral	1803:1807	arg1	loads					1809:1813	lower viral loads	1797:1813	lower viral loads	1797:1813	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	10	41	theme	glycoprotein	2028:2039	arg1	structure					2041:2049	native glycoprotein structure	2021:2049	native glycoprotein structure	2021:2049	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	6	42	theme	plant-produced	950:963	arg1	protein					965:971	The plant-produced protein	946:971	The plant-produced protein	946:971	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	3	43	theme	folding	510:516	arg1	aspects					458:464	aspects	458:464	aspects of glycosylation and glycosylation-directed folding	458:516	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	10	44	gly	glycosylation	2066:2078	arg1	antigen					2087:2093	the antigen	2083:2093	the antigen	2083:2093	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	1	45	theme	scalable	154:161	arg1	platform					174:181	a cheap, safe and scalable production platform	136:181	a cheap, safe and scalable production platform	136:181	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	1	45	theme	scalable	154:161	arg1	farming					95:101	Molecular farming	85:101	Molecular farming of vaccines	85:113	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	0	46	theme	heterologous	50:61	arg1	immunity					63:70	heterologous immunity	50:70	heterologous immunity in hamsters	50:82	A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.
36959936	4	47	theme	integrated	548:557	arg1	Generation™					602:612	NXS/T Generation™	596:612	NXS/T Generation™	596:612	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	47	theme	integrated	548:557	arg1	host					559:562	an integrated host and glyco-engineering approach	545:593	host	559:562	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	48	theme	Nicotiana	665:673	arg1	benthamiana					675:685	Nicotiana benthamiana	665:685	Nicotiana benthamiana	665:685	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	10	49	theme	challenge	1957:1965	arg1	model					1967:1971	this challenge model	1952:1971	this challenge model	1952:1971	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	5	50	theme	mammalian	913:921	arg1	antigen					937:943	the equivalent mammalian cell-produced antigen	898:943	the equivalent mammalian cell-produced antigen	898:943	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	10	51	link	cell-culture-derived	1898:1917	arg1	protein					1919:1925	the mammalian cell-culture-derived protein	1884:1925	the mammalian cell-culture-derived protein	1884:1925	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	8	52	theme	mammalian	1579:1587	arg1	antigen					1589:1595	the comparator mammalian antigen	1564:1595	the comparator mammalian antigen	1564:1595	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	4	53	theme	prefusion	639:647	arg1	trimer					655:660	a SARS-CoV-2 prefusion spike trimer	626:660	a SARS-CoV-2 prefusion spike trimer	626:660	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	53	theme	prefusion	639:647	arg1	antigen					698:704	a model antigen	690:704	a model antigen from an emerging virus	690:727	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	10	54	gly	glycoprotein	2028:2039	arg1	glycoprotein					2028:2039	native glycoprotein structure	2021:2049	native glycoprotein structure	2021:2049	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	6	55	theme	site	1047:1050	arg1	comparable					1071:1080	comparable	1071:1080	comparable	1071:1080	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	6	55	theme	site	1047:1050	arg1	occupancy					1052:1060	a site occupancy	1045:1060	a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture	1045:1141	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	9	56	theme	plant-derived	1626:1638	arg1	antigen					1640:1646	the plant-derived antigen	1622:1646	the plant-derived antigen	1622:1646	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	6	57	theme	oligomannose	1008:1019	arg1	N-glycans					1021:1029	under-processed oligomannose N-glycans	992:1029	under-processed oligomannose N-glycans	992:1029	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	4	58	theme	emerging	714:721	arg1	virus					723:727	an emerging virus	711:727	an emerging virus	711:727	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	10	59	theme	native	2021:2026	arg1	structure					2041:2049	native glycoprotein structure	2021:2049	native glycoprotein structure	2021:2049	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	7	60	theme	mammalian	1319:1327	arg1	protein					1350:1356	the mammalian cell culture-derived protein	1315:1356	the mammalian cell culture-derived protein	1315:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	2	61	theme	biosynthetic	230:241	arg1	machinery					243:251	the plant biosynthetic machinery	220:251	the plant biosynthetic machinery	220:251	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	9	62	theme	viral	1666:1670	arg1	loads					1672:1676	reduced viral loads	1658:1676	reduced viral loads	1658:1676	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	6	63	theme	equivalent	1089:1098	arg1	protein					1100:1106	the equivalent protein	1085:1106	the equivalent protein produced in mammalian cell culture	1085:1141	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	4	64	theme	model	692:696	arg1	trimer					655:660	a SARS-CoV-2 prefusion spike trimer	626:660	a SARS-CoV-2 prefusion spike trimer	626:660	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	64	theme	model	692:696	arg1	antigen					698:704	a model antigen	690:704	a model antigen from an emerging virus	690:727	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	5	65	theme	prefusion	793:801	arg1	structure					803:811	a characteristic prefusion structure	776:811	a characteristic prefusion structure	776:811	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	1	66	theme	safe	145:148	arg1	platform					174:181	a cheap, safe and scalable production platform	136:181	a cheap, safe and scalable production platform	136:181	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	1	66	theme	safe	145:148	arg1	farming					95:101	Molecular farming	85:101	Molecular farming of vaccines	85:113	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	7	67	dep	mature	1269:1274	arg1	complex					1277:1283	complex	1277:1283	complex	1277:1283	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	5	68	theme	size	734:737	arg1	protein					758:764	The size exclusion-purified protein	730:764	The size exclusion-purified protein	730:764	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	3	69	theme	secretory	353:361	arg1	pathway					363:369	the secretory pathway	349:369	the secretory pathway	349:369	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	0	70	from	immunity	63:70	arg1	hamsters					75:82	hamsters	75:82	hamsters	75:82	A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.
36959936	3	71	dep	opportunity	383:393	arg1	support					398:404	support	398:404	to support key post-translational modifications	395:441	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	3	71	dep	opportunity	383:393	arg1	tailor					451:456	tailor	451:456	to tailor aspects of glycosylation and glycosylation-directed folding	448:516	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	8	72	theme	Delta	1466:1470	arg1	variants					1483:1490	heterologous Delta SARS-CoV-2 variants	1453:1490	heterologous Delta SARS-CoV-2 variants	1453:1490	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	8	73	theme	plant-derived	1363:1375	arg1	antigen					1377:1383	The plant-derived antigen	1359:1383	The plant-derived antigen	1359:1383	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	5	74	theme	electron	841:848	arg1	microscopy					850:859	transmission electron microscopy	828:859	transmission electron microscopy	828:859	The size exclusion-purified protein exhibited a characteristic prefusion structure when viewed by transmission electron microscopy, and this was indistinguishable from the equivalent mammalian cell-produced antigen.
36959936	9	75	theme	significant	1710:1720	arg1	protection					1722:1731	significant protection	1710:1731	significant protection from SARS-CoV-2 disease	1710:1755	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	8	76	theme	immunized	1495:1503	arg1	hamsters					1505:1512	immunized hamsters	1495:1512	immunized hamsters	1495:1512	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	0	77	theme	spike	28:32	arg1	protein					34:40	A plant-produced SARS-CoV-2 spike protein	0:40	A plant-produced SARS-CoV-2 spike protein	0:40	A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.
36959936	1	78	theme	vaccines	106:113	arg1	platform					174:181	a cheap, safe and scalable production platform	136:181	a cheap, safe and scalable production platform	136:181	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	1	78	theme	vaccines	106:113	arg1	farming					95:101	Molecular farming	85:101	Molecular farming of vaccines	85:113	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	10	79	theme	associated	2055:2064	arg1	glycosylation					2066:2078	associated glycosylation	2055:2078	associated glycosylation	2055:2078	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	3	80	theme	glycosylation	469:481	arg1	aspects					458:464	aspects	458:464	aspects of glycosylation and glycosylation-directed folding	458:516	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	6	81	theme	mammalian	1120:1128	arg1	culture					1135:1141	mammalian cell culture	1120:1141	mammalian cell culture	1120:1141	The plant-produced protein was decorated with under-processed oligomannose N-glycans and exhibited a site occupancy that was comparable to the equivalent protein produced in mammalian cell culture.
36959936	3	82	theme	post-translational	410:427	arg1	modifications					429:441	key post-translational modifications	406:441	key post-translational modifications	406:441	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	7	83	located	observed	1303:1310	arg2	glycans					1285:1291	the predominantly mature, complex glycans	1251:1291	the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein	1251:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	7	83	located	observed	1303:1310	arg1	protein					1350:1356	the mammalian cell culture-derived protein	1315:1356	the mammalian cell culture-derived protein	1315:1356	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	8	84	dep	Wuhan	1443:1447	arg1	the					1431:1433	the	1431:1433	the	1431:1433	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	7	85	from	material	1216:1223	arg1	absent					1186:1191	absent	1186:1191	absent	1186:1191	Complex-type glycans were almost entirely absent from the plant-derived material, which contrasted against the predominantly mature, complex glycans that were observed on the mammalian cell culture-derived protein.
36959936	2	86	gly	glycoproteins	322:334	arg1	glycoproteins					322:334	viral glycoproteins	316:334	viral glycoproteins	316:334	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	10	87	theme	antigen	2087:2093	arg1	structure					2041:2049	native glycoprotein structure	2021:2049	native glycoprotein structure	2021:2049	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	10	87	theme	antigen	2087:2093	arg1	glycosylation					2066:2078	associated glycosylation	2055:2078	associated glycosylation	2055:2078	Nonetheless, animals immunized with the mammalian cell-culture-derived protein were better protected in this challenge model suggesting that more faithfully reproducing the native glycoprotein structure and associated glycosylation of the antigen may be desirable.
36959936	2	88	theme	viral	316:320	arg1	glycoproteins					322:334	viral glycoproteins	316:334	viral glycoproteins	316:334	In reality, however, differences in the plant biosynthetic machinery, compared to mammalian cells, can complicate the production of viral glycoproteins.
36959936	9	89	link	plant-derived	1626:1638	arg1	antigen					1640:1646	the plant-derived antigen	1622:1646	the plant-derived antigen	1622:1646	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	1	90	theme	cheap	138:142	arg1	platform					174:181	a cheap, safe and scalable production platform	136:181	a cheap, safe and scalable production platform	136:181	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	1	90	theme	cheap	138:142	arg1	farming					95:101	Molecular farming	85:101	Molecular farming of vaccines	85:113	Molecular farming of vaccines has been heralded as a cheap, safe and scalable production platform.
36959936	9	91	theme	reduced	1773:1779	arg1	pathology					1786:1794	reduced lung pathology	1773:1794	reduced lung pathology	1773:1794	Animals vaccinated with the plant-derived antigen exhibited reduced viral loads following challenge, as well as significant protection from SARS-CoV-2 disease as evidenced by reduced lung pathology, lower viral loads and protection from weight loss.
36959936	3	92	theme	glycosylation-directed	487:508	arg1	folding					510:516	glycosylation-directed folding	487:516	glycosylation-directed folding	487:516	Remodelling the secretory pathway presents an opportunity to support key post-translational modifications, and to tailor aspects of glycosylation and glycosylation-directed folding.
36959936	4	93	from	virus	723:727	arg1	trimer					655:660	a SARS-CoV-2 prefusion spike trimer	626:660	a SARS-CoV-2 prefusion spike trimer	626:660	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	93	from	virus	723:727	arg1	antigen					698:704	a model antigen	690:704	a model antigen from an emerging virus	690:727	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	8	94	link	plant-derived	1363:1375	arg1	antigen					1377:1383	The plant-derived antigen	1359:1383	The plant-derived antigen	1359:1383	The plant-derived antigen elicited neutralizing antibodies against both the matched Wuhan and heterologous Delta SARS-CoV-2 variants in immunized hamsters, although titres were lower than those induced by the comparator mammalian antigen.
36959936	4	95	theme	SARS-CoV-2	628:637	arg1	trimer					655:660	a SARS-CoV-2 prefusion spike trimer	626:660	a SARS-CoV-2 prefusion spike trimer	626:660	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	4	95	theme	SARS-CoV-2	628:637	arg1	antigen					698:704	a model antigen	690:704	a model antigen from an emerging virus	690:727	In this study, we applied an integrated host and glyco-engineering approach, NXS/T Generation™, to produce a SARS-CoV-2 prefusion spike trimer in Nicotiana benthamiana as a model antigen from an emerging virus.
36959936	0	96	theme	plant-produced	2:15	arg1	protein					34:40	A plant-produced SARS-CoV-2 spike protein	0:40	A plant-produced SARS-CoV-2 spike protein	0:40	A plant-produced SARS-CoV-2 spike protein elicits heterologous immunity in hamsters.
34972934	3	0	theme	natural	522:528	arg1	microarrays					536:546	natural mucin microarrays	522:546	natural mucin microarrays	522:546	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	1	1	theme	Mucin	59:63	arg1	facilitator					90:100	the key facilitator	82:100	the key facilitator of microbial attachment and nutrition	82:138	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	1	1	theme	Mucin	59:63	arg1	glycosylation					65:77	Mucin glycosylation	59:77	Mucin glycosylation	59:77	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	4	2	theme	natural	689:695	arg1	mucins					697:702	natural mucins	689:702	natural mucins	689:702	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	1	3	theme	multiple	254:261	arg1	factors					269:275	multiple other factors	254:275	multiple other factors	254:275	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	4	4	theme	natural	771:777	arg1	microarrays					785:795	natural mucin microarrays	771:795	natural mucin microarrays	771:795	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	2	5	theme	Mucin	278:282	arg1	glycans					284:290	Mucin glycans	278:290	Mucin glycans	278:290	Mucin glycans have also been reported to attenuate pathogen virulence and mediate biofilm dispersal.
34972934	1	6	theme	other	263:267	arg1	factors					269:275	multiple other factors	254:275	multiple other factors	254:275	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	3	7	theme	biological	502:511	arg1	sources					513:519	biological sources	502:519	biological sources	502:519	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	8	theme	quantitative	478:489	arg1	yield					491:495	their low quantitative yield	468:495	their low quantitative yield	468:495	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	1	9	theme	biological	167:176	arg1	location					178:185	biological location	167:185	biological location	167:185	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	3	10	theme	time-consuming	408:421	arg1	purification					423:434	the labor intensive and time-consuming purification	384:434	the labor intensive and time-consuming purification required for natural mucins	384:462	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	4	11	theme	microarrays	785:795	arg1	printing					759:766	the printing	755:766	the printing of natural mucin microarrays	755:795	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	4	11	theme	microarrays	785:795	arg1	source					743:748	an example biological source	721:748	an example biological source	721:748	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	4	11	theme	microarrays	785:795	arg1	sputum					711:716	sputum	711:716	sputum	711:716	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	0	12	theme	Purification	6:17	arg1	Microarrays					46:56	Purification and Printing Natural Mucin Microarrays	6:56	Purification and Printing Natural Mucin Microarrays	6:56	Mucin Purification and Printing Natural Mucin Microarrays.
34972934	1	13	theme	key	86:88	arg1	facilitator					90:100	the key facilitator	82:100	the key facilitator of microbial attachment and nutrition	82:138	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	1	13	theme	key	86:88	arg1	glycosylation					65:77	Mucin glycosylation	59:77	Mucin glycosylation	59:77	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	4	14	theme	mucin	779:783	arg1	microarrays					785:795	natural mucin microarrays	771:795	natural mucin microarrays	771:795	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	1	15	theme	health	188:193	arg1	status					207:212	health and disease status	188:212	status	207:212	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	0	16	theme	Printing	23:30	arg1	Microarrays					46:56	Purification and Printing Natural Mucin Microarrays	6:56	Purification and Printing Natural Mucin Microarrays	6:56	Mucin Purification and Printing Natural Mucin Microarrays.
34972934	3	17	from	sources	513:519	arg1	yield					491:495	their low quantitative yield	468:495	their low quantitative yield	468:495	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	17	from	sources	513:519	arg1	purification					423:434	the labor intensive and time-consuming purification	384:434	the labor intensive and time-consuming purification required for natural mucins	384:462	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	18	theme	multiplexed	573:583	arg1	platform					585:592	a convenient and multiplexed platform	556:592	a convenient and multiplexed platform to study mucin glycosylation and interactions	556:638	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	19	theme	low	474:476	arg1	yield					491:495	their low quantitative yield	468:495	their low quantitative yield	468:495	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	1	20	theme	microbial	105:113	arg1	attachment					115:124	microbial attachment	105:124	microbial attachment	105:124	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	1	21	theme	disease	199:205	arg1	status					207:212	health and disease status	188:212	status	207:212	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	0	22	theme	Mucin	40:44	arg1	Microarrays					46:56	Purification and Printing Natural Mucin Microarrays	6:56	Purification and Printing Natural Mucin Microarrays	6:56	Mucin Purification and Printing Natural Mucin Microarrays.
34972934	4	23	theme	example	724:730	arg1	source					743:748	an example biological source	721:748	an example biological source	721:748	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	4	23	theme	example	724:730	arg1	sputum					711:716	sputum	711:716	sputum	711:716	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	4	24	theme	mucins	697:702	arg1	purification					673:684	the purification	669:684	the purification of natural mucins	669:702	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	0	25	theme	Natural	32:38	arg1	Microarrays					46:56	Purification and Printing Natural Mucin Microarrays	6:56	Purification and Printing Natural Mucin Microarrays	6:56	Mucin Purification and Printing Natural Mucin Microarrays.
34972934	3	26	theme	intensive	394:402	arg1	purification					423:434	the labor intensive and time-consuming purification	384:434	the labor intensive and time-consuming purification required for natural mucins	384:462	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	27	theme	natural	449:455	arg1	mucins					457:462	natural mucins	449:462	natural mucins	449:462	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	28	theme	mucin	603:607	arg1	glycosylation					609:621	mucin glycosylation	603:621	mucin glycosylation	603:621	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	1	29	theme	attachment	115:124	arg1	facilitator					90:100	the key facilitator	82:100	the key facilitator of microbial attachment and nutrition	82:138	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	1	29	theme	attachment	115:124	arg1	glycosylation					65:77	Mucin glycosylation	59:77	Mucin glycosylation	59:77	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	2	30	theme	pathogen	329:336	arg1	virulence					338:346	pathogen virulence	329:346	pathogen virulence	329:346	Mucin glycans have also been reported to attenuate pathogen virulence and mediate biofilm dispersal.
34972934	4	31	theme	biological	732:741	arg1	source					743:748	an example biological source	721:748	an example biological source	721:748	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	4	31	theme	biological	732:741	arg1	sputum					711:716	sputum	711:716	sputum	711:716	In this chapter we describe the purification of natural mucins, using sputum as an example biological source, and the printing of natural mucin microarrays.
34972934	1	32	theme	nutrition	130:138	arg1	facilitator					90:100	the key facilitator	82:100	the key facilitator of microbial attachment and nutrition	82:138	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	1	32	theme	nutrition	130:138	arg1	glycosylation					65:77	Mucin glycosylation	59:77	Mucin glycosylation	59:77	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	1	33	theme	microbiome	215:224	arg1	composition					226:236	microbiome composition	215:236	microbiome composition	215:236	Mucin glycosylation is the key facilitator of microbial attachment and nutrition and it varies according to biological location, health and disease status, microbiome composition, infection, and multiple other factors.
34972934	3	34	theme	convenient	558:567	arg1	platform					585:592	a convenient and multiplexed platform	556:592	a convenient and multiplexed platform to study mucin glycosylation and interactions	556:638	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	3	35	theme	mucin	530:534	arg1	microarrays					536:546	natural mucin microarrays	522:546	natural mucin microarrays	522:546	With the labor intensive and time-consuming purification required for natural mucins and their low quantitative yield from biological sources, natural mucin microarrays provide a convenient and multiplexed platform to study mucin glycosylation and interactions.
34972934	2	36	theme	biofilm	360:366	arg1	dispersal					368:376	biofilm dispersal	360:376	biofilm dispersal	360:376	Mucin glycans have also been reported to attenuate pathogen virulence and mediate biofilm dispersal.
35662639	4	0	theme	Bothrops	894:901	arg1	moojeni					1028:1034	moojeni	1028:1034	moojeni	1028:1034	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	Bothrops					945:952	Bothrops	945:952	Bothrops	945:952	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	Bothrops					978:985	Bothrops	978:985	Bothrops	978:985	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	Bothrops					997:1004	Bothrops	997:1004	Bothrops	997:1004	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	Bothrops					922:929	Bothrops	922:929	Bothrops	922:929	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	neuwiedi					1049:1056	neuwiedi	1049:1056	neuwiedi	1049:1056	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	B.					964:965	B.	964:965	B.	964:965	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	jararacussu					1006:1016	jararacussu	1006:1016	jararacussu	1006:1016	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	0	theme	Bothrops	894:901	arg1	atrox					903:907	Bothrops atrox	894:907	Bothrops atrox	894:907	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	5	1	theme	various	1433:1439	arg1	types					1441:1445	various types	1433:1445	various types of low abundant enzymes	1433:1469	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	2	theme	several	1324:1330	arg1	glycoproteins					1332:1344	several glycoproteins	1324:1344	several glycoproteins	1324:1344	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	2	theme	several	1324:1330	arg1	metalloprotease					1357:1371	metalloprotease	1357:1371	metalloprotease	1357:1371	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	2	theme	several	1324:1330	arg1	protease					1381:1388	serine protease	1374:1388	serine protease	1374:1388	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	2	theme	several	1324:1330	arg1	oxidase					1409:1415	L- amino acid oxidase	1395:1415	L- amino acid oxidase	1395:1415	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	6	3	theme	different	1690:1698	arg1	venoms					1700:1705	different venoms	1690:1705	different venoms	1690:1705	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	6	4	theme	snake	1726:1730	arg1	species					1732:1738	closely related snake species	1710:1738	closely related snake species	1710:1738	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	6	5	theme	novel	1534:1538	arg1	aspects					1540:1546	novel aspects	1534:1546	novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms	1534:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	1	6	theme	prey	256:259	arg1	capture					261:267	prey capture	256:267	prey capture	256:267	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	1	7	theme	mammalian	341:349	arg1	envenomation					351:362	mammalian envenomation	341:362	mammalian envenomation	341:362	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	6	8	theme	related	1718:1724	arg1	species					1732:1738	closely related snake species	1710:1738	closely related snake species	1710:1738	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	5	9	theme	capture	1267:1273	arg1	strategy					1275:1282	The lectin capture strategy	1256:1282	The lectin capture strategy	1256:1282	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	6	10	theme	distinct	1644:1651	arg1	types					1653:1657	distinct types	1644:1657	distinct types of glycan chains	1644:1674	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	4	11	with	enrichment	1090:1099	arg1	spectrometry					1242:1253	mass spectrometry	1237:1253	mass spectrometry	1237:1253	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	11	with	enrichment	1090:1099	arg1	lectins					1112:1118	three lectins	1106:1118	three lectins	1106:1118	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	12	theme	bisecting	1160:1168	arg1	N-acetylglucosamine-					1170:1189	bisecting N-acetylglucosamine-	1160:1189	bisecting N-acetylglucosamine-	1160:1189	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	1	13	theme	venom	137:141	arg1	proteomes					143:151	Snake venom proteomes	131:151	Snake venom proteomes	131:151	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	0	14	theme	glycan	117:122	arg1	types					124:128	different glycan types	107:128	different glycan types	107:128	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	5	15	theme	amino	1398:1402	arg1	oxidase					1409:1415	L- amino acid oxidase	1395:1415	L- amino acid oxidase	1395:1415	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	4	16	theme	different	809:817	arg1	venoms					819:824	different venoms	809:824	different venoms	809:824	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	5	17	theme	acid	1404:1407	arg1	oxidase					1409:1415	L- amino acid oxidase	1395:1415	L- amino acid oxidase	1395:1415	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	2	18	theme	post-translational	398:415	arg1	Glycosylation					365:377	Glycosylation	365:377	Glycosylation	365:377	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	2	18	theme	post-translational	398:415	arg1	modification					417:428	a major protein post-translational modification	382:428	a major protein post-translational modification in venoms	382:438	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	0	19	theme	different	107:115	arg1	types					124:128	different glycan types	107:128	different glycan types	107:128	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	6	20	theme	different	1476:1484	arg1	contents					1486:1493	The different contents	1472:1493	The different contents of lectin-enriched proteins	1472:1521	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	5	21	theme	enzymes	1463:1469	arg1	types					1441:1445	various types	1433:1445	various types of low abundant enzymes	1433:1469	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	22	dep	types	1441:1445	arg1	addition					1421:1428	addition	1421:1428	addition	1421:1428	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	2	23	theme	protein	390:396	arg1	Glycosylation					365:377	Glycosylation	365:377	Glycosylation	365:377	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	2	23	theme	protein	390:396	arg1	modification					417:428	a major protein post-translational modification	382:428	a major protein post-translational modification in venoms	382:438	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	4	24	dep	venoms	886:891	arg1	moojeni					1028:1034	moojeni	1028:1034	moojeni	1028:1034	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	Bothrops					945:952	Bothrops	945:952	Bothrops	945:952	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	Bothrops					978:985	Bothrops	978:985	Bothrops	978:985	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	Bothrops					997:1004	Bothrops	997:1004	Bothrops	997:1004	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	Bothrops					922:929	Bothrops	922:929	Bothrops	922:929	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	neuwiedi					1049:1056	neuwiedi	1049:1056	neuwiedi	1049:1056	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	B.					964:965	B.	964:965	B.	964:965	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	jararacussu					1006:1016	jararacussu	1006:1016	jararacussu	1006:1016	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	24	dep	venoms	886:891	arg1	atrox					903:907	Bothrops atrox	894:907	Bothrops atrox	894:907	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	25	theme	venoms	886:891	arg1	glycoproteomes					854:867	the glycoproteomes	850:867	the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi)	850:1057	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	26	theme	sialic	1195:1200	arg1	glycoproteins					1218:1230	sialic acid-containing glycoproteins	1195:1230	sialic acid-containing glycoproteins	1195:1230	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	6	27	theme	venoms	1612:1617	arg1	subproteomes					1587:1598	the glycoprotein subproteomes	1570:1598	the glycoprotein subproteomes of Bothrops venoms	1570:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	2	28	theme	major	384:388	arg1	Glycosylation					365:377	Glycosylation	365:377	Glycosylation	365:377	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	2	28	theme	major	384:388	arg1	modification					417:428	a major protein post-translational modification	382:428	a major protein post-translational modification in venoms	382:438	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	6	29	theme	lectin-enriched	1498:1512	arg1	proteins					1514:1521	lectin-enriched proteins	1498:1521	lectin-enriched proteins	1498:1521	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	4	30	theme	Bothrops	877:884	arg1	venoms					886:891	nine Bothrops venoms	872:891	nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi)	872:1057	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	6	31	theme	chains	1669:1674	arg1	types					1653:1657	distinct types	1644:1657	distinct types of glycan chains	1644:1674	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	4	32	theme	different	1123:1131	arg1	specificities					1133:1145	different specificities	1123:1145	different specificities	1123:1145	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	6	33	gly	glycoprotein	1574:1585	arg1	glycoprotein					1574:1585	the glycoprotein subproteomes	1570:1598	the glycoprotein subproteomes of Bothrops venoms	1570:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	3	34	theme	glycoproteins	569:581	arg1	content					558:564	their content	552:564	their content of glycoproteins	552:581	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	0	35	theme	subproteomes	14:25	arg1	Profilings					0:9	Profilings	0:9	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms	0:76	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	5	36	theme	L-	1395:1396	arg1	oxidase					1409:1415	L- amino acid oxidase	1395:1415	L- amino acid oxidase	1395:1415	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	6	37	theme	subproteomes	1587:1598	arg1	variability					1555:1565	the variability	1551:1565	the variability of the glycoprotein subproteomes of Bothrops venoms	1551:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	6	38	theme	Bothrops	1603:1610	arg1	venoms					1612:1617	Bothrops venoms	1603:1617	Bothrops venoms	1603:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	0	39	theme	proteins	45:52	arg1	subproteomes					14:25	subproteomes	14:25	subproteomes of lectin-binding proteins of nine Bothrops venoms	14:76	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	4	40	theme	related	829:835	arg1	snakes					837:842	related snakes	829:842	related snakes	829:842	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	41	theme	specificities	1133:1145	arg1	spectrometry					1242:1253	mass spectrometry	1237:1253	mass spectrometry	1237:1253	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	41	theme	specificities	1133:1145	arg1	lectins					1112:1118	three lectins	1106:1118	three lectins	1106:1118	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	0	42	theme	lectin-binding	30:43	arg1	proteins					45:52	lectin-binding proteins	30:52	lectin-binding proteins of nine Bothrops venoms	30:76	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	6	43	theme	glycan	1662:1667	arg1	chains					1669:1674	glycan chains	1662:1674	glycan chains	1662:1674	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	5	44	theme	lectin	1260:1265	arg1	strategy					1275:1282	The lectin capture strategy	1256:1282	The lectin capture strategy	1256:1282	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	3	45	theme	sialic	651:656	arg1	acid					658:661	sialic acid	651:661	sialic acid	651:661	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	4	46	theme	mass	1237:1240	arg1	spectrometry					1242:1253	mass spectrometry	1237:1253	mass spectrometry	1237:1253	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	1	47	theme	active	220:225	arg1	components					227:236	biologically active components	207:236	biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation	207:362	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	2	48	theme	proteomes	482:490	arg1	diversification					463:477	the diversification	459:477	the diversification of proteomes	459:490	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	3	49	theme	most	593:596	arg1	structures					607:616	most N-glycan structures	593:616	most N-glycan structures of eight Bothrops venoms	593:641	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	6	50	theme	glycoprotein	1574:1585	arg1	subproteomes					1587:1598	the glycoprotein subproteomes	1570:1598	the glycoprotein subproteomes of Bothrops venoms	1570:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	3	51	theme	Bothrops	717:724	arg1	venom					734:738	Bothrops cotiara venom	717:738	Bothrops cotiara venom	717:738	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	4	52	gly	glycoproteins	1218:1230	arg1	glycoproteins					1218:1230	sialic acid-containing glycoproteins	1195:1230	sialic acid-containing glycoproteins	1195:1230	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	1	53	used	used	247:250	arg2	components					227:236	biologically active components	207:236	biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation	207:362	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	3	54	theme	N-glycan	598:605	arg1	structures					607:616	most N-glycan structures	593:616	most N-glycan structures of eight Bothrops venoms	593:641	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	5	55	theme	low	1450:1452	arg1	enzymes					1463:1469	low abundant enzymes	1450:1469	low abundant enzymes	1450:1469	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	3	56	theme	Bothrops	512:519	arg1	venoms					521:526	Bothrops venoms	512:526	Bothrops venoms	512:526	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	1	57	theme	pathological	306:317	arg1	effects					319:325	the pathological effects	302:325	the pathological effects observed upon mammalian envenomation	302:362	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	3	58	theme	venoms	636:641	arg1	structures					607:616	most N-glycan structures	593:616	most N-glycan structures of eight Bothrops venoms	593:641	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	5	59	theme	abundant	1454:1461	arg1	enzymes					1463:1469	low abundant enzymes	1450:1469	low abundant enzymes	1450:1469	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	1	60	theme	Snake	131:135	arg1	proteomes					143:151	Snake venom proteomes	131:151	Snake venom proteomes	131:151	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	1	61	theme	components	227:236	arg1	multitude					194:202	a multitude	192:202	a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation	192:362	Snake venom proteomes have long been investigated to explore a multitude of biologically active components that are used for prey capture and defense, and are involved in the pathological effects observed upon mammalian envenomation.
35662639	6	62	theme	types	1653:1657	arg1	role					1636:1639	the role	1632:1639	the role of distinct types of glycan chains in generating different venoms by closely related snake species	1632:1738	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	3	63	theme	bisected	670:677	arg1	N-acetylglucosamine					679:697	bisected N-acetylglucosamine	670:697	bisected N-acetylglucosamine	670:697	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	4	64	theme	venoms	819:824	arg1	generation					795:804	the generation	791:804	the generation of different venoms by related snakes	791:842	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	4	65	theme	acid-containing	1202:1216	arg1	glycoproteins					1218:1230	sialic acid-containing glycoproteins	1195:1230	sialic acid-containing glycoproteins	1195:1230	To further investigate the mechanisms involved in the generation of different venoms by related snakes, here the glycoproteomes of nine Bothrops venoms (Bothrops atrox, B. cotiara, Bothrops erythromelas, Bothrops fonsecai, B. insularis, Bothrops jararaca, Bothrops jararacussu, Bothrops moojeni and Bothrops neuwiedi) were comparatively analyzed by enrichment with three lectins of different specificities, recognizing bisecting N-acetylglucosamine- and sialic acid-containing glycoproteins, and mass spectrometry.
35662639	3	66	gly	glycoproteins	569:581	arg1	glycoproteins					569:581	glycoproteins	569:581	glycoproteins	569:581	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	6	67	theme	variability	1555:1565	arg1	aspects					1540:1546	novel aspects	1534:1546	novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms	1534:1617	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35662639	5	68	theme	venom	1294:1298	arg1	fractions					1300:1308	venom fractions	1294:1308	venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes	1294:1469	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	0	69	theme	venoms	71:76	arg1	proteins					45:52	lectin-binding proteins	30:52	lectin-binding proteins of nine Bothrops venoms	30:76	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	5	70	gly	glycoproteins	1332:1344	arg1	glycoproteins					1332:1344	several glycoproteins	1324:1344	several glycoproteins	1324:1344	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	70	gly	glycoproteins	1332:1344	arg1	metalloprotease					1357:1371	metalloprotease	1357:1371	metalloprotease	1357:1371	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	70	gly	glycoproteins	1332:1344	arg1	protease					1381:1388	serine protease	1374:1388	serine protease	1374:1388	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	5	70	gly	glycoproteins	1332:1344	arg1	oxidase					1409:1415	L- amino acid oxidase	1395:1415	L- amino acid oxidase	1395:1415	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	2	71	from	modification	417:428	arg1	venoms					433:438	venoms	433:438	venoms	433:438	Glycosylation is a major protein post-translational modification in venoms and contributes to the diversification of proteomes.
35662639	5	72	theme	serine	1374:1379	arg1	protease					1381:1388	serine protease	1374:1388	serine protease	1374:1388	The lectin capture strategy generated venom fractions enriched with several glycoproteins, including metalloprotease, serine protease, and L- amino acid oxidase, in addition to various types of low abundant enzymes.
35662639	3	73	contain	contain	643:649	arg1	structures					607:616	most N-glycan structures	593:616	most N-glycan structures of eight Bothrops venoms	593:641	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	3	73	contain	contain	643:649	arg2	acid					658:661	sialic acid	651:661	sialic acid	651:661	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	0	74	theme	Bothrops	62:69	arg1	venoms					71:76	nine Bothrops venoms	57:76	nine Bothrops venoms	57:76	Profilings of subproteomes of lectin-binding proteins of nine Bothrops venoms reveal variability driven by different glycan types.
35662639	3	75	theme	cotiara	726:732	arg1	venom					734:738	Bothrops cotiara venom	717:738	Bothrops cotiara venom	717:738	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	3	76	theme	Bothrops	627:634	arg1	venoms					636:641	eight Bothrops venoms	621:641	eight Bothrops venoms	621:641	We have shown that Bothrops venoms are markedly defined by their content of glycoproteins, and that most N-glycan structures of eight Bothrops venoms contain sialic acid, while bisected N-acetylglucosamine was identified in Bothrops cotiara venom.
35662639	6	77	theme	proteins	1514:1521	arg1	contents					1486:1493	The different contents	1472:1493	The different contents of lectin-enriched proteins	1472:1521	The different contents of lectin-enriched proteins underscore novel aspects of the variability of the glycoprotein subproteomes of Bothrops venoms and point to the role of distinct types of glycan chains in generating different venoms by closely related snake species.
35960654	10	0	theme	intact	1914:1919	arg1	analysis					1934:1941	the enhanced comprehensive quantitative intact glycopeptide analysis	1874:1941	the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling	1874:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	10	1	theme	limited	2077:2083	arg1	quantity					2092:2099	a limited sample quantity	2075:2099	a limited sample quantity	2075:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	3	2	theme	intact	566:571	arg1	glycopeptides					573:585	intact glycopeptides	566:585	intact glycopeptides from samples with limited quantity more challenging	566:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	10	3	from	targets	2026:2032	arg1	systems					2062:2068	biological systems	2051:2068	biological systems with a limited sample quantity	2051:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	9	4	theme	glycoproteomic	1758:1771	arg1	analysis					1773:1780	in-depth glycoproteomic analysis	1749:1780	in-depth glycoproteomic analysis of size-limited clinical samples	1749:1813	Our results demonstrated the feasibility of using this strategy for in-depth glycoproteomic analysis of size-limited clinical samples.
35960654	7	5	theme	AD	1512:1513	arg1	pathogenesis					1515:1526	AD pathogenesis	1512:1526	AD pathogenesis	1512:1526	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	4	6	theme	improved	687:694	arg1	strategy					714:721	an improved isobaric labeling strategy	684:721	an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu	684:871	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	5	7	theme	one-tube	900:907	arg1	workflow					927:934	a one-tube sample processing workflow	898:934	a one-tube sample processing workflow	898:934	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	10	8	from	biomarkers	2037:2046	arg1	systems					2062:2068	biological systems	2051:2068	biological systems with a limited sample quantity	2051:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	7	9	from	N-glycosylation	1346:1360	arg1	AD					1365:1366	AD	1365:1366	AD	1365:1366	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	6	10	theme	disease	1236:1242	arg1	patients					1249:1256	Alzheimer's disease (AD) patients	1224:1256	Alzheimer's disease (AD) patients	1224:1256	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	4	11	theme	labeling	705:712	arg1	strategy					714:721	an improved isobaric labeling strategy	684:721	an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu	684:871	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	10	12	theme	enhanced	1878:1885	arg1	analysis					1934:1941	the enhanced comprehensive quantitative intact glycopeptide analysis	1874:1941	the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling	1874:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	3	13	dep	challenging	627:637	arg1	more					622:625	more	622:625	more	622:625	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	9	14	theme	clinical	1798:1805	arg1	samples					1807:1813	size-limited clinical samples	1785:1813	size-limited clinical samples	1785:1813	Our results demonstrated the feasibility of using this strategy for in-depth glycoproteomic analysis of size-limited clinical samples.
35960654	2	15	theme	spectrometry	305:316	arg1	analysis					344:351	mass spectrometry (MS)-based glycoproteomic analysis	300:351	mass spectrometry (MS)-based glycoproteomic analysis	300:351	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	1	16	theme	glycosylation	208:220	arg1	information					227:237	glycosylation site information	208:237	glycosylation site information	208:237	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	5	17	gly	N-glycopeptides	981:995	arg2	N-glycopeptides					981:995	3514 quantifiable N-glycopeptides	963:995	3514 quantifiable N-glycopeptides	963:995	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	1	18	gly	glycopeptide	134:145	arg2	glycopeptide					134:145	Intact glycopeptide analysis	127:154	Intact glycopeptide analysis	127:154	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	3	19	with	samples	592:598	arg1	quantity					613:620	limited quantity	605:620	limited quantity more challenging	605:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	8	20	theme	gene	1548:1551	arg1	analysis					1574:1581	weighted gene coexpression network analysis	1539:1581	weighted gene coexpression network analysis (WGCNA)	1539:1589	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	8	20	theme	gene	1548:1551	arg1	WGCNA					1584:1588	WGCNA	1584:1588	WGCNA	1584:1588	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	10	21	theme	quantitative	1901:1912	arg1	analysis					1934:1941	the enhanced comprehensive quantitative intact glycopeptide analysis	1874:1941	the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling	1874:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	1	22	theme	Intact	127:132	arg1	analysis					147:154	Intact glycopeptide analysis	127:154	Intact glycopeptide analysis	127:154	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	8	23	theme	network	1566:1572	arg1	analysis					1574:1581	weighted gene coexpression network analysis	1539:1581	weighted gene coexpression network analysis (WGCNA)	1539:1589	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	8	23	theme	network	1566:1572	arg1	WGCNA					1584:1588	WGCNA	1584:1588	WGCNA	1584:1588	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	5	24	theme	quantifiable	968:979	arg1	N-glycopeptides					981:995	3514 quantifiable N-glycopeptides	963:995	3514 quantifiable N-glycopeptides	963:995	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	6	25	theme	non-AD	1262:1267	arg1	donors					1269:1274	non-AD donors	1262:1274	non-AD donors	1262:1274	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	0	26	theme	Tagging	52:58	arg1	Strategy					60:67	Leucine Tagging Strategy	44:67	N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis	33:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	8	27	gly	glycopeptides	1614:1626	arg2	glycopeptides					1614:1626	glycopeptides	1614:1626	glycopeptides	1614:1626	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	2	28	gly	glycopeptides	420:432	arg2	glycopeptides					420:432	glycopeptides	420:432	glycopeptides	420:432	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	4	29	theme	additional	731:740	arg1	channel					751:757	an additional boosting channel	728:757	an additional boosting channel	728:757	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	3	30	from	quantification	548:561	arg1	samples					592:598	samples	592:598	samples with limited quantity more challenging	592:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	1	31	theme	great	168:172	arg1	interest					174:181	great interest	168:181	great interest	168:181	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	0	32	theme	Comprehensive	75:87	arg1	Analysis					117:124	a Comprehensive Quantitative Glycoproteomic Analysis	73:124	a Comprehensive Quantitative Glycoproteomic Analysis	73:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	10	33	theme	glycopeptide	1921:1932	arg1	analysis					1934:1941	the enhanced comprehensive quantitative intact glycopeptide analysis	1874:1941	the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling	1874:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	5	34	theme	HeLa	1024:1027	arg1	digests					1042:1048	30 μg HeLa cell tryptic digests	1018:1048	30 μg HeLa cell tryptic digests with reliable quantification performance	1018:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	10	35	with	systems	2062:2068	arg1	quantity					2092:2099	a limited sample quantity	2075:2099	a limited sample quantity	2075:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	4	36	theme	tagging-based	799:811	arg1	N-dimethyl					772:781	N-dimethyl	772:781	N-dimethyl	772:781	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	4	36	theme	tagging-based	799:811	arg1	N					770:770	N	770:770	N	770:770	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	2	37	theme	ionization	395:404	arg1	efficiency					406:415	poor ionization efficiency	390:415	poor ionization efficiency	390:415	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	0	38	theme	Glycoproteomic	102:115	arg1	Analysis					117:124	a Comprehensive Quantitative Glycoproteomic Analysis	73:124	a Comprehensive Quantitative Glycoproteomic Analysis	73:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	5	39	theme	tryptic	1034:1040	arg1	digests					1042:1048	30 μg HeLa cell tryptic digests	1018:1048	30 μg HeLa cell tryptic digests with reliable quantification performance	1018:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	6	40	theme	cerebrospinal	1140:1152	arg1	CSF					1161:1163	CSF	1161:1163	CSF	1161:1163	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	6	40	theme	cerebrospinal	1140:1152	arg1	fluid					1154:1158	cerebrospinal fluid	1140:1158	human cerebrospinal fluid (CSF) samples	1134:1172	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	7	41	theme	cell	1403:1406	arg1	adhesion					1408:1415	cell adhesion	1403:1415	cell adhesion	1403:1415	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	0	42	theme	Enhanced	13:20	arg1	N-Dimethyl					33:42	N-Dimethyl	33:42	N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis	33:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	0	42	theme	Enhanced	13:20	arg1	N					31:31	Enhanced Isobaric N	13:31	Enhanced Isobaric N	13:31	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	3	43	dep	identification	529:542	arg1	the					525:527	the	525:527	the	525:527	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	5	44	theme	workflow	927:934	arg1	integration					883:893	the integration	879:893	the integration of a one-tube sample processing workflow and high-pH fractionation	879:960	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	3	45	theme	starting	463:470	arg1	materials					472:480	starting materials	463:480	starting materials	463:480	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	0	46	dep	N-Dimethyl	33:42	arg1	Strategy					60:67	Leucine Tagging Strategy	44:67	N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis	33:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	6	47	theme	N-glycosylation	1191:1205	arg1	profiles					1207:1214	N-glycosylation profiles	1191:1214	N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors	1191:1274	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	8	48	theme	AD	1667:1668	arg1	phenotype					1670:1678	the AD phenotype	1663:1678	the AD phenotype	1663:1678	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	10	49	theme	therapeutic	2014:2024	arg1	targets					2026:2032	novel therapeutic targets	2008:2032	novel therapeutic targets	2008:2032	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	4	50	theme	glycoproteomic	826:839	arg1	analysis					841:848	quantitative glycoproteomic analysis	813:848	quantitative glycoproteomic analysis	813:848	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	2	51	theme	glycoproteomic	329:342	arg1	analysis					344:351	mass spectrometry (MS)-based glycoproteomic analysis	300:351	mass spectrometry (MS)-based glycoproteomic analysis	300:351	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	2	52	theme	low	372:374	arg1	abundance					376:384	low abundance	372:384	low abundance	372:384	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	1	53	theme	structural	250:259	arg1	composition					261:271	glycan structural composition	243:271	glycan structural composition	243:271	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	5	54	theme	quantification	1064:1077	arg1	performance					1079:1089	reliable quantification performance	1055:1089	reliable quantification performance	1055:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	5	55	with	digests	1042:1048	arg1	performance					1079:1089	reliable quantification performance	1055:1089	reliable quantification performance	1055:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	10	56	gly	glycopeptide	1921:1932	arg2	glycopeptide					1921:1932	the enhanced comprehensive quantitative intact glycopeptide analysis	1874:1941	the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling	1874:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	2	57	theme	mass	300:303	arg1	MS					319:320	MS	319:320	MS	319:320	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	2	57	theme	mass	300:303	arg1	spectrometry					305:316	mass spectrometry	300:316	mass spectrometry (MS)-based glycoproteomic analysis	300:351	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	1	58	theme	same	280:283	arg1	time					285:288	the same time	276:288	the same time	276:288	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	7	59	theme	aberrations	1497:1507	arg1	involvement					1466:1476	the involvement	1462:1476	the involvement of N-glycosylation aberrations in AD pathogenesis	1462:1526	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	9	60	theme	in-depth	1749:1756	arg1	analysis					1773:1780	in-depth glycoproteomic analysis	1749:1780	in-depth glycoproteomic analysis of size-limited clinical samples	1749:1813	Our results demonstrated the feasibility of using this strategy for in-depth glycoproteomic analysis of size-limited clinical samples.
35960654	1	61	gly	glycosylation	208:220	arg2	information					227:237	glycosylation site information	208:237	glycosylation site information	208:237	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	1	61	gly	glycosylation	208:220	arg2	site					222:225	glycosylation site information	208:237	glycosylation site information	208:237	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	3	62	from	identification	529:542	arg1	samples					592:598	samples	592:598	samples with limited quantity more challenging	592:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	4	63	with	strategy	714:721	arg1	channel					751:757	an additional boosting channel	728:757	an additional boosting channel	728:757	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	10	64	theme	comprehensive	1887:1899	arg1	analysis					1934:1941	the enhanced comprehensive quantitative intact glycopeptide analysis	1874:1941	the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling	1874:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	5	65	theme	sample	909:914	arg1	workflow					927:934	a one-tube sample processing workflow	898:934	a one-tube sample processing workflow	898:934	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	9	66	theme	size-limited	1785:1796	arg1	samples					1807:1813	size-limited clinical samples	1785:1813	size-limited clinical samples	1785:1813	Our results demonstrated the feasibility of using this strategy for in-depth glycoproteomic analysis of size-limited clinical samples.
35960654	4	67	theme	isobaric	696:703	arg1	strategy					714:721	an improved isobaric labeling strategy	684:721	an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu	684:871	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	3	68	theme	glycopeptides	573:585	arg1	quantification					548:561	quantification	548:561	quantification	548:561	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	68	theme	glycopeptides	573:585	arg1	identification					529:542	identification	529:542	identification	529:542	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	10	69	with	analysis	1934:1941	arg1	labeling					1954:1961	DiLeu labeling	1948:1961	DiLeu labeling	1948:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	9	70	theme	samples	1807:1813	arg1	analysis					1773:1780	in-depth glycoproteomic analysis	1749:1780	in-depth glycoproteomic analysis of size-limited clinical samples	1749:1813	Our results demonstrated the feasibility of using this strategy for in-depth glycoproteomic analysis of size-limited clinical samples.
35960654	8	71	theme	weighted	1539:1546	arg1	analysis					1574:1581	weighted gene coexpression network analysis	1539:1581	weighted gene coexpression network analysis (WGCNA)	1539:1589	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	8	71	theme	weighted	1539:1546	arg1	WGCNA					1584:1588	WGCNA	1584:1588	WGCNA	1584:1588	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	5	72	theme	fractionation	948:960	arg1	integration					883:893	the integration	879:893	the integration of a one-tube sample processing workflow and high-pH fractionation	879:960	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	10	73	theme	sample	2085:2090	arg1	quantity					2092:2099	a limited sample quantity	2075:2099	a limited sample quantity	2075:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	5	74	theme	processing	916:925	arg1	workflow					927:934	a one-tube sample processing workflow	898:934	a one-tube sample processing workflow	898:934	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	1	75	theme	site	222:225	arg1	information					227:237	glycosylation site information	208:237	glycosylation site information	208:237	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	8	76	theme	coexpression	1553:1564	arg1	analysis					1574:1581	weighted gene coexpression network analysis	1539:1581	weighted gene coexpression network analysis (WGCNA)	1539:1589	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	8	76	theme	coexpression	1553:1564	arg1	WGCNA					1584:1588	WGCNA	1584:1588	WGCNA	1584:1588	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	3	77	theme	limited	605:611	arg1	quantity					613:620	limited quantity	605:620	limited quantity more challenging	605:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	4	78	theme	boosting	742:749	arg1	channel					751:757	an additional boosting channel	728:757	an additional boosting channel	728:757	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	1	79	theme	glycopeptide	134:145	arg1	analysis					147:154	Intact glycopeptide analysis	127:154	Intact glycopeptide analysis	127:154	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	3	80	gly	glycopeptides	573:585	arg1	samples					592:598	samples	592:598	samples with limited quantity more challenging	592:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	80	gly	glycopeptides	573:585	arg2	glycopeptides					573:585	intact glycopeptides	566:585	intact glycopeptides from samples with limited quantity more challenging	566:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	81	from	samples	592:598	arg1	quantification					548:561	quantification	548:561	quantification	548:561	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	81	from	samples	592:598	arg1	glycopeptides					573:585	intact glycopeptides	566:585	intact glycopeptides from samples with limited quantity more challenging	566:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	81	from	samples	592:598	arg1	identification					529:542	identification	529:542	identification	529:542	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	10	82	theme	DiLeu	1948:1952	arg1	labeling					1954:1961	DiLeu labeling	1948:1961	DiLeu labeling	1948:1961	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	4	83	dep	tagging-based	799:811	arg1	analysis					841:848	quantitative glycoproteomic analysis	813:848	quantitative glycoproteomic analysis	813:848	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	7	84	theme	extracellular	1422:1434	arg1	matrix					1436:1441	extracellular matrix	1422:1441	extracellular matrix	1422:1441	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	5	85	theme	high-pH	940:946	arg1	fractionation					948:960	high-pH fractionation	940:960	high-pH fractionation	940:960	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	8	86	theme	modules	1603:1609	arg1	modules					1603:1609	nine modules	1598:1609	nine modules	1598:1609	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	8	86	theme	modules	1603:1609	arg1	two					1629:1631	two	1629:1631	two	1629:1631	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	0	87	theme	Quantitative	89:100	arg1	Analysis					117:124	a Comprehensive Quantitative Glycoproteomic Analysis	73:124	a Comprehensive Quantitative Glycoproteomic Analysis	73:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	2	88	dep	abundance	376:384	arg1	the					368:370	the	368:370	the	368:370	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	5	89	theme	μg	1021:1022	arg1	digests					1042:1048	30 μg HeLa cell tryptic digests	1018:1048	30 μg HeLa cell tryptic digests with reliable quantification performance	1018:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	7	90	theme	N-glycosylation	1481:1495	arg1	aberrations					1497:1507	N-glycosylation aberrations	1481:1507	N-glycosylation aberrations	1481:1507	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	8	91	theme	glycopeptides	1614:1626	arg1	modules					1603:1609	nine modules	1598:1609	nine modules	1598:1609	Moreover, weighted gene coexpression network analysis (WGCNA) showed nine modules of glycopeptides, two of which were associated with the AD phenotype.
35960654	5	92	theme	cell	1029:1032	arg1	digests					1042:1048	30 μg HeLa cell tryptic digests	1018:1048	30 μg HeLa cell tryptic digests with reliable quantification performance	1018:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	6	93	theme	fluid	1154:1158	arg1	samples					1166:1172	human cerebrospinal fluid (CSF) samples	1134:1172	human cerebrospinal fluid (CSF) samples	1134:1172	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	2	94	theme	poor	390:393	arg1	efficiency					406:415	poor ionization efficiency	390:415	poor ionization efficiency	390:415	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	6	95	theme	human	1134:1138	arg1	samples					1166:1172	human cerebrospinal fluid (CSF) samples	1134:1172	human cerebrospinal fluid (CSF) samples	1134:1172	Furthermore, this strategy was applied to human cerebrospinal fluid (CSF) samples to differentiate N-glycosylation profiles between Alzheimer's disease (AD) patients and non-AD donors.
35960654	3	96	theme	large	446:450	arg1	amounts					452:458	Relatively large amounts	435:458	Relatively large amounts of starting materials	435:480	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	96	theme	large	446:450	arg1	materials					472:480	starting materials	463:480	starting materials	463:480	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	0	97	theme	Isobaric	22:29	arg1	N-Dimethyl					33:42	N-Dimethyl	33:42	N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis	33:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	0	97	theme	Isobaric	22:29	arg1	N					31:31	Enhanced Isobaric N	13:31	Enhanced Isobaric N	13:31	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	7	98	theme	platelet	1379:1386	arg1	degranulation					1388:1400	platelet degranulation	1379:1400	platelet degranulation	1379:1400	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	2	99	theme	glycopeptides	420:432	arg1	abundance					376:384	low abundance	372:384	low abundance	372:384	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	2	99	theme	glycopeptides	420:432	arg1	efficiency					406:415	poor ionization efficiency	390:415	poor ionization efficiency	390:415	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	7	100	from	involvement	1466:1476	arg1	pathogenesis					1515:1526	AD pathogenesis	1512:1526	AD pathogenesis	1512:1526	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	10	101	theme	significant	1972:1982	arg1	promise					1984:1990	significant promise	1972:1990	significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity	1972:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	3	102	theme	materials	472:480	arg1	amounts					452:458	Relatively large amounts	435:458	Relatively large amounts of starting materials	435:480	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	3	102	theme	materials	472:480	arg1	materials					472:480	starting materials	463:480	starting materials	463:480	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	0	103	theme	Leucine	44:50	arg1	Strategy					60:67	Leucine Tagging Strategy	44:67	N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis	33:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	0	104	dep	Boost-DiLeu	0:10	arg1	N-Dimethyl					33:42	N-Dimethyl	33:42	N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis	33:124	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	0	104	dep	Boost-DiLeu	0:10	arg1	N					31:31	Enhanced Isobaric N	13:31	Enhanced Isobaric N	13:31	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.
35960654	7	105	gly	N-glycosylation	1346:1360	arg1	AD					1365:1366	AD	1365:1366	AD	1365:1366	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	3	106	theme	challenging	627:637	arg1	quantity					613:620	limited quantity	605:620	limited quantity more challenging	605:637	Relatively large amounts of starting materials are needed for the enrichment, which makes the identification and quantification of intact glycopeptides from samples with limited quantity more challenging.
35960654	7	107	theme	dysregulated	1333:1344	arg1	N-glycosylation					1346:1360	dysregulated N-glycosylation	1333:1360	dysregulated N-glycosylation in AD	1333:1366	The results revealed processes and pathways affected by dysregulated N-glycosylation in AD, including platelet degranulation, cell adhesion, and extracellular matrix, which highlighted the involvement of N-glycosylation aberrations in AD pathogenesis.
35960654	10	108	theme	novel	2008:2012	arg1	targets					2026:2032	novel therapeutic targets	2008:2032	novel therapeutic targets	2008:2032	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
35960654	4	109	theme	quantitative	813:824	arg1	analysis					841:848	quantitative glycoproteomic analysis	813:848	quantitative glycoproteomic analysis	813:848	To overcome these limitations, we developed an improved isobaric labeling strategy with an additional boosting channel to enhance N,N-dimethyl leucine (DiLeu) tagging-based quantitative glycoproteomic analysis, termed as Boost-DiLeu.
35960654	2	110	theme	-based	322:327	arg1	analysis					344:351	mass spectrometry (MS)-based glycoproteomic analysis	300:351	mass spectrometry (MS)-based glycoproteomic analysis	300:351	However, mass spectrometry (MS)-based glycoproteomic analysis is hindered by the low abundance and poor ionization efficiency of glycopeptides.
35960654	1	111	theme	glycan	243:248	arg1	composition					261:271	glycan structural composition	243:271	glycan structural composition	243:271	Intact glycopeptide analysis has been of great interest because it can elucidate glycosylation site information and glycan structural composition at the same time.
35960654	5	112	theme	reliable	1055:1062	arg1	performance					1079:1089	reliable quantification performance	1055:1089	reliable quantification performance	1055:1089	With the integration of a one-tube sample processing workflow and high-pH fractionation, 3514 quantifiable N-glycopeptides were identified from 30 μg HeLa cell tryptic digests with reliable quantification performance.
35960654	10	113	theme	biological	2051:2060	arg1	systems					2062:2068	biological systems	2051:2068	biological systems with a limited sample quantity	2051:2099	Taken together, we developed and optimized a strategy for the enhanced comprehensive quantitative intact glycopeptide analysis with DiLeu labeling, showing significant promise for identifying novel therapeutic targets or biomarkers in biological systems with a limited sample quantity.
36215775	7	0	theme	enhanced	1821:1828	arg1	exposure					1833:1840	enhanced MP exposure	1821:1840	enhanced MP exposure	1821:1840	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	3	1	from	changes	645:651	arg1	response					656:663	response	656:663	response	656:663	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	4	2	theme	EPS	1045:1047	arg1	secretion					1049:1057	EPS secretion	1045:1057	EPS secretion	1045:1057	Results showed that 500 mg/L of MP concentration significantly inhibited Microcystis growth by 30.5% but enhanced EPS secretion.
36215775	9	3	theme	interaction	2132:2142	arg1	impact					2105:2110	the eco-physiological impact	2083:2110	the eco-physiological impact of phytoplankton-MP interaction in aquatic environment	2083:2165	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	5	4	theme	polysaccharide/protein	1187:1208	arg1	ratio					1178:1182	the ratio	1174:1182	the ratio of polysaccharide/protein	1174:1208	In addition, organic composition in LB-EPS and TB-EPS varied differently in response to increased MP exposure, as the ratio of polysaccharide/protein increased in the TB-EPS but decreased in LB-EPS.
36215775	2	5	from	substances	348:357	arg1	terms					385:389	terms	385:389	terms of compositions and structures in response to MPs	385:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	9	6	theme	aquatic	2147:2153	arg1	environment					2155:2165	aquatic environment	2147:2165	aquatic environment	2147:2165	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	1	7	theme	phytoplankton	274:286	arg1	biomass					288:294	phytoplankton biomass	274:294	phytoplankton biomass	274:294	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	1	8	theme	aquatic	182:188	arg1	ecosystems					190:199	aquatic ecosystems	182:199	aquatic ecosystems	182:199	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	7	9	from	aromaticity	1738:1748	arg1	fraction					1797:1804	the LB-EPS fraction	1786:1804	the LB-EPS fraction	1786:1804	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	3	10	with	fractions	610:618	arg1	changes					645:651	the time-dependent changes	626:651	the time-dependent changes in response	626:663	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	6	11	theme	component	1320:1328	arg1	variations					1330:1339	organic component variations	1312:1339	organic component variations in response to MPs	1312:1358	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	3	12	dep	Fourier	855:861	arg1	transform					863:871	transform	863:871	transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	863:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	9	13	theme	long-term	2209:2217	arg1	effects					2219:2225	the dose-dependent and long-term effects	2186:2225	the dose-dependent and long-term effects of MPs on phytoplankton	2186:2249	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	6	14	theme	tryptophan-like	1671:1685	arg1	proteins					1687:1694	the tryptophan-like proteins	1667:1694	the tryptophan-like proteins	1667:1694	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	1	15	from	ecosystems	190:199	arg1	ubiquitous					168:177	ubiquitous	168:177	ubiquitous	168:177	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	6	16	from	groups	1571:1576	arg1	LB-EPS					1585:1590	the LB-EPS	1581:1590	the LB-EPS	1581:1590	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	0	17	from	aeruginosa	103:112	arg1	EPS					81:83	EPS	81:83	EPS	81:83	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	0	17	from	aeruginosa	103:112	arg1	substances					69:78	extracellular polymeric substances	45:78	extracellular polymeric substances (EPS) from Microcystis aeruginosa	45:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	0	17	from	aeruginosa	103:112	arg1	properties					31:40	the physicochemical properties	11:40	the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa	11:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	6	18	theme	obvious	1285:1291	arg1	heterogeneities					1293:1307	obvious heterogeneities	1285:1307	obvious heterogeneities in organic component variations in response to MPs	1285:1358	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	6	19	theme	functional	1560:1569	arg1	groups					1571:1576	the carbonyl, carboxyl and amino functional groups	1527:1576	groups	1571:1576	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	6	20	theme	enhanced	1644:1651	arg1	percentage					1653:1662	the enhanced percentage	1640:1662	the enhanced percentage of the tryptophan-like proteins	1640:1694	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	9	21	theme	MPs	2230:2232	arg1	effects					2219:2225	the dose-dependent and long-term effects	2186:2225	the dose-dependent and long-term effects of MPs on phytoplankton	2186:2249	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	6	22	theme	functional	1372:1381	arg1	groups					1383:1388	the C-O functional groups	1364:1388	the C-O functional groups	1364:1388	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	3	23	with	EPS	566:568	arg1	changes					645:651	the time-dependent changes	626:651	the time-dependent changes in response	626:663	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	7	24	theme	organic	1712:1718	arg1	compositions					1720:1731	organic compositions	1712:1731	organic compositions	1712:1731	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	4	25	theme	MP	963:964	arg1	concentration					966:978	MP concentration	963:978	MP concentration	963:978	Results showed that 500 mg/L of MP concentration significantly inhibited Microcystis growth by 30.5% but enhanced EPS secretion.
36215775	9	26	from	understanding	2066:2078	arg1	impact					2105:2110	the eco-physiological impact	2083:2110	the eco-physiological impact of phytoplankton-MP interaction in aquatic environment	2083:2165	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	6	27	from	groups	1383:1388	arg1	TB-EPS					1418:1423	the TB-EPS	1414:1423	the TB-EPS	1414:1423	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	0	28	from	Changes	0:6	arg1	response					117:124	response	117:124	response to microplastics	117:141	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	3	29	theme	excitation	765:774	arg1	matrix					785:790	the fluorescence excitation emission matrix	748:790	the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	748:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	8	30	theme	EPS	1970:1972	arg1	contents					1974:1981	the EPS contents	1966:1981	not only the EPS contents but also the compositions in response to MPs exposure	1957:2035	Therefore, Microcystis can dynamically adjust not only the EPS contents but also the compositions in response to MPs exposure.
36215775	5	31	theme	organic	1073:1079	arg1	composition					1081:1091	organic composition	1073:1091	organic composition in LB-EPS and TB-EPS	1073:1112	In addition, organic composition in LB-EPS and TB-EPS varied differently in response to increased MP exposure, as the ratio of polysaccharide/protein increased in the TB-EPS but decreased in LB-EPS.
36215775	2	32	theme	compositions	394:405	arg1	terms					385:389	terms	385:389	terms of compositions and structures in response to MPs	385:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	0	33	from	properties	31:40	arg1	aeruginosa					103:112	Microcystis aeruginosa	91:112	Microcystis aeruginosa	91:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	5	34	theme	MP	1158:1159	arg1	exposure					1161:1168	increased MP exposure	1148:1168	increased MP exposure	1148:1168	In addition, organic composition in LB-EPS and TB-EPS varied differently in response to increased MP exposure, as the ratio of polysaccharide/protein increased in the TB-EPS but decreased in LB-EPS.
36215775	7	35	theme	MPs	1906:1908	arg1	result					1855:1860	a result	1853:1860	a result	1853:1860	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	7	35	theme	MPs	1906:1908	arg1	risk					1898:1901	the ecotoxicological risk	1877:1901	the ecotoxicological risk of MPs	1877:1908	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	3	36	theme	2D-FTIR-COS	908:918	arg1	analysis					921:928	correlation spectroscopy (2D-FTIR-COS) analysis	882:928	correlation spectroscopy (2D-FTIR-COS) analysis	882:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	7	37	theme	LB-EPS	1790:1795	arg1	fraction					1797:1804	the LB-EPS fraction	1786:1804	the LB-EPS fraction	1786:1804	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	5	38	from	composition	1081:1091	arg1	TB-EPS					1107:1112	TB-EPS	1107:1112	TB-EPS	1107:1112	In addition, organic composition in LB-EPS and TB-EPS varied differently in response to increased MP exposure, as the ratio of polysaccharide/protein increased in the TB-EPS but decreased in LB-EPS.
36215775	5	38	from	composition	1081:1091	arg1	LB-EPS					1096:1101	LB-EPS	1096:1101	LB-EPS	1096:1101	In addition, organic composition in LB-EPS and TB-EPS varied differently in response to increased MP exposure, as the ratio of polysaccharide/protein increased in the TB-EPS but decreased in LB-EPS.
36215775	3	39	theme	spectroscopy	894:905	arg1	analysis					921:928	correlation spectroscopy (2D-FTIR-COS) analysis	882:928	correlation spectroscopy (2D-FTIR-COS) analysis	882:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	2	40	theme	structures	411:420	arg1	terms					385:389	terms	385:389	terms of compositions and structures in response to MPs	385:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	0	41	theme	properties	31:40	arg1	Changes					0:6	Changes	0:6	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.	0:142	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	6	42	from	heterogeneities	1293:1307	arg1	variations					1330:1339	organic component variations	1312:1339	organic component variations in response to MPs	1312:1358	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	2	43	from	terms	385:389	arg1	substances					348:357	the extracellular polymeric substances	320:357	the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs	320:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	43	from	terms	385:389	arg1	EPS					360:362	EPS	360:362	EPS	360:362	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	43	from	terms	385:389	arg1	response					425:432	response	425:432	response to MPs	425:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	4	44	theme	Microcystis	1004:1014	arg1	growth					1016:1021	Microcystis growth	1004:1021	Microcystis growth	1004:1021	Results showed that 500 mg/L of MP concentration significantly inhibited Microcystis growth by 30.5% but enhanced EPS secretion.
36215775	0	45	theme	substances	69:78	arg1	properties					31:40	the physicochemical properties	11:40	the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa	11:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	0	46	theme	extracellular	45:57	arg1	EPS					81:83	EPS	81:83	EPS	81:83	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	0	46	theme	extracellular	45:57	arg1	substances					69:78	extracellular polymeric substances	45:78	extracellular polymeric substances (EPS) from Microcystis aeruginosa	45:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	2	47	from	compositions	394:405	arg1	response					425:432	response	425:432	response to MPs	425:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	3	48	theme	bound	591:595	arg1	fractions					610:618	tightly bound EPS (TB-EPS) fractions	583:618	tightly bound EPS (TB-EPS) fractions	583:618	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	2	49	theme	polymeric	338:346	arg1	substances					348:357	the extracellular polymeric substances	320:357	the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs	320:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	49	theme	polymeric	338:346	arg1	EPS					360:362	EPS	360:362	EPS	360:362	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	7	50	theme	MP	1830:1831	arg1	exposure					1833:1840	enhanced MP exposure	1821:1840	enhanced MP exposure	1821:1840	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	2	51	from	variations	306:315	arg1	substances					348:357	the extracellular polymeric substances	320:357	the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs	320:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	51	from	variations	306:315	arg1	EPS					360:362	EPS	360:362	EPS	360:362	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	52	theme	phytoplankton	368:380	arg1	substances					348:357	the extracellular polymeric substances	320:357	the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs	320:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	52	theme	phytoplankton	368:380	arg1	EPS					360:362	EPS	360:362	EPS	360:362	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	6	53	theme	glycosidic	1394:1403	arg1	bonds					1405:1409	glycosidic bonds	1394:1409	glycosidic bonds in the TB-EPS	1394:1423	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	2	54	from	response	425:432	arg1	terms					385:389	terms	385:389	terms of compositions and structures in response to MPs	385:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	6	55	from	variations	1330:1339	arg1	response					1344:1351	response	1344:1351	response to MPs	1344:1358	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	3	56	theme	different	668:676	arg1	500 mg/L					706:713	500 mg/L	706:713	500 mg/L	706:713	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	56	theme	different	668:676	arg1	10					694:695	10	694:695	10	694:695	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	56	theme	different	668:676	arg1	concentrations					678:691	different concentrations	668:691	different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	668:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	9	57	theme	phytoplankton-MP	2115:2130	arg1	interaction					2132:2142	phytoplankton-MP interaction	2115:2142	phytoplankton-MP interaction	2115:2142	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	6	58	theme	Further	1259:1265	arg1	analysis					1267:1274	Further analysis	1259:1274	Further analysis	1259:1274	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	6	59	theme	carboxyl	1541:1548	arg1	groups					1571:1576	the carbonyl, carboxyl and amino functional groups	1527:1576	groups	1571:1576	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	6	60	theme	carbonyl	1531:1538	arg1	groups					1571:1576	the carbonyl, carboxyl and amino functional groups	1527:1576	groups	1571:1576	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	9	61	from	impact	2105:2110	arg1	environment					2155:2165	aquatic environment	2147:2165	aquatic environment	2147:2165	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	3	62	theme	bound	560:564	arg1	LB-EPS					571:576	LB-EPS	571:576	LB-EPS	571:576	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	62	theme	bound	560:564	arg1	EPS					566:568	loosely bound EPS	552:568	loosely bound EPS (LB-EPS)	552:577	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	2	63	from	phytoplankton	368:380	arg1	terms					385:389	terms	385:389	terms of compositions and structures in response to MPs	385:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	6	64	theme	substances	1509:1518	arg1	domination					1469:1478	the domination	1465:1478	the domination of polysaccharides and humus substances	1465:1518	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	6	65	theme	proteins	1687:1694	arg1	percentage					1653:1662	the enhanced percentage	1640:1662	the enhanced percentage of the tryptophan-like proteins	1640:1694	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	9	66	theme	dose-dependent	2190:2203	arg1	effects					2219:2225	the dose-dependent and long-term effects	2186:2225	the dose-dependent and long-term effects of MPs on phytoplankton	2186:2249	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	6	67	theme	organic	1312:1318	arg1	variations					1330:1339	organic component variations	1312:1339	organic component variations in response to MPs	1312:1358	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	3	68	dep	transform	863:871	arg1	infrared					873:880	infrared	873:880	transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	863:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	69	theme	MPs	719:721	arg1	500 mg/L					706:713	500 mg/L	706:713	500 mg/L	706:713	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	69	theme	MPs	719:721	arg1	10					694:695	10	694:695	10	694:695	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	69	theme	MPs	719:721	arg1	concentrations					678:691	different concentrations	668:691	different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	668:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	9	70	from	effects	2219:2225	arg1	phytoplankton					2237:2249	phytoplankton	2237:2249	phytoplankton	2237:2249	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	3	71	theme	EPS	597:599	arg1	fractions					610:618	tightly bound EPS (TB-EPS) fractions	583:618	tightly bound EPS (TB-EPS) fractions	583:618	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	8	72	from	contents	1974:1981	arg1	response					2012:2019	response	2012:2019	response to MPs exposure	2012:2035	Therefore, Microcystis can dynamically adjust not only the EPS contents but also the compositions in response to MPs exposure.
36215775	3	73	theme	fluorescence	752:763	arg1	matrix					785:790	the fluorescence excitation emission matrix	748:790	the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	748:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	6	74	from	bonds	1405:1409	arg1	TB-EPS					1418:1423	the TB-EPS	1414:1423	the TB-EPS	1414:1423	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	6	75	theme	amino	1554:1558	arg1	groups					1571:1576	the carbonyl, carboxyl and amino functional groups	1527:1576	groups	1571:1576	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	3	76	theme	parallel	805:812	arg1	factor					814:819	parallel factor	805:819	parallel factor (EEM-PARAFAC)	805:833	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	76	theme	parallel	805:812	arg1	EEM-PARAFAC					822:832	EEM-PARAFAC	822:832	EEM-PARAFAC	822:832	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	6	77	theme	C-O	1368:1370	arg1	groups					1383:1388	the C-O functional groups	1364:1388	the C-O functional groups	1364:1388	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	1	78	from	ubiquitous	168:177	arg1	ecosystems					190:199	aquatic ecosystems	182:199	aquatic ecosystems	182:199	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	3	79	theme	two-dimensional	839:853	arg1	Fourier					855:861	two-dimensional Fourier	839:861	two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	839:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	8	80	from	compositions	1996:2007	arg1	response					2012:2019	response	2012:2019	response to MPs exposure	2012:2035	Therefore, Microcystis can dynamically adjust not only the EPS contents but also the compositions in response to MPs exposure.
36215775	2	81	from	structures	411:420	arg1	response					425:432	response	425:432	response to MPs	425:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	7	82	dep	aromaticity	1738:1748	arg1	the					1734:1736	the	1734:1736	the	1734:1736	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	6	83	theme	humus	1503:1507	arg1	substances					1509:1518	humus substances	1503:1518	humus substances	1503:1518	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	3	84	theme	emission	776:783	arg1	matrix					785:790	the fluorescence excitation emission matrix	748:790	the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis	748:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	85	theme	correlation	882:892	arg1	analysis					921:928	correlation spectroscopy (2D-FTIR-COS) analysis	882:928	correlation spectroscopy (2D-FTIR-COS) analysis	882:928	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	9	86	theme	future	2275:2280	arg1	study					2282:2286	future study	2275:2286	future study	2275:2286	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	6	87	theme	preferential	1604:1615	arg1	response					1617:1624	a preferential response	1602:1624	a preferential response	1602:1624	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	0	88	theme	physicochemical	15:29	arg1	properties					31:40	the physicochemical properties	11:40	the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa	11:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	1	89	theme	biomass	288:294	arg1	growth					237:242	growth	237:242	growth	237:242	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	1	89	theme	biomass	288:294	arg1	functions					261:269	functions	261:269	functions	261:269	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	1	89	theme	biomass	288:294	arg1	aggregation					245:255	aggregation	245:255	aggregation	245:255	Microplastics (MPs) are ubiquitous in aquatic ecosystems and can significantly influence the growth, aggregation and functions of phytoplankton biomass.
36215775	7	90	theme	ecotoxicological	1881:1896	arg1	result					1855:1860	a result	1853:1860	a result	1853:1860	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	7	90	theme	ecotoxicological	1881:1896	arg1	risk					1898:1901	the ecotoxicological risk	1877:1901	the ecotoxicological risk of MPs	1877:1908	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	8	91	theme	MPs	2024:2026	arg1	exposure					2028:2035	MPs exposure	2024:2035	MPs exposure	2024:2035	Therefore, Microcystis can dynamically adjust not only the EPS contents but also the compositions in response to MPs exposure.
36215775	4	92	theme	concentration	966:978	arg1	500 mg/L					951:958	500 mg/L	951:958	500 mg/L of MP concentration	951:978	Results showed that 500 mg/L of MP concentration significantly inhibited Microcystis growth by 30.5% but enhanced EPS secretion.
36215775	3	93	theme	TB-EPS	602:607	arg1	fractions					610:618	tightly bound EPS (TB-EPS) fractions	583:618	tightly bound EPS (TB-EPS) fractions	583:618	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	0	94	theme	polymeric	59:67	arg1	EPS					81:83	EPS	81:83	EPS	81:83	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	0	94	theme	polymeric	59:67	arg1	substances					69:78	extracellular polymeric substances	45:78	extracellular polymeric substances (EPS) from Microcystis aeruginosa	45:112	Changes of the physicochemical properties of extracellular polymeric substances (EPS) from Microcystis aeruginosa in response to microplastics.
36215775	7	95	from	hydrophobicity	1751:1764	arg1	fraction					1797:1804	the LB-EPS fraction	1786:1804	the LB-EPS fraction	1786:1804	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	3	96	theme	time-dependent	630:643	arg1	changes					645:651	the time-dependent changes	626:651	the time-dependent changes in response	626:663	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	3	97	theme	EPS	481:483	arg1	matrix					485:490	EPS matrix	481:490	EPS matrix of Microsystis aeruginosa	481:516	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36215775	6	98	theme	polysaccharides	1483:1497	arg1	domination					1469:1478	the domination	1465:1478	the domination of polysaccharides and humus substances	1465:1518	Further analysis revealed obvious heterogeneities in organic component variations in response to MPs, as the C-O functional groups and glycosidic bonds in the TB-EPS preferentially responded, which lead to the domination of polysaccharides and humus substances; while the carbonyl, carboxyl and amino functional groups in the LB-EPS exhibited a preferential response, which caused the enhanced percentage of the tryptophan-like proteins.
36215775	5	99	theme	increased	1148:1156	arg1	exposure					1161:1168	increased MP exposure	1148:1168	increased MP exposure	1148:1168	In addition, organic composition in LB-EPS and TB-EPS varied differently in response to increased MP exposure, as the ratio of polysaccharide/protein increased in the TB-EPS but decreased in LB-EPS.
36215775	7	100	from	humification	1770:1781	arg1	fraction					1797:1804	the LB-EPS fraction	1786:1804	the LB-EPS fraction	1786:1804	In addition to organic compositions, the aromaticity, hydrophobicity and humification in the LB-EPS fraction increased with enhanced MP exposure, which, as a result, may influence the ecotoxicological risk of MPs.
36215775	2	101	theme	extracellular	324:336	arg1	substances					348:357	the extracellular polymeric substances	320:357	the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs	320:439	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	2	101	theme	extracellular	324:336	arg1	EPS					360:362	EPS	360:362	EPS	360:362	However, variations in the extracellular polymeric substances (EPS) of phytoplankton in terms of compositions and structures in response to MPs were still not reported.
36215775	9	102	theme	eco-physiological	2087:2103	arg1	impact					2105:2110	the eco-physiological impact	2083:2110	the eco-physiological impact of phytoplankton-MP interaction in aquatic environment	2083:2165	The results can improve our understanding on the eco-physiological impact of phytoplankton-MP interaction in aquatic environment, and indicate that the dose-dependent and long-term effects of MPs on phytoplankton should be considered in future study.
36215775	3	103	theme	aeruginosa	507:516	arg1	matrix					485:490	EPS matrix	481:490	EPS matrix of Microsystis aeruginosa	481:516	In this study, EPS matrix of Microsystis aeruginosa was applied and fractionated into loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS) fractions, with the time-dependent changes in response to different concentrations (10, 100 and 500 mg/L) of MPs being explored via using the fluorescence excitation emission matrix coupled with parallel factor (EEM-PARAFAC) and two-dimensional Fourier transform infrared correlation spectroscopy (2D-FTIR-COS) analysis.
36708900	2	0	theme	composites	595:604	arg1	diameter					579:586	the hydrodynamic mean diameter	557:586	the hydrodynamic mean diameter of the composites	557:604	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	2	0	theme	composites	595:604	arg1	crystallinity					540:552	crystallinity	540:552	crystallinity	540:552	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	1	1	from	hydrophobicity	175:188	arg1	effect					137:142	the effect	133:142	the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites	133:279	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	2	theme	difference	157:166	arg1	effect					137:142	the effect	133:142	the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites	133:279	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	4	3	theme	FA	874:875	arg1	length					864:869	chain length	858:869	chain length of FA	858:875	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	6	4	theme	FA	1121:1122	arg1	release					1110:1116	the release	1106:1116	the release of FA by in vitro digestion	1106:1144	For longer FA, composite storage stability increased, but the release of FA by in vitro digestion was delayed.
36708900	0	5	theme	starch	67:72	arg1	properties					53:62	physicochemical properties	37:62	physicochemical properties of starch	37:72	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	1	6	from	difference	157:166	arg1	hydrophobicity					175:188	the hydrophobicity	171:188	the hydrophobicity of core material	171:205	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	7	theme	composites	270:279	arg1	properties					252:261	physicochemical properties	236:261	physicochemical properties of the composites	236:279	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	7	theme	composites	270:279	arg1	process					224:230	encapsulation process	210:230	encapsulation process	210:230	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	0	8	from	Effect	0:5	arg1	properties					53:62	physicochemical properties	37:62	physicochemical properties of starch	37:72	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	1	9	dep	difference	157:166	arg1	elaborate					147:155	elaborate	147:155	elaborate	147:155	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	4	10	theme	chain	858:862	arg1	length					864:869	chain length	858:869	chain length of FA	858:875	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	5	11	theme	composites	946:955	arg1	activity					930:937	the emulsification activity	911:937	the emulsification activity of the composites	911:955	The incorporation of FA enhanced the emulsification activity of the composites, and this result revealed that the composites could be applied as an emulsification agent.
36708900	3	12	dep	22	654:655	arg1	to					651:652	to	651:652	to	651:652	As the chain length of FA increased from 12 to 22, FA content in the composites increased from 1.69 to 14.85 mg/g composite.
36708900	2	13	dep	Vh-amylose	446:455	arg1	cell					474:477	crystalline unit cell	457:477	a Vh-amylose crystalline unit cell	444:477	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	6	14	theme	in	1127:1128	arg1	digestion					1136:1144	in vitro digestion	1127:1144	in vitro digestion	1127:1144	For longer FA, composite storage stability increased, but the release of FA by in vitro digestion was delayed.
36708900	6	15	theme	longer	1052:1057	arg1	FA					1059:1060	longer FA	1052:1060	longer FA	1052:1060	For longer FA, composite storage stability increased, but the release of FA by in vitro digestion was delayed.
36708900	4	16	theme	absorption	736:745	arg1	analyses					747:754	The absorption analyses	732:754	The absorption analyses of Rose Bengal on the composite surfaces	732:795	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	2	17	theme	unit	469:472	arg1	cell					474:477	crystalline unit cell	457:477	a Vh-amylose crystalline unit cell	444:477	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	2	18	theme	chain	488:492	arg1	length					494:499	the chain length	484:499	the chain length of FA	484:505	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	1	19	from	effect	137:142	arg1	properties					252:261	physicochemical properties	236:261	physicochemical properties of the composites	236:279	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	19	from	effect	137:142	arg1	hydrophobicity					175:188	the hydrophobicity	171:188	the hydrophobicity of core material	171:205	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	19	from	effect	137:142	arg1	process					224:230	encapsulation process	210:230	encapsulation process	210:230	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	0	20	dep	nanocomposites	74:87	arg1	obtained					89:96	obtained	89:96	nanocomposites obtained via nanoprecipitation	74:118	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	2	21	theme	diffraction	390:400	arg1	analyses					402:409	X-ray diffraction analyses	384:409	X-ray diffraction analyses	384:409	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	2	22	theme	crystalline	457:467	arg1	cell					474:477	crystalline unit cell	457:477	a Vh-amylose crystalline unit cell	444:477	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	3	23	theme	14.85 mg/g	710:719	arg1	composite					721:729	14.85 mg/g composite	710:729	14.85 mg/g composite	710:729	As the chain length of FA increased from 12 to 22, FA content in the composites increased from 1.69 to 14.85 mg/g composite.
36708900	5	24	theme	emulsification	1026:1039	arg1	composites					992:1001	the composites	988:1001	the composites	988:1001	The incorporation of FA enhanced the emulsification activity of the composites, and this result revealed that the composites could be applied as an emulsification agent.
36708900	5	24	theme	emulsification	1026:1039	arg1	agent					1041:1045	an emulsification agent	1023:1045	an emulsification agent	1023:1045	The incorporation of FA enhanced the emulsification activity of the composites, and this result revealed that the composites could be applied as an emulsification agent.
36708900	5	25	theme	emulsification	915:928	arg1	activity					930:937	the emulsification activity	911:937	the emulsification activity of the composites	911:955	The incorporation of FA enhanced the emulsification activity of the composites, and this result revealed that the composites could be applied as an emulsification agent.
36708900	1	26	theme	core	193:196	arg1	material					198:205	core material	193:205	core material	193:205	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	0	27	theme	acid	16:19	arg1	length					27:32	fatty acid chain length	10:32	fatty acid chain length	10:32	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	1	28	theme	starch	296:301	arg1	FA					307:308	FA	307:308	FA	307:308	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	28	theme	starch	296:301	arg1	starch					296:301	starch	296:301	starch	296:301	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	28	theme	starch	296:301	arg1	composites					282:291	composites	282:291	composites of starch and FA with various chain lengths (C:12-22)	282:345	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	4	29	from	analyses	747:754	arg1	surfaces					788:795	the composite surfaces	774:795	the composite surfaces	774:795	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	1	30	theme	material	198:205	arg1	hydrophobicity					175:188	the hydrophobicity	171:188	the hydrophobicity of core material	171:205	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	0	31	theme	fatty	10:14	arg1	length					27:32	fatty acid chain length	10:32	fatty acid chain length	10:32	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	3	32	theme	FA	630:631	arg1	length					620:625	the chain length	610:625	the chain length of FA	610:631	As the chain length of FA increased from 12 to 22, FA content in the composites increased from 1.69 to 14.85 mg/g composite.
36708900	0	33	theme	length	27:32	arg1	Effect					0:5	Effect	0:5	Effect of fatty acid chain length on physicochemical properties of starch	0:72	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	1	34	theme	FA	307:308	arg1	FA					307:308	FA	307:308	FA	307:308	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	34	theme	FA	307:308	arg1	starch					296:301	starch	296:301	starch	296:301	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	34	theme	FA	307:308	arg1	composites					282:291	composites	282:291	composites of starch and FA with various chain lengths (C:12-22)	282:345	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	4	35	theme	composite	778:786	arg1	surfaces					788:795	the composite surfaces	774:795	the composite surfaces	774:795	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	2	36	theme	X-ray	384:388	arg1	analyses					402:409	X-ray diffraction analyses	384:409	X-ray diffraction analyses	384:409	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	1	37	theme	encapsulation	210:222	arg1	process					224:230	encapsulation process	210:230	encapsulation process	210:230	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	0	38	theme	chain	21:25	arg1	length					27:32	fatty acid chain length	10:32	fatty acid chain length	10:32	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	2	39	theme	clear	524:528	arg1	change					530:535	a clear change	522:535	a clear change in crystallinity or the hydrodynamic mean diameter of the composites	522:604	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	0	40	theme	physicochemical	37:51	arg1	properties					53:62	physicochemical properties	37:62	physicochemical properties of starch	37:72	Effect of fatty acid chain length on physicochemical properties of starch nanocomposites obtained via nanoprecipitation.
36708900	1	41	theme	various	315:321	arg1	C:12-22					338:344	C:12-22	338:344	C:12-22	338:344	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	41	theme	various	315:321	arg1	lengths					329:335	various chain lengths	315:335	various chain lengths (C:12-22)	315:345	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	2	42	theme	mean	574:577	arg1	diameter					579:586	the hydrodynamic mean diameter	557:586	the hydrodynamic mean diameter of the composites	557:604	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	1	43	with	composites	282:291	arg1	C:12-22					338:344	C:12-22	338:344	C:12-22	338:344	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	43	with	composites	282:291	arg1	lengths					329:335	various chain lengths	315:335	various chain lengths (C:12-22)	315:345	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	3	44	theme	FA	658:659	arg1	content					661:667	FA content	658:667	FA content in the composites	658:685	As the chain length of FA increased from 12 to 22, FA content in the composites increased from 1.69 to 14.85 mg/g composite.
36708900	1	45	theme	chain	323:327	arg1	C:12-22					338:344	C:12-22	338:344	C:12-22	338:344	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	1	45	theme	chain	323:327	arg1	lengths					329:335	various chain lengths	315:335	various chain lengths (C:12-22)	315:345	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	2	46	theme	hydrodynamic	561:572	arg1	diameter					579:586	the hydrodynamic mean diameter	557:586	the hydrodynamic mean diameter of the composites	557:604	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	4	47	theme	Rose	759:762	arg1	Bengal					764:769	Rose Bengal	759:769	Rose Bengal	759:769	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	5	48	theme	FA	899:900	arg1	incorporation					882:894	The incorporation	878:894	The incorporation of FA	878:900	The incorporation of FA enhanced the emulsification activity of the composites, and this result revealed that the composites could be applied as an emulsification agent.
36708900	2	49	from	change	530:535	arg1	diameter					579:586	the hydrodynamic mean diameter	557:586	the hydrodynamic mean diameter of the composites	557:604	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	2	49	from	change	530:535	arg1	crystallinity					540:552	crystallinity	540:552	crystallinity	540:552	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	3	50	theme	chain	614:618	arg1	length					620:625	the chain length	610:625	the chain length of FA	610:631	As the chain length of FA increased from 12 to 22, FA content in the composites increased from 1.69 to 14.85 mg/g composite.
36708900	1	51	theme	physicochemical	236:250	arg1	properties					252:261	physicochemical properties	236:261	physicochemical properties of the composites	236:279	To evaluate the effect of elaborate difference in the hydrophobicity of core material on encapsulation process and physicochemical properties of the composites, composites of starch and FA with various chain lengths (C:12-22) were prepared via nanoprecipitation.
36708900	2	52	theme	FA	504:505	arg1	length					494:499	the chain length	484:499	the chain length of FA	484:505	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	2	53	contain	had	440:442	arg1	composites					429:438	all composites	425:438	all composites	425:438	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	2	53	contain	had	440:442	arg2	Vh-amylose					446:455	a Vh-amylose crystalline unit cell	444:477	a Vh-amylose crystalline unit cell	444:477	X-ray diffraction analyses revealed that all composites had a Vh-amylose crystalline unit cell, but the chain length of FA did not induce a clear change in crystallinity or the hydrodynamic mean diameter of the composites.
36708900	6	54	dep	in	1127:1128	arg1	vitro					1130:1134	vitro	1130:1134	vitro	1130:1134	For longer FA, composite storage stability increased, but the release of FA by in vitro digestion was delayed.
36708900	6	55	theme	storage	1073:1079	arg1	stability					1081:1089	composite storage stability	1063:1089	composite storage stability	1063:1089	For longer FA, composite storage stability increased, but the release of FA by in vitro digestion was delayed.
36708900	3	56	from	content	661:667	arg1	composites					676:685	the composites	672:685	the composites	672:685	As the chain length of FA increased from 12 to 22, FA content in the composites increased from 1.69 to 14.85 mg/g composite.
36708900	4	57	theme	Bengal	764:769	arg1	analyses					747:754	The absorption analyses	732:754	The absorption analyses of Rose Bengal on the composite surfaces	732:795	The absorption analyses of Rose Bengal on the composite surfaces revealed that their hydrophobicity increased with increasing chain length of FA.
36708900	6	58	theme	composite	1063:1071	arg1	stability					1081:1089	composite storage stability	1063:1089	composite storage stability	1063:1089	For longer FA, composite storage stability increased, but the release of FA by in vitro digestion was delayed.
36870665	0	0	theme	green	93:97	arg1	approach					99:106	sustainable green approach	81:106	sustainable green approach	81:106	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	6	1	theme	drug	822:825	arg1	network					867:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network	822:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive	822:903	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	6	2	theme	antibiotic	778:787	arg1	meropenem					794:802	antibiotic drug meropenem	778:802	antibiotic drug meropenem	778:802	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	0	3	theme	sustainable	81:91	arg1	approach					99:106	sustainable green approach	81:106	sustainable green approach	81:106	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	3	4	theme	reducing	547:554	arg1	agent					556:560	reducing agent	547:560	reducing agent	547:560	UV-Vis spectra indicated the formation of AgNPs using GA as reducing agent.
36870665	1	5	theme	green	332:336	arg1	approach					338:345	green approach	332:345	green approach for use in drug delivery (DD)	332:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	9	6	theme	Mucoadhesive	1111:1122	arg1	property					1124:1131	Mucoadhesive property	1111:1131	Mucoadhesive property	1111:1131	Mucoadhesive property exhibited by copolymers because of supra-molecular interactions.
36870665	10	7	dep	bacteria	1261:1268	arg1	flexneri					1273:1280	S. flexneri	1270:1280	bacteria S. flexneri	1261:1280	Antimicrobial characteristics were shown by copolymers against bacteria S. flexneri, P. auroginosa, and B. cereus.
36870665	8	8	theme	biocompatible	1069:1081	arg1	characteristics					1083:1097	biocompatible characteristics	1069:1097	biocompatible characteristics of polymer	1069:1108	The polymer-blood interaction demonstrated biocompatible characteristics of polymer.
36870665	7	9	theme	polymer-drug	1000:1011	arg1	interaction					1013:1023	polymer-drug interaction	1000:1023	polymer-drug interaction	1000:1023	Sustained release was due to polymer-drug interaction.
36870665	10	10	theme	S.	1270:1271	arg1	flexneri					1273:1280	S. flexneri	1270:1280	bacteria S. flexneri	1261:1280	Antimicrobial characteristics were shown by copolymers against bacteria S. flexneri, P. auroginosa, and B. cereus.
36870665	8	11	theme	polymer	1102:1108	arg1	characteristics					1083:1097	biocompatible characteristics	1069:1097	biocompatible characteristics of polymer	1069:1108	The polymer-blood interaction demonstrated biocompatible characteristics of polymer.
36870665	6	12	theme	meropenem	794:802	arg1	diffusion					765:773	The non-Fickian diffusion	749:773	The non-Fickian diffusion of antibiotic drug meropenem	749:802	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	6	13	theme	kinetic	956:962	arg1	model					964:968	Korsmeyer-Peppas kinetic model	939:968	Korsmeyer-Peppas kinetic model	939:968	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	5	14	theme	polymer	692:698	arg1	stability					679:687	thermal stability	671:687	thermal stability of polymer enhanced by grafting and incorporation of AgNPs	671:746	TGA inferred thermal stability of polymer enhanced by grafting and incorporation of AgNPs.
36870665	6	15	theme	drug	789:792	arg1	meropenem					794:802	antibiotic drug meropenem	778:802	antibiotic drug meropenem	778:802	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	0	16	theme	gum	12:14	arg1	polysaccharides					16:30	Fabricating gum polysaccharides	0:30	Fabricating gum polysaccharides	0:30	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	6	17	theme	-cl-poly	853:860	arg1	network					867:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network	822:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive	822:903	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	7	18	theme	Sustained	971:979	arg1	release					981:987	Sustained release	971:987	Sustained release	971:987	Sustained release was due to polymer-drug interaction.
36870665	1	19	theme	potential	201:209	arg1	exploration					186:196	exploration	186:196	exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD)	186:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	0	20	theme	Fabricating	0:10	arg1	polysaccharides					16:30	Fabricating gum polysaccharides	0:30	Fabricating gum polysaccharides	0:30	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	6	21	theme	Korsmeyer-Peppas	939:954	arg1	model					964:968	Korsmeyer-Peppas kinetic model	939:968	Korsmeyer-Peppas kinetic model	939:968	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	0	22	theme	based	32:36	arg1	nano-composites					38:52	Fabricating gum polysaccharides based nano-composites	0:52	Fabricating gum polysaccharides based nano-composites for drug delivery	0:70	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	6	23	theme	AAm	862:864	arg1	network					867:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network	822:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive	822:903	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	1	24	theme	Recent	109:114	arg1	advancements					116:127	Recent advancements	109:127	Recent advancements in development of natural polymer nono-composites	109:177	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	25	theme	gum	214:216	arg1	acacia					218:223	gum acacia	214:223	gum acacia (GA)	214:228	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	25	theme	gum	214:216	arg1	GA					226:227	GA	226:227	GA	226:227	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	26	theme	silver	268:273	arg1	AgNPs					290:294	AgNPs	290:294	AgNPs	290:294	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	26	theme	silver	268:273	arg1	nanoparticles					275:287	silver nanoparticles	268:287	silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD)	268:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	27	theme	drug	358:361	arg1	DD					373:374	DD	373:374	DD	373:374	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	27	theme	drug	358:361	arg1	delivery					363:370	drug delivery	358:370	drug delivery (DD)	358:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	4	28	theme	copolymeric	627:637	arg1	hydrogels					647:655	the copolymeric network hydrogels	623:655	the copolymeric network hydrogels	623:655	TEM, SEM, XPS and XRD revealed impregnation of AgNPs inside the copolymeric network hydrogels.
36870665	1	29	theme	acacia	218:223	arg1	potential					201:209	potential	201:209	potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD)	201:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	5	30	theme	thermal	671:677	arg1	stability					679:687	thermal stability	671:687	thermal stability of polymer enhanced by grafting and incorporation of AgNPs	671:746	TGA inferred thermal stability of polymer enhanced by grafting and incorporation of AgNPs.
36870665	1	31	theme	nanoparticles	275:287	arg1	design					258:263	design	258:263	design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD)	258:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	5	32	theme	AgNPs	742:746	arg1	incorporation					725:737	incorporation	725:737	incorporation	725:737	TGA inferred thermal stability of polymer enhanced by grafting and incorporation of AgNPs.
36870665	5	32	theme	AgNPs	742:746	arg1	grafting					712:719	grafting	712:719	grafting	712:719	TGA inferred thermal stability of polymer enhanced by grafting and incorporation of AgNPs.
36870665	6	33	theme	non-Fickian	753:763	arg1	diffusion					765:773	The non-Fickian diffusion	749:773	The non-Fickian diffusion of antibiotic drug meropenem	749:802	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	2	34	theme	copolymers	395:404	arg1	formation					382:390	The formation	378:390	The formation of copolymers	378:404	The formation of copolymers was confirmed by UV-Vis spectroscopy, TEM, SEM, AFM, XPS, XRD, FTIR,TGA and DSC.
36870665	4	35	theme	network	639:645	arg1	hydrogels					647:655	the copolymeric network hydrogels	623:655	the copolymeric network hydrogels	623:655	TEM, SEM, XPS and XRD revealed impregnation of AgNPs inside the copolymeric network hydrogels.
36870665	2	36	theme	UV-Vis	423:428	arg1	spectroscopy					430:441	UV-Vis spectroscopy	423:441	UV-Vis spectroscopy	423:441	The formation of copolymers was confirmed by UV-Vis spectroscopy, TEM, SEM, AFM, XPS, XRD, FTIR,TGA and DSC.
36870665	6	37	theme	AgNPs	847:851	arg1	network					867:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network	822:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive	822:903	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	3	38	theme	UV-Vis	487:492	arg1	spectra					494:500	UV-Vis spectra	487:500	UV-Vis spectra	487:500	UV-Vis spectra indicated the formation of AgNPs using GA as reducing agent.
36870665	0	39	theme	drug	58:61	arg1	delivery					63:70	drug delivery	58:70	drug delivery	58:70	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	6	40	theme	encapsulated	827:838	arg1	network					867:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network	822:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive	822:903	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	1	41	theme	nono-composites	163:177	arg1	development					132:142	development	132:142	development of natural polymer nono-composites	132:177	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	10	42	theme	Antimicrobial	1198:1210	arg1	characteristics					1212:1226	Antimicrobial characteristics	1198:1226	Antimicrobial characteristics	1198:1226	Antimicrobial characteristics were shown by copolymers against bacteria S. flexneri, P. auroginosa, and B. cereus.
36870665	6	43	theme	GA-TG-	840:845	arg1	network					867:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network	822:873	drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive	822:903	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	3	44	theme	AgNPs	529:533	arg1	formation					516:524	the formation	512:524	the formation of AgNPs using GA as reducing agent	512:560	UV-Vis spectra indicated the formation of AgNPs using GA as reducing agent.
36870665	0	45	dep	based	32:36	arg1	polysaccharides					16:30	Fabricating gum polysaccharides	0:30	Fabricating gum polysaccharides	0:30	Fabricating gum polysaccharides based nano-composites for drug delivery uses via sustainable green approach.
36870665	4	46	theme	AgNPs	610:614	arg1	impregnation					594:605	impregnation	594:605	impregnation of AgNPs inside the copolymeric network hydrogels	594:655	TEM, SEM, XPS and XRD revealed impregnation of AgNPs inside the copolymeric network hydrogels.
36870665	1	47	from	advancements	116:127	arg1	development					132:142	development	132:142	development of natural polymer nono-composites	132:177	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	6	48	theme	release	909:915	arg1	profile					917:923	release profile	909:923	release profile	909:923	The non-Fickian diffusion of antibiotic drug meropenem was revealed from drug encapsulated GA-TG-(AgNPs)-cl-poly(AAm) network which were also pH responsive and release profile was fitted in Korsmeyer-Peppas kinetic model.
36870665	1	49	theme	natural	147:153	arg1	nono-composites					163:177	natural polymer nono-composites	147:177	natural polymer nono-composites	147:177	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	8	50	theme	polymer-blood	1030:1042	arg1	interaction					1044:1054	The polymer-blood interaction	1026:1054	The polymer-blood interaction	1026:1054	The polymer-blood interaction demonstrated biocompatible characteristics of polymer.
36870665	9	51	theme	supra-molecular	1168:1182	arg1	interactions					1184:1195	supra-molecular interactions	1168:1195	supra-molecular interactions	1168:1195	Mucoadhesive property exhibited by copolymers because of supra-molecular interactions.
36870665	1	52	theme	polymer	155:161	arg1	nono-composites					163:177	natural polymer nono-composites	147:177	natural polymer nono-composites	147:177	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	53	theme	tragacanth	234:243	arg1	TG					250:251	TG	250:251	TG	250:251	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	53	theme	tragacanth	234:243	arg1	gum					245:247	tragacanth gum	234:247	tragacanth gum (TG)	234:252	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	54	theme	grafted	309:315	arg1	copolymers					317:326	grafted copolymers	309:326	grafted copolymers	309:326	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	55	from	use	351:353	arg1	DD					373:374	DD	373:374	DD	373:374	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	55	from	use	351:353	arg1	delivery					363:370	drug delivery	358:370	drug delivery (DD)	358:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
36870665	1	56	theme	gum	245:247	arg1	potential					201:209	potential	201:209	potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD)	201:375	Recent advancements in development of natural polymer nono-composites led to exploration of potential of gum acacia (GA) and tragacanth gum (TG) for design of silver nanoparticles (AgNPs) impregnated grafted copolymers via green approach for use in drug delivery (DD).
35318142	0	0	theme	lignocellulolytic	91:107	arg1	strain					130:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	3	1	theme	wild	710:713	arg1	parent					720:725	wild type parent	710:725	wild type parent	710:725	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	2	2	theme	strain	406:411	arg1	M36					413:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	0	3	theme	relevant	82:89	arg1	strain					130:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	3	4	theme	developed	689:697	arg1	strain					699:704	the developed strain	685:704	the developed strain	685:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	5	theme	loading	1285:1291	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	2	6	theme	mutant	399:404	arg1	M36					413:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	0	7	theme	emersonii	120:128	arg1	strain					130:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	3	8	theme	strain	699:704	arg1	proteome					647:654	proteome	647:654	proteome	647:654	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	8	theme	strain	699:704	arg1	level					676:680	transcriptional level	660:680	transcriptional level	660:680	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	2	9	theme	production	588:597	arg1	medium					599:604	cellulose/gram flour based production medium	561:604	cellulose/gram flour based production medium	561:604	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	1	10	theme	transcriptional	286:300	arg1	analysis					302:309	transcriptional analysis	286:309	transcriptional analysis	286:309	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	0	11	theme	Rasamsonia	109:118	arg1	strain					130:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	3	12	from	proteome	647:654	arg1	parent					720:725	wild type parent	710:725	wild type parent	710:725	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	12	from	proteome	647:654	arg1	profile					636:642	the expression profile	621:642	the expression profile at proteome and transcriptional level of the developed strain	621:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	12	from	proteome	647:654	arg1	Comparison					607:616	Comparison	607:616	Comparison of the expression profile at proteome and transcriptional level of the developed strain	607:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	2	13	theme	based	582:586	arg1	medium					599:604	cellulose/gram flour based production medium	561:604	cellulose/gram flour based production medium	561:604	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	4	14	theme	@	1270:1270	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	4	15	theme	Mycothermus	1131:1141	arg1	thermophiloides					1143:1157	Mycothermus thermophiloides	1131:1157	Mycothermus thermophiloides	1131:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	3	16	theme	polysaccharide	879:892	arg1	swollenin					909:917	swollenin	909:917	swollenin	909:917	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	16	theme	polysaccharide	879:892	arg1	monooxygenase					894:906	lytic polysaccharide monooxygenase	873:906	lytic polysaccharide monooxygenase	873:906	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	17	theme	CAZymes	785:791	arg1	up-regulation					758:770	the up-regulation	754:770	the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin)	754:918	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	18	theme	detailed	732:739	arg1	insight					741:747	detailed insight	732:747	detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin)	732:918	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	19	dep	slurry	1247:1252	arg1	IOCL					1264:1267	IOCL	1264:1267	IOCL	1264:1267	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	4	19	dep	slurry	1247:1252	arg1	PRAJ					1255:1258	PRAJ	1255:1258	PRAJ	1255:1258	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	1	20	theme	thermophilic	181:192	arg1	emersonii					212:220	thermophilic fungus Rasamsonia emersonii	181:220	thermophilic fungus Rasamsonia emersonii	181:220	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	3	21	theme	type	715:718	arg1	parent					720:725	wild type parent	710:725	wild type parent	710:725	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	22	theme	enzyme	985:990	arg1	potential					954:962	the potential	950:962	the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides	950:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	1	23	with	combination	315:325	arg1	approaches					358:367	classical strain breeding approaches	332:367	classical strain breeding approaches	332:367	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	1	24	theme	fungus	194:199	arg1	emersonii					212:220	thermophilic fungus Rasamsonia emersonii	181:220	thermophilic fungus Rasamsonia emersonii	181:220	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	4	25	theme	developed	1008:1016	arg1	strain					1018:1023	the developed strain	1004:1023	the developed strain	1004:1023	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	4	26	theme	straw	1241:1245	arg1	slurry					1247:1252	pretreated rice straw slurry	1225:1252	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	3	27	theme	lytic	873:877	arg1	swollenin					909:917	swollenin	909:917	swollenin	909:917	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	27	theme	lytic	873:877	arg1	monooxygenase					894:906	lytic polysaccharide monooxygenase	873:906	lytic polysaccharide monooxygenase	873:906	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	1	28	theme	Rasamsonia	201:210	arg1	emersonii					212:220	thermophilic fungus Rasamsonia emersonii	181:220	thermophilic fungus Rasamsonia emersonii	181:220	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	3	29	from	parent	720:725	arg1	proteome					647:654	proteome	647:654	proteome	647:654	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	29	from	parent	720:725	arg1	level					676:680	transcriptional level	660:680	transcriptional level	660:680	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	30	from	thermophiloides	1143:1157	arg1	monooxygenase					1112:1124	heterologously expressed lytic polysaccharide monooxygenase	1066:1124	heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides	1066:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	0	31	theme	biology	22:28	arg1	Combination					0:10	Combination	0:10	Combination of system biology	0:28	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	0	31	theme	biology	22:28	arg1	approaches					44:53	classical approaches	34:53	classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	34:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	3	32	dep	enzymes	864:870	arg1	swollenin					909:917	swollenin	909:917	swollenin	909:917	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	32	dep	enzymes	864:870	arg1	monooxygenase					894:906	lytic polysaccharide monooxygenase	873:906	lytic polysaccharide monooxygenase	873:906	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	33	theme	polysaccharide	1097:1110	arg1	monooxygenase					1112:1124	heterologously expressed lytic polysaccharide monooxygenase	1066:1124	heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides	1066:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	0	34	theme	system	15:20	arg1	biology					22:28	system biology	15:28	system biology	15:28	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	4	35	theme	rice	1236:1239	arg1	slurry					1247:1252	pretreated rice straw slurry	1225:1252	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	3	36	theme	profile	636:642	arg1	parent					720:725	wild type parent	710:725	wild type parent	710:725	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	36	theme	profile	636:642	arg1	Comparison					607:616	Comparison	607:616	Comparison of the expression profile at proteome and transcriptional level of the developed strain	607:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	1	37	theme	integrated	228:237	arg1	tools					254:258	integrated system biology tools	228:258	integrated system biology tools (genomics, proteomics and transcriptional analysis)	228:310	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	0	38	theme	classical	34:42	arg1	approaches					44:53	classical approaches	34:53	classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	34:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	3	39	dep	hydrolases	812:821	arg1	GH6					829:831	GH6	829:831	GH6	829:831	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	39	dep	hydrolases	812:821	arg1	GH10					844:847	GH10	844:847	GH10	844:847	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	39	dep	hydrolases	812:821	arg1	GH5					824:826	GH5	824:826	GH5	824:826	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	39	dep	hydrolases	812:821	arg1	GH3					839:841	GH3	839:841	GH3	839:841	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	39	dep	hydrolases	812:821	arg1	GH7					834:836	GH7	834:836	GH7	834:836	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	40	dep	relevant	1207:1214	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	1	41	theme	system	239:244	arg1	tools					254:258	integrated system biology tools	228:258	integrated system biology tools (genomics, proteomics and transcriptional analysis)	228:310	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	4	42	theme	lignocellulolytic	967:983	arg1	enzyme					985:990	lignocellulolytic enzyme	967:990	lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides	967:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	1	43	theme	classical	332:340	arg1	approaches					358:367	classical strain breeding approaches	332:367	classical strain breeding approaches	332:367	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	1	44	dep	tools	254:258	arg1	genomics					261:268	genomics	261:268	genomics	261:268	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	1	44	dep	tools	254:258	arg1	proteomics					271:280	proteomics	271:280	proteomics	271:280	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	1	44	dep	tools	254:258	arg1	analysis					302:309	transcriptional analysis	286:309	transcriptional analysis	286:309	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	4	45	theme	unwashed	1216:1223	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	1	46	theme	biology	246:252	arg1	tools					254:258	integrated system biology tools	228:258	integrated system biology tools (genomics, proteomics and transcriptional analysis)	228:310	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	1	47	theme	strain	342:347	arg1	approaches					358:367	classical strain breeding approaches	332:367	classical strain breeding approaches	332:367	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	2	48	theme	flour	576:580	arg1	medium					599:604	cellulose/gram flour based production medium	561:604	cellulose/gram flour based production medium	561:604	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	4	49	theme	relevant	1207:1214	arg1	biorefinery					1195:1205	biorefinery	1195:1205	biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1195:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	2	50	theme	cellulolytic	386:397	arg1	M36					413:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	1	51	theme	breeding	349:356	arg1	approaches					358:367	classical strain breeding approaches	332:367	classical strain breeding approaches	332:367	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	2	52	theme	cellulose/gram	561:574	arg1	medium					599:604	cellulose/gram flour based production medium	561:604	cellulose/gram flour based production medium	561:604	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	4	53	theme	%	1273:1273	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	3	54	theme	system	923:928	arg1	level					930:934	system level	923:934	system level	923:934	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	2	55	theme	hyper	380:384	arg1	M36					413:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	3	56	theme	different	775:783	arg1	CAZymes					785:791	different CAZymes	775:791	different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin)	775:918	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	56	theme	different	775:783	arg1	hydrolases					812:821	glycosyl hydrolases	803:821	glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10)	803:848	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	56	theme	different	775:783	arg1	enzymes					864:870	auxiliary enzymes	854:870	auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin)	854:918	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	57	theme	slurry	1247:1252	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	4	58	theme	pretreated	1225:1234	arg1	slurry					1247:1252	pretreated rice straw slurry	1225:1252	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	2	59	theme	Developed	370:378	arg1	M36					413:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36	370:415	Developed hyper cellulolytic mutant strain M36 showed endoglucanase (476.35 U/ml), β-glucosidase (70.54 U/ml), cellobiohydrolase (15.17 U/ml), FPase (4.89 U/ml) and xylanase (485.21 U/ml) on cellulose/gram flour based production medium.
35318142	3	60	theme	transcriptional	660:674	arg1	level					676:680	transcriptional level	660:680	transcriptional level	660:680	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	61	theme	expression	625:634	arg1	profile					636:642	the expression profile	621:642	the expression profile at proteome and transcriptional level of the developed strain	621:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	62	from	Comparison	607:616	arg1	proteome					647:654	proteome	647:654	proteome	647:654	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	62	from	Comparison	607:616	arg1	level					676:680	transcriptional level	660:680	transcriptional level	660:680	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	63	theme	lytic	1091:1095	arg1	monooxygenase					1112:1124	heterologously expressed lytic polysaccharide monooxygenase	1066:1124	heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides	1066:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	0	64	theme	biorefinery	70:80	arg1	strain					130:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	biorefinery relevant lignocellulolytic Rasamsonia emersonii strain	70:135	Combination of system biology and classical approaches for developing biorefinery relevant lignocellulolytic Rasamsonia emersonii strain.
35318142	4	65	theme	substrate	1275:1283	arg1	rate					1293:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1216:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	4	66	theme	designed	1036:1043	arg1	cocktail					1045:1052	custom designed cocktail	1029:1052	custom designed cocktail	1029:1052	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	1	67	theme	study	160:164	arg1	objective					142:150	The objective	138:150	The objective of this study	138:164	The objective of this study was to develop thermophilic fungus Rasamsonia emersonii using integrated system biology tools (genomics, proteomics and transcriptional analysis) in combination with classical strain breeding approaches.
35318142	4	68	theme	expressed	1081:1089	arg1	monooxygenase					1112:1124	heterologously expressed lytic polysaccharide monooxygenase	1066:1124	heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides	1066:1157	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	3	69	theme	glycosyl	803:810	arg1	hydrolases					812:821	glycosyl hydrolases	803:821	glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10)	803:848	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	70	from	level	676:680	arg1	parent					720:725	wild type parent	710:725	wild type parent	710:725	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	70	from	level	676:680	arg1	profile					636:642	the expression profile	621:642	the expression profile at proteome and transcriptional level of the developed strain	621:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	3	70	from	level	676:680	arg1	Comparison					607:616	Comparison	607:616	Comparison of the expression profile at proteome and transcriptional level of the developed strain	607:704	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
35318142	4	71	theme	biorefinery	1195:1205	arg1	hydrolysis					1181:1190	the hydrolysis	1177:1190	the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate	1177:1296	Furthermore, the potential of lignocellulolytic enzyme produced by the developed strain and custom designed cocktail spiked with heterologously expressed lytic polysaccharide monooxygenase from Mycothermus thermophiloides were analyzed for the hydrolysis of biorefinery relevant unwashed pretreated rice straw slurry (PRAJ and IOCL) @17% substrate loading rate.
35318142	3	72	theme	auxiliary	854:862	arg1	enzymes					864:870	auxiliary enzymes	854:870	auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin)	854:918	Comparison of the expression profile at proteome and transcriptional level of the developed strain and wild type parent gave detailed insight into the up-regulation of different CAZymes including glycosyl hydrolases (GH5, GH6, GH7, GH3, GH10) and auxiliary enzymes (lytic polysaccharide monooxygenase, swollenin) at system level.
37355061	0	0	from	hemicellulose	20:32	arg1	lanceolata					50:59	Cunninghamia lanceolata	37:59	Cunninghamia lanceolata	37:59	Characterization of hemicellulose in Cunninghamia lanceolata stem during xylogenesis.
37355061	6	1	theme	total	1159:1163	arg1	degree					1165:1170	the total degree	1155:1170	the total degree of acetylation	1155:1185	However, the total degree of acetylation was enhanced from 0.28 (apical) to 0.37 (basal).
37355061	6	2	theme	acetylation	1175:1185	arg1	degree					1165:1170	the total degree	1155:1170	the total degree of acetylation	1155:1185	However, the total degree of acetylation was enhanced from 0.28 (apical) to 0.37 (basal).
37355061	3	3	theme	acid	785:788	arg1	Xylp					738:741	Xylp	738:741	Xylp	738:741	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	3	theme	acid	785:788	arg1	-β-d-xylopyranosyl					718:735	(1 → 4)-β-d-xylopyranosyl	711:735	(1 → 4)-β-d-xylopyranosyl (Xylp)	711:742	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	3	theme	acid	785:788	arg1	chains					753:758	side chains	748:758	side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	748:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	1	4	theme	structure	234:242	arg1	change					220:225	the dynamic change	208:225	the dynamic change of its structure during xylogenesis	208:261	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	1	5	attach	isolated	119:126	arg1	segments					162:169	the apical, middle and basal segments	133:169	the apical, middle and basal segments of C. lanceolata stem	133:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	1	5	attach	isolated	119:126	arg2	hemicellulose					101:113	hemicellulose	101:113	hemicellulose	101:113	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	5	6	theme	xylan	1015:1019	arg1	substitutions					998:1010	glycosyl substitutions	989:1010	glycosyl substitutions of xylan and mannan	989:1030	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	1	7	theme	basal	156:160	arg1	segments					162:169	the apical, middle and basal segments	133:169	the apical, middle and basal segments of C. lanceolata stem	133:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	3	8	theme	α-L-arabinofuranose	804:822	arg1	Xylp					738:741	Xylp	738:741	Xylp	738:741	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	8	theme	α-L-arabinofuranose	804:822	arg1	-β-d-xylopyranosyl					718:735	(1 → 4)-β-d-xylopyranosyl	711:735	(1 → 4)-β-d-xylopyranosyl (Xylp)	711:742	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	8	theme	α-L-arabinofuranose	804:822	arg1	chains					753:758	side chains	748:758	side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	748:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	2	9	theme	side	507:510	arg1	α-d-galactopyranosyl					523:542	α-d-galactopyranosyl	523:542	α-d-galactopyranosyl (Galp)	523:549	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	9	theme	side	507:510	arg1	chains					512:517	the side chains	503:517	the side chains	503:517	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	0	10	from	Characterization	0:15	arg1	lanceolata					50:59	Cunninghamia lanceolata	37:59	Cunninghamia lanceolata	37:59	Characterization of hemicellulose in Cunninghamia lanceolata stem during xylogenesis.
37355061	5	11	dep	%	1057:1057	arg1	apical					1060:1065	apical	1060:1065	apical	1060:1065	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	7	12	theme	Transcriptome	1236:1248	arg1	analysis					1250:1257	Transcriptome analysis	1236:1257	Transcriptome analysis	1236:1257	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	5	13	dep	%	1101:1101	arg1	apical					1104:1109	apical	1104:1109	apical	1104:1109	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	8	14	theme	genetic	1478:1484	arg1	breeding					1486:1493	genetic breeding	1478:1493	genetic breeding	1478:1493	This study is of great significance for genetic breeding and high-value utilization of C. lanceolata.
37355061	3	15	from	structure	634:642	arg1	addition					566:573	addition	566:573	addition	566:573	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	0	16	from	lanceolata	50:59	arg1	Characterization					0:15	Characterization	0:15	Characterization of hemicellulose in Cunninghamia lanceolata	0:59	Characterization of hemicellulose in Cunninghamia lanceolata stem during xylogenesis.
37355061	6	17	dep	0.37	1222:1225	arg1	basal					1228:1232	basal	1228:1232	basal	1228:1232	However, the total degree of acetylation was enhanced from 0.28 (apical) to 0.37 (basal).
37355061	5	18	dep	%	1076:1076	arg1	basal					1079:1083	basal	1079:1083	basal	1079:1083	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	4	19	theme	molecular	893:901	arg1	weight					903:908	the molecular weight	889:908	the molecular weight of hemicellulose	889:925	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	19	theme	molecular	893:901	arg1	thickness					836:844	The thickness	832:844	The thickness of the cell wall	832:861	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	19	theme	molecular	893:901	arg1	extension					949:957	the extension	945:957	the extension of growth time	945:972	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	19	theme	molecular	893:901	arg1	ratio					868:872	the ratio	864:872	the ratio of GGM/GAX	864:883	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	1	20	theme	C.	174:175	arg1	stem					188:191	C. lanceolata stem	174:191	C. lanceolata stem	174:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	4	21	theme	time	969:972	arg1	weight					903:908	the molecular weight	889:908	the molecular weight of hemicellulose	889:925	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	21	theme	time	969:972	arg1	thickness					836:844	The thickness	832:844	The thickness of the cell wall	832:861	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	21	theme	time	969:972	arg1	extension					949:957	the extension	945:957	the extension of growth time	945:972	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	21	theme	time	969:972	arg1	ratio					868:872	the ratio	864:872	the ratio of GGM/GAX	864:883	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	1	22	theme	lanceolata	177:186	arg1	stem					188:191	C. lanceolata stem	174:191	C. lanceolata stem	174:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	7	23	theme	mature	1425:1430	arg1	part					1432:1435	mature part	1425:1435	mature part	1425:1435	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	2	24	theme	lanceolata	291:300	arg1	hemicellulose					302:314	the C. lanceolata hemicellulose	284:314	the C. lanceolata hemicellulose	284:314	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	8	25	theme	high-value	1499:1508	arg1	utilization					1510:1520	high-value utilization	1499:1520	high-value utilization of C. lanceolata	1499:1537	This study is of great significance for genetic breeding and high-value utilization of C. lanceolata.
37355061	1	26	theme	stem	188:191	arg1	segments					162:169	the apical, middle and basal segments	133:169	the apical, middle and basal segments of C. lanceolata stem	133:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	0	27	theme	hemicellulose	20:32	arg1	Characterization					0:15	Characterization	0:15	Characterization of hemicellulose in Cunninghamia lanceolata	0:59	Characterization of hemicellulose in Cunninghamia lanceolata stem during xylogenesis.
37355061	6	28	dep	0.28	1205:1208	arg1	to					1219:1220	to	1219:1220	to	1219:1220	However, the total degree of acetylation was enhanced from 0.28 (apical) to 0.37 (basal).
37355061	6	28	dep	0.28	1205:1208	arg1	apical					1211:1216	apical	1211:1216	apical	1211:1216	However, the total degree of acetylation was enhanced from 0.28 (apical) to 0.37 (basal).
37355061	6	28	dep	0.28	1205:1208	arg1	0.37					1222:1225	0.37	1222:1225	0.37	1222:1225	However, the total degree of acetylation was enhanced from 0.28 (apical) to 0.37 (basal).
37355061	3	29	theme	dominant	625:632	arg1	structure					634:642	another dominant structure	617:642	another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	617:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	2	30	theme	C.	288:289	arg1	hemicellulose					302:314	the C. lanceolata hemicellulose	284:314	the C. lanceolata hemicellulose	284:314	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	3	31	theme	-β-d-xylopyranosyl	718:735	arg1	backbone					699:706	a linear backbone	690:706	a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	690:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	0	32	theme	Cunninghamia	37:48	arg1	lanceolata					50:59	Cunninghamia lanceolata	37:59	Cunninghamia lanceolata	37:59	Characterization of hemicellulose in Cunninghamia lanceolata stem during xylogenesis.
37355061	3	33	theme	side	748:751	arg1	chains					753:758	side chains	748:758	side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	748:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	4	34	theme	GGM/GAX	877:883	arg1	weight					903:908	the molecular weight	889:908	the molecular weight of hemicellulose	889:925	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	34	theme	GGM/GAX	877:883	arg1	thickness					836:844	The thickness	832:844	The thickness of the cell wall	832:861	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	34	theme	GGM/GAX	877:883	arg1	extension					949:957	the extension	945:957	the extension of growth time	945:972	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	34	theme	GGM/GAX	877:883	arg1	ratio					868:872	the ratio	864:872	the ratio of GGM/GAX	864:883	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	5	35	theme	mannan	1025:1030	arg1	substitutions					998:1010	glycosyl substitutions	989:1010	glycosyl substitutions of xylan and mannan	989:1030	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	4	36	theme	growth	962:967	arg1	time					969:972	growth time	962:972	growth time	962:972	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	3	37	theme	chains	753:758	arg1	backbone					699:706	a linear backbone	690:706	a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	690:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	4	38	theme	wall	858:861	arg1	weight					903:908	the molecular weight	889:908	the molecular weight of hemicellulose	889:925	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	38	theme	wall	858:861	arg1	thickness					836:844	The thickness	832:844	The thickness of the cell wall	832:861	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	38	theme	wall	858:861	arg1	extension					949:957	the extension	945:957	the extension of growth time	945:972	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	38	theme	wall	858:861	arg1	ratio					868:872	the ratio	864:872	the ratio of GGM/GAX	864:883	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	39	theme	hemicellulose	913:925	arg1	weight					903:908	the molecular weight	889:908	the molecular weight of hemicellulose	889:925	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	39	theme	hemicellulose	913:925	arg1	thickness					836:844	The thickness	832:844	The thickness of the cell wall	832:861	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	39	theme	hemicellulose	913:925	arg1	extension					949:957	the extension	945:957	the extension of growth time	945:972	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	4	39	theme	hemicellulose	913:925	arg1	ratio					868:872	the ratio	864:872	the ratio of GGM/GAX	864:883	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	8	40	theme	lanceolata	1528:1537	arg1	breeding					1486:1493	genetic breeding	1478:1493	genetic breeding	1478:1493	This study is of great significance for genetic breeding and high-value utilization of C. lanceolata.
37355061	8	40	theme	lanceolata	1528:1537	arg1	utilization					1510:1520	high-value utilization	1499:1520	high-value utilization of C. lanceolata	1499:1537	This study is of great significance for genetic breeding and high-value utilization of C. lanceolata.
37355061	4	41	theme	cell	853:856	arg1	wall					858:861	the cell wall	849:861	the cell wall	849:861	The thickness of the cell wall, the ratio of GGM/GAX and the molecular weight of hemicellulose were increased as the extension of growth time.
37355061	3	42	theme	lanceolata	650:659	arg1	hemicellulose					661:673	C. lanceolata hemicellulose	647:673	C. lanceolata hemicellulose	647:673	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	43	theme	hemicellulose	661:673	arg1	structure					634:642	another dominant structure	617:642	another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	617:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	44	dep	-β-d-xylopyranosyl	718:735	arg1	1 → 4					712:716	1 → 4	712:716	1 → 4	712:716	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	7	45	dep	genes	1271:1275	arg1	GUX2					1330:1333	GUX2	1330:1333	GUX2	1330:1333	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	IRX9H1					1285:1290	IRX9H1	1285:1290	IRX9H1	1285:1290	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	GUX3					1336:1339	GUX3	1336:1339	GUX3	1336:1339	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	F8H2					1357:1360	F8H2	1357:1360	F8H2	1357:1360	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	IRX10L					1293:1298	IRX10L	1293:1298	IRX10L	1293:1298	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	TBL19					1316:1320	TBL19	1316:1320	TBL19	1316:1320	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	genes					1271:1275	genes	1271:1275	genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis	1271:1399	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	TBL25					1323:1327	TBL25	1323:1327	TBL25	1323:1327	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	GXM1					1342:1345	GXM1	1342:1345	GXM1	1342:1345	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	CSLA9					1278:1282	CSLA9	1278:1282	CSLA9	1278:1282	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	IRX15L					1301:1306	IRX15L	1301:1306	IRX15L	1301:1306	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	F8H1					1348:1351	F8H1	1348:1351	F8H1	1348:1351	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	45	dep	genes	1271:1275	arg1	GMGT1					1309:1313	GMGT1	1309:1313	GMGT1	1309:1313	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	46	theme	hemicellulose	1374:1386	arg1	biosynthesis					1388:1399	hemicellulose biosynthesis	1374:1399	hemicellulose biosynthesis	1374:1399	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	2	47	dep	bond	491:494	arg1	1 → 4					473:477	1 → 4	473:477	1 → 4	473:477	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	48	attach	linked	402:407	arg3	Glcp					462:465	Glcp	462:465	Glcp	462:465	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	48	attach	linked	402:407	arg3	bond					491:494	(1 → 4)-glycosidic bond	472:494	(1 → 4)-glycosidic bond	472:494	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	48	attach	linked	402:407	arg3	Manp					432:435	Manp	432:435	Manp	432:435	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	48	attach	linked	402:407	arg3	β-d-glucopyranosyl					442:459	β-d-glucopyranosyl	442:459	β-d-glucopyranosyl (Glcp)	442:466	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	48	attach	linked	402:407	arg3	β-d-mannopyranosyl					412:429	β-d-mannopyranosyl	412:429	β-d-mannopyranosyl (Manp)	412:436	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	2	48	attach	linked	402:407	arg2	backbone					378:385	backbone	378:385	backbone	378:385	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	5	49	dep	%	1121:1121	arg1	basal					1124:1128	basal	1124:1128	basal	1124:1128	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	1	50	theme	dynamic	212:218	arg1	change					220:225	the dynamic change	208:225	the dynamic change of its structure during xylogenesis	208:261	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	5	51	theme	glycosyl	989:996	arg1	substitutions					998:1010	glycosyl substitutions	989:1010	glycosyl substitutions of xylan and mannan	989:1030	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	5	52	theme	substitutions	998:1010	arg1	degree					979:984	The degree	975:984	The degree of glycosyl substitutions of xylan and mannan	975:1030	The degree of glycosyl substitutions of xylan and mannan was decreased from 10.34 % (apical) to 8.38 % (basal) and from 15.63 % (apical) to 10.49 % (basal), respectively.
37355061	1	53	theme	apical	137:142	arg1	segments					162:169	the apical, middle and basal segments	133:169	the apical, middle and basal segments of C. lanceolata stem	133:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	7	54	theme	related	1363:1369	arg1	GUX2					1330:1333	GUX2	1330:1333	GUX2	1330:1333	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	IRX9H1					1285:1290	IRX9H1	1285:1290	IRX9H1	1285:1290	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	GUX3					1336:1339	GUX3	1336:1339	GUX3	1336:1339	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	F8H2					1357:1360	F8H2	1357:1360	F8H2	1357:1360	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	IRX10L					1293:1298	IRX10L	1293:1298	IRX10L	1293:1298	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	TBL19					1316:1320	TBL19	1316:1320	TBL19	1316:1320	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	genes					1271:1275	genes	1271:1275	genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis	1271:1399	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	TBL25					1323:1327	TBL25	1323:1327	TBL25	1323:1327	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	GXM1					1342:1345	GXM1	1342:1345	GXM1	1342:1345	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	CSLA9					1278:1282	CSLA9	1278:1282	CSLA9	1278:1282	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	IRX15L					1301:1306	IRX15L	1301:1306	IRX15L	1301:1306	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	F8H1					1348:1351	F8H1	1348:1351	F8H1	1348:1351	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	7	54	theme	related	1363:1369	arg1	GMGT1					1309:1313	GMGT1	1309:1313	GMGT1	1309:1313	Transcriptome analysis showed that genes (CSLA9, IRX9H1, IRX10L, IRX15L, GMGT1, TBL19, TBL25, GUX2, GUX3, GXM1, F8H1 and F8H2) related to hemicellulose biosynthesis are mainly expressed in mature part.
37355061	3	55	theme	C.	647:648	arg1	hemicellulose					661:673	C. lanceolata hemicellulose	647:673	C. lanceolata hemicellulose	647:673	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	56	contain	contains	681:688	arg1	structure					634:642	another dominant structure	617:642	another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	617:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	56	contain	contains	681:688	arg2	backbone					699:706	a linear backbone	690:706	a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	690:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	8	57	theme	great	1455:1459	arg1	significance					1461:1472	great significance	1455:1472	great significance	1455:1472	This study is of great significance for genetic breeding and high-value utilization of C. lanceolata.
37355061	2	58	theme	-glycosidic	479:489	arg1	bond					491:494	(1 → 4)-glycosidic bond	472:494	(1 → 4)-glycosidic bond	472:494	Results showed that the C. lanceolata hemicellulose is mainly consisted of O-acetylgalactoglucomannan (GGM) which backbone is alternately linked by β-d-mannopyranosyl (Manp) and β-d-glucopyranosyl (Glcp) via (1 → 4)-glycosidic bond, while the side chains are α-d-galactopyranosyl (Galp) and acetyl.
37355061	3	59	theme	linear	692:697	arg1	backbone					699:706	a linear backbone	690:706	a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf)	690:829	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	1	60	theme	middle	145:150	arg1	segments					162:169	the apical, middle and basal segments	133:169	the apical, middle and basal segments of C. lanceolata stem	133:191	In this study, hemicellulose was isolated from the apical, middle and basal segments of C. lanceolata stem to investigate the dynamic change of its structure during xylogenesis.
37355061	3	61	theme	4-O-Me-α-d-glucuronic	763:783	arg1	acid					785:788	4-O-Me-α-d-glucuronic acid	763:788	4-O-Me-α-d-glucuronic acid (MeGlcpA)	763:798	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
37355061	3	61	theme	4-O-Me-α-d-glucuronic	763:783	arg1	MeGlcpA					791:797	MeGlcpA	791:797	MeGlcpA	791:797	In addition, 4-O-methylglucuronoarabinoxylan (GAX) is another dominant structure of C. lanceolata hemicellulose which contains a linear backbone of (1 → 4)-β-d-xylopyranosyl (Xylp) and side chains of 4-O-Me-α-d-glucuronic acid (MeGlcpA) and α-L-arabinofuranose (Araf).
36660462	3	0	theme	glycopeptide	506:517	arg1	expression					468:477	the global expression	457:477	the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	457:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	0	1	with	Patients	76:83	arg1	Preeclampsia					90:101	Preeclampsia	90:101	Preeclampsia	90:101	Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.
36660462	3	2	theme	pregnant	551:558	arg1	women					560:564	three healthy pregnant women	537:564	three healthy pregnant women	537:564	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	9	3	theme	glycosylation	1659:1671	arg1	occupancy					1646:1654	the occupancy	1642:1654	the occupancy of glycosylation	1642:1671	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	9	3	theme	glycosylation	1659:1671	arg1	structure					1629:1637	glycosylation structure	1615:1637	glycosylation structure	1615:1637	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	2	4	theme	expression	307:316	arg1	alterations					284:294	the global alterations	273:294	the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis	273:374	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	2	4	theme	expression	307:316	arg1	crucial					348:354	crucial	348:354	crucial	348:354	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	1	5	theme	serious	186:192	arg1	threat					194:199	a serious threat	184:199	a serious threat to maternal and perinatal health worldwide	184:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	5	6	mod	modified	987:994	arg3	glycans					1011:1017	59 N-Linked glycans	999:1017	59 N-Linked glycans	999:1017	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	5	6	mod	modified	987:994	arg1	which					910:914	which	910:914	which	910:914	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	7	7	theme	protein	1325:1331	arg1	level					1343:1347	the protein abundance level	1321:1347	the protein abundance level	1321:1347	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	3	8	theme	early-onset	587:597	arg1	PE					606:607	early-onset severe PE	587:607	early-onset severe PE	587:607	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	5	9	attach	derived	921:927	arg2	which					910:914	which	910:914	which	910:914	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	5	9	attach	derived	921:927	arg1	sites					951:955	204 glycosylated sites	934:955	204 glycosylated sites in 159 glycoproteins	934:976	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	5	10	gly	glycopeptides	868:880	arg2	glycopeptides					868:880	789 glycopeptides	864:880	789 glycopeptides	864:880	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	8	11	theme	glycoproteomic	1424:1437	arg1	characterization					1439:1454	an integrated proteomic and glycoproteomic characterization	1396:1454	characterization	1439:1454	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	4	12	theme	placental	714:722	arg1	tissues					724:730	9 placental tissues	712:730	9 placental tissues	712:730	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	5	13	gly	glycosylated	938:949	arg1	sites					951:955	204 glycosylated sites	934:955	204 glycosylated sites in 159 glycoproteins	934:976	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	3	14	from	patients	573:580	arg1	placentas					522:530	placentas	522:530	placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	522:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	14	from	patients	573:580	arg1	expression					468:477	the global expression	457:477	the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	457:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	9	15	theme	PE	1754:1755	arg1	mechanism					1741:1749	the pathogenic mechanism	1726:1749	the pathogenic mechanism of PE	1726:1755	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	8	16	theme	tissues	1469:1475	arg1	proteomic					1410:1418	proteomic	1410:1418	proteomic	1410:1418	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	3	17	with	patients	620:627	arg1	PE					606:607	early-onset severe PE	587:607	early-onset severe PE	587:607	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	17	with	patients	620:627	arg1	PE					652:653	late-onset severe PE	634:653	late-onset severe PE	634:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	1	18	theme	pregnancy	163:171	arg1	disorder					151:158	a multi-system disorder	136:158	a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide	136:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	1	18	theme	pregnancy	163:171	arg1	Preeclampsia					115:126	Background Preeclampsia	104:126	Background Preeclampsia (PE)	104:131	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	8	19	theme	PE	1480:1481	arg1	patients					1483:1490	PE patients	1480:1490	PE patients	1480:1490	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	6	20	gly	glycopeptides	1057:1069	arg2	glycopeptides					1057:1069	123 differently expressed glycopeptides	1031:1069	123 differently expressed glycopeptides	1031:1069	A total of 123 differently expressed glycopeptides, which were from 47 glycoproteins were identified among three groups.
36660462	2	21	theme	global	277:282	arg1	alterations					284:294	the global alterations	273:294	the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis	273:374	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	2	21	theme	global	277:282	arg1	crucial					348:354	crucial	348:354	crucial	348:354	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	5	22	theme	glycosylated	938:949	arg1	sites					951:955	204 glycosylated sites	934:955	204 glycosylated sites in 159 glycoproteins	934:976	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	6	23	gly	glycoproteins	1091:1103	arg1	glycoproteins					1091:1103	47 glycoproteins	1088:1103	47 glycoproteins	1088:1103	A total of 123 differently expressed glycopeptides, which were from 47 glycoproteins were identified among three groups.
36660462	3	24	gly	glycopeptide	506:517	arg2	glycopeptide					506:517	intact glycopeptide	499:517	intact glycopeptide	499:517	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	25	theme	tandem	383:388	arg1	labeling					399:406	tandem mass tag labeling	383:406	tandem mass tag labeling combined with LC-MS/MS	383:429	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	26	from	patients	620:627	arg1	placentas					522:530	placentas	522:530	placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	522:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	26	from	patients	620:627	arg1	expression					468:477	the global expression	457:477	the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	457:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	7	27	theme	combined	1151:1158	arg1	analysis					1160:1167	a combined analysis	1149:1167	a combined analysis of proteomic and glycoproteomic data	1149:1204	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	1	28	theme	Background	104:113	arg1	disorder					151:158	a multi-system disorder	136:158	a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide	136:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	1	28	theme	Background	104:113	arg1	PE					129:130	PE	129:130	PE	129:130	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	1	28	theme	Background	104:113	arg1	Preeclampsia					115:126	Background Preeclampsia	104:126	Background Preeclampsia (PE)	104:131	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	3	29	theme	global	461:466	arg1	expression					468:477	the global expression	457:477	the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	457:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	30	with	patients	573:580	arg1	PE					606:607	early-onset severe PE	587:607	early-onset severe PE	587:607	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	30	with	patients	573:580	arg1	PE					652:653	late-onset severe PE	634:653	late-onset severe PE	634:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	5	31	gly	glycoproteins	964:976	arg1	glycoproteins					964:976	159 glycoproteins	960:976	159 glycoproteins	960:976	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	9	32	theme	proteins	1583:1590	arg1	function					1571:1578	the molecular function	1557:1578	the molecular function of proteins	1557:1590	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	3	33	theme	tag	395:397	arg1	labeling					399:406	tandem mass tag labeling	383:406	tandem mass tag labeling combined with LC-MS/MS	383:429	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	34	theme	late-onset	634:643	arg1	PE					652:653	late-onset severe PE	634:653	late-onset severe PE	634:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	4	35	theme	PE	816:817	arg1	groups					819:824	the early-onset and late-onset PE groups	785:824	the early-onset and late-onset PE groups	785:824	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	3	36	theme	proteins	486:493	arg1	expression					468:477	the global expression	457:477	the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	457:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	0	37	theme	Placental	55:63	arg1	Tissues					65:71	Placental Tissues	55:71	Placental Tissues of Patients with Preeclampsia	55:101	Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.
36660462	5	38	theme	N-Linked	1002:1009	arg1	glycans					1011:1017	59 N-Linked glycans	999:1017	59 N-Linked glycans	999:1017	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	3	39	from	expression	468:477	arg1	placentas					522:530	placentas	522:530	placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	522:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	39	from	expression	468:477	arg1	patients					620:627	three patients	614:627	three patients with late-onset severe PE	614:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	39	from	expression	468:477	arg1	women					560:564	three healthy pregnant women	537:564	three healthy pregnant women	537:564	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	39	from	expression	468:477	arg1	patients					573:580	three patients	567:580	three patients with early-onset severe PE	567:607	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	1	40	theme	perinatal	217:225	arg1	worldwide					234:242	maternal and perinatal health worldwide	204:242	maternal and perinatal health worldwide	204:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	7	41	from	difference	1276:1285	arg1	level					1343:1347	the protein abundance level	1321:1347	the protein abundance level	1321:1347	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	7	41	from	difference	1276:1285	arg1	level					1304:1308	glycosylation level	1290:1308	glycosylation level	1290:1308	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	9	42	gly	occupancy	1646:1654	arg2	glycosylation					1659:1671	glycosylation	1659:1671	glycosylation	1659:1671	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	2	43	theme	PE	360:361	arg1	pathogenesis					363:374	PE pathogenesis	360:374	PE pathogenesis	360:374	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	6	44	theme	glycopeptides	1057:1069	arg1	total					1022:1026	A total	1020:1026	A total of 123 differently expressed glycopeptides, which were from 47 glycoproteins	1020:1103	A total of 123 differently expressed glycopeptides, which were from 47 glycoproteins were identified among three groups.
36660462	3	45	theme	healthy	543:549	arg1	women					560:564	three healthy pregnant women	537:564	three healthy pregnant women	537:564	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	7	46	from	changes	1229:1235	arg1	glycoproteins					1243:1255	10 glycoproteins	1240:1255	10 glycoproteins	1240:1255	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	7	47	theme	data	1201:1204	arg1	analysis					1160:1167	a combined analysis	1149:1167	a combined analysis of proteomic and glycoproteomic data	1149:1204	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	4	48	dep	expressed	772:780	arg1	compared					827:834	compared	827:834	compared to the controls	827:850	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	2	49	theme	protein	299:305	arg1	expression					307:316	protein expression	299:316	protein expression	299:316	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	9	50	theme	new	1693:1695	arg1	insights					1697:1704	new insights	1693:1704	new insights	1693:1704	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	5	51	theme	glycopeptides	868:880	arg1	total					855:859	A total	853:859	A total of 789 glycopeptides	853:880	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	9	52	dep	structure	1629:1637	arg1	the					1611:1613	the	1611:1613	the	1611:1613	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	3	53	theme	intact	499:504	arg1	glycopeptide					506:517	intact glycopeptide	499:517	intact glycopeptide	499:517	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	54	theme	severe	599:604	arg1	PE					606:607	early-onset severe PE	587:607	early-onset severe PE	587:607	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	1	55	theme	maternal	204:211	arg1	worldwide					234:242	maternal and perinatal health worldwide	204:242	maternal and perinatal health worldwide	204:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	8	56	dep	Conclusion	1350:1359	arg1	This					1361:1364	This	1361:1364	This	1361:1364	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	7	57	theme	abundance	1333:1341	arg1	level					1343:1347	the protein abundance level	1321:1347	the protein abundance level	1321:1347	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	3	58	from	women	560:564	arg1	placentas					522:530	placentas	522:530	placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	522:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	58	from	women	560:564	arg1	expression					468:477	the global expression	457:477	the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE	457:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	9	59	theme	pathogenic	1730:1739	arg1	mechanism					1741:1749	the pathogenic mechanism	1726:1749	the pathogenic mechanism of PE	1726:1755	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	8	60	theme	placental	1459:1467	arg1	tissues					1469:1475	placental tissues	1459:1475	placental tissues	1459:1475	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	0	61	theme	Patients	76:83	arg1	Tissues					65:71	Placental Tissues	55:71	Placental Tissues of Patients with Preeclampsia	55:101	Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.
36660462	1	62	theme	multi-system	138:149	arg1	disorder					151:158	a multi-system disorder	136:158	a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide	136:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	1	62	theme	multi-system	138:149	arg1	Preeclampsia					115:126	Background Preeclampsia	104:126	Background Preeclampsia (PE)	104:131	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	7	63	theme	glycoproteomic	1186:1199	arg1	data					1201:1204	proteomic and glycoproteomic data	1172:1204	proteomic and glycoproteomic data	1172:1204	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	8	64	theme	patients	1483:1490	arg1	proteomic					1410:1418	proteomic	1410:1418	proteomic	1410:1418	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	4	65	theme	proteins	680:687	arg1	total					666:670	A total	664:670	Results A total of 2260 proteins	656:687	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	7	66	theme	proteomic	1172:1180	arg1	data					1201:1204	proteomic and glycoproteomic data	1172:1204	proteomic and glycoproteomic data	1172:1204	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	9	67	theme	glycosylation	1519:1531	arg1	modification					1533:1544	glycosylation modification	1519:1544	glycosylation modification	1519:1544	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	7	68	theme	glycosylation	1290:1302	arg1	level					1304:1308	glycosylation level	1290:1308	glycosylation level	1290:1308	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	0	69	theme	Proteomic	11:19	arg1	Profiling					42:50	Proteomic and N-Glycoproteomic Profiling	11:50	Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia	11:101	Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.
36660462	3	70	theme	mass	390:393	arg1	labeling					399:406	tandem mass tag labeling	383:406	tandem mass tag labeling combined with LC-MS/MS	383:429	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	0	71	theme	N-Glycoproteomic	25:40	arg1	Profiling					42:50	Proteomic and N-Glycoproteomic Profiling	11:50	Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia	11:101	Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.
36660462	4	72	dep	Results	656:662	arg1	total					666:670	A total	664:670	Results A total of 2260 proteins	656:687	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	9	73	theme	molecular	1561:1569	arg1	function					1571:1578	the molecular function	1557:1578	the molecular function of proteins	1557:1590	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	9	74	from	changes	1600:1606	arg1	occupancy					1646:1654	the occupancy	1642:1654	the occupancy of glycosylation	1642:1671	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	9	74	from	changes	1600:1606	arg1	structure					1629:1637	glycosylation structure	1615:1637	glycosylation structure	1615:1637	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	3	75	theme	severe	645:650	arg1	PE					652:653	late-onset severe PE	634:653	late-onset severe PE	634:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	6	76	theme	expressed	1047:1055	arg1	glycopeptides					1057:1069	123 differently expressed glycopeptides	1031:1069	123 differently expressed glycopeptides	1031:1069	A total of 123 differently expressed glycopeptides, which were from 47 glycoproteins were identified among three groups.
36660462	4	77	theme	early-onset	789:799	arg1	groups					819:824	the early-onset and late-onset PE groups	785:824	the early-onset and late-onset PE groups	785:824	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	0	78	theme	Tissues	65:71	arg1	Profiling					42:50	Proteomic and N-Glycoproteomic Profiling	11:50	Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia	11:101	Integrated Proteomic and N-Glycoproteomic Profiling of Placental Tissues of Patients with Preeclampsia.
36660462	8	79	dep	proteomic	1410:1418	arg1	integrated					1399:1408	integrated	1399:1408	integrated	1399:1408	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	7	80	gly	glycoproteins	1243:1255	arg1	glycoproteins					1243:1255	10 glycoproteins	1240:1255	10 glycoproteins	1240:1255	Through a combined analysis of proteomic and glycoproteomic data, it was found that the changes in 10 glycoproteins were caused by the difference in glycosylation level but not in the protein abundance level.
36660462	4	81	theme	late-onset	805:814	arg1	groups					819:824	the early-onset and late-onset PE groups	785:824	the early-onset and late-onset PE groups	785:824	Results A total of 2260 proteins were quantified across 9 placental tissues, of which 37 and 23 were differentially expressed in the early-onset and late-onset PE groups, compared to the controls.
36660462	5	82	theme	159	960:962	arg1	glycoproteins					964:976	159 glycoproteins	960:976	159 glycoproteins	960:976	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
36660462	8	83	theme	first	1373:1377	arg1	study					1379:1383	the first study	1369:1383	the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients	1369:1490	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	8	83	theme	first	1373:1377	arg1	Conclusion					1350:1359	Conclusion	1350:1359	Conclusion This	1350:1364	Conclusion This is the first study to conduct an integrated proteomic and glycoproteomic characterization of placental tissues of PE patients.
36660462	2	84	theme	N-glycosylations	322:337	arg1	alterations					284:294	the global alterations	273:294	the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis	273:374	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	2	84	theme	N-glycosylations	322:337	arg1	crucial					348:354	crucial	348:354	crucial	348:354	This study aims to evaluate the global alterations of protein expression and N-glycosylations that are crucial for PE pathogenesis.
36660462	1	85	theme	health	227:232	arg1	worldwide					234:242	maternal and perinatal health worldwide	204:242	maternal and perinatal health worldwide	204:242	Background Preeclampsia (PE) is a multi-system disorder of pregnancy that poses a serious threat to maternal and perinatal health worldwide.
36660462	9	86	theme	glycosylation	1615:1627	arg1	structure					1629:1637	glycosylation structure	1615:1637	glycosylation structure	1615:1637	Our findings suggest that glycosylation modification may affect the molecular function of proteins through changes in the glycosylation structure or the occupancy of glycosylation, which will provide new insights to help elucidating the pathogenic mechanism of PE.
36660462	3	87	with	women	560:564	arg1	PE					606:607	early-onset severe PE	587:607	early-onset severe PE	587:607	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	3	87	with	women	560:564	arg1	PE					652:653	late-onset severe PE	634:653	late-onset severe PE	634:653	Here, tandem mass tag labeling combined with LC-MS/MS was employed to determine the global expression of all proteins and intact glycopeptide in placentas from three healthy pregnant women, three patients with early-onset severe PE, and three patients with late-onset severe PE.
36660462	5	88	from	sites	951:955	arg1	glycoproteins					964:976	159 glycoproteins	960:976	159 glycoproteins	960:976	A total of 789 glycopeptides were accurately quantified, which were derived from 204 glycosylated sites in 159 glycoproteins and were modified by 59 N-Linked glycans.
35675860	18	0	theme	distinct	3482:3489	arg1	activities					3528:3537	their distinct anti-inflammatory and anti-oxidative activities	3476:3537	their distinct anti-inflammatory and anti-oxidative activities	3476:3537	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	6	1	theme	root	1101:1104	arg1	METHODS					1067:1073	METHODS	1067:1073	METHODS	1067:1073	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	6	1	theme	root	1101:1104	arg1	MATERIALS					1053:1061	MATERIALS	1053:1061	MATERIALS	1053:1061	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	11	2	theme	rhamnogalacturonan	2397:2414	arg1	region					2418:2423	rhamnogalacturonan I region	2397:2423	rhamnogalacturonan I region	2397:2423	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	17	3	theme	anti-inflammatory	3202:3218	arg1	effects					3239:3245	better anti-inflammatory and anti-oxidative effects	3195:3245	better anti-inflammatory and anti-oxidative effects	3195:3245	It was concluded that ASP-H-AP possessed better anti-inflammatory and anti-oxidative effects, while those of ASP-T-AP was relatively poor among the four polysaccharide fractions.
35675860	8	4	theme	previous	1899:1906	arg1	report					1908:1913	the previous report	1895:1913	the previous report with minor modification	1895:1937	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	2	5	theme	various	354:360	arg1	applications					371:382	various clinical applications	354:382	various clinical applications	354:382	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	8	6	from	comparison	1379:1388	arg1	parts					1418:1422	different root parts	1403:1422	different root parts	1403:1422	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	2	7	dep	RELEVANCE	205:213	arg1	root					219:222	The root	215:222	The root of Angelica sinensis	215:243	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	17	8	theme	anti-oxidative	3224:3237	arg1	effects					3239:3245	better anti-inflammatory and anti-oxidative effects	3195:3245	better anti-inflammatory and anti-oxidative effects	3195:3245	It was concluded that ASP-H-AP possessed better anti-inflammatory and anti-oxidative effects, while those of ASP-T-AP was relatively poor among the four polysaccharide fractions.
35675860	15	9	theme	IPEC-J2	2876:2882	arg1	cells					2884:2888	IPEC-J2 cells	2876:2888	IPEC-J2 cells	2876:2888	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	7	10	theme	water	1233:1237	arg1	extraction					1239:1248	water extraction	1233:1248	water extraction	1233:1248	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	8	11	from	parts	1418:1422	arg1	comparison					1379:1388	The comparison	1375:1388	The comparison of ASPs from different root parts	1375:1422	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	11	from	parts	1418:1422	arg1	ASPs					1393:1396	ASPs	1393:1396	ASPs from different root parts	1393:1422	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	2	12	from	parts	345:349	arg1	applications					371:382	various clinical applications	354:382	various clinical applications	354:382	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	2	13	used	used	264:267	arg2	RELEVANCE					205:213	ETHNOPHARMACOLOGICAL RELEVANCE	184:213	ETHNOPHARMACOLOGICAL RELEVANCE	184:213	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	19	14	theme	pharmacological	3626:3640	arg1	activities					3642:3651	various pharmacological activities	3618:3651	various pharmacological activities	3618:3651	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	5	15	theme	anti-oxidative	863:876	arg1	activities					900:909	its anti-oxidative and anti-inflammatory activities	859:909	its anti-oxidative and anti-inflammatory activities in vitro	859:918	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	20	16	from	addition	3702:3709	arg1	valuable					3724:3731	valuable	3724:3731	valuable	3724:3731	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	9	17	theme	APSs	1974:1977	arg1	activities					1960:1969	In vitro biological activities	1940:1969	In vitro biological activities of APSs	1940:1977	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	5	18	with	polysaccharides	957:971	arg1	structures					987:996	distinct structures	978:996	distinct structures obtained from different parts of the A. sinensis root	978:1050	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	15	19	theme	polysaccharide	2839:2852	arg1	fractions					2854:2862	four polysaccharide fractions	2834:2862	four polysaccharide fractions	2834:2862	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	3	20	theme	information	556:566	arg1	dearth					535:540	a dearth	533:540	a dearth of scientific information on its water-soluble polysaccharides	533:603	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	5	21	theme	anti-inflammatory	882:898	arg1	activities					900:909	its anti-oxidative and anti-inflammatory activities	859:909	its anti-oxidative and anti-inflammatory activities in vitro	859:918	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	14	22	theme	distinct	2715:2722	arg1	structure					2732:2740	Their distinct primary structure	2709:2740	Their distinct primary structure	2709:2740	Their distinct primary structure could lead to a variety of biological activities.
35675860	15	23	theme	related	2971:2977	arg1	genes					2979:2983	related genes	2971:2983	related genes	2971:2983	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	10	24	theme	sinensis	2190:2197	arg1	ASP-H-AP					2127:2134	ASP-H-AP	2127:2134	ASP-H-AP	2127:2134	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	24	theme	sinensis	2190:2197	arg1	RESULTS					2088:2094	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP	2088:2168	RESULTS	2088:2094	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	24	theme	sinensis	2190:2197	arg1	ASP-Hb-AP					2160:2168	ASP-Hb-AP	2160:2168	ASP-Hb-AP	2160:2168	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	24	theme	sinensis	2190:2197	arg1	ASP-T-AP					2147:2154	ASP-T-AP	2147:2154	ASP-T-AP	2147:2154	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	24	theme	sinensis	2190:2197	arg1	ASP-B-AP					2137:2144	ASP-B-AP	2137:2144	ASP-B-AP	2137:2144	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	8	25	theme	gel	1780:1782	arg1	chromatography					1795:1808	gel permeation chromatography	1780:1808	gel permeation chromatography	1780:1808	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	5	26	theme	study	846:850	arg1	focus					832:836	the focus	828:836	the focus of this study	828:850	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	8	27	theme	chemical	1450:1457	arg1	compositions					1459:1470	chemical compositions	1450:1470	chemical compositions determined by colorimetric analysis	1450:1506	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	11	28	theme	long	2329:2332	arg1	region					2351:2356	a long homogalacturonan region	2327:2356	a long homogalacturonan region as the main backbone	2327:2377	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	15	29	theme	inflammation	2946:2957	arg1	factors					2959:2965	inflammation factors	2946:2965	inflammation factors	2946:2965	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	15	30	theme	biological	2801:2810	arg1	assays					2812:2817	In vitro biological assays	2792:2817	In vitro biological assays	2792:2817	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	11	31	theme	relative	2471:2478	arg1	contents					2480:2487	the relative contents	2467:2487	the relative contents of glycosidic units	2467:2507	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	4	32	theme	multiple	705:712	arg1	anti-oxidative					749:762	anti-oxidative	749:762	anti-oxidative	749:762	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	32	theme	multiple	705:712	arg1	liver					799:803	liver	799:803	liver	799:803	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	32	theme	multiple	705:712	arg1	anti-inflammatory					765:781	anti-inflammatory	765:781	anti-inflammatory	765:781	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	32	theme	multiple	705:712	arg1	activities					730:739	multiple pharmacological activities	705:739	multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection	705:814	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	2	33	theme	sinensis	236:243	arg1	root					219:222	The root	215:222	The root of Angelica sinensis	215:243	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	4	34	dep	anti-oxidative	749:762	arg1	protection					805:814	protection	805:814	protection	805:814	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	16	35	from	stress	3056:3061	arg1	cells					3074:3078	IPEC-J2 cells	3066:3078	IPEC-J2 cells	3066:3078	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	8	36	theme	colorimetric	1486:1497	arg1	analysis					1499:1506	colorimetric analysis	1486:1506	colorimetric analysis	1486:1506	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	37	theme	ASPs	1393:1396	arg1	comparison					1379:1388	The comparison	1375:1388	The comparison of ASPs from different root parts	1375:1422	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	18	38	from	parts	3431:3435	arg1	structure					3375:3383	the structure	3371:3383	the structure of pectic polysaccharides from different root parts of A. sinensis	3371:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	18	38	from	parts	3431:3435	arg1	polysaccharides					3395:3409	pectic polysaccharides	3388:3409	pectic polysaccharides from different root parts of A. sinensis	3388:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	15	39	theme	LPS-induced	2902:2912	arg1	inflammation					2914:2925	the LPS-induced inflammation	2898:2925	the LPS-induced inflammation	2898:2925	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	4	40	dep	AIM	606:608	arg1	structures					627:636	The structures	623:636	The structures of polysaccharides from plants	623:667	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	10	41	theme	various	2232:2238	arg1	contents					2240:2247	various contents	2232:2247	various contents of protein and the polyphenol	2232:2277	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	18	42	from	structure	3375:3383	arg1	parts					3431:3435	different root parts	3416:3435	different root parts of A. sinensis	3416:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	16	43	theme	antioxidant	3133:3143	arg1	enzymes					3145:3151	antioxidant enzymes	3133:3151	antioxidant enzymes	3133:3151	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	5	44	theme	in	911:912	arg1	activities					900:909	its anti-oxidative and anti-inflammatory activities	859:909	its anti-oxidative and anti-inflammatory activities in vitro	859:918	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	18	45	theme	sinensis	3443:3450	arg1	parts					3431:3435	different root parts	3416:3435	different root parts of A. sinensis	3416:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	19	46	theme	sinensis	3602:3609	arg1	parts					3590:3594	different parts	3580:3594	different parts of A. sinensis	3580:3609	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	10	47	theme	purified	2101:2108	arg1	polysaccharides					2110:2124	Four purified polysaccharides	2096:2124	Four purified polysaccharides	2096:2124	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	4	48	dep	anti-inflammatory	765:781	arg1	anti-tumor					784:793	anti-tumor	784:793	anti-tumor	784:793	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	6	49	dep	MATERIALS	1053:1061	arg1	parts					1080:1084	Four parts	1075:1084	Four parts	1075:1084	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	0	50	theme	polysaccharides	106:120	arg1	activities					92:101	intestinal anti-inflammatory and anti-oxidative activities	44:101	intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)	44:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	0	50	theme	polysaccharides	106:120	arg1	comparison					4:13	The comparison	0:13	The comparison of preliminary structure	0:38	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	13	51	contain	contained	2654:2662	arg1	fractions					2644:2652	the four polysaccharide fractions	2620:2652	the four polysaccharide fractions	2620:2652	The infrared spectrum also showed that the four polysaccharide fractions contained the characteristic peaks of polysaccharides.
35675860	13	51	contain	contained	2654:2662	arg2	peaks					2683:2687	the characteristic peaks	2664:2687	the characteristic peaks of polysaccharides	2664:2706	The infrared spectrum also showed that the four polysaccharide fractions contained the characteristic peaks of polysaccharides.
35675860	5	52	theme	distinct	978:985	arg1	structures					987:996	distinct structures	978:996	distinct structures obtained from different parts of the A. sinensis root	978:1050	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	2	53	dep	applied	314:320	arg1	divided					322:328	divided	322:328	is normally applied divided into different parts in various clinical applications	302:382	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	8	54	theme	performance	1554:1564	arg1	HPLC					1589:1592	HPLC	1589:1592	HPLC	1589:1592	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	54	theme	performance	1554:1564	arg1	chromatography					1573:1586	high performance liquid chromatography	1549:1586	high performance liquid chromatography (HPLC)	1549:1593	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	0	55	theme	different	127:135	arg1	parts					142:146	different root parts	127:146	different root parts of Angelica sinensis (Oliv.)	127:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	16	56	theme	protein	3110:3116	arg1	expressions					3118:3128	the gene and protein expressions	3097:3128	expressions	3118:3128	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	9	57	dep	In	1940:1941	arg1	vitro					1943:1947	vitro	1943:1947	vitro	1943:1947	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	15	58	dep	In	2792:2793	arg1	vitro					2795:2799	vitro	2795:2799	vitro	2795:2799	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	16	59	theme	enzymes	3145:3151	arg1	expressions					3118:3128	the gene and protein expressions	3097:3128	expressions	3118:3128	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	20	60	theme	further	3737:3743	arg1	studies					3745:3751	further studies	3737:3751	further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis	3737:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	7	61	theme	Sepharose	1322:1330	arg1	column					1348:1353	DEAE Sepharose chromatographic column	1317:1353	DEAE Sepharose chromatographic column	1317:1353	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	10	62	theme	polyphenol	2268:2277	arg1	contents					2240:2247	various contents	2232:2247	various contents of protein and the polyphenol	2232:2277	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	6	63	dep	A.	1089:1090	arg1	sinensis					1092:1099	sinensis	1092:1099	sinensis	1092:1099	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	3	64	theme	ferulic	460:466	arg1	acid					468:471	ferulic acid	460:471	ferulic acid	460:471	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	11	65	theme	units	2503:2507	arg1	subregions					2452:2461	subregions	2452:2461	subregions	2452:2461	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	11	65	theme	units	2503:2507	arg1	contents					2480:2487	the relative contents	2467:2487	the relative contents of glycosidic units	2467:2507	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	20	66	theme	root	3829:3832	arg1	parts					3834:3838	different root parts	3819:3838	different root parts of A. sinensis	3819:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	18	67	theme	pectic	3388:3393	arg1	polysaccharides					3395:3409	pectic polysaccharides	3388:3409	pectic polysaccharides from different root parts of A. sinensis	3388:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	3	68	theme	existing	413:420	arg1	studies					422:428	existing studies	413:428	existing studies	413:428	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	4	69	from	plants	662:667	arg1	structures					627:636	The structures	623:636	The structures of polysaccharides from plants	623:667	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	69	from	plants	662:667	arg1	polysaccharides					641:655	polysaccharides	641:655	polysaccharides from plants	641:667	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	2	70	theme	ETHNOPHARMACOLOGICAL	184:203	arg1	RELEVANCE					205:213	ETHNOPHARMACOLOGICAL RELEVANCE	184:213	ETHNOPHARMACOLOGICAL RELEVANCE	184:213	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	8	71	theme	different	1403:1411	arg1	parts					1418:1422	different root parts	1403:1422	different root parts	1403:1422	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	0	72	theme	structure	30:38	arg1	activities					92:101	intestinal anti-inflammatory and anti-oxidative activities	44:101	intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)	44:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	0	72	theme	structure	30:38	arg1	comparison					4:13	The comparison	0:13	The comparison of preliminary structure	0:38	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	3	73	theme	studies	422:428	arg1	majority					401:408	the majority	397:408	the majority of existing studies	397:428	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	5	74	theme	A.	1035:1036	arg1	root					1047:1050	the A. sinensis root	1031:1050	the A. sinensis root	1031:1050	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	14	75	theme	activities	2780:2789	arg1	variety					2758:2764	a variety	2756:2764	a variety of biological activities	2756:2789	Their distinct primary structure could lead to a variety of biological activities.
35675860	14	75	theme	activities	2780:2789	arg1	activities					2780:2789	biological activities	2769:2789	biological activities	2769:2789	Their distinct primary structure could lead to a variety of biological activities.
35675860	13	76	theme	infrared	2585:2592	arg1	spectrum					2594:2601	The infrared spectrum	2581:2601	The infrared spectrum	2581:2601	The infrared spectrum also showed that the four polysaccharide fractions contained the characteristic peaks of polysaccharides.
35675860	8	77	theme	linkage	1607:1613	arg1	units					1615:1619	glycosidic linkage units	1596:1619	glycosidic linkage units determined by methylation	1596:1645	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	10	78	from	root	2179:2182	arg1	ASP-H-AP					2127:2134	ASP-H-AP	2127:2134	ASP-H-AP	2127:2134	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	78	from	root	2179:2182	arg1	RESULTS					2088:2094	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP	2088:2168	RESULTS	2088:2094	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	78	from	root	2179:2182	arg1	ASP-Hb-AP					2160:2168	ASP-Hb-AP	2160:2168	ASP-Hb-AP	2160:2168	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	78	from	root	2179:2182	arg1	ASP-T-AP					2147:2154	ASP-T-AP	2147:2154	ASP-T-AP	2147:2154	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	10	78	from	root	2179:2182	arg1	ASP-B-AP					2137:2144	ASP-B-AP	2137:2144	ASP-B-AP	2137:2144	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	3	79	theme	different	488:496	arg1	parts					498:502	different parts	488:502	different parts of A. sinensis	488:517	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	0	80	theme	intestinal	44:53	arg1	activities					92:101	intestinal anti-inflammatory and anti-oxidative activities	44:101	intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)	44:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	20	81	theme	polysaccharides	3791:3805	arg1	relationship					3775:3786	structure-activity relationship	3756:3786	structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis	3756:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	5	82	theme	root	1047:1050	arg1	parts					1022:1026	different parts	1012:1026	different parts of the A. sinensis root	1012:1050	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	11	83	theme	main	2365:2368	arg1	backbone					2370:2377	the main backbone	2361:2377	the main backbone	2361:2377	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	6	84	theme	whole	1182:1186	arg1	body					1188:1191	whole body	1182:1191	whole body	1182:1191	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	2	85	theme	different	335:343	arg1	parts					345:349	different parts	335:349	different parts in various clinical applications	335:382	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	12	86	theme	polysaccharides	2532:2546	arg1	Mw					2514:2515	The Mw	2510:2515	The Mw of four pectic polysaccharides	2510:2546	The Mw of four pectic polysaccharides were ranged from 67.9-267.7 kDa.
35675860	11	87	with	polysaccharides	2306:2320	arg1	region					2351:2356	a long homogalacturonan region	2327:2356	a long homogalacturonan region as the main backbone	2327:2377	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	5	88	theme	different	1012:1020	arg1	parts					1022:1026	different parts	1012:1026	different parts of the A. sinensis root	1012:1050	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	3	89	theme	sinensis	510:517	arg1	parts					498:502	different parts	488:502	different parts of A. sinensis	488:517	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	4	90	theme	polysaccharides	641:655	arg1	structures					627:636	The structures	623:636	The structures of polysaccharides from plants	623:667	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	18	91	theme	CONCLUSION	3333:3342	arg1	results					3348:3354	CONCLUSION All results	3333:3354	CONCLUSION All results	3333:3354	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	7	92	theme	ethanol	1254:1260	arg1	method					1276:1281	ethanol precipitation method	1254:1281	ethanol precipitation method	1254:1281	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	8	93	theme	gas	1651:1653	arg1	GC-MS					1689:1693	GC-MS	1689:1693	GC-MS	1689:1693	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	93	theme	gas	1651:1653	arg1	spectrometry					1675:1686	gas chromatography-mass spectrometry	1651:1686	gas chromatography-mass spectrometry (GC-MS)	1651:1694	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	2	94	theme	clinical	362:369	arg1	applications					371:382	various clinical applications	354:382	various clinical applications	354:382	ETHNOPHARMACOLOGICAL RELEVANCE The root of Angelica sinensis, has been commonly used in gynecology for centuries, and is normally applied divided into different parts in various clinical applications.
35675860	20	95	from	valuable	3724:3731	arg1	addition					3702:3709	addition	3702:3709	addition	3702:3709	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	9	96	theme	In	1940:1941	arg1	activities					1960:1969	In vitro biological activities	1940:1969	In vitro biological activities of APSs	1940:1977	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	16	97	theme	oxidative	3046:3054	arg1	stress					3056:3061	oxidative stress	3046:3061	oxidative stress on IPEC-J2 cells	3046:3078	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	8	98	theme	minor	1920:1924	arg1	modification					1926:1937	minor modification	1920:1937	minor modification	1920:1937	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	9	99	theme	biological	1949:1958	arg1	activities					1960:1969	In vitro biological activities	1940:1969	In vitro biological activities of APSs	1940:1977	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	11	100	theme	pectic	2299:2304	arg1	polysaccharides					2306:2320	possibly pectic polysaccharides	2290:2320	possibly pectic polysaccharides with a long homogalacturonan region as the main backbone	2290:2377	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	14	101	theme	biological	2769:2778	arg1	activities					2780:2789	biological activities	2769:2789	biological activities	2769:2789	Their distinct primary structure could lead to a variety of biological activities.
35675860	19	102	theme	various	3618:3624	arg1	activities					3642:3651	various pharmacological activities	3618:3651	various pharmacological activities	3618:3651	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	8	103	theme	molecular	1744:1752	arg1	Mw					1762:1763	Mw	1762:1763	Mw	1762:1763	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	103	theme	molecular	1744:1752	arg1	weight					1754:1759	molecular weight	1744:1759	molecular weight (Mw)	1744:1764	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	18	104	theme	anti-oxidative	3513:3526	arg1	activities					3528:3537	their distinct anti-inflammatory and anti-oxidative activities	3476:3537	their distinct anti-inflammatory and anti-oxidative activities	3476:3537	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	6	105	dep	Pharmacopoeia	1146:1158	arg1	head					1161:1164	head	1161:1164	head	1161:1164	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	6	105	dep	Pharmacopoeia	1146:1158	arg1	tail					1173:1176	tail	1173:1176	tail	1173:1176	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	6	105	dep	Pharmacopoeia	1146:1158	arg1	body					1188:1191	whole body	1182:1191	whole body	1182:1191	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	6	105	dep	Pharmacopoeia	1146:1158	arg1	body					1167:1170	body	1167:1170	body	1167:1170	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	3	106	theme	scientific	545:554	arg1	information					556:566	scientific information	545:566	scientific information	545:566	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	8	107	theme	high	1549:1552	arg1	HPLC					1589:1592	HPLC	1589:1592	HPLC	1589:1592	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	107	theme	high	1549:1552	arg1	chromatography					1573:1586	high performance liquid chromatography	1549:1586	high performance liquid chromatography (HPLC)	1549:1593	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	14	108	theme	primary	2724:2730	arg1	structure					2732:2740	Their distinct primary structure	2709:2740	Their distinct primary structure	2709:2740	Their distinct primary structure could lead to a variety of biological activities.
35675860	16	109	theme	IPEC-J2	3066:3072	arg1	cells					3074:3078	IPEC-J2 cells	3066:3078	IPEC-J2 cells	3066:3078	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	15	110	theme	IPEC-J2	2988:2994	arg1	cells					2996:3000	IPEC-J2 cells	2988:3000	IPEC-J2 cells	2988:3000	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	11	111	theme	homogalacturonan	2334:2349	arg1	region					2351:2356	a long homogalacturonan region	2327:2356	a long homogalacturonan region as the main backbone	2327:2377	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	5	112	dep	A.	1035:1036	arg1	sinensis					1038:1045	sinensis	1038:1045	sinensis	1038:1045	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	4	113	from	structures	627:636	arg1	plants					662:667	plants	662:667	plants	662:667	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	19	114	theme	traditional	3682:3692	arg1	use					3694:3696	traditional use	3682:3696	traditional use	3682:3696	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	10	115	dep	RESULTS	2088:2094	arg1	polysaccharides					2110:2124	Four purified polysaccharides	2096:2124	Four purified polysaccharides	2096:2124	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	4	116	theme	STUDY	617:621	arg1	AIM					606:608	AIM	606:608	AIM OF THE STUDY	606:621	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	0	117	theme	sinensis	160:167	arg1	parts					142:146	different root parts	127:146	different root parts of Angelica sinensis (Oliv.)	127:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	3	118	theme	water-soluble	575:587	arg1	polysaccharides					589:603	its water-soluble polysaccharides	571:603	its water-soluble polysaccharides	571:603	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	18	119	theme	root	3426:3429	arg1	parts					3431:3435	different root parts	3416:3435	different root parts of A. sinensis	3416:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	8	120	theme	permeation	1784:1793	arg1	chromatography					1795:1808	gel permeation chromatography	1780:1808	gel permeation chromatography	1780:1808	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	3	121	from	dearth	535:540	arg1	polysaccharides					589:603	its water-soluble polysaccharides	571:603	its water-soluble polysaccharides	571:603	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	12	122	theme	pectic	2525:2530	arg1	polysaccharides					2532:2546	four pectic polysaccharides	2520:2546	four pectic polysaccharides	2520:2546	The Mw of four pectic polysaccharides were ranged from 67.9-267.7 kDa.
35675860	18	123	theme	polysaccharides	3395:3409	arg1	structure					3375:3383	the structure	3371:3383	the structure of pectic polysaccharides from different root parts of A. sinensis	3371:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	8	124	theme	monosaccharide	1509:1522	arg1	compositions					1524:1535	monosaccharide compositions	1509:1535	monosaccharide compositions measured by high performance liquid chromatography (HPLC)	1509:1593	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	20	125	theme	different	3819:3827	arg1	parts					3834:3838	different root parts	3819:3838	different root parts of A. sinensis	3819:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	11	126	theme	glycosidic	2492:2501	arg1	units					2503:2507	glycosidic units	2492:2507	glycosidic units	2492:2507	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	4	127	theme	pharmacological	714:728	arg1	anti-oxidative					749:762	anti-oxidative	749:762	anti-oxidative	749:762	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	127	theme	pharmacological	714:728	arg1	liver					799:803	liver	799:803	liver	799:803	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	127	theme	pharmacological	714:728	arg1	anti-inflammatory					765:781	anti-inflammatory	765:781	anti-inflammatory	765:781	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	4	127	theme	pharmacological	714:728	arg1	activities					730:739	multiple pharmacological activities	705:739	multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection	705:814	AIM OF THE STUDY The structures of polysaccharides from plants, have been reported contributing to multiple pharmacological activities such as anti-oxidative, anti-inflammatory, anti-tumor and liver protection.
35675860	17	128	theme	polysaccharide	3307:3320	arg1	fractions					3322:3330	the four polysaccharide fractions	3298:3330	the four polysaccharide fractions	3298:3330	It was concluded that ASP-H-AP possessed better anti-inflammatory and anti-oxidative effects, while those of ASP-T-AP was relatively poor among the four polysaccharide fractions.
35675860	0	129	theme	anti-oxidative	77:90	arg1	activities					92:101	intestinal anti-inflammatory and anti-oxidative activities	44:101	intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)	44:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	0	130	dep	sinensis	160:167	arg1	Oliv					170:173	Oliv	170:173	Oliv.	170:174	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	7	131	theme	gel	1359:1361	arg1	filtration					1363:1372	gel filtration	1359:1372	gel filtration	1359:1372	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	9	132	theme	oxidative	2046:2054	arg1	stress					2056:2061	oxidative stress	2046:2061	oxidative stress	2046:2061	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	7	133	theme	Crude	1194:1198	arg1	polysaccharides					1200:1214	Crude polysaccharides	1194:1214	Crude polysaccharides	1194:1214	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	20	134	theme	structure-activity	3756:3773	arg1	relationship					3775:3786	structure-activity relationship	3756:3786	structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis	3756:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	16	135	theme	gene	3101:3104	arg1	expressions					3118:3128	the gene and protein expressions	3097:3128	expressions	3118:3128	These polysaccharides also could alleviate oxidative stress on IPEC-J2 cells by up-regulating the gene and protein expressions of antioxidant enzymes.
35675860	0	136	from	comparison	4:13	arg1	parts					142:146	different root parts	127:146	different root parts of Angelica sinensis (Oliv.)	127:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	13	137	theme	characteristic	2668:2681	arg1	peaks					2683:2687	the characteristic peaks	2664:2687	the characteristic peaks of polysaccharides	2664:2706	The infrared spectrum also showed that the four polysaccharide fractions contained the characteristic peaks of polysaccharides.
35675860	10	138	theme	protein	2252:2258	arg1	contents					2240:2247	various contents	2232:2247	various contents of protein and the polyphenol	2232:2277	RESULTS Four purified polysaccharides, ASP-H-AP, ASP-B-AP, ASP-T-AP and ASP-Hb-AP from the root of A. sinensis, were obtained, and consisted of various contents of protein and the polyphenol.
35675860	11	139	theme	I	2416:2416	arg1	region					2418:2423	rhamnogalacturonan I region	2397:2423	rhamnogalacturonan I region	2397:2423	They were possibly pectic polysaccharides with a long homogalacturonan region as the main backbone and ramified with rhamnogalacturonan I region, but they were differed by subregions and the relative contents of glycosidic units.
35675860	8	140	theme	liquid	1566:1571	arg1	HPLC					1589:1592	HPLC	1589:1592	HPLC	1589:1592	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	140	theme	liquid	1566:1571	arg1	chromatography					1573:1586	high performance liquid chromatography	1549:1586	high performance liquid chromatography (HPLC)	1549:1593	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	9	141	theme	IPEC-J2	2073:2079	arg1	cells					2081:2085	IPEC-J2 cells	2073:2085	IPEC-J2 cells	2073:2085	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	9	142	dep	inflammatory	2029:2040	arg1	models					2063:2068	models	2063:2068	models	2063:2068	In vitro biological activities of APSs were compared on lipopolysaccharide (LPS)-induced inflammatory and oxidative stress models on IPEC-J2 cells.
35675860	0	143	theme	root	137:140	arg1	parts					142:146	different root parts	127:146	different root parts of Angelica sinensis (Oliv.)	127:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	7	144	theme	chromatographic	1332:1346	arg1	column					1348:1353	DEAE Sepharose chromatographic column	1317:1353	DEAE Sepharose chromatographic column	1317:1353	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	8	145	with	report	1908:1913	arg1	modification					1926:1937	minor modification	1920:1937	minor modification	1920:1937	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	3	146	theme	volatile	443:450	arg1	oil					452:454	volatile oil	443:454	volatile oil	443:454	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	13	147	theme	polysaccharide	2629:2642	arg1	fractions					2644:2652	the four polysaccharide fractions	2620:2652	the four polysaccharide fractions	2620:2652	The infrared spectrum also showed that the four polysaccharide fractions contained the characteristic peaks of polysaccharides.
35675860	18	148	theme	different	3416:3424	arg1	parts					3431:3435	different root parts	3416:3435	different root parts of A. sinensis	3416:3450	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	7	149	theme	DEAE	1317:1320	arg1	column					1348:1353	DEAE Sepharose chromatographic column	1317:1353	DEAE Sepharose chromatographic column	1317:1353	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	20	150	theme	sinensis	3846:3853	arg1	parts					3834:3838	different root parts	3819:3838	different root parts of A. sinensis	3819:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	0	151	from	activities	92:101	arg1	parts					142:146	different root parts	127:146	different root parts of Angelica sinensis (Oliv.)	127:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	0	152	theme	preliminary	18:28	arg1	structure					30:38	preliminary structure	18:38	preliminary structure	18:38	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	5	153	theme	various	949:955	arg1	polysaccharides					957:971	the various polysaccharides	945:971	the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root	945:1050	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	8	154	theme	glycosidic	1596:1605	arg1	units					1615:1619	glycosidic linkage units	1596:1619	glycosidic linkage units determined by methylation	1596:1645	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	5	155	dep	in	911:912	arg1	vitro					914:918	vitro	914:918	vitro	914:918	Therefore, the focus of this study was on its anti-oxidative and anti-inflammatory activities in vitro, which would be based on the various polysaccharides with distinct structures obtained from different parts of the A. sinensis root.
35675860	15	156	theme	In	2792:2793	arg1	assays					2812:2817	In vitro biological assays	2792:2817	In vitro biological assays	2792:2817	In vitro biological assays suggested that four polysaccharide fractions can protect IPEC-J2 cells against the LPS-induced inflammation by down-regulating inflammation factors and related genes on IPEC-J2 cells.
35675860	8	157	theme	functional	1705:1714	arg1	groups					1716:1721	organic functional groups	1697:1721	organic functional groups	1697:1721	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	6	158	theme	A.	1089:1090	arg1	root					1101:1104	A. sinensis root	1089:1104	A. sinensis root	1089:1104	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	13	159	theme	polysaccharides	2692:2706	arg1	peaks					2683:2687	the characteristic peaks	2664:2687	the characteristic peaks of polysaccharides	2664:2706	The infrared spectrum also showed that the four polysaccharide fractions contained the characteristic peaks of polysaccharides.
35675860	0	160	theme	anti-inflammatory	55:71	arg1	activities					92:101	intestinal anti-inflammatory and anti-oxidative activities	44:101	intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)	44:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	19	161	theme	factors	3568:3574	arg1	one					3557:3559	one	3557:3559	one	3557:3559	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	19	161	theme	factors	3568:3574	arg1	factors					3568:3574	the factors	3564:3574	the factors	3564:3574	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	6	162	theme	Chinese	1138:1144	arg1	Pharmacopoeia					1146:1158	the Chinese Pharmacopoeia	1134:1158	the Chinese Pharmacopoeia	1134:1158	MATERIALS AND METHODS Four parts of A. sinensis root were separated according to the Chinese Pharmacopoeia: head, body, tail and whole body.
35675860	8	163	theme	root	1413:1416	arg1	parts					1418:1422	different root parts	1403:1422	different root parts	1403:1422	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	164	theme	organic	1697:1703	arg1	groups					1716:1721	organic functional groups	1697:1721	organic functional groups	1697:1721	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	18	165	theme	anti-inflammatory	3491:3507	arg1	activities					3528:3537	their distinct anti-inflammatory and anti-oxidative activities	3476:3537	their distinct anti-inflammatory and anti-oxidative activities	3476:3537	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	3	166	dep	oil	452:454	arg1	the					439:441	the	439:441	the	439:441	At present, the majority of existing studies focus on the volatile oil and ferulic acid extracted from different parts of A. sinensis, but there is a dearth of scientific information on its water-soluble polysaccharides.
35675860	7	167	theme	precipitation	1262:1274	arg1	method					1276:1281	ethanol precipitation method	1254:1281	ethanol precipitation method	1254:1281	Crude polysaccharides were obtained by water extraction and ethanol precipitation method, and were further fractionated by DEAE Sepharose chromatographic column and gel filtration.
35675860	17	168	contain	possessed	3185:3193	arg2	effects					3239:3245	better anti-inflammatory and anti-oxidative effects	3195:3245	better anti-inflammatory and anti-oxidative effects	3195:3245	It was concluded that ASP-H-AP possessed better anti-inflammatory and anti-oxidative effects, while those of ASP-T-AP was relatively poor among the four polysaccharide fractions.
35675860	17	168	contain	possessed	3185:3193	arg1	ASP-H-AP					3176:3183	ASP-H-AP	3176:3183	ASP-H-AP	3176:3183	It was concluded that ASP-H-AP possessed better anti-inflammatory and anti-oxidative effects, while those of ASP-T-AP was relatively poor among the four polysaccharide fractions.
35675860	18	169	theme	All	3344:3346	arg1	results					3348:3354	CONCLUSION All results	3333:3354	CONCLUSION All results	3333:3354	CONCLUSION All results indicated that the structure of pectic polysaccharides from different root parts of A. sinensis differed, which lead to their distinct anti-inflammatory and anti-oxidative activities.
35675860	20	170	from	studies	3745:3751	arg1	relationship					3775:3786	structure-activity relationship	3756:3786	structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis	3756:3853	In addition, it would be valuable for further studies on structure-activity relationship of polysaccharides obtained by different root parts of A. sinensis.
35675860	8	171	theme	chromatography-mass	1655:1673	arg1	GC-MS					1689:1693	GC-MS	1689:1693	GC-MS	1689:1693	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	8	171	theme	chromatography-mass	1655:1673	arg1	spectrometry					1675:1686	gas chromatography-mass spectrometry	1651:1686	gas chromatography-mass spectrometry (GC-MS)	1651:1694	The comparison of ASPs from different root parts were performed, including chemical compositions determined by colorimetric analysis, monosaccharide compositions measured by high performance liquid chromatography (HPLC), glycosidic linkage units determined by methylation and gas chromatography-mass spectrometry (GC-MS), organic functional groups determined by FT-IR, molecular weight (Mw) demarcated by gel permeation chromatography, and the viscosities and solubilities were measured according to method published in the previous report with minor modification.
35675860	19	172	theme	different	3580:3588	arg1	parts					3590:3594	different parts	3580:3594	different parts of A. sinensis	3580:3609	This may also be one of the factors why different parts of A. sinensis showed various pharmacological activities and applied independently in traditional use.
35675860	0	173	from	parts	142:146	arg1	activities					92:101	intestinal anti-inflammatory and anti-oxidative activities	44:101	intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)	44:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	0	173	from	parts	142:146	arg1	comparison					4:13	The comparison	0:13	The comparison of preliminary structure	0:38	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35675860	0	173	from	parts	142:146	arg1	polysaccharides					106:120	polysaccharides	106:120	polysaccharides from different root parts of Angelica sinensis (Oliv.)	106:175	The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.)
35378159	1	0	theme	dulcis	150:155	arg1	HDPs					174:177	HDPs	174:177	HDPs	174:177	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	0	theme	dulcis	150:155	arg1	polysaccharides					157:171	Hovenia dulcis polysaccharides	142:171	Hovenia dulcis polysaccharides (HDPs)	142:178	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	4	1	theme	-β-D-Galp-	879:888	arg1	-β-D-Galp-					909:918	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	-β-D-Galp-	909:918	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	1	2	theme	potential	246:254	arg1	applications					256:267	potential applications	246:267	potential applications in food engineering, pharmacy science, and health care	246:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	7	3	theme	therapeutic	1199:1209	arg1	effect					1211:1216	a good therapeutic effect	1192:1216	a good therapeutic effect	1192:1216	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	3	4	theme	372.91 kDa	590:599	arg1	weight					580:585	a molecular weight	568:585	a molecular weight of 372.91 kDa	568:599	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	7	5	theme	diabetes	1243:1250	arg1	model					1227:1231	a rat model	1221:1231	a rat model of type 2 diabetes	1221:1250	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	6	6	theme	diffraction	1070:1080	arg1	results					1088:1094	X-ray diffraction (XRD) results	1064:1094	X-ray diffraction (XRD) results	1064:1094	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	3	7	theme	GalA	530:533	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	4	8	theme	1→	890:891	arg1	-β-D-Galp-					909:918	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	-β-D-Galp-	909:918	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	0	9	theme	polysaccharides	94:108	arg1	assessment					80:89	hypoglycemic activity assessment	58:89	hypoglycemic activity assessment	58:89	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	9	theme	polysaccharides	94:108	arg1	characterization					36:51	structural characterization	25:51	structural characterization	25:51	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	9	theme	polysaccharides	94:108	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	9	theme	polysaccharides	94:108	arg1	purification					11:22	purification	11:22	purification	11:22	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	6	10	theme	X-ray	1064:1068	arg1	diffraction					1070:1080	X-ray diffraction	1064:1080	X-ray diffraction (XRD) results	1064:1094	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	6	10	theme	X-ray	1064:1068	arg1	XRD					1083:1085	XRD	1083:1085	XRD	1083:1085	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	1	11	theme	food	272:275	arg1	engineering					277:287	food engineering	272:287	food engineering	272:287	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	4	12	theme	periodate	650:658	arg1	oxidation					660:668	periodate oxidation	650:668	periodate oxidation	650:668	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	4	13	theme	HDPs-2A	767:773	arg1	backbone					755:762	the backbone	751:762	the backbone of HDPs-2A	751:773	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	3	14	theme	Rha	525:527	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	3	15	theme	purified	438:445	arg1	HDPs-2A					464:470	HDPs-2A	464:470	HDPs-2A	464:470	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	3	15	theme	purified	438:445	arg1	polysaccharides					447:461	the purified polysaccharides	434:461	the purified polysaccharides (HDPs-2A)	434:471	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	0	16	theme	Hovenia	115:121	arg1	Zao					136:138	Zao	136:138	Zao	136:138	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	16	theme	Hovenia	115:121	arg1	dulcis					123:128	Hovenia dulcis	115:128	Hovenia dulcis (Guai Zao)	115:139	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	7	17	theme	rat	1223:1225	arg1	model					1227:1231	a rat model	1221:1231	a rat model of type 2 diabetes	1221:1250	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	6	18	theme	crystal	1130:1136	arg1	structure					1138:1146	a single crystal structure	1121:1146	a single crystal structure	1121:1146	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	5	19	theme	irregular	1016:1024	arg1	morphology					1043:1052	an irregular polymer particle morphology	1013:1052	an irregular polymer particle morphology in water	1013:1061	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	5	20	theme	atomic	955:960	arg1	AFM					980:982	AFM	980:982	AFM	980:982	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	5	20	theme	atomic	955:960	arg1	microscopy					968:977	atomic force microscopy	955:977	atomic force microscopy (AFM)	955:983	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	7	21	contain	have	1187:1190	arg1	HDPs-2A					1179:1185	HDPs-2A	1179:1185	HDPs-2A	1179:1185	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	7	21	contain	have	1187:1190	arg2	effect					1211:1216	a good therapeutic effect	1192:1216	a good therapeutic effect	1192:1216	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	3	22	theme	Glc	542:544	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	7	23	theme	type	1236:1239	arg1	diabetes					1243:1250	type 2 diabetes	1236:1250	type 2 diabetes	1236:1250	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	4	24	theme	HDPs-2A	619:625	arg1	structure					606:614	The structure	602:614	The structure of HDPs-2A	602:625	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	5	25	theme	microscopy	968:977	arg1	results					944:950	The results	940:950	The results of atomic force microscopy (AFM)	940:983	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	4	26	theme	Smith	671:675	arg1	degradation					677:687	Smith degradation	671:687	Smith degradation	671:687	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	6	27	theme	single	1123:1128	arg1	structure					1138:1146	a single crystal structure	1121:1146	a single crystal structure	1121:1146	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	3	28	theme	GlcA	536:539	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	7	29	theme	good	1194:1197	arg1	effect					1211:1216	a good therapeutic effect	1192:1216	a good therapeutic effect	1192:1216	Finally, we demonstrated that HDPs-2A have a good therapeutic effect on a rat model of type 2 diabetes.
35378159	5	30	from	morphology	1043:1052	arg1	water					1057:1061	water	1057:1061	water	1057:1061	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	1	31	contain	have	180:183	arg2	variety					187:193	a variety	185:193	a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care	185:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	31	contain	have	180:183	arg1	HDPs					174:177	HDPs	174:177	HDPs	174:177	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	31	contain	have	180:183	arg2	activities					219:228	important biological activities	198:228	important biological activities associated with potential applications in food engineering, pharmacy science, and health care	198:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	31	contain	have	180:183	arg1	polysaccharides					157:171	Hovenia dulcis polysaccharides	142:171	Hovenia dulcis polysaccharides (HDPs)	142:178	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	4	32	theme	-α-L-Araf-	821:830	arg1	-β-D-Galp-					909:918	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	-β-D-Galp-	909:918	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	0	33	theme	structural	25:34	arg1	characterization					36:51	structural characterization	25:51	structural characterization	25:51	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	4	34	theme	-β-D-Galp-	859:868	arg1	-β-D-Galp-					909:918	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	-β-D-Galp-	909:918	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	1	35	from	applications	256:267	arg1	pharmacy					290:297	pharmacy science	290:305	pharmacy science	290:305	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	35	from	applications	256:267	arg1	engineering					277:287	food engineering	272:287	food engineering	272:287	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	35	from	applications	256:267	arg1	care					319:322	health care	312:322	health care	312:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	3	36	theme	Ara	556:558	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	2	37	from	H.	379:380	arg1	polysaccharides					358:372	polysaccharides	358:372	polysaccharides from H. dulcis	358:387	Herein, we isolated and purified polysaccharides from H. dulcis.
35378159	1	38	theme	important	198:206	arg1	activities					219:228	important biological activities	198:228	important biological activities associated with potential applications in food engineering, pharmacy science, and health care	198:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	3	39	theme	Chemical	390:397	arg1	analysis					411:418	Chemical composition analysis	390:418	Chemical composition analysis	390:418	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	4	40	theme	-α-L-Araf-	841:850	arg1	-β-D-Galp-					909:918	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	-β-D-Galp-	909:918	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	3	41	theme	Gal	547:549	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	3	42	theme	different	490:498	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	3	43	theme	composition	399:409	arg1	analysis					411:418	Chemical composition analysis	390:418	Chemical composition analysis	390:418	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	1	44	theme	health	312:317	arg1	care					319:322	health care	312:322	health care	312:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	4	45	theme	-α-L-Araf-	803:812	arg1	-β-D-Galp-					909:918	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	-β-D-Galp-	909:918	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	0	46	from	dulcis	123:128	arg1	assessment					80:89	hypoglycemic activity assessment	58:89	hypoglycemic activity assessment	58:89	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	46	from	dulcis	123:128	arg1	characterization					36:51	structural characterization	25:51	structural characterization	25:51	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	46	from	dulcis	123:128	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	0	46	from	dulcis	123:128	arg1	purification					11:22	purification	11:22	purification	11:22	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	3	47	theme	molar	500:504	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	5	48	theme	force	962:966	arg1	AFM					980:982	AFM	980:982	AFM	980:982	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	5	48	theme	force	962:966	arg1	microscopy					968:977	atomic force microscopy	955:977	atomic force microscopy (AFM)	955:983	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	2	49	dep	H.	379:380	arg1	dulcis					382:387	H. dulcis	379:387	H. dulcis	379:387	Herein, we isolated and purified polysaccharides from H. dulcis.
35378159	4	50	dep	-β-D-Galp-	909:918	arg1	→3					906:907	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	→3	906:907	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	4	50	dep	-β-D-Galp-	909:918	arg1	T-β-D-Galp					894:903	→5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-	800:918	T-β-D-Galp	894:903	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	4	51	theme	methylation	690:700	arg1	analysis					702:709	methylation analysis	690:709	methylation analysis	690:709	The structure of HDPs-2A was assessed by FT-IR, periodate oxidation, Smith degradation, methylation analysis, and NMR, allowing us to determine that the backbone of HDPs-2A is composed primarily of →5)-α-L-Araf-(1→, →5)-α-L-Araf-(1→, →3,5)-α-L-Araf-(1→, →6)-β-D-Galp-(1→, →3,6)-β-D-Galp-(1→, T-β-D-Galp, →3)-β-D-Galp-(1→, and T-α-D-Glcp.
35378159	1	52	theme	biological	208:217	arg1	activities					219:228	important biological activities	198:228	important biological activities associated with potential applications in food engineering, pharmacy science, and health care	198:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	3	53	theme	molecular	570:578	arg1	weight					580:585	a molecular weight	568:585	a molecular weight of 372.91 kDa	568:599	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	1	54	theme	activities	219:228	arg1	variety					187:193	a variety	185:193	a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care	185:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	54	theme	activities	219:228	arg1	activities					219:228	important biological activities	198:228	important biological activities associated with potential applications in food engineering, pharmacy science, and health care	198:322	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	0	55	theme	activity	71:78	arg1	assessment					80:89	hypoglycemic activity assessment	58:89	hypoglycemic activity assessment	58:89	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	3	56	theme	mannose	516:522	arg1	ratios					506:511	different molar ratios	490:511	different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara	490:558	Chemical composition analysis revealed that the purified polysaccharides (HDPs-2A) were composed of different molar ratios of mannose, Rha, GalA, GlcA, Glc, Gal, and Ara and had a molecular weight of 372.91 kDa.
35378159	6	57	contain	have	1116:1119	arg2	structure					1138:1146	a single crystal structure	1121:1146	a single crystal structure	1121:1146	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	6	57	contain	have	1116:1119	arg1	HDPs-2A					1108:1114	HDPs-2A	1108:1114	HDPs-2A	1108:1114	X-ray diffraction (XRD) results showed that HDPs-2A have a single crystal structure.
35378159	5	58	theme	polymer	1026:1032	arg1	morphology					1043:1052	an irregular polymer particle morphology	1013:1052	an irregular polymer particle morphology in water	1013:1061	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
35378159	0	59	theme	hypoglycemic	58:69	arg1	assessment					80:89	hypoglycemic activity assessment	58:89	hypoglycemic activity assessment	58:89	Isolation, purification, structural characterization, and hypoglycemic activity assessment of polysaccharides from Hovenia dulcis (Guai Zao).
35378159	1	60	dep	pharmacy	290:297	arg1	science					299:305	science	299:305	science	299:305	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	61	theme	Hovenia	142:148	arg1	HDPs					174:177	HDPs	174:177	HDPs	174:177	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	1	61	theme	Hovenia	142:148	arg1	polysaccharides					157:171	Hovenia dulcis polysaccharides	142:171	Hovenia dulcis polysaccharides (HDPs)	142:178	Hovenia dulcis polysaccharides (HDPs) have a variety of important biological activities associated with potential applications in food engineering, pharmacy science, and health care.
35378159	5	62	theme	particle	1034:1041	arg1	morphology					1043:1052	an irregular polymer particle morphology	1013:1052	an irregular polymer particle morphology in water	1013:1061	The results of atomic force microscopy (AFM) showed that HDPs-2A present an irregular polymer particle morphology in water.
36623619	4	0	theme	ZnO	875:877	arg1	effect					856:861	the synergistic effect	840:861	the synergistic effect of CMCS and ZnO	840:877	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	1	1	theme	carboxymethyl	280:292	arg1	chitosan					294:301	carboxymethyl chitosan	280:301	carboxymethyl chitosan (CMCS)	280:308	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	1	1	theme	carboxymethyl	280:292	arg1	CMCS					304:307	CMCS	304:307	CMCS	304:307	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	0	2	theme	food	145:148	arg1	packaging					150:158	food packaging	145:158	food packaging	145:158	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	2	3	dep	spectroscopy	434:445	arg1	observation					479:489	observation	479:489	observation	479:489	The composite film successfully compounded the nanoparticles, as deduced by spectroscopy, crystallography and morphology observation.
36623619	4	4	theme	pathogenic	932:941	arg1	monocytogenes					961:973	the pathogenic bacteria Listeria monocytogenes	928:973	the pathogenic bacteria Listeria monocytogenes	928:973	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	3	5	theme	composite	727:735	arg1	film					737:740	the composite film	723:740	the composite film	723:740	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	6	theme	shielding	627:635	arg1	ability					637:643	UV shielding ability	624:643	UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film	624:740	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	1	7	theme	chitosan	294:301	arg1	nanoparticles					326:338	hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles	250:338	hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials	250:355	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	3	8	theme	application	762:772	arg1	prospects					774:782	the application prospects	758:782	the application prospects of the composite film in water-rich foods	758:824	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	9	theme	film	737:740	arg1	resistance					542:551	the solvent resistance	530:551	the solvent resistance (the water solubility of the composite film was reduced by 94.3 %)	530:618	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	9	theme	film	737:740	arg1	ability					637:643	UV shielding ability	624:643	UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film	624:740	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	5	10	dep	capacity	1148:1155	arg1	%					1173:1173	142.24 %	1166:1173	improve 142.24 %	1158:1173	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	3	11	theme	film	592:595	arg1	solubility					564:573	the water solubility	554:573	the water solubility of the composite film	554:595	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	5	12	dep	%	1173:1173	arg1	improve					1158:1164	improve	1158:1164	improve	1158:1164	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	4	13	theme	Listeria	952:959	arg1	monocytogenes					961:973	the pathogenic bacteria Listeria monocytogenes	928:973	the pathogenic bacteria Listeria monocytogenes	928:973	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	5	14	theme	CMCS	1056:1059	arg1	addition					1044:1051	The addition	1040:1051	The addition of CMCS and ZnO	1040:1067	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	3	15	from	prospects	774:782	arg1	foods					820:824	water-rich foods	809:824	water-rich foods	809:824	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	5	16	theme	film	1193:1196	arg1	elasticity					1101:1110	the elasticity	1097:1110	the elasticity (improve 494.34 %)	1097:1129	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	5	16	theme	film	1193:1196	arg1	capacity					1148:1155	maximum load capacity	1135:1155	maximum load capacity (improve 142.24 %) of the composite film	1135:1196	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	1	17	theme	solution	220:227	arg1	method					237:242	solution casting method	220:242	solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials	220:355	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	0	18	theme	carboxymethyl	97:109	arg1	CMCS					121:124	CMCS	121:124	CMCS	121:124	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	0	18	theme	carboxymethyl	97:109	arg1	chitosan					111:118	carboxymethyl chitosan	97:118	carboxymethyl chitosan (CMCS)	97:125	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	3	19	theme	UV	650:651	arg1	capacity					663:670	the UV shielding capacity	646:670	the UV shielding capacity of the composite film	646:692	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	5	20	theme	maximum	1135:1141	arg1	capacity					1148:1155	maximum load capacity	1135:1155	maximum load capacity (improve 142.24 %) of the composite film	1135:1196	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	3	21	theme	water-rich	809:818	arg1	foods					820:824	water-rich foods	809:824	water-rich foods	809:824	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	4	22	theme	composite	890:898	arg1	film					900:903	the composite film	886:903	the composite film	886:903	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	3	23	theme	composite	791:799	arg1	film					801:804	the composite film	787:804	the composite film	787:804	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	5	24	theme	load	1143:1146	arg1	capacity					1148:1155	maximum load capacity	1135:1155	maximum load capacity (improve 142.24 %) of the composite film	1135:1196	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	4	25	theme	CMCS	866:869	arg1	effect					856:861	the synergistic effect	840:861	the synergistic effect of CMCS and ZnO	840:877	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	3	26	theme	ZnO	517:519	arg1	addition					496:503	The addition	492:503	The addition of CMCS and ZnO	492:519	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	27	theme	film	801:804	arg1	prospects					774:782	the application prospects	758:782	the application prospects of the composite film in water-rich foods	758:824	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	28	dep	resistance	542:551	arg1	reduced					601:607	reduced	601:607	was reduced by 94.3 %	597:617	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	1	29	theme	casting	229:235	arg1	method					237:242	solution casting method	220:242	solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials	220:355	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	5	30	dep	elasticity	1101:1110	arg1	%					1128:1128	494.34 %	1121:1128	improve 494.34 %	1113:1128	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	4	31	theme	of	1008:1009	arg1	%					1028:1028	rate of inhibition>99.99 %	1003:1028	rate of inhibition>99.99 %	1003:1028	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	4	31	theme	of	1008:1009	arg1	aeruginosa					991:1000	Pseudomonas aeruginosa	979:1000	Pseudomonas aeruginosa (rate of inhibition>99.99 %)	979:1029	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	5	32	theme	ZnO	1065:1067	arg1	addition					1044:1051	The addition	1040:1051	The addition of CMCS and ZnO	1040:1067	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	3	33	theme	CMCS	508:511	arg1	addition					496:503	The addition	492:503	The addition of CMCS and ZnO	492:519	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	4	34	theme	rate	1003:1006	arg1	%					1028:1028	rate of inhibition>99.99 %	1003:1028	rate of inhibition>99.99 %	1003:1028	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	4	34	theme	rate	1003:1006	arg1	aeruginosa					991:1000	Pseudomonas aeruginosa	979:1000	Pseudomonas aeruginosa (rate of inhibition>99.99 %)	979:1029	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	2	35	theme	composite	362:370	arg1	film					372:375	The composite film	358:375	The composite film	358:375	The composite film successfully compounded the nanoparticles, as deduced by spectroscopy, crystallography and morphology observation.
36623619	3	36	theme	shielding	653:661	arg1	capacity					663:670	the UV shielding capacity	646:670	the UV shielding capacity of the composite film	646:692	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	1	37	theme	zinc	315:318	arg1	oxide					320:324	zinc oxide	315:324	zinc oxide	315:324	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	1	38	theme	food	165:168	arg1	packaging					170:178	food packaging	165:178	food packaging	165:178	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	0	39	theme	antibacterial	34:46	arg1	film					48:51	an antibacterial film	31:51	an antibacterial film	31:51	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	1	40	theme	hydroxyethyl	250:261	arg1	HEC					274:276	HEC	274:276	HEC	274:276	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	1	40	theme	hydroxyethyl	250:261	arg1	cellulose					263:271	hydroxyethyl cellulose	250:271	hydroxyethyl cellulose (HEC)	250:277	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	1	41	theme	oxide	320:324	arg1	nanoparticles					326:338	hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles	250:338	hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials	250:355	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	5	42	theme	composite	1183:1191	arg1	film					1193:1196	the composite film	1179:1196	the composite film	1179:1196	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	1	43	theme	cellulose	263:271	arg1	nanoparticles					326:338	hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles	250:338	hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials	250:355	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	4	44	theme	synergistic	844:854	arg1	effect					856:861	the synergistic effect	840:861	the synergistic effect of CMCS and ZnO	840:877	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	3	45	dep	ability	637:643	arg1	increased					698:706	increased	698:706	was increased by 45.73 %	694:717	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	46	theme	composite	582:590	arg1	film					592:595	the composite film	578:595	the composite film	578:595	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	0	47	theme	film	48:51	arg1	characterization					11:26	characterization	11:26	characterization	11:26	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	0	47	theme	film	48:51	arg1	Design					0:5	Design	0:5	Design	0:5	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	3	48	theme	composite	679:687	arg1	film					689:692	the composite film	675:692	the composite film	675:692	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	1	49	theme	raw	343:345	arg1	materials					347:355	raw materials	343:355	raw materials	343:355	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	3	50	theme	solvent	534:540	arg1	resistance					542:551	the solvent resistance	530:551	the solvent resistance (the water solubility of the composite film was reduced by 94.3 %)	530:618	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	51	theme	film	689:692	arg1	capacity					663:670	the UV shielding capacity	646:670	the UV shielding capacity of the composite film	646:692	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	0	52	theme	nano	132:135	arg1	ZnO					137:139	nano ZnO	132:139	nano ZnO for food packaging	132:158	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	5	53	dep	%	1128:1128	arg1	improve					1113:1119	improve	1113:1119	improve	1113:1119	The addition of CMCS and ZnO also significantly improved the elasticity (improve 494.34 %) and maximum load capacity (improve 142.24 %) of the composite film.
36623619	1	54	theme	novel	183:187	arg1	film					199:202	a novel composite film	181:202	a novel composite film	181:202	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	0	55	theme	hydroxyethyl	67:78	arg1	cellulose					80:88	hydroxyethyl cellulose	67:88	hydroxyethyl cellulose (HEC)	67:94	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	0	55	theme	hydroxyethyl	67:78	arg1	HEC					91:93	HEC	91:93	HEC	91:93	Design and characterization of an antibacterial film composited by hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and nano ZnO for food packaging.
36623619	4	56	from	monocytogenes	961:973	arg1	food					1034:1037	food	1034:1037	food	1034:1037	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
36623619	1	57	theme	composite	189:197	arg1	film					199:202	a novel composite film	181:202	a novel composite film	181:202	For food packaging, a novel composite film was prepared by solution casting method using hydroxyethyl cellulose (HEC), carboxymethyl chitosan (CMCS), and zinc oxide nanoparticles as raw materials.
36623619	3	58	theme	UV	624:625	arg1	ability					637:643	UV shielding ability	624:643	UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film	624:740	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	3	59	theme	water	558:562	arg1	solubility					564:573	the water solubility	554:573	the water solubility of the composite film	554:595	The addition of CMCS and ZnO enhanced the solvent resistance (the water solubility of the composite film was reduced by 94.3 %) and UV shielding ability (the UV shielding capacity of the composite film was increased by 45.73 %) of the composite film, thus improving the application prospects of the composite film in water-rich foods.
36623619	4	60	theme	bacteria	943:950	arg1	monocytogenes					961:973	the pathogenic bacteria Listeria monocytogenes	928:973	the pathogenic bacteria Listeria monocytogenes	928:973	In addition, the synergistic effect of CMCS and ZnO helped the composite film to efficiently inhibit the pathogenic bacteria Listeria monocytogenes and Pseudomonas aeruginosa (rate of inhibition>99.99 %) in food.
35568150	2	0	theme	film-forming	451:462	arg1	solution					464:471	the composite film-forming solution	437:471	the composite film-forming solution of XG and HPMC	437:486	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	1	theme	HPMC	360:363	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	1	theme	HPMC	360:363	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	2	theme	composite	441:449	arg1	solution					464:471	the composite film-forming solution	437:471	the composite film-forming solution of XG and HPMC	437:486	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	7	3	theme	XHT	1011:1013	arg1	films					1015:1019	XHT films	1011:1019	XHT films	1011:1019	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	7	4	theme	food	1123:1126	arg1	packaging					1128:1136	potential food packaging	1113:1136	potential food packaging	1113:1136	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	6	5	theme	green	893:897	arg1	peppers					899:905	green peppers	893:905	green peppers	893:905	Additionally, the MDA content in green peppers were 39.16% and 78.87% higher than that of unpackaged and XHT0, respectively.
35568150	7	6	theme	Practical	985:993	arg1	applications					995:1006	Practical applications	985:1006	Practical applications of XHT films in preserving fresh-cut bell peppers	985:1056	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	3	7	theme	TP	500:501	arg1	dosage					503:508	optimum TP dosage	492:508	optimum TP dosage of 6% (XHT6)	492:521	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	3	8	from	dosage	503:508	arg1	maximum					581:587	the maximum	577:587	the maximum	577:587	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	2	9	theme	HPMC	483:486	arg1	solution					464:471	the composite film-forming solution	437:471	the composite film-forming solution of XG and HPMC	437:486	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	4	10	theme	antibacterial	619:631	arg1	properties					633:642	antibacterial properties	619:642	antibacterial properties	619:642	The antioxidant activity and antibacterial properties were also enhanced, demonstrated good inhibitory ability to Staphylococcus aureus.
35568150	0	11	theme	fresh-cut	126:134	arg1	preservation					155:166	fresh-cut green bell peppers preservation	126:166	fresh-cut green bell peppers preservation	126:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	6	12	theme	higher	930:935	arg1	%					928:928	78.87%	923:928	78.87% higher than that of unpackaged and XHT0	923:968	Additionally, the MDA content in green peppers were 39.16% and 78.87% higher than that of unpackaged and XHT0, respectively.
35568150	2	13	theme	XG	476:477	arg1	solution					464:471	the composite film-forming solution	437:471	the composite film-forming solution of XG and HPMC	437:486	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	6	14	from	content	882:888	arg1	peppers					899:905	green peppers	893:905	green peppers	893:905	Additionally, the MDA content in green peppers were 39.16% and 78.87% higher than that of unpackaged and XHT0, respectively.
35568150	3	15	theme	optimum	492:498	arg1	dosage					503:508	optimum TP dosage	492:508	optimum TP dosage of 6% (XHT6)	492:521	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	1	16	theme	work	185:188	arg1	aim					173:175	The aim	169:175	The aim of this work	169:188	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	3	17	theme	%	514:514	arg1	dosage					503:508	optimum TP dosage	492:508	optimum TP dosage of 6% (XHT6)	492:521	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	6	18	theme	MDA	878:880	arg1	content					882:888	the MDA content	874:888	the MDA content in green peppers	874:905	Additionally, the MDA content in green peppers were 39.16% and 78.87% higher than that of unpackaged and XHT0, respectively.
35568150	6	18	theme	MDA	878:880	arg1	%					917:917	39.16%	912:917	39.16%	912:917	Additionally, the MDA content in green peppers were 39.16% and 78.87% higher than that of unpackaged and XHT0, respectively.
35568150	2	19	theme	xanthan	316:322	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	19	theme	xanthan	316:322	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	20	theme	polyphenols	370:380	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	20	theme	polyphenols	370:380	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	0	21	theme	gum/hydroxypropyl	23:39	arg1	films					68:72	xanthan gum/hydroxypropyl methyl cellulose composite films	15:72	xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation	15:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	1	22	theme	fresh-cut	277:285	arg1	preservation					298:309	fresh-cut vegetables preservation	277:309	fresh-cut vegetables preservation	277:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	0	23	theme	bell	142:145	arg1	preservation					155:166	fresh-cut green bell peppers preservation	126:166	fresh-cut green bell peppers preservation	126:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	4	24	theme	inhibitory	682:691	arg1	ability					693:699	good inhibitory ability	677:699	good inhibitory ability	677:699	The antioxidant activity and antibacterial properties were also enhanced, demonstrated good inhibitory ability to Staphylococcus aureus.
35568150	5	25	theme	C	763:763	arg1	amount					745:750	the amount	741:750	the amount of Vitamin C that was retained by XHT6	741:789	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	5	25	theme	C	763:763	arg1	C					763:763	Vitamin C	755:763	Vitamin C	755:763	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	5	25	theme	C	763:763	arg1	%					801:801	127.81%	795:801	127.81%	795:801	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	0	26	theme	xanthan	15:21	arg1	films					68:72	xanthan gum/hydroxypropyl methyl cellulose composite films	15:72	xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation	15:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	1	27	theme	vegetables	287:296	arg1	preservation					298:309	fresh-cut vegetables preservation	277:309	fresh-cut vegetables preservation	277:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	0	28	theme	green	136:140	arg1	preservation					155:166	fresh-cut green bell peppers preservation	126:166	fresh-cut green bell peppers preservation	126:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	1	29	used	used	268:271	arg2	performance					244:254	good performance	239:254	good performance that can be used for fresh-cut vegetables preservation	239:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	4	30	theme	good	677:680	arg1	ability					693:699	good inhibitory ability	677:699	good inhibitory ability	677:699	The antioxidant activity and antibacterial properties were also enhanced, demonstrated good inhibitory ability to Staphylococcus aureus.
35568150	7	31	theme	fresh-cut	1035:1043	arg1	peppers					1050:1056	fresh-cut bell peppers	1035:1056	fresh-cut bell peppers	1035:1056	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	3	32	dep	strength	536:543	arg1	the					524:526	the	524:526	the	524:526	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	0	33	theme	cellulose	48:56	arg1	films					68:72	xanthan gum/hydroxypropyl methyl cellulose composite films	15:72	xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation	15:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	0	34	from	polyphenol	92:101	arg1	preservation					155:166	fresh-cut green bell peppers preservation	126:166	fresh-cut green bell peppers preservation	126:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	1	35	theme	edible	208:213	arg1	material					225:232	an edible packaging material	205:232	an edible packaging material with good performance that can be used for fresh-cut vegetables preservation	205:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	0	36	theme	methyl	41:46	arg1	films					68:72	xanthan gum/hydroxypropyl methyl cellulose composite films	15:72	xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation	15:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	0	37	theme	peppers	147:153	arg1	preservation					155:166	fresh-cut green bell peppers preservation	126:166	fresh-cut green bell peppers preservation	126:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	7	38	theme	bell	1045:1048	arg1	peppers					1050:1056	fresh-cut bell peppers	1035:1056	fresh-cut bell peppers	1035:1056	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	1	39	theme	packaging	215:223	arg1	material					225:232	an edible packaging material	205:232	an edible packaging material with good performance that can be used for fresh-cut vegetables preservation	205:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	0	40	theme	films	68:72	arg1	Development					0:10	Development	0:10	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.	0:167	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	2	41	theme	methylcellulose	343:357	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	41	theme	methylcellulose	343:357	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	0	42	theme	composite	58:66	arg1	films					68:72	xanthan gum/hydroxypropyl methyl cellulose composite films	15:72	xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation	15:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	7	43	theme	positive	1073:1080	arg1	results					1082:1088	positive results	1073:1088	positive results	1073:1088	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	2	44	theme	-hydroxypropyl	328:341	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	44	theme	-hydroxypropyl	328:341	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	4	45	dep	enhanced	654:661	arg1	demonstrated					664:675	demonstrated	664:675	demonstrated good inhibitory ability to Staphylococcus aureus	664:724	The antioxidant activity and antibacterial properties were also enhanced, demonstrated good inhibitory ability to Staphylococcus aureus.
35568150	5	46	theme	unpackaged	825:834	arg1	amount					745:750	the amount	741:750	the amount of Vitamin C that was retained by XHT6	741:789	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	5	46	theme	unpackaged	825:834	arg1	%					801:801	127.81%	795:801	127.81%	795:801	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	5	46	theme	unpackaged	825:834	arg1	C					763:763	Vitamin C	755:763	Vitamin C	755:763	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	0	47	from	application	111:121	arg1	preservation					155:166	fresh-cut green bell peppers preservation	126:166	fresh-cut green bell peppers preservation	126:166	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	5	48	dep	unpackaged	825:834	arg1	than					820:823	than	820:823	than	820:823	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	5	48	dep	unpackaged	825:834	arg1	higher					813:818	higher	813:818	higher	813:818	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	0	49	theme	tea	88:90	arg1	polyphenol					92:101	tea polyphenol	88:101	tea polyphenol	88:101	Development of xanthan gum/hydroxypropyl methyl cellulose composite films incorporating tea polyphenol and its application on fresh-cut green bell peppers preservation.
35568150	2	50	theme	composite	387:395	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	50	theme	composite	387:395	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	3	51	theme	tensile	528:534	arg1	strength					536:543	tensile strength	528:543	tensile strength	528:543	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	2	52	theme	-tea	365:368	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	52	theme	-tea	365:368	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	53	theme	TP	383:384	arg1	film					397:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film	312:400	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT)	312:406	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	2	53	theme	TP	383:384	arg1	XHT					403:405	XHT	403:405	XHT	403:405	The xanthan (XG)-hydroxypropyl methylcellulose (HPMC)-tea polyphenols (TP) composite film (XHT) was prepared by adding TP to the composite film-forming solution of XG and HPMC.
35568150	1	54	theme	good	239:242	arg1	performance					244:254	good performance	239:254	good performance that can be used for fresh-cut vegetables preservation	239:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	7	55	theme	films	1015:1019	arg1	applications					995:1006	Practical applications	985:1006	Practical applications of XHT films in preserving fresh-cut bell peppers	985:1056	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	5	56	theme	Vitamin	755:761	arg1	C					763:763	Vitamin C	755:763	Vitamin C	755:763	After 8 days, the amount of Vitamin C that was retained by XHT6 was 127.81% and 7.83% higher than unpackaged and XHT0, respectively.
35568150	1	57	with	material	225:232	arg1	performance					244:254	good performance	239:254	good performance that can be used for fresh-cut vegetables preservation	239:309	The aim of this work was to develop an edible packaging material with good performance that can be used for fresh-cut vegetables preservation.
35568150	4	58	theme	antioxidant	594:604	arg1	activity					606:613	The antioxidant activity	590:613	The antioxidant activity	590:613	The antioxidant activity and antibacterial properties were also enhanced, demonstrated good inhibitory ability to Staphylococcus aureus.
35568150	7	59	theme	potential	1113:1121	arg1	packaging					1128:1136	potential food packaging	1113:1136	potential food packaging	1113:1136	Practical applications of XHT films in preserving fresh-cut bell peppers had also shown positive results, making it possible as potential food packaging.
35568150	3	60	from	break	563:567	arg1	strength					536:543	tensile strength	528:543	tensile strength	528:543	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
35568150	3	60	from	break	563:567	arg1	elongation					549:558	elongation	549:558	elongation	549:558	At optimum TP dosage of 6% (XHT6), the tensile strength and elongation at break were at the maximum.
36286461	1	0	theme	brown	168:172	arg1	algae					174:178	brown algae	168:178	brown algae	168:178	Preparations of sulfated polysaccharides obtained from brown algae are known as fucoidans.
36286461	3	1	from	composition	561:571	arg1	similar					541:547	similar	541:547	similar	541:547	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	2	2	theme	practical	309:317	arg1	applications					319:330	practical applications	309:330	practical applications	309:330	These biopolymers have attracted considerable attention due to many biological activities which may find practical applications.
36286461	4	3	theme	fucoidan	621:628	arg1	preparations					630:641	these two fucoidan preparations	611:641	these two fucoidan preparations	611:641	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	4	3	theme	fucoidan	621:628	arg1	mixtures					662:669	polysaccharide mixtures	647:669	polysaccharide mixtures which differ considerably in amount and chemical nature of components	647:739	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	3	4	from	similar	541:547	arg1	composition					561:571	chemical composition	552:571	chemical composition	552:571	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	4	from	similar	541:547	arg1	actions					588:594	biological actions	577:594	biological actions	577:594	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	0	5	from	Comparison	26:35	arg1	vesiculosus					76:86	Fucus vesiculosus	70:86	Fucus vesiculosus	70:86	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	0	5	from	Comparison	26:35	arg1	nodosum					104:110	Ascophyllum nodosum	92:110	Ascophyllum nodosum	92:110	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	3	6	theme	chemical	552:559	arg1	composition					561:571	chemical composition	552:571	chemical composition	552:571	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	7	theme	order	452:456	arg1	Fucales					458:464	the same order Fucales	443:464	the same order Fucales	443:464	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	5	8	theme	valuable	1009:1016	arg1	applications					1018:1029	valuable applications	1009:1029	valuable applications	1009:1029	In spite of these differences, fractions with carefully characterized structures prepared from both fucoidans may have valuable applications in drug development.
36286461	4	9	theme	chemical	711:718	arg1	nature					720:725	chemical nature	711:725	chemical nature	711:725	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	0	10	theme	Algae	19:23	arg1	Fucoidans					0:8	Fucoidans	0:8	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.	0:111	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	4	11	theme	properties	841:850	arg1	investigation					807:819	the investigation	803:819	the investigation of their biological properties and structure-activity relationships	803:887	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	3	12	theme	biological	577:586	arg1	actions					588:594	biological actions	577:594	biological actions	577:594	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	5	13	theme	drug	1034:1037	arg1	development					1039:1049	drug development	1034:1049	drug development	1034:1049	In spite of these differences, fractions with carefully characterized structures prepared from both fucoidans may have valuable applications in drug development.
36286461	0	14	theme	Brown	13:17	arg1	Algae					19:23	Brown Algae	13:23	Brown Algae	13:23	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	0	15	from	vesiculosus	76:86	arg1	Comparison					26:35	Comparison	26:35	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.	0:111	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	0	15	from	vesiculosus	76:86	arg1	Polysaccharides					49:63	Sulfated Polysaccharides	40:63	Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum	40:110	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	3	16	theme	commercial	490:499	arg1	fucoidans					501:509	commercial fucoidans	490:509	commercial fucoidans	490:509	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	4	17	theme	structure-activity	856:873	arg1	relationships					875:887	structure-activity relationships	856:887	structure-activity relationships	856:887	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	5	18	contain	have	1004:1007	arg1	fractions					921:929	fractions	921:929	fractions with carefully characterized structures prepared from both fucoidans	921:998	In spite of these differences, fractions with carefully characterized structures prepared from both fucoidans may have valuable applications in drug development.
36286461	5	18	contain	have	1004:1007	arg2	applications					1018:1029	valuable applications	1009:1029	valuable applications	1009:1029	In spite of these differences, fractions with carefully characterized structures prepared from both fucoidans may have valuable applications in drug development.
36286461	3	19	theme	popular	471:477	arg1	sources					479:485	popular sources	471:485	popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions	471:594	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	19	theme	popular	471:477	arg1	representatives					346:360	Two Atlantic representatives	333:360	Two Atlantic representatives	333:360	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	20	theme	same	447:450	arg1	Fucales					458:464	the same order Fucales	443:464	the same order Fucales	443:464	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	0	21	theme	Sulfated	40:47	arg1	Polysaccharides					49:63	Sulfated Polysaccharides	40:63	Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum	40:110	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	5	22	with	fractions	921:929	arg1	structures					960:969	carefully characterized structures	936:969	carefully characterized structures prepared from both fucoidans	936:998	In spite of these differences, fractions with carefully characterized structures prepared from both fucoidans may have valuable applications in drug development.
36286461	2	23	theme	considerable	237:248	arg1	attention					250:258	considerable attention	237:258	considerable attention	237:258	These biopolymers have attracted considerable attention due to many biological activities which may find practical applications.
36286461	3	24	theme	Atlantic	337:344	arg1	sources					479:485	popular sources	471:485	popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions	471:594	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	24	theme	Atlantic	337:344	arg1	representatives					346:360	Two Atlantic representatives	333:360	Two Atlantic representatives	333:360	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	4	25	theme	relationships	875:887	arg1	investigation					807:819	the investigation	803:819	the investigation of their biological properties and structure-activity relationships	803:887	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	4	26	theme	biological	830:839	arg1	properties					841:850	their biological properties	824:850	their biological properties	824:850	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	0	27	from	nodosum	104:110	arg1	Comparison					26:35	Comparison	26:35	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.	0:111	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	0	27	from	nodosum	104:110	arg1	Polysaccharides					49:63	Sulfated Polysaccharides	40:63	Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum	40:110	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	1	28	theme	sulfated	129:136	arg1	polysaccharides					138:152	sulfated polysaccharides	129:152	sulfated polysaccharides obtained from brown algae	129:178	Preparations of sulfated polysaccharides obtained from brown algae are known as fucoidans.
36286461	3	29	from	actions	588:594	arg1	similar					541:547	similar	541:547	similar	541:547	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	2	30	theme	biological	272:281	arg1	activities					283:292	many biological activities	267:292	many biological activities which may find practical applications	267:330	These biopolymers have attracted considerable attention due to many biological activities which may find practical applications.
36286461	1	31	theme	polysaccharides	138:152	arg1	Preparations					113:124	Preparations	113:124	Preparations of sulfated polysaccharides obtained from brown algae	113:178	Preparations of sulfated polysaccharides obtained from brown algae are known as fucoidans.
36286461	1	31	theme	polysaccharides	138:152	arg1	fucoidans					193:201	fucoidans	193:201	fucoidans	193:201	Preparations of sulfated polysaccharides obtained from brown algae are known as fucoidans.
36286461	3	32	theme	fucoidans	501:509	arg1	sources					479:485	popular sources	471:485	popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions	471:594	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	32	theme	fucoidans	501:509	arg1	representatives					346:360	Two Atlantic representatives	333:360	Two Atlantic representatives	333:360	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	33	theme	Phaeophyceae	365:376	arg1	sources					479:485	popular sources	471:485	popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions	471:594	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	3	33	theme	Phaeophyceae	365:376	arg1	representatives					346:360	Two Atlantic representatives	333:360	Two Atlantic representatives	333:360	Two Atlantic representatives of Phaeophyceae, namely, Fucus vesiculosus and Ascophyllum nodosum, belonging to the same order Fucales, are popular sources of commercial fucoidans, which often regarded as very similar in chemical composition and biological actions.
36286461	2	34	theme	many	267:270	arg1	activities					283:292	many biological activities	267:292	many biological activities which may find practical applications	267:330	These biopolymers have attracted considerable attention due to many biological activities which may find practical applications.
36286461	4	35	theme	components	730:739	arg1	components					730:739	components	730:739	components	730:739	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	4	35	theme	components	730:739	arg1	amount					700:705	amount	700:705	amount	700:705	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	4	35	theme	components	730:739	arg1	nature					720:725	chemical nature	711:725	chemical nature	711:725	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	0	36	theme	Polysaccharides	49:63	arg1	Comparison					26:35	Comparison	26:35	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.	0:111	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	0	37	dep	Fucoidans	0:8	arg1	Comparison					26:35	Comparison	26:35	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.	0:111	Fucoidans of Brown Algae: Comparison of Sulfated Polysaccharides from Fucus vesiculosus and Ascophyllum nodosum.
36286461	5	38	theme	characterized	946:958	arg1	structures					960:969	carefully characterized structures	936:969	carefully characterized structures prepared from both fucoidans	936:998	In spite of these differences, fractions with carefully characterized structures prepared from both fucoidans may have valuable applications in drug development.
36286461	4	39	theme	polysaccharide	647:660	arg1	preparations					630:641	these two fucoidan preparations	611:641	these two fucoidan preparations	611:641	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
36286461	4	39	theme	polysaccharide	647:660	arg1	mixtures					662:669	polysaccharide mixtures	647:669	polysaccharide mixtures which differ considerably in amount and chemical nature of components	647:739	Nevertheless, these two fucoidan preparations are polysaccharide mixtures which differ considerably in amount and chemical nature of components, and hence, this circumstance should be taken into account in the investigation of their biological properties and structure-activity relationships.
37399869	4	0	theme	Dorea	980:984	arg1	enrichment					938:947	enrichment	938:947	enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium	938:1004	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	2	1	theme	high-fat	577:584	arg1	diet					607:610	high-fat and high-cholesterol diet	577:610	high-fat and high-cholesterol diet combined with carbon tetrachloride	577:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	5	2	dep	acids	1150:1154	arg1	profile					1162:1168	profile	1162:1168	profile	1162:1168	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	3	theme	Bifidobacterium	1094:1108	arg1	alteration					1020:1029	the alteration	1016:1029	the alteration of gut microbiota	1016:1047	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	3	theme	Bifidobacterium	1094:1108	arg1	enhancement					1061:1071	enhancement	1061:1071	especially enhancement of Lactobacillus and Bifidobacterium	1050:1108	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	4	theme	deoxycholic	1185:1195	arg1	DCA					1203:1205	DCA	1203:1205	DCA	1203:1205	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	4	theme	deoxycholic	1185:1195	arg1	acid					1197:1200	increased deoxycholic acid	1175:1200	increased deoxycholic acid (DCA)	1175:1206	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	6	5	theme	BAs	1307:1309	arg1	metabolism					1311:1320	the BAs metabolism	1303:1320	the BAs metabolism	1303:1320	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	6	6	theme	other	1260:1264	arg1	BAs					1279:1281	other unconjugated BAs	1260:1281	other unconjugated BAs	1260:1281	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	1	7	theme	other	348:352	arg1	polysaccharides					368:382	other edible fungus polysaccharides	348:382	other edible fungus polysaccharides	348:382	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	4	8	theme	gut	872:874	arg1	microbiota					876:885	gut microbiota	872:885	gut microbiota	872:885	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	1	9	from	auricula	184:191	arg1	prebiotics					332:341	potential prebiotics	322:341	potential prebiotics like other edible fungus polysaccharides	322:382	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	1	9	from	auricula	184:191	arg1	polysaccharides					151:165	The polysaccharides	147:165	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties,	147:309	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	0	10	theme	gut	105:107	arg1	microbiota					109:118	gut microbiota	105:118	gut microbiota	105:118	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	1	11	theme	edible	354:359	arg1	polysaccharides					368:382	other edible fungus polysaccharides	348:382	other edible fungus polysaccharides	348:382	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	2	12	dep	AAPs	467:470	arg1	DAAPs					473:477	DAAPs	473:477	DAAPs	473:477	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	2	13	theme	carbon	626:631	arg1	tetrachloride					633:645	carbon tetrachloride	626:645	carbon tetrachloride	626:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	7	14	theme	AAPs	1456:1459	arg1	deacetylation					1439:1451	the deacetylation	1435:1451	the deacetylation of AAPs	1435:1459	Interestingly, it was found that the deacetylation of AAPs negatively affected the anti-inflammation, thereby reducing the health benefits of A. auricula-derived polysaccharides.
37399869	7	15	theme	auricula-derived	1547:1562	arg1	polysaccharides					1564:1578	A. auricula-derived polysaccharides	1544:1578	A. auricula-derived polysaccharides	1544:1578	Interestingly, it was found that the deacetylation of AAPs negatively affected the anti-inflammation, thereby reducing the health benefits of A. auricula-derived polysaccharides.
37399869	0	16	theme	bile	124:127	arg1	acids					129:133	bile acids	124:133	bile acids	124:133	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	1	17	theme	fungus	361:366	arg1	polysaccharides					368:382	other edible fungus polysaccharides	348:382	other edible fungus polysaccharides	348:382	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	7	18	link	auricula-derived	1547:1562	arg1	polysaccharides					1564:1578	A. auricula-derived polysaccharides	1544:1578	A. auricula-derived polysaccharides	1544:1578	Interestingly, it was found that the deacetylation of AAPs negatively affected the anti-inflammation, thereby reducing the health benefits of A. auricula-derived polysaccharides.
37399869	0	19	dep	microbiota	109:118	arg1	metabolism					135:144	metabolism	135:144	metabolism	135:144	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	7	20	theme	A.	1544:1545	arg1	polysaccharides					1564:1578	A. auricula-derived polysaccharides	1544:1578	A. auricula-derived polysaccharides	1544:1578	Interestingly, it was found that the deacetylation of AAPs negatively affected the anti-inflammation, thereby reducing the health benefits of A. auricula-derived polysaccharides.
37399869	3	21	theme	barrier	803:809	arg1	function					811:818	intestinal barrier function	792:818	intestinal barrier function	792:818	The results revealed that both AAPs and DAAPs could effectively relieve liver injury, inflammation and fibrosis, and maintain intestinal barrier function.
37399869	2	22	theme	present	392:398	arg1	study					400:404	the present study	388:404	the present study	388:404	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	2	23	theme	AAPs	445:448	arg1	effects					434:440	the alleviating effects	418:440	the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	418:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	0	24	from	auricula	37:44	arg1	polysaccharides					4:18	The polysaccharides	0:18	The polysaccharides from Auricularia auricula	0:44	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	2	25	theme	high-cholesterol	590:605	arg1	diet					607:610	high-fat and high-cholesterol diet	577:610	high-fat and high-cholesterol diet combined with carbon tetrachloride	577:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	4	26	theme	microbiota	876:885	arg1	disorder					860:867	the disorder	856:867	the disorder of gut microbiota	856:885	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	1	27	theme	physiological	270:282	arg1	properties					299:308	the physiological and biological properties	266:308	the physiological and biological properties	266:308	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	2	28	theme	fatty	538:542	arg1	disease					550:556	nonalcoholic fatty liver disease	525:556	nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	525:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	2	28	theme	fatty	538:542	arg1	NAFLD					559:563	NAFLD	559:563	NAFLD	559:563	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	5	29	with	profile	1162:1168	arg1	DCA					1203:1205	DCA	1203:1205	DCA	1203:1205	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	29	with	profile	1162:1168	arg1	acid					1197:1200	increased deoxycholic acid	1175:1200	increased deoxycholic acid (DCA)	1175:1206	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	2	30	theme	alleviating	422:432	arg1	effects					434:440	the alleviating effects	418:440	the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	418:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	1	31	theme	biological	288:297	arg1	properties					299:308	the physiological and biological properties	266:308	the physiological and biological properties	266:308	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	2	32	theme	nonalcoholic	525:536	arg1	disease					550:556	nonalcoholic fatty liver disease	525:556	nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	525:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	2	32	theme	nonalcoholic	525:536	arg1	NAFLD					559:563	NAFLD	559:563	NAFLD	559:563	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	6	33	theme	NAFLD	1390:1394	arg1	mice					1396:1399	NAFLD mice	1390:1399	NAFLD mice	1390:1399	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	2	34	theme	deacetylated	454:465	arg1	AAPs					467:470	deacetylated AAPs	454:470	deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment)	454:520	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	4	35	theme	Bifidobacterium	990:1004	arg1	enrichment					938:947	enrichment	938:947	enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium	938:1004	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	3	36	theme	liver	738:742	arg1	injury					744:749	liver injury	738:749	liver injury	738:749	The results revealed that both AAPs and DAAPs could effectively relieve liver injury, inflammation and fibrosis, and maintain intestinal barrier function.
37399869	4	37	theme	microbiota	922:931	arg1	composition					903:913	the composition	899:913	the composition of gut microbiota	899:931	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	7	38	theme	health	1525:1530	arg1	benefits					1532:1539	the health benefits	1521:1539	the health benefits of A. auricula-derived polysaccharides	1521:1578	Interestingly, it was found that the deacetylation of AAPs negatively affected the anti-inflammation, thereby reducing the health benefits of A. auricula-derived polysaccharides.
37399869	6	39	theme	X	1219:1219	arg1	receptor					1221:1228	Farnesoid X receptor	1209:1228	Farnesoid X receptor	1209:1228	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	1	40	theme	large	214:218	arg1	number					220:225	a large number	212:225	a large number of O-acetyl groups that are related to the physiological and biological properties	212:308	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	2	41	theme	AAPs	467:470	arg1	effects					434:440	the alleviating effects	418:440	the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	418:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	5	42	theme	bile	1145:1148	arg1	BAs					1157:1159	BAs	1157:1159	BAs	1157:1159	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	42	theme	bile	1145:1148	arg1	acids					1150:1154	bile acids	1145:1154	bile acids (BAs) profile with increased deoxycholic acid (DCA)	1145:1206	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	4	43	theme	gut	918:920	arg1	microbiota					922:931	gut microbiota	918:931	gut microbiota	918:931	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	5	44	theme	Lactobacillus	1076:1088	arg1	alteration					1020:1029	the alteration	1016:1029	the alteration of gut microbiota	1016:1047	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	44	theme	Lactobacillus	1076:1088	arg1	enhancement					1061:1071	enhancement	1061:1071	especially enhancement of Lactobacillus and Bifidobacterium	1050:1108	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	6	45	theme	Farnesoid	1209:1217	arg1	receptor					1221:1228	Farnesoid X receptor	1209:1228	Farnesoid X receptor	1209:1228	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	5	46	theme	increased	1175:1183	arg1	DCA					1203:1205	DCA	1203:1205	DCA	1203:1205	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	46	theme	increased	1175:1183	arg1	acid					1197:1200	increased deoxycholic acid	1175:1200	increased deoxycholic acid (DCA)	1175:1206	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	6	47	theme	unconjugated	1266:1277	arg1	BAs					1279:1281	other unconjugated BAs	1260:1281	other unconjugated BAs	1260:1281	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	0	48	theme	fatty	70:74	arg1	disease					82:88	non-alcoholic fatty liver disease	56:88	non-alcoholic fatty liver disease	56:88	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	5	49	theme	acids	1150:1154	arg1	changes					1134:1140	the changes	1130:1140	the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA)	1130:1206	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	0	50	theme	non-alcoholic	56:68	arg1	disease					82:88	non-alcoholic fatty liver disease	56:88	non-alcoholic fatty liver disease	56:88	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	2	51	from	effects	434:440	arg1	disease					550:556	nonalcoholic fatty liver disease	525:556	nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	525:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	2	51	from	effects	434:440	arg1	NAFLD					559:563	NAFLD	559:563	NAFLD	559:563	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	5	52	theme	gut	1034:1036	arg1	microbiota					1038:1047	gut microbiota	1034:1047	gut microbiota	1034:1047	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	6	53	from	hepatitis	1377:1385	arg1	mice					1396:1399	NAFLD mice	1390:1399	NAFLD mice	1390:1399	Farnesoid X receptor could be activated by DCA and other unconjugated BAs, which participated the BAs metabolism and alleviated the cholestasis, then protected against hepatitis in NAFLD mice.
37399869	7	54	theme	polysaccharides	1564:1578	arg1	benefits					1532:1539	the health benefits	1521:1539	the health benefits of A. auricula-derived polysaccharides	1521:1578	Interestingly, it was found that the deacetylation of AAPs negatively affected the anti-inflammation, thereby reducing the health benefits of A. auricula-derived polysaccharides.
37399869	5	55	theme	microbiota	1038:1047	arg1	alteration					1020:1029	the alteration	1016:1029	the alteration of gut microbiota	1016:1047	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	5	55	theme	microbiota	1038:1047	arg1	enhancement					1061:1071	enhancement	1061:1071	especially enhancement of Lactobacillus and Bifidobacterium	1050:1108	Further, the alteration of gut microbiota, especially enhancement of Lactobacillus and Bifidobacterium, was contributed to the changes of bile acids (BAs) profile with increased deoxycholic acid (DCA).
37399869	3	56	theme	intestinal	792:801	arg1	function					811:818	intestinal barrier function	792:818	intestinal barrier function	792:818	The results revealed that both AAPs and DAAPs could effectively relieve liver injury, inflammation and fibrosis, and maintain intestinal barrier function.
37399869	2	57	theme	liver	544:548	arg1	disease					550:556	nonalcoholic fatty liver disease	525:556	nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride	525:645	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	2	57	theme	liver	544:548	arg1	NAFLD					559:563	NAFLD	559:563	NAFLD	559:563	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37399869	1	58	theme	O-acetyl	230:237	arg1	groups					239:244	O-acetyl groups	230:244	O-acetyl groups that are related to the physiological and biological properties	230:308	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	4	59	theme	Lactobacillus	965:977	arg1	enrichment					938:947	enrichment	938:947	enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium	938:1004	Both AAPs and DAAPs could modulate the disorder of gut microbiota and altered the composition of gut microbiota with enrichment of Odoribacter, Lactobacillus, Dorea and Bifidobacterium.
37399869	1	60	contain	containing	201:210	arg2	number					220:225	a large number	212:225	a large number of O-acetyl groups that are related to the physiological and biological properties	212:308	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	1	60	contain	containing	201:210	arg1	AAPs					194:197	AAPs	194:197	AAPs	194:197	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	1	60	contain	containing	201:210	arg1	auricula					184:191	Auricularia auricula	172:191	Auricularia auricula (AAPs)	172:198	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	1	61	theme	groups	239:244	arg1	number					220:225	a large number	212:225	a large number of O-acetyl groups that are related to the physiological and biological properties	212:308	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	0	62	theme	liver	76:80	arg1	disease					82:88	non-alcoholic fatty liver disease	56:88	non-alcoholic fatty liver disease	56:88	The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism.
37399869	1	63	theme	potential	322:330	arg1	prebiotics					332:341	potential prebiotics	322:341	potential prebiotics like other edible fungus polysaccharides	322:382	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	1	63	theme	potential	322:330	arg1	polysaccharides					151:165	The polysaccharides	147:165	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties,	147:309	The polysaccharides from Auricularia auricula (AAPs), containing a large number of O-acetyl groups that are related to the physiological and biological properties, seem to be potential prebiotics like other edible fungus polysaccharides.
37399869	2	64	theme	alkaline	502:509	arg1	treatment					511:519	alkaline treatment	502:519	alkaline treatment	502:519	In the present study, therefore, the alleviating effects of AAPs and deacetylated AAPs (DAAPs, prepared from AAPs by alkaline treatment) on nonalcoholic fatty liver disease (NAFLD) induced by high-fat and high-cholesterol diet combined with carbon tetrachloride were investigated.
37111049	13	0	theme	enzymes	1945:1951	arg1	enzymes					1945:1951	the mucin-glycan modifying enzymes	1918:1951	the mucin-glycan modifying enzymes	1918:1951	Also, the expression of sialyltransferase, one of the mucin-glycan modifying enzymes, was decreased by 1-fold.
37111049	13	0	theme	enzymes	1945:1951	arg1	one					1911:1913	one	1911:1913	one	1911:1913	Also, the expression of sialyltransferase, one of the mucin-glycan modifying enzymes, was decreased by 1-fold.
37111049	13	0	theme	enzymes	1945:1951	arg1	sialyltransferase					1892:1908	sialyltransferase	1892:1908	sialyltransferase	1892:1908	Also, the expression of sialyltransferase, one of the mucin-glycan modifying enzymes, was decreased by 1-fold.
37111049	7	1	theme	mucus	1052:1056	arg1	layer					1058:1062	the mucus layer	1048:1062	the mucus layer to reach epithelial cells	1048:1088	During aging, microorganisms invaded the mucus layer to reach epithelial cells.
37111049	4	2	theme	aging	558:562	arg1	effects					547:553	the effects	543:553	the effects of aging on the colonic mucus barrier	543:591	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	12	3	theme	main	1667:1670	arg1	structure					1677:1685	the main core structure	1663:1685	the main core structure	1663:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	4	4	theme	colonic	609:615	arg1	layer					623:627	the colonic mucus layer	605:627	the colonic mucus layer	605:627	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	3	5	with	barrier	448:454	arg1	aging					461:465	aging	461:465	aging	461:465	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	11	6	theme	key	1465:1467	arg1	enzymes					1469:1475	key enzymes	1465:1475	key enzymes involved in mucin core structure formation and glycan modification	1465:1542	Further, the expression of key enzymes involved in mucin core structure formation and glycan modification also changed with aging.
37111049	1	7	theme	mucus	141:145	arg1	barrier					147:153	mucus barrier	141:153	mucus barrier	141:153	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	8	8	from	thickness	1121:1129	arg1	mice					1154:1157	aged mice	1149:1157	aged mice	1149:1157	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	1	9	theme	most	247:250	arg1	attention					252:260	the most attention	243:260	the most attention	243:260	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	14	10	theme	important	2074:2082	arg1	role					2084:2087	an important role	2071:2087	an important role	2071:2087	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	10	11	theme	cells	1306:1310	arg1	proportion					1285:1294	the proportion	1281:1294	the proportion of goblet cells	1281:1310	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	5	12	theme	age	776:778	arg1	months					766:771	different months	756:771	different months of age	756:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	12	13	dep	6-	1839:1840	arg1	to					1836:1837	to	1836:1837	to	1836:1837	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	14	theme	key	1644:1646	arg1	enzyme					1648:1653	the key enzyme	1640:1653	the key enzyme forming the main core structure	1640:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	14	theme	key	1644:1646	arg1	β1,3-galactosyltransferase					1594:1619	core 1 β1,3-galactosyltransferase	1587:1619	core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure	1587:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	0	15	from	Changes	64:70	arg1	Mucin					80:84	Muc2 Mucin	75:84	Muc2 Mucin	75:84	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	0	15	from	Changes	64:70	arg1	Colon					93:97	the Colon	89:97	the Colon	89:97	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	14	16	theme	cells/glycosyltransferase/O-glycan	2025:2058	arg1	axis					2060:2063	the goblet cells/glycosyltransferase/O-glycan axis	2014:2063	the goblet cells/glycosyltransferase/O-glycan axis	2014:2063	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	8	17	theme	layer	1140:1144	arg1	thickness					1121:1129	the thickness	1117:1129	the thickness of mucus layer in aged mice	1117:1157	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	5	18	theme	hybridization	805:817	arg1	staining					832:839	in situ hybridization fluorescence staining	797:839	in situ hybridization fluorescence staining	797:839	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	1	19	dep	function	225:232	arg1	received					234:241	received	234:241	function received the most attention	225:260	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	5	20	from	thickness	703:711	arg1	mice					748:751	mice	748:751	mice at different months of age	748:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	20	from	thickness	703:711	arg1	months					766:771	different months	756:771	different months of age	756:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	21	theme	colonic	731:737	arg1	mucus					739:743	colonic mucus	731:743	colonic mucus	731:743	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	12	22	theme	core	1587:1590	arg1	C1GalT1					1622:1628	C1GalT1	1622:1628	C1GalT1	1622:1628	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	22	theme	core	1587:1590	arg1	β1,3-galactosyltransferase					1594:1619	core 1 β1,3-galactosyltransferase	1587:1619	core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure	1587:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	22	theme	core	1587:1590	arg1	enzyme					1648:1653	the key enzyme	1640:1653	the key enzyme forming the main core structure	1640:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	5	23	theme	Microbial	683:691	arg1	invasion					693:700	Microbial invasion	683:700	Microbial invasion	683:700	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	24	from	invasion	693:700	arg1	mice					748:751	mice	748:751	mice at different months of age	748:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	24	from	invasion	693:700	arg1	months					766:771	different months	756:771	different months of age	756:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	25	theme	in	797:798	arg1	hybridization					805:817	in situ hybridization	797:817	in situ hybridization fluorescence staining	797:839	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	12	26	theme	β1,3-galactosyltransferase	1594:1619	arg1	expression					1573:1582	The expression	1569:1582	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure	1569:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	10	27	theme	older	1339:1343	arg1	mice					1345:1348	older mice	1339:1348	older mice	1339:1348	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	0	28	theme	Muc2	75:78	arg1	Mucin					80:84	Muc2 Mucin	75:84	Muc2 Mucin	75:84	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	5	29	theme	cryo-scanning	863:875	arg1	microscopy					886:895	cryo-scanning electron microscopy	863:895	cryo-scanning electron microscopy	863:895	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	9	30	theme	components	1212:1221	arg1	contents					1191:1198	the contents	1187:1198	the contents of the main components	1187:1221	And the contents of the main components and glycosylation structure of colon changed.
37111049	9	30	theme	components	1212:1221	arg1	structure					1241:1249	glycosylation structure	1227:1249	glycosylation structure of colon	1227:1258	And the contents of the main components and glycosylation structure of colon changed.
37111049	6	31	theme	mucus	993:997	arg1	properties					999:1008	mucus properties	993:1008	mucus properties	993:1008	Results showed that the aged colon exhibited intestinal mucus barrier dys-function and altered mucus properties.
37111049	14	32	theme	intestinal	2173:2182	arg1	environment					2184:2194	intestinal environment	2173:2194	intestinal environment	2173:2194	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	0	33	theme	Age-Related	0:10	arg1	Dysfunction					26:36	Age-Related Mucus Barrier Dysfunction	0:36	Age-Related Mucus Barrier Dysfunction in Mice	0:44	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	9	34	theme	glycosylation	1227:1239	arg1	structure					1241:1249	glycosylation structure	1227:1249	glycosylation structure of colon	1227:1258	And the contents of the main components and glycosylation structure of colon changed.
37111049	5	35	theme	AB/PAS	842:847	arg1	staining					849:856	AB/PAS staining	842:856	AB/PAS staining	842:856	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	2	36	theme	elderly	392:398	arg1	health					378:383	the health	374:383	the health of the elderly	374:398	Additionally, the incidence of colon-related diseases increases significantly in adulthood, posing a threat to the health of the elderly.
37111049	0	37	theme	Barrier	18:24	arg1	Dysfunction					26:36	Age-Related Mucus Barrier Dysfunction	0:36	Age-Related Mucus Barrier Dysfunction in Mice	0:44	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	6	38	theme	barrier	960:966	arg1	dys-function					968:979	intestinal mucus barrier dys-function	943:979	intestinal mucus barrier dys-function	943:979	Results showed that the aged colon exhibited intestinal mucus barrier dys-function and altered mucus properties.
37111049	10	39	theme	genes	1379:1383	arg1	expression					1359:1368	the expression	1355:1368	the expression of spdef genes that regulate goblet cell differentiation	1355:1425	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	3	40	theme	specific	414:421	arg1	changes					423:429	the specific changes	410:429	the specific changes in colonic mucus barrier with aging	410:465	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	8	41	theme	aged	1149:1152	arg1	mice					1154:1157	aged mice	1149:1157	aged mice	1149:1157	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	7	42	theme	epithelial	1073:1082	arg1	cells					1084:1088	epithelial cells	1073:1088	epithelial cells	1073:1088	During aging, microorganisms invaded the mucus layer to reach epithelial cells.
37111049	6	43	theme	intestinal	943:952	arg1	dys-function					968:979	intestinal mucus barrier dys-function	943:979	intestinal mucus barrier dys-function	943:979	Results showed that the aged colon exhibited intestinal mucus barrier dys-function and altered mucus properties.
37111049	11	44	theme	core	1495:1498	arg1	formation					1510:1518	mucin core structure formation	1489:1518	mucin core structure formation	1489:1518	Further, the expression of key enzymes involved in mucin core structure formation and glycan modification also changed with aging.
37111049	12	45	theme	core	1716:1719	arg1	N-acetylglucosaminyltransferase					1728:1758	core 2 β1,6 N-acetylglucosaminyltransferase	1716:1758	core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT)	1716:1766	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	45	theme	core	1716:1719	arg1	C2GnT					1761:1765	C2GnT	1761:1765	C2GnT	1761:1765	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	10	46	theme	cell	1406:1409	arg1	differentiation					1411:1425	goblet cell differentiation	1399:1425	goblet cell differentiation	1399:1425	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	2	47	theme	diseases	308:315	arg1	incidence					281:289	the incidence	277:289	the incidence of colon-related diseases	277:315	Additionally, the incidence of colon-related diseases increases significantly in adulthood, posing a threat to the health of the elderly.
37111049	13	48	theme	sialyltransferase	1892:1908	arg1	expression					1878:1887	the expression	1874:1887	the expression of sialyltransferase, one of the mucin-glycan modifying enzymes,	1874:1952	Also, the expression of sialyltransferase, one of the mucin-glycan modifying enzymes, was decreased by 1-fold.
37111049	14	49	theme	mucus	2146:2150	arg1	stability					2160:2168	the stability	2156:2168	the stability of intestinal environment	2156:2194	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	14	49	theme	mucus	2146:2150	arg1	properties					2124:2133	the physicochemical properties	2104:2133	the physicochemical properties of colonic mucus	2104:2150	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	11	50	theme	glycan	1524:1529	arg1	modification					1531:1542	glycan modification	1524:1542	glycan modification	1524:1542	Further, the expression of key enzymes involved in mucin core structure formation and glycan modification also changed with aging.
37111049	3	51	theme	underlying	475:484	arg1	mechanisms					486:495	the underlying mechanisms	471:495	the underlying mechanisms	471:495	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	1	52	theme	colonic	203:209	arg1	barrier					217:223	colonic mucus barrier	203:223	colonic mucus barrier	203:223	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	4	53	theme	colonic	571:577	arg1	barrier					585:591	the colonic mucus barrier	567:591	the colonic mucus barrier	567:591	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	14	54	theme	physicochemical	2108:2122	arg1	properties					2124:2133	the physicochemical properties	2104:2133	the physicochemical properties of colonic mucus	2104:2150	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	8	55	from	layer	1140:1144	arg1	mice					1154:1157	aged mice	1149:1157	aged mice	1149:1157	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	3	56	from	changes	423:429	arg1	barrier					448:454	colonic mucus barrier	434:454	colonic mucus barrier with aging	434:465	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	12	57	theme	core	1672:1675	arg1	structure					1677:1685	the main core structure	1663:1685	the main core structure	1663:1685	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	3	58	from	mechanisms	486:495	arg1	barrier					448:454	colonic mucus barrier	434:454	colonic mucus barrier with aging	434:465	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	5	59	theme	different	756:764	arg1	months					766:771	different months	756:771	different months of age	756:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	11	60	theme	enzymes	1469:1475	arg1	expression					1451:1460	the expression	1447:1460	the expression of key enzymes involved in mucin core structure formation and glycan modification	1447:1542	Further, the expression of key enzymes involved in mucin core structure formation and glycan modification also changed with aging.
37111049	1	61	theme	barrier	147:153	arg1	function					129:136	the protective function	114:136	the protective function of mucus barrier	114:153	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	8	62	theme	young	1105:1109	arg1	mice					1111:1114	young mice	1105:1114	young mice	1105:1114	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	4	63	theme	mucus	617:621	arg1	layer					623:627	the colonic mucus layer	605:627	the colonic mucus layer	605:627	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	10	64	theme	goblet	1299:1304	arg1	cells					1306:1310	goblet cells	1299:1310	goblet cells	1299:1310	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	4	65	from	changes	594:600	arg1	layer					623:627	the colonic mucus layer	605:627	the colonic mucus layer	605:627	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	5	66	theme	mucus	739:743	arg1	thickness					703:711	thickness	703:711	thickness	703:711	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	66	theme	mucus	739:743	arg1	structure					718:726	structure	718:726	structure	718:726	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	66	theme	mucus	739:743	arg1	invasion					693:700	Microbial invasion	683:700	Microbial invasion	683:700	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	14	67	theme	goblet	2018:2023	arg1	axis					2060:2063	the goblet cells/glycosyltransferase/O-glycan axis	2014:2063	the goblet cells/glycosyltransferase/O-glycan axis	2014:2063	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	8	68	from	mice	1154:1157	arg1	thickness					1121:1129	the thickness	1117:1129	the thickness of mucus layer in aged mice	1117:1157	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	8	69	theme	mucus	1134:1138	arg1	layer					1140:1144	mucus layer	1134:1144	mucus layer in aged mice	1134:1157	Compared with young mice, the thickness of mucus layer in aged mice in-creased by 11.66 μm.
37111049	4	70	theme	aged	652:655	arg1	mice					647:650	mice	647:650	mice aged 2, 12, 18, and 24 months	647:680	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	1	71	from	changes	192:198	arg1	barrier					217:223	colonic mucus barrier	203:223	colonic mucus barrier	203:223	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	5	72	theme	fluorescence	819:830	arg1	staining					832:839	in situ hybridization fluorescence staining	797:839	in situ hybridization fluorescence staining	797:839	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	3	73	theme	mucus	442:446	arg1	barrier					448:454	colonic mucus barrier	434:454	colonic mucus barrier with aging	434:465	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	6	74	theme	aged	922:925	arg1	colon					927:931	the aged colon	918:931	the aged colon	918:931	Results showed that the aged colon exhibited intestinal mucus barrier dys-function and altered mucus properties.
37111049	0	75	from	Dysfunction	26:36	arg1	Mice					41:44	Mice	41:44	Mice	41:44	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	5	76	from	months	766:771	arg1	thickness					703:711	thickness	703:711	thickness	703:711	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	76	from	months	766:771	arg1	structure					718:726	structure	718:726	structure	718:726	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	76	from	months	766:771	arg1	invasion					693:700	Microbial invasion	683:700	Microbial invasion	683:700	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	76	from	months	766:771	arg1	mice					748:751	mice	748:751	mice at different months of age	748:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	1	77	theme	protective	118:127	arg1	function					129:136	the protective function	114:136	the protective function of mucus barrier	114:153	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
37111049	4	78	from	effects	547:553	arg1	barrier					585:591	the colonic mucus barrier	567:591	the colonic mucus barrier	567:591	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	9	79	theme	main	1207:1210	arg1	components					1212:1221	the main components	1203:1221	the main components	1203:1221	And the contents of the main components and glycosylation structure of colon changed.
37111049	12	80	theme	β1,3	1779:1782	arg1	N-acetylglucosaminyltransferase					1784:1814	core 3 β1,3 N-acetylglucosaminyltransferase	1772:1814	core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT)	1772:1822	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	80	theme	β1,3	1779:1782	arg1	C3GnT					1817:1821	C3GnT	1817:1821	C3GnT	1817:1821	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	5	81	theme	electron	877:884	arg1	microscopy					886:895	cryo-scanning electron microscopy	863:895	cryo-scanning electron microscopy	863:895	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	14	82	theme	environment	2184:2194	arg1	stability					2160:2168	the stability	2156:2168	the stability of intestinal environment	2156:2194	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	14	82	theme	environment	2184:2194	arg1	properties					2124:2133	the physicochemical properties	2104:2133	the physicochemical properties of colonic mucus	2104:2150	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	0	83	theme	Mucus	12:16	arg1	Dysfunction					26:36	Age-Related Mucus Barrier Dysfunction	0:36	Age-Related Mucus Barrier Dysfunction in Mice	0:44	Age-Related Mucus Barrier Dysfunction in Mice Is Related to the Changes in Muc2 Mucin in the Colon.
37111049	5	84	from	structure	718:726	arg1	mice					748:751	mice	748:751	mice at different months of age	748:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	5	84	from	structure	718:726	arg1	months					766:771	different months	756:771	different months of age	756:778	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	13	85	theme	mucin-glycan	1922:1933	arg1	enzymes					1945:1951	the mucin-glycan modifying enzymes	1918:1951	the mucin-glycan modifying enzymes	1918:1951	Also, the expression of sialyltransferase, one of the mucin-glycan modifying enzymes, was decreased by 1-fold.
37111049	5	86	dep	in	797:798	arg1	situ					800:803	situ	800:803	situ	800:803	Microbial invasion, thickness, and structure of colonic mucus in mice at different months of age were analyzed by in situ hybridization fluorescence staining, AB/PAS staining, and cryo-scanning electron microscopy.
37111049	3	87	theme	colonic	434:440	arg1	barrier					448:454	colonic mucus barrier	434:454	colonic mucus barrier with aging	434:465	However, the specific changes in colonic mucus barrier with aging and the underlying mechanisms have not been fully elucidated.
37111049	9	88	theme	colon	1254:1258	arg1	contents					1191:1198	the contents	1187:1198	the contents of the main components	1187:1221	And the contents of the main components and glycosylation structure of colon changed.
37111049	9	88	theme	colon	1254:1258	arg1	structure					1241:1249	glycosylation structure	1227:1249	glycosylation structure of colon	1227:1258	And the contents of the main components and glycosylation structure of colon changed.
37111049	12	89	theme	core	1772:1775	arg1	N-acetylglucosaminyltransferase					1784:1814	core 3 β1,3 N-acetylglucosaminyltransferase	1772:1814	core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT)	1772:1822	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	89	theme	core	1772:1775	arg1	C3GnT					1817:1821	C3GnT	1817:1821	C3GnT	1817:1821	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	6	90	theme	mucus	954:958	arg1	dys-function					968:979	intestinal mucus barrier dys-function	943:979	intestinal mucus barrier dys-function	943:979	Results showed that the aged colon exhibited intestinal mucus barrier dys-function and altered mucus properties.
37111049	10	91	theme	spdef	1373:1377	arg1	genes					1379:1383	spdef genes	1373:1383	spdef genes that regulate goblet cell differentiation	1373:1425	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	11	92	theme	mucin	1489:1493	arg1	formation					1510:1518	mucin core structure formation	1489:1518	mucin core structure formation	1489:1518	Further, the expression of key enzymes involved in mucin core structure formation and glycan modification also changed with aging.
37111049	12	93	theme	β1,6	1723:1726	arg1	N-acetylglucosaminyltransferase					1728:1758	core 2 β1,6 N-acetylglucosaminyltransferase	1716:1758	core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT)	1716:1766	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	12	93	theme	β1,6	1723:1726	arg1	C2GnT					1761:1765	C2GnT	1761:1765	C2GnT	1761:1765	The expression of core 1 β1,3-galactosyltransferase (C1GalT1) which is the key enzyme forming the main core structure increased by one time, while core 2 β1,6 N-acetylglucosaminyltransferase (C2GnT) and core 3 β1,3 N-acetylglucosaminyltransferase (C3GnT) decreased 2 to 6- and 2-fold, respectively.
37111049	13	94	theme	modifying	1935:1943	arg1	enzymes					1945:1951	the mucin-glycan modifying enzymes	1918:1951	the mucin-glycan modifying enzymes	1918:1951	Also, the expression of sialyltransferase, one of the mucin-glycan modifying enzymes, was decreased by 1-fold.
37111049	10	95	theme	goblet	1399:1404	arg1	differentiation					1411:1425	goblet cell differentiation	1399:1425	goblet cell differentiation	1399:1425	Among them, the proportion of goblet cells decreased significantly in older mice, and the expression of spdef genes that regulate goblet cell differentiation decreased.
37111049	2	96	theme	colon-related	294:306	arg1	diseases					308:315	colon-related diseases	294:315	colon-related diseases	294:315	Additionally, the incidence of colon-related diseases increases significantly in adulthood, posing a threat to the health of the elderly.
37111049	4	97	theme	mucus	579:583	arg1	barrier					585:591	the colonic mucus barrier	567:591	the colonic mucus barrier	567:591	To understand the effects of aging on the colonic mucus barrier, changes in the colonic mucus layer were evaluated in mice aged 2, 12, 18, and 24 months.
37111049	14	98	theme	colonic	2138:2144	arg1	mucus					2146:2150	colonic mucus	2138:2150	colonic mucus	2138:2150	Overall, our results indicate that the goblet cells/glycosyltransferase/O-glycan axis plays an important role in maintaining the physicochemical properties of colonic mucus and the stability of intestinal environment.
37111049	11	99	theme	structure	1500:1508	arg1	formation					1510:1518	mucin core structure formation	1489:1518	mucin core structure formation	1489:1518	Further, the expression of key enzymes involved in mucin core structure formation and glycan modification also changed with aging.
37111049	1	100	theme	mucus	211:215	arg1	barrier					217:223	colonic mucus barrier	203:223	colonic mucus barrier	203:223	During aging, the protective function of mucus barrier is significantly reduced among which changes in colonic mucus barrier function received the most attention.
36584780	0	0	theme	alginate	77:84	arg1	lyases					86:91	alginate lyases	77:91	alginate lyases	77:91	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.
36584780	2	1	from	seaweeds	393:400	arg1	fucoidans					364:372	pure and intact fucoidans	348:372	pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	348:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	1	from	seaweeds	393:400	arg1	production					334:343	the production	330:343	the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	330:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	3	2	from	CTec2	518:522	arg1	combination					527:537	combination	527:537	combination with endo- and exo-acting thermophilic alginate lyases	527:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	1	3	theme	several	223:229	arg1	bioactivities					242:254	several beneficial bioactivities	223:254	several beneficial bioactivities	223:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	6	4	theme	high	1099:1102	arg1	fucoidans					1111:1119	The high purity fucoidans	1095:1119	The high purity fucoidans isolated by this new enzymatic extraction technique	1095:1171	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	3	5	theme	commercial	483:492	arg1	CTec2					518:522	the commercial cellulase blend Cellic® CTec2	479:522	the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases	479:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	1	6	theme	beneficial	231:240	arg1	bioactivities					242:254	several beneficial bioactivities	223:254	several beneficial bioactivities	223:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	4	7	theme	fucose	810:815	arg1	fucose					810:815	fucose	810:815	fucose	810:815	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	7	theme	fucose	810:815	arg1	amounts					799:805	significantly higher amounts	778:805	significantly higher amounts of fucose and sulfate	778:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	7	theme	fucose	810:815	arg1	sulfate					821:827	sulfate	821:827	sulfate	821:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	8	theme	main	834:837	arg1	components					839:848	the main components	830:848	the main components of fucoidans	830:861	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	9	from	fucoidans	687:695	arg1	terms					700:704	terms	700:704	terms of chemical compositions and molecular weights	700:751	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	0	10	from	seaweeds	47:54	arg1	Extraction					0:9	Extraction	0:9	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.	0:92	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.
36584780	2	11	theme	present	264:270	arg1	study					272:276	the present study	260:276	the present study	260:276	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	3	12	theme	extraction	454:463	arg1	protocol					465:472	This new extraction protocol	445:472	This new extraction protocol	445:472	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	4	13	theme	compositions	718:729	arg1	terms					700:704	terms	700:704	terms of chemical compositions and molecular weights	700:751	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	3	14	theme	Cellic®	510:516	arg1	CTec2					518:522	the commercial cellulase blend Cellic® CTec2	479:522	the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases	479:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	2	15	theme	fucoidans	364:372	arg1	production					334:343	the production	330:343	the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	330:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	0	16	theme	brown	41:45	arg1	seaweeds					47:54	brown seaweeds	41:54	brown seaweeds using cellulases and alginate lyases	41:91	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.
36584780	2	17	dep	seaweeds	393:400	arg1	latissima					413:421	Saccharina latissima	402:421	Saccharina latissima	402:421	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	17	dep	seaweeds	393:400	arg1	esculenta					434:442	Alaria esculenta	427:442	Alaria esculenta	427:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	17	dep	seaweeds	393:400	arg1	seaweeds					393:400	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	1	18	theme	cell	167:170	arg1	wall					172:175	the cell wall	163:175	the cell wall of brown seaweeds	163:193	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	5	19	theme	extracted	975:983	arg1	fucoidans					985:993	the extracted fucoidans	971:993	the extracted fucoidans	971:993	Thus, by using this combination of enzymes, the extracted fucoidans do not undergo depolymerization during extraction and additional purification steps are not needed.
36584780	1	20	located	found	154:158	arg1	wall					172:175	the cell wall	163:175	the cell wall of brown seaweeds	163:193	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	20	located	found	154:158	arg2	Fucoidans					94:102	Fucoidans	94:102	Fucoidans	94:102	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	20	located	found	154:158	arg2	polysaccharides					129:143	fucose rich sulfated polysaccharides	108:143	fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities	108:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	6	21	theme	biological	1247:1256	arg1	activities					1258:1267	biological activities	1247:1267	biological activities	1247:1267	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	4	22	theme	extracted	677:685	arg1	fucoidans					687:695	traditionally extracted fucoidans	663:695	traditionally extracted fucoidans in terms of chemical compositions and molecular weights	663:751	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	23	theme	fucoidans	853:861	arg1	components					839:848	the main components	830:848	the main components of fucoidans	830:861	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	3	24	theme	exo-acting	554:563	arg1	lyases					587:592	endo- and exo-acting thermophilic alginate lyases	544:592	endo- and exo-acting thermophilic alginate lyases	544:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	2	25	theme	pure	348:351	arg1	fucoidans					364:372	pure and intact fucoidans	348:372	pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	348:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	26	theme	Saccharina	402:411	arg1	latissima					413:421	Saccharina latissima	402:421	Saccharina latissima	402:421	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	26	theme	Saccharina	402:411	arg1	seaweeds					393:400	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	4	27	theme	weights	745:751	arg1	terms					700:704	terms	700:704	terms of chemical compositions and molecular weights	700:751	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	2	28	from	production	334:343	arg1	latissima					413:421	Saccharina latissima	402:421	Saccharina latissima	402:421	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	28	from	production	334:343	arg1	esculenta					434:442	Alaria esculenta	427:442	Alaria esculenta	427:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	28	from	production	334:343	arg1	seaweeds					393:400	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	6	29	theme	enzymatic	1142:1150	arg1	technique					1163:1171	this new enzymatic extraction technique	1133:1171	this new enzymatic extraction technique	1133:1171	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	2	30	theme	brown	387:391	arg1	latissima					413:421	Saccharina latissima	402:421	Saccharina latissima	402:421	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	30	theme	brown	387:391	arg1	esculenta					434:442	Alaria esculenta	427:442	Alaria esculenta	427:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	30	theme	brown	387:391	arg1	seaweeds					393:400	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	0	31	theme	high	14:17	arg1	fucoidans					26:34	high purity fucoidans	14:34	high purity fucoidans	14:34	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.
36584780	4	32	theme	higher	792:797	arg1	fucose					810:815	fucose	810:815	fucose	810:815	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	32	theme	higher	792:797	arg1	amounts					799:805	significantly higher amounts	778:805	significantly higher amounts of fucose and sulfate	778:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	32	theme	higher	792:797	arg1	sulfate					821:827	sulfate	821:827	sulfate	821:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	3	33	theme	endo-	544:548	arg1	lyases					587:592	endo- and exo-acting thermophilic alginate lyases	544:592	endo- and exo-acting thermophilic alginate lyases	544:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	6	34	used	used	1180:1183	arg2	fucoidans					1111:1119	The high purity fucoidans	1095:1119	The high purity fucoidans isolated by this new enzymatic extraction technique	1095:1171	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	1	35	theme	seaweeds	186:193	arg1	wall					172:175	the cell wall	163:175	the cell wall of brown seaweeds	163:193	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	2	36	theme	extraction	305:314	arg1	technique					316:324	a new enzymatic extraction technique	289:324	a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	289:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	6	37	theme	fucoidan	1223:1230	arg1	structures					1232:1241	the different fucoidan structures	1209:1241	the different fucoidan structures	1209:1241	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	1	38	contain	have	218:221	arg1	polysaccharides					129:143	fucose rich sulfated polysaccharides	108:143	fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities	108:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	38	contain	have	218:221	arg1	Fucoidans					94:102	Fucoidans	94:102	Fucoidans	94:102	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	38	contain	have	218:221	arg2	bioactivities					242:254	several beneficial bioactivities	223:254	several beneficial bioactivities	223:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	0	39	theme	fucoidans	26:34	arg1	Extraction					0:9	Extraction	0:9	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.	0:92	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.
36584780	0	40	theme	purity	19:24	arg1	fucoidans					26:34	high purity fucoidans	14:34	high purity fucoidans	14:34	Extraction of high purity fucoidans from brown seaweeds using cellulases and alginate lyases.
36584780	5	41	theme	enzymes	962:968	arg1	combination					947:957	this combination	942:957	this combination of enzymes	942:968	Thus, by using this combination of enzymes, the extracted fucoidans do not undergo depolymerization during extraction and additional purification steps are not needed.
36584780	3	42	theme	thermophilic	565:576	arg1	lyases					587:592	endo- and exo-acting thermophilic alginate lyases	544:592	endo- and exo-acting thermophilic alginate lyases	544:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	6	43	theme	purity	1104:1109	arg1	fucoidans					1111:1119	The high purity fucoidans	1095:1119	The high purity fucoidans isolated by this new enzymatic extraction technique	1095:1171	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	1	44	theme	fucose	108:113	arg1	polysaccharides					129:143	fucose rich sulfated polysaccharides	108:143	fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities	108:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	44	theme	fucose	108:113	arg1	Fucoidans					94:102	Fucoidans	94:102	Fucoidans	94:102	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	2	45	theme	Alaria	427:432	arg1	esculenta					434:442	Alaria esculenta	427:442	Alaria esculenta	427:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	45	theme	Alaria	427:432	arg1	seaweeds					393:400	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	the two brown seaweeds Saccharina latissima and Alaria esculenta	379:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	3	46	theme	new	450:452	arg1	protocol					465:472	This new extraction protocol	445:472	This new extraction protocol	445:472	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	3	47	theme	alginate	578:585	arg1	lyases					587:592	endo- and exo-acting thermophilic alginate lyases	544:592	endo- and exo-acting thermophilic alginate lyases	544:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	1	48	theme	rich	115:118	arg1	polysaccharides					129:143	fucose rich sulfated polysaccharides	108:143	fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities	108:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	48	theme	rich	115:118	arg1	Fucoidans					94:102	Fucoidans	94:102	Fucoidans	94:102	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	6	49	theme	different	1213:1221	arg1	structures					1232:1241	the different fucoidan structures	1209:1241	the different fucoidan structures	1209:1241	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	4	50	contain	contain	770:776	arg1	fucoidans					599:607	The fucoidans	595:607	The fucoidans obtained by this extraction technique	595:645	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	50	contain	contain	770:776	arg2	fucose					810:815	fucose	810:815	fucose	810:815	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	50	contain	contain	770:776	arg2	sulfate					821:827	sulfate	821:827	sulfate	821:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	50	contain	contain	770:776	arg2	amounts					799:805	significantly higher amounts	778:805	significantly higher amounts of fucose and sulfate	778:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	3	51	with	combination	527:537	arg1	lyases					587:592	endo- and exo-acting thermophilic alginate lyases	544:592	endo- and exo-acting thermophilic alginate lyases	544:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	4	52	theme	sulfate	821:827	arg1	fucose					810:815	fucose	810:815	fucose	810:815	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	52	theme	sulfate	821:827	arg1	amounts					799:805	significantly higher amounts	778:805	significantly higher amounts of fucose and sulfate	778:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	4	52	theme	sulfate	821:827	arg1	sulfate					821:827	sulfate	821:827	sulfate	821:827	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	1	53	theme	sulfated	120:127	arg1	polysaccharides					129:143	fucose rich sulfated polysaccharides	108:143	fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities	108:254	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	1	53	theme	sulfated	120:127	arg1	Fucoidans					94:102	Fucoidans	94:102	Fucoidans	94:102	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	4	54	theme	alginate	896:903	arg1	contamination					905:917	alginate contamination	896:917	alginate contamination	896:917	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	5	55	theme	additional	1049:1058	arg1	steps					1073:1077	additional purification steps	1049:1077	additional purification steps	1049:1077	Thus, by using this combination of enzymes, the extracted fucoidans do not undergo depolymerization during extraction and additional purification steps are not needed.
36584780	4	56	theme	molecular	735:743	arg1	weights					745:751	molecular weights	735:751	molecular weights	735:751	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	2	57	theme	new	291:293	arg1	technique					316:324	a new enzymatic extraction technique	289:324	a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	289:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	2	58	theme	enzymatic	295:303	arg1	technique					316:324	a new enzymatic extraction technique	289:324	a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	289:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	5	59	theme	purification	1060:1071	arg1	steps					1073:1077	additional purification steps	1049:1077	additional purification steps	1049:1077	Thus, by using this combination of enzymes, the extracted fucoidans do not undergo depolymerization during extraction and additional purification steps are not needed.
36584780	1	60	theme	brown	180:184	arg1	seaweeds					186:193	brown seaweeds	180:193	brown seaweeds	180:193	Fucoidans are fucose rich sulfated polysaccharides that are found in the cell wall of brown seaweeds and have been shown to have several beneficial bioactivities.
36584780	3	61	theme	cellulase	494:502	arg1	CTec2					518:522	the commercial cellulase blend Cellic® CTec2	479:522	the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases	479:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	2	62	theme	intact	357:362	arg1	fucoidans					364:372	pure and intact fucoidans	348:372	pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta	348:442	In the present study, we report a new enzymatic extraction technique for the production of pure and intact fucoidans from the two brown seaweeds Saccharina latissima and Alaria esculenta.
36584780	6	63	theme	extraction	1152:1161	arg1	technique					1163:1171	this new enzymatic extraction technique	1133:1171	this new enzymatic extraction technique	1133:1171	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	6	64	theme	new	1138:1140	arg1	technique					1163:1171	this new enzymatic extraction technique	1133:1171	this new enzymatic extraction technique	1133:1171	The high purity fucoidans isolated by this new enzymatic extraction technique can be used to provide insight into the different fucoidan structures and biological activities.
36584780	4	65	theme	extraction	626:635	arg1	technique					637:645	this extraction technique	621:645	this extraction technique	621:645	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36584780	3	66	theme	blend	504:508	arg1	CTec2					518:522	the commercial cellulase blend Cellic® CTec2	479:522	the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases	479:592	This new extraction protocol uses the commercial cellulase blend Cellic® CTec2 in combination with endo- and exo-acting thermophilic alginate lyases.
36584780	4	67	theme	chemical	709:716	arg1	compositions					718:729	chemical compositions	709:729	chemical compositions	709:729	The fucoidans obtained by this extraction technique are compared to traditionally extracted fucoidans in terms of chemical compositions and molecular weights and are shown to contain significantly higher amounts of fucose and sulfate, the main components of fucoidans, while cellulose, laminarin, and alginate contamination is low.
36291700	13	0	theme	fibrous	1857:1863	arg1	roots					1865:1869	<i>MaiDong</i>'s fibrous roots	1840:1869	<i>MaiDong</i>'s fibrous roots	1840:1869	It was concluded that <i>MaiDong</i>'s fibrous roots had similar components to the root, and their quality was not significantly affected by growth age.
36291700	6	1	theme	promotion	972:980	arg1	abilities					982:990	immune promotion abilities	965:990	immune promotion abilities	965:990	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	8	2	contain	contained	1218:1226	arg2	galactose					1291:1299	galactose	1291:1299	galactose	1291:1299	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	2	contain	contained	1218:1226	arg2	fructose					1228:1235	fructose	1228:1235	fructose	1228:1235	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	2	contain	contained	1218:1226	arg2	glucose					1241:1247	glucose	1241:1247	glucose	1241:1247	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	2	contain	contained	1218:1226	arg1	polysaccharides					1195:1209	All polysaccharides	1191:1209	All polysaccharides	1191:1209	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	2	contain	contained	1218:1226	arg2	xylose					1306:1311	xylose	1306:1311	xylose	1306:1311	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	2	contain	contained	1218:1226	arg2	mannose					1282:1288	mannose	1282:1288	mannose	1282:1288	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	1	3	theme	<i>Ophiopogon	181:193	arg1	herb					235:238	a tonic herb	227:238	a tonic herb in China	227:247	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	1	3	theme	<i>Ophiopogon	181:193	arg1	japonicus</i>					195:207	<i>Ophiopogon japonicus</i>	181:207	<i>Ophiopogon japonicus</i>	181:207	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	10	4	theme	fibrous	1551:1557	arg1	roots					1559:1563	fibrous roots	1551:1563	fibrous roots	1551:1563	<i>Zhe MaiDong</i> exhibited better antioxidant and immune promotion activity, and so did that of fibrous roots.
36291700	6	5	theme	immune	965:970	arg1	abilities					982:990	immune promotion abilities	965:990	immune promotion abilities	965:990	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	10	6	theme	promotion	1512:1520	arg1	activity					1522:1529	better antioxidant and immune promotion activity	1482:1529	better antioxidant and immune promotion activity	1482:1529	<i>Zhe MaiDong</i> exhibited better antioxidant and immune promotion activity, and so did that of fibrous roots.
36291700	8	7	with	fructose	1228:1235	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	7	with	fructose	1228:1235	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	6	8	theme	RAW	1048:1050	arg1	macrophages					1058:1068	RAW 264.7 macrophages	1048:1068	RAW 264.7 macrophages	1048:1068	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	4	9	from	batches	761:767	arg1	preparation					722:732	the preparation	718:732	the preparation of polysaccharides from 29 batches of <i>MaiDong</i>	718:785	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	4	9	from	batches	761:767	arg1	polysaccharides					737:751	polysaccharides	737:751	polysaccharides from 29 batches of <i>MaiDong</i>	737:785	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	7	10	theme	molecular	1169:1177	arg1	parameters					1179:1188	molecular parameters	1169:1188	molecular parameters	1169:1188	The results showed that polysaccharides in different <i>MaiDong</i> varied in molecular parameters.
36291700	2	11	theme	medica	303:308	arg1	MaiDong</i>					402:412	<i>Chuan MaiDong</i>	393:412	<i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan)	393:453	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	11	theme	medica	303:308	arg1	MaiDong</i>					524:534	<i>Hubei MaiDong</i>	515:534	<i>Hubei MaiDong</i> (<i>Liriope spicata</i>)	515:559	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	11	theme	medica	303:308	arg1	MaiDong</i>					338:348	<i>Zhe MaiDong</i>	331:348	<i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang)	331:390	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	11	theme	medica	303:308	arg1	MaiDong</i>					473:483	MaiDong</i>	473:483	MaiDong</i>	473:483	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	11	theme	medica	303:308	arg1	MaiDong					276:282	MaiDong	276:282	MaiDong of Chinese materia medica	276:308	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	8	12	with	mannose	1282:1288	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	12	with	mannose	1282:1288	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	7	13	from	polysaccharides	1115:1129	arg1	<i>MaiDong</i>					1144:1157	different <i>MaiDong</i>	1134:1157	different <i>MaiDong</i>	1134:1157	The results showed that polysaccharides in different <i>MaiDong</i> varied in molecular parameters.
36291700	2	14	theme	<i>Liriope	537:546	arg1	MaiDong</i>					524:534	<i>Hubei MaiDong</i>	515:534	<i>Hubei MaiDong</i> (<i>Liriope spicata</i>)	515:559	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	14	theme	<i>Liriope	537:546	arg1	spicata</i>					548:558	<i>Liriope spicata</i>	537:558	<i>Liriope spicata</i>	537:558	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	4	15	theme	<i>MaiDong</i>	772:785	arg1	batches					761:767	29 batches	758:767	29 batches of <i>MaiDong</i>	758:785	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	2	16	theme	materia	295:301	arg1	medica					303:308	Chinese materia medica	287:308	Chinese materia medica	287:308	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	12	17	theme	multivariate	1705:1716	arg1	analysis					1730:1737	multivariate statistical analysis	1705:1737	multivariate statistical analysis	1705:1737	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	12	18	theme	statistical	1718:1728	arg1	analysis					1730:1737	multivariate statistical analysis	1705:1737	multivariate statistical analysis	1705:1737	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	8	19	theme	small	1254:1258	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	19	theme	small	1254:1258	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	6	20	theme	ABTS	947:950	arg1	radicals					952:959	ABTS radicals	947:959	ABTS radicals	947:959	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	14	21	dep	cultivation	2010:2020	arg1	the					2006:2008	the	2006:2008	the	2006:2008	This may provide some guidance for the cultivation and use of <i>MaiDong</i>.
36291700	5	22	theme	compositional	878:890	arg1	monosaccharides					892:906	compositional monosaccharides	878:906	compositional monosaccharides	878:906	HPSEC-MALLS-RID and HPAEC-PAD were employed to investigate their molecular parameters and compositional monosaccharides, respectively.
36291700	2	23	theme	Chinese	287:293	arg1	medica					303:308	Chinese materia medica	287:308	Chinese materia medica	287:308	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	0	24	theme	Physicochemical	108:122	arg1	Properties					144:153	Physicochemical and Pharmacological Properties	108:153	Physicochemical and Pharmacological Properties of Their Polysaccharides	108:178	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	6	25	from	phagocytosis	1032:1043	arg1	macrophages					1058:1068	RAW 264.7 macrophages	1048:1068	RAW 264.7 macrophages	1048:1068	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	4	26	used	used	709:712	arg2	MAE					700:702	MAE	700:702	MAE	700:702	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	4	26	used	used	709:712	arg2	extraction					688:697	microwave-assisted extraction	669:697	microwave-assisted extraction (MAE)	669:703	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	12	27	theme	RI	1807:1808	arg1	signal					1810:1815	RI signal	1807:1815	RI signal	1807:1815	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	4	28	theme	microwave-assisted	669:686	arg1	extraction					688:697	microwave-assisted extraction	669:697	microwave-assisted extraction (MAE)	669:703	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	4	28	theme	microwave-assisted	669:686	arg1	MAE					700:702	MAE	700:702	MAE	700:702	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	7	29	theme	different	1134:1142	arg1	<i>MaiDong</i>					1144:1157	different <i>MaiDong</i>	1134:1157	different <i>MaiDong</i>	1134:1157	The results showed that polysaccharides in different <i>MaiDong</i> varied in molecular parameters.
36291700	2	30	from	japonicus</i>	365:377	arg1	Zhejiang					382:389	Zhejiang	382:389	Zhejiang	382:389	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	31	dep	MaiDong</i>	338:348	arg1	japonicus</i>					365:377	<i>Ophiopogon japonicus</i>	351:377	<i>Ophiopogon japonicus</i> in Zhejiang	351:389	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	9	32	theme	molar	1386:1390	arg1	15:1					1424:1427	15:1	1424:1427	15:1	1424:1427	For polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>, the molar ratio of Fru to Glc was roughly 15:1 and 14:1, respectively.
36291700	9	32	theme	molar	1386:1390	arg1	ratio					1392:1396	the molar ratio	1382:1396	the molar ratio of Fru to Glc	1382:1410	For polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>, the molar ratio of Fru to Glc was roughly 15:1 and 14:1, respectively.
36291700	2	33	theme	<i>Chuan	393:400	arg1	MaiDong</i>					402:412	<i>Chuan MaiDong</i>	393:412	<i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan)	393:453	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	33	theme	<i>Chuan	393:400	arg1	MaiDong					276:282	MaiDong	276:282	MaiDong of Chinese materia medica	276:308	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	0	34	theme	Quality	0:6	arg1	Evaluation					8:17	Quality Evaluation	0:17	Quality Evaluation of <i>Ophiopogon	0:34	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	9	35	theme	Fru	1401:1403	arg1	15:1					1424:1427	15:1	1424:1427	15:1	1424:1427	For polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>, the molar ratio of Fru to Glc was roughly 15:1 and 14:1, respectively.
36291700	9	35	theme	Fru	1401:1403	arg1	ratio					1392:1396	the molar ratio	1382:1396	the molar ratio of Fru to Glc	1382:1410	For polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>, the molar ratio of Fru to Glc was roughly 15:1 and 14:1, respectively.
36291700	13	36	contain	had	1871:1873	arg2	components					1883:1892	similar components	1875:1892	similar components	1875:1892	It was concluded that <i>MaiDong</i>'s fibrous roots had similar components to the root, and their quality was not significantly affected by growth age.
36291700	13	36	contain	had	1871:1873	arg1	roots					1865:1869	<i>MaiDong</i>'s fibrous roots	1840:1869	<i>MaiDong</i>'s fibrous roots	1840:1869	It was concluded that <i>MaiDong</i>'s fibrous roots had similar components to the root, and their quality was not significantly affected by growth age.
36291700	8	37	with	glucose	1241:1247	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	37	with	glucose	1241:1247	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	12	38	theme	quality	1680:1686	arg1	control					1688:1694	quality control	1680:1694	quality control	1680:1694	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	0	39	theme	<i>Ophiopogon	22:34	arg1	Evaluation					8:17	Quality Evaluation	0:17	Quality Evaluation of <i>Ophiopogon	0:34	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	12	40	theme	fructose	1793:1800	arg1	yield					1749:1753	yield	1749:1753	yield	1749:1753	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	12	40	theme	fructose	1793:1800	arg1	activity					1768:1775	antioxidant activity	1756:1775	antioxidant activity	1756:1775	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	12	40	theme	fructose	1793:1800	arg1	content					1782:1788	the content	1778:1788	the content of fructose	1778:1800	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	12	40	theme	fructose	1793:1800	arg1	signal					1810:1815	RI signal	1807:1815	RI signal	1807:1815	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	10	41	theme	<i>Zhe	1453:1458	arg1	MaiDong</i>					1460:1470	<i>Zhe MaiDong</i>	1453:1470	<i>Zhe MaiDong</i>	1453:1470	<i>Zhe MaiDong</i> exhibited better antioxidant and immune promotion activity, and so did that of fibrous roots.
36291700	11	42	from	variation	1629:1637	arg1	years					1649:1653	growth years	1642:1653	growth years	1642:1653	The pharmacological activity, however, did not account for the variation in growth years.
36291700	8	43	theme	arabinose	1271:1279	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	43	theme	arabinose	1271:1279	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	6	44	theme	oxide	1012:1016	arg1	terms					996:1000	terms	996:1000	terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages	996:1068	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	0	45	theme	Pharmacological	128:142	arg1	Properties					144:153	Physicochemical and Pharmacological Properties	108:153	Physicochemical and Pharmacological Properties of Their Polysaccharides	108:178	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	3	46	theme	quality	574:580	arg1	control					582:588	quality control	574:588	quality control	574:588	In terms of quality control, polysaccharides-based evaluations have not yet been conducted.
36291700	1	47	theme	tonic	229:233	arg1	herb					235:238	a tonic herb	227:238	a tonic herb in China	227:247	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	1	47	theme	tonic	229:233	arg1	japonicus</i>					195:207	<i>Ophiopogon japonicus</i>	181:207	<i>Ophiopogon japonicus</i>	181:207	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	8	48	with	xylose	1306:1311	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	48	with	xylose	1306:1311	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	6	49	theme	nitric	1005:1010	arg1	oxide					1012:1016	nitric oxide	1005:1016	nitric oxide releasing and phagocytosis on RAW 264.7 macrophages	1005:1068	The ability to scavenge ABTS radicals and immune promotion abilities, in terms of nitric oxide releasing and phagocytosis on RAW 264.7 macrophages, were also compared.
36291700	2	50	theme	<i>Liriope	486:495	arg1	MaiDong</i>					473:483	MaiDong</i>	473:483	MaiDong</i>	473:483	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	50	theme	<i>Liriope	486:495	arg1	muscari</i>					497:507	<i>Liriope muscari</i>	486:507	<i>Liriope muscari</i>	486:507	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	0	51	from	Origins	82:88	arg1	China					93:97	China	93:97	China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides	93:178	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	5	52	theme	molecular	853:861	arg1	parameters					863:872	their molecular parameters	847:872	their molecular parameters	847:872	HPSEC-MALLS-RID and HPAEC-PAD were employed to investigate their molecular parameters and compositional monosaccharides, respectively.
36291700	1	53	from	herb	235:238	arg1	China					243:247	China	243:247	China	243:247	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	2	54	theme	<i>Ophiopogon	415:427	arg1	japonicus</i>					429:441	<i>Ophiopogon japonicus</i>	415:441	<i>Ophiopogon japonicus</i> in Sichuan	415:452	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	0	55	theme	Authentic	59:67	arg1	Origins					82:88	Two Authentic Geographical Origins	55:88	Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides	55:178	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	3	56	theme	polysaccharides-based	591:611	arg1	evaluations					613:623	polysaccharides-based evaluations	591:623	polysaccharides-based evaluations	591:623	In terms of quality control, polysaccharides-based evaluations have not yet been conducted.
36291700	2	57	theme	<i>Ophiopogon	351:363	arg1	japonicus</i>					365:377	<i>Ophiopogon japonicus</i>	351:377	<i>Ophiopogon japonicus</i> in Zhejiang	351:389	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	0	58	theme	Polysaccharides	164:178	arg1	Properties					144:153	Physicochemical and Pharmacological Properties	108:153	Physicochemical and Pharmacological Properties of Their Polysaccharides	108:178	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	11	59	theme	growth	1642:1647	arg1	years					1649:1653	growth years	1642:1653	growth years	1642:1653	The pharmacological activity, however, did not account for the variation in growth years.
36291700	10	60	theme	immune	1505:1510	arg1	activity					1522:1529	better antioxidant and immune promotion activity	1482:1529	better antioxidant and immune promotion activity	1482:1529	<i>Zhe MaiDong</i> exhibited better antioxidant and immune promotion activity, and so did that of fibrous roots.
36291700	3	61	theme	control	582:588	arg1	terms					565:569	terms	565:569	terms of quality control	565:588	In terms of quality control, polysaccharides-based evaluations have not yet been conducted.
36291700	10	62	theme	antioxidant	1489:1499	arg1	activity					1522:1529	better antioxidant and immune promotion activity	1482:1529	better antioxidant and immune promotion activity	1482:1529	<i>Zhe MaiDong</i> exhibited better antioxidant and immune promotion activity, and so did that of fibrous roots.
36291700	4	63	theme	polysaccharides	737:751	arg1	preparation					722:732	the preparation	718:732	the preparation of polysaccharides from 29 batches of <i>MaiDong</i>	718:785	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	12	64	theme	antioxidant	1756:1766	arg1	activity					1768:1775	antioxidant activity	1756:1775	antioxidant activity	1756:1775	Finally, indicators for quality control based on multivariate statistical analysis included: yield, antioxidant activity, the content of fructose, and RI signal.
36291700	1	65	used	used	219:222	arg2	japonicus</i>					195:207	<i>Ophiopogon japonicus</i>	181:207	<i>Ophiopogon japonicus</i>	181:207	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	1	65	used	used	219:222	arg2	herb					235:238	a tonic herb	227:238	a tonic herb in China	227:247	<i>Ophiopogon japonicus</i> is widely used as a tonic herb in China.
36291700	2	66	from	japonicus</i>	429:441	arg1	Sichuan					446:452	Sichuan	446:452	Sichuan	446:452	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	67	theme	<i>Zhe	331:336	arg1	MaiDong</i>					338:348	<i>Zhe MaiDong</i>	331:348	<i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang)	331:390	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	67	theme	<i>Zhe	331:336	arg1	MaiDong					276:282	MaiDong	276:282	MaiDong of Chinese materia medica	276:308	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	4	68	from	preparation	722:732	arg1	batches					761:767	29 batches	758:767	29 batches of <i>MaiDong</i>	758:785	In this study, microwave-assisted extraction (MAE) was used for the preparation of polysaccharides from 29 batches of <i>MaiDong</i>.
36291700	13	69	theme	similar	1875:1881	arg1	components					1883:1892	similar components	1875:1892	similar components	1875:1892	It was concluded that <i>MaiDong</i>'s fibrous roots had similar components to the root, and their quality was not significantly affected by growth age.
36291700	2	70	theme	<i>Hubei	515:522	arg1	MaiDong					276:282	MaiDong	276:282	MaiDong of Chinese materia medica	276:308	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	70	theme	<i>Hubei	515:522	arg1	MaiDong</i>					524:534	<i>Hubei MaiDong</i>	515:534	<i>Hubei MaiDong</i> (<i>Liriope spicata</i>)	515:559	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	2	70	theme	<i>Hubei	515:522	arg1	spicata</i>					548:558	<i>Liriope spicata</i>	537:558	<i>Liriope spicata</i>	537:558	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	9	71	theme	MaiDong</i>	1344:1354	arg1	polysaccharides					1318:1332	polysaccharides	1318:1332	polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>	1318:1379	For polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>, the molar ratio of Fru to Glc was roughly 15:1 and 14:1, respectively.
36291700	8	72	with	galactose	1291:1299	arg1	arabinose					1271:1279	arabinose	1271:1279	arabinose	1271:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	8	72	with	galactose	1291:1299	arg1	amounts					1260:1266	small amounts	1254:1266	small amounts of arabinose	1254:1279	All polysaccharides mainly contained fructose and glucose with small amounts of arabinose, mannose, galactose, and xylose.
36291700	13	73	theme	growth	1959:1964	arg1	age					1966:1968	growth age	1959:1968	growth age	1959:1968	It was concluded that <i>MaiDong</i>'s fibrous roots had similar components to the root, and their quality was not significantly affected by growth age.
36291700	14	74	theme	<i>MaiDong</i>	2033:2046	arg1	use					2026:2028	use	2026:2028	use	2026:2028	This may provide some guidance for the cultivation and use of <i>MaiDong</i>.
36291700	14	74	theme	<i>MaiDong</i>	2033:2046	arg1	cultivation					2010:2020	cultivation	2010:2020	cultivation	2010:2020	This may provide some guidance for the cultivation and use of <i>MaiDong</i>.
36291700	0	75	theme	Geographical	69:80	arg1	Origins					82:88	Two Authentic Geographical Origins	55:88	Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides	55:178	Quality Evaluation of <i>Ophiopogon japonicus</i> from Two Authentic Geographical Origins in China Based on Physicochemical and Pharmacological Properties of Their Polysaccharides.
36291700	9	76	theme	MaiDong</i>	1369:1379	arg1	polysaccharides					1318:1332	polysaccharides	1318:1332	polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>	1318:1379	For polysaccharides of <i>Zhe MaiDong</i> and <i>Chuan MaiDong</i>, the molar ratio of Fru to Glc was roughly 15:1 and 14:1, respectively.
36291700	2	77	dep	MaiDong</i>	402:412	arg1	japonicus</i>					429:441	<i>Ophiopogon japonicus</i>	415:441	<i>Ophiopogon japonicus</i> in Sichuan	415:452	According to the origins, MaiDong of Chinese materia medica can be classified as <i>Zhe MaiDong</i> (<i>Ophiopogon japonicus</i> in Zhejiang), <i>Chuan MaiDong</i> (<i>Ophiopogon japonicus</i> in Sichuan), <i>Duanting Shan MaiDong</i> (<i>Liriope muscari</i>), and <i>Hubei MaiDong</i> (<i>Liriope spicata</i>).
36291700	11	78	theme	pharmacological	1570:1584	arg1	activity					1586:1593	The pharmacological activity	1566:1593	The pharmacological activity	1566:1593	The pharmacological activity, however, did not account for the variation in growth years.
35777212	3	0	attach	attached	848:855	arg1	scaffold					864:871	the scaffold	860:871	the scaffold	860:871	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	3	0	attach	attached	848:855	arg2	cubes					814:818	freeze-dried cubes	801:818	freeze-dried cubes	801:818	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	4	1	theme	structural	908:917	arg1	collapse					919:926	structural collapse	908:926	structural collapse	908:926	Both of them inhibited structural collapse.
35777212	3	2	theme	granules	839:846	arg1	scaffold					789:796	the scaffold	785:796	the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers	785:882	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	2	3	theme	materials	501:509	arg1	proportion					475:484	The dry proportion	467:484	The dry proportion of starch-rich materials, such as taro,	467:524	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	2	4	theme	dry	595:597	arg1	proportion					599:608	the dry proportion	591:608	the dry proportion of starch-poor materials such as apple	591:647	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	1	5	theme	freeze-dried	445:456	arg1	samples					458:464	corresponding freeze-dried samples	431:464	corresponding freeze-dried samples	431:464	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	6	theme	vegetable	266:274	arg1	cubes					276:280	freeze-dried fruit and vegetable cubes	243:280	freeze-dried fruit and vegetable cubes	243:280	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	7	theme	samples	458:464	arg1	hygroscopicity					413:426	hygroscopicity	413:426	hygroscopicity of corresponding freeze-dried samples	413:464	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	7	theme	samples	458:464	arg1	microstructure					388:401	the microstructure	384:401	the microstructure	384:401	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	8	theme	cubes	276:280	arg1	texture					200:206	texture	200:206	texture	200:206	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	8	theme	cubes	276:280	arg1	characteristics					224:238	hygroscopic characteristics	212:238	hygroscopic characteristics	212:238	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	9	theme	fresh	363:367	arg1	materials					369:377	12 fresh materials	360:377	12 fresh materials	360:377	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	3	10	theme	starch	832:837	arg1	granules					839:846	natural starch granules	824:846	natural starch granules	824:846	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	0	11	theme	fruit	126:130	arg1	cubes					146:150	freeze-dried fruit and vegetable cubes	113:150	freeze-dried fruit and vegetable cubes	113:150	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	1	12	theme	materials	369:377	arg1	hygroscopicity					413:426	hygroscopicity	413:426	hygroscopicity of corresponding freeze-dried samples	413:464	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	12	theme	materials	369:377	arg1	texture					404:410	texture	404:410	texture	404:410	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	12	theme	materials	369:377	arg1	compositions					344:355	the major chemical compositions	325:355	the major chemical compositions of 12 fresh materials	325:377	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	12	theme	materials	369:377	arg1	microstructure					388:401	the microstructure	384:401	the microstructure	384:401	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	5	13	theme	freeze-dried	1001:1012	arg1	cubes					1014:1018	freeze-dried cubes	1001:1018	freeze-dried cubes	1001:1018	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	0	14	theme	freeze-dried	113:124	arg1	cubes					146:150	freeze-dried fruit and vegetable cubes	113:150	freeze-dried fruit and vegetable cubes	113:150	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	2	15	theme	materials	625:633	arg1	proportion					599:608	the dry proportion	591:608	the dry proportion of starch-poor materials such as apple	591:647	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	5	16	theme	cubes	1014:1018	arg1	hardness					974:981	hardness	974:981	hardness	974:981	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	5	16	theme	cubes	1014:1018	arg1	crispiness					987:996	crispiness	987:996	crispiness	987:996	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	1	17	theme	critical	176:183	arg1	factors					185:191	the critical factors	172:191	the critical factors	172:191	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	0	18	theme	wall	5:8	arg1	polysaccharides					10:24	Cell wall polysaccharides	0:24	Cell wall polysaccharides	0:24	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	2	19	theme	starch-poor	613:623	arg1	materials					625:633	starch-poor materials	613:633	starch-poor materials such as apple	613:647	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	2	19	theme	starch-poor	613:623	arg1	apple					643:647	apple	643:647	apple	643:647	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	0	20	theme	Cell	0:3	arg1	polysaccharides					10:24	Cell wall polysaccharides	0:24	Cell wall polysaccharides	0:24	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	3	21	theme	cell	747:750	arg1	polysaccharides					757:771	cell wall polysaccharides	747:771	cell wall polysaccharides	747:771	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	5	22	theme	pores	1089:1093	arg1	size					1077:1080	the size	1073:1080	the size of the pores	1073:1093	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	0	23	dep	texture	83:89	arg1	the					79:81	the	79:81	the	79:81	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	1	24	theme	correlation	287:297	arg1	analysis					299:306	the correlation analysis	283:306	the correlation analysis	283:306	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	0	25	theme	vegetable	136:144	arg1	cubes					146:150	freeze-dried fruit and vegetable cubes	113:150	freeze-dried fruit and vegetable cubes	113:150	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	3	26	from	microscopy	724:733	arg1	Data					710:713	Data	710:713	Data from the microscopy	710:733	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	2	27	theme	starch-rich	489:499	arg1	materials					501:509	starch-rich materials	489:509	starch-rich materials	489:509	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	2	27	theme	starch-rich	489:499	arg1	taro					520:523	taro	520:523	taro	520:523	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	5	28	theme	excessive	1030:1038	arg1	mono-/disaccharides					1040:1058	excessive mono-/disaccharides	1030:1058	excessive mono-/disaccharides	1030:1058	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	0	29	theme	cubes	146:150	arg1	texture					83:89	texture	83:89	texture	83:89	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	0	29	theme	cubes	146:150	arg1	hygroscopicity					95:108	hygroscopicity	95:108	hygroscopicity	95:108	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	5	30	theme	severe	1105:1110	arg1	shrinkage					1112:1120	severe shrinkage	1105:1120	severe shrinkage	1105:1120	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	1	31	theme	hygroscopic	212:222	arg1	characteristics					224:238	hygroscopic characteristics	212:238	hygroscopic characteristics	212:238	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	3	32	theme	wall	752:755	arg1	polysaccharides					757:771	cell wall polysaccharides	747:771	cell wall polysaccharides	747:771	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	6	33	theme	cubes	1182:1186	arg1	hygroscopicity					1151:1164	the hygroscopicity	1147:1164	the hygroscopicity of freeze-dried cubes	1147:1186	Polysaccharides reduced the hygroscopicity of freeze-dried cubes, on the contrary, mono-/disaccharides promoted hygroscopicity, especially fructose.
35777212	0	34	theme	chemical	53:60	arg1	determinants					62:73	chemical determinants	53:73	chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes	53:150	Cell wall polysaccharides and mono-/disaccharides as chemical determinants for the texture and hygroscopicity of freeze-dried fruit and vegetable cubes.
35777212	2	35	theme	dry	471:473	arg1	proportion					475:484	The dry proportion	467:484	The dry proportion of starch-rich materials, such as taro,	467:524	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	3	36	theme	freeze-dried	801:812	arg1	cubes					814:818	freeze-dried cubes	801:818	freeze-dried cubes	801:818	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	6	37	theme	freeze-dried	1169:1180	arg1	cubes					1182:1186	freeze-dried cubes	1169:1186	freeze-dried cubes	1169:1186	Polysaccharides reduced the hygroscopicity of freeze-dried cubes, on the contrary, mono-/disaccharides promoted hygroscopicity, especially fructose.
35777212	1	38	theme	major	329:333	arg1	compositions					344:355	the major chemical compositions	325:355	the major chemical compositions of 12 fresh materials	325:377	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	2	39	theme	0.70-0.95/g	693:703	arg1	mono-/disaccharides					672:690	mono-/disaccharides	672:690	mono-/disaccharides (0.70-0.95/g db)	672:707	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	2	39	theme	0.70-0.95/g	693:703	arg1	db					705:706	0.70-0.95/g db	693:706	0.70-0.95/g db	693:706	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	3	40	theme	cubes	814:818	arg1	scaffold					789:796	the scaffold	785:796	the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers	785:882	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	2	41	theme	0.76-0.89 g/g	566:578	arg1	polysaccharides					549:563	polysaccharides	549:563	polysaccharides (0.76-0.89 g/g db)	549:582	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	2	41	theme	0.76-0.89 g/g	566:578	arg1	db					580:581	0.76-0.89 g/g db	566:581	0.76-0.89 g/g db	566:581	The dry proportion of starch-rich materials, such as taro, was mainly composed of polysaccharides (0.76-0.89 g/g db), while the dry proportion of starch-poor materials such as apple was mainly composed of mono-/disaccharides (0.70-0.95/g db).
35777212	1	42	theme	corresponding	431:443	arg1	samples					458:464	corresponding freeze-dried samples	431:464	corresponding freeze-dried samples	431:464	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	5	43	dep	hardness	974:981	arg1	the					970:972	the	970:972	the	970:972	Mono-/disaccharides were accountable for the hardness and crispiness of freeze-dried cubes, however, excessive mono-/disaccharides could reduce the size of the pores and cause severe shrinkage.
35777212	1	44	theme	freeze-dried	243:254	arg1	cubes					276:280	freeze-dried fruit and vegetable cubes	243:280	freeze-dried fruit and vegetable cubes	243:280	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	3	45	theme	natural	824:830	arg1	granules					839:846	natural starch granules	824:846	natural starch granules	824:846	Data from the microscopy showed that cell wall polysaccharides constituted the scaffold of freeze-dried cubes and natural starch granules attached to the scaffold as fillers.
35777212	1	46	theme	chemical	335:342	arg1	compositions					344:355	the major chemical compositions	325:355	the major chemical compositions of 12 fresh materials	325:377	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	47	dep	texture	200:206	arg1	the					196:198	the	196:198	the	196:198	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
35777212	1	48	theme	fruit	256:260	arg1	cubes					276:280	freeze-dried fruit and vegetable cubes	243:280	freeze-dried fruit and vegetable cubes	243:280	In order to select the critical factors on the texture and hygroscopic characteristics of freeze-dried fruit and vegetable cubes, the correlation analysis was performed on the major chemical compositions of 12 fresh materials, and the microstructure, texture, hygroscopicity of corresponding freeze-dried samples.
36773875	2	0	from	compositions	468:479	arg1	substrates					494:503	different substrates	484:503	different substrates	484:503	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	5	1	theme	moisture	809:816	arg1	amounts					798:804	small amounts	792:804	small amounts of moisture	792:816	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	5	1	theme	moisture	809:816	arg1	moisture					809:816	moisture	809:816	moisture	809:816	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	3	2	theme	pitch	689:693	arg1	increase					658:665	the increase	654:665	the increase of the chiral nematic pitch	654:693	With increasing WPU content, the reflected wavelength increased from 400 to 680 nm, which was mainly caused by the increase of the chiral nematic pitch.
36773875	5	3	from	ethanol	821:827	arg1	sensitive					779:787	sensitive	779:787	sensitive	779:787	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	10	4	theme	anti-counterfeiting	1445:1463	arg1	labels					1465:1470	anti-counterfeiting labels	1445:1470	anti-counterfeiting labels	1445:1470	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	8	5	theme	MgCl2	1167:1171	arg1	solution					1173:1180	MgCl2 solution	1167:1180	MgCl2 solution	1167:1180	By using MgCl2 solution as an ink to write invisible patterns on the coating which can be revealed temporary by ethanol.
36773875	8	5	theme	MgCl2	1167:1171	arg1	ink					1188:1190	an ink	1185:1190	an ink to write invisible patterns on the coating which can be revealed temporary by ethanol	1185:1276	By using MgCl2 solution as an ink to write invisible patterns on the coating which can be revealed temporary by ethanol.
36773875	9	6	theme	invisible	1296:1304	arg1	rewritable					1337:1346	rewritable	1337:1346	rewritable	1337:1346	In addition, the invisible pattern of photonic coating is rewritable.
36773875	9	6	theme	invisible	1296:1304	arg1	pattern					1306:1312	the invisible pattern	1292:1312	the invisible pattern of photonic coating	1292:1332	In addition, the invisible pattern of photonic coating is rewritable.
36773875	7	7	theme	wood	1130:1133	arg1	substrate					1135:1143	the wood substrate	1126:1143	the wood substrate	1126:1143	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	10	8	theme	photonic	1394:1401	arg1	composite					1403:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	7	9	used	used	994:997	arg2	wood					985:988	wood	985:988	wood	985:988	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	7	9	used	used	994:997	arg2	substrate					1006:1014	the substrate	1002:1014	the substrate	1002:1014	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	4	10	theme	WPU	758:760	arg1	content					762:768	higher WPU content	751:768	higher WPU content	751:768	In addition, the mechanical properties were better for higher WPU content.
36773875	7	11	theme	composites	1112:1121	arg1	strong					1150:1155	strong	1150:1155	strong	1150:1155	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	7	11	theme	composites	1112:1121	arg1	forces					1098:1103	the adhesion forces	1085:1103	the adhesion forces of the composites to the wood substrate	1085:1143	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	10	12	theme	friendly	1385:1392	arg1	composite					1403:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	2	13	theme	photonic	315:322	arg1	composites					324:333	potential photonic composites	305:333	potential photonic composites with a chiral nematic structure	305:365	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	4	14	theme	mechanical	713:722	arg1	properties					724:733	the mechanical properties	709:733	the mechanical properties	709:733	In addition, the mechanical properties were better for higher WPU content.
36773875	6	15	theme	reversible	913:922	arg1	shift					928:932	The reversible red shift	909:932	The reversible red shift induced by moisture	909:952	The reversible red shift induced by moisture was approximately 100 nm.
36773875	6	15	theme	reversible	913:922	arg1	100 nm					972:977	100 nm	972:977	100 nm	972:977	The reversible red shift induced by moisture was approximately 100 nm.
36773875	9	16	from	rewritable	1337:1346	arg1	addition					1282:1289	addition	1282:1289	addition	1282:1289	In addition, the invisible pattern of photonic coating is rewritable.
36773875	2	17	theme	potential	305:313	arg1	composites					324:333	potential photonic composites	305:333	potential photonic composites with a chiral nematic structure	305:365	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	5	18	theme	helical	894:900	arg1	pitch					902:906	the helical pitch	890:906	the helical pitch	890:906	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	1	19	with	materials	129:137	arg1	structure					169:177	a tunable chiral nematic structure	144:177	a tunable chiral nematic structure that can selectively reflect light dynamically	144:224	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	9	20	theme	photonic	1317:1324	arg1	coating					1326:1332	photonic coating	1317:1332	photonic coating	1317:1332	In addition, the invisible pattern of photonic coating is rewritable.
36773875	10	21	theme	decorative	1482:1491	arg1	coatings					1493:1500	smart decorative coatings	1476:1500	smart decorative coatings	1476:1500	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	2	22	theme	nematic	349:355	arg1	structure					357:365	a chiral nematic structure	340:365	a chiral nematic structure	340:365	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	6	23	theme	red	924:926	arg1	shift					928:932	The reversible red shift	909:932	The reversible red shift induced by moisture	909:952	The reversible red shift induced by moisture was approximately 100 nm.
36773875	6	23	theme	red	924:926	arg1	100 nm					972:977	100 nm	972:977	100 nm	972:977	The reversible red shift induced by moisture was approximately 100 nm.
36773875	2	24	theme	polyurethane	423:434	arg1	composites					442:451	waterborne polyurethane (WPU) composites	412:451	waterborne polyurethane (WPU) composites	412:451	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	2	25	theme	different	484:492	arg1	substrates					494:503	different substrates	484:503	different substrates	484:503	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	9	26	theme	coating	1326:1332	arg1	rewritable					1337:1346	rewritable	1337:1346	rewritable	1337:1346	In addition, the invisible pattern of photonic coating is rewritable.
36773875	9	26	theme	coating	1326:1332	arg1	pattern					1306:1312	the invisible pattern	1292:1312	the invisible pattern of photonic coating	1292:1332	In addition, the invisible pattern of photonic coating is rewritable.
36773875	10	27	theme	smart	1476:1480	arg1	coatings					1493:1500	smart decorative coatings	1476:1500	smart decorative coatings	1476:1500	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	1	28	theme	Photonic	120:127	arg1	materials					129:137	Photonic materials	120:137	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically	120:224	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	2	29	theme	waterborne	412:421	arg1	WPU					437:439	WPU	437:439	WPU	437:439	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	2	29	theme	waterborne	412:421	arg1	polyurethane					423:434	waterborne polyurethane	412:434	waterborne polyurethane (WPU) composites	412:451	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	0	30	theme	optical	43:49	arg1	materials					51:59	bio-composite optical materials	29:59	bio-composite optical materials for reversible colorimetric responsive films and coatings	29:117	Cellulose nanocrystals-based bio-composite optical materials for reversible colorimetric responsive films and coatings.
36773875	5	31	theme	swollen	842:848	arg1	WPU					850:852	the swollen WPU	838:852	the swollen WPU	838:852	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	7	32	theme	adhesion	1089:1096	arg1	strong					1150:1155	strong	1150:1155	strong	1150:1155	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	7	32	theme	adhesion	1089:1096	arg1	forces					1098:1103	the adhesion forces	1085:1103	the adhesion forces of the composites to the wood substrate	1085:1143	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	4	33	theme	higher	751:756	arg1	content					762:768	higher WPU content	751:768	higher WPU content	751:768	In addition, the mechanical properties were better for higher WPU content.
36773875	2	34	theme	chiral	342:347	arg1	structure					357:365	a chiral nematic structure	340:365	a chiral nematic structure	340:365	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	2	35	theme	different	458:466	arg1	compositions					468:479	different compositions	458:479	different compositions on different substrates	458:503	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	0	36	theme	bio-composite	29:41	arg1	materials					51:59	bio-composite optical materials	29:59	bio-composite optical materials for reversible colorimetric responsive films and coatings	29:117	Cellulose nanocrystals-based bio-composite optical materials for reversible colorimetric responsive films and coatings.
36773875	5	37	from	sensitive	779:787	arg1	ethanol					821:827	ethanol	821:827	ethanol owing to the swollen WPU	821:852	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	3	38	dep	680 nm	619:624	arg1	to					616:617	to	616:617	to	616:617	With increasing WPU content, the reflected wavelength increased from 400 to 680 nm, which was mainly caused by the increase of the chiral nematic pitch.
36773875	2	39	theme	cellulose	378:386	arg1	CNCs					402:405	CNCs	402:405	CNCs	402:405	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	2	39	theme	cellulose	378:386	arg1	nanocrystals					388:399	cellulose nanocrystals	378:399	cellulose nanocrystals (CNCs)	378:406	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	3	40	theme	nematic	681:687	arg1	pitch					689:693	the chiral nematic pitch	670:693	the chiral nematic pitch	670:693	With increasing WPU content, the reflected wavelength increased from 400 to 680 nm, which was mainly caused by the increase of the chiral nematic pitch.
36773875	8	41	theme	invisible	1201:1209	arg1	patterns					1211:1218	invisible patterns	1201:1218	invisible patterns	1201:1218	By using MgCl2 solution as an ink to write invisible patterns on the coating which can be revealed temporary by ethanol.
36773875	1	42	from	applications	243:254	arg1	materials					276:284	smart responsive materials	259:284	smart responsive materials	259:284	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	2	43	theme	evaporation-induced	508:526	arg1	self-assembly					528:540	evaporation-induced self-assembly	508:540	evaporation-induced self-assembly	508:540	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36773875	7	44	theme	nematic	1062:1068	arg1	structures					1070:1079	chiral nematic structures	1055:1079	chiral nematic structures	1055:1079	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	0	45	theme	responsive	89:98	arg1	films					100:104	reversible colorimetric responsive films	65:104	reversible colorimetric responsive films	65:104	Cellulose nanocrystals-based bio-composite optical materials for reversible colorimetric responsive films and coatings.
36773875	3	46	theme	WPU	559:561	arg1	content					563:569	WPU content	559:569	WPU content	559:569	With increasing WPU content, the reflected wavelength increased from 400 to 680 nm, which was mainly caused by the increase of the chiral nematic pitch.
36773875	0	47	theme	reversible	65:74	arg1	films					100:104	reversible colorimetric responsive films	65:104	reversible colorimetric responsive films	65:104	Cellulose nanocrystals-based bio-composite optical materials for reversible colorimetric responsive films and coatings.
36773875	1	48	theme	tunable	146:152	arg1	structure					169:177	a tunable chiral nematic structure	144:177	a tunable chiral nematic structure that can selectively reflect light dynamically	144:224	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	10	49	theme	great	1417:1421	arg1	potential					1423:1431	great potential	1417:1431	great potential	1417:1431	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	1	50	theme	chiral	154:159	arg1	structure					169:177	a tunable chiral nematic structure	144:177	a tunable chiral nematic structure that can selectively reflect light dynamically	144:224	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	4	51	from	content	762:768	arg1	addition					699:706	addition	699:706	addition	699:706	In addition, the mechanical properties were better for higher WPU content.
36773875	1	52	theme	smart	259:263	arg1	materials					276:284	smart responsive materials	259:284	smart responsive materials	259:284	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	7	53	theme	chiral	1055:1060	arg1	structures					1070:1079	chiral nematic structures	1055:1079	chiral nematic structures	1055:1079	When wood was used as the substrate, the CNCs still self-assembled to form chiral nematic structures and the adhesion forces of the composites to the wood substrate were strong.
36773875	3	54	theme	chiral	674:679	arg1	pitch					689:693	the chiral nematic pitch	670:693	the chiral nematic pitch	670:693	With increasing WPU content, the reflected wavelength increased from 400 to 680 nm, which was mainly caused by the increase of the chiral nematic pitch.
36773875	10	55	theme	environmentally	1369:1383	arg1	composite					1403:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	1	56	theme	nematic	161:167	arg1	structure					169:177	a tunable chiral nematic structure	144:177	a tunable chiral nematic structure that can selectively reflect light dynamically	144:224	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	1	57	theme	responsive	265:274	arg1	materials					276:284	smart responsive materials	259:284	smart responsive materials	259:284	Photonic materials with a tunable chiral nematic structure that can selectively reflect light dynamically are valuable for applications in smart responsive materials.
36773875	5	58	theme	small	792:796	arg1	amounts					798:804	small amounts	792:804	small amounts of moisture	792:816	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	5	58	theme	small	792:796	arg1	moisture					809:816	moisture	809:816	moisture	809:816	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	5	59	dep	absorbing	860:868	arg1	increase					881:888	increase	881:888	absorbing water will increase the helical pitch	860:906	WPU was sensitive to small amounts of moisture in ethanol owing to the swollen WPU after absorbing water will increase the helical pitch.
36773875	10	60	theme	prepared	1360:1367	arg1	composite					1403:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	3	61	theme	reflected	576:584	arg1	wavelength					586:595	the reflected wavelength	572:595	the reflected wavelength	572:595	With increasing WPU content, the reflected wavelength increased from 400 to 680 nm, which was mainly caused by the increase of the chiral nematic pitch.
36773875	0	62	theme	colorimetric	76:87	arg1	films					100:104	reversible colorimetric responsive films	65:104	reversible colorimetric responsive films	65:104	Cellulose nanocrystals-based bio-composite optical materials for reversible colorimetric responsive films and coatings.
36773875	10	63	contain	has	1413:1415	arg1	composite					1403:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite	1349:1411	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	10	63	contain	has	1413:1415	arg2	potential					1423:1431	great potential	1417:1431	great potential	1417:1431	The easily prepared environmentally friendly photonic composite has great potential in sensors, anti-counterfeiting labels and smart decorative coatings.
36773875	2	64	with	composites	324:333	arg1	structure					357:365	a chiral nematic structure	340:365	a chiral nematic structure	340:365	Here, we prepared potential photonic composites with a chiral nematic structure by forming cellulose nanocrystals (CNCs) and waterborne polyurethane (WPU) composites with different compositions on different substrates by evaporation-induced self-assembly.
36677794	0	0	theme	Potential	78:86	arg1	Applications					99:110	Potential Biomedical Applications	78:110	Potential Biomedical Applications	78:110	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	2	1	contain	have	351:354	arg2	properties					405:414	specific properties	396:414	specific properties	396:414	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	2	1	contain	have	351:354	arg1	they					346:349	they	346:349	they	346:349	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	2	1	contain	have	351:354	arg2	variations					381:390	structural variations	370:390	structural variations	370:390	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	5	2	theme	unique	822:827	arg1	behavior					845:852	a unique cell clustering behavior	820:852	the control hydrogel as well as a unique cell clustering behavior	788:852	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	5	3	theme	spherical	888:896	arg1	clusters					898:905	multicellular spherical clusters	874:905	multicellular spherical clusters (40-60 μm)	874:916	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	5	3	theme	spherical	888:896	arg1	μm					914:915	40-60 μm	908:915	40-60 μm	908:915	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	1	4	theme	cyanobacteria	152:164	arg1	cyanobacteria					152:164	the most studied cyanobacteria	135:164	the most studied cyanobacteria	135:164	Arthrospira is one of the most studied cyanobacteria and has been reported with practical applications.
36677794	1	4	theme	cyanobacteria	152:164	arg1	one					128:130	one	128:130	one	128:130	Arthrospira is one of the most studied cyanobacteria and has been reported with practical applications.
36677794	2	5	attach	derived	238:244	arg1	Arthrospira					251:261	Arthrospira	251:261	Arthrospira	251:261	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	2	5	attach	derived	238:244	arg2	substances					227:236	the substances	223:236	the substances derived from Arthrospira	223:261	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	5	6	theme	cell	829:832	arg1	behavior					845:852	a unique cell clustering behavior	820:852	the control hydrogel as well as a unique cell clustering behavior	788:852	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	6	7	theme	appropriate	954:964	arg1	range					966:970	an appropriate range	951:970	an appropriate range of concentration (5 mg/mL)	951:997	The sulfated polysaccharide, in an appropriate range of concentration (5 mg/mL), also maintained the stemness of NSCs in hydrogel and facilitated their differentiation.
36677794	7	8	theme	coating	1156:1162	arg1	material					1164:1171	a coating material	1154:1171	a coating material	1154:1171	In addition, the potentials of the new sulfated polysaccharide as a coating material and as a component for drug carrier were verified.
36677794	2	9	theme	structural	370:379	arg1	variations					381:390	structural variations	370:390	structural variations	370:390	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	0	10	theme	Applications	99:110	arg1	Extract					51:57	the Polysaccharide Extract	32:57	the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications	32:110	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	4	11	theme	polysaccharide	556:569	arg1	ability					531:537	The ability	527:537	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel	527:651	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	7	12	theme	polysaccharide	1136:1149	arg1	potentials					1105:1114	the potentials	1101:1114	the potentials of the new sulfated polysaccharide as a coating material and as a component for drug carrier	1101:1207	In addition, the potentials of the new sulfated polysaccharide as a coating material and as a component for drug carrier were verified.
36677794	4	13	theme	three-dimensional	626:642	arg1	hydrogel					644:651	three-dimensional hydrogel	626:651	three-dimensional hydrogel	626:651	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	0	14	theme	Biomedical	88:97	arg1	Applications					99:110	Potential Biomedical Applications	78:110	Potential Biomedical Applications	78:110	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	5	15	dep	formation	861:869	arg1	i.e.					855:858	i.e.	855:858	i.e.	855:858	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	2	16	theme	less	305:308	arg1	attention					310:318	relatively less attention	294:318	relatively less attention	294:318	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	9	17	theme	estimated	1530:1538	arg1	loading					1545:1551	estimated drug loading	1530:1551	estimated drug loading of ~18%	1530:1559	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	10	18	theme	cell	1643:1646	arg1	culture					1648:1654	cell culture	1643:1654	cell culture	1643:1654	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	6	19	from	stemness	1020:1027	arg1	hydrogel					1040:1047	hydrogel	1040:1047	hydrogel	1040:1047	The sulfated polysaccharide, in an appropriate range of concentration (5 mg/mL), also maintained the stemness of NSCs in hydrogel and facilitated their differentiation.
36677794	9	20	theme	drug	1540:1543	arg1	loading					1545:1551	estimated drug loading	1530:1551	estimated drug loading of ~18%	1530:1559	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	9	21	theme	nm	1523:1524	arg1	loading					1545:1551	estimated drug loading	1530:1551	estimated drug loading of ~18%	1530:1559	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	9	21	theme	nm	1523:1524	arg1	diameter					1506:1513	an average diameter	1495:1513	an average diameter of ~240 nm	1495:1524	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	0	22	theme	Polysaccharide	36:49	arg1	Extract					51:57	the Polysaccharide Extract	32:57	the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications	32:110	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	9	23	theme	Composite	1366:1374	arg1	nanoparticles					1376:1388	Composite nanoparticles	1366:1388	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides	1366:1474	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	5	24	theme	clustering	834:843	arg1	behavior					845:852	a unique cell clustering behavior	820:852	the control hydrogel as well as a unique cell clustering behavior	788:852	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	9	25	theme	%	1559:1559	arg1	loading					1545:1551	estimated drug loading	1530:1551	estimated drug loading of ~18%	1530:1559	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	9	25	theme	%	1559:1559	arg1	diameter					1506:1513	an average diameter	1495:1513	an average diameter of ~240 nm	1495:1524	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	7	26	theme	drug	1196:1199	arg1	carrier					1201:1207	drug carrier	1196:1207	drug carrier	1196:1207	In addition, the potentials of the new sulfated polysaccharide as a coating material and as a component for drug carrier were verified.
36677794	6	27	theme	sulfated	923:930	arg1	polysaccharide					932:945	The sulfated polysaccharide	919:945	The sulfated polysaccharide	919:945	The sulfated polysaccharide, in an appropriate range of concentration (5 mg/mL), also maintained the stemness of NSCs in hydrogel and facilitated their differentiation.
36677794	10	28	theme	sulfated	1590:1597	arg1	candidate					1629:1637	a promising candidate	1617:1637	a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field	1617:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	10	28	theme	sulfated	1590:1597	arg1	polysaccharide					1599:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	8	29	theme	angle	1310:1314	arg1	superhydrophilicity					1281:1299	superhydrophilicity	1281:1299	superhydrophilicity (contact angle ~9°)	1281:1319	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	8	29	theme	angle	1310:1314	arg1	~9°					1316:1318	contact angle ~9°	1302:1318	contact angle ~9°	1302:1318	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	4	30	theme	stem	605:608	arg1	NSCs					617:620	NSCs	617:620	NSCs	617:620	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	4	30	theme	stem	605:608	arg1	cells					610:614	neural stem cells	598:614	neural stem cells (NSCs)	598:621	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	7	31	theme	new	1123:1125	arg1	polysaccharide					1136:1149	the new sulfated polysaccharide	1119:1149	the new sulfated polysaccharide as a coating material and as a component for drug carrier	1119:1207	In addition, the potentials of the new sulfated polysaccharide as a coating material and as a component for drug carrier were verified.
36677794	6	32	theme	NSCs	1032:1035	arg1	stemness					1020:1027	the stemness	1016:1027	the stemness of NSCs in hydrogel	1016:1047	The sulfated polysaccharide, in an appropriate range of concentration (5 mg/mL), also maintained the stemness of NSCs in hydrogel and facilitated their differentiation.
36677794	8	33	theme	contact	1302:1308	arg1	superhydrophilicity					1281:1299	superhydrophilicity	1281:1299	superhydrophilicity (contact angle ~9°)	1281:1319	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	8	33	theme	contact	1302:1308	arg1	~9°					1316:1318	contact angle ~9°	1302:1318	contact angle ~9°	1302:1318	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	0	34	theme	Behavior	20:27	arg1	Enhancement					0:10	Enhancement	0:10	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.	0:111	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	4	35	theme	neural	598:603	arg1	NSCs					617:620	NSCs	617:620	NSCs	617:620	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	4	35	theme	neural	598:603	arg1	cells					610:614	neural stem cells	598:614	neural stem cells (NSCs)	598:621	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	5	36	theme	better	762:767	arg1	proliferation					769:781	better proliferation	762:781	better proliferation	762:781	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	8	37	theme	polysaccharide-modified	1237:1259	arg1	substrate					1261:1269	The sulfated polysaccharide-modified substrate	1224:1269	The sulfated polysaccharide-modified substrate	1224:1269	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	3	38	theme	bioactive	506:514	arg1	functions					516:524	its potential bioactive functions	492:524	its potential bioactive functions	492:524	Herein, a new Arthrospira-derived sulfated polysaccharide was explored for its potential bioactive functions.
36677794	0	39	theme	Cell	15:18	arg1	Behavior					20:27	Cell Behavior	15:27	Cell Behavior	15:27	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	5	40	theme	clusters	898:905	arg1	formation					861:869	formation	861:869	formation of multicellular spherical clusters (40-60 μm)	861:916	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	3	41	theme	Arthrospira-derived	431:449	arg1	polysaccharide					460:473	a new Arthrospira-derived sulfated polysaccharide	425:473	a new Arthrospira-derived sulfated polysaccharide	425:473	Herein, a new Arthrospira-derived sulfated polysaccharide was explored for its potential bioactive functions.
36677794	4	42	theme	cells	610:614	arg1	behavior					586:593	the behavior	582:593	the behavior of neural stem cells (NSCs) in three-dimensional hydrogel	582:651	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	3	43	theme	sulfated	451:458	arg1	polysaccharide					460:473	a new Arthrospira-derived sulfated polysaccharide	425:473	a new Arthrospira-derived sulfated polysaccharide	425:473	Herein, a new Arthrospira-derived sulfated polysaccharide was explored for its potential bioactive functions.
36677794	4	44	from	behavior	586:593	arg1	hydrogel					644:651	three-dimensional hydrogel	626:651	three-dimensional hydrogel	626:651	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	10	45	from	candidate	1629:1637	arg1	field					1728:1732	the biomedical field	1713:1732	the biomedical field	1713:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	3	46	theme	potential	496:504	arg1	functions					516:524	its potential bioactive functions	492:524	its potential bioactive functions	492:524	Herein, a new Arthrospira-derived sulfated polysaccharide was explored for its potential bioactive functions.
36677794	10	47	theme	Arthrospira-derived	1570:1588	arg1	candidate					1629:1637	a promising candidate	1617:1637	a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field	1617:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	10	47	theme	Arthrospira-derived	1570:1588	arg1	polysaccharide					1599:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	5	48	theme	control	792:798	arg1	hydrogel					800:807	the control hydrogel	788:807	the control hydrogel as well as a unique cell clustering behavior	788:852	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	5	49	theme	sulfated	711:718	arg1	hydrogel					746:753	the sulfated polysaccharide-containing hydrogel	707:753	the sulfated polysaccharide-containing hydrogel	707:753	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	10	50	theme	promising	1619:1627	arg1	candidate					1629:1637	a promising candidate	1617:1637	a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field	1617:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	10	50	theme	promising	1619:1627	arg1	polysaccharide					1599:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	3	51	link	Arthrospira-derived	431:449	arg1	polysaccharide					460:473	a new Arthrospira-derived sulfated polysaccharide	425:473	a new Arthrospira-derived sulfated polysaccharide	425:473	Herein, a new Arthrospira-derived sulfated polysaccharide was explored for its potential bioactive functions.
36677794	10	52	theme	drug-delivery	1683:1695	arg1	applications					1697:1708	drug-delivery applications	1683:1708	drug-delivery applications	1683:1708	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	2	53	theme	abundant	361:368	arg1	variations					381:390	structural variations	370:390	structural variations	370:390	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	3	54	theme	new	427:429	arg1	polysaccharide					460:473	a new Arthrospira-derived sulfated polysaccharide	425:473	a new Arthrospira-derived sulfated polysaccharide	425:473	Herein, a new Arthrospira-derived sulfated polysaccharide was explored for its potential bioactive functions.
36677794	9	55	theme	other	1434:1438	arg1	polysaccharides					1460:1474	other differently charged polysaccharides	1434:1474	other differently charged polysaccharides	1434:1474	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	5	56	theme	polysaccharide-containing	720:744	arg1	hydrogel					746:753	the sulfated polysaccharide-containing hydrogel	707:753	the sulfated polysaccharide-containing hydrogel	707:753	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	7	57	theme	sulfated	1127:1134	arg1	polysaccharide					1136:1149	the new sulfated polysaccharide	1119:1149	the new sulfated polysaccharide as a coating material and as a component for drug carrier	1119:1207	In addition, the potentials of the new sulfated polysaccharide as a coating material and as a component for drug carrier were verified.
36677794	8	58	theme	cell	1334:1337	arg1	adhesion					1339:1346	cell adhesion	1334:1346	cell adhesion to the substrate	1334:1363	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	6	59	theme	concentration	975:987	arg1	range					966:970	an appropriate range	951:970	an appropriate range of concentration (5 mg/mL)	951:997	The sulfated polysaccharide, in an appropriate range of concentration (5 mg/mL), also maintained the stemness of NSCs in hydrogel and facilitated their differentiation.
36677794	10	60	theme	biomedical	1717:1726	arg1	field					1728:1732	the biomedical field	1713:1732	the biomedical field	1713:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	9	61	theme	sulfated	1406:1413	arg1	polysaccharide					1415:1428	the sulfated polysaccharide	1402:1428	the sulfated polysaccharide	1402:1428	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	9	62	theme	charged	1452:1458	arg1	polysaccharides					1460:1474	other differently charged polysaccharides	1434:1474	other differently charged polysaccharides	1434:1474	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	10	63	theme	new	1566:1568	arg1	candidate					1629:1637	a promising candidate	1617:1637	a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field	1617:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	10	63	theme	new	1566:1568	arg1	polysaccharide					1599:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	5	64	theme	multicellular	874:886	arg1	clusters					898:905	multicellular spherical clusters	874:905	multicellular spherical clusters (40-60 μm)	874:916	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	5	64	theme	multicellular	874:886	arg1	μm					914:915	40-60 μm	908:915	40-60 μm	908:915	NSCs encapsulated in the sulfated polysaccharide-containing hydrogel showed better proliferation than the control hydrogel as well as a unique cell clustering behavior, i.e., formation of multicellular spherical clusters (40-60 μm).
36677794	6	65	from	polysaccharide	932:945	arg1	range					966:970	an appropriate range	951:970	an appropriate range of concentration (5 mg/mL)	951:997	The sulfated polysaccharide, in an appropriate range of concentration (5 mg/mL), also maintained the stemness of NSCs in hydrogel and facilitated their differentiation.
36677794	8	66	theme	sulfated	1228:1235	arg1	substrate					1261:1269	The sulfated polysaccharide-modified substrate	1224:1269	The sulfated polysaccharide-modified substrate	1224:1269	The sulfated polysaccharide-modified substrate exhibited superhydrophilicity (contact angle ~9°) and promoted cell adhesion to the substrate.
36677794	0	67	theme	Arthrospira	62:72	arg1	Extract					51:57	the Polysaccharide Extract	32:57	the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications	32:110	Enhancement of Cell Behavior by the Polysaccharide Extract of Arthrospira and Potential Biomedical Applications.
36677794	1	68	theme	practical	193:201	arg1	applications					203:214	practical applications	193:214	practical applications	193:214	Arthrospira is one of the most studied cyanobacteria and has been reported with practical applications.
36677794	2	69	theme	specific	396:403	arg1	properties					405:414	specific properties	396:414	specific properties	396:414	Among the substances derived from Arthrospira, polysaccharides have received relatively less attention than phycocyanins, though they have more abundant structural variations and specific properties.
36677794	10	70	link	Arthrospira-derived	1570:1588	arg1	candidate					1629:1637	a promising candidate	1617:1637	a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field	1617:1732	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	10	70	link	Arthrospira-derived	1570:1588	arg1	polysaccharide					1599:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide	1562:1612	The new Arthrospira-derived sulfated polysaccharide is a promising candidate for cell culture, surface-modification, and drug-delivery applications in the biomedical field.
36677794	9	71	theme	average	1498:1504	arg1	diameter					1506:1513	an average diameter	1495:1513	an average diameter of ~240 nm	1495:1524	Composite nanoparticles composed of the sulfated polysaccharide and other differently charged polysaccharides were produced with an average diameter of ~240 nm and estimated drug loading of ~18%.
36677794	4	72	theme	sulfated	547:554	arg1	polysaccharide					556:569	this sulfated polysaccharide	542:569	this sulfated polysaccharide	542:569	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	4	73	theme	first	674:678	arg1	time					680:683	the first time	670:683	the first time	670:683	The ability of this sulfated polysaccharide to promote the behavior of neural stem cells (NSCs) in three-dimensional hydrogel was examined for the first time.
36677794	1	74	theme	studied	144:150	arg1	cyanobacteria					152:164	the most studied cyanobacteria	135:164	the most studied cyanobacteria	135:164	Arthrospira is one of the most studied cyanobacteria and has been reported with practical applications.
36677759	0	0	theme	Molecular	84:92	arg1	Weights					94:100	Three Different Molecular Weights	68:100	Three Different Molecular Weights of Lycium barbarum Polysaccharides	68:135	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	6	1	theme	NMR	989:991	arg1	spectra					993:999	NMR spectra	989:999	NMR spectra	989:999	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	9	2	theme	T-lymphocytes	1342:1354	arg1	growth					1332:1337	the growth	1328:1337	the growth of T-lymphocytes and macrophages	1328:1370	In zebrafish, LBPs-2 and LBPs-3 boosted the growth of T-lymphocytes and macrophages, enhanced the immunological response, and mitigated the immune damage generated by VTI.
36677759	8	3	theme	higher	1132:1137	arg1	ORAC					1175:1178	ORAC	1175:1178	ORAC	1175:1178	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	8	3	theme	higher	1132:1137	arg1	capacity					1165:1172	higher oxygen radical absorbance capacity	1132:1172	higher oxygen radical absorbance capacity (ORAC)	1132:1179	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	0	4	theme	Different	74:82	arg1	Weights					94:100	Three Different Molecular Weights	68:100	Three Different Molecular Weights of Lycium barbarum Polysaccharides	68:135	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	0	5	from	Study	12:16	arg1	Properties					36:45	Properties	36:45	Properties	36:45	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	0	5	from	Study	12:16	arg1	Bioactivities					51:63	Bioactivities	51:63	Bioactivities	51:63	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	1	6	theme	triple-helix	164:175	arg1	conformation					177:188	the triple-helix conformation	160:188	the triple-helix conformation	160:188	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	10	7	theme	chemical	1645:1652	arg1	composition					1654:1664	the chemical composition	1641:1664	the chemical composition	1641:1664	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	8	8	theme	oxygen	1139:1144	arg1	ORAC					1175:1178	ORAC	1175:1178	ORAC	1175:1178	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	8	8	theme	oxygen	1139:1144	arg1	capacity					1165:1172	higher oxygen radical absorbance capacity	1132:1172	higher oxygen radical absorbance capacity (ORAC)	1132:1179	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	1	9	theme	polysaccharide	262:275	arg1	conjugates					277:286	the polysaccharide conjugates	258:286	the polysaccharide conjugates of polysaccharides	258:305	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	0	10	theme	Weights	94:100	arg1	Properties					36:45	Properties	36:45	Properties	36:45	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	0	10	theme	Weights	94:100	arg1	Bioactivities					51:63	Bioactivities	51:63	Bioactivities	51:63	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	10	11	theme	chemical	1675:1682	arg1	mechanism					1693:1701	the chemical reaction mechanism	1671:1701	the chemical reaction mechanism	1671:1701	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	8	12	theme	lower	1240:1244	arg1	capability					1246:1255	a lower capability	1238:1255	a lower capability for scavenging ABTS+ radicals	1238:1285	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	9	13	theme	immunological	1386:1398	arg1	response					1400:1407	the immunological response	1382:1407	the immunological response	1382:1407	In zebrafish, LBPs-2 and LBPs-3 boosted the growth of T-lymphocytes and macrophages, enhanced the immunological response, and mitigated the immune damage generated by VTI.
36677759	0	14	theme	barbarum	112:119	arg1	Polysaccharides					121:135	Lycium barbarum Polysaccharides	105:135	Lycium barbarum Polysaccharides	105:135	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	7	15	theme	antioxidant	1064:1074	arg1	capacities					1076:1085	much higher antioxidant capacities	1052:1085	much higher antioxidant capacities	1052:1085	The polysaccharides (LBPs-2 and LBPs-3) exhibited much higher antioxidant capacities than oligosaccharide (LBPs-1).
36677759	3	16	dep	kDa	630:632	arg1	LBPs-3					635:640	LBPs-3	635:640	LBPs-3	635:640	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	5	17	theme	red	905:907	arg1	experiment					909:918	the Congo red experiment	895:918	the Congo red experiment	895:918	LBPs-2 and LBPs-3 exhibited triple-helix conformations, as evidenced by the Congo red experiment and AFM data.
36677759	3	18	dep	polysaccharides	599:613	arg1	LBPs-2					616:621	LBPs-2	616:621	LBPs-2	616:621	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	0	19	theme	Lycium	105:110	arg1	Polysaccharides					121:135	Lycium barbarum Polysaccharides	105:135	Lycium barbarum Polysaccharides	105:135	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	10	20	theme	aspects	1586:1592	arg1	activities					1539:1548	the biological activities	1524:1548	the biological activities	1524:1548	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	10	20	theme	aspects	1586:1592	arg1	consequence					1563:1573	the consequence	1559:1573	the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism	1559:1701	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	4	21	theme	main	755:758	arg1	arabinose					788:796	arabinose	788:796	arabinose	788:796	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	4	21	theme	main	755:758	arg1	constituents					760:771	the main constituents	751:771	the main constituents of LBPs-3	751:781	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	8	22	theme	absorbance	1154:1163	arg1	ORAC					1175:1178	ORAC	1175:1178	ORAC	1175:1178	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	8	22	theme	absorbance	1154:1163	arg1	capacity					1165:1172	higher oxygen radical absorbance capacity	1132:1172	higher oxygen radical absorbance capacity (ORAC)	1132:1179	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	8	23	theme	scavenging	1261:1270	arg1	radicals					1278:1285	scavenging ABTS+ radicals	1261:1285	scavenging ABTS+ radicals	1261:1285	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	6	24	theme	Sugar	934:938	arg1	residues					940:947	Sugar residues	934:947	Sugar residues of LBPs-2 and LBPs-3	934:968	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	6	24	theme	Sugar	934:938	arg1	LBPs-3					963:968	LBPs-3	963:968	LBPs-3	963:968	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	6	24	theme	Sugar	934:938	arg1	LBPs-2					952:957	LBPs-2	952:957	LBPs-2	952:957	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	4	25	theme	LBPs-2	731:736	arg1	component					707:715	the major component	697:715	the major component of LBPs-1 and LBPs-2	697:736	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	4	25	theme	LBPs-2	731:736	arg1	glucose					742:748	glucose	742:748	glucose	742:748	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	3	26	dep	LBPs-2	616:621	arg1	kDa					650:652	46.239 kDa	643:652	46.239 kDa	643:652	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	3	26	dep	LBPs-2	616:621	arg1	kDa					630:632	7.481 kDa	624:632	7.481 kDa	624:632	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	0	27	theme	Comparative	0:10	arg1	Study					12:16	Comparative Study	0:16	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.	0:136	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	6	28	theme	LBPs-2	952:957	arg1	residues					940:947	Sugar residues	934:947	Sugar residues of LBPs-2 and LBPs-3	934:968	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	6	28	theme	LBPs-2	952:957	arg1	LBPs-3					963:968	LBPs-3	963:968	LBPs-3	963:968	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	6	28	theme	LBPs-2	952:957	arg1	LBPs-2					952:957	LBPs-2	952:957	LBPs-2	952:957	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	7	29	theme	higher	1057:1062	arg1	capacities					1076:1085	much higher antioxidant capacities	1052:1085	much higher antioxidant capacities	1052:1085	The polysaccharides (LBPs-2 and LBPs-3) exhibited much higher antioxidant capacities than oligosaccharide (LBPs-1).
36677759	5	30	theme	AFM	924:926	arg1	data					928:931	AFM data	924:931	AFM data	924:931	LBPs-2 and LBPs-3 exhibited triple-helix conformations, as evidenced by the Congo red experiment and AFM data.
36677759	1	31	theme	monosaccharide	195:208	arg1	content					210:216	the monosaccharide content	191:216	the monosaccharide content	191:216	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	2	32	theme	polysaccharides	454:468	arg1	bioactivity					419:429	the bioactivity	415:429	the bioactivity of the Lycium barbarum polysaccharides (LBPs)	415:475	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	1	33	theme	polysaccharides	291:305	arg1	conformation					177:188	the triple-helix conformation	160:188	the triple-helix conformation	160:188	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	33	theme	polysaccharides	291:305	arg1	conjugates					277:286	the polysaccharide conjugates	258:286	the polysaccharide conjugates of polysaccharides	258:305	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	33	theme	polysaccharides	291:305	arg1	content					210:216	the monosaccharide content	191:216	the monosaccharide content	191:216	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	33	theme	polysaccharides	291:305	arg1	weight					152:157	The molecular weight	138:157	The molecular weight	138:157	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	33	theme	polysaccharides	291:305	arg1	manner					223:228	the manner	219:228	the manner of glycosidic linkages	219:251	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	7	34	dep	polysaccharides	1006:1020	arg1	LBPs-3					1034:1039	LBPs-3	1034:1039	LBPs-3	1034:1039	The polysaccharides (LBPs-2 and LBPs-3) exhibited much higher antioxidant capacities than oligosaccharide (LBPs-1).
36677759	7	34	dep	polysaccharides	1006:1020	arg1	LBPs-2					1023:1028	LBPs-2	1023:1028	LBPs-2	1023:1028	The polysaccharides (LBPs-2 and LBPs-3) exhibited much higher antioxidant capacities than oligosaccharide (LBPs-1).
36677759	7	34	dep	polysaccharides	1006:1020	arg1	polysaccharides					1006:1020	The polysaccharides	1002:1020	The polysaccharides (LBPs-2 and LBPs-3)	1002:1040	The polysaccharides (LBPs-2 and LBPs-3) exhibited much higher antioxidant capacities than oligosaccharide (LBPs-1).
36677759	2	35	theme	Lycium	438:443	arg1	LBPs					471:474	LBPs	471:474	LBPs	471:474	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	2	35	theme	Lycium	438:443	arg1	polysaccharides					454:468	the Lycium barbarum polysaccharides	434:468	the Lycium barbarum polysaccharides (LBPs)	434:475	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	2	36	theme	barbarum	445:452	arg1	LBPs					471:474	LBPs	471:474	LBPs	471:474	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	2	36	theme	barbarum	445:452	arg1	polysaccharides					454:468	the Lycium barbarum polysaccharides	434:468	the Lycium barbarum polysaccharides (LBPs)	434:475	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	0	37	theme	Polysaccharides	121:135	arg1	Weights					94:100	Three Different Molecular Weights	68:100	Three Different Molecular Weights of Lycium barbarum Polysaccharides	68:135	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	3	38	dep	oligosaccharide	555:569	arg1	LBPs-1					572:577	LBPs-1	572:577	LBPs-1	572:577	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	3	38	dep	oligosaccharide	555:569	arg1	kDa					586:588	1.912 kDa	580:588	1.912 kDa	580:588	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	3	39	theme	ethanol-graded	481:494	arg1	precipitation					496:508	ethanol-graded precipitation	481:508	ethanol-graded precipitation	481:508	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	8	40	theme	superoxide	1185:1194	arg1	SOD					1207:1209	SOD	1207:1209	SOD	1207:1209	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	8	40	theme	superoxide	1185:1194	arg1	dismutase					1196:1204	superoxide dismutase	1185:1204	superoxide dismutase (SOD) activity than LBPs-2	1185:1231	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	3	41	theme	membrane	530:537	arg1	separation					539:548	ultrafiltration membrane separation	514:548	ultrafiltration membrane separation	514:548	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	10	42	dep	composition	1622:1632	arg1	ratio					1634:1638	ratio	1634:1638	ratio	1634:1638	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	2	43	theme	molecular	388:396	arg1	weights					398:404	different molecular weights	378:404	different molecular weights	378:404	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	0	44	theme	Structural	25:34	arg1	Properties					36:45	Properties	36:45	Properties	36:45	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	5	45	theme	triple-helix	851:862	arg1	conformations					864:876	triple-helix conformations	851:876	triple-helix conformations	851:876	LBPs-2 and LBPs-3 exhibited triple-helix conformations, as evidenced by the Congo red experiment and AFM data.
36677759	5	46	theme	Congo	899:903	arg1	experiment					909:918	the Congo red experiment	895:918	the Congo red experiment	895:918	LBPs-2 and LBPs-3 exhibited triple-helix conformations, as evidenced by the Congo red experiment and AFM data.
36677759	8	47	theme	radical	1146:1152	arg1	ORAC					1175:1178	ORAC	1175:1178	ORAC	1175:1178	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	8	47	theme	radical	1146:1152	arg1	capacity					1165:1172	higher oxygen radical absorbance capacity	1132:1172	higher oxygen radical absorbance capacity (ORAC)	1132:1179	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	10	48	theme	biological	1528:1537	arg1	activities					1539:1548	the biological activities	1524:1548	the biological activities	1524:1548	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	10	48	theme	biological	1528:1537	arg1	consequence					1563:1573	the consequence	1559:1573	the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism	1559:1701	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	10	49	theme	molecular	1479:1487	arg1	weight					1489:1494	the molecular weight	1475:1494	the molecular weight	1475:1494	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	0	50	dep	Properties	36:45	arg1	the					21:23	the	21:23	the	21:23	Comparative Study on the Structural Properties and Bioactivities of Three Different Molecular Weights of Lycium barbarum Polysaccharides.
36677759	3	51	theme	ultrafiltration	514:528	arg1	separation					539:548	ultrafiltration membrane separation	514:548	ultrafiltration membrane separation	514:548	By ethanol-graded precipitation and ultrafiltration membrane separation, one oligosaccharide (LBPs-1, 1.912 kDa) and two polysaccharides (LBPs-2, 7.481 kDa; LBPs-3, 46.239 kDa) were obtained from Lycium barbarum.
36677759	8	52	theme	dismutase	1196:1204	arg1	activity					1212:1219	superoxide dismutase (SOD) activity	1185:1219	superoxide dismutase (SOD) activity than LBPs-2	1185:1231	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	10	53	dep	weight	1489:1494	arg1	addition					1463:1470	addition	1463:1470	addition	1463:1470	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	9	54	theme	immune	1428:1433	arg1	damage					1435:1440	the immune damage	1424:1440	the immune damage generated by VTI	1424:1457	In zebrafish, LBPs-2 and LBPs-3 boosted the growth of T-lymphocytes and macrophages, enhanced the immunological response, and mitigated the immune damage generated by VTI.
36677759	2	55	theme	study	351:355	arg1	purpose					335:341	The purpose	331:341	The purpose of this study	331:355	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	4	56	theme	LBPs-3	776:781	arg1	arabinose					788:796	arabinose	788:796	arabinose	788:796	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	4	56	theme	LBPs-3	776:781	arg1	constituents					760:771	the main constituents	751:771	the main constituents of LBPs-3	751:781	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	4	57	theme	LBPs-1	720:725	arg1	component					707:715	the major component	697:715	the major component of LBPs-1 and LBPs-2	697:736	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	4	57	theme	LBPs-1	720:725	arg1	glucose					742:748	glucose	742:748	glucose	742:748	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	10	58	theme	reaction	1684:1691	arg1	mechanism					1693:1701	the chemical reaction mechanism	1671:1701	the chemical reaction mechanism	1671:1701	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	1	59	theme	molecular	142:150	arg1	weight					152:157	The molecular weight	138:157	The molecular weight	138:157	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	60	theme	glycosidic	233:242	arg1	linkages					244:251	glycosidic linkages	233:251	glycosidic linkages	233:251	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	10	61	theme	monosaccharide	1607:1620	arg1	composition					1622:1632	the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism	1603:1701	composition	1622:1632	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	2	62	theme	different	378:386	arg1	weights					398:404	different molecular weights	378:404	different molecular weights	378:404	The purpose of this study was to determine how different molecular weights affected the bioactivity of the Lycium barbarum polysaccharides (LBPs).
36677759	1	63	theme	linkages	244:251	arg1	conformation					177:188	the triple-helix conformation	160:188	the triple-helix conformation	160:188	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	63	theme	linkages	244:251	arg1	conjugates					277:286	the polysaccharide conjugates	258:286	the polysaccharide conjugates of polysaccharides	258:305	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	63	theme	linkages	244:251	arg1	content					210:216	the monosaccharide content	191:216	the monosaccharide content	191:216	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	63	theme	linkages	244:251	arg1	weight					152:157	The molecular weight	138:157	The molecular weight	138:157	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	1	63	theme	linkages	244:251	arg1	manner					223:228	the manner	219:228	the manner of glycosidic linkages	219:251	The molecular weight, the triple-helix conformation, the monosaccharide content, the manner of glycosidic linkages, and the polysaccharide conjugates of polysaccharides all affect bioactivity.
36677759	6	64	theme	LBPs-3	963:968	arg1	residues					940:947	Sugar residues	934:947	Sugar residues of LBPs-2 and LBPs-3	934:968	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	6	64	theme	LBPs-3	963:968	arg1	LBPs-3					963:968	LBPs-3	963:968	LBPs-3	963:968	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	6	64	theme	LBPs-3	963:968	arg1	LBPs-2					952:957	LBPs-2	952:957	LBPs-2	952:957	Sugar residues of LBPs-2 and LBPs-3 were elucidated by NMR spectra.
36677759	9	65	theme	macrophages	1360:1370	arg1	growth					1332:1337	the growth	1328:1337	the growth of T-lymphocytes and macrophages	1328:1370	In zebrafish, LBPs-2 and LBPs-3 boosted the growth of T-lymphocytes and macrophages, enhanced the immunological response, and mitigated the immune damage generated by VTI.
36677759	8	66	theme	ABTS+	1272:1276	arg1	radicals					1278:1285	scavenging ABTS+ radicals	1261:1285	scavenging ABTS+ radicals	1261:1285	LBPs-3 showed higher oxygen radical absorbance capacity (ORAC) and superoxide dismutase (SOD) activity than LBPs-2, but a lower capability for scavenging ABTS+ radicals.
36677759	10	67	theme	various	1578:1584	arg1	composition					1654:1664	the chemical composition	1641:1664	the chemical composition	1641:1664	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	10	67	theme	various	1578:1584	arg1	composition					1622:1632	the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism	1603:1701	composition	1622:1632	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	10	67	theme	various	1578:1584	arg1	mechanism					1693:1701	the chemical reaction mechanism	1671:1701	the chemical reaction mechanism	1671:1701	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	10	67	theme	various	1578:1584	arg1	aspects					1586:1592	various aspects	1578:1592	various aspects	1578:1592	In addition to the molecular weight, the results indicated that the biological activities would be the consequence of various aspects, such as the monosaccharide composition ratio, the chemical composition, and the chemical reaction mechanism.
36677759	4	68	theme	major	701:705	arg1	component					707:715	the major component	697:715	the major component of LBPs-1 and LBPs-2	697:736	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36677759	4	68	theme	major	701:705	arg1	glucose					742:748	glucose	742:748	glucose	742:748	While the major component of LBPs-1 and LBPs-2 was glucose, the main constituents of LBPs-3 were arabinose, galactose, and glucose.
36958456	6	0	theme	time	1335:1338	arg1	thousandth					1317:1326	only a few thousandth	1306:1326	only a few thousandth of the time	1306:1338	Compared to the conventional sample preparation methods, the MFRD took only a few thousandth of the time to accomplish degradations of plant polysaccharides.
36958456	7	1	theme	various	1470:1476	arg1	samples					1493:1499	various polysaccharide samples	1470:1499	various polysaccharide samples	1470:1499	It significantly improves sample preparations and is generally applicable to various polysaccharide samples.
36958456	6	2	theme	conventional	1251:1262	arg1	methods					1283:1289	the conventional sample preparation methods	1247:1289	the conventional sample preparation methods	1247:1289	Compared to the conventional sample preparation methods, the MFRD took only a few thousandth of the time to accomplish degradations of plant polysaccharides.
36958456	4	3	dep	peaks	938:942	arg1	e.g.					932:935	e.g.	932:935	e.g.	932:935	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	3	4	theme	HILIC-ESI--Q-OT-IT-MS/MS.	713:737	arg1	combinations					673:684	combinations	673:684	combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	673:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	1	5	theme	free	283:286	arg1	radical					288:294	microwave assisted free radical	264:294	microwave assisted free radical degradation (MFRD) of plant polysaccharides	264:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	4	6	theme	key	917:919	arg1	Q-markers					921:929	several key Q-markers	909:929	several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences	909:1033	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	4	6	theme	key	917:919	arg1	peaks					938:942	peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30	938:981	peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30	938:981	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	1	7	theme	radical	288:294	arg1	MFRD					309:312	MFRD	309:312	MFRD	309:312	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	1	7	theme	radical	288:294	arg1	degradation					296:306	microwave assisted free radical degradation	264:306	microwave assisted free radical degradation (MFRD) of plant polysaccharides	264:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	1	8	theme	small	385:389	arg1	polysaccharides					394:408	small Mw polysaccharides	385:408	small Mw polysaccharides	385:408	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	5	9	theme	amperometric	1211:1222	arg1	detection					1224:1232	pulsed amperometric detection	1204:1232	pulsed amperometric detection	1204:1232	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	4	10	theme	several	909:915	arg1	Q-markers					921:929	several key Q-markers	909:929	several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences	909:1033	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	4	10	theme	several	909:915	arg1	peaks					938:942	peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30	938:981	peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30	938:981	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	1	11	dep	establish	133:141	arg1	to					130:131	to	130:131	to	130:131	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	1	12	theme	Mw	391:392	arg1	polysaccharides					394:408	small Mw polysaccharides	385:408	small Mw polysaccharides	385:408	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	7	13	theme	sample	1419:1424	arg1	preparations					1426:1437	sample preparations	1419:1437	sample preparations	1419:1437	It significantly improves sample preparations and is generally applicable to various polysaccharide samples.
36958456	3	14	theme	SSP	827:829	arg1	separation					801:810	a clear separation	793:810	a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	793:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	6	15	theme	preparation	1271:1281	arg1	methods					1283:1289	the conventional sample preparation methods	1247:1289	the conventional sample preparation methods	1247:1289	Compared to the conventional sample preparation methods, the MFRD took only a few thousandth of the time to accomplish degradations of plant polysaccharides.
36958456	3	16	dep	based	856:860	arg1	data					882:885	data	882:885	data	882:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	16	dep	based	856:860	arg1	HILIC-ESI--QTOF-MSE					862:880	HILIC-ESI--QTOF-MSE	862:880	HILIC-ESI--QTOF-MSE	862:880	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	16	dep	based	856:860	arg1	PCA					834:836	PCA	834:836	PCA	834:836	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	1	17	theme	assessment	215:224	arg1	improvement					192:202	improvement	192:202	improvement of quality assessment	192:224	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	3	18	theme	HILIC-ESI--QTOF-MSE	689:707	arg1	combinations					673:684	combinations	673:684	combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	673:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	4	19	with	Q-markers	921:929	arg1	differences					1001:1011	significant differences	989:1011	significant differences	989:1011	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	4	19	with	Q-markers	921:929	arg1	emergences					1024:1033	stable emergences	1017:1033	stable emergences	1017:1033	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	1	20	theme	quality	207:213	arg1	assessment					215:224	quality assessment	207:224	quality assessment	207:224	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	0	21	theme	assisted	10:17	arg1	degradation					32:42	Microwave assisted free radical degradation	0:42	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.	0:119	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	2	22	theme	case	416:419	arg1	study					421:425	a case study	414:425	a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP)	414:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	22	theme	case	416:419	arg1	condition					517:525	the MFRD condition	508:525	the MFRD condition (i.e., 100 °C, 30 s and 80 W)	508:555	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	0	23	theme	Microwave	0:8	arg1	degradation					32:42	Microwave assisted free radical degradation	0:42	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.	0:119	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	3	24	theme	multivariable	752:764	arg1	analysis					778:785	multivariable statistical analysis	752:785	multivariable statistical analysis	752:785	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	2	25	dep	polysaccharides	477:491	arg1	polysaccharides					477:491	fruit polysaccharides	471:491	fruit polysaccharides (SCP and SSP)	471:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	25	dep	polysaccharides	477:491	arg1	SSP					502:504	SSP	502:504	SSP	502:504	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	25	dep	polysaccharides	477:491	arg1	SCP					494:496	SCP	494:496	SCP	494:496	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	3	26	theme	SCP	635:637	arg1	products					623:630	the MFRD products	614:630	the MFRD products of SCP and SSP	614:645	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	0	27	theme	radical	24:30	arg1	degradation					32:42	Microwave assisted free radical degradation	0:42	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.	0:119	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	3	28	theme	statistical	766:776	arg1	analysis					778:785	multivariable statistical analysis	752:785	multivariable statistical analysis	752:785	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	29	from	plots	850:854	arg1	separation					801:810	a clear separation	793:810	a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	793:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	0	30	theme	free	19:22	arg1	degradation					32:42	Microwave assisted free radical degradation	0:42	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.	0:119	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	3	31	dep	combinations	673:684	arg1	shows					787:791	shows	787:791	shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	787:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	32	from	SSP	827:829	arg1	plots					850:854	OPLS-DA plots	842:854	OPLS-DA plots	842:854	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	32	from	SSP	827:829	arg1	data					882:885	data	882:885	data	882:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	32	from	SSP	827:829	arg1	HILIC-ESI--QTOF-MSE					862:880	HILIC-ESI--QTOF-MSE	862:880	HILIC-ESI--QTOF-MSE	862:880	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	32	from	SSP	827:829	arg1	PCA					834:836	PCA	834:836	PCA	834:836	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	5	33	theme	high-performance	1152:1167	arg1	chromatography					1184:1197	a high-performance anion-exchange chromatography	1150:1197	a high-performance anion-exchange chromatography with pulsed amperometric detection	1150:1232	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	1	34	theme	sample	229:234	arg1	method					248:253	a sample preparation method	227:253	a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides	227:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	6	35	theme	polysaccharides	1376:1390	arg1	degradations					1354:1365	degradations	1354:1365	degradations of plant polysaccharides	1354:1390	Compared to the conventional sample preparation methods, the MFRD took only a few thousandth of the time to accomplish degradations of plant polysaccharides.
36958456	1	36	theme	plant	318:322	arg1	polysaccharides					324:338	plant polysaccharides	318:338	plant polysaccharides	318:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	2	37	dep	100 °C	534:539	arg1	i.e.					528:531	i.e.	528:531	i.e.	528:531	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	38	theme	chinensis	441:449	arg1	study					421:425	a case study	414:425	a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP)	414:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	38	theme	chinensis	441:449	arg1	condition					517:525	the MFRD condition	508:525	the MFRD condition (i.e., 100 °C, 30 s and 80 W)	508:555	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	39	dep	chinensis	441:449	arg1	polysaccharides					477:491	fruit polysaccharides	471:491	fruit polysaccharides (SCP and SSP)	471:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	39	dep	chinensis	441:449	arg1	SSP					502:504	SSP	502:504	SSP	502:504	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	39	dep	chinensis	441:449	arg1	SCP					494:496	SCP	494:496	SCP	494:496	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	4	40	theme	stable	1017:1022	arg1	emergences					1024:1033	stable emergences	1017:1033	stable emergences	1017:1033	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	1	41	theme	preparation	236:246	arg1	method					248:253	a sample preparation method	227:253	a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides	227:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	6	42	theme	plant	1370:1374	arg1	polysaccharides					1376:1390	plant polysaccharides	1370:1390	plant polysaccharides	1370:1390	Compared to the conventional sample preparation methods, the MFRD took only a few thousandth of the time to accomplish degradations of plant polysaccharides.
36958456	1	43	theme	polysaccharides	324:338	arg1	MFRD					309:312	MFRD	309:312	MFRD	309:312	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	1	43	theme	polysaccharides	324:338	arg1	degradation					296:306	microwave assisted free radical degradation	264:306	microwave assisted free radical degradation (MFRD) of plant polysaccharides	264:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	3	44	from	PCA	834:836	arg1	separation					801:810	a clear separation	793:810	a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	793:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	45	theme	MFRD	618:621	arg1	products					623:630	the MFRD products	614:630	the MFRD products of SCP and SSP	614:645	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	2	46	theme	fruit	471:475	arg1	polysaccharides					477:491	fruit polysaccharides	471:491	fruit polysaccharides (SCP and SSP)	471:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	46	theme	fruit	471:475	arg1	SSP					502:504	SSP	502:504	SSP	502:504	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	46	theme	fruit	471:475	arg1	SCP					494:496	SCP	494:496	SCP	494:496	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	0	47	theme	polysaccharides	58:72	arg1	degradation					32:42	Microwave assisted free radical degradation	0:42	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.	0:119	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	3	48	theme	clear	795:799	arg1	separation					801:810	a clear separation	793:810	a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	793:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	49	from	separation	801:810	arg1	plots					850:854	OPLS-DA plots	842:854	OPLS-DA plots	842:854	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	49	from	separation	801:810	arg1	data					882:885	data	882:885	data	882:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	49	from	separation	801:810	arg1	HILIC-ESI--QTOF-MSE					862:880	HILIC-ESI--QTOF-MSE	862:880	HILIC-ESI--QTOF-MSE	862:880	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	49	from	separation	801:810	arg1	PCA					834:836	PCA	834:836	PCA	834:836	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	50	theme	products	623:630	arg1	structures					600:609	The potential structures	586:609	The potential structures of the MFRD products of SCP and SSP	586:645	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	51	from	SCP	815:817	arg1	plots					850:854	OPLS-DA plots	842:854	OPLS-DA plots	842:854	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	51	from	SCP	815:817	arg1	data					882:885	data	882:885	data	882:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	51	from	SCP	815:817	arg1	HILIC-ESI--QTOF-MSE					862:880	HILIC-ESI--QTOF-MSE	862:880	HILIC-ESI--QTOF-MSE	862:880	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	51	from	SCP	815:817	arg1	PCA					834:836	PCA	834:836	PCA	834:836	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	0	52	theme	Schisandra	47:56	arg1	polysaccharides					58:72	Schisandra polysaccharides	47:72	Schisandra polysaccharides	47:72	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	4	53	theme	VIP	892:894	arg1	plot					896:899	The VIP plot	888:899	The VIP plot	888:899	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	0	54	dep	degradation	32:42	arg1	application					108:118	application	108:118	application	108:118	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	0	54	dep	degradation	32:42	arg1	identification					89:102	identification	89:102	identification	89:102	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	0	54	dep	degradation	32:42	arg1	Optimization					75:86	Optimization	75:86	Optimization	75:86	Microwave assisted free radical degradation of Schisandra polysaccharides: Optimization, identification and application.
36958456	5	55	theme	low-polymerization	1051:1068	arg1	fingerprinting					1084:1097	a low-polymerization compositional fingerprinting	1049:1097	a low-polymerization compositional fingerprinting	1049:1097	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	2	56	dep	condition	517:525	arg1	80 W					551:554	80 W	551:554	80 W	551:554	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	56	dep	condition	517:525	arg1	30 s					542:545	30 s	542:545	30 s	542:545	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	56	dep	condition	517:525	arg1	100 °C					534:539	100 °C	534:539	100 °C	534:539	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	3	57	theme	SCP	815:817	arg1	separation					801:810	a clear separation	793:810	a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data	793:885	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	6	58	theme	sample	1264:1269	arg1	methods					1283:1289	the conventional sample preparation methods	1247:1289	the conventional sample preparation methods	1247:1289	Compared to the conventional sample preparation methods, the MFRD took only a few thousandth of the time to accomplish degradations of plant polysaccharides.
36958456	7	59	theme	polysaccharide	1478:1491	arg1	samples					1493:1499	various polysaccharide samples	1470:1499	various polysaccharide samples	1470:1499	It significantly improves sample preparations and is generally applicable to various polysaccharide samples.
36958456	5	60	with	chromatography	1184:1197	arg1	detection					1224:1232	pulsed amperometric detection	1204:1232	pulsed amperometric detection	1204:1232	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	4	61	theme	significant	989:999	arg1	differences					1001:1011	significant differences	989:1011	significant differences	989:1011	The VIP plot unveils several key Q-markers (e.g., peaks 3, 8, 9, 10, 15, 25, 26, 28, 29 and 30) with significant differences and stable emergences.
36958456	5	62	theme	anion-exchange	1169:1182	arg1	chromatography					1184:1197	a high-performance anion-exchange chromatography	1150:1197	a high-performance anion-exchange chromatography with pulsed amperometric detection	1150:1232	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	3	63	theme	SSP	643:645	arg1	products					623:630	the MFRD products	614:630	the MFRD products of SCP and SSP	614:645	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	64	theme	potential	590:598	arg1	structures					600:609	The potential structures	586:609	The potential structures of the MFRD products of SCP and SSP	586:645	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	3	65	theme	OPLS-DA	842:848	arg1	plots					850:854	OPLS-DA plots	842:854	OPLS-DA plots	842:854	The potential structures of the MFRD products of SCP and SSP were further discussed by combinations of HILIC-ESI--QTOF-MSE and HILIC-ESI--Q-OT-IT-MS/MS. As followed, multivariable statistical analysis shows a clear separation of SCP and the SSP in PCA and OPLS-DA plots based HILIC-ESI--QTOF-MSE data.
36958456	1	66	theme	microwave	264:272	arg1	radical					288:294	microwave assisted free radical	264:294	microwave assisted free radical degradation (MFRD) of plant polysaccharides	264:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	2	67	theme	MFRD	512:515	arg1	study					421:425	a case study	414:425	a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP)	414:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	67	theme	MFRD	512:515	arg1	condition					517:525	the MFRD condition	508:525	the MFRD condition (i.e., 100 °C, 30 s and 80 W)	508:555	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	67	theme	MFRD	512:515	arg1	optimal					577:583	optimal	577:583	optimal	577:583	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	5	68	theme	compositional	1070:1082	arg1	fingerprinting					1084:1097	a low-polymerization compositional fingerprinting	1049:1097	a low-polymerization compositional fingerprinting	1049:1097	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	2	69	theme	sphenanthera	458:469	arg1	study					421:425	a case study	414:425	a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP)	414:505	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	2	69	theme	sphenanthera	458:469	arg1	condition					517:525	the MFRD condition	508:525	the MFRD condition (i.e., 100 °C, 30 s and 80 W)	508:555	As a case study of Schisandra chinensis and S. sphenanthera fruit polysaccharides (SCP and SSP), the MFRD condition (i.e., 100 °C, 30 s and 80 W) was confirmed to be optimal.
36958456	1	70	theme	polysaccharides	172:186	arg1	structural-fingerprinting					143:167	structural-fingerprinting	143:167	structural-fingerprinting of polysaccharides	143:186	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
36958456	5	71	theme	pulsed	1204:1209	arg1	detection					1224:1232	pulsed amperometric detection	1204:1232	pulsed amperometric detection	1204:1232	Furthermore, a low-polymerization compositional fingerprinting was successfully constructed for SCP and SSP using a high-performance anion-exchange chromatography with pulsed amperometric detection.
36958456	1	72	theme	assisted	274:281	arg1	radical					288:294	microwave assisted free radical	264:294	microwave assisted free radical degradation (MFRD) of plant polysaccharides	264:338	In order to establish structural-fingerprinting of polysaccharides for improvement of quality assessment, a sample preparation method based on microwave assisted free radical degradation (MFRD) of plant polysaccharides was proposed to produce oligosaccharides and small Mw polysaccharides.
35682636	0	0	theme	Graphene	95:102	arg1	Oxide					104:108	Graphene Oxide	95:108	Graphene Oxide	95:108	The Functional and Application Possibilities of Starch/Chitosan Polymer Composites Modified by Graphene Oxide.
35682636	2	1	theme	food	499:502	arg1	products					504:511	meat food products	494:511	meat food products	494:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	2	2	from	effects	424:430	arg1	development					439:449	the development	435:449	the development of pathogenic microflora during storage of meat food products	435:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	5	3	theme	enzymatic	892:900	arg1	hydrolyses					911:920	enzymatic and acid hydrolyses	892:920	hydrolyses	911:920	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses indicates their relatively high biodegradability.
35682636	2	4	theme	meat	494:497	arg1	products					504:511	meat food products	494:511	meat food products	494:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	1	5	theme	starch/chitosan/graphene	189:212	arg1	oxide					214:218	starch/chitosan/graphene oxide	189:218	starch/chitosan/graphene oxide (GO) obtained using the green synthesis method	189:265	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	6	6	theme	high	1001:1004	arg1	barrier					1006:1012	the high barrier	997:1012	the high barrier against many microorganisms	997:1040	The lack of toxicity and the high barrier against many microorganisms offer great potential for applications in the food industry.
35682636	1	7	theme	acid	366:369	arg1	hydrolysis					371:380	acid hydrolysis	366:380	acid hydrolysis	366:380	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	1	8	theme	optical	294:300	arg1	properties					302:311	optical properties	294:311	optical properties	294:311	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	5	9	theme	acid	906:909	arg1	hydrolyses					911:920	enzymatic and acid hydrolyses	892:920	hydrolyses	911:920	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses indicates their relatively high biodegradability.
35682636	2	10	theme	composites	403:412	arg1	toxicity					387:394	The toxicity	383:394	The toxicity of the composites	383:412	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	2	10	theme	composites	403:412	arg1	effects					424:430	their effects	418:430	their effects on the development of pathogenic microflora during storage of meat food products	418:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	2	11	theme	microflora	465:474	arg1	development					439:449	the development	435:449	the development of pathogenic microflora during storage of meat food products	435:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	4	12	theme	packaging	830:838	arg1	them					803:806	them	803:806	them	803:806	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	4	12	theme	packaging	830:838	arg1	elements					818:825	active elements	811:825	active elements of packaging	811:838	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	5	13	theme	starch	863:868	arg1	films					883:887	starch and chitosan films	863:887	starch and chitosan films	863:887	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses indicates their relatively high biodegradability.
35682636	0	14	theme	Functional	4:13	arg1	Possibilities					31:43	The Functional and Application Possibilities	0:43	Possibilities	31:43	The Functional and Application Possibilities of Starch/Chitosan Polymer Composites Modified by Graphene Oxide.
35682636	6	15	theme	toxicity	984:991	arg1	lack					976:979	The lack	972:979	The lack of toxicity	972:991	The lack of toxicity and the high barrier against many microorganisms offer great potential for applications in the food industry.
35682636	6	15	theme	toxicity	984:991	arg1	barrier					1006:1012	the high barrier	997:1012	the high barrier against many microorganisms	997:1040	The lack of toxicity and the high barrier against many microorganisms offer great potential for applications in the food industry.
35682636	4	16	theme	composites	740:749	arg1	properties					722:731	the good optical properties	705:731	the good optical properties	705:731	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	4	17	contain	containing	751:760	arg2	chitosan					762:769	chitosan	762:769	chitosan	762:769	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	4	17	contain	containing	751:760	arg1	composites					740:749	the composites	736:749	the composites containing chitosan	736:769	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	5	18	theme	high	949:952	arg1	biodegradability					954:969	their relatively high biodegradability	932:969	their relatively high biodegradability	932:969	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses indicates their relatively high biodegradability.
35682636	5	19	theme	chitosan	874:881	arg1	films					883:887	starch and chitosan films	863:887	starch and chitosan films	863:887	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses indicates their relatively high biodegradability.
35682636	0	20	theme	Application	19:29	arg1	Possibilities					31:43	The Functional and Application Possibilities	0:43	Possibilities	31:43	The Functional and Application Possibilities of Starch/Chitosan Polymer Composites Modified by Graphene Oxide.
35682636	3	21	theme	barrier	573:579	arg1	weak					615:618	weak	615:618	weak	615:618	Although the results showed that the barrier properties of the composites were weak, they were similar to those of biological systems.
35682636	3	21	theme	barrier	573:579	arg1	properties					581:590	the barrier properties	569:590	the barrier properties of the composites	569:608	Although the results showed that the barrier properties of the composites were weak, they were similar to those of biological systems.
35682636	5	22	theme	films	883:887	arg1	susceptibility					845:858	The susceptibility	841:858	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses	841:920	The susceptibility of starch and chitosan films to enzymatic and acid hydrolyses indicates their relatively high biodegradability.
35682636	4	23	theme	good	709:712	arg1	properties					722:731	the good optical properties	705:731	the good optical properties	705:731	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	3	24	theme	biological	651:660	arg1	systems					662:668	biological systems	651:668	biological systems	651:668	Although the results showed that the barrier properties of the composites were weak, they were similar to those of biological systems.
35682636	4	25	theme	active	811:816	arg1	them					803:806	them	803:806	them	803:806	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	4	25	theme	active	811:816	arg1	elements					818:825	active elements	811:825	active elements of packaging	811:838	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	1	26	theme	green	244:248	arg1	method					260:265	the green synthesis method	240:265	the green synthesis method	240:265	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	0	27	theme	Polymer	64:70	arg1	Composites					72:81	Starch/Chitosan Polymer Composites	48:81	Starch/Chitosan Polymer Composites	48:81	The Functional and Application Possibilities of Starch/Chitosan Polymer Composites Modified by Graphene Oxide.
35682636	0	28	theme	Composites	72:81	arg1	Possibilities					31:43	The Functional and Application Possibilities	0:43	Possibilities	31:43	The Functional and Application Possibilities of Starch/Chitosan Polymer Composites Modified by Graphene Oxide.
35682636	1	29	dep	oxide	214:218	arg1	GO					221:222	GO	221:222	GO	221:222	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	2	30	from	toxicity	387:394	arg1	development					439:449	the development	435:449	the development of pathogenic microflora during storage of meat food products	435:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	4	31	theme	optical	714:720	arg1	properties					722:731	the good optical properties	705:731	the good optical properties	705:731	The studies carried out confirmed the good optical properties of the composites containing chitosan, which makes it possible to use them as active elements of packaging.
35682636	0	32	theme	Starch/Chitosan	48:62	arg1	Composites					72:81	Starch/Chitosan Polymer Composites	48:81	Starch/Chitosan Polymer Composites	48:81	The Functional and Application Possibilities of Starch/Chitosan Polymer Composites Modified by Graphene Oxide.
35682636	3	33	theme	composites	599:608	arg1	weak					615:618	weak	615:618	weak	615:618	Although the results showed that the barrier properties of the composites were weak, they were similar to those of biological systems.
35682636	3	33	theme	composites	599:608	arg1	properties					581:590	the barrier properties	569:590	the barrier properties of the composites	569:608	Although the results showed that the barrier properties of the composites were weak, they were similar to those of biological systems.
35682636	1	34	theme	functional	132:141	arg1	properties					143:152	functional properties	132:152	functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties	132:311	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	1	35	theme	synthesis	250:258	arg1	method					260:265	the green synthesis method	240:265	the green synthesis method	240:265	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	6	36	theme	great	1048:1052	arg1	potential					1054:1062	great potential	1048:1062	great potential for applications	1048:1079	The lack of toxicity and the high barrier against many microorganisms offer great potential for applications in the food industry.
35682636	1	37	theme	bionanocomposites	157:173	arg1	properties					143:152	functional properties	132:152	functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties	132:311	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	1	37	theme	bionanocomposites	157:173	arg1	rate					329:332	the rate	325:332	the rate of degradation by enzymatic and acid hydrolysis	325:380	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	6	38	theme	food	1088:1091	arg1	industry					1093:1100	the food industry	1084:1100	the food industry	1084:1100	The lack of toxicity and the high barrier against many microorganisms offer great potential for applications in the food industry.
35682636	6	39	theme	many	1022:1025	arg1	microorganisms					1027:1040	many microorganisms	1022:1040	many microorganisms	1022:1040	The lack of toxicity and the high barrier against many microorganisms offer great potential for applications in the food industry.
35682636	2	40	theme	products	504:511	arg1	storage					483:489	storage	483:489	storage of meat food products	483:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
35682636	1	41	theme	degradation	337:347	arg1	properties					143:152	functional properties	132:152	functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties	132:311	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	1	41	theme	degradation	337:347	arg1	rate					329:332	the rate	325:332	the rate of degradation by enzymatic and acid hydrolysis	325:380	This study describes functional properties of bionanocomposites consisting of starch/chitosan/graphene oxide (GO) obtained using the green synthesis method, such as water-barrier and optical properties, as well as the rate of degradation by enzymatic and acid hydrolysis.
35682636	2	42	theme	pathogenic	454:463	arg1	microflora					465:474	pathogenic microflora	454:474	pathogenic microflora during storage of meat food products	454:511	The toxicity of the composites and their effects on the development of pathogenic microflora during storage of meat food products was also investigated.
36215498	5	0	theme	CAAlg	1233:1237	arg1	films					1239:1243	CAAlg films	1233:1243	CAAlg films	1233:1243	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	7	1	theme	marine	1734:1739	arg1	polysaccharides					1755:1769	marine algae-derived polysaccharides	1734:1769	marine algae-derived polysaccharides	1734:1769	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	7	2	link	algae-derived	1741:1753	arg1	polysaccharides					1755:1769	marine algae-derived polysaccharides	1734:1769	marine algae-derived polysaccharides	1734:1769	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	4	3	theme	domains	1123:1129	arg1	size					1111:1114	size	1111:1114	size of the domains scaling inversely with calcium concentration	1111:1174	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	4	3	theme	domains	1123:1129	arg1	stress					1100:1105	yield stress	1094:1105	yield stress	1094:1105	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	1	4	theme	materials	293:301	arg1	processing					262:271	processing	262:271	processing	262:271	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	0	5	theme	synthetic	110:118	arg1	polymers					120:127	synthetic polymers	110:127	synthetic polymers	110:127	Double-interpenetrating nanostructured networks of marine polysaccharides possessing properties comparable to synthetic polymers.
36215498	2	6	theme	marine	389:394	arg1	biopolymers					396:406	processing marine biopolymers	378:406	processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	378:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	7	7	theme	polysaccharides	1755:1769	arg1	adoption					1722:1729	the adoption	1718:1729	the adoption of marine algae-derived polysaccharides	1718:1769	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	5	8	theme	similar	1367:1373	arg1	N					1364:1364	13.2 ± 0.81 N	1352:1364	13.2 ± 0.81 N	1352:1364	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	8	theme	similar	1367:1373	arg1	loads					1345:1349	interfacial failure loads	1325:1349	interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N)	1325:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	2	9	theme	cross-links	594:604	arg1	phase					568:572	the elastic phase	556:572	the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	556:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	5	10	theme	ultimate	1382:1389	arg1	loads					1391:1395	the ultimate loads	1378:1395	the ultimate loads of unlaminated films (10.09 ± 1.47 N)	1378:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	11	theme	±	1425:1425	arg1	N					1432:1432	10.09 ± 1.47 N	1419:1432	10.09 ± 1.47 N	1419:1432	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	11	theme	±	1425:1425	arg1	films					1412:1416	unlaminated films	1400:1416	unlaminated films (10.09 ± 1.47 N)	1400:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	7	12	theme	materials	1822:1830	arg1	development					1778:1788	the development	1774:1788	the development of sustainable high-performance materials	1774:1830	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	2	13	theme	physical	585:592	arg1	cross-links					594:604	dynamic physical cross-links	577:604	dynamic physical cross-links	577:604	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	5	14	theme	surface	1185:1191	arg1	activation/cross-linking					1193:1216	surface activation/cross-linking	1185:1216	surface activation/cross-linking using calcium	1185:1230	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	3	15	theme	ionic	982:986	arg1	cross-linking					988:1000	ionic cross-linking	982:1000	ionic cross-linking with a divalent cation	982:1023	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	5	16	theme	interfacial	1325:1335	arg1	N					1364:1364	13.2 ± 0.81 N	1352:1364	13.2 ± 0.81 N	1352:1364	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	16	theme	interfacial	1325:1335	arg1	loads					1345:1349	interfacial failure loads	1325:1349	interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N)	1325:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	2	17	theme	dynamic	577:583	arg1	cross-links					594:604	dynamic physical cross-links	577:604	dynamic physical cross-links	577:604	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	3	18	theme	polylactic	803:812	arg1	acid					814:817	polylactic acid	803:817	polylactic acid	803:817	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	5	19	theme	0.81	1359:1362	arg1	±					1357:1357	±	1357:1357	±	1357:1357	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	7	20	theme	algae-derived	1741:1753	arg1	polysaccharides					1755:1769	marine algae-derived polysaccharides	1734:1769	marine algae-derived polysaccharides	1734:1769	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	2	21	theme	elastic	441:447	arg1	behavior					461:468	both elastic and plastic behavior	436:468	both elastic and plastic behavior	436:468	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	4	22	theme	CAAlg	1032:1036	arg1	films					1038:1042	Dried CAAlg films	1026:1042	Dried CAAlg films	1026:1042	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	5	23	theme	laminated	1299:1307	arg1	structures					1309:1318	laminated structures	1299:1318	laminated structures	1299:1318	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	6	24	theme	lines	1509:1513	arg1	array					1500:1504	an array	1497:1504	an array of lines of CAAlg	1497:1522	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	2	25	link	cross-linked	639:650	arg1	domains					652:658	stress-dissipating ionically cross-linked domains	610:658	stress-dissipating ionically cross-linked domains	610:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	1	26	theme	synthetic	224:232	arg1	polymers					234:241	synthetic polymers	224:241	synthetic polymers	224:241	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	0	27	theme	nanostructured	24:37	arg1	networks					39:46	Double-interpenetrating nanostructured networks	0:46	Double-interpenetrating nanostructured networks of marine polysaccharides	0:72	Double-interpenetrating nanostructured networks of marine polysaccharides possessing properties comparable to synthetic polymers.
36215498	4	28	theme	nano-micro-scale	1063:1078	arg1	domains					1080:1086	homogeneous nano-micro-scale domains	1051:1086	homogeneous nano-micro-scale domains	1051:1086	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	5	29	theme	wet	1278:1280	arg1	bonding					1282:1288	wet bonding	1278:1288	wet bonding	1278:1288	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	4	30	theme	Dried	1026:1030	arg1	films					1038:1042	Dried CAAlg films	1026:1042	Dried CAAlg films	1026:1042	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	5	31	theme	1.47	1427:1430	arg1	N					1432:1432	10.09 ± 1.47 N	1419:1432	10.09 ± 1.47 N	1419:1432	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	31	theme	1.47	1427:1430	arg1	films					1412:1416	unlaminated films	1400:1416	unlaminated films (10.09 ± 1.47 N)	1400:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	0	32	theme	Double-interpenetrating	0:22	arg1	networks					39:46	Double-interpenetrating nanostructured networks	0:46	Double-interpenetrating nanostructured networks of marine polysaccharides	0:72	Double-interpenetrating nanostructured networks of marine polysaccharides possessing properties comparable to synthetic polymers.
36215498	1	33	theme	small	315:319	arg1	footprint					335:343	a small environmental footprint	313:343	a small environmental footprint	313:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	3	34	with	cross-linking	988:1000	arg1	cation					1018:1023	a divalent cation	1007:1023	a divalent cation	1007:1023	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	1	35	theme	Sustainable	130:140	arg1	economy					151:157	Sustainable circular economy	130:157	Sustainable circular economy	130:157	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	3	36	theme	divalent	1009:1016	arg1	cation					1018:1023	a divalent cation	1007:1023	a divalent cation	1007:1023	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	2	37	theme	single	479:484	arg1	system					486:491	a single system	477:491	a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	477:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	1	38	theme	environmental	321:333	arg1	footprint					335:343	a small environmental footprint	313:343	a small environmental footprint	313:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	2	39	theme	cross-linked	639:650	arg1	domains					652:658	stress-dissipating ionically cross-linked domains	610:658	stress-dissipating ionically cross-linked domains	610:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	1	40	theme	circular	142:149	arg1	economy					151:157	Sustainable circular economy	130:157	Sustainable circular economy	130:157	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	6	41	theme	wood-marine	1462:1472	arg1	composites					1485:1494	wood-marine biopolymer composites	1462:1494	wood-marine biopolymer composites	1462:1494	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	3	42	theme	elastic	728:734	arg1	modulus					736:742	more than twofold higher elastic modulus	703:742	more than twofold higher elastic modulus	703:742	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	1	43	theme	comparable	210:219	arg1	profile					202:208	a property profile	191:208	a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint	191:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	5	44	theme	unlaminated	1400:1410	arg1	N					1432:1432	10.09 ± 1.47 N	1419:1432	10.09 ± 1.47 N	1419:1432	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	44	theme	unlaminated	1400:1410	arg1	films					1412:1416	unlaminated films	1400:1416	unlaminated films (10.09 ± 1.47 N)	1400:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	45	theme	failure	1337:1343	arg1	N					1364:1364	13.2 ± 0.81 N	1352:1364	13.2 ± 0.81 N	1352:1364	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	5	45	theme	failure	1337:1343	arg1	loads					1345:1349	interfacial failure loads	1325:1349	interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N)	1325:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	0	46	theme	polysaccharides	58:72	arg1	networks					39:46	Double-interpenetrating nanostructured networks	0:46	Double-interpenetrating nanostructured networks of marine polysaccharides	0:72	Double-interpenetrating nanostructured networks of marine polysaccharides possessing properties comparable to synthetic polymers.
36215498	2	47	theme	stress-dissipating	610:627	arg1	domains					652:658	stress-dissipating ionically cross-linked domains	610:658	stress-dissipating ionically cross-linked domains	610:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	2	48	contain	possess	428:434	arg2	behavior					461:468	both elastic and plastic behavior	436:468	both elastic and plastic behavior	436:468	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	2	48	contain	possess	428:434	arg1	materials					413:421	materials	413:421	materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	413:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	3	49	theme	principle	675:683	arg1	proof					666:670	a proof	664:670	a proof of principle	664:683	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	49	theme	principle	675:683	arg1	films					686:690	films	686:690	films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid	686:817	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	5	50	theme	films	1412:1416	arg1	loads					1391:1395	the ultimate loads	1378:1395	the ultimate loads of unlaminated films (10.09 ± 1.47 N)	1378:1433	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	2	51	theme	plastic	453:459	arg1	behavior					461:468	both elastic and plastic behavior	436:468	both elastic and plastic behavior	436:468	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	0	52	theme	marine	51:56	arg1	polysaccharides					58:72	marine polysaccharides	51:72	marine polysaccharides	51:72	Double-interpenetrating nanostructured networks of marine polysaccharides possessing properties comparable to synthetic polymers.
36215498	3	53	theme	water-soluble	849:861	arg1	polysaccharides					870:884	two water-soluble marine polysaccharides	845:884	two water-soluble marine polysaccharides	845:884	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	53	theme	water-soluble	849:861	arg1	acid					902:905	alginic acid	894:905	alginic acid (Alg)	894:911	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	2	54	theme	polymer	529:535	arg1	network					537:543	a double-interpenetrating polymer network	503:543	a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	503:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	6	55	with	activation	1596:1605	arg1	calcium					1612:1618	calcium	1612:1618	calcium	1612:1618	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	2	56	theme	double-interpenetrating	505:527	arg1	network					537:543	a double-interpenetrating polymer network	503:543	a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	503:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	3	57	theme	marine	863:868	arg1	polysaccharides					870:884	two water-soluble marine polysaccharides	845:884	two water-soluble marine polysaccharides	845:884	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	57	theme	marine	863:868	arg1	acid					902:905	alginic acid	894:905	alginic acid (Alg)	894:911	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	2	58	theme	elastic	560:566	arg1	phase					568:572	the elastic phase	556:572	the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	556:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	6	59	theme	bonded	1635:1640	arg1	wood					1642:1645	fully bonded wood	1629:1645	fully bonded wood	1629:1645	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	2	60	theme	processing	378:387	arg1	biopolymers					396:406	processing marine biopolymers	378:406	processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	378:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	4	61	theme	yield	1094:1098	arg1	stress					1100:1105	yield stress	1094:1105	yield stress	1094:1105	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	6	62	theme	composites	1485:1494	arg1	engineering					1447:1457	the engineering	1443:1457	the engineering of wood-marine biopolymer composites	1443:1494	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	3	63	theme	yield	776:780	arg1	stress					782:787	yield stress	776:787	yield stress	776:787	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	64	theme	tensile	754:760	arg1	strength					762:769	ultimate tensile strength	745:769	ultimate tensile strength	745:769	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	6	65	theme	wood	1540:1543	arg1	veneers					1545:1551	wood veneers	1540:1551	wood veneers (panels)	1540:1560	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	6	65	theme	wood	1540:1543	arg1	panels					1554:1559	panels	1554:1559	panels	1554:1559	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	6	66	theme	CAAlg	1518:1522	arg1	lines					1509:1513	lines	1509:1513	lines of CAAlg	1509:1522	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	3	67	theme	cross-linkable	929:942	arg1	CA					966:967	CA	966:967	CA	966:967	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	67	theme	cross-linkable	929:942	arg1	agarose					957:963	physically cross-linkable carboxylated agarose	918:963	physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation	918:1023	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	7	68	theme	high-performance	1805:1820	arg1	materials					1822:1830	sustainable high-performance materials	1793:1830	sustainable high-performance materials	1793:1830	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	3	69	theme	carboxylated	944:955	arg1	CA					966:967	CA	966:967	CA	966:967	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	69	theme	carboxylated	944:955	arg1	agarose					957:963	physically cross-linkable carboxylated agarose	918:963	physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation	918:1023	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	70	contain	possessing	692:701	arg2	strength					762:769	ultimate tensile strength	745:769	ultimate tensile strength	745:769	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	70	contain	possessing	692:701	arg2	modulus					736:742	more than twofold higher elastic modulus	703:742	more than twofold higher elastic modulus	703:742	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	70	contain	possessing	692:701	arg1	proof					666:670	a proof	664:670	a proof of principle	664:683	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	70	contain	possessing	692:701	arg2	stress					782:787	yield stress	776:787	yield stress	776:787	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	70	contain	possessing	692:701	arg1	films					686:690	films	686:690	films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid	686:817	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	2	71	theme	domains	652:658	arg1	phase					568:572	the elastic phase	556:572	the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains	556:658	Here, we present a paradigm for processing marine biopolymers into materials that possess both elastic and plastic behavior within a single system involving a double-interpenetrating polymer network comprising the elastic phase of dynamic physical cross-links and stress-dissipating ionically cross-linked domains.
36215498	1	72	contain	have	308:311	arg1	materials					293:301	raw materials	289:301	raw materials that have a small environmental footprint	289:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	1	72	contain	have	308:311	arg2	footprint					335:343	a small environmental footprint	313:343	a small environmental footprint	313:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	3	73	theme	alginic	894:900	arg1	polysaccharides					870:884	two water-soluble marine polysaccharides	845:884	two water-soluble marine polysaccharides	845:884	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	73	theme	alginic	894:900	arg1	Alg					908:910	Alg	908:910	Alg	908:910	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	3	73	theme	alginic	894:900	arg1	acid					902:905	alginic acid	894:905	alginic acid (Alg)	894:911	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	4	74	theme	homogeneous	1051:1061	arg1	domains					1080:1086	homogeneous nano-micro-scale domains	1051:1086	homogeneous nano-micro-scale domains	1051:1086	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	3	75	theme	ultimate	745:752	arg1	strength					762:769	ultimate tensile strength	745:769	ultimate tensile strength	745:769	As a proof of principle, films possessing more than twofold higher elastic modulus, ultimate tensile strength, and yield stress than those of polylactic acid were realized by blending two water-soluble marine polysaccharides, namely alginic acid (Alg) with physically cross-linkable carboxylated agarose (CA) followed by ionic cross-linking with a divalent cation.
36215498	6	76	theme	biopolymer	1474:1483	arg1	composites					1485:1494	wood-marine biopolymer composites	1462:1494	wood-marine biopolymer composites	1462:1494	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	4	77	theme	calcium	1154:1160	arg1	concentration					1162:1174	calcium concentration	1154:1174	calcium concentration	1154:1174	Dried CAAlg films showed homogeneous nano-micro-scale domains, with yield stress and size of the domains scaling inversely with calcium concentration.
36215498	6	78	dep	yield	1623:1627	arg1	laminate					1655:1662	laminate	1655:1662	laminate	1655:1662	Toward the engineering of wood-marine biopolymer composites, an array of lines of CAAlg were printed on wood veneers (panels), dried, and then bonded following activation with calcium to yield fully bonded wood two-ply laminate.
36215498	0	79	theme	comparable	96:105	arg1	properties					85:94	properties	85:94	properties comparable to synthetic polymers	85:127	Double-interpenetrating nanostructured networks of marine polysaccharides possessing properties comparable to synthetic polymers.
36215498	1	80	contain	possess	183:189	arg2	profile					202:208	a property profile	191:208	a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint	191:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	1	80	contain	possess	183:189	arg1	materials					168:176	materials	168:176	materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint	168:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	5	81	theme	13.2	1352:1355	arg1	±					1357:1357	±	1357:1357	±	1357:1357	Through surface activation/cross-linking using calcium, CAAlg films could be further processed using wet bonding to yield laminated structures with interfacial failure loads (13.2 ± 0.81 N) similar to the ultimate loads of unlaminated films (10.09 ± 1.47 N).
36215498	1	82	theme	property	193:200	arg1	profile					202:208	a property profile	191:208	a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint	191:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
36215498	7	83	theme	sustainable	1793:1803	arg1	materials					1822:1830	sustainable high-performance materials	1793:1830	sustainable high-performance materials	1793:1830	The system presented herein provides a blueprint for the adoption of marine algae-derived polysaccharides in the development of sustainable high-performance materials.
36215498	1	84	theme	raw	289:291	arg1	materials					293:301	raw materials	289:301	raw materials that have a small environmental footprint	289:343	Sustainable circular economy requires materials that possess a property profile comparable to synthetic polymers and, additionally, processing and sourcing of raw materials that have a small environmental footprint.
35569685	2	0	theme	oxide	358:362	arg1	nanoparticles					364:376	biosynthesized zinc oxide nanoparticles	338:376	biosynthesized zinc oxide nanoparticles	338:376	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	3	1	theme	ZnO	593:595	arg1	nanoparticles					597:609	ZnO nanoparticles	593:609	ZnO nanoparticles of particular interest with controlled morphology	593:659	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	1	2	theme	Xanthan	275:281	arg1	gum					283:285	Xanthan gum	275:285	Xanthan gum	275:285	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	2	theme	Xanthan	275:281	arg1	gums					244:247	three polysaccharide gums	223:247	three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	223:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	6	3	theme	ZnO	973:975	arg1	hydrogels					988:996	all synthesized chitosan incorporated ZnO composites hydrogels	935:996	all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract	935:1033	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	5	4	theme	rheological	843:853	arg1	behaviour					855:863	The rheological behaviour	839:863	The rheological behaviour of obtained hydrogels	839:885	The rheological behaviour of obtained hydrogels was evaluated.
35569685	9	5	theme	concentration	1525:1537	arg1	range					1539:1543	a wide concentration range	1518:1543	a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications	1518:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	0	6	theme	Green	0:4	arg1	synthesis					6:14	Green synthesis	0:14	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums	0:68	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	1	7	theme	zinc	192:195	arg1	oxide					197:201	zinc oxide	192:201	zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	192:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	8	theme	concentrations	1306:1319	arg1	range					1297:1301	a range	1295:1301	a range of concentrations between 50 and 1000 μg/mL	1295:1345	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	6	9	theme	chitosan	951:958	arg1	hydrogels					988:996	all synthesized chitosan incorporated ZnO composites hydrogels	935:996	all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract	935:1033	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	3	10	theme	interest	625:632	arg1	nanoparticles					597:609	ZnO nanoparticles	593:609	ZnO nanoparticles of particular interest with controlled morphology	593:659	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	9	11	theme	suitable	1571:1578	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	11	theme	suitable	1571:1578	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	8	12	theme	double	1386:1391	arg1	staining					1393:1400	Live/Dead double staining	1376:1400	Live/Dead double staining	1376:1400	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	7	13	theme	guest	1135:1139	arg1	molecules					1141:1149	various guest molecules	1127:1149	various guest molecules	1127:1149	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	9	14	theme	effective	1601:1609	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	14	theme	effective	1601:1609	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	6	15	theme	corrugated	1043:1052	arg1	topographies					1054:1065	corrugated topographies	1043:1065	corrugated topographies	1043:1065	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	7	16	theme	due	1172:1174	arg1	matrix					1165:1170	hydrogel matrix	1156:1170	hydrogel matrix due to its tuneable morphologies	1156:1203	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	3	17	theme	controlled	639:648	arg1	morphology					650:659	controlled morphology	639:659	controlled morphology	639:659	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	7	18	theme	hydrogel	1156:1163	arg1	matrix					1165:1170	hydrogel matrix	1156:1170	hydrogel matrix due to its tuneable morphologies	1156:1203	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	7	19	theme	possible	1101:1108	arg1	incorporation					1110:1122	the possible incorporation	1097:1122	the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies	1097:1203	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	9	20	theme	pharmacologic	1631:1643	arg1	agents					1645:1650	pharmacologic agents	1631:1650	pharmacologic agents for biomedical applications	1631:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	1	21	theme	synthesis	160:168	arg1	methodology					170:180	A facile, green synthesis methodology	144:180	methodology	170:180	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	4	22	theme	UV-Vis	751:756	arg1	spectroscopy					758:769	UV-Vis spectroscopy	751:769	UV-Vis spectroscopy	751:769	The formation of ZnO nanoparticles using polysaccharide gums was confirmed by FTIR, XRD, UV-Vis spectroscopy, thermal analysis, SEM, Raman and photoluminescence spectroscopies.
35569685	7	23	theme	present	1072:1078	arg1	study					1080:1084	The present study	1068:1084	The present study	1068:1084	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	6	24	theme	synthesized	939:949	arg1	hydrogels					988:996	all synthesized chitosan incorporated ZnO composites hydrogels	935:996	all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract	935:1033	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	4	25	theme	photoluminescence	805:821	arg1	spectroscopies					823:836	photoluminescence spectroscopies	805:836	photoluminescence spectroscopies	805:836	The formation of ZnO nanoparticles using polysaccharide gums was confirmed by FTIR, XRD, UV-Vis spectroscopy, thermal analysis, SEM, Raman and photoluminescence spectroscopies.
35569685	0	26	theme	novel	105:109	arg1	biomaterials					130:141	novel functional natural biomaterials	105:141	novel functional natural biomaterials	105:141	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	2	27	theme	chitosan	415:422	arg1	matrix					433:438	a sustainable chitosan hydrogel matrix	401:438	a sustainable chitosan hydrogel matrix functionalized with propolis extract	401:475	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	0	28	theme	natural	122:128	arg1	biomaterials					130:141	novel functional natural biomaterials	105:141	novel functional natural biomaterials	105:141	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	9	29	theme	biological	1427:1436	arg1	properties					1438:1447	the biological properties	1423:1447	the biological properties	1423:1447	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	30	theme	green	1462:1466	arg1	hydrogels					1468:1476	these novel green hydrogels	1450:1476	these novel green hydrogels	1450:1476	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	1	31	dep	methodology	170:180	arg1	obtain					185:190	obtain	185:190	to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	182:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	5	32	theme	hydrogels	877:885	arg1	behaviour					855:863	The rheological behaviour	839:863	The rheological behaviour of obtained hydrogels	839:885	The rheological behaviour of obtained hydrogels was evaluated.
35569685	3	33	theme	suitable	561:568	arg1	approach					570:577	a suitable approach	559:577	a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology	559:659	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	9	34	theme	novel	1456:1460	arg1	hydrogels					1468:1476	these novel green hydrogels	1450:1476	these novel green hydrogels	1450:1476	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	8	35	from	culture	1283:1289	arg1	cytocompatible					1244:1257	cytocompatible	1244:1257	cytocompatible	1244:1257	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	8	35	from	culture	1283:1289	arg1	composites					1228:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	1	36	theme	green	154:158	arg1	methodology					170:180	A facile, green synthesis methodology	144:180	methodology	170:180	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	0	37	theme	chitosan-ZnO-based	31:48	arg1	gums					65:68	bioinspired chitosan-ZnO-based polysaccharide gums	19:68	bioinspired chitosan-ZnO-based polysaccharide gums	19:68	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	1	38	theme	origin	302:307	arg1	gum					257:259	Acacia gum	250:259	Acacia gum	250:259	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	38	theme	origin	302:307	arg1	gum					267:269	Guar gum	262:269	Guar gum	262:269	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	38	theme	origin	302:307	arg1	gum					283:285	Xanthan gum	275:285	Xanthan gum	275:285	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	38	theme	origin	302:307	arg1	gums					244:247	three polysaccharide gums	223:247	three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	223:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	39	theme	obtained	1210:1217	arg1	cytocompatible					1244:1257	cytocompatible	1244:1257	cytocompatible	1244:1257	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	8	39	theme	obtained	1210:1217	arg1	composites					1228:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	2	40	theme	zinc	353:356	arg1	nanoparticles					364:376	biosynthesized zinc oxide nanoparticles	338:376	biosynthesized zinc oxide nanoparticles	338:376	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	0	41	theme	gums	65:68	arg1	synthesis					6:14	Green synthesis	0:14	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums	0:68	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	9	42	theme	attractive	1483:1492	arg1	performance					1503:1513	attractive superior performance	1483:1513	attractive superior performance	1483:1513	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	8	43	from	range	1297:1301	arg1	cytocompatible					1244:1257	cytocompatible	1244:1257	cytocompatible	1244:1257	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	8	43	from	range	1297:1301	arg1	composites					1228:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	9	44	theme	in	1563:1564	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	44	theme	in	1563:1564	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	8	45	theme	L929	1262:1265	arg1	culture					1283:1289	L929 fibroblast cell culture	1262:1289	L929 fibroblast cell culture	1262:1289	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	6	46	theme	propolis	1018:1025	arg1	extract					1027:1033	propolis extract	1018:1033	propolis extract	1018:1033	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	1	47	theme	Guar	262:265	arg1	gum					267:269	Guar gum	262:269	Guar gum	262:269	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	47	theme	Guar	262:265	arg1	gums					244:247	three polysaccharide gums	223:247	three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	223:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	48	theme	cell	1278:1281	arg1	culture					1283:1289	L929 fibroblast cell culture	1262:1289	L929 fibroblast cell culture	1262:1289	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	6	49	theme	composites	977:986	arg1	hydrogels					988:996	all synthesized chitosan incorporated ZnO composites hydrogels	935:996	all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract	935:1033	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	9	50	theme	future	1556:1561	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	50	theme	future	1556:1561	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	6	51	theme	incorporated	960:971	arg1	hydrogels					988:996	all synthesized chitosan incorporated ZnO composites hydrogels	935:996	all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract	935:1033	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	3	52	theme	particular	614:623	arg1	interest					625:632	particular interest	614:632	particular interest	614:632	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	1	53	theme	oxide	197:201	arg1	nanoparticles					203:215	zinc oxide nanoparticles	192:215	zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	192:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	54	theme	MTT	1363:1365	arg1	assays					1402:1407	MTT, LDH and Live/Dead double staining assays	1363:1407	MTT, LDH and Live/Dead double staining assays	1363:1407	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	7	55	theme	tuneable	1183:1190	arg1	morphologies					1192:1203	its tuneable morphologies	1179:1203	its tuneable morphologies	1179:1203	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	9	56	theme	natural	1580:1586	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	56	theme	natural	1580:1586	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	8	57	theme	LDH	1368:1370	arg1	assays					1402:1407	MTT, LDH and Live/Dead double staining assays	1363:1407	MTT, LDH and Live/Dead double staining assays	1363:1407	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	1	58	theme	polysaccharide	229:242	arg1	gum					257:259	Acacia gum	250:259	Acacia gum	250:259	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	58	theme	polysaccharide	229:242	arg1	gum					267:269	Guar gum	262:269	Guar gum	262:269	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	58	theme	polysaccharide	229:242	arg1	gum					283:285	Xanthan gum	275:285	Xanthan gum	275:285	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	58	theme	polysaccharide	229:242	arg1	gums					244:247	three polysaccharide gums	223:247	three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	223:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	59	from	cytocompatible	1244:1257	arg1	culture					1283:1289	L929 fibroblast cell culture	1262:1289	L929 fibroblast cell culture	1262:1289	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	8	59	from	cytocompatible	1244:1257	arg1	range					1297:1301	a range	1295:1301	a range of concentrations between 50 and 1000 μg/mL	1295:1345	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	8	60	theme	Live/Dead	1376:1384	arg1	staining					1393:1400	Live/Dead double staining	1376:1400	Live/Dead double staining	1376:1400	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	7	61	theme	molecules	1141:1149	arg1	incorporation					1110:1122	the possible incorporation	1097:1122	the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies	1097:1203	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	9	62	theme	delivery	1611:1618	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	62	theme	delivery	1611:1618	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	8	63	theme	staining	1393:1400	arg1	assays					1402:1407	MTT, LDH and Live/Dead double staining assays	1363:1407	MTT, LDH and Live/Dead double staining assays	1363:1407	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	7	64	theme	various	1127:1133	arg1	molecules					1141:1149	various guest molecules	1127:1149	various guest molecules	1127:1149	The present study highlights the possible incorporation of various guest molecules into hydrogel matrix due to its tuneable morphologies.
35569685	1	65	theme	facile	146:151	arg1	methodology					170:180	A facile, green synthesis methodology	144:180	methodology	170:180	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	4	66	theme	thermal	772:778	arg1	analysis					780:787	thermal analysis	772:787	thermal analysis	772:787	The formation of ZnO nanoparticles using polysaccharide gums was confirmed by FTIR, XRD, UV-Vis spectroscopy, thermal analysis, SEM, Raman and photoluminescence spectroscopies.
35569685	0	67	theme	propolis	85:92	arg1	extract					94:100	propolis extract	85:100	propolis extract	85:100	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	9	68	theme	agents	1645:1650	arg1	platforms					1588:1596	future in vivo suitable natural platforms	1556:1596	future in vivo suitable natural platforms	1556:1596	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	68	theme	agents	1645:1650	arg1	systems					1620:1626	effective delivery systems	1601:1626	effective delivery systems of pharmacologic agents for biomedical applications	1601:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	9	69	theme	biomedical	1656:1665	arg1	applications					1667:1678	biomedical applications	1656:1678	biomedical applications	1656:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	0	70	theme	functional	111:120	arg1	biomaterials					130:141	novel functional natural biomaterials	105:141	novel functional natural biomaterials	105:141	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	4	71	theme	nanoparticles	683:695	arg1	formation					666:674	The formation	662:674	The formation of ZnO nanoparticles using polysaccharide gums	662:721	The formation of ZnO nanoparticles using polysaccharide gums was confirmed by FTIR, XRD, UV-Vis spectroscopy, thermal analysis, SEM, Raman and photoluminescence spectroscopies.
35569685	2	72	theme	sustainable	403:413	arg1	matrix					433:438	a sustainable chitosan hydrogel matrix	401:438	a sustainable chitosan hydrogel matrix functionalized with propolis extract	401:475	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	5	73	theme	obtained	868:875	arg1	hydrogels					877:885	obtained hydrogels	868:885	obtained hydrogels	868:885	The rheological behaviour of obtained hydrogels was evaluated.
35569685	0	74	theme	bioinspired	19:29	arg1	gums					65:68	bioinspired chitosan-ZnO-based polysaccharide gums	19:68	bioinspired chitosan-ZnO-based polysaccharide gums	19:68	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	2	75	theme	propolis	460:467	arg1	extract					469:475	propolis extract	460:475	propolis extract	460:475	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	0	76	theme	polysaccharide	50:63	arg1	gums					65:68	bioinspired chitosan-ZnO-based polysaccharide gums	19:68	bioinspired chitosan-ZnO-based polysaccharide gums	19:68	Green synthesis of bioinspired chitosan-ZnO-based polysaccharide gums hydrogels with propolis extract as novel functional natural biomaterials.
35569685	1	77	theme	biological	291:300	arg1	origin					302:307	biological origin	291:307	biological origin	291:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	78	theme	hydrogel	1219:1226	arg1	cytocompatible					1244:1257	cytocompatible	1244:1257	cytocompatible	1244:1257	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	8	78	theme	hydrogel	1219:1226	arg1	composites					1228:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites	1206:1237	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	2	79	theme	hydrogel	424:431	arg1	matrix					433:438	a sustainable chitosan hydrogel matrix	401:438	a sustainable chitosan hydrogel matrix functionalized with propolis extract	401:475	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	9	80	dep	in	1563:1564	arg1	vivo					1566:1569	vivo	1566:1569	vivo	1566:1569	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	2	81	theme	biosynthesized	338:351	arg1	nanoparticles					364:376	biosynthesized zinc oxide nanoparticles	338:376	biosynthesized zinc oxide nanoparticles	338:376	Subsequently, biosynthesized zinc oxide nanoparticles were incorporated into a sustainable chitosan hydrogel matrix functionalized with propolis extract.
35569685	9	82	theme	superior	1494:1501	arg1	performance					1503:1513	attractive superior performance	1483:1513	attractive superior performance	1483:1513	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
35569685	6	83	theme	AFM	906:908	arg1	studies					910:916	The AFM studies	902:916	The AFM studies	902:916	The AFM studies demonstrate that all synthesized chitosan incorporated ZnO composites hydrogels functionalized with propolis extract exhibit corrugated topographies.
35569685	1	84	dep	gums	244:247	arg1	gum					257:259	Acacia gum	250:259	Acacia gum	250:259	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	84	dep	gums	244:247	arg1	gum					267:269	Guar gum	262:269	Guar gum	262:269	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	84	dep	gums	244:247	arg1	gum					283:285	Xanthan gum	275:285	Xanthan gum	275:285	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	84	dep	gums	244:247	arg1	gums					244:247	three polysaccharide gums	223:247	three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	223:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	3	85	theme	selected	511:518	arg1	polysaccharides					520:534	the selected polysaccharides	507:534	the selected polysaccharides as chelates	507:546	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	1	86	theme	Acacia	250:255	arg1	gum					257:259	Acacia gum	250:259	Acacia gum	250:259	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	1	86	theme	Acacia	250:255	arg1	gums					244:247	three polysaccharide gums	223:247	three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin	223:307	A facile, green synthesis methodology to obtain zinc oxide nanoparticles using three polysaccharide gums (Acacia gum, Guar gum and Xanthan gum) of biological origin was developed.
35569685	8	87	theme	fibroblast	1267:1276	arg1	culture					1283:1289	L929 fibroblast cell culture	1262:1289	L929 fibroblast cell culture	1262:1289	The obtained hydrogel composites were cytocompatible in L929 fibroblast cell culture, in a range of concentrations between 50 and 1000 μg/mL, as assessed by MTT, LDH and Live/Dead double staining assays.
35569685	4	88	theme	polysaccharide	703:716	arg1	gums					718:721	polysaccharide gums	703:721	polysaccharide gums	703:721	The formation of ZnO nanoparticles using polysaccharide gums was confirmed by FTIR, XRD, UV-Vis spectroscopy, thermal analysis, SEM, Raman and photoluminescence spectroscopies.
35569685	4	89	theme	ZnO	679:681	arg1	nanoparticles					683:695	ZnO nanoparticles	679:695	ZnO nanoparticles using polysaccharide gums	679:721	The formation of ZnO nanoparticles using polysaccharide gums was confirmed by FTIR, XRD, UV-Vis spectroscopy, thermal analysis, SEM, Raman and photoluminescence spectroscopies.
35569685	3	90	with	nanoparticles	597:609	arg1	morphology					650:659	controlled morphology	639:659	controlled morphology	639:659	This study has revealed that the selected polysaccharides as chelates represents a suitable approach to synthesize ZnO nanoparticles of particular interest with controlled morphology.
35569685	9	91	theme	wide	1520:1523	arg1	range					1539:1543	a wide concentration range	1518:1543	a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications	1518:1678	By enhancing the biological properties, these novel green hydrogels show attractive superior performance in a wide concentration range to develop future in vivo suitable natural platforms as effective delivery systems of pharmacologic agents for biomedical applications.
37328468	5	0	from	NiV	716:718	arg1	divergence					700:709	sequence divergence	691:709	sequence divergence from NiV	691:718	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	4	1	theme	prefusion	553:561	arg1	structures					563:572	the prefusion structures	549:572	the prefusion structures of MojV and LayV F proteins	549:600	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	6	2	theme	LayV	896:899	arg1	F					901:901	LayV F	896:901	LayV F	896:901	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	8	3	theme	prototypical	1319:1330	arg1	HNVs					1332:1335	prototypical HNVs	1319:1335	prototypical HNVs	1319:1335	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	3	4	theme	human	508:512	arg1	health					514:519	human health	508:519	human health	508:519	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	6	5	theme	NiV	929:931	arg1	F					933:933	NiV F	929:933	NiV F	929:933	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	4	6	theme	electron	616:623	arg1	microscopy					625:634	cryogenic electron microscopy	606:634	cryogenic electron microscopy	606:634	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	7	7	dep	LayV	1082:1085	arg1	F					1096:1096	F	1096:1096	F	1096:1096	These findings explain the distinct antigenic profile of LayV and MojV F, despite the extent to which they are otherwise structurally similar to NiV.
37328468	4	8	theme	cryogenic	606:614	arg1	microscopy					625:634	cryogenic electron microscopy	606:634	cryogenic electron microscopy	606:634	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	2	9	theme	Mòjiāng	242:248	arg1	MojV					257:260	MojV	257:260	MojV	257:260	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	9	theme	Mòjiāng	242:248	arg1	virus					250:254	Mòjiāng virus	242:254	Mòjiāng virus (MojV)	242:261	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	4	10	theme	MojV	577:580	arg1	structures					563:572	the prefusion structures	549:572	the prefusion structures of MojV and LayV F proteins	549:600	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	3	11	theme	zoonosis	410:417	arg1	spillover					361:369	The spillover	357:369	The spillover of LayV	357:377	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	3	11	theme	zoonosis	410:417	arg1	instance					392:399	the first instance	382:399	the first instance of a HNV zoonosis to humans	382:427	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	8	12	from	HNVs	1332:1335	arg1	divergence					1303:1312	an antigenic, yet not structural, divergence	1269:1312	an antigenic, yet not structural, divergence from prototypical HNVs	1269:1335	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	4	13	theme	F	591:591	arg1	proteins					593:600	LayV F proteins	586:600	LayV F proteins	586:600	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	7	14	theme	MojV	1091:1094	arg1	profile					1071:1077	the distinct antigenic profile	1048:1077	the distinct antigenic profile of LayV and MojV F	1048:1096	These findings explain the distinct antigenic profile of LayV and MojV F, despite the extent to which they are otherwise structurally similar to NiV.
37328468	4	15	theme	LayV	586:589	arg1	proteins					593:600	LayV F proteins	586:600	LayV F proteins	586:600	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	6	16	contain	contains	939:946	arg2	glycan					950:955	a glycan	948:955	a glycan that shields a site of vulnerability previously identified for NiV	948:1022	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	6	16	contain	contains	939:946	arg1	it					936:937	it	936:937	it	936:937	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	2	17	theme	HeV	343:345	arg1	members					310:316	the bat-borne HNV members	292:316	the bat-borne HNV members	292:316	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	17	theme	HeV	343:345	arg1	viruses					348:354	Hendra (HeV) viruses	335:354	Hendra (HeV) viruses	335:354	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	1	18	theme	novel	92:96	arg1	HNV					111:113	HNV	111:113	HNV	111:113	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	1	18	theme	novel	92:96	arg1	henipavirus					98:108	a novel henipavirus	90:108	a novel henipavirus (HNV) named Langya virus (LayV)	90:140	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	2	19	theme	Hendra	335:340	arg1	members					310:316	the bat-borne HNV members	292:316	the bat-borne HNV members	292:316	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	19	theme	Hendra	335:340	arg1	viruses					348:354	Hendra (HeV) viruses	335:354	Hendra (HeV) viruses	335:354	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	8	20	contain	carry	1187:1191	arg2	implications					1193:1204	implications	1193:1204	implications for broad-spectrum HNV vaccines and therapeutics	1193:1253	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	8	20	contain	carry	1187:1191	arg1	results					1179:1185	Our results	1175:1185	Our results	1175:1185	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	6	21	theme	vulnerability	980:992	arg1	vulnerability					980:992	vulnerability	980:992	vulnerability	980:992	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	6	21	theme	vulnerability	980:992	arg1	site					972:975	a site	970:975	a site of vulnerability previously identified for NiV	970:1022	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	4	22	theme	proteins	593:600	arg1	structures					563:572	the prefusion structures	549:572	the prefusion structures of MojV and LayV F proteins	549:600	In this work, we determine the prefusion structures of MojV and LayV F proteins via cryogenic electron microscopy to 2.66 and 3.37 Å, respectively.
37328468	1	23	theme	Langya	122:127	arg1	virus					129:133	Langya virus	122:133	Langya virus (LayV)	122:140	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	1	23	theme	Langya	122:127	arg1	LayV					136:139	LayV	136:139	LayV	136:139	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	0	24	theme	Henipavirus	40:50	arg1	glycoproteins					59:71	divergent Henipavirus fusion glycoproteins	30:71	divergent Henipavirus fusion glycoproteins	30:71	Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
37328468	5	25	theme	similar	753:759	arg1	structure					761:769	an overall similar structure	742:769	an overall similar structure	742:769	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	1	26	with	patients	160:167	arg1	disease					191:197	severe pneumonic disease	174:197	severe pneumonic disease in China	174:206	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	5	27	theme	sequence	691:698	arg1	divergence					700:709	sequence divergence	691:709	sequence divergence from NiV	691:718	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	1	28	theme	severe	174:179	arg1	disease					191:197	severe pneumonic disease	174:197	severe pneumonic disease in China	174:206	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	0	29	theme	divergent	30:38	arg1	glycoproteins					59:71	divergent Henipavirus fusion glycoproteins	30:71	divergent Henipavirus fusion glycoproteins	30:71	Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
37328468	8	30	theme	antigenic	1272:1280	arg1	divergence					1303:1312	an antigenic, yet not structural, divergence	1269:1312	an antigenic, yet not structural, divergence from prototypical HNVs	1269:1335	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	3	31	theme	continuing	470:479	arg1	threat					481:486	the continuing threat	466:486	the continuing threat this genus poses to human health	466:519	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	1	32	theme	pneumonic	181:189	arg1	disease					191:197	severe pneumonic disease	174:197	severe pneumonic disease in China	174:206	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	0	33	theme	glycoproteins	59:71	arg1	antigenicity					14:25	antigenicity	14:25	antigenicity	14:25	Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
37328468	0	33	theme	glycoproteins	59:71	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
37328468	5	34	theme	F	725:725	arg1	distinct					793:800	distinct	793:800	distinct	793:800	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	5	34	theme	F	725:725	arg1	proteins					727:734	the F proteins	721:734	the F proteins	721:734	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	1	35	attach	isolated	146:153	arg2	henipavirus					98:108	a novel henipavirus	90:108	a novel henipavirus (HNV) named Langya virus (LayV)	90:140	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	1	35	attach	isolated	146:153	arg2	HNV					111:113	HNV	111:113	HNV	111:113	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	1	35	attach	isolated	146:153	arg1	patients					160:167	patients	160:167	patients with severe pneumonic disease in China	160:206	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	8	36	theme	HNV	1225:1227	arg1	vaccines					1229:1236	broad-spectrum HNV vaccines	1210:1236	broad-spectrum HNV vaccines	1210:1236	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	2	37	from	members	310:316	arg1	divergent					277:285	divergent	277:285	divergent	277:285	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	5	38	theme	overall	745:751	arg1	structure					761:769	an overall similar structure	742:769	an overall similar structure	742:769	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	0	39	theme	fusion	52:57	arg1	glycoproteins					59:71	divergent Henipavirus fusion glycoproteins	30:71	divergent Henipavirus fusion glycoproteins	30:71	Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
37328468	6	40	gly	glycosylated	911:922	arg1	F					901:901	LayV F	896:901	LayV F	896:901	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	8	41	theme	broad-spectrum	1210:1223	arg1	vaccines					1229:1236	broad-spectrum HNV vaccines	1210:1236	broad-spectrum HNV vaccines	1210:1236	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	3	42	theme	first	386:390	arg1	spillover					361:369	The spillover	357:369	The spillover of LayV	357:377	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	3	42	theme	first	386:390	arg1	instance					392:399	the first instance	382:399	the first instance of a HNV zoonosis to humans	382:427	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	7	43	theme	LayV	1082:1085	arg1	profile					1071:1077	the distinct antigenic profile	1048:1077	the distinct antigenic profile of LayV and MojV F	1048:1096	These findings explain the distinct antigenic profile of LayV and MojV F, despite the extent to which they are otherwise structurally similar to NiV.
37328468	1	44	from	disease	191:197	arg1	China					202:206	China	202:206	China	202:206	In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China.
37328468	3	45	theme	LayV	374:377	arg1	spillover					361:369	The spillover	357:369	The spillover of LayV	357:377	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	3	45	theme	LayV	374:377	arg1	instance					392:399	the first instance	382:399	the first instance of a HNV zoonosis to humans	382:427	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	8	46	theme	structural	1291:1300	arg1	divergence					1303:1312	an antigenic, yet not structural, divergence	1269:1312	an antigenic, yet not structural, divergence from prototypical HNVs	1269:1335	Our results carry implications for broad-spectrum HNV vaccines and therapeutics, and indicate an antigenic, yet not structural, divergence from prototypical HNVs.
37328468	5	47	theme	known	826:830	arg1	antibodies					832:841	known antibodies	826:841	known antibodies	826:841	We show that despite sequence divergence from NiV, the F proteins adopt an overall similar structure but are antigenically distinct as they do not react to known antibodies or sera.
37328468	2	48	theme	bat-borne	296:304	arg1	Nipah					319:323	Nipah	319:323	Nipah	319:323	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	48	theme	bat-borne	296:304	arg1	members					310:316	the bat-borne HNV members	292:316	the bat-borne HNV members	292:316	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	48	theme	bat-borne	296:304	arg1	viruses					348:354	Hendra (HeV) viruses	335:354	Hendra (HeV) viruses	335:354	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	6	49	theme	Glycoproteomic	852:865	arg1	analysis					867:874	Glycoproteomic analysis	852:874	Glycoproteomic analysis	852:874	Glycoproteomic analysis revealed that while LayV F is less glycosylated than NiV F, it contains a glycan that shields a site of vulnerability previously identified for NiV.
37328468	3	50	dep	threat	481:486	arg1	poses					499:503	poses	499:503	poses to human health	499:519	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	2	51	theme	HNV	306:308	arg1	Nipah					319:323	Nipah	319:323	Nipah	319:323	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	51	theme	HNV	306:308	arg1	members					310:316	the bat-borne HNV members	292:316	the bat-borne HNV members	292:316	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	2	51	theme	HNV	306:308	arg1	viruses					348:354	Hendra (HeV) viruses	335:354	Hendra (HeV) viruses	335:354	This virus is closely related to Mòjiāng virus (MojV), and both are divergent from the bat-borne HNV members, Nipah (NiV) and Hendra (HeV) viruses.
37328468	7	52	theme	distinct	1052:1059	arg1	profile					1071:1077	the distinct antigenic profile	1048:1077	the distinct antigenic profile of LayV and MojV F	1048:1096	These findings explain the distinct antigenic profile of LayV and MojV F, despite the extent to which they are otherwise structurally similar to NiV.
37328468	0	53	gly	glycoproteins	59:71	arg1	glycoproteins					59:71	divergent Henipavirus fusion glycoproteins	30:71	divergent Henipavirus fusion glycoproteins	30:71	Structure and antigenicity of divergent Henipavirus fusion glycoproteins.
37328468	3	54	theme	HNV	406:408	arg1	zoonosis					410:417	a HNV zoonosis	404:417	a HNV zoonosis	404:417	The spillover of LayV is the first instance of a HNV zoonosis to humans outside of NiV and HeV, highlighting the continuing threat this genus poses to human health.
37328468	7	55	theme	antigenic	1061:1069	arg1	profile					1071:1077	the distinct antigenic profile	1048:1077	the distinct antigenic profile of LayV and MojV F	1048:1096	These findings explain the distinct antigenic profile of LayV and MojV F, despite the extent to which they are otherwise structurally similar to NiV.
36791651	0	0	theme	quantitative	107:118	arg1	analysis					120:127	multi-chromatography-based qualitative and quantitative analysis	64:127	multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules	64:166	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	8	1	from	molecules	1286:1294	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	4	2	from	polysaccharides	738:752	arg1	CFF					800:802	CFF	800:802	CFF	800:802	In this study, a strategy integrating HPGPC-ELSD, HPLC-PDA, UV-VIS and UPLC-QTOF-MS/MS was firstly developed to simultaneously qualify and quantify polysaccharides, as well as representative small molecules in CFF.
36791651	8	3	theme	molecular	1223:1231	arg1	weights					1233:1239	the relative molecular weights	1210:1239	the relative molecular weights	1210:1239	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	8	3	theme	molecular	1223:1231	arg1	similar					1363:1369	similar	1363:1369	similar	1363:1369	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	10	4	from	contents	1602:1609	arg1	samples					1635:1641	CM-CFF samples	1628:1641	CM-CFF samples	1628:1641	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	11	5	theme	evaluation	1752:1761	arg1	strategy					1763:1770	the proposed evaluation strategy	1739:1770	the proposed evaluation strategy	1739:1770	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	11	5	theme	evaluation	1752:1761	arg1	approach					1804:1811	a potential approach	1792:1811	a potential approach for the quality control of CFF	1792:1842	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	1	6	theme	common	266:271	arg1	Folium					192:197	Callicarpae Formosanae Folium	169:197	Callicarpae Formosanae Folium (CFF)	169:203	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	6	theme	common	266:271	arg1	herb					291:294	a common Chinese medicinal herb	264:294	a common Chinese medicinal herb used for the treatment of hematemesis	264:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	11	7	theme	quality	1821:1827	arg1	control					1829:1835	the quality control	1817:1835	the quality control of CFF	1817:1842	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	10	8	theme	terponoids	1614:1623	arg1	luteolin					1561:1568	luteolin	1561:1568	luteolin	1561:1568	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	8	theme	terponoids	1614:1623	arg1	acid					1579:1582	ursolic acid	1571:1582	ursolic acid	1571:1582	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	8	theme	terponoids	1614:1623	arg1	polysaccharides					1544:1558	polysaccharides	1544:1558	polysaccharides	1544:1558	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	8	theme	terponoids	1614:1623	arg1	contents					1602:1609	total contents	1596:1609	total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent	1596:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	3	9	theme	CFF	585:587	arg1	evaluation					571:580	quality consistency evaluation	551:580	quality consistency evaluation	551:580	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	3	9	theme	CFF	585:587	arg1	method					540:545	holistic quality method	523:545	holistic quality method	523:545	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	1	10	theme	Chinese	273:279	arg1	Folium					192:197	Callicarpae Formosanae Folium	169:197	Callicarpae Formosanae Folium (CFF)	169:203	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	10	theme	Chinese	273:279	arg1	herb					291:294	a common Chinese medicinal herb	264:294	a common Chinese medicinal herb used for the treatment of hematemesis	264:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	6	11	used	used	995:998	arg2	UV-VIS					984:989	UV-VIS	984:989	UV-VIS	984:989	UV-VIS was used to determine the total polysaccharides content, and UPLC-QTOF-MS/MS was established to characterize the small molecules.
36791651	9	12	theme	small	1386:1390	arg1	molecules					1392:1400	32 small molecules	1383:1400	32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids	1383:1461	A total of 32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids were characterized in CFF.
36791651	9	12	theme	small	1386:1390	arg1	phenylpropanoids					1414:1429	6 phenylpropanoids	1412:1429	6 phenylpropanoids	1412:1429	A total of 32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids were characterized in CFF.
36791651	9	12	theme	small	1386:1390	arg1	flavonoids					1434:1443	7 flavonoids	1432:1443	7 flavonoids	1432:1443	A total of 32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids were characterized in CFF.
36791651	9	12	theme	small	1386:1390	arg1	terpenoids					1452:1461	19 terpenoids	1449:1461	19 terpenoids	1449:1461	A total of 32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids were characterized in CFF.
36791651	10	13	theme	ursolic	1571:1577	arg1	acid					1579:1582	ursolic acid	1571:1582	ursolic acid	1571:1582	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	13	theme	ursolic	1571:1577	arg1	polysaccharides					1544:1558	polysaccharides	1544:1558	polysaccharides	1544:1558	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	12	14	theme	GAP	1920:1922	arg1	base					1925:1928	Good Agriculture Practice (GAP) base	1893:1928	Good Agriculture Practice (GAP) base	1893:1928	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	1	15	theme	Callicarpae	169:179	arg1	Folium					192:197	Callicarpae Formosanae Folium	169:197	Callicarpae Formosanae Folium (CFF)	169:203	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	15	theme	Callicarpae	169:179	arg1	herb					291:294	a common Chinese medicinal herb	264:294	a common Chinese medicinal herb used for the treatment of hematemesis	264:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	15	theme	Callicarpae	169:179	arg1	CFF					200:202	CFF	200:202	CFF	200:202	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	10	16	theme	CM-CFF	1628:1633	arg1	samples					1635:1641	CM-CFF samples	1628:1641	CM-CFF samples	1628:1641	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	9	17	theme	molecules	1392:1400	arg1	total					1374:1378	A total	1372:1378	A total of 32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids	1372:1461	A total of 32 small molecules including 6 phenylpropanoids, 7 flavonoids and 19 terpenoids were characterized in CFF.
36791651	8	18	dep	weights	1233:1239	arg1	composition					1296:1306	composition	1296:1306	composition	1296:1306	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	3	19	theme	scientific	489:498	arg1	information					500:510	limited scientific information	481:510	limited scientific information concerning holistic quality method and quality consistency evaluation of CFF	481:587	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	0	20	theme	polysaccharides	132:146	arg1	analysis					120:127	multi-chromatography-based qualitative and quantitative analysis	64:127	multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules	64:166	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	5	21	theme	weight	858:863	arg1	distribution					865:876	the molecular weight distribution	844:876	the molecular weight distribution of polysaccharides	844:895	HPGPC-ELSD was applied to characterize the molecular weight distribution of polysaccharides, HPLC-PDA was developed to qualitatively and quantitatively determine monosaccharides.
36791651	6	22	theme	total	1017:1021	arg1	content					1039:1045	the total polysaccharides content	1013:1045	the total polysaccharides content	1013:1045	UV-VIS was used to determine the total polysaccharides content, and UPLC-QTOF-MS/MS was established to characterize the small molecules.
36791651	0	23	theme	quality	9:15	arg1	evaluation					17:26	Holistic quality evaluation	0:26	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.	0:167	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	10	24	theme	total	1596:1600	arg1	polysaccharides					1544:1558	polysaccharides	1544:1558	polysaccharides	1544:1558	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	24	theme	total	1596:1600	arg1	contents					1602:1609	total contents	1596:1609	total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent	1596:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	12	25	theme	processing	1943:1952	arg1	method					1954:1959	standard processing method	1934:1959	standard processing method	1934:1959	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	8	26	theme	relative	1214:1221	arg1	weights					1233:1239	the relative molecular weights	1210:1239	the relative molecular weights	1210:1239	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	8	26	theme	relative	1214:1221	arg1	similar					1363:1369	similar	1363:1369	similar	1363:1369	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	0	27	theme	Holistic	0:7	arg1	evaluation					17:26	Holistic quality evaluation	0:26	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.	0:167	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	10	28	theme	holistic	1667:1674	arg1	quality					1676:1682	the holistic quality	1663:1682	the holistic quality of CM-CFF	1663:1692	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	28	theme	holistic	1667:1674	arg1	inconsistent					1698:1709	inconsistent	1698:1709	inconsistent	1698:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	29	from	samples	1635:1641	arg1	luteolin					1561:1568	luteolin	1561:1568	luteolin	1561:1568	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	29	from	samples	1635:1641	arg1	acid					1579:1582	ursolic acid	1571:1582	ursolic acid	1571:1582	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	29	from	samples	1635:1641	arg1	polysaccharides					1544:1558	polysaccharides	1544:1558	polysaccharides	1544:1558	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	29	from	samples	1635:1641	arg1	contents					1602:1609	total contents	1596:1609	total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent	1596:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	4	30	from	molecules	787:795	arg1	CFF					800:802	CFF	800:802	CFF	800:802	In this study, a strategy integrating HPGPC-ELSD, HPLC-PDA, UV-VIS and UPLC-QTOF-MS/MS was firstly developed to simultaneously qualify and quantify polysaccharides, as well as representative small molecules in CFF.
36791651	4	31	theme	small	781:785	arg1	molecules					787:795	representative small molecules	766:795	representative small molecules in CFF	766:802	In this study, a strategy integrating HPGPC-ELSD, HPLC-PDA, UV-VIS and UPLC-QTOF-MS/MS was firstly developed to simultaneously qualify and quantify polysaccharides, as well as representative small molecules in CFF.
36791651	8	32	theme	SC-CFF	1342:1347	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	8	33	theme	compositional	1246:1258	arg1	similar					1363:1369	similar	1363:1369	similar	1363:1369	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	8	33	theme	compositional	1246:1258	arg1	monosaccharides					1260:1274	the compositional monosaccharides	1242:1274	the compositional monosaccharides	1242:1274	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	0	34	theme	molecules	158:166	arg1	analysis					120:127	multi-chromatography-based qualitative and quantitative analysis	64:127	multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules	64:166	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	8	35	theme	CM-CFF	1311:1316	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	3	36	theme	limited	481:487	arg1	information					500:510	limited scientific information	481:510	limited scientific information concerning holistic quality method and quality consistency evaluation of CFF	481:587	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	2	37	theme	CFF	458:460	arg1	polysaccharides					413:427	polysaccharides	413:427	polysaccharides	413:427	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	37	theme	CFF	458:460	arg1	flavonoids					386:395	flavonoids	386:395	flavonoids	386:395	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	37	theme	CFF	458:460	arg1	terpenoids					398:407	terpenoids	398:407	terpenoids	398:407	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	37	theme	CFF	458:460	arg1	ingredients					443:453	the main ingredients	434:453	the main ingredients of CFF	434:460	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	37	theme	CFF	458:460	arg1	phenylpropanoids					368:383	phenylpropanoids	368:383	phenylpropanoids	368:383	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	0	38	theme	small	152:156	arg1	molecules					158:166	small molecules	152:166	small molecules	152:166	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	8	39	from	weights	1233:1239	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	3	40	theme	quality	551:557	arg1	evaluation					571:580	quality consistency evaluation	551:580	quality consistency evaluation	551:580	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	0	41	theme	Formosanae	43:52	arg1	Folium					54:59	Callicarpae Formosanae Folium	31:59	Callicarpae Formosanae Folium	31:59	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	7	42	theme	CFF	1159:1161	arg1	consistency					1133:1143	The quality consistency	1121:1143	The quality consistency of commercial CFF (CM-CFF)	1121:1170	The quality consistency of commercial CFF (CM-CFF) was also evaluated.
36791651	11	43	theme	proposed	1743:1750	arg1	strategy					1763:1770	the proposed evaluation strategy	1739:1770	the proposed evaluation strategy	1739:1770	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	11	43	theme	proposed	1743:1750	arg1	approach					1804:1811	a potential approach	1792:1811	a potential approach for the quality control of CFF	1792:1842	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	2	44	theme	main	438:441	arg1	polysaccharides					413:427	polysaccharides	413:427	polysaccharides	413:427	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	44	theme	main	438:441	arg1	flavonoids					386:395	flavonoids	386:395	flavonoids	386:395	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	44	theme	main	438:441	arg1	terpenoids					398:407	terpenoids	398:407	terpenoids	398:407	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	44	theme	main	438:441	arg1	ingredients					443:453	the main ingredients	434:453	the main ingredients of CFF	434:460	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	2	44	theme	main	438:441	arg1	phenylpropanoids					368:383	phenylpropanoids	368:383	phenylpropanoids	368:383	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	0	45	theme	Callicarpae	31:41	arg1	Folium					54:59	Callicarpae Formosanae Folium	31:59	Callicarpae Formosanae Folium	31:59	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	11	46	theme	CFF	1840:1842	arg1	control					1829:1835	the quality control	1817:1835	the quality control of CFF	1817:1842	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	10	47	from	terponoids	1614:1623	arg1	samples					1635:1641	CM-CFF samples	1628:1641	CM-CFF samples	1628:1641	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	11	48	theme	potential	1794:1802	arg1	strategy					1763:1770	the proposed evaluation strategy	1739:1770	the proposed evaluation strategy	1739:1770	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	11	48	theme	potential	1794:1802	arg1	approach					1804:1811	a potential approach	1792:1811	a potential approach for the quality control of CFF	1792:1842	The results suggested that the proposed evaluation strategy could be applied as a potential approach for the quality control of CFF.
36791651	12	49	theme	CM-CFF	1864:1869	arg1	quality					1853:1859	the quality	1849:1859	the quality of CM-CFF	1849:1869	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	1	50	theme	Callicarpa	233:242	arg1	Rolfe					254:258	Callicarpa formosana Rolfe	233:258	Callicarpa formosana Rolfe	233:258	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	8	51	theme	self-collected	1322:1335	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	6	52	theme	polysaccharides	1023:1037	arg1	content					1039:1045	the total polysaccharides content	1013:1045	the total polysaccharides content	1013:1045	UV-VIS was used to determine the total polysaccharides content, and UPLC-QTOF-MS/MS was established to characterize the small molecules.
36791651	5	53	theme	molecular	848:856	arg1	distribution					865:876	the molecular weight distribution	844:876	the molecular weight distribution of polysaccharides	844:895	HPGPC-ELSD was applied to characterize the molecular weight distribution of polysaccharides, HPLC-PDA was developed to qualitatively and quantitatively determine monosaccharides.
36791651	1	54	attach	derived	206:212	arg2	CFF					200:202	CFF	200:202	CFF	200:202	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	54	attach	derived	206:212	arg2	herb					291:294	a common Chinese medicinal herb	264:294	a common Chinese medicinal herb used for the treatment of hematemesis	264:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	54	attach	derived	206:212	arg2	Folium					192:197	Callicarpae Formosanae Folium	169:197	Callicarpae Formosanae Folium (CFF)	169:203	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	54	attach	derived	206:212	arg1	the					219:221	the	219:221	the	219:221	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	12	55	theme	Agriculture	1898:1908	arg1	base					1925:1928	Good Agriculture Practice (GAP) base	1893:1928	Good Agriculture Practice (GAP) base	1893:1928	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	3	56	theme	holistic	523:530	arg1	method					540:545	holistic quality method	523:545	holistic quality method	523:545	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	0	57	theme	Folium	54:59	arg1	evaluation					17:26	Holistic quality evaluation	0:26	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.	0:167	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	1	58	theme	hematemesis	322:332	arg1	treatment					309:317	the treatment	305:317	the treatment of hematemesis	305:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	7	59	theme	commercial	1148:1157	arg1	CM-CFF					1164:1169	CM-CFF	1164:1169	CM-CFF	1164:1169	The quality consistency of commercial CFF (CM-CFF) was also evaluated.
36791651	7	59	theme	commercial	1148:1157	arg1	CFF					1159:1161	commercial CFF	1148:1161	commercial CFF (CM-CFF)	1148:1170	The quality consistency of commercial CFF (CM-CFF) was also evaluated.
36791651	8	60	from	monosaccharides	1260:1274	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	10	61	theme	polysaccharides	1544:1558	arg1	content					1533:1539	the content	1529:1539	the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent	1529:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	3	62	theme	quality	532:538	arg1	method					540:545	holistic quality method	523:545	holistic quality method	523:545	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	10	63	theme	CM-CFF	1687:1692	arg1	quality					1676:1682	the holistic quality	1663:1682	the holistic quality of CM-CFF	1663:1692	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	63	theme	CM-CFF	1687:1692	arg1	inconsistent					1698:1709	inconsistent	1698:1709	inconsistent	1698:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	8	64	theme	small	1280:1284	arg1	molecules					1286:1294	small molecules	1280:1294	small molecules	1280:1294	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	7	65	theme	quality	1125:1131	arg1	consistency					1133:1143	The quality consistency	1121:1143	The quality consistency of commercial CFF (CM-CFF)	1121:1170	The quality consistency of commercial CFF (CM-CFF) was also evaluated.
36791651	12	66	theme	standard	1934:1941	arg1	method					1954:1959	standard processing method	1934:1959	standard processing method	1934:1959	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	4	67	theme	representative	766:779	arg1	molecules					787:795	representative small molecules	766:795	representative small molecules in CFF	766:802	In this study, a strategy integrating HPGPC-ELSD, HPLC-PDA, UV-VIS and UPLC-QTOF-MS/MS was firstly developed to simultaneously qualify and quantify polysaccharides, as well as representative small molecules in CFF.
36791651	1	68	theme	formosana	244:252	arg1	Rolfe					254:258	Callicarpa formosana Rolfe	233:258	Callicarpa formosana Rolfe	233:258	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	12	69	theme	Good	1893:1896	arg1	base					1925:1928	Good Agriculture Practice (GAP) base	1893:1928	Good Agriculture Practice (GAP) base	1893:1928	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	2	70	theme	Phytochemical	335:347	arg1	studies					349:355	Phytochemical studies	335:355	Phytochemical studies	335:355	Phytochemical studies found that phenylpropanoids, flavonoids, terpenoids and polysaccharides were the main ingredients of CFF.
36791651	1	71	theme	medicinal	281:289	arg1	Folium					192:197	Callicarpae Formosanae Folium	169:197	Callicarpae Formosanae Folium (CFF)	169:203	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	71	theme	medicinal	281:289	arg1	herb					291:294	a common Chinese medicinal herb	264:294	a common Chinese medicinal herb used for the treatment of hematemesis	264:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	10	72	from	luteolin	1561:1568	arg1	samples					1635:1641	CM-CFF samples	1628:1641	CM-CFF samples	1628:1641	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	0	73	theme	qualitative	91:101	arg1	analysis					120:127	multi-chromatography-based qualitative and quantitative analysis	64:127	multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules	64:166	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	10	74	located	observed	1517:1524	arg2	variation					1503:1511	the variation	1499:1511	the variation	1499:1511	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	10	74	located	observed	1517:1524	arg1	content					1533:1539	the content	1529:1539	the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent	1529:1709	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	1	75	dep	the	219:221	arg1	leaves					223:228	leaves	223:228	leaves	223:228	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	76	theme	Formosanae	181:190	arg1	Folium					192:197	Callicarpae Formosanae Folium	169:197	Callicarpae Formosanae Folium (CFF)	169:203	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	76	theme	Formosanae	181:190	arg1	herb					291:294	a common Chinese medicinal herb	264:294	a common Chinese medicinal herb used for the treatment of hematemesis	264:332	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	1	76	theme	Formosanae	181:190	arg1	CFF					200:202	CFF	200:202	CFF	200:202	Callicarpae Formosanae Folium (CFF), derived from the leaves of Callicarpa formosana Rolfe, is a common Chinese medicinal herb used for the treatment of hematemesis.
36791651	8	77	theme	CFF	1337:1339	arg1	samples					1350:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	CM-CFF and self-collected CFF (SC-CFF) samples	1311:1356	It was shown that the relative molecular weights, the compositional monosaccharides and small molecules composition in CM-CFF and self-collected CFF (SC-CFF) samples were similar.
36791651	10	78	from	acid	1579:1582	arg1	samples					1635:1641	CM-CFF samples	1628:1641	CM-CFF samples	1628:1641	However, the variation was observed in the content of polysaccharides, luteolin, ursolic acid, as well as total contents of terponoids in CM-CFF samples, which implied that the holistic quality of CM-CFF was inconsistent.
36791651	0	79	theme	multi-chromatography-based	64:89	arg1	analysis					120:127	multi-chromatography-based qualitative and quantitative analysis	64:127	multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules	64:166	Holistic quality evaluation of Callicarpae Formosanae Folium by multi-chromatography-based qualitative and quantitative analysis of polysaccharides and small molecules.
36791651	12	80	theme	Practice	1910:1917	arg1	base					1925:1928	Good Agriculture Practice (GAP) base	1893:1928	Good Agriculture Practice (GAP) base	1893:1928	And the quality of CM-CFF should be improved by Good Agriculture Practice (GAP) base and standard processing method.
36791651	5	81	theme	polysaccharides	881:895	arg1	distribution					865:876	the molecular weight distribution	844:876	the molecular weight distribution of polysaccharides	844:895	HPGPC-ELSD was applied to characterize the molecular weight distribution of polysaccharides, HPLC-PDA was developed to qualitatively and quantitatively determine monosaccharides.
36791651	3	82	theme	consistency	559:569	arg1	evaluation					571:580	quality consistency evaluation	551:580	quality consistency evaluation	551:580	However, there is limited scientific information concerning holistic quality method and quality consistency evaluation of CFF.
36791651	6	83	theme	small	1104:1108	arg1	molecules					1110:1118	the small molecules	1100:1118	the small molecules	1100:1118	UV-VIS was used to determine the total polysaccharides content, and UPLC-QTOF-MS/MS was established to characterize the small molecules.
37330093	2	0	theme	intracellular	494:506	arg1	polysaccharides					508:522	intracellular polysaccharides	494:522	intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae	494:588	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	0	theme	intracellular	494:506	arg1	IPS					525:527	IPS	525:527	IPS	525:527	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	7	1	theme	structure-function	1482:1499	arg1	relationship					1501:1512	a critical structure-function relationship	1471:1512	a critical structure-function relationship for IPS	1471:1520	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	3	2	theme	mycelial	747:754	arg1	17.22 ± 0.29 g/L					765:780	17.22 ± 0.29 g/L	765:780	17.22 ± 0.29 g/L	765:780	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	3	2	theme	mycelial	747:754	arg1	biomass					756:762	the highest mycelial biomass	735:762	the highest mycelial biomass (17.22 ± 0.29 g/L)	735:781	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	4	3	theme	structural	930:939	arg1	characterization					941:956	structural characterization	930:956	structural characterization	930:956	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	7	4	theme	aruicula-judae	1579:1592	arg1	mycelia					1594:1600	liquid-fermented A. aruicula-judae mycelia	1559:1600	liquid-fermented A. aruicula-judae mycelia	1559:1600	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	7	5	theme	functional	1617:1626	arg1	production					1633:1642	functional food production	1617:1642	functional food production	1617:1642	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	6	6	theme	IPS	1397:1399	arg1	related					1416:1422	related	1416:1422	related	1416:1422	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	6	theme	IPS	1397:1399	arg1	activity					1385:1392	the protective activity	1370:1392	the protective activity of IPS	1370:1399	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	3	7	theme	carbon	712:717	arg1	source					719:724	the carbon source	708:724	the carbon source	708:724	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	3	7	theme	carbon	712:717	arg1	glucose					697:703	glucose	697:703	glucose	697:703	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	0	8	from	characterization	63:78	arg1	auricula-judae					111:124	Auricularia auricula-judae	99:124	Auricularia auricula-judae	99:124	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	6	9	theme	biomass	1225:1231	arg1	r = 0.97					1234:1241	mycelial biomass (r = 0.97) and IPS yield	1216:1256	r = 0.97	1234:1241	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	9	theme	biomass	1225:1231	arg1	r = 1.00					1259:1266	r = 1.00	1259:1266	r = 1.00	1259:1266	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	2	10	from	characterization	455:470	arg1	biomass					416:422	mycelial biomass	407:422	mycelial biomass	407:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	6	11	theme	antioxidant	1280:1290	arg1	activities					1292:1301	IPS antioxidant activities	1276:1301	IPS antioxidant activities	1276:1301	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	12	theme	mycelial	1216:1223	arg1	r = 0.97					1234:1241	mycelial biomass (r = 0.97) and IPS yield	1216:1256	r = 0.97	1234:1241	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	12	theme	mycelial	1216:1223	arg1	r = 1.00					1259:1266	r = 1.00	1259:1266	r = 1.00	1259:1266	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	4	13	theme	IPSs	977:980	arg1	compositions					916:927	monosaccharide compositions	901:927	monosaccharide compositions	901:927	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	4	13	theme	IPSs	977:980	arg1	characterization					941:956	structural characterization	930:956	structural characterization	930:956	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	4	13	theme	IPSs	977:980	arg1	activities					963:972	activities	963:972	activities	963:972	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	4	13	theme	IPSs	977:980	arg1	distributions					886:898	the molecular weight (Mw) distributions	860:898	the molecular weight (Mw) distributions	860:898	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	0	14	from	production	51:60	arg1	auricula-judae					111:124	Auricularia auricula-judae	99:124	Auricularia auricula-judae	99:124	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	6	15	theme	IPS	1276:1278	arg1	activities					1292:1301	IPS antioxidant activities	1276:1301	IPS antioxidant activities	1276:1301	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	1	16	theme	essential	188:196	arg1	factor					198:203	an essential factor	185:203	an essential factor for submerged culture	185:225	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	1	16	theme	essential	188:196	arg1	source					177:182	The carbon source	166:182	The carbon source	166:182	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	0	17	theme	biomass	9:15	arg1	production					51:60	Mycelial biomass and intracellular polysaccharides production	0:60	Mycelial biomass and intracellular polysaccharides production	0:60	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	3	18	theme	highest	739:745	arg1	17.22 ± 0.29 g/L					765:780	17.22 ± 0.29 g/L	765:780	17.22 ± 0.29 g/L	765:780	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	3	18	theme	highest	739:745	arg1	biomass					756:762	the highest mycelial biomass	735:762	the highest mycelial biomass (17.22 ± 0.29 g/L)	735:781	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	4	19	theme	weight	874:879	arg1	distributions					886:898	the molecular weight (Mw) distributions	860:898	the molecular weight (Mw) distributions	860:898	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	5	20	theme	carbon	1016:1021	arg1	source					1023:1028	the carbon source	1012:1028	the carbon source	1012:1028	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	2	21	theme	carbon	337:342	arg1	mannose					395:401	mannose	395:401	mannose	395:401	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	21	theme	carbon	337:342	arg1	fructose					372:379	fructose	372:379	fructose	372:379	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	21	theme	carbon	337:342	arg1	sources					344:350	carbon sources	337:350	carbon sources	337:350	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	21	theme	carbon	337:342	arg1	glucose					363:369	glucose	363:369	glucose	363:369	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	21	theme	carbon	337:342	arg1	sucrose					382:388	sucrose	382:388	sucrose	382:388	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	5	22	theme	alloxan-damaged	1122:1136	arg1	cells					1144:1148	alloxan-damaged islet cells	1122:1148	alloxan-damaged islet cells	1122:1148	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	0	23	theme	Mycelial	0:7	arg1	biomass					9:15	Mycelial biomass	0:15	Mycelial biomass	0:15	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	4	24	theme	molecular	864:872	arg1	Mw					882:883	Mw	882:883	Mw	882:883	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	4	24	theme	molecular	864:872	arg1	weight					874:879	molecular weight	864:879	the molecular weight (Mw) distributions	860:898	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	7	25	theme	critical	1473:1480	arg1	relationship					1501:1512	a critical structure-function relationship	1471:1512	a critical structure-function relationship for IPS	1471:1520	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	0	26	theme	intracellular	21:33	arg1	polysaccharides					35:49	intracellular polysaccharides	21:49	intracellular polysaccharides	21:49	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	4	27	theme	carbon	824:829	arg1	sources					831:837	carbon sources	824:837	carbon sources	824:837	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	0	28	theme	carbon	150:155	arg1	sources					157:163	different carbon sources	140:163	different carbon sources	140:163	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	3	29	theme	mycelial	611:618	arg1	biomass					620:626	mycelial biomass	611:626	mycelial biomass	611:626	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	1	30	theme	submerged	209:217	arg1	culture					219:225	submerged culture	209:225	submerged culture	209:225	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	5	31	contain	had	1085:1087	arg2	protection					1103:1112	the strongest protection	1089:1112	the strongest protection against alloxan-damaged islet cells	1089:1148	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	5	31	contain	had	1085:1087	arg1	IPS					983:985	IPS	983:985	IPS produced with glucose as the carbon source	983:1028	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	0	32	theme	different	140:148	arg1	sources					157:163	different carbon sources	140:163	different carbon sources	140:163	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	5	33	theme	islet	1138:1142	arg1	cells					1144:1148	alloxan-damaged islet cells	1122:1148	alloxan-damaged islet cells	1122:1148	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	0	34	from	activities	85:94	arg1	auricula-judae					111:124	Auricularia auricula-judae	99:124	Auricularia auricula-judae	99:124	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	3	35	theme	biomass	620:626	arg1	production					636:645	mycelial biomass and IPS production	611:645	mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source	611:724	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	7	36	theme	liquid-fermented	1559:1574	arg1	mycelia					1594:1600	liquid-fermented A. aruicula-judae mycelia	1559:1600	liquid-fermented A. aruicula-judae mycelia	1559:1600	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	2	37	theme	mycelial	407:414	arg1	biomass					416:422	mycelial biomass	407:422	mycelial biomass	407:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	0	38	theme	polysaccharides	35:49	arg1	production					51:60	Mycelial biomass and intracellular polysaccharides production	0:60	Mycelial biomass and intracellular polysaccharides production	0:60	Mycelial biomass and intracellular polysaccharides production, characterization, and activities in Auricularia auricula-judae cultured with different carbon sources.
37330093	2	39	theme	submerged	542:550	arg1	culture					552:558	submerged culture	542:558	submerged culture of Auricularia auricula-judae	542:588	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	3	40	theme	different	659:667	arg1	sources					676:682	different carbon sources	659:682	different carbon sources	659:682	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	6	41	theme	protective	1374:1383	arg1	related					1416:1422	related	1416:1422	related	1416:1422	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	41	theme	protective	1374:1383	arg1	activity					1385:1392	the protective activity	1370:1392	the protective activity of IPS	1370:1399	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	42	theme	reducing	1431:1438	arg1	power					1440:1444	its reducing power	1427:1444	its reducing power	1427:1444	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	4	43	theme	monosaccharide	901:914	arg1	compositions					916:927	monosaccharide compositions	901:927	monosaccharide compositions	901:927	Additionally, carbon sources were found to affect the molecular weight (Mw) distributions, monosaccharide compositions, structural characterization, and activities of IPSs.
37330093	3	44	theme	carbon	669:674	arg1	sources					676:682	different carbon sources	659:682	different carbon sources	659:682	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	2	45	from	bioactivities	477:489	arg1	biomass					416:422	mycelial biomass	407:422	mycelial biomass	407:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	7	46	from	IPS	1610:1612	arg1	production					1633:1642	functional food production	1617:1642	functional food production	1617:1642	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	6	47	theme	mannose	1353:1359	arg1	content					1361:1367	mannose content	1353:1367	mannose content	1353:1367	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	5	48	theme	in	1049:1050	arg1	activities					1070:1079	the best in vitro antioxidant activities	1040:1079	the best in vitro antioxidant activities	1040:1079	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	1	49	theme	carbon	170:175	arg1	factor					198:203	an essential factor	185:203	an essential factor for submerged culture	185:225	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	1	49	theme	carbon	170:175	arg1	source					177:182	The carbon source	166:182	The carbon source	166:182	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	5	50	theme	strongest	1093:1101	arg1	protection					1103:1112	the strongest protection	1089:1112	the strongest protection against alloxan-damaged islet cells	1089:1148	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	5	51	theme	antioxidant	1058:1068	arg1	activities					1070:1079	the best in vitro antioxidant activities	1040:1079	the best in vitro antioxidant activities	1040:1079	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	6	52	theme	IPS	1248:1250	arg1	yield					1252:1256	mycelial biomass (r = 0.97) and IPS yield	1216:1256	yield	1252:1256	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	6	53	theme	Correlation	1151:1161	arg1	analysis					1163:1170	Correlation analysis	1151:1170	Correlation analysis	1151:1170	Correlation analysis revealed that Mw correlated positively with mycelial biomass (r = 0.97) and IPS yield (r = 1.00), while IPS antioxidant activities correlated positively with Mw and negatively with mannose content; the protective activity of IPS was positively related to its reducing power.
37330093	1	54	theme	fungal	236:241	arg1	production					259:268	fungal polysaccharides production	236:268	fungal polysaccharides production	236:268	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	2	55	theme	auricula-judae	575:588	arg1	culture					552:558	submerged culture	542:558	submerged culture of Auricularia auricula-judae	542:588	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	56	theme	sources	344:350	arg1	impact					327:332	the impact	323:332	the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass	323:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	56	theme	sources	344:350	arg1	production					432:441	the production	428:441	the production	428:441	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	56	theme	sources	344:350	arg1	characterization					455:470	structural characterization	444:470	structural characterization	444:470	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	56	theme	sources	344:350	arg1	bioactivities					477:489	bioactivities	477:489	bioactivities	477:489	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	1	57	theme	polysaccharides	243:257	arg1	production					259:268	fungal polysaccharides production	236:268	fungal polysaccharides production	236:268	The carbon source, an essential factor for submerged culture, affects fungal polysaccharides production, structures, and activities.
37330093	7	58	from	foundation	1534:1543	arg1	production					1633:1642	functional food production	1617:1642	functional food production	1617:1642	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	3	59	theme	IPS	632:634	arg1	production					636:645	mycelial biomass and IPS production	611:645	mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source	611:724	Results showed that mycelial biomass and IPS production varied with different carbon sources, where using glucose as the carbon source produced the highest mycelial biomass (17.22 ± 0.29 g/L) and IPS (1.62 ± 0.04 g/L).
37330093	5	60	dep	in	1049:1050	arg1	vitro					1052:1056	vitro	1052:1056	vitro	1052:1056	IPS produced with glucose as the carbon source exhibited the best in vitro antioxidant activities and had the strongest protection against alloxan-damaged islet cells.
37330093	7	61	theme	food	1628:1631	arg1	production					1633:1642	functional food production	1617:1642	functional food production	1617:1642	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	2	62	theme	polysaccharides	508:522	arg1	impact					327:332	the impact	323:332	the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass	323:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	62	theme	polysaccharides	508:522	arg1	production					432:441	the production	428:441	the production	428:441	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	62	theme	polysaccharides	508:522	arg1	characterization					455:470	structural characterization	444:470	structural characterization	444:470	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	62	theme	polysaccharides	508:522	arg1	bioactivities					477:489	bioactivities	477:489	bioactivities	477:489	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	63	from	production	432:441	arg1	biomass					416:422	mycelial biomass	407:422	mycelial biomass	407:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	7	64	theme	A.	1576:1577	arg1	mycelia					1594:1600	liquid-fermented A. aruicula-judae mycelia	1559:1600	liquid-fermented A. aruicula-judae mycelia	1559:1600	These findings indicate a critical structure-function relationship for IPS and lay the foundation for utilizing liquid-fermented A. aruicula-judae mycelia and the IPS in functional food production.
37330093	2	65	theme	structural	444:453	arg1	characterization					455:470	structural characterization	444:470	structural characterization	444:470	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
37330093	2	66	from	impact	327:332	arg1	biomass					416:422	mycelial biomass	407:422	mycelial biomass	407:422	This study investigated the impact of carbon sources, including glucose, fructose, sucrose, and mannose, on mycelial biomass and the production, structural characterization, and bioactivities of intracellular polysaccharides (IPS) produced by submerged culture of Auricularia auricula-judae.
36834619	7	0	theme	intermolecular	1046:1059	arg1	interactions					1061:1072	The intra- and intermolecular interactions	1031:1072	The intra- and intermolecular interactions of the polysaccharides	1031:1095	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	10	1	theme	Opuntia	1459:1465	arg1	species					1467:1473	this Opuntia species	1454:1473	this Opuntia species	1454:1473	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	1	2	theme	semi-wild	167:175	arg1	cultivated					184:193	a semi-wild cactus cultivated	165:193	a semi-wild cactus cultivated for its fruit	165:207	Opuntia joconostle is a semi-wild cactus cultivated for its fruit.
36834619	1	2	theme	semi-wild	167:175	arg1	joconostle					151:160	Opuntia joconostle	143:160	Opuntia joconostle	143:160	Opuntia joconostle is a semi-wild cactus cultivated for its fruit.
36834619	10	3	theme	obtained	1402:1409	arg1	data					1411:1414	The obtained data	1398:1414	The obtained data	1398:1414	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	4	4	dep	35	829:830	arg1	to					826:827	to	826:827	to	826:827	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	1	5	theme	cactus	177:182	arg1	cultivated					184:193	a semi-wild cactus cultivated	165:193	a semi-wild cactus cultivated for its fruit	165:207	Opuntia joconostle is a semi-wild cactus cultivated for its fruit.
36834619	1	5	theme	cactus	177:182	arg1	joconostle					151:160	Opuntia joconostle	143:160	Opuntia joconostle	143:160	Opuntia joconostle is a semi-wild cactus cultivated for its fruit.
36834619	10	6	theme	animal	1504:1509	arg1	feed					1511:1514	animal feed	1504:1514	animal feed	1504:1514	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	9	7	theme	Bacteroidetes	1355:1367	arg1	members					1344:1350	members	1344:1350	members of Bacteroidetes	1344:1367	Lactobacilli and Bifidobacteria were not able to utilize them, whereas members of Bacteroidetes showed utilization capacity.
36834619	10	8	theme	arid	1519:1522	arg1	areas					1524:1528	arid areas	1519:1528	arid areas	1519:1528	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	4	9	from	mol	832:834	arg1	content					810:816	a galacturonic acid content	790:816	a galacturonic acid content from 10 to 35%mol	790:834	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	7	10	theme	intra-	1035:1040	arg1	interactions					1061:1072	The intra- and intermolecular interactions	1031:1072	The intra- and intermolecular interactions of the polysaccharides	1031:1095	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	6	11	from	present	1001:1007	arg1	spectra					1022:1028	the FT IR spectra	1012:1028	the FT IR spectra	1012:1028	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	10	12	from	source	1604:1609	arg1	refinery					1622:1629	a green refinery	1614:1629	a green refinery	1614:1629	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	0	13	theme	Molecular	97:105	arg1	Dimensions					107:116	Molecular Dimensions	97:116	Molecular Dimensions	97:116	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	4	14	dep	neutral	705:711	arg1	composed					714:721	composed	714:721	composed mainly of galactose, arabinose, and xylose	714:764	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	9	15	theme	utilization	1376:1386	arg1	capacity					1388:1395	utilization capacity	1376:1395	utilization capacity	1376:1395	Lactobacilli and Bifidobacteria were not able to utilize them, whereas members of Bacteroidetes showed utilization capacity.
36834619	0	16	theme	Prebiotic	122:130	arg1	Potential					132:140	Prebiotic Potential	122:140	Prebiotic Potential	122:140	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	4	17	with	neutral	705:711	arg1	content					810:816	a galacturonic acid content	790:816	a galacturonic acid content from 10 to 35%mol	790:834	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	10	18	theme	high	1426:1429	arg1	potential					1440:1448	a high economic potential	1424:1448	a high economic potential for this Opuntia species, with potential	1424:1489	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	6	19	theme	FT	1016:1017	arg1	spectra					1022:1028	the FT IR spectra	1012:1028	the FT IR spectra	1012:1028	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	5	20	dep	2.8	889:891	arg1	to					886:887	to	886:887	to	886:887	Their average molar masses ranged from 1.8 × 105 to 2.8 × 105 g·mol-1.
36834619	4	21	dep	mol	832:834	arg1	%					831:831	%	831:831	%	831:831	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	6	22	attach	present	1001:1007	arg2	xylan					965:969	xylan	965:969	xylan	965:969	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	22	attach	present	1001:1007	arg1	spectra					1022:1028	the FT IR spectra	1012:1028	the FT IR spectra	1012:1028	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	22	attach	present	1001:1007	arg2	galactan					945:952	galactan	945:952	galactan	945:952	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	22	attach	present	1001:1007	arg2	features					928:935	Distinct structural features	908:935	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs	908:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	22	attach	present	1001:1007	arg2	arabinan					955:962	arabinan	955:962	arabinan	955:962	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	22	attach	present	1001:1007	arg2	motifs					989:994	galacturonan motifs	976:994	galacturonan motifs	976:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	0	23	attach	Isolated	41:48	arg1	Mucilage					74:81	Opuntia joconostle Mucilage	55:81	Opuntia joconostle Mucilage	55:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	0	23	attach	Isolated	41:48	arg2	Heteropolysaccharides					19:39	Neutral and Pectic Heteropolysaccharides	0:39	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage	0:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	2	24	theme	useful	277:282	arg1	mucilage					284:291	the potentially useful mucilage	261:291	the potentially useful mucilage in them	261:299	However, the cladodes are often discarded, wasting the potentially useful mucilage in them.
36834619	6	25	theme	IR	1019:1020	arg1	spectra					1022:1028	the FT IR spectra	1012:1028	the FT IR spectra	1012:1028	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	3	26	theme	vibrational	463:473	arg1	spectroscopy					475:486	vibrational spectroscopy	463:486	vibrational spectroscopy	463:486	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	4	27	dep	%	831:831	arg1	35					829:830	35	829:830	35	829:830	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	11	28	theme	interest	1708:1715	arg1	saccharides					1676:1686	the saccharides	1672:1686	the saccharides	1672:1686	Our methodology can be used to evaluate the saccharides as the phenotype of interest, helping to guide the breeding strategy.
36834619	11	28	theme	interest	1708:1715	arg1	phenotype					1695:1703	the phenotype	1691:1703	the phenotype of interest	1691:1715	Our methodology can be used to evaluate the saccharides as the phenotype of interest, helping to guide the breeding strategy.
36834619	10	29	theme	precise	1531:1537	arg1	prebiotic					1539:1547	precise prebiotic	1531:1547	precise prebiotic	1531:1547	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	3	30	theme	commensal	573:581	arg1	members					583:589	known saccharolytic commensal members	553:589	known saccharolytic commensal members of the gut microbiota	553:611	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	0	31	theme	Neutral	0:6	arg1	Heteropolysaccharides					19:39	Neutral and Pectic Heteropolysaccharides	0:39	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage	0:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	0	32	dep	Composition	84:94	arg1	Heteropolysaccharides					19:39	Neutral and Pectic Heteropolysaccharides	0:39	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage	0:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	8	33	theme	structural	1183:1192	arg1	features					1194:1201	structural features	1183:1201	structural features	1183:1201	The composition and structural features of these polysaccharides were reflected in their prebiotic potential.
36834619	5	34	theme	average	843:849	arg1	masses					857:862	Their average molar masses	837:862	Their average molar masses	837:862	Their average molar masses ranged from 1.8 × 105 to 2.8 × 105 g·mol-1.
36834619	3	35	theme	molar	386:390	arg1	distribution					397:408	their molar mass distribution	380:408	their molar mass distribution	380:408	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	6	36	theme	structural	917:926	arg1	galactan					945:952	galactan	945:952	galactan	945:952	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	36	theme	structural	917:926	arg1	motifs					989:994	galacturonan motifs	976:994	galacturonan motifs	976:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	36	theme	structural	917:926	arg1	xylan					965:969	xylan	965:969	xylan	965:969	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	36	theme	structural	917:926	arg1	arabinan					955:962	arabinan	955:962	arabinan	955:962	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	36	theme	structural	917:926	arg1	features					928:935	Distinct structural features	908:935	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs	908:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	3	37	theme	known	553:557	arg1	members					583:589	known saccharolytic commensal members	553:589	known saccharolytic commensal members of the gut microbiota	553:611	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	4	38	theme	acid	805:808	arg1	content					810:816	a galacturonic acid content	790:816	a galacturonic acid content from 10 to 35%mol	790:834	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	3	39	theme	FT	489:490	arg1	IR					492:493	FT IR	489:493	FT IR	489:493	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	3	40	theme	mass	392:395	arg1	distribution					397:408	their molar mass distribution	380:408	their molar mass distribution	380:408	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	6	41	theme	Distinct	908:915	arg1	galactan					945:952	galactan	945:952	galactan	945:952	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	41	theme	Distinct	908:915	arg1	motifs					989:994	galacturonan motifs	976:994	galacturonan motifs	976:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	41	theme	Distinct	908:915	arg1	xylan					965:969	xylan	965:969	xylan	965:969	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	41	theme	Distinct	908:915	arg1	arabinan					955:962	arabinan	955:962	arabinan	955:962	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	41	theme	Distinct	908:915	arg1	features					928:935	Distinct structural features	908:935	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs	908:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	11	42	used	used	1655:1658	arg2	methodology					1636:1646	Our methodology	1632:1646	Our methodology	1632:1646	Our methodology can be used to evaluate the saccharides as the phenotype of interest, helping to guide the breeding strategy.
36834619	3	43	theme	saccharolytic	559:571	arg1	members					583:589	known saccharolytic commensal members	553:589	known saccharolytic commensal members of the gut microbiota	553:611	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	4	44	theme	ion	639:641	arg1	chromatography					652:665	ion exchange chromatography	639:665	ion exchange chromatography	639:665	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	7	45	theme	polysaccharides	1081:1095	arg1	effect					1108:1113	their effect	1102:1113	their effect on the aggregation behavior	1102:1141	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	7	45	theme	polysaccharides	1081:1095	arg1	interactions					1061:1072	The intra- and intermolecular interactions	1031:1072	The intra- and intermolecular interactions of the polysaccharides	1031:1095	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	8	46	theme	polysaccharides	1212:1226	arg1	composition					1167:1177	composition	1167:1177	composition	1167:1177	The composition and structural features of these polysaccharides were reflected in their prebiotic potential.
36834619	8	46	theme	polysaccharides	1212:1226	arg1	features					1194:1201	structural features	1183:1201	structural features	1183:1201	The composition and structural features of these polysaccharides were reflected in their prebiotic potential.
36834619	10	47	theme	skeleton	1595:1602	arg1	source					1604:1609	the carbon skeleton source	1584:1609	the carbon skeleton source in a green refinery	1584:1629	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	3	48	theme	gut	598:600	arg1	microbiota					602:611	the gut microbiota	594:611	the gut microbiota	594:611	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	6	49	theme	galacturonan	976:987	arg1	motifs					989:994	galacturonan motifs	976:994	galacturonan motifs	976:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	3	50	theme	structural	439:448	arg1	features					450:457	structural features	439:457	structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM)	439:528	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	3	50	theme	structural	439:448	arg1	AFM					525:527	AFM	525:527	AFM	525:527	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	10	51	theme	economic	1431:1438	arg1	potential					1440:1448	a high economic potential	1424:1448	a high economic potential for this Opuntia species, with potential	1424:1489	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	3	52	theme	microbiota	602:611	arg1	members					583:589	known saccharolytic commensal members	553:589	known saccharolytic commensal members of the gut microbiota	553:611	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	7	53	theme	aggregation	1122:1132	arg1	behavior					1134:1141	the aggregation behavior	1118:1141	the aggregation behavior	1118:1141	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	0	54	theme	joconostle	63:72	arg1	Mucilage					74:81	Opuntia joconostle Mucilage	55:81	Opuntia joconostle Mucilage	55:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	5	55	theme	molar	851:855	arg1	masses					857:862	Their average molar masses	837:862	Their average molar masses	837:862	Their average molar masses ranged from 1.8 × 105 to 2.8 × 105 g·mol-1.
36834619	6	56	located	present	1001:1007	arg2	xylan					965:969	xylan	965:969	xylan	965:969	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	56	located	present	1001:1007	arg1	spectra					1022:1028	the FT IR spectra	1012:1028	the FT IR spectra	1012:1028	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	56	located	present	1001:1007	arg2	galactan					945:952	galactan	945:952	galactan	945:952	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	56	located	present	1001:1007	arg2	features					928:935	Distinct structural features	908:935	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs	908:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	56	located	present	1001:1007	arg2	arabinan					955:962	arabinan	955:962	arabinan	955:962	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	6	56	located	present	1001:1007	arg2	motifs					989:994	galacturonan motifs	976:994	galacturonan motifs	976:994	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	3	57	theme	atomic	500:505	arg1	microscopy					513:522	atomic force microscopy	500:522	atomic force microscopy	500:522	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	0	58	theme	Opuntia	55:61	arg1	Mucilage					74:81	Opuntia joconostle Mucilage	55:81	Opuntia joconostle Mucilage	55:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	3	59	theme	force	507:511	arg1	microscopy					513:522	atomic force microscopy	500:522	atomic force microscopy	500:522	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	2	60	from	mucilage	284:291	arg1	them					296:299	them	296:299	them	296:299	However, the cladodes are often discarded, wasting the potentially useful mucilage in them.
36834619	7	61	from	interactions	1061:1072	arg1	behavior					1134:1141	the aggregation behavior	1118:1141	the aggregation behavior	1118:1141	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	4	62	dep	found	694:698	arg1	neutral					705:711	neutral	705:711	neutral	705:711	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	4	62	dep	found	694:698	arg1	acidic					777:782	acidic	777:782	acidic	777:782	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	4	63	theme	galacturonic	792:803	arg1	content					810:816	a galacturonic acid content	790:816	a galacturonic acid content from 10 to 35%mol	790:834	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	10	64	theme	green	1616:1620	arg1	refinery					1622:1629	a green refinery	1614:1629	a green refinery	1614:1629	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	10	65	with	species	1467:1473	arg1	potential					1481:1489	potential	1481:1489	potential	1481:1489	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	7	66	from	effect	1108:1113	arg1	behavior					1134:1141	the aggregation behavior	1118:1141	the aggregation behavior	1118:1141	The intra- and intermolecular interactions of the polysaccharides, and their effect on the aggregation behavior, were shown by AFM.
36834619	8	67	theme	prebiotic	1252:1260	arg1	potential					1262:1270	their prebiotic potential	1246:1270	their prebiotic potential	1246:1270	The composition and structural features of these polysaccharides were reflected in their prebiotic potential.
36834619	6	68	from	spectra	1022:1028	arg1	present					1001:1007	present	1001:1007	present	1001:1007	Distinct structural features such as galactan, arabinan, xylan, and galacturonan motifs were present in the FT IR spectra.
36834619	8	69	dep	composition	1167:1177	arg1	The					1163:1165	The	1163:1165	The	1163:1165	The composition and structural features of these polysaccharides were reflected in their prebiotic potential.
36834619	10	70	theme	carbon	1588:1593	arg1	source					1604:1609	the carbon skeleton source	1584:1609	the carbon skeleton source in a green refinery	1584:1629	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	4	71	theme	exchange	643:650	arg1	chromatography					652:665	ion exchange chromatography	639:665	ion exchange chromatography	639:665	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	4	72	with	fractionation	620:632	arg1	chromatography					652:665	ion exchange chromatography	639:665	ion exchange chromatography	639:665	After fractionation with ion exchange chromatography, four polysaccharides were found: one neutral (composed mainly of galactose, arabinose, and xylose) and three acidic, with a galacturonic acid content from 10 to 35%mol.
36834619	3	73	theme	monosaccharide	411:424	arg1	composition					426:436	monosaccharide composition	411:436	monosaccharide composition	411:436	The mucilage is composed primarily of heteropolysaccharides, characterized by their molar mass distribution, monosaccharide composition, structural features (by vibrational spectroscopy, FT IR, and atomic force microscopy, AFM), and fermentability by known saccharolytic commensal members of the gut microbiota.
36834619	0	74	theme	Pectic	12:17	arg1	Heteropolysaccharides					19:39	Neutral and Pectic Heteropolysaccharides	0:39	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage	0:81	Neutral and Pectic Heteropolysaccharides Isolated from Opuntia joconostle Mucilage: Composition, Molecular Dimensions and Prebiotic Potential.
36834619	10	75	dep	suggest	1416:1422	arg1	uses					1491:1494	uses	1491:1494	suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery	1416:1629	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	10	76	theme	symbiotic	1554:1562	arg1	formulations					1564:1575	symbiotic formulations	1554:1575	symbiotic formulations	1554:1575	The obtained data suggest a high economic potential for this Opuntia species, with potential uses such as animal feed in arid areas, precise prebiotic, and symbiotic formulations, or as the carbon skeleton source in a green refinery.
36834619	11	77	theme	breeding	1739:1746	arg1	strategy					1748:1755	the breeding strategy	1735:1755	the breeding strategy	1735:1755	Our methodology can be used to evaluate the saccharides as the phenotype of interest, helping to guide the breeding strategy.
36796559	2	0	theme	PKPS	518:521	arg1	activities					504:513	the in vitro anti-aging-related activities	472:513	the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity	472:584	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	6	1	theme	smooth	1363:1368	arg1	state					1370:1374	smooth state	1363:1374	smooth state	1363:1374	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	6	2	theme	main	1151:1154	arg1	distribution					1173:1184	the main molecular weight distribution	1147:1184	the main molecular weight distribution of PKPS	1147:1192	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	2	3	from	ability	615:621	arg1	activities					504:513	the in vitro anti-aging-related activities	472:513	the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity	472:584	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	0	4	theme	related	90:96	arg1	activities					98:107	anti-aging related activities	79:107	anti-aging related activities	79:107	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	3	5	theme	superior	731:738	arg1	activity					751:758	superior anti-aging activity	731:758	superior anti-aging activity	731:758	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	2	6	dep	in	476:477	arg1	vitro					479:483	vitro	479:483	vitro	479:483	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	1	7	theme	anti-aging	185:194	arg1	value					196:200	the anti-aging value	181:200	the anti-aging value of the plants polysaccharides	181:230	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	2	8	theme	hypolipidemic	563:575	arg1	activity					577:584	hypolipidemic activity	563:584	hypolipidemic activity	563:584	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	0	9	from	Effect	0:5	arg1	activities					98:107	anti-aging related activities	79:107	anti-aging related activities	79:107	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	0	9	from	Effect	0:5	arg1	characteristics					59:73	physicochemical characteristics	43:73	physicochemical characteristics	43:73	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	6	10	theme	chemical	1240:1247	arg1	composition					1249:1259	the chemical composition	1236:1259	the chemical composition	1236:1259	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	7	11	theme	PKPS	1497:1500	arg1	structure					1484:1492	the structure	1480:1492	the structure of PKPS	1480:1500	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	1	12	theme	Polygonatum	283:293	arg1	PKPS					322:325	PKPS	322:325	PKPS	322:325	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	1	12	theme	Polygonatum	283:293	arg1	polysaccharides					305:319	the Polygonatum kingianum polysaccharides	279:319	the Polygonatum kingianum polysaccharides (PKPS)	279:326	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	6	13	dep	changed	1194:1200	arg1	microtopography					1335:1349	the initial rough and porous microtopography	1306:1349	the initial rough and porous microtopography turned into smooth state	1306:1374	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	7	14	theme	anti-aging	1537:1546	arg1	activity					1548:1555	the enhanced anti-aging activity	1524:1555	the enhanced anti-aging activity	1524:1555	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	7	15	theme	enhanced	1528:1535	arg1	activity					1548:1555	the enhanced anti-aging activity	1524:1555	the enhanced anti-aging activity	1524:1555	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	7	16	from	promising	1591:1599	arg1	modification					1619:1630	the structural modification	1604:1630	the structural modification of polysaccharides	1604:1649	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	0	17	theme	polysaccharides	134:148	arg1	activities					98:107	anti-aging related activities	79:107	anti-aging related activities	79:107	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	0	17	theme	polysaccharides	134:148	arg1	characteristics					59:73	physicochemical characteristics	43:73	physicochemical characteristics	43:73	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	6	18	theme	porous	1328:1333	arg1	microtopography					1335:1349	the initial rough and porous microtopography	1306:1349	the initial rough and porous microtopography turned into smooth state	1306:1374	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	6	19	dep	2-100 kDa	1221:1229	arg1	to					1218:1219	to	1218:1219	to	1218:1219	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	0	20	theme	kingianum	124:132	arg1	polysaccharides					134:148	Polygonatum kingianum polysaccharides	112:148	Polygonatum kingianum polysaccharides	112:148	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	1	21	theme	hydrolyzed	386:395	arg1	polysaccharides					397:411	the hydrolyzed polysaccharides	382:411	the hydrolyzed polysaccharides	382:411	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	7	22	from	alterations	1383:1393	arg1	characteristics					1414:1428	physicochemical characteristics	1398:1428	physicochemical characteristics	1398:1428	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	7	23	from	modification	1619:1630	arg1	promising					1591:1599	promising	1591:1599	promising	1591:1599	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	4	24	theme	original	900:907	arg1	polysaccharide					909:922	the original polysaccharide	896:922	the original polysaccharide	896:922	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	4	25	theme	lipofuscin	1017:1026	arg1	accumulation					1028:1039	lipofuscin accumulation	1017:1039	lipofuscin accumulation of worms	1017:1048	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	4	26	theme	movement	987:994	arg1	ability					996:1002	movement ability	987:1002	movement ability	987:1002	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	3	27	theme	anti-aging	740:749	arg1	activity					751:758	superior anti-aging activity	731:758	superior anti-aging activity	731:758	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	6	28	theme	initial	1310:1316	arg1	microtopography					1335:1349	the initial rough and porous microtopography	1306:1349	the initial rough and porous microtopography turned into smooth state	1306:1374	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	5	29	theme	optimal	1085:1091	arg1	polysaccharide					1111:1124	the optimal anti-aging active polysaccharide	1081:1124	the optimal anti-aging active polysaccharide	1081:1124	This fraction was screened as the optimal anti-aging active polysaccharide.
36796559	5	29	theme	optimal	1085:1091	arg1	fraction					1056:1063	This fraction	1051:1063	This fraction	1051:1063	This fraction was screened as the optimal anti-aging active polysaccharide.
36796559	0	30	theme	physicochemical	43:57	arg1	characteristics					59:73	physicochemical characteristics	43:73	physicochemical characteristics	43:73	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	1	31	theme	plants	209:214	arg1	polysaccharides					216:230	the plants polysaccharides	205:230	the plants polysaccharides	205:230	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	0	32	theme	modification	23:34	arg1	Effect					0:5	Effect	0:5	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.	0:149	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	4	33	theme	increased	856:864	arg1	effect					866:871	an increased effect	853:871	an increased effect of 10.09 %	853:882	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	2	34	theme	cellular	591:598	arg1	ability					615:621	cellular aging-delaying ability	591:621	cellular aging-delaying ability	591:621	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	1	35	theme	polysaccharides	216:230	arg1	value					196:200	the anti-aging value	181:200	the anti-aging value of the plants polysaccharides	181:230	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	0	36	theme	fermentation	10:21	arg1	modification					23:34	fermentation modification	10:34	fermentation modification	10:34	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	4	37	theme	Caenorhabditis	804:817	arg1	lifespan					827:834	the Caenorhabditis elegans lifespan	800:834	the Caenorhabditis elegans lifespan	800:834	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	7	38	from	influence	1467:1475	arg1	structure					1484:1492	the structure	1480:1492	the structure of PKPS	1480:1500	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	4	39	with	lifespan	827:834	arg1	effect					866:871	an increased effect	853:871	an increased effect of 10.09 %	853:882	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	6	40	theme	PKPS	1189:1192	arg1	distribution					1173:1184	the main molecular weight distribution	1147:1184	the main molecular weight distribution of PKPS	1147:1192	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	0	41	dep	characteristics	59:73	arg1	the					39:41	the	39:41	the	39:41	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	7	42	theme	physicochemical	1398:1412	arg1	characteristics					1414:1428	physicochemical characteristics	1398:1428	physicochemical characteristics	1398:1428	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	2	43	theme	anti-aging-related	485:502	arg1	activities					504:513	the in vitro anti-aging-related activities	472:513	the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity	472:584	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	4	44	theme	worms	1044:1048	arg1	accumulation					1028:1039	lipofuscin accumulation	1017:1039	lipofuscin accumulation of worms	1017:1048	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	3	45	theme	low	643:645	arg1	fraction					650:657	the low Mw fraction PS2-4	639:663	the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide	639:719	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	3	45	theme	low	643:645	arg1	10-50 kDa					666:674	10-50 kDa	666:674	10-50 kDa	666:674	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	1	46	theme	fermentation	237:248	arg1	method					250:255	the fermentation method	233:255	the fermentation method	233:255	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	0	47	theme	Polygonatum	112:122	arg1	polysaccharides					134:148	Polygonatum kingianum polysaccharides	112:148	Polygonatum kingianum polysaccharides	112:148	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	7	48	theme	polysaccharides	1635:1649	arg1	modification					1619:1630	the structural modification	1604:1630	the structural modification of polysaccharides	1604:1649	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	4	49	theme	%	882:882	arg1	effect					866:871	an increased effect	853:871	an increased effect of 10.09 %	853:882	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	3	50	theme	experimental	763:774	arg1	animals					776:782	experimental animals	763:782	experimental animals	763:782	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	2	51	theme	in	476:477	arg1	activities					504:513	the in vitro anti-aging-related activities	472:513	the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity	472:584	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	1	52	used	used	358:361	arg2	ultra-filtration					337:352	the ultra-filtration	333:352	the ultra-filtration	333:352	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	4	53	theme	original	961:968	arg1	one					970:972	the original one	957:972	the original one	957:972	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	1	54	dep	Polygonatum	283:293	arg1	kingianum					295:303	kingianum	295:303	kingianum	295:303	In order to fully investigate the anti-aging value of the plants polysaccharides, the fermentation method was applied to modify the Polygonatum kingianum polysaccharides (PKPS), and the ultra-filtration was used to further segment the hydrolyzed polysaccharides.
36796559	4	55	dep	Caenorhabditis	804:817	arg1	elegans					819:825	elegans	819:825	elegans	819:825	PS2-4 extended the Caenorhabditis elegans lifespan by 20.70 %, with an increased effect of 10.09 % compared to the original polysaccharide; it was also more effective than the original one in improving movement ability and reducing lipofuscin accumulation of worms.
36796559	5	56	theme	anti-aging	1093:1102	arg1	polysaccharide					1111:1124	the optimal anti-aging active polysaccharide	1081:1124	the optimal anti-aging active polysaccharide	1081:1124	This fraction was screened as the optimal anti-aging active polysaccharide.
36796559	5	56	theme	anti-aging	1093:1102	arg1	fraction					1056:1063	This fraction	1051:1063	This fraction	1051:1063	This fraction was screened as the optimal anti-aging active polysaccharide.
36796559	7	57	theme	structural	1608:1617	arg1	modification					1619:1630	the structural modification	1604:1630	the structural modification of polysaccharides	1604:1649	These alterations in physicochemical characteristics suggest that fermentation exerted an influence on the structure of PKPS, which contributed to the enhanced anti-aging activity, indicating that fermentation was promising in the structural modification of polysaccharides.
36796559	6	58	theme	rough	1318:1322	arg1	microtopography					1335:1349	the initial rough and porous microtopography	1306:1349	the initial rough and porous microtopography turned into smooth state	1306:1374	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	2	59	theme	aging-delaying	600:613	arg1	ability					615:621	cellular aging-delaying ability	591:621	cellular aging-delaying ability	591:621	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	5	60	theme	active	1104:1109	arg1	polysaccharide					1111:1124	the optimal anti-aging active polysaccharide	1081:1124	the optimal anti-aging active polysaccharide	1081:1124	This fraction was screened as the optimal anti-aging active polysaccharide.
36796559	5	60	theme	active	1104:1109	arg1	fraction					1056:1063	This fraction	1051:1063	This fraction	1051:1063	This fraction was screened as the optimal anti-aging active polysaccharide.
36796559	6	61	theme	monosaccharide	1265:1278	arg1	composition					1280:1290	monosaccharide composition	1265:1290	monosaccharide composition	1265:1290	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	0	62	theme	anti-aging	79:88	arg1	activities					98:107	anti-aging related activities	79:107	anti-aging related activities	79:107	Effect of fermentation modification on the physicochemical characteristics and anti-aging related activities of Polygonatum kingianum polysaccharides.
36796559	3	63	theme	fermented	696:704	arg1	polysaccharide					706:719	the fermented polysaccharide	692:719	the fermented polysaccharide	692:719	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	3	64	theme	Mw	647:648	arg1	fraction					650:657	the low Mw fraction PS2-4	639:663	the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide	639:719	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	3	64	theme	Mw	647:648	arg1	10-50 kDa					666:674	10-50 kDa	666:674	10-50 kDa	666:674	In particular, the low Mw fraction PS2-4 (10-50 kDa) separated from the fermented polysaccharide exhibited superior anti-aging activity on experimental animals.
36796559	6	65	theme	weight	1166:1171	arg1	distribution					1173:1184	the main molecular weight distribution	1147:1184	the main molecular weight distribution of PKPS	1147:1192	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
36796559	2	66	from	increase	460:467	arg1	activities					504:513	the in vitro anti-aging-related activities	472:513	the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity	472:584	It was found that the fermentation induced an increase in the in vitro anti-aging-related activities of PKPS including antioxidant, hypoglycemic and hypolipidemic activity, and cellular aging-delaying ability.
36796559	6	67	theme	molecular	1156:1164	arg1	distribution					1173:1184	the main molecular weight distribution	1147:1184	the main molecular weight distribution of PKPS	1147:1192	After fermentation, the main molecular weight distribution of PKPS changed from 50-650 kDa to 2-100 kDa, and the chemical composition and monosaccharide composition also changed; the initial rough and porous microtopography turned into smooth state.
35405153	0	0	theme	methylene	66:74	arg1	dye					81:83	methylene blue dye	66:83	methylene blue dye	66:83	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	9	1	theme	functional	1186:1195	arg1	theory					1197:1202	density functional theory	1178:1202	density functional theory	1178:1202	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	9	1	theme	functional	1186:1195	arg1	calculations					1205:1216	The DFT (density functional theory) calculations	1169:1216	The DFT (density functional theory) calculations	1169:1216	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	7	2	theme	exothermic	1008:1017	arg1	adsorption					970:979	the MB dye adsorption	959:979	the MB dye adsorption on these composites	959:999	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	7	2	theme	exothermic	1008:1017	arg1	process					1045:1051	an exothermic, spontaneous and feasible process	1005:1051	an exothermic, spontaneous and feasible process	1005:1051	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	9	3	theme	dye	1297:1299	arg1	adsorption					1280:1289	the adsorption	1276:1289	the adsorption of MB dye on the composites	1276:1317	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	6	4	theme	MB	777:778	arg1	data					795:798	MB dye adsorption data	777:798	MB dye adsorption data	777:798	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	1	5	theme	dye	224:226	arg1	removal					193:199	the removal	189:199	the removal of methylene blue (MB) dye	189:226	Cellulose/clay/sodium alginate composites were prepared and employed for the removal of methylene blue (MB) dye.
35405153	6	6	theme	adsorption	784:793	arg1	data					795:798	MB dye adsorption data	777:798	MB dye adsorption data	777:798	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	10	7	theme	Na-Alg-cellulose	1346:1361	arg1	effective					1379:1387	effective	1379:1387	effective	1379:1387	Results revealed that the Na-Alg-cellulose composites were effective for the MB dye removal.
35405153	10	7	theme	Na-Alg-cellulose	1346:1361	arg1	composites					1363:1372	the Na-Alg-cellulose composites	1342:1372	the Na-Alg-cellulose composites	1342:1372	Results revealed that the Na-Alg-cellulose composites were effective for the MB dye removal.
35405153	3	8	theme	composite	455:463	arg1	pH					415:416	pH	415:416	pH	415:416	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	3	8	theme	composite	455:463	arg1	dose					465:468	composite dose	455:468	composite dose	455:468	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	9	9	from	adsorption	1280:1289	arg1	composites					1308:1317	the composites	1304:1317	the composites	1304:1317	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	0	10	theme	dye	81:83	arg1	removal					55:61	the removal	51:61	the removal of methylene blue dye	51:83	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	6	11	theme	dye	780:782	arg1	data					795:798	MB dye adsorption data	777:798	MB dye adsorption data	777:798	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	6	12	used	used	877:880	arg2	model					867:871	a statistical physics model	845:871	a statistical physics model	845:871	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	2	13	theme	paper	260:264	arg1	mill					266:269	a paper mill waste	258:275	a paper mill waste	258:275	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	7	14	from	adsorption	970:979	arg1	composites					990:999	these composites	984:999	these composites	984:999	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	4	15	theme	equilibrium	510:520	arg1	time					522:525	an equilibrium time	507:525	an equilibrium time of 60 min	507:535	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	0	16	theme	blue	76:79	arg1	dye					81:83	methylene blue dye	66:83	methylene blue dye	66:83	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	4	17	dep	90	499:500	arg1	to					496:497	to	496:497	to	496:497	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	11	18	from	dyes	1534:1537	arg1	effluents					1553:1561	industrial effluents	1542:1561	industrial effluents	1542:1561	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	5	19	theme	MB	714:715	arg1	adsorption					717:726	MB adsorption	714:726	MB adsorption	714:726	Kinetics and isotherms of MB adsorption were quantified and modeled.
35405153	4	20	theme	optimum	540:546	arg1	level					548:552	optimum level	540:552	optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively)	540:685	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	3	21	theme	different	383:391	arg1	conditions					403:412	different operating conditions	383:412	different operating conditions (pH, initial concentration, temperature, composite dose)	383:469	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	7	22	theme	feasible	1036:1043	arg1	adsorption					970:979	the MB dye adsorption	959:979	the MB dye adsorption on these composites	959:999	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	7	22	theme	feasible	1036:1043	arg1	process					1045:1051	an exothermic, spontaneous and feasible process	1005:1051	an exothermic, spontaneous and feasible process	1005:1051	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	6	23	theme	adsorption	897:906	arg1	mechanism					908:916	the adsorption mechanism	893:916	the adsorption mechanism	893:916	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	3	24	theme	operating	393:401	arg1	conditions					403:412	different operating conditions	383:412	different operating conditions (pH, initial concentration, temperature, composite dose)	383:469	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	9	25	theme	responsible	1260:1270	arg1	interactions					1247:1258	the interactions	1243:1258	the interactions responsible for the adsorption of MB dye on the composites	1243:1317	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	4	26	theme	dose	567:570	arg1	level					548:552	optimum level	540:552	optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively)	540:685	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	0	27	theme	Cellulose	0:8	arg1	composites					36:45	Cellulose, clay and sodium alginate composites	0:45	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.	0:114	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	6	28	theme	physics	859:865	arg1	model					867:871	a statistical physics model	845:871	a statistical physics model	845:871	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	8	29	theme	subsequent	1139:1148	arg1	cycles					1161:1166	subsequent adsorption cycles	1139:1166	subsequent adsorption cycles	1139:1166	The composites were regenerated with HCl thus contributing to their reutilization in subsequent adsorption cycles.
35405153	11	30	theme	low-cost	1462:1469	arg1	adsorbents					1483:1492	low-cost alternative adsorbents	1462:1492	low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents	1462:1561	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	11	30	theme	low-cost	1462:1469	arg1	composites					1430:1439	these composites	1424:1439	these composites	1424:1439	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	4	31	dep	pH	606:607	arg1	7					616:616	7	616:616	7	616:616	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	4	31	dep	pH	606:607	arg1	11					622:623	11	622:623	11	622:623	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	8	32	theme	adsorption	1150:1159	arg1	cycles					1161:1166	subsequent adsorption cycles	1139:1166	subsequent adsorption cycles	1139:1166	The composites were regenerated with HCl thus contributing to their reutilization in subsequent adsorption cycles.
35405153	6	33	theme	statistical	847:857	arg1	model					867:871	a statistical physics model	845:871	a statistical physics model	845:871	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	0	34	theme	DFT	103:105	arg1	studies					107:113	DFT studies	103:113	DFT studies	103:113	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	11	35	theme	alternative	1471:1481	arg1	adsorbents					1483:1492	low-cost alternative adsorbents	1462:1492	low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents	1462:1561	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	11	35	theme	alternative	1471:1481	arg1	composites					1430:1439	these composites	1424:1439	these composites	1424:1439	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	0	36	theme	clay	11:14	arg1	composites					36:45	Cellulose, clay and sodium alginate composites	0:45	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.	0:114	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	7	37	theme	dye	966:968	arg1	adsorption					970:979	the MB dye adsorption	959:979	the MB dye adsorption on these composites	959:999	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	7	37	theme	dye	966:968	arg1	process					1045:1051	an exothermic, spontaneous and feasible process	1005:1051	an exothermic, spontaneous and feasible process	1005:1051	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	2	38	theme	sodium	317:322	arg1	alginate					324:331	sodium alginate	317:331	sodium alginate (Na-Alg)	317:340	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	2	38	theme	sodium	317:322	arg1	Na-Alg					334:339	Na-Alg	334:339	Na-Alg	334:339	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	4	39	theme	temperature	582:592	arg1	level					548:552	optimum level	540:552	optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively)	540:685	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	0	40	theme	alginate	27:34	arg1	composites					36:45	Cellulose, clay and sodium alginate composites	0:45	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.	0:114	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	4	41	dep	7	616:616	arg1	i.e.					610:613	i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively	610:684	i.e.	610:613	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	10	42	theme	dye	1400:1402	arg1	removal					1404:1410	the MB dye removal	1393:1410	the MB dye removal	1393:1410	Results revealed that the Na-Alg-cellulose composites were effective for the MB dye removal.
35405153	5	43	theme	adsorption	717:726	arg1	Kinetics					688:695	Kinetics	688:695	Kinetics	688:695	Kinetics and isotherms of MB adsorption were quantified and modeled.
35405153	5	43	theme	adsorption	717:726	arg1	isotherms					701:709	isotherms	701:709	isotherms	701:709	Kinetics and isotherms of MB adsorption were quantified and modeled.
35405153	4	44	theme	adsorbent	557:565	arg1	0.05 g					573:578	0.05 g	573:578	0.05 g	573:578	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	4	44	theme	adsorbent	557:565	arg1	dose					567:570	adsorbent dose	557:570	adsorbent dose (0.05 g)	557:579	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	0	45	theme	sodium	20:25	arg1	composites					36:45	Cellulose, clay and sodium alginate composites	0:45	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.	0:114	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	10	46	theme	MB	1397:1398	arg1	removal					1404:1410	the MB dye removal	1393:1410	the MB dye removal	1393:1410	Results revealed that the Na-Alg-cellulose composites were effective for the MB dye removal.
35405153	1	47	dep	blue	214:217	arg1	MB					220:221	MB	220:221	MB	220:221	Cellulose/clay/sodium alginate composites were prepared and employed for the removal of methylene blue (MB) dye.
35405153	0	48	dep	composites	36:45	arg1	studies					107:113	DFT studies	103:113	DFT studies	103:113	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	0	48	dep	composites	36:45	arg1	Experimental					86:97	Experimental	86:97	Experimental	86:97	Cellulose, clay and sodium alginate composites for the removal of methylene blue dye: Experimental and DFT studies.
35405153	8	49	from	reutilization	1122:1134	arg1	cycles					1161:1166	subsequent adsorption cycles	1139:1166	subsequent adsorption cycles	1139:1166	The composites were regenerated with HCl thus contributing to their reutilization in subsequent adsorption cycles.
35405153	3	50	theme	MB	352:353	arg1	removal					359:365	MB dye removal	352:365	MB dye removal	352:365	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	6	51	theme	order	826:830	arg1	kinetics					832:839	the pseudo-first order kinetics	809:839	the pseudo-first order kinetics	809:839	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	2	52	with	preparation	300:310	arg1	clay					346:349	clay	346:349	clay	346:349	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	2	52	with	preparation	300:310	arg1	alginate					324:331	sodium alginate	317:331	sodium alginate (Na-Alg)	317:340	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	2	52	with	preparation	300:310	arg1	Na-Alg					334:339	Na-Alg	334:339	Na-Alg	334:339	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	3	53	theme	dye	355:357	arg1	removal					359:365	MB dye removal	352:365	MB dye removal	352:365	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	6	54	theme	pseudo-first	813:824	arg1	kinetics					832:839	the pseudo-first order kinetics	809:839	the pseudo-first order kinetics	809:839	Results showed that MB dye adsorption data followed the pseudo-first order kinetics and a statistical physics model was used to analyze the adsorption mechanism.
35405153	7	55	theme	MB	963:964	arg1	adsorption					970:979	the MB dye adsorption	959:979	the MB dye adsorption on these composites	959:999	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	7	55	theme	MB	963:964	arg1	process					1045:1051	an exothermic, spontaneous and feasible process	1005:1051	an exothermic, spontaneous and feasible process	1005:1051	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	2	56	dep	mill	266:269	arg1	waste					271:275	waste	271:275	a paper mill waste	258:275	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	3	57	dep	conditions	403:412	arg1	dose					465:468	composite dose	455:468	composite dose	455:468	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	3	57	dep	conditions	403:412	arg1	temperature					442:452	temperature	442:452	temperature	442:452	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	3	57	dep	conditions	403:412	arg1	pH					415:416	pH	415:416	pH	415:416	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	3	57	dep	conditions	403:412	arg1	concentration					427:439	initial concentration	419:439	initial concentration	419:439	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	11	58	theme	pollution	1502:1510	arg1	remediation					1512:1522	the pollution remediation	1498:1522	the pollution remediation caused by dyes in industrial effluents	1498:1561	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	2	59	theme	composite	290:298	arg1	preparation					300:310	composite preparation	290:310	composite preparation with sodium alginate (Na-Alg) and clay	290:349	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	9	60	theme	MB	1294:1295	arg1	dye					1297:1299	MB dye	1294:1299	MB dye	1294:1299	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	1	61	theme	blue	214:217	arg1	dye					224:226	methylene blue (MB) dye	204:226	methylene blue (MB) dye	204:226	Cellulose/clay/sodium alginate composites were prepared and employed for the removal of methylene blue (MB) dye.
35405153	7	62	theme	Thermodynamic	919:931	arg1	calculation					933:943	Thermodynamic calculation	919:943	Thermodynamic calculation	919:943	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	9	63	theme	DFT	1173:1175	arg1	theory					1197:1202	density functional theory	1178:1202	density functional theory	1178:1202	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	9	63	theme	DFT	1173:1175	arg1	calculations					1205:1216	The DFT (density functional theory) calculations	1169:1216	The DFT (density functional theory) calculations	1169:1216	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	4	64	theme	pH	606:607	arg1	level					548:552	optimum level	540:552	optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively)	540:685	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35405153	3	65	theme	initial	419:425	arg1	pH					415:416	pH	415:416	pH	415:416	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	3	65	theme	initial	419:425	arg1	concentration					427:439	initial concentration	419:439	initial concentration	419:439	MB dye removal was analyzed at different operating conditions (pH, initial concentration, temperature, composite dose).
35405153	11	66	theme	industrial	1542:1551	arg1	effluents					1553:1561	industrial effluents	1542:1561	industrial effluents	1542:1561	Therefore, these composites can be considered as low-cost alternative adsorbents for the pollution remediation caused by dyes in industrial effluents.
35405153	1	67	theme	Cellulose/clay/sodium	116:136	arg1	composites					147:156	Cellulose/clay/sodium alginate composites	116:156	Cellulose/clay/sodium alginate composites	116:156	Cellulose/clay/sodium alginate composites were prepared and employed for the removal of methylene blue (MB) dye.
35405153	2	68	used	used	281:284	arg2	Cellulose					229:237	Cellulose	229:237	Cellulose	229:237	Cellulose was extracted from a paper mill waste and used for composite preparation with sodium alginate (Na-Alg) and clay.
35405153	7	69	theme	spontaneous	1020:1030	arg1	adsorption					970:979	the MB dye adsorption	959:979	the MB dye adsorption on these composites	959:999	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	7	69	theme	spontaneous	1020:1030	arg1	process					1045:1051	an exothermic, spontaneous and feasible process	1005:1051	an exothermic, spontaneous and feasible process	1005:1051	Thermodynamic calculation revealed that the MB dye adsorption on these composites was an exothermic, spontaneous and feasible process.
35405153	9	70	theme	density	1178:1184	arg1	theory					1197:1202	density functional theory	1178:1202	density functional theory	1178:1202	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	9	70	theme	density	1178:1184	arg1	calculations					1205:1216	The DFT (density functional theory) calculations	1169:1216	The DFT (density functional theory) calculations	1169:1216	The DFT (density functional theory) calculations were executed to explain the interactions responsible for the adsorption of MB dye on the composites.
35405153	1	71	theme	alginate	138:145	arg1	composites					147:156	Cellulose/clay/sodium alginate composites	116:156	Cellulose/clay/sodium alginate composites	116:156	Cellulose/clay/sodium alginate composites were prepared and employed for the removal of methylene blue (MB) dye.
35405153	4	72	theme	60 min	530:535	arg1	time					522:525	an equilibrium time	507:525	an equilibrium time of 60 min	507:535	The dye was adsorbed up to 90% for an equilibrium time of 60 min at optimum level of adsorbent dose (0.05 g), temperature (30 °C) and pH (i.e., 7 and 11 for cellulose-Na-Alg and cellulose-Na-Alg-clay, respectively).
35990042	4	0	from	spongy	636:641	arg1	neutral					618:624	neutral	618:624	neutral	618:624	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	7	1	from	%	1107:1107	arg1	days					1135:1138	21 days	1132:1138	21 days	1132:1138	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	7	1	from	%	1107:1107	arg1	days					1115:1118	14 days	1112:1118	14 days	1112:1118	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	8	2	theme	necrosis	1227:1234	arg1	response					1180:1187	a stable inflammatory response	1158:1187	a stable inflammatory response	1158:1187	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	8	2	theme	necrosis	1227:1234	arg1	evidence					1196:1203	no evidence	1193:1203	no evidence of cell degeneration, necrosis, or abnormal hyperplasia	1193:1259	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	9	3	theme	hemorrhagic	1347:1357	arg1	model					1365:1369	the hemorrhagic liver model	1343:1369	the hemorrhagic liver model	1343:1369	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	5	4	theme	tensile	766:772	arg1	strengths					774:782	The composite's compressive and tensile strengths	734:782	strengths	774:782	The composite's compressive and tensile strengths were 0.1 MPa and 15.2 MPa, respectively.
35990042	9	5	theme	cellulose	1427:1435	arg1	group					1447:1451	the cellulose composite group	1423:1451	the cellulose composite group	1423:1451	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	1	6	theme	bleeding	173:180	arg1	amount					163:168	the amount	159:168	the amount of bleeding	159:180	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	1	6	theme	bleeding	173:180	arg1	bleeding					173:180	bleeding	173:180	bleeding	173:180	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	6	7	theme	degradation	980:990	arg1	rate					992:995	100% degradation rate	975:995	100% degradation rate	975:995	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	3	8	theme	biodegradable	359:371	arg1	material					410:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	6	9	theme	molecule	906:913	arg1	stripping					915:923	petite molecule stripping	899:923	petite molecule stripping	899:923	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	10	10	theme	promising	1609:1617	arg1	composite					1594:1602	the novel cellulose composite	1574:1602	the novel cellulose composite	1574:1602	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	10	10	theme	promising	1609:1617	arg1	material					1642:1649	a promising implantable hemostatic material	1607:1649	a promising implantable hemostatic material in clinical settings	1607:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	10	11	theme	hemostatic	1631:1640	arg1	composite					1594:1602	the novel cellulose composite	1574:1602	the novel cellulose composite	1574:1602	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	10	11	theme	hemostatic	1631:1640	arg1	material					1642:1649	a promising implantable hemostatic material	1607:1649	a promising implantable hemostatic material in clinical settings	1607:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	6	12	theme	%	978:978	arg1	rate					992:995	100% degradation rate	975:995	100% degradation rate	975:995	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	3	13	theme	cellulose-based	373:387	arg1	material					410:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	6	14	theme	petite	899:904	arg1	stripping					915:923	petite molecule stripping	899:923	petite molecule stripping	899:923	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	10	15	from	material	1642:1649	arg1	settings					1663:1670	clinical settings	1654:1670	clinical settings	1654:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	2	16	theme	hemostatic	285:294	arg1	materials					296:304	the current hemostatic materials	273:304	the current hemostatic materials	273:304	However, none of the current hemostatic materials are ideal and have disadvantages.
35990042	6	17	theme	100	975:977	arg1	%					978:978	%	978:978	%	978:978	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	4	18	from	neutral	618:624	arg1	spongy					636:641	spongy	636:641	spongy	636:641	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	18	from	neutral	618:624	arg1	pH					629:630	pH	629:630	pH	629:630	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	19	theme	pore	711:714	arg1	size					716:719	an average pore size	700:719	an average pore size of 13.45 μm	700:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	7	20	theme	composite	1063:1071	arg1	faster					1086:1091	faster	1086:1091	faster	1086:1091	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	7	20	theme	composite	1063:1071	arg1	rate					1051:1054	the degradation rate	1035:1054	the degradation rate of the composite	1035:1071	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	2	21	theme	current	277:283	arg1	materials					296:304	the current hemostatic materials	273:304	the current hemostatic materials	273:304	However, none of the current hemostatic materials are ideal and have disadvantages.
35990042	4	22	theme	porosity	676:683	arg1	density					650:656	a density	648:656	a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm	648:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	3	23	theme	novel	353:357	arg1	material					410:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	9	24	theme	liver	1359:1363	arg1	model					1365:1369	the hemorrhagic liver model	1343:1369	the hemorrhagic liver model	1343:1369	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	25	theme	composite	1437:1445	arg1	group					1447:1451	the cellulose composite group	1423:1451	the cellulose composite group	1423:1451	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	10	26	theme	cellulose	1584:1592	arg1	composite					1594:1602	the novel cellulose composite	1574:1602	the novel cellulose composite	1574:1602	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	10	26	theme	cellulose	1584:1592	arg1	material					1642:1649	a promising implantable hemostatic material	1607:1649	a promising implantable hemostatic material in clinical settings	1607:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	8	27	theme	inflammatory	1167:1178	arg1	response					1180:1187	a stable inflammatory response	1158:1187	a stable inflammatory response	1158:1187	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	7	28	from	%	1127:1127	arg1	days					1135:1138	21 days	1132:1138	21 days	1132:1138	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	7	28	from	%	1127:1127	arg1	days					1115:1118	14 days	1112:1118	14 days	1112:1118	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	6	29	dep	in	831:832	arg1	vitro					834:838	vitro	834:838	vitro	834:838	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	1	30	theme	Degradable	92:101	arg1	materials					114:122	Degradable hemostatic materials	92:122	Degradable hemostatic materials	92:122	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	3	31	theme	carboxymethyl	455:467	arg1	CCNa					480:483	CCNa	480:483	CCNa	480:483	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	3	31	theme	carboxymethyl	455:467	arg1	cellulose					469:477	sodium carboxymethyl cellulose	448:477	sodium carboxymethyl cellulose (CCNa)	448:484	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	0	32	theme	Biological	0:9	arg1	Application					11:21	Biological Application	0:21	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.	0:90	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.
35990042	4	33	theme	cellulose	585:593	arg1	material					605:612	The resulting cellulose composite material	571:612	The resulting cellulose composite material	571:612	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	9	34	theme	medical	1489:1495	arg1	group					1503:1507	the medical gauze group	1485:1507	the medical gauze group	1485:1507	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	35	from	loss	1415:1418	arg1	group					1447:1451	the cellulose composite group	1423:1451	the cellulose composite group	1423:1451	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	1	36	theme	hemostatic	103:112	arg1	materials					114:122	Degradable hemostatic materials	92:122	Degradable hemostatic materials	92:122	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	8	37	theme	embedded	1287:1294	arg1	material					1296:1303	the embedded material	1283:1303	the embedded material	1283:1303	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	1	38	theme	surgical	198:205	arg1	time					217:220	the surgical operation time	194:220	the surgical operation time	194:220	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	0	39	theme	Novel	26:30	arg1	Composite					56:64	Novel Biodegradable Cellulose Composite	26:64	Novel Biodegradable Cellulose Composite	26:64	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.
35990042	4	40	theme	13.45 μm	724:731	arg1	0.042 g/cm3					661:671	0.042 g/cm3	661:671	0.042 g/cm3	661:671	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	40	theme	13.45 μm	724:731	arg1	porosity					676:683	a porosity	674:683	a porosity of 77.68%	674:693	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	40	theme	13.45 μm	724:731	arg1	size					716:719	an average pore size	700:719	an average pore size of 13.45 μm	700:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	7	41	theme	degradation	1039:1049	arg1	faster					1086:1091	faster	1086:1091	faster	1086:1091	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	7	41	theme	degradation	1039:1049	arg1	rate					1051:1054	the degradation rate	1035:1054	the degradation rate of the composite	1035:1071	When implanted into rats, the degradation rate of the composite was slightly faster, reaching 99.7% in 14 days and 100% in 21 days.
35990042	8	42	theme	good	1317:1320	arg1	biocompatibility					1322:1337	good biocompatibility	1317:1337	good biocompatibility	1317:1337	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	3	43	theme	hydroxyethyl	490:501	arg1	HEC					514:516	HEC	514:516	HEC	514:516	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	3	43	theme	hydroxyethyl	490:501	arg1	cellulose					503:511	hydroxyethyl cellulose	490:511	hydroxyethyl cellulose (HEC)	490:517	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	3	44	theme	hemostatic	399:408	arg1	material					410:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	3	45	theme	freeze-drying	549:561	arg1	method					563:568	an improved vacuum freeze-drying method	530:568	an improved vacuum freeze-drying method	530:568	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	9	46	theme	gauze	1497:1501	arg1	group					1503:1507	the medical gauze group	1485:1507	the medical gauze group	1485:1507	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	8	47	theme	hyperplasia	1249:1259	arg1	response					1180:1187	a stable inflammatory response	1158:1187	a stable inflammatory response	1158:1187	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	8	47	theme	hyperplasia	1249:1259	arg1	evidence					1196:1203	no evidence	1193:1203	no evidence of cell degeneration, necrosis, or abnormal hyperplasia	1193:1259	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	0	48	theme	Cellulose	46:54	arg1	Composite					56:64	Novel Biodegradable Cellulose Composite	26:64	Novel Biodegradable Cellulose Composite	26:64	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.
35990042	4	49	theme	composite	595:603	arg1	material					605:612	The resulting cellulose composite material	571:612	The resulting cellulose composite material	571:612	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	10	50	theme	novel	1578:1582	arg1	composite					1594:1602	the novel cellulose composite	1574:1602	the novel cellulose composite	1574:1602	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	10	50	theme	novel	1578:1582	arg1	material					1642:1649	a promising implantable hemostatic material	1607:1649	a promising implantable hemostatic material in clinical settings	1607:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	9	51	theme	total	1403:1407	arg1	loss					1415:1418	the total blood loss	1399:1418	the total blood loss in the cellulose composite group	1399:1451	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	52	theme	blank	1517:1521	arg1	group					1531:1535	the blank control group	1513:1535	the blank control group (P < 0.05)	1513:1546	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	52	theme	blank	1517:1521	arg1	<					1540:1540	P < 0.05	1538:1545	P < 0.05	1538:1545	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	8	53	theme	degeneration	1213:1224	arg1	response					1180:1187	a stable inflammatory response	1158:1187	a stable inflammatory response	1158:1187	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	8	53	theme	degeneration	1213:1224	arg1	evidence					1196:1203	no evidence	1193:1203	no evidence of cell degeneration, necrosis, or abnormal hyperplasia	1193:1259	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	0	54	theme	Biodegradable	32:44	arg1	Composite					56:64	Novel Biodegradable Cellulose Composite	26:64	Novel Biodegradable Cellulose Composite	26:64	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.
35990042	1	55	contain	have	124:127	arg1	materials					114:122	Degradable hemostatic materials	92:122	Degradable hemostatic materials	92:122	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	1	55	contain	have	124:127	arg2	advantages					136:145	unique advantages	129:145	unique advantages	129:145	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	3	56	theme	sodium	448:453	arg1	CCNa					480:483	CCNa	480:483	CCNa	480:483	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	3	56	theme	sodium	448:453	arg1	cellulose					469:477	sodium carboxymethyl cellulose	448:477	sodium carboxymethyl cellulose (CCNa)	448:484	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	8	57	theme	abnormal	1240:1247	arg1	hyperplasia					1249:1259	abnormal hyperplasia	1240:1259	abnormal hyperplasia	1240:1259	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	3	58	theme	composite	389:397	arg1	material					410:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	a novel biodegradable cellulose-based composite hemostatic material	351:417	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	4	59	theme	0.042 g/cm3	661:671	arg1	density					650:656	a density	648:656	a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm	648:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	8	60	theme	stable	1160:1165	arg1	response					1180:1187	a stable inflammatory response	1158:1187	a stable inflammatory response	1158:1187	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	4	61	from	pH	629:630	arg1	neutral					618:624	neutral	618:624	neutral	618:624	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	62	theme	resulting	575:583	arg1	material					605:612	The resulting cellulose composite material	571:612	The resulting cellulose composite material	571:612	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	9	63	theme	control	1523:1529	arg1	group					1531:1535	the blank control group	1513:1535	the blank control group (P < 0.05)	1513:1546	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	63	theme	control	1523:1529	arg1	<					1540:1540	P < 0.05	1538:1545	P < 0.05	1538:1545	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	1	64	theme	unique	129:134	arg1	advantages					136:145	unique advantages	129:145	unique advantages	129:145	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	0	65	theme	Composite	56:64	arg1	Application					11:21	Biological Application	0:21	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.	0:90	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.
35990042	10	66	theme	clinical	1654:1661	arg1	settings					1663:1670	clinical settings	1654:1670	clinical settings	1654:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	4	67	theme	average	703:709	arg1	size					716:719	an average pore size	700:719	an average pore size of 13.45 μm	700:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	5	68	dep	compressive	750:760	arg1	's					747:748	's	747:748	's	747:748	The composite's compressive and tensile strengths were 0.1 MPa and 15.2 MPa, respectively.
35990042	2	69	contain	have	320:323	arg2	disadvantages					325:337	disadvantages	325:337	disadvantages	325:337	However, none of the current hemostatic materials are ideal and have disadvantages.
35990042	2	69	contain	have	320:323	arg1	none					265:268	none	265:268	none	265:268	However, none of the current hemostatic materials are ideal and have disadvantages.
35990042	4	70	theme	%	693:693	arg1	0.042 g/cm3					661:671	0.042 g/cm3	661:671	0.042 g/cm3	661:671	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	70	theme	%	693:693	arg1	porosity					676:683	a porosity	674:683	a porosity of 77.68%	674:693	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	4	70	theme	%	693:693	arg1	size					716:719	an average pore size	700:719	an average pore size of 13.45 μm	700:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	10	71	theme	implantable	1619:1629	arg1	composite					1594:1602	the novel cellulose composite	1574:1602	the novel cellulose composite	1574:1602	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	10	71	theme	implantable	1619:1629	arg1	material					1642:1649	a promising implantable hemostatic material	1607:1649	a promising implantable hemostatic material in clinical settings	1607:1670	These data indicate that the novel cellulose composite is a promising implantable hemostatic material in clinical settings.
35990042	6	72	theme	in	831:832	arg1	conditions					840:849	in vitro conditions	831:849	in vitro conditions	831:849	Under in vitro conditions, the composites were degraded gradually through petite molecule stripping and dissolution, reaching 96.8% after 14 days and 100% degradation rate at 21 days.
35990042	9	73	theme	P	1538:1538	arg1	group					1531:1535	the blank control group	1513:1535	the blank control group (P < 0.05)	1513:1546	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	73	theme	P	1538:1538	arg1	<					1540:1540	P < 0.05	1538:1545	P < 0.05	1538:1545	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	4	74	theme	size	716:719	arg1	density					650:656	a density	648:656	a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm	648:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	1	75	theme	patient	237:243	arg1	prognosis					245:253	patient prognosis	237:253	patient prognosis	237:253	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	0	76	theme	Hemostatic	71:80	arg1	Material					82:89	a Hemostatic Material	69:89	a Hemostatic Material	69:89	Biological Application of Novel Biodegradable Cellulose Composite as a Hemostatic Material.
35990042	8	77	theme	cell	1208:1211	arg1	degeneration					1213:1224	cell degeneration	1208:1224	cell degeneration	1208:1224	Histology showed a stable inflammatory response and no evidence of cell degeneration, necrosis, or abnormal hyperplasia in the tissues around the embedded material, indicating good biocompatibility.
35990042	4	78	with	neutral	618:624	arg1	density					650:656	a density	648:656	a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm	648:731	The resulting cellulose composite material was neutral in pH and spongy with a density of 0.042 g/cm3, a porosity of 77.68%, and an average pore size of 13.45 μm.
35990042	1	79	theme	operation	207:215	arg1	time					217:220	the surgical operation time	194:220	the surgical operation time	194:220	Degradable hemostatic materials have unique advantages in reducing the amount of bleeding, shortening the surgical operation time, and improving patient prognosis.
35990042	3	80	theme	improved	533:540	arg1	method					563:568	an improved vacuum freeze-drying method	530:568	an improved vacuum freeze-drying method	530:568	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
35990042	9	81	theme	blood	1409:1413	arg1	loss					1415:1418	the total blood loss	1399:1418	the total blood loss in the cellulose composite group	1399:1451	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	9	82	from	hemostasis	1384:1393	arg1	group					1447:1451	the cellulose composite group	1423:1451	the cellulose composite group	1423:1451	In the hemorrhagic liver model, the time to hemostasis and the total blood loss in the cellulose composite group was significantly lower than in the medical gauze group and the blank control group (P < 0.05).
35990042	3	83	theme	vacuum	542:547	arg1	method					563:568	an improved vacuum freeze-drying method	530:568	an improved vacuum freeze-drying method	530:568	Therefore, a novel biodegradable cellulose-based composite hemostatic material was prepared by crosslinking sodium carboxymethyl cellulose (CCNa) and hydroxyethyl cellulose (HEC), following an improved vacuum freeze-drying method.
36963540	4	0	theme	weight	445:450	arg1	distribution					452:463	the molecular weight distribution	431:463	the molecular weight distribution	431:463	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	7	1	theme	immunomodulatory	820:835	arg1	action					837:842	immunomodulatory action	820:842	immunomodulatory action of longan polysaccharides	820:868	This study helps to illuminate the potential mode of immunomodulatory action of longan polysaccharides in vivo.
36963540	0	2	theme	cell	79:82	arg1	activation					84:93	dendritic cell activation	69:93	dendritic cell activation	69:93	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	4	3	theme	monosaccharide	466:479	arg1	composition					481:491	monosaccharide composition	466:491	monosaccharide composition	466:491	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	6	4	theme	significant	743:753	arg1	difference					755:764	no significant difference	740:764	no significant difference	740:764	In addition, the effects of LP and DLP on activating dendritic cells showed no significant difference.
36963540	7	5	theme	potential	802:810	arg1	mode					812:815	the potential mode	798:815	the potential mode of immunomodulatory action of longan polysaccharides	798:868	This study helps to illuminate the potential mode of immunomodulatory action of longan polysaccharides in vivo.
36963540	0	6	theme	longan	98:103	arg1	polysaccharides					105:119	longan polysaccharides	98:119	longan polysaccharides	98:119	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	0	7	from	Effects	0:6	arg1	activation					84:93	dendritic cell activation	69:93	dendritic cell activation	69:93	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	0	7	from	Effects	0:6	arg1	characteristics					49:63	structural characteristics	38:63	structural characteristics	38:63	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	1	8	from	longan	157:162	arg1	polysaccharide					132:145	An active polysaccharide	122:145	An active polysaccharide (LP) from longan	122:162	An active polysaccharide (LP) from longan was purified and characterized.
36963540	1	8	from	longan	157:162	arg1	LP					148:149	LP	148:149	LP	148:149	An active polysaccharide (LP) from longan was purified and characterized.
36963540	3	9	theme	LP	331:332	arg1	backbone					319:326	The main backbone	310:326	The main backbone of LP	310:332	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	3	9	theme	LP	331:332	arg1	n					384:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	3	10	theme	main	314:317	arg1	backbone					319:326	The main backbone	310:326	The main backbone of LP	310:332	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	3	10	theme	main	314:317	arg1	n					384:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	5	11	theme	digested	566:573	arg1	DLP					579:581	DLP	579:581	DLP	579:581	LP and digested LP (DLP) reduced phagocytosis and promoted IL-10 and IL-12 secretion of dendritic cells.
36963540	5	11	theme	digested	566:573	arg1	LP					575:576	digested LP	566:576	digested LP (DLP)	566:582	LP and digested LP (DLP) reduced phagocytosis and promoted IL-10 and IL-12 secretion of dendritic cells.
36963540	0	12	theme	polysaccharides	105:119	arg1	activation					84:93	dendritic cell activation	69:93	dendritic cell activation	69:93	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	0	12	theme	polysaccharides	105:119	arg1	characteristics					49:63	structural characteristics	38:63	structural characteristics	38:63	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	4	13	theme	molecular	435:443	arg1	distribution					452:463	the molecular weight distribution	431:463	the molecular weight distribution	431:463	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	6	14	theme	dendritic	717:725	arg1	cells					727:731	dendritic cells	717:731	dendritic cells	717:731	In addition, the effects of LP and DLP on activating dendritic cells showed no significant difference.
36963540	2	15	theme	1.5	254:256	arg1	ratio					245:249	a molar ratio	237:249	a molar ratio of 1.5: 98.5	237:262	LP consisted of galactose and glucose in a molar ratio of 1.5: 98.5, with a molecular weight of 4.67 × 107 g/mol.
36963540	2	16	theme	molecular	272:280	arg1	weight					282:287	a molecular weight	270:287	a molecular weight of 4.67 × 107 g/mol	270:307	LP consisted of galactose and glucose in a molar ratio of 1.5: 98.5, with a molecular weight of 4.67 × 107 g/mol.
36963540	0	17	theme	structural	38:47	arg1	characteristics					49:63	structural characteristics	38:63	structural characteristics	38:63	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	3	18	theme	-α-D-Glcp	374:382	arg1	backbone					319:326	The main backbone	310:326	The main backbone of LP	310:332	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	3	18	theme	-α-D-Glcp	374:382	arg1	n					384:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	0	19	theme	digestion	21:29	arg1	Effects					0:6	Effects	0:6	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.	0:120	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	4	20	theme	glycosidic	504:513	arg1	bonds					515:519	major glycosidic bonds	498:519	major glycosidic bonds	498:519	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	6	21	theme	DLP	699:701	arg1	effects					681:687	the effects	677:687	the effects of LP and DLP on activating dendritic cells	677:731	In addition, the effects of LP and DLP on activating dendritic cells showed no significant difference.
36963540	0	22	theme	simulated	11:19	arg1	digestion					21:29	simulated digestion	11:29	simulated digestion	11:29	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	4	23	theme	LP	524:525	arg1	distribution					452:463	the molecular weight distribution	431:463	the molecular weight distribution	431:463	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	4	23	theme	LP	524:525	arg1	composition					481:491	monosaccharide composition	466:491	monosaccharide composition	466:491	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	4	23	theme	LP	524:525	arg1	bonds					515:519	major glycosidic bonds	498:519	major glycosidic bonds	498:519	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	5	24	theme	dendritic	647:655	arg1	cells					657:661	dendritic cells	647:661	dendritic cells	647:661	LP and digested LP (DLP) reduced phagocytosis and promoted IL-10 and IL-12 secretion of dendritic cells.
36963540	5	25	theme	cells	657:661	arg1	secretion					634:642	IL-10 and IL-12 secretion	618:642	IL-10 and IL-12 secretion of dendritic cells	618:661	LP and digested LP (DLP) reduced phagocytosis and promoted IL-10 and IL-12 secretion of dendritic cells.
36963540	0	26	dep	characteristics	49:63	arg1	the					34:36	the	34:36	the	34:36	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	4	27	theme	gastrointestinal	403:418	arg1	digestion					420:428	simulated gastrointestinal digestion	393:428	simulated gastrointestinal digestion	393:428	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	5	28	theme	IL-10	618:622	arg1	secretion					634:642	IL-10 and IL-12 secretion	618:642	IL-10 and IL-12 secretion of dendritic cells	618:661	LP and digested LP (DLP) reduced phagocytosis and promoted IL-10 and IL-12 secretion of dendritic cells.
36963540	4	29	theme	simulated	393:401	arg1	digestion					420:428	simulated gastrointestinal digestion	393:428	simulated gastrointestinal digestion	393:428	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	6	30	theme	LP	692:693	arg1	effects					681:687	the effects	677:687	the effects of LP and DLP on activating dendritic cells	677:731	In addition, the effects of LP and DLP on activating dendritic cells showed no significant difference.
36963540	3	31	theme	-α-D-Glcp-	357:366	arg1	backbone					319:326	The main backbone	310:326	The main backbone of LP	310:332	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	3	31	theme	-α-D-Glcp-	357:366	arg1	n					384:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n	338:384	The main backbone of LP was T-α-D-Glcp-[(1 → 6)-α-D-Glcp-(1 → 6)-α-D-Glcp]n.
36963540	4	32	theme	major	498:502	arg1	bonds					515:519	major glycosidic bonds	498:519	major glycosidic bonds	498:519	After simulated gastrointestinal digestion, the molecular weight distribution, monosaccharide composition, and major glycosidic bonds of LP were not significantly changed.
36963540	1	33	theme	active	125:130	arg1	polysaccharide					132:145	An active polysaccharide	122:145	An active polysaccharide (LP) from longan	122:162	An active polysaccharide (LP) from longan was purified and characterized.
36963540	1	33	theme	active	125:130	arg1	LP					148:149	LP	148:149	LP	148:149	An active polysaccharide (LP) from longan was purified and characterized.
36963540	7	34	theme	longan	847:852	arg1	polysaccharides					854:868	longan polysaccharides	847:868	longan polysaccharides	847:868	This study helps to illuminate the potential mode of immunomodulatory action of longan polysaccharides in vivo.
36963540	5	35	theme	IL-12	628:632	arg1	secretion					634:642	IL-10 and IL-12 secretion	618:642	IL-10 and IL-12 secretion of dendritic cells	618:661	LP and digested LP (DLP) reduced phagocytosis and promoted IL-10 and IL-12 secretion of dendritic cells.
36963540	2	36	theme	4.67 × 107 g/mol	292:307	arg1	weight					282:287	a molecular weight	270:287	a molecular weight of 4.67 × 107 g/mol	270:307	LP consisted of galactose and glucose in a molar ratio of 1.5: 98.5, with a molecular weight of 4.67 × 107 g/mol.
36963540	7	37	theme	polysaccharides	854:868	arg1	action					837:842	immunomodulatory action	820:842	immunomodulatory action of longan polysaccharides	820:868	This study helps to illuminate the potential mode of immunomodulatory action of longan polysaccharides in vivo.
36963540	7	38	theme	action	837:842	arg1	mode					812:815	the potential mode	798:815	the potential mode of immunomodulatory action of longan polysaccharides	798:868	This study helps to illuminate the potential mode of immunomodulatory action of longan polysaccharides in vivo.
36963540	0	39	theme	dendritic	69:77	arg1	activation					84:93	dendritic cell activation	69:93	dendritic cell activation	69:93	Effects of simulated digestion on the structural characteristics and dendritic cell activation of longan polysaccharides.
36963540	2	40	theme	molar	239:243	arg1	ratio					245:249	a molar ratio	237:249	a molar ratio of 1.5: 98.5	237:262	LP consisted of galactose and glucose in a molar ratio of 1.5: 98.5, with a molecular weight of 4.67 × 107 g/mol.
36963540	2	41	dep	1.5	254:256	arg1	98.5					259:262	98.5	259:262	98.5	259:262	LP consisted of galactose and glucose in a molar ratio of 1.5: 98.5, with a molecular weight of 4.67 × 107 g/mol.
36736188	5	0	theme	defecation	602:611	arg1	time					613:616	the defecation time	598:616	the defecation time	598:616	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	1	1	from	effects	161:167	arg1	shells					202:207	the hard shells	193:207	the hard shells ofJuglans regiaL	193:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	0	2	theme	intestinal	66:75	arg1	function					77:84	intestinal function	66:84	intestinal function	66:84	Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo.
36736188	7	3	theme	bacteriaand	952:962	arg1	theabundances					924:936	JRPvia increasing theabundances	906:936	JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria	906:1006	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	0	4	theme	gut	90:92	arg1	microbiota					94:103	gut microbiota	90:103	gut microbiota	90:103	Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo.
36736188	6	5	theme	fatty	766:770	arg1	acids					772:776	short chain fatty acids	754:776	short chain fatty acids	754:776	After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine.
36736188	5	6	theme	colonic	567:573	arg1	moisture					581:588	colonic fecal moisture	567:588	colonic fecal moisture by JRP	567:595	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	3	7	theme	colonic	331:337	arg1	length					339:344	colonic length	331:344	colonic length	331:344	The results showed that JRP could increase the colonic length and colonic index, and ameliorate the histological characteristics of colon.
36736188	5	8	theme	fecal	575:579	arg1	moisture					581:588	colonic fecal moisture	567:588	colonic fecal moisture by JRP	567:595	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	2	9	theme	gut	260:262	arg1	microbiota					264:273	gut microbiota	260:273	gut microbiota of mice	260:281	(JRP) on intestinal function and gut microbiota of mice.
36736188	7	10	theme	community	835:843	arg1	analysis					845:852	microbial community analysis	825:852	microbial community analysis	825:852	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	4	11	theme	positive	433:440	arg1	effect					442:447	a positive effect	431:447	a positive effect on immunity of mice	431:467	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	5	12	theme	moisture	581:588	arg1	increase					555:562	increase	555:562	increase of colonic fecal moisture by JRP	555:595	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	5	12	theme	moisture	581:588	arg1	enhancement					513:523	enhancement	513:523	enhancement of intestinal peristalsis	513:549	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	1	13	theme	modulatory	150:159	arg1	effects					161:167	the modulatory effects	146:167	the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL	146:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	5	14	theme	intestinal	528:537	arg1	peristalsis					539:549	intestinal peristalsis	528:549	intestinal peristalsis	528:549	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	3	15	theme	colon	416:420	arg1	characteristics					397:411	the histological characteristics	380:411	the histological characteristics of colon	380:420	The results showed that JRP could increase the colonic length and colonic index, and ameliorate the histological characteristics of colon.
36736188	3	16	theme	colonic	350:356	arg1	index					358:362	colonic index	350:362	colonic index	350:362	The results showed that JRP could increase the colonic length and colonic index, and ameliorate the histological characteristics of colon.
36736188	0	17	from	shells	30:35	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides from the hard shells of Juglans regia L.	0:55	Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo.
36736188	4	18	from	effect	442:447	arg1	immunity					452:459	immunity	452:459	immunity	452:459	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	5	19	theme	peristalsis	539:549	arg1	increase					555:562	increase	555:562	increase of colonic fecal moisture by JRP	555:595	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	5	19	theme	peristalsis	539:549	arg1	enhancement					513:523	enhancement	513:523	enhancement of intestinal peristalsis	513:549	Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced.
36736188	7	20	theme	microbial	825:833	arg1	analysis					845:852	microbial community analysis	825:852	microbial community analysis	825:852	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	3	21	theme	histological	384:395	arg1	characteristics					397:411	the histological characteristics	380:411	the histological characteristics of colon	380:420	The results showed that JRP could increase the colonic length and colonic index, and ameliorate the histological characteristics of colon.
36736188	6	22	theme	chain	760:764	arg1	acids					772:776	short chain fatty acids	754:776	short chain fatty acids	754:776	After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine.
36736188	6	23	theme	gastrointestinal	651:666	arg1	digestion					668:676	gastrointestinal digestion	651:676	gastrointestinal digestion	651:676	After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine.
36736188	1	24	theme	polysaccharides	172:186	arg1	effects					161:167	the modulatory effects	146:167	the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL	146:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	0	25	theme	hard	25:28	arg1	shells					30:35	the hard shells	21:35	the hard shells of Juglans regia L.	21:55	Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo.
36736188	6	26	theme	short	754:758	arg1	acids					772:776	short chain fatty acids	754:776	short chain fatty acids	754:776	After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine.
36736188	2	27	theme	mice	278:281	arg1	function					247:254	intestinal function	236:254	intestinal function	236:254	(JRP) on intestinal function and gut microbiota of mice.
36736188	2	27	theme	mice	278:281	arg1	microbiota					264:273	gut microbiota	260:273	gut microbiota of mice	260:281	(JRP) on intestinal function and gut microbiota of mice.
36736188	4	28	contain	had	427:429	arg1	JRP					423:425	JRP	423:425	JRP	423:425	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	4	28	contain	had	427:429	arg2	effect					442:447	a positive effect	431:447	a positive effect on immunity of mice	431:467	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	8	29	theme	excellent	1058:1066	arg1	prebiotic					1068:1076	an excellent prebiotic	1055:1076	an excellent prebiotic to promote intestinal health	1055:1105	This study suggests that JRP can be served as an excellent prebiotic to promote intestinal health.
36736188	7	30	theme	beneficial	941:950	arg1	bacteriaand					952:962	beneficial bacteriaand	941:962	beneficial bacteriaand decreasing the richness of harmful bacteria	941:1006	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	1	31	theme	hard	197:200	arg1	shells					202:207	the hard shells	193:207	the hard shells ofJuglans regiaL	193:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	4	32	theme	organ	489:493	arg1	indexes					495:501	immune organ indexes	482:501	immune organ indexes	482:501	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	0	33	dep	Juglans	40:46	arg1	L.					54:55	Juglans regia L.	40:55	Juglans regia L.	40:55	Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo.
36736188	4	34	theme	immune	482:487	arg1	indexes					495:501	immune organ indexes	482:501	immune organ indexes	482:501	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	1	35	from	shells	202:207	arg1	polysaccharides					172:186	polysaccharides	172:186	polysaccharides from the hard shells ofJuglans regiaL	172:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	1	35	from	shells	202:207	arg1	effects					161:167	the modulatory effects	146:167	the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL	146:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	0	36	theme	Juglans	40:46	arg1	shells					30:35	the hard shells	21:35	the hard shells of Juglans regia L.	21:55	Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo.
36736188	8	37	theme	intestinal	1089:1098	arg1	health					1100:1105	intestinal health	1089:1105	intestinal health	1089:1105	This study suggests that JRP can be served as an excellent prebiotic to promote intestinal health.
36736188	7	38	theme	increasing	913:922	arg1	theabundances					924:936	JRPvia increasing theabundances	906:936	JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria	906:1006	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	7	39	theme	bacteria	999:1006	arg1	richness					979:986	the richness	975:986	the richness of harmful bacteria	975:1006	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	7	40	theme	JRPvia	906:911	arg1	theabundances					924:936	JRPvia increasing theabundances	906:936	JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria	906:1006	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	6	41	theme	intestine	806:814	arg1	pH					800:801	the pH	796:801	the pH of intestine	796:814	After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine.
36736188	2	42	theme	intestinal	236:245	arg1	function					247:254	intestinal function	236:254	intestinal function	236:254	(JRP) on intestinal function and gut microbiota of mice.
36736188	6	43	theme	intestinal	717:726	arg1	microorganisms					728:741	intestinal microorganisms	717:741	intestinal microorganisms	717:741	After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine.
36736188	7	44	theme	gut	874:876	arg1	microbiota					878:887	gut microbiota	874:887	gut microbiota	874:887	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	1	45	theme	regiaL	219:224	arg1	shells					202:207	the hard shells	193:207	the hard shells ofJuglans regiaL	193:224	This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL.
36736188	7	46	theme	harmful	991:997	arg1	bacteria					999:1006	harmful bacteria	991:1006	harmful bacteria	991:1006	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	7	47	theme	microbiota	878:887	arg1	composition					859:869	the composition	855:869	the composition of gut microbiota	855:887	Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria.
36736188	4	48	theme	mice	464:467	arg1	effect					442:447	a positive effect	431:447	a positive effect on immunity of mice	431:467	JRP had a positive effect on immunity of mice by improving immune organ indexes.
36736188	2	49	dep	function	247:254	arg1	JRP					228:230	JRP	228:230	JRP	228:230	(JRP) on intestinal function and gut microbiota of mice.
36571497	9	0	theme	dynamic	1619:1625	arg1	binding					1631:1637	highly dynamic AOS binding	1612:1637	highly dynamic AOS binding	1612:1637	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	4	1	with	AOSs	912:915	arg1	degree					933:938	increasing degree	922:938	increasing degree of polymerization (DP)	922:961	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	4	1	with	AOSs	912:915	arg1	affinities					975:984	similar affinities	967:984	similar affinities in the mid micromolar range	967:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	6	2	theme	longer	1250:1255	arg1	AOSs					1257:1260	longer AOSs	1250:1260	longer AOSs	1250:1260	Distinct sites for the shorter AOSs merged to accommodate longer AOSs.
36571497	6	3	theme	Distinct	1192:1199	arg1	sites					1201:1205	Distinct sites	1192:1205	Distinct sites for the shorter AOSs	1192:1226	Distinct sites for the shorter AOSs merged to accommodate longer AOSs.
36571497	5	4	theme	residues	1182:1189	arg1	compositions					1135:1146	diverse compositions	1127:1146	diverse compositions of charged, polar and hydrophobic residues	1127:1189	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	3	5	theme	structural	659:668	arg1	components					670:679	the block structural components	649:679	the block structural components of alginates	649:692	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	5	6	theme	polar	1160:1164	arg1	residues					1182:1189	charged, polar and hydrophobic residues	1151:1189	charged, polar and hydrophobic residues	1151:1189	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	3	7	theme	uronic	540:545	arg1	UARs					562:565	UARs	562:565	UARs	562:565	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	7	theme	uronic	540:545	arg1	residues					552:559	four, five or six uronic acid residues	522:559	four, five or six uronic acid residues (UARs)	522:566	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	9	8	theme	confined	1652:1659	arg1	conformations					1661:1673	confined conformations	1652:1673	confined conformations in the β-LgA complexes	1652:1696	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	9	9	from	conformations	1661:1673	arg1	complexes					1688:1696	the β-LgA complexes	1678:1696	the β-LgA complexes	1678:1696	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	7	10	theme	H-ligand-targeted	1355:1371	arg1	analyses					1377:1384	1 H-ligand-targeted NMR analyses	1353:1384	1 H-ligand-targeted NMR analyses	1353:1384	The AOSs bound dynamically to β-LgA, as concluded from saturation transfer difference and 1 H-ligand-targeted NMR analyses.
36571497	5	11	theme	AOS	1029:1031	arg1	sites					1041:1045	The different AOS binding sites	1015:1045	The different AOS binding sites on β-LgA	1015:1054	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	2	12	theme	initial	311:317	arg1	steps					319:323	the initial steps	307:323	the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs)	307:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	1	13	theme	complex	211:217	arg1	coacervation					219:230	complex coacervation	211:230	complex coacervation involving anionic polysaccharides and proteins	211:277	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	9	14	theme	β-LgA	1682:1686	arg1	complexes					1688:1696	the β-LgA complexes	1678:1696	the β-LgA complexes	1678:1696	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	4	15	dep	AOSs	912:915	arg1	to					905:906	to	905:906	to	905:906	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	4	16	theme	binding	860:866	arg1	stoichiometries					868:882	binding stoichiometries	860:882	binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range	860:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	8	17	theme	Schrödinger	1428:1438	arg1	2016-1					1446:1451	the Schrödinger suite 2016-1	1424:1451	the Schrödinger suite 2016-1	1424:1451	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	7	18	theme	transfer	1329:1336	arg1	difference					1338:1347	saturation transfer difference	1318:1347	saturation transfer difference	1318:1347	The AOSs bound dynamically to β-LgA, as concluded from saturation transfer difference and 1 H-ligand-targeted NMR analyses.
36571497	3	19	theme	isothermal	716:725	arg1	calorimetry					737:747	isothermal titration calorimetry	716:747	isothermal titration calorimetry	716:747	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	20	theme	resonance	767:775	arg1	NMR					791:793	NMR	791:793	NMR	791:793	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	20	theme	resonance	767:775	arg1	spectroscopy					777:788	nuclear magnetic resonance spectroscopy	750:788	nuclear magnetic resonance spectroscopy (NMR)	750:794	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	9	21	theme	first	1719:1723	arg1	steps					1725:1729	the first steps	1715:1729	the first steps towards disordered β-LgA alginate coacervate structures	1715:1785	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	3	22	theme	nuclear	750:756	arg1	NMR					791:793	NMR	791:793	NMR	791:793	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	22	theme	nuclear	750:756	arg1	spectroscopy					777:788	nuclear magnetic resonance spectroscopy	750:788	nuclear magnetic resonance spectroscopy (NMR)	750:794	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	5	23	theme	NMR	1075:1077	arg1	analyses					1107:1114	NMR chemical shift perturbation analyses	1075:1114	NMR chemical shift perturbation analyses	1075:1114	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	1	24	theme	biomaterial	156:166	arg1	design					177:182	biomaterial property design	156:182	biomaterial property design	156:182	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	2	25	from	steps	319:323	arg1	formation					339:347	condensate formation	328:347	condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs)	328:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	5	26	theme	shift	1088:1092	arg1	analyses					1107:1114	NMR chemical shift perturbation analyses	1075:1114	NMR chemical shift perturbation analyses	1075:1114	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	1	27	theme	design	177:182	arg1	control					145:151	improved control	136:151	improved control of biomaterial property design	136:182	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	9	28	from	complexes	1688:1696	arg1	lack					1644:1647	lack	1644:1647	lack of confined conformations in the β-LgA complexes	1644:1696	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	9	29	theme	β-LgA	1750:1754	arg1	structures					1776:1785	disordered β-LgA alginate coacervate structures	1739:1785	disordered β-LgA alginate coacervate structures	1739:1785	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	0	30	theme	amorphous	93:101	arg1	aggregates					103:112	their amorphous aggregates	87:112	their amorphous aggregates	87:112	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.
36571497	9	31	theme	coacervate	1765:1774	arg1	structures					1776:1785	disordered β-LgA alginate coacervate structures	1739:1785	disordered β-LgA alginate coacervate structures	1739:1785	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	4	32	theme	polymerization	943:956	arg1	degree					933:938	increasing degree	922:938	increasing degree of polymerization (DP)	922:961	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	4	32	theme	polymerization	943:956	arg1	affinities					975:984	similar affinities	967:984	similar affinities in the mid micromolar range	967:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	2	33	theme	defined	388:394	arg1	AOSs					423:426	AOSs	423:426	AOSs	423:426	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	2	33	theme	defined	388:394	arg1	oligosaccharides					405:420	nine defined alginate oligosaccharides	383:420	nine defined alginate oligosaccharides (AOSs)	383:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	0	34	theme	Molecular	0:8	arg1	insights					10:17	Molecular insights	0:17	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.	0:130	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.
36571497	4	35	theme	micromolar	997:1006	arg1	range					1008:1012	the mid micromolar range	989:1012	the mid micromolar range	989:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	8	36	theme	preferred	1515:1523	arg1	site					1539:1542	the preferred β-LgA binding site	1511:1542	the preferred β-LgA binding site resulting in similar XP glide scores	1511:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	5	37	theme	charged	1151:1157	arg1	residues					1182:1189	charged, polar and hydrophobic residues	1151:1189	charged, polar and hydrophobic residues	1151:1189	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	8	38	theme	binding	1531:1537	arg1	site					1539:1542	the preferred β-LgA binding site	1511:1542	the preferred β-LgA binding site resulting in similar XP glide scores	1511:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	0	39	theme	β-lactoglobulin	33:47	arg1	multivalencies					51:64	alginate β-lactoglobulin A multivalencies	24:64	alginate β-lactoglobulin A multivalencies	24:64	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.
36571497	4	40	from	affinities	975:984	arg1	range					1008:1012	the mid micromolar range	989:1012	the mid micromolar range	989:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	2	41	theme	structural	476:485	arg1	detail					487:492	structural detail	476:492	structural detail	476:492	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	2	42	theme	A	368:368	arg1	formation					339:347	condensate formation	328:347	condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs)	328:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	3	43	theme	AOSs	506:509	arg1	mannuronate					580:590	all mannuronate	576:590	all mannuronate (M)	576:594	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	43	theme	AOSs	506:509	arg1	Binding					495:501	Binding	495:501	Binding of AOSs containing four, five or six uronic acid residues (UARs)	495:566	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	43	theme	AOSs	506:509	arg1	M					631:631	alternating M	619:631	alternating M	619:631	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	43	theme	AOSs	506:509	arg1	G					637:637	G	637:637	G	637:637	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	43	theme	AOSs	506:509	arg1	guluronate					601:610	all guluronate	597:610	all guluronate (G)	597:614	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	8	44	theme	similar	1557:1563	arg1	scores					1574:1579	similar XP glide scores	1557:1579	similar XP glide scores	1557:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	1	45	theme	anionic	242:248	arg1	polysaccharides					250:264	anionic polysaccharides	242:264	anionic polysaccharides	242:264	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	8	46	theme	glide	1568:1572	arg1	scores					1574:1579	similar XP glide scores	1557:1579	similar XP glide scores	1557:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	3	47	theme	alternating	619:629	arg1	Binding					495:501	Binding	495:501	Binding of AOSs containing four, five or six uronic acid residues (UARs)	495:566	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	47	theme	alternating	619:629	arg1	M					631:631	alternating M	619:631	alternating M	619:631	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	48	theme	block	653:657	arg1	components					670:679	the block structural components	649:679	the block structural components of alginates	649:692	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	4	49	from	degree	933:938	arg1	range					1008:1012	the mid micromolar range	989:1012	the mid micromolar range	989:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	9	50	theme	AOS	1627:1629	arg1	binding					1631:1637	highly dynamic AOS binding	1612:1637	highly dynamic AOS binding	1612:1637	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	3	51	theme	acid	547:550	arg1	UARs					562:565	UARs	562:565	UARs	562:565	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	51	theme	acid	547:550	arg1	residues					552:559	four, five or six uronic acid residues	522:559	four, five or six uronic acid residues (UARs)	522:566	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	5	52	theme	hydrophobic	1170:1180	arg1	residues					1182:1189	charged, polar and hydrophobic residues	1151:1189	charged, polar and hydrophobic residues	1151:1189	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	3	53	theme	alginates	684:692	arg1	components					670:679	the block structural components	649:679	the block structural components of alginates	649:692	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	6	54	theme	shorter	1215:1221	arg1	AOSs					1223:1226	the shorter AOSs	1211:1226	the shorter AOSs	1211:1226	Distinct sites for the shorter AOSs merged to accommodate longer AOSs.
36571497	2	55	theme	condensate	328:337	arg1	formation					339:347	condensate formation	328:347	condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs)	328:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	1	56	theme	better	187:192	arg1	understanding					194:206	a better understanding	185:206	a better understanding of complex coacervation involving anionic polysaccharides and proteins	185:277	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	9	57	theme	conformations	1661:1673	arg1	lack					1644:1647	lack	1644:1647	lack of confined conformations in the β-LgA complexes	1644:1696	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	9	58	from	lack	1644:1647	arg1	complexes					1688:1696	the β-LgA complexes	1678:1696	the β-LgA complexes	1678:1696	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	7	59	theme	NMR	1373:1375	arg1	analyses					1377:1384	1 H-ligand-targeted NMR analyses	1353:1384	1 H-ligand-targeted NMR analyses	1353:1384	The AOSs bound dynamically to β-LgA, as concluded from saturation transfer difference and 1 H-ligand-targeted NMR analyses.
36571497	5	60	theme	binding	1033:1039	arg1	sites					1041:1045	The different AOS binding sites	1015:1045	The different AOS binding sites on β-LgA	1015:1054	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	1	61	theme	coacervation	219:230	arg1	understanding					194:206	a better understanding	185:206	a better understanding of complex coacervation involving anionic polysaccharides and proteins	185:277	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	8	62	theme	suite	1440:1444	arg1	2016-1					1446:1451	the Schrödinger suite 2016-1	1424:1451	the Schrödinger suite 2016-1	1424:1451	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	3	63	theme	titration	727:735	arg1	calorimetry					737:747	isothermal titration calorimetry	716:747	isothermal titration calorimetry	716:747	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	1	64	theme	improved	136:143	arg1	control					145:151	improved control	136:151	improved control of biomaterial property design	136:182	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	7	65	theme	saturation	1318:1327	arg1	difference					1338:1347	saturation transfer difference	1318:1347	saturation transfer difference	1318:1347	The AOSs bound dynamically to β-LgA, as concluded from saturation transfer difference and 1 H-ligand-targeted NMR analyses.
36571497	5	66	theme	different	1019:1027	arg1	sites					1041:1045	The different AOS binding sites	1015:1045	The different AOS binding sites on β-LgA	1015:1054	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	3	67	theme	molecular	801:809	arg1	docking					811:817	molecular docking	801:817	molecular docking	801:817	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	8	68	theme	AOSs	1481:1484	arg1	orientation					1466:1476	the orientation	1462:1476	the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores	1462:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	3	69	theme	magnetic	758:765	arg1	NMR					791:793	NMR	791:793	NMR	791:793	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	69	theme	magnetic	758:765	arg1	spectroscopy					777:788	nuclear magnetic resonance spectroscopy	750:788	nuclear magnetic resonance spectroscopy (NMR)	750:794	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	5	70	theme	chemical	1079:1086	arg1	analyses					1107:1114	NMR chemical shift perturbation analyses	1075:1114	NMR chemical shift perturbation analyses	1075:1114	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	1	71	theme	property	168:175	arg1	design					177:182	biomaterial property design	156:182	biomaterial property design	156:182	For improved control of biomaterial property design, a better understanding of complex coacervation involving anionic polysaccharides and proteins is needed.
36571497	9	72	theme	disordered	1739:1748	arg1	structures					1776:1785	disordered β-LgA alginate coacervate structures	1739:1785	disordered β-LgA alginate coacervate structures	1739:1785	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	2	73	from	interactions	460:471	arg1	detail					487:492	structural detail	476:492	structural detail	476:492	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	5	74	from	sites	1041:1045	arg1	β-LgA					1050:1054	β-LgA	1050:1054	β-LgA	1050:1054	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	5	75	theme	perturbation	1094:1105	arg1	analyses					1107:1114	NMR chemical shift perturbation analyses	1075:1114	NMR chemical shift perturbation analyses	1075:1114	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	9	76	theme	alginate	1756:1763	arg1	structures					1776:1785	disordered β-LgA alginate coacervate structures	1739:1785	disordered β-LgA alginate coacervate structures	1739:1785	The multivalency coupled with highly dynamic AOS binding with lack of confined conformations in the β-LgA complexes may help explain the first steps towards disordered β-LgA alginate coacervate structures.
36571497	4	77	theme	increasing	922:931	arg1	degree					933:938	increasing degree	922:938	increasing degree of polymerization (DP)	922:961	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	3	78	contain	containing	511:520	arg1	AOSs					506:509	AOSs	506:509	AOSs containing four, five or six uronic acid residues (UARs)	506:566	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	78	contain	containing	511:520	arg2	UARs					562:565	UARs	562:565	UARs	562:565	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	3	78	contain	containing	511:520	arg2	residues					552:559	four, five or six uronic acid residues	522:559	four, five or six uronic acid residues (UARs)	522:566	Binding of AOSs containing four, five or six uronic acid residues (UARs), either all mannuronate (M), all guluronate (G) or alternating M and G embodying the block structural components of alginates, was characterized by isothermal titration calorimetry, nuclear magnetic resonance spectroscopy (NMR), and molecular docking.
36571497	2	79	theme	alginate	396:403	arg1	AOSs					423:426	AOSs	423:426	AOSs	423:426	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	2	79	theme	alginate	396:403	arg1	oligosaccharides					405:420	nine defined alginate oligosaccharides	383:420	nine defined alginate oligosaccharides (AOSs)	383:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	2	80	theme	multivalent	448:458	arg1	interactions					460:471	their multivalent interactions	442:471	their multivalent interactions in structural detail	442:492	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	8	81	theme	β-LgA	1525:1529	arg1	site					1539:1542	the preferred β-LgA binding site	1511:1542	the preferred β-LgA binding site resulting in similar XP glide scores	1511:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	0	82	theme	alginate	24:31	arg1	multivalencies					51:64	alginate β-lactoglobulin A multivalencies	24:64	alginate β-lactoglobulin A multivalencies	24:64	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.
36571497	4	83	theme	mid	993:995	arg1	range					1008:1012	the mid micromolar range	989:1012	the mid micromolar range	989:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	0	84	theme	A	49:49	arg1	multivalencies					51:64	alginate β-lactoglobulin A multivalencies	24:64	alginate β-lactoglobulin A multivalencies	24:64	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.
36571497	2	85	with	formation	339:347	arg1	AOSs					423:426	AOSs	423:426	AOSs	423:426	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	2	85	with	formation	339:347	arg1	oligosaccharides					405:420	nine defined alginate oligosaccharides	383:420	nine defined alginate oligosaccharides (AOSs)	383:427	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	4	86	theme	similar	967:973	arg1	affinities					975:984	similar affinities	967:984	similar affinities in the mid micromolar range	967:1012	β-LgA was highly multivalent exhibiting binding stoichiometries decreasing from five to two AOSs with increasing degree of polymerization (DP) and similar affinities in the mid micromolar range.
36571497	8	87	theme	XP	1565:1566	arg1	scores					1574:1579	similar XP glide scores	1557:1579	similar XP glide scores	1557:1579	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	2	88	theme	β-lactoglobulin	352:366	arg1	β-LgA					371:375	β-LgA	371:375	β-LgA	371:375	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	2	88	theme	β-lactoglobulin	352:366	arg1	A					368:368	β-lactoglobulin A	352:368	β-lactoglobulin A (β-LgA)	352:376	Here, we address the initial steps in condensate formation of β-lactoglobulin A (β-LgA) with nine defined alginate oligosaccharides (AOSs) and describe their multivalent interactions in structural detail.
36571497	5	89	theme	diverse	1127:1133	arg1	compositions					1135:1146	diverse compositions	1127:1146	diverse compositions of charged, polar and hydrophobic residues	1127:1189	The different AOS binding sites on β-LgA were identified by NMR chemical shift perturbation analyses and showed diverse compositions of charged, polar and hydrophobic residues.
36571497	8	90	theme	Molecular	1387:1395	arg1	docking					1397:1403	Molecular docking	1387:1403	Molecular docking using Glide within the Schrödinger suite 2016-1	1387:1451	Molecular docking using Glide within the Schrödinger suite 2016-1 revealed the orientation of AOSs to only vary slightly at the preferred β-LgA binding site resulting in similar XP glide scores.
36571497	0	91	dep	insights	10:17	arg1	foundation					72:81	the foundation	68:81	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.	0:130	Molecular insights into alginate β-lactoglobulin A multivalencies - the foundation for their amorphous aggregates and coacervation.
36893634	0	0	theme	composite	66:74	arg1	chitosan					29:36	chitosan	29:36	chitosan	29:36	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	0	0	theme	composite	66:74	arg1	coatings					76:83	levan based composite coatings	54:83	levan based composite coatings	54:83	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	0	1	from	effects	18:24	arg1	life					98:101	the shelf life	88:101	the shelf life of sweet cherry	88:117	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	1	2	theme	cherry	126:131	arg1	fruits					151:156	Sweet cherry (Prunus avium L.) fruits	120:156	Sweet cherry (Prunus avium L.) fruits	120:156	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	0	3	theme	based	60:64	arg1	chitosan					29:36	chitosan	29:36	chitosan	29:36	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	0	3	theme	based	60:64	arg1	coatings					76:83	levan based composite coatings	54:83	levan based composite coatings	54:83	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	6	4	theme	study	1020:1024	arg1	findings					1003:1010	the findings	999:1010	the findings of this study	999:1024	Given the cost-effectiveness of the polymers used, the findings of this study indicate the feasibility of extending the shelf-life of sweet cherries on a larger scale.
36893634	1	5	theme	shelf-life	200:209	arg1	conditions					211:220	shelf-life conditions	200:220	shelf-life conditions	200:220	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	5	6	theme	stem	877:880	arg1	force					890:894	increased stem removal force	867:894	increased stem removal force	867:894	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	5	7	theme	increased	867:875	arg1	force					890:894	increased stem removal force	867:894	increased stem removal force	867:894	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	5	8	theme	removal	882:888	arg1	force					890:894	increased stem removal force	867:894	increased stem removal force	867:894	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	6	9	from	shelf-life	1068:1077	arg1	scale					1109:1113	a larger scale	1100:1113	a larger scale	1100:1113	Given the cost-effectiveness of the polymers used, the findings of this study indicate the feasibility of extending the shelf-life of sweet cherries on a larger scale.
36893634	0	10	theme	shelf	92:96	arg1	life					98:101	the shelf life	88:101	the shelf life of sweet cherry	88:117	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	3	11	theme	scalable	395:402	arg1	process					404:410	an efficient and commercially scalable process	365:410	an efficient and commercially scalable process	365:410	However, an efficient and commercially scalable process remains elusive.
36893634	5	12	theme	30th	758:761	arg1	day					763:765	the 30th day	754:765	the 30th day	754:765	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	1	13	theme	avium	141:145	arg1	Prunus					134:139	Prunus avium L.	134:148	Prunus avium L.	134:148	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	1	13	theme	avium	141:145	arg1	cherry					126:131	Sweet cherry	120:131	Sweet cherry (Prunus avium L.) fruits	120:156	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	6	14	theme	polymers	984:991	arg1	cost-effectiveness					958:975	the cost-effectiveness	954:975	the cost-effectiveness of the polymers used	954:996	Given the cost-effectiveness of the polymers used, the findings of this study indicate the feasibility of extending the shelf-life of sweet cherries on a larger scale.
36893634	5	15	theme	fungal	845:850	arg1	deterioration					852:864	fungal deterioration	845:864	fungal deterioration	845:864	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	4	16	theme	cherry	577:582	arg1	fruits					584:589	sweet cherry fruits	571:589	sweet cherry fruits	571:589	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	5	17	theme	sweet	717:721	arg1	cherries					723:730	sweet cherries	717:730	sweet cherries	717:730	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	1	18	theme	cold	226:229	arg1	storage					231:237	cold storage	226:237	cold storage due to their short post-harvest life	226:274	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	1	19	from	storage	231:237	arg1	conditions					211:220	shelf-life conditions	200:220	shelf-life conditions	200:220	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	4	20	theme	sweet	571:575	arg1	fruits					584:589	sweet cherry fruits	571:589	sweet cherry fruits	571:589	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	5	21	theme	cherries	723:730	arg1	life					709:712	the shelf life	699:712	the shelf life of sweet cherries	699:730	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	4	22	theme	storage	653:659	arg1	conditions					661:670	both market and cold storage conditions	632:670	conditions	661:670	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	2	23	theme	cherry	348:353	arg1	life					330:333	the shelf life	320:333	the shelf life of the sweet cherry	320:353	Until now efforts have been made to extend the shelf life of the sweet cherry.
36893634	4	24	theme	biobased	482:489	arg1	coatings					501:508	biobased composite coatings	482:508	biobased composite coatings	482:508	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	4	25	theme	cold	648:651	arg1	conditions					661:670	both market and cold storage conditions	632:670	conditions	661:670	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	4	26	theme	composite	491:499	arg1	coatings					501:508	biobased composite coatings	482:508	biobased composite coatings	482:508	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	2	27	theme	sweet	342:346	arg1	cherry					348:353	the sweet cherry	338:353	the sweet cherry	338:353	Until now efforts have been made to extend the shelf life of the sweet cherry.
36893634	5	28	theme	weight	832:837	arg1	loss					839:842	decreased weight loss	822:842	decreased weight loss	822:842	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	0	29	theme	cherry	112:117	arg1	life					98:101	the shelf life	88:101	the shelf life of sweet cherry	88:117	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	3	30	theme	efficient	368:376	arg1	process					404:410	an efficient and commercially scalable process	365:410	an efficient and commercially scalable process	365:410	However, an efficient and commercially scalable process remains elusive.
36893634	0	31	theme	chitosan	29:36	arg1	effects					18:24	the effects	14:24	the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry	14:117	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	0	32	theme	sweet	106:110	arg1	cherry					112:117	sweet cherry	106:117	sweet cherry	106:117	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	1	33	dep	quality	171:177	arg1	loss					192:195	loss	192:195	loss	192:195	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	5	34	theme	shelf	703:707	arg1	life					709:712	the shelf life	699:712	the shelf life of sweet cherries	699:730	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	1	35	theme	short	252:256	arg1	life					271:274	their short post-harvest life	246:274	their short post-harvest life	246:274	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	1	36	from	quantity	183:190	arg1	conditions					211:220	shelf-life conditions	200:220	shelf-life conditions	200:220	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	1	37	dep	Prunus	134:139	arg1	L.					147:148	Prunus avium L.	134:148	Prunus avium L.	134:148	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	5	38	theme	decreased	822:830	arg1	loss					839:842	decreased weight loss	822:842	decreased weight loss	822:842	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	0	39	theme	chia	39:42	arg1	chitosan					29:36	chitosan	29:36	chitosan	29:36	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	0	39	theme	chia	39:42	arg1	mucilage					44:51	chia mucilage	39:51	chia mucilage	39:51	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	1	40	theme	post-harvest	258:269	arg1	life					271:274	their short post-harvest life	246:274	their short post-harvest life	246:274	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	5	41	theme	oxalic	935:940	arg1	acid					942:945	oxalic acid	935:945	oxalic acid	935:945	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	4	42	theme	postharvest	606:616	arg1	parameters					618:627	postharvest parameters	606:627	postharvest parameters in both market and cold storage conditions	606:670	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	6	43	theme	cherries	1088:1095	arg1	shelf-life					1068:1077	the shelf-life	1064:1077	the shelf-life of sweet cherries on a larger scale	1064:1113	Given the cost-effectiveness of the polymers used, the findings of this study indicate the feasibility of extending the shelf-life of sweet cherries on a larger scale.
36893634	1	44	from	quality	171:177	arg1	conditions					211:220	shelf-life conditions	200:220	shelf-life conditions	200:220	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	6	45	theme	larger	1102:1107	arg1	scale					1109:1113	a larger scale	1100:1113	a larger scale	1100:1113	Given the cost-effectiveness of the polymers used, the findings of this study indicate the feasibility of extending the shelf-life of sweet cherries on a larger scale.
36893634	5	46	theme	total	897:901	arg1	flavonoid					903:911	total flavonoid	897:911	total flavonoid	897:911	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	6	47	theme	sweet	1082:1086	arg1	cherries					1088:1095	sweet cherries	1082:1095	sweet cherries	1082:1095	Given the cost-effectiveness of the polymers used, the findings of this study indicate the feasibility of extending the shelf-life of sweet cherries on a larger scale.
36893634	5	48	theme	post-harvest	793:804	arg1	properties					806:815	important post-harvest properties	783:815	important post-harvest properties	783:815	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	4	49	from	parameters	618:627	arg1	market					637:642	both market and cold storage conditions	632:670	market	637:642	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	4	49	from	parameters	618:627	arg1	conditions					661:670	both market and cold storage conditions	632:670	conditions	661:670	To contribute to this challenge, here in this study, biobased composite coatings consisting of chitosan, mucilage, and levan, were applied on sweet cherry fruits and tested for postharvest parameters in both market and cold storage conditions.
36893634	0	50	theme	levan	54:58	arg1	chitosan					29:36	chitosan	29:36	chitosan	29:36	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	0	50	theme	levan	54:58	arg1	coatings					76:83	levan based composite coatings	54:83	levan based composite coatings	54:83	Understanding the effects of chitosan, chia mucilage, levan based composite coatings on the shelf life of sweet cherry.
36893634	3	51	theme	commercially	382:393	arg1	process					404:410	an efficient and commercially scalable process	365:410	an efficient and commercially scalable process	365:410	However, an efficient and commercially scalable process remains elusive.
36893634	5	52	theme	important	783:791	arg1	properties					806:815	important post-harvest properties	783:815	important post-harvest properties	783:815	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	2	53	theme	shelf	324:328	arg1	life					330:333	the shelf life	320:333	the shelf life of the sweet cherry	320:353	Until now efforts have been made to extend the shelf life of the sweet cherry.
36893634	5	54	theme	l-ascorbic	914:923	arg1	acid					925:928	l-ascorbic acid	914:928	l-ascorbic acid	914:928	Results demonstrated that the shelf life of sweet cherries can be extended until the 30th day while retaining important post-harvest properties like decreased weight loss, fungal deterioration, increased stem removal force, total flavonoid, l-ascorbic acid, and oxalic acid.
36893634	1	55	theme	Sweet	120:124	arg1	Prunus					134:139	Prunus avium L.	134:148	Prunus avium L.	134:148	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
36893634	1	55	theme	Sweet	120:124	arg1	cherry					126:131	Sweet cherry	120:131	Sweet cherry (Prunus avium L.) fruits	120:156	Sweet cherry (Prunus avium L.) fruits are prone to quality and quantity loss in shelf-life conditions and cold storage due to their short post-harvest life.
37377032	4	0	theme	CHT	981:983	arg1	insolubility					965:976	the insolubility	961:976	the insolubility of CHT in physiological conditions	961:1011	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	6	1	theme	FS	1404:1405	arg1	membranes					1407:1415	FS membranes	1404:1415	FS membranes	1404:1415	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	4	2	theme	physiological	988:1000	arg1	conditions					1002:1011	physiological conditions	988:1011	physiological conditions	988:1011	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	1	3	used	used	194:197	arg2	technology					167:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	3	4	theme	wide	821:824	arg1	assemblies					898:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	3	4	theme	wide	821:824	arg1	repertoire					826:835	a wide repertoire	819:835	a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies	819:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	8	5	theme	new	1852:1854	arg1	avenues					1856:1862	new avenues	1852:1862	new avenues for the design and development of a wide array of CHT-based devices for biomedical applications	1852:1958	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	3	6	theme	electrostatic-driven	864:883	arg1	assemblies					898:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	8	7	theme	CHT	2031:2033	arg1	insolubility					2008:2019	the insolubility	2004:2019	the insolubility of native CHT under physiological conditions	2004:2064	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	5	8	theme	quaternised	1210:1220	arg1	biopolymers					1234:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	1	9	theme	multilayered	255:266	arg1	bioarchitectures					268:283	robust multilayered bioarchitectures	248:283	robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions	248:348	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	8	10	theme	physiological	2041:2053	arg1	conditions					2055:2064	physiological conditions	2041:2064	physiological conditions	2041:2064	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	6	11	theme	drug	1337:1340	arg1	rate					1350:1353	the drug release rate	1333:1353	the drug release rate	1333:1353	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	5	12	theme	membranes	1178:1186	arg1	preparation					1131:1141	the preparation	1127:1141	the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules	1127:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	6	13	theme	film	1315:1318	arg1	structure					1320:1328	the film structure	1311:1328	the film structure	1311:1328	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	2	14	theme	biomedical	584:593	arg1	applications					595:606	biomedical applications	584:606	biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties	584:728	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	3	15	theme	assemblies	898:907	arg1	assemblies					898:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	3	15	theme	assemblies	898:907	arg1	repertoire					826:835	a wide repertoire	819:835	a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies	819:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	5	16	theme	controlled	1250:1259	arg1	release					1261:1267	controlled release	1250:1267	controlled release of model drug molecules	1250:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	2	17	theme	biomaterials	567:578	arg1	fabrication					537:547	the fabrication	533:547	the fabrication of nanostructured biomaterials	533:578	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	0	18	theme	drug	118:121	arg1	delivery					123:130	controlled drug delivery	107:130	controlled drug delivery	107:130	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	8	19	theme	array	1905:1909	arg1	development					1883:1893	development	1883:1893	development	1883:1893	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	8	19	theme	array	1905:1909	arg1	design					1872:1877	design	1872:1877	design	1872:1877	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	7	20	theme	release	1819:1825	arg1	rate					1827:1830	a more sustained release rate	1802:1830	a more sustained release rate	1802:1830	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	7	21	theme	in	1686:1687	arg1	cytocompatibility					1695:1711	in vitro cytocompatibility	1686:1711	in vitro cytocompatibility	1686:1711	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	4	22	theme	as-developed	1070:1081	arg1	structures					1097:1106	the as-developed CHT-based LbL structures	1066:1106	the as-developed CHT-based LbL structures	1066:1106	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	3	23	theme	opposite	928:935	arg1	nature					944:949	their opposite charge nature	922:949	their opposite charge nature	922:949	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	4	24	from	insolubility	965:976	arg1	conditions					1002:1011	physiological conditions	988:1011	physiological conditions	988:1011	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	8	25	theme	CHT-based	1914:1922	arg1	devices					1924:1930	CHT-based devices	1914:1930	CHT-based devices for biomedical applications	1914:1958	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	4	26	theme	LbL	1093:1095	arg1	structures					1097:1106	the as-developed CHT-based LbL structures	1066:1106	the as-developed CHT-based LbL structures	1066:1106	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	6	27	from	influence	1298:1306	arg1	rate					1350:1353	the drug release rate	1333:1353	the drug release rate	1333:1353	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	28	theme	bovine	1488:1493	arg1	albumin					1501:1507	isothiocyanate-labelled bovine serum albumin	1464:1507	isothiocyanate-labelled bovine serum albumin (FITC-BSA)	1464:1518	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	28	theme	bovine	1488:1493	arg1	FITC-BSA					1510:1517	FITC-BSA	1510:1517	FITC-BSA	1510:1517	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	7	29	theme	LbL	1778:1780	arg1	ingredient					1782:1791	an intrinsic LbL ingredient	1765:1791	an intrinsic LbL ingredient denoting a more sustained release rate	1765:1830	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	7	29	theme	LbL	1778:1780	arg1	FITC-BSA					1753:1760	FITC-BSA	1753:1760	FITC-BSA	1753:1760	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	2	30	theme	sustainable	498:508	arg1	resource					520:527	a sustainable renewable resource	496:527	a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties	496:728	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	2	30	theme	sustainable	498:508	arg1	polysaccharides					476:490	marine-origin polysaccharides	462:490	marine-origin polysaccharides	462:490	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	0	31	theme	free-standing	36:48	arg1	membranes					63:71	free-standing multilayered membranes	36:71	free-standing multilayered membranes	36:71	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	0	31	theme	free-standing	36:48	arg1	nanoreservoirs					88:101	sustainable nanoreservoirs	76:101	sustainable nanoreservoirs for controlled drug delivery	76:130	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	2	32	theme	marine-origin	462:474	arg1	resource					520:527	a sustainable renewable resource	496:527	a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties	496:728	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	2	32	theme	marine-origin	462:474	arg1	polysaccharides					476:490	marine-origin polysaccharides	462:490	marine-origin polysaccharides	462:490	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	6	33	theme	building	1543:1550	arg1	block					1552:1556	an intrinsic building block	1530:1556	an intrinsic building block	1530:1556	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	5	34	theme	drug	1278:1281	arg1	molecules					1283:1291	model drug molecules	1272:1291	model drug molecules	1272:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	5	35	theme	free-standing	1146:1158	arg1	membranes					1178:1186	free-standing (FS) multilayered membranes	1146:1186	free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules	1146:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	5	35	theme	free-standing	1146:1158	arg1	FS					1161:1162	FS	1161:1162	FS	1161:1162	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	0	36	theme	sustainable	76:86	arg1	membranes					63:71	free-standing multilayered membranes	36:71	free-standing multilayered membranes	36:71	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	0	36	theme	sustainable	76:86	arg1	nanoreservoirs					88:101	sustainable nanoreservoirs	76:101	sustainable nanoreservoirs for controlled drug delivery	76:130	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	6	37	theme	LbL	1595:1597	arg1	process					1608:1614	the LbL assembly process	1591:1614	the LbL assembly process	1591:1614	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	1	38	theme	tunable	290:296	arg1	structures					298:307	tunable structures	290:307	tunable structures	290:307	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	1	39	with	bioarchitectures	268:283	arg1	functions					340:348	functions	340:348	functions	340:348	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	1	39	with	bioarchitectures	268:283	arg1	compositions					310:321	compositions	310:321	compositions	310:321	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	1	39	with	bioarchitectures	268:283	arg1	structures					298:307	tunable structures	290:307	tunable structures	290:307	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	1	39	with	bioarchitectures	268:283	arg1	properties					324:333	properties	324:333	properties	324:333	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	8	40	dep	design	1872:1877	arg1	the					1868:1870	the	1868:1870	the	1868:1870	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	3	41	theme	LbL	794:796	arg1	alginate					750:757	alginate	750:757	alginate (ALG)	750:763	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	3	41	theme	LbL	794:796	arg1	Chitosan					731:738	Chitosan	731:738	Chitosan (CHT)	731:744	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	3	41	theme	LbL	794:796	arg1	ingredients					798:808	LbL ingredients	794:808	LbL ingredients	794:808	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	6	42	theme	membranes	1407:1415	arg1	set-ups					1393:1399	two distinct set-ups	1380:1399	two distinct set-ups of FS membranes	1380:1415	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	2	43	theme	non-immunogenic	703:717	arg1	properties					719:728	non-immunogenic properties	703:728	non-immunogenic properties	703:728	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	6	44	theme	outer	1573:1577	arg1	layer					1579:1583	an outer layer	1570:1583	an outer layer after the LbL assembly process	1570:1614	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	45	theme	distinct	1384:1391	arg1	set-ups					1393:1399	two distinct set-ups	1380:1399	two distinct set-ups of FS membranes	1380:1415	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	3	46	theme	size-	840:844	arg1	assemblies					898:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	6	47	theme	isothiocyanate-labelled	1464:1486	arg1	albumin					1501:1507	isothiocyanate-labelled bovine serum albumin	1464:1507	isothiocyanate-labelled bovine serum albumin (FITC-BSA)	1464:1518	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	47	theme	isothiocyanate-labelled	1464:1486	arg1	FITC-BSA					1510:1517	FITC-BSA	1510:1517	FITC-BSA	1510:1517	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	48	theme	drug	1447:1450	arg1	fluorescein					1452:1462	the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block	1425:1556	fluorescein	1452:1462	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	5	49	theme	water-soluble	1196:1208	arg1	biopolymers					1234:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	1	50	theme	robust	248:253	arg1	bioarchitectures					268:283	robust multilayered bioarchitectures	248:283	robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions	248:348	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	4	51	theme	bioapplications	1047:1061	arg1	range					1038:1042	the range	1034:1042	the range of bioapplications of the as-developed CHT-based LbL structures	1034:1106	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	3	52	theme	multilayered	885:896	arg1	assemblies					898:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	6	53	theme	model	1429:1433	arg1	fluorescein					1452:1462	the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block	1425:1556	fluorescein	1452:1462	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	5	54	theme	CHT	1222:1224	arg1	biopolymers					1234:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	1	55	theme	LbL	153:155	arg1	technology					167:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	6	56	dep	fluorescein	1452:1462	arg1	albumin					1501:1507	isothiocyanate-labelled bovine serum albumin	1464:1507	isothiocyanate-labelled bovine serum albumin (FITC-BSA)	1464:1518	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	56	dep	fluorescein	1452:1462	arg1	block					1552:1556	an intrinsic building block	1530:1556	an intrinsic building block	1530:1556	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	56	dep	fluorescein	1452:1462	arg1	either					1520:1525	either	1520:1525	either	1520:1525	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	56	dep	fluorescein	1452:1462	arg1	FITC-BSA					1510:1517	FITC-BSA	1510:1517	FITC-BSA	1510:1517	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	7	57	theme	release	1718:1724	arg1	profile					1726:1732	release profile	1718:1732	release profile	1718:1732	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	8	58	theme	native	2024:2029	arg1	CHT					2031:2033	native CHT	2024:2033	native CHT	2024:2033	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	6	59	theme	release	1342:1348	arg1	rate					1350:1353	the drug release rate	1333:1353	the drug release rate	1333:1353	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	3	60	theme	shape-tunable	850:862	arg1	assemblies					898:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	size- and shape-tunable electrostatic-driven multilayered assemblies	840:907	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	5	61	theme	multilayered	1165:1176	arg1	membranes					1178:1186	free-standing (FS) multilayered membranes	1146:1186	free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules	1146:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	5	61	theme	multilayered	1165:1176	arg1	FS					1161:1162	FS	1161:1162	FS	1161:1162	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	1	62	theme	assembly	158:165	arg1	technology					167:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	0	63	theme	controlled	107:116	arg1	delivery					123:130	controlled drug delivery	107:130	controlled drug delivery	107:130	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	7	64	dep	in	1686:1687	arg1	vitro					1689:1693	vitro	1689:1693	vitro	1689:1693	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	4	65	theme	structures	1097:1106	arg1	bioapplications					1047:1061	bioapplications	1047:1061	bioapplications of the as-developed CHT-based LbL structures	1047:1106	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	6	66	theme	structure	1320:1328	arg1	influence					1298:1306	The influence	1294:1306	The influence of the film structure in the drug release rate	1294:1353	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	1	67	theme	building	395:402	arg1	blocks					404:409	building blocks	395:409	building blocks exhibiting complementary interactions	395:447	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	2	68	theme	nanostructured	552:565	arg1	biomaterials					567:578	nanostructured biomaterials	552:578	nanostructured biomaterials	552:578	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	5	69	theme	model	1272:1276	arg1	molecules					1283:1291	model drug molecules	1272:1291	model drug molecules	1272:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	8	70	theme	wide	1900:1903	arg1	array					1905:1909	a wide array	1898:1909	a wide array of CHT-based devices for biomedical applications	1898:1958	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	3	71	theme	charge	937:942	arg1	nature					944:949	their opposite charge nature	922:949	their opposite charge nature	922:949	Chitosan (CHT) and alginate (ALG) have been widely employed as LbL ingredients to shape a wide repertoire of size- and shape-tunable electrostatic-driven multilayered assemblies by exploring their opposite charge nature.
37377032	6	72	theme	serum	1495:1499	arg1	albumin					1501:1507	isothiocyanate-labelled bovine serum albumin	1464:1507	isothiocyanate-labelled bovine serum albumin (FITC-BSA)	1464:1518	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	72	theme	serum	1495:1499	arg1	FITC-BSA					1510:1517	FITC-BSA	1510:1517	FITC-BSA	1510:1517	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	1	73	theme	blocks	404:409	arg1	myriad					385:390	a myriad	383:390	a myriad of building blocks exhibiting complementary interactions	383:447	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	7	74	theme	sustained	1809:1817	arg1	rate					1827:1830	a more sustained release rate	1802:1830	a more sustained release rate	1802:1830	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	4	75	theme	CHT-based	1083:1091	arg1	structures					1097:1106	the as-developed CHT-based LbL structures	1066:1106	the as-developed CHT-based LbL structures	1066:1106	However, the insolubility of CHT in physiological conditions intrinsically limits the range of bioapplications of the as-developed CHT-based LbL structures.
37377032	1	76	theme	complementary	422:434	arg1	interactions					436:447	complementary interactions	422:447	complementary interactions	422:447	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	8	77	theme	devices	1924:1930	arg1	array					1905:1909	a wide array	1898:1909	a wide array of CHT-based devices for biomedical applications	1898:1958	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	7	78	contain	having	1746:1751	arg2	FITC-BSA					1753:1760	FITC-BSA	1753:1760	FITC-BSA	1753:1760	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	7	78	contain	having	1746:1751	arg2	ingredient					1782:1791	an intrinsic LbL ingredient	1765:1791	an intrinsic LbL ingredient denoting a more sustained release rate	1765:1830	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	7	78	contain	having	1746:1751	arg1	those					1740:1744	those	1740:1744	those	1740:1744	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	5	79	theme	ALG	1230:1232	arg1	biopolymers					1234:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	water-soluble quaternised CHT and ALG biopolymers	1196:1244	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	2	80	theme	renewable	510:518	arg1	resource					520:527	a sustainable renewable resource	496:527	a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties	496:728	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	2	80	theme	renewable	510:518	arg1	polysaccharides					476:490	marine-origin polysaccharides	462:490	marine-origin polysaccharides	462:490	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	0	81	theme	multilayered	50:61	arg1	membranes					63:71	free-standing multilayered membranes	36:71	free-standing multilayered membranes	36:71	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	0	81	theme	multilayered	50:61	arg1	nanoreservoirs					88:101	sustainable nanoreservoirs	76:101	sustainable nanoreservoirs for controlled drug delivery	76:130	Marine-origin polysaccharides-based free-standing multilayered membranes as sustainable nanoreservoirs for controlled drug delivery.
37377032	8	82	theme	biomedical	1936:1945	arg1	applications					1947:1958	biomedical applications	1936:1958	biomedical applications	1936:1958	This work opens up new avenues for the design and development of a wide array of CHT-based devices for biomedical applications, overcoming the limitations associated with the insolubility of native CHT under physiological conditions.
37377032	1	83	theme	layer-by-layer	137:150	arg1	technology					167:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology	133:176	The layer-by-layer (LbL) assembly technology has been widely used to functionalise surfaces and precisely engineer robust multilayered bioarchitectures with tunable structures, compositions, properties, and functions at the nanoscale by resorting to a myriad of building blocks exhibiting complementary interactions.
37377032	7	84	theme	intrinsic	1768:1776	arg1	ingredient					1782:1791	an intrinsic LbL ingredient	1765:1791	an intrinsic LbL ingredient denoting a more sustained release rate	1765:1830	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	7	84	theme	intrinsic	1768:1776	arg1	FITC-BSA					1753:1760	FITC-BSA	1753:1760	FITC-BSA	1753:1760	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
37377032	6	85	theme	intrinsic	1533:1541	arg1	block					1552:1556	an intrinsic building block	1530:1556	an intrinsic building block	1530:1556	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	5	86	theme	molecules	1283:1291	arg1	release					1261:1267	controlled release	1250:1267	controlled release of model drug molecules	1250:1291	Herein, we report the preparation of free-standing (FS) multilayered membranes made of water-soluble quaternised CHT and ALG biopolymers for controlled release of model drug molecules.
37377032	2	87	theme	wide	623:626	arg1	bioavailability					628:642	their wide bioavailability	617:642	their wide bioavailability	617:642	Among them, marine-origin polysaccharides are a sustainable renewable resource for the fabrication of nanostructured biomaterials for biomedical applications owing to their wide bioavailability, biocompatibility, biodegradability, non-cytotoxicity, and non-immunogenic properties.
37377032	6	88	theme	hydrophilic	1435:1445	arg1	fluorescein					1452:1462	the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block	1425:1556	fluorescein	1452:1462	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	6	89	theme	assembly	1599:1606	arg1	process					1608:1614	the LbL assembly process	1591:1614	the LbL assembly process	1591:1614	The influence of the film structure in the drug release rate is studied by assembling two distinct set-ups of FS membranes, having the model hydrophilic drug fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA) either as an intrinsic building block or added as an outer layer after the LbL assembly process.
37377032	7	90	theme	FS	1622:1623	arg1	membranes					1625:1633	Both FS membranes	1617:1633	Both FS membranes	1617:1633	Both FS membranes are characterised for their thickness, morphology, in vitro cytocompatibility, and release profile, with those having FITC-BSA as an intrinsic LbL ingredient denoting a more sustained release rate.
36934824	2	0	theme	structural	464:473	arg1	properties					475:484	easily modifiable structural properties	446:484	easily modifiable structural properties	446:484	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	8	1	theme	environmental	1407:1419	arg1	concept					1421:1427	the environmental concept	1403:1427	the environmental concept of resource reuse	1403:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	0	2	theme	composite	104:112	arg1	film					114:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	1	3	theme	pharmaceutical	321:334	arg1	extraction					347:356	pharmaceutical production extraction	321:356	pharmaceutical production extraction	321:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	6	4	theme	inflammatory	1047:1058	arg1	response					1060:1067	the inflammatory response	1043:1067	the inflammatory response	1043:1067	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	0	5	theme	In	120:121	arg1	healing					134:140	In vivo wound healing	120:140	In vivo wound healing application evaluation	120:163	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	1	6	theme	production	336:345	arg1	extraction					347:356	pharmaceutical production extraction	321:356	pharmaceutical production extraction	321:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	8	7	theme	wound	1378:1382	arg1	treatment					1384:1392	wound treatment	1378:1392	wound treatment based on the environmental concept of resource reuse	1378:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	3	8	theme	P.	510:511	arg1	polysaccharide					531:544	P. americana remnant polysaccharide	510:544	P. americana remnant polysaccharide (PAP)	510:550	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	8	theme	P.	510:511	arg1	PAC					502:504	PAC	502:504	PAC	502:504	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	8	theme	P.	510:511	arg1	PAP					547:549	PAP	547:549	PAP	547:549	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	8	theme	P.	510:511	arg1	materials					569:577	raw materials	565:577	raw materials	565:577	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	9	used	used	557:560	arg2	PAP					547:549	PAP	547:549	PAP	547:549	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	9	used	used	557:560	arg2	PAC					502:504	PAC	502:504	PAC	502:504	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	9	used	used	557:560	arg2	polysaccharide					531:544	P. americana remnant polysaccharide	510:544	P. americana remnant polysaccharide (PAP)	510:550	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	9	used	used	557:560	arg2	materials					569:577	raw materials	565:577	raw materials	565:577	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	6	10	theme	wound	947:951	arg1	closure					953:959	wound closure	947:959	wound closure	947:959	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	1	11	theme	large	264:268	arg1	amount					270:275	a large amount	262:275	a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction	262:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	11	theme	large	264:268	arg1	waste					286:290	solid waste	280:290	solid waste (P. americana remnant) after pharmaceutical production extraction	280:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	11	theme	large	264:268	arg1	remnant					306:312	P. americana remnant	293:312	P. americana remnant	293:312	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	0	12	theme	wound	128:132	arg1	healing					134:140	In vivo wound healing	120:140	In vivo wound healing application evaluation	120:163	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	7	13	theme	infection	1234:1242	arg1	chance					1224:1229	the chance	1220:1229	the chance of infection from multiple deliveries	1220:1267	Additionally, PAPCF was administered only once, reducing the chance of infection from multiple deliveries.
36934824	6	14	theme	species	1012:1018	arg1	levels					1020:1025	reactive oxygen species levels	996:1025	reactive oxygen species levels	996:1025	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	0	15	dep	In	120:121	arg1	vivo					123:126	vivo	123:126	vivo	123:126	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	5	16	theme	in	809:810	arg1	assays					835:840	in vivo/vitro antioxidant assays	809:840	in vivo/vitro antioxidant assays	809:840	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	6	17	theme	wound	1085:1089	arg1	healing					1091:1097	rapid wound healing	1079:1097	rapid wound healing	1079:1097	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	7	18	from	chance	1224:1229	arg1	deliveries					1258:1267	multiple deliveries	1249:1267	multiple deliveries	1249:1267	Additionally, PAPCF was administered only once, reducing the chance of infection from multiple deliveries.
36934824	4	19	theme	adsorption	718:727	arg1	assays					729:734	protein adsorption assays	710:734	protein adsorption assays	710:734	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	8	20	theme	reuse	1441:1445	arg1	concept					1421:1427	the environmental concept	1403:1427	the environmental concept of resource reuse	1403:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	2	21	theme	low	423:425	arg1	crystallinity					427:439	low crystallinity	423:439	low crystallinity	423:439	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	22	theme	modifiable	453:462	arg1	properties					475:484	easily modifiable structural properties	446:484	easily modifiable structural properties	446:484	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	8	23	attach	presents	1293:1300	arg2	paper					1287:1291	this paper	1282:1291	this paper	1282:1291	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	8	23	attach	presents	1293:1300	arg1	summary					1273:1279	summary	1273:1279	summary	1273:1279	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	4	24	theme	cell	680:683	arg1	assays					699:704	cell proliferation assays	680:704	cell proliferation assays	680:704	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	6	25	from	phase	1148:1152	arg1	mice					1157:1160	mice	1157:1160	mice	1157:1160	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	5	26	theme	antioxidant	823:833	arg1	assays					835:840	in vivo/vitro antioxidant assays	809:840	in vivo/vitro antioxidant assays	809:840	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	5	27	theme	composite	760:768	arg1	film					770:773	the composite film	756:773	the composite film	756:773	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	8	28	theme	cost-effective	1325:1338	arg1	candidate					1364:1372	an easy-to-administer, cost-effective, and effective dressing candidate	1302:1372	an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse	1302:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	2	29	theme	remnant	372:378	arg1	PAC					390:392	PAC	390:392	PAC	390:392	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	29	theme	remnant	372:378	arg1	chitosan					380:387	P. americana remnant chitosan	359:387	P. americana remnant chitosan (PAC)	359:393	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	5	30	theme	film	770:773	arg1	bioactivity					741:751	The bioactivity	737:751	The bioactivity of the composite film	737:773	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	0	31	theme	application	142:152	arg1	evaluation					154:163	In vivo wound healing application evaluation	120:163	In vivo wound healing application evaluation	120:163	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	3	32	theme	remnant	523:529	arg1	polysaccharide					531:544	P. americana remnant polysaccharide	510:544	P. americana remnant polysaccharide (PAP)	510:550	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	32	theme	remnant	523:529	arg1	PAC					502:504	PAC	502:504	PAC	502:504	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	32	theme	remnant	523:529	arg1	PAP					547:549	PAP	547:549	PAP	547:549	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	32	theme	remnant	523:529	arg1	materials					569:577	raw materials	565:577	raw materials	565:577	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	2	33	theme	low	401:403	arg1	weight					415:420	a low molecular weight	399:420	a low molecular weight	399:420	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	34	theme	molecular	405:413	arg1	weight					415:420	a low molecular weight	399:420	a low molecular weight	399:420	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	1	35	theme	solid	280:284	arg1	waste					286:290	solid waste	280:290	solid waste (P. americana remnant) after pharmaceutical production extraction	280:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	35	theme	solid	280:284	arg1	remnant					306:312	P. americana remnant	293:312	P. americana remnant	293:312	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	0	36	theme	healing	134:140	arg1	evaluation					154:163	In vivo wound healing application evaluation	120:163	In vivo wound healing application evaluation	120:163	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	8	37	theme	dressing	1355:1362	arg1	candidate					1364:1372	an easy-to-administer, cost-effective, and effective dressing candidate	1302:1372	an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse	1302:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	1	38	dep	americana	178:186	arg1	americana					192:200	P. americana	189:200	P. americana	189:200	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	2	39	theme	americana	362:370	arg1	PAC					390:392	PAC	390:392	PAC	390:392	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	39	theme	americana	362:370	arg1	chitosan					380:387	P. americana remnant chitosan	359:387	P. americana remnant chitosan (PAC)	359:393	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	0	40	theme	anti-inflammatory	32:48	arg1	americana					62:70	anti-inflammatory Periplaneta americana	32:70	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	1	41	theme	waste	286:290	arg1	amount					270:275	a large amount	262:275	a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction	262:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	41	theme	waste	286:290	arg1	waste					286:290	solid waste	280:290	solid waste (P. americana remnant) after pharmaceutical production extraction	280:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	41	theme	waste	286:290	arg1	remnant					306:312	P. americana remnant	293:312	P. americana remnant	293:312	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	7	42	theme	multiple	1249:1256	arg1	deliveries					1258:1267	multiple deliveries	1249:1267	multiple deliveries	1249:1267	Additionally, PAPCF was administered only once, reducing the chance of infection from multiple deliveries.
36934824	6	43	theme	oxygen	1005:1010	arg1	species					1012:1018	reactive oxygen species	996:1018	reactive oxygen species levels	996:1025	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	6	44	theme	healing	899:905	arg1	experiment					907:916	The wound healing experiment	889:916	The wound healing experiment	889:916	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	8	45	theme	resource	1432:1439	arg1	reuse					1441:1445	resource reuse	1432:1445	resource reuse	1432:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	1	46	used	used	220:223	arg2	americana					178:186	Periplaneta americana	166:186	Periplaneta americana (P. americana)	166:201	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	6	47	theme	reactive	996:1003	arg1	species					1012:1018	reactive oxygen species	996:1018	reactive oxygen species levels	996:1025	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	0	48	theme	americana	62:70	arg1	film					114:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	1	49	theme	P.	293:294	arg1	waste					286:290	solid waste	280:290	solid waste (P. americana remnant) after pharmaceutical production extraction	280:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	49	theme	P.	293:294	arg1	remnant					306:312	P. americana remnant	293:312	P. americana remnant	293:312	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	3	50	theme	composite	592:600	arg1	film					602:605	a composite film	590:605	a composite film (PAPCF)	590:613	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	50	theme	composite	592:600	arg1	PAPCF					608:612	PAPCF	608:612	PAPCF	608:612	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	5	51	dep	in	809:810	arg1	vivo/vitro					812:821	vivo/vitro	812:821	vivo/vitro	812:821	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	7	52	from	deliveries	1258:1267	arg1	infection					1234:1242	infection	1234:1242	infection from multiple deliveries	1234:1267	Additionally, PAPCF was administered only once, reducing the chance of infection from multiple deliveries.
36934824	7	52	from	deliveries	1258:1267	arg1	chance					1224:1229	the chance	1220:1229	the chance of infection from multiple deliveries	1220:1267	Additionally, PAPCF was administered only once, reducing the chance of infection from multiple deliveries.
36934824	4	53	theme	film	659:662	arg1	biocompatibility					625:640	The good biocompatibility	616:640	The good biocompatibility of the composite film	616:662	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	0	54	theme	Periplaneta	50:60	arg1	americana					62:70	anti-inflammatory Periplaneta americana	32:70	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	1	55	theme	americana	296:304	arg1	waste					286:290	solid waste	280:290	solid waste (P. americana remnant) after pharmaceutical production extraction	280:356	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	1	55	theme	americana	296:304	arg1	remnant					306:312	P. americana remnant	293:312	P. americana remnant	293:312	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	6	56	theme	inflammatory	1108:1119	arg1	phase					1121:1125	the inflammatory phase	1104:1125	the inflammatory phase to the proliferative phase in mice	1104:1160	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	4	57	theme	composite	649:657	arg1	film					659:662	the composite film	645:662	the composite film	645:662	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	2	58	contain	has	395:397	arg1	PAC					390:392	PAC	390:392	PAC	390:392	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	58	contain	has	395:397	arg2	crystallinity					427:439	low crystallinity	423:439	low crystallinity	423:439	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	58	contain	has	395:397	arg1	chitosan					380:387	P. americana remnant chitosan	359:387	P. americana remnant chitosan (PAC)	359:393	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	58	contain	has	395:397	arg2	weight					415:420	a low molecular weight	399:420	a low molecular weight	399:420	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	58	contain	has	395:397	arg2	properties					475:484	easily modifiable structural properties	446:484	easily modifiable structural properties	446:484	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	4	59	theme	good	620:623	arg1	biocompatibility					625:640	The good biocompatibility	616:640	The good biocompatibility of the composite film	616:662	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	3	60	dep	P.	510:511	arg1	americana					513:521	americana	513:521	americana	513:521	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	6	61	theme	rapid	1079:1083	arg1	healing					1091:1097	rapid wound healing	1079:1097	rapid wound healing	1079:1097	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	1	62	theme	wound	229:233	arg1	healing					235:241	wound healing	229:241	wound healing	229:241	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	8	63	theme	easy-to-administer	1305:1322	arg1	candidate					1364:1372	an easy-to-administer, cost-effective, and effective dressing candidate	1302:1372	an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse	1302:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	4	64	theme	protein	710:716	arg1	assays					729:734	protein adsorption assays	710:734	protein adsorption assays	710:734	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	4	65	theme	proliferation	685:697	arg1	assays					699:704	cell proliferation assays	680:704	cell proliferation assays	680:704	The good biocompatibility of the composite film was verified by cell proliferation assays and protein adsorption assays.
36934824	2	66	theme	P.	359:360	arg1	PAC					390:392	PAC	390:392	PAC	390:392	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	2	66	theme	P.	359:360	arg1	chitosan					380:387	P. americana remnant chitosan	359:387	P. americana remnant chitosan (PAC)	359:393	P. americana remnant chitosan (PAC) has a low molecular weight, low crystallinity, and easily modifiable structural properties.
36934824	5	67	theme	wound	873:877	arg1	potential					858:866	its potential	854:866	its potential	854:866	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	5	67	theme	wound	873:877	arg1	dressing					879:886	a wound dressing	871:886	a wound dressing	871:886	The bioactivity of the composite film was assessed by antibacterial and in vivo/vitro antioxidant assays to evaluate its potential as a wound dressing.
36934824	0	68	theme	chitosan/polysaccharide	80:102	arg1	film					114:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	8	69	theme	effective	1345:1353	arg1	candidate					1364:1372	an easy-to-administer, cost-effective, and effective dressing candidate	1302:1372	an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse	1302:1445	In summary, this paper presents an easy-to-administer, cost-effective, and effective dressing candidate for wound treatment based on the environmental concept of resource reuse.
36934824	3	70	theme	raw	565:567	arg1	materials					569:577	raw materials	565:577	raw materials	565:577	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	70	theme	raw	565:567	arg1	PAC					502:504	PAC	502:504	PAC	502:504	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	3	70	theme	raw	565:567	arg1	polysaccharide					531:544	P. americana remnant polysaccharide	510:544	P. americana remnant polysaccharide (PAP)	510:550	In this study, PAC and P. americana remnant polysaccharide (PAP) were used as raw materials to prepare a composite film (PAPCF).
36934824	1	71	theme	Periplaneta	166:176	arg1	americana					178:186	Periplaneta americana	166:186	Periplaneta americana (P. americana)	166:201	Periplaneta americana (P. americana), which is widely used for wound healing in China, produces a large amount of solid waste (P. americana remnant) after pharmaceutical production extraction.
36934824	6	72	theme	proliferative	1134:1146	arg1	phase					1148:1152	the proliferative phase	1130:1152	the proliferative phase in mice	1130:1160	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	0	73	theme	remnant	72:78	arg1	film					114:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	0	74	dep	evaluation	154:163	arg1	antibacterial					13:25	antibacterial	13:25	antibacterial	13:25	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	0	74	dep	evaluation	154:163	arg1	Antioxidant					0:10	Antioxidant	0:10	Antioxidant	0:10	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	0	74	dep	evaluation	154:163	arg1	film					114:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film	32:117	Antioxidant, antibacterial, and anti-inflammatory Periplaneta americana remnant chitosan/polysaccharide composite film: In vivo wound healing application evaluation.
36934824	6	75	theme	wound	893:897	arg1	healing					899:905	The wound healing	889:905	The wound healing experiment	889:916	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36934824	6	76	theme	collagen	965:972	arg1	deposition					974:983	collagen deposition	965:983	collagen deposition	965:983	The wound healing experiment revealed that PAPCF improved wound closure and collagen deposition, decreased reactive oxygen species levels, and attenuated the inflammatory response, enabling rapid wound healing from the inflammatory phase to the proliferative phase in mice.
36838941	2	0	theme	effect	479:484	arg1	analysis					463:470	the analysis	459:470	the analysis of the effect of hydrogel addition to the soil	459:517	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	7	1	theme	forestry	1426:1433	arg1	applications					1455:1466	forestry and/or agricultural applications	1426:1466	forestry and/or agricultural applications	1426:1466	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	1	2	theme	hydrogel	149:156	arg1	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	2	theme	hydrogel	149:156	arg1	fibers					198:203	cellulose fibers	188:203	cellulose fibers	188:203	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	2	theme	hydrogel	149:156	arg1	topsoil					261:267	topsoil covers	261:274	topsoil covers	261:274	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	2	theme	hydrogel	149:156	arg1	conditioners					244:255	soil conditioners	239:255	soil conditioners	239:255	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	2	theme	hydrogel	149:156	arg1	composites					158:167	bio-based hydrogel composites	139:167	bio-based hydrogel composites of xanthan gum	139:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	3	dep	topsoil	261:267	arg1	covers					269:274	covers	269:274	covers	269:274	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	6	4	theme	topsoil	1198:1204	arg1	use					1178:1180	the use	1174:1180	the use of the produced topsoil	1174:1204	Furthermore, it has been demonstrated that the use of the produced topsoil covers helped promote plant growth.
36838941	5	5	from	experiments	921:931	arg1	growth					940:945	the growth	936:945	the growth of herbaceous and tomato plants	936:977	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	1	6	theme	soil	239:242	arg1	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	6	theme	soil	239:242	arg1	fibers					198:203	cellulose fibers	188:203	cellulose fibers	188:203	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	6	theme	soil	239:242	arg1	conditioners					244:255	soil conditioners	239:255	soil conditioners	239:255	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	6	theme	soil	239:242	arg1	composites					158:167	bio-based hydrogel composites	139:167	bio-based hydrogel composites of xanthan gum	139:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	7	7	theme	investigated	1293:1304	arg1	materials					1306:1314	the investigated materials	1289:1314	the investigated materials	1289:1314	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	4	8	theme	physical	842:849	arg1	network					851:857	a physical network	840:857	a physical network	840:857	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	7	9	theme	inexpensive	1361:1371	arg1	technology					1386:1395	a simple, inexpensive and scalable technology	1351:1395	a simple, inexpensive and scalable technology	1351:1395	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	5	10	theme	Practical	911:919	arg1	experiments					921:931	Practical experiments	911:931	Practical experiments on the growth of herbaceous and tomato plants	911:977	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	0	11	theme	Agricultural	85:96	arg1	Applications					111:122	Agricultural and Forestry Applications	85:122	Agricultural and Forestry Applications	85:122	Development of a Xanthan Gum Based Superabsorbent and Water Retaining Composites for Agricultural and Forestry Applications.
36838941	4	12	theme	absorption	735:744	arg1	capacity					746:753	the water absorption capacity	725:753	the water absorption capacity	725:753	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	6	13	dep	covers	1206:1211	arg1	helped					1213:1218	helped	1213:1218	covers helped promote plant growth	1206:1239	Furthermore, it has been demonstrated that the use of the produced topsoil covers helped promote plant growth.
36838941	5	14	theme	wt	1041:1042	arg1	%					1043:1043	less than 2 wt%	1029:1043	less than 2 wt%	1029:1043	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	7	15	theme	simple	1353:1358	arg1	technology					1386:1395	a simple, inexpensive and scalable technology	1351:1395	a simple, inexpensive and scalable technology	1351:1395	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	1	16	theme	gum	180:182	arg1	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	16	theme	gum	180:182	arg1	fibers					198:203	cellulose fibers	188:203	cellulose fibers	188:203	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	16	theme	gum	180:182	arg1	topsoil					261:267	topsoil covers	261:274	topsoil covers	261:274	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	16	theme	gum	180:182	arg1	conditioners					244:255	soil conditioners	239:255	soil conditioners	239:255	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	16	theme	gum	180:182	arg1	composites					158:167	bio-based hydrogel composites	139:167	bio-based hydrogel composites of xanthan gum	139:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	7	17	theme	exceptional	1246:1256	arg1	properties					1275:1284	The exceptional water-regulating properties	1242:1284	The exceptional water-regulating properties of the investigated materials	1242:1314	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	0	18	theme	Forestry	102:109	arg1	Applications					111:122	Agricultural and Forestry Applications	85:122	Agricultural and Forestry Applications	85:122	Development of a Xanthan Gum Based Superabsorbent and Water Retaining Composites for Agricultural and Forestry Applications.
36838941	5	19	theme	%	1043:1043	arg1	addition					1017:1024	the addition	1013:1024	the addition of less than 2 wt% of hydrogels into the soil	1013:1070	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	5	20	theme	hydrogels	1048:1056	arg1	addition					1017:1024	the addition	1013:1024	the addition of less than 2 wt% of hydrogels into the soil	1013:1070	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	1	21	theme	xanthan	172:178	arg1	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	7	22	theme	technology	1386:1395	arg1	development					1336:1346	the development	1332:1346	the development of a simple, inexpensive and scalable technology	1332:1395	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	6	23	theme	plant	1228:1232	arg1	growth					1234:1239	plant growth	1228:1239	plant growth	1228:1239	Furthermore, it has been demonstrated that the use of the produced topsoil covers helped promote plant growth.
36838941	2	24	theme	water	360:364	arg1	properties					377:386	The rheological, morphological, and water absorption properties	324:386	properties	377:386	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	5	25	theme	rate	1098:1101	arg1	values					1103:1108	higher growth rate values	1084:1108	higher growth rate values than untreated soil	1084:1128	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	4	26	theme	materials	705:713	arg1	%					694:694	1.8 wt%	688:694	1.8 wt% of these materials	688:713	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	4	26	theme	materials	705:713	arg1	materials					705:713	these materials	699:713	these materials	699:713	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	0	27	theme	Xanthan	17:23	arg1	Gum					25:27	a Xanthan Gum	15:27	a Xanthan Gum	15:27	Development of a Xanthan Gum Based Superabsorbent and Water Retaining Composites for Agricultural and Forestry Applications.
36838941	4	28	theme	xanthan	877:883	arg1	gum					885:887	xanthan gum	877:887	xanthan gum	877:887	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	4	29	theme	evaporation	798:808	arg1	rate					810:813	the water evaporation rate	788:813	the water evaporation rate	788:813	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	3	30	theme	moisture	538:545	arg1	capability					558:567	the moisture absorption capability	534:567	the moisture absorption capability of these hydrogels	534:586	Specifically, the moisture absorption capability of these hydrogels was above 1000%, even after multiple dewatering/rehydration cycles.
36838941	5	31	theme	plants	972:977	arg1	growth					940:945	the growth	936:945	the growth of herbaceous and tomato plants	936:977	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	1	32	theme	cellulose	188:196	arg1	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	32	theme	cellulose	188:196	arg1	fibers					198:203	cellulose fibers	188:203	cellulose fibers	188:203	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	32	theme	cellulose	188:196	arg1	topsoil					261:267	topsoil covers	261:274	topsoil covers	261:274	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	32	theme	cellulose	188:196	arg1	conditioners					244:255	soil conditioners	239:255	soil conditioners	239:255	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	32	theme	cellulose	188:196	arg1	composites					158:167	bio-based hydrogel composites	139:167	bio-based hydrogel composites of xanthan gum	139:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	3	33	theme	dewatering/rehydration	625:646	arg1	cycles					648:653	multiple dewatering/rehydration cycles	616:653	multiple dewatering/rehydration cycles	616:653	Specifically, the moisture absorption capability of these hydrogels was above 1000%, even after multiple dewatering/rehydration cycles.
36838941	3	34	theme	absorption	547:556	arg1	capability					558:567	the moisture absorption capability	534:567	the moisture absorption capability of these hydrogels	534:586	Specifically, the moisture absorption capability of these hydrogels was above 1000%, even after multiple dewatering/rehydration cycles.
36838941	2	35	theme	hydrogels	400:408	arg1	morphological					341:353	morphological	341:353	morphological	341:353	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	5	36	theme	untreated	1115:1123	arg1	soil					1125:1128	untreated soil	1115:1128	untreated soil	1115:1128	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	7	37	theme	plant	1480:1484	arg1	resilience					1486:1495	plant resilience	1480:1495	plant resilience	1480:1495	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	4	38	theme	water	792:796	arg1	rate					810:813	the water evaporation rate	788:813	the water evaporation rate	788:813	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	2	39	theme	produced	391:398	arg1	hydrogels					400:408	produced hydrogels	391:408	produced hydrogels	391:408	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	0	40	theme	Gum	25:27	arg1	Development					0:10	Development	0:10	Development of a Xanthan Gum	0:27	Development of a Xanthan Gum Based Superabsorbent and Water Retaining Composites for Agricultural and Forestry Applications.
36838941	2	41	theme	addition	498:505	arg1	effect					479:484	the effect	475:484	the effect of hydrogel addition to the soil	475:517	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	1	42	theme	plant	288:292	arg1	growth					294:299	plant growth	288:299	plant growth	288:299	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	3	43	theme	multiple	616:623	arg1	cycles					648:653	multiple dewatering/rehydration cycles	616:653	multiple dewatering/rehydration cycles	616:653	Specifically, the moisture absorption capability of these hydrogels was above 1000%, even after multiple dewatering/rehydration cycles.
36838941	7	44	theme	materials	1306:1314	arg1	properties					1275:1284	The exceptional water-regulating properties	1242:1284	The exceptional water-regulating properties of the investigated materials	1242:1314	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	7	45	theme	scalable	1377:1384	arg1	technology					1386:1395	a simple, inexpensive and scalable technology	1351:1395	a simple, inexpensive and scalable technology	1351:1395	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	5	46	theme	higher	1084:1089	arg1	rate					1098:1101	higher growth rate	1084:1101	higher growth rate values than untreated soil	1084:1128	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	4	47	theme	network	851:857	arg1	formation					827:835	the formation	823:835	the formation of a physical network between the soil, xanthan gum and cellulose fibers	823:908	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	1	48	dep	conditioners	244:255	arg1	both					231:234	both	231:234	both	231:234	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	3	49	theme	hydrogels	578:586	arg1	capability					558:567	the moisture absorption capability	534:567	the moisture absorption capability of these hydrogels	534:586	Specifically, the moisture absorption capability of these hydrogels was above 1000%, even after multiple dewatering/rehydration cycles.
36838941	7	50	theme	water-regulating	1258:1273	arg1	properties					1275:1284	The exceptional water-regulating properties	1242:1284	The exceptional water-regulating properties of the investigated materials	1242:1314	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	4	51	theme	wt	692:693	arg1	%					694:694	1.8 wt%	688:694	1.8 wt% of these materials	688:713	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	4	51	theme	wt	692:693	arg1	materials					705:713	these materials	699:713	these materials	699:713	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	5	52	theme	growth	1091:1096	arg1	rate					1098:1101	higher growth rate	1084:1101	higher growth rate values than untreated soil	1084:1128	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	1	53	used	used	226:229	arg2	composites					158:167	bio-based hydrogel composites	139:167	bio-based hydrogel composites of xanthan gum	139:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	53	used	used	226:229	arg2	topsoil					261:267	topsoil covers	261:274	topsoil covers	261:274	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	53	used	used	226:229	arg2	fibers					198:203	cellulose fibers	188:203	cellulose fibers	188:203	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	53	used	used	226:229	arg2	conditioners					244:255	soil conditioners	239:255	soil conditioners	239:255	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	53	used	used	226:229	arg2	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	4	54	theme	water	729:733	arg1	capacity					746:753	the water absorption capacity	725:753	the water absorption capacity	725:753	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36838941	7	55	theme	climate	1532:1538	arg1	change					1540:1545	climate change	1532:1545	climate change	1532:1545	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	5	56	theme	herbaceous	950:959	arg1	growth					940:945	the growth	936:945	the growth of herbaceous and tomato plants	936:977	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	2	57	theme	hydrogel	489:496	arg1	addition					498:505	hydrogel addition	489:505	hydrogel addition	489:505	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	7	58	theme	agricultural	1442:1453	arg1	applications					1455:1466	forestry and/or agricultural applications	1426:1466	forestry and/or agricultural applications	1426:1466	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	2	59	theme	absorption	366:375	arg1	properties					377:386	The rheological, morphological, and water absorption properties	324:386	properties	377:386	The rheological, morphological, and water absorption properties of produced hydrogels were comprehensively investigated, together with the analysis of the effect of hydrogel addition to the soil.
36838941	7	60	theme	related	1521:1527	arg1	challenges					1510:1519	the challenges	1506:1519	the challenges related to climate change	1506:1545	The exceptional water-regulating properties of the investigated materials could allow for the development of a simple, inexpensive and scalable technology to be extensively applied in forestry and/or agricultural applications, to improve plant resilience and face the challenges related to climate change.
36838941	1	61	theme	forest	305:310	arg1	protection					312:321	forest protection	305:321	forest protection	305:321	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	5	62	theme	tomato	965:970	arg1	plants					972:977	tomato plants	965:977	tomato plants	965:977	Practical experiments on the growth of herbaceous and tomato plants were also performed, showing that the addition of less than 2 wt% of hydrogels into the soil resulted in higher growth rate values than untreated soil.
36838941	1	63	theme	bio-based	139:147	arg1	gum					180:182	xanthan gum	172:182	xanthan gum	172:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	63	theme	bio-based	139:147	arg1	fibers					198:203	cellulose fibers	188:203	cellulose fibers	188:203	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	63	theme	bio-based	139:147	arg1	topsoil					261:267	topsoil covers	261:274	topsoil covers	261:274	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	63	theme	bio-based	139:147	arg1	conditioners					244:255	soil conditioners	239:255	soil conditioners	239:255	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	1	63	theme	bio-based	139:147	arg1	composites					158:167	bio-based hydrogel composites	139:167	bio-based hydrogel composites of xanthan gum	139:182	In this work, bio-based hydrogel composites of xanthan gum and cellulose fibers were developed to be used both as soil conditioners and topsoil covers, to promote plant growth and forest protection.
36838941	6	64	theme	produced	1189:1196	arg1	topsoil					1198:1204	the produced topsoil	1185:1204	the produced topsoil	1185:1204	Furthermore, it has been demonstrated that the use of the produced topsoil covers helped promote plant growth.
36838941	4	65	theme	cellulose	893:901	arg1	fibers					903:908	cellulose fibers	893:908	cellulose fibers	893:908	Moreover, the soil treated with 1.8 wt% of these materials increased the water absorption capacity by approximately 60% and reduced the water evaporation rate, due to the formation of a physical network between the soil, xanthan gum and cellulose fibers.
36099721	4	0	from	rhizome	555:561	arg1	proportion					514:523	the proportion	510:523	the proportion of heteromannans (HMs) in the rhizome is nearly three-fold	510:582	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	1	dep	extractable	497:507	arg1	compared					584:591	compared	584:591	compared to that of the leave and stem	584:621	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	2	theme	wall	432:435	arg1	preparations					437:448	these wall preparations	426:448	these wall preparations	426:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	8	3	theme	rhizome	1209:1215	arg1	walls					1222:1226	rhizome cell walls	1209:1226	rhizome cell walls	1209:1226	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	0	4	from	compositions	11:22	arg1	stem					95:98	stem	95:98	stem	95:98	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	4	from	compositions	11:22	arg1	leaf					105:108	leaf	105:108	leaf	105:108	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	4	from	compositions	11:22	arg1	rhizome					86:92	rhizome	86:92	rhizome	86:92	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	7	5	theme	Water-soluble	1012:1024	arg1	fractions					1041:1049	Water-soluble polysaccharide fractions	1012:1049	Water-soluble polysaccharide fractions	1012:1049	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	6	6	theme	cell	907:910	arg1	walls					912:916	the cell walls	903:916	the cell walls in the rhizome	903:931	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	3	7	theme	structural	325:334	arg1	compositions					336:347	the structural compositions	321:347	the structural compositions of rhizome, leaf, and stem cell walls	321:385	Herein, we have investigated the structural compositions of rhizome, leaf, and stem cell walls.
36099721	8	8	theme	immune	1245:1250	arg1	response					1252:1259	specific immune response	1236:1259	specific immune response	1236:1259	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	9	theme	growth	1320:1325	arg1	GM-CSF					1335:1340	GM-CSF	1335:1340	GM-CSF	1335:1340	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	9	theme	growth	1320:1325	arg1	factors					1327:1333	hematopoietic growth factors GM-CSF and G-CSF	1306:1350	hematopoietic growth factors GM-CSF and G-CSF	1306:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	9	theme	growth	1320:1325	arg1	G-CSF					1346:1350	G-CSF	1346:1350	G-CSF	1346:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	7	10	theme	4-linked	1104:1111	arg1	Manp					1113:1116	4-linked Manp	1104:1116	4-linked Manp	1104:1116	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	7	11	link	4-linked	1104:1111	arg1	Manp					1113:1116	4-linked Manp	1104:1116	4-linked Manp	1104:1116	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	8	12	theme	specific	1236:1243	arg1	response					1252:1259	specific immune response	1236:1259	specific immune response	1236:1259	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	13	dep	factors	1327:1333	arg1	GM-CSF					1335:1340	GM-CSF	1335:1340	GM-CSF	1335:1340	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	13	dep	factors	1327:1333	arg1	factors					1327:1333	hematopoietic growth factors GM-CSF and G-CSF	1306:1350	hematopoietic growth factors GM-CSF and G-CSF	1306:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	13	dep	factors	1327:1333	arg1	G-CSF					1346:1350	G-CSF	1346:1350	G-CSF	1346:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	4	14	from	preparations	437:448	arg1	%					402:402	30-44%	397:402	30-44% of polysaccharides in these wall preparations	397:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	14	from	preparations	437:448	arg1	polysaccharides					407:421	polysaccharides	407:421	polysaccharides in these wall preparations	407:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	5	15	theme	type	732:735	arg1	arabinogalactans					740:755	type I and type II arabinogalactans	721:755	type I and type II arabinogalactans	721:755	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	8	16	attach	derived	1196:1202	arg2	polysaccharides					1172:1186	21.4 kDa pectic polysaccharides	1156:1186	21.4 kDa pectic polysaccharides	1156:1186	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	16	attach	derived	1196:1202	arg1	walls					1222:1226	rhizome cell walls	1209:1226	rhizome cell walls	1209:1226	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	5	17	theme	linkage	783:789	arg1	study					791:795	linkage study	783:795	linkage study of the sodium carbonate (Na2CO3) extract	783:836	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	7	18	theme	Man	1094:1096	arg1	proportion					1080:1089	high proportion	1075:1089	high proportion of Man	1075:1096	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	8	19	theme	cell	1217:1220	arg1	walls					1222:1226	rhizome cell walls	1209:1226	rhizome cell walls	1209:1226	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	3	20	theme	leaf	361:364	arg1	compositions					336:347	the structural compositions	321:347	the structural compositions of rhizome, leaf, and stem cell walls	321:385	Herein, we have investigated the structural compositions of rhizome, leaf, and stem cell walls.
36099721	4	21	from	heteromannans	528:540	arg1	rhizome					555:561	the rhizome	551:561	the rhizome is nearly three-fold	551:582	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	0	22	from	activities	39:48	arg1	stem					95:98	stem	95:98	stem	95:98	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	22	from	activities	39:48	arg1	leaf					105:108	leaf	105:108	leaf	105:108	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	22	from	activities	39:48	arg1	rhizome					86:92	rhizome	86:92	rhizome	86:92	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	6	23	from	walls	912:916	arg1	rhizome					925:931	the rhizome	921:931	the rhizome	921:931	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	0	24	dep	rhizome	86:92	arg1	the					82:84	the	82:84	the	82:84	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	7	25	theme	high	1075:1078	arg1	proportion					1080:1089	high proportion	1075:1089	high proportion of Man	1075:1096	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	3	26	theme	walls	381:385	arg1	compositions					336:347	the structural compositions	321:347	the structural compositions of rhizome, leaf, and stem cell walls	321:385	Herein, we have investigated the structural compositions of rhizome, leaf, and stem cell walls.
36099721	0	27	theme	Structural	0:9	arg1	compositions					11:22	Structural compositions	0:22	Structural compositions	0:22	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	2	28	theme	ailments	282:289	arg1	treatment					261:269	the treatment	257:269	the treatment of various ailments	257:289	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	6	29	theme	complex	955:961	arg1	structure					963:971	a more complex structure	948:971	a more complex structure	948:971	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	0	30	theme	biological	28:37	arg1	activities					39:48	biological activities	28:48	biological activities	28:48	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	6	31	link	2-linked	856:863	arg1	rhizome-specific					874:889	rhizome-specific	874:889	rhizome-specific	874:889	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	6	31	link	2-linked	856:863	arg1	Araf					865:868	the 2-linked Araf	852:868	the 2-linked Araf	852:868	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	4	32	from	polysaccharides	407:421	arg1	preparations					437:448	these wall preparations	426:448	these wall preparations	426:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	8	33	theme	hematopoietic	1306:1318	arg1	GM-CSF					1335:1340	GM-CSF	1335:1340	GM-CSF	1335:1340	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	33	theme	hematopoietic	1306:1318	arg1	factors					1327:1333	hematopoietic growth factors GM-CSF and G-CSF	1306:1350	hematopoietic growth factors GM-CSF and G-CSF	1306:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	8	33	theme	hematopoietic	1306:1318	arg1	G-CSF					1346:1350	G-CSF	1346:1350	G-CSF	1346:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	2	34	theme	various	274:280	arg1	ailments					282:289	various ailments	274:289	various ailments	274:289	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	8	35	theme	21.4 kDa	1156:1163	arg1	polysaccharides					1172:1186	21.4 kDa pectic polysaccharides	1156:1186	21.4 kDa pectic polysaccharides	1156:1186	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	3	36	theme	rhizome	352:358	arg1	compositions					336:347	the structural compositions	321:347	the structural compositions of rhizome, leaf, and stem cell walls	321:385	Herein, we have investigated the structural compositions of rhizome, leaf, and stem cell walls.
36099721	4	37	theme	heteromannans	528:540	arg1	proportion					514:523	the proportion	510:523	the proportion of heteromannans (HMs) in the rhizome is nearly three-fold	510:582	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	5	38	theme	rhizome	658:664	arg1	diverse					693:699	diverse	693:699	diverse	693:699	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	5	38	theme	rhizome	658:664	arg1	polysaccharides					635:649	The pectic polysaccharides	624:649	The pectic polysaccharides of the rhizome	624:664	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	7	39	theme	HMs	1147:1149	arg1	proportion					1133:1142	high proportion	1128:1142	high proportion of HMs	1128:1149	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	3	40	theme	stem	371:374	arg1	walls					381:385	stem cell walls	371:385	stem cell walls	371:385	Herein, we have investigated the structural compositions of rhizome, leaf, and stem cell walls.
36099721	0	41	theme	odoratum	125:132	arg1	stem					95:98	stem	95:98	stem	95:98	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	41	theme	odoratum	125:132	arg1	leaf					105:108	leaf	105:108	leaf	105:108	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	41	theme	odoratum	125:132	arg1	rhizome					86:92	rhizome	86:92	rhizome	86:92	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	2	42	theme	Polygonatum	149:159	arg1	odoratum					161:168	Polygonatum odoratum	149:168	Polygonatum odoratum	149:168	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	2	42	theme	Polygonatum	149:159	arg1	plant					207:211	a perennial rhizomatous medicinal plant	173:211	a perennial rhizomatous medicinal plant	173:211	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	2	43	theme	different	217:225	arg1	parts					233:237	different plant parts	217:237	different plant parts	217:237	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	7	44	theme	polysaccharide	1026:1039	arg1	fractions					1041:1049	Water-soluble polysaccharide fractions	1012:1049	Water-soluble polysaccharide fractions	1012:1049	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	3	45	theme	cell	376:379	arg1	walls					381:385	stem cell walls	371:385	stem cell walls	371:385	Herein, we have investigated the structural compositions of rhizome, leaf, and stem cell walls.
36099721	6	46	theme	2-linked	856:863	arg1	rhizome-specific					874:889	rhizome-specific	874:889	rhizome-specific	874:889	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	6	46	theme	2-linked	856:863	arg1	Araf					865:868	the 2-linked Araf	852:868	the 2-linked Araf	852:868	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	5	47	theme	type	721:724	arg1	arabinogalactans					740:755	type I and type II arabinogalactans	721:755	type I and type II arabinogalactans	721:755	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	4	48	theme	polysaccharides	407:421	arg1	%					402:402	30-44%	397:402	30-44% of polysaccharides in these wall preparations	397:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	48	theme	polysaccharides	407:421	arg1	polysaccharides					407:421	polysaccharides	407:421	polysaccharides in these wall preparations	407:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	49	from	proportion	514:523	arg1	rhizome					555:561	the rhizome	551:561	the rhizome is nearly three-fold	551:582	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	6	50	from	rhizome-specific	874:889	arg1	addition					842:849	addition	842:849	addition	842:849	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	8	51	theme	pectic	1165:1170	arg1	polysaccharides					1172:1186	21.4 kDa pectic polysaccharides	1156:1186	21.4 kDa pectic polysaccharides	1156:1186	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	0	52	theme	wall	58:61	arg1	polysaccharides					63:77	cell wall polysaccharides	53:77	cell wall polysaccharides	53:77	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	8	53	theme	macrophage	1269:1278	arg1	cells					1280:1284	mice macrophage cells	1264:1284	mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF	1264:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	7	54	theme	high	1128:1131	arg1	proportion					1133:1142	high proportion	1128:1142	high proportion of HMs	1128:1149	Water-soluble polysaccharide fractions were also investigated, high proportion of Man as in 4-linked Manp indicated high proportion of HMs.
36099721	6	55	dep	leaf	997:1000	arg1	the					993:995	the	993:995	the	993:995	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	8	56	theme	mice	1264:1267	arg1	cells					1280:1284	mice macrophage cells	1264:1284	mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF	1264:1350	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	0	57	theme	cell	53:56	arg1	polysaccharides					63:77	cell wall polysaccharides	53:77	cell wall polysaccharides	53:77	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	6	58	from	addition	842:849	arg1	rhizome-specific					874:889	rhizome-specific	874:889	rhizome-specific	874:889	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	6	58	from	addition	842:849	arg1	Araf					865:868	the 2-linked Araf	852:868	the 2-linked Araf	852:868	In addition, the 2-linked Araf was rhizome-specific, suggesting the cell walls in the rhizome had adapted to a more complex structure compared to that of the leaf and stem.
36099721	2	59	theme	rhizomatous	185:195	arg1	odoratum					161:168	Polygonatum odoratum	149:168	Polygonatum odoratum	149:168	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	2	59	theme	rhizomatous	185:195	arg1	plant					207:211	a perennial rhizomatous medicinal plant	173:211	a perennial rhizomatous medicinal plant	173:211	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	2	60	theme	medicinal	197:205	arg1	odoratum					161:168	Polygonatum odoratum	149:168	Polygonatum odoratum	149:168	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	2	60	theme	medicinal	197:205	arg1	plant					207:211	a perennial rhizomatous medicinal plant	173:211	a perennial rhizomatous medicinal plant	173:211	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	5	61	theme	extract	830:836	arg1	study					791:795	linkage study	783:795	linkage study of the sodium carbonate (Na2CO3) extract	783:836	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	2	62	theme	perennial	175:183	arg1	odoratum					161:168	Polygonatum odoratum	149:168	Polygonatum odoratum	149:168	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	2	62	theme	perennial	175:183	arg1	plant					207:211	a perennial rhizomatous medicinal plant	173:211	a perennial rhizomatous medicinal plant	173:211	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	4	63	from	%	402:402	arg1	preparations					437:448	these wall preparations	426:448	these wall preparations	426:448	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	5	64	theme	pectic	628:633	arg1	diverse					693:699	diverse	693:699	diverse	693:699	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	5	64	theme	pectic	628:633	arg1	polysaccharides					635:649	The pectic polysaccharides	624:649	The pectic polysaccharides of the rhizome	624:664	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	4	65	dep	rhizome	555:561	arg1	three-fold					573:582	three-fold	573:582	three-fold	573:582	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	66	dep	leave	608:612	arg1	the					604:606	the	604:606	the	604:606	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	8	67	dep	polysaccharides	1172:1186	arg1	The					1152:1154	The	1152:1154	The	1152:1154	The 21.4 kDa pectic polysaccharides and HMs derived from rhizome cell walls induced specific immune response in mice macrophage cells producing IL-1α and hematopoietic growth factors GM-CSF and G-CSF in vitro.
36099721	5	68	theme	carbonate	811:819	arg1	extract					830:836	the sodium carbonate (Na2CO3) extract	800:836	the sodium carbonate (Na2CO3) extract	800:836	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	0	69	dep	compositions	11:22	arg1	Mill					135:138	Mill	135:138	Mill.	135:139	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	5	70	theme	sodium	804:809	arg1	Na2CO3					822:827	Na2CO3	822:827	Na2CO3	822:827	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	5	70	theme	sodium	804:809	arg1	carbonate					811:819	sodium carbonate	804:819	the sodium carbonate (Na2CO3) extract	800:836	The pectic polysaccharides of the rhizome are also structurally more diverse, with arabinans and type I and type II arabinogalactans being richest as shown by linkage study of the sodium carbonate (Na2CO3) extract.
36099721	0	71	theme	polysaccharides	63:77	arg1	compositions					11:22	Structural compositions	0:22	Structural compositions	0:22	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	0	71	theme	polysaccharides	63:77	arg1	activities					39:48	biological activities	28:48	biological activities	28:48	Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.)
36099721	4	72	theme	cyclohexanediaminetetraacetic	455:483	arg1	CDTA					491:494	CDTA	491:494	CDTA	491:494	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	4	72	theme	cyclohexanediaminetetraacetic	455:483	arg1	acid					485:488	cyclohexanediaminetetraacetic acid	455:488	cyclohexanediaminetetraacetic acid (CDTA)	455:495	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	2	73	theme	plant	227:231	arg1	parts					233:237	different plant parts	217:237	different plant parts	217:237	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36099721	4	74	dep	found	391:395	arg1	extractable					497:507	extractable	497:507	extractable	497:507	We found 30-44% of polysaccharides in these wall preparations were cyclohexanediaminetetraacetic acid (CDTA) extractable, the proportion of heteromannans (HMs) in the rhizome is nearly three-fold compared to that of the leave and stem.
36099721	2	75	used	used	249:252	arg2	parts					233:237	different plant parts	217:237	different plant parts	217:237	Polygonatum odoratum is a perennial rhizomatous medicinal plant and different plant parts have been used in the treatment of various ailments.
36542787	0	0	theme	Chromatography-Tandem	90:110	arg1	Spectrometry					117:128	Liquid Chromatography-Tandem Mass Spectrometry	83:128	Liquid Chromatography-Tandem Mass Spectrometry	83:128	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	11	1	theme	dietary	1790:1796	arg1	polysaccharides					1798:1812	dietary polysaccharides	1790:1812	dietary polysaccharides	1790:1812	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	5	2	theme	chromatography-quadrupole	779:803	arg1	HPLC-QTOF-MS					839:850	HPLC-QTOF-MS	839:850	HPLC-QTOF-MS	839:850	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	2	theme	chromatography-quadrupole	779:803	arg1	spectrometry					825:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry	755:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	755:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	11	3	theme	microbial	1819:1827	arg1	community					1829:1837	gut microbial community	1815:1837	gut microbial community	1815:1837	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	0	4	theme	Liquid	83:88	arg1	Spectrometry					117:128	Liquid Chromatography-Tandem Mass Spectrometry	83:128	Liquid Chromatography-Tandem Mass Spectrometry	83:128	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	5	5	theme	oligosaccharide	718:732	arg1	fingerprinting					734:747	oligosaccharide fingerprinting	718:747	oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	718:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	9	6	theme	diverse	1416:1422	arg1	samples					1443:1449	food samples	1438:1449	food samples	1438:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	9	6	theme	diverse	1416:1422	arg1	set					1431:1433	a diverse sample set	1414:1433	a diverse sample set of food samples	1414:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	9	7	from	set	1431:1433	arg1	polysaccharides					1393:1407	polysaccharides	1393:1407	polysaccharides from a diverse sample set of food samples	1393:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	11	8	theme	interactions	1774:1785	arg1	understanding					1753:1765	our understanding	1749:1765	our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health	1749:1855	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	10	9	theme	polysaccharides	1484:1498	arg1	concentrations					1461:1474	Absolute concentrations	1452:1474	Absolute concentrations of nine polysaccharides from apples and onions	1452:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	7	10	theme	reference	1101:1109	arg1	material					1111:1118	a breakfast cereal standard reference material	1073:1118	a breakfast cereal standard reference material	1073:1118	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	2	11	theme	polysaccharide	307:320	arg1	analysis					322:329	polysaccharide analysis	307:329	polysaccharide analysis	307:329	Due to their compositional diversity, polysaccharide analysis remains challenging.
36542787	10	12	theme	Absolute	1452:1459	arg1	concentrations					1461:1474	Absolute concentrations	1452:1474	Absolute concentrations of nine polysaccharides from apples and onions	1452:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	0	13	theme	Mass	112:115	arg1	Spectrometry					117:128	Liquid Chromatography-Tandem Mass Spectrometry	83:128	Liquid Chromatography-Tandem Mass Spectrometry	83:128	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	11	14	theme	gut	1815:1817	arg1	community					1829:1837	gut microbial community	1815:1837	gut microbial community	1815:1837	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	1	15	from	biomolecules	167:178	arg1	nature					183:188	nature	183:188	nature	183:188	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	10	16	from	apples	1505:1510	arg1	concentrations					1461:1474	Absolute concentrations	1452:1474	Absolute concentrations of nine polysaccharides from apples and onions	1452:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	10	16	from	apples	1505:1510	arg1	polysaccharides					1484:1498	nine polysaccharides	1479:1498	nine polysaccharides from apples and onions	1479:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	4	17	theme	high-throughput	528:542	arg1	approach					562:569	a multiplexed, high-throughput, and quantitative approach	513:569	a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods	513:606	To address this gap in analytical science, we have developed a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods.
36542787	5	18	theme	chemical	679:686	arg1	process					698:704	a nonenzymatic chemical digestion process	664:704	a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	664:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	19	theme	nonenzymatic	666:677	arg1	process					698:704	a nonenzymatic chemical digestion process	664:704	a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	664:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	9	20	theme	sample	1424:1429	arg1	samples					1443:1449	food samples	1438:1449	food samples	1438:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	9	20	theme	sample	1424:1429	arg1	set					1431:1433	a diverse sample set	1414:1433	a diverse sample set of food samples	1414:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	3	21	theme	high-throughput	384:398	arg1	analysis					400:407	high-throughput analysis	384:407	high-throughput analysis for carbohydrates	384:425	Compared to other biomolecules, high-throughput analysis for carbohydrates has yet to be developed.
36542787	0	22	from	Polysaccharides	44:58	arg1	Matrices					68:75	Food Matrices	63:75	Food Matrices	63:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	5	23	theme	digestion	688:696	arg1	process					698:704	a nonenzymatic chemical digestion process	664:704	a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	664:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	7	24	theme	cereal	1085:1090	arg1	material					1111:1118	a breakfast cereal standard reference material	1073:1118	a breakfast cereal standard reference material	1073:1118	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	2	25	theme	compositional	282:294	arg1	diversity					296:304	their compositional diversity	276:304	their compositional diversity	276:304	Due to their compositional diversity, polysaccharide analysis remains challenging.
36542787	7	26	theme	Method	982:987	arg1	validation					989:998	Method validation	982:998	Method validation	982:998	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	0	27	theme	Bottom-Up	13:21	arg1	Analysis					32:39	Quantitative Bottom-Up Glycomic Analysis	0:39	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices	0:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	7	28	theme	standard	1092:1099	arg1	material					1111:1118	a breakfast cereal standard reference material	1073:1118	a breakfast cereal standard reference material	1073:1118	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	4	29	from	gap	468:470	arg1	science					486:492	science	486:492	science	486:492	To address this gap in analytical science, we have developed a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods.
36542787	0	30	theme	Quantitative	0:11	arg1	Analysis					32:39	Quantitative Bottom-Up Glycomic Analysis	0:39	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices	0:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	1	31	attach	present	229:235	arg1	fungi					262:266	fungi	262:266	fungi	262:266	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	31	attach	present	229:235	arg2	polysaccharides					209:223	polysaccharides	209:223	polysaccharides	209:223	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	31	attach	present	229:235	arg1	plants					251:256	almost all plants	240:256	almost all plants	240:256	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	10	32	theme	calibration	1555:1565	arg1	curve					1567:1571	an external calibration curve	1543:1571	an external calibration curve	1543:1571	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	8	33	theme	2-15	1321:1324	arg1	CV					1327:1328	2-15% CV	1321:1328	2-15% CV	1321:1328	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	33	theme	2-15	1321:1324	arg1	reproducibility					1304:1318	high reproducibility	1299:1318	high reproducibility (2-15% CV)	1299:1329	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	9	34	theme	food	1438:1441	arg1	samples					1443:1449	food samples	1438:1449	food samples	1438:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	5	35	theme	time-of-flight	805:818	arg1	HPLC-QTOF-MS					839:850	HPLC-QTOF-MS	839:850	HPLC-QTOF-MS	839:850	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	35	theme	time-of-flight	805:818	arg1	spectrometry					825:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry	755:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	755:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	6	36	theme	absolute	896:903	arg1	quantitation					905:916	absolute quantitation	896:916	absolute quantitation	896:916	Both label-free relative quantitation and absolute quantitation were done based on the abundances of oligosaccharides produced.
36542787	8	37	dep	starch	1143:1148	arg1	mannan					1172:1177	mannan	1172:1177	mannan	1172:1177	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	galactan					1180:1187	galactan	1180:1187	galactan	1180:1187	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	xyloglucan					1207:1216	xyloglucan	1207:1216	xyloglucan	1207:1216	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	cellulose					1151:1159	cellulose	1151:1159	cellulose	1151:1159	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	chitin					1219:1224	chitin	1219:1224	chitin	1219:1224	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	β-glucan					1162:1169	β-glucan	1162:1169	β-glucan	1162:1169	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	arabinan					1190:1197	arabinan	1190:1197	arabinan	1190:1197	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	37	dep	starch	1143:1148	arg1	xylan					1200:1204	xylan	1200:1204	xylan	1200:1204	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	10	38	from	concentrations	1461:1474	arg1	apples					1505:1510	apples	1505:1510	apples	1505:1510	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	10	38	from	concentrations	1461:1474	arg1	onions					1516:1521	onions	1516:1521	onions	1516:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	0	39	theme	Glycomic	23:30	arg1	Analysis					32:39	Quantitative Bottom-Up Glycomic Analysis	0:39	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices	0:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	9	40	theme	samples	1443:1449	arg1	samples					1443:1449	food samples	1438:1449	food samples	1438:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	9	40	theme	samples	1443:1449	arg1	set					1431:1433	a diverse sample set	1414:1433	a diverse sample set of food samples	1414:1449	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	5	41	theme	mass	820:823	arg1	HPLC-QTOF-MS					839:850	HPLC-QTOF-MS	839:850	HPLC-QTOF-MS	839:850	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	41	theme	mass	820:823	arg1	spectrometry					825:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry	755:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	755:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	10	42	located	observed	1606:1613	arg2	differences					1589:1599	varietal differences	1580:1599	varietal differences	1580:1599	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	10	42	located	observed	1606:1613	arg1	some					1618:1621	some	1618:1621	some	1618:1621	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	10	42	located	observed	1606:1613	arg1	samples					1630:1636	the samples	1626:1636	the samples	1626:1636	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	7	43	theme	material	1111:1118	arg1	range					1035:1039	a range	1033:1039	a range of polysaccharide standards and a breakfast cereal standard reference material	1033:1118	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	0	44	theme	Polysaccharides	44:58	arg1	Analysis					32:39	Quantitative Bottom-Up Glycomic Analysis	0:39	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices	0:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	11	45	theme	polysaccharides	1798:1812	arg1	interactions					1774:1785	the interactions	1770:1785	the interactions of dietary polysaccharides, gut microbial community, and human health	1770:1855	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	9	46	used	used	1361:1364	arg2	method					1350:1355	the method	1346:1355	the method	1346:1355	Additionally, the method was used to identify and quantitate polysaccharides from a diverse sample set of food samples.
36542787	11	47	theme	human	1844:1848	arg1	health					1850:1855	human health	1844:1855	human health	1844:1855	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	8	48	dep	polysaccharides	1126:1140	arg1	starch					1143:1148	starch	1143:1148	starch	1143:1148	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	6	49	theme	label-free	859:868	arg1	quantitation					879:890	label-free relative quantitation	859:890	label-free relative quantitation	859:890	Both label-free relative quantitation and absolute quantitation were done based on the abundances of oligosaccharides produced.
36542787	8	50	theme	%	1325:1325	arg1	CV					1327:1328	2-15% CV	1321:1328	2-15% CV	1321:1328	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	50	theme	%	1325:1325	arg1	reproducibility					1304:1318	high reproducibility	1299:1318	high reproducibility (2-15% CV)	1299:1329	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	11	51	theme	community	1829:1837	arg1	interactions					1774:1785	the interactions	1770:1785	the interactions of dietary polysaccharides, gut microbial community, and human health	1770:1855	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	0	52	theme	Food	63:66	arg1	Matrices					68:75	Food Matrices	63:75	Food Matrices	63:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	4	53	theme	quantitative	549:560	arg1	approach					562:569	a multiplexed, high-throughput, and quantitative approach	513:569	a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods	513:606	To address this gap in analytical science, we have developed a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods.
36542787	5	54	theme	high	755:758	arg1	HPLC-QTOF-MS					839:850	HPLC-QTOF-MS	839:850	HPLC-QTOF-MS	839:850	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	54	theme	high	755:758	arg1	spectrometry					825:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry	755:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	755:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	0	55	from	Matrices	68:75	arg1	Analysis					32:39	Quantitative Bottom-Up Glycomic Analysis	0:39	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices	0:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	4	56	theme	multiplexed	515:525	arg1	approach					562:569	a multiplexed, high-throughput, and quantitative approach	513:569	a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods	513:606	To address this gap in analytical science, we have developed a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods.
36542787	4	57	theme	polysaccharide	575:588	arg1	analysis					590:597	polysaccharide analysis	575:597	polysaccharide analysis in foods	575:606	To address this gap in analytical science, we have developed a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods.
36542787	1	58	from	fungi	262:266	arg1	present					229:235	present	229:235	present	229:235	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	59	located	present	229:235	arg1	fungi					262:266	fungi	262:266	fungi	262:266	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	59	located	present	229:235	arg2	polysaccharides					209:223	polysaccharides	209:223	polysaccharides	209:223	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	59	located	present	229:235	arg1	plants					251:256	almost all plants	240:256	almost all plants	240:256	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	10	60	theme	varietal	1580:1587	arg1	differences					1589:1599	varietal differences	1580:1599	varietal differences	1580:1599	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	6	61	theme	relative	870:877	arg1	quantitation					879:890	label-free relative quantitation	859:890	label-free relative quantitation	859:890	Both label-free relative quantitation and absolute quantitation were done based on the abundances of oligosaccharides produced.
36542787	10	62	theme	external	1546:1553	arg1	curve					1567:1571	an external calibration curve	1543:1571	an external calibration curve	1543:1571	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	7	63	theme	standards	1059:1067	arg1	range					1035:1039	a range	1033:1039	a range of polysaccharide standards and a breakfast cereal standard reference material	1033:1118	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	7	64	theme	breakfast	1075:1083	arg1	material					1111:1118	a breakfast cereal standard reference material	1073:1118	a breakfast cereal standard reference material	1073:1118	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	5	65	theme	liquid	772:777	arg1	HPLC-QTOF-MS					839:850	HPLC-QTOF-MS	839:850	HPLC-QTOF-MS	839:850	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	65	theme	liquid	772:777	arg1	spectrometry					825:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry	755:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	755:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	1	66	from	present	229:235	arg1	fungi					262:266	fungi	262:266	fungi	262:266	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	66	from	present	229:235	arg1	plants					251:256	almost all plants	240:256	almost all plants	240:256	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	11	67	theme	complementary	1692:1704	arg1	information					1727:1737	complementary polysaccharide-level information	1692:1737	complementary polysaccharide-level information	1692:1737	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	1	68	theme	all	247:249	arg1	plants					251:256	almost all plants	240:256	almost all plants	240:256	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	69	from	plants	251:256	arg1	present					229:235	present	229:235	present	229:235	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	6	70	theme	oligosaccharides	955:970	arg1	abundances					941:950	the abundances	937:950	the abundances of oligosaccharides produced	937:979	Both label-free relative quantitation and absolute quantitation were done based on the abundances of oligosaccharides produced.
36542787	8	71	theme	high	1299:1302	arg1	CV					1327:1328	2-15% CV	1321:1328	2-15% CV	1321:1328	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	71	theme	high	1299:1302	arg1	reproducibility					1304:1318	high reproducibility	1299:1318	high reproducibility (2-15% CV)	1299:1329	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	1	72	theme	abundant	158:165	arg1	biomolecules					167:178	the most abundant biomolecules	149:178	the most abundant biomolecules in nature	149:188	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	1	72	theme	abundant	158:165	arg1	Carbohydrates					131:143	Carbohydrates	131:143	Carbohydrates	131:143	Carbohydrates are the most abundant biomolecules in nature, and specifically, polysaccharides are present in almost all plants and fungi.
36542787	11	73	theme	health	1850:1855	arg1	interactions					1774:1785	the interactions	1770:1785	the interactions of dietary polysaccharides, gut microbial community, and human health	1770:1855	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	3	74	theme	other	364:368	arg1	biomolecules					370:381	other biomolecules	364:381	other biomolecules	364:381	Compared to other biomolecules, high-throughput analysis for carbohydrates has yet to be developed.
36542787	7	75	theme	polysaccharide	1044:1057	arg1	standards					1059:1067	polysaccharide standards	1044:1067	polysaccharide standards	1044:1067	Method validation included evaluating recovery for a range of polysaccharide standards and a breakfast cereal standard reference material.
36542787	11	76	theme	polysaccharide-level	1706:1725	arg1	information					1727:1737	complementary polysaccharide-level information	1692:1737	complementary polysaccharide-level information	1692:1737	The methodology developed in this study will provide complementary polysaccharide-level information to deepen our understanding of the interactions of dietary polysaccharides, gut microbial community, and human health.
36542787	8	77	theme	sufficient	1262:1271	arg1	bias					1289:1292	5-25% bias	1283:1292	5-25% bias	1283:1292	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	77	theme	sufficient	1262:1271	arg1	accuracy					1273:1280	sufficient accuracy	1262:1280	sufficient accuracy (5-25% bias)	1262:1293	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	0	78	from	Analysis	32:39	arg1	Matrices					68:75	Food Matrices	63:75	Food Matrices	63:75	Quantitative Bottom-Up Glycomic Analysis of Polysaccharides in Food Matrices Using Liquid Chromatography-Tandem Mass Spectrometry.
36542787	4	79	from	analysis	590:597	arg1	foods					602:606	foods	602:606	foods	602:606	To address this gap in analytical science, we have developed a multiplexed, high-throughput, and quantitative approach for polysaccharide analysis in foods.
36542787	10	80	from	onions	1516:1521	arg1	concentrations					1461:1474	Absolute concentrations	1452:1474	Absolute concentrations of nine polysaccharides from apples and onions	1452:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	10	80	from	onions	1516:1521	arg1	polysaccharides					1484:1498	nine polysaccharides	1479:1498	nine polysaccharides from apples and onions	1479:1521	Absolute concentrations of nine polysaccharides from apples and onions were obtained using an external calibration curve, where varietal differences were observed in some of the samples.
36542787	5	81	theme	performance	760:770	arg1	HPLC-QTOF-MS					839:850	HPLC-QTOF-MS	839:850	HPLC-QTOF-MS	839:850	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	5	81	theme	performance	760:770	arg1	spectrometry					825:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry	755:836	high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS)	755:851	Specifically, polysaccharides were depolymerized using a nonenzymatic chemical digestion process followed by oligosaccharide fingerprinting using high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (HPLC-QTOF-MS).
36542787	8	82	theme	%	1287:1287	arg1	bias					1289:1292	5-25% bias	1283:1292	5-25% bias	1283:1292	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36542787	8	82	theme	%	1287:1287	arg1	accuracy					1273:1280	sufficient accuracy	1262:1280	sufficient accuracy (5-25% bias)	1262:1293	Nine polysaccharides (starch, cellulose, β-glucan, mannan, galactan, arabinan, xylan, xyloglucan, chitin) were successfully quantitated with sufficient accuracy (5-25% bias) and high reproducibility (2-15% CV).
36043716	0	0	theme	Tissue	89:94	arg1	Engineering					96:106	Tissue Engineering	89:106	Tissue Engineering	89:106	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	5	1	theme	accelerated	542:552	arg1	electrons					554:562	High-energy accelerated electrons	530:562	High-energy accelerated electrons from the plasma	530:578	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	1	2	theme	significant	149:159	arg1	number					161:166	a significant number	147:166	a significant number of repeating units	147:185	A polymer is a macromolecule that has a significant number of repeating units.
36043716	8	3	dep	delivery	1089:1096	arg1	applications					1121:1132	applications	1121:1132	applications	1121:1132	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	4	4	theme	constituent	504:514	arg1	constituents					516:527	their constituent constituents	498:527	their constituent constituents	498:527	Polymeric materials became appealing because of their low density and ability to incorporate properties of their constituent constituents.
36043716	8	5	theme	biomedical	1050:1059	arg1	applications					1061:1072	significant biomedical applications	1038:1072	significant biomedical applications including drug delivery and tissue engineering applications	1038:1132	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	5	theme	biomedical	1050:1059	arg1	delivery					1089:1096	drug delivery	1084:1096	drug delivery	1084:1096	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	5	theme	biomedical	1050:1059	arg1	engineering					1109:1119	tissue engineering	1102:1119	tissue engineering	1102:1119	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	5	6	theme	macromolecule	669:681	arg1	radicals					683:690	macromolecule radicals	669:690	macromolecule radicals	669:690	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	5	7	theme	polymeric	617:625	arg1	structure					627:635	the polymeric structure	613:635	the polymeric structure	613:635	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	3	8	theme	natural	334:340	arg1	polymers					342:349	natural polymers	334:349	natural polymers	334:349	There are several uses for using natural polymers in culinary and medicinal applications.
36043716	5	9	theme	radicals	683:690	arg1	generation					655:664	the generation	651:664	the generation of macromolecule radicals and graft copolymerization	651:717	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	4	10	theme	Polymeric	391:399	arg1	materials					401:409	Polymeric materials	391:409	Polymeric materials	391:409	Polymeric materials became appealing because of their low density and ability to incorporate properties of their constituent constituents.
36043716	7	11	theme	unwanted	884:891	arg1	properties					893:902	desirable and unwanted properties	870:902	desirable and unwanted properties	870:902	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	0	12	from	Methodology	46:56	arg1	Engineering					96:106	Tissue Engineering	89:106	Tissue Engineering	89:106	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	5	13	from	plasma	573:578	arg1	electrons					554:562	High-energy accelerated electrons	530:562	High-energy accelerated electrons from the plasma	530:578	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	7	14	theme	properties	893:902	arg1	variety					859:865	a wide variety	852:865	a wide variety of desirable and unwanted properties	852:902	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	7	14	theme	properties	893:902	arg1	properties					893:902	desirable and unwanted properties	870:902	desirable and unwanted properties	870:902	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	8	15	theme	polysaccharides	1017:1031	arg1	copolymers					1003:1012	graft copolymers	997:1012	graft copolymers of polysaccharides	997:1031	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	7	16	theme	desirable	870:878	arg1	properties					893:902	desirable and unwanted properties	870:902	desirable and unwanted properties	870:902	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	1	17	theme	repeating	171:179	arg1	units					181:185	repeating units	171:185	repeating units	171:185	A polymer is a macromolecule that has a significant number of repeating units.
36043716	3	18	theme	culinary	354:361	arg1	applications					377:388	culinary and medicinal applications	354:388	culinary and medicinal applications	354:388	There are several uses for using natural polymers in culinary and medicinal applications.
36043716	1	19	contain	has	143:145	arg1	macromolecule					124:136	a macromolecule	122:136	a macromolecule that has a significant number of repeating units	122:185	A polymer is a macromolecule that has a significant number of repeating units.
36043716	1	19	contain	has	143:145	arg2	number					161:166	a significant number	147:166	a significant number of repeating units	147:185	A polymer is a macromolecule that has a significant number of repeating units.
36043716	1	19	contain	has	143:145	arg1	polymer					111:117	A polymer	109:117	A polymer	109:117	A polymer is a macromolecule that has a significant number of repeating units.
36043716	5	20	theme	chemical	587:594	arg1	breaking					601:608	chemical bond breaking	587:608	chemical bond breaking	587:608	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	6	21	theme	Polymer	720:726	arg1	grafting					728:735	Polymer grafting	720:735	Polymer grafting	720:735	Polymer grafting has become an important aspect of the formulation development process.
36043716	1	22	theme	units	181:185	arg1	number					161:166	a significant number	147:166	a significant number of repeating units	147:185	A polymer is a macromolecule that has a significant number of repeating units.
36043716	0	23	theme	Graft	0:4	arg1	Copolymers					6:15	Graft Copolymers	0:15	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.	0:107	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	8	24	theme	tissue	1102:1107	arg1	engineering					1109:1119	tissue engineering	1102:1119	tissue engineering	1102:1119	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	5	25	theme	bond	596:599	arg1	breaking					601:608	chemical bond breaking	587:608	chemical bond breaking	587:608	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	8	26	theme	significant	1038:1048	arg1	applications					1061:1072	significant biomedical applications	1038:1072	significant biomedical applications including drug delivery and tissue engineering applications	1038:1132	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	26	theme	significant	1038:1048	arg1	delivery					1089:1096	drug delivery	1084:1096	drug delivery	1084:1096	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	26	theme	significant	1038:1048	arg1	engineering					1109:1119	tissue engineering	1102:1119	tissue engineering	1102:1119	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	0	27	theme	Polysaccharide	20:33	arg1	Copolymers					6:15	Graft Copolymers	0:15	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.	0:107	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	0	28	dep	Copolymers	6:15	arg1	Methodology					46:56	Synthesis Methodology	36:56	Synthesis Methodology	36:56	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	0	28	dep	Copolymers	6:15	arg1	Applications					73:84	Biomedical Applications	62:84	Biomedical Applications in Tissue Engineering	62:106	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	8	29	theme	graft	997:1001	arg1	copolymers					1003:1012	graft copolymers	997:1012	graft copolymers of polysaccharides	997:1031	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	2	30	dep	modify	206:211	arg1	mixing					267:272	mixing	267:272	mixing	267:272	It is possible to modify the architecture of a polymer via grafting, bridging, mixing, or generating composites.
36043716	2	30	dep	modify	206:211	arg1	generating					278:287	generating	278:287	generating composites	278:298	It is possible to modify the architecture of a polymer via grafting, bridging, mixing, or generating composites.
36043716	2	30	dep	modify	206:211	arg1	bridging					257:264	bridging	257:264	bridging	257:264	It is possible to modify the architecture of a polymer via grafting, bridging, mixing, or generating composites.
36043716	0	31	theme	Synthesis	36:44	arg1	Methodology					46:56	Synthesis Methodology	36:56	Synthesis Methodology	36:56	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	7	32	theme	wide	854:857	arg1	variety					859:865	a wide variety	852:865	a wide variety of desirable and unwanted properties	852:902	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	7	32	theme	wide	854:857	arg1	properties					893:902	desirable and unwanted properties	870:902	desirable and unwanted properties	870:902	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	7	33	theme	polymer	813:819	arg1	groups					832:837	polymer functional groups	813:837	polymer functional groups	813:837	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36043716	3	34	dep	several	311:317	arg1	uses					319:322	uses	319:322	uses	319:322	There are several uses for using natural polymers in culinary and medicinal applications.
36043716	0	35	from	Applications	73:84	arg1	Engineering					96:106	Tissue Engineering	89:106	Tissue Engineering	89:106	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	6	36	theme	process	799:805	arg1	aspect					761:766	an important aspect	748:766	an important aspect of the formulation development process	748:805	Polymer grafting has become an important aspect of the formulation development process.
36043716	3	37	theme	medicinal	367:375	arg1	applications					377:388	culinary and medicinal applications	354:388	culinary and medicinal applications	354:388	There are several uses for using natural polymers in culinary and medicinal applications.
36043716	4	38	theme	constituents	516:527	arg1	properties					484:493	properties	484:493	properties of their constituent constituents	484:527	Polymeric materials became appealing because of their low density and ability to incorporate properties of their constituent constituents.
36043716	4	39	theme	low	445:447	arg1	density					449:455	their low density	439:455	their low density	439:455	Polymeric materials became appealing because of their low density and ability to incorporate properties of their constituent constituents.
36043716	6	40	theme	development	787:797	arg1	process					799:805	the formulation development process	771:805	the formulation development process	771:805	Polymer grafting has become an important aspect of the formulation development process.
36043716	5	41	theme	graft	696:700	arg1	copolymerization					702:717	graft copolymerization	696:717	graft copolymerization	696:717	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	6	42	theme	formulation	775:785	arg1	process					799:805	the formulation development process	771:805	the formulation development process	771:805	Polymer grafting has become an important aspect of the formulation development process.
36043716	8	43	theme	drug	1084:1087	arg1	delivery					1089:1096	drug delivery	1084:1096	drug delivery	1084:1096	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	5	44	theme	copolymerization	702:717	arg1	generation					655:664	the generation	651:664	the generation of macromolecule radicals and graft copolymerization	651:717	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	8	45	theme	literature	974:983	arg1	survey					985:990	the literature survey	970:990	the literature survey	970:990	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	46	theme	survey	985:990	arg1	findings					958:965	the findings	954:965	the findings of the literature survey	954:990	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	6	47	theme	important	751:759	arg1	aspect					761:766	an important aspect	748:766	an important aspect of the formulation development process	748:805	Polymer grafting has become an important aspect of the formulation development process.
36043716	8	48	contain	have	1033:1036	arg2	engineering					1109:1119	tissue engineering	1102:1119	tissue engineering	1102:1119	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	48	contain	have	1033:1036	arg1	copolymers					1003:1012	graft copolymers	997:1012	graft copolymers of polysaccharides	997:1031	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	48	contain	have	1033:1036	arg2	delivery					1089:1096	drug delivery	1084:1096	drug delivery	1084:1096	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	8	48	contain	have	1033:1036	arg2	applications					1061:1072	significant biomedical applications	1038:1072	significant biomedical applications including drug delivery and tissue engineering applications	1038:1132	It can be concluded from the findings of the literature survey that graft copolymers of polysaccharides have significant biomedical applications including drug delivery and tissue engineering applications.
36043716	2	49	theme	polymer	235:241	arg1	architecture					217:228	the architecture	213:228	the architecture of a polymer	213:241	It is possible to modify the architecture of a polymer via grafting, bridging, mixing, or generating composites.
36043716	0	50	theme	Biomedical	62:71	arg1	Applications					73:84	Biomedical Applications	62:84	Biomedical Applications in Tissue Engineering	62:106	Graft Copolymers of Polysaccharide: Synthesis Methodology and Biomedical Applications in Tissue Engineering.
36043716	5	51	theme	High-energy	530:540	arg1	electrons					554:562	High-energy accelerated electrons	530:562	High-energy accelerated electrons from the plasma	530:578	High-energy accelerated electrons from the plasma induce chemical bond breaking in the polymeric structure, resulting in the generation of macromolecule radicals and graft copolymerization.
36043716	7	52	theme	functional	821:830	arg1	groups					832:837	polymer functional groups	813:837	polymer functional groups	813:837	When polymer functional groups are changed, a wide variety of desirable and unwanted properties can be added or removed.
36361966	6	0	theme	1,5-linked	1282:1291	arg1	residues					1309:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	6	1	theme	alternating	1232:1242	arg1	regions					1244:1250	alternating regions	1232:1250	alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues	1232:1316	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	1	2	contain	contain	164:170	arg2	polysaccharides					186:200	polysaccharides	186:200	polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate	186:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	2	contain	contain	164:170	arg2	w/w					178:180	w/w	178:180	w/w	178:180	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	2	contain	contain	164:170	arg2	%					175:175	~13%	172:175	~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate	172:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	2	contain	contain	164:170	arg1	part					121:124	The above-ground part	104:124	The above-ground part of the Salsola passerine	104:149	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	3	3	theme	chains	575:580	arg1	acid					496:499	galacturonic acid and arabinose residues	483:522	acid	496:499	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	3	theme	chains	575:580	arg1	residues					515:522	galacturonic acid and arabinose residues	483:522	residues	515:522	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	3	theme	chains	575:580	arg1	components					542:551	the principal components	528:551	the principal components of their carbohydrate chains	528:580	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	1	4	theme	oxalate	259:265	arg1	water					219:223	water	219:223	water	219:223	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	4	theme	oxalate	259:265	arg1	solutions					237:245	aqueous solutions	229:245	aqueous solutions of ammonium oxalate and sodium carbonate	229:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	6	5	link	1,5-linked	1282:1291	arg1	residues					1309:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	5	6	link	1,2-linked	1037:1046	arg1	residues					1072:1079	1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues	1014:1079	residues	1072:1079	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	4	7	theme	extracted	661:669	arg1	fractions					686:694	the extracted polysaccharide fractions	657:694	the extracted polysaccharide fractions	657:694	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	4	8	theme	fractions	686:694	arg1	activity					645:652	antioxidant activity	633:652	antioxidant activity of the extracted polysaccharide fractions	633:694	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	5	9	theme	α-D-galactopyranosyluronic	861:886	arg1	GalpA					894:898	GalpA	894:898	GalpA	894:898	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	9	theme	α-D-galactopyranosyluronic	861:886	arg1	acid					888:891	α-D-galactopyranosyluronic acid	861:891	α-D-galactopyranosyluronic acid (GalpA)	861:899	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	1	10	theme	extractable	202:212	arg1	polysaccharides					186:200	polysaccharides	186:200	polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate	186:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	8	11	theme	scavenging	1541:1550	arg1	activity					1552:1559	the DPPH scavenging activity	1532:1559	the DPPH scavenging activity of polysaccharide fractions	1532:1587	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	7	12	theme	DPPH	1463:1466	arg1	radical					1469:1475	the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical	1428:1475	the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical	1428:1475	Polysaccharide fractions scavenged the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical at 0.2-1.8 mg/mL.
36361966	4	13	theme	magnetic	762:769	arg1	NMR					782:784	NMR	782:784	NMR	782:784	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	4	13	theme	magnetic	762:769	arg1	resonance					771:779	nuclear magnetic resonance	754:779	nuclear magnetic resonance (NMR) spectroscopy	754:798	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	5	14	theme	repeating	959:967	arg1	unit					969:972	a diglycosyl repeating unit	946:972	a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	946:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	7	15	theme	1,1-diphenyl-2-picrylhydrazyl	1432:1460	arg1	radical					1469:1475	the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical	1428:1475	the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical	1428:1475	Polysaccharide fractions scavenged the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical at 0.2-1.8 mg/mL.
36361966	6	16	theme	3,5-substituted	1262:1276	arg1	residues					1309:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	5	17	theme	alternating	990:1000	arg1	sequence					1002:1009	a strictly alternating sequence	979:1009	a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	979:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	6	18	theme	residues	1357:1364	arg1	alternation					1336:1346	no alternation	1333:1346	no alternation of these residues	1333:1364	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	1	19	theme	passerine	141:149	arg1	part					121:124	The above-ground part	104:124	The above-ground part of the Salsola passerine	104:149	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	8	20	theme	fractions	1579:1587	arg1	activity					1552:1559	the DPPH scavenging activity	1532:1559	the DPPH scavenging activity of polysaccharide fractions	1532:1587	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	5	21	contain	contains	937:944	arg2	unit					969:972	a diglycosyl repeating unit	946:972	a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	946:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	21	contain	contains	937:944	arg1	RG-I					924:927	RG-I	924:927	RG-I	924:927	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	21	contain	contains	937:944	arg1	rhamnogalacturonan-I					902:921	rhamnogalacturonan-I	902:921	rhamnogalacturonan-I (RG-I)	902:928	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	22	theme	acid	888:891	arg1	arabinan					1102:1109	arabinan	1102:1109	arabinan	1102:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	22	theme	acid	888:891	arg1	rhamnogalacturonan-I					902:921	rhamnogalacturonan-I	902:921	rhamnogalacturonan-I (RG-I)	902:928	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	22	theme	acid	888:891	arg1	residues					849:856	1,4-linked residues	838:856	1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan	838:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	22	theme	acid	888:891	arg1	acid					888:891	α-D-galactopyranosyluronic acid	861:891	α-D-galactopyranosyluronic acid (GalpA)	861:899	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	0	23	theme	Antioxidant	82:92	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.	0:102	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	23	theme	Antioxidant	82:92	arg1	Activity					94:101	Antioxidant Activity	82:101	Antioxidant Activity	82:101	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	5	24	theme	polysaccharides	1168:1182	arg1	units					1146:1150	the structural units	1131:1150	the structural units of the obtained polysaccharides	1131:1182	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	24	theme	polysaccharides	1168:1182	arg1	Homogalacturonan					801:816	Homogalacturonan	801:816	Homogalacturonan (HG)	801:821	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	2	25	contain	had	353:355	arg2	yield					369:373	the highest yield	357:373	the highest yield	357:373	The fractions extracted with aqueous sodium carbonate solutions had the highest yield.
36361966	2	25	contain	had	353:355	arg1	fractions					293:301	The fractions	289:301	The fractions extracted with aqueous sodium carbonate solutions	289:351	The fractions extracted with aqueous sodium carbonate solutions had the highest yield.
36361966	5	26	theme	1,4-linked	1014:1023	arg1	D-GalpA					1025:1031	1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues	1014:1079	D-GalpA	1025:1031	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	27	with	unit	969:972	arg1	sequence					1002:1009	a strictly alternating sequence	979:1009	a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	979:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	3	28	theme	monosaccharide	447:460	arg1	composition					462:472	similar monosaccharide composition	439:472	similar monosaccharide composition	439:472	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	8	29	theme	compounds	1633:1641	arg1	content					1613:1619	the content	1609:1619	the content of phenolic compounds (PCs)	1609:1647	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	0	30	theme	Salsola	19:25	arg1	passerina					27:35	Salsola passerina	19:35	Salsola passerina	19:35	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	1	31	theme	carbonate	278:286	arg1	water					219:223	water	219:223	water	219:223	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	31	theme	carbonate	278:286	arg1	solutions					237:245	aqueous solutions	229:245	aqueous solutions of ammonium oxalate and sodium carbonate	229:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	32	with	extractable	202:212	arg1	water					219:223	water	219:223	water	219:223	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	32	with	extractable	202:212	arg1	solutions					237:245	aqueous solutions	229:245	aqueous solutions of ammonium oxalate and sodium carbonate	229:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	4	33	theme	present	587:593	arg1	study					595:599	The present study	583:599	The present study	583:599	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	5	34	theme	residues	1072:1079	arg1	sequence					1002:1009	a strictly alternating sequence	979:1009	a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	979:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	3	35	theme	majority	399:406	arg1	fractions					408:416	majority fractions	399:416	majority fractions	399:416	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	36	theme	arabinose	505:513	arg1	acid					496:499	galacturonic acid and arabinose residues	483:522	acid	496:499	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	36	theme	arabinose	505:513	arg1	residues					515:522	galacturonic acid and arabinose residues	483:522	residues	515:522	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	36	theme	arabinose	505:513	arg1	components					542:551	the principal components	528:551	the principal components of their carbohydrate chains	528:580	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	5	37	theme	1,4-linked	838:847	arg1	arabinan					1102:1109	arabinan	1102:1109	arabinan	1102:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	37	theme	1,4-linked	838:847	arg1	rhamnogalacturonan-I					902:921	rhamnogalacturonan-I	902:921	rhamnogalacturonan-I (RG-I)	902:928	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	37	theme	1,4-linked	838:847	arg1	residues					849:856	1,4-linked residues	838:856	1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan	838:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	37	theme	1,4-linked	838:847	arg1	acid					888:891	α-D-galactopyranosyluronic acid	861:891	α-D-galactopyranosyluronic acid (GalpA)	861:899	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	2	38	theme	sodium	326:331	arg1	solutions					343:351	aqueous sodium carbonate solutions	318:351	aqueous sodium carbonate solutions	318:351	The fractions extracted with aqueous sodium carbonate solutions had the highest yield.
36361966	5	39	from	sequence	1002:1009	arg1	backbone					1088:1095	the backbone	1084:1095	the backbone	1084:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	40	theme	L-rhamnopyranose	1048:1063	arg1	residues					1072:1079	1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues	1014:1079	residues	1072:1079	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	3	41	theme	principal	532:540	arg1	acid					496:499	galacturonic acid and arabinose residues	483:522	acid	496:499	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	41	theme	principal	532:540	arg1	residues					515:522	galacturonic acid and arabinose residues	483:522	residues	515:522	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	41	theme	principal	532:540	arg1	components					542:551	the principal components	528:551	the principal components of their carbohydrate chains	528:580	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	5	42	theme	Rhap	1066:1069	arg1	residues					1072:1079	1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues	1014:1079	residues	1072:1079	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	4	43	theme	activity	645:652	arg1	elucidation					700:710	elucidation	700:710	elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy	700:798	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	4	43	theme	activity	645:652	arg1	determination					616:628	the determination	612:628	the determination of antioxidant activity of the extracted polysaccharide fractions	612:694	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	3	44	theme	carbohydrate	562:573	arg1	chains					575:580	their carbohydrate chains	556:580	their carbohydrate chains	556:580	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	1	45	theme	ammonium	250:257	arg1	oxalate					259:265	ammonium oxalate	250:265	ammonium oxalate	250:265	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	5	46	theme	rhamnogalacturonan-I	902:921	arg1	arabinan					1102:1109	arabinan	1102:1109	arabinan	1102:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	46	theme	rhamnogalacturonan-I	902:921	arg1	rhamnogalacturonan-I					902:921	rhamnogalacturonan-I	902:921	rhamnogalacturonan-I (RG-I)	902:928	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	46	theme	rhamnogalacturonan-I	902:921	arg1	residues					849:856	1,4-linked residues	838:856	1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan	838:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	46	theme	rhamnogalacturonan-I	902:921	arg1	acid					888:891	α-D-galactopyranosyluronic acid	861:891	α-D-galactopyranosyluronic acid (GalpA)	861:899	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	47	link	1,4-linked	1014:1023	arg1	D-GalpA					1025:1031	1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues	1014:1079	D-GalpA	1025:1031	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	8	48	theme	DPPH	1536:1539	arg1	activity					1552:1559	the DPPH scavenging activity	1532:1559	the DPPH scavenging activity of polysaccharide fractions	1532:1587	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	6	49	theme	HMBC	1185:1188	arg1	spectra					1190:1196	HMBC spectra	1185:1196	HMBC spectra	1185:1196	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	5	50	from	residues	1072:1079	arg1	backbone					1088:1095	the backbone	1084:1095	the backbone	1084:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	1	51	theme	polysaccharides	186:200	arg1	w/w					178:180	w/w	178:180	w/w	178:180	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	51	theme	polysaccharides	186:200	arg1	polysaccharides					186:200	polysaccharides	186:200	polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate	186:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	51	theme	polysaccharides	186:200	arg1	%					175:175	~13%	172:175	~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate	172:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	6	52	theme	arabinofuranose	1293:1307	arg1	residues					1309:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	3,5-substituted and 1,5-linked arabinofuranose residues	1262:1316	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	4	53	theme	polysaccharide	671:684	arg1	fractions					686:694	the extracted polysaccharide fractions	657:694	the extracted polysaccharide fractions	657:694	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	6	54	theme	arabinan	1373:1380	arg1	structure					1382:1390	the arabinan structure	1369:1390	the arabinan structure	1369:1390	HMBC spectra showed that arabinan consisted of alternating regions formed by 3,5-substituted and 1,5-linked arabinofuranose residues, but there was no alternation of these residues in the arabinan structure.
36361966	5	55	theme	diglycosyl	948:957	arg1	unit					969:972	a diglycosyl repeating unit	946:972	a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	946:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	8	56	theme	polysaccharide	1564:1577	arg1	fractions					1579:1587	polysaccharide fractions	1564:1587	polysaccharide fractions	1564:1587	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	4	57	theme	nuclear	754:760	arg1	NMR					782:784	NMR	782:784	NMR	782:784	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	4	57	theme	nuclear	754:760	arg1	resonance					771:779	nuclear magnetic resonance	754:779	nuclear magnetic resonance (NMR) spectroscopy	754:798	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	1	58	theme	Salsola	133:139	arg1	passerine					141:149	the Salsola passerine	129:149	the Salsola passerine	129:149	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	4	59	theme	resonance	771:779	arg1	spectroscopy					787:798	nuclear magnetic resonance (NMR) spectroscopy	754:798	nuclear magnetic resonance (NMR) spectroscopy	754:798	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	5	60	theme	arabinan	1102:1109	arg1	arabinan					1102:1109	arabinan	1102:1109	arabinan	1102:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	60	theme	arabinan	1102:1109	arg1	rhamnogalacturonan-I					902:921	rhamnogalacturonan-I	902:921	rhamnogalacturonan-I (RG-I)	902:928	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	60	theme	arabinan	1102:1109	arg1	residues					849:856	1,4-linked residues	838:856	1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan	838:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	60	theme	arabinan	1102:1109	arg1	acid					888:891	α-D-galactopyranosyluronic acid	861:891	α-D-galactopyranosyluronic acid (GalpA)	861:899	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	4	61	theme	structure	719:727	arg1	elucidation					700:710	elucidation	700:710	elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy	700:798	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	4	61	theme	structure	719:727	arg1	determination					616:628	the determination	612:628	the determination of antioxidant activity of the extracted polysaccharide fractions	612:694	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	5	62	from	backbone	1088:1095	arg1	sequence					1002:1009	a strictly alternating sequence	979:1009	a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	979:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	63	theme	obtained	1159:1166	arg1	polysaccharides					1168:1182	the obtained polysaccharides	1155:1182	the obtained polysaccharides	1155:1182	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	4	64	theme	polysaccharides	732:746	arg1	structure					719:727	the structure	715:727	the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy	715:798	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	8	65	theme	phenolic	1624:1631	arg1	PCs					1644:1646	PCs	1644:1646	PCs	1644:1646	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	8	65	theme	phenolic	1624:1631	arg1	compounds					1633:1641	phenolic compounds	1624:1641	phenolic compounds (PCs)	1624:1647	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	5	66	theme	structural	1135:1144	arg1	units					1146:1150	the structural units	1131:1150	the structural units of the obtained polysaccharides	1131:1182	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	66	theme	structural	1135:1144	arg1	Homogalacturonan					801:816	Homogalacturonan	801:816	Homogalacturonan (HG)	801:821	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	67	theme	D-GalpA	1025:1031	arg1	sequence					1002:1009	a strictly alternating sequence	979:1009	a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone	979:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	7	68	theme	Polysaccharide	1393:1406	arg1	fractions					1408:1416	Polysaccharide fractions	1393:1416	Polysaccharide fractions	1393:1416	Polysaccharide fractions scavenged the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical at 0.2-1.8 mg/mL.
36361966	3	69	theme	similar	439:445	arg1	composition					462:472	similar monosaccharide composition	439:472	similar monosaccharide composition	439:472	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	0	70	theme	passerina	27:35	arg1	Extraction					38:47	Extraction	38:47	Extraction	38:47	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	70	theme	passerina	27:35	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.	0:102	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	70	theme	passerina	27:35	arg1	Activity					94:101	Antioxidant Activity	82:101	Antioxidant Activity	82:101	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	70	theme	passerina	27:35	arg1	Characterization					61:76	Structural Characterization	50:76	Structural Characterization	50:76	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	1	71	theme	sodium	271:276	arg1	carbonate					278:286	sodium carbonate	271:286	sodium carbonate	271:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	1	72	theme	above-ground	108:119	arg1	part					121:124	The above-ground part	104:124	The above-ground part of the Salsola passerine	104:149	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
36361966	3	73	theme	galacturonic	483:494	arg1	acid					496:499	galacturonic acid and arabinose residues	483:522	acid	496:499	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	73	theme	galacturonic	483:494	arg1	residues					515:522	galacturonic acid and arabinose residues	483:522	residues	515:522	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	3	73	theme	galacturonic	483:494	arg1	components					542:551	the principal components	528:551	the principal components of their carbohydrate chains	528:580	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	0	74	theme	Structural	50:59	arg1	Characterization					61:76	Structural Characterization	50:76	Structural Characterization	50:76	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	74	theme	Structural	50:59	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.	0:102	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	3	75	theme	fractions	408:416	arg1	polysaccharides					380:394	The polysaccharides	376:394	The polysaccharides of majority fractions	376:416	The polysaccharides of majority fractions are characterized by similar monosaccharide composition; namely, galacturonic acid and arabinose residues are the principal components of their carbohydrate chains.
36361966	2	76	theme	carbonate	333:341	arg1	solutions					343:351	aqueous sodium carbonate solutions	318:351	aqueous sodium carbonate solutions	318:351	The fractions extracted with aqueous sodium carbonate solutions had the highest yield.
36361966	0	77	dep	Polysaccharides	0:14	arg1	Extraction					38:47	Extraction	38:47	Extraction	38:47	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	77	dep	Polysaccharides	0:14	arg1	Characterization					61:76	Structural Characterization	50:76	Structural Characterization	50:76	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	77	dep	Polysaccharides	0:14	arg1	Activity					94:101	Antioxidant Activity	82:101	Antioxidant Activity	82:101	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	0	77	dep	Polysaccharides	0:14	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.	0:102	Polysaccharides of Salsola passerina: Extraction, Structural Characterization and Antioxidant Activity.
36361966	5	78	theme	1,2-linked	1037:1046	arg1	residues					1072:1079	1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues	1014:1079	residues	1072:1079	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	79	link	1,4-linked	838:847	arg1	arabinan					1102:1109	arabinan	1102:1109	arabinan	1102:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	79	link	1,4-linked	838:847	arg1	rhamnogalacturonan-I					902:921	rhamnogalacturonan-I	902:921	rhamnogalacturonan-I (RG-I)	902:928	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	79	link	1,4-linked	838:847	arg1	residues					849:856	1,4-linked residues	838:856	1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan	838:1109	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	5	79	link	1,4-linked	838:847	arg1	acid					888:891	α-D-galactopyranosyluronic acid	861:891	α-D-galactopyranosyluronic acid (GalpA)	861:899	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	4	80	theme	antioxidant	633:643	arg1	activity					645:652	antioxidant activity	633:652	antioxidant activity of the extracted polysaccharide fractions	633:694	The present study focused on the determination of antioxidant activity of the extracted polysaccharide fractions and elucidation of the structure of polysaccharides using nuclear magnetic resonance (NMR) spectroscopy.
36361966	8	81	theme	correlation	1499:1509	arg1	analysis					1511:1518	The correlation analysis	1495:1518	The correlation analysis	1495:1518	The correlation analysis showed that the DPPH scavenging activity of polysaccharide fractions was associated with the content of phenolic compounds (PCs).
36361966	2	82	theme	aqueous	318:324	arg1	solutions					343:351	aqueous sodium carbonate solutions	318:351	aqueous sodium carbonate solutions	318:351	The fractions extracted with aqueous sodium carbonate solutions had the highest yield.
36361966	2	83	theme	highest	361:367	arg1	yield					369:373	the highest yield	357:373	the highest yield	357:373	The fractions extracted with aqueous sodium carbonate solutions had the highest yield.
36361966	5	84	from	D-GalpA	1025:1031	arg1	backbone					1088:1095	the backbone	1084:1095	the backbone	1084:1095	Homogalacturonan (HG), consisting of 1,4-linked residues of α-D-galactopyranosyluronic acid (GalpA), rhamnogalacturonan-I (RG-I), which contains a diglycosyl repeating unit with a strictly alternating sequence of 1,4-linked D-GalpA and 1,2-linked L-rhamnopyranose (Rhap) residues in the backbone, and arabinan, were identified as the structural units of the obtained polysaccharides.
36361966	1	85	theme	aqueous	229:235	arg1	solutions					237:245	aqueous solutions	229:245	aqueous solutions of ammonium oxalate and sodium carbonate	229:286	The above-ground part of the Salsola passerine was found to contain ~13% (w/w) of polysaccharides extractable with water and aqueous solutions of ammonium oxalate and sodium carbonate.
37119895	0	0	theme	gallica	84:90	arg1	bodies					63:68	fruiting bodies	54:68	fruiting bodies of Armillaria gallica	54:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	4	1	theme	Methylation	512:522	arg1	analysis					524:531	Methylation analysis	512:531	Methylation analysis	512:531	Methylation analysis is used to analyze the glycosidic bond composition of AGP.
37119895	5	2	theme	anti-fatigue	650:661	arg1	effect					663:668	the anti-fatigue effect	646:668	the anti-fatigue effect of AGP	646:675	The mouse model of acute fatigue was used to evaluate the anti-fatigue effect of AGP.
37119895	10	3	theme	intestinal	1406:1415	arg1	microbiota					1417:1426	intestinal microbiota	1406:1426	intestinal microbiota	1406:1426	AGP exerted an anti-fatigue effect through modulation of oxidative stress, which is related to intestinal microbiota.
37119895	10	4	theme	stress	1378:1383	arg1	modulation					1354:1363	modulation	1354:1363	modulation	1354:1363	AGP exerted an anti-fatigue effect through modulation of oxidative stress, which is related to intestinal microbiota.
37119895	0	5	theme	Armillaria	73:82	arg1	gallica					84:90	Armillaria gallica	73:90	Armillaria gallica	73:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	9	6	theme	erythroid	1263:1271	arg1	factor					1283:1288	the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2	1215:1290	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	8	7	theme	intestinal	1028:1037	arg1	microorganisms					1039:1052	some intestinal microorganisms	1023:1052	some intestinal microorganisms	1023:1052	AGP affected the composition of intestinal microbiota, the changes of some intestinal microorganisms are correlated with fatigue and oxidative stress indicators.
37119895	8	8	theme	intestinal	985:994	arg1	microbiota					996:1005	intestinal microbiota	985:1005	intestinal microbiota	985:1005	AGP affected the composition of intestinal microbiota, the changes of some intestinal microorganisms are correlated with fatigue and oxidative stress indicators.
37119895	9	9	theme	kinase/nuclear	1241:1254	arg1	factor					1283:1288	the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2	1215:1290	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	7	10	theme	dehydrogenase	880:892	arg1	levels					801:806	the levels	797:806	the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice	797:950	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	8	11	theme	microorganisms	1039:1052	arg1	changes					1012:1018	the changes	1008:1018	the changes of some intestinal microorganisms	1008:1052	AGP affected the composition of intestinal microbiota, the changes of some intestinal microorganisms are correlated with fatigue and oxidative stress indicators.
37119895	5	12	theme	acute	611:615	arg1	fatigue					617:623	acute fatigue	611:623	acute fatigue	611:623	The mouse model of acute fatigue was used to evaluate the anti-fatigue effect of AGP.
37119895	2	13	theme	activities	287:296	arg1	variety					260:266	a variety	258:266	a variety of pharmacological activities	258:296	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	2	13	theme	activities	287:296	arg1	activities					287:296	pharmacological activities	271:296	pharmacological activities	271:296	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	7	14	theme	acute	933:937	arg1	mice					947:950	acute fatigue mice	933:950	acute fatigue mice	933:950	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	2	15	contain	have	253:256	arg2	variety					260:266	a variety	258:266	a variety of pharmacological activities	258:296	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	2	15	contain	have	253:256	arg1	Polysaccharides					182:196	Polysaccharides	182:196	Polysaccharides	182:196	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	2	15	contain	have	253:256	arg2	activities					287:296	pharmacological activities	271:296	pharmacological activities	271:296	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	5	16	theme	AGP	673:675	arg1	effect					663:668	the anti-fatigue effect	646:668	the anti-fatigue effect of AGP	646:675	The mouse model of acute fatigue was used to evaluate the anti-fatigue effect of AGP.
37119895	5	17	theme	fatigue	617:623	arg1	model					602:606	The mouse model	592:606	The mouse model of acute fatigue	592:623	The mouse model of acute fatigue was used to evaluate the anti-fatigue effect of AGP.
37119895	2	18	theme	pharmacological	271:285	arg1	activities					287:296	pharmacological activities	271:296	pharmacological activities	271:296	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	10	19	theme	anti-fatigue	1326:1337	arg1	effect					1339:1344	an anti-fatigue effect	1323:1344	an anti-fatigue effect	1323:1344	AGP exerted an anti-fatigue effect through modulation of oxidative stress, which is related to intestinal microbiota.
37119895	6	20	from	endurance	710:718	arg1	mice					723:726	mice	723:726	mice	723:726	AGP-treatment improved exercise endurance in mice and reduced fatigue symptoms caused by acute exercise.
37119895	8	21	theme	microbiota	996:1005	arg1	composition					970:980	the composition	966:980	the composition of intestinal microbiota	966:1005	AGP affected the composition of intestinal microbiota, the changes of some intestinal microorganisms are correlated with fatigue and oxidative stress indicators.
37119895	7	22	theme	lactate	872:878	arg1	dehydrogenase					880:892	lactate dehydrogenase	872:892	lactate dehydrogenase	872:892	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	1	23	theme	energy	163:168	arg1	metabolism					170:179	energy metabolism	163:179	energy metabolism	163:179	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	3	24	theme	structural	399:408	arg1	characterization					410:425	structural characterization	399:425	structural characterization	399:425	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	7	25	theme	mice	947:950	arg1	triphosphate					821:832	adenosine triphosphate	811:832	adenosine triphosphate	811:832	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	25	theme	mice	947:950	arg1	glycogen					902:909	muscle glycogen	895:909	muscle glycogen	895:909	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	25	theme	mice	947:950	arg1	glycogen					921:928	liver glycogen	915:928	liver glycogen	915:928	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	26	theme	urea	854:857	arg1	nitrogen					859:866	blood urea nitrogen	848:866	blood urea nitrogen	848:866	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	5	27	used	used	629:632	arg2	model					602:606	The mouse model	592:606	The mouse model of acute fatigue	592:623	The mouse model of acute fatigue was used to evaluate the anti-fatigue effect of AGP.
37119895	8	28	theme	oxidative	1086:1094	arg1	stress					1096:1101	oxidative stress	1086:1101	oxidative stress	1086:1101	AGP affected the composition of intestinal microbiota, the changes of some intestinal microorganisms are correlated with fatigue and oxidative stress indicators.
37119895	9	29	theme	factor	1256:1261	arg1	factor					1283:1288	the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2	1215:1290	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	7	30	theme	nitrogen	859:866	arg1	levels					801:806	the levels	797:806	the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice	797:950	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	4	31	used	used	536:539	arg2	analysis					524:531	Methylation analysis	512:531	Methylation analysis	512:531	Methylation analysis is used to analyze the glycosidic bond composition of AGP.
37119895	7	32	theme	triphosphate	821:832	arg1	levels					801:806	the levels	797:806	the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice	797:950	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	5	33	theme	mouse	596:600	arg1	model					602:606	The mouse model	592:606	The mouse model of acute fatigue	592:623	The mouse model of acute fatigue was used to evaluate the anti-fatigue effect of AGP.
37119895	6	34	theme	exercise	701:708	arg1	endurance					710:718	exercise endurance	701:718	exercise endurance in mice	701:726	AGP-treatment improved exercise endurance in mice and reduced fatigue symptoms caused by acute exercise.
37119895	0	35	theme	activity	22:29	arg1	Study					0:4	Study	0:4	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.	0:91	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	4	36	theme	bond	567:570	arg1	composition					572:582	the glycosidic bond composition	552:582	the glycosidic bond composition of AGP	552:589	Methylation analysis is used to analyze the glycosidic bond composition of AGP.
37119895	7	37	theme	fatigue	939:945	arg1	mice					947:950	acute fatigue mice	933:950	acute fatigue mice	933:950	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	10	38	theme	oxidative	1368:1376	arg1	stress					1378:1383	oxidative stress	1368:1383	oxidative stress	1368:1383	AGP exerted an anti-fatigue effect through modulation of oxidative stress, which is related to intestinal microbiota.
37119895	7	39	theme	blood	848:852	arg1	nitrogen					859:866	blood urea nitrogen	848:866	blood urea nitrogen	848:866	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	3	40	theme	molecular	463:471	arg1	weight					473:478	molecular weight	463:478	molecular weight	463:478	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	0	41	theme	anti-fatigue	9:20	arg1	activity					22:29	anti-fatigue activity	9:29	anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica	9:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	4	42	theme	AGP	587:589	arg1	composition					572:582	the glycosidic bond composition	552:582	the glycosidic bond composition of AGP	552:589	Methylation analysis is used to analyze the glycosidic bond composition of AGP.
37119895	9	43	theme	factor	1283:1288	arg1	pathway					1302:1308	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	9	44	theme	oxidative	1138:1146	arg1	stress					1148:1153	oxidative stress	1138:1153	oxidative stress levels	1138:1160	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	7	45	theme	lactic	835:840	arg1	acid					842:845	lactic acid	835:845	lactic acid	835:845	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	0	46	theme	polysaccharide	34:47	arg1	activity					22:29	anti-fatigue activity	9:29	anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica	9:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	7	47	theme	adenosine	811:819	arg1	glycogen					921:928	liver glycogen	915:928	liver glycogen	915:928	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	47	theme	adenosine	811:819	arg1	glycogen					902:909	muscle glycogen	895:909	muscle glycogen	895:909	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	47	theme	adenosine	811:819	arg1	triphosphate					821:832	adenosine triphosphate	811:832	adenosine triphosphate	811:832	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	48	theme	acid	842:845	arg1	levels					801:806	the levels	797:806	the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice	797:950	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	3	49	theme	homogeneity	450:460	arg1	analysis					438:445	analysis	438:445	analysis of homogeneity	438:460	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	3	49	theme	homogeneity	450:460	arg1	composition					499:509	monosaccharide composition	484:509	monosaccharide composition	484:509	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	3	49	theme	homogeneity	450:460	arg1	weight					473:478	molecular weight	463:478	molecular weight	463:478	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	9	50	theme	regulated	1205:1213	arg1	pathway					1302:1308	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	8	51	dep	fatigue	1074:1080	arg1	indicators					1103:1112	indicators	1103:1112	indicators	1103:1112	AGP affected the composition of intestinal microbiota, the changes of some intestinal microorganisms are correlated with fatigue and oxidative stress indicators.
37119895	9	52	theme	signaling	1292:1300	arg1	pathway					1302:1308	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	3	53	from	gallica	358:364	arg1	polysaccharide					327:340	A 23.007 kDa polysaccharide	314:340	A 23.007 kDa polysaccharide from Armillaria gallica (AGP)	314:370	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	9	54	theme	stress	1148:1153	arg1	levels					1155:1160	oxidative stress levels	1138:1160	oxidative stress levels	1138:1160	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	0	55	theme	fruiting	54:61	arg1	bodies					63:68	fruiting bodies	54:68	fruiting bodies of Armillaria gallica	54:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	9	56	theme	AMP-dependent	1219:1231	arg1	factor					1283:1288	the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2	1215:1290	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	0	57	from	bodies	63:68	arg1	polysaccharide					34:47	polysaccharide	34:47	polysaccharide from fruiting bodies of Armillaria gallica	34:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	0	57	from	bodies	63:68	arg1	activity					22:29	anti-fatigue activity	9:29	anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica	9:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	1	58	theme	common	106:111	arg1	response					127:134	a common physiological response	104:134	a common physiological response that is closely related to energy metabolism	104:179	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	1	58	theme	common	106:111	arg1	Fatigue					93:99	Fatigue	93:99	Fatigue	93:99	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	1	58	theme	common	106:111	arg1	related					152:158	related	152:158	related	152:158	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	4	59	theme	glycosidic	556:565	arg1	composition					572:582	the glycosidic bond composition	552:582	the glycosidic bond composition of AGP	552:589	Methylation analysis is used to analyze the glycosidic bond composition of AGP.
37119895	2	60	theme	dietary	212:218	arg1	supplements					220:230	excellent dietary supplements	202:230	excellent dietary supplements	202:230	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	6	61	theme	acute	767:771	arg1	exercise					773:780	acute exercise	767:780	acute exercise	767:780	AGP-treatment improved exercise endurance in mice and reduced fatigue symptoms caused by acute exercise.
37119895	1	62	theme	physiological	113:125	arg1	response					127:134	a common physiological response	104:134	a common physiological response that is closely related to energy metabolism	104:179	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	1	62	theme	physiological	113:125	arg1	Fatigue					93:99	Fatigue	93:99	Fatigue	93:99	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	1	62	theme	physiological	113:125	arg1	related					152:158	related	152:158	related	152:158	Fatigue is a common physiological response that is closely related to energy metabolism.
37119895	9	63	theme	2-related	1273:1281	arg1	factor					1283:1288	the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2	1215:1290	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	2	64	theme	excellent	202:210	arg1	supplements					220:230	excellent dietary supplements	202:230	excellent dietary supplements	202:230	Polysaccharides, as excellent dietary supplements, have been proven to have a variety of pharmacological activities.
37119895	9	65	theme	increased	1163:1171	arg1	activity					1192:1199	increased antioxidant enzyme activity	1163:1199	increased antioxidant enzyme activity	1163:1199	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	9	66	theme	antioxidant	1173:1183	arg1	activity					1192:1199	increased antioxidant enzyme activity	1163:1199	increased antioxidant enzyme activity	1163:1199	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	3	67	theme	monosaccharide	484:497	arg1	composition					499:509	monosaccharide composition	484:509	monosaccharide composition	484:509	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	9	68	theme	protein	1233:1239	arg1	factor					1283:1288	the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2	1215:1290	regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway	1205:1308	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	3	69	theme	23.007 kDa	316:325	arg1	polysaccharide					327:340	A 23.007 kDa polysaccharide	314:340	A 23.007 kDa polysaccharide from Armillaria gallica (AGP)	314:370	In this study, A 23.007 kDa polysaccharide from Armillaria gallica (AGP) was purified and performed structural characterization, including analysis of homogeneity, molecular weight and monosaccharide composition.
37119895	9	70	theme	enzyme	1185:1190	arg1	activity					1192:1199	increased antioxidant enzyme activity	1163:1199	increased antioxidant enzyme activity	1163:1199	Meanwhile, AGP reduced oxidative stress levels, increased antioxidant enzyme activity and regulated the AMP-dependent protein kinase/nuclear factor erythroid 2-related factor 2 signaling pathway.
37119895	7	71	theme	liver	915:919	arg1	triphosphate					821:832	adenosine triphosphate	811:832	adenosine triphosphate	811:832	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	71	theme	liver	915:919	arg1	glycogen					921:928	liver glycogen	915:928	liver glycogen	915:928	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	0	72	from	activity	22:29	arg1	bodies					63:68	fruiting bodies	54:68	fruiting bodies of Armillaria gallica	54:90	Study of anti-fatigue activity of polysaccharide from fruiting bodies of Armillaria gallica.
37119895	6	73	theme	fatigue	740:746	arg1	symptoms					748:755	fatigue symptoms	740:755	fatigue symptoms caused by acute exercise	740:780	AGP-treatment improved exercise endurance in mice and reduced fatigue symptoms caused by acute exercise.
37119895	7	74	theme	muscle	895:900	arg1	glycogen					902:909	muscle glycogen	895:909	muscle glycogen	895:909	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
37119895	7	74	theme	muscle	895:900	arg1	triphosphate					821:832	adenosine triphosphate	811:832	adenosine triphosphate	811:832	AGP regulated the levels of adenosine triphosphate, lactic acid, blood urea nitrogen and lactate dehydrogenase, muscle glycogen and liver glycogen of acute fatigue mice.
35651042	0	0	theme	related	87:93	arg1	effects					106:112	related modulation effects	87:112	related modulation effects on gut microbiota	87:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	5	1	theme	reducing	809:816	arg1	content					824:830	reducing sugar content	809:830	reducing sugar content	809:830	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	4	2	theme	molecular	511:519	arg1	weight					521:526	molecular weight	511:526	molecular weight	511:526	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	5	3	theme	in	946:947	arg1	fermentation					955:966	the in vitro fermentation	942:966	the in vitro fermentation for 48 h	942:975	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	theme	TFP	794:796	arg1	monosaccharide					888:901	free monosaccharide	883:901	free monosaccharide released	883:910	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	theme	TFP	794:796	arg1	content					824:830	reducing sugar content	809:830	reducing sugar content	809:830	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	theme	TFP	794:796	arg1	weight					843:848	molecular weight	833:848	molecular weight	833:848	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	theme	TFP	794:796	arg1	monosaccharide					863:876	constituent monosaccharide	851:876	constituent monosaccharide	851:876	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	4	theme	TFP	794:796	arg1	characteristics					775:789	the physicochemical characteristics	755:789	the physicochemical characteristics	755:789	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	5	theme	sugar	818:822	arg1	content					824:830	reducing sugar content	809:830	reducing sugar content	809:830	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	4	6	theme	reducing	465:472	arg1	content					480:486	the reducing sugar content	461:486	the reducing sugar content	461:486	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	7	theme	digestion	724:732	arg1	conditions					734:743	different simulated digestion conditions	704:743	different simulated digestion conditions	704:743	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	7	8	theme	n-valeric	1347:1355	arg1	acids					1357:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	3	9	theme	fuciformis	388:397	arg1	TFP					416:418	TFP	416:418	TFP	416:418	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	3	9	theme	fuciformis	388:397	arg1	polysaccharides					399:413	T. fuciformis polysaccharides	385:413	T. fuciformis polysaccharides (TFP)	385:419	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	8	10	theme	simulated	1457:1465	arg1	conditions					1477:1486	the simulated digestion conditions	1453:1486	the simulated digestion conditions	1453:1486	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	7	11	theme	short-chain	1278:1288	arg1	acids					1296:1300	short-chain fatty acids	1278:1300	short-chain fatty acids	1278:1300	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	7	11	theme	short-chain	1278:1288	arg1	acids					1357:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	8	12	theme	intestinal	1514:1523	arg1	microbiota					1525:1534	intestinal microbiota	1514:1534	intestinal microbiota in human feces	1514:1549	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	0	13	theme	modulation	95:104	arg1	effects					106:112	related modulation effects	87:112	related modulation effects on gut microbiota	87:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	6	14	theme	relative	1144:1151	arg1	abundances					1153:1162	the relative abundances	1140:1162	the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium	1140:1223	Notably, TFP could obviously modulate the microbial composition via promoting the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium.
35651042	7	15	theme	n-butyric	1332:1340	arg1	acids					1357:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	0	16	theme	gut	117:119	arg1	microbiota					121:130	gut microbiota	117:130	gut microbiota	117:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	1	17	theme	medicinal	170:178	arg1	mushroom					180:187	medicinal mushroom	170:187	medicinal mushroom	170:187	Tremella fuciformis is an edible and medicinal mushroom.
35651042	2	18	from	fuciformis	214:223	arg1	Polysaccharides					190:204	Polysaccharides	190:204	Polysaccharides from T. fuciformis	190:223	Polysaccharides from T. fuciformis have received increasing attention due to their diversely pharmacological activities.
35651042	5	19	theme	intestinal	1024:1033	arg1	microbiota					1035:1044	intestinal microbiota	1024:1044	intestinal microbiota in human feces	1024:1059	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	20	from	microbiota	1035:1044	arg1	feces					1055:1059	human feces	1049:1059	human feces	1049:1059	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	0	21	from	properties	28:37	arg1	microbiota					121:130	gut microbiota	117:130	gut microbiota	117:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	0	21	from	properties	28:37	arg1	fuciformis					72:81	Tremella fuciformis	63:81	Tremella fuciformis	63:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	7	22	theme	fatty	1290:1294	arg1	acids					1296:1300	short-chain fatty acids	1278:1300	short-chain fatty acids	1278:1300	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	7	22	theme	fatty	1290:1294	arg1	acids					1357:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	7	23	theme	acids	1296:1300	arg1	production					1264:1273	the production	1260:1273	the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids	1260:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	1	24	dep	edible	159:164	arg1	an					156:157	an	156:157	an	156:157	Tremella fuciformis is an edible and medicinal mushroom.
35651042	8	25	contain	possess	1562:1568	arg2	potential					1574:1582	the potential to improve intestinal health	1570:1611	the potential to improve intestinal health	1570:1611	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	8	25	contain	possess	1562:1568	arg1	TFP					1432:1434	TFP	1432:1434	TFP	1432:1434	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	0	26	theme	In	0:1	arg1	properties					28:37	In vitro fecal fermentation properties	0:37	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis	0:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	5	27	dep	in	946:947	arg1	vitro					949:953	vitro	949:953	vitro	949:953	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	28	theme	constituent	851:861	arg1	monosaccharide					863:876	constituent monosaccharide	851:876	constituent monosaccharide	851:876	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	29	theme	physicochemical	759:773	arg1	monosaccharide					888:901	free monosaccharide	883:901	free monosaccharide released	883:910	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	29	theme	physicochemical	759:773	arg1	content					824:830	reducing sugar content	809:830	reducing sugar content	809:830	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	29	theme	physicochemical	759:773	arg1	weight					843:848	molecular weight	833:848	molecular weight	833:848	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	29	theme	physicochemical	759:773	arg1	monosaccharide					863:876	constituent monosaccharide	851:876	constituent monosaccharide	851:876	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	5	29	theme	physicochemical	759:773	arg1	characteristics					775:789	the physicochemical characteristics	755:789	the physicochemical characteristics	755:789	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	6	30	theme	microbial	1104:1112	arg1	composition					1114:1124	the microbial composition	1100:1124	the microbial composition	1100:1124	Notably, TFP could obviously modulate the microbial composition via promoting the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium.
35651042	0	31	theme	fermentation	15:26	arg1	properties					28:37	In vitro fecal fermentation properties	0:37	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis	0:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	4	32	theme	FT-IR	583:587	arg1	spectrum					589:596	FT-IR spectrum	583:596	FT-IR spectrum	583:596	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	3	33	dep	behavior	340:347	arg1	the					326:328	the	326:328	the	326:328	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	6	34	theme	Lachnoclostridium	1207:1223	arg1	abundances					1153:1162	the relative abundances	1140:1162	the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium	1140:1223	Notably, TFP could obviously modulate the microbial composition via promoting the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium.
35651042	0	35	theme	fecal	9:13	arg1	properties					28:37	In vitro fecal fermentation properties	0:37	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis	0:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	4	36	theme	TFP	601:603	arg1	property					541:548	rheological property	529:548	rheological property	529:548	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	36	theme	TFP	601:603	arg1	spectrum					589:596	FT-IR spectrum	583:596	FT-IR spectrum	583:596	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	36	theme	TFP	601:603	arg1	composition					498:508	chemical composition	489:508	chemical composition	489:508	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	36	theme	TFP	601:603	arg1	weight					521:526	molecular weight	511:526	molecular weight	511:526	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	36	theme	TFP	601:603	arg1	monosaccharide					563:576	constituent monosaccharide	551:576	constituent monosaccharide	551:576	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	36	theme	TFP	601:603	arg1	content					480:486	the reducing sugar content	461:486	the reducing sugar content	461:486	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	37	dep	in	632:633	arg1	vitro					635:639	vitro	635:639	vitro	635:639	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	7	38	theme	acetic	1313:1318	arg1	acids					1357:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	5	39	theme	free	883:886	arg1	monosaccharide					888:901	free monosaccharide	883:901	free monosaccharide released	883:910	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	6	40	theme	Bacteroides	1190:1200	arg1	abundances					1153:1162	the relative abundances	1140:1162	the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium	1140:1223	Notably, TFP could obviously modulate the microbial composition via promoting the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium.
35651042	4	41	theme	sugar	474:478	arg1	content					480:486	the reducing sugar content	461:486	the reducing sugar content	461:486	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	2	42	theme	due	260:262	arg1	attention					250:258	increasing attention	239:258	increasing attention due to their diversely pharmacological activities	239:308	Polysaccharides from T. fuciformis have received increasing attention due to their diversely pharmacological activities.
35651042	7	43	theme	in	1374:1375	arg1	fermentation					1383:1394	the in vitro fermentation	1370:1394	the in vitro fermentation for 48 h	1370:1403	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	5	44	used	utilized	1012:1019	arg2	it					994:995	it	994:995	it	994:995	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	0	45	from	fuciformis	72:81	arg1	effects					106:112	related modulation effects	87:112	related modulation effects on gut microbiota	87:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	0	45	from	fuciformis	72:81	arg1	polysaccharides					42:56	polysaccharides	42:56	polysaccharides from Tremella fuciformis	42:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	0	45	from	fuciformis	72:81	arg1	properties					28:37	In vitro fecal fermentation properties	0:37	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis	0:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	7	46	dep	in	1374:1375	arg1	vitro					1377:1381	vitro	1377:1381	vitro	1377:1381	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	3	47	theme	T.	385:386	arg1	TFP					416:418	TFP	416:418	TFP	416:418	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	3	47	theme	T.	385:386	arg1	polysaccharides					399:413	T. fuciformis polysaccharides	385:413	T. fuciformis polysaccharides (TFP)	385:419	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	5	48	theme	molecular	833:841	arg1	weight					843:848	molecular weight	833:848	molecular weight	833:848	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	4	49	theme	constituent	551:561	arg1	monosaccharide					563:576	constituent monosaccharide	551:576	constituent monosaccharide	551:576	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	8	50	used	utilized	1502:1509	arg2	TFP					1432:1434	TFP	1432:1434	TFP	1432:1434	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	2	51	theme	increasing	239:248	arg1	attention					250:258	increasing attention	239:258	increasing attention due to their diversely pharmacological activities	239:308	Polysaccharides from T. fuciformis have received increasing attention due to their diversely pharmacological activities.
35651042	0	52	theme	polysaccharides	42:56	arg1	effects					106:112	related modulation effects	87:112	related modulation effects on gut microbiota	87:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	0	52	theme	polysaccharides	42:56	arg1	properties					28:37	In vitro fecal fermentation properties	0:37	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis	0:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	3	53	theme	digestive	330:338	arg1	behavior					340:347	digestive behavior	330:347	digestive behavior	330:347	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	8	54	theme	intestinal	1595:1604	arg1	health					1606:1611	intestinal health	1595:1611	intestinal health	1595:1611	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	4	55	theme	chemical	489:496	arg1	composition					498:508	chemical composition	489:508	chemical composition	489:508	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	7	56	theme	propionic	1321:1329	arg1	acids					1357:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	acetic, propionic, n-butyric, and n-valeric acids	1313:1361	Moreover, TFP could also increase the production of short-chain fatty acids, including acetic, propionic, n-butyric, and n-valeric acids, after the in vitro fermentation for 48 h.
35651042	8	57	theme	digestion	1467:1475	arg1	conditions					1477:1486	the simulated digestion conditions	1453:1486	the simulated digestion conditions	1453:1486	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	2	58	theme	pharmacological	283:297	arg1	activities					299:308	their diversely pharmacological activities	267:308	their diversely pharmacological activities	267:308	Polysaccharides from T. fuciformis have received increasing attention due to their diversely pharmacological activities.
35651042	1	59	theme	Tremella	133:140	arg1	fuciformis					142:151	Tremella fuciformis	133:151	Tremella fuciformis	133:151	Tremella fuciformis is an edible and medicinal mushroom.
35651042	4	60	theme	in	632:633	arg1	digestion					651:659	the in vitro simulated digestion	628:659	the in vitro simulated digestion	628:659	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	0	61	from	effects	106:112	arg1	microbiota					121:130	gut microbiota	117:130	gut microbiota	117:130	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	0	61	from	effects	106:112	arg1	fuciformis					72:81	Tremella fuciformis	63:81	Tremella fuciformis	63:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	2	62	theme	diversely	273:281	arg1	activities					299:308	their diversely pharmacological activities	267:308	their diversely pharmacological activities	267:308	Polysaccharides from T. fuciformis have received increasing attention due to their diversely pharmacological activities.
35651042	8	63	theme	human	1539:1543	arg1	feces					1545:1549	human feces	1539:1549	human feces	1539:1549	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	6	64	theme	Phascolarctobacterium	1167:1187	arg1	abundances					1153:1162	the relative abundances	1140:1162	the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium	1140:1223	Notably, TFP could obviously modulate the microbial composition via promoting the relative abundances of Phascolarctobacterium, Bacteroides, and Lachnoclostridium.
35651042	8	65	from	microbiota	1525:1534	arg1	feces					1545:1549	human feces	1539:1549	human feces	1539:1549	These results showed that TFP was stable under the simulated digestion conditions, but could be utilized by intestinal microbiota in human feces, and might possess the potential to improve intestinal health.
35651042	3	66	theme	fermentation	353:364	arg1	characteristics					366:380	fermentation characteristics	353:380	fermentation characteristics	353:380	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	5	67	theme	human	1049:1053	arg1	feces					1055:1059	human feces	1049:1059	human feces	1049:1059	However, the physicochemical characteristics of TFP, including reducing sugar content, molecular weight, constituent monosaccharide, and free monosaccharide released, were obviously altered after the in vitro fermentation for 48 h, indicating that it was remarkably utilized by intestinal microbiota in human feces.
35651042	4	68	theme	simulated	714:722	arg1	conditions					734:743	different simulated digestion conditions	704:743	different simulated digestion conditions	704:743	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	4	69	theme	simulated	641:649	arg1	digestion					651:659	the in vitro simulated digestion	628:659	the in vitro simulated digestion	628:659	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	0	70	theme	Tremella	63:70	arg1	fuciformis					72:81	Tremella fuciformis	63:81	Tremella fuciformis	63:81	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	4	71	theme	rheological	529:539	arg1	property					541:548	rheological property	529:548	rheological property	529:548	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	0	72	dep	In	0:1	arg1	vitro					3:7	vitro	3:7	vitro	3:7	In vitro fecal fermentation properties of polysaccharides from Tremella fuciformis and related modulation effects on gut microbiota.
35651042	4	73	theme	different	704:712	arg1	conditions					734:743	different simulated digestion conditions	704:743	different simulated digestion conditions	704:743	The results revealed that the reducing sugar content, chemical composition, molecular weight, rheological property, constituent monosaccharide, and FT-IR spectrum of TFP were not altered after the in vitro simulated digestion, indicating that it was indigestible under different simulated digestion conditions.
35651042	3	74	theme	polysaccharides	399:413	arg1	behavior					340:347	digestive behavior	330:347	digestive behavior	330:347	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
35651042	3	74	theme	polysaccharides	399:413	arg1	characteristics					366:380	fermentation characteristics	353:380	fermentation characteristics	353:380	In this study, the digestive behavior and fermentation characteristics of T. fuciformis polysaccharides (TFP) were studied.
36603225	4	0	theme	1:2	896:898	arg1	ratio					887:891	a carboxymethyl chitosan/sodium alginate ratio	846:891	a carboxymethyl chitosan/sodium alginate ratio of 1:2	846:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	0	1	with	alginate	90:97	arg1	ability					108:114	the ability to release simvastatin for chronic wound healing	104:163	the ability to release simvastatin for chronic wound healing	104:163	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	1	2	theme	recent	254:259	arg1	attention					261:269	recent attention	254:269	recent attention	254:269	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	7	3	theme	high	1441:1444	arg1	biocompatibility					1446:1461	high biocompatibility	1441:1461	Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility	1378:1461	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	3	4	theme	growth	747:752	arg1	VEGF					762:765	VEGF	762:765	VEGF	762:765	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	4	theme	growth	747:752	arg1	factor					754:759	vascular endothelial growth factor	726:759	vascular endothelial growth factor (VEGF)	726:766	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	6	5	theme	size	1256:1259	arg1	distribution					1261:1272	uniform particle size distribution	1239:1272	uniform particle size distribution	1239:1272	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	7	6	theme	fibroblast	1477:1486	arg1	cells					1488:1492	L929 mouse fibroblast cells	1466:1492	L929 mouse fibroblast cells	1466:1492	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	4	7	theme	chitosan/sodium	862:876	arg1	ratio					887:891	a carboxymethyl chitosan/sodium alginate ratio	846:891	a carboxymethyl chitosan/sodium alginate ratio of 1:2	846:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	6	8	theme	nanostructured	1144:1157	arg1	carrier					1165:1171	The nanostructured lipid carrier	1140:1171	The nanostructured lipid carrier with optimum composition and properties	1140:1211	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	9	9	dep	occurred	1607:1614	arg1	%					1619:1619	80%	1617:1619	80%	1617:1619	The highest drug release occurred (80%) within 14 days.
36603225	3	10	theme	vascular	726:733	arg1	VEGF					762:765	VEGF	762:765	VEGF	762:765	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	10	theme	vascular	726:733	arg1	factor					754:759	vascular endothelial growth factor	726:759	vascular endothelial growth factor (VEGF)	726:766	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	6	11	theme	uniform	1239:1245	arg1	distribution					1261:1272	uniform particle size distribution	1239:1272	uniform particle size distribution	1239:1272	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	7	12	theme	L929	1466:1469	arg1	cells					1488:1492	L929 mouse fibroblast cells	1466:1492	L929 mouse fibroblast cells	1466:1492	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	0	13	theme	wound	151:155	arg1	healing					157:163	chronic wound healing	143:163	chronic wound healing	143:163	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	10	14	theme	chronic	1759:1765	arg1	wounds					1767:1772	various chronic wounds	1751:1772	various chronic wounds in skin tissues	1751:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	7	15	theme	coli	1390:1393	arg1	bacteria					1421:1428	Escherichia coli and Staphylococcus aureus bacteria	1378:1428	Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility	1378:1461	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	4	16	theme	pore	915:918	arg1	size					920:923	an average pore size	904:923	an average pore size of about 98.44 ± 26.9 μm	904:948	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	17	dep	%	972:972	arg1	±					965:965	±	965:965	±	965:965	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	7	18	theme	antibacterial	1347:1359	arg1	activity					1361:1368	excellent antibacterial activity	1337:1368	excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells	1337:1492	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	2	19	theme	lipid	521:525	arg1	carrier					527:533	a nanostructured lipid carrier	504:533	a nanostructured lipid carrier in which simvastatin has been encapsulated	504:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	6	20	theme	optimum	1178:1184	arg1	composition					1186:1196	optimum composition	1178:1196	optimum composition	1178:1196	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	4	21	with	composite	831:839	arg1	ratio					887:891	a carboxymethyl chitosan/sodium alginate ratio	846:891	a carboxymethyl chitosan/sodium alginate ratio of 1:2	846:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	1	22	theme	dressings	323:331	arg1	development					295:305	the development	291:305	the development of modern wound dressings based on synthetic and bioactive polymers	291:373	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	4	23	contain	had	900:902	arg1	composite					831:839	the hydrogel composite	818:839	the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2	818:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	23	contain	had	900:902	arg2	size					920:923	an average pore size	904:923	an average pore size of about 98.44 ± 26.9 μm	904:948	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	0	24	theme	chitosan/sodium	74:88	arg1	alginate					90:97	carboxymethyl chitosan/sodium alginate	60:97	carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing	60:163	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	10	25	from	wounds	1767:1772	arg1	tissues					1782:1788	skin tissues	1777:1788	skin tissues	1777:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	8	26	theme	loaded	1514:1519	arg1	drug					1533:1536	the loaded simvastatin drug	1510:1536	the loaded simvastatin drug	1510:1536	It can release the loaded simvastatin drug slowly and over a prolonged period of time.
36603225	4	27	theme	various	775:781	arg1	dressing					808:815	dressing	808:815	dressing	808:815	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	27	theme	various	775:781	arg1	composites					794:803	various fabricated composites	775:803	various fabricated composites of dressing	775:815	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	28	theme	707	961:963	arg1	±					965:965	±	965:965	±	965:965	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	5	29	theme	appropriate	1062:1072	arg1	properties					1074:1083	appropriate properties	1062:1083	appropriate properties	1062:1083	per day water vapor transfer rate (WVTR), demonstrating appropriate properties for absorbing exudates and maintaining wound moisture.
36603225	4	30	theme	31.9	967:970	arg1	±					965:965	±	965:965	±	965:965	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	7	31	theme	prepared	1295:1302	arg1	hydrogel					1318:1325	The prepared nanocomposite hydrogel	1291:1325	The prepared nanocomposite hydrogel	1291:1325	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	6	32	contain	had	1213:1215	arg2	shape					1229:1233	a spherical shape	1217:1233	a spherical shape	1217:1233	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	6	32	contain	had	1213:1215	arg2	distribution					1261:1272	uniform particle size distribution	1239:1272	uniform particle size distribution	1239:1272	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	6	32	contain	had	1213:1215	arg2	nm					1286:1287	74.46 ±7.9 nm	1275:1287	74.46 ±7.9 nm	1275:1287	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	6	32	contain	had	1213:1215	arg1	carrier					1165:1171	The nanostructured lipid carrier	1140:1171	The nanostructured lipid carrier with optimum composition and properties	1140:1211	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	2	33	theme	multifunctional	405:419	arg1	dressing					427:434	a multifunctional wound dressing	403:434	a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated	403:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	9	34	theme	highest	1586:1592	arg1	release					1599:1605	The highest drug release	1582:1605	The highest drug release	1582:1605	The highest drug release occurred (80%) within 14 days.
36603225	4	35	theme	±	994:994	arg1	g/m2					1001:1004	a 2116 ± 79.2 g/m2	987:1004	a 2116 ± 79.2 g/m2	987:1004	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	8	36	theme	time	1576:1579	arg1	period					1566:1571	a prolonged period	1554:1571	a prolonged period of time	1554:1579	It can release the loaded simvastatin drug slowly and over a prolonged period of time.
36603225	0	37	theme	hydrogel	42:49	arg1	characterization					14:29	characterization	14:29	characterization	14:29	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	0	37	theme	hydrogel	42:49	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis	0:8	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	1	38	theme	modern	310:315	arg1	dressings					323:331	modern wound dressings	310:331	modern wound dressings based on synthetic and bioactive polymers	310:373	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	4	39	theme	dressing	808:815	arg1	dressing					808:815	dressing	808:815	dressing	808:815	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	39	theme	dressing	808:815	arg1	composites					794:803	various fabricated composites	775:803	various fabricated composites of dressing	775:815	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	3	40	theme	wound	680:684	arg1	dressing					584:591	This dressing	579:591	This dressing	579:591	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	40	theme	wound	680:684	arg1	barrier					611:617	a barrier	609:617	a barrier against pathogens	609:635	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	40	theme	wound	680:684	arg1	healing					686:692	wound healing	680:692	wound healing	680:692	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	40	theme	wound	680:684	arg1	exudates					655:662	excess exudates	648:662	excess exudates	648:662	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	1	41	theme	wound	239:243	arg1	healing					245:251	wound healing	239:251	wound healing	239:251	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	2	42	theme	chitosan/sodium	459:473	arg1	hydrogel					484:491	carboxymethyl chitosan/sodium alginate hydrogel	445:491	carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated	445:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	10	43	theme	promising	1698:1706	arg1	candidate					1708:1716	a promising candidate	1696:1716	a promising candidate as a wound dressing for treating various chronic wounds in skin tissues	1696:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	10	43	theme	promising	1698:1706	arg1	nanocomposite					1673:1685	this novel nanocomposite	1662:1685	this novel nanocomposite	1662:1685	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	7	44	theme	mouse	1471:1475	arg1	cells					1488:1492	L929 mouse fibroblast cells	1466:1492	L929 mouse fibroblast cells	1466:1492	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	6	45	theme	lipid	1159:1163	arg1	carrier					1165:1171	The nanostructured lipid carrier	1140:1171	The nanostructured lipid carrier with optimum composition and properties	1140:1211	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	3	46	theme	factor	754:759	arg1	production					712:721	the production	708:721	the production of vascular endothelial growth factor (VEGF)	708:766	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	6	47	theme	particle	1247:1254	arg1	distribution					1261:1272	uniform particle size distribution	1239:1272	uniform particle size distribution	1239:1272	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	10	48	theme	wound	1723:1727	arg1	dressing					1729:1736	a wound dressing	1721:1736	a wound dressing for treating various chronic wounds in skin tissues	1721:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	1	49	theme	wound	172:176	arg1	dressing					178:185	wound dressing	172:185	wound dressing	172:185	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	4	50	theme	2116	989:992	arg1	g/m2					1001:1004	a 2116 ± 79.2 g/m2	987:1004	a 2116 ± 79.2 g/m2	987:1004	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	51	theme	carboxymethyl	848:860	arg1	ratio					887:891	a carboxymethyl chitosan/sodium alginate ratio	846:891	a carboxymethyl chitosan/sodium alginate ratio of 1:2	846:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	3	52	theme	endothelial	735:745	arg1	VEGF					762:765	VEGF	762:765	VEGF	762:765	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	52	theme	endothelial	735:745	arg1	factor					754:759	vascular endothelial growth factor	726:759	vascular endothelial growth factor (VEGF)	726:766	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	4	53	theme	alginate	878:885	arg1	ratio					887:891	a carboxymethyl chitosan/sodium alginate ratio	846:891	a carboxymethyl chitosan/sodium alginate ratio of 1:2	846:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	10	54	theme	various	1751:1757	arg1	wounds					1767:1772	various chronic wounds	1751:1772	various chronic wounds in skin tissues	1751:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	6	55	with	carrier	1165:1171	arg1	composition					1186:1196	optimum composition	1178:1196	optimum composition	1178:1196	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	6	55	with	carrier	1165:1171	arg1	properties					1202:1211	properties	1202:1211	properties	1202:1211	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	7	56	theme	aureus	1414:1419	arg1	bacteria					1421:1428	Escherichia coli and Staphylococcus aureus bacteria	1378:1428	Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility	1378:1461	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	0	57	theme	chronic	143:149	arg1	healing					157:163	chronic wound healing	143:163	chronic wound healing	143:163	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	1	58	theme	promising	209:217	arg1	strategy					219:226	a promising strategy	207:226	a promising strategy to improve wound healing	207:251	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	4	59	theme	±	940:940	arg1	μm					947:948	about 98.44 ± 26.9 μm	928:948	about 98.44 ± 26.9 μm	928:948	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	60	dep	swelling	974:981	arg1	%					972:972	%	972:972	%	972:972	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	10	61	theme	skin	1777:1780	arg1	tissues					1782:1788	skin tissues	1777:1788	skin tissues	1777:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	4	62	theme	average	907:913	arg1	size					920:923	an average pore size	904:923	an average pore size of about 98.44 ± 26.9 μm	904:948	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	5	63	theme	water	1014:1018	arg1	vapor					1020:1024	water vapor	1014:1024	water vapor	1014:1024	per day water vapor transfer rate (WVTR), demonstrating appropriate properties for absorbing exudates and maintaining wound moisture.
36603225	0	64	theme	carboxymethyl	60:72	arg1	alginate					90:97	carboxymethyl chitosan/sodium alginate	60:97	carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing	60:163	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	2	65	theme	nanostructured	506:519	arg1	carrier					527:533	a nanostructured lipid carrier	504:533	a nanostructured lipid carrier in which simvastatin has been encapsulated	504:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	7	66	theme	excellent	1337:1345	arg1	activity					1361:1368	excellent antibacterial activity	1337:1368	excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells	1337:1492	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	8	67	theme	simvastatin	1521:1531	arg1	drug					1533:1536	the loaded simvastatin drug	1510:1536	the loaded simvastatin drug	1510:1536	It can release the loaded simvastatin drug slowly and over a prolonged period of time.
36603225	1	68	theme	synthetic	342:350	arg1	polymers					366:373	synthetic and bioactive polymers	342:373	synthetic and bioactive polymers	342:373	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	4	69	theme	μm	947:948	arg1	size					920:923	an average pore size	904:923	an average pore size of about 98.44 ± 26.9 μm	904:948	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	1	70	theme	bioactive	356:364	arg1	polymers					366:373	synthetic and bioactive polymers	342:373	synthetic and bioactive polymers	342:373	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	7	71	theme	nanocomposite	1304:1316	arg1	hydrogel					1318:1325	The prepared nanocomposite hydrogel	1291:1325	The prepared nanocomposite hydrogel	1291:1325	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	4	72	theme	fabricated	783:792	arg1	dressing					808:815	dressing	808:815	dressing	808:815	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	4	72	theme	fabricated	783:792	arg1	composites					794:803	various fabricated composites	775:803	various fabricated composites of dressing	775:815	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	7	73	from	activity	1361:1368	arg1	cells					1488:1492	L929 mouse fibroblast cells	1466:1492	L929 mouse fibroblast cells	1466:1492	The prepared nanocomposite hydrogel displayed excellent antibacterial activity against Escherichia coli and Staphylococcus aureus bacteria as well as high biocompatibility on L929 mouse fibroblast cells.
36603225	8	74	theme	prolonged	1556:1564	arg1	period					1566:1571	a prolonged period	1554:1571	a prolonged period of time	1554:1579	It can release the loaded simvastatin drug slowly and over a prolonged period of time.
36603225	6	75	theme	spherical	1219:1227	arg1	shape					1229:1233	a spherical shape	1217:1233	a spherical shape	1217:1233	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	6	75	theme	spherical	1219:1227	arg1	nm					1286:1287	74.46 ±7.9 nm	1275:1287	74.46 ±7.9 nm	1275:1287	The nanostructured lipid carrier with optimum composition and properties had a spherical shape and uniform particle size distribution (74.46 ±7.9 nm).
36603225	2	76	theme	wound	421:425	arg1	dressing					427:434	a multifunctional wound dressing	403:434	a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated	403:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	0	77	theme	novel	36:40	arg1	hydrogel					42:49	a novel hydrogel	34:49	a novel hydrogel	34:49	Synthesis and characterization of a novel hydrogel based on carboxymethyl chitosan/sodium alginate with the ability to release simvastatin for chronic wound healing.
36603225	9	78	theme	drug	1594:1597	arg1	release					1599:1605	The highest drug release	1582:1605	The highest drug release	1582:1605	The highest drug release occurred (80%) within 14 days.
36603225	2	79	theme	alginate	475:482	arg1	hydrogel					484:491	carboxymethyl chitosan/sodium alginate hydrogel	445:491	carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated	445:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	3	80	theme	excess	648:653	arg1	dressing					584:591	This dressing	579:591	This dressing	579:591	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	80	theme	excess	648:653	arg1	barrier					611:617	a barrier	609:617	a barrier against pathogens	609:635	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	80	theme	excess	648:653	arg1	healing					686:692	wound healing	680:692	wound healing	680:692	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	3	80	theme	excess	648:653	arg1	exudates					655:662	excess exudates	648:662	excess exudates	648:662	This dressing aimed to act as a barrier against pathogens, eliminate excess exudates, and accelerate wound healing by increasing the production of vascular endothelial growth factor (VEGF).
36603225	4	81	theme	hydrogel	822:829	arg1	composite					831:839	the hydrogel composite	818:839	the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2	818:898	Among various fabricated composites of dressing, the hydrogel composite with a carboxymethyl chitosan/sodium alginate ratio of 1:2 had an average pore size of about 98.44 ± 26.9 μm and showed 707 ± 31.9 % swelling and a 2116 ± 79.2 g/m2.
36603225	2	82	contain	containing	493:502	arg2	carrier					527:533	a nanostructured lipid carrier	504:533	a nanostructured lipid carrier in which simvastatin has been encapsulated	504:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	2	82	contain	containing	493:502	arg1	hydrogel					484:491	carboxymethyl chitosan/sodium alginate hydrogel	445:491	carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated	445:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	5	83	theme	wound	1124:1128	arg1	moisture					1130:1137	wound moisture	1124:1137	wound moisture	1124:1137	per day water vapor transfer rate (WVTR), demonstrating appropriate properties for absorbing exudates and maintaining wound moisture.
36603225	2	84	theme	carboxymethyl	445:457	arg1	hydrogel					484:491	carboxymethyl chitosan/sodium alginate hydrogel	445:491	carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated	445:576	In this study, we prepared a multifunctional wound dressing based on carboxymethyl chitosan/sodium alginate hydrogel containing a nanostructured lipid carrier in which simvastatin has been encapsulated.
36603225	1	85	theme	wound	317:321	arg1	dressings					323:331	modern wound dressings	310:331	modern wound dressings based on synthetic and bioactive polymers	310:373	Since wound dressing has been considered a promising strategy to improve wound healing, recent attention has been focused on the development of modern wound dressings based on synthetic and bioactive polymers.
36603225	10	86	theme	novel	1667:1671	arg1	candidate					1708:1716	a promising candidate	1696:1716	a promising candidate as a wound dressing for treating various chronic wounds in skin tissues	1696:1788	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36603225	10	86	theme	novel	1667:1671	arg1	nanocomposite					1673:1685	this novel nanocomposite	1662:1685	this novel nanocomposite	1662:1685	The results showed that this novel nanocomposite could be a promising candidate as a wound dressing for treating various chronic wounds in skin tissues.
36746300	0	0	theme	Hericium	79:86	arg1	erinaceus					88:96	Hericium erinaceus	79:96	Hericium erinaceus	79:96	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	10	1	theme	microbiota	1306:1315	arg1	composition					1283:1293	the composition	1279:1293	the composition of the gut microbiota	1279:1315	In parallel, polysaccharides could alter the composition of the gut microbiota, indicating that increased in Bacteriodetes, Firmicutes and decreased in Klebsiella and Shigella.
36746300	11	2	theme	polysaccharides	1488:1502	arg1	effect					1468:1473	the protective effect	1453:1473	the protective effect of fermented polysaccharides on the intestinal barrier	1453:1528	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	0	3	from	comparison	2:11	arg1	protection					44:53	intestinal barrier protection	25:53	intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation	25:126	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	11	4	theme	intestinal	1511:1520	arg1	barrier					1522:1528	the intestinal barrier	1507:1528	the intestinal barrier	1507:1528	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	11	5	theme	biomacromolecules	1612:1628	arg1	properties					1592:1601	the beneficial health properties	1570:1601	the beneficial health properties of these biomacromolecules	1570:1628	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	8	6	theme	TNF-	1017:1020	arg1	P < 0.05					1046:1053	P < 0.05	1046:1053	P < 0.05	1046:1053	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	8	6	theme	TNF-	1017:1020	arg1	levels					1038:1043	TNF-, IL-1, and IL-6 levels	1017:1043	TNF-, IL-1, and IL-6 levels (P < 0.05)	1017:1054	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	11	7	from	effect	1468:1473	arg1	barrier					1522:1528	the intestinal barrier	1507:1528	the intestinal barrier	1507:1528	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	11	8	theme	health	1585:1590	arg1	properties					1592:1601	the beneficial health properties	1570:1601	the beneficial health properties of these biomacromolecules	1570:1628	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	3	9	theme	intestinal	365:374	arg1	barrier					376:382	the intestinal barrier	361:382	the intestinal barrier	361:382	The effects of two polysaccharides on the intestinal barrier were investigated in cell and mice models.
36746300	0	10	from	protection	44:53	arg1	erinaceus					88:96	Hericium erinaceus	79:96	Hericium erinaceus	79:96	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	4	11	from	injury	518:523	arg1	cell					534:537	IEC-6 cell	528:537	IEC-6 cell	528:537	The results showed that polysaccharides had a protective effect against acrylamide-induced injury in IEC-6 cell.
36746300	9	12	theme	occludin	1164:1171	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	7	13	theme	induced	854:860	arg1	expression					890:899	TJ and MUC expression	879:899	expression	890:899	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	13	theme	induced	854:860	arg1	level					872:876	level	872:876	level	872:876	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	13	theme	induced	854:860	arg1	microbiota					910:919	gut microbiota	906:919	gut microbiota	906:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	13	theme	induced	854:860	arg1	cytokines					862:870	cyclophosphamide induced cytokines	837:870	cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota	837:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	3	14	theme	polysaccharides	342:356	arg1	effects					327:333	The effects	323:333	The effects of two polysaccharides on the intestinal barrier	323:382	The effects of two polysaccharides on the intestinal barrier were investigated in cell and mice models.
36746300	4	15	theme	protective	473:482	arg1	effect					484:489	a protective effect	471:489	a protective effect	471:489	The results showed that polysaccharides had a protective effect against acrylamide-induced injury in IEC-6 cell.
36746300	3	16	dep	cell	405:408	arg1	models					419:424	models	419:424	models	419:424	The effects of two polysaccharides on the intestinal barrier were investigated in cell and mice models.
36746300	8	17	theme	IgA	975:977	arg1	levels					993:998	IgA, IgG, and IgM levels	975:998	IgA, IgG, and IgM levels	975:998	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	4	18	theme	acrylamide-induced	499:516	arg1	injury					518:523	acrylamide-induced injury	499:523	acrylamide-induced injury in IEC-6 cell	499:537	The results showed that polysaccharides had a protective effect against acrylamide-induced injury in IEC-6 cell.
36746300	11	19	theme	fermented	1478:1486	arg1	polysaccharides					1488:1502	fermented polysaccharides	1478:1502	fermented polysaccharides	1478:1502	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	9	20	theme	ZO-1	1174:1177	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	1	21	theme	harmful	175:181	arg1	substances					183:192	harmful substances	175:192	harmful substances	175:192	The intestinal barrier protects the host from harmful substances.
36746300	8	22	theme	IgG	980:982	arg1	levels					993:998	IgA, IgG, and IgM levels	975:998	IgA, IgG, and IgM levels	975:998	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	11	23	from	views	1444:1448	arg1	effect					1468:1473	the protective effect	1453:1473	the protective effect of fermented polysaccharides on the intestinal barrier	1453:1528	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	7	24	theme	cyclophosphamide	837:852	arg1	expression					890:899	TJ and MUC expression	879:899	expression	890:899	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	24	theme	cyclophosphamide	837:852	arg1	level					872:876	level	872:876	level	872:876	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	24	theme	cyclophosphamide	837:852	arg1	microbiota					910:919	gut microbiota	906:919	gut microbiota	906:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	24	theme	cyclophosphamide	837:852	arg1	cytokines					862:870	cyclophosphamide induced cytokines	837:870	cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota	837:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	25	theme	intestinal	788:797	arg1	function					807:814	the intestinal barrier function	784:814	the intestinal barrier function in mice	784:822	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	9	26	theme	claudin-2	1227:1235	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	5	27	theme	paracellular	597:608	arg1	P < 0.05					624:631	P < 0.05	624:631	P < 0.05	624:631	Compared with HEP, FHEP significantly increased TEER and paracellular permeability (P < 0.05).
36746300	5	27	theme	paracellular	597:608	arg1	permeability					610:621	paracellular permeability	597:621	paracellular permeability (P < 0.05)	597:632	Compared with HEP, FHEP significantly increased TEER and paracellular permeability (P < 0.05).
36746300	8	28	theme	IL-1	1023:1026	arg1	P < 0.05					1046:1053	P < 0.05	1046:1053	P < 0.05	1046:1053	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	8	28	theme	IL-1	1023:1026	arg1	levels					1038:1043	TNF-, IL-1, and IL-6 levels	1017:1043	TNF-, IL-1, and IL-6 levels (P < 0.05)	1017:1054	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	8	29	theme	IgM	989:991	arg1	levels					993:998	IgA, IgG, and IgM levels	975:998	IgA, IgG, and IgM levels	975:998	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	0	30	theme	study	16:20	arg1	comparison					2:11	A comparison	0:11	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.	0:127	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	7	31	theme	gut	906:908	arg1	microbiota					910:919	gut microbiota	906:919	gut microbiota	906:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	31	theme	gut	906:908	arg1	cytokines					862:870	cyclophosphamide induced cytokines	837:870	cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota	837:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	11	32	theme	important	1434:1442	arg1	views					1444:1448	important views	1434:1448	important views on the protective effect of fermented polysaccharides on the intestinal barrier	1434:1528	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	4	33	contain	had	467:469	arg1	polysaccharides					451:465	polysaccharides	451:465	polysaccharides	451:465	The results showed that polysaccharides had a protective effect against acrylamide-induced injury in IEC-6 cell.
36746300	4	33	contain	had	467:469	arg2	effect					484:489	a protective effect	471:489	a protective effect	471:489	The results showed that polysaccharides had a protective effect against acrylamide-induced injury in IEC-6 cell.
36746300	9	34	theme	ZO-2	1180:1183	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	8	35	theme	IL-6	1033:1036	arg1	P < 0.05					1046:1053	P < 0.05	1046:1053	P < 0.05	1046:1053	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	8	35	theme	IL-6	1033:1036	arg1	levels					1038:1043	TNF-, IL-1, and IL-6 levels	1017:1043	TNF-, IL-1, and IL-6 levels (P < 0.05)	1017:1054	The results showed that FHEP significantly increased IgA, IgG, and IgM levels while decreasing TNF-, IL-1, and IL-6 levels (P < 0.05).
36746300	9	36	theme	claudin-3	1186:1194	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	0	37	theme	intestinal	25:34	arg1	protection					44:53	intestinal barrier protection	25:53	intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation	25:126	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	7	38	from	function	807:814	arg1	mice					819:822	mice	819:822	mice	819:822	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	9	39	theme	immunohistochemical	1061:1079	arg1	results					1081:1087	The immunohistochemical results	1057:1087	The immunohistochemical results	1057:1087	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	9	40	theme	claudin-4	1197:1205	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	10	41	theme	gut	1302:1304	arg1	microbiota					1306:1315	the gut microbiota	1298:1315	the gut microbiota	1298:1315	In parallel, polysaccharides could alter the composition of the gut microbiota, indicating that increased in Bacteriodetes, Firmicutes and decreased in Klebsiella and Shigella.
36746300	7	42	theme	barrier	799:805	arg1	function					807:814	the intestinal barrier function	784:814	the intestinal barrier function in mice	784:822	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	0	43	theme	barrier	36:42	arg1	protection					44:53	intestinal barrier protection	25:53	intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation	25:126	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	9	44	theme	MUC2	1208:1211	arg1	expression					1150:1159	the expression	1146:1159	the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2	1146:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	11	45	theme	potential	1546:1554	arg1	mechanism					1556:1564	a potential mechanism	1544:1564	a potential mechanism for the beneficial health properties of these biomacromolecules	1544:1628	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	3	46	from	effects	327:333	arg1	barrier					376:382	the intestinal barrier	361:382	the intestinal barrier	361:382	The effects of two polysaccharides on the intestinal barrier were investigated in cell and mice models.
36746300	6	47	theme	Western	736:742	arg1	Bolt					744:747	cell Western Bolt	731:747	cell Western Bolt (WB)	731:752	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36746300	6	47	theme	Western	736:742	arg1	WB					750:751	WB	750:751	WB	750:751	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36746300	6	48	theme	tight	680:684	arg1	TJ					696:697	TJ	696:697	TJ	696:697	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36746300	6	48	theme	tight	680:684	arg1	junction					686:693	tight junction	680:693	tight junction (TJ)	680:698	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36746300	7	49	dep	cytokines	862:870	arg1	expression					890:899	TJ and MUC expression	879:899	expression	890:899	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	49	dep	cytokines	862:870	arg1	level					872:876	level	872:876	level	872:876	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	49	dep	cytokines	862:870	arg1	microbiota					910:919	gut microbiota	906:919	gut microbiota	906:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	49	dep	cytokines	862:870	arg1	cytokines					862:870	cyclophosphamide induced cytokines	837:870	cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota	837:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	9	50	theme	decreased	1217:1225	arg1	claudin-2					1227:1235	decreased claudin-2	1217:1235	decreased claudin-2	1217:1235	The immunohistochemical results showed that both polysaccharides significantly increased the expression of occludin, ZO-1, ZO-2, claudin-3, claudin-4, MUC2 and decreased claudin-2.
36746300	6	51	theme	cell	731:734	arg1	Bolt					744:747	cell Western Bolt	731:747	cell Western Bolt (WB)	731:752	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36746300	6	51	theme	cell	731:734	arg1	WB					750:751	WB	750:751	WB	750:751	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36746300	1	52	theme	intestinal	133:142	arg1	barrier					144:150	The intestinal barrier	129:150	The intestinal barrier	129:150	The intestinal barrier protects the host from harmful substances.
36746300	7	53	theme	MUC	886:888	arg1	expression					890:899	TJ and MUC expression	879:899	expression	890:899	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	53	theme	MUC	886:888	arg1	cytokines					862:870	cyclophosphamide induced cytokines	837:870	cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota	837:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	0	54	theme	polysaccharides	58:72	arg1	protection					44:53	intestinal barrier protection	25:53	intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation	25:126	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	0	55	from	erinaceus	88:96	arg1	polysaccharides					58:72	polysaccharides	58:72	polysaccharides from Hericium erinaceus	58:96	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	0	55	from	erinaceus	88:96	arg1	protection					44:53	intestinal barrier protection	25:53	intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation	25:126	A comparison of study on intestinal barrier protection of polysaccharides from Hericium erinaceus before and after fermentation.
36746300	7	56	theme	TJ	879:880	arg1	expression					890:899	TJ and MUC expression	879:899	expression	890:899	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	7	56	theme	TJ	879:880	arg1	cytokines					862:870	cyclophosphamide induced cytokines	837:870	cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota	837:919	Polysaccharides also enhance the intestinal barrier function in mice by improving cyclophosphamide induced cytokines level, TJ and MUC expression, and gut microbiota.
36746300	2	57	dep	fermentation	294:305	arg1	FHEP					316:319	FHEP	316:319	FHEP	316:319	This paper investigated two polysaccharides extracted from the Hericium erinaceus before and after fermentation (HEP and FHEP).
36746300	2	57	dep	fermentation	294:305	arg1	HEP					308:310	HEP	308:310	HEP	308:310	This paper investigated two polysaccharides extracted from the Hericium erinaceus before and after fermentation (HEP and FHEP).
36746300	11	58	theme	protective	1457:1466	arg1	effect					1468:1473	the protective effect	1453:1473	the protective effect of fermented polysaccharides on the intestinal barrier	1453:1528	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	2	59	theme	Hericium	258:265	arg1	erinaceus					267:275	the Hericium erinaceus	254:275	the Hericium erinaceus	254:275	This paper investigated two polysaccharides extracted from the Hericium erinaceus before and after fermentation (HEP and FHEP).
36746300	11	60	theme	beneficial	1574:1583	arg1	properties					1592:1601	the beneficial health properties	1570:1601	the beneficial health properties of these biomacromolecules	1570:1628	This work provides important views on the protective effect of fermented polysaccharides on the intestinal barrier, and provides a potential mechanism for the beneficial health properties of these biomacromolecules.
36746300	6	61	theme	expression	660:669	arg1	polysaccharides					640:654	Both polysaccharides	635:654	Both polysaccharides the expression of	635:672	Both polysaccharides the expression of alter tight junction (TJ) and mucin (MUC) as observed in cell Western Bolt (WB).
36151104	0	0	theme	C.	76:77	arg1	Agardh					79:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh.
36151104	4	1	theme	further	917:923	arg1	research					945:952	further biological activity research	917:952	further biological activity research	917:952	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	3	2	theme	different	616:624	arg1	locations					626:634	different locations	616:634	different locations in the same sea area	616:655	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	5	3	theme	radical	1119:1125	arg1	activity					1138:1145	ABTS radical scavenging activity	1114:1145	ABTS radical scavenging activity	1114:1145	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	6	4	theme	C.	1234:1235	arg1	toxic					1290:1294	toxic	1290:1294	toxic	1290:1294	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	4	theme	C.	1234:1235	arg1	Agardh					1237:1242	The Sargassum ilicifolium (Turner) C. Agardh	1199:1242	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1199:1281	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	5	theme	cancer	1437:1442	arg1	cells					1444:1448	A549 cancer cells	1432:1448	A549 cancer cells	1432:1448	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	4	6	theme	activity	936:943	arg1	research					945:952	further biological activity research	917:952	further biological activity research	917:952	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	5	7	theme	ilicifolium	977:987	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	5	8	from	locations	1020:1028	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	3	9	theme	significant	493:503	arg1	differences					505:515	significant differences	493:515	significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area	493:655	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	2	10	theme	biological	303:312	arg1	activity					314:321	biological activity	303:321	biological activity	303:321	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	6	11	theme	Turner	1226:1231	arg1	toxic					1290:1294	toxic	1290:1294	toxic	1290:1294	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	11	theme	Turner	1226:1231	arg1	Agardh					1237:1242	The Sargassum ilicifolium (Turner) C. Agardh	1199:1242	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1199:1281	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	5	12	theme	ABTS	1114:1117	arg1	activity					1138:1145	ABTS radical scavenging activity	1114:1145	ABTS radical scavenging activity	1114:1145	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	2	13	theme	study	257:261	arg1	purpose					241:247	The purpose	237:247	The purpose of this study	237:261	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	6	14	theme	A549	1326:1329	arg1	cells					1338:1342	A549 cancer cells	1326:1342	A549 cancer cells	1326:1342	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	1	15	theme	antitumor	147:155	arg1	effects					173:179	antitumor and antioxidant effects	147:179	antitumor and antioxidant effects	147:179	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	4	16	contain	contains	740:747	arg1	fucoidan					724:731	the fucoidan	720:731	the fucoidan	720:731	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	16	contain	contains	740:747	arg2	fucose					749:754	fucose	749:754	fucose	749:754	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	16	contain	contains	740:747	arg2	glucose					775:781	glucose	775:781	glucose	775:781	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	16	contain	contains	740:747	arg2	galactose					787:795	galactose	787:795	galactose	787:795	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	16	contain	contains	740:747	arg2	mannose					757:763	mannose	757:763	mannose	757:763	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	16	contain	contains	740:747	arg2	mannose					766:772	mannose	766:772	mannose	766:772	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	3	17	theme	same	643:646	arg1	area					652:655	the same sea area	639:655	the same sea area	639:655	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	5	18	theme	C.	998:999	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	7	19	theme	significant	1567:1577	arg1	properties					1606:1615	significant antioxidant and anticancer properties	1567:1615	significant antioxidant and anticancer properties	1567:1615	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	4	20	theme	monosaccharide	689:702	arg1	compositions					704:715	the monosaccharide compositions	685:715	the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa	685:846	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	21	contain	have	801:804	arg1	fucoidan					724:731	the fucoidan	720:731	the fucoidan	720:731	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	4	21	contain	have	801:804	arg2	weight					822:827	a low molecular weight	806:827	a low molecular weight of less than 5 kDa	806:846	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	5	22	theme	sampled	959:965	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	3	23	theme	sea	648:650	arg1	area					652:655	the same sea area	639:655	the same sea area	639:655	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	2	24	theme	Taiwan	456:461	arg1	regions					445:451	five regions	440:451	five regions of Taiwan	440:461	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	7	25	theme	ilicifolium	1493:1503	arg1	Agardh					1517:1522	the Sargassum ilicifolium (Turner) C. Agardh	1479:1522	the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1479:1561	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	1	26	theme	antioxidant	161:171	arg1	effects					173:179	antitumor and antioxidant effects	147:179	antitumor and antioxidant effects	147:179	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	6	27	contain	has	1406:1408	arg2	cytotoxicity					1415:1426	good cytotoxicity	1410:1426	good cytotoxicity for A549 cancer cells	1410:1448	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	27	contain	has	1406:1408	arg1	it					1403:1404	it	1403:1404	it	1403:1404	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	27	contain	has	1406:1408	arg2	results					1390:1396	the results	1386:1396	the results that it has good cytotoxicity for A549 cancer cells	1386:1448	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	5	28	theme	good	1036:1039	arg1	content					1052:1058	a good polyphenol content	1034:1058	a good polyphenol content	1034:1058	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	6	29	theme	A549	1432:1435	arg1	cells					1444:1448	A549 cancer cells	1432:1448	A549 cancer cells	1432:1448	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	7	30	contain	has	1563:1565	arg1	Agardh					1517:1522	the Sargassum ilicifolium (Turner) C. Agardh	1479:1522	the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1479:1561	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	7	30	contain	has	1563:1565	arg2	properties					1606:1615	significant antioxidant and anticancer properties	1567:1615	significant antioxidant and anticancer properties	1567:1615	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	0	31	theme	fucoidan	21:28	arg1	Bioactivity					0:10	Bioactivity	0:10	Bioactivity of crude fucoidan	0:28	Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh.
36151104	5	32	theme	polyphenol	1041:1050	arg1	content					1052:1058	a good polyphenol content	1034:1058	a good polyphenol content	1034:1058	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	6	33	theme	ilicifolium	1213:1223	arg1	toxic					1290:1294	toxic	1290:1294	toxic	1290:1294	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	33	theme	ilicifolium	1213:1223	arg1	Agardh					1237:1242	The Sargassum ilicifolium (Turner) C. Agardh	1199:1242	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1199:1281	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	7	34	theme	anticancer	1595:1604	arg1	properties					1606:1615	significant antioxidant and anticancer properties	1567:1615	significant antioxidant and anticancer properties	1567:1615	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	6	35	theme	cancer	1355:1360	arg1	cells					1362:1366	HCT116 cancer cells	1348:1366	HCT116 cancer cells	1348:1366	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	0	36	theme	crude	15:19	arg1	fucoidan					21:28	crude fucoidan	15:28	crude fucoidan	15:28	Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh.
36151104	6	37	theme	Sargassum	1203:1211	arg1	toxic					1290:1294	toxic	1290:1294	toxic	1290:1294	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	6	37	theme	Sargassum	1203:1211	arg1	Agardh					1237:1242	The Sargassum ilicifolium (Turner) C. Agardh	1199:1242	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1199:1281	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	7	38	theme	antioxidant	1579:1589	arg1	properties					1606:1615	significant antioxidant and anticancer properties	1567:1615	significant antioxidant and anticancer properties	1567:1615	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	7	39	theme	C.	1514:1515	arg1	Agardh					1517:1522	the Sargassum ilicifolium (Turner) C. Agardh	1479:1522	the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1479:1561	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	5	40	theme	Reducing	1183:1190	arg1	power					1192:1196	Reducing power	1183:1196	Reducing power	1183:1196	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	7	41	theme	Turner	1506:1511	arg1	Agardh					1517:1522	the Sargassum ilicifolium (Turner) C. Agardh	1479:1522	the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1479:1561	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	6	42	theme	normal	1304:1309	arg1	cells					1311:1315	L929 normal cells	1299:1315	L929 normal cells	1299:1315	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	5	43	theme	DPPH	1080:1083	arg1	activity					1104:1111	great DPPH radical scavenging activity	1074:1111	great DPPH radical scavenging activity	1074:1111	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	6	44	theme	L929	1299:1302	arg1	cells					1311:1315	L929 normal cells	1299:1315	L929 normal cells	1299:1315	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	3	45	from	locations	626:634	arg1	area					652:655	the same sea area	639:655	the same sea area	639:655	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	6	46	theme	good	1410:1413	arg1	cytotoxicity					1415:1426	good cytotoxicity	1410:1426	good cytotoxicity for A549 cancer cells	1410:1448	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	4	47	theme	less	832:835	arg1	weight					822:827	a low molecular weight	806:827	a low molecular weight of less than 5 kDa	806:846	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	3	48	theme	ilicifolium	576:586	arg1	content					555:561	total sugar content	543:561	total sugar content	543:561	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	3	48	theme	ilicifolium	576:586	arg1	sulfate					531:537	sulfate	531:537	sulfate	531:537	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	3	48	theme	ilicifolium	576:586	arg1	yield					524:528	the yield	520:528	the yield	520:528	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	3	49	theme	total	543:547	arg1	content					555:561	total sugar content	543:561	total sugar content	543:561	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	1	50	from	research	185:192	arg1	polysaccharides					206:220	sulfated polysaccharides	197:220	sulfated polysaccharides	197:220	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	0	51	theme	ilicifolium	55:65	arg1	Agardh					79:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh.
36151104	5	52	theme	Sargassum	967:975	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	5	53	theme	Turner	990:995	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	2	54	theme	fucoidan	326:333	arg1	characteristics					283:297	characteristics	283:297	characteristics	283:297	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	2	54	theme	fucoidan	326:333	arg1	activity					314:321	biological activity	303:321	biological activity	303:321	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	0	55	theme	Sargassum	45:53	arg1	Agardh					79:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh.
36151104	1	56	attach	derived	96:102	arg1	algae					115:119	brown algae	109:119	brown algae	109:119	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	1	56	attach	derived	96:102	arg2	Fucoidan					87:94	Fucoidan	87:94	Fucoidan derived from brown algae	87:119	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	5	57	contain	has	1030:1032	arg1	Agardh					1001:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh	955:1006	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations	955:1028	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	5	57	contain	has	1030:1032	arg2	content					1052:1058	a good polyphenol content	1034:1058	a good polyphenol content	1034:1058	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	1	58	theme	brown	109:113	arg1	algae					115:119	brown algae	109:119	brown algae	109:119	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	3	59	from	differences	505:515	arg1	content					555:561	total sugar content	543:561	total sugar content	543:561	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	3	59	from	differences	505:515	arg1	sulfate					531:537	sulfate	531:537	sulfate	531:537	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	3	59	from	differences	505:515	arg1	yield					524:528	the yield	520:528	the yield	520:528	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	4	60	theme	molecular	812:820	arg1	weight					822:827	a low molecular weight	806:827	a low molecular weight of less than 5 kDa	806:846	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	2	61	dep	temperatures	361:372	arg1	80 °C					382:386	80 °C	382:386	80 °C	382:386	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	2	61	dep	temperatures	361:372	arg1	65					375:376	65	375:376	65	375:376	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	5	62	theme	great	1074:1078	arg1	activity					1104:1111	great DPPH radical scavenging activity	1074:1111	great DPPH radical scavenging activity	1074:1111	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	6	63	theme	cancer	1331:1336	arg1	cells					1338:1342	A549 cancer cells	1326:1342	A549 cancer cells	1326:1342	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	1	64	theme	sulfated	197:204	arg1	polysaccharides					206:220	sulfated polysaccharides	197:220	sulfated polysaccharides	197:220	Fucoidan derived from brown algae has been shown to exhibit antitumor and antioxidant effects, so research on sulfated polysaccharides is increasing.
36151104	4	65	theme	low	808:810	arg1	weight					822:827	a low molecular weight	806:827	a low molecular weight of less than 5 kDa	806:846	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	6	66	theme	HCT116	1348:1353	arg1	cells					1362:1366	HCT116 cancer cells	1348:1366	HCT116 cancer cells	1348:1366	The Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang is not toxic to L929 normal cells, but for A549 cancer cells and HCT116 cancer cells, it is known from the results that it has good cytotoxicity for A549 cancer cells.
36151104	2	67	dep	characteristics	283:297	arg1	the					279:281	the	279:281	the	279:281	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	5	68	theme	Ferrous	1148:1154	arg1	activity					1170:1177	Ferrous ion-chelating activity	1148:1177	Ferrous ion-chelating activity	1148:1177	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	5	69	theme	radical	1085:1091	arg1	activity					1104:1111	great DPPH radical scavenging activity	1074:1111	great DPPH radical scavenging activity	1074:1111	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	0	70	theme	Turner	68:73	arg1	Agardh					79:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Sargassum ilicifolium (Turner) C. Agardh	45:84	Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh.
36151104	5	71	theme	scavenging	1127:1136	arg1	activity					1138:1145	ABTS radical scavenging activity	1114:1145	ABTS radical scavenging activity	1114:1145	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	3	72	theme	sugar	549:553	arg1	content					555:561	total sugar content	543:561	total sugar content	543:561	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	4	73	theme	biological	925:934	arg1	research					945:952	further biological activity research	917:952	further biological activity research	917:952	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	5	74	theme	ion-chelating	1156:1168	arg1	activity					1170:1177	Ferrous ion-chelating activity	1148:1177	Ferrous ion-chelating activity	1148:1177	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	5	75	theme	scavenging	1093:1102	arg1	activity					1104:1111	great DPPH radical scavenging activity	1074:1111	great DPPH radical scavenging activity	1074:1111	The sampled Sargassum ilicifolium (Turner) C. Agardh at all five locations has a good polyphenol content, and it shows great DPPH radical scavenging activity, ABTS radical scavenging activity, Ferrous ion-chelating activity and Reducing power.
36151104	7	76	theme	Sargassum	1483:1491	arg1	Agardh					1517:1522	the Sargassum ilicifolium (Turner) C. Agardh	1479:1522	the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang	1479:1561	Thus, this study found that the Sargassum ilicifolium (Turner) C. Agardh that was collected from Taitung Fugang has significant antioxidant and anticancer properties.
36151104	2	77	from	ilicifolium	404:414	arg1	temperatures					361:372	two temperatures	357:372	two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner)	357:423	The purpose of this study was to evaluate the characteristics and biological activity of fucoidan that was extracted at two temperatures (65 and 80 °C) from Sargassum ilicifolium (Turner) C. Agardh from five regions of Taiwan.
36151104	4	78	theme	fucoidan	724:731	arg1	compositions					704:715	the monosaccharide compositions	685:715	the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa	685:846	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
36151104	3	79	dep	ilicifolium	576:586	arg1	Agardh					600:605	Agardh	600:605	Agardh	600:605	The data show that there are significant differences in the yield, sulfate and total sugar content of Sargassum ilicifolium (Turner) C. Agardh grown in different locations in the same sea area.
36151104	4	80	used	used	667:670	arg2	HPLC					658:661	HPLC	658:661	HPLC	658:661	HPLC was used to determine the monosaccharide compositions of the fucoidan, which contains fucose, mannose, mannose, glucose and galactose and have a low molecular weight of less than 5 kDa, and then we will select the algae collected in Fugang, Taitung, for further biological activity research.
35144010	7	0	theme	cells	1444:1448	arg1	viability					1425:1433	the cell viability	1416:1433	the cell viability of tumor cells	1416:1448	In addition, S-CP and CM-CP decreased the cell viability of tumor cells.
35144010	6	1	theme	alleviation	1329:1339	arg1	down-regulation					1283:1297	down-regulation	1283:1297	down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase	1283:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	3	2	dep	compositions	632:643	arg1	the					619:621	the	619:621	the	619:621	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	6	3	with	association	1266:1276	arg1	down-regulation					1283:1297	down-regulation	1283:1297	down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase	1283:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	8	4	theme	anti-oxidants	1645:1657	arg1	development					1616:1626	the development	1612:1626	the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs	1612:1690	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	0	5	theme	Physicochemical	84:98	arg1	properties					100:109	Physicochemical properties	84:109	Physicochemical properties	84:109	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	8	6	theme	group	1502:1506	arg1	type					1483:1486	the type	1479:1486	the type of functional group	1479:1506	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	1	7	theme	Cyclocarya	187:196	arg1	CP					223:224	CP	223:224	CP	223:224	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	1	7	theme	Cyclocarya	187:196	arg1	polysaccharide					207:220	The Cyclocarya paliurus polysaccharide	183:220	The Cyclocarya paliurus polysaccharide (CP)	183:225	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	3	8	from	variations	605:614	arg1	compositions					632:643	chemical compositions	623:643	chemical compositions	623:643	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	3	8	from	variations	605:614	arg1	structures					658:667	apparent structures	649:667	apparent structures	649:667	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	8	9	theme	natural	1637:1643	arg1	anti-oxidants					1645:1657	novel natural anti-oxidants	1631:1657	novel natural anti-oxidants	1631:1657	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	0	10	theme	antitumor	112:120	arg1	activities					122:131	antitumor activities	112:131	antitumor activities	112:131	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	0	11	from	Effects	0:6	arg1	polysaccharides					67:81	Cyclocarya paliurus polysaccharides	47:81	Cyclocarya paliurus polysaccharides	47:81	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	6	12	theme	activities	1314:1323	arg1	down-regulation					1283:1297	down-regulation	1283:1297	down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase	1283:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	4	13	with	S-CP	676:679	arg1	glucose					708:714	glucose	708:714	glucose	708:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	4	13	with	S-CP	676:679	arg1	amount					698:703	the highest amount	686:703	the highest amount of glucose	686:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	6	14	theme	anti-apoptotic	1210:1223	arg1	effect					1225:1230	the anti-apoptotic effect	1206:1230	the anti-apoptotic effect of S-CP and CM-CP	1206:1248	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	2	15	dep	activity	363:370	arg1	the					347:349	the	347:349	the	347:349	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	8	16	theme	low-toxicity	1662:1673	arg1	drugs					1686:1690	low-toxicity anti-tumor drugs	1662:1690	low-toxicity anti-tumor drugs	1662:1690	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	8	17	theme	novel	1631:1635	arg1	anti-oxidants					1645:1657	novel natural anti-oxidants	1631:1657	novel natural anti-oxidants	1631:1657	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	6	18	theme	Further	1174:1180	arg1	experiments					1182:1192	Further experiments	1174:1192	Further experiments	1174:1192	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	6	19	theme	Caspase-9/3	1302:1312	arg1	activities					1314:1323	Caspase-9/3 activities	1302:1323	Caspase-9/3 activities	1302:1323	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	6	20	theme	S-CP	1235:1238	arg1	effect					1225:1230	the anti-apoptotic effect	1206:1230	the anti-apoptotic effect of S-CP and CM-CP	1206:1248	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	5	21	theme	intracellular	1005:1017	arg1	ROS					1044:1046	ROS	1044:1046	ROS	1044:1046	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	5	21	theme	intracellular	1005:1017	arg1	species					1035:1041	intracellular reactive oxygen species	1005:1041	intracellular reactive oxygen species (ROS)	1005:1047	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	5	22	theme	H2O2-induced	912:923	arg1	damage					925:930	H2O2-induced damage	912:930	H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis	912:1171	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	1	23	theme	paliurus	198:205	arg1	CP					223:224	CP	223:224	CP	223:224	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	1	23	theme	paliurus	198:205	arg1	polysaccharide					207:220	The Cyclocarya paliurus polysaccharide	183:220	The Cyclocarya paliurus polysaccharide (CP)	183:225	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	0	24	theme	Cyclocarya	47:56	arg1	polysaccharides					67:81	Cyclocarya paliurus polysaccharides	47:81	Cyclocarya paliurus polysaccharides	47:81	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	8	25	theme	biological	1537:1546	arg1	function					1548:1555	the biological function	1533:1555	the biological function of the derivatives	1533:1574	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	3	26	theme	remarkable	594:603	arg1	variations					605:614	remarkable variations	594:614	remarkable variations in the chemical compositions and apparent structures of CP	594:673	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	6	27	from	arrest	1355:1360	arg1	phase					1371:1375	the S phase	1365:1375	the S phase	1365:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	5	28	theme	species	1035:1041	arg1	secretion					963:971	the secretion	959:971	the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA)	959:1073	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	6	29	from	alleviation	1329:1339	arg1	phase					1371:1375	the S phase	1365:1375	the S phase	1365:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	8	30	theme	derivatives	1564:1574	arg1	function					1548:1555	the biological function	1533:1555	the biological function of the derivatives	1533:1574	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	5	31	theme	lactate	976:982	arg1	LDH					999:1001	LDH	999:1001	LDH	999:1001	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	5	31	theme	lactate	976:982	arg1	dehydrogenase					984:996	lactate dehydrogenase	976:996	lactate dehydrogenase (LDH)	976:1002	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	4	32	theme	antioxidant	734:744	arg1	capacity					746:753	the strongest antioxidant capacity	720:753	the strongest antioxidant capacity to scavenge DPPH• and HO•	720:779	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	1	33	theme	carboxymethylated	294:310	arg1	CM-CP					325:329	CM-CP	325:329	CM-CP	325:329	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	1	33	theme	carboxymethylated	294:310	arg1	derivatives					312:322	carboxymethylated derivatives	294:322	carboxymethylated derivatives (CM-CP)	294:330	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	5	34	theme	dehydrogenase	984:996	arg1	secretion					963:971	the secretion	959:971	the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA)	959:1073	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	4	35	theme	strongest	724:732	arg1	capacity					746:753	the strongest antioxidant capacity	720:753	the strongest antioxidant capacity to scavenge DPPH• and HO•	720:779	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	0	36	theme	sulfation	11:19	arg1	Effects					0:6	Effects	0:6	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.	0:181	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	6	37	from	phase	1371:1375	arg1	activities					1314:1323	Caspase-9/3 activities	1302:1323	Caspase-9/3 activities	1302:1323	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	6	37	from	phase	1371:1375	arg1	alleviation					1329:1339	alleviation	1329:1339	alleviation of cell cycle arrest in the S phase	1329:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	6	38	theme	S	1369:1369	arg1	phase					1371:1375	the S phase	1365:1375	the S phase	1365:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	2	39	theme	cytoprotective	373:386	arg1	effect					388:393	cytoprotective effect	373:393	cytoprotective effect	373:393	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	5	40	theme	malondialdehyde	1053:1067	arg1	secretion					963:971	the secretion	959:971	the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA)	959:1073	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	4	41	theme	highest	690:696	arg1	glucose					708:714	glucose	708:714	glucose	708:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	4	41	theme	highest	690:696	arg1	amount					698:703	the highest amount	686:703	the highest amount of glucose	686:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	0	42	theme	oxidative	165:173	arg1	stress					175:180	cellular oxidative stress	156:180	cellular oxidative stress	156:180	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	6	43	theme	intimate	1257:1264	arg1	association					1266:1276	intimate association	1257:1276	intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase	1257:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	4	44	theme	glucose	708:714	arg1	glucose					708:714	glucose	708:714	glucose	708:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	4	44	theme	glucose	708:714	arg1	amount					698:703	the highest amount	686:703	the highest amount of glucose	686:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	2	45	theme	functional	515:524	arg1	activity					526:533	functional activity	515:533	functional activity	515:533	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	8	46	theme	theoretical	1590:1600	arg1	basis					1602:1606	a theoretical basis	1588:1606	a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs	1588:1690	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	0	47	theme	carboxymethylation	25:42	arg1	Effects					0:6	Effects	0:6	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.	0:181	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	5	48	theme	superoxide	1103:1112	arg1	SOD					1125:1127	SOD	1125:1127	SOD	1125:1127	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	5	48	theme	superoxide	1103:1112	arg1	dismutase					1114:1122	superoxide dismutase	1103:1122	superoxide dismutase (SOD) levels	1103:1135	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	3	49	theme	CP	672:673	arg1	compositions					632:643	chemical compositions	623:643	chemical compositions	623:643	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	3	49	theme	CP	672:673	arg1	structures					658:667	apparent structures	649:667	apparent structures	649:667	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	0	50	theme	paliurus	58:65	arg1	polysaccharides					67:81	Cyclocarya paliurus polysaccharides	47:81	Cyclocarya paliurus polysaccharides	47:81	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	6	51	theme	arrest	1355:1360	arg1	activities					1314:1323	Caspase-9/3 activities	1302:1323	Caspase-9/3 activities	1302:1323	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	6	51	theme	arrest	1355:1360	arg1	alleviation					1329:1339	alleviation	1329:1339	alleviation of cell cycle arrest in the S phase	1329:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	5	52	theme	dismutase	1114:1122	arg1	levels					1130:1135	superoxide dismutase (SOD) levels	1103:1135	superoxide dismutase (SOD) levels	1103:1135	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	3	53	theme	apparent	649:656	arg1	structures					658:667	apparent structures	649:667	apparent structures	649:667	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	0	54	theme	cellular	156:163	arg1	stress					175:180	cellular oxidative stress	156:180	cellular oxidative stress	156:180	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	2	55	theme	derivatives	427:437	arg1	activity					363:370	antioxidant activity	351:370	antioxidant activity	351:370	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	2	55	theme	derivatives	427:437	arg1	effect					388:393	cytoprotective effect	373:393	cytoprotective effect	373:393	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	2	55	theme	derivatives	427:437	arg1	activity					409:416	antitumor activity	399:416	antitumor activity	399:416	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	6	56	theme	cycle	1349:1353	arg1	arrest					1355:1360	cell cycle arrest	1344:1360	cell cycle arrest in the S phase	1344:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	6	57	theme	CM-CP	1244:1248	arg1	effect					1225:1230	the anti-apoptotic effect	1206:1230	the anti-apoptotic effect of S-CP and CM-CP	1206:1248	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	3	58	theme	chemical	559:566	arg1	modifications					568:580	chemical modifications	559:580	chemical modifications	559:580	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	8	59	theme	drugs	1686:1690	arg1	development					1616:1626	the development	1612:1626	the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs	1612:1690	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	6	60	theme	cell	1344:1347	arg1	arrest					1355:1360	cell cycle arrest	1344:1360	cell cycle arrest in the S phase	1344:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	5	61	theme	oxygen	1028:1033	arg1	ROS					1044:1046	ROS	1044:1046	ROS	1044:1046	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	5	61	theme	oxygen	1028:1033	arg1	species					1035:1041	intracellular reactive oxygen species	1005:1041	intracellular reactive oxygen species (ROS)	1005:1047	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	4	62	theme	scavenging	826:835	arg1	terms					813:817	terms	813:817	terms of HO• scavenging	813:835	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	7	63	theme	tumor	1438:1442	arg1	cells					1444:1448	tumor cells	1438:1448	tumor cells	1438:1448	In addition, S-CP and CM-CP decreased the cell viability of tumor cells.
35144010	2	64	theme	antioxidant	351:361	arg1	activity					363:370	antioxidant activity	351:370	antioxidant activity	351:370	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	8	65	theme	anti-tumor	1675:1684	arg1	drugs					1686:1690	low-toxicity anti-tumor drugs	1662:1690	low-toxicity anti-tumor drugs	1662:1690	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	6	66	from	activities	1314:1323	arg1	phase					1371:1375	the S phase	1365:1375	the S phase	1365:1375	Further experiments showed that the anti-apoptotic effect of S-CP and CM-CP was in intimate association with down-regulation of Caspase-9/3 activities and alleviation of cell cycle arrest in the S phase.
35144010	5	67	theme	reactive	1019:1026	arg1	ROS					1044:1046	ROS	1044:1046	ROS	1044:1046	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	5	67	theme	reactive	1019:1026	arg1	species					1035:1041	intracellular reactive oxygen species	1005:1041	intracellular reactive oxygen species (ROS)	1005:1047	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	4	68	contain	had	716:718	arg1	S-CP					676:679	S-CP	676:679	S-CP with the highest amount of glucose	676:714	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	4	68	contain	had	716:718	arg2	capacity					746:753	the strongest antioxidant capacity	720:753	the strongest antioxidant capacity to scavenge DPPH• and HO•	720:779	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	4	69	theme	HO•	822:824	arg1	scavenging					826:835	HO• scavenging	822:835	HO• scavenging	822:835	S-CP with the highest amount of glucose had the strongest antioxidant capacity to scavenge DPPH• and HO•, but CM-CP was lower than CP in terms of HO• scavenging.
35144010	3	70	theme	chemical	623:630	arg1	compositions					632:643	chemical compositions	623:643	chemical compositions	623:643	The results found that chemical modifications resulted in remarkable variations in the chemical compositions and apparent structures of CP.
35144010	8	71	theme	functional	1491:1500	arg1	group					1502:1506	functional group	1491:1506	functional group	1491:1506	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	5	72	theme	abnormal	1154:1161	arg1	apoptosis					1163:1171	abnormal apoptosis	1154:1171	abnormal apoptosis	1154:1171	More importantly, S-CP and CM-CP more effectively protected RAW264.7 from H2O2-induced damage compared to CP by reducing the secretion of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS) and malondialdehyde (MDA), enhancing phagocytosis and superoxide dismutase (SOD) levels, and suppressing abnormal apoptosis.
35144010	2	73	theme	antitumor	399:407	arg1	activity					409:416	antitumor activity	399:416	antitumor activity	399:416	Subsequently, the antioxidant activity, cytoprotective effect and antitumor activity of these derivatives were investigated to establish the relationship between their structure and functional activity.
35144010	1	74	theme	sulfated	262:269	arg1	S-CP					284:287	S-CP	284:287	S-CP	284:287	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	1	74	theme	sulfated	262:269	arg1	derivatives					271:281	sulfated derivatives	262:281	sulfated derivatives (S-CP)	262:288	The Cyclocarya paliurus polysaccharide (CP) was chemically modified to produce sulfated derivatives (S-CP) and carboxymethylated derivatives (CM-CP).
35144010	8	75	theme	important	1514:1522	arg1	roles					1524:1528	important roles	1514:1528	important roles	1514:1528	These findings suggest that the type of functional group plays important roles in the biological function of the derivatives and provide a theoretical basis for the development of novel natural anti-oxidants or low-toxicity anti-tumor drugs.
35144010	0	76	dep	Effects	0:6	arg1	protection					137:146	protection	137:146	protection against cellular oxidative stress	137:180	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	0	76	dep	Effects	0:6	arg1	properties					100:109	Physicochemical properties	84:109	Physicochemical properties	84:109	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	0	76	dep	Effects	0:6	arg1	activities					122:131	antitumor activities	112:131	antitumor activities	112:131	Effects of sulfation and carboxymethylation on Cyclocarya paliurus polysaccharides: Physicochemical properties, antitumor activities and protection against cellular oxidative stress.
35144010	7	77	theme	cell	1420:1423	arg1	viability					1425:1433	the cell viability	1416:1433	the cell viability of tumor cells	1416:1448	In addition, S-CP and CM-CP decreased the cell viability of tumor cells.
35651768	7	0	theme	proteomic	1317:1325	arg1	results					1327:1333	Our proteomic results	1313:1333	Our proteomic results	1313:1333	Our proteomic results revealed that these glycans likely originated from proteins that maintain the redox balance crucial for proper nitrogen fixation, but also from enzymes involved in N-glycan and phenylpropanoid biosynthesis.
35651768	8	1	from	involvement	1579:1589	arg1	pathways					1628:1635	these critical pathways	1613:1635	these critical pathways	1613:1635	These findings indicate the possible involvement of Lewis-a glycans in these critical pathways during legume-rhizobia symbiosis.
35651768	6	2	theme	N-glycan	1194:1201	arg1	structures					1203:1212	complex N-glycan structures	1186:1212	complex N-glycan structures	1186:1212	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	6	2	theme	N-glycan	1194:1201	arg1	those					1228:1232	those	1228:1232	those	1228:1232	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	0	3	theme	Nodules	84:90	arg1	Mapping					8:14	Spatial Mapping	0:14	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	0:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	8	4	theme	critical	1619:1626	arg1	pathways					1628:1635	these critical pathways	1613:1635	these critical pathways	1613:1635	These findings indicate the possible involvement of Lewis-a glycans in these critical pathways during legume-rhizobia symbiosis.
35651768	4	5	theme	infected	779:786	arg1	cells					788:792	the infected cells	775:792	the infected cells within the infection zone	775:818	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	8	6	theme	legume-rhizobia	1644:1658	arg1	symbiosis					1660:1668	legume-rhizobia symbiosis	1644:1668	legume-rhizobia symbiosis	1644:1668	These findings indicate the possible involvement of Lewis-a glycans in these critical pathways during legume-rhizobia symbiosis.
35651768	7	7	theme	crucial	1427:1433	arg1	balance					1419:1425	the redox balance	1409:1425	the redox balance crucial for proper nitrogen fixation	1409:1462	Our proteomic results revealed that these glycans likely originated from proteins that maintain the redox balance crucial for proper nitrogen fixation, but also from enzymes involved in N-glycan and phenylpropanoid biosynthesis.
35651768	6	8	theme	Lewis-a	1254:1260	arg1	epitopes					1262:1269	characteristic Lewis-a epitopes	1239:1269	characteristic Lewis-a epitopes	1239:1269	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	4	9	theme	ion	683:685	arg1	images					687:692	Our ion images	679:692	Our ion images	679:692	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	3	10	theme	symbiotic	639:647	arg1	interactions					665:676	symbiotic rhizobia-legume interactions	639:676	symbiotic rhizobia-legume interactions	639:676	We additionally performed proteomics analysis to probe the potential correlation to proteome changes during symbiotic rhizobia-legume interactions.
35651768	3	11	theme	proteome	615:622	arg1	changes					624:630	proteome changes	615:630	proteome changes	615:630	We additionally performed proteomics analysis to probe the potential correlation to proteome changes during symbiotic rhizobia-legume interactions.
35651768	6	12	from	abundant	1281:1288	arg1	nodules					1304:1310	the mutant nodules	1293:1310	the mutant nodules	1293:1310	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	4	13	theme	infection	805:813	arg1	zone					815:818	the infection zone	801:818	the infection zone	801:818	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	6	14	theme	characteristic	1239:1252	arg1	epitopes					1262:1269	characteristic Lewis-a epitopes	1239:1269	characteristic Lewis-a epitopes	1239:1269	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	4	15	gly	N-glycosylation	714:728	arg2	layer					757:761	the sclerenchyma layer	740:761	the sclerenchyma layer	740:761	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	2	16	theme	N-glycans	471:479	arg1	distribution					442:453	distribution	442:453	distribution	442:453	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	2	16	theme	N-glycans	471:479	arg1	identity					459:466	identity	459:466	identity	459:466	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	3	17	theme	potential	590:598	arg1	correlation					600:610	the potential correlation	586:610	the potential correlation to proteome changes	586:630	We additionally performed proteomics analysis to probe the potential correlation to proteome changes during symbiotic rhizobia-legume interactions.
35651768	7	18	theme	nitrogen	1446:1453	arg1	fixation					1455:1462	proper nitrogen fixation	1439:1462	proper nitrogen fixation	1439:1462	Our proteomic results revealed that these glycans likely originated from proteins that maintain the redox balance crucial for proper nitrogen fixation, but also from enzymes involved in N-glycan and phenylpropanoid biosynthesis.
35651768	0	19	theme	Legume-Rhizobia	115:129	arg1	Symbiosis					131:139	Legume-Rhizobia Symbiosis	115:139	Legume-Rhizobia Symbiosis	115:139	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	4	20	dep	N-glycosylated	949:962	arg1	fewer					943:947	fewer	943:947	fewer	943:947	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	6	21	theme	complex	1186:1192	arg1	structures					1203:1212	complex N-glycan structures	1186:1212	complex N-glycan structures	1186:1212	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	6	21	theme	complex	1186:1192	arg1	those					1228:1232	those	1228:1232	those	1228:1232	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	4	22	theme	sclerenchyma	744:755	arg1	layer					757:761	the sclerenchyma layer	740:761	the sclerenchyma layer	740:761	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	2	23	theme	enzyme-assisted	330:344	arg1	spectrometry					395:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry	327:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution	327:528	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	1	24	theme	complex	204:210	arg1	modification					239:250	complex N-glycan posttranslational modification	204:250	complex N-glycan posttranslational modification in plants	204:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	0	25	theme	Spatial	0:6	arg1	Mapping					8:14	Spatial Mapping	0:14	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	0:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	3	26	theme	rhizobia-legume	649:663	arg1	interactions					665:676	symbiotic rhizobia-legume interactions	639:676	symbiotic rhizobia-legume interactions	639:676	We additionally performed proteomics analysis to probe the potential correlation to proteome changes during symbiotic rhizobia-legume interactions.
35651768	1	27	theme	N-glycan	212:219	arg1	modification					239:250	complex N-glycan posttranslational modification	204:250	complex N-glycan posttranslational modification in plants	204:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	0	28	theme	Plant	19:23	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	1	29	from	information	173:183	arg1	function					192:199	the function	188:199	the function of complex N-glycan posttranslational modification in plants	188:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	5	30	theme	root	1030:1033	arg1	nodules					1035:1041	soybean root nodules	1022:1041	soybean root nodules infected with wild-type rhizobia	1022:1074	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	1	31	theme	posttranslational	221:237	arg1	modification					239:250	complex N-glycan posttranslational modification	204:250	complex N-glycan posttranslational modification in plants	204:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	2	32	theme	soybean	484:490	arg1	nodules					497:503	soybean root nodules	484:503	soybean root nodules	484:503	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	5	33	theme	soybean	1022:1028	arg1	nodules					1035:1041	soybean root nodules	1022:1041	soybean root nodules infected with wild-type rhizobia	1022:1074	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	4	34	theme	morphological	827:839	arg1	structures					841:850	morphological structures	827:850	morphological structures such as the cortex	827:869	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	4	34	theme	morphological	827:839	arg1	cortex					864:869	the cortex	860:869	the cortex	860:869	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	2	35	theme	cellular	510:517	arg1	resolution					519:528	a cellular resolution	508:528	a cellular resolution	508:528	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	1	36	theme	modification	239:250	arg1	function					192:199	the function	188:199	the function of complex N-glycan posttranslational modification in plants	188:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	0	37	theme	Cellular	41:48	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	3	38	theme	proteomics	557:566	arg1	analysis					568:575	proteomics analysis	557:575	proteomics analysis	557:575	We additionally performed proteomics analysis to probe the potential correlation to proteome changes during symbiotic rhizobia-legume interactions.
35651768	8	39	theme	possible	1570:1577	arg1	involvement					1579:1589	the possible involvement	1566:1589	the possible involvement of Lewis-a glycans in these critical pathways	1566:1635	These findings indicate the possible involvement of Lewis-a glycans in these critical pathways during legume-rhizobia symbiosis.
35651768	5	40	theme	mutant	1100:1105	arg1	rhizobia					1107:1114	mutant rhizobia	1100:1114	mutant rhizobia incapable of efficiently fixing atmospheric nitrogen	1100:1167	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	4	41	gly	N-glycosylated	949:962	arg1	cells					883:887	uninfected cells	872:887	uninfected cells	872:887	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	4	41	gly	N-glycosylated	949:962	arg1	cells					894:898	cells	894:898	cells	894:898	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	4	41	gly	N-glycosylated	949:962	arg1	structures					841:850	morphological structures	827:850	morphological structures such as the cortex	827:869	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	4	41	gly	N-glycosylated	949:962	arg1	cortex					864:869	the cortex	860:869	the cortex	860:869	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	0	42	theme	N-Glycosylation	25:39	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	8	43	theme	Lewis-a	1594:1600	arg1	glycans					1602:1608	Lewis-a glycans	1594:1608	Lewis-a glycans	1594:1608	These findings indicate the possible involvement of Lewis-a glycans in these critical pathways during legume-rhizobia symbiosis.
35651768	2	44	theme	root	492:495	arg1	nodules					497:503	soybean root nodules	484:503	soybean root nodules	484:503	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	7	45	theme	redox	1413:1417	arg1	balance					1419:1425	the redox balance	1409:1425	the redox balance crucial for proper nitrogen fixation	1409:1462	Our proteomic results revealed that these glycans likely originated from proteins that maintain the redox balance crucial for proper nitrogen fixation, but also from enzymes involved in N-glycan and phenylpropanoid biosynthesis.
35651768	0	46	theme	Inside	64:69	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	5	47	theme	incapable	1116:1124	arg1	rhizobia					1107:1114	mutant rhizobia	1100:1114	mutant rhizobia incapable of efficiently fixing atmospheric nitrogen	1100:1167	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	1	48	from	plants	255:260	arg1	function					192:199	the function	188:199	the function of complex N-glycan posttranslational modification in plants	188:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	2	49	theme	mass	390:393	arg1	spectrometry					395:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry	327:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution	327:528	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	0	50	theme	Heterogeneity	50:62	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	7	51	theme	proper	1439:1444	arg1	fixation					1455:1462	proper nitrogen fixation	1439:1462	proper nitrogen fixation	1439:1462	Our proteomic results revealed that these glycans likely originated from proteins that maintain the redox balance crucial for proper nitrogen fixation, but also from enzymes involved in N-glycan and phenylpropanoid biosynthesis.
35651768	8	52	theme	glycans	1602:1608	arg1	involvement					1579:1589	the possible involvement	1566:1589	the possible involvement of Lewis-a glycans in these critical pathways	1566:1635	These findings indicate the possible involvement of Lewis-a glycans in these critical pathways during legume-rhizobia symbiosis.
35651768	2	53	theme	desorption/ionization	368:388	arg1	spectrometry					395:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry	327:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution	327:528	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	6	54	theme	mutant	1297:1302	arg1	nodules					1304:1310	the mutant nodules	1293:1310	the mutant nodules	1293:1310	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	5	55	theme	different	986:994	arg1	profiles					1005:1012	different N-glycan profiles	986:1012	different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen	986:1167	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	4	56	theme	uninfected	872:881	arg1	cells					883:887	uninfected cells	872:887	uninfected cells	872:887	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	4	56	theme	uninfected	872:881	arg1	cortex					864:869	the cortex	860:869	the cortex	860:869	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	1	57	from	modification	239:250	arg1	plants					255:260	plants	255:260	plants	255:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	2	58	theme	laser	362:366	arg1	spectrometry					395:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry	327:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution	327:528	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	7	59	theme	phenylpropanoid	1512:1526	arg1	biosynthesis					1528:1539	phenylpropanoid biosynthesis	1512:1539	phenylpropanoid biosynthesis	1512:1539	Our proteomic results revealed that these glycans likely originated from proteins that maintain the redox balance crucial for proper nitrogen fixation, but also from enzymes involved in N-glycan and phenylpropanoid biosynthesis.
35651768	2	60	from	distribution	442:453	arg1	nodules					497:503	soybean root nodules	484:503	soybean root nodules	484:503	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	5	61	theme	atmospheric	1148:1158	arg1	nitrogen					1160:1167	atmospheric nitrogen	1148:1167	atmospheric nitrogen	1148:1167	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	2	62	theme	matrix-assisted	346:360	arg1	spectrometry					395:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry	327:406	an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution	327:528	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	5	63	theme	N-glycan	996:1003	arg1	profiles					1005:1012	different N-glycan profiles	986:1012	different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen	986:1167	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	0	64	theme	Root	79:82	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	5	65	theme	wild-type	1057:1065	arg1	rhizobia					1067:1074	wild-type rhizobia	1057:1074	wild-type rhizobia	1057:1074	Notably, we observed different N-glycan profiles between soybean root nodules infected with wild-type rhizobia and those infected with mutant rhizobia incapable of efficiently fixing atmospheric nitrogen.
35651768	2	66	from	identity	459:466	arg1	nodules					497:503	soybean root nodules	484:503	soybean root nodules	484:503	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	4	67	theme	intense	706:712	arg1	N-glycosylation					714:728	intense N-glycosylation	706:728	intense N-glycosylation	706:728	Our ion images reveal that intense N-glycosylation occurs in the sclerenchyma layer, and inside the infected cells within the infection zone, while morphological structures such as the cortex, uninfected cells, and cells that form the attachment with the root are fewer N-glycosylated.
35651768	0	68	theme	Soybean	71:77	arg1	Nodules					84:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules	19:90	Spatial Mapping of Plant N-Glycosylation Cellular Heterogeneity Inside Soybean Root Nodules Provided Insights Into Legume-Rhizobia Symbiosis.
35651768	2	69	dep	distribution	442:453	arg1	the					438:440	the	438:440	the	438:440	In this work, we adopted an enzyme-assisted matrix-assisted laser desorption/ionization mass spectrometry imaging strategy to visualize the distribution and identity of N-glycans in soybean root nodules at a cellular resolution.
35651768	1	70	from	function	192:199	arg1	plants					255:260	plants	255:260	plants	255:260	Although ubiquitously present, information on the function of complex N-glycan posttranslational modification in plants is very limited and is often neglected.
35651768	6	71	theme	structures	1203:1212	arg1	abundant					1281:1288	abundant	1281:1288	abundant	1281:1288	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	6	71	theme	structures	1203:1212	arg1	majority					1174:1181	The majority	1170:1181	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes,	1170:1270	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	6	72	from	nodules	1304:1310	arg1	abundant					1281:1288	abundant	1281:1288	abundant	1281:1288	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
35651768	6	72	from	nodules	1304:1310	arg1	majority					1174:1181	The majority	1170:1181	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes,	1170:1270	The majority of complex N-glycan structures, particularly those with characteristic Lewis-a epitopes, are more abundant in the mutant nodules.
37331167	2	0	theme	core	515:518	arg1	fucose					520:525	core fucose	515:525	core fucose	515:525	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	0	1	from	characterization	19:34	arg1	allergy					136:142	allergy	136:142	allergy	136:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	1	from	characterization	19:34	arg1	meningoseptica					81:94	Elizabethkingia meningoseptica	65:94	Elizabethkingia meningoseptica	65:94	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	1	2	theme	Core	200:203	arg1	mannose					211:217	Core α-1,3 mannose	200:217	Core α-1,3 mannose	200:217	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	6	3	theme	PLA2	924:927	arg1	reactivity					898:907	the reactivity	894:907	the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody	894:969	And the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody decreased partially.
37331167	6	4	theme	MA3-treated	912:922	arg1	PLA2					924:927	MA3-treated PLA2	912:927	MA3-treated PLA2	912:927	And the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody decreased partially.
37331167	1	5	theme	α-1,3	205:209	arg1	mannose					211:217	Core α-1,3 mannose	200:217	Core α-1,3 mannose	200:217	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	0	6	theme	attenuation	114:124	arg1	impact					126:131	its potential attenuation impact	100:131	its potential attenuation impact on allergy	100:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	7	from	Identification	0:13	arg1	allergy					136:142	allergy	136:142	allergy	136:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	7	from	Identification	0:13	arg1	meningoseptica					81:94	Elizabethkingia meningoseptica	65:94	Elizabethkingia meningoseptica	65:94	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	5	8	from	mannose	790:796	arg1	HRP					801:803	HRP	801:803	HRP	801:803	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	0	9	theme	potential	104:112	arg1	impact					126:131	its potential attenuation impact	100:131	its potential attenuation impact on allergy	100:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	2	10	from	role	387:390	arg1	composition					421:431	the composition	417:431	the composition of glycan related epitope	417:457	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	2	11	theme	core	395:398	arg1	mannose					406:412	core α-1,3 mannose	395:412	core α-1,3 mannose	395:412	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	2	12	theme	epitope	451:457	arg1	composition					421:431	the composition	417:431	the composition of glycan related epitope	417:457	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	3	13	theme	genomic	560:566	arg1	analysis					568:575	functional genomic analysis	549:575	functional genomic analysis	549:575	Through functional genomic analysis, we identified a glycoprotein α-1,3 mannosidase and named it MA3.
37331167	5	14	theme	polyclonal	850:859	arg1	antibody					861:868	anti-core xylose polyclonal antibody	833:868	anti-core xylose polyclonal antibody	833:868	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	8	15	theme	critical	1175:1182	arg1	mannose					1160:1166	α-1,3 mannose	1154:1166	α-1,3 mannose	1154:1166	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	8	15	theme	critical	1175:1182	arg1	component					1184:1192	an critical component	1172:1192	an critical component of glycan related epitope	1172:1218	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	7	16	theme	enzyme	1029:1034	arg1	digestion					1036:1044	enzyme digestion	1029:1044	enzyme digestion	1029:1044	In addition, when PLA2 was conducted enzyme digestion by MA3, the reactivity between PLA2 and allergic patients' sera diminished.
37331167	5	17	theme	α-1,3	784:788	arg1	mannose					790:796	α-1,3 mannose	784:796	α-1,3 mannose on HRP	784:803	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	4	18	theme	horseradish	673:683	arg1	peroxidase					685:694	allergen horseradish peroxidase	664:694	allergen horseradish peroxidase (HRP)	664:700	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	4	18	theme	horseradish	673:683	arg1	HRP					697:699	HRP	697:699	HRP	697:699	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	8	19	theme	glycan	1197:1202	arg1	epitope					1212:1218	glycan related epitope	1197:1218	glycan related epitope	1197:1218	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	8	20	theme	α-1,3	1154:1158	arg1	mannose					1160:1166	α-1,3 mannose	1154:1166	α-1,3 mannose	1154:1166	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	8	20	theme	α-1,3	1154:1158	arg1	component					1184:1192	an critical component	1172:1192	an critical component of glycan related epitope	1172:1218	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	7	21	theme	allergic	1086:1093	arg1	patients					1095:1102	allergic patients'	1086:1103	allergic patients' sera	1086:1108	In addition, when PLA2 was conducted enzyme digestion by MA3, the reactivity between PLA2 and allergic patients' sera diminished.
37331167	3	22	theme	glycoprotein	594:605	arg1	mannosidase					613:623	a glycoprotein α-1,3 mannosidase	592:623	a glycoprotein α-1,3 mannosidase	592:623	Through functional genomic analysis, we identified a glycoprotein α-1,3 mannosidase and named it MA3.
37331167	1	23	theme	insect	311:316	arg1	glycoproteins					318:330	insect glycoproteins	311:330	insect glycoproteins	311:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	1	24	from	glycoproteins	318:330	arg1	pentasaccharide					280:294	core pentasaccharide	275:294	core pentasaccharide from plant and insect glycoproteins	275:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	2	25	theme	useful	350:355	arg1	Mannosidase					333:343	Mannosidase	333:343	Mannosidase	333:343	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	2	25	theme	useful	350:355	arg1	tool					357:360	a useful tool	348:360	a useful tool for characterization	348:381	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	3	26	dep	it	635:636	arg1	MA3					638:640	MA3	638:640	it MA3	635:640	Through functional genomic analysis, we identified a glycoprotein α-1,3 mannosidase and named it MA3.
37331167	5	27	theme	anti-core	833:841	arg1	antibody					861:868	anti-core xylose polyclonal antibody	833:868	anti-core xylose polyclonal antibody	833:868	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	1	28	from	plant	301:305	arg1	pentasaccharide					280:294	core pentasaccharide	275:294	core pentasaccharide from plant and insect glycoproteins	275:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	5	29	theme	HRP	824:826	arg1	reactivity					810:819	the reactivity	806:819	the reactivity of HRP with anti-core xylose polyclonal antibody	806:868	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	3	30	theme	α-1,3	607:611	arg1	mannosidase					613:623	a glycoprotein α-1,3 mannosidase	592:623	a glycoprotein α-1,3 mannosidase	592:623	Through functional genomic analysis, we identified a glycoprotein α-1,3 mannosidase and named it MA3.
37331167	4	31	used	used	646:649	arg2	We					643:644	We	643:644	We	643:644	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	4	32	theme	phospholipase	706:718	arg1	PLA2					724:727	PLA2	724:727	PLA2	724:727	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	4	32	theme	phospholipase	706:718	arg1	A2					720:721	phospholipase A2	706:721	phospholipase A2 (PLA2)	706:728	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	1	33	theme	core	244:247	arg1	xylose					249:254	core xylose	244:254	core xylose	244:254	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	0	34	theme	α-1,3	42:46	arg1	mannosidase					48:58	an α-1,3 mannosidase	39:58	an α-1,3 mannosidase from Elizabethkingia meningoseptica	39:94	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	35	theme	cross-reactive	160:173	arg1	carbohydratedeterminant					175:197	cross-reactive carbohydratedeterminant	160:197	cross-reactive carbohydratedeterminant	160:197	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	4	36	theme	allergen	664:671	arg1	peroxidase					685:694	allergen horseradish peroxidase	664:694	allergen horseradish peroxidase (HRP)	664:700	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	4	36	theme	allergen	664:671	arg1	HRP					697:699	HRP	697:699	HRP	697:699	We used MA3 to treat allergen horseradish peroxidase (HRP) and phospholipase A2 (PLA2) separately.
37331167	2	37	theme	related	443:449	arg1	epitope					451:457	glycan related epitope	436:457	glycan related epitope	436:457	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	2	38	theme	core	499:502	arg1	xylose					504:509	core xylose	499:509	core xylose	499:509	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	0	39	from	meningoseptica	81:94	arg1	characterization					19:34	characterization	19:34	characterization	19:34	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	39	from	meningoseptica	81:94	arg1	mannosidase					48:58	an α-1,3 mannosidase	39:58	an α-1,3 mannosidase from Elizabethkingia meningoseptica	39:94	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	39	from	meningoseptica	81:94	arg1	Identification					0:13	Identification	0:13	Identification	0:13	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	39	from	meningoseptica	81:94	arg1	impact					126:131	its potential attenuation impact	100:131	its potential attenuation impact on allergy	100:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	8	40	theme	epitope	1212:1218	arg1	mannose					1160:1166	α-1,3 mannose	1154:1166	α-1,3 mannose	1154:1166	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	8	40	theme	epitope	1212:1218	arg1	component					1184:1192	an critical component	1172:1192	an critical component of glycan related epitope	1172:1218	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	1	41	gly	glycoproteins	318:330	arg1	glycoproteins					318:330	insect glycoproteins	311:330	insect glycoproteins	311:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	2	42	theme	glycan	436:441	arg1	epitope					451:457	glycan related epitope	436:457	glycan related epitope	436:457	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	6	43	theme	polyclonal	951:960	arg1	antibody					962:969	anti-core fucose polyclonal antibody	934:969	anti-core fucose polyclonal antibody	934:969	And the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody decreased partially.
37331167	0	44	theme	mannosidase	48:58	arg1	characterization					19:34	characterization	19:34	characterization	19:34	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	44	theme	mannosidase	48:58	arg1	Identification					0:13	Identification	0:13	Identification	0:13	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	44	theme	mannosidase	48:58	arg1	impact					126:131	its potential attenuation impact	100:131	its potential attenuation impact on allergy	100:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	6	45	theme	fucose	944:949	arg1	antibody					962:969	anti-core fucose polyclonal antibody	934:969	anti-core fucose polyclonal antibody	934:969	And the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody decreased partially.
37331167	3	46	gly	glycoprotein	594:605	arg1	glycoprotein					594:605	a glycoprotein α-1,3 mannosidase	592:623	a glycoprotein α-1,3 mannosidase	592:623	Through functional genomic analysis, we identified a glycoprotein α-1,3 mannosidase and named it MA3.
37331167	6	47	theme	anti-core	934:942	arg1	antibody					962:969	anti-core fucose polyclonal antibody	934:969	anti-core fucose polyclonal antibody	934:969	And the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody decreased partially.
37331167	0	48	from	impact	126:131	arg1	allergy					136:142	allergy	136:142	allergy	136:142	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	0	48	from	impact	126:131	arg1	meningoseptica					81:94	Elizabethkingia meningoseptica	65:94	Elizabethkingia meningoseptica	65:94	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	1	49	dep	xylose	249:254	arg1	the					240:242	the	240:242	the	240:242	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	2	50	dep	tool	357:360	arg1	role					387:390	the role	383:390	the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved	383:538	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	5	51	with	reactivity	810:819	arg1	antibody					861:868	anti-core xylose polyclonal antibody	833:868	anti-core xylose polyclonal antibody	833:868	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	1	52	theme	core	260:263	arg1	fucose					265:270	core fucose	260:270	core fucose	260:270	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	1	53	from	fucose	265:270	arg1	pentasaccharide					280:294	core pentasaccharide	275:294	core pentasaccharide from plant and insect glycoproteins	275:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	1	54	from	xylose	249:254	arg1	pentasaccharide					280:294	core pentasaccharide	275:294	core pentasaccharide from plant and insect glycoproteins	275:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
37331167	6	55	with	reactivity	898:907	arg1	antibody					962:969	anti-core fucose polyclonal antibody	934:969	anti-core fucose polyclonal antibody	934:969	And the reactivity of MA3-treated PLA2 with anti-core fucose polyclonal antibody decreased partially.
37331167	3	56	theme	functional	549:558	arg1	analysis					568:575	functional genomic analysis	549:575	functional genomic analysis	549:575	Through functional genomic analysis, we identified a glycoprotein α-1,3 mannosidase and named it MA3.
37331167	5	57	theme	xylose	843:848	arg1	antibody					861:868	anti-core xylose polyclonal antibody	833:868	anti-core xylose polyclonal antibody	833:868	The results showed that after MA3 removed α-1,3 mannose on HRP, the reactivity of HRP with anti-core xylose polyclonal antibody almost disappeared.
37331167	2	58	theme	mannose	406:412	arg1	role					387:390	the role	383:390	the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved	383:538	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	0	59	theme	Elizabethkingia	65:79	arg1	meningoseptica					81:94	Elizabethkingia meningoseptica	65:94	Elizabethkingia meningoseptica	65:94	Identification and characterization of an α-1,3 mannosidase from Elizabethkingia meningoseptica and its potential attenuation impact on allergy associated with cross-reactive carbohydratedeterminant.
37331167	8	60	theme	related	1204:1210	arg1	epitope					1212:1218	glycan related epitope	1197:1218	glycan related epitope	1197:1218	These results demonstrated that α-1,3 mannose was an critical component of glycan related epitope.
37331167	2	61	theme	α-1,3	400:404	arg1	mannose					406:412	core α-1,3 mannose	395:412	core α-1,3 mannose	395:412	Mannosidase is a useful tool for characterization the role of core α-1,3 mannose in the composition of glycan related epitope, especially for those epitopes in which core xylose and core fucose are involved.
37331167	1	62	theme	core	275:278	arg1	pentasaccharide					280:294	core pentasaccharide	275:294	core pentasaccharide from plant and insect glycoproteins	275:330	Core α-1,3 mannose is structurally near the core xylose and core fucose on core pentasaccharide from plant and insect glycoproteins.
36996950	3	0	dep	Fourier	556:562	arg1	transform					564:572	transform	564:572	transform infrared spectroscopy characteristics of VVP	564:617	In addition, the reducing sugar, uronic acid, monosaccharide composition and Fourier transform infrared spectroscopy characteristics of VVP did not change significantly, which indicate that saliva-gastrointestinal could not digest VVP.
36996950	1	1	theme	volvacea	248:255	arg1	polysaccharide					257:270	Volvariella volvacea polysaccharide	236:270	Volvariella volvacea polysaccharide (VVP)	236:276	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	1	1	theme	volvacea	248:255	arg1	VVP					273:275	VVP	273:275	VVP	273:275	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	0	2	theme	polysaccharides	66:80	arg1	digestion					30:38	in vitro simulated digestion	11:38	in vitro simulated digestion	11:38	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	2	theme	polysaccharides	66:80	arg1	fermentation					50:61	fecal fermentation	44:61	fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea)	44:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	7	3	contain	has	1298:1300	arg1	VVP					1294:1296	VVP	1294:1296	VVP	1294:1296	Therefore, VVP has the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment.
36996950	7	3	contain	has	1298:1300	arg2	potential					1306:1314	the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment	1302:1423	the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment	1302:1423	Therefore, VVP has the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment.
36996950	0	4	theme	gut	169:171	arg1	microbiota					173:182	human gut microbiota	163:182	human gut microbiota	163:182	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	3	5	theme	reducing	496:503	arg1	sugar					505:509	the reducing sugar	492:509	the reducing sugar	492:509	In addition, the reducing sugar, uronic acid, monosaccharide composition and Fourier transform infrared spectroscopy characteristics of VVP did not change significantly, which indicate that saliva-gastrointestinal could not digest VVP.
36996950	1	6	theme	polysaccharide	257:270	arg1	behavior					224:231	the fermentation and digestion behavior	193:231	behavior	224:231	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	0	7	from	Effects	0:6	arg1	properties					148:157	its physicochemical properties	128:157	its physicochemical properties	128:157	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	7	from	Effects	0:6	arg1	microbiota					173:182	human gut microbiota	163:182	human gut microbiota	163:182	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	7	8	theme	microbial	1403:1411	arg1	environment					1413:1423	the intestinal microbial environment	1388:1423	the intestinal microbial environment	1388:1423	Therefore, VVP has the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment.
36996950	5	9	theme	short-chain	979:989	arg1	SCFAs					1004:1008	SCFAs	1004:1008	SCFAs	1004:1008	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	5	9	theme	short-chain	979:989	arg1	acids					997:1001	different short-chain fatty acids	969:1001	different short-chain fatty acids (SCFAs)	969:1009	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	5	10	theme	different	969:977	arg1	SCFAs					1004:1008	SCFAs	1004:1008	SCFAs	1004:1008	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	5	10	theme	different	969:977	arg1	acids					997:1001	different short-chain fatty acids	969:1001	different short-chain fatty acids (SCFAs)	969:1009	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	0	11	theme	straw	87:91	arg1	mushroom					93:100	straw mushroom	87:100	straw mushroom (Volvariella volvacea)	87:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	11	theme	straw	87:91	arg1	volvacea					115:122	Volvariella volvacea	103:122	Volvariella volvacea	103:122	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	5	12	theme	fatty	991:995	arg1	SCFAs					1004:1008	SCFAs	1004:1008	SCFAs	1004:1008	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	5	12	theme	fatty	991:995	arg1	acids					997:1001	different short-chain fatty acids	969:1001	different short-chain fatty acids (SCFAs)	969:1009	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	6	13	theme	unfavorable	1232:1242	arg1	bacteria					1244:1251	unfavorable bacteria	1232:1251	unfavorable bacteria such as Escherichia-shigella	1232:1280	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	6	13	theme	unfavorable	1232:1242	arg1	Escherichia-shigella					1261:1280	Escherichia-shigella	1261:1280	Escherichia-shigella	1261:1280	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	3	14	theme	monosaccharide	525:538	arg1	composition					540:550	monosaccharide composition	525:550	monosaccharide composition	525:550	In addition, the reducing sugar, uronic acid, monosaccharide composition and Fourier transform infrared spectroscopy characteristics of VVP did not change significantly, which indicate that saliva-gastrointestinal could not digest VVP.
36996950	0	15	theme	Volvariella	103:113	arg1	mushroom					93:100	straw mushroom	87:100	straw mushroom (Volvariella volvacea)	87:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	15	theme	Volvariella	103:113	arg1	volvacea					115:122	Volvariella volvacea	103:122	Volvariella volvacea	103:122	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	3	16	theme	uronic	512:517	arg1	acid					519:522	uronic acid	512:522	uronic acid	512:522	In addition, the reducing sugar, uronic acid, monosaccharide composition and Fourier transform infrared spectroscopy characteristics of VVP did not change significantly, which indicate that saliva-gastrointestinal could not digest VVP.
36996950	5	17	theme	composition	863:873	arg1	ratios					834:839	the molar ratios	824:839	the molar ratios of the monosaccharide composition	824:873	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	0	18	from	digestion	30:38	arg1	mushroom					93:100	straw mushroom	87:100	straw mushroom (Volvariella volvacea)	87:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	18	from	digestion	30:38	arg1	volvacea					115:122	Volvariella volvacea	103:122	Volvariella volvacea	103:122	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	4	19	theme	molecular	783:791	arg1	weight					793:798	its molecular weight	779:798	its molecular weight	779:798	However, 48 h of fecal fermentation of VVP dramatically reduced its molecular weight by 40.4 %.
36996950	2	20	theme	gastrointestinal	396:411	arg1	digestion					413:421	the simulated salivary gastrointestinal digestion	373:421	the simulated salivary gastrointestinal digestion	373:421	The results revealed that succeeding the simulated salivary gastrointestinal digestion, the molecular weight of VVP was reduced by only 8.9 %.
36996950	1	21	dep	in	304:305	arg1	vitro					307:311	vitro	307:311	vitro	307:311	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	2	22	theme	salivary	387:394	arg1	digestion					413:421	the simulated salivary gastrointestinal digestion	373:421	the simulated salivary gastrointestinal digestion	373:421	The results revealed that succeeding the simulated salivary gastrointestinal digestion, the molecular weight of VVP was reduced by only 8.9 %.
36996950	4	23	theme	fermentation	738:749	arg1	48 h					724:727	48 h	724:727	48 h of fecal fermentation of VVP	724:756	However, 48 h of fecal fermentation of VVP dramatically reduced its molecular weight by 40.4 %.
36996950	7	24	theme	intestinal	1392:1401	arg1	environment					1413:1423	the intestinal microbial environment	1388:1423	the intestinal microbial environment	1388:1423	Therefore, VVP has the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment.
36996950	2	25	theme	simulated	377:385	arg1	digestion					413:421	the simulated salivary gastrointestinal digestion	373:421	the simulated salivary gastrointestinal digestion	373:421	The results revealed that succeeding the simulated salivary gastrointestinal digestion, the molecular weight of VVP was reduced by only 8.9 %.
36996950	2	26	theme	VVP	448:450	arg1	weight					438:443	the molecular weight	424:443	the molecular weight of VVP	424:450	The results revealed that succeeding the simulated salivary gastrointestinal digestion, the molecular weight of VVP was reduced by only 8.9 %.
36996950	0	27	theme	in	11:12	arg1	digestion					30:38	in vitro simulated digestion	11:38	in vitro simulated digestion	11:38	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	6	28	dep	raised	1036:1041	arg1	whereas					1197:1203	whereas	1197:1203	whereas	1197:1203	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	4	29	theme	VVP	754:756	arg1	fermentation					738:749	fecal fermentation	732:749	fecal fermentation of VVP	732:756	However, 48 h of fecal fermentation of VVP dramatically reduced its molecular weight by 40.4 %.
36996950	2	30	theme	molecular	428:436	arg1	weight					438:443	the molecular weight	424:443	the molecular weight of VVP	424:450	The results revealed that succeeding the simulated salivary gastrointestinal digestion, the molecular weight of VVP was reduced by only 8.9 %.
36996950	0	31	theme	digestion	30:38	arg1	Effects					0:6	Effects	0:6	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.	0:183	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	8	32	theme	Volvariella	1493:1503	arg1	food					1538:1541	a healthy functional food	1517:1541	a healthy functional food	1517:1541	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	8	32	theme	Volvariella	1493:1503	arg1	volvacea					1505:1512	Volvariella volvacea	1493:1512	Volvariella volvacea	1493:1512	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	6	33	theme	Bacteroidetes	1061:1073	arg1	proportion					1047:1056	the proportion	1043:1056	the proportion of Bacteroidetes to Firmicutes	1043:1087	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	1	34	theme	fermentation	197:208	arg1	behavior					224:231	the fermentation and digestion behavior	193:231	behavior	224:231	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	0	35	theme	simulated	20:28	arg1	digestion					30:38	in vitro simulated digestion	11:38	in vitro simulated digestion	11:38	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	5	36	theme	monosaccharide	848:861	arg1	composition					863:873	the monosaccharide composition	844:873	the monosaccharide composition	844:873	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	0	37	theme	fecal	44:48	arg1	fermentation					50:61	fecal fermentation	44:61	fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea)	44:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	1	38	theme	in	304:305	arg1	experiment					324:333	the in vitro simulation experiment	300:333	the in vitro simulation experiment	300:333	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	0	39	from	fermentation	50:61	arg1	mushroom					93:100	straw mushroom	87:100	straw mushroom (Volvariella volvacea)	87:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	39	from	fermentation	50:61	arg1	volvacea					115:122	Volvariella volvacea	103:122	Volvariella volvacea	103:122	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	3	40	theme	infrared	574:581	arg1	spectroscopy					583:594	infrared spectroscopy characteristics	574:610	infrared spectroscopy characteristics	574:610	In addition, the reducing sugar, uronic acid, monosaccharide composition and Fourier transform infrared spectroscopy characteristics of VVP did not change significantly, which indicate that saliva-gastrointestinal could not digest VVP.
36996950	5	41	theme	VVP	922:924	arg1	degradation					907:917	the degradation	903:917	the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs)	903:1009	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	8	42	theme	theoretical	1451:1461	arg1	foundation					1463:1472	a theoretical foundation	1449:1472	a theoretical foundation to further develop Volvariella volvacea as a healthy functional food	1449:1541	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	0	43	theme	physicochemical	132:146	arg1	properties					148:157	its physicochemical properties	128:157	its physicochemical properties	128:157	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	8	44	theme	functional	1527:1536	arg1	food					1538:1541	a healthy functional food	1517:1541	a healthy functional food	1517:1541	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	8	44	theme	functional	1527:1536	arg1	volvacea					1505:1512	Volvariella volvacea	1493:1512	Volvariella volvacea	1493:1512	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	6	45	theme	bacteria	1139:1146	arg1	proliferation					1106:1118	the proliferation	1102:1118	the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium	1102:1194	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	1	46	theme	simulation	313:322	arg1	experiment					324:333	the in vitro simulation experiment	300:333	the in vitro simulation experiment	300:333	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	0	47	theme	human	163:167	arg1	microbiota					173:182	human gut microbiota	163:182	human gut microbiota	163:182	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	8	48	theme	healthy	1519:1525	arg1	food					1538:1541	a healthy functional food	1517:1541	a healthy functional food	1517:1541	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	8	48	theme	healthy	1519:1525	arg1	volvacea					1505:1512	Volvariella volvacea	1493:1512	Volvariella volvacea	1493:1512	These findings provide a theoretical foundation to further develop Volvariella volvacea as a healthy functional food.
36996950	6	49	theme	bacteria	1244:1251	arg1	growth					1222:1227	the growth	1218:1227	the growth of unfavorable bacteria such as Escherichia-shigella	1218:1280	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	4	50	theme	fecal	732:736	arg1	fermentation					738:749	fecal fermentation	732:749	fecal fermentation of VVP	732:756	However, 48 h of fecal fermentation of VVP dramatically reduced its molecular weight by 40.4 %.
36996950	1	51	theme	digestion	214:222	arg1	behavior					224:231	the fermentation and digestion behavior	193:231	behavior	224:231	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	0	52	from	mushroom	93:100	arg1	polysaccharides					66:80	polysaccharides	66:80	polysaccharides from straw mushroom (Volvariella volvacea)	66:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	52	from	mushroom	93:100	arg1	digestion					30:38	in vitro simulated digestion	11:38	in vitro simulated digestion	11:38	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	52	from	mushroom	93:100	arg1	fermentation					50:61	fecal fermentation	44:61	fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea)	44:123	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	0	53	dep	in	11:12	arg1	vitro					14:18	vitro	14:18	vitro	14:18	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	6	54	theme	beneficial	1128:1137	arg1	Phascolarctobacterium					1174:1194	Phascolarctobacterium	1174:1194	Phascolarctobacterium	1174:1194	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	6	54	theme	beneficial	1128:1137	arg1	Bacteroides					1158:1168	Bacteroides	1158:1168	Bacteroides	1158:1168	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	6	54	theme	beneficial	1128:1137	arg1	bacteria					1139:1146	some beneficial bacteria	1123:1146	some beneficial bacteria including Bacteroides and Phascolarctobacterium	1123:1194	Meanwhile, the VVP also raised the proportion of Bacteroidetes to Firmicutes and promoted the proliferation of some beneficial bacteria including Bacteroides and Phascolarctobacterium, whereas it inhibited the growth of unfavorable bacteria such as Escherichia-shigella.
36996950	7	55	theme	positive	1326:1333	arg1	influence					1335:1343	a positive influence	1324:1343	a positive influence	1324:1343	Therefore, VVP has the potential to have a positive influence on health and hinder diseases by improving the intestinal microbial environment.
36996950	3	56	dep	spectroscopy	583:594	arg1	characteristics					596:610	characteristics	596:610	infrared spectroscopy characteristics	574:610	In addition, the reducing sugar, uronic acid, monosaccharide composition and Fourier transform infrared spectroscopy characteristics of VVP did not change significantly, which indicate that saliva-gastrointestinal could not digest VVP.
36996950	0	57	theme	fermentation	50:61	arg1	Effects					0:6	Effects	0:6	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.	0:183	Effects of in vitro simulated digestion and fecal fermentation of polysaccharides from straw mushroom (Volvariella volvacea) on its physicochemical properties and human gut microbiota.
36996950	5	58	theme	molar	828:832	arg1	ratios					834:839	the molar ratios	824:839	the molar ratios of the monosaccharide composition	824:873	Furthermore, the molar ratios of the monosaccharide composition altered considerably due to the degradation of VVP by microorganisms and the metabolysis into different short-chain fatty acids (SCFAs).
36996950	1	59	theme	Volvariella	236:246	arg1	polysaccharide					257:270	Volvariella volvacea polysaccharide	236:270	Volvariella volvacea polysaccharide (VVP)	236:276	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
36996950	1	59	theme	Volvariella	236:246	arg1	VVP					273:275	VVP	273:275	VVP	273:275	Herein, the fermentation and digestion behavior of Volvariella volvacea polysaccharide (VVP) were examined through the in vitro simulation experiment.
35483514	0	0	theme	Euganean	94:101	arg1	muds					115:118	Euganean therapeutic muds	94:118	Euganean therapeutic muds	94:118	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	4	1	from	percentage	615:624	arg1	polymers					652:659	the polymers	648:659	the polymers	648:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	0	2	theme	anti-inflammatory	8:24	arg1	effects					42:48	In vivo anti-inflammatory and antioxidant effects	0:48	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides	0:77	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	4	3	theme	glucose	596:602	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	3	theme	glucose	596:602	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	5	4	theme	model	761:765	arg1	organism					767:774	the model organism	757:774	the model organism zebrafish (Danio rerio)	757:798	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	4	5	from	presence	537:544	arg1	polymers					652:659	the polymers	648:659	the polymers	648:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	7	6	theme	copper	975:980	arg1	sulfate					982:988	copper sulfate	975:988	copper sulfate	975:988	Inflammatory state was induced chemically with copper sulfate, or through tail fin amputation procedure and UVB exposure.
35483514	1	7	theme	Euganean	169:176	arg1	spas					157:160	spas	157:160	spas of the Euganean Thermal District (Italy)	157:201	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	2	8	from	embedded	317:324	arg1	matrix					347:352	a polysaccharidic matrix	329:352	a polysaccharidic matrix	329:352	Its production involves the growth of a specific microbiota embedded in a polysaccharidic matrix.
35483514	6	9	theme	effects	900:906	arg1	lack					886:889	the lack	882:889	the lack of toxic effects	882:906	The anti-inflammatory and antioxidant activities were evaluated after confirming the lack of toxic effects during development.
35483514	6	10	theme	toxic	894:898	arg1	effects					900:906	toxic effects	894:906	toxic effects	894:906	The anti-inflammatory and antioxidant activities were evaluated after confirming the lack of toxic effects during development.
35483514	0	11	theme	therapeutic	103:113	arg1	muds					115:118	Euganean therapeutic muds	94:118	Euganean therapeutic muds	94:118	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	4	12	theme	monosaccharidic	489:503	arg1	analysis					517:524	The monosaccharidic composition analysis	485:524	The monosaccharidic composition analysis	485:524	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	2	13	from	matrix	347:352	arg1	embedded					317:324	embedded	317:324	embedded	317:324	Its production involves the growth of a specific microbiota embedded in a polysaccharidic matrix.
35483514	5	14	from	involvement	678:688	arg1	efficacy					709:716	the therapeutic efficacy	693:716	the therapeutic efficacy of the mud	693:727	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	8	15	theme	inflammatory	1064:1075	arg1	condition					1077:1085	inflammatory condition	1064:1085	inflammatory condition	1064:1085	Recovery from inflammatory condition after exposure to M-PS was always observed with specific morphometric analyses, and further supported by qPCR.
35483514	4	16	theme	composition	505:515	arg1	analysis					517:524	The monosaccharidic composition analysis	485:524	The monosaccharidic composition analysis	485:524	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	5	17	dep	organism	767:774	arg1	zebrafish					776:784	zebrafish	776:784	the model organism zebrafish (Danio rerio)	757:798	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	5	17	dep	organism	767:774	arg1	rerio					793:797	Danio rerio	787:797	Danio rerio	787:797	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	9	18	theme	inflammatory	1220:1231	arg1	response					1254:1261	the inflammatory and oxidative stress response	1216:1261	the inflammatory and oxidative stress response	1216:1261	Genes linked with the inflammatory and oxidative stress response were investigated confirming the M-PS treatment's efficacy.
35483514	2	19	theme	embedded	317:324	arg1	microbiota					306:315	a specific microbiota	295:315	a specific microbiota embedded in a polysaccharidic matrix	295:352	Its production involves the growth of a specific microbiota embedded in a polysaccharidic matrix.
35483514	0	20	theme	In	0:1	arg1	effects					42:48	In vivo anti-inflammatory and antioxidant effects	0:48	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides	0:77	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	4	21	theme	xylose	577:582	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	21	theme	xylose	577:582	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	7	22	theme	Inflammatory	928:939	arg1	state					941:945	Inflammatory state	928:945	Inflammatory state	928:945	Inflammatory state was induced chemically with copper sulfate, or through tail fin amputation procedure and UVB exposure.
35483514	2	23	theme	microbiota	306:315	arg1	growth					285:290	the growth	281:290	the growth of a specific microbiota embedded in a polysaccharidic matrix	281:352	Its production involves the growth of a specific microbiota embedded in a polysaccharidic matrix.
35483514	4	24	from	polymers	652:659	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	24	from	polymers	652:659	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	3	25	theme	resident	432:439	arg1	microorganisms					441:454	the resident microorganisms	428:454	the resident microorganisms	428:454	Polysaccharides (Microbial-PolySaccharides, M-PS) released in the mud by the resident microorganisms were extracted and analyzed.
35483514	9	26	theme	oxidative	1237:1245	arg1	response					1254:1261	the inflammatory and oxidative stress response	1216:1261	the inflammatory and oxidative stress response	1216:1261	Genes linked with the inflammatory and oxidative stress response were investigated confirming the M-PS treatment's efficacy.
35483514	2	27	theme	specific	297:304	arg1	microbiota					306:315	a specific microbiota	295:315	a specific microbiota embedded in a polysaccharidic matrix	295:352	Its production involves the growth of a specific microbiota embedded in a polysaccharidic matrix.
35483514	1	28	dep	Euganean	169:176	arg1	Italy					196:200	Italy	196:200	Italy	196:200	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	1	28	dep	Euganean	169:176	arg1	District					186:193	District	186:193	District	186:193	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	4	29	theme	ribose	585:590	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	29	theme	ribose	585:590	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	9	30	theme	stress	1247:1252	arg1	response					1254:1261	the inflammatory and oxidative stress response	1216:1261	the inflammatory and oxidative stress response	1216:1261	Genes linked with the inflammatory and oxidative stress response were investigated confirming the M-PS treatment's efficacy.
35483514	1	31	theme	Therapeutic	121:131	arg1	mud					141:143	Therapeutic thermal mud	121:143	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy)	121:201	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	1	31	theme	Therapeutic	121:131	arg1	treatment					216:224	a treatment	214:224	a treatment for arthro-rheumatic diseases	214:254	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	4	32	theme	groups	638:643	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	32	theme	groups	638:643	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	33	from	groups	638:643	arg1	polymers					652:659	the polymers	648:659	the polymers	648:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	0	34	theme	antioxidant	30:40	arg1	effects					42:48	In vivo anti-inflammatory and antioxidant effects	0:48	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides	0:77	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	4	35	theme	acid	562:565	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	35	theme	acid	562:565	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	5	36	theme	mud	725:727	arg1	efficacy					709:716	the therapeutic efficacy	693:716	the therapeutic efficacy of the mud	693:727	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	1	37	used	used	206:209	arg2	treatment					216:224	a treatment	214:224	a treatment for arthro-rheumatic diseases	214:254	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	1	37	used	used	206:209	arg2	mud					141:143	Therapeutic thermal mud	121:143	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy)	121:201	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	0	38	theme	microbial	53:61	arg1	polysaccharides					63:77	microbial polysaccharides	53:77	microbial polysaccharides	53:77	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	4	39	theme	galacturonic	549:560	arg1	acid					562:565	galacturonic acid	549:565	galacturonic acid	549:565	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	8	40	theme	morphometric	1144:1155	arg1	analyses					1157:1164	specific morphometric analyses	1135:1164	specific morphometric analyses	1135:1164	Recovery from inflammatory condition after exposure to M-PS was always observed with specific morphometric analyses, and further supported by qPCR.
35483514	8	41	theme	specific	1135:1142	arg1	analyses					1157:1164	specific morphometric analyses	1135:1164	specific morphometric analyses	1135:1164	Recovery from inflammatory condition after exposure to M-PS was always observed with specific morphometric analyses, and further supported by qPCR.
35483514	1	42	theme	thermal	133:139	arg1	mud					141:143	Therapeutic thermal mud	121:143	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy)	121:201	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	1	42	theme	thermal	133:139	arg1	treatment					216:224	a treatment	214:224	a treatment for arthro-rheumatic diseases	214:254	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
35483514	5	43	theme	Danio	787:791	arg1	zebrafish					776:784	zebrafish	776:784	the model organism zebrafish (Danio rerio)	757:798	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	5	43	theme	Danio	787:791	arg1	rerio					793:797	Danio rerio	787:797	Danio rerio	787:797	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	4	44	theme	mannose	568:574	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	4	44	theme	mannose	568:574	arg1	presence					537:544	the presence	533:544	the presence of galacturonic acid, mannose, xylose, ribose and glucose	533:602	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	3	45	dep	Polysaccharides	355:369	arg1	M-PS					399:402	M-PS	399:402	M-PS	399:402	Polysaccharides (Microbial-PolySaccharides, M-PS) released in the mud by the resident microorganisms were extracted and analyzed.
35483514	3	45	dep	Polysaccharides	355:369	arg1	Microbial-PolySaccharides					372:396	Microbial-PolySaccharides	372:396	Microbial-PolySaccharides	372:396	Polysaccharides (Microbial-PolySaccharides, M-PS) released in the mud by the resident microorganisms were extracted and analyzed.
35483514	7	46	theme	fin	1007:1009	arg1	procedure					1022:1030	tail fin amputation procedure	1002:1030	tail fin amputation procedure	1002:1030	Inflammatory state was induced chemically with copper sulfate, or through tail fin amputation procedure and UVB exposure.
35483514	2	47	theme	polysaccharidic	331:345	arg1	matrix					347:352	a polysaccharidic matrix	329:352	a polysaccharidic matrix	329:352	Its production involves the growth of a specific microbiota embedded in a polysaccharidic matrix.
35483514	7	48	theme	UVB	1036:1038	arg1	exposure					1040:1047	UVB exposure	1036:1047	UVB exposure	1036:1047	Inflammatory state was induced chemically with copper sulfate, or through tail fin amputation procedure and UVB exposure.
35483514	6	49	theme	antioxidant	827:837	arg1	activities					839:848	The anti-inflammatory and antioxidant activities	801:848	The anti-inflammatory and antioxidant activities	801:848	The anti-inflammatory and antioxidant activities were evaluated after confirming the lack of toxic effects during development.
35483514	7	50	theme	amputation	1011:1020	arg1	procedure					1022:1030	tail fin amputation procedure	1002:1030	tail fin amputation procedure	1002:1030	Inflammatory state was induced chemically with copper sulfate, or through tail fin amputation procedure and UVB exposure.
35483514	5	51	theme	therapeutic	697:707	arg1	efficacy					709:716	the therapeutic efficacy	693:716	the therapeutic efficacy of the mud	693:727	To assess their involvement in the therapeutic efficacy of the mud, the M-PS were tested using the model organism zebrafish (Danio rerio).
35483514	9	52	theme	M-PS	1296:1299	arg1	efficacy					1313:1320	the M-PS treatment's efficacy	1292:1320	the M-PS treatment's efficacy	1292:1320	Genes linked with the inflammatory and oxidative stress response were investigated confirming the M-PS treatment's efficacy.
35483514	4	53	theme	high	610:613	arg1	percentage					615:624	a high percentage	608:624	a high percentage of sulfated groups in the polymers	608:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	6	54	theme	anti-inflammatory	805:821	arg1	activities					839:848	The anti-inflammatory and antioxidant activities	801:848	The anti-inflammatory and antioxidant activities	801:848	The anti-inflammatory and antioxidant activities were evaluated after confirming the lack of toxic effects during development.
35483514	7	55	theme	tail	1002:1005	arg1	procedure					1022:1030	tail fin amputation procedure	1002:1030	tail fin amputation procedure	1002:1030	Inflammatory state was induced chemically with copper sulfate, or through tail fin amputation procedure and UVB exposure.
35483514	4	56	theme	sulfated	629:636	arg1	groups					638:643	sulfated groups	629:643	sulfated groups in the polymers	629:659	The monosaccharidic composition analysis showed the presence of galacturonic acid, mannose, xylose, ribose and glucose and a high percentage of sulfated groups in the polymers.
35483514	0	57	theme	polysaccharides	63:77	arg1	effects					42:48	In vivo anti-inflammatory and antioxidant effects	0:48	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides	0:77	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	0	58	dep	In	0:1	arg1	vivo					3:6	vivo	3:6	vivo	3:6	In vivo anti-inflammatory and antioxidant effects of microbial polysaccharides extracted from Euganean therapeutic muds.
35483514	8	59	from	condition	1077:1085	arg1	Recovery					1050:1057	Recovery	1050:1057	Recovery from inflammatory condition after exposure to M-PS	1050:1108	Recovery from inflammatory condition after exposure to M-PS was always observed with specific morphometric analyses, and further supported by qPCR.
35483514	1	60	theme	arthro-rheumatic	230:245	arg1	diseases					247:254	arthro-rheumatic diseases	230:254	arthro-rheumatic diseases	230:254	Therapeutic thermal mud produced by spas of the Euganean Thermal District (Italy) is used as a treatment for arthro-rheumatic diseases.
36925243	6	0	theme	linked	1117:1122	arg1	segments					1124:1131	α-(1 → 6) linked segments	1107:1131	α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part	1107:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	4	1	theme	sequential	775:784	arg1	treatments					786:795	simultaneous or sequential treatments	759:795	simultaneous or sequential treatments	759:795	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	0	2	from	β-cyclodextrin	81:94	arg1	isomalto/malto-polysaccharides					45:74	isomalto/malto-polysaccharides	45:74	isomalto/malto-polysaccharides from β-cyclodextrin	45:94	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	0	2	from	β-cyclodextrin	81:94	arg1	synthesis					32:40	Cost-effective and controllable synthesis	0:40	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.	0:167	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	6	3	theme	linkage-type	1078:1089	arg1	distribution					1091:1102	different linkage-type distribution	1068:1102	different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part	1068:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	7	4	theme	non-reducing	1255:1266	arg1	end					1268:1270	the non-reducing end	1251:1270	the non-reducing end	1251:1270	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	8	5	theme	G4	1341:1342	arg1	Addition					1323:1330	Addition	1323:1330	Addition of G3 or G4 as specific acceptors	1323:1364	Addition of G3 or G4 as specific acceptors resulted in IMMPs exhibiting low polydispersity.
36925243	6	6	theme	different	1068:1076	arg1	distribution					1091:1102	different linkage-type distribution	1068:1102	different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part	1068:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	3	7	with	IMMPs	682:686	arg1	yield					703:707	a maximum yield	693:707	a maximum yield (16.19 %, w/w)	693:722	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	8	8	theme	low	1395:1397	arg1	polydispersity					1399:1412	low polydispersity	1395:1412	low polydispersity	1395:1412	Addition of G3 or G4 as specific acceptors resulted in IMMPs exhibiting low polydispersity.
36925243	0	9	theme	cyclodextrinase	118:132	arg1	action					108:113	combined action	99:113	combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB	99:166	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	1	10	attach	derived	208:214	arg1	maltoheptaose					252:264	maltoheptaose	252:264	maltoheptaose (G7)	252:269	Isomalto/malto-polysaccharides (IMMPs) derived from malto-oligosaccharides such as maltoheptaose (G7) are elongated non-branched gluco-oligosaccharides produced by 4,6-α-glucanotransferase (GtfB).
36925243	1	10	attach	derived	208:214	arg2	IMMPs					201:205	IMMPs	201:205	IMMPs	201:205	Isomalto/malto-polysaccharides (IMMPs) derived from malto-oligosaccharides such as maltoheptaose (G7) are elongated non-branched gluco-oligosaccharides produced by 4,6-α-glucanotransferase (GtfB).
36925243	1	10	attach	derived	208:214	arg2	Isomalto/malto-polysaccharides					169:198	Isomalto/malto-polysaccharides	169:198	Isomalto/malto-polysaccharides (IMMPs) derived from malto-oligosaccharides such as maltoheptaose (G7)	169:269	Isomalto/malto-polysaccharides (IMMPs) derived from malto-oligosaccharides such as maltoheptaose (G7) are elongated non-branched gluco-oligosaccharides produced by 4,6-α-glucanotransferase (GtfB).
36925243	1	10	attach	derived	208:214	arg1	malto-oligosaccharides					221:242	malto-oligosaccharides	221:242	malto-oligosaccharides such as maltoheptaose (G7)	221:269	Isomalto/malto-polysaccharides (IMMPs) derived from malto-oligosaccharides such as maltoheptaose (G7) are elongated non-branched gluco-oligosaccharides produced by 4,6-α-glucanotransferase (GtfB).
36925243	9	11	theme	IMMPs	1568:1572	arg1	DP					1562:1563	the average DP	1550:1563	the average DP of IMMPs	1550:1572	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	8	12	theme	specific	1347:1354	arg1	acceptors					1356:1364	specific acceptors	1347:1364	specific acceptors	1347:1364	Addition of G3 or G4 as specific acceptors resulted in IMMPs exhibiting low polydispersity.
36925243	7	13	theme	1 → 6	1224:1228	arg1	segments					1231:1238	α-(1 → 6) segments	1221:1238	α-(1 → 6) segments containing the non-reducing end	1221:1270	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	3	14	from	GtfB-ΔN	606:612	arg1	action					541:546	the combined action	528:546	the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121	528:649	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	4	15	theme	purified	729:736	arg1	IMMPs					738:742	The purified IMMPs	725:742	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq,	725:833	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	0	16	theme	4,6-α-glucanotransferase	138:161	arg1	action					108:113	combined action	99:113	combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB	99:166	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	7	17	theme	segments	1231:1238	arg1	%					1282:1282	56.76 %	1276:1282	56.76 % for IMMP-Sim	1276:1295	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	7	17	theme	segments	1231:1238	arg1	proportion					1207:1216	The proportion	1203:1216	The proportion of α-(1 → 6) segments containing the non-reducing end	1203:1270	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	0	18	dep	cyclodextrinase	118:132	arg1	GtfB					163:166	GtfB	163:166	GtfB	163:166	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	5	19	theme	G7	932:933	arg1	release					921:927	the release	917:927	the release of G7 and smaller malto-oligosaccharides by PpCD	917:976	By controlling the release of G7 and smaller malto-oligosaccharides by PpCD, IMMP-Seq was obtained of DP varying from 12.9 to 29.5.
36925243	3	20	theme	enzymatic	463:471	arg1	process					473:479	a cost-effective enzymatic process	446:479	a cost-effective enzymatic process for IMMPs synthesis	446:499	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	6	21	link	linked	1117:1122	arg1	segments					1124:1131	α-(1 → 6) linked segments	1107:1131	α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part	1107:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	9	22	theme	average	1554:1560	arg1	DP					1562:1563	the average DP	1550:1563	the average DP of IMMPs	1550:1572	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	7	23	theme	α-	1221:1222	arg1	segments					1231:1238	α-(1 → 6) segments	1221:1238	α-(1 → 6) segments containing the non-reducing end	1221:1270	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	6	24	theme	α-	1138:1139	arg1	segments					1148:1155	α-(1 → 4) segments	1138:1155	α-(1 → 4) segments embedded at the reducing end and middle part	1138:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	0	25	theme	Cost-effective	0:13	arg1	synthesis					32:40	Cost-effective and controllable synthesis	0:40	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.	0:167	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	6	26	theme	Enzymatic	1034:1042	arg1	fingerprinting					1044:1057	Enzymatic fingerprinting	1034:1057	Enzymatic fingerprinting	1034:1057	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	3	27	from	pacificus	585:593	arg1	action					541:546	the combined action	528:546	the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121	528:649	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	9	28	theme	substrate	1591:1599	arg1	composition					1601:1611	the substrate composition	1587:1611	the substrate composition	1587:1611	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	6	29	from	part	1197:1200	arg1	embedded					1157:1164	embedded	1157:1164	embedded	1157:1164	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	5	30	theme	smaller	939:945	arg1	malto-oligosaccharides					947:968	smaller malto-oligosaccharides	939:968	smaller malto-oligosaccharides	939:968	By controlling the release of G7 and smaller malto-oligosaccharides by PpCD, IMMP-Seq was obtained of DP varying from 12.9 to 29.5.
36925243	9	31	theme	novel	1450:1454	arg1	procedure					1420:1428	This procedure	1415:1428	This procedure	1415:1428	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	9	31	theme	novel	1450:1454	arg1	bioprocess					1456:1465	a novel bioprocess	1448:1465	a novel bioprocess that does not require costy high-purity malto-oligosaccharides	1448:1528	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	6	32	dep	segments	1148:1155	arg1	embedded					1157:1164	embedded	1157:1164	embedded	1157:1164	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	3	33	dep	yield	703:707	arg1	w/w					719:721	w/w	719:721	w/w	719:721	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	3	33	dep	yield	703:707	arg1	%					716:716	16.19 %	710:716	16.19 %	710:716	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	3	34	theme	cost-effective	448:461	arg1	process					473:479	a cost-effective enzymatic process	446:479	a cost-effective enzymatic process for IMMPs synthesis	446:499	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	6	35	theme	middle	1190:1195	arg1	part					1197:1200	middle part	1190:1200	middle part	1190:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	9	36	theme	DP	1562:1563	arg1	control					1539:1545	control	1539:1545	control of the average DP of IMMPs	1539:1572	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	3	37	theme	cyclodextrinase	551:565	arg1	action					541:546	the combined action	528:546	the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121	528:649	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	0	38	theme	isomalto/malto-polysaccharides	45:74	arg1	synthesis					32:40	Cost-effective and controllable synthesis	0:40	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.	0:167	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	9	39	theme	costy	1489:1493	arg1	malto-oligosaccharides					1507:1528	costy high-purity malto-oligosaccharides	1489:1528	costy high-purity malto-oligosaccharides	1489:1528	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	4	40	theme	glucosidic	881:890	arg1	linkages					892:899	α-(1 → 6) glucosidic linkages	871:899	α-(1 → 6) glucosidic linkages	871:899	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	3	41	theme	combined	532:539	arg1	action					541:546	the combined action	528:546	the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121	528:649	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	6	42	theme	1 → 4	1141:1145	arg1	segments					1148:1155	α-(1 → 4) segments	1138:1155	α-(1 → 4) segments embedded at the reducing end and middle part	1138:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	3	43	theme	maximum	695:701	arg1	yield					703:707	a maximum yield	693:707	a maximum yield (16.19 %, w/w)	693:722	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	9	44	theme	high-purity	1495:1505	arg1	malto-oligosaccharides					1507:1528	costy high-purity malto-oligosaccharides	1489:1528	costy high-purity malto-oligosaccharides	1489:1528	This procedure can be applied as a novel bioprocess that does not require costy high-purity malto-oligosaccharides and with control of the average DP of IMMPs by adjusting the substrate composition.
36925243	5	45	theme	malto-oligosaccharides	947:968	arg1	release					921:927	the release	917:927	the release of G7 and smaller malto-oligosaccharides by PpCD	917:976	By controlling the release of G7 and smaller malto-oligosaccharides by PpCD, IMMP-Seq was obtained of DP varying from 12.9 to 29.5.
36925243	8	46	theme	G3	1335:1336	arg1	Addition					1323:1330	Addition	1323:1330	Addition of G3 or G4 as specific acceptors	1323:1364	Addition of G3 or G4 as specific acceptors resulted in IMMPs exhibiting low polydispersity.
36925243	3	47	theme	IMMPs	485:489	arg1	synthesis					491:499	IMMPs synthesis	485:499	IMMPs synthesis	485:499	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	4	48	contain	possess	835:841	arg2	contents					859:866	relatively high contents	843:866	relatively high contents of α-(1 → 6) glucosidic linkages	843:899	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	4	48	contain	possess	835:841	arg1	IMMPs					738:742	The purified IMMPs	725:742	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq,	725:833	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	4	49	theme	linkages	892:899	arg1	contents					859:866	relatively high contents	843:866	relatively high contents of α-(1 → 6) glucosidic linkages	843:899	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	7	50	contain	containing	1240:1249	arg1	segments					1231:1238	α-(1 → 6) segments	1221:1238	α-(1 → 6) segments containing the non-reducing end	1221:1270	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	7	50	contain	containing	1240:1249	arg2	end					1268:1270	the non-reducing end	1251:1270	the non-reducing end	1251:1270	The proportion of α-(1 → 6) segments containing the non-reducing end was 56.76 % for IMMP-Sim but 28.98 % for IMMP-Seq.
36925243	3	51	dep	Limosilactobacillus	619:637	arg1	reuteri					639:645	reuteri	639:645	reuteri	639:645	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	4	52	theme	α-	871:872	arg1	linkages					892:899	α-(1 → 6) glucosidic linkages	871:899	α-(1 → 6) glucosidic linkages	871:899	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	6	53	from	end	1182:1184	arg1	embedded					1157:1164	embedded	1157:1164	embedded	1157:1164	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	6	54	theme	reducing	1173:1180	arg1	end					1182:1184	the reducing end	1169:1184	the reducing end	1169:1184	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	1	55	theme	non-branched	285:296	arg1	gluco-oligosaccharides					298:319	non-branched gluco-oligosaccharides	285:319	non-branched gluco-oligosaccharides produced by 4,6-α-glucanotransferase (GtfB)	285:363	Isomalto/malto-polysaccharides (IMMPs) derived from malto-oligosaccharides such as maltoheptaose (G7) are elongated non-branched gluco-oligosaccharides produced by 4,6-α-glucanotransferase (GtfB).
36925243	3	56	theme	Limosilactobacillus	619:637	arg1	121					647:649	Limosilactobacillus reuteri 121	619:649	Limosilactobacillus reuteri 121	619:649	In this study, a cost-effective enzymatic process for IMMPs synthesis is developed that utilizes the combined action of cyclodextrinase from Palaeococcus pacificus (PpCD) and GtfB-ΔN from Limosilactobacillus reuteri 121 to convert β-cyclodextrin into IMMPs with a maximum yield (16.19 %, w/w).
36925243	6	57	with	segments	1124:1131	arg1	segments					1148:1155	α-(1 → 4) segments	1138:1155	α-(1 → 4) segments embedded at the reducing end and middle part	1138:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	5	58	dep	29.5	1028:1031	arg1	to					1025:1026	to	1025:1026	to	1025:1026	By controlling the release of G7 and smaller malto-oligosaccharides by PpCD, IMMP-Seq was obtained of DP varying from 12.9 to 29.5.
36925243	0	59	theme	combined	99:106	arg1	action					108:113	combined action	99:113	combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB	99:166	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	4	60	theme	1 → 6	874:878	arg1	linkages					892:899	α-(1 → 6) glucosidic linkages	871:899	α-(1 → 6) glucosidic linkages	871:899	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	6	61	theme	segments	1124:1131	arg1	distribution					1091:1102	different linkage-type distribution	1068:1102	different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part	1068:1200	Enzymatic fingerprinting revealed different linkage-type distribution of α-(1 → 6) linked segments with α-(1 → 4) segments embedded at the reducing end and middle part.
36925243	4	62	theme	simultaneous	759:770	arg1	treatments					786:795	simultaneous or sequential treatments	759:795	simultaneous or sequential treatments	759:795	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
36925243	0	63	from	synthesis	32:40	arg1	β-cyclodextrin					81:94	β-cyclodextrin	81:94	β-cyclodextrin	81:94	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	0	64	theme	controllable	19:30	arg1	synthesis					32:40	Cost-effective and controllable synthesis	0:40	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.	0:167	Cost-effective and controllable synthesis of isomalto/malto-polysaccharides from β-cyclodextrin by combined action of cyclodextrinase and 4,6-α-glucanotransferase GtfB.
36925243	4	65	theme	high	854:857	arg1	contents					859:866	relatively high contents	843:866	relatively high contents of α-(1 → 6) glucosidic linkages	843:899	The purified IMMPs synthesized by simultaneous or sequential treatments, designated as IMMP-Sim and IMMP-Seq, possess relatively high contents of α-(1 → 6) glucosidic linkages.
35397268	8	0	theme	hepatoprotective	1343:1358	arg1	effect					1360:1365	its hepatoprotective effect	1339:1365	its hepatoprotective effect	1339:1365	With the gradual removal of protein, its hepatoprotective effect increased.
35397268	2	1	theme	ultra-high	332:341	arg1	200					353:355	200	353:355	200	353:355	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	2	1	theme	ultra-high	332:341	arg1	pressure					343:350	ultra-high pressure	332:350	ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP	332:472	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	2	1	theme	ultra-high	332:341	arg1	600 MPa					366:372	200, 400 and 600 MPa	353:372	600 MPa	366:372	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	0	2	theme	polysaccharides	73:87	arg1	bioactivity					58:68	bioactivity	58:68	bioactivity	58:68	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	0	2	theme	polysaccharides	73:87	arg1	structure					44:52	structure	44:52	structure	44:52	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	5	3	theme	electron	990:997	arg1	microscope					999:1008	the scanning electron microscope	977:1008	the scanning electron microscope	977:1008	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	4	4	from	11.7 kDa	652:659	arg1	400 MPa-LYTP					663:674	400 MPa-LYTP	663:674	400 MPa-LYTP (from 372.2 to 11.8 kDa)	663:699	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	4	from	11.7 kDa	652:659	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	4	from	11.7 kDa	652:659	arg1	600 MPa-LYTP					705:716	600 MPa-LYTP	705:716	600 MPa-LYTP (from 344 to 11.6 kDa)	705:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	4	from	11.7 kDa	652:659	arg1	200 MPa-LYTP					624:635	200 MPa-LYTP	624:635	200 MPa-LYTP (from 563.6 to 11.7 kDa)	624:660	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	4	from	11.7 kDa	652:659	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	0	5	from	Effects	0:6	arg1	bioactivity					58:68	bioactivity	58:68	bioactivity	58:68	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	0	5	from	Effects	0:6	arg1	structure					44:52	structure	44:52	structure	44:52	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	7	6	theme	Sevages	1286:1292	arg1	method					1294:1299	the Sevages method	1282:1299	the Sevages method	1282:1299	In addition, UHP treatment can more efficiently remove protein than the Sevages method.
35397268	9	7	dep	structure	1450:1458	arg1	the					1438:1440	the	1438:1440	the	1438:1440	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	0	8	theme	large	94:98	arg1	leaf					100:103	large leaf	94:103	large leaf	94:103	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	5	9	theme	microscope	999:1008	arg1	results					966:972	The results	962:972	The results of the scanning electron microscope	962:1008	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	4	10	theme	600 MPa-LYTP	705:716	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	10	theme	600 MPa-LYTP	705:716	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	0	11	from	structure	44:52	arg1	leaf					100:103	large leaf	94:103	large leaf	94:103	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	6	12	theme	liver	1192:1196	arg1	injury					1198:1203	alcohol-induced liver injury	1176:1203	alcohol-induced liver injury in mice	1176:1211	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	4	13	dep	11.7 kDa	652:659	arg1	to					649:650	to	649:650	to	649:650	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	14	dep	11.6 kDa	731:738	arg1	to					728:729	to	728:729	to	728:729	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	1	15	theme	structure	147:155	arg1	changes					136:142	the changes	132:142	the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP)	132:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	6	16	theme	alcohol-induced	1176:1190	arg1	injury					1198:1203	alcohol-induced liver injury	1176:1203	alcohol-induced liver injury in mice	1176:1211	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	3	17	theme	monosaccharide	497:510	arg1	composition					512:522	the monosaccharide composition	493:522	the monosaccharide composition of LYTP	493:530	It was found that the monosaccharide composition of LYTP changed significantly after the ultra-high pressure treatment.
35397268	4	18	theme	200 MPa-LYTP	624:635	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	18	theme	200 MPa-LYTP	624:635	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	2	19	theme	tea	401:403	arg1	polysaccharide					405:418	yellow tea polysaccharide	394:418	yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP	394:472	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	5	20	theme	ultra-high	1022:1031	arg1	pressure					1033:1040	ultra-high pressure	1022:1040	ultra-high pressure	1022:1040	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	2	21	theme	yellow	284:289	arg1	polysaccharide					295:308	Native yellow tea polysaccharide	277:308	Native yellow tea polysaccharide	277:308	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	1	22	theme	bioactivity	161:171	arg1	changes					136:142	the changes	132:142	the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP)	132:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	2	23	theme	yellow	394:399	arg1	polysaccharide					405:418	yellow tea polysaccharide	394:418	yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP	394:472	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	1	24	theme	ultra-high	250:259	arg1	UHP					271:273	UHP	271:273	UHP	271:273	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	24	theme	ultra-high	250:259	arg1	pressure					261:268	ultra-high pressure	250:268	ultra-high pressure (UHP)	250:274	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	4	25	from	11.8 kDa	691:698	arg1	400 MPa-LYTP					663:674	400 MPa-LYTP	663:674	400 MPa-LYTP (from 372.2 to 11.8 kDa)	663:699	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	25	from	11.8 kDa	691:698	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	25	from	11.8 kDa	691:698	arg1	600 MPa-LYTP					705:716	600 MPa-LYTP	705:716	600 MPa-LYTP (from 344 to 11.6 kDa)	705:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	25	from	11.8 kDa	691:698	arg1	200 MPa-LYTP					624:635	200 MPa-LYTP	624:635	200 MPa-LYTP (from 563.6 to 11.7 kDa)	624:660	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	25	from	11.8 kDa	691:698	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	2	26	theme	Native	277:282	arg1	polysaccharide					295:308	Native yellow tea polysaccharide	277:308	Native yellow tea polysaccharide	277:308	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	8	27	theme	protein	1330:1336	arg1	removal					1319:1325	the gradual removal	1307:1325	the gradual removal of protein	1307:1336	With the gradual removal of protein, its hepatoprotective effect increased.
35397268	0	28	theme	pressure	22:29	arg1	treatment					31:39	ultra-high pressure treatment	11:39	ultra-high pressure treatment	11:39	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	5	29	theme	LYTP	1093:1096	arg1	morphology					1079:1088	the surface and spatial morphology	1055:1088	the surface and spatial morphology of LYTP	1055:1096	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	4	30	theme	ultra-high	764:773	arg1	treatment					784:792	ultra-high pressure treatment	764:792	ultra-high pressure treatment	764:792	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	3	31	theme	LYTP	527:530	arg1	composition					512:522	the monosaccharide composition	493:522	the monosaccharide composition of LYTP	493:530	It was found that the monosaccharide composition of LYTP changed significantly after the ultra-high pressure treatment.
35397268	8	32	theme	gradual	1311:1317	arg1	removal					1319:1325	the gradual removal	1307:1325	the gradual removal of protein	1307:1336	With the gradual removal of protein, its hepatoprotective effect increased.
35397268	1	33	theme	polysaccharides	176:190	arg1	bioactivity					161:171	bioactivity	161:171	bioactivity	161:171	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	33	theme	polysaccharides	176:190	arg1	structure					147:155	structure	147:155	structure	147:155	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	0	34	theme	ultra-high	11:20	arg1	treatment					31:39	ultra-high pressure treatment	11:39	ultra-high pressure treatment	11:39	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	9	35	theme	LYTP	1485:1488	arg1	structure					1450:1458	primary structure	1442:1458	primary structure	1442:1458	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	9	35	theme	LYTP	1485:1488	arg1	structure					1472:1480	spatial structure	1464:1480	spatial structure	1464:1480	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	9	36	theme	spatial	1464:1470	arg1	structure					1472:1480	spatial structure	1464:1480	spatial structure	1464:1480	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	7	37	theme	UHP	1227:1229	arg1	treatment					1231:1239	UHP treatment	1227:1239	UHP treatment	1227:1239	In addition, UHP treatment can more efficiently remove protein than the Sevages method.
35397268	3	38	theme	pressure	575:582	arg1	treatment					584:592	the ultra-high pressure treatment	560:592	the ultra-high pressure treatment	560:592	It was found that the monosaccharide composition of LYTP changed significantly after the ultra-high pressure treatment.
35397268	1	39	theme	large	197:201	arg1	LYTP					220:223	LYTP	220:223	LYTP	220:223	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	39	theme	large	197:201	arg1	tea					215:217	large leaf yellow tea	197:217	large leaf yellow tea (LYTP)	197:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	0	40	theme	treatment	31:39	arg1	Effects					0:6	Effects	0:6	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf	0:103	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	5	41	theme	surface	1059:1065	arg1	morphology					1079:1088	the surface and spatial morphology	1055:1088	the surface and spatial morphology of LYTP	1055:1096	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	5	42	theme	scanning	981:988	arg1	microscope					999:1008	the scanning electron microscope	977:1008	the scanning electron microscope	977:1008	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	9	43	theme	polysaccharides	1522:1536	arg1	content					1504:1510	the content	1500:1510	the content of acidic polysaccharides	1500:1536	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	1	44	theme	leaf	203:206	arg1	LYTP					220:223	LYTP	220:223	LYTP	220:223	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	44	theme	leaf	203:206	arg1	tea					215:217	large leaf yellow tea	197:217	large leaf yellow tea (LYTP)	197:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	4	45	theme	particle	841:848	arg1	size					850:853	particle size	841:853	particle size	841:853	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	0	46	from	bioactivity	58:68	arg1	leaf					100:103	large leaf	94:103	large leaf	94:103	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	4	47	theme	pressure	775:782	arg1	treatment					784:792	ultra-high pressure treatment	764:792	ultra-high pressure treatment	764:792	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	5	48	theme	spatial	1071:1077	arg1	morphology					1079:1088	the surface and spatial morphology	1055:1088	the surface and spatial morphology of LYTP	1055:1096	The results of the scanning electron microscope showed that ultra-high pressure also changed the surface and spatial morphology of LYTP.
35397268	3	49	theme	ultra-high	564:573	arg1	treatment					584:592	the ultra-high pressure treatment	560:592	the ultra-high pressure treatment	560:592	It was found that the monosaccharide composition of LYTP changed significantly after the ultra-high pressure treatment.
35397268	4	50	theme	400 MPa-LYTP	663:674	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	50	theme	400 MPa-LYTP	663:674	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	51	dep	11.8 kDa	691:698	arg1	to					688:689	to	688:689	to	688:689	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	52	from	11.6 kDa	731:738	arg1	400 MPa-LYTP					663:674	400 MPa-LYTP	663:674	400 MPa-LYTP (from 372.2 to 11.8 kDa)	663:699	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	52	from	11.6 kDa	731:738	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	52	from	11.6 kDa	731:738	arg1	600 MPa-LYTP					705:716	600 MPa-LYTP	705:716	600 MPa-LYTP (from 344 to 11.6 kDa)	705:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	52	from	11.6 kDa	731:738	arg1	200 MPa-LYTP					624:635	200 MPa-LYTP	624:635	200 MPa-LYTP (from 563.6 to 11.7 kDa)	624:660	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	52	from	11.6 kDa	731:738	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	1	53	theme	yellow	208:213	arg1	LYTP					220:223	LYTP	220:223	LYTP	220:223	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	53	theme	yellow	208:213	arg1	tea					215:217	large leaf yellow tea	197:217	large leaf yellow tea (LYTP)	197:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	54	from	tea	215:217	arg1	bioactivity					161:171	bioactivity	161:171	bioactivity	161:171	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	54	from	tea	215:217	arg1	structure					147:155	structure	147:155	structure	147:155	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	54	from	tea	215:217	arg1	polysaccharides					176:190	polysaccharides	176:190	polysaccharides from large leaf yellow tea (LYTP)	176:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	0	55	from	leaf	100:103	arg1	polysaccharides					73:87	polysaccharides	73:87	polysaccharides from large leaf	73:103	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	0	55	from	leaf	100:103	arg1	bioactivity					58:68	bioactivity	58:68	bioactivity	58:68	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	0	55	from	leaf	100:103	arg1	structure					44:52	structure	44:52	structure	44:52	Effects of ultra-high pressure treatment on structure and bioactivity of polysaccharides from large leaf yellow tea.
35397268	6	56	theme	pressure	1121:1128	arg1	UHP-LYTP					1141:1148	UHP-LYTP	1141:1148	UHP-LYTP	1141:1148	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	6	56	theme	pressure	1121:1128	arg1	treatment					1130:1138	ultra-high pressure treatment	1110:1138	ultra-high pressure treatment (UHP-LYTP)	1110:1149	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	1	57	from	bioactivity	161:171	arg1	LYTP					220:223	LYTP	220:223	LYTP	220:223	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	57	from	bioactivity	161:171	arg1	tea					215:217	large leaf yellow tea	197:217	large leaf yellow tea (LYTP)	197:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	2	58	theme	tea	291:293	arg1	polysaccharide					295:308	Native yellow tea polysaccharide	277:308	Native yellow tea polysaccharide	277:308	Native yellow tea polysaccharide were treatmented with ultra-high pressure (200, 400 and 600 MPa) for 5 min to yield yellow tea polysaccharide including 200 MPa-LYTP, 400 MPa-LYTP and 600 MPa-LYTP.
35397268	6	59	from	injury	1198:1203	arg1	mice					1208:1211	mice	1208:1211	mice	1208:1211	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	4	60	from	weight	609:614	arg1	11.6 kDa					731:738	11.6 kDa	731:738	11.6 kDa	731:738	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	60	from	weight	609:614	arg1	11.8 kDa					691:698	11.8 kDa	691:698	11.8 kDa	691:698	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	60	from	weight	609:614	arg1	11.7 kDa					652:659	11.7 kDa	652:659	11.7 kDa	652:659	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	9	61	theme	UHP	1411:1413	arg1	treatment					1415:1423	UHP treatment	1411:1423	UHP treatment	1411:1423	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	6	62	theme	ultra-high	1110:1119	arg1	UHP-LYTP					1141:1148	UHP-LYTP	1141:1148	UHP-LYTP	1141:1148	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	6	62	theme	ultra-high	1110:1119	arg1	treatment					1130:1138	ultra-high pressure treatment	1110:1138	ultra-high pressure treatment (UHP-LYTP)	1110:1149	LYTP after ultra-high pressure treatment (UHP-LYTP) could further ameliorate alcohol-induced liver injury in mice.
35397268	9	63	theme	primary	1442:1448	arg1	structure					1450:1458	primary structure	1442:1458	primary structure	1442:1458	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	9	64	theme	acidic	1515:1520	arg1	polysaccharides					1522:1536	acidic polysaccharides	1515:1536	acidic polysaccharides	1515:1536	These findings demonstrated that UHP treatment could change the primary structure and spatial structure of LYTP, increase the content of acidic polysaccharides, and improve its bioactivity.
35397268	1	65	from	structure	147:155	arg1	LYTP					220:223	LYTP	220:223	LYTP	220:223	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	1	65	from	structure	147:155	arg1	tea					215:217	large leaf yellow tea	197:217	large leaf yellow tea (LYTP)	197:224	In this study, the changes of structure and bioactivity of polysaccharides from large leaf yellow tea (LYTP) were investigated under ultra-high pressure (UHP).
35397268	4	66	theme	molecular	599:607	arg1	Mw					617:618	Mw	617:618	Mw	617:618	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
35397268	4	66	theme	molecular	599:607	arg1	weight					609:614	The molecular weight	595:614	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa)	595:739	The molecular weight (Mw) of 200 MPa-LYTP (from 563.6 to 11.7 kDa), 400 MPa-LYTP (from 372.2 to 11.8 kDa) and 600 MPa-LYTP (from 344 to 11.6 kDa) sharply decreased upon ultra-high pressure treatment compared with LYTP (771.5 kDa), coincidentally particle size was also significantly reduced for 200 MPa-LYTP (23.2 %), 400 MPa-LYTP (40.2 %) and 600 MPa-LYTP (25.9 %).
37182975	0	0	theme	polysaccharides	76:90	arg1	mixture					55:61	a mixture	53:61	a mixture of different polysaccharides	53:90	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	0	0	theme	polysaccharides	76:90	arg1	galactan					32:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	1	1	from	polysaccharide	162:175	arg1	studies					200:206	various bioactivity studies	180:206	various bioactivity studies	180:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	4	2	theme	residues	660:667	arg1	chains					637:642	long β-1,4-galactan side chains	612:642	long β-1,4-galactan side chains of up to 80 Gal residues	612:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	2	theme	residues	660:667	arg1	chains					699:704	short β-1,4-galactan side chains	673:704	short β-1,4-galactan side chains of 0 to 3 Gal residues	673:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	3	theme	residues	720:727	arg1	chains					637:642	long β-1,4-galactan side chains	612:642	long β-1,4-galactan side chains of up to 80 Gal residues	612:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	3	theme	residues	720:727	arg1	chains					699:704	short β-1,4-galactan side chains	673:704	short β-1,4-galactan side chains of 0 to 3 Gal residues	673:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	0	4	theme	different	66:74	arg1	polysaccharides					76:90	different polysaccharides	66:90	different polysaccharides	66:90	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	4	5	theme	Gal	656:658	arg1	residues					660:667	up to 80 Gal residues	647:667	up to 80 Gal residues	647:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	6	6	theme	related	940:946	arg1	confusion					930:938	the confusion	926:938	the confusion related to commercial PG	926:963	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	2	7	theme	stated	281:286	arg1	composition					288:298	the stated composition	277:298	the stated composition	277:298	However, results using this galactan are not always consistent with the stated composition.
37182975	5	8	theme	assays	898:903	arg1	terms					845:849	terms	845:849	terms of galectin-3 binding and gut bacterial growth assays	845:903	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	3	9	theme	commercial	357:366	arg1	PG					368:369	this commercial PG	352:369	this commercial PG	352:369	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	4	10	theme	β-1,4-galactan	679:692	arg1	chains					699:704	short β-1,4-galactan side chains	673:704	short β-1,4-galactan side chains of 0 to 3 Gal residues	673:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	5	11	theme	bacterial	881:889	arg1	assays					898:903	gut bacterial growth assays	877:903	gut bacterial growth assays	877:903	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	6	12	from	polysaccharides	1014:1028	arg1	investigations					1045:1058	bioactivity investigations	1033:1058	bioactivity investigations	1033:1058	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	1	13	used	used	146:149	arg2	galactan					122:129	Commercially-supplied potato galactan	93:129	Commercially-supplied potato galactan (PG)	93:134	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	13	used	used	146:149	arg2	polysaccharide					162:175	a model polysaccharide	154:175	a model polysaccharide in various bioactivity studies	154:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	13	used	used	146:149	arg2	PG					132:133	PG	132:133	PG	132:133	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	5	14	theme	binding	865:871	arg1	terms					845:849	terms	845:849	terms of galectin-3 binding and gut bacterial growth assays	845:903	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	1	15	theme	model	156:160	arg1	polysaccharide					162:175	a model polysaccharide	154:175	a model polysaccharide in various bioactivity studies	154:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	15	theme	model	156:160	arg1	galactan					122:129	Commercially-supplied potato galactan	93:129	Commercially-supplied potato galactan (PG)	93:134	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	3	16	dep	components	396:405	arg1	components					396:405	its primary components	384:405	its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	384:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	16	dep	components	396:405	arg1	PG-Cp					423:427	PG-Cp	423:427	PG-Cp	423:427	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	16	dep	components	396:405	arg1	PG-B					414:417	PG-B	414:417	PG-B	414:417	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	16	dep	components	396:405	arg1	PG-A					408:411	PG-A	408:411	PG-A	408:411	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	17	with	PG-A	408:411	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	6	18	theme	bioactivity	1033:1043	arg1	investigations					1045:1058	bioactivity investigations	1033:1058	bioactivity investigations	1033:1058	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	4	19	theme	side	632:635	arg1	chains					637:642	long β-1,4-galactan side chains	612:642	long β-1,4-galactan side chains of up to 80 Gal residues	612:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	0	20	theme	model	4:8	arg1	mixture					55:61	a mixture	53:61	a mixture of different polysaccharides	53:90	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	0	20	theme	model	4:8	arg1	galactan					32:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	5	21	theme	gut	877:879	arg1	assays					898:903	gut bacterial growth assays	877:903	gut bacterial growth assays	877:903	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	6	22	theme	model	1008:1012	arg1	polysaccharides					1014:1028	better model polysaccharides	1001:1028	better model polysaccharides in bioactivity investigations	1001:1058	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	4	23	theme	free	526:529	arg1	chains					546:551	free β-1,4-galactan chains	526:551	free β-1,4-galactan chains	526:551	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	24	with	rhamnogalacturonans	587:605	arg1	chains					637:642	long β-1,4-galactan side chains	612:642	long β-1,4-galactan side chains of up to 80 Gal residues	612:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	24	with	rhamnogalacturonans	587:605	arg1	chains					699:704	short β-1,4-galactan side chains	673:704	short β-1,4-galactan side chains of 0 to 3 Gal residues	673:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	1	25	theme	Commercially-supplied	93:113	arg1	polysaccharide					162:175	a model polysaccharide	154:175	a model polysaccharide in various bioactivity studies	154:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	25	theme	Commercially-supplied	93:113	arg1	PG					132:133	PG	132:133	PG	132:133	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	25	theme	Commercially-supplied	93:113	arg1	galactan					122:129	Commercially-supplied potato galactan	93:129	Commercially-supplied potato galactan (PG)	93:134	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	26	theme	various	180:186	arg1	studies					200:206	various bioactivity studies	180:206	various bioactivity studies	180:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	0	27	theme	potato	25:30	arg1	mixture					55:61	a mixture	53:61	a mixture of different polysaccharides	53:90	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	0	27	theme	potato	25:30	arg1	galactan					32:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	1	28	theme	potato	115:120	arg1	polysaccharide					162:175	a model polysaccharide	154:175	a model polysaccharide in various bioactivity studies	154:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	28	theme	potato	115:120	arg1	PG					132:133	PG	132:133	PG	132:133	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	1	28	theme	potato	115:120	arg1	galactan					122:129	Commercially-supplied potato galactan	93:129	Commercially-supplied potato galactan (PG)	93:134	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	3	29	theme	molecular	450:458	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	0	30	theme	polysaccharide	10:23	arg1	mixture					55:61	a mixture	53:61	a mixture of different polysaccharides	53:90	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	0	30	theme	polysaccharide	10:23	arg1	galactan					32:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan	0:39	The model polysaccharide potato galactan is actually a mixture of different polysaccharides.
37182975	4	31	dep	80	653:654	arg1	to					650:651	to	650:651	to	650:651	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	32	dep	3	714:714	arg1	to					711:712	to	711:712	to	711:712	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	33	theme	β-1,4-galactan	531:544	arg1	chains					546:551	free β-1,4-galactan chains	526:551	free β-1,4-galactan chains	526:551	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	34	theme	lawn	754:757	arg1	pattern					760:766	lawn" pattern	754:766	lawn" pattern	754:766	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	6	35	theme	better	1001:1006	arg1	polysaccharides					1014:1028	better model polysaccharides	1001:1028	better model polysaccharides in bioactivity investigations	1001:1058	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	4	36	theme	β-1,4-galactan	617:630	arg1	chains					637:642	long β-1,4-galactan side chains	612:642	long β-1,4-galactan side chains of up to 80 Gal residues	612:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	5	37	theme	polysaccharides	789:803	arg1	Structures					769:778	Structures	769:778	Structures of these polysaccharides	769:803	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	5	38	theme	galectin-3	854:863	arg1	binding					865:871	galectin-3 binding	854:871	galectin-3 binding	854:871	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	3	39	theme	weight-averaged	434:448	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	40	theme	primary	388:394	arg1	components					396:405	its primary components	384:405	its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	384:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	40	theme	primary	388:394	arg1	PG-Cp					423:427	PG-Cp	423:427	PG-Cp	423:427	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	40	theme	primary	388:394	arg1	PG-B					414:417	PG-B	414:417	PG-B	414:417	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	3	40	theme	primary	388:394	arg1	PG-A					408:411	PG-A	408:411	PG-A	408:411	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	6	41	theme	purified	971:978	arg1	fractions					980:988	purified fractions	971:988	purified fractions serving as better model polysaccharides in bioactivity investigations	971:1058	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	4	42	theme	short	673:677	arg1	chains					699:704	short β-1,4-galactan side chains	673:704	short β-1,4-galactan side chains of 0 to 3 Gal residues	673:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	3	43	with	PG-B	414:417	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	4	44	theme	"	758:758	arg1	pattern					760:766	lawn" pattern	754:766	lawn" pattern	754:766	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	3	45	theme	93	476:477	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	4	46	theme	side	694:697	arg1	chains					699:704	short β-1,4-galactan side chains	673:704	short β-1,4-galactan side chains of 0 to 3 Gal residues	673:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	5	47	theme	growth	891:896	arg1	assays					898:903	gut bacterial growth assays	877:903	gut bacterial growth assays	877:903	Structures of these polysaccharides correlate well with their activities in terms of galectin-3 binding and gut bacterial growth assays.
37182975	3	48	with	PG-Cp	423:427	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	4	49	theme	Gal	716:718	arg1	residues					720:727	0 to 3 Gal residues	709:727	0 to 3 Gal residues	709:727	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	3	50	theme	430	471:473	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	2	51	with	consistent	261:270	arg1	composition					288:298	the stated composition	277:298	the stated composition	277:298	However, results using this galactan are not always consistent with the stated composition.
37182975	4	52	theme	long	612:615	arg1	chains					637:642	long β-1,4-galactan side chains	612:642	long β-1,4-galactan side chains of up to 80 Gal residues	612:667	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	1	53	theme	bioactivity	188:198	arg1	studies					200:206	various bioactivity studies	180:206	various bioactivity studies	180:206	Commercially-supplied potato galactan (PG) is widely used as a model polysaccharide in various bioactivity studies.
37182975	3	54	theme	11.3 kDa	484:491	arg1	weights					460:466	weight-averaged molecular weights	434:466	weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively	434:505	Here, we assessed its composition by fractionating this commercial PG and purified its primary components: PG-A, PG-B and PG-Cp with weight-averaged molecular weights of 430, 93, and 11.3 kDa, respectively.
37182975	4	55	theme	I	585:585	arg1	PG-A					562:565	PG-A	562:565	PG-A	562:565	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	55	theme	I	585:585	arg1	rhamnogalacturonans					587:605	type I rhamnogalacturonans	580:605	type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern	580:766	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	55	theme	I	585:585	arg1	PG-B					571:574	PG-B	571:574	PG-B	571:574	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	56	dep	consists	514:521	arg1	whereas					554:560	whereas	554:560	whereas	554:560	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	6	57	theme	commercial	951:960	arg1	PG					962:963	commercial PG	951:963	commercial PG	951:963	Our study clarifies the confusion related to commercial PG, with purified fractions serving as better model polysaccharides in bioactivity investigations.
37182975	4	58	theme	type	580:583	arg1	PG-A					562:565	PG-A	562:565	PG-A	562:565	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	58	theme	type	580:583	arg1	rhamnogalacturonans					587:605	type I rhamnogalacturonans	580:605	type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern	580:766	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
37182975	4	58	theme	type	580:583	arg1	PG-B					571:574	PG-B	571:574	PG-B	571:574	PG-Cp consists of free β-1,4-galactan chains, whereas PG-A and PG-B are type I rhamnogalacturonans with long β-1,4-galactan side chains of up to 80 Gal residues and short β-1,4-galactan side chains of 0 to 3 Gal residues that display a "trees in lawn" pattern.
36849074	4	0	from	change	946:951	arg1	structure					975:983	structure	975:983	structure	975:983	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	4	0	from	change	946:951	arg1	morphology					960:969	morphology	960:969	morphology	960:969	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	0	1	theme	composite	50:58	arg1	microbeads					60:69	composite microbeads	50:69	composite microbeads for drug delivery and tissue engineering	50:110	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	7	2	theme	fibrous	1488:1494	arg1	materials					1496:1504	homogenous fibrous materials	1477:1504	homogenous fibrous materials better suited for wound dressing	1477:1537	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	0	3	theme	drug	75:78	arg1	delivery					80:87	drug delivery	75:87	drug delivery	75:87	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	3	4	theme	high	619:622	arg1	tension					632:638	the high surface tension	615:638	the high surface tension existing at the emulsion water/oil interface	615:683	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	2	5	theme	water-in-oil	525:536	arg1	emulsions					538:546	water-in-oil emulsions	525:546	water-in-oil emulsions	525:546	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	6	theme	0.17-0.48 wt	462:473	arg1	alginate					490:497	0.17-0.48 wt% low-viscosity alginate	462:497	0.17-0.48 wt% low-viscosity alginate (same PLA)	462:508	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	6	theme	0.17-0.48 wt	462:473	arg1	PLA					505:507	same PLA	500:507	same PLA	500:507	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	7	used	used	405:408	arg2	Composites					342:351	Composites	342:351	Composites within 0.08-0.25 wt% medium-viscosity alginate	342:398	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	5	8	from	change	1038:1043	arg1	type					1061:1064	the alginate type	1048:1064	the alginate type	1048:1064	The change in the alginate type, revealed characteristics better suited for medical applications by the medium-viscosity alginate.
36849074	4	9	theme	inner-phase	898:908	arg1	size					910:913	the inner-phase size	894:913	the inner-phase size (alginate/water ratio)	894:936	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	4	9	theme	inner-phase	898:908	arg1	ratio					931:935	alginate/water ratio	916:935	alginate/water ratio	916:935	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	3	10	theme	better	818:823	arg1	fit					825:827	better fit	818:827	better fit to the PLA curvature	818:848	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	1	11	theme	future	313:318	arg1	applications					328:339	future medical applications	313:339	future medical applications	313:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	1	12	theme	medium-viscosity	136:151	arg1	alginate					153:160	medium-viscosity alginate	136:160	medium-viscosity alginate	136:160	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	3	13	dep	influence	605:613	arg1	reducing					686:693	reducing	686:693	reducing the total energy at this interface	686:728	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	3	13	dep	influence	605:613	arg1	facilitating					738:749	facilitating	738:749	facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature	738:848	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	1	14	theme	medical	320:326	arg1	applications					328:339	future medical applications	313:339	future medical applications	313:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	2	15	dep	used	405:408	arg1	%					431:431	6.6 wt%	425:431	6.6 wt%	425:431	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	3	16	dep	lie-flat	793:800	arg1	re-orient					803:811	re-orient	803:811	re-orient	803:811	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	0	17	theme	spun	14:17	arg1	poly					19:22	Centrifugally spun poly	0:22	Centrifugally spun poly(D,L-lactic acid)	0:39	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	6	18	contain	had	1248:1250	arg1	Composites					1165:1174	Composites	1165:1174	Composites at alginate- medium-viscosity	1165:1204	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	6	18	contain	had	1248:1250	arg2	networks					1258:1265	fiber networks	1252:1265	fiber networks interwoven with micro-beads	1252:1293	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	6	18	contain	had	1248:1250	arg1	%					1215:1215	≤0.25 wt%	1207:1215	≤0.25 wt%	1207:1215	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	6	18	contain	had	1248:1250	arg1	%					1245:1245	low-viscosity; ≤0.48 wt%	1222:1245	low-viscosity; ≤0.48 wt%	1222:1245	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	3	19	theme	emulsion	656:663	arg1	interface					675:683	the emulsion water/oil interface	652:683	the emulsion water/oil interface	652:683	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	6	20	theme	drug	1354:1357	arg1	applications					1368:1379	controlled-release drug delivery applications	1335:1379	controlled-release drug delivery applications	1335:1379	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	5	21	theme	alginate	1052:1059	arg1	type					1061:1064	the alginate type	1048:1064	the alginate type	1048:1064	The change in the alginate type, revealed characteristics better suited for medical applications by the medium-viscosity alginate.
36849074	7	22	from	%	1457:1457	arg1	composites					1428:1437	composites	1428:1437	composites with PLA at 6.6 wt%	1428:1457	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	7	22	from	%	1457:1457	arg1	%					1425:1425	1.1 wt%	1419:1425	1.1 wt%	1419:1425	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	4	23	theme	resultant	992:1000	arg1	composites					1002:1011	the resultant composites	988:1011	the resultant composites before and after FS	988:1031	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	6	24	theme	controlled-release	1335:1352	arg1	applications					1368:1379	controlled-release drug delivery applications	1335:1379	controlled-release drug delivery applications	1335:1379	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	2	25	theme	same	500:503	arg1	alginate					490:497	0.17-0.48 wt% low-viscosity alginate	462:497	0.17-0.48 wt% low-viscosity alginate (same PLA)	462:508	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	25	theme	same	500:503	arg1	PLA					505:507	same PLA	500:507	same PLA	500:507	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	4	26	dep	morphology	960:969	arg1	the					956:958	the	956:958	the	956:958	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	1	27	theme	minor	167:171	arg1	constituent					173:183	a minor constituent	165:183	a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	165:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	1	27	theme	minor	167:171	arg1	work					118:121	This work	113:121	This work	113:121	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	6	28	theme	delivery	1359:1366	arg1	applications					1368:1379	controlled-release drug delivery applications	1335:1379	controlled-release drug delivery applications	1335:1379	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	3	29	theme	water/oil	665:673	arg1	interface					675:683	the emulsion water/oil interface	652:683	the emulsion water/oil interface	652:683	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	0	30	theme	tissue	93:98	arg1	engineering					100:110	tissue engineering	93:110	tissue engineering	93:110	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	3	31	theme	alginate	576:583	arg1	presence					564:571	The presence	560:571	The presence of alginate	560:583	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	4	32	theme	composites	1002:1011	arg1	structure					975:983	structure	975:983	structure	975:983	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	4	32	theme	composites	1002:1011	arg1	morphology					960:969	morphology	960:969	morphology	960:969	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	4	33	theme	size	910:913	arg1	correlation					879:889	a direct correlation	870:889	a direct correlation of the inner-phase size (alginate/water ratio)	870:936	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	6	34	theme	≤0.48 wt	1237:1244	arg1	%					1245:1245	low-viscosity; ≤0.48 wt%	1222:1245	low-viscosity; ≤0.48 wt%	1222:1245	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	3	35	from	particles	755:763	arg1	blend					784:788	the amphiphilic blend	768:788	the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature	768:848	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	1	36	with	composites	188:197	arg1	PLA					222:224	PLA	222:224	PLA	222:224	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	1	36	with	composites	188:197	arg1	acid					216:219	poly lactic acid	204:219	poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	204:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	3	37	theme	PLA	836:838	arg1	curvature					840:848	the PLA curvature	832:848	the PLA curvature	832:848	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	2	38	theme	medium-viscosity	374:389	arg1	alginate					391:398	0.08-0.25 wt% medium-viscosity alginate	360:398	0.08-0.25 wt% medium-viscosity alginate	360:398	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	39	theme	0.08-0.25 wt	360:371	arg1	alginate					391:398	0.08-0.25 wt% medium-viscosity alginate	360:398	0.08-0.25 wt% medium-viscosity alginate	360:398	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	1	40	theme	compositional	257:269	arg1	variants					271:278	compositional variants	257:278	compositional variants	257:278	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	2	41	theme	low-viscosity	476:488	arg1	alginate					490:497	0.17-0.48 wt% low-viscosity alginate	462:497	0.17-0.48 wt% low-viscosity alginate (same PLA)	462:508	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	41	theme	low-viscosity	476:488	arg1	PLA					505:507	same PLA	500:507	same PLA	500:507	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	7	42	theme	homogenous	1477:1486	arg1	materials					1496:1504	homogenous fibrous materials	1477:1504	homogenous fibrous materials better suited for wound dressing	1477:1537	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	2	43	theme	%	372:372	arg1	alginate					391:398	0.08-0.25 wt% medium-viscosity alginate	360:398	0.08-0.25 wt% medium-viscosity alginate	360:398	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	4	44	theme	alginate/water	916:929	arg1	size					910:913	the inner-phase size	894:913	the inner-phase size (alginate/water ratio)	894:936	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	4	44	theme	alginate/water	916:929	arg1	ratio					931:935	alginate/water ratio	916:935	alginate/water ratio	916:935	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	2	45	theme	%	474:474	arg1	alginate					490:497	0.17-0.48 wt% low-viscosity alginate	462:497	0.17-0.48 wt% low-viscosity alginate (same PLA)	462:508	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	2	45	theme	%	474:474	arg1	PLA					505:507	same PLA	500:507	same PLA	500:507	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	7	46	from	%	1425:1425	arg1	type					1411:1414	each alginate type	1397:1414	each alginate type at 1.1 wt%, composites with PLA at 6.6 wt%	1397:1457	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	7	47	with	composites	1428:1437	arg1	PLA					1444:1446	PLA	1444:1446	PLA	1444:1446	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	0	48	theme	L-lactic	26:33	arg1	D					24:24	D	24:24	D	24:24	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	0	48	theme	L-lactic	26:33	arg1	acid					35:38	L-lactic acid	26:38	L-lactic acid	26:38	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	3	49	from	interface	720:728	arg1	energy					705:710	the total energy	695:710	the total energy at this interface	695:728	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	6	50	theme	alginate-	1179:1187	arg1	medium-viscosity					1189:1204	alginate- medium-viscosity	1179:1204	alginate- medium-viscosity	1179:1204	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	7	51	theme	alginate	1402:1409	arg1	type					1411:1414	each alginate type	1397:1414	each alginate type at 1.1 wt%, composites with PLA at 6.6 wt%	1397:1457	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	3	52	theme	total	699:703	arg1	energy					705:710	the total energy	695:710	the total energy at this interface	695:728	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	1	53	from	constituent	173:183	arg1	composites					188:197	composites	188:197	composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	188:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	6	54	theme	low-viscosity	1222:1234	arg1	%					1245:1245	low-viscosity; ≤0.48 wt%	1222:1245	low-viscosity; ≤0.48 wt%	1222:1245	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	7	55	theme	wound	1524:1528	arg1	dressing					1530:1537	wound dressing	1524:1537	wound dressing	1524:1537	Alternatively, each alginate type at 1.1 wt%, composites with PLA at 6.6 wt% could bring about homogenous fibrous materials better suited for wound dressing.
36849074	5	56	theme	medical	1110:1116	arg1	applications					1118:1129	medical applications	1110:1129	medical applications	1110:1129	The change in the alginate type, revealed characteristics better suited for medical applications by the medium-viscosity alginate.
36849074	0	57	dep	poly	19:22	arg1	D					24:24	D	24:24	D	24:24	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	0	57	dep	poly	19:22	arg1	acid					35:38	L-lactic acid	26:38	L-lactic acid	26:38	Centrifugally spun poly(D,L-lactic acid)-alginate composite microbeads for drug delivery and tissue engineering.
36849074	1	58	theme	poly	204:207	arg1	PLA					222:224	PLA	222:224	PLA	222:224	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	1	58	theme	poly	204:207	arg1	acid					216:219	poly lactic acid	204:219	poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	204:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	1	59	with	acid	216:219	arg1	objective					236:244	the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	232:339	the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	232:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	3	60	theme	amphiphilic	772:782	arg1	blend					784:788	the amphiphilic blend	768:788	the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature	768:848	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	1	61	theme	lactic	209:214	arg1	PLA					222:224	PLA	222:224	PLA	222:224	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	1	61	theme	lactic	209:214	arg1	acid					216:219	poly lactic acid	204:219	poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications	204:339	This work was based on medium-viscosity alginate as a minor constituent in composites with poly lactic acid (PLA) with the objective to prepare compositional variants through Forcespinning® (FS); for future medical applications.
36849074	4	62	theme	direct	872:877	arg1	correlation					879:889	a direct correlation	870:889	a direct correlation of the inner-phase size (alginate/water ratio)	870:936	The study revealed a direct correlation of the inner-phase size (alginate/water ratio), to the change in the morphology and structure of the resultant composites before and after FS.
36849074	3	63	theme	surface	624:630	arg1	tension					632:638	the high surface tension	615:638	the high surface tension existing at the emulsion water/oil interface	615:683	The presence of alginate is proposed here to influence the high surface tension existing at the emulsion water/oil interface, reducing the total energy at this interface, and/or facilitating the particles in the amphiphilic blend to lie-flat (re-orient) for better fit to the PLA curvature.
36849074	6	64	from	medium-viscosity	1189:1204	arg1	Composites					1165:1174	Composites	1165:1174	Composites at alginate- medium-viscosity	1165:1204	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
36849074	2	65	theme	fixed	414:418	arg1	PLA					420:422	fixed PLA	414:422	fixed PLA	414:422	Composites within 0.08-0.25 wt% medium-viscosity alginate were used, at fixed PLA, 6.6 wt%, compared with a study using 0.17-0.48 wt% low-viscosity alginate (same PLA), starting from water-in-oil emulsions, before FS.
36849074	5	66	theme	medium-viscosity	1138:1153	arg1	alginate					1155:1162	the medium-viscosity alginate	1134:1162	the medium-viscosity alginate	1134:1162	The change in the alginate type, revealed characteristics better suited for medical applications by the medium-viscosity alginate.
36849074	6	67	theme	fiber	1252:1256	arg1	networks					1258:1265	fiber networks	1252:1265	fiber networks interwoven with micro-beads	1252:1293	Composites at alginate- medium-viscosity; ≤0.25 wt%, and low-viscosity; ≤0.48 wt%, had fiber networks interwoven with micro-beads, with characteristics better suited for controlled-release drug delivery applications.
35278736	0	0	theme	purified	103:110	arg1	fractions					112:120	purified fractions	103:120	purified fractions	103:120	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	1	1	theme	activity-oriented	364:380	arg1	approach					382:389	the activity-oriented approach	360:389	the activity-oriented approach	360:389	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	4	2	dep	1→	1182:1183	arg1	1→					1201:1202	1→	1201:1202	1→	1201:1202	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	2	3	theme	crude	396:400	arg1	BJPs					402:405	The crude BJPs	392:405	The crude BJPs	392:405	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	1	4	theme	blackened	277:285	arg1	BJPs					311:314	BJPs	311:314	BJPs	311:314	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	1	4	theme	blackened	277:285	arg1	polysaccharides					294:308	crude blackened jujube polysaccharides	271:308	crude blackened jujube polysaccharides (BJPs)	271:315	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	3	5	dep	band	863:866	arg1	intensity					885:893	intensity	885:893	intensity	885:893	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	3	5	dep	band	863:866	arg1	pattern					874:880	peak pattern	869:880	peak pattern	869:880	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	1	6	theme	jujube	287:292	arg1	BJPs					311:314	BJPs	311:314	BJPs	311:314	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	1	6	theme	jujube	287:292	arg1	polysaccharides					294:308	crude blackened jujube polysaccharides	271:308	crude blackened jujube polysaccharides (BJPs)	271:315	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	4	7	theme	abundant	1015:1022	arg1	component					1047:1055	the most abundant and potent antioxidant component	1006:1055	the most abundant and potent antioxidant component	1006:1055	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	4	7	theme	abundant	1015:1022	arg1	backbone					1062:1069	the backbone	1058:1069	the backbone of BJP-3	1058:1078	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	0	8	from	Preparation	0:10	arg1	jujube					137:142	blackened jujube	127:142	blackened jujube	127:142	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	4	9	with	residues	1139:1146	arg1	terminals					1157:1165	two terminals	1153:1165	two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→	1153:1202	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	4	10	theme	-α-l-Araf	1125:1133	arg1	residues					1139:1146	→4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues	1103:1146	residues	1139:1146	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	1	11	theme	polysaccharides	294:308	arg1	features					225:232	the structural features	210:232	the structural features	210:232	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	1	11	theme	polysaccharides	294:308	arg1	activity					250:257	antioxidant activity	238:257	antioxidant activity in vitro	238:266	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	0	12	theme	fractions	112:120	arg1	Preparation					0:10	Preparation	0:10	Preparation	0:10	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	12	theme	fractions	112:120	arg1	characterization					24:39	structural characterization	13:39	structural characterization	13:39	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	12	theme	fractions	112:120	arg1	activity					57:64	antioxidant activity	45:64	antioxidant activity	45:64	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	5	13	theme	polysaccharides	1302:1316	arg1	properties					1261:1270	the structural and bioactive properties	1232:1270	the structural and bioactive properties of different blackened jujube polysaccharides	1232:1316	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	4	14	theme	BJP-3	1074:1078	arg1	component					1047:1055	the most abundant and potent antioxidant component	1006:1055	the most abundant and potent antioxidant component	1006:1055	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	4	14	theme	BJP-3	1074:1078	arg1	backbone					1062:1069	the backbone	1058:1069	the backbone of BJP-3	1058:1078	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	3	15	theme	1000.0-1200.0 cm-1	923:940	arg1	range					914:918	the range	910:918	the range of 1000.0-1200.0 cm-1	910:940	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	0	16	from	activity	57:64	arg1	jujube					137:142	blackened jujube	127:142	blackened jujube	127:142	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	17	theme	blackened	127:135	arg1	jujube					137:142	blackened jujube	127:142	blackened jujube	127:142	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	3	18	theme	relative	833:840	arg1	proportion					842:851	relative proportion	833:851	relative proportion	833:851	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	2	19	theme	H2O2-damaged	539:550	arg1	HUVECs					552:557	H2O2-damaged HUVECs	539:557	H2O2-damaged HUVECs	539:557	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	4	20	theme	antioxidant	1035:1045	arg1	component					1047:1055	the most abundant and potent antioxidant component	1006:1055	the most abundant and potent antioxidant component	1006:1055	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	4	20	theme	antioxidant	1035:1045	arg1	backbone					1062:1069	the backbone	1058:1069	the backbone of BJP-3	1058:1078	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	2	21	theme	scavenging	440:449	arg1	activity					451:458	dose-dependent radical scavenging activity	417:458	dose-dependent radical scavenging activity	417:458	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	2	22	theme	excellent	502:510	arg1	effects					523:529	excellent protective effects	502:529	excellent protective effects	502:529	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	2	23	theme	mitochondrial	577:589	arg1	potential					600:608	mitochondrial membrane potential	577:608	mitochondrial membrane potential	577:608	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	2	24	theme	radical	432:438	arg1	activity					451:458	dose-dependent radical scavenging activity	417:458	dose-dependent radical scavenging activity	417:458	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	4	25	theme	-α-l-GalpA	1106:1115	arg1	residues					1139:1146	→4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues	1103:1146	residues	1139:1146	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	3	26	dep	composition	811:821	arg1	type					824:827	type	824:827	type	824:827	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	3	26	dep	composition	811:821	arg1	proportion					842:851	relative proportion	833:851	relative proportion	833:851	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	1	27	theme	structural	214:223	arg1	features					225:232	the structural features	210:232	the structural features	210:232	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	3	28	theme	peak	869:872	arg1	pattern					874:880	peak pattern	869:880	peak pattern	869:880	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	0	29	theme	structural	13:22	arg1	characterization					24:39	structural characterization	13:39	structural characterization	13:39	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	3	30	theme	FTIR	858:861	arg1	band					863:866	FTIR band	858:866	FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1)	858:941	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	2	31	theme	oxygen	653:658	arg1	species					660:666	intracellular reactive oxygen species	630:666	intracellular reactive oxygen species	630:666	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	4	32	theme	T-α-l-Araf	1170:1179	arg1	terminals					1157:1165	two terminals	1153:1165	two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→	1153:1202	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	2	33	theme	reducing	470:477	arg1	capacity					479:486	total reducing capacity	464:486	total reducing capacity	464:486	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	0	34	theme	antioxidant	45:55	arg1	activity					57:64	antioxidant activity	45:64	antioxidant activity	45:64	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	5	35	theme	structural	1236:1245	arg1	properties					1261:1270	the structural and bioactive properties	1232:1270	the structural and bioactive properties of different blackened jujube polysaccharides	1232:1316	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	2	36	theme	reactive	644:651	arg1	species					660:666	intracellular reactive oxygen species	630:666	intracellular reactive oxygen species	630:666	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	2	37	theme	total	464:468	arg1	capacity					479:486	total reducing capacity	464:486	total reducing capacity	464:486	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	2	38	theme	dose-dependent	417:430	arg1	activity					451:458	dose-dependent radical scavenging activity	417:458	dose-dependent radical scavenging activity	417:458	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	1	39	theme	antioxidant	238:248	arg1	activity					250:257	antioxidant activity	238:257	antioxidant activity in vitro	238:266	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	1	40	theme	purified	326:333	arg1	polysaccharides					335:349	five purified polysaccharides	321:349	five purified polysaccharides	321:349	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	0	41	theme	activity-oriented	150:166	arg1	approach					168:175	an activity-oriented approach	147:175	an activity-oriented approach	147:175	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	5	42	theme	bioactive	1251:1259	arg1	properties					1261:1270	the structural and bioactive properties	1232:1270	the structural and bioactive properties of different blackened jujube polysaccharides	1232:1316	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	2	43	theme	membrane	591:598	arg1	potential					600:608	mitochondrial membrane potential	577:608	mitochondrial membrane potential	577:608	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	1	44	theme	polysaccharides	335:349	arg1	features					225:232	the structural features	210:232	the structural features	210:232	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	1	44	theme	polysaccharides	335:349	arg1	activity					250:257	antioxidant activity	238:257	antioxidant activity in vitro	238:266	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	3	45	theme	chemical	756:763	arg1	composition					765:775	chemical composition	756:775	chemical composition	756:775	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	3	46	theme	column	692:697	arg1	chromatography					699:712	column chromatography	692:712	column chromatography	692:712	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	4	47	dep	T-α-l-Araf	1170:1179	arg1	T-β-d-Galp					1189:1198	T-β-d-Galp	1189:1198	T-β-d-Galp	1189:1198	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	4	47	dep	T-α-l-Araf	1170:1179	arg1	1→					1182:1183	1→	1182:1183	1→	1182:1183	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	2	48	theme	intracellular	630:642	arg1	species					660:666	intracellular reactive oxygen species	630:666	intracellular reactive oxygen species	630:666	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	0	49	from	jujube	137:142	arg1	Preparation					0:10	Preparation	0:10	Preparation	0:10	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	49	from	jujube	137:142	arg1	characterization					24:39	structural characterization	13:39	structural characterization	13:39	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	49	from	jujube	137:142	arg1	activity					57:64	antioxidant activity	45:64	antioxidant activity	45:64	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	49	from	jujube	137:142	arg1	polysaccharides					83:97	water-soluble polysaccharides	69:97	water-soluble polysaccharides	69:97	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	49	from	jujube	137:142	arg1	fractions					112:120	purified fractions	103:120	purified fractions	103:120	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	4	50	theme	→4	1103:1104	arg1	residues					1139:1146	→4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues	1103:1146	residues	1139:1146	As the most abundant and potent antioxidant component, the backbone of BJP-3 was mainly composed of →4)-α-l-GalpA (1→, →5)-α-l-Araf (1→ residues with two terminals of T-α-l-Araf (1→ and T-β-d-Galp (1→.
35278736	5	51	theme	above	1209:1213	arg1	results					1215:1221	The above results	1205:1221	The above results	1205:1221	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	3	52	theme	monosaccharide	796:809	arg1	composition					811:821	monosaccharide composition	796:821	monosaccharide composition (type and relative proportion)	796:852	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	3	53	theme	protective	955:964	arg1	effects					966:972	protective effects	955:972	protective effects against H2O2-induced HUVECs	955:1000	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	5	54	theme	different	1275:1283	arg1	polysaccharides					1302:1316	different blackened jujube polysaccharides	1275:1316	different blackened jujube polysaccharides	1275:1316	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	3	55	theme	molecular	778:786	arg1	weight					788:793	molecular weight	778:793	molecular weight	778:793	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	2	56	theme	protective	512:521	arg1	effects					523:529	excellent protective effects	502:529	excellent protective effects	502:529	The crude BJPs exhibited dose-dependent radical scavenging activity and total reducing capacity, and provided excellent protective effects against H2O2-damaged HUVECs via up-regulating mitochondrial membrane potential and down-regulating intracellular reactive oxygen species.
35278736	5	57	theme	blackened	1285:1293	arg1	polysaccharides					1302:1316	different blackened jujube polysaccharides	1275:1316	different blackened jujube polysaccharides	1275:1316	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	0	58	theme	polysaccharides	83:97	arg1	Preparation					0:10	Preparation	0:10	Preparation	0:10	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	58	theme	polysaccharides	83:97	arg1	characterization					24:39	structural characterization	13:39	structural characterization	13:39	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	58	theme	polysaccharides	83:97	arg1	activity					57:64	antioxidant activity	45:64	antioxidant activity	45:64	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	5	59	theme	functional	1370:1379	arg1	foods					1381:1385	functional foods	1370:1385	functional foods	1370:1385	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	5	60	theme	jujube	1295:1300	arg1	polysaccharides					1302:1316	different blackened jujube polysaccharides	1275:1316	different blackened jujube polysaccharides	1275:1316	The above results compared the structural and bioactive properties of different blackened jujube polysaccharides and highlighted their potential as antioxidants for functional foods.
35278736	0	61	theme	water-soluble	69:81	arg1	polysaccharides					83:97	water-soluble polysaccharides	69:97	water-soluble polysaccharides	69:97	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	0	62	from	characterization	24:39	arg1	jujube					137:142	blackened jujube	127:142	blackened jujube	127:142	Preparation, structural characterization and antioxidant activity of water-soluble polysaccharides and purified fractions from blackened jujube by an activity-oriented approach.
35278736	3	63	theme	purified	724:731	arg1	components					733:742	the five purified components	715:742	the five purified components	715:742	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	3	64	theme	H2O2-induced	982:993	arg1	HUVECs					995:1000	H2O2-induced HUVECs	982:1000	H2O2-induced HUVECs	982:1000	After fractionation by column chromatography, the five purified components differed in chemical composition, molecular weight, monosaccharide composition (type and relative proportion) and FTIR band (peak pattern or intensity, especially in the range of 1000.0-1200.0 cm-1), as well as protective effects against H2O2-induced HUVECs.
35278736	1	65	theme	crude	271:275	arg1	BJPs					311:314	BJPs	311:314	BJPs	311:314	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
35278736	1	65	theme	crude	271:275	arg1	polysaccharides					294:308	crude blackened jujube polysaccharides	271:308	crude blackened jujube polysaccharides (BJPs)	271:315	This study aimed to investigate the structural features and antioxidant activity in vitro of crude blackened jujube polysaccharides (BJPs) and five purified polysaccharides based on the activity-oriented approach.
36627035	7	0	theme	TNF-α	1265:1269	arg1	expression					1251:1260	the mRNA expression	1242:1260	the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA	1242:1357	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	4	1	theme	monosaccharide	522:535	arg1	compositions					537:548	The monosaccharide compositions	518:548	The monosaccharide compositions of AMP-FW and AMP-FA	518:569	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	1	theme	monosaccharide	522:535	arg1	glucose					576:582	glucose	576:582	glucose	576:582	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	8	2	theme	different	1380:1388	arg1	TLR					1411:1413	TLR	1411:1413	TLR	1411:1413	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	8	2	theme	different	1380:1388	arg1	receptors					1400:1408	different toll-like receptors	1380:1408	different toll-like receptors (TLR)	1380:1414	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	4	3	theme	0.11:0.89	617:625	arg1	ratio					608:612	a molar ratio	600:612	a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC)	600:694	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	0	4	theme	immunoregulatory	93:108	arg1	evaluation					110:119	immunoregulatory evaluation	93:119	immunoregulatory evaluation	93:119	Inulin-type fructans obtained from Atractylodis Macrocephalae by water/alkali extraction and immunoregulatory evaluation.
36627035	4	5	theme	AMP-FA	564:569	arg1	compositions					537:548	The monosaccharide compositions	518:548	The monosaccharide compositions of AMP-FW and AMP-FA	518:569	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	5	theme	AMP-FA	564:569	arg1	glucose					576:582	glucose	576:582	glucose	576:582	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	7	6	from	studies	1113:1119	arg1	immunomodulation					1124:1139	immunomodulation	1124:1139	immunomodulation	1124:1139	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	3	7	theme	AMP-FA	402:407	arg1	weight					381:386	The molecular weight	367:386	The molecular weight of AMP-FW and AMP-FA	367:407	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	6	8	theme	electron	954:961	arg1	microscopy					963:972	scanning electron microscopy	945:972	the scanning electron microscopy (SEM) results	941:986	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	6	8	theme	electron	954:961	arg1	SEM					975:977	SEM	975:977	SEM	975:977	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	5	9	theme	functional	701:710	arg1	groups					712:717	The functional groups	697:717	The functional groups	697:717	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	6	10	theme	scanning	945:952	arg1	microscopy					963:972	scanning electron microscopy	945:972	the scanning electron microscopy (SEM) results	941:986	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	6	10	theme	scanning	945:952	arg1	SEM					975:977	SEM	975:977	SEM	975:977	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	8	11	theme	toll-like	1390:1398	arg1	TLR					1411:1413	TLR	1411:1413	TLR	1411:1413	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	8	11	theme	toll-like	1390:1398	arg1	receptors					1400:1408	different toll-like receptors	1380:1408	different toll-like receptors (TLR)	1380:1414	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	7	12	theme	immunomodulatory	1308:1323	arg1	potential					1325:1333	a relative high immunomodulatory potential	1292:1333	a relative high immunomodulatory potential	1292:1333	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	3	13	theme	AMP-FW	391:396	arg1	weight					381:386	The molecular weight	367:386	The molecular weight of AMP-FW and AMP-FA	367:407	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	5	14	from	structure	873:881	arg1	macrocephala					918:929	A. macrocephala	915:929	A. macrocephala	915:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	2	15	theme	exchange	316:323	arg1	column					325:330	anion exchange column and size exclusion chromatography	310:364	column	325:330	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	3	16	theme	gel	479:481	arg1	HPGPC					510:514	HPGPC	510:514	HPGPC	510:514	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	3	16	theme	gel	479:481	arg1	chromatography					494:507	high performance gel permeation chromatography	462:507	high performance gel permeation chromatography (HPGPC)	462:515	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	7	17	theme	mRNA	1246:1249	arg1	expression					1251:1260	the mRNA expression	1242:1260	the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA	1242:1357	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	2	18	theme	anion	310:314	arg1	column					325:330	anion exchange column and size exclusion chromatography	310:364	column	325:330	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	8	19	from	roles	1447:1451	arg1	immunoregulation					1460:1475	the immunoregulation	1456:1475	the immunoregulation	1456:1475	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	3	20	theme	permeation	483:492	arg1	HPGPC					510:514	HPGPC	510:514	HPGPC	510:514	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	3	20	theme	permeation	483:492	arg1	chromatography					494:507	high performance gel permeation chromatography	462:507	high performance gel permeation chromatography (HPGPC)	462:515	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	4	21	from	ratio	608:612	arg1	fructose					588:595	fructose	588:595	fructose	588:595	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	21	from	ratio	608:612	arg1	glucose					576:582	glucose	576:582	glucose	576:582	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	21	from	ratio	608:612	arg1	compositions					537:548	The monosaccharide compositions	518:548	The monosaccharide compositions of AMP-FW and AMP-FA	518:569	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	3	22	theme	molecular	371:379	arg1	weight					381:386	The molecular weight	367:386	The molecular weight of AMP-FW and AMP-FA	367:407	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	3	23	dep	estimated	449:457	arg1	3438 Da					426:432	3438 Da	426:432	3438 Da	426:432	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	3	23	dep	estimated	449:457	arg1	2874 Da					414:420	2874 Da	414:420	2874 Da	414:420	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	6	24	theme	microscopy	963:972	arg1	results					980:986	the scanning electron microscopy (SEM) results	941:986	the scanning electron microscopy (SEM) results	941:986	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	3	25	theme	high	462:465	arg1	HPGPC					510:514	HPGPC	510:514	HPGPC	510:514	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	3	25	theme	high	462:465	arg1	chromatography					494:507	high performance gel permeation chromatography	462:507	high performance gel permeation chromatography (HPGPC)	462:515	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	0	26	theme	Inulin-type	0:10	arg1	fructans					12:19	Inulin-type fructans	0:19	Inulin-type fructans	0:19	Inulin-type fructans obtained from Atractylodis Macrocephalae by water/alkali extraction and immunoregulatory evaluation.
36627035	6	27	theme	lamellar	1036:1043	arg1	shape					1045:1049	irregular lamellar shape	1026:1049	irregular lamellar shape for the AMP-FW and spheroid	1026:1077	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	8	28	from	activation	1366:1375	arg1	TLR					1411:1413	TLR	1411:1413	TLR	1411:1413	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	8	28	from	activation	1366:1375	arg1	receptors					1400:1408	different toll-like receptors	1380:1408	different toll-like receptors (TLR)	1380:1414	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	3	29	theme	performance	467:477	arg1	HPGPC					510:514	HPGPC	510:514	HPGPC	510:514	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	3	29	theme	performance	467:477	arg1	chromatography					494:507	high performance gel permeation chromatography	462:507	high performance gel permeation chromatography (HPGPC)	462:515	The molecular weight of AMP-FW and AMP-FA were 2874 Da and 3438 Da, respectively, estimated by high performance gel permeation chromatography (HPGPC).
36627035	5	30	theme	fructan	865:871	arg1	structure					873:881	a similar inulin-type fructan structure	843:881	a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala	843:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	5	31	theme	inulin-type	853:863	arg1	structure					873:881	a similar inulin-type fructan structure	843:881	a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala	843:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	2	32	theme	exclusion	341:349	arg1	chromatography					351:364	anion exchange column and size exclusion chromatography	310:364	chromatography	351:364	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	5	33	theme	chemical	748:755	arg1	structure					757:765	the chemical structure	744:765	the chemical structure	744:765	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	6	34	dep	AMP-FW	1059:1064	arg1	the					1055:1057	the	1055:1057	the	1055:1057	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	2	35	theme	size	336:339	arg1	chromatography					351:364	anion exchange column and size exclusion chromatography	310:364	chromatography	351:364	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	4	36	theme	molar	602:606	arg1	ratio					608:612	a molar ratio	600:612	a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC)	600:694	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	7	37	theme	further	1105:1111	arg1	studies					1113:1119	The further studies	1101:1119	The further studies on immunomodulation	1101:1139	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	7	38	theme	RAW	1213:1215	arg1	cells					1223:1227	RAW 264.7 cells	1213:1227	RAW 264.7 cells	1213:1227	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	6	39	theme	different	995:1003	arg1	microstructures					1005:1019	different microstructures	995:1019	different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA	995:1098	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	2	40	theme	water	222:226	arg1	extraction					228:237	water extraction	222:237	water extraction (AMP-FW)	222:246	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	2	40	theme	water	222:226	arg1	AMP-FW					240:245	AMP-FW	240:245	AMP-FW	240:245	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	7	41	dep	significantly	1178:1190	arg1	P < 0.05					1193:1200	P < 0.05	1193:1200	P < 0.05	1193:1200	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	5	42	theme	polysaccharides	894:908	arg1	structure					873:881	a similar inulin-type fructan structure	843:881	a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala	843:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	0	43	theme	water/alkali	65:76	arg1	extraction					78:87	water/alkali extraction	65:87	water/alkali extraction	65:87	Inulin-type fructans obtained from Atractylodis Macrocephalae by water/alkali extraction and immunoregulatory evaluation.
36627035	7	44	from	50 μg/mL	1163:1170	arg1	AMP-FW					1153:1158	AMP-FW	1153:1158	AMP-FW at 50 μg/mL	1153:1170	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	6	45	theme	irregular	1026:1034	arg1	shape					1045:1049	irregular lamellar shape	1026:1049	irregular lamellar shape for the AMP-FW and spheroid	1026:1077	However, the scanning electron microscopy (SEM) results showed different microstructures that irregular lamellar shape for the AMP-FW and spheroid shape for the AMP-FA.
36627035	9	46	theme	structure-activity	1552:1569	arg1	studies					1584:1590	further structure-activity relationship studies	1544:1590	further structure-activity relationship studies	1544:1590	Overall, these findings reported here will serve as the basis for further structure-activity relationship studies.
36627035	5	47	theme	glycosidic	720:729	arg1	linkages					731:738	glycosidic linkages	720:738	glycosidic linkages	720:738	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	2	48	theme	alkali	252:257	arg1	AMP-FA					280:285	AMP-FA	280:285	AMP-FA	280:285	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	2	48	theme	alkali	252:257	arg1	extraction					268:277	alkali solution extraction	252:277	alkali solution extraction (AMP-FA)	252:286	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	2	49	theme	solution	259:266	arg1	AMP-FA					280:285	AMP-FA	280:285	AMP-FA	280:285	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	2	49	theme	solution	259:266	arg1	extraction					268:277	alkali solution extraction	252:277	alkali solution extraction (AMP-FA)	252:286	were investigated by water extraction (AMP-FW) and alkali solution extraction (AMP-FA) after purification by anion exchange column and size exclusion chromatography.
36627035	8	50	theme	different	1437:1445	arg1	roles					1447:1451	their different roles	1431:1451	their different roles in the immunoregulation	1431:1475	Their activation on different toll-like receptors (TLR) also indicated their different roles in the immunoregulation.
36627035	7	51	theme	high	1303:1306	arg1	potential					1325:1333	a relative high immunomodulatory potential	1292:1333	a relative high immunomodulatory potential	1292:1333	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	1	52	theme	homogenous	126:135	arg1	polysaccharides					137:151	Two homogenous polysaccharides	122:151	Two homogenous polysaccharides	122:151	Two homogenous polysaccharides extracted from Atractylodes macrocephala Koidz.
36627035	4	53	theme	performance	646:656	arg1	HPAEC					689:693	HPAEC	689:693	HPAEC	689:693	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	53	theme	performance	646:656	arg1	chromatography					673:686	high performance anion exchange chromatography	641:686	high performance anion exchange chromatography (HPAEC)	641:694	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	5	54	from	macrocephala	918:929	arg1	polysaccharides					894:908	the two polysaccharides	886:908	the two polysaccharides from A. macrocephala	886:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	5	54	from	macrocephala	918:929	arg1	structure					873:881	a similar inulin-type fructan structure	843:881	a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala	843:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	7	55	theme	relative	1294:1301	arg1	potential					1325:1333	a relative high immunomodulatory potential	1292:1333	a relative high immunomodulatory potential	1292:1333	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	4	56	theme	high	641:644	arg1	HPAEC					689:693	HPAEC	689:693	HPAEC	689:693	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	56	theme	high	641:644	arg1	chromatography					673:686	high performance anion exchange chromatography	641:686	high performance anion exchange chromatography (HPAEC)	641:694	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	7	57	theme	IL-1β	1275:1279	arg1	expression					1251:1260	the mRNA expression	1242:1260	the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA	1242:1357	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	7	58	contain	had	1288:1290	arg2	potential					1325:1333	a relative high immunomodulatory potential	1292:1333	a relative high immunomodulatory potential	1292:1333	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	7	58	contain	had	1288:1290	arg1	IL-1β					1275:1279	IL-1β	1275:1279	IL-1β	1275:1279	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	7	58	contain	had	1288:1290	arg1	TNF-α					1265:1269	TNF-α	1265:1269	TNF-α	1265:1269	The further studies on immunomodulation showed that AMP-FW at 50 μg/mL could significantly (P < 0.05) stimulate RAW 264.7 cells by enhancing the mRNA expression of TNF-α and IL-1β, which had a relative high immunomodulatory potential when compared to AMP-FA.
36627035	9	59	theme	relationship	1571:1582	arg1	studies					1584:1590	further structure-activity relationship studies	1544:1590	further structure-activity relationship studies	1544:1590	Overall, these findings reported here will serve as the basis for further structure-activity relationship studies.
36627035	4	60	theme	exchange	664:671	arg1	HPAEC					689:693	HPAEC	689:693	HPAEC	689:693	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	60	theme	exchange	664:671	arg1	chromatography					673:686	high performance anion exchange chromatography	641:686	high performance anion exchange chromatography (HPAEC)	641:694	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	9	61	theme	further	1544:1550	arg1	studies					1584:1590	further structure-activity relationship studies	1544:1590	further structure-activity relationship studies	1544:1590	Overall, these findings reported here will serve as the basis for further structure-activity relationship studies.
36627035	4	62	theme	AMP-FW	553:558	arg1	compositions					537:548	The monosaccharide compositions	518:548	The monosaccharide compositions of AMP-FW and AMP-FA	518:569	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	62	theme	AMP-FW	553:558	arg1	glucose					576:582	glucose	576:582	glucose	576:582	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	5	63	theme	similar	845:851	arg1	structure					873:881	a similar inulin-type fructan structure	843:881	a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala	843:929	The functional groups, glycosidic linkages and the chemical structure were characterized by FT-IR, GC-MS and NMR, which comprehensively indicated a similar inulin-type fructan structure of the two polysaccharides from A. macrocephala.
36627035	4	64	theme	anion	658:662	arg1	HPAEC					689:693	HPAEC	689:693	HPAEC	689:693	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
36627035	4	64	theme	anion	658:662	arg1	chromatography					673:686	high performance anion exchange chromatography	641:686	high performance anion exchange chromatography (HPAEC)	641:694	The monosaccharide compositions of AMP-FW and AMP-FA were glucose and fructose at a molar ratio of 0.11:0.89 determined by high performance anion exchange chromatography (HPAEC).
35277878	8	0	theme	PRACTICAL	1066:1074	arg1	APPLICATIONS					1076:1087	PRACTICAL APPLICATIONS	1066:1087	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.	1066:1189	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	7	1	theme	potential	1002:1010	arg1	antioxidant					1012:1022	a potential antioxidant	1000:1022	a potential antioxidant for functional foods and pharmaceuticals	1000:1063	Thus, this study could provide a potential antioxidant for functional foods and pharmaceuticals.
35277878	2	2	theme	NaOH	374:377	arg1	concentration					379:391	20% NaOH concentration	370:391	20% NaOH concentration	370:391	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	6	3	theme	significant	914:924	arg1	activity					938:945	significant antioxidant activity	914:945	significant antioxidant activity	914:945	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	1	4	theme	water	265:269	arg1	solubility					271:280	water solubility	265:280	water solubility	265:280	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	8	5	theme	edible	1112:1117	arg1	nameko					1099:1104	Pholiota nameko	1090:1104	Pholiota nameko	1090:1104	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	5	theme	edible	1112:1117	arg1	mushroom					1133:1140	an edible and medicinal mushroom	1109:1140	mushroom	1133:1140	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	0	6	from	characterization	10:25	arg1	Pholiota					93:100	Pholiota	93:100	Pholiota	93:100	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	2	7	theme	%	372:372	arg1	concentration					379:391	20% NaOH concentration	370:391	20% NaOH concentration	370:391	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	8	8	from	cellulose	1166:1174	arg1	rich					1143:1146	rich	1143:1146	rich	1143:1146	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	9	9	contain	have	1257:1260	arg1	polysaccharides					1241:1255	P. nameko polysaccharides	1231:1255	P. nameko polysaccharides	1231:1255	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	9	9	contain	have	1257:1260	arg2	effects					1277:1283	many medicinal effects	1262:1283	many medicinal effects	1262:1283	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	6	10	theme	antioxidant	926:936	arg1	activity					938:945	significant antioxidant activity	914:945	significant antioxidant activity	914:945	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	4	11	theme	NMR	583:585	arg1	spectra					597:603	NMR and FT-IR spectra	583:603	NMR and FT-IR spectra	583:603	The results of NMR and FT-IR spectra showed that carboxymethylation modification was successful.
35277878	8	12	dep	APPLICATIONS	1076:1087	arg1	nameko					1099:1104	Pholiota nameko	1090:1104	Pholiota nameko	1090:1104	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	12	dep	APPLICATIONS	1076:1087	arg1	mushroom					1133:1140	an edible and medicinal mushroom	1109:1140	mushroom	1133:1140	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	2	13	with	time	435:438	arg1	acid					472:475	2 g chloroacetic acid	455:475	2 g chloroacetic acid	455:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	10	14	theme	nameko	1368:1373	arg1	polysaccharides					1375:1389	P. nameko polysaccharides	1365:1389	P. nameko polysaccharides	1365:1389	In this study, CPPN was synthesized by carboxymethylation of P. nameko polysaccharides.
35277878	1	15	theme	paper	132:136	arg1	objective					114:122	The objective	110:122	The objective of this paper	110:136	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	9	16	theme	P.	1231:1232	arg1	polysaccharides					1241:1255	P. nameko polysaccharides	1231:1255	P. nameko polysaccharides	1231:1255	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	11	17	theme	significant	1515:1525	arg1	properties					1539:1548	significant antioxidant properties	1515:1548	significant antioxidant properties	1515:1548	Through structural characterization, antioxidant activity, and solubility studies, carboxymethylated polysaccharides shown significant antioxidant properties and increased solubility.
35277878	1	18	theme	Pholiota	189:196	arg1	CPPN					206:209	CPPN	206:209	CPPN	206:209	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	1	18	theme	Pholiota	189:196	arg1	nameko					198:203	Pholiota nameko	189:203	Pholiota nameko (CPPN)	189:210	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	11	19	theme	solubility	1455:1464	arg1	studies					1466:1472	solubility studies	1455:1472	solubility studies	1455:1472	Through structural characterization, antioxidant activity, and solubility studies, carboxymethylated polysaccharides shown significant antioxidant properties and increased solubility.
35277878	5	20	dep	composition	788:798	arg1	content					800:806	content	800:806	content	800:806	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	9	21	theme	nameko	1234:1239	arg1	polysaccharides					1241:1255	P. nameko polysaccharides	1231:1255	P. nameko polysaccharides	1231:1255	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	0	22	theme	Structure	0:8	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization	0:25	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	11	23	theme	carboxymethylated	1475:1491	arg1	polysaccharides					1493:1507	carboxymethylated polysaccharides	1475:1507	carboxymethylated polysaccharides	1475:1507	Through structural characterization, antioxidant activity, and solubility studies, carboxymethylated polysaccharides shown significant antioxidant properties and increased solubility.
35277878	1	24	theme	nameko	198:203	arg1	polysaccharide					171:184	the carboxymethyl polysaccharide	153:184	the carboxymethyl polysaccharide of Pholiota nameko (CPPN)	153:210	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	2	25	theme	chloroacetic	459:470	arg1	acid					472:475	2 g chloroacetic acid	455:475	2 g chloroacetic acid	455:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	0	26	from	activity	43:50	arg1	Pholiota					93:100	Pholiota	93:100	Pholiota	93:100	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	12	27	from	application	1640:1650	arg1	food					1695:1698	functional food	1684:1698	functional food	1684:1698	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	12	27	from	application	1640:1650	arg1	industry					1719:1726	pharmaceutical industry	1704:1726	pharmaceutical industry	1704:1726	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	12	28	theme	pharmaceutical	1704:1717	arg1	industry					1719:1726	pharmaceutical industry	1704:1726	pharmaceutical industry	1704:1726	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	2	29	dep	follows	361:367	arg1	time					435:438	4 hr etherification time	415:438	4 hr etherification time	415:438	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	2	29	dep	follows	361:367	arg1	60°C					445:448	60°C	445:448	60°C with 2 g chloroacetic acid	445:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	2	29	dep	follows	361:367	arg1	concentration					379:391	20% NaOH concentration	370:391	20% NaOH concentration	370:391	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	2	29	dep	follows	361:367	arg1	alkalization					401:412	1.5 hr alkalization	394:412	1.5 hr alkalization	394:412	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	2	30	theme	2 g	455:457	arg1	acid					472:475	2 g chloroacetic acid	455:475	2 g chloroacetic acid	455:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	1	31	theme	antioxidant	287:297	arg1	activities					299:308	antioxidant activities	287:308	antioxidant activities	287:308	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	8	32	from	minerals	1181:1188	arg1	rich					1143:1146	rich	1143:1146	rich	1143:1146	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	10	33	theme	P.	1365:1366	arg1	polysaccharides					1375:1389	P. nameko polysaccharides	1365:1389	P. nameko polysaccharides	1365:1389	In this study, CPPN was synthesized by carboxymethylation of P. nameko polysaccharides.
35277878	8	34	from	carbohydrates	1151:1163	arg1	rich					1143:1146	rich	1143:1146	rich	1143:1146	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	2	35	theme	1.5 hr	394:399	arg1	alkalization					401:412	1.5 hr alkalization	394:412	1.5 hr alkalization	394:412	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	0	36	theme	antioxidant	31:41	arg1	activity					43:50	antioxidant activity	31:50	antioxidant activity	31:50	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	9	37	theme	many	1262:1265	arg1	effects					1277:1283	many medicinal effects	1262:1283	many medicinal effects	1262:1283	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	2	38	theme	carboxymethylation	323:340	arg1	conditions					342:351	The optimal carboxymethylation conditions	311:351	The optimal carboxymethylation conditions	311:351	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	4	39	theme	carboxymethylation	617:634	arg1	modification					636:647	carboxymethylation modification	617:647	carboxymethylation modification	617:647	The results of NMR and FT-IR spectra showed that carboxymethylation modification was successful.
35277878	5	40	theme	total	695:699	arg1	content					708:714	total phenol content	695:714	total phenol content	695:714	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	9	41	theme	medicinal	1267:1275	arg1	effects					1277:1283	many medicinal effects	1262:1283	many medicinal effects	1262:1283	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	2	42	theme	optimal	315:321	arg1	conditions					342:351	The optimal carboxymethylation conditions	311:351	The optimal carboxymethylation conditions	311:351	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	11	43	theme	antioxidant	1527:1537	arg1	properties					1539:1548	significant antioxidant properties	1515:1548	significant antioxidant properties	1515:1548	Through structural characterization, antioxidant activity, and solubility studies, carboxymethylated polysaccharides shown significant antioxidant properties and increased solubility.
35277878	11	44	theme	structural	1400:1409	arg1	characterization					1411:1426	structural characterization	1400:1426	structural characterization	1400:1426	Through structural characterization, antioxidant activity, and solubility studies, carboxymethylated polysaccharides shown significant antioxidant properties and increased solubility.
35277878	5	45	theme	phenol	701:706	arg1	content					708:714	total phenol content	695:714	total phenol content	695:714	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	6	46	theme	unmodified	877:886	arg1	polysaccharides					888:902	unmodified polysaccharides	877:902	unmodified polysaccharides	877:902	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	6	47	contain	had	910:912	arg2	solubility					957:966	water solubility	951:966	water solubility	951:966	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	6	47	contain	had	910:912	arg2	activity					938:945	significant antioxidant activity	914:945	significant antioxidant activity	914:945	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	6	47	contain	had	910:912	arg1	CPPN					905:908	CPPN	905:908	CPPN	905:908	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	2	48	theme	4 hr	415:418	arg1	time					435:438	4 hr etherification time	415:438	4 hr etherification time	415:438	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	8	49	theme	medicinal	1123:1131	arg1	nameko					1099:1104	Pholiota nameko	1090:1104	Pholiota nameko	1090:1104	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	49	theme	medicinal	1123:1131	arg1	mushroom					1133:1140	an edible and medicinal mushroom	1109:1140	mushroom	1133:1140	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	0	50	from	Pholiota	93:100	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization	0:25	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	0	50	from	Pholiota	93:100	arg1	activity					43:50	antioxidant activity	31:50	antioxidant activity	31:50	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	0	50	from	Pholiota	93:100	arg1	polysaccharide					73:86	carboxymethylated polysaccharide	55:86	carboxymethylated polysaccharide from Pholiota nameko	55:107	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	5	51	theme	surface	812:818	arg1	structure					820:828	surface structure	812:828	surface structure	812:828	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	10	52	theme	polysaccharides	1375:1389	arg1	carboxymethylation					1343:1360	carboxymethylation	1343:1360	carboxymethylation of P. nameko polysaccharides	1343:1389	In this study, CPPN was synthesized by carboxymethylation of P. nameko polysaccharides.
35277878	2	53	theme	etherification	420:433	arg1	time					435:438	4 hr etherification time	415:438	4 hr etherification time	415:438	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	0	54	theme	polysaccharide	73:86	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization	0:25	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	0	54	theme	polysaccharide	73:86	arg1	activity					43:50	antioxidant activity	31:50	antioxidant activity	31:50	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	12	55	theme	polysaccharides	1665:1679	arg1	application					1640:1650	the high-value application	1625:1650	the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry	1625:1726	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	8	56	theme	rich	1143:1146	arg1	nameko					1099:1104	Pholiota nameko	1090:1104	Pholiota nameko	1090:1104	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	56	theme	rich	1143:1146	arg1	mushroom					1133:1140	an edible and medicinal mushroom	1109:1140	mushroom	1133:1140	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	57	from	rich	1143:1146	arg1	cellulose					1166:1174	cellulose	1166:1174	cellulose	1166:1174	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	57	from	rich	1143:1146	arg1	minerals					1181:1188	minerals	1181:1188	minerals	1181:1188	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	57	from	rich	1143:1146	arg1	carbohydrates					1151:1163	carbohydrates	1151:1163	carbohydrates	1151:1163	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	2	58	with	60°C	445:448	arg1	acid					472:475	2 g chloroacetic acid	455:475	2 g chloroacetic acid	455:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	2	59	theme	20	370:371	arg1	%					372:372	%	372:372	%	372:372	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	0	60	theme	carboxymethylated	55:71	arg1	polysaccharide					73:86	carboxymethylated polysaccharide	55:86	carboxymethylated polysaccharide from Pholiota nameko	55:107	Structure characterization and antioxidant activity of carboxymethylated polysaccharide from Pholiota nameko.
35277878	5	61	theme	total	678:682	arg1	sugar					684:688	total sugar	678:688	total sugar	678:688	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	9	62	theme	human	1292:1296	arg1	body					1298:1301	the human body	1288:1301	the human body	1288:1301	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	8	63	theme	Pholiota	1090:1097	arg1	nameko					1099:1104	Pholiota nameko	1090:1104	Pholiota nameko	1090:1104	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	8	63	theme	Pholiota	1090:1097	arg1	mushroom					1133:1140	an edible and medicinal mushroom	1109:1140	mushroom	1133:1140	PRACTICAL APPLICATIONS: Pholiota nameko is an edible and medicinal mushroom, rich in carbohydrates, cellulose, and minerals.
35277878	7	64	theme	functional	1028:1037	arg1	foods					1039:1043	functional foods	1028:1043	functional foods	1028:1043	Thus, this study could provide a potential antioxidant for functional foods and pharmaceuticals.
35277878	3	65	theme	substitution	504:515	arg1	degree					517:522	a substitution degree	502:522	a substitution degree of 0.72	502:530	Under these conditions, a substitution degree of 0.72 and a yield of 88.3% were achieved.
35277878	12	66	theme	functional	1684:1693	arg1	food					1695:1698	functional food	1684:1698	functional food	1684:1698	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	6	67	theme	water	951:955	arg1	solubility					957:966	water solubility	951:966	water solubility	951:966	Compared with unmodified polysaccharides, CPPN had significant antioxidant activity and water solubility.
35277878	12	68	theme	high-value	1629:1638	arg1	application					1640:1650	the high-value application	1625:1650	the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry	1625:1726	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	11	69	theme	antioxidant	1429:1439	arg1	activity					1441:1448	antioxidant activity	1429:1448	antioxidant activity	1429:1448	Through structural characterization, antioxidant activity, and solubility studies, carboxymethylated polysaccharides shown significant antioxidant properties and increased solubility.
35277878	3	70	theme	%	551:551	arg1	yield					538:542	a yield	536:542	a yield of 88.3%	536:551	Under these conditions, a substitution degree of 0.72 and a yield of 88.3% were achieved.
35277878	3	70	theme	%	551:551	arg1	degree					517:522	a substitution degree	502:522	a substitution degree of 0.72	502:530	Under these conditions, a substitution degree of 0.72 and a yield of 88.3% were achieved.
35277878	4	71	theme	FT-IR	591:595	arg1	spectra					597:603	NMR and FT-IR spectra	583:603	NMR and FT-IR spectra	583:603	The results of NMR and FT-IR spectra showed that carboxymethylation modification was successful.
35277878	1	72	theme	structural	237:246	arg1	characteristics					248:262	its structural characteristics	233:262	its structural characteristics	233:262	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	5	73	theme	molecular	737:745	arg1	weight					747:752	the molecular weight	733:752	the molecular weight	733:752	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	2	74	with	concentration	379:391	arg1	acid					472:475	2 g chloroacetic acid	455:475	2 g chloroacetic acid	455:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	3	75	theme	0.72	527:530	arg1	yield					538:542	a yield	536:542	a yield of 88.3%	536:551	Under these conditions, a substitution degree of 0.72 and a yield of 88.3% were achieved.
35277878	3	75	theme	0.72	527:530	arg1	degree					517:522	a substitution degree	502:522	a substitution degree of 0.72	502:530	Under these conditions, a substitution degree of 0.72 and a yield of 88.3% were achieved.
35277878	12	76	theme	nameko	1658:1663	arg1	polysaccharides					1665:1679	P. nameko polysaccharides	1655:1679	P. nameko polysaccharides	1655:1679	Therefore, this research lays the foundation for the high-value application of P. nameko polysaccharides in functional food and pharmaceutical industry.
35277878	5	77	theme	monosaccharide	773:786	arg1	composition					788:798	the monosaccharide composition content and surface structure	769:828	composition	788:798	The protein, total sugar, and total phenol content decreased, while the molecular weight increased, and the monosaccharide composition content and surface structure changed upon carboxymethylation.
35277878	2	78	with	alkalization	401:412	arg1	acid					472:475	2 g chloroacetic acid	455:475	2 g chloroacetic acid	455:475	The optimal carboxymethylation conditions were as follows: 20% NaOH concentration, 1.5 hr alkalization, 4 hr etherification time, and 60°C with 2 g chloroacetic acid.
35277878	9	79	theme	Pharmacological	1191:1205	arg1	studies					1207:1213	Pharmacological studies	1191:1213	Pharmacological studies	1191:1213	Pharmacological studies have shown that P. nameko polysaccharides have many medicinal effects on the human body.
35277878	1	80	theme	carboxymethyl	157:169	arg1	polysaccharide					171:184	the carboxymethyl polysaccharide	153:184	the carboxymethyl polysaccharide of Pholiota nameko (CPPN)	153:210	The objective of this paper was to prepare the carboxymethyl polysaccharide of Pholiota nameko (CPPN) and further evaluate its structural characteristics, water solubility, and antioxidant activities.
35277878	4	81	theme	spectra	597:603	arg1	results					572:578	The results	568:578	The results of NMR and FT-IR spectra	568:603	The results of NMR and FT-IR spectra showed that carboxymethylation modification was successful.
36563806	0	0	theme	gut	82:84	arg1	microbiota					86:95	the gut microbiota	78:95	the gut microbiota	78:95	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
36563806	4	1	theme	FEP	502:504	arg1	characterizations					473:489	The characterizations	469:489	The characterizations of FTP and FEP	469:504	The characterizations of FTP and FEP were analyzed, including FTIR, TGA, DSC, and monosaccharide composition.
36563806	3	2	from	modulation	449:458	arg1	rats					463:466	rats	463:466	rats	463:466	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	10	3	from	potential	1617:1625	arg1	ingredients					1657:1667	functional ingredients	1646:1667	functional ingredients	1646:1667	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	10	3	from	potential	1617:1625	arg1	development					1677:1687	food development	1672:1687	food development	1672:1687	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	0	4	from	effect	13:18	arg1	colitis					52:58	colitis	52:58	colitis via regulation of the gut microbiota	52:95	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
36563806	4	5	theme	monosaccharide	551:564	arg1	composition					566:576	monosaccharide composition	551:576	monosaccharide composition	551:576	The characterizations of FTP and FEP were analyzed, including FTIR, TGA, DSC, and monosaccharide composition.
36563806	5	6	theme	FTP	727:729	arg1	preadministration					706:722	the intragastric preadministration	689:722	the intragastric preadministration of FTP and FEP	689:737	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	6	7	theme	inflammatory	802:813	arg1	IL-1β					832:836	IL-1β	832:836	IL-1β	832:836	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	7	theme	inflammatory	802:813	arg1	TNF-α					843:847	TNF-α	843:847	TNF-α	843:847	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	7	theme	inflammatory	802:813	arg1	IL-6					826:829	IL-6	826:829	IL-6	826:829	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	7	theme	inflammatory	802:813	arg1	cytokines					815:823	inflammatory cytokines	802:823	inflammatory cytokines (IL-6, IL-1β, and TNF-α)	802:848	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	8	8	theme	inflammation-related	1331:1350	arg1	bacteria					1352:1359	inflammation-related bacteria	1331:1359	inflammation-related bacteria (Oscillospiraceae and Oscillibacter)	1331:1396	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	8	theme	inflammation-related	1331:1350	arg1	Oscillibacter					1383:1395	Oscillibacter	1383:1395	Oscillibacter	1383:1395	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	8	theme	inflammation-related	1331:1350	arg1	Oscillospiraceae					1362:1377	Oscillospiraceae	1362:1377	Oscillospiraceae	1362:1377	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	9	with	prefeeding	1168:1177	arg1	polysaccharides					1194:1208	buckwheat polysaccharides	1184:1208	buckwheat polysaccharides	1184:1208	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	6	10	theme	peroxidase	952:961	arg1	levels					963:968	superoxide dismutase, catalase, and glutathione peroxidase levels	904:968	superoxide dismutase, catalase, and glutathione peroxidase levels	904:968	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	2	11	from	characteristics	192:206	arg1	prevention					314:323	colitis prevention	306:323	colitis prevention	306:323	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	5	12	theme	TNBS-induced	650:661	arg1	colitis					663:669	TNBS-induced colitis	650:669	TNBS-induced colitis	650:669	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	9	13	theme	FEP	1571:1573	arg1	group					1575:1579	the high-dose FEP group	1557:1579	the high-dose FEP group	1557:1579	In conclusion, FTP and FEP strongly improved TNBS-induced colitis through antioxidant, anti-inflammatory, and microbiota modulation properties, especially in the high-dose FEP group.
36563806	6	14	theme	glutathione	940:950	arg1	peroxidase					952:961	glutathione peroxidase	940:961	glutathione peroxidase	940:961	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	5	15	theme	FEP	735:737	arg1	preadministration					706:722	the intragastric preadministration	689:722	the intragastric preadministration of FTP and FEP	689:737	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	5	16	theme	pathological	596:607	arg1	features					609:616	the pathological features	592:616	the pathological features of colon length	592:632	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	3	17	theme	microbiota	438:447	arg1	modulation					449:458	gut microbiota modulation	434:458	gut microbiota modulation in rats	434:466	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	10	18	theme	Buckwheat	1582:1590	arg1	polysaccharides					1592:1606	Buckwheat polysaccharides	1582:1606	Buckwheat polysaccharides	1582:1606	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	10	19	theme	food	1672:1675	arg1	development					1677:1687	food development	1672:1687	food development	1672:1687	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	2	20	theme	polysaccharides	281:295	arg1	valid					333:337	valid	333:337	valid	333:337	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	20	theme	polysaccharides	281:295	arg1	characteristics					192:206	the functional characteristics	177:206	the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention	177:323	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	3	21	theme	ameliorative	365:376	arg1	effects					378:384	the ameliorative effects	361:384	the ameliorative effects of FTP and FEP against TNBS-induced colitis	361:428	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	9	22	theme	TNBS-induced	1444:1455	arg1	colitis					1457:1463	TNBS-induced colitis	1444:1463	TNBS-induced colitis	1444:1463	In conclusion, FTP and FEP strongly improved TNBS-induced colitis through antioxidant, anti-inflammatory, and microbiota modulation properties, especially in the high-dose FEP group.
36563806	3	23	theme	FTP	389:391	arg1	effects					378:384	the ameliorative effects	361:384	the ameliorative effects of FTP and FEP against TNBS-induced colitis	361:428	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	4	24	theme	FTP	494:496	arg1	characterizations					473:489	The characterizations	469:489	The characterizations of FTP and FEP	469:504	The characterizations of FTP and FEP were analyzed, including FTIR, TGA, DSC, and monosaccharide composition.
36563806	5	25	theme	colon	621:625	arg1	length					627:632	colon length	621:632	colon length	621:632	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	6	26	theme	catalase	926:933	arg1	levels					963:968	superoxide dismutase, catalase, and glutathione peroxidase levels	904:968	superoxide dismutase, catalase, and glutathione peroxidase levels	904:968	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	0	27	theme	Ameliorative	0:11	arg1	effect					13:18	Ameliorative effect	0:18	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.	0:96	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
36563806	10	28	theme	functional	1646:1655	arg1	ingredients					1657:1667	functional ingredients	1646:1667	functional ingredients	1646:1667	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	5	29	theme	length	627:632	arg1	symptoms					638:645	symptoms	638:645	symptoms in TNBS-induced colitis	638:669	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	5	29	theme	length	627:632	arg1	features					609:616	the pathological features	592:616	the pathological features of colon length	592:632	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	3	30	theme	gut	434:436	arg1	modulation					449:458	gut microbiota modulation	434:458	gut microbiota modulation in rats	434:466	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	0	31	theme	buckwheat	23:31	arg1	polysaccharides					33:47	buckwheat polysaccharides	23:47	buckwheat polysaccharides	23:47	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
36563806	2	32	theme	colitis	306:312	arg1	prevention					314:323	colitis prevention	306:323	colitis prevention	306:323	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	8	33	theme	short-chain	1259:1269	arg1	SCFA					1283:1286	SCFA	1283:1286	SCFA	1283:1286	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	33	theme	short-chain	1259:1269	arg1	acid					1277:1280	short-chain fatty acid	1259:1280	short-chain fatty acid (SCFA) production	1259:1298	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	7	34	theme	colitis	1120:1126	arg1	treatment					1094:1102	the treatment	1090:1102	the treatment of TNBS-induced colitis by buckwheat polysaccharides	1090:1155	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	5	35	from	features	609:616	arg1	colitis					663:669	TNBS-induced colitis	650:669	TNBS-induced colitis	650:669	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	5	36	theme	intragastric	693:704	arg1	preadministration					706:722	the intragastric preadministration	689:722	the intragastric preadministration of FTP and FEP	689:737	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	2	37	theme	functional	181:190	arg1	valid					333:337	valid	333:337	valid	333:337	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	37	theme	functional	181:190	arg1	characteristics					192:206	the functional characteristics	177:206	the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention	177:323	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	6	38	dep	cytokines	815:823	arg1	IL-1β					832:836	IL-1β	832:836	IL-1β	832:836	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	38	dep	cytokines	815:823	arg1	TNF-α					843:847	TNF-α	843:847	TNF-α	843:847	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	38	dep	cytokines	815:823	arg1	IL-6					826:829	IL-6	826:829	IL-6	826:829	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	38	dep	cytokines	815:823	arg1	cytokines					815:823	inflammatory cytokines	802:823	inflammatory cytokines (IL-6, IL-1β, and TNF-α)	802:848	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	8	39	dep	bacteria	1352:1359	arg1	bacteria					1352:1359	inflammation-related bacteria	1331:1359	inflammation-related bacteria (Oscillospiraceae and Oscillibacter)	1331:1396	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	39	dep	bacteria	1352:1359	arg1	Oscillibacter					1383:1395	Oscillibacter	1383:1395	Oscillibacter	1383:1395	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	39	dep	bacteria	1352:1359	arg1	Oscillospiraceae					1362:1377	Oscillospiraceae	1362:1377	Oscillospiraceae	1362:1377	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	3	40	theme	TNBS-induced	409:420	arg1	colitis					422:428	TNBS-induced colitis	409:428	TNBS-induced colitis	409:428	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	7	41	theme	signaling-associated	1020:1039	arg1	proteins					1041:1048	inflammatory signaling-associated proteins	1007:1048	inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS)	1007:1079	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	41	theme	signaling-associated	1020:1039	arg1	COX-2					1064:1068	COX-2	1064:1068	COX-2	1064:1068	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	41	theme	signaling-associated	1020:1039	arg1	iNOS					1075:1078	iNOS	1075:1078	iNOS	1075:1078	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	41	theme	signaling-associated	1020:1039	arg1	MAPK					1058:1061	MAPK	1058:1061	MAPK	1058:1061	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	41	theme	signaling-associated	1020:1039	arg1	NF-κB					1051:1055	NF-κB	1051:1055	NF-κB	1051:1055	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	42	theme	buckwheat	1131:1139	arg1	polysaccharides					1141:1155	buckwheat polysaccharides	1131:1155	buckwheat polysaccharides	1131:1155	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	8	43	theme	Firmicutes/Bacteroidetes	1224:1247	arg1	ratio					1249:1253	the Firmicutes/Bacteroidetes ratio	1220:1253	the Firmicutes/Bacteroidetes ratio	1220:1253	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	44	theme	acid	1277:1280	arg1	production					1289:1298	short-chain fatty acid (SCFA) production	1259:1298	short-chain fatty acid (SCFA) production	1259:1298	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	0	45	theme	polysaccharides	33:47	arg1	effect					13:18	Ameliorative effect	0:18	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.	0:96	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
36563806	6	46	theme	dismutase	915:923	arg1	levels					963:968	superoxide dismutase, catalase, and glutathione peroxidase levels	904:968	superoxide dismutase, catalase, and glutathione peroxidase levels	904:968	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	47	with	prefeeding	764:773	arg1	FTP					780:782	FTP	780:782	FTP	780:782	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	6	47	with	prefeeding	764:773	arg1	FEP					788:790	FEP	788:790	FEP	788:790	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	7	48	theme	TNBS-induced	1107:1118	arg1	colitis					1120:1126	TNBS-induced colitis	1107:1126	TNBS-induced colitis	1107:1126	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	8	49	theme	fatty	1271:1275	arg1	SCFA					1283:1286	SCFA	1283:1286	SCFA	1283:1286	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	8	49	theme	fatty	1271:1275	arg1	acid					1277:1280	short-chain fatty acid	1259:1280	short-chain fatty acid (SCFA) production	1259:1298	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	3	50	theme	FEP	397:399	arg1	effects					378:384	the ameliorative effects	361:384	the ameliorative effects of FTP and FEP against TNBS-induced colitis	361:428	This study evaluated the ameliorative effects of FTP and FEP against TNBS-induced colitis via gut microbiota modulation in rats.
36563806	6	51	theme	superoxide	904:913	arg1	dismutase					915:923	superoxide dismutase	904:923	superoxide dismutase	904:923	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	2	52	theme	polysaccharides	241:255	arg1	valid					333:337	valid	333:337	valid	333:337	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	52	theme	polysaccharides	241:255	arg1	characteristics					192:206	the functional characteristics	177:206	the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention	177:323	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	8	53	theme	buckwheat	1184:1192	arg1	polysaccharides					1194:1208	buckwheat polysaccharides	1184:1208	buckwheat polysaccharides	1184:1208	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	7	54	theme	inflammatory	1007:1018	arg1	proteins					1041:1048	inflammatory signaling-associated proteins	1007:1048	inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS)	1007:1079	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	54	theme	inflammatory	1007:1018	arg1	COX-2					1064:1068	COX-2	1064:1068	COX-2	1064:1068	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	54	theme	inflammatory	1007:1018	arg1	iNOS					1075:1078	iNOS	1075:1078	iNOS	1075:1078	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	54	theme	inflammatory	1007:1018	arg1	MAPK					1058:1061	MAPK	1058:1061	MAPK	1058:1061	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	54	theme	inflammatory	1007:1018	arg1	NF-κB					1051:1055	NF-κB	1051:1055	NF-κB	1051:1055	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	2	55	theme	Fagopyrum	221:229	arg1	FTP					258:260	FTP	258:260	FTP	258:260	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	55	theme	Fagopyrum	221:229	arg1	polysaccharides					241:255	buckwheat Fagopyrum tataricum polysaccharides	211:255	buckwheat Fagopyrum tataricum polysaccharides (FTP)	211:261	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	56	theme	tataricum	231:239	arg1	FTP					258:260	FTP	258:260	FTP	258:260	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	56	theme	tataricum	231:239	arg1	polysaccharides					241:255	buckwheat Fagopyrum tataricum polysaccharides	211:255	buckwheat Fagopyrum tataricum polysaccharides (FTP)	211:261	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	9	57	theme	microbiota	1509:1518	arg1	modulation					1520:1529	microbiota modulation	1509:1529	microbiota modulation	1509:1529	In conclusion, FTP and FEP strongly improved TNBS-induced colitis through antioxidant, anti-inflammatory, and microbiota modulation properties, especially in the high-dose FEP group.
36563806	5	58	from	symptoms	638:645	arg1	colitis					663:669	TNBS-induced colitis	650:669	TNBS-induced colitis	650:669	In addition, the pathological features of colon length and symptoms in TNBS-induced colitis were improved via the intragastric preadministration of FTP and FEP.
36563806	2	59	theme	buckwheat	211:219	arg1	FTP					258:260	FTP	258:260	FTP	258:260	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	59	theme	buckwheat	211:219	arg1	polysaccharides					241:255	buckwheat Fagopyrum tataricum polysaccharides	211:255	buckwheat Fagopyrum tataricum polysaccharides (FTP)	211:261	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	60	theme	esculentum	270:279	arg1	FEP					298:300	FEP	298:300	FEP	298:300	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	60	theme	esculentum	270:279	arg1	polysaccharides					281:295	F. esculentum polysaccharides	267:295	F. esculentum polysaccharides (FEP)	267:301	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	10	61	contain	have	1608:1611	arg1	polysaccharides					1592:1606	Buckwheat polysaccharides	1582:1606	Buckwheat polysaccharides	1582:1606	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	10	61	contain	have	1608:1611	arg2	potential					1617:1625	the potential	1613:1625	the potential for utilization in functional ingredients or food development	1613:1687	Buckwheat polysaccharides have the potential for utilization in functional ingredients or food development.
36563806	1	62	theme	Plant	98:102	arg1	polysaccharides					104:118	Plant polysaccharides	98:118	Plant polysaccharides	98:118	Plant polysaccharides act as prebiotics by modulating gut microbiota.
36563806	8	63	theme	bacteria	1352:1359	arg1	abundance					1318:1326	the abundance	1314:1326	the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter)	1314:1396	Moreover, prefeeding with buckwheat polysaccharides increased the Firmicutes/Bacteroidetes ratio and short-chain fatty acid (SCFA) production and decreased the abundance of inflammation-related bacteria (Oscillospiraceae and Oscillibacter).
36563806	9	64	theme	high-dose	1561:1569	arg1	group					1575:1579	the high-dose FEP group	1557:1579	the high-dose FEP group	1557:1579	In conclusion, FTP and FEP strongly improved TNBS-induced colitis through antioxidant, anti-inflammatory, and microbiota modulation properties, especially in the high-dose FEP group.
36563806	2	65	theme	F.	267:268	arg1	FEP					298:300	FEP	298:300	FEP	298:300	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	2	65	theme	F.	267:268	arg1	polysaccharides					281:295	F. esculentum polysaccharides	267:295	F. esculentum polysaccharides (FEP)	267:301	However, the functional characteristics of buckwheat Fagopyrum tataricum polysaccharides (FTP) and F. esculentum polysaccharides (FEP) on colitis prevention are not valid.
36563806	7	66	from	decrease	995:1002	arg1	proteins					1041:1048	inflammatory signaling-associated proteins	1007:1048	inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS)	1007:1079	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	66	from	decrease	995:1002	arg1	COX-2					1064:1068	COX-2	1064:1068	COX-2	1064:1068	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	66	from	decrease	995:1002	arg1	iNOS					1075:1078	iNOS	1075:1078	iNOS	1075:1078	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	66	from	decrease	995:1002	arg1	MAPK					1058:1061	MAPK	1058:1061	MAPK	1058:1061	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	66	from	decrease	995:1002	arg1	NF-κB					1051:1055	NF-κB	1051:1055	NF-κB	1051:1055	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	9	67	dep	antioxidant	1473:1483	arg1	properties					1531:1540	properties	1531:1540	properties	1531:1540	In conclusion, FTP and FEP strongly improved TNBS-induced colitis through antioxidant, anti-inflammatory, and microbiota modulation properties, especially in the high-dose FEP group.
36563806	6	68	theme	TNBS-induced	974:985	arg1	rats					987:990	TNBS-induced rats	974:990	TNBS-induced rats	974:990	The results showed that prefeeding with FTP and FEP decreased inflammatory cytokines (IL-6, IL-1β, and TNF-α), β-glucuronidase, and mucinase, as well as increasing superoxide dismutase, catalase, and glutathione peroxidase levels, in TNBS-induced rats.
36563806	7	69	dep	proteins	1041:1048	arg1	proteins					1041:1048	inflammatory signaling-associated proteins	1007:1048	inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS)	1007:1079	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	69	dep	proteins	1041:1048	arg1	COX-2					1064:1068	COX-2	1064:1068	COX-2	1064:1068	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	69	dep	proteins	1041:1048	arg1	iNOS					1075:1078	iNOS	1075:1078	iNOS	1075:1078	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	69	dep	proteins	1041:1048	arg1	MAPK					1058:1061	MAPK	1058:1061	MAPK	1058:1061	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	7	69	dep	proteins	1041:1048	arg1	NF-κB					1051:1055	NF-κB	1051:1055	NF-κB	1051:1055	A decrease in inflammatory signaling-associated proteins (NF-κB, MAPK, COX-2, and iNOS) improved the treatment of TNBS-induced colitis by buckwheat polysaccharides.
36563806	1	70	theme	gut	152:154	arg1	microbiota					156:165	gut microbiota	152:165	gut microbiota	152:165	Plant polysaccharides act as prebiotics by modulating gut microbiota.
36563806	0	71	theme	microbiota	86:95	arg1	regulation					64:73	regulation	64:73	regulation of the gut microbiota	64:95	Ameliorative effect of buckwheat polysaccharides on colitis via regulation of the gut microbiota.
36662221	0	0	theme	Brown	103:107	arg1	Seaweeds					109:116	Different Brown Seaweeds	93:116	Different Brown Seaweeds	93:116	Characterization and Cytotoxic Activity of Microwave-Assisted Extracted Crude Fucoidans from Different Brown Seaweeds.
36662221	8	1	theme	chemical	1516:1523	arg1	characterization					1525:1540	the chemical characterization	1512:1540	the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest	1512:1612	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	9	2	theme	taxonomical	1695:1705	arg1	class					1707:1711	taxonomical class	1695:1711	taxonomical class	1695:1711	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	9	3	theme	sustainability	1794:1807	arg1	goals					1809:1813	the UN sustainability goals	1787:1813	the UN sustainability goals	1787:1813	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	3	4	theme	1:25	521:524	arg1	ratio					512:516	a ratio	510:516	a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min	510:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	9	5	used	used	1717:1720	arg2	research					1627:1634	The current research	1615:1634	The current research	1615:1634	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	0	6	theme	Different	93:101	arg1	Seaweeds					109:116	Different Brown Seaweeds	93:116	Different Brown Seaweeds	93:116	Characterization and Cytotoxic Activity of Microwave-Assisted Extracted Crude Fucoidans from Different Brown Seaweeds.
36662221	8	7	theme	cytotoxic	1379:1387	arg1	activity					1389:1396	the cytotoxic activity	1375:1396	the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL	1375:1473	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	3	8	from	1:25	521:524	arg1	HCl					535:537	0.1 M HCl	529:537	0.1 M HCl containing 2 M CaCl2 for 1.0 min	529:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	1	9	theme	green	174:178	arg1	method					180:185	a green method	172:185	a green method for extraction of natural products	172:220	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	1	9	theme	green	174:178	arg1	extraction					138:147	Microwave-assisted extraction	119:147	Microwave-assisted extraction (MAE)	119:153	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	9	10	gly	heterogeneity	1658:1670	arg1	fucoidans					1675:1683	fucoidans	1675:1683	fucoidans regarding taxonomical class	1675:1711	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	7	11	theme	composition	1208:1218	arg1	results					1187:1193	the results	1183:1193	the results of monomeric composition	1183:1218	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	3	12	theme	2	550:550	arg1	M					552:552	M	552:552	M	552:552	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	8	13	from	activity	1389:1396	arg1	concentrations					1423:1436	concentrations	1423:1436	concentrations ranging from 4.9 µg/mL to 2500 µg/mL	1423:1473	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	8	14	theme	vesiculosus_MAE	1558:1572	arg1	potent					1596:1601	potent	1596:1601	potent	1596:1601	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	8	14	theme	vesiculosus_MAE	1558:1572	arg1	fucoidan					1574:1581	F. vesiculosus_MAE fucoidan	1555:1581	F. vesiculosus_MAE fucoidan	1555:1581	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	5	15	theme	Fourier-transform	973:989	arg1	spectrometry					1000:1011	Fourier-transform infrared spectrometry	973:1011	Fourier-transform infrared spectrometry which also showed a different spectrum	973:1050	Moreover, these findings were confirmed by tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum.
36662221	7	16	from	F.	1261:1262	arg1	extract					1241:1247	fucoidan extract	1232:1247	fucoidan extract by MAE from F. vesiculosus	1232:1274	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	3	17	theme	M	552:552	arg1	CaCl2					554:558	2 M CaCl2	550:558	2 M CaCl2 for 1.0 min	550:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	4	18	theme	sugar	674:678	arg1	content					680:686	the highest sugar content	662:686	the highest sugar content	662:686	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	7	19	theme	sulfated	1288:1295	arg1	galactofucans					1297:1309	sulfated galactofucans	1288:1309	sulfated galactofucans which are known for their potential bioactivities	1288:1359	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	4	20	theme	0.09	845:848	arg1	mg/mg					850:854	mg/mg	850:854	mg/mg	850:854	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	5	21	theme	infrared	991:998	arg1	spectrometry					1000:1011	Fourier-transform infrared spectrometry	973:1011	Fourier-transform infrared spectrometry which also showed a different spectrum	973:1050	Moreover, these findings were confirmed by tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum.
36662221	7	22	theme	monomeric	1198:1206	arg1	composition					1208:1218	monomeric composition	1198:1218	monomeric composition	1198:1218	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	9	23	theme	extraction	1730:1739	arg1	method					1741:1746	greener extraction method	1722:1746	greener extraction method of fucoidans toward the achievement of the UN sustainability goals	1722:1813	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	2	24	theme	fucoidans	273:281	arg1	extraction					283:292	fucoidans extraction	273:292	fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina	273:390	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	4	25	from	others	644:649	arg1	different					625:633	different	625:633	different	625:633	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	9	26	theme	chemical	1649:1656	arg1	heterogeneity					1658:1670	the chemical heterogeneity	1645:1670	the chemical heterogeneity of fucoidans regarding taxonomical class	1645:1711	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	7	27	theme	fucoidan	1232:1239	arg1	extract					1241:1247	fucoidan extract	1232:1247	fucoidan extract by MAE from F. vesiculosus	1232:1274	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	5	28	theme	tentative	931:939	arg1	elucidation					952:962	tentative structural elucidation	931:962	tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum	931:1050	Moreover, these findings were confirmed by tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum.
36662221	8	29	theme	F.	1555:1556	arg1	potent					1596:1601	potent	1596:1601	potent	1596:1601	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	8	29	theme	F.	1555:1556	arg1	fucoidan					1574:1581	F. vesiculosus_MAE fucoidan	1555:1581	F. vesiculosus_MAE fucoidan	1555:1581	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	3	30	theme	MAE	454:456	arg1	optimization					458:469	MAE optimization	454:469	MAE optimization	454:469	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	3	31	theme	several	403:409	arg1	steps					444:448	several solvent-extraction pre-treatment steps	403:448	several solvent-extraction pre-treatment steps	403:448	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	4	32	theme	mg/mg	850:854	arg1	extract					856:862	0.09 mg/mg extract	845:862	0.09 mg/mg extract	845:862	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	3	33	from	ratio	512:516	arg1	HCl					535:537	0.1 M HCl	529:537	0.1 M HCl containing 2 M CaCl2 for 1.0 min	529:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	4	34	theme	equivalent/mg	712:724	arg1	extract					726:732	0.47 mg glucose equivalent/mg extract	696:732	0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content	696:819	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	4	35	theme	monosaccharide	753:766	arg1	analysis					780:787	monosaccharide composition analysis	753:787	monosaccharide composition analysis	753:787	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	6	36	theme	melanoidins	1079:1089	arg1	formation					1091:1099	melanoidins formation	1079:1099	melanoidins formation	1079:1099	However, the MAE enhanced melanoidins formation in products, which was confirmed by the intense band at 1420 cm-1.
36662221	9	37	theme	fucoidans	1675:1683	arg1	heterogeneity					1658:1670	the chemical heterogeneity	1645:1670	the chemical heterogeneity of fucoidans regarding taxonomical class	1645:1711	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	9	38	theme	fucoidans	1751:1759	arg1	method					1741:1746	greener extraction method	1722:1746	greener extraction method of fucoidans toward the achievement of the UN sustainability goals	1722:1813	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	4	39	theme	sulfation	825:833	arg1	degree					835:840	sulfation degree	825:840	sulfation degree	825:840	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	2	40	dep	F.	354:355	arg1	spiralis					357:364	spiralis	357:364	spiralis	357:364	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	1	41	theme	natural	205:211	arg1	products					213:220	natural products	205:220	natural products	205:220	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	0	42	theme	Cytotoxic	21:29	arg1	Activity					31:38	Cytotoxic Activity	21:38	Cytotoxic Activity	21:38	Characterization and Cytotoxic Activity of Microwave-Assisted Extracted Crude Fucoidans from Different Brown Seaweeds.
36662221	5	43	theme	structural	941:950	arg1	elucidation					952:962	tentative structural elucidation	931:962	tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum	931:1050	Moreover, these findings were confirmed by tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum.
36662221	2	44	theme	brown	309:313	arg1	seaweeds					315:322	different brown seaweeds	299:322	different brown seaweeds	299:322	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	2	44	theme	brown	309:313	arg1	saccharina					381:390	saccharina	381:390	saccharina	381:390	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	2	44	theme	brown	309:313	arg1	F.					354:355	F.	354:355	F.	354:355	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	1	45	theme	products	213:220	arg1	extraction					191:200	extraction	191:200	extraction of natural products	191:220	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	0	46	theme	Microwave-Assisted	43:60	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and Cytotoxic Activity of Microwave-Assisted Extracted Crude Fucoidans from Different Brown Seaweeds.
36662221	0	46	theme	Microwave-Assisted	43:60	arg1	Activity					31:38	Cytotoxic Activity	21:38	Cytotoxic Activity	21:38	Characterization and Cytotoxic Activity of Microwave-Assisted Extracted Crude Fucoidans from Different Brown Seaweeds.
36662221	8	47	dep	µg/mL	1455:1459	arg1	to					1461:1462	to	1461:1462	to	1461:1462	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	8	48	theme	2500	1464:1467	arg1	µg/mL					1455:1459	µg/mL	1455:1459	µg/mL	1455:1459	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	5	49	theme	different	1033:1041	arg1	spectrum					1043:1050	a different spectrum	1031:1050	a different spectrum	1031:1050	Moreover, these findings were confirmed by tentative structural elucidation based on Fourier-transform infrared spectrometry which also showed a different spectrum.
36662221	6	50	from	cm-1	1162:1165	arg1	band					1149:1152	the intense band	1137:1152	the intense band at 1420 cm-1	1137:1165	However, the MAE enhanced melanoidins formation in products, which was confirmed by the intense band at 1420 cm-1.
36662221	3	51	theme	algal	476:480	arg1	biomasses					482:490	the algal biomasses	472:490	the algal biomasses	472:490	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	4	52	theme	highest	666:672	arg1	content					680:686	the highest sugar content	662:686	the highest sugar content	662:686	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	3	53	contain	containing	539:548	arg1	HCl					535:537	0.1 M HCl	529:537	0.1 M HCl containing 2 M CaCl2 for 1.0 min	529:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	3	53	contain	containing	539:548	arg2	CaCl2					554:558	2 M CaCl2	550:558	2 M CaCl2 for 1.0 min	550:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	4	54	dep	different	625:633	arg1	regarding					652:660	regarding	652:660	regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively	652:885	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	3	55	theme	solvent-extraction	411:428	arg1	steps					444:448	several solvent-extraction pre-treatment steps	403:448	several solvent-extraction pre-treatment steps	403:448	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	4	56	dep	extract	613:619	arg1	saccharina					600:609	L. saccharina's extract	597:619	L. saccharina's extract	597:619	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	4	57	theme	0.47	696:699	arg1	mg					701:702	mg	701:702	mg	701:702	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	3	58	theme	pre-treatment	430:442	arg1	steps					444:448	several solvent-extraction pre-treatment steps	403:448	several solvent-extraction pre-treatment steps	403:448	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	7	59	dep	F.	1261:1262	arg1	vesiculosus					1264:1274	F. vesiculosus	1261:1274	F. vesiculosus	1261:1274	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	7	60	theme	potential	1337:1345	arg1	bioactivities					1347:1359	their potential bioactivities	1331:1359	their potential bioactivities	1331:1359	Interestingly, the results of monomeric composition showed that fucoidan extract by MAE from F. vesiculosus belonged to sulfated galactofucans which are known for their potential bioactivities.
36662221	2	61	theme	current	227:233	arg1	research					235:242	The current research	223:242	The current research	223:242	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	6	62	theme	intense	1141:1147	arg1	band					1149:1152	the intense band	1137:1152	the intense band at 1420 cm-1	1137:1165	However, the MAE enhanced melanoidins formation in products, which was confirmed by the intense band at 1420 cm-1.
36662221	9	63	theme	UN	1791:1792	arg1	goals					1809:1813	the UN sustainability goals	1787:1813	the UN sustainability goals	1787:1813	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	8	64	theme	4.9	1451:1453	arg1	µg/mL					1455:1459	µg/mL	1455:1459	µg/mL	1455:1459	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	8	65	theme	fucoidans	1410:1418	arg1	activity					1389:1396	the cytotoxic activity	1375:1396	the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL	1375:1473	Furthermore, the cytotoxic activity of the four fucoidans in concentrations ranging from 4.9 µg/mL to 2500 µg/mL was investigated and correlated with the chemical characterization showing that F. vesiculosus_MAE fucoidan was the most potent and safest.
36662221	4	66	theme	glucose	704:710	arg1	extract					726:732	0.47 mg glucose equivalent/mg extract	696:732	0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content	696:819	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	1	67	theme	Microwave-assisted	119:136	arg1	method					180:185	a green method	172:185	a green method for extraction of natural products	172:220	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	1	67	theme	Microwave-assisted	119:136	arg1	MAE					150:152	MAE	150:152	MAE	150:152	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	1	67	theme	Microwave-assisted	119:136	arg1	extraction					138:147	Microwave-assisted extraction	119:147	Microwave-assisted extraction (MAE)	119:153	Microwave-assisted extraction (MAE) is recognized as a green method for extraction of natural products.
36662221	4	68	theme	L.	597:598	arg1	extract					613:619	L. saccharina's extract	597:619	L. saccharina's extract	597:619	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	4	69	theme	composition	768:778	arg1	analysis					780:787	monosaccharide composition analysis	753:787	monosaccharide composition analysis	753:787	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	2	70	theme	different	299:307	arg1	seaweeds					315:322	different brown seaweeds	299:322	different brown seaweeds	299:322	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	2	70	theme	different	299:307	arg1	saccharina					381:390	saccharina	381:390	saccharina	381:390	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	2	70	theme	different	299:307	arg1	F.					354:355	F.	354:355	F.	354:355	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
36662221	4	71	theme	mg	701:702	arg1	extract					726:732	0.47 mg glucose equivalent/mg extract	696:732	0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content	696:819	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	9	72	theme	goals	1809:1813	arg1	achievement					1772:1782	the achievement	1768:1782	the achievement of the UN sustainability goals	1768:1813	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	4	73	theme	fucoidan	804:811	arg1	content					813:819	the lowest fucoidan content	793:819	the lowest fucoidan content	793:819	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	3	74	from	HCl	535:537	arg1	ratio					512:516	a ratio	510:516	a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min	510:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	3	75	theme	0.1	529:531	arg1	M					533:533	M	533:533	M	533:533	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	9	76	theme	current	1619:1625	arg1	research					1627:1634	The current research	1615:1634	The current research	1615:1634	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	0	77	theme	Crude	72:76	arg1	Fucoidans					78:86	Crude Fucoidans	72:86	Crude Fucoidans	72:86	Characterization and Cytotoxic Activity of Microwave-Assisted Extracted Crude Fucoidans from Different Brown Seaweeds.
36662221	9	78	theme	greener	1722:1728	arg1	method					1741:1746	greener extraction method	1722:1746	greener extraction method of fucoidans toward the achievement of the UN sustainability goals	1722:1813	The current research revealed the chemical heterogeneity of fucoidans regarding taxonomical class and used greener extraction method of fucoidans toward the achievement of the UN sustainability goals.
36662221	4	79	theme	lowest	797:802	arg1	content					813:819	the lowest fucoidan content	793:819	the lowest fucoidan content	793:819	The results showed that L. saccharina's extract was different from the others, regarding the highest sugar content reached 0.47 mg glucose equivalent/mg extract being confirmed by monosaccharide composition analysis and the lowest fucoidan content and sulfation degree at 0.09 mg/mg extract and 0.13, respectively.
36662221	3	80	theme	M	533:533	arg1	HCl					535:537	0.1 M HCl	529:537	0.1 M HCl containing 2 M CaCl2 for 1.0 min	529:570	Following several solvent-extraction pre-treatment steps and MAE optimization, the algal biomasses were extracted in a ratio of 1:25 in 0.1 M HCl containing 2 M CaCl2 for 1.0 min.
36662221	2	81	from	seaweeds	315:322	arg1	extraction					283:292	fucoidans extraction	273:292	fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina	273:390	The current research aimed to explore the MAE for fucoidans extraction from different brown seaweeds, including Fucus vesiculosus, F. spiralis, and Laminaria saccharina.
35318082	0	0	theme	polysaccharides	93:107	arg1	bioactivities					76:88	bioactivities	76:88	bioactivities	76:88	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	0	0	theme	polysaccharides	93:107	arg1	properties					61:70	physicochemical properties	45:70	physicochemical properties	45:70	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	3	1	theme	%	940:940	arg1	%					946:946	5.15%-8.95%	936:946	5.15%-8.95%	936:946	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	1	2	from	parts	335:339	arg1	properties					231:240	physicochemical properties	215:240	physicochemical properties	215:240	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	2	from	parts	335:339	arg1	antioxidant					243:253	antioxidant	243:253	antioxidant	243:253	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	2	from	parts	335:339	arg1	polysaccharides					298:312	polysaccharides	298:312	polysaccharides (GPs) from different parts of ginseng	298:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	2	from	parts	335:339	arg1	GPs					315:317	GPs	315:317	GPs	315:317	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	2	from	parts	335:339	arg1	yields					207:212	the yields	203:212	the yields	203:212	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	2	from	parts	335:339	arg1	activities					284:293	α-glucosidase inhibitory activities	259:293	α-glucosidase inhibitory activities	259:293	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	4	3	theme	different	1103:1111	arg1	composition					1128:1138	different monosaccharide composition	1103:1138	different monosaccharide composition	1103:1138	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	1	4	theme	ultrasonic	172:181	arg1	MUE					195:197	MUE	195:197	MUE	195:197	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	4	theme	ultrasonic	172:181	arg1	extraction					183:192	multi-frequency ultrasonic extraction	156:192	multi-frequency ultrasonic extraction (MUE)	156:198	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	3	5	theme	acid	676:679	arg1	content					739:745	total phenolics content	723:745	total phenolics content (TPC: increased by 7.60% to 42.61%)	723:781	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	5	theme	acid	676:679	arg1	content					801:807	total flavonoids content	784:807	total flavonoids content	784:807	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	5	theme	acid	676:679	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	1	6	theme	α-glucosidase	259:271	arg1	activities					284:293	α-glucosidase inhibitory activities	259:293	α-glucosidase inhibitory activities	259:293	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	2	7	theme	roots	502:506	arg1	M-GLPs					546:551	M-GLPs	546:551	M-GLPs	546:551	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	2	7	theme	roots	502:506	arg1	 > leaves					535:543	roots (M-GRPs) > flowers (M-GFPs) > leaves	502:543	roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs)	502:552	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	3	8	theme	-210.87	647:653	arg1	%					654:654	up to 9.14%-210.87%	636:654	up to 9.14%-210.87%	636:654	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	9	theme	molecular	852:860	arg1	Mw					870:871	Mw	870:871	Mw	870:871	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	9	theme	molecular	852:860	arg1	weight					862:867	lower molecular weight	846:867	lower molecular weight (Mw: reduced by 6.51%- 33.08%)	846:898	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	1	10	theme	extraction	183:192	arg1	effect					146:151	The effect	142:151	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng	142:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	11	theme	inhibitory	273:282	arg1	activities					284:293	α-glucosidase inhibitory activities	259:293	α-glucosidase inhibitory activities	259:293	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	0	12	theme	different	114:122	arg1	parts					124:128	different parts	114:128	different parts of ginseng	114:139	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	0	13	from	Effects	0:6	arg1	bioactivities					76:88	bioactivities	76:88	bioactivities	76:88	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	0	13	from	Effects	0:6	arg1	properties					61:70	physicochemical properties	45:70	physicochemical properties	45:70	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	3	14	dep	increased	753:761	arg1	TPC					748:750	TPC	748:750	TPC	748:750	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	4	15	theme	antioxidant	1162:1172	arg1	activities					1203:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	3	16	theme	phenolics	729:737	arg1	content					739:745	total phenolics content	723:745	total phenolics content (TPC: increased by 7.60% to 42.61%)	723:781	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	16	theme	phenolics	729:737	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	2	17	theme	M-GFPs	528:533	arg1	M-GLPs					546:551	M-GLPs	546:551	M-GLPs	546:551	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	2	17	theme	M-GFPs	528:533	arg1	 > leaves					535:543	roots (M-GRPs) > flowers (M-GFPs) > leaves	502:543	roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs)	502:552	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	0	18	from	properties	61:70	arg1	parts					124:128	different parts	114:128	different parts of ginseng	114:139	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	3	19	theme	total	784:788	arg1	content					801:807	total flavonoids content	784:807	total flavonoids content	784:807	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	19	theme	total	784:788	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	20	dep	increased	695:703	arg1	UAC					690:692	UAC	690:692	UAC	690:692	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	21	dep	9.14	642:645	arg1	to					639:640	to	639:640	to	639:640	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	22	theme	lower	846:850	arg1	Mw					870:871	Mw	870:871	Mw	870:871	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	22	theme	lower	846:850	arg1	weight					862:867	lower molecular weight	846:867	lower molecular weight (Mw: reduced by 6.51%- 33.08%)	846:898	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	6	23	theme	physicochemical	1460:1474	arg1	properties					1491:1500	physicochemical and functional properties	1460:1500	physicochemical and functional properties	1460:1500	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	6	23	theme	physicochemical	1460:1474	arg1	yields					1452:1457	yields	1452:1457	yields	1452:1457	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	3	24	theme	flavonoids	790:799	arg1	content					801:807	total flavonoids content	784:807	total flavonoids content	784:807	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	24	theme	flavonoids	790:799	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	2	25	theme	different	424:432	arg1	parts					434:438	different parts	424:438	different parts	424:438	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	2	26	theme	 > flowers	516:525	arg1	M-GLPs					546:551	M-GLPs	546:551	M-GLPs	546:551	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	2	26	theme	 > flowers	516:525	arg1	 > leaves					535:543	roots (M-GRPs) > flowers (M-GFPs) > leaves	502:543	roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs)	502:552	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	3	27	theme	higher	662:667	arg1	content					739:745	total phenolics content	723:745	total phenolics content (TPC: increased by 7.60% to 42.61%)	723:781	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	27	theme	higher	662:667	arg1	content					801:807	total flavonoids content	784:807	total flavonoids content	784:807	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	27	theme	higher	662:667	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	6	28	theme	biological	1516:1525	arg1	activities					1527:1536	biological activities	1516:1536	biological activities of polysaccharide	1516:1554	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	3	29	dep	%	770:770	arg1	to					772:773	to	772:773	to	772:773	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	30	dep	Mw	870:871	arg1	reduced					874:880	reduced	874:880	reduced by 6.51%- 33.08%	874:897	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	4	31	theme	inhibitory	1192:1201	arg1	activities					1203:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	3	32	theme	uronic	669:674	arg1	content					739:745	total phenolics content	723:745	total phenolics content (TPC: increased by 7.60% to 42.61%)	723:781	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	32	theme	uronic	669:674	arg1	content					801:807	total flavonoids content	784:807	total flavonoids content	784:807	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	32	theme	uronic	669:674	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	1	33	from	effect	146:151	arg1	antioxidant					243:253	antioxidant	243:253	antioxidant	243:253	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	33	from	effect	146:151	arg1	yields					207:212	the yields	203:212	the yields	203:212	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	33	from	effect	146:151	arg1	properties					231:240	physicochemical properties	215:240	physicochemical properties	215:240	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	33	from	effect	146:151	arg1	activities					284:293	α-glucosidase inhibitory activities	259:293	α-glucosidase inhibitory activities	259:293	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	2	34	theme	polysaccharides	403:417	arg1	yields					393:398	yields	393:398	yields of polysaccharides from different parts	393:438	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	4	35	theme	remarkable	1151:1160	arg1	activities					1203:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	1	36	theme	polysaccharides	298:312	arg1	antioxidant					243:253	antioxidant	243:253	antioxidant	243:253	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	36	theme	polysaccharides	298:312	arg1	yields					207:212	the yields	203:212	the yields	203:212	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	36	theme	polysaccharides	298:312	arg1	properties					231:240	physicochemical properties	215:240	physicochemical properties	215:240	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	36	theme	polysaccharides	298:312	arg1	activities					284:293	α-glucosidase inhibitory activities	259:293	α-glucosidase inhibitory activities	259:293	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	4	37	theme	purified	1023:1030	arg1	polysaccharides					1032:1046	All six purified polysaccharides	1015:1046	All six purified polysaccharides extracted by MUE	1015:1063	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	2	38	from	yields	393:398	arg1	parts					434:438	different parts	424:438	different parts	424:438	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	3	39	theme	heat	569:572	arg1	extraction					581:590	heat reflux extraction	569:590	heat reflux extraction	569:590	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	0	40	theme	ultrasonic	27:36	arg1	multi-frequency					11:25	multi-frequency ultrasonic	11:36	multi-frequency ultrasonic	11:36	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	1	41	from	activities	284:293	arg1	parts					335:339	different parts	325:339	different parts of ginseng	325:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	5	42	theme	highest	1249:1255	arg1	bioactivities					1257:1269	the highest bioactivities	1245:1269	the highest bioactivities	1245:1269	Especially, M-GFP-1 exhibited the highest bioactivities, illustrated that the activities were highly correlated with UAC and TPC, Mw, and triple helical structure.
35318082	6	43	theme	polysaccharide	1541:1554	arg1	activities					1527:1536	biological activities	1516:1536	biological activities of polysaccharide	1516:1554	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	4	44	theme	monosaccharide	1113:1126	arg1	composition					1128:1138	different monosaccharide composition	1103:1138	different monosaccharide composition	1103:1138	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	0	45	theme	multi-frequency	11:25	arg1	Effects					0:6	Effects	0:6	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng	0:139	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	0	46	theme	ginseng	133:139	arg1	parts					124:128	different parts	114:128	different parts of ginseng	114:139	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	3	47	theme	GPs	629:631	arg1	yield					620:624	the yield	616:624	the yield of GPs	616:631	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	4	48	with	polysaccharide	1083:1096	arg1	composition					1128:1138	different monosaccharide composition	1103:1138	different monosaccharide composition	1103:1138	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	3	49	dep	only	601:604	arg1	not					597:599	not	597:599	not	597:599	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	5	50	theme	triple	1353:1358	arg1	structure					1368:1376	triple helical structure	1353:1376	triple helical structure	1353:1376	Especially, M-GFP-1 exhibited the highest bioactivities, illustrated that the activities were highly correlated with UAC and TPC, Mw, and triple helical structure.
35318082	4	51	dep	polysaccharide	1083:1096	arg1	possessed					1141:1149	possessed	1141:1149	possessed remarkable antioxidant and α-glucosidase inhibitory activities	1141:1212	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	3	52	theme	protein	904:910	arg1	content					912:918	protein content	904:918	protein content (PC: reduced by 5.15%-8.95%)	904:947	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	0	53	dep	properties	61:70	arg1	the					41:43	the	41:43	the	41:43	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	5	54	theme	helical	1360:1366	arg1	structure					1368:1376	triple helical structure	1353:1376	triple helical structure	1353:1376	Especially, M-GFP-1 exhibited the highest bioactivities, illustrated that the activities were highly correlated with UAC and TPC, Mw, and triple helical structure.
35318082	3	55	theme	%	712:712	arg1	%					719:719	4.99%-53.48%	708:719	4.99%-53.48%	708:719	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	2	56	theme	 > leaves	535:543	arg1	order					493:497	the order	489:497	the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs)	489:552	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	0	57	from	bioactivities	76:88	arg1	parts					124:128	different parts	114:128	different parts of ginseng	114:139	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	1	58	theme	physicochemical	215:229	arg1	properties					231:240	physicochemical properties	215:240	physicochemical properties	215:240	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	59	theme	different	325:333	arg1	parts					335:339	different parts	325:339	different parts of ginseng	325:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	60	from	antioxidant	243:253	arg1	parts					335:339	different parts	325:339	different parts of ginseng	325:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	3	61	dep	content	912:918	arg1	reduced					925:931	reduced	925:931	reduced by 5.15%-8.95%	925:946	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	62	theme	reflux	574:579	arg1	extraction					581:590	heat reflux extraction	569:590	heat reflux extraction	569:590	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	63	theme	%	832:832	arg1	%					838:838	2.52%-5.45%	828:838	2.52%-5.45%	828:838	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	0	64	theme	physicochemical	45:59	arg1	properties					61:70	physicochemical properties	45:70	physicochemical properties	45:70	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	4	65	theme	acidic	1070:1075	arg1	polysaccharide					1083:1096	acidic pyran polysaccharide	1070:1096	acidic pyran polysaccharide with different monosaccharide composition	1070:1138	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	3	66	theme	%	646:646	arg1	%					654:654	up to 9.14%-210.87%	636:654	up to 9.14%-210.87%	636:654	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	4	67	theme	pyran	1077:1081	arg1	polysaccharide					1083:1096	acidic pyran polysaccharide	1070:1096	acidic pyran polysaccharide with different monosaccharide composition	1070:1138	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	3	68	dep	content	681:687	arg1	increased					695:703	increased	695:703	increased by 4.99%-53.48%	695:719	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	68	dep	content	681:687	arg1	TFC					810:812	TFC:	810:813	higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%)	662:839	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	1	69	from	properties	231:240	arg1	parts					335:339	different parts	325:339	different parts of ginseng	325:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	0	70	from	parts	124:128	arg1	polysaccharides					93:107	polysaccharides	93:107	polysaccharides from different parts of ginseng	93:139	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	0	70	from	parts	124:128	arg1	bioactivities					76:88	bioactivities	76:88	bioactivities	76:88	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	0	70	from	parts	124:128	arg1	properties					61:70	physicochemical properties	45:70	physicochemical properties	45:70	Effects of multi-frequency ultrasonic on the physicochemical properties and bioactivities of polysaccharides from different parts of ginseng.
35318082	1	71	from	yields	207:212	arg1	parts					335:339	different parts	325:339	different parts of ginseng	325:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	3	72	theme	7.60	766:769	arg1	%					770:770	%	770:770	%	770:770	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	4	73	theme	α-glucosidase	1178:1190	arg1	activities					1203:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	remarkable antioxidant and α-glucosidase inhibitory activities	1151:1212	All six purified polysaccharides extracted by MUE were acidic pyran polysaccharide with different monosaccharide composition, possessed remarkable antioxidant and α-glucosidase inhibitory activities.
35318082	6	74	theme	efficient	1418:1426	arg1	MUE					1407:1409	MUE	1407:1409	MUE	1407:1409	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	6	74	theme	efficient	1418:1426	arg1	technique					1428:1436	an efficient technique	1415:1436	an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide	1415:1554	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	3	75	theme	total	723:727	arg1	content					739:745	total phenolics content	723:745	total phenolics content (TPC: increased by 7.60% to 42.61%)	723:781	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	75	theme	total	723:727	arg1	content					681:687	higher uronic acid content	662:687	higher uronic acid content (UAC: increased by 4.99%-53.48%)	662:720	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	6	76	theme	functional	1480:1489	arg1	properties					1491:1500	physicochemical and functional properties	1460:1500	physicochemical and functional properties	1460:1500	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	6	76	theme	functional	1480:1489	arg1	yields					1452:1457	yields	1452:1457	yields	1452:1457	These results indicate that MUE was an efficient technique for improving yields, physicochemical and functional properties and enhancing biological activities of polysaccharide.
35318082	2	77	from	parts	434:438	arg1	polysaccharides					403:417	polysaccharides	403:417	polysaccharides from different parts	403:438	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	2	77	from	parts	434:438	arg1	yields					393:398	yields	393:398	yields of polysaccharides from different parts	393:438	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	3	78	dep	content	739:745	arg1	increased					753:761	increased	753:761	increased by 7.60% to 42.61%	753:780	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	2	79	theme	M-GRPs	509:514	arg1	M-GLPs					546:551	M-GLPs	546:551	M-GLPs	546:551	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	2	79	theme	M-GRPs	509:514	arg1	 > leaves					535:543	roots (M-GRPs) > flowers (M-GFPs) > leaves	502:543	roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs)	502:552	Results demonstrated that yields of polysaccharides from different parts were found to vary significantly differences, in the order of roots (M-GRPs) > flowers (M-GFPs) > leaves (M-GLPs).
35318082	1	80	theme	ginseng	344:350	arg1	parts					335:339	different parts	325:339	different parts of ginseng	325:350	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	3	81	theme	functional	974:983	arg1	properties					985:994	their functional properties	968:994	their functional properties	968:994	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	1	82	theme	multi-frequency	156:170	arg1	MUE					195:197	MUE	195:197	MUE	195:197	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	1	82	theme	multi-frequency	156:170	arg1	extraction					183:192	multi-frequency ultrasonic extraction	156:192	multi-frequency ultrasonic extraction (MUE)	156:198	The effect of multi-frequency ultrasonic extraction (MUE) on the yields, physicochemical properties, antioxidant and α-glucosidase inhibitory activities of polysaccharides (GPs) from different parts of ginseng were compared.
35318082	3	83	theme	42.61	775:779	arg1	%					770:770	%	770:770	%	770:770	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
35318082	3	84	dep	reduced	925:931	arg1	PC					921:922	PC	921:922	PC	921:922	Compared with heat reflux extraction, MUE not only increased the yield of GPs by up to 9.14%-210.87%, with higher uronic acid content (UAC: increased by 4.99%-53.48%), total phenolics content (TPC: increased by 7.60% to 42.61%), total flavonoids content (TFC: increased by 2.52%-5.45%), and lower molecular weight (Mw: reduced by 6.51%- 33.08%) and protein content (PC: reduced by 5.15%-8.95%), but also improved their functional properties and bioactivities.
37182635	1	0	theme	Baijiu	169:174	arg1	grains					151:156	Distillers' grains	139:156	Distillers' grains of Chinese Baijiu (DGS)	139:180	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	2	1	used	utilized	294:301	arg2	study					288:292	This study	283:292	This study	283:292	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	1	2	theme	brewing	265:271	arg1	industry					273:280	the brewing industry	261:280	the brewing industry	261:280	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	6	3	theme	novel	968:972	arg1	Extrusion					953:961	Extrusion	953:961	Extrusion	953:961	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	6	3	theme	novel	968:972	arg1	approach					974:981	a novel approach	966:981	a novel approach for the recycling non-digestible polysaccharides from DGS	966:1039	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	0	4	with	extrusion	89:97	arg1	capability					127:136	enhanced antioxidation capability	104:136	enhanced antioxidation capability	104:136	Obtaining non-digestible polysaccharides from distillers' grains of Chinese baijiu after extrusion with enhanced antioxidation capability.
37182635	2	5	theme	DGS	382:384	arg1	characteristics					363:377	the morphological and crystalline characteristics	329:377	the morphological and crystalline characteristics of DGS	329:384	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	1	6	theme	industry	273:280	arg1	production					247:256	the environmentally-friendly production	218:256	the environmentally-friendly production of the brewing industry	218:280	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	0	7	theme	enhanced	104:111	arg1	capability					127:136	enhanced antioxidation capability	104:136	enhanced antioxidation capability	104:136	Obtaining non-digestible polysaccharides from distillers' grains of Chinese baijiu after extrusion with enhanced antioxidation capability.
37182635	2	8	theme	screw	303:307	arg1	extrusion					309:317	screw extrusion	303:317	screw extrusion	303:317	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	4	9	theme	extruded	661:668	arg1	DGS					670:672	extruded DGS	661:672	extruded DGS	661:672	Polysaccharides extracted from extruded DGS exhibited enhanced inhibitory capacity on α-amylase activity and starch hydrolyzation, as compared to those extracted from unextruded DGS.
37182635	6	10	from	bioactivity	1057:1067	arg1	food					1127:1130	functional food	1116:1130	functional food	1116:1130	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	5	11	theme	1.20	909:912	arg1	increase					897:904	a maximum increase	887:904	a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly	887:950	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	3	12	theme	monosaccharide	580:593	arg1	composition					595:605	monosaccharide composition	580:605	monosaccharide composition	580:605	Physiochemical characteristics of extracted polysaccharides were variated, including infrared spectrum, monosaccharide composition, and molecular weight.
37182635	5	13	theme	1.02-fold	925:933	arg1	increase					897:904	a maximum increase	887:904	a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly	887:950	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	0	14	theme	antioxidation	113:125	arg1	capability					127:136	enhanced antioxidation capability	104:136	enhanced antioxidation capability	104:136	Obtaining non-digestible polysaccharides from distillers' grains of Chinese baijiu after extrusion with enhanced antioxidation capability.
37182635	6	15	theme	extracts	1072:1079	arg1	bioactivity					1057:1067	the bioactivity	1053:1067	the bioactivity of extracts and their potential application in functional food	1053:1130	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	6	16	theme	potential	1091:1099	arg1	application					1101:1111	their potential application	1085:1111	their potential application	1085:1111	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	2	17	theme	%	406:406	arg1	increase					408:415	a 316 % increase	400:415	a 316 % increase in the yield of non-digestible polysaccharides extraction	400:473	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	0	18	theme	non-digestible	10:23	arg1	polysaccharides					25:39	non-digestible polysaccharides	10:39	non-digestible polysaccharides from distillers' grains of Chinese baijiu	10:81	Obtaining non-digestible polysaccharides from distillers' grains of Chinese baijiu after extrusion with enhanced antioxidation capability.
37182635	2	19	theme	morphological	333:345	arg1	characteristics					363:377	the morphological and crystalline characteristics	329:377	the morphological and crystalline characteristics of DGS	329:384	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	6	20	theme	application	1101:1111	arg1	bioactivity					1057:1067	the bioactivity	1053:1067	the bioactivity of extracts and their potential application in functional food	1053:1130	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	2	21	theme	316 	402:405	arg1	%					406:406	%	406:406	%	406:406	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	2	22	theme	extraction	464:473	arg1	yield					424:428	the yield	420:428	the yield of non-digestible polysaccharides extraction	420:473	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	2	23	theme	polysaccharides	448:462	arg1	extraction					464:473	non-digestible polysaccharides extraction	433:473	non-digestible polysaccharides extraction	433:473	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	6	24	from	DGS	1037:1039	arg1	polysaccharides					1016:1030	the recycling non-digestible polysaccharides	987:1030	the recycling non-digestible polysaccharides from DGS	987:1039	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	3	25	theme	molecular	612:620	arg1	weight					622:627	molecular weight	612:627	molecular weight	612:627	Physiochemical characteristics of extracted polysaccharides were variated, including infrared spectrum, monosaccharide composition, and molecular weight.
37182635	1	26	theme	significant	193:203	arg1	challenge					205:213	a significant challenge	191:213	a significant challenge to the environmentally-friendly production of the brewing industry	191:280	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	2	27	theme	non-digestible	433:446	arg1	extraction					464:473	non-digestible polysaccharides extraction	433:473	non-digestible polysaccharides extraction	433:473	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	4	28	theme	enhanced	684:691	arg1	capacity					704:711	enhanced inhibitory capacity	684:711	enhanced inhibitory capacity	684:711	Polysaccharides extracted from extruded DGS exhibited enhanced inhibitory capacity on α-amylase activity and starch hydrolyzation, as compared to those extracted from unextruded DGS.
37182635	3	29	theme	infrared	561:568	arg1	spectrum					570:577	infrared spectrum	561:577	infrared spectrum	561:577	Physiochemical characteristics of extracted polysaccharides were variated, including infrared spectrum, monosaccharide composition, and molecular weight.
37182635	3	30	theme	extracted	510:518	arg1	polysaccharides					520:534	extracted polysaccharides	510:534	extracted polysaccharides	510:534	Physiochemical characteristics of extracted polysaccharides were variated, including infrared spectrum, monosaccharide composition, and molecular weight.
37182635	5	31	theme	OH	847:848	arg1	radical					850:856	OH radical	847:856	OH radical	847:856	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	6	32	theme	functional	1116:1125	arg1	food					1127:1130	functional food	1116:1130	functional food	1116:1130	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	3	33	theme	Physiochemical	476:489	arg1	characteristics					491:505	Physiochemical characteristics	476:505	Physiochemical characteristics of extracted polysaccharides	476:534	Physiochemical characteristics of extracted polysaccharides were variated, including infrared spectrum, monosaccharide composition, and molecular weight.
37182635	5	34	theme	radical	850:856	arg1	efficiencies					869:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	5	35	theme	maximum	889:895	arg1	increase					897:904	a maximum increase	887:904	a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly	887:950	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	5	36	theme	ABTS	831:834	arg1	efficiencies					869:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	5	37	theme	scavenging	858:867	arg1	efficiencies					869:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	6	38	theme	non-digestible	1001:1014	arg1	polysaccharides					1016:1030	the recycling non-digestible polysaccharides	987:1030	the recycling non-digestible polysaccharides from DGS	987:1039	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	5	39	theme	DPPH	837:840	arg1	efficiencies					869:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	the ABTS, DPPH, and OH radical scavenging efficiencies	827:880	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	4	40	theme	unextruded	797:806	arg1	DGS					808:810	unextruded DGS	797:810	unextruded DGS	797:810	Polysaccharides extracted from extruded DGS exhibited enhanced inhibitory capacity on α-amylase activity and starch hydrolyzation, as compared to those extracted from unextruded DGS.
37182635	6	41	theme	recycling	991:999	arg1	polysaccharides					1016:1030	the recycling non-digestible polysaccharides	987:1030	the recycling non-digestible polysaccharides from DGS	987:1039	Extrusion is a novel approach for the recycling non-digestible polysaccharides from DGS, augmenting the bioactivity of extracts and their potential application in functional food.
37182635	2	42	from	increase	408:415	arg1	yield					424:428	the yield	420:428	the yield of non-digestible polysaccharides extraction	420:473	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	2	43	theme	crystalline	351:361	arg1	characteristics					363:377	the morphological and crystalline characteristics	329:377	the morphological and crystalline characteristics of DGS	329:384	This study utilized screw extrusion to modify the morphological and crystalline characteristics of DGS, resulting in a 316 % increase in the yield of non-digestible polysaccharides extraction.
37182635	1	44	theme	environmentally-friendly	222:245	arg1	production					247:256	the environmentally-friendly production	218:256	the environmentally-friendly production of the brewing industry	218:280	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	3	45	theme	polysaccharides	520:534	arg1	characteristics					491:505	Physiochemical characteristics	476:505	Physiochemical characteristics of extracted polysaccharides	476:534	Physiochemical characteristics of extracted polysaccharides were variated, including infrared spectrum, monosaccharide composition, and molecular weight.
37182635	0	46	theme	baijiu	76:81	arg1	grains					58:63	distillers' grains	46:63	distillers' grains of Chinese baijiu	46:81	Obtaining non-digestible polysaccharides from distillers' grains of Chinese baijiu after extrusion with enhanced antioxidation capability.
37182635	5	47	theme	1.38	915:918	arg1	increase					897:904	a maximum increase	887:904	a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly	887:950	Additionally, the ABTS, DPPH, and OH radical scavenging efficiencies took a maximum increase of 1.20, 1.38, and 1.02-fold, correspondingly.
37182635	4	48	theme	α-amylase	716:724	arg1	activity					726:733	α-amylase activity	716:733	α-amylase activity	716:733	Polysaccharides extracted from extruded DGS exhibited enhanced inhibitory capacity on α-amylase activity and starch hydrolyzation, as compared to those extracted from unextruded DGS.
37182635	4	49	theme	starch	739:744	arg1	hydrolyzation					746:758	starch hydrolyzation	739:758	starch hydrolyzation	739:758	Polysaccharides extracted from extruded DGS exhibited enhanced inhibitory capacity on α-amylase activity and starch hydrolyzation, as compared to those extracted from unextruded DGS.
37182635	0	50	theme	Chinese	68:74	arg1	baijiu					76:81	Chinese baijiu	68:81	Chinese baijiu	68:81	Obtaining non-digestible polysaccharides from distillers' grains of Chinese baijiu after extrusion with enhanced antioxidation capability.
37182635	1	51	theme	Chinese	161:167	arg1	DGS					177:179	DGS	177:179	DGS	177:179	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	1	51	theme	Chinese	161:167	arg1	Baijiu					169:174	Chinese Baijiu	161:174	Chinese Baijiu (DGS)	161:180	Distillers' grains of Chinese Baijiu (DGS) presents a significant challenge to the environmentally-friendly production of the brewing industry.
37182635	4	52	theme	inhibitory	693:702	arg1	capacity					704:711	enhanced inhibitory capacity	684:711	enhanced inhibitory capacity	684:711	Polysaccharides extracted from extruded DGS exhibited enhanced inhibitory capacity on α-amylase activity and starch hydrolyzation, as compared to those extracted from unextruded DGS.
35584715	2	0	theme	2 mg/mL	540:546	arg1	ratio					581:585	selenium/polysaccharide mass ratio	552:585	selenium/polysaccharide mass ratio of 1:15	552:593	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	0	theme	2 mg/mL	540:546	arg1	concentration					523:535	polysaccharide concentration	508:535	polysaccharide concentration of 2 mg/mL	508:546	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	1	theme	S	959:959	arg1	phase					961:965	S phase	959:965	S phase	959:965	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	3	2	theme	therapeutic	1112:1122	arg1	drug					1124:1127	a novel therapeutic drug	1104:1127	a novel therapeutic drug	1104:1127	These data revealed that the composites had the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments.
35584715	1	3	theme	obtained	156:163	arg1	agent					296:300	a stabilizer and dispersing agent	268:300	agent	296:300	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	3	theme	obtained	156:163	arg1	polysaccharide					197:210	the previously obtained macromolecuar-weight Astragalus polysaccharide	141:210	the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da)	141:254	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	4	contain	has	674:676	arg1	62.3 nm					659:665	62.3 nm	659:665	62.3 nm	659:665	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	4	contain	has	674:676	arg2	stability					685:693	a good stability	678:693	a good stability for 35 days	678:705	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	5	theme	mitochondrial	1017:1029	arg1	pathway					1031:1037	mitochondrial pathway	1017:1037	mitochondrial pathway	1017:1037	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	6	theme	62.3 nm	659:665	arg1	diameter					647:654	an average diameter	636:654	an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway	636:1037	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	1	7	theme	macromolecuar-weight	165:184	arg1	agent					296:300	a stabilizer and dispersing agent	268:300	agent	296:300	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	7	theme	macromolecuar-weight	165:184	arg1	polysaccharide					197:210	the previously obtained macromolecuar-weight Astragalus polysaccharide	141:210	the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da)	141:254	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	8	theme	stabilizer	270:279	arg1	agent					296:300	a stabilizer and dispersing agent	268:300	agent	296:300	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	8	theme	stabilizer	270:279	arg1	polysaccharide					197:210	the previously obtained macromolecuar-weight Astragalus polysaccharide	141:210	the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da)	141:254	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	9	theme	1:15	590:593	arg1	ratio					581:585	selenium/polysaccharide mass ratio	552:585	selenium/polysaccharide mass ratio of 1:15	552:593	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	9	theme	1:15	590:593	arg1	concentration					523:535	polysaccharide concentration	508:535	polysaccharide concentration of 2 mg/mL	508:546	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	0	10	from	Synthesis	0:8	arg1	cells					112:116	HepG2 cells	106:116	HepG2 cells	106:116	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	0	11	theme	HepG2	106:110	arg1	cells					112:116	HepG2 cells	106:116	HepG2 cells	106:116	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	1	12	theme	anti-hepatoma	384:396	arg1	activity					398:405	then the anti-hepatoma activity	375:405	then the anti-hepatoma activity on HepG2 cells	375:420	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	12	theme	anti-hepatoma	384:396	arg1	well					442:445	well	442:445	well	442:445	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	3	13	theme	novel	1106:1110	arg1	drug					1124:1127	a novel therapeutic drug	1104:1127	a novel therapeutic drug	1104:1127	These data revealed that the composites had the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments.
35584715	1	14	theme	dispersing	285:294	arg1	agent					296:300	a stabilizer and dispersing agent	268:300	agent	296:300	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	14	theme	dispersing	285:294	arg1	polysaccharide					197:210	the previously obtained macromolecuar-weight Astragalus polysaccharide	141:210	the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da)	141:254	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	15	theme	good	680:683	arg1	stability					685:693	a good stability	678:693	a good stability for 35 days	678:705	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	1	16	theme	Astragalus	186:195	arg1	agent					296:300	a stabilizer and dispersing agent	268:300	agent	296:300	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	16	theme	Astragalus	186:195	arg1	polysaccharide					197:210	the previously obtained macromolecuar-weight Astragalus polysaccharide	141:210	the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da)	141:254	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	17	theme	mass	576:579	arg1	ratio					581:585	selenium/polysaccharide mass ratio	552:585	selenium/polysaccharide mass ratio of 1:15	552:593	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	3	18	theme	hepatoma-bearing	1145:1160	arg1	treatments					1170:1179	hepatoma-bearing patient treatments	1145:1179	hepatoma-bearing patient treatments	1145:1179	These data revealed that the composites had the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments.
35584715	1	19	theme	HepG2	410:414	arg1	cells					416:420	HepG2 cells	410:420	HepG2 cells	410:420	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	20	theme	selenium/polysaccharide	552:574	arg1	ratio					581:585	selenium/polysaccharide mass ratio	552:585	selenium/polysaccharide mass ratio of 1:15	552:593	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	21	theme	cells	856:860	arg1	proliferation					833:845	the proliferation	829:845	the proliferation of HepG2 cells	829:860	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	1	22	theme	average	213:219	arg1	weight					231:236	average molecular weight	213:236	average molecular weight of 1.61 × 106 Da	213:253	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	0	23	theme	Astragalus	28:37	arg1	complex					68:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	2	24	theme	symmetrical	610:620	arg1	spheroid					622:629	symmetrical spheroid	610:629	symmetrical spheroid	610:629	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	25	theme	HepG2	850:854	arg1	cells					856:860	HepG2 cells	850:860	HepG2 cells	850:860	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	1	26	theme	molecular	221:229	arg1	weight					231:236	average molecular weight	213:236	average molecular weight of 1.61 × 106 Da	213:253	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	0	27	theme	macromolecular	13:26	arg1	complex					68:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	1	28	theme	nano-composites	306:320	arg1	preparation					322:332	nano-composites preparation	306:332	nano-composites preparation	306:332	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	0	29	theme	selenium	59:66	arg1	complex					68:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	3	30	theme	patient	1162:1168	arg1	treatments					1170:1179	hepatoma-bearing patient treatments	1145:1179	hepatoma-bearing patient treatments	1145:1179	These data revealed that the composites had the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments.
35584715	0	31	from	effects	95:101	arg1	cells					112:116	HepG2 cells	106:116	HepG2 cells	106:116	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	0	32	theme	polysaccharide-nano	39:57	arg1	complex					68:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	macromolecular Astragalus polysaccharide-nano selenium complex	13:74	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	2	33	theme	cells	993:997	arg1	apoptosis					999:1007	HepG2 cells apoptosis	987:1007	HepG2 cells apoptosis	987:1007	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	34	theme	polysaccharide	508:521	arg1	concentration					523:535	polysaccharide concentration	508:535	polysaccharide concentration of 2 mg/mL	508:546	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	1	35	theme	1.61 × 106 Da	241:253	arg1	weight					231:236	average molecular weight	213:236	average molecular weight of 1.61 × 106 Da	213:253	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	36	theme	cell	945:948	arg1	cycle					950:954	the cell cycle	941:954	the cell cycle	941:954	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	37	theme	HepG2	987:991	arg1	cells					993:997	HepG2 cells	987:997	HepG2 cells apoptosis	987:1007	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	38	theme	average	639:645	arg1	diameter					647:654	an average diameter	636:654	an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway	636:1037	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	39	theme	anti-hepatoma	742:754	arg1	experiments					756:766	the in vitro anti-hepatoma experiments	729:766	the in vitro anti-hepatoma experiments	729:766	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	0	40	theme	complex	68:74	arg1	effects					95:101	the inhibitory effects	80:101	the inhibitory effects on HepG2 cells	80:116	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	0	40	theme	complex	68:74	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex	0:74	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	1	41	theme	selenium	347:354	arg1	nanoparticles					356:368	selenium nanoparticles	347:368	selenium nanoparticles	347:368	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	42	dep	polysaccharide	197:210	arg1	weight					231:236	average molecular weight	213:236	average molecular weight of 1.61 × 106 Da	213:253	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	43	theme	present	126:132	arg1	study					134:138	the present study	122:138	the present study	122:138	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	44	used	used	260:263	arg2	agent					296:300	a stabilizer and dispersing agent	268:300	agent	296:300	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	1	44	used	used	260:263	arg2	polysaccharide					197:210	the previously obtained macromolecuar-weight Astragalus polysaccharide	141:210	the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da)	141:254	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
35584715	2	45	theme	in	733:734	arg1	experiments					756:766	the in vitro anti-hepatoma experiments	729:766	the in vitro anti-hepatoma experiments	729:766	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	46	theme	dose-dependent	867:880	arg1	manner					882:887	a dose-dependent manner	865:887	a dose-dependent manner	865:887	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	47	dep	in	733:734	arg1	vitro					736:740	vitro	736:740	vitro	736:740	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	0	48	theme	inhibitory	84:93	arg1	effects					95:101	the inhibitory effects	80:101	the inhibitory effects on HepG2 cells	80:116	Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells.
35584715	2	49	dep	4 °C.	710:714	arg1	demonstrated					768:779	demonstrated	768:779	demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway	768:1037	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	2	50	theme	morphological	911:923	arg1	changes					925:931	the morphological changes	907:931	the morphological changes	907:931	Results showed that the nano-composites were obtained under polysaccharide concentration of 2 mg/mL and selenium/polysaccharide mass ratio of 1:15, and exhibited symmetrical spheroid with an average diameter of 62.3 nm, which has a good stability for 35 days at 4 °C. Furthermore, the in vitro anti-hepatoma experiments demonstrated that the composites could significantly inhibit the proliferation of HepG2 cells in a dose-dependent manner, and could induce the morphological changes, arrest the cell cycle in S phase, finally triggering HepG2 cells apoptosis through mitochondrial pathway.
35584715	3	51	contain	had	1080:1082	arg1	composites					1069:1078	the composites	1065:1078	the composites	1065:1078	These data revealed that the composites had the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments.
35584715	3	51	contain	had	1080:1082	arg2	potential					1088:1096	the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments	1084:1179	the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments	1084:1179	These data revealed that the composites had the potential to be a novel therapeutic drug or adjuvant for hepatoma-bearing patient treatments.
35584715	1	52	from	activity	398:405	arg1	cells					416:420	HepG2 cells	410:420	HepG2 cells	410:420	In the present study, the previously obtained macromolecuar-weight Astragalus polysaccharide (average molecular weight of 1.61 × 106 Da) was used as a stabilizer and dispersing agent for nano-composites preparation by modifying selenium nanoparticles, and then the anti-hepatoma activity on HepG2 cells was investigated as well.
36446618	0	0	theme	chitin	64:69	arg1	potentials					28:37	the degradation potentials	12:37	the degradation potentials of cellulose, xylan, and chitin	12:69	Estimate of the degradation potentials of cellulose, xylan, and chitin across global prokaryotic communities.
36446618	2	1	theme	natural	442:448	arg1	environments					450:461	natural environments	442:461	natural environments	442:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	4	2	from	cellulases	768:777	arg1	communities					828:838	global prokaryotic communities	809:838	global prokaryotic communities	809:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	5	3	theme	gene	1206:1209	arg1	abundance					1211:1219	gene abundance	1206:1219	the community's alpha diversity index rather than gene abundance	1156:1219	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	2	4	from	degradation	395:405	arg1	environments					450:461	natural environments	442:461	natural environments	442:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	5	5	theme	prokaryotic	1082:1092	arg1	communities					1094:1104	prokaryotic communities	1082:1104	prokaryotic communities	1082:1104	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	3	6	theme	large-scale	472:482	arg1	alignments					484:493	large-scale alignments	472:493	large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes	472:590	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	5	7	theme	taxonomic	1017:1025	arg1	sources					1027:1033	The taxonomic sources	1013:1033	The taxonomic sources of the three enzymes	1013:1054	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	5	7	theme	taxonomic	1017:1025	arg1	diverse					1067:1073	diverse	1067:1073	diverse	1067:1073	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	0	8	theme	global	78:83	arg1	communities					97:107	global prokaryotic communities	78:107	global prokaryotic communities	78:107	Estimate of the degradation potentials of cellulose, xylan, and chitin across global prokaryotic communities.
36446618	7	9	theme	cellulose-	1446:1455	arg1	systems					1497:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	1	10	dep	polysaccharides	118:132	arg1	chitin					162:167	chitin	162:167	chitin	162:167	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	10	dep	polysaccharides	118:132	arg1	cellulose					140:148	cellulose	140:148	cellulose	140:148	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	10	dep	polysaccharides	118:132	arg1	polysaccharides					118:132	Complex polysaccharides	110:132	Complex polysaccharides (e.g. cellulose, xylan, and chitin)	110:168	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	10	dep	polysaccharides	118:132	arg1	xylan					151:155	xylan	151:155	xylan	151:155	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	3	11	theme	Earth	533:537	arg1	Project					550:556	the Earth Microbiome Project	529:556	the Earth Microbiome Project	529:556	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	6	12	theme	most	1316:1319	arg1	genera					1321:1326	most genera	1316:1326	most genera with degradation potentials	1316:1354	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	5	13	theme	enzymes	1048:1054	arg1	sources					1027:1033	The taxonomic sources	1013:1033	The taxonomic sources of the three enzymes	1013:1054	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	5	13	theme	enzymes	1048:1054	arg1	diverse					1067:1073	diverse	1067:1073	diverse	1067:1073	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	4	14	theme	putative	759:766	arg1	cellulases					768:777	putative cellulases	759:777	putative cellulases	759:777	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	6	15	theme	degradation	1333:1343	arg1	potentials					1345:1354	degradation potentials	1333:1354	degradation potentials	1333:1354	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	0	16	theme	prokaryotic	85:95	arg1	communities					97:107	global prokaryotic communities	78:107	global prokaryotic communities	78:107	Estimate of the degradation potentials of cellulose, xylan, and chitin across global prokaryotic communities.
36446618	1	17	from	microorganisms	260:273	arg1	nature					278:283	nature	278:283	nature	278:283	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	5	18	theme	diversity	1178:1186	arg1	index					1188:1192	the community's alpha diversity index	1156:1192	the community's alpha diversity index rather than gene abundance	1156:1219	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	5	18	theme	diversity	1178:1186	arg1	factor					1120:1125	the main factor	1111:1125	the main factor influencing the diversity	1111:1151	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	2	19	theme	enzymes	348:354	arg1	distribution					328:339	the global distribution	317:339	the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments	317:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	4	20	theme	enzyme	970:975	arg1	systems					977:983	these enzyme systems	964:983	these enzyme systems	964:983	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	3	21	theme	Microbiome	539:548	arg1	Project					550:556	the Earth Microbiome Project	529:556	the Earth Microbiome Project	529:556	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	2	22	theme	cellulose	410:418	arg1	degradation					395:405	the degradation	391:405	the degradation of cellulose, xylan, and chitin in natural environments	391:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	7	23	theme	xylan-	1458:1463	arg1	systems					1497:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	7	24	theme	chitin-degrading	1470:1485	arg1	systems					1497:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	0	25	theme	cellulose	42:50	arg1	potentials					28:37	the degradation potentials	12:37	the degradation potentials of cellulose, xylan, and chitin	12:69	Estimate of the degradation potentials of cellulose, xylan, and chitin across global prokaryotic communities.
36446618	7	26	theme	prokaryotic	1519:1529	arg1	communities					1531:1541	global prokaryotic communities	1512:1541	global prokaryotic communities	1512:1541	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	0	27	theme	degradation	16:26	arg1	potentials					28:37	the degradation potentials	12:37	the degradation potentials of cellulose, xylan, and chitin	12:69	Estimate of the degradation potentials of cellulose, xylan, and chitin across global prokaryotic communities.
36446618	4	28	theme	systems	977:983	arg1	abundance					951:959	abundance	951:959	abundance of these enzyme systems	951:983	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	4	28	theme	systems	977:983	arg1	composition					935:945	the composition	931:945	the composition	931:945	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	4	28	theme	systems	977:983	arg1	varied					1005:1010	varied	1005:1010	varied	1005:1010	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	6	29	theme	different	1289:1297	arg1	communities					1299:1309	different communities	1289:1309	different communities	1289:1309	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	3	30	theme	prokaryotic	623:633	arg1	communities					635:645	almost all prokaryotic communities	612:645	almost all prokaryotic communities	612:645	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	1	31	dep	cellulose	140:148	arg1	e.g.					135:138	e.g.	135:138	e.g.	135:138	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	2	32	theme	chitin	432:437	arg1	degradation					395:405	the degradation	391:405	the degradation of cellulose, xylan, and chitin in natural environments	391:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	7	33	theme	global	1512:1517	arg1	communities					1531:1541	global prokaryotic communities	1512:1541	global prokaryotic communities	1512:1541	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	5	34	theme	alpha	1172:1176	arg1	index					1188:1192	the community's alpha diversity index	1156:1192	the community's alpha diversity index rather than gene abundance	1156:1219	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	5	34	theme	alpha	1172:1176	arg1	factor					1120:1125	the main factor	1111:1125	the main factor influencing the diversity	1111:1151	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	3	35	theme	prokaryotic	572:582	arg1	genomes					584:590	sequenced prokaryotic genomes	562:590	sequenced prokaryotic genomes	562:590	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	2	36	theme	responsible	375:385	arg1	enzymes					348:354	enzymes	348:354	enzymes	348:354	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	6	37	from	differences	1250:1260	arg1	sources					1275:1281	taxonomic sources	1265:1281	taxonomic sources	1265:1281	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	7	38	theme	systems	1497:1503	arg1	panorama					1434:1441	a panorama	1432:1441	a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities	1432:1541	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	2	39	theme	microorganisms	360:373	arg1	distribution					328:339	the global distribution	317:339	the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments	317:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	6	40	theme	taxonomic	1265:1273	arg1	sources					1275:1281	taxonomic sources	1265:1281	taxonomic sources	1265:1281	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	3	41	theme	all	619:621	arg1	communities					635:645	almost all prokaryotic communities	612:645	almost all prokaryotic communities	612:645	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	4	42	theme	global	809:814	arg1	communities					828:838	global prokaryotic communities	809:838	global prokaryotic communities	809:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	2	43	theme	xylan	421:425	arg1	degradation					395:405	the degradation	391:405	the degradation of cellulose, xylan, and chitin in natural environments	391:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	4	44	theme	prokaryotic	816:826	arg1	communities					828:838	global prokaryotic communities	809:838	global prokaryotic communities	809:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	3	45	theme	functional	656:665	arg1	potentials					667:676	the functional potentials	652:676	the functional potentials	652:676	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	3	46	theme	sequenced	562:570	arg1	genomes					584:590	sequenced prokaryotic genomes	562:590	sequenced prokaryotic genomes	562:590	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	4	47	from	chitinases	795:804	arg1	communities					828:838	global prokaryotic communities	809:838	global prokaryotic communities	809:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	1	48	theme	Complex	110:116	arg1	polysaccharides					118:132	Complex polysaccharides	110:132	Complex polysaccharides (e.g. cellulose, xylan, and chitin)	110:168	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	48	theme	Complex	110:116	arg1	resources					207:215	the most abundant renewable biomass resources	171:215	the most abundant renewable biomass resources available on Earth	171:234	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	48	theme	Complex	110:116	arg1	chitin					162:167	chitin	162:167	chitin	162:167	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	48	theme	Complex	110:116	arg1	xylan					151:155	xylan	151:155	xylan	151:155	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	48	theme	Complex	110:116	arg1	cellulose					140:148	cellulose	140:148	cellulose	140:148	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	5	49	theme	main	1115:1118	arg1	index					1188:1192	the community's alpha diversity index	1156:1192	the community's alpha diversity index rather than gene abundance	1156:1219	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	5	49	theme	main	1115:1118	arg1	factor					1120:1125	the main factor	1111:1125	the main factor influencing the diversity	1111:1151	The taxonomic sources of the three enzymes are highly diverse within prokaryotic communities, and the main factor influencing the diversity is the community's alpha diversity index rather than gene abundance.
36446618	7	50	theme	enzymatic	1487:1495	arg1	systems					1497:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	cellulose-, xylan-, and chitin-degrading enzymatic systems	1446:1503	In conclusion, our analysis preliminarily depicts a panorama of cellulose-, xylan-, and chitin-degrading enzymatic systems across global prokaryotic communities.
36446618	1	51	theme	renewable	189:197	arg1	resources					207:215	the most abundant renewable biomass resources	171:215	the most abundant renewable biomass resources available on Earth	171:234	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	51	theme	renewable	189:197	arg1	polysaccharides					118:132	Complex polysaccharides	110:132	Complex polysaccharides (e.g. cellulose, xylan, and chitin)	110:168	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	6	52	theme	obvious	1242:1248	arg1	differences					1250:1260	obvious differences	1242:1260	obvious differences in taxonomic sources among different communities	1242:1309	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	4	53	theme	genes	744:748	arg1	0.51					844:847	0.51	844:847	0.51	844:847	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	4	53	theme	genes	744:748	arg1	abundances					730:739	The median abundances	719:739	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities	719:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	4	54	theme	median	723:728	arg1	0.51					844:847	0.51	844:847	0.51	844:847	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	4	54	theme	median	723:728	arg1	abundances					730:739	The median abundances	719:739	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities	719:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	1	55	theme	biomass	199:205	arg1	resources					207:215	the most abundant renewable biomass resources	171:215	the most abundant renewable biomass resources available on Earth	171:234	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	55	theme	biomass	199:205	arg1	polysaccharides					118:132	Complex polysaccharides	110:132	Complex polysaccharides (e.g. cellulose, xylan, and chitin)	110:168	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	56	theme	abundant	180:187	arg1	resources					207:215	the most abundant renewable biomass resources	171:215	the most abundant renewable biomass resources available on Earth	171:234	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	56	theme	abundant	180:187	arg1	polysaccharides					118:132	Complex polysaccharides	110:132	Complex polysaccharides (e.g. cellulose, xylan, and chitin)	110:168	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	4	57	from	xylanases	780:788	arg1	communities					828:838	global prokaryotic communities	809:838	global prokaryotic communities	809:838	The median abundances of genes encoding putative cellulases, xylanases, and chitinases in global prokaryotic communities are 0.51 (0.17-1.01), 0.24 (0.05-0.57), and 0.33 (0.11-0.71) genes/cell, respectively, and the composition and abundance of these enzyme systems are environmentally varied.
36446618	3	58	contain	have	647:650	arg2	potentials					667:676	the functional potentials	652:676	the functional potentials	652:676	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	3	58	contain	have	647:650	arg1	communities					635:645	almost all prokaryotic communities	612:645	almost all prokaryotic communities	612:645	Through large-scale alignments between the sequences released by the Earth Microbiome Project and sequenced prokaryotic genomes, we determined that almost all prokaryotic communities have the functional potentials to degrade cellulose, xylan, and chitin.
36446618	0	59	theme	xylan	53:57	arg1	potentials					28:37	the degradation potentials	12:37	the degradation potentials of cellulose, xylan, and chitin	12:69	Estimate of the degradation potentials of cellulose, xylan, and chitin across global prokaryotic communities.
36446618	2	60	dep	enzymes	348:354	arg1	the					344:346	the	344:346	the	344:346	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	6	61	with	genera	1321:1326	arg1	potentials					1345:1354	degradation potentials	1333:1354	degradation potentials	1333:1354	Moreover, there are obvious differences in taxonomic sources among different communities, and most genera with degradation potentials are narrowly distributed.
36446618	2	62	theme	global	321:326	arg1	distribution					328:339	the global distribution	317:339	the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments	317:461	However, little is known about the global distribution of the enzymes and microorganisms responsible for the degradation of cellulose, xylan, and chitin in natural environments.
36446618	1	63	theme	available	217:225	arg1	resources					207:215	the most abundant renewable biomass resources	171:215	the most abundant renewable biomass resources available on Earth	171:234	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36446618	1	63	theme	available	217:225	arg1	polysaccharides					118:132	Complex polysaccharides	110:132	Complex polysaccharides (e.g. cellulose, xylan, and chitin)	110:168	Complex polysaccharides (e.g. cellulose, xylan, and chitin), the most abundant renewable biomass resources available on Earth, are mainly degraded by microorganisms in nature.
36194692	4	0	theme	neutron	761:767	arg1	NR					784:785	NR	784:785	NR	784:785	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	0	theme	neutron	761:767	arg1	reflectometry					769:781	neutron reflectometry	761:781	neutron reflectometry (NR)	761:786	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	3	1	theme	variant	578:584	arg1	A					586:586	bovine beta-lactoglobulin variant A	552:586	bovine beta-lactoglobulin variant A (βLgA)	552:593	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	3	1	theme	variant	578:584	arg1	βLgA					589:592	βLgA	589:592	βLgA	589:592	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	8	2	with	materials	1735:1743	arg1	properties					1758:1767	desired properties	1750:1767	desired properties	1750:1767	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	3	theme	materials	1735:1743	arg1	development					1710:1720	the development	1706:1720	the development of composite materials with desired properties	1706:1767	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	7	4	theme	local	1456:1460	arg1	density					1469:1475	local charge density	1456:1475	local charge density of pectin molecules	1456:1495	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	2	5	theme	desired	422:428	arg1	properties					430:439	desired properties	422:439	desired properties	422:439	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	8	6	theme	composite	1725:1733	arg1	materials					1735:1743	composite materials	1725:1743	composite materials with desired properties	1725:1767	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	2	7	theme	assembly	298:305	arg1	mechanism					307:315	the assembly mechanism	294:315	the assembly mechanism	294:315	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	8	8	theme	physical	1513:1520	arg1	density					1591:1597	density	1591:1597	density	1591:1597	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	8	theme	physical	1513:1520	arg1	level					1603:1607	level	1603:1607	level	1603:1607	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	8	theme	physical	1513:1520	arg1	properties					1522:1531	the physical properties	1509:1531	the physical properties	1509:1531	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	2	9	theme	architecture	335:346	arg1	understanding					277:289	A comprehensive understanding	261:289	A comprehensive understanding of the assembly mechanism and the mesoscale architecture	261:346	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	5	10	theme	cohesive	1020:1027	arg1	structure					1036:1044	a cohesive matrix structure	1018:1044	a cohesive matrix structure	1018:1044	Our results show that βLgA and pectin interacted with each other and formed a cohesive matrix structure at the interface consisting of intertwined pectin chains that were cross-linked by βLgA-rich domains.
36194692	6	11	theme	matrix	1322:1327	arg1	structure					1329:1337	the matrix structure	1318:1337	the matrix structure	1318:1337	Although the complexes were fabricated in an LbL fashion, the complexes appeared to be relatively homogeneous with βLgA and pectin molecules spatially distributed within the matrix structure.
36194692	0	12	theme	Solid-liquid	100:111	arg1	Interface					113:121	the Solid-liquid Interface	96:121	the Solid-liquid Interface	96:121	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	2	13	theme	mesoscale	325:333	arg1	architecture					335:346	the mesoscale architecture	321:346	the mesoscale architecture	321:346	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	6	14	theme	LbL	1193:1195	arg1	fashion					1197:1203	an LbL fashion	1190:1203	an LbL fashion	1190:1203	Although the complexes were fabricated in an LbL fashion, the complexes appeared to be relatively homogeneous with βLgA and pectin molecules spatially distributed within the matrix structure.
36194692	3	15	theme	bovine	552:557	arg1	A					586:586	bovine beta-lactoglobulin variant A	552:586	bovine beta-lactoglobulin variant A (βLgA)	552:593	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	3	15	theme	bovine	552:557	arg1	βLgA					589:592	βLgA	589:592	βLgA	589:592	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	7	16	theme	assemblies	1409:1418	arg1	density					1378:1384	the density	1374:1384	the density of βLgA-pectin complex assemblies	1374:1418	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	4	17	theme	dissipation	726:736	arg1	QCM-D					750:754	QCM-D	750:754	QCM-D	750:754	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	17	theme	dissipation	726:736	arg1	monitoring					738:747	dissipation monitoring	726:747	dissipation monitoring (QCM-D)	726:755	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	1	18	theme	potential	209:217	arg1	use					219:221	their potential use	203:221	their potential use in medical science and biotechnology	203:258	Protein-polysaccharide composite materials have generated much interest due to their potential use in medical science and biotechnology.
36194692	0	19	theme	Assembly	4:11	arg1	Mechanism					13:21	Assembly Mechanism	4:21	Assembly Mechanism	4:21	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	3	20	theme	silica	490:495	arg1	surfaces					497:504	silica surfaces	490:504	silica surfaces	490:504	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	3	21	theme	complex	457:463	arg1	assemblies					465:474	complex assemblies	457:474	complex assemblies	457:474	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	6	22	with	homogeneous	1246:1256	arg1	molecules					1279:1287	βLgA and pectin molecules	1263:1287	βLgA and pectin molecules spatially distributed within the matrix structure	1263:1337	Although the complexes were fabricated in an LbL fashion, the complexes appeared to be relatively homogeneous with βLgA and pectin molecules spatially distributed within the matrix structure.
36194692	4	23	theme	solid-liquid	918:929	arg1	interface					931:939	the solid-liquid interface	914:939	the solid-liquid interface	914:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	24	with	microbalance	708:719	arg1	NR					784:785	NR	784:785	NR	784:785	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	24	with	microbalance	708:719	arg1	QCM-D					750:754	QCM-D	750:754	QCM-D	750:754	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	24	with	microbalance	708:719	arg1	monitoring					738:747	dissipation monitoring	726:747	dissipation monitoring (QCM-D)	726:755	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	24	with	microbalance	708:719	arg1	reflectometry					769:781	neutron reflectometry	761:781	neutron reflectometry (NR)	761:786	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	3	25	theme	model	609:613	arg1	protein					615:621	model protein	609:621	model protein	609:621	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	5	26	theme	pectin	1089:1094	arg1	chains					1096:1101	intertwined pectin chains	1077:1101	intertwined pectin chains that were cross-linked by βLgA-rich domains	1077:1145	Our results show that βLgA and pectin interacted with each other and formed a cohesive matrix structure at the interface consisting of intertwined pectin chains that were cross-linked by βLgA-rich domains.
36194692	3	27	theme	LbL	532:534	arg1	approach					537:544	a layer-by-layer (LbL) approach	514:544	a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively	514:654	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	8	28	theme	varying	1666:1672	arg1	patterns					1681:1688	varying charge patterns	1666:1688	varying charge patterns	1666:1688	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	6	29	theme	βLgA	1263:1266	arg1	molecules					1279:1287	βLgA and pectin molecules	1263:1287	βLgA and pectin molecules spatially distributed within the matrix structure	1263:1337	Although the complexes were fabricated in an LbL fashion, the complexes appeared to be relatively homogeneous with βLgA and pectin molecules spatially distributed within the matrix structure.
36194692	1	30	theme	Protein-polysaccharide	124:145	arg1	materials					157:165	Protein-polysaccharide composite materials	124:165	Protein-polysaccharide composite materials	124:165	Protein-polysaccharide composite materials have generated much interest due to their potential use in medical science and biotechnology.
36194692	7	31	theme	complex	1401:1407	arg1	assemblies					1409:1418	βLgA-pectin complex assemblies	1389:1418	βLgA-pectin complex assemblies	1389:1418	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	5	32	theme	matrix	1029:1034	arg1	structure					1036:1044	a cohesive matrix structure	1018:1044	a cohesive matrix structure	1018:1044	Our results show that βLgA and pectin interacted with each other and formed a cohesive matrix structure at the interface consisting of intertwined pectin chains that were cross-linked by βLgA-rich domains.
36194692	4	33	theme	microbalance	708:719	arg1	use					686:688	the combined use	673:688	the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface	673:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	34	theme	protein-polysaccharide	871:892	arg1	complexes					894:902	the protein-polysaccharide complexes	867:902	the protein-polysaccharide complexes formed at the solid-liquid interface	867:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	8	35	with	polysaccharides	1645:1659	arg1	patterns					1681:1688	varying charge patterns	1666:1688	varying charge patterns	1666:1688	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	3	36	theme	layer-by-layer	516:529	arg1	approach					537:544	a layer-by-layer (LbL) approach	514:544	a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively	514:654	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	0	37	theme	Mesoscale	27:35	arg1	Architecture					37:48	Mesoscale Architecture	27:48	Mesoscale Architecture	27:48	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	7	38	theme	molecules	1487:1495	arg1	density					1469:1475	local charge density	1456:1475	local charge density of pectin molecules	1456:1495	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	8	39	theme	structure	1570:1578	arg1	density					1591:1597	density	1591:1597	density	1591:1597	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	39	theme	structure	1570:1578	arg1	level					1603:1607	level	1603:1607	level	1603:1607	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	39	theme	structure	1570:1578	arg1	properties					1522:1531	the physical properties	1509:1531	the physical properties	1509:1531	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	2	40	theme	comprehensive	263:275	arg1	understanding					277:289	A comprehensive understanding	261:289	A comprehensive understanding of the assembly mechanism and the mesoscale architecture	261:346	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	8	41	theme	protein-polysaccharide	1540:1561	arg1	structure					1570:1578	the protein-polysaccharide matrix structure	1536:1578	the protein-polysaccharide matrix structure	1536:1578	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	4	42	theme	crystal	700:706	arg1	microbalance					708:719	quartz crystal microbalance	693:719	quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR)	693:786	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	0	43	theme	Protein-Polysaccharide	53:74	arg1	Complexes					76:84	Protein-Polysaccharide Complexes	53:84	Protein-Polysaccharide Complexes	53:84	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	8	44	theme	charge	1674:1679	arg1	patterns					1681:1688	varying charge patterns	1666:1688	varying charge patterns	1666:1688	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	45	theme	matrix	1563:1568	arg1	structure					1570:1578	the protein-polysaccharide matrix structure	1536:1578	the protein-polysaccharide matrix structure	1536:1578	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	7	46	theme	charge	1462:1467	arg1	density					1469:1475	local charge density	1456:1475	local charge density of pectin molecules	1456:1495	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	1	47	theme	composite	147:155	arg1	materials					157:165	Protein-polysaccharide composite materials	124:165	Protein-polysaccharide composite materials	124:165	Protein-polysaccharide composite materials have generated much interest due to their potential use in medical science and biotechnology.
36194692	8	48	theme	hydration	1612:1620	arg1	level					1603:1607	level	1603:1607	level	1603:1607	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	8	48	theme	hydration	1612:1620	arg1	density					1591:1597	density	1591:1597	density	1591:1597	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	3	49	dep	approach	537:544	arg1	using					546:550	using	546:550	using	546:550	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	4	50	theme	complexes	894:902	arg1	architecture					851:862	the internal architecture	838:862	the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface	804:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	4	50	theme	complexes	894:902	arg1	mechanism					817:825	the assembly mechanism	804:825	the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface	804:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	3	51	theme	beta-lactoglobulin	559:576	arg1	A					586:586	bovine beta-lactoglobulin variant A	552:586	bovine beta-lactoglobulin variant A (βLgA)	552:593	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	3	51	theme	beta-lactoglobulin	559:576	arg1	βLgA					589:592	βLgA	589:592	βLgA	589:592	In this study, complex assemblies were built on silica surfaces through a layer-by-layer (LbL) approach using bovine beta-lactoglobulin variant A (βLgA) and pectin as model protein and polysaccharide, respectively.
36194692	4	52	theme	internal	842:849	arg1	architecture					851:862	the internal architecture	838:862	the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface	804:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	2	53	theme	mechanism	307:315	arg1	understanding					277:289	A comprehensive understanding	261:289	A comprehensive understanding of the assembly mechanism and the mesoscale architecture	261:346	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	7	54	theme	pectin	1480:1485	arg1	molecules					1487:1495	pectin molecules	1480:1495	pectin molecules	1480:1495	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	2	55	theme	composite	397:405	arg1	materials					407:415	protein-polysaccharide composite materials	374:415	protein-polysaccharide composite materials	374:415	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	4	56	theme	assembly	808:815	arg1	mechanism					817:825	the assembly mechanism	804:825	the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface	804:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	5	57	theme	βLgA-rich	1129:1137	arg1	domains					1139:1145	βLgA-rich domains	1129:1145	βLgA-rich domains	1129:1145	Our results show that βLgA and pectin interacted with each other and formed a cohesive matrix structure at the interface consisting of intertwined pectin chains that were cross-linked by βLgA-rich domains.
36194692	0	58	dep	Mechanism	13:21	arg1	The					0:2	The	0:2	The	0:2	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	1	59	from	use	219:221	arg1	science					234:240	science	234:240	science	234:240	Protein-polysaccharide composite materials have generated much interest due to their potential use in medical science and biotechnology.
36194692	1	59	from	use	219:221	arg1	biotechnology					246:258	biotechnology	246:258	biotechnology	246:258	Protein-polysaccharide composite materials have generated much interest due to their potential use in medical science and biotechnology.
36194692	2	60	theme	protein-polysaccharide	374:395	arg1	materials					407:415	protein-polysaccharide composite materials	374:415	protein-polysaccharide composite materials	374:415	A comprehensive understanding of the assembly mechanism and the mesoscale architecture is needed for fabricating protein-polysaccharide composite materials with desired properties.
36194692	6	61	theme	pectin	1272:1277	arg1	molecules					1279:1287	βLgA and pectin molecules	1263:1287	βLgA and pectin molecules spatially distributed within the matrix structure	1263:1337	Although the complexes were fabricated in an LbL fashion, the complexes appeared to be relatively homogeneous with βLgA and pectin molecules spatially distributed within the matrix structure.
36194692	4	62	theme	quartz	693:698	arg1	microbalance					708:719	quartz crystal microbalance	693:719	quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR)	693:786	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
36194692	1	63	theme	much	182:185	arg1	interest					187:194	much interest	182:194	much interest	182:194	Protein-polysaccharide composite materials have generated much interest due to their potential use in medical science and biotechnology.
36194692	7	64	theme	βLgA-pectin	1389:1399	arg1	assemblies					1409:1418	βLgA-pectin complex assemblies	1389:1418	βLgA-pectin complex assemblies	1389:1418	Our results also demonstrate that the density of βLgA-pectin complex assemblies increased with both the overall and local charge density of pectin molecules.
36194692	0	65	theme	Complexes	76:84	arg1	Mechanism					13:21	Assembly Mechanism	4:21	Assembly Mechanism	4:21	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	0	65	theme	Complexes	76:84	arg1	Architecture					37:48	Mesoscale Architecture	27:48	Mesoscale Architecture	27:48	The Assembly Mechanism and Mesoscale Architecture of Protein-Polysaccharide Complexes Formed at the Solid-liquid Interface.
36194692	5	66	theme	intertwined	1077:1087	arg1	chains					1096:1101	intertwined pectin chains	1077:1101	intertwined pectin chains that were cross-linked by βLgA-rich domains	1077:1145	Our results show that βLgA and pectin interacted with each other and formed a cohesive matrix structure at the interface consisting of intertwined pectin chains that were cross-linked by βLgA-rich domains.
36194692	8	67	theme	desired	1750:1756	arg1	properties					1758:1767	desired properties	1750:1767	desired properties	1750:1767	Therefore, the physical properties of the protein-polysaccharide matrix structure, including density and level of hydration, can be tuned by using polysaccharides with varying charge patterns, thus promoting the development of composite materials with desired properties.
36194692	4	68	theme	combined	677:684	arg1	use					686:688	the combined use	673:688	the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface	673:939	We demonstrated the combined use of quartz crystal microbalance with dissipation monitoring (QCM-D) and neutron reflectometry (NR) for elucidating the assembly mechanism as well as the internal architecture of the protein-polysaccharide complexes formed at the solid-liquid interface.
35850794	1	0	theme	acid	819:822	arg1	assay					837:841	anthrone-sulfuric acid colorimetric assay	801:841	anthrone-sulfuric acid colorimetric assay	801:841	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	0	1	from	mass	20:23	arg1	Polygonatum					91:101	Polygonatum	91:101	Polygonatum	91:101	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	1	2	theme	prior	932:936	arg1	months					634:639	different months	624:639	different months	624:639	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	3	theme	var.grandifolium	604:619	arg1	months					634:639	different months	624:639	different months	624:639	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	4	theme	Polygonatum	192:202	arg1	species					204:210	most Polygonatum species	187:210	most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively	187:295	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	5	theme	polysaccharide	702:715	arg1	content					717:723	polysaccharide content	702:723	polysaccharide content	702:723	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	6	theme	colorimetric	824:835	arg1	assay					837:841	anthrone-sulfuric acid colorimetric assay	801:841	anthrone-sulfuric acid colorimetric assay	801:841	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	7	theme	period.New	1096:1105	arg1	sprouting					1113:1121	the growth period.New shoot sprouting	1085:1121	the growth period.New shoot sprouting promoted the accumulation of polysaccharides	1085:1166	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	2	8	theme	polysaccharides	1152:1166	arg1	accumulation					1136:1147	the accumulation	1132:1147	the accumulation of polysaccharides	1132:1166	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	4	9	theme	scientific	1774:1783	arg1	basis					1785:1789	a scientific basis	1772:1789	a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium	1772:1873	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	1	10	from	composition	420:430	arg1	changes					464:470	P.kingianum var.grandifolium changes	435:470	P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	435:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	11	theme	growth	1089:1094	arg1	sprouting					1113:1121	the growth period.New shoot sprouting	1085:1121	the growth period.New shoot sprouting promoted the accumulation of polysaccharides	1085:1166	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	2	12	from	composition	1002:1012	arg1	rhizome					1021:1027	the rhizome	1017:1027	the rhizome of P.kingianum var.grandifolium	1017:1059	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	1	13	from	species	204:210	arg1	characteristics					226:240	biological characteristics	215:240	biological characteristics	215:240	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	13	from	species	204:210	arg1	different					172:180	different	172:180	different	172:180	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	13	from	species	204:210	arg1	blooms					255:260	blooms	255:260	blooms	255:260	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	13	from	species	204:210	arg1	sprouts					243:249	sprouts	243:249	sprouts	243:249	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	14	dep	Polygonatum	132:142	arg1	var.grandifolium					154:169	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively	132:295	var.grandifolium	154:169	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	15	from	characteristics	226:240	arg1	autumn					276:281	autumn	276:281	autumn	276:281	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	15	from	characteristics	226:240	arg1	spring					265:270	spring	265:270	spring	265:270	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	16	theme	other	374:378	arg1	plants					392:397	other Polygonatum plants	374:397	other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	374:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	17	dep	months	634:639	arg1	in					621:622	P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	592:945	P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	592:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	18	with	changes	464:470	arg1	phenology					477:485	phenology	477:485	phenology	477:485	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	19	theme	high-performance	844:859	arg1	chromatography					876:889	high-performance gel-permeation chromatography	844:889	high-performance gel-permeation chromatography	844:889	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	20	theme	Polygonatum	380:390	arg1	plants					392:397	other Polygonatum plants	374:397	other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	374:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	21	theme	different	624:632	arg1	months					634:639	different months	624:639	different months	624:639	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	22	theme	gel-permeation	861:874	arg1	chromatography					876:889	high-performance gel-permeation chromatography	844:889	high-performance gel-permeation chromatography	844:889	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	23	theme	plants	392:397	arg1	patterns					362:369	the patterns	358:369	the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	358:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	24	theme	relative	741:748	arg1	mass					760:763	polysaccharide relative molecular mass	726:763	polysaccharide relative molecular mass	726:763	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	25	theme	months	634:639	arg1	medicinal					548:556	high-quality medicinal	535:556	high-quality medicinal	535:556	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	25	theme	months	634:639	arg1	substances.Samples					570:587	eatable substances.Samples	562:587	eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	562:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	26	theme	biological	215:224	arg1	characteristics					226:240	biological characteristics	215:240	biological characteristics	215:240	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	0	27	theme	molecular	10:18	arg1	mass					20:23	[Relative molecular mass distribution and monosaccharide composition	0:67	mass	20:23	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	3	28	theme	weight-average	1400:1413	arg1	P1					1426:1427	P1(2.02×10~7)	1426:1438	P1(2.02×10~7)	1426:1438	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	3	28	theme	weight-average	1400:1413	arg1	P4					1471:1472	P4(4.73×10~5)	1471:1483	P4(4.73×10~5)	1471:1483	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	3	28	theme	weight-average	1400:1413	arg1	P5					1490:1491	P5(5.11×10~3)	1490:1502	P5(5.11×10~3)	1490:1502	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	3	28	theme	weight-average	1400:1413	arg1	M_W					1415:1417	the weight-average M_W	1396:1417	the weight-average M_W	1396:1417	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	3	28	theme	weight-average	1400:1413	arg1	P3					1456:1457	P3(1.37×10~6)	1456:1468	P3(1.37×10~6)	1456:1468	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	3	28	theme	weight-average	1400:1413	arg1	P2					1441:1442	P2(5.09×10~6)	1441:1453	P2(5.09×10~6)	1441:1453	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	0	29	from	composition	57:67	arg1	Polygonatum					91:101	Polygonatum	91:101	Polygonatum	91:101	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	0	30	theme	[Relative	0:8	arg1	mass					20:23	[Relative molecular mass distribution and monosaccharide composition	0:67	mass	20:23	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	4	31	theme	study	1758:1762	arg1	results					1743:1749	The results	1739:1749	The results of the study	1739:1762	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	0	32	dep	Polygonatum	91:101	arg1	var.grandifolium					113:128	Polygonatum kingianum var.grandifolium	91:128	Polygonatum kingianum var.grandifolium	91:128	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	1	33	theme	ages	645:648	arg1	medicinal					548:556	high-quality medicinal	535:556	high-quality medicinal	535:556	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	33	theme	ages	645:648	arg1	substances.Samples					570:587	eatable substances.Samples	562:587	eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	562:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	3	34	theme	composition	1563:1573	arg1	terms					1539:1543	the highest content.In terms	1516:1543	the highest content.In terms of monosaccharide composition	1516:1573	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	1	35	theme	molecular	750:758	arg1	mass					760:763	polysaccharide relative molecular mass	726:763	polysaccharide relative molecular mass	726:763	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	36	theme	var.grandifolium	1044:1059	arg1	rhizome					1021:1027	the rhizome	1017:1027	the rhizome of P.kingianum var.grandifolium	1017:1059	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	3	37	theme	1.31∶1.00∶0.90∶0.53∶0.22∶0.21	1709:1737	arg1	ratio					1700:1704	the average molar ratio	1682:1704	the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21	1682:1737	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	1	38	theme	mass	760:763	arg1	medicinal					548:556	high-quality medicinal	535:556	high-quality medicinal	535:556	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	38	theme	mass	760:763	arg1	substances.Samples					570:587	eatable substances.Samples	562:587	eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	562:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	4	39	theme	resource	1822:1829	arg1	utilization					1831:1841	resource utilization	1822:1841	resource utilization	1822:1841	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	3	40	theme	monosaccharide	1548:1561	arg1	composition					1563:1573	monosaccharide composition	1548:1573	monosaccharide composition	1548:1573	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	0	41	theme	monosaccharide	42:55	arg1	composition					57:67	monosaccharide composition	42:67	monosaccharide composition	42:67	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	2	42	theme	shoot	1107:1111	arg1	sprouting					1113:1121	the growth period.New shoot sprouting	1085:1121	the growth period.New shoot sprouting promoted the accumulation of polysaccharides	1085:1166	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	1	43	theme	chemical	411:418	arg1	composition					420:430	the chemical composition	407:430	the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	407:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	3	44	dep	P1	1426:1427	arg1	i.e.					1420:1423	i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3)	1420:1502	i.e.	1420:1423	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	1	45	dep	P.kingianum	435:445	arg1	var.grandifolium					447:462	var.grandifolium	447:462	var.grandifolium	447:462	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	46	theme	trimethylsilane	896:910	arg1	derivatization					917:930	trimethylsilane(TMS) derivatization	896:930	trimethylsilane(TMS) derivatization	896:930	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	47	theme	polysaccharide	975:988	arg1	content					990:996	polysaccharide content	975:996	polysaccharide content	975:996	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	1	48	theme	high-quality	535:546	arg1	medicinal					548:556	high-quality medicinal	535:556	high-quality medicinal	535:556	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	49	theme	mono-saccharide	770:784	arg1	composition					786:796	mono-saccharide composition	770:796	mono-saccharide composition	770:796	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	3	50	theme	average	1686:1692	arg1	ratio					1700:1704	the average molar ratio	1682:1704	the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21	1682:1737	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	4	51	theme	precise	1799:1805	arg1	harvesting					1807:1816	precise harvesting	1799:1816	precise harvesting	1799:1816	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	1	52	theme	anthrone-sulfuric	801:817	arg1	assay					837:841	anthrone-sulfuric acid colorimetric assay	801:841	anthrone-sulfuric acid colorimetric assay	801:841	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	53	theme	polysaccharide	1233:1246	arg1	content					1248:1254	highest polysaccharide content	1225:1254	highest polysaccharide content	1225:1254	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	1	54	theme	medicinal	548:556	arg1	production					521:530	the production	517:530	the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	517:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	55	theme	composition	786:796	arg1	medicinal					548:556	high-quality medicinal	535:556	high-quality medicinal	535:556	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	55	theme	composition	786:796	arg1	substances.Samples					570:587	eatable substances.Samples	562:587	eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	562:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	56	theme	TMS	912:914	arg1	derivatization					917:930	trimethylsilane(TMS) derivatization	896:930	trimethylsilane(TMS) derivatization	896:930	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	57	theme	P.kingianum	435:445	arg1	changes					464:470	P.kingianum var.grandifolium changes	435:470	P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	435:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	58	theme	highest	1225:1231	arg1	content					1248:1254	highest polysaccharide content	1225:1254	highest polysaccharide content	1225:1254	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	1	59	from	sprouts	243:249	arg1	autumn					276:281	autumn	276:281	autumn	276:281	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	59	from	sprouts	243:249	arg1	spring					265:270	spring	265:270	spring	265:270	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	2	60	from	content	990:996	arg1	rhizome					1021:1027	the rhizome	1017:1027	the rhizome of P.kingianum var.grandifolium	1017:1059	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	4	61	dep	harvesting	1807:1816	arg1	the					1795:1797	the	1795:1797	the	1795:1797	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	3	62	theme	highest	1520:1526	arg1	terms					1539:1543	the highest content.In terms	1516:1543	the highest content.In terms of monosaccharide composition	1516:1573	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	1	63	theme	eatable	562:568	arg1	substances.Samples					570:587	eatable substances.Samples	562:587	eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	562:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	3	64	theme	content.In	1528:1537	arg1	terms					1539:1543	the highest content.In terms	1516:1543	the highest content.In terms of monosaccharide composition	1516:1573	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	0	65	dep	mass	20:23	arg1	distribution					25:36	distribution	25:36	distribution	25:36	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	1	66	theme	substances.Samples	570:587	arg1	production					521:530	the production	517:530	the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS	517:945	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	67	theme	most	187:190	arg1	species					204:210	most Polygonatum species	187:210	most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively	187:295	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	3	68	contain	had	1512:1514	arg2	terms					1539:1543	the highest content.In terms	1516:1543	the highest content.In terms of monosaccharide composition	1516:1573	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	3	68	contain	had	1512:1514	arg1	P5					1509:1510	P5	1509:1510	P5	1509:1510	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	2	69	dep	content	990:996	arg1	the					971:973	the	971:973	the	971:973	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	1	70	from	blooms	255:260	arg1	autumn					276:281	autumn	276:281	autumn	276:281	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	70	from	blooms	255:260	arg1	spring					265:270	spring	265:270	spring	265:270	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	4	71	theme	var.grandifolium	1858:1873	arg1	harvesting					1807:1816	precise harvesting	1799:1816	precise harvesting	1799:1816	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	4	71	theme	var.grandifolium	1858:1873	arg1	utilization					1831:1841	resource utilization	1822:1841	resource utilization	1822:1841	The results of the study provide a scientific basis for the precise harvesting and resource utilization of P.kingianum var.grandifolium.
35850794	2	72	located	found	1260:1264	arg2	flowering					1173:1181	flowering	1173:1181	flowering	1173:1181	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	2	72	located	found	1260:1264	arg2	fruiting					1187:1194	fruiting	1187:1194	fruiting	1187:1194	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	2	72	located	found	1260:1264	arg1	April					1269:1273	April	1269:1273	April	1269:1273	The results showed that the polysaccharide content and composition in the rhizome of P.kingianum var.grandifolium were closely related to the growth period.New shoot sprouting promoted the accumulation of polysaccharides, and flowering and fruiting consumed polysaccharides.The highest polysaccharide content was found in April, reaching 134.04 mg·g~(-1).
35850794	0	73	theme	polysaccharides	72:86	arg1	mass					20:23	[Relative molecular mass distribution and monosaccharide composition	0:67	mass	20:23	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	0	73	theme	polysaccharides	72:86	arg1	composition					57:67	monosaccharide composition	42:67	monosaccharide composition	42:67	[Relative molecular mass distribution and monosaccharide composition of polysaccharides in Polygonatum kingianum var.grandifolium].
35850794	3	74	from	Polysaccharides	1302:1316	arg1	var.grandifolium					1333:1348	P.kingianum var.grandifolium	1321:1348	P.kingianum var.grandifolium	1321:1348	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
35850794	1	75	theme	P.kingianum	592:602	arg1	months					634:639	different months	624:639	different months	624:639	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	1	76	theme	polysaccharide	726:739	arg1	mass					760:763	polysaccharide relative molecular mass	726:763	polysaccharide relative molecular mass	726:763	Polygonatum kingianum var.grandifolium, different from most Polygonatum species in biological characteristics, sprouts and blooms in spring and autumn, respectively, and it is evergreen in winter.It is difficult to learn from the patterns of other Polygonatum plants because the chemical composition in P.kingianum var.grandifolium changes with phenology, which consequently restricts the production of high-quality medicinal and eatable substances.Samples of P.kingianum var.grandifolium in different months and ages collected from Xiushan, Chongqing were analyzed for polysaccharide content, polysaccharide relative molecular mass, and mono-saccharide composition by anthrone-sulfuric acid colorimetric assay, high-performance gel-permeation chromatography, and trimethylsilane(TMS) derivatization prior to GC-MS.
35850794	3	77	theme	molar	1694:1698	arg1	ratio					1700:1704	the average molar ratio	1682:1704	the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21	1682:1737	Polysaccharides in P.kingianum var.grandifolium were divided into five fractions according to the weight-average M_W, i.e., P1(2.02×10~7), P2(5.09×10~6), P3(1.37×10~6), P4(4.73×10~5), and P5(5.11×10~3), and P5 had the highest content.In terms of monosaccharide composition, polysaccharides were mainly composed of fructose, glucose, galactose, mannose, xylose, and arabinose with the average molar ratio of 1.31∶1.00∶0.90∶0.53∶0.22∶0.21.
37327923	8	0	theme	relative	1091:1098	arg1	segments					1159:1166	highly methyl-esterified segments	1134:1166	highly methyl-esterified segments	1134:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	0	theme	relative	1091:1098	arg1	moderately-					1117:1127	moderately-	1117:1127	moderately-	1117:1127	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	0	theme	relative	1091:1098	arg1	non-					1111:1114	non-	1111:1114	non-	1111:1114	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	0	theme	relative	1091:1098	arg1	amounts					1100:1106	relative amounts	1091:1106	relative amounts of non-, moderately-, and highly methyl-esterified segments	1091:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	4	1	contain	had	699:701	arg2	%					724:724	~50 %	720:724	~50 %	720:724	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	4	1	contain	had	699:701	arg2	DM					742:743	low (<30 %) DM	730:743	low (<30 %) DM	730:743	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	4	1	contain	had	699:701	arg2	medium					712:717	a medium	710:717	a medium (~50 %)	710:725	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	4	1	contain	had	699:701	arg1	pectins					691:697	ChSS pectins	686:697	ChSS pectins	686:697	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	1	2	from	cultivars	292:300	arg1	fractions					268:276	pectin fractions	261:276	pectin fractions from 13 apple cultivars	261:300	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	2	from	cultivars	292:300	arg1	content					224:230	sugar content	218:230	sugar content	218:230	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	2	from	cultivars	292:300	arg1	methyl-esterification					236:256	methyl-esterification	236:256	methyl-esterification	236:256	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	9	3	theme	methyl-esterified	1338:1354	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	1	4	theme	sugar	218:222	arg1	content					224:230	sugar content	218:230	sugar content	218:230	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	2	5	theme	chelating-soluble	456:472	arg1	ChSS					482:485	ChSS	482:485	ChSS	482:485	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	2	5	theme	chelating-soluble	456:472	arg1	solids					474:479	chelating-soluble solids	456:479	chelating-soluble solids (ChSS)	456:486	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	6	6	theme	pectin	855:860	arg1	distribution					839:850	Methyl-ester distribution	826:850	Methyl-ester distribution of pectin	826:860	Methyl-ester distribution of pectin was described by degrees of blockiness and -hydrolysis.
37327923	10	7	theme	physicochemical	1421:1435	arg1	properties					1437:1446	physicochemical properties	1421:1446	physicochemical properties of apple and its products	1421:1472	These findings will be of help to better understand physicochemical properties of apple and its products.
37327923	1	8	theme	crucial	148:154	arg1	role					156:159	a crucial role	146:159	a crucial role	146:159	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	10	9	theme	products	1465:1472	arg1	properties					1437:1446	physicochemical properties	1421:1446	physicochemical properties of apple and its products	1421:1472	These findings will be of help to better understand physicochemical properties of apple and its products.
37327923	7	10	theme	Novel	918:922	arg1	parameters					936:945	Novel descriptive parameters	918:945	Novel descriptive parameters	918:945	Novel descriptive parameters were obtained by measuring the levels of methyl-esterified oligomers released by endo-PG (DBPGme) and PL (DBPLme).
37327923	9	11	theme	medium	1255:1260	arg1	DM					1262:1263	medium DM	1255:1263	medium DM	1255:1263	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	12	contain	had	1251:1253	arg1	pectins					1243:1249	ChSS pectins	1238:1249	ChSS pectins	1238:1249	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	12	contain	had	1251:1253	arg2	DM					1312:1313	a low DM	1306:1313	a low DM with many intermediate methyl-esterified GalA blocks	1306:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	12	contain	had	1251:1253	arg2	DM					1262:1263	medium DM	1255:1263	medium DM	1255:1263	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	12	contain	had	1251:1253	arg2	blocks					1296:1301	many non-methyl-esterified blocks	1269:1301	many non-methyl-esterified blocks	1269:1301	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	6	13	theme	Methyl-ester	826:837	arg1	distribution					839:850	Methyl-ester distribution	826:850	Methyl-ester distribution of pectin	826:860	Methyl-ester distribution of pectin was described by degrees of blockiness and -hydrolysis.
37327923	9	14	with	DM	1312:1313	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	8	15	theme	non-	1111:1114	arg1	segments					1159:1166	highly methyl-esterified segments	1134:1166	highly methyl-esterified segments	1134:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	15	theme	non-	1111:1114	arg1	moderately-					1117:1127	moderately-	1117:1127	moderately-	1117:1127	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	15	theme	non-	1111:1114	arg1	non-					1111:1114	non-	1111:1114	non-	1111:1114	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	15	theme	non-	1111:1114	arg1	amounts					1100:1106	relative amounts	1091:1106	relative amounts of non-, moderately-, and highly methyl-esterified segments	1091:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	16	theme	segments	1159:1166	arg1	segments					1159:1166	highly methyl-esterified segments	1134:1166	highly methyl-esterified segments	1134:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	16	theme	segments	1159:1166	arg1	moderately-					1117:1127	moderately-	1117:1127	moderately-	1117:1127	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	16	theme	segments	1159:1166	arg1	non-					1111:1114	non-	1111:1114	non-	1111:1114	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	16	theme	segments	1159:1166	arg1	amounts					1100:1106	relative amounts	1091:1106	relative amounts of non-, moderately-, and highly methyl-esterified segments	1091:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	3	17	theme	significant	513:523	arg1	amounts					525:531	significant amounts	513:531	significant amounts of galacturonic acid	513:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	3	17	theme	significant	513:523	arg1	acid					549:552	galacturonic acid	536:552	galacturonic acid	536:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	0	18	theme	wide	2:5	arg1	diversity					7:15	A wide diversity	0:15	A wide diversity	0:15	A wide diversity exists in pectin structure from thirteen apple cultivars.
37327923	9	19	theme	many	1269:1272	arg1	blocks					1296:1301	many non-methyl-esterified blocks	1269:1301	many non-methyl-esterified blocks	1269:1301	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	4	20	dep	low	730:732	arg1	%					739:739	<30 %	735:739	<30 %	735:739	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	2	21	theme	water-soluble	425:437	arg1	WSS					447:449	WSS	447:449	WSS	447:449	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	2	21	theme	water-soluble	425:437	arg1	solids					439:444	water-soluble solids	425:444	water-soluble solids (WSS)	425:450	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	9	22	theme	non-methyl-esterified	1274:1294	arg1	blocks					1296:1301	many non-methyl-esterified blocks	1269:1301	many non-methyl-esterified blocks	1269:1301	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	2	23	theme	alcohol-insoluble	358:374	arg1	AIS					384:386	AIS	384:386	AIS	384:386	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	2	23	theme	alcohol-insoluble	358:374	arg1	solids					376:381	alcohol-insoluble solids	358:381	alcohol-insoluble solids (AIS)	358:387	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	2	23	theme	alcohol-insoluble	358:374	arg1	polysaccharides					325:339	Cell wall polysaccharides	315:339	Cell wall polysaccharides	315:339	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	1	24	theme	pectin	261:266	arg1	fractions					268:276	pectin fractions	261:276	pectin fractions from 13 apple cultivars	261:300	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	6	25	theme	-hydrolysis	905:915	arg1	degrees					879:885	degrees	879:885	degrees of blockiness and -hydrolysis	879:915	Methyl-ester distribution of pectin was described by degrees of blockiness and -hydrolysis.
37327923	9	26	theme	WSS	1169:1171	arg1	pectins					1173:1179	WSS pectins	1169:1179	WSS pectins	1169:1179	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	3	27	theme	galacturonic	536:547	arg1	acid					549:552	galacturonic acid	536:552	galacturonic acid	536:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	1	28	theme	fractions	268:276	arg1	content					224:230	sugar content	218:230	sugar content	218:230	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	28	theme	fractions	268:276	arg1	methyl-esterification					236:256	methyl-esterification	236:256	methyl-esterification	236:256	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	29	from	methyl-esterification	236:256	arg1	cultivars					292:300	13 apple cultivars	283:300	13 apple cultivars	283:300	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	3	30	theme	acid	549:552	arg1	amounts					525:531	significant amounts	513:531	significant amounts of galacturonic acid	513:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	3	30	theme	acid	549:552	arg1	acid					549:552	galacturonic acid	536:552	galacturonic acid	536:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	4	31	theme	WSS	614:616	arg1	pectins					618:624	AIS and WSS pectins	606:624	AIS and WSS pectins	606:624	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	0	32	theme	pectin	27:32	arg1	structure					34:42	pectin structure	27:42	pectin structure from thirteen apple cultivars	27:72	A wide diversity exists in pectin structure from thirteen apple cultivars.
37327923	2	33	theme	Cell	315:318	arg1	solids					376:381	alcohol-insoluble solids	358:381	alcohol-insoluble solids (AIS)	358:387	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	2	33	theme	Cell	315:318	arg1	polysaccharides					325:339	Cell wall polysaccharides	315:339	Cell wall polysaccharides	315:339	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	10	34	theme	apple	1451:1455	arg1	properties					1437:1446	physicochemical properties	1421:1446	physicochemical properties of apple and its products	1421:1472	These findings will be of help to better understand physicochemical properties of apple and its products.
37327923	0	35	from	cultivars	64:72	arg1	structure					34:42	pectin structure	27:42	pectin structure from thirteen apple cultivars	27:72	A wide diversity exists in pectin structure from thirteen apple cultivars.
37327923	4	36	theme	methyl-esterification	645:665	arg1	degree					635:640	a degree	633:640	a degree of methyl-esterification (DM)	633:670	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	5	37	theme	major	766:770	arg1	structure					772:780	major structure	766:780	major structure	766:780	Homogalacturonan as major structure was studied using enzymatic fingerprinting.
37327923	8	38	theme	methyl-esterified	1141:1157	arg1	segments					1159:1166	highly methyl-esterified segments	1134:1166	highly methyl-esterified segments	1134:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	6	39	theme	blockiness	890:899	arg1	degrees					879:885	degrees	879:885	degrees of blockiness and -hydrolysis	879:915	Methyl-ester distribution of pectin was described by degrees of blockiness and -hydrolysis.
37327923	1	40	from	content	224:230	arg1	cultivars					292:300	13 apple cultivars	283:300	13 apple cultivars	283:300	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	41	theme	fruits	191:196	arg1	quality					180:186	quality	180:186	quality	180:186	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	41	theme	fruits	191:196	arg1	texture					168:174	texture	168:174	texture	168:174	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	42	theme	apple	286:290	arg1	cultivars					292:300	13 apple cultivars	283:300	13 apple cultivars	283:300	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	7	43	theme	oligomers	1006:1014	arg1	levels					978:983	the levels	974:983	the levels of methyl-esterified oligomers released by endo-PG (DBPGme) and PL (DBPLme)	974:1059	Novel descriptive parameters were obtained by measuring the levels of methyl-esterified oligomers released by endo-PG (DBPGme) and PL (DBPLme).
37327923	3	44	theme	sugar	561:565	arg1	compositions					567:578	sugar compositions	561:578	sugar compositions	561:578	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	2	45	theme	wall	320:323	arg1	solids					376:381	alcohol-insoluble solids	358:381	alcohol-insoluble solids (AIS)	358:387	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	2	45	theme	wall	320:323	arg1	polysaccharides					325:339	Cell wall polysaccharides	315:339	Cell wall polysaccharides	315:339	Cell wall polysaccharides were isolated as alcohol-insoluble solids (AIS) and subsequently extracted to yield water-soluble solids (WSS) and chelating-soluble solids (ChSS).
37327923	9	46	with	blocks	1296:1301	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	47	theme	non-esterified	1201:1214	arg1	sequences					1221:1229	non-esterified GalA sequences	1201:1229	non-esterified GalA sequences	1201:1229	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	48	theme	GalA	1216:1219	arg1	sequences					1221:1229	non-esterified GalA sequences	1201:1229	non-esterified GalA sequences	1201:1229	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	49	theme	ChSS	1238:1241	arg1	pectins					1243:1249	ChSS pectins	1238:1249	ChSS pectins	1238:1249	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	1	50	theme	pectin	108:113	arg1	structure					115:123	pectin structure	108:123	pectin structure	108:123	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	9	51	theme	many	1320:1323	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	8	52	theme	Pectin	1062:1067	arg1	fractions					1069:1077	Pectin fractions	1062:1077	Pectin fractions	1062:1077	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	5	53	theme	enzymatic	800:808	arg1	fingerprinting					810:823	enzymatic fingerprinting	800:823	enzymatic fingerprinting	800:823	Homogalacturonan as major structure was studied using enzymatic fingerprinting.
37327923	4	54	theme	low	730:732	arg1	DM					742:743	low (<30 %) DM	730:743	low (<30 %) DM	730:743	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	1	55	from	differences	93:103	arg1	structure					115:123	pectin structure	108:123	pectin structure	108:123	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	9	56	theme	intermediate	1325:1336	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	7	57	theme	methyl-esterified	988:1004	arg1	oligomers					1006:1014	methyl-esterified oligomers	988:1014	methyl-esterified oligomers released by endo-PG (DBPGme) and PL (DBPLme)	988:1059	Novel descriptive parameters were obtained by measuring the levels of methyl-esterified oligomers released by endo-PG (DBPGme) and PL (DBPLme).
37327923	8	58	theme	moderately-	1117:1127	arg1	segments					1159:1166	highly methyl-esterified segments	1134:1166	highly methyl-esterified segments	1134:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	58	theme	moderately-	1117:1127	arg1	moderately-					1117:1127	moderately-	1117:1127	moderately-	1117:1127	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	58	theme	moderately-	1117:1127	arg1	non-					1111:1114	non-	1111:1114	non-	1111:1114	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	8	58	theme	moderately-	1117:1127	arg1	amounts					1100:1106	relative amounts	1091:1106	relative amounts of non-, moderately-, and highly methyl-esterified segments	1091:1166	Pectin fractions differed in relative amounts of non-, moderately-, and highly methyl-esterified segments.
37327923	4	59	theme	ChSS	686:689	arg1	pectins					691:697	ChSS pectins	686:697	ChSS pectins	686:697	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	9	60	theme	low	1308:1310	arg1	DM					1312:1313	a low DM	1306:1313	a low DM with many intermediate methyl-esterified GalA blocks	1306:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	1	61	theme	vegetables	202:211	arg1	quality					180:186	quality	180:186	quality	180:186	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	1	61	theme	vegetables	202:211	arg1	texture					168:174	texture	168:174	texture	168:174	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	0	62	theme	apple	58:62	arg1	cultivars					64:72	thirteen apple cultivars	49:72	thirteen apple cultivars	49:72	A wide diversity exists in pectin structure from thirteen apple cultivars.
37327923	1	63	dep	content	224:230	arg1	the					214:216	the	214:216	the	214:216	To emphasize that differences in pectin structure among cultivars play a crucial role in the texture and quality of fruits and vegetables, the sugar content and methyl-esterification of pectin fractions from 13 apple cultivars was studied.
37327923	9	64	with	DM	1262:1263	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	9	65	theme	GalA	1356:1359	arg1	blocks					1361:1366	many intermediate methyl-esterified GalA blocks	1320:1366	many intermediate methyl-esterified GalA blocks	1320:1366	WSS pectins were mostly lacking non-esterified GalA sequences, while ChSS pectins had medium DM and many non-methyl-esterified blocks or a low DM with many intermediate methyl-esterified GalA blocks.
37327923	4	66	theme	AIS	606:608	arg1	pectins					618:624	AIS and WSS pectins	606:624	AIS and WSS pectins	606:624	AIS and WSS pectins showed a degree of methyl-esterification (DM) > 50 %, while ChSS pectins had either a medium (~50 %) or low (<30 %) DM.
37327923	7	67	theme	descriptive	924:934	arg1	parameters					936:945	Novel descriptive parameters	918:945	Novel descriptive parameters	918:945	Novel descriptive parameters were obtained by measuring the levels of methyl-esterified oligomers released by endo-PG (DBPGme) and PL (DBPLme).
37327923	3	68	contain	contained	503:511	arg2	acid					549:552	galacturonic acid	536:552	galacturonic acid	536:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	3	68	contain	contained	503:511	arg2	amounts					525:531	significant amounts	513:531	significant amounts of galacturonic acid	513:552	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
37327923	3	68	contain	contained	503:511	arg1	fractions					493:501	All fractions	489:501	All fractions	489:501	All fractions contained significant amounts of galacturonic acid, while sugar compositions varied between cultivars.
35897903	0	0	from	Study	13:17	arg1	Polysaccharides					22:36	Polysaccharides	22:36	Polysaccharides Extracted from Atractylodes chinensis	22:74	A Comparison Study on Polysaccharides Extracted from Atractylodes chinensis (DC.)
35897903	8	1	theme	weight	736:741	arg1	distribution					743:754	molecular weight distribution	726:754	molecular weight distribution	726:754	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	2	theme	yield	691:695	arg1	terms					682:686	terms	682:686	terms of yield	682:695	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	2	3	dep	Using	89:93	arg1	Characterization					125:140	Structural Characterization	114:140	Structural Characterization	114:140	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	2	3	dep	Using	89:93	arg1	Effect					160:165	Anti-SGC-7901 Effect	146:165	Anti-SGC-7901 Effect	146:165	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	8	4	theme	monosaccharide	757:770	arg1	composition					772:782	monosaccharide composition	757:782	monosaccharide composition	757:782	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	2	5	theme	Different	95:103	arg1	Methods					105:111	Different Methods	95:111	Different Methods	95:111	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	3	6	theme	years	213:217	arg1	hundreds					201:208	hundreds	201:208	hundreds of years	201:217	For hundreds of years, Atractylodes chinensis (DC.)
35897903	6	7	theme	AK	343:344	arg1	components					417:426	the important bioactive components	393:426	the important bioactive components	393:426	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	6	7	theme	AK	343:344	arg1	AKPs					363:366	AKPs	363:366	AKPs	363:366	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	6	7	theme	AK	343:344	arg1	polysaccharides					346:360	The AK polysaccharides	339:360	The AK polysaccharides (AKPs)	339:367	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	10	8	theme	strongest	1135:1143	arg1	activities					1157:1166	the strongest synergistic activities	1131:1166	the strongest synergistic activities	1131:1166	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	8	9	theme	total	698:702	arg1	content					717:723	total carbohydrate content	698:723	total carbohydrate content	698:723	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	14	10	theme	gastric	1530:1536	arg1	cancer					1538:1543	gastric cancer	1530:1543	gastric cancer	1530:1543	for the development of natural synergist and for the treatment of gastric cancer.
35897903	12	11	dep	suggested	1318:1326	arg1	DC					1452:1453	DC	1452:1453	DC.	1452:1454	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	11	12	theme	galactose	1284:1292	arg1	content					1294:1300	higher galactose content	1277:1300	higher galactose content	1277:1300	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	2	13	theme	Anti-SGC-7901	146:158	arg1	Effect					160:165	Anti-SGC-7901 Effect	146:165	Anti-SGC-7901 Effect	146:165	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	8	14	with	AKPs	817:820	arg1	apatinib					827:834	apatinib	827:834	apatinib	827:834	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	14	15	theme	cancer	1538:1543	arg1	development					1472:1482	the development	1468:1482	the development of natural synergist	1468:1503	for the development of natural synergist and for the treatment of gastric cancer.
35897903	14	15	theme	cancer	1538:1543	arg1	treatment					1517:1525	the treatment	1513:1525	the treatment of gastric cancer	1513:1543	for the development of natural synergist and for the treatment of gastric cancer.
35897903	5	16	dep	used	277:280	arg1	AK					257:258	AK	257:258	AK	257:258	(AK) has been widely used as a treatment for spleen and stomach diseases in China.
35897903	11	17	with	agreement	1185:1193	arg1	fact					1204:1207	the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content	1200:1300	the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content	1200:1300	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	8	18	theme	synergistic	789:799	arg1	activity					801:808	synergistic activity	789:808	synergistic activity	789:808	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	0	19	theme	Comparison	2:11	arg1	Study					13:17	A Comparison Study	0:17	A Comparison Study on Polysaccharides Extracted from Atractylodes chinensis (DC.)	0:80	A Comparison Study on Polysaccharides Extracted from Atractylodes chinensis (DC.)
35897903	0	19	theme	Comparison	2:11	arg1	DC					77:78	DC	77:78	DC.	77:79	A Comparison Study on Polysaccharides Extracted from Atractylodes chinensis (DC.)
35897903	10	20	theme	activity	976:983	arg1	assays					985:990	activity assays	976:990	activity assays	976:990	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	12	21	from	chinensis	1441:1449	arg1	polysaccharides					1407:1421	new polysaccharides	1403:1421	new polysaccharides from Atractylodes chinensis	1403:1449	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	10	22	dep	UAE-AKPs	1007:1014	arg1	apoptosis					1038:1046	enhanced apoptosis	1029:1046	enhanced apoptosis	1029:1046	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	10	23	theme	enhanced	1029:1036	arg1	apoptosis					1038:1046	enhanced apoptosis	1029:1046	enhanced apoptosis	1029:1046	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	5	24	theme	spleen	301:306	arg1	diseases					320:327	spleen and stomach diseases	301:327	spleen and stomach diseases in China	301:336	(AK) has been widely used as a treatment for spleen and stomach diseases in China.
35897903	3	25	dep	chinensis	233:241	arg1	DC					244:245	DC	244:245	Atractylodes chinensis (DC	220:245	For hundreds of years, Atractylodes chinensis (DC.)
35897903	3	25	dep	chinensis	233:241	arg1	hundreds					201:208	hundreds	201:208	hundreds of years	201:217	For hundreds of years, Atractylodes chinensis (DC.)
35897903	8	26	theme	enzyme	641:646	arg1	EAE					660:662	EAE	660:662	EAE	660:662	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	26	theme	enzyme	641:646	arg1	extraction					648:657	enzyme extraction	641:657	enzyme extraction (EAE)	641:663	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	12	27	theme	new	1403:1405	arg1	polysaccharides					1407:1421	new polysaccharides	1403:1421	new polysaccharides from Atractylodes chinensis	1403:1449	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	8	28	theme	AKPs	817:820	arg1	distribution					743:754	molecular weight distribution	726:754	molecular weight distribution	726:754	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	28	theme	AKPs	817:820	arg1	composition					772:782	monosaccharide composition	757:782	monosaccharide composition	757:782	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	28	theme	AKPs	817:820	arg1	content					717:723	total carbohydrate content	698:723	total carbohydrate content	698:723	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	28	theme	AKPs	817:820	arg1	activity					801:808	synergistic activity	789:808	synergistic activity	789:808	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	5	29	theme	stomach	312:318	arg1	diseases					320:327	spleen and stomach diseases	301:327	spleen and stomach diseases in China	301:336	(AK) has been widely used as a treatment for spleen and stomach diseases in China.
35897903	5	30	from	diseases	320:327	arg1	China					332:336	China	332:336	China	332:336	(AK) has been widely used as a treatment for spleen and stomach diseases in China.
35897903	8	31	theme	water	548:552	arg1	HWE					566:568	HWE	566:568	HWE	566:568	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	31	theme	water	548:552	arg1	extraction					554:563	hot water extraction	544:563	hot water extraction (HWE)	544:569	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	9	32	theme	polysaccharide	897:910	arg1	yield					884:888	the yield	880:888	the yield of the polysaccharide obtained from HWE	880:928	The results indicated that the yield of the polysaccharide obtained from HWE was higher than that of UAE and EAE.
35897903	9	32	theme	polysaccharide	897:910	arg1	higher					934:939	higher	934:939	higher	934:939	The results indicated that the yield of the polysaccharide obtained from HWE was higher than that of UAE and EAE.
35897903	10	33	theme	gastric	1057:1063	arg1	SGC-7901					1079:1086	SGC-7901	1079:1086	SGC-7901	1079:1086	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	10	33	theme	gastric	1057:1063	arg1	cells					1072:1076	human gastric cancer cells	1051:1076	human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs	1051:1122	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	2	34	theme	Combination	170:180	arg1	Characterization					125:140	Structural Characterization	114:140	Structural Characterization	114:140	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	2	34	theme	Combination	170:180	arg1	Effect					160:165	Anti-SGC-7901 Effect	146:165	Anti-SGC-7901 Effect	146:165	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	11	35	theme	smaller	1230:1236	arg1	weight					1248:1253	a smaller molecular weight	1228:1253	a smaller molecular weight	1228:1253	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	10	36	theme	human	1051:1055	arg1	SGC-7901					1079:1086	SGC-7901	1079:1086	SGC-7901	1079:1086	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	10	36	theme	human	1051:1055	arg1	cells					1072:1076	human gastric cancer cells	1051:1076	human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs	1051:1122	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	7	37	theme	extraction	468:477	arg1	methods					479:485	different extraction methods	458:485	different extraction methods	458:485	In this stud, the impacts of different extraction methods were analyzed.
35897903	2	38	with	Combination	170:180	arg1	Apatinib					187:194	Apatinib	187:194	Apatinib	187:194	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	11	39	theme	molecular	1238:1246	arg1	weight					1248:1253	a smaller molecular weight	1228:1253	a smaller molecular weight	1228:1253	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	8	40	theme	ultrasonic	590:599	arg1	extraction					601:610	ultrasonic extraction	590:610	ultrasonic extraction (UAE)	590:616	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	40	theme	ultrasonic	590:599	arg1	UAE					613:615	UAE	613:615	UAE	613:615	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	12	41	theme	friendly	1373:1380	arg1	method					1382:1387	an efficient and environmentally friendly method	1340:1387	an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis	1340:1449	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	12	41	theme	friendly	1373:1380	arg1	UAE					1333:1335	UAE	1333:1335	UAE	1333:1335	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	7	42	theme	methods	479:485	arg1	impacts					447:453	the impacts	443:453	the impacts of different extraction methods	443:485	In this stud, the impacts of different extraction methods were analyzed.
35897903	14	43	theme	synergist	1495:1503	arg1	development					1472:1482	the development	1468:1482	the development of natural synergist	1468:1503	for the development of natural synergist and for the treatment of gastric cancer.
35897903	14	43	theme	synergist	1495:1503	arg1	treatment					1517:1525	the treatment	1513:1525	the treatment of gastric cancer	1513:1543	for the development of natural synergist and for the treatment of gastric cancer.
35897903	6	44	theme	bioactive	407:415	arg1	components					417:426	the important bioactive components	393:426	the important bioactive components	393:426	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	6	44	theme	bioactive	407:415	arg1	polysaccharides					346:360	The AK polysaccharides	339:360	The AK polysaccharides (AKPs)	339:367	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	12	45	theme	environmentally	1357:1371	arg1	method					1382:1387	an efficient and environmentally friendly method	1340:1387	an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis	1340:1449	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	12	45	theme	environmentally	1357:1371	arg1	UAE					1333:1335	UAE	1333:1335	UAE	1333:1335	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	14	46	theme	natural	1487:1493	arg1	synergist					1495:1503	natural synergist	1487:1503	natural synergist	1487:1503	for the development of natural synergist and for the treatment of gastric cancer.
35897903	12	47	theme	efficient	1343:1351	arg1	method					1382:1387	an efficient and environmentally friendly method	1340:1387	an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis	1340:1449	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	12	47	theme	efficient	1343:1351	arg1	UAE					1333:1335	UAE	1333:1335	UAE	1333:1335	These findings suggested that UAE is an efficient and environmentally friendly method for producing new polysaccharides from Atractylodes chinensis (DC.)
35897903	8	48	theme	carbohydrate	704:715	arg1	content					717:723	total carbohydrate content	698:723	total carbohydrate content	698:723	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	10	49	theme	synergistic	1145:1155	arg1	activities					1157:1166	the strongest synergistic activities	1131:1166	the strongest synergistic activities	1131:1166	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	6	50	theme	important	397:405	arg1	components					417:426	the important bioactive components	393:426	the important bioactive components	393:426	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	6	50	theme	important	397:405	arg1	polysaccharides					346:360	The AK polysaccharides	339:360	The AK polysaccharides (AKPs)	339:367	The AK polysaccharides (AKPs) have been thought to be the important bioactive components.
35897903	7	51	theme	different	458:466	arg1	methods					479:485	different extraction methods	458:485	different extraction methods	458:485	In this stud, the impacts of different extraction methods were analyzed.
35897903	8	52	theme	molecular	726:734	arg1	distribution					743:754	molecular weight distribution	726:754	molecular weight distribution	726:754	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	53	theme	hot	544:546	arg1	HWE					566:568	HWE	566:568	HWE	566:568	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	8	53	theme	hot	544:546	arg1	extraction					554:563	hot water extraction	544:563	hot water extraction (HWE)	544:569	The differences between AKPs extracted by hot water extraction (HWE), AKPs extracted by ultrasonic extraction (UAE), and AKPs extracted by enzyme extraction (EAE) were compared in terms of yield, total carbohydrate content, molecular weight distribution, monosaccharide composition, and synergistic activity of the AKPs with apatinib were determined.
35897903	10	54	theme	cells	1072:1076	arg1	HWE-AKPs					1020:1027	HWE-AKPs	1020:1027	HWE-AKPs	1020:1027	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	10	54	theme	cells	1072:1076	arg1	UAE-AKPs					1007:1014	UAE-AKPs	1007:1014	UAE-AKPs	1007:1014	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	11	55	theme	higher	1277:1282	arg1	content					1294:1300	higher galactose content	1277:1300	higher galactose content	1277:1300	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	2	56	theme	Structural	114:123	arg1	Characterization					125:140	Structural Characterization	114:140	Structural Characterization	114:140	Using Different Methods: Structural Characterization and Anti-SGC-7901 Effect of Combination with Apatinib.
35897903	11	57	contain	have	1223:1226	arg2	β-configuration					1256:1270	β-configuration	1256:1270	β-configuration	1256:1270	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	11	57	contain	have	1223:1226	arg2	content					1294:1300	higher galactose content	1277:1300	higher galactose content	1277:1300	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	11	57	contain	have	1223:1226	arg2	weight					1248:1253	a smaller molecular weight	1228:1253	a smaller molecular weight	1228:1253	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	11	57	contain	have	1223:1226	arg1	UAE-AKPs					1214:1221	UAE-AKPs	1214:1221	UAE-AKPs	1214:1221	This is also in agreement with the fact that UAE-AKPs have a smaller molecular weight, β-configuration, and higher galactose content.
35897903	10	58	theme	cancer	1065:1070	arg1	SGC-7901					1079:1086	SGC-7901	1079:1086	SGC-7901	1079:1086	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35897903	10	58	theme	cancer	1065:1070	arg1	cells					1072:1076	human gastric cancer cells	1051:1076	human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs	1051:1122	However, activity assays indicated that UAE-AKPs and HWE-AKPs enhanced apoptosis of human gastric cancer cells (SGC-7901) treated with apatinib and UAE-AKPs showed the strongest synergistic activities.
35337916	7	0	theme	total	1122:1126	arg1	sugar					1128:1132	total sugar	1122:1132	total sugar	1122:1132	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	2	1	theme	gastric	372:378	arg1	digestion					380:388	gastric digestion	372:388	gastric digestion	372:388	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	0	2	theme	polysaccharides	65:79	arg1	microbiota					51:60	human fecal microbiota	39:60	human fecal microbiota of polysaccharides from Clitocybe squamulose	39:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	7	3	theme	gut	1091:1093	arg1	microbiota					1095:1104	gut microbiota	1091:1104	gut microbiota	1091:1104	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	1	4	from	effects	148:154	arg1	bioactivity					287:297	bioactivity	287:297	bioactivity	287:297	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	4	from	effects	148:154	arg1	structure					273:281	structure	273:281	structure	273:281	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	4	from	effects	148:154	arg1	composition					260:270	the chemical composition	247:270	the chemical composition	247:270	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	5	5	theme	gastric	831:837	arg1	digestion					839:847	gastric digestion	831:847	gastric digestion	831:847	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	9	6	theme	intestinal	1626:1635	arg1	microbiota					1637:1646	some beneficial intestinal microbiota	1610:1646	some beneficial intestinal microbiota	1610:1646	Simultaneously, CSFP could remarkably reduce the proportions of Firmicutes and Bacteroides (F/B) and promote the growth of some beneficial intestinal microbiota.
35337916	7	7	theme	pH	1200:1201	arg1	value					1203:1207	the pH value	1196:1207	the pH value in the fecal culture	1196:1228	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	5	8	dep	ability	899:905	arg1	inhibit					910:916	inhibit	910:916	to inhibit α-amylase activity	907:935	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	7	9	used	utilized	1309:1316	arg2	CSFP					1279:1282	CSFP	1279:1282	CSFP	1279:1282	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	9	10	theme	F/B	1579:1581	arg1	proportions					1536:1546	the proportions	1532:1546	the proportions of Firmicutes and Bacteroides (F/B)	1532:1582	Simultaneously, CSFP could remarkably reduce the proportions of Firmicutes and Bacteroides (F/B) and promote the growth of some beneficial intestinal microbiota.
35337916	7	11	theme	in	1066:1067	arg1	fermentation					1075:1086	in vitro fermentation	1066:1086	in vitro fermentation of gut microbiota	1066:1104	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	0	12	theme	Clitocybe	86:94	arg1	squamulose					96:105	Clitocybe squamulose	86:105	Clitocybe squamulose	86:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	1	13	from	squamulosa	333:342	arg1	polysaccharides					302:316	polysaccharides	302:316	polysaccharides from Clitocybe squamulosa (CSFP)	302:349	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	13	from	squamulosa	333:342	arg1	bioactivity					287:297	bioactivity	287:297	bioactivity	287:297	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	13	from	squamulosa	333:342	arg1	structure					273:281	structure	273:281	structure	273:281	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	13	from	squamulosa	333:342	arg1	composition					260:270	the chemical composition	247:270	the chemical composition	247:270	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	5	14	theme	free	985:988	arg1	cholesterol					990:1000	free cholesterol	985:1000	free cholesterol	985:1000	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	10	15	theme	functional	1690:1699	arg1	CSFP					1660:1663	CSFP	1660:1663	CSFP	1660:1663	Therefore, CSFP can potentially be a new functional food as prebiotics to promote human gut health.
35337916	10	15	theme	functional	1690:1699	arg1	food					1701:1704	a new functional food	1684:1704	a new functional food as prebiotics to promote human gut health	1684:1746	Therefore, CSFP can potentially be a new functional food as prebiotics to promote human gut health.
35337916	5	16	theme	bile	965:968	arg1	acid					970:973	bile acid	965:973	bile acid	965:973	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	5	17	theme	binding	946:952	arg1	ability					954:960	the binding ability	942:960	the binding ability to bile acid, fat, and free cholesterol	942:1000	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	10	18	theme	human	1731:1735	arg1	health					1741:1746	human gut health	1731:1746	human gut health	1731:1746	Therefore, CSFP can potentially be a new functional food as prebiotics to promote human gut health.
35337916	1	19	theme	in	159:160	arg1	digestion					202:210	in vitro simulated saliva-gastrointestinal digestion	159:210	in vitro simulated saliva-gastrointestinal digestion	159:210	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	2	20	theme	total	480:484	arg1	acid					493:496	total uronic acid	480:496	total uronic acid	480:496	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	4	21	theme	CSFP	810:813	arg1	activity					798:805	the biological activity	783:805	the biological activity of CSFP	783:813	Gastric digestion also affected the biological activity of CSFP.
35337916	2	22	theme	chemical	416:423	arg1	composition					425:435	the chemical composition	412:435	the chemical composition	412:435	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	1	23	from	bioactivity	287:297	arg1	squamulosa					333:342	Clitocybe squamulosa	323:342	Clitocybe squamulosa (CSFP)	323:349	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	23	from	bioactivity	287:297	arg1	CSFP					345:348	CSFP	345:348	CSFP	345:348	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	7	24	theme	fecal	1216:1220	arg1	culture					1222:1228	the fecal culture	1212:1228	the fecal culture	1212:1228	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	1	25	theme	simulated	168:176	arg1	digestion					202:210	in vitro simulated saliva-gastrointestinal digestion	159:210	in vitro simulated saliva-gastrointestinal digestion	159:210	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	0	26	theme	In	0:1	arg1	digestion					9:17	In vitro digestion	0:17	In vitro digestion	0:17	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	7	27	theme	microbiota	1095:1104	arg1	fermentation					1075:1086	in vitro fermentation	1066:1086	in vitro fermentation of gut microbiota	1066:1104	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	1	28	theme	saliva-gastrointestinal	178:200	arg1	digestion					202:210	in vitro simulated saliva-gastrointestinal digestion	159:210	in vitro simulated saliva-gastrointestinal digestion	159:210	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	2	29	theme	particle	557:564	arg1	size					566:569	particle size	557:569	particle size	557:569	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	7	30	dep	in	1066:1067	arg1	vitro					1069:1073	vitro	1069:1073	vitro	1069:1073	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	1	31	from	structure	273:281	arg1	squamulosa					333:342	Clitocybe squamulosa	323:342	Clitocybe squamulosa (CSFP)	323:349	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	31	from	structure	273:281	arg1	CSFP					345:348	CSFP	345:348	CSFP	345:348	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	8	32	theme	total	1382:1386	arg1	acids					1406:1410	total short-chain fatty acids	1382:1410	total short-chain fatty acids (SCFAs)	1382:1418	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	8	32	theme	total	1382:1386	arg1	SCFAs					1413:1417	SCFAs	1413:1417	SCFAs	1413:1417	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	4	33	theme	biological	787:796	arg1	activity					798:805	the biological activity	783:805	the biological activity of CSFP	783:813	Gastric digestion also affected the biological activity of CSFP.
35337916	1	34	theme	digestion	202:210	arg1	effects					148:154	the effects	144:154	the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP)	144:349	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	2	35	theme	CSFP	466:469	arg1	acid					493:496	total uronic acid	480:496	total uronic acid	480:496	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	2	35	theme	CSFP	466:469	arg1	composition					425:435	the chemical composition	412:435	the chemical composition	412:435	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	2	35	theme	CSFP	466:469	arg1	properties					452:461	structural properties	441:461	structural properties	441:461	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	1	36	theme	polysaccharides	302:316	arg1	bioactivity					287:297	bioactivity	287:297	bioactivity	287:297	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	36	theme	polysaccharides	302:316	arg1	structure					273:281	structure	273:281	structure	273:281	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	36	theme	polysaccharides	302:316	arg1	composition					260:270	the chemical composition	247:270	the chemical composition	247:270	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	2	37	theme	rheological	533:543	arg1	properties					545:554	rheological properties	533:554	rheological properties	533:554	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	10	38	theme	gut	1737:1739	arg1	health					1741:1746	human gut health	1731:1746	human gut health	1731:1746	Therefore, CSFP can potentially be a new functional food as prebiotics to promote human gut health.
35337916	5	39	theme	antioxidant	877:887	arg1	activity					889:896	its vigorous antioxidant activity	864:896	its vigorous antioxidant activity	864:896	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	10	40	theme	new	1686:1688	arg1	CSFP					1660:1663	CSFP	1660:1663	CSFP	1660:1663	Therefore, CSFP can potentially be a new functional food as prebiotics to promote human gut health.
35337916	10	40	theme	new	1686:1688	arg1	food					1701:1704	a new functional food	1684:1704	a new functional food as prebiotics to promote human gut health	1684:1746	Therefore, CSFP can potentially be a new functional food as prebiotics to promote human gut health.
35337916	1	41	from	composition	260:270	arg1	squamulosa					333:342	Clitocybe squamulosa	323:342	Clitocybe squamulosa (CSFP)	323:349	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	41	from	composition	260:270	arg1	CSFP					345:348	CSFP	345:348	CSFP	345:348	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	2	42	theme	structural	441:450	arg1	acid					493:496	total uronic acid	480:496	total uronic acid	480:496	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	2	42	theme	structural	441:450	arg1	properties					452:461	structural properties	441:461	structural properties	441:461	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	7	43	from	value	1203:1207	arg1	culture					1222:1228	the fecal culture	1212:1228	the fecal culture	1212:1228	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	5	44	theme	α-amylase	918:926	arg1	activity					928:935	α-amylase activity	918:935	α-amylase activity	918:935	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	1	45	theme	fecal	216:220	arg1	behavior					235:242	fecal fermentation behavior	216:242	fecal fermentation behavior	216:242	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	46	theme	fermentation	222:233	arg1	behavior					235:242	fecal fermentation behavior	216:242	fecal fermentation behavior	216:242	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	0	47	theme	fecal	45:49	arg1	microbiota					51:60	human fecal microbiota	39:60	human fecal microbiota of polysaccharides from Clitocybe squamulose	39:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	0	48	from	microbiota	51:60	arg1	squamulose					96:105	Clitocybe squamulose	86:105	Clitocybe squamulose	86:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	1	49	dep	in	159:160	arg1	vitro					162:166	vitro	162:166	vitro	162:166	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	1	50	theme	present	112:118	arg1	study					120:124	The present study	108:124	The present study	108:124	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	0	51	theme	human	39:43	arg1	microbiota					51:60	human fecal microbiota	39:60	human fecal microbiota of polysaccharides from Clitocybe squamulose	39:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	8	52	theme	short-chain	1388:1398	arg1	acids					1406:1410	total short-chain fatty acids	1382:1410	total short-chain fatty acids (SCFAs)	1382:1418	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	8	52	theme	short-chain	1388:1398	arg1	SCFAs					1413:1417	SCFAs	1413:1417	SCFAs	1413:1417	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	3	53	theme	reducing-sugar	685:698	arg1	content					700:706	the reducing-sugar content	681:706	the reducing-sugar content	681:706	In particular, the molecular weight decreased from 19,480 Da to 10,945 Da, while the reducing-sugar content increased from 0.149 mg/mL to 0.293 mg/mL.
35337916	7	54	theme	sugar	1128:1132	arg1	content					1111:1117	the content	1107:1117	the content of total sugar	1107:1132	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	9	55	theme	microbiota	1637:1646	arg1	growth					1600:1605	the growth	1596:1605	the growth of some beneficial intestinal microbiota	1596:1646	Simultaneously, CSFP could remarkably reduce the proportions of Firmicutes and Bacteroides (F/B) and promote the growth of some beneficial intestinal microbiota.
35337916	9	56	theme	beneficial	1615:1624	arg1	microbiota					1637:1646	some beneficial intestinal microbiota	1610:1646	some beneficial intestinal microbiota	1610:1646	Simultaneously, CSFP could remarkably reduce the proportions of Firmicutes and Bacteroides (F/B) and promote the growth of some beneficial intestinal microbiota.
35337916	2	57	theme	microscopic	576:586	arg1	morphology					588:597	microscopic morphology	576:597	microscopic morphology	576:597	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	8	58	theme	acids	1406:1410	arg1	acetic					1430:1435	acetic	1430:1435	acetic	1430:1435	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	8	58	theme	acids	1406:1410	arg1	concentrations					1364:1377	the concentrations	1360:1377	the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric	1360:1460	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	1	59	theme	behavior	235:242	arg1	effects					148:154	the effects	144:154	the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP)	144:349	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
35337916	9	60	theme	Firmicutes	1551:1560	arg1	proportions					1536:1546	the proportions	1532:1546	the proportions of Firmicutes and Bacteroides (F/B)	1532:1582	Simultaneously, CSFP could remarkably reduce the proportions of Firmicutes and Bacteroides (F/B) and promote the growth of some beneficial intestinal microbiota.
35337916	0	61	from	squamulose	96:105	arg1	polysaccharides					65:79	polysaccharides	65:79	polysaccharides from Clitocybe squamulose	65:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	0	61	from	squamulose	96:105	arg1	microbiota					51:60	human fecal microbiota	39:60	human fecal microbiota of polysaccharides from Clitocybe squamulose	39:105	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	8	62	theme	fatty	1400:1404	arg1	acids					1406:1410	total short-chain fatty acids	1382:1410	total short-chain fatty acids (SCFAs)	1382:1418	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	8	62	theme	fatty	1400:1404	arg1	SCFAs					1413:1417	SCFAs	1413:1417	SCFAs	1413:1417	Compared to the blank, the concentrations of total short-chain fatty acids (SCFAs) including acetic, propionic and n-butyric significantly increased.
35337916	4	63	theme	Gastric	751:757	arg1	digestion					759:767	Gastric digestion	751:767	Gastric digestion	751:767	Gastric digestion also affected the biological activity of CSFP.
35337916	2	64	theme	molecular	515:523	arg1	weight					525:530	molecular weight	515:530	molecular weight	515:530	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	6	65	theme	weakening	1043:1051	arg1	trend					1053:1057	an apparent weakening trend	1031:1057	an apparent weakening trend	1031:1057	However, there was an apparent weakening trend.
35337916	3	66	theme	molecular	619:627	arg1	weight					629:634	the molecular weight	615:634	the molecular weight	615:634	In particular, the molecular weight decreased from 19,480 Da to 10,945 Da, while the reducing-sugar content increased from 0.149 mg/mL to 0.293 mg/mL.
35337916	5	67	theme	vigorous	868:875	arg1	activity					889:896	its vigorous antioxidant activity	864:896	its vigorous antioxidant activity	864:896	Although after gastric digestion, CSFP retained its vigorous antioxidant activity, ability to inhibit α-amylase activity, and the binding ability to bile acid, fat, and free cholesterol in vitro.
35337916	7	68	theme	gut	1321:1323	arg1	microbiota					1325:1334	gut microbiota	1321:1334	gut microbiota	1321:1334	After in vitro fermentation of gut microbiota, the content of total sugar was significantly decreased from 11.6 mg/mL to 2.4 mg/mL, and the pH value in the fecal culture significantly decreased to 5.20, indicating that CSFP could be broken down and utilized by gut microbiota.
35337916	3	69	dep	10,945 Da	664:672	arg1	to					661:662	to	661:662	to	661:662	In particular, the molecular weight decreased from 19,480 Da to 10,945 Da, while the reducing-sugar content increased from 0.149 mg/mL to 0.293 mg/mL.
35337916	2	70	theme	uronic	486:491	arg1	acid					493:496	total uronic acid	480:496	total uronic acid	480:496	Results showed that gastric digestion significantly changed the chemical composition and structural properties of CSFP, such as total uronic acid, reducing sugar, molecular weight, rheological properties, particle size, and microscopic morphology.
35337916	0	71	dep	In	0:1	arg1	vitro					3:7	vitro	3:7	vitro	3:7	In vitro digestion and fermentation by human fecal microbiota of polysaccharides from Clitocybe squamulose.
35337916	6	72	theme	apparent	1034:1041	arg1	trend					1053:1057	an apparent weakening trend	1031:1057	an apparent weakening trend	1031:1057	However, there was an apparent weakening trend.
35337916	1	73	theme	chemical	251:258	arg1	composition					260:270	the chemical composition	247:270	the chemical composition	247:270	The present study aimed to evaluate the effects of in vitro simulated saliva-gastrointestinal digestion and fecal fermentation behavior on the chemical composition, structure and bioactivity of polysaccharides from Clitocybe squamulosa (CSFP).
36240590	7	0	theme	heart	1042:1046	arg1	process					1020:1026	the peroxidation process	1003:1026	the peroxidation process of kidney and heart in mice with acute alcoholic liver injury	1003:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	6	1	theme	strong	855:860	arg1	ability					873:879	a strong scavenging ability	853:879	a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals	853:949	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	6	2	theme	ABTS	932:935	arg1	radicals					942:949	ABTS free radicals	932:949	ABTS free radicals	932:949	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	8	3	contain	have	1281:1284	arg1	polysaccharides					1265:1279	Piperis Dahongpao polysaccharides	1247:1279	Piperis Dahongpao polysaccharides	1247:1279	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	8	3	contain	have	1281:1284	arg2	potential					1298:1306	antioxidant potential	1286:1306	antioxidant potential	1286:1306	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	7	4	theme	same	959:962	arg1	time					964:967	the same time	955:967	the same time	955:967	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	5	5	theme	microscopic	764:774	arg1	flat					802:805	flat	802:805	flat	802:805	Otherwise, the microscopic conformation of PDP-1 was flat, dense and porous.
36240590	5	5	theme	microscopic	764:774	arg1	conformation					776:787	the microscopic conformation	760:787	the microscopic conformation of PDP-1	760:796	Otherwise, the microscopic conformation of PDP-1 was flat, dense and porous.
36240590	1	6	theme	alcohol-precipitation	259:279	arg1	method					228:233	the method	224:233	the method of water-extraction and alcohol-precipitation	224:279	In this manuscript, the polysaccharide isolated from Piperis Dahongpao was extracted with the method of water-extraction and alcohol-precipitation.
36240590	0	7	theme	novel	89:93	arg1	polysaccharide					95:108	a novel polysaccharide	87:108	a novel polysaccharide from Piperis Dahongpao	87:131	Chemical structure and protective effect against alcoholic kidney and heart damages of a novel polysaccharide from Piperis Dahongpao.
36240590	8	8	theme	theoretical	1322:1332	arg1	foundation					1334:1343	a theoretical foundation	1320:1343	a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine	1320:1408	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	7	9	theme	certain	1177:1183	arg1	extent					1185:1190	a certain extent	1175:1190	a certain extent	1175:1190	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	4	10	theme	1→	695:696	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	6	11	contain	had	849:851	arg1	PDP-1					843:847	the PDP-1	839:847	the PDP-1	839:847	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	6	11	contain	had	849:851	arg2	ability					873:879	a strong scavenging ability	853:879	a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals	853:949	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	4	12	dep	D-Glcp-	735:741	arg1	1 → 					743:746	1 → 	743:746	1 → 	743:746	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	7	13	theme	alcoholic	1067:1075	arg1	injury					1083:1088	acute alcoholic liver injury	1061:1088	acute alcoholic liver injury	1061:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	2	14	theme	homogeneous	295:305	arg1	PDP-1					323:327	PDP-1	323:327	PDP-1	323:327	Besides, the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa was purified with the Sephadex G-150 column.
36240590	2	14	theme	homogeneous	295:305	arg1	polysaccharide					307:320	the homogeneous polysaccharide	291:320	the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa	291:357	Besides, the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa was purified with the Sephadex G-150 column.
36240590	7	15	theme	liver	1077:1081	arg1	injury					1083:1088	acute alcoholic liver injury	1061:1088	acute alcoholic liver injury	1061:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	6	16	theme	Hydroxyl	905:912	arg1	radicals					919:926	Hydroxyl free radicals	905:926	Hydroxyl free radicals	905:926	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	0	17	theme	alcoholic	49:57	arg1	kidney					59:64	alcoholic kidney	49:64	alcoholic kidney	49:64	Chemical structure and protective effect against alcoholic kidney and heart damages of a novel polysaccharide from Piperis Dahongpao.
36240590	4	18	theme	-Glcp-	721:726	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	4	19	dep	1→	728:729	arg1	→4					699:700	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	→4	699:700	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	6	20	theme	free	914:917	arg1	radicals					919:926	Hydroxyl free radicals	905:926	Hydroxyl free radicals	905:926	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	8	21	theme	polysaccharides	1382:1396	arg1	research					1353:1360	the research	1349:1360	the research of Piperis Dahongpa polysaccharides in medicine	1349:1408	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	8	22	theme	Dahongpa	1373:1380	arg1	polysaccharides					1382:1396	Piperis Dahongpa polysaccharides	1365:1396	Piperis Dahongpa polysaccharides	1365:1396	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	2	23	theme	G-150	390:394	arg1	column					396:401	the Sephadex G-150 column	377:401	the Sephadex G-150 column	377:401	Besides, the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa was purified with the Sephadex G-150 column.
36240590	0	24	theme	Chemical	0:7	arg1	structure					9:17	Chemical structure	0:17	Chemical structure	0:17	Chemical structure and protective effect against alcoholic kidney and heart damages of a novel polysaccharide from Piperis Dahongpao.
36240590	4	25	theme	methylation	548:558	arg1	analysis					560:567	the methylation analysis	544:567	the methylation analysis	544:567	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	2	26	theme	Sephadex	381:388	arg1	column					396:401	the Sephadex G-150 column	377:401	the Sephadex G-150 column	377:401	Besides, the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa was purified with the Sephadex G-150 column.
36240590	0	27	theme	protective	23:32	arg1	effect					34:39	protective effect	23:39	protective effect	23:39	Chemical structure and protective effect against alcoholic kidney and heart damages of a novel polysaccharide from Piperis Dahongpao.
36240590	8	28	theme	Piperis	1365:1371	arg1	polysaccharides					1382:1396	Piperis Dahongpa polysaccharides	1365:1396	Piperis Dahongpa polysaccharides	1365:1396	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	4	29	theme	-Manp-	688:693	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	1	30	attach	isolated	173:180	arg2	polysaccharide					158:171	the polysaccharide	154:171	the polysaccharide isolated from Piperis Dahongpao	154:203	In this manuscript, the polysaccharide isolated from Piperis Dahongpao was extracted with the method of water-extraction and alcohol-precipitation.
36240590	1	30	attach	isolated	173:180	arg1	Dahongpao					195:203	Dahongpao	195:203	Dahongpao	195:203	In this manuscript, the polysaccharide isolated from Piperis Dahongpao was extracted with the method of water-extraction and alcohol-precipitation.
36240590	4	31	theme	-D	685:686	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	6	32	theme	free	890:893	arg1	radicals					895:902	DPPH free radicals	885:902	DPPH free radicals	885:902	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	3	33	theme	composition	423:433	arg1	analysis					435:442	The monosaccharide composition analysis	404:442	The monosaccharide composition analysis	404:442	The monosaccharide composition analysis showed that PDP-1 consisted of Man, Glc and Gal in a ratio of 1.678:1.784:1, respectively.
36240590	7	34	theme	antioxidant	1103:1113	arg1	capacity					1115:1122	its antioxidant capacity	1099:1122	its antioxidant capacity	1099:1122	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	7	35	theme	peroxidation	1007:1018	arg1	process					1020:1026	the peroxidation process	1003:1026	the peroxidation process of kidney and heart in mice with acute alcoholic liver injury	1003:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	4	36	theme	-D-Galp-	653:660	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	6	37	theme	DPPH	885:888	arg1	radicals					895:902	DPPH free radicals	885:902	DPPH free radicals	885:902	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	8	38	from	research	1353:1360	arg1	medicine					1401:1408	medicine	1401:1408	medicine	1401:1408	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	0	39	from	Dahongpao	123:131	arg1	polysaccharide					95:108	a novel polysaccharide	87:108	a novel polysaccharide from Piperis Dahongpao	87:131	Chemical structure and protective effect against alcoholic kidney and heart damages of a novel polysaccharide from Piperis Dahongpao.
36240590	7	40	theme	kidney	1031:1036	arg1	process					1020:1026	the peroxidation process	1003:1026	the peroxidation process of kidney and heart in mice with acute alcoholic liver injury	1003:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	4	41	theme	-D	718:719	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	2	42	theme	2.47 × 103 KDa	344:357	arg1	MW					338:339	an MW	335:339	an MW of 2.47 × 103 KDa	335:357	Besides, the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa was purified with the Sephadex G-150 column.
36240590	3	43	theme	monosaccharide	408:421	arg1	composition					423:433	The monosaccharide composition	404:433	The monosaccharide composition analysis	404:442	The monosaccharide composition analysis showed that PDP-1 consisted of Man, Glc and Gal in a ratio of 1.678:1.784:1, respectively.
36240590	7	44	theme	organ	1141:1145	arg1	injury					1147:1152	the organ injury	1137:1152	the organ injury caused by alcohol to a certain extent	1137:1190	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	8	45	theme	antioxidant	1286:1296	arg1	potential					1298:1306	antioxidant potential	1286:1306	antioxidant potential	1286:1306	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	4	46	theme	-D-Galp-	669:676	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	8	47	theme	manuscript	1224:1233	arg1	results					1208:1214	the results	1204:1214	the results of this manuscript	1204:1233	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	4	48	theme	-D-Glcp-	702:709	arg1	1→					728:729	→4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→	648:729	1→	728:729	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	5	49	theme	PDP-1	792:796	arg1	flat					802:805	flat	802:805	flat	802:805	Otherwise, the microscopic conformation of PDP-1 was flat, dense and porous.
36240590	5	49	theme	PDP-1	792:796	arg1	conformation					776:787	the microscopic conformation	760:787	the microscopic conformation of PDP-1	760:796	Otherwise, the microscopic conformation of PDP-1 was flat, dense and porous.
36240590	8	50	theme	Dahongpao	1255:1263	arg1	polysaccharides					1265:1279	Piperis Dahongpao polysaccharides	1247:1279	Piperis Dahongpao polysaccharides	1247:1279	Therefore, the results of this manuscript showed that Piperis Dahongpao polysaccharides have antioxidant potential, which lays a theoretical foundation for the research of Piperis Dahongpa polysaccharides in medicine.
36240590	6	51	theme	scavenging	862:871	arg1	ability					873:879	a strong scavenging ability	853:879	a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals	853:949	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	7	52	with	mice	1051:1054	arg1	injury					1083:1088	acute alcoholic liver injury	1061:1088	acute alcoholic liver injury	1061:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	4	53	theme	alcohol	616:622	arg1	derivatives					624:634	six sugar alcohol derivatives	606:634	six sugar alcohol derivatives	606:634	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
36240590	3	54	theme	1.678:1.784:1	506:518	arg1	ratio					497:501	a ratio	495:501	a ratio of 1.678:1.784:1	495:518	The monosaccharide composition analysis showed that PDP-1 consisted of Man, Glc and Gal in a ratio of 1.678:1.784:1, respectively.
36240590	2	55	with	polysaccharide	307:320	arg1	MW					338:339	an MW	335:339	an MW of 2.47 × 103 KDa	335:357	Besides, the homogeneous polysaccharide (PDP-1) with an MW of 2.47 × 103 KDa was purified with the Sephadex G-150 column.
36240590	1	56	theme	water-extraction	238:253	arg1	method					228:233	the method	224:233	the method of water-extraction and alcohol-precipitation	224:279	In this manuscript, the polysaccharide isolated from Piperis Dahongpao was extracted with the method of water-extraction and alcohol-precipitation.
36240590	7	57	from	process	1020:1026	arg1	mice					1051:1054	mice	1051:1054	mice with acute alcoholic liver injury	1051:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	6	58	theme	free	937:940	arg1	radicals					942:949	ABTS free radicals	932:949	ABTS free radicals	932:949	In addition, the PDP-1 had a strong scavenging ability for DPPH free radicals, Hydroxyl free radicals and ABTS free radicals.
36240590	7	59	theme	acute	1061:1065	arg1	injury					1083:1088	acute alcoholic liver injury	1061:1088	acute alcoholic liver injury	1061:1088	At the same time, PDP-1 could effectively decrease the peroxidation process of kidney and heart in mice with acute alcoholic liver injury, improve its antioxidant capacity, and protect the organ injury caused by alcohol to a certain extent.
36240590	4	60	theme	sugar	610:614	arg1	derivatives					624:634	six sugar alcohol derivatives	606:634	six sugar alcohol derivatives	606:634	Besides, the methylation analysis indicated that PDP-1 was composed of six sugar alcohol derivatives, which were →4，6)-D-Galp-(1→, →4)-D-Galp-(1→, →4)-D -Manp-(1→, →4)-D-Glcp-(1→, →6)-D -Glcp-(1→ and D-Glcp-(1 → .
35868771	7	0	theme	p65	1094:1096	arg1	levels					1055:1060	The levels	1051:1060	The levels of MPO, IL-1β, IL-10, and NF-κB p65	1051:1096	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	4	1	theme	backbone	483:490	arg1	structures					492:501	backbone structures	483:501	backbone structures	483:501	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	5	2	from	stress	714:719	arg1	injury					740:745	alcohol-induced injury	724:745	alcohol-induced injury	724:745	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	5	2	from	stress	714:719	arg1	inflammation					755:766	LPS inflammation	751:766	LPS inflammation	751:766	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	5	3	contain	had	660:662	arg1	AVLP-2					653:658	AVLP-2	653:658	AVLP-2	653:658	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	5	3	contain	had	660:662	arg2	effect					689:694	a significant protective effect	664:694	a significant protective effect	664:694	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	0	4	from	Lour	57:60	arg1	Effects					0:6	Effects	0:6	Effects of a polysaccharide extract from Amomum villosum Lour.	0:61	Effects of a polysaccharide extract from Amomum villosum Lour.
35868771	0	4	from	Lour	57:60	arg1	extract					28:34	a polysaccharide extract	11:34	a polysaccharide extract from Amomum villosum Lour	11:60	Effects of a polysaccharide extract from Amomum villosum Lour.
35868771	6	5	theme	stress	902:907	arg1	status					909:914	the oxidative stress status	888:914	the oxidative stress status of the gastric mucosa	888:936	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	0	6	from	Effects	0:6	arg1	Lour					57:60	Lour	57:60	Lour	57:60	Effects of a polysaccharide extract from Amomum villosum Lour.
35868771	4	7	theme	-α-d-Galp-	582:591	arg1	-β-d-Glcp-					597:606	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	-β-d-Glcp-	597:606	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	6	8	theme	oxidative	892:900	arg1	status					909:914	the oxidative stress status	888:914	the oxidative stress status of the gastric mucosa	888:936	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	7	9	theme	NF-κB	1088:1092	arg1	p65					1094:1096	NF-κB p65	1088:1096	NF-κB p65	1088:1096	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	2	10	theme	novel	139:143	arg1	polysaccharide					152:165	a novel acidic polysaccharide	137:165	a novel acidic polysaccharide	137:165	AVLP-2, a novel acidic polysaccharide, was isolated and purified from Amomum villosum Lour.
35868771	2	10	theme	novel	139:143	arg1	AVLP-2					129:134	AVLP-2	129:134	AVLP-2	129:134	AVLP-2, a novel acidic polysaccharide, was isolated and purified from Amomum villosum Lour.
35868771	4	11	theme	glucose	419:425	arg1	monomers					427:434	glucose monomers	419:434	glucose monomers	419:434	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	12	theme	-α-d-GalAp-	543:553	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	5	13	theme	LPS	751:753	arg1	inflammation					755:766	LPS inflammation	751:766	LPS inflammation	751:766	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	4	14	theme	kDa	470:472	arg1	weight					453:458	a molecular weight	441:458	a molecular weight of 10.488 kDa	441:472	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	6	15	theme	GSH	969:971	arg1	levels					973:978	GSH levels	969:978	GSH levels	969:978	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	4	16	contain	has	437:439	arg2	weight					453:458	a molecular weight	441:458	a molecular weight of 10.488 kDa	441:472	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	16	contain	has	437:439	arg1	AVLP-2					388:393	AVLP-2	388:393	AVLP-2	388:393	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	3	17	theme	NMR	352:354	arg1	techniques					356:365	NMR techniques	352:365	NMR techniques	352:365	The structural characteristics of the polysaccharides were characterized using monosaccharide composition, methylation, FT-IR, and NMR techniques.
35868771	6	18	theme	malondialdehyde	1023:1037	arg1	generation					1009:1018	the excessive generation	995:1018	the excessive generation of malondialdehyde in tissues	995:1048	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	1	19	theme	gastric	66:72	arg1	injury					82:87	gastric mucosal injury	66:87	gastric mucosal injury	66:87	on gastric mucosal injury and its potential underlying mechanism.
35868771	5	20	theme	GES-1	775:779	arg1	cells					781:785	GES-1 cells	775:785	GES-1 cells	775:785	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	5	21	theme	oxidative	704:712	arg1	stress					714:719	oxidative stress	704:719	oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors	704:842	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	4	22	theme	1→	536:537	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	1	23	theme	mucosal	74:80	arg1	injury					82:87	gastric mucosal injury	66:87	gastric mucosal injury	66:87	on gastric mucosal injury and its potential underlying mechanism.
35868771	7	24	theme	IL-1β	1070:1074	arg1	levels					1055:1060	The levels	1051:1060	The levels of MPO, IL-1β, IL-10, and NF-κB p65	1051:1096	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	4	25	theme	1→4	593:595	arg1	-β-d-Glcp-					597:606	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	-β-d-Glcp-	597:606	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	7	26	theme	AVLP-2	1157:1162	arg1	treatment					1164:1172	AVLP-2 treatment	1157:1172	AVLP-2 treatment	1157:1172	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	3	27	theme	structural	225:234	arg1	characteristics					236:250	The structural characteristics	221:250	The structural characteristics of the polysaccharides	221:273	The structural characteristics of the polysaccharides were characterized using monosaccharide composition, methylation, FT-IR, and NMR techniques.
35868771	4	28	theme	1→	627:628	arg1	branches					630:637	1→ branches	627:637	1→ branches	627:637	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	7	29	theme	alcohol-induced	1196:1210	arg1	inflammation					1212:1223	the alcohol-induced inflammation	1192:1223	the alcohol-induced inflammation	1192:1223	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	0	30	theme	polysaccharide	13:26	arg1	extract					28:34	a polysaccharide extract	11:34	a polysaccharide extract from Amomum villosum Lour	11:60	Effects of a polysaccharide extract from Amomum villosum Lour.
35868771	4	31	theme	-α-d-GalAp-	524:534	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	32	dep	1→	570:571	arg1	→4					540:541	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	→4	540:541	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	32	dep	1→	570:571	arg1	1→					608:609	1→	608:609	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→	483:609	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	5	33	theme	alcohol-induced	724:738	arg1	injury					740:745	alcohol-induced injury	724:745	alcohol-induced injury	724:745	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	6	34	theme	SOD	952:954	arg1	activity					956:963	SOD activity	952:963	SOD activity	952:963	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	5	35	theme	significant	666:676	arg1	effect					689:694	a significant protective effect	664:694	a significant protective effect	664:694	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	1	36	theme	underlying	107:116	arg1	mechanism					118:126	its potential underlying mechanism	93:126	its potential underlying mechanism	93:126	on gastric mucosal injury and its potential underlying mechanism.
35868771	7	37	theme	IL-10	1077:1081	arg1	levels					1055:1060	The levels	1051:1060	The levels of MPO, IL-1β, IL-10, and NF-κB p65	1051:1096	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	4	38	theme	molecular	443:451	arg1	weight					453:458	a molecular weight	441:458	a molecular weight of 10.488 kDa	441:472	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	39	theme	n→6	578:580	arg1	-β-d-Glcp-					597:606	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	-β-d-Glcp-	597:606	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	0	40	theme	extract	28:34	arg1	Effects					0:6	Effects	0:6	Effects of a polysaccharide extract from Amomum villosum Lour.	0:61	Effects of a polysaccharide extract from Amomum villosum Lour.
35868771	6	41	theme	animal	852:857	arg1	experiments					859:869	the animal experiments	848:869	the animal experiments	848:869	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	3	42	theme	polysaccharides	259:273	arg1	characteristics					236:250	The structural characteristics	221:250	The structural characteristics of the polysaccharides	221:273	The structural characteristics of the polysaccharides were characterized using monosaccharide composition, methylation, FT-IR, and NMR techniques.
35868771	7	43	theme	MPO	1065:1067	arg1	levels					1055:1060	The levels	1051:1060	The levels of MPO, IL-1β, IL-10, and NF-κB p65	1051:1096	The levels of MPO, IL-1β, IL-10, and NF-κB p65 were downregulated, while that of TNF-α was upregulated by AVLP-2 treatment, thereby reducing the alcohol-induced inflammation.
35868771	4	44	theme	-α-d-GalAp-	506:516	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	2	45	theme	acidic	145:150	arg1	polysaccharide					152:165	a novel acidic polysaccharide	137:165	a novel acidic polysaccharide	137:165	AVLP-2, a novel acidic polysaccharide, was isolated and purified from Amomum villosum Lour.
35868771	2	45	theme	acidic	145:150	arg1	AVLP-2					129:134	AVLP-2	129:134	AVLP-2	129:134	AVLP-2, a novel acidic polysaccharide, was isolated and purified from Amomum villosum Lour.
35868771	2	46	theme	villosum	206:213	arg1	Lour					215:218	Amomum villosum Lour	199:218	Amomum villosum Lour	199:218	AVLP-2, a novel acidic polysaccharide, was isolated and purified from Amomum villosum Lour.
35868771	1	47	theme	potential	97:105	arg1	mechanism					118:126	its potential underlying mechanism	93:126	its potential underlying mechanism	93:126	on gastric mucosal injury and its potential underlying mechanism.
35868771	4	48	theme	→4	503:504	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	2	49	theme	Amomum	199:204	arg1	Lour					215:218	Amomum villosum Lour	199:218	Amomum villosum Lour	199:218	AVLP-2, a novel acidic polysaccharide, was isolated and purified from Amomum villosum Lour.
35868771	4	50	contain	has	479:481	arg2	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	50	contain	has	479:481	arg1	AVLP-2					388:393	AVLP-2	388:393	AVLP-2	388:393	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	50	contain	has	479:481	arg2	-β-d-Glcp-					597:606	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	-β-d-Glcp-	597:606	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	4	51	theme	1→3,4	518:522	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	6	52	theme	gastric	923:929	arg1	mucosa					931:936	the gastric mucosa	919:936	the gastric mucosa	919:936	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	5	53	theme	inflammatory	823:834	arg1	factors					836:842	inflammatory factors	823:842	inflammatory factors	823:842	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	6	54	theme	mucosa	931:936	arg1	status					909:914	the oxidative stress status	888:914	the oxidative stress status of the gastric mucosa	888:936	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	3	55	theme	monosaccharide	300:313	arg1	composition					315:325	monosaccharide composition	300:325	monosaccharide composition	300:325	The structural characteristics of the polysaccharides were characterized using monosaccharide composition, methylation, FT-IR, and NMR techniques.
35868771	5	56	theme	ROS	815:817	arg1	levels					805:810	the levels	801:810	the levels of ROS	801:817	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	5	56	theme	ROS	815:817	arg1	factors					836:842	inflammatory factors	823:842	inflammatory factors	823:842	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	4	57	theme	1→6	555:557	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	5	58	dep	injury	740:745	arg1	models					768:773	models	768:773	models	768:773	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	4	59	theme	structures	492:501	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
35868771	5	60	theme	protective	678:687	arg1	effect					689:694	a significant protective effect	664:694	a significant protective effect	664:694	Furthermore, AVLP-2 had a significant protective effect against oxidative stress in alcohol-induced injury and LPS inflammation models GES-1 cells by regulating the levels of ROS and inflammatory factors.
35868771	6	61	from	generation	1009:1018	arg1	tissues					1042:1048	tissues	1042:1048	tissues	1042:1048	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	6	62	theme	excessive	999:1007	arg1	generation					1009:1018	the excessive generation	995:1018	the excessive generation of malondialdehyde in tissues	995:1048	In the animal experiments, AVLP-2 improved the oxidative stress status of the gastric mucosa by increasing SOD activity and GSH levels and inhibiting the excessive generation of malondialdehyde in tissues.
35868771	4	63	theme	-α-d-Galp-	559:568	arg1	1→					570:571	backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-	483:606	1→	570:571	Results showed that AVLP-2 comprises galactose and glucose monomers, has a molecular weight of 10.488 kDa, and has backbone structures →4)-α-d-GalAp-(1→3,4)-α-d-GalAp-(1→, →4)-α-d-GalAp-(1→6)-α-d-Galp-(1→, and n→6)-α-d-Galp-(1→4)-β-d-Glcp-(1→, with α-d-Galp-(1→ branches.
36736520	1	0	theme	medicinal	318:326	arg1	value					344:348	important medicinal and nutritional value	308:348	important medicinal and nutritional value	308:348	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	0	1	theme	microbiota	186:195	arg1	enhancement					127:137	the enhancement	123:137	the enhancement of enzyme activities	123:158	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	0	1	theme	microbiota	186:195	arg1	modulation					168:177	the modulation	164:177	the modulation of gut microbiota	164:195	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	5	2	theme	capito	1054:1059	arg1	immunity					1014:1021	immunity	1014:1021	immunity	1014:1021	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	5	2	theme	capito	1054:1059	arg1	capacity					1039:1046	antioxidant capacity	1027:1046	antioxidant capacity	1027:1046	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	3	3	theme	current	461:467	arg1	work					469:472	the current work	457:472	the current work	457:472	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	7	4	theme	constructions	1375:1387	arg1	structures					1357:1366	the morphologic structures	1341:1366	the morphologic structures of gut constructions	1341:1387	No significant changes were screened in the morphologic structures of gut constructions.
36736520	1	5	theme	active	247:252	arg1	component					254:262	the main active component	238:262	the main active component	238:262	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	5	theme	active	247:252	arg1	polysaccharide					214:227	Lycium barbarum polysaccharide	198:227	Lycium barbarum polysaccharide (LBP)	198:233	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	3	6	theme	analysis	628:635	arg1	context					598:604	the context	594:604	the context of enzymatic activity analysis, histological observations and gut microbiota analysis	594:690	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	1	7	dep	barbarum	274:281	arg1	barbarum					287:294	L. barbarum	284:294	L. barbarum	284:294	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	0	8	theme	gut	182:184	arg1	microbiota					186:195	gut microbiota	182:195	gut microbiota	182:195	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	8	9	theme	experimental	1430:1441	arg1	basis					1443:1447	theoretical and experimental basis	1414:1447	theoretical and experimental basis for future application of LBP	1414:1477	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	4	10	theme	immune	810:815	arg1	enzyme					817:822	hepatic immune enzyme	802:822	hepatic immune enzyme	802:822	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	0	11	theme	capito	112:117	arg1	health					90:95	the health	86:95	the health of Luciobarbus capito	86:117	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	1	12	theme	nutritional	332:342	arg1	value					344:348	important medicinal and nutritional value	308:348	important medicinal and nutritional value	308:348	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	3	13	theme	underlying	492:501	arg1	effect					503:508	the underlying effect	488:508	the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito	488:589	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	14	from	effect	503:508	arg1	capito					584:589	capito	584:589	capito	584:589	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	15	theme	levels	523:528	arg1	effect					503:508	the underlying effect	488:508	the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito	488:589	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	16	theme	observations	651:662	arg1	context					598:604	the context	594:604	the context of enzymatic activity analysis, histological observations and gut microbiota analysis	594:690	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	4	17	theme	enzyme	817:822	arg1	activities					726:735	the activities	722:735	the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme	722:822	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	4	18	theme	digestive	780:788	arg1	enzymes					790:796	intestinal digestive enzymes	769:796	intestinal digestive enzymes	769:796	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	6	19	theme	microbiota	1115:1124	arg1	structures					1093:1102	the compositional structures	1075:1102	the compositional structures of the gut microbiota in L. capito	1075:1137	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	2	20	theme	LBP	374:376	arg1	treatment					378:386	LBP treatment	374:386	LBP treatment	374:386	However, the effect of LBP treatment on Luciobarbus capito (L. capito) still remains unknown.
36736520	4	21	theme	LBP	897:899	arg1	P < 0.05					912:919	P < 0.05	912:919	P < 0.05	912:919	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	4	21	theme	LBP	897:899	arg1	treatment					901:909	0.50 g/L LBP treatment	888:909	0.50 g/L LBP treatment (P < 0.05)	888:920	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	4	22	theme	intestinal	769:778	arg1	enzymes					790:796	intestinal digestive enzymes	769:796	intestinal digestive enzymes	769:796	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	8	23	theme	future	1453:1458	arg1	application					1460:1470	future application	1453:1470	future application of LBP	1453:1477	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	4	24	theme	control	707:713	arg1	group					715:719	control group	707:719	control group	707:719	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	7	25	theme	gut	1371:1373	arg1	constructions					1375:1387	gut constructions	1371:1387	gut constructions	1371:1387	No significant changes were screened in the morphologic structures of gut constructions.
36736520	3	26	dep	treatment	537:545	arg1	1.00 g/L					568:575	1.00 g/L	568:575	1.00 g/L	568:575	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	26	dep	treatment	537:545	arg1	0.50					559:562	0.50	559:562	0.50	559:562	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	26	dep	treatment	537:545	arg1	0.10					553:556	0.10	553:556	0.10	553:556	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	27	theme	histological	638:649	arg1	observations					651:662	histological observations	638:662	histological observations	638:662	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	28	theme	analysis	683:690	arg1	context					598:604	the context	594:604	the context of enzymatic activity analysis, histological observations and gut microbiota analysis	594:690	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	1	29	contain	has	304:306	arg1	component					254:262	the main active component	238:262	the main active component	238:262	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	29	contain	has	304:306	arg2	value					344:348	important medicinal and nutritional value	308:348	important medicinal and nutritional value	308:348	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	29	contain	has	304:306	arg1	polysaccharide					214:227	Lycium barbarum polysaccharide	198:227	Lycium barbarum polysaccharide (LBP)	198:233	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	6	30	theme	gut	1235:1237	arg1	microbiota					1239:1248	the gut microbiota	1231:1248	the gut microbiota	1231:1248	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	3	31	theme	enzymatic	609:617	arg1	analysis					628:635	enzymatic activity analysis	609:635	enzymatic activity analysis	609:635	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	0	32	theme	Dietary	0:6	arg1	supplementation					8:22	Dietary supplementation	0:22	Dietary supplementation with Lycium barbarum polysaccharides conducive to	0:72	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	1	33	theme	barbarum	274:281	arg1	component					254:262	the main active component	238:262	the main active component	238:262	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	33	theme	barbarum	274:281	arg1	polysaccharide					214:227	Lycium barbarum polysaccharide	198:227	Lycium barbarum polysaccharide (LBP)	198:233	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	4	34	theme	enzymes	790:796	arg1	activities					726:735	the activities	722:735	the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme	722:822	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	5	35	theme	treatment	973:981	arg1	levels					959:964	moderate levels	950:964	moderate levels of LBP treatment	950:981	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	6	36	from	structures	1093:1102	arg1	capito					1132:1137	capito	1132:1137	capito	1132:1137	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	1	37	theme	Lycium	198:203	arg1	polysaccharide					214:227	Lycium barbarum polysaccharide	198:227	Lycium barbarum polysaccharide (LBP)	198:233	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	37	theme	Lycium	198:203	arg1	component					254:262	the main active component	238:262	the main active component	238:262	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	37	theme	Lycium	198:203	arg1	LBP					230:232	LBP	230:232	LBP	230:232	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	0	38	theme	Lycium	29:34	arg1	polysaccharides					45:59	Lycium barbarum polysaccharides	29:59	Lycium barbarum polysaccharides conducive to	29:72	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	8	39	theme	LBP	1475:1477	arg1	application					1460:1470	future application	1453:1470	future application of LBP	1453:1477	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	6	40	dep	diversity	1204:1212	arg1	the					1200:1202	the	1200:1202	the	1200:1202	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	4	41	theme	enzymes	760:766	arg1	activities					726:735	the activities	722:735	the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme	722:822	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	4	42	theme	hepatic	802:808	arg1	enzyme					817:822	hepatic immune enzyme	802:822	hepatic immune enzyme	802:822	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	5	43	theme	moderate	950:957	arg1	levels					959:964	moderate levels	950:964	moderate levels of LBP treatment	950:981	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	1	44	theme	barbarum	205:212	arg1	polysaccharide					214:227	Lycium barbarum polysaccharide	198:227	Lycium barbarum polysaccharide (LBP)	198:233	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	44	theme	barbarum	205:212	arg1	component					254:262	the main active component	238:262	the main active component	238:262	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	44	theme	barbarum	205:212	arg1	LBP					230:232	LBP	230:232	LBP	230:232	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	3	45	theme	gut	668:670	arg1	analysis					683:690	gut microbiota analysis	668:690	gut microbiota analysis	668:690	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	4	46	theme	0.10 g/L	871:878	arg1	LBP					880:882	0.10 g/L LBP	871:882	0.10 g/L LBP	871:882	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	3	47	theme	different	513:521	arg1	levels					523:528	different levels	513:528	different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L)	513:576	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	3	48	theme	microbiota	672:681	arg1	analysis					683:690	gut microbiota analysis	668:690	gut microbiota analysis	668:690	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	0	49	theme	activities	149:158	arg1	enhancement					127:137	the enhancement	123:137	the enhancement of enzyme activities	123:158	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	0	49	theme	activities	149:158	arg1	modulation					168:177	the modulation	164:177	the modulation of gut microbiota	164:195	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	4	50	theme	antioxidant	748:758	arg1	enzymes					760:766	hepatic antioxidant enzymes	740:766	hepatic antioxidant enzymes	740:766	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	8	51	theme	culture	1500:1506	arg1	process					1508:1514	the culture process	1496:1514	the culture process of the farmed fish	1496:1533	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	0	52	theme	enzyme	142:147	arg1	activities					149:158	enzyme activities	142:158	enzyme activities	142:158	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	4	53	theme	hepatic	740:746	arg1	enzymes					760:766	hepatic antioxidant enzymes	740:766	hepatic antioxidant enzymes	740:766	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	2	54	from	effect	364:369	arg1	capito					414:419	capito	414:419	capito	414:419	However, the effect of LBP treatment on Luciobarbus capito (L. capito) still remains unknown.
36736520	2	54	from	effect	364:369	arg1	capito					403:408	capito	403:408	capito	403:408	However, the effect of LBP treatment on Luciobarbus capito (L. capito) still remains unknown.
36736520	2	55	theme	treatment	378:386	arg1	effect					364:369	the effect	360:369	the effect of LBP treatment on Luciobarbus capito (L. capito)	360:420	However, the effect of LBP treatment on Luciobarbus capito (L. capito) still remains unknown.
36736520	4	56	theme	0.50 g/L	888:895	arg1	P < 0.05					912:919	P < 0.05	912:919	P < 0.05	912:919	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	4	56	theme	0.50 g/L	888:895	arg1	treatment					901:909	0.50 g/L LBP treatment	888:909	0.50 g/L LBP treatment (P < 0.05)	888:920	Compared with control group, the activities of hepatic antioxidant enzymes, intestinal digestive enzymes and hepatic immune enzyme were found to be significantly increased after 0.10 g/L LBP and 0.50 g/L LBP treatment (P < 0.05).
36736520	6	57	theme	microbiota	1239:1248	arg1	diversity					1204:1212	diversity	1204:1212	diversity	1204:1212	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	6	57	theme	microbiota	1239:1248	arg1	abundance					1218:1226	abundance	1218:1226	abundance	1218:1226	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	5	58	theme	antioxidant	1027:1037	arg1	capacity					1039:1046	antioxidant capacity	1027:1046	antioxidant capacity	1027:1046	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	3	59	theme	LBP	533:535	arg1	treatment					537:545	LBP treatment	533:545	LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L)	533:576	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	6	60	theme	LBP	1177:1179	arg1	treatment					1181:1189	LBP treatment	1177:1189	LBP treatment	1177:1189	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	0	61	theme	conducive	61:69	arg1	polysaccharides					45:59	Lycium barbarum polysaccharides	29:59	Lycium barbarum polysaccharides conducive to	29:72	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	3	62	theme	activity	619:626	arg1	analysis					628:635	enzymatic activity analysis	609:635	enzymatic activity analysis	609:635	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	5	63	theme	LBP	969:971	arg1	treatment					973:981	LBP treatment	969:981	LBP treatment	969:981	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	3	64	theme	treatment	537:545	arg1	levels					523:528	different levels	513:528	different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L)	513:576	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	0	65	with	supplementation	8:22	arg1	polysaccharides					45:59	Lycium barbarum polysaccharides	29:59	Lycium barbarum polysaccharides conducive to	29:72	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	8	66	from	supplement	1482:1491	arg1	process					1508:1514	the culture process	1496:1514	the culture process of the farmed fish	1496:1533	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	0	67	dep	Lycium	29:34	arg1	barbarum					36:43	barbarum	36:43	barbarum	36:43	Dietary supplementation with Lycium barbarum polysaccharides conducive to maintaining the health of Luciobarbus capito via the enhancement of enzyme activities and the modulation of gut microbiota.
36736520	7	68	theme	significant	1304:1314	arg1	changes					1316:1322	No significant changes	1301:1322	No significant changes	1301:1322	No significant changes were screened in the morphologic structures of gut constructions.
36736520	6	69	theme	compositional	1079:1091	arg1	structures					1093:1102	the compositional structures	1075:1102	the compositional structures of the gut microbiota in L. capito	1075:1137	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	6	70	theme	gut	1111:1113	arg1	microbiota					1115:1124	the gut microbiota	1107:1124	the gut microbiota	1107:1124	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	7	71	theme	morphologic	1345:1355	arg1	structures					1357:1366	the morphologic structures	1341:1366	the morphologic structures of gut constructions	1341:1387	No significant changes were screened in the morphologic structures of gut constructions.
36736520	8	72	theme	theoretical	1414:1424	arg1	basis					1443:1447	theoretical and experimental basis	1414:1447	theoretical and experimental basis for future application of LBP	1414:1477	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	6	73	dep	found	1144:1148	arg1	whereas					1192:1198	whereas	1192:1198	whereas	1192:1198	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	6	74	dep	found	1260:1264	arg1	P > 0.05					1290:1297	P > 0.05	1290:1297	P > 0.05	1290:1297	Furthermore, the compositional structures of the gut microbiota in L. capito were found to be greatly shaped after LBP treatment, whereas the diversity and abundance of the gut microbiota were only found to be slightly changed (P > 0.05).
36736520	3	75	dep	0.10	553:556	arg1	i.e.					548:551	i.e.	548:551	i.e.	548:551	Given this, the current work aims to probe the underlying effect of different levels of LBP treatment (i.e. 0.10, 0.50 and 1.00 g/L) on L. capito in the context of enzymatic activity analysis, histological observations and gut microbiota analysis.
36736520	1	76	theme	important	308:316	arg1	value					344:348	important medicinal and nutritional value	308:348	important medicinal and nutritional value	308:348	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	5	77	dep	immunity	1014:1021	arg1	the					1010:1012	the	1010:1012	the	1010:1012	This result indicated that moderate levels of LBP treatment could dramatically enhance the immunity and antioxidant capacity of L. capito.
36736520	8	78	theme	farmed	1523:1528	arg1	fish					1530:1533	the farmed fish	1519:1533	the farmed fish	1519:1533	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	8	79	theme	fish	1530:1533	arg1	process					1508:1514	the culture process	1496:1514	the culture process of the farmed fish	1496:1533	This work would provide theoretical and experimental basis for future application of LBP as supplement in the culture process of the farmed fish.
36736520	1	80	theme	main	242:245	arg1	component					254:262	the main active component	238:262	the main active component	238:262	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
36736520	1	80	theme	main	242:245	arg1	polysaccharide					214:227	Lycium barbarum polysaccharide	198:227	Lycium barbarum polysaccharide (LBP)	198:233	Lycium barbarum polysaccharide (LBP) is the main active component of Lycium barbarum (L. barbarum), which has important medicinal and nutritional value.
37011744	8	0	theme	functional	1289:1298	arg1	industries					1324:1333	the functional food and pharmaceutical industries	1285:1333	the functional food and pharmaceutical industries	1285:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	5	1	theme	grape	733:737	arg1	polysaccharides					739:753	four wine grape polysaccharides	723:753	four wine grape polysaccharides	723:753	Furthermore, four wine grape polysaccharides exhibited antioxidant and immunomodulatory activities in a concentration-dependent manner.
37011744	6	2	theme	Moldova	846:852	arg1	polysaccharide					859:872	Moldova (MD) polysaccharide	846:872	Moldova (MD) polysaccharide	846:872	Moldova (MD) polysaccharide displayed better antioxidant activity and immunomodulatory ability.
37011744	1	3	theme	extraction	176:185	arg1	method					187:192	an efficient ultrasonic-assisted extraction method	143:192	an efficient ultrasonic-assisted extraction method	143:192	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	4	4	theme	basic	652:656	arg1	features					669:676	similar basic structural features	644:676	similar basic structural features	644:676	These findings suggest that the four wine grape polysaccharides share similar basic structural features and monosaccharide composition.
37011744	0	5	theme	polysaccharides	94:108	arg1	antioxidant					47:57	antioxidant	47:57	antioxidant	47:57	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	5	theme	polysaccharides	94:108	arg1	activities					80:89	immunomodulatory activities	63:89	immunomodulatory activities	63:89	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	5	theme	polysaccharides	94:108	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics	0:44	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	4	6	theme	wine	611:614	arg1	polysaccharides					622:636	the four wine grape polysaccharides	602:636	the four wine grape polysaccharides	602:636	These findings suggest that the four wine grape polysaccharides share similar basic structural features and monosaccharide composition.
37011744	8	7	theme	MD	1190:1191	arg1	polysaccharide					1204:1217	the MD wine grape polysaccharide	1186:1217	the MD wine grape polysaccharide	1186:1217	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	7	8	theme	rat	1026:1028	arg1	injury					1036:1041	CCl4-induced rat liver injury	1013:1041	CCl4-induced rat liver injury	1013:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	4	9	theme	similar	644:650	arg1	features					669:676	similar basic structural features	644:676	similar basic structural features	644:676	These findings suggest that the four wine grape polysaccharides share similar basic structural features and monosaccharide composition.
37011744	7	10	theme	oxidative	1102:1110	arg1	stress					1112:1117	oxidative stress	1102:1117	oxidative stress	1102:1117	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	8	11	theme	wine	1193:1196	arg1	polysaccharide					1204:1217	the MD wine grape polysaccharide	1186:1217	the MD wine grape polysaccharide	1186:1217	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	8	12	from	industries	1324:1333	arg1	prevention					1254:1263	prevention	1254:1263	prevention of liver disease in the functional food and pharmaceutical industries	1254:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	7	13	theme	liver	1030:1034	arg1	injury					1036:1041	CCl4-induced rat liver injury	1013:1041	CCl4-induced rat liver injury	1013:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	0	14	theme	wine	115:118	arg1	grapes					120:125	wine grapes	115:125	wine grapes	115:125	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	5	15	theme	antioxidant	765:775	arg1	activities					798:807	antioxidant and immunomodulatory activities	765:807	antioxidant and immunomodulatory activities	765:807	Furthermore, four wine grape polysaccharides exhibited antioxidant and immunomodulatory activities in a concentration-dependent manner.
37011744	2	16	theme	Behnken	307:313	arg1	Design					315:320	A three-level, three-factor Box Behnken Design	275:320	A three-level, three-factor Box Behnken Design combined with the response surface approach	275:364	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	4	17	theme	structural	658:667	arg1	features					669:676	similar basic structural features	644:676	similar basic structural features	644:676	These findings suggest that the four wine grape polysaccharides share similar basic structural features and monosaccharide composition.
37011744	3	18	theme	hepatoprotective	521:536	arg1	effects					538:544	hepatoprotective effects	521:544	hepatoprotective effects	521:544	Their physicochemical properties, molecular structure, antioxidant activity, immunomodulatory activity and hepatoprotective effects were examined and compared.
37011744	2	19	theme	Box	303:305	arg1	Design					315:320	A three-level, three-factor Box Behnken Design	275:320	A three-level, three-factor Box Behnken Design combined with the response surface approach	275:364	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	7	20	theme	CCl4-induced	1013:1024	arg1	injury					1036:1041	CCl4-induced rat liver injury	1013:1041	CCl4-induced rat liver injury	1013:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	0	21	from	antioxidant	47:57	arg1	grapes					120:125	wine grapes	115:125	wine grapes	115:125	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	8	22	theme	grape	1198:1202	arg1	polysaccharide					1204:1217	the MD wine grape polysaccharide	1186:1217	the MD wine grape polysaccharide	1186:1217	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	7	23	theme	therapeutic	991:1001	arg1	effect					1003:1008	a significant therapeutic effect	977:1008	a significant therapeutic effect on CCl4-induced rat liver injury	977:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	8	24	contain	have	1223:1226	arg1	polysaccharide					1204:1217	the MD wine grape polysaccharide	1186:1217	the MD wine grape polysaccharide	1186:1217	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	8	24	contain	have	1223:1226	arg2	applications					1238:1249	potential applications	1228:1249	potential applications	1228:1249	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	8	25	theme	food	1300:1303	arg1	industries					1324:1333	the functional food and pharmaceutical industries	1285:1333	the functional food and pharmaceutical industries	1285:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	6	26	theme	immunomodulatory	916:931	arg1	ability					933:939	immunomodulatory ability	916:939	immunomodulatory ability	916:939	Moldova (MD) polysaccharide displayed better antioxidant activity and immunomodulatory ability.
37011744	2	27	theme	response	340:347	arg1	approach					357:364	the response surface approach	336:364	the response surface approach	336:364	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	3	28	theme	physicochemical	420:434	arg1	properties					436:445	Their physicochemical properties	414:445	Their physicochemical properties	414:445	Their physicochemical properties, molecular structure, antioxidant activity, immunomodulatory activity and hepatoprotective effects were examined and compared.
37011744	4	29	theme	grape	616:620	arg1	polysaccharides					622:636	the four wine grape polysaccharides	602:636	the four wine grape polysaccharides	602:636	These findings suggest that the four wine grape polysaccharides share similar basic structural features and monosaccharide composition.
37011744	5	30	theme	wine	728:731	arg1	polysaccharides					739:753	four wine grape polysaccharides	723:753	four wine grape polysaccharides	723:753	Furthermore, four wine grape polysaccharides exhibited antioxidant and immunomodulatory activities in a concentration-dependent manner.
37011744	2	31	dep	three-level	277:287	arg1	three-factor					290:301	three-factor	290:301	three-factor	290:301	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	0	32	theme	characteristics	30:44	arg1	antioxidant					47:57	antioxidant	47:57	antioxidant	47:57	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	32	theme	characteristics	30:44	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics	0:44	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	32	theme	characteristics	30:44	arg1	activities					80:89	immunomodulatory activities	63:89	immunomodulatory activities	63:89	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	1	33	used	used	198:201	arg2	method					187:192	an efficient ultrasonic-assisted extraction method	143:192	an efficient ultrasonic-assisted extraction method	143:192	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	7	34	contain	has	973:975	arg1	polysaccharide					958:971	MD polysaccharide	955:971	MD polysaccharide	955:971	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	7	34	contain	has	973:975	arg2	effect					1003:1008	a significant therapeutic effect	977:1008	a significant therapeutic effect on CCl4-induced rat liver injury	977:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	2	35	used	used	370:373	arg2	Design					315:320	A three-level, three-factor Box Behnken Design	275:320	A three-level, three-factor Box Behnken Design combined with the response surface approach	275:364	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	7	36	theme	significant	979:989	arg1	effect					1003:1008	a significant therapeutic effect	977:1008	a significant therapeutic effect on CCl4-induced rat liver injury	977:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	0	37	theme	physicochemical	14:28	arg1	characteristics					30:44	physicochemical characteristics	14:44	physicochemical characteristics	14:44	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	5	38	theme	concentration-dependent	814:836	arg1	manner					838:843	a concentration-dependent manner	812:843	a concentration-dependent manner	812:843	Furthermore, four wine grape polysaccharides exhibited antioxidant and immunomodulatory activities in a concentration-dependent manner.
37011744	1	39	theme	efficient	146:154	arg1	method					187:192	an efficient ultrasonic-assisted extraction method	143:192	an efficient ultrasonic-assisted extraction method	143:192	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	3	40	theme	molecular	448:456	arg1	structure					458:466	molecular structure	448:466	molecular structure	448:466	Their physicochemical properties, molecular structure, antioxidant activity, immunomodulatory activity and hepatoprotective effects were examined and compared.
37011744	8	41	theme	potential	1228:1236	arg1	applications					1238:1249	potential applications	1228:1249	potential applications	1228:1249	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	3	42	theme	antioxidant	469:479	arg1	activity					481:488	antioxidant activity	469:488	antioxidant activity	469:488	Their physicochemical properties, molecular structure, antioxidant activity, immunomodulatory activity and hepatoprotective effects were examined and compared.
37011744	3	43	theme	immunomodulatory	491:506	arg1	activity					508:515	immunomodulatory activity	491:515	immunomodulatory activity	491:515	Their physicochemical properties, molecular structure, antioxidant activity, immunomodulatory activity and hepatoprotective effects were examined and compared.
37011744	8	44	from	prevention	1254:1263	arg1	industries					1324:1333	the functional food and pharmaceutical industries	1285:1333	the functional food and pharmaceutical industries	1285:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	8	45	from	disease	1274:1280	arg1	industries					1324:1333	the functional food and pharmaceutical industries	1285:1333	the functional food and pharmaceutical industries	1285:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	6	46	theme	antioxidant	891:901	arg1	activity					903:910	antioxidant activity	891:910	antioxidant activity	891:910	Moldova (MD) polysaccharide displayed better antioxidant activity and immunomodulatory ability.
37011744	0	47	theme	immunomodulatory	63:78	arg1	activities					80:89	immunomodulatory activities	63:89	immunomodulatory activities	63:89	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	47	theme	immunomodulatory	63:78	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics	0:44	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	8	48	theme	liver	1268:1272	arg1	disease					1274:1280	liver disease	1268:1280	liver disease in the functional food and pharmaceutical industries	1268:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	0	49	from	activities	80:89	arg1	grapes					120:125	wine grapes	115:125	wine grapes	115:125	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	5	50	theme	immunomodulatory	781:796	arg1	activities					798:807	antioxidant and immunomodulatory activities	765:807	antioxidant and immunomodulatory activities	765:807	Furthermore, four wine grape polysaccharides exhibited antioxidant and immunomodulatory activities in a concentration-dependent manner.
37011744	7	51	theme	antioxidant	1060:1070	arg1	system					1080:1085	the antioxidant defense system	1056:1085	the antioxidant defense system	1056:1085	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	7	52	theme	MD	955:956	arg1	polysaccharide					958:971	MD polysaccharide	955:971	MD polysaccharide	955:971	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	8	53	theme	pharmaceutical	1309:1322	arg1	industries					1324:1333	the functional food and pharmaceutical industries	1285:1333	the functional food and pharmaceutical industries	1285:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	8	54	theme	disease	1274:1280	arg1	prevention					1254:1263	prevention	1254:1263	prevention of liver disease in the functional food and pharmaceutical industries	1254:1333	Taken together, the MD wine grape polysaccharide may have potential applications in prevention of liver disease in the functional food and pharmaceutical industries.
37011744	7	55	theme	defense	1072:1078	arg1	system					1080:1085	the antioxidant defense system	1056:1085	the antioxidant defense system	1056:1085	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	4	56	theme	monosaccharide	682:695	arg1	composition					697:707	monosaccharide composition	682:707	monosaccharide composition	682:707	These findings suggest that the four wine grape polysaccharides share similar basic structural features and monosaccharide composition.
37011744	7	57	from	effect	1003:1008	arg1	injury					1036:1041	CCl4-induced rat liver injury	1013:1041	CCl4-induced rat liver injury	1013:1041	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	0	58	from	grapes	120:125	arg1	polysaccharides					94:108	polysaccharides	94:108	polysaccharides from wine grapes	94:125	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	58	from	grapes	120:125	arg1	antioxidant					47:57	antioxidant	47:57	antioxidant	47:57	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	58	from	grapes	120:125	arg1	activities					80:89	immunomodulatory activities	63:89	immunomodulatory activities	63:89	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	0	58	from	grapes	120:125	arg1	Comparison					0:9	Comparison	0:9	Comparison of physicochemical characteristics	0:44	Comparison of physicochemical characteristics, antioxidant and immunomodulatory activities of polysaccharides from wine grapes.
37011744	2	59	theme	three-level	277:287	arg1	Design					315:320	A three-level, three-factor Box Behnken Design	275:320	A three-level, three-factor Box Behnken Design combined with the response surface approach	275:364	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	2	60	theme	surface	349:355	arg1	approach					357:364	the response surface approach	336:364	the response surface approach	336:364	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	1	61	theme	wine	247:250	arg1	polysaccharides					258:272	four wine grape polysaccharides	242:272	four wine grape polysaccharides	242:272	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	7	62	contain	has	1139:1141	arg1	MD					1136:1137	MD	1136:1137	MD	1136:1137	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	7	62	contain	has	1139:1141	arg2	effect					1162:1167	a hepatoprotective effect	1143:1167	a hepatoprotective effect	1143:1167	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	1	63	dep	extraction	211:220	arg1	the					207:209	the	207:209	the	207:209	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	7	64	theme	hepatoprotective	1145:1160	arg1	effect					1162:1167	a hepatoprotective effect	1143:1167	a hepatoprotective effect	1143:1167	Furthermore, MD polysaccharide has a significant therapeutic effect on CCl4-induced rat liver injury by improving the antioxidant defense system and inhibiting oxidative stress, indicating that MD has a hepatoprotective effect.
37011744	2	65	theme	extraction	391:400	arg1	conditions					402:411	the extraction conditions	387:411	the extraction conditions	387:411	A three-level, three-factor Box Behnken Design combined with the response surface approach was used to optimize the extraction conditions.
37011744	1	66	theme	grape	252:256	arg1	polysaccharides					258:272	four wine grape polysaccharides	242:272	four wine grape polysaccharides	242:272	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	1	67	theme	ultrasonic-assisted	156:174	arg1	method					187:192	an efficient ultrasonic-assisted extraction method	143:192	an efficient ultrasonic-assisted extraction method	143:192	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	1	68	theme	polysaccharides	258:272	arg1	optimization					226:237	optimization	226:237	optimization	226:237	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
37011744	1	68	theme	polysaccharides	258:272	arg1	extraction					211:220	extraction	211:220	extraction	211:220	In this study, an efficient ultrasonic-assisted extraction method was used for the extraction and optimization of four wine grape polysaccharides.
35718151	4	0	theme	different	741:749	arg1	weights					761:767	different molecular weights	741:767	different molecular weights	741:767	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	9	1	theme	targeted	1598:1605	arg1	SRs					1607:1609	targeted SRs	1598:1609	targeted SRs	1598:1609	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	3	2	theme	SRs	624:626	arg1	roles					615:619	the roles	611:619	the roles of SRs in the processes	611:643	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	1	3	theme	macrophages	250:260	arg1	response					238:245	the immune response	227:245	the immune response of macrophages	227:260	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	7	4	theme	fluorescent	1340:1350	arg1	DiI					1358:1360	the fluorescent probe DiI	1336:1360	the fluorescent probe DiI	1336:1360	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	7	5	theme	binding	1301:1307	arg1	assay					1309:1313	the competitive binding assay	1285:1313	the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry	1285:1378	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	4	6	theme	2 M	728:730	arg1	FPS					732:734	2 M FPS	728:734	2 M FPS	728:734	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	1	7	from	vesiculosus	287:297	arg1	fucoidan					267:274	fucoidan	267:274	fucoidan from Fucus vesiculosus	267:297	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	1	7	from	vesiculosus	287:297	arg1	ligand					322:327	a ligand	320:327	a ligand of class A SRs (SR-A)	320:349	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	7	8	theme	SR-A	1272:1275	arg1	ligands					1261:1267	ligands	1261:1267	ligands of SR-A	1261:1275	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	3	9	theme	activities	526:535	arg1	study					496:500	a comparative study	482:500	a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages	482:604	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	2	10	from	japonica	439:446	arg1	roles					365:369	the roles	361:369	the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica	361:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	2	10	from	japonica	439:446	arg1	activity					402:409	the immunomodulatory activity	381:409	the immunomodulatory activity of fucoidan from Saccharina japonica	381:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	2	10	from	japonica	439:446	arg1	clear					456:460	clear	456:460	clear	456:460	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	6	11	theme	TLR4	1120:1123	arg1	upregulation					1104:1115	the upregulation	1100:1115	the upregulation of TLR4	1100:1123	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	3	12	theme	fucoidans	554:562	arg1	activities					526:535	the immunomodulatory activities	505:535	the immunomodulatory activities of six different fucoidans from S. japonica	505:579	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	4	13	theme	chemical	773:780	arg1	compositions					782:793	chemical compositions	773:793	chemical compositions	773:793	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	6	14	theme	SRs	1193:1195	arg1	expressions					1178:1188	different expressions	1168:1188	different expressions of SRs	1168:1195	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	8	15	with	fucoidans	1407:1415	arg1	heterogeneity					1447:1459	heterogeneity	1447:1459	heterogeneity	1447:1459	Our results revealed that fucoidans with low molecular weight and heterogeneity more easily bound to SRs and contributed to their immunomodulatory effects.
35718151	8	15	with	fucoidans	1407:1415	arg1	weight					1436:1441	low molecular weight	1422:1441	low molecular weight	1422:1441	Our results revealed that fucoidans with low molecular weight and heterogeneity more easily bound to SRs and contributed to their immunomodulatory effects.
35718151	5	16	theme	reagent	803:809	arg1	system					811:816	Griess reagent system	796:816	Griess reagent system	796:816	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	7	17	theme	1 M	1231:1233	arg1	DFPS					1235:1238	1 M DFPS	1231:1238	1 M DFPS	1231:1238	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	4	18	dep	fucoidans	663:671	arg1	FPS					732:734	2 M FPS	728:734	2 M FPS	728:734	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	18	dep	fucoidans	663:671	arg1	FPS					689:691	1 M FPS	685:691	1 M FPS	685:691	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	18	dep	fucoidans	663:671	arg1	DFPS					709:712	0.5 M DFPS	703:712	0.5 M DFPS	703:712	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	18	dep	fucoidans	663:671	arg1	DFPS					719:722	1 M DFPS	715:722	1 M DFPS	715:722	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	18	dep	fucoidans	663:671	arg1	FPS					680:682	0.5 M FPS	674:682	0.5 M FPS	674:682	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	18	dep	fucoidans	663:671	arg1	FPS					698:700	2 M FPS	694:700	2 M FPS	694:700	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	6	19	theme	expression	1073:1082	arg1	level					1084:1088	the protein expression level	1061:1088	the protein expression level	1061:1088	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	3	20	from	activities	526:535	arg1	japonica					572:579	S. japonica	569:579	S. japonica	569:579	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	5	21	from	IL-1β	945:949	arg1	upregulation					992:1003	the upregulation	988:1003	the upregulation of their gene expressiones	988:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	1	22	theme	Scavenger	156:164	arg1	SRs					177:179	SRs	177:179	SRs	177:179	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	1	22	theme	Scavenger	156:164	arg1	receptors					166:174	Scavenger receptors	156:174	Scavenger receptors (SRs)	156:180	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	9	23	theme	new	1632:1634	arg1	mechanisms					1652:1661	new pharmacological mechanisms	1632:1661	new pharmacological mechanisms of different fucoidans	1632:1684	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	5	24	from	IL-6	939:942	arg1	upregulation					992:1003	the upregulation	988:1003	the upregulation of their gene expressiones	988:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	4	25	contain	had	737:739	arg2	weights					761:767	different molecular weights	741:767	different molecular weights	741:767	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	25	contain	had	737:739	arg1	fucoidans					663:671	Six fucoidans	659:671	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS)	659:735	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	25	contain	had	737:739	arg2	compositions					782:793	chemical compositions	773:793	chemical compositions	773:793	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	9	26	theme	mechanisms	1652:1661	arg1	study					1589:1593	the biological study	1574:1593	the biological study of targeted SRs	1574:1609	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	9	26	theme	mechanisms	1652:1661	arg1	discovery					1619:1627	the discovery	1615:1627	the discovery of new pharmacological mechanisms of different fucoidans	1615:1684	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	4	27	theme	1 M	685:687	arg1	FPS					689:691	1 M FPS	685:691	1 M FPS	685:691	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	3	28	from	study	496:500	arg1	macrophages					594:604	RAW 264.7 macrophages	584:604	RAW 264.7 macrophages	584:604	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	1	29	theme	A	338:338	arg1	SRs					340:342	class A SRs	332:342	class A SRs (SR-A)	332:349	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	1	29	theme	A	338:338	arg1	SR-A					345:348	SR-A	345:348	SR-A	345:348	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	9	30	theme	different	1666:1674	arg1	fucoidans					1676:1684	different fucoidans	1666:1684	different fucoidans	1666:1684	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	0	31	theme	scavenger	110:118	arg1	receptors					120:128	scavenger receptors	110:128	scavenger receptors on RAW 264.7 macrophages	110:153	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	7	32	theme	0.5 M	1216:1220	arg1	DFPS					1222:1225	0.5 M DFPS	1216:1225	0.5 M DFPS	1216:1225	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	0	33	theme	Comparative	0:10	arg1	study					12:16	Comparative study	0:16	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica	0:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	0	34	dep	Saccharina	78:87	arg1	japonica					89:96	Saccharina japonica	78:96	Saccharina japonica	78:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	2	35	theme	SRs	374:376	arg1	roles					365:369	the roles	361:369	the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica	361:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	2	35	theme	SRs	374:376	arg1	clear					456:460	clear	456:460	clear	456:460	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	2	36	theme	Saccharina	428:437	arg1	japonica					439:446	Saccharina japonica	428:446	Saccharina japonica	428:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	8	37	theme	low	1422:1424	arg1	weight					1436:1441	low molecular weight	1422:1441	low molecular weight	1422:1441	Our results revealed that fucoidans with low molecular weight and heterogeneity more easily bound to SRs and contributed to their immunomodulatory effects.
35718151	0	38	theme	immunomodulatory	25:40	arg1	effects					42:48	the immunomodulatory effects	21:48	the immunomodulatory effects of different fucoidans from Saccharina japonica	21:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	5	39	theme	gene	1014:1017	arg1	expressiones					1019:1030	their gene expressiones	1008:1030	their gene expressiones	1008:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	2	40	theme	fucoidan	414:421	arg1	activity					402:409	the immunomodulatory activity	381:409	the immunomodulatory activity of fucoidan from Saccharina japonica	381:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	0	41	theme	fucoidans	63:71	arg1	effects					42:48	the immunomodulatory effects	21:48	the immunomodulatory effects of different fucoidans from Saccharina japonica	21:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	7	42	with	assay	1309:1313	arg1	Ac-LDL					1320:1325	Ac-LDL	1320:1325	Ac-LDL bound to the fluorescent probe DiI by flow cytometry	1320:1378	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	8	43	theme	immunomodulatory	1511:1526	arg1	effects					1528:1534	their immunomodulatory effects	1505:1534	their immunomodulatory effects	1505:1534	Our results revealed that fucoidans with low molecular weight and heterogeneity more easily bound to SRs and contributed to their immunomodulatory effects.
35718151	6	44	theme	cytometric	1038:1047	arg1	analysis					1049:1056	Flow cytometric analysis	1033:1056	Flow cytometric analysis of the protein expression level	1033:1088	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	5	45	theme	different	887:895	arg1	stimulation					897:907	different stimulation	887:907	different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones	887:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	2	46	from	roles	365:369	arg1	japonica					439:446	Saccharina japonica	428:446	Saccharina japonica	428:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	2	46	from	roles	365:369	arg1	activity					402:409	the immunomodulatory activity	381:409	the immunomodulatory activity of fucoidan from Saccharina japonica	381:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	4	47	theme	0.5 M	703:707	arg1	DFPS					709:712	0.5 M DFPS	703:712	0.5 M DFPS	703:712	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	1	48	theme	immune	231:236	arg1	response					238:245	the immune response	227:245	the immune response of macrophages	227:260	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	7	49	theme	probe	1352:1356	arg1	DiI					1358:1360	the fluorescent probe DiI	1336:1360	the fluorescent probe DiI	1336:1360	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	3	50	from	roles	615:619	arg1	processes					635:643	the processes	631:643	the processes	631:643	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	6	51	theme	different	1168:1176	arg1	expressions					1178:1188	different expressions	1168:1188	different expressions of SRs	1168:1195	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	3	52	theme	comparative	484:494	arg1	study					496:500	a comparative study	482:500	a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages	482:604	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	4	53	theme	molecular	751:759	arg1	weights					761:767	different molecular weights	741:767	different molecular weights	741:767	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	7	54	theme	competitive	1289:1299	arg1	assay					1309:1313	the competitive binding assay	1285:1313	the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry	1285:1378	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	3	55	theme	immunomodulatory	509:524	arg1	activities					526:535	the immunomodulatory activities	505:535	the immunomodulatory activities of six different fucoidans from S. japonica	505:579	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	0	56	theme	RAW	133:135	arg1	macrophages					143:153	RAW 264.7 macrophages	133:153	RAW 264.7 macrophages	133:153	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	5	57	from	NO	935:936	arg1	upregulation					992:1003	the upregulation	988:1003	the upregulation of their gene expressiones	988:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	9	58	theme	biological	1578:1587	arg1	study					1589:1593	the biological study	1574:1593	the biological study of targeted SRs	1574:1609	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	3	59	theme	different	544:552	arg1	fucoidans					554:562	six different fucoidans	540:562	six different fucoidans from S. japonica	540:579	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	5	60	theme	Griess	796:801	arg1	system					811:816	Griess reagent system	796:816	Griess reagent system	796:816	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	9	61	theme	SRs	1607:1609	arg1	study					1589:1593	the biological study	1574:1593	the biological study of targeted SRs	1574:1609	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	9	61	theme	SRs	1607:1609	arg1	discovery					1619:1627	the discovery	1615:1627	the discovery of new pharmacological mechanisms of different fucoidans	1615:1684	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	0	62	from	receptors	120:128	arg1	macrophages					143:153	RAW 264.7 macrophages	133:153	RAW 264.7 macrophages	133:153	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	5	63	theme	system	811:816	arg1	results					837:843	Griess reagent system, ELISA and RT-qPCR results	796:843	Griess reagent system, ELISA and RT-qPCR results	796:843	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	6	64	theme	level	1084:1088	arg1	analysis					1049:1056	Flow cytometric analysis	1033:1056	Flow cytometric analysis of the protein expression level	1033:1088	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	9	65	theme	comparative	1542:1552	arg1	study					1554:1558	This comparative study	1537:1558	This comparative study	1537:1558	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	6	66	theme	protein	1065:1071	arg1	level					1084:1088	the protein expression level	1061:1088	the protein expression level	1061:1088	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	9	67	theme	pharmacological	1636:1650	arg1	mechanisms					1652:1661	new pharmacological mechanisms	1632:1661	new pharmacological mechanisms of different fucoidans	1632:1684	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	0	68	from	study	12:16	arg1	Saccharina					78:87	Saccharina	78:87	Saccharina	78:87	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	1	69	theme	class	332:336	arg1	SRs					340:342	class A SRs	332:342	class A SRs (SR-A)	332:349	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	1	69	theme	class	332:336	arg1	SR-A					345:348	SR-A	345:348	SR-A	345:348	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	1	70	theme	SRs	340:342	arg1	fucoidan					267:274	fucoidan	267:274	fucoidan from Fucus vesiculosus	267:297	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	1	70	theme	SRs	340:342	arg1	ligand					322:327	a ligand	320:327	a ligand of class A SRs (SR-A)	320:349	Scavenger receptors (SRs) have been shown to participate in regulating the immune response of macrophages, and fucoidan from Fucus vesiculosus has been verified as a ligand of class A SRs (SR-A).
35718151	5	71	theme	different	857:865	arg1	fucoidans					867:875	different fucoidans	857:875	different fucoidans	857:875	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	9	72	theme	fucoidans	1676:1684	arg1	mechanisms					1652:1661	new pharmacological mechanisms	1632:1661	new pharmacological mechanisms of different fucoidans	1632:1684	This comparative study might promote the biological study of targeted SRs and the discovery of new pharmacological mechanisms of different fucoidans.
35718151	3	73	from	japonica	572:579	arg1	fucoidans					554:562	six different fucoidans	540:562	six different fucoidans from S. japonica	540:579	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	3	73	from	japonica	572:579	arg1	activities					526:535	the immunomodulatory activities	505:535	the immunomodulatory activities of six different fucoidans from S. japonica	505:579	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	5	74	from	differences	973:983	arg1	upregulation					992:1003	the upregulation	988:1003	the upregulation of their gene expressiones	988:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	5	75	theme	ELISA	819:823	arg1	results					837:843	Griess reagent system, ELISA and RT-qPCR results	796:843	Griess reagent system, ELISA and RT-qPCR results	796:843	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	2	76	theme	immunomodulatory	385:400	arg1	activity					402:409	the immunomodulatory activity	381:409	the immunomodulatory activity of fucoidan from Saccharina japonica	381:446	However, the roles of SRs in the immunomodulatory activity of fucoidan from Saccharina japonica are not clear.
35718151	0	77	from	Saccharina	78:87	arg1	effects					42:48	the immunomodulatory effects	21:48	the immunomodulatory effects of different fucoidans from Saccharina japonica	21:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	0	77	from	Saccharina	78:87	arg1	study					12:16	Comparative study	0:16	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica	0:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	5	78	theme	RT-qPCR	829:835	arg1	results					837:843	Griess reagent system, ELISA and RT-qPCR results	796:843	Griess reagent system, ELISA and RT-qPCR results	796:843	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	8	79	theme	molecular	1426:1434	arg1	weight					1436:1441	low molecular weight	1422:1441	low molecular weight	1422:1441	Our results revealed that fucoidans with low molecular weight and heterogeneity more easily bound to SRs and contributed to their immunomodulatory effects.
35718151	4	80	theme	0.5 M	674:678	arg1	FPS					680:682	0.5 M FPS	674:682	0.5 M FPS	674:682	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	0	81	theme	effects	42:48	arg1	study					12:16	Comparative study	0:16	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica	0:96	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	5	82	theme	macrophages	912:922	arg1	stimulation					897:907	different stimulation	887:907	different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones	887:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	3	83	theme	RAW	584:586	arg1	macrophages					594:604	RAW 264.7 macrophages	584:604	RAW 264.7 macrophages	584:604	Thus, we performed a comparative study of the immunomodulatory activities of six different fucoidans from S. japonica on RAW 264.7 macrophages, and the roles of SRs in the processes were studied.
35718151	5	84	from	TNF-α	955:959	arg1	upregulation					992:1003	the upregulation	988:1003	the upregulation of their gene expressiones	988:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	0	85	theme	different	53:61	arg1	fucoidans					63:71	different fucoidans	53:71	different fucoidans	53:71	Comparative study of the immunomodulatory effects of different fucoidans from Saccharina japonica mediated by scavenger receptors on RAW 264.7 macrophages.
35718151	5	86	theme	expressiones	1019:1030	arg1	upregulation					992:1003	the upregulation	988:1003	the upregulation of their gene expressiones	988:1030	Griess reagent system, ELISA and RT-qPCR results showed that different fucoidans displayed different stimulation of macrophages to secrete NO, IL-6, IL-1β and TNF-α, as well as differences in the upregulation of their gene expressiones.
35718151	4	87	theme	1 M	715:717	arg1	DFPS					719:722	1 M DFPS	715:722	1 M DFPS	715:722	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	4	88	theme	2 M	694:696	arg1	FPS					698:700	2 M FPS	694:700	2 M FPS	694:700	Six fucoidans (0.5 M FPS, 1 M FPS, 2 M FPS, 0.5 M DFPS, 1 M DFPS and 2 M FPS) had different molecular weights and chemical compositions.
35718151	7	89	theme	flow	1365:1368	arg1	cytometry					1370:1378	flow cytometry	1365:1378	flow cytometry	1365:1378	Furthermore, only 0.5 M DFPS and 1 M DFPS were confirmed to be ligands of SR-A through the competitive binding assay with Ac-LDL bound to the fluorescent probe DiI by flow cytometry.
35718151	6	90	with	treatment	1131:1139	arg1	fucoidans					1154:1162	all the fucoidans	1146:1162	all the fucoidans	1146:1162	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35718151	6	90	with	treatment	1131:1139	arg1	expressions					1178:1188	different expressions	1168:1188	different expressions of SRs	1168:1195	Flow cytometric analysis of the protein expression level indicated the upregulation of TLR4 after treatment with all the fucoidans but different expressions of SRs.
35751935	5	0	theme	15 min	781:786	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	0	theme	15 min	781:786	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	0	theme	15 min	781:786	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	0	theme	15 min	781:786	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	0	theme	15 min	781:786	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	0	1	from	extraction	21:30	arg1	maca					56:59	maca	56:59	maca (Lepidium meyenii)	56:78	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	0	1	from	extraction	21:30	arg1	meyenii					71:77	Lepidium meyenii	62:77	Lepidium meyenii	62:77	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	0	2	dep	in	113:114	arg1	vitro					116:120	vitro	116:120	vitro	116:120	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	5	3	theme	extraction	762:771	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	4	4	dep	cytokines	543:551	arg1	IL-6					564:567	IL-6	564:567	IL-6	564:567	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	4	4	dep	cytokines	543:551	arg1	TNF-α					554:558	TNF-α	554:558	TNF-α	554:558	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	4	4	dep	cytokines	543:551	arg1	cytokines					543:551	cytokines	543:551	cytokines (TNF-α and IL-6)	543:568	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	5	5	theme	energy	660:665	arg1	conditions					644:653	the optimal extraction conditions	621:653	the optimal extraction conditions	621:653	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	5	theme	energy	660:665	arg1	EADU					718:721	EADU	718:721	EADU	718:721	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	5	theme	energy	660:665	arg1	ultrasound					706:715	energy aggregation alternation dual-frequency ultrasound	660:715	energy aggregation alternation dual-frequency ultrasound (EADU)	660:722	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	4	6	dep	RAW	575:577	arg1	macrophage					585:594	macrophage	585:594	RAW 264.7 macrophage	575:594	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	3	7	theme	polysaccharides	359:373	arg1	purification					338:349	purification	338:349	purification	338:349	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	3	7	theme	polysaccharides	359:373	arg1	separation					323:332	separation	323:332	separation	323:332	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	9	8	from	medicine	1374:1381	arg1	additive					1354:1361	additive	1354:1361	additive	1354:1361	It could be an excellent functional additive in food or medicine.
35751935	9	8	from	medicine	1374:1381	arg1	It					1318:1319	It	1318:1319	It	1318:1319	It could be an excellent functional additive in food or medicine.
35751935	5	9	theme	aggregation	667:677	arg1	conditions					644:653	the optimal extraction conditions	621:653	the optimal extraction conditions	621:653	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	9	theme	aggregation	667:677	arg1	EADU					718:721	EADU	718:721	EADU	718:721	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	9	theme	aggregation	667:677	arg1	ultrasound					706:715	energy aggregation alternation dual-frequency ultrasound	660:715	energy aggregation alternation dual-frequency ultrasound (EADU)	660:722	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	3	10	theme	DEAE-52	400:406	arg1	column					418:423	the DEAE-52 cellulose column	396:423	the DEAE-52 cellulose column	396:423	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	8	11	theme	immune	1301:1306	arg1	activity					1308:1315	remarkable immune activity	1290:1315	remarkable immune activity	1290:1315	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	1	12	theme	polysaccharides	268:282	arg1	efficiency					224:233	extraction efficiency	213:233	extraction efficiency	213:233	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	1	12	theme	polysaccharides	268:282	arg1	activity					256:263	immunoregulatory activity	239:263	immunoregulatory activity	239:263	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	5	13	theme	20/35	755:759	arg1	combinations					739:750	frequency combinations	729:750	frequency combinations of 20/35	729:759	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	4	14	theme	immune	494:499	arg1	activity					501:508	Their immune activity	488:508	Their immune activity	488:508	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	5	15	theme	alternation	679:689	arg1	conditions					644:653	the optimal extraction conditions	621:653	the optimal extraction conditions	621:653	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	15	theme	alternation	679:689	arg1	EADU					718:721	EADU	718:721	EADU	718:721	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	15	theme	alternation	679:689	arg1	ultrasound					706:715	energy aggregation alternation dual-frequency ultrasound	660:715	energy aggregation alternation dual-frequency ultrasound (EADU)	660:722	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	16	theme	extraction	903:912	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	8	17	theme	TNF-α	1160:1164	arg1	release					1149:1155	the release	1145:1155	the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water)	1145:1254	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	0	18	from	maca	56:59	arg1	extraction					21:30	Multimode ultrasonic extraction	0:30	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.	0:147	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	0	18	from	maca	56:59	arg1	polysaccharides					35:49	polysaccharides	35:49	polysaccharides from maca (Lepidium meyenii)	35:78	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	1	19	from	Walp	306:309	arg1	polysaccharides					268:282	polysaccharides	268:282	polysaccharides from Lepidium meyenii Walp	268:309	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	1	19	from	Walp	306:309	arg1	efficiency					224:233	extraction efficiency	213:233	extraction efficiency	213:233	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	1	19	from	Walp	306:309	arg1	activity					256:263	immunoregulatory activity	239:263	immunoregulatory activity	239:263	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	5	20	theme	150 W/L	854:860	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	20	theme	150 W/L	854:860	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	20	theme	150 W/L	854:860	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	20	theme	150 W/L	854:860	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	20	theme	150 W/L	854:860	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	8	21	theme	purified	1207:1214	arg1	polysaccharides					1216:1230	purified polysaccharides	1207:1230	purified polysaccharides extracted by hot water	1207:1253	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	5	22	theme	time	876:879	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	3	23	theme	maca	354:357	arg1	polysaccharides					359:373	maca polysaccharides	354:373	maca polysaccharides	354:373	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	8	24	from	RAW	1180:1182	arg1	release					1149:1155	the release	1145:1155	the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water)	1145:1254	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	5	25	theme	optimal	625:631	arg1	conditions					644:653	the optimal extraction conditions	621:653	the optimal extraction conditions	621:653	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	25	theme	optimal	625:631	arg1	ultrasound					706:715	energy aggregation alternation dual-frequency ultrasound	660:715	energy aggregation alternation dual-frequency ultrasound (EADU)	660:722	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	0	26	theme	Multimode	0:8	arg1	extraction					21:30	Multimode ultrasonic extraction	0:30	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.	0:147	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	7	27	contain	contained	1037:1045	arg2	LMP					1015:1017	The LMP	1011:1017	The LMP extracted by EADU	1011:1035	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	contain	contained	1037:1045	arg1	ratios					1094:1099	the molar ratios	1084:1099	the molar ratios of 2.9:2.72:5.05	1084:1116	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	contain	contained	1037:1045	arg2	arabinose					1047:1055	arabinose	1047:1055	arabinose	1047:1055	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	contain	contained	1037:1045	arg2	galactose					1058:1066	galactose	1058:1066	galactose	1058:1066	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	contain	contained	1037:1045	arg1	LMP					1015:1017	The LMP	1011:1017	The LMP extracted by EADU	1011:1035	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	27	contain	contained	1037:1045	arg2	glucose					1073:1079	glucose	1073:1079	glucose	1073:1079	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	0	28	theme	ultrasonic	10:19	arg1	extraction					21:30	Multimode ultrasonic extraction	0:30	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.	0:147	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	5	29	theme	extraction	633:642	arg1	conditions					644:653	the optimal extraction conditions	621:653	the optimal extraction conditions	621:653	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	29	theme	extraction	633:642	arg1	ultrasound					706:715	energy aggregation alternation dual-frequency ultrasound	660:715	energy aggregation alternation dual-frequency ultrasound (EADU)	660:722	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	30	with	ultrasound	706:715	arg1	combinations					739:750	frequency combinations	729:750	frequency combinations of 20/35	729:759	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	31	theme	frequency	729:737	arg1	combinations					739:750	frequency combinations	729:750	frequency combinations of 20/35	729:759	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	1	32	from	activity	256:263	arg1	Walp					306:309	Lepidium meyenii Walp	289:309	Lepidium meyenii Walp	289:309	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	1	33	theme	Lepidium	289:296	arg1	Walp					306:309	Lepidium meyenii Walp	289:309	Lepidium meyenii Walp	289:309	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	5	34	theme	ultrasonic	824:833	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	3	35	theme	monosaccharide	434:447	arg1	compositions					449:460	the monosaccharide compositions	430:460	the monosaccharide compositions	430:460	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	5	36	theme	power	835:839	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	1	37	theme	meyenii	298:304	arg1	Walp					306:309	Lepidium meyenii Walp	289:309	Lepidium meyenii Walp	289:309	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	0	38	theme	in	113:114	arg1	activity					139:146	in vitro immunoregulatory activity	113:146	in vitro immunoregulatory activity	113:146	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	8	39	dep	RS3	1202:1204	arg1	polysaccharides					1216:1230	purified polysaccharides	1207:1230	purified polysaccharides extracted by hot water	1207:1253	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	1	40	theme	multimodal	184:193	arg1	ultrasound					195:204	multimodal ultrasound	184:204	multimodal ultrasound	184:204	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	6	41	theme	polysaccharides	968:982	arg1	rates					950:954	The extraction rates	935:954	The extraction rates of purified polysaccharides (US3)	935:988	The extraction rates of purified polysaccharides (US3) increased by 44.90%.
35751935	3	42	dep	separation	323:332	arg1	The					319:321	The	319:321	The	319:321	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	9	43	from	food	1366:1369	arg1	additive					1354:1361	additive	1354:1361	additive	1354:1361	It could be an excellent functional additive in food or medicine.
35751935	9	43	from	food	1366:1369	arg1	It					1318:1319	It	1318:1319	It	1318:1319	It could be an excellent functional additive in food or medicine.
35751935	1	44	theme	ultrasound	195:204	arg1	effect					174:179	the effect	170:179	the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp	170:309	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	5	45	theme	material/water	789:802	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	6	46	theme	purified	959:966	arg1	polysaccharides					968:982	purified polysaccharides	959:982	purified polysaccharides (US3)	959:988	The extraction rates of purified polysaccharides (US3) increased by 44.90%.
35751935	6	46	theme	purified	959:966	arg1	US3					985:987	US3	985:987	US3	985:987	The extraction rates of purified polysaccharides (US3) increased by 44.90%.
35751935	0	47	theme	immunoregulatory	122:137	arg1	activity					139:146	in vitro immunoregulatory activity	113:146	in vitro immunoregulatory activity	113:146	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	5	48	theme	4 s/3 s	890:896	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	48	theme	4 s/3 s	890:896	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	48	theme	4 s/3 s	890:896	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	48	theme	4 s/3 s	890:896	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	48	theme	4 s/3 s	890:896	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	8	49	theme	hot	1245:1247	arg1	water					1249:1253	hot water	1245:1253	hot water	1245:1253	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	0	50	theme	polysaccharides	35:49	arg1	extraction					21:30	Multimode ultrasonic extraction	0:30	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.	0:147	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	4	51	theme	cytokines	543:551	arg1	secretion					530:538	the secretion	526:538	the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage	526:594	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	8	52	dep	promoted	1136:1143	arg1	indicated					1263:1271	indicated	1263:1271	indicated that US3 exerted remarkable immune activity	1263:1315	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	8	53	theme	IL-6	1170:1173	arg1	release					1149:1155	the release	1145:1155	the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water)	1145:1254	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	4	54	from	RAW	575:577	arg1	secretion					530:538	the secretion	526:538	the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage	526:594	Their immune activity was analyzed by the secretion of cytokines (TNF-α and IL-6) from RAW 264.7 macrophage.
35751935	3	55	theme	cellulose	408:416	arg1	column					418:423	the DEAE-52 cellulose column	396:423	the DEAE-52 cellulose column	396:423	The separation and purification of maca polysaccharides were investigated by the DEAE-52 cellulose column, and the monosaccharide compositions were identified by HPGPC.
35751935	5	56	theme	dual-frequency	691:704	arg1	conditions					644:653	the optimal extraction conditions	621:653	the optimal extraction conditions	621:653	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	56	theme	dual-frequency	691:704	arg1	EADU					718:721	EADU	718:721	EADU	718:721	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	56	theme	dual-frequency	691:704	arg1	ultrasound					706:715	energy aggregation alternation dual-frequency ultrasound	660:715	energy aggregation alternation dual-frequency ultrasound (EADU)	660:722	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	1	57	dep	efficiency	224:233	arg1	the					209:211	the	209:211	the	209:211	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	5	58	theme	1:10 g/mL	813:821	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	58	theme	1:10 g/mL	813:821	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	58	theme	1:10 g/mL	813:821	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	58	theme	1:10 g/mL	813:821	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	58	theme	1:10 g/mL	813:821	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	6	59	theme	extraction	939:948	arg1	rates					950:954	The extraction rates	935:954	The extraction rates of purified polysaccharides (US3)	935:988	The extraction rates of purified polysaccharides (US3) increased by 44.90%.
35751935	8	60	dep	better	1190:1195	arg1	than					1197:1200	than	1197:1200	than	1197:1200	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	7	61	theme	2.9:2.72:5.05	1104:1116	arg1	ratios					1094:1099	the molar ratios	1084:1099	the molar ratios of 2.9:2.72:5.05	1084:1116	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	7	62	theme	molar	1088:1092	arg1	ratios					1094:1099	the molar ratios	1084:1099	the molar ratios of 2.9:2.72:5.05	1084:1116	The LMP extracted by EADU contained arabinose, galactose, and glucose in the molar ratios of 2.9:2.72:5.05.
35751935	5	63	theme	℃	932:932	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	63	theme	℃	932:932	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	63	theme	℃	932:932	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	63	theme	℃	932:932	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	63	theme	℃	932:932	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	1	64	theme	extraction	213:222	arg1	efficiency					224:233	extraction efficiency	213:233	extraction efficiency	213:233	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	1	65	from	efficiency	224:233	arg1	Walp					306:309	Lepidium meyenii Walp	289:309	Lepidium meyenii Walp	289:309	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	0	66	dep	extraction	21:30	arg1	purification					95:106	purification	95:106	purification	95:106	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	0	66	dep	extraction	21:30	arg1	Optimization					81:92	Optimization	81:92	Optimization	81:92	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	0	66	dep	extraction	21:30	arg1	activity					139:146	in vitro immunoregulatory activity	113:146	in vitro immunoregulatory activity	113:146	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	1	67	from	effect	174:179	arg1	efficiency					224:233	extraction efficiency	213:233	extraction efficiency	213:233	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	1	67	from	effect	174:179	arg1	activity					256:263	immunoregulatory activity	239:263	immunoregulatory activity	239:263	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
35751935	8	68	theme	remarkable	1290:1299	arg1	activity					1308:1315	remarkable immune activity	1290:1315	remarkable immune activity	1290:1315	In addition, US3 promoted the release of TNF-α and IL-6 from RAW 264.7 better than RS3 (purified polysaccharides extracted by hot water), which indicated that US3 exerted remarkable immune activity.
35751935	5	69	theme	intermittent	863:874	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	9	70	from	additive	1354:1361	arg1	medicine					1374:1381	medicine	1374:1381	medicine	1374:1381	It could be an excellent functional additive in food or medicine.
35751935	9	70	from	additive	1354:1361	arg1	food					1366:1369	food	1366:1369	food	1366:1369	It could be an excellent functional additive in food or medicine.
35751935	0	71	theme	Lepidium	62:69	arg1	maca					56:59	maca	56:59	maca (Lepidium meyenii)	56:78	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	0	71	theme	Lepidium	62:69	arg1	meyenii					71:77	Lepidium meyenii	62:77	Lepidium meyenii	62:77	Multimode ultrasonic extraction of polysaccharides from maca (Lepidium meyenii): Optimization, purification, and in vitro immunoregulatory activity.
35751935	5	72	dep	ultrasound	706:715	arg1	ratio					881:885	intermittent time ratio	863:885	intermittent time ratio of 4 s/3 s	863:896	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	72	dep	ultrasound	706:715	arg1	temperature					914:924	extraction temperature	903:924	extraction temperature of 50 ℃	903:932	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	72	dep	ultrasound	706:715	arg1	ratio					804:808	material/water ratio	789:808	material/water ratio of 1:10 g/mL	789:821	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	72	dep	ultrasound	706:715	arg1	time					773:776	extraction time	762:776	extraction time of 15 min	762:786	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	5	72	dep	ultrasound	706:715	arg1	intensity					841:849	ultrasonic power intensity	824:849	ultrasonic power intensity of 150 W/L	824:860	The results showed that the optimal extraction conditions were energy aggregation alternation dual-frequency ultrasound (EADU) with frequency combinations of 20/35, extraction time of 15 min, material/water ratio of 1:10 g/mL, ultrasonic power intensity of 150 W/L, intermittent time ratio of 4 s/3 s, and extraction temperature of 50 ℃.
35751935	1	73	theme	immunoregulatory	239:254	arg1	activity					256:263	immunoregulatory activity	239:263	immunoregulatory activity	239:263	This study evaluates the effect of multimodal ultrasound on the extraction efficiency and immunoregulatory activity of polysaccharides from Lepidium meyenii Walp.
37343686	6	0	theme	sulfated	856:863	arg1	polysaccharide					865:878	sulfated polysaccharide	856:878	sulfated polysaccharide containing uronic acid	856:901	FT-IR showed that SBLP-S were sulfated polysaccharide containing uronic acid.
37343686	0	1	theme	sea	92:94	arg1	buckthorn					96:104	sea buckthorn	92:104	sea buckthorn	92:104	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	2	from	characterization	6:21	arg1	buckthorn					96:104	sea buckthorn	92:104	sea buckthorn	92:104	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	9	3	theme	Crude	1121:1125	arg1	polysaccharides					1127:1141	Crude polysaccharides	1121:1141	Crude polysaccharides	1121:1141	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	2	4	theme	Ultraviolet	348:358	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	4	theme	Ultraviolet	348:358	arg1	Spectrum					383:390	Infrared Spectrum	374:390	Infrared Spectrum	374:390	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	4	theme	Ultraviolet	348:358	arg1	analysis					447:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	4	5	theme	SBLP-S-2	607:614	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	8	6	theme	helix	1101:1105	arg1	conformation					1107:1118	triple helix conformation	1094:1118	triple helix conformation	1094:1118	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	12	7	theme	functional	1525:1534	arg1	fields					1541:1546	pharmaceutical and functional food fields	1506:1546	pharmaceutical and functional food fields	1506:1546	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	7	8	theme	SBLP-S	925:930	arg1	weights					914:920	Molecular weights	904:920	Molecular weights of SBLP-S	904:930	Molecular weights of SBLP-S were 338,659 Da, 401,305 Da, 599,849 Da, 393,904 Da, 626,895 Da, and 176,862 Da.
37343686	8	9	theme	triple	1094:1099	arg1	conformation					1107:1118	triple helix conformation	1094:1118	triple helix conformation	1094:1118	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	10	10	contain	had	1259:1261	arg2	activity					1267:1274	the activity	1263:1274	the activity of immune stimulation on RAW264.7 cell	1263:1313	The six polysaccharides had the activity of immune stimulation on RAW264.7 cell.
37343686	10	10	contain	had	1259:1261	arg1	polysaccharides					1243:1257	The six polysaccharides	1235:1257	The six polysaccharides	1235:1257	The six polysaccharides had the activity of immune stimulation on RAW264.7 cell.
37343686	6	11	theme	uronic	891:896	arg1	acid					898:901	uronic acid	891:901	uronic acid	891:901	FT-IR showed that SBLP-S were sulfated polysaccharide containing uronic acid.
37343686	4	12	theme	SBLP-S-3	617:624	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	11	13	theme	NO	1382:1383	arg1	production					1385:1394	the NO production	1378:1394	the NO production	1378:1394	SBLP-S-2 promoted the phagocytosis best and SBLP-S-6 promoted the NO production best.
37343686	0	14	from	activities	57:66	arg1	buckthorn					96:104	sea buckthorn	92:104	sea buckthorn	92:104	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	2	15	theme	Performance	398:408	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	15	theme	Performance	398:408	arg1	analysis					447:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	12	16	theme	pharmaceutical	1506:1519	arg1	fields					1541:1546	pharmaceutical and functional food fields	1506:1546	pharmaceutical and functional food fields	1506:1546	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	1	17	from	buckthorn	143:151	arg1	polysaccharides					118:132	The polysaccharides	114:132	The polysaccharides from Sea buckthorn leaves (SBLPs)	114:166	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	9	18	contain	had	1143:1145	arg2	activities					1169:1178	the strong scavenging activities	1147:1178	the strong scavenging activities	1147:1178	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	9	18	contain	had	1143:1145	arg1	polysaccharides					1127:1141	Crude polysaccharides	1121:1141	Crude polysaccharides	1121:1141	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	2	19	theme	High	393:396	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	19	theme	High	393:396	arg1	analysis					447:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	7	20	theme	Molecular	904:912	arg1	weights					914:920	Molecular weights	904:920	Molecular weights of SBLP-S	904:930	Molecular weights of SBLP-S were 338,659 Da, 401,305 Da, 599,849 Da, 393,904 Da, 626,895 Da, and 176,862 Da.
37343686	8	21	theme	Congo-red	1017:1025	arg1	test					1027:1030	The Congo-red test	1013:1030	The Congo-red test	1013:1030	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	9	22	theme	scavenging	1158:1167	arg1	activities					1169:1178	the strong scavenging activities	1147:1178	the strong scavenging activities	1147:1178	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	2	23	theme	separated	300:308	arg1	polysaccharides					310:324	Six separated polysaccharides	296:324	Six separated polysaccharides	296:324	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	1	24	theme	hot	186:188	arg1	water					190:194	hot water	186:194	hot water	186:194	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	0	25	theme	Basic	0:4	arg1	characterization					6:21	Basic characterization	0:21	Basic characterization	0:21	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	8	26	contain	had	1090:1092	arg1	SBLP-S-6					1081:1088	SBLP-S-6	1081:1088	SBLP-S-6	1081:1088	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	8	26	contain	had	1090:1092	arg1	SBLP-S-4					1057:1064	SBLP-S-4	1057:1064	SBLP-S-4	1057:1064	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	8	26	contain	had	1090:1092	arg2	conformation					1107:1118	triple helix conformation	1094:1118	triple helix conformation	1094:1118	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	8	26	contain	had	1090:1092	arg1	SBLP-S-2					1047:1054	SBLP-S-2	1047:1054	SBLP-S-2	1047:1054	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	8	26	contain	had	1090:1092	arg1	SBLP-S-5					1067:1074	SBLP-S-5	1067:1074	SBLP-S-5	1067:1074	The Congo-red test indicated that SBLP-S-2, SBLP-S-4, SBLP-S-5, and SBLP-S-6 had triple helix conformation.
37343686	12	27	theme	potential	1452:1460	arg1	antioxidants					1462:1473	potential antioxidants	1452:1473	potential antioxidants	1452:1473	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	12	27	theme	potential	1452:1460	arg1	SBLPs					1429:1433	SBLPs	1429:1433	SBLPs	1429:1433	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	5	28	theme	above	787:791	arg1	components					793:802	all above components	783:802	all above components except GlcN and GluA	783:823	And SBLP-S-4 contained all above components except GlcN and GluA.
37343686	5	29	contain	contained	773:781	arg2	components					793:802	all above components	783:802	all above components except GlcN and GluA	783:823	And SBLP-S-4 contained all above components except GlcN and GluA.
37343686	5	29	contain	contained	773:781	arg1	SBLP-S-4					764:771	SBLP-S-4	764:771	SBLP-S-4	764:771	And SBLP-S-4 contained all above components except GlcN and GluA.
37343686	2	30	theme	red	443:445	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	30	theme	red	443:445	arg1	analysis					447:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	0	31	from	buckthorn	96:104	arg1	polysaccharides					71:85	polysaccharides	71:85	polysaccharides from sea buckthorn	71:104	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	31	from	buckthorn	96:104	arg1	antioxidant					24:34	antioxidant	24:34	antioxidant	24:34	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	31	from	buckthorn	96:104	arg1	activities					57:66	immunomodulatory activities	40:66	immunomodulatory activities	40:66	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	31	from	buckthorn	96:104	arg1	characterization					6:21	Basic characterization	0:21	Basic characterization	0:21	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	3	32	theme	immunological	486:498	arg1	activity					500:507	immunological activity	486:507	immunological activity	486:507	The antioxidant activity and immunological activity were investigated in vitro.
37343686	0	33	theme	immunomodulatory	40:55	arg1	activities					57:66	immunomodulatory activities	40:66	immunomodulatory activities	40:66	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	4	34	theme	SBLP-S-1	597:604	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	3	35	theme	antioxidant	461:471	arg1	activity					473:480	The antioxidant activity	457:480	The antioxidant activity	457:480	The antioxidant activity and immunological activity were investigated in vitro.
37343686	2	36	theme	Chromatographic	417:431	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	36	theme	Chromatographic	417:431	arg1	analysis					447:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	12	37	used	used	1444:1447	arg2	SBLPs					1429:1433	SBLPs	1429:1433	SBLPs	1429:1433	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	12	37	used	used	1444:1447	arg2	agents					1496:1501	immunomodulatory agents	1479:1501	immunomodulatory agents	1479:1501	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	12	37	used	used	1444:1447	arg2	antioxidants					1462:1473	potential antioxidants	1452:1473	potential antioxidants	1452:1473	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	12	38	theme	immunomodulatory	1479:1494	arg1	agents					1496:1501	immunomodulatory agents	1479:1501	immunomodulatory agents	1479:1501	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	12	38	theme	immunomodulatory	1479:1494	arg1	SBLPs					1429:1433	SBLPs	1429:1433	SBLPs	1429:1433	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	10	39	theme	RAW264.7	1301:1308	arg1	cell					1310:1313	RAW264.7 cell	1301:1313	RAW264.7 cell	1301:1313	The six polysaccharides had the activity of immune stimulation on RAW264.7 cell.
37343686	1	40	theme	DEAE	212:215	arg1	cellulose					217:225	DEAE cellulose	212:225	DEAE cellulose	212:225	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	9	41	theme	ABTS	1198:1201	arg1	radicals					1203:1210	ABTS radicals	1198:1210	ABTS radicals	1198:1210	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	1	42	dep	extracted	173:181	arg1	separated					233:241	separated	233:241	separated into six polysaccharides (SBLP-S) by DEAE-52 column	233:293	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	4	43	theme	monosaccharide	567:580	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	10	44	theme	stimulation	1286:1296	arg1	activity					1267:1274	the activity	1263:1274	the activity of immune stimulation on RAW264.7 cell	1263:1313	The six polysaccharides had the activity of immune stimulation on RAW264.7 cell.
37343686	1	45	theme	Sea	139:141	arg1	buckthorn					143:151	Sea buckthorn	139:151	Sea buckthorn	139:151	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	6	46	contain	containing	880:889	arg2	acid					898:901	uronic acid	891:901	uronic acid	891:901	FT-IR showed that SBLP-S were sulfated polysaccharide containing uronic acid.
37343686	6	46	contain	containing	880:889	arg1	polysaccharide					865:878	sulfated polysaccharide	856:878	sulfated polysaccharide containing uronic acid	856:901	FT-IR showed that SBLP-S were sulfated polysaccharide containing uronic acid.
37343686	4	47	theme	rare	732:735	arg1	glucosamine					737:747	rare glucosamine	732:747	rare glucosamine	732:747	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	10	48	theme	immune	1279:1284	arg1	stimulation					1286:1296	immune stimulation	1279:1296	immune stimulation	1279:1296	The six polysaccharides had the activity of immune stimulation on RAW264.7 cell.
37343686	9	49	theme	strong	1151:1156	arg1	activities					1169:1178	the strong scavenging activities	1147:1178	the strong scavenging activities	1147:1178	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	12	50	theme	food	1536:1539	arg1	fields					1541:1546	pharmaceutical and functional food fields	1506:1546	pharmaceutical and functional food fields	1506:1546	The results suggested that SBLPs could be used as potential antioxidants and immunomodulatory agents in pharmaceutical and functional food fields.
37343686	9	51	theme	hydroxyl	1216:1223	arg1	radicals					1225:1232	hydroxyl radicals	1216:1232	hydroxyl radicals	1216:1232	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	4	52	contain	contained	649:657	arg2	GluA					680:683	GluA	680:683	GluA	680:683	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Rib					670:672	Rib	670:672	Rib	670:672	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	GalA					686:689	GalA	686:689	GalA	686:689	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Xyl					702:704	Xyl	702:704	Xyl	702:704	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Rha					675:677	Rha	675:677	Rha	675:677	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Ara					707:709	Ara	707:709	Ara	707:709	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Gal					697:699	Gal	697:699	Gal	697:699	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Fuc					715:717	Fuc	715:717	Fuc	715:717	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	Man					659:661	Man	659:661	Man	659:661	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	52	contain	contained	649:657	arg2	GlcN					664:667	GlcN	664:667	GlcN	664:667	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	4	53	theme	SBLP-S-5	627:634	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
37343686	2	54	theme	Liquid	410:415	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	54	theme	Liquid	410:415	arg1	analysis					447:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	High Performance Liquid Chromatographic and Congo red analysis	393:454	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	9	55	theme	DPPH	1183:1186	arg1	radicals					1188:1195	DPPH radicals	1183:1195	DPPH radicals	1183:1195	Crude polysaccharides had the strong scavenging activities on DPPH radicals, ABTS radicals and hydroxyl radicals.
37343686	2	56	theme	Infrared	374:381	arg1	Spectroscopy					360:371	Ultraviolet Spectroscopy	348:371	Ultraviolet Spectroscopy	348:371	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	2	56	theme	Infrared	374:381	arg1	Spectrum					383:390	Infrared Spectrum	374:390	Infrared Spectrum	374:390	Six separated polysaccharides were characterized by Ultraviolet Spectroscopy, Infrared Spectrum, High Performance Liquid Chromatographic and Congo red analysis.
37343686	0	57	theme	polysaccharides	71:85	arg1	antioxidant					24:34	antioxidant	24:34	antioxidant	24:34	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	57	theme	polysaccharides	71:85	arg1	activities					57:66	immunomodulatory activities	40:66	immunomodulatory activities	40:66	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	57	theme	polysaccharides	71:85	arg1	characterization					6:21	Basic characterization	0:21	Basic characterization	0:21	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	0	58	from	antioxidant	24:34	arg1	buckthorn					96:104	sea buckthorn	92:104	sea buckthorn	92:104	Basic characterization, antioxidant and immunomodulatory activities of polysaccharides from sea buckthorn leaves.
37343686	10	59	from	activity	1267:1274	arg1	cell					1310:1313	RAW264.7 cell	1301:1313	RAW264.7 cell	1301:1313	The six polysaccharides had the activity of immune stimulation on RAW264.7 cell.
37343686	1	60	dep	polysaccharides	118:132	arg1	SBLPs					161:165	SBLPs	161:165	SBLPs	161:165	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	1	60	dep	polysaccharides	118:132	arg1	leaves					153:158	leaves	153:158	leaves	153:158	The polysaccharides from Sea buckthorn leaves (SBLPs) were extracted by hot water and purified by DEAE cellulose, then separated into six polysaccharides (SBLP-S) by DEAE-52 column.
37343686	4	61	theme	SBLP-S-6	640:647	arg1	composition					582:592	the monosaccharide composition	563:592	the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6	563:647	The results revealed that the monosaccharide composition of SBLP-S-1, SBLP-S-2, SBLP-S-3, SBLP-S-5 and SBLP-S-6 contained Man, GlcN, Rib, Rha, GluA, GalA, Glu, Gal, Xyl, Ara and Fuc, among them, rare glucosamine was found.
35868743	0	0	theme	bone	88:91	arg1	loss					93:96	anti-weightlessness bone loss	68:96	anti-weightlessness bone loss	68:96	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	3	1	theme	gel	347:349	arg1	analysis					377:384	gel permeation chromatography analysis	347:384	gel permeation chromatography analysis	347:384	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	7	2	theme	cell	1055:1058	arg1	lines					1060:1064	RAW264.7 cell lines	1046:1064	RAW264.7 cell lines	1046:1064	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	0	3	theme	anti-weightlessness	68:86	arg1	loss					93:96	anti-weightlessness bone loss	68:96	anti-weightlessness bone loss	68:96	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	4	4	theme	linear	545:550	arg1	backbone					552:559	a linear backbone	543:559	a linear backbone consisted of α-d-Glcp-(1→ and →1)	543:593	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	7	5	theme	bone	976:979	arg1	formation					981:989	bone formation	976:989	bone formation	976:989	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	6	6	theme	activities	862:871	arg1	analyzation					807:817	analyzation	807:817	analyzation of mechanical properties, BALP and TRAP 5b activities on femur	807:880	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	7	7	theme	In	883:884	arg1	expression					897:906	In vitro mRNA expression	883:906	In vitro mRNA expression	883:906	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	8	8	theme	anti-WIBL	1180:1188	arg1	activity					1190:1197	anti-WIBL activity	1180:1197	anti-WIBL activity	1180:1197	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	6	9	theme	properties	833:842	arg1	analyzation					807:817	analyzation	807:817	analyzation of mechanical properties, BALP and TRAP 5b activities on femur	807:880	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	3	10	with	fructose	436:443	arg1	weight					460:465	molecular weight	450:465	molecular weight of 1.433 kDa	450:478	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	4	11	theme	spectrometer	522:533	arg1	data					490:493	data	490:493	data of gas chromatography-mass spectrometer (GCMS)	490:540	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	6	12	theme	mechanical	822:831	arg1	properties					833:842	mechanical properties	822:842	mechanical properties	822:842	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	4	13	theme	chromatography-mass	502:520	arg1	GCMS					536:539	GCMS	536:539	GCMS	536:539	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	4	13	theme	chromatography-mass	502:520	arg1	spectrometer					522:533	gas chromatography-mass spectrometer	498:533	gas chromatography-mass spectrometer (GCMS)	498:540	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	5	14	theme	nuclear	646:652	arg1	resonance					663:671	nuclear magnetic resonance	646:671	nuclear magnetic resonance (NMR)	646:677	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	5	14	theme	nuclear	646:652	arg1	NMR					674:676	NMR	674:676	NMR	674:676	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	0	15	dep	activity	98:105	arg1	fructan					15:21	An inulin-type fructan	0:21	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss	0:96	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	0	15	dep	activity	98:105	arg1	AMP1-1					24:29	AMP1-1	24:29	AMP1-1	24:29	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	5	16	theme	magnetic	654:661	arg1	resonance					663:671	nuclear magnetic resonance	646:671	nuclear magnetic resonance (NMR)	646:677	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	5	16	theme	magnetic	654:661	arg1	NMR					674:676	NMR	674:676	NMR	674:676	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	7	17	dep	In	883:884	arg1	vitro					886:890	vitro	886:890	vitro	886:890	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	8	18	theme	remodeling	1203:1212	arg1	homeostasis					1219:1229	remodeling bone homeostasis	1203:1229	remodeling bone homeostasis	1203:1229	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	8	19	theme	inulin-type	1117:1127	arg1	AMP1-1					1137:1142	the inulin-type fructan AMP1-1	1113:1142	the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7	1113:1174	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	0	20	theme	inulin-type	3:13	arg1	fructan					15:21	An inulin-type fructan	0:21	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss	0:96	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	0	20	theme	inulin-type	3:13	arg1	AMP1-1					24:29	AMP1-1	24:29	AMP1-1	24:29	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	3	21	theme	permeation	351:360	arg1	analysis					377:384	gel permeation chromatography analysis	347:384	gel permeation chromatography analysis	347:384	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	8	22	theme	fructan	1129:1135	arg1	AMP1-1					1137:1142	the inulin-type fructan AMP1-1	1113:1142	the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7	1113:1174	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	7	23	theme	simulated	1072:1080	arg1	weightlessness					1082:1095	simulated weightlessness	1072:1095	simulated weightlessness	1072:1095	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	5	24	from	resonance	663:671	arg1	results					633:639	results	633:639	results from nuclear magnetic resonance (NMR)	633:677	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	3	25	theme	1.433 kDa	470:478	arg1	weight					460:465	molecular weight	450:465	molecular weight of 1.433 kDa	450:478	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	7	26	theme	AMP1-1	945:950	arg1	activity					933:940	anti-WIBL activity	923:940	anti-WIBL activity of AMP1-1	923:950	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	3	27	with	glucose	424:430	arg1	weight					460:465	molecular weight	450:465	molecular weight of 1.433 kDa	450:478	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	8	28	contain	had	1176:1178	arg1	AMP1-1					1137:1142	the inulin-type fructan AMP1-1	1113:1142	the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7	1113:1174	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	8	28	contain	had	1176:1178	arg2	activity					1190:1197	anti-WIBL activity	1180:1197	anti-WIBL activity	1180:1197	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	7	29	theme	primary	1022:1028	arg1	osteoblasts					1030:1040	primary osteoblasts	1022:1040	primary osteoblasts	1022:1040	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	1	30	theme	Atractylodes	108:119	arg1	polysaccharides					135:149	Atractylodes macrocephalon polysaccharides	108:149	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL)	108:204	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL) are rarely reported.
35868743	3	31	theme	molecular	450:458	arg1	weight					460:465	molecular weight	450:465	molecular weight of 1.433 kDa	450:478	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	5	32	theme	α-d-Glcp-1→	729:739	arg1	AMP1-1					704:709	the inulin-type fructan AMP1-1	680:709	the inulin-type fructan AMP1-1	680:709	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	5	32	theme	α-d-Glcp-1→	729:739	arg1	2-β-d-Fruf-1					741:752	α-d-Glcp-1→(2-β-d-Fruf-1)7	729:754	α-d-Glcp-1→(2-β-d-Fruf-1)7	729:754	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	8	33	with	AMP1-1	1137:1142	arg1	2-β-d-Fruf-1					1161:1172	α-d-Glcp-1→(2-β-d-Fruf-1)7	1149:1174	α-d-Glcp-1→(2-β-d-Fruf-1)7	1149:1174	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	2	34	theme	neutral	244:250	arg1	fragment					267:274	a neutral polysaccharide fragment	242:274	a neutral polysaccharide fragment named AMP1-1	242:287	In this study, a neutral polysaccharide fragment named AMP1-1 was isolated and purified.
35868743	7	35	from	resorption	1008:1017	arg1	lines					1060:1064	RAW264.7 cell lines	1046:1064	RAW264.7 cell lines	1046:1064	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	7	35	from	resorption	1008:1017	arg1	osteoblasts					1030:1040	primary osteoblasts	1022:1040	primary osteoblasts	1022:1040	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	6	36	from	analyzation	807:817	arg1	femur					876:880	femur	876:880	femur	876:880	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	8	37	theme	α-d-Glcp-1→	1149:1159	arg1	2-β-d-Fruf-1					1161:1172	α-d-Glcp-1→(2-β-d-Fruf-1)7	1149:1174	α-d-Glcp-1→(2-β-d-Fruf-1)7	1149:1174	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	4	38	theme	gas	498:500	arg1	GCMS					536:539	GCMS	536:539	GCMS	536:539	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	4	38	theme	gas	498:500	arg1	spectrometer					522:533	gas chromatography-mass spectrometer	498:533	gas chromatography-mass spectrometer (GCMS)	498:540	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	6	39	theme	AMP1-1	779:784	arg1	activity					767:774	Anti-WIBL activity	757:774	Anti-WIBL activity of AMP1-1	757:784	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	8	40	theme	bone	1214:1217	arg1	homeostasis					1219:1229	remodeling bone homeostasis	1203:1229	remodeling bone homeostasis	1203:1229	In conclusion, the inulin-type fructan AMP1-1 with α-d-Glcp-1→(2-β-d-Fruf-1)7 had anti-WIBL activity via remodeling bone homeostasis.
35868743	5	41	theme	inulin-type	684:694	arg1	AMP1-1					704:709	the inulin-type fructan AMP1-1	680:709	the inulin-type fructan AMP1-1	680:709	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	5	41	theme	inulin-type	684:694	arg1	2-β-d-Fruf-1					741:752	α-d-Glcp-1→(2-β-d-Fruf-1)7	729:754	α-d-Glcp-1→(2-β-d-Fruf-1)7	729:754	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	0	42	from	macrocephala	50:61	arg1	fructan					15:21	An inulin-type fructan	0:21	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss	0:96	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	0	42	from	macrocephala	50:61	arg1	AMP1-1					24:29	AMP1-1	24:29	AMP1-1	24:29	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	0	43	with	fructan	15:21	arg1	loss					93:96	anti-weightlessness bone loss	68:96	anti-weightlessness bone loss	68:96	An inulin-type fructan (AMP1-1) from Atractylodes macrocephala with anti-weightlessness bone loss activity.
35868743	1	44	theme	macrocephalon	121:133	arg1	polysaccharides					135:149	Atractylodes macrocephalon polysaccharides	108:149	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL)	108:204	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL) are rarely reported.
35868743	5	45	theme	fructan	696:702	arg1	AMP1-1					704:709	the inulin-type fructan AMP1-1	680:709	the inulin-type fructan AMP1-1	680:709	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	5	45	theme	fructan	696:702	arg1	2-β-d-Fruf-1					741:752	α-d-Glcp-1→(2-β-d-Fruf-1)7	729:754	α-d-Glcp-1→(2-β-d-Fruf-1)7	729:754	Combining results from nuclear magnetic resonance (NMR), the inulin-type fructan AMP1-1 was identified as α-d-Glcp-1→(2-β-d-Fruf-1)7.
35868743	6	46	theme	5b	859:860	arg1	activities					862:871	TRAP 5b activities	854:871	TRAP 5b activities	854:871	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	7	47	theme	anti-WIBL	923:931	arg1	activity					933:940	anti-WIBL activity	923:940	anti-WIBL activity of AMP1-1	923:950	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	7	48	theme	RAW264.7	1046:1053	arg1	lines					1060:1064	RAW264.7 cell lines	1046:1064	RAW264.7 cell lines	1046:1064	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	6	49	theme	TRAP	854:857	arg1	activities					862:871	TRAP 5b activities	854:871	TRAP 5b activities	854:871	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	6	50	theme	Anti-WIBL	757:765	arg1	activity					767:774	Anti-WIBL activity	757:774	Anti-WIBL activity of AMP1-1	757:784	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	3	51	theme	Monosaccharide	316:329	arg1	composition					331:341	Monosaccharide composition	316:341	Monosaccharide composition	316:341	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	7	52	theme	bone	1003:1006	arg1	resorption					1008:1017	bone resorption	1003:1017	bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness	1003:1095	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35868743	3	53	theme	chromatography	362:375	arg1	analysis					377:384	gel permeation chromatography analysis	347:384	gel permeation chromatography analysis	347:384	Monosaccharide composition and gel permeation chromatography analysis indicated that AMP1-1 was composed of glucose and fructose with molecular weight of 1.433 kDa.
35868743	6	54	theme	BALP	845:848	arg1	analyzation					807:817	analyzation	807:817	analyzation of mechanical properties, BALP and TRAP 5b activities on femur	807:880	Anti-WIBL activity of AMP1-1 was evaluated though analyzation of mechanical properties, BALP and TRAP 5b activities on femur.
35868743	1	55	theme	weightlessness-induced	166:187	arg1	WIBL					200:203	WIBL	200:203	WIBL	200:203	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL) are rarely reported.
35868743	1	55	theme	weightlessness-induced	166:187	arg1	loss					194:197	weightlessness-induced bone loss	166:197	weightlessness-induced bone loss (WIBL)	166:204	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL) are rarely reported.
35868743	4	56	dep	α-d-Glcp-	574:582	arg1	1→					584:585	1→	584:585	1→	584:585	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	4	56	dep	α-d-Glcp-	574:582	arg1	→1					591:592	→1	591:592	→1	591:592	Based on data of gas chromatography-mass spectrometer (GCMS), a linear backbone consisted of α-d-Glcp-(1→ and →1)-β-d-Fruf-2→ was discovered.
35868743	2	57	theme	polysaccharide	252:265	arg1	fragment					267:274	a neutral polysaccharide fragment	242:274	a neutral polysaccharide fragment named AMP1-1	242:287	In this study, a neutral polysaccharide fragment named AMP1-1 was isolated and purified.
35868743	1	58	theme	bone	189:192	arg1	WIBL					200:203	WIBL	200:203	WIBL	200:203	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL) are rarely reported.
35868743	1	58	theme	bone	189:192	arg1	loss					194:197	weightlessness-induced bone loss	166:197	weightlessness-induced bone loss (WIBL)	166:204	Atractylodes macrocephalon polysaccharides of alleviating weightlessness-induced bone loss (WIBL) are rarely reported.
35868743	7	59	theme	mRNA	892:895	arg1	expression					897:906	In vitro mRNA expression	883:906	In vitro mRNA expression	883:906	In vitro mRNA expression indicated that anti-WIBL activity of AMP1-1 was achieved by promote bone formation and inhibit bone resorption in primary osteoblasts and RAW264.7 cell lines under simulated weightlessness.
35551950	0	0	theme	carboxymethyl	84:96	arg1	cellulose					98:106	sodium carboxymethyl cellulose	77:106	sodium carboxymethyl cellulose	77:106	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	1	1	theme	fish	160:163	arg1	products					165:172	fish products	160:172	fish products	160:172	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	5	2	theme	strongest	906:914	arg1	bond					925:928	strongest hydrogen bond	906:928	strongest hydrogen bond	906:928	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	0	3	theme	sodium	77:82	arg1	cellulose					98:106	sodium carboxymethyl cellulose	77:106	sodium carboxymethyl cellulose	77:106	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	1	4	theme	products	165:172	arg1	growth					182:187	the growth	178:187	the growth of pathogenic bacteria	178:210	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	1	4	theme	products	165:172	arg1	spoilage					148:155	The spoilage	144:155	The spoilage of fish products	144:172	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	6	5	theme	protein	1124:1130	arg1	oxidation					1103:1111	the oxidation	1099:1111	the oxidation of fat and protein	1099:1130	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	3	6	theme	antibacterial	497:509	arg1	activities					527:536	The antibacterial and antioxidant activities	493:536	The antibacterial and antioxidant activities of NVP	493:543	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	1	7	theme	human	258:262	arg1	health					264:269	human health	258:269	human health	258:269	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	2	8	theme	packaging	473:481	arg1	material					483:490	an active packaging material	463:490	an active packaging material	463:490	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	5	9	theme	hydrogen	916:923	arg1	bond					925:928	strongest hydrogen bond	906:928	strongest hydrogen bond	906:928	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	2	10	theme	Nostoc	333:338	arg1	commune					340:346	Nostoc commune	333:346	Nostoc commune Vauch polysaccharides (NVP)	333:374	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	6	11	theme	NVP/CMC	946:952	arg1	coating					954:960	NVP/CMC coating	946:960	NVP/CMC coating	946:960	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	2	12	theme	active	466:471	arg1	material					483:490	an active packaging material	463:490	an active packaging material	463:490	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	5	13	theme	denser	885:890	arg1	structure					892:900	denser structure	885:900	denser structure	885:900	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	6	14	theme	shelf	992:996	arg1	life					998:1001	the shelf life	988:1001	the shelf life of salmon fillets	988:1019	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	7	15	theme	good	1222:1225	arg1	acceptance					1235:1244	good sensory acceptance	1222:1244	good sensory acceptance	1222:1244	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	5	16	theme	NVP	828:830	arg1	ratio					819:823	the ratio	815:823	the ratio of NVP to CMC	815:837	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	5	16	theme	NVP	828:830	arg1	1:3					843:845	1:3	843:845	1:3	843:845	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	5	17	theme	Physical	748:755	arg1	characterization					757:772	Physical characterization	748:772	Physical characterization of the coating solution	748:796	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	2	18	dep	commune	340:346	arg1	NVP					371:373	NVP	371:373	NVP	371:373	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	2	18	dep	commune	340:346	arg1	polysaccharides					354:368	Vauch polysaccharides	348:368	Nostoc commune Vauch polysaccharides (NVP)	333:374	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	6	19	theme	cold	1028:1031	arg1	storage					1033:1039	cold storage	1028:1039	cold storage	1028:1039	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	3	20	from	effects	612:618	arg1	fillets					645:651	salmon fillets	638:651	salmon fillets	638:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	5	21	theme	coating	781:787	arg1	solution					789:796	the coating solution	777:796	the coating solution	777:796	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	2	22	theme	mixed	438:442	arg1	coating					444:450	a mixed coating	436:450	a mixed coating to prepare an active packaging material	436:490	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	4	23	theme	antibacterial	706:718	arg1	activities					736:745	good antibacterial and antioxidant activities	701:745	good antibacterial and antioxidant activities	701:745	The results showed that NVP had good antibacterial and antioxidant activities.
35551950	6	24	theme	salmon	1006:1011	arg1	fillets					1013:1019	salmon fillets	1006:1019	salmon fillets	1006:1019	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	5	25	theme	solution	789:796	arg1	characterization					757:772	Physical characterization	748:772	Physical characterization of the coating solution	748:796	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	6	26	theme	microorganisms	1158:1171	arg1	growth					1148:1153	the growth	1144:1153	the growth of microorganisms	1144:1171	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	3	27	theme	NVP	541:543	arg1	properties					562:571	physicochemical properties	546:571	physicochemical properties of the mixed coating	546:592	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	27	theme	NVP	541:543	arg1	activities					527:536	The antibacterial and antioxidant activities	493:536	The antibacterial and antioxidant activities of NVP	493:543	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	27	theme	NVP	541:543	arg1	effects					612:618	preservative effects	599:618	preservative effects of the coating on salmon fillets	599:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	7	28	theme	salmon	1203:1208	arg1	fillets					1210:1216	the coated salmon fillets	1192:1216	the coated salmon fillets	1192:1216	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	7	29	theme	sensory	1227:1233	arg1	acceptance					1235:1244	good sensory acceptance	1222:1244	good sensory acceptance	1222:1244	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	0	30	theme	coating	25:31	arg1	Application					0:10	Application	0:10	Application of composite coating of Nostoc commune	0:49	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	0	31	theme	fillets	135:141	arg1	preservation					112:123	preservation	112:123	preservation of salmon fillets	112:141	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	8	32	theme	application	1302:1312	arg1	prospect					1314:1321	a broad application prospect	1294:1321	a broad application prospect	1294:1321	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	3	33	theme	antioxidant	515:525	arg1	activities					527:536	The antibacterial and antioxidant activities	493:536	The antibacterial and antioxidant activities of NVP	493:543	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	2	34	theme	sodium	391:396	arg1	CMC					423:425	CMC	423:425	CMC	423:425	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	2	34	theme	sodium	391:396	arg1	cellulose					412:420	sodium carboxymethyl cellulose	391:420	sodium carboxymethyl cellulose (CMC)	391:426	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	2	35	theme	carboxymethyl	398:410	arg1	CMC					423:425	CMC	423:425	CMC	423:425	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	2	35	theme	carboxymethyl	398:410	arg1	cellulose					412:420	sodium carboxymethyl cellulose	391:420	sodium carboxymethyl cellulose (CMC)	391:426	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	1	36	theme	fish	275:278	arg1	preservation					280:291	fish preservation	275:291	fish preservation	275:291	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	0	37	theme	salmon	128:133	arg1	fillets					135:141	salmon fillets	128:141	salmon fillets	128:141	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	8	38	theme	products	1351:1358	arg1	preservation					1330:1341	the preservation	1326:1341	the preservation of fish products	1326:1358	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	4	39	theme	good	701:704	arg1	activities					736:745	good antibacterial and antioxidant activities	701:745	good antibacterial and antioxidant activities	701:745	The results showed that NVP had good antibacterial and antioxidant activities.
35551950	3	40	from	properties	562:571	arg1	fillets					645:651	salmon fillets	638:651	salmon fillets	638:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	1	41	theme	bacteria	203:210	arg1	growth					182:187	the growth	178:187	the growth of pathogenic bacteria	178:210	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	1	41	theme	bacteria	203:210	arg1	spoilage					148:155	The spoilage	144:155	The spoilage of fish products	144:172	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	0	42	theme	Nostoc	36:41	arg1	commune					43:49	Nostoc commune	36:49	Nostoc commune	36:49	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	4	43	contain	had	697:699	arg1	NVP					693:695	NVP	693:695	NVP	693:695	The results showed that NVP had good antibacterial and antioxidant activities.
35551950	4	43	contain	had	697:699	arg2	activities					736:745	good antibacterial and antioxidant activities	701:745	good antibacterial and antioxidant activities	701:745	The results showed that NVP had good antibacterial and antioxidant activities.
35551950	8	44	theme	fish	1346:1349	arg1	products					1351:1358	fish products	1346:1358	fish products	1346:1358	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	8	45	theme	broad	1296:1300	arg1	prospect					1314:1321	a broad application prospect	1294:1321	a broad application prospect	1294:1321	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	6	46	theme	fat	1116:1118	arg1	oxidation					1103:1111	the oxidation	1099:1111	the oxidation of fat and protein	1099:1130	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	7	47	theme	coated	1196:1201	arg1	fillets					1210:1216	the coated salmon fillets	1192:1216	the coated salmon fillets	1192:1216	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	7	48	contain	had	1218:1220	arg1	fillets					1210:1216	the coated salmon fillets	1192:1216	the coated salmon fillets	1192:1216	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	7	48	contain	had	1218:1220	arg2	acceptance					1235:1244	good sensory acceptance	1222:1244	good sensory acceptance	1222:1244	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	1	49	theme	great	218:222	arg1	loss					233:236	great economic loss	218:236	great economic loss	218:236	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	8	50	theme	edible	1275:1280	arg1	coating					1282:1288	the edible coating	1271:1288	the edible coating	1271:1288	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	3	51	theme	preservative	599:610	arg1	effects					612:618	preservative effects	599:618	preservative effects of the coating on salmon fillets	599:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	6	52	dep	reducing	1044:1051	arg1	improving					1057:1065	improving	1057:1065	improving the color and texture	1057:1087	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	6	52	dep	reducing	1044:1051	arg1	delaying					1090:1097	delaying	1090:1097	delaying the oxidation of fat and protein	1090:1130	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	6	52	dep	reducing	1044:1051	arg1	inhibiting					1133:1142	inhibiting	1133:1142	inhibiting the growth of microorganisms	1133:1171	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	0	53	theme	commune	43:49	arg1	coating					25:31	composite coating	15:31	composite coating of Nostoc commune	15:49	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	1	54	theme	important	301:309	arg1	issue					311:315	very important issue	296:315	very important issue	296:315	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	3	55	theme	physicochemical	546:560	arg1	properties					562:571	physicochemical properties	546:571	physicochemical properties of the mixed coating	546:592	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	56	theme	mixed	580:584	arg1	coating					586:592	the mixed coating	576:592	the mixed coating	576:592	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	57	theme	salmon	638:643	arg1	fillets					645:651	salmon fillets	638:651	salmon fillets	638:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	58	theme	coating	586:592	arg1	properties					562:571	physicochemical properties	546:571	physicochemical properties of the mixed coating	546:592	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	58	theme	coating	586:592	arg1	activities					527:536	The antibacterial and antioxidant activities	493:536	The antibacterial and antioxidant activities of NVP	493:543	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	58	theme	coating	586:592	arg1	effects					612:618	preservative effects	599:618	preservative effects of the coating on salmon fillets	599:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	5	59	contain	had	860:862	arg2	dispersion					873:882	dispersion	873:882	dispersion	873:882	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	5	59	contain	had	860:862	arg1	coating					852:858	the coating	848:858	the coating	848:858	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	5	59	contain	had	860:862	arg2	bond					925:928	strongest hydrogen bond	906:928	strongest hydrogen bond	906:928	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	5	59	contain	had	860:862	arg2	structure					892:900	denser structure	885:900	denser structure	885:900	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	5	60	theme	best	868:871	arg1	dispersion					873:882	dispersion	873:882	dispersion	873:882	Physical characterization of the coating solution showed that when the ratio of NVP to CMC was 1:3, the coating had the best dispersion, denser structure and strongest hydrogen bond.
35551950	3	61	from	activities	527:536	arg1	fillets					645:651	salmon fillets	638:651	salmon fillets	638:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	1	62	theme	economic	224:231	arg1	loss					233:236	great economic loss	218:236	great economic loss	218:236	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	4	63	theme	antioxidant	724:734	arg1	activities					736:745	good antibacterial and antioxidant activities	701:745	good antibacterial and antioxidant activities	701:745	The results showed that NVP had good antibacterial and antioxidant activities.
35551950	7	64	theme	same	1181:1184	arg1	time					1186:1189	the same time	1177:1189	the same time	1177:1189	At the same time, the coated salmon fillets had good sensory acceptance.
35551950	3	65	theme	coating	627:633	arg1	properties					562:571	physicochemical properties	546:571	physicochemical properties of the mixed coating	546:592	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	65	theme	coating	627:633	arg1	activities					527:536	The antibacterial and antioxidant activities	493:536	The antibacterial and antioxidant activities of NVP	493:543	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	3	65	theme	coating	627:633	arg1	effects					612:618	preservative effects	599:618	preservative effects of the coating on salmon fillets	599:651	The antibacterial and antioxidant activities of NVP, physicochemical properties of the mixed coating, and preservative effects of the coating on salmon fillets were evaluated.
35551950	1	66	theme	pathogenic	192:201	arg1	bacteria					203:210	pathogenic bacteria	192:210	pathogenic bacteria	192:210	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35551950	2	67	theme	Vauch	348:352	arg1	NVP					371:373	NVP	371:373	NVP	371:373	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	2	67	theme	Vauch	348:352	arg1	polysaccharides					354:368	Vauch polysaccharides	348:368	Nostoc commune Vauch polysaccharides (NVP)	333:374	In this study, Nostoc commune Vauch polysaccharides (NVP) was added into sodium carboxymethyl cellulose (CMC) to form a mixed coating to prepare an active packaging material.
35551950	6	68	theme	fillets	1013:1019	arg1	life					998:1001	the shelf life	988:1001	the shelf life of salmon fillets	988:1019	On this basis, NVP/CMC coating can significantly prolong the shelf life of salmon fillets during cold storage by reducing pH, improving the color and texture, delaying the oxidation of fat and protein, inhibiting the growth of microorganisms.
35551950	8	69	contain	has	1290:1292	arg2	prospect					1314:1321	a broad application prospect	1294:1321	a broad application prospect	1294:1321	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	8	69	contain	has	1290:1292	arg1	coating					1282:1288	the edible coating	1271:1288	the edible coating	1271:1288	The results showed that the edible coating has a broad application prospect in the preservation of fish products.
35551950	0	70	theme	composite	15:23	arg1	coating					25:31	composite coating	15:31	composite coating of Nostoc commune	15:49	Application of composite coating of Nostoc commune Vauch polysaccharides and sodium carboxymethyl cellulose for preservation of salmon fillets.
35551950	1	71	theme	serious	242:248	arg1	harm					250:253	serious harm	242:253	serious harm	242:253	The spoilage of fish products and the growth of pathogenic bacteria cause great economic loss and serious harm to human health, so fish preservation is very important issue.
35550780	0	0	theme	dextran	78:84	arg1	Effect					0:5	Effect	0:5	Effect of water sorption on glass transition	0:43	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	0	0	theme	dextran	78:84	arg1	variation					65:73	microstructural variation	49:73	microstructural variation of dextran	49:84	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	2	1	theme	water	494:498	arg1	sorption					500:507	water sorption	494:507	water sorption	494:507	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	1	2	theme	model	132:136	arg1	Dextran					104:110	Dextran	104:110	Dextran	104:110	Dextran is widely used as a model polysaccharide to study the interactions between polysaccharides and small molecule sugars.
35550780	1	2	theme	model	132:136	arg1	polysaccharide					138:151	a model polysaccharide	130:151	a model polysaccharide to study the interactions between polysaccharides and small molecule sugars	130:227	Dextran is widely used as a model polysaccharide to study the interactions between polysaccharides and small molecule sugars.
35550780	7	3	from	changes	997:1003	arg1	mixtures					1032:1039	the mixtures	1028:1039	the mixtures	1028:1039	Furthermore, trehalose and lactose were more effective in preventing morphological changes of hydrous matrices in the mixtures.
35550780	8	4	from	humidity	1089:1096	arg1	crystallinities					1046:1060	The crystallinities	1042:1060	The crystallinities of samples at 43% relative humidity (RH)	1042:1101	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	8	4	from	humidity	1089:1096	arg1	lower					1117:1121	lower	1117:1121	lower	1117:1121	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	2	5	with	temperatures	296:307	arg1	trehalose					342:350	trehalose	342:350	trehalose	342:350	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	5	with	temperatures	296:307	arg1	sucrose					365:371	sucrose	365:371	sucrose	365:371	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	5	with	temperatures	296:307	arg1	lactose					353:359	lactose	353:359	lactose	353:359	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	0	6	theme	sugar	88:92	arg1	mixtures					94:101	sugar mixtures	88:101	sugar mixtures	88:101	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	0	7	from	Effect	0:5	arg1	transition					34:43	glass transition	28:43	glass transition	28:43	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	2	8	theme	transition	285:294	arg1	temperatures					296:307	glass transition temperatures	279:307	glass transition temperatures	279:307	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	9	theme	glass	279:283	arg1	temperatures					296:307	glass transition temperatures	279:307	glass transition temperatures	279:307	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	6	10	theme	Gordon-Taylor	836:848	arg1	model					850:854	Gordon-Taylor model	836:854	Gordon-Taylor model	836:854	Gordon-Taylor model showed dex&tre (2:1) best inhibited water plasticization.
35550780	5	11	theme	disaccharides	789:801	arg1	compatibility					760:772	The compatibility	756:772	The compatibility of dextran and disaccharides	756:801	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	5	11	theme	disaccharides	789:801	arg1	dex&suc					827:833	dex&tre > dex&lac > dex&suc	807:833	dex&tre > dex&lac > dex&suc	807:833	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	2	12	theme	relevant	482:489	arg1	adaptation					447:456	dextran's processing adaptation	426:456	dextran's processing adaptation	426:456	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	4	13	theme	constant	720:727	arg1	value					733:737	the Guggenheim constant (C) value	705:737	the Guggenheim constant (C) value of the mixtures	705:753	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	4	13	theme	constant	720:727	arg1	ratios					671:676	The higher ratios	660:676	The higher ratios of dextran, the higher	660:699	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	1	14	used	used	122:125	arg2	polysaccharide					138:151	a model polysaccharide	130:151	a model polysaccharide to study the interactions between polysaccharides and small molecule sugars	130:227	Dextran is widely used as a model polysaccharide to study the interactions between polysaccharides and small molecule sugars.
35550780	1	14	used	used	122:125	arg2	Dextran					104:110	Dextran	104:110	Dextran	104:110	Dextran is widely used as a model polysaccharide to study the interactions between polysaccharides and small molecule sugars.
35550780	8	15	theme	samples	1065:1071	arg1	crystallinities					1046:1060	The crystallinities	1042:1060	The crystallinities of samples at 43% relative humidity (RH)	1042:1101	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	8	15	theme	samples	1065:1071	arg1	lower					1117:1121	lower	1117:1121	lower	1117:1121	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	5	16	theme	dex&tre > dex&lac	807:823	arg1	dex&suc					827:833	dex&tre > dex&lac > dex&suc	807:833	dex&tre > dex&lac > dex&suc	807:833	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	5	16	theme	dex&tre > dex&lac	807:823	arg1	compatibility					760:772	The compatibility	756:772	The compatibility of dextran and disaccharides	756:801	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	2	17	theme	processing	436:445	arg1	adaptation					447:456	dextran's processing adaptation	426:456	dextran's processing adaptation	426:456	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	6	18	dep	showed	856:861	arg1	inhibited					882:890	inhibited	882:890	showed dex&tre (2:1) best inhibited water plasticization	856:911	Gordon-Taylor model showed dex&tre (2:1) best inhibited water plasticization.
35550780	4	19	theme	Guggenheim	709:718	arg1	C					730:730	C	730:730	C	730:730	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	4	19	theme	Guggenheim	709:718	arg1	constant					720:727	Guggenheim constant	709:727	the Guggenheim constant (C) value of the mixtures	705:753	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	5	20	theme	>	825:825	arg1	dex&suc					827:833	dex&tre > dex&lac > dex&suc	807:833	dex&tre > dex&lac > dex&suc	807:833	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	5	20	theme	>	825:825	arg1	compatibility					760:772	The compatibility	756:772	The compatibility of dextran and disaccharides	756:801	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	0	21	theme	sorption	16:23	arg1	Effect					0:5	Effect	0:5	Effect of water sorption on glass transition	0:43	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	0	21	theme	sorption	16:23	arg1	variation					65:73	microstructural variation	49:73	microstructural variation of dextran	49:84	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	4	22	theme	mixtures	746:753	arg1	value					733:737	the Guggenheim constant (C) value	705:737	the Guggenheim constant (C) value of the mixtures	705:753	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	4	22	theme	mixtures	746:753	arg1	ratios					671:676	The higher ratios	660:676	The higher ratios of dextran, the higher	660:699	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	0	23	theme	water	10:14	arg1	sorption					16:23	water sorption	10:23	water sorption	10:23	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	3	24	theme	dex&tre	620:626	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	24	theme	dex&tre	620:626	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	0	25	theme	glass	28:32	arg1	transition					34:43	glass transition	28:43	glass transition	28:43	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	4	26	theme	higher	664:669	arg1	value					733:737	the Guggenheim constant (C) value	705:737	the Guggenheim constant (C) value of the mixtures	705:753	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	4	26	theme	higher	664:669	arg1	ratios					671:676	The higher ratios	660:676	The higher ratios of dextran, the higher	660:699	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	7	27	theme	matrices	1016:1023	arg1	changes					997:1003	morphological changes	983:1003	morphological changes of hydrous matrices in the mixtures	983:1039	Furthermore, trehalose and lactose were more effective in preventing morphological changes of hydrous matrices in the mixtures.
35550780	5	28	theme	dextran	777:783	arg1	compatibility					760:772	The compatibility	756:772	The compatibility of dextran and disaccharides	756:801	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	5	28	theme	dextran	777:783	arg1	dex&suc					827:833	dex&tre > dex&lac > dex&suc	807:833	dex&tre > dex&lac > dex&suc	807:833	The compatibility of dextran and disaccharides was dex&tre > dex&lac > dex&suc.
35550780	3	29	theme	sucrose	579:585	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	29	theme	sucrose	579:585	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	2	30	theme	different	395:403	arg1	disaccharides					405:417	different disaccharides	395:417	different disaccharides	395:417	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	8	31	theme	%	1138:1138	arg1	RH					1140:1141	11% RH	1136:1141	11% RH	1136:1141	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	6	32	theme	water	892:896	arg1	plasticization					898:911	water plasticization	892:911	water plasticization	892:911	Gordon-Taylor model showed dex&tre (2:1) best inhibited water plasticization.
35550780	3	33	theme	&	607:607	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	33	theme	&	607:607	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	0	34	from	variation	65:73	arg1	transition					34:43	glass transition	28:43	glass transition	28:43	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	8	35	theme	11	1136:1137	arg1	%					1138:1138	%	1138:1138	%	1138:1138	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	1	36	theme	small	207:211	arg1	sugars					222:227	small molecule sugars	207:227	small molecule sugars	207:227	Dextran is widely used as a model polysaccharide to study the interactions between polysaccharides and small molecule sugars.
35550780	2	37	theme	storage	462:468	arg1	performance					470:480	storage performance	462:480	storage performance	462:480	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	8	38	theme	relative	1080:1087	arg1	RH					1099:1100	RH	1099:1100	RH	1099:1100	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	8	38	theme	relative	1080:1087	arg1	humidity					1089:1096	43% relative humidity	1076:1096	43% relative humidity (RH)	1076:1101	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	3	39	theme	dextran	569:575	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	39	theme	dextran	569:575	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	8	40	theme	%	1078:1078	arg1	RH					1099:1100	RH	1099:1100	RH	1099:1100	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	8	40	theme	%	1078:1078	arg1	humidity					1089:1096	43% relative humidity	1076:1096	43% relative humidity (RH)	1076:1101	The crystallinities of samples at 43% relative humidity (RH) were slightly lower than that at 11% RH.
35550780	2	41	theme	dextran	329:335	arg1	mixtures					317:324	mixtures	317:324	mixtures of dextran	317:335	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	7	42	theme	hydrous	1008:1014	arg1	matrices					1016:1023	hydrous matrices	1008:1023	hydrous matrices	1008:1023	Furthermore, trehalose and lactose were more effective in preventing morphological changes of hydrous matrices in the mixtures.
35550780	3	43	theme	&	577:577	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	43	theme	&	577:577	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	44	theme	trehalose	609:617	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	44	theme	trehalose	609:617	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	4	45	theme	dextran	681:687	arg1	value					733:737	the Guggenheim constant (C) value	705:737	the Guggenheim constant (C) value of the mixtures	705:753	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	4	45	theme	dextran	681:687	arg1	ratios					671:676	The higher ratios	660:676	The higher ratios of dextran, the higher	660:699	The higher ratios of dextran, the higher was the Guggenheim constant (C) value of the mixtures.
35550780	7	46	theme	morphological	983:995	arg1	changes					997:1003	morphological changes	983:1003	morphological changes of hydrous matrices in the mixtures	983:1039	Furthermore, trehalose and lactose were more effective in preventing morphological changes of hydrous matrices in the mixtures.
35550780	3	47	theme	 > dextran	596:605	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	47	theme	 > dextran	596:605	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	2	48	theme	sorption	256:263	arg1	isotherms					265:273	water sorption isotherms	250:273	water sorption isotherms	250:273	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	48	theme	sorption	256:263	arg1	Tg					310:311	Tg	310:311	Tg	310:311	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	49	theme	mixtures	317:324	arg1	isotherms					265:273	water sorption isotherms	250:273	water sorption isotherms	250:273	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	49	theme	mixtures	317:324	arg1	Tg					310:311	Tg	310:311	Tg	310:311	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	49	theme	mixtures	317:324	arg1	temperatures					296:307	glass transition temperatures	279:307	glass transition temperatures	279:307	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	1	50	theme	molecule	213:220	arg1	sugars					222:227	small molecule sugars	207:227	small molecule sugars	207:227	Dextran is widely used as a model polysaccharide to study the interactions between polysaccharides and small molecule sugars.
35550780	3	51	theme	 > dextran	628:637	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	51	theme	 > dextran	628:637	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	2	52	theme	water	250:254	arg1	isotherms					265:273	water sorption isotherms	250:273	water sorption isotherms	250:273	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	52	theme	water	250:254	arg1	Tg					310:311	Tg	310:311	Tg	310:311	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	53	with	isotherms	265:273	arg1	trehalose					342:350	trehalose	342:350	trehalose	342:350	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	53	with	isotherms	265:273	arg1	sucrose					365:371	sucrose	365:371	sucrose	365:371	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	2	53	with	isotherms	265:273	arg1	lactose					353:359	lactose	353:359	lactose	353:359	This study examined water sorption isotherms and glass transition temperatures (Tg) of mixtures of dextran with trehalose, lactose and sucrose for understanding how different disaccharides affect dextran's processing adaptation and storage performance relevant to water sorption.
35550780	3	54	theme	&	639:639	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	54	theme	&	639:639	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	55	theme	dex&suc	588:594	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	55	theme	dex&suc	588:594	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	56	theme	same	517:520	arg1	composition					531:541	the same chemical composition	513:541	the same chemical composition	513:541	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	0	57	theme	microstructural	49:63	arg1	variation					65:73	microstructural variation	49:73	microstructural variation of dextran	49:84	Effect of water sorption on glass transition and microstructural variation of dextran & sugar mixtures.
35550780	3	58	theme	monolayer	544:552	arg1	m0					561:562	m0	561:562	m0	561:562	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	58	theme	monolayer	544:552	arg1	water					554:558	monolayer water	544:558	monolayer water (m0)	544:563	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	59	theme	chemical	522:529	arg1	composition					531:541	the same chemical composition	513:541	the same chemical composition	513:541	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	60	from	composition	531:541	arg1	dex&lac					650:656	dex&lac	650:656	dex&lac	650:656	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
35550780	3	60	from	composition	531:541	arg1	lactose					641:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose	569:647	dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac)	569:657	At the same chemical composition, monolayer water (m0) was dextran & sucrose (dex&suc) > dextran & trehalose (dex&tre) > dextran & lactose (dex&lac).
36858091	5	0	from	differences	896:906	arg1	intra-species					922:934	intra-species	922:934	intra-species	922:934	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	5	0	from	differences	896:906	arg1	inter-					911:916	inter-	911:916	inter-	911:916	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	6	1	theme	Fritillaria	992:1002	arg1	species					1004:1010	Fritillaria species	992:1010	Fritillaria species	992:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	8	2	theme	gastrointestinal	1536:1551	arg1	diseases					1553:1560	gastrointestinal diseases	1536:1560	gastrointestinal diseases	1536:1560	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	0	3	from	profiling	12:20	arg1	species					88:94	Fritillaria species	76:94	Fritillaria species	76:94	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	1	4	from	effect	171:176	arg1	species					214:220	Fritillaria species	202:220	Fritillaria species	202:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	6	5	theme	glucose	1167:1173	arg1	content					1175:1181	glucose content	1167:1181	glucose content	1167:1181	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	6	theme	polysaccharides	1078:1092	arg1	content					1094:1100	higher total polysaccharides content	1065:1100	higher total polysaccharides content	1065:1100	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	3	7	theme	gut	400:402	arg1	effect					426:431	the gut microbiota regulation effect	396:431	the gut microbiota regulation effect of polysaccharides among different species	396:474	Furthermore, the gut microbiota regulation effect of polysaccharides among different species was analyzed and evaluated.
36858091	4	8	theme	polysaccharides	570:584	arg1	IR					533:534	IR	533:534	IR	533:534	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	8	theme	polysaccharides	570:584	arg1	distribution					554:565	molecular weight distribution	537:565	molecular weight distribution of polysaccharides	537:584	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	9	theme	polysaccharides	685:699	arg1	similar					724:730	similar	724:730	similar	724:730	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	9	theme	polysaccharides	685:699	arg1	profiling					520:528	The fingerprint profiling	504:528	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides)	504:717	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	3	10	theme	microbiota	404:413	arg1	effect					426:431	the gut microbiota regulation effect	396:431	the gut microbiota regulation effect of polysaccharides among different species	396:474	Furthermore, the gut microbiota regulation effect of polysaccharides among different species was analyzed and evaluated.
36858091	6	11	theme	higher	1065:1070	arg1	content					1094:1100	higher total polysaccharides content	1065:1100	higher total polysaccharides content	1065:1100	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	8	12	theme	community	1415:1423	arg1	richness					1425:1432	the bacterial community richness	1401:1432	the bacterial community richness	1401:1432	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	2	13	theme	data	370:373	arg1	fusion					375:380	data fusion	370:380	data fusion	370:380	In this study, polysaccharides extracted from ten Fritillaria species were compared and distinguished through multi-levels evaluation strategy and data fusion.
36858091	5	14	theme	oligosaccharides	823:838	arg1	abundance					840:848	oligosaccharides abundance	823:848	oligosaccharides abundance	823:848	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	4	15	theme	IR	533:534	arg1	similar					724:730	similar	724:730	similar	724:730	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	15	theme	IR	533:534	arg1	profiling					520:528	The fingerprint profiling	504:528	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides)	504:717	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	8	16	contain	possessed	1493:1501	arg2	effects					1525:1531	potential therapeutic effects	1503:1531	potential therapeutic effects on gastrointestinal diseases and nervous system diseases	1503:1588	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	8	16	contain	possessed	1493:1501	arg1	polysaccharides					1370:1384	Fritillaria polysaccharides	1358:1384	Fritillaria polysaccharides	1358:1384	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	1	17	theme	polysaccharides	181:195	arg1	effect					171:176	the quality evaluation and gut microbiota regulation effect	118:176	the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species	118:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	4	18	theme	hydrolyzed	674:683	arg1	monosaccharides					702:716	monosaccharides	702:716	monosaccharides	702:716	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	18	theme	hydrolyzed	674:683	arg1	polysaccharides					685:699	completely hydrolyzed polysaccharides	663:699	completely hydrolyzed polysaccharides (monosaccharides)	663:717	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	0	19	from	regulation	41:50	arg1	species					88:94	Fritillaria species	76:94	Fritillaria species	76:94	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	7	20	theme	data	1211:1214	arg1	model					1223:1227	data fusion model	1211:1227	data fusion model	1211:1227	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	7	20	theme	data	1211:1214	arg1	Meanwhile					1200:1208	Meanwhile	1200:1208	Meanwhile	1200:1208	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	3	21	theme	polysaccharides	436:450	arg1	effect					426:431	the gut microbiota regulation effect	396:431	the gut microbiota regulation effect of polysaccharides among different species	396:474	Furthermore, the gut microbiota regulation effect of polysaccharides among different species was analyzed and evaluated.
36858091	4	22	theme	exclusive	740:748	arg1	signals					750:756	no exclusive signals	737:756	no exclusive signals	737:756	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	7	23	theme	multi-original	1279:1292	arg1	species					1294:1300	affinis and multi-original species	1267:1300	affinis and multi-original species	1267:1300	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	4	24	theme	molecular	537:545	arg1	IR					533:534	IR	533:534	IR	533:534	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	24	theme	molecular	537:545	arg1	distribution					554:565	molecular weight distribution	537:565	molecular weight distribution of polysaccharides	537:584	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	1	25	theme	Few	97:99	arg1	studies					101:107	Few studies	97:107	Few studies	97:107	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	1	26	theme	Fritillaria	202:212	arg1	species					214:220	Fritillaria species	202:220	Fritillaria species	202:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	0	27	theme	Fingerprint	0:10	arg1	profiling					12:20	Fingerprint profiling	0:20	Fingerprint profiling	0:20	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	6	28	from	species	1004:1010	arg1	CIRR					1013:1016	CIRR	1013:1016	CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others	1013:1197	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	28	from	species	1004:1010	arg1	component					960:968	the main component	951:968	the main component of polysaccharides in Fritillaria species	951:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	28	from	species	1004:1010	arg1	Glucan					937:942	Glucan	937:942	Glucan	937:942	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	29	dep	UNI	1051:1053	arg1	PRZ					1036:1038	PRZ	1036:1038	PRZ	1036:1038	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	30	from	component	960:968	arg1	species					1004:1010	Fritillaria species	992:1010	Fritillaria species	992:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	31	theme	polysaccharides	973:987	arg1	CIRR					1013:1016	CIRR	1013:1016	CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others	1013:1197	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	31	theme	polysaccharides	973:987	arg1	component					960:968	the main component	951:968	the main component of polysaccharides in Fritillaria species	951:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	31	theme	polysaccharides	973:987	arg1	Glucan					937:942	Glucan	937:942	Glucan	937:942	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	0	32	theme	gut	26:28	arg1	regulation					41:50	gut microbiota regulation	26:50	gut microbiota regulation	26:50	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	4	33	theme	polysaccharides	624:638	arg1	similar					724:730	similar	724:730	similar	724:730	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	33	theme	polysaccharides	624:638	arg1	profiling					520:528	The fingerprint profiling	504:528	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides)	504:717	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	5	34	theme	signal	786:791	arg1	strength					793:800	the signal strength	782:800	the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion	782:879	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	2	35	theme	evaluation	346:355	arg1	strategy					357:364	multi-levels evaluation strategy	333:364	multi-levels evaluation strategy	333:364	In this study, polysaccharides extracted from ten Fritillaria species were compared and distinguished through multi-levels evaluation strategy and data fusion.
36858091	8	36	from	effects	1525:1531	arg1	diseases					1581:1588	nervous system diseases	1566:1588	nervous system diseases	1566:1588	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	8	36	from	effects	1525:1531	arg1	diseases					1553:1560	gastrointestinal diseases	1536:1560	gastrointestinal diseases	1536:1560	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	6	37	from	polysaccharides	973:987	arg1	species					1004:1010	Fritillaria species	992:1010	Fritillaria species	992:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	4	38	theme	fingerprint	508:518	arg1	similar					724:730	similar	724:730	similar	724:730	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	38	theme	fingerprint	508:518	arg1	profiling					520:528	The fingerprint profiling	504:528	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides)	504:717	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	2	39	theme	multi-levels	333:344	arg1	strategy					357:364	multi-levels evaluation strategy	333:364	multi-levels evaluation strategy	333:364	In this study, polysaccharides extracted from ten Fritillaria species were compared and distinguished through multi-levels evaluation strategy and data fusion.
36858091	5	40	theme	obvious	888:894	arg1	differences					896:906	obvious differences	888:906	obvious differences in inter- and intra-species	888:934	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	0	41	from	species	88:94	arg1	regulation					41:50	gut microbiota regulation	26:50	gut microbiota regulation	26:50	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	0	41	from	species	88:94	arg1	profiling					12:20	Fingerprint profiling	0:20	Fingerprint profiling	0:20	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	0	41	from	species	88:94	arg1	polysaccharides					55:69	polysaccharides	55:69	polysaccharides from Fritillaria species	55:94	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	6	42	attach	derived	1018:1024	arg1	DEL					1041:1043	DEL	1041:1043	DEL	1041:1043	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	42	attach	derived	1018:1024	arg1	UNI					1051:1053	UNI	1051:1053	UNI	1051:1053	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	42	attach	derived	1018:1024	arg2	CIRR					1013:1016	CIRR	1013:1016	CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others	1013:1197	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	42	attach	derived	1018:1024	arg2	component					960:968	the main component	951:968	the main component of polysaccharides in Fritillaria species	951:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	42	attach	derived	1018:1024	arg1	TAI					1046:1048	TAI	1046:1048	TAI	1046:1048	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	0	43	theme	microbiota	30:39	arg1	regulation					41:50	gut microbiota regulation	26:50	gut microbiota regulation	26:50	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	5	44	theme	functional	805:814	arg1	group					816:820	functional group	805:820	functional group	805:820	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	8	45	theme	nervous	1566:1572	arg1	diseases					1581:1588	nervous system diseases	1566:1588	nervous system diseases	1566:1588	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	3	46	theme	regulation	415:424	arg1	effect					426:431	the gut microbiota regulation effect	396:431	the gut microbiota regulation effect of polysaccharides among different species	396:474	Furthermore, the gut microbiota regulation effect of polysaccharides among different species was analyzed and evaluated.
36858091	5	47	theme	abundance	840:848	arg1	strength					793:800	the signal strength	782:800	the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion	782:879	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	0	48	theme	polysaccharides	55:69	arg1	regulation					41:50	gut microbiota regulation	26:50	gut microbiota regulation	26:50	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	0	48	theme	polysaccharides	55:69	arg1	profiling					12:20	Fingerprint profiling	0:20	Fingerprint profiling	0:20	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	5	49	theme	group	816:820	arg1	strength					793:800	the signal strength	782:800	the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion	782:879	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	4	50	theme	weight	547:552	arg1	IR					533:534	IR	533:534	IR	533:534	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	50	theme	weight	547:552	arg1	distribution					554:565	molecular weight distribution	537:565	molecular weight distribution of polysaccharides	537:584	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	1	51	theme	quality	122:128	arg1	evaluation					130:139	quality evaluation	122:139	quality evaluation	122:139	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	3	52	theme	different	458:466	arg1	species					468:474	different species	458:474	different species	458:474	Furthermore, the gut microbiota regulation effect of polysaccharides among different species was analyzed and evaluated.
36858091	4	53	theme	hydrolyzed	613:622	arg1	oligosaccharides					641:656	oligosaccharides	641:656	oligosaccharides	641:656	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	4	53	theme	hydrolyzed	613:622	arg1	polysaccharides					624:638	partially hydrolyzed polysaccharides	603:638	partially hydrolyzed polysaccharides (oligosaccharides)	603:657	The fingerprint profiling of IR, molecular weight distribution of polysaccharides, chromatogram of partially hydrolyzed polysaccharides (oligosaccharides) and completely hydrolyzed polysaccharides (monosaccharides) were similar, and no exclusive signals were observed.
36858091	6	54	theme	main	955:958	arg1	CIRR					1013:1016	CIRR	1013:1016	CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others	1013:1197	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	54	theme	main	955:958	arg1	component					960:968	the main component	951:968	the main component of polysaccharides in Fritillaria species	951:1010	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	54	theme	main	955:958	arg1	Glucan					937:942	Glucan	937:942	Glucan	937:942	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	1	55	theme	evaluation	130:139	arg1	effect					171:176	the quality evaluation and gut microbiota regulation effect	118:176	the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species	118:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	5	56	dep	group	816:820	arg1	proportion					870:879	proportion	870:879	proportion	870:879	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	8	57	theme	system	1574:1579	arg1	diseases					1581:1588	nervous system diseases	1566:1588	nervous system diseases	1566:1588	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	7	58	theme	fusion	1216:1221	arg1	model					1223:1227	data fusion model	1211:1227	data fusion model	1211:1227	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	7	58	theme	fusion	1216:1221	arg1	Meanwhile					1200:1208	Meanwhile	1200:1208	Meanwhile	1200:1208	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	8	59	theme	microbiota	1466:1475	arg1	composition					1477:1487	the gut microbiota composition	1458:1487	the gut microbiota composition	1458:1487	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	8	60	theme	gut	1462:1464	arg1	composition					1477:1487	the gut microbiota composition	1458:1487	the gut microbiota composition	1458:1487	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	6	61	theme	total	1072:1076	arg1	content					1094:1100	higher total polysaccharides content	1065:1100	higher total polysaccharides content	1065:1100	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	8	62	dep	potential	1503:1511	arg1	therapeutic					1513:1523	therapeutic	1513:1523	therapeutic	1513:1523	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	8	63	theme	potential	1503:1511	arg1	effects					1525:1531	potential therapeutic effects	1503:1531	potential therapeutic effects on gastrointestinal diseases and nervous system diseases	1503:1588	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	1	64	theme	gut	145:147	arg1	regulation					160:169	gut microbiota regulation	145:169	gut microbiota regulation	145:169	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	8	65	theme	bacterial	1405:1413	arg1	richness					1425:1432	the bacterial community richness	1401:1432	the bacterial community richness	1401:1432	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	0	66	theme	Fritillaria	76:86	arg1	species					88:94	Fritillaria species	76:94	Fritillaria species	76:94	Fingerprint profiling and gut microbiota regulation of polysaccharides from Fritillaria species.
36858091	6	67	theme	oligosaccharides	1126:1141	arg1	DP					1154:1155	DP 2-4	1154:1159	DP 2-4	1154:1159	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	6	67	theme	oligosaccharides	1126:1141	arg1	abundance					1143:1151	oligosaccharides abundance	1126:1151	oligosaccharides abundance (DP 2-4)	1126:1160	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	2	68	theme	Fritillaria	273:283	arg1	species					285:291	ten Fritillaria species	269:291	ten Fritillaria species	269:291	In this study, polysaccharides extracted from ten Fritillaria species were compared and distinguished through multi-levels evaluation strategy and data fusion.
36858091	1	69	from	species	214:220	arg1	polysaccharides					181:195	polysaccharides	181:195	polysaccharides from Fritillaria species	181:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	1	69	from	species	214:220	arg1	effect					171:176	the quality evaluation and gut microbiota regulation effect	118:176	the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species	118:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	1	70	theme	microbiota	149:158	arg1	regulation					160:169	gut microbiota regulation	145:169	gut microbiota regulation	145:169	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	8	71	theme	Fritillaria	1358:1368	arg1	polysaccharides					1370:1384	Fritillaria polysaccharides	1358:1384	Fritillaria polysaccharides	1358:1384	In addition, Fritillaria polysaccharides could increase the bacterial community richness and diversity, regulate the gut microbiota composition and possessed potential therapeutic effects on gastrointestinal diseases and nervous system diseases.
36858091	6	72	theme	polymerization	1103:1116	arg1	degree					1118:1123	polymerization degree	1103:1123	polymerization degree	1103:1123	Glucan may be the main component of polysaccharides in Fritillaria species, CIRR derived from CIR, PRZ, DEL, TAI, UNI possessed higher total polysaccharides content, polymerization degree, oligosaccharides abundance (DP 2-4), and glucose content than the others.
36858091	5	73	theme	monosaccharides	854:868	arg1	strength					793:800	the signal strength	782:800	the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion	782:879	However, the signal strength of functional group, oligosaccharides abundance and monosaccharides proportion showed obvious differences in inter- and intra-species.
36858091	7	74	theme	affinis	1267:1273	arg1	species					1294:1300	affinis and multi-original species	1267:1300	affinis and multi-original species	1267:1300	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	1	75	theme	regulation	160:169	arg1	effect					171:176	the quality evaluation and gut microbiota regulation effect	118:176	the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species	118:220	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides from Fritillaria species.
36858091	7	76	theme	species	1294:1300	arg1	accuracy					1307:1314	the accuracy	1303:1314	the accuracy	1303:1314	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	7	76	theme	species	1294:1300	arg1	identification					1249:1262	identification	1249:1262	identification of affinis and multi-original species, the accuracy of which proved to be 100 %	1249:1342	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36858091	7	76	theme	species	1294:1300	arg1	%					1342:1342	100 %	1338:1342	100 %	1338:1342	Meanwhile, data fusion model was established for identification of affinis and multi-original species, the accuracy of which proved to be 100 %.
36235191	0	0	theme	Dry	90:92	arg1	officinale					105:114	Fresh and Dry Dendrobium officinale	80:114	Fresh and Dry Dendrobium officinale	80:114	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	5	1	theme	liver	1135:1139	arg1	injury					1141:1146	CCl4-induced liver injury	1122:1146	CCl4-induced liver injury	1122:1146	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	6	2	theme	FDO	1251:1253	arg1	higher					1274:1279	higher	1274:1279	higher	1274:1279	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	6	2	theme	FDO	1251:1253	arg1	contents					1235:1242	the polysaccharide and mannose contents	1204:1242	contents	1235:1242	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	4	3	theme	increased	866:874	arg1	levels					905:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	3	4	contain	had	689:691	arg1	polysaccharides					673:687	its polysaccharides	669:687	its polysaccharides	669:687	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	3	4	contain	had	689:691	arg2	effects					710:716	more significant effects	693:716	more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals	693:764	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	3	4	contain	had	689:691	arg1	FDO					661:663	the FDO	657:663	the FDO	657:663	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	6	5	theme	molecular	1440:1448	arg1	weights					1450:1456	different molecular weights	1430:1456	different molecular weights in the DDO	1430:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	1	6	theme	Dendrobium	253:262	arg1	officinale					264:273	dried Dendrobium officinale	247:273	dried Dendrobium officinale	247:273	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	5	7	theme	protective	1067:1076	arg1	effect					1078:1083	the protective effect	1063:1083	the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury	1063:1146	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	1	8	theme	fresh	162:166	arg1	FDO					191:193	FDO	191:193	FDO	191:193	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	1	8	theme	fresh	162:166	arg1	officinale					179:188	fresh Dendrobium officinale	162:188	fresh Dendrobium officinale (FDO)	162:194	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	6	9	theme	different	1430:1438	arg1	weights					1450:1456	different molecular weights	1430:1456	different molecular weights in the DDO	1430:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	7	10	dep	FDO	1548:1550	arg1	the					1544:1546	the	1544:1546	the	1544:1546	Overall, our data identified differences in the antioxidant activities of the FDO and DDO, as well as the reasons for these differences.
36235191	0	11	theme	officinale	105:114	arg1	Comparison					0:9	Comparison	0:9	Comparison of the Antioxidant Activities	0:39	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	0	11	theme	officinale	105:114	arg1	Polysaccharide					45:58	Polysaccharide	45:58	Polysaccharide	45:58	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	6	12	from	polysaccharides	1351:1365	arg1	FDO					1374:1376	the FDO	1370:1376	the FDO	1370:1376	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	4	13	theme	peroxidation	842:853	arg1	levels					855:860	lipid peroxidation levels	836:860	lipid peroxidation levels	836:860	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	6	14	theme	polysaccharides	1174:1188	arg1	determination					1153:1165	The determination	1149:1165	The determination of the polysaccharides	1149:1188	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	7	15	theme	antioxidant	1518:1528	arg1	activities					1530:1539	the antioxidant activities	1514:1539	the antioxidant activities of the FDO and DDO	1514:1558	Overall, our data identified differences in the antioxidant activities of the FDO and DDO, as well as the reasons for these differences.
36235191	0	16	theme	Dendrobium	94:103	arg1	officinale					105:114	Fresh and Dry Dendrobium officinale	80:114	Fresh and Dry Dendrobium officinale	80:114	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	4	17	theme	lipid	836:840	arg1	peroxidation					842:853	lipid peroxidation	836:853	lipid peroxidation levels	836:860	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	0	18	dep	Kimura	116:121	arg1	Comparison					0:9	Comparison	0:9	Comparison of the Antioxidant Activities	0:39	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	0	18	dep	Kimura	116:121	arg1	Polysaccharide					45:58	Polysaccharide	45:58	Polysaccharide	45:58	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	0	18	dep	Kimura	116:121	arg1	Migo					126:129	Kimura et Migo	116:129	Kimura et Migo	116:129	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	4	19	theme	acute	925:929	arg1	damage					937:942	acute liver damage	925:942	acute liver damage caused by CCl4	925:957	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	2	20	theme	officinale	501:510	arg1	FDOPs					529:533	FDOPs	529:533	FDOPs	529:533	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	20	theme	officinale	501:510	arg1	polysaccharides					512:526	the fresh Dendrobium officinale polysaccharides	480:526	the fresh Dendrobium officinale polysaccharides (FDOPs)	480:534	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	5	21	theme	Histopathological	1019:1035	arg1	analysis					1037:1044	Histopathological analysis	1019:1044	Histopathological analysis	1019:1044	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	6	22	theme	mannose	1227:1233	arg1	higher					1274:1279	higher	1274:1279	higher	1274:1279	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	6	22	theme	mannose	1227:1233	arg1	contents					1235:1242	the polysaccharide and mannose contents	1204:1242	contents	1235:1242	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	1	23	theme	Dendrobium	168:177	arg1	FDO					191:193	FDO	191:193	FDO	191:193	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	1	23	theme	Dendrobium	168:177	arg1	officinale					179:188	fresh Dendrobium officinale	162:188	fresh Dendrobium officinale (FDO)	162:194	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	2	24	theme	Dendrobium	490:499	arg1	FDOPs					529:533	FDOPs	529:533	FDOPs	529:533	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	24	theme	Dendrobium	490:499	arg1	polysaccharides					512:526	the fresh Dendrobium officinale polysaccharides	480:526	the fresh Dendrobium officinale polysaccharides (FDOPs)	480:534	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	6	25	from	arrangement	1332:1342	arg1	FDO					1374:1376	the FDO	1370:1376	the FDO	1370:1376	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	4	26	theme	liver	931:935	arg1	damage					937:942	acute liver damage	925:942	acute liver damage caused by CCl4	925:957	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	4	27	theme	GSH	901:903	arg1	levels					905:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	2	28	theme	molecular	417:425	arg1	arrangement					434:444	the molecular weight arrangement	413:444	the molecular weight arrangement	413:444	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	3	29	theme	significant	698:708	arg1	effects					710:716	more significant effects	693:716	more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals	693:764	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	6	30	theme	polysaccharide	1208:1221	arg1	higher					1274:1279	higher	1274:1279	higher	1274:1279	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	6	30	theme	polysaccharide	1208:1221	arg1	contents					1235:1242	the polysaccharide and mannose contents	1204:1242	contents	1235:1242	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	2	31	theme	fresh	484:488	arg1	FDOPs					529:533	FDOPs	529:533	FDOPs	529:533	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	31	theme	fresh	484:488	arg1	polysaccharides					512:526	the fresh Dendrobium officinale polysaccharides	480:526	the fresh Dendrobium officinale polysaccharides (FDOPs)	480:534	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	5	32	theme	polysaccharides	1103:1117	arg1	effect					1078:1083	the protective effect	1063:1083	the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury	1063:1146	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	6	33	theme	polysaccharide	1402:1415	arg1	fragments					1417:1425	three polysaccharide fragments	1396:1425	three polysaccharide fragments of different molecular weights in the DDO	1396:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	7	34	from	reasons	1576:1582	arg1	activities					1530:1539	the antioxidant activities	1514:1539	the antioxidant activities of the FDO and DDO	1514:1558	Overall, our data identified differences in the antioxidant activities of the FDO and DDO, as well as the reasons for these differences.
36235191	2	35	theme	antioxidant	359:369	arg1	properties					371:380	their antioxidant properties	353:380	their antioxidant properties	353:380	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	0	36	theme	Antioxidant	18:28	arg1	Activities					30:39	the Antioxidant Activities	14:39	the Antioxidant Activities	14:39	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	5	37	theme	CCl4-induced	1122:1133	arg1	injury					1141:1146	CCl4-induced liver injury	1122:1146	CCl4-induced liver injury	1122:1146	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	3	38	theme	scavenging	721:730	arg1	ABTS					738:741	scavenging DPPH, ABTS, and hydroxyl radicals	721:764	ABTS	738:741	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	4	39	theme	SOD	880:882	arg1	levels					905:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	5	40	from	effect	1078:1083	arg1	injury					1141:1146	CCl4-induced liver injury	1122:1146	CCl4-induced liver injury	1122:1146	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	2	41	theme	monosaccharide	450:463	arg1	composition					465:475	monosaccharide composition	450:475	monosaccharide composition	450:475	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	3	42	theme	DPPH	732:735	arg1	ABTS					738:741	scavenging DPPH, ABTS, and hydroxyl radicals	721:764	ABTS	738:741	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	4	43	theme	CAT	892:894	arg1	levels					905:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	0	44	theme	Activities	30:39	arg1	Comparison					0:9	Comparison	0:9	Comparison of the Antioxidant Activities	0:39	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	0	44	theme	Activities	30:39	arg1	Polysaccharide					45:58	Polysaccharide	45:58	Polysaccharide	45:58	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	3	45	theme	hydroxyl	748:755	arg1	radicals					757:764	scavenging DPPH, ABTS, and hydroxyl radicals	721:764	radicals	757:764	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	4	46	theme	T-AOC	885:889	arg1	levels					905:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	increased the SOD, T-AOC, CAT, and GSH levels	866:910	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	6	47	theme	dried	1292:1296	arg1	counterparts					1298:1309	their dried counterparts	1286:1309	their dried counterparts	1286:1309	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	3	48	from	effects	710:716	arg1	ABTS					738:741	scavenging DPPH, ABTS, and hydroxyl radicals	721:764	ABTS	738:741	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	3	48	from	effects	710:716	arg1	radicals					757:764	scavenging DPPH, ABTS, and hydroxyl radicals	721:764	radicals	757:764	The results showed that the FDO and its polysaccharides had more significant effects on scavenging DPPH, ABTS, and hydroxyl radicals than the DDO.
36235191	1	49	theme	significant	205:215	arg1	activity					233:240	more significant pharmacological activity	200:240	more significant pharmacological activity than dried Dendrobium officinale	200:273	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	7	50	from	differences	1499:1509	arg1	activities					1530:1539	the antioxidant activities	1514:1539	the antioxidant activities of the FDO and DDO	1514:1558	Overall, our data identified differences in the antioxidant activities of the FDO and DDO, as well as the reasons for these differences.
36235191	2	51	theme	polysaccharides	572:586	arg1	arrangement					434:444	the molecular weight arrangement	413:444	the molecular weight arrangement	413:444	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	51	theme	polysaccharides	572:586	arg1	composition					465:475	monosaccharide composition	450:475	monosaccharide composition	450:475	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	52	theme	polysaccharides	512:526	arg1	arrangement					434:444	the molecular weight arrangement	413:444	the molecular weight arrangement	413:444	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	52	theme	polysaccharides	512:526	arg1	composition					465:475	monosaccharide composition	450:475	monosaccharide composition	450:475	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	4	53	with	mice	915:918	arg1	damage					937:942	acute liver damage	925:942	acute liver damage caused by CCl4	925:957	In addition, both the FDO and DDO significantly reduced lipid peroxidation levels and increased the SOD, T-AOC, CAT, and GSH levels in mice with acute liver damage caused by CCl4, while the FDO and its polysaccharides were more effective.
36235191	2	54	theme	weight	427:432	arg1	arrangement					434:444	the molecular weight arrangement	413:444	the molecular weight arrangement	413:444	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	5	55	theme	Dendrobium	1092:1101	arg1	polysaccharides					1103:1117	the Dendrobium polysaccharides	1088:1117	the Dendrobium polysaccharides	1088:1117	Histopathological analysis further verified the protective effect of the Dendrobium polysaccharides on CCl4-induced liver injury.
36235191	2	56	theme	officinale	561:570	arg1	DDOPs					589:593	DDOPs	589:593	DDOPs	589:593	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	56	theme	officinale	561:570	arg1	polysaccharides					572:586	the dried Dendrobium officinale polysaccharides	540:586	the dried Dendrobium officinale polysaccharides (DDOPs)	540:594	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	6	57	from	FDO	1374:1376	arg1	arrangement					1332:1342	the homogeneous arrangement	1316:1342	the homogeneous arrangement of the polysaccharides in the FDO	1316:1376	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	6	58	from	DDO	1465:1467	arg1	fragments					1417:1425	three polysaccharide fragments	1396:1425	three polysaccharide fragments of different molecular weights in the DDO	1396:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	6	59	from	fragments	1417:1425	arg1	DDO					1465:1467	the DDO	1461:1467	the DDO	1461:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	0	60	dep	Comparison	0:9	arg1	Characterization					60:75	Characterization	60:75	Characterization	60:75	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	2	61	theme	Dendrobium	550:559	arg1	DDOPs					589:593	DDOPs	589:593	DDOPs	589:593	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	61	theme	Dendrobium	550:559	arg1	polysaccharides					572:586	the dried Dendrobium officinale polysaccharides	540:586	the dried Dendrobium officinale polysaccharides (DDOPs)	540:594	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	7	62	theme	DDO	1556:1558	arg1	activities					1530:1539	the antioxidant activities	1514:1539	the antioxidant activities of the FDO and DDO	1514:1558	Overall, our data identified differences in the antioxidant activities of the FDO and DDO, as well as the reasons for these differences.
36235191	2	63	theme	dried	544:548	arg1	DDOPs					589:593	DDOPs	589:593	DDOPs	589:593	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	2	63	theme	dried	544:548	arg1	polysaccharides					572:586	the dried Dendrobium officinale polysaccharides	540:586	the dried Dendrobium officinale polysaccharides (DDOPs)	540:594	Our study compared their antioxidant properties both in vitro and in vivo, and the molecular weight arrangement and monosaccharide composition of the fresh Dendrobium officinale polysaccharides (FDOPs) and the dried Dendrobium officinale polysaccharides (DDOPs) were analyzed by HPLC-GPC and GC-MS.
36235191	1	64	contain	has	196:198	arg1	FDO					191:193	FDO	191:193	FDO	191:193	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	1	64	contain	has	196:198	arg1	officinale					179:188	fresh Dendrobium officinale	162:188	fresh Dendrobium officinale (FDO)	162:194	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	1	64	contain	has	196:198	arg2	activity					233:240	more significant pharmacological activity	200:240	more significant pharmacological activity than dried Dendrobium officinale	200:273	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	1	65	dep	significant	205:215	arg1	pharmacological					217:231	pharmacological	217:231	pharmacological	217:231	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	6	66	theme	homogeneous	1320:1330	arg1	arrangement					1332:1342	the homogeneous arrangement	1316:1342	the homogeneous arrangement of the polysaccharides in the FDO	1316:1376	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	0	67	theme	Fresh	80:84	arg1	officinale					105:114	Fresh and Dry Dendrobium officinale	80:114	Fresh and Dry Dendrobium officinale	80:114	Comparison of the Antioxidant Activities and Polysaccharide Characterization of Fresh and Dry Dendrobium officinale Kimura et Migo.
36235191	6	68	from	weights	1450:1456	arg1	DDO					1465:1467	the DDO	1461:1467	the DDO	1461:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	7	69	theme	FDO	1548:1550	arg1	activities					1530:1539	the antioxidant activities	1514:1539	the antioxidant activities of the FDO and DDO	1514:1558	Overall, our data identified differences in the antioxidant activities of the FDO and DDO, as well as the reasons for these differences.
36235191	6	70	theme	polysaccharides	1351:1365	arg1	arrangement					1332:1342	the homogeneous arrangement	1316:1342	the homogeneous arrangement of the polysaccharides in the FDO	1316:1376	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	1	71	dep	has	196:198	arg1	DDO					276:278	DDO	276:278	DDO	276:278	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
36235191	6	72	theme	weights	1450:1456	arg1	fragments					1417:1425	three polysaccharide fragments	1396:1425	three polysaccharide fragments of different molecular weights in the DDO	1396:1467	The determination of the polysaccharides revealed that the polysaccharide and mannose contents of the FDO were significantly higher than their dried counterparts, and the homogeneous arrangement of the polysaccharides in the FDO was degraded into three polysaccharide fragments of different molecular weights in the DDO.
36235191	1	73	theme	dried	247:251	arg1	officinale					264:273	dried Dendrobium officinale	247:273	dried Dendrobium officinale	247:273	It is generally believed that fresh Dendrobium officinale (FDO) has more significant pharmacological activity than dried Dendrobium officinale (DDO); however, the difference has not been clearly shown.
37224730	5	0	theme	several	729:735	arg1	types					752:756	several polysaccharide types	729:756	several polysaccharide types	729:756	Based on the sugar composition of the eluted fractions, several polysaccharide types were observed.
37224730	2	1	theme	ion-exchange	354:365	arg1	chromatography					367:380	ion-exchange chromatography	354:380	ion-exchange chromatography	354:380	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	4	2	theme	material	571:578	arg1	%					554:554	About 62%	546:554	About 62% of the applied material	546:578	About 62% of the applied material was recovered from the column, with a higher yield of the fractions eluted with 0.25 M NaCl.
37224730	4	2	theme	material	571:578	arg1	material					571:578	the applied material	559:578	the applied material	559:578	About 62% of the applied material was recovered from the column, with a higher yield of the fractions eluted with 0.25 M NaCl.
37224730	5	3	theme	polysaccharide	737:750	arg1	types					752:756	several polysaccharide types	729:756	several polysaccharide types	729:756	Based on the sugar composition of the eluted fractions, several polysaccharide types were observed.
37224730	1	4	theme	characterization	147:162	arg1	terms					134:138	terms	134:138	terms of the characterization of the natural biologically active polysaccharide complexes they contain	134:235	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	4	5	theme	applied	563:569	arg1	material					571:578	the applied material	559:578	the applied material	559:578	About 62% of the applied material was recovered from the column, with a higher yield of the fractions eluted with 0.25 M NaCl.
37224730	6	6	theme	esterified	876:885	arg1	homogalacturonan					887:902	highly esterified homogalacturonan	869:902	highly esterified homogalacturonan	869:902	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	7	theme	0.25 M	833:838	arg1	%					849:849	∼70%	846:849	∼70%	846:849	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	7	theme	0.25 M	833:838	arg1	NaCl					840:843	0.25 M NaCl	833:843	0.25 M NaCl (∼70%)	833:850	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	8	theme	galacturonic	932:943	arg1	acids					945:949	galacturonic acids	932:949	galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	932:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	7	9	theme	%	1142:1142	arg1	yield					1130:1134	a yield	1128:1134	a yield of ∼17%	1128:1142	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	2	10	with	elution	422:428	arg1	salts					435:439	salts	435:439	salts	435:439	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	6	11	theme	dominant	777:784	arg1	fractions					811:819	the fractions	807:819	the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics	807:1074	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	11	theme	dominant	777:784	arg1	components					786:795	The dominant components	773:795	The dominant components of Hw	773:801	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	3	12	theme	uronic	508:513	arg1	acids					515:519	uronic acids	508:519	uronic acids	508:519	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
37224730	7	13	theme	phenolic	1171:1178	arg1	compounds					1180:1188	phenolic compounds	1171:1188	phenolic compounds	1171:1188	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	2	14	theme	blackthorn	290:299	arg1	fruits					301:306	wild blackthorn fruits	285:306	wild blackthorn fruits	285:306	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	3	15	theme	purified	446:453	arg1	fractions					455:463	The purified fractions	442:463	The purified fractions	442:463	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
37224730	5	16	theme	eluted	711:716	arg1	fractions					718:726	the eluted fractions	707:726	the eluted fractions	707:726	Based on the sugar composition of the eluted fractions, several polysaccharide types were observed.
37224730	8	17	theme	acidic	1252:1257	arg1	arabinogalactan					1259:1273	an acidic arabinogalactan	1249:1273	an acidic arabinogalactan	1249:1273	It mainly represents an acidic arabinogalactan.
37224730	2	18	theme	wild	285:288	arg1	fruits					301:306	wild blackthorn fruits	285:306	wild blackthorn fruits	285:306	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	6	19	theme	side	1046:1049	arg1	chains					1051:1056	side chains	1046:1056	side chains	1046:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	20	with	acids	945:949	arg1	content					962:968	a low content	956:968	a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	956:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	5	21	theme	fractions	718:726	arg1	composition					692:702	the sugar composition	682:702	the sugar composition of the eluted fractions	682:726	Based on the sugar composition of the eluted fractions, several polysaccharide types were observed.
37224730	1	22	theme	Wild	78:81	arg1	berries					94:100	Wild blackthorn berries	78:100	Wild blackthorn berries	78:100	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	1	23	theme	natural	171:177	arg1	complexes					214:222	the natural biologically active polysaccharide complexes	167:222	the natural biologically active polysaccharide complexes	167:222	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	6	24	theme	Hw	800:801	arg1	fractions					811:819	the fractions	807:819	the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics	807:1074	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	24	theme	Hw	800:801	arg1	components					786:795	The dominant components	773:795	The dominant components of Hw	773:801	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	1	25	theme	blackthorn	83:92	arg1	berries					94:100	Wild blackthorn berries	78:100	Wild blackthorn berries	78:100	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	4	26	theme	fractions	638:646	arg1	yield					625:629	a higher yield	616:629	a higher yield of the fractions eluted with 0.25 M NaCl	616:670	About 62% of the applied material was recovered from the column, with a higher yield of the fractions eluted with 0.25 M NaCl.
37224730	0	27	theme	hot	31:33	arg1	water					35:39	hot water	31:39	hot water from wild Prunus spinosa L. berries	31:75	Polysaccharides extracted with hot water from wild Prunus spinosa L. berries.
37224730	2	28	theme	water	315:319	arg1	Hw					333:334	Hw	333:334	Hw	333:334	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	2	28	theme	water	315:319	arg1	extraction					321:330	hot water extraction	311:330	hot water extraction (Hw)	311:335	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	1	29	theme	active	192:197	arg1	complexes					214:222	the natural biologically active polysaccharide complexes	167:222	the natural biologically active polysaccharide complexes	167:222	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	7	30	with	material	1114:1121	arg1	content					1160:1166	a high content	1153:1166	a high content of phenolic compounds	1153:1188	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	7	30	with	material	1114:1121	arg1	yield					1130:1134	a yield	1128:1134	a yield of ∼17%	1128:1142	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	6	31	dep	arabinan	1008:1015	arg1	chains					1051:1056	side chains	1046:1056	side chains	1046:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	2	32	theme	hot	311:313	arg1	Hw					333:334	Hw	333:334	Hw	333:334	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	2	32	theme	hot	311:313	arg1	extraction					321:330	hot water extraction	311:330	hot water extraction (Hw)	311:335	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	1	33	theme	polysaccharide	199:212	arg1	complexes					214:222	the natural biologically active polysaccharide complexes	167:222	the natural biologically active polysaccharide complexes	167:222	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	7	34	theme	dark	1088:1091	arg1	material					1114:1121	a dark brown polysaccharide material	1086:1121	a dark brown polysaccharide material	1086:1121	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	0	35	from	berries	69:75	arg1	water					35:39	hot water	31:39	hot water from wild Prunus spinosa L. berries	31:75	Polysaccharides extracted with hot water from wild Prunus spinosa L. berries.
37224730	2	36	theme	antioxidant	242:252	arg1	fraction					261:268	The antioxidant active fraction	238:268	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw)	238:335	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	1	37	theme	complexes	214:222	arg1	characterization					147:162	the characterization	143:162	the characterization of the natural biologically active polysaccharide complexes	143:222	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	7	38	theme	brown	1093:1097	arg1	material					1114:1121	a dark brown polysaccharide material	1086:1121	a dark brown polysaccharide material	1086:1121	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	5	39	theme	sugar	686:690	arg1	composition					692:702	the sugar composition	682:702	the sugar composition of the eluted fractions	682:726	Based on the sugar composition of the eluted fractions, several polysaccharide types were observed.
37224730	6	40	theme	acids	945:949	arg1	acids					945:949	galacturonic acids	932:949	galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	932:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	40	theme	acids	945:949	arg1	%					927:927	up to 70-80%	916:927	up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	916:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	7	41	theme	polysaccharide	1099:1112	arg1	material					1114:1121	a dark brown polysaccharide material	1086:1121	a dark brown polysaccharide material	1086:1121	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	2	42	theme	successive	411:420	arg1	elution					422:428	successive elution	411:428	successive elution with salts	411:439	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	0	43	theme	Prunus	51:56	arg1	berries					69:75	wild Prunus spinosa L. berries	46:75	wild Prunus spinosa L. berries	46:75	Polysaccharides extracted with hot water from wild Prunus spinosa L. berries.
37224730	6	44	theme	rhamnogalacturonan	973:990	arg1	content					962:968	a low content	956:968	a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	956:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	7	45	theme	high	1155:1158	arg1	content					1160:1166	a high content	1153:1166	a high content of phenolic compounds	1153:1188	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	3	46	theme	sugars	500:505	arg1	content					481:487	the content	477:487	the content of neutral sugars, uronic acids, proteins and phenolics	477:543	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
37224730	0	47	theme	wild	46:49	arg1	berries					69:75	wild Prunus spinosa L. berries	46:75	wild Prunus spinosa L. berries	46:75	Polysaccharides extracted with hot water from wild Prunus spinosa L. berries.
37224730	6	48	dep	70-80	922:926	arg1	to					919:920	to	919:920	to	919:920	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	3	49	theme	acids	515:519	arg1	content					481:487	the content	477:487	the content of neutral sugars, uronic acids, proteins and phenolics	477:543	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
37224730	1	50	theme	unexplored	115:124	arg1	area					126:129	an unexplored area	112:129	an unexplored area	112:129	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	6	51	contain	containing	905:914	arg2	%					927:927	up to 70-80%	916:927	up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	916:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	51	contain	containing	905:914	arg2	phenolics					1066:1074	phenolics	1066:1074	phenolics	1066:1074	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	51	contain	containing	905:914	arg1	homogalacturonan					887:902	highly esterified homogalacturonan	869:902	highly esterified homogalacturonan	869:902	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	6	51	contain	containing	905:914	arg2	acids					945:949	galacturonic acids	932:949	galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	932:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	7	52	theme	compounds	1180:1188	arg1	content					1160:1166	a high content	1153:1166	a high content of phenolic compounds	1153:1188	Further, a dark brown polysaccharide material with a yield of ∼17% and with a high content of phenolic compounds, was eluted with alkali (1.0 M NaOH).
37224730	1	53	dep	terms	134:138	arg1	contain					229:235	contain	229:235	contain	229:235	Wild blackthorn berries represent an unexplored area in terms of the characterization of the natural biologically active polysaccharide complexes they contain.
37224730	3	54	theme	phenolics	535:543	arg1	content					481:487	the content	477:487	the content of neutral sugars, uronic acids, proteins and phenolics	477:543	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
37224730	3	55	theme	neutral	492:498	arg1	sugars					500:505	neutral sugars	492:505	neutral sugars	492:505	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
37224730	0	56	theme	L.	66:67	arg1	berries					69:75	wild Prunus spinosa L. berries	46:75	wild Prunus spinosa L. berries	46:75	Polysaccharides extracted with hot water from wild Prunus spinosa L. berries.
37224730	4	57	theme	higher	618:623	arg1	yield					625:629	a higher yield	616:629	a higher yield of the fractions eluted with 0.25 M NaCl	616:670	About 62% of the applied material was recovered from the column, with a higher yield of the fractions eluted with 0.25 M NaCl.
37224730	4	58	theme	0.25 M	660:665	arg1	NaCl					667:670	0.25 M NaCl	660:670	0.25 M NaCl	660:670	About 62% of the applied material was recovered from the column, with a higher yield of the fractions eluted with 0.25 M NaCl.
37224730	6	59	theme	low	958:960	arg1	content					962:968	a low content	956:968	a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains	956:1056	The dominant components of Hw are the fractions eluted with 0.25 M NaCl (∼70%), which represent highly esterified homogalacturonan, containing up to 70-80% of galacturonic acids with a low content of rhamnogalacturonan associated with arabinan, galactan or arabinogalactan side chains, but no phenolics.
37224730	0	60	theme	spinosa	58:64	arg1	berries					69:75	wild Prunus spinosa L. berries	46:75	wild Prunus spinosa L. berries	46:75	Polysaccharides extracted with hot water from wild Prunus spinosa L. berries.
37224730	2	61	theme	active	254:259	arg1	fraction					261:268	The antioxidant active fraction	238:268	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw)	238:335	The antioxidant active fraction extracted from wild blackthorn fruits by hot water extraction (Hw) was subjected to ion-exchange chromatography and yielded six fractions by successive elution with salts.
37224730	3	62	theme	proteins	522:529	arg1	content					481:487	the content	477:487	the content of neutral sugars, uronic acids, proteins and phenolics	477:543	The purified fractions differed in the content of neutral sugars, uronic acids, proteins and phenolics.
35371288	6	0	theme	histological	731:742	arg1	score					744:748	The histological score	727:748	The histological score of the colon lesion	727:768	The histological score of the colon lesion was significantly decreased upon p-HLP treatment.
35371288	1	1	theme	purified	150:157	arg1	p-HLP					193:197	p-HLP	193:197	p-HLP	193:197	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	1	1	theme	purified	150:157	arg1	polysaccharide					177:190	purified Helvella leucopus polysaccharide	150:190	purified Helvella leucopus polysaccharide (p-HLP)	150:198	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	1	2	theme	induced	239:245	arg1	colitis					247:253	dextran sulfate sodium- (DSS-) induced colitis	208:253	dextran sulfate sodium- (DSS-) induced colitis	208:253	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	1	3	theme	Helvella	159:166	arg1	p-HLP					193:197	p-HLP	193:197	p-HLP	193:197	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	1	3	theme	Helvella	159:166	arg1	polysaccharide					177:190	purified Helvella leucopus polysaccharide	150:190	purified Helvella leucopus polysaccharide (p-HLP)	150:198	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	6	4	theme	p-HLP	803:807	arg1	treatment					809:817	p-HLP treatment	803:817	p-HLP treatment	803:817	The histological score of the colon lesion was significantly decreased upon p-HLP treatment.
35371288	7	5	theme	increased	961:969	arg1	expression					971:980	increased expression	961:980	increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues	961:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	3	6	from	composition	499:509	arg1	mice					534:537	DSS-induced colitis mice	514:537	DSS-induced colitis mice	514:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	4	7	with	homopolysaccharide	560:577	arg1	weight					605:610	an average molecular weight	584:610	an average molecular weight of 39.14 × 108 Da	584:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	7	8	theme	mediators	903:911	arg1	expression					971:980	increased expression	961:980	increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues	961:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	8	theme	mediators	903:911	arg1	expression					859:868	decreased expression	849:868	decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS)	849:955	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	4	9	theme	molecular	595:603	arg1	weight					605:610	an average molecular weight	584:610	an average molecular weight of 39.14 × 108 Da	584:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	5	10	theme	DSS-induced	676:686	arg1	loss					700:703	DSS-induced body weight loss	676:703	DSS-induced body weight loss	676:703	Functionally, p-HLP significantly attenuated DSS-induced body weight loss and colon shortening.
35371288	2	11	theme	ethanol	343:349	arg1	precipitation					351:363	ethanol precipitation	343:363	ethanol precipitation	343:363	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	7	12	theme	proinflammatory	873:887	arg1	IL-1β					920:924	IL-1β	920:924	IL-1β	920:924	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	12	theme	proinflammatory	873:887	arg1	iNOS					951:954	iNOS	951:954	iNOS	951:954	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	12	theme	proinflammatory	873:887	arg1	TNF-α					930:934	TNF-α	930:934	TNF-α	930:934	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	12	theme	proinflammatory	873:887	arg1	IL-6					914:917	IL-6	914:917	IL-6	914:917	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	12	theme	proinflammatory	873:887	arg1	COX-2					941:945	COX-2	941:945	COX-2	941:945	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	12	theme	proinflammatory	873:887	arg1	cytokines					889:897	proinflammatory cytokines	873:897	proinflammatory cytokines	873:897	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	4	13	theme	average	587:593	arg1	weight					605:610	an average molecular weight	584:610	an average molecular weight of 39.14 × 108 Da	584:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	8	14	theme	MiSeq	1051:1055	arg1	sequencing					1057:1066	Illumina MiSeq sequencing	1042:1066	Illumina MiSeq sequencing	1042:1066	Illumina MiSeq sequencing revealed that p-HLP modulated the composition of the gut microbiota.
35371288	1	15	dep	Objective	90:98	arg1	was					111:113	was	111:113	was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis	111:253	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	2	16	dep	Methods	256:262	arg1	isolated					284:291	isolated	284:291	was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography	280:390	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	1	17	theme	leucopus	168:175	arg1	p-HLP					193:197	p-HLP	193:197	p-HLP	193:197	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	1	17	theme	leucopus	168:175	arg1	polysaccharide					177:190	purified Helvella leucopus polysaccharide	150:190	purified Helvella leucopus polysaccharide (p-HLP)	150:198	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	8	18	theme	Illumina	1042:1049	arg1	sequencing					1057:1066	Illumina MiSeq sequencing	1042:1066	Illumina MiSeq sequencing	1042:1066	Illumina MiSeq sequencing revealed that p-HLP modulated the composition of the gut microbiota.
35371288	1	19	theme	polysaccharide	177:190	arg1	effect					140:145	the protective effect	125:145	the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis	125:253	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	0	20	theme	Mushroom	6:13	arg1	Polysaccharide					15:28	Bachu Mushroom Polysaccharide	0:28	Bachu Mushroom Polysaccharide	0:28	Bachu Mushroom Polysaccharide Alleviates Colonic Injury by Modulating the Gut Microbiota.
35371288	3	21	from	inflammation	470:481	arg1	mice					534:537	DSS-induced colitis mice	514:537	DSS-induced colitis mice	514:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	2	22	theme	column	370:375	arg1	chromatography					377:390	column chromatography	370:390	column chromatography	370:390	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	0	23	theme	Bachu	0:4	arg1	Polysaccharide					15:28	Bachu Mushroom Polysaccharide	0:28	Bachu Mushroom Polysaccharide	0:28	Bachu Mushroom Polysaccharide Alleviates Colonic Injury by Modulating the Gut Microbiota.
35371288	2	24	theme	Bachu	298:302	arg1	mushroom					304:311	Bachu mushroom	298:311	Bachu mushroom	298:311	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	9	25	theme	DSS-induced	1207:1217	arg1	colitis					1219:1225	DSS-induced colitis	1207:1225	DSS-induced colitis	1207:1225	Conclusion p-HLP is a potent regulator that protects the lesions from DSS-induced colitis.
35371288	3	26	theme	potential	416:424	arg1	effects					426:432	the potential effects	412:432	the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice	412:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	7	27	theme	p-HLP	826:830	arg1	treatment					832:840	p-HLP treatment	826:840	p-HLP treatment	826:840	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	5	28	theme	colon	709:713	arg1	shortening					715:724	colon shortening	709:724	colon shortening	709:724	Functionally, p-HLP significantly attenuated DSS-induced body weight loss and colon shortening.
35371288	7	29	theme	decreased	849:857	arg1	expression					859:868	decreased expression	849:868	decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS)	849:955	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	3	30	theme	colonic	446:452	arg1	histopathology					454:467	colonic histopathology	446:467	colonic histopathology	446:467	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	2	31	attach	isolated	284:291	arg1	mushroom					304:311	Bachu mushroom	298:311	Bachu mushroom	298:311	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	2	31	attach	isolated	284:291	arg2	p-HLP					274:278	The novel p-HLP	264:278	The novel p-HLP	264:278	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	3	32	theme	colitis	526:532	arg1	mice					534:537	DSS-induced colitis mice	514:537	DSS-induced colitis mice	514:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	7	33	theme	colon	1027:1031	arg1	tissues					1033:1039	the colon tissues	1023:1039	the colon tissues	1023:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	4	34	theme	108 Da	623:628	arg1	weight					605:610	an average molecular weight	584:610	an average molecular weight of 39.14 × 108 Da	584:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	3	35	theme	microbiota	488:497	arg1	composition					499:509	microbiota composition	488:509	microbiota composition	488:509	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	7	36	theme	cytokines	889:897	arg1	expression					971:980	increased expression	961:980	increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues	961:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	36	theme	cytokines	889:897	arg1	expression					859:868	decreased expression	849:868	decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS)	849:955	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	3	37	theme	p-HLP	437:441	arg1	effects					426:432	the potential effects	412:432	the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice	412:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	0	38	theme	Colonic	41:47	arg1	Injury					49:54	Colonic Injury	41:54	Colonic Injury	41:54	Bachu Mushroom Polysaccharide Alleviates Colonic Injury by Modulating the Gut Microbiota.
35371288	7	39	dep	cytokines	889:897	arg1	COX-2					941:945	COX-2	941:945	COX-2	941:945	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	39	dep	cytokines	889:897	arg1	IL-1β					920:924	IL-1β	920:924	IL-1β	920:924	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	39	dep	cytokines	889:897	arg1	IL-6					914:917	IL-6	914:917	IL-6	914:917	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	39	dep	cytokines	889:897	arg1	cytokines					889:897	proinflammatory cytokines	873:897	proinflammatory cytokines	873:897	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	5	40	theme	body	688:691	arg1	loss					700:703	DSS-induced body weight loss	676:703	DSS-induced body weight loss	676:703	Functionally, p-HLP significantly attenuated DSS-induced body weight loss and colon shortening.
35371288	4	41	theme	Results	540:546	arg1	p-HLP					548:552	Results p-HLP	540:552	Results p-HLP	540:552	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	4	41	theme	Results	540:546	arg1	homopolysaccharide					560:577	a homopolysaccharide	558:577	a homopolysaccharide with an average molecular weight of 39.14 × 108 Da	558:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	5	42	theme	weight	693:698	arg1	loss					700:703	DSS-induced body weight loss	676:703	DSS-induced body weight loss	676:703	Functionally, p-HLP significantly attenuated DSS-induced body weight loss and colon shortening.
35371288	2	43	theme	novel	268:272	arg1	p-HLP					274:278	The novel p-HLP	264:278	The novel p-HLP	264:278	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	6	44	theme	lesion	763:768	arg1	score					744:748	The histological score	727:748	The histological score of the colon lesion	727:768	The histological score of the colon lesion was significantly decreased upon p-HLP treatment.
35371288	2	45	theme	water	325:329	arg1	extraction					331:340	hot water extraction	321:340	hot water extraction	321:340	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	8	46	theme	gut	1121:1123	arg1	microbiota					1125:1134	the gut microbiota	1117:1134	the gut microbiota	1117:1134	Illumina MiSeq sequencing revealed that p-HLP modulated the composition of the gut microbiota.
35371288	7	47	from	expression	859:868	arg1	tissues					1033:1039	the colon tissues	1023:1039	the colon tissues	1023:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	3	48	from	histopathology	454:467	arg1	mice					534:537	DSS-induced colitis mice	514:537	DSS-induced colitis mice	514:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	2	49	theme	hot	321:323	arg1	extraction					331:340	hot water extraction	321:340	hot water extraction	321:340	Methods The novel p-HLP was isolated from Bachu mushroom through hot water extraction, ethanol precipitation, and column chromatography.
35371288	9	50	theme	potent	1159:1164	arg1	Conclusion					1137:1146	Conclusion p-HLP	1137:1152	Conclusion p-HLP	1137:1152	Conclusion p-HLP is a potent regulator that protects the lesions from DSS-induced colitis.
35371288	9	50	theme	potent	1159:1164	arg1	regulator					1166:1174	a potent regulator	1157:1174	a potent regulator that protects the lesions from DSS-induced colitis	1157:1225	Conclusion p-HLP is a potent regulator that protects the lesions from DSS-induced colitis.
35371288	6	51	theme	colon	757:761	arg1	lesion					763:768	the colon lesion	753:768	the colon lesion	753:768	The histological score of the colon lesion was significantly decreased upon p-HLP treatment.
35371288	7	52	theme	anti-inflammatory	985:1001	arg1	IL-10					1013:1017	anti-inflammatory cytokine (IL-10)	985:1018	anti-inflammatory cytokine (IL-10)	985:1018	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	1	53	theme	protective	129:138	arg1	effect					140:145	the protective effect	125:145	the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis	125:253	Objective This study was to define the protective effect of purified Helvella leucopus polysaccharide (p-HLP) against dextran sulfate sodium- (DSS-) induced colitis.
35371288	0	54	theme	Gut	74:76	arg1	Microbiota					78:87	the Gut Microbiota	70:87	the Gut Microbiota	70:87	Bachu Mushroom Polysaccharide Alleviates Colonic Injury by Modulating the Gut Microbiota.
35371288	7	55	theme	IL-10	1013:1017	arg1	expression					971:980	increased expression	961:980	increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues	961:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	55	theme	IL-10	1013:1017	arg1	expression					859:868	decreased expression	849:868	decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS)	849:955	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	56	theme	cytokine	1003:1010	arg1	IL-10					1013:1017	anti-inflammatory cytokine (IL-10)	985:1018	anti-inflammatory cytokine (IL-10)	985:1018	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	7	57	from	expression	971:980	arg1	tissues					1033:1039	the colon tissues	1023:1039	the colon tissues	1023:1039	Also, p-HLP treatment led to decreased expression of proinflammatory cytokines and mediators (IL-6, IL-1β and TNF-α, and COX-2 and iNOS) and increased expression of anti-inflammatory cytokine (IL-10) in the colon tissues.
35371288	4	58	theme	×	621:621	arg1	108 Da					623:628	39.14 × 108 Da	615:628	39.14 × 108 Da	615:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35371288	8	59	theme	microbiota	1125:1134	arg1	composition					1102:1112	the composition	1098:1112	the composition of the gut microbiota	1098:1134	Illumina MiSeq sequencing revealed that p-HLP modulated the composition of the gut microbiota.
35371288	3	60	from	effects	426:432	arg1	composition					499:509	microbiota composition	488:509	microbiota composition	488:509	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	3	60	from	effects	426:432	arg1	inflammation					470:481	inflammation	470:481	inflammation	470:481	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	3	60	from	effects	426:432	arg1	histopathology					454:467	colonic histopathology	446:467	colonic histopathology	446:467	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	3	61	theme	DSS-induced	514:524	arg1	colitis					526:532	DSS-induced colitis	514:532	DSS-induced colitis mice	514:537	Then, we evaluated the potential effects of p-HLP on colonic histopathology, inflammation, and microbiota composition in DSS-induced colitis mice.
35371288	4	62	theme	39.14	615:619	arg1	108 Da					623:628	39.14 × 108 Da	615:628	39.14 × 108 Da	615:628	Results p-HLP was a homopolysaccharide with an average molecular weight of 39.14 × 108 Da.
35402371	0	0	theme	Automated	66:74	arg1	Toolkit					102:108	an Automated QM-Cluster Model Building Toolkit	63:108	an Automated QM-Cluster Model Building Toolkit	63:108	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	4	1	theme	deglycosylation	669:683	arg1	step					685:688	the subsequent deglycosylation step	654:688	the subsequent deglycosylation step	654:688	In the subsequent deglycosylation step, one water molecule migrates into the active site and attacks the anomeric carbon.
35402371	8	2	theme	thermodynamic	1434:1446	arg1	sink					1448:1451	This thermodynamic sink	1429:1451	This thermodynamic sink	1429:1451	This thermodynamic sink may correspond to the intermediate state which was isolated in the X-ray crystal structure.
35402371	2	3	theme	QM-cluster	365:374	arg1	models					376:381	different sized QM-cluster models	349:381	different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	349:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	6	4	from	glycosylation	948:960	arg1	models					988:993	the largest QM-cluster models	965:993	the largest QM-cluster models	965:993	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	8	5	theme	intermediate	1475:1486	arg1	state					1488:1492	the intermediate state	1471:1492	the intermediate state which was isolated in the X-ray crystal structure	1471:1542	This thermodynamic sink may correspond to the intermediate state which was isolated in the X-ray crystal structure.
35402371	9	6	theme	wild-type	1624:1632	arg1	enzyme					1646:1651	both the wild-type and mutated enzyme	1615:1651	enzyme	1646:1651	Hence, the glycosylation is validated to be the rate-limiting step in both the wild-type and mutated enzyme.
35402371	2	7	theme	sized	359:363	arg1	models					376:381	different sized QM-cluster models	349:381	different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	349:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	0	8	theme	Model	87:91	arg1	Toolkit					102:108	an Automated QM-Cluster Model Building Toolkit	63:108	an Automated QM-Cluster Model Building Toolkit	63:108	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	3	9	theme	glycosidic	607:616	arg1	oxygen					618:623	the glycosidic oxygen	603:623	the glycosidic oxygen leading to bond cleavage	603:648	The first step is the glycosylation, in which the acidic residue 217 donates a proton to the glycosidic oxygen leading to bond cleavage.
35402371	2	10	theme	Family	316:321	arg1	mechanism					283:291	The two-step retaining reaction mechanism	251:291	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7)	251:329	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	6	11	theme	acidic	1147:1152	arg1	Glu217					1162:1167	the acidic residue Glu217	1143:1167	the acidic residue Glu217	1143:1167	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	0	12	theme	QM-Cluster	76:85	arg1	Toolkit					102:108	an Automated QM-Cluster Model Building Toolkit	63:108	an Automated QM-Cluster Model Building Toolkit	63:108	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	6	13	theme	Glu217	1162:1167	arg1	mutation					1131:1138	mutation	1131:1138	mutation of the acidic residue Glu217 to Gln	1131:1174	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	14	theme	transition	1260:1269	arg1	states					1271:1276	the deglycosylation transition states	1240:1276	the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively)	1240:1358	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	2	15	theme	Hydrolase	306:314	arg1	Family					316:321	Glycoside Hydrolase Family 7	296:323	Glycoside Hydrolase Family 7 (GH7)	296:329	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	2	15	theme	Hydrolase	306:314	arg1	GH7					326:328	GH7	326:328	GH7	326:328	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	4	16	theme	water	695:699	arg1	molecule					701:708	one water molecule	691:708	one water molecule	691:708	In the subsequent deglycosylation step, one water molecule migrates into the active site and attacks the anomeric carbon.
35402371	5	17	theme	structural	834:843	arg1	results					859:865	reliable structural and energetic results	825:865	reliable structural and energetic results for proposed glycoside hydrolase mechanisms	825:909	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	5	18	theme	QM-cluster	799:808	arg1	models					810:815	Residue interaction-based QM-cluster models	773:815	Residue interaction-based QM-cluster models	773:815	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	2	19	theme	Glycoside	296:304	arg1	Family					316:321	Glycoside Hydrolase Family 7	296:323	Glycoside Hydrolase Family 7 (GH7)	296:329	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	2	19	theme	Glycoside	296:304	arg1	GH7					326:328	GH7	326:328	GH7	326:328	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	5	20	theme	proposed	871:878	arg1	mechanisms					900:909	proposed glycoside hydrolase mechanisms	871:909	proposed glycoside hydrolase mechanisms	871:909	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	2	21	theme	Interaction	404:414	arg1	Network					416:422	the Residue Interaction Network	392:422	the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	392:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	0	22	theme	Building	93:100	arg1	Toolkit					102:108	an Automated QM-Cluster Model Building Toolkit	63:108	an Automated QM-Cluster Model Building Toolkit	63:108	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	8	23	theme	X-ray	1520:1524	arg1	structure					1534:1542	the X-ray crystal structure	1516:1542	the X-ray crystal structure	1516:1542	This thermodynamic sink may correspond to the intermediate state which was isolated in the X-ray crystal structure.
35402371	1	24	theme	β-1,4	173:177	arg1	bond					190:193	the β-1,4 glycosidic bond	169:193	the β-1,4 glycosidic bond in polysaccharides	169:212	Glycoside hydrolase enzymes are important for hydrolyzing the β-1,4 glycosidic bond in polysaccharides for deconstruction of carbohydrates.
35402371	0	25	theme	Case	2:5	arg1	Study					7:11	A Case Study	0:11	A Case Study of the Glycoside Hydrolase Enzyme Mechanism	0:55	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	6	26	theme	wild-type	1049:1057	arg1	protein					1059:1065	the wild-type protein	1045:1065	the wild-type protein	1045:1065	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	4	27	dep	site	735:738	arg1	carbon					765:770	the anomeric carbon	752:770	the anomeric carbon	752:770	In the subsequent deglycosylation step, one water molecule migrates into the active site and attacks the anomeric carbon.
35402371	9	28	from	step	1607:1610	arg1	enzyme					1646:1651	both the wild-type and mutated enzyme	1615:1651	enzyme	1646:1651	Hence, the glycosylation is validated to be the rate-limiting step in both the wild-type and mutated enzyme.
35402371	1	29	theme	glycosidic	179:188	arg1	bond					190:193	the β-1,4 glycosidic bond	169:193	the β-1,4 glycosidic bond in polysaccharides	169:212	Glycoside hydrolase enzymes are important for hydrolyzing the β-1,4 glycosidic bond in polysaccharides for deconstruction of carbohydrates.
35402371	6	30	theme	deglycosylation	1244:1258	arg1	states					1271:1276	the deglycosylation transition states	1240:1276	the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively)	1240:1358	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	3	31	theme	acidic	564:569	arg1	residue					571:577	the acidic residue 217	560:581	the acidic residue 217	560:581	The first step is the glycosylation, in which the acidic residue 217 donates a proton to the glycosidic oxygen leading to bond cleavage.
35402371	5	32	theme	glycoside	880:888	arg1	mechanisms					900:909	proposed glycoside hydrolase mechanisms	871:909	proposed glycoside hydrolase mechanisms	871:909	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	8	33	theme	crystal	1526:1532	arg1	structure					1534:1542	the X-ray crystal structure	1516:1542	the X-ray crystal structure	1516:1542	This thermodynamic sink may correspond to the intermediate state which was isolated in the X-ray crystal structure.
35402371	6	34	dep	states	1271:1276	arg1	mutant					1338:1343	mutant	1338:1343	mutant	1338:1343	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	34	dep	states	1271:1276	arg1	25.5 kcal mol-1					1288:1302	25.5 kcal mol-1	1288:1302	25.5 kcal mol-1	1288:1302	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	34	dep	states	1271:1276	arg1	13.8					1279:1282	13.8	1279:1282	13.8	1279:1282	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	35	gly	glycosylation	948:960	arg1	models					988:993	the largest QM-cluster models	965:993	the largest QM-cluster models	965:993	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	5	36	theme	Residue	773:779	arg1	models					810:815	Residue interaction-based QM-cluster models	773:815	Residue interaction-based QM-cluster models	773:815	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	5	37	theme	reliable	825:832	arg1	results					859:865	reliable structural and energetic results	825:865	reliable structural and energetic results for proposed glycoside hydrolase mechanisms	825:909	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	2	38	theme	RINRUS	442:447	arg1	software					450:457	the Residue Interaction Network ResidUe Selector (RINRUS) software	392:457	the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	392:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	6	39	theme	QM-cluster	977:986	arg1	models					988:993	the largest QM-cluster models	965:993	the largest QM-cluster models	965:993	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	4	40	theme	anomeric	756:763	arg1	carbon					765:770	the anomeric carbon	752:770	the anomeric carbon	752:770	In the subsequent deglycosylation step, one water molecule migrates into the active site and attacks the anomeric carbon.
35402371	6	41	theme	down	1186:1189	arg1	reaction					1195:1202	down the reaction	1186:1202	down the reaction	1186:1202	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	4	42	theme	active	728:733	arg1	site					735:738	the active site	724:738	the active site	724:738	In the subsequent deglycosylation step, one water molecule migrates into the active site and attacks the anomeric carbon.
35402371	2	43	theme	Selector	432:439	arg1	software					450:457	the Residue Interaction Network ResidUe Selector (RINRUS) software	392:457	the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	392:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	0	44	theme	Glycoside	20:28	arg1	Mechanism					47:55	the Glycoside Hydrolase Enzyme Mechanism	16:55	the Glycoside Hydrolase Enzyme Mechanism	16:55	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	6	45	theme	largest	969:975	arg1	models					988:993	the largest QM-cluster models	965:993	the largest QM-cluster models	965:993	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	3	46	theme	bond	636:639	arg1	cleavage					641:648	bond cleavage	636:648	bond cleavage	636:648	The first step is the glycosylation, in which the acidic residue 217 donates a proton to the glycosidic oxygen leading to bond cleavage.
35402371	6	47	theme	free	1223:1226	arg1	energy					1228:1233	free energy	1223:1233	free energy	1223:1233	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	48	theme	E217Q	1075:1079	arg1	mutant					1081:1086	its E217Q mutant	1071:1086	its E217Q mutant	1071:1086	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	2	49	theme	ResidUe	424:430	arg1	software					450:457	the Residue Interaction Network ResidUe Selector (RINRUS) software	392:457	the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	392:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	2	50	theme	wild-type	474:482	arg1	protein					484:490	the wild-type protein	470:490	the wild-type protein	470:490	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	6	51	theme	wild-type	1312:1320	arg1	protein					1322:1328	the wild-type protein	1308:1328	the wild-type protein	1308:1328	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	7	52	theme	mutated	1369:1375	arg1	protein					1377:1383	the mutated protein	1365:1383	the mutated protein	1365:1383	For the mutated protein, glycosylation led to a low-energy product.
35402371	2	53	theme	Network	416:422	arg1	software					450:457	the Residue Interaction Network ResidUe Selector (RINRUS) software	392:457	the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	392:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	0	54	theme	Enzyme	40:45	arg1	Mechanism					47:55	the Glycoside Hydrolase Enzyme Mechanism	16:55	the Glycoside Hydrolase Enzyme Mechanism	16:55	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	5	55	theme	hydrolase	890:898	arg1	mechanisms					900:909	proposed glycoside hydrolase mechanisms	871:909	proposed glycoside hydrolase mechanisms	871:909	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	5	56	theme	interaction-based	781:797	arg1	models					810:815	Residue interaction-based QM-cluster models	773:815	Residue interaction-based QM-cluster models	773:815	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	2	57	theme	E217Q	500:504	arg1	mutant					506:511	its E217Q mutant	496:511	its E217Q mutant	496:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	2	58	theme	different	349:357	arg1	models					376:381	different sized QM-cluster models	349:381	different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	349:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	0	59	theme	Hydrolase	30:38	arg1	Mechanism					47:55	the Glycoside Hydrolase Enzyme Mechanism	16:55	the Glycoside Hydrolase Enzyme Mechanism	16:55	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	9	60	theme	mutated	1638:1644	arg1	enzyme					1646:1651	both the wild-type and mutated enzyme	1615:1651	enzyme	1646:1651	Hence, the glycosylation is validated to be the rate-limiting step in both the wild-type and mutated enzyme.
35402371	1	61	theme	Glycoside	111:119	arg1	enzymes					131:137	Glycoside hydrolase enzymes	111:137	Glycoside hydrolase enzymes	111:137	Glycoside hydrolase enzymes are important for hydrolyzing the β-1,4 glycosidic bond in polysaccharides for deconstruction of carbohydrates.
35402371	7	62	theme	low-energy	1409:1418	arg1	product					1420:1426	a low-energy product	1407:1426	a low-energy product	1407:1426	For the mutated protein, glycosylation led to a low-energy product.
35402371	9	63	theme	rate-limiting	1593:1605	arg1	step					1607:1610	the rate-limiting step	1589:1610	the rate-limiting step in both the wild-type and mutated enzyme	1589:1651	Hence, the glycosylation is validated to be the rate-limiting step in both the wild-type and mutated enzyme.
35402371	9	63	theme	rate-limiting	1593:1605	arg1	glycosylation					1556:1568	the glycosylation	1552:1568	the glycosylation	1552:1568	Hence, the glycosylation is validated to be the rate-limiting step in both the wild-type and mutated enzyme.
35402371	1	64	theme	hydrolase	121:129	arg1	enzymes					131:137	Glycoside hydrolase enzymes	111:137	Glycoside hydrolase enzymes	111:137	Glycoside hydrolase enzymes are important for hydrolyzing the β-1,4 glycosidic bond in polysaccharides for deconstruction of carbohydrates.
35402371	6	65	theme	residue	1154:1160	arg1	Glu217					1162:1167	the acidic residue Glu217	1143:1167	the acidic residue Glu217	1143:1167	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	2	66	theme	reaction	274:281	arg1	mechanism					283:291	The two-step retaining reaction mechanism	251:291	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7)	251:329	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	6	67	theme	experimental	1106:1117	arg1	trends					1119:1124	experimental trends	1106:1124	experimental trends	1106:1124	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	1	68	theme	carbohydrates	236:248	arg1	deconstruction					218:231	deconstruction	218:231	deconstruction of carbohydrates	218:248	Glycoside hydrolase enzymes are important for hydrolyzing the β-1,4 glycosidic bond in polysaccharides for deconstruction of carbohydrates.
35402371	5	69	theme	energetic	849:857	arg1	results					859:865	reliable structural and energetic results	825:865	reliable structural and energetic results for proposed glycoside hydrolase mechanisms	825:909	Residue interaction-based QM-cluster models lead to reliable structural and energetic results for proposed glycoside hydrolase mechanisms.
35402371	2	70	theme	retaining	264:272	arg1	mechanism					283:291	The two-step retaining reaction mechanism	251:291	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7)	251:329	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	1	71	from	bond	190:193	arg1	polysaccharides					198:212	polysaccharides	198:212	polysaccharides	198:212	Glycoside hydrolase enzymes are important for hydrolyzing the β-1,4 glycosidic bond in polysaccharides for deconstruction of carbohydrates.
35402371	3	72	theme	first	518:522	arg1	glycosylation					536:548	the glycosylation	532:548	the glycosylation	532:548	The first step is the glycosylation, in which the acidic residue 217 donates a proton to the glycosidic oxygen leading to bond cleavage.
35402371	3	72	theme	first	518:522	arg1	step					524:527	The first step	514:527	The first step	514:527	The first step is the glycosylation, in which the acidic residue 217 donates a proton to the glycosidic oxygen leading to bond cleavage.
35402371	2	73	theme	Residue	396:402	arg1	Network					416:422	the Residue Interaction Network	392:422	the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant	392:511	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	6	74	theme	free	916:919	arg1	energies					921:928	The free energies	912:928	The free energies of activation for glycosylation in the largest QM-cluster models	912:993	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	74	theme	free	916:919	arg1	19.5					1016:1019	19.5	1016:1019	19.5	1016:1019	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	0	75	theme	Mechanism	47:55	arg1	Study					7:11	A Case Study	0:11	A Case Study of the Glycoside Hydrolase Enzyme Mechanism	0:55	A Case Study of the Glycoside Hydrolase Enzyme Mechanism Using an Automated QM-Cluster Model Building Toolkit.
35402371	6	76	theme	activation	933:942	arg1	energies					921:928	The free energies	912:928	The free energies of activation for glycosylation in the largest QM-cluster models	912:993	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	6	76	theme	activation	933:942	arg1	19.5					1016:1019	19.5	1016:1019	19.5	1016:1019	The free energies of activation for glycosylation in the largest QM-cluster models were predicted to be 19.5 and 31.4 kcal mol-1 for the wild-type protein and its E217Q mutant, which agree with experimental trends that mutation of the acidic residue Glu217 to Gln will slow down the reaction; and are higher in free energy than the deglycosylation transition states (13.8 and 25.5 kcal mol-1 for the wild-type protein and its mutant, respectively).
35402371	2	77	theme	two-step	255:262	arg1	mechanism					283:291	The two-step retaining reaction mechanism	251:291	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7)	251:329	The two-step retaining reaction mechanism of Glycoside Hydrolase Family 7 (GH7) was explored with different sized QM-cluster models built by the Residue Interaction Network ResidUe Selector (RINRUS) software using both the wild-type protein and its E217Q mutant.
35402371	9	78	dep	enzyme	1646:1651	arg1	both					1615:1618	both	1615:1618	both	1615:1618	Hence, the glycosylation is validated to be the rate-limiting step in both the wild-type and mutated enzyme.
35402371	4	79	theme	subsequent	658:667	arg1	step					685:688	the subsequent deglycosylation step	654:688	the subsequent deglycosylation step	654:688	In the subsequent deglycosylation step, one water molecule migrates into the active site and attacks the anomeric carbon.
36836256	4	0	link	O-linked	681:688	arg1	mannans					690:696	N-linked and O-linked mannans	668:696	N-linked and O-linked mannans of the cell wall of C. albicans	668:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	2	1	theme	prior	345:349	arg1	step					340:343	the initial step	328:343	the initial step prior to invasion	328:361	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	2	1	theme	prior	345:349	arg1	adhesion					370:377	the adhesion	366:377	the adhesion of the fungus to endothelial cells	366:412	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	7	2	theme	isolated	1570:1577	arg1	albicans					1599:1606	live C. albicans	1591:1606	live C. albicans without N-linked mannans or isolated O-linked mannans	1591:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	7	2	theme	isolated	1570:1577	arg1	walls					1584:1588	isolated cell walls	1570:1588	isolated cell walls	1570:1588	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	4	3	link	N-linked	668:675	arg1	mannans					690:696	N-linked and O-linked mannans	668:696	N-linked and O-linked mannans of the cell wall of C. albicans	668:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	3	4	with	contact	489:495	arg1	cells					507:511	host cells	502:511	host cells	502:511	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	6	5	theme	perfusion	1349:1357	arg1	pressure					1359:1366	heart coronary perfusion pressure	1334:1366	heart coronary perfusion pressure (vascular effect)	1334:1384	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	5	theme	perfusion	1349:1357	arg1	effect					1378:1383	vascular effect	1369:1383	vascular effect	1369:1383	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	3	6	theme	host	502:505	arg1	cells					507:511	host cells	502:511	host cells	502:511	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	6	7	theme	heart	1334:1338	arg1	pressure					1359:1366	heart coronary perfusion pressure	1334:1366	heart coronary perfusion pressure (vascular effect)	1334:1384	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	7	theme	heart	1334:1338	arg1	effect					1378:1383	vascular effect	1369:1383	vascular effect	1369:1383	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	1	8	theme	opportunistic	163:175	arg1	pathogen					184:191	an opportunistic fungal pathogen	160:191	an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs	160:311	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	1	8	theme	opportunistic	163:175	arg1	albicans					148:155	Candida albicans	140:155	Candida albicans	140:155	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	0	9	theme	Cardiac	110:116	arg1	Response					118:125	the Cardiac Response	106:125	the Cardiac Response to Agonists	106:137	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	6	10	theme	ventricular	1395:1405	arg1	pressure					1407:1414	left ventricular pressure	1390:1414	left ventricular pressure (inotropic effect)	1390:1433	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	10	theme	ventricular	1395:1405	arg1	effect					1427:1432	inotropic effect	1417:1432	inotropic effect	1417:1432	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	5	11	theme	isolated	783:790	arg1	model					802:806	An isolated rat heart model	780:806	An isolated rat heart model	780:806	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	12	dep	C.	1072:1073	arg1	albicans					1075:1082	albicans	1075:1082	albicans	1075:1082	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	9	13	theme	C.	1917:1918	arg1	interaction					1929:1939	C. albicans interaction	1917:1939	C. albicans interaction	1917:1939	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	5	14	used	used	812:815	arg2	model					802:806	An isolated rat heart model	780:806	An isolated rat heart model	780:806	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	10	15	theme	Further	2074:2080	arg1	studies					2082:2088	Further studies	2074:2088	Further studies	2074:2088	Further studies are necessary to elucidate why specific receptors preferentially interact with this fungal cell wall structure.
36836256	4	16	theme	N-linked	668:675	arg1	mannans					690:696	N-linked and O-linked mannans	668:696	N-linked and O-linked mannans of the cell wall of C. albicans	668:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	8	17	theme	C.	1705:1706	arg1	HK					1717:1718	C. albicans HK	1705:1718	C. albicans HK	1705:1718	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	7	18	link	O-linked	1645:1652	arg1	mannans					1654:1660	isolated O-linked mannans	1636:1660	isolated O-linked mannans	1636:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	1	19	theme	Candida	140:146	arg1	pathogen					184:191	an opportunistic fungal pathogen	160:191	an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs	160:311	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	1	19	theme	Candida	140:146	arg1	albicans					148:155	Candida albicans	140:155	Candida albicans	140:155	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	5	20	dep	isolated	1217:1224	arg1	4					1214:1214	4	1214:1214	4	1214:1214	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	21	dep	yeasts	1055:1060	arg1	yeasts					1090:1095	C. albicans pmr1Δ yeasts	1072:1095	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	22	theme	C.	1721:1722	arg1	pmr1Δ					1733:1737	C. albicans pmr1Δ	1721:1737	C. albicans pmr1Δ	1721:1737	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	5	23	theme	live	1007:1010	arg1	yeasts					1055:1060	(1) live and heat-killed (HK) C. albicans wild-type yeasts	1003:1060	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	24	theme	cardiac	827:833	arg1	parameters					835:844	cardiac parameters	827:844	cardiac parameters	827:844	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	25	link	O-linked	1760:1767	arg1	mannans					1769:1775	O-linked mannans	1760:1775	O-linked mannans	1760:1775	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	4	26	theme	cell	705:708	arg1	wall					710:713	the cell wall	701:713	the cell wall of C. albicans	701:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	9	27	theme	coronary	1975:1982	arg1	endothelium					1984:1994	coronary endothelium	1975:1994	coronary endothelium	1975:1994	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	5	28	theme	vascular	857:864	arg1	effects					880:886	vascular and inotropic effects	857:886	vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II)	857:970	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	2	29	theme	endothelial	396:406	arg1	cells					408:412	endothelial cells	396:412	endothelial cells	396:412	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	5	30	theme	live	1153:1156	arg1	yeasts					1090:1095	C. albicans pmr1Δ yeasts	1072:1095	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	31	theme	C.	1740:1741	arg1	albicans					1743:1750	C. albicans	1740:1750	C. albicans without O-linked mannans	1740:1775	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	3	32	dep	first	472:476	arg1	come					481:484	come	481:484	to come in contact with host cells	478:511	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	10	33	theme	cell	2181:2184	arg1	structure					2191:2199	this fungal cell wall structure	2169:2199	this fungal cell wall structure	2169:2199	Further studies are necessary to elucidate why specific receptors preferentially interact with this fungal cell wall structure.
36836256	4	34	theme	O-linked	681:688	arg1	mannans					690:696	N-linked and O-linked mannans	668:696	N-linked and O-linked mannans of the cell wall of C. albicans	668:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	9	35	theme	O-linked	2005:2012	arg1	mannan					2014:2019	O-linked mannan	2005:2019	O-linked mannan	2005:2019	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	0	36	theme	O-Linked	0:7	arg1	Glycans					9:15	O-Linked Glycans	0:15	O-Linked Glycans of Candida albicans	0:35	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	5	37	theme	inotropic	870:878	arg1	effects					880:886	vascular and inotropic effects	857:886	vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II)	857:970	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	38	link	O-linked	1191:1198	arg1	mannans					1200:1206	N-linked and O-linked mannans	1178:1206	N-linked and O-linked mannans	1178:1206	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	39	theme	wild-type	1045:1053	arg1	yeasts					1055:1060	(1) live and heat-killed (HK) C. albicans wild-type yeasts	1003:1060	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	10	40	theme	fungal	2174:2179	arg1	structure					2191:2199	this fungal cell wall structure	2169:2199	this fungal cell wall structure	2169:2199	Further studies are necessary to elucidate why specific receptors preferentially interact with this fungal cell wall structure.
36836256	5	41	link	N-linked	1178:1185	arg1	mannans					1200:1206	N-linked and O-linked mannans	1178:1206	N-linked and O-linked mannans	1178:1206	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	3	42	theme	tissue	604:609	arg1	colonization					579:590	the colonization	575:590	the colonization of the host tissue	575:609	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	3	43	theme	cell	432:435	arg1	wall					437:440	the fungal cell wall	421:440	the fungal cell wall's outermost structure	421:462	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	0	44	theme	albicans	28:35	arg1	Glycans					9:15	O-Linked Glycans	0:15	O-Linked Glycans of Candida albicans	0:35	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	5	45	theme	heat-killed	1016:1026	arg1	yeasts					1055:1060	(1) live and heat-killed (HK) C. albicans wild-type yeasts	1003:1060	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	46	theme	isolated	1780:1787	arg1	mannans					1798:1804	isolated N-linked mannans	1780:1804	isolated N-linked mannans	1780:1804	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	2	47	from	adhesion	370:377	arg1	heart					321:325	the heart	317:325	the heart	317:325	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	4	48	theme	coronary	758:765	arg1	endothelium					767:777	the coronary endothelium	754:777	the coronary endothelium	754:777	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	7	49	theme	O-linked	1645:1652	arg1	mannans					1654:1660	isolated O-linked mannans	1636:1660	isolated O-linked mannans	1636:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	7	50	theme	C.	1596:1597	arg1	albicans					1599:1606	live C. albicans	1591:1606	live C. albicans without N-linked mannans or isolated O-linked mannans	1591:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	7	50	theme	C.	1596:1597	arg1	walls					1584:1588	isolated cell walls	1570:1588	isolated cell walls	1570:1588	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	4	51	theme	albicans	721:728	arg1	wall					710:713	the cell wall	701:713	the cell wall of C. albicans	701:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	5	52	theme	live	1067:1070	arg1	yeasts					1090:1095	C. albicans pmr1Δ yeasts	1072:1095	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	53	from	LVP	1841:1843	arg1	response					1848:1855	response	1848:1855	response to the same agonists	1848:1876	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	5	54	dep	treatments	977:986	arg1	isolated					1217:1224	isolated	1217:1224	(4) isolated N-linked and O-linked mannans	1213:1254	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	54	dep	treatments	977:986	arg1	consisting					988:997	consisting	988:997	consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	988:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	9	55	theme	greater	2038:2044	arg1	extent					2046:2051	a greater extent	2036:2051	a greater extent	2036:2051	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	5	56	theme	N-linked	1178:1185	arg1	mannans					1200:1206	N-linked and O-linked mannans	1178:1206	N-linked and O-linked mannans	1178:1206	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	57	theme	heart	796:800	arg1	model					802:806	An isolated rat heart model	780:806	An isolated rat heart model	780:806	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	1	58	theme	immunocompromised	231:247	arg1	patients					249:256	immunocompromised patients	231:256	immunocompromised patients	231:256	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	9	59	theme	specific	1953:1960	arg1	receptors					1962:1970	specific receptors	1953:1970	specific receptors on coronary endothelium	1953:1994	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	7	60	theme	cell	1579:1582	arg1	albicans					1599:1606	live C. albicans	1591:1606	live C. albicans without N-linked mannans or isolated O-linked mannans	1591:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	7	60	theme	cell	1579:1582	arg1	walls					1584:1588	isolated cell walls	1570:1588	isolated cell walls	1570:1588	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	8	61	theme	same	1864:1867	arg1	agonists					1869:1876	the same agonists	1860:1876	the same agonists	1860:1876	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	5	62	theme	O-linked	1191:1198	arg1	mannans					1200:1206	N-linked and O-linked mannans	1178:1206	N-linked and O-linked mannans	1178:1206	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	63	theme	O-linked	1239:1246	arg1	mannans					1248:1254	N-linked and O-linked mannans	1226:1254	N-linked and O-linked mannans	1226:1254	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	9	64	dep	C.	1917:1918	arg1	albicans					1920:1927	albicans	1920:1927	albicans	1920:1927	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	5	65	dep	N-linked	1117:1124	arg1	shorter					1109:1115	shorter	1109:1115	shorter	1109:1115	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	66	link	O-linked	1239:1246	arg1	mannans					1248:1254	N-linked and O-linked mannans	1226:1254	N-linked and O-linked mannans	1226:1254	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	9	67	link	O-linked	2005:2012	arg1	mannan					2014:2019	O-linked mannan	2005:2019	O-linked mannan	2005:2019	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	8	68	dep	CPP	1833:1835	arg1	the					1829:1831	the	1829:1831	the	1829:1831	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	6	69	theme	coronary	1340:1347	arg1	pressure					1359:1366	heart coronary perfusion pressure	1334:1366	heart coronary perfusion pressure (vascular effect)	1334:1384	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	69	theme	coronary	1340:1347	arg1	effect					1378:1383	vascular effect	1369:1383	vascular effect	1369:1383	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	5	70	theme	rat	792:794	arg1	model					802:806	An isolated rat heart model	780:806	An isolated rat heart model	780:806	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	71	dep	C.	1721:1722	arg1	albicans					1724:1731	albicans	1724:1731	albicans	1724:1731	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	7	72	theme	Similar	1535:1541	arg1	results					1543:1549	Similar results	1535:1549	Similar results	1535:1549	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	0	73	from	GPCRs	60:64	arg1	Endothelium					82:92	the Coronary Endothelium	69:92	the Coronary Endothelium	69:92	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	1	74	theme	fungal	177:182	arg1	pathogen					184:191	an opportunistic fungal pathogen	160:191	an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs	160:311	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	1	74	theme	fungal	177:182	arg1	albicans					148:155	Candida albicans	140:155	Candida albicans	140:155	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	6	75	dep	Phe	1461:1463	arg1	response					1449:1456	response	1449:1456	response	1449:1456	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	5	76	dep	yeasts	1090:1095	arg1	2					1064:1064	2	1064:1064	2	1064:1064	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	76	dep	yeasts	1090:1095	arg1	3					1150:1150	3	1150:1150	3	1150:1150	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	76	dep	yeasts	1090:1095	arg1	albicans					1161:1168	C. albicans	1158:1168	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	8	77	link	N-linked	1789:1796	arg1	mannans					1798:1804	isolated N-linked mannans	1780:1804	isolated N-linked mannans	1780:1804	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	5	78	theme	N-linked	1226:1233	arg1	mannans					1248:1254	N-linked and O-linked mannans	1226:1254	N-linked and O-linked mannans	1226:1254	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	6	79	theme	albicans	1315:1322	arg1	WT					1324:1325	C. albicans WT	1312:1325	C. albicans WT	1312:1325	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	8	80	from	able	1815:1818	arg1	contrast					1695:1702	contrast	1695:1702	contrast	1695:1702	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	9	81	from	receptors	1962:1970	arg1	endothelium					1984:1994	coronary endothelium	1975:1994	coronary endothelium	1975:1994	Taken together, our data suggest that C. albicans interaction occurs with specific receptors on coronary endothelium and that O-linked mannan contributes to a greater extent to this interaction.
36836256	6	82	theme	left	1390:1393	arg1	pressure					1407:1414	left ventricular pressure	1390:1414	left ventricular pressure (inotropic effect)	1390:1433	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	82	theme	left	1390:1393	arg1	effect					1427:1432	inotropic effect	1417:1432	inotropic effect	1417:1432	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	5	83	link	O-linked	1130:1137	arg1	mannans					1139:1145	shorter N-linked and O-linked mannans	1109:1145	shorter N-linked and O-linked mannans	1109:1145	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	4	84	theme	functional	641:650	arg1	contribution					652:663	the functional contribution	637:663	the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium	637:777	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	5	85	theme	N-linked	1117:1124	arg1	mannans					1139:1145	shorter N-linked and O-linked mannans	1109:1145	shorter N-linked and O-linked mannans	1109:1145	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	6	86	dep	pressure	1359:1366	arg1	parameters					1435:1444	parameters	1435:1444	parameters	1435:1444	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	5	87	link	N-linked	1117:1124	arg1	mannans					1139:1145	shorter N-linked and O-linked mannans	1109:1145	shorter N-linked and O-linked mannans	1109:1145	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	88	theme	O-linked	1130:1137	arg1	mannans					1139:1145	shorter N-linked and O-linked mannans	1109:1145	shorter N-linked and O-linked mannans	1109:1145	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	6	89	theme	vascular	1369:1376	arg1	pressure					1359:1366	heart coronary perfusion pressure	1334:1366	heart coronary perfusion pressure (vascular effect)	1334:1384	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	89	theme	vascular	1369:1376	arg1	effect					1378:1383	vascular effect	1369:1383	vascular effect	1369:1383	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	4	90	with	interaction	737:747	arg1	endothelium					767:777	the coronary endothelium	754:777	the coronary endothelium	754:777	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	0	91	theme	Coronary	73:80	arg1	Endothelium					82:92	the Coronary Endothelium	69:92	the Coronary Endothelium	69:92	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	5	92	dep	C.	1033:1034	arg1	albicans					1036:1043	albicans	1036:1043	albicans	1036:1043	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	1	93	theme	other	300:304	arg1	organs					306:311	other organs	300:311	other organs	300:311	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	10	94	theme	specific	2121:2128	arg1	receptors					2130:2138	specific receptors	2121:2138	specific receptors	2121:2138	Further studies are necessary to elucidate why specific receptors preferentially interact with this fungal cell wall structure.
36836256	5	95	dep	heat-killed	1016:1026	arg1	HK					1029:1030	HK	1029:1030	HK	1029:1030	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	4	96	theme	wall	710:713	arg1	mannans					690:696	N-linked and O-linked mannans	668:696	N-linked and O-linked mannans of the cell wall of C. albicans	668:728	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	3	97	theme	fungal	425:430	arg1	wall					437:440	the fungal cell wall	421:440	the fungal cell wall's outermost structure	421:462	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	8	98	theme	O-linked	1760:1767	arg1	mannans					1769:1775	O-linked mannans	1760:1775	O-linked mannans	1760:1775	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	6	99	theme	inotropic	1417:1425	arg1	pressure					1407:1414	left ventricular pressure	1390:1414	left ventricular pressure (inotropic effect)	1390:1433	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	6	99	theme	inotropic	1417:1425	arg1	effect					1427:1432	inotropic effect	1417:1432	inotropic effect	1417:1432	Our results showed that C. albicans WT alters heart coronary perfusion pressure (vascular effect) and left ventricular pressure (inotropic effect) parameters in response to Phe and Ang II but not aCh, and these effects can be reversed by mannose.
36836256	8	100	dep	C.	1705:1706	arg1	albicans					1708:1715	albicans	1708:1715	albicans	1708:1715	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	5	101	dep	live	1007:1010	arg1	C.					1033:1034	C.	1033:1034	C.	1033:1034	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	0	102	theme	Candida	20:26	arg1	albicans					28:35	Candida albicans	20:35	Candida albicans	20:35	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	3	103	theme	host	599:602	arg1	tissue					604:609	the host tissue	595:609	the host tissue	595:609	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	4	104	theme	mannans	690:696	arg1	contribution					652:663	the functional contribution	637:663	the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium	637:777	In this work, we studied the functional contribution of N-linked and O-linked mannans of the cell wall of C. albicans to the interaction with the coronary endothelium.
36836256	3	105	theme	outermost	444:452	arg1	structure					454:462	the fungal cell wall's outermost structure	421:462	the fungal cell wall's outermost structure	421:462	Being the fungal cell wall's outermost structure and the first to come in contact with host cells, it greatly modulates the interplay that later will derive in the colonization of the host tissue.
36836256	8	106	theme	N-linked	1789:1796	arg1	mannans					1798:1804	isolated N-linked mannans	1780:1804	isolated N-linked mannans	1780:1804	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	2	107	theme	fungus	386:391	arg1	step					340:343	the initial step	328:343	the initial step prior to invasion	328:361	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	2	107	theme	fungus	386:391	arg1	adhesion					370:377	the adhesion	366:377	the adhesion of the fungus to endothelial cells	366:412	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	0	108	theme	Specific	51:58	arg1	GPCRs					60:64	Specific GPCRs	51:64	Specific GPCRs in the Coronary Endothelium	51:92	O-Linked Glycans of Candida albicans Interact with Specific GPCRs in the Coronary Endothelium and Inhibit the Cardiac Response to Agonists.
36836256	7	109	theme	isolated	1636:1643	arg1	mannans					1654:1660	isolated O-linked mannans	1636:1660	isolated O-linked mannans	1636:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	7	110	theme	N-linked	1616:1623	arg1	mannans					1625:1631	N-linked mannans	1616:1631	N-linked mannans	1616:1631	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	10	111	theme	wall	2186:2189	arg1	structure					2191:2199	this fungal cell wall structure	2169:2199	this fungal cell wall structure	2169:2199	Further studies are necessary to elucidate why specific receptors preferentially interact with this fungal cell wall structure.
36836256	2	112	theme	initial	332:338	arg1	step					340:343	the initial step	328:343	the initial step prior to invasion	328:361	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	2	112	theme	initial	332:338	arg1	adhesion					370:377	the adhesion	366:377	the adhesion of the fungus to endothelial cells	366:412	In the heart, the initial step prior to invasion is the adhesion of the fungus to endothelial cells.
36836256	5	113	from	effects	880:886	arg1	response					891:898	response	891:898	response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II)	891:970	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	7	114	link	N-linked	1616:1623	arg1	mannans					1625:1631	N-linked mannans	1616:1631	N-linked mannans	1616:1631	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	8	115	from	contrast	1695:1702	arg1	able					1815:1818	able	1815:1818	able	1815:1818	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	8	116	from	CPP	1833:1835	arg1	response					1848:1855	response	1848:1855	response to the same agonists	1848:1876	In contrast, C. albicans HK, C. albicans pmr1Δ, C. albicans without O-linked mannans or isolated N-linked mannans were not able to alter the CPP and LVP in response to the same agonists.
36836256	5	117	theme	C.	1072:1073	arg1	yeasts					1090:1095	C. albicans pmr1Δ yeasts	1072:1095	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	1	118	theme	invasive	208:215	arg1	infections					217:226	invasive infections	208:226	invasive infections	208:226	Candida albicans is an opportunistic fungal pathogen that may cause invasive infections in immunocompromised patients, disseminating through the bloodstream to other organs.
36836256	7	119	theme	live	1591:1594	arg1	albicans					1599:1606	live C. albicans	1591:1606	live C. albicans without N-linked mannans or isolated O-linked mannans	1591:1660	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	7	119	theme	live	1591:1594	arg1	walls					1584:1588	isolated cell walls	1570:1588	isolated cell walls	1570:1588	Similar results were observed when isolated cell walls, live C. albicans without N-linked mannans or isolated O-linked mannans were perfused into the heart.
36836256	5	120	link	N-linked	1226:1233	arg1	mannans					1248:1254	N-linked and O-linked mannans	1226:1254	N-linked and O-linked mannans	1226:1254	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36836256	5	121	theme	pmr1Δ	1084:1088	arg1	yeasts					1090:1095	C. albicans pmr1Δ yeasts	1072:1095	(1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans;	1003:1207	An isolated rat heart model was used to assess cardiac parameters related to vascular and inotropic effects in response to phenylephrine (Phe), acetylcholine (aCh) and angiotensin II (Ang II) when treatments consisting of: (1) live and heat-killed (HK) C. albicans wild-type yeasts; (2) live C. albicans pmr1Δ yeasts (displaying shorter N-linked and O-linked mannans); (3) live C. albicans without N-linked and O-linked mannans; and (4) isolated N-linked and O-linked mannans were administered to the heart.
36749437	6	0	theme	high	1051:1054	arg1	content					1056:1062	high content	1051:1062	high content of 4-O-sulfated disaccharides	1051:1092	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	4	1	theme	liquid	620:625	arg1	spectrometry					671:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	0	2	from	leech	77:81	arg1	glycosaminoglycans					47:64	glycosaminoglycans	47:64	glycosaminoglycans from dried leech	47:81	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	0	2	from	leech	77:81	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	0	2	from	leech	77:81	arg1	activities					33:42	antioxidant activities	21:42	antioxidant activities	21:42	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	8	3	theme	structural	1320:1329	arg1	information					1331:1341	This novel structural information	1309:1341	This novel structural information	1309:1341	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	4	4	theme	trap/time-of-flight	646:664	arg1	spectrometry					671:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	5	5	theme	sulfate/dermatan	756:771	arg1	sulfate					773:779	chondroitin sulfate/dermatan sulfate	744:779	chondroitin sulfate/dermatan sulfate	744:779	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	6	6	theme	equal	922:926	arg1	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	6	theme	equal	922:926	arg1	amount					928:933	an equal amount	919:933	an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides	919:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	7	theme	sulfate	1017:1023	arg1	sulfate					1035:1041	chondroitin sulfate /dermatan sulfate	1005:1041	chondroitin sulfate /dermatan sulfate	1005:1041	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	1	8	theme	Chinese	173:179	arg1	medicine					181:188	a traditional animal-based Chinese medicine	146:188	a traditional animal-based Chinese medicine	146:188	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	8	theme	Chinese	173:179	arg1	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	8	9	from	involvement	1375:1385	arg1	activities					1430:1439	the biological activities	1415:1439	the biological activities of the dried leech	1415:1458	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	5	10	theme	Heparan	724:730	arg1	sulfate					732:738	Heparan sulfate	724:738	Heparan sulfate	724:738	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	6	11	theme	sulfate	895:901	arg1	species					903:909	Heparan sulfate species	887:909	Heparan sulfate species	887:909	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	8	12	theme	possible	1366:1373	arg1	involvement					1375:1385	the possible involvement	1362:1385	the possible involvement of these polysaccharides in the biological activities of the dried leech	1362:1458	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	4	13	theme	electrophoresis	707:721	arg1	combination					564:574	the combination	560:574	the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis	560:721	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	2	14	theme	mammalian	300:308	arg1	glycosaminoglycans					310:327	mammalian glycosaminoglycans	300:327	mammalian glycosaminoglycans	300:327	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	8	15	theme	leech	1454:1458	arg1	activities					1430:1439	the biological activities	1415:1439	the biological activities of the dried leech	1415:1458	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	5	16	theme	varied	815:820	arg1	compositions					835:846	varied disaccharide compositions	815:846	varied disaccharide compositions	815:846	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	7	17	theme	heparan	1157:1163	arg1	sulfate					1165:1171	heparan sulfate	1157:1171	heparan sulfate	1157:1171	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	8	18	theme	polysaccharides	1396:1410	arg1	involvement					1375:1385	the possible involvement	1362:1385	the possible involvement of these polysaccharides in the biological activities of the dried leech	1362:1458	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	6	19	theme	disaccharides	1080:1092	arg1	content					1056:1062	high content	1051:1062	high content of 4-O-sulfated disaccharides	1051:1092	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	4	20	theme	dried	491:495	arg1	leech					497:501	dried leech	491:501	dried leech for the first time	491:520	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	7	21	theme	chondroitin/dermatan	1177:1196	arg1	sulfate					1198:1204	chondroitin/dermatan sulfate	1177:1204	chondroitin/dermatan sulfate	1177:1204	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	5	22	theme	heterogeneous	862:874	arg1	structure					876:884	a heterogeneous structure	860:884	a heterogeneous structure	860:884	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	2	23	theme	various	239:245	arg1	activities					258:267	various biological activities	239:267	various biological activities that are often associated with mammalian glycosaminoglycans	239:327	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	1	24	theme	traditional	148:158	arg1	medicine					181:188	a traditional animal-based Chinese medicine	146:188	a traditional animal-based Chinese medicine	146:188	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	24	theme	traditional	148:158	arg1	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	0	25	from	Characterization	0:15	arg1	leech					77:81	dried leech	71:81	dried leech	71:81	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	3	26	theme	possible	358:365	arg1	characteristics					378:392	possible structural characteristics	358:392	possible structural characteristics	358:392	However, their presence and possible structural characteristics within dried leech were previously unknown.
36749437	4	27	attach	isolated	477:484	arg1	leech					497:501	dried leech	491:501	dried leech for the first time	491:520	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	4	27	attach	isolated	477:484	arg2	glycosaminoglycans					453:470	glycosaminoglycans	453:470	glycosaminoglycans	453:470	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	4	28	theme	first	511:515	arg1	time					517:520	the first time	507:520	the first time	507:520	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	9	29	theme	ABTS	1515:1518	arg1	ability					1539:1545	a strong ABTS radical scavenging ability	1506:1545	a strong ABTS radical scavenging ability	1506:1545	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	1	30	theme	Whitmania	97:105	arg1	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	30	theme	Whitmania	97:105	arg1	whitman					113:119	Whitmania pigra whitman	97:119	Whitmania pigra whitman	97:119	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	3	31	theme	dried	401:405	arg1	leech					407:411	dried leech	401:411	dried leech	401:411	However, their presence and possible structural characteristics within dried leech were previously unknown.
36749437	0	32	theme	antioxidant	21:31	arg1	activities					33:42	antioxidant activities	21:42	antioxidant activities	21:42	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	9	33	theme	scavenging	1528:1537	arg1	ability					1539:1545	a strong ABTS radical scavenging ability	1506:1545	a strong ABTS radical scavenging ability	1506:1545	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	4	34	theme	infrared	597:604	arg1	spectroscopy					606:617	Fourier-transform infrared spectroscopy	579:617	Fourier-transform infrared spectroscopy	579:617	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	9	35	theme	nutraceutical	1626:1638	arg1	industries					1659:1668	the nutraceutical and pharmaceutical industries	1622:1668	the nutraceutical and pharmaceutical industries	1622:1668	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	9	36	from	exploitation	1606:1617	arg1	industries					1659:1668	the nutraceutical and pharmaceutical industries	1622:1668	the nutraceutical and pharmaceutical industries	1622:1668	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	6	37	theme	acetylated	973:982	arg1	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	38	theme	N-sulfated	958:967	arg1	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	39	theme	2-O-sulfated	944:955	arg1	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	4	40	theme	mass	666:669	arg1	spectrometry					671:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	2	41	theme	Dried	191:195	arg1	extracts					203:210	Dried leech extracts	191:210	Dried leech extracts	191:210	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	9	42	theme	leech	1580:1584	arg1	polysaccharides					1586:1600	leech polysaccharides	1580:1600	leech polysaccharides	1580:1600	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	5	43	theme	chondroitin	744:754	arg1	sulfate					773:779	chondroitin sulfate/dermatan sulfate	744:779	chondroitin sulfate/dermatan sulfate	744:779	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	8	44	theme	novel	1314:1318	arg1	information					1331:1341	This novel structural information	1309:1341	This novel structural information	1309:1341	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	6	45	theme	/dermatan	1025:1033	arg1	sulfate					1035:1041	chondroitin sulfate /dermatan sulfate	1005:1041	chondroitin sulfate /dermatan sulfate	1005:1041	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	4	46	theme	chromatography-ion	627:644	arg1	spectrometry					671:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	liquid chromatography-ion trap/time-of-flight mass spectrometry	620:682	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	7	47	theme	chondroitin/dermatan	1248:1267	arg1	sulfate					1269:1275	chondroitin/dermatan sulfate	1248:1275	chondroitin/dermatan sulfate being by far the most abundant	1248:1306	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	1	48	theme	animal-based	160:171	arg1	medicine					181:188	a traditional animal-based Chinese medicine	146:188	a traditional animal-based Chinese medicine	146:188	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	48	theme	animal-based	160:171	arg1	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	6	49	theme	chondroitin	1005:1015	arg1	sulfate					1035:1041	chondroitin sulfate /dermatan sulfate	1005:1041	chondroitin sulfate /dermatan sulfate	1005:1041	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	1	50	used	used	138:141	arg2	whitman					113:119	Whitmania pigra whitman	97:119	Whitmania pigra whitman	97:119	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	50	used	used	138:141	arg2	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	50	used	used	138:141	arg2	medicine					181:188	a traditional animal-based Chinese medicine	146:188	a traditional animal-based Chinese medicine	146:188	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	6	51	contain	contain	1043:1049	arg2	content					1056:1062	high content	1051:1062	high content of 4-O-sulfated disaccharides	1051:1092	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	51	contain	contain	1043:1049	arg1	sulfate					1035:1041	chondroitin sulfate /dermatan sulfate	1005:1041	chondroitin sulfate /dermatan sulfate	1005:1041	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	9	52	theme	pharmaceutical	1644:1657	arg1	industries					1659:1668	the nutraceutical and pharmaceutical industries	1622:1668	the nutraceutical and pharmaceutical industries	1622:1668	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	8	53	theme	biological	1419:1428	arg1	activities					1430:1439	the biological activities	1415:1439	the biological activities of the dried leech	1415:1458	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	5	54	theme	dried	798:802	arg1	leech					804:808	dried leech	798:808	dried leech	798:808	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	6	55	theme	Heparan	887:893	arg1	sulfate					895:901	Heparan sulfate	887:901	Heparan sulfate species	887:909	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	4	56	theme	gel	703:705	arg1	electrophoresis					707:721	polyacrylamide gel electrophoresis	688:721	polyacrylamide gel electrophoresis	688:721	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	7	57	theme	dried	1209:1213	arg1	leech					1215:1219	dried leech	1209:1219	dried leech	1209:1219	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	5	58	located	detected	786:793	arg1	leech					804:808	dried leech	798:808	dried leech	798:808	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	5	58	located	detected	786:793	arg2	sulfate					732:738	Heparan sulfate	724:738	Heparan sulfate	724:738	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	5	58	located	detected	786:793	arg2	sulfate					773:779	chondroitin sulfate/dermatan sulfate	744:779	chondroitin sulfate/dermatan sulfate	744:779	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	8	59	theme	dried	1448:1452	arg1	leech					1454:1458	the dried leech	1444:1458	the dried leech	1444:1458	This novel structural information could help clarify the possible involvement of these polysaccharides in the biological activities of the dried leech.
36749437	7	60	theme	sulfate	1198:1204	arg1	contents					1145:1152	the contents	1141:1152	the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech	1141:1219	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	7	61	theme	sulfate	1165:1171	arg1	contents					1145:1152	the contents	1141:1152	the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech	1141:1219	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	6	62	theme	4-O-sulfated	1067:1078	arg1	disaccharides					1080:1092	4-O-sulfated disaccharides	1067:1092	4-O-sulfated disaccharides	1067:1092	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	2	63	theme	biological	247:256	arg1	activities					258:267	various biological activities	239:267	various biological activities that are often associated with mammalian glycosaminoglycans	239:327	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	7	64	from	contents	1145:1152	arg1	leech					1215:1219	dried leech	1209:1219	dried leech	1209:1219	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	0	65	from	activities	33:42	arg1	leech					77:81	dried leech	71:81	dried leech	71:81	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	5	66	theme	disaccharide	822:833	arg1	compositions					835:846	varied disaccharide compositions	815:846	varied disaccharide compositions	815:846	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	9	67	theme	leech	1474:1478	arg1	glycosaminoglycans					1480:1497	leech glycosaminoglycans	1474:1497	leech glycosaminoglycans	1474:1497	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	7	68	theme	quantitative	1105:1116	arg1	analysis					1118:1125	the quantitative analysis	1101:1125	the quantitative analysis	1101:1125	Also, the quantitative analysis revealed that the contents of heparan sulfate and chondroitin/dermatan sulfate in dried leech varied significantly, with chondroitin/dermatan sulfate being by far the most abundant.
36749437	5	69	contain	possess	852:858	arg2	structure					876:884	a heterogeneous structure	860:884	a heterogeneous structure	860:884	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	5	69	contain	possess	852:858	arg1	sulfate					732:738	Heparan sulfate	724:738	Heparan sulfate	724:738	Heparan sulfate and chondroitin sulfate/dermatan sulfate were detected in dried leech with varied disaccharide compositions and possess a heterogeneous structure.
36749437	1	70	theme	Dried	84:88	arg1	medicine					181:188	a traditional animal-based Chinese medicine	146:188	a traditional animal-based Chinese medicine	146:188	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	70	theme	Dried	84:88	arg1	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	70	theme	Dried	84:88	arg1	whitman					113:119	Whitmania pigra whitman	97:119	Whitmania pigra whitman	97:119	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	3	71	theme	structural	367:376	arg1	characteristics					378:392	possible structural characteristics	358:392	possible structural characteristics	358:392	However, their presence and possible structural characteristics within dried leech were previously unknown.
36749437	9	72	theme	strong	1508:1513	arg1	ability					1539:1545	a strong ABTS radical scavenging ability	1506:1545	a strong ABTS radical scavenging ability	1506:1545	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	4	73	theme	Fourier-transform	579:595	arg1	spectroscopy					606:617	Fourier-transform infrared spectroscopy	579:617	Fourier-transform infrared spectroscopy	579:617	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	9	74	theme	radical	1520:1526	arg1	ability					1539:1545	a strong ABTS radical scavenging ability	1506:1545	a strong ABTS radical scavenging ability	1506:1545	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
36749437	1	75	theme	pigra	107:111	arg1	leech					90:94	Dried leech	84:94	Dried leech (Whitmania pigra whitman)	84:120	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	1	75	theme	pigra	107:111	arg1	whitman					113:119	Whitmania pigra whitman	97:119	Whitmania pigra whitman	97:119	Dried leech (Whitmania pigra whitman) has been widely used as a traditional animal-based Chinese medicine.
36749437	4	76	theme	spectroscopy	606:617	arg1	combination					564:574	the combination	560:574	the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis	560:721	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	0	77	theme	glycosaminoglycans	47:64	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	0	77	theme	glycosaminoglycans	47:64	arg1	activities					33:42	antioxidant activities	21:42	antioxidant activities	21:42	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	6	78	theme	disaccharides	984:996	arg1	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	78	theme	disaccharides	984:996	arg1	amount					928:933	an equal amount	919:933	an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides	919:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	79	contain	possess	911:917	arg1	species					903:909	Heparan sulfate species	887:909	Heparan sulfate species	887:909	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	79	contain	possess	911:917	arg2	amount					928:933	an equal amount	919:933	an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides	919:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	6	79	contain	possess	911:917	arg2	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	0	80	theme	dried	71:75	arg1	leech					77:81	dried leech	71:81	dried leech	71:81	Characterization and antioxidant activities of glycosaminoglycans from dried leech.
36749437	4	81	theme	spectrometry	671:682	arg1	combination					564:574	the combination	560:574	the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis	560:721	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	2	82	theme	leech	197:201	arg1	extracts					203:210	Dried leech extracts	191:210	Dried leech extracts	191:210	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	6	83	theme	total	938:942	arg1	disaccharides					984:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	total 2-O-sulfated, N-sulfated and acetylated disaccharides	938:996	Heparan sulfate species possess an equal amount of total 2-O-sulfated, N-sulfated and acetylated disaccharides, while chondroitin sulfate /dermatan sulfate contain high content of 4-O-sulfated disaccharides.
36749437	4	84	theme	polyacrylamide	688:701	arg1	electrophoresis					707:721	polyacrylamide gel electrophoresis	688:721	polyacrylamide gel electrophoresis	688:721	In this study, glycosaminoglycans were isolated from dried leech for the first time and their structures were analyzed by the combination of Fourier-transform infrared spectroscopy, liquid chromatography-ion trap/time-of-flight mass spectrometry and polyacrylamide gel electrophoresis.
36749437	2	85	contain	have	234:237	arg2	activities					258:267	various biological activities	239:267	various biological activities that are often associated with mammalian glycosaminoglycans	239:327	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	2	85	contain	have	234:237	arg1	extracts					203:210	Dried leech extracts	191:210	Dried leech extracts	191:210	Dried leech extracts have been reported to have various biological activities that are often associated with mammalian glycosaminoglycans.
36749437	9	86	theme	polysaccharides	1586:1600	arg1	potential					1567:1575	the potential	1563:1575	the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries	1563:1668	Furthermore, leech glycosaminoglycans showed a strong ABTS radical scavenging ability, which suggests the potential of leech polysaccharides for exploitation in the nutraceutical and pharmaceutical industries.
37119897	2	0	theme	PS/XG	446:450	arg1	synergism					452:460	PS/XG synergism	446:460	PS/XG synergism	446:460	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	1	1	theme	unstable	166:173	arg1	interactions					175:186	The limited and unstable interactions	150:186	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM)	150:256	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	4	2	theme	enhanced	884:891	arg1	synergism					893:901	The enhanced synergism	880:901	The enhanced synergism of PS/XG after CMFT	880:921	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	1	3	theme	starchy	309:315	arg1	products					317:324	starchy products	309:324	starchy products	309:324	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	1	4	theme	simple	239:244	arg1	SM					254:255	SM	254:255	SM	254:255	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	1	4	theme	simple	239:244	arg1	mixing					246:251	simple mixing	239:251	simple mixing (SM)	239:256	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	0	5	theme	structural	103:112	arg1	characteristics					114:128	structural characteristics	103:128	structural characteristics	103:128	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	0	6	from	Effects	0:6	arg1	functionalities					86:100	functionalities	86:100	functionalities	86:100	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	0	6	from	Effects	0:6	arg1	characteristics					114:128	structural characteristics	103:128	structural characteristics	103:128	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	0	6	from	Effects	0:6	arg1	digestibility					135:147	digestibility	135:147	digestibility	135:147	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	0	6	from	Effects	0:6	arg1	properties					74:83	their physicochemical properties	52:83	their physicochemical properties	52:83	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	6	7	dep	starch	1277:1282	arg1	NMR					1300:1302	NMR	1300:1302	NMR	1300:1302	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	7	dep	starch	1277:1282	arg1	XRD					1285:1287	XRD	1285:1287	XRD	1285:1287	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	7	dep	starch	1277:1282	arg1	FTIR					1290:1293	FTIR	1290:1293	FTIR	1290:1293	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	4	8	dep	~3600	974:978	arg1	to					989:990	to	989:990	to	989:990	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	4	8	dep	~3600	974:978	arg1	Native					981:986	Native	981:986	Native	981:986	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	4	8	dep	~3600	974:978	arg1	~300 mPa·s					992:1001	~300 mPa·s	992:1001	~300 mPa·s	992:1001	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	5	9	theme	resistant	1178:1186	arg1	content					1195:1201	resistant starch content	1178:1201	resistant starch content	1178:1201	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	2	10	theme	Structural	327:336	arg1	unwinding					338:346	Structural unwinding	327:346	Structural unwinding	327:346	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	3	11	theme	decreased	818:826	arg1	WSI					828:830	the significantly decreased WSI	800:830	the significantly decreased WSI	800:830	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	6	12	theme	large	1248:1252	arg1	structures					1263:1272	large packaged structures	1248:1272	large packaged structures	1248:1272	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	13	theme	structures	1263:1272	arg1	loss					1240:1243	the partial melting and loss	1216:1243	loss	1240:1243	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	13	theme	structures	1263:1272	arg1	melting					1228:1234	the partial melting and loss	1216:1243	melting	1228:1234	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	14	theme	packaged	1254:1261	arg1	structures					1263:1272	large packaged structures	1248:1272	large packaged structures	1248:1272	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	4	15	theme	PS/XG	906:910	arg1	synergism					893:901	The enhanced synergism	880:901	The enhanced synergism of PS/XG after CMFT	880:921	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	3	16	with	clusters	616:623	arg1	surface					647:653	a rough granular surface	630:653	a rough granular surface	630:653	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	1	17	theme	potato	196:201	arg1	starch					203:208	potato starch	196:208	potato starch (PS)	196:213	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	1	17	theme	potato	196:201	arg1	PS					211:212	PS	211:212	PS	211:212	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	2	18	used	used	430:433	arg2	rearrangement					352:364	rearrangement	352:364	rearrangement	352:364	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	2	18	used	used	430:433	arg2	unwinding					338:346	Structural unwinding	327:346	Structural unwinding	327:346	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	3	19	theme	large	610:614	arg1	clusters					616:623	large clusters	610:623	large clusters with a rough granular surface	610:653	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	0	20	theme	starch-xanthan	20:33	arg1	synergism					39:47	enhanced starch-xanthan gum synergism	11:47	enhanced starch-xanthan gum synergism	11:47	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	3	21	theme	released	691:698	arg1	starches					708:715	released soluble starches	691:715	released soluble starches	691:715	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	2	22	theme	structural	509:518	arg1	properties					520:529	structural properties	509:529	structural properties	509:529	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	0	23	theme	enhanced	11:18	arg1	synergism					39:47	enhanced starch-xanthan gum synergism	11:47	enhanced starch-xanthan gum synergism	11:47	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	4	24	theme	breakdown	949:957	arg1	viscosity					959:967	the breakdown viscosity	945:967	the breakdown viscosity	945:967	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	2	25	theme	critical	382:389	arg1	melting					391:397	critical melting	382:397	critical melting	382:397	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	0	26	theme	synergism	39:47	arg1	Effects					0:6	Effects	0:6	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility	0:147	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	3	27	theme	compact	762:768	arg1	composite					747:755	the composite	743:755	the composite more compact to thermal processes, such as the significantly decreased WSI and SP	743:837	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	0	28	theme	gum	35:37	arg1	synergism					39:47	enhanced starch-xanthan gum synergism	11:47	enhanced starch-xanthan gum synergism	11:47	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	5	29	theme	functional	1100:1109	arg1	properties					1111:1120	the functional properties	1096:1120	the functional properties	1096:1120	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	5	29	theme	functional	1100:1109	arg1	content					1195:1201	resistant starch content	1178:1201	resistant starch content	1178:1201	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	5	29	theme	functional	1100:1109	arg1	absorptions					1162:1172	water/oil absorptions	1152:1172	water/oil absorptions	1152:1172	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	3	30	theme	Native	563:568	arg1	"					569:569	"Native"	562:569	"Native"	562:569	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	3	31	theme	melting	858:864	arg1	temperatures					866:877	the melting temperatures	854:877	the melting temperatures	854:877	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	1	32	theme	xanthan	219:225	arg1	XG					232:233	XG	232:233	XG	232:233	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	1	32	theme	xanthan	219:225	arg1	gum					227:229	xanthan gum	219:229	xanthan gum (XG)	219:234	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	1	33	from	changes	298:304	arg1	products					317:324	starchy products	309:324	starchy products	309:324	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	4	34	theme	final	1021:1025	arg1	viscosity					1027:1035	the final viscosity	1017:1035	the final viscosity	1017:1035	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	3	35	theme	rough	632:636	arg1	surface					647:653	a rough granular surface	630:653	a rough granular surface	630:653	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	3	36	theme	soluble	700:706	arg1	starches					708:715	released soluble starches	691:715	released soluble starches	691:715	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	6	37	theme	partial	1220:1226	arg1	melting					1228:1234	the partial melting and loss	1216:1243	melting	1228:1234	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	3	38	theme	clusters	616:623	arg1	formation					597:605	the formation	593:605	the formation of large clusters with a rough granular surface	593:653	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	6	39	theme	crystalline	1338:1348	arg1	structure					1350:1358	crystalline structure	1338:1358	crystalline structure controlled at approximately 20 % and 30 %, respectively	1338:1414	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	5	40	theme	starch	1188:1193	arg1	content					1195:1201	resistant starch content	1178:1201	resistant starch content	1178:1201	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	1	41	theme	substantial	286:296	arg1	changes					298:304	substantial changes	286:304	substantial changes in starchy products	286:324	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	3	42	theme	thermal	773:779	arg1	SP					836:837	SP	836:837	SP	836:837	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	3	42	theme	thermal	773:779	arg1	WSI					828:830	the significantly decreased WSI	800:830	the significantly decreased WSI	800:830	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	3	42	theme	thermal	773:779	arg1	processes					781:789	thermal processes	773:789	thermal processes	773:789	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	5	43	theme	PS/XG	1125:1129	arg1	composite					1131:1139	PS/XG composite	1125:1139	PS/XG composite	1125:1139	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	6	44	theme	PS/XG	1454:1458	arg1	interaction					1460:1470	PS/XG interaction	1454:1470	PS/XG interaction	1454:1470	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	45	theme	structure	1350:1358	arg1	loss					1330:1333	the loss	1326:1333	the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively	1326:1414	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	45	theme	structure	1350:1358	arg1	effective					1430:1438	effective	1430:1438	effective	1430:1438	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	6	45	theme	structure	1350:1358	arg1	melting					1314:1320	the melting	1310:1320	the melting	1310:1320	CMFT caused the partial melting and loss of large packaged structures in starch (XRD, FTIR, and NMR), and the melting and the loss of crystalline structure controlled at approximately 20 % and 30 %, respectively, are the most effective for promoting PS/XG interaction.
37119897	5	46	theme	composite	1131:1139	arg1	properties					1111:1120	the functional properties	1096:1120	the functional properties	1096:1120	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	5	46	theme	composite	1131:1139	arg1	content					1195:1201	resistant starch content	1178:1201	resistant starch content	1178:1201	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	5	46	theme	composite	1131:1139	arg1	absorptions					1162:1172	water/oil absorptions	1152:1172	water/oil absorptions	1152:1172	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
37119897	2	47	theme	XG	376:377	arg1	rearrangement					352:364	rearrangement	352:364	rearrangement	352:364	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	2	47	theme	XG	376:377	arg1	unwinding					338:346	Structural unwinding	327:346	Structural unwinding	327:346	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	4	48	dep	~2800	1042:1046	arg1	to					1057:1058	to	1057:1058	to	1057:1058	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	4	48	dep	~2800	1042:1046	arg1	Native					1049:1054	Native	1049:1054	Native	1049:1054	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	4	48	dep	~2800	1042:1046	arg1	~4800					1060:1064	~4800	1060:1064	~4800	1060:1064	The enhanced synergism of PS/XG after CMFT effectively decreased the breakdown viscosity from ~3600 (Native) to ~300 mPa·s and increased the final viscosity from ~2800 (Native) to ~4800.
37119897	1	49	theme	limited	154:160	arg1	interactions					175:186	The limited and unstable interactions	150:186	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM)	150:256	The limited and unstable interactions between potato starch (PS) and xanthan gum (XG) by simple mixing (SM) lead it difficult to induce substantial changes in starchy products.
37119897	2	50	theme	PS	369:370	arg1	rearrangement					352:364	rearrangement	352:364	rearrangement	352:364	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	2	50	theme	PS	369:370	arg1	unwinding					338:346	Structural unwinding	327:346	Structural unwinding	327:346	Structural unwinding and rearrangement of PS and XG by critical melting and freeze-thawing (CMFT) were used to promote PS/XG synergism, and the physicochemical, functionalities, and structural properties were investigated.
37119897	0	51	theme	physicochemical	58:72	arg1	properties					74:83	their physicochemical properties	52:83	their physicochemical properties	52:83	Effects of enhanced starch-xanthan gum synergism on their physicochemical properties, functionalities, structural characteristics, and digestibility.
37119897	3	52	theme	granular	638:645	arg1	surface					647:653	a rough granular surface	630:653	a rough granular surface	630:653	Compared to "Native" and SM, CMFT promoted the formation of large clusters with a rough granular surface and wrapped by a matrix composed of released soluble starches and XG (SEM), thus making the composite more compact to thermal processes, such as the significantly decreased WSI and SP, and increased the melting temperatures.
37119897	5	53	theme	water/oil	1152:1160	arg1	absorptions					1162:1172	water/oil absorptions	1152:1172	water/oil absorptions	1152:1172	CMFT significantly increased the functional properties of PS/XG composite, including water/oil absorptions and resistant starch content.
35581087	11	0	from	increase	1966:1973	arg1	activity					1992:1999	the metabolic activity	1978:1999	the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size	1978:2069	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	7	1	theme	silk	1136:1139	arg1	fibroin					1141:1147	2 wt% silk fibroin	1130:1147	2 wt% silk fibroin	1130:1147	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	3	2	theme	chitosan/silk	557:569	arg1	fibroin					571:577	chitosan/silk fibroin	557:577	chitosan/silk fibroin	557:577	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	1	3	theme	printing	279:286	arg1	process					288:294	post printing process	274:294	post printing process	274:294	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	12	4	theme	subsequent	2318:2327	arg1	biomaterials					2329:2340	subsequent biomaterials	2318:2340	subsequent biomaterials	2318:2340	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	9	5	theme	days	1553:1556	arg1	incubation					1558:1567	28 days incubation	1550:1567	28 days incubation in HEPES solution at two different pH values at 37 °C	1550:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	7	6	theme	wt	1132:1133	arg1	fibroin					1141:1147	2 wt% silk fibroin	1130:1147	2 wt% silk fibroin	1130:1147	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	4	7	from	studies	719:725	arg1	viscometry					730:739	viscometry	730:739	viscometry	730:739	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	7	from	studies	719:725	arg1	modes					757:761	oscillatory modes	745:761	oscillatory modes	745:761	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	9	8	theme	associated	1632:1641	arg1	release					1643:1649	an associated release	1629:1649	an associated release of calcium and phosphorus ions	1629:1680	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	10	9	theme	μm	1705:1706	arg1	porosity					1708:1715	300 μm porosity	1701:1715	300 μm porosity comprising the both polymers in its composition	1701:1763	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	3	10	with	solutions	544:552	arg1	ratios					594:599	different ratios	584:599	different ratios	584:599	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	3	11	theme	total	630:634	arg1	amount					636:641	the total amount	626:641	the total amount of bioceramic solids	626:662	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	3	11	theme	total	630:634	arg1	solids					657:662	bioceramic solids	646:662	bioceramic solids	646:662	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	5	12	theme	mechanical	907:916	arg1	dry					930:932	dry	930:932	dry	930:932	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	5	12	theme	mechanical	907:916	arg1	properties					918:927	mechanical properties	907:927	mechanical properties (dry and wet conditions)	907:952	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	5	12	theme	mechanical	907:916	arg1	wet					938:940	wet	938:940	wet	938:940	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	4	13	with	scaffolds	809:817	arg1	sizes					844:848	different macropore sizes	824:848	different macropore sizes (300 μm and 500 μm)	824:868	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	13	with	scaffolds	809:817	arg1	μm					855:856	300 μm and 500 μm	851:867	μm	855:856	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	13	with	scaffolds	809:817	arg1	μm					866:867	300 μm and 500 μm	851:867	μm	866:867	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	1	14	theme	bioceramic	213:222	arg1	scaffolds					224:232	composite bioceramic scaffolds	203:232	composite bioceramic scaffolds	203:232	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	9	15	theme	ions	1677:1680	arg1	release					1643:1649	an associated release	1629:1649	an associated release of calcium and phosphorus ions	1629:1680	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	0	16	theme	bone	144:147	arg1	regeneration					149:160	bone regeneration	144:160	bone regeneration	144:160	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	0	17	theme	calcium	38:44	arg1	scaffolds					66:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds	0:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.	0:161	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	12	18	dep	bone	2437:2440	arg1	substitutes					2442:2452	substitutes	2442:2452	substitutes	2442:2452	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	12	19	theme	extrusion-based	2264:2278	arg1	techniques					2303:2312	extrusion-based additive manufacturing techniques	2264:2312	extrusion-based additive manufacturing techniques	2264:2312	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	11	20	theme	combined	1913:1920	arg1	polymers					1930:1937	the combined natural polymers	1909:1937	the combined natural polymers	1909:1937	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	8	21	theme	wet	1378:1380	arg1	scaffolds					1382:1390	wet scaffolds	1378:1390	wet scaffolds	1378:1390	This trend was continued in wet scaffolds with a concomitant reduction of mechanical properties.
35581087	0	22	theme	silk	81:84	arg1	fibroin					86:92	silk fibroin	81:92	silk fibroin	81:92	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	2	23	contain	containing	350:359	arg2	concentration					368:380	a high concentration	361:380	a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	361:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	23	contain	containing	350:359	arg1	compositions					337:348	extrudable ink compositions	322:348	extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	322:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	0	24	theme	chitosan/biphasic	20:36	arg1	scaffolds					66:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds	0:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.	0:161	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	4	25	theme	oscillatory	745:755	arg1	modes					757:761	oscillatory modes	745:761	oscillatory modes	745:761	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	7	26	theme	mechanical	1212:1221	arg1	performance					1223:1233	the mechanical performance	1208:1233	the mechanical performance of the printed composite scaffolds	1208:1268	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	10	27	theme	rate	1784:1787	arg1	degradation					1789:1799	the less rate degradation	1775:1799	the less rate degradation	1775:1799	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	12	28	theme	promising	2220:2228	arg1	advances					2182:2189	The advances	2178:2189	The advances presented in this work	2178:2212	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	12	28	theme	promising	2220:2228	arg1	path					2230:2233	a promising path	2218:2233	a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials	2218:2340	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	0	29	theme	printable	102:110	arg1	inks					112:115	Tuning printable inks	95:115	Tuning printable inks	95:115	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	9	30	theme	%	1542:1542	arg1	range					1528:1532	the range	1524:1532	the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C	1524:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	12	31	with	characteristics	2387:2401	arg1	potential					2413:2421	high potential	2408:2421	high potential	2408:2421	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	4	32	theme	different	824:832	arg1	sizes					844:848	different macropore sizes	824:848	different macropore sizes (300 μm and 500 μm)	824:868	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	32	theme	different	824:832	arg1	μm					855:856	300 μm and 500 μm	851:867	μm	855:856	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	32	theme	different	824:832	arg1	μm					866:867	300 μm and 500 μm	851:867	μm	866:867	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	7	33	theme	compressive	1328:1338	arg1	strength					1340:1347	maximum compressive strength	1320:1347	maximum compressive strength	1320:1347	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	2	34	theme	chitosan	491:498	arg1	solutions					478:486	aqueous polymeric solutions	460:486	aqueous polymeric solutions of chitosan and silk fibroin	460:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	5	35	dep	dry	930:932	arg1	conditions					942:951	conditions	942:951	conditions	942:951	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	0	36	theme	Toughening	0:9	arg1	scaffolds					66:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds	0:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.	0:161	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	11	37	theme	full	2095:2098	arg1	filling					2109:2115	the full cellular filling	2091:2115	the full cellular filling of their surfaces	2091:2133	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	5	38	dep	properties	918:927	arg1	dry					930:932	dry	930:932	dry	930:932	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	5	38	dep	properties	918:927	arg1	properties					918:927	mechanical properties	907:927	mechanical properties (dry and wet conditions)	907:952	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	5	38	dep	properties	918:927	arg1	wet					938:940	wet	938:940	wet	938:940	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	2	39	theme	aqueous	460:466	arg1	solutions					478:486	aqueous polymeric solutions	460:486	aqueous polymeric solutions of chitosan and silk fibroin	460:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	7	40	theme	%	1158:1158	arg1	chitosan					1160:1167	a 5 wt% chitosan	1152:1167	a 5 wt% chitosan matrix	1152:1174	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	11	41	theme	significant	1954:1964	arg1	increase					1966:1973	a significant increase	1952:1973	a significant increase	1952:1973	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	9	42	theme	HEPES	1572:1576	arg1	solution					1578:1585	HEPES solution	1572:1585	HEPES solution	1572:1585	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	2	43	theme	embedded	448:455	arg1	hydroxyapatite					405:418	hydroxyapatite	405:418	hydroxyapatite	405:418	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	43	theme	embedded	448:455	arg1	phosphate					437:445	β-tricalcium phosphate	424:445	β-tricalcium phosphate	424:445	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	43	theme	embedded	448:455	arg1	powders					396:402	bioceramic powders	385:402	bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	385:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	0	44	theme	phosphate	46:54	arg1	scaffolds					66:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds	0:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.	0:161	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	0	45	dep	scaffolds	66:74	arg1	inks					112:115	Tuning printable inks	95:115	Tuning printable inks	95:115	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	0	45	dep	scaffolds	66:74	arg1	structure					130:138	scaffold structure	121:138	scaffold structure	121:138	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	2	46	theme	silk	504:507	arg1	fibroin					509:515	silk fibroin	504:515	silk fibroin	504:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	12	47	theme	physical	2365:2372	arg1	characteristics					2387:2401	suitable physical and chemical characteristics	2356:2401	suitable physical and chemical characteristics with high potential	2356:2421	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	7	48	dep	allows	1176:1181	arg1	reflected					1271:1279	reflected	1271:1279	reflected in high values for Young's modulus and maximum compressive strength	1271:1347	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	8	49	theme	concomitant	1399:1409	arg1	reduction					1411:1419	a concomitant reduction	1397:1419	a concomitant reduction of mechanical properties	1397:1444	This trend was continued in wet scaffolds with a concomitant reduction of mechanical properties.
35581087	3	50	theme	Polymeric	534:542	arg1	solutions					544:552	Polymeric solutions	534:552	Polymeric solutions of chitosan/silk fibroin with different ratios	534:599	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	6	51	dep	In	1012:1013	arg1	vitro					1015:1019	vitro	1015:1019	vitro	1015:1019	In vitro studies were also evaluated in the scaffolds that presented the best structural performance.
35581087	10	52	with	scaffold	1687:1694	arg1	porosity					1708:1715	300 μm porosity	1701:1715	300 μm porosity comprising the both polymers in its composition	1701:1763	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	9	53	theme	different	1594:1602	arg1	values					1607:1612	two different pH values	1590:1612	two different pH values at 37 °C	1590:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	7	54	theme	high	1284:1287	arg1	values					1289:1294	high values	1284:1294	high values for Young's modulus and maximum compressive strength	1284:1347	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	3	55	theme	30	667:668	arg1	vol					670:672	vol	670:672	vol	670:672	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	11	56	theme	cellular	2100:2107	arg1	filling					2109:2115	the full cellular filling	2091:2115	the full cellular filling of their surfaces	2091:2133	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	11	57	theme	natural	1922:1928	arg1	polymers					1930:1937	the combined natural polymers	1909:1937	the combined natural polymers	1909:1937	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	2	58	from	embedded	448:455	arg1	solutions					478:486	aqueous polymeric solutions	460:486	aqueous polymeric solutions of chitosan and silk fibroin	460:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	10	59	with	scaffolds	1822:1830	arg1	porosity					1845:1852	similar porosity	1837:1852	similar porosity	1837:1852	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	10	60	theme	similar	1837:1843	arg1	porosity					1845:1852	similar porosity	1837:1852	similar porosity	1837:1852	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	8	61	theme	properties	1435:1444	arg1	reduction					1411:1419	a concomitant reduction	1397:1419	a concomitant reduction of mechanical properties	1397:1444	This trend was continued in wet scaffolds with a concomitant reduction of mechanical properties.
35581087	0	62	with	scaffolds	66:74	arg1	fibroin					86:92	silk fibroin	81:92	silk fibroin	81:92	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	3	63	theme	fibroin	571:577	arg1	solutions					544:552	Polymeric solutions	534:552	Polymeric solutions of chitosan/silk fibroin with different ratios	534:599	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	7	64	theme	scaffolds	1260:1268	arg1	performance					1223:1233	the mechanical performance	1208:1233	the mechanical performance of the printed composite scaffolds	1208:1268	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	7	65	theme	%	1134:1134	arg1	fibroin					1141:1147	2 wt% silk fibroin	1130:1147	2 wt% silk fibroin	1130:1147	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	2	66	theme	bioceramic	385:394	arg1	hydroxyapatite					405:418	hydroxyapatite	405:418	hydroxyapatite	405:418	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	66	theme	bioceramic	385:394	arg1	phosphate					437:445	β-tricalcium phosphate	424:445	β-tricalcium phosphate	424:445	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	66	theme	bioceramic	385:394	arg1	powders					396:402	bioceramic powders	385:402	bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	385:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	1	67	theme	post	274:277	arg1	process					288:294	post printing process	274:294	post printing process	274:294	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	7	68	theme	printed	1242:1248	arg1	scaffolds					1260:1268	the printed composite scaffolds	1238:1268	the printed composite scaffolds	1238:1268	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	12	69	theme	manufacturing	2289:2301	arg1	techniques					2303:2312	extrusion-based additive manufacturing techniques	2264:2312	extrusion-based additive manufacturing techniques	2264:2312	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	11	70	theme	human	2004:2008	arg1	osteoblasts					2010:2020	human osteoblasts	2004:2020	human osteoblasts grown on the scaffolds with both macropore' size	2004:2069	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	3	71	theme	different	584:592	arg1	ratios					594:599	different ratios	584:599	different ratios	584:599	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	11	72	with	scaffolds	2035:2043	arg1	size					2066:2069	both macropore' size	2050:2069	both macropore' size	2050:2069	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	4	73	dep	sizes	844:848	arg1	sizes					844:848	different macropore sizes	824:848	different macropore sizes (300 μm and 500 μm)	824:868	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	73	dep	sizes	844:848	arg1	μm					855:856	300 μm and 500 μm	851:867	μm	855:856	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	73	dep	sizes	844:848	arg1	μm					866:867	300 μm and 500 μm	851:867	μm	866:867	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	9	74	theme	calcium	1654:1660	arg1	ions					1677:1680	calcium and phosphorus ions	1654:1680	ions	1677:1680	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	4	75	theme	rheological	707:717	arg1	studies					719:725	rheological studies	707:725	rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm)	707:868	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	2	76	theme	extrudable	322:331	arg1	compositions					337:348	extrudable ink compositions	322:348	extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	322:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	1	77	theme	composite	203:211	arg1	scaffolds					224:232	composite bioceramic scaffolds	203:232	composite bioceramic scaffolds	203:232	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	2	78	theme	ink	333:335	arg1	compositions					337:348	extrudable ink compositions	322:348	extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	322:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	9	79	theme	phosphorus	1666:1675	arg1	ions					1677:1680	calcium and phosphorus ions	1654:1680	ions	1677:1680	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	11	80	with	line	2081:2084	arg1	filling					2109:2115	the full cellular filling	2091:2115	the full cellular filling of their surfaces	2091:2133	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	3	81	theme	bioceramic	646:655	arg1	solids					657:662	bioceramic solids	646:662	bioceramic solids	646:662	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	1	82	theme	scaffolds	224:232	arg1	production					189:198	the production	185:198	the production of composite bioceramic scaffolds	185:232	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	12	83	theme	additive	2280:2287	arg1	techniques					2303:2312	extrusion-based additive manufacturing techniques	2264:2312	extrusion-based additive manufacturing techniques	2264:2312	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	12	84	theme	chemical	2378:2385	arg1	characteristics					2387:2401	suitable physical and chemical characteristics	2356:2401	suitable physical and chemical characteristics with high potential	2356:2421	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	9	85	from	°C	1620:1621	arg1	values					1607:1612	two different pH values	1590:1612	two different pH values at 37 °C	1590:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	3	86	theme	vol	670:672	arg1	%					673:673	30 vol%	667:673	30 vol%	667:673	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	9	87	theme	weight	1509:1514	arg1	loss					1516:1519	a weight loss	1507:1519	a weight loss	1507:1519	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	11	88	theme	metabolic	1982:1990	arg1	activity					1992:1999	the metabolic activity	1978:1999	the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size	1978:2069	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	9	89	from	scaffolds	1476:1484	arg1	general					1489:1495	general	1489:1495	general	1489:1495	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	12	90	from	path	2230:2233	arg1	development					2248:2258	the ink's development	2238:2258	the ink's development	2238:2258	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	9	91	from	incubation	1558:1567	arg1	solution					1578:1585	HEPES solution	1572:1585	HEPES solution	1572:1585	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	11	92	theme	confocal	2160:2167	arg1	imaging					2169:2175	confocal imaging	2160:2175	confocal imaging	2160:2175	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	2	93	from	solutions	478:486	arg1	embedded					448:455	embedded	448:455	embedded	448:455	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	0	94	theme	Tuning	95:100	arg1	inks					112:115	Tuning printable inks	95:115	Tuning printable inks	95:115	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	1	95	theme	present	167:173	arg1	work					175:178	The present work	163:178	The present work	163:178	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	6	96	theme	In	1012:1013	arg1	studies					1021:1027	In vitro studies	1012:1027	In vitro studies	1012:1027	In vitro studies were also evaluated in the scaffolds that presented the best structural performance.
35581087	0	97	theme	scaffold	121:128	arg1	structure					130:138	scaffold structure	121:138	scaffold structure	121:138	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	7	98	theme	maximum	1320:1326	arg1	strength					1340:1347	maximum compressive strength	1320:1347	maximum compressive strength	1320:1347	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	2	99	dep	powders	396:402	arg1	hydroxyapatite					405:418	hydroxyapatite	405:418	hydroxyapatite	405:418	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	99	dep	powders	396:402	arg1	phosphate					437:445	β-tricalcium phosphate	424:445	β-tricalcium phosphate	424:445	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	99	dep	powders	396:402	arg1	powders					396:402	bioceramic powders	385:402	bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	385:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	100	theme	β-tricalcium	424:435	arg1	phosphate					437:445	β-tricalcium phosphate	424:445	β-tricalcium phosphate	424:445	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	2	100	theme	β-tricalcium	424:435	arg1	powders					396:402	bioceramic powders	385:402	bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	385:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	0	101	theme	robocast	11:18	arg1	scaffolds					66:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds	0:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.	0:161	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	5	102	theme	morphological	958:970	arg1	features					972:979	morphological features	958:979	morphological features	958:979	The scaffolds were characterized by mechanical properties (dry and wet conditions) and morphological features, as well as its degradability.
35581087	9	103	from	values	1607:1612	arg1	incubation					1558:1567	28 days incubation	1550:1567	28 days incubation in HEPES solution at two different pH values at 37 °C	1550:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	11	104	theme	osteoblasts	2010:2020	arg1	activity					1992:1999	the metabolic activity	1978:1999	the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size	1978:2069	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	12	105	theme	high	2408:2411	arg1	potential					2413:2421	high potential	2408:2421	high potential	2408:2421	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	4	106	theme	printable	774:782	arg1	ones					784:787	the printable ones	770:787	the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm)	770:868	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	7	107	theme	wt	1156:1157	arg1	chitosan					1160:1167	a 5 wt% chitosan	1152:1167	a 5 wt% chitosan matrix	1152:1174	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	10	108	theme	less	1779:1782	arg1	degradation					1789:1799	the less rate degradation	1775:1799	the less rate degradation	1775:1799	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	7	109	theme	Young	1300:1304	arg1	modulus					1308:1314	Young's modulus	1300:1314	Young's modulus	1300:1314	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	2	110	theme	polymeric	468:476	arg1	solutions					478:486	aqueous polymeric solutions	460:486	aqueous polymeric solutions of chitosan and silk fibroin	460:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	9	111	attach	presented	1497:1505	arg2	scaffolds					1476:1484	the scaffolds	1472:1484	the scaffolds in general	1472:1495	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	9	111	attach	presented	1497:1505	arg1	range					1528:1532	the range	1524:1532	the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C	1524:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	10	112	theme	300	1701:1703	arg1	μm					1705:1706	μm	1705:1706	μm	1705:1706	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	0	113	theme	composite	56:64	arg1	scaffolds					66:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds	0:74	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.	0:161	Toughening robocast chitosan/biphasic calcium phosphate composite scaffolds with silk fibroin: Tuning printable inks and scaffold structure for bone regeneration.
35581087	2	114	theme	fibroin	509:515	arg1	solutions					478:486	aqueous polymeric solutions	460:486	aqueous polymeric solutions of chitosan and silk fibroin	460:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	7	115	theme	fibroin	1141:1147	arg1	addition					1118:1125	The addition	1114:1125	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix	1114:1174	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	11	116	theme	surfaces	2126:2133	arg1	filling					2109:2115	the full cellular filling	2091:2115	the full cellular filling of their surfaces	2091:2133	Moreover, the combined natural polymers gave rise to a significant increase in the metabolic activity of human osteoblasts grown on the scaffolds with both macropore' size, being in line with the full cellular filling of their surfaces, demonstrated by SEM and confocal imaging.
35581087	2	117	theme	high	363:366	arg1	concentration					368:380	a high concentration	361:380	a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	361:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	9	118	theme	pH	1604:1605	arg1	values					1607:1612	two different pH values	1590:1612	two different pH values at 37 °C	1590:1621	Regarding degradability, the scaffolds in general presented a weight loss in the range of 14-18% after 28 days incubation in HEPES solution at two different pH values at 37 °C, with an associated release of calcium and phosphorus ions.
35581087	3	119	theme	solids	657:662	arg1	amount					636:641	the total amount	626:641	the total amount of bioceramic solids	626:662	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	3	119	theme	solids	657:662	arg1	solids					657:662	bioceramic solids	646:662	bioceramic solids	646:662	Polymeric solutions of chitosan/silk fibroin with different ratios were tested, maintaining the total amount of bioceramic solids at 30 vol%.
35581087	4	120	theme	macropore	834:842	arg1	sizes					844:848	different macropore sizes	824:848	different macropore sizes (300 μm and 500 μm)	824:868	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	120	theme	macropore	834:842	arg1	μm					855:856	300 μm and 500 μm	851:867	μm	855:856	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	4	120	theme	macropore	834:842	arg1	μm					866:867	300 μm and 500 μm	851:867	μm	866:867	The inks were characterized by rheological studies in viscometry and oscillatory modes, being the printable ones selected to produce scaffolds with different macropore sizes (300 μm and 500 μm).
35581087	2	121	theme	powders	396:402	arg1	concentration					368:380	a high concentration	361:380	a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin	361:515	To achieve this purpose, extrudable ink compositions containing a high concentration of bioceramic powders (hydroxyapatite and β-tricalcium phosphate) embedded in aqueous polymeric solutions of chitosan and silk fibroin were fine-tuned.
35581087	1	122	theme	suppressing	249:259	arg1	sintering					261:269	suppressing sintering	249:269	suppressing sintering	249:269	The present work aims the production of composite bioceramic scaffolds by robocasting suppressing sintering as post printing process.
35581087	7	123	theme	composite	1250:1258	arg1	scaffolds					1260:1268	the printed composite scaffolds	1238:1268	the printed composite scaffolds	1238:1268	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
35581087	6	124	theme	structural	1090:1099	arg1	performance					1101:1111	the best structural performance	1081:1111	the best structural performance	1081:1111	In vitro studies were also evaluated in the scaffolds that presented the best structural performance.
35581087	12	125	theme	suitable	2356:2363	arg1	characteristics					2387:2401	suitable physical and chemical characteristics	2356:2401	suitable physical and chemical characteristics with high potential	2356:2421	The advances presented in this work are a promising path in the ink's development for extrusion-based additive manufacturing techniques and subsequent biomaterials, encompassing suitable physical and chemical characteristics with high potential to be used as bone substitutes.
35581087	10	126	theme	base	1886:1889	arg1	matrix					1891:1896	base matrix	1886:1896	base matrix	1886:1896	The scaffold with 300 μm porosity comprising the both polymers in its composition presented the less rate degradation when compared to the scaffolds with similar porosity and containing only chitosan as base matrix.
35581087	8	127	theme	mechanical	1424:1433	arg1	properties					1435:1444	mechanical properties	1424:1444	mechanical properties	1424:1444	This trend was continued in wet scaffolds with a concomitant reduction of mechanical properties.
35581087	7	128	theme	chitosan	1160:1167	arg1	matrix					1169:1174	a 5 wt% chitosan matrix	1152:1174	a 5 wt% chitosan matrix	1152:1174	The addition of 2 wt% silk fibroin to a 5 wt% chitosan matrix allows to significantly improve the mechanical performance of the printed composite scaffolds, reflected in high values for Young's modulus and maximum compressive strength.
34951619	2	0	theme	diets	357:361	arg1	medicines					332:340	the traditional Chinese medicines	308:340	the traditional Chinese medicines	308:340	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	2	0	theme	diets	357:361	arg1	one					301:303	one	301:303	one	301:303	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	2	0	theme	diets	357:361	arg1	diets					357:361	functional diets	346:361	functional diets	346:361	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	0	1	theme	tissue	85:90	arg1	activation					57:66	activation	57:66	activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice	57:153	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	5	2	theme	metabolic	776:784	arg1	improvements					786:797	these metabolic improvements	770:797	these metabolic improvements	770:797	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	2	3	theme	functional	346:355	arg1	diets					357:361	functional diets	346:361	functional diets	346:361	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	4	4	from	metabolism	673:682	arg1	mice					705:708	HFD induced obese mice	687:708	HFD induced obese mice (P < 0.05)	687:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	4	from	metabolism	673:682	arg1	<					713:713	P < 0.05	711:718	P < 0.05	711:718	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	5	theme	lipid	667:671	arg1	metabolism					673:682	lipid metabolism	667:682	lipid metabolism in HFD induced obese mice (P < 0.05)	667:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	5	6	theme	brown-like	844:853	arg1	adipocytes					855:864	brown-like adipocytes	844:864	brown-like adipocytes	844:864	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	1	7	theme	related	255:261	arg1	disorders					273:281	related metabolic disorders	255:281	related metabolic disorders	255:281	Improving energy homeostasis and the gut microbiota is a promising strategy to improve obesity and related metabolic disorders.
34951619	0	8	theme	modulation	96:105	arg1	activation					57:66	activation	57:66	activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice	57:153	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	6	9	theme	microbiota	1066:1075	arg1	function					1046:1053	function	1046:1053	function	1046:1053	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	6	9	theme	microbiota	1066:1075	arg1	composition					1030:1040	composition	1030:1040	composition	1030:1040	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	2	10	theme	Mulberry	284:291	arg1	leaf					293:296	Mulberry leaf	284:296	Mulberry leaf	284:296	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	1	11	theme	metabolic	263:271	arg1	disorders					273:281	related metabolic disorders	255:281	related metabolic disorders	255:281	Improving energy homeostasis and the gut microbiota is a promising strategy to improve obesity and related metabolic disorders.
34951619	0	12	theme	gut	114:116	arg1	tissue					85:90	brown adipose tissue	71:90	brown adipose tissue	71:90	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	0	12	theme	gut	114:116	arg1	modulation					96:105	modulation	96:105	modulation of the gut	96:116	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	0	13	from	activation	57:66	arg1	diet					141:144	high-fat diet	132:144	high-fat diet fed mice	132:153	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	5	14	theme	inguinal	869:876	arg1	tissue					892:897	inguinal white adipose tissue	869:897	inguinal white adipose tissue	869:897	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	6	15	theme	sequencing	962:971	arg1	results					973:979	16S rRNA sequencing results	953:979	16S rRNA sequencing results	953:979	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	1	16	theme	energy	166:171	arg1	homeostasis					173:183	energy homeostasis	166:183	energy homeostasis	166:183	Improving energy homeostasis and the gut microbiota is a promising strategy to improve obesity and related metabolic disorders.
34951619	4	17	theme	significant	519:529	arg1	effect					531:536	a significant effect	517:536	a significant effect	517:536	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	5	18	theme	white	878:882	arg1	tissue					892:897	inguinal white adipose tissue	869:897	inguinal white adipose tissue	869:897	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	5	19	theme	blot	741:744	arg1	analysis					746:753	RT-PCR and western blot analysis	722:753	analysis	746:753	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	0	20	theme	leaf	9:12	arg1	polysaccharides					14:28	Mulberry leaf polysaccharides	0:28	Mulberry leaf polysaccharides	0:28	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	4	21	theme	hepatic	634:640	arg1	steatosis					642:650	hepatic steatosis	634:650	hepatic steatosis	634:650	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	7	22	theme	supplement	1156:1165	arg1	diet					1151:1154	a diet supplement	1149:1165	a diet supplement	1149:1165	Together, these findings indicated that MLP possess great potential as a diet supplement or medication for obesity.
34951619	3	23	theme	high-fat	403:410	arg1	HFD					418:420	HFD	418:420	HFD	418:420	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	3	23	theme	high-fat	403:410	arg1	diet					412:415	high-fat diet	403:415	high-fat diet (HFD)	403:421	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	0	24	theme	Mulberry	0:7	arg1	polysaccharides					14:28	Mulberry leaf polysaccharides	0:28	Mulberry leaf polysaccharides	0:28	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	0	25	dep	tissue	85:90	arg1	microbiota					118:127	microbiota	118:127	microbiota	118:127	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	6	26	theme	rRNA	957:960	arg1	results					973:979	16S rRNA sequencing results	953:979	16S rRNA sequencing results	953:979	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	5	27	theme	brown	913:917	arg1	tissue					927:932	brown adipose tissue	913:932	brown adipose tissue activity	913:941	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	1	28	theme	gut	193:195	arg1	microbiota					197:206	the gut microbiota	189:206	the gut microbiota	189:206	Improving energy homeostasis and the gut microbiota is a promising strategy to improve obesity and related metabolic disorders.
34951619	6	29	theme	gut	1062:1064	arg1	microbiota					1066:1075	the gut microbiota	1058:1075	the gut microbiota	1058:1075	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	3	30	used	used	427:430	arg2	model					386:390	a mouse model	378:390	a mouse model induced by high-fat diet (HFD)	378:421	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	5	31	theme	tissue	927:932	arg1	activity					934:941	brown adipose tissue activity	913:941	brown adipose tissue activity	913:941	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	3	32	theme	mulberry	454:461	arg1	MLP					485:487	MLP	485:487	MLP	485:487	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	3	32	theme	mulberry	454:461	arg1	polysaccharides					468:482	mulberry leaf polysaccharides	454:482	mulberry leaf polysaccharides (MLP)	454:488	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	5	33	theme	adipocytes	855:864	arg1	development					829:839	the development	825:839	the development of brown-like adipocytes in inguinal white adipose tissue	825:897	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	4	34	theme	P	711:711	arg1	mice					705:708	HFD induced obese mice	687:708	HFD induced obese mice (P < 0.05)	687:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	34	theme	P	711:711	arg1	<					713:713	P < 0.05	711:718	P < 0.05	711:718	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	5	35	theme	RT-PCR	722:727	arg1	analysis					746:753	RT-PCR and western blot analysis	722:753	analysis	746:753	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	5	36	theme	western	733:739	arg1	analysis					746:753	RT-PCR and western blot analysis	722:753	analysis	746:753	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	0	37	theme	high-fat	132:139	arg1	diet					141:144	high-fat diet	132:144	high-fat diet fed mice	132:153	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	5	38	theme	adipose	919:925	arg1	tissue					927:932	brown adipose tissue	913:932	brown adipose tissue activity	913:941	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	3	39	theme	mouse	380:384	arg1	model					386:390	a mouse model	378:390	a mouse model induced by high-fat diet (HFD)	378:421	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	4	40	dep	had	513:515	arg1	ameliorating					621:632	ameliorating	621:632	ameliorating hepatic steatosis	621:650	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	40	dep	had	513:515	arg1	regulating					656:665	regulating	656:665	regulating lipid metabolism in HFD induced obese mice (P < 0.05)	656:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	41	contain	had	513:515	arg2	effect					531:536	a significant effect	517:536	a significant effect	517:536	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	41	contain	had	513:515	arg1	MLP					509:511	MLP	509:511	MLP	509:511	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	42	dep	gain	562:565	arg1	reduced					568:574	reduced	568:574	reduced by 19.95%, 35.47% and 52.46%, respectively	568:617	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	3	43	theme	leaf	463:466	arg1	MLP					485:487	MLP	485:487	MLP	485:487	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	3	43	theme	leaf	463:466	arg1	polysaccharides					468:482	mulberry leaf polysaccharides	454:482	mulberry leaf polysaccharides (MLP)	454:488	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	2	44	theme	medicines	332:340	arg1	medicines					332:340	the traditional Chinese medicines	308:340	the traditional Chinese medicines	308:340	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	2	44	theme	medicines	332:340	arg1	one					301:303	one	301:303	one	301:303	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	2	44	theme	medicines	332:340	arg1	diets					357:361	functional diets	346:361	functional diets	346:361	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	5	45	theme	adipose	884:890	arg1	tissue					892:897	inguinal white adipose tissue	869:897	inguinal white adipose tissue	869:897	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	4	46	theme	induced	691:697	arg1	mice					705:708	HFD induced obese mice	687:708	HFD induced obese mice (P < 0.05)	687:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	46	theme	induced	691:697	arg1	<					713:713	P < 0.05	711:718	P < 0.05	711:718	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	2	47	theme	Chinese	324:330	arg1	medicines					332:340	the traditional Chinese medicines	308:340	the traditional Chinese medicines	308:340	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	1	48	theme	promising	213:221	arg1	strategy					223:230	a promising strategy	211:230	a promising strategy to improve obesity and related metabolic disorders	211:281	Improving energy homeostasis and the gut microbiota is a promising strategy to improve obesity and related metabolic disorders.
34951619	6	49	dep	composition	1030:1040	arg1	the					1026:1028	the	1026:1028	the	1026:1028	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	4	50	theme	HFD	687:689	arg1	mice					705:708	HFD induced obese mice	687:708	HFD induced obese mice (P < 0.05)	687:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	50	theme	HFD	687:689	arg1	<					713:713	P < 0.05	711:718	P < 0.05	711:718	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	2	51	theme	traditional	312:322	arg1	medicines					332:340	the traditional Chinese medicines	308:340	the traditional Chinese medicines	308:340	Mulberry leaf is one of the traditional Chinese medicines and functional diets.
34951619	0	52	theme	adipose	77:83	arg1	tissue					85:90	brown adipose tissue	71:90	brown adipose tissue	71:90	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	6	53	theme	16S	953:955	arg1	rRNA					957:960	16S rRNA	953:960	16S rRNA sequencing results	953:979	Besides, 16S rRNA sequencing results led to the inference that MLP could mitigate the composition and function of the gut microbiota.
34951619	3	54	theme	polysaccharides	468:482	arg1	role					446:449	the role	442:449	the role of mulberry leaf polysaccharides (MLP)	442:488	In this work, a mouse model induced by high-fat diet (HFD) was used to reveal the role of mulberry leaf polysaccharides (MLP).
34951619	5	55	from	development	829:839	arg1	tissue					892:897	inguinal white adipose tissue	869:897	inguinal white adipose tissue	869:897	RT-PCR and western blot analysis suggested that these metabolic improvements were mediated by inducing the development of brown-like adipocytes in inguinal white adipose tissue and enhancing brown adipose tissue activity.
34951619	4	56	theme	weight	555:560	arg1	gain					562:565	body weight gain	550:565	body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively)	550:618	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	0	57	theme	brown	71:75	arg1	tissue					85:90	brown adipose tissue	71:90	brown adipose tissue	71:90	Mulberry leaf polysaccharides ameliorate obesity through activation of brown adipose tissue and modulation of the gut microbiota in high-fat diet fed mice.
34951619	4	58	theme	obese	699:703	arg1	mice					705:708	HFD induced obese mice	687:708	HFD induced obese mice (P < 0.05)	687:719	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	4	58	theme	obese	699:703	arg1	<					713:713	P < 0.05	711:718	P < 0.05	711:718	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
34951619	7	59	contain	possess	1122:1128	arg1	MLP					1118:1120	MLP	1118:1120	MLP	1118:1120	Together, these findings indicated that MLP possess great potential as a diet supplement or medication for obesity.
34951619	7	59	contain	possess	1122:1128	arg2	potential					1136:1144	great potential	1130:1144	great potential as a diet supplement or medication for obesity	1130:1191	Together, these findings indicated that MLP possess great potential as a diet supplement or medication for obesity.
34951619	7	60	theme	great	1130:1134	arg1	potential					1136:1144	great potential	1130:1144	great potential as a diet supplement or medication for obesity	1130:1191	Together, these findings indicated that MLP possess great potential as a diet supplement or medication for obesity.
34951619	4	61	theme	body	550:553	arg1	gain					562:565	body weight gain	550:565	body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively)	550:618	It was found that MLP had a significant effect in limiting body weight gain (reduced by 19.95%, 35.47% and 52.46%, respectively), ameliorating hepatic steatosis and regulating lipid metabolism in HFD induced obese mice (P < 0.05).
35797701	1	0	theme	bioactive	326:334	arg1	polysaccharides					336:350	its bioactive polysaccharides	322:350	its bioactive polysaccharides	322:350	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	1	1	from	information	307:317	arg1	polysaccharides					336:350	its bioactive polysaccharides	322:350	its bioactive polysaccharides	322:350	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	3	2	theme	Acidic	521:526	arg1	polysaccharides					528:542	Acidic polysaccharides	521:542	Acidic polysaccharides	521:542	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	3	3	from	material	560:567	arg1	METHODS					513:519	METHODS	513:519	METHODS	513:519	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	3	3	from	material	560:567	arg1	MATERIALS					499:507	MATERIALS	499:507	MATERIALS	499:507	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	9	4	theme	Overall	1052:1058	arg1	analysis					1071:1078	Overall structural analysis	1052:1078	Overall structural analysis	1052:1078	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	12	5	theme	potent	1582:1587	arg1	fraction					1589:1596	the highest potent fraction	1570:1596	the highest potent fraction	1570:1596	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	12	5	theme	potent	1582:1587	arg1	HMAmA1					1557:1562	HMAmA1	1557:1562	HMAmA1	1557:1562	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	5	6	theme	Glycosidic	699:708	arg1	linkages					710:717	Glycosidic linkages	699:717	Glycosidic linkages	699:717	Glycosidic linkages were determined using GC-MS.
35797701	8	7	theme	galacturonic	1033:1044	arg1	acid					1046:1049	galacturonic acid	1033:1049	galacturonic acid	1033:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	7	theme	galacturonic	1033:1044	arg1	monomers					987:994	the following monomers	973:994	the following monomers: arabinose, rhamnose, galactose, and galacturonic acid	973:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	15	8	theme	defense	1838:1844	arg1	interest					1890:1897	interest	1890:1897	interest	1890:1897	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	15	8	theme	defense	1838:1844	arg1	system					1796:1801	The complement system	1781:1801	The complement system	1781:1801	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	15	8	theme	defense	1838:1844	arg1	part					1819:1822	an important part	1806:1822	an important part of the immune defense	1806:1844	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	12	9	theme	highest	1574:1580	arg1	fraction					1589:1596	the highest potent fraction	1570:1596	the highest potent fraction	1570:1596	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	12	9	theme	highest	1574:1580	arg1	HMAmA1					1557:1562	HMAmA1	1557:1562	HMAmA1	1557:1562	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	15	10	theme	immune	1831:1836	arg1	defense					1838:1844	the immune defense	1827:1844	the immune defense	1827:1844	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	12	11	theme	strong	1513:1518	arg1	activities					1540:1549	strong complement fixation activities	1513:1549	strong complement fixation activities	1513:1549	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	8	12	dep	monomers	987:994	arg1	arabinose					997:1005	arabinose	997:1005	arabinose	997:1005	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	12	dep	monomers	987:994	arg1	acid					1046:1049	galacturonic acid	1033:1049	galacturonic acid	1033:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	12	dep	monomers	987:994	arg1	monomers					987:994	the following monomers	973:994	the following monomers: arabinose, rhamnose, galactose, and galacturonic acid	973:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	12	dep	monomers	987:994	arg1	galactose					1018:1026	galactose	1018:1026	galactose	1018:1026	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	12	dep	monomers	987:994	arg1	rhamnose					1008:1015	rhamnose	1008:1015	rhamnose	1008:1015	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	10	13	theme	galacturonans	1272:1284	arg1	presence					1260:1267	the presence	1256:1267	the presence of galacturonans alternated by rhamnogalacturonans bearing arabinose and galactose units	1256:1356	NMR data showed the presence of galacturonans alternated by rhamnogalacturonans bearing arabinose and galactose units.
35797701	9	14	theme	low	1105:1107	arg1	ratio					1109:1113	a low ratio	1103:1113	a low ratio of 1,2-linked rhamnose	1103:1136	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	8	15	contain	contained	942:950	arg1	amounts					965:971	different amounts	955:971	different amounts	955:971	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg2	monomers					987:994	the following monomers	973:994	the following monomers: arabinose, rhamnose, galactose, and galacturonic acid	973:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg1	polysaccharides					926:940	the two polysaccharides	918:940	the two polysaccharides	918:940	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg2	arabinose					997:1005	arabinose	997:1005	arabinose	997:1005	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg2	rhamnose					1008:1015	rhamnose	1008:1015	rhamnose	1008:1015	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg2	acid					1046:1049	galacturonic acid	1033:1049	galacturonic acid	1033:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg2	galactose					1018:1026	galactose	1018:1026	galactose	1018:1026	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	15	contain	contained	942:950	arg2	polysaccharides					926:940	the two polysaccharides	918:940	the two polysaccharides	918:940	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	15	16	theme	complement	1785:1794	arg1	system					1796:1801	The complement system	1781:1801	The complement system	1781:1801	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	15	16	theme	complement	1785:1794	arg1	part					1819:1822	an important part	1806:1822	an important part of the immune defense	1806:1844	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	3	17	dep	MATERIALS	499:507	arg1	polysaccharides					528:542	Acidic polysaccharides	521:542	Acidic polysaccharides	521:542	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	3	18	attach	isolated	598:605	arg1	extracts					618:625	water extracts	612:625	water extracts	612:625	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	3	18	attach	isolated	598:605	arg2	METHODS					513:519	METHODS	513:519	METHODS	513:519	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	3	18	attach	isolated	598:605	arg2	MATERIALS					499:507	MATERIALS	499:507	MATERIALS	499:507	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	9	19	theme	1,4-linked	1150:1159	arg1	acid					1174:1177	1,4-linked galacturonic acid	1150:1177	1,4-linked galacturonic acid	1150:1177	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	2	20	from	parts	477:481	arg1	structure					402:410	structure	402:410	structure	402:410	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	2	20	from	parts	477:481	arg1	polysaccharides					449:463	polysaccharides	449:463	polysaccharides from aerial parts of A. mexicana	449:496	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	2	20	from	parts	477:481	arg1	activity					437:444	the immunomodulatory activity	416:444	the immunomodulatory activity	416:444	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	1	21	from	studies	156:162	arg1	Papaveraceae					189:200	Papaveraceae	189:200	Papaveraceae	189:200	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	1	21	from	studies	156:162	arg1	Argemone					167:174	Argemone	167:174	Argemone	167:174	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	3	22	theme	plant	554:558	arg1	material					560:567	this plant material	549:567	this plant material named HMAmA1 and HMAmA2	549:591	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	15	23	theme	important	1809:1817	arg1	system					1796:1801	The complement system	1781:1801	The complement system	1781:1801	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	15	23	theme	important	1809:1817	arg1	part					1819:1822	an important part	1806:1822	an important part of the immune defense	1806:1844	The complement system is an important part of the immune defense, and compounds acting on the cascade are of interest.
35797701	0	24	theme	fixation	43:50	arg1	activity					52:59	complement fixation activity	32:59	complement fixation activity	32:59	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	2	25	dep	OBJECTIVE	366:374	arg1	determines					387:396	determines	387:396	determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana	387:496	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	13	26	theme	HMAmA1	1614:1619	arg1	value					1605:1609	ICH50 value	1599:1609	ICH50 value of HMAmA1	1599:1619	ICH50 value of HMAmA1 was 5 µg/mL, compared to the control BPII being 15.9 µg/mL.
35797701	2	27	theme	aerial	470:475	arg1	parts					477:481	aerial parts	470:481	aerial parts of A. mexicana	470:496	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	10	28	theme	NMR	1240:1242	arg1	data					1244:1247	NMR data	1240:1247	NMR data	1240:1247	NMR data showed the presence of galacturonans alternated by rhamnogalacturonans bearing arabinose and galactose units.
35797701	7	29	theme	different	850:858	arg1	doses					860:864	different doses	850:864	different doses	850:864	The polymers were tested for effects on the human complement system in vitro at different doses.
35797701	0	30	dep	Argemone	92:99	arg1	mexicana					101:108	Argemone mexicana	92:108	Argemone mexicana	92:108	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	9	31	link	1,4-linked	1150:1159	arg1	acid					1174:1177	1,4-linked galacturonic acid	1150:1177	1,4-linked galacturonic acid	1150:1177	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	9	32	theme	ratio	1109:1113	arg1	presence					1091:1098	the presence	1087:1098	the presence of a low ratio of 1,2-linked rhamnose	1087:1136	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	1	33	theme	low-mass	265:272	arg1	activities					284:293	its low-mass compounds activities	261:293	its low-mass compounds activities	261:293	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	1	34	dep	Argemone	167:174	arg1	mexicana					176:183	Argemone mexicana L.	167:186	Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali	167:244	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	1	34	dep	Argemone	167:174	arg1	L					185:185	L	185:185	Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali	167:244	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	9	35	theme	galacturonic	1161:1172	arg1	acid					1174:1177	1,4-linked galacturonic acid	1150:1177	1,4-linked galacturonic acid	1150:1177	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	2	36	theme	polysaccharides	449:463	arg1	structure					402:410	structure	402:410	structure	402:410	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	2	36	theme	polysaccharides	449:463	arg1	activity					437:444	the immunomodulatory activity	416:444	the immunomodulatory activity	416:444	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	1	37	theme	compounds	274:282	arg1	activities					284:293	its low-mass compounds activities	261:293	its low-mass compounds activities	261:293	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	8	38	theme	different	955:963	arg1	amounts					965:971	different amounts	955:971	different amounts	955:971	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	12	39	theme	fixation	1531:1538	arg1	activities					1540:1549	strong complement fixation activities	1513:1549	strong complement fixation activities	1513:1549	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	0	40	from	Argemone	92:99	arg1	characterisation					11:26	characterisation	11:26	characterisation	11:26	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	40	from	Argemone	92:99	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	40	from	Argemone	92:99	arg1	activity					52:59	complement fixation activity	32:59	complement fixation activity	32:59	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	14	41	theme	fixation	1764:1771	arg1	effect					1773:1778	a complement fixation effect	1751:1778	a complement fixation effect	1751:1778	DISCUSSION AND CONCLUSIONS Polysaccharides form A. mexicana presented a complement fixation effect.
35797701	8	42	theme	following	977:985	arg1	arabinose					997:1005	arabinose	997:1005	arabinose	997:1005	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	42	theme	following	977:985	arg1	acid					1046:1049	galacturonic acid	1033:1049	galacturonic acid	1033:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	42	theme	following	977:985	arg1	monomers					987:994	the following monomers	973:994	the following monomers: arabinose, rhamnose, galactose, and galacturonic acid	973:1049	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	42	theme	following	977:985	arg1	galactose					1018:1026	galactose	1018:1026	galactose	1018:1026	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	8	42	theme	following	977:985	arg1	rhamnose					1008:1015	rhamnose	1008:1015	rhamnose	1008:1015	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	2	43	theme	immunomodulatory	420:435	arg1	activity					437:444	the immunomodulatory activity	416:444	the immunomodulatory activity	416:444	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	2	44	theme	mexicana	489:496	arg1	parts					477:481	aerial parts	470:481	aerial parts of A. mexicana	470:496	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	9	45	link	1,2-linked	1118:1127	arg1	rhamnose					1129:1136	1,2-linked rhamnose	1118:1136	1,2-linked rhamnose	1118:1136	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	13	46	theme	control	1650:1656	arg1	BPII					1658:1661	the control BPII	1646:1661	the control BPII being 15.9 µg/mL	1646:1678	ICH50 value of HMAmA1 was 5 µg/mL, compared to the control BPII being 15.9 µg/mL.
35797701	13	47	theme	ICH50	1599:1603	arg1	value					1605:1609	ICH50 value	1599:1609	ICH50 value of HMAmA1	1599:1619	ICH50 value of HMAmA1 was 5 µg/mL, compared to the control BPII being 15.9 µg/mL.
35797701	0	48	theme	complement	32:41	arg1	activity					52:59	complement fixation activity	32:59	complement fixation activity	32:59	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	7	49	theme	complement	820:829	arg1	system					831:836	the human complement system	810:836	the human complement system in vitro at different doses	810:864	The polymers were tested for effects on the human complement system in vitro at different doses.
35797701	9	50	theme	structural	1060:1069	arg1	analysis					1071:1078	Overall structural analysis	1052:1078	Overall structural analysis	1052:1078	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	9	51	dep	showed	1080:1085	arg1	compared					1138:1145	compared	1138:1145	showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose	1080:1237	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	14	52	dep	DISCUSSION	1681:1690	arg1	Polysaccharides					1708:1722	Polysaccharides	1708:1722	Polysaccharides	1708:1722	DISCUSSION AND CONCLUSIONS Polysaccharides form A. mexicana presented a complement fixation effect.
35797701	4	53	theme	gas	679:681	arg1	chromatography					683:696	gas chromatography	679:696	gas chromatography	679:696	Their monosaccharide composition was determined by gas chromatography.
35797701	1	54	theme	little	300:305	arg1	information					307:317	little information	300:317	little information on its bioactive polysaccharides	300:350	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	12	55	theme	complement	1520:1529	arg1	activities					1540:1549	strong complement fixation activities	1513:1549	strong complement fixation activities	1513:1549	The two polysaccharides exhibited strong complement fixation activities, with HMAmA1 being the highest potent fraction.
35797701	11	56	theme	d-galacturonic	1413:1426	arg1	acid					1428:1431	d-galacturonic acid	1413:1431	d-galacturonic acid	1413:1431	α-Linkages were found for l-arabinose, l-rhamnose and d-galacturonic acid, while β-linkages were found for d-galactose.
35797701	0	57	from	antimalarials	118:130	arg1	Mali					135:138	Mali	135:138	Mali	135:138	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	3	58	theme	water	612:616	arg1	extracts					618:625	water extracts	612:625	water extracts	612:625	MATERIALS AND METHODS Acidic polysaccharides from this plant material named HMAmA1 and HMAmA2 were isolated from water extracts.
35797701	2	59	from	structure	402:410	arg1	parts					477:481	aerial parts	470:481	aerial parts of A. mexicana	470:496	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	7	60	theme	human	814:818	arg1	system					831:836	the human complement system	810:836	the human complement system in vitro at different doses	810:864	The polymers were tested for effects on the human complement system in vitro at different doses.
35797701	7	61	from	effects	799:805	arg1	system					831:836	the human complement system	810:836	the human complement system in vitro at different doses	810:864	The polymers were tested for effects on the human complement system in vitro at different doses.
35797701	8	62	dep	RESULTS	867:873	arg1	composition					894:904	The monosaccharide composition	875:904	RESULTS The monosaccharide composition	867:904	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	4	63	theme	monosaccharide	634:647	arg1	composition					649:659	Their monosaccharide composition	628:659	Their monosaccharide composition	628:659	Their monosaccharide composition was determined by gas chromatography.
35797701	1	64	from	malaria	230:236	arg1	Mali					241:244	Mali	241:244	Mali	241:244	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	10	65	theme	galactose	1342:1350	arg1	units					1352:1356	galactose units	1342:1356	galactose units	1342:1356	NMR data showed the presence of galacturonans alternated by rhamnogalacturonans bearing arabinose and galactose units.
35797701	14	66	dep	form	1724:1727	arg1	presented					1741:1749	presented	1741:1749	form A. mexicana presented a complement fixation effect	1724:1778	DISCUSSION AND CONCLUSIONS Polysaccharides form A. mexicana presented a complement fixation effect.
35797701	8	67	theme	monosaccharide	879:892	arg1	composition					894:904	The monosaccharide composition	875:904	RESULTS The monosaccharide composition	867:904	RESULTS The monosaccharide composition showed that the two polysaccharides contained in different amounts the following monomers: arabinose, rhamnose, galactose, and galacturonic acid.
35797701	0	68	theme	polysaccharides	71:85	arg1	characterisation					11:26	characterisation	11:26	characterisation	11:26	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	68	theme	polysaccharides	71:85	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	68	theme	polysaccharides	71:85	arg1	activity					52:59	complement fixation activity	32:59	complement fixation activity	32:59	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	69	used	used	110:113	arg2	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	69	used	used	110:113	arg2	activity					52:59	complement fixation activity	32:59	complement fixation activity	32:59	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	0	69	used	used	110:113	arg2	characterisation					11:26	characterisation	11:26	characterisation	11:26	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	2	70	dep	structure	402:410	arg1	the					398:400	the	398:400	the	398:400	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	9	71	theme	rhamnose	1230:1237	arg1	position					1216:1223	position 4	1216:1225	position 4 of rhamnose	1216:1237	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	1	72	theme	Global	149:154	arg1	studies					156:162	CONTEXT Global studies	141:162	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali	141:244	CONTEXT Global studies on Argemone mexicana L. (Papaveraceae) traditionally used against malaria in Mali are limited to its low-mass compounds activities, and little information on its bioactive polysaccharides is available.
35797701	14	73	theme	complement	1753:1762	arg1	effect					1773:1778	a complement fixation effect	1751:1778	a complement fixation effect	1751:1778	DISCUSSION AND CONCLUSIONS Polysaccharides form A. mexicana presented a complement fixation effect.
35797701	0	74	theme	acidic	64:69	arg1	polysaccharides					71:85	acidic polysaccharides	64:85	acidic polysaccharides	64:85	Isolation, characterisation and complement fixation activity of acidic polysaccharides from Argemone mexicana used as antimalarials in Mali.
35797701	9	75	theme	1,2-linked	1118:1127	arg1	rhamnose					1129:1136	1,2-linked rhamnose	1118:1136	1,2-linked rhamnose	1118:1136	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35797701	2	76	from	activity	437:444	arg1	parts					477:481	aerial parts	470:481	aerial parts of A. mexicana	470:496	OBJECTIVE This study determines the structure and the immunomodulatory activity of polysaccharides from aerial parts of A. mexicana.
35797701	16	77	theme	immunodulatory	1943:1956	arg1	agents					1958:1963	immunodulatory agents	1943:1963	immunodulatory agents	1943:1963	Therefore, these polymers may be useful as immunodulatory agents.
35797701	9	78	theme	rhamnose	1129:1136	arg1	ratio					1109:1113	a low ratio	1103:1113	a low ratio of 1,2-linked rhamnose	1103:1136	Overall structural analysis showed the presence of a low ratio of 1,2-linked rhamnose compared to 1,4-linked galacturonic acid with arabinogalactans substituted on position 4 of rhamnose.
35323480	12	0	theme	fucoidan/PDA	2018:2029	arg1	composite					2031:2039	a fucoidan/PDA composite	2016:2039	a fucoidan/PDA composite	2016:2039	These results suggest that a fucoidan/PDA composite promotes the osteogenic potential of PDLSCs by activation of critical molecular pathways.
35323480	6	1	theme	matrix	1238:1243	arg1	assay					1260:1264	matrix mineralization assay	1238:1264	matrix mineralization assay	1238:1264	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	2	2	theme	fucoidan-based	384:397	arg1	composites					399:408	fucoidan-based composites	384:408	fucoidan-based composites	384:408	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	6	3	theme	markers	1329:1335	arg1	expression					1304:1313	the mRNA and protein expression	1283:1313	the mRNA and protein expression of osteogenic markers	1283:1335	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	11	4	theme	cell	1876:1879	arg1	adhesion					1881:1888	cell adhesion	1876:1888	cell adhesion	1876:1888	These pathways represent cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process.
35323480	7	5	theme	enriched	1393:1400	arg1	networks					1427:1434	significantly enriched and associated molecular networks	1379:1434	significantly enriched and associated molecular networks	1379:1434	RNA sequencing was performed to identify significantly enriched and associated molecular networks.
35323480	5	6	theme	electron	1014:1021	arg1	microscopy					1023:1032	scanning electron microscopy	1005:1032	scanning electron microscopy	1005:1032	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	6	7	dep	mRNA	1287:1290	arg1	the					1283:1285	the	1283:1285	the	1283:1285	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	9	8	theme	=	1603:1603	arg1	n					1601:1601	n = 348	1601:1607	n = 348	1601:1607	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	9	8	theme	=	1603:1603	arg1	genes					1587:1591	Differentially expressed genes	1562:1591	Differentially expressed genes (DEGs) (n = 348)	1562:1608	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	6	9	theme	protein	1296:1302	arg1	expression					1304:1313	the mRNA and protein expression	1283:1313	the mRNA and protein expression of osteogenic markers	1283:1335	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	4	10	theme	culture	724:730	arg1	platform					732:739	a culture platform	722:739	a culture platform for periodontal ligament stem cells (PDLSCs)	722:784	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	10	11	theme	cytoskeleton	1776:1787	arg1	protein					1805:1811	Ras-related protein 1	1793:1813	Ras-related protein 1	1793:1813	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	10	11	theme	cytoskeleton	1776:1787	arg1	regulation					1752:1761	regulation	1752:1761	regulation of the actin cytoskeleton	1752:1787	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	10	11	theme	cytoskeleton	1776:1787	arg1	signaling					1840:1848	phosphatidylinositol signaling	1819:1848	phosphatidylinositol signaling	1819:1848	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	5	12	theme	surface	981:987	arg1	Characterization					917:932	Characterization	917:932	Characterization of the fucoidan/PDA-coated culture polystyrene surface	917:987	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	5	13	theme	X-ray	1038:1042	arg1	spectroscopy					1058:1069	X-ray photoelectron spectroscopy	1038:1069	X-ray photoelectron spectroscopy	1038:1069	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	6	14	theme	mRNA	1287:1290	arg1	expression					1304:1313	the mRNA and protein expression	1283:1313	the mRNA and protein expression of osteogenic markers	1283:1335	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	4	15	theme	composite-based	690:704	arg1	film					706:709	a fucoidan and polydopamine (PDA) composite-based film	656:709	a fucoidan and polydopamine (PDA) composite-based film	656:709	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	6	16	theme	osteogenic	1076:1085	arg1	differentiation					1087:1101	The osteogenic differentiation	1072:1101	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite	1072:1154	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	2	17	theme	tissue	419:424	arg1	applications					438:449	bone tissue engineering applications	414:449	bone tissue engineering applications	414:449	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	9	18	theme	fucoidan/PDA-induced	1633:1652	arg1	differentiation					1665:1679	fucoidan/PDA-induced osteogenic differentiation	1633:1679	fucoidan/PDA-induced osteogenic differentiation	1633:1679	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	8	19	theme	PDLSCs	1452:1457	arg1	culture					1441:1447	The culture	1437:1447	The culture of PDLSCs on the fucoidan/PDA composite	1437:1487	The culture of PDLSCs on the fucoidan/PDA composite demonstrated higher osteogenic potency than that on the control surface.
35323480	10	20	theme	Ras-related	1793:1803	arg1	protein					1805:1811	Ras-related protein 1	1793:1813	Ras-related protein 1	1793:1813	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	11	21	theme	osteogenic	1969:1978	arg1	process					1980:1986	the osteogenic process	1965:1986	the osteogenic process	1965:1986	These pathways represent cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process.
35323480	3	22	theme	molecular	608:616	arg1	level					618:622	the molecular level	604:622	the molecular level	604:622	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	8	23	from	culture	1441:1447	arg1	composite					1479:1487	the fucoidan/PDA composite	1462:1487	the fucoidan/PDA composite	1462:1487	The culture of PDLSCs on the fucoidan/PDA composite demonstrated higher osteogenic potency than that on the control surface.
35323480	9	24	theme	RNA	1684:1686	arg1	sequencing					1688:1697	RNA sequencing	1684:1697	RNA sequencing	1684:1697	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	6	25	theme	fucoidan/PDA	1133:1144	arg1	composite					1146:1154	the fucoidan/PDA composite	1129:1154	the fucoidan/PDA composite	1129:1154	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	8	26	theme	higher	1502:1507	arg1	potency					1520:1526	higher osteogenic potency	1502:1526	higher osteogenic potency	1502:1526	The culture of PDLSCs on the fucoidan/PDA composite demonstrated higher osteogenic potency than that on the control surface.
35323480	5	27	theme	scanning	1005:1012	arg1	microscopy					1023:1032	scanning electron microscopy	1005:1032	scanning electron microscopy	1005:1032	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	4	28	theme	molecular	813:821	arg1	pathways					823:830	the prominent molecular pathways	799:830	the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling	799:914	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	0	29	theme	Periodontal	104:114	arg1	Cells					130:134	Periodontal Ligament Stem Cells	104:134	Periodontal Ligament Stem Cells	104:134	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	6	30	theme	PDLSCs	1110:1115	arg1	differentiation					1087:1101	The osteogenic differentiation	1072:1101	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite	1072:1154	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	3	31	theme	bone	481:484	arg1	environment					506:516	a bone tissue regeneration environment	479:516	a bone tissue regeneration environment	479:516	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	7	32	theme	RNA	1338:1340	arg1	sequencing					1342:1351	RNA sequencing	1338:1351	RNA sequencing	1338:1351	RNA sequencing was performed to identify significantly enriched and associated molecular networks.
35323480	6	33	theme	calcium	1222:1228	arg1	levels					1230:1235	intracellular calcium levels	1208:1235	intracellular calcium levels	1208:1235	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	2	34	theme	engineering	426:436	arg1	applications					438:449	bone tissue engineering applications	414:449	bone tissue engineering applications	414:449	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	0	35	theme	Fucoidan	0:7	arg1	Surface					63:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface	0:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface	0:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	6	36	theme	phosphatase	1186:1196	arg1	activity					1198:1205	alkaline phosphatase activity	1177:1205	alkaline phosphatase activity	1177:1205	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	3	37	theme	regeneration	493:504	arg1	environment					506:516	a bone tissue regeneration environment	479:516	a bone tissue regeneration environment	479:516	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	1	38	theme	brown	193:197	arg1	algae					199:203	brown algae	193:203	brown algae	193:203	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	12	39	theme	molecular	2111:2119	arg1	pathways					2121:2128	critical molecular pathways	2102:2128	critical molecular pathways	2102:2128	These results suggest that a fucoidan/PDA composite promotes the osteogenic potential of PDLSCs by activation of critical molecular pathways.
35323480	10	40	theme	signaling	1704:1712	arg1	pathways					1714:1721	The signaling pathways	1700:1721	The signaling pathways enriched in the DEGs	1700:1742	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	11	41	theme	cytoskeleton	1894:1905	arg1	organization					1907:1918	cytoskeleton organization	1894:1918	cytoskeleton organization	1894:1918	These pathways represent cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process.
35323480	0	42	theme	Composite-Modified	44:61	arg1	Surface					63:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface	0:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface	0:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	4	43	theme	osteogenic	847:856	arg1	differentiation					858:872	osteogenic differentiation	847:872	osteogenic differentiation of PDLSCs through transcriptome profiling	847:914	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	3	44	theme	better	533:538	arg1	understanding					540:552	a better understanding	531:552	a better understanding of how fucoidan regulates osteogenic processes at the molecular level	531:622	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	3	45	theme	osteogenic	580:589	arg1	processes					591:599	osteogenic processes	580:599	osteogenic processes	580:599	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	5	46	theme	culture	961:967	arg1	surface					981:987	the fucoidan/PDA-coated culture polystyrene surface	937:987	the fucoidan/PDA-coated culture polystyrene surface	937:987	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	9	47	theme	expressed	1577:1585	arg1	DEGs					1594:1597	DEGs	1594:1597	DEGs	1594:1597	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	9	47	theme	expressed	1577:1585	arg1	n					1601:1601	n = 348	1601:1607	n = 348	1601:1607	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	9	47	theme	expressed	1577:1585	arg1	genes					1587:1591	Differentially expressed genes	1562:1591	Differentially expressed genes (DEGs) (n = 348)	1562:1608	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	7	48	theme	molecular	1417:1425	arg1	networks					1427:1434	significantly enriched and associated molecular networks	1379:1434	significantly enriched and associated molecular networks	1379:1434	RNA sequencing was performed to identify significantly enriched and associated molecular networks.
35323480	2	49	theme	composites	399:408	arg1	properties					370:379	the osteoinductive and osteoconductive properties	331:379	the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications	331:449	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	2	50	theme	Current	305:311	arg1	research					313:320	Current research	305:320	Current research	305:320	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	1	51	theme	bone	272:275	arg1	formation					277:285	bone formation	272:285	bone formation	272:285	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	6	52	theme	osteogenic	1318:1327	arg1	markers					1329:1335	osteogenic markers	1318:1335	osteogenic markers	1318:1335	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	11	53	theme	adhesion	1881:1888	arg1	functions					1920:1928	cell adhesion and cytoskeleton organization functions	1876:1928	cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process	1876:1986	These pathways represent cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process.
35323480	5	54	theme	fucoidan/PDA-coated	941:959	arg1	surface					981:987	the fucoidan/PDA-coated culture polystyrene surface	937:987	the fucoidan/PDA-coated culture polystyrene surface	937:987	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	6	55	theme	expression	1304:1313	arg1	activity					1198:1205	alkaline phosphatase activity	1177:1205	alkaline phosphatase activity	1177:1205	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	6	55	theme	expression	1304:1313	arg1	analysis					1271:1278	analysis	1271:1278	analysis of the mRNA and protein expression of osteogenic markers	1271:1335	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	6	55	theme	expression	1304:1313	arg1	assay					1260:1264	matrix mineralization assay	1238:1264	matrix mineralization assay	1238:1264	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	6	55	theme	expression	1304:1313	arg1	levels					1230:1235	intracellular calcium levels	1208:1235	intracellular calcium levels	1208:1235	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	1	56	attach	derived	180:186	arg2	polysaccharide					165:178	a marine-sulfated polysaccharide	147:178	a marine-sulfated polysaccharide derived from brown algae	147:203	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	1	56	attach	derived	180:186	arg1	algae					199:203	brown algae	193:203	brown algae	193:203	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	1	56	attach	derived	180:186	arg2	Fucoidan					137:144	Fucoidan	137:144	Fucoidan	137:144	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	2	57	theme	osteoinductive	335:348	arg1	properties					370:379	the osteoinductive and osteoconductive properties	331:379	the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications	331:449	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	4	58	from	use	715:717	arg1	platform					732:739	a culture platform	722:739	a culture platform for periodontal ligament stem cells (PDLSCs)	722:784	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	5	59	theme	polystyrene	969:979	arg1	surface					981:987	the fucoidan/PDA-coated culture polystyrene surface	937:987	the fucoidan/PDA-coated culture polystyrene surface	937:987	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	10	60	theme	actin	1770:1774	arg1	cytoskeleton					1776:1787	the actin cytoskeleton	1766:1787	the actin cytoskeleton	1766:1787	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	1	61	from	use	265:267	arg1	regeneration					291:302	regeneration	291:302	regeneration	291:302	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	1	61	from	use	265:267	arg1	formation					277:285	bone formation	272:285	bone formation	272:285	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	9	62	theme	osteogenic	1654:1663	arg1	differentiation					1665:1679	fucoidan/PDA-induced osteogenic differentiation	1633:1679	fucoidan/PDA-induced osteogenic differentiation	1633:1679	Differentially expressed genes (DEGs) (n = 348) were identified during fucoidan/PDA-induced osteogenic differentiation by RNA sequencing.
35323480	4	63	theme	stem	766:769	arg1	cells					771:775	stem cells	766:775	periodontal ligament stem cells (PDLSCs)	745:784	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	4	63	theme	stem	766:769	arg1	PDLSCs					778:783	PDLSCs	778:783	PDLSCs	778:783	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	2	64	theme	osteoconductive	354:368	arg1	properties					370:379	the osteoinductive and osteoconductive properties	331:379	the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications	331:449	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	0	65	theme	Osteogenic	80:89	arg1	Potential					91:99	Osteogenic Potential	80:99	Osteogenic Potential of Periodontal Ligament Stem Cells	80:134	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	1	66	theme	marine-sulfated	149:163	arg1	polysaccharide					165:178	a marine-sulfated polysaccharide	147:178	a marine-sulfated polysaccharide derived from brown algae	147:203	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	1	66	theme	marine-sulfated	149:163	arg1	Fucoidan					137:144	Fucoidan	137:144	Fucoidan	137:144	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	8	67	theme	fucoidan/PDA	1466:1477	arg1	composite					1479:1487	the fucoidan/PDA composite	1462:1487	the fucoidan/PDA composite	1462:1487	The culture of PDLSCs on the fucoidan/PDA composite demonstrated higher osteogenic potency than that on the control surface.
35323480	3	68	from	utility	456:462	arg1	environment					506:516	a bone tissue regeneration environment	479:516	a bone tissue regeneration environment	479:516	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	4	69	theme	periodontal	745:755	arg1	ligament					757:764	periodontal ligament stem cells (PDLSCs)	745:784	periodontal ligament stem cells (PDLSCs)	745:784	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	0	70	theme	Ligament	116:123	arg1	Cells					130:134	Periodontal Ligament Stem Cells	104:134	Periodontal Ligament Stem Cells	104:134	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	4	71	dep	ligament	757:764	arg1	cells					771:775	stem cells	766:775	periodontal ligament stem cells (PDLSCs)	745:784	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	4	71	dep	ligament	757:764	arg1	PDLSCs					778:783	PDLSCs	778:783	PDLSCs	778:783	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	8	72	theme	osteogenic	1509:1518	arg1	potency					1520:1526	higher osteogenic potency	1502:1526	higher osteogenic potency	1502:1526	The culture of PDLSCs on the fucoidan/PDA composite demonstrated higher osteogenic potency than that on the control surface.
35323480	4	73	theme	prominent	803:811	arg1	pathways					823:830	the prominent molecular pathways	799:830	the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling	799:914	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	0	74	theme	Cells	130:134	arg1	Potential					91:99	Osteogenic Potential	80:99	Osteogenic Potential of Periodontal Ligament Stem Cells	80:134	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	3	75	theme	tissue	486:491	arg1	environment					506:516	a bone tissue regeneration environment	479:516	a bone tissue regeneration environment	479:516	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	5	76	theme	photoelectron	1044:1056	arg1	spectroscopy					1058:1069	X-ray photoelectron spectroscopy	1038:1069	X-ray photoelectron spectroscopy	1038:1069	Characterization of the fucoidan/PDA-coated culture polystyrene surface was assessed by scanning electron microscopy and X-ray photoelectron spectroscopy.
35323480	6	77	theme	intracellular	1208:1220	arg1	levels					1230:1235	intracellular calcium levels	1208:1235	intracellular calcium levels	1208:1235	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	10	78	theme	phosphatidylinositol	1819:1838	arg1	signaling					1840:1848	phosphatidylinositol signaling	1819:1848	phosphatidylinositol signaling	1819:1848	The signaling pathways enriched in the DEGs include regulation of the actin cytoskeleton and Ras-related protein 1 and phosphatidylinositol signaling.
35323480	12	79	theme	critical	2102:2109	arg1	pathways					2121:2128	critical molecular pathways	2102:2128	critical molecular pathways	2102:2128	These results suggest that a fucoidan/PDA composite promotes the osteogenic potential of PDLSCs by activation of critical molecular pathways.
35323480	11	80	theme	organization	1907:1918	arg1	functions					1920:1928	cell adhesion and cytoskeleton organization functions	1876:1928	cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process	1876:1986	These pathways represent cell adhesion and cytoskeleton organization functions that are significantly involved in the osteogenic process.
35323480	8	81	theme	control	1545:1551	arg1	surface					1553:1559	the control surface	1541:1559	the control surface	1541:1559	The culture of PDLSCs on the fucoidan/PDA composite demonstrated higher osteogenic potency than that on the control surface.
35323480	2	82	theme	bone	414:417	arg1	applications					438:449	bone tissue engineering applications	414:449	bone tissue engineering applications	414:449	Current research explores the osteoinductive and osteoconductive properties of fucoidan-based composites for bone tissue engineering applications.
35323480	0	83	theme	/Polydopamine	30:42	arg1	Surface					63:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface	0:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface	0:69	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	12	84	theme	pathways	2121:2128	arg1	activation					2088:2097	activation	2088:2097	activation of critical molecular pathways	2088:2128	These results suggest that a fucoidan/PDA composite promotes the osteogenic potential of PDLSCs by activation of critical molecular pathways.
35323480	6	85	theme	alkaline	1177:1184	arg1	phosphatase					1186:1196	alkaline phosphatase	1177:1196	alkaline phosphatase activity	1177:1205	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	3	86	theme	fucoidan	467:474	arg1	utility					456:462	The utility	452:462	The utility of fucoidan in a bone tissue regeneration environment	452:516	The utility of fucoidan in a bone tissue regeneration environment necessitates a better understanding of how fucoidan regulates osteogenic processes at the molecular level.
35323480	4	87	theme	PDLSCs	877:882	arg1	differentiation					858:872	osteogenic differentiation	847:872	osteogenic differentiation of PDLSCs through transcriptome profiling	847:914	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	0	88	theme	Stem	125:128	arg1	Cells					130:134	Periodontal Ligament Stem Cells	104:134	Periodontal Ligament Stem Cells	104:134	Fucoidan (Undaria pinnatifida)/Polydopamine Composite-Modified Surface Promotes Osteogenic Potential of Periodontal Ligament Stem Cells.
35323480	12	89	theme	PDLSCs	2078:2083	arg1	potential					2065:2073	the osteogenic potential	2050:2073	the osteogenic potential of PDLSCs	2050:2083	These results suggest that a fucoidan/PDA composite promotes the osteogenic potential of PDLSCs by activation of critical molecular pathways.
35323480	4	90	dep	composite-based	690:704	arg1	polydopamine					671:682	polydopamine	671:682	polydopamine	671:682	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	4	90	dep	composite-based	690:704	arg1	fucoidan					658:665	fucoidan	658:665	fucoidan	658:665	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	4	91	theme	transcriptome	892:904	arg1	profiling					906:914	transcriptome profiling	892:914	transcriptome profiling	892:914	Therefore, this study designed a fucoidan and polydopamine (PDA) composite-based film for use in a culture platform for periodontal ligament stem cells (PDLSCs) and explored the prominent molecular pathways induced during osteogenic differentiation of PDLSCs through transcriptome profiling.
35323480	12	92	theme	osteogenic	2054:2063	arg1	potential					2065:2073	the osteogenic potential	2050:2073	the osteogenic potential of PDLSCs	2050:2083	These results suggest that a fucoidan/PDA composite promotes the osteogenic potential of PDLSCs by activation of critical molecular pathways.
35323480	6	93	theme	mineralization	1245:1258	arg1	assay					1260:1264	matrix mineralization assay	1238:1264	matrix mineralization assay	1238:1264	The osteogenic differentiation of the PDLSCs cultured on the fucoidan/PDA composite was examined through alkaline phosphatase activity, intracellular calcium levels, matrix mineralization assay, and analysis of the mRNA and protein expression of osteogenic markers.
35323480	1	94	theme	natural	241:247	arg1	biomaterial					249:259	a natural biomaterial	239:259	a natural biomaterial for use in bone formation and regeneration	239:302	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	1	94	theme	natural	241:247	arg1	Fucoidan					137:144	Fucoidan	137:144	Fucoidan	137:144	Fucoidan, a marine-sulfated polysaccharide derived from brown algae, has been recently spotlighted as a natural biomaterial for use in bone formation and regeneration.
35323480	7	95	theme	associated	1406:1415	arg1	networks					1427:1434	significantly enriched and associated molecular networks	1379:1434	significantly enriched and associated molecular networks	1379:1434	RNA sequencing was performed to identify significantly enriched and associated molecular networks.
36116592	7	0	theme	inflammation	1040:1051	arg1	levels					1053:1058	inflammation levels	1040:1058	inflammation levels	1040:1058	In addition, TA led to a rapid reduction in inflammation levels, with a wound closure rate of >92.80 % within 7 days.
36116592	3	1	theme	microspheres	486:497	arg1	properties					472:481	The excellent swelling properties	449:481	The excellent swelling properties of microspheres	449:497	The excellent swelling properties of microspheres enable them to rapidly promote thrombosis.
36116592	5	2	theme	-loaded	699:705	arg1	microspheres					707:718	tannic acid (TA)-loaded microspheres	683:718	tannic acid (TA)-loaded microspheres	683:718	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	4	3	theme	aggregation	581:591	arg1	index					593:597	the platelet aggregation index	568:597	the platelet aggregation index to 1.5	568:604	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	0	4	theme	tannic	103:108	arg1	acid					110:113	tannic acid	103:113	tannic acid for rapid wound healing	103:137	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	5	5	from	effect	747:752	arg1	TA					757:758	TA	757:758	TA	757:758	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	8	6	theme	TA-loaded	1134:1142	arg1	mCSB					1144:1147	The multifunctional TA-loaded mCSB	1114:1147	The multifunctional TA-loaded mCSB	1114:1147	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	4	7	theme	platelet	572:579	arg1	index					593:597	the platelet aggregation index	568:597	the platelet aggregation index to 1.5	568:604	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	0	8	theme	rapid	119:123	arg1	healing					131:137	rapid wound healing	119:137	rapid wound healing	119:137	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	2	9	theme	calcium	311:317	arg1	CA					329:330	CA	329:330	CA	329:330	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	9	theme	calcium	311:317	arg1	alginate					319:326	calcium alginate	311:326	calcium alginate (CA)	311:331	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	6	10	theme	126.69 	930:936	arg1	%					937:937	%	937:937	%	937:937	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	7	11	theme	%	1097:1097	arg1	rate					1082:1085	a wound closure rate	1066:1085	a wound closure rate of >92.80 % within 7 days	1066:1111	In addition, TA led to a rapid reduction in inflammation levels, with a wound closure rate of >92.80 % within 7 days.
36116592	6	12	theme	synergistic	856:866	arg1	effects					868:874	the synergistic effects	852:874	the synergistic effects of SP and TA	852:887	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	5	13	theme	antibacterial	819:831	arg1	properties					833:842	good long-lasting antibacterial properties	801:842	good long-lasting antibacterial properties	801:842	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	0	14	theme	wound	125:129	arg1	healing					131:137	rapid wound healing	119:137	rapid wound healing	119:137	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	6	15	theme	survival	939:946	arg1	rate					948:951	a 126.69 % survival rate	928:951	a 126.69 % survival rate of fibroblasts after 3 days of incubation	928:993	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	6	16	theme	fibroblasts	956:966	arg1	rate					948:951	a 126.69 % survival rate	928:951	a 126.69 % survival rate of fibroblasts after 3 days of incubation	928:993	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	1	17	theme	potential	209:217	arg1	candidates					219:228	potential candidates	209:228	potential candidates for wound dressing	209:247	Biodegradable natural polymers are receiving increasing attention as potential candidates for wound dressing.
36116592	1	17	theme	potential	209:217	arg1	attention					196:204	attention	196:204	attention	196:204	Biodegradable natural polymers are receiving increasing attention as potential candidates for wound dressing.
36116592	0	18	theme	alginate/silk	8:20	arg1	striata					47:53	Calcium alginate/silk fibroin peptide/Bletilla striata	0:53	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	5	19	theme	slow-release	734:745	arg1	effect					747:752	a slow-release effect	732:752	a slow-release effect on TA	732:758	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	8	20	contain	has	1149:1151	arg2	potential					1171:1179	great application potential	1153:1179	great application potential	1153:1179	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	8	20	contain	has	1149:1151	arg1	mCSB					1144:1147	The multifunctional TA-loaded mCSB	1114:1147	The multifunctional TA-loaded mCSB	1114:1147	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	4	21	theme	cells	644:648	arg1	index					593:597	the platelet aggregation index	568:597	the platelet aggregation index to 1.5	568:604	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	4	21	theme	cells	644:648	arg1	rate					626:629	the aggregation rate	610:629	the aggregation rate of red blood cells	610:648	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	2	22	theme	Bletilla	365:372	arg1	BSP					398:400	BSP	398:400	BSP	398:400	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	22	theme	Bletilla	365:372	arg1	polysaccharide					382:395	Bletilla striata polysaccharide	365:395	Bletilla striata polysaccharide (BSP)	365:401	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	0	23	theme	Calcium	0:6	arg1	striata					47:53	Calcium alginate/silk fibroin peptide/Bletilla striata	0:53	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	8	24	theme	great	1153:1157	arg1	potential					1171:1179	great application potential	1153:1179	great application potential	1153:1179	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	0	25	theme	blended	70:76	arg1	microspheres					78:89	polysaccharide blended microspheres	55:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	8	26	theme	application	1159:1169	arg1	potential					1171:1179	great application potential	1153:1179	great application potential	1153:1179	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	0	27	theme	peptide/Bletilla	30:45	arg1	striata					47:53	Calcium alginate/silk fibroin peptide/Bletilla striata	0:53	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	8	28	theme	multifunctional	1118:1132	arg1	mCSB					1144:1147	The multifunctional TA-loaded mCSB	1114:1147	The multifunctional TA-loaded mCSB	1114:1147	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	7	29	theme	rapid	1021:1025	arg1	reduction					1027:1035	a rapid reduction	1019:1035	a rapid reduction in inflammation levels	1019:1058	In addition, TA led to a rapid reduction in inflammation levels, with a wound closure rate of >92.80 % within 7 days.
36116592	1	30	theme	wound	234:238	arg1	dressing					240:247	wound dressing	234:247	wound dressing	234:247	Biodegradable natural polymers are receiving increasing attention as potential candidates for wound dressing.
36116592	0	31	theme	fibroin	22:28	arg1	striata					47:53	Calcium alginate/silk fibroin peptide/Bletilla striata	0:53	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	6	32	theme	incubation	984:993	arg1	3 days					974:979	3 days	974:979	3 days of incubation	974:993	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	0	33	theme	polysaccharide	55:68	arg1	microspheres					78:89	polysaccharide blended microspheres	55:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	2	34	theme	fibroin	339:345	arg1	SP					356:357	SP	356:357	SP	356:357	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	34	theme	fibroin	339:345	arg1	peptide					347:353	silk fibroin peptide	334:353	silk fibroin peptide (SP)	334:358	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	5	35	theme	tannic	683:688	arg1	TA					696:697	TA	696:697	TA	696:697	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	5	35	theme	tannic	683:688	arg1	acid					690:693	tannic acid	683:693	tannic acid (TA)-loaded microspheres	683:718	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	5	36	theme	good	801:804	arg1	properties					833:842	good long-lasting antibacterial properties	801:842	good long-lasting antibacterial properties	801:842	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	4	37	theme	blood	638:642	arg1	cells					644:648	red blood cells	634:648	red blood cells	634:648	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	7	38	theme	wound	1068:1072	arg1	closure					1074:1080	wound closure	1068:1080	a wound closure rate of >92.80 % within 7 days	1066:1111	In addition, TA led to a rapid reduction in inflammation levels, with a wound closure rate of >92.80 % within 7 days.
36116592	7	39	from	reduction	1027:1035	arg1	levels					1053:1058	inflammation levels	1040:1058	inflammation levels	1040:1058	In addition, TA led to a rapid reduction in inflammation levels, with a wound closure rate of >92.80 % within 7 days.
36116592	5	40	theme	acid	690:693	arg1	microspheres					707:718	tannic acid (TA)-loaded microspheres	683:718	tannic acid (TA)-loaded microspheres	683:718	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	6	41	theme	%	937:937	arg1	rate					948:951	a 126.69 % survival rate	928:951	a 126.69 % survival rate of fibroblasts after 3 days of incubation	928:993	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	7	42	theme	closure	1074:1080	arg1	rate					1082:1085	a wound closure rate	1066:1085	a wound closure rate of >92.80 % within 7 days	1066:1111	In addition, TA led to a rapid reduction in inflammation levels, with a wound closure rate of >92.80 % within 7 days.
36116592	4	43	theme	red	634:636	arg1	cells					644:648	red blood cells	634:648	red blood cells	634:648	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	6	44	theme	cell	894:897	arg1	senescence					899:908	the cell senescence	890:908	the cell senescence	890:908	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	2	45	theme	present	257:263	arg1	study					265:269	the present study	253:269	the present study	253:269	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	8	46	theme	wound	1226:1230	arg1	hemostasis					1232:1241	wound hemostasis	1226:1241	wound hemostasis	1226:1241	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	2	47	theme	emulsion	432:439	arg1	method					441:446	the reverse emulsion method	420:446	the reverse emulsion method	420:446	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	3	48	theme	excellent	453:461	arg1	properties					472:481	The excellent swelling properties	449:481	The excellent swelling properties of microspheres	449:497	The excellent swelling properties of microspheres enable them to rapidly promote thrombosis.
36116592	6	49	theme	SP	879:880	arg1	effects					868:874	the synergistic effects	852:874	the synergistic effects of SP and TA	852:887	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	0	50	dep	striata	47:53	arg1	microspheres					78:89	polysaccharide blended microspheres	55:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres	0:89	Calcium alginate/silk fibroin peptide/Bletilla striata polysaccharide blended microspheres loaded with tannic acid for rapid wound healing.
36116592	1	51	theme	Biodegradable	140:152	arg1	polymers					162:169	Biodegradable natural polymers	140:169	Biodegradable natural polymers	140:169	Biodegradable natural polymers are receiving increasing attention as potential candidates for wound dressing.
36116592	1	52	theme	natural	154:160	arg1	polymers					162:169	Biodegradable natural polymers	140:169	Biodegradable natural polymers	140:169	Biodegradable natural polymers are receiving increasing attention as potential candidates for wound dressing.
36116592	8	53	theme	wound	1191:1195	arg1	healing					1197:1203	rapid wound healing	1185:1203	rapid wound healing	1185:1203	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	3	54	theme	swelling	463:470	arg1	properties					472:481	The excellent swelling properties	449:481	The excellent swelling properties of microspheres	449:497	The excellent swelling properties of microspheres enable them to rapidly promote thrombosis.
36116592	2	55	theme	silk	334:337	arg1	SP					356:357	SP	356:357	SP	356:357	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	55	theme	silk	334:337	arg1	peptide					347:353	silk fibroin peptide	334:353	silk fibroin peptide (SP)	334:358	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	5	56	theme	long-lasting	806:817	arg1	properties					833:842	good long-lasting antibacterial properties	801:842	good long-lasting antibacterial properties	801:842	Furthermore, tannic acid (TA)-loaded microspheres demonstrate a slow-release effect on TA; this allows the microspheres to exhibit good long-lasting antibacterial properties.
36116592	8	57	theme	rapid	1185:1189	arg1	healing					1197:1203	rapid wound healing	1185:1203	rapid wound healing	1185:1203	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	8	58	theme	hemostasis	1232:1241	arg1	treatment					1213:1221	the treatment	1209:1221	the treatment of wound hemostasis	1209:1241	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	8	58	theme	hemostasis	1232:1241	arg1	healing					1197:1203	rapid wound healing	1185:1203	rapid wound healing	1185:1203	The multifunctional TA-loaded mCSB has great application potential for rapid wound healing and the treatment of wound hemostasis.
36116592	2	59	theme	striata	374:380	arg1	BSP					398:400	BSP	398:400	BSP	398:400	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	59	theme	striata	374:380	arg1	polysaccharide					382:395	Bletilla striata polysaccharide	365:395	Bletilla striata polysaccharide (BSP)	365:401	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	4	60	theme	aggregation	614:624	arg1	rate					626:629	the aggregation rate	610:629	the aggregation rate of red blood cells	610:648	Microspheres can increase the platelet aggregation index to 1.5 and the aggregation rate of red blood cells to as high as 80 %.
36116592	6	61	theme	TA	886:887	arg1	effects					868:874	the synergistic effects	852:874	the synergistic effects of SP and TA	852:887	Due to the synergistic effects of SP and TA, the cell senescence was delayed, with a 126.69 % survival rate of fibroblasts after 3 days of incubation.
36116592	2	62	theme	composite	272:280	arg1	microspheres					282:293	composite microspheres	272:293	composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP)	272:401	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	62	theme	composite	272:280	arg1	mCSB					296:299	mCSB	296:299	mCSB	296:299	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
36116592	2	63	theme	reverse	424:430	arg1	method					441:446	the reverse emulsion method	420:446	the reverse emulsion method	420:446	In the present study, composite microspheres (mCSB) based on calcium alginate (CA), silk fibroin peptide (SP), and Bletilla striata polysaccharide (BSP) were prepared by the reverse emulsion method.
35609460	7	0	theme	applications	1045:1056	arg1	types					1026:1030	different types	1016:1030	different types of foods and applications (e.g. coatings and packaging)	1016:1086	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	1	1	theme	starch	166:171	arg1	manufacture					173:183	wheat starch manufacture	160:183	wheat starch manufacture	160:183	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	7	2	theme	film	973:976	arg1	composition					978:988	the film composition	969:988	the film composition	969:988	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	5	3	from	decrease	674:681	arg1	region					705:710	the Ultra-Violet-B region	686:710	the Ultra-Violet-B region	686:710	Furthermore, the incorporation of WP provided UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region).
35609460	4	4	theme	concentration	497:509	arg1	increase					482:489	the increase	478:489	the increase of WP concentration from 4 to 8 % w/v	478:527	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	7	5	theme	rate	919:922	arg1	properties					931:940	the mechanical and Water Vapor Transmission rate (WVTR) properties	875:940	the mechanical and Water Vapor Transmission rate (WVTR) properties	875:940	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	4	6	from	increase	482:489	arg1	w/v					525:527	4 to 8 % w/v	516:527	4 to 8 % w/v	516:527	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	3	7	theme	films	340:344	arg1	microstructure					316:329	the microstructure	312:329	the microstructure of Al/WP films	312:344	The investigation of the microstructure of Al/WP films revealed a more compacted cross-section and homogeneous surface, comparatively to Al films.
35609460	4	8	theme	WP	494:495	arg1	concentration					497:509	WP concentration	494:509	WP concentration from 4 to 8 % w/v	494:527	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	5	9	theme	WP	623:624	arg1	incorporation					606:618	the incorporation	602:618	the incorporation of WP	602:624	Furthermore, the incorporation of WP provided UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region).
35609460	6	10	theme	water	777:781	arg1	solubility					783:792	the water solubility	773:792	the water solubility of the Al films	773:808	Additionally, the incorporation of WP in the films reduced the water solubility of the Al films.
35609460	4	11	theme	interactions	557:568	arg1	result					533:538	result	533:538	result of electrostatic interactions between WP and Al	533:586	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	4	11	theme	interactions	557:568	arg1	properties					444:453	Those properties	438:453	Those properties	438:453	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	4	12	mod	modified	464:471	arg3	increase					482:489	the increase	478:489	the increase of WP concentration from 4 to 8 % w/v	478:527	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	4	12	mod	modified	464:471	arg1	result					533:538	result	533:538	result of electrostatic interactions between WP and Al	533:586	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	4	12	mod	modified	464:471	arg1	properties					444:453	Those properties	438:453	Those properties	438:453	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	7	13	theme	Vapor	900:904	arg1	WVTR					925:928	WVTR	925:928	WVTR	925:928	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	7	13	theme	Vapor	900:904	arg1	rate					919:922	Water Vapor Transmission rate	894:922	Water Vapor Transmission rate (WVTR)	894:929	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	4	14	theme	electrostatic	543:555	arg1	interactions					557:568	electrostatic interactions	543:568	electrostatic interactions between WP and Al	543:586	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	1	15	theme	proteins	119:126	arg1	by-products					128:138	wheat proteins by-products	113:138	wheat proteins by-products	113:138	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	7	16	theme	Transmission	906:917	arg1	WVTR					925:928	WVTR	925:928	WVTR	925:928	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	7	16	theme	Transmission	906:917	arg1	rate					919:922	Water Vapor Transmission rate	894:922	Water Vapor Transmission rate (WVTR)	894:929	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	2	17	theme	alginate	266:273	arg1	solutions					280:288	alginate (Al) solutions	266:288	alginate (Al) solutions	266:288	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	3	18	theme	Al	428:429	arg1	films					431:435	Al films	428:435	Al films	428:435	The investigation of the microstructure of Al/WP films revealed a more compacted cross-section and homogeneous surface, comparatively to Al films.
35609460	3	19	theme	Al/WP	334:338	arg1	films					340:344	Al/WP films	334:344	Al/WP films	334:344	The investigation of the microstructure of Al/WP films revealed a more compacted cross-section and homogeneous surface, comparatively to Al films.
35609460	4	20	dep	w/v	525:527	arg1	%					523:523	%	523:523	%	523:523	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	7	21	dep	coatings	1064:1071	arg1	e.g.					1059:1062	e.g.	1059:1062	e.g.	1059:1062	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	0	22	theme	polysaccharides-proteins	11:34	arg1	films					36:40	Adjustable polysaccharides-proteins films	0:40	Adjustable polysaccharides-proteins films	0:40	Adjustable polysaccharides-proteins films made of aqueous wheat proteins and alginate solutions.
35609460	4	23	dep	%	523:523	arg1	8					521:521	8	521:521	8	521:521	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	7	24	theme	Water	894:898	arg1	WVTR					925:928	WVTR	925:928	WVTR	925:928	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	7	24	theme	Water	894:898	arg1	rate					919:922	Water Vapor Transmission rate	894:922	Water Vapor Transmission rate (WVTR)	894:929	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	1	25	theme	Large	97:101	arg1	amount					103:108	Large amount	97:108	Large amount of wheat proteins by-products	97:138	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	1	25	theme	Large	97:101	arg1	by-products					128:138	wheat proteins by-products	113:138	wheat proteins by-products	113:138	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	0	26	theme	Adjustable	0:9	arg1	films					36:40	Adjustable polysaccharides-proteins films	0:40	Adjustable polysaccharides-proteins films	0:40	Adjustable polysaccharides-proteins films made of aqueous wheat proteins and alginate solutions.
35609460	7	27	theme	different	1016:1024	arg1	types					1026:1030	different types	1016:1030	different types of foods and applications (e.g. coatings and packaging)	1016:1086	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	4	28	from	w/v	525:527	arg1	increase					482:489	the increase	478:489	the increase of WP concentration from 4 to 8 % w/v	478:527	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	4	28	from	w/v	525:527	arg1	concentration					497:509	WP concentration	494:509	WP concentration from 4 to 8 % w/v	494:527	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	6	29	theme	WP	749:750	arg1	incorporation					732:744	the incorporation	728:744	the incorporation of WP in the films	728:763	Additionally, the incorporation of WP in the films reduced the water solubility of the Al films.
35609460	2	30	theme	solutions	280:288	arg1	films					220:224	edible films	213:224	edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions	213:288	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	7	31	dep	applications	1045:1056	arg1	packaging					1077:1085	packaging	1077:1085	packaging	1077:1085	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	7	31	dep	applications	1045:1056	arg1	coatings					1064:1071	coatings	1064:1071	coatings	1064:1071	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	1	32	theme	wheat	113:117	arg1	by-products					128:138	wheat proteins by-products	113:138	wheat proteins by-products	113:138	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	0	33	theme	aqueous	50:56	arg1	proteins					64:71	aqueous wheat proteins	50:71	aqueous wheat proteins	50:71	Adjustable polysaccharides-proteins films made of aqueous wheat proteins and alginate solutions.
35609460	2	34	theme	wheat	242:246	arg1	WP					258:259	WP	258:259	WP	258:259	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	2	34	theme	wheat	242:246	arg1	proteins					248:255	cast aqueous wheat proteins	229:255	cast aqueous wheat proteins (WP)	229:260	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	5	35	theme	Ultra-Violet-B	690:703	arg1	region					705:710	the Ultra-Violet-B region	686:710	the Ultra-Violet-B region	686:710	Furthermore, the incorporation of WP provided UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region).
35609460	2	36	theme	aqueous	234:240	arg1	WP					258:259	WP	258:259	WP	258:259	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	2	36	theme	aqueous	234:240	arg1	proteins					248:255	cast aqueous wheat proteins	229:255	cast aqueous wheat proteins (WP)	229:260	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	5	37	dep	behaviour	656:664	arg1	decrease					674:681	4-fold decrease	667:681	4-fold decrease in the Ultra-Violet-B region	667:710	Furthermore, the incorporation of WP provided UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region).
35609460	5	38	theme	UltraViolet-blocking	635:654	arg1	behaviour					656:664	UltraViolet-blocking behaviour	635:664	UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region)	635:711	Furthermore, the incorporation of WP provided UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region).
35609460	2	39	theme	cast	229:232	arg1	WP					258:259	WP	258:259	WP	258:259	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	2	39	theme	cast	229:232	arg1	proteins					248:255	cast aqueous wheat proteins	229:255	cast aqueous wheat proteins (WP)	229:260	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	2	40	dep	solutions	280:288	arg1	Al					276:277	Al	276:277	Al	276:277	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	0	41	theme	wheat	58:62	arg1	proteins					64:71	aqueous wheat proteins	50:71	aqueous wheat proteins	50:71	Adjustable polysaccharides-proteins films made of aqueous wheat proteins and alginate solutions.
35609460	6	42	theme	films	804:808	arg1	solubility					783:792	the water solubility	773:792	the water solubility of the Al films	773:808	Additionally, the incorporation of WP in the films reduced the water solubility of the Al films.
35609460	6	43	theme	Al	801:802	arg1	films					804:808	the Al films	797:808	the Al films	797:808	Additionally, the incorporation of WP in the films reduced the water solubility of the Al films.
35609460	1	44	theme	by-products	128:138	arg1	amount					103:108	Large amount	97:108	Large amount of wheat proteins by-products	97:138	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	1	44	theme	by-products	128:138	arg1	by-products					128:138	wheat proteins by-products	113:138	wheat proteins by-products	113:138	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
35609460	7	45	theme	mechanical	879:888	arg1	properties					931:940	the mechanical and Water Vapor Transmission rate (WVTR) properties	875:940	the mechanical and Water Vapor Transmission rate (WVTR) properties	875:940	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	2	46	theme	edible	213:218	arg1	films					220:224	edible films	213:224	edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions	213:288	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	7	47	theme	WP	872:873	arg1	amounts					861:867	different amounts	851:867	different amounts of WP	851:873	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	7	47	theme	WP	872:873	arg1	WP					872:873	WP	872:873	WP	872:873	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	5	48	theme	4-fold	667:672	arg1	decrease					674:681	4-fold decrease	667:681	4-fold decrease in the Ultra-Violet-B region	667:710	Furthermore, the incorporation of WP provided UltraViolet-blocking behaviour (4-fold decrease in the Ultra-Violet-B region).
35609460	7	49	theme	foods	1035:1039	arg1	types					1026:1030	different types	1016:1030	different types of foods and applications (e.g. coatings and packaging)	1016:1086	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	6	50	from	incorporation	732:744	arg1	films					759:763	the films	755:763	the films	755:763	Additionally, the incorporation of WP in the films reduced the water solubility of the Al films.
35609460	7	51	theme	different	851:859	arg1	amounts					861:867	different amounts	851:867	different amounts of WP	851:873	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	7	51	theme	different	851:859	arg1	WP					872:873	WP	872:873	WP	872:873	It was also found that by incorporating different amounts of WP the mechanical and Water Vapor Transmission rate (WVTR) properties could also be modified, so the film composition could be adjusted to suit different types of foods and applications (e.g. coatings and packaging).
35609460	0	52	theme	alginate	77:84	arg1	solutions					86:94	alginate solutions	77:94	alginate solutions	77:94	Adjustable polysaccharides-proteins films made of aqueous wheat proteins and alginate solutions.
35609460	3	53	theme	homogeneous	390:400	arg1	surface					402:408	homogeneous surface	390:408	homogeneous surface	390:408	The investigation of the microstructure of Al/WP films revealed a more compacted cross-section and homogeneous surface, comparatively to Al films.
35609460	3	54	theme	compacted	362:370	arg1	cross-section					372:384	a more compacted cross-section	355:384	a more compacted cross-section	355:384	The investigation of the microstructure of Al/WP films revealed a more compacted cross-section and homogeneous surface, comparatively to Al films.
35609460	3	55	theme	microstructure	316:329	arg1	investigation					295:307	The investigation	291:307	The investigation of the microstructure of Al/WP films	291:344	The investigation of the microstructure of Al/WP films revealed a more compacted cross-section and homogeneous surface, comparatively to Al films.
35609460	4	56	dep	8	521:521	arg1	to					518:519	to	518:519	to	518:519	Those properties could be modified with the increase of WP concentration from 4 to 8 % w/v, as result of electrostatic interactions between WP and Al.
35609460	2	57	theme	proteins	248:255	arg1	films					220:224	edible films	213:224	edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions	213:288	This work aimed to develop edible films of cast aqueous wheat proteins (WP) and alginate (Al) solutions.
35609460	1	58	theme	wheat	160:164	arg1	manufacture					173:183	wheat starch manufacture	160:183	wheat starch manufacture	160:183	Large amount of wheat proteins by-products are produced during wheat starch manufacture.
36062844	0	0	theme	other	82:86	arg1	composites					88:97	other composites	82:97	other composites	82:97	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	8	1	from	1800 s	1202:1207	arg1	composites					1176:1185	other composites	1170:1185	other composites at 30, 60, and 1800 s after light irradiation	1170:1231	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	2	2	theme	conventional	582:593	arg1	composites					595:604	two conventional composites	578:604	two conventional composites	578:604	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	9	3	theme	similar	1428:1434	arg1	shrinkage					1418:1426	polymerization shrinkage	1403:1426	polymerization shrinkage similar to the conventional one	1403:1458	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	8	4	theme	other	1170:1174	arg1	composites					1176:1185	other composites	1170:1185	other composites at 30, 60, and 1800 s after light irradiation	1170:1231	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	9	5	dep	CONCLUSION	1344:1353	arg1	results					1372:1378	the results	1368:1378	the results	1368:1378	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	10	6	theme	Bulk-fill	1461:1469	arg1	composites					1471:1480	Bulk-fill composites	1461:1480	Bulk-fill composites reported similar or lower	1461:1506	Bulk-fill composites reported similar or lower shrinkage to conventional composites.
36062844	1	7	theme	new	342:344	arg1	[GBI					401:404	G-aenial bulk injectable [GBI	376:404	G-aenial bulk injectable [GBI	376:404	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	7	theme	new	342:344	arg1	composite					365:373	a new bulk-fill flowable composite	340:373	a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	340:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	9	8	contain	had	1399:1401	arg1	composite					1389:1397	the new composite	1381:1397	the new composite	1381:1397	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	9	8	contain	had	1399:1401	arg2	shrinkage					1418:1426	polymerization shrinkage	1403:1426	polymerization shrinkage similar to the conventional one	1403:1458	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	0	9	dep	in	103:104	arg1	vitro					106:110	vitro	106:110	vitro	106:110	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	1	10	theme	bulk-fill	346:354	arg1	[GBI					401:404	G-aenial bulk injectable [GBI	376:404	G-aenial bulk injectable [GBI	376:404	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	10	theme	bulk-fill	346:354	arg1	composite					365:373	a new bulk-fill flowable composite	340:373	a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	340:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	11	theme	other	426:430	arg1	composites					459:468	other bulk-fill and conventional composites	426:468	other bulk-fill and conventional composites	426:468	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	4	12	theme	differential	731:742	arg1	transformer					744:754	a linear variable differential transformer	713:754	a linear variable differential transformer	713:754	This assembly was transferred to a linear variable differential transformer and composite samples were cured from underneath the slides.
36062844	9	13	theme	conventional	1443:1454	arg1	one					1456:1458	the conventional one	1439:1458	the conventional one	1439:1458	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	0	14	theme	in	103:104	arg1	study					112:116	An in vitro study	100:116	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.	0:117	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	1	15	theme	flowable	356:363	arg1	[GBI					401:404	G-aenial bulk injectable [GBI	376:404	G-aenial bulk injectable [GBI	376:404	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	15	theme	flowable	356:363	arg1	composite					365:373	a new bulk-fill flowable composite	340:373	a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	340:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	16	theme	bulk-fill	432:440	arg1	composites					459:468	other bulk-fill and conventional composites	426:468	other bulk-fill and conventional composites	426:468	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	4	17	theme	composite	760:768	arg1	samples					770:776	composite samples	760:776	composite samples	760:776	This assembly was transferred to a linear variable differential transformer and composite samples were cured from underneath the slides.
36062844	5	18	theme	composite	847:855	arg1	samples					857:863	composite samples	847:863	composite samples	847:863	Dimensional changes formed in composite samples were recorded.
36062844	1	19	theme	composite	365:373	arg1	shrinkage					327:335	the polymerization shrinkage	308:335	the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	308:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	20	theme	critical	159:166	arg1	problem					168:174	a critical problem	157:174	a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites	157:468	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	3	21	theme	microscopic	629:639	arg1	slide					641:645	a microscopic slide	627:645	a microscopic slide	627:645	They were bonded to a microscopic slide and were covered by a coverslip.
36062844	1	22	theme	conventional	446:457	arg1	composites					459:468	other bulk-fill and conventional composites	426:468	other bulk-fill and conventional composites	426:468	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	8	23	theme	Filtek	1254:1259	arg1	Z250					1261:1264	Filtek Z250	1254:1264	Filtek Z250	1254:1264	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	2	24	from	MATERIALS	471:479	arg1	study					510:514	this in vitro study	496:514	this in vitro study	496:514	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	0	25	theme	shrinkage	29:37	arg1	Comparison					0:9	Comparison	0:9	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.	0:117	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	2	26	dep	in	501:502	arg1	vitro					504:508	vitro	504:508	vitro	504:508	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	4	27	theme	variable	722:729	arg1	transformer					744:754	a linear variable differential transformer	713:754	a linear variable differential transformer	713:754	This assembly was transferred to a linear variable differential transformer and composite samples were cured from underneath the slides.
36062844	9	28	theme	new	1385:1387	arg1	composite					1389:1397	the new composite	1381:1397	the new composite	1381:1397	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	1	29	theme	polymerization	183:196	arg1	shrinkage					198:206	polymerization shrinkage	183:206	polymerization shrinkage	183:206	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	0	30	theme	polymerization	14:27	arg1	shrinkage					29:37	polymerization shrinkage	14:37	polymerization shrinkage of a new bulk-fill flowable composite	14:75	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	2	31	theme	composite	520:528	arg1	MATERIALS					471:479	MATERIALS	471:479	MATERIALS	471:479	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	2	31	theme	composite	520:528	arg1	discs					530:534	25 composite discs	517:534	25 composite discs	517:534	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	1	32	theme	G-aenial	376:383	arg1	[GBI					401:404	G-aenial bulk injectable [GBI	376:404	G-aenial bulk injectable [GBI	376:404	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	32	theme	G-aenial	376:383	arg1	composite					365:373	a new bulk-fill flowable composite	340:373	a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	340:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	4	33	theme	linear	715:720	arg1	transformer					744:754	a linear variable differential transformer	713:754	a linear variable differential transformer	713:754	This assembly was transferred to a linear variable differential transformer and composite samples were cured from underneath the slides.
36062844	1	34	theme	bulk	385:388	arg1	[GBI					401:404	G-aenial bulk injectable [GBI	376:404	G-aenial bulk injectable [GBI	376:404	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	34	theme	bulk	385:388	arg1	composite					365:373	a new bulk-fill flowable composite	340:373	a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	340:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	7	35	dep	RESULTS	976:982	arg1	groups					988:993	The groups	984:993	RESULTS The groups	976:993	RESULTS The groups were significantly different regarding polymerization shrinkage.
36062844	8	36	theme	lowest	1277:1282	arg1	shrinkage					1299:1307	the lowest polymerization shrinkage	1273:1307	the lowest polymerization shrinkage	1273:1307	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	8	37	theme	light	1215:1219	arg1	irradiation					1221:1231	light irradiation	1215:1231	light irradiation	1215:1231	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	8	38	theme	universal	1098:1106	arg1	flo					1108:1110	G-aenial bulk injectable and G-aenial universal flo	1060:1110	flo	1108:1110	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	1	39	theme	injectable	390:399	arg1	[GBI					401:404	G-aenial bulk injectable [GBI	376:404	G-aenial bulk injectable [GBI	376:404	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	39	theme	injectable	390:399	arg1	composite					365:373	a new bulk-fill flowable composite	340:373	a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	340:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	1	40	theme	bulk-fill	212:220	arg1	composites					222:231	bulk-fill composites	212:231	bulk-fill composites	212:231	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	0	41	theme	bulk-fill	48:56	arg1	composite					67:75	a new bulk-fill flowable composite	42:75	a new bulk-fill flowable composite	42:75	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	2	42	theme	in	501:502	arg1	study					510:514	this in vitro study	496:514	this in vitro study	496:514	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	7	43	theme	polymerization	1034:1047	arg1	shrinkage					1049:1057	polymerization shrinkage	1034:1057	polymerization shrinkage	1034:1057	RESULTS The groups were significantly different regarding polymerization shrinkage.
36062844	2	44	from	METHODS	485:491	arg1	study					510:514	this in vitro study	496:514	this in vitro study	496:514	MATERIALS AND METHODS In this in vitro study, 25 composite discs were fabricated using three bulk-fill and two conventional composites.
36062844	0	45	theme	new	44:46	arg1	composite					67:75	a new bulk-fill flowable composite	42:75	a new bulk-fill flowable composite	42:75	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	8	46	theme	G-aenial	1089:1096	arg1	flo					1108:1110	G-aenial bulk injectable and G-aenial universal flo	1060:1110	flo	1108:1110	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	8	47	from	60	1194:1195	arg1	composites					1176:1185	other composites	1170:1185	other composites at 30, 60, and 1800 s after light irradiation	1170:1231	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	8	48	theme	polymerization	1284:1297	arg1	shrinkage					1299:1307	the lowest polymerization shrinkage	1273:1307	the lowest polymerization shrinkage	1273:1307	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	1	49	theme	polymerization	312:325	arg1	shrinkage					327:335	the polymerization shrinkage	308:335	the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI])	308:406	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36062844	8	50	theme	polymerization	1140:1153	arg1	shrinkage					1155:1163	significantly higher polymerization shrinkage	1119:1163	significantly higher polymerization shrinkage	1119:1163	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	6	51	dep	Tukey	947:951	arg1	tests					969:973	tests	969:973	tests	969:973	Data were analyzed using analysis of variance followed by post hoc Tukey's and Dunnett's tests.
36062844	0	52	with	Comparison	0:9	arg1	composites					88:97	other composites	82:97	other composites	82:97	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	10	53	theme	conventional	1521:1532	arg1	composites					1534:1543	conventional composites	1521:1543	conventional composites	1521:1543	Bulk-fill composites reported similar or lower shrinkage to conventional composites.
36062844	8	54	theme	higher	1133:1138	arg1	shrinkage					1155:1163	significantly higher polymerization shrinkage	1119:1163	significantly higher polymerization shrinkage	1119:1163	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	8	55	from	30	1190:1191	arg1	composites					1176:1185	other composites	1170:1185	other composites at 30, 60, and 1800 s after light irradiation	1170:1231	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	0	56	theme	composite	67:75	arg1	shrinkage					29:37	polymerization shrinkage	14:37	polymerization shrinkage of a new bulk-fill flowable composite	14:75	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	5	57	theme	Dimensional	817:827	arg1	changes					829:835	Dimensional changes	817:835	Dimensional changes formed in composite samples	817:863	Dimensional changes formed in composite samples were recorded.
36062844	8	58	theme	time	1331:1334	arg1	points					1336:1341	the aforementioned time points	1312:1341	the aforementioned time points	1312:1341	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	8	59	theme	X-tra	1240:1244	arg1	fil					1246:1248	X-tra fil	1240:1248	X-tra fil	1240:1248	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	9	60	theme	polymerization	1403:1416	arg1	shrinkage					1418:1426	polymerization shrinkage	1403:1426	polymerization shrinkage similar to the conventional one	1403:1458	CONCLUSION According to the results, the new composite had polymerization shrinkage similar to the conventional one.
36062844	0	61	theme	flowable	58:65	arg1	composite					67:75	a new bulk-fill flowable composite	42:75	a new bulk-fill flowable composite	42:75	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	6	62	theme	variance	917:924	arg1	analysis					905:912	analysis	905:912	analysis of variance followed by post hoc Tukey's and Dunnett's tests	905:973	Data were analyzed using analysis of variance followed by post hoc Tukey's and Dunnett's tests.
36062844	0	63	dep	Comparison	0:9	arg1	study					112:116	An in vitro study	100:116	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.	0:117	Comparison of polymerization shrinkage of a new bulk-fill flowable composite with other composites: An in vitro study.
36062844	8	64	theme	aforementioned	1316:1329	arg1	points					1336:1341	the aforementioned time points	1312:1341	the aforementioned time points	1312:1341	G-aenial bulk injectable and G-aenial universal flo showed significantly higher polymerization shrinkage than other composites at 30, 60, and 1800 s after light irradiation, while X-tra fil and Filtek Z250 showed the lowest polymerization shrinkage at the aforementioned time points.
36062844	6	65	theme	post	938:941	arg1	hoc					943:945	post hoc Tukey's and Dunnett's tests	938:973	post hoc Tukey's and Dunnett's tests	938:973	Data were analyzed using analysis of variance followed by post hoc Tukey's and Dunnett's tests.
36062844	1	66	theme	acceptable	247:256	arg1	results					258:264	acceptable results	247:264	acceptable results	247:264	OBJECTIVE Since composites still face a critical problem called polymerization shrinkage and bulk-fill composites have reported acceptable results for this issue, this study aims to assess the polymerization shrinkage of a new bulk-fill flowable composite (G-aenial bulk injectable [GBI]) and compare it to other bulk-fill and conventional composites.
36639080	0	0	theme	coffee	103:108	arg1	ground					110:115	spent coffee ground	97:115	spent coffee ground	97:115	Antioxidant and ultraviolet shielding performance of lignin-polysaccharide complex isolated from spent coffee ground.
36639080	6	1	theme	UV-shielding	1348:1359	arg1	products					1361:1368	UV-shielding products	1348:1368	UV-shielding products	1348:1368	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	3	2	theme	weight	578:583	arg1	distribution					585:596	molecular weight distribution	568:596	molecular weight distribution	568:596	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	1	3	theme	representative	149:162	arg1	ground					131:136	Spent coffee ground	118:136	Spent coffee ground (SCG)	118:142	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	3	theme	representative	149:162	arg1	type					164:167	a representative type	147:167	a representative type of biomass waste with huge annual output	147:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	4	4	theme	irradiation	839:849	arg1	4 h					828:830	4 h	828:830	4 h	828:830	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	4	4	theme	irradiation	839:849	arg1	duration					812:819	a proper duration	803:819	a proper duration (e.g., 4 h) of UV irradiation	803:849	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	5	5	theme	aromatic	1170:1177	arg1	rings					1179:1183	aromatic rings	1170:1183	aromatic rings from both LPC and the active ingredients in commercial sunscreen	1170:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	0	6	theme	spent	97:101	arg1	ground					110:115	spent coffee ground	97:115	spent coffee ground	97:115	Antioxidant and ultraviolet shielding performance of lignin-polysaccharide complex isolated from spent coffee ground.
36639080	2	7	attach	isolated	320:327	arg2	complex					302:308	the lignin-polysaccharide complex	276:308	the lignin-polysaccharide complex (LPC)	276:314	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	2	7	attach	isolated	320:327	arg1	SCG					334:336	SCG	334:336	SCG	334:336	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	2	7	attach	isolated	320:327	arg2	LPC					311:313	LPC	311:313	LPC	311:313	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	5	8	theme	commercial	1229:1238	arg1	sunscreen					1240:1248	commercial sunscreen	1229:1248	commercial sunscreen	1229:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	9	theme	rings	1179:1183	arg1	stacking					1158:1165	the π-π stacking	1150:1165	the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen	1150:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	9	theme	rings	1179:1183	arg1	resistance					1053:1062	strengthened UV resistance	1037:1062	strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures	1037:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	4	10	theme	LPC	910:912	arg1	capacity					898:905	the radical-scavenging capacity	875:905	the radical-scavenging capacity	875:905	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	3	11	theme	thermal	664:670	arg1	stability					672:680	thermal stability	664:680	thermal stability	664:680	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	3	12	theme	obtained	499:506	arg1	LPC					508:510	the obtained LPC	495:510	the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability	495:680	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	3	13	dep	analyses	483:490	arg1	addition					453:460	addition	453:460	addition	453:460	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	6	14	theme	effect	1448:1453	arg1	virtue					1374:1379	virtue	1374:1379	virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite	1374:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	6	15	theme	novel	1325:1329	arg1	antioxidants					1331:1342	novel antioxidants	1325:1342	novel antioxidants	1325:1342	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	5	16	theme	UV	1070:1071	arg1	irradiation					1073:1083	UV irradiation	1070:1083	UV irradiation	1070:1083	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	6	17	theme	antioxidants	1331:1342	arg1	development					1310:1320	the development	1306:1320	the development of novel antioxidants and UV-shielding products	1306:1368	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	3	18	theme	LPC	508:510	arg1	analyses					483:490	the comprehensive analyses	465:490	the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability	465:680	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	6	19	from	composite	1494:1502	arg1	ingredients					1473:1483	other active ingredients	1460:1483	other active ingredients from the composite	1460:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	5	20	from	resistance	1053:1062	arg1	ingredients					1214:1224	the active ingredients	1203:1224	the active ingredients in commercial sunscreen	1203:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	20	from	resistance	1053:1062	arg1	LPC					1195:1197	LPC	1195:1197	LPC	1195:1197	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	3	21	theme	radical	701:707	arg1	scavenging					709:718	radical scavenging	701:718	radical scavenging	701:718	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	5	22	from	stacking	1158:1165	arg1	ingredients					1214:1224	the active ingredients	1203:1224	the active ingredients in commercial sunscreen	1203:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	22	from	stacking	1158:1165	arg1	LPC					1195:1197	LPC	1195:1197	LPC	1195:1197	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	2	23	theme	subsequent	381:390	arg1	extraction					400:409	the subsequent solvent extraction	377:409	the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution	377:447	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	5	24	from	ingredients	1214:1224	arg1	stacking					1158:1165	the π-π stacking	1150:1165	the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen	1150:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	24	from	ingredients	1214:1224	arg1	sunscreen					1240:1248	commercial sunscreen	1229:1248	commercial sunscreen	1229:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	24	from	ingredients	1214:1224	arg1	resistance					1053:1062	strengthened UV resistance	1037:1062	strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures	1037:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	24	from	ingredients	1214:1224	arg1	rings					1179:1183	aromatic rings	1170:1183	aromatic rings from both LPC and the active ingredients in commercial sunscreen	1170:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	2	25	theme	effective	350:358	arg1	milling					365:371	effective ball milling	350:371	effective ball milling	350:371	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	4	26	theme	groups	964:969	arg1	number					942:947	the increasing number	927:947	the increasing number of antioxidant groups	927:969	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	4	27	theme	antioxidant	952:962	arg1	groups					964:969	antioxidant groups	952:969	antioxidant groups	952:969	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	6	28	theme	structure	1412:1420	arg1	virtue					1374:1379	virtue	1374:1379	virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite	1374:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	1	29	theme	biomass	172:178	arg1	waste					180:184	biomass waste	172:184	biomass waste with huge annual output	172:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	2	30	theme	%	417:417	arg1	extraction					400:409	the subsequent solvent extraction	377:409	the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution	377:447	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	2	30	theme	%	417:417	arg1	milling					365:371	effective ball milling	350:371	effective ball milling	350:371	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	4	31	theme	increasing	931:940	arg1	number					942:947	the increasing number	927:947	the increasing number of antioxidant groups	927:969	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	6	32	theme	products	1361:1368	arg1	development					1310:1320	the development	1306:1320	the development of novel antioxidants and UV-shielding products	1306:1368	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	3	33	theme	chemical	526:533	arg1	composition					535:545	its chemical composition	522:545	its chemical composition	522:545	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	1	34	theme	waste	180:184	arg1	ground					131:136	Spent coffee ground	118:136	Spent coffee ground (SCG)	118:142	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	34	theme	waste	180:184	arg1	type					164:167	a representative type	147:167	a representative type of biomass waste with huge annual output	147:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	3	35	from	potentials	687:696	arg1	scavenging					709:718	radical scavenging	701:718	radical scavenging	701:718	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	3	35	from	potentials	687:696	arg1	shielding					727:735	UV shielding	724:735	UV shielding	724:735	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	3	36	theme	UV	724:725	arg1	shielding					727:735	UV shielding	724:735	UV shielding	724:735	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	6	37	with	effect	1448:1453	arg1	ingredients					1473:1483	other active ingredients	1460:1483	other active ingredients from the composite	1460:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	6	38	with	structure	1412:1420	arg1	ingredients					1473:1483	other active ingredients	1460:1483	other active ingredients from the composite	1460:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	2	39	theme	lignin-polysaccharide	280:300	arg1	LPC					311:313	LPC	311:313	LPC	311:313	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	2	39	theme	lignin-polysaccharide	280:300	arg1	complex					302:308	the lignin-polysaccharide complex	276:308	the lignin-polysaccharide complex (LPC)	276:314	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	0	40	theme	shielding	28:36	arg1	performance					38:48	shielding performance	28:48	shielding performance	28:48	Antioxidant and ultraviolet shielding performance of lignin-polysaccharide complex isolated from spent coffee ground.
36639080	5	41	theme	π-π	1154:1156	arg1	stacking					1158:1165	the π-π stacking	1150:1165	the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen	1150:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	42	theme	LPC-containing	986:999	arg1	sunscreens					1011:1020	the LPC-containing composite sunscreens	982:1020	the LPC-containing composite sunscreens	982:1020	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	1	43	theme	Spent	118:122	arg1	SCG					139:141	SCG	139:141	SCG	139:141	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	43	theme	Spent	118:122	arg1	ground					131:136	Spent coffee ground	118:136	Spent coffee ground (SCG)	118:142	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	43	theme	Spent	118:122	arg1	type					164:167	a representative type	147:167	a representative type of biomass waste with huge annual output	147:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	6	44	theme	synergistic	1436:1446	arg1	effect					1448:1453	potential synergistic effect	1426:1453	potential synergistic effect	1426:1453	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	2	45	theme	solvent	392:398	arg1	extraction					400:409	the subsequent solvent extraction	377:409	the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution	377:447	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	6	46	theme	characteristic	1388:1401	arg1	structure					1412:1420	its characteristic chemical structure	1384:1420	its characteristic chemical structure	1384:1420	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	5	47	theme	strengthened	1037:1048	arg1	resistance					1053:1062	strengthened UV resistance	1037:1062	strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures	1037:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	1	48	theme	coffee	124:129	arg1	SCG					139:141	SCG	139:141	SCG	139:141	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	48	theme	coffee	124:129	arg1	ground					131:136	Spent coffee ground	118:136	Spent coffee ground (SCG)	118:142	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	48	theme	coffee	124:129	arg1	type					164:167	a representative type	147:167	a representative type of biomass waste with huge annual output	147:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	1	49	theme	annual	196:201	arg1	output					203:208	huge annual output	191:208	huge annual output	191:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	2	50	theme	aqueous	432:438	arg1	solution					440:447	4-dioxane aqueous solution	422:447	4-dioxane aqueous solution	422:447	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	2	50	theme	aqueous	432:438	arg1	%					417:417	96 % 1	414:419	96 % 1	414:419	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	6	51	theme	potential	1426:1434	arg1	effect					1448:1453	potential synergistic effect	1426:1453	potential synergistic effect	1426:1453	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	5	52	theme	UV	1050:1051	arg1	resistance					1053:1062	strengthened UV resistance	1037:1062	strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures	1037:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	2	53	theme	high	229:232	arg1	applications					240:251	high value applications	229:251	high value applications of SCG	229:258	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	6	54	theme	other	1460:1464	arg1	ingredients					1473:1483	other active ingredients	1460:1483	other active ingredients from the composite	1460:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	2	55	theme	4-dioxane	422:430	arg1	solution					440:447	4-dioxane aqueous solution	422:447	4-dioxane aqueous solution	422:447	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	2	55	theme	4-dioxane	422:430	arg1	%					417:417	96 % 1	414:419	96 % 1	414:419	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	5	56	theme	UV-induced	1113:1122	arg1	structures					1135:1144	the UV-induced conjugated structures	1109:1144	the UV-induced conjugated structures	1109:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	4	57	theme	radical-scavenging	879:896	arg1	capacity					898:905	the radical-scavenging capacity	875:905	the radical-scavenging capacity	875:905	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	3	58	theme	characteristic	599:612	arg1	groups					625:630	characteristic functional groups	599:630	characteristic functional groups	599:630	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	6	59	theme	chemical	1403:1410	arg1	structure					1412:1420	its characteristic chemical structure	1384:1420	its characteristic chemical structure	1384:1420	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	0	60	theme	complex	75:81	arg1	Antioxidant					0:10	Antioxidant	0:10	Antioxidant	0:10	Antioxidant and ultraviolet shielding performance of lignin-polysaccharide complex isolated from spent coffee ground.
36639080	5	61	theme	conjugated	1124:1133	arg1	structures					1135:1144	the UV-induced conjugated structures	1109:1144	the UV-induced conjugated structures	1109:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	1	62	with	waste	180:184	arg1	output					203:208	huge annual output	191:208	huge annual output	191:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	3	63	theme	functional	614:623	arg1	groups					625:630	characteristic functional groups	599:630	characteristic functional groups	599:630	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	0	64	theme	lignin-polysaccharide	53:73	arg1	complex					75:81	lignin-polysaccharide complex	53:81	lignin-polysaccharide complex	53:81	Antioxidant and ultraviolet shielding performance of lignin-polysaccharide complex isolated from spent coffee ground.
36639080	4	65	theme	proper	805:810	arg1	4 h					828:830	4 h	828:830	4 h	828:830	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	4	65	theme	proper	805:810	arg1	duration					812:819	a proper duration	803:819	a proper duration (e.g., 4 h) of UV irradiation	803:849	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	4	66	theme	UV	836:837	arg1	irradiation					839:849	UV irradiation	836:849	UV irradiation	836:849	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	5	67	theme	composite	1001:1009	arg1	sunscreens					1011:1020	the LPC-containing composite sunscreens	982:1020	the LPC-containing composite sunscreens	982:1020	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	3	68	theme	surface	548:554	arg1	morphology					556:565	surface morphology	548:565	surface morphology	548:565	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	2	69	theme	value	234:238	arg1	applications					240:251	high value applications	229:251	high value applications of SCG	229:258	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	5	70	from	LPC	1195:1197	arg1	stacking					1158:1165	the π-π stacking	1150:1165	the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen	1150:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	70	from	LPC	1195:1197	arg1	sunscreen					1240:1248	commercial sunscreen	1229:1248	commercial sunscreen	1229:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	70	from	LPC	1195:1197	arg1	resistance					1053:1062	strengthened UV resistance	1037:1062	strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures	1037:1144	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	5	70	from	LPC	1195:1197	arg1	rings					1179:1183	aromatic rings	1170:1183	aromatic rings from both LPC and the active ingredients in commercial sunscreen	1170:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
36639080	2	71	theme	SCG	256:258	arg1	applications					240:251	high value applications	229:251	high value applications of SCG	229:258	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	3	72	theme	surface	633:639	arg1	linkages					650:657	surface chemical linkages	633:657	surface chemical linkages	633:657	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	6	73	theme	active	1466:1471	arg1	ingredients					1473:1483	other active ingredients	1460:1483	other active ingredients from the composite	1460:1502	Therefore, LPC is highly promising to be exploited for the development of novel antioxidants and UV-shielding products, by virtue of its characteristic chemical structure and potential synergistic effect with other active ingredients from the composite.
36639080	3	74	theme	chemical	641:648	arg1	linkages					650:657	surface chemical linkages	633:657	surface chemical linkages	633:657	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	3	75	theme	molecular	568:576	arg1	distribution					585:596	molecular weight distribution	568:596	molecular weight distribution	568:596	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	1	76	theme	huge	191:194	arg1	output					203:208	huge annual output	191:208	huge annual output	191:208	Spent coffee ground (SCG) is a representative type of biomass waste with huge annual output.
36639080	3	77	theme	comprehensive	469:481	arg1	analyses					483:490	the comprehensive analyses	465:490	the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability	465:680	In addition to the comprehensive analyses of the obtained LPC regarding its chemical composition, surface morphology, molecular weight distribution, characteristic functional groups, surface chemical linkages, and thermal stability, its potentials in radical scavenging and UV shielding had been emphatically investigated.
36639080	2	78	theme	ball	360:363	arg1	milling					365:371	effective ball milling	350:371	effective ball milling	350:371	To better develop high value applications of SCG, in this study, the lignin-polysaccharide complex (LPC) was isolated from SCG by applying effective ball milling and the subsequent solvent extraction of 96 % 1, 4-dioxane aqueous solution.
36639080	4	79	dep	4 h	828:830	arg1	e.g.					822:825	e.g.	822:825	e.g.	822:825	As revealed from the results, a proper duration (e.g., 4 h) of UV irradiation could evidently enhance the radical-scavenging capacity of LPC, ascribed to the increasing number of antioxidant groups.
36639080	0	80	dep	Antioxidant	0:10	arg1	performance					38:48	shielding performance	28:48	shielding performance	28:48	Antioxidant and ultraviolet shielding performance of lignin-polysaccharide complex isolated from spent coffee ground.
36639080	5	81	theme	active	1207:1212	arg1	ingredients					1214:1224	the active ingredients	1203:1224	the active ingredients in commercial sunscreen	1203:1248	Moreover, the LPC-containing composite sunscreens also exhibited strengthened UV resistance after UV irradiation, which may benefit from the UV-induced conjugated structures and the π-π stacking of aromatic rings from both LPC and the active ingredients in commercial sunscreen.
35684548	0	0	theme	Lentinus	90:97	arg1	edodes					99:104	Lentinus edodes	90:104	Lentinus edodes	90:104	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	7	1	theme	hydroxyl	1073:1080	arg1	radical					1082:1088	hydroxyl radical	1073:1088	hydroxyl radical scavenging activity	1073:1108	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	6	2	theme	UV	866:867	arg1	results					802:808	the results	798:808	the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM	798:875	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	7	3	theme	radical	1082:1088	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	3	theme	radical	1082:1088	arg1	activity					1101:1108	hydroxyl radical scavenging activity	1073:1108	hydroxyl radical scavenging activity	1073:1108	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	8	4	theme	industrial	1406:1415	arg1	production					1417:1426	other industrial production	1400:1426	other industrial production	1400:1426	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	2	5	theme	antioxidant	314:324	arg1	activity					326:333	the antioxidant activity	310:333	the antioxidant activity of the polysaccharide samples	310:363	In addition, the antioxidant activity of the polysaccharide samples was also investigated.
35684548	3	6	theme	response	422:429	arg1	test					439:442	response surface test	422:442	response surface test	422:442	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	8	7	theme	other	1400:1404	arg1	production					1417:1426	other industrial production	1400:1426	other industrial production	1400:1426	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	3	8	theme	40:1	507:510	arg1	mL/g					512:515	40:1 mL/g	507:515	40:1 mL/g	507:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	9	theme	extraction	518:527	arg1	temperature					529:539	extraction temperature	518:539	extraction temperature of 147.23 °C	518:552	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	6	10	theme	FT-IR	859:863	arg1	results					802:808	the results	798:808	the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM	798:875	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	6	11	theme	molecular	841:849	arg1	weight					851:856	molecular weight	841:856	molecular weight	841:856	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	7	12	theme	hydrogen	1114:1121	arg1	peroxide					1123:1130	hydrogen peroxide	1114:1130	hydrogen peroxide scavenging activity	1114:1150	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	3	13	theme	mL/g	512:515	arg1	time					594:597	extraction time	583:597	extraction time of 17.58 min	583:610	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	13	theme	mL/g	512:515	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	13	theme	mL/g	512:515	arg1	temperature					529:539	extraction temperature	518:539	extraction temperature of 147.23 °C	518:552	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	13	theme	mL/g	512:515	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	13	theme	mL/g	512:515	arg1	content					561:567	water content	555:567	water content of 39.76%	555:577	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	0	14	theme	Antioxidant	116:126	arg1	Activities					128:137	Their Antioxidant Activities	110:137	Their Antioxidant Activities	110:137	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	7	15	theme	peroxide	1123:1130	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	15	theme	peroxide	1123:1130	arg1	activity					1143:1150	hydrogen peroxide scavenging activity	1114:1150	hydrogen peroxide scavenging activity	1114:1150	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	1	16	theme	water	174:178	arg1	SWE					192:194	SWE	192:194	SWE	192:194	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	16	theme	water	174:178	arg1	extraction					180:189	subcritical water extraction	162:189	subcritical water extraction (SWE) assisted with deep eutectic solvent (DES)	162:237	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	7	17	theme	scavenging	1052:1061	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	17	theme	scavenging	1052:1061	arg1	activity					1143:1150	hydrogen peroxide scavenging activity	1114:1150	hydrogen peroxide scavenging activity	1114:1150	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	17	theme	scavenging	1052:1061	arg1	activity					1101:1108	hydroxyl radical scavenging activity	1073:1108	hydroxyl radical scavenging activity	1073:1108	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	6	18	contain	had	905:907	arg1	extracts					896:903	the extracts	892:903	the extracts	892:903	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	6	18	contain	had	905:907	arg2	features					913:920	the features	909:920	the features of polysaccharides	909:939	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	8	19	from	edodes	1361:1366	arg1	polysaccharides					1331:1345	polysaccharides	1331:1345	polysaccharides from Lentinus edodes	1331:1366	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	7	20	theme	higher	1040:1045	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	20	theme	higher	1040:1045	arg1	activity					1143:1150	hydrogen peroxide scavenging activity	1114:1150	hydrogen peroxide scavenging activity	1114:1150	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	20	theme	higher	1040:1045	arg1	activity					1101:1108	hydroxyl radical scavenging activity	1073:1108	hydroxyl radical scavenging activity	1073:1108	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	6	21	theme	polysaccharides	925:939	arg1	features					913:920	the features	909:920	the features of polysaccharides	909:939	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	5	22	theme	water	713:717	arg1	extraction					719:728	hot water extraction	709:728	hot water extraction (HWE)	709:734	Compared with the SWE and hot water extraction (HWE), it improved by 19.24% and 17.01%, respectively.
35684548	5	22	theme	water	713:717	arg1	HWE					731:733	HWE	731:733	HWE	731:733	Compared with the SWE and hot water extraction (HWE), it improved by 19.24% and 17.01%, respectively.
35684548	6	23	theme	weight	851:856	arg1	results					802:808	the results	798:808	the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM	798:875	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	2	24	theme	samples	357:363	arg1	activity					326:333	the antioxidant activity	310:333	the antioxidant activity of the polysaccharide samples	310:363	In addition, the antioxidant activity of the polysaccharide samples was also investigated.
35684548	0	25	theme	Subcritical	0:10	arg1	Water					12:16	Subcritical Water	0:16	Subcritical Water	0:16	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	1	26	theme	extract	250:256	arg1	LEP					291:293	LEP	291:293	LEP	291:293	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	26	theme	extract	250:256	arg1	polysaccharides					274:288	extract Lentinus edodes polysaccharides	250:288	extract Lentinus edodes polysaccharides (LEP)	250:294	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	3	27	theme	min	608:610	arg1	time					594:597	extraction time	583:597	extraction time of 17.58 min	583:610	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	27	theme	min	608:610	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	27	theme	min	608:610	arg1	temperature					529:539	extraction temperature	518:539	extraction temperature of 147.23 °C	518:552	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	27	theme	min	608:610	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	27	theme	min	608:610	arg1	content					561:567	water content	555:567	water content of 39.76%	555:577	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	2	28	theme	polysaccharide	342:355	arg1	samples					357:363	the polysaccharide samples	338:363	the polysaccharide samples	338:363	In addition, the antioxidant activity of the polysaccharide samples was also investigated.
35684548	1	29	theme	Lentinus	258:265	arg1	LEP					291:293	LEP	291:293	LEP	291:293	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	29	theme	Lentinus	258:265	arg1	polysaccharides					274:288	extract Lentinus edodes polysaccharides	250:288	extract Lentinus edodes polysaccharides (LEP)	250:294	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	3	30	theme	surface	431:437	arg1	test					439:442	response surface test	422:442	response surface test	422:442	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	1	31	theme	edodes	267:272	arg1	LEP					291:293	LEP	291:293	LEP	291:293	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	31	theme	edodes	267:272	arg1	polysaccharides					274:288	extract Lentinus edodes polysaccharides	250:288	extract Lentinus edodes polysaccharides (LEP)	250:294	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	7	32	with	assisted	999:1006	arg1	procedure					1021:1029	the DES procedure	1013:1029	the DES procedure	1013:1029	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	1	33	theme	subcritical	162:172	arg1	SWE					192:194	SWE	192:194	SWE	192:194	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	33	theme	subcritical	162:172	arg1	extraction					180:189	subcritical water extraction	162:189	subcritical water extraction (SWE) assisted with deep eutectic solvent (DES)	162:237	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	4	34	theme	extraction	625:634	arg1	conditions					636:645	these extraction conditions	619:645	these extraction conditions	619:645	Under these extraction conditions, the yield of LEP was 6.26 ± 0.08%.
35684548	0	35	theme	Eutectic	37:44	arg1	Solvent					46:52	Deep Eutectic Solvent	32:52	Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities	32:137	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	6	36	theme	composition	828:838	arg1	results					802:808	the results	798:808	the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM	798:875	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	7	37	with	polysaccharides	1178:1192	arg1	method					1204:1209	this method	1199:1209	this method	1199:1209	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	1	38	used	used	242:245	arg2	SWE					192:194	SWE	192:194	SWE	192:194	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	38	used	used	242:245	arg2	DES					234:236	DES	234:236	DES	234:236	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	38	used	used	242:245	arg2	extraction					180:189	subcritical water extraction	162:189	subcritical water extraction (SWE) assisted with deep eutectic solvent (DES)	162:237	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	38	used	used	242:245	arg2	solvent					225:231	deep eutectic solvent	211:231	subcritical water extraction (SWE) assisted with deep eutectic solvent (DES)	162:237	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	8	39	theme	SWE-assisted	1285:1296	arg1	DES					1298:1300	the SWE-assisted DES	1281:1300	the SWE-assisted DES	1281:1300	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	8	39	theme	SWE-assisted	1285:1296	arg1	method					1314:1319	a strong method	1305:1319	a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production	1305:1426	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	3	40	theme	single	399:404	arg1	test					413:416	a single factor test	397:416	a single factor test	397:416	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	0	41	theme	Deep	32:35	arg1	Solvent					46:52	Deep Eutectic Solvent	32:52	Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities	32:137	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	6	42	theme	monosaccharide	813:826	arg1	composition					828:838	monosaccharide composition	813:838	monosaccharide composition	813:838	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	7	43	theme	DES	1017:1019	arg1	procedure					1021:1029	the DES procedure	1013:1029	the DES procedure	1013:1029	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	8	44	theme	Lentinus	1352:1359	arg1	edodes					1361:1366	Lentinus edodes	1352:1366	Lentinus edodes	1352:1366	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	3	45	theme	water	555:559	arg1	content					561:567	water content	555:567	water content of 39.76%	555:577	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	1	46	theme	deep	211:214	arg1	DES					234:236	DES	234:236	DES	234:236	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	46	theme	deep	211:214	arg1	solvent					225:231	deep eutectic solvent	211:231	subcritical water extraction (SWE) assisted with deep eutectic solvent (DES)	162:237	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	7	47	theme	assisted	999:1006	arg1	SWE					995:997	the SWE	991:997	the SWE assisted with the DES procedure	991:1029	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	3	48	theme	extraction	583:592	arg1	time					594:597	extraction time	583:597	extraction time of 17.58 min	583:610	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	49	theme	147.23	544:549	arg1	time					594:597	extraction time	583:597	extraction time of 17.58 min	583:610	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	49	theme	147.23	544:549	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	49	theme	147.23	544:549	arg1	temperature					529:539	extraction temperature	518:539	extraction temperature of 147.23 °C	518:552	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	49	theme	147.23	544:549	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	49	theme	147.23	544:549	arg1	content					561:567	water content	555:567	water content of 39.76%	555:577	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	50	theme	optimal	449:455	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	50	theme	optimal	449:455	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	5	51	theme	hot	709:711	arg1	extraction					719:728	hot water extraction	709:728	hot water extraction (HWE)	709:734	Compared with the SWE and hot water extraction (HWE), it improved by 19.24% and 17.01%, respectively.
35684548	5	51	theme	hot	709:711	arg1	HWE					731:733	HWE	731:733	HWE	731:733	Compared with the SWE and hot water extraction (HWE), it improved by 19.24% and 17.01%, respectively.
35684548	3	52	theme	extraction	457:466	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	52	theme	extraction	457:466	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	53	theme	factor	406:411	arg1	test					413:416	a single factor test	397:416	a single factor test	397:416	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	7	54	theme	antioxidant	1226:1236	arg1	activity					1238:1245	a stronger antioxidant activity	1215:1245	a stronger antioxidant activity	1215:1245	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	8	55	theme	strong	1307:1312	arg1	DES					1298:1300	the SWE-assisted DES	1281:1300	the SWE-assisted DES	1281:1300	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	8	55	theme	strong	1307:1312	arg1	method					1314:1319	a strong method	1305:1319	a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production	1305:1426	These findings demonstrated that the SWE-assisted DES is a strong method to obtain polysaccharides from Lentinus edodes for food, biopharmaceutical and other industrial production.
35684548	4	56	theme	LEP	661:663	arg1	yield					652:656	the yield	648:656	the yield of LEP	648:663	Under these extraction conditions, the yield of LEP was 6.26 ± 0.08%.
35684548	4	56	theme	LEP	661:663	arg1	%					680:680	6.26 ± 0.08%	669:680	6.26 ± 0.08%	669:680	Under these extraction conditions, the yield of LEP was 6.26 ± 0.08%.
35684548	1	57	theme	eutectic	216:223	arg1	DES					234:236	DES	234:236	DES	234:236	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	1	57	theme	eutectic	216:223	arg1	solvent					225:231	deep eutectic solvent	211:231	subcritical water extraction (SWE) assisted with deep eutectic solvent (DES)	162:237	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	3	58	theme	%	577:577	arg1	time					594:597	extraction time	583:597	extraction time of 17.58 min	583:610	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	58	theme	%	577:577	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	58	theme	%	577:577	arg1	temperature					529:539	extraction temperature	518:539	extraction temperature of 147.23 °C	518:552	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	58	theme	%	577:577	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	58	theme	%	577:577	arg1	content					561:567	water content	555:567	water content of 39.76%	555:577	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	7	59	theme	scavenging	1132:1141	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	59	theme	scavenging	1132:1141	arg1	activity					1143:1150	hydrogen peroxide scavenging activity	1114:1150	hydrogen peroxide scavenging activity	1114:1150	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	60	theme	scavenging	1090:1099	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	60	theme	scavenging	1090:1099	arg1	activity					1101:1108	hydroxyl radical scavenging activity	1073:1108	hydroxyl radical scavenging activity	1073:1108	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	0	61	from	edodes	99:104	arg1	Polysaccharides					69:83	Extracting Polysaccharides	58:83	Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities	58:137	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	7	62	theme	stronger	1217:1224	arg1	activity					1238:1245	a stronger antioxidant activity	1215:1245	a stronger antioxidant activity	1215:1245	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	1	63	theme	present	147:153	arg1	study					155:159	the present study	143:159	the present study	143:159	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	6	64	theme	SEM	873:875	arg1	results					802:808	the results	798:808	the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM	798:875	In addition, the results of monosaccharide composition, molecular weight, FT-IR, UV and SEM confirmed that the extracts had the features of polysaccharides.
35684548	0	65	theme	Extracting	58:67	arg1	Polysaccharides					69:83	Extracting Polysaccharides	58:83	Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities	58:137	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
35684548	7	66	theme	DPPH	1047:1050	arg1	activity					1063:1070	a higher DPPH scavenging activity	1038:1070	a higher DPPH scavenging activity	1038:1070	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	66	theme	DPPH	1047:1050	arg1	activity					1143:1150	hydrogen peroxide scavenging activity	1114:1150	hydrogen peroxide scavenging activity	1114:1150	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	66	theme	DPPH	1047:1050	arg1	activity					1101:1108	hydroxyl radical scavenging activity	1073:1108	hydroxyl radical scavenging activity	1073:1108	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	1	67	dep	assisted	197:204	arg1	with					206:209	with	206:209	with	206:209	In the present study, subcritical water extraction (SWE) assisted with deep eutectic solvent (DES) is used to extract Lentinus edodes polysaccharides (LEP).
35684548	3	68	theme	liquid-solid	483:494	arg1	solvent					496:502	a liquid-solid solvent	481:502	a liquid-solid solvent of 40:1 mL/g	481:515	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	3	68	theme	liquid-solid	483:494	arg1	factors					468:474	the optimal extraction factors	445:474	the optimal extraction factors	445:474	Based on a single factor test and response surface test, the optimal extraction factors were a liquid-solid solvent of 40:1 mL/g, extraction temperature of 147.23 °C, water content of 39.76% and extraction time of 17.58 min.
35684548	7	69	contain	had	1211:1213	arg1	polysaccharides					1178:1192	the polysaccharides	1174:1192	the polysaccharides with this method	1174:1209	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	7	69	contain	had	1211:1213	arg2	activity					1238:1245	a stronger antioxidant activity	1215:1245	a stronger antioxidant activity	1215:1245	Interestingly, the polysaccharides obtained with the SWE assisted with the DES procedure showed a higher DPPH scavenging activity, hydroxyl radical scavenging activity and hydrogen peroxide scavenging activity, which indicated that the polysaccharides with this method had a stronger antioxidant activity.
35684548	0	70	from	Activities	128:137	arg1	Polysaccharides					69:83	Extracting Polysaccharides	58:83	Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities	58:137	Subcritical Water Enhanced with Deep Eutectic Solvent for Extracting Polysaccharides from Lentinus edodes and Their Antioxidant Activities.
37230634	1	0	theme	black	312:316	arg1	ear					324:326	black woody ear	312:326	black woody ear	312:326	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	1	0	theme	black	312:316	arg1	auricula-judae					296:309	Auricularia auricula-judae	284:309	Auricularia auricula-judae (black woody ear)	284:327	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	9	1	theme	structural	1328:1337	arg1	studies					1339:1345	structural studies	1328:1345	structural studies of GXG'G″M type polysaccharides	1328:1377	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	0	2	theme	auricula-judae	93:106	arg1	bodies					71:76	fruit bodies	65:76	fruit bodies of Auricularia auricula-judae (black woody ear)	65:124	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	1	3	theme	woody	318:322	arg1	ear					324:326	black woody ear	312:326	black woody ear	312:326	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	1	3	theme	woody	318:322	arg1	auricula-judae					296:309	Auricularia auricula-judae	284:309	Auricularia auricula-judae (black woody ear)	284:327	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	7	4	from	C-2	1085:1087	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	4	from	C-2	1085:1087	arg1	backbone					1116:1123	the backbone	1112:1123	the backbone	1112:1123	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	5	from	C-4	1090:1092	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	5	from	C-4	1090:1092	arg1	backbone					1116:1123	the backbone	1112:1123	the backbone	1112:1123	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	9	6	theme	functional	1487:1496	arg1	supplements					1506:1516	functional dietary supplements	1487:1516	functional dietary supplements	1487:1516	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	6	theme	functional	1487:1496	arg1	application					1417:1427	application	1417:1427	application	1417:1427	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	6	theme	functional	1487:1496	arg1	development					1401:1411	development	1401:1411	development	1401:1411	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	7	theme	medicinal	1467:1475	arg1	application					1417:1427	application	1417:1427	application	1417:1427	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	7	theme	medicinal	1467:1475	arg1	agents					1477:1482	medicinal agents	1467:1482	medicinal agents	1467:1482	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	7	theme	medicinal	1467:1475	arg1	development					1401:1411	development	1401:1411	development	1401:1411	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	0	8	theme	woody	115:119	arg1	auricula-judae					93:106	Auricularia auricula-judae	81:106	Auricularia auricula-judae (black woody ear)	81:124	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	0	8	theme	woody	115:119	arg1	ear					121:123	black woody ear	109:123	black woody ear	109:123	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	7	9	from	positions	1023:1031	arg1	ME-2					1055:1058	ME-2	1055:1058	ME-2	1055:1058	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	8	10	theme	LPS-stimulated	1245:1258	arg1	cells					1266:1270	LPS-stimulated THP-1 cells	1245:1270	LPS-stimulated THP-1 cells	1245:1270	Finally, the anti-inflammatory activity of ME-2 was preliminarily explored on LPS-stimulated THP-1 cells.
37230634	3	11	theme	repeating	488:496	arg1	structure-unit					498:511	The repeating structure-unit	484:511	The repeating structure-unit of dME-2	484:520	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	4	12	theme	branched	710:717	arg1	polysaccharide					719:732	a highly branched polysaccharide	701:732	a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units	701:791	The dME-2 was identified as a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units.
37230634	4	12	theme	branched	710:717	arg1	dME-2					677:681	The dME-2	673:681	The dME-2	673:681	The dME-2 was identified as a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units.
37230634	0	13	theme	black	109:113	arg1	auricula-judae					93:106	Auricularia auricula-judae	81:106	Auricularia auricula-judae (black woody ear)	81:124	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	0	13	theme	black	109:113	arg1	ear					121:123	black woody ear	109:123	black woody ear	109:123	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	0	14	from	bodies	71:76	arg1	Structure					0:8	Structure	0:8	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).	0:125	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	2	15	dep	dME-2	422:426	arg1	2.13 × 105 g/mol					433:448	2.13 × 105 g/mol	433:448	2.13 × 105 g/mol	433:448	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	2	15	dep	dME-2	422:426	arg1	Mw					429:430	Mw	429:430	Mw	429:430	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	7	16	from	C-6	1095:1097	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	16	from	C-6	1095:1097	arg1	backbone					1116:1123	the backbone	1112:1123	the backbone	1112:1123	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	4	17	theme	branches	756:763	arg1	average					742:748	an average	739:748	an average of 10 branches per 10 sugar backbone units	739:791	The dME-2 was identified as a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units.
37230634	5	18	theme	repeating	816:824	arg1	backbone					798:805	The backbone	794:805	The backbone	794:805	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	5	18	theme	repeating	816:824	arg1	-α-Manp-					829:836	only repeating →3)-α-Manp-	811:836	only repeating →3)-α-Manp-	811:836	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	2	19	theme	convenient	455:464	arg1	survey					476:481	convenient structure survey	455:481	convenient structure survey	455:481	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	9	20	theme	dietary	1498:1504	arg1	supplements					1506:1516	functional dietary supplements	1487:1516	functional dietary supplements	1487:1516	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	20	theme	dietary	1498:1504	arg1	application					1417:1427	application	1417:1427	application	1417:1427	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	20	theme	dietary	1498:1504	arg1	development					1401:1411	development	1401:1411	development	1401:1411	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	2	21	theme	higher	351:356	arg1	contents					367:374	much higher O-acetyl contents	346:374	much higher O-acetyl contents	346:374	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	7	22	theme	complex	1003:1009	arg1	positions					1023:1031	the complex substituted positions	999:1031	the complex substituted positions of O-acetyl groups in ME-2	999:1058	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	23	from	C-4,6	1103:1107	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	23	from	C-4,6	1103:1107	arg1	backbone					1116:1123	the backbone	1112:1123	the backbone	1112:1123	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	6	24	dep	chains	909:914	arg1	1→					970:971	1→	970:971	1→	970:971	The side chains included β-GlcAp-(1→, β-Xylp-(1→, α-Manp-(1→, α-Galp-(1→ and β-Glcp-(1→.
37230634	6	24	dep	chains	909:914	arg1	1→					934:935	1→	934:935	1→	934:935	The side chains included β-GlcAp-(1→, β-Xylp-(1→, α-Manp-(1→, α-Galp-(1→ and β-Glcp-(1→.
37230634	7	25	theme	side	1154:1157	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	2	26	theme	deacetylated	399:410	arg1	dME-2					422:426	dME-2	422:426	dME-2	422:426	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	2	26	theme	deacetylated	399:410	arg1	products					412:419	its fully deacetylated products	389:419	its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey	389:481	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	8	27	theme	ME-2	1210:1213	arg1	activity					1198:1205	the anti-inflammatory activity	1176:1205	the anti-inflammatory activity of ME-2	1176:1213	Finally, the anti-inflammatory activity of ME-2 was preliminarily explored on LPS-stimulated THP-1 cells.
37230634	8	28	theme	anti-inflammatory	1180:1196	arg1	activity					1198:1205	the anti-inflammatory activity	1176:1205	the anti-inflammatory activity of ME-2	1176:1213	Finally, the anti-inflammatory activity of ME-2 was preliminarily explored on LPS-stimulated THP-1 cells.
37230634	7	29	theme	groups	1045:1050	arg1	positions					1023:1031	the complex substituted positions	999:1031	the complex substituted positions of O-acetyl groups in ME-2	999:1058	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	9	30	theme	above	1277:1281	arg1	date					1283:1286	The above date	1273:1286	The above date	1273:1286	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	3	31	theme	NMR	655:657	arg1	spectroscopy					659:670	1/2D NMR spectroscopy	650:670	1/2D NMR spectroscopy	650:670	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	6	32	theme	side	904:907	arg1	chains					909:914	The side chains	900:914	The side chains included β-GlcAp-	900:932	The side chains included β-GlcAp-(1→, β-Xylp-(1→, α-Manp-(1→, α-Galp-(1→ and β-Glcp-(1→.
37230634	9	33	theme	ear	1444:1446	arg1	polysaccharides					1448:1462	black woody ear polysaccharides	1432:1462	black woody ear polysaccharides	1432:1462	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	5	34	theme	C-6	875:877	arg1	positions					889:897	the C-2, C-6 and C-2,6 positions	866:897	the C-2, C-6 and C-2,6 positions	866:897	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	0	35	theme	unprecedent	16:26	arg1	glucuronoxylogalactoglucomannan					28:58	an unprecedent glucuronoxylogalactoglucomannan	13:58	an unprecedent glucuronoxylogalactoglucomannan	13:58	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	9	36	theme	polysaccharides	1448:1462	arg1	supplements					1506:1516	functional dietary supplements	1487:1516	functional dietary supplements	1487:1516	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	36	theme	polysaccharides	1448:1462	arg1	agents					1477:1482	medicinal agents	1467:1482	medicinal agents	1467:1482	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	36	theme	polysaccharides	1448:1462	arg1	application					1417:1427	application	1417:1427	application	1417:1427	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	36	theme	polysaccharides	1448:1462	arg1	development					1401:1411	development	1401:1411	development	1401:1411	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	9	37	theme	woody	1438:1442	arg1	polysaccharides					1448:1462	black woody ear polysaccharides	1432:1462	black woody ear polysaccharides	1432:1462	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	7	38	theme	O-acetyl	1036:1043	arg1	groups					1045:1050	O-acetyl groups	1036:1050	O-acetyl groups	1036:1050	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	5	39	dep	-α-Manp-	829:836	arg1	residues					841:848	1→ residues	838:848	1→ residues	838:848	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	5	39	dep	-α-Manp-	829:836	arg1	→3					826:827	→3	826:827	→3	826:827	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	3	40	theme	dME-2	516:520	arg1	structure-unit					498:511	The repeating structure-unit	484:511	The repeating structure-unit of dME-2	484:520	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	7	41	theme	substituted	1011:1021	arg1	positions					1023:1031	the complex substituted positions	999:1031	the complex substituted positions of O-acetyl groups in ME-2	999:1058	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	1	42	theme	water	266:270	arg1	extracts					272:279	water extracts	266:279	water extracts of Auricularia auricula-judae (black woody ear)	266:327	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	4	43	theme	backbone	778:785	arg1	units					787:791	10 sugar backbone units	769:791	10 sugar backbone units	769:791	The dME-2 was identified as a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units.
37230634	0	44	theme	glucuronoxylogalactoglucomannan	28:58	arg1	Structure					0:8	Structure	0:8	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).	0:125	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	4	45	with	polysaccharide	719:732	arg1	average					742:748	an average	739:748	an average of 10 branches per 10 sugar backbone units	739:791	The dME-2 was identified as a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units.
37230634	3	46	theme	Mw	552:553	arg1	determination					555:567	Mw determination	552:567	Mw determination	552:567	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	2	47	theme	O-acetyl	358:365	arg1	contents					367:374	much higher O-acetyl contents	346:374	much higher O-acetyl contents	346:374	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37230634	3	48	theme	methylation	599:609	arg1	analysis					611:618	methylation analysis	599:618	methylation analysis	599:618	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	9	49	theme	first	1310:1314	arg1	example					1316:1322	the first example	1306:1322	the first example for structural studies of GXG'G″M type polysaccharides	1306:1377	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	0	50	theme	fruit	65:69	arg1	bodies					71:76	fruit bodies	65:76	fruit bodies of Auricularia auricula-judae (black woody ear)	65:124	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	9	51	theme	black	1432:1436	arg1	polysaccharides					1448:1462	black woody ear polysaccharides	1432:1462	black woody ear polysaccharides	1432:1462	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	7	52	from	C-2	1132:1134	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	52	from	C-2	1132:1134	arg1	backbone					1116:1123	the backbone	1112:1123	the backbone	1112:1123	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	1	53	theme	auricula-judae	296:309	arg1	extracts					272:279	water extracts	266:279	water extracts of Auricularia auricula-judae (black woody ear)	266:327	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	3	54	theme	1/2D	650:653	arg1	spectroscopy					659:670	1/2D NMR spectroscopy	650:670	1/2D NMR spectroscopy	650:670	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	3	55	theme	monosaccharide	570:583	arg1	compositions					585:596	monosaccharide compositions	570:596	monosaccharide compositions	570:596	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	4	56	theme	sugar	772:776	arg1	units					787:791	10 sugar backbone units	769:791	10 sugar backbone units	769:791	The dME-2 was identified as a highly branched polysaccharide with an average of 10 branches per 10 sugar backbone units.
37230634	1	57	theme	unprecedent	130:140	arg1	ME-2					185:188	ME-2	185:188	ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %)	185:232	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	1	57	theme	unprecedent	130:140	arg1	glucuronoxylogalactoglucomannan					142:172	An unprecedent glucuronoxylogalactoglucomannan	127:172	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M)	127:182	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	1	57	theme	unprecedent	130:140	arg1	G″M					179:181	GXG'G″M	175:181	GXG'G″M	175:181	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	1	58	theme	O-acetyl	213:220	arg1	%					231:231	O-acetyl % = 16.7 %	213:231	O-acetyl % = 16.7 %	213:231	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	3	59	theme	free-radical	621:632	arg1	degradation					634:644	free-radical degradation	621:644	free-radical degradation	621:644	The repeating structure-unit of dME-2 was readily proposed based on Mw determination, monosaccharide compositions, methylation analysis, free-radical degradation and 1/2D NMR spectroscopy.
37230634	9	60	theme	G″M	1354:1356	arg1	polysaccharides					1363:1377	GXG'G″M type polysaccharides	1350:1377	GXG'G″M type polysaccharides	1350:1377	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	7	61	from	C-2,3	1140:1144	arg1	chains					1159:1164	some side chains	1149:1164	some side chains	1149:1164	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	7	61	from	C-2,3	1140:1144	arg1	backbone					1116:1123	the backbone	1112:1123	the backbone	1112:1123	Secondly, the complex substituted positions of O-acetyl groups in ME-2 were determined to be at C-2, C-4, C-6 and C-4,6 in the backbone and at C-2 and C-2,3 in some side chains.
37230634	5	62	theme	C-2	870:872	arg1	positions					889:897	the C-2, C-6 and C-2,6 positions	866:897	the C-2, C-6 and C-2,6 positions	866:897	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	1	63	theme	%	222:222	arg1	%					231:231	O-acetyl % = 16.7 %	213:231	O-acetyl % = 16.7 %	213:231	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	0	64	theme	Auricularia	81:91	arg1	auricula-judae					93:106	Auricularia auricula-judae	81:106	Auricularia auricula-judae (black woody ear)	81:124	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	0	64	theme	Auricularia	81:91	arg1	ear					121:123	black woody ear	109:123	black woody ear	109:123	Structure of an unprecedent glucuronoxylogalactoglucomannan from fruit bodies of Auricularia auricula-judae (black woody ear).
37230634	5	65	theme	only	811:814	arg1	backbone					798:805	The backbone	794:805	The backbone	794:805	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	5	65	theme	only	811:814	arg1	-α-Manp-					829:836	only repeating →3)-α-Manp-	811:836	only repeating →3)-α-Manp-	811:836	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	1	66	dep	Mw	191:192	arg1	%					231:231	O-acetyl % = 16.7 %	213:231	O-acetyl % = 16.7 %	213:231	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	1	66	dep	Mw	191:192	arg1	2.60 × 105 g/mol					195:210	2.60 × 105 g/mol	195:210	2.60 × 105 g/mol	195:210	An unprecedent glucuronoxylogalactoglucomannan (GXG'G″M), ME-2 (Mw, 2.60 × 105 g/mol; O-acetyl % = 16.7 %), was isolated and purified from water extracts of Auricularia auricula-judae (black woody ear).
37230634	5	67	theme	C-2,6	883:887	arg1	positions					889:897	the C-2, C-6 and C-2,6 positions	866:897	the C-2, C-6 and C-2,6 positions	866:897	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	9	68	theme	type	1358:1361	arg1	polysaccharides					1363:1377	GXG'G″M type polysaccharides	1350:1377	GXG'G″M type polysaccharides	1350:1377	The above date not only provided the first example for structural studies of GXG'G″M type polysaccharides, but also facilitated development and application of black woody ear polysaccharides as medicinal agents or functional dietary supplements.
37230634	8	69	theme	THP-1	1260:1264	arg1	cells					1266:1270	LPS-stimulated THP-1 cells	1245:1270	LPS-stimulated THP-1 cells	1245:1270	Finally, the anti-inflammatory activity of ME-2 was preliminarily explored on LPS-stimulated THP-1 cells.
37230634	5	70	theme	1→	838:839	arg1	residues					841:848	1→ residues	838:848	1→ residues	838:848	The backbone was only repeating →3)-α-Manp-(1→ residues, substituted at the C-2, C-6 and C-2,6 positions.
37230634	2	71	theme	structure	466:474	arg1	survey					476:481	convenient structure survey	455:481	convenient structure survey	455:481	Firstly, due to much higher O-acetyl contents, we prepared its fully deacetylated products (dME-2; Mw, 2.13 × 105 g/mol) for convenient structure survey.
37076080	0	0	theme	wound	113:117	arg1	healing					119:125	mechanosensing and tissue regenerative wound healing	74:125	healing	119:125	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	5	1	theme	barrier	811:817	arg1	properties					819:828	water barrier properties	805:828	water barrier properties	805:828	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	6	2	from	film	1076:1079	arg1	release					1043:1049	controlled release	1032:1049	controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing	1032:1148	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	1	3	theme	predominant	180:190	arg1	source					192:197	a predominant source	178:197	a predominant source in developing bioactive materials	178:231	Polysaccharides κ-carrageenan (κ-Car) have become a predominant source in developing bioactive materials.
37076080	6	4	theme	κ-Car	1060:1064	arg1	film					1076:1079	the κ-Car composite film	1056:1079	the κ-Car composite film	1056:1079	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	0	5	theme	regenerative	100:111	arg1	healing					119:125	mechanosensing and tissue regenerative wound healing	74:125	healing	119:125	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	5	6	theme	morphological	698:710	arg1	analysis					712:719	The chemical and morphological analysis	681:719	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films	681:837	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	7	7	theme	cell	1218:1221	arg1	adhesion					1223:1230	cell adhesion	1218:1230	cell adhesion	1218:1230	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	4	8	theme	morphological	546:558	arg1	characterizations					573:589	morphological and chemical characterizations	546:589	morphological and chemical characterizations	546:589	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	8	9	theme	regenerative	1494:1505	arg1	medicine					1507:1514	regenerative medicine	1494:1514	regenerative medicine	1494:1514	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	8	10	theme	CEO	1435:1437	arg1	materials					1455:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	4	11	theme	in	652:653	arg1	models					673:678	both in vitro and in vivo models	647:678	both in vitro and in vivo models	647:678	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	5	12	theme	CEO	788:790	arg1	release					792:798	CEO release	788:798	CEO release	788:798	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	8	13	theme	active	1399:1404	arg1	materials					1455:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	5	14	with	analysis	712:719	arg1	release					792:798	CEO release	788:798	CEO release	788:798	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	14	with	analysis	712:719	arg1	efficiency					776:785	encapsulation efficiency	762:785	encapsulation efficiency	762:785	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	14	with	analysis	712:719	arg1	structure					735:743	physical structure	726:743	physical structure	726:743	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	14	with	analysis	712:719	arg1	ratio					755:759	swelling ratio	746:759	swelling ratio	746:759	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	14	with	analysis	712:719	arg1	properties					819:828	water barrier properties	805:828	water barrier properties	805:828	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	3	15	theme	bioactive	508:516	arg1	materials					518:526	composite film bioactive materials	493:526	composite film bioactive materials	493:526	Initially, we loaded the CEO in to κ-Car and CEO through homogenization and ultrasonication to fabricate composite film bioactive materials.
37076080	5	16	theme	κ-Car	889:893	arg1	interaction					874:884	the structural interaction	859:884	the structural interaction of κ-Car and CEO-loaded into the polymer network	859:933	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	17	theme	polymer	919:925	arg1	network					927:933	the polymer network	915:933	the polymer network	915:933	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	4	18	from	functionalities	628:642	arg1	models					673:678	both in vitro and in vivo models	647:678	both in vitro and in vivo models	647:678	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	8	19	theme	innovative	1372:1381	arg1	perspectives					1383:1394	Our innovative perspectives	1368:1394	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials	1368:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	7	20	theme	F-actin	1233:1239	arg1	organization					1241:1252	F-actin organization	1233:1252	F-actin organization	1233:1252	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	2	21	theme	essential	309:317	arg1	CEO					324:326	CEO	324:326	CEO	324:326	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	21	theme	essential	309:317	arg1	κ-Car-CEO					330:338	κ-Car-CEO	330:338	κ-Car-CEO	330:338	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	21	theme	essential	309:317	arg1	oil					319:321	coriander essential oil	299:321	coriander essential oil (CEO) (κ-Car-CEO)	299:339	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	0	22	theme	oil	24:26	arg1	film					57:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	7	23	dep	in	1291:1292	arg1	vitro					1294:1298	vitro	1294:1298	vitro	1294:1298	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	1	24	theme	bioactive	213:221	arg1	materials					223:231	bioactive materials	213:231	bioactive materials	213:231	Polysaccharides κ-carrageenan (κ-Car) have become a predominant source in developing bioactive materials.
37076080	0	25	theme	κ-Carrageenan-essential	0:22	arg1	film					57:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	6	26	theme	controlled	1032:1041	arg1	release					1043:1049	controlled release	1032:1049	controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing	1032:1148	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	5	27	theme	chemical	685:692	arg1	analysis					712:719	The chemical and morphological analysis	681:719	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films	681:837	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	6	28	theme	adhesive	1109:1116	arg1	capabilities					1118:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	0	29	theme	composite	35:43	arg1	film					57:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	8	30	theme	functional	1439:1448	arg1	materials					1455:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	6	31	theme	cell	1104:1107	arg1	capabilities					1118:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	0	32	theme	loaded	28:33	arg1	film					57:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	4	33	theme	material	619:626	arg1	functionalities					628:642	the developed material functionalities	605:642	the developed material functionalities in both in vitro and in vivo models	605:678	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	4	34	dep	in	652:653	arg1	vitro					655:659	vitro	655:659	vitro	655:659	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	5	35	theme	structural	863:872	arg1	interaction					874:884	the structural interaction	859:884	the structural interaction of κ-Car and CEO-loaded into the polymer network	859:933	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	8	36	theme	-based	1428:1433	arg1	materials					1455:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	3	37	theme	composite	493:501	arg1	materials					518:526	composite film bioactive materials	493:526	composite film bioactive materials	493:526	Initially, we loaded the CEO in to κ-Car and CEO through homogenization and ultrasonication to fabricate composite film bioactive materials.
37076080	4	38	theme	developed	609:617	arg1	functionalities					628:642	the developed material functionalities	605:642	the developed material functionalities in both in vitro and in vivo models	605:678	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	5	39	theme	encapsulation	762:774	arg1	efficiency					776:785	encapsulation efficiency	762:785	encapsulation efficiency	762:785	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	7	40	theme	mechanosensing	1300:1313	arg1	activation					1315:1324	in vitro mechanosensing activation	1291:1324	in vitro mechanosensing activation	1291:1324	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	8	41	theme	materials	1455:1463	arg1	perspectives					1383:1394	Our innovative perspectives	1368:1394	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials	1368:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	6	42	theme	L929	1098:1101	arg1	capabilities					1118:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	0	43	theme	biomaterial	45:55	arg1	film					57:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film	0:60	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	2	44	with	κ-Car	288:292	arg1	CEO					324:326	CEO	324:326	CEO	324:326	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	44	with	κ-Car	288:292	arg1	κ-Car-CEO					330:338	κ-Car-CEO	330:338	κ-Car-CEO	330:338	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	44	with	κ-Car	288:292	arg1	oil					319:321	coriander essential oil	299:321	coriander essential oil (CEO) (κ-Car-CEO)	299:339	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	5	45	theme	films	833:837	arg1	release					792:798	CEO release	788:798	CEO release	788:798	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	45	theme	films	833:837	arg1	properties					819:828	water barrier properties	805:828	water barrier properties	805:828	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	45	theme	films	833:837	arg1	structure					735:743	physical structure	726:743	physical structure	726:743	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	45	theme	films	833:837	arg1	ratio					755:759	swelling ratio	746:759	swelling ratio	746:759	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	5	45	theme	films	833:837	arg1	efficiency					776:785	encapsulation efficiency	762:785	encapsulation efficiency	762:785	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	7	46	theme	κ-Car	1199:1203	arg1	film					1205:1208	the κ-Car film	1195:1208	the κ-Car film	1195:1208	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	2	47	theme	composite	265:273	arg1	materials					275:283	biopolymer composite materials	254:283	biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing	254:385	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	5	48	theme	CEO-loaded	899:908	arg1	interaction					874:884	the structural interaction	859:884	the structural interaction of κ-Car and CEO-loaded into the polymer network	859:933	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	0	49	theme	mechanosensing	74:87	arg1	healing					119:125	mechanosensing and tissue regenerative wound healing	74:125	healing	119:125	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	4	50	theme	chemical	564:571	arg1	characterizations					573:589	morphological and chemical characterizations	546:589	morphological and chemical characterizations	546:589	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	5	51	theme	physical	726:733	arg1	structure					735:743	physical structure	726:743	physical structure	726:743	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	2	52	theme	biopolymer	254:263	arg1	materials					275:283	biopolymer composite materials	254:283	biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing	254:385	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	53	theme	wound	373:377	arg1	healing					379:385	fibroblast-associated wound healing	351:385	fibroblast-associated wound healing	351:385	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	6	54	theme	bioactive	953:961	arg1	applications					963:974	the bioactive applications	949:974	the bioactive applications of CEO release	949:989	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	7	55	theme	collagen	1259:1266	arg1	synthesis					1268:1276	collagen synthesis	1259:1276	collagen synthesis	1259:1276	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	2	56	theme	fibroblast-associated	351:371	arg1	healing					379:385	fibroblast-associated wound healing	351:385	fibroblast-associated wound healing	351:385	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	6	57	theme	release	983:989	arg1	applications					963:974	the bioactive applications	949:974	the bioactive applications of CEO release	949:989	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	6	58	theme	burst	1006:1010	arg1	release					1012:1018	initial burst release	998:1018	initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing	998:1148	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	4	59	dep	in	665:666	arg1	vivo					668:671	vivo	668:671	vivo	668:671	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37076080	2	60	theme	coriander	299:307	arg1	CEO					324:326	CEO	324:326	CEO	324:326	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	60	theme	coriander	299:307	arg1	κ-Car-CEO					330:338	κ-Car-CEO	330:338	κ-Car-CEO	330:338	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	2	60	theme	coriander	299:307	arg1	oil					319:321	coriander essential oil	299:321	coriander essential oil (CEO) (κ-Car-CEO)	299:339	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	8	61	theme	film	1450:1453	arg1	materials					1455:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	active polysaccharide (κ-Car)-based CEO functional film materials	1399:1463	Our innovative perspectives of active polysaccharide (κ-Car)-based CEO functional film materials could potentially accomplish regenerative medicine.
37076080	3	62	theme	film	503:506	arg1	materials					518:526	composite film bioactive materials	493:526	composite film bioactive materials	493:526	Initially, we loaded the CEO in to κ-Car and CEO through homogenization and ultrasonication to fabricate composite film bioactive materials.
37076080	6	63	theme	fibroblast	1086:1095	arg1	capabilities					1118:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	5	64	theme	swelling	746:753	arg1	ratio					755:759	swelling ratio	746:759	swelling ratio	746:759	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	7	65	theme	wound	1345:1349	arg1	healing					1351:1357	wound healing	1345:1357	wound healing	1345:1357	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	6	66	with	release	1043:1049	arg1	capabilities					1118:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	fibroblast (L929) cell adhesive capabilities	1086:1129	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	6	66	with	release	1043:1049	arg1	mechanosensing					1135:1148	mechanosensing	1135:1148	mechanosensing	1135:1148	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	2	67	theme	films	341:345	arg1	materials					275:283	biopolymer composite materials	254:283	biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing	254:385	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	0	68	theme	tissue	93:98	arg1	healing					119:125	mechanosensing and tissue regenerative wound healing	74:125	healing	119:125	κ-Carrageenan-essential oil loaded composite biomaterial film facilitates mechanosensing and tissue regenerative wound healing.
37076080	2	69	theme	κ-Car	288:292	arg1	films					341:345	κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films	288:345	κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films	288:345	We aimed to develop biopolymer composite materials of κ-Car with coriander essential oil (CEO) (κ-Car-CEO) films for fibroblast-associated wound healing.
37076080	1	70	dep	Polysaccharides	128:142	arg1	κ-Car					159:163	κ-Car	159:163	κ-Car	159:163	Polysaccharides κ-carrageenan (κ-Car) have become a predominant source in developing bioactive materials.
37076080	1	70	dep	Polysaccharides	128:142	arg1	κ-carrageenan					144:156	κ-carrageenan	144:156	Polysaccharides κ-carrageenan (κ-Car)	128:164	Polysaccharides κ-carrageenan (κ-Car) have become a predominant source in developing bioactive materials.
37076080	5	71	theme	water	805:809	arg1	properties					819:828	water barrier properties	805:828	water barrier properties	805:828	The chemical and morphological analysis with physical structure, swelling ratio, encapsulation efficiency, CEO release, and water barrier properties of films examined and showed the structural interaction of κ-Car and CEO-loaded into the polymer network.
37076080	6	72	theme	CEO	979:981	arg1	release					983:989	CEO release	979:989	CEO release	979:989	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	6	73	theme	composite	1066:1074	arg1	film					1076:1079	the κ-Car composite film	1056:1079	the κ-Car composite film	1056:1079	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	7	74	theme	in	1291:1292	arg1	activation					1315:1324	in vitro mechanosensing activation	1291:1324	in vitro mechanosensing activation	1291:1324	Our results proved that the CEO-loaded into the κ-Car film impacts cell adhesion, F-actin organization, and collagen synthesis, followed by in vitro mechanosensing activation, further promoting wound healing in vivo.
37076080	6	75	theme	initial	998:1004	arg1	release					1012:1018	initial burst release	998:1018	initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing	998:1148	Furthermore, the bioactive applications of CEO release showed initial burst release followed by controlled release from the κ-Car composite film with fibroblast (L929) cell adhesive capabilities and mechanosensing.
37076080	4	76	theme	in	665:666	arg1	models					673:678	both in vitro and in vivo models	647:678	both in vitro and in vivo models	647:678	After performing morphological and chemical characterizations, we validated the developed material functionalities in both in vitro and in vivo models.
37042250	5	0	theme	BC	681:682	arg1	advantages					653:662	the advantages	649:662	the advantages of biocompatible BC	649:682	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	7	1	theme	wound	1047:1051	arg1	infections					1053:1062	clinically troublesome wound infections	1024:1062	clinically troublesome wound infections	1024:1062	Our study paves a way for treating clinically troublesome wound infections.
37042250	4	2	theme	composite	597:605	arg1	membrane					607:614	the composite membrane	593:614	the composite membrane	593:614	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	0	3	theme	Bacteria	113:120	arg1	Killing					82:88	Killing	82:88	Killing of Multidrug-Resistant Bacteria	82:120	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	6	4	theme	negligible	968:977	arg1	toxicity					979:986	negligible toxicity	968:986	negligible toxicity	968:986	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	1	5	theme	thorny	198:203	arg1	issues					205:210	thorny issues	198:210	thorny issues	198:210	Multidrug resistant (MDR) bacteria-related wound infections have long been thorny issues.
37042250	0	6	dep	Cellulose	68:76	arg1	Killing					82:88	Killing	82:88	Killing of Multidrug-Resistant Bacteria	82:120	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	2	7	theme	bacteria	313:320	arg1	infection					322:330	MDR bacteria infection	309:330	MDR bacteria infection	309:330	It is urgent to develop new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing.
37042250	6	8	theme	healing	859:865	arg1	performance					867:877	excellent wound healing performance	843:877	excellent wound healing performance	843:877	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	2	9	theme	MDR	309:311	arg1	infection					322:330	MDR bacteria infection	309:330	MDR bacteria infection	309:330	It is urgent to develop new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing.
37042250	5	10	theme	660 nm	786:791	arg1	laser					793:797	a 660 nm laser	784:797	a 660 nm laser	784:797	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	4	11	theme	BC-BITT	491:497	arg1	composites					499:508	BC-BITT composites	491:508	BC-BITT composites	491:508	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	6	12	theme	wound	853:857	arg1	healing					859:865	excellent wound healing	843:865	excellent wound healing performance	843:877	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	5	13	theme	laser	793:797	arg1	irradiation					769:779	irradiation	769:779	irradiation of a 660 nm laser	769:797	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	4	14	theme	good	514:517	arg1	transparency					519:530	good transparency	514:530	good transparency	514:530	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	6	15	theme	excellent	843:851	arg1	healing					859:865	excellent wound healing	843:865	excellent wound healing performance	843:877	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	3	16	theme	AIE	416:418	arg1	BC					467:468	BC	467:468	BC	467:468	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	16	theme	AIE	416:418	arg1	cellulose					456:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose	383:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings	383:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	0	17	theme	Multifunctional	7:21	arg1	Cellulose					68:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	6	18	theme	MDR	934:936	arg1	bacteria					938:945	MDR bacteria	934:945	MDR bacteria	934:945	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	1	19	theme	Multidrug	123:131	arg1	infections					172:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections have long been thorny issues.
37042250	0	20	theme	Visual	0:5	arg1	Cellulose					68:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	4	21	theme	healing	569:575	arg1	process					577:583	the wound healing process	559:583	the wound healing process	559:583	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	5	22	theme	biocompatible	667:679	arg1	BC					681:682	biocompatible BC	667:682	biocompatible BC	667:682	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	1	23	theme	resistant	133:141	arg1	infections					172:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections have long been thorny issues.
37042250	0	24	theme	Emission-Based	43:56	arg1	Cellulose					68:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	4	25	theme	wound	563:567	arg1	healing					569:575	wound healing	563:575	the wound healing process	559:583	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	5	26	theme	antibacterial	741:753	arg1	effects					755:761	photodynamic and photothermal synergistic antibacterial effects	699:761	photodynamic and photothermal synergistic antibacterial effects	699:761	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	6	27	theme	BC-BITT	817:823	arg1	composites					825:834	the BC-BITT composites	813:834	the BC-BITT composites	813:834	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	3	28	theme	emission	406:413	arg1	BC					467:468	BC	467:468	BC	467:468	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	28	theme	emission	406:413	arg1	cellulose					456:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose	383:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings	383:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	6	29	theme	skin	905:908	arg1	model					916:920	a mouse full-thickness skin wound model	882:920	a mouse full-thickness skin wound model infected by MDR bacteria	882:945	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	1	30	theme	MDR	144:146	arg1	infections					172:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections have long been thorny issues.
37042250	3	31	theme	BITT-composited	430:444	arg1	BC					467:468	BC	467:468	BC	467:468	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	31	theme	BITT-composited	430:444	arg1	cellulose					456:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose	383:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings	383:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	0	32	theme	Bacterial	58:66	arg1	Cellulose					68:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	3	33	theme	bacterial	446:454	arg1	BC					467:468	BC	467:468	BC	467:468	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	33	theme	bacterial	446:454	arg1	cellulose					456:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose	383:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings	383:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	34	theme	aggregation-induced	386:404	arg1	BC					467:468	BC	467:468	BC	467:468	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	34	theme	aggregation-induced	386:404	arg1	cellulose					456:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose	383:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings	383:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	35	theme	wound	474:478	arg1	dressings					480:488	wound dressings	474:488	wound dressings	474:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	5	36	theme	photodynamic	699:710	arg1	effects					755:761	photodynamic and photothermal synergistic antibacterial effects	699:761	photodynamic and photothermal synergistic antibacterial effects	699:761	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	6	37	theme	wound	910:914	arg1	model					916:920	a mouse full-thickness skin wound model	882:920	a mouse full-thickness skin wound model infected by MDR bacteria	882:945	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	2	38	theme	wound	255:259	arg1	dressings					261:269	new antibacterial wound dressings	237:269	new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing	237:361	It is urgent to develop new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing.
37042250	4	39	contain	had	510:512	arg1	composites					499:508	BC-BITT composites	491:508	BC-BITT composites	491:508	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	4	39	contain	had	510:512	arg2	transparency					519:530	good transparency	514:530	good transparency	514:530	BC-BITT composites had good transparency, making it easy to monitor the wound healing process through the composite membrane.
37042250	3	40	theme	molecule	421:428	arg1	BC					467:468	BC	467:468	BC	467:468	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	3	40	theme	molecule	421:428	arg1	cellulose					456:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose	383:464	an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings	383:488	Herein, we present an aggregation-induced emission (AIE) molecule BITT-composited bacterial cellulose (BC) as wound dressings.
37042250	2	41	theme	new	237:239	arg1	dressings					261:269	new antibacterial wound dressings	237:269	new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing	237:361	It is urgent to develop new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing.
37042250	2	42	theme	antibacterial	241:253	arg1	dressings					261:269	new antibacterial wound dressings	237:269	new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing	237:361	It is urgent to develop new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing.
37042250	1	43	theme	bacteria-related	149:164	arg1	infections					172:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections have long been thorny issues.
37042250	5	44	theme	photothermal	716:727	arg1	effects					755:761	photodynamic and photothermal synergistic antibacterial effects	699:761	photodynamic and photothermal synergistic antibacterial effects	699:761	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	6	45	theme	full-thickness	890:903	arg1	model					916:920	a mouse full-thickness skin wound model	882:920	a mouse full-thickness skin wound model infected by MDR bacteria	882:945	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	5	46	theme	BC-BITT	621:627	arg1	composites					629:638	The BC-BITT composites	617:638	The BC-BITT composites	617:638	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	1	47	theme	wound	166:170	arg1	infections					172:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections	123:181	Multidrug resistant (MDR) bacteria-related wound infections have long been thorny issues.
37042250	5	48	theme	synergistic	729:739	arg1	effects					755:761	photodynamic and photothermal synergistic antibacterial effects	699:761	photodynamic and photothermal synergistic antibacterial effects	699:761	The BC-BITT composites retained the advantages of biocompatible BC, and displayed photodynamic and photothermal synergistic antibacterial effects under irradiation of a 660 nm laser.
37042250	6	49	theme	mouse	884:888	arg1	model					916:920	a mouse full-thickness skin wound model	882:920	a mouse full-thickness skin wound model infected by MDR bacteria	882:945	Furthermore, the BC-BITT composites showed excellent wound healing performance in a mouse full-thickness skin wound model infected by MDR bacteria, simultaneously with negligible toxicity.
37042250	2	50	theme	wound	349:353	arg1	healing					355:361	wound healing	349:361	wound healing	349:361	It is urgent to develop new antibacterial wound dressings that can not only prevent wounds from MDR bacteria infection but also promote wound healing.
37042250	0	51	theme	Multidrug-Resistant	93:111	arg1	Bacteria					113:120	Multidrug-Resistant Bacteria	93:120	Multidrug-Resistant Bacteria	93:120	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	0	52	theme	Aggregation-Induced	23:41	arg1	Cellulose					68:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose	0:76	Visual Multifunctional Aggregation-Induced Emission-Based Bacterial Cellulose for Killing of Multidrug-Resistant Bacteria.
37042250	7	53	theme	troublesome	1035:1045	arg1	infections					1053:1062	clinically troublesome wound infections	1024:1062	clinically troublesome wound infections	1024:1062	Our study paves a way for treating clinically troublesome wound infections.
37313607	7	0	theme	Bifidobacterium	1379:1393	arg1	abundance					1366:1374	the abundance	1362:1374	the abundance of Bifidobacterium and Lactobacillus	1362:1411	Among the three types of biscuits, BAG increased the abundance of Bifidobacterium and Lactobacillus during fermentation in diabetic and healthy subjects' fecal microbiota.
37313607	5	1	theme	GI	1017:1018	arg1	value					1020:1024	the lowest estimated GI value	996:1024	the lowest estimated GI value	996:1024	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	7	2	theme	fecal	1467:1471	arg1	microbiota					1473:1482	' fecal microbiota	1465:1482	' fecal microbiota	1465:1482	Among the three types of biscuits, BAG increased the abundance of Bifidobacterium and Lactobacillus during fermentation in diabetic and healthy subjects' fecal microbiota.
37313607	4	3	theme	structural	680:689	arg1	properties					691:700	the rheological property and structural properties	651:700	properties	691:700	Also, the rheological property and structural properties of the polysaccharides were measured to clarify their structure-activity relationships.
37313607	3	4	theme	digestive	532:540	arg1	characteristics					556:570	the digestive and prebiotic characteristics	528:570	the digestive and prebiotic characteristics of biscuits	528:582	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	0	5	from	Effects	0:6	arg1	digestion					80:88	the in vitro digestion and fermentation characteristics	67:121	digestion	80:88	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	0	5	from	Effects	0:6	arg1	characteristics					107:121	the in vitro digestion and fermentation characteristics	67:121	characteristics	107:121	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	2	6	theme	glycemic	267:274	arg1	GI					283:284	GI	283:284	GI	283:284	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	2	6	theme	glycemic	267:274	arg1	index					276:280	a low glycemic index	261:280	a low glycemic index (GI)	261:285	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	6	7	theme	biscuits	1128:1135	arg1	types					1119:1123	the three types	1109:1123	the three types of biscuits containing polysaccharides (after digestion)	1109:1180	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	0	8	theme	in	71:72	arg1	digestion					80:88	the in vitro digestion and fermentation characteristics	67:121	digestion	80:88	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	2	9	theme	low	263:265	arg1	GI					283:284	GI	283:284	GI	283:284	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	2	9	theme	low	263:265	arg1	index					276:280	a low glycemic index	261:280	a low glycemic index (GI)	261:285	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	5	10	contain	containing	913:922	arg2	polysaccharides					924:938	polysaccharides	924:938	polysaccharides	924:938	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	10	contain	containing	913:922	arg1	biscuits					904:911	biscuits	904:911	biscuits containing polysaccharides	904:938	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	8	11	theme	polysaccharide	1545:1558	arg1	addition					1515:1522	the addition	1511:1522	the addition of a lower-viscosity polysaccharide (arabinogalactan)	1511:1576	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	8	11	theme	polysaccharide	1545:1558	arg1	beneficial					1590:1599	beneficial	1590:1599	beneficial	1590:1599	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	6	12	theme	acids	1254:1258	arg1	level					1227:1231	the level	1223:1231	the level of short-chain fatty acids	1223:1258	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	5	13	theme	gastrointestinal	837:852	arg1	digestion					854:862	simulated gastrointestinal digestion	827:862	simulated gastrointestinal digestion	827:862	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	2	14	theme	glucose	367:373	arg1	control					350:356	the control	346:356	the control of blood glucose	346:373	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	5	15	theme	biscuits	904:911	arg1	types					895:899	three types	889:899	three types of biscuits containing polysaccharides	889:938	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	8	16	theme	blood	1609:1613	arg1	control					1623:1629	the blood glucose control	1605:1629	the blood glucose control of biscuits	1605:1641	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	6	17	theme	fatty	1248:1252	arg1	acids					1254:1258	short-chain fatty acids	1236:1258	short-chain fatty acids	1236:1258	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	5	18	theme	simulated	827:835	arg1	digestion					854:862	simulated gastrointestinal digestion	827:862	simulated gastrointestinal digestion	827:862	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	8	19	theme	lower-viscosity	1529:1543	arg1	arabinogalactan					1561:1575	arabinogalactan	1561:1575	arabinogalactan	1561:1575	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	8	19	theme	lower-viscosity	1529:1543	arg1	polysaccharide					1545:1558	a lower-viscosity polysaccharide	1527:1558	a lower-viscosity polysaccharide (arabinogalactan)	1527:1576	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	3	20	from	effect	420:425	arg1	characteristics					556:570	the digestive and prebiotic characteristics	528:570	the digestive and prebiotic characteristics of biscuits	528:582	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	0	21	dep	in	71:72	arg1	vitro					74:78	vitro	74:78	vitro	74:78	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	5	22	theme	Key	790:792	arg1	findings					794:801	Key findings	790:801	Key findings	790:801	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	23	contain	had	992:994	arg1	BAG					988:990	BAG	988:990	BAG	988:990	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	23	contain	had	992:994	arg2	value					1020:1024	the lowest estimated GI value	996:1024	the lowest estimated GI value	996:1024	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	3	24	theme	fermentation	616:627	arg1	model					629:633	fermentation model	616:633	fermentation model	616:633	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	5	25	theme	lowest	1000:1005	arg1	value					1020:1024	the lowest estimated GI value	996:1024	the lowest estimated GI value	996:1024	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	6	26	dep	diabetic	1061:1068	arg1	microbiota					1097:1106	' fecal microbiota	1089:1106	' fecal microbiota	1089:1106	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	8	27	theme	biscuits	1634:1641	arg1	control					1623:1629	the blood glucose control	1605:1629	the blood glucose control of biscuits	1605:1641	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	4	28	theme	structure-activity	756:773	arg1	relationships					775:787	their structure-activity relationships	750:787	their structure-activity relationships	750:787	Also, the rheological property and structural properties of the polysaccharides were measured to clarify their structure-activity relationships.
37313607	6	29	contain	containing	1137:1146	arg2	polysaccharides					1148:1162	polysaccharides	1148:1162	polysaccharides (after digestion)	1148:1180	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	6	29	contain	containing	1137:1146	arg1	biscuits					1128:1135	biscuits	1128:1135	biscuits containing polysaccharides (after digestion)	1128:1180	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	7	30	theme	biscuits	1338:1345	arg1	types					1329:1333	the three types	1319:1333	the three types of biscuits	1319:1345	Among the three types of biscuits, BAG increased the abundance of Bifidobacterium and Lactobacillus during fermentation in diabetic and healthy subjects' fecal microbiota.
37313607	0	31	theme	gum	19:21	arg1	Effects					0:6	Effects	0:6	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits	0:133	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	6	32	dep	in	1034:1035	arg1	vitro					1037:1041	vitro	1037:1041	vitro	1037:1041	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	6	33	theme	short-chain	1236:1246	arg1	acids					1254:1258	short-chain fatty acids	1236:1258	short-chain fatty acids	1236:1258	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	3	34	theme	konjac	472:477	arg1	glucomannan					479:489	konjac glucomannan	472:489	konjac glucomannan (BKG)	472:495	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	3	34	theme	konjac	472:477	arg1	BKG					492:494	BKG	492:494	BKG	492:494	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	5	35	dep	findings	794:801	arg1	showed					877:882	showed	877:882	showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value	877:1024	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	0	36	theme	xanthan	11:17	arg1	gum					19:21	xanthan gum	11:21	xanthan gum	11:21	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	0	37	theme	fermentation	94:105	arg1	characteristics					107:121	the in vitro digestion and fermentation characteristics	67:121	characteristics	107:121	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	1	38	contain	have	179:182	arg2	impact					207:212	a significant economic impact	184:212	a significant economic impact	184:212	Background: Diabetes and its complications have a significant economic impact on individuals and their families.
37313607	1	38	contain	have	179:182	arg1	complications					165:177	its complications	161:177	its complications	161:177	Background: Diabetes and its complications have a significant economic impact on individuals and their families.
37313607	1	38	contain	have	179:182	arg1	Diabetes					148:155	Diabetes	148:155	Diabetes	148:155	Background: Diabetes and its complications have a significant economic impact on individuals and their families.
37313607	3	39	dep	gum	461:463	arg1	i.e.					447:450	i.e.	447:450	i.e.	447:450	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	1	40	theme	significant	186:196	arg1	impact					207:212	a significant economic impact	184:212	a significant economic impact	184:212	Background: Diabetes and its complications have a significant economic impact on individuals and their families.
37313607	0	41	theme	konjac	24:29	arg1	glucomannan					31:41	konjac glucomannan	24:41	konjac glucomannan	24:41	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	0	42	theme	biscuits	126:133	arg1	digestion					80:88	the in vitro digestion and fermentation characteristics	67:121	digestion	80:88	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	0	42	theme	biscuits	126:133	arg1	characteristics					107:121	the in vitro digestion and fermentation characteristics	67:121	characteristics	107:121	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	1	43	theme	economic	198:205	arg1	impact					207:212	a significant economic impact	184:212	a significant economic impact	184:212	Background: Diabetes and its complications have a significant economic impact on individuals and their families.
37313607	3	44	dep	Scope	376:380	arg1	explored					407:414	explored	407:414	explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro	407:642	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	2	45	theme	blood	361:365	arg1	glucose					367:373	blood glucose	361:373	blood glucose	361:373	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	6	46	with	fermentation	1043:1054	arg1	diabetic					1061:1068	diabetic	1061:1068	diabetic	1061:1068	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	6	46	with	fermentation	1043:1054	arg1	subjects					1081:1088	healthy subjects	1073:1088	healthy subjects	1073:1088	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	4	47	theme	polysaccharides	709:723	arg1	property					667:674	the rheological property and structural properties	651:700	property	667:674	Also, the rheological property and structural properties of the polysaccharides were measured to clarify their structure-activity relationships.
37313607	4	47	theme	polysaccharides	709:723	arg1	properties					691:700	the rheological property and structural properties	651:700	properties	691:700	Also, the rheological property and structural properties of the polysaccharides were measured to clarify their structure-activity relationships.
37313607	5	48	theme	estimated	959:967	arg1	<					972:972	estimated GI < 55	959:975	estimated GI < 55	959:975	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	48	theme	estimated	959:967	arg1	foods					952:956	low GI foods	945:956	low GI foods (estimated GI < 55)	945:976	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	49	theme	estimated	1007:1015	arg1	value					1020:1024	the lowest estimated GI value	996:1024	the lowest estimated GI value	996:1024	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	3	50	theme	polysaccharides	430:444	arg1	effect					420:425	the effect	416:425	the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits	416:582	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	0	51	theme	glucomannan	31:41	arg1	Effects					0:6	Effects	0:6	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits	0:133	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	2	52	with	diet	251:254	arg1	content					302:308	high fiber content	291:308	high fiber content	291:308	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	2	52	with	diet	251:254	arg1	GI					283:284	GI	283:284	GI	283:284	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	2	52	with	diet	251:254	arg1	index					276:280	a low glycemic index	261:280	a low glycemic index (GI)	261:285	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	5	53	theme	GI	969:970	arg1	<					972:972	estimated GI < 55	959:975	estimated GI < 55	959:975	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	53	theme	GI	969:970	arg1	foods					952:956	low GI foods	945:956	low GI foods (estimated GI < 55)	945:976	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	2	54	theme	fiber	296:300	arg1	content					302:308	high fiber content	291:308	high fiber content	291:308	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	7	55	theme	healthy	1449:1455	arg1	subjects					1457:1464	healthy subjects	1449:1464	healthy subjects	1449:1464	Among the three types of biscuits, BAG increased the abundance of Bifidobacterium and Lactobacillus during fermentation in diabetic and healthy subjects' fecal microbiota.
37313607	6	56	theme	fecal	1091:1095	arg1	microbiota					1097:1106	' fecal microbiota	1089:1106	' fecal microbiota	1089:1106	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	3	57	theme	biscuits	575:582	arg1	characteristics					556:570	the digestive and prebiotic characteristics	528:570	the digestive and prebiotic characteristics of biscuits	528:582	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	2	58	theme	high	291:294	arg1	content					302:308	high fiber content	291:308	high fiber content	291:308	A diet with a low glycemic index (GI) and high fiber content is considered to be associated with the control of blood glucose.
37313607	6	59	theme	fermentation	1196:1207	arg1	pH					1209:1210	the fermentation pH	1192:1210	the fermentation pH	1192:1210	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	3	60	theme	prebiotic	546:554	arg1	characteristics					556:570	the digestive and prebiotic characteristics	528:570	the digestive and prebiotic characteristics of biscuits	528:582	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	4	61	theme	rheological	655:665	arg1	property					667:674	the rheological property and structural properties	651:700	property	667:674	Also, the rheological property and structural properties of the polysaccharides were measured to clarify their structure-activity relationships.
37313607	8	62	theme	glucose	1615:1621	arg1	control					1623:1629	the blood glucose control	1605:1629	the blood glucose control of biscuits	1605:1641	These results showed that the addition of a lower-viscosity polysaccharide (arabinogalactan) may be more beneficial for the blood glucose control of biscuits.
37313607	6	63	theme	in	1034:1035	arg1	fermentation					1043:1054	in vitro fermentation	1034:1054	in vitro fermentation with diabetic or healthy subjects' fecal microbiota	1034:1106	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	7	64	dep	diabetic	1436:1443	arg1	microbiota					1473:1482	' fecal microbiota	1465:1482	' fecal microbiota	1465:1482	Among the three types of biscuits, BAG increased the abundance of Bifidobacterium and Lactobacillus during fermentation in diabetic and healthy subjects' fecal microbiota.
37313607	0	65	theme	arabinogalactan	48:62	arg1	Effects					0:6	Effects	0:6	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits	0:133	Effects of xanthan gum, konjac glucomannan, and arabinogalactan on the in vitro digestion and fermentation characteristics of biscuits.
37313607	7	66	theme	Lactobacillus	1399:1411	arg1	abundance					1366:1374	the abundance	1362:1374	the abundance of Bifidobacterium and Lactobacillus	1362:1411	Among the three types of biscuits, BAG increased the abundance of Bifidobacterium and Lactobacillus during fermentation in diabetic and healthy subjects' fecal microbiota.
37313607	5	67	theme	low	945:947	arg1	<					972:972	estimated GI < 55	959:975	estimated GI < 55	959:975	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	67	theme	low	945:947	arg1	foods					952:956	low GI foods	945:956	low GI foods (estimated GI < 55)	945:976	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	3	68	theme	xanthan	453:459	arg1	BXG					466:468	BXG	466:468	BXG	466:468	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	3	68	theme	xanthan	453:459	arg1	gum					461:463	xanthan gum	453:463	xanthan gum (BXG)	453:469	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	6	69	theme	healthy	1073:1079	arg1	subjects					1081:1088	healthy subjects	1073:1088	healthy subjects	1073:1088	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	6	70	theme	microbiota	1279:1288	arg1	composition					1290:1300	the microbiota composition	1275:1300	the microbiota composition over time	1275:1310	During in vitro fermentation with diabetic or healthy subjects' fecal microbiota, the three types of biscuits containing polysaccharides (after digestion) decreased the fermentation pH, increased the level of short-chain fatty acids, and modulated the microbiota composition over time.
37313607	3	71	theme	simulated	592:600	arg1	digestion					602:610	a simulated digestion	590:610	a simulated digestion	590:610	Scope and approach: This study explored the effect of polysaccharides, i.e., xanthan gum (BXG), konjac glucomannan (BKG), and arabinogalactan (BAG), on the digestive and prebiotic characteristics of biscuits using a simulated digestion and fermentation model in vitro.
37313607	5	72	theme	GI	949:950	arg1	<					972:972	estimated GI < 55	959:975	estimated GI < 55	959:975	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
37313607	5	72	theme	GI	949:950	arg1	foods					952:956	low GI foods	945:956	low GI foods (estimated GI < 55)	945:976	Key findings and conclusions: During simulated gastrointestinal digestion, the results showed that three types of biscuits containing polysaccharides were low GI foods (estimated GI < 55), in which BAG had the lowest estimated GI value.
35510935	6	0	theme	green	1102:1106	arg1	electronics					1108:1118	the future green electronics	1091:1118	the future green electronics with high flexibility, miniaturization, and increased portability	1091:1184	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	1	1	theme	composites	278:287	arg1	exfoliation					227:237	the efficient exfoliation	213:237	the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites	213:287	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	0	2	theme	Flexible	95:102	arg1	Paper-Anodes					104:115	Flexible Paper-Anodes	95:115	Flexible Paper-Anodes	95:115	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	5	3	theme	traditional	964:974	arg1	collector					993:1001	traditional metallic current collector	964:1001	traditional metallic current collector	964:1001	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	5	4	theme	heterogeneous	852:864	arg1	networks					866:873	the 1D/2D heterogeneous networks	842:873	the 1D/2D heterogeneous networks	842:873	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	6	5	theme	future	1095:1100	arg1	electronics					1108:1118	the future green electronics	1091:1118	the future green electronics with high flexibility, miniaturization, and increased portability	1091:1184	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	3	6	theme	MoS2	497:500	arg1	/graphene					502:510	the exfoliated MoS2 /graphene	482:510	the exfoliated MoS2 /graphene	482:510	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	5	7	theme	ideal	899:903	arg1	paper-anode					905:915	an ideal paper-anode	896:915	an ideal paper-anode for lithium-ion batteries (LIBs)	896:948	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	2	8	theme	dispersant	306:315	arg1	agent					317:321	an effective dispersant agent	293:321	an effective dispersant agent	293:321	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	2	8	theme	dispersant	306:315	arg1	ONFC					324:327	ONFC	324:327	ONFC	324:327	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	5	9	theme	lithium-ion	921:931	arg1	batteries					933:941	lithium-ion batteries	921:941	lithium-ion batteries (LIBs)	921:948	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	5	9	theme	lithium-ion	921:931	arg1	LIBs					944:947	LIBs	944:947	LIBs	944:947	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	5	10	theme	Ultrathin	804:812	arg1	nanosheets					819:828	Ultrathin MoS2 nanosheets	804:828	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks	804:873	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	0	11	theme	TEMPO-Oxidized	0:13	arg1	Exfoliation					50:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation	0:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.	0:116	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	6	12	theme	increased	1164:1172	arg1	portability					1174:1184	increased portability	1164:1184	increased portability	1164:1184	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	0	13	theme	Nanofibrillated	15:29	arg1	Exfoliation					50:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation	0:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.	0:116	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	3	14	theme	sonication	581:590	arg1	time					592:595	the elongated sonication time	567:595	the elongated sonication time	567:595	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	4	15	theme	flexible	712:719	arg1	skeleton					729:736	flexible fibrous skeleton	712:736	flexible fibrous skeleton	712:736	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	1	16	with	cellulose	149:157	arg1	groups					188:193	charged carboxyl groups	171:193	charged carboxyl groups	171:193	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	6	17	theme	natural	1060:1066	arg1	cellulose					1068:1076	natural cellulose	1060:1076	natural cellulose	1060:1076	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	1	18	theme	TEMPO-oxidized	118:131	arg1	ONFC					160:163	ONFC	160:163	ONFC	160:163	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	1	18	theme	TEMPO-oxidized	118:131	arg1	cellulose					149:157	TEMPO-oxidized nanofibrillated cellulose	118:157	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups	118:193	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	1	19	theme	efficient	217:225	arg1	exfoliation					227:237	the efficient exfoliation	213:237	the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites	213:287	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	0	20	theme	Assisted	41:48	arg1	Exfoliation					50:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation	0:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.	0:116	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	4	21	theme	electrical	783:792	arg1	networks					794:801	electrical networks	783:801	electrical networks	783:801	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	1	22	theme	nanofibrillated	133:147	arg1	ONFC					160:163	ONFC	160:163	ONFC	160:163	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	1	22	theme	nanofibrillated	133:147	arg1	cellulose					149:157	TEMPO-oxidized nanofibrillated cellulose	118:157	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups	118:193	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	2	23	theme	nanosheets	433:442	arg1	accumulation					402:413	the accumulation	398:413	the accumulation of the exfoliated nanosheets	398:442	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	0	24	theme	Cellulose	31:39	arg1	Exfoliation					50:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation	0:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.	0:116	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	3	25	theme	elongated	571:579	arg1	time					592:595	the elongated sonication time	567:595	the elongated sonication time	567:595	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	2	26	theme	exfoliated	422:431	arg1	nanosheets					433:442	the exfoliated nanosheets	418:442	the exfoliated nanosheets	418:442	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	3	27	theme	aqueous	542:548	arg1	dispersions					550:560	the aqueous dispersions	538:560	the aqueous dispersions	538:560	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	1	28	theme	two-dimensional	242:256	arg1	composites					278:287	two-dimensional (2D) MoS2 /graphene composites	242:287	two-dimensional (2D) MoS2 /graphene composites	242:287	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	5	29	theme	1D/2D	846:850	arg1	networks					866:873	the 1D/2D heterogeneous networks	842:873	the 1D/2D heterogeneous networks	842:873	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	6	30	theme	electrode	1031:1039	arg1	materials					1041:1049	The self-standing flexible electrode materials	1004:1049	The self-standing flexible electrode materials based on natural cellulose	1004:1076	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	4	31	theme	composite	655:663	arg1	films					665:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	3	32	theme	charged	468:474	arg1	ONFC					476:479	charged ONFC	468:479	charged ONFC	468:479	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	0	33	theme	/Graphene	70:78	arg1	Composites					80:89	MoS2 /Graphene Composites	65:89	MoS2 /Graphene Composites	65:89	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	6	34	theme	flexible	1022:1029	arg1	materials					1041:1049	The self-standing flexible electrode materials	1004:1049	The self-standing flexible electrode materials based on natural cellulose	1004:1076	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	2	35	theme	adjacent	364:371	arg1	layers					373:378	the adjacent layers	360:378	the adjacent layers	360:378	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	0	36	theme	MoS2	65:68	arg1	Composites					80:89	MoS2 /Graphene Composites	65:89	MoS2 /Graphene Composites	65:89	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	6	37	theme	self-standing	1008:1020	arg1	materials					1041:1049	The self-standing flexible electrode materials	1004:1049	The self-standing flexible electrode materials based on natural cellulose	1004:1076	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	6	38	with	electronics	1108:1118	arg1	miniaturization					1143:1157	miniaturization	1143:1157	miniaturization	1143:1157	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	6	38	with	electronics	1108:1118	arg1	flexibility					1130:1140	high flexibility	1125:1140	high flexibility	1125:1140	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	6	38	with	electronics	1108:1118	arg1	portability					1174:1184	increased portability	1164:1184	increased portability	1164:1184	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	5	39	theme	current	985:991	arg1	collector					993:1001	traditional metallic current collector	964:1001	traditional metallic current collector	964:1001	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	1	40	dep	two-dimensional	242:256	arg1	2D					259:260	2D	259:260	2D	259:260	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	4	41	theme	fibrous	721:727	arg1	skeleton					729:736	flexible fibrous skeleton	712:736	flexible fibrous skeleton	712:736	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	4	42	theme	MoS2	630:633	arg1	films					665:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	2	43	theme	effective	296:304	arg1	agent					317:321	an effective dispersant agent	293:321	an effective dispersant agent	293:321	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	2	43	theme	effective	296:304	arg1	ONFC					324:327	ONFC	324:327	ONFC	324:327	As an effective dispersant agent, ONFC can be easily absorbed between the adjacent layers, so as to prevent the accumulation of the exfoliated nanosheets.
35510935	5	44	theme	metallic	976:983	arg1	collector					993:1001	traditional metallic current collector	964:1001	traditional metallic current collector	964:1001	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	3	45	theme	exfoliated	486:495	arg1	/graphene					502:510	the exfoliated MoS2 /graphene	482:510	the exfoliated MoS2 /graphene	482:510	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	4	46	theme	self-standing	616:628	arg1	films					665:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	5	47	theme	MoS2	814:817	arg1	nanosheets					819:828	Ultrathin MoS2 nanosheets	804:828	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks	804:873	Ultrathin MoS2 nanosheets anchored on the 1D/2D heterogeneous networks is directly acted as an ideal paper-anode for lithium-ion batteries (LIBs) without using traditional metallic current collector.
35510935	6	48	theme	high	1125:1128	arg1	flexibility					1130:1140	high flexibility	1125:1140	high flexibility	1125:1140	The self-standing flexible electrode materials based on natural cellulose will promote the future green electronics with high flexibility, miniaturization, and increased portability.
35510935	3	49	theme	ONFC	476:479	arg1	assistance					454:463	the assistance	450:463	the assistance of charged ONFC	450:479	With the assistance of charged ONFC, the exfoliated MoS2 /graphene is gradually increased in the aqueous dispersions with the elongated sonication time.
35510935	1	50	theme	charged	171:177	arg1	groups					188:193	charged carboxyl groups	171:193	charged carboxyl groups	171:193	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	1	51	theme	MoS2	263:266	arg1	composites					278:287	two-dimensional (2D) MoS2 /graphene composites	242:287	two-dimensional (2D) MoS2 /graphene composites	242:287	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	0	52	theme	Composites	80:89	arg1	Exfoliation					50:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation	0:60	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.	0:116	TEMPO-Oxidized Nanofibrillated Cellulose Assisted Exfoliation of MoS2 /Graphene Composites for Flexible Paper-Anodes.
35510935	4	53	theme	/Graphene/ONFC/CNTs	635:653	arg1	films					665:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	self-standing MoS2 /Graphene/ONFC/CNTs composite films	616:669	After dewatering, self-standing MoS2 /Graphene/ONFC/CNTs composite films are rationally constructed using ONFC as flexible fibrous skeleton, and CNTs/graphene as 1D/2D interpenetrating electrical networks.
35510935	1	54	theme	carboxyl	179:186	arg1	groups					188:193	charged carboxyl groups	171:193	charged carboxyl groups	171:193	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35510935	1	55	theme	/graphene	268:276	arg1	composites					278:287	two-dimensional (2D) MoS2 /graphene composites	242:287	two-dimensional (2D) MoS2 /graphene composites	242:287	TEMPO-oxidized nanofibrillated cellulose (ONFC) with charged carboxyl groups is introduced for the efficient exfoliation of two-dimensional (2D) MoS2 /graphene composites.
35299074	5	0	theme	model	705:709	arg1	fitting					711:717	model fitting	705:717	model fitting	705:717	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	3	1	theme	basic	539:543	arg1	structures					545:554	their basic structures	533:554	their basic structures	533:554	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	0	2	theme	Advanced	96:103	arg1	rheology					105:112	Advanced rheology	96:112	Advanced rheology	96:112	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	4	3	theme	Comprehensive	557:569	arg1	studies					595:601	Comprehensive rheological and thermal studies	557:601	Comprehensive rheological and thermal studies	557:601	Comprehensive rheological and thermal studies have been performed to investigate their distinctive properties.
35299074	7	4	theme	novel	995:999	arg1	CHGs					1001:1004	novel CHGs	995:1004	novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications	995:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	2	5	theme	possible	373:380	arg1	biotoxicity					382:392	their possible biotoxicity	367:392	their possible biotoxicity	367:392	Nevertheless, chemically crosslinked synthetic HGs are commonly under specific restrictions because of their possible biotoxicity.
35299074	0	6	theme	thermal	115:121	arg1	analysis					123:130	thermal analysis	115:130	thermal analysis	115:130	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	7	7	theme	rheological	1147:1157	arg1	properties					1159:1168	other rheological properties	1141:1168	other rheological properties that will provide effective support for various future applications	1141:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	5	8	theme	CHGs	767:770	arg1	energy					757:762	the highest activation energy	734:762	the highest activation energy of CHGs	734:770	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	5	8	theme	CHGs	767:770	arg1	172,142.2 J/mol					776:790	172,142.2 J/mol	776:790	172,142.2 J/mol	776:790	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	6	9	theme	recovery	866:873	arg1	rate					875:878	The sample recovery rate	855:878	The sample recovery rate	855:878	The sample recovery rate could reach 92.6%, while the anti-freezing temperature can be as low as -20 °C.
35299074	2	10	theme	synthetic	301:309	arg1	HGs					311:313	chemically crosslinked synthetic HGs	278:313	chemically crosslinked synthetic HGs	278:313	Nevertheless, chemically crosslinked synthetic HGs are commonly under specific restrictions because of their possible biotoxicity.
35299074	4	11	theme	distinctive	644:654	arg1	properties					656:665	their distinctive properties	638:665	their distinctive properties	638:665	Comprehensive rheological and thermal studies have been performed to investigate their distinctive properties.
35299074	6	12	theme	sample	859:864	arg1	rate					875:878	The sample recovery rate	855:878	The sample recovery rate	855:878	The sample recovery rate could reach 92.6%, while the anti-freezing temperature can be as low as -20 °C.
35299074	2	13	theme	crosslinked	289:299	arg1	HGs					311:313	chemically crosslinked synthetic HGs	278:313	chemically crosslinked synthetic HGs	278:313	Nevertheless, chemically crosslinked synthetic HGs are commonly under specific restrictions because of their possible biotoxicity.
35299074	3	14	theme	novel	466:470	arg1	HGs					505:507	novel Salecan/κ-carrageenan composites HGs	466:507	novel Salecan/κ-carrageenan composites HGs (CHGs)	466:514	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	3	14	theme	novel	466:470	arg1	CHGs					510:513	CHGs	510:513	CHGs	510:513	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	5	15	theme	maximum	801:807	arg1	compliance					827:836	the maximum equilibrium creep compliance	797:836	the maximum equilibrium creep compliance	797:836	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	5	15	theme	maximum	801:807	arg1	1/Pa					849:852	0.0085 1/Pa	842:852	0.0085 1/Pa	842:852	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	7	16	theme	other	1141:1145	arg1	properties					1159:1168	other rheological properties	1141:1168	other rheological properties that will provide effective support for various future applications	1141:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	7	17	theme	first	970:974	arg1	report					976:981	the first report	966:981	the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications	966:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	7	17	theme	first	970:974	arg1	It					960:961	It	960:961	It	960:961	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	3	18	theme	Salecan/κ-carrageenan	472:492	arg1	HGs					505:507	novel Salecan/κ-carrageenan composites HGs	466:507	novel Salecan/κ-carrageenan composites HGs (CHGs)	466:514	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	3	18	theme	Salecan/κ-carrageenan	472:492	arg1	CHGs					510:513	CHGs	510:513	CHGs	510:513	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	0	19	theme	novel	2:6	arg1	hydrogel					56:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel	0:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.	0:149	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	2	20	theme	specific	334:341	arg1	restrictions					343:354	specific restrictions	334:354	specific restrictions	334:354	Nevertheless, chemically crosslinked synthetic HGs are commonly under specific restrictions because of their possible biotoxicity.
35299074	2	21	link	crosslinked	289:299	arg1	HGs					311:313	chemically crosslinked synthetic HGs	278:313	chemically crosslinked synthetic HGs	278:313	Nevertheless, chemically crosslinked synthetic HGs are commonly under specific restrictions because of their possible biotoxicity.
35299074	1	22	theme	intensive	202:210	arg1	concern					212:218	intensive concern	202:218	intensive concern	202:218	The multifunctional hydrogels (HGs) have attracted intensive concern in biomedicine, food, and flexible devices.
35299074	0	23	theme	Salecan/κ-carrageenan	24:44	arg1	hydrogel					56:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel	0:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.	0:149	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	0	24	theme	multifunctional	8:22	arg1	hydrogel					56:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel	0:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.	0:149	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	0	25	theme	model	136:140	arg1	fitting					142:148	model fitting	136:148	model fitting	136:148	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	3	26	theme	physical	435:442	arg1	approaches					444:453	physical approaches	435:453	physical approaches	435:453	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	6	27	theme	anti-freezing	909:921	arg1	low					945:947	low	945:947	low	945:947	The sample recovery rate could reach 92.6%, while the anti-freezing temperature can be as low as -20 °C.
35299074	6	27	theme	anti-freezing	909:921	arg1	temperature					923:933	the anti-freezing temperature	905:933	the anti-freezing temperature	905:933	The sample recovery rate could reach 92.6%, while the anti-freezing temperature can be as low as -20 °C.
35299074	3	28	theme	composites	494:503	arg1	HGs					505:507	novel Salecan/κ-carrageenan composites HGs	466:507	novel Salecan/κ-carrageenan composites HGs (CHGs)	466:514	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	3	28	theme	composites	494:503	arg1	CHGs					510:513	CHGs	510:513	CHGs	510:513	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	0	29	theme	composite	46:54	arg1	hydrogel					56:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel	0:63	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.	0:149	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	3	30	theme	approaches	444:453	arg1	employment					421:430	the employment	417:430	the employment of physical approaches	417:453	This study focuses on the employment of physical approaches to prepare novel Salecan/κ-carrageenan composites HGs (CHGs) without changing their basic structures.
35299074	7	31	theme	various	1210:1216	arg1	applications					1225:1236	various future applications	1210:1236	various future applications	1210:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	7	32	theme	ideal	1047:1051	arg1	ability					1067:1073	ideal anti-freezing ability	1047:1073	ideal anti-freezing ability	1047:1073	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	0	33	theme	anti-freezing	70:82	arg1	properties					84:93	anti-freezing properties	70:93	anti-freezing properties	70:93	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	4	34	theme	rheological	571:581	arg1	studies					595:601	Comprehensive rheological and thermal studies	557:601	Comprehensive rheological and thermal studies	557:601	Comprehensive rheological and thermal studies have been performed to investigate their distinctive properties.
35299074	7	35	theme	enhanced	1076:1083	arg1	thermostability					1085:1099	enhanced thermostability	1076:1099	enhanced thermostability	1076:1099	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	0	36	dep	hydrogel	56:63	arg1	rheology					105:112	Advanced rheology	96:112	Advanced rheology	96:112	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	0	36	dep	hydrogel	56:63	arg1	analysis					123:130	thermal analysis	115:130	thermal analysis	115:130	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	0	36	dep	hydrogel	56:63	arg1	fitting					142:148	model fitting	136:148	model fitting	136:148	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	7	37	theme	anti-freezing	1053:1065	arg1	ability					1067:1073	ideal anti-freezing ability	1047:1073	ideal anti-freezing ability	1047:1073	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	7	38	theme	good	1102:1105	arg1	injectability					1107:1119	good injectability	1102:1119	good injectability	1102:1119	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	5	39	theme	highest	738:744	arg1	energy					757:762	the highest activation energy	734:762	the highest activation energy of CHGs	734:770	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	5	39	theme	highest	738:744	arg1	172,142.2 J/mol					776:790	172,142.2 J/mol	776:790	172,142.2 J/mol	776:790	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	4	40	theme	thermal	587:593	arg1	studies					595:601	Comprehensive rheological and thermal studies	557:601	Comprehensive rheological and thermal studies	557:601	Comprehensive rheological and thermal studies have been performed to investigate their distinctive properties.
35299074	5	41	theme	activation	746:755	arg1	energy					757:762	the highest activation energy	734:762	the highest activation energy of CHGs	734:770	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	5	41	theme	activation	746:755	arg1	172,142.2 J/mol					776:790	172,142.2 J/mol	776:790	172,142.2 J/mol	776:790	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	7	42	theme	effective	1188:1196	arg1	support					1198:1204	effective support	1188:1204	effective support for various future applications	1188:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	5	43	theme	equilibrium	809:819	arg1	compliance					827:836	the maximum equilibrium creep compliance	797:836	the maximum equilibrium creep compliance	797:836	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	5	43	theme	equilibrium	809:819	arg1	1/Pa					849:852	0.0085 1/Pa	842:852	0.0085 1/Pa	842:852	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	1	44	theme	multifunctional	155:169	arg1	hydrogels					171:179	The multifunctional hydrogels	151:179	The multifunctional hydrogels (HGs)	151:185	The multifunctional hydrogels (HGs) have attracted intensive concern in biomedicine, food, and flexible devices.
35299074	1	44	theme	multifunctional	155:169	arg1	HGs					182:184	HGs	182:184	HGs	182:184	The multifunctional hydrogels (HGs) have attracted intensive concern in biomedicine, food, and flexible devices.
35299074	5	45	theme	creep	821:825	arg1	compliance					827:836	the maximum equilibrium creep compliance	797:836	the maximum equilibrium creep compliance	797:836	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	5	45	theme	creep	821:825	arg1	1/Pa					849:852	0.0085 1/Pa	842:852	0.0085 1/Pa	842:852	The data obtained from the tests and model fitting confirmed that the highest activation energy of CHGs was 172,142.2 J/mol, and the maximum equilibrium creep compliance was 0.0085 1/Pa.
35299074	7	46	theme	future	1218:1223	arg1	applications					1225:1236	various future applications	1210:1236	various future applications	1210:1236	It is the first report focusing on novel CHGs made from Salecan and κ-carrageenan with ideal anti-freezing ability, enhanced thermostability, good injectability, self-recovery, and other rheological properties that will provide effective support for various future applications.
35299074	0	47	with	hydrogel	56:63	arg1	properties					84:93	anti-freezing properties	70:93	anti-freezing properties	70:93	A novel multifunctional Salecan/κ-carrageenan composite hydrogel with anti-freezing properties: Advanced rheology, thermal analysis and model fitting.
35299074	1	48	theme	flexible	246:253	arg1	devices					255:261	flexible devices	246:261	flexible devices	246:261	The multifunctional hydrogels (HGs) have attracted intensive concern in biomedicine, food, and flexible devices.
36018278	0	0	theme	tomato	74:79	arg1	development					87:97	early tomato fruit development	68:97	early tomato fruit development	68:97	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	5	1	with	polysaccharides	977:991	arg1	contributions					953:965	different contributions	943:965	different contributions of cutin	943:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	4	2	theme	data	850:853	arg1	analyses					855:862	multivariate data analyses	837:862	multivariate data analyses	837:862	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	1	3	theme	polymer	137:143	arg1	cuticle					116:122	The cuticle	112:122	The cuticle	112:122	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	1	3	theme	polymer	137:143	arg1	critical					261:268	critical	261:268	critical	261:268	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	1	3	theme	polymer	137:143	arg1	matrix					145:150	a complex polymer matrix	127:150	a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development	127:290	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	4	4	theme	biochemical	869:879	arg1	analyses					881:888	biochemical analyses	869:888	biochemical analyses	869:888	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	1	5	theme	plant-environment	222:238	arg1	interactions					240:251	plant-environment interactions	222:251	plant-environment interactions	222:251	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	0	6	theme	early	68:72	arg1	development					87:97	early tomato fruit development	68:97	early tomato fruit development	68:97	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	4	7	theme	multivariate	837:848	arg1	analyses					855:862	multivariate data analyses	837:862	multivariate data analyses	837:862	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	2	8	theme	structural	333:342	arg1	features					344:351	the structural features	329:351	the structural features of cuticles	329:363	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	4	9	theme	phase	727:731	arg1	beginning					695:703	the beginning	691:703	the beginning of the cell expansion phase to the red ripe stage	691:753	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	9	10	theme	functional	1587:1596	arg1	performance					1598:1608	the functional performance	1583:1608	the functional performance of the fruit cuticle	1583:1629	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	10	11	theme	wall-cuticle	1797:1808	arg1	organization					1762:1773	the organization	1758:1773	the organization of the epidermal cell wall-cuticle	1758:1808	This study provides insights into the plant cuticle architecture and in particular into the organization of the epidermal cell wall-cuticle.
36018278	5	12	theme	cutin	1019:1023	arg1	matrix					1033:1038	the cutin polymer matrix	1015:1038	the cutin polymer matrix	1015:1038	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	3	13	theme	in-depth	533:540	arg1	architecture					542:553	the in-depth architecture	529:553	the in-depth architecture of the cutin polymer matrix during fruit development	529:606	In this work, the in-depth architecture of the cutin polymer matrix during fruit development was investigated.
36018278	9	14	theme	cuticle	1623:1629	arg1	performance					1598:1608	the functional performance	1583:1608	the functional performance of the fruit cuticle	1583:1629	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	9	14	theme	cuticle	1623:1629	arg1	adaption					1532:1539	consistent adaption	1521:1539	consistent adaption of the cutin-polysaccharide continuum	1521:1577	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	10	15	theme	epidermal	1782:1790	arg1	wall-cuticle					1797:1808	the epidermal cell wall-cuticle	1778:1808	the epidermal cell wall-cuticle	1778:1808	This study provides insights into the plant cuticle architecture and in particular into the organization of the epidermal cell wall-cuticle.
36018278	0	16	theme	fruit	81:85	arg1	development					87:97	early tomato fruit development	68:97	early tomato fruit development	68:97	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	9	17	theme	fruit	1617:1621	arg1	cuticle					1623:1629	the fruit cuticle	1613:1629	the fruit cuticle	1613:1629	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	4	18	theme	red	740:742	arg1	stage					749:753	the red ripe stage	736:753	the red ripe stage	736:753	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	9	19	theme	different	1638:1646	arg1	stages					1662:1667	the different developmental stages	1634:1667	the different developmental stages	1634:1667	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	7	20	theme	spatiotemporal	1198:1211	arg1	accumulation					1213:1224	The specific spatiotemporal accumulation	1185:1224	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids)	1185:1279	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	10	21	from	insights	1690:1697	arg1	particular					1742:1751	particular	1742:1751	particular	1742:1751	This study provides insights into the plant cuticle architecture and in particular into the organization of the epidermal cell wall-cuticle.
36018278	4	22	theme	Raman	822:826	arg1	mapping					828:834	Raman mapping	822:834	Raman mapping	822:834	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	4	23	theme	cherry	632:637	arg1	fruit					646:650	cherry tomato fruit	632:650	cherry tomato fruit (Solanum lycopersicum)	632:673	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	4	23	theme	cherry	632:637	arg1	model					680:684	a model	678:684	a model from the beginning of the cell expansion phase to the red ripe stage	678:753	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	5	24	theme	cutin	970:974	arg1	contributions					953:965	different contributions	943:965	different contributions of cutin	943:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	9	25	theme	structural	1495:1504	arg1	tuning					1506:1511	Such structural tuning	1490:1511	Such structural tuning	1490:1511	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	2	26	theme	architectural	374:386	arg1	crucial					437:443	crucial	437:443	crucial	437:443	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	2	26	theme	architectural	374:386	arg1	modeling					388:395	the architectural modeling	370:395	the architectural modeling of cuticles during plant development	370:432	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	6	27	theme	fruit	1107:1111	arg1	development					1113:1123	fruit development	1107:1123	fruit development	1107:1123	Besides, we demonstrated that these areas are finely tuned during fruit development, including compositional and macromolecular rearrangements.
36018278	5	28	theme	chemical	923:930	arg1	areas					932:936	clear chemical areas	917:936	clear chemical areas with different contributions of cutin	917:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	9	29	theme	Such	1490:1493	arg1	tuning					1506:1511	Such structural tuning	1490:1511	Such structural tuning	1490:1511	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	0	30	theme	cutin	4:8	arg1	matrix					18:23	The cutin polymer matrix	0:23	The cutin polymer matrix	0:23	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	6	31	theme	macromolecular	1154:1167	arg1	rearrangements					1169:1182	macromolecular rearrangements	1154:1182	macromolecular rearrangements	1154:1182	Besides, we demonstrated that these areas are finely tuned during fruit development, including compositional and macromolecular rearrangements.
36018278	3	32	theme	cutin	562:566	arg1	matrix					576:581	the cutin polymer matrix	558:581	the cutin polymer matrix	558:581	In this work, the in-depth architecture of the cutin polymer matrix during fruit development was investigated.
36018278	9	33	theme	consistent	1521:1530	arg1	adaption					1532:1539	consistent adaption	1521:1539	consistent adaption of the cutin-polysaccharide continuum	1521:1577	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	7	34	theme	specific	1189:1196	arg1	accumulation					1213:1224	The specific spatiotemporal accumulation	1185:1224	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids)	1185:1279	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	3	35	theme	polymer	568:574	arg1	matrix					576:581	the cutin polymer matrix	558:581	the cutin polymer matrix	558:581	In this work, the in-depth architecture of the cutin polymer matrix during fruit development was investigated.
36018278	1	36	theme	aerial	170:175	arg1	organs					177:182	all aerial organs	166:182	all aerial organs of plants	166:192	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	4	37	theme	expansion	717:725	arg1	phase					727:731	the cell expansion phase	708:731	the cell expansion phase	708:731	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	7	38	dep	compounds	1238:1246	arg1	flavonoids					1269:1278	flavonoids	1269:1278	flavonoids	1269:1278	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	7	38	dep	compounds	1238:1246	arg1	acid					1260:1263	p-coumaric acid	1249:1263	p-coumaric acid	1249:1263	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	5	39	theme	polymer	1025:1031	arg1	matrix					1033:1038	the cutin polymer matrix	1015:1038	the cutin polymer matrix	1015:1038	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	9	40	theme	developmental	1648:1660	arg1	stages					1662:1667	the different developmental stages	1634:1667	the different developmental stages	1634:1667	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	8	41	theme	polysaccharides	1436:1450	arg1	remodeling					1403:1412	an unexpected dynamic remodeling	1381:1412	an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1381:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	4	42	theme	tomato	639:644	arg1	fruit					646:650	cherry tomato fruit	632:650	cherry tomato fruit (Solanum lycopersicum)	632:673	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	4	42	theme	tomato	639:644	arg1	model					680:684	a model	678:684	a model from the beginning of the cell expansion phase to the red ripe stage	678:753	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	2	43	theme	plant	416:420	arg1	development					422:432	plant development	416:432	plant development	416:432	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	8	44	theme	unexpected	1384:1393	arg1	remodeling					1403:1412	an unexpected dynamic remodeling	1381:1412	an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1381:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	5	45	theme	different	943:951	arg1	contributions					953:965	different contributions	943:965	different contributions of cutin	943:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	2	46	theme	cuticles	400:407	arg1	crucial					437:443	crucial	437:443	crucial	437:443	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	2	46	theme	cuticles	400:407	arg1	modeling					388:395	the architectural modeling	370:395	the architectural modeling of cuticles during plant development	370:432	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	2	47	theme	physical	469:476	arg1	properties					478:487	their physical properties	463:487	their physical properties	463:487	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	1	48	theme	plant	274:278	arg1	development					280:290	plant development	274:290	plant development	274:290	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	9	49	theme	cutin-polysaccharide	1548:1567	arg1	continuum					1569:1577	the cutin-polysaccharide continuum	1544:1577	the cutin-polysaccharide continuum	1544:1577	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	3	50	theme	fruit	590:594	arg1	development					596:606	fruit development	590:606	fruit development	590:606	In this work, the in-depth architecture of the cutin polymer matrix during fruit development was investigated.
36018278	10	51	theme	cuticle	1714:1720	arg1	architecture					1722:1733	the plant cuticle architecture	1704:1733	the plant cuticle architecture	1704:1733	This study provides insights into the plant cuticle architecture and in particular into the organization of the epidermal cell wall-cuticle.
36018278	1	52	theme	plants	187:192	arg1	organs					177:182	all aerial organs	166:182	all aerial organs of plants	166:192	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	7	53	theme	compounds	1238:1246	arg1	accumulation					1213:1224	The specific spatiotemporal accumulation	1185:1224	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids)	1185:1279	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	4	54	dep	fruit	646:650	arg1	lycopersicum					661:672	Solanum lycopersicum	653:672	Solanum lycopersicum	653:672	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	0	55	theme	architectural	42:54	arg1	tuning					56:61	a fine architectural tuning	35:61	a fine architectural tuning from early tomato fruit development to ripening	35:109	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	1	56	from	roles	213:217	arg1	interactions					240:251	plant-environment interactions	222:251	plant-environment interactions	222:251	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	5	57	with	phenolics	998:1006	arg1	contributions					953:965	different contributions	943:965	different contributions of cutin	943:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	3	58	theme	matrix	576:581	arg1	architecture					542:553	the in-depth architecture	529:553	the in-depth architecture of the cutin polymer matrix during fruit development	529:606	In this work, the in-depth architecture of the cutin polymer matrix during fruit development was investigated.
36018278	8	59	theme	dynamic	1395:1401	arg1	remodeling					1403:1412	an unexpected dynamic remodeling	1381:1412	an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1381:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	10	60	theme	cell	1792:1795	arg1	wall-cuticle					1797:1808	the epidermal cell wall-cuticle	1778:1808	the epidermal cell wall-cuticle	1778:1808	This study provides insights into the plant cuticle architecture and in particular into the organization of the epidermal cell wall-cuticle.
36018278	0	61	theme	fine	37:40	arg1	tuning					56:61	a fine architectural tuning	35:61	a fine architectural tuning from early tomato fruit development to ripening	35:109	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	9	62	theme	continuum	1569:1577	arg1	performance					1598:1608	the functional performance	1583:1608	the functional performance of the fruit cuticle	1583:1629	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	9	62	theme	continuum	1569:1577	arg1	adaption					1532:1539	consistent adaption	1521:1539	consistent adaption of the cutin-polysaccharide continuum	1521:1577	Such structural tuning enables consistent adaption of the cutin-polysaccharide continuum and the functional performance of the fruit cuticle at the different developmental stages.
36018278	4	63	theme	sample	801:806	arg1	pretreatment					808:819	sample pretreatment	801:819	sample pretreatment	801:819	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	7	64	theme	distinct	1308:1315	arg1	functions					1317:1325	distinct functions	1308:1325	distinct functions	1308:1325	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	10	65	theme	plant	1708:1712	arg1	architecture					1722:1733	the plant cuticle architecture	1704:1733	the plant cuticle architecture	1704:1733	This study provides insights into the plant cuticle architecture and in particular into the organization of the epidermal cell wall-cuticle.
36018278	8	66	theme	cutin-embedded	1421:1434	arg1	pectin					1452:1457	pectin	1452:1457	pectin	1452:1457	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	8	66	theme	cutin-embedded	1421:1434	arg1	polysaccharides					1436:1450	the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1417:1487	the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1417:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	8	66	theme	cutin-embedded	1421:1434	arg1	cellulose					1460:1468	cellulose	1460:1468	cellulose	1460:1468	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	8	66	theme	cutin-embedded	1421:1434	arg1	hemicellulose					1475:1487	hemicellulose	1475:1487	hemicellulose	1475:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	4	67	theme	cell	712:715	arg1	phase					727:731	the cell expansion phase	708:731	the cell expansion phase	708:731	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	5	68	with	areas	932:936	arg1	contributions					953:965	different contributions	943:965	different contributions of cutin	943:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	0	69	from	development	87:97	arg1	tuning					56:61	a fine architectural tuning	35:61	a fine architectural tuning from early tomato fruit development to ripening	35:109	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	4	70	theme	ripe	744:747	arg1	stage					749:753	the red ripe stage	736:753	the red ripe stage	736:753	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	5	71	theme	clear	917:921	arg1	areas					932:936	clear chemical areas	917:936	clear chemical areas with different contributions of cutin	917:974	These approaches revealed clear chemical areas with different contributions of cutin, polysaccharides, and phenolics within the cutin polymer matrix.
36018278	1	72	theme	multiple	204:211	arg1	roles					213:217	multiple roles	204:217	multiple roles in plant-environment interactions	204:251	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	7	73	theme	p-coumaric	1249:1258	arg1	acid					1260:1263	p-coumaric acid	1249:1263	p-coumaric acid	1249:1263	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	8	74	dep	polysaccharides	1436:1450	arg1	pectin					1452:1457	pectin	1452:1457	pectin	1452:1457	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	8	74	dep	polysaccharides	1436:1450	arg1	polysaccharides					1436:1450	the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1417:1487	the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose	1417:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	8	74	dep	polysaccharides	1436:1450	arg1	cellulose					1460:1468	cellulose	1460:1468	cellulose	1460:1468	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	8	74	dep	polysaccharides	1436:1450	arg1	hemicellulose					1475:1487	hemicellulose	1475:1487	hemicellulose	1475:1487	In addition, we highlighted an unexpected dynamic remodeling of the cutin-embedded polysaccharides pectin, cellulose, and hemicellulose.
36018278	4	75	theme	experimental	771:782	arg1	scheme					784:789	an experimental scheme	768:789	an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses	768:888	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	7	76	theme	fruit	1334:1338	arg1	development					1340:1350	fruit development	1334:1350	fruit development	1334:1350	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
36018278	2	77	theme	cuticles	356:363	arg1	features					344:351	the structural features	329:351	the structural features of cuticles	329:363	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	4	78	from	beginning	695:703	arg1	fruit					646:650	cherry tomato fruit	632:650	cherry tomato fruit (Solanum lycopersicum)	632:673	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	4	78	from	beginning	695:703	arg1	model					680:684	a model	678:684	a model from the beginning of the cell expansion phase to the red ripe stage	678:753	Using cherry tomato fruit (Solanum lycopersicum) as a model from the beginning of the cell expansion phase to the red ripe stage, we designed an experimental scheme combining sample pretreatment, Raman mapping, multivariate data analyses, and biochemical analyses.
36018278	2	79	theme	biological	493:502	arg1	functions					504:512	biological functions	493:512	biological functions	493:512	These functions are associated with the structural features of cuticles, and the architectural modeling of cuticles during plant development is crucial for understanding their physical properties and biological functions.
36018278	0	80	theme	polymer	10:16	arg1	matrix					18:23	The cutin polymer matrix	0:23	The cutin polymer matrix	0:23	The cutin polymer matrix undergoes a fine architectural tuning from early tomato fruit development to ripening.
36018278	1	81	theme	complex	129:135	arg1	cuticle					116:122	The cuticle	112:122	The cuticle	112:122	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	1	81	theme	complex	129:135	arg1	critical					261:268	critical	261:268	critical	261:268	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	1	81	theme	complex	129:135	arg1	matrix					145:150	a complex polymer matrix	127:150	a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development	127:290	The cuticle is a complex polymer matrix that protects all aerial organs of plants, fulfills multiple roles in plant-environment interactions, and is critical for plant development.
36018278	7	82	theme	phenolic	1229:1236	arg1	compounds					1238:1246	phenolic compounds	1229:1246	phenolic compounds (p-coumaric acid and flavonoids)	1229:1279	The specific spatiotemporal accumulation of phenolic compounds (p-coumaric acid and flavonoids) suggests that they fulfill distinct functions during fruit development.
34626388	7	0	theme	disaccharides	1515:1527	arg1	amount					1476:1481	amount	1476:1481	amount	1476:1481	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	7	0	theme	disaccharides	1515:1527	arg1	structure					1487:1495	structure	1487:1495	structure	1487:1495	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	7	0	theme	disaccharides	1515:1527	arg1	disaccharides					1515:1527	acid-resistant disaccharides	1500:1527	acid-resistant disaccharides	1500:1527	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	2	1	theme	quality	368:374	arg1	control					376:382	quality control	368:382	quality control	368:382	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	1	2	theme	GAGs	272:275	arg1	types					263:267	different types	253:267	different types of GAGs	253:275	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	4	3	theme	high	913:916	arg1	chromatography					937:950	high performance liquid chromatography	913:950	high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS)	913:993	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	4	3	theme	high	913:916	arg1	HPLC					953:956	HPLC	953:956	HPLC	953:956	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	3	4	theme	GAG	737:739	arg1	purposes					757:764	GAG quality control purposes	737:764	GAG quality control purposes	737:764	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	3	5	theme	Testing	555:561	arg1	galactosamine					563:575	Testing galactosamine	555:575	Testing galactosamine in heparin	555:586	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	6	6	theme	heparan	1281:1287	arg1	sulfate					1289:1295	heparan sulfate	1281:1295	heparan sulfate	1281:1295	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	1	7	theme	negative	192:199	arg1	charge					201:206	high negative charge	187:206	high negative charge	187:206	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	3	8	theme	control	749:755	arg1	purposes					757:764	GAG quality control purposes	737:764	GAG quality control purposes	737:764	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	5	9	located	found	1012:1016	arg2	Glucosamine					996:1006	Glucosamine	996:1006	Glucosamine	996:1006	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	5	9	located	found	1012:1016	arg1	sulfate					1038:1044	chondroitin sulfate	1026:1044	chondroitin sulfate	1026:1044	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	5	9	located	found	1012:1016	arg1	sulfate					1059:1065	dermatan sulfate	1050:1065	dermatan sulfate	1050:1065	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	5	10	theme	heparan	1110:1116	arg1	sulfate					1118:1124	heparan sulfate	1110:1124	heparan sulfate	1110:1124	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	1	11	theme	thorough	230:237	arg1	separation					239:248	thorough separation	230:248	thorough separation of different types of GAGs	230:275	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	4	12	theme	liquid	930:935	arg1	chromatography					937:950	high performance liquid chromatography	913:950	high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS)	913:993	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	4	12	theme	liquid	930:935	arg1	HPLC					953:956	HPLC	953:956	HPLC	953:956	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	1	13	theme	animal	136:141	arg1	cells					143:147	all animal cells	132:147	all animal cells	132:147	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	6	14	theme	chondroitin	1238:1248	arg1	sulfate					1250:1256	chondroitin sulfate	1238:1256	chondroitin sulfate	1238:1256	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	3	15	theme	contaminated	630:641	arg1	event					651:655	contaminated heparin event	630:655	contaminated heparin event	630:655	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	1	16	theme	molecular	166:174	arg1	weight					176:181	overlapping molecular weight	154:181	overlapping molecular weight	154:181	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	6	17	theme	other	1394:1398	arg1	types					1400:1404	other types	1394:1404	other types of glycans or novel fucosylated GAG structures	1394:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	7	18	theme	hydrolysis	1596:1605	arg1	condition					1607:1615	the same hydrolysis condition	1587:1615	the same hydrolysis condition	1587:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	2	19	theme	many	533:536	arg1	years					538:542	many years	533:542	many years	533:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	4	20	theme	PCR-facilitated	775:789	arg1	assay					802:806	a PCR-facilitated hydrolysis assay	773:806	a PCR-facilitated hydrolysis assay	773:806	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	2	21	theme	sulfate	415:421	arg1	glycosaminoglycans					453:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans	385:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs)	385:477	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	21	theme	sulfate	415:421	arg1	drugs					523:527	modern drugs	516:527	modern drugs for many years	516:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	21	theme	sulfate	415:421	arg1	nutraceuticals					497:510	nutraceuticals	497:510	nutraceuticals	497:510	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	21	theme	sulfate	415:421	arg1	GAGs					473:476	GAGs	473:476	GAGs	473:476	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	0	22	theme	Glycosaminoglycan	0:16	arg1	Control					26:32	Glycosaminoglycan Quality Control	0:32	Glycosaminoglycan Quality Control	0:32	Glycosaminoglycan Quality Control by Monosaccharide Analysis.
34626388	2	23	theme	heparin	445:451	arg1	glycosaminoglycans					453:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans	385:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs)	385:477	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	23	theme	heparin	445:451	arg1	drugs					523:527	modern drugs	516:527	modern drugs for many years	516:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	23	theme	heparin	445:451	arg1	nutraceuticals					497:510	nutraceuticals	497:510	nutraceuticals	497:510	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	23	theme	heparin	445:451	arg1	GAGs					473:476	GAGs	473:476	GAGs	473:476	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	6	24	theme	structures	1442:1451	arg1	types					1400:1404	other types	1394:1404	other types of glycans or novel fucosylated GAG structures	1394:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	1	25	theme	GAG-binding	300:310	arg1	proteins					312:319	all GAG-binding proteins	296:319	all GAG-binding proteins	296:319	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	6	26	located	detected	1226:1233	arg2	fucose					1215:1220	fucose	1215:1220	fucose	1215:1220	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	6	26	located	detected	1226:1233	arg1	sulfate					1289:1295	heparan sulfate	1281:1295	heparan sulfate	1281:1295	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	6	26	located	detected	1226:1233	arg1	sulfate					1250:1256	chondroitin sulfate	1238:1256	chondroitin sulfate	1238:1256	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	6	26	located	detected	1226:1233	arg1	sulfate					1268:1274	dermatan sulfate	1259:1274	dermatan sulfate	1259:1274	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	2	27	theme	heparan	424:430	arg1	sulfate					432:438	heparan sulfate	424:438	heparan sulfate	424:438	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	6	28	theme	fucosylated	1426:1436	arg1	structures					1442:1451	novel fucosylated GAG structures	1420:1451	novel fucosylated GAG structures	1420:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	5	29	theme	different	1180:1188	arg1	types					1190:1194	different types	1180:1194	different types of GAGs	1180:1202	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	0	30	theme	Monosaccharide	37:50	arg1	Analysis					52:59	Monosaccharide Analysis	37:59	Monosaccharide Analysis	37:59	Glycosaminoglycan Quality Control by Monosaccharide Analysis.
34626388	7	31	dep	amount	1476:1481	arg1	the					1472:1474	the	1472:1474	the	1472:1474	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	3	32	theme	composition	689:699	arg1	analysis					701:708	the general monosaccharide composition analysis	662:708	the general monosaccharide composition analysis	662:708	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	2	33	theme	constant	346:353	arg1	challenge					355:363	the constant challenge	342:363	the constant challenge of quality control	342:382	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	34	dep	nutraceuticals	497:510	arg1	worldwide					544:552	worldwide	544:552	worldwide	544:552	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	0	35	dep	Control	26:32	arg1	Analysis					52:59	Monosaccharide Analysis	37:59	Monosaccharide Analysis	37:59	Glycosaminoglycan Quality Control by Monosaccharide Analysis.
34626388	8	36	theme	monosaccharide	1624:1637	arg1	analysis					1639:1646	monosaccharide analysis	1624:1646	monosaccharide analysis	1624:1646	Thus, monosaccharide analysis provides a practical and quantitative way for GAG quality control.
34626388	3	37	theme	general	666:672	arg1	composition					689:699	the general monosaccharide composition	662:699	the general monosaccharide composition analysis	662:708	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	4	38	theme	GAG	824:826	arg1	saccharides					828:838	the hydrolyzed GAG saccharides	809:838	the hydrolyzed GAG saccharides	809:838	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	2	39	theme	chondroitin	385:395	arg1	sulfate					397:403	chondroitin sulfate	385:403	chondroitin sulfate	385:403	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	8	40	theme	quality	1698:1704	arg1	control					1706:1712	GAG quality control	1694:1712	GAG quality control	1694:1712	Thus, monosaccharide analysis provides a practical and quantitative way for GAG quality control.
34626388	1	41	theme	different	253:261	arg1	types					263:267	different types	253:267	different types of GAGs	253:275	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	7	42	theme	acid-resistant	1500:1513	arg1	disaccharides					1515:1527	acid-resistant disaccharides	1500:1527	acid-resistant disaccharides	1500:1527	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	5	43	theme	chondroitin	1026:1036	arg1	sulfate					1038:1044	chondroitin sulfate	1026:1044	chondroitin sulfate	1026:1044	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	2	44	theme	control	376:382	arg1	challenge					355:363	the constant challenge	342:363	the constant challenge of quality control	342:382	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	8	45	theme	practical	1659:1667	arg1	way					1686:1688	a practical and quantitative way	1657:1688	a practical and quantitative way for GAG quality control	1657:1712	Thus, monosaccharide analysis provides a practical and quantitative way for GAG quality control.
34626388	7	46	from	type	1571:1574	arg1	condition					1607:1615	the same hydrolysis condition	1587:1615	the same hydrolysis condition	1587:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	8	47	theme	quantitative	1673:1684	arg1	way					1686:1688	a practical and quantitative way	1657:1688	a practical and quantitative way for GAG quality control	1657:1712	Thus, monosaccharide analysis provides a practical and quantitative way for GAG quality control.
34626388	3	48	theme	quality	741:747	arg1	purposes					757:764	GAG quality control purposes	737:764	GAG quality control purposes	737:764	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	1	49	theme	high	187:190	arg1	charge					201:206	high negative charge	187:206	high negative charge	187:206	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	1	50	theme	charge	201:206	arg1	densities					208:216	overlapping molecular weight and high negative charge densities	154:216	overlapping molecular weight and high negative charge densities	154:216	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	2	51	used	used	489:492	arg2	drugs					523:527	modern drugs	516:527	modern drugs for many years	516:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	51	used	used	489:492	arg2	nutraceuticals					497:510	nutraceuticals	497:510	nutraceuticals	497:510	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	51	used	used	489:492	arg2	GAGs					473:476	GAGs	473:476	GAGs	473:476	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	51	used	used	489:492	arg2	glycosaminoglycans					453:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans	385:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs)	385:477	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	6	52	theme	chondroitin	1343:1353	arg1	sulfate					1355:1361	chondroitin sulfate	1343:1361	chondroitin sulfate	1343:1361	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	5	53	located	observed	1093:1100	arg1	heparin					1130:1136	heparin	1130:1136	heparin	1130:1136	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	5	53	located	observed	1093:1100	arg2	galactosamine					1075:1087	galactosamine	1075:1087	galactosamine	1075:1087	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	5	53	located	observed	1093:1100	arg1	sulfate					1118:1124	heparan sulfate	1110:1124	heparan sulfate	1110:1124	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	6	54	theme	dermatan	1259:1266	arg1	sulfate					1268:1274	dermatan sulfate	1259:1274	dermatan sulfate	1259:1274	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	4	55	theme	performance	918:928	arg1	chromatography					937:950	high performance liquid chromatography	913:950	high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS)	913:993	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	4	55	theme	performance	918:928	arg1	HPLC					953:956	HPLC	953:956	HPLC	953:956	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	3	56	from	galactosamine	563:575	arg1	heparin					580:586	heparin	580:586	heparin	580:586	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	6	57	located	detected	1331:1338	arg2	fucose					1307:1312	fucose	1307:1312	fucose	1307:1312	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	6	57	located	detected	1331:1338	arg1	sulfate					1355:1361	chondroitin sulfate	1343:1361	chondroitin sulfate	1343:1361	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	6	57	located	detected	1331:1338	arg2	mannose					1318:1324	mannose	1318:1324	mannose	1318:1324	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	6	58	theme	glycans	1409:1415	arg1	types					1400:1404	other types	1394:1404	other types of glycans or novel fucosylated GAG structures	1394:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	3	59	theme	USP	610:612	arg1	monograph					614:622	the USP monograph	606:622	the USP monograph	606:622	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	1	60	theme	overlapping	154:164	arg1	weight					176:181	overlapping molecular weight	154:181	overlapping molecular weight	154:181	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	6	61	theme	types	1400:1404	arg1	co-presence					1379:1389	the co-presence	1375:1389	the co-presence of other types of glycans or novel fucosylated GAG structures	1375:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	5	62	theme	cross	1154:1158	arg1	contamination					1160:1172	the cross contamination	1150:1172	the cross contamination among different types of GAGs	1150:1202	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	1	63	theme	weight	176:181	arg1	densities					208:216	overlapping molecular weight and high negative charge densities	154:216	overlapping molecular weight and high negative charge densities	154:216	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	7	64	theme	same	1591:1594	arg1	condition					1607:1615	the same hydrolysis condition	1587:1615	the same hydrolysis condition	1587:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	6	65	gly	fucosylated	1426:1436	arg1	structures					1442:1451	novel fucosylated GAG structures	1420:1451	novel fucosylated GAG structures	1420:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	4	66	theme	mass	972:975	arg1	MS					991:992	MS	991:992	MS	991:992	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	4	66	theme	mass	972:975	arg1	spectrometry					977:988	mass spectrometry	972:988	mass spectrometry (MS)	972:993	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	2	67	theme	modern	516:521	arg1	glycosaminoglycans					453:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans	385:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs)	385:477	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	67	theme	modern	516:521	arg1	drugs					523:527	modern drugs	516:527	modern drugs for many years	516:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	4	68	theme	hydrolysis	791:800	arg1	assay					802:806	a PCR-facilitated hydrolysis assay	773:806	a PCR-facilitated hydrolysis assay	773:806	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	2	69	theme	dermatan	406:413	arg1	sulfate					415:421	dermatan sulfate	406:421	dermatan sulfate	406:421	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	0	70	theme	Quality	18:24	arg1	Control					26:32	Glycosaminoglycan Quality Control	0:32	Glycosaminoglycan Quality Control	0:32	Glycosaminoglycan Quality Control by Monosaccharide Analysis.
34626388	1	71	theme	heterogeneous	92:104	arg1	biomacromolecules					106:122	heterogeneous biomacromolecules	92:122	heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult	92:329	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	1	71	theme	heterogeneous	92:104	arg1	Glycosaminoglycans					62:79	Glycosaminoglycans	62:79	Glycosaminoglycans (GAGs)	62:86	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	2	72	theme	sulfate	397:403	arg1	glycosaminoglycans					453:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans	385:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs)	385:477	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	72	theme	sulfate	397:403	arg1	drugs					523:527	modern drugs	516:527	modern drugs for many years	516:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	72	theme	sulfate	397:403	arg1	nutraceuticals					497:510	nutraceuticals	497:510	nutraceuticals	497:510	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	72	theme	sulfate	397:403	arg1	GAGs					473:476	GAGs	473:476	GAGs	473:476	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	73	theme	sulfate	432:438	arg1	glycosaminoglycans					453:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans	385:470	chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs)	385:477	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	73	theme	sulfate	432:438	arg1	drugs					523:527	modern drugs	516:527	modern drugs for many years	516:542	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	73	theme	sulfate	432:438	arg1	nutraceuticals					497:510	nutraceuticals	497:510	nutraceuticals	497:510	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	2	73	theme	sulfate	432:438	arg1	GAGs					473:476	GAGs	473:476	GAGs	473:476	Even with the constant challenge of quality control, chondroitin sulfate, dermatan sulfate, heparan sulfate, and heparin glycosaminoglycans (GAGs) have been used as nutraceuticals and modern drugs for many years worldwide.
34626388	6	74	theme	GAG	1438:1440	arg1	structures					1442:1451	novel fucosylated GAG structures	1420:1451	novel fucosylated GAG structures	1420:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	1	75	theme	proteins	312:319	arg1	separation					239:248	thorough separation	230:248	thorough separation of different types of GAGs	230:275	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	1	75	theme	proteins	312:319	arg1	elimination					281:291	elimination	281:291	elimination of all GAG-binding proteins	281:319	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	7	76	theme	GAGs	1579:1582	arg1	type					1571:1574	each type	1566:1574	each type of GAGs at the same hydrolysis condition	1566:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	3	77	theme	heparin	643:649	arg1	event					651:655	contaminated heparin event	630:655	contaminated heparin event	630:655	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	6	78	theme	novel	1420:1424	arg1	structures					1442:1451	novel fucosylated GAG structures	1420:1451	novel fucosylated GAG structures	1420:1451	Moreover, fucose was detected in chondroitin sulfate, dermatan sulfate, and heparan sulfate, and both fucose and mannose were detected in chondroitin sulfate, suggesting the co-presence of other types of glycans or novel fucosylated GAG structures.
34626388	7	79	from	condition	1607:1615	arg1	type					1571:1574	each type	1566:1574	each type of GAGs at the same hydrolysis condition	1566:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	7	79	from	condition	1607:1615	arg1	GAGs					1579:1582	GAGs	1579:1582	GAGs at the same hydrolysis condition	1579:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	5	80	theme	dermatan	1050:1057	arg1	sulfate					1059:1065	dermatan sulfate	1050:1065	dermatan sulfate	1050:1065	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	3	81	theme	monosaccharide	674:687	arg1	composition					689:699	the general monosaccharide composition	662:699	the general monosaccharide composition analysis	662:708	Testing galactosamine in heparin has been added to the USP monograph after contaminated heparin event, but the general monosaccharide composition analysis has not been developed for GAG quality control purposes.
34626388	8	82	theme	GAG	1694:1696	arg1	control					1706:1712	GAG quality control	1694:1712	GAG quality control	1694:1712	Thus, monosaccharide analysis provides a practical and quantitative way for GAG quality control.
34626388	5	83	theme	GAGs	1199:1202	arg1	types					1190:1194	different types	1180:1194	different types of GAGs	1180:1202	Glucosamine was found in both chondroitin sulfate and dermatan sulfate whereas galactosamine was observed in both heparan sulfate and heparin, indicating the cross contamination among different types of GAGs.
34626388	7	84	theme	distinguishable	1537:1551	arg1	features					1553:1560	distinguishable features	1537:1560	distinguishable features for each type of GAGs at the same hydrolysis condition	1537:1615	Furthermore, both the amount and structure of acid-resistant disaccharides provide distinguishable features for each type of GAGs at the same hydrolysis condition.
34626388	4	85	theme	hydrolyzed	813:822	arg1	saccharides					828:838	the hydrolyzed GAG saccharides	809:838	the hydrolyzed GAG saccharides	809:838	Using a PCR-facilitated hydrolysis assay, the hydrolyzed GAG saccharides were labeled with 1-phenyl-3-methyl-5-pyrazolone (PMP) and quantified by high performance liquid chromatography (HPLC) coupled with mass spectrometry (MS).
34626388	1	86	theme	types	263:267	arg1	separation					239:248	thorough separation	230:248	thorough separation of different types of GAGs	230:275	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
34626388	1	86	theme	types	263:267	arg1	elimination					281:291	elimination	281:291	elimination of all GAG-binding proteins	281:319	Glycosaminoglycans (GAGs) are heterogeneous biomacromolecules made by all animal cells with overlapping molecular weight and high negative charge densities, which make thorough separation of different types of GAGs and elimination of all GAG-binding proteins difficult.
36099993	0	0	theme	emulsion-based	83:96	arg1	system					107:112	the emulsion-based delivery system	79:112	the emulsion-based delivery system for galangal flavonoids	79:136	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	4	1	theme	low-molecular-weight	627:646	arg1	polysaccharides					660:674	low-molecular-weight pectin-type polysaccharides	627:674	low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose	627:740	GP-HN and GP-UN were prepared by enzymatic-assisted high-temperature and ultrasonic extraction, which were low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose.
36099993	5	2	theme	bile	854:857	arg1	salts					859:863	bile salts	854:863	bile salts	854:863	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	1	3	from	flavonoids	159:168	arg1	rich					151:154	rich	151:154	rich	151:154	Galangal is rich in flavonoids and polysaccharides but underutilized.
36099993	0	4	theme	delivery	98:105	arg1	system					107:112	the emulsion-based delivery system	79:112	the emulsion-based delivery system for galangal flavonoids	79:136	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	1	5	from	rich	151:154	arg1	polysaccharides					174:188	polysaccharides	174:188	polysaccharides	174:188	Galangal is rich in flavonoids and polysaccharides but underutilized.
36099993	1	5	from	rich	151:154	arg1	flavonoids					159:168	flavonoids	159:168	flavonoids	159:168	Galangal is rich in flavonoids and polysaccharides but underutilized.
36099993	4	6	theme	pectin-type	648:658	arg1	polysaccharides					660:674	low-molecular-weight pectin-type polysaccharides	627:674	low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose	627:740	GP-HN and GP-UN were prepared by enzymatic-assisted high-temperature and ultrasonic extraction, which were low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose.
36099993	0	7	theme	galangal	118:125	arg1	flavonoids					127:136	galangal flavonoids	118:136	galangal flavonoids	118:136	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	2	8	theme	delivery	427:434	arg1	system					436:441	the emulsion delivery system	414:441	the emulsion delivery system	414:441	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	5	9	theme	anti-lipid	893:902	arg1	abilities					914:922	anti-lipid digestion abilities	893:922	anti-lipid digestion abilities of GPs	893:929	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	2	10	theme	emulsion	418:425	arg1	system					436:441	the emulsion delivery system	414:441	the emulsion delivery system	414:441	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	5	11	dep	salts	859:863	arg1	abilities					878:886	displacement abilities	865:886	displacement abilities	865:886	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	0	12	theme	Pectin-type	0:10	arg1	polysaccharide					12:25	Pectin-type polysaccharide	0:25	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.	0:137	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	7	13	theme	orderly	1014:1020	arg1	flavonoids					1035:1044	orderly reorganizing flavonoids	1014:1044	orderly reorganizing flavonoids	1014:1044	This study presented a method for orderly reorganizing flavonoids and polysaccharides, guiding for utilization of whole bioactive components in galangal.
36099993	5	14	theme	digestion	904:912	arg1	abilities					914:922	anti-lipid digestion abilities	893:922	anti-lipid digestion abilities of GPs	893:929	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	4	15	theme	ultrasonic	593:602	arg1	extraction					604:613	ultrasonic extraction	593:613	ultrasonic extraction	593:613	GP-HN and GP-UN were prepared by enzymatic-assisted high-temperature and ultrasonic extraction, which were low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose.
36099993	5	16	theme	due	773:775	arg1	emulsifier					762:771	the best emulsifier	753:771	the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs	753:929	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	5	16	theme	due	773:775	arg1	GP-UN					743:747	GP-UN	743:747	GP-UN	743:747	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	7	17	theme	reorganizing	1022:1033	arg1	flavonoids					1035:1044	orderly reorganizing flavonoids	1014:1044	orderly reorganizing flavonoids	1014:1044	This study presented a method for orderly reorganizing flavonoids and polysaccharides, guiding for utilization of whole bioactive components in galangal.
36099993	2	18	dep	flavonoids	233:242	arg1	GP-HN					265:269	GP-HN	265:269	GP-HN	265:269	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	18	dep	flavonoids	233:242	arg1	flavonoids					233:242	galangal flavonoids	224:242	galangal flavonoids	224:242	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	18	dep	flavonoids	233:242	arg1	GP-UN					275:279	GP-UN	275:279	GP-UN	275:279	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	19	theme	segmented	299:307	arg1	extraction					309:318	segmented extraction	299:318	segmented extraction	299:318	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	5	20	theme	GPs	927:929	arg1	properties					816:825	emulsifying properties	804:825	emulsifying properties	804:825	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	5	20	theme	GPs	927:929	arg1	resistance					840:849	interfacial resistance	828:849	interfacial resistance to bile salts displacement abilities	828:886	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	5	20	theme	GPs	927:929	arg1	abilities					914:922	anti-lipid digestion abilities	893:922	anti-lipid digestion abilities of GPs	893:929	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	5	20	theme	GPs	927:929	arg1	activities					792:801	interfacial activities	780:801	interfacial activities	780:801	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	5	21	theme	interfacial	780:790	arg1	activities					792:801	interfacial activities	780:801	interfacial activities	780:801	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	0	22	dep	emulsifier	55:64	arg1	construct					69:77	construct	69:77	to construct the emulsion-based delivery system for galangal flavonoids	66:136	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	5	23	theme	displacement	865:876	arg1	abilities					878:886	displacement abilities	865:886	displacement abilities	865:886	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	4	24	theme	enzymatic-assisted	553:570	arg1	high-temperature					572:587	enzymatic-assisted high-temperature	553:587	enzymatic-assisted high-temperature	553:587	GP-HN and GP-UN were prepared by enzymatic-assisted high-temperature and ultrasonic extraction, which were low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose.
36099993	2	25	theme	determination/structural	351:374	arg1	characterization					376:391	chemical composition determination/structural characterization	330:391	chemical composition determination/structural characterization	330:391	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	0	26	theme	efficient	45:53	arg1	emulsifier					55:64	An efficient emulsifier	42:64	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.	0:137	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	6	27	theme	GP-UN	932:936	arg1	emulsion					938:945	GP-UN emulsion	932:945	GP-UN emulsion	932:945	GP-UN emulsion could stably deliver flavonoids.
36099993	2	28	theme	galangal	224:231	arg1	GP-HN					265:269	GP-HN	265:269	GP-HN	265:269	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	28	theme	galangal	224:231	arg1	flavonoids					233:242	galangal flavonoids	224:242	galangal flavonoids	224:242	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	28	theme	galangal	224:231	arg1	GP-UN					275:279	GP-UN	275:279	GP-UN	275:279	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	7	29	theme	components	1110:1119	arg1	utilization					1079:1089	utilization	1079:1089	utilization of whole bioactive components in galangal	1079:1131	This study presented a method for orderly reorganizing flavonoids and polysaccharides, guiding for utilization of whole bioactive components in galangal.
36099993	2	30	theme	composition	339:349	arg1	characterization					376:391	chemical composition determination/structural characterization	330:391	chemical composition determination/structural characterization	330:391	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	5	31	theme	best	757:760	arg1	emulsifier					762:771	the best emulsifier	753:771	the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs	753:929	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	5	31	theme	best	757:760	arg1	GP-UN					743:747	GP-UN	743:747	GP-UN	743:747	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	2	32	theme	chemical	330:337	arg1	composition					339:349	chemical composition	330:349	chemical composition determination/structural characterization	330:391	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	7	33	theme	whole	1094:1098	arg1	components					1110:1119	whole bioactive components	1094:1119	whole bioactive components	1094:1119	This study presented a method for orderly reorganizing flavonoids and polysaccharides, guiding for utilization of whole bioactive components in galangal.
36099993	3	34	theme	flavonoids	508:517	arg1	%					497:497	71.45 %	491:497	71.45 % of total flavonoids	491:517	The results showed that galangin accounted for 71.45 % of total flavonoids.
36099993	3	34	theme	flavonoids	508:517	arg1	flavonoids					508:517	total flavonoids	502:517	total flavonoids	502:517	The results showed that galangin accounted for 71.45 % of total flavonoids.
36099993	3	35	theme	total	502:506	arg1	flavonoids					508:517	total flavonoids	502:517	total flavonoids	502:517	The results showed that galangin accounted for 71.45 % of total flavonoids.
36099993	5	36	theme	interfacial	828:838	arg1	resistance					840:849	interfacial resistance	828:849	interfacial resistance to bile salts displacement abilities	828:886	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
36099993	0	37	dep	polysaccharide	12:25	arg1	emulsifier					55:64	An efficient emulsifier	42:64	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.	0:137	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	7	38	theme	bioactive	1100:1108	arg1	components					1110:1119	whole bioactive components	1094:1119	whole bioactive components	1094:1119	This study presented a method for orderly reorganizing flavonoids and polysaccharides, guiding for utilization of whole bioactive components in galangal.
36099993	7	39	from	utilization	1079:1089	arg1	galangal					1124:1131	galangal	1124:1131	galangal	1124:1131	This study presented a method for orderly reorganizing flavonoids and polysaccharides, guiding for utilization of whole bioactive components in galangal.
36099993	2	40	used	used	321:324	arg2	GP-UN					275:279	GP-UN	275:279	GP-UN	275:279	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	40	used	used	321:324	arg2	GP-HN					265:269	GP-HN	265:269	GP-HN	265:269	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	2	40	used	used	321:324	arg2	flavonoids					233:242	galangal flavonoids	224:242	galangal flavonoids	224:242	In this study, galangal flavonoids and polysaccharides (GP-HN and GP-UN) were obtained by segmented extraction, used for chemical composition determination/structural characterization, and constructed for the emulsion delivery system.
36099993	4	41	theme	galacturonic	698:709	arg1	acid					711:714	galacturonic acid	698:714	galacturonic acid	698:714	GP-HN and GP-UN were prepared by enzymatic-assisted high-temperature and ultrasonic extraction, which were low-molecular-weight pectin-type polysaccharides mainly constructed by galacturonic acid, galactose, and arabinose.
36099993	0	42	from	galangal	32:39	arg1	polysaccharide					12:25	Pectin-type polysaccharide	0:25	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.	0:137	Pectin-type polysaccharide from galangal: An efficient emulsifier to construct the emulsion-based delivery system for galangal flavonoids.
36099993	1	43	from	polysaccharides	174:188	arg1	rich					151:154	rich	151:154	rich	151:154	Galangal is rich in flavonoids and polysaccharides but underutilized.
36099993	5	44	theme	emulsifying	804:814	arg1	properties					816:825	emulsifying properties	804:825	emulsifying properties	804:825	GP-UN was the best emulsifier due to interfacial activities, emulsifying properties, interfacial resistance to bile salts displacement abilities, and anti-lipid digestion abilities of GPs.
37093892	4	0	theme	chronic	564:570	arg1	infection					572:580	a chronic infection	562:580	a chronic infection successfully controlled by the human immune system	562:631	Thus, SFVs represent a model of zoonotic retroviruses that lead to a chronic infection successfully controlled by the human immune system.
37093892	6	1	theme	binding	862:868	arg1	domain					870:875	the receptor binding domain	849:875	the receptor binding domain (RBD)	849:881	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	6	1	theme	binding	862:868	arg1	RBD					878:880	RBD	878:880	RBD	878:880	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	16	2	theme	viruses	2304:2310	arg1	inhibition					2290:2299	the inhibition	2286:2299	the inhibition of viruses by nAbs	2286:2318	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	16	3	from	RBDs	2213:2216	arg1	RBD					2161:2163	the SFV RBD	2153:2163	the SFV RBD	2153:2163	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	16	3	from	RBDs	2213:2216	arg1	different					2181:2189	different	2181:2189	different	2181:2189	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	5	4	theme	infected	660:667	arg1	humans					669:674	infected humans	660:674	infected humans	660:674	We previously showed that infected humans develop potent neutralizing antibodies (nAbs).
37093892	13	5	theme	different	1857:1865	arg1	epitopes					1867:1874	different epitopes	1857:1874	different epitopes	1857:1874	We provide information on how nAbs specific for each of the two viral genotypes target different epitopes.
37093892	9	6	theme	SU	1157:1158	arg1	presence					1133:1140	the presence	1129:1140	the presence of recombinant SU that compete with SU at the surface of viral vector particles	1129:1220	Neutralization assays were carried out in the presence of recombinant SU that compete with SU at the surface of viral vector particles.
37093892	1	7	theme	significant	195:205	arg1	threat					207:212	a significant threat	193:212	a significant threat to human populations	193:233	Infection with viruses of animal origin pose a significant threat to human populations.
37093892	0	8	theme	foamy	135:139	arg1	virus					141:145	simian foamy virus	128:145	simian foamy virus	128:145	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	2	9	theme	foamy	243:247	arg1	SFVs					258:261	SFVs	258:261	SFVs	258:261	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	2	9	theme	foamy	243:247	arg1	viruses					249:255	Simian foamy viruses	236:255	Simian foamy viruses (SFVs)	236:262	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	15	10	theme	neutralization	2016:2029	arg1	mechanisms					2031:2040	the neutralization mechanisms	2012:2040	the neutralization mechanisms	2012:2040	We propose a model according to which the neutralization mechanisms rely on the nAbs to block the Env conformational change and/or interfere with binding to susceptible cells.
37093892	8	11	from	present	1005:1011	arg1	samples					1023:1029	plasma samples	1016:1029	plasma samples from SFV-infected individuals living in Central Africa	1016:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	9	12	theme	recombinant	1145:1155	arg1	SU					1157:1158	recombinant SU	1145:1158	recombinant SU that compete with SU at the surface of viral vector particles	1145:1220	Neutralization assays were carried out in the presence of recombinant SU that compete with SU at the surface of viral vector particles.
37093892	13	13	theme	specific	1805:1812	arg1	nAbs					1800:1803	nAbs	1800:1803	nAbs specific for each of the two viral genotypes	1800:1848	We provide information on how nAbs specific for each of the two viral genotypes target different epitopes.
37093892	5	14	theme	neutralizing	691:702	arg1	nAbs					716:719	nAbs	716:719	nAbs	716:719	We previously showed that infected humans develop potent neutralizing antibodies (nAbs).
37093892	5	14	theme	neutralizing	691:702	arg1	antibodies					704:713	potent neutralizing antibodies	684:713	potent neutralizing antibodies (nAbs)	684:720	We previously showed that infected humans develop potent neutralizing antibodies (nAbs).
37093892	0	15	theme	Genotype-specific	61:77	arg1	epitopes					79:86	Genotype-specific epitopes	61:86	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.	0:146	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	9	16	theme	vector	1205:1210	arg1	particles					1212:1220	viral vector particles	1199:1220	viral vector particles	1199:1220	Neutralization assays were carried out in the presence of recombinant SU that compete with SU at the surface of viral vector particles.
37093892	15	17	theme	conformational	2076:2089	arg1	change					2091:2096	the Env conformational change	2068:2096	the Env conformational change	2068:2096	We propose a model according to which the neutralization mechanisms rely on the nAbs to block the Env conformational change and/or interfere with binding to susceptible cells.
37093892	12	18	theme	major	1506:1510	arg1	regions					1521:1527	three major epitopic regions	1500:1527	three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8	1500:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	12	19	from	apex	1547:1550	arg1	loops					1534:1538	the loops	1530:1538	three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8	1500:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	1	20	theme	animal	174:179	arg1	origin					181:186	animal origin	174:186	animal origin	174:186	Infection with viruses of animal origin pose a significant threat to human populations.
37093892	8	21	from	individuals	1049:1059	arg1	samples					1023:1029	plasma samples	1016:1029	plasma samples from SFV-infected individuals living in Central Africa	1016:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	11	22	theme	conformational	1461:1474	arg1	epitopes					1476:1483	conformational epitopes	1461:1483	conformational epitopes	1461:1483	We observed that nAbs target conformational epitopes.
37093892	16	23	theme	retroviral	2202:2211	arg1	RBDs					2213:2216	known retroviral RBDs	2196:2216	known retroviral RBDs	2196:2216	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	0	24	theme	receptor-binding	99:114	arg1	domain					116:121	the receptor-binding domain	95:121	the receptor-binding domain from simian foamy virus	95:145	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	6	25	theme	nAbs	915:918	arg1	target					905:910	the exclusive target	891:910	the exclusive target of nAbs	891:918	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	1	26	with	Infection	148:156	arg1	viruses					163:169	viruses	163:169	viruses of animal origin	163:186	Infection with viruses of animal origin pose a significant threat to human populations.
37093892	14	27	theme	escape	1895:1900	arg1	mechanisms					1902:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	27	theme	escape	1895:1900	arg1	variation					1923:1931	sequence variation	1914:1931	sequence variation	1914:1931	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	27	theme	escape	1895:1900	arg1	shielding					1944:1952	glycan shielding	1937:1952	glycan shielding	1937:1952	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	2	28	theme	replication-competent	373:393	arg1	virus					395:399	replication-competent virus	373:399	replication-competent virus	373:399	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	14	29	theme	common	1881:1886	arg1	mechanisms					1902:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	29	theme	common	1881:1886	arg1	variation					1923:1931	sequence variation	1914:1931	sequence variation	1914:1931	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	29	theme	common	1881:1886	arg1	shielding					1944:1952	glycan shielding	1937:1952	glycan shielding	1937:1952	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	12	30	theme	RBD	1559:1561	arg1	apex					1547:1550	the apex	1543:1550	the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8	1543:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	12	31	from	vicinity	1663:1670	arg1	located					1648:1654	located	1648:1654	located	1648:1654	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	4	32	theme	retroviruses	536:547	arg1	model					518:522	a model	516:522	a model of zoonotic retroviruses that lead to a chronic infection successfully controlled by the human immune system	516:631	Thus, SFVs represent a model of zoonotic retroviruses that lead to a chronic infection successfully controlled by the human immune system.
37093892	0	33	theme	zoonotic	18:25	arg1	retroviruses					27:38	zoonotic retroviruses	18:38	zoonotic retroviruses	18:38	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	12	34	theme	site	1761:1764	arg1	N8					1766:1767	the highly conserved glycosylation site N8	1726:1767	the highly conserved glycosylation site N8	1726:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	3	35	theme	zoonotic	411:418	arg1	SFVs					420:423	zoonotic SFVs	411:423	zoonotic SFVs	411:423	However, zoonotic SFVs do not induce severe disease nor are they transmitted between humans.
37093892	10	36	theme	epitopes	1422:1429	arg1	properties					1401:1410	properties	1401:1410	properties of B-cell epitopes	1401:1429	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	12	37	gly	glycosylation	1747:1759	arg2	N8					1766:1767	the highly conserved glycosylation site N8	1726:1767	the highly conserved glycosylation site N8	1726:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	12	37	gly	glycosylation	1747:1759	arg2	site					1761:1764	the highly conserved glycosylation site N8	1726:1767	the highly conserved glycosylation site N8	1726:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	15	38	theme	susceptible	2131:2141	arg1	cells					2143:2147	susceptible cells	2131:2147	susceptible cells	2131:2147	We propose a model according to which the neutralization mechanisms rely on the nAbs to block the Env conformational change and/or interfere with binding to susceptible cells.
37093892	8	39	theme	plasma	1016:1021	arg1	samples					1023:1029	plasma samples	1016:1029	plasma samples from SFV-infected individuals living in Central Africa	1016:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	2	40	with	infection	338:346	arg1	persistence					358:368	the persistence	354:368	the persistence of replication-competent virus	354:399	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	16	41	theme	structural	2265:2274	arg1	basis					2276:2280	the structural basis	2261:2280	the structural basis for the inhibition of viruses by nAbs	2261:2318	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	15	42	theme	according	1993:2001	arg1	model					1987:1991	a model according	1985:2001	a model according to which the neutralization mechanisms rely on the nAbs to block the Env conformational change and/or interfere with binding to susceptible cells	1985:2147	We propose a model according to which the neutralization mechanisms rely on the nAbs to block the Env conformational change and/or interfere with binding to susceptible cells.
37093892	12	43	theme	conserved	1737:1745	arg1	N8					1766:1767	the highly conserved glycosylation site N8	1726:1767	the highly conserved glycosylation site N8	1726:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	6	44	theme	variable	791:798	arg1	region					800:805	a variable region	789:805	a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs	789:918	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	12	45	theme	site	1695:1698	arg1	vicinity					1663:1670	the vicinity	1659:1670	the vicinity of the heparan binding site	1659:1698	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	0	46	dep	Neutralization	0:13	arg1	epitopes					79:86	Genotype-specific epitopes	61:86	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.	0:146	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	10	47	theme	mutant	1273:1278	arg1	proteins					1283:1290	mutant SU proteins	1273:1290	mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes	1273:1429	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	12	48	dep	regions	1521:1527	arg1	loops					1534:1538	the loops	1530:1538	three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8	1500:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	10	49	theme	glycosylation	1308:1320	arg1	sites					1322:1326	the glycosylation sites	1304:1326	the glycosylation sites	1304:1326	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	6	50	theme	receptor	853:860	arg1	domain					870:875	the receptor binding domain	849:875	the receptor binding domain (RBD)	849:881	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	6	50	theme	receptor	853:860	arg1	RBD					878:880	RBD	878:880	RBD	878:880	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	17	51	dep	registration	2327:2338	arg1	registered					2355:2364	registered	2355:2364	was registered at www.clinicaltrials.gov	2351:2390	Trial registration: The study was registered at www.clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03225794/.
37093892	17	51	dep	registration	2327:2338	arg1	//clinicaltrials.gov/ct2/show/NCT03225794/					2399:2440	//clinicaltrials.gov/ct2/show/NCT03225794/	2399:2440	//clinicaltrials.gov/ct2/show/NCT03225794/	2399:2440	Trial registration: The study was registered at www.clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03225794/.
37093892	17	51	dep	registration	2327:2338	arg1	https					2393:2397	https	2393:2397	Trial registration: The study was registered at www.clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03225794/.	2321:2441	Trial registration: The study was registered at www.clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03225794/.
37093892	12	52	theme	heparan	1679:1685	arg1	site					1695:1698	the heparan binding site	1675:1698	the heparan binding site	1675:1698	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	1	53	theme	origin	181:186	arg1	viruses					163:169	viruses	163:169	viruses of animal origin	163:186	Infection with viruses of animal origin pose a significant threat to human populations.
37093892	6	54	theme	surface	760:766	arg1	SU					777:778	SU	777:778	SU	777:778	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	6	54	theme	surface	760:766	arg1	protein					768:774	the surface protein	756:774	the surface protein (SU)	756:779	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	12	55	theme	located	1648:1654	arg1	loop					1643:1646	a loop	1641:1646	a loop located in the vicinity of the heparan binding site	1641:1698	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	17	56	theme	Trial	2321:2325	arg1	registration					2327:2338	Trial registration	2321:2338	Trial registration: The study was registered at www.clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03225794/.	2321:2441	Trial registration: The study was registered at www.clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03225794/.
37093892	10	57	theme	functional	1333:1342	arg1	subregions					1344:1353	RBD functional subregions	1329:1353	RBD functional subregions	1329:1353	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	10	58	theme	RBD	1329:1331	arg1	subregions					1344:1353	RBD functional subregions	1329:1353	RBD functional subregions	1329:1353	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	13	59	theme	viral	1834:1838	arg1	genotypes					1840:1848	the two viral genotypes	1826:1848	the two viral genotypes	1826:1848	We provide information on how nAbs specific for each of the two viral genotypes target different epitopes.
37093892	6	60	theme	exclusive	895:903	arg1	target					905:910	the exclusive target	891:910	the exclusive target of nAbs	891:918	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	4	61	theme	immune	619:624	arg1	system					626:631	the human immune system	609:631	the human immune system	609:631	Thus, SFVs represent a model of zoonotic retroviruses that lead to a chronic infection successfully controlled by the human immune system.
37093892	8	62	theme	present	1005:1011	arg1	nAbs					1000:1003	nAbs	1000:1003	nAbs present in plasma samples from SFV-infected individuals living in Central Africa	1000:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	1	63	theme	human	217:221	arg1	populations					223:233	human populations	217:233	human populations	217:233	Infection with viruses of animal origin pose a significant threat to human populations.
37093892	2	64	theme	Simian	236:241	arg1	SFVs					258:261	SFVs	258:261	SFVs	258:261	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	2	64	theme	Simian	236:241	arg1	viruses					249:255	Simian foamy viruses	236:255	Simian foamy viruses (SFVs)	236:262	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	5	65	theme	potent	684:689	arg1	nAbs					716:719	nAbs	716:719	nAbs	716:719	We previously showed that infected humans develop potent neutralizing antibodies (nAbs).
37093892	5	65	theme	potent	684:689	arg1	antibodies					704:713	potent neutralizing antibodies	684:713	potent neutralizing antibodies (nAbs)	684:720	We previously showed that infected humans develop potent neutralizing antibodies (nAbs).
37093892	7	66	theme	antigenic	934:942	arg1	determinants					944:955	its antigenic determinants	930:955	its antigenic determinants	930:955	However, its antigenic determinants are not understood.
37093892	12	67	theme	Env	1628:1630	arg1	trimers					1632:1638	Env trimers	1628:1638	Env trimers	1628:1638	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	8	68	from	samples	1023:1029	arg1	present					1005:1011	present	1005:1011	present	1005:1011	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	9	69	theme	viral	1199:1203	arg1	particles					1212:1220	viral vector particles	1199:1220	viral vector particles	1199:1220	Neutralization assays were carried out in the presence of recombinant SU that compete with SU at the surface of viral vector particles.
37093892	15	70	theme	Env	2072:2074	arg1	change					2091:2096	the Env conformational change	2068:2096	the Env conformational change	2068:2096	We propose a model according to which the neutralization mechanisms rely on the nAbs to block the Env conformational change and/or interfere with binding to susceptible cells.
37093892	12	71	theme	epitopic	1512:1519	arg1	regions					1521:1527	three major epitopic regions	1500:1527	three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8	1500:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	16	72	theme	known	2196:2200	arg1	RBDs					2213:2216	known retroviral RBDs	2196:2216	known retroviral RBDs	2196:2216	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	9	73	theme	particles	1212:1220	arg1	surface					1188:1194	the surface	1184:1194	the surface of viral vector particles	1184:1220	Neutralization assays were carried out in the presence of recombinant SU that compete with SU at the surface of viral vector particles.
37093892	16	74	from	knowledge	2248:2256	arg1	basis					2276:2280	the structural basis	2261:2280	the structural basis for the inhibition of viruses by nAbs	2261:2318	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	12	75	theme	Env	1606:1608	arg1	protomers					1610:1618	Env protomers	1606:1618	Env protomers to form Env trimers	1606:1638	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	6	76	contain	carries	781:787	arg1	SU					777:778	SU	777:778	SU	777:778	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	6	76	contain	carries	781:787	arg1	protein					768:774	the surface protein	756:774	the surface protein (SU)	756:779	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	6	76	contain	carries	781:787	arg2	region					800:805	a variable region	789:805	a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs	789:918	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	10	77	theme	genotype-specific	1360:1376	arg1	sequences					1378:1386	genotype-specific sequences	1360:1386	genotype-specific sequences	1360:1386	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	14	78	theme	sequence	1914:1921	arg1	mechanisms					1902:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	78	theme	sequence	1914:1921	arg1	variation					1923:1931	sequence variation	1914:1931	sequence variation	1914:1931	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	6	79	theme	viral	734:738	arg1	Env					750:752	Env	750:752	Env	750:752	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	6	79	theme	viral	734:738	arg1	envelope					740:747	the viral envelope	730:747	the viral envelope (Env)	730:753	Within the viral envelope (Env), the surface protein (SU) carries a variable region that defines two genotypes, overlaps with the receptor binding domain (RBD), and is the exclusive target of nAbs.
37093892	0	80	theme	simian	128:133	arg1	virus					141:145	simian foamy virus	128:145	simian foamy virus	128:145	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	2	81	theme	virus	395:399	arg1	persistence					358:368	the persistence	354:368	the persistence of replication-competent virus	354:399	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	14	82	theme	immune	1888:1893	arg1	mechanisms					1902:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	82	theme	immune	1888:1893	arg1	variation					1923:1931	sequence variation	1914:1931	sequence variation	1914:1931	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	82	theme	immune	1888:1893	arg1	shielding					1944:1952	glycan shielding	1937:1952	glycan shielding	1937:1952	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	16	83	theme	fundamental	2236:2246	arg1	knowledge					2248:2256	fundamental knowledge	2236:2256	fundamental knowledge on the structural basis for the inhibition of viruses by nAbs	2236:2318	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	0	84	theme	retroviruses	27:38	arg1	Neutralization					0:13	Neutralization	0:13	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.	0:146	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	16	85	theme	SFV	2157:2159	arg1	RBD					2161:2163	the SFV RBD	2153:2163	the SFV RBD	2153:2163	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	16	85	theme	SFV	2157:2159	arg1	different					2181:2189	different	2181:2189	different	2181:2189	As the SFV RBD is structurally different from known retroviral RBDs, our data provide fundamental knowledge on the structural basis for the inhibition of viruses by nAbs.
37093892	0	86	theme	human	43:47	arg1	antibodies					49:58	human antibodies	43:58	human antibodies	43:58	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	12	87	from	located	1648:1654	arg1	vicinity					1663:1670	the vicinity	1659:1670	the vicinity of the heparan binding site	1659:1698	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	10	88	theme	B-cell	1415:1420	arg1	epitopes					1422:1429	B-cell epitopes	1415:1429	B-cell epitopes	1415:1429	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	0	89	from	virus	141:145	arg1	domain					116:121	the receptor-binding domain	95:121	the receptor-binding domain from simian foamy virus	95:145	Neutralization of zoonotic retroviruses by human antibodies: Genotype-specific epitopes within the receptor-binding domain from simian foamy virus.
37093892	8	90	theme	SFV-infected	1036:1047	arg1	individuals					1049:1059	SFV-infected individuals	1036:1059	SFV-infected individuals living in Central Africa	1036:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	8	91	attach	present	1005:1011	arg2	nAbs					1000:1003	nAbs	1000:1003	nAbs present in plasma samples from SFV-infected individuals living in Central Africa	1000:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	8	91	attach	present	1005:1011	arg1	samples					1023:1029	plasma samples	1016:1029	plasma samples from SFV-infected individuals living in Central Africa	1016:1084	Here, we characterized nAbs present in plasma samples from SFV-infected individuals living in Central Africa.
37093892	4	92	theme	zoonotic	527:534	arg1	retroviruses					536:547	zoonotic retroviruses	527:547	zoonotic retroviruses	527:547	Thus, SFVs represent a model of zoonotic retroviruses that lead to a chronic infection successfully controlled by the human immune system.
37093892	14	93	theme	glycan	1937:1942	arg1	mechanisms					1902:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms	1877:1911	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	14	93	theme	glycan	1937:1942	arg1	shielding					1944:1952	glycan shielding	1937:1952	glycan shielding	1937:1952	Two common immune escape mechanisms, sequence variation and glycan shielding, were not observed.
37093892	10	94	gly	glycosylation	1308:1320	arg2	sites					1322:1326	the glycosylation sites	1304:1326	the glycosylation sites	1304:1326	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37093892	2	95	theme	life-long	328:336	arg1	infection					338:346	a life-long infection	326:346	a life-long infection	326:346	Simian foamy viruses (SFVs) are frequently transmitted to humans, in which they establish a life-long infection, with the persistence of replication-competent virus.
37093892	12	96	theme	glycosylation	1747:1759	arg1	N8					1766:1767	the highly conserved glycosylation site N8	1726:1767	the highly conserved glycosylation site N8	1726:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	12	97	theme	proximal	1714:1721	arg1	region					1707:1712	a region	1705:1712	a region proximal to the highly conserved glycosylation site N8	1705:1767	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	9	98	theme	Neutralization	1087:1100	arg1	assays					1102:1107	Neutralization assays	1087:1107	Neutralization assays	1087:1107	Neutralization assays were carried out in the presence of recombinant SU that compete with SU at the surface of viral vector particles.
37093892	12	99	theme	binding	1687:1693	arg1	site					1695:1698	the heparan binding site	1675:1698	the heparan binding site	1675:1698	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	12	100	dep	protomers	1610:1618	arg1	form					1623:1626	form	1623:1626	to form Env trimers	1620:1638	We identified three major epitopic regions: the loops at the apex of the RBD, which likely mediate interactions between Env protomers to form Env trimers, a loop located in the vicinity of the heparan binding site, and a region proximal to the highly conserved glycosylation site N8.
37093892	3	101	theme	severe	439:444	arg1	disease					446:452	severe disease	439:452	severe disease	439:452	However, zoonotic SFVs do not induce severe disease nor are they transmitted between humans.
37093892	4	102	theme	human	613:617	arg1	system					626:631	the human immune system	609:631	the human immune system	609:631	Thus, SFVs represent a model of zoonotic retroviruses that lead to a chronic infection successfully controlled by the human immune system.
37093892	10	103	theme	SU	1280:1281	arg1	proteins					1283:1290	mutant SU proteins	1273:1290	mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes	1273:1429	We defined the regions targeted by the nAbs using mutant SU proteins modified at the glycosylation sites, RBD functional subregions, and genotype-specific sequences that present properties of B-cell epitopes.
37271268	6	0	theme	anti-proliferation	917:934	arg1	effects					936:942	anti-proliferation effects	917:942	anti-proliferation effects on A375 cells, but not on HepG2 cells	917:980	Both LNP-1 and LNP-2 exhibited anti-proliferation effects on A375 cells, but not on HepG2 cells.
37271268	7	1	theme	cellular	1016:1023	arg1	CAA					1047:1049	CAA	1047:1049	CAA	1047:1049	Furthermore, LNP-2 showed better cellular antioxidant activity (CAA) than LNP-1.
37271268	7	1	theme	cellular	1016:1023	arg1	activity					1037:1044	cellular antioxidant activity	1016:1044	cellular antioxidant activity (CAA)	1016:1050	Furthermore, LNP-2 showed better cellular antioxidant activity (CAA) than LNP-1.
37271268	3	2	from	glucose	538:544	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	0	3	theme	Cell	113:116	arg1	activities					164:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	4	from	Structure	0:8	arg1	nuda					107:110	nuda	107:110	nuda	107:110	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	3	5	theme	molar	566:570	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	3	6	theme	1.00:2.42:1.09:4.04	581:599	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	1	7	theme	biological	296:305	arg1	activities					307:316	biological activities	296:316	biological activities	296:316	Polysaccharides LNP-1 and LNP-2 were extracted and purified from Lepista nuda, and their structural characteristics and biological activities were evaluated.
37271268	6	8	theme	A375	947:950	arg1	cells					952:956	A375 cells	947:956	A375 cells	947:956	Both LNP-1 and LNP-2 exhibited anti-proliferation effects on A375 cells, but not on HepG2 cells.
37271268	8	9	theme	RT-PCR	1064:1069	arg1	results					1071:1077	RT-PCR results	1064:1077	RT-PCR results	1064:1077	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	9	10	theme	polysaccharides	1348:1362	arg1	relationship					1332:1343	the structure-function relationship	1309:1343	the structure-function relationship of polysaccharides from L. nuda	1309:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	3	11	from	galactose	551:559	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	0	12	theme	antioxidant	118:128	arg1	activities					164:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	9	13	theme	relationship	1332:1343	arg1	development					1294:1304	the further development	1282:1304	the further development of the structure-function relationship of polysaccharides from L. nuda	1282:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	3	14	from	fucose	521:526	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	5	15	theme	glycosidic	843:852	arg1	linkage					854:860	an additional 1,4-Glc glycosidic linkage	821:860	an additional 1,4-Glc glycosidic linkage	821:860	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	0	16	from	activities	42:51	arg1	nuda					107:110	nuda	107:110	nuda	107:110	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	9	17	from	nuda	1372:1375	arg1	polysaccharides					1348:1362	polysaccharides	1348:1362	polysaccharides from L. nuda	1348:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	9	17	from	nuda	1372:1375	arg1	relationship					1332:1343	the structure-function relationship	1309:1343	the structure-function relationship of polysaccharides from L. nuda	1309:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	2	18	theme	LNP-1	359:363	arg1	weights					348:354	The molecular weights	334:354	The molecular weights of LNP-1 and LNP-2	334:373	The molecular weights of LNP-1 and LNP-2 were determined to be 16,263 Da and 17,730 Da, respectively.
37271268	2	18	theme	LNP-1	359:363	arg1	16,263 Da					397:405	16,263 Da	397:405	16,263 Da	397:405	The molecular weights of LNP-1 and LNP-2 were determined to be 16,263 Da and 17,730 Da, respectively.
37271268	9	19	theme	structure-function	1313:1330	arg1	relationship					1332:1343	the structure-function relationship	1309:1343	the structure-function relationship of polysaccharides from L. nuda	1309:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	3	20	from	mannose	529:535	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	3	21	theme	1.00:2.39:1.61:4.23	605:623	arg1	ratio					572:576	a molar ratio	564:576	a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively	564:637	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	0	22	theme	biological	31:40	arg1	activities					42:51	biological activities	31:51	biological activities	31:51	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	8	23	dep	factors	1164:1170	arg1	IL-6					1176:1179	IL-6	1176:1179	IL-6	1176:1179	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	8	23	dep	factors	1164:1170	arg1	TNF-α					1186:1190	TNF-α	1186:1190	TNF-α	1186:1190	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	8	23	dep	factors	1164:1170	arg1	NO					1172:1173	NO	1172:1173	NO	1172:1173	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	8	23	dep	factors	1164:1170	arg1	factors					1164:1170	immune-modulatory factors	1146:1170	immune-modulatory factors NO, IL-6, and TNF-α	1146:1190	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	0	24	theme	anticancer	131:140	arg1	activities					164:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	25	from	nuda	107:110	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	25	from	nuda	107:110	arg1	hetero-polysaccharides					71:92	two hetero-polysaccharides	67:92	two hetero-polysaccharides from Lepista nuda	67:110	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	25	from	nuda	107:110	arg1	activities					42:51	biological activities	31:51	biological activities	31:51	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	2	26	theme	molecular	338:346	arg1	weights					348:354	The molecular weights	334:354	The molecular weights of LNP-1 and LNP-2	334:373	The molecular weights of LNP-1 and LNP-2 were determined to be 16,263 Da and 17,730 Da, respectively.
37271268	2	26	theme	molecular	338:346	arg1	16,263 Da					397:405	16,263 Da	397:405	16,263 Da	397:405	The molecular weights of LNP-1 and LNP-2 were determined to be 16,263 Da and 17,730 Da, respectively.
37271268	3	27	theme	composition	455:465	arg1	analysis					467:474	The monosaccharide composition analysis	436:474	The monosaccharide composition analysis	436:474	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	9	28	from	relationship	1332:1343	arg1	nuda					1372:1375	nuda	1372:1375	nuda	1372:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	0	29	theme	immune-modulatory	146:162	arg1	activities					164:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Cell antioxidant, anticancer and immune-modulatory activities	113:173	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	9	30	theme	theoretical	1260:1270	arg1	basis					1272:1276	a theoretical basis	1258:1276	a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda	1258:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	5	31	theme	additional	824:833	arg1	linkage					854:860	an additional 1,4-Glc glycosidic linkage	821:860	an additional 1,4-Glc glycosidic linkage	821:860	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	6	32	from	effects	936:942	arg1	cells					976:980	HepG2 cells	970:980	HepG2 cells	970:980	Both LNP-1 and LNP-2 exhibited anti-proliferation effects on A375 cells, but not on HepG2 cells.
37271268	6	32	from	effects	936:942	arg1	cells					952:956	A375 cells	947:956	A375 cells	947:956	Both LNP-1 and LNP-2 exhibited anti-proliferation effects on A375 cells, but not on HepG2 cells.
37271268	5	33	theme	1,4-Glc	835:841	arg1	linkage					854:860	an additional 1,4-Glc glycosidic linkage	821:860	an additional 1,4-Glc glycosidic linkage	821:860	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	4	34	theme	1,6-Glc	748:754	arg1	1,6-Gal					756:762	1,6-Glc 1,6-Gal	748:762	1,6-Glc 1,6-Gal	748:762	The structure analysis revealed that these two polysaccharides were mainly composed of T-Fuc, T-Man, T-Glc, 1,6-Glc 1,6-Gal, and 1,2,6-Man, 1,2,6-Gal.
37271268	3	35	theme	monosaccharide	440:453	arg1	analysis					467:474	The monosaccharide composition analysis	436:474	The monosaccharide composition analysis	436:474	The monosaccharide composition analysis showed that LNP-1 and LNP-2 were composed of fucose, mannose, glucose, and galactose in a molar ratio of 1.00:2.42:1.09:4.04 and 1.00:2.39:1.61:4.23, respectively.
37271268	6	36	theme	HepG2	970:974	arg1	cells					976:980	HepG2 cells	970:980	HepG2 cells	970:980	Both LNP-1 and LNP-2 exhibited anti-proliferation effects on A375 cells, but not on HepG2 cells.
37271268	1	37	dep	Polysaccharides	176:190	arg1	Polysaccharides					176:190	Polysaccharides LNP-1 and LNP-2	176:206	Polysaccharides LNP-1 and LNP-2	176:206	Polysaccharides LNP-1 and LNP-2 were extracted and purified from Lepista nuda, and their structural characteristics and biological activities were evaluated.
37271268	1	37	dep	Polysaccharides	176:190	arg1	LNP-2					202:206	LNP-2	202:206	LNP-2	202:206	Polysaccharides LNP-1 and LNP-2 were extracted and purified from Lepista nuda, and their structural characteristics and biological activities were evaluated.
37271268	1	37	dep	Polysaccharides	176:190	arg1	LNP-1					192:196	LNP-1	192:196	LNP-1	192:196	Polysaccharides LNP-1 and LNP-2 were extracted and purified from Lepista nuda, and their structural characteristics and biological activities were evaluated.
37271268	2	38	theme	LNP-2	369:373	arg1	weights					348:354	The molecular weights	334:354	The molecular weights of LNP-1 and LNP-2	334:373	The molecular weights of LNP-1 and LNP-2 were determined to be 16,263 Da and 17,730 Da, respectively.
37271268	2	38	theme	LNP-2	369:373	arg1	16,263 Da					397:405	16,263 Da	397:405	16,263 Da	397:405	The molecular weights of LNP-1 and LNP-2 were determined to be 16,263 Da and 17,730 Da, respectively.
37271268	8	39	theme	immune-modulatory	1146:1162	arg1	IL-6					1176:1179	IL-6	1176:1179	IL-6	1176:1179	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	8	39	theme	immune-modulatory	1146:1162	arg1	TNF-α					1186:1190	TNF-α	1186:1190	TNF-α	1186:1190	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	8	39	theme	immune-modulatory	1146:1162	arg1	NO					1172:1173	NO	1172:1173	NO	1172:1173	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	8	39	theme	immune-modulatory	1146:1162	arg1	factors					1164:1170	immune-modulatory factors	1146:1170	immune-modulatory factors NO, IL-6, and TNF-α	1146:1190	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	9	40	theme	further	1286:1292	arg1	development					1294:1304	the further development	1282:1304	the further development of the structure-function relationship of polysaccharides from L. nuda	1282:1375	Overall, this study provides a theoretical basis for the further development of the structure-function relationship of polysaccharides from L. nuda.
37271268	7	41	theme	antioxidant	1025:1035	arg1	CAA					1047:1049	CAA	1047:1049	CAA	1047:1049	Furthermore, LNP-2 showed better cellular antioxidant activity (CAA) than LNP-1.
37271268	7	41	theme	antioxidant	1025:1035	arg1	activity					1037:1044	cellular antioxidant activity	1016:1044	cellular antioxidant activity (CAA)	1016:1050	Furthermore, LNP-2 showed better cellular antioxidant activity (CAA) than LNP-1.
37271268	4	42	theme	structure	644:652	arg1	analysis					654:661	The structure analysis	640:661	The structure analysis	640:661	The structure analysis revealed that these two polysaccharides were mainly composed of T-Fuc, T-Man, T-Glc, 1,6-Glc 1,6-Gal, and 1,2,6-Man, 1,2,6-Gal.
37271268	5	43	contain	contained	811:819	arg2	LNP-2					805:809	LNP-2	805:809	LNP-2	805:809	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	5	43	contain	contained	811:819	arg2	linkage					854:860	an additional 1,4-Glc glycosidic linkage	821:860	an additional 1,4-Glc glycosidic linkage	821:860	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	5	43	contain	contained	811:819	arg1	comparison					865:874	comparison	865:874	comparison to LNP-1	865:883	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	5	43	contain	contained	811:819	arg1	LNP-2					805:809	LNP-2	805:809	LNP-2	805:809	Additionally, LNP-2 contained an additional 1,4-Glc glycosidic linkage in comparison to LNP-1.
37271268	0	44	dep	activities	164:173	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	44	dep	activities	164:173	arg1	activities					42:51	biological activities	31:51	biological activities	31:51	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	45	theme	hetero-polysaccharides	71:92	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	45	theme	hetero-polysaccharides	71:92	arg1	activities					42:51	biological activities	31:51	biological activities	31:51	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	46	dep	Structure	0:8	arg1	evaluation					53:62	evaluation	53:62	evaluation	53:62	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	0	46	dep	Structure	0:8	arg1	characterization					10:25	characterization	10:25	characterization	10:25	Structure characterization and biological activities evaluation of two hetero-polysaccharides from Lepista nuda: Cell antioxidant, anticancer and immune-modulatory activities.
37271268	8	47	theme	mRNA	1212:1215	arg1	expression					1217:1226	their mRNA expression	1206:1226	their mRNA expression	1206:1226	RT-PCR results indicated that LNP-1 and LNP-2 could induce macrophages to secrete immune-modulatory factors NO, IL-6, and TNF-α by regulating their mRNA expression.
37271268	1	48	theme	structural	265:274	arg1	characteristics					276:290	their structural characteristics	259:290	their structural characteristics	259:290	Polysaccharides LNP-1 and LNP-2 were extracted and purified from Lepista nuda, and their structural characteristics and biological activities were evaluated.
36816591	8	0	theme	BP	1039:1040	arg1	group					1042:1046	BP group	1039:1046	BP group	1039:1046	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	10	1	theme	Bacteroides	1400:1410	arg1	structure					1243:1251	structure	1243:1251	structure	1243:1251	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	10	1	theme	Bacteroides	1400:1410	arg1	composition					1227:1237	composition	1227:1237	composition	1227:1237	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	10	1	theme	Bacteroides	1400:1410	arg1	populations					1369:1379	the downregulated populations	1351:1379	the downregulated populations of Escherichia and Bacteroides	1351:1410	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	6	2	theme	gastric	759:765	arg1	digestion					782:790	gastric and intestinal digestion	759:790	gastric and intestinal digestion	759:790	The molecular weights of BP and BO remained basically unchanged in gastric and intestinal digestion.
36816591	12	3	theme	O2-	1609:1611	arg1	suppression					1594:1604	a stronger suppression	1583:1604	a stronger suppression of O2-	1583:1611	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	5	4	theme	simulating	629:638	arg1	saliva					640:645	the simulating saliva	625:645	the simulating saliva	625:645	Results The results show that the simulating saliva partly degraded BP, but had no effect on BO.
36816591	1	5	theme	Bletilla	126:133	arg1	striata					135:141	Background Bletilla striata	115:141	Background Bletilla striata	115:141	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	8	6	theme	growth	908:913	arg1	rates					915:919	the growth rates	904:919	the growth rates of the BP and BO groups	904:943	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	8	6	theme	growth	908:913	arg1	higher					950:955	higher	950:955	higher	950:955	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	10	7	theme	indicative	1272:1281	arg1	composition					1227:1237	composition	1227:1237	composition	1227:1237	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	1	8	theme	Chinese	183:189	arg1	medicine					191:198	the commonly used traditional Chinese medicine	153:198	the commonly used traditional Chinese medicine	153:198	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	9	9	theme	sugar	1108:1112	arg1	level					1114:1118	the reducing sugar level	1095:1118	the reducing sugar level in the BO group	1095:1134	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	2	10	theme	B.	293:294	arg1	striata					296:302	B. striata	293:302	B. striata	293:302	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	9	11	from	level	1176:1180	arg1	group					1192:1196	the BP group	1185:1196	the BP group	1185:1196	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	8	12	theme	BP	928:929	arg1	groups					938:943	the BP and BO groups	924:943	the BP and BO groups	924:943	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	14	13	theme	BP	1852:1853	arg1	potential					1839:1847	the potential	1835:1847	the potential of BP and BO as prebiotics in the application to human diseases	1835:1911	The study point towards the potential of BP and BO as prebiotics in the application to human diseases by selectively regulating gut microbiota in the future.
36816591	2	14	theme	components	279:288	arg1	one					263:265	one	263:265	one	263:265	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	2	14	theme	components	279:288	arg1	components					279:288	the main components	270:288	the main components	270:288	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	9	15	theme	BO	1127:1128	arg1	group					1130:1134	the BO group	1123:1134	the BO group	1123:1134	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	4	16	theme	BP	519:520	arg1	effects					508:514	different prebiotic effects	488:514	different prebiotic effects of BP and BO	488:527	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	12	17	theme	stronger	1585:1592	arg1	suppression					1594:1604	a stronger suppression	1583:1604	a stronger suppression of O2-	1583:1611	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	13	18	theme	distinct	1778:1785	arg1	degrees					1802:1808	their distinct polymerization degrees	1772:1808	their distinct polymerization degrees	1772:1808	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	10	19	theme	abundances	1302:1311	arg1	indicative					1272:1281	indicative	1272:1281	indicative	1272:1281	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	0	20	theme	striata	69:75	arg1	polysaccharides					77:91	Bletilla striata polysaccharides	60:91	Bletilla striata polysaccharides	60:91	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	8	21	theme	BO	935:936	arg1	groups					938:943	the BP and BO groups	924:943	the BP and BO groups	924:943	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	1	22	theme	used	166:169	arg1	medicine					191:198	the commonly used traditional Chinese medicine	153:198	the commonly used traditional Chinese medicine	153:198	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	12	23	theme	BP	1564:1565	arg1	group					1567:1571	the BP group	1560:1571	the BP group	1560:1571	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	10	24	theme	Veillonella	1334:1344	arg1	abundances					1302:1311	the upregulated abundances	1286:1311	the upregulated abundances of Streptococcus and Veillonella	1286:1344	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	13	25	theme	different	1703:1711	arg1	characteristics					1740:1754	different digestion and fermentation characteristics	1703:1754	different digestion and fermentation characteristics	1703:1754	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	3	26	theme	fermentation	399:410	arg1	unclear					451:457	unclear	451:457	unclear	451:457	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	3	26	theme	fermentation	399:410	arg1	characteristics					412:426	the digestion and fermentation characteristics	381:426	the digestion and fermentation characteristics of BP and BO	381:439	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	2	27	contain	have	331:334	arg2	variety					338:344	a variety	336:344	a variety of biological activities	336:369	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	2	27	contain	have	331:334	arg2	activities					360:369	biological activities	349:369	biological activities	349:369	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	2	27	contain	have	331:334	arg1	components					279:288	the main components	270:288	the main components	270:288	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	14	28	theme	BO	1859:1860	arg1	potential					1839:1847	the potential	1835:1847	the potential of BP and BO as prebiotics in the application to human diseases	1835:1911	The study point towards the potential of BP and BO as prebiotics in the application to human diseases by selectively regulating gut microbiota in the future.
36816591	12	29	theme	fermentation	1538:1549	arg1	broth					1551:1555	The fermentation broth	1534:1555	The fermentation broth of the BP group	1534:1571	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	10	30	theme	Streptococcus	1316:1328	arg1	abundances					1302:1311	the upregulated abundances	1286:1311	the upregulated abundances of Streptococcus and Veillonella	1286:1344	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	3	31	theme	digestion	385:393	arg1	unclear					451:457	unclear	451:457	unclear	451:457	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	3	31	theme	digestion	385:393	arg1	characteristics					412:426	the digestion and fermentation characteristics	381:426	the digestion and fermentation characteristics of BP and BO	381:439	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	0	32	theme	In	0:1	arg1	digestion					9:17	In vitro digestion	0:17	In vitro digestion	0:17	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	11	33	theme	SCFA	1443:1446	arg1	production					1448:1457	the SCFA production	1439:1457	the SCFA production by gut microbiota and antioxidant activities	1439:1502	There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups.
36816591	5	34	contain	had	671:673	arg2	effect					678:683	no effect	675:683	no effect	675:683	Results The results show that the simulating saliva partly degraded BP, but had no effect on BO.
36816591	5	34	contain	had	671:673	arg1	saliva					640:645	the simulating saliva	625:645	the simulating saliva	625:645	Results The results show that the simulating saliva partly degraded BP, but had no effect on BO.
36816591	10	35	theme	downregulated	1355:1367	arg1	populations					1369:1379	the downregulated populations	1351:1379	the downregulated populations of Escherichia and Bacteroides	1351:1410	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	12	36	theme	higher	1620:1625	arg1	effect					1638:1643	a higher scavenging effect	1618:1643	a higher scavenging effect on DPPH for the BO group	1618:1668	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	8	37	theme	Control	974:980	arg1	group					982:986	the Control group	970:986	the Control group	970:986	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	1	38	theme	Background	115:124	arg1	striata					135:141	Background Bletilla striata	115:141	Background Bletilla striata	115:141	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	4	39	theme	BO	526:527	arg1	effects					508:514	different prebiotic effects	488:514	different prebiotic effects of BP and BO	488:527	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	0	40	theme	human	23:27	arg1	fermentation					44:55	human gut microbiota fermentation	23:55	human gut microbiota fermentation	23:55	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	8	41	from	content	1028:1034	arg1	group					1042:1046	BP group	1039:1046	BP group	1039:1046	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	8	41	from	content	1028:1034	arg1	group					1055:1059	BO group	1052:1059	BO group	1052:1059	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	12	42	theme	BO	1661:1662	arg1	group					1664:1668	the BO group	1657:1668	the BO group	1657:1668	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	4	43	theme	different	488:496	arg1	effects					508:514	different prebiotic effects	488:514	different prebiotic effects of BP and BO	488:527	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	14	44	theme	human	1898:1902	arg1	diseases					1904:1911	human diseases	1898:1911	human diseases	1898:1911	The study point towards the potential of BP and BO as prebiotics in the application to human diseases by selectively regulating gut microbiota in the future.
36816591	0	45	theme	microbiota	33:42	arg1	fermentation					44:55	human gut microbiota fermentation	23:55	human gut microbiota fermentation	23:55	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	8	46	theme	pH	996:997	arg1	value					999:1003	the pH value	992:1003	the pH value	992:1003	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	7	47	used	utilized	846:853	arg2	BP					806:807	BP	806:807	BP	806:807	In addition, BP and BO could be rapidly degraded and utilized by gut microbiota.
36816591	13	48	theme	polymerization	1787:1800	arg1	degrees					1802:1808	their distinct polymerization degrees	1772:1808	their distinct polymerization degrees	1772:1808	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	6	49	theme	intestinal	771:780	arg1	digestion					782:790	gastric and intestinal digestion	759:790	gastric and intestinal digestion	759:790	The molecular weights of BP and BO remained basically unchanged in gastric and intestinal digestion.
36816591	8	50	theme	in	881:882	arg1	fermentation					890:901	in vitro fermentation	881:901	in vitro fermentation	881:901	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	2	51	theme	B.	201:202	arg1	BP					229:230	BP	229:230	BP	229:230	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	2	51	theme	B.	201:202	arg1	polysaccharides					212:226	B. striata polysaccharides	201:226	B. striata polysaccharides (BP)	201:231	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	8	52	theme	carbohydrate	1015:1026	arg1	content					1028:1034	total carbohydrate content	1009:1034	total carbohydrate content	1009:1034	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	0	53	dep	In	0:1	arg1	vitro					3:7	vitro	3:7	vitro	3:7	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	13	54	dep	Conclusions	1671:1681	arg1	Conclusions					1671:1681	Conclusions BP and BO	1671:1691	Conclusions BP and BO	1671:1691	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	13	54	dep	Conclusions	1671:1681	arg1	BO					1690:1691	BO	1690:1691	BO	1690:1691	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	13	54	dep	Conclusions	1671:1681	arg1	BP					1683:1684	BP	1683:1684	BP	1683:1684	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	4	55	theme	microbiota	570:579	arg1	fermentation					581:592	gut microbiota fermentation	566:592	gut microbiota fermentation	566:592	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	11	56	theme	BO	1523:1524	arg1	groups					1526:1531	the BP and BO groups	1512:1531	groups	1526:1531	There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups.
36816591	11	57	theme	antioxidant	1481:1491	arg1	activities					1493:1502	antioxidant activities	1481:1502	antioxidant activities	1481:1502	There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups.
36816591	10	58	dep	composition	1227:1237	arg1	the					1223:1225	the	1223:1225	the	1223:1225	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	12	59	from	effect	1638:1643	arg1	DPPH					1648:1651	DPPH	1648:1651	DPPH	1648:1651	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	11	60	theme	BP	1516:1517	arg1	groups					1526:1531	the BP and BO groups	1512:1531	groups	1526:1531	There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups.
36816591	2	61	theme	main	274:277	arg1	components					279:288	the main components	270:288	the main components	270:288	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	12	62	theme	scavenging	1627:1636	arg1	effect					1638:1643	a higher scavenging effect	1618:1643	a higher scavenging effect on DPPH for the BO group	1618:1668	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	1	63	theme	traditional	171:181	arg1	medicine					191:198	the commonly used traditional Chinese medicine	153:198	the commonly used traditional Chinese medicine	153:198	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	8	64	theme	BO	1052:1053	arg1	group					1055:1059	BO group	1052:1059	BO group	1052:1059	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	6	65	theme	BO	724:725	arg1	weights					706:712	The molecular weights	692:712	The molecular weights of BP and BO	692:725	The molecular weights of BP and BO remained basically unchanged in gastric and intestinal digestion.
36816591	9	66	theme	reducing	1099:1106	arg1	level					1114:1118	the reducing sugar level	1095:1118	the reducing sugar level in the BO group	1095:1134	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	2	67	theme	striata	296:302	arg1	components					279:288	the main components	270:288	the main components	270:288	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	1	68	theme	medicine	191:198	arg1	medicine					191:198	the commonly used traditional Chinese medicine	153:198	the commonly used traditional Chinese medicine	153:198	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	1	68	theme	medicine	191:198	arg1	one					146:148	one	146:148	one	146:148	Background Bletilla striata is one of the commonly used traditional Chinese medicine.
36816591	10	69	theme	microbiota	1260:1269	arg1	structure					1243:1251	structure	1243:1251	structure	1243:1251	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	10	69	theme	microbiota	1260:1269	arg1	composition					1227:1237	composition	1227:1237	composition	1227:1237	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	10	69	theme	microbiota	1260:1269	arg1	populations					1369:1379	the downregulated populations	1351:1379	the downregulated populations of Escherichia and Bacteroides	1351:1410	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	6	70	theme	BP	717:718	arg1	weights					706:712	The molecular weights	692:712	The molecular weights of BP and BO	692:725	The molecular weights of BP and BO remained basically unchanged in gastric and intestinal digestion.
36816591	11	71	from	differences	1424:1434	arg1	production					1448:1457	the SCFA production	1439:1457	the SCFA production by gut microbiota and antioxidant activities	1439:1502	There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups.
36816591	9	72	from	level	1114:1118	arg1	group					1130:1134	the BO group	1123:1134	the BO group	1123:1134	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	10	73	theme	gut	1256:1258	arg1	microbiota					1260:1269	gut microbiota	1256:1269	gut microbiota	1256:1269	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	12	74	theme	group	1567:1571	arg1	broth					1551:1555	The fermentation broth	1534:1555	The fermentation broth of the BP group	1534:1571	The fermentation broth of the BP group displayed a stronger suppression of O2-, but a higher scavenging effect on DPPH for the BO group.
36816591	8	75	dep	in	881:882	arg1	vitro					884:888	vitro	884:888	vitro	884:888	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	0	76	theme	Bletilla	60:67	arg1	polysaccharides					77:91	Bletilla striata polysaccharides	60:91	Bletilla striata polysaccharides	60:91	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	13	77	theme	fermentation	1727:1738	arg1	characteristics					1740:1754	different digestion and fermentation characteristics	1703:1754	different digestion and fermentation characteristics	1703:1754	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	0	78	theme	polysaccharides	77:91	arg1	digestion					9:17	In vitro digestion	0:17	In vitro digestion	0:17	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	0	78	theme	polysaccharides	77:91	arg1	fermentation					44:55	human gut microbiota fermentation	23:55	human gut microbiota fermentation	23:55	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	8	79	theme	groups	938:943	arg1	rates					915:919	the growth rates	904:919	the growth rates of the BP and BO groups	904:943	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	8	79	theme	groups	938:943	arg1	higher					950:955	higher	950:955	higher	950:955	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	10	80	theme	upregulated	1290:1300	arg1	abundances					1302:1311	the upregulated abundances	1286:1311	the upregulated abundances of Streptococcus and Veillonella	1286:1344	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	0	81	theme	oligosaccharides	97:112	arg1	digestion					9:17	In vitro digestion	0:17	In vitro digestion	0:17	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	0	81	theme	oligosaccharides	97:112	arg1	fermentation					44:55	human gut microbiota fermentation	23:55	human gut microbiota fermentation	23:55	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	9	82	theme	low	1172:1174	arg1	level					1176:1180	a low level	1170:1180	a low level in the BP group	1170:1196	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	8	83	from	value	999:1003	arg1	group					1042:1046	BP group	1039:1046	BP group	1039:1046	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	8	83	from	value	999:1003	arg1	group					1055:1059	BO group	1052:1059	BO group	1052:1059	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	14	84	from	prebiotics	1865:1874	arg1	application					1883:1893	the application	1879:1893	the application to human diseases	1879:1911	The study point towards the potential of BP and BO as prebiotics in the application to human diseases by selectively regulating gut microbiota in the future.
36816591	13	85	theme	digestion	1713:1721	arg1	characteristics					1740:1754	different digestion and fermentation characteristics	1703:1754	different digestion and fermentation characteristics	1703:1754	Conclusions BP and BO displayed different digestion and fermentation characteristics in vitro due to their distinct polymerization degrees.
36816591	2	86	theme	biological	349:358	arg1	activities					360:369	biological activities	349:369	biological activities	349:369	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	9	87	theme	BP	1189:1190	arg1	group					1192:1196	the BP group	1185:1196	the BP group	1185:1196	Although the reducing sugar level in the BO group decreased rapidly, it remained at a low level in the BP group.
36816591	14	88	theme	gut	1939:1941	arg1	microbiota					1943:1952	gut microbiota	1939:1952	gut microbiota	1939:1952	The study point towards the potential of BP and BO as prebiotics in the application to human diseases by selectively regulating gut microbiota in the future.
36816591	7	89	theme	gut	858:860	arg1	microbiota					862:871	gut microbiota	858:871	gut microbiota	858:871	In addition, BP and BO could be rapidly degraded and utilized by gut microbiota.
36816591	3	90	theme	BO	438:439	arg1	unclear					451:457	unclear	451:457	unclear	451:457	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	3	90	theme	BO	438:439	arg1	characteristics					412:426	the digestion and fermentation characteristics	381:426	the digestion and fermentation characteristics of BP and BO	381:439	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	0	91	theme	gut	29:31	arg1	fermentation					44:55	human gut microbiota fermentation	23:55	human gut microbiota fermentation	23:55	In vitro digestion and human gut microbiota fermentation of Bletilla striata polysaccharides and oligosaccharides.
36816591	2	92	theme	activities	360:369	arg1	variety					338:344	a variety	336:344	a variety of biological activities	336:369	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	2	92	theme	activities	360:369	arg1	activities					360:369	biological activities	349:369	biological activities	349:369	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	4	93	theme	prebiotic	498:506	arg1	effects					508:514	different prebiotic effects	488:514	different prebiotic effects of BP and BO	488:527	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	11	94	theme	gut	1462:1464	arg1	microbiota					1466:1475	gut microbiota	1462:1475	gut microbiota	1462:1475	There were differences in the SCFA production by gut microbiota and antioxidant activities between the BP and BO groups.
36816591	3	95	theme	BP	431:432	arg1	unclear					451:457	unclear	451:457	unclear	451:457	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	3	95	theme	BP	431:432	arg1	characteristics					412:426	the digestion and fermentation characteristics	381:426	the digestion and fermentation characteristics of BP and BO	381:439	However, the digestion and fermentation characteristics of BP and BO are still unclear.
36816591	5	96	dep	Results	595:601	arg1	show					615:618	show	615:618	show that the simulating saliva partly degraded BP, but had no effect on BO	615:689	Results The results show that the simulating saliva partly degraded BP, but had no effect on BO.
36816591	10	97	theme	Escherichia	1384:1394	arg1	structure					1243:1251	structure	1243:1251	structure	1243:1251	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	10	97	theme	Escherichia	1384:1394	arg1	composition					1227:1237	composition	1227:1237	composition	1227:1237	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	10	97	theme	Escherichia	1384:1394	arg1	populations					1369:1379	the downregulated populations	1351:1379	the downregulated populations of Escherichia and Bacteroides	1351:1410	Both BP and BO improved the composition and structure of gut microbiota, indicative of the upregulated abundances of Streptococcus and Veillonella, and the downregulated populations of Escherichia and Bacteroides.
36816591	6	98	theme	molecular	696:704	arg1	weights					706:712	The molecular weights	692:712	The molecular weights of BP and BO	692:725	The molecular weights of BP and BO remained basically unchanged in gastric and intestinal digestion.
36816591	4	99	dep	Methods	460:466	arg1	evaluated					478:486	evaluated	478:486	evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation	478:592	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	8	100	theme	total	1009:1013	arg1	content					1028:1034	total carbohydrate content	1009:1034	total carbohydrate content	1009:1034	During in vitro fermentation, the growth rates of the BP and BO groups were higher than that of the Control group and the pH value and total carbohydrate content in BP group and BO group decreased significantly.
36816591	4	101	theme	gut	566:568	arg1	fermentation					581:592	gut microbiota fermentation	566:592	gut microbiota fermentation	566:592	Methods The study evaluated different prebiotic effects of BP and BO by in vitro simulating digestion and gut microbiota fermentation.
36816591	2	102	theme	striata	204:210	arg1	BP					229:230	BP	229:230	BP	229:230	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
36816591	2	102	theme	striata	204:210	arg1	polysaccharides					212:226	B. striata polysaccharides	201:226	B. striata polysaccharides (BP)	201:231	B. striata polysaccharides (BP) and oligosaccharides (BO) are one of the main components of B. striata, which have been proved to have a variety of biological activities.
37156358	6	0	theme	surface	931:937	arg1	roughness					939:947	surface roughness	931:947	surface roughness	931:947	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	13	1	theme	growth	1849:1854	arg1	patterns					1827:1834	The obvious patterns	1815:1834	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process	1793:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	5	2	theme	Composite	633:641	arg1	roughness					651:659	Composite surface roughness	633:659	Composite surface roughness	633:659	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	11	3	theme	structure	1582:1590	arg1	alteration					1556:1565	alteration	1556:1565	alteration of the biofilm structure	1556:1590	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	13	4	theme	sub-micron	1862:1871	arg1	scale					1873:1877	sub-micron scale	1862:1877	sub-micron scale grooving created by the polishing process	1862:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	7	5	theme	unpolished	1100:1109	arg1	composites					1111:1120	the unpolished composites	1096:1120	the unpolished composites	1096:1120	S. mutans biofilms grew statistically significantly thicker on the unpolished composites.
37156358	1	6	theme	residence	186:194	arg1	HRT					202:204	HRT	202:204	HRT	202:204	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	1	6	theme	residence	186:194	arg1	time					196:199	hydraulic residence time	176:199	hydraulic residence time (HRT)	176:205	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	6	7	theme	15	973:974	arg1	control					1024:1030	the unpolished control	1009:1030	the unpolished control	1009:1030	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	6	7	theme	15	973:974	arg1	factor					963:968	a factor	961:968	a factor of 15 between the polished samples	961:1003	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	4	8	theme	laser	609:613	arg1	microscopy					615:624	confocal laser microscopy	600:624	confocal laser microscopy (CLM)	600:630	Biofilms were characterized by confocal laser microscopy (CLM).
37156358	5	9	theme	optical	682:688	arg1	profilometry					690:701	optical profilometry	682:701	optical profilometry	682:701	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	5	10	theme	dispersive	850:859	arg1	spectroscopy					861:872	scanning electron microscopy-energy dispersive spectroscopy	814:872	scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS)	814:882	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	5	10	theme	dispersive	850:859	arg1	SEM-EDS					875:881	SEM-EDS	875:881	SEM-EDS	875:881	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	12	11	theme	mutans	1669:1674	arg1	thickness					1684:1692	S. mutans biofilm thickness	1666:1692	S. mutans biofilm thickness followed by HRT	1666:1708	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	13	12	theme	CLINICAL	1793:1800	arg1	SIGNIFICANCE					1802:1813	CLINICAL SIGNIFICANCE	1793:1813	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process	1793:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	13	13	theme	mutans	1842:1847	arg1	growth					1849:1854	S. mutans growth	1839:1854	S. mutans growth	1839:1854	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	12	14	theme	greater	1766:1772	arg1	thickness					1782:1790	significantly greater biofilm thickness	1752:1790	significantly greater biofilm thickness	1752:1790	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	12	15	theme	important	1637:1645	arg1	factor					1647:1652	the most important factor	1628:1652	the most important factor determining S. mutans biofilm thickness followed by HRT	1628:1708	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	12	15	theme	important	1637:1645	arg1	smoothness					1614:1623	surface smoothness	1606:1623	surface smoothness	1606:1623	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	7	16	theme	mutans	1036:1041	arg1	biofilms					1043:1050	S. mutans biofilms	1033:1050	S. mutans biofilms	1033:1050	S. mutans biofilms grew statistically significantly thicker on the unpolished composites.
37156358	11	17	theme	techniques	1531:1540	arg1	characterization					1448:1463	Accurate characterization	1439:1463	Accurate characterization of oral cavity biofilms must consider shear forces	1439:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	11	17	theme	techniques	1531:1540	arg1	use					1524:1526	the use	1520:1526	the use of techniques that minimize alteration of the biofilm structure	1520:1590	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	5	18	theme	surface	743:749	arg1	structure					756:764	composite surface fine structure	733:764	composite surface fine structure	733:764	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	5	19	theme	electron	823:830	arg1	spectroscopy					861:872	scanning electron microscopy-energy dispersive spectroscopy	814:872	scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS)	814:882	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	5	19	theme	electron	823:830	arg1	SEM-EDS					875:881	SEM-EDS	875:881	SEM-EDS	875:881	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	11	20	theme	cavity	1473:1478	arg1	biofilms					1480:1487	oral cavity biofilms	1468:1487	oral cavity biofilms must consider shear forces	1468:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	11	21	theme	biofilm	1574:1580	arg1	structure					1582:1590	the biofilm structure	1570:1590	the biofilm structure	1570:1590	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	1	22	theme	roughness	161:169	arg1	effect					132:137	the effect	128:137	the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity	128:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	9	23	theme	most	1198:1201	arg1	cases					1203:1207	most cases	1198:1207	most cases	1198:1207	In most cases, biofilm thickness was not statistically significantly greater in sucrose-fed bioreactors than in glucose-fed bioreactors.
37156358	13	24	theme	shear-protected	1979:1993	arg1	grooves					1995:2001	the shear-protected grooves	1975:2001	the shear-protected grooves	1975:2001	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	5	25	theme	pre-	708:711	arg1	structure					756:764	composite surface fine structure	733:764	composite surface fine structure	733:764	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	11	26	theme	shear	1503:1507	arg1	forces					1509:1514	shear forces	1503:1514	shear forces	1503:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	5	27	theme	post-incubation	717:731	arg1	structure					756:764	composite surface fine structure	733:764	composite surface fine structure	733:764	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	1	28	from	effect	132:137	arg1	biofilms					231:238	Streptococcus mutans biofilms	210:238	Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity	210:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	14	29	theme	mutans	2091:2096	arg1	biofilms					2098:2105	S. mutans biofilms	2088:2105	S. mutans biofilms	2088:2105	These results suggest that fine polishing may help prevent the initial formation of S. mutans biofilms compared to unpolished/coarse polished composites.
37156358	2	30	theme	polishing	379:387	arg1	polishing					379:387	polishing	379:387	polishing	379:387	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	2	30	theme	polishing	379:387	arg1	amounts					368:374	varying amounts	360:374	varying amounts of polishing	360:387	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	13	31	theme	polishing	1903:1911	arg1	process					1913:1919	the polishing process	1899:1919	the polishing process	1899:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	0	32	theme	composite	22:30	arg1	roughness					32:40	composite roughness	22:40	composite roughness	22:40	Relationships between composite roughness and Streptococcus mutans biofilm depth under shear in vitro.
37156358	1	33	theme	relevant	286:293	arg1	conditions					275:284	conditions	275:284	conditions relevant to the oral cavity	275:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	6	34	theme	RESULTS	885:891	arg1	Polishing					893:901	RESULTS Polishing	885:901	RESULTS Polishing	885:901	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	14	35	theme	initial	2067:2073	arg1	formation					2075:2083	the initial formation	2063:2083	the initial formation of S. mutans biofilms	2063:2105	These results suggest that fine polishing may help prevent the initial formation of S. mutans biofilms compared to unpolished/coarse polished composites.
37156358	10	36	theme	SEM-EDS	1332:1338	arg1	analysis					1340:1347	SEM-EDS analysis	1332:1347	SEM-EDS analysis	1332:1347	SEM-EDS analysis did not identify any significant change in elemental composition after aging.
37156358	5	37	theme	elemental	770:778	arg1	composition					780:790	elemental composition	770:790	elemental composition	770:790	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	13	38	dep	grooving	1879:1886	arg1	created					1888:1894	created	1888:1894	grooving created by the polishing process	1879:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	4	39	dep	microscopy	615:624	arg1	CLM					627:629	CLM	627:629	CLM	627:629	Biofilms were characterized by confocal laser microscopy (CLM).
37156358	10	40	theme	significant	1370:1380	arg1	change					1382:1387	any significant change	1366:1387	any significant change in elemental composition after aging	1366:1424	SEM-EDS analysis did not identify any significant change in elemental composition after aging.
37156358	0	41	theme	mutans	60:65	arg1	depth					75:79	Streptococcus mutans biofilm depth	46:79	Streptococcus mutans biofilm depth	46:79	Relationships between composite roughness and Streptococcus mutans biofilm depth under shear in vitro.
37156358	8	42	theme	Biofilm	1123:1129	arg1	thickness					1131:1139	Biofilm thickness	1123:1139	Biofilm thickness	1123:1139	Biofilm thickness was greater at shorter 10-h HRT compared to 40-h HRT.
37156358	14	43	theme	polished	2137:2144	arg1	composites					2146:2155	unpolished/coarse polished composites	2119:2155	unpolished/coarse polished composites	2119:2155	These results suggest that fine polishing may help prevent the initial formation of S. mutans biofilms compared to unpolished/coarse polished composites.
37156358	2	44	theme	Dental	323:328	arg1	composites					330:339	Dental composites	323:339	Dental composites	323:339	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	14	45	theme	fine	2031:2034	arg1	polishing					2036:2044	fine polishing	2031:2044	fine polishing	2031:2044	These results suggest that fine polishing may help prevent the initial formation of S. mutans biofilms compared to unpolished/coarse polished composites.
37156358	1	46	theme	mutans	224:229	arg1	biofilms					231:238	Streptococcus mutans biofilms	210:238	Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity	210:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	8	47	theme	10-h	1164:1167	arg1	HRT					1169:1171	shorter 10-h HRT	1156:1171	shorter 10-h HRT	1156:1171	Biofilm thickness was greater at shorter 10-h HRT compared to 40-h HRT.
37156358	11	48	theme	oral	1468:1471	arg1	biofilms					1480:1487	oral cavity biofilms	1468:1487	oral cavity biofilms must consider shear forces	1468:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	1	49	theme	dental	251:256	arg1	composites					258:267	dental composites	251:267	dental composites	251:267	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	6	50	theme	significant	909:919	arg1	impact					921:926	a significant impact	907:926	a significant impact	907:926	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	8	51	theme	40-h	1185:1188	arg1	HRT					1190:1192	40-h HRT	1185:1192	40-h HRT	1185:1192	Biofilm thickness was greater at shorter 10-h HRT compared to 40-h HRT.
37156358	13	52	theme	obvious	1819:1825	arg1	patterns					1827:1834	The obvious patterns	1815:1834	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process	1793:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	9	53	theme	biofilm	1210:1216	arg1	thickness					1218:1226	biofilm thickness	1210:1226	biofilm thickness	1210:1226	In most cases, biofilm thickness was not statistically significantly greater in sucrose-fed bioreactors than in glucose-fed bioreactors.
37156358	3	54	theme	40-h	546:549	arg1	HRT					551:553	10-h or 40-h HRT	538:553	10-h or 40-h HRT for one week	538:566	S. mutans biofilms developed in the bioreactors fed sucrose or glucose and at 10-h or 40-h HRT for one week.
37156358	1	55	theme	hydraulic	176:184	arg1	HRT					202:204	HRT	202:204	HRT	202:204	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	1	55	theme	hydraulic	176:184	arg1	time					196:199	hydraulic residence time	176:199	hydraulic residence time (HRT)	176:205	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	3	56	theme	10-h	538:541	arg1	HRT					551:553	10-h or 40-h HRT	538:553	10-h or 40-h HRT for one week	538:566	S. mutans biofilms developed in the bioreactors fed sucrose or glucose and at 10-h or 40-h HRT for one week.
37156358	5	57	theme	microscopy-energy	832:848	arg1	spectroscopy					861:872	scanning electron microscopy-energy dispersive spectroscopy	814:872	scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS)	814:882	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	5	57	theme	microscopy-energy	832:848	arg1	SEM-EDS					875:881	SEM-EDS	875:881	SEM-EDS	875:881	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	12	58	theme	biofilm	1676:1682	arg1	thickness					1684:1692	S. mutans biofilm thickness	1666:1692	S. mutans biofilm thickness followed by HRT	1666:1708	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	4	59	theme	confocal	600:607	arg1	microscopy					615:624	confocal laser microscopy	600:624	confocal laser microscopy (CLM)	600:630	Biofilms were characterized by confocal laser microscopy (CLM).
37156358	11	60	dep	biofilms	1480:1487	arg1	consider					1494:1501	consider	1494:1501	must consider shear forces	1489:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	5	61	theme	surface	643:649	arg1	roughness					651:659	Composite surface roughness	633:659	Composite surface roughness	633:659	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	7	62	theme	S.	1033:1034	arg1	biofilms					1043:1050	S. mutans biofilms	1033:1050	S. mutans biofilms	1033:1050	S. mutans biofilms grew statistically significantly thicker on the unpolished composites.
37156358	9	63	theme	sucrose-fed	1275:1285	arg1	bioreactors					1287:1297	sucrose-fed bioreactors	1275:1297	sucrose-fed bioreactors	1275:1297	In most cases, biofilm thickness was not statistically significantly greater in sucrose-fed bioreactors than in glucose-fed bioreactors.
37156358	12	64	theme	surface	1606:1612	arg1	factor					1647:1652	the most important factor	1628:1652	the most important factor determining S. mutans biofilm thickness followed by HRT	1628:1708	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	12	64	theme	surface	1606:1612	arg1	smoothness					1614:1623	surface smoothness	1606:1623	surface smoothness	1606:1623	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	3	65	theme	mutans	463:468	arg1	biofilms					470:477	S. mutans biofilms	460:477	S. mutans biofilms	460:477	S. mutans biofilms developed in the bioreactors fed sucrose or glucose and at 10-h or 40-h HRT for one week.
37156358	5	66	theme	composite	733:741	arg1	structure					756:764	composite surface fine structure	733:764	composite surface fine structure	733:764	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	1	67	theme	time	196:199	arg1	effect					132:137	the effect	128:137	the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity	128:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	1	68	theme	substrate	142:150	arg1	effect					132:137	the effect	128:137	the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity	128:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	12	69	theme	biofilm	1774:1780	arg1	thickness					1782:1790	significantly greater biofilm thickness	1752:1790	significantly greater biofilm thickness	1752:1790	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	6	70	theme	unpolished	1013:1022	arg1	control					1024:1030	the unpolished control	1009:1030	the unpolished control	1009:1030	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	5	71	theme	fine	751:754	arg1	structure					756:764	composite surface fine structure	733:764	composite surface fine structure	733:764	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	9	72	theme	glucose-fed	1307:1317	arg1	bioreactors					1319:1329	glucose-fed bioreactors	1307:1329	glucose-fed bioreactors	1307:1329	In most cases, biofilm thickness was not statistically significantly greater in sucrose-fed bioreactors than in glucose-fed bioreactors.
37156358	1	73	theme	surface	153:159	arg1	roughness					161:169	surface roughness	153:169	surface roughness	153:169	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	6	74	theme	polished	988:995	arg1	samples					997:1003	the polished samples	984:1003	the polished samples	984:1003	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	13	75	dep	SIGNIFICANCE	1802:1813	arg1	patterns					1827:1834	The obvious patterns	1815:1834	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process	1793:1919	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	6	76	contain	had	903:905	arg1	Polishing					893:901	RESULTS Polishing	885:901	RESULTS Polishing	885:901	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	6	76	contain	had	903:905	arg2	impact					921:926	a significant impact	907:926	a significant impact	907:926	RESULTS Polishing had a significant impact on surface roughness, varying by a factor of 15 between the polished samples and the unpolished control.
37156358	14	77	theme	biofilms	2098:2105	arg1	formation					2075:2083	the initial formation	2063:2083	the initial formation of S. mutans biofilms	2063:2105	These results suggest that fine polishing may help prevent the initial formation of S. mutans biofilms compared to unpolished/coarse polished composites.
37156358	13	78	theme	biofilm	1944:1950	arg1	attachment					1952:1961	initial biofilm attachment	1936:1961	initial biofilm attachment	1936:1961	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	12	79	theme	sucrose	1717:1723	arg1	presence					1725:1732	sucrose presence	1717:1732	sucrose presence	1717:1732	Under shear, surface smoothness is the most important factor determining S. mutans biofilm thickness followed by HRT, while sucrose presence did not result in significantly greater biofilm thickness.
37156358	10	80	from	change	1382:1387	arg1	composition					1402:1412	elemental composition	1392:1412	elemental composition after aging	1392:1424	SEM-EDS analysis did not identify any significant change in elemental composition after aging.
37156358	2	81	theme	approximate	431:441	arg1	shear					443:447	an approximate shear	428:447	an approximate shear of 0.4 Pa.	428:458	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	2	82	dep	METHODS	315:321	arg1	incubated					393:401	incubated	393:401	incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.	393:458	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	2	82	dep	METHODS	315:321	arg1	prepared					346:353	prepared	346:353	prepared with varying amounts of polishing	346:387	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	5	83	theme	scanning	814:821	arg1	spectroscopy					861:872	scanning electron microscopy-energy dispersive spectroscopy	814:872	scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS)	814:882	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	5	83	theme	scanning	814:821	arg1	SEM-EDS					875:881	SEM-EDS	875:881	SEM-EDS	875:881	Composite surface roughness was characterized by optical profilometry, and pre- and post-incubation composite surface fine structure and elemental composition were determined using scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS).
37156358	2	84	theme	CDC	408:410	arg1	bioreactor					412:421	a CDC bioreactor	406:421	a CDC bioreactor	406:421	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	13	85	theme	initial	1936:1942	arg1	attachment					1952:1961	initial biofilm attachment	1936:1961	initial biofilm attachment	1936:1961	CLINICAL SIGNIFICANCE The obvious patterns of S. mutans growth along sub-micron scale grooving created by the polishing process suggested that initial biofilm attachment occurred in the shear-protected grooves.
37156358	2	86	theme	Pa.	456:458	arg1	shear					443:447	an approximate shear	428:447	an approximate shear of 0.4 Pa.	428:458	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	0	87	theme	biofilm	67:73	arg1	depth					75:79	Streptococcus mutans biofilm depth	46:79	Streptococcus mutans biofilm depth	46:79	Relationships between composite roughness and Streptococcus mutans biofilm depth under shear in vitro.
37156358	1	88	theme	oral	302:305	arg1	cavity					307:312	the oral cavity	298:312	the oral cavity	298:312	OBJECTIVE To investigate the effect of substrate, surface roughness, and hydraulic residence time (HRT) on Streptococcus mutans biofilms growing on dental composites under conditions relevant to the oral cavity.
37156358	14	89	theme	unpolished/coarse	2119:2135	arg1	composites					2146:2155	unpolished/coarse polished composites	2119:2155	unpolished/coarse polished composites	2119:2155	These results suggest that fine polishing may help prevent the initial formation of S. mutans biofilms compared to unpolished/coarse polished composites.
37156358	11	90	theme	biofilms	1480:1487	arg1	characterization					1448:1463	Accurate characterization	1439:1463	Accurate characterization of oral cavity biofilms must consider shear forces	1439:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	11	90	theme	biofilms	1480:1487	arg1	use					1524:1526	the use	1520:1526	the use of techniques that minimize alteration of the biofilm structure	1520:1590	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	8	91	theme	shorter	1156:1162	arg1	HRT					1169:1171	shorter 10-h HRT	1156:1171	shorter 10-h HRT	1156:1171	Biofilm thickness was greater at shorter 10-h HRT compared to 40-h HRT.
37156358	11	92	theme	Accurate	1439:1446	arg1	characterization					1448:1463	Accurate characterization	1439:1463	Accurate characterization of oral cavity biofilms must consider shear forces	1439:1514	CONCLUSIONS Accurate characterization of oral cavity biofilms must consider shear forces and the use of techniques that minimize alteration of the biofilm structure.
37156358	10	93	theme	elemental	1392:1400	arg1	composition					1402:1412	elemental composition	1392:1412	elemental composition after aging	1392:1424	SEM-EDS analysis did not identify any significant change in elemental composition after aging.
37156358	2	94	theme	varying	360:366	arg1	polishing					379:387	polishing	379:387	polishing	379:387	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37156358	2	94	theme	varying	360:366	arg1	amounts					368:374	varying amounts	360:374	varying amounts of polishing	360:387	METHODS Dental composites were prepared with varying amounts of polishing and incubated in a CDC bioreactor with an approximate shear of 0.4 Pa.
37229889	7	0	from	zebrafish	1395:1403	arg1	level					1364:1368	the level	1360:1368	the level of lipid peroxidation in zebrafish	1360:1403	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	0	from	zebrafish	1395:1403	arg1	levels					1326:1331	the reactive oxygen species levels	1298:1331	the reactive oxygen species levels in cells and zebrafish	1298:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	1	theme	reactive	1302:1309	arg1	species					1318:1324	reactive oxygen species	1302:1324	the reactive oxygen species levels in cells and zebrafish	1298:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	9	2	theme	protein-1	1767:1775	arg1	expression					1671:1680	the expression	1667:1680	the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway	1667:1838	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	0	3	from	polysaccharides	192:206	arg1	oleracea					221:228	Portulaca oleracea	211:228	Portulaca oleracea L. (PO)	211:236	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	3	from	polysaccharides	192:206	arg1	PO					234:235	PO	234:235	PO	234:235	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	9	4	theme	TYR-related	1781:1791	arg1	protein-2					1793:1801	TYR-related protein-2	1781:1801	TYR-related protein-2	1781:1801	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	7	5	from	levels	1326:1331	arg1	cells					1336:1340	cells	1336:1340	cells	1336:1340	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	5	from	levels	1326:1331	arg1	zebrafish					1346:1354	zebrafish	1346:1354	zebrafish	1346:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	5	from	levels	1326:1331	arg1	zebrafish					1395:1403	zebrafish	1395:1403	zebrafish	1395:1403	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	0	6	dep	have	238:241	arg1	remove					332:337	remove	332:337	remove free radicals in the body	332:363	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	6	dep	have	238:241	arg1	inhibit					304:310	inhibit	304:310	inhibit common bacteria	304:326	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	4	7	theme	strongest	880:888	arg1	activity					901:908	the strongest biological activity	876:908	the strongest biological activity	876:908	Among these fractions, a polysaccharide fraction (VPOP3) showed the strongest biological activity.
37229889	3	8	theme	hydroxyl	778:785	arg1	radicals					787:794	hydroxyl radicals	778:794	hydroxyl radicals	778:794	METHOD In this study, 16 fractions obtained by four enzyme-assisted extraction from PO and their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals were evaluated.
37229889	9	9	theme	TYR-related	1755:1765	arg1	protein-1					1767:1775	TYR-related protein-1	1755:1775	TYR-related protein-1	1755:1775	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	2	10	theme	PO	584:585	arg1	polysaccharide					566:579	polysaccharide	566:579	polysaccharide of PO (POP)	566:591	PURPOSE This study was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo.
37229889	3	11	dep	METHOD	615:620	arg1	evaluated					801:809	evaluated	801:809	were evaluated	796:809	METHOD In this study, 16 fractions obtained by four enzyme-assisted extraction from PO and their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals were evaluated.
37229889	2	12	theme	polysaccharide	566:579	arg1	anti-photoaging					514:528	the anti-photoaging and whitening activity mechanism	510:561	anti-photoaging	514:528	PURPOSE This study was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo.
37229889	2	12	theme	polysaccharide	566:579	arg1	mechanism					553:561	the anti-photoaging and whitening activity mechanism	510:561	mechanism	553:561	PURPOSE This study was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo.
37229889	0	13	from	radicals	344:351	arg1	body					360:363	the body	356:363	the body	356:363	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	14	dep	oleracea	221:228	arg1	L					230:230	L	230:230	Portulaca oleracea L. (PO)	211:236	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	1	15	theme	PO	415:416	arg1	use					408:410	the use	404:410	the use of PO to alleviate hyperpigmentation and photoaging damage	404:469	However, there was little research on the use of PO to alleviate hyperpigmentation and photoaging damage.
37229889	9	16	theme	whitening	1853:1861	arg1	effect					1863:1868	a whitening effect	1851:1868	a whitening effect	1851:1868	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	10	17	theme	anti-melanogenesis	1965:1982	arg1	activities					1931:1940	superior activities	1922:1940	superior activities of anti-photoaging and anti-melanogenesis	1922:1982	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	9	18	theme	other	1598:1602	arg1	hand					1604:1607	the other hand	1594:1607	the other hand	1594:1607	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	8	19	theme	signaling	1571:1579	arg1	pathways					1581:1588	mitochondrion-mediated signaling pathways	1548:1588	mitochondrion-mediated signaling pathways	1548:1588	In addition, VPOP3 inhibited UVB-induced apoptotic body formation and apoptosis by downregulating caspase-3 and Bax and upregulating Bcl-2 in mitochondrion-mediated signaling pathways.
37229889	6	20	theme	monosaccharide	1249:1262	arg1	component					1264:1272	its main monosaccharide component	1240:1272	its main monosaccharide component	1240:1272	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	10	21	dep	CONCLUSION	1871:1880	arg1	showed					1900:1905	showed	1900:1905	showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics	1900:2053	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	10	22	theme	anti-photoaging	1945:1959	arg1	activities					1931:1940	superior activities	1922:1940	superior activities of anti-photoaging and anti-melanogenesis	1922:1982	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	9	23	theme	tyrosinase	1733:1742	arg1	expression					1671:1680	the expression	1667:1680	the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway	1667:1838	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	0	24	theme	enzyme-assisted	95:109	arg1	extracts					126:133	different enzyme-assisted polysaccharide extracts	85:133	different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	85:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	2	25	dep	PURPOSE	472:478	arg1	was					491:493	was	491:493	was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo	491:612	PURPOSE This study was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo.
37229889	5	26	theme	Fourier-transform	938:954	arg1	spectroscopy					965:976	Fourier-transform infrared spectroscopy	938:976	Fourier-transform infrared spectroscopy	938:976	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	0	27	theme	extracts	126:133	arg1	anti-melanogenesis					34:51	anti-melanogenesis	34:51	anti-melanogenesis	34:51	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	27	theme	extracts	126:133	arg1	activity					73:80	anti-photoaging activity	57:80	anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	57:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	28	dep	Portulaca	140:148	arg1	L.					159:160	Portulaca oleracea L.	140:160	Portulaca oleracea L. BACKGROUND	140:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	5	29	theme	molecular	979:987	arg1	MW					997:998	MW	997:998	MW	997:998	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	5	29	theme	molecular	979:987	arg1	weight					989:994	molecular weight	979:994	molecular weight (MW)	979:999	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	2	30	theme	whitening	534:542	arg1	mechanism					553:561	the anti-photoaging and whitening activity mechanism	510:561	mechanism	553:561	PURPOSE This study was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo.
37229889	0	31	theme	Portulaca	140:148	arg1	BACKGROUND					162:171	Portulaca oleracea L. BACKGROUND	140:171	Portulaca oleracea L. BACKGROUND	140:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	1	32	theme	little	385:390	arg1	research					392:399	little research	385:399	little research	385:399	However, there was little research on the use of PO to alleviate hyperpigmentation and photoaging damage.
37229889	5	33	theme	composition	1021:1031	arg1	analysis					1033:1040	monosaccharide composition analysis	1006:1040	monosaccharide composition analysis	1006:1040	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	10	34	contain	has	1918:1920	arg2	activities					1931:1940	superior activities	1922:1940	superior activities of anti-photoaging and anti-melanogenesis	1922:1982	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	10	34	contain	has	1918:1920	arg1	resource					2014:2021	a safe resource	2007:2021	a safe resource in the manufacture of cosmetics	2007:2053	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	10	34	contain	has	1918:1920	arg1	VPOP3					1912:1916	VPOP3	1912:1916	VPOP3	1912:1916	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	0	35	from	anti-melanogenesis	34:51	arg1	BACKGROUND					162:171	Portulaca oleracea L. BACKGROUND	140:171	Portulaca oleracea L. BACKGROUND	140:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	36	theme	different	85:93	arg1	extracts					126:133	different enzyme-assisted polysaccharide extracts	85:133	different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	85:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	7	37	theme	peroxidation	1379:1390	arg1	level					1364:1368	the level	1360:1368	the level of lipid peroxidation in zebrafish	1360:1403	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	37	theme	peroxidation	1379:1390	arg1	levels					1326:1331	the reactive oxygen species levels	1298:1331	the reactive oxygen species levels in cells and zebrafish	1298:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	8	38	theme	apoptotic	1447:1455	arg1	formation					1462:1470	UVB-induced apoptotic body formation	1435:1470	UVB-induced apoptotic body formation	1435:1470	In addition, VPOP3 inhibited UVB-induced apoptotic body formation and apoptosis by downregulating caspase-3 and Bax and upregulating Bcl-2 in mitochondrion-mediated signaling pathways.
37229889	5	39	theme	protective	1051:1060	arg1	effect					1062:1067	the protective effect	1047:1067	the protective effect of VPOP3 on photoaging and hyperpigmentation	1047:1112	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	9	40	theme	microphthalmia-associated	1685:1709	arg1	factor					1725:1730	microphthalmia-associated transcription factor	1685:1730	microphthalmia-associated transcription factor	1685:1730	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	0	41	theme	anti-melanogenesis	34:51	arg1	screening					21:29	screening	21:29	screening	21:29	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	41	theme	anti-melanogenesis	34:51	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	9	42	theme	factor	1725:1730	arg1	expression					1671:1680	the expression	1667:1680	the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway	1667:1838	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	0	43	theme	anti-photoaging	57:71	arg1	activity					73:80	anti-photoaging activity	57:80	anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	57:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	10	44	used	utilized	1995:2002	arg2	VPOP3					1912:1916	VPOP3	1912:1916	VPOP3	1912:1916	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	10	44	used	utilized	1995:2002	arg2	resource					2014:2021	a safe resource	2007:2021	a safe resource in the manufacture of cosmetics	2007:2053	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	5	45	theme	VPOP3	1072:1076	arg1	effect					1062:1067	the protective effect	1047:1067	the protective effect of VPOP3 on photoaging and hyperpigmentation	1047:1112	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	7	46	from	level	1364:1368	arg1	cells					1336:1340	cells	1336:1340	cells	1336:1340	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	46	from	level	1364:1368	arg1	zebrafish					1346:1354	zebrafish	1346:1354	zebrafish	1346:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	7	46	from	level	1364:1368	arg1	zebrafish					1395:1403	zebrafish	1395:1403	zebrafish	1395:1403	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	3	47	theme	enzyme-assisted	667:681	arg1	extraction					683:692	four enzyme-assisted extraction	662:692	four enzyme-assisted extraction from PO	662:700	METHOD In this study, 16 fractions obtained by four enzyme-assisted extraction from PO and their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals were evaluated.
37229889	4	48	theme	polysaccharide	837:850	arg1	fraction					852:859	a polysaccharide fraction	835:859	a polysaccharide fraction (VPOP3)	835:867	Among these fractions, a polysaccharide fraction (VPOP3) showed the strongest biological activity.
37229889	4	48	theme	polysaccharide	837:850	arg1	VPOP3					862:866	VPOP3	862:866	VPOP3	862:866	Among these fractions, a polysaccharide fraction (VPOP3) showed the strongest biological activity.
37229889	6	49	theme	acidic	1156:1161	arg1	heteropolysaccharide					1163:1182	a low-MW acidic heteropolysaccharide	1147:1182	a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component	1147:1272	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	6	49	theme	acidic	1156:1161	arg1	VPOP3					1138:1142	RESULTS VPOP3	1130:1142	RESULTS VPOP3	1130:1142	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	6	50	with	heteropolysaccharide	1163:1182	arg1	MW					1189:1190	MW	1189:1190	MW	1189:1190	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	4	51	theme	biological	890:899	arg1	activity					901:908	the strongest biological activity	876:908	the strongest biological activity	876:908	Among these fractions, a polysaccharide fraction (VPOP3) showed the strongest biological activity.
37229889	7	52	theme	oxygen	1311:1316	arg1	species					1318:1324	reactive oxygen species	1302:1324	the reactive oxygen species levels in cells and zebrafish	1298:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	1	53	theme	photoaging	453:462	arg1	damage					464:469	photoaging damage	453:469	photoaging damage	453:469	However, there was little research on the use of PO to alleviate hyperpigmentation and photoaging damage.
37229889	10	54	theme	above	1886:1890	arg1	results					1892:1898	The above results	1882:1898	The above results	1882:1898	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	10	55	from	resource	2014:2021	arg1	manufacture					2030:2040	the manufacture	2026:2040	the manufacture of cosmetics	2026:2053	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	3	56	theme	scavenging	712:721	arg1	capabilities					723:734	their scavenging capabilities	706:734	their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals	706:794	METHOD In this study, 16 fractions obtained by four enzyme-assisted extraction from PO and their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals were evaluated.
37229889	0	57	theme	significant	243:253	arg1	effects					285:291	significant antibacterial and antioxidant effects	243:291	significant antibacterial and antioxidant effects	243:291	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	58	dep	anti-melanogenesis	34:51	arg1	polysaccharides					192:206	polysaccharides	192:206	polysaccharides	192:206	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	58	dep	anti-melanogenesis	34:51	arg1	flavonoids					177:186	flavonoids	177:186	flavonoids	177:186	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	9	59	theme	signaling	1822:1830	arg1	pathway					1832:1838	the melanogenic signaling pathway	1806:1838	the melanogenic signaling pathway	1806:1838	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	5	60	from	effect	1062:1067	arg1	hyperpigmentation					1096:1112	hyperpigmentation	1096:1112	hyperpigmentation	1096:1112	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	5	60	from	effect	1062:1067	arg1	photoaging					1081:1090	photoaging	1081:1090	photoaging	1081:1090	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	3	61	from	PO	699:700	arg1	extraction					683:692	four enzyme-assisted extraction	662:692	four enzyme-assisted extraction from PO	662:700	METHOD In this study, 16 fractions obtained by four enzyme-assisted extraction from PO and their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals were evaluated.
37229889	3	61	from	PO	699:700	arg1	capabilities					723:734	their scavenging capabilities	706:734	their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals	706:794	METHOD In this study, 16 fractions obtained by four enzyme-assisted extraction from PO and their scavenging capabilities against 2,2-diphenyl-1-picrylhydrazyl and hydroxyl radicals were evaluated.
37229889	10	62	theme	superior	1922:1929	arg1	activities					1931:1940	superior activities	1922:1940	superior activities of anti-photoaging and anti-melanogenesis	1922:1982	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	0	63	theme	common	312:317	arg1	bacteria					319:326	common bacteria	312:326	common bacteria	312:326	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	5	64	theme	infrared	956:963	arg1	spectroscopy					965:976	Fourier-transform infrared spectroscopy	938:976	Fourier-transform infrared spectroscopy	938:976	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	9	65	theme	melanogenic	1810:1820	arg1	pathway					1832:1838	the melanogenic signaling pathway	1806:1838	the melanogenic signaling pathway	1806:1838	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	8	66	theme	mitochondrion-mediated	1548:1569	arg1	pathways					1581:1588	mitochondrion-mediated signaling pathways	1548:1588	mitochondrion-mediated signaling pathways	1548:1588	In addition, VPOP3 inhibited UVB-induced apoptotic body formation and apoptosis by downregulating caspase-3 and Bax and upregulating Bcl-2 in mitochondrion-mediated signaling pathways.
37229889	0	67	contain	have	238:241	arg1	screening					21:29	screening	21:29	screening	21:29	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	67	contain	have	238:241	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	67	contain	have	238:241	arg2	effects					285:291	significant antibacterial and antioxidant effects	243:291	significant antibacterial and antioxidant effects	243:291	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	8	68	from	Bcl-2	1539:1543	arg1	pathways					1581:1588	mitochondrion-mediated signaling pathways	1548:1588	mitochondrion-mediated signaling pathways	1548:1588	In addition, VPOP3 inhibited UVB-induced apoptotic body formation and apoptosis by downregulating caspase-3 and Bax and upregulating Bcl-2 in mitochondrion-mediated signaling pathways.
37229889	0	69	theme	free	339:342	arg1	radicals					344:351	free radicals	339:351	free radicals in the body	339:363	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	70	dep	flavonoids	177:186	arg1	The					173:175	The	173:175	The	173:175	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	9	71	from	expression	1671:1680	arg1	pathway					1832:1838	the melanogenic signaling pathway	1806:1838	the melanogenic signaling pathway	1806:1838	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	6	72	theme	main	1244:1247	arg1	component					1264:1272	its main monosaccharide component	1240:1272	its main monosaccharide component	1240:1272	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	0	73	theme	polysaccharide	111:124	arg1	extracts					126:133	different enzyme-assisted polysaccharide extracts	85:133	different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	85:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	74	theme	antibacterial	255:267	arg1	effects					285:291	significant antibacterial and antioxidant effects	243:291	significant antibacterial and antioxidant effects	243:291	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	9	75	theme	high	1619:1622	arg1	concentrations					1624:1637	high concentrations	1619:1637	high concentrations	1619:1637	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	9	76	from	concentrations	1624:1637	arg1	VPOP3					1610:1614	VPOP3	1610:1614	VPOP3 at high concentrations	1610:1637	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	2	77	theme	activity	544:551	arg1	mechanism					553:561	the anti-photoaging and whitening activity mechanism	510:561	mechanism	553:561	PURPOSE This study was to investigate the anti-photoaging and whitening activity mechanism of polysaccharide of PO (POP) in vitro and in vivo.
37229889	0	78	from	activity	73:80	arg1	BACKGROUND					162:171	Portulaca oleracea L. BACKGROUND	140:171	Portulaca oleracea L. BACKGROUND	140:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	79	theme	antioxidant	273:283	arg1	effects					285:291	significant antibacterial and antioxidant effects	243:291	significant antibacterial and antioxidant effects	243:291	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	5	80	theme	monosaccharide	1006:1019	arg1	analysis					1033:1040	monosaccharide composition analysis	1006:1040	monosaccharide composition analysis	1006:1040	VPOP3 was characterized by Fourier-transform infrared spectroscopy, molecular weight (MW), and monosaccharide composition analysis, and the protective effect of VPOP3 on photoaging and hyperpigmentation was researched.
37229889	6	81	theme	RESULTS	1130:1136	arg1	heteropolysaccharide					1163:1182	a low-MW acidic heteropolysaccharide	1147:1182	a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component	1147:1272	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	6	81	theme	RESULTS	1130:1136	arg1	VPOP3					1138:1142	RESULTS VPOP3	1130:1142	RESULTS VPOP3	1130:1142	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	7	82	theme	lipid	1373:1377	arg1	peroxidation					1379:1390	lipid peroxidation	1373:1390	lipid peroxidation in zebrafish	1373:1403	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	8	83	theme	UVB-induced	1435:1445	arg1	formation					1462:1470	UVB-induced apoptotic body formation	1435:1470	UVB-induced apoptotic body formation	1435:1470	In addition, VPOP3 inhibited UVB-induced apoptotic body formation and apoptosis by downregulating caspase-3 and Bax and upregulating Bcl-2 in mitochondrion-mediated signaling pathways.
37229889	7	84	theme	species	1318:1324	arg1	levels					1326:1331	the reactive oxygen species levels	1298:1331	the reactive oxygen species levels in cells and zebrafish	1298:1354	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	9	85	theme	transcription	1711:1723	arg1	factor					1725:1730	microphthalmia-associated transcription factor	1685:1730	microphthalmia-associated transcription factor	1685:1730	On the other hand, VPOP3 at high concentrations significantly downregulated the expression of microphthalmia-associated transcription factor, tyrosinase (TYR), and TYR-related protein-1 and TYR-related protein-2 in the melanogenic signaling pathway to achieve a whitening effect.
37229889	8	86	theme	body	1457:1460	arg1	formation					1462:1470	UVB-induced apoptotic body formation	1435:1470	UVB-induced apoptotic body formation	1435:1470	In addition, VPOP3 inhibited UVB-induced apoptotic body formation and apoptosis by downregulating caspase-3 and Bax and upregulating Bcl-2 in mitochondrion-mediated signaling pathways.
37229889	0	87	theme	activity	73:80	arg1	screening					21:29	screening	21:29	screening	21:29	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	87	theme	activity	73:80	arg1	Characterization					0:15	Characterization	0:15	Characterization	0:15	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	88	from	flavonoids	177:186	arg1	oleracea					221:228	Portulaca oleracea	211:228	Portulaca oleracea L. (PO)	211:236	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	88	from	flavonoids	177:186	arg1	PO					234:235	PO	234:235	PO	234:235	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	10	89	theme	safe	2009:2012	arg1	resource					2014:2021	a safe resource	2007:2021	a safe resource in the manufacture of cosmetics	2007:2053	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	10	89	theme	safe	2009:2012	arg1	VPOP3					1912:1916	VPOP3	1912:1916	VPOP3	1912:1916	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
37229889	7	90	from	peroxidation	1379:1390	arg1	zebrafish					1395:1403	zebrafish	1395:1403	zebrafish	1395:1403	VPOP3 reliably reduced the reactive oxygen species levels in cells and zebrafish and the level of lipid peroxidation in zebrafish.
37229889	6	91	theme	low-MW	1149:1154	arg1	heteropolysaccharide					1163:1182	a low-MW acidic heteropolysaccharide	1147:1182	a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component	1147:1272	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	6	91	theme	low-MW	1149:1154	arg1	VPOP3					1138:1142	RESULTS VPOP3	1130:1142	RESULTS VPOP3	1130:1142	RESULTS VPOP3 is a low-MW acidic heteropolysaccharide with MW mainly distributed around 0.71KDa, arabinose as its main monosaccharide component.
37229889	0	92	from	BACKGROUND	162:171	arg1	extracts					126:133	different enzyme-assisted polysaccharide extracts	85:133	different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	85:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	92	from	BACKGROUND	162:171	arg1	anti-melanogenesis					34:51	anti-melanogenesis	34:51	anti-melanogenesis	34:51	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	0	92	from	BACKGROUND	162:171	arg1	activity					73:80	anti-photoaging activity	57:80	anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND	57:171	Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. BACKGROUND The flavonoids and polysaccharides in Portulaca oleracea L. (PO) have significant antibacterial and antioxidant effects, which can inhibit common bacteria and remove free radicals in the body.
37229889	10	93	theme	cosmetics	2045:2053	arg1	manufacture					2030:2040	the manufacture	2026:2040	the manufacture of cosmetics	2026:2053	CONCLUSION The above results showed that VPOP3 has superior activities of anti-photoaging and anti-melanogenesis and can be utilized as a safe resource in the manufacture of cosmetics.
35927129	5	0	theme	glucan	848:853	arg1	polysaccharide					788:801	the polysaccharide	784:801	the polysaccharide	784:801	As a result, the polysaccharide is found to be a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3).
35927129	5	0	theme	glucan	848:853	arg1	type					840:843	a novel water-soluble type	818:843	a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3)	818:935	As a result, the polysaccharide is found to be a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3).
35927129	2	1	theme	16S	343:345	arg1	analysis					361:368	16S rRNA sequence analysis	343:368	16S rRNA sequence analysis	343:368	This strain named as ZB01 was identified as Rhizobium punsense by 16S rRNA sequence analysis.
35927129	5	2	theme	water-soluble	826:838	arg1	polysaccharide					788:801	the polysaccharide	784:801	the polysaccharide	784:801	As a result, the polysaccharide is found to be a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3).
35927129	5	2	theme	water-soluble	826:838	arg1	type					840:843	a novel water-soluble type	818:843	a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3)	818:935	As a result, the polysaccharide is found to be a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3).
35927129	0	3	theme	Rhizobium	86:94	arg1	pusense					96:102	Rhizobium pusense	86:102	Rhizobium pusense	86:102	Structural characterization of a water-soluble and antimicrobial β-glucan secreted by Rhizobium pusense.
35927129	6	4	theme	antimicrobial	972:984	arg1	effects					986:992	pronounced antimicrobial effects	961:992	pronounced antimicrobial effects	961:992	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	6	5	theme	pronounced	961:970	arg1	effects					986:992	pronounced antimicrobial effects	961:992	pronounced antimicrobial effects	961:992	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	3	6	theme	resonance	601:609	arg1	spectroscopy					611:622	nuclear magnetic resonance spectroscopy	584:622	nuclear magnetic resonance spectroscopy	584:622	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	7	theme	spectroscopy	611:622	arg1	analysis					624:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	1	8	theme	saline	263:268	arg1	soils					270:274	saline soils	263:274	saline soils	263:274	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	5	9	theme	novel	820:824	arg1	polysaccharide					788:801	the polysaccharide	784:801	the polysaccharide	784:801	As a result, the polysaccharide is found to be a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3).
35927129	5	9	theme	novel	820:824	arg1	type					840:843	a novel water-soluble type	818:843	a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3)	818:935	As a result, the polysaccharide is found to be a novel water-soluble type of glucan most likely consisting of repeating two β-d-Glcp-(1 → 3) and one α-d-Glcp-(1 → 3).
35927129	1	10	with	bacterium	122:130	arg1	ability					141:147	the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa)	137:243	the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa)	137:243	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	3	11	theme	chromatography-pulsed	495:515	arg1	detector					530:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	12	theme	nuclear	584:590	arg1	resonance					601:609	nuclear magnetic resonance	584:609	nuclear magnetic resonance spectroscopy	584:622	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	13	theme	extracellular	412:424	arg1	polysaccharides					426:440	extracellular polysaccharides	412:440	extracellular polysaccharides	412:440	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	4	14	theme	morphological	651:663	arg1	characterization					665:680	the morphological characterization	647:680	the morphological characterization of extracellular polysaccharides	647:713	In addition, the morphological characterization of extracellular polysaccharides was performed by scanning electron microscopy analysis.
35927129	0	15	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a water-soluble and antimicrobial β-glucan	0:72	Structural characterization of a water-soluble and antimicrobial β-glucan secreted by Rhizobium pusense.
35927129	4	16	theme	microscopy	750:759	arg1	analysis					761:768	scanning electron microscopy analysis	732:768	scanning electron microscopy analysis	732:768	In addition, the morphological characterization of extracellular polysaccharides was performed by scanning electron microscopy analysis.
35927129	6	17	contain	has	1056:1058	arg2	potential					1064:1072	the potential to be used as a natural antibacterial agent in the future	1060:1130	the potential to be used as a natural antibacterial agent in the future	1060:1130	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	6	17	contain	has	1056:1058	arg1	it					1053:1054	it	1053:1054	it	1053:1054	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	1	18	theme	water-soluble	178:190	arg1	polysaccharide					192:205	a water-soluble polysaccharide	176:205	a water-soluble polysaccharide (with high molecular mass of 743 kDa)	176:243	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	3	19	theme	monomer	375:381	arg1	composition					383:393	monomer composition	375:393	monomer composition	375:393	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	20	dep	composition	383:393	arg1	The					371:373	The	371:373	The	371:373	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	21	theme	polysaccharides	426:440	arg1	structure					399:407	structure	399:407	structure	399:407	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	21	theme	polysaccharides	426:440	arg1	composition					383:393	monomer composition	375:393	monomer composition	375:393	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	6	22	from	agent	1112:1116	arg1	future					1125:1130	future	1125:1130	future	1125:1130	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	6	23	theme	antibacterial	1098:1110	arg1	agent					1112:1116	a natural antibacterial agent	1088:1116	a natural antibacterial agent in the future	1088:1130	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	3	24	theme	anion-exchange	480:493	arg1	detector					530:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	2	25	theme	sequence	352:359	arg1	analysis					361:368	16S rRNA sequence analysis	343:368	16S rRNA sequence analysis	343:368	This strain named as ZB01 was identified as Rhizobium punsense by 16S rRNA sequence analysis.
35927129	3	26	theme	infrared	558:565	arg1	analysis					624:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	27	theme	Fourier-transform	540:556	arg1	infrared					558:565	Fourier-transform infrared	540:565	Fourier-transform infrared	540:565	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	4	28	theme	electron	741:748	arg1	microscopy					750:759	scanning electron microscopy	732:759	scanning electron microscopy analysis	732:768	In addition, the morphological characterization of extracellular polysaccharides was performed by scanning electron microscopy analysis.
35927129	4	29	theme	scanning	732:739	arg1	microscopy					750:759	scanning electron microscopy	732:759	scanning electron microscopy analysis	732:768	In addition, the morphological characterization of extracellular polysaccharides was performed by scanning electron microscopy analysis.
35927129	1	30	theme	high	213:216	arg1	mass					228:231	high molecular mass	213:231	high molecular mass of 743 kDa	213:242	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	0	31	theme	water-soluble	33:45	arg1	β-glucan					65:72	a water-soluble and antimicrobial β-glucan	31:72	a water-soluble and antimicrobial β-glucan	31:72	Structural characterization of a water-soluble and antimicrobial β-glucan secreted by Rhizobium pusense.
35927129	1	32	theme	molecular	218:226	arg1	mass					228:231	high molecular mass	213:231	high molecular mass of 743 kDa	213:242	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	0	33	theme	β-glucan	65:72	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a water-soluble and antimicrobial β-glucan	0:72	Structural characterization of a water-soluble and antimicrobial β-glucan secreted by Rhizobium pusense.
35927129	6	34	theme	natural	1090:1096	arg1	agent					1112:1116	a natural antibacterial agent	1088:1116	a natural antibacterial agent in the future	1088:1130	Furthermore, it showed pronounced antimicrobial effects against Escherichia coli and Bacillus subtilis, suggesting it has the potential to be used as a natural antibacterial agent in the future.
35927129	0	35	theme	antimicrobial	51:63	arg1	β-glucan					65:72	a water-soluble and antimicrobial β-glucan	31:72	a water-soluble and antimicrobial β-glucan	31:72	Structural characterization of a water-soluble and antimicrobial β-glucan secreted by Rhizobium pusense.
35927129	1	36	with	polysaccharide	192:205	arg1	mass					228:231	high molecular mass	213:231	high molecular mass of 743 kDa	213:242	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	2	37	theme	Rhizobium	321:329	arg1	strain					282:287	This strain	277:287	This strain named as ZB01	277:301	This strain named as ZB01 was identified as Rhizobium punsense by 16S rRNA sequence analysis.
35927129	2	37	theme	Rhizobium	321:329	arg1	punsense					331:338	Rhizobium punsense	321:338	Rhizobium punsense	321:338	This strain named as ZB01 was identified as Rhizobium punsense by 16S rRNA sequence analysis.
35927129	3	38	theme	amperometric	517:528	arg1	detector					530:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	4	39	theme	extracellular	685:697	arg1	polysaccharides					699:713	extracellular polysaccharides	685:713	extracellular polysaccharides	685:713	In addition, the morphological characterization of extracellular polysaccharides was performed by scanning electron microscopy analysis.
35927129	3	40	theme	magnetic	592:599	arg1	resonance					601:609	nuclear magnetic resonance	584:609	nuclear magnetic resonance spectroscopy	584:622	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	41	theme	detector	530:537	arg1	analysis					624:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	42	theme	high-performance	463:478	arg1	detector					530:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	high-performance anion-exchange chromatography-pulsed amperometric detector	463:537	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	3	43	theme	methylation	568:578	arg1	analysis					624:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis	463:631	The monomer composition and structure of extracellular polysaccharides were investigated by high-performance anion-exchange chromatography-pulsed amperometric detector, Fourier-transform infrared, methylation and nuclear magnetic resonance spectroscopy analysis.
35927129	1	44	theme	743 kDa	236:242	arg1	mass					228:231	high molecular mass	213:231	high molecular mass of 743 kDa	213:242	In this study, a bacterium with the ability to extracellularly produce a water-soluble polysaccharide (with high molecular mass of 743 kDa) was obtained from saline soils.
35927129	2	45	theme	rRNA	347:350	arg1	analysis					361:368	16S rRNA sequence analysis	343:368	16S rRNA sequence analysis	343:368	This strain named as ZB01 was identified as Rhizobium punsense by 16S rRNA sequence analysis.
35927129	4	46	theme	polysaccharides	699:713	arg1	characterization					665:680	the morphological characterization	647:680	the morphological characterization of extracellular polysaccharides	647:713	In addition, the morphological characterization of extracellular polysaccharides was performed by scanning electron microscopy analysis.
36948337	6	0	theme	Fe3O4-	914:919	arg1	nanofiber					936:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	2	1	theme	inimitable	355:364	arg1	properties					366:375	their inimitable properties	349:375	their inimitable properties	349:375	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	6	2	theme	CNFs/	902:906	arg1	nanofiber					936:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	1	3	theme	Wound	174:178	arg1	infections					185:194	Wound skin infections	174:194	Wound skin infections	174:194	Wound skin infections can cause significant morbidity and even mortality.
36948337	9	4	theme	viability	1384:1392	arg1	percentage					1365:1374	the percentage	1361:1374	the percentage of cell viability	1361:1392	Moreover, CNFs and RE reduce wound area percentages and increase the percentage of cell viability, respectively.
36948337	0	5	theme	dressing	114:121	arg1	applications					123:134	wound dressing applications	108:134	wound dressing applications	108:134	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	10	6	dep	proliferation	1602:1614	arg1	ability					1630:1636	ability	1630:1636	ability	1630:1636	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	2	7	theme	nano	291:294	arg1	cellulose					296:304	nano cellulose	291:304	nano cellulose	291:304	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	6	8	theme	composite	1056:1064	arg1	design					1066:1071	central composite design	1048:1071	central composite design	1048:1071	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	9	theme	PVA	896:898	arg1	strength					841:848	tensile strength	833:848	tensile strength	833:848	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	9	theme	PVA	896:898	arg1	elongation					857:866	total elongation	851:866	total elongation	851:866	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	9	theme	PVA	896:898	arg1	nanofiber					936:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	9	theme	PVA	896:898	arg1	swelling					884:891	percentage swelling	873:891	percentage swelling of PVA	873:898	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	0	10	theme	wound	108:112	arg1	applications					123:134	wound dressing applications	108:134	wound dressing applications	108:134	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	8	11	theme	CQDs-	1242:1246	arg1	Fe3O4-RE					1248:1255	CQDs- Fe3O4-RE	1242:1255	CQDs- Fe3O4-RE	1242:1255	Also, CNFs and CQDs- Fe3O4-RE increased the tensile strength of OEN.
36948337	3	12	theme	mechanical	500:509	arg1	properties					511:520	mechanical properties	500:520	mechanical properties	500:520	In this study, in order to prepare a novel wound dressing, CNFs are composited with poly (vinyl alcohol) (PVA) to enhance mechanical properties and increase cell proliferation and migration.
36948337	10	13	theme	cell	1597:1600	arg1	proliferation					1602:1614	high cell proliferation	1592:1614	high cell proliferation	1592:1614	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	4	14	theme	rosemary	654:661	arg1	RE					672:673	RE	672:673	RE	672:673	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	14	theme	rosemary	654:661	arg1	extract					663:669	rosemary extract	654:669	rosemary extract (RE)	654:674	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	15	theme	novel	629:633	arg1	Fe3O4					603:607	Fe3O4	603:607	Fe3O4	603:607	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	15	theme	novel	629:633	arg1	dots					590:593	carbon quantum dots	575:593	carbon quantum dots (CQDs)	575:600	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	15	theme	novel	629:633	arg1	antibacterial					635:647	a novel antibacterial	627:647	a novel antibacterial	627:647	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	7	16	theme	high	1179:1182	arg1	properties					1198:1207	the high antibacterial properties	1175:1207	the high antibacterial properties of CQDs-Fe3O4-RE	1175:1224	Results exhibited, the high antibacterial properties of CQDs-Fe3O4-RE.
36948337	6	17	theme	electrospun	1088:1098	arg1	OEN					1111:1113	OEN	1111:1113	OEN	1111:1113	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	17	theme	electrospun	1088:1098	arg1	nanofiber					1100:1108	optimized electrospun nanofiber	1078:1108	optimized electrospun nanofiber (OEN) as a novel wound dressing	1078:1140	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	1	18	theme	skin	180:183	arg1	infections					185:194	Wound skin infections	174:194	Wound skin infections	174:194	Wound skin infections can cause significant morbidity and even mortality.
36948337	9	19	theme	wound	1325:1329	arg1	percentages					1336:1346	wound area percentages	1325:1346	wound area percentages	1325:1346	Moreover, CNFs and RE reduce wound area percentages and increase the percentage of cell viability, respectively.
36948337	6	20	theme	optimized	1078:1086	arg1	OEN					1111:1113	OEN	1111:1113	OEN	1111:1113	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	20	theme	optimized	1078:1086	arg1	nanofiber					1100:1108	optimized electrospun nanofiber	1078:1108	optimized electrospun nanofiber (OEN) as a novel wound dressing	1078:1140	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	21	theme	concentration	991:1003	arg1	parameters					947:956	parameters	947:956	parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE	947:1021	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	10	22	theme	high	1592:1595	arg1	proliferation					1602:1614	high cell proliferation	1592:1614	high cell proliferation	1592:1614	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	10	23	theme	due	1468:1470	arg1	dressing					1459:1466	a suitable wound dressing	1442:1466	a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability	1442:1636	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	10	23	theme	due	1468:1470	arg1	OEN					1420:1422	OEN	1420:1422	OEN	1420:1422	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	10	24	theme	suitable	1444:1451	arg1	dressing					1459:1466	a suitable wound dressing	1442:1466	a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability	1442:1636	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	10	24	theme	suitable	1444:1451	arg1	OEN					1420:1422	OEN	1420:1422	OEN	1420:1422	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	6	25	theme	duration	974:981	arg1	parameters					947:956	parameters	947:956	parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE	947:1021	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	10	26	theme	surface	1491:1497	arg1	roughness					1499:1507	its appropriate surface roughness	1475:1507	its appropriate surface roughness	1475:1507	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	8	27	theme	tensile	1271:1277	arg1	strength					1279:1286	the tensile strength	1267:1286	the tensile strength of OEN	1267:1293	Also, CNFs and CQDs- Fe3O4-RE increased the tensile strength of OEN.
36948337	3	28	theme	novel	415:419	arg1	dressing					427:434	a novel wound dressing	413:434	a novel wound dressing	413:434	In this study, in order to prepare a novel wound dressing, CNFs are composited with poly (vinyl alcohol) (PVA) to enhance mechanical properties and increase cell proliferation and migration.
36948337	10	29	theme	appropriate	1479:1489	arg1	roughness					1499:1507	its appropriate surface roughness	1475:1507	its appropriate surface roughness	1475:1507	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	6	30	theme	percentage	873:882	arg1	swelling					884:891	percentage swelling	873:891	percentage swelling of PVA	873:898	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	9	31	theme	area	1331:1334	arg1	percentages					1336:1346	wound area percentages	1325:1346	wound area percentages	1325:1346	Moreover, CNFs and RE reduce wound area percentages and increase the percentage of cell viability, respectively.
36948337	6	32	theme	CQDs-	908:912	arg1	nanofiber					936:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	1	33	theme	significant	206:216	arg1	morbidity					218:226	significant morbidity	206:226	significant morbidity	206:226	Wound skin infections can cause significant morbidity and even mortality.
36948337	0	34	theme	electrospun	16:26	arg1	Optimization					0:11	Optimization	0:11	Optimization of electrospun	0:26	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	2	35	theme	cellulose	296:304	arg1	nanofibrils					258:268	Cellulose nanofibrils	248:268	Cellulose nanofibrils (CNFs)	248:275	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	2	35	theme	cellulose	296:304	arg1	type					283:286	a type	281:286	a type of nano cellulose that have reached notable attention due to their inimitable properties	281:375	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	3	36	dep	cell	535:538	arg1	proliferation					540:552	proliferation	540:552	proliferation	540:552	In this study, in order to prepare a novel wound dressing, CNFs are composited with poly (vinyl alcohol) (PVA) to enhance mechanical properties and increase cell proliferation and migration.
36948337	5	37	theme	Fe3O4-	748:753	arg1	nanofiber					758:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	PVA - CNFs/ CQDs- Fe3O4- RE nanofiber was prepared using the electrospinning method.
36948337	0	38	theme	PVA-cellulose	49:61	arg1	nanofibrils					63:73	loaded PVA-cellulose nanofibrils	42:73	loaded PVA-cellulose nanofibrils	42:73	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	3	39	theme	vinyl	468:472	arg1	poly					462:465	poly	462:465	poly (vinyl alcohol) (PVA)	462:487	In this study, in order to prepare a novel wound dressing, CNFs are composited with poly (vinyl alcohol) (PVA) to enhance mechanical properties and increase cell proliferation and migration.
36948337	3	39	theme	vinyl	468:472	arg1	alcohol					474:480	vinyl alcohol	468:480	vinyl alcohol	468:480	In this study, in order to prepare a novel wound dressing, CNFs are composited with poly (vinyl alcohol) (PVA) to enhance mechanical properties and increase cell proliferation and migration.
36948337	6	40	theme	crosslinking	961:972	arg1	duration					974:981	crosslinking duration	961:981	crosslinking duration	961:981	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	5	41	theme	RE	755:756	arg1	nanofiber					758:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	PVA - CNFs/ CQDs- Fe3O4- RE nanofiber was prepared using the electrospinning method.
36948337	0	42	theme	loaded	42:47	arg1	nanofibrils					63:73	loaded PVA-cellulose nanofibrils	42:73	loaded PVA-cellulose nanofibrils	42:73	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	0	43	theme	in	150:151	arg1	study					167:171	in vitro release study	150:171	in vitro release study	150:171	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	2	44	theme	Cellulose	248:256	arg1	CNFs					271:274	CNFs	271:274	CNFs	271:274	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	2	44	theme	Cellulose	248:256	arg1	nanofibrils					258:268	Cellulose nanofibrils	248:268	Cellulose nanofibrils (CNFs)	248:275	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	2	44	theme	Cellulose	248:256	arg1	type					283:286	a type	281:286	a type of nano cellulose that have reached notable attention due to their inimitable properties	281:375	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	9	45	theme	cell	1379:1382	arg1	viability					1384:1392	cell viability	1379:1392	cell viability	1379:1392	Moreover, CNFs and RE reduce wound area percentages and increase the percentage of cell viability, respectively.
36948337	10	46	theme	mechanical	1510:1519	arg1	properties					1521:1530	mechanical properties	1510:1530	mechanical properties	1510:1530	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	6	47	theme	total	851:855	arg1	elongation					857:866	total elongation	851:866	total elongation	851:866	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	3	48	theme	wound	421:425	arg1	dressing					427:434	a novel wound dressing	413:434	a novel wound dressing	413:434	In this study, in order to prepare a novel wound dressing, CNFs are composited with poly (vinyl alcohol) (PVA) to enhance mechanical properties and increase cell proliferation and migration.
36948337	6	49	theme	wound	1127:1131	arg1	dressing					1133:1140	a novel wound dressing	1119:1140	a novel wound dressing	1119:1140	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	50	theme	Fe3O4-RE	1014:1021	arg1	duration					974:981	crosslinking duration	961:981	crosslinking duration	961:981	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	50	theme	Fe3O4-RE	1014:1021	arg1	concentration					991:1003	the concentration	987:1003	the concentration of CQDs- Fe3O4-RE	987:1021	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	6	51	theme	central	1048:1054	arg1	design					1066:1071	central composite design	1048:1071	central composite design	1048:1071	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	0	52	theme	release	159:165	arg1	study					167:171	in vitro release study	150:171	in vitro release study	150:171	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	6	53	theme	novel	1121:1125	arg1	dressing					1133:1140	a novel wound dressing	1119:1140	a novel wound dressing	1119:1140	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	2	54	theme	due	342:344	arg1	attention					332:340	notable attention	324:340	notable attention due to their inimitable properties	324:375	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	0	55	dep	CQDs-Fe3O4-RE	28:40	arg1	study					167:171	in vitro release study	150:171	in vitro release study	150:171	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	0	55	dep	CQDs-Fe3O4-RE	28:40	arg1	Kinetics					137:144	Kinetics	137:144	Kinetics	137:144	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	8	56	theme	OEN	1291:1293	arg1	strength					1279:1286	the tensile strength	1267:1286	the tensile strength of OEN	1267:1293	Also, CNFs and CQDs- Fe3O4-RE increased the tensile strength of OEN.
36948337	6	57	theme	electrospun	924:934	arg1	nanofiber					936:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	7	58	theme	antibacterial	1184:1196	arg1	properties					1198:1207	the high antibacterial properties	1175:1207	the high antibacterial properties of CQDs-Fe3O4-RE	1175:1224	Results exhibited, the high antibacterial properties of CQDs-Fe3O4-RE.
36948337	5	59	theme	CNFs/	736:740	arg1	nanofiber					758:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	PVA - CNFs/ CQDs- Fe3O4- RE nanofiber was prepared using the electrospinning method.
36948337	10	60	theme	prolonged	1555:1563	arg1	release					1565:1571	prolonged release	1555:1571	prolonged release	1555:1571	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	2	61	theme	notable	324:330	arg1	attention					332:340	notable attention	324:340	notable attention due to their inimitable properties	324:375	Cellulose nanofibrils (CNFs) are a type of nano cellulose that have reached notable attention due to their inimitable properties.
36948337	6	62	theme	RE	921:922	arg1	nanofiber					936:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	CNFs/ CQDs- Fe3O4- RE electrospun nanofiber	902:944	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	0	63	theme	composite	87:95	arg1	design					97:102	central composite design	79:102	central composite design for wound dressing applications	79:134	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	6	64	theme	CQDs-	1008:1012	arg1	Fe3O4-RE					1014:1021	CQDs- Fe3O4-RE	1008:1021	CQDs- Fe3O4-RE	1008:1021	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	5	65	theme	CQDs-	742:746	arg1	nanofiber					758:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	CNFs/ CQDs- Fe3O4- RE nanofiber	736:766	PVA - CNFs/ CQDs- Fe3O4- RE nanofiber was prepared using the electrospinning method.
36948337	5	66	theme	electrospinning	791:805	arg1	method					807:812	the electrospinning method	787:812	the electrospinning method	787:812	PVA - CNFs/ CQDs- Fe3O4- RE nanofiber was prepared using the electrospinning method.
36948337	7	67	theme	CQDs-Fe3O4-RE	1212:1224	arg1	properties					1198:1207	the high antibacterial properties	1175:1207	the high antibacterial properties of CQDs-Fe3O4-RE	1175:1224	Results exhibited, the high antibacterial properties of CQDs-Fe3O4-RE.
36948337	4	68	theme	quantum	582:588	arg1	CQDs					596:599	CQDs	596:599	CQDs	596:599	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	68	theme	quantum	582:588	arg1	Fe3O4					603:607	Fe3O4	603:607	Fe3O4	603:607	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	68	theme	quantum	582:588	arg1	dots					590:593	carbon quantum dots	575:593	carbon quantum dots (CQDs)	575:600	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	68	theme	quantum	582:588	arg1	antibacterial					635:647	a novel antibacterial	627:647	a novel antibacterial	627:647	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	0	69	theme	central	79:85	arg1	design					97:102	central composite design	79:102	central composite design for wound dressing applications	79:134	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	6	70	theme	tensile	833:839	arg1	strength					841:848	tensile strength	833:848	tensile strength	833:848	Then, to maximize tensile strength, total elongation, and percentage swelling of PVA - CNFs/ CQDs- Fe3O4- RE electrospun nanofiber, parameters of crosslinking duration and the concentration of CQDs- Fe3O4-RE were optimized employing central composite design, and optimized electrospun nanofiber (OEN) as a novel wound dressing was prepared.
36948337	4	71	theme	cell	715:718	arg1	toxicity					720:727	its cell toxicity	711:727	its cell toxicity	711:727	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	10	72	theme	wound	1453:1457	arg1	dressing					1459:1466	a suitable wound dressing	1442:1466	a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability	1442:1636	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	10	72	theme	wound	1453:1457	arg1	OEN					1420:1422	OEN	1420:1422	OEN	1420:1422	Therefore, OEN was introduced as a suitable wound dressing due to its appropriate surface roughness, mechanical properties, WVTR, biodegradation, prolonged release, non-toxicity, and high cell proliferation and migration ability.
36948337	0	73	dep	in	150:151	arg1	vitro					153:157	vitro	153:157	vitro	153:157	Optimization of electrospun CQDs-Fe3O4-RE loaded PVA-cellulose nanofibrils via central composite design for wound dressing applications: Kinetics and in vitro release study.
36948337	4	74	theme	carbon	575:580	arg1	CQDs					596:599	CQDs	596:599	CQDs	596:599	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	74	theme	carbon	575:580	arg1	Fe3O4					603:607	Fe3O4	603:607	Fe3O4	603:607	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	74	theme	carbon	575:580	arg1	dots					590:593	carbon quantum dots	575:593	carbon quantum dots (CQDs)	575:600	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36948337	4	74	theme	carbon	575:580	arg1	antibacterial					635:647	a novel antibacterial	627:647	a novel antibacterial	627:647	Also, carbon quantum dots (CQDs)- Fe3O4 was introduced as a novel antibacterial, and rosemary extract (RE) was composited with this to reduce its cell toxicity.
36869463	4	0	theme	chain	919:923	arg1	structure					925:933	a straight chain structure	908:933	a straight chain structure	908:933	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	4	1	theme	molecular	833:841	arg1	structure					843:851	The molecular structure	829:851	pH. The molecular structure	825:851	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	8	2	theme	minimal	1228:1234	arg1	aggregation					1236:1246	minimal aggregation	1228:1246	minimal aggregation between pH 3.6-4.4	1228:1265	LM-SPPS could stabilize a model acidified milk dispersion with minimal aggregation between pH 3.6-4.4, while HM-SPPS showed the presence of bridging flocculation caused by polysaccharide's entanglements.
36869463	5	3	theme	kidney	1032:1037	arg1	bean					1039:1042	kidney bean	1032:1042	kidney bean	1032:1042	The structure was similar to that already reported for polysaccharides from kidney bean.
36869463	1	4	theme	methyl-esterified	269:285	arg1	polysaccharides					245:259	two different pea water-soluble polysaccharides	213:259	two different pea water-soluble polysaccharides	213:259	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	4	theme	methyl-esterified	269:285	arg1	SPPS					370:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS	262:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	262:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	4	5	theme	straight	910:917	arg1	structure					925:933	a straight chain structure	908:933	a straight chain structure	908:933	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	2	6	theme	exclusion	545:553	arg1	chromatography					555:568	size exclusion chromatography	540:568	size exclusion chromatography equipped with a multi-angle light scattering detector	540:622	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	1	7	theme	structural	173:182	arg1	properties					199:208	The structural and functional properties	169:208	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	169:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	9	8	theme	electrostatic	1439:1451	arg1	repulsion					1453:1461	steric and electrostatic repulsion	1428:1461	steric and electrostatic repulsion	1428:1461	It was concluded that SPPS stabilizes acidified protein by steric and electrostatic repulsion.
36869463	2	9	theme	molecular	490:498	arg1	mass					500:503	a weight average molecular mass	473:503	a weight average molecular mass of about 1,000 kDa	473:522	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	3	10	theme	similar	654:660	arg1	compositions					668:679	similar sugar compositions	654:679	similar sugar compositions	654:679	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	10	theme	similar	654:660	arg1	sugars					780:785	their main sugars	769:785	their main sugars	769:785	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	2	11	theme	size	540:543	arg1	chromatography					555:568	size exclusion chromatography	540:568	size exclusion chromatography equipped with a multi-angle light scattering detector	540:622	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	8	12	theme	flocculation	1314:1325	arg1	presence					1293:1300	the presence	1289:1300	the presence of bridging flocculation caused by polysaccharide's entanglements	1289:1366	LM-SPPS could stabilize a model acidified milk dispersion with minimal aggregation between pH 3.6-4.4, while HM-SPPS showed the presence of bridging flocculation caused by polysaccharide's entanglements.
36869463	2	13	theme	average	482:488	arg1	mass					500:503	a weight average molecular mass	473:503	a weight average molecular mass of about 1,000 kDa	473:522	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	3	14	theme	arabinose	687:695	arg1	%					707:707	arabinose 42.2-47.1 %	687:707	arabinose 42.2-47.1 %	687:707	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	2	15	theme	scattering	604:613	arg1	detector					615:622	a multi-angle light scattering detector	584:622	a multi-angle light scattering detector	584:622	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	2	16	theme	weight	475:480	arg1	mass					500:503	a weight average molecular mass	473:503	a weight average molecular mass of about 1,000 kDa	473:522	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	1	17	theme	methyl-esterified	352:368	arg1	polysaccharides					245:259	two different pea water-soluble polysaccharides	213:259	two different pea water-soluble polysaccharides	213:259	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	17	theme	methyl-esterified	352:368	arg1	SPPS					370:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS	262:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	262:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	2	18	theme	multi-angle	586:596	arg1	detector					615:622	a multi-angle light scattering detector	584:622	a multi-angle light scattering detector	584:622	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	2	19	theme	light	598:602	arg1	detector					615:622	a multi-angle light scattering detector	584:622	a multi-angle light scattering detector	584:622	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	4	20	theme	small	940:944	arg1	branches					946:953	small branches	940:953	small branches	940:953	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	3	21	theme	main	775:778	arg1	compositions					668:679	similar sugar compositions	654:679	similar sugar compositions	654:679	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	21	theme	main	775:778	arg1	sugars					780:785	their main sugars	769:785	their main sugars	769:785	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	1	22	theme	functional	188:197	arg1	properties					199:208	The structural and functional properties	169:208	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	169:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	4	23	theme	probe	880:884	arg1	microscope					886:895	a scanning probe microscope	869:895	a scanning probe microscope	869:895	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	0	24	theme	Molecular	0:8	arg1	structures					10:19	Molecular structures	0:19	Molecular structures of high- and low-methoxy water-soluble polysaccharides	0:74	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	3	25	theme	glucose	710:716	arg1	%					728:728	glucose 26.6-31.0 %	710:728	glucose 26.6-31.0 %	710:728	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	8	26	theme	model	1191:1195	arg1	dispersion					1212:1221	a model acidified milk dispersion	1189:1221	a model acidified milk dispersion	1189:1221	LM-SPPS could stabilize a model acidified milk dispersion with minimal aggregation between pH 3.6-4.4, while HM-SPPS showed the presence of bridging flocculation caused by polysaccharide's entanglements.
36869463	9	27	theme	acidified	1407:1415	arg1	protein					1417:1423	acidified protein	1407:1423	acidified protein	1407:1423	It was concluded that SPPS stabilizes acidified protein by steric and electrostatic repulsion.
36869463	0	28	theme	high-	24:28	arg1	polysaccharides					60:74	high- and low-methoxy water-soluble polysaccharides	24:74	high- and low-methoxy water-soluble polysaccharides	24:74	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	6	29	theme	protein	1089:1095	arg1	particles					1097:1105	acidified milk protein particles	1074:1105	acidified milk protein particles	1074:1105	SPPS molecules interact with acidified milk protein particles at pH < 4.4.
36869463	8	30	theme	acidified	1197:1205	arg1	dispersion					1212:1221	a model acidified milk dispersion	1189:1221	a model acidified milk dispersion	1189:1221	LM-SPPS could stabilize a model acidified milk dispersion with minimal aggregation between pH 3.6-4.4, while HM-SPPS showed the presence of bridging flocculation caused by polysaccharide's entanglements.
36869463	5	31	from	bean	1039:1042	arg1	polysaccharides					1011:1025	polysaccharides	1011:1025	polysaccharides from kidney bean	1011:1042	The structure was similar to that already reported for polysaccharides from kidney bean.
36869463	1	32	theme	methyl	307:312	arg1	DMe					330:332	DMe	330:332	DMe	330:332	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	32	theme	methyl	307:312	arg1	esterification					314:327	methyl esterification	307:327	methyl esterification (DMe)	307:333	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	0	33	theme	milk	130:133	arg1	proteins					135:142	milk proteins	130:142	milk proteins	130:142	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	6	34	theme	milk	1084:1087	arg1	particles					1097:1105	acidified milk protein particles	1074:1105	acidified milk protein particles	1074:1105	SPPS molecules interact with acidified milk protein particles at pH < 4.4.
36869463	1	35	theme	different	217:225	arg1	polysaccharides					245:259	two different pea water-soluble polysaccharides	213:259	two different pea water-soluble polysaccharides	213:259	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	35	theme	different	217:225	arg1	SPPS					370:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS	262:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	262:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	0	36	theme	low-methoxy	34:44	arg1	polysaccharides					60:74	high- and low-methoxy water-soluble polysaccharides	24:74	high- and low-methoxy water-soluble polysaccharides	24:74	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	1	37	theme	esterification	314:327	arg1	degree					297:302	degree	297:302	HM-SPPS; degree of methyl esterification (DMe): 71.0 %	288:341	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	0	38	theme	acidic	150:155	arg1	conditions					157:166	acidic conditions	150:166	acidic conditions	150:166	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	9	39	theme	steric	1428:1433	arg1	repulsion					1453:1461	steric and electrostatic repulsion	1428:1461	steric and electrostatic repulsion	1428:1461	It was concluded that SPPS stabilizes acidified protein by steric and electrostatic repulsion.
36869463	1	40	theme	pea	227:229	arg1	polysaccharides					245:259	two different pea water-soluble polysaccharides	213:259	two different pea water-soluble polysaccharides	213:259	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	40	theme	pea	227:229	arg1	SPPS					370:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS	262:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	262:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	41	dep	SPPS	370:373	arg1	LM-SPPS					376:382	LM-SPPS	376:382	LM-SPPS; DMe: 25.2 %	376:395	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	3	42	theme	acid	748:751	arg1	%					763:763	galacturonic acid 17.5-18.0 %	735:763	galacturonic acid 17.5-18.0 %	735:763	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	1	43	theme	water-soluble	231:243	arg1	polysaccharides					245:259	two different pea water-soluble polysaccharides	213:259	two different pea water-soluble polysaccharides	213:259	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	43	theme	water-soluble	231:243	arg1	SPPS					370:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS	262:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	262:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	0	44	theme	polysaccharides	60:74	arg1	structures					10:19	Molecular structures	0:19	Molecular structures of high- and low-methoxy water-soluble polysaccharides	0:74	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	3	45	theme	galacturonic	735:746	arg1	%					763:763	galacturonic acid 17.5-18.0 %	735:763	galacturonic acid 17.5-18.0 %	735:763	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	8	46	theme	bridging	1305:1312	arg1	flocculation					1314:1325	bridging flocculation	1305:1325	bridging flocculation caused by polysaccharide's entanglements	1305:1366	LM-SPPS could stabilize a model acidified milk dispersion with minimal aggregation between pH 3.6-4.4, while HM-SPPS showed the presence of bridging flocculation caused by polysaccharide's entanglements.
36869463	6	47	theme	acidified	1074:1082	arg1	particles					1097:1105	acidified milk protein particles	1074:1105	acidified milk protein particles	1074:1105	SPPS molecules interact with acidified milk protein particles at pH < 4.4.
36869463	0	48	theme	water-soluble	46:58	arg1	polysaccharides					60:74	high- and low-methoxy water-soluble polysaccharides	24:74	high- and low-methoxy water-soluble polysaccharides	24:74	Molecular structures of high- and low-methoxy water-soluble polysaccharides derived from peas and their functions for stabilizing milk proteins under acidic conditions.
36869463	1	49	dep	HM-SPPS	288:294	arg1	degree					297:302	degree	297:302	HM-SPPS; degree of methyl esterification (DMe): 71.0 %	288:341	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	49	dep	HM-SPPS	288:294	arg1	%					341:341	71.0 %	336:341	HM-SPPS; degree of methyl esterification (DMe): 71.0 %	288:341	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	4	50	theme	structure	843:851	arg1	function					813:820	a function	811:820	a function of pH. The molecular structure	811:851	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	1	51	theme	polysaccharides	245:259	arg1	properties					199:208	The structural and functional properties	169:208	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	169:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	2	52	theme	kDa	520:522	arg1	mass					500:503	a weight average molecular mass	473:503	a weight average molecular mass of about 1,000 kDa	473:522	The two extracts did not vary in composition and showed a weight average molecular mass of about 1,000 kDa, as measured by size exclusion chromatography equipped with a multi-angle light scattering detector.
36869463	1	53	dep	methyl-esterified	269:285	arg1	HM-SPPS					288:294	HM-SPPS	288:294	HM-SPPS; degree of methyl esterification (DMe): 71.0 %	288:341	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	4	54	theme	scanning	871:878	arg1	microscope					886:895	a scanning probe microscope	869:895	a scanning probe microscope	869:895	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	4	55	dep	structure	843:851	arg1	pH.					825:827	pH. The molecular structure	825:851	pH. The molecular structure	825:851	Their charge varied as a function of pH. The molecular structure was observed by a scanning probe microscope and showed a straight chain structure with small branches.
36869463	8	56	theme	milk	1207:1210	arg1	dispersion					1212:1221	a model acidified milk dispersion	1189:1221	a model acidified milk dispersion	1189:1221	LM-SPPS could stabilize a model acidified milk dispersion with minimal aggregation between pH 3.6-4.4, while HM-SPPS showed the presence of bridging flocculation caused by polysaccharide's entanglements.
36869463	6	57	theme	SPPS	1045:1048	arg1	molecules					1050:1058	SPPS molecules	1045:1058	SPPS molecules	1045:1058	SPPS molecules interact with acidified milk protein particles at pH < 4.4.
36869463	1	58	dep	LM-SPPS	376:382	arg1	DMe					385:387	DMe	385:387	LM-SPPS; DMe: 25.2 %	376:395	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	58	dep	LM-SPPS	376:382	arg1	%					395:395	25.2 %	390:395	LM-SPPS; DMe: 25.2 %	376:395	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	3	59	theme	sugar	662:666	arg1	compositions					668:679	similar sugar compositions	654:679	similar sugar compositions	654:679	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	59	theme	sugar	662:666	arg1	sugars					780:785	their main sugars	769:785	their main sugars	769:785	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	60	contain	had	650:652	arg2	sugars					780:785	their main sugars	769:785	their main sugars	769:785	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	60	contain	had	650:652	arg1	HM-SPPS					630:636	HM-SPPS	630:636	HM-SPPS	630:636	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	60	contain	had	650:652	arg2	compositions					668:679	similar sugar compositions	654:679	similar sugar compositions	654:679	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	3	60	contain	had	650:652	arg1	LM-SPPS					642:648	LM-SPPS	642:648	LM-SPPS	642:648	Both HM-SPPS and LM-SPPS had similar sugar compositions, with arabinose 42.2-47.1 %, glucose 26.6-31.0 %, and galacturonic acid 17.5-18.0 %, as their main sugars.
36869463	1	61	theme	high	264:267	arg1	polysaccharides					245:259	two different pea water-soluble polysaccharides	213:259	two different pea water-soluble polysaccharides	213:259	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
36869463	1	61	theme	high	264:267	arg1	SPPS					370:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS	262:373	a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %)	262:396	The structural and functional properties of two different pea water-soluble polysaccharides, a high methyl-esterified (HM-SPPS; degree of methyl esterification (DMe): 71.0 %) and low methyl-esterified SPPS (LM-SPPS; DMe: 25.2 %) were investigated.
35916484	9	0	theme	linkage	1574:1580	arg1	preference					1594:1603	the linkage specificity preference	1570:1603	the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis	1570:1852	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	7	1	theme	proximal	1205:1212	arg1	cis-peptide					1143:1153	a non-prolyl cis-peptide	1130:1153	a non-prolyl cis-peptide	1130:1153	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	9	2	theme	periodontitis	1840:1852	arg1	treatment					1827:1835	the treatment	1823:1835	the treatment of periodontitis	1823:1852	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	7	3	theme	domain	1076:1081	arg1	structure					1083:1091	The catalytic domain structure	1062:1091	The catalytic domain structure	1062:1091	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	4	4	from	analysis	663:670	arg1	apo-form					700:707	its apo-form	696:707	its apo-form	696:707	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	4	4	from	analysis	663:670	arg1	complex					716:722	complex	716:722	complex with a sialic acid analogue/ inhibitor (Oseltamivir)	716:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	4	5	theme	thorough	643:650	arg1	analysis					663:670	a thorough structural analysis	641:670	a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir)	641:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	2	6	theme	forsythia	298:306	arg1	sialidase					274:282	The NanH sialidase	265:282	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease	265:370	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	1	7	theme	glycosidic	196:205	arg1	bond					207:210	the glycosidic bond	192:210	the glycosidic bond between terminal sialic acids and underlying sugars	192:262	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	9	8	theme	sialidase	1623:1631	arg1	preference					1594:1603	the linkage specificity preference	1570:1603	the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis	1570:1852	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	8	9	from	residues	1362:1369	arg1	proximity					1374:1382	proximity	1374:1382	proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates	1374:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	10	from	mutation	1350:1357	arg1	proximity					1374:1382	proximity	1374:1382	proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates	1374:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	5	11	theme	D237A	805:809	arg1	variant					812:818	non-catalytic (D237A) variant	790:818	non-catalytic (D237A) variant	790:818	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	8	12	dep	residues	1293:1300	arg1	D237					1303:1306	D237	1303:1306	D237	1303:1306	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	12	dep	residues	1293:1300	arg1	residues					1293:1300	key active site residues	1277:1300	key active site residues (D237, R212 and Y518)	1277:1322	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	12	dep	residues	1293:1300	arg1	Y518					1318:1321	Y518	1318:1321	Y518	1318:1321	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	12	dep	residues	1293:1300	arg1	R212					1309:1312	R212	1309:1312	R212	1309:1312	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	4	13	with	complex	716:722	arg1	Oseltamivir					764:774	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	5	14	theme	natural	885:891	arg1	substrates					893:902	the natural substrates 3- and 6-siallylactose	881:925	the natural substrates 3- and 6-siallylactose	881:925	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	8	15	theme	glycosidic	1391:1400	arg1	linkage					1402:1408	the glycosidic linkage	1387:1408	the glycosidic linkage within 2,3 and 2,6-linked substrates	1387:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	9	16	dep	information	1743:1753	arg1	that					1755:1758	that	1755:1758	that	1755:1758	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	6	17	theme	CAZy	997:1000	arg1	CBM					992:994	CBM	992:994	CBM	992:994	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	6	17	theme	CAZy	997:1000	arg1	CBM					1002:1004	CAZy CBM 93	997:1007	CAZy CBM 93	997:1007	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	8	18	theme	key	1277:1279	arg1	D237					1303:1306	D237	1303:1306	D237	1303:1306	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	18	theme	key	1277:1279	arg1	residues					1293:1300	key active site residues	1277:1300	key active site residues (D237, R212 and Y518)	1277:1322	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	18	theme	key	1277:1279	arg1	Y518					1318:1321	Y518	1318:1321	Y518	1318:1321	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	18	theme	key	1277:1279	arg1	R212					1309:1312	R212	1309:1312	R212	1309:1312	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	0	19	theme	functional	15:24	arg1	characterisation					26:41	Structural and functional characterisation	0:41	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.	0:138	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	1	20	theme	hydrolase	164:172	arg1	Sialidases					140:149	Sialidases	140:149	Sialidases	140:149	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	1	20	theme	hydrolase	164:172	arg1	enzymes					174:180	glycosyl hydrolase enzymes	155:180	glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars	155:262	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	5	21	with	complex	868:874	arg1	substrates					893:902	the natural substrates 3- and 6-siallylactose	881:925	the natural substrates 3- and 6-siallylactose	881:925	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	4	22	theme	enzyme	686:691	arg1	analysis					663:670	a thorough structural analysis	641:670	a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir)	641:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	0	23	theme	sialidase	85:93	arg1	characterisation					26:41	Structural and functional characterisation	0:41	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.	0:138	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	9	24	theme	structural	1732:1741	arg1	information					1743:1753	key structural information	1728:1753	key structural information that for in silico design of specific inhibitors of this enzyme	1728:1817	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	6	25	dep	module	984:989	arg1	has					1010:1012	has	1010:1012	has a novel fold made of antiparallel beta-strands	1010:1059	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	6	25	dep	module	984:989	arg1	CBM					992:994	CBM	992:994	CBM	992:994	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	6	25	dep	module	984:989	arg1	CBM					1002:1004	CAZy CBM 93	997:1007	CAZy CBM 93	997:1007	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	4	26	theme	acid	738:741	arg1	Oseltamivir					764:774	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	6	27	theme	NanH	958:961	arg1	module					984:989	the NanH carbohydrate-binding module	954:989	the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands	954:1059	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	4	28	theme	inhibitor	753:761	arg1	Oseltamivir					764:774	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	0	29	theme	pathogen	109:116	arg1	forsythia					129:137	the oral pathogen Tannerella forsythia	100:137	the oral pathogen Tannerella forsythia	100:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	9	30	theme	in	1764:1765	arg1	design					1774:1779	in silico design	1764:1779	in silico design of specific inhibitors of this enzyme	1764:1817	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	0	31	theme	Structural	0:9	arg1	characterisation					26:41	Structural and functional characterisation	0:41	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.	0:138	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	6	32	theme	novel	1016:1020	arg1	fold					1022:1025	a novel fold	1014:1025	a novel fold made of antiparallel beta-strands	1014:1059	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	9	33	theme	adjacent	1520:1527	arg1	R306					1488:1491	R306	1488:1491	R306	1488:1491	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	33	theme	adjacent	1520:1527	arg1	residues					1497:1504	residues S235 and V236	1497:1518	residues	1497:1504	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	7	34	theme	non-prolyl	1132:1141	arg1	cis-peptide					1143:1153	a non-prolyl cis-peptide	1130:1153	a non-prolyl cis-peptide	1130:1153	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	9	35	theme	specific	1784:1791	arg1	inhibitors					1793:1802	specific inhibitors	1784:1802	specific inhibitors of this enzyme	1784:1817	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	36	theme	inhibitors	1793:1802	arg1	design					1774:1779	in silico design	1764:1779	in silico design of specific inhibitors of this enzyme	1764:1817	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	0	37	dep	stable	48:53	arg1	broad-specificity					56:72	broad-specificity	56:72	broad-specificity	56:72	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	3	38	theme	sialic	495:500	arg1	acids					502:506	α2,3 over α2,6 linked sialic acids	473:506	α2,3 over α2,6 linked sialic acids	473:506	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	0	39	theme	stable	48:53	arg1	sialidase					85:93	a stable, broad-specificity multimeric sialidase	46:93	a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia	46:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	0	40	from	characterisation	26:41	arg1	forsythia					129:137	the oral pathogen Tannerella forsythia	100:137	the oral pathogen Tannerella forsythia	100:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	9	41	theme	acid-base	1536:1544	arg1	D237					1555:1558	the acid-base catalyst D237	1532:1558	the acid-base catalyst D237	1532:1558	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	42	theme	enzyme	1812:1817	arg1	inhibitors					1793:1802	specific inhibitors	1784:1802	specific inhibitors of this enzyme	1784:1817	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	2	43	theme	NanH	269:272	arg1	sialidase					274:282	The NanH sialidase	265:282	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease	265:370	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	8	44	theme	mutation	1350:1357	arg1	effects					1339:1345	the effects	1335:1345	the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates	1335:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	2	45	theme	periodontal	352:362	arg1	disease					364:370	severe periodontal disease	345:370	severe periodontal disease	345:370	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	1	46	theme	underlying	246:255	arg1	sugars					257:262	underlying sugars	246:262	underlying sugars	246:262	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	5	47	theme	non-catalytic	790:802	arg1	variant					812:818	non-catalytic (D237A) variant	790:818	non-catalytic (D237A) variant	790:818	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	8	48	theme	residues	1362:1369	arg1	mutation					1350:1357	mutation	1350:1357	mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates	1350:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	3	49	theme	complex	517:523	arg1	glycans					525:531	complex glycans	517:531	complex glycans but not those containing Neu5,9Ac	517:565	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	7	50	theme	active	1221:1226	arg1	site					1228:1231	the active site	1217:1231	the active site	1217:1231	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	0	51	from	forsythia	129:137	arg1	sialidase					85:93	a stable, broad-specificity multimeric sialidase	46:93	a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia	46:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	0	51	from	forsythia	129:137	arg1	characterisation					26:41	Structural and functional characterisation	0:41	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.	0:138	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	9	52	theme	specificity	1582:1592	arg1	preference					1594:1603	the linkage specificity preference	1570:1603	the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis	1570:1852	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	6	53	theme	antiparallel	1035:1046	arg1	beta-strands					1048:1059	antiparallel beta-strands	1035:1059	antiparallel beta-strands	1035:1059	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	7	54	theme	catalytic	1066:1074	arg1	structure					1083:1091	The catalytic domain structure	1062:1091	The catalytic domain structure	1062:1091	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	8	55	theme	site	1288:1291	arg1	D237					1303:1306	D237	1303:1306	D237	1303:1306	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	55	theme	site	1288:1291	arg1	residues					1293:1300	key active site residues	1277:1300	key active site residues (D237, R212 and Y518)	1277:1322	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	55	theme	site	1288:1291	arg1	Y518					1318:1321	Y518	1318:1321	Y518	1318:1321	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	55	theme	site	1288:1291	arg1	R212					1309:1312	R212	1309:1312	R212	1309:1312	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	9	56	dep	in	1764:1765	arg1	silico					1767:1772	silico	1767:1772	silico	1767:1772	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	57	theme	bacterial	1613:1621	arg1	opening					1634:1640	opening	1634:1640	opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis	1634:1852	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	57	theme	bacterial	1613:1621	arg1	sialidase					1623:1631	this bacterial sialidase	1608:1631	this bacterial sialidase	1608:1631	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	5	58	theme	molecular	836:844	arg1	interactions					846:857	molecular interactions	836:857	molecular interactions	836:857	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	4	59	theme	structural	652:661	arg1	analysis					663:670	a thorough structural analysis	641:670	a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir)	641:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	2	60	theme	bacteria	320:327	arg1	one					309:311	one	309:311	one	309:311	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	2	60	theme	bacteria	320:327	arg1	bacteria					320:327	the bacteria	316:327	the bacteria associated with severe periodontal disease	316:370	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	2	60	theme	bacteria	320:327	arg1	forsythia					298:306	Tannerella forsythia	287:306	Tannerella forsythia	287:306	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	1	61	theme	terminal	220:227	arg1	acids					236:240	terminal sialic acids	220:240	terminal sialic acids	220:240	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	8	62	theme	active	1281:1286	arg1	D237					1303:1306	D237	1303:1306	D237	1303:1306	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	62	theme	active	1281:1286	arg1	residues					1293:1300	key active site residues	1277:1300	key active site residues (D237, R212 and Y518)	1277:1322	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	62	theme	active	1281:1286	arg1	Y518					1318:1321	Y518	1318:1321	Y518	1318:1321	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	62	theme	active	1281:1286	arg1	R212					1309:1312	R212	1309:1312	R212	1309:1312	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	4	63	theme	dimeric	614:620	arg1	it					589:590	it	589:590	it	589:590	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	4	63	theme	dimeric	614:620	arg1	enzyme					622:627	a highly stable dimeric enzyme	598:627	a highly stable dimeric enzyme	598:627	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	7	64	theme	arginine	1171:1178	arg1	sidechain					1180:1188	an uncommon arginine sidechain	1159:1188	an uncommon arginine sidechain	1159:1188	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	3	65	link	linked	488:493	arg1	acids					502:506	α2,3 over α2,6 linked sialic acids	473:506	α2,3 over α2,6 linked sialic acids	473:506	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	8	66	theme	mutagenesis	1240:1250	arg1	programme					1252:1260	a mutagenesis programme	1238:1260	a mutagenesis programme	1238:1260	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	2	67	theme	Tannerella	287:296	arg1	one					309:311	one	309:311	one	309:311	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	2	67	theme	Tannerella	287:296	arg1	bacteria					320:327	the bacteria	316:327	the bacteria associated with severe periodontal disease	316:370	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	2	67	theme	Tannerella	287:296	arg1	forsythia					298:306	Tannerella forsythia	287:306	Tannerella forsythia	287:306	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	9	68	theme	glycotechology	1686:1699	arg1	applications					1701:1712	glycotechology applications	1686:1712	glycotechology applications	1686:1712	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	5	69	dep	substrates	893:902	arg1	6-siallylactose					911:925	6-siallylactose	911:925	6-siallylactose	911:925	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	5	69	dep	substrates	893:902	arg1	3-					904:905	3-	904:905	3-	904:905	We also use non-catalytic (D237A) variant to characterise molecular interactions while in complex with the natural substrates 3- and 6-siallylactose.
35916484	0	70	theme	multimeric	74:83	arg1	sialidase					85:93	a stable, broad-specificity multimeric sialidase	46:93	a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia	46:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	1	71	theme	glycosyl	155:162	arg1	Sialidases					140:149	Sialidases	140:149	Sialidases	140:149	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	1	71	theme	glycosyl	155:162	arg1	enzymes					174:180	glycosyl hydrolase enzymes	155:180	glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars	155:262	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	8	72	theme	2,6-linked	1425:1434	arg1	substrates					1436:1445	2,6-linked substrates	1425:1445	2,6-linked substrates	1425:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	8	73	from	proximity	1374:1382	arg1	mutation					1350:1357	mutation	1350:1357	mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates	1350:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	9	74	theme	key	1728:1730	arg1	information					1743:1753	key structural information	1728:1753	key structural information that for in silico design of specific inhibitors of this enzyme	1728:1817	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	4	75	theme	native	679:684	arg1	enzyme					686:691	the native enzyme	675:691	the native enzyme	675:691	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	7	76	contain	contains	1093:1100	arg1	structure					1083:1091	The catalytic domain structure	1062:1091	The catalytic domain structure	1062:1091	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	7	76	contain	contains	1093:1100	arg2	features					1108:1115	novel features	1102:1115	novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site	1102:1231	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	0	77	theme	oral	104:107	arg1	forsythia					129:137	the oral pathogen Tannerella forsythia	100:137	the oral pathogen Tannerella forsythia	100:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	6	78	theme	carbohydrate-binding	963:982	arg1	module					984:989	the NanH carbohydrate-binding module	954:989	the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands	954:1059	This dataset also reveals the NanH carbohydrate-binding module (CBM, CAZy CBM 93) has a novel fold made of antiparallel beta-strands.
35916484	4	79	theme	sialic	731:736	arg1	Oseltamivir					764:774	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	2	80	theme	severe	345:350	arg1	disease					364:370	severe periodontal disease	345:370	severe periodontal disease	345:370	The NanH sialidase of Tannerella forsythia, one of the bacteria associated with severe periodontal disease plays a role in virulence.
35916484	0	81	theme	Tannerella	118:127	arg1	forsythia					129:137	the oral pathogen Tannerella forsythia	100:137	the oral pathogen Tannerella forsythia	100:137	Structural and functional characterisation of a stable, broad-specificity multimeric sialidase from the oral pathogen Tannerella forsythia.
35916484	1	82	theme	sialic	229:234	arg1	acids					236:240	terminal sialic acids	220:240	terminal sialic acids	220:240	Sialidases are glycosyl hydrolase enzymes targeting the glycosidic bond between terminal sialic acids and underlying sugars.
35916484	9	83	theme	R306	1488:1491	arg1	R306					1488:1491	R306	1488:1491	R306	1488:1491	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	83	theme	R306	1488:1491	arg1	mutagenesis					1473:1483	mutagenesis	1473:1483	mutagenesis of R306	1473:1491	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	9	83	theme	R306	1488:1491	arg1	residues					1497:1504	residues S235 and V236	1497:1518	residues	1497:1504	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	4	84	theme	analogue/	743:751	arg1	Oseltamivir					764:774	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	a sialic acid analogue/ inhibitor (Oseltamivir)	729:775	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	3	85	theme	higher	453:458	arg1	affinity					460:467	but higher affinity	449:467	but higher affinity for α2,3 over α2,6 linked sialic acids	449:506	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	3	86	dep	enzyme	441:446	arg1	affinity					460:467	but higher affinity	449:467	but higher affinity for α2,3 over α2,6 linked sialic acids	449:506	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	3	87	theme	broad-specificity	423:439	arg1	enzyme					441:446	this broad-specificity enzyme	418:446	this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids)	418:507	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	7	88	theme	uncommon	1162:1169	arg1	sidechain					1180:1188	an uncommon arginine sidechain	1159:1188	an uncommon arginine sidechain	1159:1188	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	7	89	theme	novel	1102:1106	arg1	features					1108:1115	novel features	1102:1115	novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site	1102:1231	The catalytic domain structure contains novel features that include a non-prolyl cis-peptide and an uncommon arginine sidechain rotamer (R306) proximal to the active site.
35916484	3	90	contain	containing	547:556	arg1	those					541:545	those	541:545	those	541:545	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	3	90	contain	containing	547:556	arg2	Neu5,9Ac					558:565	Neu5,9Ac	558:565	Neu5,9Ac	558:565	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	9	91	theme	catalyst	1546:1553	arg1	D237					1555:1558	the acid-base catalyst D237	1532:1558	the acid-base catalyst D237	1532:1558	These data revealed that mutagenesis of R306 and residues S235 and V236 adjacent to the acid-base catalyst D237 influence the linkage specificity preference of this bacterial sialidase, opening up possibilities for enzyme engineering for glycotechology applications and providing key structural information that for in silico design of specific inhibitors of this enzyme for the treatment of periodontitis.
35916484	8	92	link	2,6-linked	1425:1434	arg1	substrates					1436:1445	2,6-linked substrates	1425:1445	2,6-linked substrates	1425:1445	Via a mutagenesis programme, we identified key active site residues (D237, R212 and Y518) and probed the effects of mutation of residues in proximity to the glycosidic linkage within 2,3 and 2,6-linked substrates.
35916484	3	93	theme	linked	488:493	arg1	acids					502:506	α2,3 over α2,6 linked sialic acids	473:506	α2,3 over α2,6 linked sialic acids	473:506	Here, we show that this broad-specificity enzyme (but higher affinity for α2,3 over α2,6 linked sialic acids) digests complex glycans but not those containing Neu5,9Ac.
35916484	4	94	theme	stable	607:612	arg1	it					589:590	it	589:590	it	589:590	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
35916484	4	94	theme	stable	607:612	arg1	enzyme					622:627	a highly stable dimeric enzyme	598:627	a highly stable dimeric enzyme	598:627	Furthermore, we show it to be a highly stable dimeric enzyme and present a thorough structural analysis of the native enzyme in its apo-form and in complex with a sialic acid analogue/ inhibitor (Oseltamivir).
36703594	7	0	theme	Adenanthera	1296:1306	arg1	seeds					1320:1324	Adenanthera pavonina L. seeds	1296:1324	Adenanthera pavonina L. seeds	1296:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	9	1	theme	film	1711:1714	arg1	structure					1694:1702	the structure	1690:1702	the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant	1690:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	7	2	from	seeds	1320:1324	arg1	monosaccharides					1254:1268	monosaccharides	1254:1268	monosaccharides of the galactomannan from Adenanthera pavonina L. seeds	1254:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	7	2	from	seeds	1320:1324	arg1	galactomannan					1277:1289	the galactomannan	1273:1289	the galactomannan from Adenanthera pavonina L. seeds	1273:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	3	3	theme	pavonina	767:774	arg1	L					776:776	Adenanthera pavonina L	755:776	Adenanthera pavonina L	755:776	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	8	4	from	increment	1442:1450	arg1	state-of-the-art					1459:1474	the state-of-the-art	1455:1474	the state-of-the-art of this biomaterial	1455:1494	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	6	5	dep	peaks	1110:1114	arg1	second					1160:1165	second	1160:1165	second	1160:1165	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	6	5	dep	peaks	1110:1114	arg1	first					1120:1124	first	1120:1124	first	1120:1124	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	1	6	theme	biodegradable	206:218	arg1	materials					238:246	biodegradable and biocompatible materials	206:246	biodegradable and biocompatible materials	206:246	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	9	7	attach	presence	1669:1676	arg2	water					1681:1685	water	1681:1685	water	1681:1685	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	9	7	attach	presence	1669:1676	arg1	structure					1694:1702	the structure	1690:1702	the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant	1690:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	0	8	theme	L.	142:143	arg1	Seeds					145:149	Adenanthera pavonina L. Seeds	121:149	Adenanthera pavonina L. Seeds	121:149	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	1	9	theme	promising	417:425	arg1	materials					431:439	important and promising raw materials	403:439	important and promising raw materials for biotechnology and electronic industries	403:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	1	9	theme	promising	417:425	arg1	structures					370:379	polysaccharide-based composite structures	339:379	polysaccharide-based composite structures	339:379	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	5	10	theme	Polymeric	870:878	arg1	films					880:884	Polymeric films	870:884	Polymeric films	870:884	Polymeric films were prepared by solvent slow evaporation at low temperatures.
36703594	1	11	used	used	395:398	arg2	structures					370:379	polysaccharide-based composite structures	339:379	polysaccharide-based composite structures	339:379	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	1	11	used	used	395:398	arg2	materials					431:439	important and promising raw materials	403:439	important and promising raw materials for biotechnology and electronic industries	403:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	9	12	theme	high	1760:1763	arg1	value					1765:1769	the relatively high value	1745:1769	the relatively high value of the dielectric constant	1745:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	7	13	from	monosaccharides	1254:1268	arg1	seeds					1320:1324	Adenanthera pavonina L. seeds	1296:1324	Adenanthera pavonina L. seeds	1296:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	1	14	theme	biotechnology	445:457	arg1	industries					474:483	biotechnology and electronic industries	445:483	biotechnology and electronic industries	445:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	9	15	theme	dielectric	1778:1787	arg1	constant					1789:1796	the dielectric constant	1774:1796	the dielectric constant	1774:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	1	16	theme	electronic	463:472	arg1	industries					474:483	biotechnology and electronic industries	445:483	biotechnology and electronic industries	445:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	6	17	theme	due	1077:1079	arg1	structure					1067:1075	a semi-crystalline structure	1048:1075	a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°	1048:1193	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	8	18	theme	relaxations	1535:1545	arg1	existence					1511:1519	the existence	1507:1519	the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism	1507:1628	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	0	19	theme	Galactomannan	66:78	arg1	Purification					12:23	Purification	12:23	Purification	12:23	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	0	19	theme	Galactomannan	66:78	arg1	Characterization					40:55	Electrical Characterization	29:55	Electrical Characterization	29:55	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	0	19	theme	Galactomannan	66:78	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	1	20	theme	self-sustainable	162:177	arg1	production					179:188	self-sustainable production	162:188	self-sustainable production	162:188	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	6	21	theme	semi-crystalline	1050:1065	arg1	structure					1067:1075	a semi-crystalline structure	1048:1075	a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°	1048:1193	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	2	22	theme	microbiological	547:561	arg1	sources					563:569	microbiological sources	547:569	microbiological sources	547:569	Galactomannans are polysaccharides, extracted from seeds and microbiological sources, consisting of mannose and galactose.
36703594	8	23	theme	independent	1548:1558	arg1	relaxations					1535:1545	dielectric relaxations	1524:1545	dielectric relaxations	1524:1545	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	0	24	theme	Purified	84:91	arg1	Galactomannan					93:105	Purified Galactomannan	84:105	Purified Galactomannan	84:105	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	4	25	theme	ethyl	818:822	arg1	alcohol					824:830	ethyl alcohol	818:830	ethyl alcohol	818:830	The purification process was made with ethyl alcohol at concentrations of 70, 80 and 90 %.
36703594	0	26	theme	Adenanthera	121:131	arg1	Seeds					145:149	Adenanthera pavonina L. Seeds	121:149	Adenanthera pavonina L. Seeds	121:149	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	1	27	theme	important	403:411	arg1	materials					431:439	important and promising raw materials	403:439	important and promising raw materials for biotechnology and electronic industries	403:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	1	27	theme	important	403:411	arg1	structures					370:379	polysaccharide-based composite structures	339:379	polysaccharide-based composite structures	339:379	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	8	28	theme	impedance	1416:1424	arg1	results					1426:1432	The impedance results	1412:1432	The impedance results	1412:1432	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	7	29	theme	functional	1220:1229	arg1	groups					1231:1236	the functional groups	1216:1236	the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds	1216:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	1	30	theme	physicochemical	289:303	arg1	characteristics					320:334	the physicochemical and dielectric characteristics	285:334	the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries	285:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	9	31	from	presence	1669:1676	arg1	structure					1694:1702	the structure	1690:1702	the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant	1690:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	6	32	theme	peaks	1110:1114	arg1	identification					1088:1101	the identification	1084:1101	the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°	1084:1193	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	6	33	contain	has	1044:1046	arg2	structure					1067:1075	a semi-crystalline structure	1048:1075	a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°	1048:1193	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	6	33	contain	has	1044:1046	arg1	Galactomannan					980:992	Galactomannan	980:992	Galactomannan from Adenanthera pavonina L.	980:1021	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	1	34	theme	dielectric	309:318	arg1	characteristics					320:334	the physicochemical and dielectric characteristics	285:334	the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries	285:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	8	35	theme	modulus	1612:1618	arg1	formalism					1620:1628	the dielectric modulus formalism	1597:1628	the dielectric modulus formalism	1597:1628	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	0	36	theme	Electrical	29:38	arg1	Characterization					40:55	Electrical Characterization	29:55	Electrical Characterization	29:55	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	7	37	theme	FTIR	1196:1199	arg1	spectra					1201:1207	FTIR spectra	1196:1207	FTIR spectra	1196:1207	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	7	38	theme	typical	1342:1348	arg1	bands					1365:1369	typical polysaccharide bands	1342:1369	typical polysaccharide bands	1342:1369	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	4	39	theme	%	867:867	arg1	concentrations					835:848	concentrations	835:848	concentrations of 70, 80 and 90 %	835:867	The purification process was made with ethyl alcohol at concentrations of 70, 80 and 90 %.
36703594	1	40	theme	composite	360:368	arg1	materials					431:439	important and promising raw materials	403:439	important and promising raw materials for biotechnology and electronic industries	403:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	1	40	theme	composite	360:368	arg1	structures					370:379	polysaccharide-based composite structures	339:379	polysaccharide-based composite structures	339:379	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	3	41	theme	XRD	681:683	arg1	spectroscopy					705:716	XRD, FTIR and impedance spectroscopy	681:716	spectroscopy	705:716	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	6	42	from	Adenanthera	999:1009	arg1	Galactomannan					980:992	Galactomannan	980:992	Galactomannan from Adenanthera pavonina L.	980:1021	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	3	43	theme	spectroscopy	705:716	arg1	galactomannan					718:730	XRD, FTIR and impedance spectroscopy galactomannan	681:730	XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L	681:776	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	8	44	theme	biomaterial	1484:1494	arg1	state-of-the-art					1459:1474	the state-of-the-art	1455:1474	the state-of-the-art of this biomaterial	1455:1494	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	7	45	dep	bands	1365:1369	arg1	the					1338:1340	the	1338:1340	the	1338:1340	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	3	46	theme	Adenanthera	755:765	arg1	L					776:776	Adenanthera pavonina L	755:776	Adenanthera pavonina L	755:776	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	3	47	theme	L	776:776	arg1	seeds					746:750	seeds	746:750	seeds of Adenanthera pavonina L	746:776	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	10	48	from	applications	1905:1916	arg1	industry					1937:1944	the electronics industry	1921:1944	the electronics industry	1921:1944	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	6	49	theme	XRD	949:951	arg1	measurements					953:964	XRD measurements	949:964	XRD measurements	949:964	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	5	50	theme	low	931:933	arg1	temperatures					935:946	low temperatures	931:946	low temperatures	931:946	Polymeric films were prepared by solvent slow evaporation at low temperatures.
36703594	10	51	theme	dielectric	1974:1983	arg1	material					1985:1992	a green and eco-friendly dielectric material	1949:1992	material	1985:1992	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	5	52	theme	solvent	903:909	arg1	evaporation					916:926	solvent slow evaporation	903:926	solvent slow evaporation at low temperatures	903:946	Polymeric films were prepared by solvent slow evaporation at low temperatures.
36703594	1	53	theme	raw	427:429	arg1	materials					431:439	important and promising raw materials	403:439	important and promising raw materials for biotechnology and electronic industries	403:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	1	53	theme	raw	427:429	arg1	structures					370:379	polysaccharide-based composite structures	339:379	polysaccharide-based composite structures	339:379	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	10	54	theme	purified	1851:1858	arg1	galactomannan					1860:1872	purified galactomannan	1851:1872	purified galactomannan	1851:1872	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	5	55	theme	slow	911:914	arg1	evaporation					916:926	solvent slow evaporation	903:926	solvent slow evaporation at low temperatures	903:946	Polymeric films were prepared by solvent slow evaporation at low temperatures.
36703594	6	56	dep	Adenanthera	999:1009	arg1	L.					1020:1021	Adenanthera pavonina L.	999:1021	Adenanthera pavonina L.	999:1021	XRD measurements revealed that Galactomannan from Adenanthera pavonina L., after purification, has a semi-crystalline structure due to the identification of two peaks the first between 5.849° and 6.118° and the second between 20.011° and 20.247°.
36703594	8	57	theme	dielectric	1524:1533	arg1	relaxations					1535:1545	dielectric relaxations	1524:1545	dielectric relaxations	1524:1545	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	9	58	theme	constant	1789:1796	arg1	value					1765:1769	the relatively high value	1745:1769	the relatively high value of the dielectric constant	1745:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	1	59	dep	need	272:275	arg1	the					268:270	the	268:270	the	268:270	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	7	60	theme	galactomannan	1277:1289	arg1	monosaccharides					1254:1268	monosaccharides	1254:1268	monosaccharides of the galactomannan from Adenanthera pavonina L. seeds	1254:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	7	61	theme	literature	1395:1404	arg1	data					1406:1409	literature data	1395:1409	literature data	1395:1409	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	0	62	theme	Galactomannan	93:105	arg1	Purification					12:23	Purification	12:23	Purification	12:23	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	0	62	theme	Galactomannan	93:105	arg1	Characterization					40:55	Electrical Characterization	29:55	Electrical Characterization	29:55	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	0	62	theme	Galactomannan	93:105	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	1	63	theme	production	179:188	arg1	Aiming					152:157	Aiming	152:157	Aiming	152:157	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	8	64	theme	degree	1567:1572	arg1	independent					1548:1558	independent	1548:1558	independent	1548:1558	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	7	65	dep	showed	1209:1214	arg1	confirmed					1382:1390	confirmed	1382:1390	confirmed by literature data	1382:1409	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	5	66	from	temperatures	935:946	arg1	evaporation					916:926	solvent slow evaporation	903:926	solvent slow evaporation at low temperatures	903:946	Polymeric films were prepared by solvent slow evaporation at low temperatures.
36703594	8	67	theme	purification	1577:1588	arg1	degree					1567:1572	the degree	1563:1572	the degree of purification, using the dielectric modulus formalism	1563:1628	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	0	68	theme	pavonina	133:140	arg1	Seeds					145:149	Adenanthera pavonina L. Seeds	121:149	Adenanthera pavonina L. Seeds	121:149	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	1	69	theme	biocompatible	224:236	arg1	materials					238:246	biodegradable and biocompatible materials	206:246	biodegradable and biocompatible materials	206:246	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	7	70	dep	Adenanthera	1296:1306	arg1	L.					1317:1318	Adenanthera pavonina L.	1296:1318	Adenanthera pavonina L. seeds	1296:1324	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	8	71	theme	dielectric	1601:1610	arg1	formalism					1620:1628	the dielectric modulus formalism	1597:1628	the dielectric modulus formalism	1597:1628	The impedance results give an increment on the state-of-the-art of this biomaterial by showing the existence of dielectric relaxations, independent of the degree of purification, using the dielectric modulus formalism.
36703594	4	72	theme	purification	783:794	arg1	process					796:802	The purification process	779:802	The purification process	779:802	The purification process was made with ethyl alcohol at concentrations of 70, 80 and 90 %.
36703594	9	73	theme	permittivity	1635:1646	arg1	analysis					1648:1655	The permittivity analysis	1631:1655	The permittivity analysis	1631:1655	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	7	74	theme	polysaccharide	1350:1363	arg1	bands					1365:1369	typical polysaccharide bands	1342:1369	typical polysaccharide bands	1342:1369	FTIR spectra showed the functional groups associated with monosaccharides of the galactomannan from Adenanthera pavonina L. seeds, as well as the typical polysaccharide bands and peaks, confirmed by literature data.
36703594	3	75	theme	FTIR	686:689	arg1	spectroscopy					705:716	XRD, FTIR and impedance spectroscopy	681:716	spectroscopy	705:716	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	10	76	contain	has	1874:1876	arg2	potential					1882:1890	the potential	1878:1890	the potential for possible applications in the electronics industry	1878:1944	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	10	76	contain	has	1874:1876	arg2	green					1951:1955	green	1951:1955	green	1951:1955	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	10	76	contain	has	1874:1876	arg1	galactomannan					1860:1872	purified galactomannan	1851:1872	purified galactomannan	1851:1872	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	10	77	theme	possible	1896:1903	arg1	applications					1905:1916	possible applications	1896:1916	possible applications in the electronics industry	1896:1944	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	4	78	theme	80	857:858	arg1	concentrations					835:848	concentrations	835:848	concentrations of 70, 80 and 90 %	835:867	The purification process was made with ethyl alcohol at concentrations of 70, 80 and 90 %.
36703594	0	79	theme	Gross	60:64	arg1	Galactomannan					66:78	Gross Galactomannan	60:78	Gross Galactomannan	60:78	Extraction, Purification and Electrical Characterization of Gross Galactomannan and Purified Galactomannan Obtained from Adenanthera pavonina L. Seeds.
36703594	1	80	theme	polysaccharide-based	339:358	arg1	materials					431:439	important and promising raw materials	403:439	important and promising raw materials for biotechnology and electronic industries	403:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	1	80	theme	polysaccharide-based	339:358	arg1	structures					370:379	polysaccharide-based composite structures	339:379	polysaccharide-based composite structures	339:379	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	10	81	theme	electronics	1925:1935	arg1	industry					1937:1944	the electronics industry	1921:1944	the electronics industry	1921:1944	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	1	82	theme	structures	370:379	arg1	characteristics					320:334	the physicochemical and dielectric characteristics	285:334	the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries	285:483	Aiming of self-sustainable production, the search for biodegradable and biocompatible materials has brought with it the need to know the physicochemical and dielectric characteristics of polysaccharide-based composite structures, which can be used as important and promising raw materials for biotechnology and electronic industries.
36703594	9	83	theme	water	1681:1685	arg1	presence					1669:1676	the presence	1665:1676	the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant	1665:1796	The permittivity analysis reveals the presence of water in the structure of the film, whose dipoles contribute to the relatively high value of the dielectric constant.
36703594	3	84	theme	impedance	695:703	arg1	spectroscopy					705:716	XRD, FTIR and impedance spectroscopy	681:716	spectroscopy	705:716	In this context, this work aimed to extract, purify and characterize by XRD, FTIR and impedance spectroscopy galactomannan obtained from seeds of Adenanthera pavonina L.
36703594	10	85	theme	eco-friendly	1961:1972	arg1	material					1985:1992	a green and eco-friendly dielectric material	1949:1992	material	1985:1992	From the results obtained, it can be concluded that purified galactomannan has the potential for possible applications in the electronics industry as a green and eco-friendly dielectric material.
36703594	4	86	theme	70	853:854	arg1	concentrations					835:848	concentrations	835:848	concentrations of 70, 80 and 90 %	835:867	The purification process was made with ethyl alcohol at concentrations of 70, 80 and 90 %.
36216103	2	0	theme	esterification	453:466	arg1	reaction					468:475	the esterification reaction	449:475	the esterification reaction	449:475	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	5	1	from	97.6°	941:945	arg1	detail					843:848	detail	843:848	detail	843:848	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	0	2	theme	modified	84:91	arg1	pectin					93:98	modified pectin	84:98	modified pectin	84:98	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	5	3	theme	highest	855:861	arg1	angle					871:875	the highest contact angle	851:875	the highest contact angle of the composite membrane incorporated with modified pectin	851:935	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	5	3	theme	highest	855:861	arg1	97.6°					941:945	97.6°	941:945	97.6°	941:945	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	2	4	theme	grafting	494:501	arg1	ratio					503:507	the highest grafting ratio	482:507	the highest grafting ratio	482:507	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	2	4	theme	grafting	494:501	arg1	%					518:518	7.89 %	513:518	7.89 %	513:518	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	5	5	theme	modified	921:928	arg1	pectin					930:935	modified pectin	921:935	modified pectin	921:935	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	7	6	dep	properties	1198:1207	arg1	the					1183:1185	the	1183:1185	the	1183:1185	Furthermore, the mechanical properties and transparency of the composite membranes could be improved by grafting docosanoic acid into pectin.
36216103	2	7	theme	highest	486:492	arg1	ratio					503:507	the highest grafting ratio	482:507	the highest grafting ratio	482:507	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	2	7	theme	highest	486:492	arg1	%					518:518	7.89 %	513:518	7.89 %	513:518	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	6	8	theme	water	1055:1059	arg1	permeability					1067:1078	the water vapor permeability	1051:1078	the water vapor permeability of the composite membranes	1051:1105	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	3	9	dep	activity	574:581	arg1	the					558:560	the	558:560	the	558:560	After grafting with docosanoic acid, the emulsifying activity and stability of pectin were significantly enhanced from 1.23 × 10-2 and 9.27 % to 4.78 × 10-2 and 26.73 %.
36216103	6	10	theme	membranes	1097:1105	arg1	permeability					1067:1078	the water vapor permeability	1051:1078	the water vapor permeability of the composite membranes	1051:1105	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	6	11	theme	composite	1087:1095	arg1	membranes					1097:1105	the composite membranes	1083:1105	the composite membranes	1083:1105	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	6	12	theme	grafting	1015:1022	arg1	ratio					1024:1028	the grafting ratio	1011:1028	the grafting ratio of pectin	1011:1038	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	7	13	theme	docosanoic	1283:1292	arg1	acid					1294:1297	docosanoic acid	1283:1297	docosanoic acid	1283:1297	Furthermore, the mechanical properties and transparency of the composite membranes could be improved by grafting docosanoic acid into pectin.
36216103	8	14	theme	food	1510:1513	arg1	packaging					1515:1523	food packaging	1510:1523	food packaging	1510:1523	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	4	15	theme	membranes	805:813	arg1	hydrophobicity					773:786	the hydrophobicity	769:786	the hydrophobicity of the composite membranes	769:813	Moreover, when modified pectin was blended with CMC instead of native pectin, the hydrophobicity of the composite membranes increased significantly.
36216103	5	16	theme	composite	884:892	arg1	membrane					894:901	the composite membrane	880:901	the composite membrane incorporated with modified pectin	880:935	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	1	17	theme	docosanoic	171:180	arg1	acid					212:215	a very long chain fatty acid	188:215	a very long chain fatty acid	188:215	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	17	theme	docosanoic	171:180	arg1	acid					182:185	docosanoic acid	171:185	docosanoic acid	171:185	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	4	18	theme	composite	795:803	arg1	membranes					805:813	the composite membranes	791:813	the composite membranes	791:813	Moreover, when modified pectin was blended with CMC instead of native pectin, the hydrophobicity of the composite membranes increased significantly.
36216103	5	19	theme	membrane	894:901	arg1	angle					871:875	the highest contact angle	851:875	the highest contact angle of the composite membrane incorporated with modified pectin	851:935	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	5	19	theme	membrane	894:901	arg1	97.6°					941:945	97.6°	941:945	97.6°	941:945	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	7	20	theme	composite	1233:1241	arg1	membranes					1243:1251	the composite membranes	1229:1251	the composite membranes	1229:1251	Furthermore, the mechanical properties and transparency of the composite membranes could be improved by grafting docosanoic acid into pectin.
36216103	8	21	theme	comprehensive	1401:1413	arg1	properties					1415:1424	the comprehensive properties	1397:1424	the comprehensive properties of the composite membranes based on polysaccharides	1397:1476	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	2	22	theme	docosanoic	403:412	arg1	acid					414:417	docosanoic acid	403:417	docosanoic acid	403:417	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	4	23	theme	native	754:759	arg1	pectin					761:766	native pectin	754:766	CMC instead of native pectin	739:766	Moreover, when modified pectin was blended with CMC instead of native pectin, the hydrophobicity of the composite membranes increased significantly.
36216103	0	24	theme	long-chain	123:132	arg1	acid					150:153	a long-chain saturated fatty acid	121:153	a long-chain saturated fatty acid	121:153	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	4	25	theme	modified	706:713	arg1	pectin					715:720	modified pectin	706:720	modified pectin	706:720	Moreover, when modified pectin was blended with CMC instead of native pectin, the hydrophobicity of the composite membranes increased significantly.
36216103	0	26	theme	hydrophobic	15:25	arg1	membranes					37:45	hydrophobic composite membranes	15:45	hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin	15:98	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	1	27	theme	hydrophobic	329:339	arg1	composite					341:349	a hydrophobic composite	327:349	a hydrophobic composite	327:349	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	6	28	theme	vapor	1061:1065	arg1	permeability					1067:1078	the water vapor permeability	1051:1078	the water vapor permeability of the composite membranes	1051:1105	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	2	29	theme	characterisation	374:389	arg1	Results					352:358	Results	352:358	Results of structural characterisation	352:389	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	0	30	theme	fatty	144:148	arg1	acid					150:153	a long-chain saturated fatty acid	121:153	a long-chain saturated fatty acid	121:153	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	7	31	theme	mechanical	1187:1196	arg1	properties					1198:1207	mechanical properties	1187:1207	mechanical properties	1187:1207	Furthermore, the mechanical properties and transparency of the composite membranes could be improved by grafting docosanoic acid into pectin.
36216103	2	32	theme	structural	363:372	arg1	characterisation					374:389	structural characterisation	363:389	structural characterisation	363:389	Results of structural characterisation showed that docosanoic acid was grafted to pectin through the esterification reaction, and the highest grafting ratio was 7.89 %.
36216103	0	33	theme	membranes	37:45	arg1	Preparation					0:10	Preparation	0:10	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.	0:154	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	0	34	theme	saturated	134:142	arg1	acid					150:153	a long-chain saturated fatty acid	121:153	a long-chain saturated fatty acid	121:153	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	1	35	used	used	222:225	arg2	acid					182:185	docosanoic acid	171:185	docosanoic acid	171:185	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	35	used	used	222:225	arg2	acid					212:215	a very long chain fatty acid	188:215	a very long chain fatty acid	188:215	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	0	36	theme	composite	27:35	arg1	membranes					37:45	hydrophobic composite membranes	15:45	hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin	15:98	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	1	37	theme	long	195:198	arg1	acid					212:215	a very long chain fatty acid	188:215	a very long chain fatty acid	188:215	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	37	theme	long	195:198	arg1	acid					182:185	docosanoic acid	171:185	docosanoic acid	171:185	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	0	38	theme	carboxymethyl	56:68	arg1	cellulose					70:78	carboxymethyl cellulose	56:78	carboxymethyl cellulose	56:78	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36216103	3	39	theme	pectin	600:605	arg1	activity					574:581	emulsifying activity	562:581	emulsifying activity	562:581	After grafting with docosanoic acid, the emulsifying activity and stability of pectin were significantly enhanced from 1.23 × 10-2 and 9.27 % to 4.78 × 10-2 and 26.73 %.
36216103	3	39	theme	pectin	600:605	arg1	stability					587:595	stability	587:595	stability	587:595	After grafting with docosanoic acid, the emulsifying activity and stability of pectin were significantly enhanced from 1.23 × 10-2 and 9.27 % to 4.78 × 10-2 and 26.73 %.
36216103	3	40	theme	docosanoic	541:550	arg1	acid					552:555	docosanoic acid	541:555	docosanoic acid	541:555	After grafting with docosanoic acid, the emulsifying activity and stability of pectin were significantly enhanced from 1.23 × 10-2 and 9.27 % to 4.78 × 10-2 and 26.73 %.
36216103	5	41	theme	contact	863:869	arg1	angle					871:875	the highest contact angle	851:875	the highest contact angle of the composite membrane incorporated with modified pectin	851:935	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	5	41	theme	contact	863:869	arg1	97.6°					941:945	97.6°	941:945	97.6°	941:945	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	8	42	from	application	1495:1505	arg1	packaging					1515:1523	food packaging	1510:1523	food packaging	1510:1523	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	8	43	theme	membranes	1443:1451	arg1	properties					1415:1424	the comprehensive properties	1397:1424	the comprehensive properties of the composite membranes based on polysaccharides	1397:1476	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	5	44	theme	native	985:990	arg1	68.9°					1000:1004	68.9°	1000:1004	68.9°	1000:1004	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	5	44	theme	native	985:990	arg1	pectin					992:997	native pectin	985:997	native pectin (68.9°)	985:1005	In detail, the highest contact angle of the composite membrane incorporated with modified pectin was 97.6°, which was much higher than that with native pectin (68.9°).
36216103	8	45	theme	docosanoic	1357:1366	arg1	acid					1368:1371	docosanoic acid	1357:1371	docosanoic acid	1357:1371	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	8	46	theme	composite	1433:1441	arg1	membranes					1443:1451	the composite membranes	1429:1451	the composite membranes based on polysaccharides	1429:1476	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	6	47	theme	water	1142:1146	arg1	absorption					1148:1157	the water absorption	1138:1157	the water absorption	1138:1157	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	8	48	dep	helped	1382:1387	arg1	expand					1482:1487	expand	1482:1487	expand their application in food packaging	1482:1523	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	8	48	dep	helped	1382:1387	arg1	improve					1389:1395	improve	1389:1395	improve the comprehensive properties of the composite membranes based on polysaccharides	1389:1476	All the results indicated that incorporating docosanoic acid possibly helped improve the comprehensive properties of the composite membranes based on polysaccharides and expand their application in food packaging.
36216103	1	49	theme	chain	200:204	arg1	acid					212:215	a very long chain fatty acid	188:215	a very long chain fatty acid	188:215	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	49	theme	chain	200:204	arg1	acid					182:185	docosanoic acid	171:185	docosanoic acid	171:185	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	50	theme	fatty	206:210	arg1	acid					212:215	a very long chain fatty acid	188:215	a very long chain fatty acid	188:215	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	50	theme	fatty	206:210	arg1	acid					182:185	docosanoic acid	171:185	docosanoic acid	171:185	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	7	51	theme	membranes	1243:1251	arg1	transparency					1213:1224	transparency	1213:1224	transparency	1213:1224	Furthermore, the mechanical properties and transparency of the composite membranes could be improved by grafting docosanoic acid into pectin.
36216103	7	51	theme	membranes	1243:1251	arg1	properties					1198:1207	mechanical properties	1187:1207	mechanical properties	1187:1207	Furthermore, the mechanical properties and transparency of the composite membranes could be improved by grafting docosanoic acid into pectin.
36216103	3	52	theme	emulsifying	562:572	arg1	activity					574:581	emulsifying activity	562:581	emulsifying activity	562:581	After grafting with docosanoic acid, the emulsifying activity and stability of pectin were significantly enhanced from 1.23 × 10-2 and 9.27 % to 4.78 × 10-2 and 26.73 %.
36216103	6	53	theme	pectin	1033:1038	arg1	ratio					1024:1028	the grafting ratio	1011:1028	the grafting ratio of pectin	1011:1038	As the grafting ratio of pectin increased, the water vapor permeability of the composite membranes significantly increased, while the water absorption decreased.
36216103	1	54	theme	carboxylmethyl	285:298	arg1	CMC					311:313	CMC	311:313	CMC	311:313	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	1	54	theme	carboxylmethyl	285:298	arg1	cellulose					300:308	carboxylmethyl cellulose	285:308	carboxylmethyl cellulose (CMC)	285:314	In this study, docosanoic acid, a very long chain fatty acid, was used to modify pectin, and the products were incorporated with carboxylmethyl cellulose (CMC) to prepare a hydrophobic composite.
36216103	0	55	dep	Preparation	0:10	arg1	Effects					101:107	Effects	101:107	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.	0:154	Preparation of hydrophobic composite membranes based on carboxymethyl cellulose and modified pectin: Effects of grafting a long-chain saturated fatty acid.
36754603	0	0	theme	gut	85:87	arg1	regulation					100:109	gut microbiota regulation	85:109	gut microbiota regulation	85:109	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	5	1	theme	microbiota	770:779	arg1	regulation					781:790	gut microbiota regulation	766:790	gut microbiota regulation	766:790	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	7	2	dep	proteins	1196:1203	arg1	Occludin					1205:1212	Occludin	1205:1212	Occludin	1205:1212	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	2	dep	proteins	1196:1203	arg1	proteins					1196:1203	intestinal tight junction proteins Occludin and ZO-1	1170:1221	intestinal tight junction proteins Occludin and ZO-1	1170:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	2	dep	proteins	1196:1203	arg1	ZO-1					1218:1221	ZO-1	1218:1221	ZO-1	1218:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	9	3	theme	bacteria	1419:1426	arg1	well					1497:1500	well	1497:1500	well	1497:1500	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	3	theme	bacteria	1419:1426	arg1	abundance					1390:1398	The abundance	1386:1398	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae)	1386:1479	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	11	4	theme	functional	1712:1721	arg1	foods					1723:1727	functional foods	1712:1727	functional foods for intestinal health	1712:1749	GEPs may be used as an ingredient to develop functional foods for intestinal health.
36754603	1	5	theme	autoimmune	261:270	arg1	diseases					272:279	autoimmune diseases	261:279	autoimmune diseases	261:279	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	6	6	from	secretion	970:978	arg1	serum					1035:1039	the serum	1031:1039	the serum	1031:1039	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	6	7	theme	thymus	934:939	arg1	indices					919:925	organ indices	913:925	organ indices of the thymus and spleen	913:950	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	4	8	theme	Previous	459:466	arg1	studies					468:474	Previous studies	459:474	Previous studies	459:474	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	9	9	dep	bacteria	1419:1426	arg1	Prevotellaceae					1445:1458	Prevotellaceae	1445:1458	Prevotellaceae	1445:1458	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	9	dep	bacteria	1419:1426	arg1	Bacteroidaceae					1465:1478	Bacteroidaceae	1465:1478	Bacteroidaceae	1465:1478	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	9	dep	bacteria	1419:1426	arg1	Muribaculaceae					1429:1442	Muribaculaceae	1429:1442	Muribaculaceae	1429:1442	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	9	dep	bacteria	1419:1426	arg1	bacteria					1419:1426	SCFAs-producing bacteria	1403:1426	SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae)	1403:1479	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	1	10	theme	diseases	272:279	arg1	treatment					227:235	the treatment	223:235	the treatment of malignant tumors and autoimmune diseases	223:279	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	3	11	theme	agents	376:381	arg1	Development					357:367	Development	357:367	Development of new agents to counteract these side effects of CTX	357:421	Development of new agents to counteract these side effects of CTX is becoming increasingly important.
36754603	0	12	from	Effects	0:6	arg1	elata					42:46	Gastrodia elata	32:46	Gastrodia elata	32:46	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	0	12	from	Effects	0:6	arg1	activity					72:79	immunomodulatory activity	55:79	immunomodulatory activity	55:79	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	0	12	from	Effects	0:6	arg1	regulation					100:109	gut microbiota regulation	85:109	gut microbiota regulation	85:109	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	10	13	theme	gut	1631:1633	arg1	microbiota					1635:1644	gut microbiota	1631:1644	gut microbiota in CTX-treated mice	1631:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	6	14	theme	immunoglobulins	1012:1026	arg1	secretion					970:978	the secretion	966:978	the secretion of immune-related cytokines and immunoglobulins in the serum	966:1039	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	0	15	theme	microbiota	89:98	arg1	regulation					100:109	gut microbiota regulation	85:109	gut microbiota regulation	85:109	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	5	16	from	effects	687:693	arg1	function					752:759	intestinal barrier function	733:759	intestinal barrier function	733:759	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	5	16	from	effects	687:693	arg1	activity					723:730	immunomodulatory activity	706:730	immunomodulatory activity	706:730	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	5	16	from	effects	687:693	arg1	regulation					781:790	gut microbiota regulation	766:790	gut microbiota regulation	766:790	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	4	17	from	elata	527:531	arg1	polysaccharides					496:510	the polysaccharides	492:510	the polysaccharides from Gastrodia elata (GEPs)	492:538	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	8	18	theme	short-chain	1330:1340	arg1	SCFAs					1355:1359	SCFAs	1355:1359	SCFAs	1355:1359	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	8	18	theme	short-chain	1330:1340	arg1	acids					1348:1352	short-chain fatty acids	1330:1352	short-chain fatty acids (SCFAs)	1330:1360	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	0	19	theme	cyclophosphamide-treated	114:137	arg1	mice					139:142	cyclophosphamide-treated mice	114:142	cyclophosphamide-treated mice	114:142	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	7	20	theme	barrier	1122:1128	arg1	function					1130:1137	the intestinal barrier function	1107:1137	the intestinal barrier function	1107:1137	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	8	21	from	contents	1318:1325	arg1	content					1377:1383	the colonic content	1365:1383	the colonic content	1365:1383	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	4	22	contain	have	540:543	arg2	functions					592:600	their functions	586:600	their functions	586:600	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	4	22	contain	have	540:543	arg2	activity					567:574	high immune-enhancing activity	545:574	high immune-enhancing activity	545:574	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	4	22	contain	have	540:543	arg1	polysaccharides					496:510	the polysaccharides	492:510	the polysaccharides from Gastrodia elata (GEPs)	492:538	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	8	23	theme	gut	1285:1287	arg1	microbiota					1289:1298	the gut microbiota	1281:1298	the gut microbiota	1281:1298	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	3	24	theme	new	372:374	arg1	agents					376:381	new agents	372:381	new agents	372:381	Development of new agents to counteract these side effects of CTX is becoming increasingly important.
36754603	0	25	from	elata	42:46	arg1	polysaccharides					11:25	polysaccharides	11:25	polysaccharides from Gastrodia elata	11:46	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	0	25	from	elata	42:46	arg1	Effects					0:6	Effects	0:6	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice	0:142	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	7	26	theme	tight	1181:1185	arg1	Occludin					1205:1212	Occludin	1205:1212	Occludin	1205:1212	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	26	theme	tight	1181:1185	arg1	proteins					1196:1203	intestinal tight junction proteins Occludin and ZO-1	1170:1221	intestinal tight junction proteins Occludin and ZO-1	1170:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	26	theme	tight	1181:1185	arg1	ZO-1					1218:1221	ZO-1	1218:1221	ZO-1	1218:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	8	27	theme	colonic	1369:1375	arg1	content					1377:1383	the colonic content	1365:1383	the colonic content	1365:1383	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	3	28	theme	side	403:406	arg1	effects					408:414	these side effects	397:414	these side effects of CTX	397:421	Development of new agents to counteract these side effects of CTX is becoming increasingly important.
36754603	10	29	theme	intestinal	1581:1590	arg1	integrity					1600:1608	the intestinal barrier integrity	1577:1608	the intestinal barrier integrity	1577:1608	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	1	30	theme	used	191:194	arg1	Cyclophosphamide					156:171	BACKGROUND Cyclophosphamide	145:171	BACKGROUND Cyclophosphamide (CTX)	145:177	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	1	30	theme	used	191:194	arg1	agent					213:217	a widely used chemotherapeutic agent	182:217	a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases	182:279	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	10	31	theme	CTX-treated	1649:1659	arg1	mice					1661:1664	CTX-treated mice	1649:1664	CTX-treated mice	1649:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	6	32	theme	cytokines	998:1006	arg1	secretion					970:978	the secretion	966:978	the secretion of immune-related cytokines and immunoglobulins in the serum	966:1039	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	7	33	theme	intestinal	1111:1120	arg1	function					1130:1137	the intestinal barrier function	1107:1137	the intestinal barrier function	1107:1137	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	11	34	used	used	1679:1682	arg2	GEPs					1667:1670	GEPs	1667:1670	GEPs	1667:1670	GEPs may be used as an ingredient to develop functional foods for intestinal health.
36754603	11	34	used	used	1679:1682	arg2	ingredient					1690:1699	an ingredient	1687:1699	an ingredient	1687:1699	GEPs may be used as an ingredient to develop functional foods for intestinal health.
36754603	10	35	theme	CONCLUSIONS	1503:1513	arg1	GEPs					1515:1518	CONCLUSIONS GEPs	1503:1518	CONCLUSIONS GEPs	1503:1518	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	10	36	from	integrity	1600:1608	arg1	mice					1661:1664	CTX-treated mice	1649:1664	CTX-treated mice	1649:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	1	37	theme	chemotherapeutic	196:211	arg1	Cyclophosphamide					156:171	BACKGROUND Cyclophosphamide	145:171	BACKGROUND Cyclophosphamide (CTX)	145:177	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	1	37	theme	chemotherapeutic	196:211	arg1	agent					213:217	a widely used chemotherapeutic agent	182:217	a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases	182:279	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	6	38	from	decrease	901:908	arg1	indices					919:925	organ indices	913:925	organ indices of the thymus and spleen	913:950	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	6	39	theme	immune-related	983:996	arg1	cytokines					998:1006	immune-related cytokines	983:1006	immune-related cytokines	983:1006	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	0	40	dep	activity	72:79	arg1	the					51:53	the	51:53	the	51:53	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	5	41	theme	immunosuppression	842:858	arg1	model					821:825	a mouse model	813:825	a mouse model of CTX-induced immunosuppression	813:858	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	0	42	theme	polysaccharides	11:25	arg1	Effects					0:6	Effects	0:6	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice	0:142	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	5	43	theme	immunomodulatory	706:721	arg1	activity					723:730	immunomodulatory activity	706:730	immunomodulatory activity	706:730	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	8	44	theme	microbiota	1289:1298	arg1	abundance					1268:1276	abundance	1268:1276	abundance	1268:1276	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	8	44	theme	microbiota	1289:1298	arg1	composition					1252:1262	composition	1252:1262	composition	1252:1262	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	5	45	theme	barrier	744:750	arg1	function					752:759	intestinal barrier function	733:759	intestinal barrier function	733:759	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	6	46	theme	organ	913:917	arg1	indices					919:925	organ indices	913:925	organ indices of the thymus and spleen	913:950	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	7	47	theme	intestinal	1073:1082	arg1	pathology					1084:1092	the intestinal pathology	1069:1092	the intestinal pathology	1069:1092	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	6	48	theme	CTX-induced	889:899	arg1	decrease					901:908	the CTX-induced decrease	885:908	the CTX-induced decrease in organ indices of the thymus and spleen	885:950	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	8	49	theme	fatty	1342:1346	arg1	SCFAs					1355:1359	SCFAs	1355:1359	SCFAs	1355:1359	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	8	49	theme	fatty	1342:1346	arg1	acids					1348:1352	short-chain fatty acids	1330:1352	short-chain fatty acids (SCFAs)	1330:1360	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	0	50	theme	Gastrodia	32:40	arg1	elata					42:46	Gastrodia elata	32:46	Gastrodia elata	32:46	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	4	51	theme	high	545:548	arg1	activity					567:574	high immune-enhancing activity	545:574	high immune-enhancing activity	545:574	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	7	52	theme	junction	1187:1194	arg1	Occludin					1205:1212	Occludin	1205:1212	Occludin	1205:1212	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	52	theme	junction	1187:1194	arg1	proteins					1196:1203	intestinal tight junction proteins Occludin and ZO-1	1170:1221	intestinal tight junction proteins Occludin and ZO-1	1170:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	52	theme	junction	1187:1194	arg1	ZO-1					1218:1221	ZO-1	1218:1221	ZO-1	1218:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	0	53	from	activity	72:79	arg1	mice					139:142	cyclophosphamide-treated mice	114:142	cyclophosphamide-treated mice	114:142	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	7	54	theme	proteins	1196:1203	arg1	expression					1156:1165	the expression	1152:1165	the expression of intestinal tight junction proteins Occludin and ZO-1	1152:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	10	55	from	microbiota	1635:1644	arg1	mice					1661:1664	CTX-treated mice	1649:1664	CTX-treated mice	1649:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	5	56	theme	intestinal	733:742	arg1	function					752:759	intestinal barrier function	733:759	intestinal barrier function	733:759	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	5	57	theme	gut	766:768	arg1	regulation					781:790	gut microbiota regulation	766:790	gut microbiota regulation	766:790	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	4	58	theme	Gastrodia	517:525	arg1	GEPs					534:537	GEPs	534:537	GEPs	534:537	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	4	58	theme	Gastrodia	517:525	arg1	elata					527:531	Gastrodia elata	517:531	Gastrodia elata (GEPs)	517:538	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	8	59	theme	acids	1348:1352	arg1	contents					1318:1325	the contents	1314:1325	the contents of short-chain fatty acids (SCFAs) in the colonic content	1314:1383	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	3	60	theme	CTX	419:421	arg1	effects					408:414	these side effects	397:414	these side effects of CTX	397:421	Development of new agents to counteract these side effects of CTX is becoming increasingly important.
36754603	10	61	from	structure	1618:1626	arg1	mice					1661:1664	CTX-treated mice	1649:1664	CTX-treated mice	1649:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	10	62	theme	barrier	1592:1598	arg1	integrity					1600:1608	the intestinal barrier integrity	1577:1608	the intestinal barrier integrity	1577:1608	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	2	63	dep	immunosuppression	305:321	arg1	mucosa					349:354	the intestinal mucosa	334:354	the intestinal mucosa	334:354	However, CTX can cause immunosuppression and damage the intestinal mucosa.
36754603	8	64	dep	composition	1252:1262	arg1	the					1248:1250	the	1248:1250	the	1248:1250	Moreover, GEPs restored the composition and abundance of the gut microbiota and increased the contents of short-chain fatty acids (SCFAs) in the colonic content.
36754603	4	65	theme	immune-enhancing	550:565	arg1	activity					567:574	high immune-enhancing activity	545:574	high immune-enhancing activity	545:574	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	6	66	theme	RESULTS	861:867	arg1	GEPs					869:872	RESULTS GEPs	861:872	RESULTS GEPs	861:872	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	7	67	theme	intestinal	1170:1179	arg1	Occludin					1205:1212	Occludin	1205:1212	Occludin	1205:1212	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	67	theme	intestinal	1170:1179	arg1	proteins					1196:1203	intestinal tight junction proteins Occludin and ZO-1	1170:1221	intestinal tight junction proteins Occludin and ZO-1	1170:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	7	67	theme	intestinal	1170:1179	arg1	ZO-1					1218:1221	ZO-1	1218:1221	ZO-1	1218:1221	In addition, GEPs improved the intestinal pathology and restored the intestinal barrier function by elevating the expression of intestinal tight junction proteins Occludin and ZO-1.
36754603	1	68	theme	BACKGROUND	145:154	arg1	CTX					174:176	CTX	174:176	CTX	174:176	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	1	68	theme	BACKGROUND	145:154	arg1	Cyclophosphamide					156:171	BACKGROUND Cyclophosphamide	145:171	BACKGROUND Cyclophosphamide (CTX)	145:177	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	1	68	theme	BACKGROUND	145:154	arg1	agent					213:217	a widely used chemotherapeutic agent	182:217	a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases	182:279	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	9	69	theme	SCFAs-producing	1403:1417	arg1	Prevotellaceae					1445:1458	Prevotellaceae	1445:1458	Prevotellaceae	1445:1458	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	69	theme	SCFAs-producing	1403:1417	arg1	Bacteroidaceae					1465:1478	Bacteroidaceae	1465:1478	Bacteroidaceae	1465:1478	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	69	theme	SCFAs-producing	1403:1417	arg1	Muribaculaceae					1429:1442	Muribaculaceae	1429:1442	Muribaculaceae	1429:1442	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	9	69	theme	SCFAs-producing	1403:1417	arg1	bacteria					1419:1426	SCFAs-producing bacteria	1403:1426	SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae)	1403:1479	The abundance of SCFAs-producing bacteria (Muribaculaceae, Prevotellaceae, and Bacteroidaceae) was promoted as well.
36754603	5	70	theme	GEPs	698:701	arg1	effects					687:693	the effects	683:693	the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation	683:790	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	0	71	from	regulation	100:109	arg1	mice					139:142	cyclophosphamide-treated mice	114:142	cyclophosphamide-treated mice	114:142	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	10	72	from	mice	1661:1664	arg1	integrity					1600:1608	the intestinal barrier integrity	1577:1608	the intestinal barrier integrity	1577:1608	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	10	72	from	mice	1661:1664	arg1	structure					1618:1626	the structure	1614:1626	the structure of gut microbiota in CTX-treated mice	1614:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	2	73	theme	intestinal	338:347	arg1	mucosa					349:354	the intestinal mucosa	334:354	the intestinal mucosa	334:354	However, CTX can cause immunosuppression and damage the intestinal mucosa.
36754603	1	74	theme	malignant	240:248	arg1	tumors					250:255	malignant tumors	240:255	malignant tumors	240:255	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	1	75	theme	tumors	250:255	arg1	treatment					227:235	the treatment	223:235	the treatment of malignant tumors and autoimmune diseases	223:279	BACKGROUND Cyclophosphamide (CTX) is a widely used chemotherapeutic agent for the treatment of malignant tumors and autoimmune diseases.
36754603	0	76	theme	immunomodulatory	55:70	arg1	activity					72:79	immunomodulatory activity	55:79	immunomodulatory activity	55:79	Effects of polysaccharides from Gastrodia elata on the immunomodulatory activity and gut microbiota regulation in cyclophosphamide-treated mice.
36754603	6	77	theme	spleen	945:950	arg1	indices					919:925	organ indices	913:925	organ indices of the thymus and spleen	913:950	RESULTS GEPs attenuated the CTX-induced decrease in organ indices of the thymus and spleen, and promoted the secretion of immune-related cytokines and immunoglobulins in the serum.
36754603	5	78	theme	CTX-induced	830:840	arg1	immunosuppression					842:858	CTX-induced immunosuppression	830:858	CTX-induced immunosuppression	830:858	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	10	79	theme	microbiota	1635:1644	arg1	integrity					1600:1608	the intestinal barrier integrity	1577:1608	the intestinal barrier integrity	1577:1608	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	10	79	theme	microbiota	1635:1644	arg1	structure					1618:1626	the structure	1614:1626	the structure of gut microbiota in CTX-treated mice	1614:1664	CONCLUSIONS GEPs can effectively alleviate immunosuppression and regulate the intestinal barrier integrity and the structure of gut microbiota in CTX-treated mice.
36754603	5	80	theme	mouse	815:819	arg1	model					821:825	a mouse model	813:825	a mouse model of CTX-induced immunosuppression	813:858	In this study, the effects of GEPs on immunomodulatory activity, intestinal barrier function, and gut microbiota regulation were investigated in a mouse model of CTX-induced immunosuppression.
36754603	11	81	theme	intestinal	1733:1742	arg1	health					1744:1749	intestinal health	1733:1749	intestinal health	1733:1749	GEPs may be used as an ingredient to develop functional foods for intestinal health.
36754603	4	82	theme	underlying	628:637	arg1	unclear					659:665	unclear	659:665	unclear	659:665	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36754603	4	82	theme	underlying	628:637	arg1	mechanism					639:647	the underlying mechanism	624:647	the underlying mechanism	624:647	Previous studies have shown that the polysaccharides from Gastrodia elata (GEPs) have high immune-enhancing activity, however, their functions to the intestines and the underlying mechanism are still unclear.
36869514	3	0	theme	random	589:594	arg1	level					601:605	the random coil level	585:605	the random coil level of CA	585:611	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	4	1	theme	functional	772:781	arg1	properties					783:792	the functional properties	768:792	the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity)	768:902	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	2	2	theme	grafting	400:407	arg1	degree					409:414	the highest grafting degree	388:414	the highest grafting degree of CA with CP or AG	388:434	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	0	3	with	reaction	79:86	arg1	pectin					93:98	pectin	93:98	pectin	93:98	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	0	3	with	reaction	79:86	arg1	arabinogalactan					103:117	arabinogalactan	103:117	arabinogalactan	103:117	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	4	4	theme	emulsifying	837:847	arg1	property					849:856	emulsifying property	837:856	emulsifying property	837:856	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	0	5	from	Changes	0:6	arg1	properties					26:35	the functional properties	11:35	the functional properties of casein conjugates	11:56	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	2	6	with	CA	419:420	arg1	CP					427:428	CP	427:428	CP	427:428	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	2	6	with	CA	419:420	arg1	AG					433:434	AG	433:434	AG	433:434	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	4	7	theme	CA-CP	641:645	arg1	treatment					628:636	Glycosylation treatment	614:636	Glycosylation treatment of CA-CP and CA-AG	614:655	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	3	8	theme	CA	610:611	arg1	level					601:605	the random coil level	585:605	the random coil level of CA	585:611	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	4	9	theme	higher	700:705	arg1	values					728:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	4	10	dep	solubility	807:816	arg1	e.g.					801:804	e.g.	801:804	e.g.	801:804	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	1	11	theme	CP	297:298	arg1	effects					286:292	the effects	282:292	the effects of CP or AG on the structural and functional properties of casein	282:358	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	4	12	theme	CA-AG	651:655	arg1	treatment					628:636	Glycosylation treatment	614:636	Glycosylation treatment of CA-CP and CA-AG	614:655	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	4	13	dep	lower	667:671	arg1	hydrophobicity					681:694	surface hydrophobicity	673:694	surface hydrophobicity	673:694	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	0	14	theme	Maillard	70:77	arg1	reaction					79:86	Maillard reaction	70:86	Maillard reaction with pectin or arabinogalactan	70:117	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	3	15	with	grafting	522:529	arg1	AG					542:543	AG	542:543	AG	542:543	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	3	15	with	grafting	522:529	arg1	CP					536:537	CP	536:537	CP	536:537	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	4	16	theme	Glycosylation	614:626	arg1	treatment					628:636	Glycosylation treatment	614:636	Glycosylation treatment of CA-CP and CA-AG	614:655	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	1	17	theme	casein	171:176	arg1	conjugates					157:166	conjugates	157:166	conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG)	157:222	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	18	from	effects	286:292	arg1	properties					339:348	the structural and functional properties	309:348	the structural and functional properties of casein	309:358	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	19	theme	casein	353:358	arg1	properties					339:348	the structural and functional properties	309:348	the structural and functional properties of casein	309:358	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	20	theme	AG	303:304	arg1	effects					286:292	the effects	282:292	the effects of CP or AG on the structural and functional properties of casein	282:358	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	2	21	theme	highest	392:398	arg1	degree					409:414	the highest grafting degree	388:414	the highest grafting degree of CA with CP or AG	388:434	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	1	22	theme	Maillard	231:238	arg1	wet-heating					250:260	wet-heating	250:260	wet-heating	250:260	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	22	theme	Maillard	231:238	arg1	reaction					240:247	the Maillard reaction	227:247	the Maillard reaction (wet-heating)	227:261	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	4	23	theme	absolute	707:714	arg1	values					728:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	2	24	located	observed	440:447	arg1	90 °C					452:456	90 °C	452:456	90 °C	452:456	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	2	24	located	observed	440:447	arg2	degree					409:414	the highest grafting degree	388:414	the highest grafting degree of CA with CP or AG	388:434	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	4	25	theme	antioxidant	882:892	arg1	activity					894:901	antioxidant activity	882:901	antioxidant activity	882:901	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	4	26	theme	foaming	819:825	arg1	property					827:834	foaming property	819:834	foaming property	819:834	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	0	27	theme	functional	15:24	arg1	properties					26:35	the functional properties	11:35	the functional properties of casein conjugates	11:56	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	0	28	theme	conjugates	47:56	arg1	properties					26:35	the functional properties	11:35	the functional properties of casein conjugates	11:56	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	1	29	theme	structural	313:322	arg1	properties					339:348	the structural and functional properties	309:348	the structural and functional properties of casein	309:358	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	3	30	theme	coil	596:599	arg1	level					601:605	the random coil level	585:605	the random coil level of CA	585:611	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	0	31	theme	casein	40:45	arg1	conjugates					47:56	casein conjugates	40:56	casein conjugates	40:56	Changes in the functional properties of casein conjugates prepared by Maillard reaction with pectin or arabinogalactan.
36869514	5	32	theme	Maillard	1023:1030	arg1	reaction					1032:1039	the Maillard reaction	1019:1039	the Maillard reaction	1019:1039	Accordingly, our results indicated that it is feasible for CP or AG to improve the functional properties of CA by the Maillard reaction.
36869514	4	33	theme	CA	797:798	arg1	properties					783:792	the functional properties	768:792	the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity)	768:902	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	3	34	theme	α-helix	557:563	arg1	level					565:569	the α-helix level	553:569	the α-helix level	553:569	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	4	35	theme	ζ-potential	716:726	arg1	values					728:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	1	36	theme	functional	328:337	arg1	properties					339:348	the structural and functional properties	309:348	the structural and functional properties of casein	309:358	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	4	37	theme	surface	673:679	arg1	hydrophobicity					681:694	surface hydrophobicity	673:694	surface hydrophobicity	673:694	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	3	38	theme	Secondary	490:498	arg1	structure					500:508	Secondary structure	490:508	Secondary structure	490:508	Secondary structure showed that grafting with CP or AG reduced the α-helix level and increased the random coil level of CA.
36869514	1	39	with	conjugates	157:166	arg1	CP					196:197	CP	196:197	CP	196:197	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	39	with	conjugates	157:166	arg1	arabinogalactan					203:217	arabinogalactan	203:217	arabinogalactan (AG)	203:222	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	39	with	conjugates	157:166	arg1	pectin					188:193	pectin	188:193	pectin (CP)	188:198	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	1	39	with	conjugates	157:166	arg1	AG					220:221	AG	220:221	AG	220:221	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
36869514	4	40	theme	lower	667:671	arg1	values					728:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	lower surface hydrophobicity and higher absolute ζ-potential values	667:733	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	2	41	theme	CA	419:420	arg1	degree					409:414	the highest grafting degree	388:414	the highest grafting degree of CA with CP or AG	388:434	The results indicated that the highest grafting degree of CA with CP or AG was observed at 90 °C for 1.5 h or 1 h, respectively.
36869514	5	42	theme	CA	1013:1014	arg1	properties					999:1008	the functional properties	984:1008	the functional properties of CA	984:1014	Accordingly, our results indicated that it is feasible for CP or AG to improve the functional properties of CA by the Maillard reaction.
36869514	4	43	theme	thermal	859:865	arg1	stability					867:875	thermal stability	859:875	thermal stability	859:875	Glycosylation treatment of CA-CP and CA-AG exhibited lower surface hydrophobicity and higher absolute ζ-potential values, further significantly improving the functional properties of CA (e.g., solubility, foaming property, emulsifying property, thermal stability, and antioxidant activity).
36869514	5	44	theme	functional	988:997	arg1	properties					999:1008	the functional properties	984:1008	the functional properties of CA	984:1014	Accordingly, our results indicated that it is feasible for CP or AG to improve the functional properties of CA by the Maillard reaction.
36869514	1	45	theme	study	136:140	arg1	aim					124:126	The aim	120:126	The aim of this study	120:140	The aim of this study was to prepare conjugates of casein (CA) with pectin (CP) or arabinogalactan (AG) by the Maillard reaction (wet-heating) and to investigate the effects of CP or AG on the structural and functional properties of casein.
35484695	0	0	theme	Ilex	87:90	arg1	Fruits					100:105	Ilex cornuta Fruits	87:105	Ilex cornuta Fruits	87:105	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	4	1	theme	protein	928:934	arg1	content					936:942	the protein content	924:942	the protein content	924:942	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	4	1	theme	protein	928:934	arg1	%					954:954	0.246 %	948:954	0.246 %	948:954	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	2	2	theme	magnetic	586:593	arg1	NMR					606:608	NMR	606:608	NMR	606:608	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	2	theme	magnetic	586:593	arg1	resonance					595:603	nuclear magnetic resonance	578:603	nuclear magnetic resonance (NMR) spectroscopy	578:622	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	1	3	from	fruits	165:170	arg1	polysaccharide					132:145	a polysaccharide	130:145	a polysaccharide from Ilex cornuta fruits (LCFP-3)	130:179	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	1	4	theme	Diethyaminoethyl	219:234	arg1	column					274:279	Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column	219:279	Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column	219:279	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	7	5	theme	RAW246.7	1402:1409	arg1	macrophages					1411:1421	lipopolysaccharide (LPS)-induced RAW246.7 macrophages	1369:1421	lipopolysaccharide (LPS)-induced RAW246.7 macrophages	1369:1421	The anti-inflammatory activity of LCFP-3 was evaluated using lipopolysaccharide (LPS)-induced RAW246.7 macrophages.
35484695	2	6	theme	nuclear	578:584	arg1	NMR					606:608	NMR	606:608	NMR	606:608	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	6	theme	nuclear	578:584	arg1	resonance					595:603	nuclear magnetic resonance	578:603	nuclear magnetic resonance (NMR) spectroscopy	578:622	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	1	7	theme	Ilex	152:155	arg1	LCFP-3					173:178	LCFP-3	173:178	LCFP-3	173:178	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	1	7	theme	Ilex	152:155	arg1	fruits					165:170	Ilex cornuta fruits	152:170	Ilex cornuta fruits (LCFP-3)	152:179	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	3	8	theme	Monosaccharide	625:638	arg1	analysis					652:659	Monosaccharide composition analysis	625:659	Monosaccharide composition analysis	625:659	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	4	9	theme	LCFP-3	901:906	arg1	%					918:918	90.31 %	912:918	90.31 %	912:918	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	4	9	theme	LCFP-3	901:906	arg1	content					890:896	the total sugar content	874:896	the total sugar content of LCFP-3	874:906	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	4	10	theme	Chemical	832:839	arg1	analysis					853:860	Chemical composition analysis	832:860	Chemical composition analysis	832:860	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	3	11	theme	small	773:777	arg1	percentage					779:788	small percentage	773:788	small percentage of Rhamnose	773:800	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	0	12	theme	cornuta	92:98	arg1	Fruits					100:105	Ilex cornuta Fruits	87:105	Ilex cornuta Fruits	87:105	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	5	13	theme	molecular	1026:1034	arg1	weight					1036:1041	its average molecular weight	1014:1041	its average molecular weight	1014:1041	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	7	14	theme	-induced	1393:1400	arg1	macrophages					1411:1421	lipopolysaccharide (LPS)-induced RAW246.7 macrophages	1369:1421	lipopolysaccharide (LPS)-induced RAW246.7 macrophages	1369:1421	The anti-inflammatory activity of LCFP-3 was evaluated using lipopolysaccharide (LPS)-induced RAW246.7 macrophages.
35484695	2	15	dep	Fourier	526:532	arg1	transform					534:542	transform	534:542	transform infrared (FT-IR) spectroscopy	534:572	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	1	16	theme	cornuta	157:163	arg1	LCFP-3					173:178	LCFP-3	173:178	LCFP-3	173:178	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	1	16	theme	cornuta	157:163	arg1	fruits					165:170	Ilex cornuta fruits	152:170	Ilex cornuta fruits (LCFP-3)	152:179	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	2	17	theme	electron	499:506	arg1	microscopy					508:517	scanning electron microscopy	490:517	scanning electron microscopy (SEM)	490:523	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	17	theme	electron	499:506	arg1	SEM					520:522	SEM	520:522	SEM	520:522	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	18	theme	performance	389:399	arg1	chromatography					416:429	high performance anion exchange chromatography	384:429	high performance anion exchange chromatography (HPAEC)	384:437	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	18	theme	performance	389:399	arg1	HPAEC					432:436	HPAEC	432:436	HPAEC	432:436	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	9	19	theme	great	1665:1669	arg1	ingredient					1697:1706	a functional ingredient	1684:1706	a functional ingredient	1684:1706	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	9	19	theme	great	1665:1669	arg1	potential					1671:1679	great potential	1665:1679	great potential	1665:1679	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	2	20	theme	scanning	490:497	arg1	microscopy					508:517	scanning electron microscopy	490:517	scanning electron microscopy (SEM)	490:523	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	20	theme	scanning	490:497	arg1	SEM					520:522	SEM	520:522	SEM	520:522	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	4	21	theme	composition	841:851	arg1	analysis					853:860	Chemical composition analysis	832:860	Chemical composition analysis	832:860	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	2	22	theme	high	384:387	arg1	chromatography					416:429	high performance anion exchange chromatography	384:429	high performance anion exchange chromatography (HPAEC)	384:437	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	22	theme	high	384:387	arg1	HPAEC					432:436	HPAEC	432:436	HPAEC	432:436	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	23	theme	gas	440:442	arg1	GC/MS					482:486	GC/MS	482:486	GC/MS	482:486	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	23	theme	gas	440:442	arg1	chromatography					444:457	gas chromatography	440:457	gas chromatography	440:457	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	8	24	theme	LPS-induced	1506:1516	arg1	toxicity					1518:1525	LPS-induced toxicity	1506:1525	LPS-induced toxicity	1506:1525	The results showed that 1-200 μg/mL LCFP-3 could dose-dependently protect against LPS-induced toxicity and 1 μg/mL LCFP-3 could significantly inhibit LPS-induced NO production.
35484695	2	25	theme	resonance	595:603	arg1	spectroscopy					611:622	nuclear magnetic resonance (NMR) spectroscopy	578:622	nuclear magnetic resonance (NMR) spectroscopy	578:622	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	7	26	theme	LCFP-3	1342:1347	arg1	activity					1330:1337	The anti-inflammatory activity	1308:1337	The anti-inflammatory activity of LCFP-3	1308:1347	The anti-inflammatory activity of LCFP-3 was evaluated using lipopolysaccharide (LPS)-induced RAW246.7 macrophages.
35484695	1	27	theme	chromatography	259:272	arg1	column					274:279	Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column	219:279	Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column	219:279	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	4	28	theme	total	878:882	arg1	%					918:918	90.31 %	912:918	90.31 %	912:918	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	4	28	theme	total	878:882	arg1	content					890:896	the total sugar content	874:896	the total sugar content of LCFP-3	874:906	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	7	29	theme	anti-inflammatory	1312:1328	arg1	activity					1330:1337	The anti-inflammatory activity	1308:1337	The anti-inflammatory activity of LCFP-3	1308:1347	The anti-inflammatory activity of LCFP-3 was evaluated using lipopolysaccharide (LPS)-induced RAW246.7 macrophages.
35484695	0	30	theme	Structural	11:20	arg1	Analysis					22:29	Structural Analysis	11:29	Structural Analysis	11:29	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	3	31	dep	revealed	661:668	arg1	contained					677:685	contained	677:685	revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose	661:829	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	1	32	dep	extraction	207:216	arg1	purification					311:322	purification	311:322	purification	311:322	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	0	33	theme	Anti-Inflammatory	35:51	arg1	Activity					53:60	Anti-Inflammatory Activity	35:60	Anti-Inflammatory Activity	35:60	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	9	34	theme	functional	1686:1695	arg1	ingredient					1697:1706	a functional ingredient	1684:1706	a functional ingredient	1684:1706	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	9	34	theme	functional	1686:1695	arg1	potential					1671:1679	great potential	1665:1679	great potential	1665:1679	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	3	35	theme	composition	640:650	arg1	analysis					652:659	Monosaccharide composition analysis	625:659	Monosaccharide composition analysis	625:659	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	9	36	contain	has	1661:1663	arg2	potential					1671:1679	great potential	1665:1679	great potential	1665:1679	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	9	36	contain	has	1661:1663	arg2	ingredient					1697:1706	a functional ingredient	1684:1706	a functional ingredient	1684:1706	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	9	36	contain	has	1661:1663	arg1	LCFP-3					1612:1617	LCFP-3	1612:1617	LCFP-3	1612:1617	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	2	37	theme	anion	401:405	arg1	chromatography					416:429	high performance anion exchange chromatography	384:429	high performance anion exchange chromatography (HPAEC)	384:437	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	37	theme	anion	401:405	arg1	HPAEC					432:436	HPAEC	432:436	HPAEC	432:436	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	1	38	theme	Sephadex	285:292	arg1	column					304:309	Sephadex G-100 gel column	285:309	Sephadex G-100 gel column	285:309	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	3	39	theme	Rhamnose	793:800	arg1	percentage					779:788	small percentage	773:788	small percentage of Rhamnose	773:800	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	5	40	theme	Gel	957:959	arg1	GPC					988:990	GPC	988:990	GPC	988:990	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	5	40	theme	Gel	957:959	arg1	chromatography					972:985	Gel permeation chromatography	957:985	Gel permeation chromatography (GPC) analysis	957:1000	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	2	41	theme	exchange	407:414	arg1	chromatography					416:429	high performance anion exchange chromatography	384:429	high performance anion exchange chromatography (HPAEC)	384:437	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	41	theme	exchange	407:414	arg1	HPAEC					432:436	HPAEC	432:436	HPAEC	432:436	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	2	42	theme	mass	463:466	arg1	spectrometry					468:479	mass spectrometry	463:479	mass spectrometry	463:479	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	1	43	theme	G-100	294:298	arg1	column					304:309	Sephadex G-100 gel column	285:309	Sephadex G-100 gel column	285:309	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	5	44	theme	average	1018:1024	arg1	weight					1036:1041	its average molecular weight	1014:1041	its average molecular weight	1014:1041	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	5	45	theme	permeation	961:970	arg1	GPC					988:990	GPC	988:990	GPC	988:990	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	5	45	theme	permeation	961:970	arg1	chromatography					972:985	Gel permeation chromatography	957:985	Gel permeation chromatography (GPC) analysis	957:1000	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	2	46	theme	structural	329:338	arg1	characteristics					340:354	Its structural characteristics	325:354	Its structural characteristics	325:354	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	4	47	theme	sugar	884:888	arg1	%					918:918	90.31 %	912:918	90.31 %	912:918	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	4	47	theme	sugar	884:888	arg1	content					890:896	the total sugar content	874:896	the total sugar content of LCFP-3	874:906	Chemical composition analysis showed that the total sugar content of LCFP-3 was 90.31 % and the protein content was 0.246 %.
35484695	1	48	theme	gel	300:302	arg1	column					304:309	Sephadex G-100 gel column	285:309	Sephadex G-100 gel column	285:309	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	2	49	theme	FT-IR	554:558	arg1	spectroscopy					561:572	infrared (FT-IR) spectroscopy	544:572	infrared (FT-IR) spectroscopy	544:572	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	5	50	theme	chromatography	972:985	arg1	analysis					993:1000	Gel permeation chromatography (GPC) analysis	957:1000	Gel permeation chromatography (GPC) analysis	957:1000	Gel permeation chromatography (GPC) analysis showed that its average molecular weight was 41.199 kDa.
35484695	1	51	theme	present	115:121	arg1	study					123:127	the present study	111:127	the present study	111:127	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	3	52	theme	Galacturonic	739:750	arg1	acid					752:755	Galacturonic acid	739:755	Galacturonic acid (23.35 %) while small percentage of Rhamnose	739:800	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	3	52	theme	Galacturonic	739:750	arg1	%					764:764	23.35 %	758:764	23.35 %	758:764	Monosaccharide composition analysis revealed LCFP-3 contained mainly Galactose (31.92 %), Arabinose (25.87 %) and Galacturonic acid (23.35 %) while small percentage of Rhamnose, Glucose, Mannose and Xylose.
35484695	6	53	theme	Structural	1059:1068	arg1	analysis					1070:1077	Structural analysis	1059:1077	Structural analysis	1059:1077	Structural analysis showed that LCFP-3 may be composed of residues, T-α-Arap, T-α-Rhap, 1,3-α-Arap, 1,4-α-Arap, T-β-Galp, 1,4-α-GalpA(OMe), 1,4-β-Glcp, 1,3-β-Galp, 1,3,6-β-Manp, 1,6-β-Galp, 1,3,4-β-GalpA, 1,4,6-β-Manp, 1,3,6-β-Glcp, 1,2,3,4-α-Xylp.
35484695	1	54	theme	hot	197:199	arg1	extraction					207:216	hot water extraction	197:216	hot water extraction	197:216	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	2	55	theme	infrared	544:551	arg1	spectroscopy					561:572	infrared (FT-IR) spectroscopy	544:572	infrared (FT-IR) spectroscopy	544:572	Its structural characteristics were further explored using high performance anion exchange chromatography (HPAEC), gas chromatography and mass spectrometry (GC/MS), scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy.
35484695	0	56	from	Fruits	100:105	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	0	56	from	Fruits	100:105	arg1	Analysis					22:29	Structural Analysis	11:29	Structural Analysis	11:29	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	0	56	from	Fruits	100:105	arg1	Activity					53:60	Anti-Inflammatory Activity	35:60	Anti-Inflammatory Activity	35:60	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	9	57	theme	anti-inflammatory	1630:1646	arg1	activity					1648:1655	an anti-inflammatory activity	1627:1655	an anti-inflammatory activity	1627:1655	Therefore, LCFP-3 exerted an anti-inflammatory activity and has great potential as a functional ingredient.
35484695	1	58	theme	water	201:205	arg1	extraction					207:216	hot water extraction	197:216	hot water extraction	197:216	In the present study, a polysaccharide from Ilex cornuta fruits (LCFP-3) was obtained by hot water extraction, Diethyaminoethyl cellulose-52 (DEAE-52) chromatography column and Sephadex G-100 gel column purification.
35484695	0	59	theme	Polysaccharide	67:80	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	0	59	theme	Polysaccharide	67:80	arg1	Analysis					22:29	Structural Analysis	11:29	Structural Analysis	11:29	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	0	59	theme	Polysaccharide	67:80	arg1	Activity					53:60	Anti-Inflammatory Activity	35:60	Anti-Inflammatory Activity	35:60	Isolation, Structural Analysis and Anti-Inflammatory Activity of a Polysaccharide from Ilex cornuta Fruits.
35484695	8	60	theme	NO	1586:1587	arg1	production					1589:1598	LPS-induced NO production	1574:1598	LPS-induced NO production	1574:1598	The results showed that 1-200 μg/mL LCFP-3 could dose-dependently protect against LPS-induced toxicity and 1 μg/mL LCFP-3 could significantly inhibit LPS-induced NO production.
35484695	8	61	theme	LPS-induced	1574:1584	arg1	production					1589:1598	LPS-induced NO production	1574:1598	LPS-induced NO production	1574:1598	The results showed that 1-200 μg/mL LCFP-3 could dose-dependently protect against LPS-induced toxicity and 1 μg/mL LCFP-3 could significantly inhibit LPS-induced NO production.
35484695	8	62	theme	1-200 μg/mL	1448:1458	arg1	LCFP-3					1460:1465	1-200 μg/mL LCFP-3	1448:1465	1-200 μg/mL LCFP-3	1448:1465	The results showed that 1-200 μg/mL LCFP-3 could dose-dependently protect against LPS-induced toxicity and 1 μg/mL LCFP-3 could significantly inhibit LPS-induced NO production.
35484695	8	63	theme	1 μg/mL	1531:1537	arg1	LCFP-3					1539:1544	1 μg/mL LCFP-3	1531:1544	1 μg/mL LCFP-3	1531:1544	The results showed that 1-200 μg/mL LCFP-3 could dose-dependently protect against LPS-induced toxicity and 1 μg/mL LCFP-3 could significantly inhibit LPS-induced NO production.
35943155	5	0	link	α1,3/4-linked	998:1010	arg1	fucose					1012:1017	α1,3/4-linked fucose	998:1017	α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose	998:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	15	1	theme	such	2473:2476	arg1	processes					2478:2486	such processes	2473:2486	such processes	2473:2486	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	3	2	theme	complete	524:531	arg1	sequence					540:547	a complete coding sequence	522:547	a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	522:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	9	3	theme	broad	1473:1477	arg1	specificity					1489:1499	a broad substrate specificity	1471:1499	a broad substrate specificity	1471:1499	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	13	4	theme	IMPORTANCE	2076:2085	arg1	residues					2099:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	3	5	with	sequence	540:547	arg1	sequences					573:581	deduced amino acid sequences	554:581	deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	554:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	3	6	theme	acid	568:571	arg1	sequences					573:581	deduced amino acid sequences	554:581	deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	554:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	8	7	link	α1,6-linked	1380:1390	arg1	l-fucose					1392:1399	α1,6-linked l-fucose	1380:1399	α1,6-linked l-fucose	1380:1399	Fuc30 displayed activity only on α1,6-linked l-fucose, and Fuc5372 showed a preference for α1,2 linkages.
35943155	7	8	from	antigens	1323:1330	arg1	linkages					1287:1294	α1,2/3/4/6 linkages	1276:1294	α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN	1276:1344	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	19	9	from	microbiota	3161:3170	arg1	enzymes					3122:3128	These novel glycosidase enzymes	3098:3128	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases,	3098:3223	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	12	10	gly	fucosylated	1996:2006	arg1	glycans					2008:2014	fucosylated glycans	1996:2014	fucosylated glycans	1996:2014	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	3	11	theme	deduced	554:560	arg1	sequences					573:581	deduced amino acid sequences	554:581	deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	554:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	1	12	theme	key	210:212	arg1	roles					214:218	key roles	210:218	key roles	210:218	The gastrointestinal microbiota members produce α-l-fucosidases that play key roles in mucosal, human milk, and dietary oligosaccharide assimilation.
35943155	6	13	theme	N-glycans	1228:1236	arg1	fucosylation					1212:1223	the core fucosylation	1203:1223	the core fucosylation of N-glycans	1203:1236	In addition, Fuc1584 also hydrolyzed fucosyl-α-1,6-N-acetylglucosamine (6FN), a component of the core fucosylation of N-glycans.
35943155	14	14	theme	responses	2424:2432	arg1	adhesion					2391:2398	adhesion	2391:2398	adhesion of pathogens and immune responses	2391:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	3	15	theme	highest	598:604	arg1	degree					606:611	the highest degree	594:611	the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	594:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	12	16	theme	newborn	2044:2050	arg1	composition					2063:2073	the newborn microbiota composition	2040:2073	shaping the newborn microbiota composition	2032:2073	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	9	17	from	antigens	1563:1570	arg1	HMOs					1573:1576	HMOs	1573:1576	HMOs	1573:1576	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	9	17	from	antigens	1563:1570	arg1	6FN					1583:1585	6FN	1583:1585	6FN	1583:1585	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	9	17	from	antigens	1563:1570	arg1	l-fucose					1511:1518	l-fucose	1511:1518	l-fucose from all the tested free histo-blood group antigens	1511:1570	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	6	18	theme	fucosylation	1212:1223	arg1	component					1190:1198	a component	1188:1198	a component of the core fucosylation of N-glycans	1188:1236	In addition, Fuc1584 also hydrolyzed fucosyl-α-1,6-N-acetylglucosamine (6FN), a component of the core fucosylation of N-glycans.
35943155	6	18	theme	fucosylation	1212:1223	arg1	fucosyl-α-1,6-N-acetylglucosamine					1147:1179	fucosyl-α-1,6-N-acetylglucosamine	1147:1179	fucosyl-α-1,6-N-acetylglucosamine (6FN)	1147:1185	In addition, Fuc1584 also hydrolyzed fucosyl-α-1,6-N-acetylglucosamine (6FN), a component of the core fucosylation of N-glycans.
35943155	6	19	gly	fucosylation	1212:1223	arg1	N-glycans					1228:1236	N-glycans	1228:1236	N-glycans	1228:1236	In addition, Fuc1584 also hydrolyzed fucosyl-α-1,6-N-acetylglucosamine (6FN), a component of the core fucosylation of N-glycans.
35943155	11	20	theme	acid	1838:1841	arg1	glycoprotein					1843:1854	human α-1 acid glycoprotein	1828:1854	human α-1 acid glycoprotein	1828:1854	Fuc18, Fuc19A, and Fuc39 also removed l-fucose from neoglycoproteins and human α-1 acid glycoprotein.
35943155	15	21	theme	l-fucose	2453:2460	arg1	content					2462:2468	l-fucose content	2453:2468	l-fucose content in such processes	2453:2486	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	9	22	theme	tested	1533:1538	arg1	antigens					1563:1570	all the tested free histo-blood group antigens	1525:1570	all the tested free histo-blood group antigens	1525:1570	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	7	23	from	activity	1264:1271	arg1	linkages					1287:1294	α1,2/3/4/6 linkages	1276:1294	α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN	1276:1344	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	18	24	theme	occurring	3051:3059	arg1	glycoproteins					3061:3073	naturally occurring glycoproteins	3041:3073	naturally occurring glycoproteins	3041:3073	These enzymes showed different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins.
35943155	9	25	theme	histo-blood	1545:1555	arg1	antigens					1563:1570	all the tested free histo-blood group antigens	1525:1570	all the tested free histo-blood group antigens	1525:1570	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	12	26	from	diversity	1899:1907	arg1	microbiota					1948:1957	the infant gut microbiota	1933:1957	the infant gut microbiota	1933:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	0	27	from	Activity	63:70	arg1	Oligosaccharides					98:113	Fucosylated Human Milk Oligosaccharides	75:113	Fucosylated Human Milk Oligosaccharides	75:113	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	0	27	from	Activity	63:70	arg1	Glycoconjugates					119:133	Glycoconjugates	119:133	Glycoconjugates	119:133	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	13	28	theme	human	2165:2169	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	28	theme	human	2165:2169	arg1	HMOs					2194:2197	HMOs	2194:2197	HMOs	2194:2197	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	5	29	theme	hydrolytic	975:984	arg1	activity					986:993	hydrolytic activity	975:993	hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose	975:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	30	attach	present	1019:1025	arg1	antigens					1042:1049	Lewis blood antigens	1030:1049	Lewis blood antigens	1030:1049	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	30	attach	present	1019:1025	arg2	fucose					1012:1017	α1,3/4-linked fucose	998:1017	α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose	998:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	30	attach	present	1019:1025	arg1	3-fucosyllactose					1092:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	8	31	theme	α1,2	1438:1441	arg1	linkages					1443:1450	α1,2 linkages	1438:1450	α1,2 linkages	1438:1450	Fuc30 displayed activity only on α1,6-linked l-fucose, and Fuc5372 showed a preference for α1,2 linkages.
35943155	15	32	theme	molecular	2537:2545	arg1	interactions					2547:2558	molecular interactions	2537:2558	molecular interactions	2537:2558	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	1	33	theme	microbiota	157:166	arg1	members					168:174	The gastrointestinal microbiota members	136:174	The gastrointestinal microbiota members	136:174	The gastrointestinal microbiota members produce α-l-fucosidases that play key roles in mucosal, human milk, and dietary oligosaccharide assimilation.
35943155	17	34	theme	samples	2936:2942	arg1	metagenome					2916:2925	the metagenome	2912:2925	the metagenome of fecal samples of breastfed infants	2912:2963	In this work, α-l-fucosidases from the GH29 family were identified and characterized from the metagenome of fecal samples of breastfed infants.
35943155	10	35	theme	glycoprotein	1735:1746	arg1	mucin					1748:1752	the glycoprotein mucin	1731:1752	the glycoprotein mucin	1731:1752	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	14	36	theme	pathogens	2403:2411	arg1	adhesion					2391:2398	adhesion	2391:2398	adhesion of pathogens and immune responses	2391:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	7	37	theme	type-2	1303:1308	arg1	HMOs					1333:1336	HMOs	1333:1336	HMOs	1333:1336	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	7	37	theme	type-2	1303:1308	arg1	antigens					1323:1330	H type-2, Lewis blood antigens	1301:1330	antigens	1323:1330	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	7	37	theme	type-2	1303:1308	arg1	6FN					1342:1344	6FN	1342:1344	6FN	1342:1344	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	17	38	theme	breastfed	2947:2955	arg1	infants					2957:2963	breastfed infants	2947:2963	breastfed infants	2947:2963	In this work, α-l-fucosidases from the GH29 family were identified and characterized from the metagenome of fecal samples of breastfed infants.
35943155	11	39	theme	human	1828:1832	arg1	glycoprotein					1843:1854	human α-1 acid glycoprotein	1828:1854	human α-1 acid glycoprotein	1828:1854	Fuc18, Fuc19A, and Fuc39 also removed l-fucose from neoglycoproteins and human α-1 acid glycoprotein.
35943155	0	40	theme	Fucosylated	75:85	arg1	Oligosaccharides					98:113	Fucosylated Human Milk Oligosaccharides	75:113	Fucosylated Human Milk Oligosaccharides	75:113	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	18	41	theme	substrate	2997:3005	arg1	specificities					3007:3019	different substrate specificities	2987:3019	different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins	2987:3095	These enzymes showed different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins.
35943155	15	42	from	modulation	2439:2448	arg1	processes					2478:2486	such processes	2473:2486	such processes	2473:2486	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	19	43	theme	novel	3104:3108	arg1	enzymes					3122:3128	These novel glycosidase enzymes	3098:3128	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases,	3098:3223	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	14	44	theme	physiological	2356:2368	arg1	processes					2370:2378	mammalian physiological processes	2346:2378	mammalian physiological processes	2346:2378	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	14	44	theme	physiological	2356:2368	arg1	adhesion					2391:2398	adhesion	2391:2398	adhesion of pathogens and immune responses	2391:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	0	45	theme	Milk	93:96	arg1	Oligosaccharides					98:113	Fucosylated Human Milk Oligosaccharides	75:113	Fucosylated Human Milk Oligosaccharides	75:113	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	2	46	theme	reading	300:306	arg1	ORFs					316:319	ORFs	316:319	ORFs	316:319	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	2	46	theme	reading	300:306	arg1	frames					308:313	36 open reading frames	292:313	36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29)	292:405	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	5	47	theme	blood	1036:1040	arg1	antigens					1042:1049	Lewis blood antigens	1030:1049	Lewis blood antigens	1030:1049	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	16	48	theme	free	2695:2698	arg1	oligosaccharides					2700:2715	free oligosaccharides	2695:2715	free oligosaccharides	2695:2715	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	16	49	used	used	2753:2756	arg2	exoglycosidases					2641:2655	exoglycosidases	2641:2655	exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides	2641:2819	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	16	49	used	used	2753:2756	arg2	α-l-fucosidases					2621:2635	Microbial α-l-fucosidases	2611:2635	Microbial α-l-fucosidases	2611:2635	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	4	50	theme	α-l-fucosidase	827:840	arg1	genes					842:846	10 α-l-fucosidase genes	824:846	10 α-l-fucosidase genes	824:846	Based on sequence homology, 10 α-l-fucosidase genes were selected for substrate specificity characterization.
35943155	13	51	theme	many	2134:2137	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	51	theme	many	2134:2137	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	51	theme	many	2134:2137	arg1	glycans					2148:2154	many relevant glycans	2134:2154	many relevant glycans	2134:2154	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	51	theme	many	2134:2137	arg1	epitopes					2241:2248	epitopes	2241:2248	epitopes on cell surface glycoconjugate receptors	2241:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	12	52	theme	gut	1944:1946	arg1	microbiota					1948:1957	the infant gut microbiota	1933:1957	the infant gut microbiota	1933:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	5	53	from	activity	986:993	arg1	fucose					1012:1017	α1,3/4-linked fucose	998:1017	α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose	998:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	2	54	theme	infant	465:470	arg1	microbiome					478:487	breast-fed infant fecal microbiome	454:487	breast-fed infant fecal microbiome	454:487	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	12	55	dep	shaping	2032:2038	arg1	composition					2063:2073	the newborn microbiota composition	2040:2073	shaping the newborn microbiota composition	2032:2073	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	0	56	theme	Infant	0:5	arg1	Mining					32:37	Infant Gut Microbial Metagenome Mining	0:37	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.	0:134	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	15	57	from	processes	2478:2486	arg1	modulation					2439:2448	The modulation	2435:2448	The modulation of l-fucose content in such processes	2435:2486	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	4	58	theme	sequence	805:812	arg1	homology					814:821	sequence homology	805:821	sequence homology	805:821	Based on sequence homology, 10 α-l-fucosidase genes were selected for substrate specificity characterization.
35943155	13	59	attach	present	2123:2129	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	59	attach	present	2123:2129	arg2	residues					2099:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	59	attach	present	2123:2129	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	59	attach	present	2123:2129	arg1	glycans					2148:2154	many relevant glycans	2134:2154	many relevant glycans	2134:2154	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	59	attach	present	2123:2129	arg1	epitopes					2241:2248	epitopes	2241:2248	epitopes on cell surface glycoconjugate receptors	2241:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	2	60	theme	metagenome	431:440	arg1	analysis					442:449	metagenome analysis	431:449	metagenome analysis of breast-fed infant fecal microbiome	431:487	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	0	61	theme	Microbial	11:19	arg1	Mining					32:37	Infant Gut Microbial Metagenome Mining	0:37	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.	0:134	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	12	62	theme	α-l-fucosidases	1912:1926	arg1	diversity					1899:1907	the great diversity	1889:1907	the great diversity of α-l-fucosidases from the infant gut microbiota	1889:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	7	63	dep	antigens	1323:1330	arg1	Lewis					1311:1315	H type-2, Lewis blood antigens	1301:1330	Lewis	1311:1315	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	4	64	theme	specificity	876:886	arg1	characterization					888:903	substrate specificity characterization	866:903	substrate specificity characterization	866:903	Based on sequence homology, 10 α-l-fucosidase genes were selected for substrate specificity characterization.
35943155	5	65	theme	HMO	1087:1089	arg1	3-fucosyllactose					1092:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	2	66	theme	microbiome	478:487	arg1	analysis					442:449	metagenome analysis	431:449	metagenome analysis of breast-fed infant fecal microbiome	431:487	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	19	67	theme	good	3193:3196	arg1	source					3198:3203	a good source	3191:3203	a good source of α-l-fucosidases	3191:3222	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	3	68	theme	ORFs	510:513	arg1	ORFs					510:513	those ORFs	504:513	those ORFs	504:513	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	3	68	theme	ORFs	510:513	arg1	Twenty-two					490:499	Twenty-two	490:499	Twenty-two	490:499	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	0	69	theme	α-l-Fucosidases	42:56	arg1	Mining					32:37	Infant Gut Microbial Metagenome Mining	0:37	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.	0:134	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	13	70	theme	surface	2258:2264	arg1	receptors					2281:2289	cell surface glycoconjugate receptors	2253:2289	cell surface glycoconjugate receptors	2253:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	16	71	theme	Microbial	2611:2619	arg1	exoglycosidases					2641:2655	exoglycosidases	2641:2655	exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides	2641:2819	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	16	71	theme	Microbial	2611:2619	arg1	α-l-fucosidases					2621:2635	Microbial α-l-fucosidases	2611:2635	Microbial α-l-fucosidases	2611:2635	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	16	72	theme	transglycosylation	2761:2778	arg1	reactions					2780:2788	transglycosylation reactions	2761:2788	transglycosylation reactions	2761:2788	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	19	73	theme	α-l-fucosidases	3208:3222	arg1	source					3198:3203	a good source	3191:3203	a good source of α-l-fucosidases	3191:3222	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	2	74	theme	putative	333:340	arg1	α-l-fucosidases					342:356	putative α-l-fucosidases	333:356	putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29)	333:405	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	5	75	theme	human	1059:1063	arg1	3-fucosyllactose					1092:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	13	76	from	oligosaccharides	2176:2191	arg1	receptors					2281:2289	cell surface glycoconjugate receptors	2253:2289	cell surface glycoconjugate receptors	2253:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	11	77	gly	glycoprotein	1843:1854	arg1	glycoprotein					1843:1854	human α-1 acid glycoprotein	1828:1854	human α-1 acid glycoprotein	1828:1854	Fuc18, Fuc19A, and Fuc39 also removed l-fucose from neoglycoproteins and human α-1 acid glycoprotein.
35943155	3	78	theme	coding	533:538	arg1	sequence					540:547	a complete coding sequence	522:547	a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	522:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	1	79	theme	dietary	248:254	arg1	assimilation					272:283	dietary oligosaccharide assimilation	248:283	dietary oligosaccharide assimilation	248:283	The gastrointestinal microbiota members produce α-l-fucosidases that play key roles in mucosal, human milk, and dietary oligosaccharide assimilation.
35943155	5	80	theme	oligosaccharide	1070:1084	arg1	3-fucosyllactose					1092:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	14	81	gly	fucosylated	2298:2308	arg1	glycans					2310:2316	These fucosylated glycans	2292:2316	These fucosylated glycans	2292:2316	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	18	82	gly	glycoproteins	3061:3073	arg1	glycoproteins					3061:3073	naturally occurring glycoproteins	3041:3073	naturally occurring glycoproteins	3041:3073	These enzymes showed different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins.
35943155	10	83	theme	latest	1593:1598	arg1	enzyme					1600:1605	This latest enzyme	1588:1605	This latest enzyme	1588:1605	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	0	84	with	Mining	32:37	arg1	Activity					63:70	Activity	63:70	Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates	63:133	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	2	85	theme	glycosyl	371:378	arg1	GH29					401:404	GH29	401:404	GH29	401:404	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	2	85	theme	glycosyl	371:378	arg1	family					390:395	glycosyl hydrolase family 29	371:398	glycosyl hydrolase family 29 (GH29)	371:405	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	13	86	theme	group	2213:2217	arg1	HBGAs					2229:2233	HBGAs	2229:2233	HBGAs	2229:2233	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	86	theme	group	2213:2217	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	16	87	from	glycoconjugates	2721:2735	arg1	residues					2681:2688	α-l-fucosyl residues	2669:2688	α-l-fucosyl residues from free oligosaccharides and glycoconjugates	2669:2735	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	3	88	theme	amino	562:566	arg1	sequences					573:581	deduced amino acid sequences	554:581	deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	554:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	9	89	theme	substrate	1479:1487	arg1	specificity					1489:1499	a broad substrate specificity	1471:1499	a broad substrate specificity	1471:1499	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	12	90	theme	microbiota	2052:2061	arg1	composition					2063:2073	the newborn microbiota composition	2040:2073	shaping the newborn microbiota composition	2032:2073	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	2	91	theme	open	295:298	arg1	ORFs					316:319	ORFs	316:319	ORFs	316:319	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	2	91	theme	open	295:298	arg1	frames					308:313	36 open reading frames	292:313	36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29)	292:405	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	17	92	theme	fecal	2930:2934	arg1	samples					2936:2942	fecal samples	2930:2942	fecal samples of breastfed infants	2930:2963	In this work, α-l-fucosidases from the GH29 family were identified and characterized from the metagenome of fecal samples of breastfed infants.
35943155	17	93	theme	GH29	2861:2864	arg1	family					2866:2871	the GH29 family	2857:2871	the GH29 family	2857:2871	In this work, α-l-fucosidases from the GH29 family were identified and characterized from the metagenome of fecal samples of breastfed infants.
35943155	17	94	from	family	2866:2871	arg1	α-l-fucosidases					2836:2850	α-l-fucosidases	2836:2850	α-l-fucosidases from the GH29 family	2836:2871	In this work, α-l-fucosidases from the GH29 family were identified and characterized from the metagenome of fecal samples of breastfed infants.
35943155	13	95	from	present	2123:2129	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	95	from	present	2123:2129	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	95	from	present	2123:2129	arg1	glycans					2148:2154	many relevant glycans	2134:2154	many relevant glycans	2134:2154	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	95	from	present	2123:2129	arg1	epitopes					2241:2248	epitopes	2241:2248	epitopes on cell surface glycoconjugate receptors	2241:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	14	96	theme	immune	2417:2422	arg1	responses					2424:2432	immune responses	2417:2432	immune responses	2417:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	5	97	from	3-fucosyllactose	1092:1107	arg1	present					1019:1025	present	1019:1025	present	1019:1025	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	6	98	theme	core	1207:1210	arg1	fucosylation					1212:1223	the core fucosylation	1203:1223	the core fucosylation of N-glycans	1203:1236	In addition, Fuc1584 also hydrolyzed fucosyl-α-1,6-N-acetylglucosamine (6FN), a component of the core fucosylation of N-glycans.
35943155	3	99	from	dorei	735:739	arg1	α-l-fucosidases					630:644	α-l-fucosidases	630:644	α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	630:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	19	100	theme	biotechnological	3236:3251	arg1	potential					3253:3261	great biotechnological potential	3230:3261	great biotechnological potential	3230:3261	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	10	101	gly	glycoprotein	1735:1746	arg1	glycoprotein					1735:1746	the glycoprotein mucin	1731:1752	the glycoprotein mucin	1731:1752	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	3	102	theme	identity	616:623	arg1	degree					606:611	the highest degree	594:611	the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	594:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	9	103	theme	free	1540:1543	arg1	antigens					1563:1570	all the tested free histo-blood group antigens	1525:1570	all the tested free histo-blood group antigens	1525:1570	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	12	104	theme	fucosylated	1996:2006	arg1	glycans					2008:2014	fucosylated glycans	1996:2014	fucosylated glycans	1996:2014	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	13	105	from	glycans	2148:2154	arg1	present					2123:2129	present	2123:2129	present	2123:2129	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	16	106	from	oligosaccharides	2700:2715	arg1	residues					2681:2688	α-l-fucosyl residues	2669:2688	α-l-fucosyl residues from free oligosaccharides and glycoconjugates	2669:2735	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	13	107	theme	histo-blood	2201:2211	arg1	HBGAs					2229:2233	HBGAs	2229:2233	HBGAs	2229:2233	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	107	theme	histo-blood	2201:2211	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	9	108	theme	group	1557:1561	arg1	antigens					1563:1570	all the tested free histo-blood group antigens	1525:1570	all the tested free histo-blood group antigens	1525:1570	Fuc2358 exhibited a broad substrate specificity releasing l-fucose from all the tested free histo-blood group antigens, HMOs, and 6FN.
35943155	18	109	theme	different	2987:2995	arg1	specificities					3007:3019	different substrate specificities	2987:3019	different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins	2987:3095	These enzymes showed different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins.
35943155	19	110	contain	have	3225:3228	arg1	enzymes					3122:3128	These novel glycosidase enzymes	3098:3128	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases,	3098:3223	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	19	110	contain	have	3225:3228	arg2	potential					3253:3261	great biotechnological potential	3230:3261	great biotechnological potential	3230:3261	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	13	111	theme	milk	2171:2174	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	111	theme	milk	2171:2174	arg1	HMOs					2194:2197	HMOs	2194:2197	HMOs	2194:2197	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	1	112	theme	gastrointestinal	140:155	arg1	members					168:174	The gastrointestinal microbiota members	136:174	The gastrointestinal microbiota members	136:174	The gastrointestinal microbiota members produce α-l-fucosidases that play key roles in mucosal, human milk, and dietary oligosaccharide assimilation.
35943155	13	113	located	present	2123:2129	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	113	located	present	2123:2129	arg2	residues					2099:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	113	located	present	2123:2129	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	113	located	present	2123:2129	arg1	glycans					2148:2154	many relevant glycans	2134:2154	many relevant glycans	2134:2154	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	113	located	present	2123:2129	arg1	epitopes					2241:2248	epitopes	2241:2248	epitopes on cell surface glycoconjugate receptors	2241:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	7	114	theme	H	1301:1301	arg1	HMOs					1333:1336	HMOs	1333:1336	HMOs	1333:1336	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	7	114	theme	H	1301:1301	arg1	antigens					1323:1330	H type-2, Lewis blood antigens	1301:1330	antigens	1323:1330	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	7	114	theme	H	1301:1301	arg1	6FN					1342:1344	6FN	1342:1344	6FN	1342:1344	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	16	115	theme	α-l-fucosyl	2669:2679	arg1	residues					2681:2688	α-l-fucosyl residues	2669:2688	α-l-fucosyl residues from free oligosaccharides and glycoconjugates	2669:2735	Microbial α-l-fucosidases are exoglycosidases that remove α-l-fucosyl residues from free oligosaccharides and glycoconjugates and can be also used in transglycosylation reactions to synthesize oligosaccharides.
35943155	7	116	theme	α1,2/3/4/6	1276:1285	arg1	linkages					1287:1294	α1,2/3/4/6 linkages	1276:1294	α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN	1276:1344	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	0	117	theme	Human	87:91	arg1	Oligosaccharides					98:113	Fucosylated Human Milk Oligosaccharides	75:113	Fucosylated Human Milk Oligosaccharides	75:113	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	17	118	theme	infants	2957:2963	arg1	samples					2936:2942	fecal samples	2930:2942	fecal samples of breastfed infants	2930:2963	In this work, α-l-fucosidases from the GH29 family were identified and characterized from the metagenome of fecal samples of breastfed infants.
35943155	8	119	theme	α1,6-linked	1380:1390	arg1	l-fucose					1392:1399	α1,6-linked l-fucose	1380:1399	α1,6-linked l-fucose	1380:1399	Fuc30 displayed activity only on α1,6-linked l-fucose, and Fuc5372 showed a preference for α1,2 linkages.
35943155	14	120	theme	processes	2370:2378	arg1	number					2336:2341	a number	2334:2341	a number of mammalian physiological processes, including adhesion of pathogens and immune responses	2334:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	14	120	theme	processes	2370:2378	arg1	adhesion					2391:2398	adhesion	2391:2398	adhesion of pathogens and immune responses	2391:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	11	121	theme	α-1	1834:1836	arg1	glycoprotein					1843:1854	human α-1 acid glycoprotein	1828:1854	human α-1 acid glycoprotein	1828:1854	Fuc18, Fuc19A, and Fuc39 also removed l-fucose from neoglycoproteins and human α-1 acid glycoprotein.
35943155	15	122	theme	new	2500:2502	arg1	insights					2504:2511	new insights	2500:2511	new insights	2500:2511	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	5	123	theme	Lewis	1030:1034	arg1	antigens					1042:1049	Lewis blood antigens	1030:1049	Lewis blood antigens	1030:1049	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	12	124	from	microbiota	1948:1957	arg1	diversity					1899:1907	the great diversity	1889:1907	the great diversity of α-l-fucosidases from the infant gut microbiota	1889:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	12	124	from	microbiota	1948:1957	arg1	α-l-fucosidases					1912:1926	α-l-fucosidases	1912:1926	α-l-fucosidases from the infant gut microbiota	1912:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	19	125	theme	glycosidase	3110:3120	arg1	enzymes					3122:3128	These novel glycosidase enzymes	3098:3128	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases,	3098:3223	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	14	126	theme	mammalian	2346:2354	arg1	processes					2370:2378	mammalian physiological processes	2346:2378	mammalian physiological processes	2346:2378	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	14	126	theme	mammalian	2346:2354	arg1	adhesion					2391:2398	adhesion	2391:2398	adhesion of pathogens and immune responses	2391:2432	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	3	127	with	identity	616:623	arg1	α-l-fucosidases					630:644	α-l-fucosidases	630:644	α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis	630:793	Twenty-two of those ORFs showed a complete coding sequence with deduced amino acid sequences displaying the highest degree of identity with α-l-fucosidases from Bacteroides thetaiotaomicron, Bacteroides caccae, Phocaeicola vulgatus, Phocaeicola dorei, Ruminococcus gnavus, and Streptococcus parasanguinis.
35943155	15	128	from	content	2462:2468	arg1	processes					2478:2486	such processes	2473:2486	such processes	2473:2486	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	19	129	theme	gut	3157:3159	arg1	microbiota					3161:3170	the breast-fed infant gut microbiota	3135:3170	the breast-fed infant gut microbiota	3135:3170	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	11	130	gly	neoglycoproteins	1807:1822	arg1	neoglycoproteins					1807:1822	neoglycoproteins	1807:1822	neoglycoproteins	1807:1822	Fuc18, Fuc19A, and Fuc39 also removed l-fucose from neoglycoproteins and human α-1 acid glycoprotein.
35943155	0	131	theme	Gut	7:9	arg1	Mining					32:37	Infant Gut Microbial Metagenome Mining	0:37	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.	0:134	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	13	132	theme	relevant	2139:2146	arg1	oligosaccharides					2176:2191	human milk oligosaccharides	2165:2191	human milk oligosaccharides (HMOs)	2165:2198	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	132	theme	relevant	2139:2146	arg1	antigens					2219:2226	histo-blood group antigens	2201:2226	histo-blood group antigens (HBGAs)	2201:2234	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	132	theme	relevant	2139:2146	arg1	glycans					2148:2154	many relevant glycans	2134:2154	many relevant glycans	2134:2154	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	132	theme	relevant	2139:2146	arg1	epitopes					2241:2248	epitopes	2241:2248	epitopes on cell surface glycoconjugate receptors	2241:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	14	133	theme	fucosylated	2298:2308	arg1	glycans					2310:2316	These fucosylated glycans	2292:2316	These fucosylated glycans	2292:2316	These fucosylated glycans are involved in a number of mammalian physiological processes, including adhesion of pathogens and immune responses.
35943155	5	134	theme	α1,3/4-linked	998:1010	arg1	fucose					1012:1017	α1,3/4-linked fucose	998:1017	α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose	998:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	2	135	theme	breast-fed	454:463	arg1	microbiome					478:487	breast-fed infant fecal microbiome	454:487	breast-fed infant fecal microbiome	454:487	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	19	136	theme	breast-fed	3139:3148	arg1	microbiota					3161:3170	the breast-fed infant gut microbiota	3135:3170	the breast-fed infant gut microbiota	3135:3170	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	19	137	theme	infant	3150:3155	arg1	microbiota					3161:3170	the breast-fed infant gut microbiota	3135:3170	the breast-fed infant gut microbiota	3135:3170	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	15	138	theme	content	2462:2468	arg1	modulation					2439:2448	The modulation	2435:2448	The modulation of l-fucose content in such processes	2435:2486	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	0	139	theme	Metagenome	21:30	arg1	Mining					32:37	Infant Gut Microbial Metagenome Mining	0:37	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.	0:134	Infant Gut Microbial Metagenome Mining of α-l-Fucosidases with Activity on Fucosylated Human Milk Oligosaccharides and Glycoconjugates.
35943155	15	140	theme	new	2583:2585	arg1	strategies					2599:2608	new therapeutic strategies	2583:2608	new therapeutic strategies	2583:2608	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	5	141	theme	present	1019:1025	arg1	fucose					1012:1017	α1,3/4-linked fucose	998:1017	α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose	998:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	12	142	theme	infant	1937:1942	arg1	microbiota					1948:1957	the infant gut microbiota	1933:1957	the infant gut microbiota	1933:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	1	143	theme	human	232:236	arg1	milk					238:241	human milk	232:241	human milk	232:241	The gastrointestinal microbiota members produce α-l-fucosidases that play key roles in mucosal, human milk, and dietary oligosaccharide assimilation.
35943155	10	144	contain	carrying	1650:1657	arg2	lacto-N-fucopentaose					1693:1712	lacto-N-fucopentaose III	1693:1716	lacto-N-fucopentaose III (Lex)	1693:1722	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	10	144	contain	carrying	1650:1657	arg2	Lex					1719:1721	Lex	1719:1721	Lex	1719:1721	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	10	144	contain	carrying	1650:1657	arg2	Lea					1684:1686	Lea	1684:1686	Lea	1684:1686	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	10	144	contain	carrying	1650:1657	arg2	lacto-N-fucopentaose					1659:1678	lacto-N-fucopentaose II	1659:1681	lacto-N-fucopentaose II (Lea)	1659:1687	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	10	144	contain	carrying	1650:1657	arg1	glycoconjugates					1634:1648	glycoconjugates	1634:1648	glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex)	1634:1722	This latest enzyme also displayed activity in glycoconjugates carrying lacto-N-fucopentaose II (Lea) and lacto-N-fucopentaose III (Lex) and in the glycoprotein mucin.
35943155	13	145	from	antigens	2219:2226	arg1	receptors					2281:2289	cell surface glycoconjugate receptors	2253:2289	cell surface glycoconjugate receptors	2253:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	4	146	theme	substrate	866:874	arg1	characterization					888:903	substrate specificity characterization	866:903	substrate specificity characterization	866:903	Based on sequence homology, 10 α-l-fucosidase genes were selected for substrate specificity characterization.
35943155	13	147	theme	α-l-Fucosyl	2087:2097	arg1	residues					2099:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues	2076:2106	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	13	148	theme	cell	2253:2256	arg1	receptors					2281:2289	cell surface glycoconjugate receptors	2253:2289	cell surface glycoconjugate receptors	2253:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	12	149	theme	great	1893:1897	arg1	diversity					1899:1907	the great diversity	1889:1907	the great diversity of α-l-fucosidases from the infant gut microbiota	1889:1957	These results give insight into the great diversity of α-l-fucosidases from the infant gut microbiota, thus supporting the hypothesis that fucosylated glycans are crucial for shaping the newborn microbiota composition.
35943155	2	150	theme	fecal	472:476	arg1	microbiome					478:487	breast-fed infant fecal microbiome	454:487	breast-fed infant fecal microbiome	454:487	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	13	151	from	epitopes	2241:2248	arg1	receptors					2281:2289	cell surface glycoconjugate receptors	2253:2289	cell surface glycoconjugate receptors	2253:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	5	152	from	present	1019:1025	arg1	antigens					1042:1049	Lewis blood antigens	1030:1049	Lewis blood antigens	1030:1049	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	152	from	present	1019:1025	arg1	3-fucosyllactose					1092:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	13	153	theme	glycoconjugate	2266:2279	arg1	receptors					2281:2289	cell surface glycoconjugate receptors	2253:2289	cell surface glycoconjugate receptors	2253:2289	IMPORTANCE α-l-Fucosyl residues are frequently present in many relevant glycans, such as human milk oligosaccharides (HMOs), histo-blood group antigens (HBGAs), and epitopes on cell surface glycoconjugate receptors.
35943155	15	154	theme	therapeutic	2587:2597	arg1	strategies					2599:2608	new therapeutic strategies	2583:2608	new therapeutic strategies	2583:2608	The modulation of l-fucose content in such processes may provide new insights and knowledge regarding molecular interactions and may help to devise new therapeutic strategies.
35943155	5	155	theme	milk	1065:1068	arg1	3-fucosyllactose					1092:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	the human milk oligosaccharide (HMO) 3-fucosyllactose	1055:1107	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	7	156	theme	blood	1317:1321	arg1	HMOs					1333:1336	HMOs	1333:1336	HMOs	1333:1336	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	7	156	theme	blood	1317:1321	arg1	antigens					1323:1330	H type-2, Lewis blood antigens	1301:1330	antigens	1323:1330	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	7	156	theme	blood	1317:1321	arg1	6FN					1342:1344	6FN	1342:1344	6FN	1342:1344	Fuc35A and Fuc193 showed activity on α1,2/3/4/6 linkages from H type-2, Lewis blood antigens, HMOs and 6FN.
35943155	18	157	gly	neoglycoproteins	3080:3095	arg1	neoglycoproteins					3080:3095	neoglycoproteins	3080:3095	neoglycoproteins	3080:3095	These enzymes showed different substrate specificities toward HMOs, HBGAs, naturally occurring glycoproteins, and neoglycoproteins.
35943155	5	158	dep	α-l-fucosidases	910:924	arg1	α-l-fucosidases					910:924	The α-l-fucosidases	906:924	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584	906:966	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	158	dep	α-l-fucosidases	910:924	arg1	Fuc18					926:930	Fuc18	926:930	Fuc18	926:930	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	158	dep	α-l-fucosidases	910:924	arg1	Fuc39					949:953	Fuc39	949:953	Fuc39	949:953	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	158	dep	α-l-fucosidases	910:924	arg1	Fuc1584					960:966	Fuc1584	960:966	Fuc1584	960:966	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	158	dep	α-l-fucosidases	910:924	arg1	Fuc19A					933:938	Fuc19A	933:938	Fuc19A	933:938	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	5	158	dep	α-l-fucosidases	910:924	arg1	Fuc35B					941:946	Fuc35B	941:946	Fuc35B	941:946	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	19	159	theme	great	3230:3234	arg1	potential					3253:3261	great biotechnological potential	3230:3261	great biotechnological potential	3230:3261	These novel glycosidase enzymes from the breast-fed infant gut microbiota, which resulted in a good source of α-l-fucosidases, have great biotechnological potential.
35943155	2	160	theme	hydrolase	380:388	arg1	GH29					401:404	GH29	401:404	GH29	401:404	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	2	160	theme	hydrolase	380:388	arg1	family					390:395	glycosyl hydrolase family 29	371:398	glycosyl hydrolase family 29 (GH29)	371:405	Here, 36 open reading frames (ORFs) coding for putative α-l-fucosidases belonging to glycosyl hydrolase family 29 (GH29) were identified through metagenome analysis of breast-fed infant fecal microbiome.
35943155	5	161	from	antigens	1042:1049	arg1	present					1019:1025	present	1019:1025	present	1019:1025	The α-l-fucosidases Fuc18, Fuc19A, Fuc35B, Fuc39, and Fuc1584 showed hydrolytic activity on α1,3/4-linked fucose present in Lewis blood antigens and the human milk oligosaccharide (HMO) 3-fucosyllactose.
35943155	1	162	theme	oligosaccharide	256:270	arg1	assimilation					272:283	dietary oligosaccharide assimilation	248:283	dietary oligosaccharide assimilation	248:283	The gastrointestinal microbiota members produce α-l-fucosidases that play key roles in mucosal, human milk, and dietary oligosaccharide assimilation.
37249735	0	0	theme	Polysaccharide	88:101	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	0	0	theme	Polysaccharide	88:101	arg1	Digestion					39:47	Simulated Digestion	29:47	Simulated Digestion	29:47	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	0	0	theme	Polysaccharide	88:101	arg1	Activities					64:73	Anti-Aging Activities	53:73	Anti-Aging Activities	53:73	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	5	1	theme	short-chain	936:946	arg1	SCFA					961:964	SCFA	961:964	SCFA	961:964	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	1	theme	short-chain	936:946	arg1	acids					954:958	short-chain fatty acids	936:958	short-chain fatty acids (SCFA)	936:965	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	7	2	theme	Salvia	1266:1271	arg1	miltiorrhiza					1273:1284	Salvia miltiorrhiza	1266:1284	Salvia miltiorrhiza	1266:1284	This work lays a foundation for the development of functional foods related to Salvia miltiorrhiza.
37249735	3	3	theme	simulated	420:428	arg1	digestion					430:438	simulated digestion	420:438	simulated digestion in vitro	420:447	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	5	4	from	levels	824:829	arg1	tissue					900:905	brain tissue	894:905	brain tissue	894:905	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	0	5	theme	Acidic	81:86	arg1	Polysaccharide					88:101	an Acidic Polysaccharide	78:101	an Acidic Polysaccharide from Salvia Miltiorrhiza	78:126	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	0	6	from	Characterization	11:26	arg1	Miltiorrhiza					115:126	Miltiorrhiza	115:126	Miltiorrhiza	115:126	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	6	7	theme	relative	1079:1086	arg1	abundance					1088:1096	the relative abundance	1075:1096	the relative abundance of Firmicutes and Bacteroidetes	1075:1128	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	3	8	theme	digestion	430:438	arg1	results					409:415	The results	405:415	The results of simulated digestion in vitro	405:447	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	5	9	theme	acids	954:958	arg1	content					925:931	the content	921:931	the content of short-chain fatty acids (SCFA) in the intestine	921:982	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	3	10	from	digestion	430:438	arg1	vitro					443:447	vitro	443:447	vitro	443:447	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	7	11	theme	foods	1249:1253	arg1	development					1223:1233	the development	1219:1233	the development of functional foods related to Salvia miltiorrhiza	1219:1284	This work lays a foundation for the development of functional foods related to Salvia miltiorrhiza.
37249735	6	12	theme	Proteobacteria	1171:1184	arg1	abundance					1158:1166	the relative abundance	1145:1166	the relative abundance of Proteobacteria	1145:1184	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	0	13	from	Activities	64:73	arg1	Miltiorrhiza					115:126	Miltiorrhiza	115:126	Miltiorrhiza	115:126	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	7	14	theme	related	1255:1261	arg1	foods					1249:1253	functional foods	1238:1253	functional foods related to Salvia miltiorrhiza	1238:1284	This work lays a foundation for the development of functional foods related to Salvia miltiorrhiza.
37249735	2	15	theme	molar	279:283	arg1	percentages					285:295	molar percentages	279:295	molar percentages	279:295	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	5	16	theme	catalase	722:729	arg1	activity					679:686	the activity	675:686	the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue	675:761	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	1	17	with	polysaccharide	139:152	arg1	Mw					185:186	Mw	185:186	Mw	185:186	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	1	17	with	polysaccharide	139:152	arg1	weight					177:182	a molecular weight	165:182	a molecular weight (Mw) of 1.28 × 106 Da	165:204	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	3	18	from	vitro	443:447	arg1	results					409:415	The results	405:415	The results of simulated digestion in vitro	405:447	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	1	19	theme	molecular	167:175	arg1	Mw					185:186	Mw	185:186	Mw	185:186	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	1	19	theme	molecular	167:175	arg1	weight					177:182	a molecular weight	165:182	a molecular weight (Mw) of 1.28 × 106 Da	165:204	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	5	20	theme	dismutase	702:710	arg1	activity					679:686	the activity	675:686	the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue	675:761	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	4	21	theme	new	548:550	arg1	test					571:574	new object recognition test	548:574	new object recognition test	548:574	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	5	22	theme	superoxide	691:700	arg1	dismutase					702:710	superoxide dismutase	691:710	superoxide dismutase (SOD)	691:716	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	22	theme	superoxide	691:700	arg1	SOD					713:715	SOD	713:715	SOD	713:715	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	0	23	from	Digestion	39:47	arg1	Miltiorrhiza					115:126	Miltiorrhiza	115:126	Miltiorrhiza	115:126	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	5	24	theme	malondialdehyde	788:802	arg1	content					777:783	the content	773:783	the content of malondialdehyde (MDA)	773:808	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	0	25	theme	Structural	0:9	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	6	26	theme	flora	1037:1041	arg1	structure					1043:1051	the intestinal flora structure	1022:1051	the intestinal flora structure	1022:1051	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	3	27	from	results	409:415	arg1	vitro					443:447	vitro	443:447	vitro	443:447	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	5	28	theme	fatty	948:952	arg1	SCFA					961:964	SCFA	961:964	SCFA	961:964	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	28	theme	fatty	948:952	arg1	acids					954:958	short-chain fatty acids	936:958	short-chain fatty acids (SCFA)	936:965	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	4	29	theme	recognition	559:569	arg1	test					571:574	new object recognition test	548:574	new object recognition test	548:574	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	0	30	theme	Simulated	29:37	arg1	Digestion					39:47	Simulated Digestion	29:47	Simulated Digestion	29:47	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	6	31	theme	relative	1149:1156	arg1	abundance					1158:1166	the relative abundance	1145:1166	the relative abundance of Proteobacteria	1145:1184	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	5	32	theme	necrosis	865:872	arg1	TNF-α					884:888	TNF-α	884:888	TNF-α	884:888	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	32	theme	necrosis	865:872	arg1	factor-α					874:881	tumor necrosis factor-α	859:881	tumor necrosis factor-α (TNF-α)	859:889	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	4	33	theme	mice	645:648	arg1	impairment					625:634	the working memory impairment	606:634	the working memory impairment of aging mice	606:648	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	6	34	theme	intestinal	1026:1035	arg1	structure					1043:1051	the intestinal flora structure	1022:1051	the intestinal flora structure	1022:1051	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	2	35	theme	Ara	371:373	arg1	 = 6.15					375:381	arabinose (Ara) = 6.15	360:381	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	4	36	theme	aging	639:643	arg1	mice					645:648	aging mice	639:648	aging mice	639:648	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	4	37	theme	Y	532:532	arg1	test					539:542	The Y maze test	528:542	The Y maze test	528:542	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	2	38	theme	galacturonic	317:328	arg1	GalA					336:339	GalA	336:339	GalA	336:339	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	38	theme	galacturonic	317:328	arg1	acid					330:333	galacturonic acid	317:333	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	5	39	theme	brain	894:898	arg1	tissue					900:905	brain tissue	894:905	brain tissue	894:905	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	1	40	attach	isolated	210:217	arg2	SMP					155:157	SMP	155:157	SMP	155:157	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	1	40	attach	isolated	210:217	arg1	miltiorrhiza					231:242	Salvia miltiorrhiza	224:242	Salvia miltiorrhiza	224:242	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	1	40	attach	isolated	210:217	arg2	polysaccharide					139:152	An acidic polysaccharide	129:152	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da	129:204	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	2	41	theme	arabinose	360:368	arg1	 = 6.15					375:381	arabinose (Ara) = 6.15	360:381	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	4	42	theme	object	552:557	arg1	test					571:574	new object recognition test	548:574	new object recognition test	548:574	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	1	43	theme	Da	203:204	arg1	Mw					185:186	Mw	185:186	Mw	185:186	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	1	43	theme	Da	203:204	arg1	weight					177:182	a molecular weight	165:182	a molecular weight (Mw) of 1.28 × 106 Da	165:204	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	6	44	theme	Bacteroidetes	1116:1128	arg1	abundance					1088:1096	the relative abundance	1075:1096	the relative abundance of Firmicutes and Bacteroidetes	1075:1128	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	5	45	theme	tumor	859:863	arg1	TNF-α					884:888	TNF-α	884:888	TNF-α	884:888	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	45	theme	tumor	859:863	arg1	factor-α					874:881	tumor necrosis factor-α	859:881	tumor necrosis factor-α (TNF-α)	859:889	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	46	from	content	925:931	arg1	intestine					974:982	the intestine	970:982	the intestine	970:982	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	2	47	dep	rhamnose	301:308	arg1	Gal					354:356	Gal	354:356	Gal	354:356	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	 = 6.15					375:381	arabinose (Ara) = 6.15	360:381	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	GalA					336:339	GalA	336:339	GalA	336:339	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	55.98					384:388	55.98	384:388	55.98	384:388	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	21.27					391:395	21.27	391:395	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	galactose					343:351	galactose	343:351	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	acid					330:333	galacturonic acid	317:333	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	47	dep	rhamnose	301:308	arg1	16.69					398:402	16.69	398:402	16.69	398:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	0	48	theme	Anti-Aging	53:62	arg1	Activities					64:73	Anti-Aging Activities	53:73	Anti-Aging Activities	53:73	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	5	49	theme	factor-α	874:881	arg1	levels					824:829	the levels	820:829	the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue	820:905	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	3	50	theme	gastric	493:499	arg1	juice					501:505	gastric juice	493:505	gastric juice	493:505	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	1	51	theme	acidic	132:137	arg1	polysaccharide					139:152	An acidic polysaccharide	129:152	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da	129:204	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	1	51	theme	acidic	132:137	arg1	SMP					155:157	SMP	155:157	SMP	155:157	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
37249735	6	52	theme	Firmicutes	1101:1110	arg1	abundance					1088:1096	the relative abundance	1075:1096	the relative abundance of Firmicutes and Bacteroidetes	1075:1128	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	0	53	from	Miltiorrhiza	115:126	arg1	Polysaccharide					88:101	an Acidic Polysaccharide	78:101	an Acidic Polysaccharide from Salvia Miltiorrhiza	78:126	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	0	53	from	Miltiorrhiza	115:126	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	0	53	from	Miltiorrhiza	115:126	arg1	Digestion					39:47	Simulated Digestion	29:47	Simulated Digestion	29:47	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	0	53	from	Miltiorrhiza	115:126	arg1	Activities					64:73	Anti-Aging Activities	53:73	Anti-Aging Activities	53:73	Structural Characterization, Simulated Digestion and Anti-Aging Activities of an Acidic Polysaccharide from Salvia Miltiorrhiza.
37249735	2	54	theme	monosaccharide	249:262	arg1	rhamnose					301:308	rhamnose	301:308	rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69	301:402	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	2	54	theme	monosaccharide	249:262	arg1	composition					264:274	The monosaccharide composition	245:274	The monosaccharide composition in molar percentages	245:295	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	4	55	theme	memory	618:623	arg1	impairment					625:634	the working memory impairment	606:634	the working memory impairment of aging mice	606:648	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	2	56	from	composition	264:274	arg1	percentages					285:295	molar percentages	279:295	molar percentages	279:295	The monosaccharide composition in molar percentages was rhamnose (Rha): galacturonic acid (GalA): galactose (Gal): arabinose (Ara) = 6.15: 55.98: 21.27: 16.69.
37249735	7	57	theme	functional	1238:1247	arg1	foods					1249:1253	functional foods	1238:1253	functional foods related to Salvia miltiorrhiza	1238:1284	This work lays a foundation for the development of functional foods related to Salvia miltiorrhiza.
37249735	5	58	theme	interleukin-6	834:846	arg1	levels					824:829	the levels	820:829	the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue	820:905	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	4	59	theme	working	610:616	arg1	memory					618:623	working memory	610:623	the working memory impairment of aging mice	606:648	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	3	60	theme	intestinal	510:519	arg1	juice					521:525	intestinal juice	510:525	intestinal juice	510:525	The results of simulated digestion in vitro showed that SMP was not degraded in saliva, gastric juice or intestinal juice.
37249735	4	61	theme	maze	534:537	arg1	test					539:542	The Y maze test	528:542	The Y maze test	528:542	The Y maze test and new object recognition test showed that SMP could improve the working memory impairment of aging mice.
37249735	6	62	dep	regulate	1013:1020	arg1	decreasing					1134:1143	decreasing	1134:1143	decreasing the relative abundance of Proteobacteria	1134:1184	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	6	62	dep	regulate	1013:1020	arg1	increasing					1064:1073	increasing	1064:1073	increasing the relative abundance of Firmicutes and Bacteroidetes	1064:1128	In addition, SMP could also regulate the intestinal flora structure, including increasing the relative abundance of Firmicutes and Bacteroidetes and decreasing the relative abundance of Proteobacteria.
37249735	5	63	from	activity	679:686	arg1	tissue					756:761	brain tissue	750:761	brain tissue	750:761	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	63	from	activity	679:686	arg1	serum					740:744	serum	740:744	serum	740:744	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	5	64	theme	brain	750:754	arg1	tissue					756:761	brain tissue	750:761	brain tissue	750:761	SMP could also increase the activity of superoxide dismutase (SOD) and catalase (CAT) in serum and brain tissue, decrease the content of malondialdehyde (MDA), decrease the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in brain tissue, and increase the content of short-chain fatty acids (SCFA) in the intestine.
37249735	1	65	theme	Salvia	224:229	arg1	miltiorrhiza					231:242	Salvia miltiorrhiza	224:242	Salvia miltiorrhiza	224:242	An acidic polysaccharide (SMP) with a molecular weight (Mw) of 1.28 × 106 Da was isolated from Salvia miltiorrhiza.
36828088	0	0	theme	purple	89:94	arg1	potato					102:107	purple sweet potato	89:107	purple sweet potato (Ipomoea Batatas (L.) Lam)	89:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	7	1	theme	D-Xylp-	818:824	arg1	1→					826:827	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	826:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	6	2	theme	1 → and	725:731	arg1	1→					748:749	→6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→	713:749	1→	748:749	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	6	3	theme	-D-Glcp-	716:723	arg1	1→					748:749	→6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→	713:749	1→	748:749	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	0	4	dep	Batatas	118:124	arg1	Lam					131:133	Lam	131:133	Ipomoea Batatas (L.) Lam	110:133	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	4	5	theme	neutral	508:514	arg1	PSP					499:501	The PSP	495:501	The PSP	495:501	The PSP is a neutral polysaccharide with Mw of 470 kDa.
36828088	4	5	theme	neutral	508:514	arg1	polysaccharide					516:529	a neutral polysaccharide	506:529	a neutral polysaccharide with Mw of 470 kDa	506:548	The PSP is a neutral polysaccharide with Mw of 470 kDa.
36828088	9	6	theme	cells	1023:1027	arg1	effect					994:999	the effect	990:999	the effect on apoptosis of HT-29 cells	990:1027	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	2	7	with	deproteinization	340:355	arg1	Sephadex					407:414	Sephadex G-100	407:420	Sephadex G-100	407:420	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	7	with	deproteinization	340:355	arg1	reagent					368:374	Sevag reagent	362:374	Sevag reagent	362:374	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	7	with	deproteinization	340:355	arg1	ethanol					331:337	ethanol	331:337	ethanol	331:337	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	7	with	deproteinization	340:355	arg1	water					305:309	hot water	301:309	hot water	301:309	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	10	8	theme	induction	1135:1143	arg1	apoptosis					1145:1153	induction apoptosis	1135:1153	induction apoptosis	1135:1153	The results revealed that the PSP can significantly inhibit the proliferation of HT-29 cells from induction apoptosis.
36828088	0	9	theme	sweet	96:100	arg1	potato					102:107	purple sweet potato	89:107	purple sweet potato (Ipomoea Batatas (L.) Lam)	89:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	0	10	from	apoptosis	56:64	arg1	potato					102:107	purple sweet potato	89:107	purple sweet potato (Ipomoea Batatas (L.) Lam)	89:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	6	11	theme	PSP	677:679	arg1	backbone					665:672	The backbone	661:672	The backbone of PSP	661:679	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	7	12	theme	-D-Galp-	801:808	arg1	1→					810:811	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	810:811	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	5	13	theme	monosaccharide	555:568	arg1	composition					570:580	The monosaccharide composition	551:580	The monosaccharide composition of PSP	551:587	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36828088	0	14	dep	potato	102:107	arg1	L.					127:128	L.	127:128	L.	127:128	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	0	14	dep	potato	102:107	arg1	Batatas					118:124	Batatas	118:124	Batatas	118:124	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	11	15	theme	purple	1258:1263	arg1	potato					1271:1276	purple sweet potato	1258:1276	purple sweet potato	1258:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	11	16	theme	structural	1203:1212	arg1	characteristics					1214:1228	structural characteristics	1203:1228	structural characteristics of the polysaccharides from purple sweet potato	1203:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	9	17	theme	MDC	926:928	arg1	staining					930:937	MDC staining	926:937	MDC staining	926:937	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	9	17	theme	MDC	926:928	arg1	staining					916:923	the SEM, AO staining	904:923	staining	916:923	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	11	18	from	characteristics	1214:1228	arg1	potato					1271:1276	purple sweet potato	1258:1276	purple sweet potato	1258:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	6	19	theme	1→	748:749	arg1	1→					748:749	→6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→	713:749	1→	748:749	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	6	19	theme	1→	748:749	arg1	residues					701:708	the residues	697:708	the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→	697:749	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	8	20	theme	HT-29	887:891	arg1	cells					893:897	HT-29 cells	887:897	HT-29 cells	887:897	The antitumor activity in vitro of PSP was analyzed with HT-29 cells.
36828088	11	21	theme	valuable	1180:1187	arg1	knowledges					1189:1198	valuable knowledges	1180:1198	valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato	1180:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	9	22	theme	HT-29	1017:1021	arg1	cells					1023:1027	HT-29 cells	1017:1027	HT-29 cells	1017:1027	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	11	23	theme	polysaccharides	1237:1251	arg1	characteristics					1214:1228	structural characteristics	1203:1228	structural characteristics of the polysaccharides from purple sweet potato	1203:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	0	24	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	10	25	from	apoptosis	1145:1153	arg1	cells					1124:1128	HT-29 cells	1118:1128	HT-29 cells from induction apoptosis	1118:1153	The results revealed that the PSP can significantly inhibit the proliferation of HT-29 cells from induction apoptosis.
36828088	10	25	from	apoptosis	1145:1153	arg1	proliferation					1101:1113	the proliferation	1097:1113	the proliferation of HT-29 cells from induction apoptosis	1097:1153	The results revealed that the PSP can significantly inhibit the proliferation of HT-29 cells from induction apoptosis.
36828088	2	26	with	precipitation	312:324	arg1	Sephadex					407:414	Sephadex G-100	407:420	Sephadex G-100	407:420	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	26	with	precipitation	312:324	arg1	reagent					368:374	Sevag reagent	362:374	Sevag reagent	362:374	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	26	with	precipitation	312:324	arg1	ethanol					331:337	ethanol	331:337	ethanol	331:337	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	26	with	precipitation	312:324	arg1	water					305:309	hot water	301:309	hot water	301:309	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	27	theme	sweet	269:273	arg1	potato					275:280	purple sweet potato	262:280	purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100	262:420	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	9	28	theme	SEM	908:910	arg1	staining					930:937	MDC staining	926:937	MDC staining	926:937	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	9	28	theme	SEM	908:910	arg1	staining					916:923	the SEM, AO staining	904:923	staining	916:923	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	1	29	theme	main	161:164	arg1	carbohydrate					141:152	The carbohydrate	137:152	The carbohydrate	137:152	The carbohydrate is the main ingredient of purple sweet potato.
36828088	1	29	theme	main	161:164	arg1	ingredient					166:175	the main ingredient	157:175	the main ingredient of purple sweet potato	157:198	The carbohydrate is the main ingredient of purple sweet potato.
36828088	10	30	from	proliferation	1101:1113	arg1	apoptosis					1145:1153	induction apoptosis	1135:1153	induction apoptosis	1135:1153	The results revealed that the PSP can significantly inhibit the proliferation of HT-29 cells from induction apoptosis.
36828088	8	31	theme	antitumor	834:842	arg1	activity					844:851	The antitumor activity	830:851	The antitumor activity in vitro of PSP	830:867	The antitumor activity in vitro of PSP was analyzed with HT-29 cells.
36828088	2	32	theme	purple	262:267	arg1	potato					275:280	purple sweet potato	262:280	purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100	262:420	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	7	33	theme	1→	810:811	arg1	residues					786:793	the residues	782:793	the residues of →3)-D-Galp-(1→, and D-Xylp-(1→	782:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	33	theme	1→	810:811	arg1	1→					826:827	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	826:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	33	theme	1→	810:811	arg1	1→					810:811	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	810:811	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	2	34	theme	column	380:385	arg1	chromatography					387:400	column chromatography	380:400	column chromatography	380:400	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	9	35	theme	33342	951:955	arg1	staining					957:964	hoechst 33342 staining	943:964	hoechst 33342 staining	943:964	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	2	36	with	extraction	285:294	arg1	Sephadex					407:414	Sephadex G-100	407:420	Sephadex G-100	407:420	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	36	with	extraction	285:294	arg1	reagent					368:374	Sevag reagent	362:374	Sevag reagent	362:374	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	36	with	extraction	285:294	arg1	ethanol					331:337	ethanol	331:337	ethanol	331:337	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	36	with	extraction	285:294	arg1	water					305:309	hot water	301:309	hot water	301:309	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	11	37	theme	sweet	1265:1269	arg1	potato					1271:1276	purple sweet potato	1258:1276	purple sweet potato	1258:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	0	38	theme	tumor	45:49	arg1	apoptosis					56:64	tumor cell apoptosis	45:64	tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam)	45:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	6	39	theme	-D-Glcp-	739:746	arg1	1→					748:749	→6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→	713:749	1→	748:749	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	10	40	theme	cells	1124:1128	arg1	proliferation					1101:1113	the proliferation	1097:1113	the proliferation of HT-29 cells from induction apoptosis	1097:1153	The results revealed that the PSP can significantly inhibit the proliferation of HT-29 cells from induction apoptosis.
36828088	1	41	theme	purple	180:185	arg1	potato					193:198	purple sweet potato	180:198	purple sweet potato	180:198	The carbohydrate is the main ingredient of purple sweet potato.
36828088	7	42	contain	contained	772:780	arg2	residues					786:793	the residues	782:793	the residues of →3)-D-Galp-(1→, and D-Xylp-(1→	782:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	42	contain	contained	772:780	arg1	branches					756:763	The branches	752:763	The branches of PSP	752:770	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	42	contain	contained	772:780	arg2	1→					826:827	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	826:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	42	contain	contained	772:780	arg2	1→					810:811	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	810:811	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	5	43	theme	1.3	656:658	arg1	ratio					637:641	ratio	637:641	ratio of 1.0: 8.3: 1.3	637:658	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36828088	11	44	from	potato	1271:1276	arg1	characteristics					1214:1228	structural characteristics	1203:1228	structural characteristics of the polysaccharides from purple sweet potato	1203:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	11	44	from	potato	1271:1276	arg1	polysaccharides					1237:1251	the polysaccharides	1233:1251	the polysaccharides from purple sweet potato	1233:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	2	45	theme	Sevag	362:366	arg1	reagent					368:374	Sevag reagent	362:374	Sevag reagent	362:374	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	0	46	theme	apoptosis	56:64	arg1	induction					32:40	induction	32:40	induction	32:40	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	0	46	theme	apoptosis	56:64	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	9	47	dep	staining	916:923	arg1	AO					913:914	the SEM, AO staining	904:923	AO	913:914	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	2	48	with	chromatography	387:400	arg1	Sephadex					407:414	Sephadex G-100	407:420	Sephadex G-100	407:420	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	48	with	chromatography	387:400	arg1	reagent					368:374	Sevag reagent	362:374	Sevag reagent	362:374	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	48	with	chromatography	387:400	arg1	ethanol					331:337	ethanol	331:337	ethanol	331:337	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	48	with	chromatography	387:400	arg1	water					305:309	hot water	301:309	hot water	301:309	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	2	49	theme	hot	301:303	arg1	water					305:309	hot water	301:309	hot water	301:309	A polysaccharide, named PSP, was separated and purified from purple sweet potato by extraction with hot water, precipitation with ethanol, deproteinization with Sevag reagent and column chromatography with Sephadex G-100.
36828088	0	50	theme	cell	51:54	arg1	apoptosis					56:64	tumor cell apoptosis	45:64	tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam)	45:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	10	51	theme	HT-29	1118:1122	arg1	cells					1124:1128	HT-29 cells	1118:1128	HT-29 cells from induction apoptosis	1118:1153	The results revealed that the PSP can significantly inhibit the proliferation of HT-29 cells from induction apoptosis.
36828088	5	52	theme	PSP	585:587	arg1	composition					570:580	The monosaccharide composition	551:580	The monosaccharide composition of PSP	551:587	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36828088	6	53	theme	→2	733:734	arg1	1→					748:749	→6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→	713:749	1→	748:749	The backbone of PSP was composed of the residues of →6)-D-Glcp-(1 → and →2, 6)-D-Glcp-(1→.
36828088	9	54	from	effect	994:999	arg1	apoptosis					1004:1012	apoptosis	1004:1012	apoptosis	1004:1012	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	1	55	theme	potato	193:198	arg1	carbohydrate					141:152	The carbohydrate	137:152	The carbohydrate	137:152	The carbohydrate is the main ingredient of purple sweet potato.
36828088	1	55	theme	potato	193:198	arg1	ingredient					166:175	the main ingredient	157:175	the main ingredient of purple sweet potato	157:198	The carbohydrate is the main ingredient of purple sweet potato.
36828088	11	56	from	knowledges	1189:1198	arg1	characteristics					1214:1228	structural characteristics	1203:1228	structural characteristics of the polysaccharides from purple sweet potato	1203:1276	The manuscript provided valuable knowledges on structural characteristics of the polysaccharides from purple sweet potato.
36828088	0	57	from	potato	102:107	arg1	polysaccharide					69:82	polysaccharide	69:82	polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam)	69:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	0	57	from	potato	102:107	arg1	apoptosis					56:64	tumor cell apoptosis	45:64	tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam)	45:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	9	58	theme	hoechst	943:949	arg1	staining					957:964	hoechst 33342 staining	943:964	hoechst 33342 staining	943:964	And the SEM, AO staining, MDC staining and hoechst 33342 staining were performed to study the effect on apoptosis of HT-29 cells by PSP.
36828088	0	59	theme	polysaccharide	69:82	arg1	apoptosis					56:64	tumor cell apoptosis	45:64	tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam)	45:134	Structural characterization and induction of tumor cell apoptosis of polysaccharide from purple sweet potato (Ipomoea Batatas (L.) Lam).
36828088	1	60	theme	sweet	187:191	arg1	potato					193:198	purple sweet potato	180:198	purple sweet potato	180:198	The carbohydrate is the main ingredient of purple sweet potato.
36828088	4	61	with	polysaccharide	516:529	arg1	Mw					536:537	Mw	536:537	Mw of 470 kDa	536:548	The PSP is a neutral polysaccharide with Mw of 470 kDa.
36828088	7	62	theme	1→	826:827	arg1	residues					786:793	the residues	782:793	the residues of →3)-D-Galp-(1→, and D-Xylp-(1→	782:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	62	theme	1→	826:827	arg1	1→					826:827	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	826:827	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	7	62	theme	1→	826:827	arg1	1→					810:811	→3)-D-Galp-(1→, and D-Xylp-(1→	798:827	1→	810:811	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	8	63	from	activity	844:851	arg1	vitro					856:860	vitro	856:860	vitro of PSP	856:867	The antitumor activity in vitro of PSP was analyzed with HT-29 cells.
36828088	7	64	theme	PSP	768:770	arg1	branches					756:763	The branches	752:763	The branches of PSP	752:770	The branches of PSP contained the residues of →3)-D-Galp-(1→, and D-Xylp-(1→.
36828088	4	65	theme	470 kDa	542:548	arg1	Mw					536:537	Mw	536:537	Mw of 470 kDa	536:548	The PSP is a neutral polysaccharide with Mw of 470 kDa.
36828088	5	66	contain	contained	589:597	arg2	d-glucose					609:617	d-glucose	609:617	d-glucose	609:617	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36828088	5	66	contain	contained	589:597	arg2	D-xylose					599:606	D-xylose	599:606	D-xylose	599:606	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36828088	5	66	contain	contained	589:597	arg1	composition					570:580	The monosaccharide composition	551:580	The monosaccharide composition of PSP	551:587	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36828088	5	66	contain	contained	589:597	arg2	D-galactose					620:630	D-galactose	620:630	D-galactose	620:630	The monosaccharide composition of PSP contained D-xylose, d-glucose, D-galactose with ratio of 1.0: 8.3: 1.3.
36087998	0	0	theme	fractions	95:103	arg1	activities					66:75	in vitro hypoglycemic activities	44:75	in vitro hypoglycemic activities	44:75	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	0	0	theme	fractions	95:103	arg1	properties					29:38	Physicochemical, rheological properties	0:38	properties	29:38	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	2	1	theme	monosaccharide	468:481	arg1	composition					483:493	monosaccharide composition	468:493	monosaccharide composition	468:493	These three kinds of polysaccharide fractions exhibited a similar arabinogalactan structure according to FTIR spectrum and monosaccharide composition.
36087998	1	2	theme	room	224:227	arg1	temperature					229:239	room temperature water-soluble	224:253	room temperature water-soluble (PG-WE)	224:261	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	1	2	theme	room	224:227	arg1	PG-WE					256:260	PG-WE	256:260	PG-WE	256:260	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	0	3	theme	polysaccharide	80:93	arg1	fractions					95:103	polysaccharide fractions	80:103	polysaccharide fractions from peach gum	80:118	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	1	4	theme	alkali-soluble	296:309	arg1	fractions					334:342	alkali-soluble (PG-AE) polysaccharide fractions	296:342	alkali-soluble (PG-AE) polysaccharide fractions	296:342	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	3	5	theme	different	650:658	arg1	behavior					672:679	different rheological behavior	650:679	different rheological behavior	650:679	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	0	6	theme	peach	110:114	arg1	gum					116:118	peach gum	110:118	peach gum	110:118	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	3	7	theme	high-performance	575:590	arg1	chromatography					607:620	high-performance size exclusion chromatography	575:620	high-performance size exclusion chromatography analysis	575:629	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	3	8	theme	chain	532:536	arg1	conformation					538:549	chain conformation	532:549	chain conformation	532:549	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	1	9	theme	water-soluble	241:253	arg1	temperature					229:239	room temperature water-soluble	224:253	room temperature water-soluble (PG-WE)	224:261	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	1	9	theme	water-soluble	241:253	arg1	PG-WE					256:260	PG-WE	256:260	PG-WE	256:260	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	1	10	theme	PG-AE	312:316	arg1	fractions					334:342	alkali-soluble (PG-AE) polysaccharide fractions	296:342	alkali-soluble (PG-AE) polysaccharide fractions	296:342	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	4	11	theme	non-Newtonian	709:721	arg1	behavior					723:730	non-Newtonian behavior	709:730	non-Newtonian behavior	709:730	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	6	12	theme	α-glucosidase	1166:1178	arg1	fluorescence					1150:1161	the fluorescence	1146:1161	the fluorescence of α-glucosidase	1146:1178	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	6	13	theme	in	1056:1057	arg1	inhibition					1065:1074	significant in vitro inhibition	1044:1074	significant in vitro inhibition against α-glucosidase activity	1044:1105	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	5	14	theme	gel-like	957:964	arg1	structures					966:975	gel-like structures	957:975	gel-like structures	957:975	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	5	15	theme	Dynamic	844:850	arg1	tests					858:862	Dynamic sweep tests	844:862	Dynamic sweep tests	844:862	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	1	16	theme	polysaccharide	319:332	arg1	fractions					334:342	alkali-soluble (PG-AE) polysaccharide fractions	296:342	alkali-soluble (PG-AE) polysaccharide fractions	296:342	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	2	17	theme	arabinogalactan	411:425	arg1	structure					427:435	a similar arabinogalactan structure	401:435	a similar arabinogalactan structure	401:435	These three kinds of polysaccharide fractions exhibited a similar arabinogalactan structure according to FTIR spectrum and monosaccharide composition.
36087998	5	18	theme	sweep	852:856	arg1	tests					858:862	Dynamic sweep tests	844:862	Dynamic sweep tests	844:862	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	4	19	theme	PG-WE	763:767	arg1	higher					773:778	higher	773:778	higher	773:778	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	4	19	theme	PG-WE	763:767	arg1	viscosity					750:758	the apparent viscosity	737:758	the apparent viscosity of PG-WE	737:767	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	0	20	theme	Physicochemical	0:14	arg1	properties					29:38	Physicochemical, rheological properties	0:38	properties	29:38	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	5	21	theme	PG-WE	926:930	arg1	solutions					932:940	PG-WE solutions	926:940	PG-WE solutions	926:940	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	2	22	theme	similar	403:409	arg1	structure					427:435	a similar arabinogalactan structure	401:435	a similar arabinogalactan structure	401:435	These three kinds of polysaccharide fractions exhibited a similar arabinogalactan structure according to FTIR spectrum and monosaccharide composition.
36087998	6	23	theme	quenching	1196:1204	arg1	mechanism					1206:1214	dynamic quenching mechanism	1188:1214	dynamic quenching mechanism	1188:1214	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	4	24	theme	%	835:835	arg1	concentrations					803:816	concentrations	803:816	concentrations of 2.0 % and 3.0 % (w/w)	803:841	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	0	25	theme	rheological	17:27	arg1	properties					29:38	Physicochemical, rheological properties	0:38	properties	29:38	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	3	26	theme	rheological	660:670	arg1	behavior					672:679	different rheological behavior	650:679	different rheological behavior	650:679	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	2	27	theme	fractions	381:389	arg1	kinds					357:361	These three kinds	345:361	These three kinds of polysaccharide fractions	345:389	These three kinds of polysaccharide fractions exhibited a similar arabinogalactan structure according to FTIR spectrum and monosaccharide composition.
36087998	0	28	theme	in	44:45	arg1	activities					66:75	in vitro hypoglycemic activities	44:75	in vitro hypoglycemic activities	44:75	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	3	29	theme	exclusion	597:605	arg1	chromatography					607:620	high-performance size exclusion chromatography	575:620	high-performance size exclusion chromatography analysis	575:629	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	2	30	theme	polysaccharide	366:379	arg1	fractions					381:389	polysaccharide fractions	366:389	polysaccharide fractions	366:389	These three kinds of polysaccharide fractions exhibited a similar arabinogalactan structure according to FTIR spectrum and monosaccharide composition.
36087998	2	31	theme	FTIR	450:453	arg1	spectrum					455:462	FTIR spectrum	450:462	FTIR spectrum	450:462	These three kinds of polysaccharide fractions exhibited a similar arabinogalactan structure according to FTIR spectrum and monosaccharide composition.
36087998	3	32	theme	chromatography	607:620	arg1	analysis					622:629	high-performance size exclusion chromatography analysis	575:629	high-performance size exclusion chromatography analysis	575:629	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	1	33	from	95 °C	192:196	arg1	water					176:180	water	176:180	water at 25 °C, 95 °C and 0.1 M NaOH	176:211	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	0	34	theme	hypoglycemic	53:64	arg1	activities					66:75	in vitro hypoglycemic activities	44:75	in vitro hypoglycemic activities	44:75	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	0	35	from	activities	66:75	arg1	gum					116:118	peach gum	110:118	peach gum	110:118	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	0	36	dep	in	44:45	arg1	vitro					47:51	vitro	47:51	vitro	47:51	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	6	37	theme	α-glucosidase	1084:1096	arg1	activity					1098:1105	α-glucosidase activity	1084:1105	α-glucosidase activity	1084:1105	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	6	38	theme	dose-dependent	1112:1125	arg1	manner					1127:1132	a dose-dependent manner	1110:1132	a dose-dependent manner	1110:1132	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	3	39	theme	size	592:595	arg1	chromatography					607:620	high-performance size exclusion chromatography	575:620	high-performance size exclusion chromatography analysis	575:629	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36087998	1	40	from	25 °C	185:189	arg1	water					176:180	water	176:180	water at 25 °C, 95 °C and 0.1 M NaOH	176:211	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	5	41	theme	viscous	904:910	arg1	fluids					912:917	viscous fluids	904:917	viscous fluids	904:917	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	0	42	from	gum	116:118	arg1	activities					66:75	in vitro hypoglycemic activities	44:75	in vitro hypoglycemic activities	44:75	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	0	42	from	gum	116:118	arg1	properties					29:38	Physicochemical, rheological properties	0:38	properties	29:38	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	0	42	from	gum	116:118	arg1	fractions					95:103	polysaccharide fractions	80:103	polysaccharide fractions from peach gum	80:118	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	4	43	theme	%	825:825	arg1	concentrations					803:816	concentrations	803:816	concentrations of 2.0 % and 3.0 % (w/w)	803:841	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	6	44	dep	in	1056:1057	arg1	vitro					1059:1063	vitro	1059:1063	vitro	1059:1063	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	1	45	theme	0.1 M	202:206	arg1	NaOH					208:211	0.1 M NaOH	202:211	0.1 M NaOH	202:211	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	1	46	from	NaOH	208:211	arg1	water					176:180	water	176:180	water at 25 °C, 95 °C and 0.1 M NaOH	176:211	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	4	47	theme	apparent	741:748	arg1	higher					773:778	higher	773:778	higher	773:778	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	4	47	theme	apparent	741:748	arg1	viscosity					750:758	the apparent viscosity	737:758	the apparent viscosity of PG-WE	737:767	PG-WE and PG-HWE presented non-Newtonian behavior, and the apparent viscosity of PG-WE was higher than that of PG-HWE at concentrations of 2.0 % and 3.0 % (w/w).
36087998	5	48	theme	PG-HWE	876:881	arg1	solutions					883:891	PG-HWE solutions	876:891	PG-HWE solutions	876:891	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	5	49	theme	higher	995:1000	arg1	concentrations					980:993	concentrations	980:993	concentrations higher than 2 % (w/w)	980:1015	Dynamic sweep tests showed that PG-HWE solutions behaved as viscous fluids, while PG-WE solutions tended to form gel-like structures at concentrations higher than 2 % (w/w).
36087998	1	50	theme	peach	136:140	arg1	gum					142:144	peach gum	136:144	peach gum	136:144	In this study, peach gum was sequentially extracted by water at 25 °C, 95 °C and 0.1 M NaOH, obtaining room temperature water-soluble (PG-WE), hot water-soluble (PG-HWE), and alkali-soluble (PG-AE) polysaccharide fractions.
36087998	6	51	theme	significant	1044:1054	arg1	inhibition					1065:1074	significant in vitro inhibition	1044:1074	significant in vitro inhibition against α-glucosidase activity	1044:1105	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	0	52	from	properties	29:38	arg1	gum					116:118	peach gum	110:118	peach gum	110:118	Physicochemical, rheological properties and in vitro hypoglycemic activities of polysaccharide fractions from peach gum.
36087998	6	53	theme	dynamic	1188:1194	arg1	mechanism					1206:1214	dynamic quenching mechanism	1188:1214	dynamic quenching mechanism	1188:1214	Furthermore, PG-WE showed significant in vitro inhibition against α-glucosidase activity in a dose-dependent manner and reduced the fluorescence of α-glucosidase through dynamic quenching mechanism.
36087998	3	54	theme	molecular	511:519	arg1	weight					521:526	their molecular weight	505:526	their molecular weight	505:526	However, their molecular weight and chain conformation were different based on high-performance size exclusion chromatography analysis, which resulted in different rheological behavior.
36126811	8	0	theme	strains	1270:1276	arg1	effects					1246:1252	different effects	1236:1252	different effects of L. plantarum strains on intestinal barrier dysfunction	1236:1310	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	0	1	from	effects	27:33	arg1	dysfunction					84:94	intestinal barrier dysfunction	65:94	intestinal barrier dysfunction	65:94	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	7	2	theme	mole	1088:1091	arg1	ratios					1093:1098	mole ratios	1088:1098	mole ratios	1088:1098	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	9	3	theme	potential	1643:1651	arg1	component					1669:1677	a potential functional food component	1641:1677	a potential functional food component against intestinal barrier dysfunction	1641:1716	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	1	4	theme	systemic	258:265	arg1	diseases					267:274	systemic diseases	258:274	systemic diseases	258:274	The intestinal barrier is integral to the host's defense, and disrupting its integrity contributes to gut and systemic diseases.
36126811	4	5	theme	L.	516:517	arg1	strains					529:535	55 L. plantarum strains	513:535	55 L. plantarum strains	513:535	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	7	6	theme	gut	1201:1203	arg1	barrier					1205:1211	the gut barrier	1197:1211	the gut barrier	1197:1211	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	2	7	from	effect	350:355	arg1	barrier					368:374	the gut barrier	360:374	the gut barrier	360:374	Lactobacillus plantarum has been widely reported to exhibit a protective effect on the gut barrier.
36126811	2	8	theme	gut	364:366	arg1	barrier					368:374	the gut barrier	360:374	the gut barrier	360:374	Lactobacillus plantarum has been widely reported to exhibit a protective effect on the gut barrier.
36126811	7	9	from	effects	1186:1192	arg1	barrier					1205:1211	the gut barrier	1197:1211	the gut barrier	1197:1211	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	7	10	theme	strain-specific	1159:1173	arg1	effects					1186:1192	strain-specific protective effects	1159:1192	strain-specific protective effects on the gut barrier	1159:1211	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	4	11	theme	strains	529:535	arg1	model					648:652	a dextran sulfate sodium-induced colitis animal model	600:652	a dextran sulfate sodium-induced colitis animal model	600:652	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	4	11	theme	strains	529:535	arg1	effects					502:508	the regulative effects	487:508	the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells	487:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	9	12	theme	food	1664:1667	arg1	component					1669:1677	a potential functional food component	1641:1677	a potential functional food component against intestinal barrier dysfunction	1641:1716	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	4	13	theme	sodium-induced	618:631	arg1	model					648:652	a dextran sulfate sodium-induced colitis animal model	600:652	a dextran sulfate sodium-induced colitis animal model	600:652	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	5	14	theme	plantarum	773:781	arg1	ability					759:765	the ability	755:765	the ability of L. plantarum to regulate the intestinal barrier	755:816	Comparative genomic analysis suggested that the ability of L. plantarum to regulate the intestinal barrier is exerted in part by genes encoding proteins associated with polysaccharide synthesis.
36126811	6	15	theme	polysaccharides	967:981	arg1	experiments					994:1004	surface protein/capsular polysaccharides separation experiments	942:1004	surface protein/capsular polysaccharides separation experiments	942:1004	This observation was verified using surface protein/capsular polysaccharides separation experiments.
36126811	4	16	theme	sulfate	610:616	arg1	model					648:652	a dextran sulfate sodium-induced colitis animal model	600:652	a dextran sulfate sodium-induced colitis animal model	600:652	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	4	17	theme	regulative	491:500	arg1	effects					502:508	the regulative effects	487:508	the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells	487:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	8	18	theme	capsular	1388:1395	arg1	polysaccharides					1397:1411	the capsular polysaccharides	1384:1411	the capsular polysaccharides of the strains	1384:1426	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	0	19	theme	capsular	122:129	arg1	polysaccharides					131:145	their capsular polysaccharides	116:145	their capsular polysaccharides	116:145	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	6	20	theme	surface	942:948	arg1	experiments					994:1004	surface protein/capsular polysaccharides separation experiments	942:1004	surface protein/capsular polysaccharides separation experiments	942:1004	This observation was verified using surface protein/capsular polysaccharides separation experiments.
36126811	4	21	theme	dextran	602:608	arg1	model					648:652	a dextran sulfate sodium-induced colitis animal model	600:652	a dextran sulfate sodium-induced colitis animal model	600:652	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	7	22	theme	capsular	1030:1037	arg1	polysaccharides					1039:1053	capsular polysaccharides	1030:1053	capsular polysaccharides	1030:1053	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	9	23	theme	intestinal	1687:1696	arg1	dysfunction					1706:1716	intestinal barrier dysfunction	1687:1716	intestinal barrier dysfunction	1687:1716	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	0	24	theme	regulative	16:25	arg1	effects					27:33	Strain-specific regulative effects	0:33	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction	0:94	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	8	25	theme	plantarum	1260:1268	arg1	strains					1270:1276	L. plantarum strains	1257:1276	L. plantarum strains	1257:1276	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	4	26	from	effects	502:508	arg1	barrier					555:561	the intestinal barrier	540:561	the intestinal barrier using TNF-α-induced Caco-2 cells	540:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	7	27	theme	polysaccharides	1039:1053	arg1	analysis					1018:1025	Structural analysis	1007:1025	Structural analysis of capsular polysaccharides	1007:1053	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	9	28	theme	barrier	1698:1704	arg1	dysfunction					1706:1716	intestinal barrier dysfunction	1687:1716	intestinal barrier dysfunction	1687:1716	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	6	29	theme	protein/capsular	950:965	arg1	experiments					994:1004	surface protein/capsular polysaccharides separation experiments	942:1004	surface protein/capsular polysaccharides separation experiments	942:1004	This observation was verified using surface protein/capsular polysaccharides separation experiments.
36126811	3	30	theme	function	436:443	arg1	mechanism					406:414	the strain-specific mechanism	386:414	the strain-specific mechanism of this bacterium's function	386:443	However, the strain-specific mechanism of this bacterium's function remains unclear.
36126811	0	31	theme	Strain-specific	0:14	arg1	effects					27:33	Strain-specific regulative effects	0:33	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction	0:94	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	4	32	theme	Caco-2	583:588	arg1	cells					590:594	TNF-α-induced Caco-2 cells	569:594	TNF-α-induced Caco-2 cells	569:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	9	33	theme	gut	1550:1552	arg1	barrier					1554:1560	the gut barrier	1546:1560	the gut barrier	1546:1560	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	8	34	from	effects	1246:1252	arg1	dysfunction					1300:1310	intestinal barrier dysfunction	1281:1310	intestinal barrier dysfunction	1281:1310	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	4	35	theme	TNF-α-induced	569:581	arg1	cells					590:594	TNF-α-induced Caco-2 cells	569:594	TNF-α-induced Caco-2 cells	569:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	7	36	theme	molecular	1067:1075	arg1	weight					1077:1082	molecular weight	1067:1082	molecular weight	1067:1082	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	8	37	theme	polysaccharides	1397:1411	arg1	characteristic					1366:1379	the characteristic	1362:1379	the characteristic of the capsular polysaccharides of the strains	1362:1426	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	9	38	theme	functional	1653:1662	arg1	component					1669:1677	a potential functional food component	1641:1677	a potential functional food component against intestinal barrier dysfunction	1641:1716	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	5	39	theme	polysaccharide	880:893	arg1	synthesis					895:903	polysaccharide synthesis	880:903	polysaccharide synthesis	880:903	Comparative genomic analysis suggested that the ability of L. plantarum to regulate the intestinal barrier is exerted in part by genes encoding proteins associated with polysaccharide synthesis.
36126811	0	40	theme	plantarum	52:60	arg1	effects					27:33	Strain-specific regulative effects	0:33	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction	0:94	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	7	41	theme	protective	1175:1184	arg1	effects					1186:1192	strain-specific protective effects	1159:1192	strain-specific protective effects on the gut barrier	1159:1211	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	9	42	dep	suggested	1567:1575	arg1	explored					1629:1636	explored	1629:1636	suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction	1567:1716	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	4	43	theme	regulative	673:682	arg1	strain-specific					694:708	strain-specific	694:708	strain-specific	694:708	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	4	43	theme	regulative	673:682	arg1	effect					684:689	the regulative effect	669:689	the regulative effect	669:689	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	8	44	theme	regulative	1333:1342	arg1	ability					1344:1350	this regulative ability	1328:1350	this regulative ability	1328:1350	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	4	45	theme	intestinal	544:553	arg1	barrier					555:561	the intestinal barrier	540:561	the intestinal barrier using TNF-α-induced Caco-2 cells	540:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	8	46	theme	barrier	1292:1298	arg1	dysfunction					1300:1310	intestinal barrier dysfunction	1281:1310	intestinal barrier dysfunction	1281:1310	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	0	47	theme	intestinal	65:74	arg1	dysfunction					84:94	intestinal barrier dysfunction	65:94	intestinal barrier dysfunction	65:94	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	8	48	theme	intestinal	1281:1290	arg1	dysfunction					1300:1310	intestinal barrier dysfunction	1281:1310	intestinal barrier dysfunction	1281:1310	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	5	49	theme	Comparative	711:721	arg1	analysis					731:738	Comparative genomic analysis	711:738	Comparative genomic analysis	711:738	Comparative genomic analysis suggested that the ability of L. plantarum to regulate the intestinal barrier is exerted in part by genes encoding proteins associated with polysaccharide synthesis.
36126811	4	50	from	model	648:652	arg1	barrier					555:561	the intestinal barrier	540:561	the intestinal barrier using TNF-α-induced Caco-2 cells	540:594	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	9	51	theme	plantarum	1612:1620	arg1	polysaccharides					1590:1604	the capsular polysaccharides	1577:1604	the capsular polysaccharides of L. plantarum	1577:1620	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	6	52	theme	separation	983:992	arg1	experiments					994:1004	surface protein/capsular polysaccharides separation experiments	942:1004	surface protein/capsular polysaccharides separation experiments	942:1004	This observation was verified using surface protein/capsular polysaccharides separation experiments.
36126811	9	53	theme	plantarum	1500:1508	arg1	strains					1510:1516	L. plantarum strains	1497:1516	L. plantarum strains	1497:1516	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	5	54	theme	genomic	723:729	arg1	analysis					731:738	Comparative genomic analysis	711:738	Comparative genomic analysis	711:738	Comparative genomic analysis suggested that the ability of L. plantarum to regulate the intestinal barrier is exerted in part by genes encoding proteins associated with polysaccharide synthesis.
36126811	7	55	theme	monosaccharide	1103:1116	arg1	compositions					1118:1129	monosaccharide compositions	1103:1129	monosaccharide compositions	1103:1129	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	8	56	theme	strains	1420:1426	arg1	polysaccharides					1397:1411	the capsular polysaccharides	1384:1411	the capsular polysaccharides of the strains	1384:1426	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	7	57	theme	important	1140:1148	arg1	roles					1150:1154	important roles	1140:1154	important roles	1140:1154	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	5	58	theme	intestinal	799:808	arg1	barrier					810:816	the intestinal barrier	795:816	the intestinal barrier	795:816	Comparative genomic analysis suggested that the ability of L. plantarum to regulate the intestinal barrier is exerted in part by genes encoding proteins associated with polysaccharide synthesis.
36126811	1	59	theme	intestinal	152:161	arg1	integral					174:181	integral	174:181	integral	174:181	The intestinal barrier is integral to the host's defense, and disrupting its integrity contributes to gut and systemic diseases.
36126811	1	59	theme	intestinal	152:161	arg1	barrier					163:169	The intestinal barrier	148:169	The intestinal barrier	148:169	The intestinal barrier is integral to the host's defense, and disrupting its integrity contributes to gut and systemic diseases.
36126811	7	60	theme	Structural	1007:1016	arg1	analysis					1018:1025	Structural analysis	1007:1025	Structural analysis of capsular polysaccharides	1007:1053	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	4	61	theme	animal	641:646	arg1	model					648:652	a dextran sulfate sodium-induced colitis animal model	600:652	a dextran sulfate sodium-induced colitis animal model	600:652	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	7	62	theme	compositions	1118:1129	arg1	ratios					1093:1098	mole ratios	1088:1098	mole ratios	1088:1098	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	7	62	theme	compositions	1118:1129	arg1	weight					1077:1082	molecular weight	1067:1082	molecular weight	1067:1082	Structural analysis of capsular polysaccharides showed that molecular weight and mole ratios of monosaccharide compositions may play important roles in strain-specific protective effects on the gut barrier.
36126811	2	63	theme	protective	339:348	arg1	effect					350:355	a protective effect	337:355	a protective effect on the gut barrier	337:374	Lactobacillus plantarum has been widely reported to exhibit a protective effect on the gut barrier.
36126811	4	64	theme	colitis	633:639	arg1	model					648:652	a dextran sulfate sodium-induced colitis animal model	600:652	a dextran sulfate sodium-induced colitis animal model	600:652	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	8	65	theme	L.	1257:1258	arg1	strains					1270:1276	L. plantarum strains	1257:1276	L. plantarum strains	1257:1276	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	9	66	theme	genetic	1453:1459	arg1	targets					1461:1467	genetic targets	1453:1467	genetic targets	1453:1467	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	9	67	theme	capsular	1581:1588	arg1	polysaccharides					1590:1604	the capsular polysaccharides	1577:1604	the capsular polysaccharides of L. plantarum	1577:1620	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
36126811	0	68	theme	barrier	76:82	arg1	dysfunction					84:94	intestinal barrier dysfunction	65:94	intestinal barrier dysfunction	65:94	Strain-specific regulative effects of Lactobacillus plantarum on intestinal barrier dysfunction are associated with their capsular polysaccharides.
36126811	4	69	theme	plantarum	519:527	arg1	strains					529:535	55 L. plantarum strains	513:535	55 L. plantarum strains	513:535	This study characterized the regulative effects of 55 L. plantarum strains on the intestinal barrier using TNF-α-induced Caco-2 cells and a dextran sulfate sodium-induced colitis animal model and found that the regulative effect is strain-specific.
36126811	3	70	theme	strain-specific	390:404	arg1	mechanism					406:414	the strain-specific mechanism	386:414	the strain-specific mechanism of this bacterium's function	386:443	However, the strain-specific mechanism of this bacterium's function remains unclear.
36126811	8	71	theme	different	1236:1244	arg1	effects					1246:1252	different effects	1236:1252	different effects of L. plantarum strains on intestinal barrier dysfunction	1236:1310	This study identified different effects of L. plantarum strains on intestinal barrier dysfunction and proved that this regulative ability relies on the characteristic of the capsular polysaccharides of the strains.
36126811	9	72	theme	L.	1497:1498	arg1	strains					1510:1516	L. plantarum strains	1497:1516	L. plantarum strains	1497:1516	Thus, our data provided genetic targets and molecular for screening L. plantarum strains with the ability to protect the gut barrier, and suggested the capsular polysaccharides of L. plantarum may be explored as a potential functional food component against intestinal barrier dysfunction.
35367606	6	0	contain	had	683:685	arg2	effect					694:699	little effect	687:699	little effect	687:699	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	6	0	contain	had	683:685	arg1	HTL					660:662	Catalytic HTL	650:662	Catalytic HTL with Co-Mo/γ-Al2O3	650:681	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	1	1	with	chitin	151:156	arg1	Pd/C					163:166	Pd/C	163:166	Pd/C	163:166	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	8	2	theme	biocrude	927:934	arg1	yields					936:941	biocrude yields	927:941	biocrude yields	927:941	Finally, a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture is presented.
35367606	6	3	theme	little	687:692	arg1	effect					694:699	little effect	687:699	little effect	687:699	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	4	4	theme	pectin	564:569	arg1	HTL					546:548	HTL	546:548	HTL of chitin and pectin	546:569	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	6	5	theme	biocrudes	737:745	arg1	composition					718:728	the elemental composition	704:728	the elemental composition of the biocrudes	704:745	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	5	6	theme	elemental	608:616	arg1	analysis					618:625	elemental analysis	608:625	elemental analysis	608:625	The biocrudes were characterized by elemental analysis, TGA, FT-IR and GC-MS.
35367606	1	7	theme	Hydrothermal	85:96	arg1	liquefaction					98:109	Hydrothermal liquefaction	85:109	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite	85:194	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	7	theme	Hydrothermal	85:96	arg1	HTL					112:114	HTL	112:114	HTL	112:114	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	7	8	theme	%	831:831	arg1	portion					804:810	the low-boiling portion	788:810	the low-boiling portion of biocrude from<30%	788:831	The presence of Co-Mo/γ-Al2O3 increased the low-boiling portion of biocrude from<30% to over 50% for HTL of starch.
35367606	0	9	theme	Hydrothermal	0:11	arg1	liquefaction					13:24	Hydrothermal liquefaction	0:24	Hydrothermal liquefaction of polysaccharide	0:42	Hydrothermal liquefaction of polysaccharide feedstocks with heterogeneous catalysts.
35367606	2	10	from	starch	312:317	arg1	yields					300:305	the highest biocrude yields	279:305	the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%)	279:349	Using Co-Mo/γ-Al2O3 at 5 wt% loading led to the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%).
35367606	2	11	theme	%	262:262	arg1	loading					264:270	5 wt% loading	258:270	5 wt% loading	258:270	Using Co-Mo/γ-Al2O3 at 5 wt% loading led to the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%).
35367606	1	12	with	pectin	139:144	arg1	Pd/C					163:166	Pd/C	163:166	Pd/C	163:166	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	7	13	theme	biocrude	815:822	arg1	%					831:831	biocrude from<30%	815:831	biocrude from<30%	815:831	The presence of Co-Mo/γ-Al2O3 increased the low-boiling portion of biocrude from<30% to over 50% for HTL of starch.
35367606	2	14	theme	5 wt	258:261	arg1	loading					264:270	5 wt% loading	258:270	5 wt% loading	258:270	Using Co-Mo/γ-Al2O3 at 5 wt% loading led to the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%).
35367606	8	15	theme	additivity	885:894	arg1	model					896:900	a component additivity model	873:900	a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture	873:973	Finally, a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture is presented.
35367606	6	16	theme	Catalytic	650:658	arg1	HTL					660:662	Catalytic HTL	650:662	Catalytic HTL with Co-Mo/γ-Al2O3	650:681	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	2	17	theme	biocrude	291:298	arg1	yields					300:305	the highest biocrude yields	279:305	the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%)	279:349	Using Co-Mo/γ-Al2O3 at 5 wt% loading led to the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%).
35367606	1	18	theme	Co-Mo/γ-Al2O3	169:181	arg1	liquefaction					98:109	Hydrothermal liquefaction	85:109	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite	85:194	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	18	theme	Co-Mo/γ-Al2O3	169:181	arg1	HTL					112:114	HTL	112:114	HTL	112:114	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	19	with	starch	120:125	arg1	Pd/C					163:166	Pd/C	163:166	Pd/C	163:166	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	20	with	cellulose	128:136	arg1	Pd/C					163:166	Pd/C	163:166	Pd/C	163:166	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	2	21	theme	highest	283:289	arg1	yields					300:305	the highest biocrude yields	279:305	the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%)	279:349	Using Co-Mo/γ-Al2O3 at 5 wt% loading led to the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%).
35367606	0	22	theme	polysaccharide	29:42	arg1	liquefaction					13:24	Hydrothermal liquefaction	0:24	Hydrothermal liquefaction of polysaccharide	0:42	Hydrothermal liquefaction of polysaccharide feedstocks with heterogeneous catalysts.
35367606	4	23	theme	%	483:483	arg1	loading					485:491	25 wt% loading	478:491	25 wt% loading	478:491	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	4	23	theme	%	483:483	arg1	catalyst					468:475	the only catalyst	459:475	the only catalyst (25 wt% loading)	459:492	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	4	24	dep	increase	497:504	arg1	%					538:538	1.6 - 2.6 wt%	526:538	1.6 - 2.6 wt%	526:538	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	1	25	theme	starch	120:125	arg1	liquefaction					98:109	Hydrothermal liquefaction	85:109	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite	85:194	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	25	theme	starch	120:125	arg1	HTL					112:114	HTL	112:114	HTL	112:114	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	26	theme	zeolite	188:194	arg1	liquefaction					98:109	Hydrothermal liquefaction	85:109	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite	85:194	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	26	theme	zeolite	188:194	arg1	HTL					112:114	HTL	112:114	HTL	112:114	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	4	27	theme	25 wt	478:482	arg1	loading					485:491	25 wt% loading	478:491	25 wt% loading	478:491	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	4	27	theme	25 wt	478:482	arg1	catalyst					468:475	the only catalyst	459:475	the only catalyst (25 wt% loading)	459:492	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	8	28	theme	catalytic	948:956	arg1	HTL					958:960	catalytic HTL	948:960	catalytic HTL of a mixture	948:973	Finally, a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture is presented.
35367606	6	29	with	HTL	660:662	arg1	Co-Mo/γ-Al2O3					669:681	Co-Mo/γ-Al2O3	669:681	Co-Mo/γ-Al2O3	669:681	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	1	30	with	Co-Mo/γ-Al2O3	169:181	arg1	Pd/C					163:166	Pd/C	163:166	Pd/C	163:166	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	2	31	from	cellulose	332:340	arg1	yields					300:305	the highest biocrude yields	279:305	the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%)	279:349	Using Co-Mo/γ-Al2O3 at 5 wt% loading led to the highest biocrude yields from starch (25 wt%) and cellulose (23 wt%).
35367606	0	32	theme	heterogeneous	60:72	arg1	catalysts					74:82	heterogeneous catalysts	60:82	heterogeneous catalysts	60:82	Hydrothermal liquefaction of polysaccharide feedstocks with heterogeneous catalysts.
35367606	4	33	theme	only	463:466	arg1	loading					485:491	25 wt% loading	478:491	25 wt% loading	478:491	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	4	33	theme	only	463:466	arg1	catalyst					468:475	the only catalyst	459:475	the only catalyst (25 wt% loading)	459:492	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	4	33	theme	only	463:466	arg1	Co-Mo/γ-Al2O3					436:448	Co-Mo/γ-Al2O3	436:448	Co-Mo/γ-Al2O3	436:448	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	6	34	theme	elemental	708:716	arg1	composition					718:728	the elemental composition	704:728	the elemental composition of the biocrudes	704:745	Catalytic HTL with Co-Mo/γ-Al2O3 had little effect on the elemental composition of the biocrudes.
35367606	7	35	theme	starch	856:861	arg1	HTL					849:851	HTL	849:851	HTL of starch	849:861	The presence of Co-Mo/γ-Al2O3 increased the low-boiling portion of biocrude from<30% to over 50% for HTL of starch.
35367606	1	36	theme	cellulose	128:136	arg1	liquefaction					98:109	Hydrothermal liquefaction	85:109	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite	85:194	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	1	36	theme	cellulose	128:136	arg1	HTL					112:114	HTL	112:114	HTL	112:114	Hydrothermal liquefaction (HTL) of starch, cellulose, pectin, and chitin with Pd/C, Co-Mo/γ-Al2O3, and zeolite was investigated at 320 °C for 30 min.
35367606	3	37	theme	noncatalytic	409:420	arg1	HTL					422:424	noncatalytic HTL	409:424	noncatalytic HTL (11 wt%)	409:433	The yields from cellulose are more than twice those from noncatalytic HTL (11 wt%).
35367606	3	37	theme	noncatalytic	409:420	arg1	%					432:432	11 wt%	427:432	11 wt%	427:432	The yields from cellulose are more than twice those from noncatalytic HTL (11 wt%).
35367606	7	38	theme	low-boiling	792:802	arg1	portion					804:810	the low-boiling portion	788:810	the low-boiling portion of biocrude from<30%	788:831	The presence of Co-Mo/γ-Al2O3 increased the low-boiling portion of biocrude from<30% to over 50% for HTL of starch.
35367606	8	39	theme	mixture	967:973	arg1	HTL					958:960	catalytic HTL	948:960	catalytic HTL of a mixture	948:973	Finally, a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture is presented.
35367606	7	40	theme	Co-Mo/γ-Al2O3	764:776	arg1	presence					752:759	The presence	748:759	The presence of Co-Mo/γ-Al2O3	748:776	The presence of Co-Mo/γ-Al2O3 increased the low-boiling portion of biocrude from<30% to over 50% for HTL of starch.
35367606	4	41	theme	biocrude	506:513	arg1	yields					515:520	biocrude yields	506:520	biocrude yields	506:520	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
35367606	3	42	from	cellulose	368:376	arg1	more					382:385	more	382:385	more	382:385	The yields from cellulose are more than twice those from noncatalytic HTL (11 wt%).
35367606	3	42	from	cellulose	368:376	arg1	yields					356:361	The yields	352:361	The yields from cellulose	352:376	The yields from cellulose are more than twice those from noncatalytic HTL (11 wt%).
35367606	8	43	theme	component	875:883	arg1	model					896:900	a component additivity model	873:900	a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture	873:973	Finally, a component additivity model that accurately predicts biocrude yields from catalytic HTL of a mixture is presented.
35367606	4	44	theme	chitin	553:558	arg1	HTL					546:548	HTL	546:548	HTL of chitin and pectin	546:569	Co-Mo/γ-Al2O3 was also the only catalyst (25 wt% loading) to increase biocrude yields (by 1.6 - 2.6 wt%) from HTL of chitin and pectin.
36356868	4	0	theme	purified	979:986	arg1	H-SFP5					1017:1022	H-SFP5	1017:1022	H-SFP5	1017:1022	The SFP prepared by HAE (H-SFP) was purified by cellulose DEAE-52 ion-exchange chromatography, obtaining two purified fractions, namely H-SFP3 and H-SFP5.
36356868	4	0	theme	purified	979:986	arg1	fractions					988:996	two purified fractions	975:996	two purified fractions	975:996	The SFP prepared by HAE (H-SFP) was purified by cellulose DEAE-52 ion-exchange chromatography, obtaining two purified fractions, namely H-SFP3 and H-SFP5.
36356868	4	0	theme	purified	979:986	arg1	H-SFP3					1006:1011	H-SFP3	1006:1011	H-SFP3	1006:1011	The SFP prepared by HAE (H-SFP) was purified by cellulose DEAE-52 ion-exchange chromatography, obtaining two purified fractions, namely H-SFP3 and H-SFP5.
36356868	2	1	theme	acid-assisted	631:643	arg1	HAE					657:659	HAE	657:659	HAE	657:659	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	1	theme	acid-assisted	631:643	arg1	extraction					645:654	hydrogen peroxide/ascorbic acid-assisted extraction	604:654	hydrogen peroxide/ascorbic acid-assisted extraction (HAE)	604:660	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	5	2	theme	capacity	1117:1124	arg1	analyses					1029:1036	The analyses	1025:1036	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity	1025:1124	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity were performed.
36356868	1	3	theme	Sargassum	196:204	arg1	SFP					233:235	SFP	233:235	SFP	233:235	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	1	3	theme	Sargassum	196:204	arg1	polysaccharides					216:230	Sargassum fusiforme polysaccharides	196:230	Sargassum fusiforme polysaccharides (SFP)	196:236	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	2	4	with	SFP	349:351	arg1	yield					363:367	high yield	358:367	high yield	358:367	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	4	with	SFP	349:351	arg1	activities					384:393	biological activities	373:393	biological activities	373:393	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	4	with	SFP	349:351	arg1	extraction					546:555	ultrasonic-assisted extraction	526:555	ultrasonic-assisted extraction (UAE)	526:561	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	4	with	SFP	349:351	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	4	with	SFP	349:351	arg1	methods					411:417	six extraction methods	396:417	six extraction methods	396:417	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	7	5	theme	RAW264.7	1475:1482	arg1	cells					1484:1488	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	2	6	theme	peroxide/ascorbic	613:629	arg1	HAE					657:659	HAE	657:659	HAE	657:659	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	6	theme	peroxide/ascorbic	613:629	arg1	extraction					645:654	hydrogen peroxide/ascorbic acid-assisted extraction	604:654	hydrogen peroxide/ascorbic acid-assisted extraction (HAE)	604:660	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	1	7	theme	fusiforme	206:214	arg1	SFP					233:235	SFP	233:235	SFP	233:235	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	1	7	theme	fusiforme	206:214	arg1	polysaccharides					216:230	Sargassum fusiforme polysaccharides	196:230	Sargassum fusiforme polysaccharides (SFP)	196:236	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	0	8	theme	hydrogen	114:121	arg1	extraction					155:164	hydrogen peroxide/ascorbic acid-assisted extraction	114:164	hydrogen peroxide/ascorbic acid-assisted extraction	114:164	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	9	from	Purification	0:11	arg1	Sargassum					91:99	Sargassum	91:99	Sargassum	91:99	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	2	10	theme	hydrogen	604:611	arg1	HAE					657:659	HAE	657:659	HAE	657:659	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	10	theme	hydrogen	604:611	arg1	extraction					645:654	hydrogen peroxide/ascorbic acid-assisted extraction	604:654	hydrogen peroxide/ascorbic acid-assisted extraction (HAE)	604:660	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	8	11	contain	has	1519:1521	arg2	potential					1527:1535	the potential	1523:1535	the potential as a natural non-toxic antioxidant	1523:1570	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	8	11	contain	has	1519:1521	arg1	SFP					1495:1497	The SFP	1491:1497	The SFP prepared by the HAE	1491:1517	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	8	11	contain	has	1519:1521	arg1	ingredient					1594:1603	an ingredient	1591:1603	an ingredient in functional foods	1591:1623	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	7	12	from	activity	1433:1440	arg1	cells					1484:1488	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	4	13	theme	cellulose	918:926	arg1	chromatography					949:962	cellulose DEAE-52 ion-exchange chromatography	918:962	cellulose DEAE-52 ion-exchange chromatography	918:962	The SFP prepared by HAE (H-SFP) was purified by cellulose DEAE-52 ion-exchange chromatography, obtaining two purified fractions, namely H-SFP3 and H-SFP5.
36356868	7	14	theme	oxidative	1458:1466	arg1	stress					1468:1473	H2O2-induced oxidative stress	1445:1473	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	2	15	theme	extraction	323:332	arg1	technology					334:343	the optimum extraction technology	311:343	the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE)	311:561	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	7	16	theme	superoxide	1406:1415	arg1	SOD					1428:1430	SOD	1428:1430	SOD	1428:1430	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	7	16	theme	superoxide	1406:1415	arg1	dismutase					1417:1425	superoxide dismutase	1406:1425	the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells	1402:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	0	17	theme	acid-assisted	141:153	arg1	extraction					155:164	hydrogen peroxide/ascorbic acid-assisted extraction	114:164	hydrogen peroxide/ascorbic acid-assisted extraction	114:164	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	18	from	activity	58:65	arg1	Sargassum					91:99	Sargassum	91:99	Sargassum	91:99	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	6	19	theme	ABTS•+	1263:1268	arg1	radicals					1270:1277	DPPH, hydroxyl and ABTS•+ radicals	1244:1277	radicals	1270:1277	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	2	20	theme	optimum	315:321	arg1	technology					334:343	the optimum extraction technology	311:343	the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE)	311:561	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	1	21	theme	polysaccharides	216:230	arg1	activities					182:191	The biological activities	167:191	The biological activities of Sargassum fusiforme polysaccharides (SFP)	167:236	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	0	22	theme	peroxide/ascorbic	123:139	arg1	extraction					155:164	hydrogen peroxide/ascorbic acid-assisted extraction	114:164	hydrogen peroxide/ascorbic acid-assisted extraction	114:164	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	5	23	theme	antioxidant	1105:1115	arg1	capacity					1117:1124	the antioxidant capacity	1101:1124	the antioxidant capacity	1101:1124	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity were performed.
36356868	2	24	theme	alkali-assisted	491:505	arg1	ALAE					519:522	ALAE	519:522	ALAE	519:522	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	24	theme	alkali-assisted	491:505	arg1	extraction					507:516	alkali-assisted extraction	491:516	alkali-assisted extraction (ALAE)	491:523	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	24	theme	alkali-assisted	491:505	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	6	25	theme	crude	1164:1168	arg1	SFP					1170:1172	the crude SFP	1160:1172	the crude SFP	1160:1172	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	2	26	theme	ultrasonic-assisted	526:544	arg1	UAE					558:560	UAE	558:560	UAE	558:560	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	26	theme	ultrasonic-assisted	526:544	arg1	activities					384:393	biological activities	373:393	biological activities	373:393	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	26	theme	ultrasonic-assisted	526:544	arg1	extraction					546:555	ultrasonic-assisted extraction	526:555	ultrasonic-assisted extraction (UAE)	526:561	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	3	27	theme	in	727:728	arg1	activity					748:755	in vitro antioxidant activity	727:755	in vitro antioxidant activity	727:755	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	6	28	contain	possessed	1201:1209	arg1	SFP					1170:1172	the crude SFP	1160:1172	the crude SFP	1160:1172	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	6	28	contain	possessed	1201:1209	arg2	ability					1224:1230	considerable ability	1211:1230	considerable ability	1211:1230	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	6	28	contain	possessed	1201:1209	arg1	fractions					1191:1199	the purified fractions	1178:1199	the purified fractions	1178:1199	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	2	29	theme	SFP	699:701	arg1	preparation					684:694	the preparation	680:694	the preparation of SFP	680:701	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	30	theme	high	358:361	arg1	yield					363:367	high yield	358:367	high yield	358:367	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	3	31	theme	antioxidant	736:746	arg1	activity					748:755	in vitro antioxidant activity	727:755	in vitro antioxidant activity	727:755	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	8	32	used	used	1583:1586	arg2	SFP					1495:1497	The SFP	1491:1497	The SFP prepared by the HAE	1491:1517	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	8	32	used	used	1583:1586	arg2	ingredient					1594:1603	an ingredient	1591:1603	an ingredient in functional foods	1591:1623	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	7	33	theme	stress	1468:1473	arg1	cells					1484:1488	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	7	34	theme	dismutase	1417:1425	arg1	activity					1433:1440	the superoxide dismutase (SOD) activity	1402:1440	the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells	1402:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	8	35	theme	functional	1608:1617	arg1	foods					1619:1623	functional foods	1608:1623	functional foods	1608:1623	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	2	36	theme	acid-assisted	458:470	arg1	extraction					472:481	acid-assisted extraction	458:481	acid-assisted extraction (ACAE)	458:488	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	36	theme	acid-assisted	458:470	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	36	theme	acid-assisted	458:470	arg1	ACAE					484:487	ACAE	484:487	ACAE	484:487	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	3	37	theme	crude	764:768	arg1	polysaccharides					770:784	the crude polysaccharides	760:784	the crude polysaccharides obtained by the six extraction methods	760:823	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	2	38	theme	microwave-assisted	564:581	arg1	MAE					595:597	MAE	595:597	MAE	595:597	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	38	theme	microwave-assisted	564:581	arg1	extraction					583:592	microwave-assisted extraction	564:592	microwave-assisted extraction (MAE)	564:598	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	0	39	theme	physico-chemical	14:29	arg1	properties					31:40	physico-chemical properties	14:40	physico-chemical properties	14:40	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	8	40	theme	non-toxic	1550:1558	arg1	antioxidant					1560:1570	a natural non-toxic antioxidant	1540:1570	a natural non-toxic antioxidant	1540:1570	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	5	41	theme	composition	1056:1066	arg1	analyses					1029:1036	The analyses	1025:1036	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity	1025:1124	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity were performed.
36356868	0	42	theme	antioxidant	46:56	arg1	activity					58:65	antioxidant activity	46:65	antioxidant activity	46:65	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	3	43	dep	yield	717:721	arg1	the					713:715	the	713:715	the	713:715	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	0	44	from	Sargassum	91:99	arg1	Purification					0:11	Purification	0:11	Purification	0:11	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	44	from	Sargassum	91:99	arg1	properties					31:40	physico-chemical properties	14:40	physico-chemical properties	14:40	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	44	from	Sargassum	91:99	arg1	activity					58:65	antioxidant activity	46:65	antioxidant activity	46:65	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	44	from	Sargassum	91:99	arg1	polysaccharides					70:84	polysaccharides	70:84	polysaccharides from Sargassum	70:99	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	6	45	theme	DPPH	1244:1247	arg1	radicals					1270:1277	DPPH, hydroxyl and ABTS•+ radicals	1244:1277	radicals	1270:1277	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	2	46	theme	water	434:438	arg1	extraction					472:481	acid-assisted extraction	458:481	acid-assisted extraction (ACAE)	458:488	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	46	theme	water	434:438	arg1	extraction					507:516	alkali-assisted extraction	491:516	alkali-assisted extraction (ALAE)	491:523	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	46	theme	water	434:438	arg1	HWE					452:454	HWE	452:454	HWE	452:454	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	46	theme	water	434:438	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	5	47	theme	physico-chemical	1069:1084	arg1	properties					1086:1095	physico-chemical properties	1069:1095	physico-chemical properties	1069:1095	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity were performed.
36356868	7	48	theme	H2O2-induced	1445:1456	arg1	stress					1468:1473	H2O2-induced oxidative stress	1445:1473	H2O2-induced oxidative stress RAW264.7 cells	1445:1488	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	4	49	theme	ion-exchange	936:947	arg1	chromatography					949:962	cellulose DEAE-52 ion-exchange chromatography	918:962	cellulose DEAE-52 ion-exchange chromatography	918:962	The SFP prepared by HAE (H-SFP) was purified by cellulose DEAE-52 ion-exchange chromatography, obtaining two purified fractions, namely H-SFP3 and H-SFP5.
36356868	3	50	dep	in	727:728	arg1	vitro					730:734	vitro	730:734	vitro	730:734	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	5	51	theme	properties	1086:1095	arg1	analyses					1029:1036	The analyses	1025:1036	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity	1025:1124	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity were performed.
36356868	3	52	theme	polysaccharides	770:784	arg1	activity					748:755	in vitro antioxidant activity	727:755	in vitro antioxidant activity	727:755	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	3	52	theme	polysaccharides	770:784	arg1	yield					717:721	yield	717:721	yield	717:721	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	8	53	from	ingredient	1594:1603	arg1	foods					1619:1623	functional foods	1608:1623	functional foods	1608:1623	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	8	54	theme	natural	1542:1548	arg1	antioxidant					1560:1570	a natural non-toxic antioxidant	1540:1570	a natural non-toxic antioxidant	1540:1570	The SFP prepared by the HAE has the potential as a natural non-toxic antioxidant and can be used as an ingredient in functional foods.
36356868	4	55	theme	DEAE-52	928:934	arg1	chromatography					949:962	cellulose DEAE-52 ion-exchange chromatography	918:962	cellulose DEAE-52 ion-exchange chromatography	918:962	The SFP prepared by HAE (H-SFP) was purified by cellulose DEAE-52 ion-exchange chromatography, obtaining two purified fractions, namely H-SFP3 and H-SFP5.
36356868	2	56	theme	biological	373:382	arg1	activities					384:393	biological activities	373:393	biological activities	373:393	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	56	theme	biological	373:382	arg1	extraction					546:555	ultrasonic-assisted extraction	526:555	ultrasonic-assisted extraction (UAE)	526:561	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	56	theme	biological	373:382	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	56	theme	biological	373:382	arg1	methods					411:417	six extraction methods	396:417	six extraction methods	396:417	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	7	57	theme	oxygen	1362:1367	arg1	species					1369:1375	reactive oxygen species	1353:1375	the reactive oxygen species (ROS) level	1349:1387	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	7	57	theme	oxygen	1362:1367	arg1	ROS					1378:1380	ROS	1378:1380	ROS	1378:1380	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	7	58	theme	species	1369:1375	arg1	level					1383:1387	the reactive oxygen species (ROS) level	1349:1387	the reactive oxygen species (ROS) level	1349:1387	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	6	59	theme	considerable	1211:1222	arg1	ability					1224:1230	considerable ability	1211:1230	considerable ability	1211:1230	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	6	60	theme	hydroxyl	1250:1257	arg1	radicals					1270:1277	DPPH, hydroxyl and ABTS•+ radicals	1244:1277	radicals	1270:1277	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	3	61	theme	SFP	865:867	arg1	extraction					851:860	the extraction	847:860	the extraction of SFP	847:867	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
36356868	7	62	theme	polysaccharide	1286:1299	arg1	fractions					1301:1309	These polysaccharide fractions	1280:1309	These polysaccharide fractions	1280:1309	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	1	63	theme	biological	171:180	arg1	activities					182:191	The biological activities	167:191	The biological activities of Sargassum fusiforme polysaccharides (SFP)	167:236	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	1	64	theme	extraction	273:282	arg1	method					284:289	the extraction method	269:289	the extraction method	269:289	The biological activities of Sargassum fusiforme polysaccharides (SFP) were affected significantly by the extraction method.
36356868	5	65	theme	chemical	1047:1054	arg1	composition					1056:1066	their chemical composition	1041:1066	their chemical composition	1041:1066	The analyses of their chemical composition, physico-chemical properties and the antioxidant capacity were performed.
36356868	7	66	theme	reactive	1353:1360	arg1	species					1369:1375	reactive oxygen species	1353:1375	the reactive oxygen species (ROS) level	1349:1387	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	7	66	theme	reactive	1353:1360	arg1	ROS					1378:1380	ROS	1378:1380	ROS	1378:1380	These polysaccharide fractions were also found to effectively reduce the reactive oxygen species (ROS) level and increase the superoxide dismutase (SOD) activity in H2O2-induced oxidative stress RAW264.7 cells.
36356868	2	67	theme	hot	430:432	arg1	extraction					472:481	acid-assisted extraction	458:481	acid-assisted extraction (ACAE)	458:488	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	67	theme	hot	430:432	arg1	extraction					507:516	alkali-assisted extraction	491:516	alkali-assisted extraction (ALAE)	491:523	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	67	theme	hot	430:432	arg1	HWE					452:454	HWE	452:454	HWE	452:454	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	67	theme	hot	430:432	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	0	68	theme	polysaccharides	70:84	arg1	Purification					0:11	Purification	0:11	Purification	0:11	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	68	theme	polysaccharides	70:84	arg1	properties					31:40	physico-chemical properties	14:40	physico-chemical properties	14:40	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	68	theme	polysaccharides	70:84	arg1	activity					58:65	antioxidant activity	46:65	antioxidant activity	46:65	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	0	69	from	properties	31:40	arg1	Sargassum					91:99	Sargassum	91:99	Sargassum	91:99	Purification, physico-chemical properties and antioxidant activity of polysaccharides from Sargassum fusiforme by hydrogen peroxide/ascorbic acid-assisted extraction.
36356868	6	70	theme	purified	1182:1189	arg1	fractions					1191:1199	the purified fractions	1178:1199	the purified fractions	1178:1199	It was found that the crude SFP and the purified fractions possessed considerable ability to scavenge DPPH, hydroxyl and ABTS•+ radicals.
36356868	2	71	theme	extraction	400:409	arg1	activities					384:393	biological activities	373:393	biological activities	373:393	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	71	theme	extraction	400:409	arg1	extraction					440:449	hot water extraction	430:449	hot water extraction (HWE)	430:455	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	2	71	theme	extraction	400:409	arg1	methods					411:417	six extraction methods	396:417	six extraction methods	396:417	In order to screen the optimum extraction technology for SFP with high yield and biological activities, six extraction methods, including hot water extraction (HWE), acid-assisted extraction (ACAE), alkali-assisted extraction (ALAE), ultrasonic-assisted extraction (UAE), microwave-assisted extraction (MAE) and hydrogen peroxide/ascorbic acid-assisted extraction (HAE) were compared for the preparation of SFP.
36356868	3	72	theme	extraction	806:815	arg1	methods					817:823	the six extraction methods	798:823	the six extraction methods	798:823	Based on the yield and in vitro antioxidant activity of the crude polysaccharides obtained by the six extraction methods, HAE was selected for the extraction of SFP.
35144082	4	0	theme	HA	527:528	arg1	based-films					546:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	7	1	theme	monolayer	1127:1135	arg1	deposition					1108:1117	The deposition	1104:1117	The deposition of ChiS monolayer	1104:1135	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	9	2	theme	Biological	1343:1352	arg1	assay					1354:1358	Biological assay	1343:1358	Biological assay	1343:1358	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	1	3	theme	medical	207:213	arg1	use					215:217	medical use	207:217	medical use	207:217	The development of blood-interacting surfaces is critical to fabricate biomaterials for medical use, such as prostheses, implants, biosensors, and membranes.
35144082	5	4	theme	native	768:773	arg1	Chi					775:777	native Chi	768:777	native Chi	768:777	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	9	5	theme	adhesion	1491:1498	arg1	reduction					1468:1476	a significant reduction	1454:1476	a significant reduction of platelets adhesion to ChiS-functionalized films	1454:1527	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	7	6	theme	ChiS	1122:1125	arg1	monolayer					1127:1135	ChiS monolayer	1122:1135	ChiS monolayer	1122:1135	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	6	7	theme	composition	999:1009	arg1	assessment					1011:1020	chemical composition assessment	990:1020	chemical composition assessment	990:1020	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	7	8	theme	films	1208:1212	arg1	hydrophilicity					1179:1192	hydrophilicity	1179:1192	hydrophilicity of the HA/Chi films	1179:1212	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	7	8	theme	films	1208:1212	arg1	decrease					1148:1155	a decrease	1146:1155	a decrease in both roughness	1146:1173	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	4	9	theme	/chitosan	530:538	arg1	based-films					546:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	2	10	theme	leading	316:322	arg1	problems					333:340	the leading clinical problems	312:340	the leading clinical problems	312:340	For instance, thrombosis is one of the leading clinical problems when polymer-based materials interact with blood.
35144082	6	11	theme	chemical	990:997	arg1	assessment					1011:1020	chemical composition assessment	990:1020	chemical composition assessment	990:1020	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	5	12	dep	abilities	800:808	arg1	limit					892:896	limit	892:896	to limit calcification	889:910	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	5	12	dep	abilities	800:808	arg1	reduce					853:858	reduce	853:858	to reduce protein adsorption	850:877	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	5	12	dep	abilities	800:808	arg1	confer					813:818	confer	813:818	to confer anti-thrombogenic properties	810:847	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	10	13	theme	biomaterials	1659:1670	arg1	development					1621:1631	the development	1617:1631	the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces	1617:1740	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	9	14	theme	HA/Chi	1554:1559	arg1	films					1561:1565	HA/Chi films	1554:1565	HA/Chi films	1554:1565	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	10	15	theme	new	1601:1603	arg1	insight					1605:1611	a new insight	1599:1611	a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces	1599:1740	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	8	16	theme	films	1304:1308	arg1	composition					1269:1279	the chemical composition	1256:1279	the chemical composition of ChiS-functionalized films	1256:1308	In addition, the appearance of sulfur in the chemical composition of ChiS-functionalized films confirmed the film modification.
35144082	5	17	theme	unique	793:798	arg1	abilities					800:808	the unique abilities	789:808	the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification	789:910	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	9	18	theme	significant	1456:1466	arg1	reduction					1468:1476	a significant reduction	1454:1476	a significant reduction of platelets adhesion to ChiS-functionalized films	1454:1527	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	10	19	theme	new	1684:1686	arg1	possibilities					1688:1700	new possibilities	1684:1700	new possibilities for devising blood-interaction surfaces	1684:1740	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	6	20	theme	hydrophilicity	1077:1090	arg1	evaluation					1092:1101	hydrophilicity evaluation	1077:1101	hydrophilicity evaluation	1077:1101	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	7	21	theme	HA/Chi	1201:1206	arg1	films					1208:1212	the HA/Chi films	1197:1212	the HA/Chi films	1197:1212	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	7	22	from	hydrophilicity	1179:1192	arg1	roughness					1165:1173	both roughness	1160:1173	both roughness	1160:1173	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	9	23	theme	platelet	1420:1427	arg1	adhesion					1429:1436	platelet adhesion	1420:1436	platelet adhesion	1420:1436	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	5	24	theme	protein	860:866	arg1	adsorption					868:877	protein adsorption	860:877	protein adsorption	860:877	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	0	25	theme	layer-by-layer	21:34	arg1	nanoarchitectonics					36:53	Polysaccharide-based layer-by-layer nanoarchitectonics	0:53	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.	0:117	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.
35144082	4	26	theme	hyaluronan	515:524	arg1	based-films					546:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	9	27	theme	platelets	1481:1489	arg1	adhesion					1491:1498	platelets adhesion	1481:1498	platelets adhesion to ChiS-functionalized films	1481:1527	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	0	28	theme	Polysaccharide-based	0:19	arg1	nanoarchitectonics					36:53	Polysaccharide-based layer-by-layer nanoarchitectonics	0:53	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.	0:117	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.
35144082	2	29	theme	problems	333:340	arg1	problems					333:340	the leading clinical problems	312:340	the leading clinical problems	312:340	For instance, thrombosis is one of the leading clinical problems when polymer-based materials interact with blood.
35144082	2	29	theme	problems	333:340	arg1	one					305:307	one	305:307	one	305:307	For instance, thrombosis is one of the leading clinical problems when polymer-based materials interact with blood.
35144082	6	30	theme	contact	1059:1065	arg1	angle					1067:1071	contact angle	1059:1071	contact angle for hydrophilicity evaluation	1059:1101	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	2	31	theme	clinical	324:331	arg1	problems					333:340	the leading clinical problems	312:340	the leading clinical problems	312:340	For instance, thrombosis is one of the leading clinical problems when polymer-based materials interact with blood.
35144082	5	32	theme	anti-thrombogenic	820:836	arg1	properties					838:847	anti-thrombogenic properties	820:847	anti-thrombogenic properties	820:847	ChiS, when compared to native Chi, presents the unique abilities to confer anti-thrombogenic properties, to reduce protein adsorption, and also to limit calcification.
35144082	1	33	theme	surfaces	156:163	arg1	critical					168:175	critical	168:175	critical	168:175	The development of blood-interacting surfaces is critical to fabricate biomaterials for medical use, such as prostheses, implants, biosensors, and membranes.
35144082	1	33	theme	surfaces	156:163	arg1	development					123:133	The development	119:133	The development of blood-interacting surfaces	119:163	The development of blood-interacting surfaces is critical to fabricate biomaterials for medical use, such as prostheses, implants, biosensors, and membranes.
35144082	6	34	theme	Film	913:916	arg1	characterization					934:949	Film physicochemical characterization	913:949	Film physicochemical characterization	913:949	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	9	35	theme	ChiS-functionalized	1503:1521	arg1	films					1523:1527	ChiS-functionalized films	1503:1527	ChiS-functionalized films	1503:1527	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	8	36	theme	sulfur	1246:1251	arg1	appearance					1232:1241	the appearance	1228:1241	the appearance of sulfur in the chemical composition of ChiS-functionalized films	1228:1308	In addition, the appearance of sulfur in the chemical composition of ChiS-functionalized films confirmed the film modification.
35144082	10	37	theme	blood-interaction	1715:1731	arg1	surfaces					1733:1740	blood-interaction surfaces	1715:1740	blood-interaction surfaces	1715:1740	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	0	38	theme	sulfated	60:67	arg1	chitosan					69:76	sulfated chitosan	60:76	sulfated chitosan	60:76	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.
35144082	3	39	dep	platelets	466:474	arg1	adhesion					476:483	adhesion	476:483	adhesion	476:483	To overcome this limitation is necessary to develop strategies that limit platelets adhesion and activation.
35144082	3	39	dep	platelets	466:474	arg1	platelets					466:474	platelets adhesion and activation	466:498	platelets adhesion and activation	466:498	To overcome this limitation is necessary to develop strategies that limit platelets adhesion and activation.
35144082	3	39	dep	platelets	466:474	arg1	activation					489:498	activation	489:498	activation	489:498	To overcome this limitation is necessary to develop strategies that limit platelets adhesion and activation.
35144082	6	40	theme	surface	1035:1041	arg1	morphology					1043:1052	the surface morphology	1031:1052	the surface morphology	1031:1052	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	0	41	theme	tuning	82:87	arg1	properties					107:116	tuning anti-thrombogenic properties	82:116	tuning anti-thrombogenic properties	82:116	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.
35144082	4	42	theme	Chi	541:543	arg1	based-films					546:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	hyaluronan (HA)/chitosan (Chi) based-films	515:556	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	4	43	dep	developed	637:645	arg1	functionalized					666:679	functionalized	666:679	functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique	666:742	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	0	44	with	nanoarchitectonics	36:53	arg1	chitosan					69:76	sulfated chitosan	60:76	sulfated chitosan	60:76	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.
35144082	8	45	theme	film	1324:1327	arg1	modification					1329:1340	the film modification	1320:1340	the film modification	1320:1340	In addition, the appearance of sulfur in the chemical composition of ChiS-functionalized films confirmed the film modification.
35144082	10	46	theme	antithrombogenic	1642:1657	arg1	biomaterials					1659:1670	novel antithrombogenic biomaterials	1636:1670	novel antithrombogenic biomaterials	1636:1670	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	10	46	theme	antithrombogenic	1642:1657	arg1	opening					1673:1679	opening	1673:1679	opening up new possibilities for devising blood-interaction surfaces	1673:1740	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	9	47	theme	sulfated	1396:1403	arg1	groups					1405:1410	sulfated groups	1396:1410	sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films	1396:1527	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	8	48	theme	ChiS-functionalized	1284:1302	arg1	films					1304:1308	ChiS-functionalized films	1284:1308	ChiS-functionalized films	1284:1308	In addition, the appearance of sulfur in the chemical composition of ChiS-functionalized films confirmed the film modification.
35144082	9	49	theme	groups	1405:1410	arg1	incorporation					1379:1391	the incorporation	1375:1391	the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films	1375:1527	Biological assay indicated that the incorporation of sulfated groups limited platelet adhesion, mainly because a significant reduction of platelets adhesion to ChiS-functionalized films was observed compared to HA/Chi films.
35144082	7	50	from	decrease	1148:1155	arg1	roughness					1165:1173	both roughness	1160:1173	both roughness	1160:1173	The deposition of ChiS monolayer promoted a decrease in both roughness and hydrophilicity of the HA/Chi films.
35144082	4	51	theme	layer-by-layer	719:732	arg1	technique					734:742	a layer-by-layer technique	717:742	a layer-by-layer technique	717:742	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	1	52	theme	blood-interacting	138:154	arg1	surfaces					156:163	blood-interacting surfaces	138:163	blood-interacting surfaces	138:163	The development of blood-interacting surfaces is critical to fabricate biomaterials for medical use, such as prostheses, implants, biosensors, and membranes.
35144082	4	53	theme	cell	618:621	arg1	capture					623:629	tumor cell capture	612:629	tumor cell capture	612:629	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	8	54	from	appearance	1232:1241	arg1	composition					1269:1279	the chemical composition	1256:1279	the chemical composition of ChiS-functionalized films	1256:1308	In addition, the appearance of sulfur in the chemical composition of ChiS-functionalized films confirmed the film modification.
35144082	2	55	theme	polymer-based	347:359	arg1	materials					361:369	polymer-based materials	347:369	polymer-based materials	347:369	For instance, thrombosis is one of the leading clinical problems when polymer-based materials interact with blood.
35144082	4	56	theme	tumor	612:616	arg1	capture					623:629	tumor cell capture	612:629	tumor cell capture	612:629	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	8	57	theme	chemical	1260:1267	arg1	composition					1269:1279	the chemical composition	1256:1279	the chemical composition of ChiS-functionalized films	1256:1308	In addition, the appearance of sulfur in the chemical composition of ChiS-functionalized films confirmed the film modification.
35144082	0	58	theme	anti-thrombogenic	89:105	arg1	properties					107:116	tuning anti-thrombogenic properties	82:116	tuning anti-thrombogenic properties	82:116	Polysaccharide-based layer-by-layer nanoarchitectonics with sulfated chitosan for tuning anti-thrombogenic properties.
35144082	6	59	theme	physicochemical	918:932	arg1	characterization					934:949	Film physicochemical characterization	913:949	Film physicochemical characterization	913:949	Film physicochemical characterization was carried out using FTIR and XPS for chemical composition assessment, AFM for the surface morphology, and contact angle for hydrophilicity evaluation.
35144082	10	60	theme	novel	1636:1640	arg1	biomaterials					1659:1670	novel antithrombogenic biomaterials	1636:1670	novel antithrombogenic biomaterials	1636:1670	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	10	60	theme	novel	1636:1640	arg1	opening					1673:1679	opening	1673:1679	opening up new possibilities for devising blood-interaction surfaces	1673:1740	On balance, this work provides a new insight for the development of novel antithrombogenic biomaterials, opening up new possibilities for devising blood-interaction surfaces.
35144082	4	61	theme	sulfated	686:693	arg1	ChiS					705:708	ChiS	705:708	ChiS	705:708	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
35144082	4	61	theme	sulfated	686:693	arg1	chitosan					695:702	sulfated chitosan	686:702	sulfated chitosan (ChiS)	686:709	In this work, hyaluronan (HA)/chitosan (Chi) based-films, recently reported in the literature as platforms for tumor cell capture, were developed and, subsequently, functionalized with sulfated chitosan (ChiS) using a layer-by-layer technique.
36174863	5	0	theme	LPS-induced	715:725	arg1	impairment					737:746	LPS-induced cognitive impairment	715:746	LPS-induced cognitive impairment	715:746	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	2	1	theme	antioxidant	320:330	arg1	effects					347:353	its anti-inflammatory, antioxidant, and prebiotic effects	297:353	its anti-inflammatory, antioxidant, and prebiotic effects	297:353	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	4	2	theme	present	525:531	arg1	study					533:537	the present study	521:537	the present study	521:537	In the present study, we found that Fuc treatment protected HT22 cells from LPS-induced damage by inhibiting the activation of NLRP3 inflammasomes.
36174863	5	3	theme	cognitive	727:735	arg1	impairment					737:746	LPS-induced cognitive impairment	715:746	LPS-induced cognitive impairment	715:746	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	3	4	from	effects	369:375	arg1	damage					449:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	3	4	from	effects	369:375	arg1	impairment					470:479	cognitive impairment	460:479	cognitive impairment	460:479	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	7	5	theme	cognitive	1093:1101	arg1	impairment					1103:1112	cognitive impairment	1093:1112	cognitive impairment	1093:1112	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	3	6	theme	cognitive	460:468	arg1	impairment					470:479	cognitive impairment	460:479	cognitive impairment	460:479	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	4	7	theme	LPS-induced	594:604	arg1	damage					606:611	LPS-induced damage	594:611	LPS-induced damage	594:611	In the present study, we found that Fuc treatment protected HT22 cells from LPS-induced damage by inhibiting the activation of NLRP3 inflammasomes.
36174863	7	8	from	damage	1082:1087	arg1	mice					1117:1120	mice	1117:1120	mice	1117:1120	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	5	9	theme	neuroprotective	678:692	arg1	effects					694:700	neuroprotective effects	678:700	neuroprotective effects	678:700	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	6	10	theme	Fuc	894:896	arg1	supplement					898:907	Fuc supplement	894:907	Fuc supplement	894:907	Mechanistically, Fuc supplement significantly restructured the gut microbiota composition, which may be related to glucose and fructose metabolism.
36174863	3	11	from	impairment	470:479	arg1	mice					484:487	mice	484:487	mice	484:487	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	2	12	theme	brown	262:266	arg1	algae					268:272	brown algae	262:272	brown algae	262:272	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	1	13	theme	impairment	115:124	arg1	incidence					92:100	The incidence	88:100	The incidence of cognitive impairment	88:124	The incidence of cognitive impairment is rising globally, but there is no effective therapy.
36174863	3	14	theme	Fuc	395:397	arg1	mechanisms					381:390	mechanisms	381:390	mechanisms	381:390	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	3	14	theme	Fuc	395:397	arg1	effects					369:375	effects	369:375	effects	369:375	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	0	15	from	damage	47:52	arg1	mice					82:85	mice	82:85	mice	82:85	Fucoidan ameliorates LPS-induced neuronal cell damage and cognitive impairment in mice.
36174863	1	16	theme	effective	162:170	arg1	therapy					172:178	no effective therapy	159:178	no effective therapy	159:178	The incidence of cognitive impairment is rising globally, but there is no effective therapy.
36174863	7	17	theme	homologous	1171:1180	arg1	agent					1193:1197	a medicinal and food homologous functional agent	1150:1197	a medicinal and food homologous functional agent to improve cognitive function	1150:1227	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	7	17	theme	homologous	1171:1180	arg1	Fuc					1139:1141	Fuc	1139:1141	Fuc	1139:1141	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	3	18	dep	effects	369:375	arg1	the					365:367	the	365:367	the	365:367	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	5	19	theme	barrier	855:861	arg1	permeability					863:874	intestinal barrier permeability	844:874	intestinal barrier permeability	844:874	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	7	20	theme	functional	1182:1191	arg1	agent					1193:1197	a medicinal and food homologous functional agent	1150:1197	a medicinal and food homologous functional agent to improve cognitive function	1150:1227	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	7	20	theme	functional	1182:1191	arg1	Fuc					1139:1141	Fuc	1139:1141	Fuc	1139:1141	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	7	21	theme	medicinal	1152:1160	arg1	agent					1193:1197	a medicinal and food homologous functional agent	1150:1197	a medicinal and food homologous functional agent to improve cognitive function	1150:1227	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	7	21	theme	medicinal	1152:1160	arg1	Fuc					1139:1141	Fuc	1139:1141	Fuc	1139:1141	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	5	22	theme	intestinal	844:853	arg1	permeability					863:874	intestinal barrier permeability	844:874	intestinal barrier permeability	844:874	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	2	23	theme	prebiotic	337:345	arg1	effects					347:353	its anti-inflammatory, antioxidant, and prebiotic effects	297:353	its anti-inflammatory, antioxidant, and prebiotic effects	297:353	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	0	24	theme	neuronal	33:40	arg1	damage					47:52	LPS-induced neuronal cell damage	21:52	LPS-induced neuronal cell damage	21:52	Fucoidan ameliorates LPS-induced neuronal cell damage and cognitive impairment in mice.
36174863	7	25	from	impairment	1103:1112	arg1	mice					1117:1120	mice	1117:1120	mice	1117:1120	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	3	26	from	damage	449:454	arg1	mice					484:487	mice	484:487	mice	484:487	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	0	27	theme	LPS-induced	21:31	arg1	damage					47:52	LPS-induced neuronal cell damage	21:52	LPS-induced neuronal cell damage	21:52	Fucoidan ameliorates LPS-induced neuronal cell damage and cognitive impairment in mice.
36174863	1	28	theme	cognitive	105:113	arg1	impairment					115:124	cognitive impairment	105:124	cognitive impairment	105:124	The incidence of cognitive impairment is rising globally, but there is no effective therapy.
36174863	7	29	theme	neuronal	1068:1075	arg1	damage					1082:1087	LPS-induced neuronal cell damage	1056:1087	LPS-induced neuronal cell damage	1056:1087	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	5	30	theme	blood-brain	820:830	arg1	barrier					832:838	blood-brain barrier	820:838	blood-brain barrier	820:838	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	0	31	theme	cell	42:45	arg1	damage					47:52	LPS-induced neuronal cell damage	21:52	LPS-induced neuronal cell damage	21:52	Fucoidan ameliorates LPS-induced neuronal cell damage and cognitive impairment in mice.
36174863	7	32	theme	cell	1077:1080	arg1	damage					1082:1087	LPS-induced neuronal cell damage	1056:1087	LPS-induced neuronal cell damage	1056:1087	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	4	33	theme	HT22	578:581	arg1	cells					583:587	HT22 cells	578:587	HT22 cells	578:587	In the present study, we found that Fuc treatment protected HT22 cells from LPS-induced damage by inhibiting the activation of NLRP3 inflammasomes.
36174863	0	34	theme	cognitive	58:66	arg1	impairment					68:77	cognitive impairment	58:77	cognitive impairment	58:77	Fucoidan ameliorates LPS-induced neuronal cell damage and cognitive impairment in mice.
36174863	0	35	from	impairment	68:77	arg1	mice					82:85	mice	82:85	mice	82:85	Fucoidan ameliorates LPS-induced neuronal cell damage and cognitive impairment in mice.
36174863	2	36	theme	anti-inflammatory	301:317	arg1	effects					347:353	its anti-inflammatory, antioxidant, and prebiotic effects	297:353	its anti-inflammatory, antioxidant, and prebiotic effects	297:353	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	3	37	theme	cell	444:447	arg1	damage					449:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	6	38	theme	microbiota	944:953	arg1	composition					955:965	the gut microbiota composition	936:965	the gut microbiota composition	936:965	Mechanistically, Fuc supplement significantly restructured the gut microbiota composition, which may be related to glucose and fructose metabolism.
36174863	6	38	theme	microbiota	944:953	arg1	related					981:987	related	981:987	related	981:987	Mechanistically, Fuc supplement significantly restructured the gut microbiota composition, which may be related to glucose and fructose metabolism.
36174863	7	39	theme	LPS-induced	1056:1066	arg1	damage					1082:1087	LPS-induced neuronal cell damage	1056:1087	LPS-induced neuronal cell damage	1056:1087	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	4	40	theme	NLRP3	645:649	arg1	inflammasomes					651:663	NLRP3 inflammasomes	645:663	NLRP3 inflammasomes	645:663	In the present study, we found that Fuc treatment protected HT22 cells from LPS-induced damage by inhibiting the activation of NLRP3 inflammasomes.
36174863	6	41	theme	gut	940:942	arg1	composition					955:965	the gut microbiota composition	936:965	the gut microbiota composition	936:965	Mechanistically, Fuc supplement significantly restructured the gut microbiota composition, which may be related to glucose and fructose metabolism.
36174863	6	41	theme	gut	940:942	arg1	related					981:987	related	981:987	related	981:987	Mechanistically, Fuc supplement significantly restructured the gut microbiota composition, which may be related to glucose and fructose metabolism.
36174863	4	42	theme	inflammasomes	651:663	arg1	activation					631:640	the activation	627:640	the activation of NLRP3 inflammasomes	627:663	In the present study, we found that Fuc treatment protected HT22 cells from LPS-induced damage by inhibiting the activation of NLRP3 inflammasomes.
36174863	3	43	theme	-induced	426:433	arg1	damage					449:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	2	44	theme	sulfated	226:233	arg1	fucoidan					208:215	fucoidan	208:215	fucoidan (Fuc)	208:221	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	2	44	theme	sulfated	226:233	arg1	polysaccharide					235:248	a sulfated polysaccharide	224:248	a sulfated polysaccharide enriched in brown algae	224:272	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	3	45	from	mechanisms	381:390	arg1	damage					449:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	3	45	from	mechanisms	381:390	arg1	impairment					470:479	cognitive impairment	460:479	cognitive impairment	460:479	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	3	46	theme	neuronal	435:442	arg1	damage					449:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	lipopolysaccharide (LPS)-induced neuronal cell damage	402:454	However, the effects and mechanisms of Fuc on lipopolysaccharide (LPS)-induced neuronal cell damage and cognitive impairment in mice need to be explored further.
36174863	2	47	theme	Recent	181:186	arg1	studies					188:194	Recent studies	181:194	Recent studies	181:194	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	5	48	with	mice	705:708	arg1	impairment					737:746	LPS-induced cognitive impairment	715:746	LPS-induced cognitive impairment	715:746	Fuc exerted neuroprotective effects in mice with LPS-induced cognitive impairment by ameliorating neuroinflammation, promoting neurogenesis, and reducing blood-brain barrier and intestinal barrier permeability.
36174863	2	49	used	used	285:288	arg2	polysaccharide					235:248	a sulfated polysaccharide	224:248	a sulfated polysaccharide enriched in brown algae	224:272	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	2	49	used	used	285:288	arg2	fucoidan					208:215	fucoidan	208:215	fucoidan (Fuc)	208:221	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	2	49	used	used	285:288	arg2	Fuc					218:220	Fuc	218:220	Fuc	218:220	Recent studies showed that fucoidan (Fuc), a sulfated polysaccharide enriched in brown algae, is widely used due to its anti-inflammatory, antioxidant, and prebiotic effects.
36174863	4	50	theme	Fuc	554:556	arg1	treatment					558:566	Fuc treatment	554:566	Fuc treatment	554:566	In the present study, we found that Fuc treatment protected HT22 cells from LPS-induced damage by inhibiting the activation of NLRP3 inflammasomes.
36174863	6	51	dep	glucose	992:998	arg1	metabolism					1013:1022	metabolism	1013:1022	metabolism	1013:1022	Mechanistically, Fuc supplement significantly restructured the gut microbiota composition, which may be related to glucose and fructose metabolism.
36174863	7	52	theme	food	1166:1169	arg1	agent					1193:1197	a medicinal and food homologous functional agent	1150:1197	a medicinal and food homologous functional agent to improve cognitive function	1150:1227	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	7	52	theme	food	1166:1169	arg1	Fuc					1139:1141	Fuc	1139:1141	Fuc	1139:1141	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
36174863	7	53	theme	cognitive	1210:1218	arg1	function					1220:1227	cognitive function	1210:1227	cognitive function	1210:1227	In conclusion, Fuc ameliorated LPS-induced neuronal cell damage and cognitive impairment in mice, suggesting that Fuc may be a medicinal and food homologous functional agent to improve cognitive function.
37150381	0	0	theme	phycocyanin	95:105	arg1	stability					113:121	phycocyanin color stability	95:121	phycocyanin color stability	95:121	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	0	1	with	complexation	37:48	arg1	κ-carrageenan					67:79	κ-carrageenan	67:79	κ-carrageenan	67:79	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	0	1	with	complexation	37:48	arg1	fucoidan					55:62	fucoidan	55:62	fucoidan	55:62	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	4	2	theme	acidic	706:711	arg1	conditions					713:722	acidic conditions	706:722	acidic conditions	706:722	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	11	3	theme	hydrogel	1507:1514	arg1	beads					1516:1520	mixed hydrogel beads	1501:1520	mixed hydrogel beads	1501:1520	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	6	4	used	used	898:901	arg2	beads					887:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	7	5	theme	model	959:963	arg1	systems					965:971	model systems	959:971	model systems simulating acidic conditions	959:1000	The prepared samples were added into model systems simulating acidic conditions and then characterized during storage at 4 and 25 °C under dark conditions.
37150381	10	6	theme	beads	1364:1368	arg1	color					1351:1355	the blue color	1342:1355	the blue color of the beads	1342:1368	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	11	7	from	encapsulation	1484:1496	arg1	beads					1516:1520	mixed hydrogel beads	1501:1520	mixed hydrogel beads	1501:1520	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	7	8	theme	acidic	984:989	arg1	conditions					991:1000	acidic conditions	984:1000	acidic conditions	984:1000	The prepared samples were added into model systems simulating acidic conditions and then characterized during storage at 4 and 25 °C under dark conditions.
37150381	1	9	theme	acidic	279:284	arg1	environments					286:297	acidic environments	279:297	acidic environments	279:297	Phycocyanin (PC), as a pigment-protein complex, aggregates and precipitates in acidic environments.
37150381	0	10	theme	color	107:111	arg1	stability					113:121	phycocyanin color stability	95:121	phycocyanin color stability	95:121	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	2	11	with	formation	325:333	arg1	polysaccharides					348:362	anionic polysaccharides	340:362	anionic polysaccharides	340:362	In this context, complex formation with anionic polysaccharides is a strategy to enhance protein solubility.
37150381	10	12	dep	alginate-PCS	1250:1261	arg1	i.e.					1245:1248	i.e.	1245:1248	i.e.	1245:1248	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	3	13	theme	blue	467:470	arg1	color					472:476	the inherent blue color	454:476	the inherent blue color	454:476	Besides, acidic conditions negatively affect the inherent blue color of PC, which can be prevented by encapsulation.
37150381	11	14	theme	PC	1557:1558	arg1	solubility					1560:1569	PC solubility	1557:1569	PC solubility	1557:1569	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	4	15	theme	PC	662:663	arg1	solubility					665:674	PC solubility	662:674	PC solubility	662:674	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	0	16	theme	phycocyanin	10:20	arg1	solubility					22:31	phycocyanin solubility	10:31	phycocyanin solubility	10:31	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	6	17	theme	gel	883:885	arg1	beads					887:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	2	18	from	strategy	369:376	arg1	context					308:314	this context	303:314	this context	303:314	In this context, complex formation with anionic polysaccharides is a strategy to enhance protein solubility.
37150381	8	19	theme	colloidal	1090:1098	arg1	stabilities					1100:1110	Appropriate colloidal stabilities	1078:1110	Appropriate colloidal stabilities	1078:1110	Appropriate colloidal stabilities were observed for fucoidan/PC and KC/PC model systems.
37150381	10	20	from	Thereupon	1331:1339	arg1	time					1317:1320	time	1317:1320	time at 4 °C. Thereupon	1317:1339	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	11	21	theme	promising	1526:1534	arg1	routes					1536:1541	promising routes	1526:1541	promising routes for improving PC solubility and its color stability, respectively	1526:1607	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	11	21	theme	promising	1526:1534	arg1	complexation					1447:1458	complexation	1447:1458	complexation with fucoidan or KC	1447:1478	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	11	21	theme	promising	1526:1534	arg1	encapsulation					1484:1496	encapsulation	1484:1496	encapsulation in mixed hydrogel beads	1484:1520	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	6	22	theme	Calcium	823:829	arg1	PCS					868:870	PCS	868:870	PCS	868:870	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	6	22	theme	Calcium	823:829	arg1	starch					860:865	Calcium alginate-pregelatinized corn starch	823:865	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	6	23	theme	starch	860:865	arg1	beads					887:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	3	24	theme	inherent	458:465	arg1	color					472:476	the inherent blue color	454:476	the inherent blue color	454:476	Besides, acidic conditions negatively affect the inherent blue color of PC, which can be prevented by encapsulation.
37150381	0	25	theme	alginate-pregelatinized	143:165	arg1	beads					193:197	alginate-pregelatinized corn starch composite gel beads	143:197	alginate-pregelatinized corn starch composite gel beads	143:197	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	7	26	theme	prepared	926:933	arg1	samples					935:941	The prepared samples	922:941	The prepared samples	922:941	The prepared samples were added into model systems simulating acidic conditions and then characterized during storage at 4 and 25 °C under dark conditions.
37150381	2	27	theme	complex	317:323	arg1	formation					325:333	complex formation	317:333	complex formation with anionic polysaccharides	317:362	In this context, complex formation with anionic polysaccharides is a strategy to enhance protein solubility.
37150381	2	27	theme	complex	317:323	arg1	strategy					369:376	a strategy	367:376	a strategy to enhance protein solubility	367:406	In this context, complex formation with anionic polysaccharides is a strategy to enhance protein solubility.
37150381	9	28	theme	samples	1184:1190	arg1	color					1171:1175	The color	1167:1175	The color of the samples	1167:1190	The color of the samples remained stable at 4 °C.
37150381	4	29	theme	biopolymer-based	573:588	arg1	systems					590:596	two different biopolymer-based systems	559:596	two different biopolymer-based systems	559:596	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	4	29	theme	biopolymer-based	573:588	arg1	complexes					606:614	complexes	606:614	complexes	606:614	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	4	29	theme	biopolymer-based	573:588	arg1	beads					629:633	hydrogel beads	620:633	hydrogel beads	620:633	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	8	30	theme	Appropriate	1078:1088	arg1	stabilities					1100:1110	Appropriate colloidal stabilities	1078:1110	Appropriate colloidal stabilities	1078:1110	Appropriate colloidal stabilities were observed for fucoidan/PC and KC/PC model systems.
37150381	6	31	theme	composite	873:881	arg1	beads					887:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	10	32	theme	pH	1298:1299	arg1	conditions					1301:1310	low pH conditions	1294:1310	low pH conditions	1294:1310	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	4	33	theme	different	563:571	arg1	systems					590:596	two different biopolymer-based systems	559:596	two different biopolymer-based systems	559:596	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	4	33	theme	different	563:571	arg1	complexes					606:614	complexes	606:614	complexes	606:614	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	4	33	theme	different	563:571	arg1	beads					629:633	hydrogel beads	620:633	hydrogel beads	620:633	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	0	34	theme	starch	172:177	arg1	beads					193:197	alginate-pregelatinized corn starch composite gel beads	143:197	alginate-pregelatinized corn starch composite gel beads	143:197	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	10	35	theme	low	1294:1296	arg1	conditions					1301:1310	low pH conditions	1294:1310	low pH conditions	1294:1310	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	0	36	theme	corn	167:170	arg1	beads					193:197	alginate-pregelatinized corn starch composite gel beads	143:197	alginate-pregelatinized corn starch composite gel beads	143:197	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	11	37	with	complexation	1447:1458	arg1	KC					1477:1478	KC	1477:1478	KC	1477:1478	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	11	37	with	complexation	1447:1458	arg1	fucoidan					1465:1472	fucoidan	1465:1472	fucoidan	1465:1472	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	11	38	theme	color	1579:1583	arg1	stability					1585:1593	its color stability	1575:1593	its color stability	1575:1593	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	3	39	theme	PC	481:482	arg1	color					472:476	the inherent blue color	454:476	the inherent blue color	454:476	Besides, acidic conditions negatively affect the inherent blue color of PC, which can be prevented by encapsulation.
37150381	3	40	theme	acidic	418:423	arg1	conditions					425:434	acidic conditions	418:434	acidic conditions	418:434	Besides, acidic conditions negatively affect the inherent blue color of PC, which can be prevented by encapsulation.
37150381	0	41	theme	gel	189:191	arg1	beads					193:197	alginate-pregelatinized corn starch composite gel beads	143:197	alginate-pregelatinized corn starch composite gel beads	143:197	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	11	42	from	complexation	1447:1458	arg1	beads					1516:1520	mixed hydrogel beads	1501:1520	mixed hydrogel beads	1501:1520	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	10	43	theme	4 °C.	1325:1329	arg1	Thereupon					1331:1339	4 °C. Thereupon	1325:1339	4 °C. Thereupon	1325:1339	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	7	44	theme	dark	1061:1064	arg1	conditions					1066:1075	dark conditions	1061:1075	dark conditions	1061:1075	The prepared samples were added into model systems simulating acidic conditions and then characterized during storage at 4 and 25 °C under dark conditions.
37150381	5	45	used	utilized	787:794	arg2	Fucoidan					739:746	Fucoidan	739:746	Fucoidan	739:746	Fucoidan and κ-carrageenan (KC) were separately utilized to make a complex with PC.
37150381	5	45	used	utilized	787:794	arg2	KC					767:768	KC	767:768	KC	767:768	Fucoidan and κ-carrageenan (KC) were separately utilized to make a complex with PC.
37150381	5	45	used	utilized	787:794	arg2	κ-carrageenan					752:764	κ-carrageenan	752:764	κ-carrageenan	752:764	Fucoidan and κ-carrageenan (KC) were separately utilized to make a complex with PC.
37150381	0	46	theme	composite	179:187	arg1	beads					193:197	alginate-pregelatinized corn starch composite gel beads	143:197	alginate-pregelatinized corn starch composite gel beads	143:197	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	0	47	from	encapsulation	126:138	arg1	beads					193:197	alginate-pregelatinized corn starch composite gel beads	143:197	alginate-pregelatinized corn starch composite gel beads	143:197	Enhancing phycocyanin solubility via complexation with fucoidan or κ-carrageenan and improving phycocyanin color stability by encapsulation in alginate-pregelatinized corn starch composite gel beads.
37150381	4	48	theme	present	544:550	arg1	study					552:556	the present study	540:556	the present study	540:556	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	6	49	theme	corn	855:858	arg1	PCS					868:870	PCS	868:870	PCS	868:870	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	6	49	theme	corn	855:858	arg1	starch					860:865	Calcium alginate-pregelatinized corn starch	823:865	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	5	50	with	complex	806:812	arg1	PC					819:820	PC	819:820	PC	819:820	Fucoidan and κ-carrageenan (KC) were separately utilized to make a complex with PC.
37150381	4	51	theme	hydrogel	620:627	arg1	systems					590:596	two different biopolymer-based systems	559:596	two different biopolymer-based systems	559:596	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	4	51	theme	hydrogel	620:627	arg1	beads					629:633	hydrogel beads	620:633	hydrogel beads	620:633	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	6	52	theme	alginate-pregelatinized	831:853	arg1	PCS					868:870	PCS	868:870	PCS	868:870	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	6	52	theme	alginate-pregelatinized	831:853	arg1	starch					860:865	Calcium alginate-pregelatinized corn starch	823:865	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads	823:891	Calcium alginate-pregelatinized corn starch (PCS) composite gel beads were used to encapsulate PC.
37150381	2	53	theme	anionic	340:346	arg1	polysaccharides					348:362	anionic polysaccharides	340:362	anionic polysaccharides	340:362	In this context, complex formation with anionic polysaccharides is a strategy to enhance protein solubility.
37150381	7	54	from	4	1043:1043	arg1	storage					1032:1038	storage	1032:1038	storage at 4 and 25 °C	1032:1053	The prepared samples were added into model systems simulating acidic conditions and then characterized during storage at 4 and 25 °C under dark conditions.
37150381	8	55	theme	model	1152:1156	arg1	systems					1158:1164	KC/PC model systems	1146:1164	KC/PC model systems	1146:1164	Appropriate colloidal stabilities were observed for fucoidan/PC and KC/PC model systems.
37150381	1	56	theme	pigment-protein	223:237	arg1	complex					239:245	a pigment-protein complex	221:245	a pigment-protein complex	221:245	Phycocyanin (PC), as a pigment-protein complex, aggregates and precipitates in acidic environments.
37150381	10	57	theme	blue	1346:1349	arg1	color					1351:1355	the blue color	1342:1355	the blue color of the beads	1342:1368	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	2	58	theme	protein	389:395	arg1	solubility					397:406	protein solubility	389:406	protein solubility	389:406	In this context, complex formation with anionic polysaccharides is a strategy to enhance protein solubility.
37150381	10	59	theme	bead	1230:1233	arg1	carriers					1235:1242	the bead carriers	1226:1242	the bead carriers (i.e. alginate-PCS)	1226:1262	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	10	59	theme	bead	1230:1233	arg1	alginate-PCS					1250:1261	alginate-PCS	1250:1261	alginate-PCS	1250:1261	As well, the bead carriers (i.e. alginate-PCS) properly protected PC against low pH conditions over time at 4 °C. Thereupon, the blue color of the beads satisfactorily remained stable at this temperature.
37150381	8	60	theme	KC/PC	1146:1150	arg1	systems					1158:1164	KC/PC model systems	1146:1164	KC/PC model systems	1146:1164	Appropriate colloidal stabilities were observed for fucoidan/PC and KC/PC model systems.
37150381	11	61	with	encapsulation	1484:1496	arg1	KC					1477:1478	KC	1477:1478	KC	1477:1478	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	11	61	with	encapsulation	1484:1496	arg1	fucoidan					1465:1472	fucoidan	1465:1472	fucoidan	1465:1472	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	4	62	theme	color	684:688	arg1	stability					690:698	its color stability	680:698	its color stability	680:698	Thereupon, in the present study, two different biopolymer-based systems, namely complexes and hydrogel beads, were prepared to increase PC solubility and its color stability under acidic conditions, respectively.
37150381	11	63	theme	mixed	1501:1505	arg1	beads					1516:1520	mixed hydrogel beads	1501:1520	mixed hydrogel beads	1501:1520	The findings showed that complexation with fucoidan or KC and encapsulation in mixed hydrogel beads are promising routes for improving PC solubility and its color stability, respectively.
37150381	7	64	from	25 °C	1049:1053	arg1	storage					1032:1038	storage	1032:1038	storage at 4 and 25 °C	1032:1053	The prepared samples were added into model systems simulating acidic conditions and then characterized during storage at 4 and 25 °C under dark conditions.
37298817	0	0	theme	Fucoidan	82:89	arg1	Characterization					11:26	Characterization	11:26	Characterization	11:26	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	0	0	theme	Fucoidan	82:89	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	0	0	theme	Fucoidan	82:89	arg1	Activity					68:75	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	6	1	theme	-stimulated	869:879	arg1	fibrosis					881:888	fibrosis	881:888	fibrosis	881:888	Moreover, in vivo study found that CCP treatment alleviated bleomycin (BLM)-stimulated fibrosis and inflammation in mice lung tissue.
37298817	7	2	theme	lung	1065:1068	arg1	cells					1070:1074	lung cells	1065:1074	lung cells	1065:1074	In conclusion, the present study suggests that CCP could protect the lung from fibrosis by relieving the EMT process and inflammation in lung cells.
37298817	1	3	theme	progressive	147:157	arg1	disease					170:176	a chronic, progressive, and fatal disease	136:176	a chronic, progressive, and fatal disease of the interstitial lung	136:201	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	1	3	theme	progressive	147:157	arg1	fibrosis					124:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	4	4	theme	C.	483:484	arg1	CCP					510:512	CCP	510:512	CCP	510:512	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	4	4	theme	C.	483:484	arg1	polysaccharide					494:507	C. costata polysaccharide	483:507	C. costata polysaccharide (CCP)	483:513	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	5	5	theme	TGF-β/Smad	745:754	arg1	pathways					784:791	the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways	741:791	the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways	741:791	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	0	6	theme	Costaria	96:103	arg1	costata					105:111	Costaria costata	96:111	Costaria costata	96:111	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	5	7	theme	Further	616:622	arg1	study					624:628	Further study	616:628	Further study	616:628	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	4	8	theme	sulfate	583:589	arg1	content					597:603	a sulfate group content	581:603	a sulfate group content of 18.54%	581:613	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	4	9	theme	%	613:613	arg1	content					597:603	a sulfate group content	581:603	a sulfate group content of 18.54%	581:613	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	0	10	theme	Pulmonary	49:57	arg1	Fibrosis					59:66	Anti-Idiopathic Pulmonary Fibrosis	33:66	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	4	11	theme	composition	450:460	arg1	analysis					462:469	The chemical composition analysis	437:469	The chemical composition analysis	437:469	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	3	12	theme	fibrosis	375:382	arg1	activity					384:391	its anti-idiopathic fibrosis activity	355:391	its anti-idiopathic fibrosis activity	355:391	In this study, a fucoidan from Costaria costata was isolated, and its anti-idiopathic fibrosis activity was investigated both in vitro and in vivo.
37298817	1	13	theme	fatal	164:168	arg1	disease					170:176	a chronic, progressive, and fatal disease	136:176	a chronic, progressive, and fatal disease of the interstitial lung	136:201	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	1	13	theme	fatal	164:168	arg1	fibrosis					124:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	5	14	theme	PI3K/AKT/mTOR	760:772	arg1	pathways					784:791	the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways	741:791	the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways	741:791	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	4	15	theme	chemical	441:448	arg1	analysis					462:469	The chemical composition analysis	437:469	The chemical composition analysis	437:469	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	6	16	dep	in	804:805	arg1	vivo					807:810	vivo	807:810	vivo	807:810	Moreover, in vivo study found that CCP treatment alleviated bleomycin (BLM)-stimulated fibrosis and inflammation in mice lung tissue.
37298817	5	17	theme	signaling	774:782	arg1	pathways					784:791	the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways	741:791	the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways	741:791	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	7	18	theme	EMT	1033:1035	arg1	process					1037:1043	the EMT process	1029:1043	the EMT process	1029:1043	In conclusion, the present study suggests that CCP could protect the lung from fibrosis by relieving the EMT process and inflammation in lung cells.
37298817	2	19	theme	patients	279:286	arg1	prognosis					266:274	the prognosis	262:274	the prognosis of patients	262:286	There is currently a lack of efficient therapy to reverse the prognosis of patients.
37298817	4	20	theme	group	591:595	arg1	content					597:603	a sulfate group content	581:603	a sulfate group content of 18.54%	581:613	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	6	21	theme	CCP	829:831	arg1	treatment					833:841	CCP treatment	829:841	CCP treatment	829:841	Moreover, in vivo study found that CCP treatment alleviated bleomycin (BLM)-stimulated fibrosis and inflammation in mice lung tissue.
37298817	1	22	theme	interstitial	185:196	arg1	lung					198:201	the interstitial lung	181:201	the interstitial lung	181:201	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	0	23	theme	Anti-Idiopathic	33:47	arg1	Fibrosis					59:66	Anti-Idiopathic Pulmonary Fibrosis	33:66	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	6	24	theme	lung	915:918	arg1	tissue					920:925	mice lung tissue	910:925	mice lung tissue	910:925	Moreover, in vivo study found that CCP treatment alleviated bleomycin (BLM)-stimulated fibrosis and inflammation in mice lung tissue.
37298817	5	25	theme	TGF-β1-induced	658:671	arg1	EMT					708:710	EMT	708:710	EMT	708:710	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	5	25	theme	TGF-β1-induced	658:671	arg1	transition					696:705	TGF-β1-induced epithelial-mesenchymal transition	658:705	TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells	658:725	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	1	26	theme	lung	198:201	arg1	disease					170:176	a chronic, progressive, and fatal disease	136:176	a chronic, progressive, and fatal disease of the interstitial lung	136:201	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	1	26	theme	lung	198:201	arg1	fibrosis					124:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	6	27	theme	mice	910:913	arg1	tissue					920:925	mice lung tissue	910:925	mice lung tissue	910:925	Moreover, in vivo study found that CCP treatment alleviated bleomycin (BLM)-stimulated fibrosis and inflammation in mice lung tissue.
37298817	5	28	theme	epithelial-mesenchymal	673:694	arg1	EMT					708:710	EMT	708:710	EMT	708:710	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	5	28	theme	epithelial-mesenchymal	673:694	arg1	transition					696:705	TGF-β1-induced epithelial-mesenchymal transition	658:705	TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells	658:725	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	5	29	from	transition	696:705	arg1	cells					721:725	A549 cells	716:725	A549 cells	716:725	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
37298817	0	30	theme	Fibrosis	59:66	arg1	Activity					68:75	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	4	31	theme	costata	486:492	arg1	CCP					510:512	CCP	510:512	CCP	510:512	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	4	31	theme	costata	486:492	arg1	polysaccharide					494:507	C. costata polysaccharide	483:507	C. costata polysaccharide (CCP)	483:513	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	3	32	from	costata	329:335	arg1	fucoidan					306:313	a fucoidan	304:313	a fucoidan from Costaria costata	304:335	In this study, a fucoidan from Costaria costata was isolated, and its anti-idiopathic fibrosis activity was investigated both in vitro and in vivo.
37298817	4	33	with	monosaccharides	560:574	arg1	content					597:603	a sulfate group content	581:603	a sulfate group content of 18.54%	581:613	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	1	34	theme	Pulmonary	114:122	arg1	disease					170:176	a chronic, progressive, and fatal disease	136:176	a chronic, progressive, and fatal disease of the interstitial lung	136:201	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	1	34	theme	Pulmonary	114:122	arg1	fibrosis					124:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	3	35	theme	anti-idiopathic	359:373	arg1	activity					384:391	its anti-idiopathic fibrosis activity	355:391	its anti-idiopathic fibrosis activity	355:391	In this study, a fucoidan from Costaria costata was isolated, and its anti-idiopathic fibrosis activity was investigated both in vitro and in vivo.
37298817	6	36	theme	in	804:805	arg1	study					812:816	in vivo study	804:816	in vivo study	804:816	Moreover, in vivo study found that CCP treatment alleviated bleomycin (BLM)-stimulated fibrosis and inflammation in mice lung tissue.
37298817	0	37	from	costata	105:111	arg1	Characterization					11:26	Characterization	11:26	Characterization	11:26	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	0	37	from	costata	105:111	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	0	37	from	costata	105:111	arg1	Activity					68:75	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Anti-Idiopathic Pulmonary Fibrosis Activity	33:75	Isolation, Characterization, and Anti-Idiopathic Pulmonary Fibrosis Activity of a Fucoidan from Costaria costata.
37298817	2	38	theme	therapy	243:249	arg1	lack					225:228	a lack	223:228	a lack of efficient therapy to reverse the prognosis of patients	223:286	There is currently a lack of efficient therapy to reverse the prognosis of patients.
37298817	2	39	theme	efficient	233:241	arg1	therapy					243:249	efficient therapy	233:249	efficient therapy	233:249	There is currently a lack of efficient therapy to reverse the prognosis of patients.
37298817	4	40	theme	main	555:558	arg1	monosaccharides					560:574	the main monosaccharides	551:574	the main monosaccharides with a sulfate group content of 18.54%	551:613	The chemical composition analysis showed that C. costata polysaccharide (CCP) consists of galactose and fucose as the main monosaccharides with a sulfate group content of 18.54%.
37298817	7	41	theme	present	947:953	arg1	study					955:959	the present study	943:959	the present study	943:959	In conclusion, the present study suggests that CCP could protect the lung from fibrosis by relieving the EMT process and inflammation in lung cells.
37298817	1	42	theme	chronic	138:144	arg1	disease					170:176	a chronic, progressive, and fatal disease	136:176	a chronic, progressive, and fatal disease of the interstitial lung	136:201	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	1	42	theme	chronic	138:144	arg1	fibrosis					124:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis	114:131	Pulmonary fibrosis is a chronic, progressive, and fatal disease of the interstitial lung.
37298817	5	43	theme	A549	716:719	arg1	cells					721:725	A549 cells	716:725	A549 cells	716:725	Further study found that CCP could resist TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cells by inhibiting the TGF-β/Smad and PI3K/AKT/mTOR signaling pathways.
36869469	1	0	theme	functional	276:285	arg1	oligosaccharides					202:217	Glucose-based short-chain oligosaccharides	176:217	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS)	176:249	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	1	0	theme	functional	276:285	arg1	ingredients					292:302	functional food ingredients	276:302	functional food ingredients with health-promoting properties	276:335	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	4	1	theme	chemical	629:636	arg1	process					638:644	a facile chemical process	620:644	a facile chemical process	620:644	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	9	2	theme	prebiotic	1792:1800	arg1	GlcOS					1802:1806	the prebiotic GlcOS	1788:1806	the prebiotic GlcOS	1788:1806	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	9	3	with	cellobiose	1679:1688	arg1	structures					1713:1722	structures	1713:1722	structures	1713:1722	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	9	3	with	cellobiose	1679:1688	arg1	yield					1703:1707	similar yield	1695:1707	similar yield	1695:1707	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	3	4	theme	prebiotic	575:583	arg1	GlcOS					585:589	prebiotic GlcOS	575:589	prebiotic GlcOS	575:589	Therefore, developing efficient technologies for large-scale production of prebiotic GlcOS is highly desirable.
36869469	5	5	theme	glucose	883:889	arg1	loading					891:897	50 % initial glucose loading	870:897	50 % initial glucose loading	870:897	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	4	6	theme	dehydration	717:727	arg1	condensation					729:740	enhanced dehydration condensation	708:740	enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %)	708:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	6	7	with	linkages	1268:1275	arg1	degree					1027:1032	a degree	1025:1032	a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4),	1025:1241	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	8	8	theme	promotion	1545:1553	arg1	effect					1555:1560	their promotion effect	1539:1560	their promotion effect	1539:1560	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	6	9	dep	β-	1208:1209	arg1	1→6					1211:1213	1→6	1211:1213	1→6	1211:1213	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	10	theme	synthesized	969:979	arg1	oligomers					1010:1018	short-chain oligomers	998:1018	short-chain oligomers	998:1018	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	10	theme	synthesized	969:979	arg1	GlcOS					981:985	the synthesized GlcOS	965:985	the synthesized GlcOS	965:985	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	4	11	theme	potential	683:691	arg1	GlcOS					674:678	GlcOS	674:678	GlcOS	674:678	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	4	11	theme	potential	683:691	arg1	prebiotics					693:702	potential prebiotics	683:702	potential prebiotics	683:702	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	5	12	theme	%	873:873	arg1	loading					891:897	50 % initial glucose loading	870:897	50 % initial glucose loading	870:897	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	6	13	theme	larger	1133:1138	arg1	oligosaccharides					1140:1155	larger oligosaccharides	1133:1155	larger oligosaccharides	1133:1155	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	14	theme	α-	1201:1202	arg1	linkages					1216:1223	predominantly α- and β-(1→6) linkages	1187:1223	predominantly α- and β-(1→6) linkages along with (1→4)	1187:1240	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	4	15	theme	sulfuric	769:776	arg1	acid					778:781	concentrated sulfuric acid	756:781	concentrated sulfuric acid (60-92 %)	756:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	4	15	theme	sulfuric	769:776	arg1	%					790:790	60-92 %	784:790	60-92 %	784:790	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	6	16	theme	percentage	1119:1128	arg1	degree					1027:1032	a degree	1025:1032	a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4),	1025:1241	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	0	17	theme	probiotic	156:164	arg1	bacteria					166:173	probiotic bacteria	156:173	probiotic bacteria	156:173	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	9	18	with	maltose	1667:1673	arg1	structures					1713:1722	structures	1713:1722	structures	1713:1722	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	9	18	with	maltose	1667:1673	arg1	yield					1703:1707	similar yield	1695:1707	similar yield	1695:1707	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	8	19	theme	prebiotic	1605:1613	arg1	IMOs					1615:1618	three commercial prebiotic IMOs	1588:1618	three commercial prebiotic IMOs	1588:1618	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	5	20	theme	20 min	923:928	arg1	condition					857:865	the optimal condition	845:865	the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min	845:928	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	6	21	theme	1↔1	1263:1265	arg1	linkages					1268:1275	(1↔1) linkages	1262:1275	(1↔1) linkages	1262:1275	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	22	with	oligomers	1010:1018	arg1	degree					1027:1032	a degree	1025:1032	a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4),	1025:1241	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	9	23	theme	inexpensive	1822:1832	arg1	starch					1834:1839	inexpensive starch	1822:1839	inexpensive starch	1822:1839	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	5	24	theme	maximum	798:804	arg1	yield					812:816	The maximum GlcOS yield	794:816	The maximum GlcOS yield of 83 %	794:824	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	5	25	theme	optimal	849:855	arg1	condition					857:865	the optimal condition	845:865	the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min	845:928	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	5	26	theme	%	903:903	arg1	H2SO4					905:909	76 % H2SO4	900:909	76 % H2SO4	900:909	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	6	27	theme	short-chain	998:1008	arg1	1→ 3					1244:1247	1→ 3	1244:1247	1→ 3	1244:1247	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	27	theme	short-chain	998:1008	arg1	oligomers					1010:1018	short-chain oligomers	998:1018	short-chain oligomers	998:1018	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	27	theme	short-chain	998:1008	arg1	1→2					1252:1254	1→2	1252:1254	1→2	1252:1254	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	27	theme	short-chain	998:1008	arg1	GlcOS					981:985	the synthesized GlcOS	965:985	the synthesized GlcOS	965:985	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	0	28	theme	glycosidic	87:96	arg1	linkages					98:105	diverse glycosidic linkages	79:105	diverse glycosidic linkages as potential prebiotics	79:129	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	2	29	theme	yield	479:483	arg1	challenges					461:470	the challenges	457:470	the challenges of low yield and high cost	457:497	Currently, GlcOS (e.g., isomalto-oligosaccharides, IMOs) are commercially produced via enzymatic processes, which face the challenges of low yield and high cost.
36869469	7	30	dep	In	1278:1279	arg1	vitro					1281:1285	vitro	1281:1285	vitro	1281:1285	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	0	31	theme	efficient	11:19	arg1	synthesis					30:38	efficient chemical synthesis	11:38	efficient chemical synthesis	11:38	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	8	32	theme	bacterial	1517:1525	arg1	growth					1527:1532	bacterial growth	1517:1532	bacterial growth	1517:1532	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	6	33	theme	polymerization	1037:1050	arg1	degree					1027:1032	a degree	1025:1032	a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4),	1025:1241	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	2	34	theme	high	489:492	arg1	cost					494:497	high cost	489:497	high cost	489:497	Currently, GlcOS (e.g., isomalto-oligosaccharides, IMOs) are commercially produced via enzymatic processes, which face the challenges of low yield and high cost.
36869469	8	35	theme	DSM	1400:1402	arg1	10140					1404:1408	lactis DSM 10140	1393:1408	lactis DSM 10140	1393:1408	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	0	36	theme	gluco-oligosaccharides	43:64	arg1	Facile					0:5	Facile	0:5	Facile	0:5	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	0	36	theme	gluco-oligosaccharides	43:64	arg1	synthesis					30:38	efficient chemical synthesis	11:38	efficient chemical synthesis	11:38	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	7	37	theme	Bifidobacterium	1325:1339	arg1	subsp					1386:1390	Bifidobacterium animalis subsp	1361:1390	Bifidobacterium animalis subsp	1361:1390	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	7	37	theme	Bifidobacterium	1325:1339	arg1	ATCC					1349:1352	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	0	38	with	Facile	0:5	arg1	linkages					98:105	diverse glycosidic linkages	79:105	diverse glycosidic linkages as potential prebiotics	79:129	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	4	39	from	acid	778:781	arg1	condensation					729:740	enhanced dehydration condensation	708:740	enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %)	708:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	9	40	theme	similar	1695:1701	arg1	yield					1703:1707	similar yield	1695:1707	similar yield	1695:1707	GlcOS were also successfully synthesized from maltose and cellobiose with similar yield and structures to those from glucose, implying the possibility of synthesizing the prebiotic GlcOS directly from inexpensive starch and cellulose.
36869469	8	41	theme	Limosilactobacillus	1415:1433	arg1	ATCC					1443:1446	Limosilactobacillus reuteri ATCC 6475	1415:1451	Limosilactobacillus reuteri ATCC 6475	1415:1451	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	3	42	theme	large-scale	549:559	arg1	production					561:570	large-scale production	549:570	large-scale production of prebiotic GlcOS	549:589	Therefore, developing efficient technologies for large-scale production of prebiotic GlcOS is highly desirable.
36869469	1	43	theme	Glucose-based	176:188	arg1	oligosaccharides					202:217	Glucose-based short-chain oligosaccharides	176:217	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS)	176:249	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	1	43	theme	Glucose-based	176:188	arg1	ingredients					292:302	functional food ingredients	276:302	functional food ingredients with health-promoting properties	276:335	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	1	43	theme	Glucose-based	176:188	arg1	GlcOS					244:248	GlcOS	244:248	GlcOS	244:248	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	7	44	theme	fermentation	1287:1298	arg1	experiments					1300:1310	In vitro fermentation experiments	1278:1310	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.	1278:1391	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	6	45	theme	%	1077:1077	arg1	DP					1101:1102	46 % DP 2, 22 % DP 3, 12 % DP 4	1074:1104	DP	1101:1102	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	45	theme	%	1077:1077	arg1	2					1065:1065	2	1065:1065	2	1065:1065	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	5	46	theme	GlcOS	806:810	arg1	yield					812:816	The maximum GlcOS yield	794:816	The maximum GlcOS yield of 83 %	794:824	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	0	47	with	synthesis	30:38	arg1	linkages					98:105	diverse glycosidic linkages	79:105	diverse glycosidic linkages as potential prebiotics	79:129	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	4	48	from	glucose	745:751	arg1	acid					778:781	concentrated sulfuric acid	756:781	concentrated sulfuric acid (60-92 %)	756:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	4	48	from	glucose	745:751	arg1	%					790:790	60-92 %	784:790	60-92 %	784:790	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	7	49	theme	In	1278:1279	arg1	experiments					1300:1310	In vitro fermentation experiments	1278:1310	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.	1278:1391	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	3	50	theme	GlcOS	585:589	arg1	production					561:570	large-scale production	549:570	large-scale production of prebiotic GlcOS	549:589	Therefore, developing efficient technologies for large-scale production of prebiotic GlcOS is highly desirable.
36869469	4	51	from	condensation	729:740	arg1	acid					778:781	concentrated sulfuric acid	756:781	concentrated sulfuric acid (60-92 %)	756:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	4	51	from	condensation	729:740	arg1	%					790:790	60-92 %	784:790	60-92 %	784:790	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	1	52	theme	food	287:290	arg1	oligosaccharides					202:217	Glucose-based short-chain oligosaccharides	176:217	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS)	176:249	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	1	52	theme	food	287:290	arg1	ingredients					292:302	functional food ingredients	276:302	functional food ingredients with health-promoting properties	276:335	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	4	53	theme	facile	622:627	arg1	process					638:644	a facile chemical process	620:644	a facile chemical process	620:644	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	5	54	theme	loading	891:897	arg1	condition					857:865	the optimal condition	845:865	the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min	845:928	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	5	55	theme	initial	875:881	arg1	loading					891:897	50 % initial glucose loading	870:897	50 % initial glucose loading	870:897	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	6	56	theme	%	1099:1099	arg1	DP					1101:1102	46 % DP 2, 22 % DP 3, 12 % DP 4	1074:1104	DP	1101:1102	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	56	theme	%	1099:1099	arg1	2					1065:1065	2	1065:1065	2	1065:1065	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	1	57	theme	short-chain	190:200	arg1	oligosaccharides					202:217	Glucose-based short-chain oligosaccharides	176:217	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS)	176:249	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	1	57	theme	short-chain	190:200	arg1	ingredients					292:302	functional food ingredients	276:302	functional food ingredients with health-promoting properties	276:335	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	1	57	theme	short-chain	190:200	arg1	GlcOS					244:248	GlcOS	244:248	GlcOS	244:248	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	6	58	attach	linked	1177:1182	arg2	DP					1053:1054	DP	1053:1054	DP	1053:1054	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	58	attach	linked	1177:1182	arg2	polymerization					1037:1050	polymerization	1037:1050	polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4)	1037:1105	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	58	attach	linked	1177:1182	arg2	DP					1158:1159	DP 5-9	1158:1163	DP 5-9	1158:1163	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	58	attach	linked	1177:1182	arg2	percentage					1119:1128	a small percentage	1111:1128	a small percentage of larger oligosaccharides	1111:1155	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	58	attach	linked	1177:1182	arg3	linkages					1216:1223	predominantly α- and β-(1→6) linkages	1187:1223	predominantly α- and β-(1→6) linkages along with (1→4)	1187:1240	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	4	59	theme	enhanced	708:715	arg1	condensation					729:740	enhanced dehydration condensation	708:740	enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %)	708:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	6	60	theme	DP	1090:1091	arg1	DP					1101:1102	46 % DP 2, 22 % DP 3, 12 % DP 4	1074:1104	DP	1101:1102	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	60	theme	DP	1090:1091	arg1	2					1065:1065	2	1065:1065	2	1065:1065	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	5	61	theme	50 	870:872	arg1	%					873:873	%	873:873	%	873:873	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	6	62	theme	oligosaccharides	1140:1155	arg1	DP					1053:1054	DP	1053:1054	DP	1053:1054	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	62	theme	oligosaccharides	1140:1155	arg1	polymerization					1037:1050	polymerization	1037:1050	polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4)	1037:1105	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	62	theme	oligosaccharides	1140:1155	arg1	percentage					1119:1128	a small percentage	1111:1128	a small percentage of larger oligosaccharides	1111:1155	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	62	theme	oligosaccharides	1140:1155	arg1	DP					1158:1159	DP 5-9	1158:1163	DP 5-9	1158:1163	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	63	theme	β-	1208:1209	arg1	linkages					1216:1223	predominantly α- and β-(1→6) linkages	1187:1223	predominantly α- and β-(1→6) linkages along with (1→4)	1187:1240	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	5	64	theme	70 °C	912:916	arg1	condition					857:865	the optimal condition	845:865	the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min	845:928	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	6	65	theme	Structural	931:940	arg1	analysis					942:949	Structural analysis	931:949	Structural analysis	931:949	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	4	66	theme	concentrated	756:767	arg1	acid					778:781	concentrated sulfuric acid	756:781	concentrated sulfuric acid (60-92 %)	756:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	4	66	theme	concentrated	756:767	arg1	%					790:790	60-92 %	784:790	60-92 %	784:790	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	0	67	theme	bacteria	166:173	arg1	growth					146:151	the growth	142:151	the growth of probiotic bacteria	142:173	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	6	68	theme	small	1113:1117	arg1	percentage					1119:1128	a small percentage	1111:1128	a small percentage of larger oligosaccharides	1111:1155	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	8	69	theme	commercial	1594:1603	arg1	IMOs					1615:1618	three commercial prebiotic IMOs	1588:1618	three commercial prebiotic IMOs	1588:1618	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	5	70	theme	76 	900:902	arg1	H2SO4					905:909	76 % H2SO4	900:909	76 % H2SO4	900:909	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	0	71	theme	diverse	79:85	arg1	linkages					98:105	diverse glycosidic linkages	79:105	diverse glycosidic linkages as potential prebiotics	79:129	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	5	72	theme	H2SO4	905:909	arg1	condition					857:865	the optimal condition	845:865	the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min	845:928	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	4	73	theme	glucose	745:751	arg1	condensation					729:740	enhanced dehydration condensation	708:740	enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %)	708:791	Herein, a facile chemical process was developed to synthesize GlcOS as potential prebiotics via enhanced dehydration condensation of glucose in concentrated sulfuric acid (60-92 %).
36869469	7	74	theme	animalis	1377:1384	arg1	subsp					1386:1390	Bifidobacterium animalis subsp	1361:1390	Bifidobacterium animalis subsp	1361:1390	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	7	74	theme	animalis	1377:1384	arg1	ATCC					1349:1352	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	0	75	theme	potential	110:118	arg1	prebiotics					120:129	potential prebiotics	110:129	potential prebiotics	110:129	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	2	76	theme	enzymatic	425:433	arg1	processes					435:443	enzymatic processes	425:443	enzymatic processes	425:443	Currently, GlcOS (e.g., isomalto-oligosaccharides, IMOs) are commercially produced via enzymatic processes, which face the challenges of low yield and high cost.
36869469	2	77	theme	low	475:477	arg1	yield					479:483	low yield	475:483	low yield	475:483	Currently, GlcOS (e.g., isomalto-oligosaccharides, IMOs) are commercially produced via enzymatic processes, which face the challenges of low yield and high cost.
36869469	0	78	theme	chemical	21:28	arg1	synthesis					30:38	efficient chemical synthesis	11:38	efficient chemical synthesis	11:38	Facile and efficient chemical synthesis of gluco-oligosaccharides (GlcOS) with diverse glycosidic linkages as potential prebiotics to promote the growth of probiotic bacteria.
36869469	1	79	theme	health-promoting	309:324	arg1	properties					326:335	health-promoting properties	309:335	health-promoting properties	309:335	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	8	80	theme	lactis	1393:1398	arg1	10140					1404:1408	lactis DSM 10140	1393:1408	lactis DSM 10140	1393:1408	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	2	81	dep	isomalto-oligosaccharides	362:386	arg1	e.g.					356:359	e.g.	356:359	e.g.	356:359	Currently, GlcOS (e.g., isomalto-oligosaccharides, IMOs) are commercially produced via enzymatic processes, which face the challenges of low yield and high cost.
36869469	7	82	theme	Bifidobacterium	1361:1375	arg1	subsp					1386:1390	Bifidobacterium animalis subsp	1361:1390	Bifidobacterium animalis subsp	1361:1390	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	7	82	theme	Bifidobacterium	1361:1375	arg1	ATCC					1349:1352	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	2	83	theme	cost	494:497	arg1	challenges					461:470	the challenges	457:470	the challenges of low yield and high cost	457:497	Currently, GlcOS (e.g., isomalto-oligosaccharides, IMOs) are commercially produced via enzymatic processes, which face the challenges of low yield and high cost.
36869469	8	84	used	utilized	1485:1492	arg2	GlcOS					1472:1476	the GlcOS	1468:1476	the GlcOS	1468:1476	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	8	84	used	utilized	1485:1492	arg2	source					1506:1511	a carbon source	1497:1511	a carbon source for bacterial growth	1497:1532	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	5	85	theme	%	824:824	arg1	yield					812:816	The maximum GlcOS yield	794:816	The maximum GlcOS yield of 83 %	794:824	The maximum GlcOS yield of 83 % was achieved under the optimal condition of 50 % initial glucose loading, 76 % H2SO4, 70 °C, and 20 min.
36869469	1	86	with	ingredients	292:302	arg1	properties					326:335	health-promoting properties	309:335	health-promoting properties	309:335	Glucose-based short-chain oligosaccharides (gluco-oligosaccharides, GlcOS) have been established as functional food ingredients with health-promoting properties.
36869469	6	87	theme	%	1088:1088	arg1	DP					1101:1102	46 % DP 2, 22 % DP 3, 12 % DP 4	1074:1104	DP	1101:1102	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	87	theme	%	1088:1088	arg1	2					1065:1065	2	1065:1065	2	1065:1065	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	3	88	theme	efficient	522:530	arg1	technologies					532:543	efficient technologies	522:543	efficient technologies for large-scale production of prebiotic GlcOS	522:589	Therefore, developing efficient technologies for large-scale production of prebiotic GlcOS is highly desirable.
36869469	7	89	theme	bifidum	1341:1347	arg1	subsp					1386:1390	Bifidobacterium animalis subsp	1361:1390	Bifidobacterium animalis subsp	1361:1390	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	7	89	theme	bifidum	1341:1347	arg1	ATCC					1349:1352	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	8	90	theme	reuteri	1435:1441	arg1	ATCC					1443:1446	Limosilactobacillus reuteri ATCC 6475	1415:1451	Limosilactobacillus reuteri ATCC 6475	1415:1451	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	7	91	theme	probiotic	1315:1323	arg1	subsp					1386:1390	Bifidobacterium animalis subsp	1361:1390	Bifidobacterium animalis subsp	1361:1390	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	7	91	theme	probiotic	1315:1323	arg1	ATCC					1349:1352	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	probiotic Bifidobacterium bifidum ATCC 29521	1315:1358	In vitro fermentation experiments by probiotic Bifidobacterium bifidum ATCC 29521, Bifidobacterium animalis subsp.
36869469	6	92	theme	DP	1079:1080	arg1	DP					1101:1102	46 % DP 2, 22 % DP 3, 12 % DP 4	1074:1104	DP	1101:1102	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	6	92	theme	DP	1079:1080	arg1	2					1065:1065	2	1065:1065	2	1065:1065	Structural analysis revealed that the synthesized GlcOS are mainly short-chain oligomers with a degree of polymerization (DP) between 2 and 4 (46 % DP 2, 22 % DP 3, 12 % DP 4) and a small percentage of larger oligosaccharides (DP 5-9), which are linked by predominantly α- and β-(1→6) linkages along with (1→4), (1→ 3), (1→2), and (1↔1) linkages.
36869469	8	93	theme	carbon	1499:1504	arg1	source					1506:1511	a carbon source	1497:1511	a carbon source for bacterial growth	1497:1532	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36869469	8	93	theme	carbon	1499:1504	arg1	GlcOS					1472:1476	the GlcOS	1468:1476	the GlcOS	1468:1476	lactis DSM 10140, and Limosilactobacillus reuteri ATCC 6475 indicated that the GlcOS can be utilized as a carbon source for bacterial growth, and their promotion effect was overall comparable to three commercial prebiotic IMOs.
36080458	0	0	from	Analysis	20:27	arg1	BCG					98:100	the Mycobacterium Bovis BCG	74:100	the Mycobacterium Bovis BCG	74:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	6	1	theme	stronger	1021:1028	arg1	effects					1030:1036	similar or stronger effects	1010:1036	similar or stronger effects	1010:1036	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	6	2	dep	mediators	900:908	arg1	NO					911:912	NO	911:912	NO	911:912	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	0	3	theme	Bovis	92:96	arg1	BCG					98:100	the Mycobacterium Bovis BCG	74:100	the Mycobacterium Bovis BCG	74:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	4	4	theme	NMR	571:573	arg1	data					575:578	NMR data	571:578	NMR data	571:578	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	3	5	dep	polysaccharides	407:421	arg1	BCG-2					434:438	BCG-2	434:438	BCG-2	434:438	Herein, two polysaccharides (BCG-1 and BCG-2) were purified and their structures were characterized.
36080458	3	5	dep	polysaccharides	407:421	arg1	BCG-1					424:428	BCG-1	424:428	BCG-1	424:428	Herein, two polysaccharides (BCG-1 and BCG-2) were purified and their structures were characterized.
36080458	3	5	dep	polysaccharides	407:421	arg1	polysaccharides					407:421	two polysaccharides	403:421	two polysaccharides (BCG-1 and BCG-2)	403:439	Herein, two polysaccharides (BCG-1 and BCG-2) were purified and their structures were characterized.
36080458	4	6	theme	α-D-	619:622	arg1	1→4					624:626	1→4	624:626	1→4	624:626	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	6	theme	α-D-	619:622	arg1	BCG-2					605:609	BCG-2	605:609	BCG-2	605:609	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	6	theme	α-D-	619:622	arg1	BCG-1					595:599	BCG-1	595:599	BCG-1	595:599	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	6	theme	α-D-	619:622	arg1	-mannan					628:634	an α-D-(1→4)-mannan	616:634	an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches	616:713	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	5	7	from	BCG-PSN	754:760	arg1	mannan					742:747	the mannan	738:747	the mannan from BCG-PSN	738:760	Herein, the mannan from BCG-PSN was first reported.
36080458	6	8	theme	Bioactivity	782:792	arg1	assays					794:799	Bioactivity assays	782:799	Bioactivity assays	782:799	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	2	9	theme	potential	308:316	arg1	efficacy					334:341	potential pharmacological efficacy	308:341	potential pharmacological efficacy	308:341	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	6	10	dep	NO	911:912	arg1	IL-1β					928:932	IL-1β	928:932	IL-1β	928:932	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	6	10	dep	NO	911:912	arg1	IL-10					939:943	IL-10	939:943	IL-10	939:943	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	6	10	dep	NO	911:912	arg1	IL-6					922:925	IL-6	922:925	IL-6	922:925	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	6	10	dep	NO	911:912	arg1	TNF-α					915:919	TNF-α	915:919	TNF-α	915:919	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	7	11	theme	active	1131:1136	arg1	BCG-2					1105:1109	BCG-2	1105:1109	BCG-2	1105:1109	These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.
36080458	7	11	theme	active	1131:1136	arg1	BCG-1					1095:1099	BCG-1	1095:1099	BCG-1	1095:1099	These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.
36080458	7	11	theme	active	1131:1136	arg1	ingredients					1138:1148	the active ingredients	1127:1148	the active ingredients of BCG-PSN	1127:1159	These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.
36080458	4	12	dep	-glucan	680:686	arg1	1→4					676:678	1→4	676:678	1→4	676:678	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	13	theme	composition	511:521	arg1	analysis					523:530	Monosaccharide composition analysis	496:530	Monosaccharide composition analysis combined with methylation analysis and NMR data	496:578	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	2	14	from	BCG-PSN	371:377	arg1	efficacy					334:341	potential pharmacological efficacy	308:341	potential pharmacological efficacy	308:341	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	2	14	from	BCG-PSN	371:377	arg1	polysaccharides					350:364	the polysaccharides	346:364	the polysaccharides from BCG-PSN	346:377	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	2	14	from	BCG-PSN	371:377	arg1	characteristics					288:302	the structural characteristics	273:302	the structural characteristics	273:302	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	6	15	theme	similar	1010:1016	arg1	effects					1030:1036	similar or stronger effects	1010:1036	similar or stronger effects	1010:1036	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	6	16	from	production	873:882	arg1	cells					993:997	RAW264.7 cells	984:997	RAW264.7 cells	984:997	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	2	17	theme	structural	277:286	arg1	characteristics					288:302	the structural characteristics	273:302	the structural characteristics	273:302	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	1	18	theme	Mycobacterium	186:198	arg1	bovis					200:204	Mycobacterium bovis	186:204	Mycobacterium bovis	186:204	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	0	19	theme	Structural	9:18	arg1	Analysis					20:27	Detailed Structural Analysis	0:27	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG	0:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	7	20	theme	BCG-PSN	1153:1159	arg1	BCG-2					1105:1109	BCG-2	1105:1109	BCG-2	1105:1109	These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.
36080458	7	20	theme	BCG-PSN	1153:1159	arg1	BCG-1					1095:1099	BCG-1	1095:1099	BCG-1	1095:1099	These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.
36080458	7	20	theme	BCG-PSN	1153:1159	arg1	ingredients					1138:1148	the active ingredients	1127:1148	the active ingredients of BCG-PSN	1127:1159	These data suggest that BCG-1 and BCG-2 are very likely the active ingredients of BCG-PSN.
36080458	0	21	theme	Detailed	0:7	arg1	Analysis					20:27	Detailed Structural Analysis	0:27	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG	0:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	1	22	theme	Bacillus	103:110	arg1	acid					155:158	nucleic acid	147:158	nucleic acid (BCG-PSN)	147:168	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	22	theme	Bacillus	103:110	arg1	medicine					230:237	an immunoregulatory medicine	210:237	an immunoregulatory medicine commonly used in clinic	210:261	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	22	theme	Bacillus	103:110	arg1	polysaccharide					128:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	4	23	theme	α-D-	671:674	arg1	-glucan					680:686	an α-D-(1→4)-glucan	668:686	an α-D-(1→4)-glucan	668:686	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	24	theme	methylation	546:556	arg1	analysis					558:565	methylation analysis	546:565	methylation analysis	546:565	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	1	25	theme	Calmette-Guérin	112:126	arg1	acid					155:158	nucleic acid	147:158	nucleic acid (BCG-PSN)	147:168	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	25	theme	Calmette-Guérin	112:126	arg1	medicine					230:237	an immunoregulatory medicine	210:237	an immunoregulatory medicine commonly used in clinic	210:261	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	25	theme	Calmette-Guérin	112:126	arg1	polysaccharide					128:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	4	26	theme	-linked	646:652	arg1	branches					654:661	-linked branches	646:661	(1→2)-linked branches	641:661	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	0	27	from	BCG	98:100	arg1	Analysis					20:27	Detailed Structural Analysis	0:27	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG	0:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	0	27	from	BCG	98:100	arg1	Polysaccharides					53:67	the Immunoregulatory Polysaccharides	32:67	the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG	32:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	2	28	theme	pharmacological	318:332	arg1	efficacy					334:341	potential pharmacological efficacy	308:341	potential pharmacological efficacy	308:341	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	6	29	theme	RAW264.7	984:991	arg1	cells					993:997	RAW264.7 cells	984:997	RAW264.7 cells	984:997	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	0	30	theme	Immunoregulatory	36:51	arg1	Polysaccharides					53:67	the Immunoregulatory Polysaccharides	32:67	the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG	32:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	6	31	dep	increased	859:867	arg1	both					1000:1003	both	1000:1003	both	1000:1003	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	1	32	theme	immunoregulatory	213:228	arg1	acid					155:158	nucleic acid	147:158	nucleic acid (BCG-PSN)	147:168	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	32	theme	immunoregulatory	213:228	arg1	polysaccharide					128:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	32	theme	immunoregulatory	213:228	arg1	medicine					230:237	an immunoregulatory medicine	210:237	an immunoregulatory medicine commonly used in clinic	210:261	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	4	33	theme	Monosaccharide	496:509	arg1	analysis					523:530	Monosaccharide composition analysis	496:530	Monosaccharide composition analysis combined with methylation analysis and NMR data	496:578	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	34	dep	branches	654:661	arg1	1→2					642:644	1→2	642:644	1→2	642:644	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	6	35	theme	expressions	969:979	arg1	production					873:882	the production	869:882	the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells	869:997	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	0	36	theme	Polysaccharides	53:67	arg1	Analysis					20:27	Detailed Structural Analysis	0:27	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG	0:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	6	37	theme	mediators	900:908	arg1	production					873:882	the production	869:882	the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells	869:997	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	4	38	with	-mannan	628:634	arg1	-glucan					680:686	an α-D-(1→4)-glucan	668:686	an α-D-(1→4)-glucan	668:686	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	38	with	-mannan	628:634	arg1	branches					654:661	-linked branches	646:661	(1→2)-linked branches	641:661	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	4	38	with	-mannan	628:634	arg1	branches					706:713	(1→6)-linked branches	693:713	(1→6)-linked branches	693:713	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	1	39	theme	nucleic	147:153	arg1	acid					155:158	nucleic acid	147:158	nucleic acid (BCG-PSN)	147:168	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	39	theme	nucleic	147:153	arg1	polysaccharide					128:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide	103:141	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	39	theme	nucleic	147:153	arg1	BCG-PSN					161:167	BCG-PSN	161:167	BCG-PSN	161:167	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	1	39	theme	nucleic	147:153	arg1	medicine					230:237	an immunoregulatory medicine	210:237	an immunoregulatory medicine commonly used in clinic	210:261	Bacillus Calmette-Guérin polysaccharide and nucleic acid (BCG-PSN), extracted from Mycobacterium bovis, is an immunoregulatory medicine commonly used in clinic.
36080458	2	40	from	characteristics	288:302	arg1	BCG-PSN					371:377	BCG-PSN	371:377	BCG-PSN	371:377	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	4	41	theme	-linked	698:704	arg1	branches					706:713	(1→6)-linked branches	693:713	(1→6)-linked branches	693:713	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	6	42	theme	mRNA	964:967	arg1	expressions					969:979	their mRNA expressions	958:979	their mRNA expressions	958:979	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	4	43	link	-linked	698:704	arg1	branches					706:713	(1→6)-linked branches	693:713	(1→6)-linked branches	693:713	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	2	44	theme	polysaccharides	350:364	arg1	efficacy					334:341	potential pharmacological efficacy	308:341	potential pharmacological efficacy	308:341	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	2	44	theme	polysaccharides	350:364	arg1	characteristics					288:302	the structural characteristics	273:302	the structural characteristics	273:302	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36080458	6	45	theme	BCG-PSN	1052:1058	arg1	injection					1060:1068	BCG-PSN injection	1052:1068	BCG-PSN injection	1052:1068	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	0	46	theme	Mycobacterium	78:90	arg1	BCG					98:100	the Mycobacterium Bovis BCG	74:100	the Mycobacterium Bovis BCG	74:100	Detailed Structural Analysis of the Immunoregulatory Polysaccharides from the Mycobacterium Bovis BCG.
36080458	4	47	link	-linked	646:652	arg1	branches					654:661	-linked branches	646:661	(1→2)-linked branches	641:661	Monosaccharide composition analysis combined with methylation analysis and NMR data indicated that BCG-1 and BCG-2 were an α-D-(1→4)-mannan with (1→2)-linked branches, and an α-D-(1→4)-glucan with (1→6)-linked branches, respectively.
36080458	6	48	theme	inflammatory	887:898	arg1	mediators					900:908	inflammatory mediators	887:908	inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10)	887:944	Bioactivity assays showed that BCG-1 and BCG-2 dose-dependently and potently increased the production of inflammatory mediators (NO, TNF-α, IL-6, IL-1β, and IL-10), as well as their mRNA expressions in RAW264.7 cells; both have similar or stronger effects compared with BCG-PSN injection.
36080458	2	49	from	efficacy	334:341	arg1	BCG-PSN					371:377	BCG-PSN	371:377	BCG-PSN	371:377	However, the structural characteristics and potential pharmacological efficacy of the polysaccharides from BCG-PSN remain unclear.
36009354	11	0	theme	alterations	1677:1687	arg1	predominance					1649:1660	a strong predominance	1640:1660	a strong predominance of copy number alterations	1640:1687	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	2	1	theme	Complex	173:179	arg1	machinery					181:189	Complex machinery	173:189	Complex machinery	173:189	Complex machinery establishes the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications.
36009354	9	2	theme	co-expressed	1295:1306	arg1	genes					1308:1312	tightly co-expressed genes	1287:1312	tightly co-expressed genes	1287:1312	In addition, clusters of tightly co-expressed genes suggest a glycosylation code underlying tissue identity.
36009354	6	3	link	lipid-linked	845:856	arg1	glycosylation					858:870	lipid-linked glycosylation	845:870	lipid-linked glycosylation	845:870	These were categorized as involved in N-, O- and lipid-linked glycosylation, glypiation, and glycosaminoglycan synthesis.
36009354	5	4	theme	human	680:684	arg1	transferases					719:730	transferases	719:730	transferases	719:730	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	5	4	theme	human	680:684	arg1	hydrolases					733:742	hydrolases	733:742	hydrolases	733:742	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	5	4	theme	human	680:684	arg1	factors					700:706	human glycosylation factors	680:706	human glycosylation factors	680:706	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	5	4	theme	human	680:684	arg1	genes					754:758	other genes	748:758	other genes directly involved in glycosylation	748:793	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	6	5	theme	lipid-linked	845:856	arg1	glycosylation					858:870	lipid-linked glycosylation	845:870	lipid-linked glycosylation	845:870	These were categorized as involved in N-, O- and lipid-linked glycosylation, glypiation, and glycosaminoglycan synthesis.
36009354	0	6	theme	Concerted	0:8	arg1	Regulation					10:19	Concerted Regulation	0:19	Concerted Regulation of Glycosylation Factors	0:44	Concerted Regulation of Glycosylation Factors Sustains Tissue Identity and Function.
36009354	5	7	theme	factors	700:706	arg1	catalogue					667:675	a catalogue	665:675	a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation	665:793	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	12	8	theme	distinct	1755:1762	arg1	compositions					1773:1784	distinct cellular compositions	1755:1784	distinct cellular compositions of the tumor microenvironment	1755:1814	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	9	9	theme	underlying	1343:1352	arg1	identity					1361:1368	underlying tissue identity	1343:1368	underlying tissue identity	1343:1368	In addition, clusters of tightly co-expressed genes suggest a glycosylation code underlying tissue identity.
36009354	13	10	theme	glycosylation	1948:1960	arg1	machinery					1962:1970	the glycosylation machinery	1944:1970	the glycosylation machinery	1944:1970	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	3	11	theme	temporal	366:373	arg1	diversity					375:383	spatial and temporal diversity	354:383	spatial and temporal diversity	354:383	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	4	12	theme	genome	508:513	arg1	profiles					533:540	genome and transcriptome profiles	508:540	genome and transcriptome profiles of healthy and diseased tissues	508:572	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	2	13	theme	greater	254:260	arg1	diversity					273:281	greater structural diversity	254:281	greater structural diversity than other post-translational modifications	254:325	Complex machinery establishes the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications.
36009354	3	14	theme	spatial	354:360	arg1	diversity					375:383	spatial and temporal diversity	354:383	spatial and temporal diversity	354:383	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	7	15	theme	lipid	1115:1119	arg1	glycosylation					1121:1133	O-linked and lipid glycosylation	1102:1133	glycosylation	1121:1133	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	3	16	from	evolution	390:398	arg1	level					453:457	the tissue-specific level	433:457	the tissue-specific level	433:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	13	17	theme	therapeutic	2114:2124	arg1	roles					2080:2084	novel potential roles	2064:2084	novel potential roles	2064:2084	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	13	17	theme	therapeutic	2114:2124	arg1	targets					2126:2132	therapeutic targets	2114:2132	therapeutic targets	2114:2132	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	2	18	theme	other	288:292	arg1	modifications					313:325	other post-translational modifications	288:325	other post-translational modifications	288:325	Complex machinery establishes the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications.
36009354	8	19	theme	human	1177:1181	arg1	tissues					1183:1189	30 healthy human tissues	1166:1189	30 healthy human tissues	1166:1189	The transcriptome profiles of 30 healthy human tissues revealed tissue-specific expression patterns preserved across mammals.
36009354	12	20	theme	glycosylation	1700:1712	arg1	dysregulation					1721:1733	glycosylation factor dysregulation	1700:1733	glycosylation factor dysregulation	1700:1733	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	13	21	theme	potential	2070:2078	arg1	roles					2080:2084	novel potential roles	2064:2084	novel potential roles	2064:2084	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	13	21	theme	potential	2070:2078	arg1	biomarkers					2100:2109	prognostic biomarkers	2089:2109	prognostic biomarkers	2089:2109	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	13	21	theme	potential	2070:2078	arg1	targets					2126:2132	therapeutic targets	2114:2132	therapeutic targets	2114:2132	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	7	22	theme	large	1048:1052	arg1	duplications					1059:1070	large gene duplications	1048:1070	large gene duplications	1048:1070	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	9	23	dep	suggest	1314:1320	arg1	code					1338:1341	code	1338:1341	suggest a glycosylation code underlying tissue identity	1314:1368	In addition, clusters of tightly co-expressed genes suggest a glycosylation code underlying tissue identity.
36009354	4	24	theme	tissues	566:572	arg1	profiles					533:540	genome and transcriptome profiles	508:540	genome and transcriptome profiles of healthy and diseased tissues	508:572	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	11	25	theme	copy	1665:1668	arg1	alterations					1677:1687	copy number alterations	1665:1687	copy number alterations	1665:1687	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	11	26	theme	strong	1642:1647	arg1	predominance					1649:1660	a strong predominance	1640:1660	a strong predominance of copy number alterations	1640:1687	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	3	27	theme	glycosylation	403:415	arg1	evolution					390:398	the evolution	386:398	the evolution of glycosylation and its role at the tissue-specific level	386:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	4	28	theme	transcriptome	519:531	arg1	profiles					533:540	genome and transcriptome profiles	508:540	genome and transcriptome profiles of healthy and diseased tissues	508:572	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	10	29	theme	tissue-specific	1423:1437	arg1	profiles					1439:1446	tissue-specific profiles	1423:1446	tissue-specific profiles varying with age	1423:1463	Interestingly, several glycosylation factors showed tissue-specific profiles varying with age, suggesting a role in ageing-related disorders.
36009354	3	30	theme	tissue-specific	437:451	arg1	level					453:457	the tissue-specific level	433:457	the tissue-specific level	433:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	4	31	from	role	617:620	arg1	humans					642:647	humans	642:647	humans	642:647	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	7	32	theme	genes	999:1003	arg1	family					989:994	an ancient family	978:994	an ancient family	978:994	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	12	33	theme	tumor	1793:1797	arg1	microenvironment					1799:1814	the tumor microenvironment	1789:1814	the tumor microenvironment	1789:1814	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	10	34	from	role	1479:1482	arg1	disorders					1502:1510	ageing-related disorders	1487:1510	ageing-related disorders	1487:1510	Interestingly, several glycosylation factors showed tissue-specific profiles varying with age, suggesting a role in ageing-related disorders.
36009354	11	35	theme	number	1670:1675	arg1	alterations					1677:1687	copy number alterations	1665:1687	copy number alterations	1665:1687	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	1	36	theme	cellular	116:123	arg1	process					125:131	a fundamental cellular process	102:131	a fundamental cellular process affecting human development and health	102:170	Glycosylation is a fundamental cellular process affecting human development and health.
36009354	1	36	theme	cellular	116:123	arg1	Glycosylation					85:97	Glycosylation	85:97	Glycosylation	85:97	Glycosylation is a fundamental cellular process affecting human development and health.
36009354	0	37	theme	Factors	38:44	arg1	Regulation					10:19	Concerted Regulation	0:19	Concerted Regulation of Glycosylation Factors	0:44	Concerted Regulation of Glycosylation Factors Sustains Tissue Identity and Function.
36009354	3	38	gly	glycosylation	403:415	arg1	level					453:457	the tissue-specific level	433:457	the tissue-specific level	433:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	3	38	gly	glycosylation	403:415	arg2	level					453:457	the tissue-specific level	433:457	the tissue-specific level	433:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	0	39	theme	Tissue	55:60	arg1	Identity					62:69	Tissue Identity	55:69	Tissue Identity	55:69	Concerted Regulation of Glycosylation Factors Sustains Tissue Identity and Function.
36009354	8	40	theme	expression	1216:1225	arg1	patterns					1227:1234	tissue-specific expression patterns	1200:1234	tissue-specific expression patterns preserved across mammals	1200:1259	The transcriptome profiles of 30 healthy human tissues revealed tissue-specific expression patterns preserved across mammals.
36009354	6	41	theme	glycosaminoglycan	889:905	arg1	synthesis					907:915	glycosaminoglycan synthesis	889:915	glycosaminoglycan synthesis	889:915	These were categorized as involved in N-, O- and lipid-linked glycosylation, glypiation, and glycosaminoglycan synthesis.
36009354	10	42	theme	glycosylation	1394:1406	arg1	factors					1408:1414	several glycosylation factors	1386:1414	several glycosylation factors	1386:1414	Interestingly, several glycosylation factors showed tissue-specific profiles varying with age, suggesting a role in ageing-related disorders.
36009354	7	43	theme	ancient	981:987	arg1	family					989:994	an ancient family	978:994	an ancient family	978:994	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	13	44	theme	healthy	1996:2002	arg1	tissues					2004:2010	healthy tissues	1996:2010	healthy tissues	1996:2010	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	10	45	theme	ageing-related	1487:1500	arg1	disorders					1502:1510	ageing-related disorders	1487:1510	ageing-related disorders	1487:1510	Interestingly, several glycosylation factors showed tissue-specific profiles varying with age, suggesting a role in ageing-related disorders.
36009354	4	46	theme	glycosylation	625:637	arg1	role					617:620	the complex role	605:620	the complex role of glycosylation in humans	605:647	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	11	47	theme	glycosylation	1551:1563	arg1	factors					1565:1571	glycosylation factors	1551:1571	glycosylation factors	1551:1571	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	7	48	theme	glycosylation	945:957	arg1	factors					959:965	these glycosylation factors	939:965	these glycosylation factors	939:965	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	9	49	theme	genes	1308:1312	arg1	clusters					1275:1282	clusters	1275:1282	clusters of tightly co-expressed genes	1275:1312	In addition, clusters of tightly co-expressed genes suggest a glycosylation code underlying tissue identity.
36009354	13	50	theme	genome-wide	1918:1928	arg1	evidence					1930:1937	genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis	1918:2051	genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis	1918:2051	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	5	51	theme	glycosylation	686:698	arg1	transferases					719:730	transferases	719:730	transferases	719:730	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	5	51	theme	glycosylation	686:698	arg1	hydrolases					733:742	hydrolases	733:742	hydrolases	733:742	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	5	51	theme	glycosylation	686:698	arg1	factors					700:706	human glycosylation factors	680:706	human glycosylation factors	680:706	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	5	51	theme	glycosylation	686:698	arg1	genes					754:758	other genes	748:758	other genes directly involved in glycosylation	748:793	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	12	52	theme	cellular	1764:1771	arg1	compositions					1773:1784	distinct cellular compositions	1755:1784	distinct cellular compositions of the tumor microenvironment	1755:1814	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	9	53	theme	tissue	1354:1359	arg1	identity					1361:1368	underlying tissue identity	1343:1368	underlying tissue identity	1343:1368	In addition, clusters of tightly co-expressed genes suggest a glycosylation code underlying tissue identity.
36009354	10	54	theme	several	1386:1392	arg1	factors					1408:1414	several glycosylation factors	1386:1414	several glycosylation factors	1386:1414	Interestingly, several glycosylation factors showed tissue-specific profiles varying with age, suggesting a role in ageing-related disorders.
36009354	2	55	theme	structural	262:271	arg1	diversity					273:281	greater structural diversity	254:281	greater structural diversity than other post-translational modifications	254:325	Complex machinery establishes the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications.
36009354	7	56	theme	O-linked	1102:1109	arg1	glycosylation					1121:1133	O-linked and lipid glycosylation	1102:1133	glycosylation	1121:1133	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	9	57	gly	glycosylation	1324:1336	arg1	addition					1265:1272	addition	1265:1272	addition	1265:1272	In addition, clusters of tightly co-expressed genes suggest a glycosylation code underlying tissue identity.
36009354	13	58	theme	prognostic	2089:2098	arg1	roles					2080:2084	novel potential roles	2064:2084	novel potential roles	2064:2084	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	13	58	theme	prognostic	2089:2098	arg1	biomarkers					2100:2109	prognostic biomarkers	2089:2109	prognostic biomarkers	2089:2109	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	7	59	link	O-linked	1102:1109	arg1	glycosylation					1121:1133	O-linked and lipid glycosylation	1102:1133	glycosylation	1121:1133	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	5	60	theme	other	748:752	arg1	genes					754:758	other genes	748:758	other genes directly involved in glycosylation	748:793	We constructed a catalogue of human glycosylation factors, including transferases, hydrolases and other genes directly involved in glycosylation.
36009354	1	61	theme	human	143:147	arg1	development					149:159	human development	143:159	human development	143:159	Glycosylation is a fundamental cellular process affecting human development and health.
36009354	12	62	theme	immune	1875:1880	arg1	system					1882:1887	the immune system	1871:1887	the immune system	1871:1887	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	11	63	theme	transcriptome	1613:1625	arg1	levels					1627:1632	the genome and transcriptome levels	1598:1632	the genome and transcriptome levels	1598:1632	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	2	64	theme	post-translational	294:311	arg1	modifications					313:325	other post-translational modifications	288:325	other post-translational modifications	288:325	Complex machinery establishes the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications.
36009354	12	65	theme	factor	1714:1719	arg1	dysregulation					1721:1733	glycosylation factor dysregulation	1700:1733	glycosylation factor dysregulation	1700:1733	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	4	66	theme	diseased	557:564	arg1	tissues					566:572	healthy and diseased tissues	545:572	healthy and diseased tissues	545:572	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	11	67	dep	genome	1602:1607	arg1	the					1598:1600	the	1598:1600	the	1598:1600	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	13	68	theme	novel	2064:2068	arg1	roles					2080:2084	novel potential roles	2064:2084	novel potential roles	2064:2084	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	13	68	theme	novel	2064:2068	arg1	biomarkers					2100:2109	prognostic biomarkers	2089:2109	prognostic biomarkers	2089:2109	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	13	68	theme	novel	2064:2068	arg1	targets					2126:2132	therapeutic targets	2114:2132	therapeutic targets	2114:2132	Overall, this work provides genome-wide evidence that the glycosylation machinery is tightly regulated in healthy tissues and impaired in ageing and tumorigenesis, unveiling novel potential roles as prognostic biomarkers or therapeutic targets.
36009354	12	69	theme	glycosylation	1843:1855	arg1	impact					1833:1838	the impact	1829:1838	the impact of glycosylation in modulating the immune system	1829:1887	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	7	70	theme	gene	1054:1057	arg1	duplications					1059:1070	large gene duplications	1048:1070	large gene duplications	1048:1070	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	3	71	theme	role	425:428	arg1	evolution					390:398	the evolution	386:398	the evolution of glycosylation and its role at the tissue-specific level	386:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	8	72	theme	transcriptome	1140:1152	arg1	profiles					1154:1161	The transcriptome profiles	1136:1161	The transcriptome profiles of 30 healthy human tissues	1136:1189	The transcriptome profiles of 30 healthy human tissues revealed tissue-specific expression patterns preserved across mammals.
36009354	4	73	theme	healthy	545:551	arg1	tissues					566:572	healthy and diseased tissues	545:572	healthy and diseased tissues	545:572	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	3	74	from	level	453:457	arg1	evolution					390:398	the evolution	386:398	the evolution of glycosylation and its role at the tissue-specific level	386:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	3	74	from	level	453:457	arg1	glycosylation					403:415	glycosylation	403:415	glycosylation	403:415	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	3	74	from	level	453:457	arg1	role					425:428	its role	421:428	its role at the tissue-specific level	421:457	Although known to present spatial and temporal diversity, the evolution of glycosylation and its role at the tissue-specific level is poorly understood.
36009354	7	75	theme	evolutionary	1012:1023	arg1	constraints					1025:1035	evolutionary constraints	1012:1035	evolutionary constraints	1012:1035	Our data showed that these glycosylation factors constitute an ancient family of genes, where evolutionary constraints suppressed large gene duplications, except for genes involved in O-linked and lipid glycosylation.
36009354	4	76	theme	complex	609:615	arg1	role					617:620	the complex role	605:620	the complex role of glycosylation in humans	605:647	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	11	77	theme	genome	1602:1607	arg1	levels					1627:1632	the genome and transcriptome levels	1598:1632	the genome and transcriptome levels	1598:1632	In cancer, our analysis revealed that glycosylation factors are highly perturbed, at the genome and transcriptome levels, with a strong predominance of copy number alterations.
36009354	0	78	theme	Glycosylation	24:36	arg1	Factors					38:44	Glycosylation Factors	24:44	Glycosylation Factors	24:44	Concerted Regulation of Glycosylation Factors Sustains Tissue Identity and Function.
36009354	8	79	theme	healthy	1169:1175	arg1	tissues					1183:1189	30 healthy human tissues	1166:1189	30 healthy human tissues	1166:1189	The transcriptome profiles of 30 healthy human tissues revealed tissue-specific expression patterns preserved across mammals.
36009354	1	80	theme	fundamental	104:114	arg1	process					125:131	a fundamental cellular process	102:131	a fundamental cellular process affecting human development and health	102:170	Glycosylation is a fundamental cellular process affecting human development and health.
36009354	1	80	theme	fundamental	104:114	arg1	Glycosylation					85:97	Glycosylation	85:97	Glycosylation	85:97	Glycosylation is a fundamental cellular process affecting human development and health.
36009354	2	81	theme	glycan	207:212	arg1	structures					214:223	the glycan structures	203:223	the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications	203:325	Complex machinery establishes the glycan structures whose heterogeneity provides greater structural diversity than other post-translational modifications.
36009354	8	82	theme	tissues	1183:1189	arg1	profiles					1154:1161	The transcriptome profiles	1136:1161	The transcriptome profiles of 30 healthy human tissues	1136:1189	The transcriptome profiles of 30 healthy human tissues revealed tissue-specific expression patterns preserved across mammals.
36009354	12	83	theme	microenvironment	1799:1814	arg1	compositions					1773:1784	distinct cellular compositions	1755:1784	distinct cellular compositions of the tumor microenvironment	1755:1814	Moreover, glycosylation factor dysregulation was associated with distinct cellular compositions of the tumor microenvironment, reinforcing the impact of glycosylation in modulating the immune system.
36009354	4	84	theme	novel	585:589	arg1	insights					591:598	novel insights	585:598	novel insights into the complex role of glycosylation in humans	585:647	In this study, we combined genome and transcriptome profiles of healthy and diseased tissues to uncover novel insights into the complex role of glycosylation in humans.
36009354	8	85	theme	tissue-specific	1200:1214	arg1	patterns					1227:1234	tissue-specific expression patterns	1200:1234	tissue-specific expression patterns preserved across mammals	1200:1259	The transcriptome profiles of 30 healthy human tissues revealed tissue-specific expression patterns preserved across mammals.
36565826	0	0	theme	physio-chemical	111:125	arg1	properties					127:136	ameliorative physio-chemical properties	98:136	ameliorative physio-chemical properties	98:136	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	7	1	theme	flocculating	1126:1137	arg1	ability					1139:1145	obviously improved flocculating ability	1107:1145	obviously improved flocculating ability	1107:1145	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	2	2	theme	carbon	331:336	arg1	MWCNT					348:352	MWCNT	348:352	MWCNT	348:352	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	2	theme	carbon	331:336	arg1	nanotube					338:345	multiwalled carbon nanotube	319:345	multiwalled carbon nanotube (MWCNT)	319:353	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	2	theme	carbon	331:336	arg1	CNMs					278:281	four CNMs	273:281	four CNMs	273:281	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	9	3	theme	CNMs	1428:1431	arg1	application					1413:1423	the application	1409:1423	the application of CNMs	1409:1431	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	0	4	theme	ameliorative	98:109	arg1	properties					127:136	ameliorative physio-chemical properties	98:136	ameliorative physio-chemical properties	98:136	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	3	5	theme	CNMs	616:619	arg1	concentration					582:594	A proper concentration	573:594	A proper concentration (15 mg L-1) of four CNMs	573:619	A proper concentration (15 mg L-1) of four CNMs was chosen for use after a preliminary test.
36565826	3	5	theme	CNMs	616:619	arg1	15 mg L-1					597:605	15 mg L-1	597:605	15 mg L-1	597:605	A proper concentration (15 mg L-1) of four CNMs was chosen for use after a preliminary test.
36565826	2	6	theme	cell	535:538	arg1	culture					540:546	cell culture	535:546	cell culture of Nostoc flagelliforme	535:570	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	7	theme	multiwalled	319:329	arg1	MWCNT					348:352	MWCNT	348:352	MWCNT	348:352	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	7	theme	multiwalled	319:329	arg1	nanotube					338:345	multiwalled carbon nanotube	319:345	multiwalled carbon nanotube (MWCNT)	319:353	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	7	theme	multiwalled	319:329	arg1	CNMs					278:281	four CNMs	273:281	four CNMs	273:281	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	8	8	theme	physio-chemical	1294:1308	arg1	alteration					1319:1328	physio-chemical property alteration	1294:1328	physio-chemical property alteration	1294:1328	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	4	9	theme	nontreated	793:802	arg1	control					804:810	the nontreated control	789:810	the nontreated control	789:810	Upon GO treatment, the biomass was improved by 11.1 % and the EPS production was increased by 36.1 % on day 16 compared to the nontreated control.
36565826	9	10	theme	induced	1440:1446	arg1	production					1448:1457	induced production	1440:1457	induced production	1440:1457	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	8	11	theme	EPS	1337:1339	arg1	alteration					1319:1328	physio-chemical property alteration	1294:1328	physio-chemical property alteration	1294:1328	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	8	11	theme	EPS	1337:1339	arg1	production					1279:1288	production	1279:1288	production	1279:1288	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	5	12	theme	cellular	856:863	arg1	levels					879:884	cellular O2·- and H2O2 levels	856:884	cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities	856:940	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	6	13	theme	CNM	1039:1041	arg1	treatments					1043:1052	the CNM treatments	1035:1052	the CNM treatments	1035:1052	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	7	14	theme	improved	1117:1124	arg1	ability					1139:1145	obviously improved flocculating ability	1107:1145	obviously improved flocculating ability	1107:1145	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	8	15	theme	distinct	1252:1259	arg1	influences					1261:1270	distinct influences	1252:1270	distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture	1252:1367	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	5	16	theme	O2·-	865:868	arg1	levels					879:884	cellular O2·- and H2O2 levels	856:884	cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities	856:940	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	7	17	theme	oxygen	1187:1192	arg1	species					1194:1200	reactive oxygen species	1178:1200	reactive oxygen species scavenging ability	1178:1219	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	3	18	theme	preliminary	648:658	arg1	test					660:663	a preliminary test	646:663	a preliminary test	646:663	A proper concentration (15 mg L-1) of four CNMs was chosen for use after a preliminary test.
36565826	0	19	with	exopolysaccharides	74:91	arg1	properties					127:136	ameliorative physio-chemical properties	98:136	ameliorative physio-chemical properties	98:136	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	9	20	theme	application	1413:1423	arg1	understanding					1392:1404	our understanding	1388:1404	our understanding of the application of CNMs	1388:1431	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	2	21	theme	flagelliforme	558:570	arg1	culture					540:546	cell culture	535:546	cell culture of Nostoc flagelliforme	535:570	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	4	22	dep	increased	747:755	arg1	compared					777:784	compared	777:784	compared to the nontreated control	777:810	Upon GO treatment, the biomass was improved by 11.1 % and the EPS production was increased by 36.1 % on day 16 compared to the nontreated control.
36565826	1	23	theme	algal	204:208	arg1	biotechnology					210:222	algal biotechnology	204:222	algal biotechnology	204:222	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	0	24	theme	nanomaterial-treated	7:26	arg1	cultures					33:40	Carbon nanomaterial-treated cell cultures	0:40	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme	0:64	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	2	25	theme	exopolysaccharide	429:445	arg1	production					453:462	cell growth and exopolysaccharide (EPS) production	413:462	cell growth and exopolysaccharide (EPS) production	413:462	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	26	theme	Nostoc	551:556	arg1	flagelliforme					558:570	Nostoc flagelliforme	551:570	Nostoc flagelliforme	551:570	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	9	27	theme	polysaccharides	1490:1504	arg1	production					1448:1457	induced production	1440:1457	induced production	1440:1457	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	9	27	theme	polysaccharides	1490:1504	arg1	modification					1474:1485	functional modification	1463:1485	functional modification	1463:1485	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	5	28	theme	CNM	818:820	arg1	treatments					822:831	Four CNM treatments	813:831	Four CNM treatments	813:831	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	7	29	theme	GO	1073:1074	arg1	EPS					1096:1098	the GO treatment-resulting EPS	1069:1098	the GO treatment-resulting EPS	1069:1098	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	9	30	dep	production	1448:1457	arg1	the					1436:1438	the	1436:1438	the	1436:1438	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	0	31	theme	Carbon	0:5	arg1	cultures					33:40	Carbon nanomaterial-treated cell cultures	0:40	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme	0:64	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	2	32	theme	graphene	298:305	arg1	CNMs					278:281	four CNMs	273:281	four CNMs	273:281	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	32	theme	graphene	298:305	arg1	oxide					307:311	graphene oxide (GO)	298:316	graphene oxide (GO)	298:316	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	9	33	theme	algal	1513:1517	arg1	cultivation					1519:1529	algal cultivation	1513:1529	algal cultivation	1513:1529	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	8	34	dep	production	1279:1288	arg1	the					1275:1277	the	1275:1277	the	1275:1277	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	1	35	from	efficiency	159:168	arg1	biotechnology					210:222	algal biotechnology	204:222	algal biotechnology	204:222	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	8	36	theme	property	1310:1317	arg1	alteration					1319:1328	physio-chemical property alteration	1294:1328	physio-chemical property alteration	1294:1328	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	2	37	from	influences	259:268	arg1	properties					495:504	the physiochemical properties	476:504	the physiochemical properties of EPS	476:511	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	37	from	influences	259:268	arg1	production					453:462	cell growth and exopolysaccharide (EPS) production	413:462	cell growth and exopolysaccharide (EPS) production	413:462	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	6	38	theme	monosaccharide	947:960	arg1	compositions					962:973	The monosaccharide compositions	943:973	The monosaccharide compositions	943:973	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	0	39	theme	cell	28:31	arg1	cultures					33:40	Carbon nanomaterial-treated cell cultures	0:40	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme	0:64	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	2	40	theme	physiochemical	480:493	arg1	properties					495:504	the physiochemical properties	476:504	the physiochemical properties of EPS	476:511	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	4	41	dep	treatment	674:682	arg1	GO					671:672	GO	671:672	GO	671:672	Upon GO treatment, the biomass was improved by 11.1 % and the EPS production was increased by 36.1 % on day 16 compared to the nontreated control.
36565826	2	42	theme	carbon	381:386	arg1	CNMs					278:281	four CNMs	273:281	four CNMs	273:281	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	42	theme	carbon	381:386	arg1	nanotube					388:395	aminated multiwalled carbon nanotube	360:395	aminated multiwalled carbon nanotube	360:395	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	0	43	theme	Nostoc	45:50	arg1	flagelliforme					52:64	Nostoc flagelliforme	45:64	Nostoc flagelliforme	45:64	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	7	44	theme	treatment-resulting	1076:1094	arg1	EPS					1096:1098	the GO treatment-resulting EPS	1069:1098	the GO treatment-resulting EPS	1069:1098	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	5	45	theme	superoxide	897:906	arg1	dismutase					908:916	superoxide dismutase	897:916	superoxide dismutase	897:916	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	2	46	theme	multiwalled	369:379	arg1	CNMs					278:281	four CNMs	273:281	four CNMs	273:281	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	46	theme	multiwalled	369:379	arg1	nanotube					388:395	aminated multiwalled carbon nanotube	360:395	aminated multiwalled carbon nanotube	360:395	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	47	theme	growth	418:423	arg1	production					453:462	cell growth and exopolysaccharide (EPS) production	413:462	cell growth and exopolysaccharide (EPS) production	413:462	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	5	48	theme	dismutase	908:916	arg1	activities					931:940	superoxide dismutase and catalase activities	897:940	cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities	856:940	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	2	49	theme	aminated	360:367	arg1	CNMs					278:281	four CNMs	273:281	four CNMs	273:281	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	49	theme	aminated	360:367	arg1	nanotube					388:395	aminated multiwalled carbon nanotube	360:395	aminated multiwalled carbon nanotube	360:395	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	50	theme	cell	413:416	arg1	growth					418:423	cell growth	413:423	cell growth	413:423	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	3	51	theme	proper	575:580	arg1	concentration					582:594	A proper concentration	573:594	A proper concentration (15 mg L-1) of four CNMs	573:619	A proper concentration (15 mg L-1) of four CNMs was chosen for use after a preliminary test.
36565826	3	51	theme	proper	575:580	arg1	15 mg L-1					597:605	15 mg L-1	597:605	15 mg L-1	597:605	A proper concentration (15 mg L-1) of four CNMs was chosen for use after a preliminary test.
36565826	4	52	theme	EPS	728:730	arg1	production					732:741	the EPS production	724:741	the EPS production	724:741	Upon GO treatment, the biomass was improved by 11.1 % and the EPS production was increased by 36.1 % on day 16 compared to the nontreated control.
36565826	4	53	from	%	765:765	arg1	day					770:772	day 16	770:775	day 16	770:775	Upon GO treatment, the biomass was improved by 11.1 % and the EPS production was increased by 36.1 % on day 16 compared to the nontreated control.
36565826	0	54	theme	flagelliforme	52:64	arg1	cultures					33:40	Carbon nanomaterial-treated cell cultures	0:40	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme	0:64	Carbon nanomaterial-treated cell cultures of Nostoc flagelliforme produce exopolysaccharides with ameliorative physio-chemical properties.
36565826	9	55	theme	functional	1463:1472	arg1	modification					1474:1485	functional modification	1463:1485	functional modification	1463:1485	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	5	56	theme	catalase	922:929	arg1	activities					931:940	superoxide dismutase and catalase activities	897:940	cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities	856:940	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	7	57	theme	species	1194:1200	arg1	ability					1213:1219	reactive oxygen species scavenging ability	1178:1219	reactive oxygen species scavenging ability	1178:1219	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	7	58	theme	scavenging	1202:1211	arg1	ability					1213:1219	reactive oxygen species scavenging ability	1178:1219	reactive oxygen species scavenging ability	1178:1219	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	2	59	theme	EPS	509:511	arg1	properties					495:504	the physiochemical properties	476:504	the physiochemical properties of EPS	476:511	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	59	theme	EPS	509:511	arg1	production					453:462	cell growth and exopolysaccharide (EPS) production	413:462	cell growth and exopolysaccharide (EPS) production	413:462	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	8	60	theme	N.	1344:1345	arg1	culture					1361:1367	N. flagelliforme culture	1344:1367	N. flagelliforme culture	1344:1367	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	2	61	theme	CNMs	278:281	arg1	influences					259:268	the influences	255:268	the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS,	255:512	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	2	62	dep	oxide	307:311	arg1	GO					314:315	GO	314:315	GO	314:315	In this study, the influences of four CNMs, graphene (G), graphene oxide (GO), multiwalled carbon nanotube (MWCNT), and aminated multiwalled carbon nanotube (MWCNT-NH2), on cell growth and exopolysaccharide (EPS) production, as well as the physiochemical properties of EPS, were investigated in cell culture of Nostoc flagelliforme.
36565826	1	63	from	feasibility	143:153	arg1	biotechnology					210:222	algal biotechnology	204:222	algal biotechnology	204:222	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	5	64	theme	H2O2	874:877	arg1	levels					879:884	cellular O2·- and H2O2 levels	856:884	cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities	856:940	Four CNM treatments significantly improved cellular O2·- and H2O2 levels as well as superoxide dismutase and catalase activities.
36565826	8	65	from	alteration	1319:1328	arg1	culture					1361:1367	N. flagelliforme culture	1344:1367	N. flagelliforme culture	1344:1367	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	1	66	theme	carbon	173:178	arg1	CNMs					195:198	CNMs	195:198	CNMs	195:198	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	1	66	theme	carbon	173:178	arg1	nanomaterials					180:192	carbon nanomaterials	173:192	carbon nanomaterials (CNMs)	173:199	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	8	67	from	influences	1261:1270	arg1	alteration					1319:1328	physio-chemical property alteration	1294:1328	physio-chemical property alteration	1294:1328	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	8	67	from	influences	1261:1270	arg1	production					1279:1288	production	1279:1288	production	1279:1288	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	7	68	theme	reactive	1178:1185	arg1	species					1194:1200	reactive oxygen species	1178:1200	reactive oxygen species scavenging ability	1178:1219	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	8	69	from	production	1279:1288	arg1	culture					1361:1367	N. flagelliforme culture	1344:1367	N. flagelliforme culture	1344:1367	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	9	70	from	expands	1380:1386	arg1	production					1448:1457	induced production	1440:1457	induced production	1440:1457	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	9	70	from	expands	1380:1386	arg1	modification					1474:1485	functional modification	1463:1485	functional modification	1463:1485	This work expands our understanding of the application of CNMs in the induced production and functional modification of polysaccharides during algal cultivation.
36565826	1	71	theme	nanomaterials	180:192	arg1	known					233:237	known	233:237	known	233:237	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	1	71	theme	nanomaterials	180:192	arg1	efficiency					159:168	efficiency	159:168	efficiency	159:168	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	1	71	theme	nanomaterials	180:192	arg1	feasibility					143:153	The feasibility	139:153	The feasibility	139:153	The feasibility and efficiency of carbon nanomaterials (CNMs) in algal biotechnology are less known.
36565826	6	72	theme	functional	979:988	arg1	EPSs					1004:1007	the EPSs	1000:1007	the EPSs	1000:1007	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	6	72	theme	functional	979:988	arg1	groups					990:995	functional groups	979:995	functional groups of the EPSs	979:1007	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	7	73	theme	water	1148:1152	arg1	ability					1165:1171	water absorption ability	1148:1171	water absorption ability	1148:1171	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
36565826	8	74	theme	flagelliforme	1347:1359	arg1	culture					1361:1367	N. flagelliforme culture	1344:1367	N. flagelliforme culture	1344:1367	In general, four CNMs exerted distinct influences on the production and physio-chemical property alteration of the EPS in N. flagelliforme culture.
36565826	6	75	theme	EPSs	1004:1007	arg1	EPSs					1004:1007	the EPSs	1000:1007	the EPSs	1000:1007	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	6	75	theme	EPSs	1004:1007	arg1	compositions					962:973	The monosaccharide compositions	943:973	The monosaccharide compositions	943:973	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	6	75	theme	EPSs	1004:1007	arg1	groups					990:995	functional groups	979:995	functional groups of the EPSs	979:1007	The monosaccharide compositions and functional groups of the EPSs were obviously altered by the CNM treatments.
36565826	7	76	theme	absorption	1154:1163	arg1	ability					1165:1171	water absorption ability	1148:1171	water absorption ability	1148:1171	Particularly, the GO treatment-resulting EPS showed obviously improved flocculating ability, water absorption ability, and reactive oxygen species scavenging ability.
37282868	3	0	theme	chemical	487:494	arg1	modification					496:507	chemical modification	487:507	chemical modification	487:507	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	4	1	theme	relationship	760:771	arg1	progress					704:711	the research progress	691:711	the research progress of structure, function, and structure-activity relationship of LBPs	691:779	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	2	2	theme	neuroprotective	330:344	arg1	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	5	3	theme	value	1032:1036	arg1	LBPs					986:989	LBPs	986:989	LBPs	986:989	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	5	3	theme	value	1032:1036	arg1	exploration					1004:1014	in-depth exploration	995:1014	in-depth exploration of their health value	995:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	5	4	theme	LBPs	986:989	arg1	utilization					971:981	the high value utilization	956:981	the high value utilization of LBPs and in-depth exploration of their health value	956:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	4	5	theme	structure-activity	741:758	arg1	relationship					760:771	structure-activity relationship	741:771	structure-activity relationship	741:771	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	5	6	theme	high	960:963	arg1	utilization					971:981	the high value utilization	956:981	the high value utilization of LBPs and in-depth exploration of their health value	956:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	3	7	theme	LBPs	535:538	arg1	modification					496:507	chemical modification	487:507	chemical modification	487:507	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	composition					422:432	monosaccharide composition	407:432	monosaccharide composition	407:432	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	related					552:558	related	552:558	related	552:558	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	content					478:484	protein content	470:484	protein content	470:484	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	weight					399:404	The molecular weight	385:404	The molecular weight	385:404	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	structure					522:530	spatial structure	514:530	spatial structure	514:530	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	bond					446:449	glycosidic bond	435:449	glycosidic bond	435:449	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	7	theme	LBPs	535:538	arg1	degree					462:467	branching degree	452:467	branching degree	452:467	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	8	theme	protein	470:476	arg1	content					478:484	protein content	470:484	protein content	470:484	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	1	9	theme	traditional	75:85	arg1	fruits					125:130	the fruits	121:130	the fruits of Lycium barbarum	121:149	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	9	theme	traditional	75:85	arg1	herb					95:98	a traditional Chinese herb	73:98	a traditional Chinese herb	73:98	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	3	10	theme	monosaccharide	407:420	arg1	composition					422:432	monosaccharide composition	407:432	monosaccharide composition	407:432	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	1	11	theme	Chinese	87:93	arg1	fruits					125:130	the fruits	121:130	the fruits of Lycium barbarum	121:149	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	11	theme	Chinese	87:93	arg1	herb					95:98	a traditional Chinese herb	73:98	a traditional Chinese herb	73:98	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	3	12	theme	glycosidic	435:444	arg1	bond					446:449	glycosidic bond	435:449	glycosidic bond	435:449	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	5	13	theme	same	789:792	arg1	time					794:797	the same time	785:797	the same time	785:797	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	3	14	theme	spatial	514:520	arg1	structure					522:530	spatial structure	514:530	spatial structure	514:530	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	2	15	theme	prebiotic	363:371	arg1	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	0	16	theme	[Structure-activity	0:18	arg1	relationship					20:31	[Structure-activity relationship	0:31	[Structure-activity relationship of Lycium barbarum polysaccharides	0:66	[Structure-activity relationship of Lycium barbarum polysaccharides].
37282868	2	17	theme	immunomodulatory	285:300	arg1	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	5	18	theme	relationship	870:881	arg1	clarification					830:842	the clarification	826:842	the clarification of the structure-activity relationship of LBPs	826:889	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	0	19	theme	Lycium	36:41	arg1	polysaccharides					52:66	Lycium barbarum polysaccharides	36:66	Lycium barbarum polysaccharides	36:66	[Structure-activity relationship of Lycium barbarum polysaccharides].
37282868	3	20	theme	biological	569:578	arg1	activity					580:587	their biological activity	563:587	their biological activity	563:587	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	1	21	theme	functional	104:113	arg1	fruits					125:130	the fruits	121:130	the fruits of Lycium barbarum	121:149	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	21	theme	functional	104:113	arg1	food					115:118	functional food	104:118	functional food	104:118	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	3	22	theme	branching	452:460	arg1	degree					462:467	branching degree	452:467	branching degree	452:467	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	4	23	theme	structure	716:724	arg1	progress					704:711	the research progress	691:711	the research progress of structure, function, and structure-activity relationship of LBPs	691:779	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	2	24	theme	active	255:260	arg1	components					262:271	predominant active components	243:271	predominant active components	243:271	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	24	theme	active	255:260	arg1	polysaccharides					217:231	L. barbarum polysaccharides	205:231	L. barbarum polysaccharides(LBPs)	205:237	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	4	25	theme	function	727:734	arg1	progress					704:711	the research progress	691:711	the research progress of structure, function, and structure-activity relationship of LBPs	691:779	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	1	26	theme	years	189:193	arg1	thousands					176:184	thousands	176:184	thousands of years in China	176:202	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	0	27	theme	polysaccharides	52:66	arg1	relationship					20:31	[Structure-activity relationship	0:31	[Structure-activity relationship of Lycium barbarum polysaccharides	0:66	[Structure-activity relationship of Lycium barbarum polysaccharides].
37282868	5	28	theme	exploration	1004:1014	arg1	utilization					971:981	the high value utilization	956:981	the high value utilization of LBPs and in-depth exploration of their health value	956:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	4	29	theme	research	628:635	arg1	team					637:640	this research team	623:640	this research team	623:640	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	0	30	theme	barbarum	43:50	arg1	polysaccharides					52:66	Lycium barbarum polysaccharides	36:66	Lycium barbarum polysaccharides	36:66	[Structure-activity relationship of Lycium barbarum polysaccharides].
37282868	5	31	theme	structure-activity	851:868	arg1	relationship					870:881	the structure-activity relationship	847:881	the structure-activity relationship of LBPs	847:889	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	2	32	theme	barbarum	208:215	arg1	components					262:271	predominant active components	243:271	predominant active components	243:271	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	32	theme	barbarum	208:215	arg1	LBPs					233:236	LBPs	233:236	LBPs	233:236	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	32	theme	barbarum	208:215	arg1	polysaccharides					217:231	L. barbarum polysaccharides	205:231	L. barbarum polysaccharides(LBPs)	205:237	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	33	contain	have	280:283	arg1	components					262:271	predominant active components	243:271	predominant active components	243:271	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	33	contain	have	280:283	arg1	polysaccharides					217:231	L. barbarum polysaccharides	205:231	L. barbarum polysaccharides(LBPs)	205:237	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	33	contain	have	280:283	arg2	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	34	theme	L.	205:206	arg1	components					262:271	predominant active components	243:271	predominant active components	243:271	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	34	theme	L.	205:206	arg1	LBPs					233:236	LBPs	233:236	LBPs	233:236	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	34	theme	L.	205:206	arg1	polysaccharides					217:231	L. barbarum polysaccharides	205:231	L. barbarum polysaccharides(LBPs)	205:237	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	1	35	from	China	198:202	arg1	thousands					176:184	thousands	176:184	thousands of years in China	176:202	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	4	36	theme	research	695:702	arg1	progress					704:711	the research progress	691:711	the research progress of structure, function, and structure-activity relationship of LBPs	691:779	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	3	37	theme	molecular	389:397	arg1	related					552:558	related	552:558	related	552:558	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	3	37	theme	molecular	389:397	arg1	weight					399:404	The molecular weight	385:404	The molecular weight	385:404	The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity.
37282868	5	38	theme	health	1025:1030	arg1	value					1032:1036	their health value	1019:1036	their health value	1019:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	1	39	theme	barbarum	142:149	arg1	fruits					125:130	the fruits	121:130	the fruits of Lycium barbarum	121:149	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	39	theme	barbarum	142:149	arg1	herb					95:98	a traditional Chinese herb	73:98	a traditional Chinese herb	73:98	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	39	theme	barbarum	142:149	arg1	food					115:118	functional food	104:118	functional food	104:118	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	2	40	theme	hypoglycemic	316:327	arg1	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	1	41	from	years	189:193	arg1	China					198:202	China	198:202	China	198:202	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	2	42	theme	predominant	243:253	arg1	components					262:271	predominant active components	243:271	predominant active components	243:271	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	2	42	theme	predominant	243:253	arg1	polysaccharides					217:231	L. barbarum polysaccharides	205:231	L. barbarum polysaccharides(LBPs)	205:237	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	4	43	theme	LBPs	776:779	arg1	function					727:734	function	727:734	function	727:734	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	4	43	theme	LBPs	776:779	arg1	structure					716:724	structure	716:724	structure	716:724	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	4	43	theme	LBPs	776:779	arg1	relationship					760:771	structure-activity relationship	741:771	structure-activity relationship	741:771	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	2	44	theme	antioxidant	303:313	arg1	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
37282868	5	45	theme	value	965:969	arg1	utilization					971:981	the high value utilization	956:981	the high value utilization of LBPs and in-depth exploration of their health value	956:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	1	46	used	used	167:170	arg2	food					115:118	functional food	104:118	functional food	104:118	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	46	used	used	167:170	arg2	herb					95:98	a traditional Chinese herb	73:98	a traditional Chinese herb	73:98	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	46	used	used	167:170	arg2	fruits					125:130	the fruits	121:130	the fruits of Lycium barbarum	121:149	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	1	47	from	thousands	176:184	arg1	China					198:202	China	198:202	China	198:202	As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China.
37282868	5	48	theme	LBPs	886:889	arg1	relationship					870:881	the structure-activity relationship	847:881	the structure-activity relationship of LBPs	847:889	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	4	49	theme	team	637:640	arg1	studies					612:618	the previous studies	599:618	the previous studies of this research team	599:640	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	4	50	theme	previous	603:610	arg1	studies					612:618	the previous studies	599:618	the previous studies of this research team	599:640	Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs.
37282868	5	51	theme	in-depth	995:1002	arg1	exploration					1004:1014	in-depth exploration	995:1014	in-depth exploration of their health value	995:1036	At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
37282868	2	52	theme	anti-tumor	347:356	arg1	activities					373:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities	285:382	L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities.
36813338	7	0	dep	structure	1200:1208	arg1	improvement					1247:1257	improvement	1247:1257	improvement	1247:1257	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	2	1	theme	low	403:405	arg1	solubility					407:416	low solubility	403:416	low solubility in cold water	403:430	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	4	2	theme	carrageenan	635:645	arg1	backbone					647:654	the carrageenan backbone	631:654	the carrageenan backbone	631:654	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	4	3	from	interaction	664:674	arg1	systems					693:699	drug delivery systems	679:699	drug delivery systems	679:699	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	6	4	theme	unit	1029:1032	arg1	0.086 g					948:954	0.086 g	948:954	0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83	948:1040	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	7	5	theme	derivatives	1266:1276	arg1	stability					1237:1245	thermal stability	1229:1245	thermal stability	1229:1245	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	7	5	theme	derivatives	1266:1276	arg1	structure					1200:1208	the commercial structure	1185:1208	the commercial structure of carrageenan	1185:1223	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	3	6	theme	substitution	551:562	arg1	degree					532:537	the degree	528:537	the degree of cationic substitution	528:562	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	3	6	theme	substitution	551:562	arg1	solubility					577:586	the film solubility	568:586	the film solubility	568:586	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	0	7	theme	biological	118:127	arg1	properties					129:138	biological properties	118:138	biological properties	118:138	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	6	8	theme	repeating	1019:1027	arg1	unit					1029:1032	sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit	959:1032	unit	1029:1032	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	5	9	theme	Statistical	729:739	arg1	analysis					741:748	Statistical analysis	729:748	Statistical analysis	729:748	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	2	10	theme	non-toxic	337:345	arg1	Carrageenan					299:309	Carrageenan	299:309	Carrageenan	299:309	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	2	10	theme	non-toxic	337:345	arg1	polysaccharide					347:360	a widely available and non-toxic polysaccharide	314:360	a widely available and non-toxic polysaccharide	314:360	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	6	11	theme	solubility	1093:1102	arg1	degree					1059:1064	65.47 % degree	1051:1064	65.47 % degree of substitution and 4.03 % solubility	1051:1102	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	5	12	theme	molar	800:804	arg1	ratio					806:810	only the molar ratio	791:810	only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan	791:893	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	6	13	theme	glycidyltrimethylammonium/disaccharide	980:1017	arg1	unit					1029:1032	sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit	959:1032	unit	1029:1032	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	3	14	theme	cationic	542:549	arg1	substitution					551:562	cationic substitution	542:562	cationic substitution	542:562	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	6	15	theme	%	1091:1091	arg1	solubility					1093:1102	4.03 % solubility	1086:1102	4.03 % solubility	1086:1102	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	7	16	theme	thermal	1229:1235	arg1	stability					1237:1245	thermal stability	1229:1245	thermal stability	1229:1245	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	2	17	theme	available	323:331	arg1	Carrageenan					299:309	Carrageenan	299:309	Carrageenan	299:309	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	2	17	theme	available	323:331	arg1	polysaccharide					347:360	a widely available and non-toxic polysaccharide	314:360	a widely available and non-toxic polysaccharide	314:360	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	0	18	theme	properties	129:138	arg1	investigation					101:113	investigation	101:113	investigation	101:113	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	0	18	theme	properties	129:138	arg1	release					89:95	model-drug release	78:95	model-drug release	78:95	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	6	19	theme	hydroxide	966:974	arg1	0.086 g					948:954	0.086 g	948:954	0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83	948:1040	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	3	20	theme	central	448:454	arg1	experiment					473:482	a central composite design experiment	446:482	a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility	446:586	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	5	21	theme	carrageenan	883:893	arg1	unit					875:878	the repeating disaccharide unit	848:878	the repeating disaccharide unit of carrageenan	848:893	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	5	21	theme	carrageenan	883:893	arg1	reagent					836:842	the cationizing reagent	820:842	the cationizing reagent	820:842	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	6	22	theme	65.47 	1051:1056	arg1	%					1057:1057	%	1057:1057	%	1057:1057	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	6	23	theme	sodium	959:964	arg1	hydroxide					966:974	sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit	959:1032	hydroxide	966:974	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	7	24	theme	carrageenan	1213:1223	arg1	stability					1237:1245	thermal stability	1229:1245	thermal stability	1229:1245	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	7	24	theme	carrageenan	1213:1223	arg1	structure					1200:1208	the commercial structure	1185:1208	the commercial structure of carrageenan	1185:1223	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	6	25	theme	4.03 	1086:1090	arg1	%					1091:1091	%	1091:1091	%	1091:1091	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	3	26	theme	design	466:471	arg1	experiment					473:482	a central composite design experiment	446:482	a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility	446:586	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	4	27	from	groups	621:626	arg1	backbone					647:654	the carrageenan backbone	631:654	the carrageenan backbone	631:654	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	4	28	theme	ammonium	612:619	arg1	groups					621:626	Hydrophilic quaternary ammonium groups	589:626	Hydrophilic quaternary ammonium groups on the carrageenan backbone	589:654	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	2	29	theme	cold	421:424	arg1	water					426:430	cold water	421:430	cold water	421:430	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	0	30	theme	cationization	34:46	arg1	Optimization					0:11	Optimization	0:11	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.	0:139	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	4	31	theme	quaternary	601:610	arg1	groups					621:626	Hydrophilic quaternary ammonium groups	589:626	Hydrophilic quaternary ammonium groups on the carrageenan backbone	589:654	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	5	32	theme	studied	776:782	arg1	range					784:788	the studied range	772:788	the studied range	772:788	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	2	33	from	solubility	407:416	arg1	water					426:430	cold water	421:430	cold water	421:430	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	1	34	theme	permanent	240:248	arg1	charges					259:265	permanent positive charges	240:265	permanent positive charges	240:265	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	0	35	theme	kappa-carrageenan	16:32	arg1	cationization					34:46	kappa-carrageenan cationization	16:46	kappa-carrageenan cationization	16:46	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	6	36	theme	substitution	1069:1080	arg1	degree					1059:1064	65.47 % degree	1051:1064	65.47 % degree of substitution and 4.03 % solubility	1051:1102	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	3	37	theme	film	572:575	arg1	solubility					577:586	the film solubility	568:586	the film solubility	568:586	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	1	38	theme	positive	250:257	arg1	charges					259:265	permanent positive charges	240:265	permanent positive charges	240:265	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	0	39	theme	experimental	54:65	arg1	design					67:72	experimental design	54:72	experimental design	54:72	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	5	40	contain	had	895:897	arg1	ratio					806:810	only the molar ratio	791:810	only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan	791:893	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	5	40	contain	had	895:897	arg2	effect					913:918	a significant effect	899:918	a significant effect	899:918	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	4	41	theme	active	712:717	arg1	surfaces					719:726	active surfaces	712:726	active surfaces	712:726	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	3	42	theme	composite	456:464	arg1	experiment					473:482	a central composite design experiment	446:482	a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility	446:586	We performed a central composite design experiment to check the parameters that most influence the degree of cationic substitution and the film solubility.
36813338	5	43	theme	repeating	852:860	arg1	unit					875:878	the repeating disaccharide unit	848:878	the repeating disaccharide unit of carrageenan	848:893	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	7	44	theme	effective	1137:1145	arg1	incorporation					1147:1159	the effective incorporation	1133:1159	the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives	1133:1276	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	5	45	theme	disaccharide	862:873	arg1	unit					875:878	the repeating disaccharide unit	848:878	the repeating disaccharide unit of carrageenan	848:893	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	6	46	theme	%	1057:1057	arg1	degree					1059:1064	65.47 % degree	1051:1064	65.47 % degree of substitution and 4.03 % solubility	1051:1102	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	7	47	theme	groups	1173:1178	arg1	incorporation					1147:1159	the effective incorporation	1133:1159	the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives	1133:1276	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	5	48	theme	cationizing	824:834	arg1	reagent					836:842	the cationizing reagent	820:842	the cationizing reagent	820:842	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	7	49	theme	commercial	1189:1198	arg1	structure					1200:1208	the commercial structure	1185:1208	the commercial structure of carrageenan	1185:1223	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	4	50	theme	Hydrophilic	589:599	arg1	groups					621:626	Hydrophilic quaternary ammonium groups	589:626	Hydrophilic quaternary ammonium groups on the carrageenan backbone	589:654	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	6	51	theme	Optimized	921:929	arg1	parameters					931:940	Optimized parameters	921:940	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83	921:1040	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	2	52	theme	food	380:383	arg1	industry					385:392	food industry	380:392	food industry	380:392	Carrageenan is a widely available and non-toxic polysaccharide, commonly used in food industry but with low solubility in cold water.
36813338	7	53	theme	cationic	1164:1171	arg1	groups					1173:1178	cationic groups	1164:1178	cationic groups	1164:1178	Characterizations confirmed the effective incorporation of cationic groups into the commercial structure of carrageenan and thermal stability improvement of the derivatives.
36813338	1	54	theme	promising	160:168	arg1	Cationization					141:153	Cationization	141:153	Cationization	141:153	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	1	54	theme	promising	160:168	arg1	technique					192:200	a promising chemical modification technique	158:200	a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers	158:296	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	5	55	theme	significant	901:911	arg1	effect					913:918	a significant effect	899:918	a significant effect	899:918	Statistical analysis indicated that within the studied range, only the molar ratio between the cationizing reagent and the repeating disaccharide unit of carrageenan had a significant effect.
36813338	1	56	theme	chemical	170:177	arg1	Cationization					141:153	Cationization	141:153	Cationization	141:153	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	1	56	theme	chemical	170:177	arg1	technique					192:200	a promising chemical modification technique	158:200	a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers	158:296	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	4	57	theme	delivery	684:691	arg1	systems					693:699	drug delivery systems	679:699	drug delivery systems	679:699	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	0	58	theme	model-drug	78:87	arg1	release					89:95	model-drug release	78:95	model-drug release	78:95	Optimization of kappa-carrageenan cationization using experimental design for model-drug release and investigation of biological properties.
36813338	6	59	theme	6.83	1037:1040	arg1	unit					1029:1032	sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit	959:1032	unit	1029:1032	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	6	59	theme	6.83	1037:1040	arg1	hydroxide					966:974	sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit	959:1032	hydroxide	966:974	Optimized parameters using 0.086 g of sodium hydroxide and glycidyltrimethylammonium/disaccharide repeating unit of 6.83 achieved 65.47 % degree of substitution and 4.03 % solubility.
36813338	4	60	theme	drug	679:682	arg1	systems					693:699	drug delivery systems	679:699	drug delivery systems	679:699	Hydrophilic quaternary ammonium groups on the carrageenan backbone enhance interaction in drug delivery systems and create active surfaces.
36813338	1	61	theme	modification	179:190	arg1	Cationization					141:153	Cationization	141:153	Cationization	141:153	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	1	61	theme	modification	179:190	arg1	technique					192:200	a promising chemical modification technique	158:200	a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers	158:296	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
36813338	1	62	theme	biopolymers	286:296	arg1	backbone					274:281	the backbone	270:281	the backbone of biopolymers	270:296	Cationization is a promising chemical modification technique that improves properties by attaching permanent positive charges to the backbone of biopolymers.
37282928	4	0	theme	molecular	618:626	arg1	weight					628:633	the relative molecular weight	605:633	the relative molecular weight	605:633	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	1	1	theme	medicine	178:185	arg1	fields					187:192	food and medicine fields	169:192	food and medicine fields	169:192	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	4	2	theme	relative	609:616	arg1	weight					628:633	the relative molecular weight	605:633	the relative molecular weight	605:633	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	1	3	contain	have	138:141	arg1	Polysaccharides					75:89	Polysaccharides	75:89	Polysaccharides	75:89	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	1	3	contain	have	138:141	arg2	value					160:164	good development value	143:164	good development value in food and medicine fields	143:192	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	4	4	theme	polysaccharides	739:753	arg1	weight					628:633	the relative molecular weight	605:633	the relative molecular weight	605:633	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	4	theme	polysaccharides	739:753	arg1	regulation					770:779	the immune regulation	759:779	the immune regulation	759:779	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	4	theme	polysaccharides	739:753	arg1	types					680:684	glycosidic bond types	664:684	glycosidic bond types	664:684	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	4	theme	polysaccharides	739:753	arg1	conformation					723:734	advanced conformation	714:734	advanced conformation	714:734	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	4	theme	polysaccharides	739:753	arg1	composition					651:661	monosaccharide composition	636:661	monosaccharide composition	636:661	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	4	theme	polysaccharides	739:753	arg1	modification					696:707	chemical modification	687:707	chemical modification	687:707	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	5	theme	bond	675:678	arg1	types					680:684	glycosidic bond types	664:684	glycosidic bond types	664:684	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	2	6	theme	polysaccharides	279:293	arg1	structure					246:254	chemical structure	237:254	chemical structure	237:254	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	2	6	theme	polysaccharides	279:293	arg1	activity					267:274	immune activity	260:274	immune activity	260:274	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	2	7	from	studies	222:228	arg1	structure					246:254	chemical structure	237:254	chemical structure	237:254	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	2	7	from	studies	222:228	arg1	activity					267:274	immune activity	260:274	immune activity	260:274	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	2	8	theme	further	396:402	arg1	development					404:414	the further development	392:414	the further development	392:414	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	4	9	theme	monosaccharide	636:649	arg1	composition					651:661	monosaccharide composition	636:661	monosaccharide composition	636:661	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	2	10	dep	structure	246:254	arg1	the					233:235	the	233:235	the	233:235	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	1	11	from	value	160:164	arg1	fields					187:192	food and medicine fields	169:192	food and medicine fields	169:192	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	1	12	theme	significant	96:106	arg1	activity					125:132	significant immunomodulatory activity	96:132	significant immunomodulatory activity	96:132	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	4	13	theme	advanced	714:721	arg1	conformation					723:734	advanced conformation	714:734	advanced conformation	714:734	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	1	14	contain	have	91:94	arg1	Polysaccharides					75:89	Polysaccharides	75:89	Polysaccharides	75:89	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	1	14	contain	have	91:94	arg2	activity					125:132	significant immunomodulatory activity	96:132	significant immunomodulatory activity	96:132	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	1	15	theme	immunomodulatory	108:123	arg1	activity					125:132	significant immunomodulatory activity	96:132	significant immunomodulatory activity	96:132	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	2	16	theme	resources	450:458	arg1	utilization					420:430	utilization	420:430	utilization of polysaccharide resources	420:458	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	2	16	theme	resources	450:458	arg1	development					404:414	the further development	392:414	the further development	392:414	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	4	17	theme	utilization	888:898	arg1	study					828:832	the profound study	815:832	the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides	815:917	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	2	18	theme	polysaccharide	435:448	arg1	resources					450:458	polysaccharide resources	435:458	polysaccharide resources	435:458	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	3	19	theme	own	528:530	arg1	structure					532:540	their own structure	522:540	their own structure	522:540	The immune activity of polysaccharides is closely related to their own structure.
37282928	3	20	theme	polysaccharides	484:498	arg1	related					511:517	related	511:517	related	511:517	The immune activity of polysaccharides is closely related to their own structure.
37282928	3	20	theme	polysaccharides	484:498	arg1	activity					472:479	The immune activity	461:479	The immune activity of polysaccharides	461:498	The immune activity of polysaccharides is closely related to their own structure.
37282928	4	21	theme	chemical	687:694	arg1	modification					696:707	chemical modification	687:707	chemical modification	687:707	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	2	22	theme	chemical	237:244	arg1	structure					246:254	chemical structure	237:254	chemical structure	237:254	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	3	23	theme	immune	465:470	arg1	related					511:517	related	511:517	related	511:517	The immune activity of polysaccharides is closely related to their own structure.
37282928	3	23	theme	immune	465:470	arg1	activity					472:479	The immune activity	461:479	The immune activity of polysaccharides	461:498	The immune activity of polysaccharides is closely related to their own structure.
37282928	0	24	theme	polysaccharides	57:71	arg1	structure					44:52	structure	44:52	structure	44:52	[Relationship between immune regulation and structure of polysaccharides].
37282928	0	24	theme	polysaccharides	57:71	arg1	regulation					29:38	immune regulation	22:38	immune regulation	22:38	[Relationship between immune regulation and structure of polysaccharides].
37282928	4	25	theme	polysaccharides	903:917	arg1	utilization					888:898	utilization	888:898	utilization of polysaccharides	888:917	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	25	theme	polysaccharides	903:917	arg1	relationship					871:882	polysaccharide structure-activity relationship	837:882	polysaccharide structure-activity relationship	837:882	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	26	theme	immune	763:768	arg1	regulation					770:779	the immune regulation	759:779	the immune regulation	759:779	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	2	27	theme	many	217:220	arg1	studies					222:228	many studies	217:228	many studies on the chemical structure and immune activity of polysaccharides	217:293	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	1	28	theme	good	143:146	arg1	value					160:164	good development value	143:164	good development value in food and medicine fields	143:192	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	4	29	theme	structure-activity	852:869	arg1	relationship					871:882	polysaccharide structure-activity relationship	837:882	polysaccharide structure-activity relationship	837:882	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	30	theme	polysaccharide	837:850	arg1	relationship					871:882	polysaccharide structure-activity relationship	837:882	polysaccharide structure-activity relationship	837:882	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	1	31	theme	development	148:158	arg1	value					160:164	good development value	143:164	good development value in food and medicine fields	143:192	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
37282928	4	32	theme	profound	819:826	arg1	study					828:832	the profound study	815:832	the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides	815:917	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	2	33	theme	immune	260:265	arg1	activity					267:274	immune activity	260:274	immune activity	260:274	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	2	34	theme	polysaccharides	333:347	arg1	relationship					304:315	the relationship	300:315	the relationship between them of polysaccharides	300:347	At present, there are many studies on the chemical structure and immune activity of polysaccharides, but the relationship between them of polysaccharides has not been fully explained, which limits the further development and utilization of polysaccharide resources.
37282928	4	35	theme	relationship	871:882	arg1	study					828:832	the profound study	815:832	the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides	815:917	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	4	36	theme	glycosidic	664:673	arg1	types					680:684	glycosidic bond types	664:684	glycosidic bond types	664:684	This paper systematically summarized the relationship between the relative molecular weight, monosaccharide composition, glycosidic bond types, chemical modification, and advanced conformation of polysaccharides and the immune regulation, aiming to provide references for the profound study of polysaccharide structure-activity relationship and utilization of polysaccharides.
37282928	0	37	theme	immune	22:27	arg1	regulation					29:38	immune regulation	22:38	immune regulation	22:38	[Relationship between immune regulation and structure of polysaccharides].
37282928	1	38	theme	food	169:172	arg1	fields					187:192	food and medicine fields	169:192	food and medicine fields	169:192	Polysaccharides have significant immunomodulatory activity and have good development value in food and medicine fields.
35483859	0	0	theme	wall	82:85	arg1	polysaccharide					87:100	cell wall polysaccharide	77:100	cell wall polysaccharide	77:100	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	5	1	dep	in	783:784	arg1	vitro					786:790	vitro	786:790	vitro	786:790	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	1	2	theme	yeast	153:157	arg1	MC-MPS					178:183	MC-MPS	178:183	MC-MPS	178:183	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	1	2	theme	yeast	153:157	arg1	G-MPS					190:194	G-MPS	190:194	G-MPS	190:194	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	1	2	theme	yeast	153:157	arg1	LZ-MPS					170:175	LZ-MPS	170:175	LZ-MPS	170:175	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	1	2	theme	yeast	153:157	arg1	α-mannans					159:167	three yeast α-mannans	147:167	three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS)	147:195	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	0	3	theme	cell	77:80	arg1	polysaccharide					87:100	cell wall polysaccharide	77:100	cell wall polysaccharide	77:100	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	3	4	theme	nuclear	522:528	arg1	resonance					539:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	4	5	theme	α-mannans	584:592	arg1	chain					559:563	The main chain	550:563	The main chain of the three yeast α-mannans	550:592	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	7	6	theme	Bacteroides	1088:1098	arg1	abundances					1074:1083	the relative abundances	1061:1083	the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium	1061:1142	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	2	7	theme	sugar	273:277	arg1	content					279:285	The total sugar content	263:285	The total sugar content of the three α-mannans	263:308	The total sugar content of the three α-mannans ranged from 91.13-97.10%, whereas no proteins were detected.
35483859	0	8	theme	polysaccharide	87:100	arg1	isolation					12:20	isolation	12:20	isolation	12:20	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	0	8	theme	polysaccharide	87:100	arg1	characterization					34:49	structural characterization	23:49	structural characterization	23:49	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	0	8	theme	polysaccharide	87:100	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	0	8	theme	polysaccharide	87:100	arg1	activity					65:72	prebiotic activity	55:72	prebiotic activity	55:72	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	2	9	theme	total	267:271	arg1	content					279:285	The total sugar content	263:285	The total sugar content of the three α-mannans	263:308	The total sugar content of the three α-mannans ranged from 91.13-97.10%, whereas no proteins were detected.
35483859	3	10	theme	two-dimensional	506:520	arg1	resonance					539:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	1	11	theme	marxianus	252:260	arg1	sources					227:233	different sources	217:233	different sources of Kluyveromyces marxianus	217:260	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	5	12	theme	prebiotic	715:723	arg1	potential					725:733	The prebiotic potential	711:733	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS	711:762	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	3	13	theme	ultraviolet	415:425	arg1	spectroscopy					427:438	ultraviolet spectroscopy	415:438	ultraviolet spectroscopy	415:438	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	0	14	theme	Kluyveromyces	107:119	arg1	marxianus					121:129	Kluyveromyces marxianus	107:129	Kluyveromyces marxianus	107:129	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	6	15	theme	yeast	846:850	arg1	α-mannans					852:860	The three yeast α-mannans	836:860	The three yeast α-mannans	836:860	The three yeast α-mannans could be utilised as substrates for the growth of Lactobacillus and Lactococcus strains.
35483859	6	15	theme	yeast	846:850	arg1	substrates					883:892	substrates	883:892	substrates for the growth of Lactobacillus and Lactococcus strains	883:948	The three yeast α-mannans could be utilised as substrates for the growth of Lactobacillus and Lactococcus strains.
35483859	7	16	theme	pathogenic	1176:1185	arg1	bacteria					1187:1194	pathogenic bacteria	1176:1194	pathogenic bacteria	1176:1194	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	7	17	theme	bacteria	1187:1194	arg1	abundance					1163:1171	the abundance	1159:1171	the abundance of pathogenic bacteria	1159:1194	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	5	18	theme	MC-MPS	746:751	arg1	potential					725:733	The prebiotic potential	711:733	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS	711:762	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	7	19	theme	microbiota	1024:1033	arg1	composition					1035:1045	the intestinal microbiota composition	1009:1045	the intestinal microbiota composition	1009:1045	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	6	20	theme	strains	942:948	arg1	growth					902:907	the growth	898:907	the growth of Lactobacillus and Lactococcus strains	898:948	The three yeast α-mannans could be utilised as substrates for the growth of Lactobacillus and Lactococcus strains.
35483859	4	21	theme	branch	693:698	arg1	structure					700:708	the branch structure	689:708	the branch structure	689:708	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	1	22	dep	α-mannans	159:167	arg1	MC-MPS					178:183	MC-MPS	178:183	MC-MPS	178:183	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	1	22	dep	α-mannans	159:167	arg1	G-MPS					190:194	G-MPS	190:194	G-MPS	190:194	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	1	22	dep	α-mannans	159:167	arg1	LZ-MPS					170:175	LZ-MPS	170:175	LZ-MPS	170:175	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	1	22	dep	α-mannans	159:167	arg1	α-mannans					159:167	three yeast α-mannans	147:167	three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS)	147:195	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35483859	5	23	theme	in	783:784	arg1	fermentation					792:803	in vitro fermentation	783:803	in vitro fermentation with pure and faecal cultures	783:833	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	6	24	theme	Lactococcus	930:940	arg1	strains					942:948	Lactococcus strains	930:948	Lactococcus strains	930:948	The three yeast α-mannans could be utilised as substrates for the growth of Lactobacillus and Lactococcus strains.
35483859	7	25	theme	Parabacteroides	1101:1115	arg1	abundances					1074:1083	the relative abundances	1061:1083	the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium	1061:1142	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	5	26	theme	G-MPS	758:762	arg1	potential					725:733	The prebiotic potential	711:733	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS	711:762	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	3	27	theme	infrared	459:466	arg1	spectroscopy					468:479	Fourier-transform infrared spectroscopy	441:479	Fourier-transform infrared spectroscopy	441:479	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	4	28	theme	yeast	578:582	arg1	α-mannans					584:592	the three yeast α-mannans	568:592	the three yeast α-mannans	568:592	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	4	29	theme	repeating	671:679	arg1	unit					681:684	the repeating unit	667:684	the repeating unit of the branch structure	667:708	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	6	30	theme	Lactobacillus	912:924	arg1	growth					902:907	the growth	898:907	the growth of Lactobacillus and Lactococcus strains	898:948	The three yeast α-mannans could be utilised as substrates for the growth of Lactobacillus and Lactococcus strains.
35483859	5	31	with	fermentation	792:803	arg1	pure					810:813	pure	810:813	pure	810:813	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	5	31	with	fermentation	792:803	arg1	faecal					819:824	faecal	819:824	faecal	819:824	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	0	32	theme	structural	23:32	arg1	characterization					34:49	structural characterization	23:49	structural characterization	23:49	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	7	33	theme	yeast	974:978	arg1	α-mannans					980:988	the three yeast α-mannans	964:988	the three yeast α-mannans	964:988	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	3	34	theme	Fourier-transform	441:457	arg1	spectroscopy					468:479	Fourier-transform infrared spectroscopy	441:479	Fourier-transform infrared spectroscopy	441:479	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	0	35	theme	prebiotic	55:63	arg1	activity					65:72	prebiotic activity	55:72	prebiotic activity	55:72	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	3	36	theme	one-dimensional	486:500	arg1	resonance					539:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	3	37	theme	structural	373:382	arg1	arrangement					384:394	A structural arrangement	371:394	A structural arrangement	371:394	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	7	38	theme	intestinal	1013:1022	arg1	composition					1035:1045	the intestinal microbiota composition	1009:1045	the intestinal microbiota composition	1009:1045	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	0	39	from	marxianus	121:129	arg1	isolation					12:20	isolation	12:20	isolation	12:20	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	0	39	from	marxianus	121:129	arg1	characterization					34:49	structural characterization	23:49	structural characterization	23:49	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	0	39	from	marxianus	121:129	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	0	39	from	marxianus	121:129	arg1	activity					65:72	prebiotic activity	55:72	prebiotic activity	55:72	Extraction, isolation, structural characterization and prebiotic activity of cell wall polysaccharide from Kluyveromyces marxianus.
35483859	4	40	theme	main	554:557	arg1	chain					559:563	The main chain	550:563	The main chain of the three yeast α-mannans	550:592	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	7	41	theme	Phascolarctobacterium	1122:1142	arg1	abundances					1074:1083	the relative abundances	1061:1083	the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium	1061:1142	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	5	42	dep	pure	810:813	arg1	cultures					826:833	cultures	826:833	cultures	826:833	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	4	43	theme	structure	700:708	arg1	unit					681:684	the repeating unit	667:684	the repeating unit of the branch structure	667:708	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	4	44	theme	→6	610:611	arg1	unit					627:630	a →6)-α-D-Manp-(1→ unit	608:630	a →6)-α-D-Manp-(1→ unit	608:630	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	4	44	theme	→6	610:611	arg1	different					652:660	different	652:660	different	652:660	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	2	45	theme	α-mannans	300:308	arg1	content					279:285	The total sugar content	263:285	The total sugar content of the three α-mannans	263:308	The total sugar content of the three α-mannans ranged from 91.13-97.10%, whereas no proteins were detected.
35483859	7	46	theme	relative	1065:1072	arg1	abundances					1074:1083	the relative abundances	1061:1083	the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium	1061:1142	In addition, the three yeast α-mannans markedly regulated the intestinal microbiota composition by increasing the relative abundances of Bacteroides, Parabacteroides, and Phascolarctobacterium and decreasing the abundance of pathogenic bacteria.
35483859	4	47	theme	1→	624:625	arg1	unit					627:630	a →6)-α-D-Manp-(1→ unit	608:630	a →6)-α-D-Manp-(1→ unit	608:630	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	4	47	theme	1→	624:625	arg1	different					652:660	different	652:660	different	652:660	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	3	48	theme	magnetic	530:537	arg1	resonance					539:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	one-dimensional and two-dimensional nuclear magnetic resonance	486:547	A structural arrangement was proposed using ultraviolet spectroscopy, Fourier-transform infrared spectroscopy, and one-dimensional and two-dimensional nuclear magnetic resonance.
35483859	4	49	theme	-α-D-Manp-	613:622	arg1	unit					627:630	a →6)-α-D-Manp-(1→ unit	608:630	a →6)-α-D-Manp-(1→ unit	608:630	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	4	49	theme	-α-D-Manp-	613:622	arg1	different					652:660	different	652:660	different	652:660	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	5	50	theme	LZ-MPS	738:743	arg1	potential					725:733	The prebiotic potential	711:733	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS	711:762	The prebiotic potential of LZ-MPS, MC-MPS, and G-MPS was assessed using in vitro fermentation with pure and faecal cultures.
35483859	4	51	from	unit	681:684	arg1	unit					627:630	a →6)-α-D-Manp-(1→ unit	608:630	a →6)-α-D-Manp-(1→ unit	608:630	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	4	51	from	unit	681:684	arg1	different					652:660	different	652:660	different	652:660	The main chain of the three yeast α-mannans was formed by a →6)-α-D-Manp-(1→ unit, which was slightly different from the repeating unit of the branch structure.
35483859	1	52	theme	different	217:225	arg1	sources					227:233	different sources	217:233	different sources of Kluyveromyces marxianus	217:260	In this study, three yeast α-mannans (LZ-MPS, MC-MPS, and G-MPS) were extracted from different sources of Kluyveromyces marxianus.
35358579	0	0	theme	-β-D-xylan	79:88	arg1	bioactivity					36:46	bioactivity	36:46	bioactivity	36:46	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	0	0	theme	-β-D-xylan	79:88	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	0	0	theme	-β-D-xylan	79:88	arg1	characterization					15:30	NMR characterization	11:30	NMR characterization	11:30	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	3	1	theme	4-O-methyl-α-D-glucurono	678:701	arg1	-D-xylan					703:710	a (4-O-methyl-α-D-glucurono)-D-xylan	675:710	a (4-O-methyl-α-D-glucurono)-D-xylan	675:710	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	3	1	theme	4-O-methyl-α-D-glucurono	678:701	arg1	structure					644:652	the chemical structure	631:652	the chemical structure of polysaccharide	631:670	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	2	2	theme	galactoglucomannans	377:395	arg1	mixture					366:372	a mixture	364:372	a mixture of galactoglucomannans (GGM) and glucuronoxylans (MGX)	364:427	GE-300 presented a mixture of galactoglucomannans (GGM) and glucuronoxylans (MGX), while the GR-300 fraction is composed only of MGX.
35358579	4	3	theme	precise	722:728	arg1	determination					749:761	precise NMR chemical shift determination	722:761	precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units	722:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	7	4	theme	chemical	1368:1375	arg1	characteristics					1377:1391	the chemical characteristics	1364:1391	the chemical characteristics of C. xanthocarpa hemicelluloses	1364:1424	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	1	5	theme	Campomanesia	187:198	arg1	fruits					212:217	Campomanesia xanthocarpa fruits	187:217	Campomanesia xanthocarpa fruits	187:217	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	1	6	theme	eluted	298:303	arg1	fractions					336:344	eluted (GE-300) and retained (GR-300) fractions	298:344	eluted (GE-300) and retained (GR-300) fractions	298:344	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	0	7	theme	Campomanesia	95:106	arg1	fruits					125:130	Campomanesia xanthocarpa Berg fruits	95:130	Campomanesia xanthocarpa Berg fruits	95:130	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	3	8	theme	chemical	635:642	arg1	structure					644:652	the chemical structure	631:652	the chemical structure of polysaccharide	631:670	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	3	8	theme	chemical	635:642	arg1	-D-xylan					703:710	a (4-O-methyl-α-D-glucurono)-D-xylan	675:710	a (4-O-methyl-α-D-glucurono)-D-xylan	675:710	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	6	9	theme	violet	1201:1206	arg1	assays					1208:1213	neutral red and crystal violet assays	1177:1213	neutral red and crystal violet assays	1177:1213	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	5	10	theme	acid	940:943	arg1	group					945:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	1	11	attach	isolated	173:180	arg2	polysaccharides					152:166	Hemicellulose-type polysaccharides	133:166	Hemicellulose-type polysaccharides	133:166	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	1	11	attach	isolated	173:180	arg1	fruits					212:217	Campomanesia xanthocarpa fruits	187:217	Campomanesia xanthocarpa fruits	187:217	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	4	12	theme	1D	825:826	arg1	TOCSY					828:832	1D TOCSY	825:832	1D TOCSY	825:832	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	6	13	theme	crystal	1193:1199	arg1	assays					1208:1213	neutral red and crystal violet assays	1177:1213	neutral red and crystal violet assays	1177:1213	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	5	14	dep	demonstrated	871:882	arg1	linked					954:959	linked	954:959	is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain	951:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	7	15	theme	structure-property	1470:1487	arg1	studies					1489:1495	future structure-property studies	1463:1495	future structure-property studies	1463:1495	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	0	16	theme	Berg	120:123	arg1	fruits					125:130	Campomanesia xanthocarpa Berg fruits	95:130	Campomanesia xanthocarpa Berg fruits	95:130	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	4	17	theme	glycosyl	792:799	arg1	units					801:805	clean and specific 1H NMR glycosyl units	766:805	clean and specific 1H NMR glycosyl units	766:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	6	18	theme	DPPH	1037:1040	arg1	radical					1042:1048	DPPH radical	1037:1048	DPPH radical (0.5 to 1.0 mg mL-1)	1037:1069	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	6	18	theme	DPPH	1037:1040	arg1	1.0 mg mL-1					1058:1068	0.5 to 1.0 mg mL-1	1051:1068	0.5 to 1.0 mg mL-1	1051:1068	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	4	19	theme	NMR	730:732	arg1	determination					749:761	precise NMR chemical shift determination	722:761	precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units	722:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	1	20	theme	xanthocarpa	200:210	arg1	fruits					212:217	Campomanesia xanthocarpa fruits	187:217	Campomanesia xanthocarpa fruits	187:217	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	0	21	theme	xanthocarpa	108:118	arg1	fruits					125:130	Campomanesia xanthocarpa Berg fruits	95:130	Campomanesia xanthocarpa Berg fruits	95:130	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	3	22	theme	polysaccharide	657:670	arg1	structure					644:652	the chemical structure	631:652	the chemical structure of polysaccharide	631:670	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	3	22	theme	polysaccharide	657:670	arg1	-D-xylan					703:710	a (4-O-methyl-α-D-glucurono)-D-xylan	675:710	a (4-O-methyl-α-D-glucurono)-D-xylan	675:710	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	4	23	theme	NMR	788:790	arg1	units					801:805	clean and specific 1H NMR glycosyl units	766:805	clean and specific 1H NMR glycosyl units	766:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	3	24	theme	MGX	520:522	arg1	structure					507:515	the chemical structure	494:515	the chemical structure	494:515	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	7	25	theme	future	1463:1468	arg1	studies					1489:1495	future structure-property studies	1463:1495	future structure-property studies	1463:1495	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	2	26	theme	glucuronoxylans	407:421	arg1	mixture					366:372	a mixture	364:372	a mixture of galactoglucomannans (GGM) and glucuronoxylans (MGX)	364:427	GE-300 presented a mixture of galactoglucomannans (GGM) and glucuronoxylans (MGX), while the GR-300 fraction is composed only of MGX.
35358579	5	27	theme	1 → 4	974:978	arg1	-β-D-xylan					980:989	a (1 → 4)-β-D-xylan	971:989	a (1 → 4)-β-D-xylan in the main chain	971:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	7	28	theme	hemicelluloses	1411:1424	arg1	characteristics					1377:1391	the chemical characteristics	1364:1391	the chemical characteristics of C. xanthocarpa hemicelluloses	1364:1424	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	6	29	theme	neutral	1177:1183	arg1	assays					1208:1213	neutral red and crystal violet assays	1177:1213	neutral red and crystal violet assays	1177:1213	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	5	30	from	O-2	964:966	arg1	chain					1003:1007	the main chain	994:1007	the main chain	994:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	4	31	theme	units	801:805	arg1	determination					749:761	precise NMR chemical shift determination	722:761	precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units	722:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	4	31	theme	units	801:805	arg1	Deep					713:716	Deep	713:716	Deep	713:716	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	6	32	dep	in	1227:1228	arg1	vitro					1230:1234	vitro	1230:1234	vitro	1230:1234	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	1	33	theme	alkaline	222:229	arg1	extraction					231:240	alkaline extraction	222:240	alkaline extraction	222:240	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	5	34	theme	-β-D-xylan	980:989	arg1	O-2					964:966	O-2	964:966	O-2 of a (1 → 4)-β-D-xylan in the main chain	964:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	5	35	theme	4-O-methyl-α-D-glucopyranosyl	903:931	arg1	group					945:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	5	36	from	-β-D-xylan	980:989	arg1	chain					1003:1007	the main chain	994:1007	the main chain	994:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	0	37	theme	NMR	11:13	arg1	characterization					15:30	NMR characterization	11:30	NMR characterization	11:30	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	1	38	theme	retained	318:325	arg1	fractions					336:344	eluted (GE-300) and retained (GR-300) fractions	298:344	eluted (GE-300) and retained (GR-300) fractions	298:344	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	6	39	theme	human	1096:1100	arg1	fibroblasts					1109:1119	human dermal fibroblasts	1096:1119	human dermal fibroblasts	1096:1119	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	3	40	theme	HMBC	594:597	arg1	spectroscopy					603:614	1H-13C HMBC NMR spectroscopy	587:614	1H-13C HMBC NMR spectroscopy	587:614	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	5	41	theme	uronic	933:938	arg1	group					945:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	3	42	theme	NMR	599:601	arg1	spectroscopy					603:614	1H-13C HMBC NMR spectroscopy	587:614	1H-13C HMBC NMR spectroscopy	587:614	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	3	43	theme	2D	556:557	arg1	HSQC					566:569	2D 1H-13C HSQC	556:569	2D 1H-13C HSQC	556:569	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	7	44	theme	C.	1396:1397	arg1	hemicelluloses					1411:1424	C. xanthocarpa hemicelluloses	1396:1424	C. xanthocarpa hemicelluloses	1396:1424	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	6	45	theme	red	1185:1187	arg1	assays					1208:1213	neutral red and crystal violet assays	1177:1213	neutral red and crystal violet assays	1177:1213	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	5	46	attach	linked	954:959	arg2	group					945:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	4-O-methyl-α-D-glucopyranosyl uronic acid group	903:949	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	5	46	attach	linked	954:959	arg1	O-2					964:966	O-2	964:966	O-2 of a (1 → 4)-β-D-xylan in the main chain	964:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	7	47	theme	structure	1258:1266	arg1	elucidation					1268:1278	The structure elucidation	1254:1278	The structure elucidation of GR-300 together with its bioactivity assessment	1254:1329	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	3	48	theme	1H-13C	559:564	arg1	HSQC					566:569	2D 1H-13C HSQC	556:569	2D 1H-13C HSQC	556:569	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	7	49	theme	bioactivity	1308:1318	arg1	assessment					1320:1329	its bioactivity assessment	1304:1329	its bioactivity assessment	1304:1329	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	4	50	theme	1D	838:839	arg1	analysis					847:854	1D NOESY analysis	838:854	1D NOESY analysis	838:854	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	3	51	theme	1H-13C	587:592	arg1	spectroscopy					603:614	1H-13C HMBC NMR spectroscopy	587:614	1H-13C HMBC NMR spectroscopy	587:614	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	4	52	theme	1H	785:786	arg1	units					801:805	clean and specific 1H NMR glycosyl units	766:805	clean and specific 1H NMR glycosyl units	766:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	7	53	theme	xanthocarpa	1399:1409	arg1	hemicelluloses					1411:1424	C. xanthocarpa hemicelluloses	1396:1424	C. xanthocarpa hemicelluloses	1396:1424	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	7	54	theme	structural	1442:1451	arg1	basis					1453:1457	structural basis	1442:1457	structural basis for future structure-property studies	1442:1495	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	6	55	theme	dermal	1102:1107	arg1	fibroblasts					1109:1119	human dermal fibroblasts	1096:1119	human dermal fibroblasts	1096:1119	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	4	56	theme	specific	776:783	arg1	units					801:805	clean and specific 1H NMR glycosyl units	766:805	clean and specific 1H NMR glycosyl units	766:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	7	57	theme	GR-300	1283:1288	arg1	elucidation					1268:1278	The structure elucidation	1254:1278	The structure elucidation of GR-300 together with its bioactivity assessment	1254:1329	The structure elucidation of GR-300 together with its bioactivity assessment contributed to better understand the chemical characteristics of C. xanthocarpa hemicelluloses and may provide structural basis for future structure-property studies.
35358579	6	58	theme	in	1227:1228	arg1	biocompatibility					1236:1251	in vitro biocompatibility	1227:1251	in vitro biocompatibility	1227:1251	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	4	59	theme	shift	743:747	arg1	determination					749:761	precise NMR chemical shift determination	722:761	precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units	722:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	3	60	theme	1H-1H	572:576	arg1	COSY					578:581	1H-1H COSY	572:581	1H-1H COSY	572:581	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	4	61	theme	clean	766:770	arg1	units					801:805	clean and specific 1H NMR glycosyl units	766:805	clean and specific 1H NMR glycosyl units	766:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	1	62	theme	Hemicellulose-type	133:150	arg1	polysaccharides					152:166	Hemicellulose-type polysaccharides	133:166	Hemicellulose-type polysaccharides	133:166	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	1	63	theme	fractionation	259:271	arg1	processes					273:281	fractionation processes	259:281	fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions	259:344	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	4	64	theme	NOESY	841:845	arg1	analysis					847:854	1D NOESY analysis	838:854	1D NOESY analysis	838:854	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	5	65	theme	main	998:1001	arg1	chain					1003:1007	the main chain	994:1007	the main chain	994:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	4	66	theme	chemical	734:741	arg1	determination					749:761	precise NMR chemical shift determination	722:761	precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units	722:805	Deep and precise NMR chemical shift determination of clean and specific 1H NMR glycosyl units were developed by 1D TOCSY and 1D NOESY analysis.
35358579	0	67	theme	4-O-methyl-α-D-glucurono	54:77	arg1	-β-D-xylan					79:88	a (4-O-methyl-α-D-glucurono)-β-D-xylan	51:88	a (4-O-methyl-α-D-glucurono)-β-D-xylan	51:88	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	1	68	dep	eluted	298:303	arg1	GE-300					306:311	GE-300	306:311	GE-300	306:311	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	3	69	theme	chemical	498:505	arg1	structure					507:515	the chemical structure	494:515	the chemical structure	494:515	In this way, the chemical structure of MGX, investigated by 1D 1H, 13C and 2D 1H-13C HSQC, 1H-1H COSY and 1H-13C HMBC NMR spectroscopy, revealed that the chemical structure of polysaccharide is a (4-O-methyl-α-D-glucurono)-D-xylan.
35358579	5	70	from	chain	1003:1007	arg1	O-2					964:966	O-2	964:966	O-2 of a (1 → 4)-β-D-xylan in the main chain	964:1007	This approach demonstrated unequivocally that 4-O-methyl-α-D-glucopyranosyl uronic acid group is linked to O-2 of a (1 → 4)-β-D-xylan in the main chain.
35358579	1	71	dep	retained	318:325	arg1	GR-300					328:333	GR-300	328:333	GR-300	328:333	Hemicellulose-type polysaccharides were isolated from Campomanesia xanthocarpa fruits by alkaline extraction and submitted to fractionation processes giving rise to eluted (GE-300) and retained (GR-300) fractions.
35358579	6	72	dep	1.0 mg mL-1	1058:1068	arg1	to					1055:1056	to	1055:1056	to	1055:1056	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	6	73	dep	1.0 mg mL-1	1145:1155	arg1	up					1139:1140	up	1139:1140	up	1139:1140	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	6	74	from	concentrations	1124:1137	arg1	cytotoxic					1083:1091	cytotoxic	1083:1091	cytotoxic	1083:1091	Furthermore, MGX scavenged DPPH radical (0.5 to 1.0 mg mL-1) and was not cytotoxic to human dermal fibroblasts at concentrations up to 1.0 mg mL-1, as demonstrated by neutral red and crystal violet assays, evidencing in vitro biocompatibility.
35358579	0	75	from	fruits	125:130	arg1	bioactivity					36:46	bioactivity	36:46	bioactivity	36:46	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	0	75	from	fruits	125:130	arg1	Isolation					0:8	Isolation	0:8	Isolation	0:8	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
35358579	0	75	from	fruits	125:130	arg1	characterization					15:30	NMR characterization	11:30	NMR characterization	11:30	Isolation, NMR characterization and bioactivity of a (4-O-methyl-α-D-glucurono)-β-D-xylan from Campomanesia xanthocarpa Berg fruits.
37049724	10	0	theme	agricultural	1421:1432	arg1	byproducts					1434:1443	agricultural byproducts	1421:1443	agricultural byproducts	1421:1443	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	6	1	theme	In	818:819	arg1	experiments					846:856	In vitro iron (III) release experiments	818:856	In vitro iron (III) release experiments	818:856	In vitro iron (III) release experiments revealed that all four complexes were rapidly released and acted as iron (III) supplements.
37049724	4	2	theme	structural	604:613	arg1	characterization					615:630	The structural characterization	600:630	The structural characterization	600:630	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	4	3	theme	iron	706:709	arg1	nuclei					711:716	stable β-FeOOH iron nuclei	691:716	stable β-FeOOH iron nuclei	691:716	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	1	4	theme	agricultural	209:220	arg1	byproduct					229:237	an agricultural cereal byproduct	206:237	an agricultural cereal byproduct	206:237	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	1	4	theme	agricultural	209:220	arg1	cob					201:203	sweet corn cob	190:203	sweet corn cob	190:203	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	10	5	used	used	1452:1455	arg2	complexes					1397:1405	the complexes	1393:1405	the complexes prepared from agricultural byproducts	1393:1443	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	10	5	used	used	1452:1455	arg2	supplement					1477:1486	a potential iron supplement	1460:1486	a potential iron supplement	1460:1486	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	2	6	theme	different	312:320	arg1	temperatures					322:333	four different temperatures	307:333	four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C)	307:366	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	1	7	theme	cereal	222:227	arg1	byproduct					229:237	an agricultural cereal byproduct	206:237	an agricultural cereal byproduct	206:237	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	1	7	theme	cereal	222:227	arg1	cob					201:203	sweet corn cob	190:203	sweet corn cob	190:203	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	0	8	theme	Corn	91:94	arg1	Complexes					126:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	3	9	theme	chemical	525:532	arg1	composition					534:544	chemical composition	525:544	chemical composition	525:544	It was demonstrated that the complexes prepared at different temperatures were successfully bound to iron (III), and there was no significant difference in chemical composition; and SCCP-Fe-C demonstrated the highest iron content.
37049724	2	10	theme	polysaccharide-ron	255:272	arg1	complexes					280:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	0	11	theme	Sweet	85:89	arg1	Complexes					126:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	7	12	theme	α-glucosidase	982:994	arg1	studies					1022:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	2	13	theme	cob	251:253	arg1	complexes					280:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	6	14	dep	In	818:819	arg1	vitro					821:825	vitro	821:825	vitro	821:825	In vitro iron (III) release experiments revealed that all four complexes were rapidly released and acted as iron (III) supplements.
37049724	0	15	theme	Polysaccharide	100:113	arg1	Complexes					126:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	2	16	theme	corn	246:249	arg1	complexes					280:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	3	17	from	difference	511:520	arg1	composition					534:544	chemical composition	525:544	chemical composition	525:544	It was demonstrated that the complexes prepared at different temperatures were successfully bound to iron (III), and there was no significant difference in chemical composition; and SCCP-Fe-C demonstrated the highest iron content.
37049724	9	18	theme	agricultural	1311:1322	arg1	byproduct					1331:1339	a natural agricultural cereal byproduct	1301:1339	a natural agricultural cereal byproduct	1301:1339	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	18	theme	agricultural	1311:1322	arg1	cobs					1295:1298	sweet corn cobs	1284:1298	sweet corn cobs	1284:1298	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	0	19	theme	Cob	96:98	arg1	Complexes					126:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	7	20	theme	antioxidant	969:979	arg1	studies					1022:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	2	21	theme	Sweet	240:244	arg1	complexes					280:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes	240:288	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	4	22	theme	β-FeOOH	698:704	arg1	nuclei					711:716	stable β-FeOOH iron nuclei	691:716	stable β-FeOOH iron nuclei	691:716	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	7	23	theme	biological	1048:1057	arg1	activities					1059:1068	the biological activities	1044:1068	the biological activities of all four complexes	1044:1090	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	4	24	theme	cob	658:660	arg1	polysaccharide					662:675	sweet corn cob polysaccharide	647:675	sweet corn cob polysaccharide (SCCP)	647:682	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	4	24	theme	cob	658:660	arg1	SCCP					678:681	SCCP	678:681	SCCP	678:681	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	0	25	theme	Structural	0:9	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	7	26	theme	in	960:961	arg1	studies					1022:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	4	27	theme	corn	653:656	arg1	polysaccharide					662:675	sweet corn cob polysaccharide	647:675	sweet corn cob polysaccharide (SCCP)	647:682	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	4	27	theme	corn	653:656	arg1	SCCP					678:681	SCCP	678:681	SCCP	678:681	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	0	28	theme	In	29:30	arg1	Property					48:55	In Vitro Digestion Property	29:55	In Vitro Digestion Property	29:55	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	1	29	theme	utilization	169:179	arg1	value					181:185	the utilization value	165:185	the utilization value of sweet corn cob, an agricultural cereal byproduct	165:237	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	10	30	theme	potential	1462:1470	arg1	supplement					1477:1486	a potential iron supplement	1460:1486	a potential iron supplement	1460:1486	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	10	30	theme	potential	1462:1470	arg1	complexes					1397:1405	the complexes	1393:1405	the complexes prepared from agricultural byproducts	1393:1443	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	0	31	theme	Iron	115:118	arg1	Complexes					126:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Sweet Corn Cob Polysaccharide Iron (III) Complexes	85:134	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	3	32	theme	different	420:428	arg1	temperatures					430:441	different temperatures	420:441	different temperatures	420:441	It was demonstrated that the complexes prepared at different temperatures were successfully bound to iron (III), and there was no significant difference in chemical composition; and SCCP-Fe-C demonstrated the highest iron content.
37049724	9	33	theme	natural	1303:1309	arg1	byproduct					1331:1339	a natural agricultural cereal byproduct	1301:1339	a natural agricultural cereal byproduct	1301:1339	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	33	theme	natural	1303:1309	arg1	cobs					1295:1298	sweet corn cobs	1284:1298	sweet corn cobs	1284:1298	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	34	theme	functional	1345:1354	arg1	foods					1356:1360	functional foods	1345:1360	functional foods	1345:1360	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	0	35	theme	Digestion	38:46	arg1	Property					48:55	In Vitro Digestion Property	29:55	In Vitro Digestion Property	29:55	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	6	36	theme	release	838:844	arg1	experiments					846:856	In vitro iron (III) release experiments	818:856	In vitro iron (III) release experiments	818:856	In vitro iron (III) release experiments revealed that all four complexes were rapidly released and acted as iron (III) supplements.
37049724	9	37	from	cobs	1295:1298	arg1	foods					1356:1360	functional foods	1345:1360	functional foods	1345:1360	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	6	38	theme	iron	926:929	arg1	supplements					937:947	iron (III) supplements	926:947	iron (III) supplements	926:947	In vitro iron (III) release experiments revealed that all four complexes were rapidly released and acted as iron (III) supplements.
37049724	7	39	dep	in	960:961	arg1	vitro					963:967	vitro	963:967	vitro	963:967	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	10	40	theme	iron	1472:1475	arg1	supplement					1477:1486	a potential iron supplement	1460:1486	a potential iron supplement	1460:1486	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	10	40	theme	iron	1472:1475	arg1	complexes					1397:1405	the complexes	1393:1405	the complexes prepared from agricultural byproducts	1393:1443	Furthermore, we proposed that the complexes prepared from agricultural byproducts can be used as a potential iron supplement.
37049724	1	41	theme	sweet	190:194	arg1	byproduct					229:237	an agricultural cereal byproduct	206:237	an agricultural cereal byproduct	206:237	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	1	41	theme	sweet	190:194	arg1	cob					201:203	sweet corn cob	190:203	sweet corn cob	190:203	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	7	42	theme	α-amylase	1001:1009	arg1	studies					1022:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	9	43	theme	cereal	1324:1329	arg1	byproduct					1331:1339	a natural agricultural cereal byproduct	1301:1339	a natural agricultural cereal byproduct	1301:1339	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	43	theme	cereal	1324:1329	arg1	cobs					1295:1298	sweet corn cobs	1284:1298	sweet corn cobs	1284:1298	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	8	44	theme	α-amylase	1222:1230	arg1	abilities					1243:1251	α-amylase inhibition abilities	1222:1251	α-amylase inhibition abilities	1222:1251	SCCP-Fe-B and SCCP-Fe-C exhibited the highest in vitro antioxidant, α-glucosidase, and α-amylase inhibition abilities.
37049724	8	45	theme	highest	1173:1179	arg1	antioxidant					1190:1200	in vitro antioxidant	1181:1200	in vitro antioxidant	1181:1200	SCCP-Fe-B and SCCP-Fe-C exhibited the highest in vitro antioxidant, α-glucosidase, and α-amylase inhibition abilities.
37049724	7	46	theme	inhibition	1011:1020	arg1	studies					1022:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies	960:1028	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
37049724	0	47	theme	Complexes	126:134	arg1	Activity					73:80	Biological Activity	62:80	Biological Activity	62:80	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	0	47	theme	Complexes	126:134	arg1	Property					48:55	In Vitro Digestion Property	29:55	In Vitro Digestion Property	29:55	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	0	47	theme	Complexes	126:134	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	3	48	theme	highest	578:584	arg1	content					591:597	the highest iron content	574:597	the highest iron content	574:597	It was demonstrated that the complexes prepared at different temperatures were successfully bound to iron (III), and there was no significant difference in chemical composition; and SCCP-Fe-C demonstrated the highest iron content.
37049724	6	49	theme	iron	827:830	arg1	experiments					846:856	In vitro iron (III) release experiments	818:856	In vitro iron (III) release experiments	818:856	In vitro iron (III) release experiments revealed that all four complexes were rapidly released and acted as iron (III) supplements.
37049724	3	50	theme	iron	586:589	arg1	content					591:597	the highest iron content	574:597	the highest iron content	574:597	It was demonstrated that the complexes prepared at different temperatures were successfully bound to iron (III), and there was no significant difference in chemical composition; and SCCP-Fe-C demonstrated the highest iron content.
37049724	0	51	dep	In	29:30	arg1	Vitro					32:36	Vitro	32:36	Vitro	32:36	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	4	52	theme	sweet	647:651	arg1	polysaccharide					662:675	sweet corn cob polysaccharide	647:675	sweet corn cob polysaccharide (SCCP)	647:682	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	4	52	theme	sweet	647:651	arg1	SCCP					678:681	SCCP	678:681	SCCP	678:681	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	8	53	theme	inhibition	1232:1241	arg1	abilities					1243:1251	α-amylase inhibition abilities	1222:1251	α-amylase inhibition abilities	1222:1251	SCCP-Fe-B and SCCP-Fe-C exhibited the highest in vitro antioxidant, α-glucosidase, and α-amylase inhibition abilities.
37049724	1	54	theme	corn	196:199	arg1	byproduct					229:237	an agricultural cereal byproduct	206:237	an agricultural cereal byproduct	206:237	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	1	54	theme	corn	196:199	arg1	cob					201:203	sweet corn cob	190:203	sweet corn cob	190:203	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	4	55	theme	stable	691:696	arg1	nuclei					711:716	stable β-FeOOH iron nuclei	691:716	stable β-FeOOH iron nuclei	691:716	The structural characterization suggested that sweet corn cob polysaccharide (SCCP) formed stable β-FeOOH iron nuclei with -OH and -OOH.
37049724	8	56	dep	in	1181:1182	arg1	vitro					1184:1188	vitro	1184:1188	vitro	1184:1188	SCCP-Fe-B and SCCP-Fe-C exhibited the highest in vitro antioxidant, α-glucosidase, and α-amylase inhibition abilities.
37049724	2	57	dep	temperatures	322:333	arg1	°C					364:365	60 °C, and 70 °C	350:365	60 °C, and 70 °C	350:365	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	2	57	dep	temperatures	322:333	arg1	°C					339:340	40 °C	336:340	40 °C	336:340	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	2	57	dep	temperatures	322:333	arg1	°C					346:347	50 °C	343:347	50 °C	343:347	Sweet corn cob polysaccharide-ron (III) complexes were prepared at four different temperatures (40 °C, 50 °C, 60 °C, and 70 °C).
37049724	8	58	theme	in	1181:1182	arg1	antioxidant					1190:1200	in vitro antioxidant	1181:1200	in vitro antioxidant	1181:1200	SCCP-Fe-B and SCCP-Fe-C exhibited the highest in vitro antioxidant, α-glucosidase, and α-amylase inhibition abilities.
37049724	1	59	theme	cob	201:203	arg1	value					181:185	the utilization value	165:185	the utilization value of sweet corn cob, an agricultural cereal byproduct	165:237	This study aimed to enhance the utilization value of sweet corn cob, an agricultural cereal byproduct.
37049724	0	60	theme	Biological	62:71	arg1	Activity					73:80	Biological Activity	62:80	Biological Activity	62:80	Structural Characterization, In Vitro Digestion Property, and Biological Activity of Sweet Corn Cob Polysaccharide Iron (III) Complexes.
37049724	3	61	theme	significant	499:509	arg1	difference					511:520	no significant difference	496:520	no significant difference in chemical composition	496:544	It was demonstrated that the complexes prepared at different temperatures were successfully bound to iron (III), and there was no significant difference in chemical composition; and SCCP-Fe-C demonstrated the highest iron content.
37049724	5	62	theme	thermal	761:767	arg1	stability					769:777	All the four complexes' thermal stability	737:777	All the four complexes' thermal stability	737:777	All the four complexes' thermal stability was enhanced, especially in SCCP-Fe-C.
37049724	9	63	theme	sweet	1284:1288	arg1	byproduct					1331:1339	a natural agricultural cereal byproduct	1301:1339	a natural agricultural cereal byproduct	1301:1339	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	63	theme	sweet	1284:1288	arg1	cobs					1295:1298	sweet corn cobs	1284:1298	sweet corn cobs	1284:1298	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	64	theme	corn	1290:1293	arg1	byproduct					1331:1339	a natural agricultural cereal byproduct	1301:1339	a natural agricultural cereal byproduct	1301:1339	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	9	64	theme	corn	1290:1293	arg1	cobs					1295:1298	sweet corn cobs	1284:1298	sweet corn cobs	1284:1298	This study will suggest using sweet corn cobs, a natural agricultural cereal byproduct, in functional foods.
37049724	7	65	theme	complexes	1082:1090	arg1	activities					1059:1068	the biological activities	1044:1068	the biological activities of all four complexes	1044:1090	Moreover, in vitro antioxidant, α-glucosidase, and α-amylase inhibition studies revealed that the biological activities of all four complexes were enhanced compared with those of SCCP.
36901937	0	0	theme	Panax	87:91	arg1	notoginseng					93:103	Panax notoginseng	87:103	Panax notoginseng	87:103	Extraction, Structural, and Antioxidant Properties of Oligosaccharides Hydrolyzed from Panax notoginseng by Ultrasonic-Assisted Fenton Degradation.
36901937	1	1	theme	biological	183:192	arg1	activities					194:203	many biological activities	178:203	many biological activities that are remarkably affected by molecular size and structures	178:265	Plant polysaccharides exhibit many biological activities that are remarkably affected by molecular size and structures.
36901937	4	2	theme	molecular	600:608	arg1	weight					610:615	the molecular weight	596:615	the molecular weight (Mw) of the degraded fractions	596:646	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	4	2	theme	molecular	600:608	arg1	Mw					618:619	Mw	618:619	Mw	618:619	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	5	3	theme	PP-degraded	804:814	arg1	products					816:823	PP-degraded products	804:823	PP-degraded products	804:823	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	3	4	theme	different	520:528	arg1	treatments					546:555	different Fenton reaction treatments	520:555	different Fenton reaction treatments	520:555	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	2	5	theme	notoginseng	375:385	arg1	polysaccharide					387:400	the Panax notoginseng polysaccharide	365:400	the Panax notoginseng polysaccharide (PP)	365:405	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	2	5	theme	notoginseng	375:385	arg1	PP					403:404	PP	403:404	PP	403:404	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	5	6	theme	conformational	751:764	arg1	structure					766:774	conformational structure	751:774	conformational structure	751:774	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	5	7	from	patterns	950:957	arg1	spectra					922:928	FT-IR spectra	916:928	FT-IR spectra	916:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	2	8	theme	ultrasonic-assisted	326:344	arg1	reaction					353:360	ultrasonic-assisted Fenton reaction	326:360	ultrasonic-assisted Fenton reaction	326:360	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	5	9	theme	differential	937:948	arg1	patterns					950:957	X-ray differential patterns	931:957	X-ray differential patterns	931:957	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	3	10	theme	hot	495:497	arg1	extraction					505:514	optimized hot water extraction	485:514	optimized hot water extraction	485:514	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	0	11	theme	Fenton	128:133	arg1	Degradation					135:145	Ultrasonic-Assisted Fenton Degradation	108:145	Ultrasonic-Assisted Fenton Degradation	108:145	Extraction, Structural, and Antioxidant Properties of Oligosaccharides Hydrolyzed from Panax notoginseng by Ultrasonic-Assisted Fenton Degradation.
36901937	7	12	theme	molecular	1300:1308	arg1	size					1310:1313	the molecular size	1296:1313	the molecular size	1296:1313	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	3	13	dep	products	437:444	arg1	PP5					452:454	PP5	452:454	PP5	452:454	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	3	13	dep	products	437:444	arg1	PP7					461:463	PP7	461:463	PP7	461:463	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	3	13	dep	products	437:444	arg1	PP3					447:449	PP3	447:449	PP3	447:449	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	3	13	dep	products	437:444	arg1	products					437:444	three degradation products	419:444	its three degradation products (PP3, PP5, and PP7)	415:464	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	4	14	theme	degraded	629:636	arg1	fractions					638:646	the degraded fractions	625:646	the degraded fractions	625:646	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	6	15	with	PP7	1003:1005	arg1	Mw					1016:1017	an Mw	1013:1017	an Mw of 5.89 kDa	1013:1029	In addition, PP7, with an Mw of 5.89 kDa, exhibited stronger antioxidant activities in both the chemiluminescence-based and HHL5 cell-based methods.
36901937	5	16	theme	proton	964:969	arg1	signals					971:977	proton signals	964:977	proton signals	964:977	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	6	17	theme	antioxidant	1051:1061	arg1	activities					1063:1072	stronger antioxidant activities	1042:1072	stronger antioxidant activities	1042:1072	In addition, PP7, with an Mw of 5.89 kDa, exhibited stronger antioxidant activities in both the chemiluminescence-based and HHL5 cell-based methods.
36901937	0	18	theme	Ultrasonic-Assisted	108:126	arg1	Degradation					135:145	Ultrasonic-Assisted Fenton Degradation	108:145	Ultrasonic-Assisted Fenton Degradation	108:145	Extraction, Structural, and Antioxidant Properties of Oligosaccharides Hydrolyzed from Panax notoginseng by Ultrasonic-Assisted Fenton Degradation.
36901937	7	19	theme	Fenton	1186:1191	arg1	degradation					1193:1203	ultrasonic-assisted Fenton degradation	1166:1203	ultrasonic-assisted Fenton degradation	1166:1203	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	2	20	theme	degradation	304:314	arg1	effect					316:321	the degradation effect	300:321	the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP)	300:405	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	7	21	theme	natural	1259:1265	arg1	polysaccharides					1267:1281	natural polysaccharides	1259:1281	natural polysaccharides	1259:1281	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	5	22	from	signals	971:977	arg1	spectra					922:928	FT-IR spectra	916:928	FT-IR spectra	916:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	5	23	theme	FT-IR	916:920	arg1	spectra					922:928	FT-IR spectra	916:928	FT-IR spectra	916:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	3	24	theme	degradation	425:435	arg1	PP5					452:454	PP5	452:454	PP5	452:454	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	3	24	theme	degradation	425:435	arg1	PP7					461:463	PP7	461:463	PP7	461:463	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	3	24	theme	degradation	425:435	arg1	PP3					447:449	PP3	447:449	PP3	447:449	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	3	24	theme	degradation	425:435	arg1	products					437:444	three degradation products	419:444	its three degradation products (PP3, PP5, and PP7)	415:464	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	5	25	theme	1H	982:983	arg1	NMR					985:987	1H NMR	982:987	1H NMR	982:987	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	2	26	theme	reaction	353:360	arg1	effect					316:321	the degradation effect	300:321	the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP)	300:405	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	4	27	theme	fractions	638:646	arg1	weight					610:615	the molecular weight	596:615	the molecular weight (Mw) of the degraded fractions	596:646	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	4	27	theme	fractions	638:646	arg1	Mw					618:619	Mw	618:619	Mw	618:619	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	5	28	theme	monosaccharides	859:873	arg1	composition					875:885	monosaccharides composition	859:885	monosaccharides composition	859:885	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	5	29	theme	backbone	722:729	arg1	similar					781:787	similar	781:787	similar	781:787	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	5	29	theme	backbone	722:729	arg1	characteristics					731:745	the backbone characteristics	718:745	the backbone characteristics	718:745	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	2	30	theme	Fenton	346:351	arg1	reaction					353:360	ultrasonic-assisted Fenton reaction	326:360	ultrasonic-assisted Fenton reaction	326:360	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	1	31	theme	molecular	237:245	arg1	size					247:250	molecular size	237:250	molecular size	237:250	Plant polysaccharides exhibit many biological activities that are remarkably affected by molecular size and structures.
36901937	0	32	theme	Antioxidant	28:38	arg1	Properties					40:49	Antioxidant Properties	28:49	Antioxidant Properties	28:49	Extraction, Structural, and Antioxidant Properties of Oligosaccharides Hydrolyzed from Panax notoginseng by Ultrasonic-Assisted Fenton Degradation.
36901937	6	33	theme	stronger	1042:1049	arg1	activities					1063:1072	stronger antioxidant activities	1042:1072	stronger antioxidant activities	1042:1072	In addition, PP7, with an Mw of 5.89 kDa, exhibited stronger antioxidant activities in both the chemiluminescence-based and HHL5 cell-based methods.
36901937	5	34	theme	functional	888:897	arg1	signals					905:911	functional group signals	888:911	functional group signals in FT-IR spectra	888:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	7	35	used	used	1214:1217	arg2	degradation					1193:1203	ultrasonic-assisted Fenton degradation	1166:1203	ultrasonic-assisted Fenton degradation	1166:1203	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	4	36	with	treatment	678:686	arg1	reaction					704:711	the Fenton reaction	693:711	the Fenton reaction	693:711	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	5	37	theme	group	899:903	arg1	signals					905:911	functional group signals	888:911	functional group signals in FT-IR spectra	888:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	7	38	theme	biological	1234:1243	arg1	activities					1245:1254	the biological activities	1230:1254	the biological activities of natural polysaccharides	1230:1281	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	3	39	theme	water	499:503	arg1	extraction					505:514	optimized hot water extraction	485:514	optimized hot water extraction	485:514	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	7	40	theme	ultrasonic-assisted	1166:1184	arg1	degradation					1193:1203	ultrasonic-assisted Fenton degradation	1166:1203	ultrasonic-assisted Fenton degradation	1166:1203	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	1	41	theme	many	178:181	arg1	activities					194:203	many biological activities	178:203	many biological activities that are remarkably affected by molecular size and structures	178:265	Plant polysaccharides exhibit many biological activities that are remarkably affected by molecular size and structures.
36901937	5	42	from	composition	875:885	arg1	spectra					922:928	FT-IR spectra	916:928	FT-IR spectra	916:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	2	43	from	effect	316:321	arg1	polysaccharide					387:400	the Panax notoginseng polysaccharide	365:400	the Panax notoginseng polysaccharide (PP)	365:405	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	2	43	from	effect	316:321	arg1	PP					403:404	PP	403:404	PP	403:404	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	6	44	theme	kDa	1027:1029	arg1	Mw					1016:1017	an Mw	1013:1017	an Mw of 5.89 kDa	1013:1029	In addition, PP7, with an Mw of 5.89 kDa, exhibited stronger antioxidant activities in both the chemiluminescence-based and HHL5 cell-based methods.
36901937	4	45	theme	Fenton	697:702	arg1	reaction					704:711	the Fenton reaction	693:711	the Fenton reaction	693:711	The results showed that the molecular weight (Mw) of the degraded fractions significantly decreased after treatment with the Fenton reaction.
36901937	1	46	theme	Plant	148:152	arg1	polysaccharides					154:168	Plant polysaccharides	148:168	Plant polysaccharides	148:168	Plant polysaccharides exhibit many biological activities that are remarkably affected by molecular size and structures.
36901937	6	47	dep	chemiluminescence-based	1086:1108	arg1	methods					1130:1136	methods	1130:1136	methods	1130:1136	In addition, PP7, with an Mw of 5.89 kDa, exhibited stronger antioxidant activities in both the chemiluminescence-based and HHL5 cell-based methods.
36901937	6	47	dep	chemiluminescence-based	1086:1108	arg1	the					1082:1084	the	1082:1084	the	1082:1084	In addition, PP7, with an Mw of 5.89 kDa, exhibited stronger antioxidant activities in both the chemiluminescence-based and HHL5 cell-based methods.
36901937	2	48	theme	Panax	369:373	arg1	polysaccharide					387:400	the Panax notoginseng polysaccharide	365:400	the Panax notoginseng polysaccharide (PP)	365:405	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	2	48	theme	Panax	369:373	arg1	PP					403:404	PP	403:404	PP	403:404	This study aimed to investigate the degradation effect of ultrasonic-assisted Fenton reaction on the Panax notoginseng polysaccharide (PP).
36901937	3	49	theme	optimized	485:493	arg1	extraction					505:514	optimized hot water extraction	485:514	optimized hot water extraction	485:514	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	7	50	theme	polysaccharides	1267:1281	arg1	activities					1245:1254	the biological activities	1230:1254	the biological activities of natural polysaccharides	1230:1281	The results indicated that ultrasonic-assisted Fenton degradation might be used to improve the biological activities of natural polysaccharides by adjusting the molecular size.
36901937	5	51	theme	X-ray	931:935	arg1	patterns					950:957	X-ray differential patterns	931:957	X-ray differential patterns	931:957	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	3	52	theme	Fenton	530:535	arg1	treatments					546:555	different Fenton reaction treatments	520:555	different Fenton reaction treatments	520:555	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
36901937	0	53	theme	Oligosaccharides	54:69	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, Structural, and Antioxidant Properties of Oligosaccharides Hydrolyzed from Panax notoginseng by Ultrasonic-Assisted Fenton Degradation.
36901937	0	53	theme	Oligosaccharides	54:69	arg1	Properties					40:49	Antioxidant Properties	28:49	Antioxidant Properties	28:49	Extraction, Structural, and Antioxidant Properties of Oligosaccharides Hydrolyzed from Panax notoginseng by Ultrasonic-Assisted Fenton Degradation.
36901937	5	54	from	signals	905:911	arg1	spectra					922:928	FT-IR spectra	916:928	FT-IR spectra	916:928	But the backbone characteristics and conformational structure were similar between PP and PP-degraded products, which was estimated by comparing monosaccharides composition, functional group signals in FT-IR spectra, X-ray differential patterns, and proton signals in 1H NMR.
36901937	3	55	theme	reaction	537:544	arg1	treatments					546:555	different Fenton reaction treatments	520:555	different Fenton reaction treatments	520:555	PP and its three degradation products (PP3, PP5, and PP7) were obtained from optimized hot water extraction and different Fenton reaction treatments, respectively.
35963380	3	0	theme	extracellular	537:549	arg1	substances					561:570	different extracellular polymeric substances	527:570	different extracellular polymeric substances	527:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	1	1	theme	crucial	261:267	arg1	processes					279:287	crucial ecosystem processes	261:287	crucial ecosystem processes	261:287	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	13	2	theme	flow	1882:1885	arg1	condition					1887:1895	turbulent flow condition	1872:1895	turbulent flow condition	1872:1895	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	5	3	theme	turbulent	737:745	arg1	flow					747:750	turbulent flow	737:750	turbulent flow with high shear force	737:772	The biofilms formed in turbulent flow with high shear force were thin but dense.
35963380	11	4	theme	extracellular	1603:1615	arg1	polysaccharides					1617:1631	extracellular polysaccharides	1603:1631	extracellular polysaccharides	1603:1631	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	9	5	theme	extracellular	1291:1303	arg1	proteins					1305:1312	extracellular proteins	1291:1312	extracellular proteins	1291:1312	Under the turbulent flow condition, bacteria, exopolysaccharides, and extracellular proteins permeated through the biofilm, and more extracellular polysaccharides enveloped bacteria and extracellular proteins.
35963380	3	6	theme	biofilms	597:604	arg1	distribution					511:522	spatiotemporal distribution	496:522	spatiotemporal distribution of different extracellular polymeric substances	496:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	6	theme	biofilms	597:604	arg1	architecture					581:592	the architecture	577:592	the architecture of biofilms	577:604	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	6	theme	biofilms	597:604	arg1	composition					483:493	the composition	479:493	the composition	479:493	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	15	7	theme	TB-EPS	2199:2204	arg1	capability					2185:2194	flocculation capability	2172:2194	flocculation capability of TB-EPS	2172:2204	In particular, the adhesion of LB-EPS and flocculation capability of TB-EPS play some role in regulating biofilm formation.
35963380	15	7	theme	TB-EPS	2199:2204	arg1	adhesion					2149:2156	the adhesion	2145:2156	the adhesion of LB-EPS	2145:2166	In particular, the adhesion of LB-EPS and flocculation capability of TB-EPS play some role in regulating biofilm formation.
35963380	7	8	from	those	985:989	arg1	thickness					891:899	thickness	891:899	thickness	891:899	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	7	8	from	those	985:989	arg1	different					970:978	different	970:978	different	970:978	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	11	9	theme	extracellular	1634:1646	arg1	proteins					1648:1655	extracellular proteins	1634:1655	extracellular proteins	1634:1655	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	5	10	theme	shear	762:766	arg1	force					768:772	high shear force	757:772	high shear force	757:772	The biofilms formed in turbulent flow with high shear force were thin but dense.
35963380	11	11	theme	laminar	1559:1565	arg1	condition					1572:1580	the laminar flow condition	1555:1580	the laminar flow condition	1555:1580	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	0	12	theme	spatiotemporal	55:68	arg1	distribution					70:81	spatiotemporal distribution	55:81	spatiotemporal distribution of different extracellular polymeric substances	55:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	1	13	from	common	188:193	arg1	rivers					241:246	rivers	241:246	rivers	241:246	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	1	14	theme	Microbial	165:173	arg1	biofilms					175:182	Microbial biofilms	165:182	Microbial biofilms	165:182	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	12	15	theme	extracellular	1787:1799	arg1	proteins					1801:1808	extracellular proteins	1787:1808	extracellular proteins	1787:1808	The number of extracellular polysaccharides was greater than that of extracellular proteins.
35963380	1	16	from	rivers	241:246	arg1	common					188:193	common	188:193	common	188:193	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	10	17	theme	flow	1347:1350	arg1	condition					1352:1360	the transitional flow condition	1330:1360	the transitional flow condition	1330:1360	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	13	18	from	EPS	1831:1833	arg1	biofilm					1842:1848	the biofilm	1838:1848	the biofilm	1838:1848	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	15	19	theme	biofilm	2235:2241	arg1	formation					2243:2251	biofilm formation	2235:2251	biofilm formation	2235:2251	In particular, the adhesion of LB-EPS and flocculation capability of TB-EPS play some role in regulating biofilm formation.
35963380	0	20	from	Effects	0:6	arg1	composition					42:52	the composition	38:52	the composition	38:52	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	0	20	from	Effects	0:6	arg1	architecture					139:150	the architecture	135:150	the architecture of biofilms	135:162	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	0	20	from	Effects	0:6	arg1	distribution					70:81	spatiotemporal distribution	55:81	spatiotemporal distribution of different extracellular polymeric substances	55:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	10	21	theme	upper	1521:1525	arg1	layer					1527:1531	the upper layer	1517:1531	the upper layer of the biofilm	1517:1546	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	9	22	theme	turbulent	1115:1123	arg1	condition					1130:1138	the turbulent flow condition	1111:1138	the turbulent flow condition	1111:1138	Under the turbulent flow condition, bacteria, exopolysaccharides, and extracellular proteins permeated through the biofilm, and more extracellular polysaccharides enveloped bacteria and extracellular proteins.
35963380	0	23	theme	extracellular	96:108	arg1	substances					120:129	different extracellular polymeric substances	86:129	different extracellular polymeric substances	86:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	10	24	theme	extracellular	1367:1379	arg1	polysaccharides					1381:1395	the extracellular polysaccharides	1363:1395	the extracellular polysaccharides	1363:1395	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	10	24	theme	extracellular	1367:1379	arg1	fewer					1415:1419	fewer	1415:1419	fewer	1415:1419	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	3	25	theme	different	442:450	arg1	conditions					465:474	different hydrodynamic conditions	442:474	different hydrodynamic conditions	442:474	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	0	26	theme	substances	120:129	arg1	composition					42:52	the composition	38:52	the composition	38:52	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	0	26	theme	substances	120:129	arg1	distribution					70:81	spatiotemporal distribution	55:81	spatiotemporal distribution of different extracellular polymeric substances	55:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	0	26	theme	substances	120:129	arg1	architecture					139:150	the architecture	135:150	the architecture of biofilms	135:162	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	10	27	theme	biofilm	1540:1546	arg1	layer					1527:1531	the upper layer	1517:1531	the upper layer of the biofilm	1517:1546	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	13	28	theme	flow	1972:1975	arg1	condition					1977:1985	laminar flow condition	1964:1985	laminar flow condition	1964:1985	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	13	29	theme	flow	1934:1937	arg1	condition					1939:1947	transitional flow condition	1921:1947	transitional flow condition	1921:1947	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	0	30	theme	hydrodynamic	11:22	arg1	conditions					24:33	hydrodynamic conditions	11:33	hydrodynamic conditions	11:33	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	12	31	theme	polysaccharides	1746:1760	arg1	greater					1766:1772	greater	1766:1772	greater	1766:1772	The number of extracellular polysaccharides was greater than that of extracellular proteins.
35963380	12	31	theme	polysaccharides	1746:1760	arg1	number					1722:1727	The number	1718:1727	The number of extracellular polysaccharides	1718:1760	The number of extracellular polysaccharides was greater than that of extracellular proteins.
35963380	16	32	theme	biofilm	2313:2319	arg1	formation					2321:2329	biofilm formation	2313:2329	biofilm formation	2313:2329	This study would help to perfect the five-stages theory of biofilm formation.
35963380	3	33	theme	conditions	465:474	arg1	effects					431:437	the effects	427:437	the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms	427:604	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	13	34	from	number	1821:1826	arg1	biofilm					1842:1848	the biofilm	1838:1848	the biofilm	1838:1848	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	2	35	theme	polymeric	369:377	arg1	EPS					390:392	EPS	390:392	EPS	390:392	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	2	35	theme	polymeric	369:377	arg1	substance					379:387	a self-produced extracellular polymeric substance	339:387	a self-produced extracellular polymeric substance (EPS)	339:393	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	2	36	theme	self-produced	341:353	arg1	EPS					390:392	EPS	390:392	EPS	390:392	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	2	36	theme	self-produced	341:353	arg1	substance					379:387	a self-produced extracellular polymeric substance	339:387	a self-produced extracellular polymeric substance (EPS)	339:393	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	3	37	theme	polymeric	551:559	arg1	substances					561:570	different extracellular polymeric substances	527:570	different extracellular polymeric substances	527:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	8	38	theme	compact	1018:1024	arg1	structure					1026:1034	The compact structure	1014:1034	The compact structure of the biofilm	1014:1049	The compact structure of the biofilm helped to resist shear forces to minimize detachment.
35963380	4	39	theme	architecture	675:686	arg1	correlations					688:699	complex architecture correlations	667:699	complex architecture correlations in biofilms	667:711	Multidisciplinary methods offer complementary insights into complex architecture correlations in biofilms.
35963380	10	40	theme	turbulent	1442:1450	arg1	condition					1457:1465	the turbulent flow condition	1438:1465	the turbulent flow condition	1438:1465	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	3	41	theme	different	527:535	arg1	substances					561:570	different extracellular polymeric substances	527:570	different extracellular polymeric substances	527:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	7	42	theme	transitional	947:958	arg1	flow					960:963	the transitional flow	943:963	the transitional flow	943:963	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	13	43	theme	turbulent	1872:1880	arg1	flow					1882:1885	turbulent flow	1872:1885	turbulent flow condition	1872:1895	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	9	44	theme	extracellular	1238:1250	arg1	polysaccharides					1252:1266	more extracellular polysaccharides	1233:1266	more extracellular polysaccharides	1233:1266	Under the turbulent flow condition, bacteria, exopolysaccharides, and extracellular proteins permeated through the biofilm, and more extracellular polysaccharides enveloped bacteria and extracellular proteins.
35963380	1	45	theme	ecosystem	269:277	arg1	processes					279:287	crucial ecosystem processes	261:287	crucial ecosystem processes	261:287	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	8	46	theme	biofilm	1043:1049	arg1	structure					1026:1034	The compact structure	1014:1034	The compact structure of the biofilm	1014:1049	The compact structure of the biofilm helped to resist shear forces to minimize detachment.
35963380	4	47	theme	complementary	639:651	arg1	insights					653:660	complementary insights	639:660	complementary insights into complex architecture correlations in biofilms	639:711	Multidisciplinary methods offer complementary insights into complex architecture correlations in biofilms.
35963380	11	48	theme	polysaccharides	1617:1631	arg1	uniform					1686:1692	uniform	1686:1692	uniform	1686:1692	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	11	48	theme	polysaccharides	1617:1631	arg1	distribution					1587:1598	the distribution	1583:1598	the distribution of extracellular polysaccharides, extracellular proteins, and bacteria	1583:1669	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	7	49	theme	biofilms	924:931	arg1	thickness					891:899	thickness	891:899	thickness	891:899	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	7	49	theme	biofilms	924:931	arg1	different					970:978	different	970:978	different	970:978	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	7	49	theme	biofilms	924:931	arg1	compactness					905:915	compactness	905:915	compactness	905:915	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	14	50	theme	soluble	2018:2024	arg1	S-EPS					2031:2035	S-EPS	2031:2035	S-EPS	2031:2035	This study also observed that soluble EPS (S-EPS) were secreted first, followed by loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS).
35963380	14	50	theme	soluble	2018:2024	arg1	EPS					2026:2028	soluble EPS	2018:2028	soluble EPS (S-EPS)	2018:2036	This study also observed that soluble EPS (S-EPS) were secreted first, followed by loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS).
35963380	11	51	theme	bacteria	1662:1669	arg1	uniform					1686:1692	uniform	1686:1692	uniform	1686:1692	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	11	51	theme	bacteria	1662:1669	arg1	distribution					1587:1598	the distribution	1583:1598	the distribution of extracellular polysaccharides, extracellular proteins, and bacteria	1583:1669	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	1	52	theme	abiotic	198:204	arg1	surfaces					217:224	abiotic and biotic surfaces	198:224	abiotic and biotic surfaces	198:224	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	8	53	theme	shear	1068:1072	arg1	forces					1074:1079	shear forces	1068:1079	shear forces	1068:1079	The compact structure of the biofilm helped to resist shear forces to minimize detachment.
35963380	6	54	theme	flow	838:841	arg1	conditions					843:852	laminar flow conditions	830:852	laminar flow conditions	830:852	However, the biofilms formed under laminar flow conditions were thick but relatively loose.
35963380	6	55	theme	laminar	830:836	arg1	conditions					843:852	laminar flow conditions	830:852	laminar flow conditions	830:852	However, the biofilms formed under laminar flow conditions were thick but relatively loose.
35963380	1	56	theme	biotic	210:215	arg1	surfaces					217:224	abiotic and biotic surfaces	198:224	abiotic and biotic surfaces	198:224	Microbial biofilms are common on abiotic and biotic surfaces, especially in rivers, which drive crucial ecosystem processes.
35963380	13	57	theme	EPS	1831:1833	arg1	largest					1858:1864	largest	1858:1864	largest	1858:1864	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	13	57	theme	EPS	1831:1833	arg1	number					1821:1826	The total number	1811:1826	The total number of EPS in the biofilm	1811:1848	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	0	58	theme	biofilms	155:162	arg1	composition					42:52	the composition	38:52	the composition	38:52	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	0	58	theme	biofilms	155:162	arg1	distribution					70:81	spatiotemporal distribution	55:81	spatiotemporal distribution of different extracellular polymeric substances	55:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	0	58	theme	biofilms	155:162	arg1	architecture					139:150	the architecture	135:150	the architecture of biofilms	135:162	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	15	59	theme	flocculation	2172:2183	arg1	capability					2185:2194	flocculation capability	2172:2194	flocculation capability of TB-EPS	2172:2204	In particular, the adhesion of LB-EPS and flocculation capability of TB-EPS play some role in regulating biofilm formation.
35963380	11	60	theme	proteins	1648:1655	arg1	uniform					1686:1692	uniform	1686:1692	uniform	1686:1692	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	11	60	theme	proteins	1648:1655	arg1	distribution					1587:1598	the distribution	1583:1598	the distribution of extracellular polysaccharides, extracellular proteins, and bacteria	1583:1669	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	11	61	theme	flow	1567:1570	arg1	condition					1572:1580	the laminar flow condition	1555:1580	the laminar flow condition	1555:1580	Under the laminar flow condition, the distribution of extracellular polysaccharides, extracellular proteins, and bacteria was relatively uniform throughout the biofilm.
35963380	5	62	theme	high	757:760	arg1	force					768:772	high shear force	757:772	high shear force	757:772	The biofilms formed in turbulent flow with high shear force were thin but dense.
35963380	4	63	from	correlations	688:699	arg1	biofilms					704:711	biofilms	704:711	biofilms	704:711	Multidisciplinary methods offer complementary insights into complex architecture correlations in biofilms.
35963380	0	64	theme	different	86:94	arg1	substances					120:129	different extracellular polymeric substances	86:129	different extracellular polymeric substances	86:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	13	65	from	biofilm	1842:1848	arg1	largest					1858:1864	largest	1858:1864	largest	1858:1864	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	13	65	from	biofilm	1842:1848	arg1	number					1821:1826	The total number	1811:1826	The total number of EPS in the biofilm	1811:1848	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	13	66	theme	total	1815:1819	arg1	largest					1858:1864	largest	1858:1864	largest	1858:1864	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	13	66	theme	total	1815:1819	arg1	number					1821:1826	The total number	1811:1826	The total number of EPS in the biofilm	1811:1848	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	10	67	theme	transitional	1334:1345	arg1	condition					1352:1360	the transitional flow condition	1330:1360	the transitional flow condition	1330:1360	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	0	68	theme	polymeric	110:118	arg1	substances					120:129	different extracellular polymeric substances	86:129	different extracellular polymeric substances	86:129	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	2	69	theme	biofilms	312:319	arg1	microorganisms					294:307	The microorganisms	290:307	The microorganisms of biofilms	290:319	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	9	70	theme	flow	1125:1128	arg1	condition					1130:1138	the turbulent flow condition	1111:1138	the turbulent flow condition	1111:1138	Under the turbulent flow condition, bacteria, exopolysaccharides, and extracellular proteins permeated through the biofilm, and more extracellular polysaccharides enveloped bacteria and extracellular proteins.
35963380	13	71	theme	laminar	1964:1970	arg1	condition					1977:1985	laminar flow condition	1964:1985	laminar flow condition	1964:1985	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	3	72	theme	hydrodynamic	452:463	arg1	conditions					465:474	different hydrodynamic conditions	442:474	different hydrodynamic conditions	442:474	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	7	73	theme	other	998:1002	arg1	biofilms					1004:1011	the other biofilms	994:1011	the other biofilms	994:1011	The thickness and compactness of the biofilms formed in the transitional flow were different from those of the other biofilms.
35963380	14	74	theme	bound	2079:2083	arg1	LB-EPS					2090:2095	LB-EPS	2090:2095	LB-EPS	2090:2095	This study also observed that soluble EPS (S-EPS) were secreted first, followed by loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS).
35963380	14	74	theme	bound	2079:2083	arg1	EPS					2085:2087	loosely bound EPS	2071:2087	loosely bound EPS (LB-EPS)	2071:2096	This study also observed that soluble EPS (S-EPS) were secreted first, followed by loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS).
35963380	5	75	with	flow	747:750	arg1	force					768:772	high shear force	757:772	high shear force	757:772	The biofilms formed in turbulent flow with high shear force were thin but dense.
35963380	13	76	theme	transitional	1921:1932	arg1	condition					1939:1947	transitional flow condition	1921:1947	transitional flow condition	1921:1947	The total number of EPS in the biofilm was the largest under turbulent flow condition, followed by that under transitional flow condition and then under laminar flow condition.
35963380	0	77	theme	conditions	24:33	arg1	Effects					0:6	Effects	0:6	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms	0:162	Effects of hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances and the architecture of biofilms.
35963380	4	78	theme	Multidisciplinary	607:623	arg1	methods					625:631	Multidisciplinary methods	607:631	Multidisciplinary methods	607:631	Multidisciplinary methods offer complementary insights into complex architecture correlations in biofilms.
35963380	16	79	theme	formation	2321:2329	arg1	theory					2303:2308	the five-stages theory	2287:2308	the five-stages theory of biofilm formation	2287:2329	This study would help to perfect the five-stages theory of biofilm formation.
35963380	15	80	theme	LB-EPS	2161:2166	arg1	capability					2185:2194	flocculation capability	2172:2194	flocculation capability of TB-EPS	2172:2204	In particular, the adhesion of LB-EPS and flocculation capability of TB-EPS play some role in regulating biofilm formation.
35963380	15	80	theme	LB-EPS	2161:2166	arg1	adhesion					2149:2156	the adhesion	2145:2156	the adhesion of LB-EPS	2145:2166	In particular, the adhesion of LB-EPS and flocculation capability of TB-EPS play some role in regulating biofilm formation.
35963380	12	81	theme	extracellular	1732:1744	arg1	polysaccharides					1746:1760	extracellular polysaccharides	1732:1760	extracellular polysaccharides	1732:1760	The number of extracellular polysaccharides was greater than that of extracellular proteins.
35963380	9	82	theme	extracellular	1175:1187	arg1	proteins					1189:1196	extracellular proteins	1175:1196	extracellular proteins permeated through the biofilm	1175:1226	Under the turbulent flow condition, bacteria, exopolysaccharides, and extracellular proteins permeated through the biofilm, and more extracellular polysaccharides enveloped bacteria and extracellular proteins.
35963380	14	83	theme	bound	2110:2114	arg1	TB-EPS					2121:2126	TB-EPS	2121:2126	TB-EPS	2121:2126	This study also observed that soluble EPS (S-EPS) were secreted first, followed by loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS).
35963380	14	83	theme	bound	2110:2114	arg1	EPS					2116:2118	tightly bound EPS	2102:2118	tightly bound EPS (TB-EPS)	2102:2127	This study also observed that soluble EPS (S-EPS) were secreted first, followed by loosely bound EPS (LB-EPS) and tightly bound EPS (TB-EPS).
35963380	2	84	theme	extracellular	355:367	arg1	EPS					390:392	EPS	390:392	EPS	390:392	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	2	84	theme	extracellular	355:367	arg1	substance					379:387	a self-produced extracellular polymeric substance	339:387	a self-produced extracellular polymeric substance (EPS)	339:393	The microorganisms of biofilms are surrounded by a self-produced extracellular polymeric substance (EPS).
35963380	4	85	theme	complex	667:673	arg1	correlations					688:699	complex architecture correlations	667:699	complex architecture correlations in biofilms	667:711	Multidisciplinary methods offer complementary insights into complex architecture correlations in biofilms.
35963380	3	86	from	effects	431:437	arg1	distribution					511:522	spatiotemporal distribution	496:522	spatiotemporal distribution of different extracellular polymeric substances	496:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	86	from	effects	431:437	arg1	architecture					581:592	the architecture	577:592	the architecture of biofilms	577:604	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	86	from	effects	431:437	arg1	composition					483:493	the composition	479:493	the composition	479:493	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	87	theme	spatiotemporal	496:509	arg1	distribution					511:522	spatiotemporal distribution	496:522	spatiotemporal distribution of different extracellular polymeric substances	496:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	16	88	theme	five-stages	2291:2301	arg1	theory					2303:2308	the five-stages theory	2287:2308	the five-stages theory of biofilm formation	2287:2329	This study would help to perfect the five-stages theory of biofilm formation.
35963380	10	89	theme	flow	1452:1455	arg1	condition					1457:1465	the turbulent flow condition	1438:1465	the turbulent flow condition	1438:1465	However, under the transitional flow condition, the extracellular polysaccharides and proteins were fewer than those under the turbulent flow condition; bacteria and algae were seen more prominently in the upper layer of the biofilm.
35963380	3	90	theme	substances	561:570	arg1	distribution					511:522	spatiotemporal distribution	496:522	spatiotemporal distribution of different extracellular polymeric substances	496:570	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	90	theme	substances	561:570	arg1	architecture					581:592	the architecture	577:592	the architecture of biofilms	577:604	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35963380	3	90	theme	substances	561:570	arg1	composition					483:493	the composition	479:493	the composition	479:493	In this study, we investigated the effects of different hydrodynamic conditions on the composition, spatiotemporal distribution of different extracellular polymeric substances, and the architecture of biofilms.
35993963	6	0	theme	peroxide-induced	905:920	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	18	1	theme	promising	2068:2076	arg1	GLPs					2059:2062	GLPs	2059:2062	GLPs	2059:2062	GLPs are promising compounds to be developed into natural antioxidants and potentially used in cosmetics, health products, and functional foods.
35993963	18	1	theme	promising	2068:2076	arg1	compounds					2078:2086	promising compounds	2068:2086	promising compounds to be developed into natural antioxidants and potentially used in cosmetics, health products, and functional foods	2068:2201	GLPs are promising compounds to be developed into natural antioxidants and potentially used in cosmetics, health products, and functional foods.
35993963	2	2	theme	composition	340:350	arg1	GLPs					416:419	GLPs	416:419	GLPs	416:419	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	2	2	theme	composition	340:350	arg1	polysaccharides					399:413	G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides	321:413	G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs)	321:420	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	17	3	theme	significant	2025:2035	arg1	activity					2049:2056	significant antioxidant activity	2025:2056	significant antioxidant activity	2025:2056	GLPs showed no whitening but had significant antioxidant activity.
35993963	4	4	theme	cosmetic	570:577	arg1	efficacy					579:586	the cosmetic efficacy	566:586	the cosmetic efficacy of six types of GLPs	566:607	Therefore, this study sought to evaluate the cosmetic efficacy of six types of GLPs and analyze the structure of the identified polysaccharides.
35993963	15	5	theme	Morphological	1705:1717	arg1	analysis					1719:1726	Morphological analysis	1705:1726	Morphological analysis	1705:1726	Morphological analysis showed that there were significant differences between GLP1 and its two components.
35993963	6	6	theme	HaCaT	875:879	arg1	cells					881:885	HaCaT cells	875:885	HaCaT cells	875:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	11	7	theme	strong	1339:1344	arg1	effect					1357:1362	strong inhibitory effect	1339:1362	strong inhibitory effect	1339:1362	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	13	8	theme	comprehensive	1596:1608	arg1	score					1610:1614	The comprehensive score	1592:1614	The comprehensive score of GLP1	1592:1622	The comprehensive score of GLP1 was the highest.
35993963	13	8	theme	comprehensive	1596:1608	arg1	highest					1632:1638	highest	1632:1638	highest	1632:1638	The comprehensive score of GLP1 was the highest.
35993963	16	9	theme	gel	1914:1916	arg1	chromatography					1930:1943	high-performance gel penetration chromatography	1897:1943	high-performance gel penetration chromatography	1897:1943	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	4	10	theme	GLPs	604:607	arg1	types					595:599	six types	591:599	six types of GLPs	591:607	Therefore, this study sought to evaluate the cosmetic efficacy of six types of GLPs and analyze the structure of the identified polysaccharides.
35993963	0	11	theme	Reishi	128:133	arg1	Strains					106:112	Different Strains	96:112	Different Strains of Lingzhi or Reishi Medicinal Mushroom	96:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	6	12	theme	skin	954:957	arg1	fibroblasts					959:969	human skin fibroblasts	948:969	human skin fibroblasts (HSFs)	948:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	12	theme	skin	954:957	arg1	HSFs					972:975	HSFs	972:975	HSFs	972:975	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	7	13	theme	GLP1-GLP6	1052:1060	arg1	effects					1041:1047	The whitening, anti-inflammatory, and antioxidative effects	989:1047	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6	989:1060	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6 were determined.
35993963	1	14	theme	tonic	222:226	arg1	medicine					228:235	a popular tonic medicine	212:235	a popular tonic medicine in China	212:244	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	1	14	theme	tonic	222:226	arg1	lucidum					201:207	Ganoderma lucidum	191:207	Ganoderma lucidum	191:207	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	0	15	theme	Ganoderma	155:163	arg1	lucidum					165:171	Ganoderma lucidum	155:171	Ganoderma lucidum (Agaricomycetes)	155:188	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	0	15	theme	Ganoderma	155:163	arg1	Comparison					0:9	Comparison	0:9	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	0:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	0	15	theme	Ganoderma	155:163	arg1	Agaricomycetes					174:187	Agaricomycetes	174:187	Agaricomycetes	174:187	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	6	16	theme	stress	932:937	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	14	17	theme	exchange	1689:1696	arg1	resin					1698:1702	DEAE-52 ion exchange resin	1677:1702	DEAE-52 ion exchange resin	1677:1702	GLP1-I and GLP1-II were obtained by DEAE-52 ion exchange resin.
35993963	0	18	from	Strains	106:112	arg1	Activities					52:61	the Anti-Inflammatory and Antioxidant Activities	14:61	the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	14:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	0	18	from	Strains	106:112	arg1	Polysaccharides					75:89	Mycelial Polysaccharides	66:89	Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	66:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	4	19	theme	polysaccharides	653:667	arg1	structure					625:633	the structure	621:633	the structure of the identified polysaccharides	621:667	Therefore, this study sought to evaluate the cosmetic efficacy of six types of GLPs and analyze the structure of the identified polysaccharides.
35993963	16	20	contain	had	1964:1966	arg2	weight					1984:1989	a low molecular weight	1968:1989	a low molecular weight	1968:1989	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	16	20	contain	had	1964:1966	arg1	GLP1-I					1957:1962	GLP1-I	1957:1962	GLP1-I	1957:1962	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	14	21	theme	DEAE-52	1677:1683	arg1	resin					1698:1702	DEAE-52 ion exchange resin	1677:1702	DEAE-52 ion exchange resin	1677:1702	GLP1-I and GLP1-II were obtained by DEAE-52 ion exchange resin.
35993963	12	22	theme	cells	1585:1589	arg1	proportion					1561:1570	the proportion	1557:1570	the proportion of senescent cells	1557:1589	All GLPs could significantly increase the activity of HSFs and reduce the proportion of senescent cells.
35993963	10	23	theme	cellular	1263:1270	arg1	level					1283:1287	cellular tyrosinase level	1263:1287	cellular tyrosinase level	1263:1287	GLP1-GLP6 had no whitening effect as assessed by cellular tyrosinase level and melanin content.
35993963	5	24	theme	G.	744:745	arg1	strains					755:761	six G. lucidum strains	740:761	six G. lucidum strains	740:761	GLPs (GLP1-GLP6) were prepared with conventional methods by selecting six G. lucidum strains.
35993963	6	25	theme	melanin	794:800	arg1	model					802:806	The 8-methoxypsoralan-induced melanin model	764:806	The 8-methoxypsoralan-induced melanin model of B16 cells	764:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	0	26	dep	Lingzhi	117:123	arg1	Mushroom					145:152	Medicinal Mushroom	135:152	Medicinal Mushroom	135:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	18	27	theme	functional	2186:2195	arg1	foods					2197:2201	functional foods	2186:2201	functional foods	2186:2201	GLPs are promising compounds to be developed into natural antioxidants and potentially used in cosmetics, health products, and functional foods.
35993963	0	28	from	Activities	52:61	arg1	Strains					106:112	Different Strains	96:112	Different Strains of Lingzhi or Reishi Medicinal Mushroom	96:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	11	29	theme	inflammatory	1449:1460	arg1	interleukin-1α					1471:1484	inflammatory cytokine interleukin-1α	1449:1484	inflammatory cytokine interleukin-1α	1449:1484	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	0	30	theme	Lingzhi	117:123	arg1	Strains					106:112	Different Strains	96:112	Different Strains of Lingzhi or Reishi Medicinal Mushroom	96:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	0	31	theme	Antioxidant	40:50	arg1	Activities					52:61	the Anti-Inflammatory and Antioxidant Activities	14:61	the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	14:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	1	32	theme	health	295:300	arg1	benefits					302:309	health benefits	295:309	health benefits	295:309	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	2	33	theme	molecular	368:376	arg1	weight					378:383	molecular weight	368:383	molecular weight	368:383	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	11	34	theme	interleukin-1α	1471:1484	arg1	expression					1435:1444	the relative expression	1422:1444	the relative expression of inflammatory cytokine interleukin-1α	1422:1484	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	2	35	theme	lucidum	391:397	arg1	weight					378:383	molecular weight	368:383	molecular weight	368:383	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	2	35	theme	lucidum	391:397	arg1	structure					353:361	structure	353:361	structure	353:361	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	2	35	theme	lucidum	391:397	arg1	lucidum					324:330	lucidum	324:330	lucidum	324:330	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	2	35	theme	lucidum	391:397	arg1	composition					340:350	composition	340:350	composition	340:350	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	8	36	theme	initial	1085:1091	arg1	screening					1093:1101	initial screening	1085:1101	initial screening	1085:1101	After initial screening, promising GLPs were selected for further analysis.
35993963	6	37	theme	inflammation	853:864	arg1	model					866:870	the lipopolysaccharide-induced inflammation model	822:870	the lipopolysaccharide-induced inflammation model of HaCaT cells	822:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	17	38	contain	had	2021:2023	arg2	activity					2049:2056	significant antioxidant activity	2025:2056	significant antioxidant activity	2025:2056	GLPs showed no whitening but had significant antioxidant activity.
35993963	17	38	contain	had	2021:2023	arg1	GLPs					1992:1995	GLPs	1992:1995	GLPs	1992:1995	GLPs showed no whitening but had significant antioxidant activity.
35993963	0	39	theme	Mycelial	66:73	arg1	Polysaccharides					75:89	Mycelial Polysaccharides	66:89	Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	66:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	0	40	theme	Activities	52:61	arg1	lucidum					165:171	Ganoderma lucidum	155:171	Ganoderma lucidum (Agaricomycetes)	155:188	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	0	40	theme	Activities	52:61	arg1	Comparison					0:9	Comparison	0:9	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	0:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	16	41	theme	spectroscopy	1836:1847	arg1	results					1816:1822	The results	1812:1822	The results of infrared spectroscopy	1812:1847	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	16	42	theme	low	1970:1972	arg1	weight					1984:1989	a low molecular weight	1968:1989	a low molecular weight	1968:1989	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	12	43	theme	HSFs	1541:1544	arg1	activity					1529:1536	the activity	1525:1536	the activity of HSFs	1525:1544	All GLPs could significantly increase the activity of HSFs and reduce the proportion of senescent cells.
35993963	2	44	theme	lucidum	324:330	arg1	GLPs					416:419	GLPs	416:419	GLPs	416:419	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	2	44	theme	lucidum	324:330	arg1	polysaccharides					399:413	G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides	321:413	G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs)	321:420	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	6	45	theme	cells	815:819	arg1	model					866:870	the lipopolysaccharide-induced inflammation model	822:870	the lipopolysaccharide-induced inflammation model of HaCaT cells	822:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	45	theme	cells	815:819	arg1	model					802:806	The 8-methoxypsoralan-induced melanin model	764:806	The 8-methoxypsoralan-induced melanin model of B16 cells	764:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	45	theme	cells	815:819	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	10	46	theme	tyrosinase	1272:1281	arg1	level					1283:1287	cellular tyrosinase level	1263:1287	cellular tyrosinase level	1263:1287	GLP1-GLP6 had no whitening effect as assessed by cellular tyrosinase level and melanin content.
35993963	6	47	theme	oxidative	922:930	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	18	48	theme	health	2165:2170	arg1	products					2172:2179	health products	2165:2179	health products	2165:2179	GLPs are promising compounds to be developed into natural antioxidants and potentially used in cosmetics, health products, and functional foods.
35993963	8	49	theme	further	1137:1143	arg1	analysis					1145:1152	further analysis	1137:1152	further analysis	1137:1152	After initial screening, promising GLPs were selected for further analysis.
35993963	6	50	theme	hydrogen	896:903	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	18	51	theme	natural	2109:2115	arg1	antioxidants					2117:2128	natural antioxidants	2109:2128	natural antioxidants	2109:2128	GLPs are promising compounds to be developed into natural antioxidants and potentially used in cosmetics, health products, and functional foods.
35993963	6	52	used	used	983:986	arg2	model					802:806	The 8-methoxypsoralan-induced melanin model	764:806	The 8-methoxypsoralan-induced melanin model of B16 cells	764:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	52	used	used	983:986	arg2	model					866:870	the lipopolysaccharide-induced inflammation model	822:870	the lipopolysaccharide-induced inflammation model of HaCaT cells	822:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	52	used	used	983:986	arg2	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	13	53	theme	GLP1	1619:1622	arg1	score					1610:1614	The comprehensive score	1592:1614	The comprehensive score of GLP1	1592:1622	The comprehensive score of GLP1 was the highest.
35993963	13	53	theme	GLP1	1619:1622	arg1	highest					1632:1638	highest	1632:1638	highest	1632:1638	The comprehensive score of GLP1 was the highest.
35993963	17	54	theme	antioxidant	2037:2047	arg1	activity					2049:2056	significant antioxidant activity	2025:2056	significant antioxidant activity	2025:2056	GLPs showed no whitening but had significant antioxidant activity.
35993963	6	55	theme	8-methoxypsoralan-induced	768:792	arg1	model					802:806	The 8-methoxypsoralan-induced melanin model	764:806	The 8-methoxypsoralan-induced melanin model of B16 cells	764:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	1	56	theme	Ganoderma	191:199	arg1	medicine					228:235	a popular tonic medicine	212:235	a popular tonic medicine in China	212:244	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	1	56	theme	Ganoderma	191:199	arg1	lucidum					201:207	Ganoderma lucidum	191:207	Ganoderma lucidum	191:207	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	16	57	theme	high-performance	1897:1912	arg1	chromatography					1930:1943	high-performance gel penetration chromatography	1897:1943	high-performance gel penetration chromatography	1897:1943	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	6	58	theme	cells	881:885	arg1	model					866:870	the lipopolysaccharide-induced inflammation model	822:870	the lipopolysaccharide-induced inflammation model of HaCaT cells	822:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	58	theme	cells	881:885	arg1	model					802:806	The 8-methoxypsoralan-induced melanin model	764:806	The 8-methoxypsoralan-induced melanin model of B16 cells	764:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	58	theme	cells	881:885	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	3	59	from	studies	464:470	arg1	relationship					479:490	the relationship	475:490	the relationship between GLPs and their function	475:522	There are limited studies on the relationship between GLPs and their function.
35993963	16	60	theme	penetration	1918:1928	arg1	chromatography					1930:1943	high-performance gel penetration chromatography	1897:1943	high-performance gel penetration chromatography	1897:1943	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	0	61	theme	Medicinal	135:143	arg1	Mushroom					145:152	Medicinal Mushroom	135:152	Medicinal Mushroom	135:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	10	62	contain	had	1224:1226	arg1	GLP1-GLP6					1214:1222	GLP1-GLP6	1214:1222	GLP1-GLP6	1214:1222	GLP1-GLP6 had no whitening effect as assessed by cellular tyrosinase level and melanin content.
35993963	10	62	contain	had	1224:1226	arg2	effect					1241:1246	no whitening effect	1228:1246	no whitening effect	1228:1246	GLP1-GLP6 had no whitening effect as assessed by cellular tyrosinase level and melanin content.
35993963	6	63	theme	fibroblasts	959:969	arg1	model					866:870	the lipopolysaccharide-induced inflammation model	822:870	the lipopolysaccharide-induced inflammation model of HaCaT cells	822:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	63	theme	fibroblasts	959:969	arg1	model					802:806	The 8-methoxypsoralan-induced melanin model	764:806	The 8-methoxypsoralan-induced melanin model of B16 cells	764:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	63	theme	fibroblasts	959:969	arg1	model					939:943	the hydrogen peroxide-induced oxidative stress model	892:943	the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs)	892:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	1	64	theme	popular	214:220	arg1	medicine					228:235	a popular tonic medicine	212:235	a popular tonic medicine in China	212:244	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	1	64	theme	popular	214:220	arg1	lucidum					201:207	Ganoderma lucidum	191:207	Ganoderma lucidum	191:207	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	6	65	theme	human	948:952	arg1	fibroblasts					959:969	human skin fibroblasts	948:969	human skin fibroblasts (HSFs)	948:976	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	6	65	theme	human	948:952	arg1	HSFs					972:975	HSFs	972:975	HSFs	972:975	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	11	66	theme	inhibitory	1346:1355	arg1	effect					1357:1362	strong inhibitory effect	1339:1362	strong inhibitory effect	1339:1362	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	7	67	theme	antioxidative	1027:1039	arg1	effects					1041:1047	The whitening, anti-inflammatory, and antioxidative effects	989:1047	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6	989:1060	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6 were determined.
35993963	7	68	theme	anti-inflammatory	1004:1020	arg1	effects					1041:1047	The whitening, anti-inflammatory, and antioxidative effects	989:1047	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6	989:1060	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6 were determined.
35993963	1	69	from	medicine	228:235	arg1	China					240:244	China	240:244	China	240:244	Ganoderma lucidum is a popular tonic medicine in China, and its polysaccharides are believed to promote health benefits.
35993963	7	70	theme	whitening	993:1001	arg1	effects					1041:1047	The whitening, anti-inflammatory, and antioxidative effects	989:1047	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6	989:1060	The whitening, anti-inflammatory, and antioxidative effects of GLP1-GLP6 were determined.
35993963	12	71	theme	senescent	1575:1583	arg1	cells					1585:1589	senescent cells	1575:1589	senescent cells	1575:1589	All GLPs could significantly increase the activity of HSFs and reduce the proportion of senescent cells.
35993963	10	72	theme	whitening	1231:1239	arg1	effect					1241:1246	no whitening effect	1228:1246	no whitening effect	1228:1246	GLP1-GLP6 had no whitening effect as assessed by cellular tyrosinase level and melanin content.
35993963	3	73	theme	limited	456:462	arg1	studies					464:470	limited studies	456:470	limited studies on the relationship between GLPs and their function	456:522	There are limited studies on the relationship between GLPs and their function.
35993963	0	74	theme	Polysaccharides	75:89	arg1	Activities					52:61	the Anti-Inflammatory and Antioxidant Activities	14:61	the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	14:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	14	75	theme	ion	1685:1687	arg1	resin					1698:1702	DEAE-52 ion exchange resin	1677:1702	DEAE-52 ion exchange resin	1677:1702	GLP1-I and GLP1-II were obtained by DEAE-52 ion exchange resin.
35993963	16	76	theme	β-glycosidic	1874:1885	arg1	bond					1887:1890	a β-glycosidic bond	1872:1890	a β-glycosidic bond	1872:1890	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	11	77	contain	had	1335:1337	arg1	Meanwhile					1310:1318	Meanwhile	1310:1318	Meanwhile	1310:1318	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	11	77	contain	had	1335:1337	arg2	effect					1357:1362	strong inhibitory effect	1339:1362	strong inhibitory effect	1339:1362	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	11	77	contain	had	1335:1337	arg1	GLP4					1330:1333	GLP4	1330:1333	GLP4	1330:1333	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	11	77	contain	had	1335:1337	arg1	GLP1					1321:1324	GLP1	1321:1324	GLP1	1321:1324	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	4	78	theme	identified	642:651	arg1	polysaccharides					653:667	the identified polysaccharides	638:667	the identified polysaccharides	638:667	Therefore, this study sought to evaluate the cosmetic efficacy of six types of GLPs and analyze the structure of the identified polysaccharides.
35993963	15	79	theme	significant	1751:1761	arg1	differences					1763:1773	significant differences	1751:1773	significant differences between GLP1 and its two components	1751:1809	Morphological analysis showed that there were significant differences between GLP1 and its two components.
35993963	0	80	theme	Different	96:104	arg1	Strains					106:112	Different Strains	96:112	Different Strains of Lingzhi or Reishi Medicinal Mushroom	96:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	5	81	theme	conventional	706:717	arg1	methods					719:725	conventional methods	706:725	conventional methods	706:725	GLPs (GLP1-GLP6) were prepared with conventional methods by selecting six G. lucidum strains.
35993963	11	82	theme	relative	1426:1433	arg1	expression					1435:1444	the relative expression	1422:1444	the relative expression of inflammatory cytokine interleukin-1α	1422:1484	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	16	83	contain	had	1868:1870	arg1	GLP1-I					1861:1866	GLP1-I	1861:1866	GLP1-I	1861:1866	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	16	83	contain	had	1868:1870	arg2	bond					1887:1890	a β-glycosidic bond	1872:1890	a β-glycosidic bond	1872:1890	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	0	84	theme	Anti-Inflammatory	18:34	arg1	Activities					52:61	the Anti-Inflammatory and Antioxidant Activities	14:61	the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom	14:152	Comparison of the Anti-Inflammatory and Antioxidant Activities of Mycelial Polysaccharides from Different Strains of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).
35993963	11	85	theme	cytokine	1462:1469	arg1	interleukin-1α					1471:1484	inflammatory cytokine interleukin-1α	1449:1484	inflammatory cytokine interleukin-1α	1449:1484	Meanwhile, GLP1 and GLP4 had strong inhibitory effect on hyaluronidase, and GLP1 and GLP2 significantly reduced the relative expression of inflammatory cytokine interleukin-1α.
35993963	5	86	theme	lucidum	747:753	arg1	strains					755:761	six G. lucidum strains	740:761	six G. lucidum strains	740:761	GLPs (GLP1-GLP6) were prepared with conventional methods by selecting six G. lucidum strains.
35993963	10	87	theme	melanin	1293:1299	arg1	content					1301:1307	melanin content	1293:1307	melanin content	1293:1307	GLP1-GLP6 had no whitening effect as assessed by cellular tyrosinase level and melanin content.
35993963	2	88	theme	G.	388:389	arg1	lucidum					391:397	G. lucidum	388:397	G. lucidum	388:397	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	8	89	theme	promising	1104:1112	arg1	GLPs					1114:1117	promising GLPs	1104:1117	promising GLPs	1104:1117	After initial screening, promising GLPs were selected for further analysis.
35993963	6	90	theme	lipopolysaccharide-induced	826:851	arg1	model					866:870	the lipopolysaccharide-induced inflammation model	822:870	the lipopolysaccharide-induced inflammation model of HaCaT cells	822:885	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	16	91	theme	molecular	1974:1982	arg1	weight					1984:1989	a low molecular weight	1968:1989	a low molecular weight	1968:1989	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	16	92	theme	infrared	1827:1834	arg1	spectroscopy					1836:1847	infrared spectroscopy	1827:1847	infrared spectroscopy	1827:1847	The results of infrared spectroscopy showed that GLP1-I had a β-glycosidic bond, and high-performance gel penetration chromatography showed that GLP1-I had a low molecular weight.
35993963	2	93	theme	G.	321:322	arg1	GLPs					416:419	GLPs	416:419	GLPs	416:419	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	2	93	theme	G.	321:322	arg1	polysaccharides					399:413	G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides	321:413	G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs)	321:420	However, G. lucidum and the composition, structure, and molecular weight of G. lucidum polysaccharides (GLPs) are very heterogeneous.
35993963	6	94	theme	B16	811:813	arg1	cells					815:819	B16 cells	811:819	B16 cells	811:819	The 8-methoxypsoralan-induced melanin model of B16 cells, the lipopolysaccharide-induced inflammation model of HaCaT cells, and the hydrogen peroxide-induced oxidative stress model of human skin fibroblasts (HSFs) were used.
35993963	4	95	theme	types	595:599	arg1	efficacy					579:586	the cosmetic efficacy	566:586	the cosmetic efficacy of six types of GLPs	566:607	Therefore, this study sought to evaluate the cosmetic efficacy of six types of GLPs and analyze the structure of the identified polysaccharides.
37331542	5	0	theme	1.6 × 104 Da	807:818	arg1	weight					797:802	the molecular weight	783:802	the molecular weight of 1.6 × 104 Da	783:818	The results indicated that HSM-1-1 was a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da.
37331542	6	1	theme	proliferation	967:979	arg1	activity					992:999	potent proliferation inhibition activity	960:999	potent proliferation inhibition activity	960:999	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	3	2	from	echinocaulis	439:450	arg1	bioactivity					389:399	bioactivity	389:399	bioactivity	389:399	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	3	2	from	echinocaulis	439:450	arg1	polysaccharide					406:419	a polysaccharide	404:419	a polysaccharide (HSM-1-1) from A. echinocaulis	404:450	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	3	2	from	echinocaulis	439:450	arg1	purification					372:383	purification	372:383	purification	372:383	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	3	2	from	echinocaulis	439:450	arg1	isolation					361:369	isolation	361:369	isolation	361:369	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	3	2	from	echinocaulis	439:450	arg1	HSM-1-1					422:428	HSM-1-1	422:428	HSM-1-1	422:428	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	1	3	theme	important	165:173	arg1	discovery					109:117	The discovery	105:117	The discovery of active constituents from food plants	105:157	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	1	3	theme	important	165:173	arg1	area					175:178	an important area	162:178	an important area of research in pharmaceutical sciences	162:217	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	6	4	theme	potent	960:965	arg1	activity					992:999	potent proliferation inhibition activity	960:999	potent proliferation inhibition activity	960:999	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	4	5	theme	weight	518:523	arg1	distribution					525:536	the molecular weight distribution	504:536	the molecular weight distribution	504:536	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	6	6	from	concentration	1075:1087	arg1	rate					1047:1050	an inhibition rate	1033:1050	an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1033:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	6	6	from	concentration	1075:1087	arg1	%					1068:1068	17.57 ± 1.03 %	1055:1068	17.57 ± 1.03 % at a concentration of 600 μg/mL	1055:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	1	7	from	area	175:178	arg1	sciences					210:217	pharmaceutical sciences	195:217	pharmaceutical sciences	195:217	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	6	8	with	SW480	1022:1026	arg1	rate					1047:1050	an inhibition rate	1033:1050	an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1033:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	2	9	from	arthritis	317:325	arg1	China					330:334	China	330:334	China	330:334	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	4	10	theme	nuclear	616:622	arg1	resonance					633:641	nuclear magnetic resonance	616:641	nuclear magnetic resonance spectra	616:649	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	7	11	theme	natural	1291:1297	arg1	product					1299:1305	an adjuvant natural product	1279:1305	an adjuvant natural product with antitumor effects	1279:1328	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	3	12	from	purification	372:383	arg1	echinocaulis					439:450	A. echinocaulis	436:450	A. echinocaulis	436:450	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	5	13	theme	new	693:695	arg1	4-O-methylglucuronoxylan					697:720	a new 4-O-methylglucuronoxylan	691:720	a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da	691:818	The results indicated that HSM-1-1 was a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da.
37331542	5	13	theme	new	693:695	arg1	HSM-1-1					679:685	HSM-1-1	679:685	HSM-1-1	679:685	The results indicated that HSM-1-1 was a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da.
37331542	6	14	theme	anti-inflammatory	852:868	arg1	activities					870:879	the antitumor and anti-inflammatory activities	834:879	the antitumor and anti-inflammatory activities of HSM-1-1 in vitro	834:899	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	6	15	theme	inhibition	1036:1045	arg1	rate					1047:1050	an inhibition rate	1033:1050	an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1033:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	6	16	from	rate	1047:1050	arg1	concentration					1075:1087	a concentration	1073:1087	a concentration of 600 μg/mL	1073:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	6	17	contain	had	956:958	arg2	activity					992:999	potent proliferation inhibition activity	960:999	potent proliferation inhibition activity	960:999	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	6	17	contain	had	956:958	arg1	HSM-1-1					948:954	HSM-1-1	948:954	HSM-1-1	948:954	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	5	18	theme	molecular	787:795	arg1	weight					797:802	the molecular weight	783:802	the molecular weight of 1.6 × 104 Da	783:818	The results indicated that HSM-1-1 was a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da.
37331542	3	19	from	bioactivity	389:399	arg1	echinocaulis					439:450	A. echinocaulis	436:450	A. echinocaulis	436:450	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	7	20	with	product	1299:1305	arg1	effects					1322:1328	antitumor effects	1312:1328	antitumor effects	1312:1328	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	6	21	theme	antitumor	838:846	arg1	activities					870:879	the antitumor and anti-inflammatory activities	834:879	the antitumor and anti-inflammatory activities of HSM-1-1 in vitro	834:899	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	1	22	theme	research	183:190	arg1	discovery					109:117	The discovery	105:117	The discovery of active constituents from food plants	105:157	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	1	22	theme	research	183:190	arg1	area					175:178	an important area	162:178	an important area of research in pharmaceutical sciences	162:217	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	1	23	from	plants	152:157	arg1	discovery					109:117	The discovery	105:117	The discovery of active constituents from food plants	105:157	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	1	23	from	plants	152:157	arg1	area					175:178	an important area	162:178	an important area of research in pharmaceutical sciences	162:217	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	4	24	theme	chromatography-mass	571:589	arg1	GC-MS					605:609	GC-MS	605:609	GC-MS	605:609	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	4	24	theme	chromatography-mass	571:589	arg1	spectrometry					591:602	gas chromatography-mass spectrometry	567:602	gas chromatography-mass spectrometry (GC-MS)	567:610	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	1	25	theme	pharmaceutical	195:208	arg1	sciences					210:217	pharmaceutical sciences	195:217	pharmaceutical sciences	195:217	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	7	26	theme	polysaccharide	1180:1193	arg1	structure					1195:1203	a polysaccharide structure	1178:1203	a polysaccharide structure obtained from A. echinocaulis and its bioactivities	1178:1255	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	4	27	theme	gas	567:569	arg1	GC-MS					605:609	GC-MS	605:609	GC-MS	605:609	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	4	27	theme	gas	567:569	arg1	spectrometry					591:602	gas chromatography-mass spectrometry	567:602	gas chromatography-mass spectrometry (GC-MS)	567:610	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	2	28	theme	rheumatoid	306:315	arg1	arthritis					317:325	rheumatoid arthritis	306:325	rheumatoid arthritis in China	306:334	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	7	29	theme	structure	1195:1203	arg1	this					1150:1153	this	1150:1153	this	1150:1153	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	7	29	theme	structure	1195:1203	arg1	report					1168:1173	the first report	1158:1173	the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities	1158:1255	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	1	30	theme	active	122:127	arg1	constituents					129:140	active constituents	122:140	active constituents	122:140	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	6	31	theme	cell	1017:1020	arg1	SW480					1022:1026	colon cancer cell SW480	1004:1026	colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1004:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	5	32	theme	4-O-methyl	751:760	arg1	acid					773:776	4-O-methyl glucuronic acid	751:776	4-O-methyl glucuronic acid	751:776	The results indicated that HSM-1-1 was a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da.
37331542	0	33	from	echinocaulis	91:102	arg1	characterization					14:29	characterization	14:29	characterization	14:29	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	0	33	from	echinocaulis	91:102	arg1	Purification					0:11	Purification	0:11	Purification	0:11	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	0	33	from	echinocaulis	91:102	arg1	bioactivities					35:47	bioactivities	35:47	bioactivities	35:47	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	2	34	theme	food	255:258	arg1	plant					260:264	a medicinal food plant	243:264	a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China	243:334	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	2	34	theme	food	255:258	arg1	echinocaulis					227:238	Aralia echinocaulis	220:238	Aralia echinocaulis	220:238	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	6	35	theme	600 μg/mL	1092:1100	arg1	concentration					1075:1087	a concentration	1073:1087	a concentration of 600 μg/mL	1073:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	4	36	theme	monosaccharide	539:552	arg1	composition					554:564	monosaccharide composition	539:564	monosaccharide composition	539:564	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	5	37	theme	glucuronic	762:771	arg1	acid					773:776	4-O-methyl glucuronic acid	751:776	4-O-methyl glucuronic acid	751:776	The results indicated that HSM-1-1 was a new 4-O-methylglucuronoxylan mainly composed of xylan and 4-O-methyl glucuronic acid with the molecular weight of 1.6 × 104 Da.
37331542	3	38	from	isolation	361:369	arg1	echinocaulis					439:450	A. echinocaulis	436:450	A. echinocaulis	436:450	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	2	39	theme	medicinal	245:253	arg1	plant					260:264	a medicinal food plant	243:264	a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China	243:334	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	2	39	theme	medicinal	245:253	arg1	echinocaulis					227:238	Aralia echinocaulis	220:238	Aralia echinocaulis	220:238	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	0	40	theme	4-O-methylglucuronoxylan	54:77	arg1	characterization					14:29	characterization	14:29	characterization	14:29	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	0	40	theme	4-O-methylglucuronoxylan	54:77	arg1	Purification					0:11	Purification	0:11	Purification	0:11	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	0	40	theme	4-O-methylglucuronoxylan	54:77	arg1	bioactivities					35:47	bioactivities	35:47	bioactivities	35:47	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	6	41	theme	colon	1004:1008	arg1	SW480					1022:1026	colon cancer cell SW480	1004:1026	colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1004:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	4	42	theme	structural	457:466	arg1	features					468:475	Its structural features	453:475	Its structural features	453:475	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	1	43	theme	constituents	129:140	arg1	discovery					109:117	The discovery	105:117	The discovery of active constituents from food plants	105:157	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	1	43	theme	constituents	129:140	arg1	area					175:178	an important area	162:178	an important area of research in pharmaceutical sciences	162:217	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	3	44	theme	polysaccharide	406:419	arg1	bioactivity					389:399	bioactivity	389:399	bioactivity	389:399	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	3	44	theme	polysaccharide	406:419	arg1	purification					372:383	purification	372:383	purification	372:383	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	3	44	theme	polysaccharide	406:419	arg1	isolation					361:369	isolation	361:369	isolation	361:369	This paper reported the isolation, purification and bioactivity of a polysaccharide (HSM-1-1) from A. echinocaulis.
37331542	6	45	theme	inhibition	981:990	arg1	activity					992:999	potent proliferation inhibition activity	960:999	potent proliferation inhibition activity	960:999	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	7	46	theme	antitumor	1312:1320	arg1	effects					1322:1328	antitumor effects	1312:1328	antitumor effects	1312:1328	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	6	47	theme	cancer	1010:1015	arg1	SW480					1022:1026	colon cancer cell SW480	1004:1026	colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1004:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	2	48	theme	Aralia	220:225	arg1	plant					260:264	a medicinal food plant	243:264	a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China	243:334	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	2	48	theme	Aralia	220:225	arg1	echinocaulis					227:238	Aralia echinocaulis	220:238	Aralia echinocaulis	220:238	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	1	49	theme	food	147:150	arg1	plants					152:157	food plants	147:157	food plants	147:157	The discovery of active constituents from food plants is an important area of research in pharmaceutical sciences.
37331542	4	50	theme	resonance	633:641	arg1	spectra					643:649	nuclear magnetic resonance spectra	616:649	nuclear magnetic resonance spectra	616:649	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	4	51	theme	magnetic	624:631	arg1	resonance					633:641	nuclear magnetic resonance	616:641	nuclear magnetic resonance spectra	616:649	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	0	52	theme	Aralia	84:89	arg1	echinocaulis					91:102	Aralia echinocaulis	84:102	Aralia echinocaulis	84:102	Purification, characterization and bioactivities of a 4-O-methylglucuronoxylan from Aralia echinocaulis.
37331542	6	53	theme	HSM-1-1	884:890	arg1	activities					870:879	the antitumor and anti-inflammatory activities	834:879	the antitumor and anti-inflammatory activities of HSM-1-1 in vitro	834:899	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	6	54	theme	MTS	1119:1121	arg1	methods					1123:1129	MTS methods	1119:1129	MTS methods	1119:1129	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
37331542	7	55	theme	first	1162:1166	arg1	this					1150:1153	this	1150:1153	this	1150:1153	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	7	55	theme	first	1162:1166	arg1	report					1168:1173	the first report	1158:1173	the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities	1158:1255	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	4	56	theme	molecular	508:516	arg1	distribution					525:536	the molecular weight distribution	504:536	the molecular weight distribution	504:536	Its structural features were analyzed according to the molecular weight distribution, monosaccharide composition, gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance spectra.
37331542	7	57	theme	adjuvant	1282:1289	arg1	product					1299:1305	an adjuvant natural product	1279:1305	an adjuvant natural product with antitumor effects	1279:1328	To our knowledge, this is the first report of a polysaccharide structure obtained from A. echinocaulis and its bioactivities, and its potential as an adjuvant natural product with antitumor effects is shown.
37331542	2	58	used	used	281:284	arg2	echinocaulis					227:238	Aralia echinocaulis	220:238	Aralia echinocaulis	220:238	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	2	58	used	used	281:284	arg2	plant					260:264	a medicinal food plant	243:264	a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China	243:334	Aralia echinocaulis is a medicinal food plant that is mainly used to prevent or treat rheumatoid arthritis in China.
37331542	6	59	theme	%	1068:1068	arg1	rate					1047:1050	an inhibition rate	1033:1050	an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL	1033:1100	Furthermore, the antitumor and anti-inflammatory activities of HSM-1-1 in vitro were investigated, and the results showed that HSM-1-1 had potent proliferation inhibition activity on colon cancer cell SW480 with an inhibition rate of 17.57 ± 1.03 % at a concentration of 600 μg/mL, as measured via MTS methods.
34626383	5	0	theme	polysaccharides	806:820	arg1	composition					785:795	the composition	781:795	the composition of these polysaccharides	781:820	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	5	0	theme	polysaccharides	806:820	arg1	techniques					827:836	techniques	827:836	techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures	827:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	4	1	theme	high-resolution	516:530	arg1	techniques					532:541	high-resolution techniques	516:541	high-resolution techniques like mass spectrometry	516:564	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	0	2	theme	Sulfate	67:73	arg1	Analysis					35:42	the Analysis	31:42	the Analysis of Heparin and Heparan Sulfate	31:73	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.
34626383	1	3	theme	structural	153:162	arg1	microheterogeneity					164:181	structural microheterogeneity	153:181	structural microheterogeneity	153:181	Glycosaminoglycans like heparin and heparan sulfate exhibit a high degree of structural microheterogeneity.
34626383	4	4	theme	available	617:625	arg1	methodologies					603:615	methodologies	603:615	methodologies available to probe the fine structural details of heparin and heparan sulfate	603:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	3	5	theme	normal	368:373	arg1	physiology					375:384	normal physiology	368:384	normal physiology	368:384	Heparin and heparan sulfate play critical roles in normal physiology and pathophysiology, hence it is important to understand how their structural features may influence overall activity.
34626383	1	6	theme	microheterogeneity	164:181	arg1	degree					143:148	a high degree	136:148	a high degree of structural microheterogeneity	136:181	Glycosaminoglycans like heparin and heparan sulfate exhibit a high degree of structural microheterogeneity.
34626383	0	7	theme	Spectrometric	5:17	arg1	Methods					19:25	Mass Spectrometric Methods	0:25	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.	0:74	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.
34626383	3	8	theme	critical	350:357	arg1	roles					359:363	critical roles	350:363	critical roles	350:363	Heparin and heparan sulfate play critical roles in normal physiology and pathophysiology, hence it is important to understand how their structural features may influence overall activity.
34626383	0	9	theme	Mass	0:3	arg1	Methods					19:25	Mass Spectrometric Methods	0:25	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.	0:74	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.
34626383	4	10	theme	suite	594:598	arg1	part					582:585	a key part	576:585	a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate	576:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	3	11	theme	structural	453:462	arg1	features					464:471	their structural features	447:471	their structural features	447:471	Heparin and heparan sulfate play critical roles in normal physiology and pathophysiology, hence it is important to understand how their structural features may influence overall activity.
34626383	4	12	theme	methodologies	603:615	arg1	suite					594:598	the suite	590:598	the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate	590:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	2	13	theme	structural	189:198	arg1	heterogeneity					200:212	This structural heterogeneity	184:212	This structural heterogeneity	184:212	This structural heterogeneity results from the biosynthetic process that produces these linear polysaccharides in cells and tissues.
34626383	4	14	theme	heparin	667:673	arg1	details					656:662	the fine structural details	636:662	the fine structural details of heparin and heparan sulfate	636:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	5	15	theme	oligosaccharide	880:894	arg1	fragments					896:904	oligosaccharide fragments	880:904	oligosaccharide fragments in these mixtures	880:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	4	16	theme	sulfate	687:693	arg1	details					656:662	the fine structural details	636:662	the fine structural details of heparin and heparan sulfate	636:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	4	17	theme	key	578:580	arg1	part					582:585	a key part	576:585	a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate	576:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	5	18	theme	fragments	896:904	arg1	analysis					868:875	an analysis	865:875	an analysis of oligosaccharide fragments in these mixtures	865:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	4	19	theme	heparan	679:685	arg1	sulfate					687:693	heparan sulfate	679:693	heparan sulfate	679:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	0	20	theme	Heparin	47:53	arg1	Analysis					35:42	the Analysis	31:42	the Analysis of Heparin and Heparan Sulfate	31:73	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.
34626383	3	21	theme	heparan	329:335	arg1	sulfate					337:343	heparan sulfate	329:343	heparan sulfate	329:343	Heparin and heparan sulfate play critical roles in normal physiology and pathophysiology, hence it is important to understand how their structural features may influence overall activity.
34626383	5	22	from	fragments	896:904	arg1	mixtures					915:922	these mixtures	909:922	these mixtures	909:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	1	23	theme	heparan	112:118	arg1	sulfate					120:126	heparan sulfate	112:126	heparan sulfate	112:126	Glycosaminoglycans like heparin and heparan sulfate exhibit a high degree of structural microheterogeneity.
34626383	2	24	theme	biosynthetic	231:242	arg1	process					244:250	the biosynthetic process	227:250	the biosynthetic process that produces these linear polysaccharides in cells and tissues	227:314	This structural heterogeneity results from the biosynthetic process that produces these linear polysaccharides in cells and tissues.
34626383	5	25	from	analysis	868:875	arg1	mixtures					915:922	these mixtures	909:922	these mixtures	909:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	4	26	theme	structural	645:654	arg1	details					656:662	the fine structural details	636:662	the fine structural details of heparin and heparan sulfate	636:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	5	27	theme	techniques	737:746	arg1	application					722:732	the application	718:732	the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures	718:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	5	28	from	mixtures	915:922	arg1	analysis					868:875	an analysis	865:875	an analysis of oligosaccharide fragments in these mixtures	865:922	This chapter outlines the application of techniques like LC-MS and LC-MS/MS to study the composition of these polysaccharides, and techniques like GPC-MS that allow for an analysis of oligosaccharide fragments in these mixtures.
34626383	4	29	theme	fine	640:643	arg1	details					656:662	the fine structural details	636:662	the fine structural details of heparin and heparan sulfate	636:693	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
34626383	0	30	theme	Heparan	59:65	arg1	Sulfate					67:73	Heparan Sulfate	59:73	Heparan Sulfate	59:73	Mass Spectrometric Methods for the Analysis of Heparin and Heparan Sulfate.
34626383	3	31	theme	overall	487:493	arg1	activity					495:502	overall activity	487:502	overall activity	487:502	Heparin and heparan sulfate play critical roles in normal physiology and pathophysiology, hence it is important to understand how their structural features may influence overall activity.
34626383	2	32	theme	linear	272:277	arg1	polysaccharides					279:293	these linear polysaccharides	266:293	these linear polysaccharides	266:293	This structural heterogeneity results from the biosynthetic process that produces these linear polysaccharides in cells and tissues.
34626383	1	33	theme	high	138:141	arg1	degree					143:148	a high degree	136:148	a high degree of structural microheterogeneity	136:181	Glycosaminoglycans like heparin and heparan sulfate exhibit a high degree of structural microheterogeneity.
34626383	4	34	theme	mass	548:551	arg1	spectrometry					553:564	mass spectrometry	548:564	mass spectrometry	548:564	Therefore, high-resolution techniques like mass spectrometry represent a key part of the suite of methodologies available to probe the fine structural details of heparin and heparan sulfate.
36366726	0	0	theme	hemostatic	96:105	arg1	material					107:114	composite hemostatic material	86:114	composite hemostatic material prepared by a green fabrication approach	86:155	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	4	1	theme	swelling	733:740	arg1	Group					724:728	Group 1	724:730	especially Group 1 (swelling ratio reached 5792%)	713:761	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	1	theme	swelling	733:740	arg1	%					760:760	swelling ratio reached 5792%	733:760	swelling ratio reached 5792%	733:760	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	5	2	theme	clotting	844:851	arg1	BCI					860:862	BCI	860:862	BCI	860:862	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	5	2	theme	clotting	844:851	arg1	index					853:857	blood clotting index	838:857	blood clotting index (BCI)	838:863	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	2	3	theme	carboxymethyl	382:394	arg1	chitosan					396:403	carboxymethyl chitosan	382:403	carboxymethyl chitosan which possess excellent hemostatic effect	382:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	0	4	theme	composite	86:94	arg1	material					107:114	composite hemostatic material	86:114	composite hemostatic material prepared by a green fabrication approach	86:155	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	5	5	theme	negative	1081:1088	arg1	charge					1090:1095	the negative charge	1077:1095	the negative charge on the surface of the red blood cells	1077:1133	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	6	6	theme	implanted	1231:1239	arg1	AMPCs					1241:1245	implanted AMPCs	1231:1245	implanted AMPCs into the back of Sprague-Dawley rats	1231:1282	The biosafety was a preliminary evaluation by implanted AMPCs into the back of Sprague-Dawley rats and the tissue was harvested after feeding for 28 days.
36366726	3	7	theme	carboxymethyl	538:550	arg1	chitosan					552:559	carboxymethyl chitosan	538:559	carboxymethyl chitosan with different properties	538:585	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	5	8	from	charge	1015:1020	arg1	surface					1029:1035	the surface	1025:1035	the surface of the cations in the salts	1025:1063	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	7	9	theme	serum	1499:1503	arg1	indicators					1505:1514	some serum indicators	1494:1514	some serum indicators	1494:1514	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	5	10	theme	electrostatic	1139:1151	arg1	reaction					1168:1175	an electrostatic neutralization reaction	1136:1175	an electrostatic neutralization reaction	1136:1175	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	3	11	with	chitosan	552:559	arg1	properties					576:585	different properties	566:585	different properties	566:585	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	2	12	theme	macroporous	305:315	arg1	polysaccharides					317:331	the absorbable macroporous polysaccharides	290:331	the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect	290:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	8	13	theme	safe	1731:1734	arg1	agent					1747:1751	a highly functional and safe hemostatic agent	1707:1751	a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies	1707:1817	These findings demonstrate that expecting to develop a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies.
36366726	4	14	theme	physical	632:639	arg1	properties					654:663	the physical and chemical properties	628:663	the physical and chemical properties	628:663	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	5	15	from	cations	1044:1050	arg1	salts					1059:1063	the salts	1055:1063	the salts	1055:1063	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	7	16	theme	AMPCs	1466:1470	arg1	degradation					1451:1461	the degradation	1447:1461	the degradation of AMPCs	1447:1470	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	2	17	theme	absorbable	294:303	arg1	polysaccharides					317:331	the absorbable macroporous polysaccharides	290:331	the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect	290:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	5	18	theme	neutralization	1153:1166	arg1	reaction					1168:1175	an electrostatic neutralization reaction	1136:1175	an electrostatic neutralization reaction	1136:1175	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	5	19	from	surface	1029:1035	arg1	salts					1059:1063	the salts	1055:1063	the salts	1055:1063	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	6	20	theme	preliminary	1205:1215	arg1	biosafety					1189:1197	The biosafety	1185:1197	The biosafety	1185:1197	The biosafety was a preliminary evaluation by implanted AMPCs into the back of Sprague-Dawley rats and the tissue was harvested after feeding for 28 days.
36366726	6	20	theme	preliminary	1205:1215	arg1	evaluation					1217:1226	a preliminary evaluation	1203:1226	a preliminary evaluation by implanted AMPCs into the back of Sprague-Dawley rats	1203:1282	The biosafety was a preliminary evaluation by implanted AMPCs into the back of Sprague-Dawley rats and the tissue was harvested after feeding for 28 days.
36366726	7	21	theme	good	1360:1363	arg1	biosafety					1365:1373	good biosafety	1360:1373	good biosafety for whole blood and major organs	1360:1406	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	3	22	theme	different	566:574	arg1	properties					576:585	different properties	566:585	different properties	566:585	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	3	23	used	used	592:595	arg2	chitosan					552:559	carboxymethyl chitosan	538:559	carboxymethyl chitosan with different properties	538:585	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	0	24	dep	material	107:114	arg1	effect					11:16	Hemostatic effect	0:16	Hemostatic effect	0:16	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	0	24	dep	material	107:114	arg1	evaluation					29:38	safety evaluation	22:38	safety evaluation of the absorbable macroporous polysaccharides	22:84	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	2	25	theme	hemostatic	429:438	arg1	effect					440:445	excellent hemostatic effect	419:445	excellent hemostatic effect	419:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	5	26	from	salts	1059:1063	arg1	surface					1029:1035	the surface	1025:1035	the surface of the cations in the salts	1025:1063	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	5	27	theme	cells	1129:1133	arg1	surface					1104:1110	the surface	1100:1110	the surface of the red blood cells	1100:1133	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	4	28	theme	absorption	693:702	arg1	ability					704:710	high water absorption ability	682:710	high water absorption ability	682:710	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	28	theme	absorption	693:702	arg1	Group					724:728	Group 1	724:730	especially Group 1 (swelling ratio reached 5792%)	713:761	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	8	29	from	applications	1791:1802	arg1	emergencies					1807:1817	emergencies	1807:1817	emergencies	1807:1817	These findings demonstrate that expecting to develop a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies.
36366726	7	30	theme	gross	1610:1614	arg1	observation					1616:1626	gross observation	1610:1626	gross observation	1610:1626	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	2	31	theme	excellent	419:427	arg1	effect					440:445	excellent hemostatic effect	419:445	excellent hemostatic effect	419:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	0	32	theme	Hemostatic	0:9	arg1	effect					11:16	Hemostatic effect	0:16	Hemostatic effect	0:16	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	7	33	theme	whole	1379:1383	arg1	blood					1385:1389	whole blood	1379:1389	whole blood	1379:1389	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	8	34	theme	hemostasis	1780:1789	arg1	applications					1791:1802	rapid hemostasis applications	1774:1802	rapid hemostasis applications in emergencies	1774:1817	These findings demonstrate that expecting to develop a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies.
36366726	5	35	theme	higher	933:938	arg1	capacity					952:959	a slightly higher coagulation capacity	922:959	a slightly higher coagulation capacity	922:959	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	4	36	theme	rapid	786:790	arg1	formation					792:800	the rapid formation	782:800	the rapid formation of blood clots	782:815	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	1	37	theme	medical	203:209	arg1	field					211:215	the medical field	199:215	the medical field	199:215	Carboxymethyl chitosan is widely used in the medical field such as wound healing and other medical fields.
36366726	0	38	theme	safety	22:27	arg1	evaluation					29:38	safety evaluation	22:38	safety evaluation of the absorbable macroporous polysaccharides	22:84	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	5	39	theme	red	1119:1121	arg1	cells					1129:1133	the red blood cells	1115:1133	the red blood cells	1115:1133	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	0	40	theme	fabrication	136:146	arg1	approach					148:155	a green fabrication approach	128:155	a green fabrication approach	128:155	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	8	41	theme	rapid	1774:1778	arg1	applications					1791:1802	rapid hemostasis applications	1774:1802	rapid hemostasis applications in emergencies	1774:1817	These findings demonstrate that expecting to develop a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies.
36366726	2	42	theme	composite	333:341	arg1	AMPCs					356:360	AMPCs	356:360	AMPCs	356:360	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	2	42	theme	composite	333:341	arg1	hemostatics					343:353	composite hemostatics	333:353	the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect	290:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	3	43	theme	hemostatic	496:505	arg1	effect					507:512	the hemostatic effect	492:512	the hemostatic effect	492:512	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	5	44	theme	blood	838:842	arg1	BCI					860:862	BCI	860:862	BCI	860:862	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	5	44	theme	blood	838:842	arg1	index					853:857	blood clotting index	838:857	blood clotting index (BCI)	838:863	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	5	45	theme	blood	1123:1127	arg1	cells					1129:1133	the red blood cells	1115:1133	the red blood cells	1115:1133	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	0	46	theme	green	130:134	arg1	approach					148:155	a green fabrication approach	128:155	a green fabrication approach	128:155	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	2	47	contain	possess	411:417	arg2	effect					440:445	excellent hemostatic effect	419:445	excellent hemostatic effect	419:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	2	47	contain	possess	411:417	arg1	chitosan					396:403	carboxymethyl chitosan	382:403	carboxymethyl chitosan which possess excellent hemostatic effect	382:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	3	48	theme	AMPCs	531:535	arg1	biosafety					518:526	biosafety	518:526	biosafety of AMPCs	518:535	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	3	48	theme	AMPCs	531:535	arg1	effect					507:512	the hemostatic effect	492:512	the hemostatic effect	492:512	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	7	49	theme	histological	1631:1642	arg1	analysis					1644:1651	histological analysis	1631:1651	histological analysis	1631:1651	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	5	50	theme	coagulation	875:885	arg1	tests					887:891	blood coagulation tests	869:891	blood coagulation tests	869:891	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	4	51	theme	water	687:691	arg1	ability					704:710	high water absorption ability	682:710	high water absorption ability	682:710	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	51	theme	water	687:691	arg1	Group					724:728	Group 1	724:730	especially Group 1 (swelling ratio reached 5792%)	713:761	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	5	52	from	charge	1090:1095	arg1	surface					1104:1110	the surface	1100:1110	the surface of the red blood cells	1100:1133	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	7	53	theme	inflammatory	1539:1550	arg1	infiltration					1557:1568	inflammatory cell infiltration	1539:1568	inflammatory cell infiltration	1539:1568	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	5	54	theme	blood	869:873	arg1	tests					887:891	blood coagulation tests	869:891	blood coagulation tests	869:891	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	4	55	theme	ratio	742:746	arg1	Group					724:728	Group 1	724:730	especially Group 1 (swelling ratio reached 5792%)	713:761	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	55	theme	ratio	742:746	arg1	%					760:760	swelling ratio reached 5792%	733:760	swelling ratio reached 5792%	733:760	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	7	56	theme	major	1395:1399	arg1	organs					1401:1406	major organs	1395:1406	major organs	1395:1406	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	1	57	theme	wound	225:229	arg1	healing					231:237	wound healing	225:237	wound healing	225:237	Carboxymethyl chitosan is widely used in the medical field such as wound healing and other medical fields.
36366726	0	58	theme	absorbable	47:56	arg1	polysaccharides					70:84	the absorbable macroporous polysaccharides	43:84	the absorbable macroporous polysaccharides	43:84	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	7	59	theme	cell	1552:1555	arg1	infiltration					1557:1568	inflammatory cell infiltration	1539:1568	inflammatory cell infiltration	1539:1568	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	5	60	dep	showed	915:920	arg1	due					995:997	due	995:997	due	995:997	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	5	61	theme	cations	1044:1050	arg1	surface					1029:1035	the surface	1025:1035	the surface of the cations in the salts	1025:1063	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	4	62	theme	reached	748:754	arg1	Group					724:728	Group 1	724:730	especially Group 1 (swelling ratio reached 5792%)	713:761	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	62	theme	reached	748:754	arg1	%					760:760	swelling ratio reached 5792%	733:760	swelling ratio reached 5792%	733:760	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	6	63	theme	Sprague-Dawley	1264:1277	arg1	rats					1279:1282	Sprague-Dawley rats	1264:1282	Sprague-Dawley rats	1264:1282	The biosafety was a preliminary evaluation by implanted AMPCs into the back of Sprague-Dawley rats and the tissue was harvested after feeding for 28 days.
36366726	7	64	located	observed	1574:1581	arg2	necrosis					1527:1534	no tissue necrosis	1517:1534	no tissue necrosis	1517:1534	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	7	64	located	observed	1574:1581	arg1	organs					1592:1597	these organs	1586:1597	these organs	1586:1597	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	7	64	located	observed	1574:1581	arg2	infiltration					1557:1568	inflammatory cell infiltration	1539:1568	inflammatory cell infiltration	1539:1568	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	7	65	from	changes	1483:1489	arg1	indicators					1505:1514	some serum indicators	1494:1514	some serum indicators	1494:1514	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	5	66	theme	positive	1006:1013	arg1	charge					1015:1020	the positive charge	1002:1020	the positive charge on the surface of the cations in the salts	1002:1063	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	2	67	dep	polysaccharides	317:331	arg1	AMPCs					356:360	AMPCs	356:360	AMPCs	356:360	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	2	67	dep	polysaccharides	317:331	arg1	hemostatics					343:353	composite hemostatics	333:353	the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect	290:445	We previously fabricated the absorbable macroporous polysaccharides composite hemostatics (AMPCs) mainly composed of carboxymethyl chitosan which possess excellent hemostatic effect.
36366726	4	68	theme	clots	811:815	arg1	formation					792:800	the rapid formation	782:800	the rapid formation of blood clots	782:815	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	8	69	theme	functional	1716:1725	arg1	agent					1747:1751	a highly functional and safe hemostatic agent	1707:1751	a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies	1707:1817	These findings demonstrate that expecting to develop a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies.
36366726	5	70	theme	coagulation	940:950	arg1	capacity					952:959	a slightly higher coagulation capacity	922:959	a slightly higher coagulation capacity	922:959	It was confirmed by blood clotting index (BCI) and blood coagulation tests in vitro that Group 1 showed a slightly higher coagulation capacity than groups 2 and 3, which may be due to the positive charge on the surface of the cations in the salts attaches to the negative charge on the surface of the red blood cells, an electrostatic neutralization reaction occurs.
36366726	4	71	theme	chemical	645:652	arg1	properties					654:663	the physical and chemical properties	628:663	the physical and chemical properties	628:663	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	72	theme	blood	805:809	arg1	clots					811:815	blood clots	805:815	blood clots	805:815	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	7	73	dep	organs	1592:1597	arg1	either					1600:1605	either	1600:1605	either	1600:1605	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	7	74	theme	tissue	1520:1525	arg1	necrosis					1527:1534	no tissue necrosis	1517:1534	no tissue necrosis	1517:1534	The AMPCs exhibited good biosafety for whole blood and major organs during the degradation in vivo: during the degradation of AMPCs, excluding changes in some serum indicators, no tissue necrosis or inflammatory cell infiltration was observed in these organs, either by gross observation or histological analysis.
36366726	0	75	theme	polysaccharides	70:84	arg1	effect					11:16	Hemostatic effect	0:16	Hemostatic effect	0:16	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	0	75	theme	polysaccharides	70:84	arg1	evaluation					29:38	safety evaluation	22:38	safety evaluation of the absorbable macroporous polysaccharides	22:84	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	4	76	theme	high	682:685	arg1	ability					704:710	high water absorption ability	682:710	high water absorption ability	682:710	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	4	76	theme	high	682:685	arg1	Group					724:728	Group 1	724:730	especially Group 1 (swelling ratio reached 5792%)	713:761	By comparing the physical and chemical properties, AMPCs performed high water absorption ability, especially Group 1 (swelling ratio reached 5792%), which facilitated the rapid formation of blood clots.
36366726	3	77	from	impact	473:478	arg1	biosafety					518:526	biosafety	518:526	biosafety of AMPCs	518:535	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	3	77	from	impact	473:478	arg1	effect					507:512	the hemostatic effect	492:512	the hemostatic effect	492:512	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	1	78	theme	Carboxymethyl	158:170	arg1	chitosan					172:179	Carboxymethyl chitosan	158:179	Carboxymethyl chitosan	158:179	Carboxymethyl chitosan is widely used in the medical field such as wound healing and other medical fields.
36366726	3	79	theme	CMCTs	483:487	arg1	impact					473:478	the impact	469:478	the impact of CMCTs on the hemostatic effect and biosafety of AMPCs	469:535	To further elucidate the impact of CMCTs on the hemostatic effect and biosafety of AMPCs, carboxymethyl chitosan with different properties were used to prepare AMPCs.
36366726	1	80	theme	other	243:247	arg1	fields					257:262	other medical fields	243:262	other medical fields	243:262	Carboxymethyl chitosan is widely used in the medical field such as wound healing and other medical fields.
36366726	0	81	theme	macroporous	58:68	arg1	polysaccharides					70:84	the absorbable macroporous polysaccharides	43:84	the absorbable macroporous polysaccharides	43:84	Hemostatic effect and safety evaluation of the absorbable macroporous polysaccharides composite hemostatic material prepared by a green fabrication approach.
36366726	1	82	used	used	191:194	arg2	chitosan					172:179	Carboxymethyl chitosan	158:179	Carboxymethyl chitosan	158:179	Carboxymethyl chitosan is widely used in the medical field such as wound healing and other medical fields.
36366726	8	83	theme	hemostatic	1736:1745	arg1	agent					1747:1751	a highly functional and safe hemostatic agent	1707:1751	a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies	1707:1817	These findings demonstrate that expecting to develop a highly functional and safe hemostatic agent based on Group 1 for rapid hemostasis applications in emergencies.
36366726	1	84	theme	medical	249:255	arg1	fields					257:262	other medical fields	243:262	other medical fields	243:262	Carboxymethyl chitosan is widely used in the medical field such as wound healing and other medical fields.
35133383	6	0	theme	number-average	877:890	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	7	1	theme	immune	997:1002	arg1	statuses					1004:1011	the innate immune statuses	986:1011	the innate immune statuses of the mice	986:1023	Additionally, the innate immune statuses of the mice were improved by treatment with AOHP, while no obvious damage was identified.
35133383	6	2	with	-α-D-Glcp	860:868	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	2	with	-α-D-Glcp	860:868	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	5	3	from	indexes	712:718	arg1	spleens					742:748	the spleens	738:748	the spleens of the mice	738:760	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	5	4	theme	AOHP	672:675	arg1	administration					654:667	oral administration	649:667	oral administration of AOHP	649:675	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	2	5	used	used	355:358	arg2	DEAE-52					315:321	Cellulose DEAE-52	305:321	Cellulose DEAE-52	305:321	Cellulose DEAE-52 and Sephadex G-100 columns were used to obtain purified AOHP.
35133383	2	5	used	used	355:358	arg2	columns					342:348	Sephadex G-100 columns	327:348	Sephadex G-100 columns	327:348	Cellulose DEAE-52 and Sephadex G-100 columns were used to obtain purified AOHP.
35133383	5	6	from	cytokines	725:733	arg1	spleens					742:748	the spleens	738:748	the spleens of the mice	738:760	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	0	7	from	Characterization	0:15	arg1	mice					99:102	mice	99:102	mice	99:102	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	3	8	theme	physicochemical	526:540	arg1	properties					542:551	the physicochemical properties	522:551	the physicochemical properties	522:551	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	4	9	theme	AOHP	617:620	arg1	influence					604:612	the influence	600:612	the influence of AOHP on mice	600:628	Then, the influence of AOHP on mice was studied.
35133383	5	10	theme	organ	678:682	arg1	indexes					684:690	organ indexes	678:690	organ indexes	678:690	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	1	11	theme	regulating	268:277	arg1	effect					279:284	its regulating effect	264:284	its regulating effect on mouse immunity	264:302	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	4	12	from	influence	604:612	arg1	mice					625:628	mice	625:628	mice	625:628	Then, the influence of AOHP on mice was studied.
35133383	3	13	theme	weight	473:478	arg1	determination					480:492	molecular weight determination	463:492	molecular weight determination	463:492	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	3	14	theme	monosaccharide	424:437	arg1	composition					439:449	monosaccharide composition	424:449	monosaccharide composition	424:449	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	1	15	theme	novel	167:171	arg1	polysaccharide					187:200	a novel water-soluble polysaccharide	165:200	a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance	165:248	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	1	15	theme	novel	167:171	arg1	AOHP					203:206	AOHP	203:206	AOHP	203:206	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	6	16	theme	1,4,6	854:858	arg1	-α-D-Glcp					860:868	(1,4,6)-α-D-Glcp	853:868	(1,4,6)-α-D-Glcp	853:868	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	17	theme	kDa	967:969	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	17	theme	kDa	967:969	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	3	18	theme	structural	557:566	arg1	characterization					568:583	structural characterization	557:583	structural characterization of AOHP	557:591	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	1	19	theme	water-soluble	173:185	arg1	polysaccharide					187:200	a novel water-soluble polysaccharide	165:200	a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance	165:248	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	1	19	theme	water-soluble	173:185	arg1	AOHP					203:206	AOHP	203:206	AOHP	203:206	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	1	20	from	effect	279:284	arg1	immunity					295:302	mouse immunity	289:302	mouse immunity	289:302	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	1	21	theme	polysaccharide	187:200	arg1	features					153:160	the structural features	138:160	the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance	138:248	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	8	22	theme	immunomodulatory	1120:1135	arg1	activity					1137:1144	the immunomodulatory activity	1116:1144	the immunomodulatory activity	1116:1144	To conclude, the immunomodulatory activity and biological safety make AOHP a viable candidate as an ingredient for healthcare drugs.
35133383	6	23	theme	molecular	942:950	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	24	with	-α-D-Glcp	839:847	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	24	with	-α-D-Glcp	839:847	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	8	25	theme	biological	1150:1159	arg1	safety					1161:1166	biological safety	1150:1166	biological safety	1150:1166	To conclude, the immunomodulatory activity and biological safety make AOHP a viable candidate as an ingredient for healthcare drugs.
35133383	6	26	theme	weight-average	927:940	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	2	27	theme	Cellulose	305:313	arg1	DEAE-52					315:321	Cellulose DEAE-52	305:321	Cellulose DEAE-52	305:321	Cellulose DEAE-52 and Sephadex G-100 columns were used to obtain purified AOHP.
35133383	3	28	theme	molecular	463:471	arg1	determination					480:492	molecular weight determination	463:492	molecular weight determination	463:492	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	0	29	theme	Alpinia	20:26	arg1	polysaccharide					46:59	Alpinia officinarum Hance polysaccharide	20:59	Alpinia officinarum Hance polysaccharide	20:59	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	1	30	theme	mouse	289:293	arg1	immunity					295:302	mouse immunity	289:302	mouse immunity	289:302	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	1	31	theme	structural	142:151	arg1	features					153:160	the structural features	138:160	the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance	138:248	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	0	32	theme	polysaccharide	46:59	arg1	activity					87:94	its immune modulatory activity	65:94	its immune modulatory activity in mice	65:102	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	0	32	theme	polysaccharide	46:59	arg1	Characterization					0:15	Characterization	0:15	Characterization of Alpinia officinarum Hance polysaccharide	0:59	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	5	33	theme	oral	649:652	arg1	administration					654:667	oral administration	649:667	oral administration of AOHP	649:675	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	0	34	from	activity	87:94	arg1	mice					99:102	mice	99:102	mice	99:102	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	0	35	theme	Hance	40:44	arg1	polysaccharide					46:59	Alpinia officinarum Hance polysaccharide	20:59	Alpinia officinarum Hance polysaccharide	20:59	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	6	36	theme	kDa	917:919	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	36	theme	kDa	917:919	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	7	37	theme	mice	1020:1023	arg1	statuses					1004:1011	the innate immune statuses	986:1011	the innate immune statuses of the mice	986:1023	Additionally, the innate immune statuses of the mice were improved by treatment with AOHP, while no obvious damage was identified.
35133383	8	38	theme	healthcare	1218:1227	arg1	drugs					1229:1233	healthcare drugs	1218:1233	healthcare drugs	1218:1233	To conclude, the immunomodulatory activity and biological safety make AOHP a viable candidate as an ingredient for healthcare drugs.
35133383	7	39	theme	obvious	1072:1078	arg1	damage					1080:1085	no obvious damage	1069:1085	no obvious damage	1069:1085	Additionally, the innate immune statuses of the mice were improved by treatment with AOHP, while no obvious damage was identified.
35133383	5	40	theme	mice	757:760	arg1	spleens					742:748	the spleens	738:748	the spleens of the mice	738:760	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	7	41	theme	innate	990:995	arg1	statuses					1004:1011	the innate immune statuses	986:1011	the innate immune statuses of the mice	986:1023	Additionally, the innate immune statuses of the mice were improved by treatment with AOHP, while no obvious damage was identified.
35133383	7	42	with	treatment	1042:1050	arg1	AOHP					1057:1060	AOHP	1057:1060	AOHP	1057:1060	Additionally, the innate immune statuses of the mice were improved by treatment with AOHP, while no obvious damage was identified.
35133383	6	43	dep	-α-D-Glcp	839:847	arg1	1,4					835:837	1,4	835:837	1,4	835:837	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	5	44	theme	serum	693:697	arg1	indexes					712:718	serum biochemistry indexes	693:718	serum biochemistry indexes	693:718	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	2	45	theme	G-100	336:340	arg1	columns					342:348	Sephadex G-100 columns	327:348	Sephadex G-100 columns	327:348	Cellulose DEAE-52 and Sephadex G-100 columns were used to obtain purified AOHP.
35133383	3	46	theme	AOHP	588:591	arg1	characterization					568:583	structural characterization	557:583	structural characterization of AOHP	557:591	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	3	46	theme	AOHP	588:591	arg1	properties					542:551	the physicochemical properties	522:551	the physicochemical properties	522:551	Techniques including NMR, methylation, monosaccharide composition, FT-IR, and molecular weight determination were applied to investigate the physicochemical properties and structural characterization of AOHP.
35133383	1	47	theme	Alpinia	224:230	arg1	Hance					244:248	Alpinia officinarum Hance	224:248	Alpinia officinarum Hance	224:248	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	5	48	theme	biochemistry	699:710	arg1	indexes					712:718	serum biochemistry indexes	693:718	serum biochemistry indexes	693:718	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	0	49	dep	Alpinia	20:26	arg1	officinarum					28:38	officinarum	28:38	officinarum	28:38	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	2	50	theme	Sephadex	327:334	arg1	columns					342:348	Sephadex G-100 columns	327:348	Sephadex G-100 columns	327:348	Cellulose DEAE-52 and Sephadex G-100 columns were used to obtain purified AOHP.
35133383	1	51	theme	officinarum	232:242	arg1	Hance					244:248	Alpinia officinarum Hance	224:248	Alpinia officinarum Hance	224:248	This study aimed to characterize the structural features of a novel water-soluble polysaccharide (AOHP) extracted from Alpinia officinarum Hance and to verify its regulating effect on mouse immunity.
35133383	0	52	theme	modulatory	76:85	arg1	activity					87:94	its immune modulatory activity	65:94	its immune modulatory activity in mice	65:102	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	6	53	with	T-α-D-Glcp	822:831	arg1	weight					952:957	a weight-average molecular weight	925:957	a weight-average molecular weight of 52.8 kDa	925:969	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	6	53	with	T-α-D-Glcp	822:831	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
35133383	2	54	theme	purified	370:377	arg1	AOHP					379:382	purified AOHP	370:382	purified AOHP	370:382	Cellulose DEAE-52 and Sephadex G-100 columns were used to obtain purified AOHP.
35133383	8	55	theme	viable	1180:1185	arg1	candidate					1187:1195	a viable candidate	1178:1195	a viable candidate as an ingredient for healthcare drugs	1178:1233	To conclude, the immunomodulatory activity and biological safety make AOHP a viable candidate as an ingredient for healthcare drugs.
35133383	5	56	from	indexes	684:690	arg1	spleens					742:748	the spleens	738:748	the spleens of the mice	738:760	After oral administration of AOHP, organ indexes, serum biochemistry indexes, and cytokines in the spleens of the mice were analysed.
35133383	0	57	theme	immune	69:74	arg1	activity					87:94	its immune modulatory activity	65:94	its immune modulatory activity in mice	65:102	Characterization of Alpinia officinarum Hance polysaccharide and its immune modulatory activity in mice.
35133383	6	58	theme	molecular	892:900	arg1	weight					902:907	a number-average molecular weight	875:907	a number-average molecular weight of 26.0 kDa	875:919	The results showed that AOHP was composed of T-α-D-Glcp, (1,4)-α-D-Glcp and (1,4,6)-α-D-Glcp with a number-average molecular weight of 26.0 kDa and a weight-average molecular weight of 52.8 kDa.
36410535	0	0	theme	bioactive	95:103	arg1	protein					126:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	5	1	dep	higher	784:789	arg1	p < 0.05					792:799	p < 0.05	792:799	p < 0.05	792:799	MP-WPIs also had higher (p < 0.05) thermal stability via TGA and DSC analysis.
36410535	8	2	theme	probiotic	1115:1123	arg1	survival					1156:1163	probiotic Lactobacillus acidophilus (LA) survival	1115:1163	probiotic Lactobacillus acidophilus (LA) survival	1115:1163	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	10	3	with	delivery	1524:1531	arg1	potential					1538:1546	potential	1538:1546	potential	1538:1546	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	1	4	theme	Momordica	248:256	arg1	charantia					258:266	Momordica charantia	248:266	Momordica charantia which contains arabinose, galactose, xylose, and rhamnose	248:324	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	0	5	theme	charantia	85:93	arg1	protein					126:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	1	6	with	polysaccharide	175:188	arg1	weight					213:218	a molecular weight	201:218	a molecular weight of 38 kDa	201:228	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	4	7	theme	WPI	757:759	arg1	gels					761:764	WPI gels	757:764	WPI gels	757:764	MP-WPIs demonstrated superior (p < 0.05) water holding capacity and emulsifying properties than WPI gels.
36410535	0	8	theme	protein	126:132	arg1	characterization					13:28	characterization	13:28	characterization	13:28	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	0	8	theme	protein	126:132	arg1	Development					0:10	Development	0:10	Development	0:10	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	0	8	theme	protein	126:132	arg1	ability					58:64	probiotic encapsulating ability	34:64	probiotic encapsulating ability	34:64	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	3	9	theme	%	658:658	arg1	concentration					639:651	MP concentration	636:651	MP concentration of 2 %	636:658	Results showed that the highest complex index was obtained at MP concentration of 2 %.
36410535	7	10	theme	hydrogen	1056:1063	arg1	interactions					1065:1076	electrostatic, hydrophobic and hydrogen interactions	1025:1076	electrostatic, hydrophobic and hydrogen interactions	1025:1076	Also, FTIR revealed that MP and WPI bonded mainly through electrostatic, hydrophobic and hydrogen interactions.
36410535	2	11	dep	used	337:340	arg1	MP1					328:330	MP1	328:330	MP1	328:330	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	0	12	theme	polysaccharides/whey	105:124	arg1	protein					126:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	9	13	theme	LA	1275:1276	arg1	survival					1278:1285	LA survival	1275:1285	LA survival	1275:1285	MP-WPIs improved LA survival upon digestion suggesting a potential prebiotic activity.
36410535	10	14	theme	formulation	1364:1374	arg1	LA-MP-WPIs					1376:1385	synbiotic formulation LA-MP-WPIs	1354:1385	synbiotic formulation LA-MP-WPIs	1354:1385	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	0	15	theme	composite	142:150	arg1	gels					152:155	composite gels	142:155	composite gels	142:155	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	6	16	theme	MP-WPI	846:851	arg1	morphology					853:862	MP-WPI morphology	846:862	MP-WPI morphology	846:862	MP-WPI morphology was observed via SEM whereas protein structure as affected by MP concentration was studied using CLSM.
36410535	7	17	theme	hydrophobic	1040:1050	arg1	interactions					1065:1076	electrostatic, hydrophobic and hydrogen interactions	1025:1076	electrostatic, hydrophobic and hydrogen interactions	1025:1076	Also, FTIR revealed that MP and WPI bonded mainly through electrostatic, hydrophobic and hydrogen interactions.
36410535	10	18	theme	synbiotic	1354:1362	arg1	LA-MP-WPIs					1376:1385	synbiotic formulation LA-MP-WPIs	1354:1385	synbiotic formulation LA-MP-WPIs	1354:1385	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	2	19	theme	Whey	375:378	arg1	Isolate					388:394	Whey Protein Isolate	375:394	Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS)	375:571	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	2	19	theme	Whey	375:378	arg1	WPI					397:399	WPI	397:399	WPI	397:399	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	8	20	theme	acidophilus	1139:1149	arg1	survival					1156:1163	probiotic Lactobacillus acidophilus (LA) survival	1115:1163	probiotic Lactobacillus acidophilus (LA) survival	1115:1163	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	10	21	theme	propitious	1463:1472	arg1	MP-WPIs					1450:1456	MP-WPIs	1450:1456	MP-WPIs	1450:1456	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	10	21	theme	propitious	1463:1472	arg1	strategy					1474:1481	a propitious strategy	1461:1481	a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS	1461:1556	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	7	22	theme	electrostatic	1025:1037	arg1	interactions					1065:1076	electrostatic, hydrophobic and hydrogen interactions	1025:1076	electrostatic, hydrophobic and hydrogen interactions	1025:1076	Also, FTIR revealed that MP and WPI bonded mainly through electrostatic, hydrophobic and hydrogen interactions.
36410535	0	23	theme	Momordica	75:83	arg1	protein					126:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	4	24	theme	water	702:706	arg1	capacity					716:723	superior (p < 0.05) water holding capacity	682:723	superior (p < 0.05) water holding capacity	682:723	MP-WPIs demonstrated superior (p < 0.05) water holding capacity and emulsifying properties than WPI gels.
36410535	10	25	theme	biological	1407:1416	arg1	activity					1418:1425	effective biological activity	1397:1425	effective biological activity	1397:1425	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	4	26	theme	emulsifying	729:739	arg1	properties					741:750	emulsifying properties	729:750	emulsifying properties	729:750	MP-WPIs demonstrated superior (p < 0.05) water holding capacity and emulsifying properties than WPI gels.
36410535	2	27	theme	composite	355:363	arg1	gels					365:368	composite gels	355:368	composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS)	355:571	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	5	28	theme	higher	784:789	arg1	stability					810:818	higher (p < 0.05) thermal stability	784:818	higher (p < 0.05) thermal stability	784:818	MP-WPIs also had higher (p < 0.05) thermal stability via TGA and DSC analysis.
36410535	6	29	theme	MP	926:927	arg1	concentration					929:941	MP concentration	926:941	MP concentration	926:941	MP-WPI morphology was observed via SEM whereas protein structure as affected by MP concentration was studied using CLSM.
36410535	10	30	theme	gastrointestinal	1507:1522	arg1	delivery					1524:1531	effective probiotic gastrointestinal delivery	1487:1531	effective probiotic gastrointestinal delivery with potential toward MS	1487:1556	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	10	31	theme	effective	1397:1405	arg1	activity					1418:1425	effective biological activity	1397:1425	effective biological activity	1397:1425	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	9	32	theme	potential	1315:1323	arg1	activity					1335:1342	a potential prebiotic activity	1313:1342	a potential prebiotic activity	1313:1342	MP-WPIs improved LA survival upon digestion suggesting a potential prebiotic activity.
36410535	10	33	theme	probiotic	1497:1505	arg1	delivery					1524:1531	effective probiotic gastrointestinal delivery	1487:1531	effective probiotic gastrointestinal delivery with potential toward MS	1487:1556	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	4	34	theme	holding	708:714	arg1	capacity					716:723	superior (p < 0.05) water holding capacity	682:723	superior (p < 0.05) water holding capacity	682:723	MP-WPIs demonstrated superior (p < 0.05) water holding capacity and emulsifying properties than WPI gels.
36410535	1	35	theme	molecular	203:211	arg1	weight					213:218	a molecular weight	201:218	a molecular weight of 38 kDa	201:228	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	0	36	theme	encapsulating	44:56	arg1	ability					58:64	probiotic encapsulating ability	34:64	probiotic encapsulating ability	34:64	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	9	37	theme	prebiotic	1325:1333	arg1	activity					1335:1342	a potential prebiotic activity	1313:1342	a potential prebiotic activity	1313:1342	MP-WPIs improved LA survival upon digestion suggesting a potential prebiotic activity.
36410535	10	38	theme	effective	1487:1495	arg1	delivery					1524:1531	effective probiotic gastrointestinal delivery	1487:1531	effective probiotic gastrointestinal delivery with potential toward MS	1487:1556	Finally, synbiotic formulation LA-MP-WPIs exhibited effective biological activity against MS. Therefore, MP-WPIs is a propitious strategy for effective probiotic gastrointestinal delivery with potential toward MS.
36410535	8	39	theme	storage	1239:1245	arg1	stability					1247:1255	improved storage stability	1230:1255	improved storage stability	1230:1255	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	5	40	theme	DSC	832:834	arg1	analysis					836:843	DSC analysis	832:843	DSC analysis	832:843	MP-WPIs also had higher (p < 0.05) thermal stability via TGA and DSC analysis.
36410535	5	41	theme	thermal	802:808	arg1	stability					810:818	higher (p < 0.05) thermal stability	784:818	higher (p < 0.05) thermal stability	784:818	MP-WPIs also had higher (p < 0.05) thermal stability via TGA and DSC analysis.
36410535	0	42	theme	probiotic	34:42	arg1	ability					58:64	probiotic encapsulating ability	34:64	probiotic encapsulating ability	34:64	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	2	43	theme	functional	436:445	arg1	properties					447:456	their functional properties	430:456	their functional properties	430:456	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	3	44	theme	complex	606:612	arg1	index					614:618	the highest complex index	594:618	the highest complex index	594:618	Results showed that the highest complex index was obtained at MP concentration of 2 %.
36410535	2	45	theme	Protein	380:386	arg1	Isolate					388:394	Whey Protein Isolate	375:394	Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS)	375:571	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	2	45	theme	Protein	380:386	arg1	WPI					397:399	WPI	397:399	WPI	397:399	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	8	46	theme	encapsulation	1194:1206	arg1	efficiency					1208:1217	high encapsulation efficiency	1189:1217	high encapsulation efficiency (98 %)	1189:1224	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	8	46	theme	encapsulation	1194:1206	arg1	%					1223:1223	98 %	1220:1223	98 %	1220:1223	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	2	47	theme	encapsulating	505:517	arg1	ability					519:525	probiotic encapsulating ability	495:525	probiotic encapsulating ability	495:525	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	6	48	dep	structure	901:909	arg1	affected					914:921	affected	914:921	affected by MP concentration	914:941	MP-WPI morphology was observed via SEM whereas protein structure as affected by MP concentration was studied using CLSM.
36410535	4	49	theme	superior	682:689	arg1	capacity					716:723	superior (p < 0.05) water holding capacity	682:723	superior (p < 0.05) water holding capacity	682:723	MP-WPIs demonstrated superior (p < 0.05) water holding capacity and emulsifying properties than WPI gels.
36410535	8	50	theme	high	1189:1192	arg1	efficiency					1208:1217	high encapsulation efficiency	1189:1217	high encapsulation efficiency (98 %)	1189:1224	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	8	50	theme	high	1189:1192	arg1	%					1223:1223	98 %	1220:1223	98 %	1220:1223	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	6	51	theme	protein	893:899	arg1	structure					901:909	protein structure	893:909	protein structure as affected by MP concentration	893:941	MP-WPI morphology was observed via SEM whereas protein structure as affected by MP concentration was studied using CLSM.
36410535	1	52	attach	isolated	234:241	arg2	polysaccharide					175:188	a polysaccharide	173:188	a polysaccharide (MP1) with a molecular weight of 38 kDa	173:228	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	1	52	attach	isolated	234:241	arg1	charantia					258:266	Momordica charantia	248:266	Momordica charantia which contains arabinose, galactose, xylose, and rhamnose	248:324	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	1	52	attach	isolated	234:241	arg2	MP1					191:193	MP1	191:193	MP1	191:193	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	5	53	contain	had	780:782	arg1	MP-WPIs					767:773	MP-WPIs	767:773	MP-WPIs	767:773	MP-WPIs also had higher (p < 0.05) thermal stability via TGA and DSC analysis.
36410535	5	53	contain	had	780:782	arg2	stability					810:818	higher (p < 0.05) thermal stability	784:818	higher (p < 0.05) thermal stability	784:818	MP-WPIs also had higher (p < 0.05) thermal stability via TGA and DSC analysis.
36410535	2	54	theme	metabolic	549:557	arg1	MS					569:570	MS	569:570	MS	569:570	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	2	54	theme	metabolic	549:557	arg1	syndrome					559:566	metabolic syndrome	549:566	metabolic syndrome (MS)	549:571	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	1	55	contain	contains	274:281	arg2	rhamnose					317:324	rhamnose	317:324	rhamnose	317:324	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	1	55	contain	contains	274:281	arg1	charantia					258:266	Momordica charantia	248:266	Momordica charantia which contains arabinose, galactose, xylose, and rhamnose	248:324	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	1	55	contain	contains	274:281	arg2	galactose					294:302	galactose	294:302	galactose	294:302	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	1	55	contain	contains	274:281	arg2	xylose					305:310	xylose	305:310	xylose	305:310	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	1	55	contain	contains	274:281	arg2	arabinose					283:291	arabinose	283:291	arabinose	283:291	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	4	56	theme	p < 0.05	692:699	arg1	capacity					716:723	superior (p < 0.05) water holding capacity	682:723	superior (p < 0.05) water holding capacity	682:723	MP-WPIs demonstrated superior (p < 0.05) water holding capacity and emulsifying properties than WPI gels.
36410535	1	57	theme	38 kDa	223:228	arg1	weight					213:218	a molecular weight	201:218	a molecular weight of 38 kDa	201:228	In this study, a polysaccharide (MP1) with a molecular weight of 38 kDa was isolated from Momordica charantia which contains arabinose, galactose, xylose, and rhamnose.
36410535	3	58	theme	highest	598:604	arg1	index					614:618	the highest complex index	594:618	the highest complex index	594:618	Results showed that the highest complex index was obtained at MP concentration of 2 %.
36410535	2	59	theme	thermal	475:481	arg1	resistance					483:492	thermal resistance	475:492	thermal resistance	475:492	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	3	60	theme	MP	636:637	arg1	concentration					639:651	MP concentration	636:651	MP concentration of 2 %	636:658	Results showed that the highest complex index was obtained at MP concentration of 2 %.
36410535	8	61	theme	improved	1230:1237	arg1	stability					1247:1255	improved storage stability	1230:1255	improved storage stability	1230:1255	More, MP-WPIs successfully enhanced probiotic Lactobacillus acidophilus (LA) survival upon freeze-drying with high encapsulation efficiency (98 %) and improved storage stability.
36410535	0	62	theme	novel	69:73	arg1	protein					126:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	novel Momordica charantia bioactive polysaccharides/whey protein	69:132	Development, characterization and probiotic encapsulating ability of novel Momordica charantia bioactive polysaccharides/whey protein isolate composite gels.
36410535	2	63	with	gels	365:368	arg1	Isolate					388:394	Whey Protein Isolate	375:394	Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS)	375:571	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	2	63	with	gels	365:368	arg1	WPI					397:399	WPI	397:399	WPI	397:399	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
36410535	2	64	theme	probiotic	495:503	arg1	ability					519:525	probiotic encapsulating ability	495:525	probiotic encapsulating ability	495:525	(MP1) was used to formulate composite gels with Whey Protein Isolate (WPI) that were characterized for their functional properties, microstructure, thermal resistance, probiotic encapsulating ability, and potential toward metabolic syndrome (MS).
37156274	3	0	theme	Male	582:585	arg1	Institute					587:595	Male Institute	582:595	METHODS Male Institute of Cancer Research (ICR) mice	574:625	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	3	1	theme	ICR	617:619	arg1	mice					622:625	Cancer Research (ICR) mice	600:625	Cancer Research (ICR) mice	600:625	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	1	2	theme	behavioral	305:314	arg1	deficits					316:323	behavioral deficits	305:323	behavioral deficits	305:323	BACKGROUND Chronic stress alters gut microbiota composition, as well as induces inflammatory responses and behavioral deficits.
37156274	3	3	theme	Research	607:614	arg1	mice					622:625	Cancer Research (ICR) mice	600:625	Cancer Research (ICR) mice	600:625	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	1	4	theme	Chronic	209:215	arg1	stress					217:222	BACKGROUND Chronic stress	198:222	BACKGROUND Chronic stress	198:222	BACKGROUND Chronic stress alters gut microbiota composition, as well as induces inflammatory responses and behavioral deficits.
37156274	7	5	theme	signaling	1440:1448	arg1	pathway					1450:1456	the microglia-mediated TLR4/NFκB/MAPK signaling pathway	1402:1456	the microglia-mediated TLR4/NFκB/MAPK signaling pathway	1402:1456	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	6	6	theme	Lactobacillaceae	1155:1170	arg1	abundance					1142:1150	the abundance	1138:1150	the abundance of Lactobacillaceae	1138:1170	RESULTS We found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement.
37156274	11	7	theme	CONCLUSIONS	1934:1944	arg1	EPs					1946:1948	CONCLUSIONS EPs	1934:1948	CONCLUSIONS EPs	1934:1948	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	10	8	theme	EPs	1864:1866	arg1	remodeling					1868:1877	EPs remodeling the gut microbiota and improved behavior	1864:1918	remodeling	1868:1877	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	1	9	theme	microbiota	235:244	arg1	composition					246:256	gut microbiota composition	231:256	gut microbiota composition	231:256	BACKGROUND Chronic stress alters gut microbiota composition, as well as induces inflammatory responses and behavioral deficits.
37156274	6	10	theme	barrier	1272:1278	arg1	derangement					1280:1290	barrier derangement	1272:1290	barrier derangement	1272:1290	RESULTS We found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement.
37156274	11	11	theme	CUMS-induced	1980:1991	arg1	neuroinflammation					1993:2009	CUMS-induced neuroinflammation	1980:2009	CUMS-induced neuroinflammation	1980:2009	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	0	12	theme	Beneficial	144:153	arg1	dysbiosis					58:66	gut microbiota dysbiosis	43:66	gut microbiota dysbiosis	43:66	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	0	13	from	neuroinflammation	72:88	arg1	mice					93:96	mice	93:96	mice exposed to chronic unpredictable mild stress	93:141	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	7	14	theme	TLR4/NFκB/MAPK	1425:1438	arg1	pathway					1450:1456	the microglia-mediated TLR4/NFκB/MAPK signaling pathway	1402:1456	the microglia-mediated TLR4/NFκB/MAPK signaling pathway	1402:1456	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	3	15	theme	chronic	643:649	arg1	CUMS					673:676	CUMS	673:676	CUMS	673:676	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	3	15	theme	chronic	643:649	arg1	stress					665:670	chronic unpredictable stress	643:670	chronic unpredictable stress (CUMS)	643:677	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	5	16	theme	ribosomal	946:954	arg1	rRNA					961:964	rRNA	961:964	rRNA	961:964	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	5	16	theme	ribosomal	946:954	arg1	RNA					956:958	16S ribosomal RNA	942:958	16S ribosomal RNA (rRNA) gene sequencing	942:981	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	10	17	from	behavior	1911:1918	arg1	mice					1928:1931	CUMS mice	1923:1931	CUMS mice	1923:1931	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	7	18	from	response	1500:1507	arg1	hippocampus					1516:1526	the hippocampus	1512:1526	the hippocampus	1512:1526	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	8	19	theme	hippocampal	1574:1584	arg1	neurogenesis					1586:1597	hippocampal neurogenesis	1574:1597	hippocampal neurogenesis	1574:1597	These contributed to restoring the rhythm of hippocampal neurogenesis and alleviating behavioral abnormalities in CUMS mice.
37156274	4	20	theme	anxiolytic	815:824	arg1	effects					826:832	Behavioral test-specific antidepressant and anxiolytic effects	771:832	Behavioral test-specific antidepressant and anxiolytic effects of EPs	771:839	Behavioral test-specific antidepressant and anxiolytic effects of EPs were assessed in FST, TST, EPM, and OFT.
37156274	2	21	theme	Eucommiae	326:334	arg1	EPs					360:362	EPs	360:362	EPs	360:362	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	2	21	theme	Eucommiae	326:334	arg1	polysaccharides					343:357	Eucommiae cortex polysaccharides	326:357	Eucommiae cortex polysaccharides (EPs)	326:363	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	5	22	theme	quantitative	984:995	arg1	RT-PCR					997:1002	quantitative RT-PCR	984:1002	quantitative RT-PCR	984:1002	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	0	23	from	dysbiosis	58:66	arg1	mice					93:96	mice	93:96	mice exposed to chronic unpredictable mild stress	93:141	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	2	24	theme	systemic	449:456	arg1	inflammation					468:479	obesogenic diet-induced systemic low-grade inflammation	425:479	obesogenic diet-induced systemic low-grade inflammation	425:479	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	0	25	theme	unpredictable	117:129	arg1	stress					136:141	chronic unpredictable mild stress	109:141	chronic unpredictable mild stress	109:141	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	2	26	theme	stress-induced	500:513	arg1	changes					544:550	stress-induced behavioral and physiological changes	500:550	stress-induced behavioral and physiological changes	500:550	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	6	27	dep	RESULTS	1043:1049	arg1	found					1054:1058	found	1054:1058	found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement	1054:1290	RESULTS We found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement.
37156274	4	28	theme	Behavioral	771:780	arg1	effects					826:832	Behavioral test-specific antidepressant and anxiolytic effects	771:832	Behavioral test-specific antidepressant and anxiolytic effects of EPs	771:839	Behavioral test-specific antidepressant and anxiolytic effects of EPs were assessed in FST, TST, EPM, and OFT.
37156274	2	29	theme	obesogenic	425:434	arg1	inflammation					468:479	obesogenic diet-induced systemic low-grade inflammation	425:479	obesogenic diet-induced systemic low-grade inflammation	425:479	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	0	30	theme	Eucommiae	0:8	arg1	polysaccharides					17:31	Eucommiae cortex polysaccharides	0:31	Eucommiae cortex polysaccharides	0:31	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	6	31	theme	gut	1081:1083	arg1	dysbiosis					1085:1093	gut dysbiosis	1081:1093	gut dysbiosis caused by CUMS	1081:1108	RESULTS We found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement.
37156274	4	32	theme	antidepressant	796:809	arg1	effects					826:832	Behavioral test-specific antidepressant and anxiolytic effects	771:832	Behavioral test-specific antidepressant and anxiolytic effects of EPs	771:839	Behavioral test-specific antidepressant and anxiolytic effects of EPs were assessed in FST, TST, EPM, and OFT.
37156274	11	33	theme	gut	2102:2104	arg1	composition					2116:2126	gut microbial composition	2102:2126	gut microbial composition	2102:2126	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	9	34	theme	perturbed-gut	1691:1703	arg1	microbiota					1705:1714	the perturbed-gut microbiota	1687:1714	the perturbed-gut microbiota	1687:1714	Correlation analysis showed that the perturbed-gut microbiota was strongly correlated with behavioral abnormalities and neuroinflammation.
37156274	0	35	theme	gut	43:45	arg1	dysbiosis					58:66	gut microbiota dysbiosis	43:66	gut microbiota dysbiosis	43:66	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	7	36	theme	bacterial-derived	1333:1349	arg1	lipopolysaccharides					1351:1369	bacterial-derived lipopolysaccharides	1333:1369	bacterial-derived lipopolysaccharides (LPS, endotoxin)	1333:1386	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	2	37	from	role	492:495	arg1	changes					544:550	stress-induced behavioral and physiological changes	500:550	stress-induced behavioral and physiological changes	500:550	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	10	38	theme	causal	1836:1841	arg1	relationship					1843:1854	the causal relationship	1832:1854	the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice	1832:1931	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	9	39	theme	behavioral	1745:1754	arg1	abnormalities					1756:1768	behavioral abnormalities	1745:1768	behavioral abnormalities	1745:1768	Correlation analysis showed that the perturbed-gut microbiota was strongly correlated with behavioral abnormalities and neuroinflammation.
37156274	10	40	theme	gut	1883:1885	arg1	microbiota					1887:1896	the gut microbiota	1879:1896	the gut microbiota	1879:1896	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	5	41	theme	Microbiota	882:891	arg1	composition					893:903	Microbiota composition	882:903	Microbiota composition	882:903	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	2	42	theme	gut	395:397	arg1	microbiota					399:408	gut microbiota	395:408	gut microbiota	395:408	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	1	43	theme	inflammatory	278:289	arg1	responses					291:299	inflammatory responses	278:299	inflammatory responses	278:299	BACKGROUND Chronic stress alters gut microbiota composition, as well as induces inflammatory responses and behavioral deficits.
37156274	7	44	link	bacterial-derived	1333:1349	arg1	lipopolysaccharides					1351:1369	bacterial-derived lipopolysaccharides	1333:1369	bacterial-derived lipopolysaccharides (LPS, endotoxin)	1333:1386	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	2	45	theme	cortex	336:341	arg1	EPs					360:362	EPs	360:362	EPs	360:362	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	2	45	theme	cortex	336:341	arg1	polysaccharides					343:357	Eucommiae cortex polysaccharides	326:357	Eucommiae cortex polysaccharides (EPs)	326:363	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	3	46	theme	Cancer	600:605	arg1	mice					622:625	Cancer Research (ICR) mice	600:625	Cancer Research (ICR) mice	600:625	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	1	47	theme	BACKGROUND	198:207	arg1	stress					217:222	BACKGROUND Chronic stress	198:222	BACKGROUND Chronic stress	198:222	BACKGROUND Chronic stress alters gut microbiota composition, as well as induces inflammatory responses and behavioral deficits.
37156274	10	48	from	remodeling	1868:1877	arg1	mice					1928:1931	CUMS mice	1923:1931	CUMS mice	1923:1931	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	7	49	theme	pro-inflammatory	1483:1498	arg1	response					1500:1507	the pro-inflammatory response	1479:1507	the pro-inflammatory response in the hippocampus	1479:1526	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	11	50	theme	ameliorative	1956:1967	arg1	effects					1969:1975	ameliorative effects	1956:1975	ameliorative effects	1956:1975	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	10	51	theme	CUMS	1923:1926	arg1	mice					1928:1931	CUMS mice	1923:1931	CUMS mice	1923:1931	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	1	52	theme	gut	231:233	arg1	composition					246:256	gut microbiota composition	231:256	gut microbiota composition	231:256	BACKGROUND Chronic stress alters gut microbiota composition, as well as induces inflammatory responses and behavioral deficits.
37156274	3	53	from	dose	727:730	arg1	EPs					718:720	EPs	718:720	EPs at a dose of 400 mg/kg once per day for 2 weeks	718:768	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	3	54	theme	unpredictable	651:663	arg1	CUMS					673:676	CUMS	673:676	CUMS	673:676	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	3	54	theme	unpredictable	651:663	arg1	stress					665:670	chronic unpredictable stress	643:670	chronic unpredictable stress (CUMS)	643:677	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	11	55	from	effects	2091:2097	arg1	composition					2116:2126	gut microbial composition	2102:2126	gut microbial composition	2102:2126	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	0	56	theme	depressive-like	171:185	arg1	behaviors					187:195	depressive-like behaviors	171:195	depressive-like behaviors	171:195	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	5	57	theme	16S	942:944	arg1	rRNA					961:964	rRNA	961:964	rRNA	961:964	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	5	57	theme	16S	942:944	arg1	RNA					956:958	16S ribosomal RNA	942:958	16S ribosomal RNA (rRNA) gene sequencing	942:981	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	6	58	theme	intestinal	1244:1253	arg1	inflammation					1255:1266	intestinal inflammation	1244:1266	intestinal inflammation	1244:1266	RESULTS We found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement.
37156274	5	59	theme	RNA	956:958	arg1	sequencing					972:981	16S ribosomal RNA (rRNA) gene sequencing	942:981	16S ribosomal RNA (rRNA) gene sequencing	942:981	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	7	60	theme	microglia-mediated	1406:1423	arg1	pathway					1450:1456	the microglia-mediated TLR4/NFκB/MAPK signaling pathway	1402:1456	the microglia-mediated TLR4/NFκB/MAPK signaling pathway	1402:1456	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	8	61	theme	neurogenesis	1586:1597	arg1	rhythm					1564:1569	the rhythm	1560:1569	the rhythm of hippocampal neurogenesis	1560:1597	These contributed to restoring the rhythm of hippocampal neurogenesis and alleviating behavioral abnormalities in CUMS mice.
37156274	6	62	theme	Proteobacteria	1209:1222	arg1	expansion					1192:1200	the expansion	1188:1200	the expansion of the Proteobacteria	1188:1222	RESULTS We found that EPs ameliorated gut dysbiosis caused by CUMS, as evidenced by increasing the abundance of Lactobacillaceae and suppressing the expansion of the Proteobacteria, thereby mitigating intestinal inflammation and barrier derangement.
37156274	0	63	theme	chronic	109:115	arg1	stress					136:141	chronic unpredictable mild stress	109:141	chronic unpredictable mild stress	109:141	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	3	64	theme	mice	622:625	arg1	Institute					587:595	Male Institute	582:595	METHODS Male Institute of Cancer Research (ICR) mice	574:625	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	0	65	theme	mild	131:134	arg1	stress					136:141	chronic unpredictable mild stress	109:141	chronic unpredictable mild stress	109:141	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	9	66	theme	Correlation	1654:1664	arg1	analysis					1666:1673	Correlation analysis	1654:1673	Correlation analysis	1654:1673	Correlation analysis showed that the perturbed-gut microbiota was strongly correlated with behavioral abnormalities and neuroinflammation.
37156274	8	67	theme	CUMS	1643:1646	arg1	mice					1648:1651	CUMS mice	1643:1651	CUMS mice	1643:1651	These contributed to restoring the rhythm of hippocampal neurogenesis and alleviating behavioral abnormalities in CUMS mice.
37156274	2	68	theme	diet-induced	436:447	arg1	inflammation					468:479	obesogenic diet-induced systemic low-grade inflammation	425:479	obesogenic diet-induced systemic low-grade inflammation	425:479	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	0	69	theme	cortex	10:15	arg1	polysaccharides					17:31	Eucommiae cortex polysaccharides	0:31	Eucommiae cortex polysaccharides	0:31	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	3	70	dep	METHODS	574:580	arg1	Institute					587:595	Male Institute	582:595	METHODS Male Institute of Cancer Research (ICR) mice	574:625	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	8	71	theme	behavioral	1615:1624	arg1	abnormalities					1626:1638	behavioral abnormalities	1615:1638	behavioral abnormalities in CUMS mice	1615:1651	These contributed to restoring the rhythm of hippocampal neurogenesis and alleviating behavioral abnormalities in CUMS mice.
37156274	5	72	theme	gene	967:970	arg1	sequencing					972:981	16S ribosomal RNA (rRNA) gene sequencing	942:981	16S ribosomal RNA (rRNA) gene sequencing	942:981	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	7	73	theme	lipopolysaccharides	1351:1369	arg1	release					1322:1328	the release	1318:1328	the release of bacterial-derived lipopolysaccharides (LPS, endotoxin)	1318:1386	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	4	74	theme	test-specific	782:794	arg1	effects					826:832	Behavioral test-specific antidepressant and anxiolytic effects	771:832	Behavioral test-specific antidepressant and anxiolytic effects of EPs	771:839	Behavioral test-specific antidepressant and anxiolytic effects of EPs were assessed in FST, TST, EPM, and OFT.
37156274	10	75	theme	improved	1902:1909	arg1	behavior					1911:1918	improved behavior	1902:1918	improved behavior	1902:1918	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	11	76	theme	microbial	2106:2114	arg1	composition					2116:2126	gut microbial composition	2102:2126	gut microbial composition	2102:2126	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	0	77	theme	microbiota	47:56	arg1	dysbiosis					58:66	gut microbiota dysbiosis	43:66	gut microbiota dysbiosis	43:66	Eucommiae cortex polysaccharides attenuate gut microbiota dysbiosis and neuroinflammation in mice exposed to chronic unpredictable mild stress: Beneficial in ameliorating depressive-like behaviors.
37156274	2	78	theme	physiological	530:542	arg1	changes					544:550	stress-induced behavioral and physiological changes	500:550	stress-induced behavioral and physiological changes	500:550	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	2	79	theme	low-grade	458:466	arg1	inflammation					468:479	obesogenic diet-induced systemic low-grade inflammation	425:479	obesogenic diet-induced systemic low-grade inflammation	425:479	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	8	80	from	abnormalities	1626:1638	arg1	mice					1648:1651	CUMS mice	1643:1651	CUMS mice	1643:1651	These contributed to restoring the rhythm of hippocampal neurogenesis and alleviating behavioral abnormalities in CUMS mice.
37156274	2	81	theme	behavioral	515:524	arg1	changes					544:550	stress-induced behavioral and physiological changes	500:550	stress-induced behavioral and physiological changes	500:550	Eucommiae cortex polysaccharides (EPs) have been reported to remodel gut microbiota and ameliorate obesogenic diet-induced systemic low-grade inflammation, but their role in stress-induced behavioral and physiological changes is poorly understood.
37156274	5	82	theme	western	1005:1011	arg1	blot					1013:1016	western blot	1005:1016	western blot	1005:1016	Microbiota composition and inflammation were detected using 16S ribosomal RNA (rRNA) gene sequencing, quantitative RT-PCR, western blot, and immunofluorescence.
37156274	4	83	theme	EPs	837:839	arg1	effects					826:832	Behavioral test-specific antidepressant and anxiolytic effects	771:832	Behavioral test-specific antidepressant and anxiolytic effects of EPs	771:839	Behavioral test-specific antidepressant and anxiolytic effects of EPs were assessed in FST, TST, EPM, and OFT.
37156274	11	84	theme	depression-like	2015:2029	arg1	symptoms					2031:2038	depression-like symptoms	2015:2038	depression-like symptoms	2015:2038	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	7	85	dep	lipopolysaccharides	1351:1369	arg1	endotoxin					1377:1385	endotoxin	1377:1385	endotoxin	1377:1385	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	7	85	dep	lipopolysaccharides	1351:1369	arg1	LPS					1372:1374	LPS	1372:1374	LPS	1372:1374	Importantly, EPs reduced the release of bacterial-derived lipopolysaccharides (LPS, endotoxin) and inhibited the microglia-mediated TLR4/NFκB/MAPK signaling pathway, thereby attenuating the pro-inflammatory response in the hippocampus.
37156274	10	86	dep	remodeling	1868:1877	arg1	microbiota					1887:1896	the gut microbiota	1879:1896	the gut microbiota	1879:1896	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
37156274	11	87	theme	beneficial	2080:2089	arg1	effects					2091:2097	their beneficial effects	2074:2097	their beneficial effects on gut microbial composition	2074:2126	CONCLUSIONS EPs exert ameliorative effects on CUMS-induced neuroinflammation and depression-like symptoms, which may be strongly related to their beneficial effects on gut microbial composition.
37156274	3	88	theme	400 mg/kg	735:743	arg1	dose					727:730	a dose	725:730	a dose of 400 mg/kg once per day for 2 weeks	725:768	METHODS Male Institute of Cancer Research (ICR) mice were exposed to chronic unpredictable stress (CUMS) for 4 weeks and then supplemented with EPs at a dose of 400 mg/kg once per day for 2 weeks.
37156274	10	89	dep	LIMITATIONS	1793:1803	arg1	clarify					1824:1830	clarify	1824:1830	did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice	1816:1931	LIMITATIONS This study did not clarify the causal relationship between EPs remodeling the gut microbiota and improved behavior in CUMS mice.
35792532	5	0	theme	cell	768:771	arg1	compositions					778:789	the cell wall compositions	764:789	the cell wall compositions of the gltps-silenced strains	764:819	Furthermore, the cell wall compositions of the gltps-silenced strains were also altered, which showed that the chitin and β-1,3-glucan contents were significantly decreased.
35792532	4	1	theme	extracellular	549:561	arg1	polysaccharide content					563:584	the extracellular polysaccharide content	545:584	the extracellular polysaccharide content	545:584	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	0	2	theme	Ganoderma	95:103	arg1	lucidum					105:111	Ganoderma lucidum	95:111	Ganoderma lucidum	95:111	Trehalose-6-phosphate synthase influences polysaccharide synthesis and cell wall components in Ganoderma lucidum.
35792532	7	3	theme	gltps-silenced	1074:1087	arg1	strains					1089:1095	gltps-silenced strains	1074:1095	gltps-silenced strains	1074:1095	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	3	4	theme	RNA	495:497	arg1	interference					499:510	RNA interference	495:510	RNA interference	495:510	And gltps-silenced strains were constructed by RNA interference.
35792532	1	5	theme	trehalose	268:276	arg1	phosphatase					278:288	trehalose phosphatase	268:288	trehalose phosphatase	268:288	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	1	6	theme	large	346:350	arg1	basidiomycetes					352:365	large basidiomycetes	346:365	large basidiomycetes	346:365	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	8	7	theme	important	1256:1264	arg1	effect					1266:1271	an important effect	1253:1271	an important effect	1253:1271	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	6	8	theme	%	986:986	arg1	%					990:990	20%-50%	984:990	20%-50%	984:990	Compared with WT, the concentration of chitin decreased by 20%-50% and that of β-1, 3-glucan decreased by 15%-30%.
35792532	7	9	theme	cell	1206:1209	arg1	wall					1211:1214	the cell wall	1202:1214	the cell wall	1202:1214	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	1	10	from	role	299:302	arg1	fungi					307:311	fungi	307:311	fungi	307:311	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	7	11	from	structure	1189:1197	arg1	compounds					1175:1183	the compounds	1171:1183	the compounds	1171:1183	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	4	12	located	found	534:538	arg1	study					521:525	this study	516:525	this study	516:525	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	4	12	located	found	534:538	arg2	it					528:529	it	528:529	it	528:529	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	2	13	theme	tps	387:389	arg1	gltps					441:445	gltps	441:445	gltps	441:445	In this study, the tps gene of Ganoderma lucidum was cloned and named as gltps.
35792532	2	13	theme	tps	387:389	arg1	gene					391:394	the tps gene	383:394	the tps gene of Ganoderma lucidum	383:415	In this study, the tps gene of Ganoderma lucidum was cloned and named as gltps.
35792532	5	14	theme	gltps-silenced	798:811	arg1	strains					813:819	the gltps-silenced strains	794:819	the gltps-silenced strains	794:819	Furthermore, the cell wall compositions of the gltps-silenced strains were also altered, which showed that the chitin and β-1,3-glucan contents were significantly decreased.
35792532	1	15	theme	trehalose	188:196	arg1	metabolism					198:207	trehalose metabolism	188:207	trehalose metabolism	188:207	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	5	16	theme	strains	813:819	arg1	compositions					778:789	the cell wall compositions	764:789	the cell wall compositions of the gltps-silenced strains	764:819	Furthermore, the cell wall compositions of the gltps-silenced strains were also altered, which showed that the chitin and β-1,3-glucan contents were significantly decreased.
35792532	5	17	theme	wall	773:776	arg1	compositions					778:789	the cell wall compositions	764:789	the cell wall compositions of the gltps-silenced strains	764:819	Furthermore, the cell wall compositions of the gltps-silenced strains were also altered, which showed that the chitin and β-1,3-glucan contents were significantly decreased.
35792532	7	18	theme	wall	1125:1128	arg1	stress					1130:1135	cell wall stress	1120:1135	cell wall stress	1120:1135	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	6	19	theme	-30	1034:1036	arg1	%					1033:1033	%	1033:1033	%	1033:1033	Compared with WT, the concentration of chitin decreased by 20%-50% and that of β-1, 3-glucan decreased by 15%-30%.
35792532	0	20	theme	Trehalose-6-phosphate	0:20	arg1	synthase					22:29	Trehalose-6-phosphate synthase	0:29	Trehalose-6-phosphate synthase	0:29	Trehalose-6-phosphate synthase influences polysaccharide synthesis and cell wall components in Ganoderma lucidum.
35792532	1	21	theme	Trehalose-6-phosphate	114:134	arg1	enzyme					160:165	a key enzyme	154:165	a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase	154:288	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	1	21	theme	Trehalose-6-phosphate	114:134	arg1	TPS					146:148	TPS	146:148	TPS	146:148	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	1	21	theme	Trehalose-6-phosphate	114:134	arg1	synthase					136:143	Trehalose-6-phosphate synthase	114:143	Trehalose-6-phosphate synthase (TPS)	114:149	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	4	22	from	change	637:642	arg1	polysaccharide content					661:682	intracellular polysaccharide content	647:682	intracellular polysaccharide content	647:682	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	4	22	from	change	637:642	arg1	strains					702:708	gltps-silenced strains	687:708	gltps-silenced strains	687:708	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	5	23	theme	β-1,3-glucan	873:884	arg1	contents					886:893	the chitin and β-1,3-glucan contents	858:893	the chitin and β-1,3-glucan contents	858:893	Furthermore, the cell wall compositions of the gltps-silenced strains were also altered, which showed that the chitin and β-1,3-glucan contents were significantly decreased.
35792532	0	24	theme	polysaccharide	42:55	arg1	synthesis					57:65	polysaccharide synthesis	42:65	polysaccharide synthesis	42:65	Trehalose-6-phosphate synthase influences polysaccharide synthesis and cell wall components in Ganoderma lucidum.
35792532	8	25	contain	had	1249:1251	arg1	gltps					1243:1247	gltps	1243:1247	gltps	1243:1247	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	8	25	contain	had	1249:1251	arg2	effect					1266:1271	an important effect	1253:1271	an important effect	1253:1271	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	4	26	dep	wild-type	728:736	arg1	WT					739:740	WT	739:740	WT	739:740	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	2	27	theme	lucidum	409:415	arg1	gltps					441:445	gltps	441:445	gltps	441:445	In this study, the tps gene of Ganoderma lucidum was cloned and named as gltps.
35792532	2	27	theme	lucidum	409:415	arg1	gene					391:394	the tps gene	383:394	the tps gene of Ganoderma lucidum	383:415	In this study, the tps gene of Ganoderma lucidum was cloned and named as gltps.
35792532	7	28	theme	cell	1120:1123	arg1	stress					1130:1135	cell wall stress	1120:1135	cell wall stress	1120:1135	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	8	29	theme	carbohydrate	1276:1287	arg1	metabolism					1289:1298	carbohydrate metabolism	1276:1298	carbohydrate metabolism of G. lucidum cells	1276:1318	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	8	30	theme	G.	1303:1304	arg1	cells					1314:1318	G. lucidum cells	1303:1318	G. lucidum cells	1303:1318	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	2	31	theme	Ganoderma	399:407	arg1	lucidum					409:415	Ganoderma lucidum	399:415	Ganoderma lucidum	399:415	In this study, the tps gene of Ganoderma lucidum was cloned and named as gltps.
35792532	6	32	theme	chitin	964:969	arg1	concentration					947:959	the concentration	943:959	the concentration of chitin	943:969	Compared with WT, the concentration of chitin decreased by 20%-50% and that of β-1, 3-glucan decreased by 15%-30%.
35792532	4	33	theme	intracellular	647:659	arg1	polysaccharide content					661:682	intracellular polysaccharide content	647:682	intracellular polysaccharide content	647:682	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	8	34	theme	cells	1314:1318	arg1	metabolism					1289:1298	carbohydrate metabolism	1276:1298	carbohydrate metabolism of G. lucidum cells	1276:1318	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	4	35	theme	significant	625:635	arg1	change					637:642	no significant change	622:642	no significant change on intracellular polysaccharide content in gltps-silenced strains	622:708	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	0	36	theme	wall	76:79	arg1	components					81:90	cell wall components	71:90	cell wall components	71:90	Trehalose-6-phosphate synthase influences polysaccharide synthesis and cell wall components in Ganoderma lucidum.
35792532	4	37	theme	wild-type	728:736	arg1	strain					743:748	the wild-type (WT) strain	724:748	the wild-type (WT) strain	724:748	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35792532	0	38	theme	cell	71:74	arg1	components					81:90	cell wall components	71:90	cell wall components	71:90	Trehalose-6-phosphate synthase influences polysaccharide synthesis and cell wall components in Ganoderma lucidum.
35792532	6	39	dep	decreased	971:979	arg1	decreased					1018:1026	decreased	1018:1026	decreased by 15%-30%	1018:1037	Compared with WT, the concentration of chitin decreased by 20%-50% and that of β-1, 3-glucan decreased by 15%-30%.
35792532	7	40	theme	wall	1211:1214	arg1	structure					1189:1197	structure	1189:1197	structure of the cell wall	1189:1214	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	7	40	theme	wall	1211:1214	arg1	changes					1160:1166	changes	1160:1166	changes in the compounds	1160:1183	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	3	41	theme	gltps-silenced	452:465	arg1	strains					467:473	gltps-silenced strains	452:473	gltps-silenced strains	452:473	And gltps-silenced strains were constructed by RNA interference.
35792532	8	42	theme	lucidum	1306:1312	arg1	cells					1314:1318	G. lucidum cells	1303:1318	G. lucidum cells	1303:1318	These results showed that gltps had an important effect on carbohydrate metabolism of G. lucidum cells.
35792532	7	43	from	changes	1160:1166	arg1	compounds					1175:1183	the compounds	1171:1183	the compounds	1171:1183	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	6	44	theme	15	1031:1032	arg1	%					1033:1033	%	1033:1033	%	1033:1033	Compared with WT, the concentration of chitin decreased by 20%-50% and that of β-1, 3-glucan decreased by 15%-30%.
35792532	1	45	with	pathway	255:261	arg1	phosphatase					278:288	trehalose phosphatase	268:288	trehalose phosphatase	268:288	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	1	46	theme	key	156:158	arg1	enzyme					160:165	a key enzyme	154:165	a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase	154:288	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	1	46	theme	key	156:158	arg1	synthase					136:143	Trehalose-6-phosphate synthase	114:143	Trehalose-6-phosphate synthase (TPS)	114:149	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	5	47	theme	chitin	862:867	arg1	contents					886:893	the chitin and β-1,3-glucan contents	858:893	the chitin and β-1,3-glucan contents	858:893	Furthermore, the cell wall compositions of the gltps-silenced strains were also altered, which showed that the chitin and β-1,3-glucan contents were significantly decreased.
35792532	1	48	theme	two-step	246:253	arg1	pathway					255:261	a two-step pathway	244:261	a two-step pathway with trehalose phosphatase	244:288	Trehalose-6-phosphate synthase (TPS) is a key enzyme that participates in trehalose metabolism, which can synthesize trehalose in a two-step pathway with trehalose phosphatase, but its role in fungi is rarely studied, especially in large basidiomycetes.
35792532	7	49	theme	strains	1089:1095	arg1	cells					1065:1069	the cells	1061:1069	the cells of gltps-silenced strains	1061:1095	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	7	49	theme	strains	1089:1095	arg1	sensitive					1107:1115	sensitive	1107:1115	sensitive	1107:1115	The study found that the cells of gltps-silenced strains were more sensitive to cell wall stress, which might be due to changes in the compounds and structure of the cell wall.
35792532	4	50	theme	gltps-silenced	687:700	arg1	strains					702:708	gltps-silenced strains	687:708	gltps-silenced strains	687:708	In this study, it is found that the extracellular polysaccharide content increased 1.6-2-fold, but there was no significant change on intracellular polysaccharide content in gltps-silenced strains compared with the wild-type (WT) strain.
35678155	4	0	theme	g	888:888	arg1	mol-1					890:894	1.01 × 105 g mol-1	877:894	1.01 × 105 g mol-1 for APS2	877:903	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	3	1	theme	APS	644:646	arg1	kinds					635:639	the two kinds	627:639	the two kinds of APS	627:646	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	5	2	theme	monomer	1003:1009	arg1	residues					1011:1018	similar monomer residues	995:1018	similar monomer residues	995:1018	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	6	3	theme	Fas	1222:1224	arg1	expression					1187:1196	mRNA expression	1182:1196	mRNA expression of Ppar-γ, C/ebp-α, and Fas	1182:1224	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	3	4	theme	same	656:659	arg1	compositions					669:680	the same monomer compositions	652:680	the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1	652:788	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	5	theme	galacturonic	762:773	arg1	acid					775:778	galacturonic acid	762:778	galacturonic acid	762:778	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	7	6	theme	potential	1404:1412	arg1	candidates					1414:1423	potential candidates	1404:1423	potential candidates for antiadipogenic use	1404:1446	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	6	7	theme	Ppar-γ	1201:1206	arg1	expression					1187:1196	mRNA expression	1182:1196	mRNA expression of Ppar-γ, C/ebp-α, and Fas	1182:1224	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	7	8	theme	functional	1456:1465	arg1	food					1467:1470	functional food	1456:1470	functional food	1456:1470	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	4	9	theme	mol-1	856:860	arg1	mass					835:838	a greater molar mass	819:838	a greater molar mass of 1.77 × 105 g mol-1	819:860	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	0	10	from	Influence	0:8	arg1	bioactivities					78:90	bioactivities	78:90	bioactivities	78:90	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	0	10	from	Influence	0:8	arg1	characteristics					58:72	structural characteristics	47:72	structural characteristics	47:72	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	7	11	theme	structural	1340:1349	arg1	characteristics					1351:1365	the structural characteristics	1336:1365	the structural characteristics	1336:1365	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	1	12	theme	bioactivities	223:235	arg1	bioactivities					223:235	bioactivities	223:235	bioactivities	223:235	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	1	12	theme	bioactivities	223:235	arg1	variety					212:218	a variety	210:218	a variety of bioactivities	210:235	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	0	13	theme	polysaccharides	95:109	arg1	bioactivities					78:90	bioactivities	78:90	bioactivities	78:90	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	0	13	theme	polysaccharides	95:109	arg1	characteristics					58:72	structural characteristics	47:72	structural characteristics	47:72	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	1	14	theme	environment	312:322	arg1	effects					286:292	the effects	282:292	the effects of the ecological environment on the structural characteristics and bioactivities of APS	282:381	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	2	15	theme	normal	555:560	arg1	APS1					568:571	APS1	568:571	APS1	568:571	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	2	15	theme	normal	555:560	arg1	soil					562:565	normal soil	555:565	normal soil (APS1)	555:572	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	0	16	dep	alfalfa	116:122	arg1	L					141:141	Medicago sativa L	125:141	Medicago sativa L.	125:142	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	6	17	theme	superior	1236:1243	arg1	effects					1260:1266	superior antiadipogenic effects	1236:1266	superior antiadipogenic effects	1236:1266	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	7	18	theme	APS	1387:1389	arg1	biofunctions					1371:1382	biofunctions	1371:1382	biofunctions	1371:1382	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	7	18	theme	APS	1387:1389	arg1	characteristics					1351:1365	the structural characteristics	1336:1365	the structural characteristics	1336:1365	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	3	19	theme	monomer	661:667	arg1	compositions					669:680	the same monomer compositions	652:680	the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1	652:788	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	20	from	compositions	669:680	arg1	proportions					701:711	different molar proportions	685:711	different molar proportions	685:711	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	21	theme	arabinose	748:756	arg1	content					737:743	greater content	729:743	greater content of arabinose	729:756	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	21	theme	arabinose	748:756	arg1	acid					775:778	galacturonic acid	762:778	galacturonic acid	762:778	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	2	22	theme	structural	420:429	arg1	characteristics					431:445	the structural characteristics	416:445	the structural characteristics	416:445	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	5	23	theme	similar	995:1001	arg1	residues					1011:1018	similar monomer residues	995:1018	similar monomer residues	995:1018	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	2	24	theme	saline-alkali	577:589	arg1	APS2					597:600	APS2	597:600	APS2	597:600	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	2	24	theme	saline-alkali	577:589	arg1	soil					591:594	saline-alkali soil	577:594	saline-alkali soil (APS2)	577:601	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	8	25	with	polysaccharides	1548:1562	arg1	bioactivities					1578:1590	specific bioactivities	1569:1590	specific bioactivities	1569:1590	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	1	26	theme	structural	331:340	arg1	characteristics					342:356	the structural characteristics	327:356	the structural characteristics	327:356	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	4	27	theme	×	882:882	arg1	mol-1					890:894	1.01 × 105 g mol-1	877:894	1.01 × 105 g mol-1 for APS2	877:903	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	7	28	theme	ecological	1305:1314	arg1	environment					1316:1326	the ecological environment	1301:1326	the ecological environment	1301:1326	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	4	29	theme	greater	821:827	arg1	mass					835:838	a greater molar mass	819:838	a greater molar mass of 1.77 × 105 g mol-1	819:860	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	1	30	theme	Medicago	176:183	arg1	L					192:192	Medicago sativa L	176:192	Medicago sativa L.	176:193	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	3	31	theme	different	685:693	arg1	proportions					701:711	different molar proportions	685:711	different molar proportions	685:711	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	6	32	theme	mRNA	1182:1185	arg1	expression					1187:1196	mRNA expression	1182:1196	mRNA expression of Ppar-γ, C/ebp-α, and Fas	1182:1224	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	1	33	theme	sativa	185:190	arg1	L					192:192	Medicago sativa L	176:192	Medicago sativa L.	176:193	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	0	34	theme	ecological	17:26	arg1	environment					28:38	the ecological environment	13:38	the ecological environment	13:38	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	3	35	theme	molar	695:699	arg1	proportions					701:711	different molar proportions	685:711	different molar proportions	685:711	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	0	36	theme	sativa	134:139	arg1	L					141:141	Medicago sativa L	125:141	Medicago sativa L.	125:142	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	1	37	theme	little	247:252	arg1	information					254:264	little information	247:264	little information	247:264	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	0	38	theme	Medicago	125:132	arg1	L					141:141	Medicago sativa L	125:141	Medicago sativa L.	125:142	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	0	39	dep	characteristics	58:72	arg1	the					43:45	the	43:45	the	43:45	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	5	40	contain	had	930:932	arg1	APS2					925:928	APS2	925:928	APS2	925:928	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	5	40	contain	had	930:932	arg1	APS1					916:919	APS1	916:919	APS1	916:919	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	5	40	contain	had	930:932	arg2	molecules					950:958	highly branched molecules	934:958	highly branched molecules	934:958	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	4	41	theme	g	854:854	arg1	mol-1					856:860	1.77 × 105 g mol-1	843:860	1.77 × 105 g mol-1	843:860	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	0	42	from	bioactivities	78:90	arg1	alfalfa					116:122	alfalfa	116:122	alfalfa (Medicago sativa L.)	116:143	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	6	43	theme	3T3-L1	1151:1156	arg1	cells					1158:1162	3T3-L1 cells	1151:1162	3T3-L1 cells	1151:1162	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	0	44	theme	environment	28:38	arg1	Influence					0:8	Influence	0:8	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).	0:144	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	5	45	theme	glycosidic	1039:1048	arg1	linkages					1050:1057	different glycosidic linkages	1029:1057	different glycosidic linkages	1029:1057	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	5	46	theme	crosslinking	965:976	arg1	nets					978:981	crosslinking nets	965:981	crosslinking nets composed of similar monomer residues	965:1018	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	6	47	theme	antiadipogenic	1245:1258	arg1	effects					1260:1266	superior antiadipogenic effects	1236:1266	superior antiadipogenic effects	1236:1266	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	1	48	from	effects	286:292	arg1	bioactivities					362:374	bioactivities	362:374	bioactivities	362:374	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	1	48	from	effects	286:292	arg1	characteristics					342:356	the structural characteristics	327:356	the structural characteristics	327:356	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	8	49	theme	novel	1498:1502	arg1	perspective					1504:1514	a novel perspective	1496:1514	a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities	1496:1590	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	4	50	theme	molar	829:833	arg1	mass					835:838	a greater molar mass	819:838	a greater molar mass of 1.77 × 105 g mol-1	819:860	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	0	51	from	characteristics	58:72	arg1	alfalfa					116:122	alfalfa	116:122	alfalfa (Medicago sativa L.)	116:143	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	1	52	dep	alfalfa	167:173	arg1	L					192:192	Medicago sativa L	176:192	Medicago sativa L.	176:193	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	1	53	theme	ecological	301:310	arg1	environment					312:322	the ecological environment	297:322	the ecological environment	297:322	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	4	54	theme	×	848:848	arg1	mol-1					856:860	1.77 × 105 g mol-1	843:860	1.77 × 105 g mol-1	843:860	Furthermore, APS1 exhibited a greater molar mass of 1.77 × 105 g mol-1 as compared to 1.01 × 105 g mol-1 for APS2.
35678155	1	55	theme	APS	379:381	arg1	bioactivities					362:374	bioactivities	362:374	bioactivities	362:374	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	1	55	theme	APS	379:381	arg1	characteristics					342:356	the structural characteristics	327:356	the structural characteristics	327:356	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	6	56	theme	lipid	1129:1133	arg1	accumulation					1135:1146	lipid accumulation	1129:1146	lipid accumulation	1129:1146	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	2	57	attach	isolated	482:489	arg1	alfalfa					496:502	alfalfa	496:502	alfalfa	496:502	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	2	57	attach	isolated	482:489	arg2	types					476:480	two APS types	468:480	two APS types isolated from alfalfa	468:502	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	3	58	contain	had	648:650	arg2	compositions					669:680	the same monomer compositions	652:680	the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1	652:788	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	58	contain	had	648:650	arg1	kinds					635:639	the two kinds	627:639	the two kinds of APS	627:646	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	8	59	theme	growth	1607:1612	arg1	conditions					1628:1637	growth environmental conditions	1607:1637	growth environmental conditions	1607:1637	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	0	60	from	alfalfa	116:122	arg1	bioactivities					78:90	bioactivities	78:90	bioactivities	78:90	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	0	60	from	alfalfa	116:122	arg1	characteristics					58:72	structural characteristics	47:72	structural characteristics	47:72	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	0	60	from	alfalfa	116:122	arg1	polysaccharides					95:109	polysaccharides	95:109	polysaccharides from alfalfa (Medicago sativa L.)	95:143	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	7	61	theme	antiadipogenic	1429:1442	arg1	use					1444:1446	antiadipogenic use	1429:1446	antiadipogenic use	1429:1446	Altogether, the ecological environment impacts the structural characteristics and biofunctions of APS, making them potential candidates for antiadipogenic use through functional food.
35678155	6	62	theme	C/ebp-α	1209:1215	arg1	expression					1187:1196	mRNA expression	1182:1196	mRNA expression of Ppar-γ, C/ebp-α, and Fas	1182:1224	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	3	63	contain	had	725:727	arg2	acid					775:778	galacturonic acid	762:778	galacturonic acid	762:778	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	63	contain	had	725:727	arg2	content					737:743	greater content	729:743	greater content of arabinose	729:756	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	3	63	contain	had	725:727	arg1	APS2					720:723	APS2	720:723	APS2	720:723	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35678155	2	64	theme	APS	472:474	arg1	types					476:480	two APS types	468:480	two APS types isolated from alfalfa	468:502	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	6	65	contain	had	1232:1234	arg1	APS2					1227:1230	APS2	1227:1230	APS2	1227:1230	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	6	65	contain	had	1232:1234	arg2	effects					1260:1266	superior antiadipogenic effects	1236:1266	superior antiadipogenic effects	1236:1266	Additionally, both APS significantly inhibited both adipogenesis and lipid accumulation in 3T3-L1 cells by downregulating mRNA expression of Ppar-γ, C/ebp-α, and Fas; APS2 had superior antiadipogenic effects as compared to APS1.
35678155	2	66	theme	types	476:480	arg1	characteristics					431:445	the structural characteristics	416:445	the structural characteristics	416:445	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	2	66	theme	types	476:480	arg1	bioactivities					451:463	bioactivities	451:463	bioactivities	451:463	This study aimed to investigate the structural characteristics and bioactivities of two APS types isolated from alfalfa; these APSs were obtained from alfalfa cultured in normal soil (APS1) or saline-alkali soil (APS2).
35678155	5	67	theme	branched	941:948	arg1	molecules					950:958	highly branched molecules	934:958	highly branched molecules	934:958	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	5	68	theme	different	1029:1037	arg1	linkages					1050:1057	different glycosidic linkages	1029:1057	different glycosidic linkages	1029:1057	Likewise, APS1 and APS2 had highly branched molecules with crosslinking nets composed of similar monomer residues but with different glycosidic linkages.
35678155	8	69	theme	environmental	1614:1626	arg1	conditions					1628:1637	growth environmental conditions	1607:1637	growth environmental conditions	1607:1637	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	8	70	theme	polysaccharides	1548:1562	arg1	selection					1524:1532	the selection	1520:1532	the selection of phytogenic polysaccharides with specific bioactivities	1520:1590	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	0	71	theme	structural	47:56	arg1	characteristics					58:72	structural characteristics	47:72	structural characteristics	47:72	Influence of the ecological environment on the structural characteristics and bioactivities of polysaccharides from alfalfa (Medicago sativa L.).
35678155	8	72	theme	phytogenic	1537:1546	arg1	polysaccharides					1548:1562	phytogenic polysaccharides	1537:1562	phytogenic polysaccharides with specific bioactivities	1537:1590	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	1	73	from	alfalfa	167:173	arg1	Polysaccharides					146:160	Polysaccharides	146:160	Polysaccharides from alfalfa (Medicago sativa L.) (APS)	146:200	Polysaccharides from alfalfa (Medicago sativa L.) (APS) exhibit a variety of bioactivities; however, little information is available on the effects of the ecological environment on the structural characteristics and bioactivities of APS.
35678155	8	74	theme	specific	1569:1576	arg1	bioactivities					1578:1590	specific bioactivities	1569:1590	specific bioactivities	1569:1590	These findings provide a novel perspective for the selection of phytogenic polysaccharides with specific bioactivities by considering growth environmental conditions.
35678155	3	75	theme	greater	729:735	arg1	content					737:743	greater content	729:743	greater content of arabinose	729:756	Results indicated that the two kinds of APS had the same monomer compositions in different molar proportions, where APS2 had greater content of arabinose and galacturonic acid than APS1.
35749894	3	0	theme	substances	770:779	arg1	synthesis					705:713	synthesis	705:713	synthesis of photosynthetic pigments and extracellular polymeric substances (EPS)	705:785	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	3	0	theme	substances	770:779	arg1	production					690:699	biofilm biomass production	674:699	biofilm biomass production	674:699	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	5	1	theme	EPS	1253:1255	arg1	hydrophobicity					1257:1270	EPS hydrophobicity	1253:1270	EPS hydrophobicity	1253:1270	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	1	theme	EPS	1253:1255	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	7	2	theme	sediments	1555:1563	arg1	underneath					1565:1574	the sediments underneath	1551:1574	the sediments underneath	1551:1574	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	1	3	theme	culture	311:317	arg1	vessel					319:324	a biofilm-promoting culture vessel	291:324	a biofilm-promoting culture vessel	291:324	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	6	4	theme	proteins	1310:1317	arg1	Ratios					1287:1292	Ratios	1287:1292	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides	1287:1421	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	3	5	theme	PAH	591:593	arg1	challenge					595:603	PAH challenge	591:603	PAH challenge	591:603	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	1	6	theme	world	224:228	arg1	forest					255:260	the world's largest tidal mangrove forest	220:260	the world's largest tidal mangrove forest	220:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	7	7	theme	phototrophic	1483:1494	arg1	biofilm					1496:1502	the overlying phototrophic biofilm	1469:1502	the overlying phototrophic biofilm	1469:1502	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	6	8	theme	released	1297:1304	arg1	proteins					1310:1317	released RPS proteins	1297:1317	released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides	1297:1421	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	3	9	theme	biofilm	623:629	arg1	composition					654:664	the biofilm phototrophic community composition	619:664	the biofilm phototrophic community composition	619:664	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	1	10	theme	largest	232:238	arg1	world					224:228	the world's largest	220:238	the world's largest tidal mangrove forest	220:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	6	11	theme	proteins	1397:1404	arg1	ratios					1383:1388	the ratios	1379:1388	the ratios of CPS proteins	1379:1404	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	1	12	theme	mangrove	246:253	arg1	forest					255:260	the world's largest tidal mangrove forest	220:260	the world's largest tidal mangrove forest	220:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	13	theme	liquid	934:939	arg1	medium					941:946	the liquid medium	930:946	the liquid medium as well as inside the biofilm	930:976	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	7	14	theme	Efficacious	1442:1452	arg1	removal					1458:1464	Efficacious PAH removal	1442:1464	Efficacious PAH removal by the overlying phototrophic biofilm	1442:1502	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	5	15	theme	released	1108:1115	arg1	carbohydrates					1139:1151	polysaccharidic (RPS) carbohydrates	1117:1151	polysaccharidic (RPS) carbohydrates	1117:1151	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	15	theme	released	1108:1115	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	3	16	theme	community	644:652	arg1	composition					654:664	the biofilm phototrophic community composition	619:664	the biofilm phototrophic community composition	619:664	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	1	17	theme	Phototrophic	159:170	arg1	biofilms					172:179	Phototrophic biofilms	159:179	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest	159:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	4	18	theme	Photosynthetic	802:815	arg1	pigment					817:823	Photosynthetic pigment	802:823	Photosynthetic pigment	802:823	Photosynthetic pigment and EPS synthesis were sensitive to vessel-surface property.
35749894	5	19	theme	polysaccharidic	1181:1195	arg1	carbohydrates					1203:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	19	theme	polysaccharidic	1181:1195	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	3	20	theme	biofilm	674:680	arg1	biomass					682:688	biofilm biomass	674:688	biofilm biomass production	674:699	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	1	21	theme	intertidal	196:205	arg1	sediments					207:215	intertidal sediments	196:215	intertidal sediments of the world's largest tidal mangrove forest	196:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	22	theme	hydrophilic	333:343	arg1	surface					351:357	hydrophilic glass surface	333:357	hydrophilic glass surface	333:357	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	7	23	theme	contaminants	1535:1546	arg1	entry					1520:1524	the entry	1516:1524	the entry of these contaminants in the sediments underneath	1516:1574	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	0	24	theme	hydrophobic	96:106	arg1	vessels					150:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	1	25	theme	wherein	407:413	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	25	theme	wherein	407:413	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	2	26	theme	pollutants	579:588	arg1	%					563:563	98-100%	557:563	98-100% of the spiked pollutants	557:588	Biofilms from three locations of the forest were most active in sequestering 98-100% of the spiked pollutants.
35749894	2	26	theme	pollutants	579:588	arg1	pollutants					579:588	the spiked pollutants	568:588	the spiked pollutants	568:588	Biofilms from three locations of the forest were most active in sequestering 98-100% of the spiked pollutants.
35749894	0	27	theme	hydrophilic	112:122	arg1	vessels					150:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	5	28	from	amounts	911:917	arg1	medium					941:946	the liquid medium	930:946	the liquid medium as well as inside the biofilm	930:976	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	7	29	theme	natural	1626:1632	arg1	"					1642:1642	monitored natural recovery"	1616:1642	"monitored natural recovery"	1615:1642	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	4	30	theme	vessel-surface	861:874	arg1	property					876:883	vessel-surface property	861:883	vessel-surface property	861:883	Photosynthetic pigment and EPS synthesis were sensitive to vessel-surface property.
35749894	0	31	theme	culture	142:148	arg1	vessels					150:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	1	32	theme	aromatic	438:445	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	32	theme	aromatic	438:445	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	33	theme	highest	1054:1060	arg1	hydrophobicity					1257:1270	EPS hydrophobicity	1253:1270	EPS hydrophobicity	1253:1270	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	acids					1165:1169	RPS uronic acids	1154:1169	RPS uronic acids	1154:1169	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	acids					1243:1247	CPS uronic acids	1232:1247	CPS uronic acids	1232:1247	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	carbohydrates					1203:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	chlorophyll					1095:1105	total chlorophyll	1089:1105	total chlorophyll	1089:1105	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	carbohydrates					1139:1151	polysaccharidic (RPS) carbohydrates	1117:1151	polysaccharidic (RPS) carbohydrates	1117:1151	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	33	theme	highest	1054:1060	arg1	proteins					1222:1229	CPS proteins	1218:1229	CPS proteins	1218:1229	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	0	34	theme	Polycyclic	0:9	arg1	hydrocarbon					20:30	Polycyclic aromatic hydrocarbon	0:30	Polycyclic aromatic hydrocarbon	0:30	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	1	35	theme	vessel	319:324	arg1	vessel					319:324	a biofilm-promoting culture vessel	291:324	a biofilm-promoting culture vessel	291:324	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	35	theme	vessel	319:324	arg1	sets					283:286	two sets	279:286	two sets of a biofilm-promoting culture vessel having hydrophilic glass surface	279:357	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	36	theme	uronic	1236:1241	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	36	theme	uronic	1236:1241	arg1	acids					1243:1247	CPS uronic acids	1232:1247	CPS uronic acids	1232:1247	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	3	37	theme	photosynthetic	718:731	arg1	pigments					733:740	photosynthetic pigments	718:740	photosynthetic pigments	718:740	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	5	38	theme	total	1089:1093	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	38	theme	total	1089:1093	arg1	chlorophyll					1095:1105	total chlorophyll	1089:1105	total chlorophyll	1089:1105	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	39	theme	lowest	890:895	arg1	PAHs					922:925	PAHs	922:925	PAHs	922:925	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	39	theme	lowest	890:895	arg1	amounts					911:917	The lowest mean residual amounts	886:917	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm	886:976	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	40	theme	CPS	1218:1220	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	40	theme	CPS	1218:1220	arg1	proteins					1222:1229	CPS proteins	1218:1229	CPS proteins	1218:1229	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	1	41	theme	methacrylate	386:397	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	41	theme	methacrylate	386:397	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	3	42	theme	polymeric	760:768	arg1	EPS					782:784	EPS	782:784	EPS	782:784	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	3	42	theme	polymeric	760:768	arg1	substances					770:779	extracellular polymeric substances	746:779	extracellular polymeric substances (EPS)	746:785	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	5	43	from	cultivated	1012:1021	arg1	flask					1042:1046	the hydrophobic flask	1026:1046	the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained	1026:1284	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	hydrophobicity					1257:1270	EPS hydrophobicity	1253:1270	EPS hydrophobicity	1253:1270	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	acids					1165:1169	RPS uronic acids	1154:1169	RPS uronic acids	1154:1169	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	acids					1243:1247	CPS uronic acids	1232:1247	CPS uronic acids	1232:1247	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	carbohydrates					1203:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	chlorophyll					1095:1105	total chlorophyll	1089:1105	total chlorophyll	1089:1105	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	carbohydrates					1139:1151	polysaccharidic (RPS) carbohydrates	1117:1151	polysaccharidic (RPS) carbohydrates	1117:1151	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	44	theme	biomass	1080:1086	arg1	proteins					1222:1229	CPS proteins	1218:1229	CPS proteins	1218:1229	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	6	45	theme	PAH	1353:1355	arg1	sequestration					1357:1369	PAH sequestration	1353:1369	PAH sequestration	1353:1369	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	6	46	dep	proteins	1310:1317	arg1	polysaccharides					1407:1421	polysaccharides	1407:1421	released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides	1297:1421	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	6	46	dep	proteins	1310:1317	arg1	polysaccharides					1320:1334	polysaccharides	1320:1334	released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides	1297:1421	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	1	47	theme	biofilm-promoting	293:309	arg1	vessel					319:324	a biofilm-promoting culture vessel	291:324	a biofilm-promoting culture vessel	291:324	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	48	theme	residual	902:909	arg1	PAHs					922:925	PAHs	922:925	PAHs	922:925	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	48	theme	residual	902:909	arg1	amounts					911:917	The lowest mean residual amounts	886:917	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm	886:976	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	1	49	contain	having	326:331	arg1	vessel					319:324	a biofilm-promoting culture vessel	291:324	a biofilm-promoting culture vessel	291:324	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	49	contain	having	326:331	arg1	sets					283:286	two sets	279:286	two sets of a biofilm-promoting culture vessel having hydrophilic glass surface	279:357	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	49	contain	having	326:331	arg2	surface					351:357	hydrophilic glass surface	333:357	hydrophilic glass surface	333:357	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	0	50	theme	phototrophic	60:71	arg1	biofilms					73:80	intertidal phototrophic biofilms	49:80	intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels	49:156	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	1	51	theme	hydrophobic	363:373	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	51	theme	hydrophobic	363:373	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	6	52	theme	RPS	1306:1308	arg1	proteins					1310:1317	released RPS proteins	1297:1317	released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides	1297:1421	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	5	53	theme	CPS	1198:1200	arg1	carbohydrates					1203:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	53	theme	CPS	1198:1200	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	1	54	theme	tidal	240:244	arg1	forest					255:260	the world's largest tidal mangrove forest	220:260	the world's largest tidal mangrove forest	220:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	7	55	theme	overlying	1473:1481	arg1	biofilm					1496:1502	the overlying phototrophic biofilm	1469:1502	the overlying phototrophic biofilm	1469:1502	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	6	56	theme	CPS	1393:1395	arg1	proteins					1397:1404	CPS proteins	1393:1404	CPS proteins	1393:1404	Ratios of released RPS proteins: polysaccharides increased during PAH sequestration whereas the ratios of CPS proteins: polysaccharides remained constant.
35749894	1	57	theme	forest	255:260	arg1	sediments					207:215	intertidal sediments	196:215	intertidal sediments of the world's largest tidal mangrove forest	196:260	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	58	theme	RPS	1154:1156	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	58	theme	RPS	1154:1156	arg1	acids					1165:1169	RPS uronic acids	1154:1169	RPS uronic acids	1154:1169	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	3	59	theme	phototrophic	631:642	arg1	composition					654:664	the biofilm phototrophic community composition	619:664	the biofilm phototrophic community composition	619:664	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	7	60	theme	PAH	1454:1456	arg1	removal					1458:1464	Efficacious PAH removal	1442:1464	Efficacious PAH removal by the overlying phototrophic biofilm	1442:1502	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	5	61	theme	polysaccharidic	1117:1131	arg1	carbohydrates					1139:1151	polysaccharidic (RPS) carbohydrates	1117:1151	polysaccharidic (RPS) carbohydrates	1117:1151	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	61	theme	polysaccharidic	1117:1131	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	3	62	theme	biomass	682:688	arg1	production					690:699	biofilm biomass production	674:699	biofilm biomass production	674:699	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	5	63	theme	RPS	1134:1136	arg1	carbohydrates					1139:1151	polysaccharidic (RPS) carbohydrates	1117:1151	polysaccharidic (RPS) carbohydrates	1117:1151	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	63	theme	RPS	1134:1136	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	64	theme	PAHs	922:925	arg1	PAHs					922:925	PAHs	922:925	PAHs	922:925	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	64	theme	PAHs	922:925	arg1	amounts					911:917	The lowest mean residual amounts	886:917	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm	886:976	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	2	65	from	locations	500:508	arg1	Biofilms					480:487	Biofilms	480:487	Biofilms from three locations of the forest	480:522	Biofilms from three locations of the forest were most active in sequestering 98-100% of the spiked pollutants.
35749894	1	66	theme	surface	399:405	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	66	theme	surface	399:405	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	67	theme	priority	418:425	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	67	theme	priority	418:425	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	7	68	theme	recovery	1634:1641	arg1	"					1642:1642	monitored natural recovery"	1616:1642	"monitored natural recovery"	1615:1642	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	0	69	theme	biofilm-promoting	124:140	arg1	vessels					150:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	hydrophobic and hydrophilic biofilm-promoting culture vessels	96:156	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	5	70	theme	hydrophobic	1030:1040	arg1	flask					1042:1046	the hydrophobic flask	1026:1046	the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained	1026:1284	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	7	71	from	entry	1520:1524	arg1	underneath					1565:1574	the sediments underneath	1551:1574	the sediments underneath	1551:1574	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	7	72	theme	monitored	1616:1624	arg1	"					1642:1642	monitored natural recovery"	1616:1642	"monitored natural recovery"	1615:1642	Efficacious PAH removal by the overlying phototrophic biofilm will reduce the entry of these contaminants in the sediments underneath and this strategy could be a model for "monitored natural recovery".
35749894	2	73	theme	spiked	572:577	arg1	pollutants					579:588	the spiked pollutants	568:588	the spiked pollutants	568:588	Biofilms from three locations of the forest were most active in sequestering 98-100% of the spiked pollutants.
35749894	1	74	theme	polycyclic	427:436	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	74	theme	polycyclic	427:436	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	75	theme	mean	897:900	arg1	PAHs					922:925	PAHs	922:925	PAHs	922:925	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	75	theme	mean	897:900	arg1	amounts					911:917	The lowest mean residual amounts	886:917	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm	886:976	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	76	theme	capsular	1172:1179	arg1	carbohydrates					1203:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	capsular polysaccharidic (CPS) carbohydrates	1172:1215	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	76	theme	capsular	1172:1179	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	77	theme	biofilm	1004:1010	arg1	cultivated					1012:1021	the very biofilm cultivated	995:1021	the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained	995:1284	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	78	theme	CPS	1232:1234	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	78	theme	CPS	1232:1234	arg1	acids					1243:1247	CPS uronic acids	1232:1247	CPS uronic acids	1232:1247	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	4	79	theme	EPS	829:831	arg1	synthesis					833:841	EPS synthesis	829:841	EPS synthesis	829:841	Photosynthetic pigment and EPS synthesis were sensitive to vessel-surface property.
35749894	0	80	theme	intertidal	49:58	arg1	biofilms					73:80	intertidal phototrophic biofilms	49:80	intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels	49:156	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
35749894	1	81	theme	glass	345:349	arg1	surface					351:357	hydrophilic glass surface	333:357	hydrophilic glass surface	333:357	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	5	82	theme	uronic	1158:1163	arg1	values					1062:1067	highest values	1054:1067	highest values of biofilm biomass	1054:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	5	82	theme	uronic	1158:1163	arg1	acids					1165:1169	RPS uronic acids	1154:1169	RPS uronic acids	1154:1169	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	2	83	theme	forest	517:522	arg1	locations					500:508	three locations	494:508	three locations of the forest	494:522	Biofilms from three locations of the forest were most active in sequestering 98-100% of the spiked pollutants.
35749894	3	84	theme	extracellular	746:758	arg1	EPS					782:784	EPS	782:784	EPS	782:784	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	3	84	theme	extracellular	746:758	arg1	substances					770:779	extracellular polymeric substances	746:779	extracellular polymeric substances (EPS)	746:785	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	1	85	theme	polymethyl	375:384	arg1	PAHs					461:464	PAHs	461:464	PAHs	461:464	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	1	85	theme	polymethyl	375:384	arg1	hydrocarbons					447:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons	363:458	hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs)	363:465	Phototrophic biofilms collected from intertidal sediments of the world's largest tidal mangrove forest were cultured in two sets of a biofilm-promoting culture vessel having hydrophilic glass surface and hydrophobic polymethyl methacrylate surface wherein 16 priority polycyclic aromatic hydrocarbons (PAHs) were spiked.
35749894	3	86	theme	pigments	733:740	arg1	synthesis					705:713	synthesis	705:713	synthesis of photosynthetic pigments and extracellular polymeric substances (EPS)	705:785	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	3	86	theme	pigments	733:740	arg1	production					690:699	biofilm biomass production	674:699	biofilm biomass production	674:699	PAH challenge did not alter the biofilm phototrophic community composition; rather biofilm biomass production and synthesis of photosynthetic pigments and extracellular polymeric substances (EPS) were enhanced.
35749894	5	87	theme	biofilm	1072:1078	arg1	biomass					1080:1086	biofilm biomass	1072:1086	biofilm biomass	1072:1086	The lowest mean residual amounts of PAHs in the liquid medium as well as inside the biofilm were recorded in the very biofilm cultivated in the hydrophobic flask where highest values of biofilm biomass, total chlorophyll, released polysaccharidic (RPS) carbohydrates, RPS uronic acids, capsular polysaccharidic (CPS) carbohydrates, CPS proteins, CPS uronic acids and EPS hydrophobicity were obtained.
35749894	0	88	theme	aromatic	11:18	arg1	hydrocarbon					20:30	Polycyclic aromatic hydrocarbon	0:30	Polycyclic aromatic hydrocarbon	0:30	Polycyclic aromatic hydrocarbon sequestration by intertidal phototrophic biofilms cultivated in hydrophobic and hydrophilic biofilm-promoting culture vessels.
36628504	9	0	theme	protein	1582:1588	arg1	content					1590:1596	the higher protein content	1571:1596	the higher protein content of SHPS and the Na+ residue of sodium citrate	1571:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	6	1	theme	SHPS	1055:1058	arg1	emulsion					1060:1067	the SHPS emulsion	1051:1067	the SHPS emulsion	1051:1067	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	6	1	theme	SHPS	1055:1058	arg1	system					1113:1118	a smaller particle size and more stable system	1073:1118	a smaller particle size and more stable system	1073:1118	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	3	2	contain	had	571:573	arg1	SHPS					566:569	SHPS	566:569	SHPS	566:569	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	3	2	contain	had	571:573	arg2	polysaccharide					580:593	polysaccharide	580:593	polysaccharide	580:593	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	3	2	contain	had	571:573	arg2	protein					596:602	protein	596:602	protein	596:602	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	3	2	contain	had	571:573	arg2	weight					626:631	higher molecular weight	609:631	higher molecular weight	609:631	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	2	3	theme	ammonium	346:353	arg1	oxalate					355:361	ammonium oxalate	346:361	ammonium oxalate (SHPA)	346:368	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	3	theme	ammonium	346:353	arg1	SHPA					364:367	SHPA	364:367	SHPA	364:367	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	8	4	dep	composition	1457:1467	arg1	the					1453:1455	the	1453:1455	the	1453:1455	CONCLUSION Overall, ammonium oxalate and sodium citrate significantly influenced the composition and properties of the SHP.
36628504	6	5	theme	SHPA	1140:1143	arg1	emulsion					1145:1152	SHPA emulsion	1140:1152	SHPA emulsion	1140:1152	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	9	6	theme	better	1513:1518	arg1	ability					1532:1538	a better emulsifying ability	1511:1538	a better emulsifying ability	1511:1538	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	2	7	from	effect	336:341	arg1	conformation					403:414	conformation	403:414	conformation	403:414	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	7	from	effect	336:341	arg1	properties					433:442	physicochemical properties	417:442	physicochemical properties	417:442	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	7	from	effect	336:341	arg1	ability					460:466	emulsifying ability	448:466	emulsifying ability	448:466	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	6	8	theme	mL-1	1200:1203	arg1	concentration					1178:1190	the SHPS concentration	1169:1190	the SHPS concentration of 9 mg mL-1	1169:1203	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	4	9	theme	SHPA	813:816	arg1	molecules					818:826	SHPA molecules	813:826	SHPA molecules	813:826	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	10	10	theme	SHP	1704:1706	arg1	extraction					1674:1683	extraction	1674:1683	extraction	1674:1683	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	10	10	theme	SHP	1704:1706	arg1	application					1689:1699	application	1689:1699	application	1689:1699	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	7	11	theme	oil	1340:1342	arg1	droplets					1344:1351	the oil droplets	1336:1351	the oil droplets	1336:1351	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	9	12	theme	citrate	1636:1642	arg1	citrate					1636:1642	sodium citrate	1629:1642	sodium citrate	1629:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	9	12	theme	citrate	1636:1642	arg1	SHPS					1601:1604	SHPS	1601:1604	SHPS	1601:1604	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	9	12	theme	citrate	1636:1642	arg1	residue					1618:1624	the Na+ residue	1610:1624	the Na+ residue of sodium citrate	1610:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	8	13	theme	Overall	1383:1389	arg1	CONCLUSION					1372:1381	CONCLUSION Overall	1372:1389	CONCLUSION Overall	1372:1389	CONCLUSION Overall, ammonium oxalate and sodium citrate significantly influenced the composition and properties of the SHP.
36628504	9	14	dep	due	1564:1566	arg1	SHPA					1545:1548	SHPA	1545:1548	SHPA	1545:1548	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	1	15	from	polysaccharides	242:256	arg1	rich					222:225	rich	222:225	rich	222:225	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	10	16	theme	polysaccharides	1730:1744	arg1	extraction					1674:1683	extraction	1674:1683	extraction	1674:1683	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	10	16	theme	polysaccharides	1730:1744	arg1	application					1689:1699	application	1689:1699	application	1689:1699	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	1	17	theme	processing	207:216	arg1	hull					180:183	BACKGROUND Soy hull	165:183	BACKGROUND Soy hull	165:183	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	1	17	theme	processing	207:216	arg1	by-product					188:197	a by-product	186:197	a by-product of crop processing	186:216	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	4	18	theme	rough	860:864	arg1	surface					879:885	rough and wrinkled surface	860:885	surface	879:885	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	8	19	theme	ammonium	1392:1399	arg1	oxalate					1401:1407	ammonium oxalate	1392:1407	ammonium oxalate	1392:1407	CONCLUSION Overall, ammonium oxalate and sodium citrate significantly influenced the composition and properties of the SHP.
36628504	6	20	theme	SHPS	1173:1176	arg1	concentration					1178:1190	the SHPS concentration	1169:1190	the SHPS concentration of 9 mg mL-1	1169:1203	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	10	21	theme	other	1712:1716	arg1	polysaccharides					1730:1744	other plant-based polysaccharides	1712:1744	other plant-based polysaccharides	1712:1744	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	4	22	theme	wrinkled	870:877	arg1	surface					879:885	rough and wrinkled surface	860:885	surface	879:885	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	4	23	theme	scanning	688:695	arg1	microscope					706:715	scanning electron microscope	688:715	scanning electron microscope	688:715	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	2	24	theme	polysaccharide	481:494	arg1	conformation					403:414	conformation	403:414	conformation	403:414	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	24	theme	polysaccharide	481:494	arg1	properties					433:442	physicochemical properties	417:442	physicochemical properties	417:442	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	24	theme	polysaccharide	481:494	arg1	ability					460:466	emulsifying ability	448:466	emulsifying ability	448:466	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	7	25	theme	clearer	1292:1298	arg1	structure					1308:1316	clearer network structure	1292:1316	clearer network structure	1292:1316	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	4	26	theme	force	661:665	arg1	microscopy					667:676	atomic force microscopy	654:676	atomic force microscopy (AFM)	654:682	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	4	26	theme	force	661:665	arg1	SEM					718:720	SEM	718:720	SEM	718:720	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	4	26	theme	force	661:665	arg1	AFM					679:681	AFM	679:681	AFM	679:681	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	6	27	from	concentration	1178:1190	arg1	emulsion					1060:1067	the SHPS emulsion	1051:1067	the SHPS emulsion	1051:1067	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	6	27	from	concentration	1178:1190	arg1	system					1113:1118	a smaller particle size and more stable system	1073:1118	a smaller particle size and more stable system	1073:1118	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	2	28	theme	soy	471:473	arg1	SHP					497:499	SHP	497:499	SHP	497:499	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	28	theme	soy	471:473	arg1	polysaccharide					481:494	soy hulls polysaccharide	471:494	soy hulls polysaccharide (SHP)	471:500	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	0	29	theme	soy	73:75	arg1	polysaccharides					82:96	soy hull polysaccharides	73:96	soy hull polysaccharides	73:96	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	1	30	theme	BACKGROUND	165:174	arg1	hull					180:183	BACKGROUND Soy hull	165:183	BACKGROUND Soy hull	165:183	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	1	30	theme	BACKGROUND	165:174	arg1	by-product					188:197	a by-product	186:197	a by-product of crop processing	186:216	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	0	31	theme	polysaccharides	82:96	arg1	morphology					13:22	morphology	13:22	morphology	13:22	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	0	31	theme	polysaccharides	82:96	arg1	rheology					37:44	interfacial rheology	25:44	interfacial rheology	25:44	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	0	31	theme	polysaccharides	82:96	arg1	Composition					0:10	Composition	0:10	Composition	0:10	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	0	31	theme	polysaccharides	82:96	arg1	ability					62:68	emulsifying ability	50:68	emulsifying ability	50:68	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	4	32	theme	SHPS	735:738	arg1	molecules					740:748	SHPS molecules	735:748	SHPS molecules	735:748	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	2	33	theme	citrate	381:387	arg1	effect					336:341	The effect	332:341	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP)	332:500	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	34	theme	physicochemical	417:431	arg1	properties					433:442	physicochemical properties	417:442	physicochemical properties	417:442	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	4	35	theme	microscope	706:715	arg1	Images					644:649	Images	644:649	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM)	644:721	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	9	36	theme	emulsifying	1520:1530	arg1	ability					1532:1538	a better emulsifying ability	1511:1538	a better emulsifying ability	1511:1538	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	6	37	theme	prepared	1020:1027	arg1	emulsions					1029:1037	the prepared emulsions	1016:1037	the prepared emulsions	1016:1037	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	4	38	theme	smooth	781:786	arg1	surfaces					797:804	smooth and firm surfaces	781:804	surfaces	797:804	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	0	39	theme	interfacial	25:35	arg1	rheology					37:44	interfacial rheology	25:44	interfacial rheology	25:44	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	7	40	dep	demonstrated	1267:1278	arg1	formed					1285:1290	formed	1285:1290	formed	1285:1290	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	3	41	theme	molecular	616:624	arg1	weight					626:631	higher molecular weight	609:631	higher molecular weight	609:631	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	4	42	theme	firm	792:795	arg1	surfaces					797:804	smooth and firm surfaces	781:804	surfaces	797:804	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	1	43	theme	emulsifying	306:316	arg1	applications					318:329	emulsifying applications	306:329	emulsifying applications	306:329	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	9	44	theme	SHPS	1601:1604	arg1	content					1590:1596	the higher protein content	1571:1596	the higher protein content of SHPS and the Na+ residue of sodium citrate	1571:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	7	45	theme	electron	1231:1238	arg1	cryo-SEM					1252:1259	cryo-SEM	1252:1259	cryo-SEM	1252:1259	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	7	45	theme	electron	1231:1238	arg1	microscopy					1240:1249	cryo-scanning electron microscopy	1217:1249	cryo-scanning electron microscopy (cryo-SEM)	1217:1260	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	6	46	dep	smaller	1075:1081	arg1	size					1092:1095	particle size	1083:1095	particle size	1083:1095	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	5	47	theme	interfacial	963:973	arg1	layer					975:979	a more elastic interfacial layer	948:979	a more elastic interfacial layer	948:979	At the oil-water interface, SHPS adsorbed faster and formed a more elastic interfacial layer than SHPA.
36628504	2	48	theme	oxalate	355:361	arg1	effect					336:341	The effect	332:341	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP)	332:500	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	1	49	theme	pectin-like	230:240	arg1	polysaccharides					242:256	pectin-like polysaccharides	230:256	pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications	230:329	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	9	50	theme	Na+	1614:1616	arg1	citrate					1636:1642	sodium citrate	1629:1642	sodium citrate	1629:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	9	50	theme	Na+	1614:1616	arg1	residue					1618:1624	the Na+ residue	1610:1624	the Na+ residue of sodium citrate	1610:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	4	51	theme	chain-like	837:846	arg1	bodies					848:853	chain-like bodies	837:853	chain-like bodies	837:853	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	1	52	theme	Soy	176:178	arg1	hull					180:183	BACKGROUND Soy hull	165:183	BACKGROUND Soy hull	165:183	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	1	52	theme	Soy	176:178	arg1	by-product					188:197	a by-product	186:197	a by-product of crop processing	186:216	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	6	53	theme	mg	1197:1198	arg1	mL-1					1200:1203	9 mg mL-1	1195:1203	9 mg mL-1	1195:1203	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	9	54	theme	residue	1618:1624	arg1	content					1590:1596	the higher protein content	1571:1596	the higher protein content of SHPS and the Na+ residue of sodium citrate	1571:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	6	55	theme	stable	1106:1111	arg1	emulsion					1060:1067	the SHPS emulsion	1051:1067	the SHPS emulsion	1051:1067	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	6	55	theme	stable	1106:1111	arg1	system					1113:1118	a smaller particle size and more stable system	1073:1118	a smaller particle size and more stable system	1073:1118	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	3	56	theme	composition	533:543	arg1	analysis					545:552	The composition analysis	529:552	The composition analysis	529:552	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	9	57	theme	sodium	1629:1634	arg1	citrate					1636:1642	sodium citrate	1629:1642	sodium citrate	1629:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	7	58	theme	droplets	1344:1351	arg1	surface					1325:1331	the surface	1321:1331	the surface of the oil droplets	1321:1351	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	6	59	theme	particle	1083:1090	arg1	size					1092:1095	particle size	1083:1095	particle size	1083:1095	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	1	60	theme	crop	202:205	arg1	processing					207:216	crop processing	202:216	crop processing	202:216	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	1	61	from	rich	222:225	arg1	polysaccharides					242:256	pectin-like polysaccharides	230:256	pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications	230:329	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	10	62	theme	plant-based	1718:1728	arg1	polysaccharides					1730:1744	other plant-based polysaccharides	1712:1744	other plant-based polysaccharides	1712:1744	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	10	63	dep	extraction	1674:1683	arg1	the					1670:1672	the	1670:1672	the	1670:1672	This study is useful for the extraction and application of SHP and other plant-based polysaccharides.
36628504	8	64	theme	sodium	1413:1418	arg1	citrate					1420:1426	sodium citrate	1413:1426	sodium citrate	1413:1426	CONCLUSION Overall, ammonium oxalate and sodium citrate significantly influenced the composition and properties of the SHP.
36628504	1	65	contain	have	263:266	arg1	polysaccharides					242:256	pectin-like polysaccharides	230:256	pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications	230:329	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	1	65	contain	have	263:266	arg2	potential					268:276	potential	268:276	potential for thickening, gelling and emulsifying applications	268:329	BACKGROUND Soy hull, a by-product of crop processing, is rich in pectin-like polysaccharides that have potential for thickening, gelling and emulsifying applications.
36628504	3	66	dep	RESULTS	521:527	arg1	showed					554:559	showed	554:559	showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA	554:641	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	2	67	theme	hulls	475:479	arg1	SHP					497:499	SHP	497:499	SHP	497:499	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	67	theme	hulls	475:479	arg1	polysaccharide					481:494	soy hulls polysaccharide	471:494	soy hulls polysaccharide (SHP)	471:500	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	7	68	theme	network	1300:1306	arg1	structure					1308:1316	clearer network structure	1292:1316	clearer network structure	1292:1316	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	4	69	theme	atomic	654:659	arg1	microscopy					667:676	atomic force microscopy	654:676	atomic force microscopy (AFM)	654:682	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	4	69	theme	atomic	654:659	arg1	SEM					718:720	SEM	718:720	SEM	718:720	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	4	69	theme	atomic	654:659	arg1	AFM					679:681	AFM	679:681	AFM	679:681	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	0	70	theme	hull	77:80	arg1	polysaccharides					82:96	soy hull polysaccharides	73:96	soy hull polysaccharides	73:96	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	4	71	theme	microscopy	667:676	arg1	Images					644:649	Images	644:649	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM)	644:721	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	0	72	theme	ammonium	113:120	arg1	oxalate					122:128	ammonium oxalate	113:128	ammonium oxalate	113:128	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	2	73	dep	conformation	403:414	arg1	the					399:401	the	399:401	the	399:401	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	8	74	theme	SHP	1491:1493	arg1	composition					1457:1467	composition	1457:1467	composition	1457:1467	CONCLUSION Overall, ammonium oxalate and sodium citrate significantly influenced the composition and properties of the SHP.
36628504	8	74	theme	SHP	1491:1493	arg1	properties					1473:1482	properties	1473:1482	properties	1473:1482	CONCLUSION Overall, ammonium oxalate and sodium citrate significantly influenced the composition and properties of the SHP.
36628504	2	75	theme	sodium	374:379	arg1	SHPS					390:393	SHPS	390:393	SHPS	390:393	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	2	75	theme	sodium	374:379	arg1	citrate					381:387	sodium citrate	374:387	sodium citrate (SHPS)	374:394	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	5	76	theme	oil-water	895:903	arg1	interface					905:913	the oil-water interface	891:913	the oil-water interface	891:913	At the oil-water interface, SHPS adsorbed faster and formed a more elastic interfacial layer than SHPA.
36628504	6	77	theme	emulsions	1029:1037	arg1	characterization					996:1011	The characterization	992:1011	The characterization of the prepared emulsions	992:1037	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	4	78	theme	electron	697:704	arg1	microscope					706:715	scanning electron microscope	688:715	scanning electron microscope	688:715	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
36628504	7	79	theme	microscopy	1240:1249	arg1	Images					1207:1212	Images	1207:1212	Images of cryo-scanning electron microscopy (cryo-SEM)	1207:1260	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	2	80	theme	emulsifying	448:458	arg1	ability					460:466	emulsifying ability	448:466	emulsifying ability	448:466	The effect of ammonium oxalate (SHPA) and sodium citrate (SHPS) on the conformation, physicochemical properties and emulsifying ability of soy hulls polysaccharide (SHP) were investigated.
36628504	3	81	theme	higher	609:614	arg1	weight					626:631	higher molecular weight	609:631	higher molecular weight	609:631	RESULTS The composition analysis showed that SHPS had more polysaccharide, protein, and higher molecular weight than SHPA.
36628504	0	82	theme	emulsifying	50:60	arg1	ability					62:68	emulsifying ability	50:68	emulsifying ability	50:68	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	7	83	theme	cryo-scanning	1217:1229	arg1	cryo-SEM					1252:1259	cryo-SEM	1252:1259	cryo-SEM	1252:1259	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	7	83	theme	cryo-scanning	1217:1229	arg1	microscopy					1240:1249	cryo-scanning electron microscopy	1217:1249	cryo-scanning electron microscopy (cryo-SEM)	1217:1260	Images of cryo-scanning electron microscopy (cryo-SEM) also demonstrated SHPS formed clearer network structure on the surface of the oil droplets, compared to SHPA.
36628504	0	84	theme	sodium	134:139	arg1	citrate					141:147	sodium citrate	134:147	sodium citrate	134:147	Composition, morphology, interfacial rheology and emulsifying ability of soy hull polysaccharides extracted with ammonium oxalate and sodium citrate as extractants.
36628504	9	85	theme	higher	1575:1580	arg1	content					1590:1596	the higher protein content	1571:1596	the higher protein content of SHPS and the Na+ residue of sodium citrate	1571:1642	SHPS exhibited a better emulsifying ability than SHPA, which mainly due to the higher protein content of SHPS and the Na+ residue of sodium citrate.
36628504	6	86	theme	smaller	1075:1081	arg1	emulsion					1060:1067	the SHPS emulsion	1051:1067	the SHPS emulsion	1051:1067	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	6	86	theme	smaller	1075:1081	arg1	system					1113:1118	a smaller particle size and more stable system	1073:1118	a smaller particle size and more stable system	1073:1118	The characterization of the prepared emulsions showed that the SHPS emulsion was a smaller particle size and more stable system within 30 days than SHPA emulsion, especially at the SHPS concentration of 9 mg mL-1 .
36628504	5	87	theme	elastic	955:961	arg1	layer					975:979	a more elastic interfacial layer	948:979	a more elastic interfacial layer	948:979	At the oil-water interface, SHPS adsorbed faster and formed a more elastic interfacial layer than SHPA.
36628504	4	88	theme	spherical	759:767	arg1	bodies					769:774	spherical bodies	759:774	spherical bodies	759:774	Images of atomic force microscopy (AFM) and scanning electron microscope (SEM) showed that SHPS molecules appeared spherical bodies with smooth and firm surfaces, while SHPA molecules appeared chain-like bodies with rough and wrinkled surface.
37330100	2	0	theme	pivotal	330:336	arg1	role					338:341	a pivotal role	328:341	a pivotal role	328:341	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	0	1	theme	induced	89:95	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	1	theme	induced	89:95	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	1	2	theme	rice	227:230	arg1	diseases					215:222	the most serious diseases	198:222	the most serious diseases of rice	198:230	Sheath blight, caused by Rhizoctonia solani (R. solani), is one of the most serious diseases of rice.
37330100	0	3	theme	rice	111:114	arg1	sheath					116:121	rice sheath blight	111:128	rice sheath blight	111:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	2	4	contain	have	323:326	arg2	role					338:341	a pivotal role	328:341	a pivotal role	328:341	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	2	4	contain	have	323:326	arg1	microbes					309:316	microbes	309:316	microbes that have a pivotal role in the plant-microbe interaction	309:374	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	4	5	theme	NMR	754:756	arg1	analysis					758:765	NMR analysis	754:765	NMR analysis	754:765	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	4	6	theme	S-300HR	655:661	arg1	column					663:668	Sephacryl S-300HR column	645:668	Sephacryl S-300HR column	645:668	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	4	7	theme	Sephacryl	645:653	arg1	column					663:668	Sephacryl S-300HR column	645:668	Sephacryl S-300HR column	645:668	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	6	8	theme	enhanced	1357:1364	arg1	resistance					1366:1375	enhanced resistance	1357:1375	enhanced resistance to sheath blight	1357:1392	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	3	9	dep	solani	497:502	arg1	exists					504:509	exists	504:509	exists	504:509	At present, many studies have been carried out on R. solani, but it is not very clear whether the EPS is secreted by R. solani exists.
37330100	5	10	with	galactose	913:921	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	6	11	theme	rice	1267:1270	arg1	pretreatment					1251:1262	their pretreatment	1245:1262	their pretreatment of rice	1245:1270	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	4	12	theme	further	670:676	arg1	purification					678:689	further purification	670:689	further purification	670:689	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	5	13	dep	composed	882:889	arg1	residues					1082:1089	1→ residues	1079:1089	1→ residues	1079:1089	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	4	14	dep	EPS	586:588	arg1	EW-I					591:594	EW-I	591:594	EW-I	591:594	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	4	14	dep	EPS	586:588	arg1	EPS					586:588	EPS	586:588	EPS (EW-I and ES-I)	586:604	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	4	14	dep	EPS	586:588	arg1	ES-I					600:603	ES-I	600:603	ES-I	600:603	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	5	15	theme	beside	1092:1097	arg1	ES-I					1099:1102	beside ES-I	1092:1102	beside ES-I	1092:1102	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	0	16	theme	solani	12:17	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	16	theme	solani	12:17	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	16	theme	solani	12:17	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	2	17	theme	plant-microbe	350:362	arg1	interaction					364:374	the plant-microbe interaction	346:374	the plant-microbe interaction	346:374	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	0	18	theme	Rhizoctonia	0:10	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	18	theme	Rhizoctonia	0:10	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	18	theme	Rhizoctonia	0:10	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	6	19	theme	pathway	1335:1341	arg1	activation					1302:1311	activation	1302:1311	activation of the salicylic acid pathway	1302:1341	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	0	20	theme	IA	23:24	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	20	theme	IA	23:24	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	20	theme	IA	23:24	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	6	21	theme	acid	1330:1333	arg1	pathway					1335:1341	the salicylic acid pathway	1316:1341	the salicylic acid pathway	1316:1341	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	2	22	theme	complex	273:279	arg1	polysaccharides					247:261	Extracellular polysaccharides	233:261	Extracellular polysaccharides (EPS)	233:267	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	2	22	theme	complex	273:279	arg1	polysaccharides					281:295	complex polysaccharides	273:295	complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction	273:374	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	5	23	with	mannose	937:943	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	0	24	theme	AG1	19:21	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	24	theme	AG1	19:21	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	24	theme	AG1	19:21	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	5	25	theme	different	849:857	arg1	ratio					865:869	different molar ratio	849:869	different molar ratio	849:869	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	26	theme	monosaccharide	818:831	arg1	composition					833:843	similar monosaccharide composition	810:843	similar monosaccharide composition	810:843	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	27	contain	had	806:808	arg2	ratio					865:869	different molar ratio	849:869	different molar ratio	849:869	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	27	contain	had	806:808	arg1	ES-I					801:804	ES-I	801:804	ES-I	801:804	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	27	contain	had	806:808	arg1	EW-I					792:795	EW-I	792:795	EW-I	792:795	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	27	contain	had	806:808	arg2	composition					833:843	similar monosaccharide composition	810:843	similar monosaccharide composition	810:843	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	6	28	theme	EW-I	1171:1174	arg1	application					1156:1166	The exogenous application	1142:1166	The exogenous application of EW-I and ES-I	1142:1183	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	6	29	theme	IA	1230:1231	arg1	growth					1206:1211	the growth	1202:1211	the growth of R. solani AG1 IA itself	1202:1238	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	0	30	theme	extracellular	26:38	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	30	theme	extracellular	26:38	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	30	theme	extracellular	26:38	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	3	31	theme	many	389:392	arg1	studies					394:400	many studies	389:400	many studies	389:400	At present, many studies have been carried out on R. solani, but it is not very clear whether the EPS is secreted by R. solani exists.
37330100	6	32	theme	ES-I	1180:1183	arg1	application					1156:1166	The exogenous application	1142:1166	The exogenous application of EW-I and ES-I	1142:1183	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	6	33	theme	salicylic	1320:1328	arg1	pathway					1335:1341	the salicylic acid pathway	1316:1341	the salicylic acid pathway	1316:1341	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	0	34	theme	Structural	57:66	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	34	theme	Structural	57:66	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	5	35	with	fucose	894:899	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	0	36	dep	polysaccharides	40:54	arg1	polysaccharides					40:54	Rhizoctonia solani AG1 IA extracellular polysaccharides	0:54	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.	0:129	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	36	dep	polysaccharides	40:54	arg1	characterization					68:83	Structural characterization	57:83	Structural characterization	57:83	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	0	36	dep	polysaccharides	40:54	arg1	resistance					97:106	induced resistance	89:106	induced resistance to rice sheath blight	89:128	Rhizoctonia solani AG1 IA extracellular polysaccharides: Structural characterization and induced resistance to rice sheath blight.
37330100	6	37	theme	exogenous	1146:1154	arg1	application					1156:1166	The exogenous application	1142:1166	The exogenous application of EW-I and ES-I	1142:1183	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	5	38	with	glucose	924:930	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	39	with	backbone	1039:1046	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	6	40	contain	had	1185:1187	arg2	effect					1192:1197	no effect	1189:1197	no effect	1189:1197	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	6	40	contain	had	1185:1187	arg1	application					1156:1166	The exogenous application	1142:1166	The exogenous application of EW-I and ES-I	1142:1183	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	5	41	with	12.98	1002:1006	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	1	42	theme	Sheath	131:136	arg1	blight					138:143	Sheath blight	131:143	Sheath blight	131:143	Sheath blight, caused by Rhizoctonia solani (R. solani), is one of the most serious diseases of rice.
37330100	6	43	theme	AG1	1226:1228	arg1	IA					1230:1231	R. solani AG1 IA	1216:1231	R. solani AG1 IA itself	1216:1238	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	2	44	theme	Extracellular	233:245	arg1	EPS					264:266	EPS	264:266	EPS	264:266	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	2	44	theme	Extracellular	233:245	arg1	polysaccharides					247:261	Extracellular polysaccharides	233:261	Extracellular polysaccharides (EPS)	233:267	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	2	44	theme	Extracellular	233:245	arg1	polysaccharides					281:295	complex polysaccharides	273:295	complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction	273:374	Extracellular polysaccharides (EPS) are complex polysaccharides secreted by microbes that have a pivotal role in the plant-microbe interaction.
37330100	4	45	dep	DEAE-cellulose	623:636	arg1	purification					678:689	further purification	670:689	further purification	670:689	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	5	46	theme	similar	810:816	arg1	composition					833:843	similar monosaccharide composition	810:843	similar monosaccharide composition	810:843	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	5	47	theme	molar	859:863	arg1	ratio					865:869	different molar ratio	849:869	different molar ratio	849:869	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	6	48	theme	R.	1216:1217	arg1	IA					1230:1231	R. solani AG1 IA	1216:1231	R. solani AG1 IA itself	1216:1238	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	1	49	theme	most	202:205	arg1	diseases					215:222	the most serious diseases	198:222	the most serious diseases of rice	198:230	Sheath blight, caused by Rhizoctonia solani (R. solani), is one of the most serious diseases of rice.
37330100	5	50	with	arabinose	902:910	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	6	51	theme	solani	1219:1224	arg1	IA					1230:1231	R. solani AG1 IA	1216:1231	R. solani AG1 IA itself	1216:1238	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	1	52	theme	serious	207:213	arg1	diseases					215:222	the most serious diseases	198:222	the most serious diseases of rice	198:230	Sheath blight, caused by Rhizoctonia solani (R. solani), is one of the most serious diseases of rice.
37330100	5	53	theme	7.49	961:964	arg1	ratio					952:956	a ratio	950:956	a ratio of 7.49	950:964	The results showed that EW-I and ES-I had similar monosaccharide composition but different molar ratio, they were composed of fucose, arabinose, galactose, glucose, and mannose with a ratio of 7.49: 27.72: 2.98: 6.66: 55.15 and 3.81: 12.98: 6.15: 10.83: 66.23, and their backbone may be composed of →2)-α-Manp-(1→ residues, beside ES-I was highly branched compared to EW-I.
37330100	6	54	theme	plant	1280:1284	arg1	defense					1286:1292	plant defense	1280:1292	plant defense	1280:1292	The exogenous application of EW-I and ES-I had no effect on the growth of R. solani AG1 IA itself, but their pretreatment of rice induced plant defense through activation of the salicylic acid pathway, resulting in enhanced resistance to sheath blight.
37330100	4	55	theme	EPS	586:588	arg1	kinds					577:581	two kinds	573:581	two kinds of EPS (EW-I and ES-I)	573:604	Therefore, we isolated and extracted the EPS from R. solani, two kinds of EPS (EW-I and ES-I) were obtained by DEAE-cellulose 52 and Sephacryl S-300HR column further purification, and their structures were characterized by FT-IR, UV, GC, and NMR analysis.
37330100	1	56	theme	diseases	215:222	arg1	diseases					215:222	the most serious diseases	198:222	the most serious diseases of rice	198:230	Sheath blight, caused by Rhizoctonia solani (R. solani), is one of the most serious diseases of rice.
37330100	1	56	theme	diseases	215:222	arg1	one					191:193	one	191:193	one	191:193	Sheath blight, caused by Rhizoctonia solani (R. solani), is one of the most serious diseases of rice.
35420791	4	0	theme	ring-opening	836:847	arg1	polymerization					849:862	anionic ring-opening polymerization	828:862	anionic ring-opening polymerization	828:862	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	7	1	theme	functional	1241:1250	arg1	mimetics					1267:1274	otherwise inaccessible functional polysaccharide mimetics	1218:1274	otherwise inaccessible functional polysaccharide mimetics	1218:1274	This new methodology provides access to otherwise inaccessible functional polysaccharide mimetics for biomedical applications.
35420791	2	2	theme	compositional	415:427	arg1	control					429:435	compositional control	415:435	compositional control with regards to stereo- and regioselectivity	415:480	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	6	3	theme	anionic	1092:1098	arg1	polymers					1100:1107	The resulting anionic polymers	1078:1107	The resulting anionic polymers	1078:1107	The resulting anionic polymers are water soluble and non-cytotoxic and adopt helical conformations.
35420791	6	3	theme	anionic	1092:1098	arg1	soluble					1119:1125	soluble	1119:1125	soluble	1119:1125	The resulting anionic polymers are water soluble and non-cytotoxic and adopt helical conformations.
35420791	4	4	theme	anionic	828:834	arg1	polymerization					849:862	anionic ring-opening polymerization	828:862	anionic ring-opening polymerization	828:862	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	6	5	theme	resulting	1082:1090	arg1	polymers					1100:1107	The resulting anionic polymers	1078:1107	The resulting anionic polymers	1078:1107	The resulting anionic polymers are water soluble and non-cytotoxic and adopt helical conformations.
35420791	6	5	theme	resulting	1082:1090	arg1	soluble					1119:1125	soluble	1119:1125	soluble	1119:1125	The resulting anionic polymers are water soluble and non-cytotoxic and adopt helical conformations.
35420791	4	6	theme	12	916:917	arg1	polymerization					898:911	polymerization	898:911	polymerization of 12, 25, and 50	898:929	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	2	7	theme	isolation	339:347	arg1	protocols					349:357	tedious isolation protocols	331:357	tedious isolation protocols	331:357	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	5	8	theme	Regioselective	932:945	arg1	deprotection					947:958	Regioselective deprotection	932:958	Regioselective deprotection followed by functionalization and global deprotection	932:1012	Regioselective deprotection followed by functionalization and global deprotection affords the sulfated and phosphorylated poly-amido-saccharides.
35420791	2	9	theme	tedious	331:337	arg1	protocols					349:357	tedious isolation protocols	331:357	tedious isolation protocols	331:357	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	2	10	theme	polysaccharides	520:534	arg1	utility					509:515	utility	509:515	utility	509:515	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	2	10	theme	polysaccharides	520:534	arg1	development					493:503	development	493:503	development	493:503	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	2	11	theme	batch-to-batch	375:388	arg1	consistency					390:400	batch-to-batch consistency	375:400	batch-to-batch consistency	375:400	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	5	12	theme	sulfated	1026:1033	arg1	poly-amido-saccharides					1054:1075	the sulfated and phosphorylated poly-amido-saccharides	1022:1075	the sulfated and phosphorylated poly-amido-saccharides	1022:1075	Regioselective deprotection followed by functionalization and global deprotection affords the sulfated and phosphorylated poly-amido-saccharides.
35420791	1	13	from	nature	164:169	arg1	abundant					152:159	abundant	152:159	abundant	152:159	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	3	14	theme	sulfate	673:679	arg1	groups					694:699	sulfate or phosphate groups	673:699	sulfate or phosphate groups using post-polymerization modification reactions	673:748	We report a synthetic strategy to regioselectively functionalize poly-amido-saccharides with sulfate or phosphate groups using post-polymerization modification reactions.
35420791	1	15	theme	tissue	246:251	arg1	engineering					253:263	tissue engineering	246:263	tissue engineering	246:263	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	6	16	theme	helical	1155:1161	arg1	conformations					1163:1175	helical conformations	1155:1175	helical conformations	1155:1175	The resulting anionic polymers are water soluble and non-cytotoxic and adopt helical conformations.
35420791	4	17	theme	polymerization	898:911	arg1	degrees					887:893	degrees	887:893	degrees of polymerization of 12, 25, and 50	887:929	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	4	18	theme	protected	764:772	arg1	monomers					783:790	Orthogonally protected β-lactam monomers	751:790	Orthogonally protected β-lactam monomers	751:790	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	3	19	theme	synthetic	592:600	arg1	strategy					602:609	a synthetic strategy	590:609	a synthetic strategy to regioselectively functionalize poly-amido-saccharides with sulfate or phosphate groups using post-polymerization modification reactions	590:748	We report a synthetic strategy to regioselectively functionalize poly-amido-saccharides with sulfate or phosphate groups using post-polymerization modification reactions.
35420791	5	20	theme	phosphorylated	1039:1052	arg1	poly-amido-saccharides					1054:1075	the sulfated and phosphorylated poly-amido-saccharides	1022:1075	the sulfated and phosphorylated poly-amido-saccharides	1022:1075	Regioselective deprotection followed by functionalization and global deprotection affords the sulfated and phosphorylated poly-amido-saccharides.
35420791	5	21	theme	global	994:999	arg1	deprotection					1001:1012	global deprotection	994:1012	global deprotection	994:1012	Regioselective deprotection followed by functionalization and global deprotection affords the sulfated and phosphorylated poly-amido-saccharides.
35420791	0	22	theme	Regioselectively	34:49	arg1	Characterization					14:29	Characterization	14:29	Characterization	14:29	Synthesis and Characterization of Regioselectively Functionalized Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides.
35420791	0	22	theme	Regioselectively	34:49	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis	0:8	Synthesis and Characterization of Regioselectively Functionalized Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides.
35420791	7	23	theme	biomedical	1280:1289	arg1	applications					1291:1302	biomedical applications	1280:1302	biomedical applications	1280:1302	This new methodology provides access to otherwise inaccessible functional polysaccharide mimetics for biomedical applications.
35420791	4	24	theme	β-lactam	774:781	arg1	monomers					783:790	Orthogonally protected β-lactam monomers	751:790	Orthogonally protected β-lactam monomers	751:790	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	7	25	theme	polysaccharide	1252:1265	arg1	mimetics					1267:1274	otherwise inaccessible functional polysaccharide mimetics	1218:1274	otherwise inaccessible functional polysaccharide mimetics	1218:1274	This new methodology provides access to otherwise inaccessible functional polysaccharide mimetics for biomedical applications.
35420791	2	26	dep	development	493:503	arg1	the					489:491	the	489:491	the	489:491	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	0	27	theme	Mono-Sulfated	66:78	arg1	Poly-Amido-Saccharides					108:129	Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides	66:129	Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides	66:129	Synthesis and Characterization of Regioselectively Functionalized Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides.
35420791	3	28	theme	phosphate	684:692	arg1	groups					694:699	sulfate or phosphate groups	673:699	sulfate or phosphate groups using post-polymerization modification reactions	673:748	We report a synthetic strategy to regioselectively functionalize poly-amido-saccharides with sulfate or phosphate groups using post-polymerization modification reactions.
35420791	1	29	from	abundant	152:159	arg1	nature					164:169	nature	164:169	nature	164:169	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	4	30	theme	50	928:929	arg1	polymerization					898:911	polymerization	898:911	polymerization of 12, 25, and 50	898:929	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	7	31	theme	inaccessible	1228:1239	arg1	mimetics					1267:1274	otherwise inaccessible functional polysaccharide mimetics	1218:1274	otherwise inaccessible functional polysaccharide mimetics	1218:1274	This new methodology provides access to otherwise inaccessible functional polysaccharide mimetics for biomedical applications.
35420791	1	32	theme	drug	281:284	arg1	systems					295:301	drug delivery systems	281:301	drug delivery systems	281:301	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	4	33	theme	25	920:921	arg1	polymerization					898:911	polymerization	898:911	polymerization of 12, 25, and 50	898:929	Orthogonally protected β-lactam monomers, synthesized from D-glucal, undergo anionic ring-opening polymerization to yield polymers with degrees of polymerization of 12, 25, and 50.
35420791	7	34	theme	new	1183:1185	arg1	methodology					1187:1197	This new methodology	1178:1197	This new methodology	1178:1197	This new methodology provides access to otherwise inaccessible functional polysaccharide mimetics for biomedical applications.
35420791	1	35	theme	biomedical	195:204	arg1	applications					206:217	various biomedical applications	187:217	various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems	187:301	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	1	36	theme	delivery	286:293	arg1	systems					295:301	drug delivery systems	281:301	drug delivery systems	281:301	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	0	37	theme	Anionic	100:106	arg1	Poly-Amido-Saccharides					108:129	Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides	66:129	Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides	66:129	Synthesis and Characterization of Regioselectively Functionalized Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides.
35420791	2	38	with	control	429:435	arg1	regards					442:448	regards	442:448	regards to stereo- and regioselectivity	442:480	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	3	39	theme	post-polymerization	707:725	arg1	reactions					740:748	post-polymerization modification reactions	707:748	post-polymerization modification reactions	707:748	We report a synthetic strategy to regioselectively functionalize poly-amido-saccharides with sulfate or phosphate groups using post-polymerization modification reactions.
35420791	1	40	theme	various	187:193	arg1	applications					206:217	various biomedical applications	187:217	various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems	187:301	Polysaccharides are abundant in nature and employed in various biomedical applications ranging from scaffolds for tissue engineering to carriers for drug delivery systems.
35420791	0	41	theme	-Phosphorylated	84:98	arg1	Poly-Amido-Saccharides					108:129	Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides	66:129	Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides	66:129	Synthesis and Characterization of Regioselectively Functionalized Mono-Sulfated and -Phosphorylated Anionic Poly-Amido-Saccharides.
35420791	3	42	theme	modification	727:738	arg1	reactions					740:748	post-polymerization modification reactions	707:748	post-polymerization modification reactions	707:748	We report a synthetic strategy to regioselectively functionalize poly-amido-saccharides with sulfate or phosphate groups using post-polymerization modification reactions.
35420791	2	43	theme	control	429:435	arg1	contamination					360:372	contamination	360:372	contamination	360:372	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	2	43	theme	control	429:435	arg1	consistency					390:400	batch-to-batch consistency	375:400	batch-to-batch consistency	375:400	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	2	43	theme	control	429:435	arg1	protocols					349:357	tedious isolation protocols	331:357	tedious isolation protocols	331:357	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35420791	2	43	theme	control	429:435	arg1	lack					407:410	lack	407:410	lack of compositional control with regards to stereo- and regioselectivity	407:480	However, drawbacks such as tedious isolation protocols, contamination, batch-to-batch consistency, and lack of compositional control with regards to stereo- and regioselectivity impede the development and utility of polysaccharides, and thus mimetics are highly sought after.
35287855	5	0	theme	great	1061:1065	arg1	deal					1067:1070	a great deal	1059:1070	a great deal of potential for use in the food industry	1059:1112	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	5	1	from	use	1089:1091	arg1	industry					1105:1112	the food industry	1096:1112	the food industry	1096:1112	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	5	2	theme	functional	1025:1034	arg1	attributes					1036:1045	technical and functional attributes	1011:1045	technical and functional attributes	1011:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	3	3	theme	amorphous	614:622	arg1	structure					624:632	the amorphous structure	610:632	the amorphous structure	610:632	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	4	4	theme	properties	874:883	arg1	level					853:857	a strong level	844:857	a strong level of antioxidant properties	844:883	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	3	5	theme	layer-like	667:676	arg1	morphology					678:687	the layer-like morphology	663:687	the layer-like morphology	663:687	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	2	6	theme	core	296:299	arg1	structure					301:309	The core structure	292:309	The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6	292:414	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	4	7	theme	antioxidant	862:872	arg1	properties					874:883	antioxidant properties	862:883	antioxidant properties	862:883	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	8	contain	had	701:703	arg1	glucan					694:699	The glucan	690:699	The glucan	690:699	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	8	contain	had	701:703	arg2	values					805:810	water solubility index (80.7%) values	774:810	water solubility index (80.7%) values	774:810	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	8	contain	had	701:703	arg2	activity					720:727	an antioxidant activity	705:727	an antioxidant activity (89.5%)	705:735	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	8	contain	had	701:703	arg2	capacity					752:759	water-holding capacity	738:759	water-holding capacity (103.7%)	738:768	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	8	contain	had	701:703	arg2	%					767:767	103.7%	762:767	103.7%	762:767	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	8	contain	had	701:703	arg2	%					734:734	89.5%	730:734	89.5%	730:734	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	3	9	theme	thermal	516:522	arg1	stability					524:532	a superior thermal stability	505:532	a superior thermal stability	505:532	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	4	10	theme	good	886:889	arg1	capacity					905:912	good water binding capacity	886:912	good water binding capacity	886:912	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	5	11	theme	attributes	1036:1045	arg1	combination					996:1006	a good combination	989:1006	a good combination of technical and functional attributes	989:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	4	12	theme	water-holding	738:750	arg1	capacity					752:759	water-holding capacity	738:759	water-holding capacity (103.7%)	738:768	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	12	theme	water-holding	738:750	arg1	%					767:767	103.7%	762:767	103.7%	762:767	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	13	contain	had	840:842	arg1	glucan					833:838	the glucan	829:838	the glucan	829:838	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	13	contain	had	840:842	arg2	level					853:857	a strong level	844:857	a strong level of antioxidant properties	844:883	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	14	theme	index	791:795	arg1	values					805:810	water solubility index (80.7%) values	774:810	water solubility index (80.7%) values	774:810	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	2	15	theme	FTIR	472:475	arg1	analysis					477:484	FTIR analysis	472:484	FTIR analysis	472:484	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	2	16	theme	α-d-glucose	372:382	arg1	branches					384:391	(1 → 3)-linked α-d-glucose branches	357:391	(1 → 3)-linked α-d-glucose branches	357:391	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	0	17	theme	Bioactive	0:8	arg1	properties					28:37	Bioactive and technological properties	0:37	Bioactive and technological properties of an α-D-glucan	0:54	Bioactive and technological properties of an α-D-glucan synthesized by Weissella cibaria PDER21.
35287855	5	18	theme	good	991:994	arg1	combination					996:1006	a good combination	989:1006	a good combination of technical and functional attributes	989:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	3	19	theme	no	546:547	arg1	degradation					549:559	almost no degradation	539:559	almost no degradation in structure	539:572	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	3	20	from	degradation	549:559	arg1	structure					564:572	structure	564:572	structure	564:572	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	2	21	theme	-linked	364:370	arg1	branches					384:391	(1 → 3)-linked α-d-glucose branches	357:391	(1 → 3)-linked α-d-glucose branches	357:391	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	4	22	theme	antioxidant	708:718	arg1	activity					720:727	an antioxidant activity	705:727	an antioxidant activity (89.5%)	705:735	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	22	theme	antioxidant	708:718	arg1	%					734:734	89.5%	730:734	89.5%	730:734	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	23	theme	strong	846:851	arg1	level					853:857	a strong level	844:857	a strong level of antioxidant properties	844:883	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	1	24	theme	slimy-mucinous-type	99:117	arg1	colony					119:124	A slimy-mucinous-type colony	97:124	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21	97:166	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21 was isolated and identified.
35287855	2	25	theme	93.4/6.6	407:414	arg1	ratio					398:402	a ratio	396:402	a ratio of 93.4/6.6	396:414	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	0	26	theme	technological	14:26	arg1	properties					28:37	Bioactive and technological properties	0:37	Bioactive and technological properties of an α-D-glucan	0:54	Bioactive and technological properties of an α-D-glucan synthesized by Weissella cibaria PDER21.
35287855	2	27	theme	monomer	201:207	arg1	glucose					225:231	glucose	225:231	glucose	225:231	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	2	27	theme	monomer	201:207	arg1	composition					209:219	The monomer composition	197:219	The monomer composition	197:219	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	5	28	contain	possessing	978:987	arg1	PDER21					951:956	The glucan PDER21	940:956	The glucan PDER21	940:956	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	5	28	contain	possessing	978:987	arg1	polysaccharide					963:976	a polysaccharide	961:976	a polysaccharide possessing a good combination of technical and functional attributes	961:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	5	28	contain	possessing	978:987	arg2	combination					996:1006	a good combination	989:1006	a good combination of technical and functional attributes	989:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	4	29	theme	binding	897:903	arg1	capacity					905:912	good water binding capacity	886:912	good water binding capacity	886:912	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	2	30	theme	α-d-glucose	329:339	arg1	units					341:345	(1 → 6)-linked α-d-glucose units	314:345	(1 → 6)-linked α-d-glucose units	314:345	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	2	31	link	-linked	364:370	arg1	branches					384:391	(1 → 3)-linked α-d-glucose branches	357:391	(1 → 3)-linked α-d-glucose branches	357:391	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	5	32	theme	glucan	944:949	arg1	PDER21					951:956	The glucan PDER21	940:956	The glucan PDER21	940:956	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	5	32	theme	glucan	944:949	arg1	polysaccharide					963:976	a polysaccharide	961:976	a polysaccharide possessing a good combination of technical and functional attributes	961:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	2	33	theme	NMR	443:445	arg1	spectra					447:453	13C NMR spectra	439:453	13C NMR spectra	439:453	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	5	34	theme	potential	1075:1083	arg1	deal					1067:1070	a great deal	1059:1070	a great deal of potential for use in the food industry	1059:1112	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	4	35	theme	excellent	918:926	arg1	solubility					928:937	excellent solubility	918:937	excellent solubility	918:937	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	5	36	theme	technical	1011:1019	arg1	attributes					1036:1045	technical and functional attributes	1011:1045	technical and functional attributes	1011:1045	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	2	37	theme	13C	439:441	arg1	spectra					447:453	13C NMR spectra	439:453	13C NMR spectra	439:453	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	5	38	theme	food	1100:1103	arg1	industry					1105:1112	the food industry	1096:1112	the food industry	1096:1112	The glucan PDER21 is a polysaccharide possessing a good combination of technical and functional attributes, suggesting a great deal of potential for use in the food industry.
35287855	4	39	theme	solubility	780:789	arg1	index					791:795	water solubility index	774:795	water solubility index (80.7%) values	774:810	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	39	theme	solubility	780:789	arg1	%					802:802	80.7%	798:802	80.7%	798:802	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	2	40	theme	units	341:345	arg1	structure					301:309	The core structure	292:309	The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6	292:414	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	0	41	theme	α-D-glucan	45:54	arg1	properties					28:37	Bioactive and technological properties	0:37	Bioactive and technological properties of an α-D-glucan	0:54	Bioactive and technological properties of an α-D-glucan synthesized by Weissella cibaria PDER21.
35287855	4	42	theme	water	774:778	arg1	index					791:795	water solubility index	774:795	water solubility index (80.7%) values	774:810	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	4	42	theme	water	774:778	arg1	%					802:802	80.7%	798:802	80.7%	798:802	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	1	43	theme	EPS-producing	129:141	arg1	PDER21					161:166	EPS-producing Weissella cibaria PDER21	129:166	EPS-producing Weissella cibaria PDER21	129:166	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21 was isolated and identified.
35287855	3	44	theme	XRD	588:590	arg1	analysis					592:599	300 °C. XRD analysis	580:599	300 °C. XRD analysis	580:599	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	2	45	theme	type	267:270	arg1	homopolysaccharide					272:289	a glucan type homopolysaccharide	258:289	a glucan type homopolysaccharide	258:289	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	2	45	theme	type	267:270	arg1	EPS					251:253	the EPS	247:253	the EPS	247:253	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	1	46	theme	Weissella	143:151	arg1	PDER21					161:166	EPS-producing Weissella cibaria PDER21	129:166	EPS-producing Weissella cibaria PDER21	129:166	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21 was isolated and identified.
35287855	2	47	theme	glucan	260:265	arg1	homopolysaccharide					272:289	a glucan type homopolysaccharide	258:289	a glucan type homopolysaccharide	258:289	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	2	47	theme	glucan	260:265	arg1	EPS					251:253	the EPS	247:253	the EPS	247:253	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	1	48	theme	cibaria	153:159	arg1	PDER21					161:166	EPS-producing Weissella cibaria PDER21	129:166	EPS-producing Weissella cibaria PDER21	129:166	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21 was isolated and identified.
35287855	2	49	theme	-linked	321:327	arg1	units					341:345	(1 → 6)-linked α-d-glucose units	314:345	(1 → 6)-linked α-d-glucose units	314:345	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	0	50	theme	Weissella	71:79	arg1	cibaria					81:87	Weissella cibaria PDER21	71:94	Weissella cibaria PDER21	71:94	Bioactive and technological properties of an α-D-glucan synthesized by Weissella cibaria PDER21.
35287855	3	51	theme	SEM	640:642	arg1	analysis					644:651	SEM analysis	640:651	SEM analysis	640:651	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	3	52	theme	superior	507:514	arg1	stability					524:532	a superior thermal stability	505:532	a superior thermal stability	505:532	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
35287855	1	53	theme	PDER21	161:166	arg1	colony					119:124	A slimy-mucinous-type colony	97:124	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21	97:166	A slimy-mucinous-type colony of EPS-producing Weissella cibaria PDER21 was isolated and identified.
35287855	4	54	theme	water	891:895	arg1	capacity					905:912	good water binding capacity	886:912	good water binding capacity	886:912	The glucan had an antioxidant activity (89.5%), water-holding capacity (103.7%) and water solubility index (80.7%) values, suggesting that the glucan had a strong level of antioxidant properties; good water binding capacity and excellent solubility.
35287855	2	55	link	-linked	321:327	arg1	units					341:345	(1 → 6)-linked α-d-glucose units	314:345	(1 → 6)-linked α-d-glucose units	314:345	The monomer composition was glucose, showing that the EPS is a glucan type homopolysaccharide, The core structure of (1 → 6)-linked α-d-glucose units including (1 → 3)-linked α-d-glucose branches at a ratio of 93.4/6.6 was revealed by 1H and 13C NMR spectra and confirmed by FTIR analysis.
35287855	3	56	theme	300 °C.	580:586	arg1	analysis					592:599	300 °C. XRD analysis	580:599	300 °C. XRD analysis	580:599	The glucan showed a superior thermal stability with almost no degradation in structure up to 300 °C. XRD analysis revealed the amorphous structure while SEM analysis confirmed the layer-like morphology.
37182617	0	0	theme	linteus	98:104	arg1	fermentation					130:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	4	1	theme	total	688:692	arg1	sugar					694:698	total sugar	688:698	total sugar	688:698	After 48 h fermentation, the Mw, total sugar, reducing sugar, pH and monosaccharides composition were decreased.
37182617	0	2	theme	Phellinus	88:96	arg1	fermentation					130:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	6	3	theme	fatty	1116:1120	arg1	acids					1122:1126	short-chain fatty acids	1104:1126	short-chain fatty acids	1104:1126	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	0	4	theme	in	121:122	arg1	fermentation					130:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	0	5	theme	polysaccharide	106:119	arg1	fermentation					130:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Phellinus linteus polysaccharide in vitro fermentation	88:141	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	5	6	theme	pathogenic	971:980	arg1	Intestinimonas					1036:1049	Intestinimonas	1036:1049	Intestinimonas	1036:1049	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	5	6	theme	pathogenic	971:980	arg1	Morganella					1021:1030	Morganella	1021:1030	Morganella	1021:1030	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	5	6	theme	pathogenic	971:980	arg1	bacteria					982:989	pathogenic bacteria	971:989	pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas	971:1049	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	5	6	theme	pathogenic	971:980	arg1	Escherichia-Shigella					999:1018	Escherichia-Shigella	999:1018	Escherichia-Shigella	999:1018	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	3	7	theme	molecular	580:588	arg1	Mw					599:600	Mw	599:600	Mw	599:600	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	3	7	theme	molecular	580:588	arg1	weights					590:596	molecular weights	580:596	molecular weights (Mw)	580:601	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	7	8	theme	PLP	1299:1301	arg1	genus					1359:1363	the key genus to regulate these metabolic pathways	1351:1400	the key genus to regulate these metabolic pathways	1351:1400	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	8	theme	PLP	1299:1301	arg1	pathways					1287:1294	the main metabolic pathways	1268:1294	the main metabolic pathways of PLP regulating host health	1268:1324	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	8	theme	PLP	1299:1301	arg1	butyrate					1221:1228	butyrate	1221:1228	butyrate	1221:1228	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	8	theme	PLP	1299:1301	arg1	Bacteroides					1335:1345	the Bacteroides	1331:1345	the Bacteroides	1331:1345	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	0	9	theme	fermentation	130:141	arg1	characteristics					69:83	prebiotic characteristics	59:83	prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation	59:141	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	7	10	theme	metabolic	1277:1285	arg1	butyrate					1221:1228	butyrate	1221:1228	butyrate	1221:1228	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	10	theme	metabolic	1277:1285	arg1	pathways					1287:1294	the main metabolic pathways	1268:1294	the main metabolic pathways of PLP regulating host health	1268:1324	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	0	11	dep	in	121:122	arg1	vitro					124:128	vitro	124:128	vitro	124:128	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	6	12	theme	short-chain	1104:1114	arg1	acids					1122:1126	short-chain fatty acids	1104:1126	short-chain fatty acids	1104:1126	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	8	13	theme	gut	1534:1536	arg1	microbiota					1538:1547	gut microbiota	1534:1547	gut microbiota	1534:1547	In conclusion, our finding suggested that PLP may be used as a prebiotic agent for human health because of its ability to regulate gut microbiota.
37182617	1	14	theme	increasing	196:205	arg1	attention					207:215	increasing attention	196:215	increasing attention	196:215	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	7	15	theme	purine	1245:1250	arg1	butyrate					1221:1228	butyrate	1221:1228	butyrate	1221:1228	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	15	theme	purine	1245:1250	arg1	metabolism					1252:1261	purine metabolism	1245:1261	purine metabolism	1245:1261	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	3	16	theme	chromatographic	554:568	arg1	peaks					570:574	three gel chromatographic peaks	544:574	three gel chromatographic peaks	544:574	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	5	17	theme	beneficial	869:878	arg1	Butyricimonas					925:937	Butyricimonas	925:937	Butyricimonas	925:937	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	5	17	theme	beneficial	869:878	arg1	Prevotella					910:919	Prevotella	910:919	Prevotella	910:919	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	5	17	theme	beneficial	869:878	arg1	bacteria					880:887	beneficial bacteria	869:887	beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas	869:937	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	5	18	theme	gut	814:816	arg1	microbiota					818:827	gut microbiota	814:827	gut microbiota	814:827	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	3	19	with	monosaccharides	522:536	arg1	Mw					599:600	Mw	599:600	Mw	599:600	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	3	19	with	monosaccharides	522:536	arg1	peaks					570:574	three gel chromatographic peaks	544:574	three gel chromatographic peaks	544:574	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	3	19	with	monosaccharides	522:536	arg1	weights					590:596	molecular weights	580:596	molecular weights (Mw)	580:601	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	5	20	theme	bacteria	880:887	arg1	proliferation					852:864	the proliferation	848:864	the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas	848:937	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	0	21	theme	metabolite	26:35	arg1	analysis					47:54	metabolite profiling analysis	26:54	metabolite profiling analysis	26:54	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	2	22	theme	PLP	330:332	arg1	extraction					272:281	extraction	272:281	extraction	272:281	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	2	22	theme	PLP	330:332	arg1	fermentation					314:325	in vitro fermentation	305:325	in vitro fermentation	305:325	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	2	22	theme	PLP	330:332	arg1	characterization					284:299	characterization	284:299	characterization	284:299	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	2	23	theme	in	305:306	arg1	fermentation					314:325	in vitro fermentation	305:325	in vitro fermentation	305:325	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	7	24	theme	main	1272:1275	arg1	butyrate					1221:1228	butyrate	1221:1228	butyrate	1221:1228	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	24	theme	main	1272:1275	arg1	pathways					1287:1294	the main metabolic pathways	1268:1294	the main metabolic pathways of PLP regulating host health	1268:1324	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	2	25	dep	in	305:306	arg1	vitro					308:312	vitro	308:312	vitro	308:312	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	4	26	theme	reducing	701:708	arg1	sugar					710:714	reducing sugar	701:714	reducing sugar	701:714	After 48 h fermentation, the Mw, total sugar, reducing sugar, pH and monosaccharides composition were decreased.
37182617	4	27	theme	48 h	661:664	arg1	fermentation					666:677	48 h fermentation	661:677	48 h fermentation	661:677	After 48 h fermentation, the Mw, total sugar, reducing sugar, pH and monosaccharides composition were decreased.
37182617	1	28	theme	multiple	228:235	arg1	activities					248:257	its multiple biological activities	224:257	its multiple biological activities	224:257	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	0	29	theme	profiling	37:45	arg1	analysis					47:54	metabolite profiling analysis	26:54	metabolite profiling analysis	26:54	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	5	30	theme	microbiota	818:827	arg1	composition					799:809	the composition	795:809	the composition of gut microbiota	795:827	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	1	31	theme	biological	237:246	arg1	activities					248:257	its multiple biological activities	224:257	its multiple biological activities	224:257	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	0	32	theme	prebiotic	59:67	arg1	characteristics					69:83	prebiotic characteristics	59:83	prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation	59:141	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	7	33	theme	bile	1231:1234	arg1	butyrate					1221:1228	butyrate	1221:1228	butyrate	1221:1228	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	33	theme	bile	1231:1234	arg1	acid					1236:1239	bile acid	1231:1239	bile acid	1231:1239	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	6	34	theme	microbiota	1056:1065	arg1	regulators					1142:1151	the main regulators	1133:1151	the main regulators that impact the host health	1133:1179	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	6	34	theme	microbiota	1056:1065	arg1	metabolites					1067:1077	Gut microbiota metabolites	1052:1077	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids	1052:1126	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	7	35	theme	metabolic	1383:1391	arg1	pathways					1393:1400	these metabolic pathways	1377:1400	these metabolic pathways	1377:1400	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	2	36	theme	physiochemical	362:375	arg1	properties					377:386	its physiochemical properties	358:386	its physiochemical properties	358:386	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	3	37	theme	308.45 kDa	606:615	arg1	Mw					599:600	Mw	599:600	Mw	599:600	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	3	37	theme	308.45 kDa	606:615	arg1	peaks					570:574	three gel chromatographic peaks	544:574	three gel chromatographic peaks	544:574	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	3	37	theme	308.45 kDa	606:615	arg1	weights					590:596	molecular weights	580:596	molecular weights (Mw)	580:601	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
37182617	1	38	theme	Phellinus	144:152	arg1	PLP					178:180	PLP	178:180	PLP	178:180	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	1	38	theme	Phellinus	144:152	arg1	polysaccharide					162:175	Phellinus linteus polysaccharide	144:175	Phellinus linteus polysaccharide (PLP)	144:181	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	8	39	used	used	1456:1459	arg2	agent					1476:1480	a prebiotic agent	1464:1480	a prebiotic agent for human health	1464:1497	In conclusion, our finding suggested that PLP may be used as a prebiotic agent for human health because of its ability to regulate gut microbiota.
37182617	8	39	used	used	1456:1459	arg2	PLP					1445:1447	PLP	1445:1447	PLP	1445:1447	In conclusion, our finding suggested that PLP may be used as a prebiotic agent for human health because of its ability to regulate gut microbiota.
37182617	7	40	theme	Bioinformatics	1182:1195	arg1	analysis					1197:1204	Bioinformatics analysis	1182:1204	Bioinformatics analysis	1182:1204	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	8	41	theme	prebiotic	1466:1474	arg1	agent					1476:1480	a prebiotic agent	1464:1480	a prebiotic agent for human health	1464:1497	In conclusion, our finding suggested that PLP may be used as a prebiotic agent for human health because of its ability to regulate gut microbiota.
37182617	8	41	theme	prebiotic	1466:1474	arg1	PLP					1445:1447	PLP	1445:1447	PLP	1445:1447	In conclusion, our finding suggested that PLP may be used as a prebiotic agent for human health because of its ability to regulate gut microbiota.
37182617	4	42	dep	Mw	684:685	arg1	composition					740:750	composition	740:750	composition	740:750	After 48 h fermentation, the Mw, total sugar, reducing sugar, pH and monosaccharides composition were decreased.
37182617	1	43	theme	linteus	154:160	arg1	PLP					178:180	PLP	178:180	PLP	178:180	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	1	43	theme	linteus	154:160	arg1	polysaccharide					162:175	Phellinus linteus polysaccharide	144:175	Phellinus linteus polysaccharide (PLP)	144:181	Phellinus linteus polysaccharide (PLP) had received increasing attention due to its multiple biological activities.
37182617	6	44	theme	host	1169:1172	arg1	health					1174:1179	the host health	1165:1179	the host health	1165:1179	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	6	45	theme	Gut	1052:1054	arg1	regulators					1142:1151	the main regulators	1133:1151	the main regulators that impact the host health	1133:1179	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	6	45	theme	Gut	1052:1054	arg1	metabolites					1067:1077	Gut microbiota metabolites	1052:1077	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids	1052:1126	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	8	46	theme	human	1486:1490	arg1	health					1492:1497	human health	1486:1497	human health	1486:1497	In conclusion, our finding suggested that PLP may be used as a prebiotic agent for human health because of its ability to regulate gut microbiota.
37182617	6	47	theme	main	1137:1140	arg1	regulators					1142:1151	the main regulators	1133:1151	the main regulators that impact the host health	1133:1179	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	6	47	theme	main	1137:1140	arg1	metabolites					1067:1077	Gut microbiota metabolites	1052:1077	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids	1052:1126	Gut microbiota metabolites regulated by PLP such as short-chain fatty acids were the main regulators that impact the host health.
37182617	5	48	theme	bacteria	982:989	arg1	growth					961:966	the growth	957:966	the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas	957:1049	Furthermore, PLP regulated the composition of gut microbiota, such as promoting the proliferation of beneficial bacteria such as Bacteroides, Prevotella and Butyricimonas, while preventing the growth of pathogenic bacteria such as Escherichia-Shigella, Morganella and Intestinimonas.
37182617	2	49	dep	gut	430:432	arg1	microbiota					434:443	microbiota	434:443	microbiota	434:443	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	2	50	theme	interaction	396:406	arg1	mechanism					408:416	the interaction mechanism	392:416	the interaction mechanism	392:416	Herein, the extraction, characterization and in vitro fermentation of PLP were studied to explore its physiochemical properties and the interaction mechanism between the gut microbiota and PLP.
37182617	7	51	theme	key	1355:1357	arg1	genus					1359:1363	the key genus to regulate these metabolic pathways	1351:1400	the key genus to regulate these metabolic pathways	1351:1400	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	7	51	theme	key	1355:1357	arg1	Bacteroides					1335:1345	the Bacteroides	1331:1345	the Bacteroides	1331:1345	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	0	52	theme	characteristics	69:83	arg1	analysis					47:54	metabolite profiling analysis	26:54	metabolite profiling analysis	26:54	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	0	52	theme	characteristics	69:83	arg1	microbiota					11:20	microbiota	11:20	microbiota	11:20	Integrated microbiota and metabolite profiling analysis of prebiotic characteristics of Phellinus linteus polysaccharide in vitro fermentation.
37182617	7	53	theme	host	1314:1317	arg1	health					1319:1324	host health	1314:1324	host health	1314:1324	Bioinformatics analysis indicated that butyrate, bile acid and purine metabolism were the main metabolic pathways of PLP regulating host health, and the Bacteroides was the key genus to regulate these metabolic pathways.
37182617	3	54	theme	gel	550:552	arg1	peaks					570:574	three gel chromatographic peaks	544:574	three gel chromatographic peaks	544:574	The results obtained demonstrated that PLP was mainly composed of 9 monosaccharides, with three gel chromatographic peaks and molecular weights (Mw) of 308.45 kDa, 13.58 kD and 3.33 kDa, respectively.
35483846	5	0	theme	defensive	838:846	arg1	modulation					848:857	defensive modulation	838:857	defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	838:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	7	1	theme	aging	1232:1236	arg1	prevention					1203:1212	prevention	1203:1212	prevention	1203:1212	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	7	1	theme	aging	1232:1236	arg1	management					1218:1227	management	1218:1227	management	1218:1227	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	7	2	theme	worth	1133:1137	arg1	exploration					1147:1157	worth further exploration	1133:1157	worth further exploration	1133:1157	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	3	3	theme	composition	532:542	arg1	analysis					578:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	5	4	theme	supplied	811:818	arg1	LFP-05S					820:826	Orally supplied LFP-05S	804:826	Orally supplied LFP-05S	804:826	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	0	5	theme	LFP-05S	81:87	arg1	elegans					53:59	Caenorhabditis elegans	38:59	Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus	38:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	7	6	theme	promising	1162:1170	arg1	candidates					1184:1193	promising redox-based candidates	1162:1193	promising redox-based candidates for the prevention and management of aging and related disorders	1162:1258	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	4	7	theme	LFP-05S	615:621	arg1	population					601:610	The dominant population	588:610	The dominant population of LFP-05S	588:621	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	3	8	theme	analysis	578:585	arg1	strategy					469:476	a combination strategy	455:476	a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	455:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	4	9	theme	domains	753:759	arg1	sequences					705:713	alternating sequences	693:713	alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan	693:801	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	7	10	dep	LFP-05S	1106:1112	arg1	exploration					1147:1157	worth further exploration	1133:1157	worth further exploration	1133:1157	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	4	11	theme	arabinogalactan	774:788	arg1	sequences					705:713	alternating sequences	693:713	alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan	693:801	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	0	12	from	elegans	53:59	arg1	fructus					100:106	Lycii fructus	94:106	Lycii fructus	94:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	3	13	theme	NMR	561:563	arg1	spectroscopy					565:576	NMR spectroscopy	561:576	NMR spectroscopy	561:576	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	4	14	theme	intra-rhamnogalacturonans-I	718:744	arg1	domains					753:759	intra-rhamnogalacturonans-I (RG-I) domains	718:759	intra-rhamnogalacturonans-I (RG-I) domains	718:759	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	2	15	from	centers	216:222	arg1	application					241:251	the potential application	227:251	the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay	227:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	2	16	theme	stress	293:298	arg1	alleviation					300:310	oxidative stress alleviation	283:310	oxidative stress alleviation	283:310	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	7	17	dep	prevention	1203:1212	arg1	the					1199:1201	the	1199:1201	the	1199:1201	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	4	18	theme	alternating	693:703	arg1	sequences					705:713	alternating sequences	693:713	alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan	693:801	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	6	19	theme	normal	977:982	arg1	conditions					984:993	normal conditions	977:993	normal conditions	977:993	Under normal conditions, LFP-05S extended the lifespan without significant impairment of propagation.
35483846	1	20	dep	initiation	157:166	arg1	the					153:155	the	153:155	the	153:155	Oxidative stress is closely associated with the initiation and progression of aging.
35483846	2	21	from	application	241:251	arg1	senescence					316:325	senescence	316:325	senescence	316:325	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	2	21	from	application	241:251	arg1	alleviation					300:310	oxidative stress alleviation	283:310	oxidative stress alleviation	283:310	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	1	22	theme	aging	187:191	arg1	progression					172:182	progression	172:182	progression	172:182	Oxidative stress is closely associated with the initiation and progression of aging.
35483846	1	22	theme	aging	187:191	arg1	initiation					157:166	initiation	157:166	initiation	157:166	Oxidative stress is closely associated with the initiation and progression of aging.
35483846	5	23	theme	-damaged	875:882	arg1	elegans					916:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	4	24	theme	dominant	592:599	arg1	population					601:610	The dominant population	588:610	The dominant population of LFP-05S	588:621	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	2	25	from	polysaccharides	264:278	arg1	senescence					316:325	senescence	316:325	senescence	316:325	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	2	25	from	polysaccharides	264:278	arg1	alleviation					300:310	oxidative stress alleviation	283:310	oxidative stress alleviation	283:310	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	3	26	theme	combination	457:467	arg1	strategy					469:476	a combination strategy	455:476	a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	455:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	5	27	theme	oxidative	884:892	arg1	elegans					916:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	7	28	theme	redox-based	1172:1182	arg1	candidates					1184:1193	promising redox-based candidates	1162:1193	promising redox-based candidates for the prevention and management of aging and related disorders	1162:1258	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	5	29	theme	Caenorhabditis	901:914	arg1	elegans					916:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	0	30	theme	oxidative	18:26	arg1	stress					28:33	oxidative stress	18:33	oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus	18:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	6	31	theme	propagation	1060:1070	arg1	impairment					1046:1055	significant impairment	1034:1055	significant impairment of propagation	1034:1070	Under normal conditions, LFP-05S extended the lifespan without significant impairment of propagation.
35483846	1	32	theme	Oxidative	109:117	arg1	stress					119:124	Oxidative stress	109:124	Oxidative stress	109:124	Oxidative stress is closely associated with the initiation and progression of aging.
35483846	3	33	theme	methylation	545:555	arg1	analysis					578:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	0	34	theme	Caenorhabditis	38:51	arg1	elegans					53:59	Caenorhabditis elegans	38:59	Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus	38:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	3	35	theme	molecular	481:489	arg1	weight					491:496	molecular weight	481:496	molecular weight	481:496	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	3	35	theme	molecular	481:489	arg1	MW					499:500	MW	499:500	MW	499:500	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	4	36	theme	RG-I	747:750	arg1	domains					753:759	intra-rhamnogalacturonans-I (RG-I) domains	718:759	intra-rhamnogalacturonans-I (RG-I) domains	718:759	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	5	37	theme	paraquat	862:869	arg1	elegans					916:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	3	38	theme	weight	491:496	arg1	analysis					578:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	7	39	theme	related	1242:1248	arg1	disorders					1250:1258	related disorders	1242:1258	related disorders	1242:1258	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	5	40	theme	defense	954:960	arg1	systems					962:968	the internal defense systems	941:968	the internal defense systems	941:968	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	7	41	theme	further	1139:1145	arg1	exploration					1147:1157	worth further exploration	1133:1157	worth further exploration	1133:1157	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	3	42	from	fructus	393:399	arg1	LFP-05S					342:348	LFP-05S	342:348	LFP-05S	342:348	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	3	42	from	fructus	393:399	arg1	heteropolysaccharide					361:380	an acidic heteropolysaccharide	351:380	an acidic heteropolysaccharide from Lycii fructus	351:399	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	2	43	theme	potential	231:239	arg1	application					241:251	the potential application	227:251	the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay	227:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	4	44	theme	branched	765:772	arg1	arabinogalactan					774:788	arabinogalactan	774:788	arabinogalactan	774:788	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	7	45	theme	disorders	1250:1258	arg1	prevention					1203:1212	prevention	1203:1212	prevention	1203:1212	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	7	45	theme	disorders	1250:1258	arg1	management					1218:1227	management	1218:1227	management	1218:1227	Overall, these results suggested LFP-05S and L. fructus are worth further exploration as promising redox-based candidates for the prevention and management of aging and related disorders.
35483846	3	46	theme	monosaccharide	517:530	arg1	composition					532:542	monosaccharide composition	517:542	monosaccharide composition	517:542	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	2	47	from	alleviation	300:310	arg1	application					241:251	the potential application	227:251	the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay	227:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	5	48	from	modulation	848:857	arg1	elegans					916:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	2	49	theme	oxidative	283:291	arg1	alleviation					300:310	oxidative stress alleviation	283:310	oxidative stress alleviation	283:310	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	4	50	theme	homogalacturonan	644:659	arg1	backbone					666:673	long homogalacturonan (HG) backbone	639:673	long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan	639:801	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	3	51	theme	spectroscopy	565:576	arg1	analysis					578:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	0	52	from	fructus	100:106	arg1	LFP-05S					81:87	a polysaccharide LFP-05S	64:87	a polysaccharide LFP-05S from Lycii fructus	64:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	0	52	from	fructus	100:106	arg1	elegans					53:59	Caenorhabditis elegans	38:59	Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus	38:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	5	53	theme	stress	894:899	arg1	elegans					916:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans	862:922	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	3	54	theme	distribution	503:514	arg1	analysis					578:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis	481:585	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	2	55	from	senescence	316:325	arg1	application					241:251	the potential application	227:251	the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay	227:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	4	56	theme	long	639:642	arg1	backbone					666:673	long homogalacturonan (HG) backbone	639:673	long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan	639:801	The dominant population of LFP-05S was composed of long homogalacturonan (HG) backbone interspersed with alternating sequences of intra-rhamnogalacturonans-I (RG-I) domains and branched arabinogalactan and arabinan.
35483846	0	57	theme	polysaccharide	66:79	arg1	LFP-05S					81:87	a polysaccharide LFP-05S	64:87	a polysaccharide LFP-05S from Lycii fructus	64:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	2	58	theme	Considerable	194:205	arg1	interest					207:214	Considerable interest	194:214	Considerable interest	194:214	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	2	59	theme	polysaccharides	264:278	arg1	application					241:251	the potential application	227:251	the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay	227:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	2	60	dep	alleviation	300:310	arg1	delay					327:331	delay	327:331	delay	327:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	5	61	theme	internal	945:952	arg1	systems					962:968	the internal defense systems	941:968	the internal defense systems	941:968	Orally supplied LFP-05S exhibited defensive modulation in paraquat (PQ)-damaged oxidative stress Caenorhabditis elegans by strengthening the internal defense systems.
35483846	3	62	theme	acidic	354:359	arg1	LFP-05S					342:348	LFP-05S	342:348	LFP-05S	342:348	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	3	62	theme	acidic	354:359	arg1	heteropolysaccharide					361:380	an acidic heteropolysaccharide	351:380	an acidic heteropolysaccharide from Lycii fructus	351:399	Herein, LFP-05S, an acidic heteropolysaccharide from Lycii fructus, was purified and structurally characterized based on a combination strategy of molecular weight (MW) distribution, monosaccharide composition, methylation and NMR spectroscopy analysis.
35483846	0	63	from	stress	28:33	arg1	elegans					53:59	Caenorhabditis elegans	38:59	Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus	38:106	Defensing against oxidative stress in Caenorhabditis elegans of a polysaccharide LFP-05S from Lycii fructus.
35483846	2	64	theme	natural	256:262	arg1	polysaccharides					264:278	natural polysaccharides	256:278	natural polysaccharides in oxidative stress alleviation and senescence delay	256:331	Considerable interest centers in the potential application of natural polysaccharides in oxidative stress alleviation and senescence delay.
35483846	6	65	theme	significant	1034:1044	arg1	impairment					1046:1055	significant impairment	1034:1055	significant impairment of propagation	1034:1070	Under normal conditions, LFP-05S extended the lifespan without significant impairment of propagation.
35841635	2	0	theme	mg/kg	617:621	arg1	XOS + IAPS					728:737	XOS + IAPS	728:737	XOS + IAPS	728:737	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	0	theme	mg/kg	617:621	arg1	CTC					642:644	CTC	642:644	CTC	642:644	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	0	theme	mg/kg	617:621	arg1	chlortetracycline					623:639	50 mg/kg chlortetracycline	614:639	50 mg/kg chlortetracycline (CTC)	614:645	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	8	1	dep	XOS	1581:1583	arg1	treatments					1594:1603	treatments	1594:1603	treatments	1594:1603	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	11	2	theme	CTC	2323:2325	arg1	effect					2313:2318	individual effect	2302:2318	individual effect of CTC, XOS, or IAPS in the current study	2302:2360	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	6	3	theme	duodenal	1312:1319	arg1	cells					1347:1351	duodenal and jejunal IgA-producing cells	1312:1351	duodenal and jejunal IgA-producing cells number	1312:1358	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	5	4	theme	serum	1075:1079	arg1	concentration					1097:1109	lower serum malondialdehyde concentration	1069:1109	lower serum malondialdehyde concentration	1069:1109	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	11	5	theme	cytokine	2148:2155	arg1	expression					2162:2171	cytokine gene expression	2148:2171	cytokine gene expression	2148:2171	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	6	theme	combination	2244:2254	arg1	better					2282:2287	better	2282:2287	better	2282:2287	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	6	theme	combination	2244:2254	arg1	effect					2256:2261	the combination effect	2240:2261	the combination effect of XOS and IAPS	2240:2277	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	1	7	theme	gamma-irradiated	292:307	arg1	IAPS					337:340	IAPS	337:340	IAPS	337:340	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	1	7	theme	gamma-irradiated	292:307	arg1	polysaccharides					320:334	gamma-irradiated astragalus polysaccharides	292:334	gamma-irradiated astragalus polysaccharides (IAPS)	292:341	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	9	8	theme	CTC	1688:1690	arg1	administration					1692:1705	Dietary CTC administration	1680:1705	Dietary CTC administration	1680:1705	Dietary CTC administration increased the proportion of Bacteroides, and decreased the proportion of Negativibacillus (P < 0.05).
35841635	11	9	theme	intestinal	2074:2083	arg1	immunity					2093:2100	intestinal mucosal immunity	2074:2100	intestinal mucosal immunity	2074:2100	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	1	10	theme	present	194:200	arg1	study					202:206	The present study	190:206	The present study	190:206	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	9	11	theme	Bacteroides	1735:1745	arg1	proportion					1721:1730	the proportion	1717:1730	the proportion of Bacteroides	1717:1745	Dietary CTC administration increased the proportion of Bacteroides, and decreased the proportion of Negativibacillus (P < 0.05).
35841635	11	12	theme	IAPS	2336:2339	arg1	effect					2313:2318	individual effect	2302:2318	individual effect of CTC, XOS, or IAPS in the current study	2302:2360	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	3	13	theme	lysozyme	842:849	arg1	activity					851:858	serum lysozyme activity	836:858	serum lysozyme activity	836:858	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	5	14	contain	had	1065:1067	arg1	Birds					1026:1030	Birds	1026:1030	Birds in the CTC and XOS + IAPS groups	1026:1063	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	14	contain	had	1065:1067	arg2	concentration					1097:1109	lower serum malondialdehyde concentration	1069:1109	lower serum malondialdehyde concentration	1069:1109	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	14	contain	had	1065:1067	arg2	activity					1155:1162	higher serum total antioxidant capacity activity	1115:1162	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	4	15	theme	lysozyme	996:1003	arg1	activity					1005:1012	the serum lysozyme activity	986:1012	the serum lysozyme activity (P < 0.05)	986:1023	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	4	15	theme	lysozyme	996:1003	arg1	<					1017:1017	P < 0.05	1015:1022	P < 0.05	1015:1022	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	9	16	theme	Negativibacillus	1780:1795	arg1	proportion					1766:1775	the proportion	1762:1775	the proportion of Negativibacillus (P < 0.05)	1762:1806	Dietary CTC administration increased the proportion of Bacteroides, and decreased the proportion of Negativibacillus (P < 0.05).
35841635	1	17	theme	individual	225:234	arg1	effects					249:255	the individual and combined effects	221:255	the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens	221:444	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	11	18	theme	XOS	2328:2330	arg1	effect					2313:2318	individual effect	2302:2318	individual effect of CTC, XOS, or IAPS in the current study	2302:2360	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	0	19	theme	intestinal	143:152	arg1	composition					165:175	intestinal microbiota composition	143:175	intestinal microbiota composition of broilers	143:187	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	1	20	theme	chickens	437:444	arg1	response					357:364	the immune response	346:364	the immune response	346:364	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	1	20	theme	chickens	437:444	arg1	capacity					379:386	antioxidant capacity	367:386	antioxidant capacity	367:386	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	1	20	theme	chickens	437:444	arg1	composition					414:424	intestinal microbiota composition	392:424	intestinal microbiota composition	392:424	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	11	21	theme	gene	2157:2160	arg1	expression					2162:2171	cytokine gene expression	2148:2171	cytokine gene expression	2148:2171	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	1	22	theme	combined	240:247	arg1	effects					249:255	the individual and combined effects	221:255	the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens	221:444	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	7	23	theme	individual	1441:1450	arg1	XOS					1452:1454	dietary individual XOS or IAPS administration	1433:1477	XOS	1452:1454	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	1	24	theme	polysaccharides	320:334	arg1	effects					249:255	the individual and combined effects	221:255	the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens	221:444	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	10	25	theme	Negativibacillus	1987:2002	arg1	proportion					1957:1966	the proportion	1953:1966	the proportion of Barnesiella and Negativibacillus	1953:2002	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	10	26	theme	Barnesiella	1971:1981	arg1	proportion					1957:1966	the proportion	1953:1966	the proportion of Barnesiella and Negativibacillus	1953:2002	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	5	27	theme	interleukin	1176:1186	arg1	expression					1195:1204	mucosal interleukin 2 mRNA expression	1168:1204	mucosal interleukin 2 mRNA expression	1168:1204	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	10	28	theme	dietary	1818:1824	arg1	administration					1837:1850	dietary XOS + IAPS administration	1818:1850	dietary XOS + IAPS administration	1818:1850	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	0	29	theme	broilers	180:187	arg1	impact					13:18	The combined impact	0:18	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response	0:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	29	theme	broilers	180:187	arg1	composition					165:175	intestinal microbiota composition	143:175	intestinal microbiota composition of broilers	143:187	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	29	theme	broilers	180:187	arg1	capacity					129:136	antioxidant capacity	117:136	antioxidant capacity	117:136	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	7	30	theme	CTC	1422:1424	arg1	group					1426:1430	the CTC group	1418:1430	the CTC group	1418:1430	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	5	31	theme	mRNA	1190:1193	arg1	expression					1195:1204	mucosal interleukin 2 mRNA expression	1168:1204	mucosal interleukin 2 mRNA expression	1168:1204	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	0	32	theme	polysaccharides	77:91	arg1	impact					13:18	The combined impact	0:18	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response	0:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	32	theme	polysaccharides	77:91	arg1	composition					165:175	intestinal microbiota composition	143:175	intestinal microbiota composition of broilers	143:187	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	32	theme	polysaccharides	77:91	arg1	capacity					129:136	antioxidant capacity	117:136	antioxidant capacity	117:136	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	8	33	theme	increasing	1608:1617	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	33	theme	increasing	1608:1617	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	3	34	theme	thymus	819:824	arg1	index					826:830	the thymus index	815:830	the thymus index	815:830	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	0	35	from	impact	13:18	arg1	response					107:114	the immune response	96:114	the immune response	96:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	10	36	theme	P	2005:2005	arg1	<					2007:2007	P < 0.05	2005:2012	P < 0.05	2005:2012	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	5	37	theme	capacity	1146:1153	arg1	activity					1155:1162	higher serum total antioxidant capacity activity	1115:1162	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	1	38	theme	antioxidant	367:377	arg1	capacity					379:386	antioxidant capacity	367:386	antioxidant capacity	367:386	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	2	39	theme	mg/kg	652:656	arg1	XOS					663:665	XOS	663:665	XOS	663:665	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	39	theme	mg/kg	652:656	arg1	XOS					658:660	100 mg/kg XOS	648:660	100 mg/kg XOS (XOS)	648:666	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	11	40	theme	XOS	2266:2268	arg1	better					2282:2287	better	2282:2287	better	2282:2287	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	40	theme	XOS	2266:2268	arg1	effect					2256:2261	the combination effect	2240:2261	the combination effect of XOS and IAPS	2240:2277	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	8	41	theme	IgA-Producing	1640:1652	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	41	theme	IgA-Producing	1640:1652	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	7	42	theme	P	1526:1526	arg1	number					1518:1523	duodenal IgA-producing cells number	1489:1523	duodenal IgA-producing cells number (P < 0.05)	1489:1534	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	7	42	theme	P	1526:1526	arg1	<					1528:1528	P < 0.05	1526:1533	P < 0.05	1526:1533	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	11	43	theme	IgA-producing	2174:2186	arg1	production					2193:2202	IgA-producing cell production	2174:2202	IgA-producing cell production	2174:2202	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	0	44	theme	antioxidant	117:127	arg1	capacity					129:136	antioxidant capacity	117:136	antioxidant capacity	117:136	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	1	45	theme	microbiota	403:412	arg1	composition					414:424	intestinal microbiota composition	392:424	intestinal microbiota composition	392:424	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	3	46	dep	lower	809:813	arg1	activity					851:858	serum lysozyme activity	836:858	serum lysozyme activity	836:858	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	3	46	dep	lower	809:813	arg1	index					826:830	the thymus index	815:830	the thymus index	815:830	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	5	47	theme	control	1235:1241	arg1	group					1243:1247	the control group	1231:1247	the control group (P < 0.05)	1231:1258	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	47	theme	control	1235:1241	arg1	<					1252:1252	P < 0.05	1250:1257	P < 0.05	1250:1257	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	1	48	theme	astragalus	309:318	arg1	IAPS					337:340	IAPS	337:340	IAPS	337:340	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	1	48	theme	astragalus	309:318	arg1	polysaccharides					320:334	gamma-irradiated astragalus polysaccharides	292:334	gamma-irradiated astragalus polysaccharides (IAPS)	292:341	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	8	49	theme	P	1669:1669	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	49	theme	P	1669:1669	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	7	50	theme	IgA-producing	1498:1510	arg1	cells					1512:1516	duodenal IgA-producing cells	1489:1516	duodenal IgA-producing cells number (P < 0.05)	1489:1534	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	2	51	theme	hatched	468:474	arg1	chicks					485:490	240 newly hatched Ross 308 chicks	458:490	240 newly hatched Ross 308 chicks	458:490	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	3	52	from	birds	778:782	arg1	group					799:803	the control group	787:803	the control group	787:803	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	0	53	theme	xylo-oligosaccharides	23:43	arg1	impact					13:18	The combined impact	0:18	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response	0:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	53	theme	xylo-oligosaccharides	23:43	arg1	composition					165:175	intestinal microbiota composition	143:175	intestinal microbiota composition of broilers	143:187	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	53	theme	xylo-oligosaccharides	23:43	arg1	capacity					129:136	antioxidant capacity	117:136	antioxidant capacity	117:136	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	0	54	theme	gamma-irradiated	49:64	arg1	polysaccharides					77:91	gamma-irradiated astragalus polysaccharides	49:91	gamma-irradiated astragalus polysaccharides	49:91	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	3	55	theme	other	878:882	arg1	groups					886:891	the other 4 groups	874:891	the other 4 groups (P < 0.05)	874:902	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	3	55	theme	other	878:882	arg1	<					896:896	P < 0.05	894:901	P < 0.05	894:901	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	11	56	theme	broilers	2126:2133	arg1	immunity					2093:2100	intestinal mucosal immunity	2074:2100	intestinal mucosal immunity	2074:2100	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	56	theme	broilers	2126:2133	arg1	function					2114:2121	barrier function	2106:2121	barrier function of broilers	2106:2133	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	4	57	theme	serum	990:994	arg1	activity					1005:1012	the serum lysozyme activity	986:1012	the serum lysozyme activity (P < 0.05)	986:1023	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	4	57	theme	serum	990:994	arg1	<					1017:1017	P < 0.05	1015:1022	P < 0.05	1015:1022	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	6	58	theme	IgA-producing	1333:1345	arg1	cells					1347:1351	duodenal and jejunal IgA-producing cells	1312:1351	duodenal and jejunal IgA-producing cells number	1312:1358	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	1	59	theme	xylo-oligosaccharides	260:280	arg1	effects					249:255	the individual and combined effects	221:255	the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens	221:444	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	3	60	theme	P	894:894	arg1	groups					886:891	the other 4 groups	874:891	the other 4 groups (P < 0.05)	874:902	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	3	60	theme	P	894:894	arg1	<					896:896	P < 0.05	894:901	P < 0.05	894:901	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	9	61	theme	Dietary	1680:1686	arg1	administration					1692:1705	Dietary CTC administration	1680:1705	Dietary CTC administration	1680:1705	Dietary CTC administration increased the proportion of Bacteroides, and decreased the proportion of Negativibacillus (P < 0.05).
35841635	11	62	theme	current	2348:2354	arg1	study					2356:2360	the current study	2344:2360	the current study	2344:2360	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	5	63	theme	lower	1069:1073	arg1	concentration					1097:1109	lower serum malondialdehyde concentration	1069:1109	lower serum malondialdehyde concentration	1069:1109	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	2	64	theme	50	614:615	arg1	mg/kg					617:621	mg/kg	617:621	mg/kg	617:621	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	5	65	from	Birds	1026:1030	arg1	groups					1058:1063	the CTC and XOS + IAPS groups	1035:1063	groups	1058:1063	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	66	theme	malondialdehyde	1081:1095	arg1	concentration					1097:1109	lower serum malondialdehyde concentration	1069:1109	lower serum malondialdehyde concentration	1069:1109	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	10	67	dep	decreased	1943:1951	arg1	<					2007:2007	P < 0.05	2005:2012	P < 0.05	2005:2012	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	2	68	theme	mg/kg	716:720	arg1	IAPS					722:725	XOS + 600 mg/kg IAPS	706:725	XOS + 600 mg/kg IAPS	706:725	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	0	69	from	composition	165:175	arg1	response					107:114	the immune response	96:114	the immune response	96:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	6	70	theme	P	1390:1390	arg1	groups					1382:1387	other 4 groups	1374:1387	other 4 groups (P < 0.05)	1374:1398	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	6	70	theme	P	1390:1390	arg1	<					1392:1392	P < 0.05	1390:1397	P < 0.05	1390:1397	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	2	71	dep	chlortetracycline	623:639	arg1	IAPS					722:725	XOS + 600 mg/kg IAPS	706:725	XOS + 600 mg/kg IAPS	706:725	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	7	72	theme	IAPS	1459:1462	arg1	administration					1464:1477	dietary individual XOS or IAPS administration	1433:1477	administration	1464:1477	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	8	73	from	interaction	1561:1571	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	73	from	interaction	1561:1571	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	6	74	theme	other	1374:1378	arg1	groups					1382:1387	other 4 groups	1374:1387	other 4 groups (P < 0.05)	1374:1398	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	6	74	theme	other	1374:1378	arg1	<					1392:1392	P < 0.05	1390:1397	P < 0.05	1390:1397	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	11	75	from	effect	2313:2318	arg1	study					2356:2360	the current study	2344:2360	the current study	2344:2360	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	4	76	theme	P	1015:1015	arg1	activity					1005:1012	the serum lysozyme activity	986:1012	the serum lysozyme activity (P < 0.05)	986:1023	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	4	76	theme	P	1015:1015	arg1	<					1017:1017	P < 0.05	1015:1022	P < 0.05	1015:1022	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	0	77	theme	microbiota	154:163	arg1	composition					165:175	intestinal microbiota composition	143:175	intestinal microbiota composition of broilers	143:187	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	1	78	theme	broiler	429:435	arg1	chickens					437:444	broiler chickens	429:444	broiler chickens	429:444	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	7	79	theme	dietary	1433:1439	arg1	XOS					1452:1454	dietary individual XOS or IAPS administration	1433:1477	XOS	1452:1454	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	1	80	theme	immune	350:355	arg1	response					357:364	the immune response	346:364	the immune response	346:364	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	2	81	theme	basal	585:589	arg1	diet					591:594	the basal diet	581:594	the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively	581:751	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	0	82	from	capacity	129:136	arg1	response					107:114	the immune response	96:114	the immune response	96:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	2	83	theme	mg/kg	673:677	arg1	IAPS					679:682	600 mg/kg IAPS	669:682	600 mg/kg IAPS (IAPS)	669:689	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	83	theme	mg/kg	673:677	arg1	IAPS					685:688	IAPS	685:688	IAPS	685:688	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	5	84	theme	mucosal	1168:1174	arg1	expression					1195:1204	mucosal interleukin 2 mRNA expression	1168:1204	mucosal interleukin 2 mRNA expression	1168:1204	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	1	85	from	effects	249:255	arg1	response					357:364	the immune response	346:364	the immune response	346:364	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	1	85	from	effects	249:255	arg1	capacity					379:386	antioxidant capacity	367:386	antioxidant capacity	367:386	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	1	85	from	effects	249:255	arg1	composition					414:424	intestinal microbiota composition	392:424	intestinal microbiota composition	392:424	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	9	86	theme	P	1798:1798	arg1	Negativibacillus					1780:1795	Negativibacillus	1780:1795	Negativibacillus (P < 0.05)	1780:1806	Dietary CTC administration increased the proportion of Bacteroides, and decreased the proportion of Negativibacillus (P < 0.05).
35841635	9	86	theme	P	1798:1798	arg1	<					1800:1800	P < 0.05	1798:1805	P < 0.05	1798:1805	Dietary CTC administration increased the proportion of Bacteroides, and decreased the proportion of Negativibacillus (P < 0.05).
35841635	11	87	theme	barrier	2106:2112	arg1	function					2114:2121	barrier function	2106:2121	barrier function of broilers	2106:2133	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	6	88	from	birds	1274:1278	arg1	groups					1295:1300	the control groups	1283:1300	the control groups	1283:1300	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	3	89	theme	control	791:797	arg1	group					799:803	the control group	787:803	the control group	787:803	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	2	90	theme	dietary	523:529	arg1	treatments					531:540	5 dietary treatments	521:540	5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively	521:751	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	90	theme	dietary	523:529	arg1	diet					591:594	the basal diet	581:594	the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively	581:751	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	90	theme	dietary	523:529	arg1	diet					562:565	the basal diet	552:565	the basal diet (control)	552:575	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	5	91	theme	antioxidant	1134:1144	arg1	capacity					1146:1153	serum total antioxidant capacity	1122:1153	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	11	92	theme	IAPS	2043:2046	arg1	combination					2048:2058	the XOS and IAPS combination	2031:2058	the XOS and IAPS combination	2031:2058	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	0	93	theme	immune	100:105	arg1	response					107:114	the immune response	96:114	the immune response	96:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	11	94	theme	IAPS	2274:2277	arg1	better					2282:2287	better	2282:2287	better	2282:2287	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	94	theme	IAPS	2274:2277	arg1	effect					2256:2261	the combination effect	2240:2261	the combination effect of XOS and IAPS	2240:2277	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	95	theme	cell	2188:2191	arg1	production					2193:2202	IgA-producing cell production	2174:2202	IgA-producing cell production	2174:2202	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	8	96	theme	duodenal	1619:1626	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	96	theme	duodenal	1619:1626	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	2	97	theme	basal	556:560	arg1	control					568:574	control	568:574	control	568:574	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	2	97	theme	basal	556:560	arg1	diet					562:565	the basal diet	552:565	the basal diet (control)	552:575	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	11	98	theme	individual	2302:2311	arg1	effect					2313:2318	individual effect	2302:2318	individual effect of CTC, XOS, or IAPS in the current study	2302:2360	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	99	theme	mucosal	2085:2091	arg1	immunity					2093:2100	intestinal mucosal immunity	2074:2100	intestinal mucosal immunity	2074:2100	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	10	100	theme	XOS + IAPS	1826:1835	arg1	administration					1837:1850	dietary XOS + IAPS administration	1818:1850	dietary XOS + IAPS administration	1818:1850	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	1	101	theme	intestinal	392:401	arg1	composition					414:424	intestinal microbiota composition	392:424	intestinal microbiota composition	392:424	The present study investigated the individual and combined effects of xylo-oligosaccharides (XOS) and gamma-irradiated astragalus polysaccharides (IAPS) on the immune response, antioxidant capacity and intestinal microbiota composition of broiler chickens.
35841635	4	102	dep	XOS	948:950	arg1	treatments					961:970	treatments	961:970	treatments	961:970	Moreover, there was an interaction between XOS and IAPS treatments on increasing the serum lysozyme activity (P < 0.05).
35841635	10	103	theme	Bacteroidetes	1876:1888	arg1	ratio					1890:1894	Bacteroidetes ratio	1876:1894	Bacteroidetes ratio	1876:1894	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	10	103	theme	Bacteroidetes	1876:1888	arg1	proportion					1901:1910	the proportion	1897:1910	the proportion of Ruminococcaceae	1897:1929	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	11	104	theme	XOS	2035:2037	arg1	combination					2048:2058	the XOS and IAPS combination	2031:2058	the XOS and IAPS combination	2031:2058	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	11	105	theme	cecal	2218:2222	arg1	microbiota					2224:2233	cecal microbiota	2218:2233	cecal microbiota	2218:2233	In conclusion, the XOS and IAPS combination could improve intestinal mucosal immunity and barrier function of broilers by enhancing cytokine gene expression, IgA-producing cell production and modulates cecal microbiota, and the combination effect of XOS and IAPS is better than that of individual effect of CTC, XOS, or IAPS in the current study.
35841635	0	106	theme	combined	4:11	arg1	impact					13:18	The combined impact	0:18	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response	0:114	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	8	107	theme	cells	1654:1658	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	107	theme	cells	1654:1658	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	3	108	theme	serum	836:840	arg1	activity					851:858	serum lysozyme activity	836:858	serum lysozyme activity	836:858	The results showed that birds in the control group had lower the thymus index and serum lysozyme activity than those in the other 4 groups (P < 0.05).
35841635	2	109	theme	Ross	476:479	arg1	chicks					485:490	240 newly hatched Ross 308 chicks	458:490	240 newly hatched Ross 308 chicks	458:490	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	6	110	theme	control	1287:1293	arg1	groups					1295:1300	the control groups	1283:1300	the control groups	1283:1300	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	5	111	theme	XOS + IAPS	1047:1056	arg1	groups					1058:1063	the CTC and XOS + IAPS groups	1035:1063	groups	1058:1063	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	8	112	theme	jejunal	1632:1638	arg1	numbers					1660:1666	increasing duodenal and jejunal IgA-Producing cells numbers	1608:1666	increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05)	1608:1677	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	8	112	theme	jejunal	1632:1638	arg1	<					1671:1671	P < 0.05	1669:1676	P < 0.05	1669:1676	Meanwhile, there was an interaction between XOS and IAPS treatments on increasing duodenal and jejunal IgA-Producing cells numbers (P < 0.05).
35841635	7	113	theme	cells	1512:1516	arg1	number					1518:1523	duodenal IgA-producing cells number	1489:1523	duodenal IgA-producing cells number (P < 0.05)	1489:1534	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	7	113	theme	cells	1512:1516	arg1	<					1528:1528	P < 0.05	1526:1533	P < 0.05	1526:1533	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	5	114	theme	jejunum	1209:1215	arg1	activity					1155:1162	higher serum total antioxidant capacity activity	1115:1162	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	114	theme	jejunum	1209:1215	arg1	expression					1195:1204	mucosal interleukin 2 mRNA expression	1168:1204	mucosal interleukin 2 mRNA expression	1168:1204	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	114	theme	jejunum	1209:1215	arg1	concentration					1097:1109	lower serum malondialdehyde concentration	1069:1109	lower serum malondialdehyde concentration	1069:1109	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	7	115	theme	duodenal	1489:1496	arg1	cells					1512:1516	duodenal IgA-producing cells	1489:1516	duodenal IgA-producing cells number (P < 0.05)	1489:1534	As compared with the CTC group, dietary individual XOS or IAPS administration increased duodenal IgA-producing cells number (P < 0.05).
35841635	5	116	theme	serum	1122:1126	arg1	capacity					1146:1153	serum total antioxidant capacity	1122:1153	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	0	117	theme	astragalus	66:75	arg1	polysaccharides					77:91	gamma-irradiated astragalus polysaccharides	49:91	gamma-irradiated astragalus polysaccharides	49:91	The combined impact of xylo-oligosaccharides and gamma-irradiated astragalus polysaccharides on the immune response, antioxidant capacity, and intestinal microbiota composition of broilers.
35841635	6	118	dep	lower	1306:1310	arg1	number					1353:1358	duodenal and jejunal IgA-producing cells number	1312:1358	duodenal and jejunal IgA-producing cells number	1312:1358	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	2	119	theme	chicks	485:490	arg1	total					449:453	A total	447:453	A total of 240 newly hatched Ross 308 chicks	447:490	A total of 240 newly hatched Ross 308 chicks were randomly allocated into 5 dietary treatments including the basal diet (control), or the basal diet supplemented with 50 mg/kg chlortetracycline (CTC), 100 mg/kg XOS (XOS), 600 mg/kg IAPS (IAPS), and 100 mg/kg XOS + 600 mg/kg IAPS (XOS + IAPS) respectively.
35841635	5	120	theme	CTC	1039:1041	arg1	groups					1058:1063	the CTC and XOS + IAPS groups	1035:1063	groups	1058:1063	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	6	121	theme	cells	1347:1351	arg1	number					1353:1358	duodenal and jejunal IgA-producing cells number	1312:1358	duodenal and jejunal IgA-producing cells number	1312:1358	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	5	122	theme	higher	1115:1120	arg1	activity					1155:1162	higher serum total antioxidant capacity activity	1115:1162	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	10	123	theme	Ruminococcaceae	1915:1929	arg1	ratio					1890:1894	Bacteroidetes ratio	1876:1894	Bacteroidetes ratio	1876:1894	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	10	123	theme	Ruminococcaceae	1915:1929	arg1	proportion					1901:1910	the proportion	1897:1910	the proportion of Ruminococcaceae	1897:1929	However, dietary XOS + IAPS administration increased Firmicutes to Bacteroidetes ratio, the proportion of Ruminococcaceae, as well as decreased the proportion of Barnesiella and Negativibacillus (P < 0.05).
35841635	5	124	theme	P	1250:1250	arg1	group					1243:1247	the control group	1231:1247	the control group (P < 0.05)	1231:1258	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	5	124	theme	P	1250:1250	arg1	<					1252:1252	P < 0.05	1250:1257	P < 0.05	1250:1257	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35841635	6	125	theme	jejunal	1325:1331	arg1	cells					1347:1351	duodenal and jejunal IgA-producing cells	1312:1351	duodenal and jejunal IgA-producing cells number	1312:1358	In addition, birds in the control groups had lower duodenal and jejunal IgA-producing cells number than these in other 4 groups (P < 0.05).
35841635	5	126	theme	total	1128:1132	arg1	capacity					1146:1153	serum total antioxidant capacity	1122:1153	higher serum total antioxidant capacity activity	1115:1162	Birds in the CTC and XOS + IAPS groups had lower serum malondialdehyde concentration and higher serum total antioxidant capacity activity and mucosal interleukin 2 mRNA expression of jejunum than those in the control group (P < 0.05).
35484857	9	0	theme	protective	1734:1743	arg1	effect					1745:1750	the protective effect	1730:1750	the protective effect of HPS on ALI	1730:1764	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	12	1	theme	functional	2158:2167	arg1	food					2169:2172	a functional food	2156:2172	a functional food	2156:2172	Second, this work also complements the pharmacological activity of Radix Hedysari and provides a basis for the development of Radix Hedysari as a functional food.
35484857	12	1	theme	functional	2158:2167	arg1	basis					2109:2113	a basis	2107:2113	a basis for the development of Radix Hedysari	2107:2151	Second, this work also complements the pharmacological activity of Radix Hedysari and provides a basis for the development of Radix Hedysari as a functional food.
35484857	12	2	theme	Hedysari	2144:2151	arg1	development					2123:2133	the development	2119:2133	the development of Radix Hedysari	2119:2151	Second, this work also complements the pharmacological activity of Radix Hedysari and provides a basis for the development of Radix Hedysari as a functional food.
35484857	6	3	dep	%	1187:1187	arg1	to					1180:1181	to	1180:1181	to	1180:1181	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	7	4	theme	chain	1349:1353	arg1	conformation					1355:1366	chain conformation	1349:1366	chain conformation	1349:1366	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	9	5	from	effect	1745:1750	arg1	ALI					1762:1764	ALI	1762:1764	ALI	1762:1764	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	3	6	theme	in	532:533	arg1	results					540:546	The in vivo results	528:546	The in vivo results	528:546	The in vivo results showed that compared with HPS-80, HPS-50 showed stronger hepatoprotection, which improved histopathological changes to normal levels.
35484857	4	7	theme	GSH	793:795	arg1	activities					765:774	the activities	761:774	the activities of SOD, CAT, and GSH	761:795	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	7	8	theme	HPS-50-P	1283:1290	arg1	structure					1270:1278	the structure	1266:1278	the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology	1266:1390	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	6	9	theme	%	1178:1178	arg1	%					1187:1187	54.8% to 94.7%	1174:1187	54.8% to 94.7%	1174:1187	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	6	10	dep	phase	1208:1212	arg1	cells					1214:1218	cells	1214:1218	the S phase cells	1202:1218	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	6	11	theme	59.40	1225:1229	arg1	%					1230:1230	%	1230:1230	%	1230:1230	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	2	12	theme	HPS	297:299	arg1	effects					286:292	the effects	282:292	the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells	282:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	12	theme	HPS	297:299	arg1	relationship					447:458	the relationship	443:458	the relationship between structural characteristics and hepatoprotective activities	443:525	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	7	13	theme	highest	1498:1504	arg1	weight					1516:1521	highest molecular weight	1498:1521	highest molecular weight	1498:1521	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	6	14	theme	cells	1163:1167	arg1	percentage					1142:1151	the percentage	1138:1151	the percentage of normal cells	1138:1167	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	5	15	theme	significant	991:1001	arg1	roles					1014:1018	significant protective roles	991:1018	significant protective roles against LPS-induced injury in LO2 cells	991:1058	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	5	16	from	roles	1014:1018	arg1	cells					1054:1058	LO2 cells	1050:1058	LO2 cells	1050:1058	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	1	17	theme	pharmacological	205:219	arg1	activities					221:230	great pharmacological activities	199:230	great pharmacological activities in our previous research	199:255	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	6	18	dep	%	1230:1230	arg1	to					1232:1233	to	1232:1233	to	1232:1233	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	4	19	theme	TNF-α	852:856	arg1	production					838:847	the LPS/D-GalN-triggered production	813:847	the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05)	813:883	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	2	20	from	relationship	447:458	arg1	ALI					382:384	ALI	382:384	ALI	382:384	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	20	from	relationship	447:458	arg1	injury					374:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury	304:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice	304:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	20	from	relationship	447:458	arg1	injury					411:416	LPS-induced injury	399:416	LPS-induced injury in LO2 cells	399:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	6	21	theme	S	1206:1206	arg1	phase					1208:1212	the S phase cells	1202:1218	the S phase cells	1202:1218	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	8	22	theme	functional	1632:1641	arg1	foods					1643:1647	functional foods	1632:1647	functional foods	1632:1647	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	4	23	theme	IL-1β	859:863	arg1	production					838:847	the LPS/D-GalN-triggered production	813:847	the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05)	813:883	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	4	24	theme	ALT	727:729	arg1	levels					717:722	the levels	713:722	the levels of ALT, AST, MPO, and MDA	713:748	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	3	25	dep	in	532:533	arg1	vivo					535:538	vivo	535:538	vivo	535:538	The in vivo results showed that compared with HPS-80, HPS-50 showed stronger hepatoprotection, which improved histopathological changes to normal levels.
35484857	12	26	theme	Hedysari	2085:2092	arg1	activity					2067:2074	the pharmacological activity	2047:2074	the pharmacological activity of Radix Hedysari	2047:2092	Second, this work also complements the pharmacological activity of Radix Hedysari and provides a basis for the development of Radix Hedysari as a functional food.
35484857	9	27	theme	potential	1839:1847	arg1	HPS-50-2					1812:1819	HPS-50-2	1812:1819	HPS-50-2	1812:1819	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	9	27	theme	potential	1839:1847	arg1	ingredient					1856:1865	a potential active ingredient	1837:1865	a potential active ingredient	1837:1865	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	10	28	theme	practical	1887:1895	arg1	applications					1897:1908	two practical applications	1883:1908	two practical applications	1883:1908	This study has two practical applications.
35484857	2	29	theme	hepatoprotective	499:514	arg1	activities					516:525	hepatoprotective activities	499:525	hepatoprotective activities	499:525	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	8	30	theme	ALI	1686:1688	arg1	prevention					1672:1681	prevention	1672:1681	prevention	1672:1681	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	8	30	theme	ALI	1686:1688	arg1	protection					1657:1666	protection	1657:1666	protection	1657:1666	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	7	31	theme	protective	1421:1430	arg1	effect					1432:1437	the best protective effect	1412:1437	the best protective effect of HPS-50-2	1412:1449	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	12	32	theme	pharmacological	2051:2065	arg1	activity					2067:2074	the pharmacological activity	2047:2074	the pharmacological activity of Radix Hedysari	2047:2092	Second, this work also complements the pharmacological activity of Radix Hedysari and provides a basis for the development of Radix Hedysari as a functional food.
35484857	5	33	theme	LPS-induced	1028:1038	arg1	injury					1040:1045	LPS-induced injury	1028:1045	LPS-induced injury	1028:1045	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	2	34	theme	LO2	421:423	arg1	cells					425:429	LO2 cells	421:429	LO2 cells	421:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	10	35	contain	has	1879:1881	arg2	applications					1897:1908	two practical applications	1883:1908	two practical applications	1883:1908	This study has two practical applications.
35484857	10	35	contain	has	1879:1881	arg1	study					1873:1877	This study	1868:1877	This study	1868:1877	This study has two practical applications.
35484857	4	36	theme	AST	732:734	arg1	levels					717:722	the levels	713:722	the levels of ALT, AST, MPO, and MDA	713:748	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	0	37	theme	Hepatoprotective	0:15	arg1	effect					17:22	Hepatoprotective effect	0:22	Hepatoprotective effect	0:22	Hepatoprotective effect and structural analysis of Hedysarum polysaccharides in vivo and in vitro.
35484857	7	38	theme	high	1528:1531	arg1	glucose					1533:1539	high glucose	1528:1539	high glucose	1528:1539	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	4	39	theme	MPO	737:739	arg1	levels					717:722	the levels	713:722	the levels of ALT, AST, MPO, and MDA	713:748	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	5	40	theme	cycle	1106:1110	arg1	arrest					1112:1117	cell cycle arrest	1101:1117	cell cycle arrest	1101:1117	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	1	41	theme	crude	103:107	arg1	polysaccharides					119:133	The crude Hedysarum polysaccharides	99:133	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari	99:187	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	3	42	theme	histopathological	638:654	arg1	changes					656:662	histopathological changes	638:662	histopathological changes to normal levels	638:679	The in vivo results showed that compared with HPS-80, HPS-50 showed stronger hepatoprotection, which improved histopathological changes to normal levels.
35484857	2	43	from	injury	374:379	arg1	mice					390:393	mice	390:393	mice	390:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	43	from	injury	374:379	arg1	cells					425:429	LO2 cells	421:429	LO2 cells	421:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	0	44	theme	Hedysarum	51:59	arg1	polysaccharides					61:75	Hedysarum polysaccharides	51:75	Hedysarum polysaccharides	51:75	Hepatoprotective effect and structural analysis of Hedysarum polysaccharides in vivo and in vitro.
35484857	8	45	dep	protection	1657:1666	arg1	the					1653:1655	the	1653:1655	the	1653:1655	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	2	46	theme	acute	362:366	arg1	ALI					382:384	ALI	382:384	ALI	382:384	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	46	theme	acute	362:366	arg1	injury					374:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury	304:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice	304:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	7	47	theme	molecular	1331:1339	arg1	weight					1341:1346	molecular weight	1331:1346	molecular weight	1331:1346	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	4	48	theme	LPS/D-GalN-triggered	817:836	arg1	production					838:847	the LPS/D-GalN-triggered production	813:847	the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05)	813:883	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	7	49	theme	monosaccharide	1303:1316	arg1	composition					1318:1328	monosaccharide composition	1303:1328	monosaccharide composition	1303:1328	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	9	50	theme	HPS	1755:1757	arg1	effect					1745:1750	the protective effect	1730:1750	the protective effect of HPS on ALI	1730:1764	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	9	51	dep	APPLICATIONS	1701:1712	arg1	screened					1825:1832	screened	1825:1832	was screened as a potential active ingredient	1821:1865	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	9	51	dep	APPLICATIONS	1701:1712	arg1	evaluated					1770:1778	evaluated	1770:1778	was evaluated from multiple perspectives	1766:1805	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	11	52	theme	new	1962:1964	arg1	option					1966:1971	a new option	1960:1971	a new option for patients	1960:1984	First, it provides a new way to improve ALI, and a new option for patients to prevent and treat ALI.
35484857	11	53	dep	way	1936:1938	arg1	improve					1943:1949	improve	1943:1949	to improve ALI	1940:1953	First, it provides a new way to improve ALI, and a new option for patients to prevent and treat ALI.
35484857	11	53	dep	way	1936:1938	arg1	prevent					1989:1995	prevent	1989:1995	prevent	1989:1995	First, it provides a new way to improve ALI, and a new option for patients to prevent and treat ALI.
35484857	7	54	theme	molecular	1506:1514	arg1	weight					1516:1521	highest molecular weight	1498:1521	highest molecular weight	1498:1521	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	9	55	theme	multiple	1785:1792	arg1	perspectives					1794:1805	multiple perspectives	1785:1805	multiple perspectives	1785:1805	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	1	56	theme	great	199:203	arg1	activities					221:230	great pharmacological activities	199:230	great pharmacological activities in our previous research	199:255	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	7	57	theme	beta	1478:1481	arg1	configuration					1483:1495	its beta configuration	1474:1495	its beta configuration	1474:1495	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	4	58	theme	IL-6	870:873	arg1	production					838:847	the LPS/D-GalN-triggered production	813:847	the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05)	813:883	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	6	59	theme	normal	1156:1161	arg1	cells					1163:1167	normal cells	1156:1167	normal cells	1156:1167	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	5	60	dep	HPS-50-P	919:926	arg1	HPS-50-2					939:946	HPS-50-2	939:946	HPS-50-2	939:946	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	5	60	dep	HPS-50-P	919:926	arg1	HPS-50-3					953:960	HPS-50-3	953:960	HPS-50-3	953:960	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	5	60	dep	HPS-50-P	919:926	arg1	HPS-50-1					929:936	HPS-50-1	929:936	HPS-50-1	929:936	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	5	61	theme	protective	1003:1012	arg1	roles					1014:1018	significant protective roles	991:1018	significant protective roles against LPS-induced injury in LO2 cells	991:1058	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	8	62	theme	promising	1612:1620	arg1	source					1622:1627	a promising source	1610:1627	a promising source of functional foods for the protection and prevention of ALI	1610:1688	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	8	62	theme	promising	1612:1620	arg1	HPS-50					1594:1599	HPS-50	1594:1599	HPS-50	1594:1599	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	1	63	theme	Hedysarum	109:117	arg1	polysaccharides					119:133	The crude Hedysarum polysaccharides	99:133	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari	99:187	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	11	64	theme	new	1932:1934	arg1	way					1936:1938	a new way	1930:1938	a new way to improve ALI, and a new option for patients to prevent and treat ALI	1930:2009	First, it provides a new way to improve ALI, and a new option for patients to prevent and treat ALI.
35484857	1	65	from	activities	221:230	arg1	research					248:255	our previous research	235:255	our previous research	235:255	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	3	66	theme	stronger	596:603	arg1	hepatoprotection					605:620	stronger hepatoprotection	596:620	stronger hepatoprotection	596:620	The in vivo results showed that compared with HPS-80, HPS-50 showed stronger hepatoprotection, which improved histopathological changes to normal levels.
35484857	8	67	theme	foods	1643:1647	arg1	source					1622:1627	a promising source	1610:1627	a promising source of functional foods for the protection and prevention of ALI	1610:1688	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	8	67	theme	foods	1643:1647	arg1	HPS-50					1594:1599	HPS-50	1594:1599	HPS-50	1594:1599	These findings indicate that HPS-50 might be a promising source of functional foods for the protection and prevention of ALI.
35484857	2	68	from	effects	286:292	arg1	ALI					382:384	ALI	382:384	ALI	382:384	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	68	from	effects	286:292	arg1	injury					374:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury	304:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice	304:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	68	from	effects	286:292	arg1	injury					411:416	LPS-induced injury	399:416	LPS-induced injury in LO2 cells	399:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	7	69	theme	HPS-50-2	1442:1449	arg1	effect					1432:1437	the best protective effect	1412:1437	the best protective effect of HPS-50-2	1412:1449	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	2	70	from	injury	411:416	arg1	mice					390:393	mice	390:393	mice	390:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	70	from	injury	411:416	arg1	cells					425:429	LO2 cells	421:429	LO2 cells	421:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	5	71	theme	LO2	1050:1052	arg1	cells					1054:1058	LO2 cells	1050:1058	LO2 cells	1050:1058	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	9	72	theme	active	1849:1854	arg1	HPS-50-2					1812:1819	HPS-50-2	1812:1819	HPS-50-2	1812:1819	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	9	72	theme	active	1849:1854	arg1	ingredient					1856:1865	a potential active ingredient	1837:1865	a potential active ingredient	1837:1865	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	7	73	theme	best	1416:1419	arg1	effect					1432:1437	the best protective effect	1412:1437	the best protective effect of HPS-50-2	1412:1449	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	1	74	dep	HPS	136:138	arg1	HPS-50					141:146	HPS-50	141:146	HPS-50	141:146	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	1	74	dep	HPS	136:138	arg1	HPS-80					152:157	HPS-80	152:157	HPS-80	152:157	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	6	75	theme	47.05	1235:1239	arg1	%					1230:1230	%	1230:1230	%	1230:1230	HPS-50-2 restored the percentage of normal cells from 54.8% to 94.7%, and reduced the S phase cells from 59.40% to 47.05% (p < .01).
35484857	2	76	theme	structural	468:477	arg1	characteristics					479:493	structural characteristics	468:493	structural characteristics	468:493	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	1	77	dep	polysaccharides	119:133	arg1	HPS					136:138	HPS	136:138	HPS: HPS-50 and HPS-80	136:157	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35484857	7	78	theme	galactose	1545:1553	arg1	contents					1555:1562	high glucose and galactose contents	1528:1562	high glucose and galactose contents	1528:1562	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	2	79	theme	liver	368:372	arg1	ALI					382:384	ALI	382:384	ALI	382:384	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	79	theme	liver	368:372	arg1	injury					374:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury	304:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice	304:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	0	80	theme	structural	28:37	arg1	analysis					39:46	structural analysis	28:46	structural analysis of Hedysarum polysaccharides in vivo and in vitro	28:96	Hepatoprotective effect and structural analysis of Hedysarum polysaccharides in vivo and in vitro.
35484857	5	81	theme	cell	1101:1104	arg1	arrest					1112:1117	cell cycle arrest	1101:1117	cell cycle arrest	1101:1117	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	7	82	theme	glucose	1533:1539	arg1	contents					1555:1562	high glucose and galactose contents	1528:1562	high glucose and galactose contents	1528:1562	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	2	83	theme	LPS-induced	399:409	arg1	injury					411:416	LPS-induced injury	399:416	LPS-induced injury in LO2 cells	399:429	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	9	84	theme	PRACTICAL	1691:1699	arg1	APPLICATIONS					1701:1712	PRACTICAL APPLICATIONS	1691:1712	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.	1691:1866	PRACTICAL APPLICATIONS: In this study, the protective effect of HPS on ALI was evaluated from multiple perspectives, and HPS-50-2 was screened as a potential active ingredient.
35484857	4	85	theme	SOD	779:781	arg1	activities					765:774	the activities	761:774	the activities of SOD, CAT, and GSH	761:795	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	0	86	theme	polysaccharides	61:75	arg1	effect					17:22	Hepatoprotective effect	0:22	Hepatoprotective effect	0:22	Hepatoprotective effect and structural analysis of Hedysarum polysaccharides in vivo and in vitro.
35484857	0	86	theme	polysaccharides	61:75	arg1	analysis					39:46	structural analysis	28:46	structural analysis of Hedysarum polysaccharides in vivo and in vitro	28:96	Hepatoprotective effect and structural analysis of Hedysarum polysaccharides in vivo and in vitro.
35484857	5	87	theme	cell	1072:1075	arg1	apoptosis					1077:1085	cell apoptosis	1072:1085	cell apoptosis	1072:1085	The results in vitro showed that HPS-50-P (HPS-50-1, HPS-50-2, and HPS-50-3) purified from HPS-50 played significant protective roles against LPS-induced injury in LO2 cells by reducing cell apoptosis and relieving cell cycle arrest.
35484857	3	88	theme	normal	667:672	arg1	levels					674:679	normal levels	667:679	normal levels	667:679	The in vivo results showed that compared with HPS-80, HPS-50 showed stronger hepatoprotection, which improved histopathological changes to normal levels.
35484857	4	89	theme	CAT	784:786	arg1	activities					765:774	the activities	761:774	the activities of SOD, CAT, and GSH	761:795	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	4	90	theme	MDA	746:748	arg1	levels					717:722	the levels	713:722	the levels of ALT, AST, MPO, and MDA	713:748	HPS-50 significantly decreased the levels of ALT, AST, MPO, and MDA, increased the activities of SOD, CAT, and GSH, and suppressed the LPS/D-GalN-triggered production of TNF-α, IL-1β, and IL-6 (p < .05).
35484857	7	91	theme	surface	1373:1379	arg1	morphology					1381:1390	surface morphology	1373:1390	surface morphology	1373:1390	By analyzing the structure of HPS-50-P, including monosaccharide composition, molecular weight, chain conformation, and surface morphology, we speculated that the best protective effect of HPS-50-2 might be attributed to its beta configuration, highest molecular weight, and high glucose and galactose contents.
35484857	2	92	theme	-induced	353:360	arg1	ALI					382:384	ALI	382:384	ALI	382:384	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	2	92	theme	-induced	353:360	arg1	injury					374:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury	304:379	lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice	304:393	This study investigated the effects of HPS on lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver injury (ALI) in mice and LPS-induced injury in LO2 cells, as well as the relationship between structural characteristics and hepatoprotective activities.
35484857	1	93	theme	previous	239:246	arg1	research					248:255	our previous research	235:255	our previous research	235:255	The crude Hedysarum polysaccharides (HPS: HPS-50 and HPS-80) obtained from Radix Hedysari exhibited great pharmacological activities in our previous research.
35439332	4	0	theme	molecules	909:917	arg1	design					824:829	design	824:829	design	824:829	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	4	0	theme	molecules	909:917	arg1	synthesis					841:849	chemical synthesis	832:849	chemical synthesis	832:849	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	4	0	theme	molecules	909:917	arg1	immunobiology					855:867	immunobiology	855:867	immunobiology	855:867	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	8	1	theme	unnatural	1710:1718	arg1	β					1720:1720	unnatural β	1710:1720	unnatural β	1710:1720	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	1	2	theme	downstream	258:267	arg1	pathways					279:286	the downstream signaling pathways	254:286	the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense	254:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	7	3	theme	multiple	1554:1561	arg1	residues					1593:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	6	4	theme	challenging	1306:1316	arg1	β					1318:1318	a challenging β	1304:1318	a challenging β	1304:1318	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	7	5	theme	glycolipids	1532:1542	arg1	synthesis					1481:1489	Divergent streamlined synthesis	1459:1489	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups	1459:1634	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	4	6	theme	novel	872:876	arg1	molecules					909:917	novel glycan-based lipid A-mimicking molecules	872:917	novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity	872:1000	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	7	7	theme	streamlined	1469:1479	arg1	synthesis					1481:1489	Divergent streamlined synthesis	1459:1489	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups	1459:1634	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	7	8	link	β-1,1'-linked	1496:1508	arg1	glycolipids					1532:1542	β-1,1'-linked diglucosamine-derived glycolipids	1496:1542	β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues	1496:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	3	9	theme	activating	745:754	arg1	biomolecules					756:767	novel TLR4 activating biomolecules	734:767	novel TLR4 activating biomolecules other than lipid A	734:786	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	6	10	from	stereoselectivity	1283:1299	arg1	β					1318:1318	a challenging β	1304:1318	a challenging β	1304:1318	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	8	11	theme	efficient	1830:1838	arg1	induction					1840:1848	efficient induction	1830:1848	efficient induction of the TLR4-mediated signaling	1830:1879	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	7	12	theme	β-1,1'-linked	1496:1508	arg1	glycolipids					1532:1542	β-1,1'-linked diglucosamine-derived glycolipids	1496:1542	β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues	1496:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	4	13	theme	lipid	891:895	arg1	molecules					909:917	novel glycan-based lipid A-mimicking molecules	872:917	novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity	872:1000	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	6	14	theme	Excellent	1273:1281	arg1	stereoselectivity					1283:1299	Excellent stereoselectivity	1273:1299	Excellent stereoselectivity in a challenging β	1273:1318	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	5	15	dep	created	1055:1061	arg1	Exploiting					1003:1012	Exploiting	1003:1012	Exploiting crystal structure - based design	1003:1045	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	3	16	theme	lipid	780:784	arg1	A					786:786	lipid A	780:786	novel TLR4 activating biomolecules other than lipid A	734:786	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	1	17	theme	protective	402:411	arg1	responses					430:438	protective pro-inflammatory responses	402:438	protective pro-inflammatory responses involved in immune defense	402:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	8	18	theme	TLR4-mediated	1857:1869	arg1	signaling					1871:1879	the TLR4-mediated signaling	1853:1879	the TLR4-mediated signaling	1853:1879	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	4	19	theme	picomolar	983:991	arg1	affinity					993:1000	picomolar affinity	983:1000	picomolar affinity	983:1000	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	5	20	theme	flexible	1128:1135	arg1	backbone					1165:1172	the inherently flexible β(1→6)-linked diglucosamine backbone	1113:1172	the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A	1113:1183	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	1	21	theme	associated	212:221	arg1	patterns					233:240	danger- associated molecular patterns	204:240	danger- associated molecular patterns	204:240	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	4	22	theme	human	937:941	arg1	signaling					968:976	human and murine TLR4-mediated signaling	937:976	human and murine TLR4-mediated signaling	937:976	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	3	23	theme	vast	794:797	arg1	importance					799:808	vast importance	794:808	vast importance	794:808	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	3	24	theme	TLR4	643:646	arg1	tool					663:666	an emerging tool	651:666	an emerging tool for management of a variety of human diseases	651:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	3	24	theme	TLR4	643:646	arg1	targeting					630:638	therapeutic targeting	618:638	therapeutic targeting of TLR4	618:646	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	8	25	theme	species-independent	1886:1904	arg1	manner					1906:1911	a species-independent manner	1884:1911	a species-independent manner	1884:1911	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	4	26	theme	murine	947:952	arg1	signaling					968:976	human and murine TLR4-mediated signaling	937:976	human and murine TLR4-mediated signaling	937:976	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	6	27	theme	protective	1419:1428	arg1	strategy					1449:1456	protective group manipulation strategy	1419:1456	protective group manipulation strategy	1419:1456	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	5	28	theme	diglucosamine	1151:1163	arg1	backbone					1165:1172	the inherently flexible β(1→6)-linked diglucosamine backbone	1113:1172	the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A	1113:1183	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	2	29	with	ligand	506:511	arg1	relationships					592:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	1	30	theme	key	142:144	arg1	TLR4					132:135	TLR4	132:135	TLR4	132:135	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	30	theme	key	142:144	arg1	receptor					166:173	a key pattern recognition receptor	140:173	a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense	140:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	0	31	theme	TLR4	68:71	arg1	Agonists					73:80	Potent TLR4 Agonists	61:80	Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants	61:129	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	1	32	theme	recognition	154:164	arg1	TLR4					132:135	TLR4	132:135	TLR4	132:135	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	32	theme	recognition	154:164	arg1	receptor					166:173	a key pattern recognition receptor	140:173	a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense	140:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	8	33	link	β-1,1'-linked	1722:1734	arg1	diglucosamine					1736:1748	β-1,1'-linked diglucosamine	1722:1748	β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation	1722:1798	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	7	34	theme	phosphate	1619:1627	arg1	groups					1629:1634	up two three phosphate groups	1606:1634	up two three phosphate groups	1606:1634	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	0	35	theme	Potent	61:66	arg1	Agonists					73:80	Potent TLR4 Agonists	61:80	Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants	61:129	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	0	36	theme	Lipid	0:4	arg1	A					6:6	Lipid A	0:6	Lipid A Mimetics	0:15	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	2	37	theme	lipid	478:482	arg1	A					484:484	Bacterial lipid A	468:484	Bacterial lipid A	468:484	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	2	37	theme	lipid	478:482	arg1	ligand					506:511	the primary TLR4 ligand	489:511	the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships	489:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	6	38	theme	molecules	1403:1411	arg1	reactivities					1368:1379	the reactivities	1364:1379	the reactivities of donor and acceptor molecules using protective group manipulation strategy	1364:1456	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	5	39	theme	restrained	1222:1231	arg1	scaffold					1263:1270	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	5	40	theme	crystal	1014:1020	arg1	structure					1022:1030	crystal structure	1014:1030	crystal structure	1014:1030	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	5	41	theme	A	1183:1183	arg1	backbone					1165:1172	the inherently flexible β(1→6)-linked diglucosamine backbone	1113:1172	the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A	1113:1183	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	5	42	theme	lipid	1082:1086	arg1	A					1088:1088	novel disaccharide lipid A	1063:1088	novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1063:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	2	43	theme	primary	493:499	arg1	A					484:484	Bacterial lipid A	468:484	Bacterial lipid A	468:484	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	2	43	theme	primary	493:499	arg1	ligand					506:511	the primary TLR4 ligand	489:511	the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships	489:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	0	44	theme	Disaccharide	36:47	arg1	Scaffold					49:56	Unnatural Disaccharide Scaffold	26:56	Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants	26:129	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	3	45	dep	other	769:773	arg1	than					775:778	than	775:778	than	775:778	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	7	46	theme	-3-	1577:1579	arg1	residues					1593:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	8	47	theme	Specific	1651:1658	arg1	shape					1673:1677	Specific 3D-molecular shape	1651:1677	Specific 3D-molecular shape	1651:1677	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	8	48	theme	β-1,1'-linked	1722:1734	arg1	diglucosamine					1736:1748	β-1,1'-linked diglucosamine	1722:1748	β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation	1722:1798	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	1	49	theme	molecular	223:231	arg1	patterns					233:240	danger- associated molecular patterns	204:240	danger- associated molecular patterns	204:240	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	7	50	theme	R	1575:1575	arg1	residues					1593:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	3	51	theme	diseases	705:712	arg1	variety					688:694	a variety	686:694	a variety of human diseases	686:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	3	51	theme	diseases	705:712	arg1	diseases					705:712	human diseases	699:712	human diseases	699:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	7	52	theme	long-chain	1563:1572	arg1	residues					1593:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	5	53	theme	novel	1063:1067	arg1	A					1088:1088	novel disaccharide lipid A	1063:1088	novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1063:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	8	54	theme	conformational	1683:1696	arg1	rigidity					1698:1705	conformational rigidity	1683:1705	conformational rigidity	1683:1705	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	3	55	theme	TLR4	740:743	arg1	biomolecules					756:767	novel TLR4 activating biomolecules	734:767	novel TLR4 activating biomolecules other than lipid A	734:786	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	5	56	theme	βGlcN	1246:1250	arg1	scaffold					1263:1270	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	4	57	theme	A-mimicking	897:907	arg1	molecules					909:917	novel glycan-based lipid A-mimicking molecules	872:917	novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity	872:1000	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	1	58	theme	signaling	269:277	arg1	pathways					279:286	the downstream signaling pathways	254:286	the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense	254:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	7	59	theme	diglucosamine-derived	1510:1530	arg1	glycolipids					1532:1542	β-1,1'-linked diglucosamine-derived glycolipids	1496:1542	β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues	1496:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	7	60	theme	β	1494:1494	arg1	synthesis					1481:1489	Divergent streamlined synthesis	1459:1489	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups	1459:1634	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	8	61	theme	β	1720:1720	arg1	shape					1673:1677	Specific 3D-molecular shape	1651:1677	Specific 3D-molecular shape	1651:1677	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	8	61	theme	β	1720:1720	arg1	rigidity					1698:1705	conformational rigidity	1683:1705	conformational rigidity	1683:1705	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	8	61	theme	β	1720:1720	arg1	diglucosamine					1736:1748	β-1,1'-linked diglucosamine	1722:1748	β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation	1722:1798	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	8	61	theme	β	1720:1720	arg1	pattern					1814:1820	acylation pattern	1804:1820	acylation pattern	1804:1820	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	8	62	theme	acylation	1804:1812	arg1	pattern					1814:1820	acylation pattern	1804:1820	acylation pattern	1804:1820	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	6	63	theme	manipulation	1436:1447	arg1	strategy					1449:1456	protective group manipulation strategy	1419:1456	protective group manipulation strategy	1419:1456	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	7	64	link	diglucosamine-derived	1510:1530	arg1	glycolipids					1532:1542	β-1,1'-linked diglucosamine-derived glycolipids	1496:1542	β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues	1496:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	1	65	theme	transcription	325:337	arg1	factors					339:345	transcription factors	325:345	transcription factors	325:345	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	3	66	theme	biomolecules	756:767	arg1	development					719:729	the development	715:729	the development of novel TLR4 activating biomolecules other than lipid A	715:786	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	3	67	theme	therapeutic	618:628	arg1	tool					663:666	an emerging tool	651:666	an emerging tool for management of a variety of human diseases	651:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	3	67	theme	therapeutic	618:628	arg1	targeting					630:638	therapeutic targeting	618:638	therapeutic targeting of TLR4	618:646	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	4	68	theme	glycan-based	878:889	arg1	molecules					909:917	novel glycan-based lipid A-mimicking molecules	872:917	novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity	872:1000	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	7	69	theme	Divergent	1459:1467	arg1	synthesis					1481:1489	Divergent streamlined synthesis	1459:1489	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups	1459:1634	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	4	70	theme	TLR4-mediated	954:966	arg1	signaling					968:976	human and murine TLR4-mediated signaling	937:976	human and murine TLR4-mediated signaling	937:976	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	3	71	theme	A	786:786	arg1	development					719:729	the development	715:729	the development of novel TLR4 activating biomolecules other than lipid A	715:786	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	1	72	theme	pro-inflammatory	413:428	arg1	responses					430:438	protective pro-inflammatory responses	402:438	protective pro-inflammatory responses involved in immune defense	402:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	73	theme	danger-	204:210	arg1	patterns					233:240	danger- associated molecular patterns	204:240	danger- associated molecular patterns	204:240	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	2	74	theme	predictable	561:571	arg1	relationships					592:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	6	75	theme	acceptor	1394:1401	arg1	molecules					1403:1411	donor and acceptor molecules	1384:1411	donor and acceptor molecules using protective group manipulation strategy	1384:1456	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	8	76	theme	signaling	1871:1879	arg1	induction					1840:1848	efficient induction	1830:1848	efficient induction of the TLR4-mediated signaling	1830:1879	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	5	77	theme	lipid	1177:1181	arg1	A					1183:1183	lipid A	1177:1183	lipid A	1177:1183	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	1	78	theme	immune	452:457	arg1	defense					459:465	immune defense	452:465	immune defense	452:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	6	79	theme	group	1430:1434	arg1	strategy					1449:1456	protective group manipulation strategy	1419:1456	protective group manipulation strategy	1419:1456	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	3	80	theme	emerging	654:661	arg1	tool					663:666	an emerging tool	651:666	an emerging tool for management of a variety of human diseases	651:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	3	80	theme	emerging	654:661	arg1	targeting					630:638	therapeutic targeting	618:638	therapeutic targeting of TLR4	618:646	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	2	81	theme	complex	523:529	arg1	relationships					592:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	1	82	theme	pattern	146:152	arg1	TLR4					132:135	TLR4	132:135	TLR4	132:135	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	82	theme	pattern	146:152	arg1	receptor					166:173	a key pattern recognition receptor	140:173	a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense	140:465	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	7	83	theme	groups	1629:1634	arg1	synthesis					1481:1489	Divergent streamlined synthesis	1459:1489	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups	1459:1634	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	0	84	theme	Prospective	86:96	arg1	Immunotherapeutics					98:115	Prospective Immunotherapeutics	86:115	Prospective Immunotherapeutics	86:115	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	1	85	theme	interferons	365:375	arg1	expression					351:360	expression	351:360	expression of interferons and cytokines	351:389	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	85	theme	interferons	365:375	arg1	upregulation					309:320	the upregulation	305:320	the upregulation of transcription factors	305:345	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	6	86	theme	donor	1384:1388	arg1	molecules					1403:1411	donor and acceptor molecules	1384:1411	donor and acceptor molecules using protective group manipulation strategy	1384:1456	Excellent stereoselectivity in a challenging β,β-1,1' glycosylation was achieved by tuning the reactivities of donor and acceptor molecules using protective group manipulation strategy.
35439332	1	87	theme	cytokines	381:389	arg1	expression					351:360	expression	351:360	expression of interferons and cytokines	351:389	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	87	theme	cytokines	381:389	arg1	upregulation					309:320	the upregulation	305:320	the upregulation of transcription factors	305:345	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	5	88	theme	based	1034:1038	arg1	design					1040:1045	based design	1034:1045	based design	1034:1045	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	2	89	theme	species-specific	532:547	arg1	relationships					592:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	0	90	theme	A	6:6	arg1	Mimetics					8:15	Lipid A Mimetics	0:15	Lipid A Mimetics	0:15	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	2	91	theme	structure-activity	573:590	arg1	relationships					592:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	very complex, species-specific, and barely predictable structure-activity relationships	518:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	2	92	theme	Bacterial	468:476	arg1	A					484:484	Bacterial lipid A	468:484	Bacterial lipid A	468:484	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	2	92	theme	Bacterial	468:476	arg1	ligand					506:511	the primary TLR4 ligand	489:511	the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships	489:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	3	93	theme	variety	688:694	arg1	management					672:681	management	672:681	management of a variety of human diseases	672:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	0	94	theme	Unnatural	26:34	arg1	Scaffold					49:56	Unnatural Disaccharide Scaffold	26:56	Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants	26:129	Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
35439332	5	95	theme	non-reducing	1233:1244	arg1	1↔1					1252:1254	1↔1'	1252:1255	1↔1'	1252:1255	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	5	95	theme	non-reducing	1233:1244	arg1	βGlcN					1246:1250	non-reducing βGlcN	1233:1250	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	5	96	theme	disaccharide	1069:1080	arg1	A					1088:1088	novel disaccharide lipid A	1063:1088	novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1063:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	2	97	theme	TLR4	501:504	arg1	A					484:484	Bacterial lipid A	468:484	Bacterial lipid A	468:484	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	2	97	theme	TLR4	501:504	arg1	ligand					506:511	the primary TLR4 ligand	489:511	the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships	489:604	Bacterial lipid A is the primary TLR4 ligand with very complex, species-specific, and barely predictable structure-activity relationships.
35439332	4	98	theme	chemical	832:839	arg1	synthesis					841:849	chemical synthesis	832:849	chemical synthesis	832:849	We report on design, chemical synthesis and immunobiology of novel glycan-based lipid A-mimicking molecules that can activate human and murine TLR4-mediated signaling with picomolar affinity.
35439332	5	99	theme	A	1088:1088	arg1	DLAMs					1100:1104	DLAMs	1100:1104	DLAMs	1100:1104	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	5	99	theme	A	1088:1088	arg1	mimetics					1090:1097	novel disaccharide lipid A mimetics	1063:1097	novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1063:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	8	100	theme	3D-molecular	1660:1671	arg1	shape					1673:1677	Specific 3D-molecular shape	1651:1677	Specific 3D-molecular shape	1651:1677	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
35439332	1	101	theme	factors	339:345	arg1	expression					351:360	expression	351:360	expression of interferons and cytokines	351:389	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	1	101	theme	factors	339:345	arg1	upregulation					309:320	the upregulation	305:320	the upregulation of transcription factors	305:345	TLR4 is a key pattern recognition receptor that can sense pathogen- and danger- associated molecular patterns to activate the downstream signaling pathways which results in the upregulation of transcription factors and expression of interferons and cytokines to mediate protective pro-inflammatory responses involved in immune defense.
35439332	7	102	theme	acyloxyacyl	1581:1591	arg1	residues					1593:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	multiple long-chain (R)-3- acyloxyacyl residues	1554:1600	Divergent streamlined synthesis of β,β-1,1'-linked diglucosamine-derived glycolipids entailing multiple long-chain (R)-3- acyloxyacyl residues and up two three phosphate groups was developed.
35439332	5	103	dep	flexible	1128:1135	arg1	-linked					1143:1149	-linked	1143:1149	-linked	1143:1149	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	3	104	theme	human	699:703	arg1	diseases					705:712	human diseases	699:712	human diseases	699:712	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	5	105	theme	βGlcN	1257:1261	arg1	scaffold					1263:1270	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold	1203:1270	Exploiting crystal structure - based design we have created novel disaccharide lipid A mimetics (DLAMs) where the inherently flexible β(1→6)-linked diglucosamine backbone of lipid A is exchanged with a conformationally restrained non-reducing βGlcN(1↔1')βGlcN scaffold.
35439332	3	106	theme	novel	734:738	arg1	biomolecules					756:767	novel TLR4 activating biomolecules	734:767	novel TLR4 activating biomolecules other than lipid A	734:786	Given that therapeutic targeting of TLR4 is an emerging tool for management of a variety of human diseases, the development of novel TLR4 activating biomolecules other than lipid A is of vast importance.
35439332	8	107	theme	optimized	1774:1782	arg1	phosphorylation					1784:1798	carefully optimized phosphorylation	1764:1798	carefully optimized phosphorylation	1764:1798	Specific 3D-molecular shape and conformational rigidity of unnatural β,β-1,1'-linked diglucosamine combined with carefully optimized phosphorylation and acylation pattern ensured efficient induction of the TLR4-mediated signaling in a species-independent manner.
36934161	0	0	theme	glucan	76:81	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	0	0	theme	glucan	76:81	arg1	characterization					23:38	structural characterization	12:38	structural characterization	12:38	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	0	0	theme	glucan	76:81	arg1	activities					56:65	biological activities	45:65	biological activities	45:65	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	0	1	theme	new	72:74	arg1	glucan					76:81	a new glucan	70:81	a new glucan	70:81	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	9	2	theme	extraction	1124:1133	arg1	rate					1135:1138	the extraction rate	1120:1138	the extraction rate of polysaccharides from C. pilosula	1120:1174	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	1	3	theme	rapid	139:143	arg1	system					163:168	a powerful and rapid aqueous two-phase system	124:168	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	1	3	theme	rapid	139:143	arg1	ATPS					171:174	ATPS	171:174	ATPS	171:174	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	1	4	theme	Codonopsis	225:234	arg1	pilosula					236:243	Codonopsis pilosula	225:243	Codonopsis pilosula	225:243	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	0	5	theme	Codonopsis	88:97	arg1	pilosula					99:106	Codonopsis pilosula	88:106	Codonopsis pilosula	88:106	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	9	6	dep	composition	1273:1283	arg1	the					1269:1271	the	1269:1271	the	1269:1271	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	7	7	theme	strong	901:906	arg1	activity					920:927	strong antioxidant activity	901:927	strong antioxidant activity	901:927	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	3	8	theme	polysaccharides	471:485	arg1	yield					462:466	the total extraction yield	441:466	the total extraction yield of polysaccharides	441:485	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	9	theme	ammonium	327:334	arg1	concentration					344:356	an ammonium sulfate concentration	324:356	an ammonium sulfate concentration of 17%	324:363	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	6	10	theme	Activity	758:765	arg1	studies					767:773	Activity studies	758:773	Activity studies	758:773	Activity studies showed that the IC50 of CPP 2-4 for DPPH radical scavenging was 0.105 mg/mL.
36934161	9	11	theme	polysaccharides	1302:1316	arg1	structure					1289:1297	structure	1289:1297	structure	1289:1297	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	11	theme	polysaccharides	1302:1316	arg1	composition					1273:1283	composition	1273:1283	composition	1273:1283	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	12	theme	better	1245:1250	arg1	understanding					1252:1264	a better understanding	1243:1264	a better understanding of the composition and structure of polysaccharides from C. pilosula	1243:1333	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	13	theme	polysaccharides	1143:1157	arg1	rate					1135:1138	the extraction rate	1120:1138	the extraction rate of polysaccharides from C. pilosula	1120:1174	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	2	14	theme	ATPS	250:253	arg1	process					255:261	The ATPS process	246:261	The ATPS process	246:261	The ATPS process was investigated with response surface methodology (RSM).
36934161	4	15	theme	3.9 × 104 kDa	609:621	arg1	weight					599:604	molecular weight	589:604	molecular weight of 3.9 × 104 kDa	589:621	After separation and purification, a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa was obtained from the bottom phase.
36934161	1	16	theme	aqueous	145:151	arg1	system					163:168	a powerful and rapid aqueous two-phase system	124:168	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	1	16	theme	aqueous	145:151	arg1	ATPS					171:174	ATPS	171:174	ATPS	171:174	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	5	17	theme	structural	694:703	arg1	features					705:712	structural features	694:712	structural features	694:712	The physicochemical properties and structural features confirmed that CPP 2-4 was an α-1,6-glucan.
36934161	9	18	from	structure	1289:1297	arg1	pilosula					1326:1333	C. pilosula	1323:1333	C. pilosula	1323:1333	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	1	19	theme	two-phase	153:161	arg1	system					163:168	a powerful and rapid aqueous two-phase system	124:168	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	1	19	theme	two-phase	153:161	arg1	ATPS					171:174	ATPS	171:174	ATPS	171:174	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	6	20	theme	radical	816:822	arg1	scavenging					824:833	DPPH radical scavenging	811:833	DPPH radical scavenging	811:833	Activity studies showed that the IC50 of CPP 2-4 for DPPH radical scavenging was 0.105 mg/mL.
36934161	8	21	theme	RAW264.7	1002:1009	arg1	cells					1011:1015	RAW264.7 cells	1002:1015	RAW264.7 cells induced by lipopolysaccharide, which indicated a certain anti-inflammatory effect	1002:1097	Furthermore, CPP 2-4 inhibited NO release in RAW264.7 cells induced by lipopolysaccharide, which indicated a certain anti-inflammatory effect.
36934161	2	22	theme	surface	294:300	arg1	RSM					315:317	RSM	315:317	RSM	315:317	The ATPS process was investigated with response surface methodology (RSM).
36934161	2	22	theme	surface	294:300	arg1	methodology					302:312	response surface methodology	285:312	response surface methodology (RSM)	285:318	The ATPS process was investigated with response surface methodology (RSM).
36934161	1	23	theme	system	163:168	arg1	method					177:182	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	9	24	theme	composition	1273:1283	arg1	understanding					1252:1264	a better understanding	1243:1264	a better understanding of the composition and structure of polysaccharides from C. pilosula	1243:1333	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	25	from	composition	1273:1283	arg1	pilosula					1326:1333	C. pilosula	1323:1333	C. pilosula	1323:1333	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	3	26	from	pH	435:436	arg1	temperature					411:421	extraction temperature	400:421	extraction temperature of 40 °C at pH 6	400:438	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	26	from	pH	435:436	arg1	concentration					344:356	an ammonium sulfate concentration	324:356	an ammonium sulfate concentration of 17%	324:363	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	26	from	pH	435:436	arg1	concentration					374:386	ethanol concentration	366:386	ethanol concentration of 30%	366:393	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	2	27	theme	response	285:292	arg1	RSM					315:317	RSM	315:317	RSM	315:317	The ATPS process was investigated with response surface methodology (RSM).
36934161	2	27	theme	response	285:292	arg1	methodology					302:312	response surface methodology	285:312	response surface methodology (RSM)	285:318	The ATPS process was investigated with response surface methodology (RSM).
36934161	3	28	theme	sulfate	336:342	arg1	concentration					344:356	an ammonium sulfate concentration	324:356	an ammonium sulfate concentration of 17%	324:363	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	7	29	theme	ABTS	865:868	arg1	assays					870:875	The FRAP and ABTS assays	852:875	assays	870:875	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	1	30	from	pilosula	236:243	arg1	polysaccharides					204:218	extract polysaccharides	196:218	extract polysaccharides from Codonopsis pilosula	196:243	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	9	31	theme	pilosula	1401:1408	arg1	homology					1386:1393	food homology	1381:1393	food homology	1381:1393	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	31	theme	pilosula	1401:1408	arg1	medicine					1368:1375	medicine	1368:1375	medicine	1368:1375	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	0	32	theme	structural	12:21	arg1	characterization					23:38	structural characterization	12:38	structural characterization	12:38	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	6	33	theme	DPPH	811:814	arg1	scavenging					824:833	DPPH radical scavenging	811:833	DPPH radical scavenging	811:833	Activity studies showed that the IC50 of CPP 2-4 for DPPH radical scavenging was 0.105 mg/mL.
36934161	9	34	from	rate	1135:1138	arg1	pilosula					1167:1174	C. pilosula	1164:1174	C. pilosula	1164:1174	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	4	35	theme	polysaccharide	561:574	arg1	CPP					576:578	a homogenized polysaccharide CPP 2-4	547:582	a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa	547:621	After separation and purification, a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa was obtained from the bottom phase.
36934161	3	36	theme	ethanol	366:372	arg1	concentration					374:386	ethanol concentration	366:386	ethanol concentration of 30%	366:393	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	7	37	contain	had	897:899	arg2	activity					920:927	strong antioxidant activity	901:927	strong antioxidant activity	901:927	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	7	37	contain	had	897:899	arg1	CPP					889:891	CPP 2-4	889:895	CPP 2-4	889:895	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	3	38	theme	%	393:393	arg1	temperature					411:421	extraction temperature	400:421	extraction temperature of 40 °C at pH 6	400:438	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	38	theme	%	393:393	arg1	concentration					344:356	an ammonium sulfate concentration	324:356	an ammonium sulfate concentration of 17%	324:363	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	38	theme	%	393:393	arg1	concentration					374:386	ethanol concentration	366:386	ethanol concentration of 30%	366:393	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	9	39	dep	medicine	1368:1375	arg1	the					1364:1366	the	1364:1366	the	1364:1366	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	4	40	theme	homogenized	549:559	arg1	CPP					576:578	a homogenized polysaccharide CPP 2-4	547:582	a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa	547:621	After separation and purification, a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa was obtained from the bottom phase.
36934161	3	41	theme	extraction	400:409	arg1	temperature					411:421	extraction temperature	400:421	extraction temperature of 40 °C at pH 6	400:438	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	42	theme	%	363:363	arg1	temperature					411:421	extraction temperature	400:421	extraction temperature of 40 °C at pH 6	400:438	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	42	theme	%	363:363	arg1	concentration					344:356	an ammonium sulfate concentration	324:356	an ammonium sulfate concentration of 17%	324:363	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	42	theme	%	363:363	arg1	concentration					374:386	ethanol concentration	366:386	ethanol concentration of 30%	366:393	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	5	43	theme	physicochemical	663:677	arg1	properties					679:688	The physicochemical properties	659:688	The physicochemical properties	659:688	The physicochemical properties and structural features confirmed that CPP 2-4 was an α-1,6-glucan.
36934161	6	44	theme	CPP	799:801	arg1	IC50					791:794	the IC50	787:794	the IC50 of CPP 2-4 for DPPH radical scavenging	787:833	Activity studies showed that the IC50 of CPP 2-4 for DPPH radical scavenging was 0.105 mg/mL.
36934161	6	44	theme	CPP	799:801	arg1	0.105 mg/mL					839:849	0.105 mg/mL	839:849	0.105 mg/mL	839:849	Activity studies showed that the IC50 of CPP 2-4 for DPPH radical scavenging was 0.105 mg/mL.
36934161	9	45	from	pilosula	1167:1174	arg1	polysaccharides					1143:1157	polysaccharides	1143:1157	polysaccharides from C. pilosula	1143:1174	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	45	from	pilosula	1167:1174	arg1	rate					1135:1138	the extraction rate	1120:1138	the extraction rate of polysaccharides from C. pilosula	1120:1174	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	0	46	theme	biological	45:54	arg1	activities					56:65	biological activities	45:65	biological activities	45:65	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	8	47	from	release	991:997	arg1	cells					1011:1015	RAW264.7 cells	1002:1015	RAW264.7 cells induced by lipopolysaccharide, which indicated a certain anti-inflammatory effect	1002:1097	Furthermore, CPP 2-4 inhibited NO release in RAW264.7 cells induced by lipopolysaccharide, which indicated a certain anti-inflammatory effect.
36934161	9	48	theme	first	1208:1212	arg1	time					1214:1217	the first time	1204:1217	the first time	1204:1217	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	7	49	theme	dose-dependent	934:947	arg1	manner					949:954	a dose-dependent manner	932:954	a dose-dependent manner	932:954	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	4	50	theme	bottom	645:650	arg1	phase					652:656	the bottom phase	641:656	the bottom phase	641:656	After separation and purification, a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa was obtained from the bottom phase.
36934161	7	51	theme	FRAP	856:859	arg1	assays					870:875	The FRAP and ABTS assays	852:875	assays	870:875	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	9	52	from	pilosula	1326:1333	arg1	polysaccharides					1302:1316	polysaccharides	1302:1316	polysaccharides from C. pilosula	1302:1333	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	52	from	pilosula	1326:1333	arg1	structure					1289:1297	structure	1289:1297	structure	1289:1297	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	9	52	from	pilosula	1326:1333	arg1	composition					1273:1283	composition	1273:1283	composition	1273:1283	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	0	53	from	pilosula	99:106	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	0	53	from	pilosula	99:106	arg1	characterization					23:38	structural characterization	12:38	structural characterization	12:38	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	0	53	from	pilosula	99:106	arg1	activities					56:65	biological activities	45:65	biological activities	45:65	Extraction, structural characterization, and biological activities of a new glucan from Codonopsis pilosula.
36934161	9	54	theme	structure	1289:1297	arg1	understanding					1252:1264	a better understanding	1243:1264	a better understanding of the composition and structure of polysaccharides from C. pilosula	1243:1333	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	3	55	theme	40 °C	426:430	arg1	temperature					411:421	extraction temperature	400:421	extraction temperature of 40 °C at pH 6	400:438	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	55	theme	40 °C	426:430	arg1	concentration					344:356	an ammonium sulfate concentration	324:356	an ammonium sulfate concentration of 17%	324:363	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	3	55	theme	40 °C	426:430	arg1	concentration					374:386	ethanol concentration	366:386	ethanol concentration of 30%	366:393	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	9	56	theme	food	1381:1384	arg1	homology					1386:1393	food homology	1381:1393	food homology	1381:1393	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
36934161	4	57	with	CPP	576:578	arg1	weight					599:604	molecular weight	589:604	molecular weight of 3.9 × 104 kDa	589:621	After separation and purification, a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa was obtained from the bottom phase.
36934161	1	58	theme	powerful	126:133	arg1	system					163:168	a powerful and rapid aqueous two-phase system	124:168	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	1	58	theme	powerful	126:133	arg1	ATPS					171:174	ATPS	171:174	ATPS	171:174	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	8	59	theme	anti-inflammatory	1074:1090	arg1	effect					1092:1097	a certain anti-inflammatory effect	1064:1097	a certain anti-inflammatory effect	1064:1097	Furthermore, CPP 2-4 inhibited NO release in RAW264.7 cells induced by lipopolysaccharide, which indicated a certain anti-inflammatory effect.
36934161	1	60	used	used	188:191	arg2	method					177:182	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	a powerful and rapid aqueous two-phase system (ATPS) method	124:182	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	3	61	theme	total	445:449	arg1	yield					462:466	the total extraction yield	441:466	the total extraction yield of polysaccharides	441:485	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	4	62	theme	molecular	589:597	arg1	weight					599:604	molecular weight	589:604	molecular weight of 3.9 × 104 kDa	589:621	After separation and purification, a homogenized polysaccharide CPP 2-4 with molecular weight of 3.9 × 104 kDa was obtained from the bottom phase.
36934161	1	63	theme	extract	196:202	arg1	polysaccharides					204:218	extract polysaccharides	196:218	extract polysaccharides from Codonopsis pilosula	196:243	In this study, a powerful and rapid aqueous two-phase system (ATPS) method was used to extract polysaccharides from Codonopsis pilosula.
36934161	8	64	theme	certain	1066:1072	arg1	effect					1092:1097	a certain anti-inflammatory effect	1064:1097	a certain anti-inflammatory effect	1064:1097	Furthermore, CPP 2-4 inhibited NO release in RAW264.7 cells induced by lipopolysaccharide, which indicated a certain anti-inflammatory effect.
36934161	7	65	theme	antioxidant	908:918	arg1	activity					920:927	strong antioxidant activity	901:927	strong antioxidant activity	901:927	The FRAP and ABTS assays showed that CPP 2-4 had strong antioxidant activity in a dose-dependent manner.
36934161	3	66	theme	extraction	451:460	arg1	yield					462:466	the total extraction yield	441:466	the total extraction yield of polysaccharides	441:485	At an ammonium sulfate concentration of 17%, ethanol concentration of 30%, and extraction temperature of 40 °C at pH 6, the total extraction yield of polysaccharides reached (31.57 ± 1.28)%.
36934161	9	67	theme	data	1347:1350	arg1	support					1352:1358	data support	1347:1358	data support for the medicine and food homology of C. pilosula	1347:1408	This study improved the extraction rate of polysaccharides from C. pilosula and identified a glucan for the first time, that can contribute to a better understanding of the composition and structure of polysaccharides from C. pilosula and provide data support for the medicine and food homology of C. pilosula.
35698386	5	0	theme	small	881:885	arg1	particles					887:895	small particles	881:895	small particles within aggregates of reductive cellulose molecules	881:946	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	3	1	from	size	526:529	arg1	surfaces					555:562	the cellulose fibril surfaces	534:562	the cellulose fibril surfaces	534:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	2	2	theme	cellulose	437:445	arg1	nanofibrils					447:457	individual carboxymethylated cellulose nanofibrils	408:457	individual carboxymethylated cellulose nanofibrils	408:457	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	5	3	theme	particles	887:895	arg1	responsible					964:974	responsible	964:974	responsible	964:974	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	5	3	theme	particles	887:895	arg1	confinement					866:876	The confinement	862:876	The confinement of small particles within aggregates of reductive cellulose molecules	862:946	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	2	4	theme	carboxymethylated	419:435	arg1	nanofibrils					447:457	individual carboxymethylated cellulose nanofibrils	408:457	individual carboxymethylated cellulose nanofibrils	408:457	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	3	5	from	increase	495:502	arg1	surfaces					555:562	the cellulose fibril surfaces	534:562	the cellulose fibril surfaces	534:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	3	5	from	increase	495:502	arg1	size					526:529	magnetite particle size	507:529	magnetite particle size on the cellulose fibril surfaces	507:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	2	6	theme	3.6-16.4 nm	347:357	arg1	particles					334:342	2.0-4.0 nm or secondary particles	310:342	2.0-4.0 nm or secondary particles of 3.6-16.4 nm	310:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	6	7	theme	release	1134:1140	arg1	rate					1142:1145	release rate	1134:1145	release rate controlled by daylight illumination	1134:1181	The possibility for using the material in drug delivery applications with release rate controlled by daylight illumination is presented.
35698386	3	8	theme	carboxymethyl	644:656	arg1	aggregates					668:677	the carboxymethyl cellulose aggregates	640:677	the carboxymethyl cellulose aggregates	640:677	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	2	9	theme	Applied	190:196	arg1	conditions					211:220	Applied experimental conditions	190:220	Applied experimental conditions	190:220	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	2	10	theme	particles	334:342	arg1	sizes					301:305	primary particle sizes	284:305	primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm	284:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	2	11	theme	individual	408:417	arg1	nanofibrils					447:457	individual carboxymethylated cellulose nanofibrils	408:457	individual carboxymethylated cellulose nanofibrils	408:457	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	1	12	theme	benign	77:82	arg1	synthesis					84:92	An environmentally benign synthesis	58:92	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material	58:175	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material is reported.
35698386	2	13	theme	fibril	474:479	arg1	surfaces					481:488	exposed fibril surfaces	466:488	exposed fibril surfaces	466:488	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	6	14	theme	delivery	1107:1114	arg1	applications					1116:1127	drug delivery applications	1102:1127	drug delivery applications	1102:1127	The possibility for using the material in drug delivery applications with release rate controlled by daylight illumination is presented.
35698386	3	15	from	surfaces	555:562	arg1	increase					495:502	The increase	491:502	The increase in magnetite particle size on the cellulose fibril surfaces	491:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	3	16	theme	small	610:614	arg1	particles					616:624	the small particles	606:624	the small particles formed within the carboxymethyl cellulose aggregates	606:677	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	3	16	theme	small	610:614	arg1	interactions					709:720	steric interactions	702:720	steric interactions	702:720	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	2	17	theme	exposed	466:472	arg1	surfaces					481:488	exposed fibril surfaces	466:488	exposed fibril surfaces	466:488	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	5	18	theme	cellulose	928:936	arg1	molecules					938:946	reductive cellulose molecules	918:946	reductive cellulose molecules	918:946	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	2	19	dep	occurred	391:398	arg1	depending					359:367	depending	359:367	depending	359:367	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	5	20	theme	magnetic	1006:1013	arg1	characteristics					1015:1029	magnetic characteristics	1006:1029	magnetic characteristics	1006:1029	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	5	21	theme	molecules	938:946	arg1	aggregates					904:913	aggregates	904:913	aggregates of reductive cellulose molecules	904:946	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	3	22	theme	cellulose	658:666	arg1	aggregates					668:677	the carboxymethyl cellulose aggregates	640:677	the carboxymethyl cellulose aggregates	640:677	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	3	23	theme	magnetite	507:515	arg1	size					526:529	magnetite particle size	507:529	magnetite particle size on the cellulose fibril surfaces	507:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	4	24	theme	"	848:848	arg1	assemblies					850:859	large "fibre-like" assemblies	831:859	large "fibre-like" assemblies	831:859	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
35698386	5	25	theme	material	1050:1057	arg1	storage					1034:1040	storage	1034:1040	storage of this material	1034:1057	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	6	26	with	material	1090:1097	arg1	rate					1142:1145	release rate	1134:1145	release rate controlled by daylight illumination	1134:1181	The possibility for using the material in drug delivery applications with release rate controlled by daylight illumination is presented.
35698386	3	27	theme	cellulose	538:546	arg1	surfaces					555:562	the cellulose fibril surfaces	534:562	the cellulose fibril surfaces	534:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	0	28	theme	ferria	17:22	arg1	Self-assembly					0:12	Self-assembly	0:12	Self-assembly of ferria	0:22	Self-assembly of ferria - nanocellulose composite fibres.
35698386	6	29	theme	drug	1102:1105	arg1	applications					1116:1127	drug delivery applications	1102:1127	drug delivery applications	1102:1127	The possibility for using the material in drug delivery applications with release rate controlled by daylight illumination is presented.
35698386	2	30	theme	secondary	324:332	arg1	particles					334:342	2.0-4.0 nm or secondary particles	310:342	2.0-4.0 nm or secondary particles of 3.6-16.4 nm	310:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	1	31	theme	responsive	112:121	arg1	material					168:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material is reported.
35698386	3	32	theme	fibril	548:553	arg1	surfaces					555:562	the cellulose fibril surfaces	534:562	the cellulose fibril surfaces	534:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	0	33	theme	composite	40:48	arg1	fibres					50:55	nanocellulose composite fibres	26:55	nanocellulose composite fibres	26:55	Self-assembly of ferria - nanocellulose composite fibres.
35698386	2	34	theme	primary	284:290	arg1	sizes					301:305	primary particle sizes	284:305	primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm	284:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	5	35	theme	characteristics	1015:1029	arg1	conservation					990:1001	excellent conservation	980:1001	excellent conservation of magnetic characteristics on storage of this material	980:1057	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	0	36	theme	nanocellulose	26:38	arg1	fibres					50:55	nanocellulose composite fibres	26:55	nanocellulose composite fibres	26:55	Self-assembly of ferria - nanocellulose composite fibres.
35698386	6	37	theme	daylight	1161:1168	arg1	illumination					1170:1181	daylight illumination	1161:1181	daylight illumination	1161:1181	The possibility for using the material in drug delivery applications with release rate controlled by daylight illumination is presented.
35698386	5	38	theme	excellent	980:988	arg1	conservation					990:1001	excellent conservation	980:1001	excellent conservation of magnetic characteristics on storage of this material	980:1057	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	3	39	theme	Ostwald	582:588	arg1	ripening					590:597	Ostwald ripening	582:597	Ostwald ripening	582:597	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	2	40	theme	experimental	198:209	arg1	conditions					211:220	Applied experimental conditions	190:220	Applied experimental conditions	190:220	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	2	41	theme	nanoparticles	265:277	arg1	formation					242:250	the in-situ formation	230:250	the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm	230:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	6	42	from	material	1090:1097	arg1	applications					1116:1127	drug delivery applications	1102:1127	drug delivery applications	1102:1127	The possibility for using the material in drug delivery applications with release rate controlled by daylight illumination is presented.
35698386	1	43	theme	carboxymethylated	123:139	arg1	material					168:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material is reported.
35698386	5	44	theme	reductive	918:926	arg1	molecules					938:946	reductive cellulose molecules	918:946	reductive cellulose molecules	918:946	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	2	45	theme	magnetite	255:263	arg1	nanoparticles					265:277	magnetite nanoparticles	255:277	magnetite nanoparticles	255:277	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	1	46	theme	cellulose	141:149	arg1	material					168:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material is reported.
35698386	3	47	theme	particle	517:524	arg1	size					526:529	magnetite particle size	507:529	magnetite particle size on the cellulose fibril surfaces	507:562	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	3	48	theme	steric	702:707	arg1	particles					616:624	the small particles	606:624	the small particles formed within the carboxymethyl cellulose aggregates	606:677	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	3	48	theme	steric	702:707	arg1	interactions					709:720	steric interactions	702:720	steric interactions	702:720	The increase in magnetite particle size on the cellulose fibril surfaces was attributed to Ostwald ripening, while the small particles formed within the carboxymethyl cellulose aggregates were presumably due to steric interactions.
35698386	4	49	theme	large	831:835	arg1	assemblies					850:859	large "fibre-like" assemblies	831:859	large "fibre-like" assemblies	831:859	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
35698386	2	50	theme	2.0-4.0 nm	310:319	arg1	particles					334:342	2.0-4.0 nm or secondary particles	310:342	2.0-4.0 nm or secondary particles of 3.6-16.4 nm	310:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	1	51	theme	nanofibril-based	151:166	arg1	material					168:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	a magnetically responsive carboxymethylated cellulose nanofibril-based material	97:175	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material is reported.
35698386	2	52	theme	in-situ	234:240	arg1	formation					242:250	the in-situ formation	230:250	the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm	230:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	1	53	theme	material	168:175	arg1	synthesis					84:92	An environmentally benign synthesis	58:92	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material	58:175	An environmentally benign synthesis of a magnetically responsive carboxymethylated cellulose nanofibril-based material is reported.
35698386	4	54	theme	fibre-like	838:847	arg1	assemblies					850:859	large "fibre-like" assemblies	831:859	large "fibre-like" assemblies	831:859	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
35698386	4	55	theme	magnetite	727:735	arg1	nanoparticles					737:749	The magnetite nanoparticles	723:749	The magnetite nanoparticles	723:749	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
35698386	4	55	theme	magnetite	727:735	arg1	capable					756:762	capable	756:762	capable	756:762	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
35698386	4	56	theme	cellulose	801:809	arg1	nanofibrils					811:821	carboxymethylated cellulose nanofibrils	783:821	carboxymethylated cellulose nanofibrils	783:821	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
35698386	2	57	with	formation	242:250	arg1	sizes					301:305	primary particle sizes	284:305	primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm	284:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	2	58	theme	particle	292:299	arg1	sizes					301:305	primary particle sizes	284:305	primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm	284:357	Applied experimental conditions lead to the in-situ formation of magnetite nanoparticles with primary particle sizes of 2.0-4.0 nm or secondary particles of 3.6-16.4 nm depending on whether nucleation occurred between individual carboxymethylated cellulose nanofibrils, or on exposed fibril surfaces.
35698386	5	59	from	conservation	990:1001	arg1	storage					1034:1040	storage	1034:1040	storage of this material	1034:1057	The confinement of small particles within aggregates of reductive cellulose molecules was most likely responsible for excellent conservation of magnetic characteristics on storage of this material.
35698386	4	60	theme	carboxymethylated	783:799	arg1	nanofibrils					811:821	carboxymethylated cellulose nanofibrils	783:821	carboxymethylated cellulose nanofibrils	783:821	The magnetite nanoparticles were capable of coordinating to carboxymethylated cellulose nanofibrils to form large "fibre-like" assemblies.
36963137	7	0	theme	food	1072:1075	arg1	ABP					1053:1055	ABP	1053:1055	ABP	1053:1055	The results suggested that ABP is a promising food component with prebiotic potential.
36963137	7	0	theme	food	1072:1075	arg1	component					1077:1085	a promising food component	1060:1085	a promising food component with prebiotic potential	1060:1110	The results suggested that ABP is a promising food component with prebiotic potential.
36963137	3	1	theme	gut	472:474	arg1	microbiota					476:485	gut microbiota	472:485	gut microbiota	472:485	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	6	2	theme	gut	947:949	arg1	composition					962:972	the gut microbiota composition	943:972	the gut microbiota composition	943:972	Meanwhile, ABP modulated the gut microbiota composition by increasing the abundance of beneficial bacteria.
36963137	6	3	theme	beneficial	1005:1014	arg1	bacteria					1016:1023	beneficial bacteria	1005:1023	beneficial bacteria	1005:1023	Meanwhile, ABP modulated the gut microbiota composition by increasing the abundance of beneficial bacteria.
36963137	7	4	theme	promising	1062:1070	arg1	ABP					1053:1055	ABP	1053:1055	ABP	1053:1055	The results suggested that ABP is a promising food component with prebiotic potential.
36963137	7	4	theme	promising	1062:1070	arg1	component					1077:1085	a promising food component	1060:1085	a promising food component with prebiotic potential	1060:1110	The results suggested that ABP is a promising food component with prebiotic potential.
36963137	1	5	theme	consumed	164:171	arg1	worldwide					173:181	grown and consumed worldwide	154:181	grown and consumed worldwide for its delicious taste and multiple health benefits	154:234	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	2	6	theme	bioactive	284:292	arg1	polysaccharides					249:263	bisporus polysaccharides	240:263	A. bisporus polysaccharides (ABP)	237:269	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	2	6	theme	bioactive	284:292	arg1	ingredient					294:303	the main bioactive ingredient	275:303	the main bioactive ingredient of the mushroom that confers health benefits	275:348	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	2	7	theme	mushroom	312:319	arg1	polysaccharides					249:263	bisporus polysaccharides	240:263	A. bisporus polysaccharides (ABP)	237:269	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	2	7	theme	mushroom	312:319	arg1	ingredient					294:303	the main bioactive ingredient	275:303	the main bioactive ingredient of the mushroom that confers health benefits	275:348	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	3	8	theme	simulated	514:522	arg1	digestion					524:532	in vitro simulated digestion	505:532	in vitro simulated digestion	505:532	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	2	9	theme	main	279:282	arg1	polysaccharides					249:263	bisporus polysaccharides	240:263	A. bisporus polysaccharides (ABP)	237:269	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	2	9	theme	main	279:282	arg1	ingredient					294:303	the main bioactive ingredient	275:303	the main bioactive ingredient of the mushroom that confers health benefits	275:348	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	4	10	theme	free	681:684	arg1	monosaccharide					686:699	no free monosaccharide	678:699	no free monosaccharide	678:699	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	5	11	theme	fatty	871:875	arg1	acids					877:881	short-chain fatty acids	859:881	short-chain fatty acids	859:881	However, after the fermentation, gut microbiota degraded and utilized ABP, which produced short-chain fatty acids and caused a decrease in pH value.
36963137	3	12	dep	in	505:506	arg1	vitro					508:512	vitro	508:512	vitro	508:512	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	4	13	theme	molecular	635:643	arg1	unchanged					663:671	unchanged	663:671	unchanged	663:671	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	4	13	theme	molecular	635:643	arg1	weight					645:650	the molecular weight	631:650	the molecular weight of ABP	631:657	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	5	14	theme	short-chain	859:869	arg1	acids					877:881	short-chain fatty acids	859:881	short-chain fatty acids	859:881	However, after the fermentation, gut microbiota degraded and utilized ABP, which produced short-chain fatty acids and caused a decrease in pH value.
36963137	3	15	from	effect	455:460	arg1	microbiota					476:485	gut microbiota	472:485	gut microbiota	472:485	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	3	16	theme	in	505:506	arg1	digestion					524:532	in vitro simulated digestion	505:532	in vitro simulated digestion	505:532	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	7	17	with	component	1077:1085	arg1	potential					1102:1110	prebiotic potential	1092:1110	prebiotic potential	1092:1110	The results suggested that ABP is a promising food component with prebiotic potential.
36963137	3	18	theme	fermentation	420:431	arg1	prosperities					433:444	fermentation prosperities	420:444	fermentation prosperities	420:444	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	0	19	theme	gastrointestinal	10:25	arg1	digestion					27:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	3	20	theme	gut	538:540	arg1	fermentation					553:564	gut microbiota fermentation	538:564	gut microbiota fermentation	538:564	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	0	21	theme	Simulated	0:8	arg1	digestion					27:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	3	22	theme	microbiota	542:551	arg1	fermentation					553:564	gut microbiota fermentation	538:564	gut microbiota fermentation	538:564	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	1	23	theme	delicious	191:199	arg1	taste					201:205	its delicious taste	187:205	its delicious taste	187:205	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	4	24	theme	digestion	612:620	arg1	process					622:628	the simulated digestion process	598:628	the simulated digestion process	598:628	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	5	25	used	utilized	830:837	arg2	microbiota					806:815	gut microbiota	802:815	gut microbiota	802:815	However, after the fermentation, gut microbiota degraded and utilized ABP, which produced short-chain fatty acids and caused a decrease in pH value.
36963137	0	26	from	bisporus	102:109	arg1	digestion					27:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	0	26	from	bisporus	102:109	arg1	fermentation					56:67	gut microbiota fermentation	41:67	gut microbiota fermentation	41:67	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	5	27	theme	pH	908:909	arg1	value					911:915	pH value	908:915	pH value	908:915	However, after the fermentation, gut microbiota degraded and utilized ABP, which produced short-chain fatty acids and caused a decrease in pH value.
36963137	4	28	theme	simulated	602:610	arg1	process					622:628	the simulated digestion process	598:628	the simulated digestion process	598:628	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	0	29	theme	microbiota	45:54	arg1	fermentation					56:67	gut microbiota fermentation	41:67	gut microbiota fermentation	41:67	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	2	30	theme	health	334:339	arg1	benefits					341:348	health benefits	334:348	health benefits	334:348	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	5	31	theme	gut	802:804	arg1	microbiota					806:815	gut microbiota	802:815	gut microbiota	802:815	However, after the fermentation, gut microbiota degraded and utilized ABP, which produced short-chain fatty acids and caused a decrease in pH value.
36963137	2	32	theme	bisporus	240:247	arg1	ABP					266:268	ABP	266:268	ABP	266:268	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	2	32	theme	bisporus	240:247	arg1	ingredient					294:303	the main bioactive ingredient	275:303	the main bioactive ingredient of the mushroom that confers health benefits	275:348	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	2	32	theme	bisporus	240:247	arg1	polysaccharides					249:263	bisporus polysaccharides	240:263	A. bisporus polysaccharides (ABP)	237:269	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	5	33	from	decrease	896:903	arg1	value					911:915	pH value	908:915	pH value	908:915	However, after the fermentation, gut microbiota degraded and utilized ABP, which produced short-chain fatty acids and caused a decrease in pH value.
36963137	1	34	theme	multiple	211:218	arg1	benefits					227:234	multiple health benefits	211:234	multiple health benefits	211:234	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	0	35	theme	gut	41:43	arg1	fermentation					56:67	gut microbiota fermentation	41:67	gut microbiota fermentation	41:67	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	3	36	from	prosperities	433:444	arg1	microbiota					476:485	gut microbiota	472:485	gut microbiota	472:485	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	1	37	theme	health	220:225	arg1	benefits					227:234	multiple health benefits	211:234	multiple health benefits	211:234	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	3	38	theme	ABP	465:467	arg1	effect					455:460	the effect	451:460	the effect of ABP on gut microbiota	451:485	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	3	38	theme	ABP	465:467	arg1	digestion					409:417	the digestion	405:417	the digestion	405:417	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	3	38	theme	ABP	465:467	arg1	prosperities					433:444	fermentation prosperities	420:444	fermentation prosperities	420:444	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	7	39	theme	prebiotic	1092:1100	arg1	potential					1102:1110	prebiotic potential	1092:1110	prebiotic potential	1092:1110	The results suggested that ABP is a promising food component with prebiotic potential.
36963137	1	40	theme	edible	134:139	arg1	mushroom					141:148	an edible mushroom	131:148	an edible mushroom	131:148	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	1	40	theme	edible	134:139	arg1	bisporus					121:128	bisporus	121:128	bisporus	121:128	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	6	41	theme	bacteria	1016:1023	arg1	abundance					992:1000	the abundance	988:1000	the abundance of beneficial bacteria	988:1023	Meanwhile, ABP modulated the gut microbiota composition by increasing the abundance of beneficial bacteria.
36963137	4	42	theme	ABP	655:657	arg1	unchanged					663:671	unchanged	663:671	unchanged	663:671	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	4	42	theme	ABP	655:657	arg1	weight					645:650	the molecular weight	631:650	the molecular weight of ABP	631:657	The results showed that during the simulated digestion process, the molecular weight of ABP was unchanged, and no free monosaccharide was produced, indicating that ABP could not be digested completely.
36963137	3	43	from	digestion	409:417	arg1	microbiota					476:485	gut microbiota	472:485	gut microbiota	472:485	In this study, we prepared and characterized ABP, and the digestion, fermentation prosperities, and the effect of ABP on gut microbiota were detected via in vitro simulated digestion and gut microbiota fermentation.
36963137	2	44	dep	polysaccharides	249:263	arg1	A.					237:238	A. bisporus polysaccharides (ABP)	237:269	A. bisporus polysaccharides (ABP)	237:269	A. bisporus polysaccharides (ABP) are the main bioactive ingredient of the mushroom that confers health benefits.
36963137	0	45	theme	polysaccharides	72:86	arg1	digestion					27:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion	0:35	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	0	45	theme	polysaccharides	72:86	arg1	fermentation					56:67	gut microbiota fermentation	41:67	gut microbiota fermentation	41:67	Simulated gastrointestinal digestion and gut microbiota fermentation of polysaccharides from Agaricus bisporus.
36963137	1	46	theme	grown	154:158	arg1	worldwide					173:181	grown and consumed worldwide	154:181	grown and consumed worldwide for its delicious taste and multiple health benefits	154:234	Agaricus bisporus, an edible mushroom, is grown and consumed worldwide for its delicious taste and multiple health benefits.
36963137	6	47	theme	microbiota	951:960	arg1	composition					962:972	the gut microbiota composition	943:972	the gut microbiota composition	943:972	Meanwhile, ABP modulated the gut microbiota composition by increasing the abundance of beneficial bacteria.
35104037	0	0	theme	Trametes	101:108	arg1	Lloyd					120:124	Trametes sanguinea Lloyd	101:124	Trametes sanguinea Lloyd	101:124	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	4	1	theme	strong	879:884	arg1	effects					897:903	strong inhibitory effects	879:903	strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis	879:1063	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	6	2	theme	tumor	1455:1459	arg1	therapy					1461:1467	tumor therapy	1455:1467	tumor therapy	1455:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	0	3	from	Characterization	11:26	arg1	Lloyd					120:124	Trametes sanguinea Lloyd	101:124	Trametes sanguinea Lloyd	101:124	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	4	4	theme	cell	1111:1114	arg1	lines					1116:1120	human TNBC cell lines	1100:1120	human TNBC cell lines	1100:1120	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	5	theme	TNBC	1106:1109	arg1	lines					1116:1120	human TNBC cell lines	1100:1120	human TNBC cell lines	1100:1120	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	2	6	dep	1	363:363	arg1	4					366:366	4	366:366	4	366:366	The structural characterization of TsLTP was elucidated mutually by TsL1 and TsL2, whose mass ratio is 1: 4.
35104037	5	7	contain	possesses	1169:1177	arg2	inhibition					1193:1202	a significant inhibition	1179:1202	a significant inhibition of tumor microvascular activity	1179:1234	Taken together, our study suggests that TsLTP possesses a significant inhibition of tumor microvascular activity both in vitro and in vivo.
35104037	5	7	contain	possesses	1169:1177	arg1	TsLTP					1163:1167	TsLTP	1163:1167	TsLTP	1163:1167	Taken together, our study suggests that TsLTP possesses a significant inhibition of tumor microvascular activity both in vitro and in vivo.
35104037	0	8	theme	sanguinea	110:118	arg1	Lloyd					120:124	Trametes sanguinea Lloyd	101:124	Trametes sanguinea Lloyd	101:124	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	6	9	theme	genus	1437:1441	arg1	Trametes					1443:1450	the genus Trametes	1433:1450	the genus Trametes in tumor therapy	1433:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	3	10	theme	molar	828:832	arg1	ratio					834:838	a molar ratio	826:838	a molar ratio of 1.0: 2.1: 7.6: 1.4	826:860	TsL1 is mainly composed of mannose, glucose, galactose, and fucose, and consist of T-Linked-Fucp, T-Linked-Manp, T-Linked-Galp, 1,4-Linked-Manp, 1,4-Linked-Glcp, 1,6-Linked-Manp, 1,6-Linked-Galp, 1,3,4-Linked-Glcp, 1,4,6-Linked-Glcp and 1,3,6-Linked-Glcp, with a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2, while TsL2 mainly comprise of glucose and consist of T-Linked-Glcp, 1,3-Linked-Glcp, 1,4-Linked-Glcp and 1,4,6-Linked-Glcp, with a molar ratio of 1.0: 2.1: 7.6: 1.4.
35104037	5	11	theme	activity	1227:1234	arg1	inhibition					1193:1202	a significant inhibition	1179:1202	a significant inhibition of tumor microvascular activity	1179:1234	Taken together, our study suggests that TsLTP possesses a significant inhibition of tumor microvascular activity both in vitro and in vivo.
35104037	5	12	theme	microvascular	1213:1225	arg1	activity					1227:1234	tumor microvascular activity	1207:1234	tumor microvascular activity	1207:1234	Taken together, our study suggests that TsLTP possesses a significant inhibition of tumor microvascular activity both in vitro and in vivo.
35104037	0	13	from	Activity	63:70	arg1	Lloyd					120:124	Trametes sanguinea Lloyd	101:124	Trametes sanguinea Lloyd	101:124	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	5	14	theme	tumor	1207:1211	arg1	activity					1227:1234	tumor microvascular activity	1207:1234	tumor microvascular activity	1207:1234	Taken together, our study suggests that TsLTP possesses a significant inhibition of tumor microvascular activity both in vitro and in vivo.
35104037	6	15	theme	monosaccharide	1293:1306	arg1	composition					1308:1318	novel monosaccharide composition	1287:1318	novel monosaccharide composition	1287:1318	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	1	16	dep	Lloyd	146:150	arg1	TsLTP					174:178	TsLTP	174:178	TsLTP	174:178	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	1	16	dep	Lloyd	146:150	arg1	polysaccharide					158:171	total polysaccharide	152:171	total polysaccharide (TsLTP)	152:179	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	4	17	theme	chorioallantoic	1021:1035	arg1	CAM					1047:1049	CAM	1047:1049	CAM	1047:1049	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	17	theme	chorioallantoic	1021:1035	arg1	membrane					1037:1044	chick embryo chorioallantoic membrane	1008:1044	chick embryo chorioallantoic membrane (CAM)	1008:1050	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	6	18	theme	microvascular	1330:1342	arg1	activity					1355:1362	tumor microvascular inhibitory activity	1324:1362	tumor microvascular inhibitory activity	1324:1362	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	4	19	theme	inhibitory	1077:1086	arg1	activity					1088:1095	no inhibitory activity	1074:1095	no inhibitory activity on human TNBC cell lines	1074:1120	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	20	theme	embryo	1014:1019	arg1	CAM					1047:1049	CAM	1047:1049	CAM	1047:1049	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	20	theme	embryo	1014:1019	arg1	membrane					1037:1044	chick embryo chorioallantoic membrane	1008:1044	chick embryo chorioallantoic membrane (CAM)	1008:1050	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	0	21	theme	Structural	0:9	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	4	22	dep	migration	912:920	arg1	angiogenesis					1052:1063	angiogenesis	1052:1063	angiogenesis	1052:1063	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	23	theme	human	1100:1104	arg1	lines					1116:1120	human TNBC cell lines	1100:1120	human TNBC cell lines	1100:1120	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	6	24	from	application	1398:1408	arg1	Trametes					1443:1450	the genus Trametes	1433:1450	the genus Trametes in tumor therapy	1433:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	1	25	theme	water	198:202	arg1	extraction					204:213	water extraction	198:213	water extraction	198:213	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	0	26	theme	Tumor	32:36	arg1	Activity					63:70	Tumor Microvascular Inhibition Activity	32:70	Tumor Microvascular Inhibition Activity	32:70	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	4	27	theme	chick	1008:1012	arg1	CAM					1047:1049	CAM	1047:1049	CAM	1047:1049	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	27	theme	chick	1008:1012	arg1	membrane					1037:1044	chick embryo chorioallantoic membrane	1008:1044	chick embryo chorioallantoic membrane (CAM)	1008:1050	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	28	from	activity	1088:1095	arg1	lines					1116:1120	human TNBC cell lines	1100:1120	human TNBC cell lines	1100:1120	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	29	theme	cells	988:992	arg1	formation					942:950	tube formation	937:950	tube formation of human umbilical vein endothelial cells (iHUVECs)	937:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	29	theme	cells	988:992	arg1	CAM					1047:1049	CAM	1047:1049	CAM	1047:1049	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	29	theme	cells	988:992	arg1	membrane					1037:1044	chick embryo chorioallantoic membrane	1008:1044	chick embryo chorioallantoic membrane (CAM)	1008:1050	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	29	theme	cells	988:992	arg1	invasion					923:930	invasion	923:930	invasion	923:930	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	29	theme	cells	988:992	arg1	migration					912:920	the migration	908:920	the migration	908:920	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	6	30	theme	tumor	1324:1328	arg1	activity					1355:1362	tumor microvascular inhibitory activity	1324:1362	tumor microvascular inhibitory activity	1324:1362	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	31	theme	novel	1287:1291	arg1	composition					1308:1318	novel monosaccharide composition	1287:1318	novel monosaccharide composition	1287:1318	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	1	32	theme	Trametes	127:134	arg1	Lloyd					146:150	Trametes sanguinea Lloyd	127:150	Trametes sanguinea Lloyd	127:150	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	5	33	theme	significant	1181:1191	arg1	inhibition					1193:1202	a significant inhibition	1179:1202	a significant inhibition of tumor microvascular activity	1179:1234	Taken together, our study suggests that TsLTP possesses a significant inhibition of tumor microvascular activity both in vitro and in vivo.
35104037	6	34	theme	beneficial	1375:1384	arg1	study					1267:1271	The study	1263:1271	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity	1263:1362	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	34	theme	beneficial	1375:1384	arg1	attempt					1386:1392	a beneficial attempt	1373:1392	a beneficial attempt	1373:1392	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	0	35	theme	Inhibition	52:61	arg1	Activity					63:70	Tumor Microvascular Inhibition Activity	32:70	Tumor Microvascular Inhibition Activity	32:70	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	3	36	theme	2.1	647:649	arg1	ratio					638:642	a molar ratio	630:642	a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2	630:694	TsL1 is mainly composed of mannose, glucose, galactose, and fucose, and consist of T-Linked-Fucp, T-Linked-Manp, T-Linked-Galp, 1,4-Linked-Manp, 1,4-Linked-Glcp, 1,6-Linked-Manp, 1,6-Linked-Galp, 1,3,4-Linked-Glcp, 1,4,6-Linked-Glcp and 1,3,6-Linked-Glcp, with a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2, while TsL2 mainly comprise of glucose and consist of T-Linked-Glcp, 1,3-Linked-Glcp, 1,4-Linked-Glcp and 1,4,6-Linked-Glcp, with a molar ratio of 1.0: 2.1: 7.6: 1.4.
35104037	1	37	theme	ethanol	219:225	arg1	precipitation					227:239	ethanol precipitation	219:239	ethanol precipitation	219:239	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	0	38	theme	Microvascular	38:50	arg1	Activity					63:70	Tumor Microvascular Inhibition Activity	32:70	Tumor Microvascular Inhibition Activity	32:70	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	4	39	theme	inhibitory	886:895	arg1	effects					897:903	strong inhibitory effects	879:903	strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis	879:1063	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	3	40	theme	molar	632:636	arg1	ratio					638:642	a molar ratio	630:642	a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2	630:694	TsL1 is mainly composed of mannose, glucose, galactose, and fucose, and consist of T-Linked-Fucp, T-Linked-Manp, T-Linked-Galp, 1,4-Linked-Manp, 1,4-Linked-Glcp, 1,6-Linked-Manp, 1,6-Linked-Galp, 1,3,4-Linked-Glcp, 1,4,6-Linked-Glcp and 1,3,6-Linked-Glcp, with a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2, while TsL2 mainly comprise of glucose and consist of T-Linked-Glcp, 1,3-Linked-Glcp, 1,4-Linked-Glcp and 1,4,6-Linked-Glcp, with a molar ratio of 1.0: 2.1: 7.6: 1.4.
35104037	3	41	theme	1.4	858:860	arg1	ratio					834:838	a molar ratio	826:838	a molar ratio of 1.0: 2.1: 7.6: 1.4	826:860	TsL1 is mainly composed of mannose, glucose, galactose, and fucose, and consist of T-Linked-Fucp, T-Linked-Manp, T-Linked-Galp, 1,4-Linked-Manp, 1,4-Linked-Glcp, 1,6-Linked-Manp, 1,6-Linked-Galp, 1,3,4-Linked-Glcp, 1,4,6-Linked-Glcp and 1,3,6-Linked-Glcp, with a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2, while TsL2 mainly comprise of glucose and consist of T-Linked-Glcp, 1,3-Linked-Glcp, 1,4-Linked-Glcp and 1,4,6-Linked-Glcp, with a molar ratio of 1.0: 2.1: 7.6: 1.4.
35104037	1	42	theme	sanguinea	136:144	arg1	Lloyd					146:150	Trametes sanguinea Lloyd	127:150	Trametes sanguinea Lloyd	127:150	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	6	43	theme	TsLTP	1276:1280	arg1	attempt					1386:1392	a beneficial attempt	1373:1392	a beneficial attempt	1373:1392	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	43	theme	TsLTP	1276:1280	arg1	study					1267:1271	The study	1263:1271	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity	1263:1362	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	4	44	from	effects	897:903	arg1	formation					942:950	tube formation	937:950	tube formation of human umbilical vein endothelial cells (iHUVECs)	937:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	44	from	effects	897:903	arg1	CAM					1047:1049	CAM	1047:1049	CAM	1047:1049	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	44	from	effects	897:903	arg1	membrane					1037:1044	chick embryo chorioallantoic membrane	1008:1044	chick embryo chorioallantoic membrane (CAM)	1008:1050	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	44	from	effects	897:903	arg1	invasion					923:930	invasion	923:930	invasion	923:930	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	44	from	effects	897:903	arg1	migration					912:920	the migration	908:920	the migration	908:920	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	2	45	theme	mass	349:352	arg1	ratio					354:358	ratio	354:358	ratio	354:358	The structural characterization of TsLTP was elucidated mutually by TsL1 and TsL2, whose mass ratio is 1: 4.
35104037	4	46	theme	umbilical	961:969	arg1	iHUVECs					995:1001	iHUVECs	995:1001	iHUVECs	995:1001	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	46	theme	umbilical	961:969	arg1	cells					988:992	human umbilical vein endothelial cells	955:992	human umbilical vein endothelial cells (iHUVECs)	955:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	6	47	with	study	1267:1271	arg1	activity					1355:1362	tumor microvascular inhibitory activity	1324:1362	tumor microvascular inhibitory activity	1324:1362	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	47	with	study	1267:1271	arg1	composition					1308:1318	novel monosaccharide composition	1287:1318	novel monosaccharide composition	1287:1318	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	1	48	theme	total	152:156	arg1	TsLTP					174:178	TsLTP	174:178	TsLTP	174:178	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	1	48	theme	total	152:156	arg1	polysaccharide					158:171	total polysaccharide	152:171	total polysaccharide (TsLTP)	152:179	Trametes sanguinea Lloyd total polysaccharide (TsLTP), was obtained by water extraction and ethanol precipitation from T. sanguinea.
35104037	4	49	theme	human	955:959	arg1	iHUVECs					995:1001	iHUVECs	995:1001	iHUVECs	995:1001	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	49	theme	human	955:959	arg1	cells					988:992	human umbilical vein endothelial cells	955:992	human umbilical vein endothelial cells (iHUVECs)	955:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	2	50	theme	TsLTP	295:299	arg1	characterization					275:290	The structural characterization	260:290	The structural characterization of TsLTP	260:299	The structural characterization of TsLTP was elucidated mutually by TsL1 and TsL2, whose mass ratio is 1: 4.
35104037	0	51	from	Lloyd	120:124	arg1	Activity					63:70	Tumor Microvascular Inhibition Activity	32:70	Tumor Microvascular Inhibition Activity	32:70	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	0	51	from	Lloyd	120:124	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	0	51	from	Lloyd	120:124	arg1	Polysaccharide					81:94	Total Polysaccharide	75:94	Total Polysaccharide from Trametes sanguinea Lloyd	75:124	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	6	52	from	Trametes	1443:1450	arg1	polysaccharide					1413:1426	polysaccharide	1413:1426	polysaccharide from the genus Trametes in tumor therapy	1413:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	52	from	Trametes	1443:1450	arg1	application					1398:1408	application	1398:1408	application of polysaccharide from the genus Trametes in tumor therapy	1398:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	52	from	Trametes	1443:1450	arg1	therapy					1461:1467	tumor therapy	1455:1467	tumor therapy	1455:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	6	53	theme	polysaccharide	1413:1426	arg1	application					1398:1408	application	1398:1408	application of polysaccharide from the genus Trametes in tumor therapy	1398:1467	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	4	54	theme	endothelial	976:986	arg1	iHUVECs					995:1001	iHUVECs	995:1001	iHUVECs	995:1001	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	54	theme	endothelial	976:986	arg1	cells					988:992	human umbilical vein endothelial cells	955:992	human umbilical vein endothelial cells (iHUVECs)	955:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	3	55	dep	ratio	638:642	arg1	1.2					692:694	1.2	692:694	1.2	692:694	TsL1 is mainly composed of mannose, glucose, galactose, and fucose, and consist of T-Linked-Fucp, T-Linked-Manp, T-Linked-Galp, 1,4-Linked-Manp, 1,4-Linked-Glcp, 1,6-Linked-Manp, 1,6-Linked-Galp, 1,3,4-Linked-Glcp, 1,4,6-Linked-Glcp and 1,3,6-Linked-Glcp, with a molar ratio of 2.1: 1.7: 1.4: 1.0: 3.6: 2.0: 8.6: 1.3: 2.2: 1.2, while TsL2 mainly comprise of glucose and consist of T-Linked-Glcp, 1,3-Linked-Glcp, 1,4-Linked-Glcp and 1,4,6-Linked-Glcp, with a molar ratio of 1.0: 2.1: 7.6: 1.4.
35104037	0	56	theme	Polysaccharide	81:94	arg1	Activity					63:70	Tumor Microvascular Inhibition Activity	32:70	Tumor Microvascular Inhibition Activity	32:70	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	0	56	theme	Polysaccharide	81:94	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	6	57	theme	inhibitory	1344:1353	arg1	activity					1355:1362	tumor microvascular inhibitory activity	1324:1362	tumor microvascular inhibitory activity	1324:1362	The study of TsLTP with novel monosaccharide composition and tumor microvascular inhibitory activity might be a beneficial attempt for application of polysaccharide from the genus Trametes in tumor therapy.
35104037	2	58	theme	structural	264:273	arg1	characterization					275:290	The structural characterization	260:290	The structural characterization of TsLTP	260:299	The structural characterization of TsLTP was elucidated mutually by TsL1 and TsL2, whose mass ratio is 1: 4.
35104037	4	59	theme	vein	971:974	arg1	iHUVECs					995:1001	iHUVECs	995:1001	iHUVECs	995:1001	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	4	59	theme	vein	971:974	arg1	cells					988:992	human umbilical vein endothelial cells	955:992	human umbilical vein endothelial cells (iHUVECs)	955:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
35104037	0	60	theme	Total	75:79	arg1	Polysaccharide					81:94	Total Polysaccharide	75:94	Total Polysaccharide from Trametes sanguinea Lloyd	75:124	Structural Characterization and Tumor Microvascular Inhibition Activity of Total Polysaccharide from Trametes sanguinea Lloyd.
35104037	4	61	theme	tube	937:940	arg1	formation					942:950	tube formation	937:950	tube formation of human umbilical vein endothelial cells (iHUVECs)	937:1002	TsLTP exhibited strong inhibitory effects on the migration, invasion, and tube formation of human umbilical vein endothelial cells (iHUVECs) and chick embryo chorioallantoic membrane (CAM) angiogenesis, whereas no inhibitory activity on human TNBC cell lines.
37321750	0	0	theme	cell	82:85	arg1	types					87:91	different cell types	72:91	different cell types	72:91	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	5	1	dep	increased	1095:1103	arg1	compared					1171:1178	compared	1171:1178	compared to the S2 stage	1171:1194	The content of lignin and polysaccharides increased by over 130 % and 60 % respectively when the S3 layer was formed, compared to the S2 stage.
37321750	6	2	theme	corresponding	1311:1323	arg1	tracheids					1331:1339	corresponding axial tracheids	1311:1339	corresponding axial tracheids	1311:1339	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	1	3	theme	scientific	256:265	arg1	ways					267:270	new scientific ways	252:270	new scientific ways	252:270	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	0	4	theme	different	72:80	arg1	types					87:91	different cell types	72:91	different cell types	72:91	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	7	5	from	%	1476:1476	arg1	tracheids					1499:1507	the axial tracheids	1489:1507	the axial tracheids during secondary wall thickening	1489:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	6	6	theme	similar	1374:1380	arg1	order					1382:1386	a similar order	1372:1386	a similar order	1372:1386	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	1	7	theme	events	164:169	arg1	understanding					143:155	An improved understanding	131:155	An improved understanding of the events involved in cell wall polymers deposition during xylem development	131:236	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	7	8	theme	secondary	1516:1524	arg1	thickening					1531:1540	secondary wall thickening	1516:1540	secondary wall thickening	1516:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	4	9	theme	glucomannan	846:856	arg1	deposition					818:827	the deposition	814:827	the deposition of cellulose and glucomannan	814:856	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	6	10	theme	ray	1200:1202	arg1	cells					1204:1208	ray cells	1200:1208	ray cells	1200:1208	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	7	11	theme	polysaccharides	1421:1435	arg1	concentration					1393:1405	The concentration	1389:1405	The concentration of lignin and polysaccharides in ray cells	1389:1448	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	11	theme	polysaccharides	1421:1435	arg1	that					1481:1484	that	1481:1484	that	1481:1484	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	11	theme	polysaccharides	1421:1435	arg1	%					1476:1476	only approximately 50 %	1454:1476	only approximately 50 % of that in the axial tracheids during secondary wall thickening	1454:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	4	12	located	observed	862:869	arg1	stages					882:887	earlier stages	874:887	earlier stages of secondary wall thickening than that of xylan and lignin	874:946	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	4	12	located	observed	862:869	arg1	tracheids					803:811	axial tracheids	797:811	axial tracheids	797:811	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	4	12	located	observed	862:869	arg2	deposition					818:827	the deposition	814:827	the deposition of cellulose and glucomannan	814:856	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	4	13	theme	spatial	998:1004	arg1	distribution					1006:1017	spatial distribution	998:1017	spatial distribution of lignin during differentiation	998:1050	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	5	14	theme	S3	1150:1151	arg1	layer					1153:1157	the S3 layer	1146:1157	the S3 layer	1146:1157	The content of lignin and polysaccharides increased by over 130 % and 60 % respectively when the S3 layer was formed, compared to the S2 stage.
37321750	3	15	theme	cell	592:595	arg1	types					597:601	two cell types	588:601	two cell types	588:601	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	7	16	from	tracheids	1499:1507	arg1	concentration					1393:1405	The concentration	1389:1405	The concentration of lignin and polysaccharides in ray cells	1389:1448	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	16	from	tracheids	1499:1507	arg1	that					1481:1484	that	1481:1484	that	1481:1484	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	16	from	tracheids	1499:1507	arg1	%					1476:1476	only approximately 50 %	1454:1476	only approximately 50 % of that in the axial tracheids during secondary wall thickening	1454:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	1	17	theme	molecular	276:284	arg1	regulation					286:295	molecular regulation	276:295	molecular regulation	276:295	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	0	18	theme	xylem	108:112	arg1	differentiation					114:128	conifer xylem differentiation	100:128	conifer xylem differentiation	100:128	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	2	19	contain	have	377:380	arg1	cells					339:343	Axial and radial cells	322:343	Axial and radial cells	322:343	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	2	19	contain	have	377:380	arg2	behavior					420:427	highly cross-correlated developmental behavior	382:427	highly cross-correlated developmental behavior	382:427	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	4	20	theme	thickening	907:916	arg1	stages					882:887	earlier stages	874:887	earlier stages of secondary wall thickening than that of xylan and lignin	874:946	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	3	21	theme	wall	571:574	arg1	polymers					576:583	cell wall polymers	566:583	cell wall polymers of two cell types	566:601	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	6	22	theme	crystalline	1229:1239	arg1	cellulose					1241:1249	crystalline cellulose	1229:1249	crystalline cellulose	1229:1249	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	0	23	theme	conifer	100:106	arg1	differentiation					114:128	conifer xylem differentiation	100:128	conifer xylem differentiation	100:128	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	4	24	theme	wall	902:905	arg1	thickening					907:916	secondary wall thickening	892:916	secondary wall thickening than that of xylan and lignin	892:946	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	4	25	theme	cellulose	832:840	arg1	deposition					818:827	the deposition	814:827	the deposition of cellulose and glucomannan	814:856	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	4	26	theme	lignin	1022:1027	arg1	distribution					1006:1017	spatial distribution	998:1017	spatial distribution of lignin during differentiation	998:1050	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	3	27	theme	bungeana	784:791	arg1	development					763:773	the development	759:773	the development of Pinus bungeana	759:791	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	2	28	theme	radial	332:337	arg1	cells					339:343	Axial and radial cells	322:343	Axial and radial cells	322:343	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	7	29	theme	that	1481:1484	arg1	concentration					1393:1405	The concentration	1389:1405	The concentration of lignin and polysaccharides in ray cells	1389:1448	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	29	theme	that	1481:1484	arg1	that					1481:1484	that	1481:1484	that	1481:1484	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	29	theme	that	1481:1484	arg1	%					1476:1476	only approximately 50 %	1454:1476	only approximately 50 % of that in the axial tracheids during secondary wall thickening	1454:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	1	30	theme	cell	183:186	arg1	deposition					202:211	cell wall polymers deposition	183:211	cell wall polymers deposition during xylem development	183:236	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	2	31	theme	polymers	480:487	arg1	deposition					442:451	the deposition	438:451	the deposition of corresponding cell wall polymers during xylem differentiation	438:516	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	6	32	theme	lignin	1263:1268	arg1	deposition					1215:1224	the deposition	1211:1224	the deposition of crystalline cellulose, xylan, and lignin	1211:1268	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	4	33	theme	axial	797:801	arg1	tracheids					803:811	axial tracheids	797:811	axial tracheids	797:811	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	0	34	theme	wall	43:46	arg1	polymers					48:55	cell wall polymers	38:55	cell wall polymers	38:55	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	1	35	theme	wall	188:191	arg1	deposition					202:211	cell wall polymers deposition	183:211	cell wall polymers deposition during xylem development	183:236	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	2	36	theme	wall	475:478	arg1	polymers					480:487	corresponding cell wall polymers	456:487	corresponding cell wall polymers	456:487	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	7	37	theme	ray	1440:1442	arg1	cells					1444:1448	ray cells	1440:1448	ray cells	1440:1448	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	2	38	theme	Axial	322:326	arg1	cells					339:343	Axial and radial cells	322:343	Axial and radial cells	322:343	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	7	39	from	concentration	1393:1405	arg1	cells					1444:1448	ray cells	1440:1448	ray cells	1440:1448	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	1	40	theme	polymers	193:200	arg1	deposition					202:211	cell wall polymers deposition	183:211	cell wall polymers deposition during xylem development	183:236	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	2	41	theme	cell	470:473	arg1	polymers					480:487	corresponding cell wall polymers	456:487	corresponding cell wall polymers	456:487	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	1	42	theme	biomass	301:307	arg1	utilization					309:319	biomass utilization	301:319	biomass utilization	301:319	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	3	43	theme	spectral	701:708	arg1	imaging					710:716	label-free in situ spectral imaging	682:716	label-free in situ spectral imaging of different polymer compositions	682:750	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	3	44	theme	types	597:601	arg1	polymers					576:583	cell wall polymers	566:583	cell wall polymers of two cell types	566:601	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	0	45	theme	cell	38:41	arg1	polymers					48:55	cell wall polymers	38:55	cell wall polymers	38:55	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	6	46	theme	xylan	1252:1256	arg1	deposition					1215:1224	the deposition	1211:1224	the deposition of crystalline cellulose, xylan, and lignin	1211:1268	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	5	47	theme	polysaccharides	1079:1093	arg1	content					1057:1063	The content	1053:1063	The content of lignin and polysaccharides	1053:1093	The content of lignin and polysaccharides increased by over 130 % and 60 % respectively when the S3 layer was formed, compared to the S2 stage.
37321750	2	48	theme	developmental	406:418	arg1	behavior					420:427	highly cross-correlated developmental behavior	382:427	highly cross-correlated developmental behavior	382:427	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	5	49	theme	S2	1187:1188	arg1	stage					1190:1194	the S2 stage	1183:1194	the S2 stage	1183:1194	The content of lignin and polysaccharides increased by over 130 % and 60 % respectively when the S3 layer was formed, compared to the S2 stage.
37321750	3	50	theme	in	693:694	arg1	imaging					710:716	label-free in situ spectral imaging	682:716	label-free in situ spectral imaging of different polymer compositions	682:750	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	3	51	theme	hierarchical	644:655	arg1	visualization					657:669	hierarchical visualization	644:669	hierarchical visualization	644:669	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	1	52	theme	xylem	220:224	arg1	development					226:236	xylem development	220:236	xylem development	220:236	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	0	53	theme	polymers	48:55	arg1	changes					27:33	asynchronous changes	14:33	asynchronous changes of cell wall polymers	14:55	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	7	54	theme	lignin	1410:1415	arg1	concentration					1393:1405	The concentration	1389:1405	The concentration of lignin and polysaccharides in ray cells	1389:1448	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	54	theme	lignin	1410:1415	arg1	that					1481:1484	that	1481:1484	that	1481:1484	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	7	54	theme	lignin	1410:1415	arg1	%					1476:1476	only approximately 50 %	1454:1476	only approximately 50 % of that in the axial tracheids during secondary wall thickening	1454:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	4	55	theme	secondary	892:900	arg1	thickening					907:916	secondary wall thickening	892:916	secondary wall thickening than that of xylan and lignin	892:946	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	2	56	theme	xylem	496:500	arg1	differentiation					502:516	xylem differentiation	496:516	xylem differentiation	496:516	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	3	57	theme	polymer	731:737	arg1	compositions					739:750	different polymer compositions	721:750	different polymer compositions	721:750	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	7	58	theme	wall	1526:1529	arg1	thickening					1531:1540	secondary wall thickening	1516:1540	secondary wall thickening	1516:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	6	59	theme	axial	1325:1329	arg1	tracheids					1331:1339	corresponding axial tracheids	1311:1339	corresponding axial tracheids	1311:1339	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	3	60	theme	compositions	739:750	arg1	imaging					710:716	label-free in situ spectral imaging	682:716	label-free in situ spectral imaging of different polymer compositions	682:750	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	6	61	theme	cellulose	1241:1249	arg1	deposition					1215:1224	the deposition	1211:1224	the deposition of crystalline cellulose, xylan, and lignin	1211:1268	In ray cells, the deposition of crystalline cellulose, xylan, and lignin was generally lagged compared to that in corresponding axial tracheids, although the process followed a similar order.
37321750	4	62	theme	earlier	874:880	arg1	stages					882:887	earlier stages	874:887	earlier stages of secondary wall thickening than that of xylan and lignin	874:946	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	2	63	dep	heterogeneous	359:371	arg1	whereas					430:436	whereas	430:436	whereas	430:436	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	3	64	dep	in	693:694	arg1	situ					696:699	situ	696:699	situ	696:699	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	4	65	theme	xylan	955:959	arg1	distribution					961:972	xylan distribution	955:972	xylan distribution	955:972	In axial tracheids, the deposition of cellulose and glucomannan was observed on earlier stages of secondary wall thickening than that of xylan and lignin, while xylan distribution was strongly related to spatial distribution of lignin during differentiation.
37321750	3	66	theme	label-free	682:691	arg1	imaging					710:716	label-free in situ spectral imaging	682:716	label-free in situ spectral imaging of different polymer compositions	682:750	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	1	67	theme	improved	134:141	arg1	understanding					143:155	An improved understanding	131:155	An improved understanding of the events involved in cell wall polymers deposition during xylem development	131:236	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
37321750	3	68	theme	different	721:729	arg1	compositions					739:750	different polymer compositions	721:750	different polymer compositions	721:750	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	5	69	theme	lignin	1068:1073	arg1	content					1057:1063	The content	1053:1063	The content of lignin and polysaccharides	1053:1093	The content of lignin and polysaccharides increased by over 130 % and 60 % respectively when the S3 layer was formed, compared to the S2 stage.
37321750	2	70	theme	corresponding	456:468	arg1	polymers					480:487	corresponding cell wall polymers	456:487	corresponding cell wall polymers	456:487	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	2	71	theme	cross-correlated	389:404	arg1	behavior					420:427	highly cross-correlated developmental behavior	382:427	highly cross-correlated developmental behavior	382:427	Axial and radial cells are spatially heterogeneous and have highly cross-correlated developmental behavior, whereas the deposition of corresponding cell wall polymers during xylem differentiation is less studied.
37321750	7	72	theme	axial	1493:1497	arg1	tracheids					1499:1507	the axial tracheids	1489:1507	the axial tracheids during secondary wall thickening	1489:1540	The concentration of lignin and polysaccharides in ray cells was only approximately 50 % of that in the axial tracheids during secondary wall thickening.
37321750	0	73	theme	asynchronous	14:25	arg1	changes					27:33	asynchronous changes	14:33	asynchronous changes of cell wall polymers	14:55	Insights into asynchronous changes of cell wall polymers accumulated in different cell types during conifer xylem differentiation.
37321750	3	74	theme	cell	566:569	arg1	polymers					576:583	cell wall polymers	566:583	cell wall polymers of two cell types	566:601	To clarify our hypothesis that cell wall polymers of two cell types accumulated asynchronously, we performed hierarchical visualization, including label-free in situ spectral imaging of different polymer compositions during the development of Pinus bungeana.
37321750	1	75	theme	new	252:254	arg1	ways					267:270	new scientific ways	252:270	new scientific ways	252:270	An improved understanding of the events involved in cell wall polymers deposition during xylem development could provide new scientific ways for molecular regulation and biomass utilization.
35200645	6	0	theme	Vero	1238:1241	arg1	cell					1243:1246	Vero cell	1238:1246	Vero cell	1238:1246	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	7	1	theme	NMR	1343:1345	arg1	spectroscopic					1347:1359	FTIR and 1H NMR spectroscopic	1331:1359	FTIR and 1H NMR spectroscopic	1331:1359	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	8	2	theme	potential	1486:1494	arg1	utilization					1496:1506	The potential utilization	1482:1506	The potential utilization of seaweed stranding as a source of antiviral compounds	1482:1562	The potential utilization of seaweed stranding as a source of antiviral compounds is addressed.
35200645	6	3	theme	post-infection	1259:1272	arg1	assay					1274:1278	the post-infection assay	1255:1278	the post-infection assay	1255:1278	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	5	4	theme	Rhodophyta	886:895	arg1	floresii					907:914	the Rhodophyta Halymenia floresii	882:914	the Rhodophyta Halymenia floresii	882:914	Among them, the sr-SPs from the Rhodophyta Halymenia floresii showed stronger activity EC50 0.68 μg/mL with SI 1470, without cytotoxicity.
35200645	6	5	from	protection	1224:1233	arg1	cell					1243:1246	Vero cell	1238:1246	Vero cell	1238:1246	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	0	6	theme	simplex	109:115	arg1	Virus					117:121	Herpes simplex Virus 1	102:123	Herpes simplex Virus 1	102:123	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	7	7	theme	FTIR	1331:1334	arg1	spectroscopic					1347:1359	FTIR and 1H NMR spectroscopic	1331:1359	FTIR and 1H NMR spectroscopic	1331:1359	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	8	theme	sr-SPs	1391:1396	arg1	weights					1376:1382	molecular weights	1366:1382	molecular weights of the sr-SPs from H. floresii	1366:1413	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	8	theme	sr-SPs	1391:1396	arg1	composition					1318:1328	The chemical composition	1305:1328	The chemical composition	1305:1328	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	8	theme	sr-SPs	1391:1396	arg1	spectroscopic					1347:1359	FTIR and 1H NMR spectroscopic	1331:1359	FTIR and 1H NMR spectroscopic	1331:1359	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	0	9	theme	Herpes	102:107	arg1	Virus					117:121	Herpes simplex Virus 1	102:123	Herpes simplex Virus 1	102:123	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	6	10	theme	adsorption	1130:1139	arg1	assays					1141:1146	the viral adsorption assays	1120:1146	the viral adsorption assays	1120:1146	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	3	11	theme	sulfated	534:541	arg1	SPs					560:562	SPs	560:562	SPs	560:562	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	3	11	theme	sulfated	534:541	arg1	polysaccharides					543:557	sulfated polysaccharides	534:557	sulfated polysaccharides (SPs)	534:563	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	2	12	dep	evidence	342:349	arg1	promotes					362:369	promotes	362:369	promotes neurodegenerative disorders	362:397	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	4	13	theme	activity	700:707	arg1	evaluation					709:718	The anti-herpetic activity evaluation	682:718	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	682:809	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	4	14	theme	anti-herpetic	686:698	arg1	evaluation					709:718	The anti-herpetic activity evaluation	682:718	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	682:809	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	4	15	theme	antiviral	834:842	arg1	activity					844:851	antiviral activity	834:851	antiviral activity	834:851	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	6	16	theme	sr-SPs	1032:1037	arg1	activity					1016:1023	the antiviral activity	1002:1023	the antiviral activity of the sr-SPs evaluated at different treatment schemes	1002:1078	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	3	17	theme	anti-herpetic	508:520	arg1	activity					522:529	the in vitro anti-herpetic activity	495:529	the in vitro anti-herpetic activity	495:529	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	6	18	theme	different	1052:1060	arg1	schemes					1072:1078	different treatment schemes	1052:1078	different treatment schemes	1052:1078	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	7	19	from	spectroscopic	1347:1359	arg1	H.					1403:1404	H.	1403:1404	H.	1403:1404	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	4	20	theme	fractions	801:809	arg1	evaluation					709:718	The anti-herpetic activity evaluation	682:718	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	682:809	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	6	21	theme	viral	1124:1128	arg1	assays					1141:1146	the viral adsorption assays	1120:1146	the viral adsorption assays	1120:1146	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	6	22	theme	treatment	1062:1070	arg1	schemes					1072:1078	different treatment schemes	1052:1078	different treatment schemes	1052:1078	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	7	23	from	H.	1403:1404	arg1	weights					1376:1382	molecular weights	1366:1382	molecular weights of the sr-SPs from H. floresii	1366:1413	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	23	from	H.	1403:1404	arg1	sr-SPs					1391:1396	the sr-SPs	1387:1396	the sr-SPs from H. floresii	1387:1413	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	23	from	H.	1403:1404	arg1	composition					1318:1328	The chemical composition	1305:1328	The chemical composition	1305:1328	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	23	from	H.	1403:1404	arg1	spectroscopic					1347:1359	FTIR and 1H NMR spectroscopic	1331:1359	FTIR and 1H NMR spectroscopic	1331:1359	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	0	24	from	Strandings	38:47	arg1	Polysaccharides					9:23	Sulfated Polysaccharides	0:23	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.	0:124	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	5	25	theme	activity	932:939	arg1	μg/mL					951:955	stronger activity EC50 0.68 μg/mL	923:955	stronger activity EC50 0.68 μg/mL	923:955	Among them, the sr-SPs from the Rhodophyta Halymenia floresii showed stronger activity EC50 0.68 μg/mL with SI 1470, without cytotoxicity.
35200645	1	26	theme	prominent	167:175	arg1	concern					184:190	a prominent health concern	165:190	a prominent health concern widespread all over the world	165:220	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	0	27	theme	Sulfated	0:7	arg1	Polysaccharides					9:23	Sulfated Polysaccharides	0:23	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.	0:124	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	8	28	theme	stranding	1519:1527	arg1	utilization					1496:1506	The potential utilization	1482:1506	The potential utilization of seaweed stranding as a source of antiviral compounds	1482:1562	The potential utilization of seaweed stranding as a source of antiviral compounds is addressed.
35200645	4	29	theme	activity	844:851	arg1	range					825:829	a wide range	818:829	a wide range of antiviral activity	818:851	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	5	30	theme	EC50	941:944	arg1	μg/mL					951:955	stronger activity EC50 0.68 μg/mL	923:955	stronger activity EC50 0.68 μg/mL	923:955	Among them, the sr-SPs from the Rhodophyta Halymenia floresii showed stronger activity EC50 0.68 μg/mL with SI 1470, without cytotoxicity.
35200645	2	31	theme	neurodegenerative	371:387	arg1	disorders					389:397	neurodegenerative disorders	371:397	neurodegenerative disorders	371:397	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	0	32	theme	Seaweed	30:36	arg1	Strandings					38:47	Seaweed Strandings	30:47	Seaweed Strandings	30:47	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	3	33	theme	hot	588:590	arg1	water					592:596	hot water	588:596	hot water	588:596	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	5	34	theme	stronger	923:930	arg1	μg/mL					951:955	stronger activity EC50 0.68 μg/mL	923:955	stronger activity EC50 0.68 μg/mL	923:955	Among them, the sr-SPs from the Rhodophyta Halymenia floresii showed stronger activity EC50 0.68 μg/mL with SI 1470, without cytotoxicity.
35200645	3	35	theme	polysaccharides	543:557	arg1	activity					522:529	the in vitro anti-herpetic activity	495:529	the in vitro anti-herpetic activity	495:529	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	5	36	from	floresii	907:914	arg1	sr-SPs					870:875	the sr-SPs	866:875	the sr-SPs from the Rhodophyta Halymenia floresii	866:914	Among them, the sr-SPs from the Rhodophyta Halymenia floresii showed stronger activity EC50 0.68 μg/mL with SI 1470, without cytotoxicity.
35200645	2	37	theme	drug	421:424	arg1	resistance					426:435	drug resistance	421:435	drug resistance	421:435	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	38	theme	resistance	426:435	arg1	emergence					408:416	the emergence	404:416	the emergence of drug resistance	404:435	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	38	theme	resistance	426:435	arg1	transmission					304:315	transmission	304:315	transmission	304:315	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	38	theme	resistance	426:435	arg1	evidence					342:349	the cumulative evidence	327:349	the cumulative evidence that HSV-1 promotes neurodegenerative disorders	327:397	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	38	theme	resistance	426:435	arg1	acquisition					288:298	acquisition	288:298	acquisition	288:298	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	4	39	theme	different	769:777	arg1	exchange					783:790	different ion exchange	769:790	different ion exchange	769:790	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	4	40	theme	semi-refined-polysaccharides	727:754	arg1	fractions					801:809	the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	723:809	the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	723:809	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	7	41	theme	molecular	1366:1374	arg1	weights					1376:1382	molecular weights	1366:1382	molecular weights of the sr-SPs from H. floresii	1366:1413	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	1	42	theme	widespread	192:201	arg1	concern					184:190	a prominent health concern	165:190	a prominent health concern widespread all over the world	165:220	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	6	43	dep	h	1302:1302	arg1	up					1294:1295	up	1294:1295	up	1294:1295	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	6	44	theme	μg/mL	1107:1111	arg1	EC50					1094:1097	a high EC50	1087:1097	a high EC50 of 0.38 μg/mL	1087:1111	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	7	45	from	composition	1318:1328	arg1	H.					1403:1404	H.	1403:1404	H.	1403:1404	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	4	46	theme	purified	792:799	arg1	fractions					801:809	the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	723:809	the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	723:809	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	1	47	theme	health	177:182	arg1	concern					184:190	a prominent health concern	165:190	a prominent health concern widespread all over the world	165:220	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	2	48	theme	antiviral	462:470	arg1	agents					472:477	new antiviral agents	458:477	new antiviral agents	458:477	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	7	49	dep	H.	1403:1404	arg1	floresii					1406:1413	H. floresii	1403:1413	H. floresii	1403:1413	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	7	50	theme	1H	1340:1341	arg1	NMR					1343:1345	1H NMR	1340:1345	1H NMR	1340:1345	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	8	51	theme	antiviral	1544:1552	arg1	compounds					1554:1562	antiviral compounds	1544:1562	antiviral compounds	1544:1562	The potential utilization of seaweed stranding as a source of antiviral compounds is addressed.
35200645	2	52	theme	new	458:460	arg1	agents					472:477	new antiviral agents	458:477	new antiviral agents	458:477	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	7	53	theme	chemical	1309:1316	arg1	composition					1318:1328	The chemical composition	1305:1328	The chemical composition	1305:1328	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	8	54	theme	seaweed	1511:1517	arg1	stranding					1519:1527	seaweed stranding	1511:1527	seaweed stranding	1511:1527	The potential utilization of seaweed stranding as a source of antiviral compounds is addressed.
35200645	2	55	theme	cumulative	331:340	arg1	evidence					342:349	the cumulative evidence	327:349	the cumulative evidence that HSV-1 promotes neurodegenerative disorders	327:397	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	0	56	theme	Renewable	52:60	arg1	Source					62:67	Renewable Source	52:67	Renewable Source for Potential Antivirals against Herpes simplex Virus 1	52:123	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	8	57	theme	compounds	1554:1562	arg1	source					1534:1539	a source	1532:1539	a source of antiviral compounds	1532:1562	The potential utilization of seaweed stranding as a source of antiviral compounds is addressed.
35200645	3	58	theme	stranding	648:656	arg1	events					658:663	stranding events	648:663	stranding events	648:663	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	4	59	theme	wide	820:823	arg1	range					825:829	a wide range	818:829	a wide range of antiviral activity	818:851	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	1	60	theme	Herpes	126:131	arg1	virus					141:145	Herpes simplex virus 1	126:147	Herpes simplex virus 1 (HSV-1)	126:155	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	1	60	theme	Herpes	126:131	arg1	HSV-1					150:154	HSV-1	150:154	HSV-1	150:154	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	2	61	theme	increasing	227:236	arg1	infections					246:255	The increasing genital infections	223:255	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance	223:435	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	4	62	theme	exchange	783:790	arg1	fractions					801:809	the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	723:809	the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions	723:809	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	1	63	theme	simplex	133:139	arg1	virus					141:145	Herpes simplex virus 1	126:147	Herpes simplex virus 1 (HSV-1)	126:155	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	1	63	theme	simplex	133:139	arg1	HSV-1					150:154	HSV-1	150:154	HSV-1	150:154	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	3	64	dep	in	499:500	arg1	vitro					502:506	vitro	502:506	vitro	502:506	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	5	65	theme	Halymenia	897:905	arg1	floresii					907:914	the Rhodophyta Halymenia floresii	882:914	the Rhodophyta Halymenia floresii	882:914	Among them, the sr-SPs from the Rhodophyta Halymenia floresii showed stronger activity EC50 0.68 μg/mL with SI 1470, without cytotoxicity.
35200645	4	66	theme	ion	779:781	arg1	exchange					783:790	different ion exchange	769:790	different ion exchange	769:790	The anti-herpetic activity evaluation of the semi-refined-polysaccharides (sr-SPs) and different ion exchange purified fractions showed a wide range of antiviral activity.
35200645	2	67	theme	HIV-1	320:324	arg1	emergence					408:416	the emergence	404:416	the emergence of drug resistance	404:435	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	67	theme	HIV-1	320:324	arg1	transmission					304:315	transmission	304:315	transmission	304:315	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	67	theme	HIV-1	320:324	arg1	evidence					342:349	the cumulative evidence	327:349	the cumulative evidence that HSV-1 promotes neurodegenerative disorders	327:397	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	2	67	theme	HIV-1	320:324	arg1	acquisition					288:298	acquisition	288:298	acquisition	288:298	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	6	68	theme	antiviral	1006:1014	arg1	activity					1016:1023	the antiviral activity	1002:1023	the antiviral activity of the sr-SPs evaluated at different treatment schemes	1002:1078	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35200645	0	69	theme	Potential	73:81	arg1	Antivirals					83:92	Potential Antivirals	73:92	Potential Antivirals against Herpes simplex Virus 1	73:123	Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes simplex Virus 1.
35200645	7	70	theme	anti-herpetic	1458:1470	arg1	activity					1472:1479	the anti-herpetic activity	1454:1479	the anti-herpetic activity	1454:1479	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	2	71	theme	genital	238:244	arg1	infections					246:255	The increasing genital infections	223:255	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance	223:435	The increasing genital infections by HSV-1 that might facilitate acquisition and transmission of HIV-1, the cumulative evidence that HSV-1 promotes neurodegenerative disorders, and the emergence of drug resistance signify the need for new antiviral agents.
35200645	3	72	theme	in	499:500	arg1	activity					522:529	the in vitro anti-herpetic activity	495:529	the in vitro anti-herpetic activity	495:529	In this study, the in vitro anti-herpetic activity of sulfated polysaccharides (SPs) extracted by enzyme or hot water from seaweeds collected in France and Mexico from stranding events, were evaluated.
35200645	7	73	from	weights	1376:1382	arg1	H.					1403:1404	H.	1403:1404	H.	1403:1404	The chemical composition, FTIR and 1H NMR spectroscopic, and molecular weights of the sr-SPs from H. floresii were determined and discussed based on the anti-herpetic activity.
35200645	1	74	dep	widespread	192:201	arg1	all					203:205	all	203:205	all	203:205	Herpes simplex virus 1 (HSV-1) remains a prominent health concern widespread all over the world.
35200645	6	75	theme	high	1089:1092	arg1	EC50					1094:1097	a high EC50	1087:1097	a high EC50 of 0.38 μg/mL	1087:1111	Further, the antiviral activity of the sr-SPs evaluated at different treatment schemes showed a high EC50 of 0.38 μg/mL during the viral adsorption assays when the polysaccharide and the virus were added simultaneously, whilst the protection on Vero cell during the post-infection assay was effective up to 1 h.
35247423	5	0	from	domains	981:987	arg1	rich					961:964	rich	961:964	rich	961:964	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	2	1	theme	pectin	458:463	arg1	WRIP-A-B					489:496	WRIP-A-B	489:496	WRIP-A-B	489:496	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	1	theme	pectin	458:463	arg1	WRIP-A-A					476:483	WRIP-A-A	476:483	WRIP-A-A	476:483	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	1	theme	pectin	458:463	arg1	fractions					465:473	two pectin fractions	454:473	two pectin fractions (WRIP-A-A and WRIP-A-B)	454:497	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	5	2	theme	α-L-1,5-arabinan	1061:1076	arg1	chains					1083:1088	α-L-1,5-arabinan side chains	1061:1088	α-L-1,5-arabinan side chains	1061:1088	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	5	3	theme	type	1025:1028	arg1	AG-II					1050:1054	AG-II	1050:1054	AG-II	1050:1054	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	5	3	theme	type	1025:1028	arg1	arabinogalactan					1033:1047	type II arabinogalactan	1025:1047	type II arabinogalactan (AG-II)	1025:1055	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	1	4	attach	isolated	144:151	arg2	polysaccharides					123:137	Water-soluble polysaccharides	109:137	Water-soluble polysaccharides	109:137	Water-soluble polysaccharides were isolated from the leaves and roots of Isatis indigotica Fort., and their structural features were studied and compared.
35247423	1	4	attach	isolated	144:151	arg1	roots					173:177	roots	173:177	roots	173:177	Water-soluble polysaccharides were isolated from the leaves and roots of Isatis indigotica Fort., and their structural features were studied and compared.
35247423	1	4	attach	isolated	144:151	arg1	leaves					162:167	leaves	162:167	leaves	162:167	Water-soluble polysaccharides were isolated from the leaves and roots of Isatis indigotica Fort., and their structural features were studied and compared.
35247423	1	5	dep	leaves	162:167	arg1	the					158:160	the	158:160	the	158:160	Water-soluble polysaccharides were isolated from the leaves and roots of Isatis indigotica Fort., and their structural features were studied and compared.
35247423	4	6	with	rhamnogalacturonan	766:783	arg1	ratios					869:874	mass ratios	864:874	mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively	864:919	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	4	7	theme	0.3:1.0:1.7	895:905	arg1	ratios					869:874	mass ratios	864:874	mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively	864:919	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	5	8	from	rich	961:964	arg1	RG-I					969:972	RG-I	969:972	RG-I	969:972	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	5	8	from	rich	961:964	arg1	domains					981:987	HG domains	978:987	HG domains	978:987	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	2	9	theme	polysaccharide	276:289	arg1	WFIP-N					301:306	WFIP-N	301:306	WFIP-N	301:306	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	9	theme	polysaccharide	276:289	arg1	fraction					291:298	One neutral polysaccharide fraction	264:298	One neutral polysaccharide fraction (WFIP-N)	264:307	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	4	10	theme	Monosaccharide	622:635	arg1	composition					637:647	Monosaccharide composition	622:647	Monosaccharide composition	622:647	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	2	11	theme	pectin	319:324	arg1	WFIP-A-A					337:344	WFIP-A-A	337:344	WFIP-A-A	337:344	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	11	theme	pectin	319:324	arg1	fractions					326:334	three pectin fractions	313:334	three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C)	313:368	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	11	theme	pectin	319:324	arg1	WFIP-A-C					360:367	WFIP-A-C	360:367	WFIP-A-C	360:367	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	11	theme	pectin	319:324	arg1	WFIP-A-B					347:354	WFIP-A-B	347:354	WFIP-A-B	347:354	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	4	12	dep	rhamnogalacturonan	766:783	arg1	domains					851:857	domains	851:857	domains	851:857	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	0	13	theme	Comparative	0:10	arg1	study					12:16	Comparative study	0:16	Comparative study of water-soluble polysaccharides	0:49	Comparative study of water-soluble polysaccharides isolated from leaves and roots of Isatis indigotica Fort.
35247423	2	14	dep	fractions	326:334	arg1	WFIP-A-A					337:344	WFIP-A-A	337:344	WFIP-A-A	337:344	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	14	dep	fractions	326:334	arg1	fractions					326:334	three pectin fractions	313:334	three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C)	313:368	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	14	dep	fractions	326:334	arg1	WFIP-A-C					360:367	WFIP-A-C	360:367	WFIP-A-C	360:367	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	14	dep	fractions	326:334	arg1	WFIP-A-B					347:354	WFIP-A-B	347:354	WFIP-A-B	347:354	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	0	15	theme	water-soluble	21:33	arg1	polysaccharides					35:49	water-soluble polysaccharides	21:49	water-soluble polysaccharides	21:49	Comparative study of water-soluble polysaccharides isolated from leaves and roots of Isatis indigotica Fort.
35247423	2	16	theme	neutral	409:415	arg1	fraction					432:439	one neutral polysaccharide fraction	405:439	one neutral polysaccharide fraction (WRIP-N)	405:448	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	16	theme	neutral	409:415	arg1	WRIP-N					442:447	WRIP-N	442:447	WRIP-N	442:447	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	1	17	theme	Water-soluble	109:121	arg1	polysaccharides					123:137	Water-soluble polysaccharides	109:137	Water-soluble polysaccharides	109:137	Water-soluble polysaccharides were isolated from the leaves and roots of Isatis indigotica Fort., and their structural features were studied and compared.
35247423	6	18	theme	structural	1164:1173	arg1	features					1175:1182	structural features	1164:1182	structural features	1164:1182	Our results provide structural features and differences between these polysaccharides which will help to elucidate their functional differences.
35247423	5	19	from	RG-I	969:972	arg1	rich					961:964	rich	961:964	rich	961:964	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	0	20	theme	polysaccharides	35:49	arg1	study					12:16	Comparative study	0:16	Comparative study of water-soluble polysaccharides	0:49	Comparative study of water-soluble polysaccharides isolated from leaves and roots of Isatis indigotica Fort.
35247423	4	21	theme	1.5:1.0:0.4	879:889	arg1	ratios					869:874	mass ratios	864:874	mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively	864:919	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	3	22	theme	major	592:596	arg1	polysaccharides					605:619	the major pectic polysaccharides	588:619	the major pectic polysaccharides	588:619	WFIP-A-B (Mw = 34.6 kDa) and WRIP-A-B (Mw = 29.9 kDa) were the major pectic polysaccharides.
35247423	3	22	theme	major	592:596	arg1	WFIP-A-B					529:536	WFIP-A-B	529:536	WFIP-A-B (Mw = 34.6 kDa)	529:552	WFIP-A-B (Mw = 34.6 kDa) and WRIP-A-B (Mw = 29.9 kDa) were the major pectic polysaccharides.
35247423	3	22	theme	major	592:596	arg1	WRIP-A-B					558:565	WRIP-A-B	558:565	WRIP-A-B (Mw = 29.9 kDa)	558:581	WFIP-A-B (Mw = 34.6 kDa) and WRIP-A-B (Mw = 29.9 kDa) were the major pectic polysaccharides.
35247423	2	23	theme	polysaccharide	417:430	arg1	fraction					432:439	one neutral polysaccharide fraction	405:439	one neutral polysaccharide fraction (WRIP-N)	405:448	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	23	theme	polysaccharide	417:430	arg1	WRIP-N					442:447	WRIP-N	442:447	WRIP-N	442:447	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	1	24	theme	structural	217:226	arg1	features					228:235	their structural features	211:235	their structural features	211:235	Water-soluble polysaccharides were isolated from the leaves and roots of Isatis indigotica Fort., and their structural features were studied and compared.
35247423	2	25	dep	fractions	465:473	arg1	WRIP-A-B					489:496	WRIP-A-B	489:496	WRIP-A-B	489:496	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	25	dep	fractions	465:473	arg1	WRIP-A-A					476:483	WRIP-A-A	476:483	WRIP-A-A	476:483	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	25	dep	fractions	465:473	arg1	fractions					465:473	two pectin fractions	454:473	two pectin fractions (WRIP-A-A and WRIP-A-B)	454:497	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	3	26	theme	pectic	598:603	arg1	polysaccharides					605:619	the major pectic polysaccharides	588:619	the major pectic polysaccharides	588:619	WFIP-A-B (Mw = 34.6 kDa) and WRIP-A-B (Mw = 29.9 kDa) were the major pectic polysaccharides.
35247423	3	26	theme	pectic	598:603	arg1	WFIP-A-B					529:536	WFIP-A-B	529:536	WFIP-A-B (Mw = 34.6 kDa)	529:552	WFIP-A-B (Mw = 34.6 kDa) and WRIP-A-B (Mw = 29.9 kDa) were the major pectic polysaccharides.
35247423	3	26	theme	pectic	598:603	arg1	WRIP-A-B					558:565	WRIP-A-B	558:565	WRIP-A-B (Mw = 29.9 kDa)	558:581	WFIP-A-B (Mw = 34.6 kDa) and WRIP-A-B (Mw = 29.9 kDa) were the major pectic polysaccharides.
35247423	5	27	theme	side	1078:1081	arg1	chains					1083:1088	α-L-1,5-arabinan side chains	1061:1088	α-L-1,5-arabinan side chains	1061:1088	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	5	28	theme	HG	978:979	arg1	domains					981:987	HG domains	978:987	HG domains	978:987	WFIP-A-B and WRIP-A-B were found to be rich in RG-I and HG domains, respectively, and mainly contained type II arabinogalactan (AG-II) and α-L-1,5-arabinan side chains, but those in WRIP-A-B were more numerous and longer.
35247423	4	29	theme	mass	864:867	arg1	ratios					869:874	mass ratios	864:874	mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively	864:919	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	2	30	theme	neutral	268:274	arg1	WFIP-N					301:306	WFIP-N	301:306	WFIP-N	301:306	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	2	30	theme	neutral	268:274	arg1	fraction					291:298	One neutral polysaccharide fraction	264:298	One neutral polysaccharide fraction (WFIP-N)	264:307	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	6	31	theme	functional	1265:1274	arg1	differences					1276:1286	their functional differences	1259:1286	their functional differences	1259:1286	Our results provide structural features and differences between these polysaccharides which will help to elucidate their functional differences.
35247423	4	32	with	rhamnogalacturonan	795:812	arg1	ratios					869:874	mass ratios	864:874	mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively	864:919	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	4	33	theme	methylation	687:697	arg1	analysis					699:706	methylation analysis	687:706	methylation analysis	687:706	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	4	34	with	homogalacturonan	829:844	arg1	ratios					869:874	mass ratios	864:874	mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively	864:919	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
35247423	2	35	dep	the	389:391	arg1	leaves					393:398	leaves	393:398	leaves	393:398	One neutral polysaccharide fraction (WFIP-N) and three pectin fractions (WFIP-A-A, WFIP-A-B and WFIP-A-C) were obtained from the leaves, and one neutral polysaccharide fraction (WRIP-N) and two pectin fractions (WRIP-A-A and WRIP-A-B) were obtained from the roots.
35247423	4	36	theme	enzymatic	657:665	arg1	hydrolysis					667:676	enzymatic hydrolysis	657:676	enzymatic hydrolysis	657:676	Monosaccharide composition, FT-IR, enzymatic hydrolysis, NMR and methylation analysis indicated that both WFIP-A-B and WRIP-A-B are composed of rhamnogalacturonan I (RG-I), rhamnogalacturonan II (RG-II) and homogalacturonan (HG) domains with mass ratios of 1.5:1.0:0.4 and 0.3:1.0:1.7, respectively.
37080111	6	0	theme	lower	913:917	arg1	yields					919:924	lower yields	913:924	lower yields	913:924	Cell encapsulation of the juice in the flesh contributed to lower yields.
37080111	7	1	theme	apple	931:935	arg1	variety					937:943	apple variety	931:943	apple variety	931:943	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	7	1	theme	apple	931:935	arg1	means					986:990	a means	984:990	a means to better control juice yield variations	984:1031	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	7	1	theme	apple	931:935	arg1	mode					960:963	harvesting mode	949:963	harvesting mode	949:963	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	1	2	theme	fresh	231:235	arg1	flesh					253:257	fresh and plasmolyzed flesh	231:257	fresh and plasmolyzed flesh	231:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	0	3	theme	apples	88:93	arg1	yield					73:77	the juice yield	63:77	the juice yield of cider apples	63:93	A multimodal and multiscale investigation of factors affecting the juice yield of cider apples.
37080111	3	4	theme	fruit	627:631	arg1	firmness					633:640	fruit firmness	627:640	fruit firmness	627:640	Cellulose organization and cell wall pectin hydration were affected by ripening and are related to fruit firmness.
37080111	4	5	theme	juice	716:720	arg1	yields					722:727	juice yields	716:727	juice yields	716:727	Flesh viscoelastic mechanical properties were not general indications of juice yields.
37080111	4	6	theme	general	693:699	arg1	indications					701:711	general indications	693:711	general indications of juice yields	693:727	Flesh viscoelastic mechanical properties were not general indications of juice yields.
37080111	0	7	theme	cider	82:86	arg1	apples					88:93	cider apples	82:93	cider apples	82:93	A multimodal and multiscale investigation of factors affecting the juice yield of cider apples.
37080111	6	8	theme	Cell	853:856	arg1	encapsulation					858:870	Cell encapsulation	853:870	Cell encapsulation of the juice in the flesh	853:896	Cell encapsulation of the juice in the flesh contributed to lower yields.
37080111	1	9	from	harvest	123:129	arg1	yield					114:118	Apple cider juice yield	96:118	Apple cider juice yield at harvest and after 15 and 30 days of storage durations	96:175	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	10	theme	plasmolyzed	241:251	arg1	flesh					253:257	fresh and plasmolyzed flesh	231:257	fresh and plasmolyzed flesh	231:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	2	11	theme	Juice	453:457	arg1	yield					459:463	Juice yield	453:463	Juice yield	453:463	Juice yield mainly depended on the apple variety and the storage duration.
37080111	1	12	theme	apples	341:346	arg1	organization					321:332	organization	321:332	organization	321:332	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	12	theme	apples	341:346	arg1	composition					305:315	cell wall polysaccharide composition	280:315	cell wall polysaccharide composition	280:315	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	12	theme	apples	341:346	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	4	13	theme	yields	722:727	arg1	indications					701:711	general indications	693:711	general indications of juice yields	693:727	Flesh viscoelastic mechanical properties were not general indications of juice yields.
37080111	1	14	dep	Judor	433:437	arg1	jaune					446:450	Petit jaune	440:450	Petit jaune	440:450	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	0	15	theme	multimodal	2:11	arg1	investigation					28:40	A multimodal and multiscale investigation	0:40	A multimodal and multiscale investigation of factors	0:51	A multimodal and multiscale investigation of factors affecting the juice yield of cider apples.
37080111	5	16	theme	ice	825:827	arg1	crystals					829:836	ice crystals	825:836	ice crystals	825:836	However, these properties helped distinguish the varieties according to flesh damage caused by ice crystals upon freezing.
37080111	1	17	theme	flesh	253:257	arg1	organization					321:332	organization	321:332	organization	321:332	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	17	theme	flesh	253:257	arg1	composition					305:315	cell wall polysaccharide composition	280:315	cell wall polysaccharide composition	280:315	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	17	theme	flesh	253:257	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	17	theme	flesh	253:257	arg1	distribution					266:277	water distribution	260:277	water distribution	260:277	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	18	theme	storage	159:165	arg1	durations					167:175	storage durations	159:175	storage durations	159:175	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	0	19	theme	multiscale	17:26	arg1	investigation					28:40	A multimodal and multiscale investigation	0:40	A multimodal and multiscale investigation of factors	0:51	A multimodal and multiscale investigation of factors affecting the juice yield of cider apples.
37080111	2	20	theme	apple	488:492	arg1	variety					494:500	the apple variety	484:500	the apple variety	484:500	Juice yield mainly depended on the apple variety and the storage duration.
37080111	1	21	theme	durations	167:175	arg1	durations					167:175	storage durations	159:175	storage durations	159:175	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	21	theme	durations	167:175	arg1	15					141:142	15	141:142	15	141:142	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	22	theme	water	260:264	arg1	distribution					266:277	water distribution	260:277	water distribution	260:277	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	22	theme	water	260:264	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	7	23	theme	yield	1016:1020	arg1	variations					1022:1031	juice yield variations	1010:1031	juice yield variations	1010:1031	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	1	24	theme	Apple	96:100	arg1	yield					114:118	Apple cider juice yield	96:118	Apple cider juice yield at harvest and after 15 and 30 days of storage durations	96:175	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	7	25	dep	variety	937:943	arg1	The					927:929	The	927:929	The	927:929	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	4	26	theme	Flesh	643:647	arg1	properties					673:682	Flesh viscoelastic mechanical properties	643:682	Flesh viscoelastic mechanical properties	643:682	Flesh viscoelastic mechanical properties were not general indications of juice yields.
37080111	3	27	theme	Cellulose	528:536	arg1	organization					538:549	Cellulose organization	528:549	Cellulose organization	528:549	Cellulose organization and cell wall pectin hydration were affected by ripening and are related to fruit firmness.
37080111	5	28	theme	flesh	802:806	arg1	damage					808:813	flesh damage	802:813	flesh damage caused by ice crystals upon freezing	802:850	However, these properties helped distinguish the varieties according to flesh damage caused by ice crystals upon freezing.
37080111	1	29	theme	cell	280:283	arg1	composition					305:315	cell wall polysaccharide composition	280:315	cell wall polysaccharide composition	280:315	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	29	theme	cell	280:283	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	2	30	theme	storage	510:516	arg1	duration					518:525	the storage duration	506:525	the storage duration	506:525	Juice yield mainly depended on the apple variety and the storage duration.
37080111	7	31	theme	harvesting	949:958	arg1	means					986:990	a means	984:990	a means to better control juice yield variations	984:1031	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	7	31	theme	harvesting	949:958	arg1	mode					960:963	harvesting mode	949:963	harvesting mode	949:963	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	7	31	theme	harvesting	949:958	arg1	variety					937:943	apple variety	931:943	apple variety	931:943	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	1	32	theme	cider	102:106	arg1	yield					114:118	Apple cider juice yield	96:118	Apple cider juice yield at harvest and after 15 and 30 days of storage durations	96:175	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	0	33	theme	factors	45:51	arg1	investigation					28:40	A multimodal and multiscale investigation	0:40	A multimodal and multiscale investigation of factors	0:51	A multimodal and multiscale investigation of factors affecting the juice yield of cider apples.
37080111	1	34	theme	wall	285:288	arg1	composition					305:315	cell wall polysaccharide composition	280:315	cell wall polysaccharide composition	280:315	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	34	theme	wall	285:288	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	7	35	theme	juice	1010:1014	arg1	variations					1022:1031	juice yield variations	1010:1031	juice yield variations	1010:1031	The apple variety and harvesting mode are recommended as a means to better control juice yield variations.
37080111	1	36	theme	apple	368:372	arg1	varieties					374:382	the apple varieties	364:382	the apple varieties used	364:387	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	36	theme	apple	368:372	arg1	Judor					433:437	Judor	433:437	Judor	433:437	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	37	theme	Petit	440:444	arg1	jaune					446:450	Petit jaune	440:450	Petit jaune	440:450	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	38	theme	juice	108:112	arg1	yield					114:118	Apple cider juice yield	96:118	Apple cider juice yield at harvest and after 15 and 30 days of storage durations	96:175	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	39	theme	polysaccharide	290:303	arg1	composition					305:315	cell wall polysaccharide composition	280:315	cell wall polysaccharide composition	280:315	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	39	theme	polysaccharide	290:303	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	4	40	theme	viscoelastic	649:660	arg1	properties					673:682	Flesh viscoelastic mechanical properties	643:682	Flesh viscoelastic mechanical properties	643:682	Flesh viscoelastic mechanical properties were not general indications of juice yields.
37080111	3	41	theme	wall	560:563	arg1	hydration					572:580	cell wall pectin hydration	555:580	cell wall pectin hydration	555:580	Cellulose organization and cell wall pectin hydration were affected by ripening and are related to fruit firmness.
37080111	3	42	theme	pectin	565:570	arg1	hydration					572:580	cell wall pectin hydration	555:580	cell wall pectin hydration	555:580	Cellulose organization and cell wall pectin hydration were affected by ripening and are related to fruit firmness.
37080111	4	43	theme	mechanical	662:671	arg1	properties					673:682	Flesh viscoelastic mechanical properties	643:682	Flesh viscoelastic mechanical properties	643:682	Flesh viscoelastic mechanical properties were not general indications of juice yields.
37080111	0	44	theme	juice	67:71	arg1	yield					73:77	the juice yield	63:77	the juice yield of cider apples	63:93	A multimodal and multiscale investigation of factors affecting the juice yield of cider apples.
37080111	1	45	theme	mechanical	206:215	arg1	organization					321:332	organization	321:332	organization	321:332	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	45	theme	mechanical	206:215	arg1	composition					305:315	cell wall polysaccharide composition	280:315	cell wall polysaccharide composition	280:315	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	45	theme	mechanical	206:215	arg1	properties					217:226	the mechanical properties	202:226	the mechanical properties of fresh and plasmolyzed flesh	202:257	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	1	45	theme	mechanical	206:215	arg1	distribution					266:277	water distribution	260:277	water distribution	260:277	Apple cider juice yield at harvest and after 15 and 30 days of storage durations was studied by analyzing the mechanical properties of fresh and plasmolyzed flesh, water distribution, cell wall polysaccharide composition and organization of the apples; in this study, the apple varieties used were Avrolles, Douce coetligne, Douce moen, Judor, Petit jaune.
37080111	6	46	from	encapsulation	858:870	arg1	flesh					892:896	the flesh	888:896	the flesh	888:896	Cell encapsulation of the juice in the flesh contributed to lower yields.
37080111	6	47	theme	juice	879:883	arg1	encapsulation					858:870	Cell encapsulation	853:870	Cell encapsulation of the juice in the flesh	853:896	Cell encapsulation of the juice in the flesh contributed to lower yields.
37080111	3	48	theme	cell	555:558	arg1	hydration					572:580	cell wall pectin hydration	555:580	cell wall pectin hydration	555:580	Cellulose organization and cell wall pectin hydration were affected by ripening and are related to fruit firmness.
35461856	6	0	theme	skin	914:917	arg1	substrates					919:928	pork skin substrates	909:928	pork skin substrates	909:928	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	7	1	theme	adhesion	935:942	arg1	strength					944:951	The adhesion strength	931:951	The adhesion strength	931:951	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	7	1	theme	adhesion	935:942	arg1	higher					956:961	higher	956:961	higher	956:961	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	5	2	theme	solutions	684:692	arg1	strength					668:675	The adhesion strength	655:675	The adhesion strength of the solutions	655:692	The adhesion strength of the solutions was evaluated on paper and polylactide (PLA) substrates to evaluate their potential as environmentally friendly adhesive.
35461856	1	3	theme	optimized	318:326	arg1	conditions					339:348	optimized extraction conditions	318:348	optimized extraction conditions (OP%US)	318:356	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	3	theme	optimized	318:326	arg1	%					353:353	OP%	351:353	OP%US	351:355	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	6	4	theme	OP	816:817	arg1	%					818:818	OP%	816:818	OP%US	816:820	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	9	5	theme	cohesive	1393:1400	arg1	failure					1415:1421	both cohesive and adhesive failure	1388:1421	both cohesive and adhesive failure	1388:1421	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	8	6	theme	adhesives	1267:1275	arg1	type					1295:1298	the substrate type	1281:1298	the substrate type	1281:1298	The correlation between rheological properties and adhesion strength indicates that the adhesion strength strongly depends on the state of adhesives and the substrate type.
35461856	8	6	theme	adhesives	1267:1275	arg1	state					1258:1262	the state	1254:1262	the state of adhesives	1254:1275	The correlation between rheological properties and adhesion strength indicates that the adhesion strength strongly depends on the state of adhesives and the substrate type.
35461856	9	7	dep	strength	1340:1347	arg1	intermediate					1350:1361	intermediate	1350:1361	intermediate	1350:1361	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	9	7	dep	strength	1340:1347	arg1	states					1371:1376	gel states	1367:1376	gel states	1367:1376	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	1	8	theme	extraction	328:337	arg1	conditions					339:348	optimized extraction conditions	318:348	optimized extraction conditions (OP%US)	318:356	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	8	theme	extraction	328:337	arg1	%					353:353	OP%	351:353	OP%US	351:355	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	7	9	theme	capillary	1036:1044	arg1	force					1046:1050	the capillary force	1032:1050	the capillary force of paper which allows penetration of adhesive into the micropores of paper	1032:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	8	10	theme	substrate	1285:1293	arg1	type					1295:1298	the substrate type	1281:1298	the substrate type	1281:1298	The correlation between rheological properties and adhesion strength indicates that the adhesion strength strongly depends on the state of adhesives and the substrate type.
35461856	9	11	theme	gel	1367:1369	arg1	states					1371:1376	gel states	1367:1376	gel states	1367:1376	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	5	12	theme	paper	711:715	arg1	substrates					739:748	paper and polylactide (PLA) substrates	711:748	paper and polylactide (PLA) substrates	711:748	The adhesion strength of the solutions was evaluated on paper and polylactide (PLA) substrates to evaluate their potential as environmentally friendly adhesive.
35461856	9	13	dep	show	1314:1317	arg1	whereas					1424:1430	whereas	1424:1430	whereas	1424:1430	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	10	14	theme	adhesive	1577:1584	arg1	tissue					1570:1575	tissue adhesive	1570:1584	tissue adhesive in medical applications	1570:1608	Therefore, these polysaccharides extracts could be very promising as tissue adhesive in medical applications.
35461856	4	15	theme	gel	616:618	arg1	states					620:625	gel states	616:625	gel states	616:625	Rheological measurements allowed determining the liquid, intermediate and gel states of the extract's solutions.
35461856	9	16	theme	PLA	1485:1487	arg1	substrates					1489:1498	PLA substrates	1485:1498	PLA substrates	1485:1498	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	8	17	theme	adhesion	1179:1186	arg1	strength					1188:1195	adhesion strength	1179:1195	adhesion strength	1179:1195	The correlation between rheological properties and adhesion strength indicates that the adhesion strength strongly depends on the state of adhesives and the substrate type.
35461856	5	18	theme	polylactide	721:731	arg1	substrates					739:748	paper and polylactide (PLA) substrates	711:748	paper and polylactide (PLA) substrates	711:748	The adhesion strength of the solutions was evaluated on paper and polylactide (PLA) substrates to evaluate their potential as environmentally friendly adhesive.
35461856	1	19	theme	OP	351:352	arg1	conditions					339:348	optimized extraction conditions	318:348	optimized extraction conditions (OP%US)	318:356	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	19	theme	OP	351:352	arg1	%					353:353	OP%	351:353	OP%US	351:355	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	8	20	theme	adhesion	1216:1223	arg1	strength					1225:1232	the adhesion strength	1212:1232	the adhesion strength	1212:1232	The correlation between rheological properties and adhesion strength indicates that the adhesion strength strongly depends on the state of adhesives and the substrate type.
35461856	10	21	theme	medical	1589:1595	arg1	applications					1597:1608	medical applications	1589:1608	medical applications	1589:1608	Therefore, these polysaccharides extracts could be very promising as tissue adhesive in medical applications.
35461856	2	22	theme	proteins	401:408	arg1	content					410:416	The total carbohydrates content (TCC) and proteins content	359:416	The total carbohydrates content (TCC) and proteins content of the extracts	359:432	The total carbohydrates content (TCC) and proteins content of the extracts were determined.
35461856	6	23	dep	%	818:818	arg1	US					819:820	US	819:820	US	819:820	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	1	24	dep	%	294:294	arg1	US					295:296	US	295:296	US	295:296	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	7	25	theme	due	1025:1027	arg1	substrate					1015:1023	skin/skin (411 kPa) substrate	995:1023	skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper	995:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	1	26	theme	different	243:251	arg1	ultrasound					253:262	different ultrasound	243:262	different ultrasound (US) treatment times (0%US, 50%US, 100%US)	243:305	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	7	27	theme	adhesive	1089:1096	arg1	penetration					1074:1084	penetration	1074:1084	penetration of adhesive into the micropores of paper	1074:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	7	28	theme	411 kPa	1006:1012	arg1	substrate					1015:1023	skin/skin (411 kPa) substrate	995:1023	skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper	995:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	3	29	theme	extracts	520:527	arg1	composition					529:539	the extracts composition	516:539	the extracts composition	516:539	Data show that the extraction parameters significantly influence the extracts composition.
35461856	9	30	theme	adhesive	1406:1413	arg1	failure					1415:1421	both cohesive and adhesive failure	1388:1421	both cohesive and adhesive failure	1388:1421	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	0	31	theme	rheological	21:31	arg1	properties					48:57	rheological and mechanical properties	21:57	properties	48:57	Correlations between rheological and mechanical properties of fructo-polysaccharides extracted from Ornithogalum billardieri as biobased adhesive for biomedical applications.
35461856	4	32	theme	Rheological	542:552	arg1	measurements					554:565	Rheological measurements	542:565	Rheological measurements	542:565	Rheological measurements allowed determining the liquid, intermediate and gel states of the extract's solutions.
35461856	0	33	theme	biomedical	150:159	arg1	applications					161:172	biomedical applications	150:172	biomedical applications	150:172	Correlations between rheological and mechanical properties of fructo-polysaccharides extracted from Ornithogalum billardieri as biobased adhesive for biomedical applications.
35461856	6	34	theme	adhesion	843:850	arg1	1418.3 kPa					862:871	1418.3 kPa	862:871	1418.3 kPa	862:871	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	6	34	theme	adhesion	843:850	arg1	strength					852:859	the highest adhesion strength	831:859	the highest adhesion strength (1418.3 kPa) on paper	831:881	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	9	35	theme	liquid	1469:1474	arg1	state					1476:1480	liquid state	1469:1480	liquid state	1469:1480	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	2	36	theme	content	383:389	arg1	content					410:416	The total carbohydrates content (TCC) and proteins content	359:416	The total carbohydrates content (TCC) and proteins content of the extracts	359:432	The total carbohydrates content (TCC) and proteins content of the extracts were determined.
35461856	2	37	theme	extracts	425:432	arg1	content					410:416	The total carbohydrates content (TCC) and proteins content	359:416	The total carbohydrates content (TCC) and proteins content of the extracts	359:432	The total carbohydrates content (TCC) and proteins content of the extracts were determined.
35461856	6	38	theme	pork	909:912	arg1	substrates					919:928	pork skin substrates	909:928	pork skin substrates	909:928	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	7	39	theme	skin/skin	995:1003	arg1	substrate					1015:1023	skin/skin (411 kPa) substrate	995:1023	skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper	995:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	6	40	theme	highest	835:841	arg1	1418.3 kPa					862:871	1418.3 kPa	862:871	1418.3 kPa	862:871	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	6	40	theme	highest	835:841	arg1	strength					852:859	the highest adhesion strength	831:859	the highest adhesion strength (1418.3 kPa) on paper	831:881	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
35461856	4	41	theme	solutions	644:652	arg1	liquid					591:596	liquid	591:596	liquid	591:596	Rheological measurements allowed determining the liquid, intermediate and gel states of the extract's solutions.
35461856	2	42	theme	carbohydrates	369:381	arg1	TCC					392:394	TCC	392:394	TCC	392:394	The total carbohydrates content (TCC) and proteins content of the extracts were determined.
35461856	2	42	theme	carbohydrates	369:381	arg1	content					383:389	carbohydrates content	369:389	carbohydrates content (TCC)	369:395	The total carbohydrates content (TCC) and proteins content of the extracts were determined.
35461856	0	43	theme	mechanical	37:46	arg1	properties					48:57	rheological and mechanical properties	21:57	properties	48:57	Correlations between rheological and mechanical properties of fructo-polysaccharides extracted from Ornithogalum billardieri as biobased adhesive for biomedical applications.
35461856	9	44	theme	SEM	1301:1303	arg1	analyses					1305:1312	SEM analyses	1301:1312	SEM analyses	1301:1312	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	7	45	theme	paper	1121:1125	arg1	micropores					1107:1116	the micropores	1103:1116	the micropores of paper	1103:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	2	46	theme	total	363:367	arg1	content					410:416	The total carbohydrates content (TCC) and proteins content	359:416	The total carbohydrates content (TCC) and proteins content of the extracts	359:432	The total carbohydrates content (TCC) and proteins content of the extracts were determined.
35461856	0	47	theme	fructo-polysaccharides	62:83	arg1	Correlations					0:11	Correlations	0:11	Correlations between rheological and mechanical properties of fructo-polysaccharides extracted from Ornithogalum billardieri	0:123	Correlations between rheological and mechanical properties of fructo-polysaccharides extracted from Ornithogalum billardieri as biobased adhesive for biomedical applications.
35461856	1	48	dep	%	353:353	arg1	US					354:355	US	354:355	US	354:355	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	9	49	located	observed	1457:1464	arg1	state					1476:1480	liquid state	1469:1480	liquid state	1469:1480	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	9	49	located	observed	1457:1464	arg1	substrates					1489:1498	PLA substrates	1485:1498	PLA substrates	1485:1498	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	9	49	located	observed	1457:1464	arg2	failure					1446:1452	only adhesive failure	1432:1452	only adhesive failure	1432:1452	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	10	50	from	tissue	1570:1575	arg1	applications					1597:1608	medical applications	1589:1608	medical applications	1589:1608	Therefore, these polysaccharides extracts could be very promising as tissue adhesive in medical applications.
35461856	1	51	dep	%	302:302	arg1	US					303:304	US	303:304	US	303:304	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	8	52	theme	rheological	1152:1162	arg1	properties					1164:1173	rheological properties	1152:1173	rheological properties	1152:1173	The correlation between rheological properties and adhesion strength indicates that the adhesion strength strongly depends on the state of adhesives and the substrate type.
35461856	5	53	theme	adhesion	659:666	arg1	strength					668:675	The adhesion strength	655:675	The adhesion strength of the solutions	655:692	The adhesion strength of the solutions was evaluated on paper and polylactide (PLA) substrates to evaluate their potential as environmentally friendly adhesive.
35461856	7	54	theme	paper	1055:1059	arg1	force					1046:1050	the capillary force	1032:1050	the capillary force of paper which allows penetration of adhesive into the micropores of paper	1032:1125	The adhesion strength is higher on skin/paper (870 kPa) than on skin/skin (411 kPa) substrate due to the capillary force of paper which allows penetration of adhesive into the micropores of paper.
35461856	9	55	theme	adhesive	1437:1444	arg1	failure					1446:1452	only adhesive failure	1432:1452	only adhesive failure	1432:1452	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	9	56	theme	higher	1324:1329	arg1	strength					1340:1347	higher adhesion strength	1324:1347	higher adhesion strength (intermediate and gel states)	1324:1377	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	1	57	theme	treatment	269:277	arg1	times					279:283	treatment times	269:283	different ultrasound (US) treatment times (0%US, 50%US, 100%US)	243:305	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	57	theme	treatment	269:277	arg1	%					287:287	0%US, 50%US, 100%US	286:304	%	287:287	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	58	dep	%	287:287	arg1	US					288:289	US	288:289	US	288:289	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	9	59	theme	adhesion	1331:1338	arg1	strength					1340:1347	higher adhesion strength	1324:1347	higher adhesion strength (intermediate and gel states)	1324:1377	SEM analyses show that higher adhesion strength (intermediate and gel states) involves both cohesive and adhesive failure, whereas only adhesive failure is observed in liquid state on PLA substrates.
35461856	4	60	dep	liquid	591:596	arg1	the					587:589	the	587:589	the	587:589	Rheological measurements allowed determining the liquid, intermediate and gel states of the extract's solutions.
35461856	1	61	dep	ultrasound	253:262	arg1	US					265:266	US	265:266	US	265:266	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	61	dep	ultrasound	253:262	arg1	times					279:283	treatment times	269:283	different ultrasound (US) treatment times (0%US, 50%US, 100%US)	243:305	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	1	61	dep	ultrasound	253:262	arg1	%					287:287	0%US, 50%US, 100%US	286:304	%	287:287	Polysaccharides are extracted from Ornithogalum by maceration using different ultrasound (US) treatment times (0%US, 50%US, 100%US), and under optimized extraction conditions (OP%US).
35461856	10	62	theme	polysaccharides	1518:1532	arg1	extracts					1534:1541	these polysaccharides extracts	1512:1541	these polysaccharides extracts	1512:1541	Therefore, these polysaccharides extracts could be very promising as tissue adhesive in medical applications.
35461856	3	63	theme	extraction	470:479	arg1	parameters					481:490	the extraction parameters	466:490	the extraction parameters	466:490	Data show that the extraction parameters significantly influence the extracts composition.
35461856	6	64	from	strength	852:859	arg1	paper					877:881	paper	877:881	paper	877:881	OP%US presents the highest adhesion strength (1418.3 kPa) on paper, and is further tested on pork skin substrates.
36581037	0	0	with	loading	48:54	arg1	polyphenols					75:85	Malus baccata polyphenols	61:85	Malus baccata polyphenols	61:85	Protein-polysaccharides based nanoparticles for loading with Malus baccata polyphenols and their digestibility in vitro.
36581037	0	0	with	loading	48:54	arg1	digestibility					97:109	their digestibility	91:109	their digestibility in vitro	91:118	Protein-polysaccharides based nanoparticles for loading with Malus baccata polyphenols and their digestibility in vitro.
36581037	1	1	theme	absorption	162:171	arg1	rate					173:176	low absorption rate	158:176	low absorption rate	158:176	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	4	2	theme	gastrointestinal	601:616	arg1	digestion					618:626	gastrointestinal digestion	601:626	gastrointestinal digestion in vitro	601:635	During gastrointestinal digestion in vitro, the release characteristic and variation in phenolic composition of MBP-NPs were evaluated.
36581037	8	3	theme	phenolic	1247:1254	arg1	composition					1256:1266	the phenolic composition	1243:1266	the phenolic composition of MBP-NPs	1243:1277	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	7	4	theme	sustained	1056:1064	arg1	characteristics					1074:1088	the sustained release characteristics	1052:1088	the sustained release characteristics	1052:1088	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	5	5	theme	spherical	841:849	arg1	shapes					851:856	the regularly spherical shapes	827:856	the regularly spherical shapes	827:856	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	1	6	theme	gastrointestinal	263:278	arg1	digestion					280:288	gastrointestinal digestion	263:288	gastrointestinal digestion	263:288	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	8	7	theme	MBP-NPs	1271:1277	arg1	composition					1256:1266	the phenolic composition	1243:1266	the phenolic composition of MBP-NPs	1243:1277	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	7	8	theme	release	1066:1072	arg1	characteristics					1074:1088	the sustained release characteristics	1052:1088	the sustained release characteristics	1052:1088	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	3	9	theme	different	541:549	arg1	condition					551:559	different condition	541:559	different condition	541:559	The physicochemical properties and morphology of MBP-NPs prepared by different condition were respectively characterized.
36581037	5	10	theme	hydrogen	772:779	arg1	bonding					781:787	hydrogen bonding	772:787	hydrogen bonding	772:787	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	1	11	theme	poor	125:128	arg1	solubility					130:139	The poor solubility	121:139	The poor solubility	121:139	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	2	12	theme	Hohenbuehelia	396:408	arg1	polysaccharides					419:433	mucin (MC) and Hohenbuehelia serotina polysaccharides	381:433	polysaccharides	419:433	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	0	13	theme	Malus	61:65	arg1	polyphenols					75:85	Malus baccata polyphenols	61:85	Malus baccata polyphenols	61:85	Protein-polysaccharides based nanoparticles for loading with Malus baccata polyphenols and their digestibility in vitro.
36581037	6	14	theme	physicochemical	953:967	arg1	stability					969:977	the excellent physicochemical stability	939:977	the excellent physicochemical stability	939:977	Moreover, MBP-NPs presented the excellent physicochemical stability.
36581037	4	15	theme	phenolic	682:689	arg1	composition					691:701	phenolic composition	682:701	phenolic composition of MBP-NPs	682:712	During gastrointestinal digestion in vitro, the release characteristic and variation in phenolic composition of MBP-NPs were evaluated.
36581037	6	16	theme	excellent	943:951	arg1	stability					969:977	the excellent physicochemical stability	939:977	the excellent physicochemical stability	939:977	Moreover, MBP-NPs presented the excellent physicochemical stability.
36581037	4	17	theme	MBP-NPs	706:712	arg1	composition					691:701	phenolic composition	682:701	phenolic composition of MBP-NPs	682:712	During gastrointestinal digestion in vitro, the release characteristic and variation in phenolic composition of MBP-NPs were evaluated.
36581037	5	18	theme	smooth	862:867	arg1	surfaces					869:876	smooth surfaces	862:876	smooth surfaces	862:876	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	9	19	theme	polyphenols	1447:1457	arg1	bioavailability					1428:1442	the bioavailability	1424:1442	the bioavailability of polyphenols	1424:1457	This study provides a novel strategy to improve the bioavailability of polyphenols.
36581037	9	20	theme	novel	1398:1402	arg1	strategy					1404:1411	a novel strategy	1396:1411	a novel strategy to improve the bioavailability of polyphenols	1396:1457	This study provides a novel strategy to improve the bioavailability of polyphenols.
36581037	8	21	theme	compounds	1365:1373	arg1	degradation					1322:1332	degradation	1322:1332	degradation	1322:1332	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	8	21	theme	compounds	1365:1373	arg1	transformation					1338:1351	transformation	1338:1351	transformation	1338:1351	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	2	22	theme	limitable	313:321	arg1	problems					323:330	the limitable problems	309:330	the limitable problems	309:330	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	4	23	from	variation	669:677	arg1	composition					691:701	phenolic composition	682:701	phenolic composition of MBP-NPs	682:712	During gastrointestinal digestion in vitro, the release characteristic and variation in phenolic composition of MBP-NPs were evaluated.
36581037	1	24	theme	polyphenols	210:220	arg1	bioavailability					191:205	the bioavailability	187:205	the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion	187:288	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	7	25	theme	compounds	1102:1110	arg1	characteristics					1074:1088	the sustained release characteristics	1052:1088	the sustained release characteristics	1052:1088	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	8	26	theme	unencapsulated	1181:1194	arg1	MBP					1196:1198	unencapsulated MBP	1181:1198	unencapsulated MBP	1181:1198	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	4	27	theme	characteristic	650:663	arg1	release					642:648	the release characteristic	638:663	the release characteristic	638:663	During gastrointestinal digestion in vitro, the release characteristic and variation in phenolic composition of MBP-NPs were evaluated.
36581037	8	28	dep	degradation	1322:1332	arg1	the					1318:1320	the	1318:1320	the	1318:1320	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	8	29	theme	phenolic	1356:1363	arg1	compounds					1365:1373	phenolic compounds	1356:1373	phenolic compounds	1356:1373	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	2	30	theme	serotina	410:417	arg1	polysaccharides					419:433	mucin (MC) and Hohenbuehelia serotina polysaccharides	381:433	polysaccharides	419:433	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	0	31	theme	baccata	67:73	arg1	polyphenols					75:85	Malus baccata polyphenols	61:85	Malus baccata polyphenols	61:85	Protein-polysaccharides based nanoparticles for loading with Malus baccata polyphenols and their digestibility in vitro.
36581037	3	32	theme	physicochemical	476:490	arg1	properties					492:501	The physicochemical properties	472:501	The physicochemical properties	472:501	The physicochemical properties and morphology of MBP-NPs prepared by different condition were respectively characterized.
36581037	2	33	theme	MBP	457:459	arg1	delivery					445:452	delivery	445:452	delivery of MBP (MBP-NPs)	445:469	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	8	34	theme	significant	1205:1215	arg1	variation					1217:1225	the significant variation	1201:1225	the significant variation	1201:1225	Compared with that of unencapsulated MBP, the significant variation was occurred in the phenolic composition of MBP-NPs, indicating that MBP-NPs could prevent the degradation and transformation of phenolic compounds.
36581037	1	35	attach	isolated	222:229	arg1	MBP					251:253	MBP	251:253	MBP	251:253	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	1	35	attach	isolated	222:229	arg1	baccata					242:248	Malus baccata	236:248	Malus baccata (MBP)	236:254	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	1	35	attach	isolated	222:229	arg2	polyphenols					210:220	polyphenols	210:220	polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion	210:288	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	1	36	theme	low	158:160	arg1	rate					173:176	low absorption rate	158:176	low absorption rate	158:176	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	7	37	theme	gastrointestinal	997:1012	arg1	digestion					1014:1022	simulated gastrointestinal digestion	987:1022	simulated gastrointestinal digestion in vitro	987:1031	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	2	38	theme	food-grade	337:346	arg1	nanoparticles					348:360	the food-grade nanoparticles	333:360	the food-grade nanoparticles	333:360	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	7	39	theme	SDS-PAGE	1137:1144	arg1	measurement					1146:1156	SDS-PAGE measurement	1137:1156	SDS-PAGE measurement	1137:1156	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	7	40	theme	phenolic	1093:1100	arg1	compounds					1102:1110	phenolic compounds	1093:1110	phenolic compounds	1093:1110	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	2	41	theme	mucin	381:385	arg1	MC					388:389	mucin (MC) and Hohenbuehelia serotina polysaccharides	381:433	MC	388:389	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	2	41	theme	mucin	381:385	arg1	HSP					436:438	HSP	436:438	HSP	436:438	In order to solve the limitable problems, the food-grade nanoparticles were fabricated by mucin (MC) and Hohenbuehelia serotina polysaccharides (HSP) for delivery of MBP (MBP-NPs).
36581037	4	42	from	release	642:648	arg1	composition					691:701	phenolic composition	682:701	phenolic composition of MBP-NPs	682:712	During gastrointestinal digestion in vitro, the release characteristic and variation in phenolic composition of MBP-NPs were evaluated.
36581037	1	43	theme	Malus	236:240	arg1	MBP					251:253	MBP	251:253	MBP	251:253	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	1	43	theme	Malus	236:240	arg1	baccata					242:248	Malus baccata	236:248	Malus baccata (MBP)	236:254	The poor solubility, instability and low absorption rate obstruct the bioavailability of polyphenols isolated from Malus baccata (MBP) during gastrointestinal digestion.
36581037	5	44	theme	semi-crystalline	882:897	arg1	properties					899:908	semi-crystalline properties	882:908	semi-crystalline properties	882:908	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	7	45	theme	simulated	987:995	arg1	digestion					1014:1022	simulated gastrointestinal digestion	987:1022	simulated gastrointestinal digestion in vitro	987:1031	During simulated gastrointestinal digestion in vitro, MBP-NPs exhibited the sustained release characteristics of phenolic compounds, which were confirmed by SDS-PAGE measurement.
36581037	5	46	theme	hydrophobic	793:803	arg1	interaction					805:815	hydrophobic interaction	793:815	hydrophobic interaction	793:815	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	5	47	contain	possessed	817:825	arg2	surfaces					869:876	smooth surfaces	862:876	smooth surfaces	862:876	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	5	47	contain	possessed	817:825	arg2	shapes					851:856	the regularly spherical shapes	827:856	the regularly spherical shapes	827:856	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	5	47	contain	possessed	817:825	arg2	properties					899:908	semi-crystalline properties	882:908	semi-crystalline properties	882:908	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	5	47	contain	possessed	817:825	arg1	MBP-NPs					754:760	MBP-NPs	754:760	MBP-NPs formed by hydrogen bonding and hydrophobic interaction	754:815	The results showed that MBP-NPs formed by hydrogen bonding and hydrophobic interaction possessed the regularly spherical shapes and smooth surfaces and semi-crystalline properties.
36581037	3	48	theme	MBP-NPs	521:527	arg1	morphology					507:516	morphology	507:516	morphology	507:516	The physicochemical properties and morphology of MBP-NPs prepared by different condition were respectively characterized.
36581037	3	48	theme	MBP-NPs	521:527	arg1	properties					492:501	The physicochemical properties	472:501	The physicochemical properties	472:501	The physicochemical properties and morphology of MBP-NPs prepared by different condition were respectively characterized.
36675089	0	0	theme	Alcohol	89:95	arg1	Material					35:42	An Active Bio-Based Food Packaging Material	0:42	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.	0:138	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	8	1	theme	shielding	1012:1020	arg1	investigation					1022:1034	The light shielding investigation	1002:1034	The light shielding investigation	1002:1034	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	9	2	dep	coli	1182:1185	arg1	coli					1191:1194	E. coli	1188:1194	E. coli	1188:1194	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	0	3	theme	Polyphenols/Cellulose/Polyvinyl	57:87	arg1	Alcohol					89:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	5	4	theme	unique	634:639	arg1	functions					641:649	their unique functions	628:649	their unique functions	628:649	All of these components share their unique functions with the composite's properties.
36675089	7	5	with	material	939:946	arg1	dosage					963:968	only a 1% dosage	953:968	only a 1% dosage of the three components in PVA	953:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	3	6	dep	structure	414:422	arg1	The					410:412	The	410:412	The	410:412	The structure and morphology of the composite were fully analyzed using XRD, FTIR, SEM and XPS.
36675089	2	7	theme	polyphenols/cellulose/polyvinyl	304:334	arg1	ZnPCP					345:349	ZnPCP	345:349	ZnPCP	345:349	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	2	7	theme	polyphenols/cellulose/polyvinyl	304:334	arg1	alcohol					336:342	biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol	281:342	biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP)	281:350	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	2	8	dep	hydrothermal	376:387	arg1	methods					401:407	methods	401:407	methods	401:407	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	2	9	theme	ZnO/plant	294:302	arg1	ZnPCP					345:349	ZnPCP	345:349	ZnPCP	345:349	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	2	9	theme	ZnO/plant	294:302	arg1	alcohol					336:342	biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol	281:342	biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP)	281:350	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	7	10	from	components	983:992	arg1	PVA					997:999	PVA	997:999	PVA	997:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	10	11	theme	easy	1359:1362	arg1	degradation					1364:1374	easy degradation	1359:1374	easy degradation	1359:1374	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	2	12	theme	biocomposite	281:292	arg1	ZnPCP					345:349	ZnPCP	345:349	ZnPCP	345:349	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	2	12	theme	biocomposite	281:292	arg1	alcohol					336:342	biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol	281:342	biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP)	281:350	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	10	13	theme	packaging	1440:1448	arg1	industry					1450:1457	the packaging industry	1436:1457	the packaging industry	1436:1457	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	9	14	theme	inhibition	1270:1279	arg1	zones					1281:1285	4.4 and 6.3 mm inhibition zones	1255:1285	4.4 and 6.3 mm inhibition zones	1255:1285	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	0	15	theme	Active	3:8	arg1	Material					35:42	An Active Bio-Based Food Packaging Material	0:42	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.	0:138	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	6	16	theme	PVA	830:832	arg1	barrier					819:825	the water barrier	809:825	the water barrier of PVA	809:832	This study shows that PPL in the composite not only improves the ZnO dispersivity in PVA as a crosslinker, but also enhances the water barrier of PVA.
36675089	8	17	theme	light	1006:1010	arg1	investigation					1022:1034	The light shielding investigation	1002:1034	The light shielding investigation	1002:1034	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	10	18	theme	enhanced	1334:1341	arg1	performance					1343:1353	performance	1343:1353	performance	1343:1353	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	6	19	theme	ZnO	749:751	arg1	dispersivity					753:764	the ZnO dispersivity	745:764	the ZnO dispersivity in PVA as a crosslinker	745:788	This study shows that PPL in the composite not only improves the ZnO dispersivity in PVA as a crosslinker, but also enhances the water barrier of PVA.
36675089	6	20	from	PPL	706:708	arg1	composite					717:725	the composite	713:725	the composite	713:725	This study shows that PPL in the composite not only improves the ZnO dispersivity in PVA as a crosslinker, but also enhances the water barrier of PVA.
36675089	0	21	theme	Food	20:23	arg1	Material					35:42	An Active Bio-Based Food Packaging Material	0:42	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.	0:138	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	7	22	from	PVA	997:999	arg1	dosage					963:968	only a 1% dosage	953:968	only a 1% dosage of the three components in PVA	953:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	10	23	theme	biocomposite	1388:1399	arg1	material					1424:1431	a prospect material	1413:1431	a prospect material	1413:1431	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	10	23	theme	biocomposite	1388:1399	arg1	ZnPCP					1401:1405	the biocomposite ZnPCP	1384:1405	the biocomposite ZnPCP	1384:1405	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	9	24	theme	antibacterial	1113:1125	arg1	activities					1127:1136	The antibacterial activities	1109:1136	The antibacterial activities	1109:1136	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	0	25	theme	Bio-Based	10:18	arg1	Material					35:42	An Active Bio-Based Food Packaging Material	0:42	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.	0:138	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	7	26	theme	components	983:992	arg1	dosage					963:968	only a 1% dosage	953:968	only a 1% dosage of the three components in PVA	953:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	9	27	dep	zones	1281:1285	arg1	mm					1267:1268	mm	1267:1268	mm	1267:1268	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	1	28	theme	shelf	214:218	arg1	life					220:223	its shelf life	210:223	its shelf life	210:223	Active packaging materials protect food from deterioration and extend its shelf life.
36675089	0	29	theme	Packaging	25:33	arg1	Material					35:42	An Active Bio-Based Food Packaging Material	0:42	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.	0:138	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	9	30	dep	aureus	1230:1235	arg1	aureus					1241:1246	S. aureus	1238:1246	S. aureus	1238:1246	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	3	31	theme	composite	446:454	arg1	structure					414:422	structure	414:422	structure	414:422	The structure and morphology of the composite were fully analyzed using XRD, FTIR, SEM and XPS.
36675089	3	31	theme	composite	446:454	arg1	morphology					428:437	morphology	428:437	morphology	428:437	The structure and morphology of the composite were fully analyzed using XRD, FTIR, SEM and XPS.
36675089	6	32	theme	water	813:817	arg1	barrier					819:825	the water barrier	809:825	the water barrier of PVA	809:832	This study shows that PPL in the composite not only improves the ZnO dispersivity in PVA as a crosslinker, but also enhances the water barrier of PVA.
36675089	8	33	theme	visible	1094:1100	arg1	light					1102:1106	visible light	1094:1106	visible light	1094:1106	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	6	34	from	dispersivity	753:764	arg1	PVA					769:771	PVA	769:771	PVA	769:771	This study shows that PPL in the composite not only improves the ZnO dispersivity in PVA as a crosslinker, but also enhances the water barrier of PVA.
36675089	0	35	theme	ZnO	47:49	arg1	Alcohol					89:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	4	36	theme	plant	525:529	arg1	PPL					544:546	PPL	544:546	PPL	544:546	The ZnO particles, plant polyphenols (PPL) and cellulose were found to be dispersed in PVA.
36675089	4	36	theme	plant	525:529	arg1	polyphenols					531:541	plant polyphenols	525:541	plant polyphenols (PPL)	525:547	The ZnO particles, plant polyphenols (PPL) and cellulose were found to be dispersed in PVA.
36675089	7	37	theme	%	961:961	arg1	dosage					963:968	only a 1% dosage	953:968	only a 1% dosage of the three components in PVA	953:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	0	38	dep	Material	35:42	arg1	DESIGN					98:103	DESIGN	98:103	DESIGN	98:103	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	0	38	dep	Material	35:42	arg1	Application					127:137	Application	127:137	Application	127:137	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	0	38	dep	Material	35:42	arg1	Characterization					106:121	Characterization	106:121	Characterization	106:121	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	5	39	theme	composite	660:668	arg1	properties					672:681	the composite's properties	656:681	the composite's properties	656:681	All of these components share their unique functions with the composite's properties.
36675089	7	40	theme	packaging	929:937	arg1	material					939:946	a good food packaging material	917:946	a good food packaging material with only a 1% dosage of the three components in PVA	917:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	9	41	dep	mm	1267:1268	arg1	4.4					1255:1257	4.4	1255:1257	4.4	1255:1257	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	9	41	dep	mm	1267:1268	arg1	6.3					1263:1265	6.3	1263:1265	6.3	1263:1265	The antibacterial activities were evaluated by Gram-negative Escherichia coli (E. coli) and Gram-positive staphylococcus aureus (S. aureus), with 4.4 and 6.3 mm inhibition zones, respectively, being achieved by ZnPCP-10.
36675089	10	42	from	material	1424:1431	arg1	industry					1450:1457	the packaging industry	1436:1457	the packaging industry	1436:1457	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	7	43	theme	1	960:960	arg1	%					961:961	%	961:961	%	961:961	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	2	44	theme	packaging	260:268	arg1	materials					270:278	intriguing packaging materials	249:278	intriguing packaging materials	249:278	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	7	45	theme	good	919:922	arg1	material					939:946	a good food packaging material	917:946	a good food packaging material with only a 1% dosage of the three components in PVA	917:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	1	46	theme	Active	140:145	arg1	materials					157:165	Active packaging materials	140:165	Active packaging materials	140:165	Active packaging materials protect food from deterioration and extend its shelf life.
36675089	8	47	theme	light	1102:1106	arg1	%					1077:1077	almost 100%	1067:1077	almost 100% of both UV and visible light	1067:1106	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	8	47	theme	light	1102:1106	arg1	UV					1087:1088	UV	1087:1088	UV	1087:1088	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	8	47	theme	light	1102:1106	arg1	light					1102:1106	visible light	1094:1106	visible light	1094:1106	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	0	48	theme	Plant	51:55	arg1	Alcohol					89:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	2	49	theme	intriguing	249:258	arg1	materials					270:278	intriguing packaging materials	249:278	intriguing packaging materials	249:278	In the quest to design intriguing packaging materials, biocomposite ZnO/plant polyphenols/cellulose/polyvinyl alcohol (ZnPCP) was prepared via simple hydrothermal and casting methods.
36675089	7	50	theme	food	924:927	arg1	material					939:946	a good food packaging material	917:946	a good food packaging material with only a 1% dosage of the three components in PVA	917:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36675089	1	51	theme	packaging	147:155	arg1	materials					157:165	Active packaging materials	140:165	Active packaging materials	140:165	Active packaging materials protect food from deterioration and extend its shelf life.
36675089	10	52	theme	prospect	1415:1422	arg1	material					1424:1431	a prospect material	1413:1431	a prospect material	1413:1431	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	10	52	theme	prospect	1415:1422	arg1	ZnPCP					1401:1405	the biocomposite ZnPCP	1384:1405	the biocomposite ZnPCP	1384:1405	The enhanced performance and easy degradation enables the biocomposite ZnPCP to be a prospect material in the packaging industry.
36675089	0	53	theme	@	50:50	arg1	Alcohol					89:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol	47:95	An Active Bio-Based Food Packaging Material of ZnO@Plant Polyphenols/Cellulose/Polyvinyl Alcohol: DESIGN, Characterization and Application.
36675089	4	54	theme	ZnO	510:512	arg1	particles					514:522	The ZnO particles	506:522	The ZnO particles	506:522	The ZnO particles, plant polyphenols (PPL) and cellulose were found to be dispersed in PVA.
36675089	8	55	theme	UV	1087:1088	arg1	%					1077:1077	almost 100%	1067:1077	almost 100% of both UV and visible light	1067:1106	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	8	55	theme	UV	1087:1088	arg1	UV					1087:1088	UV	1087:1088	UV	1087:1088	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	8	55	theme	UV	1087:1088	arg1	light					1102:1106	visible light	1094:1106	visible light	1094:1106	The light shielding investigation showed that ZnPCP-10 can block almost 100% of both UV and visible light.
36675089	7	56	from	dosage	963:968	arg1	PVA					997:999	PVA	997:999	PVA	997:999	The ZnO, PPL and cellulose work together, enabling the biocomposite to perform as a good food packaging material with only a 1% dosage of the three components in PVA.
36925257	0	0	theme	mast	97:100	arg1	Effects					0:6	Effects	0:6	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.	0:136	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	0	theme	mast	97:100	arg1	activity					128:135	mast cell membrane stabilizing activity	97:135	mast cell membrane stabilizing activity	97:135	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	5	1	with	spinosum	909:916	arg1	strains					936:942	the selected strains	923:942	the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus	923:1005	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	6	2	theme	more	1106:1109	arg1	acid					1122:1125	more glucuronic acid	1106:1125	more glucuronic acid	1106:1125	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	1	3	theme	biological	181:190	arg1	activities					192:201	biological activities	181:201	biological activities	181:201	Eucheuma polysaccharides have varieties of biological activities.
36925257	0	4	theme	Lactobacillus	11:23	arg1	fermentation					25:36	Lactobacillus fermentation	11:36	Lactobacillus fermentation	11:36	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	3	5	theme	fermented	333:341	arg1	F-ESP					378:382	F-ESP	378:382	F-ESP	378:382	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	5	theme	fermented	333:341	arg1	polysaccharides					361:375	fermented Eucheuma spinosum polysaccharides	333:375	fermented Eucheuma spinosum polysaccharides (F-ESP)	333:383	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	5	6	theme	spinosum	909:916	arg1	fermentation					884:895	fermentation	884:895	fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus	884:1005	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	1	7	theme	activities	192:201	arg1	varieties					168:176	varieties	168:176	varieties of biological activities	168:201	Eucheuma polysaccharides have varieties of biological activities.
36925257	1	7	theme	activities	192:201	arg1	activities					192:201	biological activities	181:201	biological activities	181:201	Eucheuma polysaccharides have varieties of biological activities.
36925257	9	8	theme	cutaneous	1552:1560	arg1	anaphylaxis					1562:1572	mast cell-mediated passive cutaneous anaphylaxis	1525:1572	mast cell-mediated passive cutaneous anaphylaxis	1525:1572	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	0	9	theme	membrane	107:114	arg1	Effects					0:6	Effects	0:6	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.	0:136	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	9	theme	membrane	107:114	arg1	activity					128:135	mast cell membrane stabilizing activity	97:135	mast cell membrane stabilizing activity	97:135	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	10	from	Effects	0:6	arg1	polysaccharides					59:73	Eucheuma spinosum polysaccharides	41:73	Eucheuma spinosum polysaccharides	41:73	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	9	11	contain	have	1604:1607	arg1	F1-ESP-3					1591:1598	F1-ESP-3	1591:1598	F1-ESP-3	1591:1598	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	9	11	contain	have	1604:1607	arg2	activity					1630:1637	better anti-allergic activity	1609:1637	better anti-allergic activity	1609:1637	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	8	12	theme	F-actin	1467:1473	arg1	depolymerization					1447:1462	depolymerization	1447:1462	depolymerization of F-actin and Ca2+ influx	1447:1489	Moreover, F1-ESP-3 significantly inhibited RBL-2H3 cell degranulation by reducing depolymerization of F-actin and Ca2+ influx.
36925257	8	13	theme	influx	1484:1489	arg1	depolymerization					1447:1462	depolymerization	1447:1462	depolymerization of F-actin and Ca2+ influx	1447:1489	Moreover, F1-ESP-3 significantly inhibited RBL-2H3 cell degranulation by reducing depolymerization of F-actin and Ca2+ influx.
36925257	6	14	theme	component	1035:1043	arg1	L-ESP-3					1045:1051	the purified component L-ESP-3	1022:1051	the purified component L-ESP-3	1022:1051	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	0	15	theme	cell	102:105	arg1	Effects					0:6	Effects	0:6	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.	0:136	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	15	theme	cell	102:105	arg1	activity					128:135	mast cell membrane stabilizing activity	97:135	mast cell membrane stabilizing activity	97:135	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	9	16	theme	anti-allergic	1616:1628	arg1	activity					1630:1637	better anti-allergic activity	1609:1637	better anti-allergic activity	1609:1637	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	3	17	theme	L-ESP	575:579	arg1	method					498:503	the freeze-thaw method	482:503	the freeze-thaw method	482:503	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	17	theme	L-ESP	575:579	arg1	evaluation					586:595	evaluation	586:595	evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model	586:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	17	theme	L-ESP	575:579	arg1	composition					519:529	the composition	515:529	the composition	515:529	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	17	theme	L-ESP	575:579	arg1	characteristics					546:560	structural characteristics	535:560	structural characteristics	535:560	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	6	18	theme	purified	1026:1033	arg1	L-ESP-3					1045:1051	the purified component L-ESP-3	1022:1051	the purified component L-ESP-3	1022:1051	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	4	19	theme	L-ESP	723:727	arg1	activity					711:718	the activity	707:718	the activity of L-ESP and F-ESP in vivo	707:745	Then, the activity of L-ESP and F-ESP in vivo was preliminarily evaluated using a passive cutaneous anaphylaxis model.
36925257	6	20	theme	molecular	1132:1140	arg1	weight					1142:1147	the molecular weight	1128:1147	the molecular weight	1128:1147	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	2	21	theme	low	292:294	arg1	utilization					296:306	low utilization	292:306	low utilization	292:306	However, it is accompanied by problems like large molecular weight, high viscosity, and low utilization.
36925257	5	22	dep	Lactobacillus.sakei	947:965	arg1	subsp.sakei					967:977	Lactobacillus.sakei subsp.sakei	947:977	Lactobacillus.sakei subsp.sakei	947:977	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	0	23	theme	stabilizing	116:126	arg1	Effects					0:6	Effects	0:6	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.	0:136	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	23	theme	stabilizing	116:126	arg1	activity					128:135	mast cell membrane stabilizing activity	97:135	mast cell membrane stabilizing activity	97:135	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	3	24	theme	low-temperature	430:444	arg1	L-ESP					463:467	L-ESP	463:467	L-ESP	463:467	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	24	theme	low-temperature	430:444	arg1	ESP					458:460	low-temperature freeze-thaw ESP	430:460	low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model	430:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	25	theme	F-ESP	565:569	arg1	method					498:503	the freeze-thaw method	482:503	the freeze-thaw method	482:503	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	25	theme	F-ESP	565:569	arg1	evaluation					586:595	evaluation	586:595	evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model	586:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	25	theme	F-ESP	565:569	arg1	composition					519:529	the composition	515:529	the composition	515:529	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	25	theme	F-ESP	565:569	arg1	characteristics					546:560	structural characteristics	535:560	structural characteristics	535:560	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	4	26	theme	cutaneous	791:799	arg1	model					813:817	a passive cutaneous anaphylaxis model	781:817	a passive cutaneous anaphylaxis model	781:817	Then, the activity of L-ESP and F-ESP in vivo was preliminarily evaluated using a passive cutaneous anaphylaxis model.
36925257	5	27	theme	Lactobacillus.sakei	947:965	arg1	strains					936:942	the selected strains	923:942	the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus	923:1005	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	6	28	contain	contains	1097:1104	arg1	composition					1073:1083	the monosaccharide composition	1054:1083	the monosaccharide composition of F1-ESP-3	1054:1095	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	6	28	contain	contains	1097:1104	arg2	acid					1122:1125	more glucuronic acid	1106:1125	more glucuronic acid	1106:1125	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	9	29	theme	anaphylaxis	1562:1572	arg1	symptoms					1513:1520	the symptoms	1509:1520	the symptoms of mast cell-mediated passive cutaneous anaphylaxis	1509:1572	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	6	30	theme	apparent	1272:1279	arg1	viscosity					1281:1289	lower apparent viscosity	1266:1289	lower apparent viscosity	1266:1289	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	8	31	theme	RBL-2H3	1408:1414	arg1	degranulation					1421:1433	RBL-2H3 cell degranulation	1408:1433	RBL-2H3 cell degranulation	1408:1433	Moreover, F1-ESP-3 significantly inhibited RBL-2H3 cell degranulation by reducing depolymerization of F-actin and Ca2+ influx.
36925257	7	32	theme	ESP	1360:1362	arg1	ESP					1360:1362	ESP	1360:1362	ESP	1360:1362	Fermentation did not destroy the functional groups and structure of ESP.
36925257	7	32	theme	ESP	1360:1362	arg1	structure					1347:1355	structure	1347:1355	structure	1347:1355	Fermentation did not destroy the functional groups and structure of ESP.
36925257	7	32	theme	ESP	1360:1362	arg1	groups					1336:1341	the functional groups	1321:1341	the functional groups	1321:1341	Fermentation did not destroy the functional groups and structure of ESP.
36925257	0	33	theme	fermentation	25:36	arg1	Effects					0:6	Effects	0:6	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.	0:136	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	33	theme	fermentation	25:36	arg1	Characterization					76:91	Characterization	76:91	Characterization	76:91	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	33	theme	fermentation	25:36	arg1	activity					128:135	mast cell membrane stabilizing activity	97:135	mast cell membrane stabilizing activity	97:135	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	3	34	theme	samples	625:631	arg1	ability					604:610	the ability	600:610	the ability of different samples to inhibit mast cell degranulation using classical mast cell model	600:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	6	35	theme	higher	1244:1249	arg1	solubility					1251:1260	higher solubility	1244:1260	higher solubility	1244:1260	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	6	36	theme	glucuronic	1111:1120	arg1	acid					1122:1125	more glucuronic acid	1106:1125	more glucuronic acid	1106:1125	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	3	37	theme	Lactobacillus	388:400	arg1	fermentation					402:413	Lactobacillus fermentation	388:413	Lactobacillus fermentation	388:413	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	9	38	theme	cell-mediated	1530:1542	arg1	anaphylaxis					1562:1572	mast cell-mediated passive cutaneous anaphylaxis	1525:1572	mast cell-mediated passive cutaneous anaphylaxis	1525:1572	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	4	39	theme	passive	783:789	arg1	model					813:817	a passive cutaneous anaphylaxis model	781:817	a passive cutaneous anaphylaxis model	781:817	Then, the activity of L-ESP and F-ESP in vivo was preliminarily evaluated using a passive cutaneous anaphylaxis model.
36925257	5	40	theme	Lactobacillus.rhamnosus	983:1005	arg1	strains					936:942	the selected strains	923:942	the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus	923:1005	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	8	41	theme	cell	1416:1419	arg1	degranulation					1421:1433	RBL-2H3 cell degranulation	1408:1433	RBL-2H3 cell degranulation	1408:1433	Moreover, F1-ESP-3 significantly inhibited RBL-2H3 cell degranulation by reducing depolymerization of F-actin and Ca2+ influx.
36925257	3	42	theme	freeze-thaw	486:496	arg1	method					498:503	the freeze-thaw method	482:503	the freeze-thaw method	482:503	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	0	43	theme	Eucheuma	41:48	arg1	polysaccharides					59:73	Eucheuma spinosum polysaccharides	41:73	Eucheuma spinosum polysaccharides	41:73	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	5	44	theme	selected	927:934	arg1	strains					936:942	the selected strains	923:942	the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus	923:1005	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	3	45	theme	classical	674:682	arg1	model					694:698	classical mast cell model	674:698	classical mast cell model	674:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	6	46	theme	lower	1266:1270	arg1	viscosity					1281:1289	lower apparent viscosity	1266:1289	lower apparent viscosity	1266:1289	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	7	47	theme	functional	1325:1334	arg1	ESP					1360:1362	ESP	1360:1362	ESP	1360:1362	Fermentation did not destroy the functional groups and structure of ESP.
36925257	7	47	theme	functional	1325:1334	arg1	groups					1336:1341	the functional groups	1321:1341	the functional groups	1321:1341	Fermentation did not destroy the functional groups and structure of ESP.
36925257	3	48	theme	freeze-thaw	446:456	arg1	L-ESP					463:467	L-ESP	463:467	L-ESP	463:467	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	48	theme	freeze-thaw	446:456	arg1	ESP					458:460	low-temperature freeze-thaw ESP	430:460	low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model	430:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	49	theme	cell	649:652	arg1	degranulation					654:666	mast cell degranulation	644:666	mast cell degranulation using classical mast cell model	644:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	2	50	theme	molecular	254:262	arg1	weight					264:269	large molecular weight	248:269	large molecular weight	248:269	However, it is accompanied by problems like large molecular weight, high viscosity, and low utilization.
36925257	6	51	theme	F1-ESP-3	1088:1095	arg1	composition					1073:1083	the monosaccharide composition	1054:1083	the monosaccharide composition of F1-ESP-3	1054:1095	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	5	52	theme	F-ESP	833:837	arg1	kinds					824:828	Two kinds	820:828	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3	820:865	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36925257	2	53	theme	large	248:252	arg1	weight					264:269	large molecular weight	248:269	large molecular weight	248:269	However, it is accompanied by problems like large molecular weight, high viscosity, and low utilization.
36925257	3	54	theme	explored	506:513	arg1	composition					519:529	the composition	515:529	the composition	515:529	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	0	55	theme	spinosum	50:57	arg1	polysaccharides					59:73	Eucheuma spinosum polysaccharides	41:73	Eucheuma spinosum polysaccharides	41:73	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	3	56	theme	ability	604:610	arg1	method					498:503	the freeze-thaw method	482:503	the freeze-thaw method	482:503	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	56	theme	ability	604:610	arg1	evaluation					586:595	evaluation	586:595	evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model	586:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	56	theme	ability	604:610	arg1	composition					519:529	the composition	515:529	the composition	515:529	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	56	theme	ability	604:610	arg1	characteristics					546:560	structural characteristics	535:560	structural characteristics	535:560	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	1	57	theme	Eucheuma	138:145	arg1	polysaccharides					147:161	Eucheuma polysaccharides	138:161	Eucheuma polysaccharides	138:161	Eucheuma polysaccharides have varieties of biological activities.
36925257	6	58	contain	has	1240:1242	arg1	F1-ESP-3					1231:1238	F1-ESP-3	1231:1238	F1-ESP-3	1231:1238	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	6	58	contain	has	1240:1242	arg2	solubility					1251:1260	higher solubility	1244:1260	higher solubility	1244:1260	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	6	58	contain	has	1240:1242	arg2	viscosity					1281:1289	lower apparent viscosity	1266:1289	lower apparent viscosity	1266:1289	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	8	59	theme	Ca2+	1479:1482	arg1	influx					1484:1489	Ca2+ influx	1479:1489	Ca2+ influx	1479:1489	Moreover, F1-ESP-3 significantly inhibited RBL-2H3 cell degranulation by reducing depolymerization of F-actin and Ca2+ influx.
36925257	4	60	theme	anaphylaxis	801:811	arg1	model					813:817	a passive cutaneous anaphylaxis model	781:817	a passive cutaneous anaphylaxis model	781:817	Then, the activity of L-ESP and F-ESP in vivo was preliminarily evaluated using a passive cutaneous anaphylaxis model.
36925257	3	61	theme	different	615:623	arg1	samples					625:631	different samples	615:631	different samples	615:631	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	4	62	theme	F-ESP	733:737	arg1	activity					711:718	the activity	707:718	the activity of L-ESP and F-ESP in vivo	707:745	Then, the activity of L-ESP and F-ESP in vivo was preliminarily evaluated using a passive cutaneous anaphylaxis model.
36925257	3	63	theme	mast	684:687	arg1	model					694:698	classical mast cell model	674:698	classical mast cell model	674:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	64	theme	mast	644:647	arg1	degranulation					654:666	mast cell degranulation	644:666	mast cell degranulation using classical mast cell model	644:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	65	theme	Eucheuma	343:350	arg1	F-ESP					378:382	F-ESP	378:382	F-ESP	378:382	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	65	theme	Eucheuma	343:350	arg1	polysaccharides					361:375	fermented Eucheuma spinosum polysaccharides	333:375	fermented Eucheuma spinosum polysaccharides (F-ESP)	333:383	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	66	theme	cell	689:692	arg1	model					694:698	classical mast cell model	674:698	classical mast cell model	674:698	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	2	67	theme	high	272:275	arg1	viscosity					277:285	high viscosity	272:285	high viscosity	272:285	However, it is accompanied by problems like large molecular weight, high viscosity, and low utilization.
36925257	3	68	theme	structural	535:544	arg1	characteristics					546:560	structural characteristics	535:560	structural characteristics	535:560	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	9	69	theme	passive	1544:1550	arg1	anaphylaxis					1562:1572	mast cell-mediated passive cutaneous anaphylaxis	1525:1572	mast cell-mediated passive cutaneous anaphylaxis	1525:1572	F1-ESP-3 reduced the symptoms of mast cell-mediated passive cutaneous anaphylaxis, indicating that F1-ESP-3 may have better anti-allergic activity in vivo.
36925257	6	70	theme	monosaccharide	1058:1071	arg1	composition					1073:1083	the monosaccharide composition	1054:1083	the monosaccharide composition of F1-ESP-3	1054:1095	Compared with the purified component L-ESP-3, the monosaccharide composition of F1-ESP-3 contains more glucuronic acid, the molecular weight reduced from >600 kDa (L-ESP-3) to 28.30 kDa (F1-ESP-3) and 33.58 kDa (F2-ESP-3), F1-ESP-3 has higher solubility and lower apparent viscosity.
36925257	3	71	theme	spinosum	352:359	arg1	F-ESP					378:382	F-ESP	378:382	F-ESP	378:382	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	3	71	theme	spinosum	352:359	arg1	polysaccharides					361:375	fermented Eucheuma spinosum polysaccharides	333:375	fermented Eucheuma spinosum polysaccharides (F-ESP)	333:383	Here, we first prepared fermented Eucheuma spinosum polysaccharides (F-ESP) by Lactobacillus fermentation, compared with low-temperature freeze-thaw ESP (L-ESP) prepared by the freeze-thaw method, explored the composition and structural characteristics of F-ESP and L-ESP, and evaluation of the ability of different samples to inhibit mast cell degranulation using classical mast cell model.
36925257	1	72	contain	have	163:166	arg1	polysaccharides					147:161	Eucheuma polysaccharides	138:161	Eucheuma polysaccharides	138:161	Eucheuma polysaccharides have varieties of biological activities.
36925257	1	72	contain	have	163:166	arg2	activities					192:201	biological activities	181:201	biological activities	181:201	Eucheuma polysaccharides have varieties of biological activities.
36925257	1	72	contain	have	163:166	arg2	varieties					168:176	varieties	168:176	varieties of biological activities	168:201	Eucheuma polysaccharides have varieties of biological activities.
36925257	0	73	dep	Effects	0:6	arg1	Effects					0:6	Effects	0:6	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.	0:136	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	73	dep	Effects	0:6	arg1	Characterization					76:91	Characterization	76:91	Characterization	76:91	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	0	73	dep	Effects	0:6	arg1	activity					128:135	mast cell membrane stabilizing activity	97:135	mast cell membrane stabilizing activity	97:135	Effects of Lactobacillus fermentation on Eucheuma spinosum polysaccharides: Characterization and mast cell membrane stabilizing activity.
36925257	5	74	theme	Eucheuma	900:907	arg1	spinosum					909:916	Eucheuma spinosum	900:916	Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus	900:1005	Two kinds of F-ESP named F1-ESP-3 and F2-ESP-3 were obtained by fermentation of Eucheuma spinosum with the selected strains of Lactobacillus.sakei subsp.sakei and Lactobacillus.rhamnosus.
36894060	5	0	theme	trisaccharides	540:553	arg1	series					512:517	a series	510:517	a series of disaccharides and trisaccharides	510:553	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	1	1	theme	Vaginulus	140:148	arg1	medicine					171:178	folk medicine	166:178	folk medicine in China	166:187	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	1	1	theme	Vaginulus	140:148	arg1	alte					150:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	7	2	theme	probiotic	925:933	arg1	effects					935:941	probiotic effects	925:941	probiotic effects in vitro	925:950	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	0	3	theme	Vaginulus	71:79	arg1	alte					81:84	the slug Vaginulus alte	62:84	the slug Vaginulus alte	62:84	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	0	4	from	characterization	10:25	arg1	alte					81:84	the slug Vaginulus alte	62:84	the slug Vaginulus alte	62:84	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	7	5	theme	thetaiotaomicron	1001:1016	arg1	growth					988:993	the growth	984:993	the growth of B. thetaiotaomicron and B. ovatus	984:1030	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	5	6	theme	precise	491:497	arg1	structure					499:507	its precise structure	487:507	its precise structure	487:507	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	4	7	theme	composition	378:388	arg1	analysis					390:397	Chemical composition analysis	369:397	Chemical composition analysis	369:397	Chemical composition analysis showed that VAG was composed of D-galactose (75 %) and L-galactose (25 %).
36894060	10	8	from	structures	1279:1288	arg1	alte					1335:1338	the V. alte	1328:1338	the V. alte	1328:1338	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	10	9	theme	specific	1270:1277	arg1	structures					1279:1288	specific structures	1270:1288	specific structures	1270:1288	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	6	10	theme	oligosaccharides	723:738	arg1	analysis					687:694	methylation analysis	675:694	methylation analysis	675:694	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	6	10	theme	oligosaccharides	723:738	arg1	analysis					711:718	structural analysis	700:718	structural analysis	700:718	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	6	11	theme	distinct	865:872	arg1	α-L-galactose					889:901	distinct (1 → 2)-linked α-L-galactose	865:901	distinct (1 → 2)-linked α-L-galactose	865:901	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	6	12	theme	branched	772:779	arg1	VAG					741:743	VAG	741:743	VAG	741:743	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	6	12	theme	branched	772:779	arg1	polysaccharide					781:794	a highly branched polysaccharide	763:794	a highly branched polysaccharide	763:794	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	6	13	link	-linked	881:887	arg1	α-L-galactose					889:901	distinct (1 → 2)-linked α-L-galactose	865:901	distinct (1 → 2)-linked α-L-galactose	865:901	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	1	14	theme	galactan	230:237	arg1	components					239:248	its galactan components	226:248	its galactan components	226:248	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	5	15	theme	1D/2D	642:646	arg1	spectroscopy					652:663	1D/2D NMR spectroscopy	642:663	1D/2D NMR spectroscopy	642:663	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	8	16	theme	animalis	1133:1140	arg1	subsp					1142:1146	animalis subsp	1133:1146	animalis subsp	1133:1146	infantis and B. animalis subsp.
36894060	0	17	theme	utilization	94:104	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.	0:129	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	0	18	theme	branched	39:46	arg1	galactan					48:55	a highly branched galactan	30:55	a highly branched galactan from the slug Vaginulus alte	30:84	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	6	19	theme	structural	700:709	arg1	analysis					711:718	structural analysis	700:718	structural analysis	700:718	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	10	20	theme	polysaccharides	1307:1321	arg1	structures					1279:1288	specific structures	1270:1288	specific structures	1270:1288	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	10	20	theme	polysaccharides	1307:1321	arg1	functions					1294:1302	functions	1294:1302	functions	1294:1302	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	7	21	theme	acidophilus	1073:1083	arg1	growth					1060:1065	the growth	1056:1065	the growth of L. acidophilus, L. rhamnosus, B. longum subsp	1056:1114	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	5	22	theme	disaccharides	522:534	arg1	series					512:517	a series	510:517	a series of disaccharides and trisaccharides	510:553	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	2	23	from	alte	301:304	arg1	galactan					284:291	the galactan	280:291	the galactan from V. alte (VAG)	280:310	Here, the galactan from V. alte (VAG) was purified.
36894060	7	24	theme	effects	935:941	arg1	investigation					908:920	The investigation	904:920	The investigation of probiotic effects in vitro	904:950	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	0	25	theme	Structure	0:8	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.	0:129	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	1	26	theme	components	239:248	arg1	structure					198:206	structure	198:206	structure	198:206	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	1	26	theme	components	239:248	arg1	activities					212:221	activities	212:221	activities	212:221	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	1	27	theme	folk	166:169	arg1	medicine					171:178	folk medicine	166:178	folk medicine in China	166:187	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	1	27	theme	folk	166:169	arg1	alte					150:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	9	28	theme	Mw	1173:1174	arg1	~1.0 kDa					1176:1183	Mw ~1.0 kDa	1173:1183	Mw ~1.0 kDa	1173:1183	lactis, but dVAG-3 with Mw ~1.0 kDa could promote the growth of L. acidophilus.
36894060	0	29	theme	gut	115:117	arg1	microbiota					119:128	human gut microbiota	109:128	human gut microbiota	109:128	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	6	30	theme	methylation	675:685	arg1	analysis					687:694	methylation analysis	675:694	methylation analysis	675:694	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	1	31	dep	structure	198:206	arg1	the					194:196	the	194:196	the	194:196	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	0	32	theme	human	109:113	arg1	microbiota					119:128	human gut microbiota	109:128	human gut microbiota	109:128	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	0	33	from	alte	81:84	arg1	utilization					94:104	its utilization	90:104	its utilization by human gut microbiota	90:128	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	0	33	from	alte	81:84	arg1	galactan					48:55	a highly branched galactan	30:55	a highly branched galactan from the slug Vaginulus alte	30:84	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	0	33	from	alte	81:84	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.	0:129	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	3	34	theme	VAG	336:338	arg1	~28.8 kDa					358:366	~28.8 kDa	358:366	~28.8 kDa	358:366	The Mw of VAG was determined as ~28.8 kDa.
36894060	3	34	theme	VAG	336:338	arg1	Mw					330:331	The Mw	326:331	The Mw of VAG	326:338	The Mw of VAG was determined as ~28.8 kDa.
36894060	6	35	theme	-linked	838:844	arg1	β-D-galactose					846:858	(1 → 3)-linked β-D-galactose	831:858	(1 → 3)-linked β-D-galactose	831:858	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	10	36	theme	V.	1332:1333	arg1	alte					1335:1338	the V. alte	1328:1338	the V. alte	1328:1338	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	4	37	theme	Chemical	369:376	arg1	analysis					390:397	Chemical composition analysis	369:397	Chemical composition analysis	369:397	Chemical composition analysis showed that VAG was composed of D-galactose (75 %) and L-galactose (25 %).
36894060	10	38	dep	provide	1248:1254	arg1	will					1243:1246	will	1243:1246	will	1243:1246	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	6	39	theme	1 → 2	875:879	arg1	α-L-galactose					889:901	distinct (1 → 2)-linked α-L-galactose	865:901	distinct (1 → 2)-linked α-L-galactose	865:901	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	6	40	link	-linked	838:844	arg1	β-D-galactose					846:858	(1 → 3)-linked β-D-galactose	831:858	(1 → 3)-linked β-D-galactose	831:858	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	5	41	theme	NMR	648:650	arg1	spectroscopy					652:663	1D/2D NMR spectroscopy	642:663	1D/2D NMR spectroscopy	642:663	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	10	42	from	functions	1294:1302	arg1	alte					1335:1338	the V. alte	1328:1338	the V. alte	1328:1338	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	5	43	theme	mild	574:577	arg1	VAG					595:597	mild acid hydrolyzed VAG	574:597	mild acid hydrolyzed VAG	574:597	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	2	44	theme	V.	298:299	arg1	VAG					307:309	VAG	307:309	VAG	307:309	Here, the galactan from V. alte (VAG) was purified.
36894060	2	44	theme	V.	298:299	arg1	alte					301:304	V. alte	298:304	V. alte (VAG)	298:310	Here, the galactan from V. alte (VAG) was purified.
36894060	0	45	theme	galactan	48:55	arg1	characterization					10:25	Structure characterization	0:25	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.	0:129	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	5	46	theme	acid	579:582	arg1	VAG					595:597	mild acid hydrolyzed VAG	574:597	mild acid hydrolyzed VAG	574:597	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	6	47	dep	β-D-galactose	846:858	arg1	1 → 3					832:836	1 → 3	832:836	1 → 3	832:836	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
36894060	7	48	dep	B.	1022:1023	arg1	ovatus					1025:1030	B. ovatus	1022:1030	B. ovatus	1022:1030	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	1	49	from	medicine	171:178	arg1	China					183:187	China	183:187	China	183:187	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	5	50	theme	hydrolyzed	584:593	arg1	VAG					595:597	mild acid hydrolyzed VAG	574:597	mild acid hydrolyzed VAG	574:597	To elucidate its precise structure, a series of disaccharides and trisaccharides were purified from mild acid hydrolyzed VAG and their structures were characterized by 1D/2D NMR spectroscopy.
36894060	7	51	theme	B.	1022:1023	arg1	growth					988:993	the growth	984:993	the growth of B. thetaiotaomicron and B. ovatus	984:1030	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	7	52	dep	B.	1100:1101	arg1	longum					1103:1108	longum	1103:1108	longum	1103:1108	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	8	53	dep	subsp	1142:1146	arg1	B.					1130:1131	B.	1130:1131	B.	1130:1131	infantis and B. animalis subsp.
36894060	8	53	dep	subsp	1142:1146	arg1	infantis					1117:1124	infantis	1117:1124	infantis	1117:1124	infantis and B. animalis subsp.
36894060	9	54	theme	acidophilus	1216:1226	arg1	growth					1203:1208	the growth	1199:1208	the growth of L. acidophilus	1199:1226	lactis, but dVAG-3 with Mw ~1.0 kDa could promote the growth of L. acidophilus.
36894060	0	55	theme	slug	66:69	arg1	alte					81:84	the slug Vaginulus alte	62:84	the slug Vaginulus alte	62:84	Structure characterization of a highly branched galactan from the slug Vaginulus alte and its utilization by human gut microbiota.
36894060	1	56	used	used	158:161	arg2	alte					150:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	1	56	used	used	158:161	arg2	medicine					171:178	folk medicine	166:178	folk medicine in China	166:187	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	7	57	theme	B.	1100:1101	arg1	acidophilus					1073:1083	L. acidophilus	1070:1083	L. acidophilus	1070:1083	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	7	57	theme	B.	1100:1101	arg1	subsp					1110:1114	B. longum subsp	1100:1114	B. longum subsp	1100:1114	The investigation of probiotic effects in vitro revealed that VAG could promote the growth of B. thetaiotaomicron and B. ovatus, while had no effect on the growth of L. acidophilus, L. rhamnosus, B. longum subsp.
36894060	9	58	with	dVAG-3	1161:1166	arg1	~1.0 kDa					1176:1183	Mw ~1.0 kDa	1173:1183	Mw ~1.0 kDa	1173:1183	lactis, but dVAG-3 with Mw ~1.0 kDa could promote the growth of L. acidophilus.
36894060	10	59	from	alte	1335:1338	arg1	structures					1279:1288	specific structures	1270:1288	specific structures	1270:1288	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	10	59	from	alte	1335:1338	arg1	polysaccharides					1307:1321	polysaccharides	1307:1321	polysaccharides from the V. alte	1307:1338	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	10	59	from	alte	1335:1338	arg1	functions					1294:1302	functions	1294:1302	functions	1294:1302	These results will provide insights into specific structures and functions of polysaccharides from the V. alte.
36894060	1	60	theme	slug	135:138	arg1	medicine					171:178	folk medicine	166:178	folk medicine in China	166:187	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	1	60	theme	slug	135:138	arg1	alte					150:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte	131:153	The slug Vaginulus alte is used as folk medicine in China, but the structure and activities of its galactan components remain to be clarified.
36894060	6	61	theme	-linked	881:887	arg1	α-L-galactose					889:901	distinct (1 → 2)-linked α-L-galactose	865:901	distinct (1 → 2)-linked α-L-galactose	865:901	Based on methylation analysis and structural analysis of oligosaccharides, VAG was elucidated as a highly branched polysaccharide and mainly composed of (1 → 6)- or (1 → 3)-linked β-D-galactose, and distinct (1 → 2)-linked α-L-galactose.
37185988	8	0	theme	bread-making	1568:1579	arg1	process					1581:1587	the bread-making process	1564:1587	the bread-making process	1564:1587	The present study showed that the cell wall combines the starch granules during the bread-making process; thus, the diffusion of enzymes through the cell wall was hindered.
37185988	4	1	theme	bread	770:774	arg1	digestion					757:765	the starch digestion	746:765	the starch digestion of bread	746:774	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	2	2	from	effects	299:305	arg1	structure					373:381	structure	373:381	structure	373:381	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	2	2	from	effects	299:305	arg1	composition					357:367	wheat grain cell wall composition	335:367	wheat grain cell wall composition	335:367	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	6	3	theme	starch	1156:1161	arg1	granules					1163:1170	starch granules	1156:1170	starch granules	1156:1170	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	3	4	theme	cell	530:533	arg1	walls					535:539	aleurone cell walls	521:539	aleurone cell walls	521:539	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	7	5	theme	cell	1399:1402	arg1	structure					1409:1417	the cell wall structure	1395:1417	the cell wall structure	1395:1417	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	5	6	dep	RESULTS	777:783	arg1	thickness					808:816	The aleurone cell wall thickness	785:816	RESULTS The aleurone cell wall thickness	777:816	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	4	7	theme	wall	648:651	arg1	structure					653:661	different aleurone cell wall structure	624:661	different aleurone cell wall structure	624:661	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	5	8	theme	4.67	841:844	arg1	μm					835:836	μm	835:836	μm	835:836	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	7	9	from	changes	1384:1390	arg1	structure					1409:1417	the cell wall structure	1395:1417	the cell wall structure	1395:1417	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	3	10	theme	starch	550:555	arg1	properties					567:576	grain starch digestion properties	544:576	grain starch digestion properties	544:576	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	4	11	theme	aleurone	634:641	arg1	structure					653:661	different aleurone cell wall structure	624:661	different aleurone cell wall structure	624:661	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	5	12	theme	wall	803:806	arg1	thickness					808:816	The aleurone cell wall thickness	785:816	RESULTS The aleurone cell wall thickness	777:816	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	1	13	theme	important	104:112	arg1	crop					119:122	an important food crop	101:122	an important food crop	101:122	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	1	13	theme	important	104:112	arg1	Wheat					92:96	BACKGROUND Wheat	81:96	BACKGROUND Wheat	81:96	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	5	14	theme	water-extractable	888:904	arg1	arabinoxylan					906:917	water-extractable arabinoxylan	888:917	water-extractable arabinoxylan	888:917	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	0	15	theme	structure	50:58	arg1	Effects					0:6	Effects	0:6	Effects of cereal grain cell wall composition and structure on starch digestion	0:78	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	6	16	theme	wall	985:988	arg1	thickness					990:998	cell wall thickness	980:998	cell wall thickness	980:998	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	4	17	theme	simple	693:698	arg1	system					709:714	a simple research system	691:714	a simple research system used to study their effect on the starch digestion of bread	691:774	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	0	18	theme	starch	63:68	arg1	digestion					70:78	starch digestion	63:78	starch digestion	63:78	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	0	19	from	Effects	0:6	arg1	digestion					70:78	starch digestion	63:78	starch digestion	63:78	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	4	20	theme	starch	750:755	arg1	digestion					757:765	the starch digestion	746:765	the starch digestion of bread	746:774	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	6	21	theme	arabinoxylans	955:967	arg1	content					969:975	arabinoxylans content	955:975	arabinoxylans content	955:975	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	7	22	contain	has	1252:1254	arg1	structure					1242:1250	the wheat cell wall structure	1222:1250	the wheat cell wall structure	1222:1250	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	7	22	contain	has	1252:1254	arg2	impact					1264:1269	a great impact	1256:1269	a great impact on starch hydrolysis	1256:1290	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	7	23	from	change	1313:1318	arg1	digestibility					1327:1339	the digestibility	1323:1339	the digestibility of starch in flour and bread	1323:1368	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	5	24	theme	cell	798:801	arg1	thickness					808:816	The aleurone cell wall thickness	785:816	RESULTS The aleurone cell wall thickness	777:816	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	1	25	theme	BACKGROUND	81:90	arg1	crop					119:122	an important food crop	101:122	an important food crop	101:122	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	1	25	theme	BACKGROUND	81:90	arg1	Wheat					92:96	BACKGROUND Wheat	81:96	BACKGROUND Wheat	81:96	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	8	26	theme	present	1488:1494	arg1	study					1496:1500	The present study	1484:1500	The present study	1484:1500	The present study showed that the cell wall combines the starch granules during the bread-making process; thus, the diffusion of enzymes through the cell wall was hindered.
37185988	6	27	from	changes	1101:1107	arg1	interaction					1116:1126	the interaction	1112:1126	the interaction between polysaccharides and starch granules in this process	1112:1186	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	3	28	theme	walls	441:445	arg1	structure					414:422	the structure	410:422	the structure of aleurone cell walls between different wheat samples	410:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	0	29	theme	cereal	11:16	arg1	composition					34:44	cereal grain cell wall composition	11:44	cereal grain cell wall composition	11:44	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	1	30	theme	grains	264:269	arg1	composition					245:255	the composition	241:255	the composition of the grains	241:269	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	3	31	theme	aleurone	427:434	arg1	walls					441:445	aleurone cell walls	427:445	aleurone cell walls between different wheat samples	427:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	0	32	theme	cell	24:27	arg1	composition					34:44	cereal grain cell wall composition	11:44	cereal grain cell wall composition	11:44	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	7	33	theme	great	1258:1262	arg1	impact					1264:1269	a great impact	1256:1269	a great impact on starch hydrolysis	1256:1290	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	2	34	theme	factors	324:330	arg1	effects					299:305	the effects	295:305	the effects of environmental factors on wheat grain cell wall composition and structure	295:381	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	0	35	theme	composition	34:44	arg1	Effects					0:6	Effects	0:6	Effects of cereal grain cell wall composition and structure on starch digestion	0:78	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	7	36	from	impact	1264:1269	arg1	hydrolysis					1281:1290	starch hydrolysis	1274:1290	starch hydrolysis	1274:1290	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	3	37	theme	different	455:463	arg1	samples					471:477	different wheat samples	455:477	different wheat samples	455:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	1	38	theme	different	194:202	arg1	environments					204:215	different environments	194:215	different environments	194:215	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	7	39	theme	different	1430:1438	arg1	combinations					1440:1451	different combinations	1430:1451	different combinations	1430:1451	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	7	40	theme	wall	1237:1240	arg1	structure					1242:1250	the wheat cell wall structure	1222:1250	the wheat cell wall structure	1222:1250	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	4	41	theme	different	583:591	arg1	varieties					593:601	Ten different varieties	579:601	Ten different varieties of wheat grains with different aleurone cell wall structure and composition	579:677	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	4	41	theme	different	583:591	arg1	grains					612:617	wheat grains	606:617	wheat grains with different aleurone cell wall structure and composition	606:677	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	4	42	with	grains	612:617	arg1	composition					667:677	composition	667:677	composition	667:677	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	4	42	with	grains	612:617	arg1	structure					653:661	different aleurone cell wall structure	624:661	different aleurone cell wall structure	624:661	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	2	43	theme	cell	347:350	arg1	composition					357:367	wheat grain cell wall composition	335:367	wheat grain cell wall composition	335:367	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	7	44	theme	wheat	1226:1230	arg1	structure					1242:1250	the wheat cell wall structure	1222:1250	the wheat cell wall structure	1222:1250	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	2	45	theme	wheat	335:339	arg1	composition					357:367	wheat grain cell wall composition	335:367	wheat grain cell wall composition	335:367	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	7	46	theme	wall	1404:1407	arg1	structure					1409:1417	the cell wall structure	1395:1417	the cell wall structure	1395:1417	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	3	47	theme	aleurone	521:528	arg1	walls					535:539	aleurone cell walls	521:539	aleurone cell walls	521:539	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	8	48	theme	cell	1633:1636	arg1	wall					1638:1641	the cell wall	1629:1641	the cell wall	1629:1641	The present study showed that the cell wall combines the starch granules during the bread-making process; thus, the diffusion of enzymes through the cell wall was hindered.
37185988	4	49	theme	cell	643:646	arg1	structure					653:661	different aleurone cell wall structure	624:661	different aleurone cell wall structure	624:661	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	3	50	theme	grain	544:548	arg1	properties					567:576	grain starch digestion properties	544:576	grain starch digestion properties	544:576	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	3	51	theme	walls	535:539	arg1	effects					510:516	the effects	506:516	the effects of aleurone cell walls on grain starch digestion properties	506:576	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	4	52	theme	grains	612:617	arg1	varieties					593:601	Ten different varieties	579:601	Ten different varieties of wheat grains with different aleurone cell wall structure and composition	579:677	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	4	52	theme	grains	612:617	arg1	grains					612:617	wheat grains	606:617	wheat grains with different aleurone cell wall structure and composition	606:677	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	5	53	theme	3.05	830:833	arg1	μm					835:836	μm	835:836	μm	835:836	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	7	54	theme	starch	1344:1349	arg1	digestibility					1327:1339	the digestibility	1323:1339	the digestibility of starch in flour and bread	1323:1368	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	4	55	theme	different	624:632	arg1	structure					653:661	different aleurone cell wall structure	624:661	different aleurone cell wall structure	624:661	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	6	56	theme	total	1005:1009	arg1	digestibility					1011:1023	the total digestibility	1001:1023	the total digestibility of starch within the bread	1001:1050	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	3	57	theme	digestion	557:565	arg1	properties					567:576	grain starch digestion properties	544:576	grain starch digestion properties	544:576	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	5	58	theme	xylose	871:876	arg1	0.79-0.97					923:931	0.79-0.97	923:931	0.79-0.97	923:931	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	5	58	theme	xylose	871:876	arg1	ration					878:883	the arabinose to xylose ration	854:883	the arabinose to xylose ration of water-extractable arabinoxylan	854:917	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	4	59	theme	research	700:707	arg1	system					709:714	a simple research system	691:714	a simple research system used to study their effect on the starch digestion of bread	691:774	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	1	60	theme	food	114:117	arg1	crop					119:122	an important food crop	101:122	an important food crop	101:122	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	1	60	theme	food	114:117	arg1	Wheat					92:96	BACKGROUND Wheat	81:96	BACKGROUND Wheat	81:96	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	3	61	from	effects	510:516	arg1	properties					567:576	grain starch digestion properties	544:576	grain starch digestion properties	544:576	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	5	62	theme	arabinose	858:866	arg1	0.79-0.97					923:931	0.79-0.97	923:931	0.79-0.97	923:931	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	5	62	theme	arabinose	858:866	arg1	ration					878:883	the arabinose to xylose ration	854:883	the arabinose to xylose ration of water-extractable arabinoxylan	854:917	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	6	63	theme	cell	980:983	arg1	thickness					990:998	cell wall thickness	980:998	cell wall thickness	980:998	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	3	64	from	variations	396:405	arg1	structure					414:422	the structure	410:422	the structure of aleurone cell walls between different wheat samples	410:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	3	65	dep	METHODS	384:390	arg1	variations					396:405	The variations	392:405	METHODS The variations in the structure of aleurone cell walls between different wheat samples	384:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	5	66	dep	ration	878:883	arg1	to					868:869	to	868:869	to	868:869	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	5	67	theme	aleurone	789:796	arg1	thickness					808:816	The aleurone cell wall thickness	785:816	RESULTS The aleurone cell wall thickness	777:816	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	4	68	from	effect	736:741	arg1	digestion					757:765	the starch digestion	746:765	the starch digestion of bread	746:774	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	5	69	theme	arabinoxylan	906:917	arg1	0.79-0.97					923:931	0.79-0.97	923:931	0.79-0.97	923:931	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	5	69	theme	arabinoxylan	906:917	arg1	ration					878:883	the arabinose to xylose ration	854:883	the arabinose to xylose ration of water-extractable arabinoxylan	854:917	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	7	70	theme	starch	1274:1279	arg1	hydrolysis					1281:1290	starch hydrolysis	1274:1290	starch hydrolysis	1274:1290	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	2	71	theme	wall	352:355	arg1	composition					357:367	wheat grain cell wall composition	335:367	wheat grain cell wall composition	335:367	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	0	72	theme	grain	18:22	arg1	composition					34:44	cereal grain cell wall composition	11:44	cereal grain cell wall composition	11:44	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	7	73	from	digestibility	1327:1339	arg1	bread					1364:1368	bread	1364:1368	bread	1364:1368	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	7	73	from	digestibility	1327:1339	arg1	flour					1354:1358	flour	1354:1358	flour	1354:1358	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	6	74	theme	starch	1028:1033	arg1	digestibility					1011:1023	the total digestibility	1001:1023	the total digestibility of starch within the bread	1001:1050	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	7	75	dep	CONCLUSION	1189:1198	arg1	showed					1210:1215	showed	1210:1215	showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility	1210:1481	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	6	76	from	interaction	1116:1126	arg1	process					1180:1186	this process	1175:1186	this process	1175:1186	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	0	77	theme	wall	29:32	arg1	composition					34:44	cereal grain cell wall composition	11:44	cereal grain cell wall composition	11:44	Effects of cereal grain cell wall composition and structure on starch digestion.
37185988	1	78	theme	cultivation	181:191	arg1	region					171:176	the region	167:176	the region of cultivation	167:191	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	8	79	theme	cell	1518:1521	arg1	wall					1523:1526	the cell wall	1514:1526	the cell wall	1514:1526	The present study showed that the cell wall combines the starch granules during the bread-making process; thus, the diffusion of enzymes through the cell wall was hindered.
37185988	6	80	from	increase	943:950	arg1	thickness					990:998	cell wall thickness	980:998	cell wall thickness	980:998	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	6	80	from	increase	943:950	arg1	content					969:975	arabinoxylans content	955:975	arabinoxylans content	955:975	With the increase in arabinoxylans content or cell wall thickness, the total digestibility of starch within the bread decreased; this phenomenon may be related to the changes in the interaction between polysaccharides and starch granules in this process.
37185988	3	81	theme	cell	436:439	arg1	walls					441:445	aleurone cell walls	427:445	aleurone cell walls between different wheat samples	427:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	2	82	theme	environmental	310:322	arg1	factors					324:330	environmental factors	310:330	environmental factors	310:330	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	1	83	contain	have	217:220	arg1	environments					204:215	different environments	194:215	different environments	194:215	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	1	83	contain	have	217:220	arg2	effects					230:236	varying effects	222:236	varying effects	222:236	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
37185988	7	84	theme	cell	1232:1235	arg1	structure					1242:1250	the wheat cell wall structure	1222:1250	the wheat cell wall structure	1222:1250	CONCLUSION Our study showed that the wheat cell wall structure has a great impact on starch hydrolysis, indicating that the change in the digestibility of starch in flour and bread may be due to changes in the cell wall structure leading to different combinations, thus affecting digestibility.
37185988	8	85	theme	starch	1541:1546	arg1	granules					1548:1555	the starch granules	1537:1555	the starch granules	1537:1555	The present study showed that the cell wall combines the starch granules during the bread-making process; thus, the diffusion of enzymes through the cell wall was hindered.
37185988	5	86	dep	μm	835:836	arg1	to					838:839	to	838:839	to	838:839	RESULTS The aleurone cell wall thickness ranged from 3.05 μm to 4.67 μm, and the arabinose to xylose ration of water-extractable arabinoxylan was 0.79-0.97.
37185988	3	87	theme	wheat	465:469	arg1	samples					471:477	different wheat samples	455:477	different wheat samples	455:477	METHODS The variations in the structure of aleurone cell walls between different wheat samples were examined to determine the effects of aleurone cell walls on grain starch digestion properties.
37185988	4	88	theme	wheat	606:610	arg1	grains					612:617	wheat grains	606:617	wheat grains with different aleurone cell wall structure and composition	606:677	Ten different varieties of wheat grains with different aleurone cell wall structure and composition constituted a simple research system used to study their effect on the starch digestion of bread.
37185988	2	89	theme	grain	341:345	arg1	composition					357:367	wheat grain cell wall composition	335:367	wheat grain cell wall composition	335:367	We previously reported the effects of environmental factors on wheat grain cell wall composition and structure.
37185988	8	90	theme	enzymes	1613:1619	arg1	diffusion					1600:1608	the diffusion	1596:1608	the diffusion of enzymes through the cell wall	1596:1641	The present study showed that the cell wall combines the starch granules during the bread-making process; thus, the diffusion of enzymes through the cell wall was hindered.
37185988	1	91	theme	varying	222:228	arg1	effects					230:236	varying effects	222:236	varying effects	222:236	BACKGROUND Wheat is an important food crop, and its characteristics vary depending on the region of cultivation; different environments have varying effects on the composition of the grains.
36549030	0	0	theme	in	86:87	arg1	generations					94:104	in situ generations	86:104	in situ generations of magnesium hydroxide and cross-linked Ca-alginate	86:156	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	4	1	theme	composite	579:587	arg1	aerogel					589:595	the agar/polyvinyl alcohol composite aerogel	552:595	the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	552:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	1	2	theme	aerogel	173:179	arg1	materials					181:189	Biomass-based aerogel materials	159:189	Biomass-based aerogel materials	159:189	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	8	3	theme	total	1379:1383	arg1	release					1390:1396	the total heat release	1375:1396	the total heat release	1375:1396	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	5	4	theme	composites	910:919	arg1	stability					893:901	the mechanical and thermal stability	866:901	the mechanical and thermal stability of the composites	866:919	The results showed that the MH/SA dramatically enhanced the mechanical and thermal stability of the composites.
36549030	2	5	theme	cushioning	374:383	arg1	fields					353:358	the fields	349:358	the fields of packaging, cushioning and green building insulation	349:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	4	6	theme	MH	783:784	arg1	generation					769:778	in-situ generation	761:778	in-situ generation of MH	761:784	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	2	7	theme	broad	318:322	arg1	potential					336:344	broad development potential	318:344	broad development potential in the fields of packaging, cushioning and green building insulation	318:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	7	8	theme	V-0	1088:1090	arg1	level					1092:1096	V-0 level	1088:1096	V-0 level	1088:1096	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	9	theme	MH	1185:1186	arg1	effect					1188:1193	a single MH effect	1176:1193	a single MH effect	1176:1193	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	8	10	theme	MH/SA	1239:1243	arg1	system					1271:1276	the MH/SA composite flame retardant system	1235:1276	the MH/SA composite flame retardant system	1235:1276	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	0	11	theme	magnesium	109:117	arg1	hydroxide					119:127	magnesium hydroxide	109:127	magnesium hydroxide	109:127	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	8	12	theme	cone	1200:1203	arg1	test					1218:1221	The cone calorimetric test	1196:1221	The cone calorimetric test	1196:1221	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	0	13	link	cross-linked	133:144	arg1	Ca-alginate					146:156	cross-linked Ca-alginate	133:156	cross-linked Ca-alginate	133:156	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	8	14	theme	retardant	1261:1269	arg1	system					1271:1276	the MH/SA composite flame retardant system	1235:1276	the MH/SA composite flame retardant system	1235:1276	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	7	15	theme	burning	1114:1120	arg1	test					1122:1125	the vertical burning test	1101:1125	the vertical burning test	1101:1125	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	15	theme	burning	1114:1120	arg1	better					1138:1143	better	1138:1143	better	1138:1143	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	16	theme	AP-M35S15	1055:1063	arg1	%					1074:1074	34.1 %	1069:1074	34.1 %	1069:1074	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	16	theme	AP-M35S15	1055:1063	arg1	value					1046:1050	The limiting oxygen index value	1020:1050	The limiting oxygen index value of AP-M35S15	1020:1063	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	4	17	theme	generation	769:778	arg1	crosslinking					790:801	crosslinking	790:801	crosslinking of SA	790:807	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	4	17	theme	generation	769:778	arg1	technology					730:739	a freeze-dried technology	715:739	a freeze-dried technology	715:739	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	4	17	theme	generation	769:778	arg1	strategy					749:756	the strategy	745:756	the strategy	745:756	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	1	18	theme	many	196:199	arg1	advantages					201:210	many advantages	196:210	many advantages	196:210	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	1	18	theme	many	196:199	arg1	non-toxicity					250:261	non-toxicity	250:261	non-toxicity	250:261	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	1	18	theme	many	196:199	arg1	conductivity					233:244	low thermal conductivity	221:244	low thermal conductivity	221:244	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	0	19	dep	in	86:87	arg1	situ					89:92	situ	89:92	situ	89:92	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	3	20	theme	low	442:444	arg1	strength					457:464	low mechanical strength	442:464	low mechanical strength	442:464	However, defects, such as low mechanical strength and poor fire safety, greatly limit the application of these materials.
36549030	0	21	theme	Facile	0:5	arg1	construction					7:18	Facile construction	0:18	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.	0:157	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	4	22	theme	agar/polyvinyl	556:569	arg1	aerogel					589:595	the agar/polyvinyl alcohol composite aerogel	552:595	the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	552:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	5	23	theme	thermal	885:891	arg1	stability					893:901	the mechanical and thermal stability	866:901	the mechanical and thermal stability of the composites	866:919	The results showed that the MH/SA dramatically enhanced the mechanical and thermal stability of the composites.
36549030	2	24	theme	insulation	404:413	arg1	fields					353:358	the fields	349:358	the fields of packaging, cushioning and green building insulation	349:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	0	25	theme	agar-based	23:32	arg1	aerogels					49:56	agar-based fire-resistant aerogels	23:56	agar-based fire-resistant aerogels	23:56	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	8	26	theme	composite	1245:1253	arg1	system					1271:1276	the MH/SA composite flame retardant system	1235:1276	the MH/SA composite flame retardant system	1235:1276	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	4	27	theme	/sodium	637:643	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	8	28	theme	ignition	1312:1319	arg1	time					1321:1324	the ignition time	1308:1324	the ignition time	1308:1324	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	2	29	contain	have	313:316	arg1	materials					270:278	These materials	264:278	These materials	264:278	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	2	29	contain	have	313:316	arg2	potential					336:344	broad development potential	318:344	broad development potential in the fields of packaging, cushioning and green building insulation	318:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	2	29	contain	have	313:316	arg1	friendly					300:307	environmentally friendly	284:307	environmentally friendly	284:307	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	0	30	theme	hydroxide	119:127	arg1	generations					94:104	in situ generations	86:104	in situ generations of magnesium hydroxide and cross-linked Ca-alginate	86:156	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	8	31	theme	heat	1385:1388	arg1	release					1390:1396	the total heat release	1375:1396	the total heat release	1375:1396	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	2	32	theme	development	324:334	arg1	potential					336:344	broad development potential	318:344	broad development potential in the fields of packaging, cushioning and green building insulation	318:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	3	33	theme	materials	527:535	arg1	application					506:516	the application	502:516	the application of these materials	502:535	However, defects, such as low mechanical strength and poor fire safety, greatly limit the application of these materials.
36549030	0	34	theme	aerogels	49:56	arg1	construction					7:18	Facile construction	0:18	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.	0:157	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	4	35	theme	alcohol	571:577	arg1	aerogel					589:595	the agar/polyvinyl alcohol composite aerogel	552:595	the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	552:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	0	36	theme	Ca-alginate	146:156	arg1	generations					94:104	in situ generations	86:104	in situ generations of magnesium hydroxide and cross-linked Ca-alginate	86:156	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	3	37	theme	poor	470:473	arg1	safety					480:485	poor fire safety	470:485	poor fire safety	470:485	However, defects, such as low mechanical strength and poor fire safety, greatly limit the application of these materials.
36549030	4	38	theme	alginate	645:652	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	3	39	theme	mechanical	446:455	arg1	strength					457:464	low mechanical strength	442:464	low mechanical strength	442:464	However, defects, such as low mechanical strength and poor fire safety, greatly limit the application of these materials.
36549030	1	40	theme	low	221:223	arg1	conductivity					233:244	low thermal conductivity	221:244	low thermal conductivity	221:244	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	0	41	theme	fire-resistant	34:47	arg1	aerogels					49:56	agar-based fire-resistant aerogels	23:56	agar-based fire-resistant aerogels	23:56	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	6	42	theme	AP-M35S15	949:957	arg1	2.37 MPa					963:970	2.37 MPa	963:970	2.37 MPa	963:970	The compression modulus of AP-M35S15 was 2.37 MPa, which was 152.13 % higher than that of AP-M50.
36549030	6	42	theme	AP-M35S15	949:957	arg1	modulus					938:944	The compression modulus	922:944	The compression modulus of AP-M35S15	922:957	The compression modulus of AP-M35S15 was 2.37 MPa, which was 152.13 % higher than that of AP-M50.
36549030	0	43	theme	cross-linked	133:144	arg1	Ca-alginate					146:156	cross-linked Ca-alginate	133:156	cross-linked Ca-alginate	133:156	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	4	44	theme	SA	806:807	arg1	crosslinking					790:801	crosslinking	790:801	crosslinking of SA	790:807	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	4	44	theme	SA	806:807	arg1	technology					730:739	a freeze-dried technology	715:739	a freeze-dried technology	715:739	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	4	44	theme	SA	806:807	arg1	strategy					749:756	the strategy	745:756	the strategy	745:756	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	1	45	theme	thermal	225:231	arg1	conductivity					233:244	low thermal conductivity	221:244	low thermal conductivity	221:244	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	4	46	theme	flame	669:673	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	7	47	theme	limiting	1024:1031	arg1	%					1074:1074	34.1 %	1069:1074	34.1 %	1069:1074	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	47	theme	limiting	1024:1031	arg1	value					1046:1050	The limiting oxygen index value	1020:1050	The limiting oxygen index value of AP-M35S15	1020:1063	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	1	48	contain	have	191:194	arg2	non-toxicity					250:261	non-toxicity	250:261	non-toxicity	250:261	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	1	48	contain	have	191:194	arg2	conductivity					233:244	low thermal conductivity	221:244	low thermal conductivity	221:244	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	1	48	contain	have	191:194	arg2	advantages					201:210	many advantages	196:210	many advantages	196:210	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	1	48	contain	have	191:194	arg1	materials					181:189	Biomass-based aerogel materials	159:189	Biomass-based aerogel materials	159:189	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	8	49	theme	release	1349:1355	arg1	rate					1357:1360	the heat release rate	1340:1360	the heat release rate	1340:1360	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	8	50	theme	flame	1255:1259	arg1	system					1271:1276	the MH/SA composite flame retardant system	1235:1276	the MH/SA composite flame retardant system	1235:1276	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	7	51	theme	vertical	1105:1112	arg1	test					1122:1125	the vertical burning test	1101:1125	the vertical burning test	1101:1125	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	51	theme	vertical	1105:1112	arg1	better					1138:1143	better	1138:1143	better	1138:1143	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	52	theme	oxygen	1033:1038	arg1	%					1074:1074	34.1 %	1069:1074	34.1 %	1069:1074	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	52	theme	oxygen	1033:1038	arg1	value					1046:1050	The limiting oxygen index value	1020:1050	The limiting oxygen index value of AP-M35S15	1020:1063	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	8	53	theme	heat	1344:1347	arg1	rate					1357:1360	the heat release rate	1340:1360	the heat release rate	1340:1360	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	2	54	theme	packaging	363:371	arg1	fields					353:358	the fields	349:358	the fields of packaging, cushioning and green building insulation	349:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	6	55	theme	compression	926:936	arg1	2.37 MPa					963:970	2.37 MPa	963:970	2.37 MPa	963:970	The compression modulus of AP-M35S15 was 2.37 MPa, which was 152.13 % higher than that of AP-M50.
36549030	6	55	theme	compression	926:936	arg1	modulus					938:944	The compression modulus	922:944	The compression modulus of AP-M35S15	922:957	The compression modulus of AP-M35S15 was 2.37 MPa, which was 152.13 % higher than that of AP-M50.
36549030	4	56	theme	composite	659:667	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	2	57	theme	environmentally	284:298	arg1	materials					270:278	These materials	264:278	These materials	264:278	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	2	57	theme	environmentally	284:298	arg1	friendly					300:307	environmentally friendly	284:307	environmentally friendly	284:307	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	4	58	theme	retardant	675:683	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	4	59	theme	freeze-dried	717:728	arg1	technology					730:739	a freeze-dried technology	715:739	a freeze-dried technology	715:739	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	5	60	theme	mechanical	870:879	arg1	stability					893:901	the mechanical and thermal stability	866:901	the mechanical and thermal stability of the composites	866:919	The results showed that the MH/SA dramatically enhanced the mechanical and thermal stability of the composites.
36549030	4	61	theme	hydroxide	623:631	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	8	62	theme	complete	1413:1420	arg1	structure					1435:1443	a more complete dense carbon structure	1406:1443	a more complete dense carbon structure	1406:1443	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	4	63	theme	in-situ	761:767	arg1	generation					769:778	in-situ generation	761:778	in-situ generation of MH	761:784	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	8	64	theme	dense	1422:1426	arg1	structure					1435:1443	a more complete dense carbon structure	1406:1443	a more complete dense carbon structure	1406:1443	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	1	65	theme	Biomass-based	159:171	arg1	materials					181:189	Biomass-based aerogel materials	159:189	Biomass-based aerogel materials	159:189	Biomass-based aerogel materials have many advantages, such as low thermal conductivity and non-toxicity.
36549030	8	66	contain	had	1402:1404	arg1	system					1271:1276	the MH/SA composite flame retardant system	1235:1276	the MH/SA composite flame retardant system	1235:1276	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	8	66	contain	had	1402:1404	arg2	structure					1435:1443	a more complete dense carbon structure	1406:1443	a more complete dense carbon structure	1406:1443	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	4	67	theme	magnesium	613:621	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	7	68	theme	single	1178:1183	arg1	effect					1188:1193	a single MH effect	1176:1193	a single MH effect	1176:1193	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	3	69	theme	fire	475:478	arg1	safety					480:485	poor fire safety	470:485	poor fire safety	470:485	However, defects, such as low mechanical strength and poor fire safety, greatly limit the application of these materials.
36549030	0	70	dep	construction	7:18	arg1	strategy					73:80	A synergistic strategy	59:80	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.	0:157	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	8	71	theme	calorimetric	1205:1216	arg1	test					1218:1221	The cone calorimetric test	1196:1221	The cone calorimetric test	1196:1221	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	2	72	theme	building	395:402	arg1	insulation					404:413	green building insulation	389:413	green building insulation	389:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	4	73	theme	SA	655:656	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	4	74	theme	MH	634:635	arg1	system					685:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system	609:690	In this work, the agar/polyvinyl alcohol composite aerogel modified by the magnesium hydroxide (MH)/sodium alginate (SA) composite flame retardant system was developed by using a freeze-dried technology and the strategy of in-situ generation of MH and crosslinking of SA.
36549030	0	75	theme	synergistic	61:71	arg1	strategy					73:80	A synergistic strategy	59:80	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.	0:157	Facile construction of agar-based fire-resistant aerogels: A synergistic strategy via in situ generations of magnesium hydroxide and cross-linked Ca-alginate.
36549030	8	76	theme	carbon	1428:1433	arg1	structure					1435:1443	a more complete dense carbon structure	1406:1443	a more complete dense carbon structure	1406:1443	The cone calorimetric test showed that the MH/SA composite flame retardant system performed better in extending the ignition time, slowing down the heat release rate and reducing the total heat release and had a more complete dense carbon structure after burning.
36549030	7	77	theme	index	1040:1044	arg1	%					1074:1074	34.1 %	1069:1074	34.1 %	1069:1074	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	7	77	theme	index	1040:1044	arg1	value					1046:1050	The limiting oxygen index value	1020:1050	The limiting oxygen index value of AP-M35S15	1020:1063	The limiting oxygen index value of AP-M35S15 was 34.1 % and reached V-0 level in the vertical burning test, which was better than those of the samples with a single MH effect.
36549030	2	78	theme	green	389:393	arg1	insulation					404:413	green building insulation	389:413	green building insulation	389:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
36549030	2	79	from	potential	336:344	arg1	fields					353:358	the fields	349:358	the fields of packaging, cushioning and green building insulation	349:413	These materials are environmentally friendly and have broad development potential in the fields of packaging, cushioning and green building insulation.
35918881	5	0	theme	RNP	833:835	arg1	preadministration					812:828	intragastric preadministration	799:828	intragastric preadministration of RNP and OP for 3 weeks	799:854	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	1	1	contain	have	150:153	arg1	polysaccharides					134:148	Plant polysaccharides	128:148	Plant polysaccharides	128:148	Plant polysaccharides have prebiotic properties for gut microbiota and immune modulation.
35918881	1	1	contain	have	150:153	arg2	properties					165:174	prebiotic properties	155:174	prebiotic properties for gut microbiota and immune modulation	155:215	Plant polysaccharides have prebiotic properties for gut microbiota and immune modulation.
35918881	1	2	theme	gut	180:182	arg1	microbiota					184:193	gut microbiota	180:193	gut microbiota	180:193	Plant polysaccharides have prebiotic properties for gut microbiota and immune modulation.
35918881	4	3	theme	OP	634:635	arg1	properties					612:621	The prebiotic properties	598:621	The prebiotic properties of RNP and OP	598:635	The prebiotic properties of RNP and OP were determined in vitro.
35918881	8	4	theme	colitis	1287:1293	arg1	symptoms					1275:1282	the symptoms	1271:1282	the symptoms of colitis	1271:1293	In conclusion, intragastric gavage of RNP and OP significantly modulated the gut microbiota and immune response, consequently alleviating the symptoms of colitis.
35918881	9	5	theme	polysaccharides	1387:1401	arg1	strategy					1339:1346	an alternative strategy	1324:1346	an alternative strategy	1324:1346	This novel finding provides an alternative strategy and potential application of these two polysaccharides for colitis prevention and treatment.
35918881	9	5	theme	polysaccharides	1387:1401	arg1	application					1362:1372	potential application	1352:1372	potential application of these two polysaccharides	1352:1401	This novel finding provides an alternative strategy and potential application of these two polysaccharides for colitis prevention and treatment.
35918881	0	6	theme	gut	112:114	arg1	microbiota					116:125	the gut microbiota	108:125	the gut microbiota	108:125	Rhinacanthus nasutus and okara polysaccharides attenuate colitis via inhibiting inflammation and modulating the gut microbiota.
35918881	3	7	dep	transform	483:491	arg1	infrared					493:500	infrared	493:500	transform infrared	483:500	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	5	8	theme	colon	705:709	arg1	length					711:716	colon length	705:716	colon length	705:716	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	9	9	theme	colitis	1407:1413	arg1	prevention					1415:1424	colitis prevention	1407:1424	colitis prevention	1407:1424	This novel finding provides an alternative strategy and potential application of these two polysaccharides for colitis prevention and treatment.
35918881	5	10	theme	length	711:716	arg1	levels					744:749	inflammatory cytokine levels	722:749	inflammatory cytokine levels in acetic acid-induced colitis	722:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	5	10	theme	length	711:716	arg1	features					693:700	the pathological features	676:700	the pathological features of colon length	676:716	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	7	11	theme	acids-producing	1014:1028	arg1	bacteria					1030:1037	short-chain fatty acids-producing bacteria	996:1037	short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae)	996:1089	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	11	theme	acids-producing	1014:1028	arg1	Lactobacilli					1057:1068	Lactobacilli	1057:1068	Lactobacilli	1057:1068	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	11	theme	acids-producing	1014:1028	arg1	Prevotellaceae					1075:1088	Prevotellaceae	1075:1088	Prevotellaceae	1075:1088	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	11	theme	acids-producing	1014:1028	arg1	Lachnospiraceae					1040:1054	Lachnospiraceae	1040:1054	Lachnospiraceae	1040:1054	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	3	12	theme	scanning	544:551	arg1	calorimetry					553:563	differential scanning calorimetry	531:563	differential scanning calorimetry	531:563	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	2	13	theme	Sprague-Dawley	360:373	arg1	rats					375:378	Sprague-Dawley rats	360:378	Sprague-Dawley rats with acetic acid-induced colitis	360:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	7	14	theme	bacteria	1030:1037	arg1	abundance					983:991	the abundance	979:991	the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae)	979:1089	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	3	15	theme	monosaccharide	570:583	arg1	composition					585:595	monosaccharide composition	570:595	monosaccharide composition	570:595	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	5	16	theme	intragastric	799:810	arg1	preadministration					812:828	intragastric preadministration	799:828	intragastric preadministration of RNP and OP for 3 weeks	799:854	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	6	17	from	hepatotoxicity	888:901	arg1	rats					906:909	rats	906:909	rats	906:909	There was no nephrotoxicity or hepatotoxicity in rats via histopathological assessment after RNP and OP intake.
35918881	7	18	theme	short-chain	996:1006	arg1	bacteria					1030:1037	short-chain fatty acids-producing bacteria	996:1037	short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae)	996:1089	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	18	theme	short-chain	996:1006	arg1	Lactobacilli					1057:1068	Lactobacilli	1057:1068	Lactobacilli	1057:1068	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	18	theme	short-chain	996:1006	arg1	Prevotellaceae					1075:1088	Prevotellaceae	1075:1088	Prevotellaceae	1075:1088	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	18	theme	short-chain	996:1006	arg1	Lachnospiraceae					1040:1054	Lachnospiraceae	1040:1054	Lachnospiraceae	1040:1054	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	2	19	theme	polysaccharide	306:319	arg1	abilities					265:273	the prevention abilities	250:273	the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis	250:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	2	20	from	abilities	265:273	arg1	rats					375:378	Sprague-Dawley rats	360:378	Sprague-Dawley rats with acetic acid-induced colitis	360:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	1	21	theme	immune	199:204	arg1	modulation					206:215	immune modulation	199:215	immune modulation	199:215	Plant polysaccharides have prebiotic properties for gut microbiota and immune modulation.
35918881	8	22	theme	intragastric	1148:1159	arg1	gavage					1161:1166	intragastric gavage	1148:1166	intragastric gavage of RNP and OP	1148:1180	In conclusion, intragastric gavage of RNP and OP significantly modulated the gut microbiota and immune response, consequently alleviating the symptoms of colitis.
35918881	7	23	theme	fatty	1008:1012	arg1	bacteria					1030:1037	short-chain fatty acids-producing bacteria	996:1037	short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae)	996:1089	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	23	theme	fatty	1008:1012	arg1	Lactobacilli					1057:1068	Lactobacilli	1057:1068	Lactobacilli	1057:1068	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	23	theme	fatty	1008:1012	arg1	Prevotellaceae					1075:1088	Prevotellaceae	1075:1088	Prevotellaceae	1075:1088	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	23	theme	fatty	1008:1012	arg1	Lachnospiraceae					1040:1054	Lachnospiraceae	1040:1054	Lachnospiraceae	1040:1054	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	6	24	theme	OP	958:959	arg1	intake					961:966	OP intake	958:966	OP intake	958:966	There was no nephrotoxicity or hepatotoxicity in rats via histopathological assessment after RNP and OP intake.
35918881	6	25	from	nephrotoxicity	870:883	arg1	rats					906:909	rats	906:909	rats	906:909	There was no nephrotoxicity or hepatotoxicity in rats via histopathological assessment after RNP and OP intake.
35918881	0	26	theme	Rhinacanthus	0:11	arg1	nasutus					13:19	Rhinacanthus nasutus and okara polysaccharides	0:45	nasutus	13:19	Rhinacanthus nasutus and okara polysaccharides attenuate colitis via inhibiting inflammation and modulating the gut microbiota.
35918881	8	27	theme	OP	1179:1180	arg1	gavage					1161:1166	intragastric gavage	1148:1166	intragastric gavage of RNP and OP	1148:1180	In conclusion, intragastric gavage of RNP and OP significantly modulated the gut microbiota and immune response, consequently alleviating the symptoms of colitis.
35918881	5	28	theme	pathological	680:691	arg1	features					693:700	the pathological features	676:700	the pathological features of colon length	676:716	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	9	29	theme	novel	1301:1305	arg1	finding					1307:1313	This novel finding	1296:1313	This novel finding	1296:1313	This novel finding provides an alternative strategy and potential application of these two polysaccharides for colitis prevention and treatment.
35918881	2	30	theme	polysaccharide	337:350	arg1	abilities					265:273	the prevention abilities	250:273	the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis	250:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	8	31	theme	immune	1229:1234	arg1	response					1236:1243	immune response	1229:1243	immune response	1229:1243	In conclusion, intragastric gavage of RNP and OP significantly modulated the gut microbiota and immune response, consequently alleviating the symptoms of colitis.
35918881	2	32	dep	Rhinacanthus	285:296	arg1	nasutus					298:304	nasutus	298:304	nasutus	298:304	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	0	33	theme	okara	25:29	arg1	polysaccharides					31:45	Rhinacanthus nasutus and okara polysaccharides	0:45	polysaccharides	31:45	Rhinacanthus nasutus and okara polysaccharides attenuate colitis via inhibiting inflammation and modulating the gut microbiota.
35918881	4	34	theme	prebiotic	602:610	arg1	properties					612:621	The prebiotic properties	598:621	The prebiotic properties of RNP and OP	598:635	The prebiotic properties of RNP and OP were determined in vitro.
35918881	2	35	theme	okara	331:335	arg1	OP					353:354	OP	353:354	OP	353:354	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	2	35	theme	okara	331:335	arg1	polysaccharide					337:350	okara polysaccharide	331:350	okara polysaccharide (OP)	331:355	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	4	36	theme	RNP	626:628	arg1	properties					612:621	The prebiotic properties	598:621	The prebiotic properties of RNP and OP	598:635	The prebiotic properties of RNP and OP were determined in vitro.
35918881	5	37	theme	acetic	754:759	arg1	colitis					774:780	acetic acid-induced colitis	754:780	acetic acid-induced colitis	754:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	5	38	theme	OP	841:842	arg1	preadministration					812:828	intragastric preadministration	799:828	intragastric preadministration of RNP and OP for 3 weeks	799:854	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	5	39	theme	acid-induced	761:772	arg1	colitis					774:780	acetic acid-induced colitis	754:780	acetic acid-induced colitis	754:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	3	40	theme	OP	447:448	arg1	characterizations					418:434	The characterizations	414:434	The characterizations of RNP and OP	414:448	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	8	41	theme	RNP	1171:1173	arg1	gavage					1161:1166	intragastric gavage	1148:1166	intragastric gavage of RNP and OP	1148:1180	In conclusion, intragastric gavage of RNP and OP significantly modulated the gut microbiota and immune response, consequently alleviating the symptoms of colitis.
35918881	6	42	theme	histopathological	915:931	arg1	assessment					933:942	histopathological assessment	915:942	histopathological assessment	915:942	There was no nephrotoxicity or hepatotoxicity in rats via histopathological assessment after RNP and OP intake.
35918881	2	43	theme	prevention	254:263	arg1	abilities					265:273	the prevention abilities	250:273	the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis	250:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	9	44	theme	alternative	1327:1337	arg1	strategy					1339:1346	an alternative strategy	1324:1346	an alternative strategy	1324:1346	This novel finding provides an alternative strategy and potential application of these two polysaccharides for colitis prevention and treatment.
35918881	1	45	theme	Plant	128:132	arg1	polysaccharides					134:148	Plant polysaccharides	128:148	Plant polysaccharides	128:148	Plant polysaccharides have prebiotic properties for gut microbiota and immune modulation.
35918881	3	46	theme	RNP	439:441	arg1	characterizations					418:434	The characterizations	414:434	The characterizations of RNP and OP	414:448	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	5	47	from	features	693:700	arg1	colitis					774:780	acetic acid-induced colitis	754:780	acetic acid-induced colitis	754:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	5	48	theme	inflammatory	722:733	arg1	levels					744:749	inflammatory cytokine levels	722:749	inflammatory cytokine levels in acetic acid-induced colitis	722:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	9	49	theme	potential	1352:1360	arg1	application					1362:1372	potential application	1352:1372	potential application of these two polysaccharides	1352:1401	This novel finding provides an alternative strategy and potential application of these two polysaccharides for colitis prevention and treatment.
35918881	3	50	theme	differential	531:542	arg1	calorimetry					553:563	differential scanning calorimetry	531:563	differential scanning calorimetry	531:563	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	5	51	theme	cytokine	735:742	arg1	levels					744:749	inflammatory cytokine levels	722:749	inflammatory cytokine levels in acetic acid-induced colitis	722:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	2	52	with	rats	375:378	arg1	colitis					405:411	acetic acid-induced colitis	385:411	acetic acid-induced colitis	385:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	3	53	dep	Fourier	475:481	arg1	transform					483:491	transform	483:491	transform infrared	483:500	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	3	54	theme	thermogravimetric	503:519	arg1	analysis					521:528	thermogravimetric analysis	503:528	thermogravimetric analysis	503:528	The characterizations of RNP and OP were analyzed, including Fourier transform infrared, thermogravimetric analysis, differential scanning calorimetry, and monosaccharide composition.
35918881	7	55	dep	bacteria	1030:1037	arg1	bacteria					1030:1037	short-chain fatty acids-producing bacteria	996:1037	short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae)	996:1089	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	55	dep	bacteria	1030:1037	arg1	Lactobacilli					1057:1068	Lactobacilli	1057:1068	Lactobacilli	1057:1068	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	55	dep	bacteria	1030:1037	arg1	Prevotellaceae					1075:1088	Prevotellaceae	1075:1088	Prevotellaceae	1075:1088	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	55	dep	bacteria	1030:1037	arg1	Lachnospiraceae					1040:1054	Lachnospiraceae	1040:1054	Lachnospiraceae	1040:1054	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	7	56	theme	RNP	1112:1114	arg1	supplementation					1116:1130	RNP supplementation	1112:1130	RNP supplementation	1112:1130	Moreover, the abundance of short-chain fatty acids-producing bacteria (Lachnospiraceae, Lactobacilli, and Prevotellaceae) were increased after RNP supplementation.
35918881	2	57	theme	Rhinacanthus	285:296	arg1	RNP					322:324	RNP	322:324	RNP	322:324	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	2	57	theme	Rhinacanthus	285:296	arg1	polysaccharide					306:319	edible Rhinacanthus nasutus polysaccharide	278:319	edible Rhinacanthus nasutus polysaccharide (RNP)	278:325	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	1	58	theme	prebiotic	155:163	arg1	properties					165:174	prebiotic properties	155:174	prebiotic properties for gut microbiota and immune modulation	155:215	Plant polysaccharides have prebiotic properties for gut microbiota and immune modulation.
35918881	5	59	from	levels	744:749	arg1	colitis					774:780	acetic acid-induced colitis	754:780	acetic acid-induced colitis	754:780	In addition, the pathological features of colon length and inflammatory cytokine levels in acetic acid-induced colitis were improved by intragastric preadministration of RNP and OP for 3 weeks.
35918881	2	60	theme	edible	278:283	arg1	RNP					322:324	RNP	322:324	RNP	322:324	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	2	60	theme	edible	278:283	arg1	polysaccharide					306:319	edible Rhinacanthus nasutus polysaccharide	278:319	edible Rhinacanthus nasutus polysaccharide (RNP)	278:325	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	2	61	theme	acid-induced	392:403	arg1	colitis					405:411	acetic acid-induced colitis	385:411	acetic acid-induced colitis	385:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35918881	8	62	theme	gut	1210:1212	arg1	microbiota					1214:1223	the gut microbiota	1206:1223	the gut microbiota	1206:1223	In conclusion, intragastric gavage of RNP and OP significantly modulated the gut microbiota and immune response, consequently alleviating the symptoms of colitis.
35918881	2	63	theme	acetic	385:390	arg1	colitis					405:411	acetic acid-induced colitis	385:411	acetic acid-induced colitis	385:411	This study aimed to investigate the prevention abilities of edible Rhinacanthus nasutus polysaccharide (RNP) and okara polysaccharide (OP) in Sprague-Dawley rats with acetic acid-induced colitis.
35882139	0	0	theme	wound	108:112	arg1	healing					114:120	full-thickness dermal wound healing	86:120	full-thickness dermal wound healing	86:120	Skin-inspired injectable adhesive gelatin/HA biocomposite hydrogel for hemostasis and full-thickness dermal wound healing.
35882139	5	1	theme	therapeutic	1281:1291	arg1	effects					1293:1299	integrated therapeutic effects	1270:1299	integrated therapeutic effects	1270:1299	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	0	2	theme	dermal	101:106	arg1	healing					114:120	full-thickness dermal wound healing	86:120	full-thickness dermal wound healing	86:120	Skin-inspired injectable adhesive gelatin/HA biocomposite hydrogel for hemostasis and full-thickness dermal wound healing.
35882139	3	3	theme	double	761:766	arg1	3D-structure					776:787	a highly skin-bionic interconnected internal double network 3D-structure	716:787	a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties	716:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	4	4	theme	hemostatic	970:979	arg1	deposition					958:967	collagen deposition	949:967	collagen deposition	949:967	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	4	4	theme	hemostatic	970:979	arg1	effects					981:987	hemostatic effects	970:987	hemostatic effects	970:987	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	2	5	theme	adhesive	402:409	arg1	hydrogel					411:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel	344:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel)	344:430	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	5	theme	adhesive	402:409	arg1	HI/DA-Gel					421:429	HI/DA-Gel	421:429	HI/DA-Gel	421:429	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	3	6	with	3D-structure	776:787	arg1	properties					866:875	adhesive and mechanical properties	842:875	properties	866:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	6	with	3D-structure	776:787	arg1	thermal-stablity					824:839	thermal-stablity	824:839	thermal-stablity	824:839	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	6	with	3D-structure	776:787	arg1	wettability					811:821	elevated surface wettability	794:821	elevated surface wettability	794:821	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	7	dep	skin-bionic	725:735	arg1	interconnected					737:750	interconnected	737:750	interconnected	737:750	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	8	theme	network	768:774	arg1	3D-structure					776:787	a highly skin-bionic interconnected internal double network 3D-structure	716:787	a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties	716:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	2	9	theme	double-injection	307:322	arg1	approach					324:331	a simple double-injection approach	298:331	a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid	298:614	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	4	10	theme	hemostasis	1050:1059	arg1	strategy					1101:1108	an effective hemostasis and full-thickness dermal wound healing strategy	1037:1108	an effective hemostasis and full-thickness dermal wound healing strategy	1037:1108	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	5	11	theme	injectable	1231:1240	arg1	hydrogels					1256:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	2	12	theme	simple	300:305	arg1	approach					324:331	a simple double-injection approach	298:331	a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid	298:614	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	4	13	theme	dermal	1080:1085	arg1	healing					1093:1099	full-thickness dermal wound healing	1065:1099	full-thickness dermal wound healing	1065:1099	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	5	14	theme	bio-composite	1242:1254	arg1	hydrogels					1256:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	4	15	theme	collagen	949:956	arg1	deposition					958:967	collagen deposition	949:967	collagen deposition	949:967	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	4	15	theme	collagen	949:956	arg1	effects					981:987	hemostatic effects	970:987	hemostatic effects	970:987	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	1	16	theme	therapeutic	189:199	arg1	efficacy					201:208	therapeutic efficacy	189:208	therapeutic efficacy	189:208	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	4	17	theme	full-thickness	1065:1078	arg1	healing					1093:1099	full-thickness dermal wound healing	1065:1099	full-thickness dermal wound healing	1065:1099	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	3	18	theme	elevated	794:801	arg1	properties					866:875	adhesive and mechanical properties	842:875	properties	866:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	18	theme	elevated	794:801	arg1	thermal-stablity					824:839	thermal-stablity	824:839	thermal-stablity	824:839	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	18	theme	elevated	794:801	arg1	wettability					811:821	elevated surface wettability	794:821	elevated surface wettability	794:821	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	0	19	theme	injectable	14:23	arg1	gelatin/HA					34:43	Skin-inspired injectable adhesive gelatin/HA	0:43	Skin-inspired injectable adhesive gelatin/HA	0:43	Skin-inspired injectable adhesive gelatin/HA biocomposite hydrogel for hemostasis and full-thickness dermal wound healing.
35882139	3	20	theme	surface	803:809	arg1	properties					866:875	adhesive and mechanical properties	842:875	properties	866:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	20	theme	surface	803:809	arg1	thermal-stablity					824:839	thermal-stablity	824:839	thermal-stablity	824:839	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	20	theme	surface	803:809	arg1	wettability					811:821	elevated surface wettability	794:821	elevated surface wettability	794:821	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	0	21	theme	full-thickness	86:99	arg1	healing					114:120	full-thickness dermal wound healing	86:120	full-thickness dermal wound healing	86:120	Skin-inspired injectable adhesive gelatin/HA biocomposite hydrogel for hemostasis and full-thickness dermal wound healing.
35882139	3	22	theme	integrative	621:631	arg1	crosslinking					633:644	The integrative crosslinking	617:644	The integrative crosslinking	617:644	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	4	23	dep	In	890:891	arg1	vivo					902:905	vivo	902:905	vivo	902:905	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	0	24	theme	Skin-inspired	0:12	arg1	gelatin/HA					34:43	Skin-inspired injectable adhesive gelatin/HA	0:43	Skin-inspired injectable adhesive gelatin/HA	0:43	Skin-inspired injectable adhesive gelatin/HA biocomposite hydrogel for hemostasis and full-thickness dermal wound healing.
35882139	3	25	theme	adhesive	842:849	arg1	properties					866:875	adhesive and mechanical properties	842:875	properties	866:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	25	theme	adhesive	842:849	arg1	wettability					811:821	elevated surface wettability	794:821	elevated surface wettability	794:821	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	2	26	theme	genipin	500:506	arg1	crosslinking					455:466	simultaneous crosslinking	442:466	simultaneous crosslinking	442:466	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	26	theme	genipin	500:506	arg1	strategy					488:495	bio-compositing strategy	472:495	bio-compositing strategy	472:495	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	5	27	theme	multi-functional	1214:1229	arg1	hydrogels					1256:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	3	28	with	HI/DA-Gel	701:709	arg1	3D-structure					776:787	a highly skin-bionic interconnected internal double network 3D-structure	716:787	a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties	716:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	0	29	theme	adhesive	25:32	arg1	gelatin/HA					34:43	Skin-inspired injectable adhesive gelatin/HA	0:43	Skin-inspired injectable adhesive gelatin/HA	0:43	Skin-inspired injectable adhesive gelatin/HA biocomposite hydrogel for hemostasis and full-thickness dermal wound healing.
35882139	2	30	theme	hyaluronic	600:609	arg1	acid					611:614	hyaluronic acid	600:614	hyaluronic acid	600:614	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	5	31	theme	gelatin/	1189:1196	arg1	acid					1209:1212	gelatin/ hyaluronic acid	1189:1212	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	1	32	theme	insufficient	126:137	arg1	adhesion					139:146	An insufficient adhesion	123:146	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy	123:208	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	1	32	theme	insufficient	126:137	arg1	limitations					214:224	limitations	214:224	limitations to the application of gelatin and hyaluronic acid	214:274	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	2	33	theme	bio-compositing	472:486	arg1	strategy					488:495	bio-compositing strategy	472:495	bio-compositing strategy	472:495	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	4	34	theme	effective	1040:1048	arg1	hemostasis					1050:1059	an effective hemostasis	1037:1059	an effective hemostasis	1037:1059	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	5	35	theme	hyaluronic	1198:1207	arg1	acid					1209:1212	gelatin/ hyaluronic acid	1189:1212	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	5	36	theme	novel	1132:1136	arg1	approach					1162:1169	a novel facile double-injection approach	1130:1169	a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects	1130:1299	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	4	37	theme	healing	1093:1099	arg1	strategy					1101:1108	an effective hemostasis and full-thickness dermal wound healing strategy	1037:1108	an effective hemostasis and full-thickness dermal wound healing strategy	1037:1108	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	2	38	theme	simultaneous	442:453	arg1	crosslinking					455:466	simultaneous crosslinking	442:466	simultaneous crosslinking	442:466	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	5	39	theme	acid	1209:1212	arg1	hydrogels					1256:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1189:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	2	40	dep	crosslinking	455:466	arg1	a					440:440	a	440:440	a	440:440	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	3	41	theme	HI/DA-Gel	701:709	arg1	formation					686:694	the formation	682:694	the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties	682:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	5	42	theme	double-injection	1145:1160	arg1	approach					1162:1169	a novel facile double-injection approach	1130:1169	a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects	1130:1299	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	5	43	theme	hydrogels	1256:1264	arg1	design					1179:1184	the design	1175:1184	the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels	1175:1264	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	2	44	theme	remoistenable	388:400	arg1	hydrogel					411:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel	344:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel)	344:430	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	44	theme	remoistenable	388:400	arg1	HI/DA-Gel					421:429	HI/DA-Gel	421:429	HI/DA-Gel	421:429	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	3	45	theme	mechanical	855:864	arg1	properties					866:875	adhesive and mechanical properties	842:875	properties	866:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	45	theme	mechanical	855:864	arg1	wettability					811:821	elevated surface wettability	794:821	elevated surface wettability	794:821	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	3	46	theme	bio-compositing	650:664	arg1	strategy					666:673	bio-compositing strategy	650:673	bio-compositing strategy	650:673	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	2	47	theme	injectable	377:386	arg1	hydrogel					411:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel	344:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel)	344:430	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	47	theme	injectable	377:386	arg1	HI/DA-Gel					421:429	HI/DA-Gel	421:429	HI/DA-Gel	421:429	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	4	48	theme	CD31	1023:1026	arg1	production					1009:1018	the production	1005:1018	the production of CD31	1005:1026	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	3	49	theme	internal	752:759	arg1	3D-structure					776:787	a highly skin-bionic interconnected internal double network 3D-structure	716:787	a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties	716:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	4	50	theme	In	890:891	arg1	biostudies					907:916	In vitro/in vivo biostudies	890:916	In vitro/in vivo biostudies	890:916	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	5	51	theme	facile	1138:1143	arg1	approach					1162:1169	a novel facile double-injection approach	1130:1169	a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects	1130:1299	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	1	52	theme	wet	151:153	arg1	surfaces					155:162	wet surfaces	151:162	wet surfaces	151:162	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	1	53	theme	gelatin	248:254	arg1	application					233:243	the application	229:243	the application of gelatin and hyaluronic acid	229:274	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	2	54	theme	skin-inspired	346:358	arg1	hydrogel					411:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel	344:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel)	344:430	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	54	theme	skin-inspired	346:358	arg1	HI/DA-Gel					421:429	HI/DA-Gel	421:429	HI/DA-Gel	421:429	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	55	theme	gelatin/HA-based	360:375	arg1	hydrogel					411:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel	344:418	a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel)	344:430	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	55	theme	gelatin/HA-based	360:375	arg1	HI/DA-Gel					421:429	HI/DA-Gel	421:429	HI/DA-Gel	421:429	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	56	theme	N-hydroxy	560:568	arg1	NHS					583:585	NHS	583:585	NHS	583:585	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	2	56	theme	N-hydroxy	560:568	arg1	succinimide					570:580	N-hydroxy succinimide	560:580	N-hydroxy succinimide (NHS)	560:586	Herein, we developed a simple double-injection approach to prepare a skin-inspired gelatin/HA-based injectable remoistenable adhesive hydrogel (HI/DA-Gel) through a simultaneous crosslinking and bio-compositing strategy of genipin incorporated with dopamine (DA) grafted gelatin and N-hydroxy succinimide (NHS) merged with hyaluronic acid.
35882139	3	57	theme	skin-bionic	725:735	arg1	3D-structure					776:787	a highly skin-bionic interconnected internal double network 3D-structure	716:787	a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties	716:875	The integrative crosslinking and bio-compositing strategy led to the formation of a HI/DA-Gel with a highly skin-bionic interconnected internal double network 3D-structure with elevated surface wettability, thermal-stablity, adhesive and mechanical properties as expected.
35882139	1	58	theme	hyaluronic	260:269	arg1	acid					271:274	hyaluronic acid	260:274	hyaluronic acid	260:274	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	4	59	theme	wound	1087:1091	arg1	healing					1093:1099	full-thickness dermal wound healing	1065:1099	full-thickness dermal wound healing	1065:1099	In vitro/in vivo biostudies showed that HI/DA-Gel enhanced collagen deposition, hemostatic effects and upregulated the production of CD31, showing an effective hemostasis and full-thickness dermal wound healing strategy.
35882139	5	60	theme	integrated	1270:1279	arg1	effects					1293:1299	integrated therapeutic effects	1270:1299	integrated therapeutic effects	1270:1299	This work proposes a novel facile double-injection approach for the design of gelatin/ hyaluronic acid multi-functional injectable bio-composite hydrogels for integrated therapeutic effects.
35882139	1	61	theme	biased	168:173	arg1	functions					175:183	biased functions	168:183	biased functions	168:183	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
35882139	1	62	theme	acid	271:274	arg1	application					233:243	the application	229:243	the application of gelatin and hyaluronic acid	229:274	An insufficient adhesion to wet surfaces and biased functions for therapeutic efficacy are limitations to the application of gelatin and hyaluronic acid.
36330862	1	0	from	cellulose	277:285	arg1	rich					269:272	rich	269:272	rich	269:272	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	8	1	theme	cellulose	899:907	arg1	TF					909:910	The micro cellulose TF	889:910	The micro cellulose TF	889:910	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	0	2	theme	delinigfication	67:81	arg1	process					56:62	the process	52:62	the process of delinigfication and maceration	52:96	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	1	3	from	polysaccharides	287:301	arg1	rich					216:219	rich	216:219	rich	216:219	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	2	4	theme	cellulose	323:331	arg1	approach					373:380	an alternative reinforcement approach	344:380	an alternative reinforcement approach in a bio-composite application	344:411	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	2	4	theme	cellulose	323:331	arg1	Isolation					304:312	Isolation	304:312	Isolation of micro cellulose from TF	304:339	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	1	5	theme	cellulose	224:232	arg1	polysaccharides					287:301	cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	224:301	cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	224:301	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	1	6	from	rich	269:272	arg1	cellulose					277:285	cellulose	277:285	cellulose	277:285	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	6	7	theme	TF	785:786	arg1	crystallinity					758:770	crystallinity	758:770	crystallinity	758:770	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	6	7	theme	TF	785:786	arg1	size					749:752	crystal size	741:752	crystal size	741:752	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	7	8	theme	highest	826:832	arg1	stability					842:850	the highest thermal stability	822:850	the highest thermal stability	822:850	TGA also revealed that the highest thermal stability had been found in the hydrolyzed TF.
36330862	0	9	theme	maceration	87:96	arg1	process					56:62	the process	52:62	the process of delinigfication and maceration	52:96	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	5	10	theme	materials	643:651	arg1	amount					619:624	the maximum amount	607:624	the maximum amount of noncellulosic materials	607:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	5	10	theme	materials	643:651	arg1	materials					643:651	noncellulosic materials	629:651	noncellulosic materials	629:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	6	11	theme	XRD	683:685	arg1	result					687:692	The XRD result	679:692	The XRD result	679:692	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	8	12	theme	interesting	927:937	arg1	source					939:944	an interesting source	924:944	an interesting source of cellulose reinforcing materials	924:979	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	2	13	theme	alternative	347:357	arg1	approach					373:380	an alternative reinforcement approach	344:380	an alternative reinforcement approach in a bio-composite application	344:411	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	2	13	theme	alternative	347:357	arg1	Isolation					304:312	Isolation	304:312	Isolation of micro cellulose from TF	304:339	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	0	14	from	fiber	40:44	arg1	Isolation					0:8	Isolation	0:8	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.	0:167	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	7	15	located	found	861:865	arg1	TF					885:886	the hydrolyzed TF	870:886	the hydrolyzed TF	870:886	TGA also revealed that the highest thermal stability had been found in the hydrolyzed TF.
36330862	7	15	located	found	861:865	arg2	stability					842:850	the highest thermal stability	822:850	the highest thermal stability	822:850	TGA also revealed that the highest thermal stability had been found in the hydrolyzed TF.
36330862	8	16	theme	cellulose	949:957	arg1	materials					971:979	cellulose reinforcing materials	949:979	cellulose reinforcing materials	949:979	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	2	17	theme	reinforcement	359:371	arg1	approach					373:380	an alternative reinforcement approach	344:380	an alternative reinforcement approach in a bio-composite application	344:411	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	2	17	theme	reinforcement	359:371	arg1	Isolation					304:312	Isolation	304:312	Isolation of micro cellulose from TF	304:339	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	1	18	from	rich	216:219	arg1	polysaccharides					287:301	cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	224:301	cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	224:301	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	1	19	theme	Timoho	169:174	arg1	bio-fiber					206:214	a biodegradable bio-fiber	190:214	a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	190:301	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	1	19	theme	Timoho	169:174	arg1	TF					183:184	TF	183:184	TF	183:184	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	1	19	theme	Timoho	169:174	arg1	fiber					176:180	Timoho fiber	169:180	Timoho fiber (TF)	169:185	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	8	20	theme	micro	893:897	arg1	TF					909:910	The micro cellulose TF	889:910	The micro cellulose TF	889:910	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	1	21	theme	renewable	240:248	arg1	fiber					263:267	a renewable agro textile fiber	238:267	a renewable agro textile fiber rich in cellulose	238:285	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	5	22	theme	maximum	611:617	arg1	amount					619:624	the maximum amount	607:624	the maximum amount of noncellulosic materials	607:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	5	22	theme	maximum	611:617	arg1	materials					643:651	noncellulosic materials	629:651	noncellulosic materials	629:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	8	23	theme	materials	971:979	arg1	source					939:944	an interesting source	924:944	an interesting source of cellulose reinforcing materials	924:979	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	0	24	theme	properties	157:166	arg1	Evaluation					99:108	Evaluation	99:108	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.	0:167	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	1	25	theme	agro	250:253	arg1	fiber					263:267	a renewable agro textile fiber	238:267	a renewable agro textile fiber rich in cellulose	238:285	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	2	26	from	TF	338:339	arg1	approach					373:380	an alternative reinforcement approach	344:380	an alternative reinforcement approach in a bio-composite application	344:411	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	2	26	from	TF	338:339	arg1	Isolation					304:312	Isolation	304:312	Isolation of micro cellulose from TF	304:339	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	0	27	theme	microcellulose	13:26	arg1	Isolation					0:8	Isolation	0:8	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.	0:167	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	1	28	theme	textile	255:261	arg1	fiber					263:267	a renewable agro textile fiber	238:267	a renewable agro textile fiber rich in cellulose	238:285	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	0	29	theme	physical	113:120	arg1	properties					157:166	physical, chemical, structural, and thermal properties	113:166	physical, chemical, structural, and thermal properties	113:166	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	2	30	theme	bio-composite	387:399	arg1	application					401:411	a bio-composite application	385:411	a bio-composite application	385:411	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	1	31	theme	fiber	263:267	arg1	polysaccharides					287:301	cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	224:301	cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	224:301	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	8	32	theme	cellulose	1028:1036	arg1	form					1015:1018	the form	1011:1018	the form of nano cellulose	1011:1036	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	5	33	attach	removed	662:668	arg2	materials					643:651	noncellulosic materials	629:651	noncellulosic materials	629:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	5	33	attach	removed	662:668	arg2	amount					619:624	the maximum amount	607:624	the maximum amount of noncellulosic materials	607:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	5	33	attach	removed	662:668	arg1	TF					675:676	TF	675:676	TF	675:676	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	0	34	theme	timoho	33:38	arg1	fiber					40:44	timoho fiber	33:44	timoho fiber using the process of delinigfication and maceration	33:96	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	1	35	theme	rich	269:272	arg1	fiber					263:267	a renewable agro textile fiber	238:267	a renewable agro textile fiber rich in cellulose	238:285	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	0	36	theme	chemical	123:130	arg1	properties					157:166	physical, chemical, structural, and thermal properties	113:166	physical, chemical, structural, and thermal properties	113:166	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	8	37	theme	reinforcing	959:969	arg1	materials					971:979	cellulose reinforcing materials	949:979	cellulose reinforcing materials	949:979	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	6	38	theme	crystal	741:747	arg1	size					749:752	crystal size	741:752	crystal size	741:752	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	2	39	theme	micro	317:321	arg1	cellulose					323:331	micro cellulose	317:331	micro cellulose	317:331	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	8	40	theme	nano	1023:1026	arg1	cellulose					1028:1036	nano cellulose	1023:1036	nano cellulose	1023:1036	The micro cellulose TF represented an interesting source of cellulose reinforcing materials, and it might be continued in the form of nano cellulose.
36330862	0	41	theme	structural	133:142	arg1	properties					157:166	physical, chemical, structural, and thermal properties	113:166	physical, chemical, structural, and thermal properties	113:166	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	2	42	from	approach	373:380	arg1	application					401:411	a bio-composite application	385:411	a bio-composite application	385:411	Isolation of micro cellulose from TF is an alternative reinforcement approach in a bio-composite application.
36330862	5	43	theme	noncellulosic	629:641	arg1	materials					643:651	noncellulosic materials	629:651	noncellulosic materials	629:651	FTIR confirmed that the maximum amount of noncellulosic materials had been removed from TF.
36330862	7	44	theme	hydrolyzed	874:883	arg1	TF					885:886	the hydrolyzed TF	870:886	the hydrolyzed TF	870:886	TGA also revealed that the highest thermal stability had been found in the hydrolyzed TF.
36330862	0	45	theme	thermal	149:155	arg1	properties					157:166	physical, chemical, structural, and thermal properties	113:166	physical, chemical, structural, and thermal properties	113:166	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	7	46	theme	thermal	834:840	arg1	stability					842:850	the highest thermal stability	822:850	the highest thermal stability	822:850	TGA also revealed that the highest thermal stability had been found in the hydrolyzed TF.
36330862	6	47	theme	hydrolysis	706:715	arg1	treatment					717:725	hydrolysis treatment	706:725	hydrolysis treatment	706:725	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	1	48	theme	biodegradable	192:204	arg1	bio-fiber					206:214	a biodegradable bio-fiber	190:214	a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	190:301	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	1	48	theme	biodegradable	192:204	arg1	fiber					176:180	Timoho fiber	169:180	Timoho fiber (TF)	169:185	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	6	49	dep	size	749:752	arg1	index					772:776	index	772:776	index	772:776	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	6	49	dep	size	749:752	arg1	the					737:739	the	737:739	the	737:739	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	0	50	dep	Isolation	0:8	arg1	Evaluation					99:108	Evaluation	99:108	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.	0:167	Isolation of microcellulose from timoho fiber using the process of delinigfication and maceration: Evaluation of physical, chemical, structural, and thermal properties.
36330862	6	51	dep	increased	727:735	arg1	%					795:795	88.68 %	789:795	88.68 %	789:795	The XRD result showed that hydrolysis treatment increased the crystal size and crystallinity index of the TF (88.68 %).
36330862	1	52	theme	rich	216:219	arg1	bio-fiber					206:214	a biodegradable bio-fiber	190:214	a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides	190:301	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
36330862	1	52	theme	rich	216:219	arg1	fiber					176:180	Timoho fiber	169:180	Timoho fiber (TF)	169:185	Timoho fiber (TF) is a biodegradable bio-fiber rich in cellulose and a renewable agro textile fiber rich in cellulose polysaccharides.
35839340	7	0	theme	ripening	1101:1108	arg1	status					1110:1115	the ripening status	1097:1115	the ripening status of the grapes	1097:1129	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
35839340	2	1	theme	dynamic	390:396	arg1	change					398:403	a dynamic change	388:403	a dynamic change of extractability	388:421	During ripening, both compound groups undergo pronounced structural and compositional changes, resulting in a dynamic change of extractability.
35839340	0	2	theme	Polyphenols	66:76	arg1	Extraction					52:61	the Extraction	48:61	the Extraction of Polyphenols during Fermentation in Microvinifications	48:118	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	5	3	theme	higher	732:737	arg1	maturity					754:761	higher polysaccharide maturity	732:761	higher polysaccharide maturity	732:761	With higher polysaccharide maturity, the effects became more pronounced.
35839340	0	4	from	Influence	0:8	arg1	Extraction					52:61	the Extraction	48:61	the Extraction of Polyphenols during Fermentation in Microvinifications	48:118	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	5	5	theme	polysaccharide	739:752	arg1	maturity					754:761	higher polysaccharide maturity	732:761	higher polysaccharide maturity	732:761	With higher polysaccharide maturity, the effects became more pronounced.
35839340	3	6	dep	Sauvignon	523:531	arg1	grapes					548:553	grapes	548:553	grapes	548:553	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	8	7	theme	polysaccharides	1176:1190	arg1	changes					1165:1171	structural changes	1154:1171	structural changes of polysaccharides during ripening	1154:1206	It was concluded that structural changes of polysaccharides during ripening affect the extraction of tannins and monomeric flavanols the most.
35839340	8	8	theme	structural	1154:1163	arg1	changes					1165:1171	structural changes	1154:1171	structural changes of polysaccharides during ripening	1154:1206	It was concluded that structural changes of polysaccharides during ripening affect the extraction of tannins and monomeric flavanols the most.
35839340	7	9	theme	less	1080:1083	arg1	concentrations					1021:1034	the concentrations	1017:1034	the concentrations in anthocyanins and polymeric pigments much less	1017:1083	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
35839340	2	10	theme	compound	302:309	arg1	groups					311:316	both compound groups	297:316	both compound groups	297:316	During ripening, both compound groups undergo pronounced structural and compositional changes, resulting in a dynamic change of extractability.
35839340	1	11	theme	phenolic	181:188	arg1	compounds					190:198	phenolic compounds	181:198	phenolic compounds	181:198	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	7	12	theme	polymeric	1056:1064	arg1	pigments					1066:1073	polymeric pigments	1056:1073	polymeric pigments	1056:1073	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
35839340	1	13	theme	compounds	190:198	arg1	extraction					167:176	the extraction	163:176	the extraction of phenolic compounds	163:198	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	3	14	theme	Grape	424:428	arg1	polysaccharides					440:454	Grape cell wall polysaccharides	424:454	Grape cell wall polysaccharides from different ripe grapes	424:481	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	4	15	theme	monomeric	638:646	arg1	flavanols					648:656	monomeric flavanols	638:656	monomeric flavanols	638:656	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	2	16	theme	compositional	352:364	arg1	changes					366:372	pronounced structural and compositional changes	326:372	pronounced structural and compositional changes	326:372	During ripening, both compound groups undergo pronounced structural and compositional changes, resulting in a dynamic change of extractability.
35839340	3	17	theme	ripe	471:474	arg1	grapes					476:481	different ripe grapes	461:481	different ripe grapes	461:481	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	3	18	theme	cell	430:433	arg1	polysaccharides					440:454	Grape cell wall polysaccharides	424:454	Grape cell wall polysaccharides from different ripe grapes	424:481	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	4	19	from	concentrations	608:621	arg1	wines					665:669	the wines	661:669	the wines	661:669	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	2	20	theme	extractability	408:421	arg1	change					398:403	a dynamic change	388:403	a dynamic change of extractability	388:421	During ripening, both compound groups undergo pronounced structural and compositional changes, resulting in a dynamic change of extractability.
35839340	0	21	theme	Cell	19:22	arg1	Polysaccharides					29:43	Grape Cell Wall Polysaccharides	13:43	Grape Cell Wall Polysaccharides	13:43	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	4	22	theme	tannins	626:632	arg1	concentrations					608:621	the concentrations	604:621	the concentrations of tannins and monomeric flavanols in the wines	604:669	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	2	23	theme	structural	337:346	arg1	changes					366:372	pronounced structural and compositional changes	326:372	pronounced structural and compositional changes	326:372	During ripening, both compound groups undergo pronounced structural and compositional changes, resulting in a dynamic change of extractability.
35839340	4	24	theme	added	704:708	arg1	polysaccharides					710:724	the added polysaccharides	700:724	the added polysaccharides	700:724	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	0	25	theme	Grape	13:17	arg1	Polysaccharides					29:43	Grape Cell Wall Polysaccharides	13:43	Grape Cell Wall Polysaccharides	13:43	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	4	26	theme	flavanols	648:656	arg1	concentrations					608:621	the concentrations	604:621	the concentrations of tannins and monomeric flavanols in the wines	604:669	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	2	27	theme	pronounced	326:335	arg1	changes					366:372	pronounced structural and compositional changes	326:372	pronounced structural and compositional changes	326:372	During ripening, both compound groups undergo pronounced structural and compositional changes, resulting in a dynamic change of extractability.
35839340	0	28	theme	Polysaccharides	29:43	arg1	Influence					0:8	Influence	0:8	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.	0:119	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	3	29	theme	noir	543:546	arg1	fermentations					497:509	fermentations	497:509	fermentations of Cabernet Sauvignon and Pinot noir grapes	497:553	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	1	30	theme	polyphenol	235:244	arg1	concentrations					246:259	polyphenol concentrations	235:259	polyphenol concentrations	235:259	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	0	31	theme	Wall	24:27	arg1	Polysaccharides					29:43	Grape Cell Wall Polysaccharides	13:43	Grape Cell Wall Polysaccharides	13:43	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	3	32	theme	different	461:469	arg1	grapes					476:481	different ripe grapes	461:481	different ripe grapes	461:481	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	4	33	theme	polysaccharides	710:724	arg1	maturity					688:695	the maturity	684:695	the maturity of the added polysaccharides	684:724	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	3	34	theme	wall	435:438	arg1	polysaccharides					440:454	Grape cell wall polysaccharides	424:454	Grape cell wall polysaccharides from different ripe grapes	424:481	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	8	35	theme	tannins	1233:1239	arg1	extraction					1219:1228	the extraction	1215:1228	the extraction of tannins and monomeric flavanols	1215:1263	It was concluded that structural changes of polysaccharides during ripening affect the extraction of tannins and monomeric flavanols the most.
35839340	6	36	dep	precipitated	920:931	arg1	masked					936:941	masked	936:941	masked these compounds in Cabernet Sauvignon	936:979	Polysaccharides protected monomeric flavanols and tannin in Pinot noir, thereby increasing the concentrations, but they precipitated or masked these compounds in Cabernet Sauvignon.
35839340	6	37	theme	Pinot	860:864	arg1	noir					866:869	Pinot noir	860:869	Pinot noir	860:869	Polysaccharides protected monomeric flavanols and tannin in Pinot noir, thereby increasing the concentrations, but they precipitated or masked these compounds in Cabernet Sauvignon.
35839340	1	38	theme	Grape	121:125	arg1	polysaccharides					137:151	Grape cell wall polysaccharides	121:151	Grape cell wall polysaccharides	121:151	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	4	39	theme	Polyphenol-polysaccharide	556:580	arg1	interactions					582:593	Polyphenol-polysaccharide interactions	556:593	Polyphenol-polysaccharide interactions	556:593	Polyphenol-polysaccharide interactions affected the concentrations of tannins and monomeric flavanols in the wines depending on the maturity of the added polysaccharides.
35839340	1	40	theme	cell	127:130	arg1	polysaccharides					137:151	Grape cell wall polysaccharides	121:151	Grape cell wall polysaccharides	121:151	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	8	41	theme	monomeric	1245:1253	arg1	flavanols					1255:1263	monomeric flavanols	1245:1263	monomeric flavanols	1245:1263	It was concluded that structural changes of polysaccharides during ripening affect the extraction of tannins and monomeric flavanols the most.
35839340	7	42	theme	grapes	1124:1129	arg1	status					1110:1115	the ripening status	1097:1115	the ripening status of the grapes	1097:1129	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
35839340	1	43	theme	wall	132:135	arg1	polysaccharides					137:151	Grape cell wall polysaccharides	121:151	Grape cell wall polysaccharides	121:151	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	7	44	from	concentrations	1021:1034	arg1	anthocyanins					1039:1050	anthocyanins	1039:1050	anthocyanins	1039:1050	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
35839340	7	44	from	concentrations	1021:1034	arg1	pigments					1066:1073	polymeric pigments	1056:1073	polymeric pigments	1056:1073	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
35839340	3	45	theme	Sauvignon	523:531	arg1	fermentations					497:509	fermentations	497:509	fermentations of Cabernet Sauvignon and Pinot noir grapes	497:553	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	0	46	from	Fermentation	85:96	arg1	Microvinifications					101:118	Microvinifications	101:118	Microvinifications	101:118	Influence of Grape Cell Wall Polysaccharides on the Extraction of Polyphenols during Fermentation in Microvinifications.
35839340	3	47	from	grapes	476:481	arg1	polysaccharides					440:454	Grape cell wall polysaccharides	424:454	Grape cell wall polysaccharides from different ripe grapes	424:481	Grape cell wall polysaccharides from different ripe grapes were added to fermentations of Cabernet Sauvignon and Pinot noir grapes.
35839340	1	48	theme	final	268:272	arg1	wine					274:277	the final wine	264:277	the final wine	264:277	Grape cell wall polysaccharides influence the extraction of phenolic compounds during winemaking and consequently polyphenol concentrations in the final wine.
35839340	8	49	theme	flavanols	1255:1263	arg1	extraction					1219:1228	the extraction	1215:1228	the extraction of tannins and monomeric flavanols	1215:1263	It was concluded that structural changes of polysaccharides during ripening affect the extraction of tannins and monomeric flavanols the most.
35839340	6	50	theme	monomeric	826:834	arg1	flavanols					836:844	monomeric flavanols	826:844	monomeric flavanols	826:844	Polysaccharides protected monomeric flavanols and tannin in Pinot noir, thereby increasing the concentrations, but they precipitated or masked these compounds in Cabernet Sauvignon.
35839340	7	51	theme	added	986:990	arg1	polysaccharides					992:1006	The added polysaccharides	982:1006	The added polysaccharides	982:1006	The added polysaccharides affected the concentrations in anthocyanins and polymeric pigments much less compared to the ripening status of the grapes.
37233483	7	0	theme	tumor	1092:1096	arg1	apoptosis					1098:1106	HEL tumor apoptosis	1088:1106	HEL tumor apoptosis	1088:1106	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	4	1	from	mechanisms	522:531	arg1	cells					552:556	HEL cells	548:556	HEL cells	548:556	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	5	2	theme	%	802:802	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	9	3	theme	adjuvant	1405:1412	arg1	2205					1353:1356	SFP 2205	1349:1356	SFP 2205	1349:1356	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	9	3	theme	adjuvant	1405:1412	arg1	food					1388:1391	a potential functional food	1365:1391	a potential functional food additive or adjuvant	1365:1412	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	4	4	theme	mouse	574:578	arg1	model					580:584	a xenograft mouse model	562:584	a xenograft mouse model	562:584	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	6	5	theme	xenografts	901:910	arg1	growth					881:886	growth	881:886	growth of HEL tumor xenografts with no discernible toxicity to normal tissues	881:957	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	0	6	from	Activity	14:21	arg1	Sargassum					46:54	Sargassum	46:54	Sargassum	46:54	Anti-Leukemia Activity of Polysaccharide from Sargassum fusiforme via the PI3K/AKT/BAD Pathway In Vivo and In Vitro.
37233483	5	7	theme	molecular	634:642	arg1	weight					644:649	a molecular weight	632:649	a molecular weight of 41.85 kDa	632:662	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	2	8	theme	HEL	349:351	arg1	cells					354:358	human erythroleukemia (HEL) cells	326:358	human erythroleukemia (HEL) cells	326:358	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	2	9	from	apoptosis	313:321	arg1	cells					354:358	human erythroleukemia (HEL) cells	326:358	human erythroleukemia (HEL) cells	326:358	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	4	10	theme	xenograft	564:572	arg1	model					580:584	a xenograft mouse model	562:584	a xenograft mouse model	562:584	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	7	11	theme	Caspase-3	1035:1043	arg1	expression					1053:1062	Caspase-3 protein expression	1035:1062	Caspase-3 protein expression	1035:1062	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	4	12	theme	anticancer	511:520	arg1	mechanisms					522:531	anticancer mechanisms	511:531	anticancer mechanisms	511:531	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	7	13	theme	2205	993:996	arg1	therapy					998:1004	SFP 2205 therapy	989:1004	SFP 2205 therapy	989:1004	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	8	14	theme	pathway	1258:1264	arg1	activator					1232:1240	an activator	1229:1240	an activator of the PI3K/AKT pathway	1229:1264	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	8	14	theme	pathway	1258:1264	arg1	Y-P					1224:1226	740 Y-P	1220:1226	740 Y-P	1220:1226	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	4	15	from	model	580:584	arg1	cells					552:556	HEL cells	548:556	HEL cells	548:556	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	16	from	characteristics	491:505	arg1	cells					552:556	HEL cells	548:556	HEL cells	548:556	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	0	17	theme	Anti-Leukemia	0:12	arg1	Activity					14:21	Anti-Leukemia Activity	0:21	Anti-Leukemia Activity of Polysaccharide from Sargassum	0:54	Anti-Leukemia Activity of Polysaccharide from Sargassum fusiforme via the PI3K/AKT/BAD Pathway In Vivo and In Vitro.
37233483	5	18	theme	%	788:788	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	9	19	theme	functional	1377:1386	arg1	2205					1353:1356	SFP 2205	1349:1356	SFP 2205	1349:1356	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	9	19	theme	functional	1377:1386	arg1	food					1388:1391	a potential functional food	1365:1391	a potential functional food additive or adjuvant	1365:1412	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	3	20	dep	characterization	385:400	arg1	the					370:372	the	370:372	the	370:372	However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain.
37233483	5	21	theme	%	781:781	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	5	22	with	fucose	728:733	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	8	23	from	effects	1279:1285	arg1	cell					1306:1309	HEL cell proliferation and apoptosis	1302:1337	HEL cell proliferation and apoptosis	1302:1337	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	3	24	theme	2205	436:439	arg1	characterization					385:400	structural characterization	374:400	structural characterization	374:400	However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain.
37233483	3	24	theme	2205	436:439	arg1	mechanisms					418:427	antitumoral mechanisms	406:427	antitumoral mechanisms	406:427	However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain.
37233483	0	25	from	Sargassum	46:54	arg1	Polysaccharide					26:39	Polysaccharide	26:39	Polysaccharide from Sargassum	26:54	Anti-Leukemia Activity of Polysaccharide from Sargassum fusiforme via the PI3K/AKT/BAD Pathway In Vivo and In Vitro.
37233483	0	25	from	Sargassum	46:54	arg1	Activity					14:21	Anti-Leukemia Activity	0:21	Anti-Leukemia Activity of Polysaccharide from Sargassum	0:54	Anti-Leukemia Activity of Polysaccharide from Sargassum fusiforme via the PI3K/AKT/BAD Pathway In Vivo and In Vitro.
37233483	7	26	theme	SFP	989:991	arg1	therapy					998:1004	SFP 2205 therapy	989:1004	SFP 2205 therapy	989:1004	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	2	27	theme	Sargassum	271:279	arg1	SFP					292:294	SFP 2205	292:299	SFP 2205	292:299	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	2	27	theme	Sargassum	271:279	arg1	fusiforme					281:289	Sargassum fusiforme	271:289	Sargassum fusiforme	271:289	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	8	28	theme	signaling	1198:1206	arg1	pathway					1208:1214	the PI3K/AKT signaling pathway	1185:1214	the PI3K/AKT signaling pathway	1185:1214	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	8	29	theme	SFP	1290:1292	arg1	2205					1294:1297	SFP 2205	1290:1297	SFP 2205	1290:1297	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	5	30	with	rhamnose	686:693	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	3	31	theme	structural	374:383	arg1	characterization					385:400	structural characterization	374:400	structural characterization	374:400	However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain.
37233483	5	32	theme	SFP	617:619	arg1	2205					621:624	SFP 2205	617:624	SFP 2205	617:624	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	3	33	theme	SFP	432:434	arg1	2205					436:439	SFP 2205	432:439	SFP 2205	432:439	However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain.
37233483	0	34	theme	Polysaccharide	26:39	arg1	Activity					14:21	Anti-Leukemia Activity	0:21	Anti-Leukemia Activity of Polysaccharide from Sargassum	0:54	Anti-Leukemia Activity of Polysaccharide from Sargassum fusiforme via the PI3K/AKT/BAD Pathway In Vivo and In Vitro.
37233483	4	35	theme	HEL	548:550	arg1	cells					552:556	HEL cells	548:556	HEL cells	548:556	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	8	36	theme	PI3K/AKT	1189:1196	arg1	pathway					1208:1214	the PI3K/AKT signaling pathway	1185:1214	the PI3K/AKT signaling pathway	1185:1214	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	6	37	with	xenografts	901:910	arg1	toxicity					932:939	no discernible toxicity	917:939	no discernible toxicity to normal tissues	917:957	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	1	38	theme	herbal	192:197	arg1	treatments					199:208	effective herbal treatments	182:208	effective herbal treatments for leukemia	182:221	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	1	38	theme	herbal	192:197	arg1	fusiforme					151:159	Sargassum fusiforme	141:159	Sargassum fusiforme	141:159	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	1	38	theme	herbal	192:197	arg1	extracts					169:176	its extracts	165:176	its extracts	165:176	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	7	39	theme	protein	1045:1051	arg1	expression					1053:1062	Caspase-3 protein expression	1035:1062	Caspase-3 protein expression	1035:1062	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	7	40	theme	Western	960:966	arg1	blotting					968:975	Western blotting	960:975	Western blotting	960:975	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	7	41	theme	pathway	1134:1140	arg1	involvement					1142:1152	mitochondrial pathway involvement	1120:1152	mitochondrial pathway involvement	1120:1152	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	9	42	theme	additive	1393:1400	arg1	2205					1353:1356	SFP 2205	1349:1356	SFP 2205	1349:1356	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	9	42	theme	additive	1393:1400	arg1	food					1388:1391	a potential functional food	1365:1391	a potential functional food additive or adjuvant	1365:1412	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	5	43	theme	%	775:775	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	3	44	theme	antitumoral	406:416	arg1	mechanisms					418:427	antitumoral mechanisms	406:427	antitumoral mechanisms	406:427	However, the structural characterization and antitumoral mechanisms of SFP 2205 remain uncertain.
37233483	1	45	theme	effective	182:190	arg1	treatments					199:208	effective herbal treatments	182:208	effective herbal treatments for leukemia	182:221	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	1	45	theme	effective	182:190	arg1	fusiforme					151:159	Sargassum fusiforme	141:159	Sargassum fusiforme	141:159	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	1	45	theme	effective	182:190	arg1	extracts					169:176	its extracts	165:176	its extracts	165:176	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	6	46	theme	discernible	920:930	arg1	toxicity					932:939	no discernible toxicity	917:939	no discernible toxicity to normal tissues	917:957	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	4	47	from	2205	540:543	arg1	cells					552:556	HEL cells	548:556	HEL cells	548:556	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	48	theme	SFP	536:538	arg1	2205					540:543	SFP 2205	536:543	SFP 2205 in HEL cells	536:556	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	9	49	theme	SFP	1349:1351	arg1	2205					1353:1356	SFP 2205	1349:1356	SFP 2205	1349:1356	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	9	49	theme	SFP	1349:1351	arg1	food					1388:1391	a potential functional food	1365:1391	a potential functional food additive or adjuvant	1365:1412	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	4	50	from	cells	552:556	arg1	model					580:584	a xenograft mouse model	562:584	a xenograft mouse model	562:584	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	50	from	cells	552:556	arg1	characteristics					491:505	structural characteristics	480:505	structural characteristics	480:505	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	50	from	cells	552:556	arg1	mechanisms					522:531	anticancer mechanisms	511:531	anticancer mechanisms	511:531	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	51	dep	characteristics	491:505	arg1	the					476:478	the	476:478	the	476:478	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	5	52	theme	monosaccharides	740:754	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	6	53	theme	animal	833:838	arg1	assays					840:845	animal assays	833:845	animal assays	833:845	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	8	54	theme	PI3K/AKT	1249:1256	arg1	pathway					1258:1264	the PI3K/AKT pathway	1245:1264	the PI3K/AKT pathway	1245:1264	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	6	55	theme	SFP	848:850	arg1	2205					852:855	SFP 2205	848:855	SFP 2205	848:855	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	4	56	theme	structural	480:489	arg1	characteristics					491:505	structural characteristics	480:505	structural characteristics	480:505	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	8	57	dep	cell	1306:1309	arg1	apoptosis					1329:1337	apoptosis	1329:1337	apoptosis	1329:1337	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	8	57	dep	cell	1306:1309	arg1	proliferation					1311:1323	proliferation	1311:1323	proliferation	1311:1323	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	5	58	theme	kDa	660:662	arg1	weight					644:649	a molecular weight	632:649	a molecular weight of 41.85 kDa	632:662	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	5	59	with	galactose	696:704	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	7	60	theme	HEL	1088:1090	arg1	apoptosis					1098:1106	HEL tumor apoptosis	1088:1106	HEL tumor apoptosis	1088:1106	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	2	61	theme	erythroleukemia	332:346	arg1	cells					354:358	human erythroleukemia (HEL) cells	326:358	human erythroleukemia (HEL) cells	326:358	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	2	62	from	fusiforme	281:289	arg1	polysaccharide					251:264	a polysaccharide	249:264	a polysaccharide from Sargassum fusiforme, SFP 2205,	249:300	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	4	63	theme	2205	540:543	arg1	model					580:584	a xenograft mouse model	562:584	a xenograft mouse model	562:584	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	63	theme	2205	540:543	arg1	characteristics					491:505	structural characteristics	480:505	structural characteristics	480:505	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	4	63	theme	2205	540:543	arg1	mechanisms					522:531	anticancer mechanisms	511:531	anticancer mechanisms	511:531	Here, we studied the structural characteristics and anticancer mechanisms of SFP 2205 in HEL cells and a xenograft mouse model.
37233483	8	64	theme	2205	1294:1297	arg1	effects					1279:1285	the effects	1275:1285	the effects of SFP 2205 on HEL cell proliferation and apoptosis	1275:1337	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	5	65	with	xylose	707:712	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	2	66	theme	human	326:330	arg1	cells					354:358	human erythroleukemia (HEL) cells	326:358	human erythroleukemia (HEL) cells	326:358	We previously found that a polysaccharide from Sargassum fusiforme, SFP 2205, stimulated apoptosis in human erythroleukemia (HEL) cells.
37233483	5	67	theme	%	795:795	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	8	68	theme	SFP	1168:1170	arg1	2205					1172:1175	SFP 2205	1168:1175	SFP 2205	1168:1175	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	6	69	theme	normal	944:949	arg1	tissues					951:957	normal tissues	944:957	normal tissues	944:957	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	5	70	with	2205	621:624	arg1	weight					644:649	a molecular weight	632:649	a molecular weight of 41.85 kDa	632:662	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	5	71	theme	%	813:813	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	0	72	theme	PI3K/AKT/BAD	74:85	arg1	Pathway					87:93	the PI3K/AKT/BAD Pathway	70:93	the PI3K/AKT/BAD Pathway	70:93	Anti-Leukemia Activity of Polysaccharide from Sargassum fusiforme via the PI3K/AKT/BAD Pathway In Vivo and In Vitro.
37233483	5	73	with	mannose	677:683	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	8	74	theme	HEL	1302:1304	arg1	cell					1306:1309	HEL cell proliferation and apoptosis	1302:1337	HEL cell proliferation and apoptosis	1302:1337	Furthermore, SFP 2205 blocked the PI3K/AKT signaling pathway and 740 Y-P, an activator of the PI3K/AKT pathway, rescued the effects of SFP 2205 on HEL cell proliferation and apoptosis.
37233483	9	75	theme	potential	1367:1375	arg1	2205					1353:1356	SFP 2205	1349:1356	SFP 2205	1349:1356	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	9	75	theme	potential	1367:1375	arg1	food					1388:1391	a potential functional food	1365:1391	a potential functional food additive or adjuvant	1365:1412	Overall, SFP 2205 may be a potential functional food additive or adjuvant for preventing or treating leukemia.
37233483	6	76	theme	tumor	895:899	arg1	xenografts					901:910	HEL tumor xenografts	891:910	HEL tumor xenografts with no discernible toxicity to normal tissues	891:957	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37233483	5	77	with	glucose	715:721	arg1	composition					756:766	monosaccharides composition	740:766	monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively	740:827	The results demonstrated that SFP 2205, with a molecular weight of 41.85 kDa, consists of mannose, rhamnose, galactose, xylose, glucose, and fucose with monosaccharides composition of 14.2%, 9.4%, 11.8%, 13.7%, 11.0%, and 38.3%, respectively.
37233483	1	78	theme	Sargassum	141:149	arg1	treatments					199:208	effective herbal treatments	182:208	effective herbal treatments for leukemia	182:221	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	1	78	theme	Sargassum	141:149	arg1	fusiforme					151:159	Sargassum fusiforme	141:159	Sargassum fusiforme	141:159	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	1	78	theme	Sargassum	141:149	arg1	extracts					169:176	its extracts	165:176	its extracts	165:176	Studies have shown that Sargassum fusiforme and its extracts are effective herbal treatments for leukemia.
37233483	7	79	theme	mitochondrial	1120:1132	arg1	involvement					1142:1152	mitochondrial pathway involvement	1120:1152	mitochondrial pathway involvement	1120:1152	Western blotting showed that SFP 2205 therapy improved Bad, Caspase-9, and Caspase-3 protein expression, and ultimately induced HEL tumor apoptosis, indicating mitochondrial pathway involvement.
37233483	6	80	theme	HEL	891:893	arg1	xenografts					901:910	HEL tumor xenografts	891:910	HEL tumor xenografts with no discernible toxicity to normal tissues	891:957	On animal assays, SFP 2205 significantly inhibited growth of HEL tumor xenografts with no discernible toxicity to normal tissues.
37364810	0	0	theme	rabbitfish	86:95	arg1	microbes					101:108	rabbitfish gut microbes	86:108	rabbitfish gut microbes	86:108	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	2	1	theme	3,6-anhydro-α-l-galactopyranose	449:479	arg1	mainstay					420:427	the linear mainstay	409:427	the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units	409:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	5	2	theme	harmful	867:873	arg1	bacteria					875:882	feasibly harmful bacteria	858:882	feasibly harmful bacteria (such as Vibrio)	858:899	Furthermore, the adequacy of feasibly harmful bacteria (such as Vibrio) declined.
37364810	2	3	theme	linked	442:447	arg1	3,6-anhydro-α-l-galactopyranose					449:479	α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose	432:479	α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose	432:479	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	7	4	theme	intestinal	1077:1086	arg1	microbes					1088:1095	the intestinal microbes	1073:1095	the intestinal microbes	1073:1095	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	5	5	theme	bacteria	875:882	arg1	adequacy					846:853	the adequacy	842:853	the adequacy of feasibly harmful bacteria (such as Vibrio)	842:899	Furthermore, the adequacy of feasibly harmful bacteria (such as Vibrio) declined.
37364810	1	6	theme	SW	250:251	arg1	aspects					239:245	the fermentation aspects	222:245	the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes	222:317	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	2	7	theme	-linked	494:500	arg1	units					518:522	β-(1 → 3)-linked galactopyranose units	485:522	β-(1 → 3)-linked galactopyranose units	485:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	0	8	theme	gut	97:99	arg1	microbes					101:108	rabbitfish gut microbes	86:108	rabbitfish gut microbes	86:108	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	3	9	theme	gut	687:689	arg1	microbiota					691:700	gut microbiota	687:700	gut microbiota	687:700	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	1	10	theme	GLP	257:259	arg1	aspects					239:245	the fermentation aspects	222:245	the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes	222:317	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	1	11	dep	microbes	310:317	arg1	canaliculatus					284:296	Siganus canaliculatus	276:296	Siganus canaliculatus	276:296	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	1	12	link	-derived	180:187	arg1	GLP					205:207	GLP	205:207	GLP	205:207	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	1	12	link	-derived	180:187	arg1	polysaccharide					189:202	the Gracilaria lemaneiformis (SW)-derived polysaccharide	147:202	the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP)	147:208	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	7	13	theme	molecular	1133:1141	arg1	reduction					1150:1158	the molecular weight reduction	1129:1158	the molecular weight reduction from 1.36 × 105 g/mol	1129:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	14	from	%	1124:1124	arg1	1.36 × 105 g/mol					1165:1180	1.36 × 105 g/mol	1165:1180	1.36 × 105 g/mol	1165:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	15	dep	degrade	1097:1103	arg1	0 h					1186:1188	0 h	1186:1188	0 h	1186:1188	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	15	dep	degrade	1097:1103	arg1	24 h					1214:1217	24 h	1214:1217	24 h	1214:1217	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	16	with	GLP	1109:1111	arg1	reduction					1150:1158	the molecular weight reduction	1129:1158	the molecular weight reduction from 1.36 × 105 g/mol	1129:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	16	with	GLP	1109:1111	arg1	%					1124:1124	88.21 %	1118:1124	88.21 % of the molecular weight reduction from 1.36 × 105 g/mol	1118:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	8	17	contain	have	1273:1276	arg1	GLP					1269:1271	GLP	1269:1271	GLP	1269:1271	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	8	17	contain	have	1273:1276	arg1	additives					1338:1346	functional feed additives	1322:1346	functional feed additives in aquaculture	1322:1361	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	8	17	contain	have	1273:1276	arg1	SW					1262:1263	SW	1262:1263	SW	1262:1263	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	8	17	contain	have	1273:1276	arg2	potential					1288:1296	prebiotic potential	1278:1296	prebiotic potential	1278:1296	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	3	18	theme	fermentation	538:549	arg1	results					551:557	The in vitro fermentation results	525:557	The in vitro fermentation results	525:557	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	3	19	theme	microbiota	691:700	arg1	diversity					658:666	diversity	658:666	diversity	658:666	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	3	19	theme	microbiota	691:700	arg1	composition					672:682	composition	672:682	composition	672:682	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	1	20	theme	-derived	180:187	arg1	GLP					205:207	GLP	205:207	GLP	205:207	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	1	20	theme	-derived	180:187	arg1	polysaccharide					189:202	the Gracilaria lemaneiformis (SW)-derived polysaccharide	147:202	the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP)	147:208	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	0	21	theme	In	0:1	arg1	fermentation					9:20	In vitro fermentation	0:20	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.	0:109	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	4	22	theme	Proteobacteria	803:816	arg1	abundance					818:826	the Proteobacteria abundance	799:826	the Proteobacteria abundance	799:826	Moreover, GLP boosted the Fusobacteria and reduced the Firmicutes abundance, while SW increased the Proteobacteria abundance.
37364810	2	23	theme	linear	413:418	arg1	mainstay					420:427	the linear mainstay	409:427	the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units	409:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	1	24	theme	rabbitfish	264:273	arg1	microbes					310:317	rabbitfish (Siganus canaliculatus) intestinal microbes	264:317	rabbitfish (Siganus canaliculatus) intestinal microbes	264:317	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	6	25	theme	most	926:929	arg1	processes					941:949	most metabolic processes	926:949	most metabolic processes	926:949	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
37364810	3	26	theme	in	529:530	arg1	results					551:557	The in vitro fermentation results	525:557	The in vitro fermentation results	525:557	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	5	27	dep	bacteria	875:882	arg1	such					885:888	such	885:888	such	885:888	Furthermore, the adequacy of feasibly harmful bacteria (such as Vibrio) declined.
37364810	3	28	dep	diversity	658:666	arg1	the					654:656	the	654:656	the	654:656	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	3	29	theme	fatty	618:622	arg1	production					632:641	the short-chain fatty (SCFAs) production	602:641	the short-chain fatty (SCFAs) production	602:641	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	6	30	theme	-treated	1043:1050	arg1	groups					1052:1057	the control and galactooligosaccharide (GOS)-treated groups	999:1057	the control and galactooligosaccharide (GOS)-treated groups	999:1057	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
37364810	8	31	from	additives	1338:1346	arg1	aquaculture					1351:1361	aquaculture	1351:1361	aquaculture	1351:1361	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	0	32	theme	lemaneiformis	36:48	arg1	fermentation					9:20	In vitro fermentation	0:20	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.	0:109	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	2	33	theme	units	518:522	arg1	mainstay					420:427	the linear mainstay	409:427	the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units	409:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	0	34	theme	Gracilaria	25:34	arg1	lemaneiformis					36:48	Gracilaria lemaneiformis	25:48	Gracilaria lemaneiformis	25:48	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	2	35	theme	galactopyranose	502:516	arg1	units					518:522	β-(1 → 3)-linked galactopyranose units	485:522	β-(1 → 3)-linked galactopyranose units	485:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	6	36	dep	-treated	1043:1050	arg1	control					1003:1009	control	1003:1009	control	1003:1009	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
37364810	6	36	dep	-treated	1043:1050	arg1	galactooligosaccharide					1015:1036	galactooligosaccharide	1015:1036	galactooligosaccharide	1015:1036	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
37364810	2	37	theme	2.0:0.75 M	386:395	arg1	ratio					397:401	2.0:0.75 M ratio	386:401	2.0:0.75 M ratio	386:401	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	7	38	theme	weight	1143:1148	arg1	reduction					1150:1158	the molecular weight reduction	1129:1158	the molecular weight reduction from 1.36 × 105 g/mol	1129:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	6	39	theme	metabolic	931:939	arg1	processes					941:949	most metabolic processes	926:949	most metabolic processes	926:949	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
37364810	8	40	theme	functional	1322:1331	arg1	additives					1338:1346	functional feed additives	1322:1346	functional feed additives in aquaculture	1322:1361	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	8	40	theme	functional	1322:1331	arg1	SW					1262:1263	SW	1262:1263	SW	1262:1263	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	2	41	link	linked	442:447	arg1	3,6-anhydro-α-l-galactopyranose					449:479	α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose	432:479	α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose	432:479	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	1	42	theme	intestinal	299:308	arg1	microbes					310:317	rabbitfish (Siganus canaliculatus) intestinal microbes	264:317	rabbitfish (Siganus canaliculatus) intestinal microbes	264:317	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	7	43	theme	reduction	1150:1158	arg1	reduction					1150:1158	the molecular weight reduction	1129:1158	the molecular weight reduction from 1.36 × 105 g/mol	1129:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	43	theme	reduction	1150:1158	arg1	%					1124:1124	88.21 %	1118:1124	88.21 % of the molecular weight reduction from 1.36 × 105 g/mol	1118:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	4	44	theme	Firmicutes	758:767	arg1	abundance					769:777	the Firmicutes abundance	754:777	the Firmicutes abundance	754:777	Moreover, GLP boosted the Fusobacteria and reduced the Firmicutes abundance, while SW increased the Proteobacteria abundance.
37364810	7	45	from	1.36 × 105 g/mol	1165:1180	arg1	reduction					1150:1158	the molecular weight reduction	1129:1158	the molecular weight reduction from 1.36 × 105 g/mol	1129:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	7	45	from	1.36 × 105 g/mol	1165:1180	arg1	%					1124:1124	88.21 %	1118:1124	88.21 % of the molecular weight reduction from 1.36 × 105 g/mol	1118:1180	In addition, the intestinal microbes degrade the GLP with 88.21 % of the molecular weight reduction from 1.36 × 105 g/mol (at 0 h) to 1.6 × 104 g/mol (at 24 h).
37364810	8	46	theme	prebiotic	1278:1286	arg1	potential					1288:1296	prebiotic potential	1278:1296	prebiotic potential	1278:1296	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	2	47	with	galactose	351:359	arg1	mainstay					420:427	the linear mainstay	409:427	the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units	409:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	8	48	theme	feed	1333:1336	arg1	additives					1338:1346	functional feed additives	1322:1346	functional feed additives in aquaculture	1322:1361	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	8	48	theme	feed	1333:1336	arg1	SW					1262:1263	SW	1262:1263	SW	1262:1263	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	2	49	from	ratio	397:401	arg1	anhydrogalactose					365:380	anhydrogalactose	365:380	anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units	365:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	2	49	from	ratio	397:401	arg1	galactose					351:359	galactose	351:359	galactose	351:359	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	6	50	theme	SW	984:985	arg1	groups					987:992	the GLP and SW groups	972:992	groups	987:992	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
37364810	0	51	theme	polysaccharides	67:81	arg1	fermentation					9:20	In vitro fermentation	0:20	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.	0:109	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	8	52	dep	SW	1262:1263	arg1	the					1258:1260	the	1258:1260	the	1258:1260	Therefore, the findings suggest that the SW and GLP have prebiotic potential and could be applied as functional feed additives in aquaculture.
37364810	3	53	dep	in	529:530	arg1	vitro					532:536	vitro	532:536	vitro	532:536	The in vitro fermentation results showed that the SW and GLP could reinforce the short-chain fatty (SCFAs) production and change the diversity and composition of gut microbiota.
37364810	1	54	theme	fermentation	226:237	arg1	aspects					239:245	the fermentation aspects	222:245	the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes	222:317	This study intended to characterize the Gracilaria lemaneiformis (SW)-derived polysaccharide (GLP) and explore the fermentation aspects of SW and GLP by rabbitfish (Siganus canaliculatus) intestinal microbes.
37364810	0	55	theme	sulfated	58:65	arg1	polysaccharides					67:81	its sulfated polysaccharides	54:81	its sulfated polysaccharides	54:81	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	2	56	with	anhydrogalactose	365:380	arg1	mainstay					420:427	the linear mainstay	409:427	the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units	409:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	0	57	dep	In	0:1	arg1	vitro					3:7	vitro	3:7	vitro	3:7	In vitro fermentation of Gracilaria lemaneiformis and its sulfated polysaccharides by rabbitfish gut microbes.
37364810	2	58	link	-linked	494:500	arg1	units					518:522	β-(1 → 3)-linked galactopyranose units	485:522	β-(1 → 3)-linked galactopyranose units	485:522	The GLP was mainly composed of galactose and anhydrogalactose (at 2.0:0.75 M ratio) with the linear mainstay of α-(1 → 4) linked 3,6-anhydro-α-l-galactopyranose and β-(1 → 3)-linked galactopyranose units.
37364810	6	59	theme	GLP	976:978	arg1	groups					987:992	the GLP and SW groups	972:992	groups	987:992	Interestingly, most metabolic processes were correlated with the GLP and SW groups than the control and galactooligosaccharide (GOS)-treated groups.
36087977	4	0	from	domain	836:841	arg1	intensity					784:792	The intensity	780:792	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI	780:876	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	1	1	theme	biological	213:222	arg1	tissues					224:230	biological tissues	213:230	biological tissues	213:230	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	4	2	theme	cortical	797:804	arg1	signals					806:812	cortical signals	797:812	cortical signals	797:812	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	5	3	theme	obvious	1108:1114	arg1	response					1129:1136	obvious inflammatory response	1108:1136	obvious inflammatory response	1108:1136	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	3	4	theme	excellent	639:647	arg1	electro-biosensing					649:666	excellent electro-biosensing	639:666	excellent electro-biosensing	639:666	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	6	5	dep	EEI	1152:1154	arg1	designed					1159:1166	designed	1159:1166	designed	1159:1166	Overall, the EEI we designed contributes to improving tissue-device integration as well as bioelectronic device's performance and further leads to more effective human-computer interfaces.
36087977	6	6	theme	tissue-device	1193:1205	arg1	integration					1207:1217	improving tissue-device integration	1183:1217	improving tissue-device integration as well as bioelectronic device's performance	1183:1263	Overall, the EEI we designed contributes to improving tissue-device integration as well as bioelectronic device's performance and further leads to more effective human-computer interfaces.
36087977	2	7	theme	inherent	328:335	arg1	tradeoff					337:344	an inherent tradeoff	325:344	an inherent tradeoff among EEI's electrochemical characteristics, mechanical properties and biocompatibility	325:432	However, there is an inherent tradeoff among EEI's electrochemical characteristics, mechanical properties and biocompatibility when considering the desired nanostructure and optimum composition.
36087977	2	8	theme	optimum	481:487	arg1	composition					489:499	optimum composition	481:499	optimum composition	481:499	However, there is an inherent tradeoff among EEI's electrochemical characteristics, mechanical properties and biocompatibility when considering the desired nanostructure and optimum composition.
36087977	5	9	theme	tissue	1037:1042	arg1	interest					1052:1059	interest	1052:1059	interest	1052:1059	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	5	9	theme	tissue	1037:1042	arg1	site					1044:1047	the tissue site	1033:1047	the tissue site of interest	1033:1059	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	0	10	link	crosslinked	78:88	arg1	hydrogel					111:118	multiple crosslinked polysaccharide-based hydrogel	69:118	multiple crosslinked polysaccharide-based hydrogel	69:118	Tissue-like electrophysiological electrode interface construction by multiple crosslinked polysaccharide-based hydrogel.
36087977	5	11	theme	seamless	992:999	arg1	bio-integration					1001:1015	seamless bio-integration	992:1015	seamless bio-integration between EEI and the tissue site of interest	992:1059	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	0	12	theme	electrophysiological	12:31	arg1	electrode					33:41	Tissue-like electrophysiological electrode	0:41	Tissue-like electrophysiological electrode	0:41	Tissue-like electrophysiological electrode interface construction by multiple crosslinked polysaccharide-based hydrogel.
36087977	6	13	theme	bioelectronic	1230:1242	arg1	performance					1253:1263	bioelectronic device's performance	1230:1263	improving tissue-device integration as well as bioelectronic device's performance	1183:1263	Overall, the EEI we designed contributes to improving tissue-device integration as well as bioelectronic device's performance and further leads to more effective human-computer interfaces.
36087977	1	14	theme	reliable	123:130	arg1	indispensable					235:247	indispensable	235:247	indispensable	235:247	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	14	theme	reliable	123:130	arg1	EEI					174:176	EEI	174:176	EEI	174:176	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	14	theme	reliable	123:130	arg1	interface					163:171	A reliable electrophysiological electrode interface	121:171	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues	121:230	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	0	15	theme	Tissue-like	0:10	arg1	electrode					33:41	Tissue-like electrophysiological electrode	0:41	Tissue-like electrophysiological electrode	0:41	Tissue-like electrophysiological electrode interface construction by multiple crosslinked polysaccharide-based hydrogel.
36087977	1	16	theme	electrophysiological	132:151	arg1	indispensable					235:247	indispensable	235:247	indispensable	235:247	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	16	theme	electrophysiological	132:151	arg1	EEI					174:176	EEI	174:176	EEI	174:176	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	16	theme	electrophysiological	132:151	arg1	interface					163:171	A reliable electrophysiological electrode interface	121:171	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues	121:230	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	2	17	theme	desired	455:461	arg1	nanostructure					463:475	the desired nanostructure	451:475	the desired nanostructure	451:475	However, there is an inherent tradeoff among EEI's electrochemical characteristics, mechanical properties and biocompatibility when considering the desired nanostructure and optimum composition.
36087977	1	18	theme	electrode	153:161	arg1	indispensable					235:247	indispensable	235:247	indispensable	235:247	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	18	theme	electrode	153:161	arg1	EEI					174:176	EEI	174:176	EEI	174:176	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	18	theme	electrode	153:161	arg1	interface					163:171	A reliable electrophysiological electrode interface	121:171	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues	121:230	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	5	19	theme	gel	967:969	arg1	matrix					971:976	the natural gel matrix	955:976	the natural gel matrix	955:976	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	2	20	theme	electrochemical	358:372	arg1	characteristics					374:388	EEI's electrochemical characteristics	352:388	EEI's electrochemical characteristics	352:388	However, there is an inherent tradeoff among EEI's electrochemical characteristics, mechanical properties and biocompatibility when considering the desired nanostructure and optimum composition.
36087977	5	21	theme	signal	1073:1078	arg1	dissipation					1080:1090	signal dissipation	1073:1090	signal dissipation	1073:1090	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	3	22	theme	tissue-like	587:597	arg1	EEI					580:582	a mechanically matched, highly conductive and biocompatible EEI	520:582	a mechanically matched, highly conductive and biocompatible EEI	520:582	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	22	theme	tissue-like	587:597	arg1	hydrogel					611:618	a tissue-like metal-doped hydrogel	585:618	a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing	585:666	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	23	theme	metal-doped	599:609	arg1	EEI					580:582	a mechanically matched, highly conductive and biocompatible EEI	520:582	a mechanically matched, highly conductive and biocompatible EEI	520:582	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	23	theme	metal-doped	599:609	arg1	hydrogel					611:618	a tissue-like metal-doped hydrogel	585:618	a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing	585:666	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	24	theme	matched	535:541	arg1	EEI					580:582	a mechanically matched, highly conductive and biocompatible EEI	520:582	a mechanically matched, highly conductive and biocompatible EEI	520:582	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	24	theme	matched	535:541	arg1	hydrogel					611:618	a tissue-like metal-doped hydrogel	585:618	a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing	585:666	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	25	theme	silver	700:705	arg1	nanowires					707:715	disulfide modified silver nanowires	681:715	disulfide modified silver nanowires	681:715	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	4	26	theme	signals	806:812	arg1	intensity					784:792	The intensity	780:792	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI	780:876	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	1	27	theme	high	264:267	arg1	recording					278:286	the high fidelity recording	260:286	the high fidelity recording of bioelectricity	260:304	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	4	28	theme	frequency	826:834	arg1	domain					836:841	specific frequency domain	817:841	specific frequency domain recorded by the hydrogel-based EEI	817:876	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	1	29	theme	fidelity	269:276	arg1	recording					278:286	the high fidelity recording	260:286	the high fidelity recording of bioelectricity	260:304	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	0	30	theme	crosslinked	78:88	arg1	hydrogel					111:118	multiple crosslinked polysaccharide-based hydrogel	69:118	multiple crosslinked polysaccharide-based hydrogel	69:118	Tissue-like electrophysiological electrode interface construction by multiple crosslinked polysaccharide-based hydrogel.
36087977	5	31	theme	natural	959:965	arg1	matrix					971:976	the natural gel matrix	955:976	the natural gel matrix	955:976	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	3	32	theme	disulfide	681:689	arg1	nanowires					707:715	disulfide modified silver nanowires	681:715	disulfide modified silver nanowires	681:715	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	0	33	theme	multiple	69:76	arg1	hydrogel					111:118	multiple crosslinked polysaccharide-based hydrogel	69:118	multiple crosslinked polysaccharide-based hydrogel	69:118	Tissue-like electrophysiological electrode interface construction by multiple crosslinked polysaccharide-based hydrogel.
36087977	3	34	theme	modified	691:698	arg1	nanowires					707:715	disulfide modified silver nanowires	681:715	disulfide modified silver nanowires	681:715	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	4	35	theme	epilepsy	932:939	arg1	diagnosis					919:927	the diagnosis	915:927	the diagnosis of epilepsy	915:939	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	3	36	dep	matched	535:541	arg1	biocompatible					566:578	biocompatible	566:578	biocompatible	566:578	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	36	dep	matched	535:541	arg1	conductive					551:560	conductive	551:560	conductive	551:560	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	3	37	theme	hyaluronan/carboxymethyl	735:758	arg1	composite					769:777	difunctional hyaluronan/carboxymethyl chitosan composite	722:777	difunctional hyaluronan/carboxymethyl chitosan composite	722:777	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	2	38	theme	mechanical	391:400	arg1	properties					402:411	mechanical properties	391:411	mechanical properties	391:411	However, there is an inherent tradeoff among EEI's electrochemical characteristics, mechanical properties and biocompatibility when considering the desired nanostructure and optimum composition.
36087977	6	39	theme	human-computer	1301:1314	arg1	interfaces					1316:1325	more effective human-computer interfaces	1286:1325	more effective human-computer interfaces	1286:1325	Overall, the EEI we designed contributes to improving tissue-device integration as well as bioelectronic device's performance and further leads to more effective human-computer interfaces.
36087977	3	40	theme	chitosan	760:767	arg1	composite					769:777	difunctional hyaluronan/carboxymethyl chitosan composite	722:777	difunctional hyaluronan/carboxymethyl chitosan composite	722:777	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	4	41	theme	hydrogel-based	859:872	arg1	EEI					874:876	the hydrogel-based EEI	855:876	the hydrogel-based EEI	855:876	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	5	42	theme	interest	1052:1059	arg1	EEI					1025:1027	EEI	1025:1027	EEI	1025:1027	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	5	42	theme	interest	1052:1059	arg1	interest					1052:1059	interest	1052:1059	interest	1052:1059	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	5	42	theme	interest	1052:1059	arg1	site					1044:1047	the tissue site	1033:1047	the tissue site of interest	1033:1059	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	5	43	theme	inflammatory	1116:1127	arg1	response					1129:1136	obvious inflammatory response	1108:1136	obvious inflammatory response	1108:1136	Furthermore, the natural gel matrix could lead to seamless bio-integration between EEI and the tissue site of interest, minimizing signal dissipation without causing obvious inflammatory response.
36087977	1	44	theme	bioelectronic	187:199	arg1	devices					201:207	bioelectronic devices	187:207	bioelectronic devices	187:207	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	1	45	theme	bioelectricity	291:304	arg1	recording					278:286	the high fidelity recording	260:286	the high fidelity recording of bioelectricity	260:304	A reliable electrophysiological electrode interface (EEI) between bioelectronic devices and biological tissues is indispensable to achieve the high fidelity recording of bioelectricity.
36087977	0	46	theme	polysaccharide-based	90:109	arg1	hydrogel					111:118	multiple crosslinked polysaccharide-based hydrogel	69:118	multiple crosslinked polysaccharide-based hydrogel	69:118	Tissue-like electrophysiological electrode interface construction by multiple crosslinked polysaccharide-based hydrogel.
36087977	6	47	theme	effective	1291:1299	arg1	interfaces					1316:1325	more effective human-computer interfaces	1286:1325	more effective human-computer interfaces	1286:1325	Overall, the EEI we designed contributes to improving tissue-device integration as well as bioelectronic device's performance and further leads to more effective human-computer interfaces.
36087977	3	48	theme	difunctional	722:733	arg1	composite					769:777	difunctional hyaluronan/carboxymethyl chitosan composite	722:777	difunctional hyaluronan/carboxymethyl chitosan composite	722:777	Here, we proposed a mechanically matched, highly conductive and biocompatible EEI, a tissue-like metal-doped hydrogel which could enable excellent electro-biosensing, by bringing disulfide modified silver nanowires into difunctional hyaluronan/carboxymethyl chitosan composite.
36087977	4	49	theme	specific	817:824	arg1	domain					836:841	specific frequency domain	817:841	specific frequency domain recorded by the hydrogel-based EEI	817:876	The intensity of cortical signals at specific frequency domain recorded by the hydrogel-based EEI is doubled, which is significant for the diagnosis of epilepsy.
36087977	6	50	theme	improving	1183:1191	arg1	integration					1207:1217	improving tissue-device integration	1183:1217	improving tissue-device integration as well as bioelectronic device's performance	1183:1263	Overall, the EEI we designed contributes to improving tissue-device integration as well as bioelectronic device's performance and further leads to more effective human-computer interfaces.
36142298	3	0	with	-α-D-Manp-	636:645	arg1	acetylation					666:676	partial acetylation	658:676	partial acetylation of C6-OH in mannoses	658:697	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	1	theme	}	649:649	arg1	n					650:650	1→}n	647:650	1→}n	647:650	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	0	2	theme	Acetylation	76:86	arg1	Role					68:71	Essential Role	58:71	Essential Role of Acetylation in Immunomodulation	58:106	An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation.
36142298	3	3	dep	-α-D-Manp-	636:645	arg1	1→2					631:633	1→2	631:633	1→2	631:633	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	3	dep	-α-D-Manp-	636:645	arg1	n					650:650	1→}n	647:650	1→}n	647:650	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	2	4	theme	0.9:1.0:3.2:1.2	448:462	arg1	ratio					439:443	a ratio	437:443	a ratio of 0.9:1.0:3.2:1.2	437:462	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	5	theme	NMR	282:284	arg1	analysis					286:293	NMR analysis	282:293	NMR analysis	282:293	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	3	6	theme	C6-OH	681:685	arg1	acetylation					666:676	partial acetylation	658:676	partial acetylation of C6-OH in mannoses	658:697	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	4	7	theme	μg/mL	737:741	arg1	concentration					718:730	a concentration	716:730	a concentration of 1 μg/mL	716:741	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	8	theme	-α-D-Manp-	589:598	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	8	theme	-α-D-Manp-	589:598	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	4	9	with	interaction	847:857	arg1	TLR4					886:889	TLR4	886:889	TLR4	886:889	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	4	9	with	interaction	847:857	arg1	receptor					874:881	toll-like receptor 4	864:883	toll-like receptor 4 (TLR4)	864:890	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	10	from	C6-OH	681:685	arg1	mannoses					690:697	mannoses	690:697	mannoses	690:697	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	11	theme	1→	647:648	arg1	n					650:650	1→}n	647:650	1→}n	647:650	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	2	12	contain	contained	350:358	arg1	ratio					439:443	a ratio	437:443	a ratio of 0.9:1.0:3.2:1.2	437:462	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg1	it					347:348	it	347:348	it	347:348	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	acid					421:424	glucuronic acid	410:424	glucuronic acid (GlcAp)	410:432	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	Fucp					368:371	Fucp	368:371	Fucp	368:371	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	xylose					375:380	xylose	375:380	xylose (Xylp)	375:387	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	it					347:348	it	347:348	it	347:348	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	mannose					390:396	mannose	390:396	mannose (Manp)	390:403	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	fucose					360:365	fucose	360:365	fucose (Fucp)	360:372	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	GlcAp					427:431	GlcAp	427:431	GlcAp	427:431	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	12	contain	contained	350:358	arg2	Manp					399:402	Manp	399:402	Manp	399:402	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	1	13	theme	high	167:170	arg1	weight					182:187	a high molecular weight	165:187	a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1	165:248	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	1	13	theme	high	167:170	arg1	kDa					201:203	1.87 × 103 kDa	190:203	1.87 × 103 kDa	190:203	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	3	14	theme	1→3	585:587	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	14	theme	1→3	585:587	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	5	15	theme	activities	960:969	arg1	loss					935:938	the loss	931:938	the loss of immunomodulatory activities	931:969	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	2	16	theme	Monosaccharide	251:264	arg1	composition					266:276	Monosaccharide composition	251:276	Monosaccharide composition	251:276	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	1	17	theme	molecular	172:180	arg1	weight					182:187	a high molecular weight	165:187	a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1	165:248	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	1	17	theme	molecular	172:180	arg1	kDa					201:203	1.87 × 103 kDa	190:203	1.87 × 103 kDa	190:203	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	0	18	theme	Immunological	3:15	arg1	Polysaccharide					17:30	An Immunological Polysaccharide	0:30	An Immunological Polysaccharide from Tremella	0:44	An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation.
36142298	0	19	from	Tremella	37:44	arg1	Polysaccharide					17:30	An Immunological Polysaccharide	0:30	An Immunological Polysaccharide from Tremella	0:44	An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation.
36142298	2	20	theme	polysaccharide	302:315	arg1	derivatives					325:335	its derivatives	321:335	its derivatives	321:335	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	20	theme	polysaccharide	302:315	arg1	composition					266:276	Monosaccharide composition	251:276	Monosaccharide composition	251:276	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	20	theme	polysaccharide	302:315	arg1	analysis					286:293	NMR analysis	282:293	NMR analysis	282:293	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	1	21	contain	have	160:163	arg1	fuciformis					136:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	1	21	contain	have	160:163	arg2	kDa					201:203	1.87 × 103 kDa	190:203	1.87 × 103 kDa	190:203	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	1	21	contain	have	160:163	arg2	weight					182:187	a high molecular weight	165:187	a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1	165:248	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	4	22	theme	IL-6	801:804	arg1	secretion					778:786	the secretion	774:786	the secretion of TNF-α and IL-6 in J774A.1 macrophage cells	774:832	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	23	theme	-[α-L-Fucp-	604:614	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	23	theme	-[α-L-Fucp-	604:614	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	24	theme	GC-MS	484:488	arg1	data					504:507	IR, NMR, and GC-MS spectroscopic data	471:507	IR, NMR, and GC-MS spectroscopic data	471:507	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	5	25	theme	cytokines	1078:1086	arg1	production					1047:1056	the production	1043:1056	the production of pro-inflammatory cytokines	1043:1086	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	4	26	theme	macrophage	817:826	arg1	cells					828:832	J774A.1 macrophage cells	809:832	J774A.1 macrophage cells	809:832	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	27	theme	NMR	475:477	arg1	data					504:507	IR, NMR, and GC-MS spectroscopic data	471:507	IR, NMR, and GC-MS spectroscopic data	471:507	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	4	28	theme	J774A.1	809:815	arg1	cells					828:832	J774A.1 macrophage cells	809:832	J774A.1 macrophage cells	809:832	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	29	theme	1→3	600:602	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	29	theme	1→3	600:602	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	30	theme	{	552:552	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	30	theme	{	552:552	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	1	31	theme	edible	113:118	arg1	fuciformis					136:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	1	32	theme	×	195:195	arg1	weight					182:187	a high molecular weight	165:187	a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1	165:248	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	1	32	theme	×	195:195	arg1	kDa					201:203	1.87 × 103 kDa	190:203	1.87 × 103 kDa	190:203	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	5	33	theme	immunomodulatory	943:958	arg1	activities					960:969	immunomodulatory activities	943:969	immunomodulatory activities	943:969	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	3	34	theme	→3	553:554	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	34	theme	→3	553:554	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	1	35	dep	weight	182:187	arg1	polysaccharide					216:229	bioactive polysaccharide	206:229	bioactive polysaccharide	206:229	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	5	36	theme	pro-inflammatory	1061:1076	arg1	cytokines					1078:1086	pro-inflammatory cytokines	1061:1086	pro-inflammatory cytokines	1061:1086	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	2	37	theme	glucuronic	410:419	arg1	GlcAp					427:431	GlcAp	427:431	GlcAp	427:431	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	2	37	theme	glucuronic	410:419	arg1	acid					421:424	glucuronic acid	410:424	glucuronic acid (GlcAp)	410:432	Monosaccharide composition and NMR analysis of the polysaccharide and its derivatives indicated it contained fucose (Fucp), xylose (Xylp), mannose (Manp), and glucuronic acid (GlcAp) in a ratio of 0.9:1.0:3.2:1.2.
36142298	3	38	theme	-β-D-Xylp-	620:629	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	38	theme	-β-D-Xylp-	620:629	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	4	39	located	found	755:759	arg1	concentration					718:730	a concentration	716:730	a concentration of 1 μg/mL	716:741	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	4	39	located	found	755:759	arg2	TFP-F1					744:749	TFP-F1	744:749	TFP-F1	744:749	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	0	40	theme	Essential	58:66	arg1	Role					68:71	Essential Role	58:71	Essential Role of Acetylation in Immunomodulation	58:106	An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation.
36142298	5	41	theme	O-acetyl	908:915	arg1	groups					917:922	O-acetyl groups	908:922	O-acetyl groups	908:922	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	0	42	from	Role	68:71	arg1	Immunomodulation					91:106	Immunomodulation	91:106	Immunomodulation	91:106	An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation.
36142298	3	43	theme	spectroscopic	490:502	arg1	data					504:507	IR, NMR, and GC-MS spectroscopic data	471:507	IR, NMR, and GC-MS spectroscopic data	471:507	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	1	44	theme	fungus	120:125	arg1	fuciformis					136:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	4	45	theme	TNF-α	791:795	arg1	secretion					778:786	the secretion	774:786	the secretion of TNF-α and IL-6 in J774A.1 macrophage cells	774:832	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	46	theme	1→2	616:618	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	46	theme	1→2	616:618	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	1	47	theme	Tremella	127:134	arg1	fuciformis					136:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis	109:145	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	3	48	theme	partial	658:664	arg1	acetylation					666:676	partial acetylation	658:676	partial acetylation of C6-OH in mannoses	658:697	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	4	49	from	secretion	778:786	arg1	cells					828:832	J774A.1 macrophage cells	809:832	J774A.1 macrophage cells	809:832	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	50	theme	1→2	569:571	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	50	theme	1→2	569:571	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	51	theme	TFP-F1	527:532	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	51	theme	TFP-F1	527:532	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	52	from	acetylation	666:676	arg1	mannoses					690:697	mannoses	690:697	mannoses	690:697	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	53	from	mannoses	690:697	arg1	acetylation					666:676	partial acetylation	658:676	partial acetylation of C6-OH in mannoses	658:697	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	54	theme	IR	471:472	arg1	data					504:507	IR, NMR, and GC-MS spectroscopic data	471:507	IR, NMR, and GC-MS spectroscopic data	471:507	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	1	55	theme	bioactive	206:214	arg1	polysaccharide					216:229	bioactive polysaccharide	206:229	bioactive polysaccharide	206:229	The edible fungus Tremella fuciformis was shown to have a high molecular weight (1.87 × 103 kDa) bioactive polysaccharide, denoted as TFP-F1.
36142298	3	56	theme	-[β-D-GlcAp-	556:567	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	56	theme	-[β-D-GlcAp-	556:567	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	4	57	theme	toll-like	864:872	arg1	TLR4					886:889	TLR4	886:889	TLR4	886:889	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	4	57	theme	toll-like	864:872	arg1	receptor					874:881	toll-like receptor 4	864:883	toll-like receptor 4 (TLR4)	864:890	Furthermore, at a concentration of 1 μg/mL, TFP-F1 was found to stimulate the secretion of TNF-α and IL-6 in J774A.1 macrophage cells in vitro via interaction with toll-like receptor 4 (TLR4).
36142298	3	58	theme	-α-D-Manp-	574:583	arg1	-α-D-Manp-					636:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	{→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-	552:645	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	3	58	theme	-α-D-Manp-	574:583	arg1	structure					514:522	the structure	510:522	the structure of TFP-F1	510:532	Using IR, NMR, and GC-MS spectroscopic data, the structure of TFP-F1 was elucidated as {→3)-[β-D-GlcAp-(1→2)]-α-D-Manp-(1→3)-α-D-Manp-(1→3)-[α-L-Fucp-(1→2)-β-D-Xylp-(1→2)]-α-D-Manp-(1→}n, with partial acetylation of C6-OH in mannoses.
36142298	5	59	theme	O-acetyl	991:998	arg1	groups					1000:1005	O-acetyl groups	991:1005	O-acetyl groups	991:1005	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	5	60	theme	essential	1015:1023	arg1	role					1025:1028	an essential role	1012:1028	an essential role	1012:1028	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
36142298	5	61	theme	groups	917:922	arg1	removal					897:903	The removal	893:903	The removal of O-acetyl groups	893:922	The removal of O-acetyl groups led to the loss of immunomodulatory activities, demonstrating that O-acetyl groups play an essential role in enhancing the production of pro-inflammatory cytokines.
35930130	0	0	theme	profunda	81:88	arg1	SM-A87					90:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	6	1	theme	disaccharide	1465:1476	arg1	backbone					1478:1485	a hybrid disaccharide backbone	1456:1485	a hybrid disaccharide backbone	1456:1485	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	1	2	theme	Flavobacteriaceae	246:262	arg1	genus					237:241	a new genus	231:241	a new genus of Flavobacteriaceae	231:262	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	0	3	theme	Zunongwangia	68:79	arg1	SM-A87					90:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	0	4	from	determination	11:23	arg1	SM-A87					90:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	1	5	theme	deep-sea	156:163	arg1	profunda					135:142	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	1	5	theme	deep-sea	156:163	arg1	bacterium					177:185	a deep-sea sedimentary bacterium	154:185	a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae	154:262	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	6	6	theme	chains	1400:1405	arg1	content					1338:1344	a high content	1331:1344	a high content of branched, odd-numbered, and unsaturated fatty acid chains	1331:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	5	7	dep	levels	1105:1110	arg1	both					1129:1132	both	1129:1132	both	1129:1132	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	4	8	theme	lipid	751:755	arg1	A					757:757	the lipid A	747:757	the lipid A	747:757	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	6	9	theme	acid	1395:1398	arg1	chains					1400:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	4	10	theme	CPS	909:911	arg1	fraction					913:920	the CPS fraction	905:920	the CPS fraction	905:920	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	5	11	theme	lipid	1046:1050	arg1	blend					1078:1082	a blend	1076:1082	a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1076:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	5	11	theme	lipid	1046:1050	arg1	A					1052:1052	lipid A	1046:1052	Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1027:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	5	12	with	blend	1078:1082	arg1	levels					1105:1110	high levels	1100:1110	high levels of heterogeneity	1100:1127	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	6	13	theme	hybrid	1458:1463	arg1	backbone					1478:1485	a hybrid disaccharide backbone	1456:1485	a hybrid disaccharide backbone	1456:1485	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	5	14	theme	acylation	1141:1149	arg1	pattern					1171:1177	the acylation and phosphorylation pattern	1137:1177	pattern	1171:1177	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	0	15	theme	small-scale	100:110	arg1	approach					112:119	a small-scale approach	98:119	a small-scale approach	98:119	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	4	16	theme	glycolipid	713:722	arg1	part					724:727	the glycolipid part	709:727	the glycolipid part of this LPS	709:739	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	17	theme	full	822:825	arg1	LPS					827:829	the full LPS	818:829	the full LPS	818:829	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	18	theme	LPS	737:739	arg1	part					724:727	the glycolipid part	709:727	the glycolipid part of this LPS	709:739	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	6	19	theme	unsaturated	1377:1387	arg1	chains					1400:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	1	20	theme	sedimentary	165:175	arg1	profunda					135:142	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	1	20	theme	sedimentary	165:175	arg1	bacterium					177:185	a deep-sea sedimentary bacterium	154:185	a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae	154:262	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	6	21	theme	odd-numbered	1359:1370	arg1	chains					1400:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	2	22	theme	high	460:463	arg1	salinities					465:474	high salinities	460:474	high salinities	460:474	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	4	23	theme	bacterial	926:934	arg1	cells					936:940	bacterial cells	926:940	bacterial cells	926:940	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	5	24	theme	profunda	1030:1037	arg1	isolation					1014:1022	the isolation	1010:1022	the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1010:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	2	25	theme	high	327:330	arg1	quantities					332:341	high quantities	327:341	high quantities of capsular polysaccharides (CPS)	327:375	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	6	26	theme	tetra-	1252:1257	arg1	species					1286:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	2	27	theme	rheological	394:404	arg1	properties					406:415	interesting rheological properties	382:415	interesting rheological properties	382:415	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	2	27	theme	rheological	394:404	arg1	tolerance					447:455	tolerance	447:455	tolerance to high salinities and temperatures	447:491	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	2	27	theme	rheological	394:404	arg1	viscosity					433:441	high viscosity	428:441	high viscosity	428:441	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	0	28	theme	Structural	0:9	arg1	determination					11:23	Structural determination	0:23	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87	0:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	5	29	theme	high	1100:1103	arg1	levels					1105:1110	high levels	1100:1110	high levels of heterogeneity	1100:1127	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	4	30	theme	LPS	827:829	arg1	procedure					805:813	the extraction procedure	790:813	the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells	790:940	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	2	31	theme	interesting	382:392	arg1	properties					406:415	interesting rheological properties	382:415	interesting rheological properties	382:415	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	2	31	theme	interesting	382:392	arg1	tolerance					447:455	tolerance	447:455	tolerance to high salinities and temperatures	447:491	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	2	31	theme	interesting	382:392	arg1	viscosity					433:441	high viscosity	428:441	high viscosity	428:441	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	5	32	theme	dual	957:960	arg1	approach					962:969	a dual approach	955:969	a dual approach	955:969	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	1	33	theme	phylum	196:201	arg1	Bacteroidetes					203:215	the phylum Bacteroidetes	192:215	the phylum Bacteroidetes	192:215	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	6	34	theme	fatty	1389:1393	arg1	chains					1400:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	6	35	theme	A	1284:1284	arg1	species					1286:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	0	36	dep	approach	112:119	arg1	determination					11:23	Structural determination	0:23	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87	0:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	0	37	theme	A	38:38	arg1	determination					11:23	Structural determination	0:23	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87	0:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	5	38	theme	heterogeneity	1115:1127	arg1	levels					1105:1110	high levels	1100:1110	high levels of heterogeneity	1100:1127	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	6	39	theme	lipid	1278:1282	arg1	species					1286:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	4	40	theme	extraction	794:803	arg1	procedure					805:813	the extraction procedure	790:813	the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells	790:940	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	41	contain	contained	890:898	arg1	product					875:881	the ethanol precipitation product	849:881	the ethanol precipitation product	849:881	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	41	contain	contained	890:898	arg2	cells					936:940	bacterial cells	926:940	bacterial cells	926:940	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	41	contain	contained	890:898	arg2	fraction					913:920	the CPS fraction	905:920	the CPS fraction	905:920	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	2	42	theme	high	428:431	arg1	viscosity					433:441	high viscosity	428:441	high viscosity	428:441	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	0	43	theme	lipid	32:36	arg1	A					38:38	the lipid A	28:38	the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87	28:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	6	44	theme	high	1333:1336	arg1	content					1338:1344	a high content	1331:1344	a high content of branched, odd-numbered, and unsaturated fatty acid chains	1331:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	6	45	theme	penta-acylated	1263:1276	arg1	species					1286:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	3	46	theme	outer	637:641	arg1	membrane					643:650	its outer membrane	633:650	its outer membrane	633:650	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	6	47	theme	branched	1349:1356	arg1	chains					1400:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	branched, odd-numbered, and unsaturated fatty acid chains	1349:1405	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	4	48	theme	precipitation	861:873	arg1	product					875:881	the ethanol precipitation product	849:881	the ethanol precipitation product	849:881	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	3	49	theme	membrane	643:650	arg1	leaflet					622:628	the external leaflet	609:628	the external leaflet of its outer membrane	609:650	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	3	50	theme	main	590:593	arg1	lipopolysaccharides					557:575	lipopolysaccharides	557:575	lipopolysaccharides (LPS)	557:581	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	3	50	theme	main	590:593	arg1	components					595:604	the main components	586:604	the main components of the external leaflet of its outer membrane	586:650	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	4	51	from	procedure	805:813	arg1	product					875:881	the ethanol precipitation product	849:881	the ethanol precipitation product	849:881	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	2	52	theme	polysaccharides	355:369	arg1	quantities					332:341	high quantities	327:341	high quantities of capsular polysaccharides (CPS)	327:375	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	5	53	theme	species	1087:1093	arg1	blend					1078:1082	a blend	1076:1082	a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1076:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	5	53	theme	species	1087:1093	arg1	A					1052:1052	lipid A	1046:1052	Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1027:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	4	54	theme	ethanol	853:859	arg1	product					875:881	the ethanol precipitation product	849:881	the ethanol precipitation product	849:881	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	2	55	theme	capsular	346:353	arg1	CPS					372:374	CPS	372:374	CPS	372:374	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	2	55	theme	capsular	346:353	arg1	polysaccharides					355:369	capsular polysaccharides	346:369	capsular polysaccharides (CPS)	346:375	It was previously investigated for its capability of yielding high quantities of capsular polysaccharides (CPS) with interesting rheological properties, including high viscosity and tolerance to high salinities and temperatures.
35930130	5	56	theme	phosphorylation	1155:1169	arg1	pattern					1171:1177	the acylation and phosphorylation pattern	1137:1177	pattern	1171:1177	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	6	57	theme	Mono-phosphorylated	1232:1250	arg1	species					1286:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species	1232:1292	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	1	58	from	Bacteroidetes	203:215	arg1	profunda					135:142	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	1	58	from	Bacteroidetes	203:215	arg1	bacterium					177:185	a deep-sea sedimentary bacterium	154:185	a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae	154:262	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	1	59	theme	Zunongwangia	122:133	arg1	profunda					135:142	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87	122:149	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	1	59	theme	Zunongwangia	122:133	arg1	bacterium					177:185	a deep-sea sedimentary bacterium	154:185	a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae	154:262	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	5	60	theme	hydrophilic	1198:1208	arg1	composition					1219:1229	the hydrophilic backbone composition	1194:1229	the hydrophilic backbone composition	1194:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	5	61	dep	profunda	1030:1037	arg1	blend					1078:1082	a blend	1076:1082	a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1076:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	5	61	dep	profunda	1030:1037	arg1	A					1052:1052	lipid A	1046:1052	Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition	1027:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	4	62	dep	isolation	675:683	arg1	the					671:673	the	671:673	the	671:673	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	63	theme	part	724:727	arg1	characterization					689:704	characterization	689:704	characterization	689:704	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	4	63	theme	part	724:727	arg1	isolation					675:683	isolation	675:683	isolation	675:683	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35930130	5	64	theme	backbone	1210:1217	arg1	composition					1219:1229	the hydrophilic backbone composition	1194:1229	the hydrophilic backbone composition	1194:1229	To this aim a dual approach was adopted and all analyses confirmed the isolation of Z. profunda SM-A87 lipid A that turned out to be a blend of species with high levels of heterogeneity both in the acylation and phosphorylation pattern, as well as in the hydrophilic backbone composition.
35930130	1	65	theme	new	233:235	arg1	genus					237:241	a new genus	231:241	a new genus of Flavobacteriaceae	231:262	Zunongwangia profunda SM-A87 is a deep-sea sedimentary bacterium from the phylum Bacteroidetes, representing a new genus of Flavobacteriaceae.
35930130	0	66	theme	bacterium	58:66	arg1	SM-A87					90:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	0	67	from	SM-A87	90:95	arg1	A					38:38	the lipid A	28:38	the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87	28:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	0	67	from	SM-A87	90:95	arg1	determination					11:23	Structural determination	0:23	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87	0:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	3	68	theme	external	613:620	arg1	leaflet					622:628	the external leaflet	609:628	the external leaflet of its outer membrane	609:650	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	0	69	theme	deep-sea	49:56	arg1	SM-A87					90:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	the deep-sea bacterium Zunongwangia profunda SM-A87	45:95	Structural determination of the lipid A from the deep-sea bacterium Zunongwangia profunda SM-A87: a small-scale approach.
35930130	3	70	theme	leaflet	622:628	arg1	lipopolysaccharides					557:575	lipopolysaccharides	557:575	lipopolysaccharides (LPS)	557:581	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	3	70	theme	leaflet	622:628	arg1	components					595:604	the main components	586:604	the main components of the external leaflet of its outer membrane	586:650	However, as a Gram-negative, Z. profunda SM-A87 also expresses lipopolysaccharides (LPS) as the main components of the external leaflet of its outer membrane.
35930130	6	71	theme	backbone	1478:1485	arg1	presence					1444:1451	the presence	1440:1451	the presence of a hybrid disaccharide backbone	1440:1485	Mono-phosphorylated tetra- and penta-acylated lipid A species were identified and characterized by a high content of branched, odd-numbered, and unsaturated fatty acid chains as well as, for some species, by the presence of a hybrid disaccharide backbone.
35930130	4	72	dep	A	757:757	arg1	i.e.					742:745	i.e.	742:745	i.e.	742:745	Here, we describe the isolation and characterization of the glycolipid part of this LPS, i.e. the lipid A, which was achieved by-passing the extraction procedure of the full LPS and by working on the ethanol precipitation product, which contained both the CPS fraction and bacterial cells.
35869610	1	0	theme	water	235:239	arg1	transport					241:249	a plant's water transport	225:249	a plant's water transport	225:249	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	4	1	theme	remaining	895:903	arg1	%					908:908	the remaining 10 %	891:908	the remaining 10 % with progressively degraded structures	891:947	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	8	2	theme	diverse	1687:1693	arg1	variations					1706:1715	diverse structural variations	1687:1715	diverse structural variations in grapevine	1687:1728	CONCLUSIONS Intervessel PMs displayed diverse structural variations in grapevine.
35869610	3	3	theme	microscopy	532:541	arg1	technique					543:551	an immunogold-scanning electron microscopy technique	500:551	an immunogold-scanning electron microscopy technique	500:551	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	3	4	theme	immunogold-scanning	503:521	arg1	microscopy					532:541	an immunogold-scanning electron microscopy	500:541	an immunogold-scanning electron microscopy technique	500:551	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	1	5	theme	wall	172:175	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	5	theme	wall	172:175	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	4	6	theme	smooth	871:876	arg1	surfaces					878:885	smooth or relatively smooth surfaces	850:885	smooth or relatively smooth surfaces	850:885	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	6	7	theme	intervessel	1194:1204	arg1	PMs					1206:1208	intervessel PMs	1194:1208	intervessel PMs	1194:1208	Four groups of pectic and hemicellulosic polysaccharides were immunolocalized in intervessel PMs and differed in their spatial distribution and abundance.
35869610	2	8	theme	Functional	296:305	arg1	roles					307:311	Functional roles	296:311	Functional roles of intervessel PMs	296:330	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	9	9	theme	major	1754:1758	arg1	polysaccharides					1796:1810	pectic and hemicellulosic polysaccharides	1770:1810	pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1770:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	9	9	theme	major	1754:1758	arg1	groups					1760:1765	certain major groups	1746:1765	certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1746:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	10	10	theme	transport	2030:2038	arg1	regulation					2010:2019	the regulation	2006:2019	the regulation of water transport	2006:2038	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	7	11	dep	homogalacturonans	1401:1417	arg1	HMe-HGs					1420:1426	HMe-HGs	1420:1426	HMe-HGs	1420:1426	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	5	12	theme	natural	1092:1098	arg1	degradation					1100:1110	its natural degradation	1088:1110	its natural degradation	1088:1110	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	3	13	theme	intervessel	598:608	arg1	structures					613:622	intervessel PM structures	598:622	intervessel PM structures	598:622	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	3	14	theme	high	582:585	arg1	resolution					587:596	high resolution	582:596	high resolution	582:596	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	1	15	theme	pit	133:135	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	15	theme	pit	133:135	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	15	theme	pit	133:135	arg1	PMs					148:150	PMs	148:150	PMs	148:150	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	7	16	theme	PM	1645:1646	arg1	depths					1619:1624	different depths	1609:1624	different depths of the intervessel PM	1609:1646	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	9	17	theme	polysaccharides	1796:1810	arg1	polysaccharides					1796:1810	pectic and hemicellulosic polysaccharides	1770:1810	pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1770:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	9	17	theme	polysaccharides	1796:1810	arg1	groups					1760:1765	certain major groups	1746:1765	certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1746:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	4	18	theme	functional	737:746	arg1	xylem					748:752	functional xylem	737:752	functional xylem	737:752	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	4	19	theme	structural	773:782	arg1	variation					784:792	significant structural variation	761:792	significant structural variation	761:792	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	10	20	theme	vascular	2082:2089	arg1	diseases					2091:2098	vascular diseases	2082:2098	vascular diseases	2082:2098	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	3	21	theme	major	628:632	arg1	polysaccharides					660:674	major pectic and hemicellulosic polysaccharides	628:674	major pectic and hemicellulosic polysaccharides	628:674	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	1	22	from	structures	177:186	arg1	system					202:207	the vessel system	191:207	the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases	191:293	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	7	23	located	found	1492:1496	arg1	layers					1508:1513	deeper layers	1501:1513	deeper layers	1501:1513	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	7	23	located	found	1492:1496	arg2	homogalacturonans					1401:1417	heavily methyl-esterified homogalacturonans	1375:1417	heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7)	1375:1445	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	7	23	located	found	1492:1496	arg2	xylans					1451:1456	xylans	1451:1456	xylans	1451:1456	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	9	24	theme	different	1817:1825	arg1	distributions					1835:1847	different spatial distributions	1817:1847	different spatial distributions	1817:1847	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	6	25	theme	spatial	1232:1238	arg1	distribution					1240:1251	their spatial distribution	1226:1251	their spatial distribution	1226:1251	Four groups of pectic and hemicellulosic polysaccharides were immunolocalized in intervessel PMs and differed in their spatial distribution and abundance.
35869610	7	26	theme	methyl-esterified	1275:1291	arg1	homogalacturonans					1293:1309	Weakly methyl-esterified homogalacturonans	1268:1309	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5)	1268:1337	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	1	27	theme	important	157:165	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	27	theme	important	157:165	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	10	28	theme	wall	1951:1954	arg1	profiling					1921:1929	the polysaccharide profiling	1902:1929	the polysaccharide profiling of the primary cell wall	1902:1954	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	8	29	dep	CONCLUSIONS	1649:1659	arg1	displayed					1677:1685	displayed	1677:1685	displayed diverse structural variations in grapevine	1677:1728	CONCLUSIONS Intervessel PMs displayed diverse structural variations in grapevine.
35869610	8	30	from	variations	1706:1715	arg1	grapevine					1720:1728	grapevine	1720:1728	grapevine	1720:1728	CONCLUSIONS Intervessel PMs displayed diverse structural variations in grapevine.
35869610	9	31	with	polysaccharides	1796:1810	arg1	distributions					1835:1847	different spatial distributions	1817:1847	different spatial distributions	1817:1847	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	9	31	with	polysaccharides	1796:1810	arg1	abundance					1853:1861	abundance	1853:1861	abundance	1853:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	5	32	theme	process	1001:1007	arg1	details					978:984	details	978:984	details of the removal process of cell wall materials	978:1030	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	1	33	theme	vascular	277:284	arg1	diseases					286:293	vascular diseases	277:293	vascular diseases	277:293	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	2	34	theme	polysaccharide	370:383	arg1	composition					385:395	polysaccharide composition	370:395	polysaccharide composition	370:395	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	2	34	theme	polysaccharide	370:383	arg1	structure					356:364	their structure	350:364	their structure	350:364	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	2	34	theme	polysaccharide	370:383	arg1	targets					412:418	the targets	408:418	the targets of this study	408:432	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	0	35	theme	Structural	0:9	arg1	variation					11:19	Structural variation	0:19	Structural variation	0:19	Structural variation and spatial polysaccharide profiling of intervessel pit membranes in grapevine.
35869610	1	36	theme	BACKGROUND	101:110	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	36	theme	BACKGROUND	101:110	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	36	theme	BACKGROUND	101:110	arg1	PMs					148:150	PMs	148:150	PMs	148:150	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	7	37	theme	methyl-esterified	1383:1399	arg1	homogalacturonans					1401:1417	heavily methyl-esterified homogalacturonans	1375:1417	heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7)	1375:1445	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	3	38	used	used	458:461	arg2	METHODS					435:441	METHODS	435:441	METHODS With grapevine	435:456	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	1	39	theme	AIMS	116:119	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	39	theme	AIMS	116:119	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	39	theme	AIMS	116:119	arg1	PMs					148:150	PMs	148:150	PMs	148:150	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	4	40	with	%	908:908	arg1	structures					938:947	progressively degraded structures	915:947	progressively degraded structures	915:947	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	10	41	theme	cell	1946:1949	arg1	wall					1951:1954	the primary cell wall	1934:1954	the primary cell wall	1934:1954	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	0	42	theme	pit	73:75	arg1	membranes					77:85	intervessel pit membranes	61:85	intervessel pit membranes	61:85	Structural variation and spatial polysaccharide profiling of intervessel pit membranes in grapevine.
35869610	3	43	theme	model	468:472	arg1	plant					474:478	a model plant	466:478	a model plant	466:478	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	5	44	theme	PM	1053:1054	arg1	surface					1056:1062	the intervessel PM surface	1037:1062	the intervessel PM surface toward its depth during its natural degradation	1037:1110	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	6	45	theme	hemicellulosic	1139:1152	arg1	polysaccharides					1154:1168	pectic and hemicellulosic polysaccharides	1128:1168	pectic and hemicellulosic polysaccharides	1128:1168	Four groups of pectic and hemicellulosic polysaccharides were immunolocalized in intervessel PMs and differed in their spatial distribution and abundance.
35869610	3	46	theme	intervessel	689:699	arg1	PMs					701:703	intervessel PMs	689:703	intervessel PMs	689:703	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	2	47	theme	intervessel	316:326	arg1	PMs					328:330	intervessel PMs	316:330	intervessel PMs	316:330	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	8	48	theme	structural	1695:1704	arg1	variations					1706:1715	diverse structural variations	1687:1715	diverse structural variations in grapevine	1687:1728	CONCLUSIONS Intervessel PMs displayed diverse structural variations in grapevine.
35869610	5	49	theme	cell	1012:1015	arg1	materials					1022:1030	cell wall materials	1012:1030	cell wall materials	1012:1030	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	6	50	theme	pectic	1128:1133	arg1	polysaccharides					1154:1168	pectic and hemicellulosic polysaccharides	1128:1168	pectic and hemicellulosic polysaccharides	1128:1168	Four groups of pectic and hemicellulosic polysaccharides were immunolocalized in intervessel PMs and differed in their spatial distribution and abundance.
35869610	4	51	theme	them	814:817	arg1	them					814:817	them	814:817	them	814:817	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	4	51	theme	them	814:817	arg1	%					809:809	about 90 %	800:809	about 90 % of them	800:817	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	7	52	theme	fucosylated	1520:1530	arg1	xyloglucans					1532:1542	fucosylated xyloglucans	1520:1542	fucosylated xyloglucans (F-XyGs, detected by CCRC-M1)	1520:1572	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	5	53	theme	materials	1022:1030	arg1	process					1001:1007	the removal process	989:1007	the removal process of cell wall materials	989:1030	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	10	54	theme	intervessel	1987:1997	arg1	PMs					1999:2001	intervessel PMs	1987:2001	intervessel PMs	1987:2001	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	8	55	theme	Intervessel	1661:1671	arg1	PMs					1673:1675	Intervessel PMs	1661:1675	Intervessel PMs	1661:1675	CONCLUSIONS Intervessel PMs displayed diverse structural variations in grapevine.
35869610	3	56	theme	electron	523:530	arg1	microscopy					532:541	an immunogold-scanning electron microscopy	500:541	an immunogold-scanning electron microscopy technique	500:551	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	7	57	theme	deeper	1501:1506	arg1	layers					1508:1513	deeper layers	1501:1513	deeper layers	1501:1513	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	1	58	theme	cell	167:170	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	58	theme	cell	167:170	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	4	59	theme	smooth	850:855	arg1	surfaces					878:885	smooth or relatively smooth surfaces	850:885	smooth or relatively smooth surfaces	850:885	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	10	60	from	roles	1978:1982	arg1	regulation					2010:2019	the regulation	2006:2019	the regulation of water transport	2006:2038	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	10	60	from	roles	1978:1982	arg1	susceptibility					2064:2077	a plant's susceptibility	2054:2077	a plant's susceptibility to vascular diseases	2054:2098	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	9	61	theme	certain	1746:1752	arg1	polysaccharides					1796:1810	pectic and hemicellulosic polysaccharides	1770:1810	pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1770:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	9	61	theme	certain	1746:1752	arg1	groups					1760:1765	certain major groups	1746:1765	certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1746:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	3	62	with	METHODS	435:441	arg1	grapevine					448:456	grapevine	448:456	grapevine	448:456	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	4	63	theme	degraded	929:936	arg1	structures					938:947	progressively degraded structures	915:947	progressively degraded structures	915:947	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	10	64	theme	water	2024:2028	arg1	transport					2030:2038	water transport	2024:2038	water transport	2024:2038	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	9	65	theme	pectic	1770:1775	arg1	polysaccharides					1796:1810	pectic and hemicellulosic polysaccharides	1770:1810	pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1770:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	1	66	theme	Intervessel	121:131	arg1	membranes					137:145	BACKGROUND AND AIMS Intervessel pit membranes	101:145	BACKGROUND AND AIMS Intervessel pit membranes (PMs)	101:151	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	66	theme	Intervessel	121:131	arg1	structures					177:186	important cell wall structures	157:186	important cell wall structures	157:186	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	1	66	theme	Intervessel	121:131	arg1	PMs					148:150	PMs	148:150	PMs	148:150	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	7	67	theme	intervessel	1633:1643	arg1	PM					1645:1646	the intervessel PM	1629:1646	the intervessel PM	1629:1646	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	9	68	theme	hemicellulosic	1781:1794	arg1	polysaccharides					1796:1810	pectic and hemicellulosic polysaccharides	1770:1810	pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1770:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	4	69	theme	Intervessel	718:728	arg1	PMs					730:732	Intervessel PMs	718:732	Intervessel PMs in functional xylem	718:752	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	4	70	with	intact	838:843	arg1	%					908:908	the remaining 10 %	891:908	the remaining 10 % with progressively degraded structures	891:947	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	4	70	with	intact	838:843	arg1	surfaces					878:885	smooth or relatively smooth surfaces	850:885	smooth or relatively smooth surfaces	850:885	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	3	71	theme	PM	610:611	arg1	structures					613:622	intervessel PM structures	598:622	intervessel PM structures	598:622	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	4	72	with	surfaces	878:885	arg1	structures					938:947	progressively degraded structures	915:947	progressively degraded structures	915:947	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	7	73	theme	different	1609:1617	arg1	depths					1619:1624	different depths	1609:1624	different depths of the intervessel PM	1609:1646	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	9	74	theme	spatial	1827:1833	arg1	distributions					1835:1847	different spatial distributions	1817:1847	different spatial distributions	1817:1847	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	4	75	theme	KEY	706:708	arg1	RESULTS					710:716	KEY RESULTS	706:716	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.	706:948	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	4	76	dep	RESULTS	710:716	arg1	showed					754:759	showed	754:759	showed	754:759	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	10	77	theme	polysaccharide	1906:1919	arg1	profiling					1921:1929	the polysaccharide profiling	1902:1929	the polysaccharide profiling of the primary cell wall	1902:1954	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	1	78	theme	vessel	195:200	arg1	system					202:207	the vessel system	191:207	the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases	191:293	BACKGROUND AND AIMS Intervessel pit membranes (PMs) are important cell wall structures in the vessel system that may impact a plant's water transport and its susceptibility to vascular diseases.
35869610	5	79	theme	removal	993:999	arg1	process					1001:1007	the removal process	989:1007	the removal process of cell wall materials	989:1030	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	7	80	dep	homogalacturonans	1293:1309	arg1	WMe-HGs					1312:1318	WMe-HGs	1312:1318	WMe-HGs	1312:1318	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	7	81	theme	surface	1360:1366	arg1	layer					1368:1372	the surface layer	1356:1372	the surface layer	1356:1372	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	2	82	theme	study	428:432	arg1	composition					385:395	polysaccharide composition	370:395	polysaccharide composition	370:395	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	2	82	theme	study	428:432	arg1	structure					356:364	their structure	350:364	their structure	350:364	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	2	82	theme	study	428:432	arg1	targets					412:418	the targets	408:418	the targets of this study	408:432	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	0	83	theme	spatial	25:31	arg1	polysaccharide					33:46	spatial polysaccharide	25:46	spatial polysaccharide	25:46	Structural variation and spatial polysaccharide profiling of intervessel pit membranes in grapevine.
35869610	7	84	gly	fucosylated	1520:1530	arg1	xyloglucans					1532:1542	fucosylated xyloglucans	1520:1542	fucosylated xyloglucans (F-XyGs, detected by CCRC-M1)	1520:1572	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	3	85	theme	hemicellulosic	645:658	arg1	polysaccharides					660:674	major pectic and hemicellulosic polysaccharides	628:674	major pectic and hemicellulosic polysaccharides	628:674	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	4	86	theme	significant	761:771	arg1	variation					784:792	significant structural variation	761:792	significant structural variation	761:792	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	9	87	contain	contained	1736:1744	arg1	They					1731:1734	They	1731:1734	They	1731:1734	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	9	87	contain	contained	1736:1744	arg2	polysaccharides					1796:1810	pectic and hemicellulosic polysaccharides	1770:1810	pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1770:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	9	87	contain	contained	1736:1744	arg2	groups					1760:1765	certain major groups	1746:1765	certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance	1746:1861	They contained certain major groups of pectic and hemicellulosic polysaccharides with different spatial distributions and abundance.
35869610	7	88	dep	xyloglucans	1532:1542	arg1	F-XyGs					1545:1550	F-XyGs	1545:1550	F-XyGs	1545:1550	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	3	89	theme	pectic	634:639	arg1	polysaccharides					660:674	major pectic and hemicellulosic polysaccharides	628:674	major pectic and hemicellulosic polysaccharides	628:674	METHODS With grapevine used as a model plant, this study applied an immunogold-scanning electron microscopy technique to simultaneously analyse at high resolution intervessel PM structures and major pectic and hemicellulosic polysaccharides that make up intervessel PMs.
35869610	0	90	theme	intervessel	61:71	arg1	membranes					77:85	intervessel pit membranes	61:85	intervessel pit membranes	61:85	Structural variation and spatial polysaccharide profiling of intervessel pit membranes in grapevine.
35869610	5	91	theme	intervessel	1041:1051	arg1	surface					1056:1062	the intervessel PM surface	1037:1062	the intervessel PM surface toward its depth during its natural degradation	1037:1110	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	7	92	from	abundant	1344:1351	arg1	layer					1368:1372	the surface layer	1356:1372	the surface layer	1356:1372	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	6	93	theme	polysaccharides	1154:1168	arg1	groups					1118:1123	Four groups	1113:1123	Four groups of pectic and hemicellulosic polysaccharides	1113:1168	Four groups of pectic and hemicellulosic polysaccharides were immunolocalized in intervessel PMs and differed in their spatial distribution and abundance.
35869610	6	93	theme	polysaccharides	1154:1168	arg1	polysaccharides					1154:1168	pectic and hemicellulosic polysaccharides	1128:1168	pectic and hemicellulosic polysaccharides	1128:1168	Four groups of pectic and hemicellulosic polysaccharides were immunolocalized in intervessel PMs and differed in their spatial distribution and abundance.
35869610	2	94	theme	PMs	328:330	arg1	roles					307:311	Functional roles	296:311	Functional roles of intervessel PMs	296:330	Functional roles of intervessel PMs largely depend on their structure and polysaccharide composition, which are the targets of this study.
35869610	10	95	theme	primary	1938:1944	arg1	wall					1951:1954	the primary cell wall	1934:1954	the primary cell wall	1934:1954	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
35869610	4	96	from	PMs	730:732	arg1	xylem					748:752	functional xylem	737:752	functional xylem	737:752	KEY RESULTS Intervessel PMs in functional xylem showed significant structural variation, with about 90 % of them being structurally intact with smooth or relatively smooth surfaces and the remaining 10 % with progressively degraded structures.
35869610	5	97	theme	wall	1017:1020	arg1	materials					1022:1030	cell wall materials	1012:1030	cell wall materials	1012:1030	The results also elucidated details of the removal process of cell wall materials from the intervessel PM surface toward its depth during its natural degradation.
35869610	7	98	from	layer	1368:1372	arg1	abundant					1344:1351	abundant	1344:1351	abundant	1344:1351	Weakly methyl-esterified homogalacturonans (WMe-HGs, detected by JIM5) were abundant in the surface layer, heavily methyl-esterified homogalacturonans (HMe-HGs, detected by JIM7) and xylans detected by CCRC-M140 were mostly found in deeper layers, and fucosylated xyloglucans (F-XyGs, detected by CCRC-M1) were more uniformly distributed at different depths of the intervessel PM.
35869610	10	99	theme	PMs	1999:2001	arg1	roles					1978:1982	the roles	1974:1982	the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases	1974:2098	This information is crucial to reveal the polysaccharide profiling of the primary cell wall and to understand the roles of intervessel PMs in the regulation of water transport as well as in a plant's susceptibility to vascular diseases.
37336379	6	0	theme	SEC-MALLS	1032:1040	arg1	results					1070:1076	SEC-MALLS, monosaccharide composition results	1032:1076	SEC-MALLS, monosaccharide composition results	1032:1076	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	1	dep	SFILs	1237:1241	arg1	anions					1284:1289	anions	1284:1289	anions as nucleophile	1284:1304	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	1	dep	SFILs	1237:1241	arg1	cations					1259:1265	cations	1259:1265	cations as proton donor	1259:1281	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	1	dep	SFILs	1237:1241	arg1	group					1250:1254	-SO3H group	1244:1254	-SO3H group of cations as proton donor	1244:1281	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	2	theme	polysaccharide	1169:1182	arg1	fragments					1184:1192	polysaccharide fragments	1169:1192	low molecular mass polysaccharide fragments	1150:1192	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	1	3	theme	Se	267:268	arg1	polysaccharides					270:284	Se polysaccharides	267:284	Se polysaccharides	267:284	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	1	4	theme	controllable	162:173	arg1	strategy					188:195	controllable selenylation strategy	162:195	controllable selenylation strategy	162:195	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	1	5	theme	polysaccharides	270:284	arg1	relationship					251:262	the structure-activity relationship	228:262	the structure-activity relationship of Se polysaccharides	228:284	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	7	6	theme	chain	1456:1460	arg1	agglomeration					1424:1436	agglomeration	1424:1436	agglomeration	1424:1436	In addition, the strong attractions between the seleno-groups generated agglomeration of polysaccharide chain, which was proved by applying AFM analysis.
37336379	6	7	from	effect	1210:1215	arg1	SFILs					1237:1241	SFILs	1237:1241	SFILs (-SO3H group of cations as proton donor, anions as nucleophile)	1237:1305	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	7	8	theme	strong	1369:1374	arg1	attractions					1376:1386	the strong attractions	1365:1386	the strong attractions between the seleno-groups	1365:1412	In addition, the strong attractions between the seleno-groups generated agglomeration of polysaccharide chain, which was proved by applying AFM analysis.
37336379	2	9	theme	sphaerocephala	315:328	arg1	SePASs					347:352	SePASs	347:352	SePASs	347:352	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	9	theme	sphaerocephala	315:328	arg1	polysaccharides					330:344	selenized Artemisia sphaerocephala polysaccharides	295:344	selenized Artemisia sphaerocephala polysaccharides (SePASs)	295:353	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	4	10	theme	potential	796:804	arg1	effect					818:823	potential dissolution effect	796:823	potential dissolution effect	796:823	Further, reaction mechanism and potential dissolution effect was supported by DFT calculation and polarized light microscopy.
37336379	2	11	theme	polysaccharide	547:560	arg1	structure					562:570	Se polysaccharide structure	544:570	Se polysaccharide structure	544:570	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	8	12	theme	polysaccharides	1589:1603	arg1	MW					1580:1581	MW	1580:1581	MW of Se polysaccharides	1580:1603	Therefore, this work provided a new insight for manipulate Se content and MW of Se polysaccharides.
37336379	8	12	theme	polysaccharides	1589:1603	arg1	content					1568:1574	manipulate Se content	1554:1574	manipulate Se content	1554:1574	Therefore, this work provided a new insight for manipulate Se content and MW of Se polysaccharides.
37336379	1	13	dep	design	135:140	arg1	The					122:124	The	122:124	The	122:124	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	2	14	theme	Artemisia	305:313	arg1	SePASs					347:352	SePASs	347:352	SePASs	347:352	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	14	theme	Artemisia	305:313	arg1	polysaccharides					330:344	selenized Artemisia sphaerocephala polysaccharides	295:344	selenized Artemisia sphaerocephala polysaccharides (SePASs)	295:353	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	6	15	theme	strong	1092:1097	arg1	acidity					1099:1105	strong acidity	1092:1105	strong acidity of SFILs	1092:1114	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	2	16	theme	Se	544:545	arg1	structure					562:570	Se polysaccharide structure	544:570	Se polysaccharide structure	544:570	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	8	17	theme	Se	1586:1587	arg1	polysaccharides					1589:1603	Se polysaccharides	1586:1603	Se polysaccharides	1586:1603	Therefore, this work provided a new insight for manipulate Se content and MW of Se polysaccharides.
37336379	6	18	theme	molecular	1336:1344	arg1	mass					1346:1349	average molecular mass	1328:1349	average molecular mass	1328:1349	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	19	theme	molecular	1154:1162	arg1	mass					1164:1167	low molecular mass polysaccharide fragments	1150:1192	low molecular mass polysaccharide fragments	1150:1192	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	2	20	theme	selenized	295:303	arg1	SePASs					347:352	SePASs	347:352	SePASs	347:352	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	20	theme	selenized	295:303	arg1	polysaccharides					330:344	selenized Artemisia sphaerocephala polysaccharides	295:344	selenized Artemisia sphaerocephala polysaccharides (SePASs)	295:353	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	1	21	theme	selenylation	175:186	arg1	strategy					188:195	controllable selenylation strategy	162:195	controllable selenylation strategy	162:195	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	8	22	dep	content	1568:1574	arg1	manipulate					1554:1563	manipulate	1554:1563	manipulate	1554:1563	Therefore, this work provided a new insight for manipulate Se content and MW of Se polysaccharides.
37336379	3	23	dep	cation/anions	718:730	arg1	content					736:742	Se content	733:742	Se content up to 5582.7 μg/g	733:760	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	2	24	dep	functionalized	395:408	arg1	SFILs					425:429	SFILs	425:429	SFILs	425:429	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	24	dep	functionalized	395:408	arg1	liquids					416:422	ionic liquids	410:422	ionic liquids (SFILs)	410:430	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	1	25	theme	strategy	188:195	arg1	construction					146:157	construction	146:157	construction	146:157	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	1	25	theme	strategy	188:195	arg1	design					135:140	design	135:140	design	135:140	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	7	26	theme	AFM	1492:1494	arg1	analysis					1496:1503	AFM analysis	1492:1503	AFM analysis	1492:1503	In addition, the strong attractions between the seleno-groups generated agglomeration of polysaccharide chain, which was proved by applying AFM analysis.
37336379	5	27	theme	SePASs	928:933	arg1	analysis					916:923	13C NMR and FT-IR spectra analysis	890:923	13C NMR and FT-IR spectra analysis of SePASs	890:933	13C NMR and FT-IR spectra analysis of SePASs exhibited that selenite existed in polysaccharides and the substitution position occured at C-6.
37336379	6	28	theme	monosaccharide	1043:1056	arg1	SEC-MALLS					1032:1040	SEC-MALLS	1032:1040	SEC-MALLS	1032:1040	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	28	theme	monosaccharide	1043:1056	arg1	composition					1058:1068	monosaccharide composition	1043:1068	monosaccharide composition	1043:1068	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	0	29	dep	liquids	79:85	arg1	effect					98:103	Synergism effect	88:103	ionic liquids: Synergism effect of anion/cation	73:119	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
37336379	3	30	from	substitution	621:632	arg1	backbone					672:679	the polysaccharide backbone	653:679	the polysaccharide backbone	653:679	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	0	31	theme	polysaccharide	16:29	arg1	Synthesis					0:8	Synthesis	0:8	Synthesis of Se polysaccharide catalyzed by sulfonic acid	0:56	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
37336379	4	32	theme	dissolution	806:816	arg1	effect					818:823	potential dissolution effect	796:823	potential dissolution effect	796:823	Further, reaction mechanism and potential dissolution effect was supported by DFT calculation and polarized light microscopy.
37336379	3	33	theme	seleno-group	637:648	arg1	substitution					621:632	the efficient substitution	607:632	the efficient substitution of seleno-group on the polysaccharide backbone	607:679	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	5	34	theme	NMR	894:896	arg1	analysis					916:923	13C NMR and FT-IR spectra analysis	890:923	13C NMR and FT-IR spectra analysis of SePASs	890:933	13C NMR and FT-IR spectra analysis of SePASs exhibited that selenite existed in polysaccharides and the substitution position occured at C-6.
37336379	0	35	theme	Se	13:14	arg1	polysaccharide					16:29	Se polysaccharide	13:29	Se polysaccharide	13:29	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
37336379	2	36	dep	cation/anion	485:496	arg1	constitute					498:507	constitute	498:507	constitute on the selenylation efficiency and Se polysaccharide structure	498:570	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	37	theme	sulfonic	381:388	arg1	acid					390:393	sulfonic acid	381:393	sulfonic acid functionalized ionic liquids (SFILs)	381:430	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	37	theme	sulfonic	381:388	arg1	catalysts					435:443	catalysts	435:443	catalysts	435:443	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	6	38	from	SFILs	1237:1241	arg1	effect					1210:1215	synergistic effect	1198:1215	synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile)	1198:1305	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	5	39	theme	FT-IR	902:906	arg1	spectra					908:914	FT-IR spectra	902:914	FT-IR spectra	902:914	13C NMR and FT-IR spectra analysis of SePASs exhibited that selenite existed in polysaccharides and the substitution position occured at C-6.
37336379	0	40	theme	anion/cation	108:119	arg1	effect					98:103	Synergism effect	88:103	ionic liquids: Synergism effect of anion/cation	73:119	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
37336379	3	41	theme	efficient	611:619	arg1	substitution					621:632	the efficient substitution	607:632	the efficient substitution of seleno-group on the polysaccharide backbone	607:679	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	2	42	theme	cation/anion	485:496	arg1	regulation					467:476	the regulation	463:476	the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure	463:570	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	6	43	from	regulation	1314:1323	arg1	mass					1346:1349	average molecular mass	1328:1349	average molecular mass	1328:1349	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	8	44	theme	new	1538:1540	arg1	insight					1542:1548	a new insight	1536:1548	a new insight for manipulate Se content and MW of Se polysaccharides	1536:1603	Therefore, this work provided a new insight for manipulate Se content and MW of Se polysaccharides.
37336379	4	45	theme	light	872:876	arg1	microscopy					878:887	polarized light microscopy	862:887	polarized light microscopy	862:887	Further, reaction mechanism and potential dissolution effect was supported by DFT calculation and polarized light microscopy.
37336379	1	46	from	study	219:223	arg1	relationship					251:262	the structure-activity relationship	228:262	the structure-activity relationship of Se polysaccharides	228:284	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	5	47	theme	spectra	908:914	arg1	analysis					916:923	13C NMR and FT-IR spectra analysis	890:923	13C NMR and FT-IR spectra analysis of SePASs	890:933	13C NMR and FT-IR spectra analysis of SePASs exhibited that selenite existed in polysaccharides and the substitution position occured at C-6.
37336379	5	48	theme	13C	890:892	arg1	NMR					894:896	13C NMR	890:896	13C NMR	890:896	13C NMR and FT-IR spectra analysis of SePASs exhibited that selenite existed in polysaccharides and the substitution position occured at C-6.
37336379	3	49	theme	synergistic	693:703	arg1	catalysis					705:713	the synergistic catalysis	689:713	the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g)	689:761	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	6	50	theme	anion/cations	1220:1232	arg1	effect					1210:1215	synergistic effect	1198:1215	synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile)	1198:1305	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	0	51	theme	sulfonic	44:51	arg1	acid					53:56	sulfonic acid	44:56	sulfonic acid	44:56	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
37336379	6	52	theme	cations	1259:1265	arg1	anions					1284:1289	anions	1284:1289	anions as nucleophile	1284:1304	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	52	theme	cations	1259:1265	arg1	cations					1259:1265	cations	1259:1265	cations as proton donor	1259:1281	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	52	theme	cations	1259:1265	arg1	group					1250:1254	-SO3H group	1244:1254	-SO3H group of cations as proton donor	1244:1281	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	3	53	theme	Se	733:734	arg1	content					736:742	Se content	733:742	Se content up to 5582.7 μg/g	733:760	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	6	54	theme	average	1328:1334	arg1	mass					1346:1349	average molecular mass	1328:1349	average molecular mass	1328:1349	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	55	from	anion/cations	1220:1232	arg1	SFILs					1237:1241	SFILs	1237:1241	SFILs (-SO3H group of cations as proton donor, anions as nucleophile)	1237:1305	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	4	56	theme	reaction	773:780	arg1	mechanism					782:790	reaction mechanism	773:790	reaction mechanism	773:790	Further, reaction mechanism and potential dissolution effect was supported by DFT calculation and polarized light microscopy.
37336379	6	57	theme	proton	1270:1275	arg1	donor					1277:1281	proton donor	1270:1281	proton donor	1270:1281	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	7	58	theme	polysaccharide	1441:1454	arg1	chain					1456:1460	polysaccharide chain	1441:1460	polysaccharide chain	1441:1460	In addition, the strong attractions between the seleno-groups generated agglomeration of polysaccharide chain, which was proved by applying AFM analysis.
37336379	6	59	dep	mass	1164:1167	arg1	fragments					1184:1192	polysaccharide fragments	1169:1192	low molecular mass polysaccharide fragments	1150:1192	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	1	60	theme	rational	126:133	arg1	design					135:140	design	135:140	design	135:140	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	6	61	theme	synergistic	1198:1208	arg1	effect					1210:1215	synergistic effect	1198:1215	synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile)	1198:1305	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	6	62	theme	SFILs	1110:1114	arg1	acidity					1099:1105	strong acidity	1092:1105	strong acidity of SFILs	1092:1114	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	8	63	theme	Se	1565:1566	arg1	content					1568:1574	manipulate Se content	1554:1574	manipulate Se content	1554:1574	Therefore, this work provided a new insight for manipulate Se content and MW of Se polysaccharides.
37336379	4	64	theme	DFT	842:844	arg1	calculation					846:856	DFT calculation	842:856	DFT calculation	842:856	Further, reaction mechanism and potential dissolution effect was supported by DFT calculation and polarized light microscopy.
37336379	5	65	theme	substitution	994:1005	arg1	position					1007:1014	the substitution position	990:1014	the substitution position	990:1014	13C NMR and FT-IR spectra analysis of SePASs exhibited that selenite existed in polysaccharides and the substitution position occured at C-6.
37336379	1	66	theme	structure-activity	232:249	arg1	relationship					251:262	the structure-activity relationship	228:262	the structure-activity relationship of Se polysaccharides	228:284	The rational design and construction of controllable selenylation strategy are important for the study on the structure-activity relationship of Se polysaccharides.
37336379	0	67	theme	ionic	73:77	arg1	liquids					79:85	ionic liquids	73:85	ionic liquids: Synergism effect of anion/cation	73:119	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
37336379	4	68	theme	polarized	862:870	arg1	microscopy					878:887	polarized light microscopy	862:887	polarized light microscopy	862:887	Further, reaction mechanism and potential dissolution effect was supported by DFT calculation and polarized light microscopy.
37336379	6	69	theme	driving	1128:1134	arg1	forces					1136:1141	the driving forces	1124:1141	the driving forces toward low molecular mass polysaccharide fragments	1124:1192	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	2	70	theme	ionic	410:414	arg1	SFILs					425:429	SFILs	425:429	SFILs	425:429	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	70	theme	ionic	410:414	arg1	liquids					416:422	ionic liquids	410:422	ionic liquids (SFILs)	410:430	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	6	71	theme	low	1150:1152	arg1	mass					1164:1167	low molecular mass polysaccharide fragments	1150:1192	low molecular mass polysaccharide fragments	1150:1192	SEC-MALLS, monosaccharide composition results revealed that strong acidity of SFILs lead to the driving forces toward low molecular mass polysaccharide fragments and synergistic effect of anion/cations in SFILs (-SO3H group of cations as proton donor, anions as nucleophile) showed regulation on average molecular mass.
37336379	2	72	theme	selenylation	516:527	arg1	efficiency					529:538	the selenylation efficiency	512:538	the selenylation efficiency	512:538	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	3	73	theme	polysaccharide	657:670	arg1	backbone					672:679	the polysaccharide backbone	653:679	the polysaccharide backbone	653:679	Impressively, SFILs could promote the efficient substitution of seleno-group on the polysaccharide backbone through the synergistic catalysis by cation/anions (Se content up to 5582.7 μg/g).
37336379	2	74	theme	functionalized	395:408	arg1	acid					390:393	sulfonic acid	381:393	sulfonic acid functionalized ionic liquids (SFILs)	381:430	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	2	74	theme	functionalized	395:408	arg1	catalysts					435:443	catalysts	435:443	catalysts	435:443	Herein, selenized Artemisia sphaerocephala polysaccharides (SePASs) were synthesized by using sulfonic acid functionalized ionic liquids (SFILs) as catalysts in order to study the regulation of the cation/anion constitute on the selenylation efficiency and Se polysaccharide structure.
37336379	0	75	theme	Synergism	88:96	arg1	effect					98:103	Synergism effect	88:103	ionic liquids: Synergism effect of anion/cation	73:119	Synthesis of Se polysaccharide catalyzed by sulfonic acid functionalized ionic liquids: Synergism effect of anion/cation.
36083622	4	0	theme	inflammatory	1038:1049	arg1	injury					1051:1056	inflammatory injury	1038:1056	inflammatory injury in LPS-induced RAW 264.7 cells	1038:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	2	1	theme	4.72:2.5:1.68:1	549:563	arg1	ratio					540:544	a molar ratio	532:544	a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition	532:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	5	2	theme	theoretical	1120:1130	arg1	basis					1132:1136	a theoretical basis	1118:1136	a theoretical basis for practical application of the novel polysaccharide	1118:1190	These results would provide a theoretical basis for practical application of the novel polysaccharide as an anti-inflammatory adjuvant.
36083622	5	2	theme	theoretical	1120:1130	arg1	adjuvant					1216:1223	adjuvant	1216:1223	adjuvant	1216:1223	These results would provide a theoretical basis for practical application of the novel polysaccharide as an anti-inflammatory adjuvant.
36083622	2	3	from	arabinose	519:527	arg1	basis					572:576	the basis	568:576	the basis of monosaccharide composition	568:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	3	from	arabinose	519:527	arg1	ratio					540:544	a molar ratio	532:544	a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition	532:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	4	theme	26.05 kDa	442:450	arg1	weight					432:437	a molecular weight	420:437	a molecular weight of 26.05 kDa	420:450	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	0	5	from	characterization	11:26	arg1	production					112:121	the production	108:121	the production of NO, TNF-α and IL-6	108:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	0	5	from	characterization	11:26	arg1	tea					74:76	laoshan green tea	60:76	laoshan green tea	60:76	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	2	6	from	acid	489:492	arg1	basis					572:576	the basis	568:576	the basis of monosaccharide composition	568:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	6	from	acid	489:492	arg1	ratio					540:544	a molar ratio	532:544	a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition	532:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	3	7	theme	-Araf-	805:810	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	8	theme	-Rhap-	749:754	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	1	9	theme	Laoshan	223:229	arg1	GTPS					257:260	GTPS	257:260	GTPS	257:260	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	1	9	theme	Laoshan	223:229	arg1	polysaccharide					241:254	Laoshan green tea polysaccharide	223:254	Laoshan green tea polysaccharide (GTPS)	223:261	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	0	10	theme	effects	97:103	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.	0:144	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	1	11	theme	S-300	310:314	arg1	columns					316:322	Sephacryl S-300 columns	300:322	Sephacryl S-300 columns	300:322	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	3	12	theme	-Rhap-	821:826	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	4	13	theme	NO	953:954	arg1	production					939:948	the production	935:948	the production of NO, TNF-α and IL-6	935:970	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	1	14	theme	green	231:235	arg1	GTPS					257:260	GTPS	257:260	GTPS	257:260	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	1	14	theme	green	231:235	arg1	polysaccharide					241:254	Laoshan green tea polysaccharide	223:254	Laoshan green tea polysaccharide (GTPS)	223:261	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	0	15	theme	inhibitory	86:95	arg1	effects					97:103	its inhibitory effects	82:103	its inhibitory effects on the production of NO, TNF-α and IL-6	82:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	2	16	theme	molar	534:538	arg1	ratio					540:544	a molar ratio	532:544	a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition	532:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	17	theme	composition	596:606	arg1	basis					572:576	the basis	568:576	the basis of monosaccharide composition	568:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	3	18	theme	1→	767:768	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	1	19	theme	tea	237:239	arg1	GTPS					257:260	GTPS	257:260	GTPS	257:260	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	1	19	theme	tea	237:239	arg1	polysaccharide					241:254	Laoshan green tea polysaccharide	223:254	Laoshan green tea polysaccharide (GTPS)	223:261	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	3	20	theme	analysis	620:627	arg1	results					629:635	Structural analysis results	609:635	Structural analysis results	609:635	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	21	theme	1→	828:829	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	2	22	theme	monosaccharide	581:594	arg1	composition					596:606	monosaccharide composition	581:606	monosaccharide composition	581:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	0	23	from	polysaccharide	40:53	arg1	production					112:121	the production	108:121	the production of NO, TNF-α and IL-6	108:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	3	24	theme	-Araf-	735:740	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	0	25	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.	0:144	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	3	26	dep	Rhap-	832:836	arg1	GalpA-					760:765	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	GalpA-	760:765	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	→2					716:717	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	→2	716:717	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	→3,5					730:733	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	→3,5	730:733	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	→2,4					816:819	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	→2,4	816:819	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	→4					787:788	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	→4	787:788	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	→5					802:803	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	→5	802:803	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	1→					838:839	1→	838:839	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→	702:839	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	26	dep	Rhap-	832:836	arg1	→3,4					771:774	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	→3,4	771:774	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	1	27	theme	novel	148:152	arg1	polysaccharide					161:174	A novel pectic polysaccharide	146:174	A novel pectic polysaccharide	146:174	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	3	28	theme	NMR	890:892	arg1	analyses					894:901	NMR analyses	890:901	NMR analyses	890:901	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	29	theme	-Galp-	705:710	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	1	30	theme	pectic	154:159	arg1	polysaccharide					161:174	A novel pectic polysaccharide	146:174	A novel pectic polysaccharide	146:174	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	1	31	theme	Sephacryl	300:308	arg1	columns					316:322	Sephacryl S-300 columns	300:322	Sephacryl S-300 columns	300:322	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	2	32	from	ratio	540:544	arg1	basis					572:576	the basis	568:576	the basis of monosaccharide composition	568:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	3	33	theme	1→	812:813	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	5	34	theme	novel	1171:1175	arg1	polysaccharide					1177:1190	the novel polysaccharide	1167:1190	the novel polysaccharide	1167:1190	These results would provide a theoretical basis for practical application of the novel polysaccharide as an anti-inflammatory adjuvant.
36083622	3	35	theme	-Galp-	776:781	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	5	36	theme	polysaccharide	1177:1190	arg1	application					1152:1162	practical application	1142:1162	practical application of the novel polysaccharide	1142:1190	These results would provide a theoretical basis for practical application of the novel polysaccharide as an anti-inflammatory adjuvant.
36083622	4	37	theme	TNF-α	957:961	arg1	production					939:948	the production	935:948	the production of NO, TNF-α and IL-6	935:970	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	5	38	theme	practical	1142:1150	arg1	application					1152:1162	practical application	1142:1162	practical application of the novel polysaccharide	1142:1190	These results would provide a theoretical basis for practical application of the novel polysaccharide as an anti-inflammatory adjuvant.
36083622	4	39	from	cells	1083:1087	arg1	amelioration					1022:1033	the amelioration	1018:1033	the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells	1018:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	4	40	theme	dose-dependent	977:990	arg1	manner					992:997	a dose-dependent manner	975:997	a dose-dependent manner	975:997	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	2	41	theme	molecular	422:430	arg1	weight					432:437	a molecular weight	420:437	a molecular weight of 26.05 kDa	420:450	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	0	42	theme	polysaccharide	40:53	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.	0:144	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	3	43	theme	Structural	609:618	arg1	results					629:635	Structural analysis results	609:635	Structural analysis results	609:635	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	0	44	theme	pectic	33:38	arg1	polysaccharide					40:53	a pectic polysaccharide	31:53	a pectic polysaccharide from laoshan green tea	31:76	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	0	45	theme	NO	126:127	arg1	production					112:121	the production	108:121	the production of NO, TNF-α and IL-6	108:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	0	46	from	tea	74:76	arg1	polysaccharide					40:53	a pectic polysaccharide	31:53	a pectic polysaccharide from laoshan green tea	31:76	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	0	46	from	tea	74:76	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.	0:144	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	0	46	from	tea	74:76	arg1	effects					97:103	its inhibitory effects	82:103	its inhibitory effects on the production of NO, TNF-α and IL-6	82:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	3	47	theme	-Rhap-	719:724	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	2	48	with	GTPS3-1	406:412	arg1	weight					432:437	a molecular weight	420:437	a molecular weight of 26.05 kDa	420:450	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	49	from	basis	572:576	arg1	arabinose					519:527	arabinose	519:527	arabinose	519:527	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	49	from	basis	572:576	arg1	rhamnose					506:513	rhamnose	506:513	rhamnose	506:513	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	49	from	basis	572:576	arg1	galactose					495:503	galactose	495:503	galactose	495:503	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	49	from	basis	572:576	arg1	acid					489:492	galacturonic acid	476:492	galacturonic acid	476:492	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	0	50	theme	laoshan	60:66	arg1	tea					74:76	laoshan green tea	60:76	laoshan green tea	60:76	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	3	51	dep	pectin	681:686	arg1	1→					851:852	1→	851:852	1→	851:852	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	4	52	theme	RAW	1073:1075	arg1	cells					1083:1087	LPS-induced RAW 264.7 cells	1061:1087	LPS-induced RAW 264.7 cells	1061:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	2	53	theme	galacturonic	476:487	arg1	acid					489:492	galacturonic acid	476:492	galacturonic acid	476:492	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	3	54	theme	branched	672:679	arg1	pectin					681:686	a highly branched pectin	663:686	a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-	663:849	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	54	theme	branched	672:679	arg1	GTPS3-1					651:657	GTPS3-1	651:657	GTPS3-1	651:657	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	55	theme	1→	712:713	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	0	56	theme	TNF-α	130:134	arg1	production					112:121	the production	108:121	the production of NO, TNF-α and IL-6	108:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	1	57	theme	anti-inflammatory	365:381	arg1	activity					383:390	its anti-inflammatory activity	361:390	its anti-inflammatory activity	361:390	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	4	58	from	amelioration	1022:1033	arg1	cells					1083:1087	LPS-induced RAW 264.7 cells	1061:1087	LPS-induced RAW 264.7 cells	1061:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	3	59	theme	1→	783:784	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	4	60	from	injury	1051:1056	arg1	cells					1083:1087	LPS-induced RAW 264.7 cells	1061:1087	LPS-induced RAW 264.7 cells	1061:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	1	61	theme	Fast	286:289	arg1	Flow					291:294	DEAE Sepharose Fast Flow	271:294	DEAE Sepharose Fast Flow	271:294	A novel pectic polysaccharide, named GTPS3-1, was isolated and purified from Laoshan green tea polysaccharide (GTPS) through DEAE Sepharose Fast Flow and Sephacryl S-300 columns, its structure was characterized and its anti-inflammatory activity was explored.
36083622	4	62	theme	IL-6	967:970	arg1	production					939:948	the production	935:948	the production of NO, TNF-α and IL-6	935:970	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	2	63	from	galactose	495:503	arg1	basis					572:576	the basis	568:576	the basis of monosaccharide composition	568:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	63	from	galactose	495:503	arg1	ratio					540:544	a molar ratio	532:544	a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition	532:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	0	64	theme	IL-6	140:143	arg1	production					112:121	the production	108:121	the production of NO, TNF-α and IL-6	108:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	0	65	from	effects	97:103	arg1	production					112:121	the production	108:121	the production of NO, TNF-α and IL-6	108:143	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	4	66	theme	LPS-induced	1061:1071	arg1	cells					1083:1087	LPS-induced RAW 264.7 cells	1061:1087	LPS-induced RAW 264.7 cells	1061:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	3	67	theme	1→	798:799	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	4	68	dep	inhibited	925:933	arg1	resulted					1006:1013	resulted	1006:1013	resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells	1006:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	2	69	from	rhamnose	506:513	arg1	basis					572:576	the basis	568:576	the basis of monosaccharide composition	568:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	2	69	from	rhamnose	506:513	arg1	ratio					540:544	a molar ratio	532:544	a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition	532:606	GTPS3-1, with a molecular weight of 26.05 kDa, was mainly composed of galacturonic acid, galactose, rhamnose and arabinose in a molar ratio of 4.72:2.5:1.68:1 on the basis of monosaccharide composition.
36083622	0	70	theme	green	68:72	arg1	tea					74:76	laoshan green tea	60:76	laoshan green tea	60:76	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
36083622	4	71	theme	injury	1051:1056	arg1	amelioration					1022:1033	the amelioration	1018:1033	the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells	1018:1087	In addition, GTPS3-1 inhibited the production of NO, TNF-α and IL-6 in a dose-dependent manner, which resulted in the amelioration of inflammatory injury in LPS-induced RAW 264.7 cells.
36083622	3	72	theme	-GalpA-	790:796	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	73	theme	1→	726:727	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	3	74	theme	1→	756:757	arg1	Rhap-					832:836	→3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-	702:836	Rhap-	832:836	Structural analysis results revealed that GTPS3-1 was a highly branched pectin consisting of →3)-Galp-(1→, →2)-Rhap-(1→, →3,5)-Araf-(1→, →3)-Rhap-(1→, GalpA-(1→, →3,4)-Galp-(1→, →4)-GalpA-(1→, →5)-Araf-(1→, →2,4)-Rhap-(1→, Rhap-(1→ and Araf-(1→ according to FT-IR, methylation and NMR analyses.
36083622	0	75	from	production	112:121	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.	0:144	Structural characterization of a pectic polysaccharide from laoshan green tea and its inhibitory effects on the production of NO, TNF-α and IL-6.
37270132	2	0	theme	metabolism	515:524	arg1	effects					455:461	potential effects	445:461	potential effects against T2DM-induced imbalance of glucose and lipid metabolism	445:524	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	3	1	theme	beneficial	866:875	arg1	metabolites					877:887	the beneficial metabolites	862:887	the beneficial metabolites in liver	862:896	Besides, HEP-1 promoted the production of beneficial bacteria in the gut, and increased the beneficial metabolites in liver through the gut-liver axis, consequently, resisting the occurrence of T2DM.
37270132	3	2	theme	beneficial	816:825	arg1	bacteria					827:834	beneficial bacteria	816:834	beneficial bacteria	816:834	Besides, HEP-1 promoted the production of beneficial bacteria in the gut, and increased the beneficial metabolites in liver through the gut-liver axis, consequently, resisting the occurrence of T2DM.
37270132	0	3	theme	anti-T2DM	87:95	arg1	polysaccharides					50:64	Hericium erinaceus polysaccharides	31:64	Hericium erinaceus polysaccharides	31:64	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	0	3	theme	anti-T2DM	87:95	arg1	mechanism					74:82	the mechanism	70:82	the mechanism of anti-T2DM	70:95	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	2	4	theme	signaling	626:634	arg1	pathway					636:642	the IRS/PI3K/AKT signaling pathway	609:642	the IRS/PI3K/AKT signaling pathway	609:642	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	5	theme	-β-D-Glcp-	258:267	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	5	theme	-β-D-Glcp-	258:267	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	6	theme	glucose	549:555	arg1	uptake					557:562	the serum glucose uptake	539:562	the serum glucose uptake by hepatic glycogen synthesis	539:592	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	2	7	theme	IRS/PI3K/AKT	613:624	arg1	pathway					636:642	the IRS/PI3K/AKT signaling pathway	609:642	the IRS/PI3K/AKT signaling pathway	609:642	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	2	8	theme	T2DM-induced	471:482	arg1	imbalance					484:492	T2DM-induced imbalance	471:492	T2DM-induced imbalance	471:492	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	2	9	theme	serum	543:547	arg1	uptake					557:562	the serum glucose uptake	539:562	the serum glucose uptake by hepatic glycogen synthesis	539:592	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	10	theme	Hericium	385:392	arg1	erinaceus					394:402	Hericium erinaceus	385:402	Hericium erinaceus	385:402	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	11	theme	AMPK/SREBP-1c	740:752	arg1	pathways					764:771	the AMPK/SREBP-1c signaling pathways	736:771	the AMPK/SREBP-1c signaling pathways	736:771	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	12	theme	1→	269:270	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	12	theme	1→	269:270	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	13	theme	-β-D-Glcp-	313:322	arg1	1→					324:325	-β-D-Glcp-(1→	313:325	-β-D-Glcp-(1→	313:325	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	14	theme	erinaceus	394:402	arg1	body					377:380	the fruiting body	364:380	the fruiting body of Hericium erinaceus	364:402	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	0	15	theme	gut	115:117	arg1	microbiota					119:128	the gut microbiota	111:128	the gut microbiota	111:128	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	1	16	theme	HEP-1	189:193	arg1	weight					163:168	A low molecular weight polysaccharides	147:184	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→,	147:326	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	17	dep	1→	287:288	arg1	→3					273:274	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	→3	273:274	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	18	theme	glycogen	575:582	arg1	synthesis					584:592	hepatic glycogen synthesis	567:592	hepatic glycogen synthesis	567:592	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	19	dep	weight	163:168	arg1	polysaccharides					170:184	polysaccharides	170:184	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→,	147:326	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	20	dep	β-D-Glcp-	291:299	arg1	→3,6					308:311	→3,6	308:311	→3,6	308:311	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	20	dep	β-D-Glcp-	291:299	arg1	1→					301:302	1→	301:302	1→	301:302	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	0	21	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.	0:145	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	2	22	theme	hepatic	567:573	arg1	synthesis					584:592	hepatic glycogen synthesis	567:592	hepatic glycogen synthesis	567:592	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	0	23	theme	Hericium	31:38	arg1	polysaccharides					50:64	Hericium erinaceus polysaccharides	31:64	Hericium erinaceus polysaccharides	31:64	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	2	24	theme	lipid	509:513	arg1	metabolism					515:524	glucose and lipid metabolism	497:524	metabolism	515:524	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	25	theme	molecular	201:209	arg1	weights					211:217	molecular weights	201:217	molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)	201:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	3	26	theme	gut-liver	910:918	arg1	axis					920:923	the gut-liver axis	906:923	the gut-liver axis	906:923	Besides, HEP-1 promoted the production of beneficial bacteria in the gut, and increased the beneficial metabolites in liver through the gut-liver axis, consequently, resisting the occurrence of T2DM.
37270132	0	27	theme	polysaccharides	50:64	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.	0:145	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	1	28	theme	-β-D-Glcp-	276:285	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	28	theme	-β-D-Glcp-	276:285	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	29	theme	glucose	497:503	arg1	metabolism					515:524	glucose and lipid metabolism	497:524	metabolism	515:524	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	2	30	theme	signaling	754:762	arg1	pathways					764:771	the AMPK/SREBP-1c signaling pathways	736:771	the AMPK/SREBP-1c signaling pathways	736:771	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	0	31	theme	erinaceus	40:48	arg1	polysaccharides					50:64	Hericium erinaceus polysaccharides	31:64	Hericium erinaceus polysaccharides	31:64	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	3	32	theme	bacteria	827:834	arg1	production					802:811	the production	798:811	the production of beneficial bacteria	798:834	Besides, HEP-1 promoted the production of beneficial bacteria in the gut, and increased the beneficial metabolites in liver through the gut-liver axis, consequently, resisting the occurrence of T2DM.
37270132	1	33	theme	1.67 × 104 Da	222:234	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	33	theme	1.67 × 104 Da	222:234	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	34	theme	1→	287:288	arg1	weights					211:217	molecular weights	201:217	molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)	201:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	35	dep	HEP-1	189:193	arg1	1→					324:325	-β-D-Glcp-(1→	313:325	-β-D-Glcp-(1→	313:325	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	36	theme	acid	666:669	arg1	synthesis					671:679	fatty acid synthesis	660:679	fatty acid synthesis	660:679	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	3	37	from	metabolites	877:887	arg1	liver					892:896	liver	892:896	liver	892:896	Besides, HEP-1 promoted the production of beneficial bacteria in the gut, and increased the beneficial metabolites in liver through the gut-liver axis, consequently, resisting the occurrence of T2DM.
37270132	2	38	theme	fatty	660:664	arg1	synthesis					671:679	fatty acid synthesis	660:679	fatty acid synthesis	660:679	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	39	with	HEP-1	189:193	arg1	weights					211:217	molecular weights	201:217	molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)	201:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	3	40	theme	T2DM	968:971	arg1	occurrence					954:963	the occurrence	950:963	the occurrence of T2DM	950:971	Besides, HEP-1 promoted the production of beneficial bacteria in the gut, and increased the beneficial metabolites in liver through the gut-liver axis, consequently, resisting the occurrence of T2DM.
37270132	1	41	theme	composition	240:250	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	41	theme	composition	240:250	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	42	theme	potential	445:453	arg1	effects					455:461	potential effects	445:461	potential effects against T2DM-induced imbalance of glucose and lipid metabolism	445:524	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	43	theme	fruiting	368:375	arg1	body					377:380	the fruiting body	364:380	the fruiting body of Hericium erinaceus	364:402	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	2	44	theme	lipid	702:706	arg1	accumulation					708:719	hepatic lipid accumulation	694:719	hepatic lipid accumulation	694:719	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	45	theme	low	149:151	arg1	weight					163:168	A low molecular weight polysaccharides	147:184	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→,	147:326	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	46	theme	of	252:253	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	46	theme	of	252:253	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	0	47	theme	mechanism	74:82	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.	0:145	Structural characterization of Hericium erinaceus polysaccharides and the mechanism of anti-T2DM by modulating the gut microbiota and metabolites.
37270132	2	48	theme	hepatic	694:700	arg1	accumulation					708:719	hepatic lipid accumulation	694:719	hepatic lipid accumulation	694:719	The results indicated that HEP-1 showed potential effects against T2DM-induced imbalance of glucose and lipid metabolism by promoting the serum glucose uptake by hepatic glycogen synthesis via activating the IRS/PI3K/AKT signaling pathway, and inhibiting fatty acid synthesis and reducing hepatic lipid accumulation via activating the AMPK/SREBP-1c signaling pathways.
37270132	1	49	theme	molecular	153:161	arg1	weight					163:168	A low molecular weight polysaccharides	147:184	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→,	147:326	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	50	theme	→6	255:256	arg1	1→					287:288	1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→	222:288	1→	287:288	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
37270132	1	50	theme	→6	255:256	arg1	β-D-Glcp-					291:299	β-D-Glcp-	291:299	β-D-Glcp-(1→ and →3,6)	291:312	A low molecular weight polysaccharides of HEP-1, with molecular weights of 1.67 × 104 Da and composition of →6)-β-D-Glcp-(1→, →3)-β-D-Glcp-(1→, β-D-Glcp-(1→ and →3,6)-β-D-Glcp-(1→, was isolated and characterized from the fruiting body of Hericium erinaceus.
36740127	7	0	theme	although	1160:1167	arg1	introduction					1173:1184	the introduction	1169:1184	although the introduction of CGO	1160:1191	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	6	1	theme	composite	1122:1130	arg1	Tg					1112:1113	Tg	1112:1113	Tg of the composite	1112:1130	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	8	2	theme	epoxy-based	1296:1306	arg1	nanocomposites					1308:1321	epoxy-based nanocomposites	1296:1321	epoxy-based nanocomposites	1296:1321	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	1	3	theme	composites	263:272	arg1	morphology					228:237	morphology	228:237	morphology	228:237	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	1	3	theme	composites	263:272	arg1	properties					243:252	properties	243:252	properties	243:252	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	8	4	from	result	1328:1333	arg1	matrix					1433:1438	the epoxy matrix	1423:1438	the epoxy matrix	1423:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	1	5	theme	biodegradable	164:176	arg1	CGO					216:218	CGO	216:218	CGO	216:218	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	1	5	theme	biodegradable	164:176	arg1	Oxide					209:213	biodegradable Chitosan-encapsulated Graphene Oxide	164:213	biodegradable Chitosan-encapsulated Graphene Oxide (CGO)	164:219	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	4	6	theme	composites	811:820	arg1	strength					788:795	the strength	784:795	the strength of epoxy/CGOs composites	784:820	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	1	7	with	mixing	298:303	arg1	loadings					327:334	different filler loadings	310:334	different filler loadings	310:334	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	4	8	theme	Mechanical	648:657	arg1	tests					671:675	Mechanical and thermal tests	648:675	Mechanical and thermal tests	648:675	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	1	9	theme	Graphene	200:207	arg1	CGO					216:218	CGO	216:218	CGO	216:218	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	1	9	theme	Graphene	200:207	arg1	Oxide					209:213	biodegradable Chitosan-encapsulated Graphene Oxide	164:213	biodegradable Chitosan-encapsulated Graphene Oxide (CGO)	164:219	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	6	10	theme	epoxy	1089:1093	arg1	matrix					1095:1100	the epoxy matrix	1085:1100	the epoxy matrix	1085:1100	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	3	11	theme	CGO	544:546	arg1	composition					548:558	the CGO composition	540:558	the CGO composition	540:558	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	5	12	theme	interactions	995:1006	arg1	result					973:978	a result	971:978	a result of interfacial interactions between CGO and the matrix	971:1033	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	5	12	theme	interactions	995:1006	arg1	increase					906:913	a 65 % increase	899:913	a 65 % increase in elastic modulus due to the improved load transfer	899:966	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	8	13	theme	GO	1377:1378	arg1	effect					1354:1359	the synergistic effect	1338:1359	the synergistic effect of chitosan and GO	1338:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	5	14	theme	65 	901:903	arg1	%					904:904	%	904:904	%	904:904	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	2	15	theme	DMTA	477:480	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	8	16	theme	3-D	1401:1403	arg1	structures					1409:1418	3-D CGO structures	1401:1418	3-D CGO structures in the epoxy matrix	1401:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	4	17	theme	thermal	663:669	arg1	tests					671:675	Mechanical and thermal tests	648:675	Mechanical and thermal tests	648:675	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	2	18	theme	analysis	467:474	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	8	19	theme	structures	1409:1418	arg1	properties					1282:1291	the final properties	1272:1291	the final properties of epoxy-based nanocomposites	1272:1321	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	19	theme	structures	1409:1418	arg1	result					1328:1333	a result	1326:1333	a result of the synergistic effect of chitosan and GO	1326:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	19	theme	structures	1409:1418	arg1	formation					1388:1396	the formation	1384:1396	the formation of 3-D CGO structures in the epoxy matrix	1384:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	7	20	theme	TGA	1150:1152	arg1	test					1154:1157	the TGA test	1146:1157	the TGA test	1146:1157	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	2	21	dep	microstructures	341:355	arg1	The					337:339	The	337:339	The	337:339	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	2	22	theme	TG	486:487	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	8	23	from	formation	1388:1396	arg1	matrix					1433:1438	the epoxy matrix	1423:1438	the epoxy matrix	1423:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	4	24	theme	CGO	713:715	arg1	factors					763:769	the main factors	754:769	the main factors that changed the strength of epoxy/CGOs composites	754:820	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	24	theme	CGO	713:715	arg1	ratio					725:729	the ratio	721:729	the ratio of chitosan to GO	721:747	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	24	theme	CGO	713:715	arg1	level					704:708	the loading level	692:708	the loading level of CGO	692:715	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	3	25	from	distribution	603:614	arg1	matrix					640:645	the epoxy matrix	630:645	the epoxy matrix	630:645	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	0	26	theme	Biodegradable	0:12	arg1	oxide					32:36	Biodegradable chitosan-graphene oxide	0:36	Biodegradable chitosan-graphene oxide	0:36	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	7	27	theme	resins	1251:1256	arg1	temperature					1221:1231	higher decomposition temperature	1200:1231	higher decomposition temperature of the CGO filled resins	1200:1256	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	3	28	from	content	568:574	arg1	matrix					583:588	the matrix	579:588	the matrix	579:588	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	8	29	from	structures	1409:1418	arg1	matrix					1433:1438	the epoxy matrix	1423:1438	the epoxy matrix	1423:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	1	30	theme	solution	289:296	arg1	mixing					298:303	solution mixing	289:303	solution mixing with different filler loadings	289:334	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	5	31	theme	elastic	918:924	arg1	modulus					926:932	elastic modulus	918:932	elastic modulus	918:932	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	7	32	theme	CGO	1240:1242	arg1	resins					1251:1256	the CGO filled resins	1236:1256	the CGO filled resins	1236:1256	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	3	33	theme	fillers	619:625	arg1	distribution					603:614	the distribution	599:614	the distribution of fillers in the epoxy matrix	599:645	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	6	34	from	presence	1066:1073	arg1	matrix					1095:1100	the epoxy matrix	1085:1100	the epoxy matrix	1085:1100	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	0	35	theme	green	54:58	arg1	filler					60:65	an affective green filler	41:65	an affective green filler for improving of properties in epoxy nanocomposites	41:117	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	1	36	theme	filler	320:325	arg1	loadings					327:334	different filler loadings	310:334	different filler loadings	310:334	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	5	37	theme	interfacial	983:993	arg1	interactions					995:1006	interfacial interactions	983:1006	interfacial interactions between CGO and the matrix	983:1033	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	7	38	theme	decomposition	1207:1219	arg1	temperature					1221:1231	higher decomposition temperature	1200:1231	higher decomposition temperature of the CGO filled resins	1200:1256	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	8	39	theme	effect	1354:1359	arg1	properties					1282:1291	the final properties	1272:1291	the final properties of epoxy-based nanocomposites	1272:1321	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	39	theme	effect	1354:1359	arg1	result					1328:1333	a result	1326:1333	a result of the synergistic effect of chitosan and GO	1326:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	39	theme	effect	1354:1359	arg1	formation					1388:1396	the formation	1384:1396	the formation of 3-D CGO structures in the epoxy matrix	1384:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	5	40	theme	load	954:957	arg1	transfer					959:966	the improved load transfer	941:966	the improved load transfer	941:966	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	8	41	theme	chitosan	1364:1371	arg1	effect					1354:1359	the synergistic effect	1338:1359	the synergistic effect of chitosan and GO	1338:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	5	42	from	increase	906:913	arg1	modulus					926:932	elastic modulus	918:932	elastic modulus	918:932	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	1	43	theme	epoxy	257:261	arg1	composites					263:272	epoxy composites	257:272	epoxy composites prepared using solution mixing with different filler loadings	257:334	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	3	44	theme	Microstructural	496:510	arg1	observations					512:523	Microstructural observations	496:523	Microstructural observations	496:523	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	5	45	theme	tensile	827:833	arg1	analysis					835:842	The tensile analysis	823:842	The tensile analysis	823:842	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	8	46	from	matrix	1433:1438	arg1	properties					1282:1291	the final properties	1272:1291	the final properties of epoxy-based nanocomposites	1272:1321	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	46	from	matrix	1433:1438	arg1	result					1328:1333	a result	1326:1333	a result of the synergistic effect of chitosan and GO	1326:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	46	from	matrix	1433:1438	arg1	formation					1388:1396	the formation	1384:1396	the formation of 3-D CGO structures in the epoxy matrix	1384:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	1	47	theme	Chitosan-encapsulated	178:198	arg1	CGO					216:218	CGO	216:218	CGO	216:218	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	1	47	theme	Chitosan-encapsulated	178:198	arg1	Oxide					209:213	biodegradable Chitosan-encapsulated Graphene Oxide	164:213	biodegradable Chitosan-encapsulated Graphene Oxide (CGO)	164:219	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	4	48	theme	epoxy/CGOs	800:809	arg1	composites					811:820	epoxy/CGOs composites	800:820	epoxy/CGOs composites	800:820	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	1	49	theme	Oxide	209:213	arg1	effect					154:159	the effect	150:159	the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings	150:334	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	1	50	dep	morphology	228:237	arg1	the					224:226	the	224:226	the	224:226	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	6	51	theme	CGO	1078:1080	arg1	presence					1066:1073	the presence	1062:1073	the presence of CGO in the epoxy matrix	1062:1100	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	8	52	theme	CGO	1405:1407	arg1	structures					1409:1418	3-D CGO structures	1401:1418	3-D CGO structures in the epoxy matrix	1401:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	5	53	contain	containing	874:883	arg1	nanocomposites					859:872	nanocomposites	859:872	nanocomposites containing CGO	859:887	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	5	53	contain	containing	874:883	arg2	CGO					885:887	CGO	885:887	CGO	885:887	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	4	54	theme	loading	696:702	arg1	ratio					725:729	the ratio	721:729	the ratio of chitosan to GO	721:747	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	54	theme	loading	696:702	arg1	factors					763:769	the main factors	754:769	the main factors that changed the strength of epoxy/CGOs composites	754:820	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	54	theme	loading	696:702	arg1	level					704:708	the loading level	692:708	the loading level of CGO	692:715	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	3	55	from	composition	548:558	arg1	matrix					583:588	the matrix	579:588	the matrix	579:588	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	2	56	theme	bending	459:465	arg1	analysis					467:474	bending analysis	459:474	bending analysis	459:474	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	8	57	theme	epoxy	1427:1431	arg1	matrix					1433:1438	the epoxy matrix	1423:1438	the epoxy matrix	1423:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	3	58	theme	epoxy	634:638	arg1	matrix					640:645	the epoxy matrix	630:645	the epoxy matrix	630:645	Microstructural observations confirmed that the CGO composition and its content in the matrix affected the distribution of fillers in the epoxy matrix.
36740127	0	59	from	properties	84:93	arg1	nanocomposites					104:117	epoxy nanocomposites	98:117	epoxy nanocomposites	98:117	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	0	60	theme	epoxy	98:102	arg1	nanocomposites					104:117	epoxy nanocomposites	98:117	epoxy nanocomposites	98:117	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	0	61	dep	oxide	32:36	arg1	filler					60:65	an affective green filler	41:65	an affective green filler for improving of properties in epoxy nanocomposites	41:117	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	1	62	from	effect	154:159	arg1	morphology					228:237	morphology	228:237	morphology	228:237	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	1	62	from	effect	154:159	arg1	properties					243:252	properties	243:252	properties	243:252	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	6	63	theme	DMTA	1036:1039	arg1	analysis					1041:1048	DMTA analysis	1036:1048	DMTA analysis	1036:1048	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	8	64	theme	final	1276:1280	arg1	properties					1282:1291	the final properties	1272:1291	the final properties of epoxy-based nanocomposites	1272:1321	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	64	theme	final	1276:1280	arg1	result					1328:1333	a result	1326:1333	a result of the synergistic effect of chitosan and GO	1326:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	64	theme	final	1276:1280	arg1	formation					1388:1396	the formation	1384:1396	the formation of 3-D CGO structures in the epoxy matrix	1384:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	0	65	theme	chitosan-graphene	14:30	arg1	oxide					32:36	Biodegradable chitosan-graphene oxide	0:36	Biodegradable chitosan-graphene oxide	0:36	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	5	66	theme	%	904:904	arg1	result					973:978	a result	971:978	a result of interfacial interactions between CGO and the matrix	971:1033	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	5	66	theme	%	904:904	arg1	increase					906:913	a 65 % increase	899:913	a 65 % increase in elastic modulus due to the improved load transfer	899:966	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	7	67	theme	filled	1244:1249	arg1	resins					1251:1256	the CGO filled resins	1236:1256	the CGO filled resins	1236:1256	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	2	68	theme	TEM	437:439	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	2	69	theme	composites	391:400	arg1	microstructures					341:355	microstructures	341:355	microstructures	341:355	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	2	69	theme	composites	391:400	arg1	properties					361:370	properties	361:370	properties	361:370	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	4	70	theme	main	758:761	arg1	ratio					725:729	the ratio	721:729	the ratio of chitosan to GO	721:747	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	70	theme	main	758:761	arg1	factors					763:769	the main factors	754:769	the main factors that changed the strength of epoxy/CGOs composites	754:820	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	70	theme	main	758:761	arg1	level					704:708	the loading level	692:708	the loading level of CGO	692:715	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	2	71	theme	SEM	432:434	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	8	72	theme	nanocomposites	1308:1321	arg1	properties					1282:1291	the final properties	1272:1291	the final properties of epoxy-based nanocomposites	1272:1321	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	72	theme	nanocomposites	1308:1321	arg1	result					1328:1333	a result	1326:1333	a result of the synergistic effect of chitosan and GO	1326:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	8	72	theme	nanocomposites	1308:1321	arg1	formation					1388:1396	the formation	1384:1396	the formation of 3-D CGO structures in the epoxy matrix	1384:1438	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	2	73	theme	XRD	427:429	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	0	74	theme	affective	44:52	arg1	filler					60:65	an affective green filler	41:65	an affective green filler for improving of properties in epoxy nanocomposites	41:117	Biodegradable chitosan-graphene oxide as an affective green filler for improving of properties in epoxy nanocomposites.
36740127	2	75	theme	impact	451:456	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	2	76	theme	FTIR	421:424	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	1	77	theme	different	310:318	arg1	loadings					327:334	different filler loadings	310:334	different filler loadings	310:334	In this work, we investigated the effect of biodegradable Chitosan-encapsulated Graphene Oxide (CGO) on the morphology and properties of epoxy composites prepared using solution mixing with different filler loadings.
36740127	7	78	theme	higher	1200:1205	arg1	temperature					1221:1231	higher decomposition temperature	1200:1231	higher decomposition temperature of the CGO filled resins	1200:1256	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	2	79	theme	tensile	442:448	arg1	tests					489:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests	421:493	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	5	80	theme	improved	945:952	arg1	transfer					959:966	the improved load transfer	941:966	the improved load transfer	941:966	The tensile analysis confirmed that nanocomposites containing CGO exhibited a 65 % increase in elastic modulus due to the improved load transfer as a result of interfacial interactions between CGO and the matrix.
36740127	7	81	theme	CGO	1189:1191	arg1	introduction					1173:1184	the introduction	1169:1184	although the introduction of CGO	1160:1191	In the TGA test, although the introduction of CGO caused higher decomposition temperature of the CGO filled resins.
36740127	4	82	theme	chitosan	734:741	arg1	factors					763:769	the main factors	754:769	the main factors that changed the strength of epoxy/CGOs composites	754:820	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	82	theme	chitosan	734:741	arg1	ratio					725:729	the ratio	721:729	the ratio of chitosan to GO	721:747	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	4	82	theme	chitosan	734:741	arg1	level					704:708	the loading level	692:708	the loading level of CGO	692:715	Mechanical and thermal tests indicated that the loading level of CGO and the ratio of chitosan to GO were the main factors that changed the strength of epoxy/CGOs composites.
36740127	6	83	attach	presence	1066:1073	arg1	matrix					1095:1100	the epoxy matrix	1085:1100	the epoxy matrix	1085:1100	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	6	83	attach	presence	1066:1073	arg2	CGO					1078:1080	CGO	1078:1080	CGO	1078:1080	DMTA analysis showed that the presence of CGO in the epoxy matrix increased Tg of the composite by ~30 °C.
36740127	8	84	theme	synergistic	1342:1352	arg1	effect					1354:1359	the synergistic effect	1338:1359	the synergistic effect of chitosan and GO	1338:1378	CGO enhanced the final properties of epoxy-based nanocomposites as a result of the synergistic effect of chitosan and GO and the formation of 3-D CGO structures in the epoxy matrix.
36740127	2	85	theme	chitosan-GO	375:385	arg1	microstructures					341:355	microstructures	341:355	microstructures	341:355	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36740127	2	85	theme	chitosan-GO	375:385	arg1	properties					361:370	properties	361:370	properties	361:370	The microstructures and properties of chitosan-GO and composites were studied using FTIR, XRD, SEM, TEM, tensile, impact, bending analysis, DMTA and TG tests.
36448941	5	0	theme	polysaccharides	806:820	arg1	fractions					793:801	different fractions	783:801	different fractions of polysaccharides	783:820	Further, we investigated the antioxidant activities of different fractions of polysaccharides.
36448941	4	1	dep	Fourier	572:578	arg1	transform					580:588	transform	580:588	transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM)	580:657	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	4	2	used	used	664:667	arg2	Fourier					572:578	Fourier	572:578	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM)	572:657	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	6	3	theme	h.	1015:1016	arg1	time					1003:1006	extraction time	992:1006	extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value	992:1120	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	3	theme	h.	1015:1016	arg1	ratio					936:940	a liquid-solid ratio	921:940	a liquid-solid ratio of 26 mL/g	921:951	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	3	theme	h.	1015:1016	arg1	temperature					965:975	extraction temperature	954:975	extraction temperature of 85.5 ℃	954:985	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	3	theme	h.	1015:1016	arg1	conditions					884:893	the optimum extraction conditions	861:893	the optimum extraction conditions for polysaccharides	861:913	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	5	4	theme	different	783:791	arg1	fractions					793:801	different fractions	783:801	different fractions of polysaccharides	783:820	Further, we investigated the antioxidant activities of different fractions of polysaccharides.
36448941	8	5	theme	infrared	1343:1350	arg1	spectra					1363:1369	similar infrared absorption spectra	1335:1369	similar infrared absorption spectra	1335:1369	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	3	6	from	minima	455:460	arg1	polysaccharides					424:438	the crude polysaccharides	414:438	the crude polysaccharides from Centipeda minima	414:460	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	6	7	theme	optimum	865:871	arg1	ratio					936:940	a liquid-solid ratio	921:940	a liquid-solid ratio of 26 mL/g	921:951	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	7	theme	optimum	865:871	arg1	conditions					884:893	the optimum extraction conditions	861:893	the optimum extraction conditions for polysaccharides	861:913	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	2	8	theme	Centipeda	384:392	arg1	minima					394:399	Centipeda minima	384:399	Centipeda minima	384:399	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	11	9	theme	food	1735:1738	arg1	processing					1740:1749	food processing	1735:1749	food processing	1735:1749	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	5	10	theme	antioxidant	757:767	arg1	activities					769:778	the antioxidant activities	753:778	the antioxidant activities of different fractions of polysaccharides	753:820	Further, we investigated the antioxidant activities of different fractions of polysaccharides.
36448941	2	11	from	process	352:358	arg1	minima					394:399	Centipeda minima	384:399	Centipeda minima	384:399	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	4	12	theme	structural	684:693	arg1	features					695:702	the structural features	680:702	the structural features of the polysaccharides	680:725	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	4	13	theme	electron	633:640	arg1	SEM					654:656	SEM	654:656	SEM	654:656	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	4	13	theme	electron	633:640	arg1	microscopy					642:651	scanning electron microscopy	624:651	scanning electron microscopy (SEM)	624:657	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	0	14	theme	Centipeda	97:105	arg1	minima					107:112	Centipeda minima	97:112	Centipeda minima	97:112	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	6	15	theme	mL/g	948:951	arg1	time					1003:1006	extraction time	992:1006	extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value	992:1120	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	15	theme	mL/g	948:951	arg1	ratio					936:940	a liquid-solid ratio	921:940	a liquid-solid ratio of 26 mL/g	921:951	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	15	theme	mL/g	948:951	arg1	temperature					965:975	extraction temperature	954:975	extraction temperature of 85.5 ℃	954:985	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	15	theme	mL/g	948:951	arg1	conditions					884:893	the optimum extraction conditions	861:893	the optimum extraction conditions for polysaccharides	861:913	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	10	16	theme	antioxidant	1480:1490	arg1	activity					1492:1499	good antioxidant activity	1475:1499	good antioxidant activity	1475:1499	Besides, CMP displayed good antioxidant activity, with potential to scavenge DPPH radical, hydroxyl radical, and superoxide radical.
36448941	4	17	theme	scanning	624:631	arg1	SEM					654:656	SEM	654:656	SEM	654:656	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	4	17	theme	scanning	624:631	arg1	microscopy					642:651	scanning electron microscopy	624:651	scanning electron microscopy (SEM)	624:657	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	11	18	theme	theoretical	1708:1718	arg1	foundation					1720:1729	a theoretical foundation	1706:1729	a theoretical foundation for food processing and medicinal development of CMP	1706:1782	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	10	19	theme	DPPH	1529:1532	arg1	radical					1534:1540	DPPH radical	1529:1540	DPPH radical	1529:1540	Besides, CMP displayed good antioxidant activity, with potential to scavenge DPPH radical, hydroxyl radical, and superoxide radical.
36448941	6	20	theme	predicted	1106:1114	arg1	value					1116:1120	the predicted value	1102:1120	the predicted value	1102:1120	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	20	theme	predicted	1106:1114	arg1	yield					1032:1036	the yield	1028:1036	the yield of polysaccharides measured under these conditions	1028:1087	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	3	21	theme	fraction	562:569	arg1	purity					489:494	purity	489:494	purity	489:494	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	3	21	theme	fraction	562:569	arg1	composition					512:522	monosaccharide composition	497:522	monosaccharide composition	497:522	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	3	21	theme	fraction	562:569	arg1	weight					539:544	molecular weight	529:544	molecular weight	529:544	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	1	22	theme	extraction	160:169	arg1	process					171:177	the extraction process	156:177	the extraction process	156:177	The purpose of this study is to optimize the extraction process and study antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	0	23	theme	antioxidant	43:53	arg1	activity					55:62	antioxidant activity	43:62	antioxidant activity of Polysaccharide	43:80	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	2	24	from	minima	394:399	arg1	polysaccharides					363:377	polysaccharides	363:377	polysaccharides from Centipeda minima	363:399	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	2	24	from	minima	394:399	arg1	process					352:358	the extraction process	337:358	the extraction process of polysaccharides from Centipeda minima	337:399	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	2	25	theme	surface	293:299	arg1	methodology					301:311	The Box-Behnken design-response surface methodology	261:311	The Box-Behnken design-response surface methodology	261:311	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	11	26	theme	CMP	1692:1694	arg1	structure					1655:1663	structure	1655:1663	structure	1655:1663	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	11	26	theme	CMP	1692:1694	arg1	activity					1680:1687	biological activity	1669:1687	biological activity	1669:1687	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	3	27	theme	crude	418:422	arg1	polysaccharides					424:438	the crude polysaccharides	414:438	the crude polysaccharides from Centipeda minima	414:460	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	6	28	theme	extraction	992:1001	arg1	time					1003:1006	extraction time	992:1006	extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value	992:1120	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	5	29	theme	fractions	793:801	arg1	activities					769:778	the antioxidant activities	753:778	the antioxidant activities of different fractions of polysaccharides	753:820	Further, we investigated the antioxidant activities of different fractions of polysaccharides.
36448941	2	30	theme	extraction	341:350	arg1	process					352:358	the extraction process	337:358	the extraction process of polysaccharides from Centipeda minima	337:399	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	10	31	theme	superoxide	1565:1574	arg1	radical					1576:1582	superoxide radical	1565:1582	superoxide radical	1565:1582	Besides, CMP displayed good antioxidant activity, with potential to scavenge DPPH radical, hydroxyl radical, and superoxide radical.
36448941	6	32	theme	extraction	954:963	arg1	temperature					965:975	extraction temperature	954:975	extraction temperature of 85.5 ℃	954:985	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	11	33	theme	medicinal	1755:1763	arg1	development					1765:1775	medicinal development	1755:1775	medicinal development	1755:1775	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	8	34	theme	structural	1276:1285	arg1	characteristics					1287:1301	structural characteristics	1276:1301	structural characteristics	1276:1301	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	0	35	theme	extraction	20:29	arg1	process					31:37	the extraction process	16:37	the extraction process	16:37	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	11	36	dep	structure	1655:1663	arg1	the					1651:1653	the	1651:1653	the	1651:1653	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	1	37	theme	antioxidant	189:199	arg1	activity					201:208	antioxidant activity	189:208	antioxidant activity of Polysaccharide extracted from Centipeda minima	189:258	The purpose of this study is to optimize the extraction process and study antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	11	38	theme	biological	1669:1678	arg1	activity					1680:1687	biological activity	1669:1687	biological activity	1669:1687	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	10	39	theme	hydroxyl	1543:1550	arg1	radical					1552:1558	hydroxyl radical	1543:1558	hydroxyl radical	1543:1558	Besides, CMP displayed good antioxidant activity, with potential to scavenge DPPH radical, hydroxyl radical, and superoxide radical.
36448941	6	40	theme	liquid-solid	923:934	arg1	ratio					936:940	a liquid-solid ratio	921:940	a liquid-solid ratio of 26 mL/g	921:951	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	40	theme	liquid-solid	923:934	arg1	conditions					884:893	the optimum extraction conditions	861:893	the optimum extraction conditions for polysaccharides	861:913	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	3	41	theme	monosaccharide	497:510	arg1	composition					512:522	monosaccharide composition	497:522	monosaccharide composition	497:522	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	7	42	theme	Centipeda	1174:1182	arg1	CMP					1208:1210	CMP	1208:1210	CMP	1208:1210	After purification, we obtained four components of Centipeda minima polysaccharides (CMP).
36448941	7	42	theme	Centipeda	1174:1182	arg1	minima polysaccharides					1184:1205	Centipeda minima polysaccharides	1174:1205	Centipeda minima polysaccharides (CMP)	1174:1211	After purification, we obtained four components of Centipeda minima polysaccharides (CMP).
36448941	3	43	theme	molecular	529:537	arg1	weight					539:544	molecular weight	529:544	molecular weight	529:544	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	8	44	theme	absorption	1352:1361	arg1	spectra					1363:1369	similar infrared absorption spectra	1335:1369	similar infrared absorption spectra	1335:1369	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	11	45	from	research	1639:1646	arg1	structure					1655:1663	structure	1655:1663	structure	1655:1663	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	11	45	from	research	1639:1646	arg1	activity					1680:1687	biological activity	1669:1687	biological activity	1669:1687	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	0	46	theme	process	31:37	arg1	Optimization					0:11	Optimization	0:11	Optimization of the extraction process	0:37	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	0	46	theme	process	31:37	arg1	activity					55:62	antioxidant activity	43:62	antioxidant activity of Polysaccharide	43:80	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	9	47	theme	infrared	1396:1403	arg1	characteristic					1416:1429	a typical infrared absorption characteristic	1386:1429	a typical infrared absorption characteristic of a polysaccharide	1386:1449	CMP exhibited a typical infrared absorption characteristic of a polysaccharide.
36448941	7	48	theme	minima polysaccharides	1184:1205	arg1	components					1160:1169	four components	1155:1169	four components of Centipeda minima polysaccharides (CMP)	1155:1211	After purification, we obtained four components of Centipeda minima polysaccharides (CMP).
36448941	8	49	theme	monosaccharide	1226:1239	arg1	composition					1241:1251	monosaccharide composition	1226:1251	monosaccharide composition	1226:1251	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	1	50	theme	Polysaccharide	213:226	arg1	activity					201:208	antioxidant activity	189:208	antioxidant activity of Polysaccharide extracted from Centipeda minima	189:258	The purpose of this study is to optimize the extraction process and study antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	9	51	theme	absorption	1405:1414	arg1	characteristic					1416:1429	a typical infrared absorption characteristic	1386:1429	a typical infrared absorption characteristic of a polysaccharide	1386:1449	CMP exhibited a typical infrared absorption characteristic of a polysaccharide.
36448941	11	52	theme	CMP	1780:1782	arg1	processing					1740:1749	food processing	1735:1749	food processing	1735:1749	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	11	52	theme	CMP	1780:1782	arg1	development					1765:1775	medicinal development	1755:1775	medicinal development	1755:1775	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	3	53	theme	Centipeda	445:453	arg1	minima					455:460	Centipeda minima	445:460	Centipeda minima	445:460	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
36448941	6	54	theme	℃	985:985	arg1	time					1003:1006	extraction time	992:1006	extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value	992:1120	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	54	theme	℃	985:985	arg1	ratio					936:940	a liquid-solid ratio	921:940	a liquid-solid ratio of 26 mL/g	921:951	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	54	theme	℃	985:985	arg1	temperature					965:975	extraction temperature	954:975	extraction temperature of 85.5 ℃	954:985	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	54	theme	℃	985:985	arg1	conditions					884:893	the optimum extraction conditions	861:893	the optimum extraction conditions for polysaccharides	861:913	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	9	55	theme	polysaccharide	1436:1449	arg1	characteristic					1416:1429	a typical infrared absorption characteristic	1386:1429	a typical infrared absorption characteristic of a polysaccharide	1386:1449	CMP exhibited a typical infrared absorption characteristic of a polysaccharide.
36448941	2	56	theme	polysaccharides	363:377	arg1	process					352:358	the extraction process	337:358	the extraction process of polysaccharides from Centipeda minima	337:399	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	8	57	dep	purity	1218:1223	arg1	The					1214:1216	The	1214:1216	The	1214:1216	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	10	58	theme	good	1475:1478	arg1	activity					1492:1499	good antioxidant activity	1475:1499	good antioxidant activity	1475:1499	Besides, CMP displayed good antioxidant activity, with potential to scavenge DPPH radical, hydroxyl radical, and superoxide radical.
36448941	2	59	theme	design-response	277:291	arg1	methodology					301:311	The Box-Behnken design-response surface methodology	261:311	The Box-Behnken design-response surface methodology	261:311	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	11	60	theme	future	1632:1637	arg1	research					1639:1646	future research	1632:1646	future research on the structure and biological activity of CMP	1632:1694	Therefore, this study provides a reference for future research on the structure and biological activity of CMP, and lays a theoretical foundation for food processing and medicinal development of CMP.
36448941	8	61	theme	similar	1335:1341	arg1	spectra					1363:1369	similar infrared absorption spectra	1335:1369	similar infrared absorption spectra	1335:1369	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	8	62	theme	molecular	1254:1262	arg1	weight					1264:1269	molecular weight	1254:1269	molecular weight	1254:1269	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	2	63	theme	Box-Behnken	265:275	arg1	methodology					301:311	The Box-Behnken design-response surface methodology	261:311	The Box-Behnken design-response surface methodology	261:311	The Box-Behnken design-response surface methodology was adopted to optimize the extraction process of polysaccharides from Centipeda minima.
36448941	1	64	theme	study	135:139	arg1	purpose					119:125	The purpose	115:125	The purpose of this study	115:139	The purpose of this study is to optimize the extraction process and study antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	6	65	theme	polysaccharides	1041:1055	arg1	value					1116:1120	the predicted value	1102:1120	the predicted value	1102:1120	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	65	theme	polysaccharides	1041:1055	arg1	yield					1032:1036	the yield	1028:1036	the yield of polysaccharides measured under these conditions	1028:1087	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	0	66	theme	Polysaccharide	67:80	arg1	Optimization					0:11	Optimization	0:11	Optimization of the extraction process	0:37	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	0	66	theme	Polysaccharide	67:80	arg1	activity					55:62	antioxidant activity	43:62	antioxidant activity of Polysaccharide	43:80	Optimization of the extraction process and antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	6	67	theme	extraction	873:882	arg1	ratio					936:940	a liquid-solid ratio	921:940	a liquid-solid ratio of 26 mL/g	921:951	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	6	67	theme	extraction	873:882	arg1	conditions					884:893	the optimum extraction conditions	861:893	the optimum extraction conditions for polysaccharides	861:913	Consequently, the results showed that the optimum extraction conditions for polysaccharides were: a liquid-solid ratio of 26 mL/g, extraction temperature of 85.5 ℃, and extraction time of 2.4 h. Moreover, the yield of polysaccharides measured under these conditions was close to the predicted value.
36448941	8	68	theme	CMP	1306:1308	arg1	characteristics					1287:1301	structural characteristics	1276:1301	structural characteristics	1276:1301	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	8	68	theme	CMP	1306:1308	arg1	purity					1218:1223	purity	1218:1223	purity	1218:1223	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	8	68	theme	CMP	1306:1308	arg1	composition					1241:1251	monosaccharide composition	1226:1251	monosaccharide composition	1226:1251	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	8	68	theme	CMP	1306:1308	arg1	weight					1264:1269	molecular weight	1254:1269	molecular weight	1254:1269	The purity, monosaccharide composition, molecular weight, and structural characteristics of CMP were different, but with similar infrared absorption spectra.
36448941	4	69	theme	polysaccharides	711:725	arg1	features					695:702	the structural features	680:702	the structural features of the polysaccharides	680:725	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	9	70	theme	typical	1388:1394	arg1	characteristic					1416:1429	a typical infrared absorption characteristic	1386:1429	a typical infrared absorption characteristic of a polysaccharide	1386:1449	CMP exhibited a typical infrared absorption characteristic of a polysaccharide.
36448941	1	71	theme	Centipeda	243:251	arg1	minima					253:258	Centipeda minima	243:258	Centipeda minima	243:258	The purpose of this study is to optimize the extraction process and study antioxidant activity of Polysaccharide extracted from Centipeda minima.
36448941	4	72	dep	transform	580:588	arg1	infrared					590:597	infrared	590:597	transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM)	580:657	Fourier transform infrared spectrometer (FT-IR) and scanning electron microscopy (SEM) were used to analyze the structural features of the polysaccharides.
36448941	3	73	theme	purified	553:560	arg1	fraction					562:569	the purified fraction	549:569	the purified fraction	549:569	We purified the crude polysaccharides from Centipeda minima, as well as determined the purity, monosaccharide composition, and molecular weight of the purified fraction.
35566103	8	0	theme	biodegradable	1330:1342	arg1	RA-H20MB					1304:1311	RA-H20MB	1304:1311	RA-H20MB	1304:1311	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	8	0	theme	biodegradable	1330:1342	arg1	indicator					1355:1363	a biodegradable pH sensing indicator	1328:1363	a biodegradable pH sensing indicator	1328:1363	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	2	1	theme	hydroxypropyl	373:385	arg1	HPMC					404:407	HPMC	404:407	HPMC	404:407	A solid material for a pH-responsive indicator was developed from hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC).
35566103	2	1	theme	hydroxypropyl	373:385	arg1	methylcellulose					387:401	hydroxypropyl methylcellulose	373:401	hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC)	373:457	A solid material for a pH-responsive indicator was developed from hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC).
35566103	1	2	theme	food	272:275	arg1	safety					277:282	food safety	272:282	food safety	272:282	Intelligent packaging with indicators that provide information about the quality of food products can inform the consumer regarding food safety and reduce food waste.
35566103	4	3	dep	%	661:661	arg1	10					651:652	10	651:652	10	651:652	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	3	dep	%	661:661	arg1	20					659:660	20	659:660	20	659:660	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	7	4	theme	tenderloin	1192:1201	arg1	change					1174:1179	quality change	1166:1179	quality change of chicken tenderloin	1166:1201	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	7	4	theme	tenderloin	1192:1201	arg1	change					1122:1127	a clear color change	1108:1127	a clear color change with respect to ammonia exposure	1108:1160	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	3	5	theme	films	624:628	arg1	barrier					547:553	the physical, barrier, thermal, and optical properties	533:586	barrier	547:553	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	3	5	theme	films	624:628	arg1	properties					577:586	the physical, barrier, thermal, and optical properties	533:586	properties	577:586	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	6	6	theme	freshness	1048:1056	arg1	status					1058:1063	tracking freshness status	1039:1063	tracking freshness status of chicken tenderloin	1039:1085	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	3	7	theme	HPMC	517:520	arg1	matrix					522:527	the HPMC matrix	513:527	the HPMC matrix	513:527	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	6	8	theme	tracking	1039:1046	arg1	status					1058:1063	tracking freshness status	1039:1063	tracking freshness status of chicken tenderloin	1039:1085	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	7	9	theme	clear	1110:1114	arg1	change					1122:1127	a clear color change	1108:1127	a clear color change with respect to ammonia exposure	1108:1160	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	4	10	dep	MCC	663:665	arg1	%					661:661	%	661:661	%	661:661	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	0	11	theme	Chicken	120:126	arg1	Tenderloin					128:137	Chicken Tenderloin	120:137	Chicken Tenderloin	120:137	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	3	12	from	%	487:487	arg1	MCC					460:462	MCC	460:462	MCC at 5%, 10%, 20%, and 30% w/w	460:491	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	4	13	theme	improved	668:675	arg1	transparency					689:700	improved mechanical, transparency, and barrier properties	668:724	transparency	689:700	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	6	14	theme	chicken	1068:1074	arg1	tenderloin					1076:1085	chicken tenderloin	1068:1085	chicken tenderloin	1068:1085	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	1	15	with	packaging	152:160	arg1	indicators					167:176	indicators	167:176	indicators that provide information about the quality of food products	167:236	Intelligent packaging with indicators that provide information about the quality of food products can inform the consumer regarding food safety and reduce food waste.
35566103	3	16	from	%	473:473	arg1	MCC					460:462	MCC	460:462	MCC at 5%, 10%, 20%, and 30% w/w	460:491	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	5	17	theme	solid	855:859	arg1	material					861:868	the biodegradable solid material	837:868	the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators	837:932	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	5	17	theme	solid	855:859	arg1	H20MB					815:819	H20MB	815:819	H20MB	815:819	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	8	18	theme	food	1378:1381	arg1	quality					1383:1389	food quality	1378:1389	food quality	1378:1389	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	6	19	theme	ammonia	1021:1027	arg1	vapor					1029:1033	ammonia vapor	1021:1033	ammonia vapor	1021:1033	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	1	20	theme	food	295:298	arg1	waste					300:304	food waste	295:304	food waste	295:304	Intelligent packaging with indicators that provide information about the quality of food products can inform the consumer regarding food safety and reduce food waste.
35566103	7	21	theme	chicken	1184:1190	arg1	tenderloin					1192:1201	chicken tenderloin	1184:1201	chicken tenderloin	1184:1201	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	0	22	theme	Anthocyanin	28:38	arg1	Indicator					40:48	Natural Anthocyanin Indicator	20:48	Natural Anthocyanin Indicator	20:48	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	3	23	from	%	478:478	arg1	MCC					460:462	MCC	460:462	MCC at 5%, 10%, 20%, and 30% w/w	460:491	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	7	24	theme	quality	1166:1172	arg1	change					1174:1179	quality change	1166:1179	quality change of chicken tenderloin	1166:1201	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	0	25	theme	Natural	20:26	arg1	Indicator					40:48	Natural Anthocyanin Indicator	20:48	Natural Anthocyanin Indicator	20:48	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	0	26	theme	Tenderloin	128:137	arg1	Freshness					107:115	the Freshness	103:115	the Freshness of Chicken Tenderloin	103:137	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	2	27	theme	solid	309:313	arg1	material					315:322	A solid material	307:322	A solid material for a pH-responsive indicator	307:352	A solid material for a pH-responsive indicator was developed from hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC).
35566103	1	28	theme	food	224:227	arg1	products					229:236	food products	224:236	food products	224:236	Intelligent packaging with indicators that provide information about the quality of food products can inform the consumer regarding food safety and reduce food waste.
35566103	7	29	theme	color	1116:1120	arg1	change					1122:1127	a clear color change	1108:1127	a clear color change with respect to ammonia exposure	1108:1160	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	4	30	theme	barrier	707:713	arg1	properties					715:724	improved mechanical, transparency, and barrier properties	668:724	properties	715:724	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	1	31	theme	products	229:236	arg1	quality					213:219	the quality	209:219	the quality of food products	209:236	Intelligent packaging with indicators that provide information about the quality of food products can inform the consumer regarding food safety and reduce food waste.
35566103	0	32	theme	Indicator	40:48	arg1	Characterization					0:15	Characterization	0:15	Characterization of Natural Anthocyanin Indicator	0:48	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	4	33	theme	best	786:789	arg1	performance					791:801	the best performance	782:801	the best performance	782:801	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	3	34	theme	optical	569:575	arg1	properties					577:586	the physical, barrier, thermal, and optical properties	533:586	properties	577:586	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	5	35	theme	Roselle	886:892	arg1	RA					908:909	RA	908:909	RA	908:909	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	5	35	theme	Roselle	886:892	arg1	anthocyanins					894:905	Roselle anthocyanins	886:905	Roselle anthocyanins (RA) pH sensing indicators	886:932	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	2	36	theme	microcrystalline	426:441	arg1	cellulose					443:451	microcrystalline cellulose	426:451	microcrystalline cellulose (MCC)	426:457	A solid material for a pH-responsive indicator was developed from hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC).
35566103	2	36	theme	microcrystalline	426:441	arg1	MCC					454:456	MCC	454:456	MCC	454:456	A solid material for a pH-responsive indicator was developed from hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC).
35566103	0	37	theme	Cellulose	59:67	arg1	Film					83:86	Cellulose Bio-Composite Film	59:86	Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin	59:137	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	5	38	theme	anthocyanins	894:905	arg1	pH					912:913	Roselle anthocyanins (RA) pH	886:913	Roselle anthocyanins (RA) pH sensing indicators	886:932	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	3	39	from	%	468:468	arg1	MCC					460:462	MCC	460:462	MCC at 5%, 10%, 20%, and 30% w/w	460:491	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	8	40	theme	sensing	1347:1353	arg1	RA-H20MB					1304:1311	RA-H20MB	1304:1311	RA-H20MB	1304:1311	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	8	40	theme	sensing	1347:1353	arg1	indicator					1355:1363	a biodegradable pH sensing indicator	1328:1363	a biodegradable pH sensing indicator	1328:1363	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	4	41	theme	MCC	763:765	arg1	H20MB					768:772	H20MB	768:772	H20MB	768:772	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	41	theme	MCC	763:765	arg1	MCC					763:765	MCC	763:765	MCC (H20MB)	763:773	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	41	theme	MCC	763:765	arg1	%					758:758	20%	756:758	20% of MCC (H20MB)	756:773	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	3	42	theme	physical	537:544	arg1	barrier					547:553	the physical, barrier, thermal, and optical properties	533:586	barrier	547:553	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	7	43	theme	ammonia	1145:1151	arg1	exposure					1153:1160	ammonia exposure	1145:1160	ammonia exposure	1145:1160	The RA-H20MB showed a clear color change with respect to ammonia exposure and quality change of chicken tenderloin; the color changed from red to magenta, purple and green, respectively.
35566103	8	44	used	used	1320:1323	arg2	indicator					1355:1363	a biodegradable pH sensing indicator	1328:1363	a biodegradable pH sensing indicator	1328:1363	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	8	44	used	used	1320:1323	arg2	RA-H20MB					1304:1311	RA-H20MB	1304:1311	RA-H20MB	1304:1311	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	6	45	theme	tenderloin	1076:1085	arg1	status					1058:1063	tracking freshness status	1039:1063	tracking freshness status of chicken tenderloin	1039:1085	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	6	45	theme	tenderloin	1076:1085	arg1	response					1009:1016	its response	1005:1016	its response to ammonia vapor	1005:1033	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	5	46	theme	biodegradable	841:853	arg1	material					861:868	the biodegradable solid material	837:868	the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators	837:932	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	5	46	theme	biodegradable	841:853	arg1	H20MB					815:819	H20MB	815:819	H20MB	815:819	Therefore, H20MB was selected as the biodegradable solid material for fabricating Roselle anthocyanins (RA) pH sensing indicators.
35566103	1	47	theme	Intelligent	140:150	arg1	packaging					152:160	Intelligent packaging	140:160	Intelligent packaging with indicators that provide information about the quality of food products	140:236	Intelligent packaging with indicators that provide information about the quality of food products can inform the consumer regarding food safety and reduce food waste.
35566103	3	48	theme	HPMC/MCC	595:602	arg1	bio-composite					604:616	HPMC/MCC bio-composite	595:616	the HPMC/MCC bio-composite (HMB) films	591:628	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	3	48	theme	HPMC/MCC	595:602	arg1	HMB					619:621	HMB	619:621	HMB	619:621	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	4	49	theme	mechanical	677:686	arg1	transparency					689:700	improved mechanical, transparency, and barrier properties	668:724	transparency	689:700	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	2	50	theme	pH-responsive	330:342	arg1	indicator					344:352	a pH-responsive indicator	328:352	a pH-responsive indicator	328:352	A solid material for a pH-responsive indicator was developed from hydroxypropyl methylcellulose (HPMC) composited with microcrystalline cellulose (MCC).
35566103	3	51	theme	bio-composite	604:616	arg1	films					624:628	the HPMC/MCC bio-composite (HMB) films	591:628	the HPMC/MCC bio-composite (HMB) films	591:628	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	4	52	with	HMB	747:749	arg1	H20MB					768:772	H20MB	768:772	H20MB	768:772	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	52	with	HMB	747:749	arg1	MCC					763:765	MCC	763:765	MCC (H20MB)	763:773	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	52	with	HMB	747:749	arg1	%					758:758	20%	756:758	20% of MCC (H20MB)	756:773	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	6	53	theme	indicator	967:975	arg1	performance					939:949	The performance	935:949	The performance of the RA-H20MB indicator	935:975	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	0	54	theme	Bio-Composite	69:81	arg1	Film					83:86	Cellulose Bio-Composite Film	59:86	Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin	59:137	Characterization of Natural Anthocyanin Indicator Based on Cellulose Bio-Composite Film for Monitoring the Freshness of Chicken Tenderloin.
35566103	8	55	theme	pH	1344:1345	arg1	RA-H20MB					1304:1311	RA-H20MB	1304:1311	RA-H20MB	1304:1311	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	8	55	theme	pH	1344:1345	arg1	indicator					1355:1363	a biodegradable pH sensing indicator	1328:1363	a biodegradable pH sensing indicator	1328:1363	These results indicated that RA-H20MB can be used as a biodegradable pH sensing indicator to determine food quality and freshness.
35566103	3	56	theme	thermal	556:562	arg1	barrier					547:553	the physical, barrier, thermal, and optical properties	533:586	barrier	547:553	MCC at 5%, 10%, 20%, and 30% w/w was introduced into the HPMC matrix and the physical, barrier, thermal, and optical properties of the HPMC/MCC bio-composite (HMB) films were analyzed.
35566103	6	57	theme	RA-H20MB	958:965	arg1	indicator					967:975	the RA-H20MB indicator	954:975	the RA-H20MB indicator	954:975	The performance of the RA-H20MB indicator was evaluated by monitoring its response to ammonia vapor and tracking freshness status of chicken tenderloin.
35566103	4	58	located	observed	731:738	arg1	MCC					663:665	5, 10, and 20% MCC	648:665	5, 10, and 20% MCC	648:665	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	58	located	observed	731:738	arg2	properties					715:724	improved mechanical, transparency, and barrier properties	668:724	properties	715:724	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
35566103	4	58	located	observed	731:738	arg2	transparency					689:700	improved mechanical, transparency, and barrier properties	668:724	transparency	689:700	At 5, 10, and 20% MCC, improved mechanical, transparency, and barrier properties were observed, where HMB with 20% of MCC (H20MB) showed the best performance.
36863676	0	0	from	Ostrea	21:26	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides from Ostrea	0:26	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	4	1	theme	ALT	607:609	arg1	contents					581:588	the contents	577:588	the contents of serum AST and ALT	577:609	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	7	2	theme	intestinal	987:996	arg1	function					1006:1013	intestinal barrier function	987:1013	intestinal barrier function	987:1013	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	5	3	theme	intestinal	697:706	arg1	function					716:723	the intestinal barrier function	693:723	the intestinal barrier function	693:723	ORP could also enhance the intestinal barrier function.
36863676	0	4	theme	fatty	104:108	arg1	disease					116:122	non-alcoholic fatty liver disease	90:122	non-alcoholic fatty liver disease in ApoE-/- mice	90:138	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	7	5	theme	intestinal	1023:1032	arg1	permeability					1034:1045	intestinal permeability	1023:1045	intestinal permeability	1023:1045	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	6	6	theme	16sRNA	726:731	arg1	analysis					733:740	16sRNA analysis	726:740	16sRNA analysis	726:740	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	3	7	theme	LDL	491:493	arg1	level					495:499	LDL level	491:499	LDL level	491:499	ORP could significantly reduce TC, TG and LDL level, and increase HDL level in serum of HFD mice.
36863676	6	8	dep	Firmicutes/	835:845	arg1	Bacteroidetes					847:859	Firmicutes/ Bacteroidetes	835:859	Firmicutes/ Bacteroidetes	835:859	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	0	9	theme	non-alcoholic	90:102	arg1	disease					116:122	non-alcoholic fatty liver disease	90:122	non-alcoholic fatty liver disease in ApoE-/- mice	90:138	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	8	10	theme	functional	1221:1230	arg1	polysaccharide					1141:1154	an ideal polysaccharide	1132:1154	an ideal polysaccharide	1132:1154	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	8	10	theme	functional	1221:1230	arg1	food					1232:1235	functional food	1221:1235	functional food	1221:1235	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	6	11	theme	Proteobacteria	803:816	arg1	ratio					826:830	the ratio	822:830	the ratio of Firmicutes/ Bacteroidetes at the phylum level	822:879	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	6	11	theme	Proteobacteria	803:816	arg1	abundance					775:783	the abundance	771:783	the abundance of Firmicutes and Proteobacteria	771:816	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	1	12	theme	study	161:165	arg1	purpose					145:151	The purpose	141:151	The purpose of this study	141:165	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	0	13	theme	liver	110:114	arg1	disease					116:122	non-alcoholic fatty liver disease	90:122	non-alcoholic fatty liver disease in ApoE-/- mice	90:138	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	2	14	contain	had	412:414	arg2	lesions					440:446	significant fatty liver lesions	416:446	significant fatty liver lesions	416:446	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	2	14	contain	had	412:414	arg1	mice					407:410	NAFLD model group mice	389:410	NAFLD model group mice	389:410	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	8	15	theme	candidate	1240:1248	arg1	polysaccharide					1141:1154	an ideal polysaccharide	1132:1154	an ideal polysaccharide	1132:1154	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	8	15	theme	candidate	1240:1248	arg1	drugs					1250:1254	candidate drugs	1240:1254	candidate drugs	1240:1254	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	6	16	theme	Firmicutes/	835:845	arg1	ratio					826:830	the ratio	822:830	the ratio of Firmicutes/ Bacteroidetes at the phylum level	822:879	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	6	16	theme	Firmicutes/	835:845	arg1	abundance					775:783	the abundance	771:783	the abundance of Firmicutes and Proteobacteria	771:816	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	6	17	theme	Firmicutes	788:797	arg1	ratio					826:830	the ratio	822:830	the ratio of Firmicutes/ Bacteroidetes at the phylum level	822:879	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	6	17	theme	Firmicutes	788:797	arg1	abundance					775:783	the abundance	771:783	the abundance of Firmicutes and Proteobacteria	771:816	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	7	18	theme	barrier	998:1004	arg1	function					1006:1013	intestinal barrier function	987:1013	intestinal barrier function	987:1013	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	4	19	theme	fatty	649:653	arg1	disease					661:667	fatty liver disease	649:667	fatty liver disease	649:667	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	7	20	theme	NAFLD	967:971	arg1	mice					973:976	NAFLD mice	967:976	NAFLD mice	967:976	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	2	21	theme	group	401:405	arg1	mice					407:410	NAFLD model group mice	389:410	NAFLD model group mice	389:410	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	1	22	theme	high-fat	258:265	arg1	HFD					273:275	HFD	273:275	HFD	273:275	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	22	theme	high-fat	258:265	arg1	diet					267:270	high-fat diet	258:270	high-fat diet (HFD)	258:276	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	8	23	theme	ideal	1135:1139	arg1	polysaccharide					1141:1154	an ideal polysaccharide	1132:1154	an ideal polysaccharide	1132:1154	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	8	23	theme	ideal	1135:1139	arg1	food					1232:1235	functional food	1221:1235	functional food	1221:1235	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	8	23	theme	ideal	1135:1139	arg1	drugs					1250:1254	candidate drugs	1240:1254	candidate drugs	1240:1254	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	8	23	theme	ideal	1135:1139	arg1	ORP					1125:1127	ORP	1125:1127	ORP	1125:1127	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	3	24	theme	HDL	515:517	arg1	level					519:523	HDL level	515:523	HDL level in serum of HFD mice	515:544	ORP could significantly reduce TC, TG and LDL level, and increase HDL level in serum of HFD mice.
36863676	3	25	from	level	519:523	arg1	serum					528:532	serum	528:532	serum of HFD mice	528:544	ORP could significantly reduce TC, TG and LDL level, and increase HDL level in serum of HFD mice.
36863676	2	26	theme	model	395:399	arg1	mice					407:410	NAFLD model group mice	389:410	NAFLD model group mice	389:410	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	0	27	theme	ApoE-/-	127:133	arg1	mice					135:138	ApoE-/- mice	127:138	ApoE-/- mice	127:138	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	4	28	theme	disease	661:667	arg1	changes					638:644	pathological changes	625:644	pathological changes of fatty liver disease	625:667	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	2	29	theme	NAFLD	389:393	arg1	mice					407:410	NAFLD model group mice	389:410	NAFLD model group mice	389:410	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	6	30	from	level	875:879	arg1	ratio					826:830	the ratio	822:830	the ratio of Firmicutes/ Bacteroidetes at the phylum level	822:879	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	6	30	from	level	875:879	arg1	abundance					775:783	the abundance	771:783	the abundance of Firmicutes and Proteobacteria	771:816	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	4	31	theme	liver	655:659	arg1	disease					661:667	fatty liver disease	649:667	fatty liver disease	649:667	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	1	32	theme	preventive	190:199	arg1	effects					201:207	the preventive effects	186:207	the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism	186:362	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	2	33	theme	liver	434:438	arg1	lesions					440:446	significant fatty liver lesions	416:446	significant fatty liver lesions	416:446	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	1	34	theme	underlying	343:352	arg1	mechanism					354:362	the underlying mechanism	339:362	the underlying mechanism	339:362	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	7	35	from	composition	934:944	arg1	mice					973:976	NAFLD mice	967:976	NAFLD mice	967:976	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	2	36	theme	fatty	428:432	arg1	lesions					440:446	significant fatty liver lesions	416:446	significant fatty liver lesions	416:446	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	6	37	theme	phylum	868:873	arg1	level					875:879	the phylum level	864:879	the phylum level	864:879	16sRNA analysis showed that ORP could reduce the abundance of Firmicutes and Proteobacteria and the ratio of Firmicutes/ Bacteroidetes at the phylum level.
36863676	1	38	from	effects	201:207	arg1	mechanism					354:362	the underlying mechanism	339:362	the underlying mechanism	339:362	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	38	from	effects	201:207	arg1	ORP					250:252	ORP	250:252	ORP	250:252	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	38	from	effects	201:207	arg1	rivularis					239:247	Ostrea rivularis	232:247	Ostrea rivularis (ORP)	232:253	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	38	from	effects	201:207	arg1	NAFLD					320:324	NAFLD	320:324	NAFLD	320:324	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	38	from	effects	201:207	arg1	disease					311:317	nonalcoholic fatty liver disease	286:317	nonalcoholic fatty liver disease (NAFLD) in mice	286:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	7	39	theme	NAFLD	1108:1112	arg1	occurrence					1094:1103	the occurrence	1090:1103	the occurrence of NAFLD	1090:1112	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	2	40	theme	significant	416:426	arg1	lesions					440:446	significant fatty liver lesions	416:446	significant fatty liver lesions	416:446	The results showed that NAFLD model group mice had significant fatty liver lesions.
36863676	1	41	from	mechanism	354:362	arg1	mice					330:333	mice	330:333	mice	330:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	5	42	theme	barrier	708:714	arg1	function					716:723	the intestinal barrier function	693:723	the intestinal barrier function	693:723	ORP could also enhance the intestinal barrier function.
36863676	8	43	from	polysaccharide	1141:1154	arg1	brief					1118:1122	brief	1118:1122	brief	1118:1122	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	1	44	from	disease	311:317	arg1	mice					330:333	mice	330:333	mice	330:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	45	theme	nonalcoholic	286:297	arg1	NAFLD					320:324	NAFLD	320:324	NAFLD	320:324	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	45	theme	nonalcoholic	286:297	arg1	disease					311:317	nonalcoholic fatty liver disease	286:317	nonalcoholic fatty liver disease (NAFLD) in mice	286:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	46	from	rivularis	239:247	arg1	polysaccharide					212:225	polysaccharide	212:225	polysaccharide from Ostrea rivularis (ORP)	212:253	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	46	from	rivularis	239:247	arg1	effects					201:207	the preventive effects	186:207	the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism	186:362	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	0	47	from	disease	116:122	arg1	mice					135:138	ApoE-/- mice	127:138	ApoE-/- mice	127:138	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	8	48	theme	NAFLD	1188:1192	arg1	treatment					1175:1183	treatment	1175:1183	treatment	1175:1183	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	8	48	theme	NAFLD	1188:1192	arg1	prevention					1160:1169	prevention	1160:1169	prevention	1160:1169	In brief, ORP is an ideal polysaccharide for prevention and treatment of NAFLD, which can be developed as functional food or candidate drugs.
36863676	1	49	theme	fatty	299:303	arg1	NAFLD					320:324	NAFLD	320:324	NAFLD	320:324	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	49	theme	fatty	299:303	arg1	disease					311:317	nonalcoholic fatty liver disease	286:317	nonalcoholic fatty liver disease (NAFLD) in mice	286:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	7	50	theme	gut	949:951	arg1	microbiota					953:962	gut microbiota	949:962	gut microbiota	949:962	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	1	51	theme	polysaccharide	212:225	arg1	effects					201:207	the preventive effects	186:207	the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism	186:362	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	7	52	theme	microbiota	953:962	arg1	composition					934:944	the composition	930:944	the composition of gut microbiota in NAFLD mice	930:976	These results suggested that ORP could regulate the composition of gut microbiota in NAFLD mice, enhance intestinal barrier function, reduce intestinal permeability, and finally delay the progress and reduce the occurrence of NAFLD.
36863676	4	53	theme	pathological	625:636	arg1	changes					638:644	pathological changes	625:644	pathological changes of fatty liver disease	625:667	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	0	54	theme	microbiota	65:74	arg1	balance					50:56	the balance	46:56	the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice	46:138	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	3	55	theme	HFD	537:539	arg1	mice					541:544	HFD mice	537:544	HFD mice	537:544	ORP could significantly reduce TC, TG and LDL level, and increase HDL level in serum of HFD mice.
36863676	4	56	theme	AST	599:601	arg1	contents					581:588	the contents	577:588	the contents of serum AST and ALT	577:609	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	1	57	theme	Ostrea	232:237	arg1	ORP					250:252	ORP	250:252	ORP	250:252	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	57	theme	Ostrea	232:237	arg1	rivularis					239:247	Ostrea rivularis	232:247	Ostrea rivularis (ORP)	232:253	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	0	58	theme	gut	61:63	arg1	microbiota					65:74	gut microbiota	61:74	gut microbiota	61:74	Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.
36863676	1	59	theme	liver	305:309	arg1	NAFLD					320:324	NAFLD	320:324	NAFLD	320:324	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	59	theme	liver	305:309	arg1	disease					311:317	nonalcoholic fatty liver disease	286:317	nonalcoholic fatty liver disease (NAFLD) in mice	286:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	3	60	theme	mice	541:544	arg1	serum					528:532	serum	528:532	serum of HFD mice	528:544	ORP could significantly reduce TC, TG and LDL level, and increase HDL level in serum of HFD mice.
36863676	4	61	theme	serum	593:597	arg1	AST					599:601	serum AST	593:601	serum AST	593:601	Besides, it could also reduce the contents of serum AST and ALT and alleviate pathological changes of fatty liver disease.
36863676	1	62	theme	-induced	277:284	arg1	NAFLD					320:324	NAFLD	320:324	NAFLD	320:324	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
36863676	1	62	theme	-induced	277:284	arg1	disease					311:317	nonalcoholic fatty liver disease	286:317	nonalcoholic fatty liver disease (NAFLD) in mice	286:333	The purpose of this study was to investigate the preventive effects of polysaccharide from Ostrea rivularis (ORP) on high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) in mice and the underlying mechanism.
35921143	0	0	theme	Polysaccharide	96:109	arg1	Monooxygenase					111:123	Lytic Polysaccharide Monooxygenase and Fenton Reaction	90:143	Monooxygenase	111:123	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	0	1	from	Process	15:21	arg1	Depolymerization					36:51	Cellulose Depolymerization	26:51	Cellulose Depolymerization	26:51	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	4	2	theme	enzymatic	705:713	arg1	reaction					737:744	composite enzymatic photocatalysis-Fenton reaction	695:744	a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3	693:773	Here, we designed a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3.
35921143	7	3	theme	innovative	1042:1051	arg1	approach					1053:1060	The innovative approach	1038:1060	The innovative approach	1038:1060	The innovative approach finalized the cellulose degradation process with a total liquefaction yield of 93%.
35921143	2	4	theme	high	398:401	arg1	potential					403:411	a high potential	396:411	a high potential for industrial biorefinery	396:438	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	6	5	theme	light-induced	944:956	arg1	reaction					965:972	a light-induced Fenton reaction	942:972	a light-induced Fenton reaction	942:972	Furthermore, a light-induced Fenton reaction was integrated to increase the liquefaction yield of cellulose.
35921143	0	6	theme	Lytic	90:94	arg1	Monooxygenase					111:123	Lytic Polysaccharide Monooxygenase and Fenton Reaction	90:143	Monooxygenase	111:123	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	1	7	theme	fermentable	187:197	arg1	sugars					199:204	fermentable sugars	187:204	fermentable sugars for biofuel production	187:227	To transform cellulose from biomass into fermentable sugars for biofuel production requires efficient enzymatic degradation of cellulosic feedstocks.
35921143	2	8	contain	has	392:394	arg2	potential					403:411	a high potential	396:411	a high potential for industrial biorefinery	396:438	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	8	contain	has	392:394	arg1	monooxygenase					370:382	lytic polysaccharide monooxygenase	349:382	lytic polysaccharide monooxygenase (LPMO)	349:389	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	8	contain	has	392:394	arg1	family					320:325	The recently discovered family	296:325	The recently discovered family of oxidative enzymes	296:346	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	6	9	theme	Fenton	958:963	arg1	reaction					965:972	a light-induced Fenton reaction	942:972	a light-induced Fenton reaction	942:972	Furthermore, a light-induced Fenton reaction was integrated to increase the liquefaction yield of cellulose.
35921143	2	10	contain	have	489:492	arg2	room					494:497	room	494:497	room for improvement	494:513	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	10	contain	have	489:492	arg1	scalability					471:481	scalability	471:481	scalability	471:481	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	10	contain	have	489:492	arg1	efficiency					456:465	its energy efficiency	445:465	its energy efficiency	445:465	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	11	theme	enzymes	340:346	arg1	monooxygenase					370:382	lytic polysaccharide monooxygenase	349:382	lytic polysaccharide monooxygenase (LPMO)	349:389	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	11	theme	enzymes	340:346	arg1	family					320:325	The recently discovered family	296:325	The recently discovered family of oxidative enzymes	296:346	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	4	12	theme	composite	695:703	arg1	reaction					737:744	composite enzymatic photocatalysis-Fenton reaction	695:744	a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3	693:773	Here, we designed a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3.
35921143	5	13	theme	oxidative	886:894	arg1	degradation					896:906	LPMO-catalyzed cellulose oxidative degradation	861:906	LPMO-catalyzed cellulose oxidative degradation in water	861:915	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	2	14	theme	oxidative	330:338	arg1	enzymes					340:346	oxidative enzymes	330:346	oxidative enzymes	330:346	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	0	15	theme	Fenton	129:134	arg1	Reaction					136:143	Lytic Polysaccharide Monooxygenase and Fenton Reaction	90:143	Reaction	136:143	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	7	16	theme	degradation	1086:1096	arg1	process					1098:1104	the cellulose degradation process	1072:1104	the cellulose degradation process	1072:1104	The innovative approach finalized the cellulose degradation process with a total liquefaction yield of 93%.
35921143	8	17	dep	reactions	1181:1189	arg1	the					1160:1162	the	1160:1162	the	1160:1162	Nevertheless, the complex chemical reactions and products involved in this system require further investigation.
35921143	0	18	theme	Two-Step	6:13	arg1	Process					15:21	Novel Two-Step Process	0:21	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.	0:144	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	5	19	theme	α-Fe2O3	801:807	arg1	nanoparticles					809:821	α-Fe2O3 nanoparticles	801:821	α-Fe2O3 nanoparticles	801:821	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	5	19	theme	α-Fe2O3	801:807	arg1	catalyst					838:845	a composite catalyst	826:845	a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water	826:915	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	8	20	theme	complex	1164:1170	arg1	reactions					1181:1189	complex chemical reactions	1164:1189	complex chemical reactions	1164:1189	Nevertheless, the complex chemical reactions and products involved in this system require further investigation.
35921143	1	21	theme	biofuel	210:216	arg1	production					218:227	biofuel production	210:227	biofuel production	210:227	To transform cellulose from biomass into fermentable sugars for biofuel production requires efficient enzymatic degradation of cellulosic feedstocks.
35921143	0	22	theme	Novel	0:4	arg1	Process					15:21	Novel Two-Step Process	0:21	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.	0:144	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	2	23	theme	industrial	417:426	arg1	biorefinery					428:438	industrial biorefinery	417:438	industrial biorefinery	417:438	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	6	24	theme	cellulose	1027:1035	arg1	yield					1018:1022	the liquefaction yield	1001:1022	the liquefaction yield of cellulose	1001:1035	Furthermore, a light-induced Fenton reaction was integrated to increase the liquefaction yield of cellulose.
35921143	2	25	theme	polysaccharide	355:368	arg1	LPMO					385:388	LPMO	385:388	LPMO	385:388	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	25	theme	polysaccharide	355:368	arg1	monooxygenase					370:382	lytic polysaccharide monooxygenase	349:382	lytic polysaccharide monooxygenase (LPMO)	349:389	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	25	theme	polysaccharide	355:368	arg1	family					320:325	The recently discovered family	296:325	The recently discovered family of oxidative enzymes	296:346	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	5	26	theme	cellulose	876:884	arg1	degradation					896:906	LPMO-catalyzed cellulose oxidative degradation	861:906	LPMO-catalyzed cellulose oxidative degradation in water	861:915	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	5	27	theme	LPMO-catalyzed	861:874	arg1	degradation					896:906	LPMO-catalyzed cellulose oxidative degradation	861:906	LPMO-catalyzed cellulose oxidative degradation in water	861:915	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	7	28	theme	%	1143:1143	arg1	yield					1132:1136	a total liquefaction yield	1111:1136	a total liquefaction yield of 93%	1111:1143	The innovative approach finalized the cellulose degradation process with a total liquefaction yield of 93%.
35921143	2	29	theme	lytic	349:353	arg1	LPMO					385:388	LPMO	385:388	LPMO	385:388	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	29	theme	lytic	349:353	arg1	monooxygenase					370:382	lytic polysaccharide monooxygenase	349:382	lytic polysaccharide monooxygenase (LPMO)	349:389	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	29	theme	lytic	349:353	arg1	family					320:325	The recently discovered family	296:325	The recently discovered family of oxidative enzymes	296:346	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	1	30	theme	efficient	238:246	arg1	degradation					258:268	efficient enzymatic degradation	238:268	efficient enzymatic degradation of cellulosic feedstocks	238:293	To transform cellulose from biomass into fermentable sugars for biofuel production requires efficient enzymatic degradation of cellulosic feedstocks.
35921143	8	31	theme	chemical	1172:1179	arg1	reactions					1181:1189	complex chemical reactions	1164:1189	complex chemical reactions	1164:1189	Nevertheless, the complex chemical reactions and products involved in this system require further investigation.
35921143	1	32	theme	enzymatic	248:256	arg1	degradation					258:268	efficient enzymatic degradation	238:268	efficient enzymatic degradation of cellulosic feedstocks	238:293	To transform cellulose from biomass into fermentable sugars for biofuel production requires efficient enzymatic degradation of cellulosic feedstocks.
35921143	2	33	theme	energy	449:454	arg1	efficiency					456:465	its energy efficiency	445:465	its energy efficiency	445:465	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	0	34	theme	Cellulose	26:34	arg1	Depolymerization					36:51	Cellulose Depolymerization	26:51	Cellulose Depolymerization	26:51	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	6	35	theme	liquefaction	1005:1016	arg1	yield					1018:1022	the liquefaction yield	1001:1022	the liquefaction yield of cellulose	1001:1035	Furthermore, a light-induced Fenton reaction was integrated to increase the liquefaction yield of cellulose.
35921143	5	36	from	degradation	896:906	arg1	water					911:915	water	911:915	water	911:915	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	8	37	theme	further	1236:1242	arg1	investigation					1244:1256	further investigation	1236:1256	further investigation	1236:1256	Nevertheless, the complex chemical reactions and products involved in this system require further investigation.
35921143	0	38	theme	Hematite-Mediated	54:70	arg1	Photocatalysis					72:85	Hematite-Mediated Photocatalysis	54:85	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.	0:144	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	7	39	theme	total	1113:1117	arg1	yield					1132:1136	a total liquefaction yield	1111:1136	a total liquefaction yield of 93%	1111:1143	The innovative approach finalized the cellulose degradation process with a total liquefaction yield of 93%.
35921143	3	40	theme	low	617:619	arg1	cost					621:624	low cost	617:624	low cost	617:624	Hematite (α-Fe2O3) can act as a photocatalyst by providing electrons to LPMO-catalyzed reactions, is low cost, and is found abundantly on the Earth's surface.
35921143	4	41	theme	reaction	737:744	arg1	system					746:751	a composite enzymatic photocatalysis-Fenton reaction system	693:751	a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3	693:773	Here, we designed a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3.
35921143	5	42	theme	composite	828:836	arg1	nanoparticles					809:821	α-Fe2O3 nanoparticles	801:821	α-Fe2O3 nanoparticles	801:821	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	5	42	theme	composite	828:836	arg1	catalyst					838:845	a composite catalyst	826:845	a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water	826:915	The feasibility of using α-Fe2O3 nanoparticles as a composite catalyst to facilitate LPMO-catalyzed cellulose oxidative degradation in water was tested.
35921143	7	43	theme	liquefaction	1119:1130	arg1	yield					1132:1136	a total liquefaction yield	1111:1136	a total liquefaction yield of 93%	1111:1143	The innovative approach finalized the cellulose degradation process with a total liquefaction yield of 93%.
35921143	4	44	theme	photocatalysis-Fenton	715:735	arg1	reaction					737:744	composite enzymatic photocatalysis-Fenton reaction	695:744	a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3	693:773	Here, we designed a composite enzymatic photocatalysis-Fenton reaction system based on nano-α-Fe2O3.
35921143	7	45	theme	cellulose	1076:1084	arg1	process					1098:1104	the cellulose degradation process	1072:1104	the cellulose degradation process	1072:1104	The innovative approach finalized the cellulose degradation process with a total liquefaction yield of 93%.
35921143	3	46	theme	LPMO-catalyzed	588:601	arg1	reactions					603:611	LPMO-catalyzed reactions	588:611	LPMO-catalyzed reactions	588:611	Hematite (α-Fe2O3) can act as a photocatalyst by providing electrons to LPMO-catalyzed reactions, is low cost, and is found abundantly on the Earth's surface.
35921143	0	47	dep	Process	15:21	arg1	Photocatalysis					72:85	Hematite-Mediated Photocatalysis	54:85	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.	0:144	Novel Two-Step Process in Cellulose Depolymerization: Hematite-Mediated Photocatalysis by Lytic Polysaccharide Monooxygenase and Fenton Reaction.
35921143	3	48	located	found	634:638	arg2	Hematite					516:523	Hematite	516:523	Hematite (α-Fe2O3)	516:533	Hematite (α-Fe2O3) can act as a photocatalyst by providing electrons to LPMO-catalyzed reactions, is low cost, and is found abundantly on the Earth's surface.
35921143	3	48	located	found	634:638	arg2	photocatalyst					548:560	a photocatalyst	546:560	a photocatalyst	546:560	Hematite (α-Fe2O3) can act as a photocatalyst by providing electrons to LPMO-catalyzed reactions, is low cost, and is found abundantly on the Earth's surface.
35921143	3	48	located	found	634:638	arg1	surface					666:672	the Earth's surface	654:672	the Earth's surface	654:672	Hematite (α-Fe2O3) can act as a photocatalyst by providing electrons to LPMO-catalyzed reactions, is low cost, and is found abundantly on the Earth's surface.
35921143	3	48	located	found	634:638	arg2	α-Fe2O3					526:532	α-Fe2O3	526:532	α-Fe2O3	526:532	Hematite (α-Fe2O3) can act as a photocatalyst by providing electrons to LPMO-catalyzed reactions, is low cost, and is found abundantly on the Earth's surface.
35921143	1	49	theme	cellulosic	273:282	arg1	feedstocks					284:293	cellulosic feedstocks	273:293	cellulosic feedstocks	273:293	To transform cellulose from biomass into fermentable sugars for biofuel production requires efficient enzymatic degradation of cellulosic feedstocks.
35921143	1	50	theme	feedstocks	284:293	arg1	degradation					258:268	efficient enzymatic degradation	238:268	efficient enzymatic degradation of cellulosic feedstocks	238:293	To transform cellulose from biomass into fermentable sugars for biofuel production requires efficient enzymatic degradation of cellulosic feedstocks.
35921143	2	51	theme	discovered	309:318	arg1	monooxygenase					370:382	lytic polysaccharide monooxygenase	349:382	lytic polysaccharide monooxygenase (LPMO)	349:389	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
35921143	2	51	theme	discovered	309:318	arg1	family					320:325	The recently discovered family	296:325	The recently discovered family of oxidative enzymes	296:346	The recently discovered family of oxidative enzymes, lytic polysaccharide monooxygenase (LPMO), has a high potential for industrial biorefinery, but its energy efficiency and scalability still have room for improvement.
36972173	5	0	theme	N-linked	649:656	arg1	sites					676:680	the 22 N-linked glycan attachment sites	642:680	the 22 N-linked glycan attachment sites present on SARS-CoV-2	642:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	1	1	theme	pandemics	153:161	arg1	risk					136:139	a significant risk	122:139	a significant risk of emergent pandemics	122:161	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	7	2	theme	shield	1020:1025	arg1	density					1027:1033	a low glycan shield density	1007:1033	a low glycan shield density	1007:1033	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	5	3	theme	glycan	658:663	arg1	sites					676:680	the 22 N-linked glycan attachment sites	642:680	the 22 N-linked glycan attachment sites present on SARS-CoV-2	642:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	6	4	theme	glycan	815:820	arg1	sites					822:826	glycan sites	815:826	glycan sites in the N-terminal domain	815:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	1	5	theme	pandemic	245:252	arg1	coronavirus					218:228	the severe acute respiratory syndrome coronavirus	180:228	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	180:252	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	5	6	theme	attachment	665:674	arg1	sites					676:680	the 22 N-linked glycan attachment sites	642:680	the 22 N-linked glycan attachment sites present on SARS-CoV-2	642:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	3	7	theme	potential	521:529	arg1	epitopes					540:547	potential antibody epitopes	521:547	potential antibody epitopes on spike glycoproteins	521:570	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	3	8	theme	spike	552:556	arg1	glycoproteins					558:570	spike glycoproteins	552:570	spike glycoproteins	552:570	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	1	9	theme	sarbecoviruses	97:110	arg1	reservoirs					83:92	Animal reservoirs	76:92	Animal reservoirs of sarbecoviruses	76:110	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	8	10	theme	S2	1040:1041	arg1	domain					1043:1048	The S2 domain	1036:1048	The S2 domain	1036:1048	The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.
36972173	8	11	theme	attractive	1079:1088	arg1	target					1090:1095	a more attractive target	1072:1095	a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response	1072:1179	The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.
36972173	2	12	theme	further	342:348	arg1	zoonosis					362:369	further coronavirus zoonosis	342:369	further coronavirus zoonosis	342:369	Vaccines remain successful at limiting severe disease and death, but the potential for further coronavirus zoonosis motivates the search for pan-coronavirus vaccines.
36972173	8	13	theme	pan-coronavirus	1147:1161	arg1	response					1172:1179	a pan-coronavirus antibody response	1145:1179	a pan-coronavirus antibody response	1145:1179	The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.
36972173	3	14	theme	shields	477:483	arg1	understanding					449:461	a better understanding	440:461	a better understanding	440:461	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	3	15	theme	better	442:447	arg1	understanding					449:461	a better understanding	440:461	a better understanding	440:461	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	7	16	contain	contain	942:948	arg1	sites					894:898	glycosylation sites	880:898	glycosylation sites in the S2 domain	880:915	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	7	16	contain	contain	942:948	arg2	abundance					956:964	a low abundance	950:964	a low abundance of oligomannose-type glycans	950:993	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	1	17	theme	Animal	76:81	arg1	reservoirs					83:92	Animal reservoirs	76:92	Animal reservoirs of sarbecoviruses	76:110	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	8	18	theme	antibody	1163:1170	arg1	response					1172:1179	a pan-coronavirus antibody response	1145:1179	a pan-coronavirus antibody response	1145:1179	The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.
36972173	7	19	gly	glycosylation	880:892	arg2	sites					894:898	glycosylation sites	880:898	glycosylation sites in the S2 domain	880:915	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	7	20	theme	S2	907:908	arg1	domain					910:915	the S2 domain	903:915	the S2 domain	903:915	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	7	21	from	sites	894:898	arg1	domain					910:915	the S2 domain	903:915	the S2 domain	903:915	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	6	22	theme	processing	795:804	arg1	state					806:810	the processing state	791:810	the processing state at glycan sites in the N-terminal domain	791:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	5	23	attach	present	682:688	arg2	sites					676:680	the 22 N-linked glycan attachment sites	642:680	the 22 N-linked glycan attachment sites present on SARS-CoV-2	642:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	5	23	attach	present	682:688	arg1	SARS-CoV-2					693:702	SARS-CoV-2	693:702	SARS-CoV-2	693:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	3	24	theme	glycan	470:475	arg1	shields					477:483	the glycan shields	466:483	the glycan shields of coronaviruses	466:500	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	7	25	theme	oligomannose-type	969:985	arg1	glycans					987:993	oligomannose-type glycans	969:993	oligomannose-type glycans	969:993	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	2	26	theme	severe	294:299	arg1	disease					301:307	severe disease	294:307	severe disease	294:307	Vaccines remain successful at limiting severe disease and death, but the potential for further coronavirus zoonosis motivates the search for pan-coronavirus vaccines.
36972173	1	27	theme	acute	191:195	arg1	coronavirus					218:228	the severe acute respiratory syndrome coronavirus	180:228	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	180:252	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	6	28	from	differences	776:786	arg1	state					806:810	the processing state	791:810	the processing state at glycan sites in the N-terminal domain	791:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	6	28	from	differences	776:786	arg1	sites					822:826	glycan sites	815:826	glycan sites in the N-terminal domain	815:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	5	29	link	N-linked	649:656	arg1	sites					676:680	the 22 N-linked glycan attachment sites	642:680	the 22 N-linked glycan attachment sites present on SARS-CoV-2	642:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	1	30	theme	respiratory	197:207	arg1	coronavirus					218:228	the severe acute respiratory syndrome coronavirus	180:228	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	180:252	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	0	31	theme	glycan	21:26	arg1	diversity					4:12	The diversity	0:12	The diversity of the glycan	0:26	The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2.
36972173	6	32	from	sites	822:826	arg1	state					806:810	the processing state	791:810	the processing state at glycan sites in the N-terminal domain	791:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	6	32	from	sites	822:826	arg1	N165					862:865	N165	862:865	N165	862:865	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	6	32	from	sites	822:826	arg1	differences					776:786	significant differences	764:786	significant differences	764:786	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	6	32	from	sites	822:826	arg1	domain					846:851	the N-terminal domain	831:851	the N-terminal domain	831:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	2	33	theme	pan-coronavirus	396:410	arg1	vaccines					412:419	pan-coronavirus vaccines	396:419	pan-coronavirus vaccines	396:419	Vaccines remain successful at limiting severe disease and death, but the potential for further coronavirus zoonosis motivates the search for pan-coronavirus vaccines.
36972173	5	34	theme	present	682:688	arg1	sites					676:680	the 22 N-linked glycan attachment sites	642:680	the 22 N-linked glycan attachment sites present on SARS-CoV-2	642:702	Of the 22 N-linked glycan attachment sites present on SARS-CoV-2, 15 are shared by all 12 sarbecoviruses.
36972173	8	35	theme	immunogen	1101:1109	arg1	efforts					1118:1124	immunogen design efforts	1101:1124	immunogen design efforts aiming to generate a pan-coronavirus antibody response	1101:1179	The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.
36972173	2	36	theme	coronavirus	350:360	arg1	zoonosis					362:369	further coronavirus zoonosis	342:369	further coronavirus zoonosis	342:369	Vaccines remain successful at limiting severe disease and death, but the potential for further coronavirus zoonosis motivates the search for pan-coronavirus vaccines.
36972173	6	37	theme	N-terminal	835:844	arg1	domain					846:851	the N-terminal domain	831:851	the N-terminal domain	831:851	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	1	38	theme	emergent	144:151	arg1	pandemics					153:161	emergent pandemics	144:161	emergent pandemics	144:161	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	7	39	theme	glycans	987:993	arg1	abundance					956:964	a low abundance	950:964	a low abundance of oligomannose-type glycans	950:993	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	6	40	theme	significant	764:774	arg1	N165					862:865	N165	862:865	N165	862:865	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	6	40	theme	significant	764:774	arg1	differences					776:786	significant differences	764:786	significant differences	764:786	However, there are significant differences in the processing state at glycan sites in the N-terminal domain, such as N165.
36972173	7	41	theme	low	1009:1011	arg1	density					1027:1033	a low glycan shield density	1007:1033	a low glycan shield density	1007:1033	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	1	42	theme	significant	124:134	arg1	risk					136:139	a significant risk	122:139	a significant risk of emergent pandemics	122:161	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	4	43	theme	sarbecovirus	610:621	arg1	shields					630:636	12 sarbecovirus glycan shields	607:636	12 sarbecovirus glycan shields	607:636	Here, we compare the structure of 12 sarbecovirus glycan shields.
36972173	7	44	theme	glycan	1013:1018	arg1	density					1027:1033	a low glycan shield density	1007:1033	a low glycan shield density	1007:1033	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	3	45	theme	coronaviruses	488:500	arg1	shields					477:483	the glycan shields	466:483	the glycan shields of coronaviruses	466:500	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	7	46	theme	glycosylation	880:892	arg1	sites					894:898	glycosylation sites	880:898	glycosylation sites in the S2 domain	880:915	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	8	47	theme	design	1111:1116	arg1	efforts					1118:1124	immunogen design efforts	1101:1124	immunogen design efforts aiming to generate a pan-coronavirus antibody response	1101:1179	The S2 domain may therefore provide a more attractive target for immunogen design efforts aiming to generate a pan-coronavirus antibody response.
36972173	1	48	theme	syndrome	209:216	arg1	coronavirus					218:228	the severe acute respiratory syndrome coronavirus	180:228	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	180:252	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	1	49	theme	severe	184:189	arg1	coronavirus					218:228	the severe acute respiratory syndrome coronavirus	180:228	the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic	180:252	Animal reservoirs of sarbecoviruses represent a significant risk of emergent pandemics, as evidenced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
36972173	3	50	gly	glycoproteins	558:570	arg1	glycoproteins					558:570	spike glycoproteins	552:570	spike glycoproteins	552:570	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	4	51	theme	shields	630:636	arg1	structure					594:602	the structure	590:602	the structure of 12 sarbecovirus glycan shields	590:636	Here, we compare the structure of 12 sarbecovirus glycan shields.
36972173	0	52	theme	related	53:59	arg1	sarbecoviruses					38:51	sarbecoviruses	38:51	sarbecoviruses related to SARS-CoV-2	38:73	The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2.
36972173	7	53	theme	low	952:954	arg1	abundance					956:964	a low abundance	950:964	a low abundance of oligomannose-type glycans	950:993	Conversely, glycosylation sites in the S2 domain are highly conserved and contain a low abundance of oligomannose-type glycans, suggesting a low glycan shield density.
36972173	3	54	theme	antibody	531:538	arg1	epitopes					540:547	potential antibody epitopes	521:547	potential antibody epitopes on spike glycoproteins	521:570	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	3	55	from	epitopes	540:547	arg1	glycoproteins					558:570	spike glycoproteins	552:570	spike glycoproteins	552:570	This necessitates a better understanding of the glycan shields of coronaviruses, which can occlude potential antibody epitopes on spike glycoproteins.
36972173	4	56	theme	glycan	623:628	arg1	shields					630:636	12 sarbecovirus glycan shields	607:636	12 sarbecovirus glycan shields	607:636	Here, we compare the structure of 12 sarbecovirus glycan shields.
35698346	5	0	theme	oxalate	617:623	arg1	extract					625:631	The oxalate extract	613:631	The oxalate extract	613:631	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	7	1	theme	lamella	948:954	arg1	disappearance					920:932	the disappearance	916:932	the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength	916:1034	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	1	2	theme	elementary	139:148	arg1	fibres					150:155	elementary fibres	139:155	elementary fibres glued together thanks to the middle lamella	139:199	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	0	3	theme	mechanical	66:75	arg1	properties					77:86	the mechanical properties	62:86	the mechanical properties of flax fibre bundles	62:108	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	6	4	theme	KOH	795:797	arg1	stage					799:803	The KOH stage	791:803	The KOH stage	791:803	The KOH stage resulted in the appearance of cellulose II in flax bundles.
35698346	1	5	theme	fibres	150:155	arg1	bundles					117:123	Fibre bundles	111:123	Fibre bundles	111:123	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	5	theme	fibres	150:155	arg1	fraction					219:226	the main fraction	210:226	the main fraction in plant fibre composites	210:252	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	5	theme	fibres	150:155	arg1	groups					129:134	groups	129:134	groups of elementary fibres glued together thanks to the middle lamella	129:199	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	5	theme	fibres	150:155	arg1	fibres					150:155	elementary fibres	139:155	elementary fibres glued together thanks to the middle lamella	139:199	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	0	6	theme	flax	91:94	arg1	bundles					102:108	flax fibre bundles	91:108	flax fibre bundles	91:108	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	0	7	from	Impact	0:5	arg1	properties					77:86	the mechanical properties	62:86	the mechanical properties of flax fibre bundles	62:108	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	1	8	theme	plant	231:235	arg1	composites					243:252	plant fibre composites	231:252	plant fibre composites	231:252	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	9	from	groups	129:134	arg1	composites					243:252	plant fibre composites	231:252	plant fibre composites	231:252	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	2	10	theme	fibre	325:329	arg1	bundles					331:337	flax fibre bundles	320:337	flax fibre bundles	320:337	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	2	10	theme	fibre	325:329	arg1	composition					349:359	chemical composition	340:359	chemical composition	340:359	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	2	10	theme	fibre	325:329	arg1	structure					375:383	cellulose structure	365:383	cellulose structure	365:383	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	1	11	theme	fibre	237:241	arg1	composites					243:252	plant fibre composites	231:252	plant fibre composites	231:252	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	0	12	theme	bundles	102:108	arg1	properties					77:86	the mechanical properties	62:86	the mechanical properties of flax fibre bundles	62:108	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	2	13	theme	cellulose	365:373	arg1	bundles					331:337	flax fibre bundles	320:337	flax fibre bundles	320:337	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	2	13	theme	cellulose	365:373	arg1	structure					375:383	cellulose structure	365:383	cellulose structure	365:383	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	0	14	theme	fibre	96:100	arg1	bundles					102:108	flax fibre bundles	91:108	flax fibre bundles	91:108	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	4	15	theme	Fibre	466:470	arg1	bundles					472:478	Fibre bundles	466:478	Fibre bundles	466:478	Fibre bundles were first depectinated by oxalate extraction, and then the hemicelluloses were extracted by LiCl/dimethyl sulfoxide (DMSO) and KOH.
35698346	8	16	theme	fibre	1050:1054	arg1	composition					1063:1073	the fibre bundle composition	1046:1073	the fibre bundle composition	1046:1073	Finally, the fibre bundle composition, ultrastructure and mechanical properties are discussed together in view of the thin middle lamella.
35698346	7	17	theme	tensile	991:997	arg1	modulus					1007:1013	the tensile Young's modulus	987:1013	the tensile Young's modulus	987:1013	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	5	18	theme	xyloglucans	778:788	arg1	extract					767:773	the KOH extract	759:773	the KOH extract of xyloglucans	759:788	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	5	18	theme	xyloglucans	778:788	arg1	glucomannans					742:753	glucomannans	742:753	glucomannans	742:753	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	6	19	from	appearance	821:830	arg1	bundles					856:862	flax bundles	851:862	flax bundles	851:862	The KOH stage resulted in the appearance of cellulose II in flax bundles.
35698346	2	20	theme	chemical	340:347	arg1	bundles					331:337	flax fibre bundles	320:337	flax fibre bundles	320:337	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	2	20	theme	chemical	340:347	arg1	composition					349:359	chemical composition	340:359	chemical composition	340:359	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	0	21	theme	wall	15:18	arg1	polymers					50:57	cell wall non-cellulosic and cellulosic polymers	10:57	cell wall non-cellulosic and cellulosic polymers	10:57	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	7	22	theme	hemicelluloses	894:907	arg1	extraction					869:878	The extraction	865:878	The extraction of pectin and hemicelluloses	865:907	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	8	23	theme	middle	1160:1165	arg1	lamella					1167:1173	the thin middle lamella	1151:1173	the thin middle lamella	1151:1173	Finally, the fibre bundle composition, ultrastructure and mechanical properties are discussed together in view of the thin middle lamella.
35698346	3	24	theme	biopolymer	427:436	arg1	extraction					438:447	a sequential biopolymer extraction	414:447	a sequential biopolymer extraction	414:447	To do so, a sequential biopolymer extraction was implemented.
35698346	0	25	theme	cell	10:13	arg1	polymers					50:57	cell wall non-cellulosic and cellulosic polymers	10:57	cell wall non-cellulosic and cellulosic polymers	10:57	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	2	26	theme	flax	320:323	arg1	bundles					331:337	flax fibre bundles	320:337	flax fibre bundles	320:337	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	2	26	theme	flax	320:323	arg1	composition					349:359	chemical composition	340:359	chemical composition	340:359	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	2	26	theme	flax	320:323	arg1	structure					375:383	cellulose structure	365:383	cellulose structure	365:383	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	1	27	theme	middle	186:191	arg1	lamella					193:199	the middle lamella	182:199	the middle lamella	182:199	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	28	from	fraction	219:226	arg1	composites					243:252	plant fibre composites	231:252	plant fibre composites	231:252	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	6	29	theme	cellulose	835:843	arg1	appearance					821:830	the appearance	817:830	the appearance of cellulose II in flax bundles	817:862	The KOH stage resulted in the appearance of cellulose II in flax bundles.
35698346	0	30	theme	non-cellulosic	20:33	arg1	polymers					50:57	cell wall non-cellulosic and cellulosic polymers	10:57	cell wall non-cellulosic and cellulosic polymers	10:57	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	4	31	theme	oxalate	507:513	arg1	extraction					515:524	oxalate extraction	507:524	oxalate extraction	507:524	Fibre bundles were first depectinated by oxalate extraction, and then the hemicelluloses were extracted by LiCl/dimethyl sulfoxide (DMSO) and KOH.
35698346	5	32	theme	KOH	763:765	arg1	extract					767:773	the KOH extract	759:773	the KOH extract of xyloglucans	759:788	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	7	33	theme	Young	999:1003	arg1	modulus					1007:1013	the tensile Young's modulus	987:1013	the tensile Young's modulus	987:1013	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	3	34	theme	sequential	416:425	arg1	extraction					438:447	a sequential biopolymer extraction	414:447	a sequential biopolymer extraction	414:447	To do so, a sequential biopolymer extraction was implemented.
35698346	0	35	theme	polymers	50:57	arg1	Impact					0:5	Impact	0:5	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.	0:109	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	5	36	theme	LiCl	706:709	arg1	extract					711:717	the LiCl extract	702:717	the LiCl extract	702:717	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	8	37	theme	lamella	1167:1173	arg1	view					1143:1146	view	1143:1146	view of the thin middle lamella	1143:1173	Finally, the fibre bundle composition, ultrastructure and mechanical properties are discussed together in view of the thin middle lamella.
35698346	6	38	theme	flax	851:854	arg1	bundles					856:862	flax bundles	851:862	flax bundles	851:862	The KOH stage resulted in the appearance of cellulose II in flax bundles.
35698346	7	39	theme	maximum	1019:1025	arg1	strength					1027:1034	maximum strength	1019:1034	maximum strength	1019:1034	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	0	40	theme	cellulosic	39:48	arg1	polymers					50:57	cell wall non-cellulosic and cellulosic polymers	10:57	cell wall non-cellulosic and cellulosic polymers	10:57	Impact of cell wall non-cellulosic and cellulosic polymers on the mechanical properties of flax fibre bundles.
35698346	8	41	theme	bundle	1056:1061	arg1	composition					1063:1073	the fibre bundle composition	1046:1073	the fibre bundle composition	1046:1073	Finally, the fibre bundle composition, ultrastructure and mechanical properties are discussed together in view of the thin middle lamella.
35698346	1	42	theme	Fibre	111:115	arg1	bundles					117:123	Fibre bundles	111:123	Fibre bundles	111:123	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	42	theme	Fibre	111:115	arg1	groups					129:134	groups	129:134	groups of elementary fibres glued together thanks to the middle lamella	129:199	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	1	42	theme	Fibre	111:115	arg1	fibres					150:155	elementary fibres	139:155	elementary fibres glued together thanks to the middle lamella	139:199	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
35698346	5	43	theme	type	668:671	arg1	rhamnogalacturonans					675:693	type I rhamnogalacturonans	668:693	type I rhamnogalacturonans	668:693	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	2	44	theme	mechanical	295:304	arg1	properties					306:315	the mechanical properties	291:315	the mechanical properties of flax fibre bundles, chemical composition and cellulose structure	291:383	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	7	45	theme	pectin	883:888	arg1	extraction					869:878	The extraction	865:878	The extraction of pectin and hemicelluloses	865:907	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	5	46	theme	I	673:673	arg1	rhamnogalacturonans					675:693	type I rhamnogalacturonans	668:693	type I rhamnogalacturonans	668:693	The oxalate extract consisted of homogalacturonans and type I rhamnogalacturonans, while the LiCl extract was composed mainly of glucomannans and the KOH extract of xyloglucans.
35698346	7	47	theme	concomitant	956:966	arg1	lamella					948:954	the middle lamella	937:954	the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength	937:1034	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	8	48	theme	mechanical	1095:1104	arg1	properties					1106:1115	mechanical properties	1095:1115	mechanical properties	1095:1115	Finally, the fibre bundle composition, ultrastructure and mechanical properties are discussed together in view of the thin middle lamella.
35698346	7	49	with	concomitant	956:966	arg1	decrease					975:982	a decrease	973:982	a decrease in the tensile Young's modulus and maximum strength	973:1034	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	4	50	theme	LiCl/dimethyl	573:585	arg1	DMSO					598:601	DMSO	598:601	DMSO	598:601	Fibre bundles were first depectinated by oxalate extraction, and then the hemicelluloses were extracted by LiCl/dimethyl sulfoxide (DMSO) and KOH.
35698346	4	50	theme	LiCl/dimethyl	573:585	arg1	sulfoxide					587:595	LiCl/dimethyl sulfoxide	573:595	LiCl/dimethyl sulfoxide (DMSO)	573:602	Fibre bundles were first depectinated by oxalate extraction, and then the hemicelluloses were extracted by LiCl/dimethyl sulfoxide (DMSO) and KOH.
35698346	8	51	theme	thin	1155:1158	arg1	lamella					1167:1173	the thin middle lamella	1151:1173	the thin middle lamella	1151:1173	Finally, the fibre bundle composition, ultrastructure and mechanical properties are discussed together in view of the thin middle lamella.
35698346	7	52	theme	middle	941:946	arg1	lamella					948:954	the middle lamella	937:954	the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength	937:1034	The extraction of pectin and hemicelluloses led to the disappearance of the middle lamella concomitant with a decrease in the tensile Young's modulus and maximum strength.
35698346	2	53	theme	bundles	331:337	arg1	properties					306:315	the mechanical properties	291:315	the mechanical properties of flax fibre bundles, chemical composition and cellulose structure	291:383	In this study, relationship between the mechanical properties of flax fibre bundles, chemical composition and cellulose structure were investigated.
35698346	1	54	theme	main	214:217	arg1	fraction					219:226	the main fraction	210:226	the main fraction in plant fibre composites	210:252	Fibre bundles are groups of elementary fibres glued together thanks to the middle lamella, and are the main fraction in plant fibre composites.
37028629	1	0	theme	oil	272:274	arg1	addition					193:200	the addition	189:200	the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS)	189:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	6	1	theme	microscopy	1124:1133	arg1	analysis					1135:1142	Scanning electron microscopy analysis	1106:1142	Scanning electron microscopy analysis	1106:1142	Scanning electron microscopy analysis indicated that nZnO and TTEO were evenly dispersed in the SSPS matrix.
37028629	2	2	theme	functional	441:450	arg1	properties					452:461	physical, mechanical and functional properties	416:461	physical, mechanical and functional properties of SSPS films	416:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	7	3	dep	nZnO	1241:1244	arg1	endowed					1255:1261	endowed	1255:1261	endowed	1255:1261	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	7	4	theme	excellent	1282:1290	arg1	activity					1306:1313	excellent antibacterial activity	1282:1313	excellent antibacterial activity against E. coli and S. aureus	1282:1343	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	0	5	theme	oil	61:63	arg1	effect					12:17	Synergistic effect	0:17	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films	0:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	0	6	from	effect	12:17	arg1	properties					72:81	the properties	68:81	the properties of soluble soybean polysaccharide films	68:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	4	7	theme	nZnO	766:769	arg1	addition					745:752	The addition	741:752	The addition of TTEO and nZnO	741:769	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	8	dep	%	944:944	arg1	to					946:947	to	946:947	to	946:947	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	5	9	theme	scavenging	974:983	arg1	activity					985:992	The DPPH radical scavenging activity	957:992	The DPPH radical scavenging activity of the films	957:1005	The DPPH radical scavenging activity of the films significantly increased from 46.8 % (SSPS) to 67.7 % (SSPS/TTEO/nZnO) due to the presence of TTEO.
37028629	2	10	theme	physical	416:423	arg1	properties					452:461	physical, mechanical and functional properties	416:461	physical, mechanical and functional properties of SSPS films	416:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	3	11	theme	thermal	591:597	arg1	stability					599:607	thermal stability	591:607	thermal stability	591:607	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	11	theme	thermal	591:597	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	4	12	theme	significant	778:788	arg1	effect					790:795	no significant effect	775:795	no significant effect	775:795	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	13	contain	had	771:773	arg2	effect					790:795	no significant effect	775:795	no significant effect	775:795	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	13	contain	had	771:773	arg1	addition					745:752	The addition	741:752	The addition of TTEO and nZnO	741:769	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	3	14	theme	light	721:725	arg1	transmission					727:738	ultraviolet light transmission	709:738	ultraviolet light transmission	709:738	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	7	15	theme	nZnO	1241:1244	arg1	effect					1231:1236	The synergistic effect	1215:1236	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus	1215:1343	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	7	16	theme	active	1420:1425	arg1	applications					1437:1448	active packaging applications	1420:1448	active packaging applications	1420:1448	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	7	17	theme	SSPS	1267:1270	arg1	film					1272:1275	the SSPS film	1263:1275	the SSPS film	1263:1275	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	4	18	from	break	839:843	arg1	elongation					825:834	elongation	825:834	elongation	825:834	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	18	from	break	839:843	arg1	strength					812:819	tensile strength	804:819	tensile strength	804:819	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	0	19	theme	soluble	86:92	arg1	films					117:121	soluble soybean polysaccharide films	86:121	soluble soybean polysaccharide films	86:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	3	20	theme	surface	628:634	arg1	wettability					636:646	surface wettability	628:646	surface wettability	628:646	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	20	theme	surface	628:634	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	7	21	theme	packaging	1427:1435	arg1	applications					1437:1448	active packaging applications	1420:1448	active packaging applications	1420:1448	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	2	22	dep	microstructure	397:410	arg1	the					393:395	the	393:395	the	393:395	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	4	23	theme	85.5 	939:943	arg1	%					944:944	%	944:944	%	944:944	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	24	dep	strength	812:819	arg1	the					800:802	the	800:802	the	800:802	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	3	25	theme	water	610:614	arg1	resistance					616:625	water resistance	610:625	water resistance	610:625	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	25	theme	water	610:614	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	26	theme	ultraviolet	709:719	arg1	transmission					727:738	ultraviolet light transmission	709:738	ultraviolet light transmission	709:738	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	27	theme	color	659:663	arg1	difference					665:674	total color difference	653:674	total color difference	653:674	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	27	theme	color	659:663	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	2	28	theme	combination	361:371	arg1	effect					347:352	The effect	343:352	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films	343:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	2	29	theme	nZnO	376:379	arg1	combination					361:371	the combination	357:371	the combination of nZnO and TTEO	357:388	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	2	30	theme	mechanical	426:435	arg1	properties					452:461	physical, mechanical and functional properties	416:461	physical, mechanical and functional properties of SSPS films	416:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	5	31	theme	DPPH	961:964	arg1	activity					985:992	The DPPH radical scavenging activity	957:992	The DPPH radical scavenging activity of the films	957:1005	The DPPH radical scavenging activity of the films significantly increased from 46.8 % (SSPS) to 67.7 % (SSPS/TTEO/nZnO) due to the presence of TTEO.
37028629	1	32	theme	-based	161:166	arg1	films					178:182	Soluble soybean polysaccharide (SSPS)-based composite films	124:182	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS)	124:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	0	33	theme	Synergistic	0:10	arg1	effect					12:17	Synergistic effect	0:17	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films	0:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	7	34	theme	antibacterial	1292:1304	arg1	activity					1306:1313	excellent antibacterial activity	1282:1313	excellent antibacterial activity against E. coli and S. aureus	1282:1343	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	3	35	theme	vapor	565:569	arg1	stability					599:607	thermal stability	591:607	thermal stability	591:607	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	35	theme	vapor	565:569	arg1	resistance					616:625	water resistance	610:625	water resistance	610:625	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	35	theme	vapor	565:569	arg1	wettability					636:646	surface wettability	628:646	surface wettability	628:646	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	35	theme	vapor	565:569	arg1	difference					665:674	total color difference	653:674	total color difference	653:674	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	35	theme	vapor	565:569	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	4	36	theme	transmittance	897:909	arg1	percentage					877:886	the percentage	873:886	the percentage of light transmittance of the films	873:922	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	7	37	theme	SSPS/TTEO/nZnO	1366:1379	arg1	material					1407:1414	a promising material	1395:1414	a promising material for active packaging applications	1395:1448	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	7	37	theme	SSPS/TTEO/nZnO	1366:1379	arg1	film					1381:1384	the SSPS/TTEO/nZnO film	1362:1384	the SSPS/TTEO/nZnO film	1362:1384	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	1	38	theme	composite	168:176	arg1	films					178:182	Soluble soybean polysaccharide (SSPS)-based composite films	124:182	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS)	124:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	0	39	theme	nano	22:25	arg1	oxide					32:36	nano zinc oxide	22:36	nano zinc oxide	22:36	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	3	40	theme	total	653:657	arg1	difference					665:674	total color difference	653:674	total color difference	653:674	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	40	theme	total	653:657	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	0	41	theme	polysaccharide	102:115	arg1	films					117:121	soluble soybean polysaccharide films	86:121	soluble soybean polysaccharide films	86:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	3	42	theme	enhanced	550:557	arg1	stability					599:607	thermal stability	591:607	thermal stability	591:607	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	42	theme	enhanced	550:557	arg1	resistance					616:625	water resistance	610:625	water resistance	610:625	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	42	theme	enhanced	550:557	arg1	wettability					636:646	surface wettability	628:646	surface wettability	628:646	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	42	theme	enhanced	550:557	arg1	difference					665:674	total color difference	653:674	total color difference	653:674	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	42	theme	enhanced	550:557	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	7	43	theme	synergistic	1219:1229	arg1	effect					1231:1236	The synergistic effect	1215:1236	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus	1215:1343	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	4	44	theme	films	918:922	arg1	percentage					877:886	the percentage	873:886	the percentage of light transmittance of the films	873:922	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	0	45	theme	soybean	94:100	arg1	films					117:121	soluble soybean polysaccharide films	86:121	soluble soybean polysaccharide films	86:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	7	46	with	endowed	1255:1261	arg1	activity					1306:1313	excellent antibacterial activity	1282:1313	excellent antibacterial activity against E. coli and S. aureus	1282:1343	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	5	47	theme	radical	966:972	arg1	activity					985:992	The DPPH radical scavenging activity	957:992	The DPPH radical scavenging activity of the films	957:1005	The DPPH radical scavenging activity of the films significantly increased from 46.8 % (SSPS) to 67.7 % (SSPS/TTEO/nZnO) due to the presence of TTEO.
37028629	5	48	theme	TTEO	1100:1103	arg1	presence					1088:1095	the presence	1084:1095	the presence of TTEO	1084:1103	The DPPH radical scavenging activity of the films significantly increased from 46.8 % (SSPS) to 67.7 % (SSPS/TTEO/nZnO) due to the presence of TTEO.
37028629	0	49	theme	oxide	32:36	arg1	effect					12:17	Synergistic effect	0:17	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films	0:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	1	50	dep	oil	272:274	arg1	TTEO					277:280	TTEO	277:280	TTEO	277:280	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	1	50	dep	oil	272:274	arg1	%					288:288	10 wt%	283:288	10 wt% based on SSPS	283:302	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	1	51	with	films	178:182	arg1	addition					193:200	the addition	189:200	the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS)	189:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	1	52	dep	oxide	215:219	arg1	nZnO					222:225	nZnO	222:225	nZnO	222:225	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	1	52	dep	oxide	215:219	arg1	%					232:232	5 wt%	228:232	5 wt% based on SSPS	228:246	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	5	53	theme	films	1001:1005	arg1	activity					985:992	The DPPH radical scavenging activity	957:992	The DPPH radical scavenging activity of the films	957:1005	The DPPH radical scavenging activity of the films significantly increased from 46.8 % (SSPS) to 67.7 % (SSPS/TTEO/nZnO) due to the presence of TTEO.
37028629	0	54	theme	zinc	27:30	arg1	oxide					32:36	nano zinc oxide	22:36	nano zinc oxide	22:36	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	6	55	theme	electron	1115:1122	arg1	microscopy					1124:1133	Scanning electron microscopy	1106:1133	Scanning electron microscopy analysis	1106:1142	Scanning electron microscopy analysis indicated that nZnO and TTEO were evenly dispersed in the SSPS matrix.
37028629	0	56	theme	films	117:121	arg1	properties					72:81	the properties	68:81	the properties of soluble soybean polysaccharide films	68:121	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	3	57	theme	SSPS/TTEO/nZnO	520:533	arg1	film					535:538	the SSPS/TTEO/nZnO film	516:538	the SSPS/TTEO/nZnO film	516:538	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	7	58	theme	promising	1397:1405	arg1	material					1407:1414	a promising material	1395:1414	a promising material for active packaging applications	1395:1448	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	7	58	theme	promising	1397:1405	arg1	film					1381:1384	the SSPS/TTEO/nZnO film	1362:1384	the SSPS/TTEO/nZnO film	1362:1384	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	0	59	theme	tea	42:44	arg1	oil					61:63	tea tree essential oil	42:63	tea tree essential oil	42:63	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	6	60	theme	SSPS	1202:1205	arg1	matrix					1207:1212	the SSPS matrix	1198:1212	the SSPS matrix	1198:1212	Scanning electron microscopy analysis indicated that nZnO and TTEO were evenly dispersed in the SSPS matrix.
37028629	2	61	theme	films	471:475	arg1	microstructure					397:410	microstructure	397:410	microstructure	397:410	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	2	61	theme	films	471:475	arg1	properties					452:461	physical, mechanical and functional properties	416:461	physical, mechanical and functional properties of SSPS films	416:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	2	62	theme	TTEO	385:388	arg1	combination					361:371	the combination	357:371	the combination of nZnO and TTEO	357:388	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	4	63	theme	TTEO	757:760	arg1	addition					745:752	The addition	741:752	The addition of TTEO and nZnO	741:769	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	64	theme	light	891:895	arg1	transmittance					897:909	light transmittance	891:909	light transmittance	891:909	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	1	65	theme	tea	253:255	arg1	oil					272:274	tea tree essential oil	253:274	tea tree essential oil (TTEO, 10 wt% based on SSPS)	253:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	2	66	theme	SSPS	466:469	arg1	films					471:475	SSPS films	466:475	SSPS films	466:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	3	67	theme	barrier	571:577	arg1	stability					599:607	thermal stability	591:607	thermal stability	591:607	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	67	theme	barrier	571:577	arg1	resistance					616:625	water resistance	610:625	water resistance	610:625	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	67	theme	barrier	571:577	arg1	wettability					636:646	surface wettability	628:646	surface wettability	628:646	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	67	theme	barrier	571:577	arg1	difference					665:674	total color difference	653:674	total color difference	653:674	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	67	theme	barrier	571:577	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	4	68	from	%	954:954	arg1	600 nm					927:932	600 nm	927:932	600 nm from 85.5 % to 10.1 %	927:954	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	2	69	from	effect	347:352	arg1	microstructure					397:410	microstructure	397:410	microstructure	397:410	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	2	69	from	effect	347:352	arg1	properties					452:461	physical, mechanical and functional properties	416:461	physical, mechanical and functional properties of SSPS films	416:475	The effect of the combination of nZnO and TTEO on the microstructure and physical, mechanical and functional properties of SSPS films was evaluated.
37028629	1	70	theme	tree	257:260	arg1	oil					272:274	tea tree essential oil	253:274	tea tree essential oil (TTEO, 10 wt% based on SSPS)	253:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	4	71	theme	tensile	804:810	arg1	strength					812:819	tensile strength	804:819	tensile strength	804:819	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	7	72	theme	TTEO	1250:1253	arg1	effect					1231:1236	The synergistic effect	1215:1236	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus	1215:1343	The synergistic effect of nZnO and TTEO endowed the SSPS film with excellent antibacterial activity against E. coli and S. aureus, suggesting that the SSPS/TTEO/nZnO film could be a promising material for active packaging applications.
37028629	4	73	theme	10.1 	949:953	arg1	%					944:944	%	944:944	%	944:944	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	3	74	theme	water	559:563	arg1	stability					599:607	thermal stability	591:607	thermal stability	591:607	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	74	theme	water	559:563	arg1	resistance					616:625	water resistance	610:625	water resistance	610:625	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	74	theme	water	559:563	arg1	wettability					636:646	surface wettability	628:646	surface wettability	628:646	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	74	theme	water	559:563	arg1	difference					665:674	total color difference	653:674	total color difference	653:674	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	3	74	theme	water	559:563	arg1	properties					579:588	enhanced water vapor barrier properties	550:588	enhanced water vapor barrier properties	550:588	The results showed that the SSPS/TTEO/nZnO film exhibited enhanced water vapor barrier properties, thermal stability, water resistance, surface wettability, and total color difference, and almost completely prevented ultraviolet light transmission.
37028629	1	75	theme	nano	205:208	arg1	oxide					215:219	nano zinc oxide	205:219	nano zinc oxide (nZnO, 5 wt% based on SSPS)	205:247	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	0	76	theme	essential	51:59	arg1	oil					61:63	tea tree essential oil	42:63	tea tree essential oil	42:63	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	1	77	theme	casting	327:333	arg1	method					335:340	the casting method	323:340	the casting method	323:340	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	4	78	theme	films	852:856	arg1	elongation					825:834	elongation	825:834	elongation	825:834	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	4	78	theme	films	852:856	arg1	strength					812:819	tensile strength	804:819	tensile strength	804:819	The addition of TTEO and nZnO had no significant effect on the tensile strength and elongation at break of the films, but decreased the percentage of light transmittance of the films at 600 nm from 85.5 % to 10.1 %.
37028629	1	79	theme	zinc	210:213	arg1	oxide					215:219	nano zinc oxide	205:219	nano zinc oxide (nZnO, 5 wt% based on SSPS)	205:247	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	0	80	theme	tree	46:49	arg1	oil					61:63	tea tree essential oil	42:63	tea tree essential oil	42:63	Synergistic effect of nano zinc oxide and tea tree essential oil on the properties of soluble soybean polysaccharide films.
37028629	1	81	theme	essential	262:270	arg1	oil					272:274	tea tree essential oil	253:274	tea tree essential oil (TTEO, 10 wt% based on SSPS)	253:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
37028629	6	82	theme	Scanning	1106:1113	arg1	microscopy					1124:1133	Scanning electron microscopy	1106:1133	Scanning electron microscopy analysis	1106:1142	Scanning electron microscopy analysis indicated that nZnO and TTEO were evenly dispersed in the SSPS matrix.
37028629	1	83	theme	oxide	215:219	arg1	addition					193:200	the addition	189:200	the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS)	189:303	Soluble soybean polysaccharide (SSPS)-based composite films with the addition of nano zinc oxide (nZnO, 5 wt% based on SSPS) and tea tree essential oil (TTEO, 10 wt% based on SSPS) were developed by the casting method.
36603720	11	0	theme	composite	1496:1504	arg1	films					1506:1510	The anisotropic composite films	1480:1510	The anisotropic composite films	1480:1510	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	5	1	theme	biodegradable	637:649	arg1	polyurethane					651:662	A biodegradable polyurethane	635:662	A biodegradable polyurethane	635:662	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	8	2	with	annealing	1202:1210	arg1	pre-strain					1217:1226	pre-strain	1217:1226	pre-strain	1217:1226	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	4	3	theme	anisotropic	612:622	arg1	materials					624:632	stretchable and anisotropic materials	596:632	stretchable and anisotropic materials	596:632	In the current study, cellulose nanofibers (CNFs) were integrated in chitosan-polyurethane composites to prepare stretchable and anisotropic materials.
36603720	8	4	theme	Anisotropic	1153:1163	arg1	films					1165:1169	Anisotropic films	1153:1169	Anisotropic films	1153:1169	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	6	5	theme	polyurethane-CNF-chitosan	916:940	arg1	composites					949:958	polyurethane-CNF-chitosan (DPFC) composites	916:958	polyurethane-CNF-chitosan (DPFC) composites	916:958	The waterborne DPF crosslinker was then blended with chitosan solution to make polyurethane-CNF-chitosan (DPFC) composites.
36603720	11	6	theme	tissue	1614:1619	arg1	engineering					1621:1631	tissue engineering	1614:1631	tissue engineering	1614:1631	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	10	7	dep	In	1334:1335	arg1	situ					1337:1340	situ	1337:1340	situ	1337:1340	In situ SAXS/WAXS analyses unveiled that rearrangement and alignment of the microstructure during tension annealing accounted for the anisotropy.
36603720	3	8	theme	insufficient	433:444	arg1	strength					446:453	insufficient strength	433:453	insufficient strength	433:453	Chitosan-polyurethane composites were recently developed but had insufficient strength and limited stretchability.
36603720	8	9	theme	cast	1078:1081	arg1	films					1072:1076	Composite films	1062:1076	Composite films cast and dried from the blends	1062:1107	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	9	10	theme	%	1257:1257	arg1	pre-strain					1259:1268	200 % pre-strain	1253:1268	200 % pre-strain	1253:1268	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	8	11	theme	Composite	1062:1070	arg1	films					1072:1076	Composite films	1062:1076	Composite films cast and dried from the blends	1062:1107	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	4	12	theme	chitosan-polyurethane	552:572	arg1	composites					574:583	chitosan-polyurethane composites	552:583	chitosan-polyurethane composites	552:583	In the current study, cellulose nanofibers (CNFs) were integrated in chitosan-polyurethane composites to prepare stretchable and anisotropic materials.
36603720	5	13	theme	dialdehyde	722:731	arg1	DP					747:748	DP	747:748	DP	747:748	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	5	13	theme	dialdehyde	722:731	arg1	polyurethane					733:744	dialdehyde polyurethane	722:744	dialdehyde polyurethane (DP) nanoparticles	722:763	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	2	14	theme	versatile	329:337	arg1	properties					339:348	versatile properties	329:348	versatile properties	329:348	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	11	15	theme	neural	1552:1557	arg1	cells					1564:1568	neural stem cells	1552:1568	neural stem cells	1552:1568	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	4	16	theme	current	490:496	arg1	study					498:502	the current study	486:502	the current study	486:502	In the current study, cellulose nanofibers (CNFs) were integrated in chitosan-polyurethane composites to prepare stretchable and anisotropic materials.
36603720	11	17	theme	stem	1559:1562	arg1	cells					1564:1568	neural stem cells	1552:1568	neural stem cells	1552:1568	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	11	18	theme	cells	1564:1568	arg1	growth					1542:1547	the growth	1538:1547	the growth of neural stem cells	1538:1568	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	6	19	theme	chitosan	890:897	arg1	solution					899:906	chitosan solution	890:906	chitosan solution	890:906	The waterborne DPF crosslinker was then blended with chitosan solution to make polyurethane-CNF-chitosan (DPFC) composites.
36603720	2	20	theme	polyurethanes	310:322	arg1	polyurethanes					310:322	polyurethanes	310:322	polyurethanes	310:322	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	2	20	theme	polyurethanes	310:322	arg1	composites					296:305	composites	296:305	composites of polyurethanes	296:322	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	1	21	theme	chemical	207:214	arg1	modification					216:227	chemical modification	207:227	chemical modification	207:227	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	22	with	polymer	155:161	arg1	abundancy					168:176	abundancy	168:176	abundancy	168:176	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	22	with	polymer	155:161	arg1	sustainability					179:192	sustainability	179:192	sustainability	179:192	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	22	with	polymer	155:161	arg1	ease					199:202	ease	199:202	ease	199:202	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	23	theme	modification	216:227	arg1	abundancy					168:176	abundancy	168:176	abundancy	168:176	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	23	theme	modification	216:227	arg1	sustainability					179:192	sustainability	179:192	sustainability	179:192	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	23	theme	modification	216:227	arg1	ease					199:202	ease	199:202	ease	199:202	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	8	24	theme	good	1116:1119	arg1	elongation					1121:1130	good elongation	1116:1130	good elongation (~420.2 %)	1116:1141	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	8	24	theme	good	1116:1119	arg1	%					1140:1140	~420.2 %	1133:1140	~420.2 %	1133:1140	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	10	25	theme	tension	1432:1438	arg1	annealing					1440:1448	tension annealing	1432:1448	tension annealing	1432:1448	In situ SAXS/WAXS analyses unveiled that rearrangement and alignment of the microstructure during tension annealing accounted for the anisotropy.
36603720	9	26	theme	large	1280:1284	arg1	anisotropy					1294:1303	large elastic anisotropy	1280:1303	large elastic anisotropy	1280:1303	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	2	27	contain	have	324:327	arg2	properties					339:348	versatile properties	329:348	versatile properties	329:348	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	2	27	contain	have	324:327	arg2	applications					354:365	applications	354:365	applications	354:365	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	2	27	contain	have	324:327	arg1	composites					296:305	composites	296:305	composites of polyurethanes	296:322	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	2	27	contain	have	324:327	arg1	polyurethanes					310:322	polyurethanes	310:322	polyurethanes	310:322	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	5	28	theme	DP-CNF	801:806	arg1	DPF					831:833	DPF	831:833	DPF	831:833	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	5	28	theme	DP-CNF	801:806	arg1	crosslinker					818:828	the DP-CNF composite crosslinker	797:828	the DP-CNF composite crosslinker (DPF)	797:834	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	5	29	theme	polyurethane	733:744	arg1	nanoparticles					751:763	dialdehyde polyurethane (DP) nanoparticles	722:763	dialdehyde polyurethane (DP) nanoparticles	722:763	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	1	30	theme	derived	133:139	arg1	Chitosan					109:116	Chitosan	109:116	Chitosan	109:116	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	30	theme	derived	133:139	arg1	polymer					155:161	a naturally derived biodegradable polymer	121:161	a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification	121:227	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	3	31	theme	limited	459:465	arg1	stretchability					467:480	limited stretchability	459:480	limited stretchability	459:480	Chitosan-polyurethane composites were recently developed but had insufficient strength and limited stretchability.
36603720	5	32	theme	composite	808:816	arg1	DPF					831:833	DPF	831:833	DPF	831:833	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	5	32	theme	composite	808:816	arg1	crosslinker					818:828	the DP-CNF composite crosslinker	797:828	the DP-CNF composite crosslinker (DPF)	797:834	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	1	33	theme	biodegradable	141:153	arg1	Chitosan					109:116	Chitosan	109:116	Chitosan	109:116	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	33	theme	biodegradable	141:153	arg1	polymer					155:161	a naturally derived biodegradable polymer	121:161	a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification	121:227	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	10	34	theme	microstructure	1410:1423	arg1	alignment					1393:1401	alignment	1393:1401	alignment	1393:1401	In situ SAXS/WAXS analyses unveiled that rearrangement and alignment of the microstructure during tension annealing accounted for the anisotropy.
36603720	10	34	theme	microstructure	1410:1423	arg1	rearrangement					1375:1387	rearrangement	1375:1387	rearrangement	1375:1387	In situ SAXS/WAXS analyses unveiled that rearrangement and alignment of the microstructure during tension annealing accounted for the anisotropy.
36603720	5	35	with	end-capped	687:696	arg1	aldehyde					703:710	aldehyde	703:710	aldehyde to become dialdehyde polyurethane (DP) nanoparticles	703:763	A biodegradable polyurethane was first synthesized, end-capped with aldehyde to become dialdehyde polyurethane (DP) nanoparticles, and added with CNFs to prepare the DP-CNF composite crosslinker (DPF).
36603720	2	36	theme	polymers	282:289	arg1	Polyurethanes					230:242	Polyurethanes	230:242	Polyurethanes	230:242	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	2	36	theme	polymers	282:289	arg1	family					250:255	a family	248:255	a family of elastic biocompatible polymers	248:289	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	9	37	theme	annealed	1233:1240	arg1	films					1242:1246	The annealed films	1229:1246	The annealed films with 200 % pre-strain	1229:1268	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	11	38	theme	anisotropic	1484:1494	arg1	films					1506:1510	The anisotropic composite films	1480:1510	The anisotropic composite films	1480:1510	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	2	39	theme	biocompatible	268:280	arg1	polymers					282:289	elastic biocompatible polymers	260:289	elastic biocompatible polymers	260:289	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	0	40	theme	anisotropic	86:96	arg1	composites					72:81	composites	72:81	composites	72:81	Stretchable and biodegradable chitosan-polyurethane-cellulose nanofiber composites as anisotropic materials.
36603720	0	40	theme	anisotropic	86:96	arg1	materials					98:106	anisotropic materials	86:106	anisotropic materials	86:106	Stretchable and biodegradable chitosan-polyurethane-cellulose nanofiber composites as anisotropic materials.
36603720	8	41	theme	tension	1194:1200	arg1	annealing					1202:1210	tension annealing	1194:1210	tension annealing with pre-strain	1194:1226	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	2	42	theme	elastic	260:266	arg1	polymers					282:289	elastic biocompatible polymers	260:289	elastic biocompatible polymers	260:289	Polyurethanes are a family of elastic biocompatible polymers, and composites of polyurethanes have versatile properties and applications.
36603720	3	43	theme	Chitosan-polyurethane	368:388	arg1	composites					390:399	Chitosan-polyurethane composites	368:399	Chitosan-polyurethane composites	368:399	Chitosan-polyurethane composites were recently developed but had insufficient strength and limited stretchability.
36603720	4	44	theme	cellulose	505:513	arg1	nanofibers					515:524	cellulose nanofibers	505:524	cellulose nanofibers (CNFs)	505:531	In the current study, cellulose nanofibers (CNFs) were integrated in chitosan-polyurethane composites to prepare stretchable and anisotropic materials.
36603720	4	44	theme	cellulose	505:513	arg1	CNFs					527:530	CNFs	527:530	CNFs	527:530	In the current study, cellulose nanofibers (CNFs) were integrated in chitosan-polyurethane composites to prepare stretchable and anisotropic materials.
36603720	6	45	theme	DPF	852:854	arg1	crosslinker					856:866	The waterborne DPF crosslinker	837:866	The waterborne DPF crosslinker	837:866	The waterborne DPF crosslinker was then blended with chitosan solution to make polyurethane-CNF-chitosan (DPFC) composites.
36603720	11	46	theme	biomimetic	1599:1608	arg1	applications					1633:1644	biomimetic and tissue engineering applications	1599:1644	biomimetic and tissue engineering applications	1599:1644	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	9	47	theme	anisotropic	1315:1325	arg1	ratio					1327:1331	~4.9 anisotropic ratio	1310:1331	~4.9 anisotropic ratio	1310:1331	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	6	48	theme	waterborne	841:850	arg1	crosslinker					856:866	The waterborne DPF crosslinker	837:866	The waterborne DPF crosslinker	837:866	The waterborne DPF crosslinker was then blended with chitosan solution to make polyurethane-CNF-chitosan (DPFC) composites.
36603720	8	49	theme	dried	1087:1091	arg1	films					1072:1076	Composite films	1062:1076	Composite films cast and dried from the blends	1062:1107	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	7	50	theme	room	1014:1017	arg1	temperature					1019:1029	room temperature	1014:1029	room temperature	1014:1029	After blending, DPFC may form hydrogel in ~33 min at room temperature, which confirmed crosslinking.
36603720	7	51	from	hydrogel	991:998	arg1	~33 min					1003:1009	~33 min	1003:1009	~33 min	1003:1009	After blending, DPFC may form hydrogel in ~33 min at room temperature, which confirmed crosslinking.
36603720	9	52	theme	elastic	1286:1292	arg1	anisotropy					1294:1303	large elastic anisotropy	1280:1303	large elastic anisotropy	1280:1303	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	1	53	link	derived	133:139	arg1	Chitosan					109:116	Chitosan	109:116	Chitosan	109:116	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	1	53	link	derived	133:139	arg1	polymer					155:161	a naturally derived biodegradable polymer	121:161	a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification	121:227	Chitosan is a naturally derived biodegradable polymer with abundancy, sustainability, and ease of chemical modification.
36603720	10	54	theme	SAXS/WAXS	1342:1350	arg1	analyses					1352:1359	In situ SAXS/WAXS analyses	1334:1359	In situ SAXS/WAXS analyses	1334:1359	In situ SAXS/WAXS analyses unveiled that rearrangement and alignment of the microstructure during tension annealing accounted for the anisotropy.
36603720	11	55	theme	engineering	1621:1631	arg1	applications					1633:1644	biomimetic and tissue engineering applications	1599:1644	biomimetic and tissue engineering applications	1599:1644	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	10	56	theme	In	1334:1335	arg1	analyses					1352:1359	In situ SAXS/WAXS analyses	1334:1359	In situ SAXS/WAXS analyses	1334:1359	In situ SAXS/WAXS analyses unveiled that rearrangement and alignment of the microstructure during tension annealing accounted for the anisotropy.
36603720	9	57	with	films	1242:1246	arg1	pre-strain					1259:1268	200 % pre-strain	1253:1268	200 % pre-strain	1253:1268	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	8	58	dep	60 °C.	1146:1151	arg1	generated					1181:1189	generated	1181:1189	were then generated by tension annealing with pre-strain	1171:1226	Composite films cast and dried from the blends showed good elongation (~420.2 %) at 60 °C. Anisotropic films were then generated by tension annealing with pre-strain.
36603720	4	59	theme	stretchable	596:606	arg1	materials					624:632	stretchable and anisotropic materials	596:632	stretchable and anisotropic materials	596:632	In the current study, cellulose nanofibers (CNFs) were integrated in chitosan-polyurethane composites to prepare stretchable and anisotropic materials.
36603720	0	60	theme	biodegradable	16:28	arg1	chitosan-polyurethane-cellulose					30:60	biodegradable chitosan-polyurethane-cellulose	16:60	biodegradable chitosan-polyurethane-cellulose	16:60	Stretchable and biodegradable chitosan-polyurethane-cellulose nanofiber composites as anisotropic materials.
36603720	9	61	theme	200 	1253:1256	arg1	%					1257:1257	%	1257:1257	%	1257:1257	The annealed films with 200 % pre-strain exhibited large elastic anisotropy with ~4.9 anisotropic ratio.
36603720	11	62	contain	had	1512:1514	arg1	films					1506:1510	The anisotropic composite films	1480:1510	The anisotropic composite films	1480:1510	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
36603720	11	62	contain	had	1512:1514	arg2	ability					1520:1526	the ability to orient the growth of neural stem cells	1516:1568	the ability to orient the growth of neural stem cells	1516:1568	The anisotropic composite films had the ability to orient the growth of neural stem cells and showed the potential for biomimetic and tissue engineering applications.
35166281	0	0	theme	diet-induced	93:104	arg1	obesity					106:112	high-fat diet-induced obesity	84:112	high-fat diet-induced obesity in mice	84:120	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	1	1	theme	sufficient	353:362	arg1	attention					364:372	sufficient attention	353:372	sufficient attention	353:372	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	1	2	from	rich	190:193	arg1	alginate					253:260	alginate	253:260	alginate	253:260	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	1	2	from	rich	190:193	arg1	polysaccharides					198:212	polysaccharides	198:212	polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention	198:372	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	1	2	from	rich	190:193	arg1	polysaccharides					233:247	sulfated polysaccharides	224:247	sulfated polysaccharides	224:247	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	1	3	theme	Brown	173:177	arg1	seaweed					179:185	Brown seaweed	173:185	Brown seaweed	173:185	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	3	4	dep	UPP	744:746	arg1	UPSP					755:758	UPSP	755:758	UPSP	755:758	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	4	dep	UPP	744:746	arg1	UPA					749:751	UPA	749:751	UPA	749:751	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	0	5	theme	high-fat	84:91	arg1	obesity					106:112	high-fat diet-induced obesity	84:112	high-fat diet-induced obesity in mice	84:120	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	3	6	theme	inflammatory	663:674	arg1	response					676:683	inflammatory response	663:683	inflammatory response	663:683	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	4	7	contain	had	951:953	arg1	UPP					947:949	UPP	947:949	UPP	947:949	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	7	contain	had	951:953	arg2	effect					962:967	better effect	955:967	better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status	955:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	5	8	dep	in	1183:1184	arg1	vitro					1186:1190	vitro	1186:1190	vitro	1186:1190	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	9	theme	culture	1211:1217	arg1	model					1192:1196	The in vitro model	1179:1196	The in vitro model of bacterial culture	1179:1217	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	4	10	with	correlations	1116:1127	arg1	improvement					1138:1148	the improvement	1134:1148	the improvement of the physiological status	1134:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	5	11	theme	bacterial	1201:1209	arg1	culture					1211:1217	bacterial culture	1201:1217	bacterial culture	1201:1217	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	12	theme	community	1372:1380	arg1	stability					1341:1349	stability	1341:1349	stability	1341:1349	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	12	theme	community	1372:1380	arg1	diversity					1327:1335	diversity	1327:1335	diversity	1327:1335	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	4	13	theme	positive	1107:1114	arg1	correlations					1116:1127	positive correlations	1107:1127	positive correlations with the improvement of the physiological status	1107:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	1	14	theme	health	285:290	arg1	benefits					292:299	health benefits	285:299	health benefits	285:299	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	5	15	from	use	1237:1239	arg1	UPA					1259:1261	UPA	1259:1261	UPA	1259:1261	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	15	from	use	1237:1239	arg1	UPSP					1267:1270	UPSP	1267:1270	UPSP	1267:1270	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	3	16	theme	compound	698:705	arg1	polysaccharides					707:721	compound polysaccharides	698:721	compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP)	698:759	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	6	17	theme	intestinal	1492:1501	arg1	helpful					1530:1536	helpful	1530:1536	helpful	1530:1536	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	6	17	theme	intestinal	1492:1501	arg1	microecology					1503:1514	the intestinal microecology	1488:1514	the intestinal microecology	1488:1514	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	0	18	from	pinnatifida	50:60	arg1	Polysaccharides					0:14	Polysaccharides	0:14	Polysaccharides from edible brown seaweed Undaria pinnatifida	0:60	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	4	19	from	reduction	1046:1054	arg1	Clostridiales					1064:1076	Clostridiales	1064:1076	Clostridiales	1064:1076	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	19	from	reduction	1046:1054	arg1	Bacteroidales					1028:1040	Bacteroidales	1028:1040	Bacteroidales	1028:1040	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	19	from	reduction	1046:1054	arg1	Lactobacillales					1082:1096	Lactobacillales	1082:1096	Lactobacillales	1082:1096	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	5	20	dep	diversity	1327:1335	arg1	the					1323:1325	the	1323:1325	the	1323:1325	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	4	21	theme	physiological	1157:1169	arg1	status					1171:1176	the physiological status	1153:1176	the physiological status	1153:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	3	22	from	deposition	602:611	arg1	organs					633:638	organs	633:638	organs	633:638	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	22	from	deposition	602:611	arg1	mice					688:691	mice	688:691	mice	688:691	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	22	from	deposition	602:611	arg1	tissues					621:627	body tissues	616:627	body tissues	616:627	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	2	23	theme	Undaria	404:410	arg1	UPA					425:427	UPA	425:427	UPA	425:427	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	2	23	theme	Undaria	404:410	arg1	pinnatifida					412:422	Undaria pinnatifida	404:422	Undaria pinnatifida (UPA)	404:428	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	4	24	contain	had	1103:1105	arg2	correlations					1116:1127	positive correlations	1107:1127	positive correlations with the improvement of the physiological status	1107:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	24	contain	had	1103:1105	arg1	effect					962:967	better effect	955:967	better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status	955:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	3	25	from	pinnatifida	731:741	arg1	polysaccharides					707:721	compound polysaccharides	698:721	compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP)	698:759	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	6	26	theme	edible	1561:1566	arg1	seaweed					1574:1580	edible brown seaweed	1561:1580	edible brown seaweed in health foods	1561:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	3	27	from	abnormality	647:657	arg1	organs					633:638	organs	633:638	organs	633:638	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	27	from	abnormality	647:657	arg1	mice					688:691	mice	688:691	mice	688:691	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	27	from	abnormality	647:657	arg1	tissues					621:627	body tissues	616:627	body tissues	616:627	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	2	28	from	pinnatifida	467:477	arg1	UPA					425:427	UPA	425:427	UPA	425:427	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	2	28	from	pinnatifida	467:477	arg1	pinnatifida					412:422	Undaria pinnatifida	404:422	Undaria pinnatifida (UPA)	404:428	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	2	28	from	pinnatifida	467:477	arg1	UPSP					480:483	UPSP	480:483	UPSP	480:483	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	2	28	from	pinnatifida	467:477	arg1	polysaccharides					443:457	sulfated polysaccharides	434:457	sulfated polysaccharides from U. pinnatifida (UPSP)	434:484	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	6	29	from	foods	1592:1596	arg1	application					1546:1556	the application	1542:1556	the application of edible brown seaweed in health foods	1542:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	2	30	theme	high	534:537	arg1	mice					552:555	high fat diet-fed mice	534:555	high fat diet-fed mice	534:555	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	3	31	theme	lipid	641:645	arg1	abnormality					647:657	lipid abnormality	641:657	lipid abnormality	641:657	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	5	32	theme	Bacteroides	1244:1254	arg1	species					1276:1282	species	1276:1282	species	1276:1282	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	32	theme	Bacteroides	1244:1254	arg1	use					1237:1239	the use	1233:1239	the use of Bacteroides on UPA and UPSP	1233:1270	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	32	theme	Bacteroides	1244:1254	arg1	dependent					1284:1292	dependent	1284:1292	dependent	1284:1292	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	0	33	theme	brown	28:32	arg1	pinnatifida					50:60	edible brown seaweed Undaria pinnatifida	21:60	edible brown seaweed Undaria pinnatifida	21:60	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	4	34	from	changes	972:978	arg1	microbiota					991:1000	the gut microbiota	983:1000	the gut microbiota	983:1000	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	2	35	theme	diet-fed	543:550	arg1	mice					552:555	high fat diet-fed mice	534:555	high fat diet-fed mice	534:555	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	4	36	theme	status	1171:1176	arg1	improvement					1138:1148	the improvement	1134:1148	the improvement of the physiological status	1134:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	5	37	theme	Bacteroidales	1358:1370	arg1	community					1372:1380	the Bacteroidales community	1354:1380	the Bacteroidales community	1354:1380	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	2	38	theme	sulfated	434:441	arg1	UPSP					480:483	UPSP	480:483	UPSP	480:483	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	2	38	theme	sulfated	434:441	arg1	polysaccharides					443:457	sulfated polysaccharides	434:457	sulfated polysaccharides from U. pinnatifida (UPSP)	434:484	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	2	39	theme	fat	539:541	arg1	mice					552:555	high fat diet-fed mice	534:555	high fat diet-fed mice	534:555	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	3	40	from	effect	774:779	arg1	indexes					803:809	some physiological indexes	784:809	some physiological indexes	784:809	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	41	theme	gut	864:866	arg1	microbiota					868:877	the gut microbiota	860:877	the gut microbiota	860:877	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	1	42	theme	sulfated	224:231	arg1	polysaccharides					233:247	sulfated polysaccharides	224:247	sulfated polysaccharides	224:247	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	0	43	theme	Undaria	42:48	arg1	pinnatifida					50:60	edible brown seaweed Undaria pinnatifida	21:60	edible brown seaweed Undaria pinnatifida	21:60	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	4	44	from	effect	962:967	arg1	reduction					1046:1054	reduction	1046:1054	reduction in both Clostridiales and Lactobacillales	1046:1096	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	44	from	effect	962:967	arg1	increase					1016:1023	an increase	1013:1023	an increase in Bacteroidales	1013:1040	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	44	from	effect	962:967	arg1	changes					972:978	changes	972:978	changes	972:978	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	0	45	theme	intestinal	148:157	arg1	microecology					159:170	intestinal microecology	148:170	intestinal microecology	148:170	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	3	46	theme	body	580:583	arg1	composition					585:595	body composition	580:595	body composition	580:595	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	47	from	composition	585:595	arg1	organs					633:638	organs	633:638	organs	633:638	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	47	from	composition	585:595	arg1	mice					688:691	mice	688:691	mice	688:691	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	47	from	composition	585:595	arg1	tissues					621:627	body tissues	616:627	body tissues	616:627	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	0	48	theme	seaweed	34:40	arg1	pinnatifida					50:60	edible brown seaweed Undaria pinnatifida	21:60	edible brown seaweed Undaria pinnatifida	21:60	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	3	49	from	response	676:683	arg1	organs					633:638	organs	633:638	organs	633:638	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	49	from	response	676:683	arg1	mice					688:691	mice	688:691	mice	688:691	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	49	from	response	676:683	arg1	tissues					621:627	body tissues	616:627	body tissues	616:627	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	50	theme	body	616:619	arg1	tissues					621:627	body tissues	616:627	body tissues	616:627	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	4	51	theme	better	955:960	arg1	effect					962:967	better effect	955:967	better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status	955:1176	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	6	52	from	seaweed	1574:1580	arg1	foods					1592:1596	health foods	1585:1596	health foods	1585:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	4	53	theme	diet-induced	908:919	arg1	dysbiosis					932:940	diet-induced microbiota dysbiosis	908:940	diet-induced microbiota dysbiosis	908:940	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	6	54	from	seaweed	1443:1449	arg1	polysaccharides					1409:1423	polysaccharides	1409:1423	polysaccharides from edible brown seaweed	1409:1449	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	5	55	dep	dependent	1284:1292	arg1	use					1237:1239	the use	1233:1239	the use of Bacteroides on UPA and UPSP	1233:1270	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	55	dep	dependent	1284:1292	arg1	species					1276:1282	species	1276:1282	species	1276:1282	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	5	55	dep	dependent	1284:1292	arg1	dependent					1284:1292	dependent	1284:1292	dependent	1284:1292	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	0	56	theme	microecology	159:170	arg1	modulation					134:143	the modulation	130:143	the modulation of intestinal microecology	130:170	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	2	57	from	pinnatifida	412:422	arg1	alginate					390:397	alginate	390:397	alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP)	390:484	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	4	58	from	increase	1016:1023	arg1	Clostridiales					1064:1076	Clostridiales	1064:1076	Clostridiales	1064:1076	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	58	from	increase	1016:1023	arg1	Bacteroidales					1028:1040	Bacteroidales	1028:1040	Bacteroidales	1028:1040	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	4	58	from	increase	1016:1023	arg1	Lactobacillales					1082:1096	Lactobacillales	1082:1096	Lactobacillales	1082:1096	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	3	59	contain	had	761:763	arg2	effect					774:779	a better effect	765:779	a better effect	765:779	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	59	contain	had	761:763	arg1	polysaccharides					707:721	compound polysaccharides	698:721	compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP)	698:759	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	6	60	theme	brown	1568:1572	arg1	seaweed					1574:1580	edible brown seaweed	1561:1580	edible brown seaweed in health foods	1561:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	6	61	theme	health	1585:1590	arg1	foods					1592:1596	health foods	1585:1596	health foods	1585:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	6	62	theme	brown	1437:1441	arg1	seaweed					1443:1449	edible brown seaweed	1430:1449	edible brown seaweed	1430:1449	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	6	63	theme	seaweed	1574:1580	arg1	application					1546:1556	the application	1542:1556	the application of edible brown seaweed in health foods	1542:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	3	64	from	differences	845:855	arg1	microbiota					868:877	the gut microbiota	860:877	the gut microbiota	860:877	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	6	65	from	application	1546:1556	arg1	foods					1592:1596	health foods	1585:1596	health foods	1585:1596	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	6	66	theme	host	1463:1466	arg1	health					1468:1473	host health	1463:1473	host health	1463:1473	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	3	67	theme	physiological	789:801	arg1	indexes					803:809	some physiological indexes	784:809	some physiological indexes	784:809	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	5	68	theme	in	1183:1184	arg1	model					1192:1196	The in vitro model	1179:1196	The in vitro model of bacterial culture	1179:1217	The in vitro model of bacterial culture revealed that the use of Bacteroides on UPA and UPSP was species dependent, and UPP can better maintain the diversity and stability of the Bacteroidales community.
35166281	4	69	theme	microbiota	921:930	arg1	dysbiosis					932:940	diet-induced microbiota dysbiosis	908:940	diet-induced microbiota dysbiosis	908:940	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35166281	0	70	from	obesity	106:112	arg1	mice					117:120	mice	117:120	mice	117:120	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	1	71	from	polysaccharides	198:212	arg1	rich					190:193	rich	190:193	rich	190:193	Brown seaweed is rich in polysaccharides including sulfated polysaccharides and alginate, both of which provide health benefits to the host but whose differences have not received sufficient attention.
35166281	6	72	theme	edible	1430:1435	arg1	seaweed					1443:1449	edible brown seaweed	1430:1449	edible brown seaweed	1430:1449	This study indicated that polysaccharides from edible brown seaweed can benefit host health by improving the intestinal microecology, which can be helpful for the application of edible brown seaweed in health foods.
35166281	3	73	dep	pinnatifida	731:741	arg1	UPP					744:746	UPP	744:746	UPP	744:746	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	74	theme	fat	598:600	arg1	deposition					602:611	fat deposition	598:611	fat deposition in body tissues and organs	598:638	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	3	75	theme	better	767:772	arg1	effect					774:779	a better effect	765:779	a better effect	765:779	UPA and UPSP improved body composition, fat deposition in body tissues and organs, lipid abnormality and inflammatory response in mice, and compound polysaccharides from U. pinnatifida (UPP: UPA + UPSP) had a better effect on some physiological indexes, which could be attributed to the differences in the gut microbiota.
35166281	2	76	from	polysaccharides	443:457	arg1	alginate					390:397	alginate	390:397	alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP)	390:484	In this study, alginate from Undaria pinnatifida (UPA) and sulfated polysaccharides from U. pinnatifida (UPSP) were isolated, and their action was analyzed in high fat diet-fed mice.
35166281	0	77	theme	edible	21:26	arg1	pinnatifida					50:60	edible brown seaweed Undaria pinnatifida	21:60	edible brown seaweed Undaria pinnatifida	21:60	Polysaccharides from edible brown seaweed Undaria pinnatifida are effective against high-fat diet-induced obesity in mice through the modulation of intestinal microecology.
35166281	4	78	theme	gut	987:989	arg1	microbiota					991:1000	the gut microbiota	983:1000	the gut microbiota	983:1000	Both UPSP and UPA modulated diet-induced microbiota dysbiosis, and UPP had better effect on changes in the gut microbiota, including an increase in Bacteroidales and reduction in both Clostridiales and Lactobacillales that had positive correlations with the improvement of the physiological status.
35338508	3	0	theme	striata	506:512	arg1	samples					514:520	13 representative B. striata samples	485:520	13 representative B. striata samples	485:520	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	8	1	dep	content	1707:1713	arg1	the					1688:1690	the	1688:1690	the	1688:1690	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	0	2	theme	differential	71:82	arg1	metabolites					84:94	differential metabolites	71:94	differential metabolites	71:94	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	6	3	theme	metabolites	1278:1288	arg1	contents					1260:1267	the contents	1256:1267	the contents of these metabolites	1256:1288	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	8	4	theme	phase	1761:1765	arg1	research					1780:1787	phase metabolomics research	1761:1787	phase metabolomics research	1761:1787	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	5	5	theme	species	920:926	arg1	polysaccharides					896:910	the polysaccharides	892:910	the polysaccharides of both species	892:926	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	3	6	dep	B.	529:530	arg1	ochracea					532:539	ochracea	532:539	ochracea	532:539	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	6	7	from	differences	1241:1251	arg1	contents					1260:1267	the contents	1256:1267	the contents of these metabolites	1256:1288	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	3	8	theme	polysaccharide	628:641	arg1	yields					643:648	polysaccharide yields	628:648	polysaccharide yields	628:648	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	4	9	from	difference	791:800	arg1	yields					809:814	the yields	805:814	the yields of polysaccharides	805:833	The results revealed that there was a significant difference in the yields of polysaccharides between B. striata and B. ochracea (p = 0.006).
35338508	2	10	theme	species	286:292	arg1	emergence					261:269	the emergence	257:269	the emergence of counterfeit species	257:292	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	3	11	theme	O.	559:560	arg1	samples					570:576	three O. foliosa samples	553:576	three O. foliosa samples	553:576	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	3	12	theme	foliosa	562:568	arg1	samples					570:576	three O. foliosa samples	553:576	three O. foliosa samples	553:576	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	7	13	dep	same	1449:1452	arg1	mannose					1467:1473	mannose	1467:1473	mannose	1467:1473	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	13	dep	same	1449:1452	arg1	glucose					1455:1461	glucose	1455:1461	glucose	1455:1461	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	1	14	from	plant	149:153	arg1	striata					184:190	the Orchidaceae, Bletilla striata	158:190	the Orchidaceae, Bletilla striata	158:190	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	2	15	theme	counterfeit	274:284	arg1	species					286:292	counterfeit species	274:292	counterfeit species	274:292	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	2	16	theme	medicinal	317:325	arg1	process					359:365	the basic medicinal materials source identification process	307:365	the basic medicinal materials source identification process	307:365	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	8	17	dep	B.	1824:1825	arg1	striata					1827:1833	striata	1827:1833	B. striata	1824:1833	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	2	18	theme	identification	344:357	arg1	process					359:365	the basic medicinal materials source identification process	307:365	the basic medicinal materials source identification process	307:365	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	7	19	dep	O.	1383:1384	arg1	foliosa					1386:1392	O. foliosa	1383:1392	O. foliosa (p = 0.074)	1383:1404	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	3	20	theme	B.	529:530	arg1	samples					541:547	three B. ochracea samples	523:547	three B. ochracea samples	523:547	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	7	21	theme	polysaccharide	1343:1356	arg1	yields					1358:1363	the polysaccharide yields	1339:1363	the polysaccharide yields of B. striata and O. foliosa (p = 0.074)	1339:1404	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	6	22	theme	metabolites	1173:1183	arg1	types					1164:1168	the types	1160:1168	the types of metabolites	1160:1183	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	3	23	theme	representative	488:501	arg1	samples					514:520	13 representative B. striata samples	485:520	13 representative B. striata samples	485:520	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	1	24	theme	Bletilla	175:182	arg1	striata					184:190	the Orchidaceae, Bletilla striata	158:190	the Orchidaceae, Bletilla striata	158:190	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	5	25	theme	monosaccharides	993:1007	arg1	ratio					976:980	the molar ratio	966:980	the molar ratio of the two monosaccharides	966:1007	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	5	25	theme	monosaccharides	993:1007	arg1	different					1013:1021	different	1013:1021	different	1013:1021	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	8	26	dep	B.	1836:1837	arg1	ochracea					1839:1846	B. ochracea	1836:1846	B. ochracea	1836:1846	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	2	27	theme	basic	311:315	arg1	process					359:365	the basic medicinal materials source identification process	307:365	the basic medicinal materials source identification process	307:365	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	6	28	theme	metabolomics	1098:1109	arg1	results					1111:1117	The metabolomics results	1094:1117	The metabolomics results	1094:1117	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	7	29	theme	significant	1313:1323	arg1	difference					1325:1334	no significant difference	1310:1334	no significant difference	1310:1334	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	2	30	theme	representative	445:458	arg1	species					460:466	two representative species	441:466	two representative species	441:466	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	2	30	theme	representative	445:458	arg1	ochracea					387:394	Bletilla ochracea	378:394	Bletilla ochracea	378:394	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	2	30	theme	representative	445:458	arg1	foliosa					410:416	Oreorchis foliosa	400:416	Oreorchis foliosa	400:416	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	7	31	theme	different	1482:1490	arg1	metabolites					1492:1502	many different metabolites	1477:1502	many different metabolites	1477:1502	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	4	32	theme	significant	779:789	arg1	difference					791:800	a significant difference	777:800	a significant difference in the yields of polysaccharides between B. striata and B. ochracea (p = 0.006)	777:880	The results revealed that there was a significant difference in the yields of polysaccharides between B. striata and B. ochracea (p = 0.006).
35338508	7	33	theme	striata	1371:1377	arg1	composition					1429:1439	the monosaccharide composition	1410:1439	the monosaccharide composition was the same (glucose and mannose)	1410:1474	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	33	theme	striata	1371:1377	arg1	yields					1358:1363	the polysaccharide yields	1339:1363	the polysaccharide yields of B. striata and O. foliosa (p = 0.074)	1339:1404	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	4	34	theme	polysaccharides	819:833	arg1	yields					809:814	the yields	805:814	the yields of polysaccharides	805:833	The results revealed that there was a significant difference in the yields of polysaccharides between B. striata and B. ochracea (p = 0.006).
35338508	6	35	dep	B.	1193:1194	arg1	ochracea					1211:1218	ochracea	1211:1218	ochracea	1211:1218	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	6	35	dep	B.	1193:1194	arg1	striata					1196:1202	striata	1196:1202	striata	1196:1202	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	8	36	theme	metabolomics	1767:1778	arg1	research					1780:1787	phase metabolomics research	1761:1787	phase metabolomics research	1761:1787	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	5	37	theme	molar	970:974	arg1	ratio					976:980	the molar ratio	966:980	the molar ratio of the two monosaccharides	966:1007	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	5	37	theme	molar	970:974	arg1	different					1013:1021	different	1013:1021	different	1013:1021	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	0	38	theme	Bletilla	13:20	arg1	Screening					0:8	Screening	0:8	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites	0:94	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	7	39	dep	O.	1640:1641	arg1	foliosa					1643:1649	O. foliosa	1640:1649	O. foliosa	1640:1649	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	3	40	theme	monosaccharide	654:667	arg1	composition					669:679	monosaccharide composition	654:679	monosaccharide composition	654:679	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	0	41	dep	Oreorchis	53:61	arg1	foliosa					63:69	Oreorchis foliosa	53:69	Oreorchis foliosa	53:69	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	7	42	theme	C39	1614:1616	arg1	O22					1622:1624	substance C39 H54 O22	1604:1624	substance C39 H54 O22	1604:1624	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	43	theme	B.	1368:1369	arg1	striata					1371:1377	B. striata	1368:1377	B. striata	1368:1377	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	0	44	theme	Bletilla	31:38	arg1	Screening					0:8	Screening	0:8	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites	0:94	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	3	45	theme	B.	503:504	arg1	samples					514:520	13 representative B. striata samples	485:520	13 representative B. striata samples	485:520	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	3	46	theme	composition	669:679	arg1	determination					611:623	the systematic determination	596:623	the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS	596:738	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	7	47	theme	O.	1383:1384	arg1	composition					1429:1439	the monosaccharide composition	1410:1439	the monosaccharide composition was the same (glucose and mannose)	1410:1474	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	47	theme	O.	1383:1384	arg1	yields					1358:1363	the polysaccharide yields	1339:1363	the polysaccharide yields of B. striata and O. foliosa (p = 0.074)	1339:1404	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	48	theme	H54	1618:1620	arg1	O22					1622:1624	substance C39 H54 O22	1604:1624	substance C39 H54 O22	1604:1624	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	4	49	dep	B.	843:844	arg1	striata					846:852	striata	846:852	striata	846:852	The results revealed that there was a significant difference in the yields of polysaccharides between B. striata and B. ochracea (p = 0.006).
35338508	3	50	theme	yields	643:648	arg1	determination					611:623	the systematic determination	596:623	the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS	596:738	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	8	51	theme	polysaccharide	1692:1705	arg1	content					1707:1713	polysaccharide content	1692:1713	polysaccharide content	1692:1713	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	1	52	theme	pharmacological	211:225	arg1	roles					227:231	pharmacological roles	211:231	pharmacological roles	211:231	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	7	53	theme	B.	1586:1587	arg1	striata					1589:1595	B. striata	1586:1595	B. striata	1586:1595	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	54	theme	substance	1604:1612	arg1	O22					1622:1624	substance C39 H54 O22	1604:1624	substance C39 H54 O22	1604:1624	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	0	55	dep	Bletilla	31:38	arg1	ochracea					40:47	Bletilla ochracea	31:47	Bletilla ochracea	31:47	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	1	56	theme	As	119:120	arg1	plant					149:153	As a representative medicinal plant	119:153	As a representative medicinal plant in the Orchidaceae, Bletilla striata	119:190	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	3	57	theme	secondary	707:715	arg1	metabolites					717:727	secondary metabolites	707:727	secondary metabolites	707:727	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	3	58	theme	further	686:692	arg1	detection					694:702	further detection	686:702	further detection of secondary metabolites by HPLC-MS	686:738	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	6	59	from	differences	1145:1155	arg1	types					1164:1168	the types	1160:1168	the types of metabolites	1160:1183	The metabolomics results showed that there were no differences in the types of metabolites between B. striata and B. ochracea; however, there were differences in the contents of these metabolites.
35338508	2	60	theme	source	337:342	arg1	process					359:365	the basic medicinal materials source identification process	307:365	the basic medicinal materials source identification process	307:365	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	8	61	theme	preliminary	1792:1802	arg1	distinction					1804:1814	a preliminary distinction	1790:1814	a preliminary distinction between B. striata, B. ochracea and O. foliosa	1790:1861	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	3	62	theme	detection	694:702	arg1	determination					611:623	the systematic determination	596:623	the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS	596:738	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	8	63	theme	content	1707:1713	arg1	analysis					1676:1683	the analysis	1672:1683	the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research	1672:1787	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	1	64	theme	representative	124:137	arg1	plant					149:153	As a representative medicinal plant	119:153	As a representative medicinal plant in the Orchidaceae, Bletilla striata	119:190	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	1	65	theme	roles	227:231	arg1	variety					200:206	a variety	198:206	a variety of pharmacological roles	198:231	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	1	65	theme	roles	227:231	arg1	roles					227:231	pharmacological roles	211:231	pharmacological roles	211:231	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	7	66	theme	monosaccharide	1414:1427	arg1	composition					1429:1439	the monosaccharide composition	1410:1439	the monosaccharide composition was the same (glucose and mannose)	1410:1474	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	67	theme	many	1477:1480	arg1	metabolites					1492:1502	many different metabolites	1477:1502	many different metabolites	1477:1502	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	0	68	dep	Bletilla	13:20	arg1	striata					22:28	striata	22:28	striata	22:28	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	0	68	dep	Bletilla	13:20	arg1	metabolites					84:94	differential metabolites	71:94	differential metabolites	71:94	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	8	69	theme	composition	1734:1744	arg1	analysis					1676:1683	the analysis	1672:1683	the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research	1672:1787	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	1	70	theme	medicinal	139:147	arg1	plant					149:153	As a representative medicinal plant	119:153	As a representative medicinal plant in the Orchidaceae, Bletilla striata	119:190	As a representative medicinal plant in the Orchidaceae, Bletilla striata plays a variety of pharmacological roles in the clinic.
35338508	2	71	theme	materials	327:335	arg1	process					359:365	the basic medicinal materials source identification process	307:365	the basic medicinal materials source identification process	307:365	However, the emergence of counterfeit species is affecting the basic medicinal materials source identification process, for which Bletilla ochracea and Oreorchis foliosa of the Orchidaceae are two representative species.
35338508	8	72	dep	O.	1852:1853	arg1	foliosa					1855:1861	O. foliosa	1852:1861	O. foliosa	1852:1861	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	5	73	theme	polysaccharides	1062:1076	arg1	different					1083:1091	different	1083:1091	different	1083:1091	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	5	73	theme	polysaccharides	1062:1076	arg1	structures					1044:1053	the structures	1040:1053	the structures of the polysaccharides	1040:1076	Although the polysaccharides of both species were composed of glucose and mannose, the molar ratio of the two monosaccharides was different, suggesting that the structures of the polysaccharides were different.
35338508	3	74	theme	systematic	600:609	arg1	determination					611:623	the systematic determination	596:623	the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS	596:738	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	8	75	theme	monosaccharide	1719:1732	arg1	composition					1734:1744	monosaccharide composition	1719:1744	monosaccharide composition	1719:1744	Therefore, based on the analysis of the polysaccharide content and monosaccharide composition, combined with phase metabolomics research, a preliminary distinction between B. striata, B. ochracea and O. foliosa was achieved.
35338508	0	76	theme	Oreorchis	53:61	arg1	Screening					0:8	Screening	0:8	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites	0:94	Screening of Bletilla striata, Bletilla ochracea and Oreorchis foliosa differential metabolites based on metabolomics.
35338508	3	77	theme	metabolites	717:727	arg1	yields					643:648	polysaccharide yields	628:648	polysaccharide yields	628:648	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	3	77	theme	metabolites	717:727	arg1	composition					669:679	monosaccharide composition	654:679	monosaccharide composition	654:679	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	3	77	theme	metabolites	717:727	arg1	detection					694:702	further detection	686:702	further detection of secondary metabolites by HPLC-MS	686:738	For this study, 13 representative B. striata samples, three B. ochracea samples and three O. foliosa samples were selected for the systematic determination of polysaccharide yields and monosaccharide composition, and further detection of secondary metabolites by HPLC-MS.
35338508	7	78	theme	H34	1562:1564	arg1	O11					1566:1568	C36 H34 O11	1558:1568	C36 H34 O11	1558:1568	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
35338508	7	79	theme	C36	1558:1560	arg1	O11					1566:1568	C36 H34 O11	1558:1568	C36 H34 O11	1558:1568	Although there was no significant difference in the polysaccharide yields of B. striata and O. foliosa (p = 0.074) and the monosaccharide composition was the same (glucose and mannose), many different metabolites were screened out between them: six compounds such as C36 H34 O11 existed only in B. striata, while substance C39 H54 O22 was unique to O. foliosa.
36648436	0	0	theme	cancer-associated	78:94	arg1	changes					96:102	cancer-associated changes	78:102	cancer-associated changes in glycosylation	78:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	4	1	theme	molecular	873:881	arg1	targets					839:845	the well-described targets	820:845	the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC)	820:910	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	1	theme	molecular	873:881	arg1	C1GALT1C1					894:902	C1GALT1C1	894:902	C1GALT1C1 (COSMC)	894:910	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	1	theme	molecular	873:881	arg1	chaperone					883:891	its molecular chaperone	869:891	its molecular chaperone	869:891	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	6	2	gly	α2,6-sialylated	1187:1201	arg1	structures					1203:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	7	3	theme	cancer	1423:1428	arg1	tissue					1430:1435	cancer tissue	1423:1435	cancer tissue	1423:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	3	4	theme	monoclonal	706:715	arg1	antibodies					717:726	monoclonal antibodies	706:726	monoclonal antibodies against Tn and STn	706:745	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	8	5	theme	ZIP9	1550:1553	arg1	dysregulation					1533:1545	dysregulation	1533:1545	dysregulation of ZIP9 and Zn2+	1533:1562	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36648436	1	6	gly	sialylated	215:224	arg1	form					226:229	its sialylated form	211:229	its sialylated form (STn)	211:235	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	1	6	gly	sialylated	215:224	arg1	STn					232:234	STn	232:234	STn	232:234	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	6	7	theme	oligo-mannose	1155:1167	arg1	structures					1203:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	4	8	theme	cancer-associated	946:962	arg1	O-glycans					964:972	cancer-associated O-glycans	946:972	cancer-associated O-glycans	946:972	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	1	9	theme	immunological	314:326	arg1	escape					328:333	immunological escape	314:333	immunological escape	314:333	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	4	10	theme	Zn2+-transporter	777:792	arg1	ZIP9					803:806	ZIP9	803:806	ZIP9	803:806	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	10	theme	Zn2+-transporter	777:792	arg1	SLC39A9					794:800	the Zn2+-transporter SLC39A9	773:800	the Zn2+-transporter SLC39A9 (ZIP9)	773:807	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	0	11	theme	changes	96:102	arg1	ZIP9					25:28	ZIP9	25:28	ZIP9	25:28	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	11	theme	changes	96:102	arg1	homeostasis					52:62	dysregulated Zn2+ homeostasis	34:62	dysregulated Zn2+ homeostasis	34:62	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	11	theme	changes	96:102	arg1	cause					69:73	a cause	67:73	a cause of cancer-associated changes in glycosylation	67:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	6	12	theme	tri-	1244:1247	arg1	structures					1269:1278	tri- and tetra-antennary structures	1244:1278	tri- and tetra-antennary structures	1244:1278	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	5	13	theme	other	978:982	arg1	perturbations					989:1001	No other gene perturbations	975:1001	No other gene perturbations	975:1001	No other gene perturbations were found to reliably induce O-glycan truncation.
36648436	7	14	theme	COSMC	1466:1470	arg1	over-expression					1447:1461	over-expression	1447:1461	over-expression of COSMC	1447:1470	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	5	15	theme	gene	984:987	arg1	perturbations					989:1001	No other gene perturbations	975:1001	No other gene perturbations	975:1001	No other gene perturbations were found to reliably induce O-glycan truncation.
36648436	6	16	theme	knockout	1084:1091	arg1	ZIP9					1079:1082	ZIP9 knockout	1079:1091	ZIP9 knockout	1079:1091	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	6	17	theme	N-linked	1101:1108	arg1	glycosylation					1110:1122	N-linked glycosylation	1101:1122	N-linked glycosylation	1101:1122	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	4	18	theme	O-glycans	964:972	arg1	surface-expression					924:941	surface-expression	924:941	surface-expression of cancer-associated O-glycans	924:972	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	8	19	theme	cell	1605:1608	arg1	surface					1610:1616	the cell surface	1601:1616	the cell surface	1601:1616	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36648436	8	20	gly	glycosylation	1584:1596	arg1	surface					1610:1616	the cell surface	1601:1616	the cell surface	1601:1616	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36648436	7	21	from	accumulation	1310:1321	arg1	pathway					1348:1354	the secretory pathway	1334:1354	the secretory pathway	1334:1354	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	4	22	theme	SLC39A9	794:800	arg1	knockout					761:768	knockout	761:768	knockout	761:768	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	6	23	theme	α2,6-sialylated	1187:1201	arg1	structures					1203:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	1	24	theme	Thomson-nouveau	178:192	arg1	Tn					203:204	Tn	203:204	Tn	203:204	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	1	24	theme	Thomson-nouveau	178:192	arg1	antigen					194:200	the Thomson-nouveau antigen	174:200	the Thomson-nouveau antigen (Tn)	174:205	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	6	25	link	N-linked	1101:1108	arg1	glycosylation					1110:1122	N-linked glycosylation	1101:1122	N-linked glycosylation	1101:1122	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	0	26	from	changes	96:102	arg1	glycosylation					107:119	glycosylation	107:119	glycosylation	107:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	7	27	from	tissue	1430:1435	arg1	presentation					1384:1395	cell-surface presentation	1371:1395	cell-surface presentation of truncated O-glycans in cancer tissue	1371:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	7	28	theme	cell-surface	1371:1382	arg1	presentation					1384:1395	cell-surface presentation	1371:1395	cell-surface presentation of truncated O-glycans in cancer tissue	1371:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	6	29	theme	tetra-antennary	1253:1267	arg1	structures					1269:1278	tri- and tetra-antennary structures	1244:1278	tri- and tetra-antennary structures	1244:1278	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	4	30	theme	well-described	824:837	arg1	chaperone					883:891	its molecular chaperone	869:891	its molecular chaperone	869:891	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	30	theme	well-described	824:837	arg1	targets					839:845	the well-described targets	820:845	the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC)	820:910	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	30	theme	well-described	824:837	arg1	C1GALT1					847:853	C1GALT1	847:853	C1GALT1 (C1GalT1)	847:863	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	2	31	theme	cancer	406:411	arg1	development					413:423	cancer development	406:423	cancer development	406:423	Recent studies have shown that these carbohydrate epitopes facilitate cancer development and can be targeted therapeutically; however, the mechanism underpinning their expression remains unclear.
36648436	7	32	theme	secretory	1338:1346	arg1	pathway					1348:1354	the secretory pathway	1334:1354	the secretory pathway	1334:1354	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	7	33	theme	such	1482:1485	arg1	changes					1487:1493	such changes	1482:1493	such changes	1482:1493	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	6	34	theme	hybrid-type	1170:1180	arg1	structures					1203:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	oligo-mannose, hybrid-type, and α2,6-sialylated structures	1155:1212	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	4	35	dep	targets	839:845	arg1	targets					839:845	the well-described targets	820:845	the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC)	820:910	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	35	dep	targets	839:845	arg1	C1GALT1C1					894:902	C1GALT1C1	894:902	C1GALT1C1 (COSMC)	894:910	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	35	dep	targets	839:845	arg1	chaperone					883:891	its molecular chaperone	869:891	its molecular chaperone	869:891	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	35	dep	targets	839:845	arg1	C1GalT1					856:862	C1GalT1	856:862	C1GalT1	856:862	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	4	35	dep	targets	839:845	arg1	C1GALT1					847:853	C1GALT1	847:853	C1GALT1 (C1GalT1)	847:863	We show that knockout of the Zn2+-transporter SLC39A9 (ZIP9), alongside the well-described targets C1GALT1 (C1GalT1) and its molecular chaperone, C1GALT1C1 (COSMC), results in surface-expression of cancer-associated O-glycans.
36648436	0	36	theme	Zn2+	47:50	arg1	ZIP9					25:28	ZIP9	25:28	ZIP9	25:28	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	36	theme	Zn2+	47:50	arg1	homeostasis					52:62	dysregulated Zn2+ homeostasis	34:62	dysregulated Zn2+ homeostasis	34:62	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	36	theme	Zn2+	47:50	arg1	cause					69:73	a cause	67:73	a cause of cancer-associated changes in glycosylation	67:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	1	37	theme	cell	262:265	arg1	surface					267:273	the cell surface	258:273	the cell surface	258:273	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	7	38	from	O-glycans	1410:1418	arg1	tissue					1430:1435	cancer tissue	1423:1435	cancer tissue	1423:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	3	39	theme	O-glycans	607:615	arg1	expression					575:584	the expression	571:584	the expression of cancer-associated O-glycans	571:615	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	0	40	theme	dysregulated	34:45	arg1	ZIP9					25:28	ZIP9	25:28	ZIP9	25:28	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	40	theme	dysregulated	34:45	arg1	homeostasis					52:62	dysregulated Zn2+ homeostasis	34:62	dysregulated Zn2+ homeostasis	34:62	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	40	theme	dysregulated	34:45	arg1	cause					69:73	a cause	67:73	a cause of cancer-associated changes in glycosylation	67:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	41	from	cause	69:73	arg1	glycosylation					107:119	glycosylation	107:119	glycosylation	107:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	5	42	theme	O-glycan	1033:1040	arg1	truncation					1042:1051	O-glycan truncation	1033:1051	O-glycan truncation	1033:1051	No other gene perturbations were found to reliably induce O-glycan truncation.
36648436	2	43	theme	carbohydrate	373:384	arg1	epitopes					386:393	these carbohydrate epitopes	367:393	these carbohydrate epitopes	367:393	Recent studies have shown that these carbohydrate epitopes facilitate cancer development and can be targeted therapeutically; however, the mechanism underpinning their expression remains unclear.
36648436	8	44	theme	glycosylation	1635:1647	arg1	machinery					1649:1657	the glycosylation machinery	1631:1657	the glycosylation machinery	1631:1657	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36648436	6	45	theme	structures	1269:1278	arg1	down-regulation					1225:1239	down-regulation	1225:1239	up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures	1138:1278	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	6	45	theme	structures	1269:1278	arg1	up-regulation					1138:1150	up-regulation	1138:1150	up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures	1138:1278	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	7	46	theme	Zn2+	1326:1329	arg1	accumulation					1310:1321	accumulation	1310:1321	accumulation of Zn2+ in the secretory pathway	1310:1354	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	8	47	from	glycosylation	1584:1596	arg1	surface					1610:1616	the cell surface	1601:1616	the cell surface	1601:1616	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36648436	8	48	theme	Zn2+	1559:1562	arg1	dysregulation					1533:1545	dysregulation	1533:1545	dysregulation of ZIP9 and Zn2+	1533:1562	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36648436	3	49	theme	cancer-associated	589:605	arg1	O-glycans					607:615	cancer-associated O-glycans	589:615	cancer-associated O-glycans	589:615	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	1	50	theme	epithelial	125:134	arg1	cancers					136:142	epithelial cancers	125:142	epithelial cancers	125:142	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	0	51	from	glycosylation	107:119	arg1	ZIP9					25:28	ZIP9	25:28	ZIP9	25:28	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	51	from	glycosylation	107:119	arg1	homeostasis					52:62	dysregulated Zn2+ homeostasis	34:62	dysregulated Zn2+ homeostasis	34:62	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	0	51	from	glycosylation	107:119	arg1	cause					69:73	a cause	67:73	a cause of cancer-associated changes in glycosylation	67:119	CRISPR-screen identifies ZIP9 and dysregulated Zn2+ homeostasis as a cause of cancer-associated changes in glycosylation.
36648436	6	52	theme	structures	1203:1212	arg1	down-regulation					1225:1239	down-regulation	1225:1239	up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures	1138:1278	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	6	52	theme	structures	1203:1212	arg1	up-regulation					1138:1150	up-regulation	1138:1150	up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures	1138:1278	We furthermore show that ZIP9 knockout affects N-linked glycosylation, resulting in up-regulation of oligo-mannose, hybrid-type, and α2,6-sialylated structures as well as down-regulation of tri- and tetra-antennary structures.
36648436	3	53	theme	genome	670:675	arg1	knockout-screen					684:698	an unbiased, positive-selection, whole genome CRISPR knockout-screen	631:698	an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn	631:745	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	3	54	theme	unbiased	634:641	arg1	knockout-screen					684:698	an unbiased, positive-selection, whole genome CRISPR knockout-screen	631:698	an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn	631:745	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	1	55	theme	sialylated	215:224	arg1	form					226:229	its sialylated form	211:229	its sialylated form (STn)	211:235	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	1	55	theme	sialylated	215:224	arg1	STn					232:234	STn	232:234	STn	232:234	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	3	56	dep	unbiased	634:641	arg1	whole					664:668	whole	664:668	whole	664:668	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	3	56	dep	unbiased	634:641	arg1	positive-selection					644:661	positive-selection	644:661	positive-selection	644:661	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	3	57	theme	CRISPR	677:682	arg1	knockout-screen					684:698	an unbiased, positive-selection, whole genome CRISPR knockout-screen	631:698	an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn	631:745	To identify genes directly influencing the expression of cancer-associated O-glycans, we conducted an unbiased, positive-selection, whole genome CRISPR knockout-screen using monoclonal antibodies against Tn and STn.
36648436	7	58	theme	truncated	1400:1408	arg1	O-glycans					1410:1418	truncated O-glycans	1400:1418	truncated O-glycans in cancer tissue	1400:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	1	59	theme	truncated	145:153	arg1	form					226:229	its sialylated form	211:229	its sialylated form (STn)	211:235	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	1	59	theme	truncated	145:153	arg1	O-glycans					155:163	truncated O-glycans	145:163	truncated O-glycans	145:163	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	1	59	theme	truncated	145:153	arg1	antigen					194:200	the Thomson-nouveau antigen	174:200	the Thomson-nouveau antigen (Tn)	174:205	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	1	60	theme	poor	295:298	arg1	prognosis					300:308	poor prognosis	295:308	poor prognosis	295:308	In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are up-regulated on the cell surface and associated with poor prognosis and immunological escape.
36648436	7	61	theme	O-glycans	1410:1418	arg1	presentation					1384:1395	cell-surface presentation	1371:1395	cell-surface presentation of truncated O-glycans in cancer tissue	1371:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	7	62	from	presentation	1384:1395	arg1	tissue					1430:1435	cancer tissue	1423:1435	cancer tissue	1423:1435	Finally, we demonstrate that accumulation of Zn2+ in the secretory pathway coincides with cell-surface presentation of truncated O-glycans in cancer tissue, and that over-expression of COSMC mitigates such changes.
36648436	2	63	theme	Recent	336:341	arg1	studies					343:349	Recent studies	336:349	Recent studies	336:349	Recent studies have shown that these carbohydrate epitopes facilitate cancer development and can be targeted therapeutically; however, the mechanism underpinning their expression remains unclear.
36648436	8	64	theme	cancer-like	1572:1582	arg1	glycosylation					1584:1596	cancer-like glycosylation	1572:1596	cancer-like glycosylation on the cell surface	1572:1616	Collectively, the findings show that dysregulation of ZIP9 and Zn2+ induces cancer-like glycosylation on the cell surface by affecting the glycosylation machinery.
36181715	0	0	theme	Solid-State	87:97	arg1	Spectroscopy					103:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	0	1	from	Interactions	21:32	arg1	Walls					49:53	Fungal Cell Walls	37:53	Fungal Cell Walls	37:53	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	2	2	theme	Basidiomycota	653:665	arg1	phylum					667:672	the Basidiomycota phylum	649:672	the Basidiomycota phylum	649:672	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	3	dep	composition	536:546	arg1	the					519:521	the	519:521	the	519:521	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	4	theme	field	388:392	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	4	5	theme	molecular	1077:1085	arg1	make-up					1087:1093	the molecular make-up	1073:1093	the molecular make-up of cells wall	1073:1107	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	3	6	theme	metal	865:869	arg1	concentrations					875:888	high metal ion concentrations	860:888	high metal ion concentrations	860:888	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	0	7	theme	H-Detected	76:85	arg1	Spectroscopy					103:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	2	8	theme	atomic-level	523:534	arg1	composition					536:546	atomic-level composition	523:546	atomic-level composition	523:546	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	1	9	theme	non-destructive	170:184	arg1	characterization					186:201	the non-destructive characterization	166:201	the non-destructive characterization of structurally heterogeneous biomolecules in their native setting	166:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	4	10	theme	cells	1098:1102	arg1	wall					1104:1107	cells wall	1098:1107	cells wall	1098:1107	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	3	11	theme	ion	871:873	arg1	concentrations					875:888	high metal ion concentrations	860:888	high metal ion concentrations	860:888	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	2	12	theme	ultra-high	377:386	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	0	13	theme	NMR	99:101	arg1	Spectroscopy					103:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	4	14	dep	proteins	1036:1043	arg1	SC3					1045:1047	SC3	1045:1047	SC3	1045:1047	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	15	theme	layer	1155:1159	arg1	proteins					1036:1043	the hydrophobin proteins	1020:1043	the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	1020:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	15	theme	layer	1155:1159	arg1	positioning					1124:1134	the positioning	1120:1134	the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	1020:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	3	16	theme	high	860:863	arg1	concentrations					875:888	high metal ion concentrations	860:888	high metal ion concentrations	860:888	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	5	17	from	relevance	1208:1216	arg1	material					1252:1259	material	1252:1259	material	1252:1259	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36181715	5	17	from	relevance	1208:1216	arg1	contexts					1284:1291	biomedical contexts	1273:1291	biomedical contexts	1273:1291	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36181715	4	18	theme	polypeptide	1143:1153	arg1	layer					1155:1159	the polypeptide layer	1139:1159	the polypeptide layer	1139:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	2	19	theme	spectroscopy	422:433	arg1	utility					357:363	the utility	353:363	the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum	353:672	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	20	theme	structural	552:561	arg1	arrangement					563:573	structural arrangement	552:573	structural arrangement	552:573	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	3	21	theme	antifungal	740:749	arg1	Cathelicidin-2					759:772	the antifungal peptide Cathelicidin-2	736:772	the antifungal peptide Cathelicidin-2	736:772	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	5	22	theme	future	1222:1227	arg1	research					1229:1236	future research	1222:1236	future research into fungi	1222:1247	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36181715	2	23	theme	ssNMR	416:420	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	0	24	theme	Cell-Surface	8:19	arg1	Interactions					21:32	Cell-Surface Interactions	8:32	Cell-Surface Interactions in Fungal Cell Walls	8:53	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	3	25	theme	peptide	751:757	arg1	Cathelicidin-2					759:772	the antifungal peptide Cathelicidin-2	736:772	the antifungal peptide Cathelicidin-2	736:772	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	2	26	theme	MAS	412:414	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	27	theme	spectral	477:484	arg1	resolution					486:495	spectral resolution	477:495	spectral resolution	477:495	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	3	28	theme	cell	789:792	arg1	proteins					799:806	cell wall proteins	789:806	cell wall proteins	789:806	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	1	29	theme	heterogeneous	219:231	arg1	biomolecules					233:244	structurally heterogeneous biomolecules	206:244	structurally heterogeneous biomolecules in their native setting	206:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	3	30	theme	wall	794:797	arg1	proteins					799:806	cell wall proteins	789:806	cell wall proteins	789:806	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	2	31	theme	Schizophyllum	595:607	arg1	fungus					637:642	a mushroom-forming fungus	618:642	a mushroom-forming fungus from the Basidiomycota phylum	618:672	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	31	theme	Schizophyllum	595:607	arg1	commune					609:615	Schizophyllum commune	595:615	Schizophyllum commune	595:615	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	1	32	theme	biomolecules	233:244	arg1	characterization					186:201	the non-destructive characterization	166:201	the non-destructive characterization of structurally heterogeneous biomolecules in their native setting	166:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	1	33	theme	Solid-state	117:127	arg1	spectroscopy					141:152	Solid-state NMR (ssNMR) spectroscopy	117:152	Solid-state NMR (ssNMR) spectroscopy	117:152	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	4	34	contain	containing	953:962	arg2	galactosamine					973:985	N-acetyl galactosamine	964:985	N-acetyl galactosamine (GalNAc)	964:994	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	34	contain	containing	953:962	arg2	GalNAc					988:993	GalNAc	988:993	GalNAc	988:993	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	34	contain	containing	953:962	arg2	proteins					1000:1007	proteins	1000:1007	proteins	1000:1007	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	34	contain	containing	953:962	arg2	proteins					1036:1043	the hydrophobin proteins	1020:1043	the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	1020:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	34	contain	containing	953:962	arg1	polysaccharides					937:951	polysaccharides	937:951	polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	937:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	34	contain	containing	953:962	arg2	positioning					1124:1134	the positioning	1120:1134	the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	1020:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	0	35	theme	Cell	44:47	arg1	Walls					49:53	Fungal Cell Walls	37:53	Fungal Cell Walls	37:53	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	2	36	theme	wall	587:590	arg1	composition					536:546	atomic-level composition	523:546	atomic-level composition	523:546	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	36	theme	wall	587:590	arg1	arrangement					563:573	structural arrangement	552:573	structural arrangement	552:573	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	37	theme	fast	407:410	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	0	38	theme	Fungal	37:42	arg1	Walls					49:53	Fungal Cell Walls	37:53	Fungal Cell Walls	37:53	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	3	39	theme	low	811:813	arg1	concentrations					815:828	low concentrations	811:828	low concentrations while glucans are targeted at high metal ion concentrations	811:888	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	2	40	theme	cell	582:585	arg1	wall					587:590	the cell wall	578:590	the cell wall	578:590	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	1	41	theme	native	255:260	arg1	setting					262:268	their native setting	249:268	their native setting	249:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	2	42	from	phylum	667:672	arg1	fungus					637:642	a mushroom-forming fungus	618:642	a mushroom-forming fungus from the Basidiomycota phylum	618:672	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	42	from	phylum	667:672	arg1	commune					609:615	Schizophyllum commune	595:615	Schizophyllum commune	595:615	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	43	theme	mushroom-forming	620:635	arg1	fungus					637:642	a mushroom-forming fungus	618:642	a mushroom-forming fungus from the Basidiomycota phylum	618:672	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	43	theme	mushroom-forming	620:635	arg1	commune					609:615	Schizophyllum commune	595:615	Schizophyllum commune	595:615	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	5	44	theme	critical	1199:1206	arg1	relevance					1208:1216	critical relevance	1199:1216	critical relevance for future research into fungi	1199:1247	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36181715	4	45	theme	polysaccharides	937:951	arg1	presence					925:932	the presence	921:932	the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	921:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	1	46	theme	NMR	129:131	arg1	spectroscopy					141:152	Solid-state NMR (ssNMR) spectroscopy	117:152	Solid-state NMR (ssNMR) spectroscopy	117:152	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	4	47	theme	N-acetyl	964:971	arg1	GalNAc					988:993	GalNAc	988:993	GalNAc	988:993	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	4	47	theme	N-acetyl	964:971	arg1	galactosamine					973:985	N-acetyl galactosamine	964:985	N-acetyl galactosamine (GalNAc)	964:994	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	5	48	dep	material	1252:1259	arg1	science					1261:1267	science	1261:1267	science	1261:1267	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36181715	1	49	from	biomolecules	233:244	arg1	setting					262:268	their native setting	249:268	their native setting	249:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	2	50	theme	high	368:371	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	5	51	theme	such	1172:1175	arg1	information					1177:1187	such information	1172:1187	such information	1172:1187	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36181715	1	52	from	setting	262:268	arg1	characterization					186:201	the non-destructive characterization	166:201	the non-destructive characterization of structurally heterogeneous biomolecules in their native setting	166:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	1	53	theme	ssNMR	134:138	arg1	spectroscopy					141:152	Solid-state NMR (ssNMR) spectroscopy	117:152	Solid-state NMR (ssNMR) spectroscopy	117:152	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	4	54	theme	wall	1104:1107	arg1	make-up					1087:1093	the molecular make-up	1073:1093	the molecular make-up of cells wall	1073:1107	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	2	55	theme	commune	609:615	arg1	composition					536:546	atomic-level composition	523:546	atomic-level composition	523:546	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	55	theme	commune	609:615	arg1	arrangement					563:573	structural arrangement	552:573	structural arrangement	552:573	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	3	56	theme	Cu	720:721	arg1	ions					727:730	Cu(II) ions	720:730	Cu(II) ions	720:730	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	2	57	theme	increased	451:459	arg1	sensitivity					461:471	increased sensitivity	451:471	increased sensitivity	451:471	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	2	58	theme	H-detected	396:405	arg1	spectroscopy					422:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy	368:433	Here we demonstrate the utility of high and ultra-high field 1 H-detected fast MAS ssNMR spectroscopy, which exhibits increased sensitivity and spectral resolution, to further elucidate the atomic-level composition and structural arrangement of the cell wall of Schizophyllum commune, a mushroom-forming fungus from the Basidiomycota phylum.
36181715	0	59	theme	High-Resolution	58:72	arg1	Spectroscopy					103:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	High-Resolution 1 H-Detected Solid-State NMR Spectroscopy	58:114	Probing Cell-Surface Interactions in Fungal Cell Walls by High-Resolution 1 H-Detected Solid-State NMR Spectroscopy.
36181715	4	60	theme	hydrophobin	1024:1034	arg1	proteins					1036:1043	the hydrophobin proteins	1020:1043	the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer	1020:1159	In addition, our data suggest the presence of polysaccharides containing N-acetyl galactosamine (GalNAc) and proteins, including the hydrophobin proteins SC3, shedding more light on the molecular make-up of cells wall as well as the positioning of the polypeptide layer.
36181715	1	61	from	characterization	186:201	arg1	setting					262:268	their native setting	249:268	their native setting	249:268	Solid-state NMR (ssNMR) spectroscopy facilitates the non-destructive characterization of structurally heterogeneous biomolecules in their native setting, for example, comprising proteins, lipids and polysaccharides.
36181715	3	62	dep	concentrations	815:828	arg1	targeted					848:855	targeted	848:855	are targeted at high metal ion concentrations	844:888	These advancements allowed us to reveal that Cu(II) ions and the antifungal peptide Cathelicidin-2 mainly bind to cell wall proteins at low concentrations while glucans are targeted at high metal ion concentrations.
36181715	5	63	theme	biomedical	1273:1282	arg1	contexts					1284:1291	biomedical contexts	1273:1291	biomedical contexts	1273:1291	Obtaining such information may be of critical relevance for future research into fungi in material science and biomedical contexts.
36596166	4	0	theme	tea	730:732	arg1	polysaccharides					734:748	Tibetan tea polysaccharides	722:748	Tibetan tea polysaccharides	722:748	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	1	1	theme	functional	162:171	arg1	prebiotic					173:181	a functional prebiotic	160:181	a functional prebiotic	160:181	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	2	2	theme	fermentation	536:547	arg1	stages					549:554	fecal fermentation stages	530:554	fecal fermentation stages	530:554	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	6	3	theme	gut	1241:1243	arg1	microbiota					1245:1254	human gut microbiota	1235:1254	human gut microbiota	1235:1254	These results suggest that Tibetan tea polysaccharides could be developed as a prebiotic to regulate human gut microbiota.
36596166	0	4	theme	polysaccharides	89:103	arg1	fermentation					73:84	colonic fermentation	65:84	colonic fermentation of polysaccharides from four varieties of Tibetan tea	65:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	4	5	theme	bacteria	792:799	arg1	growth					766:771	the growth	762:771	the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs)	762:978	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	1	6	theme	functional	286:295	arg1	components					304:313	the functional active components	282:313	the functional active components	282:313	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	4	7	theme	intestinal	892:901	arg1	microorganisms					903:916	intestinal microorganisms	892:916	intestinal microorganisms	892:916	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	6	8	theme	tea	1169:1171	arg1	polysaccharides					1173:1187	Tibetan tea polysaccharides	1161:1187	Tibetan tea polysaccharides	1161:1187	These results suggest that Tibetan tea polysaccharides could be developed as a prebiotic to regulate human gut microbiota.
36596166	6	8	theme	tea	1169:1171	arg1	prebiotic					1213:1221	a prebiotic	1211:1221	a prebiotic to regulate human gut microbiota	1211:1254	These results suggest that Tibetan tea polysaccharides could be developed as a prebiotic to regulate human gut microbiota.
36596166	2	9	theme	physicochemical	381:395	arg1	characteristics					397:411	the physicochemical characteristics	377:411	the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas	377:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	2	10	theme	simulated	467:475	arg1	stages					487:492	simulated digestion stages	467:492	simulated digestion stages	467:492	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	2	11	theme	teas	459:462	arg1	kinds					442:446	four kinds	437:446	four kinds of Tibetan teas	437:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	6	12	theme	Tibetan	1161:1167	arg1	polysaccharides					1173:1187	Tibetan tea polysaccharides	1161:1187	Tibetan tea polysaccharides	1161:1187	These results suggest that Tibetan tea polysaccharides could be developed as a prebiotic to regulate human gut microbiota.
36596166	6	12	theme	Tibetan	1161:1167	arg1	prebiotic					1213:1221	a prebiotic	1211:1221	a prebiotic to regulate human gut microbiota	1211:1254	These results suggest that Tibetan tea polysaccharides could be developed as a prebiotic to regulate human gut microbiota.
36596166	4	13	theme	in	683:684	arg1	fermentation					708:719	in vitro fecal microbial fermentation	683:719	in vitro fecal microbial fermentation	683:719	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	2	14	from	stages	487:492	arg1	microbiota					516:525	the microbiota	512:525	the microbiota of fecal fermentation stages	512:554	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	6	15	theme	human	1235:1239	arg1	microbiota					1245:1254	human gut microbiota	1235:1254	human gut microbiota	1235:1254	These results suggest that Tibetan tea polysaccharides could be developed as a prebiotic to regulate human gut microbiota.
36596166	1	16	theme	numerous	188:195	arg1	activities					197:206	numerous activities	188:206	numerous activities such as regulating intestinal microorganisms	188:251	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	0	17	theme	In	0:1	arg1	digestion					19:27	In vitro simulated digestion	0:27	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.	0:139	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	1	18	theme	active	297:302	arg1	components					304:313	the functional active components	282:313	the functional active components	282:313	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	4	19	theme	microorganisms	903:916	arg1	composition					877:887	the composition	873:887	the composition of intestinal microorganisms	873:916	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	20	theme	fecal	692:696	arg1	fermentation					708:719	in vitro fecal microbial fermentation	683:719	in vitro fecal microbial fermentation	683:719	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	2	21	theme	Tibetan	451:457	arg1	teas					459:462	Tibetan teas	451:462	Tibetan teas	451:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	1	22	theme	components	304:313	arg1	components					304:313	the functional active components	282:313	the functional active components	282:313	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	1	22	theme	components	304:313	arg1	one					275:277	one	275:277	one	275:277	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	0	23	theme	Tibetan	128:134	arg1	tea					136:138	Tibetan tea	128:138	Tibetan tea	128:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	4	24	theme	beneficial	781:790	arg1	Phascolarctobacterium					841:861	Phascolarctobacterium	841:861	Phascolarctobacterium	841:861	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	24	theme	beneficial	781:790	arg1	Prevotella					826:835	Prevotella	826:835	Prevotella	826:835	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	24	theme	beneficial	781:790	arg1	bacteria					792:799	some beneficial bacteria	776:799	some beneficial bacteria such as Bifidobacterium	776:823	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	24	theme	beneficial	781:790	arg1	Bifidobacterium					809:823	Bifidobacterium	809:823	Bifidobacterium	809:823	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	2	25	from	effect	502:507	arg1	microbiota					516:525	the microbiota	512:525	the microbiota of fecal fermentation stages	512:554	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	4	26	theme	Tibetan	722:728	arg1	polysaccharides					734:748	Tibetan tea polysaccharides	722:748	Tibetan tea polysaccharides	722:748	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	27	theme	microbial	698:706	arg1	fermentation					708:719	in vitro fecal microbial fermentation	683:719	in vitro fecal microbial fermentation	683:719	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	0	28	from	fermentation	73:84	arg1	tea					136:138	Tibetan tea	128:138	Tibetan tea	128:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	0	28	from	fermentation	73:84	arg1	varieties					115:123	four varieties	110:123	four varieties of Tibetan tea	110:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	5	29	theme	microorganisms	1057:1070	arg1	production					1033:1042	the production	1029:1042	the production of SCFAs and microorganisms including Bacteroides, Bifidobacterium and Lachnoclostridium	1029:1131	Finally, a strong correlation was found between the production of SCFAs and microorganisms including Bacteroides, Bifidobacterium and Lachnoclostridium.
36596166	0	30	theme	tea	136:138	arg1	tea					136:138	Tibetan tea	128:138	Tibetan tea	128:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	0	30	theme	tea	136:138	arg1	varieties					115:123	four varieties	110:123	four varieties of Tibetan tea	110:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	1	31	contain	have	183:186	arg2	activities					197:206	numerous activities	188:206	numerous activities such as regulating intestinal microorganisms	188:251	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	1	31	contain	have	183:186	arg1	Polysaccharides					141:155	Polysaccharides	141:155	Polysaccharides as a functional prebiotic	141:181	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	2	32	theme	stages	549:554	arg1	microbiota					516:525	the microbiota	512:525	the microbiota of fecal fermentation stages	512:554	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	1	33	theme	intestinal	227:236	arg1	microorganisms					238:251	intestinal microorganisms	227:251	intestinal microorganisms	227:251	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	2	34	theme	digestion	477:485	arg1	stages					487:492	simulated digestion stages	467:492	simulated digestion stages	467:492	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	4	35	theme	fatty	960:964	arg1	acids					966:970	short-chain fatty acids	948:970	short-chain fatty acids (SCFAs)	948:978	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	35	theme	fatty	960:964	arg1	SCFAs					973:977	SCFAs	973:977	SCFAs	973:977	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	3	36	theme	Tibetan	592:598	arg1	polysaccharides					604:618	Tibetan tea polysaccharides	592:618	Tibetan tea polysaccharides	592:618	The results revealed that Tibetan tea polysaccharides were partially digested during digestion.
36596166	0	37	theme	microbial	36:44	arg1	characteristics					46:60	and microbial characteristics	32:60	and microbial characteristics	32:60	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	4	38	theme	short-chain	948:958	arg1	acids					966:970	short-chain fatty acids	948:970	short-chain fatty acids (SCFAs)	948:978	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	4	38	theme	short-chain	948:958	arg1	SCFAs					973:977	SCFAs	973:977	SCFAs	973:977	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	0	39	from	varieties	115:123	arg1	fermentation					73:84	colonic fermentation	65:84	colonic fermentation of polysaccharides from four varieties of Tibetan tea	65:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	0	39	from	varieties	115:123	arg1	polysaccharides					89:103	polysaccharides	89:103	polysaccharides from four varieties of Tibetan tea	89:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	3	40	theme	tea	600:602	arg1	polysaccharides					604:618	Tibetan tea polysaccharides	592:618	Tibetan tea polysaccharides	592:618	The results revealed that Tibetan tea polysaccharides were partially digested during digestion.
36596166	4	41	dep	in	683:684	arg1	vitro					686:690	vitro	686:690	vitro	686:690	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	2	42	from	characteristics	397:411	arg1	kinds					442:446	four kinds	437:446	four kinds of Tibetan teas	437:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	5	43	theme	strong	992:997	arg1	correlation					999:1009	a strong correlation	990:1009	a strong correlation	990:1009	Finally, a strong correlation was found between the production of SCFAs and microorganisms including Bacteroides, Bifidobacterium and Lachnoclostridium.
36596166	4	44	theme	acids	966:970	arg1	production					934:943	the production	930:943	the production of short-chain fatty acids (SCFAs)	930:978	Additionally, during in vitro fecal microbial fermentation, Tibetan tea polysaccharides can promote the growth of some beneficial bacteria such as Bifidobacterium, Prevotella and Phascolarctobacterium to change the composition of intestinal microorganisms and promote the production of short-chain fatty acids (SCFAs).
36596166	1	45	dep	one	275:277	arg1	known					331:335	known	331:335	has been known	322:335	Polysaccharides as a functional prebiotic have numerous activities such as regulating intestinal microorganisms and polysaccharide is one of the functional active components in tea has been known.
36596166	0	46	theme	colonic	65:71	arg1	fermentation					73:84	colonic fermentation	65:84	colonic fermentation of polysaccharides from four varieties of Tibetan tea	65:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	2	47	theme	polysaccharides	416:430	arg1	characteristics					397:411	the physicochemical characteristics	377:411	the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas	377:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	5	48	theme	SCFAs	1047:1051	arg1	production					1033:1042	the production	1029:1042	the production of SCFAs and microorganisms including Bacteroides, Bifidobacterium and Lachnoclostridium	1029:1131	Finally, a strong correlation was found between the production of SCFAs and microorganisms including Bacteroides, Bifidobacterium and Lachnoclostridium.
36596166	0	49	theme	characteristics	46:60	arg1	digestion					19:27	In vitro simulated digestion	0:27	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.	0:139	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	0	50	from	digestion	19:27	arg1	fermentation					73:84	colonic fermentation	65:84	colonic fermentation of polysaccharides from four varieties of Tibetan tea	65:138	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	0	51	dep	In	0:1	arg1	simulated					9:17	simulated	9:17	simulated	9:17	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	0	51	dep	In	0:1	arg1	vitro					3:7	vitro	3:7	vitro	3:7	In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea.
36596166	2	52	from	kinds	442:446	arg1	characteristics					397:411	the physicochemical characteristics	377:411	the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas	377:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	2	52	from	kinds	442:446	arg1	polysaccharides					416:430	polysaccharides	416:430	polysaccharides from four kinds of Tibetan teas	416:462	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
36596166	2	53	theme	fecal	530:534	arg1	stages					549:554	fecal fermentation stages	530:554	fecal fermentation stages	530:554	In this study, we aimed to investigate the physicochemical characteristics of polysaccharides from four kinds of Tibetan teas at simulated digestion stages and the effect on the microbiota of fecal fermentation stages in vitro.
37146861	0	0	theme	polysaccharides	96:110	arg1	Comparison					0:9	Comparison	0:9	Comparison	0:9	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	0	0	theme	polysaccharides	96:110	arg1	method					53:58	the lipid-lowering ability evaluation method	15:58	the lipid-lowering ability evaluation method	15:58	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	2	1	theme	apparent	671:678	arg1	viscosity					680:688	apparent viscosity	671:688	apparent viscosity	671:688	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	1	2	theme	typical	177:183	arg1	glucomannans					196:207	typical acetylated glucomannans	177:207	typical acetylated glucomannans	177:207	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	4	3	theme	apparent	1115:1122	arg1	viscosity					1124:1132	high apparent viscosity	1110:1132	high apparent viscosity	1110:1132	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	0	4	theme	officinale	85:94	arg1	polysaccharides					96:110	Dendrobium officinale polysaccharides	74:110	Dendrobium officinale polysaccharides from different origins	74:133	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	3	5	theme	component	755:763	arg1	PCA					775:777	PCA	775:777	PCA	775:777	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	3	5	theme	component	755:763	arg1	analysis					765:772	Principal component analysis	745:772	Principal component analysis (PCA)	745:778	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	3	5	theme	component	755:763	arg1	method					783:788	a method	781:788	a method for analyzing multiple variables	781:821	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	1	6	theme	acetylated	185:194	arg1	glucomannans					196:207	typical acetylated glucomannans	177:207	typical acetylated glucomannans	177:207	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	4	7	theme	large	1138:1142	arg1	ratio					1167:1171	large D-mannose-to-d-glucose ratio	1138:1171	large D-mannose-to-d-glucose ratio	1138:1171	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	3	8	theme	structural	893:902	arg1	properties					904:913	the physicochemical and structural properties	869:913	the physicochemical and structural properties	869:913	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	0	9	theme	different	117:125	arg1	origins					127:133	different origins	117:133	different origins	117:133	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	0	10	from	Comparison	0:9	arg1	origins					127:133	different origins	117:133	different origins	117:133	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	1	11	theme	structural	294:303	arg1	characteristics					305:319	their structural characteristics	288:319	their structural characteristics	288:319	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	2	12	theme	composition	585:595	arg1	degree					544:549	the degree	540:549	the degree of acetylation and monosaccharide composition	540:595	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	13	theme	water	650:654	arg1	absorption					656:665	water absorption	650:665	water absorption	650:665	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	3	14	theme	physicochemical	873:887	arg1	properties					904:913	the physicochemical and structural properties	869:913	the physicochemical and structural properties	869:913	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	2	15	theme	monosaccharide	570:583	arg1	composition					585:595	monosaccharide composition	570:595	monosaccharide composition	570:595	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	0	16	from	method	53:58	arg1	origins					127:133	different origins	117:133	different origins	117:133	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	2	17	theme	lipid-lowering	699:712	arg1	activity					714:721	the lipid-lowering activity	695:721	the lipid-lowering activity of the obtained DOPs	695:742	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	5	18	theme	officinale	1310:1319	arg1	application					1292:1302	application	1292:1302	application	1292:1302	Therefore, this study provides a reference for the selection and application of D. officinale.
37146861	5	18	theme	officinale	1310:1319	arg1	selection					1278:1286	selection	1278:1286	selection	1278:1286	Therefore, this study provides a reference for the selection and application of D. officinale.
37146861	4	19	theme	lipid-lowering	1041:1054	arg1	activity					1056:1063	lipid-lowering activity	1041:1063	lipid-lowering activity	1041:1063	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	2	20	theme	structural	504:513	arg1	viscosity					680:688	apparent viscosity	671:688	apparent viscosity	671:688	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	20	theme	structural	504:513	arg1	solubility					638:647	solubility	638:647	solubility	638:647	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	20	theme	structural	504:513	arg1	degree					544:549	the degree	540:549	the degree of acetylation and monosaccharide composition	540:595	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	20	theme	structural	504:513	arg1	characteristics					515:529	the structural characteristics	500:529	the structural characteristics	500:529	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	20	theme	structural	504:513	arg1	absorption					656:665	water absorption	650:665	water absorption	650:665	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	21	theme	acetylation	554:564	arg1	degree					544:549	the degree	540:549	the degree of acetylation and monosaccharide composition	540:595	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	1	22	theme	Dendrobium	210:219	arg1	DOPs					249:252	DOPs	249:252	DOPs	249:252	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	1	22	theme	Dendrobium	210:219	arg1	polysaccharides					232:246	Dendrobium officinale polysaccharides	210:246	Dendrobium officinale polysaccharides (DOPs) from different origins	210:276	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	3	23	theme	multiple	804:811	arg1	variables					813:821	multiple variables	804:821	multiple variables	804:821	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	2	24	theme	DOPs	739:742	arg1	activity					714:721	the lipid-lowering activity	695:721	the lipid-lowering activity of the obtained DOPs	695:742	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	24	theme	DOPs	739:742	arg1	solubility					638:647	solubility	638:647	solubility	638:647	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	24	theme	DOPs	739:742	arg1	degree					544:549	the degree	540:549	the degree of acetylation and monosaccharide composition	540:595	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	24	theme	DOPs	739:742	arg1	viscosity					680:688	apparent viscosity	671:688	apparent viscosity	671:688	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	24	theme	DOPs	739:742	arg1	characteristics					515:529	the structural characteristics	500:529	the structural characteristics	500:529	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	24	theme	DOPs	739:742	arg1	properties					618:627	the physicochemical properties	598:627	the physicochemical properties	598:627	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	24	theme	DOPs	739:742	arg1	absorption					656:665	water absorption	650:665	water absorption	650:665	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	4	25	theme	greater	1194:1200	arg1	activity					1217:1224	greater lipid-lowering activity	1194:1224	greater lipid-lowering activity	1194:1224	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	1	26	theme	officinale	221:230	arg1	DOPs					249:252	DOPs	249:252	DOPs	249:252	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	1	26	theme	officinale	221:230	arg1	polysaccharides					232:246	Dendrobium officinale polysaccharides	210:246	Dendrobium officinale polysaccharides (DOPs) from different origins	210:276	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	0	27	theme	lipid-lowering	19:32	arg1	method					53:58	the lipid-lowering ability evaluation method	15:58	the lipid-lowering ability evaluation method	15:58	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	0	28	theme	principal	144:152	arg1	analysis					164:171	principal component analysis	144:171	principal component analysis	144:171	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	2	29	theme	obtained	730:737	arg1	DOPs					739:742	the obtained DOPs	726:742	the obtained DOPs	726:742	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	4	30	contain	had	1014:1016	arg1	characteristics					998:1012	the structural and physicochemical characteristics	963:1012	the structural and physicochemical characteristics	963:1012	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	30	contain	had	1014:1016	arg2	effects					1030:1036	significant effects	1018:1036	significant effects	1018:1036	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	2	31	theme	different	469:477	arg1	origins					479:485	different origins	469:485	different origins	469:485	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	0	32	theme	evaluation	42:51	arg1	method					53:58	the lipid-lowering ability evaluation method	15:58	the lipid-lowering ability evaluation method	15:58	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	2	33	theme	physicochemical	602:616	arg1	properties					618:627	the physicochemical properties	598:627	the physicochemical properties	598:627	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	33	theme	physicochemical	602:616	arg1	solubility					638:647	solubility	638:647	solubility	638:647	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	33	theme	physicochemical	602:616	arg1	absorption					656:665	water absorption	650:665	water absorption	650:665	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	33	theme	physicochemical	602:616	arg1	viscosity					680:688	apparent viscosity	671:688	apparent viscosity	671:688	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	2	33	theme	physicochemical	602:616	arg1	degree					544:549	the degree	540:549	the degree of acetylation and monosaccharide composition	540:595	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	4	34	theme	lipid-lowering	1202:1215	arg1	activity					1217:1224	greater lipid-lowering activity	1194:1224	greater lipid-lowering activity	1194:1224	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	0	35	theme	ability	34:40	arg1	method					53:58	the lipid-lowering ability evaluation method	15:58	the lipid-lowering ability evaluation method	15:58	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	1	36	theme	physicochemical	339:353	arg1	properties					355:364	their physicochemical properties	333:364	their physicochemical properties	333:364	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	0	37	theme	component	154:162	arg1	analysis					164:171	principal component analysis	144:171	principal component analysis	144:171	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	4	38	theme	high	1110:1113	arg1	viscosity					1124:1132	high apparent viscosity	1110:1132	high apparent viscosity	1110:1132	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	39	with	DOPs	1070:1073	arg1	ratio					1167:1171	large D-mannose-to-d-glucose ratio	1138:1171	large D-mannose-to-d-glucose ratio	1138:1171	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	39	with	DOPs	1070:1073	arg1	degree					1087:1092	a high degree	1080:1092	a high degree of acetylation	1080:1107	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	39	with	DOPs	1070:1073	arg1	viscosity					1124:1132	high apparent viscosity	1110:1132	high apparent viscosity	1110:1132	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	1	40	from	origins	270:276	arg1	DOPs					249:252	DOPs	249:252	DOPs	249:252	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	1	40	from	origins	270:276	arg1	polysaccharides					232:246	Dendrobium officinale polysaccharides	210:246	Dendrobium officinale polysaccharides (DOPs) from different origins	210:276	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	2	41	theme	officinale	388:397	arg1	plants					399:404	D. officinale plants	385:404	D. officinale plants	385:404	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	4	42	theme	high	1082:1085	arg1	degree					1087:1092	a high degree	1080:1092	a high degree of acetylation	1080:1107	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	43	theme	physicochemical	982:996	arg1	characteristics					998:1012	the structural and physicochemical characteristics	963:1012	the structural and physicochemical characteristics	963:1012	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	3	44	theme	Principal	745:753	arg1	PCA					775:777	PCA	775:777	PCA	775:777	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	3	44	theme	Principal	745:753	arg1	analysis					765:772	Principal component analysis	745:772	Principal component analysis (PCA)	745:778	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	3	44	theme	Principal	745:753	arg1	method					783:788	a method	781:788	a method for analyzing multiple variables	781:821	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	2	45	theme	D.	385:386	arg1	plants					399:404	D. officinale plants	385:404	D. officinale plants	385:404	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	4	46	theme	structural	967:976	arg1	characteristics					998:1012	the structural and physicochemical characteristics	963:1012	the structural and physicochemical characteristics	963:1012	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	0	47	from	origins	127:133	arg1	Comparison					0:9	Comparison	0:9	Comparison	0:9	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	0	47	from	origins	127:133	arg1	polysaccharides					96:110	Dendrobium officinale polysaccharides	74:110	Dendrobium officinale polysaccharides from different origins	74:133	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	0	47	from	origins	127:133	arg1	method					53:58	the lipid-lowering ability evaluation method	15:58	the lipid-lowering ability evaluation method	15:58	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	3	48	theme	lipid-lowering	920:933	arg1	activity					935:942	lipid-lowering activity	920:942	lipid-lowering activity	920:942	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	1	49	theme	different	260:268	arg1	origins					270:276	different origins	260:276	different origins	260:276	As typical acetylated glucomannans, Dendrobium officinale polysaccharides (DOPs) from different origins differ in their structural characteristics and some of their physicochemical properties.
37146861	0	50	theme	Dendrobium	74:83	arg1	polysaccharides					96:110	Dendrobium officinale polysaccharides	74:110	Dendrobium officinale polysaccharides from different origins	74:133	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	3	51	used	used	828:831	arg2	method					783:788	a method	781:788	a method for analyzing multiple variables	781:821	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	3	51	used	used	828:831	arg2	PCA					775:777	PCA	775:777	PCA	775:777	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	3	51	used	used	828:831	arg2	analysis					765:772	Principal component analysis	745:772	Principal component analysis (PCA)	745:778	Principal component analysis (PCA), a method for analyzing multiple variables, was used to analyze the relationship between the physicochemical and structural properties, and lipid-lowering activity.
37146861	4	52	theme	D-mannose-to-d-glucose	1144:1165	arg1	ratio					1167:1171	large D-mannose-to-d-glucose ratio	1138:1171	large D-mannose-to-d-glucose ratio	1138:1171	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	5	53	theme	D.	1307:1308	arg1	officinale					1310:1319	D. officinale	1307:1319	D. officinale	1307:1319	Therefore, this study provides a reference for the selection and application of D. officinale.
37146861	5	54	dep	selection	1278:1286	arg1	the					1274:1276	the	1274:1276	the	1274:1276	Therefore, this study provides a reference for the selection and application of D. officinale.
37146861	0	55	dep	Comparison	0:9	arg1	discussion					60:69	discussion	60:69	discussion	60:69	Comparison and the lipid-lowering ability evaluation method discussion of Dendrobium officinale polysaccharides from different origins based on principal component analysis.
37146861	2	56	from	origins	479:485	arg1	DOPs					459:462	DOPs	459:462	DOPs from different origins	459:485	To rapidly select D. officinale plants, we systematically investigate the differences among DOPs from different origins and analyzed the structural characteristics, such as the degree of acetylation and monosaccharide composition; the physicochemical properties, such as solubility, water absorption and apparent viscosity; and the lipid-lowering activity of the obtained DOPs.
37146861	4	57	theme	acetylation	1097:1107	arg1	ratio					1167:1171	large D-mannose-to-d-glucose ratio	1138:1171	large D-mannose-to-d-glucose ratio	1138:1171	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	57	theme	acetylation	1097:1107	arg1	degree					1087:1092	a high degree	1080:1092	a high degree of acetylation	1080:1107	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	57	theme	acetylation	1097:1107	arg1	viscosity					1124:1132	high apparent viscosity	1110:1132	high apparent viscosity	1110:1132	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
37146861	4	58	theme	significant	1018:1028	arg1	effects					1030:1036	significant effects	1018:1036	significant effects	1018:1036	It was found that the structural and physicochemical characteristics had significant effects on lipid-lowering activity, and DOPs with a high degree of acetylation, high apparent viscosity and large D-mannose-to-d-glucose ratio were associated with greater lipid-lowering activity.
35413324	8	0	theme	Pearson	1057:1063	arg1	correlation					1065:1075	Pearson correlation	1057:1075	Pearson correlation	1057:1075	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	10	1	theme	density	1361:1367	arg1	30 g/L					1346:1351	30 g/L	1346:1351	30 g/L	1346:1351	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	7	2	theme	maximum	985:991	arg1	rate					1001:1004	the maximum binding rate	981:1004	the maximum binding rate of Mn and Li to EPS	981:1024	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	7	2	theme	maximum	985:991	arg1	%					1032:1032	43%	1030:1032	43%	1030:1032	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	3	3	from	densities	519:527	arg1	SCCs					498:501	SCCs	498:501	SCCs at various pulp densities using adapted Penicillium citrinum	498:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	3	3	from	densities	519:527	arg1	bioleaching					483:493	the bioleaching	479:493	the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum	479:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	5	4	theme	high	741:744	arg1	concentration					746:758	a high concentration	739:758	a high concentration of polysaccharides	739:777	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	5	5	contain	contained	729:737	arg2	concentration					746:758	a high concentration	739:758	a high concentration of polysaccharides	739:777	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	5	5	contain	contained	729:737	arg1	LB-EPS					721:726	LB-EPS	721:726	LB-EPS	721:726	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	5	5	contain	contained	729:737	arg1	EPS					716:718	loosely bound EPS	702:718	loosely bound EPS (LB-EPS)	702:727	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	10	6	theme	pulp	1356:1359	arg1	density					1361:1367	pulp density	1356:1367	pulp density	1356:1367	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	6	7	theme	most	793:796	arg1	content					806:812	the most protein content	789:812	the most protein content	789:812	Instead, the most protein content was concentrated at tightly bound EPS (TB-EPS).
35413324	3	8	theme	SCCs	498:501	arg1	bioleaching					483:493	the bioleaching	479:493	the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum	479:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	1	9	theme	bioleaching	246:256	arg1	process					258:264	the bioleaching process	242:264	the bioleaching process	242:264	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	0	10	theme	spent	106:110	arg1	cells					117:121	spent coin cells	106:121	spent coin cells	106:121	Insights into the polysaccharides and proteins production from Penicillium citrinum during bioleaching of spent coin cells.
35413324	8	11	from	correlation	1100:1110	arg1	efficiencies					1174:1185	bioleaching efficiencies	1162:1185	bioleaching efficiencies	1162:1185	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	7	12	theme	density	928:934	arg1	20 g/L					913:918	20 g/L	913:918	20 g/L of pulp density during the entire period of bioleaching	913:974	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	2	13	from	role	307:310	arg1	bioleaching					341:351	the bioleaching	337:351	the bioleaching of spent coin cells (SCCs)	337:378	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	4	14	theme	tolerance	593:601	arg1	index					603:607	the tolerance index	589:607	the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L	589:667	The adaptation improved the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L.
35413324	8	15	from	content	1151:1157	arg1	efficiencies					1174:1185	bioleaching efficiencies	1162:1185	bioleaching efficiencies	1162:1185	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	3	16	theme	adapted	535:541	arg1	citrinum					555:562	adapted Penicillium citrinum	535:562	adapted Penicillium citrinum	535:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	0	17	theme	cells	117:121	arg1	bioleaching					91:101	bioleaching	91:101	bioleaching of spent coin cells	91:121	Insights into the polysaccharides and proteins production from Penicillium citrinum during bioleaching of spent coin cells.
35413324	8	18	theme	positive	1091:1098	arg1	correlation					1100:1110	the positive correlation	1087:1110	the positive correlation of the protein	1087:1125	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	10	19	theme	FE-SEM	1295:1300	arg1	analysis					1302:1309	The FE-SEM analysis	1291:1309	The FE-SEM analysis	1291:1309	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	3	20	theme	pulp	514:517	arg1	densities					519:527	various pulp densities	506:527	various pulp densities using adapted Penicillium citrinum	506:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	2	21	theme	coin	362:365	arg1	cells					367:371	spent coin cells	356:371	spent coin cells (SCCs)	356:378	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	2	21	theme	coin	362:365	arg1	SCCs					374:377	SCCs	374:377	SCCs	374:377	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	3	22	theme	protein	405:411	arg1	production					432:441	protein and polysaccharide production	405:441	production	432:441	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	3	22	theme	protein	405:411	arg1	macromolecules					457:470	biological macromolecules	446:470	biological macromolecules	446:470	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	0	23	theme	coin	112:115	arg1	cells					117:121	spent coin cells	106:121	spent coin cells	106:121	Insights into the polysaccharides and proteins production from Penicillium citrinum during bioleaching of spent coin cells.
35413324	9	24	theme	functional	1230:1239	arg1	OH					1274:1275	OH	1274:1275	OH	1274:1275	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	9	24	theme	functional	1230:1239	arg1	groups					1241:1246	the principal functional groups	1216:1246	the principal functional groups on Mn and Li binding	1216:1267	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	10	25	theme	toxic	1390:1394	arg1	effect					1396:1401	the toxic effect	1386:1401	the toxic effect of this pulp density	1386:1422	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	1	26	theme	extracellular	178:190	arg1	EPS					214:216	EPS	214:216	EPS	214:216	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	1	26	theme	extracellular	178:190	arg1	substances					202:211	extracellular polymeric substances	178:211	extracellular polymeric substances (EPS)	178:217	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	10	27	theme	EPS	1339:1341	arg1	deformation					1324:1334	the deformation	1320:1334	the deformation of EPS	1320:1341	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	10	28	theme	pulp	1411:1414	arg1	density					1416:1422	this pulp density	1406:1422	this pulp density	1406:1422	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	1	29	theme	polymeric	192:200	arg1	EPS					214:216	EPS	214:216	EPS	214:216	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	1	29	theme	polymeric	192:200	arg1	substances					202:211	extracellular polymeric substances	178:211	extracellular polymeric substances (EPS)	178:217	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	9	30	theme	principal	1220:1228	arg1	OH					1274:1275	OH	1274:1275	OH	1274:1275	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	9	30	theme	principal	1220:1228	arg1	groups					1241:1246	the principal functional groups	1216:1246	the principal functional groups on Mn and Li binding	1216:1267	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	8	31	theme	bioleaching	1162:1172	arg1	efficiencies					1174:1185	bioleaching efficiencies	1162:1185	bioleaching efficiencies	1162:1185	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	2	32	theme	spent	356:360	arg1	cells					367:371	spent coin cells	356:371	spent coin cells (SCCs)	356:378	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	2	32	theme	spent	356:360	arg1	SCCs					374:377	SCCs	374:377	SCCs	374:377	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	8	33	theme	protein	1119:1125	arg1	correlation					1100:1110	the positive correlation	1087:1110	the positive correlation of the protein	1087:1125	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	8	33	theme	protein	1119:1125	arg1	content					1151:1157	the polysaccharides content	1131:1157	the polysaccharides content on bioleaching efficiencies	1131:1185	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	3	34	from	bioleaching	483:493	arg1	densities					519:527	various pulp densities	506:527	various pulp densities using adapted Penicillium citrinum	506:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	3	35	theme	Penicillium	543:553	arg1	citrinum					555:562	adapted Penicillium citrinum	535:562	adapted Penicillium citrinum	535:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	7	36	theme	pulp	923:926	arg1	density					928:934	pulp density	923:934	pulp density	923:934	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	4	37	theme	bioleaching	626:636	arg1	up					638:639	the bioleaching up	622:639	the bioleaching up to a pulp density of 30 g/L	622:667	The adaptation improved the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L.
35413324	7	38	theme	Li	1016:1017	arg1	rate					1001:1004	the maximum binding rate	981:1004	the maximum binding rate of Mn and Li to EPS	981:1024	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	7	38	theme	Li	1016:1017	arg1	%					1032:1032	43%	1030:1032	43%	1030:1032	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	6	39	theme	EPS	848:850	arg1	TB-EPS					853:858	tightly bound EPS (TB-EPS)	834:859	tightly bound EPS (TB-EPS)	834:859	Instead, the most protein content was concentrated at tightly bound EPS (TB-EPS).
35413324	1	40	theme	proteins	166:173	arg1	role					138:141	The essential role	124:141	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS)	124:217	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	3	41	theme	biological	446:455	arg1	production					432:441	protein and polysaccharide production	405:441	production	432:441	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	3	41	theme	biological	446:455	arg1	macromolecules					457:470	biological macromolecules	446:470	biological macromolecules	446:470	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	6	42	theme	bound	842:846	arg1	TB-EPS					853:858	tightly bound EPS (TB-EPS)	834:859	tightly bound EPS (TB-EPS)	834:859	Instead, the most protein content was concentrated at tightly bound EPS (TB-EPS).
35413324	1	43	theme	substances	202:211	arg1	polysaccharides					146:160	polysaccharides	146:160	polysaccharides	146:160	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	1	43	theme	substances	202:211	arg1	proteins					166:173	proteins	166:173	proteins	166:173	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	3	44	theme	polysaccharide	417:430	arg1	production					432:441	protein and polysaccharide production	405:441	production	432:441	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	3	44	theme	polysaccharide	417:430	arg1	macromolecules					457:470	biological macromolecules	446:470	biological macromolecules	446:470	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	4	45	theme	pulp	646:649	arg1	density					651:657	a pulp density	644:657	a pulp density of 30 g/L	644:667	The adaptation improved the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L.
35413324	9	46	dep	Mn	1251:1252	arg1	binding					1261:1267	binding	1261:1267	binding	1261:1267	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	7	47	theme	Mn	1009:1010	arg1	rate					1001:1004	the maximum binding rate	981:1004	the maximum binding rate of Mn and Li to EPS	981:1024	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	7	47	theme	Mn	1009:1010	arg1	%					1032:1032	43%	1030:1032	43%	1030:1032	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	0	48	from	citrinum	75:82	arg1	production					47:56	production	47:56	production	47:56	Insights into the polysaccharides and proteins production from Penicillium citrinum during bioleaching of spent coin cells.
35413324	9	49	from	groups	1241:1246	arg1	Li					1258:1259	Li	1258:1259	Li	1258:1259	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	9	49	from	groups	1241:1246	arg1	Mn					1251:1252	Mn	1251:1252	Mn	1251:1252	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	5	50	theme	polysaccharides	763:777	arg1	concentration					746:758	a high concentration	739:758	a high concentration of polysaccharides	739:777	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	5	51	theme	bound	710:714	arg1	LB-EPS					721:726	LB-EPS	721:726	LB-EPS	721:726	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	5	51	theme	bound	710:714	arg1	EPS					716:718	loosely bound EPS	702:718	loosely bound EPS (LB-EPS)	702:727	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	7	52	theme	binding	993:999	arg1	rate					1001:1004	the maximum binding rate	981:1004	the maximum binding rate of Mn and Li to EPS	981:1024	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	7	52	theme	binding	993:999	arg1	%					1032:1032	43%	1030:1032	43%	1030:1032	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	2	53	theme	compositions	321:332	arg1	role					307:310	the role	303:310	the role of these compositions in the bioleaching of spent coin cells (SCCs)	303:378	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	8	54	theme	polysaccharides	1135:1149	arg1	content					1151:1157	the polysaccharides content	1131:1157	the polysaccharides content on bioleaching efficiencies	1131:1185	Pearson correlation indicated the positive correlation of the protein and the polysaccharides content on bioleaching efficiencies.
35413324	7	55	theme	bioleaching	964:974	arg1	period					954:959	the entire period	943:959	the entire period of bioleaching	943:974	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	10	56	theme	density	1416:1422	arg1	effect					1396:1401	the toxic effect	1386:1401	the toxic effect of this pulp density	1386:1422	The FE-SEM analysis revealed the deformation of EPS at 30 g/L of pulp density, which suggested the toxic effect of this pulp density.
35413324	4	57	theme	30 g/L	662:667	arg1	density					651:657	a pulp density	644:657	a pulp density of 30 g/L	644:667	The adaptation improved the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L.
35413324	1	58	theme	essential	128:136	arg1	role					138:141	The essential role	124:141	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS)	124:217	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	5	59	theme	EPS	674:676	arg1	analysis					678:685	The EPS analysis	670:685	The EPS analysis	670:685	The EPS analysis indicated that loosely bound EPS (LB-EPS) contained a high concentration of polysaccharides.
35413324	9	60	theme	FTIR	1197:1200	arg1	spectroscopy					1202:1213	the FTIR spectroscopy	1193:1213	the FTIR spectroscopy	1193:1213	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	7	61	theme	entire	947:952	arg1	period					954:959	the entire period	943:959	the entire period of bioleaching	943:974	Both protein and polysaccharide keep growing up to 20 g/L of pulp density during the entire period of bioleaching, and the maximum binding rate of Mn and Li to EPS was 43% and 15%, respectively.
35413324	3	62	theme	various	506:512	arg1	densities					519:527	various pulp densities	506:527	various pulp densities using adapted Penicillium citrinum	506:562	This study investigated protein and polysaccharide production as biological macromolecules during the bioleaching of SCCs at various pulp densities using adapted Penicillium citrinum.
35413324	6	63	theme	protein	798:804	arg1	content					806:812	the most protein content	789:812	the most protein content	789:812	Instead, the most protein content was concentrated at tightly bound EPS (TB-EPS).
35413324	2	64	theme	cells	367:371	arg1	bioleaching					341:351	the bioleaching	337:351	the bioleaching of spent coin cells (SCCs)	337:378	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	9	65	from	spectroscopy	1202:1213	arg1	carboxyl					1281:1288	carboxyl	1281:1288	carboxyl	1281:1288	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	9	65	from	spectroscopy	1202:1213	arg1	OH					1274:1275	OH	1274:1275	OH	1274:1275	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	9	65	from	spectroscopy	1202:1213	arg1	groups					1241:1246	the principal functional groups	1216:1246	the principal functional groups on Mn and Li binding	1216:1267	From the FTIR spectroscopy, the principal functional groups on Mn and Li binding were OH and carboxyl.
35413324	1	66	theme	polysaccharides	146:160	arg1	role					138:141	The essential role	124:141	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS)	124:217	The essential role of polysaccharides and proteins of extracellular polymeric substances (EPS) has been well known in the bioleaching process.
35413324	2	67	from	information	288:298	arg1	role					307:310	the role	303:310	the role of these compositions in the bioleaching of spent coin cells (SCCs)	303:378	However, there is no information on the role of these compositions in the bioleaching of spent coin cells (SCCs).
35413324	4	68	theme	fungi	612:616	arg1	index					603:607	the tolerance index	589:607	the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L	589:667	The adaptation improved the tolerance index of fungi for the bioleaching up to a pulp density of 30 g/L.
36760814	7	0	theme	16s	1133:1135	arg1	rRNA					1137:1140	16s rRNA	1133:1140	16s rRNA high- throughput sequencing technology	1133:1179	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	4	1	theme	Macrocephala	585:596	arg1	AMP					622:624	AMP	622:624	AMP	622:624	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	4	1	theme	Macrocephala	585:596	arg1	polysaccharide					606:619	Atractylodes Macrocephala Rhizoma polysaccharide	572:619	Atractylodes Macrocephala Rhizoma polysaccharide (AMP)	572:625	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	0	2	with	rats	100:103	arg1	hyperplasia					124:134	mammary gland hyperplasia	110:134	mammary gland hyperplasia	110:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	3	3	theme	intestinal	504:513	arg1	homeostasis					515:525	intestinal homeostasis	504:525	intestinal homeostasis	504:525	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	5	4	from	rats	895:898	arg1	group					908:912	each group	903:912	each group	903:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	9	5	theme	microbiological	1711:1725	arg1	environment					1727:1737	the intestinal microbiological environment	1696:1737	the intestinal microbiological environment of MGH rats	1696:1749	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	4	6	theme	polysaccharide	606:619	arg1	effect					562:567	the effect	558:567	the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats	558:661	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	7	7	theme	P	1042:1042	arg1	levels					1028:1033	The levels	1024:1033	The levels of E2, P, and PRL in the serum of rats	1024:1072	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	1	8	theme	endocrine	253:261	arg1	disorders					263:271	endocrine disorders	253:271	endocrine disorders	253:271	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	6	9	theme	gastric	1006:1012	arg1	infusion					1014:1021	AMP gastric infusion	1002:1021	AMP gastric infusion	1002:1021	MGH rat models were established by estradiol-progesterone combination and treated with AMP gastric infusion.
36760814	4	10	theme	rats	658:661	arg1	flora					645:649	the intestinal flora	630:649	the intestinal flora of MGH rats	630:661	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	8	11	theme	flora	1466:1470	arg1	diversity					1442:1450	diversity	1442:1450	diversity of intestinal flora of MGH rats	1442:1482	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	11	theme	flora	1466:1470	arg1	abundance					1428:1436	the abundance	1424:1436	the abundance	1424:1436	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	9	12	theme	rats	1746:1749	arg1	environment					1727:1737	the intestinal microbiological environment	1696:1737	the intestinal microbiological environment of MGH rats	1696:1749	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	8	13	dep	has	1255:1257	arg1	increasing					1354:1363	increasing	1354:1363	increasing progesterone (P) levels	1354:1387	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	13	dep	has	1255:1257	arg1	decreasing					1297:1306	decreasing	1297:1306	decreasing estradiol (E2) and prolactin (PRL) levels	1297:1348	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	4	14	theme	intestinal	634:643	arg1	flora					645:649	the intestinal flora	630:649	the intestinal flora of MGH rats	630:661	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	8	15	theme	community	1556:1564	arg1	structure					1566:1574	the community structure	1552:1574	the community structure	1552:1574	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	5	16	theme	blank	822:826	arg1	Con					843:845	Con	843:845	Con	843:845	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	16	theme	blank	822:826	arg1	group					836:840	blank control group	822:840	blank control group (Con)	822:846	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	16	theme	blank	822:826	arg1	groups					814:819	three groups	808:819	three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group	808:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	8	17	theme	flora	1520:1524	arg1	disorder					1497:1504	the disorder	1493:1504	the disorder of intestinal flora caused by MGH	1493:1538	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	9	18	theme	microecological	1765:1779	arg1	balance					1781:1787	the microecological balance	1761:1787	the microecological balance of intestinal microbial	1761:1811	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	8	19	theme	intestinal	1455:1464	arg1	flora					1466:1470	intestinal flora	1455:1470	intestinal flora of MGH rats	1455:1482	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	20	theme	prolactin	1327:1335	arg1	levels					1343:1348	estradiol (E2) and prolactin (PRL) levels	1308:1348	estradiol (E2) and prolactin (PRL) levels	1308:1348	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	9	21	theme	microbial	1803:1811	arg1	balance					1781:1787	the microecological balance	1761:1787	the microecological balance of intestinal microbial	1761:1811	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	4	22	theme	MGH	717:719	arg1	treatment					704:712	polysaccharide treatment	689:712	polysaccharide treatment of MGH	689:719	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	1	23	theme	recent	151:156	arg1	years					158:162	recent years	151:162	recent years	151:162	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	4	24	theme	new	676:678	arg1	idea					680:683	a new idea	674:683	a new idea for polysaccharide treatment of MGH	674:719	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	5	25	theme	female	753:758	arg1	rats					763:766	Eighteen female SD rats	744:766	Materials and methods Eighteen female SD rats	722:766	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	7	26	theme	rats	1069:1072	arg1	serum					1060:1064	the serum	1056:1064	the serum of rats	1056:1072	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	8	27	theme	flora	1614:1618	arg1	abundance					1590:1598	the abundance	1586:1598	the abundance of beneficial flora	1586:1618	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	5	28	theme	control	855:861	arg1	group					863:867	model control group	849:867	model control group (Mod)	849:873	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	28	theme	control	855:861	arg1	Mod					870:872	Mod	870:872	Mod	870:872	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	28	theme	control	855:861	arg1	groups					814:819	three groups	808:819	three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group	808:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	8	29	theme	MGH	1475:1477	arg1	rats					1479:1482	MGH rats	1475:1482	MGH rats	1475:1482	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	30	contain	has	1255:1257	arg2	effects					1276:1282	good therapeutic effects	1259:1282	good therapeutic effects	1259:1282	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	30	contain	has	1255:1257	arg1	AMP					1251:1253	Results AMP	1243:1253	Results AMP	1243:1253	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	9	31	theme	MGH	1826:1828	arg1	symptoms					1830:1837	MGH symptoms	1826:1837	MGH symptoms	1826:1837	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	1	32	theme	gland	173:177	arg1	MGH					192:194	MGH	192:194	MGH	192:194	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	1	32	theme	gland	173:177	arg1	hyperplasia					179:189	mammary gland hyperplasia	165:189	mammary gland hyperplasia (MGH)	165:195	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	6	33	theme	rat	919:921	arg1	models					923:928	MGH rat models	915:928	MGH rat models	915:928	MGH rat models were established by estradiol-progesterone combination and treated with AMP gastric infusion.
36760814	0	34	from	Effects	0:6	arg1	composition					85:95	intestinal microbiota composition	63:95	intestinal microbiota composition in rats with mammary gland hyperplasia	63:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	3	35	contain	has	471:473	arg2	medicine					406:413	a commonly used medicine	390:413	a commonly used medicine in clinical practice	390:434	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	3	35	contain	has	471:473	arg2	functions					480:488	good functions	475:488	good functions	475:488	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	3	35	contain	has	471:473	arg1	Rhizoma					463:469	Rhizoma	463:469	Rhizoma	463:469	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	3	36	theme	clinical	418:425	arg1	practice					427:434	clinical practice	418:434	clinical practice	418:434	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	0	37	theme	gland	118:122	arg1	hyperplasia					124:134	mammary gland hyperplasia	110:134	mammary gland hyperplasia	110:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	7	38	theme	MGH	1233:1235	arg1	rats					1237:1240	the MGH rats	1229:1240	the MGH rats	1229:1240	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	8	39	theme	good	1259:1262	arg1	effects					1276:1282	good therapeutic effects	1259:1282	good therapeutic effects	1259:1282	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	4	40	from	effect	562:567	arg1	flora					645:649	the intestinal flora	630:649	the intestinal flora of MGH rats	630:661	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	8	41	theme	flora	1662:1666	arg1	abundance					1638:1646	the abundance	1634:1646	the abundance of pathogenic flora	1634:1666	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	6	42	theme	AMP	1002:1004	arg1	infusion					1014:1021	AMP gastric infusion	1002:1021	AMP gastric infusion	1002:1021	MGH rat models were established by estradiol-progesterone combination and treated with AMP gastric infusion.
36760814	7	43	from	levels	1028:1033	arg1	serum					1060:1064	the serum	1056:1064	the serum of rats	1056:1072	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	0	44	theme	Atractylodes	11:22	arg1	polysaccharide					45:58	Atractylodes Macrocephala Rhizoma polysaccharide	11:58	Atractylodes Macrocephala Rhizoma polysaccharide	11:58	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	7	45	theme	intestinal	1209:1218	arg1	flora					1220:1224	intestinal flora	1209:1224	intestinal flora	1209:1224	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	8	46	theme	MGH	1287:1289	arg1	rats					1291:1294	MGH rats	1287:1294	MGH rats	1287:1294	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	0	47	theme	Rhizoma	37:43	arg1	polysaccharide					45:58	Atractylodes Macrocephala Rhizoma polysaccharide	11:58	Atractylodes Macrocephala Rhizoma polysaccharide	11:58	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	0	48	theme	microbiota	74:83	arg1	composition					85:95	intestinal microbiota composition	63:95	intestinal microbiota composition in rats with mammary gland hyperplasia	63:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	7	49	theme	E2	1038:1039	arg1	levels					1028:1033	The levels	1024:1033	The levels of E2, P, and PRL in the serum of rats	1024:1072	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	8	50	theme	estradiol	1308:1316	arg1	levels					1343:1348	estradiol (E2) and prolactin (PRL) levels	1308:1348	estradiol (E2) and prolactin (PRL) levels	1308:1348	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	51	theme	rats	1479:1482	arg1	flora					1466:1470	intestinal flora	1455:1470	intestinal flora of MGH rats	1455:1482	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	0	52	theme	intestinal	63:72	arg1	composition					85:95	intestinal microbiota composition	63:95	intestinal microbiota composition in rats with mammary gland hyperplasia	63:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	7	53	theme	throughput	1148:1157	arg1	technology					1170:1179	16s rRNA high- throughput sequencing technology	1133:1179	16s rRNA high- throughput sequencing technology	1133:1179	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	1	54	theme	diseases	234:241	arg1	one					223:225	one	223:225	one	223:225	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	1	54	theme	diseases	234:241	arg1	diseases					234:241	the diseases	230:241	the diseases caused by endocrine disorders	230:271	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	5	55	dep	groups	814:819	arg1	rats					895:898	six rats	891:898	six rats in each group	891:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	55	dep	groups	814:819	arg1	group					836:840	blank control group	822:840	blank control group (Con)	822:846	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	55	dep	groups	814:819	arg1	group					863:867	model control group	849:867	model control group (Mod)	849:873	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	55	dep	groups	814:819	arg1	group					884:888	AMP group	880:888	AMP group	880:888	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	55	dep	groups	814:819	arg1	groups					814:819	three groups	808:819	three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group	808:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	55	dep	groups	814:819	arg1	Con					843:845	Con	843:845	Con	843:845	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	55	dep	groups	814:819	arg1	Mod					870:872	Mod	870:872	Mod	870:872	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	7	56	theme	rRNA	1137:1140	arg1	technology					1170:1179	16s rRNA high- throughput sequencing technology	1133:1179	16s rRNA high- throughput sequencing technology	1133:1179	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	9	57	theme	intestinal	1700:1709	arg1	environment					1727:1737	the intestinal microbiological environment	1696:1737	the intestinal microbiological environment of MGH rats	1696:1749	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	4	58	theme	Atractylodes	572:583	arg1	AMP					622:624	AMP	622:624	AMP	622:624	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	4	58	theme	Atractylodes	572:583	arg1	polysaccharide					606:619	Atractylodes Macrocephala Rhizoma polysaccharide	572:619	Atractylodes Macrocephala Rhizoma polysaccharide (AMP)	572:625	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	8	59	theme	intestinal	1509:1518	arg1	flora					1520:1524	intestinal flora	1509:1524	intestinal flora	1509:1524	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	4	60	theme	Rhizoma	598:604	arg1	AMP					622:624	AMP	622:624	AMP	622:624	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	4	60	theme	Rhizoma	598:604	arg1	polysaccharide					606:619	Atractylodes Macrocephala Rhizoma polysaccharide	572:619	Atractylodes Macrocephala Rhizoma polysaccharide (AMP)	572:625	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	9	61	theme	MGH	1742:1744	arg1	rats					1746:1749	MGH rats	1742:1749	MGH rats	1742:1749	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	4	62	theme	MGH	654:656	arg1	rats					658:661	MGH rats	654:661	MGH rats	654:661	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	8	63	dep	regulate	1415:1422	arg1	improve					1485:1491	improve	1485:1491	improve the disorder of intestinal flora caused by MGH	1485:1538	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	63	dep	regulate	1415:1422	arg1	increase					1577:1584	increase	1577:1584	increase the abundance of beneficial flora	1577:1618	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	63	dep	regulate	1415:1422	arg1	decrease					1625:1632	decrease	1625:1632	decrease the abundance of pathogenic flora	1625:1666	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	63	dep	regulate	1415:1422	arg1	change					1545:1550	change	1545:1550	change the community structure	1545:1574	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	5	64	theme	control	828:834	arg1	Con					843:845	Con	843:845	Con	843:845	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	64	theme	control	828:834	arg1	group					836:840	blank control group	822:840	blank control group (Con)	822:846	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	64	theme	control	828:834	arg1	groups					814:819	three groups	808:819	three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group	808:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	0	65	from	composition	85:95	arg1	rats					100:103	rats	100:103	rats with mammary gland hyperplasia	100:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	0	66	theme	mammary	110:116	arg1	hyperplasia					124:134	mammary gland hyperplasia	110:134	mammary gland hyperplasia	110:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	4	67	theme	polysaccharide	689:702	arg1	treatment					704:712	polysaccharide treatment	689:712	polysaccharide treatment of MGH	689:719	Therefore, this paper studied the effect of Atractylodes Macrocephala Rhizoma polysaccharide (AMP) on the intestinal flora of MGH rats, providing a new idea for polysaccharide treatment of MGH.
36760814	6	68	theme	estradiol-progesterone	950:971	arg1	combination					973:983	estradiol-progesterone combination	950:983	estradiol-progesterone combination	950:983	MGH rat models were established by estradiol-progesterone combination and treated with AMP gastric infusion.
36760814	5	69	dep	Materials	722:730	arg1	rats					763:766	Eighteen female SD rats	744:766	Materials and methods Eighteen female SD rats	722:766	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	70	theme	model	849:853	arg1	group					863:867	model control group	849:867	model control group (Mod)	849:873	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	70	theme	model	849:853	arg1	Mod					870:872	Mod	870:872	Mod	870:872	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	70	theme	model	849:853	arg1	groups					814:819	three groups	808:819	three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group	808:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	8	71	theme	progesterone	1365:1376	arg1	levels					1382:1387	progesterone (P) levels	1365:1387	progesterone (P) levels	1365:1387	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	5	72	theme	SD	760:761	arg1	rats					763:766	Eighteen female SD rats	744:766	Materials and methods Eighteen female SD rats	722:766	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	8	73	theme	beneficial	1603:1612	arg1	flora					1614:1618	beneficial flora	1603:1618	beneficial flora	1603:1618	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	1	74	theme	mammary	165:171	arg1	MGH					192:194	MGH	192:194	MGH	192:194	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	1	74	theme	mammary	165:171	arg1	hyperplasia					179:189	mammary gland hyperplasia	165:189	mammary gland hyperplasia (MGH)	165:195	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	7	75	theme	intestinal	1093:1102	arg1	contents					1104:1111	the intestinal contents	1089:1111	the intestinal contents	1089:1111	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	6	76	theme	MGH	915:917	arg1	models					923:928	MGH rat models	915:928	MGH rat models	915:928	MGH rat models were established by estradiol-progesterone combination and treated with AMP gastric infusion.
36760814	1	77	dep	Background	137:146	arg1	considered					206:215	considered	206:215	has been considered to be one of the diseases caused by endocrine disorders	197:271	Background In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders.
36760814	5	78	theme	AMP	880:882	arg1	group					884:888	AMP group	880:888	AMP group	880:888	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	78	theme	AMP	880:882	arg1	rats					895:898	six rats	891:898	six rats in each group	891:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	5	78	theme	AMP	880:882	arg1	groups					814:819	three groups	808:819	three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group	808:912	Materials and methods Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group.
36760814	7	79	theme	flora	1220:1224	arg1	changes					1198:1204	the changes	1194:1204	the changes of intestinal flora in the MGH rats	1194:1240	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	8	80	theme	same	1397:1400	arg1	time					1402:1405	the same time	1393:1405	the same time	1393:1405	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	0	81	theme	Macrocephala	24:35	arg1	polysaccharide					45:58	Atractylodes Macrocephala Rhizoma polysaccharide	11:58	Atractylodes Macrocephala Rhizoma polysaccharide	11:58	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	8	82	theme	pathogenic	1651:1660	arg1	flora					1662:1666	pathogenic flora	1651:1666	pathogenic flora	1651:1666	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	8	83	theme	therapeutic	1264:1274	arg1	effects					1276:1282	good therapeutic effects	1259:1282	good therapeutic effects	1259:1282	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	0	84	theme	polysaccharide	45:58	arg1	Effects					0:6	Effects	0:6	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia	0:134	Effects of Atractylodes Macrocephala Rhizoma polysaccharide on intestinal microbiota composition in rats with mammary gland hyperplasia.
36760814	3	85	theme	used	401:404	arg1	functions					480:488	good functions	475:488	good functions	475:488	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	3	85	theme	used	401:404	arg1	medicine					406:413	a commonly used medicine	390:413	a commonly used medicine in clinical practice	390:434	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	7	86	theme	PRL	1049:1051	arg1	levels					1028:1033	The levels	1024:1033	The levels of E2, P, and PRL in the serum of rats	1024:1072	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	7	87	from	changes	1198:1204	arg1	rats					1237:1240	the MGH rats	1229:1240	the MGH rats	1229:1240	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	2	88	theme	endocrine	316:324	arg1	disorders					326:334	endocrine disorders	316:334	endocrine disorders	316:334	It has been shown that diseases caused by endocrine disorders can be treated by regulating intestinal microbial.
36760814	7	89	theme	sequencing	1159:1168	arg1	technology					1170:1179	16s rRNA high- throughput sequencing technology	1133:1179	16s rRNA high- throughput sequencing technology	1133:1179	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
36760814	9	90	theme	Conclusion	1669:1678	arg1	AMP					1680:1682	Conclusion AMP	1669:1682	Conclusion AMP	1669:1682	Conclusion AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.
36760814	8	91	theme	Results	1243:1249	arg1	AMP					1251:1253	Results AMP	1243:1253	Results AMP	1243:1253	Results AMP has good therapeutic effects on MGH rats, decreasing estradiol (E2) and prolactin (PRL) levels and increasing progesterone (P) levels; at the same time, it can regulate the abundance and diversity of intestinal flora of MGH rats, improve the disorder of intestinal flora caused by MGH, and change the community structure, increase the abundance of beneficial flora, and decrease the abundance of pathogenic flora.
36760814	3	92	from	medicine	406:413	arg1	practice					427:434	clinical practice	418:434	clinical practice	418:434	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	3	93	theme	good	475:478	arg1	functions					480:488	good functions	475:488	good functions	475:488	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	3	93	theme	good	475:478	arg1	medicine					406:413	a commonly used medicine	390:413	a commonly used medicine in clinical practice	390:434	As a commonly used medicine in clinical practice, Atractylodes Macrocephala Rhizoma has good functions in regulating intestinal homeostasis.
36760814	7	94	theme	high-	1142:1146	arg1	technology					1170:1179	16s rRNA high- throughput sequencing technology	1133:1179	16s rRNA high- throughput sequencing technology	1133:1179	The levels of E2, P, and PRL in the serum of rats were measured, the intestinal contents were collected, and 16s rRNA high- throughput sequencing technology was analyzed the changes of intestinal flora in the MGH rats.
35526773	5	0	theme	in	779:780	arg1	assays					798:803	in vitro and in vivo biological assays	766:803	in vitro and in vivo biological assays	766:803	Furthermore, in vitro and in vivo biological assays were performed.
35526773	4	1	theme	porosity	704:711	arg1	characters					643:652	physical characters	634:652	physical characters	634:652	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	1	theme	porosity	704:711	arg1	morphology					597:606	surface morphology	589:606	surface morphology	589:606	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	1	theme	porosity	704:711	arg1	structures					618:627	chemical structures	609:627	chemical structures	609:627	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	8	2	theme	L929	1308:1311	arg1	cells					1313:1317	L929 cells	1308:1317	L929 cells	1308:1317	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	1	3	theme	bacteria-contaminated	250:270	arg1	wounds					272:277	the bacteria-contaminated wounds	246:277	the bacteria-contaminated wounds	246:277	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	0	4	theme	wound	95:99	arg1	healing					101:107	wound healing	95:107	wound healing	95:107	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	6	5	theme	2QCSX-DAC	834:842	arg1	sponges					844:850	The obtained 2QCSX-DAC sponges	821:850	The obtained 2QCSX-DAC sponges	821:850	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	1	6	theme	first-aid	170:178	arg1	treatment					191:199	the first-aid hemostatic treatment	166:199	the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds	166:277	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	4	7	theme	surface	589:595	arg1	morphology					597:606	surface morphology	589:606	surface morphology	589:606	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	7	8	theme	low	1233:1235	arg1	rates					1247:1251	low hemolysis rates	1233:1251	blank control and Celox™ as well as low hemolysis rates (<5%)	1197:1257	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	7	8	theme	low	1233:1235	arg1	%					1256:1256	<5%	1254:1256	<5%	1254:1256	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	6	9	theme	uptake	936:941	arg1	performance					943:953	excellent water uptake performance	920:953	excellent water uptake performance	920:953	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	6	10	theme	obtained	825:832	arg1	sponges					844:850	The obtained 2QCSX-DAC sponges	821:850	The obtained 2QCSX-DAC sponges	821:850	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	8	11	theme	infected	1353:1360	arg1	healing					1368:1374	the infected wound healing	1349:1374	the infected wound healing of rats	1349:1382	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	4	12	theme	water	681:685	arg1	behavior					694:701	water uptake behavior	681:701	water uptake behavior	681:701	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	13	theme	chemical	609:616	arg1	structures					618:627	chemical structures	609:627	chemical structures	609:627	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	7	14	theme	hemolysis	1237:1245	arg1	rates					1247:1251	low hemolysis rates	1233:1251	blank control and Celox™ as well as low hemolysis rates (<5%)	1197:1257	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	7	14	theme	hemolysis	1237:1245	arg1	%					1256:1256	<5%	1254:1256	<5%	1254:1256	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	6	15	theme	water	930:934	arg1	performance					943:953	excellent water uptake performance	920:953	excellent water uptake performance	920:953	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	8	16	contain	had	1281:1283	arg1	Meanwhile					1260:1268	Meanwhile	1260:1268	Meanwhile	1260:1268	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	8	16	contain	had	1281:1283	arg2	cytotoxicity					1292:1303	benign cytotoxicity	1285:1303	benign cytotoxicity of L929 cells	1285:1317	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	8	16	contain	had	1281:1283	arg1	2QCS3-DAC					1271:1279	2QCS3-DAC	1271:1279	2QCS3-DAC	1271:1279	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	9	17	from	care	1497:1500	arg1	hospitals					1514:1522	civilian hospitals	1505:1522	civilian hospitals	1505:1522	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	2	18	theme	quaternized	295:305	arg1	chitosan					307:314	serial quaternized chitosan	288:314	serial quaternized chitosan with varying degrees of substitution (QCSX)	288:358	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	2	19	theme	substitution	340:351	arg1	degrees					329:335	varying degrees	321:335	varying degrees of substitution (QCSX)	321:358	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	6	20	theme	excellent	920:928	arg1	performance					943:953	excellent water uptake performance	920:953	excellent water uptake performance	920:953	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	9	21	dep	care	1497:1500	arg1	hemostasis					1538:1547	hemostasis	1538:1547	hemostasis	1538:1547	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	2	22	theme	serial	288:293	arg1	chitosan					307:314	serial quaternized chitosan	288:314	serial quaternized chitosan with varying degrees of substitution (QCSX)	288:358	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	4	23	theme	behavior	694:701	arg1	characters					643:652	physical characters	634:652	physical characters	634:652	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	23	theme	behavior	694:701	arg1	morphology					597:606	surface morphology	589:606	surface morphology	589:606	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	23	theme	behavior	694:701	arg1	structures					618:627	chemical structures	609:627	chemical structures	609:627	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	1	24	theme	hemostatic	180:189	arg1	treatment					191:199	the first-aid hemostatic treatment	166:199	the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds	166:277	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	5	25	theme	in	766:767	arg1	assays					798:803	in vitro and in vivo biological assays	766:803	in vitro and in vivo biological assays	766:803	Furthermore, in vitro and in vivo biological assays were performed.
35526773	5	26	theme	biological	787:796	arg1	assays					798:803	in vitro and in vivo biological assays	766:803	in vitro and in vivo biological assays	766:803	Furthermore, in vitro and in vivo biological assays were performed.
35526773	7	27	theme	blood	1133:1137	arg1	time					1151:1154	the blood coagulation time	1129:1154	the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%)	1129:1257	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	3	28	theme	composite	554:562	arg1	sponges					564:570	the corresponding composite sponges	536:570	the corresponding composite sponges (2QCSX-DAC)	536:582	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	3	28	theme	composite	554:562	arg1	2QCSX-DAC					573:581	2QCSX-DAC	573:581	2QCSX-DAC	573:581	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	2	29	theme	chloride	404:411	arg1	modification					413:424	glycidyl trimethyl ammonium chloride modification	376:424	glycidyl trimethyl ammonium chloride modification	376:424	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	0	30	theme	chitosan/cellulose	12:29	arg1	composites					31:40	chitosan/cellulose composites	12:40	chitosan/cellulose composites	12:40	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	0	30	theme	chitosan/cellulose	12:29	arg1	sponges					83:89	enhanced hemostatic and antibacterial sponges	45:89	enhanced hemostatic and antibacterial sponges for wound healing	45:107	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	7	31	theme	coagulation	1139:1149	arg1	time					1151:1154	the blood coagulation time	1129:1154	the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%)	1129:1257	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	8	32	theme	rats	1379:1382	arg1	healing					1368:1374	the infected wound healing	1349:1374	the infected wound healing of rats	1349:1382	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	7	33	theme	coagulation	1102:1112	arg1	abilities					1114:1122	superior blood coagulation abilities	1087:1122	superior blood coagulation abilities	1087:1122	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	2	34	theme	ammonium	395:402	arg1	chloride					404:411	glycidyl trimethyl ammonium chloride	376:411	glycidyl trimethyl ammonium chloride modification	376:424	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	7	35	theme	blank	1197:1201	arg1	control					1203:1209	blank control	1197:1209	blank control	1197:1209	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	9	36	from	dressing	1472:1479	arg1	battlefields					1552:1563	battlefields	1552:1563	battlefields	1552:1563	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	2	37	theme	trimethyl	385:393	arg1	chloride					404:411	glycidyl trimethyl ammonium chloride	376:411	glycidyl trimethyl ammonium chloride modification	376:424	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	9	38	theme	wound	1466:1470	arg1	dressing					1472:1479	a viable wound dressing	1457:1479	a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields	1457:1563	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	9	38	theme	wound	1466:1470	arg1	sponge					1436:1441	this composite sponge	1421:1441	this composite sponge	1421:1441	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	5	39	dep	in	779:780	arg1	vivo					782:785	vivo	782:785	vivo	782:785	Furthermore, in vitro and in vivo biological assays were performed.
35526773	9	40	theme	composite	1426:1434	arg1	dressing					1472:1479	a viable wound dressing	1457:1479	a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields	1457:1563	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	9	40	theme	composite	1426:1434	arg1	sponge					1436:1441	this composite sponge	1421:1441	this composite sponge	1421:1441	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	2	41	theme	varying	321:327	arg1	degrees					329:335	varying degrees	321:335	varying degrees of substitution (QCSX)	321:358	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	8	42	theme	early	1391:1395	arg1	stage					1397:1401	the early stage	1387:1401	the early stage	1387:1401	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	3	43	theme	corresponding	540:552	arg1	sponges					564:570	the corresponding composite sponges	536:570	the corresponding composite sponges (2QCSX-DAC)	536:582	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	3	43	theme	corresponding	540:552	arg1	2QCSX-DAC					573:581	2QCSX-DAC	573:581	2QCSX-DAC	573:581	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	6	44	theme	mechanical	897:906	arg1	properties					908:917	moderate mechanical properties	888:917	moderate mechanical properties	888:917	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	1	45	theme	healing	212:218	arg1	delay					220:224	the healing delay	208:224	the healing delay	208:224	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	0	46	theme	hemostatic	54:63	arg1	composites					31:40	chitosan/cellulose composites	12:40	chitosan/cellulose composites	12:40	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	0	46	theme	hemostatic	54:63	arg1	sponges					83:89	enhanced hemostatic and antibacterial sponges	45:89	enhanced hemostatic and antibacterial sponges for wound healing	45:107	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	4	47	theme	degradation	718:728	arg1	characters					643:652	physical characters	634:652	physical characters	634:652	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	47	theme	degradation	718:728	arg1	morphology					597:606	surface morphology	589:606	surface morphology	589:606	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	47	theme	degradation	718:728	arg1	structures					618:627	chemical structures	609:627	chemical structures	609:627	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	48	theme	measurement	668:678	arg1	characters					643:652	physical characters	634:652	physical characters	634:652	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	48	theme	measurement	668:678	arg1	morphology					597:606	surface morphology	589:606	surface morphology	589:606	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	48	theme	measurement	668:678	arg1	structures					618:627	chemical structures	609:627	chemical structures	609:627	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	49	dep	measurement	668:678	arg1	tests					730:734	tests	730:734	tests	730:734	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	50	theme	uptake	687:692	arg1	behavior					694:701	water uptake behavior	681:701	water uptake behavior	681:701	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	3	51	theme	dialdehyde	470:479	arg1	cellulose					481:489	dialdehyde cellulose	470:489	dialdehyde cellulose (DAC)	470:495	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	3	51	theme	dialdehyde	470:479	arg1	DAC					492:494	DAC	492:494	DAC	492:494	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	0	52	theme	enhanced	45:52	arg1	composites					31:40	chitosan/cellulose composites	12:40	chitosan/cellulose composites	12:40	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	0	52	theme	enhanced	45:52	arg1	sponges					83:89	enhanced hemostatic and antibacterial sponges	45:89	enhanced hemostatic and antibacterial sponges for wound healing	45:107	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	1	53	from	wounds	272:277	arg1	delay					220:224	the healing delay	208:224	the healing delay	208:224	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	1	53	from	wounds	272:277	arg1	death					235:239	even death	230:239	even death from the bacteria-contaminated wounds	230:277	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	4	54	dep	morphology	597:606	arg1	The					585:587	The	585:587	The	585:587	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	4	55	theme	physical	634:641	arg1	characters					643:652	physical characters	634:652	physical characters	634:652	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	7	56	theme	composite	1064:1072	arg1	sponges					1074:1080	these porous composite sponges	1051:1080	these porous composite sponges	1051:1080	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	4	57	theme	mechanical	657:666	arg1	measurement					668:678	mechanical measurement	657:678	mechanical measurement	657:678	The surface morphology, chemical structures, and physical characters of mechanical measurement, water uptake behavior, porosity, and degradation tests were determined.
35526773	0	58	theme	antibacterial	69:81	arg1	composites					31:40	chitosan/cellulose composites	12:40	chitosan/cellulose composites	12:40	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	0	58	theme	antibacterial	69:81	arg1	sponges					83:89	enhanced hemostatic and antibacterial sponges	45:89	enhanced hemostatic and antibacterial sponges for wound healing	45:107	Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing.
35526773	9	59	theme	civilian	1505:1512	arg1	hospitals					1514:1522	civilian hospitals	1505:1522	civilian hospitals	1505:1522	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	7	60	theme	blood	1096:1100	arg1	abilities					1114:1122	superior blood coagulation abilities	1087:1122	superior blood coagulation abilities	1087:1122	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	9	61	theme	viable	1459:1464	arg1	dressing					1472:1479	a viable wound dressing	1457:1479	a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields	1457:1563	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	9	61	theme	viable	1459:1464	arg1	sponge					1436:1441	this composite sponge	1421:1441	this composite sponge	1421:1441	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	3	62	theme	Schiff	505:510	arg1	reaction					517:524	Schiff base reaction	505:524	Schiff base reaction	505:524	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	9	63	theme	wound	1491:1495	arg1	care					1497:1500	daily wound care	1485:1500	daily wound care in civilian hospitals	1485:1522	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	6	64	theme	bactericidal	970:981	arg1	rates					983:987	effective bactericidal rates	960:987	effective bactericidal rates	960:987	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	5	65	dep	in	766:767	arg1	vitro					769:773	vitro	769:773	vitro	769:773	Furthermore, in vitro and in vivo biological assays were performed.
35526773	6	66	theme	porous	869:874	arg1	structures					876:885	abundant porous structures	860:885	abundant porous structures	860:885	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	3	67	theme	base	512:515	arg1	reaction					517:524	Schiff base reaction	505:524	Schiff base reaction	505:524	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35526773	6	68	theme	effective	960:968	arg1	rates					983:987	effective bactericidal rates	960:987	effective bactericidal rates	960:987	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	6	69	theme	abundant	860:867	arg1	structures					876:885	abundant porous structures	860:885	abundant porous structures	860:885	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	7	70	theme	porous	1057:1062	arg1	sponges					1074:1080	these porous composite sponges	1051:1080	these porous composite sponges	1051:1080	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	9	71	theme	daily	1485:1489	arg1	care					1497:1500	daily wound care	1485:1500	daily wound care in civilian hospitals	1485:1522	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	8	72	theme	wound	1362:1366	arg1	healing					1368:1374	the infected wound healing	1349:1374	the infected wound healing of rats	1349:1382	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	1	73	theme	even	230:233	arg1	death					235:239	even death	230:239	even death from the bacteria-contaminated wounds	230:277	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	7	74	theme	superior	1087:1094	arg1	abilities					1114:1122	superior blood coagulation abilities	1087:1122	superior blood coagulation abilities	1087:1122	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	1	75	theme	antibacterial	141:153	arg1	arsenal					155:161	our antibacterial arsenal	137:161	our antibacterial arsenal	137:161	It is essential to enhance our antibacterial arsenal in the first-aid hemostatic treatment due to the healing delay and even death from the bacteria-contaminated wounds.
35526773	6	76	theme	moderate	888:895	arg1	properties					908:917	moderate mechanical properties	888:917	moderate mechanical properties	888:917	The obtained 2QCSX-DAC sponges exhibit abundant porous structures, moderate mechanical properties, excellent water uptake performance, and effective bactericidal rates against Staphylococcus aureus and Escherichia coli.
35526773	8	77	theme	benign	1285:1290	arg1	cytotoxicity					1292:1303	benign cytotoxicity	1285:1303	benign cytotoxicity of L929 cells	1285:1317	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	9	78	from	emergency	1528:1536	arg1	hospitals					1514:1522	civilian hospitals	1505:1522	civilian hospitals	1505:1522	Overall, this composite sponge appears to be a viable wound dressing for daily wound care in civilian hospitals and emergency hemostasis on battlefields.
35526773	2	79	theme	glycidyl	376:383	arg1	chloride					404:411	glycidyl trimethyl ammonium chloride	376:411	glycidyl trimethyl ammonium chloride modification	376:424	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	8	80	theme	cells	1313:1317	arg1	cytotoxicity					1292:1303	benign cytotoxicity	1285:1303	benign cytotoxicity of L929 cells	1285:1317	Meanwhile, 2QCS3-DAC had benign cytotoxicity of L929 cells in vitro and could accelerate the infected wound healing of rats at the early stage in vivo.
35526773	2	81	with	chitosan	307:314	arg1	degrees					329:335	varying degrees	321:335	varying degrees of substitution (QCSX)	321:358	Herein, serial quaternized chitosan with varying degrees of substitution (QCSX) was prepared by glycidyl trimethyl ammonium chloride modification.
35526773	7	82	contain	have	1082:1085	arg2	abilities					1114:1122	superior blood coagulation abilities	1087:1122	superior blood coagulation abilities	1087:1122	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	7	82	contain	have	1082:1085	arg1	sponges					1074:1080	these porous composite sponges	1051:1080	these porous composite sponges	1051:1080	Moreover, these porous composite sponges have superior blood coagulation abilities with the blood coagulation time reduced by 76.6% and 59.8% compared with blank control and Celox™ as well as low hemolysis rates (<5%).
35526773	3	83	theme	obtained	436:443	arg1	QCSX					445:448	the obtained QCSX	432:448	the obtained QCSX	432:448	Then the obtained QCSX was conjugated with dialdehyde cellulose (DAC) through Schiff base reaction to obtain the corresponding composite sponges (2QCSX-DAC).
35179194	11	0	from	HMOs	1860:1863	arg1	secretors					1868:1876	secretors	1868:1876	secretors	1868:1876	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	2	1	theme	Advanced	319:326	arg1	methods					339:345	Advanced analytical methods	319:345	OBJECTIVES Advanced analytical methods	308:345	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	1	2	theme	infant	237:242	arg1	development					218:228	the development	214:228	the development of the infant, and specifically the brain, immune system, and gut microbiome	214:305	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	9	3	theme	structures	1516:1525	arg1	concentrations					1479:1492	relatively high concentrations	1463:1492	relatively high concentrations of α(1,2)-fucosylated structures] in their populations	1463:1547	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	11	4	from	secretors	1868:1876	arg1	abundances					1846:1855	total abundances	1840:1855	total abundances of HMOs in secretors	1840:1876	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	4	5	dep	potential	737:745	arg1	biological					747:756	biological	747:756	biological	747:756	The profiles revealed their structural heterogeneity and their potential biological roles.
35179194	11	6	theme	geographical	2000:2011	arg1	location					2013:2020	geographical location	2000:2020	geographical location	2000:2020	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	10	7	dep	secretors	1747:1755	arg1	Africa					1764:1769	Africa	1764:1769	Africa	1764:1769	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	10	8	theme	∼	1807:1807	arg1	%					1811:1811	Malawi ∼ 75%	1800:1811	Malawi ∼ 75%	1800:1811	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	7	9	theme	structural	1123:1132	arg1	abundances					1134:1143	structural abundances	1123:1143	structural abundances	1123:1143	The greatest variations in structural abundances were associated with the presence of α(1,2)-fucosylated species.
35179194	5	10	theme	age	836:838	arg1	groups					840:845	different age groups	826:845	different age groups	826:845	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	9	11	theme	secretors	1439:1447	arg1	[mothers					1449:1456	phenotypic secretors [mothers	1428:1456	phenotypic secretors [mothers	1428:1456	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	13	12	theme	HMO	2200:2202	arg1	study					2204:2208	the largest structural HMO study	2177:2208	the largest structural HMO study	2177:2208	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	11	13	from	abundances	1846:1855	arg1	secretors					1868:1876	secretors	1868:1876	secretors	1868:1876	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	3	14	theme	analytical	559:568	arg1	methods					570:576	LC-MS-based analytical methods	547:576	LC-MS-based analytical methods	547:576	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	5	15	theme	residing	885:892	arg1	locations					907:915	residing geographical locations	885:915	residing geographical locations	885:915	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	5	16	theme	periods	858:864	arg1	mothers					815:821	mothers	815:821	mothers of different age groups, lactation periods, infant sexes, and residing geographical locations	815:915	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	9	17	theme	higher	1406:1411	arg1	proportions					1413:1423	higher proportions	1406:1423	higher proportions of phenotypic secretors [mothers	1406:1456	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	10	18	theme	lowest	1726:1731	arg1	proportion					1733:1742	the lowest proportion	1722:1742	the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%)	1722:1812	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	5	19	theme	infant	867:872	arg1	sexes					874:878	infant sexes	867:878	infant sexes	867:878	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	10	20	dep	sampled	1693:1699	arg1	manifested					1711:1720	manifested	1711:1720	manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%)	1711:1812	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	11	21	theme	lower	1938:1942	arg1	abundances					1944:1953	lower abundances	1938:1953	lower abundances of HMOs	1938:1961	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	4	22	theme	potential	737:745	arg1	roles					758:762	their potential biological roles	731:762	their potential biological roles	731:762	The profiles revealed their structural heterogeneity and their potential biological roles.
35179194	13	23	theme	largest	2181:2187	arg1	study					2204:2208	the largest structural HMO study	2177:2208	the largest structural HMO study	2177:2208	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	9	24	from	%	1667:1667	arg1	Bolivia					1589:1595	Bolivia	1589:1595	Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%	1589:1667	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	2	25	theme	semirural	471:479	arg1	sites					492:496	urban, semirural, and rural sites	464:496	urban, semirural, and rural sites across geographically diverse countries	464:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	5	26	theme	HMO	780:782	arg1	compositions					784:795	HMO compositions	780:795	HMO compositions	780:795	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	1	27	theme	gut	292:294	arg1	microbiome					296:305	gut microbiome	292:305	gut microbiome	292:305	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	3	28	dep	METHODS	539:545	arg1	used					583:586	used	583:586	were used to profile the compounds with broad structural coverage and quantitative information	578:671	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	2	29	theme	urban	464:468	arg1	sites					492:496	urban, semirural, and rural sites	464:496	urban, semirural, and rural sites across geographically diverse countries	464:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	4	30	theme	structural	702:711	arg1	heterogeneity					713:725	their structural heterogeneity	696:725	their structural heterogeneity	696:725	The profiles revealed their structural heterogeneity and their potential biological roles.
35179194	1	31	theme	compounds	160:168	arg1	class					151:155	an abundant class	139:155	an abundant class of compounds found in human milk	139:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	31	theme	compounds	160:168	arg1	oligosaccharides					111:126	BACKGROUND Human milk oligosaccharides	89:126	BACKGROUND Human milk oligosaccharides (HMOs)	89:133	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	8	32	theme	-fucosylated	1328:1339	arg1	structures					1341:1350	α(1,2)-fucosylated structures	1322:1350	α(1,2)-fucosylated structures	1322:1350	Genomic analyses of the mothers were not performed; instead, milk was phenotyped according to the abundances of α(1,2)-fucosylated structures.
35179194	0	33	from	Variations	58:67	arg1	Nutrition					78:86	Early Nutrition	72:86	Early Nutrition	72:86	Human Milk Oligosaccharide Compositions Illustrate Global Variations in Early Nutrition.
35179194	12	34	theme	geographical	2119:2130	arg1	locations					2132:2140	geographical locations	2119:2140	geographical locations	2119:2140	We also observed compositional differences of the 50+ most abundant HMOs between milk types and geographical locations.
35179194	2	35	theme	relative	367:374	arg1	quantitation					376:387	relative quantitation	367:387	relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries	367:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	1	36	theme	BACKGROUND	89:98	arg1	class					151:155	an abundant class	139:155	an abundant class of compounds found in human milk	139:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	36	theme	BACKGROUND	89:98	arg1	HMOs					129:132	HMOs	129:132	HMOs	129:132	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	36	theme	BACKGROUND	89:98	arg1	oligosaccharides					111:126	BACKGROUND Human milk oligosaccharides	89:126	BACKGROUND Human milk oligosaccharides (HMOs)	89:133	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	12	37	theme	abundant	2082:2089	arg1	HMOs					2091:2094	the 50+ most abundant HMOs	2069:2094	the 50+ most abundant HMOs	2069:2094	We also observed compositional differences of the 50+ most abundant HMOs between milk types and geographical locations.
35179194	0	38	theme	Human	0:4	arg1	Compositions					27:38	Human Milk Oligosaccharide Compositions	0:38	Human Milk Oligosaccharide Compositions	0:38	Human Milk Oligosaccharide Compositions Illustrate Global Variations in Early Nutrition.
35179194	1	39	theme	milk	106:109	arg1	class					151:155	an abundant class	139:155	an abundant class of compounds found in human milk	139:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	39	theme	milk	106:109	arg1	HMOs					129:132	HMOs	129:132	HMOs	129:132	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	39	theme	milk	106:109	arg1	oligosaccharides					111:126	BACKGROUND Human milk oligosaccharides	89:126	BACKGROUND Human milk oligosaccharides (HMOs)	89:133	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	7	40	from	variations	1109:1118	arg1	abundances					1134:1143	structural abundances	1123:1143	structural abundances	1123:1143	The greatest variations in structural abundances were associated with the presence of α(1,2)-fucosylated species.
35179194	6	41	from	decrease	972:979	arg1	abundances					988:997	HMO abundances	984:997	HMO abundances	984:997	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	2	42	dep	OBJECTIVES	308:317	arg1	methods					339:345	Advanced analytical methods	319:345	OBJECTIVES Advanced analytical methods	308:345	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	2	43	theme	structures	397:406	arg1	quantitation					376:387	relative quantitation	367:387	relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries	367:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	0	44	theme	Oligosaccharide	11:25	arg1	Compositions					27:38	Human Milk Oligosaccharide Compositions	0:38	Human Milk Oligosaccharide Compositions	0:38	Human Milk Oligosaccharide Compositions Illustrate Global Variations in Early Nutrition.
35179194	1	45	theme	brain	266:270	arg1	development					218:228	the development	214:228	the development of the infant, and specifically the brain, immune system, and gut microbiome	214:305	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	5	46	theme	geographical	894:905	arg1	locations					907:915	residing geographical locations	885:915	residing geographical locations	885:915	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	0	47	theme	Early	72:76	arg1	Nutrition					78:86	Early Nutrition	72:86	Early Nutrition	72:86	Human Milk Oligosaccharide Compositions Illustrate Global Variations in Early Nutrition.
35179194	7	48	theme	-fucosylated	1188:1199	arg1	species					1201:1207	α(1,2)-fucosylated species	1182:1207	α(1,2)-fucosylated species	1182:1207	The greatest variations in structural abundances were associated with the presence of α(1,2)-fucosylated species.
35179194	9	49	theme	phenotypic	1428:1437	arg1	[mothers					1449:1456	phenotypic secretors [mothers	1428:1456	phenotypic secretors [mothers	1428:1456	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	1	50	theme	immune	273:278	arg1	system					280:285	immune system	273:285	immune system	273:285	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	9	51	from	concentrations	1479:1492	arg1	populations					1537:1547	their populations	1531:1547	their populations	1531:1547	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	3	52	theme	structural	624:633	arg1	coverage					635:642	broad structural coverage	618:642	broad structural coverage	618:642	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	13	53	theme	different	2282:2290	arg1	populations					2292:2302	different populations	2282:2302	different populations	2282:2302	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	10	54	theme	Gambia	1782:1787	arg1	%					1793:1793	the Gambia ∼ 64%	1778:1793	the Gambia ∼ 64%	1778:1793	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	7	55	gly	-fucosylated	1188:1199	arg1	species					1201:1207	α(1,2)-fucosylated species	1182:1207	α(1,2)-fucosylated species	1182:1207	The greatest variations in structural abundances were associated with the presence of α(1,2)-fucosylated species.
35179194	9	56	theme	American	1376:1383	arg1	sites					1385:1389	the South American sites	1366:1389	the South American sites	1366:1389	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	57	from	sites	1385:1389	arg1	Mothers					1353:1359	Mothers	1353:1359	Mothers from the South American sites	1353:1389	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	58	theme	∼100	1600:1603	arg1	%					1604:1604	%	1604:1604	%	1604:1604	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	5	59	theme	locations	907:915	arg1	mothers					815:821	mothers	815:821	mothers of different age groups, lactation periods, infant sexes, and residing geographical locations	815:915	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	13	60	theme	HMOs	2254:2257	arg1	behavior					2242:2249	the general behavior	2230:2249	the general behavior of HMOs	2230:2257	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	2	61	theme	analytical	328:337	arg1	methods					339:345	Advanced analytical methods	319:345	OBJECTIVES Advanced analytical methods	308:345	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	6	62	theme	common	928:933	arg1	decrease					972:979	a decrease	970:979	a decrease in HMO abundances	970:997	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	6	62	theme	common	928:933	arg1	behavior					935:942	A common behavior	926:942	A common behavior found among all sites	926:964	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	10	63	dep	Africa	1764:1769	arg1	%					1775:1775	63%	1773:1775	63%	1773:1775	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	10	63	dep	Africa	1764:1769	arg1	%					1793:1793	the Gambia ∼ 64%	1778:1793	the Gambia ∼ 64%	1778:1793	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	10	63	dep	Africa	1764:1769	arg1	%					1811:1811	Malawi ∼ 75%	1800:1811	Malawi ∼ 75%	1800:1811	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	11	64	contain	have	1933:1936	arg1	nonsecretors					1920:1931	nonsecretors	1920:1931	nonsecretors	1920:1931	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	11	64	contain	have	1933:1936	arg2	abundances					1944:1953	lower abundances	1938:1953	lower abundances of HMOs	1938:1961	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	1	65	theme	human	179:183	arg1	milk					185:188	human milk	179:188	human milk	179:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	5	66	theme	sexes	874:878	arg1	mothers					815:821	mothers	815:821	mothers of different age groups, lactation periods, infant sexes, and residing geographical locations	815:915	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	10	67	theme	Malawi	1800:1805	arg1	%					1811:1811	Malawi ∼ 75%	1800:1811	Malawi ∼ 75%	1800:1811	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	7	68	theme	greatest	1100:1107	arg1	variations					1109:1118	The greatest variations	1096:1118	The greatest variations in structural abundances	1096:1143	The greatest variations in structural abundances were associated with the presence of α(1,2)-fucosylated species.
35179194	3	69	theme	LC-MS-based	547:557	arg1	methods					570:576	LC-MS-based analytical methods	547:576	LC-MS-based analytical methods	547:576	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	9	70	theme	[mothers	1449:1456	arg1	proportions					1413:1423	higher proportions	1406:1423	higher proportions of phenotypic secretors [mothers	1406:1456	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	6	71	theme	HMO	984:986	arg1	abundances					988:997	HMO abundances	984:997	HMO abundances	984:997	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	9	72	contain	have	1401:1404	arg2	proportions					1413:1423	higher proportions	1406:1423	higher proportions of phenotypic secretors [mothers	1406:1456	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	72	contain	have	1401:1404	arg1	Mothers					1353:1359	Mothers	1353:1359	Mothers from the South American sites	1353:1389	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	5	73	theme	lactation	848:856	arg1	periods					858:864	lactation periods	848:864	lactation periods	848:864	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	8	74	theme	Genomic	1210:1216	arg1	analyses					1218:1225	Genomic analyses	1210:1225	Genomic analyses of the mothers	1210:1240	Genomic analyses of the mothers were not performed; instead, milk was phenotyped according to the abundances of α(1,2)-fucosylated structures.
35179194	2	75	theme	diverse	520:526	arg1	countries					528:536	geographically diverse countries	505:536	geographically diverse countries	505:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	1	76	theme	abundant	142:149	arg1	class					151:155	an abundant class	139:155	an abundant class of compounds found in human milk	139:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	76	theme	abundant	142:149	arg1	oligosaccharides					111:126	BACKGROUND Human milk oligosaccharides	89:126	BACKGROUND Human milk oligosaccharides (HMOs)	89:133	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	77	located	found	170:174	arg2	compounds					160:168	compounds	160:168	compounds found in human milk	160:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	77	located	found	170:174	arg1	milk					185:188	human milk	179:188	human milk	179:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	8	78	theme	mothers	1234:1240	arg1	analyses					1218:1225	Genomic analyses	1210:1225	Genomic analyses of the mothers	1210:1240	Genomic analyses of the mothers were not performed; instead, milk was phenotyped according to the abundances of α(1,2)-fucosylated structures.
35179194	11	79	theme	HMOs	1958:1961	arg1	abundances					1944:1953	lower abundances	1938:1953	lower abundances of HMOs	1938:1961	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	11	80	theme	total	1840:1844	arg1	abundances					1846:1855	total abundances	1840:1855	total abundances of HMOs in secretors	1840:1876	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	2	81	used	used	352:355	arg2	OBJECTIVES					308:317	OBJECTIVES Advanced analytical methods	308:345	OBJECTIVES Advanced analytical methods	308:345	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	3	82	used	used	583:586	arg2	methods					570:576	LC-MS-based analytical methods	547:576	LC-MS-based analytical methods	547:576	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	3	83	with	profile	591:597	arg1	coverage					635:642	broad structural coverage	618:642	broad structural coverage	618:642	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	3	83	with	profile	591:597	arg1	information					661:671	quantitative information	648:671	quantitative information	648:671	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	10	84	theme	secretors	1747:1755	arg1	proportion					1733:1742	the lowest proportion	1722:1742	the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%)	1722:1812	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	13	85	theme	structural	2189:2198	arg1	study					2204:2208	the largest structural HMO study	2177:2208	the largest structural HMO study	2177:2208	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	9	86	theme	-fucosylated	1503:1514	arg1	structures					1516:1525	α(1,2)-fucosylated structures]	1497:1526	α(1,2)-fucosylated structures]	1497:1526	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	6	87	theme	postnatal	1036:1044	arg1	month					1046:1050	approximately postnatal month 6	1022:1052	approximately postnatal month 6	1022:1052	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	5	88	theme	compositions	784:795	arg1	Comparisons					765:775	Comparisons	765:775	Comparisons of HMO compositions	765:795	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	1	89	theme	microbiome	296:305	arg1	development					218:228	the development	214:228	the development of the infant, and specifically the brain, immune system, and gut microbiome	214:305	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	90	attach	linked	204:209	arg1	development					218:228	the development	214:228	the development of the infant, and specifically the brain, immune system, and gut microbiome	214:305	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	90	attach	linked	204:209	arg2	HMOs					129:132	HMOs	129:132	HMOs	129:132	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	90	attach	linked	204:209	arg2	class					151:155	an abundant class	139:155	an abundant class of compounds found in human milk	139:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	90	attach	linked	204:209	arg2	oligosaccharides					111:126	BACKGROUND Human milk oligosaccharides	89:126	BACKGROUND Human milk oligosaccharides (HMOs)	89:133	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	2	91	theme	rural	486:490	arg1	sites					492:496	urban, semirural, and rural sites	464:496	urban, semirural, and rural sites across geographically diverse countries	464:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	12	92	theme	milk	2104:2107	arg1	types					2109:2113	milk types	2104:2113	milk types	2104:2113	We also observed compositional differences of the 50+ most abundant HMOs between milk types and geographical locations.
35179194	7	93	theme	species	1201:1207	arg1	presence					1170:1177	the presence	1166:1177	the presence of α(1,2)-fucosylated species	1166:1207	The greatest variations in structural abundances were associated with the presence of α(1,2)-fucosylated species.
35179194	9	94	theme	high	1474:1477	arg1	concentrations					1479:1492	relatively high concentrations	1463:1492	relatively high concentrations of α(1,2)-fucosylated structures] in their populations	1463:1547	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	95	from	secretors	1606:1614	arg1	Bolivia					1589:1595	Bolivia	1589:1595	Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%	1589:1667	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	2	96	from	mothers	453:459	arg1	samples					430:436	approximately 2000 samples	411:436	approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries	411:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	2	96	from	mothers	453:459	arg1	quantitation					376:387	relative quantitation	367:387	relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries	367:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	2	96	from	mothers	453:459	arg1	sites					492:496	urban, semirural, and rural sites	464:496	urban, semirural, and rural sites across geographically diverse countries	464:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	8	97	theme	structures	1341:1350	arg1	abundances					1308:1317	the abundances	1304:1317	the abundances of α(1,2)-fucosylated structures	1304:1350	Genomic analyses of the mothers were not performed; instead, milk was phenotyped according to the abundances of α(1,2)-fucosylated structures.
35179194	5	98	theme	different	826:834	arg1	groups					840:845	different age groups	826:845	different age groups	826:845	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	1	99	theme	Human	100:104	arg1	class					151:155	an abundant class	139:155	an abundant class of compounds found in human milk	139:188	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	99	theme	Human	100:104	arg1	HMOs					129:132	HMOs	129:132	HMOs	129:132	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	1	99	theme	Human	100:104	arg1	oligosaccharides					111:126	BACKGROUND Human milk oligosaccharides	89:126	BACKGROUND Human milk oligosaccharides (HMOs)	89:133	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	9	100	gly	-fucosylated	1503:1514	arg1	structures					1516:1525	α(1,2)-fucosylated structures]	1497:1526	α(1,2)-fucosylated structures]	1497:1526	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	12	101	theme	50+ most	2073:2080	arg1	HMOs					2091:2094	the 50+ most abundant HMOs	2069:2094	the 50+ most abundant HMOs	2069:2094	We also observed compositional differences of the 50+ most abundant HMOs between milk types and geographical locations.
35179194	5	102	theme	groups	840:845	arg1	mothers					815:821	mothers	815:821	mothers of different age groups, lactation periods, infant sexes, and residing geographical locations	815:915	Comparisons of HMO compositions were made between mothers of different age groups, lactation periods, infant sexes, and residing geographical locations.
35179194	8	103	gly	-fucosylated	1328:1339	arg1	structures					1341:1350	α(1,2)-fucosylated structures	1322:1350	α(1,2)-fucosylated structures	1322:1350	Genomic analyses of the mothers were not performed; instead, milk was phenotyped according to the abundances of α(1,2)-fucosylated structures.
35179194	12	104	theme	HMOs	2091:2094	arg1	differences					2054:2064	compositional differences	2040:2064	compositional differences of the 50+ most abundant HMOs between milk types and geographical locations	2040:2140	We also observed compositional differences of the 50+ most abundant HMOs between milk types and geographical locations.
35179194	2	105	theme	many	392:395	arg1	structures					397:406	many structures	392:406	many structures	392:406	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	0	106	theme	Global	51:56	arg1	Variations					58:67	Global Variations	51:67	Global Variations in Early Nutrition	51:86	Human Milk Oligosaccharide Compositions Illustrate Global Variations in Early Nutrition.
35179194	9	107	theme	globe	1577:1581	arg1	rest					1565:1568	the rest	1561:1568	the rest of the globe	1561:1581	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	13	108	dep	CONCLUSIONS	2143:2153	arg1	represents					2166:2175	represents	2166:2175	represents the largest structural HMO study to date	2166:2216	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	13	108	dep	CONCLUSIONS	2143:2153	arg1	reveals					2222:2228	reveals	2222:2228	reveals the general behavior of HMOs during lactation among different populations	2222:2302	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	3	109	theme	broad	618:622	arg1	coverage					635:642	broad structural coverage	618:642	broad structural coverage	618:642	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	12	110	theme	compositional	2040:2052	arg1	differences					2054:2064	compositional differences	2040:2064	compositional differences of the 50+ most abundant HMOs between milk types and geographical locations	2040:2140	We also observed compositional differences of the 50+ most abundant HMOs between milk types and geographical locations.
35179194	1	111	theme	system	280:285	arg1	development					218:228	the development	214:228	the development of the infant, and specifically the brain, immune system, and gut microbiome	214:305	BACKGROUND Human milk oligosaccharides (HMOs) are an abundant class of compounds found in human milk and have been linked to the development of the infant, and specifically the brain, immune system, and gut microbiome.
35179194	10	112	theme	∼	1789:1789	arg1	%					1793:1793	the Gambia ∼ 64%	1778:1793	the Gambia ∼ 64%	1778:1793	Conversely, the cohort sampled in Africa manifested the lowest proportion of secretors (South Africa ∼ 63%, the Gambia ∼ 64%, and Malawi ∼ 75%).
35179194	13	113	theme	general	2234:2240	arg1	behavior					2242:2249	the general behavior	2230:2249	the general behavior of HMOs	2230:2257	CONCLUSIONS This study represents the largest structural HMO study to date and reveals the general behavior of HMOs during lactation among different populations.
35179194	11	114	theme	HMOs	1860:1863	arg1	abundances					1846:1855	total abundances	1840:1855	total abundances of HMOs in secretors	1840:1876	Furthermore, we compared total abundances of HMOs in secretors compared with nonsecretors and found that nonsecretors have lower abundances of HMOs compared to secretors, regardless of geographical location.
35179194	3	115	theme	quantitative	648:659	arg1	information					661:671	quantitative information	648:671	quantitative information	648:671	METHODS LC-MS-based analytical methods were used to profile the compounds with broad structural coverage and quantitative information.
35179194	9	116	theme	%	1604:1604	arg1	Brazil					1631:1636	Brazil	1631:1636	Brazil	1631:1636	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	116	theme	%	1604:1604	arg1	Peru					1617:1620	Peru	1617:1620	Peru	1617:1620	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	116	theme	%	1604:1604	arg1	Argentina					1651:1659	Argentina	1651:1659	Argentina	1651:1659	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	9	116	theme	%	1604:1604	arg1	secretors					1606:1614	∼100% secretors	1600:1614	∼100% secretors	1600:1614	Mothers from the South American sites tended to have higher proportions of phenotypic secretors [mothers with relatively high concentrations of α(1,2)-fucosylated structures] in their populations compared to the rest of the globe, with Bolivia at ∼100% secretors, Peru at ∼97%, Brazil at ∼90%, and Argentina at ∼85%.
35179194	2	117	from	quantitation	376:387	arg1	samples					430:436	approximately 2000 samples	411:436	approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries	411:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	2	117	from	quantitation	376:387	arg1	mothers					453:459	over 1000 mothers	443:459	over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries	443:536	OBJECTIVES Advanced analytical methods were used to obtain relative quantitation of many structures in approximately 2000 samples from over 1000 mothers in urban, semirural, and rural sites across geographically diverse countries.
35179194	6	118	dep	RESULTS	918:924	arg1	decrease					972:979	a decrease	970:979	a decrease in HMO abundances	970:997	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	6	118	dep	RESULTS	918:924	arg1	behavior					935:942	A common behavior	926:942	A common behavior found among all sites	926:964	RESULTS A common behavior found among all sites was a decrease in HMO abundances during lactation until approximately postnatal month 6, where they remained relatively constant.
35179194	0	119	theme	Milk	6:9	arg1	Compositions					27:38	Human Milk Oligosaccharide Compositions	0:38	Human Milk Oligosaccharide Compositions	0:38	Human Milk Oligosaccharide Compositions Illustrate Global Variations in Early Nutrition.
35642413	0	0	theme	Karachi	81:87	arg1	algae					72:76	Hypnea musciformis red algae	49:76	Hypnea musciformis red algae of Karachi	49:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	8	1	from	Mg	1050:1051	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	8	2	from	Ca	1068:1069	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	6	3	from	present	718:724	arg1	%					755:755	>25.0%	750:755	>25.0%	750:755	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	3	from	present	718:724	arg1	amounts					741:747	the highest amounts	729:747	the highest amounts (>25.0%) in dialysed acidic extracts	729:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	7	4	theme	crude	842:846	arg1	extracts					867:874	only crude aqueous and acidic extracts	837:874	only crude aqueous and acidic extracts	837:874	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	8	5	from	%	1025:1025	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	1	6	theme	crude	155:159	arg1	weight					147:152	high molecular weight	132:152	high molecular weight	132:152	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	4	7	theme	crude	516:520	arg1	extracts					522:529	crude extracts	516:529	crude extracts	516:529	The numbers of elements found in crude extracts were greater than that in the dialysed extracts.
35642413	5	8	theme	dialysed	656:663	arg1	extract					672:678	dialysed acidic extract	656:678	dialysed acidic extract	656:678	All extracts contained the higher concentrations of C followed by O (except dialysed acidic extract).
35642413	5	9	theme	higher	607:612	arg1	concentrations					614:627	the higher concentrations	603:627	the higher concentrations of C followed by O (except dialysed acidic extract)	603:679	All extracts contained the higher concentrations of C followed by O (except dialysed acidic extract).
35642413	7	10	from	concentrations	819:832	arg1	extracts					867:874	only crude aqueous and acidic extracts	837:874	only crude aqueous and acidic extracts	837:874	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	5	11	theme	acidic	665:670	arg1	extract					672:678	dialysed acidic extract	656:678	dialysed acidic extract	656:678	All extracts contained the higher concentrations of C followed by O (except dialysed acidic extract).
35642413	6	12	theme	dialysed	761:768	arg1	extracts					777:784	dialysed acidic extracts	761:784	dialysed acidic extracts	761:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	8	13	from	%	953:953	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	9	14	theme	major	1165:1169	arg1	elements					1171:1178	major elements	1165:1178	major elements such that Na, Mg, Ca, K and Zn	1165:1209	The study confirmed the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities.
35642413	8	15	from	%	1013:1013	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	8	16	theme	crude	1087:1091	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	5	17	theme	C	632:632	arg1	concentrations					614:627	the higher concentrations	603:627	the higher concentrations of C followed by O (except dialysed acidic extract)	603:679	All extracts contained the higher concentrations of C followed by O (except dialysed acidic extract).
35642413	2	18	theme	elemental	276:284	arg1	composition					286:296	The elemental composition	272:296	The elemental composition	272:296	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	3	19	theme	mineral	427:433	arg1	elements					435:442	multiple mineral elements	418:442	multiple mineral elements	418:442	After analyzing multiple mineral elements were detected in different quantities.
35642413	2	20	theme	techniques	390:399	arg1	one					349:351	one	349:351	one	349:351	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	2	20	theme	techniques	390:399	arg1	techniques					390:399	the modern, reliable and accurate techniques	356:399	the modern, reliable and accurate techniques	356:399	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	8	21	from	Cl	1061:1062	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	4	22	theme	elements	498:505	arg1	numbers					487:493	The numbers	483:493	The numbers of elements found in crude extracts	483:529	The numbers of elements found in crude extracts were greater than that in the dialysed extracts.
35642413	4	22	theme	elements	498:505	arg1	greater					536:542	greater	536:542	greater	536:542	The numbers of elements found in crude extracts were greater than that in the dialysed extracts.
35642413	9	23	from	presence	1153:1160	arg1	quantities					1219:1228	high quantities	1214:1228	high quantities	1214:1228	The study confirmed the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities.
35642413	0	24	attach	isolated	35:42	arg2	carrageenans					22:33	carrageenans	22:33	carrageenans isolated from Hypnea musciformis red algae of Karachi	22:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	0	24	attach	isolated	35:42	arg1	algae					72:76	Hypnea musciformis red algae	49:76	Hypnea musciformis red algae of Karachi	49:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	6	25	attach	present	718:724	arg2	Cl					704:705	Cl	704:705	Cl	704:705	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	25	attach	present	718:724	arg1	%					755:755	>25.0%	750:755	>25.0%	750:755	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	25	attach	present	718:724	arg2	K					711:711	K	711:711	K	711:711	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	25	attach	present	718:724	arg1	amounts					741:747	the highest amounts	729:747	the highest amounts (>25.0%) in dialysed acidic extracts	729:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	10	26	theme	pharmaceutical	1365:1378	arg1	industries					1380:1389	food and pharmaceutical industries	1356:1389	food and pharmaceutical industries	1356:1389	However, there was no toxic element identified like Cd, Hg and Pb which show that these carrageenans are safer to utilize in food and pharmaceutical industries.
35642413	1	27	theme	dialysed	165:172	arg1	fractions					189:197	dialysed polysaccharide fractions	165:197	dialysed polysaccharide fractions	165:197	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	8	28	from	%	965:965	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	8	29	from	S	1058:1058	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	2	30	theme	SEM-EDX	322:328	arg1	technique					330:338	SEM-EDX technique	322:338	SEM-EDX technique which is one of the modern, reliable and accurate techniques	322:399	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	6	31	theme	other	688:692	arg1	elements					694:701	other elements	688:701	other elements	688:701	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	1	32	theme	polysaccharide	174:187	arg1	fractions					189:197	dialysed polysaccharide fractions	165:197	dialysed polysaccharide fractions	165:197	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	0	33	theme	Elemental	0:8	arg1	analysis					10:17	Elemental analysis	0:17	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi	0:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	8	34	from	%	974:974	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	1	35	with	carrageenans	114:125	arg1	weight					147:152	high molecular weight	132:152	high molecular weight	132:152	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	6	36	located	present	718:724	arg2	Cl					704:705	Cl	704:705	Cl	704:705	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	36	located	present	718:724	arg1	%					755:755	>25.0%	750:755	>25.0%	750:755	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	36	located	present	718:724	arg2	K					711:711	K	711:711	K	711:711	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	36	located	present	718:724	arg1	amounts					741:747	the highest amounts	729:747	the highest amounts (>25.0%) in dialysed acidic extracts	729:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	2	37	theme	reliable	368:375	arg1	techniques					390:399	the modern, reliable and accurate techniques	356:399	the modern, reliable and accurate techniques	356:399	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	0	38	theme	carrageenans	22:33	arg1	analysis					10:17	Elemental analysis	0:17	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi	0:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	10	39	theme	toxic	1253:1257	arg1	element					1259:1265	no toxic element	1250:1265	no toxic element identified like Cd, Hg and Pb which show that these carrageenans are safer to utilize in food and pharmaceutical industries	1250:1389	However, there was no toxic element identified like Cd, Hg and Pb which show that these carrageenans are safer to utilize in food and pharmaceutical industries.
35642413	8	40	dep	%	927:927	arg1	Al					1054:1055	30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts	916:1113	Al	1054:1055	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	5	41	contain	contained	593:601	arg1	extracts					584:591	All extracts	580:591	All extracts	580:591	All extracts contained the higher concentrations of C followed by O (except dialysed acidic extract).
35642413	5	41	contain	contained	593:601	arg2	concentrations					614:627	the higher concentrations	603:627	the higher concentrations of C followed by O (except dialysed acidic extract)	603:679	All extracts contained the higher concentrations of C followed by O (except dialysed acidic extract).
35642413	8	42	from	Zn	1075:1076	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	9	43	attach	presence	1153:1160	arg2	elements					1171:1178	major elements	1165:1178	major elements such that Na, Mg, Ca, K and Zn	1165:1209	The study confirmed the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities.
35642413	9	43	attach	presence	1153:1160	arg1	quantities					1219:1228	high quantities	1214:1228	high quantities	1214:1228	The study confirmed the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities.
35642413	4	44	theme	dialysed	561:568	arg1	extracts					570:577	the dialysed extracts	557:577	the dialysed extracts	557:577	The numbers of elements found in crude extracts were greater than that in the dialysed extracts.
35642413	8	45	from	%	1034:1034	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	9	46	theme	high	1214:1217	arg1	quantities					1219:1228	high quantities	1214:1228	high quantities	1214:1228	The study confirmed the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities.
35642413	1	47	theme	Hypnea	213:218	arg1	algae					236:240	Hypnea musciformis red algae	213:240	Hypnea musciformis red algae of Karachi	213:251	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	3	48	theme	multiple	418:425	arg1	elements					435:442	multiple mineral elements	418:442	multiple mineral elements	418:442	After analyzing multiple mineral elements were detected in different quantities.
35642413	8	49	from	K	1065:1065	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	10	50	theme	food	1356:1359	arg1	industries					1380:1389	food and pharmaceutical industries	1356:1389	food and pharmaceutical industries	1356:1389	However, there was no toxic element identified like Cd, Hg and Pb which show that these carrageenans are safer to utilize in food and pharmaceutical industries.
35642413	1	51	theme	musciformis	220:230	arg1	algae					236:240	Hypnea musciformis red algae	213:240	Hypnea musciformis red algae of Karachi	213:251	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	0	52	theme	musciformis	56:66	arg1	algae					72:76	Hypnea musciformis red algae	49:76	Hypnea musciformis red algae of Karachi	49:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	8	53	from	%	987:987	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	6	54	theme	highest	733:739	arg1	%					755:755	>25.0%	750:755	>25.0%	750:755	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	54	theme	highest	733:739	arg1	amounts					741:747	the highest amounts	729:747	the highest amounts (>25.0%) in dialysed acidic extracts	729:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	4	55	located	found	507:511	arg2	elements					498:505	elements	498:505	elements found in crude extracts	498:529	The numbers of elements found in crude extracts were greater than that in the dialysed extracts.
35642413	4	55	located	found	507:511	arg1	extracts					522:529	crude extracts	516:529	crude extracts	516:529	The numbers of elements found in crude extracts were greater than that in the dialysed extracts.
35642413	0	56	theme	Hypnea	49:54	arg1	algae					72:76	Hypnea musciformis red algae	49:76	Hypnea musciformis red algae of Karachi	49:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	9	57	theme	elements	1171:1178	arg1	presence					1153:1160	the presence	1149:1160	the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities	1149:1228	The study confirmed the presence of major elements such that Na, Mg, Ca, K and Zn in high quantities.
35642413	1	58	with	fractions	189:197	arg1	weight					147:152	high molecular weight	132:152	high molecular weight	132:152	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	8	59	theme	concentrations	889:902	arg1	ranges					904:909	The mineral concentrations ranges	877:909	The mineral concentrations ranges	877:909	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	8	60	from	%	941:941	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	7	61	theme	acidic	860:865	arg1	extracts					867:874	only crude aqueous and acidic extracts	837:874	only crude aqueous and acidic extracts	837:874	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	7	62	located	detected	803:810	arg1	concentrations					819:832	low concentrations	815:832	low concentrations in only crude aqueous and acidic extracts	815:874	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	7	62	located	detected	803:810	arg2	Al					796:797	Al	796:797	Al	796:797	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	8	63	from	O	1043:1043	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	6	64	theme	acidic	770:775	arg1	extracts					777:784	dialysed acidic extracts	761:784	dialysed acidic extracts	761:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	65	from	amounts	741:747	arg1	present					718:724	present	718:724	present	718:724	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	6	65	from	amounts	741:747	arg1	extracts					777:784	dialysed acidic extracts	761:784	dialysed acidic extracts	761:784	Among other elements, Cl and K were present in the highest amounts (>25.0%) in dialysed acidic extracts.
35642413	1	66	theme	red	232:234	arg1	algae					236:240	Hypnea musciformis red algae	213:240	Hypnea musciformis red algae of Karachi	213:251	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	8	67	theme	mineral	881:887	arg1	concentrations					889:902	The mineral concentrations	877:902	The mineral concentrations ranges	877:909	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	7	68	theme	low	815:817	arg1	concentrations					819:832	low concentrations	815:832	low concentrations in only crude aqueous and acidic extracts	815:874	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	1	69	theme	high	132:135	arg1	weight					147:152	high molecular weight	132:152	high molecular weight	132:152	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	7	70	theme	aqueous	848:854	arg1	extracts					867:874	only crude aqueous and acidic extracts	837:874	only crude aqueous and acidic extracts	837:874	However, Al was detected in low concentrations in only crude aqueous and acidic extracts.
35642413	8	71	theme	dialyzed	1097:1104	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	3	72	theme	different	461:469	arg1	quantities					471:480	different quantities	461:480	different quantities	461:480	After analyzing multiple mineral elements were detected in different quantities.
35642413	8	73	from	%	927:927	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	1	74	theme	molecular	137:145	arg1	weight					147:152	high molecular weight	132:152	high molecular weight	132:152	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
35642413	2	75	theme	accurate	381:388	arg1	techniques					390:399	the modern, reliable and accurate techniques	356:399	the modern, reliable and accurate techniques	356:399	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	8	76	from	%	1000:1000	arg1	extracts					1106:1113	these crude and dialyzed extracts	1081:1113	these crude and dialyzed extracts	1081:1113	The mineral concentrations ranges were 30.34-52.46%, 17.00-43.46%, 0.63-4.05%, 0.49-3.35%, 0-0.33%, 0.74-17.92%, 0.59-25.31%, 0.58-25.46%, 1.10-6.72%, 0-2.60% for C, O, Na, Mg, Al, S, Cl, K, Ca and Zn in these crude and dialyzed extracts respectively.
35642413	0	77	theme	red	68:70	arg1	algae					72:76	Hypnea musciformis red algae	49:76	Hypnea musciformis red algae of Karachi	49:87	Elemental analysis of carrageenans isolated from Hypnea musciformis red algae of Karachi coast using SEM-EDX.
35642413	2	78	theme	modern	360:365	arg1	techniques					390:399	the modern, reliable and accurate techniques	356:399	the modern, reliable and accurate techniques	356:399	The elemental composition was determined by using SEM-EDX technique which is one of the modern, reliable and accurate techniques.
35642413	1	79	theme	Karachi	245:251	arg1	algae					236:240	Hypnea musciformis red algae	213:240	Hypnea musciformis red algae of Karachi	213:251	The carrageenans with high molecular weight, crude and dialysed polysaccharide fractions obtained from Hypnea musciformis red algae of Karachi coast in Pakistan.
36942838	0	0	theme	Postmenopausal	85:98	arg1	Women					100:104	Postmenopausal Women	85:104	Postmenopausal Women	85:104	Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
36942838	5	1	theme	controlled	745:754	arg1	cohort					756:761	a controlled cohort	743:761	a controlled cohort of postmenopausal women	743:785	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	7	2	theme	bacterial	1009:1017	arg1	species					1019:1025	bacterial species	1009:1025	bacterial species that significantly associated with urinary GAG concentration	1009:1086	We also associated urinary GAGs with urobiome composition and identified bacterial species that significantly associated with urinary GAG concentration.
36942838	4	3	theme	GAG	565:567	arg1	composition					569:579	the urinary GAG composition	553:579	the urinary GAG composition in postmenopausal women	553:603	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	6	4	theme	urinary	885:891	arg1	CS					893:894	urinary CS	885:894	urinary CS	885:894	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	4	5	theme	urinary	507:513	arg1	composition					519:529	urinary GAG composition	507:529	urinary GAG composition in mixed cohorts	507:546	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	6	6	theme	chondroitin	802:812	arg1	CS					823:824	CS	823:824	CS	823:824	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	6	6	theme	chondroitin	802:812	arg1	sulfate					814:820	chondroitin sulfate	802:820	chondroitin sulfate (CS)	802:825	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	6	6	theme	chondroitin	802:812	arg1	GAG					848:850	the major urinary GAG	830:850	the major urinary GAG in postmenopausal women	830:874	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	4	7	theme	urinary	557:563	arg1	composition					569:579	the urinary GAG composition	553:579	the urinary GAG composition in postmenopausal women	553:603	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	4	8	from	composition	569:579	arg1	women					599:603	postmenopausal women	584:603	postmenopausal women	584:603	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	2	9	theme	epithelium	289:298	arg1	surface					266:272	The luminal surface	254:272	The luminal surface of the bladder epithelium	254:298	The luminal surface of the bladder epithelium is coated with a GAG layer.
36942838	1	10	dep	linear	137:142	arg1	charged					156:162	charged	156:162	charged	156:162	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	9	11	theme	GAG	1385:1387	arg1	composition					1389:1399	urinary GAG composition	1377:1399	urinary GAG composition	1377:1399	Altogether, this work defines changes in urinary GAG composition associated with rUTI and identifies new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology.
36942838	8	12	theme	urinary	1324:1330	arg1	CS					1332:1333	urinary CS	1324:1333	urinary CS	1324:1333	Corynebacterium amycolatum, Porphyromonas somerae, and Staphylococcus pasteuri were positively associated with heparin sulfate or hyaluronic acid, and bacterial species associated with vaginal dysbiosis were negatively correlated with urinary CS.
36942838	5	13	theme	urinary	727:733	arg1	GAGs					735:738	urinary GAGs	727:738	urinary GAGs in a controlled cohort of postmenopausal women	727:785	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	0	14	from	UTI	57:59	arg1	Women					100:104	Postmenopausal Women	85:104	Postmenopausal Women	85:104	Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
36942838	9	15	from	changes	1366:1372	arg1	composition					1389:1399	urinary GAG composition	1377:1399	urinary GAG composition	1377:1399	Altogether, this work defines changes in urinary GAG composition associated with rUTI and identifies new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology.
36942838	2	16	theme	bladder	281:287	arg1	epithelium					289:298	the bladder epithelium	277:298	the bladder epithelium	277:298	The luminal surface of the bladder epithelium is coated with a GAG layer.
36942838	9	17	theme	urinary	1462:1468	arg1	GAGs					1470:1473	urinary GAGs	1462:1473	urinary GAGs	1462:1473	Altogether, this work defines changes in urinary GAG composition associated with rUTI and identifies new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology.
36942838	4	18	theme	Previous	476:483	arg1	studies					485:491	Previous studies	476:491	Previous studies	476:491	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	9	19	theme	new	1437:1439	arg1	associations					1441:1452	new associations	1437:1452	new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology	1437:1532	Altogether, this work defines changes in urinary GAG composition associated with rUTI and identifies new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology.
36942838	4	20	theme	postmenopausal	584:597	arg1	women					599:603	postmenopausal women	584:603	postmenopausal women	584:603	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	5	21	dep	recurrent	673:681	arg1	urinary					683:689	urinary	683:689	urinary	683:689	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	3	22	theme	protective	375:384	arg1	barrier					386:392	a protective barrier	373:392	a protective barrier	373:392	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	7	23	theme	urinary	1062:1068	arg1	concentration					1074:1086	urinary GAG concentration	1062:1086	urinary GAG concentration	1062:1086	We also associated urinary GAGs with urobiome composition and identified bacterial species that significantly associated with urinary GAG concentration.
36942838	2	24	theme	GAG	317:319	arg1	layer					321:325	a GAG layer	315:325	a GAG layer	315:325	The luminal surface of the bladder epithelium is coated with a GAG layer.
36942838	6	25	theme	postmenopausal	855:868	arg1	women					870:874	postmenopausal women	855:874	postmenopausal women	855:874	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	3	26	theme	potential	409:417	arg1	site					431:434	a potential interaction site	407:434	a potential interaction site with the urinary microbiome (urobiome)	407:473	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	3	26	theme	potential	409:417	arg1	GAGs					345:348	These urothelial GAGs	328:348	These urothelial GAGs	328:348	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	0	27	theme	Urinary	0:6	arg1	Glycosaminoglycans					8:25	Urinary Glycosaminoglycans	0:25	Urinary Glycosaminoglycans	0:25	Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
36942838	7	28	theme	GAG	1070:1072	arg1	concentration					1074:1086	urinary GAG concentration	1062:1086	urinary GAG concentration	1062:1086	We also associated urinary GAGs with urobiome composition and identified bacterial species that significantly associated with urinary GAG concentration.
36942838	3	29	theme	interaction	419:429	arg1	site					431:434	a potential interaction site	407:434	a potential interaction site with the urinary microbiome (urobiome)	407:473	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	3	29	theme	interaction	419:429	arg1	GAGs					345:348	These urothelial GAGs	328:348	These urothelial GAGs	328:348	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	5	30	theme	women	781:785	arg1	cohort					756:761	a controlled cohort	743:761	a controlled cohort of postmenopausal women	743:785	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	6	31	theme	active	923:928	arg1	rUTI					930:933	active rUTI	923:933	active rUTI	923:933	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	6	32	theme	urinary	840:846	arg1	GAG					848:850	the major urinary GAG	830:850	the major urinary GAG in postmenopausal women	830:874	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	6	32	theme	urinary	840:846	arg1	sulfate					814:820	chondroitin sulfate	802:820	chondroitin sulfate (CS)	802:825	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	8	33	theme	vaginal	1274:1280	arg1	dysbiosis					1282:1290	vaginal dysbiosis	1274:1290	vaginal dysbiosis	1274:1290	Corynebacterium amycolatum, Porphyromonas somerae, and Staphylococcus pasteuri were positively associated with heparin sulfate or hyaluronic acid, and bacterial species associated with vaginal dysbiosis were negatively correlated with urinary CS.
36942838	0	34	theme	Recurrent	47:55	arg1	UTI					57:59	Recurrent UTI	47:59	Recurrent UTI	47:59	Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
36942838	5	35	from	GAGs	735:738	arg1	cohort					756:761	a controlled cohort	743:761	a controlled cohort of postmenopausal women	743:785	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	1	36	theme	disaccharide	202:213	arg1	units					215:219	disaccharide units	202:219	disaccharide units of uronic acid and amino sugars	202:251	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	1	37	theme	uronic	224:229	arg1	acid					231:234	uronic acid	224:234	uronic acid	224:234	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	5	38	theme	postmenopausal	766:779	arg1	women					781:785	postmenopausal women	766:785	postmenopausal women	766:785	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	9	39	theme	urinary	1377:1383	arg1	composition					1389:1399	urinary GAG composition	1377:1399	urinary GAG composition	1377:1399	Altogether, this work defines changes in urinary GAG composition associated with rUTI and identifies new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology.
36942838	8	40	theme	hyaluronic	1219:1228	arg1	acid					1230:1233	hyaluronic acid	1219:1233	hyaluronic acid	1219:1233	Corynebacterium amycolatum, Porphyromonas somerae, and Staphylococcus pasteuri were positively associated with heparin sulfate or hyaluronic acid, and bacterial species associated with vaginal dysbiosis were negatively correlated with urinary CS.
36942838	0	41	from	Ecology	74:80	arg1	Women					100:104	Postmenopausal Women	85:104	Postmenopausal Women	85:104	Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
36942838	7	42	theme	urobiome	973:980	arg1	composition					982:992	urobiome composition	973:992	urobiome composition	973:992	We also associated urinary GAGs with urobiome composition and identified bacterial species that significantly associated with urinary GAG concentration.
36942838	1	43	theme	acid	231:234	arg1	units					215:219	disaccharide units	202:219	disaccharide units of uronic acid and amino sugars	202:251	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	4	44	from	composition	519:529	arg1	cohorts					540:546	mixed cohorts	534:546	mixed cohorts	534:546	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	4	45	theme	GAG	515:517	arg1	composition					519:529	urinary GAG composition	507:529	urinary GAG composition in mixed cohorts	507:546	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	5	46	theme	recurrent	673:681	arg1	rUTI					708:711	rUTI	708:711	rUTI	708:711	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	5	46	theme	recurrent	673:681	arg1	infection					697:705	recurrent urinary tract infection	673:705	recurrent urinary tract infection (rUTI)	673:712	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	0	47	theme	Urobiome	65:72	arg1	Ecology					74:80	Urobiome Ecology	65:80	Urobiome Ecology	65:80	Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.
36942838	5	48	theme	tract	691:695	arg1	rUTI					708:711	rUTI	708:711	rUTI	708:711	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	5	48	theme	tract	691:695	arg1	infection					697:705	recurrent urinary tract infection	673:705	recurrent urinary tract infection (rUTI)	673:712	To investigate the relationship between GAGs and recurrent urinary tract infection (rUTI), we profiled urinary GAGs in a controlled cohort of postmenopausal women.
36942838	4	49	theme	mixed	534:538	arg1	cohorts					540:546	mixed cohorts	534:546	mixed cohorts	534:546	Previous studies have profiled urinary GAG composition in mixed cohorts, but the urinary GAG composition in postmenopausal women remains undefined.
36942838	3	50	with	site	431:434	arg1	urobiome					465:472	urobiome	465:472	urobiome	465:472	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	3	50	with	site	431:434	arg1	microbiome					453:462	the urinary microbiome	441:462	the urinary microbiome (urobiome)	441:473	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	9	51	theme	rUTI	1516:1519	arg1	pathobiology					1521:1532	rUTI pathobiology	1516:1532	rUTI pathobiology	1516:1532	Altogether, this work defines changes in urinary GAG composition associated with rUTI and identifies new associations between urinary GAGs and the urobiome that may play a role in rUTI pathobiology.
36942838	6	52	with	women	912:916	arg1	rUTI					930:933	active rUTI	923:933	active rUTI	923:933	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	8	53	theme	Porphyromonas	1117:1129	arg1	somerae					1131:1137	Porphyromonas somerae	1117:1137	Porphyromonas somerae	1117:1137	Corynebacterium amycolatum, Porphyromonas somerae, and Staphylococcus pasteuri were positively associated with heparin sulfate or hyaluronic acid, and bacterial species associated with vaginal dysbiosis were negatively correlated with urinary CS.
36942838	1	54	theme	linear	137:142	arg1	Glycosaminoglycans					107:124	Glycosaminoglycans	107:124	Glycosaminoglycans (GAGs)	107:131	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	1	54	theme	linear	137:142	arg1	polysaccharides					164:178	linear, negatively charged polysaccharides	137:178	linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars	137:251	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	1	55	theme	amino	240:244	arg1	sugars					246:251	amino sugars	240:251	amino sugars	240:251	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	6	56	theme	major	834:838	arg1	GAG					848:850	the major urinary GAG	830:850	the major urinary GAG in postmenopausal women	830:874	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	6	56	theme	major	834:838	arg1	sulfate					814:820	chondroitin sulfate	802:820	chondroitin sulfate (CS)	802:825	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36942838	3	57	theme	urinary	445:451	arg1	urobiome					465:472	urobiome	465:472	urobiome	465:472	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	3	57	theme	urinary	445:451	arg1	microbiome					453:462	the urinary microbiome	441:462	the urinary microbiome (urobiome)	441:473	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	2	58	theme	luminal	258:264	arg1	surface					266:272	The luminal surface	254:272	The luminal surface of the bladder epithelium	254:298	The luminal surface of the bladder epithelium is coated with a GAG layer.
36942838	7	59	theme	urinary	955:961	arg1	GAGs					963:966	urinary GAGs	955:966	urinary GAGs	955:966	We also associated urinary GAGs with urobiome composition and identified bacterial species that significantly associated with urinary GAG concentration.
36942838	8	60	theme	bacterial	1240:1248	arg1	species					1250:1256	bacterial species	1240:1256	bacterial species associated with vaginal dysbiosis	1240:1290	Corynebacterium amycolatum, Porphyromonas somerae, and Staphylococcus pasteuri were positively associated with heparin sulfate or hyaluronic acid, and bacterial species associated with vaginal dysbiosis were negatively correlated with urinary CS.
36942838	1	61	theme	sugars	246:251	arg1	units					215:219	disaccharide units	202:219	disaccharide units of uronic acid and amino sugars	202:251	Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides composed of repeating disaccharide units of uronic acid and amino sugars.
36942838	3	62	theme	urothelial	334:343	arg1	site					431:434	a potential interaction site	407:434	a potential interaction site with the urinary microbiome (urobiome)	407:473	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	3	62	theme	urothelial	334:343	arg1	GAGs					345:348	These urothelial GAGs	328:348	These urothelial GAGs	328:348	These urothelial GAGs are thought to provide a protective barrier and serve as a potential interaction site with the urinary microbiome (urobiome).
36942838	8	63	theme	heparin	1200:1206	arg1	sulfate					1208:1214	heparin sulfate	1200:1214	heparin sulfate	1200:1214	Corynebacterium amycolatum, Porphyromonas somerae, and Staphylococcus pasteuri were positively associated with heparin sulfate or hyaluronic acid, and bacterial species associated with vaginal dysbiosis were negatively correlated with urinary CS.
36942838	6	64	from	GAG	848:850	arg1	women					870:874	postmenopausal women	855:874	postmenopausal women	855:874	We found that chondroitin sulfate (CS) is the major urinary GAG in postmenopausal women and that urinary CS was elevated in women with active rUTI.
36263848	5	0	theme	optimal	788:794	arg1	1:15					833:836	1:15	833:836	1:15	833:836	The optimal conditions for subcritical water are 1:15, 150°C, and 10 min.
36263848	5	0	theme	optimal	788:794	arg1	conditions					796:805	The optimal conditions	784:805	The optimal conditions for subcritical water	784:827	The optimal conditions for subcritical water are 1:15, 150°C, and 10 min.
36263848	6	1	theme	good	978:981	arg1	ability					1007:1013	good free-radical scavenging ability	978:1013	good free-radical scavenging ability	978:1013	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	1	2	theme	biological	273:282	arg1	activities					284:293	biological activities	273:293	biological activities	273:293	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	0	3	theme	Anti-Diabetic	92:104	arg1	Effects					106:112	Anti-Diabetic Effects	92:112	Anti-Diabetic Effects	92:112	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	4	4	theme	hypolipidemic	594:606	arg1	potential					608:616	The hypoglycemic and hypolipidemic potential	573:616	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide	573:642	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	7	5	theme	MDA	1228:1230	arg1	concentrations					1167:1180	the concentrations	1163:1180	the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA	1163:1230	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	1	6	dep	properties	258:267	arg1	the					238:240	the	238:240	the	238:240	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	0	7	theme	T2DM	117:120	arg1	Rats					122:125	T2DM Rats	117:125	T2DM Rats	117:125	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	7	8	theme	LDL-C	1217:1221	arg1	concentrations					1167:1180	the concentrations	1163:1180	the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA	1163:1230	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	9	9	theme	functional	1555:1564	arg1	ingredients					1571:1581	functional food ingredients	1555:1581	functional food ingredients	1555:1581	CONCLUSION Pumpkin polysaccharide extracted by SWE shows great potential as functional food ingredients and candidates for T2DM treatment.
36263848	8	10	theme	pancreatic	1447:1456	arg1	organs					1458:1463	pancreatic organs	1447:1463	pancreatic organs	1447:1463	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	2	11	theme	RESULTS	334:340	arg1	water					354:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water is used to extract pumpkin polysaccharide.
36263848	9	12	theme	great	1536:1540	arg1	potential					1542:1550	great potential	1536:1550	great potential as functional food ingredients and candidates for T2DM treatment	1536:1615	CONCLUSION Pumpkin polysaccharide extracted by SWE shows great potential as functional food ingredients and candidates for T2DM treatment.
36263848	7	13	from	treatment	1116:1124	arg1	rats					1134:1137	T2DM rats	1129:1137	T2DM rats	1129:1137	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	6	14	theme	α-glucosidase	1044:1056	arg1	inhibition					1019:1028	inhibition	1019:1028	inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities	1019:1090	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	6	14	theme	α-glucosidase	1044:1056	arg1	ability					1007:1013	good free-radical scavenging ability	978:1013	good free-radical scavenging ability	978:1013	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	2	15	theme	METHODS	322:328	arg1	water					354:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water is used to extract pumpkin polysaccharide.
36263848	1	16	theme	pumpkin	298:304	arg1	polysaccharide					306:319	pumpkin polysaccharide	298:319	pumpkin polysaccharide	298:319	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	6	17	contain	has	881:883	arg2	α-configurations					885:900	α-configurations	885:900	α-configurations	885:900	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	6	17	contain	has	881:883	arg1	polysaccharide					866:879	Pumpkin polysaccharide	858:879	Pumpkin polysaccharide	858:879	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	6	18	theme	scavenging	996:1005	arg1	ability					1007:1013	good free-radical scavenging ability	978:1013	good free-radical scavenging ability	978:1013	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	7	19	theme	TG	1213:1214	arg1	concentrations					1167:1180	the concentrations	1163:1180	the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA	1163:1230	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	20	dep	enzymes	1293:1299	arg1	CAT					1321:1323	CAT	1321:1323	CAT	1321:1323	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	20	dep	enzymes	1293:1299	arg1	SOD					1313:1315	SOD	1313:1315	SOD	1313:1315	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	20	dep	enzymes	1293:1299	arg1	activities					1301:1310	activities	1301:1310	the antioxidant enzymes activities (SOD and CAT)	1277:1324	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	1	21	dep	SCOPE	128:132	arg1	aims					145:148	aims	145:148	aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide	145:319	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	3	22	theme	infrared	475:482	arg1	spectroscopy					484:495	infrared spectroscopy	475:495	infrared spectroscopy	475:495	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	6	23	theme	free-radical	983:994	arg1	ability					1007:1013	good free-radical scavenging ability	978:1013	good free-radical scavenging ability	978:1013	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	2	24	used	used	363:366	arg2	water					354:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water is used to extract pumpkin polysaccharide.
36263848	3	25	theme	pumpkin	436:442	arg1	polysaccharide					444:457	pumpkin polysaccharide	436:457	pumpkin polysaccharide	436:457	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	1	26	theme	pumpkin	180:186	arg1	polysaccharide					188:201	pumpkin polysaccharide	180:201	pumpkin polysaccharide	180:201	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	4	27	dep	aere	644:647	arg1	determined					649:658	determined	649:658	aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet	644:781	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	7	28	theme	TC	1209:1210	arg1	concentrations					1167:1180	the concentrations	1163:1180	the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA	1163:1230	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	29	theme	polysaccharide	1101:1114	arg1	treatment					1116:1124	Pumpkin polysaccharide treatment	1093:1124	Pumpkin polysaccharide treatment in T2DM rats	1093:1137	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	30	theme	blood	1185:1189	arg1	glucose					1191:1197	blood glucose	1185:1197	blood glucose	1185:1197	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	1	31	theme	polysaccharide	188:201	arg1	extraction					166:175	the extraction	162:175	the extraction of pumpkin polysaccharide by subcritical water	162:222	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	0	32	theme	Pumpkin	0:6	arg1	Polysaccharide					8:21	Pumpkin Polysaccharide	0:21	Pumpkin Polysaccharide	0:21	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	1	33	theme	polysaccharide	306:319	arg1	properties					258:267	physicochemical properties	242:267	physicochemical properties	242:267	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	1	33	theme	polysaccharide	306:319	arg1	activities					284:293	biological activities	273:293	biological activities	273:293	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	8	34	theme	pumpkin	1387:1393	arg1	polysaccharide					1395:1408	pumpkin polysaccharide	1387:1408	pumpkin polysaccharide	1387:1408	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	8	35	from	effects	1425:1431	arg1	organs					1458:1463	pancreatic organs	1447:1463	pancreatic organs	1447:1463	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	8	35	from	effects	1425:1431	arg1	kidney					1436:1441	kidney	1436:1441	kidney	1436:1441	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	8	36	theme	T2DM	1468:1471	arg1	rats					1473:1476	T2DM rats	1468:1476	T2DM rats	1468:1476	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	6	37	theme	activities	1081:1090	arg1	inhibition					1019:1028	inhibition	1019:1028	inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities	1019:1090	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	6	37	theme	activities	1081:1090	arg1	ability					1007:1013	good free-radical scavenging ability	978:1013	good free-radical scavenging ability	978:1013	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	7	38	theme	insulin	1200:1206	arg1	concentrations					1167:1180	the concentrations	1163:1180	the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA	1163:1230	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	6	39	theme	Pumpkin	858:864	arg1	polysaccharide					866:879	Pumpkin polysaccharide	858:879	Pumpkin polysaccharide	858:879	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	2	40	theme	Subcritical	342:352	arg1	water					354:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water	322:358	METHODS AND RESULTS Subcritical water is used to extract pumpkin polysaccharide.
36263848	9	41	theme	food	1566:1569	arg1	ingredients					1571:1581	functional food ingredients	1555:1581	functional food ingredients	1555:1581	CONCLUSION Pumpkin polysaccharide extracted by SWE shows great potential as functional food ingredients and candidates for T2DM treatment.
36263848	1	42	theme	subcritical	206:216	arg1	water					218:222	subcritical water	206:222	subcritical water	206:222	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	7	43	theme	HDL-C	1257:1261	arg1	levels					1247:1252	the levels	1243:1252	the levels of HDL-C	1243:1261	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	6	44	theme	lipase	1074:1079	arg1	activities					1081:1090	pancreatic lipase activities	1063:1090	pancreatic lipase activities	1063:1090	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	8	45	theme	immunohistochemical	1346:1364	arg1	analyses					1366:1373	Histopathology and immunohistochemical analyses	1327:1373	Histopathology and immunohistochemical analyses	1327:1373	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	0	46	from	Effects	106:112	arg1	Rats					122:125	T2DM Rats	117:125	T2DM Rats	117:125	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	1	47	dep	optimize	153:160	arg1	investigates					225:236	investigates	225:236	investigates the physicochemical properties and biological activities of pumpkin polysaccharide	225:319	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	4	48	theme	high-fat	769:776	arg1	diet					778:781	high-fat diet	769:781	high-fat diet	769:781	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	5	49	theme	subcritical	811:821	arg1	water					823:827	subcritical water	811:827	subcritical water	811:827	The optimal conditions for subcritical water are 1:15, 150°C, and 10 min.
36263848	6	50	theme	pancreatic	1063:1072	arg1	activities					1081:1090	pancreatic lipase activities	1063:1090	pancreatic lipase activities	1063:1090	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	9	51	theme	CONCLUSION	1479:1488	arg1	polysaccharide					1498:1511	CONCLUSION Pumpkin polysaccharide	1479:1511	CONCLUSION Pumpkin polysaccharide extracted by SWE	1479:1528	CONCLUSION Pumpkin polysaccharide extracted by SWE shows great potential as functional food ingredients and candidates for T2DM treatment.
36263848	3	52	theme	filtration	502:511	arg1	chromatography					513:526	gel filtration chromatography	498:526	gel filtration chromatography	498:526	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	0	53	theme	Subcritical	36:46	arg1	Water					48:52	Subcritical Water	36:52	Subcritical Water	36:52	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	4	54	theme	physicochemical	667:681	arg1	indexes					683:689	the physicochemical indexes	663:689	the physicochemical indexes	663:689	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	9	55	theme	T2DM	1602:1605	arg1	treatment					1607:1615	T2DM treatment	1602:1615	T2DM treatment	1602:1615	CONCLUSION Pumpkin polysaccharide extracted by SWE shows great potential as functional food ingredients and candidates for T2DM treatment.
36263848	0	56	theme	Physicochemical	55:69	arg1	Characterization					71:86	Physicochemical Characterization	55:86	Physicochemical Characterization	55:86	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	7	57	theme	antioxidant	1281:1291	arg1	enzymes					1293:1299	the antioxidant enzymes	1277:1299	the antioxidant enzymes activities (SOD and CAT)	1277:1324	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	8	58	contain	has	1410:1412	arg1	polysaccharide					1395:1408	pumpkin polysaccharide	1387:1408	pumpkin polysaccharide	1387:1408	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	8	58	contain	has	1410:1412	arg2	effects					1425:1431	protective effects	1414:1431	protective effects on kidney and pancreatic organs	1414:1463	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	0	59	from	Characterization	71:86	arg1	Rats					122:125	T2DM Rats	117:125	T2DM Rats	117:125	Pumpkin Polysaccharide Extracted by Subcritical Water: Physicochemical Characterization and Anti-Diabetic Effects in T2DM Rats.
36263848	2	60	theme	pumpkin	379:385	arg1	polysaccharide					387:400	extract pumpkin polysaccharide	371:400	extract pumpkin polysaccharide	371:400	METHODS AND RESULTS Subcritical water is used to extract pumpkin polysaccharide.
36263848	4	61	theme	polysaccharide	629:642	arg1	potential					608:616	The hypoglycemic and hypolipidemic potential	573:616	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide	573:642	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	6	62	theme	α-amylase	1033:1041	arg1	inhibition					1019:1028	inhibition	1019:1028	inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities	1019:1090	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	6	62	theme	α-amylase	1033:1041	arg1	ability					1007:1013	good free-radical scavenging ability	978:1013	good free-radical scavenging ability	978:1013	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	7	63	theme	T2DM	1129:1132	arg1	rats					1134:1137	T2DM rats	1129:1137	T2DM rats	1129:1137	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	2	64	theme	extract	371:377	arg1	polysaccharide					387:400	extract pumpkin polysaccharide	371:400	extract pumpkin polysaccharide	371:400	METHODS AND RESULTS Subcritical water is used to extract pumpkin polysaccharide.
36263848	4	65	theme	pumpkin	621:627	arg1	polysaccharide					629:642	pumpkin polysaccharide	621:642	pumpkin polysaccharide	621:642	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	6	66	theme	different	935:943	arg1	monosaccharides					945:959	seven different monosaccharides	929:959	seven different monosaccharides	929:959	Pumpkin polysaccharide has α-configurations and are mainly composed of seven different monosaccharides, and it exhibits good free-radical scavenging ability and inhibition of α-amylase, α-glucosidase, and pancreatic lipase activities.
36263848	7	67	dep	activities	1301:1310	arg1	CAT					1321:1323	CAT	1321:1323	CAT	1321:1323	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	67	dep	activities	1301:1310	arg1	SOD					1313:1315	SOD	1313:1315	SOD	1313:1315	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	67	dep	activities	1301:1310	arg1	activities					1301:1310	activities	1301:1310	the antioxidant enzymes activities (SOD and CAT)	1277:1324	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	3	68	theme	high-performance	533:548	arg1	chromatography					557:570	high-performance liquid chromatography	533:570	high-performance liquid chromatography	533:570	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	9	69	theme	Pumpkin	1490:1496	arg1	polysaccharide					1498:1511	CONCLUSION Pumpkin polysaccharide	1479:1511	CONCLUSION Pumpkin polysaccharide extracted by SWE	1479:1528	CONCLUSION Pumpkin polysaccharide extracted by SWE shows great potential as functional food ingredients and candidates for T2DM treatment.
36263848	3	70	dep	structure	407:415	arg1	The					403:405	The	403:405	The	403:405	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	3	71	theme	liquid	550:555	arg1	chromatography					557:570	high-performance liquid chromatography	533:570	high-performance liquid chromatography	533:570	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	1	72	theme	physicochemical	242:256	arg1	properties					258:267	physicochemical properties	242:267	physicochemical properties	242:267	SCOPE This study aims to optimize the extraction of pumpkin polysaccharide by subcritical water, investigates the physicochemical properties and biological activities of pumpkin polysaccharide.
36263848	8	73	theme	Histopathology	1327:1340	arg1	analyses					1366:1373	Histopathology and immunohistochemical analyses	1327:1373	Histopathology and immunohistochemical analyses	1327:1373	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	4	74	theme	T2DM	742:745	arg1	rats					747:750	T2DM rats	742:750	T2DM rats induced by STZ + high-fat diet	742:781	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	3	75	theme	gel	498:500	arg1	chromatography					513:526	gel filtration chromatography	498:526	gel filtration chromatography	498:526	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	3	76	theme	polysaccharide	444:457	arg1	composition					421:431	composition	421:431	composition	421:431	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	3	76	theme	polysaccharide	444:457	arg1	structure					407:415	structure	407:415	structure	407:415	The structure and composition of pumpkin polysaccharide are analyzed by infrared spectroscopy, gel filtration chromatography, and high-performance liquid chromatography.
36263848	4	77	theme	hypoglycemic	577:588	arg1	potential					608:616	The hypoglycemic and hypolipidemic potential	573:616	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide	573:642	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
36263848	7	78	theme	glucose	1191:1197	arg1	concentrations					1167:1180	the concentrations	1163:1180	the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA	1163:1230	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	7	79	theme	Pumpkin	1093:1099	arg1	treatment					1116:1124	Pumpkin polysaccharide treatment	1093:1124	Pumpkin polysaccharide treatment in T2DM rats	1093:1137	Pumpkin polysaccharide treatment in T2DM rats significantly decreases the concentrations of blood glucose, insulin, TC, TG, LDL-C, and MDA; increases the levels of HDL-C; and enhances the antioxidant enzymes activities (SOD and CAT).
36263848	8	80	theme	protective	1414:1423	arg1	effects					1425:1431	protective effects	1414:1431	protective effects on kidney and pancreatic organs	1414:1463	Histopathology and immunohistochemical analyses reveal that pumpkin polysaccharide has protective effects on kidney and pancreatic organs in T2DM rats.
36263848	4	81	theme	immunohistochemical	710:728	arg1	analysis					730:737	immunohistochemical analysis	710:737	immunohistochemical analysis	710:737	The hypoglycemic and hypolipidemic potential of pumpkin polysaccharide aere determined by the physicochemical indexes, pathological, and immunohistochemical analysis in T2DM rats induced by STZ + high-fat diet.
35483863	3	0	theme	stable	760:765	arg1	isomers					767:773	the more stable isomers	751:773	the more stable isomers	751:773	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	1	1	theme	identical	277:285	arg1	compositions					302:313	identical monosaccharide compositions	277:313	identical monosaccharide compositions	277:313	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	0	2	theme	mass	117:120	arg1	spectrometry					122:133	mass spectrometry	117:133	mass spectrometry	117:133	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	1	3	theme	monosaccharide	287:300	arg1	compositions					302:313	identical monosaccharide compositions	277:313	identical monosaccharide compositions	277:313	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	5	4	theme	good	1028:1031	arg1	robustness					1033:1042	good robustness	1028:1042	good robustness	1028:1042	Furthermore, precision measurements for each method were below 12% demonstrating good robustness.
35483863	4	5	theme	Linear	776:781	arg1	relationships					783:795	Linear relationships	776:795	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration	776:911	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	6	6	theme	isomeric	1165:1172	arg1	polysaccharides					1187:1201	isomeric pneumococcal polysaccharides	1165:1201	isomeric pneumococcal polysaccharides	1165:1201	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	4	7	theme	marker	846:851	arg1	concentration					899:911	the starting pneumococcal polysaccharides concentration	857:911	the starting pneumococcal polysaccharides concentration	857:911	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	4	7	theme	marker	846:851	arg1	abundance					813:821	the ion abundance	805:821	the ion abundance of the oligosaccharide marker	805:851	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	5	8	theme	precision	960:968	arg1	measurements					970:981	precision measurements	960:981	precision measurements for each method	960:997	Furthermore, precision measurements for each method were below 12% demonstrating good robustness.
35483863	3	9	theme	unique	604:609	arg1	ions					611:614	unique ions	604:614	unique ions for the isomers with the weakest glycosidic bonds	604:664	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	2	10	theme	spectrometry	458:469	arg1	approach					471:478	a partial chemical degradation mass spectrometry approach	422:478	a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other	422:550	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	2	11	theme	polysaccharides	374:388	arg1	quantitation					336:347	quantitation	336:347	quantitation	336:347	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	2	11	theme	polysaccharides	374:388	arg1	Differentiation					316:330	Differentiation	316:330	Differentiation	316:330	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	2	12	theme	mass	453:456	arg1	approach					471:478	a partial chemical degradation mass spectrometry approach	422:478	a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other	422:550	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	3	13	with	isomers	624:630	arg1	bonds					660:664	the weakest glycosidic bonds	637:664	the weakest glycosidic bonds	637:664	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	1	14	from	Quantitation	136:147	arg1	vaccines					193:200	vaccines	193:200	vaccines	193:200	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	2	15	theme	pneumococcal	361:372	arg1	polysaccharides					374:388	isomeric pneumococcal polysaccharides	352:388	isomeric pneumococcal polysaccharides	352:388	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	2	16	theme	degradation	441:451	arg1	approach					471:478	a partial chemical degradation mass spectrometry approach	422:478	a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other	422:550	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	6	17	theme	chemical	1064:1071	arg1	degradation					1073:1083	partial chemical degradation	1056:1083	partial chemical degradation followed by mass spectrometry	1056:1113	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	2	18	theme	isomeric	352:359	arg1	polysaccharides					374:388	isomeric pneumococcal polysaccharides	352:388	isomeric pneumococcal polysaccharides	352:388	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	2	19	theme	oligosaccharide	495:509	arg1	marker					511:516	an oligosaccharide marker	492:516	an oligosaccharide marker for one isomer, and not the other	492:550	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	6	20	theme	partial	1056:1062	arg1	degradation					1073:1083	partial chemical degradation	1056:1083	partial chemical degradation followed by mass spectrometry	1056:1113	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	2	21	theme	chemical	432:439	arg1	approach					471:478	a partial chemical degradation mass spectrometry approach	422:478	a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other	422:550	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
35483863	4	22	theme	ion	809:811	arg1	abundance					813:821	the ion abundance	805:821	the ion abundance of the oligosaccharide marker	805:851	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	1	23	theme	mixture	231:237	arg1	complexity					239:248	mixture complexity	231:248	mixture complexity	231:248	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	0	24	theme	pneumococcal	44:55	arg1	polysaccharides					57:71	isomeric pneumococcal polysaccharides	35:71	isomeric pneumococcal polysaccharides	35:71	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	1	25	theme	due	224:226	arg1	task					219:222	a challenging task	205:222	a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions	205:313	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	1	25	theme	due	224:226	arg1	Quantitation					136:147	Quantitation	136:147	Quantitation of isomeric pneumococcal polysaccharides in vaccines	136:200	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	0	26	theme	isomeric	35:42	arg1	polysaccharides					57:71	isomeric pneumococcal polysaccharides	35:71	isomeric pneumococcal polysaccharides	35:71	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	6	27	theme	mass	1097:1100	arg1	spectrometry					1102:1113	mass spectrometry	1097:1113	mass spectrometry	1097:1113	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	3	28	theme	acid	689:692	arg1	conditions					694:703	strong base and acid conditions	673:703	conditions	694:703	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	4	29	theme	polysaccharides	883:897	arg1	concentration					899:911	the starting pneumococcal polysaccharides concentration	857:911	the starting pneumococcal polysaccharides concentration	857:911	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	3	30	theme	weakest	641:647	arg1	bonds					660:664	the weakest glycosidic bonds	637:664	the weakest glycosidic bonds	637:664	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	6	31	theme	bacterial	1232:1240	arg1	types					1242:1246	other bacterial types	1226:1246	other bacterial types	1226:1246	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	3	32	theme	Mild	553:556	arg1	conditions					563:572	Mild base conditions	553:572	Mild base conditions	553:572	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	0	33	theme	polysaccharides	57:71	arg1	quantitation					19:30	quantitation	19:30	quantitation	19:30	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	0	33	theme	polysaccharides	57:71	arg1	Identification					0:13	Identification	0:13	Identification	0:13	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	3	34	theme	unique	735:740	arg1	ions					742:745	unique ions	735:745	unique ions for the more stable isomers	735:773	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	3	35	theme	glycosidic	649:658	arg1	bonds					660:664	the weakest glycosidic bonds	637:664	the weakest glycosidic bonds	637:664	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	3	36	theme	base	558:561	arg1	conditions					563:572	Mild base conditions	553:572	Mild base conditions	553:572	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	4	37	theme	starting	861:868	arg1	concentration					899:911	the starting pneumococcal polysaccharides concentration	857:911	the starting pneumococcal polysaccharides concentration	857:911	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	1	38	theme	isomeric	152:159	arg1	polysaccharides					174:188	isomeric pneumococcal polysaccharides	152:188	isomeric pneumococcal polysaccharides	152:188	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	4	39	theme	oligosaccharide	830:844	arg1	marker					846:851	the oligosaccharide marker	826:851	the oligosaccharide marker	826:851	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	1	40	theme	pneumococcal	161:172	arg1	polysaccharides					174:188	isomeric pneumococcal polysaccharides	152:188	isomeric pneumococcal polysaccharides	152:188	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	1	41	theme	low	257:259	arg1	quantities					261:270	their low quantities	251:270	their low quantities	251:270	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	0	42	theme	chemical	84:91	arg1	degradation					93:103	partial chemical degradation	76:103	partial chemical degradation	76:103	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	6	43	theme	other	1226:1230	arg1	types					1242:1246	other bacterial types	1226:1246	other bacterial types	1226:1246	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	4	44	theme	pneumococcal	870:881	arg1	concentration					899:911	the starting pneumococcal polysaccharides concentration	857:911	the starting pneumococcal polysaccharides concentration	857:911	Linear relationships between the ion abundance of the oligosaccharide marker and the starting pneumococcal polysaccharides concentration were established for all isomers.
35483863	6	45	theme	pneumococcal	1174:1185	arg1	polysaccharides					1187:1201	isomeric pneumococcal polysaccharides	1165:1201	isomeric pneumococcal polysaccharides	1165:1201	Therefore, partial chemical degradation followed by mass spectrometry was successful at differentiating and quantifying isomeric pneumococcal polysaccharides and may be adopted for other bacterial types.
35483863	1	46	theme	polysaccharides	174:188	arg1	task					219:222	a challenging task	205:222	a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions	205:313	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	1	46	theme	polysaccharides	174:188	arg1	Quantitation					136:147	Quantitation	136:147	Quantitation of isomeric pneumococcal polysaccharides in vaccines	136:200	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	1	47	theme	challenging	207:217	arg1	task					219:222	a challenging task	205:222	a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions	205:313	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	1	47	theme	challenging	207:217	arg1	Quantitation					136:147	Quantitation	136:147	Quantitation of isomeric pneumococcal polysaccharides in vaccines	136:200	Quantitation of isomeric pneumococcal polysaccharides in vaccines is a challenging task due to mixture complexity, their low quantities, and identical monosaccharide compositions.
35483863	0	48	theme	partial	76:82	arg1	degradation					93:103	partial chemical degradation	76:103	partial chemical degradation	76:103	Identification and quantitation of isomeric pneumococcal polysaccharides by partial chemical degradation followed by mass spectrometry.
35483863	3	49	theme	strong	673:678	arg1	base					680:683	strong base and acid conditions	673:703	base	680:683	Mild base conditions were successful at generating unique ions for the isomers with the weakest glycosidic bonds, while strong base and acid conditions were successful at generating unique ions for the more stable isomers.
35483863	2	50	theme	partial	424:430	arg1	approach					471:478	a partial chemical degradation mass spectrometry approach	422:478	a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other	422:550	Differentiation and quantitation of isomeric pneumococcal polysaccharides were investigated here based on a partial chemical degradation mass spectrometry approach to generate an oligosaccharide marker for one isomer, and not the other.
37366623	9	0	theme	envelope	1729:1736	arg1	gB					1754:1755	gB	1754:1755	gB	1754:1755	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	0	theme	envelope	1729:1736	arg1	B					1751:1751	the envelope glycoprotein B	1725:1751	the envelope glycoprotein B (gB) of HSV-1	1725:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	6	1	theme	viral	1344:1348	arg1	neurovirulence					1350:1363	viral neurovirulence	1344:1363	viral neurovirulence	1344:1363	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	1	theme	viral	1344:1348	arg1	impacts					1286:1292	dual impacts	1281:1292	dual impacts	1281:1292	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	7	2	theme	Herpes	1377:1382	arg1	HSV-1					1401:1405	HSV-1	1401:1405	HSV-1	1401:1405	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	7	2	theme	Herpes	1377:1382	arg1	virus					1392:1396	Herpes simplex virus 1	1377:1398	IMPORTANCE Herpes simplex virus 1 (HSV-1)	1366:1406	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	6	3	contain	has	1277:1279	arg2	impacts					1286:1292	dual impacts	1281:1292	dual impacts	1281:1292	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	3	contain	has	1277:1279	arg2	neurovirulence					1350:1363	viral neurovirulence	1344:1363	viral neurovirulence	1344:1363	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	3	contain	has	1277:1279	arg2	evasion					1302:1308	evasion	1302:1308	evasion from human antibodies in vivo	1302:1338	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	3	contain	has	1277:1279	arg1	N-glycan					1244:1251	a critical N-glycan shield	1233:1258	a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence	1233:1363	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	9	4	theme	B	1751:1751	arg1	site					1717:1720	the specific site	1704:1720	the specific site of the envelope glycoprotein B (gB) of HSV-1	1704:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	4	theme	B	1751:1751	arg1	B					1751:1751	the envelope glycoprotein B	1725:1751	the envelope glycoprotein B (gB) of HSV-1	1725:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	8	5	theme	virus	1543:1547	arg1	transmission					1523:1534	transmission	1523:1534	transmission of the virus to new human host(s)	1523:1568	To produce recurrent infections that contribute to transmission of the virus to new human host(s), the virus must be able to evade the antibodies persisting in latently infected individuals.
37366623	5	6	theme	HSV-1	1126:1130	arg1	neurovirulence					1132:1145	HSV-1 neurovirulence	1126:1145	HSV-1 neurovirulence	1126:1145	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	10	7	dep	N-glycan	1878:1885	arg1	shield					1887:1892	shield	1887:1892	shield on the specific site of gB	1887:1919	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	9	8	gly	glycoprotein	1738:1749	arg1	glycoprotein					1738:1749	the envelope glycoprotein B	1725:1751	the envelope glycoprotein B (gB) of HSV-1	1725:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	3	9	from	replication	696:706	arg1	eyes					717:720	their eyes	711:720	their eyes of a mutant virus lacking the glycosylation site	711:769	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	6	10	theme	critical	1235:1242	arg1	N-glycan					1244:1251	a critical N-glycan shield	1233:1258	a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence	1233:1363	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	11	from	antibodies	1321:1330	arg1	evasion					1302:1308	evasion	1302:1308	evasion from human antibodies in vivo	1302:1338	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	11	from	antibodies	1321:1330	arg1	neurovirulence					1350:1363	viral neurovirulence	1344:1363	viral neurovirulence	1344:1363	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	11	from	antibodies	1321:1330	arg1	impacts					1286:1292	dual impacts	1281:1292	dual impacts	1281:1292	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	1	12	theme	evasion	173:179	arg1	mechanisms					153:162	the mechanisms	149:162	the mechanisms of viral evasion from human antibodies	149:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	2	13	theme	pooled	504:509	arg1	γ-globulins					511:521	pooled γ-globulins	504:521	pooled γ-globulins derived from human blood	504:546	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	9	14	theme	glycoprotein	1738:1749	arg1	gB					1754:1755	gB	1754:1755	gB	1754:1755	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	14	theme	glycoprotein	1738:1749	arg1	B					1751:1751	the envelope glycoprotein B	1725:1751	the envelope glycoprotein B (gB) of HSV-1	1725:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	10	15	theme	HSV-1	1946:1950	arg1	neurovirulence					1952:1965	HSV-1 neurovirulence	1946:1965	HSV-1 neurovirulence in naïve mice	1946:1979	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	3	16	theme	virus	734:738	arg1	eyes					717:720	their eyes	711:720	their eyes of a mutant virus lacking the glycosylation site	711:769	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	5	17	from	significant	1110:1120	arg1	system					1186:1191	the central nervous system	1166:1191	the central nervous system of naïve mice	1166:1205	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	4	18	theme	HSV-1	977:981	arg1	immunity					983:990	HSV-1 immunity	977:990	HSV-1 immunity induced by viral infection in vivo	977:1025	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	1	19	theme	human	186:190	arg1	antibodies					192:201	human antibodies	186:201	human antibodies	186:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	6	20	dep	N-glycan	1244:1251	arg1	shield					1253:1258	shield	1253:1258	shield	1253:1258	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	2	21	from	neutralization	437:450	arg1	evasion					424:430	evasion	424:430	evasion from neutralization and antibody-dependent cellular cytotoxicity	424:495	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	22	theme	human	536:540	arg1	blood					542:546	human blood	536:546	human blood	536:546	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	5	23	theme	naïve	1196:1200	arg1	mice					1202:1205	naïve mice	1196:1205	naïve mice	1196:1205	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	3	24	theme	human	591:595	arg1	γ-globulins					597:607	human γ-globulins	591:607	human γ-globulins	591:607	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	1	25	from	mechanisms	153:162	arg1	antibodies					192:201	human antibodies	186:201	human antibodies	186:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	3	26	attach	presence	579:586	arg1	mice					612:615	mice	612:615	mice	612:615	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	3	26	attach	presence	579:586	arg2	γ-globulins					597:607	human γ-globulins	591:607	human γ-globulins	591:607	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	3	26	attach	presence	579:586	arg1	immunity					621:628	immunity	621:628	immunity to HSV-1 induced by viral infection in mice	621:672	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	4	27	theme	gB	918:919	arg1	gB					918:919	HSV-1 envelope gB	903:919	HSV-1 envelope gB	903:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	4	27	theme	gB	918:919	arg1	site					895:898	a specific site	884:898	a specific site of HSV-1 envelope gB	884:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	2	28	from	cytotoxicity	484:495	arg1	evasion					424:430	evasion	424:430	evasion from neutralization and antibody-dependent cellular cytotoxicity	424:495	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	6	29	theme	dual	1281:1284	arg1	evasion					1302:1308	evasion	1302:1308	evasion from human antibodies in vivo	1302:1338	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	29	theme	dual	1281:1284	arg1	neurovirulence					1350:1363	viral neurovirulence	1344:1363	viral neurovirulence	1344:1363	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	29	theme	dual	1281:1284	arg1	impacts					1286:1292	dual impacts	1281:1292	dual impacts	1281:1292	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	11	30	theme	infection	2025:2033	arg1	features					2007:2014	the clinical features	1994:2014	the clinical features of HSV-1 infection	1994:2033	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	5	31	theme	HSV-1	1097:1101	arg1	gB					1103:1104	HSV-1 gB	1097:1104	HSV-1 gB	1097:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	5	32	theme	central	1170:1176	arg1	system					1186:1191	the central nervous system	1166:1191	the central nervous system of naïve mice	1166:1205	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	4	33	from	immunity	983:990	arg1	evasion					930:936	evasion	930:936	evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo	930:1025	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	3	34	theme	repaired	819:826	arg1	virus					828:832	its repaired virus	815:832	its repaired virus	815:832	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	11	35	theme	HSV-1	2205:2209	arg1	pathogenesis					2211:2222	HSV-1 pathogenesis	2205:2222	HSV-1 pathogenesis during the initial infection	2205:2251	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	0	36	theme	HSV-1	66:70	arg1	B					61:61	the envelope glycoprotein B	35:61	the envelope glycoprotein B of HSV-1	35:70	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	10	37	theme	specific	1901:1908	arg1	site					1910:1913	the specific site	1897:1913	the specific site of gB	1897:1919	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	10	37	theme	specific	1901:1908	arg1	gB					1918:1919	gB	1918:1919	gB	1918:1919	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	0	38	gly	glycoprotein	48:59	arg1	glycoprotein					48:59	the envelope glycoprotein B	35:61	the envelope glycoprotein B of HSV-1	35:70	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	2	39	theme	cellular	475:482	arg1	cytotoxicity					484:495	antibody-dependent cellular cytotoxicity	456:495	antibody-dependent cellular cytotoxicity	456:495	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	3	40	from	presence	579:586	arg1	mice					612:615	mice	612:615	mice	612:615	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	3	40	from	presence	579:586	arg1	immunity					621:628	immunity	621:628	immunity to HSV-1 induced by viral infection in mice	621:672	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	2	41	theme	simplex	362:368	arg1	virus					370:374	the herpes simplex virus 1	351:376	the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB)	351:413	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	41	theme	simplex	362:368	arg1	HSV-1					379:383	HSV-1	379:383	HSV-1	379:383	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	4	42	dep	N-glycan	865:872	arg1	shield					874:879	shield	874:879	shield on a specific site of HSV-1 envelope gB	874:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	1	43	theme	effective	274:282	arg1	vaccines					284:291	effective vaccines	274:291	effective vaccines	274:291	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	11	44	theme	initial	2235:2241	arg1	infection					2243:2251	the initial infection	2231:2251	the initial infection	2231:2251	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	0	45	theme	Dual	0:3	arg1	neurovirulence					115:128	neurovirulence	115:128	neurovirulence	115:128	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	45	theme	Dual	0:3	arg1	evasion					73:79	evasion	73:79	evasion from human antibodies in vivo	73:109	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	45	theme	Dual	0:3	arg1	impacts					5:11	Dual impacts	0:11	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.	0:129	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	7	46	dep	IMPORTANCE	1366:1375	arg1	HSV-1					1401:1405	HSV-1	1401:1405	HSV-1	1401:1405	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	7	46	dep	IMPORTANCE	1366:1375	arg1	virus					1392:1396	Herpes simplex virus 1	1377:1398	IMPORTANCE Herpes simplex virus 1 (HSV-1)	1366:1406	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	2	47	theme	envelope	386:393	arg1	gB					411:412	gB	411:412	gB	411:412	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	47	theme	envelope	386:393	arg1	B					408:408	envelope glycoprotein B	386:408	the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB)	351:413	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	5	48	dep	N-glycan	1059:1066	arg1	shield					1068:1073	shield	1068:1073	shield on a specific site of HSV-1 gB	1068:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	6	49	theme	human	1315:1319	arg1	antibodies					1321:1330	human antibodies	1315:1330	human antibodies	1315:1330	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	6	50	from	N-glycan	1244:1251	arg1	gB					1269:1270	HSV-1 gB	1263:1270	HSV-1 gB	1263:1270	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	7	51	from	infections	1450:1459	arg1	humans					1464:1469	humans	1464:1469	humans	1464:1469	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	7	52	theme	latent	1429:1434	arg1	infections					1450:1459	lifelong latent and recurrent infections	1420:1459	lifelong latent and recurrent infections in humans	1420:1469	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	4	53	theme	human	943:947	arg1	antibodies					949:958	human antibodies	943:958	human antibodies	943:958	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	0	54	theme	glycan	18:23	arg1	neurovirulence					115:128	neurovirulence	115:128	neurovirulence	115:128	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	54	theme	glycan	18:23	arg1	evasion					73:79	evasion	73:79	evasion from human antibodies in vivo	73:109	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	54	theme	glycan	18:23	arg1	impacts					5:11	Dual impacts	0:11	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.	0:129	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	9	55	from	γ-globulins	1796:1806	arg1	evasion					1776:1782	evasion	1776:1782	evasion from pooled γ-globulins derived from human blood both in cell cultures and mice	1776:1862	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	11	56	theme	clinical	1998:2005	arg1	features					2007:2014	the clinical features	1994:2014	the clinical features of HSV-1 infection	1994:2033	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	0	57	theme	envelope	39:46	arg1	B					61:61	the envelope glycoprotein B	35:61	the envelope glycoprotein B of HSV-1	35:70	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	58	dep	glycan	18:23	arg1	shield					25:30	shield	25:30	shield on the envelope glycoprotein B of HSV-1	25:70	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	4	59	theme	HSV-1	903:907	arg1	gB					918:919	HSV-1 envelope gB	903:919	HSV-1 envelope gB	903:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	10	60	from	neurovirulence	1952:1965	arg1	mice					1976:1979	naïve mice	1970:1979	naïve mice	1970:1979	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	3	61	contain	had	775:777	arg1	presence					579:586	the presence	575:586	the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice	575:672	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	3	61	contain	had	775:777	arg2	effect					786:791	little effect	779:791	little effect	779:791	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	8	62	theme	human	1556:1560	arg1	s					1567:1567	new human host(s)	1552:1568	new human host(s)	1552:1568	To produce recurrent infections that contribute to transmission of the virus to new human host(s), the virus must be able to evade the antibodies persisting in latently infected individuals.
37366623	7	63	theme	simplex	1384:1390	arg1	HSV-1					1401:1405	HSV-1	1401:1405	HSV-1	1401:1405	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	7	63	theme	simplex	1384:1390	arg1	virus					1392:1396	Herpes simplex virus 1	1377:1398	IMPORTANCE Herpes simplex virus 1 (HSV-1)	1366:1406	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	3	64	theme	glycosylation	752:764	arg1	site					766:769	the glycosylation site	748:769	the glycosylation site	748:769	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	10	65	theme	gB	1918:1919	arg1	site					1910:1913	the specific site	1897:1913	the specific site of gB	1897:1919	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	10	65	theme	gB	1918:1919	arg1	gB					1918:1919	gB	1918:1919	gB	1918:1919	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	4	66	theme	viral	1003:1007	arg1	infection					1009:1017	viral infection	1003:1017	viral infection	1003:1017	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	3	67	theme	viral	650:654	arg1	infection					656:664	viral infection	650:664	viral infection in mice	650:672	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	1	68	theme	viral	237:241	arg1	pathogenesis					243:254	viral pathogenesis	237:254	viral pathogenesis	237:254	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	5	69	from	system	1186:1191	arg1	significant					1110:1120	significant	1110:1120	significant	1110:1120	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	5	69	from	system	1186:1191	arg1	N-glycan					1059:1066	an N-glycan	1056:1066	an N-glycan shield on a specific site of HSV-1 gB	1056:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	1	70	theme	mechanisms	153:162	arg1	Identification					131:144	Identification	131:144	Identification of the mechanisms of viral evasion from human antibodies	131:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	9	71	dep	N-glycan	1685:1692	arg1	shield					1694:1699	shield	1694:1699	shield on the specific site of the envelope glycoprotein B (gB) of HSV-1	1694:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	72	theme	HSV-1	1761:1765	arg1	gB					1754:1755	gB	1754:1755	gB	1754:1755	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	72	theme	HSV-1	1761:1765	arg1	B					1751:1751	the envelope glycoprotein B	1725:1751	the envelope glycoprotein B (gB) of HSV-1	1725:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	2	73	attach	derived	523:529	arg1	blood					542:546	human blood	536:546	human blood	536:546	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	73	attach	derived	523:529	arg2	γ-globulins					511:521	pooled γ-globulins	504:521	pooled γ-globulins derived from human blood	504:546	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	1	74	theme	viral	167:171	arg1	evasion					173:179	viral evasion	167:179	viral evasion from human antibodies	167:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	1	75	dep	crucial	206:212	arg1	designing					264:272	designing	264:272	designing effective vaccines	264:291	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	1	75	dep	crucial	206:212	arg1	understanding					223:235	understanding	223:235	understanding viral pathogenesis	223:254	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	11	76	theme	recurrent	2102:2110	arg1	infections					2118:2127	recurrent HSV-1 infections	2102:2127	recurrent HSV-1 infections in latently infected humans	2102:2155	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	10	77	theme	naïve	1970:1974	arg1	mice					1976:1979	naïve mice	1970:1979	naïve mice	1970:1979	Notably, the N-glycan shield on the specific site of gB was also significant for HSV-1 neurovirulence in naïve mice.
37366623	9	78	attach	derived	1808:1814	arg1	blood					1827:1831	human blood	1821:1831	human blood	1821:1831	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	78	attach	derived	1808:1814	arg2	γ-globulins					1796:1806	pooled γ-globulins	1789:1806	pooled γ-globulins derived from human blood both in cell cultures and mice	1789:1862	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	79	dep	blood	1827:1831	arg1	both					1833:1836	both	1833:1836	both	1833:1836	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	80	theme	pooled	1789:1794	arg1	γ-globulins					1796:1806	pooled γ-globulins	1789:1806	pooled γ-globulins derived from human blood both in cell cultures and mice	1789:1862	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	3	81	from	infection	656:664	arg1	mice					669:672	mice	669:672	mice	669:672	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	11	82	from	infections	2118:2127	arg1	humans					2150:2155	latently infected humans	2132:2155	latently infected humans	2132:2155	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	3	83	theme	mutant	727:732	arg1	virus					734:738	a mutant virus	725:738	a mutant virus lacking the glycosylation site	725:769	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	1	84	from	antibodies	192:201	arg1	mechanisms					153:162	the mechanisms	149:162	the mechanisms of viral evasion from human antibodies	149:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	1	84	from	antibodies	192:201	arg1	evasion					173:179	viral evasion	167:179	viral evasion from human antibodies	167:201	Identification of the mechanisms of viral evasion from human antibodies is crucial both for understanding viral pathogenesis and for designing effective vaccines.
37366623	3	85	gly	glycosylation	752:764	arg2	site					766:769	the glycosylation site	748:769	the glycosylation site	748:769	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	9	86	theme	human	1821:1825	arg1	blood					1827:1831	human blood	1821:1831	human blood	1821:1831	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	5	87	theme	mice	1202:1205	arg1	system					1186:1191	the central nervous system	1166:1191	the central nervous system of naïve mice	1166:1205	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	0	88	theme	glycoprotein	48:59	arg1	B					61:61	the envelope glycoprotein B	35:61	the envelope glycoprotein B of HSV-1	35:70	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	8	89	theme	infected	1641:1648	arg1	individuals					1650:1660	latently infected individuals	1632:1660	latently infected individuals	1632:1660	To produce recurrent infections that contribute to transmission of the virus to new human host(s), the virus must be able to evade the antibodies persisting in latently infected individuals.
37366623	4	90	theme	envelope	909:916	arg1	gB					918:919	HSV-1 envelope gB	903:919	HSV-1 envelope gB	903:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	6	91	theme	HSV-1	1263:1267	arg1	gB					1269:1270	HSV-1 gB	1263:1270	HSV-1 gB	1263:1270	Thus, we have identified a critical N-glycan shield on HSV-1 gB that has dual impacts, namely evasion from human antibodies in vivo and viral neurovirulence.
37366623	0	92	theme	human	86:90	arg1	antibodies					92:101	human antibodies	86:101	human antibodies	86:101	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	9	93	theme	cell	1841:1844	arg1	cultures					1846:1853	cell cultures	1841:1853	cell cultures	1841:1853	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	5	94	theme	nervous	1178:1184	arg1	system					1186:1191	the central nervous system	1166:1191	the central nervous system of naïve mice	1166:1205	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	3	95	theme	virus	828:832	arg1	replication					800:810	the replication	796:810	the replication of its repaired virus	796:832	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	7	96	theme	recurrent	1440:1448	arg1	infections					1450:1459	lifelong latent and recurrent infections	1420:1459	lifelong latent and recurrent infections in humans	1420:1469	IMPORTANCE Herpes simplex virus 1 (HSV-1) establishes lifelong latent and recurrent infections in humans.
37366623	4	97	theme	specific	886:893	arg1	gB					918:919	HSV-1 envelope gB	903:919	HSV-1 envelope gB	903:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	4	97	theme	specific	886:893	arg1	site					895:898	a specific site	884:898	a specific site of HSV-1 envelope gB	884:919	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	3	98	theme	little	779:784	arg1	effect					786:791	little effect	779:791	little effect	779:791	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	2	99	theme	antibody-dependent	456:473	arg1	cytotoxicity					484:495	antibody-dependent cellular cytotoxicity	456:495	antibody-dependent cellular cytotoxicity	456:495	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	100	theme	herpes	355:360	arg1	virus					370:374	the herpes simplex virus 1	351:376	the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB)	351:413	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	100	theme	herpes	355:360	arg1	HSV-1					379:383	HSV-1	379:383	HSV-1	379:383	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	101	theme	glycoprotein	395:406	arg1	gB					411:412	gB	411:412	gB	411:412	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	101	theme	glycoprotein	395:406	arg1	B					408:408	envelope glycoprotein B	386:408	the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB)	351:413	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	11	102	theme	HSV-1	2112:2116	arg1	infections					2118:2127	recurrent HSV-1 infections	2102:2127	recurrent HSV-1 infections in latently infected humans	2102:2155	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	5	103	theme	gB	1103:1104	arg1	site					1089:1092	a specific site	1078:1092	a specific site of HSV-1 gB	1078:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	5	103	theme	gB	1103:1104	arg1	gB					1103:1104	HSV-1 gB	1097:1104	HSV-1 gB	1097:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	11	104	theme	HSV-1	2019:2023	arg1	infection					2025:2033	HSV-1 infection	2019:2033	HSV-1 infection	2019:2033	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	3	105	theme	γ-globulins	597:607	arg1	presence					579:586	the presence	575:586	the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice	575:672	We also demonstrated that the presence of human γ-globulins in mice and immunity to HSV-1 induced by viral infection in mice significantly reduced replication in their eyes of a mutant virus lacking the glycosylation site but had little effect on the replication of its repaired virus.
37366623	2	106	dep	virus	370:374	arg1	gB					411:412	gB	411:412	gB	411:412	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	2	106	dep	virus	370:374	arg1	B					408:408	envelope glycoprotein B	386:408	the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB)	351:413	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	4	107	from	antibodies	949:958	arg1	evasion					930:936	evasion	930:936	evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo	930:1025	These results suggest that an N-glycan shield on a specific site of HSV-1 envelope gB mediated evasion from human antibodies in vivo and from HSV-1 immunity induced by viral infection in vivo.
37366623	8	108	theme	recurrent	1483:1491	arg1	infections					1493:1502	recurrent infections	1483:1502	recurrent infections that contribute to transmission of the virus to new human host(s)	1483:1568	To produce recurrent infections that contribute to transmission of the virus to new human host(s), the virus must be able to evade the antibodies persisting in latently infected individuals.
37366623	2	109	theme	cell	310:313	arg1	cultures					315:322	cell cultures	310:322	cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood	310:546	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	8	110	theme	new	1552:1554	arg1	s					1567:1567	new human host(s)	1552:1568	new human host(s)	1552:1568	To produce recurrent infections that contribute to transmission of the virus to new human host(s), the virus must be able to evade the antibodies persisting in latently infected individuals.
37366623	5	111	theme	specific	1080:1087	arg1	site					1089:1092	a specific site	1078:1092	a specific site of HSV-1 gB	1078:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	5	111	theme	specific	1080:1087	arg1	gB					1103:1104	HSV-1 gB	1097:1104	HSV-1 gB	1097:1104	Notably, we also found that an N-glycan shield on a specific site of HSV-1 gB was significant for HSV-1 neurovirulence and replication in the central nervous system of naïve mice.
37366623	2	112	gly	glycoprotein	395:406	arg1	glycoprotein					395:406	envelope glycoprotein B	386:408	the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB)	351:413	Here we show in cell cultures that an N-glycan shield on the herpes simplex virus 1 (HSV-1) envelope glycoprotein B (gB) mediated evasion from neutralization and antibody-dependent cellular cytotoxicity due to pooled γ-globulins derived from human blood.
37366623	9	113	theme	specific	1708:1715	arg1	site					1717:1720	the specific site	1704:1720	the specific site of the envelope glycoprotein B (gB) of HSV-1	1704:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	9	113	theme	specific	1708:1715	arg1	B					1751:1751	the envelope glycoprotein B	1725:1751	the envelope glycoprotein B (gB) of HSV-1	1725:1765	Here, we show that an N-glycan shield on the specific site of the envelope glycoprotein B (gB) of HSV-1 mediates evasion from pooled γ-globulins derived from human blood both in cell cultures and mice.
37366623	11	114	dep	glycan	2067:2072	arg1	only					2085:2088	only	2085:2088	only	2085:2088	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	11	114	dep	glycan	2067:2072	arg1	shield					2074:2079	shield	2074:2079	shield	2074:2079	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	8	115	theme	host	1562:1565	arg1	s					1567:1567	new human host(s)	1552:1568	new human host(s)	1552:1568	To produce recurrent infections that contribute to transmission of the virus to new human host(s), the virus must be able to evade the antibodies persisting in latently infected individuals.
37366623	0	116	dep	impacts	5:11	arg1	neurovirulence					115:128	neurovirulence	115:128	neurovirulence	115:128	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	116	dep	impacts	5:11	arg1	evasion					73:79	evasion	73:79	evasion from human antibodies in vivo	73:109	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	116	dep	impacts	5:11	arg1	impacts					5:11	Dual impacts	0:11	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.	0:129	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	11	117	theme	infected	2141:2148	arg1	humans					2150:2155	latently infected humans	2132:2155	latently infected humans	2132:2155	Considering the clinical features of HSV-1 infection, these results suggest that the glycan shield not only facilitates recurrent HSV-1 infections in latently infected humans by evading antibodies but is also important for HSV-1 pathogenesis during the initial infection.
37366623	0	118	from	antibodies	92:101	arg1	neurovirulence					115:128	neurovirulence	115:128	neurovirulence	115:128	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	118	from	antibodies	92:101	arg1	evasion					73:79	evasion	73:79	evasion from human antibodies in vivo	73:109	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37366623	0	118	from	antibodies	92:101	arg1	impacts					5:11	Dual impacts	0:11	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.	0:129	Dual impacts of a glycan shield on the envelope glycoprotein B of HSV-1: evasion from human antibodies in vivo and neurovirulence.
37349961	0	0	theme	cellobiose	64:73	arg1	degradation					75:85	dietary cellobiose degradation	56:85	dietary cellobiose degradation	56:85	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	7	1	dep	cellobiose	1026:1035	arg1	reshaped					1037:1044	reshaped	1037:1044	reshaped the composition of gut microbiota	1037:1078	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	7	1	dep	cellobiose	1026:1035	arg1	modified					1093:1100	modified	1093:1100	probably modified the metabolic function of bacteria	1084:1135	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	5	2	dep	cellulases	648:657	arg1	BACOVA_02626GH5					659:673	BACOVA_02626GH5	659:673	BACOVA_02626GH5	659:673	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	5	2	dep	cellulases	648:657	arg1	cellulases					648:657	two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5	640:693	two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface	640:713	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	5	2	dep	cellulases	648:657	arg1	BACOVA_02630GH5					679:693	BACOVA_02630GH5	679:693	BACOVA_02630GH5	679:693	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	0	3	theme	dietary	56:62	arg1	degradation					75:85	dietary cellobiose degradation	56:85	dietary cellobiose degradation	56:85	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	0	4	from	claim	4:8	arg1	degradation					75:85	dietary cellobiose degradation	56:85	dietary cellobiose degradation	56:85	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	1	5	from	gut	148:150	arg1	bacterium					127:135	cellulose degrading bacterium	107:135	cellulose degrading bacterium from human gut	107:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	1	5	from	gut	148:150	arg1	demonstration					90:102	A demonstration	88:102	A demonstration of cellulose degrading bacterium from human gut	88:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	6	6	theme	predicted	789:797	arg1	structures					799:808	The predicted structures	785:808	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5	785:847	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	6	6	theme	predicted	789:797	arg1	homologous					861:870	homologous	861:870	homologous	861:870	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	8	7	from	cellulose	1306:1314	arg1	field					1280:1284	the field	1276:1284	the field of investigation on cellulose	1276:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	5	8	theme	new	644:646	arg1	BACOVA_02626GH5					659:673	BACOVA_02626GH5	659:673	BACOVA_02626GH5	659:673	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	5	8	theme	new	644:646	arg1	cellulases					648:657	two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5	640:693	two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface	640:713	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	5	8	theme	new	644:646	arg1	BACOVA_02630GH5					679:693	BACOVA_02630GH5	679:693	BACOVA_02630GH5	679:693	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	7	9	theme	microbiota	1069:1078	arg1	composition					1050:1060	the composition	1046:1060	the composition of gut microbiota	1046:1078	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	4	10	theme	new	522:524	arg1	PUL					560:562	PUL	560:562	PUL	560:562	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	4	10	theme	new	522:524	arg1	locus					553:557	a new polysaccharide utilization locus	520:557	a new polysaccharide utilization locus (PUL) from BO	520:571	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	8	11	theme	investigation	1289:1301	arg1	field					1280:1284	the field	1276:1284	the field of investigation on cellulose	1276:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	3	12	theme	molecular	475:483	arg1	mechanism					485:493	the molecular mechanism	471:493	the molecular mechanism	471:493	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	8	13	theme	new	1261:1263	arg1	insight					1265:1271	new insight	1261:1271	new insight in the field of investigation on cellulose	1261:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	2	14	theme	gut	267:269	arg1	microbiota					271:280	human gut microbiota	261:280	human gut microbiota	261:280	However, investigation of cellulose degradation by human gut microbiota on molecular level has not been completed so far.
37349961	7	15	theme	metabolic	1106:1114	arg1	function					1116:1123	the metabolic function	1102:1123	the metabolic function of bacteria	1102:1135	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	6	16	theme	BACOVA_02630GH5	833:847	arg1	structures					799:808	The predicted structures	785:808	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5	785:847	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	6	16	theme	BACOVA_02630GH5	833:847	arg1	homologous					861:870	homologous	861:870	homologous	861:870	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	7	17	theme	gut	1065:1067	arg1	microbiota					1069:1078	gut microbiota	1065:1078	gut microbiota	1065:1078	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	2	18	theme	human	261:265	arg1	microbiota					271:280	human gut microbiota	261:280	human gut microbiota	261:280	However, investigation of cellulose degradation by human gut microbiota on molecular level has not been completed so far.
37349961	2	19	from	investigation	219:231	arg1	level					295:299	molecular level	285:299	molecular level	285:299	However, investigation of cellulose degradation by human gut microbiota on molecular level has not been completed so far.
37349961	3	20	theme	human	404:408	arg1	ovatus					447:452	Bacteroides ovatus	435:452	Bacteroides ovatus (BO)	435:457	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	3	20	theme	human	404:408	arg1	members					418:424	human gut key members	404:424	human gut key members	404:424	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	7	21	theme	murine	995:1000	arg1	experiment					1002:1011	murine experiment	995:1011	murine experiment	995:1011	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	5	22	theme	cell	702:705	arg1	surface					707:713	the cell surface	698:713	the cell surface	698:713	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	8	23	from	field	1280:1284	arg1	cellulose					1306:1314	cellulose	1306:1314	cellulose	1306:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	6	24	from	bacteria	901:908	arg1	cellulase					881:889	the cellulase	877:889	the cellulase from soil bacteria	877:908	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	5	25	theme	cellobiose	744:753	arg1	degradation					729:739	the degradation	725:739	the degradation of cellobiose	725:753	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	5	26	dep	performed	715:723	arg1	determined					773:782	determined	773:782	were determined	768:782	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	4	27	from	BO	570:571	arg1	PUL					560:562	PUL	560:562	PUL	560:562	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	4	27	from	BO	570:571	arg1	locus					553:557	a new polysaccharide utilization locus	520:557	a new polysaccharide utilization locus (PUL) from BO	520:571	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	1	28	theme	human	174:178	arg1	cannot					180:185	human cannot	174:185	human cannot	174:185	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	0	29	theme	primacy	13:19	arg1	claim					4:8	The claim	0:8	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.	0:86	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	6	30	theme	catalytic	919:927	arg1	conservative					950:961	conservative	950:961	conservative	950:961	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	6	30	theme	catalytic	919:927	arg1	residues					929:936	the catalytic residues	915:936	the catalytic residues	915:936	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	8	31	from	insight	1265:1271	arg1	field					1280:1284	the field	1276:1284	the field of investigation on cellulose	1276:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	3	32	theme	members	418:424	arg1	growth					394:399	the growth	390:399	the growth of human gut key members, such as Bacteroides ovatus (BO),	390:458	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	6	33	theme	BACOVA_02626GH5	813:827	arg1	structures					799:808	The predicted structures	785:808	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5	785:847	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	6	33	theme	BACOVA_02626GH5	813:827	arg1	homologous					861:870	homologous	861:870	homologous	861:870	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	2	34	theme	molecular	285:293	arg1	level					295:299	molecular level	285:299	molecular level	285:299	However, investigation of cellulose degradation by human gut microbiota on molecular level has not been completed so far.
37349961	0	35	theme	human	24:28	arg1	ovatus					46:51	human gut Bacteroides ovatus	24:51	human gut Bacteroides ovatus	24:51	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	6	36	with	homologous	861:870	arg1	cellulase					881:889	the cellulase	877:889	the cellulase from soil bacteria	877:908	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	8	37	from	investigation	1289:1301	arg1	cellulose					1306:1314	cellulose	1306:1314	cellulose	1306:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	3	38	theme	gut	410:412	arg1	ovatus					447:452	Bacteroides ovatus	435:452	Bacteroides ovatus (BO)	435:457	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	3	38	theme	gut	410:412	arg1	members					418:424	human gut key members	404:424	human gut key members	404:424	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	8	39	dep	highlight	1175:1183	arg1	degraded					1218:1225	degraded	1218:1225	can be degraded by human gut microbes	1211:1247	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	8	39	dep	highlight	1175:1183	arg1	provide					1253:1259	provide	1253:1259	provide new insight in the field of investigation on cellulose	1253:1314	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	7	40	theme	bacteria	1128:1135	arg1	function					1116:1123	the metabolic function	1102:1123	the metabolic function of bacteria	1102:1135	In murine experiment, we observed cellobiose reshaped the composition of gut microbiota and probably modified the metabolic function of bacteria.
37349961	3	41	theme	key	414:416	arg1	ovatus					447:452	Bacteroides ovatus	435:452	Bacteroides ovatus (BO)	435:457	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	3	41	theme	key	414:416	arg1	members					418:424	human gut key members	404:424	human gut key members	404:424	We showed here, using cellobiose as a model that promoted the growth of human gut key members, such as Bacteroides ovatus (BO), to clarify the molecular mechanism.
37349961	0	42	theme	Bacteroides	34:44	arg1	ovatus					46:51	human gut Bacteroides ovatus	24:51	human gut Bacteroides ovatus	24:51	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	5	43	from	cellulases	648:657	arg1	surface					707:713	the cell surface	698:713	the cell surface	698:713	Further, two new cellulases BACOVA_02626GH5 and BACOVA_02630GH5 on the cell surface performed the degradation of cellobiose into glucose were determined.
37349961	0	44	theme	gut	30:32	arg1	ovatus					46:51	human gut Bacteroides ovatus	24:51	human gut Bacteroides ovatus	24:51	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	6	45	theme	soil	896:899	arg1	bacteria					901:908	soil bacteria	896:908	soil bacteria	896:908	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	1	46	theme	cellulose	107:115	arg1	bacterium					127:135	cellulose degrading bacterium	107:135	cellulose degrading bacterium from human gut	107:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	1	47	theme	degrading	117:125	arg1	bacterium					127:135	cellulose degrading bacterium	107:135	cellulose degrading bacterium from human gut	107:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	1	48	from	demonstration	90:102	arg1	gut					148:150	human gut	142:150	human gut	142:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	4	49	theme	utilization	541:551	arg1	PUL					560:562	PUL	560:562	PUL	560:562	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	4	49	theme	utilization	541:551	arg1	locus					553:557	a new polysaccharide utilization locus	520:557	a new polysaccharide utilization locus (PUL) from BO	520:571	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	4	50	dep	cellobiose	593:602	arg1	degradation					618:628	degradation	618:628	degradation	618:628	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	4	50	dep	cellobiose	593:602	arg1	capturing					604:612	capturing	604:612	capturing	604:612	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	2	51	theme	degradation	246:256	arg1	investigation					219:231	investigation	219:231	investigation of cellulose degradation by human gut microbiota on molecular level	219:299	However, investigation of cellulose degradation by human gut microbiota on molecular level has not been completed so far.
37349961	1	52	theme	bacterium	127:135	arg1	demonstration					90:102	A demonstration	88:102	A demonstration of cellulose degrading bacterium from human gut	88:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
37349961	4	53	theme	polysaccharide	526:539	arg1	PUL					560:562	PUL	560:562	PUL	560:562	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	4	53	theme	polysaccharide	526:539	arg1	locus					553:557	a new polysaccharide utilization locus	520:557	a new polysaccharide utilization locus (PUL) from BO	520:571	Our results showed that a new polysaccharide utilization locus (PUL) from BO was involved in the cellobiose capturing and degradation.
37349961	8	54	theme	gut	1236:1238	arg1	microbes					1240:1247	human gut microbes	1230:1247	human gut microbes	1230:1247	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	2	55	theme	cellulose	236:244	arg1	degradation					246:256	cellulose degradation	236:256	cellulose degradation	236:256	However, investigation of cellulose degradation by human gut microbiota on molecular level has not been completed so far.
37349961	8	56	theme	human	1230:1234	arg1	microbes					1240:1247	human gut microbes	1230:1247	human gut microbes	1230:1247	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	8	57	theme	cellulose	1201:1209	arg1	evidence					1189:1196	the evidence	1185:1196	the evidence of cellulose	1185:1209	Taken together, our findings further highlight the evidence of cellulose can be degraded by human gut microbes and provide new insight in the field of investigation on cellulose.
37349961	6	58	theme	glutamate	972:980	arg1	residues					982:989	two glutamate residues	968:989	two glutamate residues	968:989	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	0	59	theme	ovatus	46:51	arg1	primacy					13:19	primacy	13:19	primacy of human gut Bacteroides ovatus	13:51	The claim of primacy of human gut Bacteroides ovatus in dietary cellobiose degradation.
37349961	6	60	with	conservative	950:961	arg1	residues					982:989	two glutamate residues	968:989	two glutamate residues	968:989	The predicted structures of BACOVA_02626GH5 and BACOVA_02630GH5 were highly homologous with the cellulase from soil bacteria, and the catalytic residues were highly conservative with two glutamate residues.
37349961	1	61	theme	human	142:146	arg1	gut					148:150	human gut	142:150	human gut	142:150	A demonstration of cellulose degrading bacterium from human gut changed our view that human cannot degrade the cellulose.
36311785	4	0	theme	200mg/kg	931:938	arg1	YG					940:941	200mg/kg YG	931:941	200mg/kg YG	931:941	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	7	1	theme	cytokine	1336:1343	arg1	levels					1345:1350	serum cytokine levels	1330:1350	serum cytokine levels	1330:1350	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	10	2	theme	biosynthesis	2262:2273	arg1	pathways					2319:2326	fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways	2251:2326	fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways	2251:2326	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	3	theme	fatty	2251:2255	arg1	biosynthesis					2262:2273	fatty acid biosynthesis	2251:2273	fatty acid biosynthesis	2251:2273	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	4	theme	unsaturated	2295:2305	arg1	acids					2313:2317	unsaturated fatty acids	2295:2317	unsaturated fatty acids	2295:2317	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	4	5	theme	integrated	709:718	arg1	technology					740:749	an integrated 16S-rRNA sequencing technology	706:749	an integrated 16S-rRNA sequencing technology	706:749	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	1	6	theme	intestinal	203:212	arg1	microbiome					214:223	The intestinal microbiome	199:223	The intestinal microbiome	199:223	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	1	6	theme	intestinal	203:212	arg1	responsible					228:238	responsible	228:238	responsible	228:238	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	10	7	theme	biosynthesis	2279:2290	arg1	pathways					2319:2326	fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways	2251:2326	fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways	2251:2326	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	4	8	theme	sequencing	729:738	arg1	technology					740:749	an integrated 16S-rRNA sequencing technology	706:749	an integrated 16S-rRNA sequencing technology	706:749	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	0	9	with	metabolites	110:120	arg1	polysaccharide					148:161	dietary Enteromorpha polysaccharide	127:161	dietary Enteromorpha polysaccharide	127:161	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	0	9	with	metabolites	110:120	arg1	glycoprotein					173:184	Yeast glycoprotein	167:184	Yeast glycoprotein in chickens	167:196	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	9	10	theme	related	1858:1864	arg1	metabolites					1846:1856	metabolites	1846:1856	metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid	1846:1944	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	11	11	theme	important	2520:2528	arg1	pathways					2541:2548	the important metabolism pathways	2516:2548	the important metabolism pathways	2516:2548	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	4	12	theme	present	687:693	arg1	study					695:699	The present study	683:699	The present study	683:699	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	0	13	theme	Enteromorpha	135:146	arg1	polysaccharide					148:161	dietary Enteromorpha polysaccharide	127:161	dietary Enteromorpha polysaccharide	127:161	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	9	14	theme	lipid	1869:1873	arg1	acid					1915:1918	oleic acid	1909:1918	oleic acid	1909:1918	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	9	14	theme	lipid	1869:1873	arg1	metabolisms					1875:1885	lipid metabolisms	1869:1885	lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid	1869:1944	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	9	14	theme	lipid	1869:1873	arg1	acid					1941:1944	docosahexaenoic acid	1925:1944	docosahexaenoic acid	1925:1944	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	9	14	theme	lipid	1869:1873	arg1	acid					1903:1906	malonic acid	1895:1906	malonic acid	1895:1906	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	8	15	theme	energy	1579:1584	arg1	metabolism					1586:1595	energy metabolism	1579:1595	energy metabolism	1579:1595	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	10	16	theme	acids	2313:2317	arg1	biosynthesis					2279:2290	biosynthesis	2279:2290	biosynthesis of unsaturated fatty acids	2279:2317	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	16	theme	acids	2313:2317	arg1	biosynthesis					2262:2273	fatty acid biosynthesis	2251:2273	fatty acid biosynthesis	2251:2273	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	17	theme	enrichment	1964:1973	arg1	results					1984:1990	The quantitative enrichment analysis results	1947:1990	The quantitative enrichment analysis results	1947:1990	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	9	18	theme	Metabolomics	1627:1638	arg1	analysis					1640:1647	Metabolomics analysis	1627:1647	Metabolomics analysis	1627:1647	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	3	19	theme	action	634:639	arg1	mechanism					621:629	the mechanism	617:629	the mechanism of action of these polysaccharides	617:664	However, the mechanism of action of these polysaccharides remains elusive.
36311785	5	20	theme	EP+YG	969:973	arg1	supplementation					975:989	EP+YG supplementation	969:989	EP+YG supplementation	969:989	The results showed that EP+YG supplementation altered the overall structure of caecal microbiota as evidenced by β diversities analysis.
36311785	9	21	theme	malonic	1895:1901	arg1	acid					1903:1906	malonic acid	1895:1906	malonic acid	1895:1906	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	8	22	theme	carbohydrate	1602:1613	arg1	metabolism					1615:1624	carbohydrate metabolism	1602:1624	carbohydrate metabolism	1602:1624	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	8	23	theme	Predicted	1410:1418	arg1	analysis					1431:1438	Predicted functional analysis	1410:1438	Predicted functional analysis	1410:1438	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	9	24	theme	EP+YG	1664:1668	arg1	supplementation					1670:1684	EP+YG supplementation	1664:1684	EP+YG supplementation	1664:1684	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	9	25	theme	caecal	1708:1713	arg1	metabolites					1715:1725	caecal metabolites	1708:1725	caecal metabolites	1708:1725	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	7	26	theme	serum	1330:1334	arg1	levels					1345:1350	serum cytokine levels	1330:1350	serum cytokine levels	1330:1350	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	2	27	theme	serum	549:553	arg1	profile					561:567	serum lipid profile	549:567	serum lipid profile	549:567	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	2	28	gly	glycoprotein	467:478	arg1	YG					481:482	YG	481:482	YG	481:482	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	2	28	gly	glycoprotein	467:478	arg1	glycoprotein					467:478	yeast glycoprotein	461:478	yeast glycoprotein (YG)	461:483	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	4	29	theme	metabolomics	766:777	arg1	technique					779:787	untargeted metabolomics technique	755:787	untargeted metabolomics technique	755:787	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	0	30	theme	caecal	88:93	arg1	microbiota					95:104	caecal microbiota	88:104	caecal microbiota	88:104	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	2	31	theme	acid	580:583	arg1	metabolism					585:594	fatty acid metabolism	574:594	fatty acid metabolism	574:594	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	4	32	theme	supplementation	832:846	arg1	action					816:821	action	816:821	action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG)	816:942	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	7	33	theme	altered	1301:1307	arg1	genera					1320:1325	altered microbiota genera	1301:1325	altered microbiota genera	1301:1325	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	5	34	theme	microbiota	1031:1040	arg1	structure					1011:1019	the overall structure	999:1019	the overall structure of caecal microbiota	999:1040	The results showed that EP+YG supplementation altered the overall structure of caecal microbiota as evidenced by β diversities analysis.
36311785	4	35	theme	broiler	851:857	arg1	chickens					859:866	broiler chickens	851:866	broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG)	851:942	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	8	36	theme	acid	1503:1506	arg1	metabolism					1508:1517	amino acid metabolism	1497:1517	amino acid metabolism	1497:1517	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	0	37	theme	Microbiome-metabolome	0:20	arg1	analysis					22:29	Microbiome-metabolome analysis	0:29	Microbiome-metabolome analysis	0:29	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	5	38	theme	overall	1003:1009	arg1	structure					1011:1019	the overall structure	999:1019	the overall structure of caecal microbiota	999:1040	The results showed that EP+YG supplementation altered the overall structure of caecal microbiota as evidenced by β diversities analysis.
36311785	11	39	dep	results	2396:2402	arg1	uncovered					2404:2412	uncovered	2404:2412	uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways	2404:2548	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	4	40	dep	EP+YG	910:914	arg1	EP					926:927	200mg/kg EP	917:927	200mg/kg EP	917:927	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	4	40	dep	EP+YG	910:914	arg1	YG					940:941	200mg/kg YG	931:941	200mg/kg YG	931:941	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	1	41	theme	microbiota-derived	333:350	arg1	metabolites					352:362	gut microbiota-derived metabolites	329:362	gut microbiota-derived metabolites	329:362	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	11	42	theme	untargeted	2372:2381	arg1	metabolomics					2383:2394	the 16S-rRNA and untargeted metabolomics	2355:2394	the 16S-rRNA and untargeted metabolomics	2355:2394	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	10	43	theme	citric	2040:2045	arg1	glycolysis/gluconeogenesis					2012:2037	glycolysis/gluconeogenesis	2012:2037	glycolysis/gluconeogenesis	2012:2037	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	pathways					2195:2202	the most important enriched pathways	2167:2202	the most important enriched pathways identified with enrichment ratio >11	2167:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	metabolism					2111:2120	threonine metabolism	2101:2120	threonine metabolism	2101:2120	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	glycine					2080:2086	glycine	2080:2086	glycine	2080:2086	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	serine					2089:2094	serine	2089:2094	serine	2089:2094	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	cycle					2052:2056	citric acid cycle	2040:2056	citric acid cycle	2040:2056	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	cysteine					2127:2134	cysteine	2127:2134	cysteine	2127:2134	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	43	theme	citric	2040:2045	arg1	metabolism					2068:2077	tyrosine metabolism	2059:2077	tyrosine metabolism	2059:2077	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	2	44	theme	yeast	461:465	arg1	YG					481:482	YG	481:482	YG	481:482	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	2	44	theme	yeast	461:465	arg1	glycoprotein					467:478	yeast glycoprotein	461:478	yeast glycoprotein (YG)	461:483	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	7	45	theme	Spearman	1227:1234	arg1	analysis					1248:1255	Spearman correlation analysis	1227:1255	Spearman correlation analysis	1227:1255	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	0	46	dep	composition	58:68	arg1	the					54:56	the	54:56	the	54:56	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	11	47	theme	16S-rRNA	2359:2366	arg1	metabolomics					2383:2394	the 16S-rRNA and untargeted metabolomics	2355:2394	the 16S-rRNA and untargeted metabolomics	2355:2394	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	9	48	theme	oleic	1909:1913	arg1	acid					1915:1918	oleic acid	1909:1918	oleic acid	1909:1918	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	8	49	theme	glycan	1543:1548	arg1	biosynthesis					1550:1561	glycan biosynthesis	1543:1561	glycan biosynthesis	1543:1561	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	11	50	theme	EP+YG	2419:2423	arg1	supplementation					2425:2439	EP+YG supplementation	2419:2439	EP+YG supplementation	2419:2439	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	6	51	theme	genus	1200:1204	arg1	levels					1206:1211	the phylum and genus levels	1185:1211	levels	1206:1211	Besides, EP+YG supplementation changed the microbiota composition by altering the community profile at the phylum and genus levels.
36311785	10	52	theme	tyrosine	2059:2066	arg1	glycolysis/gluconeogenesis					2012:2037	glycolysis/gluconeogenesis	2012:2037	glycolysis/gluconeogenesis	2012:2037	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	pathways					2195:2202	the most important enriched pathways	2167:2202	the most important enriched pathways identified with enrichment ratio >11	2167:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	metabolism					2111:2120	threonine metabolism	2101:2120	threonine metabolism	2101:2120	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	glycine					2080:2086	glycine	2080:2086	glycine	2080:2086	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	serine					2089:2094	serine	2089:2094	serine	2089:2094	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	cycle					2052:2056	citric acid cycle	2040:2056	citric acid cycle	2040:2056	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	cysteine					2127:2134	cysteine	2127:2134	cysteine	2127:2134	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	52	theme	tyrosine	2059:2066	arg1	metabolism					2068:2077	tyrosine metabolism	2059:2077	tyrosine metabolism	2059:2077	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	9	53	theme	pyruvic	1769:1775	arg1	acid					1777:1780	pyruvic acid	1769:1780	pyruvic acid	1769:1780	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	6	54	theme	phylum	1189:1194	arg1	levels					1206:1211	the phylum and genus levels	1185:1211	levels	1206:1211	Besides, EP+YG supplementation changed the microbiota composition by altering the community profile at the phylum and genus levels.
36311785	11	55	theme	metabolism	2530:2539	arg1	pathways					2541:2548	the important metabolism pathways	2516:2548	the important metabolism pathways	2516:2548	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	2	56	theme	Enteromorpha	424:435	arg1	EP					453:454	EP	453:454	EP	453:454	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	2	56	theme	Enteromorpha	424:435	arg1	polysaccharide					437:450	Enteromorpha polysaccharide	424:450	Enteromorpha polysaccharide (EP)	424:455	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	1	57	theme	carbohydrates	272:284	arg1	fermentation					248:259	the fermentation	244:259	the fermentation of complex carbohydrates	244:284	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	7	58	theme	microbiota	1356:1365	arg1	genera					1367:1372	microbiota genera	1356:1372	microbiota genera	1356:1372	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	7	59	theme	microbiota	1309:1318	arg1	genera					1320:1325	altered microbiota genera	1301:1325	altered microbiota genera	1301:1325	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	6	60	theme	community	1164:1172	arg1	profile					1174:1180	the community profile	1160:1180	the community profile	1160:1180	Besides, EP+YG supplementation changed the microbiota composition by altering the community profile at the phylum and genus levels.
36311785	10	61	theme	acid	2257:2260	arg1	biosynthesis					2262:2273	fatty acid biosynthesis	2251:2273	fatty acid biosynthesis	2251:2273	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	1	62	theme	immune	307:312	arg1	system					314:319	the immune system	303:319	the immune system	303:319	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	10	63	theme	fatty	2307:2311	arg1	acids					2313:2317	unsaturated fatty acids	2295:2317	unsaturated fatty acids	2295:2317	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	0	64	from	glycoprotein	173:184	arg1	chickens					189:196	chickens	189:196	chickens	189:196	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	10	65	theme	threonine	2101:2109	arg1	glycolysis/gluconeogenesis					2012:2037	glycolysis/gluconeogenesis	2012:2037	glycolysis/gluconeogenesis	2012:2037	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	pathways					2195:2202	the most important enriched pathways	2167:2202	the most important enriched pathways identified with enrichment ratio >11	2167:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	metabolism					2111:2120	threonine metabolism	2101:2120	threonine metabolism	2101:2120	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	glycine					2080:2086	glycine	2080:2086	glycine	2080:2086	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	serine					2089:2094	serine	2089:2094	serine	2089:2094	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	cycle					2052:2056	citric acid cycle	2040:2056	citric acid cycle	2040:2056	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	cysteine					2127:2134	cysteine	2127:2134	cysteine	2127:2134	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	65	theme	threonine	2101:2109	arg1	metabolism					2068:2077	tyrosine metabolism	2059:2077	tyrosine metabolism	2059:2077	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	2	66	from	supplementation	405:419	arg1	combination					488:498	combination	488:498	combination	488:498	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	2	67	theme	previous	372:379	arg1	study					381:385	our previous study	368:385	our previous study	368:385	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	4	68	theme	200mg/kg	917:924	arg1	EP					926:927	200mg/kg EP	917:927	200mg/kg EP	917:927	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	4	69	theme	16S-rRNA	720:727	arg1	technology					740:749	an integrated 16S-rRNA sequencing technology	706:749	an integrated 16S-rRNA sequencing technology	706:749	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	7	70	theme	fatty	1386:1390	arg1	acids					1392:1396	volatile fatty acids	1377:1396	volatile fatty acids	1377:1396	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	0	71	theme	Yeast	167:171	arg1	glycoprotein					173:184	Yeast glycoprotein	167:184	Yeast glycoprotein in chickens	167:196	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	10	72	theme	analysis	1975:1982	arg1	results					1984:1990	The quantitative enrichment analysis results	1947:1990	The quantitative enrichment analysis results	1947:1990	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	11	73	theme	intestinal	2451:2460	arg1	microbiota					2462:2471	intestinal microbiota	2451:2471	intestinal microbiota	2451:2471	Together, the 16S-rRNA and untargeted metabolomics results uncovered that EP+YG supplementation modulates intestinal microbiota and their metabolites, thereby influencing the important metabolism pathways, suggesting a potential feed additive.
36311785	10	74	theme	quantitative	1951:1962	arg1	results					1984:1990	The quantitative enrichment analysis results	1947:1990	The quantitative enrichment analysis results	1947:1990	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	75	theme	methionine	2140:2149	arg1	metabolism					2151:2160	methionine metabolism	2140:2160	methionine metabolism	2140:2160	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	6	76	theme	EP+YG	1091:1095	arg1	supplementation					1097:1111	EP+YG supplementation	1091:1111	EP+YG supplementation	1091:1111	Besides, EP+YG supplementation changed the microbiota composition by altering the community profile at the phylum and genus levels.
36311785	0	77	from	metabolites	110:120	arg1	metabolism					74:83	metabolism	74:83	metabolism	74:83	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	0	77	from	metabolites	110:120	arg1	composition					58:68	composition	58:68	composition	58:68	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	10	78	theme	enriched	2186:2193	arg1	glycolysis/gluconeogenesis					2012:2037	glycolysis/gluconeogenesis	2012:2037	glycolysis/gluconeogenesis	2012:2037	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	pathways					2195:2202	the most important enriched pathways	2167:2202	the most important enriched pathways identified with enrichment ratio >11	2167:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	metabolism					2111:2120	threonine metabolism	2101:2120	threonine metabolism	2101:2120	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	glycine					2080:2086	glycine	2080:2086	glycine	2080:2086	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	serine					2089:2094	serine	2089:2094	serine	2089:2094	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	cycle					2052:2056	citric acid cycle	2040:2056	citric acid cycle	2040:2056	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	cysteine					2127:2134	cysteine	2127:2134	cysteine	2127:2134	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	78	theme	enriched	2186:2193	arg1	metabolism					2068:2077	tyrosine metabolism	2059:2077	tyrosine metabolism	2059:2077	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	3	79	theme	polysaccharides	650:664	arg1	action					634:639	action	634:639	action of these polysaccharides	634:664	However, the mechanism of action of these polysaccharides remains elusive.
36311785	4	80	used	used	701:704	arg2	study					695:699	The present study	683:699	The present study	683:699	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	0	81	gly	glycoprotein	173:184	arg1	glycoprotein					173:184	Yeast glycoprotein	167:184	Yeast glycoprotein in chickens	167:196	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	2	82	theme	lipid	555:559	arg1	profile					561:567	serum lipid profile	549:567	serum lipid profile	549:567	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	0	83	from	alterations	39:49	arg1	metabolism					74:83	metabolism	74:83	metabolism	74:83	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	0	83	from	alterations	39:49	arg1	composition					58:68	composition	58:68	composition	58:68	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	8	84	theme	functional	1420:1429	arg1	analysis					1431:1438	Predicted functional analysis	1410:1438	Predicted functional analysis	1410:1438	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	9	85	theme	docosahexaenoic	1925:1939	arg1	acid					1941:1944	docosahexaenoic acid	1925:1944	docosahexaenoic acid	1925:1944	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	0	86	theme	microbiota	95:104	arg1	metabolism					74:83	metabolism	74:83	metabolism	74:83	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	0	86	theme	microbiota	95:104	arg1	composition					58:68	composition	58:68	composition	58:68	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	4	87	from	chickens	859:866	arg1	mechanism					803:811	the mechanism	799:811	the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG)	799:942	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	4	88	theme	untargeted	755:764	arg1	technique					779:787	untargeted metabolomics technique	755:787	untargeted metabolomics technique	755:787	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	10	89	theme	enrichment	2220:2229	arg1	ratio					2231:2235	enrichment ratio >11	2220:2239	enrichment ratio >11	2220:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	5	90	theme	caecal	1024:1029	arg1	microbiota					1031:1040	caecal microbiota	1024:1040	caecal microbiota	1024:1040	The results showed that EP+YG supplementation altered the overall structure of caecal microbiota as evidenced by β diversities analysis.
36311785	2	91	theme	fatty	574:578	arg1	metabolism					585:594	fatty acid metabolism	574:594	fatty acid metabolism	574:594	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	8	92	theme	EP+YG	1452:1456	arg1	supplementation					1458:1472	EP+YG supplementation	1452:1472	EP+YG supplementation	1452:1472	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	4	93	theme	EP+YG	826:830	arg1	supplementation					832:846	EP+YG supplementation	826:846	EP+YG supplementation	826:846	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	0	94	theme	dietary	127:133	arg1	polysaccharide					148:161	dietary Enteromorpha polysaccharide	127:161	dietary Enteromorpha polysaccharide	127:161	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	9	95	theme	metabolites	1715:1725	arg1	myriad					1698:1703	a myriad	1696:1703	a myriad of caecal metabolites	1696:1725	Metabolomics analysis confirmed that EP+YG supplementation modulates a myriad of caecal metabolites by increasing some metabolites, including pyruvic acid, pyridoxine, spermidine, spermine, and dopamine, and decreasing metabolites related to lipid metabolisms such as malonic acid, oleic acid, and docosahexaenoic acid.
36311785	7	96	theme	significant	1269:1279	arg1	correlation					1281:1291	a significant correlation	1267:1291	a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production	1267:1407	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	4	97	from	action	816:821	arg1	chickens					859:866	broiler chickens	851:866	broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG)	851:942	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	8	98	theme	amino	1497:1501	arg1	metabolism					1508:1517	amino acid metabolism	1497:1517	amino acid metabolism	1497:1517	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	2	99	theme	polysaccharide	437:450	arg1	supplementation					405:419	supplementation	405:419	supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination	405:498	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	7	100	theme	correlation	1236:1246	arg1	analysis					1248:1255	Spearman correlation analysis	1227:1255	Spearman correlation analysis	1227:1255	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	1	101	theme	gut	329:331	arg1	metabolites					352:362	gut microbiota-derived metabolites	329:362	gut microbiota-derived metabolites	329:362	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	4	102	from	mechanism	803:811	arg1	chickens					859:866	broiler chickens	851:866	broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG)	851:942	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	6	103	theme	microbiota	1125:1134	arg1	composition					1136:1146	the microbiota composition	1121:1146	the microbiota composition	1121:1146	Besides, EP+YG supplementation changed the microbiota composition by altering the community profile at the phylum and genus levels.
36311785	10	104	theme	acid	2047:2050	arg1	glycolysis/gluconeogenesis					2012:2037	glycolysis/gluconeogenesis	2012:2037	glycolysis/gluconeogenesis	2012:2037	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	pathways					2195:2202	the most important enriched pathways	2167:2202	the most important enriched pathways identified with enrichment ratio >11	2167:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	metabolism					2111:2120	threonine metabolism	2101:2120	threonine metabolism	2101:2120	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	glycine					2080:2086	glycine	2080:2086	glycine	2080:2086	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	serine					2089:2094	serine	2089:2094	serine	2089:2094	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	cycle					2052:2056	citric acid cycle	2040:2056	citric acid cycle	2040:2056	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	cysteine					2127:2134	cysteine	2127:2134	cysteine	2127:2134	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	104	theme	acid	2047:2050	arg1	metabolism					2068:2077	tyrosine metabolism	2059:2077	tyrosine metabolism	2059:2077	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	4	105	theme	action	816:821	arg1	mechanism					803:811	the mechanism	799:811	the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG)	799:942	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36311785	2	106	theme	glycoprotein	467:478	arg1	supplementation					405:419	supplementation	405:419	supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination	405:498	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	7	107	theme	acids	1392:1396	arg1	production					1398:1407	microbiota genera vs volatile fatty acids production	1356:1407	microbiota genera vs volatile fatty acids production	1356:1407	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	2	108	theme	antioxidant	525:535	arg1	activities					537:546	antioxidant activities	525:546	antioxidant activities	525:546	In our previous study, we reported that supplementation of Enteromorpha polysaccharide (EP) and yeast glycoprotein (YG) in combination synergistically improved antioxidant activities, serum lipid profile, and fatty acid metabolism in chicken.
36311785	8	109	theme	nucleotide	1520:1529	arg1	metabolism					1531:1540	nucleotide metabolism	1520:1540	nucleotide metabolism	1520:1540	Predicted functional analysis showed that EP+YG supplementation significantly enriched amino acid metabolism, nucleotide metabolism, glycan biosynthesis and metabolism, energy metabolism, and carbohydrate metabolism.
36311785	0	110	with	alterations	39:49	arg1	polysaccharide					148:161	dietary Enteromorpha polysaccharide	127:161	dietary Enteromorpha polysaccharide	127:161	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	0	110	with	alterations	39:49	arg1	glycoprotein					173:184	Yeast glycoprotein	167:184	Yeast glycoprotein in chickens	167:196	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	7	111	theme	volatile	1377:1384	arg1	acids					1392:1396	volatile fatty acids	1377:1396	volatile fatty acids	1377:1396	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	7	112	theme	genera	1367:1372	arg1	production					1398:1407	microbiota genera vs volatile fatty acids production	1356:1407	microbiota genera vs volatile fatty acids production	1356:1407	Furthermore, Spearman correlation analysis indicated a significant correlation between altered microbiota genera vs serum cytokine levels and microbiota genera vs volatile fatty acids production.
36311785	10	113	theme	important	2176:2184	arg1	glycolysis/gluconeogenesis					2012:2037	glycolysis/gluconeogenesis	2012:2037	glycolysis/gluconeogenesis	2012:2037	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	pathways					2195:2202	the most important enriched pathways	2167:2202	the most important enriched pathways identified with enrichment ratio >11	2167:2239	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	metabolism					2111:2120	threonine metabolism	2101:2120	threonine metabolism	2101:2120	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	glycine					2080:2086	glycine	2080:2086	glycine	2080:2086	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	serine					2089:2094	serine	2089:2094	serine	2089:2094	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	cycle					2052:2056	citric acid cycle	2040:2056	citric acid cycle	2040:2056	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	cysteine					2127:2134	cysteine	2127:2134	cysteine	2127:2134	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	10	113	theme	important	2176:2184	arg1	metabolism					2068:2077	tyrosine metabolism	2059:2077	tyrosine metabolism	2059:2077	The quantitative enrichment analysis results further showed that glycolysis/gluconeogenesis, citric acid cycle, tyrosine metabolism, glycine, serine, and threonine metabolism, and cysteine and methionine metabolism were the most important enriched pathways identified with enrichment ratio >11, whereas, fatty acid biosynthesis and biosynthesis of unsaturated fatty acids pathways were suppressed.
36311785	1	114	link	microbiota-derived	333:350	arg1	metabolites					352:362	gut microbiota-derived metabolites	329:362	gut microbiota-derived metabolites	329:362	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	1	115	theme	complex	264:270	arg1	carbohydrates					272:284	complex carbohydrates	264:284	complex carbohydrates	264:284	The intestinal microbiome is responsible for the fermentation of complex carbohydrates and orchestrates the immune system through gut microbiota-derived metabolites.
36311785	5	116	theme	diversities	1060:1070	arg1	analysis					1072:1079	β diversities analysis	1058:1079	β diversities analysis	1058:1079	The results showed that EP+YG supplementation altered the overall structure of caecal microbiota as evidenced by β diversities analysis.
36311785	0	117	from	polysaccharide	148:161	arg1	chickens					189:196	chickens	189:196	chickens	189:196	Microbiome-metabolome analysis reveals alterations in the composition and metabolism of caecal microbiota and metabolites with dietary Enteromorpha polysaccharide and Yeast glycoprotein in chickens.
36311785	4	118	theme	basal	872:876	arg1	diet					878:881	basal diet	872:881	basal diet	872:881	The present study used an integrated 16S-rRNA sequencing technology and untargeted metabolomics technique to reveal the mechanism of action of EP+YG supplementation in broiler chickens fed basal diet or diets supplemented with EP+YG (200mg/kg EP + 200mg/kg YG).
36732731	8	0	theme	Fucose-rich	1311:1321	arg1	polysaccharides					1332:1346	Fucose-rich sulfated polysaccharides	1311:1346	Fucose-rich sulfated polysaccharides (fucoidans)	1311:1358	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	0	theme	Fucose-rich	1311:1321	arg1	fucoidans					1349:1357	fucoidans	1349:1357	fucoidans	1349:1357	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	11	1	from	dysbiosis	2030:2038	arg1	recovery					2016:2023	recovery	2016:2023	recovery from dysbiosis	2016:2038	In the non-supplemented group, Parabacteroides mediated recovery from dysbiosis but failed to decolonize P. aeruginosa.
36732731	7	2	theme	multiple	1281:1288	arg1	glycans					1302:1308	multiple fucosylated glycans	1281:1308	multiple fucosylated glycans	1281:1308	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	9	3	theme	gastrointestinal	1588:1603	arg1	colonization					1605:1616	P. aeruginosa gastrointestinal colonization	1574:1616	P. aeruginosa gastrointestinal colonization	1574:1616	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36732731	6	4	theme	family	1069:1074	arg1	TpsA2/CdiA1					1112:1122	TpsA2/CdiA1	1112:1122	TpsA2/CdiA1	1112:1122	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	4	theme	family	1069:1074	arg1	proteins					1076:1083	two-partner secretion (TPS) family proteins	1041:1083	two-partner secretion (TPS) family proteins	1041:1083	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	4	theme	family	1069:1074	arg1	TpsA1/CdiA2					1096:1106	TpsA1/CdiA2	1096:1106	TpsA1/CdiA2	1096:1106	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	4	5	theme	hemagglutinin	733:745	arg1	interaction					754:764	hemagglutinin domain interaction	733:764	hemagglutinin domain interaction	733:764	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	13	6	theme	grade	2418:2422	arg1	fucoidans					2424:2432	nutritional grade fucoidans	2406:2432	nutritional grade fucoidans	2406:2432	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	12	7	theme	virulence	2255:2263	arg1	TpsA/CdiA					2273:2281	TpsA/CdiA	2273:2281	TpsA/CdiA	2273:2281	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	12	7	theme	virulence	2255:2263	arg1	factor					2265:2270	secreted virulence factor	2246:2270	secreted virulence factor (TpsA/CdiA) interaction with mucins	2246:2306	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	6	8	theme	TPS	1064:1066	arg1	TpsA2/CdiA1					1112:1122	TpsA2/CdiA1	1112:1122	TpsA2/CdiA1	1112:1122	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	8	theme	TPS	1064:1066	arg1	proteins					1076:1083	two-partner secretion (TPS) family proteins	1041:1083	two-partner secretion (TPS) family proteins	1041:1083	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	8	theme	TPS	1064:1066	arg1	TpsA1/CdiA2					1096:1106	TpsA1/CdiA2	1096:1106	TpsA1/CdiA2	1096:1106	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	10	9	from	reductions	1885:1894	arg1	Enterococcaceae					1931:1945	Enterococcaceae	1931:1945	Enterococcaceae	1931:1945	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	9	from	reductions	1885:1894	arg1	bloom					1899:1903	bloom	1899:1903	bloom	1899:1903	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	12	10	theme	Bacteroides	2347:2357	arg1	population					2359:2368	beneficial Bacteroides population	2336:2368	beneficial Bacteroides population	2336:2368	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	10	11	theme	post-infection	1827:1840	arg1	abundance					1848:1856	post-infection day-3 abundance	1827:1856	post-infection day-3 abundance	1827:1856	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	11	theme	post-infection	1827:1840	arg1	%					1864:1864	29-50%	1859:1864	29-50%	1859:1864	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	1	12	theme	intestinal	213:222	arg1	rates					233:237	Pseudomonas aeruginosa intestinal carriage rates	190:237	Pseudomonas aeruginosa intestinal carriage rates	190:237	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	12	13	theme	aeruginosa	2212:2221	arg1	decolonization					2191:2204	decolonization	2191:2204	decolonization	2191:2204	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	12	13	theme	aeruginosa	2212:2221	arg1	dysbiosis					2177:2185	dysbiosis	2177:2185	dysbiosis	2177:2185	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	6	14	theme	secretion	1053:1061	arg1	TpsA2/CdiA1					1112:1122	TpsA2/CdiA1	1112:1122	TpsA2/CdiA1	1112:1122	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	14	theme	secretion	1053:1061	arg1	proteins					1076:1083	two-partner secretion (TPS) family proteins	1041:1083	two-partner secretion (TPS) family proteins	1041:1083	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	14	theme	secretion	1053:1061	arg1	TpsA1/CdiA2					1096:1106	TpsA1/CdiA2	1096:1106	TpsA1/CdiA2	1096:1106	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	9	15	theme	antibiotic-induced	1527:1544	arg1	dysbiosis					1546:1554	antibiotic-induced dysbiosis	1527:1554	antibiotic-induced dysbiosis	1527:1554	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36732731	8	16	theme	N-terminal	1436:1445	arg1	TpsA					1471:1474	TpsA	1471:1474	TpsA (TpsA-NT-HAD) binding to mucins	1471:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	16	theme	N-terminal	1436:1445	arg1	domain					1461:1466	the recombinant N-terminal hemagglutinin domain	1420:1466	the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins	1420:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	9	17	dep	P.	1574:1575	arg1	aeruginosa					1577:1586	aeruginosa	1577:1586	aeruginosa	1577:1586	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36732731	8	18	theme	domain	1461:1466	arg1	inhibitors					1406:1415	potent inhibitors	1399:1415	potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins	1399:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	5	19	theme	mouse	874:878	arg1	model					880:884	a mouse model	872:884	a mouse model	872:884	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	0	20	from	gut	72:74	arg1	decolonization					26:39	decolonization	26:39	decolonization of Pseudomonas aeruginosa from gut	26:74	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	5	21	theme	nutritional	841:851	arg1	fucoidans					859:867	nutritional grade fucoidans	841:867	nutritional grade fucoidans	841:867	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	8	22	theme	TpsA	1471:1474	arg1	TpsA					1471:1474	TpsA	1471:1474	TpsA (TpsA-NT-HAD) binding to mucins	1471:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	22	theme	TpsA	1471:1474	arg1	domain					1461:1466	the recombinant N-terminal hemagglutinin domain	1420:1466	the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins	1420:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	10	23	theme	remarkable	1790:1799	arg1	expansion					1801:1809	remarkable expansion	1790:1809	remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%)	1790:1865	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	7	24	theme	Pfam	1213:1216	arg1	[ID					1229:1231	Pfam identifier [ID] PF05860	1213:1240	Pfam identifier [ID] PF05860	1213:1240	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	7	24	theme	Pfam	1213:1216	arg1	domain					1205:1210	a conserved hemagglutinin domain	1179:1210	a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1179:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	5	25	theme	grade	853:857	arg1	fucoidans					859:867	nutritional grade fucoidans	841:867	nutritional grade fucoidans	841:867	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	13	26	theme	aeruginosa	2568:2577	arg1	transmission					2538:2549	transmission	2538:2549	transmission	2538:2549	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	13	26	theme	aeruginosa	2568:2577	arg1	infection					2524:2532	infection	2524:2532	infection	2524:2532	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	5	27	theme	RNA	909:911	arg1	sequencing					913:922	16S ribosomal RNA sequencing	895:922	16S ribosomal RNA sequencing	895:922	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	10	28	theme	fucoidans	1643:1651	arg1	supplementation					1653:1667	prophylactic oral fucoidans supplementation	1625:1667	prophylactic oral fucoidans supplementation	1625:1667	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	5	29	used	used	890:893	arg2	We					813:814	We	813:814	We	813:814	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	1	30	theme	Pseudomonas	190:200	arg1	rates					233:237	Pseudomonas aeruginosa intestinal carriage rates	190:237	Pseudomonas aeruginosa intestinal carriage rates	190:237	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	12	31	from	gut	2228:2230	arg1	recovery					2163:2170	earlier recovery	2155:2170	earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut	2155:2230	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	10	32	theme	prophylactic	1625:1636	arg1	supplementation					1653:1667	prophylactic oral fucoidans supplementation	1625:1667	prophylactic oral fucoidans supplementation	1625:1667	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	7	33	contain	carry	1275:1279	arg2	glycans					1302:1308	multiple fucosylated glycans	1281:1308	multiple fucosylated glycans	1281:1308	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	7	33	contain	carry	1275:1279	arg1	mucins					1263:1268	mucins	1263:1268	mucins that carry multiple fucosylated glycans	1263:1308	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	0	34	theme	virulence	99:107	arg1	interactions					116:127	secreted virulence factor interactions	90:127	secreted virulence factor interactions with mucins	90:139	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	7	35	theme	Lectin	1125:1130	arg1	activity					1137:1144	Lectin like activity	1125:1144	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1125:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	10	36	theme	higher	1672:1677	arg1	proportion					1679:1688	a higher proportion	1670:1688	a higher proportion (60%) of the mice	1670:1706	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	36	theme	higher	1672:1677	arg1	%					1693:1693	60%	1691:1693	60%	1691:1693	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	5	37	theme	16S	895:897	arg1	sequencing					913:922	16S ribosomal RNA sequencing	895:922	16S ribosomal RNA sequencing	895:922	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	12	38	theme	marine	2116:2121	arg1	fucoidans					2133:2141	marine prebiotic fucoidans	2116:2141	marine prebiotic fucoidans	2116:2141	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	2	39	theme	modulation	549:558	arg1	properties					560:569	the anti-adherence and gut microbiota modulation properties	511:569	the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans	511:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	9	40	theme	mouse	1514:1518	arg1	model					1520:1524	a mouse model	1512:1524	a mouse model	1512:1524	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36732731	1	41	dep	BACKGROUND	179:188	arg1	higher					257:262	higher	257:262	higher	257:262	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	2	42	theme	gastrointestinal	471:486	arg1	tract					488:492	gastrointestinal tract	471:492	gastrointestinal tract	471:492	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	0	43	theme	Marine	0:5	arg1	prebiotics					7:16	Marine prebiotics	0:16	Marine prebiotics	0:16	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	1	44	theme	increased	341:349	arg1	risk					351:354	increased risk	341:354	increased risk of infections and antibiotic-associated diarrhea	341:403	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	12	45	theme	beneficial	2336:2345	arg1	population					2359:2368	beneficial Bacteroides population	2336:2368	beneficial Bacteroides population	2336:2368	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	2	46	theme	gut	534:536	arg1	properties					560:569	the anti-adherence and gut microbiota modulation properties	511:569	the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans	511:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	2	47	theme	anti-adherence	515:528	arg1	properties					560:569	the anti-adherence and gut microbiota modulation properties	511:569	the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans	511:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	13	48	theme	individuals	2501:2511	arg1	tract					2484:2488	gastrointestinal tract	2467:2488	gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa	2467:2577	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	6	49	theme	two-partner	1041:1051	arg1	TpsA2/CdiA1					1112:1122	TpsA2/CdiA1	1112:1122	TpsA2/CdiA1	1112:1122	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	49	theme	two-partner	1041:1051	arg1	proteins					1076:1083	two-partner secretion (TPS) family proteins	1041:1083	two-partner secretion (TPS) family proteins	1041:1083	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	49	theme	two-partner	1041:1051	arg1	TpsA1/CdiA2					1096:1106	TpsA1/CdiA2	1096:1106	TpsA1/CdiA2	1096:1106	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	2	50	theme	prebiotic	581:589	arg1	fucoidans					591:599	marine prebiotic fucoidans	574:599	marine prebiotic fucoidans	574:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	4	51	theme	lectin-based	685:696	arg1	assay					726:730	lectin-based enzyme-linked immunosorbent assay	685:730	lectin-based enzyme-linked immunosorbent assay	685:730	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	5	52	theme	fecal	935:939	arg1	composition					952:962	fecal microbiota composition	935:962	fecal microbiota composition	935:962	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	10	53	theme	mice	1703:1706	arg1	proportion					1679:1688	a higher proportion	1670:1688	a higher proportion (60%) of the mice	1670:1706	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	53	theme	mice	1703:1706	arg1	%					1693:1693	60%	1691:1693	60%	1691:1693	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	3	54	theme	METHODS	602:608	arg1	analysis					620:627	METHODS Proteomic analysis	602:627	METHODS Proteomic analysis of culture supernatant	602:650	METHODS Proteomic analysis of culture supernatant was performed by LC-MS/MS.
36732731	0	55	theme	aeruginosa	56:65	arg1	decolonization					26:39	decolonization	26:39	decolonization of Pseudomonas aeruginosa from gut	26:74	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	1	56	theme	diarrhea	396:403	arg1	risk					351:354	increased risk	341:354	increased risk of infections and antibiotic-associated diarrhea	341:403	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	10	57	theme	consequential	1871:1883	arg1	reductions					1885:1894	consequential reductions	1871:1894	consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations	1871:1957	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	1	58	theme	immunosuppressed	267:282	arg1	individuals					284:294	immunosuppressed individuals	267:294	immunosuppressed individuals	267:294	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	9	59	from	essential	1560:1568	arg1	model					1520:1524	a mouse model	1512:1524	a mouse model	1512:1524	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36732731	6	60	theme	supernatant	993:1003	arg1	proteins					1005:1012	culture supernatant proteins	985:1012	culture supernatant proteins	985:1012	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	4	61	theme	domain	747:752	arg1	interaction					754:764	hemagglutinin domain interaction	733:764	hemagglutinin domain interaction	733:764	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	3	62	theme	culture	632:638	arg1	supernatant					640:650	culture supernatant	632:650	culture supernatant	632:650	METHODS Proteomic analysis of culture supernatant was performed by LC-MS/MS.
36732731	7	63	from	N-terminal	1153:1162	arg1	activity					1137:1144	Lectin like activity	1125:1144	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1125:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	5	64	from	role	833:836	arg1	model					880:884	a mouse model	872:884	a mouse model	872:884	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	5	65	theme	microbiota	941:950	arg1	composition					952:962	fecal microbiota composition	935:962	fecal microbiota composition	935:962	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	4	66	link	enzyme-linked	698:710	arg1	assay					726:730	lectin-based enzyme-linked immunosorbent assay	685:730	lectin-based enzyme-linked immunosorbent assay	685:730	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	6	67	theme	proteins	1076:1083	arg1	secretion					1028:1036	the secretion	1024:1036	the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1	1024:1122	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	4	68	theme	immunosorbent	712:724	arg1	assay					726:730	lectin-based enzyme-linked immunosorbent assay	685:730	lectin-based enzyme-linked immunosorbent assay	685:730	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	10	69	dep	Bacteroides	1814:1824	arg1	abundance					1848:1856	post-infection day-3 abundance	1827:1856	post-infection day-3 abundance	1827:1856	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	69	dep	Bacteroides	1814:1824	arg1	%					1864:1864	29-50%	1859:1864	29-50%	1859:1864	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	13	70	theme	nutritional	2406:2416	arg1	fucoidans					2424:2432	nutritional grade fucoidans	2406:2432	nutritional grade fucoidans	2406:2432	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	8	71	theme	sulfated	1323:1330	arg1	polysaccharides					1332:1346	Fucose-rich sulfated polysaccharides	1311:1346	Fucose-rich sulfated polysaccharides (fucoidans)	1311:1358	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	71	theme	sulfated	1323:1330	arg1	fucoidans					1349:1357	fucoidans	1349:1357	fucoidans	1349:1357	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	10	72	from	expansion	1801:1809	arg1	Enterococcaceae					1931:1945	Enterococcaceae	1931:1945	Enterococcaceae	1931:1945	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	72	from	expansion	1801:1809	arg1	bloom					1899:1903	bloom	1899:1903	bloom	1899:1903	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	73	theme	resisted	1739:1746	arg1	re-colonization					1748:1762	resisted re-colonization	1739:1762	resisted re-colonization	1739:1762	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	12	74	theme	secreted	2246:2253	arg1	TpsA/CdiA					2273:2281	TpsA/CdiA	2273:2281	TpsA/CdiA	2273:2281	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	12	74	theme	secreted	2246:2253	arg1	factor					2265:2270	secreted virulence factor	2246:2270	secreted virulence factor (TpsA/CdiA) interaction with mucins	2246:2306	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	13	75	theme	gastrointestinal	2467:2482	arg1	tract					2484:2488	gastrointestinal tract	2467:2488	gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa	2467:2577	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	8	76	theme	potent	1399:1404	arg1	inhibitors					1406:1415	potent inhibitors	1399:1415	potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins	1399:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	0	77	with	interactions	116:127	arg1	mucins					134:139	mucins	134:139	mucins	134:139	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	1	78	theme	carriage	224:231	arg1	rates					233:237	Pseudomonas aeruginosa intestinal carriage rates	190:237	Pseudomonas aeruginosa intestinal carriage rates	190:237	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	6	79	dep	RESULTS	965:971	arg1	Analysis					973:980	Analysis	973:980	RESULTS Analysis of culture supernatant proteins	965:1012	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	5	80	theme	fucoidans	859:867	arg1	role					833:836	the role	829:836	the role of nutritional grade fucoidans in a mouse model	829:884	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	12	81	with	interaction	2284:2294	arg1	mucins					2301:2306	mucins	2301:2306	mucins	2301:2306	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	8	82	theme	sulfated	1364:1371	arg1	dextrans					1373:1380	sulfated dextrans	1364:1380	sulfated dextrans	1364:1380	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	83	theme	recombinant	1424:1434	arg1	TpsA					1471:1474	TpsA	1471:1474	TpsA (TpsA-NT-HAD) binding to mucins	1471:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	83	theme	recombinant	1424:1434	arg1	domain					1461:1466	the recombinant N-terminal hemagglutinin domain	1420:1466	the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins	1420:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	10	84	theme	Bacteroides	1814:1824	arg1	reductions					1885:1894	consequential reductions	1871:1894	consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations	1871:1957	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	84	theme	Bacteroides	1814:1824	arg1	expansion					1801:1809	remarkable expansion	1790:1809	remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%)	1790:1865	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	2	85	theme	intestinal	416:425	arg1	dysbiosis					427:435	intestinal dysbiosis	416:435	intestinal dysbiosis	416:435	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	0	86	theme	Bacteroides	155:165	arg1	population					167:176	Bacteroides population	155:176	Bacteroides population	155:176	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	4	87	with	inhibition	770:779	arg1	biomolecules					786:797	biomolecules	786:797	biomolecules	786:797	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	8	88	theme	hemagglutinin	1447:1459	arg1	TpsA					1471:1474	TpsA	1471:1474	TpsA (TpsA-NT-HAD) binding to mucins	1471:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	8	88	theme	hemagglutinin	1447:1459	arg1	domain					1461:1466	the recombinant N-terminal hemagglutinin domain	1420:1466	the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins	1420:1506	Fucose-rich sulfated polysaccharides (fucoidans) and sulfated dextrans were found to be potent inhibitors of the recombinant N-terminal hemagglutinin domain of TpsA (TpsA-NT-HAD) binding to mucins.
36732731	13	89	theme	prophylactic	2386:2397	arg1	use					2399:2401	the prophylactic use	2382:2401	the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa	2382:2577	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	4	90	with	interaction	754:764	arg1	biomolecules					786:797	biomolecules	786:797	biomolecules	786:797	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	7	91	theme	conserved	1181:1189	arg1	[ID					1229:1231	Pfam identifier [ID] PF05860	1213:1240	Pfam identifier [ID] PF05860	1213:1240	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	7	91	theme	conserved	1181:1189	arg1	domain					1205:1210	a conserved hemagglutinin domain	1179:1210	a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1179:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	12	92	from	decolonization	2191:2204	arg1	recovery					2163:2170	earlier recovery	2155:2170	earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut	2155:2230	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	7	93	theme	hemagglutinin	1191:1203	arg1	[ID					1229:1231	Pfam identifier [ID] PF05860	1213:1240	Pfam identifier [ID] PF05860	1213:1240	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	7	93	theme	hemagglutinin	1191:1203	arg1	domain					1205:1210	a conserved hemagglutinin domain	1179:1210	a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1179:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	1	94	contain	have	336:339	arg1	individuals					284:294	immunosuppressed individuals	267:294	immunosuppressed individuals	267:294	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	1	94	contain	have	336:339	arg2	risk					351:354	increased risk	341:354	increased risk of infections and antibiotic-associated diarrhea	341:403	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	1	94	contain	have	336:339	arg1	patients					313:320	hospitalized patients	300:320	hospitalized patients	300:320	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	5	95	theme	ribosomal	899:907	arg1	sequencing					913:922	16S ribosomal RNA sequencing	895:922	16S ribosomal RNA sequencing	895:922	We investigated the role of nutritional grade fucoidans in a mouse model and used 16S ribosomal RNA sequencing to examine fecal microbiota composition.
36732731	4	96	with	assay	726:730	arg1	biomolecules					786:797	biomolecules	786:797	biomolecules	786:797	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	7	97	theme	TpsA	1167:1170	arg1	N-terminal					1153:1162	N-terminal	1153:1162	N-terminal	1153:1162	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	7	98	theme	identifier	1218:1227	arg1	[ID					1229:1231	Pfam identifier [ID] PF05860	1213:1240	Pfam identifier [ID] PF05860	1213:1240	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	7	98	theme	identifier	1218:1227	arg1	domain					1205:1210	a conserved hemagglutinin domain	1179:1210	a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1179:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	13	99	theme	fucoidans	2424:2432	arg1	use					2399:2401	the prophylactic use	2382:2401	the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa	2382:2577	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	0	100	theme	secreted	90:97	arg1	interactions					116:127	secreted virulence factor interactions	90:127	secreted virulence factor interactions with mucins	90:139	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	12	101	theme	earlier	2155:2161	arg1	recovery					2163:2170	earlier recovery	2155:2170	earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut	2155:2230	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	2	102	theme	fucoidans	591:599	arg1	properties					560:569	the anti-adherence and gut microbiota modulation properties	511:569	the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans	511:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	10	103	theme	oral	1638:1641	arg1	supplementation					1653:1667	prophylactic oral fucoidans supplementation	1625:1667	prophylactic oral fucoidans supplementation	1625:1667	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	0	104	theme	factor	109:114	arg1	interactions					116:127	secreted virulence factor interactions	90:127	secreted virulence factor interactions with mucins	90:139	Marine prebiotics mediate decolonization of Pseudomonas aeruginosa from gut by inhibiting secreted virulence factor interactions with mucins and enriching Bacteroides population.
36732731	9	105	from	model	1520:1524	arg1	essential					1560:1568	essential	1560:1568	essential	1560:1568	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36732731	10	106	dep	bloom	1899:1903	arg1	populations					1947:1957	populations	1947:1957	populations	1947:1957	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	11	107	theme	non-supplemented	1967:1982	arg1	group					1984:1988	the non-supplemented group	1963:1988	the non-supplemented group	1963:1988	In the non-supplemented group, Parabacteroides mediated recovery from dysbiosis but failed to decolonize P. aeruginosa.
36732731	12	108	theme	prebiotic	2123:2131	arg1	fucoidans					2133:2141	marine prebiotic fucoidans	2116:2141	marine prebiotic fucoidans	2116:2141	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	7	109	theme	like	1132:1135	arg1	activity					1137:1144	Lectin like activity	1125:1144	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860)	1125:1241	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	10	110	theme	day-3	1842:1846	arg1	abundance					1848:1856	post-infection day-3 abundance	1827:1856	post-infection day-3 abundance	1827:1856	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	10	110	theme	day-3	1842:1846	arg1	%					1864:1864	29-50%	1859:1864	29-50%	1859:1864	After prophylactic oral fucoidans supplementation, a higher proportion (60%) of the mice were decolonized over time and resisted re-colonization, this was associated with remarkable expansion of Bacteroides (post-infection day-3 abundance, 29-50%) and consequential reductions in bloom of Enterobacteriaceae and Enterococcaceae populations.
36732731	2	111	theme	microbiota	538:547	arg1	properties					560:569	the anti-adherence and gut microbiota modulation properties	511:569	the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans	511:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	12	112	from	dysbiosis	2177:2185	arg1	recovery					2163:2170	earlier recovery	2155:2170	earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut	2155:2230	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	1	113	dep	Pseudomonas	190:200	arg1	aeruginosa					202:211	aeruginosa	202:211	aeruginosa	202:211	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	13	114	theme	at-risk	2493:2499	arg1	individuals					2501:2511	at-risk individuals	2493:2511	at-risk individuals	2493:2511	We suggest the prophylactic use of nutritional grade fucoidans to decolonize P. aeruginosa from gastrointestinal tract of at-risk individuals to prevent infection and transmission of colonizing P. aeruginosa.
36732731	4	115	theme	enzyme-linked	698:710	arg1	assay					726:730	lectin-based enzyme-linked immunosorbent assay	685:730	lectin-based enzyme-linked immunosorbent assay	685:730	Using lectin-based enzyme-linked immunosorbent assay, hemagglutinin domain interaction and inhibition with biomolecules were studied.
36732731	1	116	theme	infections	359:368	arg1	risk					351:354	increased risk	341:354	increased risk of infections and antibiotic-associated diarrhea	341:403	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	2	117	theme	marine	574:579	arg1	fucoidans					591:599	marine prebiotic fucoidans	574:599	marine prebiotic fucoidans	574:599	To combat intestinal dysbiosis and decolonize P. aeruginosa from gastrointestinal tract, we investigated the anti-adherence and gut microbiota modulation properties of marine prebiotic fucoidans.
36732731	7	118	theme	fucosylated	1290:1300	arg1	glycans					1302:1308	multiple fucosylated glycans	1281:1308	multiple fucosylated glycans	1281:1308	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	1	119	theme	antibiotic-associated	374:394	arg1	diarrhea					396:403	antibiotic-associated diarrhea	374:403	antibiotic-associated diarrhea	374:403	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	12	120	theme	population	2359:2368	arg1	growth					2326:2331	the growth	2322:2331	the growth of beneficial Bacteroides population	2322:2368	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	12	121	theme	factor	2265:2270	arg1	interaction					2284:2294	secreted virulence factor (TpsA/CdiA) interaction	2246:2294	secreted virulence factor (TpsA/CdiA) interaction with mucins	2246:2306	CONCLUSIONS Supplementing diet with marine prebiotic fucoidans can mediate earlier recovery from dysbiosis and decolonization of P. aeruginosa from gut by inhibiting secreted virulence factor (TpsA/CdiA) interaction with mucins and promoting the growth of beneficial Bacteroides population.
36732731	7	122	gly	fucosylated	1290:1300	arg1	glycans					1302:1308	multiple fucosylated glycans	1281:1308	multiple fucosylated glycans	1281:1308	Lectin like activity at the N-terminal of TpsA due to a conserved hemagglutinin domain (Pfam identifier [ID] PF05860) mediates binding to mucins that carry multiple fucosylated glycans.
36732731	3	123	theme	Proteomic	610:618	arg1	analysis					620:627	METHODS Proteomic analysis	602:627	METHODS Proteomic analysis of culture supernatant	602:650	METHODS Proteomic analysis of culture supernatant was performed by LC-MS/MS.
36732731	6	124	theme	proteins	1005:1012	arg1	Analysis					973:980	Analysis	973:980	RESULTS Analysis of culture supernatant proteins	965:1012	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	6	125	theme	culture	985:991	arg1	supernatant					993:1003	culture supernatant	985:1003	culture supernatant proteins	985:1012	RESULTS Analysis of culture supernatant proteins indicated the secretion of two-partner secretion (TPS) family proteins, including TpsA1/CdiA2 and TpsA2/CdiA1.
36732731	1	126	theme	hospitalized	300:311	arg1	patients					313:320	hospitalized patients	300:320	hospitalized patients	300:320	BACKGROUND Pseudomonas aeruginosa intestinal carriage rates are significantly higher in immunosuppressed individuals and hospitalized patients who therefore have increased risk of infections and antibiotic-associated diarrhea.
36732731	3	127	theme	supernatant	640:650	arg1	analysis					620:627	METHODS Proteomic analysis	602:627	METHODS Proteomic analysis of culture supernatant	602:650	METHODS Proteomic analysis of culture supernatant was performed by LC-MS/MS.
36732731	9	128	theme	P.	1574:1575	arg1	colonization					1605:1616	P. aeruginosa gastrointestinal colonization	1574:1616	P. aeruginosa gastrointestinal colonization	1574:1616	In a mouse model, antibiotic-induced dysbiosis was essential for P. aeruginosa gastrointestinal colonization.
36628918	7	0	theme	colonic	736:742	arg1	fermentation					744:755	colonic fermentation	736:755	colonic fermentation model	736:761	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	0	1	dep	in	128:129	arg1	vitro					131:135	vitro	131:135	vitro	131:135	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	9	2	theme	barrier	1109:1115	arg1	function					1117:1124	barrier function	1109:1124	barrier function	1109:1124	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	1	3	theme	polymerization	226:239	arg1	degree					216:221	a low degree	210:221	a low degree of polymerization	210:239	Human body can digest only a few sugars with a low degree of polymerization.
36628918	7	4	theme	adlay	840:844	arg1	microbiota					876:885	adlay polysaccharides-treated fecal microbiota	840:885	adlay polysaccharides-treated fecal microbiota	840:885	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	9	5	contain	has	1133:1135	arg1	which					1127:1131	which	1127:1131	which	1127:1131	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	9	5	contain	has	1133:1135	arg2	potential					1141:1149	the potential to be developed as novel functional food ingredients to protect intestinal health	1137:1231	the potential to be developed as novel functional food ingredients to protect intestinal health	1137:1231	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	5	6	theme	adlay	620:624	arg1	polysaccharide					626:639	adlay polysaccharide	620:639	adlay polysaccharide	620:639	Major molecular weight of adlay polysaccharide is 27 kDa.
36628918	2	7	theme	microbiota	339:348	arg1	composition					350:360	gut microbiota composition	335:360	gut microbiota composition	335:360	The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health.
36628918	0	8	theme	Clostridioides	97:110	arg1	difficile					112:120	Clostridioides difficile	97:120	Clostridioides difficile in an in vitro colonic fermentation model	97:162	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	5	9	theme	polysaccharide	626:639	arg1	weight					610:615	Major molecular weight	594:615	Major molecular weight of adlay polysaccharide	594:639	Major molecular weight of adlay polysaccharide is 27 kDa.
36628918	8	10	theme	adlay	901:905	arg1	polysaccharide					907:920	adlay polysaccharide	901:920	adlay polysaccharide	901:920	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	4	11	theme	dehulled	463:470	arg1	polysaccharide					486:499	dehulled adlay-derived polysaccharide	463:499	dehulled adlay-derived polysaccharide	463:499	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
36628918	9	12	theme	functional	1176:1185	arg1	ingredients					1192:1202	novel functional food ingredients	1170:1202	novel functional food ingredients	1170:1202	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	2	13	theme	carbohydrates	258:270	arg1	rest					246:249	The rest	242:249	The rest of the carbohydrates	242:270	The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health.
36628918	5	14	theme	Major	594:598	arg1	weight					610:615	Major molecular weight	594:615	Major molecular weight of adlay polysaccharide	594:639	Major molecular weight of adlay polysaccharide is 27 kDa.
36628918	8	15	theme	proteins	964:971	arg1	expression					935:944	the expression	931:944	the expression of tight junction proteins and mucin in intestinal cells	931:1001	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	4	16	theme	adlay-derived	472:484	arg1	polysaccharide					486:499	dehulled adlay-derived polysaccharide	463:499	dehulled adlay-derived polysaccharide	463:499	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
36628918	5	17	theme	molecular	600:608	arg1	weight					610:615	Major molecular weight	594:615	Major molecular weight of adlay polysaccharide	594:639	Major molecular weight of adlay polysaccharide is 27 kDa.
36628918	2	18	theme	symbiotic	305:313	arg1	bacteria					315:322	gastrointestinal symbiotic bacteria	288:322	gastrointestinal symbiotic bacteria	288:322	The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health.
36628918	3	19	theme	homologous	410:419	arg1	Adlay					380:384	Adlay	380:384	Adlay	380:384	Adlay is a medicinal and food homologous crop.
36628918	3	19	theme	homologous	410:419	arg1	crop					421:424	a medicinal and food homologous crop	389:424	a medicinal and food homologous crop	389:424	Adlay is a medicinal and food homologous crop.
36628918	9	20	theme	adlay	1026:1030	arg1	polysaccharide					1032:1045	adlay polysaccharide	1026:1045	adlay polysaccharide	1026:1045	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	9	20	theme	adlay	1026:1030	arg1	prebiotics					1062:1071	prebiotics	1062:1071	prebiotics	1062:1071	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	4	21	theme	difficile	573:581	arg1	infection					583:591	Clostridioides difficile infection	558:591	Clostridioides difficile infection	558:591	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
36628918	2	22	theme	gastrointestinal	288:303	arg1	bacteria					315:322	gastrointestinal symbiotic bacteria	288:322	gastrointestinal symbiotic bacteria	288:322	The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health.
36628918	8	23	theme	junction	955:962	arg1	proteins					964:971	tight junction proteins	949:971	tight junction proteins	949:971	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	4	24	theme	Clostridioides	558:571	arg1	infection					583:591	Clostridioides difficile infection	558:591	Clostridioides difficile infection	558:591	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
36628918	0	25	theme	in	128:129	arg1	model					158:162	an in vitro colonic fermentation model	125:162	an in vitro colonic fermentation model	125:162	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	7	26	theme	condition	820:828	arg1	medium					830:835	the condition medium	816:835	the condition medium of adlay polysaccharides-treated fecal microbiota	816:885	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	8	27	theme	tight	949:953	arg1	proteins					964:971	tight junction proteins	949:971	tight junction proteins	949:971	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	0	28	theme	polysaccharide	10:23	arg1	Effect					0:5	Effect	0:5	Effect of polysaccharide	0:23	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	9	29	used	used	1054:1057	arg2	prebiotics					1062:1071	prebiotics	1062:1071	prebiotics	1062:1071	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	9	29	used	used	1054:1057	arg2	polysaccharide					1032:1045	adlay polysaccharide	1026:1045	adlay polysaccharide	1026:1045	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	7	30	theme	fermentation	744:755	arg1	model					757:761	colonic fermentation model	736:761	colonic fermentation model	736:761	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	1	31	theme	Human	165:169	arg1	body					171:174	Human body	165:174	Human body	165:174	Human body can digest only a few sugars with a low degree of polymerization.
36628918	6	32	theme	adlay	710:714	arg1	polysaccharides					716:730	adlay polysaccharides	710:730	adlay polysaccharides	710:730	The growth of next-generation probiotics were promoted by adlay polysaccharides.
36628918	0	33	theme	dehulled	38:45	arg1	adlay					47:51	dehulled adlay	38:51	dehulled adlay	38:51	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	0	34	theme	colonic	137:143	arg1	model					158:162	an in vitro colonic fermentation model	125:162	an in vitro colonic fermentation model	125:162	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	7	35	theme	microbiota	876:885	arg1	medium					830:835	the condition medium	816:835	the condition medium of adlay polysaccharides-treated fecal microbiota	816:885	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	3	36	theme	food	405:408	arg1	Adlay					380:384	Adlay	380:384	Adlay	380:384	Adlay is a medicinal and food homologous crop.
36628918	3	36	theme	food	405:408	arg1	crop					421:424	a medicinal and food homologous crop	389:424	a medicinal and food homologous crop	389:424	Adlay is a medicinal and food homologous crop.
36628918	8	37	from	expression	935:944	arg1	cells					997:1001	intestinal cells	986:1001	intestinal cells	986:1001	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	9	38	theme	novel	1170:1174	arg1	ingredients					1192:1202	novel functional food ingredients	1170:1202	novel functional food ingredients	1170:1202	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	4	39	link	adlay-derived	472:484	arg1	polysaccharide					486:499	dehulled adlay-derived polysaccharide	463:499	dehulled adlay-derived polysaccharide	463:499	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
36628918	7	40	theme	polysaccharides-treated	846:868	arg1	microbiota					876:885	adlay polysaccharides-treated fecal microbiota	840:885	adlay polysaccharides-treated fecal microbiota	840:885	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	8	41	theme	mucin	977:981	arg1	expression					935:944	the expression	931:944	the expression of tight junction proteins and mucin in intestinal cells	931:1001	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	2	42	theme	gut	335:337	arg1	composition					350:360	gut microbiota composition	335:360	gut microbiota composition	335:360	The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health.
36628918	3	43	theme	medicinal	391:399	arg1	Adlay					380:384	Adlay	380:384	Adlay	380:384	Adlay is a medicinal and food homologous crop.
36628918	3	43	theme	medicinal	391:399	arg1	crop					421:424	a medicinal and food homologous crop	389:424	a medicinal and food homologous crop	389:424	Adlay is a medicinal and food homologous crop.
36628918	0	44	theme	fermentation	145:156	arg1	model					158:162	an in vitro colonic fermentation model	125:162	an in vitro colonic fermentation model	125:162	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	9	45	theme	food	1187:1190	arg1	ingredients					1192:1202	novel functional food ingredients	1170:1202	novel functional food ingredients	1170:1202	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	0	46	from	difficile	112:120	arg1	model					158:162	an in vitro colonic fermentation model	125:162	an in vitro colonic fermentation model	125:162	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	8	47	theme	intestinal	986:995	arg1	cells					997:1001	intestinal cells	986:1001	intestinal cells	986:1001	In addition, adlay polysaccharide promoted the expression of tight junction proteins and mucin in intestinal cells.
36628918	7	48	theme	fecal	870:874	arg1	microbiota					876:885	adlay polysaccharides-treated fecal microbiota	840:885	adlay polysaccharides-treated fecal microbiota	840:885	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	6	49	theme	probiotics	682:691	arg1	growth					656:661	The growth	652:661	The growth of next-generation probiotics	652:691	The growth of next-generation probiotics were promoted by adlay polysaccharides.
36628918	1	50	theme	low	212:214	arg1	degree					216:221	a low degree	210:221	a low degree of polymerization	210:239	Human body can digest only a few sugars with a low degree of polymerization.
36628918	0	51	theme	gut	67:69	arg1	microbiota					71:80	gut microbiota	67:80	gut microbiota	67:80	Effect of polysaccharide derived from dehulled adlay on regulating gut microbiota and inhibiting Clostridioides difficile in an in vitro colonic fermentation model.
36628918	2	52	theme	human	366:370	arg1	health					372:377	human health	366:377	human health	366:377	The rest of the carbohydrates become food for gastrointestinal symbiotic bacteria, affecting gut microbiota composition and human health.
36628918	6	53	theme	next-generation	666:680	arg1	probiotics					682:691	next-generation probiotics	666:691	next-generation probiotics	666:691	The growth of next-generation probiotics were promoted by adlay polysaccharides.
36628918	7	54	theme	C.	777:778	arg1	difficile					780:788	C. difficile	777:788	C. difficile	777:788	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	4	55	theme	gut	511:513	arg1	microbiota					515:524	gut microbiota	511:524	gut microbiota	511:524	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
36628918	7	56	theme	difficile	780:788	arg1	ratio					768:772	the ratio	764:772	the ratio of C. difficile	764:788	In colonic fermentation model, the ratio of C. difficile was decreased when adding the condition medium of adlay polysaccharides-treated fecal microbiota.
36628918	9	57	theme	intestinal	1215:1224	arg1	health					1226:1231	intestinal health	1215:1231	intestinal health	1215:1231	This study shows that adlay polysaccharide can be used as prebiotics to regulate microbiota and maintain barrier function, which has the potential to be developed as novel functional food ingredients to protect intestinal health.
36628918	4	58	theme	barrier	530:536	arg1	function					538:545	barrier function	530:545	barrier function	530:545	The study aims to determine whether dehulled adlay-derived polysaccharide regulates gut microbiota and barrier function to against Clostridioides difficile infection.
35976799	12	0	theme	significant	1686:1696	arg1	implications					1698:1709	significant implications	1686:1709	significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources	1686:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	8	1	theme	PRACTICAL	950:958	arg1	APPLICATIONS					960:971	PRACTICAL APPLICATIONS	950:971	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.	950:1095	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	2	2	theme	molar	357:361	arg1	ratio					363:367	a molar ratio	355:367	a molar ratio of 2.3: 1.5: 1.5	355:384	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	12	3	dep	processing	1759:1768	arg1	help					1798:1801	help	1798:1801	can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources	1784:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	9	4	theme	functions	1292:1300	arg1	variety					1270:1276	a variety	1268:1276	a variety of biological functions	1268:1300	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	9	4	theme	functions	1292:1300	arg1	functions					1292:1300	biological functions	1281:1300	biological functions	1281:1300	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	6	5	theme	IκB	846:848	arg1	phosphorylation					827:841	the phosphorylation	823:841	the phosphorylation of IκB and p65	823:856	Furthermore, AP2-c inhibited the phosphorylation of IκB and p65 via NF-κB pathway.
35976799	10	6	theme	structural	1430:1439	arg1	features					1441:1448	structural features	1430:1448	structural features	1430:1448	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	5	7	theme	mRNA	689:692	arg1	levels					705:710	the mRNA expression levels	685:710	the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages	685:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	12	8	theme	wasting	1867:1873	arg1	resources					1875:1883	wasting resources	1867:1883	wasting resources	1867:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	8	9	dep	APPLICATIONS	960:971	arg1	abandoned					1032:1040	abandoned	1032:1040	was always abandoned as waste	1021:1049	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	8	9	dep	APPLICATIONS	960:971	arg1	used					1074:1077	used	1074:1077	had not been fully used for exploitation	1055:1094	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	7	10	theme	obvious	914:920	arg1	activity					940:947	obvious anti-inflammatory activity	914:947	obvious anti-inflammatory activity	914:947	The results indicated that AP2-c had obvious anti-inflammatory activity.
35976799	9	11	theme	more	1128:1131	arg1	half					1138:1141	more than half	1128:1141	more than half of the total plant's weight	1128:1169	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	5	12	from	levels	705:710	arg1	macrophages					752:762	LPS-induced macrophages	740:762	LPS-induced macrophages	740:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	8	13	used	used	1074:1077	arg2	waste					1045:1049	waste	1045:1049	waste	1045:1049	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	8	13	used	used	1074:1077	arg2	okra					1016:1019	lignified okra	1006:1019	lignified okra	1006:1019	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	9	14	theme	than	1133:1136	arg1	half					1138:1141	more than half	1128:1141	more than half of the total plant's weight	1128:1169	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	0	15	theme	polysaccharide	71:84	arg1	AP2-c					86:90	a pectin polysaccharide AP2-c	62:90	a pectin polysaccharide AP2-c from the lignified okra	62:114	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	2	16	theme	monosaccharide	240:253	arg1	analysis					267:274	The monosaccharide composition analysis	236:274	The monosaccharide composition analysis	236:274	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	1	17	theme	polysaccharide	141:154	arg1	AP2-c					156:160	a pectin polysaccharide AP2-c	132:160	a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da	132:196	In this paper, a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da was obtained from the lignified okra.
35976799	9	18	theme	total	1150:1154	arg1	weight					1164:1169	the total plant's weight	1146:1169	the total plant's weight	1146:1169	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	4	19	dep	1→	644:645	arg1	α-L-Rhap-					634:642	→3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→	596:645	α-L-Rhap-	634:642	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	6	20	theme	NF-κB	862:866	arg1	pathway					868:874	NF-κB pathway	862:874	NF-κB pathway	862:874	Furthermore, AP2-c inhibited the phosphorylation of IκB and p65 via NF-κB pathway.
35976799	11	21	theme	inflammatory	1647:1658	arg1	factors					1660:1666	related inflammatory factors	1639:1666	related inflammatory factors	1639:1666	It was detected that AP2-c exhibited anti-inflammatory activity by blocking NF-κB pathway and thus lowering the expression of related inflammatory factors.
35976799	0	22	theme	lignified	101:109	arg1	okra					111:114	the lignified okra	97:114	the lignified okra	97:114	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	6	23	theme	p65	854:856	arg1	phosphorylation					827:841	the phosphorylation	823:841	the phosphorylation of IκB and p65	823:856	Furthermore, AP2-c inhibited the phosphorylation of IκB and p65 via NF-κB pathway.
35976799	2	24	dep	2.3	372:374	arg1	1.5					382:384	1.5	382:384	1.5	382:384	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	2	24	dep	2.3	372:374	arg1	1.5					377:379	1.5	377:379	1.5	377:379	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	0	25	from	activity	50:57	arg1	okra					111:114	the lignified okra	97:114	the lignified okra	97:114	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	7	26	contain	had	910:912	arg2	activity					940:947	obvious anti-inflammatory activity	914:947	obvious anti-inflammatory activity	914:947	The results indicated that AP2-c had obvious anti-inflammatory activity.
35976799	7	26	contain	had	910:912	arg1	AP2-c					904:908	AP2-c	904:908	AP2-c	904:908	The results indicated that AP2-c had obvious anti-inflammatory activity.
35976799	0	27	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	10	28	theme	pectin	1333:1338	arg1	AP2-c					1355:1359	the purified pectin polysaccharide AP2-c	1320:1359	the purified pectin polysaccharide AP2-c	1320:1359	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	3	29	theme	AP2-c	452:456	arg1	chain					443:447	the main chain	434:447	the main chain of AP2-c	434:456	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	5	30	theme	expression	694:703	arg1	levels					705:710	the mRNA expression levels	685:710	the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages	685:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	9	31	theme	cell	1191:1194	arg1	components					1238:1247	the main components	1229:1247	the main components of okra	1229:1255	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	9	31	theme	cell	1191:1194	arg1	polysaccharides					1201:1215	cell wall polysaccharides	1191:1215	cell wall polysaccharides	1191:1215	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	12	32	theme	processing	1759:1768	arg1	application					1731:1741	the value-added application	1715:1741	the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources	1715:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	5	33	theme	LPS-induced	740:750	arg1	macrophages					752:762	LPS-induced macrophages	740:762	LPS-induced macrophages	740:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	3	34	theme	structural	391:400	arg1	characterization					402:417	The structural characterization	387:417	The structural characterization	387:417	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	11	35	theme	NF-κB	1589:1593	arg1	pathway					1595:1601	NF-κB pathway	1589:1601	NF-κB pathway	1589:1601	It was detected that AP2-c exhibited anti-inflammatory activity by blocking NF-κB pathway and thus lowering the expression of related inflammatory factors.
35976799	5	36	theme	IL-1β	722:726	arg1	levels					705:710	the mRNA expression levels	685:710	the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages	685:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	1	37	theme	lignified	220:228	arg1	okra					230:233	the lignified okra	216:233	the lignified okra	216:233	In this paper, a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da was obtained from the lignified okra.
35976799	2	38	theme	2.3	372:374	arg1	ratio					363:367	a molar ratio	355:367	a molar ratio of 2.3: 1.5: 1.5	355:384	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	8	39	theme	lignified	1006:1014	arg1	waste					1045:1049	waste	1045:1049	waste	1045:1049	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	8	39	theme	lignified	1006:1014	arg1	okra					1016:1019	lignified okra	1006:1019	lignified okra	1006:1019	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	10	40	theme	lignified	1379:1387	arg1	okra					1389:1392	lignified okra	1379:1392	lignified okra	1379:1392	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	9	41	theme	okra	1252:1255	arg1	components					1238:1247	the main components	1229:1247	the main components of okra	1229:1255	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	9	41	theme	okra	1252:1255	arg1	polysaccharides					1201:1215	cell wall polysaccharides	1191:1215	cell wall polysaccharides	1191:1215	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	12	42	theme	anti-inflammatory	1818:1834	arg1	application					1836:1846	the anti-inflammatory application	1814:1846	the anti-inflammatory application of AP2-c	1814:1855	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	3	43	theme	-α-D-GalAp-	498:508	arg1	1→					510:511	-α-D-GalAp-(1→	498:511	→2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→	474:511	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	10	44	theme	physicochemical	1402:1416	arg1	properties					1418:1427	its physicochemical properties	1398:1427	its physicochemical properties	1398:1427	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	11	45	theme	anti-inflammatory	1550:1566	arg1	activity					1568:1575	anti-inflammatory activity	1550:1575	anti-inflammatory activity	1550:1575	It was detected that AP2-c exhibited anti-inflammatory activity by blocking NF-κB pathway and thus lowering the expression of related inflammatory factors.
35976799	5	46	theme	iNOS	732:735	arg1	levels					705:710	the mRNA expression levels	685:710	the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages	685:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	1	47	theme	molecular	167:175	arg1	weight					177:182	molecular weight	167:182	molecular weight 6.69 × 105 Da	167:196	In this paper, a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da was obtained from the lignified okra.
35976799	10	48	theme	anti-inflammatory	1454:1470	arg1	activity					1472:1479	anti-inflammatory activity	1454:1479	anti-inflammatory activity	1454:1479	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	9	49	theme	biological	1281:1290	arg1	functions					1292:1300	biological functions	1281:1300	biological functions	1281:1300	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	12	50	contain	have	1681:1684	arg1	results					1673:1679	The results	1669:1679	The results	1669:1679	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	12	50	contain	have	1681:1684	arg2	implications					1698:1709	significant implications	1686:1709	significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources	1686:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	7	51	theme	anti-inflammatory	922:938	arg1	activity					940:947	obvious anti-inflammatory activity	914:947	obvious anti-inflammatory activity	914:947	The results indicated that AP2-c had obvious anti-inflammatory activity.
35976799	5	52	theme	TNF-α	715:719	arg1	levels					705:710	the mRNA expression levels	685:710	the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages	685:762	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	12	53	theme	AP2-c	1851:1855	arg1	application					1836:1846	the anti-inflammatory application	1814:1846	the anti-inflammatory application of AP2-c	1814:1855	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	4	54	theme	branched	568:575	arg1	chain					577:581	the branched chain	564:581	the branched chain	564:581	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	4	55	dep	-α-L-Rhap-	517:526	arg1	1→					528:529	1→	528:529	→2)-α-L-Rhap-(1→	514:529	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	5	56	theme	dose-dependent	771:784	arg1	manner					786:791	a dose-dependent manner	769:791	a dose-dependent manner	769:791	AP2-c could inhibit the mRNA expression levels of TNF-α, IL-1β and iNOS in LPS-induced macrophages with a dose-dependent manner.
35976799	4	57	dep	position	547:554	arg1	O-4					556:558	O-4	556:558	position O-4	547:558	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	0	58	from	okra	111:114	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	0	58	from	okra	111:114	arg1	activity					50:57	anti-inflammatory activity	32:57	anti-inflammatory activity	32:57	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	0	58	from	okra	111:114	arg1	AP2-c					86:90	a pectin polysaccharide AP2-c	62:90	a pectin polysaccharide AP2-c from the lignified okra	62:114	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	4	59	theme	-β-D-Galp-	619:628	arg1	1→					644:645	→3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→	596:645	1→	644:645	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	11	60	theme	related	1639:1645	arg1	factors					1660:1666	related inflammatory factors	1639:1666	related inflammatory factors	1639:1666	It was detected that AP2-c exhibited anti-inflammatory activity by blocking NF-κB pathway and thus lowering the expression of related inflammatory factors.
35976799	0	61	theme	AP2-c	86:90	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	0	61	theme	AP2-c	86:90	arg1	activity					50:57	anti-inflammatory activity	32:57	anti-inflammatory activity	32:57	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	2	62	theme	composition	255:265	arg1	analysis					267:274	The monosaccharide composition analysis	236:274	The monosaccharide composition analysis	236:274	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	1	63	theme	pectin	134:139	arg1	AP2-c					156:160	a pectin polysaccharide AP2-c	132:160	a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da	132:196	In this paper, a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da was obtained from the lignified okra.
35976799	4	64	theme	-β-D-Galp-	601:610	arg1	1→					644:645	→3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→	596:645	1→	644:645	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	1	65	with	AP2-c	156:160	arg1	weight					177:182	molecular weight	167:182	molecular weight 6.69 × 105 Da	167:196	In this paper, a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da was obtained from the lignified okra.
35976799	0	66	from	characterization	11:26	arg1	okra					111:114	the lignified okra	97:114	the lignified okra	97:114	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	9	67	from	polysaccharides	1201:1215	arg1	abundant					1179:1186	abundant	1179:1186	abundant	1179:1186	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	11	68	theme	factors	1660:1666	arg1	expression					1625:1634	the expression	1621:1634	the expression of related inflammatory factors	1621:1666	It was detected that AP2-c exhibited anti-inflammatory activity by blocking NF-κB pathway and thus lowering the expression of related inflammatory factors.
35976799	4	69	theme	β-D-Galp-	651:659	arg1	1→					661:662	β-D-Galp-(1→	651:662	β-D-Galp-(1→	651:662	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	3	70	theme	main	438:441	arg1	chain					443:447	the main chain	434:447	the main chain of AP2-c	434:456	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	9	71	from	abundant	1179:1186	arg1	components					1238:1247	the main components	1229:1247	the main components of okra	1229:1255	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	9	71	from	abundant	1179:1186	arg1	polysaccharides					1201:1215	cell wall polysaccharides	1191:1215	cell wall polysaccharides	1191:1215	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	3	72	dep	-α-L-Rhap-	477:486	arg1	→2					474:475	→2	474:475	→2	474:475	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	3	72	dep	-α-L-Rhap-	477:486	arg1	→4					495:496	→4	495:496	→4	495:496	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	3	72	dep	-α-L-Rhap-	477:486	arg1	1→					488:489	1→	488:489	1→	488:489	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	3	72	dep	-α-L-Rhap-	477:486	arg1	1→					510:511	-α-D-GalAp-(1→	498:511	→2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→	474:511	The structural characterization indicated that the main chain of AP2-c was composed of →2)-α-L-Rhap-(1→ and →4)-α-D-GalAp-(1→.
35976799	4	73	theme	1→	630:631	arg1	1→					644:645	→3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→	596:645	1→	644:645	→2)-α-L-Rhap-(1→ was branched at position O-4 and the branched chain consisted of →3,6)-β-D-Galp-(1→, →6)-β-D-Galp-(1→, α-L-Rhap-(1→ and β-D-Galp-(1→.
35976799	0	74	theme	anti-inflammatory	32:48	arg1	activity					50:57	anti-inflammatory activity	32:57	anti-inflammatory activity	32:57	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	12	75	theme	side	1770:1773	arg1	products					1775:1782	side products	1770:1782	side products	1770:1782	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	10	76	theme	purified	1324:1331	arg1	AP2-c					1355:1359	the purified pectin polysaccharide AP2-c	1320:1359	the purified pectin polysaccharide AP2-c	1320:1359	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	9	77	theme	wall	1196:1199	arg1	components					1238:1247	the main components	1229:1247	the main components of okra	1229:1255	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	9	77	theme	wall	1196:1199	arg1	polysaccharides					1201:1215	cell wall polysaccharides	1191:1215	cell wall polysaccharides	1191:1215	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	8	78	theme	okra	979:982	arg1	seeds					984:988	okra seeds	979:988	okra seeds	979:988	PRACTICAL APPLICATIONS: When okra seeds were harvested, lignified okra was always abandoned as waste and had not been fully used for exploitation.
35976799	0	79	theme	pectin	64:69	arg1	AP2-c					86:90	a pectin polysaccharide AP2-c	62:90	a pectin polysaccharide AP2-c from the lignified okra	62:114	Structural characterization and anti-inflammatory activity of a pectin polysaccharide AP2-c from the lignified okra.
35976799	12	80	theme	okra	1746:1749	arg1	application					1731:1741	the value-added application	1715:1741	the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources	1715:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	1	81	dep	weight	177:182	arg1	Da					195:196	6.69 × 105 Da	184:196	molecular weight 6.69 × 105 Da	167:196	In this paper, a pectin polysaccharide AP2-c with molecular weight 6.69 × 105 Da was obtained from the lignified okra.
35976799	12	82	theme	value-added	1719:1729	arg1	application					1731:1741	the value-added application	1715:1741	the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources	1715:1883	The results have significant implications for the value-added application of okra and its processing side products can obviously help to promote the anti-inflammatory application of AP2-c and avoid wasting resources.
35976799	10	83	theme	polysaccharide	1340:1353	arg1	AP2-c					1355:1359	the purified pectin polysaccharide AP2-c	1320:1359	the purified pectin polysaccharide AP2-c	1320:1359	In the research, the purified pectin polysaccharide AP2-c was obtained from lignified okra and its physicochemical properties, structural features and anti-inflammatory activity were systematically researched.
35976799	2	84	theme	galacturonic	334:345	arg1	acid					347:350	galacturonic acid	334:350	galacturonic acid	334:350	The monosaccharide composition analysis indicated that AP2-c consisted of galactose, rhamnose and galacturonic acid in a molar ratio of 2.3: 1.5: 1.5.
35976799	9	85	theme	main	1233:1236	arg1	components					1238:1247	the main components	1229:1247	the main components of okra	1229:1255	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35976799	9	85	theme	main	1233:1236	arg1	polysaccharides					1201:1215	cell wall polysaccharides	1191:1215	cell wall polysaccharides	1191:1215	Nevertheless, it accounted for more than half of the total plant's weight and was abundant in cell wall polysaccharides, which were the main components of okra to perform a variety of biological functions.
35661666	9	0	from	deficits	1412:1419	arg1	mice					1430:1433	5xFAD mice	1424:1433	5xFAD mice	1424:1433	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	2	1	theme	monomeric	355:363	arg1	polysaccharide					365:378	a monomeric polysaccharide	353:378	a monomeric polysaccharide named PSP-1 from PSPs	353:400	Here we initially isolated and purified a monomeric polysaccharide named PSP-1 from PSPs.
35661666	1	2	theme	beneficial	242:251	arg1	intelligence					253:264	beneficial intelligence	242:264	beneficial intelligence	242:264	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	6	3	theme	synaptic	852:859	arg1	loss					861:864	synaptic loss	852:864	synaptic loss	852:864	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	5	4	theme	PSP-1	580:584	arg1	administration					591:604	PSP-1 oral administration	580:604	PSP-1 oral administration	580:604	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	1	5	theme	sibiricum	162:170	arg1	PSPs					189:192	PSPs	189:192	PSPs	189:192	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	1	5	theme	sibiricum	162:170	arg1	polysaccharides					172:186	Polygonatum sibiricum polysaccharides	150:186	Polygonatum sibiricum polysaccharides (PSPs)	150:193	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	5	6	from	6 months	730:737	arg1	rRNA					658:661	the 16S rRNA	650:661	the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age	650:744	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	7	7	theme	microbiota	1036:1045	arg1	composition					1047:1057	the gut microbiota composition	1028:1057	the gut microbiota composition	1028:1057	Moreover, PSP-1 reconstructed the gut microbiota composition, including reducing the relative abundance of Helicobacter, and increasing Akkermansia muciniphila.
35661666	5	8	theme	oral	586:589	arg1	administration					591:604	PSP-1 oral administration	580:604	PSP-1 oral administration	580:604	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	4	9	theme	PSP-1	477:481	arg1	18.796 kDa					487:496	18.796 kDa	487:496	18.796 kDa	487:496	The molecular weight of PSP-1 was 18.796 kDa.
35661666	4	9	theme	PSP-1	477:481	arg1	weight					467:472	The molecular weight	453:472	The molecular weight of PSP-1	453:481	The molecular weight of PSP-1 was 18.796 kDa.
35661666	5	10	theme	administration	591:604	arg1	time					572:575	the initial time	560:575	the initial time of PSP-1 oral administration	560:604	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	10	theme	administration	591:604	arg1	3 months					610:617	3 months	610:617	3 months of age for mice	610:633	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	3	11	used	utilized	418:425	arg2	IR					410:411	IR	410:411	IR	410:411	UV and IR were utilized for characterizing PSP-1.
35661666	3	11	used	utilized	418:425	arg2	UV					403:404	UV	403:404	UV	403:404	UV and IR were utilized for characterizing PSP-1.
35661666	8	12	theme	PSP-1	1276:1280	arg1	treatment					1282:1290	the PSP-1 treatment	1272:1290	the PSP-1 treatment	1272:1290	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	7	13	theme	Akkermansia	1134:1144	arg1	muciniphila					1146:1156	Akkermansia muciniphila	1134:1156	Akkermansia muciniphila	1134:1156	Moreover, PSP-1 reconstructed the gut microbiota composition, including reducing the relative abundance of Helicobacter, and increasing Akkermansia muciniphila.
35661666	0	14	from	sibiricum	44:52	arg1	polysaccharide					12:25	A monomeric polysaccharide	0:25	A monomeric polysaccharide from Polygonatum sibiricum	0:52	A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota.
35661666	7	15	theme	gut	1032:1034	arg1	composition					1047:1057	the gut microbiota composition	1028:1057	the gut microbiota composition	1028:1057	Moreover, PSP-1 reconstructed the gut microbiota composition, including reducing the relative abundance of Helicobacter, and increasing Akkermansia muciniphila.
35661666	6	16	theme	pathological	786:797	arg1	behaviors					799:807	the pathological behaviors	782:807	the pathological behaviors related to memory and cognition	782:839	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	5	17	theme	5xFAD	509:513	arg1	model					534:538	a research model	523:538	a research model	523:538	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	17	theme	5xFAD	509:513	arg1	mice					515:518	5xFAD mice	509:518	5xFAD mice	509:518	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	0	18	theme	monomeric	2:10	arg1	polysaccharide					12:25	A monomeric polysaccharide	0:25	A monomeric polysaccharide from Polygonatum sibiricum	0:52	A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota.
35661666	9	19	theme	present	1297:1303	arg1	study					1305:1309	The present study	1293:1309	The present study	1293:1309	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	5	20	theme	age	622:624	arg1	time					572:575	the initial time	560:575	the initial time of PSP-1 oral administration	560:604	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	20	theme	age	622:624	arg1	3 months					610:617	3 months	610:617	3 months of age for mice	610:633	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	21	theme	initial	564:570	arg1	time					572:575	the initial time	560:575	the initial time of PSP-1 oral administration	560:604	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	21	theme	initial	564:570	arg1	3 months					610:617	3 months	610:617	3 months of age for mice	610:633	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	8	22	theme	inflammatory	1197:1208	arg1	responses					1210:1218	the inflammatory responses	1193:1218	the inflammatory responses	1193:1218	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	5	23	theme	wild	685:688	arg1	WT					696:697	WT	696:697	WT	696:697	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	23	theme	wild	685:688	arg1	type					690:693	wild type	685:693	wild type (WT)	685:698	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	24	from	mice	710:713	arg1	rRNA					658:661	the 16S rRNA	650:661	the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age	650:744	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	24	from	mice	710:713	arg1	samples					672:678	fecal samples	666:678	fecal samples from wild type (WT) and 5xFAD mice	666:713	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	6	25	theme	mice	992:995	arg1	brains					976:981	the brains	972:981	the brains of 5xFAD mice	972:995	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	8	26	theme	barrier	1167:1173	arg1	integrity					1175:1183	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition	1159:1252	integrity	1175:1183	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	1	27	theme	underlying	275:284	arg1	mechanisms					286:295	the underlying mechanisms	271:295	the underlying mechanisms	271:295	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	5	28	theme	samples	672:678	arg1	rRNA					658:661	the 16S rRNA	650:661	the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age	650:744	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	8	29	theme	gut	1163:1165	arg1	integrity					1175:1183	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition	1159:1252	integrity	1175:1183	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	6	30	theme	5xFAD	986:990	arg1	mice					992:995	5xFAD mice	986:995	5xFAD mice	986:995	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	7	31	theme	Helicobacter	1105:1116	arg1	abundance					1092:1100	the relative abundance	1079:1100	the relative abundance of Helicobacter	1079:1116	Moreover, PSP-1 reconstructed the gut microbiota composition, including reducing the relative abundance of Helicobacter, and increasing Akkermansia muciniphila.
35661666	6	32	theme	plaques	906:912	arg1	phagocytosis					887:898	microglial phagocytosis	876:898	microglial phagocytosis of Aβ plaques	876:912	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	7	33	theme	relative	1083:1090	arg1	abundance					1092:1100	the relative abundance	1079:1100	the relative abundance of Helicobacter	1079:1116	Moreover, PSP-1 reconstructed the gut microbiota composition, including reducing the relative abundance of Helicobacter, and increasing Akkermansia muciniphila.
35661666	6	34	theme	Aβ	903:904	arg1	plaques					906:912	Aβ plaques	903:912	Aβ plaques	903:912	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	0	35	theme	gut	134:136	arg1	microbiota					138:147	the gut microbiota	130:147	the gut microbiota	130:147	A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota.
35661666	6	36	theme	related	809:815	arg1	behaviors					799:807	the pathological behaviors	782:807	the pathological behaviors related to memory and cognition	782:839	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	9	37	theme	5xFAD	1424:1428	arg1	mice					1430:1433	5xFAD mice	1424:1433	5xFAD mice	1424:1433	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	9	38	theme	gut	1484:1486	arg1	microbiome					1488:1497	the reshaped gut microbiome	1471:1497	the reshaped gut microbiome	1471:1497	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	9	39	theme	cognitive	1402:1410	arg1	deficits					1412:1419	the cognitive deficits	1398:1419	the cognitive deficits	1398:1419	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	5	40	theme	type	690:693	arg1	mice					710:713	wild type (WT) and 5xFAD mice	685:713	wild type (WT) and 5xFAD mice	685:713	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	0	41	theme	cognitive	63:71	arg1	functions					73:81	cognitive functions	63:81	cognitive functions	63:81	A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota.
35661666	5	42	theme	16S	654:656	arg1	rRNA					658:661	the 16S rRNA	650:661	the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age	650:744	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	4	43	theme	molecular	457:465	arg1	18.796 kDa					487:496	18.796 kDa	487:496	18.796 kDa	487:496	The molecular weight of PSP-1 was 18.796 kDa.
35661666	4	43	theme	molecular	457:465	arg1	weight					467:472	The molecular weight	453:472	The molecular weight of PSP-1	453:481	The molecular weight of PSP-1 was 18.796 kDa.
35661666	8	44	theme	Aβ	1240:1241	arg1	deposition					1243:1252	the intestinal Aβ deposition	1225:1252	the intestinal Aβ deposition	1225:1252	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	5	45	theme	age	742:744	arg1	6 months					730:737	6 months	730:737	6 months	730:737	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	45	theme	age	742:744	arg1	3 months					718:725	3 months	718:725	3 months	718:725	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	6	46	theme	microglial	876:885	arg1	phagocytosis					887:898	microglial phagocytosis	876:898	microglial phagocytosis of Aβ plaques	876:912	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	8	47	dep	integrity	1175:1183	arg1	damage					1185:1190	damage	1185:1190	damage	1185:1190	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	8	48	theme	intestinal	1229:1238	arg1	deposition					1243:1252	the intestinal Aβ deposition	1225:1252	the intestinal Aβ deposition	1225:1252	The gut barrier integrity damage, the inflammatory responses, and the intestinal Aβ deposition were prevented by the PSP-1 treatment.
35661666	9	49	theme	monomeric	1324:1332	arg1	polysaccharide					1334:1347	a monomeric polysaccharide	1322:1347	a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome	1322:1497	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	5	50	from	3 months	718:725	arg1	rRNA					658:661	the 16S rRNA	650:661	the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age	650:744	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	6	51	theme	3-month	749:755	arg1	course					757:762	A 3-month course	747:762	A 3-month course of PSP-1	747:771	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	5	52	theme	fecal	666:670	arg1	samples					672:678	fecal samples	666:678	fecal samples from wild type (WT) and 5xFAD mice	666:713	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	6	53	theme	PSP-1	767:771	arg1	course					757:762	A 3-month course	747:762	A 3-month course of PSP-1	747:771	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	6	54	theme	Aβ1-42	962:967	arg1	concentrations					933:946	the concentrations	929:946	the concentrations of Aβ1-40 and Aβ1-42	929:967	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	5	55	theme	5xFAD	704:708	arg1	mice					710:713	wild type (WT) and 5xFAD mice	685:713	wild type (WT) and 5xFAD mice	685:713	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	1	56	contain	have	195:198	arg1	PSPs					189:192	PSPs	189:192	PSPs	189:192	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	1	56	contain	have	195:198	arg1	polysaccharides					172:186	Polygonatum sibiricum polysaccharides	150:186	Polygonatum sibiricum polysaccharides (PSPs)	150:193	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	1	56	contain	have	195:198	arg2	function					204:211	the function	200:211	the function of nourishing the nerves and beneficial intelligence	200:264	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	1	57	theme	Polygonatum	150:160	arg1	PSPs					189:192	PSPs	189:192	PSPs	189:192	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	1	57	theme	Polygonatum	150:160	arg1	polysaccharides					172:186	Polygonatum sibiricum polysaccharides	150:186	Polygonatum sibiricum polysaccharides (PSPs)	150:193	Polygonatum sibiricum polysaccharides (PSPs) have the function of nourishing the nerves and beneficial intelligence, but the underlying mechanisms remain unclear.
35661666	6	58	theme	Aβ1-40	951:956	arg1	concentrations					933:946	the concentrations	929:946	the concentrations of Aβ1-40 and Aβ1-42	929:967	A 3-month course of PSP-1 improved the pathological behaviors related to memory and cognition, prevented synaptic loss, enhanced microglial phagocytosis of Aβ plaques, and decreased the concentrations of Aβ1-40 and Aβ1-42 in the brains of 5xFAD mice.
35661666	5	59	theme	research	525:532	arg1	model					534:538	a research model	523:538	a research model	523:538	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	5	59	theme	research	525:532	arg1	mice					515:518	5xFAD mice	509:518	5xFAD mice	509:518	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
35661666	9	60	theme	reshaped	1475:1482	arg1	microbiome					1488:1497	the reshaped gut microbiome	1471:1497	the reshaped gut microbiome	1471:1497	The present study identified a monomeric polysaccharide purified from PSPs that significantly attenuates the cognitive deficits in 5xFAD mice, which could be partly explained by the reshaped gut microbiome.
35661666	5	61	from	rRNA	658:661	arg1	mice					710:713	wild type (WT) and 5xFAD mice	685:713	wild type (WT) and 5xFAD mice	685:713	Utilizing 5xFAD mice as a research model, we identified that the initial time of PSP-1 oral administration was 3 months of age for mice by determining the 16S rRNA of fecal samples from wild type (WT) and 5xFAD mice at 3 months or 6 months of age.
37103342	6	0	theme	human	778:782	arg1	cells					802:806	human HCT116 colorectal cells	778:806	human HCT116 colorectal cells	778:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	10	1	theme	adhesion	1166:1173	arg1	potential					1175:1183	the anti-cell adhesion potential	1152:1183	the anti-cell adhesion potential of fucoidans on HCT116 cells	1152:1212	Lastly, the anti-cell adhesion potential of fucoidans on HCT116 cells was also investigated.
37103342	2	2	from	alarm	284:288	arg1	countries					310:318	highly developed countries	293:318	highly developed countries	293:318	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	4	3	theme	African	546:552	arg1	seaweeds					554:561	South African seaweeds	540:561	South African seaweeds	540:561	Fucoidans from South African seaweeds were hot water extracted and structurally characterised using FTIR, NMR and TGA.
37103342	6	4	theme	fucoidans	765:773	arg1	properties					747:756	the anti-cancer properties	731:756	the anti-cancer properties of the fucoidans on human HCT116 colorectal cells	731:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	16	5	theme	further	1847:1853	arg1	analyses					1855:1862	their further analyses	1841:1862	their further analyses	1841:1862	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	8	6	theme	fucoidans	967:975	arg1	potential					954:962	the anti-colony formation potential	928:962	the anti-colony formation potential of fucoidans	928:975	Thereafter, the anti-colony formation potential of fucoidans was explored.
37103342	6	7	theme	anti-cancer	735:745	arg1	properties					747:756	the anti-cancer properties	731:756	the anti-cancer properties of the fucoidans on human HCT116 colorectal cells	731:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	15	8	theme	long-term	1668:1676	arg1	formation					1685:1693	long-term colony formation	1668:1693	long-term colony formation	1668:1693	Moreover, some fucoidan extracts hindered long-term colony formation by HCT116 cancer cells.
37103342	12	9	contain	had	1281:1283	arg1	Fucoidans					1271:1279	Fucoidans	1271:1279	Fucoidans	1271:1279	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	12	9	contain	had	1281:1283	arg2	content					1307:1313	a higher carbohydrate content	1285:1313	a higher carbohydrate content	1285:1313	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	12	9	contain	had	1281:1283	arg2	content					1334:1340	lower sulphate content	1319:1340	lower sulphate content	1319:1340	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	0	10	theme	Long-Term	106:114	arg1	Survival					116:123	Long-Term Survival	106:123	Long-Term Survival	106:123	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	2	11	theme	CRC	263:265	arg1	incidence					250:258	The incidence	246:258	The incidence of CRC	246:265	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	2	11	theme	CRC	263:265	arg1	increasing					273:282	increasing	273:282	increasing alarm in highly developed countries, as well as in middle to low-income countries	273:364	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	16	12	dep	extracts	1758:1765	arg1	demonstrated					1767:1778	demonstrated	1767:1778	extracts demonstrated promising anti-cancer activities in vitro	1758:1820	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	1	13	theme	recurrent	188:196	arg1	tumour					216:221	a recurrent, deadly malignant tumour	186:221	a recurrent, deadly malignant tumour with a high incidence	186:243	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	1	13	theme	recurrent	188:196	arg1	cancer					170:175	Human colorectal cancer	153:175	Human colorectal cancer (CRC)	153:181	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	0	14	from	Seaweeds	59:66	arg1	Fucoidans					24:32	Fucoidans	24:32	Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells	24:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	0	14	from	Seaweeds	59:66	arg1	Analyses					12:19	Comparative Analyses	0:19	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.	0:151	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	12	15	theme	lower	1319:1323	arg1	content					1334:1340	lower sulphate content	1319:1340	lower sulphate content	1319:1340	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	6	16	from	cells	802:806	arg1	properties					747:756	the anti-cancer properties	731:756	the anti-cancer properties of the fucoidans on human HCT116 colorectal cells	731:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	0	17	theme	Cancer	139:144	arg1	Cells					146:150	Colorectal Cancer Cells	128:150	Colorectal Cancer Cells	128:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	4	18	dep	water	572:576	arg1	extracted					578:586	extracted	578:586	extracted	578:586	Fucoidans from South African seaweeds were hot water extracted and structurally characterised using FTIR, NMR and TGA.
37103342	4	18	dep	water	572:576	arg1	characterised					605:617	characterised	605:617	structurally characterised using FTIR, NMR and TGA	592:641	Fucoidans from South African seaweeds were hot water extracted and structurally characterised using FTIR, NMR and TGA.
37103342	8	19	theme	anti-colony	932:942	arg1	potential					954:962	the anti-colony formation potential	928:962	the anti-colony formation potential of fucoidans	928:975	Thereafter, the anti-colony formation potential of fucoidans was explored.
37103342	12	20	theme	higher	1287:1292	arg1	content					1307:1313	a higher carbohydrate content	1285:1313	a higher carbohydrate content	1285:1313	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	9	21	theme	fucoidans	1006:1014	arg1	potency					995:1001	The potency	991:1001	The potency of fucoidans on the 2D and 3D migration of HCT116 cells	991:1057	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	10	22	theme	anti-cell	1156:1164	arg1	potential					1175:1183	the anti-cell adhesion potential	1152:1183	the anti-cell adhesion potential of fucoidans on HCT116 cells	1152:1212	Lastly, the anti-cell adhesion potential of fucoidans on HCT116 cells was also investigated.
37103342	15	23	theme	cancer	1705:1710	arg1	cells					1712:1716	HCT116 cancer cells	1698:1716	HCT116 cancer cells	1698:1716	Moreover, some fucoidan extracts hindered long-term colony formation by HCT116 cancer cells.
37103342	4	24	from	seaweeds	554:561	arg1	Fucoidans					525:533	Fucoidans	525:533	Fucoidans from South African seaweeds	525:561	Fucoidans from South African seaweeds were hot water extracted and structurally characterised using FTIR, NMR and TGA.
37103342	1	25	theme	Human	153:157	arg1	CRC					178:180	CRC	178:180	CRC	178:180	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	1	25	theme	Human	153:157	arg1	cancer					170:175	Human colorectal cancer	153:175	Human colorectal cancer (CRC)	153:181	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	1	25	theme	Human	153:157	arg1	tumour					216:221	a recurrent, deadly malignant tumour	186:221	a recurrent, deadly malignant tumour with a high incidence	186:243	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	13	26	theme	colorectal	1463:1472	arg1	cells					1481:1485	HCT116 colorectal cancer cells	1456:1485	HCT116 colorectal cancer cells	1456:1485	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	14	27	theme	HCT116	1597:1602	arg1	adhesion					1609:1616	HCT116 cell adhesion	1597:1616	HCT116 cell adhesion	1597:1616	This concentration of fucoidans also significantly inhibited HCT116 cell adhesion by 40%.
37103342	7	28	theme	resazurin	899:907	arg1	assay					909:913	the resazurin assay	895:913	the resazurin assay	895:913	The effect of fucoidans on HCT116 cell viability was explored using the resazurin assay.
37103342	2	29	theme	health	395:400	arg1	challenge					402:410	a significant global health challenge	374:410	a significant global health challenge	374:410	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	9	30	theme	HCT116	1046:1051	arg1	cells					1053:1057	HCT116 cells	1046:1057	HCT116 cells	1046:1057	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	13	31	theme	cells	1481:1485	arg1	migration					1443:1451	2D and 3D migration	1433:1451	2D and 3D migration of HCT116 colorectal cancer cells to 80%	1433:1492	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	0	32	theme	Comparative	0:10	arg1	Analyses					12:19	Comparative Analyses	0:19	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.	0:151	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	2	33	theme	significant	376:386	arg1	challenge					402:410	a significant global health challenge	374:410	a significant global health challenge	374:410	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	13	34	theme	3D	1440:1441	arg1	migration					1443:1451	2D and 3D migration	1433:1451	2D and 3D migration of HCT116 colorectal cancer cells to 80%	1433:1492	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	2	35	dep	countries	356:364	arg1	middle					335:340	middle	335:340	middle	335:340	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	6	36	from	properties	747:756	arg1	cells					802:806	human HCT116 colorectal cells	778:806	human HCT116 colorectal cells	778:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	9	37	theme	healing	1085:1091	arg1	assay					1093:1097	wound healing assay	1079:1097	wound healing assay	1079:1097	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	2	38	theme	developed	300:308	arg1	countries					310:318	highly developed countries	293:318	highly developed countries	293:318	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	0	39	theme	African	45:51	arg1	Seaweeds					59:66	South African Brown Seaweeds	39:66	South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells	39:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	16	40	theme	anti-cancer	1790:1800	arg1	activities					1802:1811	promising anti-cancer activities	1780:1811	promising anti-cancer activities	1780:1811	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	13	41	theme	2D	1433:1434	arg1	migration					1443:1451	2D and 3D migration	1433:1451	2D and 3D migration of HCT116 colorectal cancer cells to 80%	1433:1492	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	6	42	theme	colorectal	791:800	arg1	cells					802:806	human HCT116 colorectal cells	778:806	human HCT116 colorectal cells	778:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	2	43	theme	low-income	345:354	arg1	countries					356:364	low-income countries	345:364	low-income countries	345:364	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	9	44	theme	migration	1112:1120	arg1	assays					1122:1127	spheroid migration assays	1103:1127	spheroid migration assays	1103:1127	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	4	45	theme	hot	568:570	arg1	water					572:576	hot water	568:576	hot water extracted and structurally characterised using FTIR, NMR and TGA	568:641	Fucoidans from South African seaweeds were hot water extracted and structurally characterised using FTIR, NMR and TGA.
37103342	7	46	theme	HCT116	854:859	arg1	viability					866:874	HCT116 cell viability	854:874	HCT116 cell viability	854:874	The effect of fucoidans on HCT116 cell viability was explored using the resazurin assay.
37103342	8	47	theme	formation	944:952	arg1	potential					954:962	the anti-colony formation potential	928:962	the anti-colony formation potential of fucoidans	928:975	Thereafter, the anti-colony formation potential of fucoidans was explored.
37103342	15	48	theme	colony	1678:1683	arg1	formation					1685:1693	long-term colony formation	1668:1693	long-term colony formation	1668:1693	Moreover, some fucoidan extracts hindered long-term colony formation by HCT116 cancer cells.
37103342	7	49	theme	fucoidans	841:849	arg1	effect					831:836	The effect	827:836	The effect of fucoidans on HCT116 cell viability	827:874	The effect of fucoidans on HCT116 cell viability was explored using the resazurin assay.
37103342	1	50	theme	high	230:233	arg1	incidence					235:243	a high incidence	228:243	a high incidence	228:243	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	3	51	theme	CRC	520:522	arg1	morbidity					493:501	morbidity	493:501	morbidity	493:501	Therefore, novel management and prevention strategies are vital in reducing the morbidity and mortality of CRC.
37103342	3	51	theme	CRC	520:522	arg1	mortality					507:515	mortality	507:515	mortality	507:515	Therefore, novel management and prevention strategies are vital in reducing the morbidity and mortality of CRC.
37103342	1	52	theme	colorectal	159:168	arg1	CRC					178:180	CRC	178:180	CRC	178:180	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	1	52	theme	colorectal	159:168	arg1	cancer					170:175	Human colorectal cancer	153:175	Human colorectal cancer (CRC)	153:181	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	1	52	theme	colorectal	159:168	arg1	tumour					216:221	a recurrent, deadly malignant tumour	186:221	a recurrent, deadly malignant tumour with a high incidence	186:243	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	12	53	theme	commercial	1369:1378	arg1	fucoidans					1398:1406	commercial Fucus vesiculosus fucoidans	1369:1406	commercial Fucus vesiculosus fucoidans	1369:1406	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	15	54	theme	fucoidan	1641:1648	arg1	extracts					1650:1657	some fucoidan extracts	1636:1657	some fucoidan extracts	1636:1657	Moreover, some fucoidan extracts hindered long-term colony formation by HCT116 cancer cells.
37103342	13	55	theme	µg/mL	1529:1533	arg1	concentration					1508:1520	a fucoidan concentration	1497:1520	a fucoidan concentration of 100 µg/mL	1497:1533	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	16	56	theme	pre-clinical	1867:1878	arg1	studies					1893:1899	pre-clinical and clinical studies	1867:1899	pre-clinical and clinical studies	1867:1899	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	12	57	theme	sulphate	1325:1332	arg1	content					1334:1340	lower sulphate content	1319:1340	lower sulphate content	1319:1340	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	16	58	theme	clinical	1884:1891	arg1	studies					1893:1899	pre-clinical and clinical studies	1867:1899	pre-clinical and clinical studies	1867:1899	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	0	59	theme	Colorectal	128:137	arg1	Cells					146:150	Colorectal Cancer Cells	128:150	Colorectal Cancer Cells	128:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	13	60	theme	fucoidan	1499:1506	arg1	concentration					1508:1520	a fucoidan concentration	1497:1520	a fucoidan concentration of 100 µg/mL	1497:1533	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	12	61	theme	carbohydrate	1294:1305	arg1	content					1307:1313	a higher carbohydrate content	1285:1313	a higher carbohydrate content	1285:1313	Fucoidans had a higher carbohydrate content and lower sulphate content than Sargassum elegans and commercial Fucus vesiculosus fucoidans.
37103342	0	62	theme	Cells	146:150	arg1	Migration					91:99	Migration	91:99	Migration	91:99	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	0	62	theme	Cells	146:150	arg1	Adhesion					81:88	Adhesion	81:88	Adhesion	81:88	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	0	62	theme	Cells	146:150	arg1	Survival					116:123	Long-Term Survival	106:123	Long-Term Survival	106:123	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	14	63	theme	fucoidans	1558:1566	arg1	concentration					1541:1553	This concentration	1536:1553	This concentration of fucoidans	1536:1566	This concentration of fucoidans also significantly inhibited HCT116 cell adhesion by 40%.
37103342	10	64	theme	HCT116	1201:1206	arg1	cells					1208:1212	HCT116 cells	1201:1212	HCT116 cells	1201:1212	Lastly, the anti-cell adhesion potential of fucoidans on HCT116 cells was also investigated.
37103342	10	65	from	potential	1175:1183	arg1	cells					1208:1212	HCT116 cells	1201:1212	HCT116 cells	1201:1212	Lastly, the anti-cell adhesion potential of fucoidans on HCT116 cells was also investigated.
37103342	10	66	theme	fucoidans	1188:1196	arg1	potential					1175:1183	the anti-cell adhesion potential	1152:1183	the anti-cell adhesion potential of fucoidans on HCT116 cells	1152:1212	Lastly, the anti-cell adhesion potential of fucoidans on HCT116 cells was also investigated.
37103342	3	67	theme	novel	424:428	arg1	management					430:439	novel management and prevention strategies	424:465	management	430:439	Therefore, novel management and prevention strategies are vital in reducing the morbidity and mortality of CRC.
37103342	15	68	theme	HCT116	1698:1703	arg1	cells					1712:1716	HCT116 cancer cells	1698:1716	HCT116 cancer cells	1698:1716	Moreover, some fucoidan extracts hindered long-term colony formation by HCT116 cancer cells.
37103342	0	69	from	Analyses	12:19	arg1	Seaweeds					59:66	South African Brown Seaweeds	39:66	South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells	39:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	9	70	theme	2D	1023:1024	arg1	migration					1033:1041	the 2D and 3D migration	1019:1041	the 2D and 3D migration of HCT116 cells	1019:1057	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	9	71	theme	3D	1030:1031	arg1	migration					1033:1041	the 2D and 3D migration	1019:1041	the 2D and 3D migration of HCT116 cells	1019:1057	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	14	72	theme	cell	1604:1607	arg1	adhesion					1609:1616	HCT116 cell adhesion	1597:1616	HCT116 cell adhesion	1597:1616	This concentration of fucoidans also significantly inhibited HCT116 cell adhesion by 40%.
37103342	6	73	from	fucoidans	765:773	arg1	cells					802:806	human HCT116 colorectal cells	778:806	human HCT116 colorectal cells	778:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	13	74	theme	cancer	1474:1479	arg1	cells					1481:1485	HCT116 colorectal cancer cells	1456:1485	HCT116 colorectal cancer cells	1456:1485	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	2	75	theme	global	388:393	arg1	challenge					402:410	a significant global health challenge	374:410	a significant global health challenge	374:410	The incidence of CRC is of increasing alarm in highly developed countries, as well as in middle to low-income countries, posing a significant global health challenge.
37103342	11	76	theme	Ecklonia	1258:1265	arg1	sp					1267:1268	Ecklonia sp	1258:1268	Ecklonia sp	1258:1268	Our study found that Ecklonia sp.
37103342	9	77	theme	cells	1053:1057	arg1	migration					1033:1041	the 2D and 3D migration	1019:1041	the 2D and 3D migration of HCT116 cells	1019:1057	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	0	78	theme	Fucoidans	24:32	arg1	Analyses					12:19	Comparative Analyses	0:19	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.	0:151	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	11	79	dep	found	1247:1251	arg1	sp					1267:1268	Ecklonia sp	1258:1268	Ecklonia sp	1258:1268	Our study found that Ecklonia sp.
37103342	9	80	from	potency	995:1001	arg1	migration					1033:1041	the 2D and 3D migration	1019:1041	the 2D and 3D migration of HCT116 cells	1019:1057	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	0	81	theme	South	39:43	arg1	Seaweeds					59:66	South African Brown Seaweeds	39:66	South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells	39:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	16	82	theme	characterised	1735:1747	arg1	fucoidan					1749:1756	the characterised fucoidan	1731:1756	the characterised fucoidan	1731:1756	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	9	83	theme	wound	1079:1083	arg1	healing					1085:1091	wound healing	1079:1091	wound healing assay	1079:1097	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	13	84	theme	HCT116	1456:1461	arg1	cells					1481:1485	HCT116 colorectal cancer cells	1456:1485	HCT116 colorectal cancer cells	1456:1485	The fucoidans prevented 2D and 3D migration of HCT116 colorectal cancer cells to 80% at a fucoidan concentration of 100 µg/mL.
37103342	0	85	theme	Brown	53:57	arg1	Seaweeds					59:66	South African Brown Seaweeds	39:66	South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells	39:150	Comparative Analyses of Fucoidans from South African Brown Seaweeds That Inhibit Adhesion, Migration, and Long-Term Survival of Colorectal Cancer Cells.
37103342	3	86	theme	prevention	445:454	arg1	strategies					456:465	novel management and prevention strategies	424:465	strategies	456:465	Therefore, novel management and prevention strategies are vital in reducing the morbidity and mortality of CRC.
37103342	16	87	theme	promising	1780:1788	arg1	activities					1802:1811	promising anti-cancer activities	1780:1811	promising anti-cancer activities	1780:1811	In summary, the characterised fucoidan extracts demonstrated promising anti-cancer activities in vitro, and this warrants their further analyses in pre-clinical and clinical studies.
37103342	1	88	dep	recurrent	188:196	arg1	malignant					206:214	malignant	206:214	malignant	206:214	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	9	89	theme	spheroid	1103:1110	arg1	assays					1122:1127	spheroid migration assays	1103:1127	spheroid migration assays	1103:1127	The potency of fucoidans on the 2D and 3D migration of HCT116 cells was investigated by wound healing assay and spheroid migration assays, respectively.
37103342	7	90	theme	cell	861:864	arg1	viability					866:874	HCT116 cell viability	854:874	HCT116 cell viability	854:874	The effect of fucoidans on HCT116 cell viability was explored using the resazurin assay.
37103342	6	91	theme	HCT116	784:789	arg1	cells					802:806	human HCT116 colorectal cells	778:806	human HCT116 colorectal cells	778:806	In addition, the anti-cancer properties of the fucoidans on human HCT116 colorectal cells were investigated.
37103342	1	92	with	tumour	216:221	arg1	incidence					235:243	a high incidence	228:243	a high incidence	228:243	Human colorectal cancer (CRC) is a recurrent, deadly malignant tumour with a high incidence.
37103342	7	93	from	effect	831:836	arg1	viability					866:874	HCT116 cell viability	854:874	HCT116 cell viability	854:874	The effect of fucoidans on HCT116 cell viability was explored using the resazurin assay.
36940546	2	0	theme	dose-depend	449:459	arg1	manner					461:466	a dose-depend manner	447:466	a dose-depend manner	447:466	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	3	1	dep	bacteria	727:734	arg1	Ruminococcaceae					805:819	Ruminococcaceae	805:819	Ruminococcaceae	805:819	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	1	dep	bacteria	727:734	arg1	Prevotellaceae					786:799	Prevotellaceae	786:799	Prevotellaceae	786:799	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	1	dep	bacteria	727:734	arg1	bacteria					727:734	beneficial bacteria	716:734	beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae	716:819	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	1	dep	bacteria	727:734	arg1	Lactobacillaceae					752:767	Lactobacillaceae	752:767	Lactobacillaceae	752:767	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	2	theme	bacteria	727:734	arg1	abundances					702:711	the abundances	698:711	the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators	698:891	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	1	3	attach	isolated	313:320	arg2	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	3	attach	isolated	313:320	arg1	tea					339:341	mature Hawk tea	327:341	mature Hawk tea leaves	327:348	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	3	attach	isolated	313:320	arg2	HTP-1					192:196	HTP-1	192:196	HTP-1	192:196	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	3	attach	isolated	313:320	arg2	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	0	4	theme	immunomodulatory	68:83	arg1	activity					85:92	immunomodulatory activity	68:92	immunomodulatory activity	68:92	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	1	5	theme	analogous	288:296	arg1	backbone					278:285	the backbone	274:285	the backbone	274:285	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	2	6	theme	immunoglobulins	562:576	arg1	levels					516:521	the levels	512:521	the levels of immune organ indexes, cytokines and immunoglobulins	512:576	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	1	7	theme	novel	154:158	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	7	theme	novel	154:158	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	7	theme	novel	154:158	arg1	HTP-1					192:196	HTP-1	192:196	HTP-1	192:196	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	3	8	theme	immune	875:880	arg1	indicators					882:891	most immune indicators	870:891	most immune indicators	870:891	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	9	theme	strong	837:842	arg1	correlation					853:863	a strong positive correlation	835:863	a strong positive correlation with most immune indicators	835:891	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	2	10	from	activities	396:405	arg1	mice					439:442	CTX-induced immunosuppressed mice	410:442	CTX-induced immunosuppressed mice	410:442	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	4	11	theme	HTP-1	961:965	arg1	action					951:956	the immunomodulatory action	930:956	the immunomodulatory action of HTP-1	930:965	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	2	12	theme	cytokines	548:556	arg1	levels					516:521	the levels	512:521	the levels of immune organ indexes, cytokines and immunoglobulins	512:576	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	1	13	theme	-Rhap-	230:235	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	13	theme	-Rhap-	230:235	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	2	14	theme	jejunum	483:489	arg1	injury					491:496	jejunum injury	483:496	jejunum injury	483:496	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	3	15	with	correlation	853:863	arg1	indicators					882:891	most immune indicators	870:891	most immune indicators	870:891	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	1	16	theme	28.6 kDa	160:167	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	16	theme	28.6 kDa	160:167	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	16	theme	28.6 kDa	160:167	arg1	HTP-1					192:196	HTP-1	192:196	HTP-1	192:196	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	0	17	from	tea	31:33	arg1	polysaccharide					6:19	A new polysaccharide	0:19	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity	0:92	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	1	18	theme	-GalpA-	215:221	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	18	theme	-GalpA-	215:221	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	19	theme	acidic	169:174	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	19	theme	acidic	169:174	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	19	theme	acidic	169:174	arg1	HTP-1					192:196	HTP-1	192:196	HTP-1	192:196	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	0	20	theme	new	2:4	arg1	polysaccharide					6:19	A new polysaccharide	0:19	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity	0:92	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	1	21	dep	1 → residues	258:269	arg1	→2					227:228	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	→2	227:228	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	4	22	theme	current	898:904	arg1	findings					906:913	The current findings	894:913	The current findings	894:913	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	3	23	theme	intestinalmicrobiota	653:672	arg1	composition					674:684	the intestinalmicrobiota composition	649:684	the intestinalmicrobiota composition	649:684	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	4	24	theme	HTP-1	1099:1103	arg1	exploitation					1083:1094	the future exploitation	1072:1094	the future exploitation of HTP-1 as functional foods	1072:1123	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	2	25	theme	immunoregulatory	379:394	arg1	activities					396:405	significant immunoregulatory activities	367:405	significant immunoregulatory activities on CTX-induced immunosuppressed mice	367:442	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	1	26	theme	1 → and → 3,6	237:249	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	26	theme	1 → and → 3,6	237:249	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	4	27	theme	immunomodulatory	934:949	arg1	action					951:956	the immunomodulatory action	930:956	the immunomodulatory action of HTP-1	930:965	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	2	28	theme	significant	367:377	arg1	activities					396:405	significant immunoregulatory activities	367:405	significant immunoregulatory activities on CTX-induced immunosuppressed mice	367:442	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	3	29	theme	beneficial	716:725	arg1	Ruminococcaceae					805:819	Ruminococcaceae	805:819	Ruminococcaceae	805:819	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	29	theme	beneficial	716:725	arg1	Prevotellaceae					786:799	Prevotellaceae	786:799	Prevotellaceae	786:799	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	29	theme	beneficial	716:725	arg1	bacteria					727:734	beneficial bacteria	716:734	beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae	716:819	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	29	theme	beneficial	716:725	arg1	Lactobacillaceae					752:767	Lactobacillaceae	752:767	Lactobacillaceae	752:767	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	4	30	theme	functional	1108:1117	arg1	foods					1119:1123	functional foods	1108:1123	functional foods	1108:1123	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	4	31	theme	microbiota	1007:1016	arg1	regulation					985:994	the regulation	981:994	the regulation of the gut microbiota	981:1016	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	1	32	theme	-Galp-	251:256	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	32	theme	-Galp-	251:256	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	33	theme	mature	327:332	arg1	tea					339:341	mature Hawk tea	327:341	mature Hawk tea leaves	327:348	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	0	34	theme	gut	121:123	arg1	microbiota					125:134	gut microbiota	121:134	gut microbiota	121:134	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	0	35	theme	Hawk	26:29	arg1	tea					31:33	Hawk tea	26:33	Hawk tea	26:33	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	4	36	theme	gut	1003:1005	arg1	microbiota					1007:1016	the gut microbiota	999:1016	the gut microbiota	999:1016	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	1	37	theme	Hawk	334:337	arg1	tea					339:341	mature Hawk tea	327:341	mature Hawk tea leaves	327:348	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	0	38	theme	Structural	36:45	arg1	characterization					47:62	Structural characterization	36:62	Structural characterization	36:62	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	2	39	theme	CTX-induced	410:420	arg1	mice					439:442	CTX-induced immunosuppressed mice	410:442	CTX-induced immunosuppressed mice	410:442	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	2	40	theme	indexes	539:545	arg1	levels					516:521	the levels	512:521	the levels of immune organ indexes, cytokines and immunoglobulins	512:576	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	2	41	theme	organ	533:537	arg1	indexes					539:545	immune organ indexes	526:545	immune organ indexes	526:545	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	3	42	theme	HTP-1	589:593	arg1	supplementation					595:609	HTP-1 supplementation	589:609	HTP-1 supplementation	589:609	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	3	43	theme	most	870:873	arg1	indicators					882:891	most immune indicators	870:891	most immune indicators	870:891	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	2	44	theme	immune	526:531	arg1	indexes					539:545	immune organ indexes	526:545	immune organ indexes	526:545	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	3	45	theme	SCFAs	634:638	arg1	content					623:629	the content	619:629	the content of SCFAs	619:638	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	0	46	dep	polysaccharide	6:19	arg1	characterization					47:62	Structural characterization	36:62	Structural characterization	36:62	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	0	46	dep	polysaccharide	6:19	arg1	activity					85:92	immunomodulatory activity	68:92	immunomodulatory activity	68:92	A new polysaccharide from Hawk tea: Structural characterization and immunomodulatory activity associated with regulating gut microbiota.
36940546	3	47	theme	positive	844:851	arg1	correlation					853:863	a strong positive correlation	835:863	a strong positive correlation with most immune indicators	835:891	Moreover, HTP-1 supplementation boosted the content of SCFAs, altered the intestinalmicrobiota composition, and raised the abundances of beneficial bacteria Muribaculaceae, Lactobacillaceae, Bacteroidaceae, Prevotellaceae and Ruminococcaceae, which showed a strong positive correlation with most immune indicators.
36940546	1	48	dep	tea	339:341	arg1	leaves					343:348	leaves	343:348	leaves	343:348	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	4	49	theme	future	1076:1081	arg1	exploitation					1083:1094	the future exploitation	1072:1094	the future exploitation of HTP-1 as functional foods	1072:1123	The current findings suggested that the immunomodulatory action of HTP-1 might rely on the regulation of the gut microbiota, and these results may also serve as a foundation for the future exploitation of HTP-1 as functional foods.
36940546	2	50	theme	immunosuppressed	422:437	arg1	mice					439:442	CTX-induced immunosuppressed mice	410:442	CTX-induced immunosuppressed mice	410:442	HTP-1 exhibited significant immunoregulatory activities on CTX-induced immunosuppressed mice in a dose-depend manner by alleviating jejunum injury and improving the levels of immune organ indexes, cytokines and immunoglobulins.
36940546	1	51	theme	1→	223:224	arg1	polysaccharide					176:189	a novel 28.6 kDa acidic polysaccharide	152:189	a novel 28.6 kDa acidic polysaccharide (HTP-1)	152:197	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
36940546	1	51	theme	1→	223:224	arg1	1 → residues					258:269	containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues	200:269	1 → residues	258:269	In this study, a novel 28.6 kDa acidic polysaccharide (HTP-1), containing → 4)-GalpA-(1→, →2)-Rhap-(1 → and → 3,6)-Galp-(1 → residues as the backbone, analogous to pectin, was isolated from mature Hawk tea leaves.
35597036	7	0	theme	fermentation	901:912	arg1	solution					914:921	the fermentation solution	897:921	the fermentation solution rather than FBTPS-3 itself	897:948	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	5	1	theme	IBD	704:706	arg1	microbiota					712:721	IBD gut microbiota	704:721	IBD gut microbiota	704:721	Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group.
35597036	6	2	theme	gut	806:808	arg1	microbiota					810:819	IBD gut microbiota	802:819	IBD gut microbiota	802:819	FBTPS-3 showed a superior modulated effect on IBD gut microbiota by increasing Bacteroides and decreasing Escherichia/Shigella.
35597036	4	3	theme	gut	572:574	arg1	microbiota					576:585	gut microbiota	572:585	gut microbiota	572:585	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	3	4	theme	anaerobic	449:457	arg1	fermentation					459:470	the anaerobic fermentation	445:470	the anaerobic fermentation in vitro	445:479	Thus, the anaerobic fermentation in vitro was used to investigate the potential mechanism.
35597036	4	5	used	utilized	547:554	arg2	FBTPS-3					530:536	FBTPS-3	530:536	FBTPS-3	530:536	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	6	6	theme	IBD	802:804	arg1	microbiota					810:819	IBD gut microbiota	802:819	IBD gut microbiota	802:819	FBTPS-3 showed a superior modulated effect on IBD gut microbiota by increasing Bacteroides and decreasing Escherichia/Shigella.
35597036	4	7	theme	inflammatory	592:603	arg1	disease					611:617	inflammatory bowel disease	592:617	inflammatory bowel disease (IBD) subjects	592:632	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	4	7	theme	inflammatory	592:603	arg1	IBD					620:622	IBD	620:622	IBD	620:622	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	0	8	theme	gut	84:86	arg1	microbiota					88:97	the gut microbiota	80:97	the gut microbiota	80:97	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	0	9	theme	colitis	104:110	arg1	subjects					112:119	colitis subjects	104:119	colitis subjects	104:119	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	7	10	theme	lipopolysaccharide-treated	986:1011	arg1	macrophages					1022:1032	lipopolysaccharide-treated RAW264.7 macrophages	986:1032	lipopolysaccharide-treated RAW264.7 macrophages	986:1032	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	5	11	dep	composition	675:685	arg1	the					671:673	the	671:673	the	671:673	Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group.
35597036	6	12	theme	modulated	782:790	arg1	effect					792:797	a superior modulated effect	771:797	a superior modulated effect on IBD gut microbiota	771:819	FBTPS-3 showed a superior modulated effect on IBD gut microbiota by increasing Bacteroides and decreasing Escherichia/Shigella.
35597036	4	13	theme	bowel	605:609	arg1	disease					611:617	inflammatory bowel disease	592:617	inflammatory bowel disease (IBD) subjects	592:632	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	4	13	theme	bowel	605:609	arg1	IBD					620:622	IBD	620:622	IBD	620:622	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	6	14	dep	modulated	782:790	arg1	superior					773:780	superior	773:780	superior	773:780	FBTPS-3 showed a superior modulated effect on IBD gut microbiota by increasing Bacteroides and decreasing Escherichia/Shigella.
35597036	6	15	from	effect	792:797	arg1	microbiota					810:819	IBD gut microbiota	802:819	IBD gut microbiota	802:819	FBTPS-3 showed a superior modulated effect on IBD gut microbiota by increasing Bacteroides and decreasing Escherichia/Shigella.
35597036	0	16	theme	brick	8:12	arg1	candidate					55:63	a promising candidate	43:63	a promising candidate for remodeling the gut microbiota from colitis subjects in vitro	43:128	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	0	16	theme	brick	8:12	arg1	polysaccharides					18:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	7	17	theme	fatty	1093:1097	arg1	SCFAs					1106:1110	SCFAs	1106:1110	SCFAs	1106:1110	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	7	17	theme	fatty	1093:1097	arg1	acids					1099:1103	short-chain fatty acids	1081:1103	short-chain fatty acids (SCFAs)	1081:1111	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	0	18	theme	Fermentation	131:142	arg1	characteristic					144:157	Fermentation characteristic	131:157	Fermentation characteristic	131:157	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	2	19	theme	FBTPS-3	390:396	arg1	microbiota					410:419	the gut microbiota	402:419	the gut microbiota	402:419	However, the relationship between anti-inflammatory effect of FBTPS-3 and the gut microbiota is still unknown.
35597036	2	19	theme	FBTPS-3	390:396	arg1	effect					380:385	anti-inflammatory effect	362:385	anti-inflammatory effect of FBTPS-3	362:396	However, the relationship between anti-inflammatory effect of FBTPS-3 and the gut microbiota is still unknown.
35597036	0	20	theme	Fuzhuan	0:6	arg1	candidate					55:63	a promising candidate	43:63	a promising candidate for remodeling the gut microbiota from colitis subjects in vitro	43:128	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	0	20	theme	Fuzhuan	0:6	arg1	polysaccharides					18:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	1	21	theme	purified	195:202	arg1	fraction					204:211	The purified fraction 3	191:213	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3)	191:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	3	22	used	used	485:488	arg2	fermentation					459:470	the anaerobic fermentation	445:470	the anaerobic fermentation in vitro	445:479	Thus, the anaerobic fermentation in vitro was used to investigate the potential mechanism.
35597036	7	23	theme	RAW264.7	1013:1020	arg1	macrophages					1022:1032	lipopolysaccharide-treated RAW264.7 macrophages	986:1032	lipopolysaccharide-treated RAW264.7 macrophages	986:1032	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	0	24	theme	tea	14:16	arg1	candidate					55:63	a promising candidate	43:63	a promising candidate for remodeling the gut microbiota from colitis subjects in vitro	43:128	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	0	24	theme	tea	14:16	arg1	polysaccharides					18:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	3	25	from	fermentation	459:470	arg1	vitro					475:479	vitro	475:479	vitro	475:479	Thus, the anaerobic fermentation in vitro was used to investigate the potential mechanism.
35597036	5	26	theme	gut	708:710	arg1	microbiota					712:721	IBD gut microbiota	704:721	IBD gut microbiota	704:721	Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group.
35597036	5	27	theme	microbiota	712:721	arg1	structure					691:699	structure	691:699	structure	691:699	Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group.
35597036	5	27	theme	microbiota	712:721	arg1	composition					675:685	composition	675:685	composition	675:685	Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group.
35597036	1	28	theme	polysaccharides	218:232	arg1	fraction					204:211	The purified fraction 3	191:213	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3)	191:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	0	29	theme	promising	45:53	arg1	candidate					55:63	a promising candidate	43:63	a promising candidate for remodeling the gut microbiota from colitis subjects in vitro	43:128	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	0	29	theme	promising	45:53	arg1	polysaccharides					18:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides	0:32	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	8	30	theme	IBD	1181:1183	arg1	treatment					1168:1176	treatment	1168:1176	treatment of IBD	1168:1183	Thus, FBTPS-3 can be expected as novel prebiotics for treatment of IBD via modulating gut microbiota, and promoting the production of SCFAs.
35597036	7	31	theme	short-chain	1081:1091	arg1	SCFAs					1106:1110	SCFAs	1106:1110	SCFAs	1106:1110	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	7	31	theme	short-chain	1081:1091	arg1	acids					1099:1103	short-chain fatty acids	1081:1103	short-chain fatty acids (SCFAs)	1081:1111	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	1	32	theme	gut	312:314	arg1	microbiota					316:325	the gut microbiota	308:325	the gut microbiota	308:325	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	1	33	from	tea	253:255	arg1	fraction					204:211	The purified fraction 3	191:213	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3)	191:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	1	33	from	tea	253:255	arg1	polysaccharides					218:232	polysaccharides	218:232	polysaccharides from Fuzhuan brick tea (FBTPS-3)	218:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	0	34	dep	serve	34:38	arg1	characteristic					144:157	Fermentation characteristic	131:157	Fermentation characteristic	131:157	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	0	34	dep	serve	34:38	arg1	activity					181:188	anti-inflammatory activity	163:188	anti-inflammatory activity	163:188	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	1	35	from	fraction	204:211	arg1	FBTPS-3					258:264	FBTPS-3	258:264	FBTPS-3	258:264	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	1	35	from	fraction	204:211	arg1	tea					253:255	Fuzhuan brick tea	239:255	Fuzhuan brick tea (FBTPS-3)	239:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	0	36	theme	anti-inflammatory	163:179	arg1	activity					181:188	anti-inflammatory activity	163:188	anti-inflammatory activity	163:188	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35597036	7	37	theme	anti-inflammatory	957:973	arg1	effects					975:981	anti-inflammatory effects	957:981	anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs)	957:1111	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	4	38	theme	disease	611:617	arg1	subjects					625:632	inflammatory bowel disease (IBD) subjects	592:632	inflammatory bowel disease (IBD) subjects	592:632	FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects.
35597036	8	39	theme	gut	1200:1202	arg1	microbiota					1204:1213	gut microbiota	1200:1213	gut microbiota	1200:1213	Thus, FBTPS-3 can be expected as novel prebiotics for treatment of IBD via modulating gut microbiota, and promoting the production of SCFAs.
35597036	7	40	from	effects	975:981	arg1	macrophages					1022:1032	lipopolysaccharide-treated RAW264.7 macrophages	986:1032	lipopolysaccharide-treated RAW264.7 macrophages	986:1032	Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs).
35597036	1	41	theme	Fuzhuan	239:245	arg1	FBTPS-3					258:264	FBTPS-3	258:264	FBTPS-3	258:264	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	1	41	theme	Fuzhuan	239:245	arg1	tea					253:255	Fuzhuan brick tea	239:255	Fuzhuan brick tea (FBTPS-3)	239:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	5	42	theme	healthy	741:747	arg1	group					749:753	healthy group	741:753	healthy group	741:753	Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group.
35597036	2	43	theme	gut	406:408	arg1	microbiota					410:419	the gut microbiota	402:419	the gut microbiota	402:419	However, the relationship between anti-inflammatory effect of FBTPS-3 and the gut microbiota is still unknown.
35597036	3	44	theme	potential	509:517	arg1	mechanism					519:527	the potential mechanism	505:527	the potential mechanism	505:527	Thus, the anaerobic fermentation in vitro was used to investigate the potential mechanism.
35597036	8	45	theme	SCFAs	1248:1252	arg1	production					1234:1243	the production	1230:1243	the production of SCFAs	1230:1252	Thus, FBTPS-3 can be expected as novel prebiotics for treatment of IBD via modulating gut microbiota, and promoting the production of SCFAs.
35597036	1	46	theme	brick	247:251	arg1	FBTPS-3					258:264	FBTPS-3	258:264	FBTPS-3	258:264	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	1	46	theme	brick	247:251	arg1	tea					253:255	Fuzhuan brick tea	239:255	Fuzhuan brick tea (FBTPS-3)	239:265	The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota.
35597036	8	47	theme	novel	1147:1151	arg1	FBTPS-3					1120:1126	FBTPS-3	1120:1126	FBTPS-3	1120:1126	Thus, FBTPS-3 can be expected as novel prebiotics for treatment of IBD via modulating gut microbiota, and promoting the production of SCFAs.
35597036	8	47	theme	novel	1147:1151	arg1	prebiotics					1153:1162	novel prebiotics	1147:1162	novel prebiotics for treatment of IBD	1147:1183	Thus, FBTPS-3 can be expected as novel prebiotics for treatment of IBD via modulating gut microbiota, and promoting the production of SCFAs.
35597036	2	48	theme	anti-inflammatory	362:378	arg1	effect					380:385	anti-inflammatory effect	362:385	anti-inflammatory effect of FBTPS-3	362:396	However, the relationship between anti-inflammatory effect of FBTPS-3 and the gut microbiota is still unknown.
35597036	0	49	from	subjects	112:119	arg1	remodeling					69:78	remodeling	69:78	remodeling	69:78	Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity.
35618090	3	0	with	mannan	446:451	arg1	backbone					460:467	a backbone	458:467	a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp	458:633	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	2	1	theme	electron	393:400	arg1	microscopy					402:411	scanning electron microscopy	384:411	scanning electron microscopy	384:411	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	0	2	from	characterization	11:26	arg1	leucopus					84:91	leucopus	84:91	leucopus	84:91	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	5	3	theme	necrosis	819:826	arg1	TNF-α					838:842	TNF-α	838:842	TNF-α	838:842	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	5	3	theme	necrosis	819:826	arg1	factor-α					828:835	tumor necrosis factor-α	813:835	tumor necrosis factor-α (TNF-α)	813:843	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	2	4	theme	scanning	384:391	arg1	microscopy					402:411	scanning electron microscopy	384:411	scanning electron microscopy	384:411	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	6	5	theme	macrophage	913:922	arg1	activation					924:933	macrophage activation	913:933	macrophage activation	913:933	HLP-1 induced macrophage activation via NF-κB signal pathway.
35618090	7	6	theme	immune	1013:1018	arg1	HLP-1					991:995	HLP-1	991:995	HLP-1	991:995	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	7	6	theme	immune	1013:1018	arg1	agent					1032:1036	a potential immune enhancement agent	1001:1036	a potential immune enhancement agent applied in functional foods	1001:1064	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	5	7	theme	tumor	813:817	arg1	TNF-α					838:842	TNF-α	838:842	TNF-α	838:842	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	5	7	theme	tumor	813:817	arg1	factor-α					828:835	tumor necrosis factor-α	813:835	tumor necrosis factor-α (TNF-α)	813:843	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	3	8	theme	1 → 4	533:537	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	5	9	theme	interleukin-1	846:858	arg1	IL-1β					866:870	IL-1β	866:870	IL-1β	866:870	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	5	9	theme	interleukin-1	846:858	arg1	beta					860:863	interleukin-1 beta	846:863	interleukin-1 beta (IL-1β)	846:871	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	4	10	theme	red	710:712	arg1	phagocytosis					714:725	neutral red phagocytosis	702:725	neutral red phagocytosis	702:725	Moreover, HLP-1 could significantly improve the proliferation and neutral red phagocytosis of RAW264.7.
35618090	3	11	theme	-α-D-Manp	523:531	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	5	12	theme	oxide	796:800	arg1	production					775:784	the production	771:784	the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)	771:896	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	5	13	theme	beta	860:863	arg1	production					775:784	the production	771:784	the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)	771:896	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	2	14	theme	composition	299:309	arg1	analysis					311:318	monosaccharide composition analysis	284:318	monosaccharide composition analysis	284:318	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	1	15	theme	fruiting	168:175	arg1	bodies					177:182	the fruiting bodies	164:182	the fruiting bodies of Helvella leucopus	164:203	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	5	16	theme	factor-α	828:835	arg1	production					775:784	the production	771:784	the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)	771:896	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	7	17	theme	potential	1003:1011	arg1	HLP-1					991:995	HLP-1	991:995	HLP-1	991:995	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	7	17	theme	potential	1003:1011	arg1	agent					1032:1036	a potential immune enhancement agent	1001:1036	a potential immune enhancement agent applied in functional foods	1001:1064	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	2	18	theme	monosaccharide	284:297	arg1	analysis					311:318	monosaccharide composition analysis	284:318	monosaccharide composition analysis	284:318	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	3	19	theme	O-6	591:593	arg1	position					595:602	the O-6 position	587:602	the O-6 position	587:602	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	0	20	from	activity	49:56	arg1	leucopus					84:91	leucopus	84:91	leucopus	84:91	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	2	21	theme	nuclear	343:349	arg1	resonance					360:368	nuclear magnetic resonance	343:368	nuclear magnetic resonance spectroscopy	343:381	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	2	22	theme	red	423:425	arg1	assay					427:431	Congo red assay	417:431	Congo red assay	417:431	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	0	23	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	4	24	dep	proliferation	684:696	arg1	the					680:682	the	680:682	the	680:682	Moreover, HLP-1 could significantly improve the proliferation and neutral red phagocytosis of RAW264.7.
35618090	1	25	theme	new	96:98	arg1	fraction					115:122	A new polysaccharide fraction HLP-1 (2.55 × 105 Da)	94:144	A new polysaccharide fraction HLP-1 (2.55 × 105 Da)	94:144	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	2	26	theme	Congo	417:421	arg1	assay					427:431	Congo red assay	417:431	Congo red assay	417:431	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	0	27	theme	immunomodulatory	32:47	arg1	activity					49:56	immunomodulatory activity	32:56	immunomodulatory activity	32:56	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	7	28	theme	enhancement	1020:1030	arg1	HLP-1					991:995	HLP-1	991:995	HLP-1	991:995	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	7	28	theme	enhancement	1020:1030	arg1	agent					1032:1036	a potential immune enhancement agent	1001:1036	a potential immune enhancement agent applied in functional foods	1001:1064	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	1	29	theme	polysaccharide	100:113	arg1	fraction					115:122	A new polysaccharide fraction HLP-1 (2.55 × 105 Da)	94:144	A new polysaccharide fraction HLP-1 (2.55 × 105 Da)	94:144	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	3	30	theme	-α-D-Manp	475:483	arg1	1 → 4					485:489	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	1 → 4	485:489	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	3	31	theme	-α-D-Manp	507:515	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	4	32	theme	RAW264.7	730:737	arg1	phagocytosis					714:725	neutral red phagocytosis	702:725	neutral red phagocytosis	702:725	Moreover, HLP-1 could significantly improve the proliferation and neutral red phagocytosis of RAW264.7.
35618090	4	32	theme	RAW264.7	730:737	arg1	proliferation					684:696	proliferation	684:696	proliferation	684:696	Moreover, HLP-1 could significantly improve the proliferation and neutral red phagocytosis of RAW264.7.
35618090	2	33	theme	methylation	321:331	arg1	analysis					333:340	methylation analysis	321:340	methylation analysis	321:340	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	5	34	theme	nitric	789:794	arg1	oxide					796:800	nitric oxide	789:800	nitric oxide (NO)	789:805	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	5	34	theme	nitric	789:794	arg1	NO					803:804	NO	803:804	NO	803:804	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	0	35	from	leucopus	84:91	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	0	35	from	leucopus	84:91	arg1	activity					49:56	immunomodulatory activity	32:56	immunomodulatory activity	32:56	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	0	35	from	leucopus	84:91	arg1	mannan					63:68	a mannan	61:68	a mannan from Helvella leucopus	61:91	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	1	36	theme	Helvella	187:194	arg1	bodies					177:182	the fruiting bodies	164:182	the fruiting bodies of Helvella leucopus	164:203	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	3	37	theme	-α-D-Manp	539:547	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	1	38	dep	Helvella	187:194	arg1	leucopus					196:203	Helvella leucopus	187:203	Helvella leucopus	187:203	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	6	39	theme	NF-κB	939:943	arg1	pathway					952:958	NF-κB signal pathway	939:958	NF-κB signal pathway	939:958	HLP-1 induced macrophage activation via NF-κB signal pathway.
35618090	0	40	theme	mannan	63:68	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	0	40	theme	mannan	63:68	arg1	activity					49:56	immunomodulatory activity	32:56	immunomodulatory activity	32:56	Structural characterization and immunomodulatory activity of a mannan from Helvella leucopus.
35618090	2	41	theme	HLP-1	237:241	arg1	characterization					217:232	Structural characterization	206:232	Structural characterization of HLP-1	206:241	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	7	42	theme	functional	1049:1058	arg1	foods					1060:1064	functional foods	1049:1064	functional foods	1049:1064	These findings indicated that HLP-1 was a potential immune enhancement agent applied in functional foods.
35618090	3	43	theme	1 →6	502:505	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	3	44	theme	α-D-Manp	493:500	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	2	45	theme	Structural	206:215	arg1	characterization					217:232	Structural characterization	206:232	Structural characterization of HLP-1	206:241	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	3	46	theme	-α-D-Manp	555:563	arg1	backbone					460:467	a backbone	458:467	a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp	458:633	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	2	47	theme	resonance	360:368	arg1	spectroscopy					370:381	nuclear magnetic resonance spectroscopy	343:381	nuclear magnetic resonance spectroscopy	343:381	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	4	48	theme	neutral	702:708	arg1	phagocytosis					714:725	neutral red phagocytosis	702:725	neutral red phagocytosis	702:725	Moreover, HLP-1 could significantly improve the proliferation and neutral red phagocytosis of RAW264.7.
35618090	3	49	theme	1 → 3	517:521	arg1	-α-D-Manp					555:563	→6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→	472:566	-α-D-Manp	555:563	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	2	50	theme	magnetic	351:358	arg1	resonance					360:368	nuclear magnetic resonance	343:368	nuclear magnetic resonance spectroscopy	343:381	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	3	51	theme	1 → 4	485:489	arg1	backbone					460:467	a backbone	458:467	a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp	458:633	HLP-1 was a mannan with a backbone of →6)-α-D-Manp(1 → 4)- α-D-Manp(1 →6)-α-D-Manp(1 → 3)-α-D-Manp(1 → 4)-α-D-Manp(1 → 3)-α-D-Manp(1→, which branched at the O-6 position and terminated with T-β-D-Manp.
35618090	5	52	theme	interleukin-6	877:889	arg1	production					775:784	the production	771:784	the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)	771:896	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	2	53	theme	infrared	261:268	arg1	spectroscopy					270:281	infrared spectroscopy	261:281	infrared spectroscopy	261:281	Structural characterization of HLP-1 was elucidated by infrared spectroscopy, monosaccharide composition analysis, methylation analysis, nuclear magnetic resonance spectroscopy, scanning electron microscopy and Congo red assay.
35618090	5	54	theme	ROS	808:810	arg1	production					775:784	the production	771:784	the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6)	771:896	Besides, HLP-1 could stimulate the production of nitric oxide (NO), ROS, tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6).
35618090	1	55	dep	fraction	115:122	arg1	2.55 × 105 Da					131:143	2.55 × 105 Da	131:143	2.55 × 105 Da	131:143	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	1	55	dep	fraction	115:122	arg1	HLP-1					124:128	HLP-1	124:128	A new polysaccharide fraction HLP-1 (2.55 × 105 Da)	94:144	A new polysaccharide fraction HLP-1 (2.55 × 105 Da) was obtained from the fruiting bodies of Helvella leucopus.
35618090	6	56	theme	signal	945:950	arg1	pathway					952:958	NF-κB signal pathway	939:958	NF-κB signal pathway	939:958	HLP-1 induced macrophage activation via NF-κB signal pathway.
36437417	11	0	theme	fluids	1606:1611	arg1	properties					1578:1587	the properties	1574:1587	the properties of non-Newtonian fluids	1574:1611	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	10	1	theme	polysaccharides	1370:1384	arg1	molecules					1386:1394	polysaccharides molecules	1370:1394	polysaccharides molecules	1370:1394	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	4	2	from	differences	519:529	arg1	composition					553:563	the monosaccharide composition	534:563	the monosaccharide composition	534:563	There were also some differences in the monosaccharide composition between ZOP and ZOP-1.
36437417	9	3	theme	ZOP-1	1179:1183	arg1	surface					1168:1174	the surface	1164:1174	the surface of ZOP-1	1164:1183	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	9	3	theme	ZOP-1	1179:1183	arg1	uneven					1189:1194	uneven	1189:1194	uneven	1189:1194	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	2	4	theme	sugar	331:335	arg1	contents					337:344	The total soluble sugar contents	313:344	The total soluble sugar contents of ZOP and ZOP-1	313:361	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	2	4	theme	sugar	331:335	arg1	%					393:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	11	5	theme	dilution	1627:1634	arg1	phenomenon					1636:1645	shear dilution phenomenon	1621:1645	shear dilution phenomenon	1621:1645	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	10	6	theme	bond	1409:1412	arg1	association					1414:1424	hydrogen bond association	1400:1424	hydrogen bond association between sugar chains	1400:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	2	7	theme	total	317:321	arg1	contents					337:344	The total soluble sugar contents	313:344	The total soluble sugar contents of ZOP and ZOP-1	313:361	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	2	7	theme	total	317:321	arg1	%					393:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	1	8	theme	anti-inflammatory	215:231	arg1	activities					233:242	antioxidant and anti-inflammatory activities	199:242	antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP)	199:287	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	11	9	dep	had	1570:1572	arg1	showed					1614:1619	showed	1614:1619	showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine	1614:1728	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	10	theme	ion	1531:1533	arg1	concentrations					1535:1548	salt ion concentrations	1526:1548	salt ion concentrations	1526:1548	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	7	11	theme	good	929:932	arg1	stability					942:950	good thermal stability	929:950	good thermal stability	929:950	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	6	12	contain	contain	886:892	arg1	polysaccharides					799:813	the two polysaccharides	791:813	the two polysaccharides	791:813	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	12	contain	contain	886:892	arg2	protein					911:917	protein	911:917	protein	911:917	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	12	contain	contain	886:892	arg2	acid					902:905	nucleic acid	894:905	nucleic acid	894:905	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	1	13	theme	officinale	256:265	arg1	ZOP					284:286	ZOP	284:286	ZOP	284:286	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	1	13	theme	officinale	256:265	arg1	polysaccharides					267:281	Zingiber officinale polysaccharides	247:281	Zingiber officinale polysaccharides (ZOP)	247:287	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	8	14	from	differences	1029:1039	arg1	microstructure					1044:1057	microstructure	1044:1057	microstructure	1044:1057	ZOP and ZOP-1 had obvious differences in microstructure.
36437417	10	15	contain	contain	1457:1463	arg1	both					1452:1455	both	1452:1455	both	1452:1455	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	10	15	contain	contain	1457:1463	arg2	pyranose					1467:1474	α pyranose	1465:1474	α pyranose	1465:1474	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	11	16	from	thickener	1697:1705	arg1	food					1710:1713	food	1710:1713	food	1710:1713	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	16	from	thickener	1697:1705	arg1	biomedicine					1718:1728	biomedicine	1718:1728	biomedicine	1718:1728	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	1	17	theme	structural	147:156	arg1	characteristics					158:172	The structural characteristics	143:172	The structural characteristics	143:172	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	0	18	from	officinale	131:140	arg1	Polysaccharides					101:115	Polysaccharides	101:115	Polysaccharides from Zingiber officinale	101:140	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	18	from	officinale	131:140	arg1	Antioxidant					53:63	Antioxidant	53:63	Antioxidant	53:63	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	18	from	officinale	131:140	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	18	from	officinale	131:140	arg1	Properties					41:50	Rheological Properties	29:50	Rheological Properties	29:50	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	18	from	officinale	131:140	arg1	Activities					87:96	Anti-Inflammatory Activities	69:96	Anti-Inflammatory Activities	69:96	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	8	19	contain	had	1017:1019	arg2	differences					1029:1039	obvious differences	1021:1039	obvious differences in microstructure	1021:1057	ZOP and ZOP-1 had obvious differences in microstructure.
36437417	8	19	contain	had	1017:1019	arg1	ZOP					1003:1005	ZOP	1003:1005	ZOP	1003:1005	ZOP and ZOP-1 had obvious differences in microstructure.
36437417	8	19	contain	had	1017:1019	arg1	ZOP-1					1011:1015	ZOP-1	1011:1015	ZOP-1	1011:1015	ZOP and ZOP-1 had obvious differences in microstructure.
36437417	0	20	theme	Anti-Inflammatory	69:85	arg1	Activities					87:96	Anti-Inflammatory Activities	69:96	Anti-Inflammatory Activities	69:96	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	7	21	theme	sheet	986:990	arg1	structure					992:1000	amorphous sheet structure	976:1000	amorphous sheet structure	976:1000	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	6	22	contain	had	815:817	arg1	polysaccharides					799:813	the two polysaccharides	791:813	the two polysaccharides	791:813	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	22	contain	had	815:817	arg2	peaks					849:853	the characteristic absorption peaks	819:853	the characteristic absorption peaks of polysaccharides	819:872	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	5	23	theme	ZOP-1	623:627	arg1	monosaccharide					597:610	The main monosaccharide	588:610	The main monosaccharide of ZOP and ZOP-1	588:627	The main monosaccharide of ZOP and ZOP-1 was glucose (Glc) and galactose (Gal), respectively.
36437417	5	23	theme	ZOP-1	623:627	arg1	glucose					633:639	glucose	633:639	glucose (Glc)	633:645	The main monosaccharide of ZOP and ZOP-1 was glucose (Glc) and galactose (Gal), respectively.
36437417	1	24	theme	antioxidant	199:209	arg1	activities					233:242	antioxidant and anti-inflammatory activities	199:242	antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP)	199:287	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	9	25	theme	ZOP	1075:1077	arg1	surface					1064:1070	The surface	1060:1070	The surface of ZOP	1060:1077	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	9	25	theme	ZOP	1075:1077	arg1	smooth					1083:1088	smooth	1083:1088	smooth	1083:1088	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	7	26	theme	trihelix	953:960	arg1	structure					962:970	trihelix structure	953:970	trihelix structure	953:970	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	0	27	from	Antioxidant	53:63	arg1	officinale					131:140	Zingiber officinale	122:140	Zingiber officinale	122:140	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	28	from	Properties	41:50	arg1	officinale					131:140	Zingiber officinale	122:140	Zingiber officinale	122:140	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	7	29	contain	had	925:927	arg2	structure					962:970	trihelix structure	953:970	trihelix structure	953:970	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	7	29	contain	had	925:927	arg1	They					920:923	They	920:923	They	920:923	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	7	29	contain	had	925:927	arg2	structure					992:1000	amorphous sheet structure	976:1000	amorphous sheet structure	976:1000	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	7	29	contain	had	925:927	arg2	stability					942:950	good thermal stability	929:950	good thermal stability	929:950	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	6	30	dep	spectroscopy	702:713	arg1	UV-Vis					716:721	UV-Vis	716:721	UV-Vis	716:721	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	31	theme	spectroscopy	702:713	arg1	results					771:777	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results	682:777	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results	682:777	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	3	32	theme	molecular	448:456	arg1	weight					458:463	a larger molecular weight	439:463	a larger molecular weight	439:463	Compared with ZOP, ZOP-1 had a larger molecular weight and a more uniform distribution.
36437417	0	33	theme	Structural	0:9	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	5	34	theme	ZOP	615:617	arg1	monosaccharide					597:610	The main monosaccharide	588:610	The main monosaccharide of ZOP and ZOP-1	588:627	The main monosaccharide of ZOP and ZOP-1 was glucose (Glc) and galactose (Gal), respectively.
36437417	5	34	theme	ZOP	615:617	arg1	glucose					633:639	glucose	633:639	glucose (Glc)	633:645	The main monosaccharide of ZOP and ZOP-1 was glucose (Glc) and galactose (Gal), respectively.
36437417	6	35	theme	Ultraviolet	682:692	arg1	FT-IR					764:768	FT-IR	764:768	FT-IR	764:768	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	35	theme	Ultraviolet	682:692	arg1	spectroscopy					702:713	Ultraviolet visible spectroscopy	682:713	Ultraviolet visible spectroscopy (UV-Vis)	682:722	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	9	36	with	uneven	1189:1194	arg1	accumulation					1208:1219	spiral accumulation	1201:1219	spiral accumulation	1201:1219	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	10	37	theme	molecular	1292:1300	arg1	polymers					1302:1309	polysaccharides molecular polymers	1276:1309	polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains	1276:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	12	38	theme	antioxidant	1772:1782	arg1	activities					1806:1815	superior antioxidant and anti-inflammatory activities	1763:1815	superior antioxidant and anti-inflammatory activities	1763:1815	Compared with ZOP, ZOP-1 showed superior antioxidant and anti-inflammatory activities in vitro.
36437417	10	39	theme	van	1335:1337	arg1	waals					1343:1347	van der waals	1335:1347	van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains	1335:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	12	40	theme	anti-inflammatory	1788:1804	arg1	activities					1806:1815	superior antioxidant and anti-inflammatory activities	1763:1815	superior antioxidant and anti-inflammatory activities	1763:1815	Compared with ZOP, ZOP-1 showed superior antioxidant and anti-inflammatory activities in vitro.
36437417	6	41	dep	fourier	728:734	arg1	transform					736:744	transform	736:744	transform infrared spectra	736:761	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	9	42	theme	angular	1143:1149	arg1	shape					1151:1155	angular shape	1143:1155	angular shape	1143:1155	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	6	43	theme	absorption	838:847	arg1	peaks					849:853	the characteristic absorption peaks	819:853	the characteristic absorption peaks of polysaccharides	819:872	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	11	44	theme	texture	1677:1683	arg1	modifier					1685:1692	a texture modifier or thickener	1675:1705	modifier	1685:1692	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	45	theme	non-Newtonian	1592:1604	arg1	fluids					1606:1611	non-Newtonian fluids	1592:1611	non-Newtonian fluids	1592:1611	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	46	theme	shear	1621:1625	arg1	phenomenon					1636:1645	shear dilution phenomenon	1621:1645	shear dilution phenomenon	1621:1645	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	3	47	contain	had	435:437	arg2	distribution					484:495	a more uniform distribution	469:495	a more uniform distribution	469:495	Compared with ZOP, ZOP-1 had a larger molecular weight and a more uniform distribution.
36437417	3	47	contain	had	435:437	arg2	weight					458:463	a larger molecular weight	439:463	a larger molecular weight	439:463	Compared with ZOP, ZOP-1 had a larger molecular weight and a more uniform distribution.
36437417	3	47	contain	had	435:437	arg1	ZOP-1					429:433	ZOP-1	429:433	ZOP-1	429:433	Compared with ZOP, ZOP-1 had a larger molecular weight and a more uniform distribution.
36437417	11	48	theme	salt	1526:1529	arg1	concentrations					1535:1548	salt ion concentrations	1526:1548	salt ion concentrations	1526:1548	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	2	49	theme	soluble	323:329	arg1	contents					337:344	The total soluble sugar contents	313:344	The total soluble sugar contents of ZOP and ZOP-1	313:361	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	2	49	theme	soluble	323:329	arg1	%					393:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	6	50	theme	nucleic	894:900	arg1	acid					902:905	nucleic acid	894:905	nucleic acid	894:905	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	10	51	theme	hydrogen	1400:1407	arg1	bond					1409:1412	hydrogen bond	1400:1412	hydrogen bond association between sugar chains	1400:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	2	52	theme	ZOP-1	357:361	arg1	contents					337:344	The total soluble sugar contents	313:344	The total soluble sugar contents of ZOP and ZOP-1	313:361	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	2	52	theme	ZOP-1	357:361	arg1	%					393:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	4	53	theme	monosaccharide	538:551	arg1	composition					553:563	the monosaccharide composition	534:563	the monosaccharide composition	534:563	There were also some differences in the monosaccharide composition between ZOP and ZOP-1.
36437417	8	54	theme	obvious	1021:1027	arg1	differences					1029:1039	obvious differences	1021:1039	obvious differences in microstructure	1021:1057	ZOP and ZOP-1 had obvious differences in microstructure.
36437417	9	55	theme	spiral	1201:1206	arg1	accumulation					1208:1219	spiral accumulation	1201:1219	spiral accumulation	1201:1219	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	2	56	theme	ZOP	349:351	arg1	contents					337:344	The total soluble sugar contents	313:344	The total soluble sugar contents of ZOP and ZOP-1	313:361	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	2	56	theme	ZOP	349:351	arg1	%					393:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	78.6 ± 0.6 and 79.4 ± 0.4%	368:393	The total soluble sugar contents of ZOP and ZOP-1 were 78.6 ± 0.6 and 79.4 ± 0.4%, respectively.
36437417	1	57	theme	Zingiber	247:254	arg1	ZOP					284:286	ZOP	284:286	ZOP	284:286	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	1	57	theme	Zingiber	247:254	arg1	polysaccharides					267:281	Zingiber officinale polysaccharides	247:281	Zingiber officinale polysaccharides (ZOP)	247:287	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	9	58	with	compact	1119:1125	arg1	shape					1151:1155	angular shape	1143:1155	angular shape	1143:1155	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	1	59	theme	polysaccharides	267:281	arg1	characteristics					158:172	The structural characteristics	143:172	The structural characteristics	143:172	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	1	59	theme	polysaccharides	267:281	arg1	activities					233:242	antioxidant and anti-inflammatory activities	199:242	antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP)	199:287	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	1	59	theme	polysaccharides	267:281	arg1	ZOP-1					293:297	ZOP-1	293:297	ZOP-1	293:297	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	1	59	theme	polysaccharides	267:281	arg1	properties					187:196	rheological properties	175:196	rheological properties	175:196	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	0	60	from	Activities	87:96	arg1	officinale					131:140	Zingiber officinale	122:140	Zingiber officinale	122:140	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	11	61	contain	had	1570:1572	arg2	properties					1578:1587	the properties	1574:1587	the properties of non-Newtonian fluids	1574:1611	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	61	contain	had	1570:1572	arg1	temperature					1506:1516	temperature	1506:1516	temperature	1506:1516	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	5	62	theme	main	592:595	arg1	monosaccharide					597:610	The main monosaccharide	588:610	The main monosaccharide of ZOP and ZOP-1	588:627	The main monosaccharide of ZOP and ZOP-1 was glucose (Glc) and galactose (Gal), respectively.
36437417	5	62	theme	main	592:595	arg1	glucose					633:639	glucose	633:639	glucose (Glc)	633:645	The main monosaccharide of ZOP and ZOP-1 was glucose (Glc) and galactose (Gal), respectively.
36437417	1	63	theme	rheological	175:185	arg1	properties					187:196	rheological properties	175:196	rheological properties	175:196	The structural characteristics, rheological properties, antioxidant and anti-inflammatory activities of Zingiber officinale polysaccharides (ZOP) and ZOP-1 were studied.
36437417	0	64	theme	Polysaccharides	101:115	arg1	Antioxidant					53:63	Antioxidant	53:63	Antioxidant	53:63	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	64	theme	Polysaccharides	101:115	arg1	Characterization					11:26	Structural Characterization	0:26	Structural Characterization	0:26	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	64	theme	Polysaccharides	101:115	arg1	Properties					41:50	Rheological Properties	29:50	Rheological Properties	29:50	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	0	64	theme	Polysaccharides	101:115	arg1	Activities					87:96	Anti-Inflammatory Activities	69:96	Anti-Inflammatory Activities	69:96	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	11	65	contain	had	1654:1656	arg1	phenomenon					1636:1645	shear dilution phenomenon	1621:1645	shear dilution phenomenon	1621:1645	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	65	contain	had	1654:1656	arg2	potential					1662:1670	the potential	1658:1670	the potential as a texture modifier or thickener in food or biomedicine	1658:1728	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	0	66	from	Characterization	11:26	arg1	officinale					131:140	Zingiber officinale	122:140	Zingiber officinale	122:140	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	10	67	theme	sugar	1434:1438	arg1	chains					1440:1445	sugar chains	1434:1445	sugar chains	1434:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	11	68	theme	different	1480:1488	arg1	concentrations					1490:1503	different concentrations	1480:1503	different concentrations	1480:1503	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	0	69	theme	Zingiber	122:129	arg1	officinale					131:140	Zingiber officinale	122:140	Zingiber officinale	122:140	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	7	70	theme	amorphous	976:984	arg1	structure					992:1000	amorphous sheet structure	976:1000	amorphous sheet structure	976:1000	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	10	71	theme	polysaccharides	1276:1290	arg1	polymers					1302:1309	polysaccharides molecular polymers	1276:1309	polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains	1276:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	11	72	from	modifier	1685:1692	arg1	food					1710:1713	food	1710:1713	food	1710:1713	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	11	72	from	modifier	1685:1692	arg1	biomedicine					1718:1728	biomedicine	1718:1728	biomedicine	1718:1728	At different concentrations, temperature, pH and salt ion concentrations, both ZOP and ZOP-1 had the properties of non-Newtonian fluids, showed shear dilution phenomenon, which had the potential as a texture modifier or thickener in food or biomedicine.
36437417	6	73	theme	visible	694:700	arg1	FT-IR					764:768	FT-IR	764:768	FT-IR	764:768	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	73	theme	visible	694:700	arg1	spectroscopy					702:713	Ultraviolet visible spectroscopy	682:713	Ultraviolet visible spectroscopy (UV-Vis)	682:722	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	0	74	theme	Rheological	29:39	arg1	Properties					41:50	Rheological Properties	29:50	Rheological Properties	29:50	Structural Characterization, Rheological Properties, Antioxidant and Anti-Inflammatory Activities of Polysaccharides from Zingiber officinale.
36437417	7	75	theme	thermal	934:940	arg1	stability					942:950	good thermal stability	929:950	good thermal stability	929:950	They had good thermal stability, trihelix structure and amorphous sheet structure.
36437417	3	76	theme	larger	441:446	arg1	weight					458:463	a larger molecular weight	439:463	a larger molecular weight	439:463	Compared with ZOP, ZOP-1 had a larger molecular weight and a more uniform distribution.
36437417	10	77	theme	α	1465:1465	arg1	pyranose					1467:1474	α pyranose	1465:1474	α pyranose	1465:1474	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	9	78	theme	broken	1098:1103	arg1	structure					1105:1113	the broken structure	1094:1113	the broken structure	1094:1113	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	9	78	theme	broken	1098:1103	arg1	compact					1119:1125	compact	1119:1125	compact	1119:1125	The surface of ZOP was smooth and the broken structure was compact and stable with angular shape, while the surface of ZOP-1 was uneven with spiral accumulation and not closely arranged.
36437417	10	79	theme	der	1339:1341	arg1	waals					1343:1347	van der waals	1335:1347	van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains	1335:1445	Moreover, ZOP and ZOP-1 were polysaccharides molecular polymers which were entangled by van der waals' force (VDW) between polysaccharides molecules and hydrogen bond association between sugar chains, and both contain α pyranose.
36437417	3	80	theme	uniform	476:482	arg1	distribution					484:495	a more uniform distribution	469:495	a more uniform distribution	469:495	Compared with ZOP, ZOP-1 had a larger molecular weight and a more uniform distribution.
36437417	6	81	theme	polysaccharides	858:872	arg1	peaks					849:853	the characteristic absorption peaks	819:853	the characteristic absorption peaks of polysaccharides	819:872	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	12	82	theme	superior	1763:1770	arg1	activities					1806:1815	superior antioxidant and anti-inflammatory activities	1763:1815	superior antioxidant and anti-inflammatory activities	1763:1815	Compared with ZOP, ZOP-1 showed superior antioxidant and anti-inflammatory activities in vitro.
36437417	6	83	theme	infrared	746:753	arg1	spectra					755:761	infrared spectra	746:761	infrared spectra	746:761	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	84	theme	characteristic	823:836	arg1	peaks					849:853	the characteristic absorption peaks	819:853	the characteristic absorption peaks of polysaccharides	819:872	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
36437417	6	85	theme	fourier	728:734	arg1	results					771:777	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results	682:777	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results	682:777	Ultraviolet visible spectroscopy (UV-Vis) and fourier transform infrared spectra (FT-IR) results showed that the two polysaccharides had the characteristic absorption peaks of polysaccharides and did not contain nucleic acid and protein.
34985061	4	0	theme	promising	830:838	arg1	effect					840:845	a promising effect	828:845	a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice	828:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	4	1	theme	-induced	997:1004	arg1	mice					1024:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	1	2	theme	extraction	237:246	arg1	effect					190:195	the effect	186:195	the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs)	186:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	3	3	theme	phosphatase	710:720	arg1	activity					722:729	acid phosphatase activity	705:729	acid phosphatase activity	705:729	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	4	4	from	features	900:907	arg1	mice					1024:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	3	5	contain	had	652:654	arg2	ability					665:671	stronger ability	656:671	stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro	656:785	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	3	5	contain	had	652:654	arg1	A-FBTPs					644:650	A-FBTPs	644:650	A-FBTPs	644:650	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	4	6	from	activities	922:931	arg1	mice					1024:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	6	7	theme	high-quality	1511:1522	arg1	polysaccharides					1531:1545	high-quality acidic polysaccharides	1511:1545	high-quality acidic polysaccharides from Fuzhuan brick tea (FBT)	1511:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	5	8	dep	-producing	1233:1242	arg1	acid					1222:1225	short chain fatty acid	1204:1225	short chain fatty acid	1204:1225	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	3	9	theme	oxide	742:746	arg1	secretion					753:761	nitric oxide (NO) secretion	735:761	nitric oxide (NO) secretion	735:761	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	1	10	from	characteristics	266:280	arg1	tea					350:352	Fuzhuan brick tea	336:352	Fuzhuan brick tea (FBTPs)	336:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	10	from	characteristics	266:280	arg1	FBTPs					355:359	FBTPs	355:359	FBTPs	355:359	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	2	11	contain	had	459:461	arg1	FBTPs					443:447	alkali-extracted FBTPs	426:447	alkali-extracted FBTPs (A-FBTPs)	426:457	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	11	contain	had	459:461	arg2	compositions					518:529	different monosaccharide compositions	493:529	different monosaccharide compositions	493:529	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	11	contain	had	459:461	arg1	FBTPs					406:410	water-extracted FBTPs	390:410	water-extracted FBTPs (W-FBTPs)	390:420	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	11	contain	had	459:461	arg1	W-FBTPs					413:419	W-FBTPs	413:419	W-FBTPs	413:419	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	11	contain	had	459:461	arg1	A-FBTPs					450:456	A-FBTPs	450:456	A-FBTPs	450:456	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	11	contain	had	459:461	arg2	weights					481:487	similar molecular weights	463:487	similar molecular weights	463:487	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	12	theme	promising	1487:1495	arg1	way					1497:1499	a promising way	1485:1499	a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT)	1485:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	12	theme	promising	1487:1495	arg1	extraction					1465:1474	alkaline extraction	1456:1474	alkaline extraction	1456:1474	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	4	13	dep	in	795:796	arg1	vivo					798:801	vivo	798:801	vivo	798:801	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	4	14	theme	body	895:898	arg1	features					900:907	the body features	891:907	the body features	891:907	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	5	15	theme	A-FBTP	1039:1044	arg1	supplementation					1046:1060	A-FBTP supplementation	1039:1060	A-FBTP supplementation	1039:1060	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	2	16	theme	uronic	572:577	arg1	groups					584:589	uronic acid groups	572:589	uronic acid groups	572:589	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	17	theme	further	1663:1669	arg1	application					1671:1681	further application	1663:1681	further application in food formulations	1663:1702	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	4	18	theme	immune	934:939	arg1	response					941:948	immune response	934:948	immune response	934:948	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	5	19	dep	Lactobacillus	1185:1197	arg1	e.g.					1179:1182	e.g.	1179:1182	e.g.	1179:1182	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	0	20	theme	brick	71:75	arg1	tea					77:79	Fuzhuan brick tea	63:79	Fuzhuan brick tea	63:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	5	21	theme	microbiota	1099:1108	arg1	dysbiosis					1110:1118	CTX-induced gut microbiota dysbiosis	1083:1118	CTX-induced gut microbiota dysbiosis	1083:1118	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	6	22	theme	Fuzhuan	1552:1558	arg1	FBT					1571:1573	FBT	1571:1573	FBT	1571:1573	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	22	theme	Fuzhuan	1552:1558	arg1	tea					1566:1568	Fuzhuan brick tea	1552:1568	Fuzhuan brick tea (FBT)	1552:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	2	23	theme	higher	555:560	arg1	yield					562:566	a higher yield	553:566	a higher yield	553:566	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	24	theme	potential	1617:1625	arg1	prebiotics					1627:1636	novel potential prebiotics	1611:1636	novel potential prebiotics	1611:1636	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	24	theme	potential	1617:1625	arg1	A-FBTPs					1581:1587	A-FBTPs	1581:1587	A-FBTPs	1581:1587	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	0	25	from	Comparison	0:9	arg1	tea					77:79	Fuzhuan brick tea	63:79	Fuzhuan brick tea	63:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	5	26	theme	-producing	1233:1242	arg1	bacteria					1244:1251	short chain fatty acid (SCFA)-producing bacteria	1204:1251	short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae)	1204:1311	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	0	27	theme	immunomodulatory	91:106	arg1	effects					108:114	their immunomodulatory effects	85:114	their immunomodulatory effects in vitro and in vivo	85:135	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	2	28	theme	water-extracted	390:404	arg1	W-FBTPs					413:419	W-FBTPs	413:419	W-FBTPs	413:419	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	28	theme	water-extracted	390:404	arg1	FBTPs					406:410	water-extracted FBTPs	390:410	water-extracted FBTPs (W-FBTPs)	390:420	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	5	29	theme	CTX-induced	1083:1093	arg1	dysbiosis					1110:1118	CTX-induced gut microbiota dysbiosis	1083:1118	CTX-induced gut microbiota dysbiosis	1083:1118	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	2	30	theme	similar	463:469	arg1	weights					481:487	similar molecular weights	463:487	similar molecular weights	463:487	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	31	from	application	1671:1681	arg1	formulations					1691:1702	food formulations	1686:1702	food formulations	1686:1702	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	2	32	theme	different	493:501	arg1	compositions					518:529	different monosaccharide compositions	493:529	different monosaccharide compositions	493:529	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	1	33	theme	structural	255:264	arg1	characteristics					266:280	structural characteristics	255:280	structural characteristics	255:280	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	2	34	theme	alkali-extracted	426:441	arg1	FBTPs					443:447	alkali-extracted FBTPs	426:447	alkali-extracted FBTPs (A-FBTPs)	426:457	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	34	theme	alkali-extracted	426:441	arg1	A-FBTPs					450:456	A-FBTPs	450:456	A-FBTPs	450:456	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	0	35	theme	water-	14:19	arg1	polysaccharides					42:56	water- and alkali-extracted polysaccharides	14:56	water- and alkali-extracted polysaccharides from Fuzhuan brick tea	14:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	4	36	theme	mucosal	965:971	arg1	barrier					973:979	intestinal mucosal barrier	954:979	intestinal mucosal barrier	954:979	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	0	37	theme	alkali-extracted	25:40	arg1	polysaccharides					42:56	water- and alkali-extracted polysaccharides	14:56	water- and alkali-extracted polysaccharides from Fuzhuan brick tea	14:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	1	38	theme	polysaccharides	315:329	arg1	characteristics					266:280	structural characteristics	255:280	structural characteristics	255:280	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	38	theme	polysaccharides	315:329	arg1	activity					303:310	immunomodulatory activity	286:310	immunomodulatory activity	286:310	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	39	theme	Fuzhuan	336:342	arg1	tea					350:352	Fuzhuan brick tea	336:352	Fuzhuan brick tea (FBTPs)	336:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	39	theme	Fuzhuan	336:342	arg1	FBTPs					355:359	FBTPs	355:359	FBTPs	355:359	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	5	40	theme	microbes	1371:1378	arg1	growth					1338:1343	the growth	1334:1343	the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter)	1334:1423	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	5	41	theme	short	1204:1208	arg1	acid					1222:1225	short chain fatty acid	1204:1225	short chain fatty acid	1204:1225	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	5	42	dep	Prevotellaceae	1277:1290	arg1	e.g.					1254:1257	e.g.	1254:1257	e.g.	1254:1257	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	6	43	theme	alkaline	1456:1463	arg1	way					1497:1499	a promising way	1485:1499	a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT)	1485:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	43	theme	alkaline	1456:1463	arg1	extraction					1465:1474	alkaline extraction	1456:1474	alkaline extraction	1456:1474	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	5	44	theme	fatty	1216:1220	arg1	acid					1222:1225	short chain fatty acid	1204:1225	short chain fatty acid	1204:1225	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	4	45	theme	immunosuppressive	1006:1022	arg1	mice					1024:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	1	46	theme	alkali-assisted	221:235	arg1	extraction					237:246	alkali-assisted extraction	221:246	alkali-assisted extraction	221:246	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	47	from	activity	303:310	arg1	tea					350:352	Fuzhuan brick tea	336:352	Fuzhuan brick tea (FBTPs)	336:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	47	from	activity	303:310	arg1	FBTPs					355:359	FBTPs	355:359	FBTPs	355:359	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	2	48	theme	acid	579:582	arg1	groups					584:589	uronic acid groups	572:589	uronic acid groups	572:589	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	49	from	tea	1566:1568	arg1	polysaccharides					1531:1545	high-quality acidic polysaccharides	1511:1545	high-quality acidic polysaccharides from Fuzhuan brick tea (FBT)	1511:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	50	theme	acidic	1524:1529	arg1	polysaccharides					1531:1545	high-quality acidic polysaccharides	1511:1545	high-quality acidic polysaccharides from Fuzhuan brick tea (FBT)	1511:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	3	51	theme	acid	705:708	arg1	phosphatase					710:720	acid phosphatase	705:720	acid phosphatase activity	705:729	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	2	52	theme	galacturonic	608:619	arg1	acid					621:624	galacturonic acid	608:624	galacturonic acid (GalA)	608:631	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	52	theme	galacturonic	608:619	arg1	GalA					627:630	GalA	627:630	GalA	627:630	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	53	theme	food	1686:1689	arg1	formulations					1691:1702	food formulations	1686:1702	food formulations	1686:1702	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	3	54	theme	nitric	735:740	arg1	oxide					742:746	nitric oxide	735:746	nitric oxide (NO) secretion	735:761	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	3	54	theme	nitric	735:740	arg1	NO					749:750	NO	749:750	NO	749:750	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	0	55	from	tea	77:79	arg1	effects					108:114	their immunomodulatory effects	85:114	their immunomodulatory effects in vitro and in vivo	85:135	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	0	55	from	tea	77:79	arg1	Comparison					0:9	Comparison	0:9	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea	0:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	0	55	from	tea	77:79	arg1	polysaccharides					42:56	water- and alkali-extracted polysaccharides	14:56	water- and alkali-extracted polysaccharides from Fuzhuan brick tea	14:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	1	56	from	effect	190:195	arg1	characteristics					266:280	structural characteristics	255:280	structural characteristics	255:280	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	56	from	effect	190:195	arg1	activity					303:310	immunomodulatory activity	286:310	immunomodulatory activity	286:310	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	57	dep	characteristics	266:280	arg1	the					251:253	the	251:253	the	251:253	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	5	58	theme	bacteria	1244:1251	arg1	abundance					1145:1153	the abundance	1141:1153	the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae)	1141:1311	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	5	59	theme	chain	1210:1214	arg1	acid					1222:1225	short chain fatty acid	1204:1225	short chain fatty acid	1204:1225	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	0	60	theme	polysaccharides	42:56	arg1	effects					108:114	their immunomodulatory effects	85:114	their immunomodulatory effects in vitro and in vivo	85:135	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	0	60	theme	polysaccharides	42:56	arg1	Comparison					0:9	Comparison	0:9	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea	0:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	4	61	theme	immune	861:866	arg1	imbalance					868:876	the immune imbalance	857:876	the immune imbalance	857:876	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	0	62	from	effects	108:114	arg1	tea					77:79	Fuzhuan brick tea	63:79	Fuzhuan brick tea	63:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	6	63	theme	brick	1560:1564	arg1	FBT					1571:1573	FBT	1571:1573	FBT	1571:1573	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	63	theme	brick	1560:1564	arg1	tea					1566:1568	Fuzhuan brick tea	1552:1568	Fuzhuan brick tea (FBT)	1552:1574	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	1	64	theme	brick	344:348	arg1	tea					350:352	Fuzhuan brick tea	336:352	Fuzhuan brick tea (FBTPs)	336:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	64	theme	brick	344:348	arg1	FBTPs					355:359	FBTPs	355:359	FBTPs	355:359	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	65	theme	present	145:151	arg1	study					153:157	the present study	141:157	the present study	141:157	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	5	66	dep	Desulfovibrionaceae	1387:1405	arg1	e.g.					1381:1384	e.g.	1381:1384	e.g.	1381:1384	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	2	67	theme	molecular	471:479	arg1	weights					481:487	similar molecular weights	463:487	similar molecular weights	463:487	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	6	68	theme	novel	1611:1615	arg1	prebiotics					1627:1636	novel potential prebiotics	1611:1636	novel potential prebiotics	1611:1636	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	6	68	theme	novel	1611:1615	arg1	A-FBTPs					1581:1587	A-FBTPs	1581:1587	A-FBTPs	1581:1587	These findings suggested that alkaline extraction might be a promising way to obtain high-quality acidic polysaccharides from Fuzhuan brick tea (FBT), and A-FBTPs could be developed as novel potential prebiotics and immunomodulators for further application in food formulations.
34985061	2	69	theme	monosaccharide	503:516	arg1	compositions					518:529	different monosaccharide compositions	493:529	different monosaccharide compositions	493:529	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	1	70	theme	water	200:204	arg1	extraction					206:215	water extraction	200:215	water extraction	200:215	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	2	71	contain	had	549:551	arg2	yield					562:566	a higher yield	553:566	a higher yield	553:566	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	71	contain	had	549:551	arg1	A-FBTPs					541:547	A-FBTPs	541:547	A-FBTPs	541:547	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	2	71	contain	had	549:551	arg2	groups					584:589	uronic acid groups	572:589	uronic acid groups	572:589	The results indicated that water-extracted FBTPs (W-FBTPs) and alkali-extracted FBTPs (A-FBTPs) had similar molecular weights but different monosaccharide compositions, of which A-FBTPs had a higher yield and uronic acid groups corresponding to galacturonic acid (GalA).
34985061	5	72	theme	gut	1095:1097	arg1	dysbiosis					1110:1118	CTX-induced gut microbiota dysbiosis	1083:1118	CTX-induced gut microbiota dysbiosis	1083:1118	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	5	73	theme	bacteria	1169:1176	arg1	abundance					1145:1153	the abundance	1141:1153	the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae)	1141:1311	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	1	74	from	tea	350:352	arg1	polysaccharides					315:329	polysaccharides	315:329	polysaccharides from Fuzhuan brick tea (FBTPs)	315:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	74	from	tea	350:352	arg1	characteristics					266:280	structural characteristics	255:280	structural characteristics	255:280	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	74	from	tea	350:352	arg1	activity					303:310	immunomodulatory activity	286:310	immunomodulatory activity	286:310	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	1	75	theme	immunomodulatory	286:301	arg1	activity					303:310	immunomodulatory activity	286:310	immunomodulatory activity	286:310	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	4	76	theme	intestinal	954:963	arg1	barrier					973:979	intestinal mucosal barrier	954:979	intestinal mucosal barrier	954:979	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	1	77	theme	extraction	206:215	arg1	effect					190:195	the effect	186:195	the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs)	186:360	In the present study, the purpose is to compare the effect of water extraction and alkali-assisted extraction on the structural characteristics and immunomodulatory activity of polysaccharides from Fuzhuan brick tea (FBTPs).
34985061	4	78	theme	antioxidant	910:920	arg1	activities					922:931	antioxidant activities	910:931	antioxidant activities	910:931	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	0	79	theme	Fuzhuan	63:69	arg1	tea					77:79	Fuzhuan brick tea	63:79	Fuzhuan brick tea	63:79	Comparison of water- and alkali-extracted polysaccharides from Fuzhuan brick tea and their immunomodulatory effects in vitro and in vivo.
34985061	4	80	from	barrier	973:979	arg1	mice					1024:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	5	81	dep	along	1314:1318	arg1	with					1320:1323	with	1320:1323	with	1320:1323	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	3	82	theme	stronger	656:663	arg1	ability					665:671	stronger ability	656:671	stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro	656:785	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
34985061	4	83	theme	in	795:796	arg1	study					803:807	the in vivo study	791:807	the in vivo study	791:807	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	5	84	theme	pathogenic	1360:1369	arg1	microbes					1371:1378	potentially pathogenic microbes	1348:1378	potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter)	1348:1423	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	4	85	from	response	941:948	arg1	mice					1024:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	cytoxan (CTX)-induced immunosuppressive mice	984:1027	In the in vivo study, A-FBTPs exhibited a promising effect to adjust the immune imbalance by enhancing the body features, antioxidant activities, immune response and intestinal mucosal barrier in cytoxan (CTX)-induced immunosuppressive mice.
34985061	5	86	theme	beneficial	1158:1167	arg1	bacteria					1169:1176	beneficial bacteria	1158:1176	beneficial bacteria (e.g., Lactobacillus)	1158:1198	Besides, A-FBTP supplementation effectively improved CTX-induced gut microbiota dysbiosis, including promoting the abundance of beneficial bacteria (e.g., Lactobacillus) and short chain fatty acid (SCFA)-producing bacteria (e.g., Lachnospiraceae, Prevotellaceae and Ruminococcaceae), along with reducing the growth of potentially pathogenic microbes (e.g., Desulfovibrionaceae and Helicobacter).
34985061	3	87	theme	phagocytic	684:693	arg1	capacity					695:702	phagocytic capacity	684:702	phagocytic capacity	684:702	Moreover, A-FBTPs had stronger ability to promote phagocytic capacity, acid phosphatase activity and nitric oxide (NO) secretion in macrophages in vitro.
36882980	9	0	theme	2.0 MPa	1256:1262	arg1	modulus					1229:1235	modulus	1229:1235	modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa	1229:1291	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	8	1	theme	implants	1006:1013	arg1	printing					967:974	3D printing	964:974	3D printing of partially absorbable smart implants	964:1013	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	8	2	theme	feedstock	933:941	arg1	filaments					949:957	feedstock stock filaments	933:957	feedstock stock filaments (for 3D printing of partially absorbable smart implants)	933:1014	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	3	3	theme	sensing	522:528	arg1	capability					530:539	online sensing capability	515:539	online sensing capability	515:539	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	9	4	dep	properties	1209:1218	arg1	such					1221:1224	such	1221:1224	such	1221:1224	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	5	5	theme	absorbable	754:763	arg1	implant					771:777	a partially absorbable smart implant	742:777	a partially absorbable smart implant for the canine	742:792	%) to fabricate a partially absorbable smart implant for the canine.
36882980	5	6	theme	smart	765:769	arg1	implant					771:777	a partially absorbable smart implant	742:777	a partially absorbable smart implant for the canine	742:792	%) to fabricate a partially absorbable smart implant for the canine.
36882980	8	7	theme	smart	1000:1004	arg1	implants					1006:1013	partially absorbable smart implants	979:1013	partially absorbable smart implants	979:1013	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	2	8	theme	patients	352:359	arg1	monitoring					327:336	online health monitoring	313:336	online health monitoring of veterinary patients	313:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	9	9	theme	online	1393:1398	arg1	capabilities					1408:1419	online sensing capabilities	1393:1419	online sensing capabilities (for health monitoring)	1393:1443	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	10	10	dep	infrared	1531:1538	arg1	ATR-FTIR					1541:1548	ATR-FTIR	1541:1548	ATR-FTIR	1541:1548	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	9	11	theme	health	1426:1431	arg1	monitoring					1433:1442	health monitoring	1426:1442	health monitoring	1426:1442	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	12	theme	PVDF	1171:1174	arg1	composite					1176:1184	PVDF composite	1171:1184	PVDF composite	1171:1184	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	13	theme	selected	1136:1143	arg1	composition/proportion					1145:1166	the selected composition/proportion	1132:1166	the selected composition/proportion of PVDF composite	1132:1184	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	3	14	from	canines	566:572	arg1	orthopedic					546:555	orthopedic	546:555	orthopedic	546:555	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	9	15	theme	Young	1265:1269	arg1	889 MPa					1285:1291	Young's modulus (E) 889 MPa	1265:1291	Young's modulus (E) 889 MPa	1265:1291	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	15	theme	Young	1265:1269	arg1	2.0 MPa					1256:1262	toughness (MoT) 2.0 MPa	1240:1262	toughness (MoT) 2.0 MPa	1240:1262	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	10	16	theme	reflection	1502:1511	arg1	Fourier					1513:1519	attenuated total reflection Fourier	1485:1519	attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis	1485:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	9	17	dep	properties	1310:1319	arg1	30°C					1371:1374	30°C	1371:1374	30°C	1371:1374	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	17	dep	properties	1310:1319	arg1	20 MHz					1381:1386	20 MHz	1381:1386	20 MHz	1381:1386	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	17	dep	properties	1310:1319	arg1	ε					1343:1343	ε	1343:1343	ε	1343:1343	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	17	dep	properties	1310:1319	arg1	properties					1310:1319	dielectric properties	1299:1319	dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring)	1299:1443	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	17	dep	properties	1310:1319	arg1	constant					1333:1340	dielectric constant (ε) 9.6	1322:1348	dielectric constant (ε) 9.6 at room temperature (30°C)	1322:1375	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	10	18	theme	spectroscopy	1635:1646	arg1	analysis					1654:1661	energy dispersive spectroscopy (EDS) analysis	1617:1661	energy dispersive spectroscopy (EDS) analysis	1617:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	8	19	theme	3D	964:965	arg1	printing					967:974	3D printing	964:974	3D printing of partially absorbable smart implants	964:1013	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	4	20	theme	various	695:701	arg1	proportions					710:720	various weight proportions	695:720	various weight proportions	695:720	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	4	21	theme	chitosan	600:607	arg1	nanoparticles					614:626	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles	575:626	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles	575:626	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	3	22	dep	orthopedic	546:555	arg1	needs					557:561	needs	557:561	needs	557:561	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	9	23	theme	composite	1176:1184	arg1	composition/proportion					1145:1166	the selected composition/proportion	1132:1166	the selected composition/proportion of PVDF composite	1132:1184	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	2	24	theme	smart	266:270	arg1	implants					272:279	the partially absorbable smart implants	241:279	the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients	241:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	3	25	theme	affordable	414:423	arg1	implants					500:507	affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	414:507	affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	414:507	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	4	26	with	route	684:688	arg1	proportions					710:720	various weight proportions	695:720	various weight proportions	695:720	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	3	27	dep	affordable	414:423	arg1	composite-based					457:471	composite-based	457:471	composite-based	457:471	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	2	28	theme	absorbable	255:264	arg1	implants					272:279	the partially absorbable smart implants	241:279	the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients	241:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	1	29	theme	different	166:174	arg1	metals/alloys					176:188	different metals/alloys	166:188	different metals/alloys	166:188	For various orthopedic needs, several studies have been testified on non-absorbable implants, prepared with different metals/alloys, and composites.
36882980	0	30	theme	PVDF	3:6	arg1	composite					8:16	PVDF composite	3:16	PVDF composite as partially absorbable smart implants	3:55	On PVDF composite as partially absorbable smart implants.
36882980	9	31	theme	E	1282:1282	arg1	889 MPa					1285:1291	Young's modulus (E) 889 MPa	1265:1291	Young's modulus (E) 889 MPa	1265:1291	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	31	theme	E	1282:1282	arg1	2.0 MPa					1256:1262	toughness (MoT) 2.0 MPa	1240:1262	toughness (MoT) 2.0 MPa	1240:1262	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	10	32	dep	Fourier	1513:1519	arg1	transform					1521:1529	transform	1521:1529	transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis	1521:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	9	33	theme	acceptable	1187:1196	arg1	properties					1209:1218	acceptable mechanical properties	1187:1218	acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa)	1187:1292	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	2	34	theme	online	313:318	arg1	monitoring					327:336	online health monitoring	313:336	online health monitoring of veterinary patients	313:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	7	35	theme	%	830:830	arg1	HAp					832:834	% HAp	830:834	% HAp	830:834	% HAp and 2.0 wt.
36882980	4	36	theme	melt	668:671	arg1	route					684:688	a melt processing route	666:688	a melt processing route with various weight proportions	666:720	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	9	37	from	temperature	1358:1368	arg1	30°C					1371:1374	30°C	1371:1374	30°C	1371:1374	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	37	from	temperature	1358:1368	arg1	20 MHz					1381:1386	20 MHz	1381:1386	20 MHz	1381:1386	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	37	from	temperature	1358:1368	arg1	ε					1343:1343	ε	1343:1343	ε	1343:1343	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	37	from	temperature	1358:1368	arg1	properties					1310:1319	dielectric properties	1299:1319	dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring)	1299:1443	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	37	from	temperature	1358:1368	arg1	constant					1333:1340	dielectric constant (ε) 9.6	1322:1348	dielectric constant (ε) 9.6 at room temperature (30°C)	1322:1375	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	4	38	theme	Hydroxyapatite	575:588	arg1	nanoparticles					614:626	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles	575:626	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles	575:626	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	8	39	theme	rheological	1026:1036	arg1	characteristics					1111:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	8	40	theme	absorbable	989:998	arg1	implants					1006:1013	partially absorbable smart implants	979:1013	partially absorbable smart implants	979:1013	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	10	41	dep	transform	1521:1529	arg1	infrared					1531:1538	infrared	1531:1538	infrared	1531:1538	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	42	theme	scanning	1577:1584	arg1	microscopy					1595:1604	scanning electron microscopy	1577:1604	scanning electron microscopy (SEM)	1577:1610	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	42	theme	scanning	1577:1584	arg1	SEM					1607:1609	SEM	1607:1609	SEM	1607:1609	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	9	43	theme	mechanical	1198:1207	arg1	properties					1209:1218	acceptable mechanical properties	1187:1218	acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa)	1187:1292	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	2	44	theme	composites	298:307	arg1	implants					272:279	the partially absorbable smart implants	241:279	the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients	241:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	3	45	theme	absorbable	483:492	arg1	implants					500:507	affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	414:507	affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	414:507	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	10	46	theme	dispersive	1624:1633	arg1	spectroscopy					1635:1646	energy dispersive spectroscopy	1617:1646	energy dispersive spectroscopy (EDS) analysis	1617:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	46	theme	dispersive	1624:1633	arg1	EDS					1649:1651	EDS	1649:1651	EDS	1649:1651	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	8	47	theme	mechanical	1039:1048	arg1	characteristics					1111:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	2	48	theme	thermoplastic	284:296	arg1	composites					298:307	thermoplastic composites	284:307	thermoplastic composites for online health monitoring of veterinary patients	284:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	9	49	theme	room	1353:1356	arg1	temperature					1358:1368	room temperature	1353:1368	room temperature	1353:1368	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	3	50	theme	smart	494:498	arg1	implants					500:507	affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	414:507	affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	414:507	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	0	51	theme	absorbable	31:40	arg1	implants					48:55	partially absorbable smart implants	21:55	partially absorbable smart implants	21:55	On PVDF composite as partially absorbable smart implants.
36882980	3	52	theme	online	515:520	arg1	capability					530:539	online sensing capability	515:539	online sensing capability	515:539	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	9	53	theme	modulus	1273:1279	arg1	889 MPa					1285:1291	Young's modulus (E) 889 MPa	1265:1291	Young's modulus (E) 889 MPa	1265:1291	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	53	theme	modulus	1273:1279	arg1	2.0 MPa					1256:1262	toughness (MoT) 2.0 MPa	1240:1262	toughness (MoT) 2.0 MPa	1240:1262	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	8	54	from	CS	849:850	arg1	PVDF					855:858	PVDF	855:858	PVDF	855:858	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	4	55	theme	PVDF	651:654	arg1	matrix					656:661	the PVDF matrix	647:661	the PVDF matrix	647:661	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	8	56	theme	thermal	1051:1057	arg1	characteristics					1111:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	10	57	theme	total	1496:1500	arg1	Fourier					1513:1519	attenuated total reflection Fourier	1485:1519	attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis	1485:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	9	58	theme	dielectric	1299:1308	arg1	20 MHz					1381:1386	20 MHz	1381:1386	20 MHz	1381:1386	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	58	theme	dielectric	1299:1308	arg1	properties					1310:1319	dielectric properties	1299:1319	dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring)	1299:1443	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	58	theme	dielectric	1299:1308	arg1	constant					1333:1340	dielectric constant (ε) 9.6	1322:1348	dielectric constant (ε) 9.6 at room temperature (30°C)	1322:1375	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	59	theme	sensing	1400:1406	arg1	capabilities					1408:1419	online sensing capabilities	1393:1419	online sensing capabilities (for health monitoring)	1393:1443	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	8	60	theme	superlative	867:877	arg1	CS					849:850	% CS	847:850	% CS in PVDF	847:858	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	8	60	theme	superlative	867:877	arg1	composition/proportion					879:900	the superlative composition/proportion	863:900	the superlative composition/proportion	863:900	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	2	61	theme	veterinary	341:350	arg1	patients					352:359	veterinary patients	341:359	veterinary patients	341:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	0	62	theme	smart	42:46	arg1	implants					48:55	partially absorbable smart implants	21:55	partially absorbable smart implants	21:55	On PVDF composite as partially absorbable smart implants.
36882980	8	63	theme	dielectric	1060:1069	arg1	characteristics					1111:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	4	64	dep	reinforced	633:642	arg1	wt					723:724	wt	723:724	wt	723:724	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	8	65	theme	reinforcement	905:917	arg1	CS					849:850	% CS	847:850	% CS in PVDF	847:858	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	8	65	theme	reinforcement	905:917	arg1	composition/proportion					879:900	the superlative composition/proportion	863:900	the superlative composition/proportion	863:900	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	1	66	dep	orthopedic	70:79	arg1	needs					81:85	needs	81:85	needs	81:85	For various orthopedic needs, several studies have been testified on non-absorbable implants, prepared with different metals/alloys, and composites.
36882980	8	67	theme	%	847:847	arg1	CS					849:850	% CS	847:850	% CS in PVDF	847:858	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	8	67	theme	%	847:847	arg1	composition/proportion					879:900	the superlative composition/proportion	863:900	the superlative composition/proportion	863:900	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	8	68	theme	voltage-current-resistance	1076:1101	arg1	characteristics					1111:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics	1026:1125	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	9	69	theme	toughness	1240:1248	arg1	2.0 MPa					1256:1262	toughness (MoT) 2.0 MPa	1240:1262	toughness (MoT) 2.0 MPa	1240:1262	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	69	theme	toughness	1240:1248	arg1	889 MPa					1285:1291	Young's modulus (E) 889 MPa	1265:1291	Young's modulus (E) 889 MPa	1265:1291	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	4	70	theme	processing	673:682	arg1	route					684:688	a melt processing route	666:688	a melt processing route with various weight proportions	666:720	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36882980	3	71	theme	implants	500:507	arg1	development					399:409	the in-house development	386:409	the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	386:507	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	1	72	theme	several	88:94	arg1	studies					96:102	several studies	88:102	several studies	88:102	For various orthopedic needs, several studies have been testified on non-absorbable implants, prepared with different metals/alloys, and composites.
36882980	9	73	theme	dielectric	1322:1331	arg1	30°C					1371:1374	30°C	1371:1374	30°C	1371:1374	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	73	theme	dielectric	1322:1331	arg1	ε					1343:1343	ε	1343:1343	ε	1343:1343	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	73	theme	dielectric	1322:1331	arg1	properties					1310:1319	dielectric properties	1299:1319	dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring)	1299:1443	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	73	theme	dielectric	1322:1331	arg1	constant					1333:1340	dielectric constant (ε) 9.6	1322:1348	dielectric constant (ε) 9.6 at room temperature (30°C)	1322:1375	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	10	74	theme	energy	1617:1622	arg1	spectroscopy					1635:1646	energy dispersive spectroscopy	1617:1646	energy dispersive spectroscopy (EDS) analysis	1617:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	74	theme	energy	1617:1622	arg1	EDS					1649:1651	EDS	1649:1651	EDS	1649:1651	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	2	75	theme	health	320:325	arg1	monitoring					327:336	online health monitoring	313:336	online health monitoring of veterinary patients	313:359	But yet little has been stated on the partially absorbable smart implants of thermoplastic composites for online health monitoring of veterinary patients.
36882980	10	76	theme	electron	1586:1593	arg1	microscopy					1595:1604	scanning electron microscopy	1577:1604	scanning electron microscopy (SEM)	1577:1610	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	76	theme	electron	1586:1593	arg1	SEM					1607:1609	SEM	1607:1609	SEM	1607:1609	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	9	77	theme	MoT	1251:1253	arg1	2.0 MPa					1256:1262	toughness (MoT) 2.0 MPa	1240:1262	toughness (MoT) 2.0 MPa	1240:1262	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	9	77	theme	MoT	1251:1253	arg1	889 MPa					1285:1291	Young's modulus (E) 889 MPa	1265:1291	Young's modulus (E) 889 MPa	1265:1291	For the selected composition/proportion of PVDF composite, acceptable mechanical properties (such as modulus of toughness (MoT) 2.0 MPa, Young's modulus (E) 889 MPa), and dielectric properties (dielectric constant (ε) 9.6 at room temperature (30°C) and 20 MHz) for online sensing capabilities (for health monitoring) was observed.
36882980	1	78	theme	non-absorbable	127:140	arg1	implants					142:149	non-absorbable implants	127:149	non-absorbable implants	127:149	For various orthopedic needs, several studies have been testified on non-absorbable implants, prepared with different metals/alloys, and composites.
36882980	10	79	theme	X-ray	1552:1556	arg1	XRD					1571:1573	XRD	1571:1573	XRD	1571:1573	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	79	theme	X-ray	1552:1556	arg1	diffraction					1558:1568	X-ray diffraction	1552:1568	X-ray diffraction (XRD)	1552:1574	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	10	80	theme	attenuated	1485:1494	arg1	Fourier					1513:1519	attenuated total reflection Fourier	1485:1519	attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis	1485:1661	The results are braced by attenuated total reflection Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS) analysis.
36882980	8	81	theme	stock	943:947	arg1	filaments					949:957	feedstock stock filaments	933:957	feedstock stock filaments (for 3D printing of partially absorbable smart implants)	933:1014	% CS in PVDF is the superlative composition/proportion of reinforcement for preparing feedstock stock filaments (for 3D printing of partially absorbable smart implants), based on rheological, mechanical, thermal, dielectric, and voltage-current-resistance (V-I-R) characteristics.
36882980	3	82	theme	in-house	390:397	arg1	development					399:409	the in-house development	386:409	the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants	386:507	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	3	83	from	orthopedic	546:555	arg1	canines					566:572	canines	566:572	canines	566:572	This article highlights the in-house development of affordable, polyvinylidene fluoride (PVDF) composite-based partially absorbable smart implants (with online sensing capability) for orthopedic needs in canines.
36882980	4	84	theme	weight	703:708	arg1	proportions					710:720	various weight proportions	695:720	various weight proportions	695:720	Hydroxyapatite (HAp) and chitosan (CS) nanoparticles were reinforced in the PVDF matrix by a melt processing route with various weight proportions (wt.
36502942	1	0	theme	different	271:279	arg1	geometries					281:290	different geometries	271:290	different geometries	271:290	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	0	1	from	celluloses	6:15	arg1	geometries					30:39	different geometries	20:39	different geometries	20:39	Using celluloses in different geometries to reinforce collagen-based composites: Effect of cellulose concentration.
36502942	8	2	contain	possessed	1245:1253	arg1	composites					1234:1243	COL/CNF composites	1226:1243	COL/CNF composites	1226:1243	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	8	2	contain	possessed	1245:1253	arg2	behaviors					1273:1281	better mechanical behaviors	1255:1281	better mechanical behaviors	1255:1281	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	5	3	theme	COL/CF	905:910	arg1	composites					912:921	COL/CF composites	905:921	COL/CF composites	905:921	Besides, FTIR showed a increased hydrogen bonding for COL/CNF and COL/CNC composite films, but decrease for COL/CF composites.
36502942	6	4	theme	composites	986:995	arg1	strength					974:981	the strength	970:981	the strength of composites	970:995	As the concentration of CF and CNF increased, the strength of composites improved.
36502942	0	5	theme	concentration	101:113	arg1	Effect					81:86	Effect	81:86	Effect of cellulose concentration	81:113	Using celluloses in different geometries to reinforce collagen-based composites: Effect of cellulose concentration.
36502942	3	6	theme	concentration	520:532	arg1	effect					510:515	The effect	506:515	The effect of concentration of the three celluloses	506:556	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	3	7	theme	celluloses	547:556	arg1	concentration					520:532	concentration	520:532	concentration of the three celluloses	520:556	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	9	8	theme	COL/CNF	1401:1407	arg1	composites					1409:1418	COL/CNF composites	1401:1418	COL/CNF composites	1401:1418	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	0	9	theme	cellulose	91:99	arg1	concentration					101:113	cellulose concentration	91:113	cellulose concentration	91:113	Using celluloses in different geometries to reinforce collagen-based composites: Effect of cellulose concentration.
36502942	8	10	theme	COL/CNC	1307:1313	arg1	composites					1315:1324	COL/CF and COL/CNC composites	1296:1324	COL/CF and COL/CNC composites	1296:1324	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	9	11	theme	composites	1409:1418	arg1	modulus					1390:1396	the modulus	1386:1396	the modulus of COL/CNF composites	1386:1418	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	8	12	theme	mechanical	1262:1271	arg1	behaviors					1273:1281	better mechanical behaviors	1255:1281	better mechanical behaviors	1255:1281	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	8	13	theme	better	1255:1260	arg1	behaviors					1273:1281	better mechanical behaviors	1255:1281	better mechanical behaviors	1255:1281	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	4	14	theme	films	790:794	arg1	watertightness					742:755	watertightness	742:755	watertightness	742:755	The addition of celluloses increased the watertightness and thermostability of composite films.
36502942	4	14	theme	films	790:794	arg1	thermostability					761:775	thermostability	761:775	thermostability	761:775	The addition of celluloses increased the watertightness and thermostability of composite films.
36502942	8	15	theme	hydrogen	1180:1187	arg1	bonding					1189:1195	hydrogen bonding	1180:1195	hydrogen bonding	1180:1195	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	4	16	theme	composite	780:788	arg1	films					790:794	composite films	780:794	composite films	780:794	The addition of celluloses increased the watertightness and thermostability of composite films.
36502942	1	17	theme	few	183:185	arg1	literature					187:196	few literature	183:196	few literature	183:196	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	7	18	dep	increased	1081:1089	arg1	compared					1092:1099	compared	1092:1099	compared with that of collagen ones (90 MPa)	1092:1135	The TS for COL/CNF (124 MPa) and COL/CF composites (113 MPa) were largely increased, compared with that of collagen ones (90 MPa).
36502942	6	19	theme	CNF	955:957	arg1	concentration					931:943	the concentration	927:943	the concentration of CF and CNF	927:957	As the concentration of CF and CNF increased, the strength of composites improved.
36502942	8	20	theme	tortuosity	1214:1223	arg1	factors					1154:1160	the factors	1150:1160	the factors of crystallinity, hydrogen bonding, and interfacial tortuosity	1150:1223	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	3	21	theme	COL	689:691	arg1	films					694:698	collagen (COL) films	679:698	collagen (COL) films	679:698	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	7	22	theme	COL/CF	1040:1045	arg1	113 MPa					1059:1065	113 MPa	1059:1065	113 MPa	1059:1065	The TS for COL/CNF (124 MPa) and COL/CF composites (113 MPa) were largely increased, compared with that of collagen ones (90 MPa).
36502942	7	22	theme	COL/CF	1040:1045	arg1	composites					1047:1056	COL/CF composites	1040:1056	COL/CF composites (113 MPa)	1040:1066	The TS for COL/CNF (124 MPa) and COL/CF composites (113 MPa) were largely increased, compared with that of collagen ones (90 MPa).
36502942	1	23	used	used	140:143	arg2	Cellulose					116:124	Cellulose	116:124	Cellulose	116:124	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	8	24	theme	interfacial	1202:1212	arg1	tortuosity					1214:1223	interfacial tortuosity	1202:1223	interfacial tortuosity	1202:1223	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	0	25	theme	different	20:28	arg1	geometries					30:39	different geometries	20:39	different geometries	20:39	Using celluloses in different geometries to reinforce collagen-based composites: Effect of cellulose concentration.
36502942	8	26	theme	COL/CNF	1226:1232	arg1	composites					1234:1243	COL/CNF composites	1226:1243	COL/CNF composites	1226:1243	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	3	27	theme	barrier	578:584	arg1	properties					586:595	the barrier properties	574:595	the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films	574:698	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	8	28	theme	COL/CF	1296:1301	arg1	composites					1315:1324	COL/CF and COL/CNC composites	1296:1324	COL/CF and COL/CNC composites	1296:1324	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	2	29	theme	cellulose	441:449	arg1	CNF					462:464	CNF	462:464	CNF	462:464	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	29	theme	cellulose	441:449	arg1	nanofiber					451:459	long-chain cellulose nanofiber	430:459	long-chain cellulose nanofiber (CNF)	430:465	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	7	30	theme	collagen	1114:1121	arg1	90 MPa					1129:1134	90 MPa	1129:1134	90 MPa	1129:1134	The TS for COL/CNF (124 MPa) and COL/CF composites (113 MPa) were largely increased, compared with that of collagen ones (90 MPa).
36502942	7	30	theme	collagen	1114:1121	arg1	ones					1123:1126	collagen ones	1114:1126	collagen ones (90 MPa)	1114:1135	The TS for COL/CNF (124 MPa) and COL/CF composites (113 MPa) were largely increased, compared with that of collagen ones (90 MPa).
36502942	1	31	theme	composites	322:331	arg1	reinforcement					299:311	the reinforcement	295:311	the reinforcement of these composites	295:331	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	3	32	theme	mechanical	654:663	arg1	properties					665:674	mechanical properties	654:674	mechanical properties of collagen (COL) films	654:698	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	2	33	theme	long-chain	430:439	arg1	CNF					462:464	CNF	462:464	CNF	462:464	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	33	theme	long-chain	430:439	arg1	nanofiber					451:459	long-chain cellulose nanofiber	430:459	long-chain cellulose nanofiber (CNF)	430:465	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	8	34	theme	crystallinity	1165:1177	arg1	factors					1154:1160	the factors	1150:1160	the factors of crystallinity, hydrogen bonding, and interfacial tortuosity	1150:1223	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	1	35	from	geometries	281:290	arg1	concentration					240:252	concentration	240:252	concentration of celluloses in different geometries	240:290	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	5	36	theme	increased	820:828	arg1	bonding					839:845	a increased hydrogen bonding	818:845	a increased hydrogen bonding for COL/CNF and COL/CNC composite films	818:885	Besides, FTIR showed a increased hydrogen bonding for COL/CNF and COL/CNC composite films, but decrease for COL/CF composites.
36502942	1	37	from	effects	229:235	arg1	reinforcement					299:311	the reinforcement	295:311	the reinforcement of these composites	295:331	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	0	38	theme	collagen-based	54:67	arg1	composites					69:78	collagen-based composites	54:78	collagen-based composites	54:78	Using celluloses in different geometries to reinforce collagen-based composites: Effect of cellulose concentration.
36502942	6	39	theme	CF	948:949	arg1	concentration					931:943	the concentration	927:943	the concentration of CF and CNF	927:957	As the concentration of CF and CNF increased, the strength of composites improved.
36502942	1	40	from	celluloses	257:266	arg1	geometries					281:290	different geometries	271:290	different geometries	271:290	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	9	41	theme	percolation	1449:1459	arg1	%					1478:1478	2.7 wt%	1472:1478	2.7 wt%	1472:1478	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	9	41	theme	percolation	1449:1459	arg1	threshold					1461:1469	above percolation threshold	1443:1469	above percolation threshold (2.7 wt%)	1443:1479	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	2	42	theme	celluloses	366:375	arg1	nanocrystalline					407:421	rod-like cellulose nanocrystalline	388:421	rod-like cellulose nanocrystalline (CNC)	388:427	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	42	theme	celluloses	366:375	arg1	fines					494:498	microscopic cellulosic fines	471:498	microscopic cellulosic fines (CF)	471:503	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	42	theme	celluloses	366:375	arg1	types					357:361	three types	351:361	three types	351:361	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	42	theme	celluloses	366:375	arg1	nanofiber					451:459	long-chain cellulose nanofiber	430:459	long-chain cellulose nanofiber (CNF)	430:465	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	43	theme	microscopic	471:481	arg1	CF					501:502	CF	501:502	CF	501:502	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	43	theme	microscopic	471:481	arg1	fines					494:498	microscopic cellulosic fines	471:498	microscopic cellulosic fines (CF)	471:503	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	3	44	theme	collagen	679:686	arg1	films					694:698	collagen (COL) films	679:698	collagen (COL) films	679:698	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	9	45	theme	above	1443:1447	arg1	%					1478:1478	2.7 wt%	1472:1478	2.7 wt%	1472:1478	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	9	45	theme	above	1443:1447	arg1	threshold					1461:1469	above percolation threshold	1443:1469	above percolation threshold (2.7 wt%)	1443:1479	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	4	46	dep	watertightness	742:755	arg1	the					738:740	the	738:740	the	738:740	The addition of celluloses increased the watertightness and thermostability of composite films.
36502942	9	47	theme	Ouali	1358:1362	arg1	models					1364:1369	Halpin-Kardos and Ouali models	1340:1369	Halpin-Kardos and Ouali models	1340:1369	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
36502942	1	48	from	concentration	240:252	arg1	geometries					281:290	different geometries	271:290	different geometries	271:290	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	5	49	dep	COL/CNF	851:857	arg1	films					881:885	composite films	871:885	composite films	871:885	Besides, FTIR showed a increased hydrogen bonding for COL/CNF and COL/CNC composite films, but decrease for COL/CF composites.
36502942	4	50	theme	celluloses	717:726	arg1	addition					705:712	The addition	701:712	The addition of celluloses	701:726	The addition of celluloses increased the watertightness and thermostability of composite films.
36502942	1	51	theme	concentration	240:252	arg1	effects					229:235	the effects	225:235	the effects of concentration of celluloses in different geometries on the reinforcement of these composites	225:331	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	5	52	theme	hydrogen	830:837	arg1	bonding					839:845	a increased hydrogen bonding	818:845	a increased hydrogen bonding for COL/CNF and COL/CNC composite films	818:885	Besides, FTIR showed a increased hydrogen bonding for COL/CNF and COL/CNC composite films, but decrease for COL/CF composites.
36502942	1	53	theme	biocomposite	159:170	arg1	films					172:176	biocomposite films	159:176	biocomposite films	159:176	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	8	54	theme	bonding	1189:1195	arg1	factors					1154:1160	the factors	1150:1160	the factors of crystallinity, hydrogen bonding, and interfacial tortuosity	1150:1223	Considering the factors of crystallinity, hydrogen bonding, and interfacial tortuosity, COL/CNF composites possessed better mechanical behaviors than that of COL/CF and COL/CNC composites.
36502942	2	55	theme	cellulose	397:405	arg1	CNC					424:426	CNC	424:426	CNC	424:426	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	55	theme	cellulose	397:405	arg1	nanocrystalline					407:421	rod-like cellulose nanocrystalline	388:421	rod-like cellulose nanocrystalline (CNC)	388:427	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	5	56	theme	composite	871:879	arg1	films					881:885	composite films	871:885	composite films	871:885	Besides, FTIR showed a increased hydrogen bonding for COL/CNF and COL/CNC composite films, but decrease for COL/CF composites.
36502942	1	57	theme	celluloses	257:266	arg1	concentration					240:252	concentration	240:252	concentration of celluloses in different geometries	240:290	Cellulose is frequently used to strengthen biocomposite films, but few literature systematically deliberates the effects of concentration of celluloses in different geometries on the reinforcement of these composites.
36502942	2	58	theme	cellulosic	483:492	arg1	CF					501:502	CF	501:502	CF	501:502	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	58	theme	cellulosic	483:492	arg1	fines					494:498	microscopic cellulosic fines	471:498	microscopic cellulosic fines (CF)	471:503	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	3	59	theme	films	694:698	arg1	water					600:604	water	600:604	water	600:604	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	3	59	theme	films	694:698	arg1	microstructure					634:647	microstructure	634:647	microstructure	634:647	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	3	59	theme	films	694:698	arg1	thermostability					617:631	thermostability	617:631	thermostability	617:631	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	3	59	theme	films	694:698	arg1	light					610:614	light	610:614	light	610:614	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	3	59	theme	films	694:698	arg1	properties					665:674	mechanical properties	654:674	mechanical properties of collagen (COL) films	654:698	The effect of concentration of the three celluloses was examined on the barrier properties to water and light, thermostability, microstructure, and mechanical properties of collagen (COL) films.
36502942	0	60	dep	Using	0:4	arg1	Effect					81:86	Effect	81:86	Effect of cellulose concentration	81:113	Using celluloses in different geometries to reinforce collagen-based composites: Effect of cellulose concentration.
36502942	2	61	theme	rod-like	388:395	arg1	CNC					424:426	CNC	424:426	CNC	424:426	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	2	61	theme	rod-like	388:395	arg1	nanocrystalline					407:421	rod-like cellulose nanocrystalline	388:421	rod-like cellulose nanocrystalline (CNC)	388:427	Here we prepared three types of celluloses, including rod-like cellulose nanocrystalline (CNC), long-chain cellulose nanofiber (CNF) and microscopic cellulosic fines (CF).
36502942	9	62	theme	Halpin-Kardos	1340:1352	arg1	models					1364:1369	Halpin-Kardos and Ouali models	1340:1369	Halpin-Kardos and Ouali models	1340:1369	Furthermore, Halpin-Kardos and Ouali models well predicted the modulus of COL/CNF composites when CNF was below and above percolation threshold (2.7 wt%), respectively.
35987361	3	0	theme	current	328:334	arg1	work					336:339	current work	328:339	current work	328:339	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	1	theme	LPPs	624:627	arg1	characterizations					551:567	the physicochemical characterizations	531:567	the physicochemical characterizations	531:567	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	1	theme	LPPs	624:627	arg1	activities					582:591	antioxidant activities	570:591	antioxidant activities	570:591	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	1	theme	LPPs	624:627	arg1	activities					610:619	hypoglycemic activities	597:619	hypoglycemic activities	597:619	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	2	theme	protein	1215:1221	arg1	contents					1188:1195	their higher contents	1175:1195	their higher contents of neutral sugar, protein and uronic acid	1175:1237	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	2	theme	protein	1215:1221	arg1	weight					1259:1264	lower molecular weight	1243:1264	lower molecular weight than LPPA and LPPI	1243:1283	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	7	3	theme	F.	1354:1355	arg1	time					1325:1328	half drying time	1313:1328	half drying time	1313:1328	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	7	3	theme	F.	1354:1355	arg1	energy					1344:1349	one fifth energy	1334:1349	one fifth energy	1334:1349	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	6	4	theme	stronger	1007:1014	arg1	activities					1148:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	5	theme	higher	1069:1074	arg1	power					1092:1096	higher ferric-reducing power	1069:1096	higher ferric-reducing power	1069:1096	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	0	6	theme	antioxidant	75:85	arg1	activities					87:96	antioxidant activities	75:96	antioxidant activities	75:96	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	3	7	theme	hypoglycemic	597:608	arg1	activities					610:619	hypoglycemic activities	597:619	hypoglycemic activities	597:619	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	8	theme	oxygen	1016:1021	arg1	activities					1148:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	1	9	theme	pulp	161:164	arg1	polysaccharides					166:180	pulp polysaccharides	161:180	pulp polysaccharides.	161:181	pulp polysaccharides.
35987361	3	10	theme	physicochemical	535:549	arg1	characterizations					551:567	the physicochemical characterizations	531:567	the physicochemical characterizations	531:567	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	0	11	theme	hypoglycemic	102:113	arg1	activities					115:124	hypoglycemic activities	102:124	hypoglycemic activities	102:124	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	0	12	from	Effect	0:5	arg1	characterizations					56:72	the physicochemical characterizations	36:72	the physicochemical characterizations	36:72	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	0	12	from	Effect	0:5	arg1	activities					87:96	antioxidant activities	75:96	antioxidant activities	75:96	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	0	12	from	Effect	0:5	arg1	activities					115:124	hypoglycemic activities	102:124	hypoglycemic activities	102:124	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	4	13	theme	serious	782:788	arg1	drying					765:770	drying	765:770	drying	765:770	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	4	13	theme	serious	782:788	arg1	aggregations					794:805	the aggregations	790:805	the more serious the aggregations	773:805	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	6	14	theme	ferric-reducing	1076:1090	arg1	power					1092:1096	higher ferric-reducing power	1069:1096	higher ferric-reducing power	1069:1096	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	7	15	theme	fifth	1338:1342	arg1	energy					1344:1349	one fifth energy	1334:1349	one fifth energy	1334:1349	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	6	16	theme	scavenging	1046:1055	arg1	activities					1057:1066	DPPH and ABTS radical scavenging activities	1024:1066	DPPH and ABTS radical scavenging activities	1024:1066	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	3	17	theme	drying	362:367	arg1	drying					408:413	infrared drying	399:413	infrared drying (I)	399:417	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	17	theme	drying	362:367	arg1	drying					430:435	heat pump drying	420:435	heat pump drying (H)	420:439	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	17	theme	drying	362:367	arg1	drying					387:392	i.e. air drying	378:392	i.e. air drying (A)	378:396	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	17	theme	drying	362:367	arg1	drying					485:490	freeze vacuum drying	471:490	freeze vacuum drying	471:490	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	17	theme	drying	362:367	arg1	drying					456:461	vacuum freeze drying	442:461	vacuum freeze drying (F)	442:465	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	17	theme	drying	362:367	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	18	theme	α-amylase	1127:1135	arg1	inhibition					1137:1146	better α-glycosidase and α-amylase inhibition	1102:1146	better α-glycosidase and α-amylase inhibition	1102:1146	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	19	theme	neutral	1200:1206	arg1	sugar					1208:1212	neutral sugar	1200:1212	neutral sugar	1200:1212	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	2	20	theme	polysaccharides	301:315	arg1	quality					278:284	physicochemical and pharmacological quality	242:284	physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs)	242:322	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	5	21	theme	thermal	831:837	arg1	aggregation					839:849	the thermal aggregation	827:849	the thermal aggregation	827:849	Additionally, the thermal aggregation significantly affected the composition, structure and biological activity of LPPs.
35987361	2	22	theme	pulp	296:299	arg1	polysaccharides					301:315	lychee pulp polysaccharides	289:315	lychee pulp polysaccharides (LPPs)	289:322	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	2	22	theme	pulp	296:299	arg1	LPPs					318:321	LPPs	318:321	LPPs	318:321	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	2	23	theme	lychee	289:294	arg1	polysaccharides					301:315	lychee pulp polysaccharides	289:315	lychee pulp polysaccharides (LPPs)	289:322	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	2	23	theme	lychee	289:294	arg1	LPPs					318:321	LPPs	318:321	LPPs	318:321	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	7	24	theme	drying	1318:1323	arg1	time					1325:1328	half drying time	1313:1328	half drying time	1313:1328	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	3	25	theme	i.e.	378:381	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	25	theme	i.e.	378:381	arg1	A					395:395	A	395:395	A	395:395	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	25	theme	i.e.	378:381	arg1	drying					387:392	i.e. air drying	378:392	i.e. air drying (A)	378:396	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	26	theme	methods	369:375	arg1	effects					346:352	the effects	342:352	the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs	342:627	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	27	theme	higher	1181:1186	arg1	contents					1188:1195	their higher contents	1175:1195	their higher contents of neutral sugar, protein and uronic acid	1175:1237	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	3	28	theme	vacuum	478:483	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	28	theme	vacuum	478:483	arg1	drying					485:490	freeze vacuum drying	471:490	freeze vacuum drying	471:490	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	29	theme	air	383:385	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	29	theme	air	383:385	arg1	A					395:395	A	395:395	A	395:395	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	29	theme	air	383:385	arg1	drying					387:392	i.e. air drying	378:392	i.e. air drying (A)	378:396	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	30	theme	infrared	399:406	arg1	drying					408:413	infrared drying	399:413	infrared drying (I)	399:417	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	30	theme	infrared	399:406	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	30	theme	infrared	399:406	arg1	I					416:416	I	416:416	I	416:416	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	0	31	theme	drying	18:23	arg1	methods					25:31	various drying methods	10:31	various drying methods	10:31	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	4	32	theme	drying	668:673	arg1	methods					675:681	all five drying methods	659:681	all five drying methods	659:681	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	3	33	theme	heat	506:509	arg1	FH					524:525	FH	524:525	FH	524:525	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	33	theme	heat	506:509	arg1	drying					516:521	heat pump drying	506:521	heat pump drying (FH)	506:526	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	0	34	theme	various	10:16	arg1	methods					25:31	various drying methods	10:31	various drying methods	10:31	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	7	35	theme	energy	1540:1545	arg1	consumption					1547:1557	energy consumption	1540:1557	energy consumption	1540:1557	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	0	36	theme	lychee	129:134	arg1	characterizations					56:72	the physicochemical characterizations	36:72	the physicochemical characterizations	36:72	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	0	36	theme	lychee	129:134	arg1	activities					87:96	antioxidant activities	75:96	antioxidant activities	75:96	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	0	36	theme	lychee	129:134	arg1	activities					115:124	hypoglycemic activities	102:124	hypoglycemic activities	102:124	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	2	37	theme	drying	192:197	arg1	method					199:204	Suitable drying method	183:204	Suitable drying method	183:204	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	3	38	theme	freeze	471:476	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	38	theme	freeze	471:476	arg1	drying					485:490	freeze vacuum drying	471:490	freeze vacuum drying	471:490	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	39	theme	heat	420:423	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	39	theme	heat	420:423	arg1	H					438:438	H	438:438	H	438:438	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	39	theme	heat	420:423	arg1	drying					430:435	heat pump drying	420:435	heat pump drying (H)	420:439	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	5	40	theme	LPPs	928:931	arg1	structure					891:899	structure	891:899	structure	891:899	Additionally, the thermal aggregation significantly affected the composition, structure and biological activity of LPPs.
35987361	5	40	theme	LPPs	928:931	arg1	activity					916:923	biological activity	905:923	biological activity	905:923	Additionally, the thermal aggregation significantly affected the composition, structure and biological activity of LPPs.
35987361	5	40	theme	LPPs	928:931	arg1	composition					878:888	composition	878:888	composition	878:888	Additionally, the thermal aggregation significantly affected the composition, structure and biological activity of LPPs.
35987361	6	41	theme	molecular	1249:1257	arg1	weight					1259:1264	lower molecular weight	1243:1264	lower molecular weight than LPPA and LPPI	1243:1283	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	2	42	theme	Suitable	183:190	arg1	method					199:204	Suitable drying method	183:204	Suitable drying method	183:204	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	2	43	theme	physicochemical	242:256	arg1	quality					278:284	physicochemical and pharmacological quality	242:284	physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs)	242:322	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	6	44	theme	α-glycosidase	1109:1121	arg1	inhibition					1137:1146	better α-glycosidase and α-amylase inhibition	1102:1146	better α-glycosidase and α-amylase inhibition	1102:1146	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	4	45	dep	stronger	726:733	arg1	effect					747:752	the thermal effect	735:752	the stronger the thermal effect induced by drying, the more serious the aggregations	722:805	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	0	46	theme	methods	25:31	arg1	Effect					0:5	Effect	0:5	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee	0:134	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	6	47	theme	lower	1243:1247	arg1	weight					1259:1264	lower molecular weight	1243:1264	lower molecular weight than LPPA and LPPI	1243:1283	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	3	48	theme	pump	511:514	arg1	FH					524:525	FH	524:525	FH	524:525	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	48	theme	pump	511:514	arg1	drying					516:521	heat pump drying	506:521	heat pump drying (FH)	506:526	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	0	49	theme	physicochemical	40:54	arg1	characterizations					56:72	the physicochemical characterizations	36:72	the physicochemical characterizations	36:72	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	4	50	theme	thermal	739:745	arg1	effect					747:752	the thermal effect	735:752	the stronger the thermal effect induced by drying, the more serious the aggregations	722:805	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	6	51	theme	uronic	1227:1232	arg1	acid					1234:1237	uronic acid	1227:1237	uronic acid	1227:1237	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	52	theme	radical	1038:1044	arg1	scavenging					1046:1055	ABTS radical scavenging	1033:1055	ABTS radical scavenging	1033:1055	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	53	located	observed	963:970	arg2	aggregation					947:957	Less thermal aggregation	934:957	Less thermal aggregation	934:957	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	53	located	observed	963:970	arg1	LPPFH					984:988	LPPFH	984:988	LPPFH	984:988	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	53	located	observed	963:970	arg1	LPPF					975:978	LPPF	975:978	LPPF	975:978	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	54	theme	acid	1234:1237	arg1	contents					1188:1195	their higher contents	1175:1195	their higher contents of neutral sugar, protein and uronic acid	1175:1237	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	54	theme	acid	1234:1237	arg1	weight					1259:1264	lower molecular weight	1243:1264	lower molecular weight than LPPA and LPPI	1243:1283	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	55	theme	activities	1057:1066	arg1	activities					1148:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	56	theme	ABTS	1033:1036	arg1	scavenging					1046:1055	ABTS radical scavenging	1033:1055	ABTS radical scavenging	1033:1055	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	7	57	theme	industrial	1373:1382	arg1	perspective					1384:1394	industrial perspective	1373:1394	industrial perspective	1373:1394	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	4	58	theme	LPPs	713:716	arg1	aggregation					698:708	thermal aggregation	690:708	thermal aggregation of LPPs	690:716	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	3	59	from	effects	346:352	arg1	characterizations					551:567	the physicochemical characterizations	531:567	the physicochemical characterizations	531:567	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	59	from	effects	346:352	arg1	activities					582:591	antioxidant activities	570:591	antioxidant activities	570:591	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	59	from	effects	346:352	arg1	activities					610:619	hypoglycemic activities	597:619	hypoglycemic activities	597:619	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	60	theme	inhibition	1137:1146	arg1	activities					1148:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	5	61	theme	biological	905:914	arg1	activity					916:923	biological activity	905:923	biological activity	905:923	Additionally, the thermal aggregation significantly affected the composition, structure and biological activity of LPPs.
35987361	6	62	theme	thermal	939:945	arg1	aggregation					947:957	Less thermal aggregation	934:957	Less thermal aggregation	934:957	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	3	63	theme	pump	425:428	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	63	theme	pump	425:428	arg1	H					438:438	H	438:438	H	438:438	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	63	theme	pump	425:428	arg1	drying					430:435	heat pump drying	420:435	heat pump drying (H)	420:439	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	64	theme	DPPH	1024:1027	arg1	activities					1057:1066	DPPH and ABTS radical scavenging activities	1024:1066	DPPH and ABTS radical scavenging activities	1024:1066	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	7	65	theme	half	1313:1316	arg1	time					1325:1328	half drying time	1313:1328	half drying time	1313:1328	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	4	66	theme	thermal	690:696	arg1	aggregation					698:708	thermal aggregation	690:708	thermal aggregation of LPPs	690:716	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	2	67	theme	quality	278:284	arg1	preservation					226:237	the preservation	222:237	the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs)	222:322	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	4	68	dep	showed	652:657	arg1	led					683:685	led	683:685	showed all five drying methods led to thermal aggregation of LPPs	652:716	Results showed all five drying methods led to thermal aggregation of LPPs and the stronger the thermal effect induced by drying, the more serious the aggregations were.
35987361	5	69	dep	composition	878:888	arg1	the					874:876	the	874:876	the	874:876	Additionally, the thermal aggregation significantly affected the composition, structure and biological activity of LPPs.
35987361	3	70	theme	antioxidant	570:580	arg1	activities					582:591	antioxidant activities	570:591	antioxidant activities	570:591	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	2	71	theme	pharmacological	262:276	arg1	quality					278:284	physicochemical and pharmacological quality	242:284	physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs)	242:322	Suitable drying method is critical for the preservation of physicochemical and pharmacological quality of lychee pulp polysaccharides (LPPs).
35987361	3	72	theme	vacuum	442:447	arg1	F					464:464	F	464:464	F	464:464	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	72	theme	vacuum	442:447	arg1	drying					456:461	vacuum freeze drying	442:461	vacuum freeze drying (F)	442:465	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	72	theme	vacuum	442:447	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	73	theme	power	1092:1096	arg1	activities					1148:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities	1007:1157	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	7	74	from	perspective	1384:1394	arg1	FH					1397:1398	FH	1397:1398	FH	1397:1398	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	7	74	from	perspective	1384:1394	arg1	FH					1295:1296	FH	1295:1296	FH consumed about half drying time and one fifth energy of F.	1295:1355	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	7	74	from	perspective	1384:1394	arg1	alternative					1415:1425	a promising alternative	1403:1425	a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption	1403:1557	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	0	75	dep	Effect	0:5	arg1	Sonn					154:157	Sonn	154:157	Sonn	154:157	Effect of various drying methods on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of lychee (Litchi chinensis Sonn.)
35987361	7	76	theme	promising	1405:1413	arg1	FH					1397:1398	FH	1397:1398	FH	1397:1398	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	7	76	theme	promising	1405:1413	arg1	FH					1295:1296	FH	1295:1296	FH consumed about half drying time and one fifth energy of F.	1295:1355	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	7	76	theme	promising	1405:1413	arg1	alternative					1415:1425	a promising alternative	1403:1425	a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption	1403:1557	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
35987361	3	77	theme	freeze	449:454	arg1	F					464:464	F	464:464	F	464:464	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	77	theme	freeze	449:454	arg1	drying					456:461	vacuum freeze drying	442:461	vacuum freeze drying (F)	442:465	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	3	77	theme	freeze	449:454	arg1	methods					369:375	five drying methods	357:375	five drying methods	357:375	In current work, the effects of five drying methods, i.e. air drying (A), infrared drying (I), heat pump drying (H), vacuum freeze drying (F) and freeze vacuum drying combined with heat pump drying (FH) on the physicochemical characterizations, antioxidant activities and hypoglycemic activities of LPPs were explored.
35987361	6	78	theme	sugar	1208:1212	arg1	contents					1188:1195	their higher contents	1175:1195	their higher contents of neutral sugar, protein and uronic acid	1175:1237	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	6	78	theme	sugar	1208:1212	arg1	weight					1259:1264	lower molecular weight	1243:1264	lower molecular weight than LPPA and LPPI	1243:1283	Less thermal aggregation was observed in LPPF and LPPFH, which exhibited stronger oxygen, DPPH and ABTS radical scavenging activities, higher ferric-reducing power and better α-glycosidase and α-amylase inhibition activities, resulting from their higher contents of neutral sugar, protein and uronic acid and lower molecular weight than LPPA and LPPI.
35987361	7	79	theme	physicochemical	1482:1496	arg1	characterizations					1498:1514	physicochemical characterizations	1482:1514	physicochemical characterizations	1482:1514	Besides, FH consumed about half drying time and one fifth energy of F. Therefore, from industrial perspective, FH is a promising alternative to F for producing LPPs by comprehensively considering physicochemical characterizations, bioactivity as well as energy consumption.
36080277	6	0	theme	physicochemical	864:878	arg1	properties					895:904	The physicochemical and mechanical properties	860:904	The physicochemical and mechanical properties	860:904	The physicochemical and mechanical properties were controlled by forming a different composition of GG and HA.
36080277	7	1	theme	weight	1067:1072	arg1	loss					1074:1077	a weight loss	1065:1077	a weight loss test	1065:1082	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	3	2	theme	hydrogel	495:502	arg1	environment					476:486	the 2D environment	469:486	the 2D environment of the hydrogel	469:502	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	3	2	theme	hydrogel	495:502	arg1	matrix					515:520	the 3D matrix	508:520	the 3D matrix	508:520	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	4	3	theme	mechanical	587:596	arg1	cue					598:600	a significant mechanical cue	573:600	a significant mechanical cue for the control of cellular activities	573:639	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	10	4	theme	hydrogel	1689:1696	arg1	property					1667:1674	the time-dependent stress relaxation property	1630:1674	the time-dependent stress relaxation property of the GG/HA hydrogel	1630:1696	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	13	5	theme	prospective	2157:2167	arg1	hydrogel					2143:2150	GG/HA hydrogel	2137:2150	GG/HA hydrogel	2137:2150	Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
36080277	13	5	theme	prospective	2157:2167	arg1	candidate					2169:2177	a prospective candidate	2155:2177	a prospective candidate for retinal TE biomaterial	2155:2204	Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
36080277	12	6	theme	property	2064:2071	arg1	hydrogel					1996:2003	an injectable hydrogel	1982:2003	an injectable hydrogel for retinal TE	1982:2018	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	12	6	theme	property	2064:2071	arg1	importance					2028:2037	the importance	2024:2037	the importance of the stress relaxation property	2024:2071	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	7	7	theme	fraction	1049:1056	arg1	study					1058:1062	a sol fraction study	1043:1062	a sol fraction study	1043:1062	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	7	theme	fraction	1049:1056	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	4	8	theme	stress	541:546	arg1	relaxation					548:557	time-dependent stress relaxation	526:557	time-dependent stress relaxation	526:557	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	4	9	theme	cellular	621:628	arg1	activities					630:639	cellular activities	621:639	cellular activities	621:639	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	9	10	with	Hydrogels	1484:1492	arg1	HA					1519:1520	HA	1519:1520	HA	1519:1520	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	9	10	with	Hydrogels	1484:1492	arg1	amounts					1508:1514	moderate amounts	1499:1514	moderate amounts of HA	1499:1520	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	10	11	theme	stress	1649:1654	arg1	property					1667:1674	the time-dependent stress relaxation property	1630:1674	the time-dependent stress relaxation property of the GG/HA hydrogel	1630:1696	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	1	12	theme	age-related	214:224	arg1	AMD					248:250	AMD	248:250	AMD	248:250	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	1	12	theme	age-related	214:224	arg1	degeneration					234:245	age-related macular degeneration	214:245	age-related macular degeneration (AMD) treatment	214:261	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	12	13	theme	retinal	2009:2015	arg1	TE					2017:2018	retinal TE	2009:2018	retinal TE	2009:2018	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	11	14	theme	in	1822:1823	arg1	experiments					1831:1841	in vitro experiments	1822:1841	in vitro experiments	1822:1841	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
36080277	8	15	theme	biological	1187:1196	arg1	activity					1198:1205	The biological activity	1183:1205	The biological activity of the cells encapsulated in 3D constructs	1183:1248	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	0	16	theme	Stress	140:145	arg1	Relaxation					147:156	Substrate Stress Relaxation	130:156	Substrate Stress Relaxation	130:156	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	10	17	theme	HA	1742:1743	arg1	HA					1742:1743	HA	1742:1743	HA	1742:1743	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	10	17	theme	HA	1742:1743	arg1	amount					1732:1737	the appropriate amount	1716:1737	the appropriate amount of HA	1716:1743	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	1	18	theme	degeneration	234:245	arg1	treatment					253:261	age-related macular degeneration (AMD) treatment	214:261	age-related macular degeneration (AMD) treatment	214:261	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	8	19	theme	immunofluorescence	1356:1373	arg1	staining					1375:1382	immunofluorescence staining	1356:1382	immunofluorescence staining	1356:1382	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	11	20	theme	fast-relaxing	1877:1889	arg1	hydrogel					1891:1898	the fast-relaxing hydrogel	1873:1898	the fast-relaxing hydrogel	1873:1898	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
36080277	6	21	theme	mechanical	884:893	arg1	properties					895:904	The physicochemical and mechanical properties	860:904	The physicochemical and mechanical properties	860:904	The physicochemical and mechanical properties were controlled by forming a different composition of GG and HA.
36080277	8	22	theme	cells	1214:1218	arg1	activity					1198:1205	The biological activity	1183:1205	The biological activity of the cells encapsulated in 3D constructs	1183:1248	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	0	23	theme	Pigment	169:175	arg1	Cells					188:192	Retinal Pigment Epithelial Cells	161:192	Retinal Pigment Epithelial Cells	161:192	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	12	24	theme	injectable	1985:1994	arg1	hydrogel					1996:2003	an injectable hydrogel	1982:2003	an injectable hydrogel for retinal TE	1982:2018	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	5	25	theme	physical	830:837	arg1	method					852:857	a facile physical crosslinking method	821:857	a facile physical crosslinking method	821:857	Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method.
36080277	6	26	theme	HA	967:968	arg1	composition					945:955	a different composition	933:955	a different composition of GG and HA	933:968	The physicochemical and mechanical properties were controlled by forming a different composition of GG and HA.
36080277	8	27	theme	expression	1396:1405	arg1	study					1407:1411	a gene expression study	1389:1411	a gene expression study	1389:1411	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	4	28	theme	retinal	684:690	arg1	engineering					699:709	retinal tissue engineering	684:709	retinal tissue engineering (TE)	684:714	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	4	28	theme	retinal	684:690	arg1	TE					712:713	TE	712:713	TE	712:713	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	0	29	theme	Tissue	78:83	arg1	Engineering					85:95	Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells	70:192	Engineering	85:95	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	6	30	theme	GG	960:961	arg1	composition					945:955	a different composition	933:955	a different composition of GG and HA	933:968	The physicochemical and mechanical properties were controlled by forming a different composition of GG and HA.
36080277	2	31	located	observed	361:368	arg2	activity					343:350	cell activity	338:350	cell activity	338:350	Until now, cell activity has been observed only in terms of the modulus of the hydrogel.
36080277	2	31	located	observed	361:368	arg1	terms					378:382	terms	378:382	terms of the modulus of the hydrogel	378:413	Until now, cell activity has been observed only in terms of the modulus of the hydrogel.
36080277	7	32	theme	force	1116:1120	arg1	study					1122:1126	an injection force study	1103:1126	an injection force study	1103:1126	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	32	theme	force	1116:1120	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	8	33	theme	appropriate	1435:1445	arg1	material					1447:1454	the most appropriate material	1426:1454	the most appropriate material for retinal TE biomaterial	1426:1481	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	8	34	theme	morphological	1280:1292	arg1	study					1294:1298	a morphological study	1278:1298	a morphological study	1278:1298	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	2	35	theme	modulus	391:397	arg1	terms					378:382	terms	378:382	terms of the modulus of the hydrogel	378:413	Until now, cell activity has been observed only in terms of the modulus of the hydrogel.
36080277	4	36	theme	time-dependent	526:539	arg1	relaxation					548:557	time-dependent stress relaxation	526:557	time-dependent stress relaxation	526:557	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	11	37	from	compatibility	1783:1795	arg1	experiments					1831:1841	in vitro experiments	1822:1841	in vitro experiments	1822:1841	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
36080277	5	38	theme	acid	781:784	arg1	hydrogel					791:798	a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel	752:798	a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel	752:798	Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method.
36080277	10	39	theme	GG/HA	1683:1687	arg1	hydrogel					1689:1696	the GG/HA hydrogel	1679:1696	the GG/HA hydrogel	1679:1696	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	9	40	theme	moderate	1499:1506	arg1	HA					1519:1520	HA	1519:1520	HA	1519:1520	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	9	40	theme	moderate	1499:1506	arg1	amounts					1508:1514	moderate amounts	1499:1514	moderate amounts of HA	1499:1520	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	13	41	theme	retinal	2183:2189	arg1	biomaterial					2194:2204	retinal TE biomaterial	2183:2204	retinal TE biomaterial	2183:2204	Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
36080277	8	42	theme	TE	1468:1469	arg1	biomaterial					1471:1481	retinal TE biomaterial	1460:1481	retinal TE biomaterial	1460:1481	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	8	43	theme	proliferation	1303:1315	arg1	test					1317:1320	a proliferation test	1301:1320	a proliferation test	1301:1320	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	0	44	theme	Gellan	30:35	arg1	Hydrogel					57:64	Gellan Gum/Hyaluronic Acid Hydrogel	30:64	Gellan Gum/Hyaluronic Acid Hydrogel	30:64	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	11	45	dep	in	1822:1823	arg1	vitro					1825:1829	vitro	1825:1829	vitro	1825:1829	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
36080277	10	46	theme	time-dependent	1634:1647	arg1	property					1667:1674	the time-dependent stress relaxation property	1630:1674	the time-dependent stress relaxation property of the GG/HA hydrogel	1630:1696	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	0	47	theme	Acid	52:55	arg1	Hydrogel					57:64	Gellan Gum/Hyaluronic Acid Hydrogel	30:64	Gellan Gum/Hyaluronic Acid Hydrogel	30:64	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	8	48	theme	live/dead	1325:1333	arg1	analysis					1335:1342	a live/dead analysis	1323:1342	a live/dead analysis	1323:1342	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	9	49	theme	physicochemical	1538:1552	arg1	properties					1569:1578	improved physicochemical and mechanical properties	1529:1578	improved physicochemical and mechanical properties suitable for injection into the retina	1529:1617	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	13	50	theme	TE	2191:2192	arg1	biomaterial					2194:2204	retinal TE biomaterial	2183:2204	retinal TE biomaterial	2183:2204	Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
36080277	11	51	theme	GG/HA	1804:1808	arg1	hydrogel					1810:1817	the GG/HA hydrogel	1800:1817	the GG/HA hydrogel	1800:1817	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
36080277	7	52	theme	loss	1074:1077	arg1	test					1079:1082	a weight loss test	1065:1082	a weight loss test	1065:1082	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	52	theme	loss	1074:1077	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	9	53	theme	mechanical	1558:1567	arg1	properties					1569:1578	improved physicochemical and mechanical properties	1529:1578	improved physicochemical and mechanical properties suitable for injection into the retina	1529:1617	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	7	54	theme	relaxation	1162:1171	arg1	analysis					1173:1180	a stress relaxation analysis	1153:1180	a stress relaxation analysis	1153:1180	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	54	theme	relaxation	1162:1171	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	10	55	theme	relaxation	1656:1665	arg1	property					1667:1674	the time-dependent stress relaxation property	1630:1674	the time-dependent stress relaxation property of the GG/HA hydrogel	1630:1696	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	12	56	theme	hydrogel	1970:1977	arg1	potential					1951:1959	the remarkable potential	1936:1959	the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property	1936:2071	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	9	57	theme	suitable	1580:1587	arg1	properties					1569:1578	improved physicochemical and mechanical properties	1529:1578	improved physicochemical and mechanical properties suitable for injection into the retina	1529:1617	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	10	58	theme	appropriate	1720:1730	arg1	HA					1742:1743	HA	1742:1743	HA	1742:1743	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	10	58	theme	appropriate	1720:1730	arg1	amount					1732:1737	the appropriate amount	1716:1737	the appropriate amount of HA	1716:1743	Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded.
36080277	4	59	theme	significant	575:585	arg1	cue					598:600	a significant mechanical cue	573:600	a significant mechanical cue for the control of cellular activities	573:639	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	11	60	theme	cellular	1774:1781	arg1	compatibility					1783:1795	the cellular compatibility	1770:1795	the cellular compatibility of the GG/HA hydrogel in in vitro experiments	1770:1841	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
36080277	7	61	theme	sol	1045:1047	arg1	study					1058:1062	a sol fraction study	1043:1062	a sol fraction study	1043:1062	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	61	theme	sol	1045:1047	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	3	62	theme	3D	512:513	arg1	matrix					515:520	the 3D matrix	508:520	the 3D matrix	508:520	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	12	63	theme	remarkable	1940:1949	arg1	potential					1951:1959	the remarkable potential	1936:1959	the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property	1936:2071	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	12	64	theme	relaxation	2053:2062	arg1	property					2064:2071	the stress relaxation property	2042:2071	the stress relaxation property	2042:2071	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	7	65	theme	compression	1131:1141	arg1	test					1143:1146	a compression test	1129:1146	a compression test	1129:1146	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	65	theme	compression	1131:1141	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	2	66	theme	cell	338:341	arg1	activity					343:350	cell activity	338:350	cell activity	338:350	Until now, cell activity has been observed only in terms of the modulus of the hydrogel.
36080277	1	67	theme	Cell	195:198	arg1	therapies					200:208	Cell therapies	195:208	Cell therapies for age-related macular degeneration (AMD) treatment	195:261	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	6	68	theme	different	935:943	arg1	composition					945:955	a different composition	933:955	a different composition of GG and HA	933:968	The physicochemical and mechanical properties were controlled by forming a different composition of GG and HA.
36080277	0	69	theme	Substrate	130:138	arg1	Relaxation					147:156	Substrate Stress Relaxation	130:156	Substrate Stress Relaxation	130:156	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	0	70	from	Engineering	85:95	arg1	Cells					188:192	Retinal Pigment Epithelial Cells	161:192	Retinal Pigment Epithelial Cells	161:192	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	0	71	theme	Relaxation	147:156	arg1	Engineering					85:95	Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells	70:192	Engineering	85:95	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	0	71	theme	Relaxation	147:156	arg1	Influence					117:125	the Influence	113:125	the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells	113:192	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	1	72	theme	macular	226:232	arg1	AMD					248:250	AMD	248:250	AMD	248:250	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	1	72	theme	macular	226:232	arg1	degeneration					234:245	age-related macular degeneration	214:245	age-related macular degeneration (AMD) treatment	214:261	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	4	73	theme	activities	630:639	arg1	control					610:616	the control	606:616	the control of cellular activities	606:639	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	0	74	theme	Retinal	161:167	arg1	Cells					188:192	Retinal Pigment Epithelial Cells	161:192	Retinal Pigment Epithelial Cells	161:192	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	7	75	theme	swelling	1027:1034	arg1	study					1122:1126	an injection force study	1103:1126	an injection force study	1103:1126	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	75	theme	swelling	1027:1034	arg1	test					1097:1100	a viscosity test	1085:1100	a viscosity test	1085:1100	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	75	theme	swelling	1027:1034	arg1	test					1143:1146	a compression test	1129:1146	a compression test	1129:1146	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	75	theme	swelling	1027:1034	arg1	test					1079:1082	a weight loss test	1065:1082	a weight loss test	1065:1082	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	75	theme	swelling	1027:1034	arg1	analysis					1173:1180	a stress relaxation analysis	1153:1180	a stress relaxation analysis	1153:1180	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	75	theme	swelling	1027:1034	arg1	study					1058:1062	a sol fraction study	1043:1062	a sol fraction study	1043:1062	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	75	theme	swelling	1027:1034	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	0	76	from	Influence	117:125	arg1	Cells					188:192	Retinal Pigment Epithelial Cells	161:192	Retinal Pigment Epithelial Cells	161:192	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	4	77	theme	tissue	692:697	arg1	engineering					699:709	retinal tissue engineering	684:709	retinal tissue engineering (TE)	684:714	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	4	77	theme	tissue	692:697	arg1	TE					712:713	TE	712:713	TE	712:713	As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint.
36080277	7	78	theme	viscosity	1087:1095	arg1	test					1097:1100	a viscosity test	1085:1100	a viscosity test	1085:1100	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	78	theme	viscosity	1087:1095	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	0	79	theme	Epithelial	177:186	arg1	Cells					188:192	Retinal Pigment Epithelial Cells	161:192	Retinal Pigment Epithelial Cells	161:192	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	12	80	theme	TE	2096:2097	arg1	hydrogels					2099:2107	retinal TE hydrogels	2088:2107	retinal TE hydrogels	2088:2107	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	8	81	theme	gene	1391:1394	arg1	study					1407:1411	a gene expression study	1389:1411	a gene expression study	1389:1411	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	0	82	theme	Retinal	70:76	arg1	Engineering					85:95	Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells	70:192	Engineering	85:95	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	5	83	theme	facile	823:828	arg1	method					852:857	a facile physical crosslinking method	821:857	a facile physical crosslinking method	821:857	Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method.
36080277	5	84	theme	crosslinking	839:850	arg1	method					852:857	a facile physical crosslinking method	821:857	a facile physical crosslinking method	821:857	Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method.
36080277	8	85	theme	3D	1236:1237	arg1	constructs					1239:1248	3D constructs	1236:1248	3D constructs	1236:1248	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	3	86	located	observed	457:464	arg1	environment					476:486	the 2D environment	469:486	the 2D environment of the hydrogel	469:502	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	3	86	located	observed	457:464	arg2	behavior					434:441	cell behavior	429:441	cell behavior	429:441	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	3	86	located	observed	457:464	arg1	matrix					515:520	the 3D matrix	508:520	the 3D matrix	508:520	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	3	86	located	observed	457:464	arg1	addition					419:426	addition	419:426	addition	419:426	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	7	87	theme	injection	1106:1114	arg1	study					1122:1126	an injection force study	1103:1126	an injection force study	1103:1126	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	87	theme	injection	1106:1114	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	0	88	dep	Engineering	85:95	arg1	Biomaterial					97:107	Biomaterial	97:107	Biomaterial	97:107	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	8	89	theme	retinal	1460:1466	arg1	biomaterial					1471:1481	retinal TE biomaterial	1460:1481	retinal TE biomaterial	1460:1481	The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial.
36080277	3	90	theme	cell	429:432	arg1	behavior					434:441	cell behavior	429:441	cell behavior	429:441	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	5	91	theme	/Hyaluronic	769:779	arg1	HA					787:788	HA	787:788	HA	787:788	Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method.
36080277	5	91	theme	/Hyaluronic	769:779	arg1	acid					781:784	a gellan Gum (GG)/Hyaluronic acid	752:784	a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel	752:798	Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method.
36080277	1	92	theme	hydrogel-based	298:311	arg1	biomaterials					313:324	hydrogel-based biomaterials	298:324	hydrogel-based biomaterials	298:324	Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials.
36080277	0	93	theme	Gum/Hyaluronic	37:50	arg1	Hydrogel					57:64	Gellan Gum/Hyaluronic Acid Hydrogel	30:64	Gellan Gum/Hyaluronic Acid Hydrogel	30:64	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	12	94	theme	stress	2046:2051	arg1	property					2064:2071	the stress relaxation property	2042:2071	the stress relaxation property	2042:2071	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	2	95	theme	hydrogel	406:413	arg1	modulus					391:397	the modulus	387:397	the modulus of the hydrogel	387:413	Until now, cell activity has been observed only in terms of the modulus of the hydrogel.
36080277	0	96	theme	Hydrogel	57:64	arg1	Evaluation					16:25	Evaluation	16:25	Evaluation	16:25	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	0	96	theme	Hydrogel	57:64	arg1	Fabrication					0:10	Fabrication	0:10	Fabrication	0:10	Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for Retinal Tissue Engineering Biomaterial and the Influence of Substrate Stress Relaxation on Retinal Pigment Epithelial Cells.
36080277	13	97	theme	GG/HA	2137:2141	arg1	hydrogel					2143:2150	GG/HA hydrogel	2137:2150	GG/HA hydrogel	2137:2150	Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
36080277	13	97	theme	GG/HA	2137:2141	arg1	candidate					2169:2177	a prospective candidate	2155:2177	a prospective candidate for retinal TE biomaterial	2155:2204	Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
36080277	9	98	theme	HA	1519:1520	arg1	HA					1519:1520	HA	1519:1520	HA	1519:1520	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	9	98	theme	HA	1519:1520	arg1	amounts					1508:1514	moderate amounts	1499:1514	moderate amounts of HA	1499:1520	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	7	99	theme	mass	1022:1025	arg1	study					1122:1126	an injection force study	1103:1126	an injection force study	1103:1126	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	99	theme	mass	1022:1025	arg1	test					1097:1100	a viscosity test	1085:1100	a viscosity test	1085:1100	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	99	theme	mass	1022:1025	arg1	test					1143:1146	a compression test	1129:1146	a compression test	1129:1146	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	99	theme	mass	1022:1025	arg1	test					1079:1082	a weight loss test	1065:1082	a weight loss test	1065:1082	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	99	theme	mass	1022:1025	arg1	analysis					1173:1180	a stress relaxation analysis	1153:1180	a stress relaxation analysis	1153:1180	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	99	theme	mass	1022:1025	arg1	study					1058:1062	a sol fraction study	1043:1062	a sol fraction study	1043:1062	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	99	theme	mass	1022:1025	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	9	100	theme	improved	1529:1536	arg1	properties					1569:1578	improved physicochemical and mechanical properties	1529:1578	improved physicochemical and mechanical properties suitable for injection into the retina	1529:1617	Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina.
36080277	12	101	theme	retinal	2088:2094	arg1	hydrogels					2099:2107	retinal TE hydrogels	2088:2107	retinal TE hydrogels	2088:2107	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	3	102	theme	2D	473:474	arg1	environment					476:486	the 2D environment	469:486	the 2D environment of the hydrogel	469:502	In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix.
36080277	12	103	theme	GG/HA	1964:1968	arg1	hydrogel					1970:1977	GG/HA hydrogel	1964:1977	GG/HA hydrogel	1964:1977	Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels.
36080277	7	104	theme	stress	1155:1160	arg1	analysis					1173:1180	a stress relaxation analysis	1153:1180	a stress relaxation analysis	1153:1180	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	7	104	theme	stress	1155:1160	arg1	study					1036:1040	a mass swelling study	1020:1040	a mass swelling study	1020:1040	The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis.
36080277	11	105	theme	hydrogel	1810:1817	arg1	compatibility					1783:1795	the cellular compatibility	1770:1795	the cellular compatibility of the GG/HA hydrogel in in vitro experiments	1770:1841	In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel.
37182944	3	0	from	components	647:656	arg1	glucuronoarabinoxylan					661:681	glucuronoarabinoxylan	661:681	glucuronoarabinoxylan	661:681	Xylose (about 46 %) and arabinose (about 32 %) were the main components in glucuronoarabinoxylan.
37182944	7	1	theme	corn	1226:1229	arg1	fiber					1231:1235	corn fiber	1226:1235	corn fiber	1226:1235	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	4	2	theme	than	689:692	arg1	half					694:697	More than half	684:697	More than half of the xylose units in the glucuronoarabinoxylan backbone chain	684:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	2	3	from	hemicelluloses	455:468	arg1	fiber					478:482	corn fiber	473:482	corn fiber	473:482	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	2	4	theme	nuclear	394:400	arg1	resonance					411:419	nuclear magnetic resonance	394:419	nuclear magnetic resonance spectroscopy	394:432	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	4	5	theme	More	684:687	arg1	half					694:697	More than half	684:697	More than half of the xylose units in the glucuronoarabinoxylan backbone chain	684:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	1	6	theme	de-starched	291:301	arg1	fiber					308:312	de-starched corn fiber	291:312	de-starched corn fiber	291:312	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	0	7	theme	degradation	103:113	arg1	enzymes					115:121	degradation enzymes	103:121	degradation enzymes	103:121	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	7	8	theme	systems	1370:1376	arg1	construction					1324:1335	the rational construction	1311:1335	the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass	1311:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	2	9	theme	chemical	324:331	arg1	composition					333:343	chemical composition	324:343	chemical composition	324:343	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	7	10	theme	biomass	1417:1423	arg1	degradation					1386:1396	the degradation	1382:1396	the degradation of lignocellulosic biomass	1382:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	1	11	theme	corn	303:306	arg1	fiber					308:312	de-starched corn fiber	291:312	de-starched corn fiber	291:312	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	5	12	theme	Penicillium	921:931	arg1	enzymes					947:953	Penicillium oxalicum MCAX enzymes	921:953	Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber	921:992	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	5	13	theme	enzymatic	959:967	arg1	hydrolysis					969:978	enzymatic hydrolysis	959:978	enzymatic hydrolysis of corn fiber	959:992	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	4	14	from	chain	757:761	arg1	half					694:697	More than half	684:697	More than half of the xylose units in the glucuronoarabinoxylan backbone chain	684:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	4	15	theme	backbone	748:755	arg1	chain					757:761	the glucuronoarabinoxylan backbone chain	722:761	the glucuronoarabinoxylan backbone chain	722:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	4	16	theme	side	832:835	arg1	chains					837:842	oligomeric side chains	821:842	oligomeric side chains	821:842	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	6	17	theme	fiber	1084:1088	arg1	yield					1070:1074	the sugar yield	1060:1074	the sugar yield of corn fiber	1060:1088	The results showed that the addition of hemicellulases increased the sugar yield of corn fiber.
37182944	6	18	theme	sugar	1064:1068	arg1	yield					1070:1074	the sugar yield	1060:1074	the sugar yield of corn fiber	1060:1088	The results showed that the addition of hemicellulases increased the sugar yield of corn fiber.
37182944	1	19	theme	dimethyl	189:196	arg1	sulfoxide					198:206	dimethyl sulfoxide	189:206	dimethyl sulfoxide extraction	189:217	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	0	20	theme	enzymes	115:121	arg1	screening					90:98	screening	90:98	screening	90:98	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	0	20	theme	enzymes	115:121	arg1	solvent					78:84	organic solvent	70:84	organic solvent	70:84	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	4	21	theme	oligomeric	821:830	arg1	chains					837:842	oligomeric side chains	821:842	oligomeric side chains	821:842	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	7	22	theme	chemical	1187:1194	arg1	structure					1196:1204	the chemical structure	1183:1204	the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber	1183:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	1	23	theme	sulfoxide	198:206	arg1	extraction					208:217	dimethyl sulfoxide extraction	189:217	dimethyl sulfoxide extraction	189:217	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	2	24	theme	weight	356:361	arg1	distribution					363:374	molecular weight distribution	346:374	molecular weight distribution	346:374	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	5	25	theme	structure	854:862	arg1	analysis					864:871	structure analysis	854:871	structure analysis	854:871	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	0	26	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of corn fiber hemicelluloses	0:55	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	7	27	theme	consortium	1145:1154	arg1	effectiveness					1121:1133	the effectiveness	1117:1133	the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber	1117:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	2	28	theme	molecular	346:354	arg1	distribution					363:374	molecular weight distribution	346:374	molecular weight distribution	346:374	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	0	29	theme	corn	31:34	arg1	hemicelluloses					42:55	corn fiber hemicelluloses	31:55	corn fiber hemicelluloses	31:55	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	4	30	theme	units	713:717	arg1	half					694:697	More than half	684:697	More than half of the xylose units in the glucuronoarabinoxylan backbone chain	684:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	4	31	from	units	713:717	arg1	chain					757:761	the glucuronoarabinoxylan backbone chain	722:761	the glucuronoarabinoxylan backbone chain	722:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	4	32	theme	glucuronoarabinoxylan	726:746	arg1	chain					757:761	the glucuronoarabinoxylan backbone chain	722:761	the glucuronoarabinoxylan backbone chain	722:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	2	33	theme	corn	473:476	arg1	fiber					478:482	corn fiber	473:482	corn fiber	473:482	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	5	34	theme	oxalicum	933:940	arg1	enzymes					947:953	Penicillium oxalicum MCAX enzymes	921:953	Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber	921:992	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	7	35	from	structure	1196:1204	arg1	fiber					1231:1235	corn fiber	1226:1235	corn fiber	1226:1235	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	6	36	theme	corn	1079:1082	arg1	fiber					1084:1088	corn fiber	1079:1088	corn fiber	1079:1088	The results showed that the addition of hemicellulases increased the sugar yield of corn fiber.
37182944	1	37	theme	ethanol	224:230	arg1	precipitation					232:244	ethanol precipitation	224:244	ethanol precipitation	224:244	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	0	38	theme	hemicelluloses	42:55	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization of corn fiber hemicelluloses	0:55	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	7	39	theme	corn	1260:1263	arg1	fiber					1265:1269	corn fiber	1260:1269	corn fiber	1260:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	4	40	theme	various	801:807	arg1	monomers					809:816	various monomers	801:816	various monomers	801:816	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	7	41	theme	general	1290:1296	arg1	solution					1298:1305	a general solution	1288:1305	a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass	1288:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	0	42	theme	fiber	36:40	arg1	hemicelluloses					42:55	corn fiber hemicelluloses	31:55	corn fiber hemicelluloses	31:55	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	7	43	theme	lignocellulosic	1401:1415	arg1	biomass					1417:1423	lignocellulosic biomass	1401:1423	lignocellulosic biomass	1401:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	7	44	from	hemicellulose	1209:1221	arg1	fiber					1231:1235	corn fiber	1226:1235	corn fiber	1226:1235	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	6	45	theme	hemicellulases	1035:1048	arg1	addition					1023:1030	the addition	1019:1030	the addition of hemicellulases	1019:1048	The results showed that the addition of hemicellulases increased the sugar yield of corn fiber.
37182944	7	46	theme	hemicellulose	1209:1221	arg1	structure					1196:1204	the chemical structure	1183:1204	the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber	1183:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	2	47	theme	magnetic	402:409	arg1	resonance					411:419	nuclear magnetic resonance	394:419	nuclear magnetic resonance spectroscopy	394:432	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	7	48	from	fiber	1231:1235	arg1	structure					1196:1204	the chemical structure	1183:1204	the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber	1183:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	7	49	theme	targeted	1340:1347	arg1	systems					1370:1376	targeted and efficient enzyme systems	1340:1376	targeted and efficient enzyme systems for the degradation of lignocellulosic biomass	1340:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	1	50	theme	integrated	127:136	arg1	delignification					172:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	7	51	theme	fiber	1265:1269	arg1	degradation					1245:1255	the degradation	1241:1255	the degradation of corn fiber	1241:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	7	52	theme	enzyme	1138:1143	arg1	consortium					1145:1154	enzyme consortium	1138:1154	enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber	1138:1269	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	1	53	theme	peracetic	157:165	arg1	delignification					172:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	5	54	theme	corn	983:986	arg1	fiber					988:992	corn fiber	983:992	corn fiber	983:992	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	1	55	theme	treatment	138:146	arg1	delignification					172:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	5	56	theme	MCAX	942:945	arg1	enzymes					947:953	Penicillium oxalicum MCAX enzymes	921:953	Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber	921:992	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	5	57	theme	fiber	988:992	arg1	hydrolysis					969:978	enzymatic hydrolysis	959:978	enzymatic hydrolysis of corn fiber	959:992	Based on structure analysis, five hemicellulases were selected and added to Penicillium oxalicum MCAX enzymes for enzymatic hydrolysis of corn fiber.
37182944	1	58	theme	coupling	148:155	arg1	delignification					172:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
37182944	7	59	theme	rational	1315:1322	arg1	construction					1324:1335	the rational construction	1311:1335	the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass	1311:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	4	60	theme	xylose	706:711	arg1	units					713:717	the xylose units	702:717	the xylose units in the glucuronoarabinoxylan backbone chain	702:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	3	61	theme	main	642:645	arg1	Xylose					586:591	Xylose	586:591	Xylose (about 46 %)	586:604	Xylose (about 46 %) and arabinose (about 32 %) were the main components in glucuronoarabinoxylan.
37182944	3	61	theme	main	642:645	arg1	components					647:656	the main components	638:656	the main components in glucuronoarabinoxylan	638:681	Xylose (about 46 %) and arabinose (about 32 %) were the main components in glucuronoarabinoxylan.
37182944	3	61	theme	main	642:645	arg1	arabinose					610:618	arabinose	610:618	arabinose (about 32 %)	610:631	Xylose (about 46 %) and arabinose (about 32 %) were the main components in glucuronoarabinoxylan.
37182944	2	62	theme	resonance	411:419	arg1	spectroscopy					421:432	nuclear magnetic resonance spectroscopy	394:432	nuclear magnetic resonance spectroscopy	394:432	Based on chemical composition, molecular weight distribution, methylation, and nuclear magnetic resonance spectroscopy, it is proposed that hemicelluloses in corn fiber were composed of two polysaccharides, glucuronoarabinoxylan (about 80 %) and xyloglucan (about 20 %).
37182944	4	63	from	half	694:697	arg1	chain					757:761	the glucuronoarabinoxylan backbone chain	722:761	the glucuronoarabinoxylan backbone chain	722:761	More than half of the xylose units in the glucuronoarabinoxylan backbone chain were substituted at O-2 and/or O-3 by various monomers or oligomeric side chains.
37182944	0	64	theme	organic	70:76	arg1	solvent					78:84	organic solvent	70:84	organic solvent	70:84	Structural characterization of corn fiber hemicelluloses extracted by organic solvent and screening of degradation enzymes.
37182944	7	65	theme	enzyme	1363:1368	arg1	systems					1370:1376	targeted and efficient enzyme systems	1340:1376	targeted and efficient enzyme systems for the degradation of lignocellulosic biomass	1340:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	7	66	theme	efficient	1353:1361	arg1	systems					1370:1376	targeted and efficient enzyme systems	1340:1376	targeted and efficient enzyme systems for the degradation of lignocellulosic biomass	1340:1423	These results demonstrate the effectiveness of enzyme consortium constructed by elucidating the chemical structure of hemicellulose in corn fiber for the degradation of corn fiber and also provide a general solution for the rational construction of targeted and efficient enzyme systems for the degradation of lignocellulosic biomass.
37182944	1	67	theme	acid	167:170	arg1	delignification					172:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification	124:186	An integrated treatment coupling peracetic acid delignification, dimethyl sulfoxide extraction, and ethanol precipitation were performed to isolate hemicellulose from de-starched corn fiber.
36430185	2	0	theme	resultant	519:527	arg1	composite					542:550	the resultant hybrid epoxy composite	515:550	the resultant hybrid epoxy composite	515:550	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	3	1	theme	total	847:851	arg1	values					866:871	total heat release values	847:871	total heat release values	847:871	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	1	2	theme	manganese	225:233	arg1	MnO2					244:247	MnO2	244:247	MnO2	244:247	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	2	theme	manganese	225:233	arg1	dioxide					235:241	manganese dioxide	225:241	manganese dioxide (MnO2) nanosheets as the core structure	225:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	3	theme	surface	362:368	arg1	nanosheets					250:259	manganese dioxide (MnO2) nanosheets	225:259	manganese dioxide (MnO2) nanosheets as the core structure	225:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	3	theme	surface	362:368	arg1	species					346:352	nickel species	339:352	nickel species (Ni)	339:357	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	3	theme	surface	362:368	arg1	layers					370:375	surface layers	362:375	surface layers	362:375	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	3	theme	surface	362:368	arg1	chitosan					298:305	self-assembly chitosan	284:305	self-assembly chitosan (CHS)	284:311	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	3	theme	surface	362:368	arg1	alginate					321:328	sodium alginate	314:328	sodium alginate (SA)	314:333	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	6	4	theme	proposed	1304:1311	arg1	structure					1326:1334	the proposed hierarchical structure	1300:1334	the proposed hierarchical structure	1300:1334	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	2	5	theme	layered	656:662	arg1	structure					664:672	a compact layered structure	646:672	a compact layered structure that enhanced its fire-resistive effectiveness	646:719	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	4	6	theme	production	941:950	arg1	rate					952:955	peak smoke production rate	930:955	peak smoke production rate	930:955	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	4	7	theme	pristine	1090:1097	arg1	EP					1099:1100	pristine EP	1090:1100	pristine EP	1090:1100	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	5	8	theme	NO	1156:1157	arg1	release					1159:1165	NO release	1156:1165	NO release	1156:1165	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	2	9	theme	epoxy	536:540	arg1	composite					542:550	the resultant hybrid epoxy composite	515:550	the resultant hybrid epoxy composite	515:550	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	6	10	dep	flammability	1396:1407	arg1	reductions					1429:1438	reductions	1429:1438	reductions	1429:1438	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	6	11	theme	fire-testing	1276:1287	arg1	effective					1353:1361	effective	1353:1361	effective	1353:1361	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	6	11	theme	fire-testing	1276:1287	arg1	outcome					1289:1295	a significant fire-testing outcome	1262:1295	a significant fire-testing outcome of the proposed hierarchical structure	1262:1334	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	1	12	theme	@	187:187	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	12	theme	@	187:187	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	0	13	theme	Epoxy	127:131	arg1	Resin					133:137	Epoxy Resin	127:137	Epoxy Resin	127:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	1	14	theme	@	191:191	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	14	theme	@	191:191	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	4	15	theme	peak	930:933	arg1	rate					952:955	peak smoke production rate	930:955	peak smoke production rate	930:955	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	1	16	theme	@	194:194	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	16	theme	@	194:194	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	4	17	theme	EP/MnO2	994:1000	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	1	18	theme	nickel	339:344	arg1	layers					370:375	surface layers	362:375	surface layers	362:375	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	18	theme	nickel	339:344	arg1	alginate					321:328	sodium alginate	314:328	sodium alginate (SA)	314:333	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	18	theme	nickel	339:344	arg1	nanosheets					250:259	manganese dioxide (MnO2) nanosheets	225:259	manganese dioxide (MnO2) nanosheets as the core structure	225:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	18	theme	nickel	339:344	arg1	species					346:352	nickel species	339:352	nickel species (Ni)	339:357	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	18	theme	nickel	339:344	arg1	chitosan					298:305	self-assembly chitosan	284:305	self-assembly chitosan (CHS)	284:311	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	18	theme	nickel	339:344	arg1	Ni					355:356	Ni	355:356	Ni	355:356	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	19	theme	@	766:766	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	4	20	theme	Ni	1009:1010	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	4	21	theme	CHS	1002:1004	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	3	22	theme	%	760:760	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	4	23	theme	smoke	967:971	arg1	production					973:982	total smoke production	961:982	total smoke production	961:982	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	0	24	theme	Nanocrystal-Decorated	58:78	arg1	Dioxides					90:97	Nickle Nanocrystal-Decorated Manganese Dioxides	51:97	Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin	51:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	1	25	theme	self-assembly	284:296	arg1	layers					370:375	surface layers	362:375	surface layers	362:375	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	25	theme	self-assembly	284:296	arg1	alginate					321:328	sodium alginate	314:328	sodium alginate (SA)	314:333	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	25	theme	self-assembly	284:296	arg1	nanosheets					250:259	manganese dioxide (MnO2) nanosheets	225:259	manganese dioxide (MnO2) nanosheets as the core structure	225:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	25	theme	self-assembly	284:296	arg1	species					346:352	nickel species	339:352	nickel species (Ni)	339:357	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	25	theme	self-assembly	284:296	arg1	chitosan					298:305	self-assembly chitosan	284:305	self-assembly chitosan (CHS)	284:311	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	25	theme	self-assembly	284:296	arg1	CHS					308:310	CHS	308:310	CHS	308:310	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	6	26	theme	structure	1326:1334	arg1	effective					1353:1361	effective	1353:1361	effective	1353:1361	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	6	26	theme	structure	1326:1334	arg1	outcome					1289:1295	a significant fire-testing outcome	1262:1295	a significant fire-testing outcome of the proposed hierarchical structure	1262:1334	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	3	27	theme	@	773:773	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	5	28	theme	TG-IR	1238:1242	arg1	results					1244:1250	TG-IR results	1238:1250	TG-IR results	1238:1250	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	6	29	theme	smoke	1410:1414	arg1	terms					1387:1391	terms	1387:1391	terms of flammability, smoke and toxicity reductions	1387:1438	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	1	30	theme	hybrid	165:170	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	30	theme	hybrid	165:170	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	31	theme	@	770:770	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	4	32	theme	%	1013:1013	arg1	values					984:989	the peak smoke production rate and total smoke production values	926:989	the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2%	926:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	2	33	contain	possessed	552:560	arg2	effect					615:620	an exceptional nano-barrier and synergistic charring effect	562:620	effect	615:620	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	2	33	contain	possessed	552:560	arg1	composite					542:550	the resultant hybrid epoxy composite	515:550	the resultant hybrid epoxy composite	515:550	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	2	33	contain	possessed	552:560	arg2	nano-barrier					577:588	an exceptional nano-barrier and synergistic charring effect	562:620	nano-barrier	577:588	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	4	34	theme	production	973:982	arg1	values					984:989	the peak smoke production rate and total smoke production values	926:989	the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2%	926:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	6	35	theme	flammability	1396:1407	arg1	terms					1387:1391	terms	1387:1391	terms of flammability, smoke and toxicity reductions	1387:1438	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	4	36	theme	rate	952:955	arg1	values					984:989	the peak smoke production rate and total smoke production values	926:989	the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2%	926:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	5	37	theme	gases	1206:1210	arg1	suppression					1131:1141	the suppression	1127:1141	the suppression of toxic CO	1127:1153	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	5	37	theme	gases	1206:1210	arg1	release					1159:1165	NO release	1156:1165	NO release	1156:1165	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	5	37	theme	gases	1206:1210	arg1	diffusion					1175:1183	the diffusion	1171:1183	the diffusion of thermal pyrolysis gases during combustion through TG-IR results	1171:1250	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	1	38	theme	hazard	450:455	arg1	suppression					457:467	fire hazard suppression	445:467	fire hazard suppression	445:467	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	39	theme	sodium	314:319	arg1	layers					370:375	surface layers	362:375	surface layers	362:375	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	39	theme	sodium	314:319	arg1	alginate					321:328	sodium alginate	314:328	sodium alginate (SA)	314:333	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	39	theme	sodium	314:319	arg1	nanosheets					250:259	manganese dioxide (MnO2) nanosheets	225:259	manganese dioxide (MnO2) nanosheets as the core structure	225:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	39	theme	sodium	314:319	arg1	species					346:352	nickel species	339:352	nickel species (Ni)	339:357	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	39	theme	sodium	314:319	arg1	chitosan					298:305	self-assembly chitosan	284:305	self-assembly chitosan (CHS)	284:311	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	39	theme	sodium	314:319	arg1	SA					331:332	SA	331:332	SA	331:332	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	40	theme	hybrids	777:783	arg1	addition					739:746	the addition	735:746	the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids	735:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	6	41	theme	other	1471:1475	arg1	materials					1487:1495	other polymeric materials	1471:1495	other polymeric materials	1471:1495	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	4	42	theme	SA	1006:1007	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	3	43	theme	matrix	909:914	arg1	values					866:871	total heat release values	847:871	total heat release values	847:871	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	3	43	theme	matrix	909:914	arg1	rate					838:841	peak heat release rate	820:841	peak heat release rate	820:841	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	5	44	theme	thermal	1188:1194	arg1	gases					1206:1210	thermal pyrolysis gases	1188:1210	thermal pyrolysis gases	1188:1210	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	2	45	theme	synergistic	594:604	arg1	effect					615:620	an exceptional nano-barrier and synergistic charring effect	562:620	effect	615:620	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	1	46	theme	self-assembly	481:493	arg1	technology					495:504	surface self-assembly technology	473:504	surface self-assembly technology	473:504	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	0	47	theme	Hierarchically	10:23	arg1	Hybrids					34:40	Hierarchically Tailored Hybrids	10:40	Hierarchically Tailored Hybrids	10:40	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	3	48	theme	dramatic	794:801	arg1	reduction					803:811	a dramatic reduction	792:811	a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix	792:914	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	0	49	theme	Hybrids	34:40	arg1	Design					0:5	Design	0:5	Design of Hierarchically Tailored Hybrids	0:40	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	3	50	theme	release	830:836	arg1	rate					838:841	peak heat release rate	820:841	peak heat release rate	820:841	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	5	51	theme	toxic	1146:1150	arg1	CO					1152:1153	toxic CO	1146:1153	toxic CO	1146:1153	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	3	52	theme	peak	820:823	arg1	rate					838:841	peak heat release rate	820:841	peak heat release rate	820:841	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	3	53	theme	heat	853:856	arg1	values					866:871	total heat release values	847:871	total heat release values	847:871	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	4	54	theme	EP	1099:1100	arg1	data					1082:1085	the corresponding data	1064:1085	the corresponding data of pristine EP	1064:1100	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	3	55	dep	%	883:883	arg1	ca.					877:879	ca. 33% and 27.8%	877:893	ca. 33% and 27.8%	877:893	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	1	56	theme	dioxide	235:241	arg1	nanosheets					250:259	manganese dioxide (MnO2) nanosheets	225:259	manganese dioxide (MnO2) nanosheets as the core structure	225:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	56	theme	dioxide	235:241	arg1	species					346:352	nickel species	339:352	nickel species (Ni)	339:357	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	56	theme	dioxide	235:241	arg1	layers					370:375	surface layers	362:375	surface layers	362:375	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	56	theme	dioxide	235:241	arg1	chitosan					298:305	self-assembly chitosan	284:305	self-assembly chitosan (CHS)	284:311	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	56	theme	dioxide	235:241	arg1	alginate					321:328	sodium alginate	314:328	sodium alginate (SA)	314:333	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	2	57	theme	fire-resistive	692:705	arg1	effectiveness					707:719	its fire-resistive effectiveness	688:719	its fire-resistive effectiveness	688:719	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	4	58	theme	corresponding	1068:1080	arg1	data					1082:1085	the corresponding data	1064:1085	the corresponding data of pristine EP	1064:1100	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	5	59	theme	pyrolysis	1196:1204	arg1	gases					1206:1210	thermal pyrolysis gases	1188:1210	thermal pyrolysis gases	1188:1210	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	4	60	theme	total	961:965	arg1	production					973:982	total smoke production	961:982	total smoke production	961:982	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	3	61	dep	rate	838:841	arg1	the					816:818	the	816:818	the	816:818	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	1	62	theme	MnO2	183:186	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	62	theme	MnO2	183:186	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	2	63	theme	hybrid	529:534	arg1	composite					542:550	the resultant hybrid epoxy composite	515:550	the resultant hybrid epoxy composite	515:550	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	0	64	theme	Resin	133:137	arg1	Safety					117:122	Enhanced Fire Safety	103:122	Enhanced Fire Safety of Epoxy Resin	103:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	6	65	theme	significant	1264:1274	arg1	effective					1353:1361	effective	1353:1361	effective	1353:1361	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	6	65	theme	significant	1264:1274	arg1	outcome					1289:1295	a significant fire-testing outcome	1262:1295	a significant fire-testing outcome of the proposed hierarchical structure	1262:1334	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	1	66	theme	CHS	188:190	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	66	theme	CHS	188:190	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	4	67	theme	smoke	935:939	arg1	rate					952:955	peak smoke production rate	930:955	peak smoke production rate	930:955	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	1	68	theme	SA	192:193	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	68	theme	SA	192:193	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	69	from	reduction	803:811	arg1	values					866:871	total heat release values	847:871	total heat release values	847:871	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	3	69	from	reduction	803:811	arg1	rate					838:841	peak heat release rate	820:841	peak heat release rate	820:841	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	4	70	theme	@	1001:1001	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	4	71	theme	@	1005:1005	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	3	72	theme	CHS	767:769	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	6	73	theme	toxicity	1420:1427	arg1	terms					1387:1391	terms	1387:1391	terms of flammability, smoke and toxicity reductions	1387:1438	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	2	74	theme	structure	664:672	arg1	formation					633:641	the formation	629:641	the formation of a compact layered structure that enhanced its fire-resistive effectiveness	629:719	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	0	75	theme	Manganese	80:88	arg1	Dioxides					90:97	Nickle Nanocrystal-Decorated Manganese Dioxides	51:97	Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin	51:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	6	76	from	composites	1373:1382	arg1	terms					1387:1391	terms	1387:1391	terms of flammability, smoke and toxicity reductions	1387:1438	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	1	77	theme	novel	142:146	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	77	theme	novel	142:146	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	78	theme	MnO2	762:765	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	2	79	theme	compact	648:654	arg1	structure					664:672	a compact layered structure	646:672	a compact layered structure that enhanced its fire-resistive effectiveness	646:719	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	0	80	theme	Enhanced	103:110	arg1	Safety					117:122	Enhanced Fire Safety	103:122	Enhanced Fire Safety of Epoxy Resin	103:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	6	81	theme	hierarchical	1313:1324	arg1	structure					1326:1334	the proposed hierarchical structure	1300:1334	the proposed hierarchical structure	1300:1334	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	1	82	theme	hierarchical	152:163	arg1	composite					172:180	A novel and hierarchical hybrid composite	140:180	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni)	140:197	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	1	82	theme	hierarchical	152:163	arg1	Ni					195:196	MnO2@CHS@SA@Ni	183:196	MnO2@CHS@SA@Ni	183:196	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	83	theme	Ni	774:775	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	6	84	theme	respective	1504:1513	arg1	fields					1515:1520	the respective fields	1500:1520	the respective fields	1500:1520	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	3	85	theme	wt	758:759	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	0	86	theme	Fire	112:115	arg1	Safety					117:122	Enhanced Fire Safety	103:122	Enhanced Fire Safety of Epoxy Resin	103:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	3	87	theme	SA	771:772	arg1	hybrids					777:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	only 2 wt% MnO2@CHS@SA@Ni hybrids	751:783	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	2	88	theme	exceptional	565:575	arg1	nano-barrier					577:588	an exceptional nano-barrier and synergistic charring effect	562:620	nano-barrier	577:588	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	1	89	theme	fire	445:448	arg1	suppression					457:467	fire hazard suppression	445:467	fire hazard suppression	445:467	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	6	90	theme	polymeric	1477:1485	arg1	materials					1487:1495	other polymeric materials	1471:1495	other polymeric materials	1471:1495	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	4	91	theme	@	1008:1008	arg1	%					1013:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	EP/MnO2@CHS@SA@Ni 2%	994:1013	Notably, the peak smoke production rate and total smoke production values of EP/MnO2@CHS@SA@Ni 2% were decreased by ca. 16.9 and 38.4% compared to the corresponding data of pristine EP.
36430185	3	92	theme	epoxy	903:907	arg1	matrix					909:914	the epoxy matrix	899:914	the epoxy matrix	899:914	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	2	93	theme	charring	606:613	arg1	effect					615:620	an exceptional nano-barrier and synergistic charring effect	562:620	effect	615:620	Herein, the resultant hybrid epoxy composite possessed an exceptional nano-barrier and synergistic charring effect to aid the formation of a compact layered structure that enhanced its fire-resistive effectiveness.
36430185	1	94	theme	surface	473:479	arg1	technology					495:504	surface self-assembly technology	473:504	surface self-assembly technology	473:504	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	0	95	theme	Tailored	25:32	arg1	Hybrids					34:40	Hierarchically Tailored Hybrids	10:40	Hierarchically Tailored Hybrids	10:40	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	6	96	theme	epoxy	1367:1371	arg1	composites					1373:1382	epoxy composites	1367:1382	epoxy composites in terms of flammability, smoke and toxicity reductions	1367:1438	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	6	97	from	prospects	1458:1466	arg1	materials					1487:1495	other polymeric materials	1471:1495	other polymeric materials	1471:1495	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	6	97	from	prospects	1458:1466	arg1	fields					1515:1520	the respective fields	1500:1520	the respective fields	1500:1520	Overall, a significant fire-testing outcome of the proposed hierarchical structure was proven to be effective for epoxy composites in terms of flammability, smoke and toxicity reductions, optimizing their prospects in other polymeric materials in the respective fields.
36430185	0	98	theme	Nickle	51:56	arg1	Dioxides					90:97	Nickle Nanocrystal-Decorated Manganese Dioxides	51:97	Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin	51:137	Design of Hierarchically Tailored Hybrids Based on Nickle Nanocrystal-Decorated Manganese Dioxides for Enhanced Fire Safety of Epoxy Resin.
36430185	1	99	theme	core	268:271	arg1	structure					273:281	the core structure	264:281	the core structure	264:281	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	5	100	theme	CO	1152:1153	arg1	suppression					1131:1141	the suppression	1127:1141	the suppression of toxic CO	1127:1153	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	5	100	theme	CO	1152:1153	arg1	release					1159:1165	NO release	1156:1165	NO release	1156:1165	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	5	100	theme	CO	1152:1153	arg1	diffusion					1175:1183	the diffusion	1171:1183	the diffusion of thermal pyrolysis gases during combustion through TG-IR results	1171:1250	This was accompanied by the suppression of toxic CO, NO release and the diffusion of thermal pyrolysis gases during combustion through TG-IR results.
36430185	3	101	theme	heat	825:828	arg1	rate					838:841	peak heat release rate	820:841	peak heat release rate	820:841	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
36430185	1	102	theme	epoxy	418:422	arg1	matrix					424:429	an epoxy matrix	415:429	an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology	415:504	A novel and hierarchical hybrid composite (MnO2@CHS@SA@Ni) was synthesized utilizing manganese dioxide (MnO2) nanosheets as the core structure, self-assembly chitosan (CHS), sodium alginate (SA) and nickel species (Ni) as surface layers, and it was further incorporated into an epoxy matrix for achieving fire hazard suppression via surface self-assembly technology.
36430185	3	103	theme	release	858:864	arg1	values					866:871	total heat release values	847:871	total heat release values	847:871	As a result, the addition of only 2 wt% MnO2@CHS@SA@Ni hybrids led to a dramatic reduction in the peak heat release rate and total heat release values (by ca. 33% and 27.8%) of the epoxy matrix.
35140278	8	0	theme	membrane	1144:1151	arg1	capacity					1116:1123	The drug delivery capacity	1098:1123	The drug delivery capacity of the produced BC membrane	1098:1151	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	8	1	theme	produced	1132:1139	arg1	membrane					1144:1151	the produced BC membrane	1128:1151	the produced BC membrane	1128:1151	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	5	2	theme	BC	691:692	arg1	production					694:703	maximal BC production	683:703	maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches	683:791	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
35140278	6	3	theme	yeast	895:899	arg1	MgSO4					910:914	MgSO4	910:914	MgSO4	910:914	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	3	theme	yeast	895:899	arg1	variables					950:958	the most significant variables	929:958	the most significant variables influencing BC production	929:984	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	3	theme	yeast	895:899	arg1	pH					921:922	pH	921:922	pH	921:922	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	3	theme	yeast	895:899	arg1	extract					901:907	yeast extract	895:907	yeast extract	895:907	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	4	4	theme	16S	613:615	arg1	sequencing					622:631	16S rRNA sequencing	613:631	16S rRNA sequencing	613:631	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	8	5	theme	BC	1141:1142	arg1	membrane					1144:1151	the produced BC membrane	1128:1151	the produced BC membrane	1128:1151	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	6	6	theme	highest	858:864	arg1	2.7 g/l					876:882	2.7 g/l	876:882	2.7 g/l	876:882	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	6	theme	highest	858:864	arg1	yield					869:873	the highest BC yield	854:873	the highest BC yield (2.7 g/l)	854:883	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	3	7	theme	novel	382:386	arg1	organisms					388:396	novel organisms	382:396	novel organisms	382:396	Mining for novel organisms with well-optimized growth conditions will be important for the adoption of BC.
35140278	10	8	theme	antibacterial	1558:1570	arg1	activity					1572:1579	potent antibacterial activity	1551:1579	potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans	1551:1676	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	10	9	theme	composites	1484:1493	arg1	activity					1463:1470	The antimicrobial activity	1445:1470	The antimicrobial activity of prepared composites	1445:1493	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	5	10	theme	Culture	634:640	arg1	conditions					642:651	Culture conditions	634:651	Culture conditions	634:651	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
35140278	2	11	theme	bacterial	318:326	arg1	strains					339:345	bacterial production strains	318:345	bacterial production strains	318:345	Its use is limited by the capacity of bacterial production strains and cost of the medium.
35140278	9	12	dep	membranes	1272:1280	arg1	fabricated					1294:1303	fabricated	1294:1303	fabricated	1294:1303	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	9	12	dep	membranes	1272:1280	arg1	normal					1283:1288	normal	1283:1288	normal	1283:1288	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	5	13	theme	Box	763:765	arg1	approaches					782:791	Box Behnken design approaches	763:791	Box Behnken design approaches	763:791	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
35140278	10	14	theme	prepared	1475:1482	arg1	composites					1484:1493	prepared composites	1475:1493	prepared composites	1475:1493	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	9	15	theme	X-ray	1399:1403	arg1	diffraction					1405:1415	X-ray diffraction	1399:1415	X-ray diffraction	1399:1415	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	4	16	theme	rRNA	617:620	arg1	sequencing					622:631	16S rRNA sequencing	613:631	16S rRNA sequencing	613:631	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	0	17	theme	antimicrobial	139:151	arg1	assessment					153:162	antimicrobial assessment	139:162	antimicrobial assessment	139:162	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	4	18	dep	Lactiplantibacillus	578:596	arg1	plantarum					598:606	Lactiplantibacillus plantarum	578:606	Lactiplantibacillus plantarum from 16S rRNA sequencing	578:631	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	10	19	theme	human	1522:1526	arg1	pathogens					1528:1536	six human pathogens	1518:1536	six human pathogens	1518:1536	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	10	20	theme	detected	1687:1694	arg1	activity					1696:1703	no detected activity	1684:1703	no detected activity against Pseudomonas aeruginosa and Candida albicans	1684:1755	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	5	21	theme	design	775:780	arg1	approaches					782:791	Box Behnken design approaches	763:791	Box Behnken design approaches	763:791	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
35140278	4	22	theme	BC-producing	501:512	arg1	Lactiplantibacillus					578:596	Lactiplantibacillus	578:596	Lactiplantibacillus	578:596	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	4	22	theme	BC-producing	501:512	arg1	strain					514:519	a novel BC-producing strain	493:519	a novel BC-producing strain	493:519	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	6	23	theme	Yamanaka	828:835	arg1	medium					837:842	a modified Yamanaka medium	817:842	a modified Yamanaka medium	817:842	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	3	24	theme	BC	474:475	arg1	adoption					462:469	the adoption	458:469	the adoption of BC	458:475	Mining for novel organisms with well-optimized growth conditions will be important for the adoption of BC.
35140278	3	25	theme	growth	418:423	arg1	conditions					425:434	well-optimized growth conditions	403:434	well-optimized growth conditions	403:434	Mining for novel organisms with well-optimized growth conditions will be important for the adoption of BC.
35140278	4	26	theme	novel	495:499	arg1	Lactiplantibacillus					578:596	Lactiplantibacillus	578:596	Lactiplantibacillus	578:596	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	4	26	theme	novel	495:499	arg1	strain					514:519	a novel BC-producing strain	493:519	a novel BC-producing strain	493:519	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	6	27	theme	modified	819:826	arg1	medium					837:842	a modified Yamanaka medium	817:842	a modified Yamanaka medium	817:842	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	9	28	theme	scanning	1328:1335	arg1	microscope					1346:1355	scanning electron microscope	1328:1355	scanning electron microscope	1328:1355	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	0	29	theme	Bioprocess	0:9	arg1	development					11:21	Bioprocess development	0:21	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.	0:186	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	5	30	theme	maximal	683:689	arg1	production					694:703	maximal BC production	683:703	maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches	683:791	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
35140278	10	31	theme	antimicrobial	1449:1461	arg1	activity					1463:1470	The antimicrobial activity	1445:1470	The antimicrobial activity of prepared composites	1445:1493	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	0	32	theme	bacterial	27:35	arg1	biosynthesis					47:58	bacterial cellulose biosynthesis	27:58	bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane	27:185	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	9	33	theme	Fourier	1358:1364	arg1	spectroscopy					1385:1396	Fourier transform-infrared spectroscopy	1358:1396	Fourier transform-infrared spectroscopy	1358:1396	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	10	34	theme	potent	1551:1556	arg1	activity					1572:1579	potent antibacterial activity	1551:1579	potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans	1551:1676	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	2	35	theme	strains	339:345	arg1	capacity					306:313	the capacity	302:313	the capacity of bacterial production strains	302:345	Its use is limited by the capacity of bacterial production strains and cost of the medium.
35140278	2	35	theme	strains	339:345	arg1	cost					351:354	cost	351:354	cost of the medium	351:368	Its use is limited by the capacity of bacterial production strains and cost of the medium.
35140278	1	36	theme	ecofriendly	219:229	arg1	biopolymer					231:240	an ecofriendly biopolymer	216:240	an ecofriendly biopolymer with diverse commercial applications	216:277	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	1	36	theme	ecofriendly	219:229	arg1	cellulose					198:206	Bacterial cellulose	188:206	Bacterial cellulose (BC)	188:211	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	3	37	theme	well-optimized	403:416	arg1	conditions					425:434	well-optimized growth conditions	403:434	well-optimized growth conditions	403:434	Mining for novel organisms with well-optimized growth conditions will be important for the adoption of BC.
35140278	6	38	theme	BC	972:973	arg1	production					975:984	BC production	972:984	BC production	972:984	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	5	39	theme	Plackett-Burman	735:749	arg1	design					751:756	Plackett-Burman design	735:756	Plackett-Burman design	735:756	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
35140278	2	40	theme	production	328:337	arg1	strains					339:345	bacterial production strains	318:345	bacterial production strains	318:345	Its use is limited by the capacity of bacterial production strains and cost of the medium.
35140278	8	41	theme	antibiotic	1223:1232	arg1	alginate					1199:1206	sodium alginate	1192:1206	sodium alginate	1192:1206	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	0	42	theme	membrane	178:185	arg1	characterization					118:133	characterization	118:133	characterization	118:133	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	0	42	theme	membrane	178:185	arg1	assessment					153:162	antimicrobial assessment	139:162	antimicrobial assessment	139:162	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	3	43	with	Mining	371:376	arg1	conditions					425:434	well-optimized growth conditions	403:434	well-optimized growth conditions	403:434	Mining for novel organisms with well-optimized growth conditions will be important for the adoption of BC.
35140278	9	44	theme	transform-infrared	1366:1383	arg1	spectroscopy					1385:1396	Fourier transform-infrared spectroscopy	1358:1396	Fourier transform-infrared spectroscopy	1358:1396	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	0	45	theme	cellulose	37:45	arg1	biosynthesis					47:58	bacterial cellulose biosynthesis	27:58	bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane	27:185	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	4	46	theme	fruit	546:550	arg1	samples					552:558	rotten fruit samples	539:558	rotten fruit samples	539:558	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	0	47	theme	fabricated	167:176	arg1	membrane					178:185	fabricated membrane	167:185	fabricated membrane	167:185	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	7	48	theme	variables	1024:1032	arg1	levels					1008:1013	the levels	1004:1013	the levels of these variables	1004:1032	After optimizing the levels of these variables through Box Behnken design, BC yield was increased to 4.51 g/l.
35140278	1	49	theme	diverse	247:253	arg1	applications					266:277	diverse commercial applications	247:277	diverse commercial applications	247:277	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	0	50	theme	novel	63:67	arg1	isolate					99:105	novel Lactiplantibacillus plantarum isolate	63:105	novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane	63:185	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	4	51	theme	rotten	539:544	arg1	samples					552:558	rotten fruit samples	539:558	rotten fruit samples	539:558	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	8	52	theme	delivery	1107:1114	arg1	capacity					1116:1123	The drug delivery capacity	1098:1123	The drug delivery capacity of the produced BC membrane	1098:1151	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	9	53	theme	electron	1337:1344	arg1	microscope					1346:1355	scanning electron microscope	1328:1355	scanning electron microscope	1328:1355	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	1	54	with	biopolymer	231:240	arg1	applications					266:277	diverse commercial applications	247:277	diverse commercial applications	247:277	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	8	55	theme	drug	1102:1105	arg1	capacity					1116:1123	The drug delivery capacity	1098:1123	The drug delivery capacity of the produced BC membrane	1098:1151	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	8	56	from	concentrations	1252:1265	arg1	antibiotic					1223:1232	antibiotic	1223:1232	antibiotic	1223:1232	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	2	57	theme	medium	363:368	arg1	capacity					306:313	the capacity	302:313	the capacity of bacterial production strains	302:345	Its use is limited by the capacity of bacterial production strains and cost of the medium.
35140278	2	57	theme	medium	363:368	arg1	cost					351:354	cost	351:354	cost of the medium	351:368	Its use is limited by the capacity of bacterial production strains and cost of the medium.
35140278	8	58	theme	sodium	1192:1197	arg1	alginate					1199:1206	sodium alginate	1192:1206	sodium alginate	1192:1206	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	7	59	theme	Box	1042:1044	arg1	design					1054:1059	Box Behnken design	1042:1059	Box Behnken design	1042:1059	After optimizing the levels of these variables through Box Behnken design, BC yield was increased to 4.51 g/l.
35140278	8	60	with	fabrication	1175:1185	arg1	alginate					1199:1206	sodium alginate	1192:1206	sodium alginate	1192:1206	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	8	60	with	fabrication	1175:1185	arg1	gentamycin					1212:1221	gentamycin	1212:1221	gentamycin	1212:1221	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	4	61	attach	isolated	525:532	arg1	samples					552:558	rotten fruit samples	539:558	rotten fruit samples	539:558	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	4	61	attach	isolated	525:532	arg2	Lactiplantibacillus					578:596	Lactiplantibacillus	578:596	Lactiplantibacillus	578:596	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	4	61	attach	isolated	525:532	arg2	strain					514:519	a novel BC-producing strain	493:519	a novel BC-producing strain	493:519	In this study, a novel BC-producing strain was isolated from rotten fruit samples and identified as Lactiplantibacillus plantarum from 16S rRNA sequencing.
35140278	1	62	theme	commercial	255:264	arg1	applications					266:277	diverse commercial applications	247:277	diverse commercial applications	247:277	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	7	63	theme	Behnken	1046:1052	arg1	design					1054:1059	Box Behnken design	1042:1059	Box Behnken design	1042:1059	After optimizing the levels of these variables through Box Behnken design, BC yield was increased to 4.51 g/l.
35140278	10	64	theme	Candida	1740:1746	arg1	albicans					1748:1755	Candida albicans	1740:1755	Candida albicans	1740:1755	The antimicrobial activity of prepared composites was evaluated by using six human pathogens and revealed potent antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus mutans, with no detected activity against Pseudomonas aeruginosa and Candida albicans.
35140278	9	65	theme	mechanical	1422:1431	arg1	properties					1433:1442	mechanical properties	1422:1442	mechanical properties	1422:1442	All membranes (normal and fabricated) were characterized by scanning electron microscope, Fourier transform-infrared spectroscopy, X-ray diffraction, and mechanical properties.
35140278	0	66	theme	plantarum	89:97	arg1	isolate					99:105	novel Lactiplantibacillus plantarum isolate	63:105	novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane	63:185	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	6	67	theme	BC	866:867	arg1	2.7 g/l					876:882	2.7 g/l	876:882	2.7 g/l	876:882	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	67	theme	BC	866:867	arg1	yield					869:873	the highest BC yield	854:873	the highest BC yield (2.7 g/l)	854:883	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	8	68	theme	different	1242:1250	arg1	concentrations					1252:1265	four different concentrations	1237:1265	four different concentrations	1237:1265	The drug delivery capacity of the produced BC membrane was evaluated through fabrication with sodium alginate and gentamycin antibiotic at four different concentrations.
35140278	0	69	theme	Lactiplantibacillus	69:87	arg1	isolate					99:105	novel Lactiplantibacillus plantarum isolate	63:105	novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane	63:185	Bioprocess development for bacterial cellulose biosynthesis by novel Lactiplantibacillus plantarum isolate along with characterization and antimicrobial assessment of fabricated membrane.
35140278	7	70	theme	BC	1062:1063	arg1	yield					1065:1069	BC yield	1062:1069	BC yield	1062:1069	After optimizing the levels of these variables through Box Behnken design, BC yield was increased to 4.51 g/l.
35140278	1	71	theme	Bacterial	188:196	arg1	biopolymer					231:240	an ecofriendly biopolymer	216:240	an ecofriendly biopolymer with diverse commercial applications	216:277	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	1	71	theme	Bacterial	188:196	arg1	BC					209:210	BC	209:210	BC	209:210	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	1	71	theme	Bacterial	188:196	arg1	cellulose					198:206	Bacterial cellulose	188:206	Bacterial cellulose (BC)	188:211	Bacterial cellulose (BC) is an ecofriendly biopolymer with diverse commercial applications.
35140278	6	72	theme	significant	938:948	arg1	MgSO4					910:914	MgSO4	910:914	MgSO4	910:914	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	72	theme	significant	938:948	arg1	variables					950:958	the most significant variables	929:958	the most significant variables influencing BC production	929:984	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	72	theme	significant	938:948	arg1	pH					921:922	pH	921:922	pH	921:922	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	6	72	theme	significant	938:948	arg1	extract					901:907	yeast extract	895:907	yeast extract	895:907	Results indicated that a modified Yamanaka medium supported the highest BC yield (2.7 g/l), and that yeast extract, MgSO4, and pH were the most significant variables influencing BC production.
35140278	5	73	theme	Behnken	767:773	arg1	approaches					782:791	Box Behnken design approaches	763:791	Box Behnken design approaches	763:791	Culture conditions were optimized for supporting maximal BC production using one variable at a time, Plackett-Burman design, and Box Behnken design approaches.
36408941	0	0	theme	protein	80:86	arg1	separation					88:97	protein separation	80:97	protein separation	80:97	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	7	1	theme	albumin	1135:1141	arg1	contamination					1143:1155	serum albumin contamination	1129:1155	serum albumin contamination in neutral proteins	1129:1175	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	2	2	theme	diatom	357:362	arg1	earth					364:368	diatom earth	357:368	diatom earth	357:368	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	4	3	theme	solution	615:622	arg1	mixture					624:630	the solution mixture	611:630	the solution mixture of bovine serum albumin and bovine ɤ-globulin	611:676	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	6	4	theme	bovine	848:853	arg1	albumin					861:867	bovine serum albumin	848:867	bovine serum albumin	848:867	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	4	5	theme	flow-through	722:733	arg1	fraction					735:742	the flow-through fraction	718:742	the flow-through fraction	718:742	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	6	6	theme	acetate	1020:1026	arg1	buffer					1028:1033	a 10 mM acetate buffer	1012:1033	a 10 mM acetate buffer	1012:1033	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	7	7	theme	bioproduction	1207:1219	arg1	processes					1221:1229	bioproduction processes	1207:1229	bioproduction processes	1207:1229	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	6	8	contain	containing	956:965	arg1	buffer					949:954	a buffer	947:954	a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer	947:1033	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	6	8	contain	containing	956:965	arg2	regeneration					994:1005	subsequent regeneration	983:1005	subsequent regeneration	983:1005	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	6	8	contain	containing	956:965	arg2	NaCl					974:977	400 mM NaCl	967:977	400 mM NaCl	967:977	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	6	9	theme	10 mM	1014:1018	arg1	buffer					1028:1033	a 10 mM acetate buffer	1012:1033	a 10 mM acetate buffer	1012:1033	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	7	10	theme	serum	1129:1133	arg1	albumin					1135:1141	serum albumin	1129:1141	serum albumin contamination in neutral proteins	1129:1175	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	2	11	theme	propyl	296:301	arg1	chloride					313:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	2	11	theme	propyl	296:301	arg1	chitosan					252:259	Quaternized chitosan	240:259	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water	240:340	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	5	12	dep	5.5	825:827	arg1	to					822:823	to	822:823	to	822:823	The adsorption selectivity was enhanced by changing the solution pH from 6.8 to 5.5.
36408941	4	13	theme	bovine	660:665	arg1	ɤ-globulin					667:676	bovine ɤ-globulin	660:676	bovine ɤ-globulin	660:676	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	7	14	theme	neutral	1160:1166	arg1	proteins					1168:1175	neutral proteins	1160:1175	neutral proteins	1160:1175	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	1	15	with	monoliths	125:133	arg1	structures					147:156	porous structures	140:156	porous structures	140:156	In this study, composite monoliths with porous structures were prepared using quaternized chitosan and diatom earth for protein separation.
36408941	2	16	theme	2-hydroxy-3-trimethylammonium	266:294	arg1	chloride					313:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	2	16	theme	2-hydroxy-3-trimethylammonium	266:294	arg1	chitosan					252:259	Quaternized chitosan	240:259	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water	240:340	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	3	17	theme	Interconnected	458:471	arg1	monoliths					480:488	Interconnected porous monoliths	458:488	Interconnected porous monoliths	458:488	Interconnected porous monoliths were obtained after removing ice crystals from the cryogel.
36408941	7	18	from	ɤ-globulins	1191:1201	arg1	processes					1221:1229	bioproduction processes	1207:1229	bioproduction processes	1207:1229	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	19	theme	acidic	1104:1109	arg1	proteins					1111:1118	acidic proteins	1104:1118	acidic proteins	1104:1118	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	19	theme	acidic	1104:1109	arg1	contamination					1143:1155	serum albumin contamination	1129:1155	serum albumin contamination in neutral proteins	1129:1175	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	1	20	theme	quaternized	178:188	arg1	chitosan					190:197	quaternized chitosan	178:197	quaternized chitosan	178:197	In this study, composite monoliths with porous structures were prepared using quaternized chitosan and diatom earth for protein separation.
36408941	7	21	theme	proteins	1111:1118	arg1	removal					1093:1099	the removal	1089:1099	the removal of acidic proteins, such as serum albumin contamination in neutral proteins	1089:1175	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	0	22	theme	monoliths	25:33	arg1	Preparation					0:10	Preparation	0:10	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.	0:98	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	4	23	theme	serum	580:584	arg1	albumin					586:592	bovine serum albumin	573:592	bovine serum albumin	573:592	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	6	24	with	NaCl	974:977	arg1	buffer					1028:1033	a 10 mM acetate buffer	1012:1033	a 10 mM acetate buffer	1012:1033	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	4	25	theme	ɤ-globulin	667:676	arg1	mixture					624:630	the solution mixture	611:630	the solution mixture of bovine serum albumin and bovine ɤ-globulin	611:676	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	0	26	theme	composite	15:23	arg1	monoliths					25:33	composite monoliths	15:33	composite monoliths of quaternized chitosan and diatom earth	15:74	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	6	27	theme	subsequent	983:992	arg1	regeneration					994:1005	subsequent regeneration	983:1005	subsequent regeneration	983:1005	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	4	28	theme	serum	642:646	arg1	albumin					648:654	bovine serum albumin	635:654	bovine serum albumin	635:654	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	2	29	theme	chitosan	304:311	arg1	chloride					313:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	2	29	theme	chitosan	304:311	arg1	chitosan					252:259	Quaternized chitosan	240:259	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water	240:340	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	1	30	theme	diatom	203:208	arg1	earth					210:214	diatom earth	203:214	diatom earth	203:214	In this study, composite monoliths with porous structures were prepared using quaternized chitosan and diatom earth for protein separation.
36408941	0	31	theme	quaternized	38:48	arg1	chitosan					50:57	quaternized chitosan	38:57	quaternized chitosan	38:57	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	5	32	theme	adsorption	749:758	arg1	selectivity					760:770	The adsorption selectivity	745:770	The adsorption selectivity	745:770	The adsorption selectivity was enhanced by changing the solution pH from 6.8 to 5.5.
36408941	2	33	theme	Quaternized	240:250	arg1	chloride					313:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	2	33	theme	Quaternized	240:250	arg1	chitosan					252:259	Quaternized chitosan	240:259	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water	240:340	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	3	34	theme	porous	473:478	arg1	monoliths					480:488	Interconnected porous monoliths	458:488	Interconnected porous monoliths	458:488	Interconnected porous monoliths were obtained after removing ice crystals from the cryogel.
36408941	7	35	theme	composited	1040:1049	arg1	adsorbent					1075:1083	adsorbent	1075:1083	adsorbent	1075:1083	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	35	theme	composited	1040:1049	arg1	ɤ-globulins					1191:1201	ɤ-globulins	1191:1201	ɤ-globulins	1191:1201	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	35	theme	composited	1040:1049	arg1	monolith					1051:1058	The composited monolith	1036:1058	The composited monolith	1036:1058	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	2	36	theme	low-temperature	412:426	arg1	conditions					428:437	low-temperature conditions	412:437	low-temperature conditions	412:437	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	6	37	theme	400 mM	967:972	arg1	NaCl					974:977	400 mM NaCl	967:977	400 mM NaCl	967:977	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	5	38	theme	solution	801:808	arg1	pH					810:811	the solution pH	797:811	the solution pH from 6.8 to 5.5	797:827	The adsorption selectivity was enhanced by changing the solution pH from 6.8 to 5.5.
36408941	3	39	theme	ice	519:521	arg1	crystals					523:530	ice crystals	519:530	ice crystals	519:530	Interconnected porous monoliths were obtained after removing ice crystals from the cryogel.
36408941	0	40	theme	chitosan	50:57	arg1	monoliths					25:33	composite monoliths	15:33	composite monoliths of quaternized chitosan and diatom earth	15:74	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	4	41	theme	bovine	573:578	arg1	albumin					586:592	bovine serum albumin	573:592	bovine serum albumin	573:592	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	7	42	from	contamination	1143:1155	arg1	proteins					1168:1175	neutral proteins	1160:1175	neutral proteins	1160:1175	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	43	dep	ɤ-globulins	1191:1201	arg1	adsorbent					1075:1083	adsorbent	1075:1083	adsorbent	1075:1083	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	43	dep	ɤ-globulins	1191:1201	arg1	ɤ-globulins					1191:1201	ɤ-globulins	1191:1201	ɤ-globulins	1191:1201	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	43	dep	ɤ-globulins	1191:1201	arg1	monolith					1051:1058	The composited monolith	1036:1058	The composited monolith	1036:1058	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	1	44	theme	composite	115:123	arg1	monoliths					125:133	composite monoliths	115:133	composite monoliths with porous structures	115:156	In this study, composite monoliths with porous structures were prepared using quaternized chitosan and diatom earth for protein separation.
36408941	1	45	theme	protein	220:226	arg1	separation					228:237	protein separation	220:237	protein separation	220:237	In this study, composite monoliths with porous structures were prepared using quaternized chitosan and diatom earth for protein separation.
36408941	6	46	with	regeneration	994:1005	arg1	buffer					1028:1033	a 10 mM acetate buffer	1012:1033	a 10 mM acetate buffer	1012:1033	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	6	47	theme	albumin	861:867	arg1	adsorption					834:843	The adsorption	830:843	The adsorption of bovine serum albumin by the monolith	830:883	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	2	48	theme	N-[	262:264	arg1	chloride					313:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride	262:320	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	2	48	theme	N-[	262:264	arg1	chitosan					252:259	Quaternized chitosan	240:259	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water	240:340	Quaternized chitosan (N-[(2-hydroxy-3-trimethylammonium)propyl] chitosan chloride) dissolved in water was mixed with diatom earth and crosslinked with glutaraldehyde under low-temperature conditions to form a cryogel.
36408941	4	49	theme	bovine	635:640	arg1	albumin					648:654	bovine serum albumin	635:654	bovine serum albumin	635:654	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	0	50	theme	earth	70:74	arg1	monoliths					25:33	composite monoliths	15:33	composite monoliths of quaternized chitosan and diatom earth	15:74	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	6	51	theme	serum	855:859	arg1	albumin					861:867	bovine serum albumin	848:867	bovine serum albumin	848:867	The adsorption of bovine serum albumin by the monolith was replicated at least five times following its washing with a buffer containing 400 mM NaCl and subsequent regeneration with a 10 mM acetate buffer.
36408941	4	52	theme	bovine	683:688	arg1	ɤ-globulin					690:699	bovine ɤ-globulin	683:699	bovine ɤ-globulin	683:699	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36408941	0	53	theme	diatom	63:68	arg1	earth					70:74	diatom earth	63:74	diatom earth	63:74	Preparation of composite monoliths of quaternized chitosan and diatom earth for protein separation.
36408941	5	54	from	5.5	825:827	arg1	pH					810:811	the solution pH	797:811	the solution pH from 6.8 to 5.5	797:827	The adsorption selectivity was enhanced by changing the solution pH from 6.8 to 5.5.
36408941	7	55	from	processes	1221:1229	arg1	monolith					1051:1058	The composited monolith	1036:1058	The composited monolith	1036:1058	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	55	from	processes	1221:1229	arg1	adsorbent					1075:1083	adsorbent	1075:1083	adsorbent	1075:1083	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	7	55	from	processes	1221:1229	arg1	ɤ-globulins					1191:1201	ɤ-globulins	1191:1201	ɤ-globulins	1191:1201	The composited monolith is a promising adsorbent for the removal of acidic proteins, such as serum albumin contamination in neutral proteins, for example, ɤ-globulins, in bioproduction processes.
36408941	1	56	theme	porous	140:145	arg1	structures					147:156	porous structures	140:156	porous structures	140:156	In this study, composite monoliths with porous structures were prepared using quaternized chitosan and diatom earth for protein separation.
36408941	4	57	theme	albumin	648:654	arg1	mixture					624:630	the solution mixture	611:630	the solution mixture of bovine serum albumin and bovine ɤ-globulin	611:676	The monoliths adsorbed bovine serum albumin selectively from the solution mixture of bovine serum albumin and bovine ɤ-globulin, and bovine ɤ-globulin was recovered in the flow-through fraction.
36749055	9	0	from	militaris	1311:1319	arg1	commercial					1280:1289	commercial	1280:1289	commercial	1280:1289	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	4	1	theme	yield	682:686	arg1	percentage					658:667	The highest percentage	646:667	The highest percentage of increased yield	646:686	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	1	theme	yield	682:686	arg1	%					704:704	82.52 ± 0.48%	692:704	82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL	692:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	9	2	theme	scale	1245:1249	arg1	fermentations					1262:1274	large scale industrial fermentations	1239:1274	large scale industrial fermentations	1239:1274	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	2	3	theme	vitamin	474:480	arg1	VB6					486:488	VB6	486:488	VB6	486:488	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	2	3	theme	vitamin	474:480	arg1	B6					482:483	vitamin B6	474:483	vitamin B6 (VB6)	474:489	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	9	4	dep	commercial	1280:1289	arg1	uses					1291:1294	uses	1291:1294	uses	1291:1294	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	2	5	theme	IPS	361:363	arg1	yield					365:369	the IPS yield	357:369	the IPS yield	357:369	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	0	6	theme	Polysaccharides	111:125	arg1	Activity					85:92	Antibacterial Activity	71:92	Antibacterial Activity	71:92	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	6	theme	Polysaccharides	111:125	arg1	Yield					36:40	the Yield	32:40	the Yield	32:40	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	6	theme	Polysaccharides	111:125	arg1	Synthase					58:65	Polysaccharide Synthase	43:65	Polysaccharide Synthase	43:65	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	9	7	theme	large	1239:1243	arg1	fermentations					1262:1274	large scale industrial fermentations	1239:1274	large scale industrial fermentations	1239:1274	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	3	8	theme	complex	557:563	arg1	elicitor					565:572	the complex elicitor	553:572	the complex elicitor	553:572	We combined these elicitors and optimized the composition of the complex elicitor using response surface methodology to further improve the yield of IPS.
36749055	2	9	from	effects	323:329	arg1	yield					365:369	the IPS yield	357:369	the IPS yield	357:369	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	0	10	theme	Intracellular	97:109	arg1	Polysaccharides					111:125	Intracellular Polysaccharides	97:125	Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes)	97:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	11	from	Synthase	58:65	arg1	Culture					142:148	Submerged Culture	132:148	Submerged Culture of Cordyceps milifaris (Ascomycetes)	132:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	4	12	theme	mg/mL	798:802	arg1	concentration					726:738	a Tween concentration	718:738	a Tween concentration of 0.41% (w/v)	718:753	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	12	theme	mg/mL	798:802	arg1	concentration					776:788	VB6 concentration	772:788	VB6 concentration of 0.17 mg/mL	772:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	12	theme	mg/mL	798:802	arg1	pH					756:757	pH	756:757	pH of 4.98	756:765	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	13	theme	Tween	720:724	arg1	concentration					726:738	a Tween concentration	718:738	a Tween concentration of 0.41% (w/v)	718:753	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	14	theme	±	698:698	arg1	%					704:704	82.52 ± 0.48%	692:704	82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL	692:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	14	theme	±	698:698	arg1	percentage					658:667	The highest percentage	646:667	The highest percentage of increased yield	646:686	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	0	15	theme	Submerged	132:140	arg1	Culture					142:148	Submerged Culture	132:148	Submerged Culture of Cordyceps milifaris (Ascomycetes)	132:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	9	16	theme	industrial	1251:1260	arg1	fermentations					1262:1274	large scale industrial fermentations	1239:1274	large scale industrial fermentations	1239:1274	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	7	17	theme	antibacterial	1022:1034	arg1	activity					1036:1043	the antibacterial activity	1018:1043	the antibacterial activity against Staphylococcus aureus and Escherichia coli	1018:1094	Furthermore, the antibacterial activity against Staphylococcus aureus and Escherichia coli was evaluated.
36749055	5	18	theme	high	848:851	arg1	yield					853:857	high yield	848:857	high yield of IPS	848:864	Simultaneously, the mechanism of promoting high yield of IPS was preliminarily discussed.
36749055	2	19	theme	significant	408:418	arg1	effect					430:435	significant promoting effect	408:435	significant promoting effect	408:435	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	6	20	theme	IPS	945:947	arg1	synthesis					932:940	the synthesis	928:940	the synthesis of IPS	928:947	The complex elicitor may promote the synthesis of IPS by influencing the activity of polysaccharide synthase.
36749055	8	21	theme	IPS	1188:1190	arg1	activity					1176:1183	the antibacterial activity	1158:1183	the antibacterial activity of IPS	1158:1190	The addition of the complex elicitor increased the antibacterial activity of IPS.
36749055	8	22	theme	complex	1131:1137	arg1	elicitor					1139:1146	the complex elicitor	1127:1146	the complex elicitor	1127:1146	The addition of the complex elicitor increased the antibacterial activity of IPS.
36749055	0	23	from	Yield	36:40	arg1	Culture					142:148	Submerged Culture	132:148	Submerged Culture of Cordyceps milifaris (Ascomycetes)	132:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	4	24	theme	highest	650:656	arg1	percentage					658:667	The highest percentage	646:667	The highest percentage of increased yield	646:686	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	24	theme	highest	650:656	arg1	%					704:704	82.52 ± 0.48%	692:704	82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL	692:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	0	25	theme	Polysaccharide	0:13	arg1	Elicitors					15:23	Polysaccharide Elicitors	0:23	Polysaccharide Elicitors	0:23	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	6	26	theme	complex	899:905	arg1	elicitor					907:914	The complex elicitor	895:914	The complex elicitor	895:914	The complex elicitor may promote the synthesis of IPS by influencing the activity of polysaccharide synthase.
36749055	4	27	theme	VB6	772:774	arg1	concentration					776:788	VB6 concentration	772:788	VB6 concentration of 0.17 mg/mL	772:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	5	28	theme	IPS	862:864	arg1	yield					853:857	high yield	848:857	high yield of IPS	848:864	Simultaneously, the mechanism of promoting high yield of IPS was preliminarily discussed.
36749055	2	29	theme	polysaccharide	378:391	arg1	elicitors					393:401	three polysaccharide elicitors	372:401	three polysaccharide elicitors with significant promoting effect	372:435	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	4	30	theme	4.98	762:765	arg1	concentration					726:738	a Tween concentration	718:738	a Tween concentration of 0.41% (w/v)	718:753	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	30	theme	4.98	762:765	arg1	concentration					776:788	VB6 concentration	772:788	VB6 concentration of 0.17 mg/mL	772:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	30	theme	4.98	762:765	arg1	pH					756:757	pH	756:757	pH of 4.98	756:765	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	8	31	theme	elicitor	1139:1146	arg1	addition					1115:1122	The addition	1111:1122	The addition of the complex elicitor	1111:1146	The addition of the complex elicitor increased the antibacterial activity of IPS.
36749055	4	32	theme	increased	672:680	arg1	yield					682:686	increased yield	672:686	increased yield	672:686	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	8	33	theme	antibacterial	1162:1174	arg1	activity					1176:1183	the antibacterial activity	1158:1183	the antibacterial activity of IPS	1158:1190	The addition of the complex elicitor increased the antibacterial activity of IPS.
36749055	9	34	theme	IPS	1299:1301	arg1	commercial					1280:1289	commercial	1280:1289	commercial	1280:1289	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	0	35	theme	milifaris	163:171	arg1	Culture					142:148	Submerged Culture	132:148	Submerged Culture of Cordyceps milifaris (Ascomycetes)	132:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	36	from	Activity	85:92	arg1	Culture					142:148	Submerged Culture	132:148	Submerged Culture of Cordyceps milifaris (Ascomycetes)	132:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	6	37	theme	polysaccharide	980:993	arg1	synthase					995:1002	polysaccharide synthase	980:1002	polysaccharide synthase	980:1002	The complex elicitor may promote the synthesis of IPS by influencing the activity of polysaccharide synthase.
36749055	6	38	theme	synthase	995:1002	arg1	activity					968:975	the activity	964:975	the activity of polysaccharide synthase	964:1002	The complex elicitor may promote the synthesis of IPS by influencing the activity of polysaccharide synthase.
36749055	0	39	theme	Cordyceps	153:161	arg1	Ascomycetes					174:184	Ascomycetes	174:184	Ascomycetes	174:184	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	39	theme	Cordyceps	153:161	arg1	milifaris					163:171	Cordyceps milifaris	153:171	Cordyceps milifaris (Ascomycetes)	153:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	3	40	theme	response	580:587	arg1	methodology					597:607	response surface methodology	580:607	response surface methodology	580:607	We combined these elicitors and optimized the composition of the complex elicitor using response surface methodology to further improve the yield of IPS.
36749055	2	41	theme	promoting	420:428	arg1	effect					430:435	significant promoting effect	408:435	significant promoting effect	408:435	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	2	42	dep	screened	442:449	arg1	Tween					456:460	Tween	456:460	Tween	456:460	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	2	42	dep	screened	442:449	arg1	pH					466:467	pH	466:467	pH	466:467	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	2	42	dep	screened	442:449	arg1	VB6					486:488	VB6	486:488	VB6	486:488	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	2	42	dep	screened	442:449	arg1	B6					482:483	vitamin B6	474:483	vitamin B6 (VB6)	474:489	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	0	43	theme	Polysaccharide	43:56	arg1	Synthase					58:65	Polysaccharide Synthase	43:65	Polysaccharide Synthase	43:65	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	3	44	theme	elicitor	565:572	arg1	composition					538:548	the composition	534:548	the composition of the complex elicitor	534:572	We combined these elicitors and optimized the composition of the complex elicitor using response surface methodology to further improve the yield of IPS.
36749055	2	45	theme	elicitors	344:352	arg1	effects					323:329	the effects	319:329	the effects of different elicitors on the IPS yield	319:369	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	1	46	theme	Cordyceps	230:238	arg1	IPS					280:282	IPS	280:282	IPS	280:282	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36749055	1	46	theme	Cordyceps	230:238	arg1	polysaccharide					264:277	Cordyceps militaris intracellular polysaccharide	230:277	Cordyceps militaris intracellular polysaccharide (IPS)	230:283	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36749055	3	47	theme	IPS	641:643	arg1	yield					632:636	the yield	628:636	the yield of IPS	628:643	We combined these elicitors and optimized the composition of the complex elicitor using response surface methodology to further improve the yield of IPS.
36749055	4	48	theme	%	747:747	arg1	concentration					726:738	a Tween concentration	718:738	a Tween concentration of 0.41% (w/v)	718:753	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	48	theme	%	747:747	arg1	concentration					776:788	VB6 concentration	772:788	VB6 concentration of 0.17 mg/mL	772:802	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	4	48	theme	%	747:747	arg1	pH					756:757	pH	756:757	pH of 4.98	756:765	The highest percentage of increased yield was 82.52 ± 0.48% obtained at a Tween concentration of 0.41% (w/v), pH of 4.98, and VB6 concentration of 0.17 mg/mL.
36749055	2	49	theme	different	334:342	arg1	elicitors					344:352	different elicitors	334:352	different elicitors	334:352	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	1	50	theme	militaris	240:248	arg1	IPS					280:282	IPS	280:282	IPS	280:282	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36749055	1	50	theme	militaris	240:248	arg1	polysaccharide					264:277	Cordyceps militaris intracellular polysaccharide	230:277	Cordyceps militaris intracellular polysaccharide (IPS)	230:283	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36749055	0	51	theme	Antibacterial	71:83	arg1	Activity					85:92	Antibacterial Activity	71:92	Antibacterial Activity	71:92	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	3	52	theme	surface	589:595	arg1	methodology					597:607	response surface methodology	580:607	response surface methodology	580:607	We combined these elicitors and optimized the composition of the complex elicitor using response surface methodology to further improve the yield of IPS.
36749055	1	53	theme	intracellular	250:262	arg1	IPS					280:282	IPS	280:282	IPS	280:282	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36749055	1	53	theme	intracellular	250:262	arg1	polysaccharide					264:277	Cordyceps militaris intracellular polysaccharide	230:277	Cordyceps militaris intracellular polysaccharide (IPS)	230:283	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36749055	2	54	with	elicitors	393:401	arg1	effect					430:435	significant promoting effect	408:435	significant promoting effect	408:435	By comparing the effects of different elicitors on the IPS yield, three polysaccharide elicitors with significant promoting effect were screened out: Tween 80, pH, and vitamin B6 (VB6).
36749055	0	55	from	Culture	142:148	arg1	Activity					85:92	Antibacterial Activity	71:92	Antibacterial Activity	71:92	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	55	from	Culture	142:148	arg1	Polysaccharides					111:125	Intracellular Polysaccharides	97:125	Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes)	97:185	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	55	from	Culture	142:148	arg1	Yield					36:40	the Yield	32:40	the Yield	32:40	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	0	55	from	Culture	142:148	arg1	Synthase					58:65	Polysaccharide Synthase	43:65	Polysaccharide Synthase	43:65	Polysaccharide Elicitors Affect the Yield, Polysaccharide Synthase and Antibacterial Activity of Intracellular Polysaccharides from Submerged Culture of Cordyceps milifaris (Ascomycetes).
36749055	9	56	theme	antibacterial	1324:1336	arg1	constituents					1338:1349	antibacterial constituents	1324:1349	antibacterial constituents	1324:1349	Therefore, our findings will lead the way for large scale industrial fermentations and commercial uses of IPS from C. militaris as antibacterial constituents.
36749055	1	57	theme	polysaccharide	264:277	arg1	yield					221:225	the yield	217:225	the yield of Cordyceps militaris intracellular polysaccharide (IPS)	217:283	This study aimed to increase the yield of Cordyceps militaris intracellular polysaccharide (IPS) by adding elicitors.
36563803	0	0	theme	polylactic	94:103	arg1	films					147:151	polylactic acid/microcrystalline cellulose composite films	94:151	polylactic acid/microcrystalline cellulose composite films	94:151	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	6	1	theme	acid/microcrystalline	1088:1108	arg1	films					1130:1134	Polylactic acid/microcrystalline cellulose composite films	1077:1134	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw	1077:1168	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw have been proved the most effective.
36563803	5	2	theme	weight	964:969	arg1	loss					971:974	the lessened weight loss	951:974	the lessened weight loss rate	951:979	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	7	3	theme	microcrystalline	1287:1302	arg1	films					1335:1339	microcrystalline celluloses-based biocompatible films	1287:1339	microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily	1287:1372	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	4	4	contain	had	769:771	arg1	celluloses					733:742	Microcrystalline celluloses	716:742	Microcrystalline celluloses from sweet sorghum stalk	716:767	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	4	4	contain	had	769:771	arg2	degree					782:787	a higher degree	773:787	a higher degree of polymerization (327) and crystallinity (70.52 %)	773:839	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	1	5	theme	Microcrystalline	191:206	arg1	celluloses					208:217	Microcrystalline celluloses	191:217	Microcrystalline celluloses	191:217	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	6	theme	Jerusalem	297:305	arg1	stalk					317:321	Jerusalem artichoke stalk	297:321	Jerusalem artichoke stalk	297:321	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	0	7	theme	cellulose	127:135	arg1	films					147:151	polylactic acid/microcrystalline cellulose composite films	94:151	polylactic acid/microcrystalline cellulose composite films	94:151	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	5	8	theme	oxidation	1056:1064	arg1	reactions					1066:1074	the repressed oxidation reactions	1042:1074	the repressed oxidation reactions	1042:1074	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	3	9	theme	residues-derived	595:610	arg1	celluloses					629:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	1	10	theme	artichoke	307:315	arg1	stalk					317:321	Jerusalem artichoke stalk	297:321	Jerusalem artichoke stalk	297:321	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	0	11	theme	acid/microcrystalline	105:125	arg1	films					147:151	polylactic acid/microcrystalline cellulose composite films	94:151	polylactic acid/microcrystalline cellulose composite films	94:151	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	7	12	theme	lily	1369:1372	arg1	preservation					1345:1356	preservation	1345:1356	preservation of Lanzhou lily	1345:1372	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	3	13	theme	microcrystalline	612:627	arg1	celluloses					629:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	4	14	from	stalk	763:767	arg1	celluloses					733:742	Microcrystalline celluloses	716:742	Microcrystalline celluloses from sweet sorghum stalk	716:767	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	6	15	theme	Polylactic	1077:1086	arg1	films					1130:1134	Polylactic acid/microcrystalline cellulose composite films	1077:1134	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw	1077:1168	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw have been proved the most effective.
36563803	2	16	theme	lily	568:571	arg1	preservation					544:555	the preservation	540:555	the preservation of Lanzhou lily	540:571	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	0	17	from	residues	60:67	arg1	Preparation					0:10	Preparation	0:10	Preparation of microcrystalline cellulose from agricultural residues	0:67	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	0	17	from	residues	60:67	arg1	application					79:89	their application	73:89	their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily	73:188	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	7	18	theme	agricultural	1254:1265	arg1	residues					1267:1274	agricultural residues	1254:1274	agricultural residues	1254:1274	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	4	19	theme	sweet	749:753	arg1	stalk					763:767	sweet sorghum stalk	749:767	sweet sorghum stalk	749:767	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	0	20	theme	composite	137:145	arg1	films					147:151	polylactic acid/microcrystalline cellulose composite films	94:151	polylactic acid/microcrystalline cellulose composite films	94:151	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	1	21	theme	physicochemical	397:411	arg1	properties					428:437	physicochemical and structural properties	397:437	physicochemical and structural properties	397:437	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	7	22	theme	value-added	1231:1241	arg1	outlet					1243:1248	a value-added outlet	1229:1248	a value-added outlet for agricultural residues	1229:1274	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	7	23	theme	celluloses-based	1304:1319	arg1	films					1335:1339	microcrystalline celluloses-based biocompatible films	1287:1339	microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily	1287:1372	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	3	24	theme	agricultural	582:593	arg1	celluloses					629:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	3	25	link	residues-derived	595:610	arg1	celluloses					629:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses	574:638	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	2	26	theme	polylactic	502:511	arg1	acid					513:516	polylactic acid	502:516	polylactic acid	502:516	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	3	27	theme	cellulose	648:656	arg1	structure					661:669	cellulose Iβ structure	648:669	cellulose Iβ structure with high purity and good thermal stability	648:713	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	4	28	theme	sorghum	755:761	arg1	stalk					763:767	sweet sorghum stalk	749:767	sweet sorghum stalk	749:767	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	0	29	theme	cellulose	32:40	arg1	Preparation					0:10	Preparation	0:10	Preparation of microcrystalline cellulose from agricultural residues	0:67	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	0	29	theme	cellulose	32:40	arg1	application					79:89	their application	73:89	their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily	73:188	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	1	30	theme	grains	324:329	arg1	stillage					331:338	grains stillage	324:338	grains stillage	324:338	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	5	31	dep	improved	929:936	arg1	indicated					938:946	indicated	938:946	indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions	938:1074	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	6	32	theme	sweet	1150:1154	arg1	straw					1164:1168	sweet sorghum straw	1150:1168	sweet sorghum straw	1150:1168	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw have been proved the most effective.
36563803	0	33	theme	microcrystalline	15:30	arg1	cellulose					32:40	microcrystalline cellulose	15:40	microcrystalline cellulose	15:40	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	1	34	theme	structural	417:426	arg1	properties					428:437	physicochemical and structural properties	397:437	physicochemical and structural properties	397:437	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	4	35	theme	crystallinity	817:829	arg1	degree					782:787	a higher degree	773:787	a higher degree of polymerization (327) and crystallinity (70.52 %)	773:839	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	1	36	theme	agricultural	243:254	arg1	stillage					331:338	grains stillage	324:338	grains stillage	324:338	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	36	theme	agricultural	243:254	arg1	residue					358:364	Chinese herb residue	345:364	Chinese herb residue	345:364	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	36	theme	agricultural	243:254	arg1	residues					256:263	four agricultural residues	238:263	four agricultural residues	238:263	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	36	theme	agricultural	243:254	arg1	stalk					290:294	sweet sorghum stalk	276:294	sweet sorghum stalk	276:294	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	36	theme	agricultural	243:254	arg1	stalk					317:321	Jerusalem artichoke stalk	297:321	Jerusalem artichoke stalk	297:321	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	0	37	theme	agricultural	47:58	arg1	residues					60:67	agricultural residues	47:67	agricultural residues	47:67	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	1	38	theme	properties	428:437	arg1	terms					388:392	terms	388:392	terms of physicochemical and structural properties	388:437	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	4	39	theme	Microcrystalline	716:731	arg1	celluloses					733:742	Microcrystalline celluloses	716:742	Microcrystalline celluloses from sweet sorghum stalk	716:767	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	6	40	theme	sorghum	1156:1162	arg1	straw					1164:1168	sweet sorghum straw	1150:1168	sweet sorghum straw	1150:1168	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw have been proved the most effective.
36563803	2	41	theme	microcrystalline	453:468	arg1	celluloses					470:479	The obtained microcrystalline celluloses	440:479	The obtained microcrystalline celluloses	440:479	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	2	41	theme	microcrystalline	453:468	arg1	film					531:534	a packing film	521:534	a packing film for the preservation of Lanzhou lily	521:571	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	2	42	theme	packing	523:529	arg1	celluloses					470:479	The obtained microcrystalline celluloses	440:479	The obtained microcrystalline celluloses	440:479	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	2	42	theme	packing	523:529	arg1	film					531:534	a packing film	521:534	a packing film for the preservation of Lanzhou lily	521:571	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	3	43	theme	high	676:679	arg1	purity					681:686	high purity	676:686	high purity	676:686	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	2	44	theme	Lanzhou	560:566	arg1	lily					568:571	Lanzhou lily	560:571	Lanzhou lily	560:571	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	1	45	theme	Chinese	345:351	arg1	herb					353:356	Chinese herb	345:356	Chinese herb residue	345:364	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	0	46	theme	lily	185:188	arg1	preservation					161:172	the preservation	157:172	the preservation of Lanzhou lily	157:188	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	1	47	attach	isolated	224:231	arg1	residue					358:364	Chinese herb residue	345:364	Chinese herb residue	345:364	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	47	attach	isolated	224:231	arg1	stalk					290:294	sweet sorghum stalk	276:294	sweet sorghum stalk	276:294	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	47	attach	isolated	224:231	arg1	stillage					331:338	grains stillage	324:338	grains stillage	324:338	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	47	attach	isolated	224:231	arg2	celluloses					208:217	Microcrystalline celluloses	191:217	Microcrystalline celluloses	191:217	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	47	attach	isolated	224:231	arg1	residues					256:263	four agricultural residues	238:263	four agricultural residues	238:263	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	1	47	attach	isolated	224:231	arg1	stalk					317:321	Jerusalem artichoke stalk	297:321	Jerusalem artichoke stalk	297:321	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	3	48	theme	Iβ	658:659	arg1	structure					661:669	cellulose Iβ structure	648:669	cellulose Iβ structure with high purity and good thermal stability	648:713	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	4	49	theme	polymerization	792:805	arg1	degree					782:787	a higher degree	773:787	a higher degree of polymerization (327) and crystallinity (70.52 %)	773:839	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	5	50	theme	preservation	858:869	arg1	effect					871:876	The preservation effect	854:876	The preservation effect of lily bulbs packaged by films	854:908	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	1	51	theme	herb	353:356	arg1	residue					358:364	Chinese herb residue	345:364	Chinese herb residue	345:364	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	0	52	theme	Lanzhou	177:183	arg1	lily					185:188	Lanzhou lily	177:188	Lanzhou lily	177:188	Preparation of microcrystalline cellulose from agricultural residues and their application as polylactic acid/microcrystalline cellulose composite films for the preservation of Lanzhou lily.
36563803	5	53	theme	lily	881:884	arg1	bulbs					886:890	lily bulbs	881:890	lily bulbs packaged by films	881:908	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	7	54	theme	biocompatible	1321:1333	arg1	films					1335:1339	microcrystalline celluloses-based biocompatible films	1287:1339	microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily	1287:1372	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	5	55	theme	repressed	1046:1054	arg1	reactions					1066:1074	the repressed oxidation reactions	1042:1074	the repressed oxidation reactions	1042:1074	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	3	56	theme	good	692:695	arg1	stability					705:713	good thermal stability	692:713	good thermal stability	692:713	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	6	57	theme	cellulose	1110:1118	arg1	films					1130:1134	Polylactic acid/microcrystalline cellulose composite films	1077:1134	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw	1077:1168	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw have been proved the most effective.
36563803	5	58	theme	loss	971:974	arg1	rate					976:979	the lessened weight loss rate	951:979	the lessened weight loss rate	951:979	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	4	59	theme	higher	775:780	arg1	degree					782:787	a higher degree	773:787	a higher degree of polymerization (327) and crystallinity (70.52 %)	773:839	Microcrystalline celluloses from sweet sorghum stalk had a higher degree of polymerization (327) and crystallinity (70.52 %) than others.
36563803	6	60	theme	composite	1120:1128	arg1	films					1130:1134	Polylactic acid/microcrystalline cellulose composite films	1077:1134	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw	1077:1168	Polylactic acid/microcrystalline cellulose composite films prepared from sweet sorghum straw have been proved the most effective.
36563803	3	61	theme	thermal	697:703	arg1	stability					705:713	good thermal stability	692:713	good thermal stability	692:713	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	5	62	theme	meliorative	989:999	arg1	hardness					1001:1008	the meliorative hardness	985:1008	the meliorative hardness	985:1008	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	1	63	theme	sweet	276:280	arg1	stalk					290:294	sweet sorghum stalk	276:294	sweet sorghum stalk	276:294	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	2	64	theme	obtained	444:451	arg1	celluloses					470:479	The obtained microcrystalline celluloses	440:479	The obtained microcrystalline celluloses	440:479	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	2	64	theme	obtained	444:451	arg1	film					531:534	a packing film	521:534	a packing film for the preservation of Lanzhou lily	521:571	The obtained microcrystalline celluloses were composited with polylactic acid as a packing film for the preservation of Lanzhou lily.
36563803	1	65	theme	sorghum	282:288	arg1	stalk					290:294	sweet sorghum stalk	276:294	sweet sorghum stalk	276:294	Microcrystalline celluloses were isolated from four agricultural residues, including sweet sorghum stalk, Jerusalem artichoke stalk, grains stillage, and Chinese herb residue, and characterized in terms of physicochemical and structural properties.
36563803	5	66	theme	bulbs	886:890	arg1	effect					871:876	The preservation effect	854:876	The preservation effect of lily bulbs packaged by films	854:908	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	5	67	theme	lessened	955:962	arg1	loss					971:974	the lessened weight loss	951:974	the lessened weight loss rate	951:979	The preservation effect of lily bulbs packaged by films were significantly improved indicated by the lessened weight loss rate and the meliorative hardness and whiteness, which ascribe to the repressed oxidation reactions.
36563803	7	68	theme	Lanzhou	1361:1367	arg1	lily					1369:1372	Lanzhou lily	1361:1372	Lanzhou lily	1361:1372	This work could offer a value-added outlet for agricultural residues to produce microcrystalline celluloses-based biocompatible films for preservation of Lanzhou lily.
36563803	3	69	with	structure	661:669	arg1	stability					705:713	good thermal stability	692:713	good thermal stability	692:713	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
36563803	3	69	with	structure	661:669	arg1	purity					681:686	high purity	676:686	high purity	676:686	All the agricultural residues-derived microcrystalline celluloses were in cellulose Iβ structure with high purity and good thermal stability.
37141744	6	0	theme	MCC	1294:1296	arg1	cells					1298:1302	MCC cells	1294:1302	MCC cells	1294:1302	L929 exhibited good biocompatibility for fibroblast cells and was determined to support the formation of MCC cells.
37141744	7	1	theme	day	1453:1455	arg1	end					1438:1440	the end	1434:1440	the end of the 7th day	1434:1455	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	7	2	theme	mass	1426:1429	arg1	rate					1405:1408	a high degradation rate	1386:1408	a high degradation rate	1386:1408	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	7	2	theme	mass	1426:1429	arg1	loss					1418:1421	64% loss	1414:1421	64% loss of mass	1414:1429	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	8	3	theme	applicable	1651:1660	arg1	bone					1662:1665	an easily applicable bone	1641:1665	an easily applicable bone	1641:1665	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	3	4	theme	2AgHA-XG/PEI	564:575	arg1	film					591:594	2AgHA-XG/PEI nanocomposite film	564:594	2AgHA-XG/PEI nanocomposite film	564:594	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	1	5	theme	reinforced	268:277	arg1	biocomposite					323:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	3	6	theme	activity	693:700	arg1	analysis					702:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis	626:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity)	626:770	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	8	7	from	treatment	1602:1610	arg1	tissue					1631:1636	bone tissue	1626:1636	bone tissue	1626:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	3	8	dep	structural	614:623	arg1	analysis					702:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis	626:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity)	626:770	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	7	9	theme	64	1414:1415	arg1	%					1416:1416	%	1416:1416	%	1416:1416	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	1	10	theme	bone	405:408	arg1	tissue					410:415	bone tissue	405:415	bone tissue	405:415	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	3	11	dep	morphological	626:638	arg1	FT-IR					651:655	FT-IR	651:655	FT-IR	651:655	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	11	dep	morphological	626:638	arg1	Raman					671:675	Raman	671:675	Raman	671:675	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	11	dep	morphological	626:638	arg1	TGA					658:660	TGA	658:660	TGA	658:660	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	11	dep	morphological	626:638	arg1	SEM					641:643	SEM	641:643	SEM	641:643	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	11	dep	morphological	626:638	arg1	XRD					646:648	XRD	646:648	XRD	646:648	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	11	dep	morphological	626:638	arg1	TM					663:664	TM	663:664	TM	663:664	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	12	theme	film	591:594	arg1	Characteristics					545:559	Characteristics	545:559	Characteristics of 2AgHA-XG/PEI nanocomposite film	545:594	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	1	13	theme	Xanthan	223:229	arg1	XG					236:237	XG	236:237	XG	236:237	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	1	13	theme	Xanthan	223:229	arg1	gum					231:233	silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum	177:233	silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG)	177:238	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	7	14	theme	high	1388:1391	arg1	rate					1405:1408	a high degradation rate	1386:1408	a high degradation rate	1386:1408	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	3	15	theme	antimicrobial	748:760	arg1	activity					762:769	antimicrobial activity	748:769	antimicrobial activity	748:769	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	8	16	from	defects	1615:1621	arg1	tissue					1631:1636	bone tissue	1626:1636	bone tissue	1626:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	3	17	theme	morphological	626:638	arg1	analysis					702:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis	626:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity)	626:770	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	5	18	theme	high	1043:1046	arg1	activity					1062:1069	high antibacterial activity	1043:1069	high antibacterial activity against Acinetobacter Baumannii (A.Baumannii), Staphylococcus aureus (S.aureus), and Streptococcus mutans (S.mutans)	1043:1186	The nanocomposites showed high antibacterial activity against Acinetobacter Baumannii (A.Baumannii), Staphylococcus aureus (S.aureus), and Streptococcus mutans (S.mutans).
37141744	3	19	theme	structural	614:623	arg1	techniques					772:781	structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques	614:781	structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques	614:781	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	4	20	theme	XG/PEI-IPN	904:913	arg1	membrane					915:922	the XG/PEI-IPN membrane	900:922	the XG/PEI-IPN membrane	900:922	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	2	21	theme	simultaneous	499:510	arg1	condensation					512:523	simultaneous condensation	499:523	simultaneous condensation	499:523	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	7	22	theme	composite	1349:1357	arg1	material					1359:1366	a resorbable 2AgHA-XG/PEI composite material	1323:1366	a resorbable 2AgHA-XG/PEI composite material	1323:1366	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	0	23	theme	silver	57:62	arg1	composite					112:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	9	24	theme	dental-bone	1772:1782	arg1	treatments					1784:1793	dental-bone treatments	1772:1793	dental-bone treatments for coating, filling, and occlusion	1772:1829	Besides, it was noted that 2AgHA-XG/PEI biocomposite could increase cell viability, especially in dental-bone treatments for coating, filling, and occlusion.
37141744	8	25	theme	developed	1477:1485	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	0	26	theme	XG/PEI	96:101	arg1	composite					112:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	0	27	theme	composite	112:120	arg1	characterization					37:52	In vitro characterization	28:52	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.	0:121	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	8	28	theme	XG-2AgHA/PEI	1519:1530	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	7	29	theme	2AgHA-XG/PEI	1336:1347	arg1	material					1359:1366	a resorbable 2AgHA-XG/PEI composite material	1323:1366	a resorbable 2AgHA-XG/PEI composite material	1323:1366	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	2	30	theme	IPN	441:443	arg1	films					445:449	XG/PEI IPN films	434:449	XG/PEI IPN films containing 2AgHA nanoparticles	434:480	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	8	31	theme	semi-IPN	1546:1553	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	0	32	theme	Resorbable	0:9	arg1	design					20:25	Resorbable membrane design	0:25	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.	0:121	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	1	33	theme	semi-interpenetrating	279:299	arg1	biocomposite					323:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	6	34	theme	good	1204:1207	arg1	biocompatibility					1209:1224	good biocompatibility	1204:1224	good biocompatibility for fibroblast cells	1204:1245	L929 exhibited good biocompatibility for fibroblast cells and was determined to support the formation of MCC cells.
37141744	1	35	theme	network	309:315	arg1	biocomposite					323:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	4	36	theme	film	1001:1004	arg1	stability					977:985	the thermal and mechanical stability	950:985	the thermal and mechanical stability of the formed film	950:1004	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	4	36	theme	film	1001:1004	arg1	high					1011:1014	high	1011:1014	high	1011:1014	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	8	37	theme	important	1574:1582	arg1	potential					1584:1592	an important potential	1571:1592	an important potential for the treatment of defects in bone tissue	1571:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	4	38	theme	physicochemical	791:805	arg1	characterization					807:822	the physicochemical characterization	787:822	the physicochemical characterization	787:822	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	0	39	theme	In	28:29	arg1	characterization					37:52	In vitro characterization	28:52	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.	0:121	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	1	40	theme	IPN	318:320	arg1	biocomposite					323:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	4	41	theme	formed	994:999	arg1	film					1001:1004	the formed film	990:1004	the formed film	990:1004	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	1	42	dep	material	368:375	arg1	cover					362:366	cover	362:366	cover	362:366	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	0	43	dep	In	28:29	arg1	vitro					31:35	vitro	31:35	vitro	31:35	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	1	44	dep	gum	231:233	arg1	biocomposite					323:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	8	45	contain	possessed	1561:1569	arg2	potential					1584:1592	an important potential	1571:1592	an important potential for the treatment of defects in bone tissue	1571:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	8	45	contain	possessed	1561:1569	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	0	46	dep	design	20:25	arg1	characterization					37:52	In vitro characterization	28:52	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.	0:121	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	8	47	theme	defects	1615:1621	arg1	treatment					1602:1610	the treatment	1598:1610	the treatment of defects in bone tissue	1598:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	8	48	theme	bone	1626:1629	arg1	tissue					1631:1636	bone tissue	1626:1636	bone tissue	1626:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	3	49	theme	biological	682:691	arg1	analysis					702:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis	626:709	morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity)	626:770	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	6	50	theme	cells	1298:1302	arg1	formation					1281:1289	the formation	1277:1289	the formation of MCC cells	1277:1302	L929 exhibited good biocompatibility for fibroblast cells and was determined to support the formation of MCC cells.
37141744	7	51	theme	7th	1449:1451	arg1	day					1453:1455	the 7th day	1445:1455	the 7th day	1445:1455	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	4	52	theme	2AgHA	848:852	arg1	nanoparticles					854:866	2AgHA nanoparticles	848:866	2AgHA nanoparticles	848:866	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	2	53	contain	containing	451:460	arg2	nanoparticles					468:480	2AgHA nanoparticles	462:480	2AgHA nanoparticles	462:480	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	2	53	contain	containing	451:460	arg1	films					445:449	XG/PEI IPN films	434:449	XG/PEI IPN films containing 2AgHA nanoparticles	434:480	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	7	54	theme	%	1416:1416	arg1	loss					1418:1421	64% loss	1414:1421	64% loss of mass	1414:1429	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	8	55	from	tissue	1631:1636	arg1	treatment					1602:1610	the treatment	1598:1610	the treatment of defects in bone tissue	1598:1636	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	3	56	theme	nanocomposite	577:589	arg1	film					591:594	2AgHA-XG/PEI nanocomposite film	564:594	2AgHA-XG/PEI nanocomposite film	564:594	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	1	57	theme	reinforced	212:221	arg1	XG					236:237	XG	236:237	XG	236:237	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	1	57	theme	reinforced	212:221	arg1	gum					231:233	silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum	177:233	silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG)	177:238	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	9	58	theme	2AgHA-XG/PEI	1701:1712	arg1	biocomposite					1714:1725	2AgHA-XG/PEI biocomposite	1701:1725	2AgHA-XG/PEI biocomposite	1701:1725	Besides, it was noted that 2AgHA-XG/PEI biocomposite could increase cell viability, especially in dental-bone treatments for coating, filling, and occlusion.
37141744	1	59	theme	therapeutic	381:391	arg1	purposes					393:400	therapeutic purposes	381:400	therapeutic purposes in bone tissue	381:415	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	1	60	theme	gum	231:233	arg1	characterization					157:172	characterization	157:172	characterization	157:172	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	1	60	theme	gum	231:233	arg1	production					142:151	production	142:151	production	142:151	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	4	61	theme	high	927:930	arg1	concentration					932:944	high concentration	927:944	high concentration	927:944	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	7	62	theme	degradation	1393:1403	arg1	rate					1405:1408	a high degradation rate	1386:1408	a high degradation rate	1386:1408	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	9	63	theme	cell	1742:1745	arg1	viability					1747:1755	cell viability	1742:1755	cell viability	1742:1755	Besides, it was noted that 2AgHA-XG/PEI biocomposite could increase cell viability, especially in dental-bone treatments for coating, filling, and occlusion.
37141744	6	64	theme	fibroblast	1230:1239	arg1	cells					1241:1245	fibroblast cells	1230:1245	fibroblast cells	1230:1245	L929 exhibited good biocompatibility for fibroblast cells and was determined to support the formation of MCC cells.
37141744	5	65	theme	antibacterial	1048:1060	arg1	activity					1062:1069	high antibacterial activity	1043:1069	high antibacterial activity against Acinetobacter Baumannii (A.Baumannii), Staphylococcus aureus (S.aureus), and Streptococcus mutans (S.mutans)	1043:1186	The nanocomposites showed high antibacterial activity against Acinetobacter Baumannii (A.Baumannii), Staphylococcus aureus (S.aureus), and Streptococcus mutans (S.mutans).
37141744	8	66	theme	Physico-chemically	1458:1475	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	0	67	theme	doped-hydroxyapatite-reinforced	64:94	arg1	composite					112:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	4	68	theme	mechanical	966:975	arg1	stability					977:985	the thermal and mechanical stability	950:985	the thermal and mechanical stability of the formed film	950:1004	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	4	68	theme	mechanical	966:975	arg1	high					1011:1014	high	1011:1014	high	1011:1014	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	8	69	theme	biocompatible	1487:1499	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	8	70	dep	cover	1667:1671	arg1	bone					1662:1665	an easily applicable bone	1641:1665	an easily applicable bone	1641:1665	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	8	70	dep	cover	1667:1671	arg1	as					1638:1639	as	1638:1639	as	1638:1639	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	0	71	theme	semi-IPN	103:110	arg1	composite					112:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite	57:120	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	8	72	theme	biodegradable	1505:1517	arg1	XG-2AgHA/PEI					1519:1530	biodegradable XG-2AgHA/PEI	1505:1530	biodegradable XG-2AgHA/PEI	1505:1530	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	1	73	from	purposes	393:400	arg1	tissue					410:415	bone tissue	405:415	bone tissue	405:415	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	2	74	theme	ionic	529:533	arg1	gelation					535:542	ionic gelation	529:542	ionic gelation	529:542	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	8	75	theme	nanocomposite	1532:1544	arg1	films					1555:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films	1458:1559	Physico-chemically developed biocompatible and biodegradable XG-2AgHA/PEI nanocomposite semi-IPN films possessed an important potential for the treatment of defects in bone tissue as an easily applicable bone cover.
37141744	1	76	dep	production	142:151	arg1	the					138:140	the	138:140	the	138:140	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	1	77	theme	bone	357:360	arg1	material					368:375	bone cover material	357:375	bone cover material for therapeutic purposes in bone tissue	357:415	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	7	78	theme	resorbable	1325:1334	arg1	material					1359:1366	a resorbable 2AgHA-XG/PEI composite material	1323:1366	a resorbable 2AgHA-XG/PEI composite material	1323:1366	It was shown that a resorbable 2AgHA-XG/PEI composite material was obtained with a high degradation rate and 64% loss of mass at the end of the 7th day.
37141744	4	79	theme	thermal	954:960	arg1	stability					977:985	the thermal and mechanical stability	950:985	the thermal and mechanical stability of the formed film	950:1004	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	4	79	theme	thermal	954:960	arg1	high					1011:1014	high	1011:1014	high	1011:1014	In the physicochemical characterization, it was determined that 2AgHA nanoparticles were homogeneously dispersed in the XG/PEI-IPN membrane at high concentration and the thermal and mechanical stability of the formed film were high.
37141744	0	80	theme	membrane	11:18	arg1	design					20:25	Resorbable membrane design	0:25	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.	0:121	Resorbable membrane design: In vitro characterization of silver doped-hydroxyapatite-reinforced XG/PEI semi-IPN composite.
37141744	2	81	theme	XG/PEI	434:439	arg1	films					445:449	XG/PEI IPN films	434:449	XG/PEI IPN films containing 2AgHA nanoparticles	434:480	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	1	82	theme	polymer	301:307	arg1	biocomposite					323:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	reinforced semi-interpenetrating polymer network (IPN) biocomposite	268:334	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	2	83	theme	2AgHA	462:466	arg1	nanoparticles					468:480	2AgHA nanoparticles	462:480	2AgHA nanoparticles	462:480	XG/PEI IPN films containing 2AgHA nanoparticles were produced by simultaneous condensation and ionic gelation.
37141744	3	84	dep	analysis	702:709	arg1	degradation					712:722	degradation	712:722	degradation	712:722	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	84	dep	analysis	702:709	arg1	genotoxicity					730:741	genotoxicity	730:741	genotoxicity	730:741	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	84	dep	analysis	702:709	arg1	MTT					725:727	MTT	725:727	MTT	725:727	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	3	84	dep	analysis	702:709	arg1	activity					762:769	antimicrobial activity	748:769	antimicrobial activity	748:769	Characteristics of 2AgHA-XG/PEI nanocomposite film were evaluated by structural, morphological (SEM, XRD, FT-IR, TGA, TM, and Raman) and biological activity analysis (degradation, MTT, genotoxicity, and antimicrobial activity) techniques.
37141744	1	85	theme	Polyethyleneimine	244:260	arg1	characterization					157:172	characterization	157:172	characterization	157:172	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
37141744	1	85	theme	Polyethyleneimine	244:260	arg1	production					142:151	production	142:151	production	142:151	In this study, the production and characterization of silver-doped hydroxyapatite (AgHA) reinforced Xanthan gum (XG) and Polyethyleneimine (PEI) reinforced semi-interpenetrating polymer network (IPN) biocomposite, known to be used as bone cover material for therapeutic purposes in bone tissue, were performed.
36374421	4	0	theme	cell	762:765	arg1	types					767:771	cell types	762:771	cell types	762:771	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	1	1	theme	animal	244:249	arg1	cells					251:255	all animal cells	240:255	all animal cells	240:255	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	5	2	theme	GAG-protein	910:920	arg1	interactions					922:933	GAG-protein interactions	910:933	GAG-protein interactions	910:933	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	6	3	theme	human	1293:1297	arg1	disease					1299:1305	human disease	1293:1305	human disease	1293:1305	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	3	4	theme	cell	514:517	arg1	surface					519:525	the cell surface	510:525	the cell surface	510:525	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	1	5	theme	cells	251:255	arg1	matrix					230:235	the extracellular matrix	212:235	the extracellular matrix of all animal cells	212:255	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	5	6	theme	structural	961:970	arg1	composition					972:982	the structural composition	957:982	the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate	957:1064	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	3	7	dep	arrangement	394:404	arg1	The					390:392	The	390:392	The	390:392	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	6	8	theme	GAG	1197:1199	arg1	structure					1201:1209	GAG structure	1197:1209	GAG structure	1197:1209	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	3	9	theme	binding	493:499	arg1	sites					501:505	distinct ligand binding sites	477:505	distinct ligand binding sites	477:505	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	6	10	theme	cell	1276:1279	arg1	biology					1281:1287	cell biology	1276:1287	cell biology	1276:1287	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	3	11	theme	residues	444:451	arg1	orientation					410:420	orientation	410:420	orientation	410:420	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	3	11	theme	residues	444:451	arg1	arrangement					394:404	arrangement	394:404	arrangement	394:404	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	1	12	dep	long	124:127	arg1	linear					130:135	linear	130:135	linear	130:135	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	5	13	theme	radiolabeling	1119:1131	arg1	techniques					1133:1142	radiolabeling techniques	1119:1142	radiolabeling techniques	1119:1142	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	3	14	theme	sulfated	429:436	arg1	residues					444:451	the sulfated sugar residues	425:451	the sulfated sugar residues	425:451	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	0	15	theme	Glycosaminoglycan	0:16	arg1	Analysis					18:25	Glycosaminoglycan Analysis	0:25	Glycosaminoglycan Analysis	0:25	Glycosaminoglycan Analysis: Purification, Structural Profiling, and GAG-Protein Interactions.
36374421	6	16	theme	function	1215:1222	arg1	evaluation					1183:1192	the evaluation	1179:1192	the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease	1179:1305	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	2	17	theme	glucosamine	314:324	arg1	acids					337:341	glucosamine and uronic acids	314:341	glucosamine and uronic acids that can be heterogeneously N- and O-sulfated	314:387	These complex carbohydrates are composed of alternating glucosamine and uronic acids that can be heterogeneously N- and O-sulfated.
36374421	3	18	theme	sugar	438:442	arg1	residues					444:451	the sulfated sugar residues	425:451	the sulfated sugar residues	425:451	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	4	19	theme	structural	715:724	arg1	diversity					726:734	their inherent structural diversity	700:734	their inherent structural diversity across different tissues, cell types, and disease states	700:791	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	4	20	theme	different	743:751	arg1	tissues					753:759	different tissues	743:759	different tissues	743:759	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	3	21	theme	cell	571:574	arg1	growth					576:581	cell growth	571:581	cell growth	571:581	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	5	22	theme	liquid	1073:1078	arg1	chromatography					1080:1093	liquid chromatography	1073:1093	liquid chromatography	1073:1093	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	6	23	dep	roles	1246:1250	arg1	play					1268:1271	play	1268:1271	play in cell biology and human disease	1268:1305	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	3	24	theme	distinct	477:484	arg1	sites					501:505	distinct ligand binding sites	477:505	distinct ligand binding sites	477:505	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	0	25	theme	Structural	42:51	arg1	Profiling					53:61	Structural Profiling	42:61	Structural Profiling	42:61	Glycosaminoglycan Analysis: Purification, Structural Profiling, and GAG-Protein Interactions.
36374421	4	26	theme	GAGs	691:694	arg1	nature					681:686	The heterogeneous nature	663:686	The heterogeneous nature of GAGs	663:694	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	4	26	theme	GAGs	691:694	arg1	diversity					726:734	their inherent structural diversity	700:734	their inherent structural diversity across different tissues, cell types, and disease states	700:791	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	1	27	theme	cell	192:195	arg1	surface					197:203	the cell surface	188:203	the cell surface	188:203	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	5	28	theme	heparan	1017:1023	arg1	GAGs					1011:1014	sulfated GAGs	1002:1014	sulfated GAGs	1002:1014	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	5	28	theme	heparan	1017:1023	arg1	sulfate					1025:1031	heparan sulfate	1017:1031	heparan sulfate	1017:1031	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	5	29	theme	mass	1096:1099	arg1	spectrometry					1101:1112	mass spectrometry	1096:1112	mass spectrometry	1096:1112	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	6	30	theme	unique	1239:1244	arg1	roles					1246:1250	the unique roles	1235:1250	the unique roles these molecules play in cell biology and human disease	1235:1305	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	3	31	from	location	465:472	arg1	surface					519:525	the cell surface	510:525	the cell surface	510:525	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	3	32	theme	sites	501:505	arg1	location					465:472	the location	461:472	the location of distinct ligand binding sites on the cell surface	461:525	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	5	33	theme	chondroitin/dermatan	1037:1056	arg1	GAGs					1011:1014	sulfated GAGs	1002:1014	sulfated GAGs	1002:1014	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	5	33	theme	chondroitin/dermatan	1037:1056	arg1	sulfate					1058:1064	chondroitin/dermatan sulfate	1037:1064	chondroitin/dermatan sulfate	1037:1064	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	1	34	theme	long	124:127	arg1	Glycosaminoglycans					94:111	Glycosaminoglycans	94:111	Glycosaminoglycans (GAGs)	94:118	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	1	34	theme	long	124:127	arg1	polysaccharides					137:151	long, linear polysaccharides	124:151	long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells	124:255	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	5	35	theme	GAGs	1011:1014	arg1	classes					991:997	two classes	987:997	two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate	987:1064	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	5	36	theme	classes	991:997	arg1	composition					972:982	the structural composition	957:982	the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate	957:1064	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	0	37	dep	Purification	28:39	arg1	Analysis					18:25	Glycosaminoglycan Analysis	0:25	Glycosaminoglycan Analysis	0:25	Glycosaminoglycan Analysis: Purification, Structural Profiling, and GAG-Protein Interactions.
36374421	3	38	theme	ligand	486:491	arg1	sites					501:505	distinct ligand binding sites	477:505	distinct ligand binding sites	477:505	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	1	39	theme	extracellular	216:228	arg1	matrix					230:235	the extracellular matrix	212:235	the extracellular matrix of all animal cells	212:255	Glycosaminoglycans (GAGs) are long, linear polysaccharides that are ubiquitously expressed on the cell surface and in the extracellular matrix of all animal cells.
36374421	2	40	theme	complex	264:270	arg1	carbohydrates					272:284	These complex carbohydrates	258:284	These complex carbohydrates	258:284	These complex carbohydrates are composed of alternating glucosamine and uronic acids that can be heterogeneously N- and O-sulfated.
36374421	6	41	theme	structure	1201:1209	arg1	evaluation					1183:1192	the evaluation	1179:1192	the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease	1179:1305	Overall, these methods facilitate the evaluation of GAG structure and function to uncover the unique roles these molecules play in cell biology and human disease.
36374421	2	42	theme	uronic	330:335	arg1	acids					337:341	glucosamine and uronic acids	314:341	glucosamine and uronic acids that can be heterogeneously N- and O-sulfated	314:387	These complex carbohydrates are composed of alternating glucosamine and uronic acids that can be heterogeneously N- and O-sulfated.
36374421	4	43	theme	inherent	706:713	arg1	diversity					726:734	their inherent structural diversity	700:734	their inherent structural diversity across different tissues, cell types, and disease states	700:791	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	0	44	theme	GAG-Protein	68:78	arg1	Interactions					80:91	GAG-Protein Interactions	68:91	GAG-Protein Interactions	68:91	Glycosaminoglycan Analysis: Purification, Structural Profiling, and GAG-Protein Interactions.
36374421	3	45	theme	normal	644:649	arg1	physiology					651:660	normal physiology	644:660	normal physiology	644:660	The arrangement and orientation of the sulfated sugar residues specify the location of distinct ligand binding sites on the cell surface, and their capacity to bind ligands impacts cell growth and development, the ability to form tissues and organs, and normal physiology.
36374421	5	46	theme	sulfated	1002:1009	arg1	GAGs					1011:1014	sulfated GAGs	1002:1014	sulfated GAGs	1002:1014	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	5	46	theme	sulfated	1002:1009	arg1	sulfate					1025:1031	heparan sulfate	1017:1031	heparan sulfate	1017:1031	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	5	46	theme	sulfated	1002:1009	arg1	sulfate					1058:1064	chondroitin/dermatan sulfate	1037:1064	chondroitin/dermatan sulfate	1037:1064	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36374421	4	47	theme	heterogeneous	667:679	arg1	nature					681:686	The heterogeneous nature	663:686	The heterogeneous nature of GAGs	663:694	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	4	48	theme	disease	778:784	arg1	states					786:791	disease states	778:791	disease states	778:791	The heterogeneous nature of GAGs and their inherent structural diversity across different tissues, cell types, and disease states creates challenges to characterizing their structure and function.
36374421	5	49	theme	detailed	878:885	arg1	methods					887:893	detailed methods	878:893	detailed methods	878:893	Here, we describe detailed methods to investigate GAG-protein interactions in vitro and evaluate the structural composition of two classes of sulfated GAGs, heparan sulfate and chondroitin/dermatan sulfate, using liquid chromatography, mass spectrometry, and radiolabeling techniques.
36871693	0	0	theme	polysaccharides	101:115	arg1	features					31:38	physicochemical features	15:38	physicochemical features	15:38	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	0	0	theme	polysaccharides	101:115	arg1	potentials					61:70	hepatoprotective potentials	44:70	hepatoprotective potentials	44:70	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	3	1	from	changes	390:396	arg1	toxicity					414:421	toxicity	414:421	toxicity	414:421	The changes in efficacy and toxicity of PM during the processing are closely related to the changes in chemical composition.
36871693	3	1	from	changes	390:396	arg1	efficacy					401:408	efficacy	401:408	efficacy	401:408	The changes in efficacy and toxicity of PM during the processing are closely related to the changes in chemical composition.
36871693	5	2	theme	main	640:643	arg1	components					645:654	main components	640:654	main components of PM	640:660	Polysaccharides, as main components of PM, showed many pharmacological effects, but its changes in the processing has been neglected for a long time.
36871693	1	3	theme	multiflorum	183:193	arg1	PM					202:203	PM	202:203	PM	202:203	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	1	3	theme	multiflorum	183:193	arg1	Thunb					195:199	processed Polygonum multiflorum Thunb	163:199	processed Polygonum multiflorum Thunb (PM)	163:204	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	0	4	theme	processed	91:99	arg1	polysaccharides					101:115	unprocessed and processed polysaccharides	75:115	unprocessed and processed polysaccharides from Polygonum multiflorum Thunb	75:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	9	5	theme	polysaccharide	1419:1432	arg1	higher					1471:1476	higher	1471:1476	higher	1471:1476	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	9	5	theme	polysaccharide	1419:1432	arg1	yield					1434:1438	the polysaccharide yield	1415:1438	the polysaccharide yield of processed PM	1415:1454	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	3	6	from	changes	478:484	arg1	composition					498:508	chemical composition	489:508	chemical composition	489:508	The changes in efficacy and toxicity of PM during the processing are closely related to the changes in chemical composition.
36871693	6	7	used	utilized	933:940	arg2	model					898:902	the liver injury model	881:902	the liver injury model induced by acetaminophen	881:927	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	10	8	theme	present	1608:1614	arg1	work					1616:1619	The present work	1604:1619	The present work	1604:1619	The present work provides an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM.
36871693	0	9	theme	Polygonum	122:130	arg1	Thunb					144:148	Polygonum multiflorum Thunb	122:148	Polygonum multiflorum Thunb	122:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	6	10	from	impact	958:963	arg1	liver					991:995	the liver	987:995	the liver	987:995	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	11	11	theme	liver	1923:1927	arg1	injury					1929:1934	less liver injury	1918:1934	less liver injury	1918:1934	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	6	12	from	RPMPs	823:827	arg1	polysaccharides					789:803	the polysaccharides	785:803	the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs)	785:859	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	6	13	theme	processed	834:842	arg1	PPMPs					854:858	PPMPs	854:858	PPMPs	854:858	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	6	13	theme	processed	834:842	arg1	products					844:851	processed products	834:851	processed products (PPMPs)	834:859	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	5	14	theme	PM	659:660	arg1	components					645:654	main components	640:654	main components of PM	640:660	Polysaccharides, as main components of PM, showed many pharmacological effects, but its changes in the processing has been neglected for a long time.
36871693	9	15	theme	processed	1443:1451	arg1	PM					1453:1454	processed PM	1443:1454	processed PM	1443:1454	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	4	16	theme	anthraquinone	566:578	arg1	glycosides					593:602	anthraquinone and stilbene glycosides	566:602	anthraquinone and stilbene glycosides	566:602	Previous studies have mainly focused on the changes of anthraquinone and stilbene glycosides during process.
36871693	0	17	from	potentials	61:70	arg1	Thunb					144:148	Polygonum multiflorum Thunb	122:148	Polygonum multiflorum Thunb	122:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	7	18	theme	heteropolysaccharides	1022:1042	arg1	RPMPs					1044:1048	the heteropolysaccharides RPMPs	1018:1048	the heteropolysaccharides RPMPs	1018:1048	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	8	19	dep	exerted	1289:1295	arg1	both					1284:1287	both	1284:1287	both	1284:1287	In vivo analysis, results showed that demonstrated that RPMPs and PPMPs both exerted hepatoprotective effects by upregulating antioxidant enzymes and repressing lipid peroxidation.
36871693	1	20	contain	have	277:280	arg1	PM					248:249	PM	248:249	PM	248:249	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	1	20	contain	have	277:280	arg2	effects					294:300	hepatotoxic effects	282:300	hepatotoxic effects	282:300	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	0	21	theme	multiflorum	132:142	arg1	Thunb					144:148	Polygonum multiflorum Thunb	122:148	Polygonum multiflorum Thunb	122:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	6	22	from	polysaccharides	789:803	arg1	RPMPs					823:827	the raw (RPMPs)	814:828	the raw (RPMPs)	814:828	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	6	22	from	polysaccharides	789:803	arg1	PPMPs					854:858	PPMPs	854:858	PPMPs	854:858	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	6	22	from	polysaccharides	789:803	arg1	products					844:851	processed products	834:851	processed products (PPMPs)	834:859	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	10	23	theme	important	1633:1641	arg1	foundation					1643:1652	an important foundation	1630:1652	an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM	1630:1752	The present work provides an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM.
36871693	3	24	theme	PM	426:427	arg1	toxicity					414:421	toxicity	414:421	toxicity	414:421	The changes in efficacy and toxicity of PM during the processing are closely related to the changes in chemical composition.
36871693	3	24	theme	PM	426:427	arg1	efficacy					401:408	efficacy	401:408	efficacy	401:408	The changes in efficacy and toxicity of PM during the processing are closely related to the changes in chemical composition.
36871693	7	25	theme	monosaccharide	1177:1190	arg1	composition					1192:1202	monosaccharide composition	1177:1202	monosaccharide composition	1177:1202	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	2	26	theme	mounting	313:320	arg1	evidence					322:329	mounting evidence	313:329	mounting evidence	313:329	Moreover, mounting evidence indicates that processed PM is less toxic than raw PM.
36871693	9	27	theme	same	1580:1583	arg1	dose					1585:1588	the same dose	1576:1588	the same dose of decoction	1576:1601	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	2	28	theme	raw	378:380	arg1	PM					382:383	raw PM	378:383	raw PM	378:383	Moreover, mounting evidence indicates that processed PM is less toxic than raw PM.
36871693	10	29	theme	PM	1751:1752	arg1	mechanism					1738:1746	the processing mechanism	1723:1746	the processing mechanism of PM	1723:1752	The present work provides an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM.
36871693	6	30	theme	PM	808:809	arg1	polysaccharides					789:803	the polysaccharides	785:803	the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs)	785:859	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	9	31	contain	has	1537:1539	arg2	effects					1565:1571	better hepatoprotective effects	1541:1571	better hepatoprotective effects	1541:1571	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	9	31	contain	has	1537:1539	arg1	PM					1534:1535	processed PM	1524:1535	processed PM	1524:1535	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	0	32	theme	features	31:38	arg1	Comparisons					0:10	Comparisons	0:10	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.	0:149	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	9	33	theme	processed	1524:1532	arg1	PM					1534:1535	processed PM	1524:1535	processed PM	1524:1535	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	6	34	theme	injury	891:896	arg1	model					898:902	the liver injury model	881:902	the liver injury model induced by acetaminophen	881:927	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	7	35	theme	polysaccharide	1140:1153	arg1	yield					1155:1159	polysaccharide yield	1140:1159	polysaccharide yield	1140:1159	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	9	36	theme	raw	1491:1493	arg1	PM					1495:1496	raw PM	1491:1496	raw PM	1491:1496	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	11	37	dep	hypothesis	1786:1795	arg1	reason					1884:1889	another reason that the product PM causes less liver injury	1876:1934	another reason that the product PM causes less liver injury	1876:1934	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	11	37	dep	hypothesis	1786:1795	arg1	increase					1818:1825	the significant increase	1802:1825	the significant increase of polysaccharide content in processed PM	1802:1867	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	10	38	theme	processing	1727:1736	arg1	mechanism					1738:1746	the processing mechanism	1723:1746	the processing mechanism of PM	1723:1752	The present work provides an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM.
36871693	0	39	theme	physicochemical	15:29	arg1	features					31:38	physicochemical features	15:38	physicochemical features	15:38	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	1	40	theme	hepatotoxic	282:292	arg1	effects					294:300	hepatotoxic effects	282:300	hepatotoxic effects	282:300	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	9	41	theme	decoction	1593:1601	arg1	dose					1585:1588	the same dose	1576:1588	the same dose of decoction	1576:1601	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	8	42	theme	vivo	1215:1218	arg1	analysis					1220:1227	vivo analysis	1215:1227	vivo analysis	1215:1227	In vivo analysis, results showed that demonstrated that RPMPs and PPMPs both exerted hepatoprotective effects by upregulating antioxidant enzymes and repressing lipid peroxidation.
36871693	9	43	theme	PM	1453:1454	arg1	higher					1471:1476	higher	1471:1476	higher	1471:1476	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	9	43	theme	PM	1453:1454	arg1	yield					1434:1438	the polysaccharide yield	1415:1438	the polysaccharide yield of processed PM	1415:1454	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	3	44	theme	chemical	489:496	arg1	composition					498:508	chemical composition	489:508	chemical composition	489:508	The changes in efficacy and toxicity of PM during the processing are closely related to the changes in chemical composition.
36871693	0	45	theme	hepatoprotective	44:59	arg1	potentials					61:70	hepatoprotective potentials	44:70	hepatoprotective potentials	44:70	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	6	46	theme	liver	885:889	arg1	model					898:902	the liver injury model	881:902	the liver injury model induced by acetaminophen	881:927	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	11	47	theme	product	1900:1906	arg1	PM					1908:1909	the product PM	1896:1909	the product PM	1896:1909	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	6	48	theme	raw	818:820	arg1	RPMPs					823:827	the raw (RPMPs)	814:828	the raw (RPMPs)	814:828	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	10	49	theme	PM	1698:1699	arg1	activity					1686:1693	the polysaccharide activity	1667:1693	the polysaccharide activity of PM	1667:1699	The present work provides an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM.
36871693	11	50	theme	new	1782:1784	arg1	hypothesis					1786:1795	a new hypothesis	1780:1795	a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury	1780:1934	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	6	51	theme	polysaccharides	968:982	arg1	impact					958:963	the impact	954:963	the impact of polysaccharides on the liver	954:995	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	5	52	theme	long	759:762	arg1	time					764:767	a long time	757:767	a long time	757:767	Polysaccharides, as main components of PM, showed many pharmacological effects, but its changes in the processing has been neglected for a long time.
36871693	4	53	theme	Previous	511:518	arg1	studies					520:526	Previous studies	511:526	Previous studies	511:526	Previous studies have mainly focused on the changes of anthraquinone and stilbene glycosides during process.
36871693	11	54	theme	processed	1856:1864	arg1	PM					1866:1867	processed PM	1856:1867	processed PM	1856:1867	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	8	55	theme	lipid	1373:1377	arg1	peroxidation					1379:1390	lipid peroxidation	1373:1390	lipid peroxidation	1373:1390	In vivo analysis, results showed that demonstrated that RPMPs and PPMPs both exerted hepatoprotective effects by upregulating antioxidant enzymes and repressing lipid peroxidation.
36871693	11	56	from	increase	1818:1825	arg1	PM					1866:1867	processed PM	1856:1867	processed PM	1856:1867	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	1	57	theme	different	224:232	arg1	diseases					234:241	different diseases	224:241	different diseases	224:241	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	6	58	from	PM	808:809	arg1	RPMPs					823:827	the raw (RPMPs)	814:828	the raw (RPMPs)	814:828	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	6	58	from	PM	808:809	arg1	PPMPs					854:858	PPMPs	854:858	PPMPs	854:858	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	6	58	from	PM	808:809	arg1	products					844:851	processed products	834:851	processed products (PPMPs)	834:859	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	11	59	theme	content	1845:1851	arg1	reason					1884:1889	another reason that the product PM causes less liver injury	1876:1934	another reason that the product PM causes less liver injury	1876:1934	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	11	59	theme	content	1845:1851	arg1	increase					1818:1825	the significant increase	1802:1825	the significant increase of polysaccharide content in processed PM	1802:1867	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	6	60	from	products	844:851	arg1	polysaccharides					789:803	the polysaccharides	785:803	the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs)	785:859	In this study, the polysaccharides of PM in the raw (RPMPs) and processed products (PPMPs) were determined and the liver injury model induced by acetaminophen was utilized to evaluate the impact of polysaccharides on the liver.
36871693	8	61	theme	hepatoprotective	1297:1312	arg1	effects					1314:1320	hepatoprotective effects	1297:1320	hepatoprotective effects	1297:1320	In vivo analysis, results showed that demonstrated that RPMPs and PPMPs both exerted hepatoprotective effects by upregulating antioxidant enzymes and repressing lipid peroxidation.
36871693	2	62	theme	processed	346:354	arg1	PM					356:357	processed PM	346:357	processed PM	346:357	Moreover, mounting evidence indicates that processed PM is less toxic than raw PM.
36871693	0	63	theme	potentials	61:70	arg1	Comparisons					0:10	Comparisons	0:10	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.	0:149	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	5	64	dep	processing	723:732	arg1	neglected					743:751	neglected	743:751	has been neglected for a long time	734:767	Polysaccharides, as main components of PM, showed many pharmacological effects, but its changes in the processing has been neglected for a long time.
36871693	0	65	from	Thunb	144:148	arg1	features					31:38	physicochemical features	15:38	physicochemical features	15:38	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	0	65	from	Thunb	144:148	arg1	potentials					61:70	hepatoprotective potentials	44:70	hepatoprotective potentials	44:70	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	0	65	from	Thunb	144:148	arg1	polysaccharides					101:115	unprocessed and processed polysaccharides	75:115	unprocessed and processed polysaccharides from Polygonum multiflorum Thunb	75:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	1	66	used	used	210:213	arg2	Thunb					195:199	processed Polygonum multiflorum Thunb	163:199	processed Polygonum multiflorum Thunb (PM)	163:204	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	1	66	used	used	210:213	arg2	PM					202:203	PM	202:203	PM	202:203	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	1	66	used	used	210:213	arg2	raw					155:157	The raw	151:157	The raw	151:157	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	9	67	theme	better	1541:1546	arg1	effects					1565:1571	better hepatoprotective effects	1541:1571	better hepatoprotective effects	1541:1571	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	5	68	theme	many	670:673	arg1	effects					691:697	many pharmacological effects	670:697	many pharmacological effects	670:697	Polysaccharides, as main components of PM, showed many pharmacological effects, but its changes in the processing has been neglected for a long time.
36871693	10	69	theme	polysaccharide	1671:1684	arg1	activity					1686:1693	the polysaccharide activity	1667:1693	the polysaccharide activity of PM	1667:1699	The present work provides an important foundation for studying the polysaccharide activity of PM and further revealing the processing mechanism of PM.
36871693	4	70	theme	glycosides	593:602	arg1	changes					555:561	the changes	551:561	the changes of anthraquinone and stilbene glycosides during process	551:617	Previous studies have mainly focused on the changes of anthraquinone and stilbene glycosides during process.
36871693	5	71	theme	pharmacological	675:689	arg1	effects					691:697	many pharmacological effects	670:697	many pharmacological effects	670:697	Polysaccharides, as main components of PM, showed many pharmacological effects, but its changes in the processing has been neglected for a long time.
36871693	7	72	theme	molar	1162:1166	arg1	ratio					1168:1172	molar ratio	1162:1172	molar ratio of monosaccharide composition	1162:1202	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	4	73	theme	stilbene	584:591	arg1	glycosides					593:602	anthraquinone and stilbene glycosides	566:602	anthraquinone and stilbene glycosides	566:602	Previous studies have mainly focused on the changes of anthraquinone and stilbene glycosides during process.
36871693	9	74	theme	hepatoprotective	1548:1563	arg1	effects					1565:1571	better hepatoprotective effects	1541:1571	better hepatoprotective effects	1541:1571	It is noteworthy that the polysaccharide yield of processed PM was seven-fold higher than that of raw PM, so it is speculated that processed PM has better hepatoprotective effects at the same dose of decoction.
36871693	7	75	theme	composition	1192:1202	arg1	Mw					1208:1209	Mw	1208:1209	Mw	1208:1209	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	7	75	theme	composition	1192:1202	arg1	yield					1155:1159	polysaccharide yield	1140:1159	polysaccharide yield	1140:1159	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	7	75	theme	composition	1192:1202	arg1	ratio					1168:1172	molar ratio	1162:1172	molar ratio of monosaccharide composition	1162:1202	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	8	76	theme	antioxidant	1338:1348	arg1	enzymes					1350:1356	antioxidant enzymes	1338:1356	antioxidant enzymes	1338:1356	In vivo analysis, results showed that demonstrated that RPMPs and PPMPs both exerted hepatoprotective effects by upregulating antioxidant enzymes and repressing lipid peroxidation.
36871693	11	77	theme	polysaccharide	1830:1843	arg1	content					1845:1851	polysaccharide content	1830:1851	polysaccharide content	1830:1851	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	1	78	theme	processed	163:171	arg1	PM					202:203	PM	202:203	PM	202:203	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	1	78	theme	processed	163:171	arg1	Thunb					195:199	processed Polygonum multiflorum Thunb	163:199	processed Polygonum multiflorum Thunb (PM)	163:204	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	11	79	theme	significant	1806:1816	arg1	reason					1884:1889	another reason that the product PM causes less liver injury	1876:1934	another reason that the product PM causes less liver injury	1876:1934	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	11	79	theme	significant	1806:1816	arg1	increase					1818:1825	the significant increase	1802:1825	the significant increase of polysaccharide content in processed PM	1802:1867	This study also proposed a new hypothesis that the significant increase of polysaccharide content in processed PM may be another reason that the product PM causes less liver injury.
36871693	0	80	theme	unprocessed	75:85	arg1	polysaccharides					101:115	unprocessed and processed polysaccharides	75:115	unprocessed and processed polysaccharides from Polygonum multiflorum Thunb	75:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	0	81	from	features	31:38	arg1	Thunb					144:148	Polygonum multiflorum Thunb	122:148	Polygonum multiflorum Thunb	122:148	Comparisons of physicochemical features and hepatoprotective potentials of unprocessed and processed polysaccharides from Polygonum multiflorum Thunb.
36871693	7	82	dep	comprised	1065:1073	arg1	both					1060:1063	both	1060:1063	both	1060:1063	Results showed that the heteropolysaccharides RPMPs and PPMPs both comprised Man, Rha, GlcA, GalA, Glc, Ara and Xyl, but markedly differed in polysaccharide yield, molar ratio of monosaccharide composition and Mw.
36871693	1	83	theme	Polygonum	173:181	arg1	PM					202:203	PM	202:203	PM	202:203	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36871693	1	83	theme	Polygonum	173:181	arg1	Thunb					195:199	processed Polygonum multiflorum Thunb	163:199	processed Polygonum multiflorum Thunb (PM)	163:204	The raw and processed Polygonum multiflorum Thunb (PM) are used to treat different diseases, and PM has also been reported to have hepatotoxic effects.
36410537	7	0	theme	drug	1210:1213	arg1	delivery					1215:1222	drug delivery	1210:1222	drug delivery	1210:1222	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	3	1	theme	dissociation	551:562	arg1	conditions					531:540	conditions	531:540	conditions of lower dissociation i.e.	531:567	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	2	2	dep	5-10 kPa	359:366	arg1	ratios					381:386	ratios	381:386	ratios	381:386	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	6	3	theme	composite	997:1005	arg1	hydrogels					1007:1015	The composite hydrogels	993:1015	The composite hydrogels	993:1015	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	5	4	from	nanoplatelets	941:953	arg1	presence					962:969	the presence	958:969	the presence of both Car and Chit	958:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	5	5	from	exfoliation	917:927	arg1	presence					962:969	the presence	958:969	the presence of both Car and Chit	958:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	1	6	theme	physical	163:170	arg1	hydrogels					204:212	physical carrageenan/chitosan (Car/Chit) hydrogels	163:212	physical carrageenan/chitosan (Car/Chit) hydrogels	163:212	In this work physical carrageenan/chitosan (Car/Chit) hydrogels are prepared by electrostatic complexation between the two oppositely charged polysaccharides.
36410537	4	7	dep	concentration	704:716	arg1	decreases					737:745	the swelling ratio decreases	718:745	its concentration the swelling ratio decreases	700:745	Chit appears to act as a crosslinker for Car as increasing its concentration the swelling ratio decreases and the moduli increase.
36410537	2	8	theme	5-10 kPa	359:366	arg1	order					350:354	the order	346:354	the order of 5-10 kPa and swelling ratios	346:386	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	2	9	theme	%	414:414	arg1	order					395:399	the order	391:399	the order of 5000-6000 %	391:414	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	6	10	theme	pH	1091:1092	arg1	range					1094:1098	the studied pH range	1079:1098	the studied pH range (pH 2 to pH 7)	1079:1113	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	6	10	theme	pH	1091:1092	arg1	pH 7					1109:1112	pH 7	1109:1112	pH 7	1109:1112	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	1	11	theme	electrostatic	230:242	arg1	complexation					244:255	electrostatic complexation	230:255	electrostatic complexation between the two oppositely charged polysaccharides	230:306	In this work physical carrageenan/chitosan (Car/Chit) hydrogels are prepared by electrostatic complexation between the two oppositely charged polysaccharides.
36410537	7	12	theme	multifunctional	1177:1191	arg1	biomaterials					1193:1204	multifunctional biomaterials	1177:1204	multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications	1177:1277	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	7	12	theme	multifunctional	1177:1191	arg1	hydrogels					1140:1148	the prepared hydrogels	1127:1148	the prepared hydrogels	1127:1148	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	7	13	theme	prepared	1131:1138	arg1	biomaterials					1193:1204	multifunctional biomaterials	1177:1204	multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications	1177:1277	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	7	13	theme	prepared	1131:1138	arg1	hydrogels					1140:1148	the prepared hydrogels	1127:1148	the prepared hydrogels	1127:1148	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	5	14	theme	Chit	987:990	arg1	presence					962:969	the presence	958:969	the presence of both Car and Chit	958:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	6	15	theme	studied	1083:1089	arg1	range					1094:1098	the studied pH range	1079:1098	the studied pH range (pH 2 to pH 7)	1079:1113	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	6	15	theme	studied	1083:1089	arg1	pH 7					1109:1112	pH 7	1109:1112	pH 7	1109:1112	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	3	16	from	conditions	531:540	arg1	ones					523:526	the ones	519:526	the ones at conditions of lower dissociation i.e.	519:567	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	4	17	theme	moduli	755:760	arg1	increase					762:769	the moduli increase	751:769	the moduli increase	751:769	Chit appears to act as a crosslinker for Car as increasing its concentration the swelling ratio decreases and the moduli increase.
36410537	0	18	theme	Physicochemical	0:14	arg1	properties					16:25	Physicochemical properties	0:25	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite	0:123	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite nanocomposite hydrogels.
36410537	3	19	theme	opposite	592:599	arg1	trend					601:605	the opposite trend	588:605	the opposite trend	588:605	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	2	20	from	moduli	336:341	arg1	order					350:354	the order	346:354	the order of 5-10 kPa and swelling ratios	346:386	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	3	21	theme	swelling	488:495	arg1	ratios					497:502	the swelling ratios	484:502	the swelling ratios	484:502	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	3	21	theme	swelling	488:495	arg1	lower					508:512	lower	508:512	lower	508:512	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	0	22	link	crosslinked	48:58	arg1	hydrogels					81:89	electrostatically crosslinked carrageenan/chitosan hydrogels	30:89	electrostatically crosslinked carrageenan/chitosan hydrogels	30:89	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite nanocomposite hydrogels.
36410537	5	23	theme	hybrid	839:844	arg1	nanocomposites					846:859	hybrid nanocomposites	839:859	hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit	839:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	2	24	theme	swelling	372:379	arg1	order					350:354	the order	346:354	the order of 5-10 kPa and swelling ratios	346:386	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	6	25	theme	Car/Chit	1057:1064	arg1	hydrogels					1066:1074	the Car/Chit hydrogels	1053:1074	the Car/Chit hydrogels	1053:1074	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	0	26	theme	carrageenan/chitosan	60:79	arg1	hydrogels					81:89	electrostatically crosslinked carrageenan/chitosan hydrogels	30:89	electrostatically crosslinked carrageenan/chitosan hydrogels	30:89	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite nanocomposite hydrogels.
36410537	4	27	theme	swelling	722:729	arg1	decreases					737:745	the swelling ratio decreases	718:745	its concentration the swelling ratio decreases	700:745	Chit appears to act as a crosslinker for Car as increasing its concentration the swelling ratio decreases and the moduli increase.
36410537	7	28	used	used	1169:1172	arg2	hydrogels					1140:1148	the prepared hydrogels	1127:1148	the prepared hydrogels	1127:1148	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	7	28	used	used	1169:1172	arg2	biomaterials					1193:1204	multifunctional biomaterials	1177:1204	multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications	1177:1277	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	1	29	theme	charged	284:290	arg1	polysaccharides					292:306	the two oppositely charged polysaccharides	265:306	the two oppositely charged polysaccharides	265:306	In this work physical carrageenan/chitosan (Car/Chit) hydrogels are prepared by electrostatic complexation between the two oppositely charged polysaccharides.
36410537	0	30	theme	crosslinked	48:58	arg1	hydrogels					81:89	electrostatically crosslinked carrageenan/chitosan hydrogels	30:89	electrostatically crosslinked carrageenan/chitosan hydrogels	30:89	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite nanocomposite hydrogels.
36410537	5	31	theme	nanoclay	806:813	arg1	Laponite					815:822	the nanoclay Laponite	802:822	the nanoclay Laponite (Lap)	802:828	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	5	31	theme	nanoclay	806:813	arg1	Lap					825:827	Lap	825:827	Lap	825:827	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	3	32	theme	storage	624:630	arg1	modulus					632:638	the storage modulus	620:638	the storage modulus	620:638	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	7	33	theme	tissue	1225:1230	arg1	engineering					1232:1242	tissue engineering	1225:1242	tissue engineering	1225:1242	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	5	34	theme	Car	979:981	arg1	presence					962:969	the presence	958:969	the presence of both Car and Chit	958:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	1	35	theme	carrageenan/chitosan	172:191	arg1	hydrogels					204:212	physical carrageenan/chitosan (Car/Chit) hydrogels	163:212	physical carrageenan/chitosan (Car/Chit) hydrogels	163:212	In this work physical carrageenan/chitosan (Car/Chit) hydrogels are prepared by electrostatic complexation between the two oppositely charged polysaccharides.
36410537	0	36	theme	hydrogels	81:89	arg1	properties					16:25	Physicochemical properties	0:25	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite	0:123	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite nanocomposite hydrogels.
36410537	3	37	theme	lower	545:549	arg1	dissociation					551:562	lower dissociation	545:562	lower dissociation i.e.	545:567	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	5	38	from	presence	962:969	arg1	exfoliation					917:927	exfoliation	917:927	exfoliation of the clay nanoplatelets in the presence of both Car and Chit	917:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	4	39	theme	ratio	731:735	arg1	decreases					737:745	the swelling ratio decreases	718:745	its concentration the swelling ratio decreases	700:745	Chit appears to act as a crosslinker for Car as increasing its concentration the swelling ratio decreases and the moduli increase.
36410537	3	40	dep	lower	508:512	arg1	pH 5					478:481	pH 5	478:481	pH 5	478:481	At conditions where both polysaccharides are highly charged (pH 5) the swelling ratios are lower than the ones at conditions of lower dissociation i.e., at pH 2 and 7 and the opposite trend is found for the storage modulus.
36410537	6	41	theme	mechanical	1028:1037	arg1	properties					1039:1048	the mechanical properties	1024:1048	the mechanical properties of the Car/Chit hydrogels	1024:1074	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	1	42	theme	Car/Chit	194:201	arg1	hydrogels					204:212	physical carrageenan/chitosan (Car/Chit) hydrogels	163:212	physical carrageenan/chitosan (Car/Chit) hydrogels	163:212	In this work physical carrageenan/chitosan (Car/Chit) hydrogels are prepared by electrostatic complexation between the two oppositely charged polysaccharides.
36410537	6	43	dep	pH 7	1109:1112	arg1	to					1106:1107	to	1106:1107	to	1106:1107	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	5	44	theme	nanoplatelets	941:953	arg1	exfoliation					917:927	exfoliation	917:927	exfoliation of the clay nanoplatelets in the presence of both Car and Chit	917:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	5	45	theme	clay	936:939	arg1	nanoplatelets					941:953	the clay nanoplatelets	932:953	the clay nanoplatelets in the presence of both Car and Chit	932:990	The hydrogels can incorporate the nanoclay Laponite (Lap) and form hybrid nanocomposites where the intercalation by the two biopolymers leads to exfoliation of the clay nanoplatelets in the presence of both Car and Chit.
36410537	6	46	theme	hydrogels	1066:1074	arg1	properties					1039:1048	the mechanical properties	1024:1048	the mechanical properties of the Car/Chit hydrogels	1024:1074	The composite hydrogels retain the mechanical properties of the Car/Chit hydrogels at the studied pH range (pH 2 to pH 7).
36410537	7	47	theme	bone	1248:1251	arg1	applications					1266:1277	bone regeneration applications	1248:1277	bone regeneration applications	1248:1277	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	0	48	theme	carrageenan/chitosan/Laponite	95:123	arg1	properties					16:25	Physicochemical properties	0:25	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite	0:123	Physicochemical properties of electrostatically crosslinked carrageenan/chitosan hydrogels and carrageenan/chitosan/Laponite nanocomposite hydrogels.
36410537	2	49	theme	storage	328:334	arg1	moduli					336:341	storage moduli	328:341	storage moduli in the order of 5-10 kPa and swelling ratios	328:386	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	7	50	theme	regeneration	1253:1264	arg1	applications					1266:1277	bone regeneration applications	1248:1277	bone regeneration applications	1248:1277	This shows the prepared hydrogels can be potentially used as multifunctional biomaterials for drug delivery, tissue engineering and bone regeneration applications.
36410537	2	51	contain	have	323:326	arg1	hydrogels					313:321	The hydrogels	309:321	The hydrogels	309:321	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
36410537	2	51	contain	have	323:326	arg2	moduli					336:341	storage moduli	328:341	storage moduli in the order of 5-10 kPa and swelling ratios	328:386	The hydrogels have storage moduli in the order of 5-10 kPa and swelling ratios in the order of 5000-6000 %.
37254322	4	0	theme	similar	705:711	arg1	characteristics					746:760	similar digestion and fecal fermentation characteristics	705:760	similar digestion and fecal fermentation characteristics	705:760	Both SP and FSP showed similar digestion and fecal fermentation characteristics, that is, they could not be digested by saliva and gastric juice, but could be partially degraded by small intestine.
37254322	0	1	dep	Bacillus	119:126	arg1	subtilis					128:135	subtilis	128:135	subtilis	128:135	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	1	2	theme	cucumber	241:248	arg1	polysaccharide					250:263	sea cucumber polysaccharide	237:263	sea cucumber polysaccharide fermented by Bacillus subtilis Natto	237:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	1	3	dep	Bacillus	278:285	arg1	subtilis					287:294	subtilis	287:294	subtilis	287:294	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	1	4	theme	polysaccharide	250:263	arg1	behaviors					224:232	the structural, digestion and fecal fermentation behaviors	175:232	the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto	175:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	5	theme	cucumber	82:89	arg1	polysaccharide					91:104	sea cucumber polysaccharide	78:104	sea cucumber polysaccharide	78:104	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	6	from	Structure	0:8	arg1	microbiota					64:73	gut microbiota	60:73	gut microbiota	60:73	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	6	7	from	microbiota	1056:1065	arg1	terms					1032:1036	terms	1032:1036	terms of impacts on gut microbiota	1032:1065	In terms of impacts on gut microbiota, Lachnospira, Bacteroides finegoldii, and Bifidobacteriaceae were significantly increased in SP, while Acinetobacter was significantly increased in FSP.
37254322	5	8	theme	fecal	956:960	arg1	fermentation					962:973	fecal fermentation	956:973	fecal fermentation	956:973	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	5	9	theme	molecular	989:997	arg1	mass					999:1002	the relative molecular mass	976:1002	the relative molecular mass of SP and FSP	976:1016	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	0	10	theme	sea	78:80	arg1	polysaccharide					91:104	sea cucumber polysaccharide	78:104	sea cucumber polysaccharide	78:104	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	11	from	effect	50:55	arg1	microbiota					64:73	gut microbiota	60:73	gut microbiota	60:73	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	4	12	theme	small	863:867	arg1	intestine					869:877	small intestine	863:877	small intestine	863:877	Both SP and FSP showed similar digestion and fecal fermentation characteristics, that is, they could not be digested by saliva and gastric juice, but could be partially degraded by small intestine.
37254322	2	13	contain	containing	446:455	arg1	polysaccharides					423:437	sulfated polysaccharides	414:437	sulfated polysaccharides mainly containing fucose	414:462	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	2	13	contain	containing	446:455	arg2	fucose					457:462	fucose	457:462	fucose	457:462	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	3	14	theme	thermal	513:519	arg1	property					521:528	thermal property	513:528	thermal property	513:528	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	3	15	theme	molecular	495:503	arg1	weight					505:510	molecular weight	495:510	molecular weight	495:510	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	7	16	dep	structure	1283:1291	arg1	the					1279:1281	the	1279:1281	the	1279:1281	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	17	theme	good	1242:1245	arg1	understanding					1247:1259	a good understanding	1240:1259	a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation	1240:1376	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	18	theme	digestive	1297:1305	arg1	characteristics					1307:1321	digestive characteristics	1297:1321	digestive characteristics	1297:1321	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	3	19	theme	functional	535:544	arg1	groups					546:551	functional groups	535:551	functional groups	535:551	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	5	20	theme	glycosidic	908:917	arg1	bonds					919:923	glycosidic bonds	908:923	glycosidic bonds	908:923	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	7	21	theme	sea	1326:1328	arg1	cucumber					1330:1337	sea cucumber	1326:1337	sea cucumber polysaccharides caused by fermentation	1326:1376	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	0	22	theme	polysaccharide	91:104	arg1	characteristics					30:44	in vitro digestive characteristics	11:44	in vitro digestive characteristics	11:44	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	22	theme	polysaccharide	91:104	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	22	theme	polysaccharide	91:104	arg1	effect					50:55	effect	50:55	effect on gut microbiota	50:73	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	23	from	characteristics	30:44	arg1	microbiota					64:73	gut microbiota	60:73	gut microbiota	60:73	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	6	24	theme	gut	1052:1054	arg1	microbiota					1056:1065	gut microbiota	1052:1065	gut microbiota	1052:1065	In terms of impacts on gut microbiota, Lachnospira, Bacteroides finegoldii, and Bifidobacteriaceae were significantly increased in SP, while Acinetobacter was significantly increased in FSP.
37254322	2	25	theme	cucumber	379:386	arg1	polysaccharide					388:401	fermented sea cucumber polysaccharide	365:401	fermented sea cucumber polysaccharide (FSP)	365:407	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	2	25	theme	cucumber	379:386	arg1	FSP					404:406	FSP	404:406	FSP	404:406	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	1	26	theme	Bacillus	278:285	arg1	Natto					296:300	Bacillus subtilis Natto	278:300	Bacillus subtilis Natto	278:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	4	27	theme	fecal	727:731	arg1	fermentation					733:744	fecal fermentation	727:744	fecal fermentation	727:744	Both SP and FSP showed similar digestion and fecal fermentation characteristics, that is, they could not be digested by saliva and gastric juice, but could be partially degraded by small intestine.
37254322	7	28	from	changes	1268:1274	arg1	structure					1283:1291	structure	1283:1291	structure	1283:1291	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	28	from	changes	1268:1274	arg1	characteristics					1307:1321	digestive characteristics	1297:1321	digestive characteristics	1297:1321	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	5	29	theme	intestinal	931:940	arg1	digestion					942:950	intestinal digestion	931:950	intestinal digestion	931:950	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	1	30	theme	structural	179:188	arg1	behaviors					224:232	the structural, digestion and fecal fermentation behaviors	175:232	the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto	175:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	0	31	theme	Bacillus	119:126	arg1	Natto					137:141	Bacillus subtilis Natto	119:141	Bacillus subtilis Natto	119:141	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	5	32	theme	bonds	919:923	arg1	decomposition					891:903	the decomposition	887:903	the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation	887:973	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	3	33	theme	significant	561:571	arg1	difference					573:582	no significant difference	558:582	no significant difference between SP and FSP	558:601	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	3	33	theme	significant	561:571	arg1	property					485:492	The physicochemical property	465:492	The physicochemical property	465:492	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	5	34	theme	SP	1007:1008	arg1	mass					999:1002	the relative molecular mass	976:1002	the relative molecular mass of SP and FSP	976:1016	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	2	35	theme	sulfated	414:421	arg1	polysaccharides					423:437	sulfated polysaccharides	414:437	sulfated polysaccharides mainly containing fucose	414:462	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	0	36	theme	in	11:12	arg1	characteristics					30:44	in vitro digestive characteristics	11:44	in vitro digestive characteristics	11:44	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	8	37	theme	cucumber	1472:1479	arg1	products					1481:1488	new fermented sea cucumber products	1454:1488	new fermented sea cucumber products	1454:1488	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	8	38	theme	fermented	1458:1466	arg1	products					1481:1488	new fermented sea cucumber products	1454:1488	new fermented sea cucumber products	1454:1488	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	1	39	theme	digestion	191:199	arg1	behaviors					224:232	the structural, digestion and fecal fermentation behaviors	175:232	the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto	175:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	3	40	theme	FSP	669:671	arg1	morphology					624:633	microscopic morphology	612:633	microscopic morphology	612:633	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	3	40	theme	FSP	669:671	arg1	composition					654:664	monosaccharide composition	639:664	monosaccharide composition	639:664	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	4	41	theme	gastric	813:819	arg1	juice					821:825	gastric juice	813:825	gastric juice	813:825	Both SP and FSP showed similar digestion and fecal fermentation characteristics, that is, they could not be digested by saliva and gastric juice, but could be partially degraded by small intestine.
37254322	2	42	theme	sea	375:377	arg1	polysaccharide					388:401	fermented sea cucumber polysaccharide	365:401	fermented sea cucumber polysaccharide (FSP)	365:407	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	2	42	theme	sea	375:377	arg1	FSP					404:406	FSP	404:406	FSP	404:406	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	3	43	dep	morphology	624:633	arg1	the					608:610	the	608:610	the	608:610	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	0	44	theme	digestive	20:28	arg1	characteristics					30:44	in vitro digestive characteristics	11:44	in vitro digestive characteristics	11:44	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	3	45	theme	monosaccharide	639:652	arg1	composition					654:664	monosaccharide composition	639:664	monosaccharide composition	639:664	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	1	46	theme	fecal	205:209	arg1	behaviors					224:232	the structural, digestion and fecal fermentation behaviors	175:232	the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto	175:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	8	47	theme	sea	1468:1470	arg1	products					1481:1488	new fermented sea cucumber products	1454:1488	new fermented sea cucumber products	1454:1488	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	5	48	theme	FSP	1014:1016	arg1	mass					999:1002	the relative molecular mass	976:1002	the relative molecular mass of SP and FSP	976:1016	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	7	49	from	structure	1283:1291	arg1	understanding					1247:1259	a good understanding	1240:1259	a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation	1240:1376	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	50	theme	changes	1268:1274	arg1	understanding					1247:1259	a good understanding	1240:1259	a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation	1240:1376	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	6	51	theme	impacts	1041:1047	arg1	terms					1032:1036	terms	1032:1036	terms of impacts on gut microbiota	1032:1065	In terms of impacts on gut microbiota, Lachnospira, Bacteroides finegoldii, and Bifidobacteriaceae were significantly increased in SP, while Acinetobacter was significantly increased in FSP.
37254322	4	52	theme	digestion	713:721	arg1	characteristics					746:760	similar digestion and fecal fermentation characteristics	705:760	similar digestion and fecal fermentation characteristics	705:760	Both SP and FSP showed similar digestion and fecal fermentation characteristics, that is, they could not be digested by saliva and gastric juice, but could be partially degraded by small intestine.
37254322	8	53	theme	new	1454:1456	arg1	products					1481:1488	new fermented sea cucumber products	1454:1488	new fermented sea cucumber products	1454:1488	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	6	54	from	terms	1032:1036	arg1	microbiota					1056:1065	gut microbiota	1052:1065	gut microbiota	1052:1065	In terms of impacts on gut microbiota, Lachnospira, Bacteroides finegoldii, and Bifidobacteriaceae were significantly increased in SP, while Acinetobacter was significantly increased in FSP.
37254322	8	55	theme	products	1481:1488	arg1	application					1439:1449	application	1439:1449	application	1439:1449	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	8	55	theme	products	1481:1488	arg1	development					1423:1433	development	1423:1433	development	1423:1433	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	5	56	theme	relative	980:987	arg1	mass					999:1002	the relative molecular mass	976:1002	the relative molecular mass of SP and FSP	976:1016	Due to the decomposition of glycosidic bonds after intestinal digestion and fecal fermentation, the relative molecular mass of SP and FSP decreased.
37254322	6	57	from	impacts	1041:1047	arg1	microbiota					1056:1065	gut microbiota	1052:1065	gut microbiota	1052:1065	In terms of impacts on gut microbiota, Lachnospira, Bacteroides finegoldii, and Bifidobacteriaceae were significantly increased in SP, while Acinetobacter was significantly increased in FSP.
37254322	2	58	theme	cucumber	332:339	arg1	polysaccharide					341:354	sea cucumber polysaccharide	328:354	sea cucumber polysaccharide (SP)	328:359	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	2	58	theme	cucumber	332:339	arg1	SP					357:358	SP	357:358	SP	357:358	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	1	59	theme	fermentation	211:222	arg1	behaviors					224:232	the structural, digestion and fecal fermentation behaviors	175:232	the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto	175:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	8	60	dep	development	1423:1433	arg1	the					1419:1421	the	1419:1421	the	1419:1421	That information will be beneficial for the development and application of new fermented sea cucumber products.
37254322	0	61	dep	in	11:12	arg1	vitro					14:18	vitro	14:18	vitro	14:18	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	7	62	from	characteristics	1307:1321	arg1	understanding					1247:1259	a good understanding	1240:1259	a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation	1240:1376	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	2	63	theme	sea	328:330	arg1	polysaccharide					341:354	sea cucumber polysaccharide	328:354	sea cucumber polysaccharide (SP)	328:359	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	2	63	theme	sea	328:330	arg1	SP					357:358	SP	357:358	SP	357:358	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	4	64	theme	fermentation	733:744	arg1	characteristics					746:760	similar digestion and fecal fermentation characteristics	705:760	similar digestion and fecal fermentation characteristics	705:760	Both SP and FSP showed similar digestion and fecal fermentation characteristics, that is, they could not be digested by saliva and gastric juice, but could be partially degraded by small intestine.
37254322	0	65	theme	gut	60:62	arg1	microbiota					64:73	gut microbiota	60:73	gut microbiota	60:73	Structure, in vitro digestive characteristics and effect on gut microbiota of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37254322	7	66	theme	polysaccharides	1339:1353	arg1	structure					1283:1291	structure	1283:1291	structure	1283:1291	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	66	theme	polysaccharides	1339:1353	arg1	characteristics					1307:1321	digestive characteristics	1297:1321	digestive characteristics	1297:1321	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	3	67	theme	physicochemical	469:483	arg1	difference					573:582	no significant difference	558:582	no significant difference between SP and FSP	558:601	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	3	67	theme	physicochemical	469:483	arg1	property					485:492	The physicochemical property	465:492	The physicochemical property	465:492	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	2	68	theme	fermented	365:373	arg1	polysaccharide					388:401	fermented sea cucumber polysaccharide	365:401	fermented sea cucumber polysaccharide (FSP)	365:407	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	2	68	theme	fermented	365:373	arg1	FSP					404:406	FSP	404:406	FSP	404:406	Results showed that both sea cucumber polysaccharide (SP) and fermented sea cucumber polysaccharide (FSP) were sulfated polysaccharides mainly containing fucose.
37254322	7	69	theme	cucumber	1330:1337	arg1	polysaccharides					1339:1353	sea cucumber polysaccharides	1326:1353	sea cucumber polysaccharides caused by fermentation	1326:1376	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	70	from	understanding	1247:1259	arg1	structure					1283:1291	structure	1283:1291	structure	1283:1291	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	7	70	from	understanding	1247:1259	arg1	characteristics					1307:1321	digestive characteristics	1297:1321	digestive characteristics	1297:1321	This study provides a good understanding of the changes in the structure and digestive characteristics of sea cucumber polysaccharides caused by fermentation.
37254322	3	71	theme	microscopic	612:622	arg1	morphology					624:633	microscopic morphology	612:633	microscopic morphology	612:633	The physicochemical property, molecular weight, thermal property, and functional groups were no significant difference between SP and FSP, but the microscopic morphology and monosaccharide composition of FSP changed.
37254322	1	72	theme	sea	237:239	arg1	polysaccharide					250:263	sea cucumber polysaccharide	237:263	sea cucumber polysaccharide fermented by Bacillus subtilis Natto	237:300	This study aimed to understand the structural, digestion and fecal fermentation behaviors of sea cucumber polysaccharide fermented by Bacillus subtilis Natto.
37108402	4	0	theme	jujube	599:604	arg1	fruits					606:611	jujube fruits	599:611	jujube fruits	599:611	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	9	1	theme	primary	1340:1346	arg1	monosaccharides					1294:1308	The monosaccharides	1290:1308	The monosaccharides	1290:1308	The monosaccharides, GalA, Glc, and Ara, were the primary monosaccharides.
37108402	9	1	theme	primary	1340:1346	arg1	monosaccharides					1348:1362	the primary monosaccharides	1336:1362	the primary monosaccharides	1336:1362	The monosaccharides, GalA, Glc, and Ara, were the primary monosaccharides.
37108402	5	2	theme	1.31	682:685	arg1	%					686:686	%	686:686	%	686:686	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	6	3	theme	producing	843:851	arg1	areas					853:857	eight producing areas	837:857	eight producing areas	837:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	5	4	theme	jujube	656:661	arg1	fruits					663:668	jujube fruits	656:668	jujube fruits ranged from 1.31% to 2.22%	656:695	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	3	5	theme	Few	260:262	arg1	studies					264:270	Few studies	260:270	Few studies	260:270	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	8	6	theme	2-4	1221:1223	arg1	DP					1217:1218	DP	1217:1218	DP	1217:1218	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	3	7	from	effect	334:339	arg1	areas					402:406	different producing areas	382:406	different producing areas	382:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	4	8	theme	multi-level	431:441	arg1	profiling					455:463	multi-level fingerprint profiling	431:463	multi-level fingerprint profiling	431:463	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	5	9	theme	molecular	706:714	arg1	MWD					737:739	MWD	737:739	MWD	737:739	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	5	9	theme	molecular	706:714	arg1	distribution					723:734	the molecular weight distribution	702:734	the molecular weight distribution (MWD)	702:740	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	2	10	theme	abundant	206:213	arg1	value					227:231	abundant nutritional value	206:231	abundant nutritional value	206:231	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	8	11	theme	galacturonic	1189:1200	arg1	components					1173:1182	the main components	1164:1182	the main components	1164:1182	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	8	11	theme	galacturonic	1189:1200	arg1	polymers					1207:1214	galacturonic acid polymers	1189:1214	galacturonic acid polymers (DP, 2-4)	1189:1224	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	6	12	theme	spectroscopy	900:911	arg1	profile					880:886	the profile	876:886	the profile of infrared spectroscopy (IR)	876:916	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	3	13	theme	quality	285:291	arg1	evaluation					293:302	quality evaluation	285:302	quality evaluation	285:302	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	7	14	theme	discrimination	1007:1020	arg1	model					1022:1026	a discrimination model	1005:1026	a discrimination model for the identification of jujube fruits from different areas	1005:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	8	15	dep	polymers	1207:1214	arg1	DP					1217:1218	DP	1217:1218	DP	1217:1218	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	7	16	theme	characteristic	946:959	arg1	signals					961:967	The characteristic signals	942:967	The characteristic signals	942:967	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	7	17	used	used	987:990	arg2	signals					961:967	The characteristic signals	942:967	The characteristic signals	942:967	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	3	18	theme	microbiota	312:321	arg1	regulation					323:332	gut microbiota regulation	308:332	gut microbiota regulation	308:332	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	3	19	theme	polysaccharides	344:358	arg1	effect					334:339	the quality evaluation and gut microbiota regulation effect	281:339	the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas	281:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	0	20	theme	jujuba	97:102	arg1	Mill					104:107	jujuba Mill	97:107	Ziziphus jujuba Mill.	88:108	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	5	21	dep	%	686:686	arg1	to					688:689	to	688:689	to	688:689	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	0	22	theme	Fingerprinting	0:13	arg1	Evaluation					15:24	Fingerprinting Evaluation	0:24	Fingerprinting Evaluation	0:24	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	7	23	theme	fruits	1061:1066	arg1	identification					1036:1049	the identification	1032:1049	the identification of jujube fruits from different areas	1032:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	3	24	theme	jujube	363:368	arg1	fruits					370:375	jujube fruits	363:375	jujube fruits	363:375	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	4	25	theme	quality	556:562	arg1	evaluation					564:573	the quality evaluation	552:573	the quality evaluation of polysaccharides from jujube fruits	552:611	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	10	26	theme	composing	1428:1436	arg1	proportion					1438:1447	the composing proportion	1424:1447	the composing proportion of monosaccharides	1424:1466	Although the fingerprint of monosaccharides was semblable, the composing proportion of monosaccharides revealed significant differences.
37108402	2	27	theme	broad	165:169	arg1	masses					171:176	the broad masses	161:176	the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties	161:257	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	7	28	theme	identification	1110:1123	arg1	accuracy					1098:1105	the accuracy	1094:1105	the accuracy of identification	1094:1123	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	0	29	theme	Microbiota	34:43	arg1	Regulation					45:54	Gut Microbiota Regulation	30:54	Gut Microbiota Regulation	30:54	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	6	30	theme	polysaccharides	816:830	arg1	similar					863:869	similar	863:869	similar	863:869	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	6	30	theme	polysaccharides	816:830	arg1	profiling					803:811	The MWD fingerprint profiling	783:811	The MWD fingerprint profiling of polysaccharides from eight producing areas	783:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	3	31	theme	producing	392:400	arg1	areas					402:406	different producing areas	382:406	different producing areas	382:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	7	32	from	areas	1083:1087	arg1	fruits					1061:1066	jujube fruits	1054:1066	jujube fruits from different areas	1054:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	7	32	from	areas	1083:1087	arg1	identification					1036:1049	the identification	1032:1049	the identification of jujube fruits from different areas	1032:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	6	33	theme	MWD	787:789	arg1	similar					863:869	similar	863:869	similar	863:869	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	6	33	theme	MWD	787:789	arg1	profiling					803:811	The MWD fingerprint profiling	783:811	The MWD fingerprint profiling of polysaccharides from eight producing areas	783:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	2	34	theme	due	178:180	arg1	masses					171:176	the broad masses	161:176	the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties	161:257	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	2	35	theme	Jujube	118:123	arg1	fruit					125:129	Jujube fruit	118:129	Jujube fruit	118:129	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	11	36	theme	microbiota	1575:1584	arg1	composition					1586:1596	the gut microbiota composition	1567:1596	the gut microbiota composition	1567:1596	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	6	37	from	areas	853:857	arg1	polysaccharides					816:830	polysaccharides	816:830	polysaccharides from eight producing areas	816:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	6	37	from	areas	853:857	arg1	profiling					803:811	The MWD fingerprint profiling	783:811	The MWD fingerprint profiling of polysaccharides from eight producing areas	783:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	6	37	from	areas	853:857	arg1	similar					863:869	similar	863:869	similar	863:869	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	11	38	theme	potential	1610:1618	arg1	effects					1632:1638	potential therapeutic effects	1610:1638	potential therapeutic effects on dysentery and nervous system diseases	1610:1679	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	7	39	theme	different	1073:1081	arg1	areas					1083:1087	different areas	1073:1087	different areas	1073:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	7	40	from	identification	1036:1049	arg1	areas					1083:1087	different areas	1073:1087	different areas	1073:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	11	41	theme	nervous	1657:1663	arg1	system					1665:1670	nervous system	1657:1670	nervous system	1657:1670	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	5	42	theme	total	639:643	arg1	content					645:651	the total content	635:651	the total content in jujube fruits ranged from 1.31% to 2.22%	635:695	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	5	43	dep	1.73	768:771	arg1	to					765:766	to	765:766	to	765:766	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	8	44	theme	acid	1202:1205	arg1	components					1173:1182	the main components	1164:1182	the main components	1164:1182	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	8	44	theme	acid	1202:1205	arg1	polymers					1207:1214	galacturonic acid polymers	1189:1214	galacturonic acid polymers (DP, 2-4)	1189:1224	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	11	45	theme	jujube	1538:1543	arg1	fruits					1545:1550	jujube fruits	1538:1550	jujube fruits	1538:1550	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	7	46	theme	jujube	1054:1059	arg1	fruits					1061:1066	jujube fruits	1054:1066	jujube fruits from different areas	1054:1087	The characteristic signals were screened and used to establish a discrimination model for the identification of jujube fruits from different areas, and the accuracy of identification reached 100.00%.
37108402	4	47	theme	fingerprint	443:453	arg1	profiling					455:463	multi-level fingerprint profiling	431:463	multi-level fingerprint profiling	431:463	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	2	48	theme	nutritional	215:225	arg1	value					227:231	abundant nutritional value	206:231	abundant nutritional value	206:231	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	8	49	theme	main	1168:1171	arg1	components					1173:1182	the main components	1164:1182	the main components	1164:1182	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	8	49	theme	main	1168:1171	arg1	polymers					1207:1214	galacturonic acid polymers	1189:1214	galacturonic acid polymers (DP, 2-4)	1189:1224	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	0	50	from	Jujube	80:85	arg1	Regulation					45:54	Gut Microbiota Regulation	30:54	Gut Microbiota Regulation	30:54	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	0	50	from	Jujube	80:85	arg1	Evaluation					15:24	Fingerprinting Evaluation	0:24	Fingerprinting Evaluation	0:24	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	0	50	from	Jujube	80:85	arg1	Polysaccharides					59:73	Polysaccharides	59:73	Polysaccharides from Jujube (Ziziphus jujuba Mill.)	59:109	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	4	51	from	evaluation	564:573	arg1	fruits					606:611	jujube fruits	599:611	jujube fruits	599:611	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	6	52	from	profiling	803:811	arg1	areas					853:857	eight producing areas	837:857	eight producing areas	837:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	5	53	from	distribution	723:734	arg1	fruits					663:668	jujube fruits	656:668	jujube fruits ranged from 1.31% to 2.22%	656:695	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	6	54	theme	infrared	891:898	arg1	spectroscopy					900:911	infrared spectroscopy	891:911	infrared spectroscopy (IR)	891:916	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	6	54	theme	infrared	891:898	arg1	IR					914:915	IR	914:915	IR	914:915	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	3	55	theme	evaluation	293:302	arg1	effect					334:339	the quality evaluation and gut microbiota regulation effect	281:339	the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas	281:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	4	56	theme	present	416:422	arg1	study					424:428	the present study	412:428	the present study	412:428	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	5	57	theme	2.22	691:694	arg1	%					686:686	%	686:686	%	686:686	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	2	58	theme	medicinal	238:246	arg1	properties					248:257	medicinal properties	238:257	medicinal properties	238:257	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	3	59	theme	regulation	323:332	arg1	effect					334:339	the quality evaluation and gut microbiota regulation effect	281:339	the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas	281:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	8	60	theme	oligosaccharides	1246:1261	arg1	profile					1235:1241	the profile	1231:1241	the profile of oligosaccharides	1231:1261	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	4	61	from	fruits	606:611	arg1	evaluation					564:573	the quality evaluation	552:573	the quality evaluation of polysaccharides from jujube fruits	552:611	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	4	61	from	fruits	606:611	arg1	polysaccharides					578:592	polysaccharides	578:592	polysaccharides from jujube fruits	578:611	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	3	62	from	areas	402:406	arg1	polysaccharides					344:358	polysaccharides	344:358	polysaccharides of jujube fruits from different producing areas	344:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	3	62	from	areas	402:406	arg1	effect					334:339	the quality evaluation and gut microbiota regulation effect	281:339	the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas	281:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	3	63	theme	gut	308:310	arg1	regulation					323:332	gut microbiota regulation	308:332	gut microbiota regulation	308:332	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	0	64	from	Evaluation	15:24	arg1	Jujube					80:85	Jujube	80:85	Jujube	80:85	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	8	65	theme	high	1273:1276	arg1	similarity					1278:1287	high similarity	1273:1287	high similarity	1273:1287	For oligosaccharides, the main components were galacturonic acid polymers (DP, 2-4), and the profile of oligosaccharides exhibited high similarity.
37108402	5	66	theme	weight	716:721	arg1	MWD					737:739	MWD	737:739	MWD	737:739	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	5	66	theme	weight	716:721	arg1	distribution					723:734	the molecular weight distribution	702:734	the molecular weight distribution (MWD)	702:740	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	0	67	from	Regulation	45:54	arg1	Jujube					80:85	Jujube	80:85	Jujube	80:85	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	5	68	theme	×	773:773	arg1	Da					779:780	1.14 × 105 to 1.73 × 106 Da	754:780	1.14 × 105 to 1.73 × 106 Da	754:780	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	0	69	dep	Ziziphus	88:95	arg1	Mill					104:107	jujuba Mill	97:107	Ziziphus jujuba Mill.	88:108	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	3	70	theme	different	382:390	arg1	areas					402:406	different producing areas	382:406	different producing areas	382:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	10	71	theme	monosaccharides	1393:1407	arg1	fingerprint					1378:1388	the fingerprint	1374:1388	the fingerprint of monosaccharides	1374:1407	Although the fingerprint of monosaccharides was semblable, the composing proportion of monosaccharides revealed significant differences.
37108402	10	71	theme	monosaccharides	1393:1407	arg1	semblable					1413:1421	semblable	1413:1421	semblable	1413:1421	Although the fingerprint of monosaccharides was semblable, the composing proportion of monosaccharides revealed significant differences.
37108402	0	72	theme	Gut	30:32	arg1	Regulation					45:54	Gut Microbiota Regulation	30:54	Gut Microbiota Regulation	30:54	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	11	73	dep	potential	1610:1618	arg1	therapeutic					1620:1630	therapeutic	1620:1630	therapeutic	1620:1630	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	0	74	dep	Jujube	80:85	arg1	Ziziphus					88:95	Ziziphus	88:95	Ziziphus	88:95	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	11	75	contain	possess	1602:1608	arg1	polysaccharides					1519:1533	the polysaccharides	1515:1533	the polysaccharides of jujube fruits	1515:1550	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	11	75	contain	possess	1602:1608	arg2	effects					1632:1638	potential therapeutic effects	1610:1638	potential therapeutic effects on dysentery and nervous system diseases	1610:1679	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	3	76	theme	fruits	370:375	arg1	polysaccharides					344:358	polysaccharides	344:358	polysaccharides of jujube fruits from different producing areas	344:406	Few studies reported the quality evaluation and gut microbiota regulation effect of polysaccharides of jujube fruits from different producing areas.
37108402	4	77	theme	polysaccharides	578:592	arg1	evaluation					564:573	the quality evaluation	552:573	the quality evaluation of polysaccharides from jujube fruits	552:611	In the present study, multi-level fingerprint profiling, including polysaccharides, oligosaccharides, and monosaccharides, was established for the quality evaluation of polysaccharides from jujube fruits.
37108402	5	78	theme	×	759:759	arg1	Da					779:780	1.14 × 105 to 1.73 × 106 Da	754:780	1.14 × 105 to 1.73 × 106 Da	754:780	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	5	79	from	content	645:651	arg1	fruits					663:668	jujube fruits	656:668	jujube fruits ranged from 1.31% to 2.22%	656:695	For polysaccharides, the total content in jujube fruits ranged from 1.31% to 2.22%, and the molecular weight distribution (MWD) ranged from 1.14 × 105 to 1.73 × 106 Da.
37108402	0	80	theme	Polysaccharides	59:73	arg1	Regulation					45:54	Gut Microbiota Regulation	30:54	Gut Microbiota Regulation	30:54	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	0	80	theme	Polysaccharides	59:73	arg1	Evaluation					15:24	Fingerprinting Evaluation	0:24	Fingerprinting Evaluation	0:24	Fingerprinting Evaluation and Gut Microbiota Regulation of Polysaccharides from Jujube (Ziziphus jujuba Mill.)
37108402	11	81	dep	dysentery	1643:1651	arg1	diseases					1672:1679	diseases	1672:1679	diseases	1672:1679	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	11	82	from	effects	1632:1638	arg1	dysentery					1643:1651	dysentery	1643:1651	dysentery	1643:1651	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	11	82	from	effects	1632:1638	arg1	system					1665:1670	nervous system	1657:1670	nervous system	1657:1670	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	10	83	theme	significant	1477:1487	arg1	differences					1489:1499	significant differences	1477:1499	significant differences	1477:1499	Although the fingerprint of monosaccharides was semblable, the composing proportion of monosaccharides revealed significant differences.
37108402	2	84	theme	delicious	189:197	arg1	taste					199:203	its delicious taste	185:203	its delicious taste	185:203	Jujube fruit was well-loved and praised by the broad masses due to its delicious taste, abundant nutritional value, and medicinal properties.
37108402	11	85	theme	fruits	1545:1550	arg1	polysaccharides					1519:1533	the polysaccharides	1515:1533	the polysaccharides of jujube fruits	1515:1550	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
37108402	6	86	theme	fingerprint	791:801	arg1	similar					863:869	similar	863:869	similar	863:869	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	6	86	theme	fingerprint	791:801	arg1	profiling					803:811	The MWD fingerprint profiling	783:811	The MWD fingerprint profiling of polysaccharides from eight producing areas	783:857	The MWD fingerprint profiling of polysaccharides from eight producing areas was similar, but the profile of infrared spectroscopy (IR) showed differentiation.
37108402	10	87	theme	monosaccharides	1452:1466	arg1	proportion					1438:1447	the composing proportion	1424:1447	the composing proportion of monosaccharides	1424:1466	Although the fingerprint of monosaccharides was semblable, the composing proportion of monosaccharides revealed significant differences.
37108402	11	88	theme	gut	1571:1573	arg1	composition					1586:1596	the gut microbiota composition	1567:1596	the gut microbiota composition	1567:1596	In addition, the polysaccharides of jujube fruits could regulate the gut microbiota composition and possess potential therapeutic effects on dysentery and nervous system diseases.
34983180	6	0	theme	IONPs	855:859	arg1	surface					861:867	IONPs surface	855:867	IONPs surface	855:867	The increased protein favors the formation of protein coronas on IONPs surface, which would promote Cd adsorption during NP-metal-EPS interaction.
34983180	10	1	theme	EPS	1432:1434	arg1	role					1424:1427	the role	1420:1427	the role of EPS in NP-metal-EPS interaction	1420:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	1	2	theme	Bacterial	147:155	arg1	EPS					193:195	EPS	193:195	EPS	193:195	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	1	2	theme	Bacterial	147:155	arg1	substances					181:190	Bacterial extracellular polymeric substances	147:190	Bacterial extracellular polymeric substances (EPS)	147:196	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	6	3	theme	Cd	890:891	arg1	adsorption					893:902	Cd adsorption	890:902	Cd adsorption	890:902	The increased protein favors the formation of protein coronas on IONPs surface, which would promote Cd adsorption during NP-metal-EPS interaction.
34983180	4	4	theme	mg	630:631	arg1	L-1					633:635	136.3 mg L-1	624:635	136.3 mg L-1	624:635	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	4	theme	mg	630:631	arg1	proteins					614:621	EPS proteins	610:621	EPS proteins (136.3 mg L-1)	610:636	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	1	5	theme	metal	246:250	arg1	removal					252:258	metal removal	246:258	metal removal in nanoenhanced bioremediation	246:289	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	8	6	theme	monomer	1073:1079	arg1	analyses					1081:1088	Glycosyl monomer analyses	1064:1088	Glycosyl monomer analyses	1064:1088	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	6	7	theme	increased	794:802	arg1	protein					804:810	The increased protein	790:810	The increased protein	790:810	The increased protein favors the formation of protein coronas on IONPs surface, which would promote Cd adsorption during NP-metal-EPS interaction.
34983180	4	8	theme	polysaccharides	679:693	arg1	production					665:674	the most production	656:674	the most production of polysaccharides (241.0 mg L-1)	656:708	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	9	theme	most	660:663	arg1	production					665:674	the most production	656:674	the most production of polysaccharides (241.0 mg L-1)	656:708	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	10	10	from	interaction	1452:1462	arg1	understanding					1403:1415	greater understanding	1395:1415	greater understanding of the role of EPS in NP-metal-EPS interaction	1395:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	8	11	theme	Glycosyl	1064:1071	arg1	analyses					1081:1088	Glycosyl monomer analyses	1064:1088	Glycosyl monomer analyses	1064:1088	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	4	12	theme	mg	544:545	arg1	nanoparticles					519:531	coated iron oxide nanoparticles	501:531	coated iron oxide nanoparticles (IONPs, 20 mg L-1)	501:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	12	theme	mg	544:545	arg1	L-1					547:549	IONPs, 20 mg L-1	534:549	L-1	547:549	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	13	theme	in	444:445	arg1	exposure					452:459	in vivo exposure	444:459	in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1)	444:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	7	14	theme	IONPs	992:996	arg1	coexistence					970:980	the coexistence	966:980	the coexistence of Cd and IONPs	966:996	FTIR analysis indicated that the coexistence of Cd and IONPs interacted with proteins more strongly than with polysaccharides.
34983180	8	15	from	changes	1203:1209	arg1	profiles					1229:1236	monosaccharide profiles	1214:1236	monosaccharide profiles	1214:1236	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	1	16	theme	polymeric	171:179	arg1	EPS					193:195	EPS	193:195	EPS	193:195	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	1	16	theme	polymeric	171:179	arg1	substances					181:190	Bacterial extracellular polymeric substances	147:190	Bacterial extracellular polymeric substances (EPS)	147:196	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	10	17	theme	underpinning	1484:1495	arg1	knowledge					1497:1505	a better underpinning knowledge	1475:1505	a better underpinning knowledge for the application of NP-enhanced bioremediation	1475:1555	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	9	18	theme	secondary	1247:1255	arg1	structures					1257:1266	Protein secondary structures	1239:1266	Protein secondary structures	1239:1266	Protein secondary structures changed in all treatments, but we could not distinguish stresses induced by metals from those by IONPs.
34983180	10	19	theme	greater	1395:1401	arg1	understanding					1403:1415	greater understanding	1395:1415	greater understanding of the role of EPS in NP-metal-EPS interaction	1395:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	10	20	from	understanding	1403:1415	arg1	interaction					1452:1462	NP-metal-EPS interaction	1439:1462	NP-metal-EPS interaction	1439:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	10	21	theme	bioremediation	1542:1555	arg1	application					1515:1525	the application	1511:1525	the application of NP-enhanced bioremediation	1511:1555	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	10	22	from	role	1424:1427	arg1	interaction					1452:1462	NP-metal-EPS interaction	1439:1462	NP-metal-EPS interaction	1439:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	7	23	theme	Cd	985:986	arg1	coexistence					970:980	the coexistence	966:980	the coexistence of Cd and IONPs	966:996	FTIR analysis indicated that the coexistence of Cd and IONPs interacted with proteins more strongly than with polysaccharides.
34983180	10	24	theme	better	1477:1482	arg1	knowledge					1497:1505	a better underpinning knowledge	1475:1505	a better underpinning knowledge for the application of NP-enhanced bioremediation	1475:1555	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	9	25	theme	Protein	1239:1245	arg1	structures					1257:1266	Protein secondary structures	1239:1266	Protein secondary structures	1239:1266	Protein secondary structures changed in all treatments, but we could not distinguish stresses induced by metals from those by IONPs.
34983180	4	26	theme	proteins	614:621	arg1	concentrations					592:605	the highest concentrations	580:605	the highest concentrations of EPS proteins (136.3 mg L-1)	580:636	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	10	27	theme	NP-enhanced	1530:1540	arg1	bioremediation					1542:1555	NP-enhanced bioremediation	1530:1555	NP-enhanced bioremediation	1530:1555	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	1	28	theme	nanoenhanced	263:274	arg1	bioremediation					276:289	nanoenhanced bioremediation	263:289	nanoenhanced bioremediation	263:289	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	4	29	theme	EPS	610:612	arg1	L-1					633:635	136.3 mg L-1	624:635	136.3 mg L-1	624:635	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	29	theme	EPS	610:612	arg1	proteins					614:621	EPS proteins	610:621	EPS proteins (136.3 mg L-1)	610:636	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	5	30	theme	protein/polysaccharides	727:749	arg1	ratio					751:755	protein/polysaccharides ratio	727:755	protein/polysaccharides ratio	727:755	IONPs increased protein/polysaccharides ratio from 0.2 (Cd) to 1.2 (Cd-IONPs).
34983180	4	31	theme	oxide	513:517	arg1	nanoparticles					519:531	coated iron oxide nanoparticles	501:531	coated iron oxide nanoparticles (IONPs, 20 mg L-1)	501:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	31	theme	oxide	513:517	arg1	L-1					547:549	IONPs, 20 mg L-1	534:549	L-1	547:549	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	0	32	theme	Nanoparticle-Enhanced	99:119	arg1	Bioremediation					121:134	Nanoparticle-Enhanced Bioremediation	99:134	Nanoparticle-Enhanced Bioremediation to Metals	99:144	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	0	33	dep	In	51:52	arg1	Vivo					54:57	Vivo	54:57	Vivo	54:57	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	4	34	theme	IONPs	534:538	arg1	nanoparticles					519:531	coated iron oxide nanoparticles	501:531	coated iron oxide nanoparticles (IONPs, 20 mg L-1)	501:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	34	theme	IONPs	534:538	arg1	L-1					547:549	IONPs, 20 mg L-1	534:549	L-1	547:549	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	10	35	theme	role	1424:1427	arg1	understanding					1403:1415	greater understanding	1395:1415	greater understanding of the role of EPS in NP-metal-EPS interaction	1395:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	1	36	theme	extracellular	157:169	arg1	EPS					193:195	EPS	193:195	EPS	193:195	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	1	36	theme	extracellular	157:169	arg1	substances					181:190	Bacterial extracellular polymeric substances	147:190	Bacterial extracellular polymeric substances (EPS)	147:196	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	4	37	dep	in	444:445	arg1	vivo					447:450	vivo	447:450	vivo	447:450	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	8	38	theme	metal-induced	1189:1201	arg1	changes					1203:1209	metal-induced changes	1189:1209	metal-induced changes in monosaccharide profiles	1189:1236	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	4	39	theme	highest	584:590	arg1	concentrations					592:605	the highest concentrations	580:605	the highest concentrations of EPS proteins (136.3 mg L-1)	580:636	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	8	40	theme	target	1123:1128	arg1	sugars					1130:1135	target sugars	1123:1135	target sugars	1123:1135	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	6	41	theme	coronas	844:850	arg1	formation					823:831	the formation	819:831	the formation of protein coronas	819:850	The increased protein favors the formation of protein coronas on IONPs surface, which would promote Cd adsorption during NP-metal-EPS interaction.
34983180	0	42	theme	Bioremediation	121:134	arg1	Mechanisms					85:94	the Mechanisms	81:94	the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals	81:144	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	4	43	dep	Cd/Pb	464:468	arg1	nanoparticles					519:531	coated iron oxide nanoparticles	501:531	coated iron oxide nanoparticles (IONPs, 20 mg L-1)	501:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	43	dep	Cd/Pb	464:468	arg1	L-1					547:549	IONPs, 20 mg L-1	534:549	L-1	547:549	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	0	44	theme	EPS	44:46	arg1	Composition					14:24	Composition	14:24	Composition	14:24	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	0	44	theme	EPS	44:46	arg1	Structure					31:39	Structure	31:39	Structure	31:39	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	0	44	theme	EPS	44:46	arg1	Contribution					0:11	Contribution	0:11	Contribution	0:11	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	6	45	theme	protein	836:842	arg1	coronas					844:850	protein coronas	836:850	protein coronas	836:850	The increased protein favors the formation of protein coronas on IONPs surface, which would promote Cd adsorption during NP-metal-EPS interaction.
34983180	4	46	theme	EPS	434:436	arg1	role					426:429	the role	422:429	the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs	422:569	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	2	47	theme	EPS-metal	335:343	arg1	interactions					345:356	EPS-metal interactions	335:356	EPS-metal interactions	335:356	However, the mechanism by which NPs affect EPS-metal interactions is not fully known.
34983180	8	48	with	complexation	1145:1156	arg1	metals					1163:1168	metals	1163:1168	metals	1163:1168	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	4	49	theme	iron	508:511	arg1	nanoparticles					519:531	coated iron oxide nanoparticles	501:531	coated iron oxide nanoparticles (IONPs, 20 mg L-1)	501:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	49	theme	iron	508:511	arg1	L-1					547:549	IONPs, 20 mg L-1	534:549	L-1	547:549	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	1	50	from	removal	252:258	arg1	bioremediation					276:289	nanoenhanced bioremediation	263:289	nanoenhanced bioremediation	263:289	Bacterial extracellular polymeric substances (EPS) have been recently found to contribute most for metal removal in nanoenhanced bioremediation.
34983180	4	51	theme	coated	501:506	arg1	nanoparticles					519:531	coated iron oxide nanoparticles	501:531	coated iron oxide nanoparticles (IONPs, 20 mg L-1)	501:550	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	51	theme	coated	501:506	arg1	L-1					547:549	IONPs, 20 mg L-1	534:549	L-1	547:549	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	7	52	theme	FTIR	937:940	arg1	analysis					942:949	FTIR analysis	937:949	FTIR analysis	937:949	FTIR analysis indicated that the coexistence of Cd and IONPs interacted with proteins more strongly than with polysaccharides.
34983180	4	53	theme	mg	702:703	arg1	polysaccharides					679:693	polysaccharides	679:693	polysaccharides (241.0 mg L-1)	679:708	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	4	53	theme	mg	702:703	arg1	L-1					705:707	241.0 mg L-1	696:707	241.0 mg L-1	696:707	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	8	54	theme	monosaccharide	1214:1227	arg1	profiles					1229:1236	monosaccharide profiles	1214:1236	monosaccharide profiles	1214:1236	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	8	55	theme	EPS	1141:1143	arg1	complexation					1145:1156	EPS complexation	1141:1156	EPS complexation with metals	1141:1168	Glycosyl monomer analyses suggested mannose and glucose as target sugars for EPS complexation with metals, and IONPs reduced metal-induced changes in monosaccharide profiles.
34983180	6	56	theme	NP-metal-EPS	911:922	arg1	interaction					924:934	NP-metal-EPS interaction	911:934	NP-metal-EPS interaction	911:934	The increased protein favors the formation of protein coronas on IONPs surface, which would promote Cd adsorption during NP-metal-EPS interaction.
34983180	0	57	theme	In	51:52	arg1	Exposure					59:66	In Vivo Exposure	51:66	In Vivo Exposure	51:66	Contribution, Composition, and Structure of EPS by In Vivo Exposure to Elucidate the Mechanisms of Nanoparticle-Enhanced Bioremediation to Metals.
34983180	10	58	theme	NP-metal-EPS	1439:1450	arg1	interaction					1452:1462	NP-metal-EPS interaction	1439:1462	NP-metal-EPS interaction	1439:1462	These findings provide greater understanding of the role of EPS in NP-metal-EPS interaction, providing a better underpinning knowledge for the application of NP-enhanced bioremediation.
34983180	4	59	theme	h.	559:560	arg1	Cd-IONPs					562:569	72 h. Cd-IONPs	556:569	72 h. Cd-IONPs	556:569	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
34983180	3	60	theme	Halomonas	384:392	arg1	sp					394:395	Halomonas sp	384:395	Halomonas sp	384:395	Here, Halomonas sp.
34983180	5	61	dep	0.2	762:764	arg1	to					771:772	to	771:772	to	771:772	IONPs increased protein/polysaccharides ratio from 0.2 (Cd) to 1.2 (Cd-IONPs).
34983180	5	61	dep	0.2	762:764	arg1	Cd-IONPs					779:786	Cd-IONPs	779:786	Cd-IONPs	779:786	IONPs increased protein/polysaccharides ratio from 0.2 (Cd) to 1.2 (Cd-IONPs).
34983180	5	61	dep	0.2	762:764	arg1	1.2					774:776	1.2	774:776	1.2	774:776	IONPs increased protein/polysaccharides ratio from 0.2 (Cd) to 1.2 (Cd-IONPs).
34983180	4	62	dep	employed	402:409	arg1	produced					571:578	produced	571:578	produced	571:578	was employed to explore the role of EPS after in vivo exposure to Cd/Pb and polyvinylpyrrolidone (PVP) coated iron oxide nanoparticles (IONPs, 20 mg L-1) for 72 h. Cd-IONPs produced the highest concentrations of EPS proteins (136.3 mg L-1), while Cd induced the most production of polysaccharides (241.0 mg L-1).
35892192	4	0	theme	honeycomb	828:836	arg1	structure					838:846	a rough surface and porous honeycomb structure	801:846	structure	838:846	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	3	1	from	13.5:33:40.3:13.2	636:652	arg1	percentage					675:684	a molar percentage	667:684	a molar percentage of 2.1:90.3:5.8:1.8	667:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	2	from	profiles	495:502	arg1	ratios					590:595	different composition ratios	568:595	different composition ratios	568:595	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	2	3	theme	native	357:362	arg1	polysaccharide					364:377	native polysaccharide	357:377	native polysaccharide (PCP)	357:383	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	2	3	theme	native	357:362	arg1	PCP					380:382	PCP	380:382	PCP	380:382	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	6	4	theme	IL-6	1178:1181	arg1	ability					1116:1122	the phagocytic ability	1101:1122	the phagocytic ability	1101:1122	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	6	4	theme	IL-6	1178:1181	arg1	production					1128:1137	NO production	1125:1137	NO production	1125:1137	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	6	4	theme	IL-6	1178:1181	arg1	levels					1158:1163	the secretion levels	1144:1163	the secretion levels of TNF-α and IL-6 in RAW 264.7 cells	1144:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	3	5	from	PCP	607:609	arg1	percentage					622:631	a molar percentage	614:631	a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	614:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	8	6	with	extract	1437:1443	arg1	yields					1480:1485	improved yields	1471:1485	improved yields owing to this technology's benefits of low energy consumption and high efficiency	1471:1567	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	1	7	theme	polysaccharide	271:284	arg1	characteristics					221:235	structural characteristics	210:235	structural characteristics	210:235	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	1	7	theme	polysaccharide	271:284	arg1	activity					259:266	immunostimulatory activity	241:266	immunostimulatory activity	241:266	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	4	8	theme	rough	803:807	arg1	surface					809:815	a rough surface and porous honeycomb structure	801:846	surface	809:815	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	3	9	theme	molar	669:673	arg1	percentage					675:684	a molar percentage	667:684	a molar percentage of 2.1:90.3:5.8:1.8	667:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	1	10	theme	steam	169:173	arg1	explosion					175:183	steam explosion	169:183	steam explosion (SE) pretreatment	169:201	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	6	11	theme	NO	1125:1126	arg1	production					1128:1137	NO production	1125:1137	NO production	1125:1137	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	3	12	from	percentage	675:684	arg1	percentage					622:631	a molar percentage	614:631	a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	614:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	0	13	attach	isolated	57:64	arg1	cocos					77:81	Poria cocos	71:81	Poria cocos	71:81	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	0	13	attach	isolated	57:64	arg2	polysaccharide					42:55	polysaccharide	42:55	polysaccharide isolated from Poria cocos	42:81	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	6	14	theme	RAW	1186:1188	arg1	cells					1196:1200	RAW 264.7 cells	1186:1200	RAW 264.7 cells	1186:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	3	15	from	SEPCP	658:662	arg1	percentage					675:684	a molar percentage	667:684	a molar percentage of 2.1:90.3:5.8:1.8	667:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	1	16	from	activity	259:266	arg1	cocos					297:301	Poria cocos	291:301	Poria cocos	291:301	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	3	17	theme	composition	578:588	arg1	ratios					590:595	different composition ratios	568:595	different composition ratios	568:595	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	9	18	theme	extraction	1685:1694	arg1	yields					1696:1701	the extraction yields	1681:1701	the extraction yields of P. cocos polysaccharide (PCP)	1681:1734	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	7	19	theme	immunostimulatory	1316:1332	arg1	activity					1334:1341	the immunostimulatory activity	1312:1341	the immunostimulatory activity of polysaccharide from P. cocos	1312:1373	Collectively, our observations supported that SE pretreatment could help to change the structure and improve the immunostimulatory activity of polysaccharide from P. cocos.
35892192	10	20	theme	SE	1748:1749	arg1	Meanwhile					1737:1745	Meanwhile	1737:1745	Meanwhile	1737:1745	Meanwhile, SE pretreatment also could change the structural features and improve the immunostimulatory activity of PCP.
35892192	10	20	theme	SE	1748:1749	arg1	pretreatment					1751:1762	SE pretreatment	1748:1762	SE pretreatment	1748:1762	Meanwhile, SE pretreatment also could change the structural features and improve the immunostimulatory activity of PCP.
35892192	5	21	theme	PCP	875:877	arg1	types					866:870	The main linkage types	849:870	The main linkage types of PCP	849:877	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	6	22	contain	had	1066:1068	arg1	SEPCP					1060:1064	SEPCP	1060:1064	SEPCP	1060:1064	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	6	22	contain	had	1066:1068	arg2	enhancement					1086:1096	a better immune enhancement	1070:1096	a better immune enhancement	1070:1096	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	6	23	theme	TNF-α	1168:1172	arg1	ability					1116:1122	the phagocytic ability	1101:1122	the phagocytic ability	1101:1122	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	6	23	theme	TNF-α	1168:1172	arg1	production					1128:1137	NO production	1125:1137	NO production	1125:1137	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	6	23	theme	TNF-α	1168:1172	arg1	levels					1158:1163	the secretion levels	1144:1163	the secretion levels of TNF-α and IL-6 in RAW 264.7 cells	1144:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	12	24	theme	explosion	2059:2067	arg1	technology					2069:2078	steam explosion technology	2053:2078	steam explosion technology	2053:2078	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	10	25	theme	structural	1786:1795	arg1	features					1797:1804	the structural features	1782:1804	the structural features	1782:1804	Meanwhile, SE pretreatment also could change the structural features and improve the immunostimulatory activity of PCP.
35892192	7	26	from	cocos	1369:1373	arg1	activity					1334:1341	the immunostimulatory activity	1312:1341	the immunostimulatory activity of polysaccharide from P. cocos	1312:1373	Collectively, our observations supported that SE pretreatment could help to change the structure and improve the immunostimulatory activity of polysaccharide from P. cocos.
35892192	9	27	theme	cocos	1709:1713	arg1	PCP					1731:1733	PCP	1731:1733	PCP	1731:1733	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	9	27	theme	cocos	1709:1713	arg1	polysaccharide					1715:1728	P. cocos polysaccharide	1706:1728	P. cocos polysaccharide (PCP)	1706:1734	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	8	28	theme	bioactive	1445:1453	arg1	components					1455:1464	bioactive components	1445:1464	bioactive components	1445:1464	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	12	29	from	information	2019:2029	arg1	application					2038:2048	the application	2034:2048	the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields	2034:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	5	30	theme	main	853:856	arg1	types					866:870	The main linkage types	849:870	The main linkage types of PCP	849:877	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	12	31	from	utilization	2119:2129	arg1	fields					2180:2185	the pharmaceutical and functional food fields	2141:2185	the pharmaceutical and functional food fields	2141:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	0	32	from	Effect	0:5	arg1	polysaccharide					42:55	polysaccharide	42:55	polysaccharide isolated from Poria cocos	42:81	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	4	33	theme	PCP	732:734	arg1	structure					719:727	The surface structure	707:727	The surface structure of PCP	707:734	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	12	34	from	development	2103:2113	arg1	fields					2180:2185	the pharmaceutical and functional food fields	2141:2185	the pharmaceutical and functional food fields	2141:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	4	35	theme	smooth	743:748	arg1	particles					772:780	smooth and densely spherical particles	743:780	smooth and densely spherical particles	743:780	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	6	36	from	production	1128:1137	arg1	cells					1196:1200	RAW 264.7 cells	1186:1200	RAW 264.7 cells	1186:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	2	37	theme	polysaccharide	403:416	arg1	weights					346:352	the average molecular weights	324:352	the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP)	324:424	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	2	37	theme	polysaccharide	403:416	arg1	18.67					431:435	18.67	431:435	18.67	431:435	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	0	38	theme	immunostimulatory	98:114	arg1	activity					116:123	immunostimulatory activity	98:123	immunostimulatory activity	98:123	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	9	39	theme	structure	1642:1650	arg1	destruction					1617:1627	the destruction	1613:1627	the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP)	1613:1734	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	11	40	theme	immunoregulatory	1919:1934	arg1	effect					1936:1941	strengthened immunoregulatory effect	1906:1941	strengthened immunoregulatory effect	1906:1941	This study revealed that more bioactive PCP with strengthened immunoregulatory effect was obtained pretreated by SE.
35892192	0	41	theme	steam	10:14	arg1	pretreatment					26:37	steam explosion pretreatment	10:37	steam explosion pretreatment	10:37	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	8	42	theme	low	1526:1528	arg1	consumption					1537:1547	low energy consumption	1526:1547	low energy consumption	1526:1547	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	0	43	theme	pretreatment	26:37	arg1	Effect					0:5	Effect	0:5	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.	0:124	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	9	44	theme	SE	1570:1571	arg1	pretreatment					1573:1584	SE pretreatment	1570:1584	SE pretreatment	1570:1584	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	7	45	theme	SE	1249:1250	arg1	pretreatment					1252:1263	SE pretreatment	1249:1263	SE pretreatment	1249:1263	Collectively, our observations supported that SE pretreatment could help to change the structure and improve the immunostimulatory activity of polysaccharide from P. cocos.
35892192	8	46	theme	consumption	1537:1547	arg1	benefits					1514:1521	this technology's benefits	1496:1521	this technology's benefits of low energy consumption and high efficiency	1496:1567	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	12	47	theme	food	2175:2178	arg1	fields					2180:2185	the pharmaceutical and functional food fields	2141:2185	the pharmaceutical and functional food fields	2141:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	8	48	theme	high	1553:1556	arg1	efficiency					1558:1567	high efficiency	1553:1567	high efficiency	1553:1567	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	3	49	theme	13.5:33:40.3:13.2	636:652	arg1	percentage					622:631	a molar percentage	614:631	a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	614:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	12	50	theme	PCP	2134:2136	arg1	development					2103:2113	further development	2095:2113	further development	2095:2113	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	12	50	theme	PCP	2134:2136	arg1	utilization					2119:2129	utilization	2119:2129	utilization	2119:2129	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	5	51	theme	T-β-d-Glcp	995:1004	arg1	branches					1006:1013	1,3-β-d-Glcp backbone and T-β-d-Glcp branches	969:1013	branches	1006:1013	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	2	52	theme	molecular	336:344	arg1	weights					346:352	the average molecular weights	324:352	the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP)	324:424	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	2	52	theme	molecular	336:344	arg1	18.67					431:435	18.67	431:435	18.67	431:435	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	12	53	dep	development	2103:2113	arg1	the					2091:2093	the	2091:2093	the	2091:2093	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	6	54	theme	immune	1079:1084	arg1	enhancement					1086:1096	a better immune enhancement	1070:1096	a better immune enhancement	1070:1096	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	8	55	theme	SE	1400:1401	arg1	technology					1403:1412	SE technology	1400:1412	SE technology	1400:1412	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	3	56	theme	monosaccharides	507:521	arg1	PCP					607:609	PCP	607:609	PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	607:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	56	theme	monosaccharides	507:521	arg1	profiles					495:502	the same profiles	486:502	the same profiles	486:502	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	0	57	dep	Effect	0:5	arg1	Structure					84:92	Structure	84:92	Structure	84:92	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	0	57	dep	Effect	0:5	arg1	activity					116:123	immunostimulatory activity	98:123	immunostimulatory activity	98:123	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	2	58	theme	polysaccharide	364:377	arg1	weights					346:352	the average molecular weights	324:352	the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP)	324:424	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	2	58	theme	polysaccharide	364:377	arg1	18.67					431:435	18.67	431:435	18.67	431:435	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	1	59	theme	immunostimulatory	241:257	arg1	activity					259:266	immunostimulatory activity	241:266	immunostimulatory activity	241:266	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	4	60	theme	porous	821:826	arg1	structure					838:846	a rough surface and porous honeycomb structure	801:846	structure	838:846	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	5	61	contain	contained	959:967	arg2	branches					1006:1013	1,3-β-d-Glcp backbone and T-β-d-Glcp branches	969:1013	branches	1006:1013	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	5	61	contain	contained	959:967	arg2	backbone					982:989	1,3-β-d-Glcp backbone and T-β-d-Glcp branches	969:1013	backbone	982:989	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	5	61	contain	contained	959:967	arg1	SEPCP					943:947	SEPCP	943:947	SEPCP	943:947	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	3	62	theme	SEPCP	658:662	arg1	percentage					622:631	a molar percentage	614:631	a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	614:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	9	63	theme	cell-wall	1632:1640	arg1	structure					1642:1650	cell-wall structure	1632:1650	cell-wall structure	1632:1650	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	3	64	theme	2.1:90.3:5.8:1.8	689:704	arg1	percentage					675:684	a molar percentage	667:684	a molar percentage of 2.1:90.3:5.8:1.8	667:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	1	65	from	cocos	297:301	arg1	characteristics					221:235	structural characteristics	210:235	structural characteristics	210:235	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	1	65	from	cocos	297:301	arg1	activity					259:266	immunostimulatory activity	241:266	immunostimulatory activity	241:266	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	1	65	from	cocos	297:301	arg1	polysaccharide					271:284	polysaccharide	271:284	polysaccharide from Poria cocos	271:301	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	12	66	theme	further	2095:2101	arg1	development					2103:2113	further development	2095:2113	further development	2095:2113	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	1	67	theme	explosion	175:183	arg1	pretreatment					190:201	steam explosion (SE) pretreatment	169:201	steam explosion (SE) pretreatment	169:201	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	1	67	theme	explosion	175:183	arg1	SE					186:187	SE	186:187	SE	186:187	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	8	68	used	used	1429:1432	arg2	technology					1403:1412	SE technology	1400:1412	SE technology	1400:1412	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	1	69	dep	characteristics	221:235	arg1	the					206:208	the	206:208	the	206:208	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	6	70	theme	phagocytic	1105:1114	arg1	ability					1116:1122	the phagocytic ability	1101:1122	the phagocytic ability	1101:1122	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	12	71	theme	technology	2069:2078	arg1	application					2038:2048	the application	2034:2048	the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields	2034:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	11	72	with	PCP	1897:1899	arg1	effect					1936:1941	strengthened immunoregulatory effect	1906:1941	strengthened immunoregulatory effect	1906:1941	This study revealed that more bioactive PCP with strengthened immunoregulatory effect was obtained pretreated by SE.
35892192	3	73	theme	different	568:576	arg1	ratios					590:595	different composition ratios	568:595	different composition ratios	568:595	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	1	74	theme	pretreatment	190:201	arg1	effects					158:164	the effects	154:164	the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos	154:301	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	7	75	theme	polysaccharide	1346:1359	arg1	activity					1334:1341	the immunostimulatory activity	1312:1341	the immunostimulatory activity of polysaccharide from P. cocos	1312:1373	Collectively, our observations supported that SE pretreatment could help to change the structure and improve the immunostimulatory activity of polysaccharide from P. cocos.
35892192	1	76	from	characteristics	221:235	arg1	cocos					297:301	Poria cocos	291:301	Poria cocos	291:301	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	11	77	theme	strengthened	1906:1917	arg1	effect					1936:1941	strengthened immunoregulatory effect	1906:1941	strengthened immunoregulatory effect	1906:1941	This study revealed that more bioactive PCP with strengthened immunoregulatory effect was obtained pretreated by SE.
35892192	10	78	theme	PCP	1852:1854	arg1	activity					1840:1847	the immunostimulatory activity	1818:1847	the immunostimulatory activity of PCP	1818:1854	Meanwhile, SE pretreatment also could change the structural features and improve the immunostimulatory activity of PCP.
35892192	8	79	dep	APPLICATIONS	1386:1397	arg1	used					1429:1432	used	1429:1432	is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency	1414:1567	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	9	80	theme	P.	1706:1707	arg1	PCP					1731:1733	PCP	1731:1733	PCP	1731:1733	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	9	80	theme	P.	1706:1707	arg1	polysaccharide					1715:1728	P. cocos polysaccharide	1706:1728	P. cocos polysaccharide (PCP)	1706:1734	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	12	81	theme	steam	2053:2057	arg1	technology					2069:2078	steam explosion technology	2053:2078	steam explosion technology	2053:2078	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	0	82	theme	Poria	71:75	arg1	cocos					77:81	Poria cocos	71:81	Poria cocos	71:81	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	9	83	theme	polysaccharide	1715:1728	arg1	yields					1696:1701	the extraction yields	1681:1701	the extraction yields of P. cocos polysaccharide (PCP)	1681:1734	SE pretreatment was found to contribute to the destruction of cell-wall structure, which could help to enhance the extraction yields of P. cocos polysaccharide (PCP).
35892192	8	84	theme	improved	1471:1478	arg1	yields					1480:1485	improved yields	1471:1485	improved yields owing to this technology's benefits of low energy consumption and high efficiency	1471:1567	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	6	85	theme	secretion	1148:1156	arg1	levels					1158:1163	the secretion levels	1144:1163	the secretion levels of TNF-α and IL-6 in RAW 264.7 cells	1144:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	12	86	theme	effective	2009:2017	arg1	information					2019:2029	the effective information	2005:2029	the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields	2005:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	6	87	from	levels	1158:1163	arg1	cells					1196:1200	RAW 264.7 cells	1186:1200	RAW 264.7 cells	1186:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	5	88	theme	linkage	858:864	arg1	types					866:870	The main linkage types	849:870	The main linkage types of PCP	849:877	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	4	89	contain	had	797:799	arg2	structure					838:846	a rough surface and porous honeycomb structure	801:846	structure	838:846	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	4	89	contain	had	797:799	arg1	SEPCP					791:795	SEPCP	791:795	SEPCP	791:795	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	4	89	contain	had	797:799	arg2	surface					809:815	a rough surface and porous honeycomb structure	801:846	surface	809:815	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	1	90	from	effects	158:164	arg1	characteristics					221:235	structural characteristics	210:235	structural characteristics	210:235	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	1	90	from	effects	158:164	arg1	activity					259:266	immunostimulatory activity	241:266	immunostimulatory activity	241:266	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	7	91	theme	P.	1366:1367	arg1	cocos					1369:1373	P. cocos	1366:1373	P. cocos	1366:1373	Collectively, our observations supported that SE pretreatment could help to change the structure and improve the immunostimulatory activity of polysaccharide from P. cocos.
35892192	2	92	theme	SE-pretreated	389:401	arg1	SEPCP					419:423	SEPCP	419:423	SEPCP	419:423	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	2	92	theme	SE-pretreated	389:401	arg1	polysaccharide					403:416	SE-pretreated polysaccharide	389:416	SE-pretreated polysaccharide (SEPCP)	389:424	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	6	93	from	ability	1116:1122	arg1	cells					1196:1200	RAW 264.7 cells	1186:1200	RAW 264.7 cells	1186:1200	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	0	94	theme	explosion	16:24	arg1	pretreatment					26:37	steam explosion pretreatment	10:37	steam explosion pretreatment	10:37	Effect of steam explosion pretreatment on polysaccharide isolated from Poria cocos: Structure and immunostimulatory activity.
35892192	1	95	theme	Poria	291:295	arg1	cocos					297:301	Poria cocos	291:301	Poria cocos	291:301	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	3	96	dep	monosaccharides	507:521	arg1	glucose					533:539	glucose	533:539	glucose	533:539	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	96	dep	monosaccharides	507:521	arg1	mannose					524:530	mannose	524:530	mannose	524:530	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	96	dep	monosaccharides	507:521	arg1	monosaccharides					507:521	monosaccharides	507:521	monosaccharides (mannose, glucose, galactose, and fucose)	507:563	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	96	dep	monosaccharides	507:521	arg1	galactose					542:550	galactose	542:550	galactose	542:550	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	96	dep	monosaccharides	507:521	arg1	fucose					557:562	fucose	557:562	fucose	557:562	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	8	97	theme	energy	1530:1535	arg1	consumption					1537:1547	low energy consumption	1526:1547	low energy consumption	1526:1547	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	10	98	theme	immunostimulatory	1822:1838	arg1	activity					1840:1847	the immunostimulatory activity	1818:1847	the immunostimulatory activity of PCP	1818:1854	Meanwhile, SE pretreatment also could change the structural features and improve the immunostimulatory activity of PCP.
35892192	4	99	theme	surface	711:717	arg1	structure					719:727	The surface structure	707:727	The surface structure of PCP	707:734	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
35892192	12	100	theme	pharmaceutical	2145:2158	arg1	fields					2180:2185	the pharmaceutical and functional food fields	2141:2185	the pharmaceutical and functional food fields	2141:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	11	101	theme	bioactive	1887:1895	arg1	PCP					1897:1899	more bioactive PCP	1882:1899	more bioactive PCP with strengthened immunoregulatory effect	1882:1941	This study revealed that more bioactive PCP with strengthened immunoregulatory effect was obtained pretreated by SE.
35892192	8	102	theme	efficiency	1558:1567	arg1	benefits					1514:1521	this technology's benefits	1496:1521	this technology's benefits of low energy consumption and high efficiency	1496:1567	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	12	103	theme	functional	2164:2173	arg1	fields					2180:2185	the pharmaceutical and functional food fields	2141:2185	the pharmaceutical and functional food fields	2141:2185	This study was able to provide the effective information on the application of steam explosion technology to promote the further development and utilization of PCP in the pharmaceutical and functional food fields.
35892192	3	104	theme	same	490:493	arg1	PCP					607:609	PCP	607:609	PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	607:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	104	theme	same	490:493	arg1	profiles					495:502	the same profiles	486:502	the same profiles	486:502	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	3	105	theme	molar	616:620	arg1	percentage					622:631	a molar percentage	614:631	a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8	614:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	8	106	theme	PRACTICAL	1376:1384	arg1	APPLICATIONS					1386:1397	PRACTICAL APPLICATIONS	1376:1397	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.	1376:1568	PRACTICAL APPLICATIONS: SE technology is extensively used to extract bioactive components with improved yields owing to this technology's benefits of low energy consumption and high efficiency.
35892192	2	107	theme	average	328:334	arg1	weights					346:352	the average molecular weights	324:352	the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP)	324:424	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	2	107	theme	average	328:334	arg1	18.67					431:435	18.67	431:435	18.67	431:435	Results showed that the average molecular weights of native polysaccharide (PCP) and SE-pretreated polysaccharide (SEPCP) were 18.67 and 6.52 kDa, respectively.
35892192	1	108	theme	structural	210:219	arg1	characteristics					221:235	structural characteristics	210:235	structural characteristics	210:235	This study aimed to examine the effects of steam explosion (SE) pretreatment on the structural characteristics and immunostimulatory activity of polysaccharide from Poria cocos.
35892192	5	109	theme	1,3-β-d-Glcp	969:980	arg1	backbone					982:989	1,3-β-d-Glcp backbone and T-β-d-Glcp branches	969:1013	backbone	982:989	The main linkage types of PCP comprised 1,6-α-d-Galp, 1,2,6-α-d-Glcp, and T-α-d-Manp, whereas SEPCP primarily contained 1,3-β-d-Glcp backbone and T-β-d-Glcp branches.
35892192	6	110	theme	better	1072:1077	arg1	enhancement					1086:1096	a better immune enhancement	1070:1096	a better immune enhancement	1070:1096	Compared with PCP, we further revealed that SEPCP had a better immune enhancement on the phagocytic ability, NO production, and the secretion levels of TNF-α and IL-6 in RAW 264.7 cells.
35892192	3	111	from	percentage	622:631	arg1	percentage					675:684	a molar percentage	667:684	a molar percentage of 2.1:90.3:5.8:1.8	667:704	PCP and SEPCP shared the same profiles of monosaccharides (mannose, glucose, galactose, and fucose) in different composition ratios, that is, PCP in a molar percentage of 13.5:33:40.3:13.2 and SEPCP in a molar percentage of 2.1:90.3:5.8:1.8.
35892192	4	112	theme	spherical	762:770	arg1	particles					772:780	smooth and densely spherical particles	743:780	smooth and densely spherical particles	743:780	The surface structure of PCP showed smooth and densely spherical particles, whereas SEPCP had a rough surface and porous honeycomb structure.
37347675	3	0	theme	automated	563:571	arg1	approach					590:597	an automated, high-throughput approach	560:597	an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates	560:666	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	6	1	theme	small	1249:1253	arg1	library					1255:1261	a small library	1247:1261	a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues	1247:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	3	2	theme	polyelectrolyte	613:627	arg1	PEMs					642:645	PEMs	642:645	PEMs	642:645	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	3	2	theme	polyelectrolyte	613:627	arg1	multilayers					629:639	polyelectrolyte multilayers	613:639	polyelectrolyte multilayers (PEMs)	613:646	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	6	3	theme	different	1327:1335	arg1	levels					1337:1342	different levels	1327:1342	different levels of ionizable and hydrophobic amino acid residues	1327:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	0	4	theme	Automated	0:8	arg1	Screening					27:35	Automated, High-Throughput Screening	0:35	Screening	27:35	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	4	5	theme	science	919:925	arg1	settings					931:938	science lab settings	919:938	the materials science lab settings	905:938	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	7	6	theme	species	1489:1495	arg1	signal					1457:1462	the signal	1453:1462	the signal of fluorescently labeled species (chitosan or ELP-mCherry)	1453:1521	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	9	7	theme	multilayer	2025:2034	arg1	films					2036:2040	multilayer films	2025:2040	multilayer films that demand high levels of testing and optimization	2025:2092	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	5	8	theme	polysaccharide-based	1008:1027	arg1	films					1029:1033	polysaccharide-based films	1008:1033	polysaccharide-based films	1008:1033	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	2	9	theme	designed	339:346	arg1	blocks					357:362	newly designed building blocks	333:362	newly designed building blocks	333:362	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	5	10	theme	single	1158:1163	arg1	batch					1165:1169	one single batch	1154:1169	one single batch	1154:1169	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	8	11	theme	ionization	1847:1856	arg1	degree					1858:1863	a low ionization degree	1841:1863	a low ionization degree	1841:1863	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	1	12	theme	mild	257:260	arg1	conditions					271:280	mild chemical conditions	257:280	mild chemical conditions	257:280	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	6	13	theme	polypeptides	1302:1313	arg1	library					1255:1261	a small library	1247:1261	a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues	1247:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	9	14	theme	high	2054:2057	arg1	levels					2059:2064	high levels	2054:2064	high levels of testing and optimization	2054:2092	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	4	15	theme	HT-LbL	782:787	arg1	method					790:795	This high-throughput layer-by-layer (HT-LbL) method	745:795	This high-throughput layer-by-layer (HT-LbL) method	745:795	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	6	16	theme	residues	1384:1391	arg1	levels					1337:1342	different levels	1327:1342	different levels of ionizable and hydrophobic amino acid residues	1327:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	3	17	theme	multiwell	651:659	arg1	plates					661:666	multiwell plates	651:666	multiwell plates	651:666	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	3	18	dep	automated	563:571	arg1	high-throughput					574:588	high-throughput	574:588	high-throughput	574:588	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	6	19	theme	engineered	1278:1287	arg1	polypeptides					1302:1313	genetically engineered elastin-like polypeptides	1266:1313	genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues	1266:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	6	19	theme	engineered	1278:1287	arg1	ELPs					1316:1319	ELPs	1316:1319	ELPs	1316:1319	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	5	20	theme	films	1029:1033	arg1	deposition					994:1003	the deposition	990:1003	the deposition of polysaccharide-based films in multiwell plates	990:1053	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	6	21	theme	amino	1373:1377	arg1	residues					1384:1391	ionizable and hydrophobic amino acid residues	1347:1391	residues	1384:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	2	22	theme	multilayer	301:310	arg1	films					312:316	multilayer films	301:316	multilayer films	301:316	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	1	23	theme	great	175:179	arg1	method					204:209	a method	202:209	a method for engineering bio-functional surfaces under mild chemical conditions	202:280	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	1	23	theme	great	175:179	arg1	deal					181:184	a great deal	173:184	a great deal of attention	173:197	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	7	24	theme	films	1425:1429	arg1	deposition					1398:1407	The deposition	1394:1407	The deposition of ELP/chitosan films	1394:1429	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	0	25	theme	Multilayer	87:96	arg1	Deposition					103:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	6	26	used	used	1199:1202	arg2	method					1183:1188	The HT-LbL method	1172:1188	The HT-LbL method	1172:1188	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	4	27	theme	layer-by-layer	766:779	arg1	method					790:795	This high-throughput layer-by-layer (HT-LbL) method	745:795	This high-throughput layer-by-layer (HT-LbL) method	745:795	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	0	28	theme	Deposition	103:112	arg1	Screening					27:35	Automated, High-Throughput Screening	0:35	Screening	27:35	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	2	29	theme	minimal	441:447	arg1	changes					449:455	minimal changes	441:455	minimal changes in the macromolecular composition	441:489	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	7	30	theme	ELP/chitosan	1412:1423	arg1	films					1425:1429	ELP/chitosan films	1412:1429	ELP/chitosan films	1412:1429	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	4	31	dep	materials	909:917	arg1	settings					931:938	science lab settings	919:938	the materials science lab settings	905:938	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	1	32	theme	self-assembled	119:132	arg1	technique					149:157	The self-assembled layer-by-layer technique	115:157	The self-assembled layer-by-layer technique	115:157	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	4	33	theme	affordable	808:817	arg1	platform					837:844	an affordable, fully commercial platform	805:844	an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings	805:938	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	2	34	theme	macromolecular	464:477	arg1	composition					479:489	the macromolecular composition	460:489	the macromolecular composition	460:489	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	3	35	theme	formulations	711:722	arg1	screening					682:690	the screening	678:690	the screening of nearly 100 film formulations in the same process	678:742	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	5	36	theme	stained	1099:1105	arg1	PEMs					1136:1139	PEMs	1136:1139	PEMs	1136:1139	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	5	36	theme	stained	1099:1105	arg1	multilayers					1123:1133	ionically stained polyelectrolyte multilayers	1089:1133	ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch	1089:1169	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	8	37	theme	ELP-mCherry/chitosan	1656:1675	arg1	films					1677:1681	ELP-mCherry/chitosan films	1656:1681	ELP-mCherry/chitosan films	1656:1681	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	0	38	theme	Elastin-like	47:58	arg1	Deposition					103:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	5	39	theme	multilayers	1123:1133	arg1	signal					1079:1084	the absorbance signal	1064:1084	the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch	1064:1169	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	4	40	theme	Python-coded	852:863	arg1	routines					865:872	Python-coded routines	852:872	Python-coded routines that can be easily adapted for the materials science lab settings	852:938	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	8	41	theme	higher	1737:1742	arg1	growth					1749:1754	a higher film growth and a rougher	1735:1768	growth	1749:1754	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	1	42	theme	chemical	262:269	arg1	conditions					271:280	mild chemical conditions	257:280	mild chemical conditions	257:280	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	5	43	theme	absorbance	1068:1077	arg1	signal					1079:1084	the absorbance signal	1064:1084	the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch	1064:1169	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	9	44	theme	multilayer	1955:1964	arg1	films					1966:1970	multilayer films	1955:1970	multilayer films	1955:1970	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	7	45	theme	hydrophobic	1566:1576	arg1	residues					1578:1585	both electrostatic and hydrophobic residues	1543:1585	both electrostatic and hydrophobic residues	1543:1585	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	6	46	theme	HT-LbL	1176:1181	arg1	method					1183:1188	The HT-LbL method	1172:1188	The HT-LbL method	1172:1188	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	6	47	theme	hydrophobic	1361:1371	arg1	residues					1384:1391	ionizable and hydrophobic amino acid residues	1347:1391	residues	1384:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	8	48	theme	a	1760:1760	arg1	rougher					1762:1768	a higher film growth and a rougher	1735:1768	rougher	1762:1768	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	7	49	theme	electrostatic	1548:1560	arg1	residues					1578:1585	both electrostatic and hydrophobic residues	1543:1585	both electrostatic and hydrophobic residues	1543:1585	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	4	50	theme	lab	927:929	arg1	settings					931:938	science lab settings	919:938	the materials science lab settings	905:938	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	6	51	theme	ionizable	1347:1355	arg1	residues					1384:1391	ionizable and hydrophobic amino acid residues	1347:1391	residues	1384:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	9	52	dep	growth	1930:1935	arg1	the					1926:1928	the	1926:1928	the	1926:1928	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	7	53	dep	species	1489:1495	arg1	species					1489:1495	fluorescently labeled species	1467:1495	fluorescently labeled species (chitosan or ELP-mCherry)	1467:1521	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	7	53	dep	species	1489:1495	arg1	ELP-mCherry					1510:1520	ELP-mCherry	1510:1520	ELP-mCherry	1510:1520	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	7	53	dep	species	1489:1495	arg1	chitosan					1498:1505	chitosan	1498:1505	chitosan	1498:1505	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	9	54	dep	illustrates	1886:1896	arg1	accelerate					1995:2004	accelerate	1995:2004	can accelerate the development of multilayer films that demand high levels of testing and optimization	1991:2092	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	8	55	theme	hydrophobic	1779:1789	arg1	surface					1791:1797	more hydrophobic surface	1774:1797	more hydrophobic surface	1774:1797	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	6	56	theme	PEMs	1237:1240	arg1	deposition					1223:1232	the deposition	1219:1232	the deposition of PEMs	1219:1240	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	2	57	dep	production	287:296	arg1	starting					319:326	starting	319:326	starting from newly designed building blocks	319:362	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	2	58	theme	building	348:355	arg1	blocks					357:362	newly designed building blocks	333:362	newly designed building blocks	333:362	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	1	59	theme	bio-functional	227:240	arg1	surfaces					242:249	bio-functional surfaces	227:249	bio-functional surfaces	227:249	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	7	60	theme	labeled	1481:1487	arg1	species					1489:1495	fluorescently labeled species	1467:1495	fluorescently labeled species (chitosan or ELP-mCherry)	1467:1521	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	7	60	theme	labeled	1481:1487	arg1	ELP-mCherry					1510:1520	ELP-mCherry	1510:1520	ELP-mCherry	1510:1520	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	7	60	theme	labeled	1481:1487	arg1	chitosan					1498:1505	chitosan	1498:1505	chitosan	1498:1505	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	9	61	theme	films	2036:2040	arg1	development					2010:2020	the development	2006:2020	the development of multilayer films that demand high levels of testing and optimization	2006:2092	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	8	62	theme	low	1843:1845	arg1	degree					1858:1863	a low ionization degree	1841:1863	a low ionization degree	1841:1863	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	4	63	dep	affordable	808:817	arg1	commercial					826:835	commercial	826:835	commercial	826:835	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	6	64	theme	elastin-like	1289:1300	arg1	polypeptides					1302:1313	genetically engineered elastin-like polypeptides	1266:1313	genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues	1266:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	6	64	theme	elastin-like	1289:1300	arg1	ELPs					1316:1319	ELPs	1316:1319	ELPs	1316:1319	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	6	65	theme	acid	1379:1382	arg1	residues					1384:1391	ionizable and hydrophobic amino acid residues	1347:1391	residues	1384:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	2	66	theme	films	312:316	arg1	laborious					372:380	laborious	372:380	laborious	372:380	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	2	66	theme	films	312:316	arg1	production					287:296	The production	283:296	The production	283:296	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	6	67	with	polypeptides	1302:1313	arg1	levels					1337:1342	different levels	1327:1342	different levels of ionizable and hydrophobic amino acid residues	1327:1391	The HT-LbL method was also used to investigate the deposition of PEMs with a small library of genetically engineered elastin-like polypeptides (ELPs) with different levels of ionizable and hydrophobic amino acid residues.
37347675	9	68	theme	testing	2069:2075	arg1	levels					2059:2064	high levels	2054:2064	high levels of testing and optimization	2054:2092	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	0	69	theme	Film	98:101	arg1	Deposition					103:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	5	70	theme	HT-LbL	945:950	arg1	system					952:957	The HT-LbL system	941:957	The HT-LbL system	941:957	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	9	71	theme	optimization	2081:2092	arg1	levels					2059:2064	high levels	2054:2064	high levels of testing and optimization	2054:2092	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	1	72	theme	attention	189:197	arg1	method					204:209	a method	202:209	a method for engineering bio-functional surfaces under mild chemical conditions	202:280	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	1	72	theme	attention	189:197	arg1	deal					181:184	a great deal	173:184	a great deal of attention	173:197	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	4	73	theme	high-throughput	750:764	arg1	method					790:795	This high-throughput layer-by-layer (HT-LbL) method	745:795	This high-throughput layer-by-layer (HT-LbL) method	745:795	This high-throughput layer-by-layer (HT-LbL) method runs in an affordable, fully commercial platform using Python-coded routines that can be easily adapted for the materials science lab settings.
37347675	5	74	theme	multiwell	1038:1046	arg1	plates					1048:1053	multiwell plates	1038:1053	multiwell plates	1038:1053	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	8	75	theme	growth	1623:1628	arg1	properties					1642:1651	The growth and surface properties	1619:1651	properties	1642:1651	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	3	76	from	screening	682:690	arg1	process					736:742	the same process	727:742	the same process	727:742	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	5	77	from	deposition	994:1003	arg1	plates					1048:1053	multiwell plates	1038:1053	multiwell plates	1038:1053	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	8	78	theme	surface	1634:1640	arg1	properties					1642:1651	The growth and surface properties	1619:1651	properties	1642:1651	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	1	79	theme	layer-by-layer	134:147	arg1	technique					149:157	The self-assembled layer-by-layer technique	115:157	The self-assembled layer-by-layer technique	115:157	The self-assembled layer-by-layer technique has attracted a great deal of attention as a method for engineering bio-functional surfaces under mild chemical conditions.
37347675	3	80	theme	film	706:709	arg1	formulations					711:722	nearly 100 film formulations	695:722	nearly 100 film formulations	695:722	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	0	81	theme	Hybrid	40:45	arg1	Deposition					103:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	8	82	theme	films	1677:1681	arg1	properties					1642:1651	The growth and surface properties	1619:1651	properties	1642:1651	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	0	83	theme	Polysaccharide/Polypeptide	60:85	arg1	Deposition					103:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition	40:112	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	5	84	theme	polyelectrolyte	1107:1121	arg1	PEMs					1136:1139	PEMs	1136:1139	PEMs	1136:1139	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	5	84	theme	polyelectrolyte	1107:1121	arg1	multilayers					1123:1133	ionically stained polyelectrolyte multilayers	1089:1133	ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch	1089:1169	The HT-LbL system was validated by investigating the deposition of polysaccharide-based films in multiwell plates, probing the absorbance signal of ionically stained polyelectrolyte multilayers (PEMs) prepared in one single batch.
37347675	2	85	theme	film	507:510	arg1	deposition					512:521	film deposition	507:521	film deposition	507:521	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	3	86	theme	same	731:734	arg1	process					736:742	the same process	727:742	the same process	727:742	This paper presents an automated, high-throughput approach to depositing polyelectrolyte multilayers (PEMs) in multiwell plates, enabling the screening of nearly 100 film formulations in the same process.
37347675	8	87	theme	film	1744:1747	arg1	growth					1749:1754	a higher film growth and a rougher	1735:1768	growth	1749:1754	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	7	88	theme	film	1605:1608	arg1	buildup					1610:1616	film buildup	1605:1616	film buildup	1605:1616	The deposition of ELP/chitosan films was assessed based on the signal of fluorescently labeled species (chitosan or ELP-mCherry), demonstrating that both electrostatic and hydrophobic residues are essential for film buildup.
37347675	0	89	dep	Screening	27:35	arg1	High-Throughput					11:25	Automated, High-Throughput Screening	0:35	High-Throughput	11:25	Automated, High-Throughput Screening of Hybrid Elastin-like Polysaccharide/Polypeptide Multilayer Film Deposition.
37347675	2	90	from	changes	449:455	arg1	composition					479:489	the macromolecular composition	460:489	the macromolecular composition	460:489	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
37347675	9	91	theme	films	1966:1970	arg1	properties					1941:1950	properties	1941:1950	properties	1941:1950	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	9	91	theme	films	1966:1970	arg1	growth					1930:1935	growth	1930:1935	growth	1930:1935	Overall, this study illustrates the challenge of predicting the growth and properties of multilayer films and how the HT-LbL can accelerate the development of multilayer films that demand high levels of testing and optimization.
37347675	8	92	theme	assembly	1714:1721	arg1	pH					1723:1724	the assembly pH	1710:1724	the assembly pH	1710:1724	The growth and surface properties of ELP-mCherry/chitosan films also seemed susceptible to the assembly pH, forming a higher film growth and a rougher and more hydrophobic surface for both polyelectrolytes deposited under a low ionization degree.
37347675	2	93	theme	inherent	399:406	arg1	limitations					408:418	the inherent limitations	395:418	the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance	395:537	The production of multilayer films, starting from newly designed building blocks, may be laborious, considering the inherent limitations for anticipating how minimal changes in the macromolecular composition may impact both film deposition and performance.
36290159	6	0	theme	%	943:943	arg1	paraformaldehyde					951:966	4% (v/v) paraformaldehyde	942:966	4% (v/v) paraformaldehyde	942:966	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	1	theme	phase	3037:3041	arg1	cells					3011:3015	the isthmus non-ciliated cells	2986:3015	the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2986:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	2	theme	glycoconjugate	1107:1120	arg1	characterization					1122:1137	glycoconjugate characterization	1107:1137	glycoconjugate characterization	1107:1137	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	3	theme	non-ciliated	3281:3292	arg1	cells					3294:3298	the ampulla non-ciliated cells	3269:3298	the ampulla non-ciliated cells	3269:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	4	4	theme	epithelium	598:607	arg1	composition					566:576	the glycan composition	555:576	the glycan composition of baboon oviductal epithelium during the menstrual cycle	555:634	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	4	4	theme	epithelium	598:607	arg1	morphology					540:549	the morphology	536:549	the morphology	536:549	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	7	5	theme	menstrual	1536:1544	arg1	phases					1546:1551	other menstrual phases	1530:1551	other menstrual phases	1530:1551	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	6	theme	cells	2152:2156	arg1	protrusions					2124:2134	the apical protrusions	2113:2134	the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase	2113:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	7	theme	healthy	684:690	arg1	hamadryas					711:719	14 healthy adult female Papio hamadryas	681:719	14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features	681:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	9	8	theme	sialic	2595:2600	arg1	acids					2602:2606	sialic acids	2595:2606	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2595:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	9	theme	cycle	2786:2790	arg1	phases					2762:2767	all phases	2758:2767	all phases of the menstrual cycle	2758:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	10	theme	histomorphological	1144:1161	arg1	analysis					1163:1170	The histomorphological analysis	1140:1170	The histomorphological analysis	1140:1170	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	11	theme	SNA	2381:2383	arg1	affinity					2385:2392	SNA affinity	2381:2392	SNA affinity	2381:2392	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	11	theme	SNA	2381:2383	arg1	ones					2375:2378	α2,6-linked ones	2363:2378	α2,6-linked ones (SNA affinity)	2363:2393	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	12	theme	cytology	810:817	arg1	features					819:826	the vaginal cytology features	798:826	the vaginal cytology features	798:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	9	13	located	detected	2405:2412	arg2	ones					2375:2378	α2,6-linked ones	2363:2378	α2,6-linked ones (SNA affinity)	2363:2393	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	13	located	detected	2405:2412	arg1	surface					2421:2427	the surface	2417:2427	the surface of the luteal phase	2417:2447	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	13	located	detected	2405:2412	arg2	affinity					2385:2392	SNA affinity	2381:2392	SNA affinity	2381:2392	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	14	theme	cells	3011:3015	arg1	luteal					2902:2907	the luteal	2898:2907	the luteal	2898:2907	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	14	theme	cells	3011:3015	arg1	phases					2926:2931	preovulatory phases	2913:2931	preovulatory phases	2913:2931	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	14	theme	cells	3011:3015	arg1	protrusions					2971:2981	the apical protrusions	2960:2981	the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2960:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	11	15	theme	segments	3738:3745	arg1	function					3712:3719	the function	3708:3719	the function of the oviductal segments	3708:3745	Particularly, the sex hormone fluctuation affects the glycan pattern in a region-specific manner, probably related to the function of the oviductal segments.
36290159	10	16	theme	oviductal	3541:3549	arg1	epithelium					3551:3560	the baboon oviductal epithelium	3530:3560	the baboon oviductal epithelium during the menstrual cycle	3530:3587	These results demonstrate for the first time that morphological and glycan changes occur in the baboon oviductal epithelium during the menstrual cycle.
36290159	1	17	theme	specialized	162:172	arg1	structure					174:182	a highly specialized structure	153:182	a highly specialized structure where fertilization and early embryonic development occur	153:240	The mammalian oviduct is a highly specialized structure where fertilization and early embryonic development occur.
36290159	1	17	theme	specialized	162:172	arg1	oviduct					142:148	The mammalian oviduct	128:148	The mammalian oviduct	128:148	The mammalian oviduct is a highly specialized structure where fertilization and early embryonic development occur.
36290159	9	18	located	found	2713:2717	arg2	KsSBA					2701:2705	KsSBA	2701:2705	KsSBA	2701:2705	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	18	located	found	2713:2717	arg1	surface					2743:2749	the entire oviductal surface	2722:2749	the entire oviductal surface during all phases of the menstrual cycle	2722:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	18	located	found	2713:2717	arg2	N-acetylgalactosamine					2665:2685	terminal N-acetylgalactosamine	2656:2685	terminal N-acetylgalactosamine	2656:2685	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	18	located	found	2713:2717	arg2	antigen					2691:2697	Tn antigen	2688:2697	Tn antigen	2688:2697	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	18	located	found	2713:2717	arg2	sialoglycans					2577:2588	O-linked sialoglycans	2568:2588	O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2568:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	19	theme	preovulatory	2184:2195	arg1	phase					2197:2201	the preovulatory phase	2180:2201	the preovulatory phase	2180:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	20	theme	apical	3247:3252	arg1	protrusions					3254:3264	the apical protrusions	3243:3264	the apical protrusions of the ampulla non-ciliated cells	3243:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	2	21	theme	intraluminal	318:329	arg1	fluid					331:335	a dynamic intraluminal fluid	308:335	a dynamic intraluminal fluid	308:335	Its mucosal epithelium is involved in maintaining and modulating a dynamic intraluminal fluid.
36290159	9	22	theme	T	2633:2633	arg1	Galβl,3GalNAc					2618:2630	Galβl,3GalNAc	2618:2630	Galβl,3GalNAc (T antigen) (KsPNA)	2618:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	22	theme	T	2633:2633	arg1	antigen					2635:2641	T antigen	2633:2641	T antigen	2633:2641	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	23	theme	paraffin	981:988	arg1	wax					990:992	paraffin wax	981:992	paraffin wax	981:992	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	24	from	present	3232:3238	arg1	protrusions					3254:3264	the apical protrusions	3243:3264	the apical protrusions of the ampulla non-ciliated cells	3243:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	0	25	theme	Menstrual	111:119	arg1	Cycle					121:125	the Menstrual Cycle	107:125	the Menstrual Cycle	107:125	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	11	26	theme	region-specific	3664:3678	arg1	manner					3680:3685	a region-specific manner	3662:3685	a region-specific manner	3662:3685	Particularly, the sex hormone fluctuation affects the glycan pattern in a region-specific manner, probably related to the function of the oviductal segments.
36290159	9	27	theme	HPA	2836:2838	arg1	staining					2840:2847	HPA staining	2836:2847	HPA staining	2836:2847	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	27	theme	HPA	2836:2838	arg1	glycans					2827:2833	O-linked glycans	2818:2833	O-linked glycans (HPA staining)	2818:2848	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	28	theme	high-mannosylated	1950:1966	arg1	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	28	theme	high-mannosylated	1950:1966	arg1	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	29	theme	fucosylated	3053:3063	arg1	glycans					3065:3071	(iv) fucosylated glycans	3048:3071	(iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	3048:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	30	theme	ampulla	3273:3279	arg1	cells					3294:3298	the ampulla non-ciliated cells	3269:3298	the ampulla non-ciliated cells	3269:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	31	dep	follows	1937:1943	arg1	present					2009:2015	present	2009:2015	present	2009:2015	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	1	32	theme	embryonic	214:222	arg1	development					224:234	early embryonic development	208:234	early embryonic development	208:234	The mammalian oviduct is a highly specialized structure where fertilization and early embryonic development occur.
36290159	10	33	theme	first	3472:3476	arg1	time					3478:3481	the first time	3468:3481	the first time	3468:3481	These results demonstrate for the first time that morphological and glycan changes occur in the baboon oviductal epithelium during the menstrual cycle.
36290159	7	34	theme	apical	1420:1425	arg1	protrusions					1427:1437	apical protrusions	1420:1437	apical protrusions	1420:1437	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	11	35	theme	glycan	3644:3649	arg1	pattern					3651:3657	the glycan pattern	3640:3657	the glycan pattern	3640:3657	Particularly, the sex hormone fluctuation affects the glycan pattern in a region-specific manner, probably related to the function of the oviductal segments.
36290159	9	36	theme	cells	3294:3298	arg1	protrusions					3254:3264	the apical protrusions	3243:3264	the apical protrusions of the ampulla non-ciliated cells	3243:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	12	37	theme	excellent	3854:3862	arg1	model					3864:3868	an excellent model	3851:3868	an excellent model for female reproduction studies	3851:3900	The findings add new data concerning baboons which, due to their anatomical similarity to humans, make an excellent model for female reproduction studies.
36290159	8	38	theme	cycle	1906:1910	arg1	phases					1882:1887	the different phases	1868:1887	the different phases of the menstrual cycle	1868:1910	The glycan characterization revealed a complex and region-specific composition during the different phases of the menstrual cycle.
36290159	7	39	theme	cells	1760:1764	arg1	presence					1739:1746	the lower presence	1729:1746	the lower presence of ciliated cells in the isthmus	1729:1779	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	10	40	theme	baboon	3534:3539	arg1	epithelium					3551:3560	the baboon oviductal epithelium	3530:3560	the baboon oviductal epithelium during the menstrual cycle	3530:3587	These results demonstrate for the first time that morphological and glycan changes occur in the baboon oviductal epithelium during the menstrual cycle.
36290159	9	41	theme	Con	1986:1988	arg1	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	41	theme	Con	1986:1988	arg1	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	42	theme	α2,3-linked	2227:2237	arg1	acids					2246:2250	α2,3-linked sialic acids	2227:2250	α2,3-linked sialic acids (MAL II binding)	2227:2267	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	42	theme	α2,3-linked	2227:2237	arg1	binding					2260:2266	MAL II binding	2253:2266	MAL II binding	2253:2266	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	43	theme	menstrual	727:735	arg1	phase					743:747	menstrual cycle phase	727:747	menstrual cycle phase	727:747	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	12	44	theme	female	3874:3879	arg1	studies					3894:3900	female reproduction studies	3874:3900	female reproduction studies	3874:3900	The findings add new data concerning baboons which, due to their anatomical similarity to humans, make an excellent model for female reproduction studies.
36290159	9	45	theme	phase	2443:2447	arg1	surface					2421:2427	the surface	2417:2427	the surface of the luteal phase	2417:2447	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	46	theme	morphological	1034:1046	arg1	analyses					1048:1055	morphological analyses	1034:1055	morphological analyses	1034:1055	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	3	47	theme	oviductal	342:350	arg1	epithelium					352:361	The oviductal epithelium	338:361	The oviductal epithelium	338:361	The oviductal epithelium consists of ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent.
36290159	9	48	theme	LTA	3098:3100	arg1	fucose					3090:3095	α1,2-linked fucose	3078:3095	α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells	3078:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	48	theme	LTA	3098:3100	arg1	reactivity					3102:3111	LTA reactivity	3098:3111	LTA reactivity	3098:3111	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	0	49	theme	Oviductal	53:61	arg1	Epithelium					63:72	the Oviductal Epithelium	49:72	the Oviductal Epithelium of Baboon Papio hamadryas	49:98	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	2	50	theme	mucosal	247:253	arg1	epithelium					255:264	Its mucosal epithelium	243:264	Its mucosal epithelium	243:264	Its mucosal epithelium is involved in maintaining and modulating a dynamic intraluminal fluid.
36290159	9	51	from	cells	3011:3015	arg1	surface					3318:3324	the apical surface	3307:3324	the apical surface of isthmus during the preovulatory phase	3307:3365	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	52	theme	lower	1733:1737	arg1	presence					1739:1746	the lower presence	1729:1746	the lower presence of ciliated cells in the isthmus	1729:1779	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	53	theme	p	1608:1608	arg1	≤					1610:1610	p ≤ 0.05	1608:1615	p ≤ 0.05	1608:1615	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	54	theme	entire	2879:2884	arg1	oviducts					2886:2893	the entire oviducts	2875:2893	the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2875:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	55	attach	presence	1739:1746	arg2	cells					1760:1764	ciliated cells	1751:1764	ciliated cells	1751:1764	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	55	attach	presence	1739:1746	arg1	isthmus					1773:1779	the isthmus	1769:1779	the isthmus	1769:1779	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	10	56	theme	glycan	3506:3511	arg1	changes					3513:3519	morphological and glycan changes	3488:3519	morphological and glycan changes	3488:3519	These results demonstrate for the first time that morphological and glycan changes occur in the baboon oviductal epithelium during the menstrual cycle.
36290159	9	57	theme	MAL	2253:2255	arg1	acids					2246:2250	α2,3-linked sialic acids	2227:2250	α2,3-linked sialic acids (MAL II binding)	2227:2267	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	57	theme	MAL	2253:2255	arg1	binding					2260:2266	MAL II binding	2253:2266	MAL II binding	2253:2266	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	58	theme	female	698:703	arg1	hamadryas					711:719	14 healthy adult female Papio hamadryas	681:719	14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features	681:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	3	59	theme	ciliated	375:382	arg1	cells					413:417	ciliated and non-ciliated (secretory) cells	375:417	ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent	375:478	The oviductal epithelium consists of ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent.
36290159	5	60	attach	removed	668:674	arg2	Oviducts					637:644	Oviducts	637:644	Oviducts	637:644	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	5	60	attach	removed	668:674	arg1	hamadryas					711:719	14 healthy adult female Papio hamadryas	681:719	14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features	681:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	9	61	from	protrusions	3254:3264	arg1	present					3232:3238	present	3232:3238	present	3232:3238	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	0	62	theme	Papio	84:88	arg1	hamadryas					90:98	Baboon Papio hamadryas	77:98	Baboon Papio hamadryas	77:98	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	12	63	theme	anatomical	3813:3822	arg1	similarity					3824:3833	their anatomical similarity	3807:3833	their anatomical similarity to humans	3807:3843	The findings add new data concerning baboons which, due to their anatomical similarity to humans, make an excellent model for female reproduction studies.
36290159	7	64	theme	oviductal	1705:1713	arg1	segments					1715:1722	the other oviductal segments	1695:1722	the other oviductal segments	1695:1722	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	65	theme	ciliated	1578:1585	arg1	cells					1587:1591	ciliated cells	1578:1591	ciliated cells	1578:1591	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	66	theme	luteal	2902:2907	arg1	oviducts					2886:2893	the entire oviducts	2875:2893	the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2875:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	67	theme	oviductal	2032:2040	arg1	epithelium					2042:2051	the oviductal epithelium	2028:2051	the oviductal epithelium during the entire menstrual cycle	2028:2085	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	68	theme	apical	3130:3135	arg1	surface					3137:3143	the apical surface	3126:3143	the apical surface of fimbriae	3126:3155	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	69	theme	sex	775:777	arg1	levels					787:792	the sex hormone levels	771:792	the sex hormone levels	771:792	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	0	70	theme	Pattern	38:44	arg1	Modification					0:11	Modification	0:11	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.	0:126	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	9	71	theme	sialic	2239:2244	arg1	acids					2246:2250	α2,3-linked sialic acids	2227:2250	α2,3-linked sialic acids (MAL II binding)	2227:2267	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	71	theme	sialic	2239:2244	arg1	binding					2260:2266	MAL II binding	2253:2266	MAL II binding	2253:2266	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	72	theme	fluorescent	1083:1093	arg1	lectins					1095:1101	nine fluorescent lectins	1078:1101	nine fluorescent lectins for glycoconjugate characterization	1078:1137	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	3	73	theme	secretory	402:410	arg1	cells					413:417	ciliated and non-ciliated (secretory) cells	375:417	ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent	375:478	The oviductal epithelium consists of ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent.
36290159	9	74	theme	preovulatory	2913:2924	arg1	phases					2926:2931	preovulatory phases	2913:2931	preovulatory phases	2913:2931	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	0	75	theme	Epithelium	63:72	arg1	Morphology					16:25	Morphology	16:25	Morphology	16:25	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	0	75	theme	Epithelium	63:72	arg1	Pattern					38:44	Glycan Pattern	31:44	Glycan Pattern	31:44	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	6	76	from	wax	990:992	arg1	embedded					969:976	embedded	969:976	embedded	969:976	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	77	gly	fucosylated	3053:3063	arg1	glycans					3065:3071	(iv) fucosylated glycans	3048:3071	(iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	3048:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	78	link	α2,3-linked	2227:2237	arg1	acids					2246:2250	α2,3-linked sialic acids	2227:2250	α2,3-linked sialic acids (MAL II binding)	2227:2267	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	78	link	α2,3-linked	2227:2237	arg1	binding					2260:2266	MAL II binding	2253:2266	MAL II binding	2253:2266	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	12	79	theme	new	3765:3767	arg1	data					3769:3772	new data	3765:3772	new data concerning baboons which, due to their anatomical similarity to humans, make an excellent model for female reproduction studies	3765:3900	The findings add new data concerning baboons which, due to their anatomical similarity to humans, make an excellent model for female reproduction studies.
36290159	7	80	theme	preovulatory	1363:1374	arg1	phase					1376:1380	the preovulatory phase	1359:1380	the preovulatory phase	1359:1380	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	3	81	theme	non-ciliated	388:399	arg1	cells					413:417	ciliated and non-ciliated (secretory) cells	375:417	ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent	375:478	The oviductal epithelium consists of ciliated and non-ciliated (secretory) cells whose differentiation and activity are sex hormone-dependent.
36290159	4	82	theme	glycan	559:564	arg1	composition					566:576	the glycan composition	555:576	the glycan composition of baboon oviductal epithelium during the menstrual cycle	555:634	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	7	83	dep	cells	1242:1246	arg1	ii					1441:1442	ii	1441:1442	ii	1441:1442	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	83	dep	cells	1242:1246	arg1	indistinguishable					1253:1269	indistinguishable	1253:1269	indistinguishable	1253:1269	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	83	dep	cells	1242:1246	arg1	height					1460:1465	the epithelium height	1445:1465	the epithelium height	1445:1465	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	83	dep	cells	1242:1246	arg1	iii					1559:1561	iii	1559:1561	iii	1559:1561	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	83	dep	cells	1242:1246	arg1	higher					1485:1490	higher	1485:1490	higher	1485:1490	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	84	theme	entire	2064:2069	arg1	cycle					2081:2085	the entire menstrual cycle	2060:2085	the entire menstrual cycle	2060:2085	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	85	theme	entire	2294:2299	arg1	surface					2311:2317	the entire oviductal surface	2290:2317	the entire oviductal surface	2290:2317	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	0	86	theme	Morphology	16:25	arg1	Modification					0:11	Modification	0:11	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.	0:126	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	9	87	with	glycans	3065:3071	arg1	fucose					3090:3095	α1,2-linked fucose	3078:3095	α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells	3078:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	87	with	glycans	3065:3071	arg1	reactivity					3102:3111	LTA reactivity	3098:3111	LTA reactivity	3098:3111	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	88	link	O-linked	2568:2575	arg1	sialoglycans					2577:2588	O-linked sialoglycans	2568:2588	O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2568:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	88	link	O-linked	2568:2575	arg1	antigen					2691:2697	Tn antigen	2688:2697	Tn antigen	2688:2697	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	88	link	O-linked	2568:2575	arg1	KsSBA					2701:2705	KsSBA	2701:2705	KsSBA	2701:2705	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	89	theme	entire	2726:2731	arg1	surface					2743:2749	the entire oviductal surface	2722:2749	the entire oviductal surface during all phases of the menstrual cycle	2722:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	90	attach	present	3232:3238	arg2	fucose					3204:3209	α1,3/4-linked fucose	3190:3209	α1,3/4-linked fucose (UEA I binders)	3190:3225	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	90	attach	present	3232:3238	arg1	protrusions					3254:3264	the apical protrusions	3243:3264	the apical protrusions of the ampulla non-ciliated cells	3243:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	90	attach	present	3232:3238	arg2	binders					3218:3224	UEA I binders	3212:3224	UEA I binders	3212:3224	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	91	dep	indistinguishable	1253:1269	arg1	ii					1441:1442	ii	1441:1442	ii	1441:1442	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	91	dep	indistinguishable	1253:1269	arg1	indistinguishable					1253:1269	indistinguishable	1253:1269	indistinguishable	1253:1269	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	91	dep	indistinguishable	1253:1269	arg1	height					1460:1465	the epithelium height	1445:1465	the epithelium height	1445:1465	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	91	dep	indistinguishable	1253:1269	arg1	higher					1485:1490	higher	1485:1490	higher	1485:1490	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	92	theme	luteal	3168:3173	arg1	phase					3175:3179	the luteal phase	3164:3179	the luteal phase	3164:3179	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	93	theme	entire	1193:1198	arg1	oviduct					1200:1206	the entire oviduct	1189:1206	the entire oviduct	1189:1206	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	0	94	theme	Glycan	31:36	arg1	Pattern					38:44	Glycan Pattern	31:44	Glycan Pattern	31:44	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	9	95	theme	apical	3311:3316	arg1	surface					3318:3324	the apical surface	3307:3324	the apical surface of isthmus during the preovulatory phase	3307:3365	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	96	from	glycans	3065:3071	arg1	surface					3318:3324	the apical surface	3307:3324	the apical surface of isthmus during the preovulatory phase	3307:3365	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	97	theme	apical	3393:3398	arg1	surface					3400:3406	the isthmus apical surface	3381:3406	the isthmus apical surface of follicular-phase oviducts	3381:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	4	98	theme	first	520:524	arg1	time					526:529	the first time	516:529	the first time	516:529	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	9	99	theme	α1,3/4-linked	3190:3202	arg1	fucose					3204:3209	α1,3/4-linked fucose	3190:3209	α1,3/4-linked fucose (UEA I binders)	3190:3225	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	99	theme	α1,3/4-linked	3190:3202	arg1	binders					3218:3224	UEA I binders	3212:3224	UEA I binders	3212:3224	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	100	theme	preovulatory	2335:2346	arg1	phase					2348:2352	the preovulatory phase	2331:2352	the preovulatory phase	2331:2352	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	101	link	O-linked	2818:2825	arg1	staining					2840:2847	HPA staining	2836:2847	HPA staining	2836:2847	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	101	link	O-linked	2818:2825	arg1	glycans					2827:2833	O-linked glycans	2818:2833	O-linked glycans (HPA staining)	2818:2848	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	102	dep	glycans	3065:3071	arg1	iv					3049:3050	iv	3049:3050	iv	3049:3050	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	4	103	theme	menstrual	620:628	arg1	cycle					630:634	the menstrual cycle	616:634	the menstrual cycle	616:634	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	9	104	dep	glycocalyx	2531:2540	arg1	found					2713:2717	found	2713:2717	were found in the entire oviductal surface during all phases of the menstrual cycle	2708:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	105	theme	Tn	2688:2689	arg1	sialoglycans					2577:2588	O-linked sialoglycans	2568:2588	O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2568:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	105	theme	Tn	2688:2689	arg1	antigen					2691:2697	Tn antigen	2688:2697	Tn antigen	2688:2697	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	106	theme	oviducts	3428:3435	arg1	surface					3400:3406	the isthmus apical surface	3381:3406	the isthmus apical surface of follicular-phase oviducts	3381:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	107	theme	O-linked	2568:2575	arg1	sialoglycans					2577:2588	O-linked sialoglycans	2568:2588	O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2568:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	107	theme	O-linked	2568:2575	arg1	antigen					2691:2697	Tn antigen	2688:2697	Tn antigen	2688:2697	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	107	theme	O-linked	2568:2575	arg1	KsSBA					2701:2705	KsSBA	2701:2705	KsSBA	2701:2705	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	108	theme	other	1530:1534	arg1	phases					1546:1551	other menstrual phases	1530:1551	other menstrual phases	1530:1551	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	109	theme	menstrual	2776:2784	arg1	cycle					2786:2790	the menstrual cycle	2772:2790	the menstrual cycle	2772:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	110	theme	luteal	1297:1302	arg1	phases					1304:1309	luteal phases	1297:1309	luteal phases	1297:1309	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	111	theme	non-ciliated	2998:3009	arg1	cells					3011:3015	the isthmus non-ciliated cells	2986:3015	the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2986:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	112	theme	non-ciliated	2139:2150	arg1	cells					2152:2156	non-ciliated cells	2139:2156	non-ciliated cells of the ampulla during the preovulatory phase	2139:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	113	theme	α2,6-linked	2363:2373	arg1	affinity					2385:2392	SNA affinity	2381:2392	SNA affinity	2381:2392	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	113	theme	α2,6-linked	2363:2373	arg1	ones					2375:2378	α2,6-linked ones	2363:2378	α2,6-linked ones (SNA affinity)	2363:2393	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	114	theme	4	942:942	arg1	%					943:943	%	943:943	%	943:943	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	4	115	theme	oviductal	588:596	arg1	epithelium					598:607	baboon oviductal epithelium	581:607	baboon oviductal epithelium during the menstrual cycle	581:634	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	5	116	theme	adult	692:696	arg1	hamadryas					711:719	14 healthy adult female Papio hamadryas	681:719	14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features	681:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	7	117	theme	preovulatory	1499:1510	arg1	phase					1512:1516	the preovulatory phase	1495:1516	the preovulatory phase compared to other menstrual phases	1495:1551	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	118	theme	summarized	1923:1932	arg1	GalNAc					2799:2804	summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc	1923:2804	summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc	1923:2804	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	119	dep	%	943:943	arg1	v/v					946:948	v/v	946:948	v/v	946:948	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	6	120	from	fixed	933:937	arg1	paraformaldehyde					951:966	4% (v/v) paraformaldehyde	942:966	4% (v/v) paraformaldehyde	942:966	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	121	theme	ampulla	2165:2171	arg1	cells					2152:2156	non-ciliated cells	2139:2156	non-ciliated cells of the ampulla during the preovulatory phase	2139:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	122	theme	Histological	829:840	arg1	investigations					842:855	Histological investigations	829:855	Histological investigations	829:855	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	10	123	theme	morphological	3488:3500	arg1	changes					3513:3519	morphological and glycan changes	3488:3519	morphological and glycan changes	3488:3519	These results demonstrate for the first time that morphological and glycan changes occur in the baboon oviductal epithelium during the menstrual cycle.
36290159	7	124	from	presence	1739:1746	arg1	isthmus					1773:1779	the isthmus	1769:1779	the isthmus	1769:1779	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	125	theme	isthmus	2549:2555	arg1	cilia					2557:2561	the isthmus cilia	2545:2561	the isthmus cilia	2545:2561	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	126	theme	O-linked	2818:2825	arg1	staining					2840:2847	HPA staining	2836:2847	HPA staining	2836:2847	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	126	theme	O-linked	2818:2825	arg1	glycans					2827:2833	O-linked glycans	2818:2833	O-linked glycans (HPA staining)	2818:2848	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	127	theme	epithelium	1449:1458	arg1	ii					1441:1442	ii	1441:1442	ii	1441:1442	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	127	theme	epithelium	1449:1458	arg1	indistinguishable					1253:1269	indistinguishable	1253:1269	indistinguishable	1253:1269	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	127	theme	epithelium	1449:1458	arg1	height					1460:1465	the epithelium height	1445:1465	the epithelium height	1445:1465	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	127	theme	epithelium	1449:1458	arg1	higher					1485:1490	higher	1485:1490	higher	1485:1490	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	128	link	α1,3/4-linked	3190:3202	arg1	fucose					3204:3209	α1,3/4-linked fucose	3190:3209	α1,3/4-linked fucose (UEA I binders)	3190:3225	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	128	link	α1,3/4-linked	3190:3202	arg1	binders					3218:3224	UEA I binders	3212:3224	UEA I binders	3212:3224	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	129	theme	cycle	737:741	arg1	phase					743:747	menstrual cycle phase	727:747	menstrual cycle phase	727:747	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	2	130	theme	dynamic	310:316	arg1	fluid					331:335	a dynamic intraluminal fluid	308:335	a dynamic intraluminal fluid	308:335	Its mucosal epithelium is involved in maintaining and modulating a dynamic intraluminal fluid.
36290159	11	131	theme	sex	3608:3610	arg1	fluctuation					3620:3630	the sex hormone fluctuation	3604:3630	the sex hormone fluctuation	3604:3630	Particularly, the sex hormone fluctuation affects the glycan pattern in a region-specific manner, probably related to the function of the oviductal segments.
36290159	9	132	located	present	3232:3238	arg1	protrusions					3254:3264	the apical protrusions	3243:3264	the apical protrusions of the ampulla non-ciliated cells	3243:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	132	located	present	3232:3238	arg2	fucose					3204:3209	α1,3/4-linked fucose	3190:3209	α1,3/4-linked fucose (UEA I binders)	3190:3225	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	132	located	present	3232:3238	arg2	binders					3218:3224	UEA I binders	3212:3224	UEA I binders	3212:3224	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	11	133	theme	hormone	3612:3618	arg1	fluctuation					3620:3630	the sex hormone fluctuation	3604:3630	the sex hormone fluctuation	3604:3630	Particularly, the sex hormone fluctuation affects the glycan pattern in a region-specific manner, probably related to the function of the oviductal segments.
36290159	12	134	theme	reproduction	3881:3892	arg1	studies					3894:3900	female reproduction studies	3874:3900	female reproduction studies	3874:3900	The findings add new data concerning baboons which, due to their anatomical similarity to humans, make an excellent model for female reproduction studies.
36290159	1	135	theme	early	208:212	arg1	development					224:234	early embryonic development	208:234	early embryonic development	208:234	The mammalian oviduct is a highly specialized structure where fertilization and early embryonic development occur.
36290159	9	136	theme	N-linked	1968:1975	arg1	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	136	theme	N-linked	1968:1975	arg1	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	137	theme	glycans	3065:3071	arg1	cells					3011:3015	the isthmus non-ciliated cells	2986:3015	the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2986:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	138	theme	isthmus	3329:3335	arg1	surface					3318:3324	the apical surface	3307:3324	the apical surface of isthmus during the preovulatory phase	3307:3365	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	139	theme	Papio	705:709	arg1	hamadryas					711:719	14 healthy adult female Papio hamadryas	681:719	14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features	681:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	9	140	link	N-linked	1968:1975	arg1	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	140	link	N-linked	1968:1975	arg1	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	141	link	α2,6-linked	2363:2373	arg1	affinity					2385:2392	SNA affinity	2381:2392	SNA affinity	2381:2392	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	141	link	α2,6-linked	2363:2373	arg1	ones					2375:2378	α2,6-linked ones	2363:2378	α2,6-linked ones (SNA affinity)	2363:2393	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	142	dep	expressed	2274:2282	arg1	whereas					2355:2361	whereas	2355:2361	whereas	2355:2361	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	142	dep	expressed	2274:2282	arg1	sialoglycans					2209:2220	sialoglycans	2209:2220	sialoglycans	2209:2220	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	142	dep	expressed	2274:2282	arg1	with					2222:2225	with	2222:2225	with	2222:2225	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	143	theme	α1,2-linked	3078:3088	arg1	fucose					3090:3095	α1,2-linked fucose	3078:3095	α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells	3078:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	143	theme	α1,2-linked	3078:3088	arg1	reactivity					3102:3111	LTA reactivity	3098:3111	LTA reactivity	3098:3111	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	144	gly	high-mannosylated	1950:1966	arg1	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	144	gly	high-mannosylated	1950:1966	arg1	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	145	with	sialoglycans	2577:2588	arg1	acids					2602:2606	sialic acids	2595:2606	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2595:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	146	theme	luteal	2436:2441	arg1	phase					2443:2447	the luteal phase	2432:2447	the luteal phase	2432:2447	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	147	theme	preovulatory	3024:3035	arg1	phase					3037:3041	the preovulatory phase	3020:3041	the preovulatory phase	3020:3041	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	148	theme	terminal	2656:2663	arg1	N-acetylgalactosamine					2665:2685	terminal N-acetylgalactosamine	2656:2685	terminal N-acetylgalactosamine	2656:2685	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	149	theme	A	1990:1990	arg1	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	149	theme	A	1990:1990	arg1	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	150	attach	present	2009:2015	arg2	reactivity					1992:2001	Con A reactivity	1986:2001	Con A reactivity	1986:2001	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	150	attach	present	2009:2015	arg2	glycans					1977:1983	(i) high-mannosylated N-linked glycans	1946:1983	(i) high-mannosylated N-linked glycans (Con A reactivity)	1946:2002	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	150	attach	present	2009:2015	arg1	protrusions					2124:2134	the apical protrusions	2113:2134	the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase	2113:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	151	theme	hormone	779:785	arg1	levels					787:792	the sex hormone levels	771:792	the sex hormone levels	771:792	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	7	152	dep	significantly	1593:1605	arg1	≤					1610:1610	p ≤ 0.05	1608:1615	p ≤ 0.05	1608:1615	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	8	153	theme	glycan	1786:1791	arg1	characterization					1793:1808	The glycan characterization	1782:1808	The glycan characterization	1782:1808	The glycan characterization revealed a complex and region-specific composition during the different phases of the menstrual cycle.
36290159	1	154	theme	mammalian	132:140	arg1	structure					174:182	a highly specialized structure	153:182	a highly specialized structure where fertilization and early embryonic development occur	153:240	The mammalian oviduct is a highly specialized structure where fertilization and early embryonic development occur.
36290159	1	154	theme	mammalian	132:140	arg1	oviduct					142:148	The mammalian oviduct	128:148	The mammalian oviduct	128:148	The mammalian oviduct is a highly specialized structure where fertilization and early embryonic development occur.
36290159	7	155	theme	ciliated	1751:1758	arg1	cells					1760:1764	ciliated cells	1751:1764	ciliated cells	1751:1764	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	10	156	theme	menstrual	3573:3581	arg1	cycle					3583:3587	the menstrual cycle	3569:3587	the menstrual cycle	3569:3587	These results demonstrate for the first time that morphological and glycan changes occur in the baboon oviductal epithelium during the menstrual cycle.
36290159	6	157	dep	and	995:997	arg1	fixed					933:937	fixed	933:937	fixed	933:937	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	7	158	theme	non-ciliated	1391:1402	arg1	cells					1404:1408	the non-ciliated cells	1387:1408	the non-ciliated cells	1387:1408	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	159	theme	non-ciliated	1229:1240	arg1	cells					1242:1246	non-ciliated cells	1229:1246	non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii)	1229:1562	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	0	160	theme	Baboon	77:82	arg1	hamadryas					90:98	Baboon Papio hamadryas	77:98	Baboon Papio hamadryas	77:98	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	9	161	link	α1,2-linked	3078:3088	arg1	fucose					3090:3095	α1,2-linked fucose	3078:3095	α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells	3078:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	161	link	α1,2-linked	3078:3088	arg1	reactivity					3102:3111	LTA reactivity	3098:3111	LTA reactivity	3098:3111	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	162	theme	cells	1587:1591	arg1	ciliated					1216:1223	ciliated	1216:1223	ciliated	1216:1223	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	163	dep	GalNAc	2799:2804	arg1	follows					1937:1943	follows	1937:1943	follows	1937:1943	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	0	164	theme	hamadryas	90:98	arg1	Epithelium					63:72	the Oviductal Epithelium	49:72	the Oviductal Epithelium of Baboon Papio hamadryas	49:98	Modification of Morphology and Glycan Pattern of the Oviductal Epithelium of Baboon Papio hamadryas during the Menstrual Cycle.
36290159	9	165	theme	preovulatory	2470:2481	arg1	phase					2483:2487	the preovulatory phase	2466:2487	the preovulatory phase	2466:2487	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	8	166	theme	complex	1821:1827	arg1	composition					1849:1859	a complex and region-specific composition	1819:1859	a complex and region-specific composition during the different phases of the menstrual cycle	1819:1910	The glycan characterization revealed a complex and region-specific composition during the different phases of the menstrual cycle.
36290159	9	167	with	N-acetylgalactosamine	2665:2685	arg1	acids					2602:2606	sialic acids	2595:2606	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2595:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	168	from	protrusions	2124:2134	arg1	present					2009:2015	present	2009:2015	present	2009:2015	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	169	from	present	2009:2015	arg1	protrusions					2124:2134	the apical protrusions	2113:2134	the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase	2113:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	8	170	theme	region-specific	1833:1847	arg1	composition					1849:1859	a complex and region-specific composition	1819:1859	a complex and region-specific composition during the different phases of the menstrual cycle	1819:1910	The glycan characterization revealed a complex and region-specific composition during the different phases of the menstrual cycle.
36290159	9	171	dep	present	2009:2015	arg1	iii					2794:2796	iii	2794:2796	iii	2794:2796	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	171	dep	present	2009:2015	arg1	expressed					2274:2282	expressed	2274:2282	were expressed along the entire oviductal surface only during the preovulatory phase	2269:2352	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	171	dep	present	2009:2015	arg1	ii					2205:2206	ii	2205:2206	ii	2205:2206	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	172	theme	lectins	1095:1101	arg1	panel					1069:1073	a panel	1067:1073	a panel of nine fluorescent lectins for glycoconjugate characterization	1067:1137	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	11	173	theme	oviductal	3728:3736	arg1	segments					3738:3745	the oviductal segments	3724:3745	the oviductal segments	3724:3745	Particularly, the sex hormone fluctuation affects the glycan pattern in a region-specific manner, probably related to the function of the oviductal segments.
36290159	7	174	theme	other	1699:1703	arg1	segments					1715:1722	the other oviductal segments	1695:1722	the other oviductal segments	1695:1722	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	175	theme	phases	2926:2931	arg1	oviducts					2886:2893	the entire oviducts	2875:2893	the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2875:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	176	theme	fimbriae	3148:3155	arg1	surface					3137:3143	the apical surface	3126:3143	the apical surface of fimbriae	3126:3155	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	8	177	theme	different	1872:1880	arg1	phases					1882:1887	the different phases	1868:1887	the different phases of the menstrual cycle	1868:1910	The glycan characterization revealed a complex and region-specific composition during the different phases of the menstrual cycle.
36290159	4	178	theme	baboon	581:586	arg1	epithelium					598:607	baboon oviductal epithelium	581:607	baboon oviductal epithelium during the menstrual cycle	581:634	In this study, we investigated for the first time both the morphology and the glycan composition of baboon oviductal epithelium during the menstrual cycle.
36290159	6	179	from	embedded	969:976	arg1	wax					990:992	paraffin wax	981:992	paraffin wax	981:992	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	180	theme	menstrual	2071:2079	arg1	cycle					2081:2085	the entire menstrual cycle	2060:2085	the entire menstrual cycle	2060:2085	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	181	attach	linked	2608:2613	arg2	acids					2602:2606	sialic acids	2595:2606	sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA)	2595:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	181	attach	linked	2608:2613	arg1	antigen					2635:2641	T antigen	2633:2641	T antigen	2633:2641	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	181	attach	linked	2608:2613	arg1	KsPNA					2645:2649	KsPNA	2645:2649	KsPNA	2645:2649	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	181	attach	linked	2608:2613	arg1	Galβl,3GalNAc					2618:2630	Galβl,3GalNAc	2618:2630	Galβl,3GalNAc (T antigen) (KsPNA)	2618:2650	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	182	theme	oviductal	2301:2309	arg1	surface					2311:2317	the entire oviductal surface	2290:2317	the entire oviductal surface	2290:2317	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	5	183	theme	vaginal	802:808	arg1	features					819:826	the vaginal cytology features	798:826	the vaginal cytology features	798:826	Oviducts were laparoscopically removed from 14 healthy adult female Papio hamadryas whose menstrual cycle phase was assessed based on the sex hormone levels and the vaginal cytology features.
36290159	9	184	theme	oviductal	2733:2741	arg1	surface					2743:2749	the entire oviductal surface	2722:2749	the entire oviductal surface during all phases of the menstrual cycle	2722:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	185	located	found	2518:2522	arg1	glycocalyx					2531:2540	the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle	2527:2790	the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle	2527:2790	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	185	located	found	2518:2522	arg2	they					2489:2492	they	2489:2492	they	2489:2492	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	186	dep	glycans	1977:1983	arg1	i					1947:1947	i	1947:1947	i	1947:1947	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	187	theme	preovulatory	3348:3359	arg1	phase					3361:3365	the preovulatory phase	3344:3365	the preovulatory phase	3344:3365	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	188	theme	isthmus	3385:3391	arg1	surface					3400:3406	the isthmus apical surface	3381:3406	the isthmus apical surface of follicular-phase oviducts	3381:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	8	189	theme	menstrual	1896:1904	arg1	cycle					1906:1910	the menstrual cycle	1892:1910	the menstrual cycle	1892:1910	The glycan characterization revealed a complex and region-specific composition during the different phases of the menstrual cycle.
36290159	9	190	theme	apical	2964:2969	arg1	protrusions					2971:2981	the apical protrusions	2960:2981	the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2960:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	7	191	dep	ciliated	1216:1223	arg1	the					1212:1214	the	1212:1214	the	1212:1214	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	191	dep	ciliated	1216:1223	arg1	i					1209:1209	i	1209:1209	i	1209:1209	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	7	191	dep	ciliated	1216:1223	arg1	number					1568:1573	the number	1564:1573	the number	1564:1573	The histomorphological analysis revealed that in the entire oviduct (i) the ciliated and non-ciliated cells were indistinguishable during the follicular and luteal phases, whereas they were highly differentiated during the preovulatory phase when the non-ciliated cells exhibited apical protrusions, (ii) the epithelium height was significantly higher in the preovulatory phase compared to other menstrual phases, and (iii) the number of ciliated cells significantly (p ≤ 0.05) increased from the fimbriae to the infundibulum and progressively reduced in the other oviductal segments with the lower presence of ciliated cells in the isthmus.
36290159	9	192	from	surface	3318:3324	arg1	cells					3011:3015	the isthmus non-ciliated cells	2986:3015	the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2986:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	193	with	phase	3037:3041	arg1	fucose					3090:3095	α1,2-linked fucose	3078:3095	α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells	3078:3298	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	193	with	phase	3037:3041	arg1	reactivity					3102:3111	LTA reactivity	3098:3111	LTA reactivity	3098:3111	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	6	194	from	paraformaldehyde	951:966	arg1	fixed					933:937	fixed	933:937	fixed	933:937	Histological investigations were carried out on fimbriae, infundibulum, ampulla, and isthmus separately fixed in 4% (v/v) paraformaldehyde, embedded in paraffin wax, and stained with hematoxylin-eosin for morphological analyses and using a panel of nine fluorescent lectins for glycoconjugate characterization.
36290159	9	195	theme	apical	2117:2122	arg1	protrusions					2124:2134	the apical protrusions	2113:2134	the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase	2113:2201	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	196	theme	follicular-phase	3411:3426	arg1	oviducts					3428:3435	follicular-phase oviducts	3411:3435	follicular-phase oviducts	3411:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	197	theme	isthmus	2990:2996	arg1	cells					3011:3015	the isthmus non-ciliated cells	2986:3015	the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts	2986:3435	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	198	theme	UEA	3212:3214	arg1	fucose					3204:3209	α1,3/4-linked fucose	3190:3209	α1,3/4-linked fucose (UEA I binders)	3190:3225	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	198	theme	UEA	3212:3214	arg1	binders					3218:3224	UEA I binders	3212:3224	UEA I binders	3212:3224	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36290159	9	199	from	phase	3037:3041	arg1	surface					3318:3324	the apical surface	3307:3324	the apical surface of isthmus during the preovulatory phase	3307:3365	It can be summarized as follows: (i) high-mannosylated N-linked glycans (Con A reactivity) were present throughout the oviductal epithelium during the entire menstrual cycle and characteristically in the apical protrusions of non-ciliated cells of the ampulla during the preovulatory phase; (ii) sialoglycans with α2,3-linked sialic acids (MAL II binding) were expressed along the entire oviductal surface only during the preovulatory phase, whereas α2,6-linked ones (SNA affinity) were also detected in the surface of the luteal phase, although during the preovulatory phase they were characteristically found in the glycocalyx of the isthmus cilia, and O-linked sialoglycans with sialic acids linked to Galβl,3GalNAc (T antigen) (KsPNA) and terminal N-acetylgalactosamine (Tn antigen) (KsSBA) were found in the entire oviductal surface during all phases of the menstrual cycle; (iii) GalNAc terminating O-linked glycans (HPA staining) were mainly expressed in the entire oviducts of the luteal and preovulatory phases, and characteristically in the apical protrusions of the isthmus non-ciliated cells of the preovulatory phase; and (iv) fucosylated glycans with α1,2-linked fucose (LTA reactivity) occurred in the apical surface of fimbriae during the luteal phase, whereas α1,3/4-linked fucose (UEA I binders) were present in the apical protrusions of the ampulla non-ciliated cells and in the apical surface of isthmus during the preovulatory phase as well as in the isthmus apical surface of follicular-phase oviducts.
36648986	5	0	from	pathways	779:786	arg1	DRGI					817:820	DRGI	817:820	DRGI	817:820	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	5	0	from	pathways	779:786	arg1	RGI					809:811	RGI	809:811	RGI	809:811	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	7	1	theme	gut	1097:1099	arg1	effect					1123:1128	the gut microbiota modulatory effect	1093:1128	the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1093:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	1	2	theme	high	156:159	arg1	rhamnogalacturonan					161:178	high rhamnogalacturonan I pectic polysaccharides (RGI)	156:209	high rhamnogalacturonan I pectic polysaccharides (RGI)	156:209	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	6	3	theme	better	966:971	arg1	performance					973:983	better performance	966:983	better performance in glucolipid metabolism and energy metabolism	966:1030	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	5	4	from	composition	753:763	arg1	DRGI					817:820	DRGI	817:820	DRGI	817:820	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	5	4	from	composition	753:763	arg1	RGI					809:811	RGI	809:811	RGI	809:811	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	6	5	from	performance	973:983	arg1	metabolism					1021:1030	energy metabolism	1014:1030	energy metabolism	1014:1030	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	6	5	from	performance	973:983	arg1	metabolism					999:1008	glucolipid metabolism	988:1008	glucolipid metabolism	988:1008	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	7	6	theme	molecular	1065:1073	arg1	matters					1082:1088	large molecular weight matters	1059:1088	large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1059:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	1	7	theme	rhamnogalacturonan	161:178	arg1	characteristics					137:151	the fermentation characteristics	120:151	the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI)	120:246	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	6	8	theme	RGI	871:873	arg1	bacteria					859:866	the dominant bacteria	846:866	the dominant bacteria of RGI (such as [Eubacterium]_eligens_group)	846:911	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	6	9	dep	such	876:879	arg1	as					881:882	as	881:882	as	881:882	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	7	10	theme	weight	1075:1080	arg1	matters					1082:1088	large molecular weight matters	1059:1088	large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1059:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	7	11	theme	modulatory	1112:1121	arg1	effect					1123:1128	the gut microbiota modulatory effect	1093:1128	the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1093:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	6	12	theme	dominant	850:857	arg1	bacteria					859:866	the dominant bacteria	846:866	the dominant bacteria of RGI (such as [Eubacterium]_eligens_group)	846:911	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	6	13	theme	glucolipid	988:997	arg1	metabolism					999:1008	glucolipid metabolism	988:1008	glucolipid metabolism	988:1008	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	1	14	theme	pectic	182:187	arg1	polysaccharides					189:203	pectic polysaccharides	182:203	high rhamnogalacturonan I pectic polysaccharides (RGI)	156:209	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	1	14	theme	pectic	182:187	arg1	RGI					206:208	RGI	206:208	RGI	206:208	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	0	15	theme	Pectic	9:14	arg1	Polysaccharides					16:30	RGI-Type Pectic Polysaccharides	0:30	RGI-Type Pectic Polysaccharides	0:30	RGI-Type Pectic Polysaccharides Modulate Gut Microbiota in a Molecular Weight-Dependent Manner In Vitro.
36648986	7	16	from	matters	1082:1088	arg1	effect					1123:1128	the gut microbiota modulatory effect	1093:1128	the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1093:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	5	17	dep	composition	753:763	arg1	the					749:751	the	749:751	the	749:751	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	4	18	theme	Bacteroides	651:661	arg1	development					636:646	the development	632:646	the development of Bacteroides, Bifidobacterium, and Lactobacillus	632:697	Both of them reduced the Firmicutes/Bacteroidetes ratio and promoted the development of Bacteroides, Bifidobacterium, and Lactobacillus, bringing benefits to the gut ecosystem.
36648986	0	19	theme	RGI-Type	0:7	arg1	Polysaccharides					16:30	RGI-Type Pectic Polysaccharides	0:30	RGI-Type Pectic Polysaccharides	0:30	RGI-Type Pectic Polysaccharides Modulate Gut Microbiota in a Molecular Weight-Dependent Manner In Vitro.
36648986	2	20	dep	11.6	413:416	arg1	to					410:411	to	410:411	to	410:411	As a result, the Mw of RGI decreased from 246.8 to 11.6 kDa, and the branches were broken dramatically.
36648986	1	21	dep	rhamnogalacturonan	161:178	arg1	polysaccharides					189:203	pectic polysaccharides	182:203	high rhamnogalacturonan I pectic polysaccharides (RGI)	156:209	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	1	21	dep	rhamnogalacturonan	161:178	arg1	RGI					206:208	RGI	206:208	RGI	206:208	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	6	22	dep	[Eubacterium	884:895	arg1	_eligens_group					897:910	_eligens_group	897:910	_eligens_group	897:910	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	5	23	theme	microbiota	795:804	arg1	composition					753:763	composition	753:763	composition	753:763	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	5	23	theme	microbiota	795:804	arg1	pathways					779:786	metabolic pathways	769:786	metabolic pathways	769:786	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	1	24	theme	human	268:272	arg1	model					299:303	a human fecal batch-fermentation model	266:303	a human fecal batch-fermentation model	266:303	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	7	25	theme	polysaccharides	1149:1163	arg1	effect					1123:1128	the gut microbiota modulatory effect	1093:1128	the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1093:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	1	26	theme	fecal	274:278	arg1	model					299:303	a human fecal batch-fermentation model	266:303	a human fecal batch-fermentation model	266:303	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	4	27	theme	gut	725:727	arg1	ecosystem					729:737	the gut ecosystem	721:737	the gut ecosystem	721:737	Both of them reduced the Firmicutes/Bacteroidetes ratio and promoted the development of Bacteroides, Bifidobacterium, and Lactobacillus, bringing benefits to the gut ecosystem.
36648986	4	28	theme	Firmicutes/Bacteroidetes	588:611	arg1	ratio					613:617	the Firmicutes/Bacteroidetes ratio	584:617	the Firmicutes/Bacteroidetes ratio	584:617	Both of them reduced the Firmicutes/Bacteroidetes ratio and promoted the development of Bacteroides, Bifidobacterium, and Lactobacillus, bringing benefits to the gut ecosystem.
36648986	1	29	theme	batch-fermentation	280:297	arg1	model					299:303	a human fecal batch-fermentation model	266:303	a human fecal batch-fermentation model	266:303	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	6	30	theme	energy	1014:1019	arg1	metabolism					1021:1030	energy metabolism	1014:1030	energy metabolism	1014:1030	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	2	31	theme	RGI	385:387	arg1	Mw					379:380	the Mw	375:380	the Mw of RGI	375:387	As a result, the Mw of RGI decreased from 246.8 to 11.6 kDa, and the branches were broken dramatically.
36648986	0	32	theme	Gut	41:43	arg1	Microbiota					45:54	Gut Microbiota	41:54	Gut Microbiota	41:54	RGI-Type Pectic Polysaccharides Modulate Gut Microbiota in a Molecular Weight-Dependent Manner In Vitro.
36648986	7	33	theme	RGI-type	1133:1140	arg1	polysaccharides					1149:1163	RGI-type pectic polysaccharides	1133:1163	RGI-type pectic polysaccharides	1133:1163	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	7	34	theme	pectic	1142:1147	arg1	polysaccharides					1149:1163	RGI-type pectic polysaccharides	1133:1163	RGI-type pectic polysaccharides	1133:1163	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	1	35	theme	free-radical	215:226	arg1	DRGI					242:245	DRGI	242:245	DRGI	242:245	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	1	35	theme	free-radical	215:226	arg1	RGI					237:239	free-radical degraded RGI	215:239	free-radical degraded RGI (DRGI)	215:246	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	5	36	theme	metabolic	769:777	arg1	pathways					779:786	metabolic pathways	769:786	metabolic pathways	769:786	However, the composition and metabolic pathways of the microbiota in RGI and DRGI were different.
36648986	6	37	theme	carbohydrate	929:940	arg1	utilization					942:952	carbohydrate utilization	929:952	carbohydrate utilization	929:952	Most of the dominant bacteria of RGI (such as [Eubacterium]_eligens_group) participated in carbohydrate utilization, leading to better performance in glucolipid metabolism and energy metabolism.
36648986	7	38	theme	large	1059:1063	arg1	matters					1082:1088	large molecular weight matters	1059:1088	large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1059:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	7	39	theme	microbiota	1101:1110	arg1	effect					1123:1128	the gut microbiota modulatory effect	1093:1128	the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro	1093:1172	This work elucidated that large molecular weight matters in the gut microbiota modulatory effect of RGI-type pectic polysaccharides in vitro.
36648986	4	40	theme	Lactobacillus	685:697	arg1	development					636:646	the development	632:646	the development of Bacteroides, Bifidobacterium, and Lactobacillus	632:697	Both of them reduced the Firmicutes/Bacteroidetes ratio and promoted the development of Bacteroides, Bifidobacterium, and Lactobacillus, bringing benefits to the gut ecosystem.
36648986	1	41	theme	degraded	228:235	arg1	DRGI					242:245	DRGI	242:245	DRGI	242:245	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	1	41	theme	degraded	228:235	arg1	RGI					237:239	free-radical degraded RGI	215:239	free-radical degraded RGI (DRGI)	215:246	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	1	42	theme	fermentation	124:135	arg1	characteristics					137:151	the fermentation characteristics	120:151	the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI)	120:246	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	1	43	theme	RGI	237:239	arg1	characteristics					137:151	the fermentation characteristics	120:151	the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI)	120:246	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36648986	0	44	theme	Weight-Dependent	71:86	arg1	Manner					88:93	a Molecular Weight-Dependent Manner	59:93	a Molecular Weight-Dependent Manner	59:93	RGI-Type Pectic Polysaccharides Modulate Gut Microbiota in a Molecular Weight-Dependent Manner In Vitro.
36648986	4	45	theme	Bifidobacterium	664:678	arg1	development					636:646	the development	632:646	the development of Bacteroides, Bifidobacterium, and Lactobacillus	632:697	Both of them reduced the Firmicutes/Bacteroidetes ratio and promoted the development of Bacteroides, Bifidobacterium, and Lactobacillus, bringing benefits to the gut ecosystem.
36648986	0	46	theme	Molecular	61:69	arg1	Manner					88:93	a Molecular Weight-Dependent Manner	59:93	a Molecular Weight-Dependent Manner	59:93	RGI-Type Pectic Polysaccharides Modulate Gut Microbiota in a Molecular Weight-Dependent Manner In Vitro.
36648986	1	47	theme	structural	316:325	arg1	properties					327:336	their structural properties	310:336	their structural properties	310:336	In this study, the fermentation characteristics of high rhamnogalacturonan I pectic polysaccharides (RGI) and free-radical degraded RGI (DRGI) were evaluated by a human fecal batch-fermentation model, and their structural properties were also investigated.
36336155	0	0	theme	water	83:87	arg1	treatment					89:97	water treatment	83:97	water treatment	83:97	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	4	1	dep	indicated	599:607	arg1	reduce					647:652	reduce	647:652	indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption	599:719	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	1	2	theme	biomass	145:151	arg1	material					163:170	a biomass composite material	143:170	a biomass composite material (CS@NC@PA-Na)	143:184	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	2	theme	biomass	145:151	arg1	PA-Na					179:183	CS@NC@PA-Na	173:183	CS@NC@PA-Na	173:183	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	5	3	theme	%	742:742	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	2	4	theme	prepared	271:278	arg1	products					280:287	The prepared products	267:287	The prepared products	267:287	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	5	theme	photoelectron	435:447	arg1	XPS					463:465	XPS	463:465	XPS	463:465	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	5	theme	photoelectron	435:447	arg1	spectrometry					449:460	X-ray photoelectron spectrometry	429:460	X-ray photoelectron spectrometry (XPS)	429:466	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	6	dep	transform	389:397	arg1	infrared					399:406	infrared	399:406	transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD)	389:494	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	5	7	theme	oxygen	784:789	arg1	value					803:807	the limiting oxygen index (LOI) value	771:807	the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %	771:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	4	8	theme	@	614:614	arg1	50 mg					622:626	50 mg	622:626	50 mg	622:626	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	4	8	theme	@	614:614	arg1	PA-Na					615:619	CS@NC@PA-Na	609:619	CS@NC@PA-Na (50 mg)	609:627	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	2	9	theme	X-ray	429:433	arg1	XPS					463:465	XPS	463:465	XPS	463:465	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	9	theme	X-ray	429:433	arg1	spectrometry					449:460	X-ray photoelectron spectrometry	429:460	X-ray photoelectron spectrometry (XPS)	429:466	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	5	10	theme	heat/smoke	877:886	arg1	rate					896:899	the peak heat/smoke release rate	868:899	the peak heat/smoke release rate by 29.5 and 33.3 %, respectively	868:932	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	2	11	dep	Fourier	381:387	arg1	transform					389:397	transform	389:397	transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD)	389:494	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	5	12	theme	index	791:795	arg1	value					803:807	the limiting oxygen index (LOI) value	771:807	the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %	771:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	5	13	dep	30.1 	847:851	arg1	to					844:845	to	844:845	to	844:845	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	5	14	theme	release	888:894	arg1	rate					896:899	the peak heat/smoke release rate	868:899	the peak heat/smoke release rate by 29.5 and 33.3 %, respectively	868:932	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	3	15	dep	safety	512:517	arg1	The					497:499	The	497:499	The	497:499	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	6	16	theme	CS	945:946	arg1	PA-Na					951:955	CS@NC@PA-Na	945:955	CS@NC@PA-Na	945:955	Moreover, CS@NC@PA-Na also exhibited excellent antibacterial effect.
36336155	1	17	theme	CS	173:174	arg1	material					163:170	a biomass composite material	143:170	a biomass composite material (CS@NC@PA-Na)	143:184	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	17	theme	CS	173:174	arg1	PA-Na					179:183	CS@NC@PA-Na	173:183	CS@NC@PA-Na	173:183	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	7	18	theme	multi-functional	1099:1114	arg1	materials					1133:1141	multi-functional CS-based biomass materials	1099:1141	multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1099:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	0	19	theme	antibacterial	103:115	arg1	properties					117:126	antibacterial properties	103:126	antibacterial properties	103:126	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	5	20	theme	CS	744:745	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	7	21	dep	fields	1169:1174	arg1	fields					1169:1174	the fields	1165:1174	the fields of fire safety and environmental conservation	1165:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	7	21	dep	fields	1169:1174	arg1	safety					1184:1189	safety	1184:1189	safety	1184:1189	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	7	21	dep	fields	1169:1174	arg1	conservation					1209:1220	environmental conservation	1195:1220	environmental conservation	1195:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	7	22	theme	large-scale	1073:1083	arg1	production					1085:1094	large-scale production	1073:1094	large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1073:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	5	23	theme	LOI	798:800	arg1	value					803:807	the limiting oxygen index (LOI) value	771:807	the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %	771:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	5	24	dep	Meanwhile	722:730	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	2	25	theme	electron	320:327	arg1	SEM					341:343	SEM	341:343	SEM	341:343	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	25	theme	electron	320:327	arg1	microscopy					329:338	scanning electron microscopy	311:338	scanning electron microscopy (SEM)	311:344	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	25	theme	electron	320:327	arg1	Fourier					381:387	Fourier	381:387	Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD)	381:494	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	25	theme	electron	320:327	arg1	analysis					365:372	thermogravimetric analysis	347:372	thermogravimetric analysis (TGA)	347:378	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	4	26	theme	30 min	703:708	arg1	adsorption					710:719	30 min adsorption	703:719	30 min adsorption	703:719	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	4	27	theme	NC	612:613	arg1	50 mg					622:626	50 mg	622:626	50 mg	622:626	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	4	27	theme	NC	612:613	arg1	PA-Na					615:619	CS@NC@PA-Na	609:619	CS@NC@PA-Na (50 mg)	609:627	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	2	28	theme	scanning	311:318	arg1	SEM					341:343	SEM	341:343	SEM	341:343	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	28	theme	scanning	311:318	arg1	microscopy					329:338	scanning electron microscopy	311:338	scanning electron microscopy (SEM)	311:344	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	28	theme	scanning	311:318	arg1	Fourier					381:387	Fourier	381:387	Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD)	381:494	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	28	theme	scanning	311:318	arg1	analysis					365:372	thermogravimetric analysis	347:372	thermogravimetric analysis (TGA)	347:378	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	4	29	theme	@	611:611	arg1	50 mg					622:626	50 mg	622:626	50 mg	622:626	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	4	29	theme	@	611:611	arg1	PA-Na					615:619	CS@NC@PA-Na	609:619	CS@NC@PA-Na (50 mg)	609:627	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	1	30	theme	@	175:175	arg1	material					163:170	a biomass composite material	143:170	a biomass composite material (CS@NC@PA-Na)	143:184	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	30	theme	@	175:175	arg1	PA-Na					179:183	CS@NC@PA-Na	173:183	CS@NC@PA-Na	173:183	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	7	31	theme	biomass	1125:1131	arg1	materials					1133:1141	multi-functional CS-based biomass materials	1099:1141	multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1099:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	6	32	theme	excellent	972:980	arg1	effect					996:1001	excellent antibacterial effect	972:1001	excellent antibacterial effect	972:1001	Moreover, CS@NC@PA-Na also exhibited excellent antibacterial effect.
36336155	5	33	theme	resin	818:822	arg1	value					803:807	the limiting oxygen index (LOI) value	771:807	the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %	771:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	1	34	theme	NC	176:177	arg1	material					163:170	a biomass composite material	143:170	a biomass composite material (CS@NC@PA-Na)	143:184	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	34	theme	NC	176:177	arg1	PA-Na					179:183	CS@NC@PA-Na	173:183	CS@NC@PA-Na	173:183	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	2	35	theme	thermogravimetric	347:363	arg1	TGA					375:377	TGA	375:377	TGA	375:377	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	35	theme	thermogravimetric	347:363	arg1	microscopy					329:338	scanning electron microscopy	311:338	scanning electron microscopy (SEM)	311:344	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	35	theme	thermogravimetric	347:363	arg1	analysis					365:372	thermogravimetric analysis	347:372	thermogravimetric analysis (TGA)	347:378	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	7	36	theme	fire	1179:1182	arg1	fields					1169:1174	the fields	1165:1174	the fields of fire safety and environmental conservation	1165:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	7	36	theme	fire	1179:1182	arg1	safety					1184:1189	safety	1184:1189	safety	1184:1189	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	7	36	theme	fire	1179:1182	arg1	conservation					1209:1220	environmental conservation	1195:1220	environmental conservation	1195:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	6	37	theme	NC	948:949	arg1	PA-Na					951:955	CS@NC@PA-Na	945:955	CS@NC@PA-Na	945:955	Moreover, CS@NC@PA-Na also exhibited excellent antibacterial effect.
36336155	1	38	theme	composite	153:161	arg1	material					163:170	a biomass composite material	143:170	a biomass composite material (CS@NC@PA-Na)	143:184	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	38	theme	composite	153:161	arg1	PA-Na					179:183	CS@NC@PA-Na	173:183	CS@NC@PA-Na	173:183	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	7	39	used	used	1157:1160	arg2	materials					1133:1141	multi-functional CS-based biomass materials	1099:1141	multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1099:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	1	40	theme	@	178:178	arg1	material					163:170	a biomass composite material	143:170	a biomass composite material (CS@NC@PA-Na)	143:184	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	40	theme	@	178:178	arg1	PA-Na					179:183	CS@NC@PA-Na	173:183	CS@NC@PA-Na	173:183	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	0	41	theme	biomass	46:52	arg1	composites					54:63	chitosan-based biomass composites	31:63	chitosan-based biomass composites	31:63	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	3	42	theme	CS	555:556	arg1	PA-Na					561:565	the CS@NC@PA-Na	551:565	the CS@NC@PA-Na	551:565	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	4	43	theme	methyl	675:680	arg1	orange					682:687	methyl orange	675:687	methyl orange	675:687	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	7	44	theme	eco-friendly	1050:1061	arg1	route					1063:1067	an efficient, feasible and eco-friendly route	1023:1067	an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1023:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	0	45	theme	chitosan-based	31:44	arg1	composites					54:63	chitosan-based biomass composites	31:63	chitosan-based biomass composites	31:63	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	5	46	theme	composite	824:832	arg1	resin					818:822	epoxy resin	812:822	epoxy resin composite from 24.5 to 30.1 %	812:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	1	47	theme	sodium	243:248	arg1	PA-Na					259:263	PA-Na	259:263	PA-Na	259:263	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	1	47	theme	sodium	243:248	arg1	phytate					250:256	sodium phytate	243:256	sodium phytate (PA-Na)	243:264	In this work, a biomass composite material (CS@NC@PA-Na) was prepared from chitosan (CS), nano-cellulose (NC) and sodium phytate (PA-Na).
36336155	5	48	theme	peak	872:875	arg1	rate					896:899	the peak heat/smoke release rate	868:899	the peak heat/smoke release rate by 29.5 and 33.3 %, respectively	868:932	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	6	49	theme	antibacterial	982:994	arg1	effect					996:1001	excellent antibacterial effect	972:1001	excellent antibacterial effect	972:1001	Moreover, CS@NC@PA-Na also exhibited excellent antibacterial effect.
36336155	0	50	with	application	16:26	arg1	safety					75:80	fire safety	70:80	fire safety	70:80	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	0	50	with	application	16:26	arg1	treatment					89:97	water treatment	83:97	water treatment	83:97	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	0	50	with	application	16:26	arg1	properties					117:126	antibacterial properties	103:126	antibacterial properties	103:126	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	5	51	theme	@	746:746	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	0	52	theme	composites	54:63	arg1	application					16:26	application	16:26	application	16:26	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	0	52	theme	composites	54:63	arg1	Fabrication					0:10	Fabrication	0:10	Fabrication	0:10	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	6	53	theme	@	947:947	arg1	PA-Na					951:955	CS@NC@PA-Na	945:955	CS@NC@PA-Na	945:955	Moreover, CS@NC@PA-Na also exhibited excellent antibacterial effect.
36336155	3	54	theme	@	560:560	arg1	PA-Na					561:565	the CS@NC@PA-Na	551:565	the CS@NC@PA-Na	551:565	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	4	55	theme	orange	682:687	arg1	concentration					658:670	the concentration	654:670	the concentration of methyl orange	654:687	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	7	56	theme	feasible	1037:1044	arg1	route					1063:1067	an efficient, feasible and eco-friendly route	1023:1067	an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1023:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	5	57	theme	NC	747:748	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	6	58	theme	@	950:950	arg1	PA-Na					951:955	CS@NC@PA-Na	945:955	CS@NC@PA-Na	945:955	Moreover, CS@NC@PA-Na also exhibited excellent antibacterial effect.
36336155	2	59	theme	X-ray	472:476	arg1	XRD					491:493	XRD	491:493	XRD	491:493	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	2	59	theme	X-ray	472:476	arg1	diffraction					478:488	X-ray diffraction	472:488	X-ray diffraction (XRD)	472:494	The prepared products were characterized by scanning electron microscopy (SEM), thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectrometry (XPS) and X-ray diffraction (XRD).
36336155	3	60	theme	PA-Na	561:565	arg1	safety					512:517	fire/water safety	501:517	fire/water safety	501:517	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	3	60	theme	PA-Na	561:565	arg1	properties					537:546	antimicrobial properties	523:546	antimicrobial properties	523:546	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	7	61	theme	materials	1133:1141	arg1	production					1085:1094	large-scale production	1073:1094	large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1073:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	0	62	with	Fabrication	0:10	arg1	safety					75:80	fire safety	70:80	fire safety	70:80	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	0	62	with	Fabrication	0:10	arg1	treatment					89:97	water treatment	83:97	water treatment	83:97	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	0	62	with	Fabrication	0:10	arg1	properties					117:126	antibacterial properties	103:126	antibacterial properties	103:126	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	4	63	theme	CS	609:610	arg1	50 mg					622:626	50 mg	622:626	50 mg	622:626	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	4	63	theme	CS	609:610	arg1	PA-Na					615:619	CS@NC@PA-Na	609:619	CS@NC@PA-Na (50 mg)	609:627	The results indicated CS@NC@PA-Na (50 mg) could effectively reduce the concentration of methyl orange by 85 % under 30 min adsorption.
36336155	7	64	theme	environmental	1195:1207	arg1	fields					1169:1174	the fields	1165:1174	the fields of fire safety and environmental conservation	1165:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	7	64	theme	environmental	1195:1207	arg1	conservation					1209:1220	environmental conservation	1195:1220	environmental conservation	1195:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	3	65	theme	@	557:557	arg1	PA-Na					561:565	the CS@NC@PA-Na	551:565	the CS@NC@PA-Na	551:565	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	3	66	theme	antimicrobial	523:535	arg1	properties					537:546	antimicrobial properties	523:546	antimicrobial properties	523:546	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	5	67	theme	@	749:749	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	5	68	from	%	852:852	arg1	composite					824:832	composite	824:832	composite	824:832	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	3	69	theme	NC	558:559	arg1	PA-Na					561:565	the CS@NC@PA-Na	551:565	the CS@NC@PA-Na	551:565	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	3	70	theme	fire/water	501:510	arg1	safety					512:517	fire/water safety	501:517	fire/water safety	501:517	The fire/water safety and antimicrobial properties of the CS@NC@PA-Na were fully studied.
36336155	5	71	theme	limiting	775:782	arg1	value					803:807	the limiting oxygen index (LOI) value	771:807	the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %	771:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	7	72	theme	CS-based	1116:1123	arg1	materials					1133:1141	multi-functional CS-based biomass materials	1099:1141	multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1099:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	0	73	theme	fire	70:73	arg1	safety					75:80	fire safety	70:80	fire safety	70:80	Fabrication and application of chitosan-based biomass composites with fire safety, water treatment and antibacterial properties.
36336155	5	74	theme	epoxy	812:816	arg1	resin					818:822	epoxy resin	812:822	epoxy resin composite from 24.5 to 30.1 %	812:852	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
36336155	7	75	theme	efficient	1026:1034	arg1	route					1063:1067	an efficient, feasible and eco-friendly route	1023:1067	an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation	1023:1220	This work provides an efficient, feasible and eco-friendly route for large-scale production of multi-functional CS-based biomass materials that could be used in the fields of fire safety and environmental conservation.
36336155	5	76	theme	5 wt	738:741	arg1	PA-Na					750:754	5 wt% CS@NC@PA-Na	738:754	5 wt% CS@NC@PA-Na	738:754	Meanwhile, only 5 wt% CS@NC@PA-Na could increase the limiting oxygen index (LOI) value of epoxy resin composite from 24.5 to 30.1 %, and decrease the peak heat/smoke release rate by 29.5 and 33.3 %, respectively.
35460266	5	0	dep	Chun	811:814	arg1	Pan					868:870	Pan'	868:871	Pan'	868:871	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	5	0	dep	Chun	811:814	arg1	Shanxi					855:860	Shanxi	855:860	Shanxi	855:860	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	5	0	dep	Chun	811:814	arg1	Henan					838:842	Henan	838:842	Henan	838:842	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	1	1	theme	antioxidant	255:265	arg1	properties					299:308	antioxidant, hypoglycemic and hypolipidemic properties	255:308	antioxidant, hypoglycemic and hypolipidemic properties	255:308	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	5	2	dep	China	804:808	arg1	Zhejiang					820:827	Zhejiang	820:827	Zhejiang	820:827	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	5	2	dep	China	804:808	arg1	Chun					811:814	Chun	811:814	Chun	811:814	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	5	2	dep	China	804:808	arg1	Zhejiang					876:883	Zhejiang	876:883	Zhejiang	876:883	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	11	3	contain	had	1603:1605	arg2	structure					1622:1630	a triple-helix structure	1607:1630	a triple-helix structure	1607:1630	Congo red test indicated that XXHN, DFSX, and PAZJ had a triple-helix structure.
35460266	11	3	contain	had	1603:1605	arg1	DFSX					1588:1591	DFSX	1588:1591	DFSX	1588:1591	Congo red test indicated that XXHN, DFSX, and PAZJ had a triple-helix structure.
35460266	11	3	contain	had	1603:1605	arg1	PAZJ					1598:1601	PAZJ	1598:1601	PAZJ	1598:1601	Congo red test indicated that XXHN, DFSX, and PAZJ had a triple-helix structure.
35460266	11	3	contain	had	1603:1605	arg1	XXHN					1582:1585	XXHN	1582:1585	XXHN	1582:1585	Congo red test indicated that XXHN, DFSX, and PAZJ had a triple-helix structure.
35460266	1	4	theme	hypoglycemic	268:279	arg1	properties					299:308	antioxidant, hypoglycemic and hypolipidemic properties	255:308	antioxidant, hypoglycemic and hypolipidemic properties	255:308	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	13	5	theme	activities	1816:1825	arg1	degrees					1776:1782	different degrees	1766:1782	different degrees of antioxidant and hypoglycemic activities	1766:1825	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	4	6	theme	neutral	674:680	arg1	polysaccharides					682:696	the neutral polysaccharides	670:696	the neutral polysaccharides from different sources of PR	670:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	3	7	theme	monosaccharide	562:575	arg1	composition					577:587	monosaccharide composition	562:587	monosaccharide composition	562:587	This behavior was shown to be closely connected to the chemical structure, monosaccharide composition, and glycosidic bond type.
35460266	4	8	theme	chemical	645:652	arg1	constituents					654:665	the chemical constituents	641:665	the chemical constituents of the neutral polysaccharides from different sources of PR	641:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	10	9	theme	ring	1492:1495	arg1	structure					1497:1505	a pyranose ring structure	1481:1505	a pyranose ring structure	1481:1505	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	1	10	from	polysaccharides	192:206	arg1	rich					184:187	rich	184:187	rich	184:187	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	4	11	theme	PR	724:725	arg1	sources					713:719	different sources	703:719	different sources of PR	703:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	5	12	theme	PAZJ	916:919	arg1	regions					793:799	four different regions	778:799	four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	778:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	3	13	theme	glycosidic	594:603	arg1	type					610:613	glycosidic bond type	594:613	glycosidic bond type	594:613	This behavior was shown to be closely connected to the chemical structure, monosaccharide composition, and glycosidic bond type.
35460266	1	14	from	rich	184:187	arg1	polysaccharides					192:206	polysaccharides	192:206	polysaccharides	192:206	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	13	15	theme	antioxidant	1787:1797	arg1	activities					1816:1825	antioxidant and hypoglycemic activities	1787:1825	antioxidant and hypoglycemic activities	1787:1825	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	15	16	used	used	2122:2125	arg2	agents					2178:2183	hypoglycemic agents	2165:2183	hypoglycemic agents	2165:2183	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	16	used	used	2122:2125	arg2	polysaccharides					2097:2111	neutral polysaccharides	2089:2111	neutral polysaccharides	2089:2111	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	16	used	used	2122:2125	arg2	antioxidants					2148:2159	potential natural antioxidants	2130:2159	potential natural antioxidants	2130:2159	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	13	17	theme	hypoglycemic	1803:1814	arg1	activities					1816:1825	antioxidant and hypoglycemic activities	1787:1825	antioxidant and hypoglycemic activities	1787:1825	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	0	18	theme	different	75:83	arg1	sources					85:91	different sources	75:91	different sources of Polygonatum Mill	75:111	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	5	19	from	regions	793:799	arg1	polysaccharides					751:765	neutral polysaccharides	743:765	neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	743:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	9	20	theme	bond	1399:1402	arg1	existence					1373:1381	the existence	1369:1381	the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides	1369:1447	Infrared spectra illustrated the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides.
35460266	8	21	theme	molecular	1233:1241	arg1	weights					1243:1249	The molecular weights	1229:1249	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ	1229:1279	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	8	21	theme	molecular	1233:1241	arg1	14.119					1286:1291	14.119	1286:1291	14.119	1286:1291	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	11	22	theme	triple-helix	1609:1620	arg1	structure					1622:1630	a triple-helix structure	1607:1630	a triple-helix structure	1607:1630	Congo red test indicated that XXHN, DFSX, and PAZJ had a triple-helix structure.
35460266	9	23	theme	β-glycosidic	1408:1419	arg1	bond					1421:1424	β-glycosidic bond	1408:1424	β-glycosidic bond	1408:1424	Infrared spectra illustrated the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides.
35460266	15	24	theme	natural	2140:2146	arg1	polysaccharides					2097:2111	neutral polysaccharides	2089:2111	neutral polysaccharides	2089:2111	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	24	theme	natural	2140:2146	arg1	antioxidants					2148:2159	potential natural antioxidants	2130:2159	potential natural antioxidants	2130:2159	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	14	25	theme	protein	2045:2051	arg1	content					2053:2059	protein content	2045:2059	protein content	2045:2059	Correlation analysis revealed that the bioactivities of polysaccharides was significantly related to monosaccharide composition, uronic acid, and protein content.
35460266	0	26	theme	Mill	108:111	arg1	sources					85:91	different sources	75:91	different sources of Polygonatum Mill	75:111	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	5	27	theme	neutral	743:749	arg1	polysaccharides					751:765	neutral polysaccharides	743:765	neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	743:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	14	28	theme	uronic	2028:2033	arg1	acid					2035:2038	uronic acid	2028:2038	uronic acid	2028:2038	Correlation analysis revealed that the bioactivities of polysaccharides was significantly related to monosaccharide composition, uronic acid, and protein content.
35460266	14	29	theme	Correlation	1899:1909	arg1	analysis					1911:1918	Correlation analysis	1899:1918	Correlation analysis	1899:1918	Correlation analysis revealed that the bioactivities of polysaccharides was significantly related to monosaccharide composition, uronic acid, and protein content.
35460266	15	30	theme	potential	2130:2138	arg1	polysaccharides					2097:2111	neutral polysaccharides	2089:2111	neutral polysaccharides	2089:2111	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	30	theme	potential	2130:2138	arg1	antioxidants					2148:2159	potential natural antioxidants	2130:2159	potential natural antioxidants	2130:2159	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	8	31	theme	PAZJ	1276:1279	arg1	weights					1243:1249	The molecular weights	1229:1249	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ	1229:1279	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	8	31	theme	PAZJ	1276:1279	arg1	14.119					1286:1291	14.119	1286:1291	14.119	1286:1291	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	10	32	theme	furanose	1527:1534	arg1	structure					1541:1549	a furanose ring structure	1525:1549	a furanose ring structure	1525:1549	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	5	33	theme	different	783:791	arg1	regions					793:799	four different regions	778:799	four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	778:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	5	34	theme	DFSX	906:909	arg1	regions					793:799	four different regions	778:799	four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	778:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	2	35	theme	biological	466:475	arg1	activity					477:484	the biological activity	462:484	the biological activity	462:484	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	0	36	theme	polysaccharides	54:68	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	0	36	theme	polysaccharides	54:68	arg1	bioactivity					31:41	bioactivity	31:41	bioactivity	31:41	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	10	37	contain	possessed	1471:1479	arg2	structure					1497:1505	a pyranose ring structure	1481:1505	a pyranose ring structure	1481:1505	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	10	37	contain	possessed	1471:1479	arg1	CAZJ					1450:1453	CAZJ	1450:1453	CAZJ	1450:1453	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	10	37	contain	possessed	1471:1479	arg1	DFSX					1466:1469	DFSX	1466:1469	DFSX	1466:1469	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	10	37	contain	possessed	1471:1479	arg1	XXHN					1456:1459	XXHN	1456:1459	XXHN	1456:1459	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	14	38	theme	polysaccharides	1955:1969	arg1	bioactivities					1938:1950	the bioactivities	1934:1950	the bioactivities of polysaccharides	1934:1969	Correlation analysis revealed that the bioactivities of polysaccharides was significantly related to monosaccharide composition, uronic acid, and protein content.
35460266	9	39	from	existence	1373:1381	arg1	polysaccharides					1433:1447	the polysaccharides	1429:1447	the polysaccharides	1429:1447	Infrared spectra illustrated the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides.
35460266	5	40	theme	CAZJ	894:897	arg1	regions					793:799	four different regions	778:799	four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	778:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	12	41	theme	X-ray	1633:1637	arg1	diffraction					1639:1649	X-ray diffraction	1633:1649	X-ray diffraction	1633:1649	X-ray diffraction showed that the polysaccharides consisted of crystalline and amorphous regions.
35460266	1	42	theme	traditional	141:151	arg1	product					172:178	a traditional medical and edible product	139:178	a traditional medical and edible product	139:178	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	1	42	theme	traditional	141:151	arg1	rhizoma					125:131	Polygonati rhizoma	114:131	Polygonati rhizoma (PR)	114:136	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	2	43	theme	active	376:381	arg1	ingredients					383:393	the main active ingredients	367:393	the main active ingredients of Polygonatum	367:408	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	0	44	dep	Structure	0:8	arg1	characterization					10:25	characterization	10:25	characterization	10:25	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	7	45	theme	monosaccharide	1140:1153	arg1	composition					1155:1165	monosaccharide composition	1140:1165	monosaccharide composition	1140:1165	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	12	46	dep	crystalline	1696:1706	arg1	regions					1722:1728	regions	1722:1728	regions	1722:1728	X-ray diffraction showed that the polysaccharides consisted of crystalline and amorphous regions.
35460266	5	47	theme	PR	770:771	arg1	polysaccharides					751:765	neutral polysaccharides	743:765	neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	743:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	3	48	theme	chemical	542:549	arg1	structure					551:559	the chemical structure	538:559	the chemical structure	538:559	This behavior was shown to be closely connected to the chemical structure, monosaccharide composition, and glycosidic bond type.
35460266	10	49	contain	had	1521:1523	arg1	PAZJ					1516:1519	PAZJ	1516:1519	PAZJ	1516:1519	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	10	49	contain	had	1521:1523	arg2	structure					1541:1549	a furanose ring structure	1525:1549	a furanose ring structure	1525:1549	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	13	50	from	manner	1849:1854	arg1	range					1892:1896	the 1.0-10.0 mg/mL concentration range	1859:1896	the 1.0-10.0 mg/mL concentration range	1859:1896	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	13	51	theme	1.0-10.0 mg/mL concentration	1863:1890	arg1	range					1892:1896	the 1.0-10.0 mg/mL concentration range	1859:1896	the 1.0-10.0 mg/mL concentration range	1859:1896	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	1	52	theme	edible	165:170	arg1	product					172:178	a traditional medical and edible product	139:178	a traditional medical and edible product	139:178	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	1	52	theme	edible	165:170	arg1	rhizoma					125:131	Polygonati rhizoma	114:131	Polygonati rhizoma (PR)	114:136	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	7	53	from	composition	1155:1165	arg1	sources					1213:1219	different sources	1203:1219	different sources	1203:1219	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	10	54	dep	possessed	1471:1479	arg1	whereas					1508:1514	whereas	1508:1514	whereas	1508:1514	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	4	55	from	constituents	654:665	arg1	sources					713:719	different sources	703:719	different sources of PR	703:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	15	56	theme	neutral	2089:2095	arg1	polysaccharides					2097:2111	neutral polysaccharides	2089:2111	neutral polysaccharides	2089:2111	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	56	theme	neutral	2089:2095	arg1	antioxidants					2148:2159	potential natural antioxidants	2130:2159	potential natural antioxidants	2130:2159	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	56	theme	neutral	2089:2095	arg1	agents					2178:2183	hypoglycemic agents	2165:2183	hypoglycemic agents	2165:2183	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	7	57	from	content	1171:1177	arg1	sources					1213:1219	different sources	1203:1219	different sources	1203:1219	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	13	58	theme	dose-dependent	1834:1847	arg1	manner					1849:1854	a dose-dependent manner	1832:1854	a dose-dependent manner in the 1.0-10.0 mg/mL concentration range	1832:1896	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	6	59	theme	polysaccharides	1026:1040	arg1	Structures					1003:1012	Structures	1003:1012	Structures of the four polysaccharides	1003:1040	Structures of the four polysaccharides were investigated.
35460266	3	60	theme	bond	605:608	arg1	type					610:613	glycosidic bond type	594:613	glycosidic bond type	594:613	This behavior was shown to be closely connected to the chemical structure, monosaccharide composition, and glycosidic bond type.
35460266	4	61	from	reports	630:636	arg1	constituents					654:665	the chemical constituents	641:665	the chemical constituents of the neutral polysaccharides from different sources of PR	641:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	9	62	theme	Infrared	1340:1347	arg1	spectra					1349:1355	Infrared spectra	1340:1355	Infrared spectra	1340:1355	Infrared spectra illustrated the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides.
35460266	0	63	from	sources	85:91	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	0	63	from	sources	85:91	arg1	bioactivity					31:41	bioactivity	31:41	bioactivity	31:41	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	10	64	theme	pyranose	1483:1490	arg1	structure					1497:1505	a pyranose ring structure	1481:1505	a pyranose ring structure	1481:1505	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	5	65	theme	anion-exchange	953:966	arg1	chromatography					987:1000	anion-exchange and gel-permeation chromatography	953:1000	anion-exchange and gel-permeation chromatography	953:1000	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	15	66	theme	hypoglycemic	2165:2176	arg1	polysaccharides					2097:2111	neutral polysaccharides	2089:2111	neutral polysaccharides	2089:2111	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	66	theme	hypoglycemic	2165:2176	arg1	agents					2178:2183	hypoglycemic agents	2165:2183	hypoglycemic agents	2165:2183	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	9	67	theme	bond	1421:1424	arg1	existence					1373:1381	the existence	1369:1381	the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides	1369:1447	Infrared spectra illustrated the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides.
35460266	9	68	theme	α-glycosidic	1386:1397	arg1	bond					1399:1402	α-glycosidic bond	1386:1402	α-glycosidic bond	1386:1402	Infrared spectra illustrated the existence of α-glycosidic bond and β-glycosidic bond in the polysaccharides.
35460266	4	69	theme	polysaccharides	682:696	arg1	constituents					654:665	the chemical constituents	641:665	the chemical constituents of the neutral polysaccharides from different sources of PR	641:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	0	70	theme	Polygonatum	96:106	arg1	Mill					108:111	Polygonatum Mill	96:111	Polygonatum Mill	96:111	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	1	71	theme	medical	153:159	arg1	product					172:178	a traditional medical and edible product	139:178	a traditional medical and edible product	139:178	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	1	71	theme	medical	153:159	arg1	rhizoma					125:131	Polygonati rhizoma	114:131	Polygonati rhizoma (PR)	114:136	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	4	72	theme	different	703:711	arg1	sources					713:719	different sources	703:719	different sources of PR	703:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	13	73	theme	different	1766:1774	arg1	degrees					1776:1782	different degrees	1766:1782	different degrees of antioxidant and hypoglycemic activities	1766:1825	All four polysaccharides exhibited different degrees of antioxidant and hypoglycemic activities with a dose-dependent manner in the 1.0-10.0 mg/mL concentration range.
35460266	7	74	dep	composition	1155:1165	arg1	the					1136:1138	the	1136:1138	the	1136:1138	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	2	75	theme	Neutral	311:317	arg1	polysaccharides					319:333	Neutral polysaccharides	311:333	Neutral polysaccharides	311:333	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	5	76	theme	gel-permeation	972:985	arg1	chromatography					987:1000	anion-exchange and gel-permeation chromatography	953:1000	anion-exchange and gel-permeation chromatography	953:1000	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	8	77	theme	CAZJ	1254:1257	arg1	weights					1243:1249	The molecular weights	1229:1249	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ	1229:1279	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	8	77	theme	CAZJ	1254:1257	arg1	14.119					1286:1291	14.119	1286:1291	14.119	1286:1291	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	2	78	theme	Polygonatum	398:408	arg1	ingredients					383:393	the main active ingredients	367:393	the main active ingredients of Polygonatum	367:408	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	5	79	theme	China	804:808	arg1	regions					793:799	four different regions	778:799	four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively,	778:934	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	8	80	theme	XXHN	1260:1263	arg1	weights					1243:1249	The molecular weights	1229:1249	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ	1229:1279	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	8	80	theme	XXHN	1260:1263	arg1	14.119					1286:1291	14.119	1286:1291	14.119	1286:1291	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	2	81	theme	ingredients	383:393	arg1	ingredients					383:393	the main active ingredients	367:393	the main active ingredients of Polygonatum	367:408	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	2	81	theme	ingredients	383:393	arg1	one					360:362	one	360:362	one	360:362	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	1	82	theme	hypolipidemic	285:297	arg1	properties					299:308	antioxidant, hypoglycemic and hypolipidemic properties	255:308	antioxidant, hypoglycemic and hypolipidemic properties	255:308	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	1	83	theme	Polygonati	114:123	arg1	product					172:178	a traditional medical and edible product	139:178	a traditional medical and edible product	139:178	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	1	83	theme	Polygonati	114:123	arg1	PR					134:135	PR	134:135	PR	134:135	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	1	83	theme	Polygonati	114:123	arg1	rhizoma					125:131	Polygonati rhizoma	114:131	Polygonati rhizoma (PR)	114:136	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	7	84	theme	different	1203:1211	arg1	sources					1213:1219	different sources	1203:1219	different sources	1203:1219	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	2	85	theme	fractions	430:438	arg1	many					416:419	many	416:419	many	416:419	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	2	85	theme	fractions	430:438	arg1	fractions					430:438	these fractions	424:438	these fractions	424:438	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	14	86	theme	monosaccharide	2000:2013	arg1	composition					2015:2025	monosaccharide composition	2000:2025	monosaccharide composition	2000:2025	Correlation analysis revealed that the bioactivities of polysaccharides was significantly related to monosaccharide composition, uronic acid, and protein content.
35460266	11	87	theme	red	1558:1560	arg1	test					1562:1565	Congo red test	1552:1565	Congo red test	1552:1565	Congo red test indicated that XXHN, DFSX, and PAZJ had a triple-helix structure.
35460266	8	88	theme	DFSX	1266:1269	arg1	weights					1243:1249	The molecular weights	1229:1249	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ	1229:1279	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	8	88	theme	DFSX	1266:1269	arg1	14.119					1286:1291	14.119	1286:1291	14.119	1286:1291	The molecular weights of CAZJ, XXHN, DFSX, and PAZJ were 14.119, 22.352, 18.127, and 15.699 kDa, respectively.
35460266	10	89	theme	ring	1536:1539	arg1	structure					1541:1549	a furanose ring structure	1525:1549	a furanose ring structure	1525:1549	CAZJ, XXHN, and DFSX possessed a pyranose ring structure, whereas PAZJ had a furanose ring structure.
35460266	0	90	theme	neutral	46:52	arg1	polysaccharides					54:68	neutral polysaccharides	46:68	neutral polysaccharides	46:68	Structure characterization and bioactivity of neutral polysaccharides from different sources of Polygonatum Mill.
35460266	7	91	theme	polysaccharides	1182:1196	arg1	content					1171:1177	content	1171:1177	content	1171:1177	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	7	91	theme	polysaccharides	1182:1196	arg1	composition					1155:1165	monosaccharide composition	1140:1165	monosaccharide composition	1140:1165	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	5	92	dep	Henan	838:842	arg1	an					872:873	an	872:873	an	872:873	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	15	93	theme	nutraceutical	2204:2216	arg1	applications					2218:2229	functional and nutraceutical applications	2189:2229	functional and nutraceutical applications	2189:2229	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	15	94	theme	functional	2189:2198	arg1	applications					2218:2229	functional and nutraceutical applications	2189:2229	functional and nutraceutical applications	2189:2229	The results suggested that neutral polysaccharides could be used as potential natural antioxidants and hypoglycemic agents for functional and nutraceutical applications.
35460266	5	95	theme	named	888:892	arg1	CAZJ					894:897	named CAZJ	888:897	named CAZJ	888:897	In this study, neutral polysaccharides of PR from four different regions of China (Chun'an (Zhejiang), Xixia (Henan), Danfeng (Shanxi), and Pan'an (Zhejiang)), named CAZJ, XXHN, DFSX, and PAZJ, respectively, were isolated by anion-exchange and gel-permeation chromatography.
35460266	7	96	from	sources	1213:1219	arg1	polysaccharides					1182:1196	polysaccharides	1182:1196	polysaccharides from different sources	1182:1219	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	7	96	from	sources	1213:1219	arg1	content					1171:1177	content	1171:1177	content	1171:1177	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	7	96	from	sources	1213:1219	arg1	composition					1155:1165	monosaccharide composition	1140:1165	monosaccharide composition	1140:1165	The results showed that all of them were mainly glucose and mannose, while the monosaccharide composition and content of polysaccharides from different sources varied.
35460266	1	97	theme	physiological	221:233	arg1	activity					235:242	physiological activity	221:242	physiological activity	221:242	Polygonati rhizoma (PR), a traditional medical and edible product, is rich in polysaccharides and exhibits physiological activity, including antioxidant, hypoglycemic and hypolipidemic properties.
35460266	4	98	theme	few	626:628	arg1	reports					630:636	few reports	626:636	few reports on the chemical constituents of the neutral polysaccharides from different sources of PR	626:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	2	99	theme	main	371:374	arg1	ingredients					383:393	the main active ingredients	367:393	the main active ingredients of Polygonatum	367:408	Neutral polysaccharides have been reported to be one of the main active ingredients of Polygonatum, with many of these fractions being responsible for the biological activity.
35460266	4	100	from	sources	713:719	arg1	polysaccharides					682:696	the neutral polysaccharides	670:696	the neutral polysaccharides from different sources of PR	670:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
35460266	4	100	from	sources	713:719	arg1	constituents					654:665	the chemical constituents	641:665	the chemical constituents of the neutral polysaccharides from different sources of PR	641:725	There are few reports on the chemical constituents of the neutral polysaccharides from different sources of PR.
37149979	7	0	with	elicitors	897:905	arg1	activity					926:933	high inducing activity	912:933	high inducing activity	912:933	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	4	1	theme	elicitors	587:595	arg1	activity					571:578	inducing activity	562:578	inducing activity of CIP elicitors	562:595	(A. macrocephala) and explored the main reasons for the differences of inducing activity of CIP elicitors.
37149979	6	2	theme	regional	823:830	arg1	differences					832:842	definite regional differences	814:842	definite regional differences	814:842	The results showed that 19 batches of CIPs had definite regional differences in inducing activity and monosaccharide content.
37149979	7	3	theme	CIP	893:895	arg1	elicitors					897:905	CIP elicitors	893:905	CIP elicitors with high inducing activity	893:933	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	5	4	theme	good	667:670	arg1	predictability					672:685	good predictability	667:685	good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors	667:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	2	5	theme	diverse	296:302	arg1	sources					304:310	diverse sources	296:310	diverse sources	296:310	However, it is still obscure whether elicitor activity is influenced by diverse sources.
37149979	5	6	theme	analysis	628:635	arg1	method					656:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	1	7	theme	immune	187:192	arg1	resistance					194:203	plant immune resistance	181:203	plant immune resistance against pathogens	181:221	Application of elicitors can greatly enhance plant immune resistance against pathogens.
37149979	5	8	theme	entropy	641:647	arg1	weight					649:654	entropy weight	641:654	entropy weight	641:654	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	8	9	theme	Rha	1262:1264	arg1	contents					1250:1257	the high contents	1241:1257	the high contents of Rha, Ara and GalA	1241:1278	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	9	10	theme	plant	1539:1543	arg1	resistance					1552:1561	plant immune resistance	1539:1561	plant immune resistance	1539:1561	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	9	11	theme	high	1437:1440	arg1	activity					1451:1458	high inducing activity	1437:1458	high inducing activity	1437:1458	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	8	12	theme	high	1208:1211	arg1	activity					1222:1229	high inducing activity	1208:1229	high inducing activity	1208:1229	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	8	13	theme	Ara	1267:1269	arg1	contents					1250:1257	the high contents	1241:1257	the high contents of Rha, Ara and GalA	1241:1278	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	5	14	theme	elicitors	722:730	arg1	evaluation					704:713	the activity evaluation	691:713	the activity evaluation of CIP elicitors and other plant-derived elicitors	691:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	8	15	theme	GalA	1275:1278	arg1	contents					1250:1257	the high contents	1241:1257	the high contents of Rha, Ara and GalA	1241:1278	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	7	16	theme	relative	1034:1041	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	16	theme	relative	1034:1041	arg1	level					1057:1061	the mRNA relative transcription level	1025:1061	the mRNA relative transcription level of CAT	1025:1068	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	17	from	accumulation	968:979	arg1	medium					1118:1123	the medium	1114:1123	the medium	1114:1123	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	5	18	theme	activity	695:702	arg1	evaluation					704:713	the activity evaluation	691:713	the activity evaluation of CIP elicitors and other plant-derived elicitors	691:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	7	19	theme	transcription	1043:1055	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	19	theme	transcription	1043:1055	arg1	level					1057:1061	the mRNA relative transcription level	1025:1061	the mRNA relative transcription level of CAT	1025:1068	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	0	20	theme	diverse	54:60	arg1	sources					62:68	diverse sources	54:68	diverse sources	54:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	7	21	theme	Ⅲ	1022:1022	arg1	accumulation					968:979	the accumulation	964:979	the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium	964:1123	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	8	22	theme	main	1300:1303	arg1	contributor					1305:1315	the main contributor	1296:1315	the main contributor to their high activity	1296:1338	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	8	22	theme	main	1300:1303	arg1	which					1281:1285	which	1281:1285	which	1281:1285	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	5	23	theme	other	736:740	arg1	elicitors					756:764	other plant-derived elicitors	736:764	other plant-derived elicitors	736:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	7	24	theme	Atractylenolide	984:998	arg1	POD					1071:1073	POD	1071:1073	POD	1071:1073	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	24	theme	Atractylenolide	984:998	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	24	theme	Atractylenolide	984:998	arg1	amount					1091:1096	the amount	1087:1096	the amount of pH change	1087:1109	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	24	theme	Atractylenolide	984:998	arg1	change					1104:1109	pH change	1101:1109	pH change	1101:1109	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	24	theme	Atractylenolide	984:998	arg1	level					1057:1061	the mRNA relative transcription level	1025:1061	the mRNA relative transcription level of CAT	1025:1068	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	24	theme	Atractylenolide	984:998	arg1	genes					1080:1084	PAL genes	1076:1084	PAL genes	1076:1084	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	9	25	theme	functional	1507:1516	arg1	elicitors					1518:1526	more functional elicitors	1502:1526	more functional elicitors related to plant immune resistance	1502:1561	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	3	26	theme	spraying	358:365	arg1	effect					341:346	the effect	337:346	the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz	337:488	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	8	27	theme	high	1326:1329	arg1	activity					1331:1338	their high activity	1320:1338	their high activity	1320:1338	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	5	28	theme	elicitors	756:764	arg1	evaluation					704:713	the activity evaluation	691:713	the activity evaluation of CIP elicitors and other plant-derived elicitors	691:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	9	29	theme	related	1528:1534	arg1	elicitors					1518:1526	more functional elicitors	1502:1526	more functional elicitors related to plant immune resistance	1502:1561	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	3	30	theme	indicum	398:404	arg1	CIPs					423:426	CIPs	423:426	CIPs	423:426	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	3	30	theme	indicum	398:404	arg1	polysaccharides					406:420	Chrysanthemum indicum polysaccharides	384:420	Chrysanthemum indicum polysaccharides (CIPs)	384:427	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	5	31	theme	CIP	718:720	arg1	elicitors					722:730	CIP elicitors	718:730	CIP elicitors	718:730	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	7	32	theme	macrocephala	1172:1183	arg1	index					1160:1164	the disease index	1148:1164	the disease index of A. macrocephala	1148:1183	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	33	theme	pH	1101:1102	arg1	change					1104:1109	pH change	1101:1109	pH change	1101:1109	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	3	34	theme	Koidz	484:488	arg1	resistance					444:453	the disease resistance	432:453	the disease resistance of Atractylodes macrocephala Koidz	432:488	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	0	35	theme	inducing	14:21	arg1	activity					23:30	inducing activity	14:30	inducing activity of CIP elicitors from diverse sources	14:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	8	36	dep	exhibited	1231:1239	arg1	contributor					1305:1315	the main contributor	1296:1315	the main contributor to their high activity	1296:1338	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	8	36	dep	exhibited	1231:1239	arg1	which					1281:1285	which	1281:1285	which	1281:1285	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	4	37	theme	activity	571:578	arg1	differences					547:557	the differences	543:557	the differences of inducing activity of CIP elicitors	543:595	(A. macrocephala) and explored the main reasons for the differences of inducing activity of CIP elicitors.
37149979	7	38	theme	disease	1152:1158	arg1	index					1160:1164	the disease index	1148:1164	the disease index of A. macrocephala	1148:1183	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	6	39	theme	monosaccharide	869:882	arg1	content					884:890	monosaccharide content	869:890	monosaccharide content	869:890	The results showed that 19 batches of CIPs had definite regional differences in inducing activity and monosaccharide content.
37149979	3	40	theme	foliar	351:356	arg1	spraying					358:365	foliar spraying	351:365	foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs)	351:427	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	0	41	theme	elicitors	39:47	arg1	activity					23:30	inducing activity	14:30	inducing activity of CIP elicitors from diverse sources	14:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	4	42	dep	explored	513:520	arg1	macrocephala					495:506	macrocephala	495:506	macrocephala	495:506	(A. macrocephala) and explored the main reasons for the differences of inducing activity of CIP elicitors.
37149979	7	43	theme	change	1104:1109	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	43	theme	change	1104:1109	arg1	amount					1091:1096	the amount	1087:1096	the amount of pH change	1087:1109	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	43	theme	change	1104:1109	arg1	change					1104:1109	pH change	1101:1109	pH change	1101:1109	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	5	44	contain	had	663:665	arg1	method					656:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	5	44	contain	had	663:665	arg2	predictability					672:685	good predictability	667:685	good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors	667:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	5	45	theme	weight	649:654	arg1	method					656:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	7	46	theme	high	912:915	arg1	activity					926:933	high inducing activity	912:933	high inducing activity	912:933	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	4	47	theme	CIP	583:585	arg1	elicitors					587:595	CIP elicitors	583:595	CIP elicitors	583:595	(A. macrocephala) and explored the main reasons for the differences of inducing activity of CIP elicitors.
37149979	6	48	theme	definite	814:821	arg1	differences					832:842	definite regional differences	814:842	definite regional differences	814:842	The results showed that 19 batches of CIPs had definite regional differences in inducing activity and monosaccharide content.
37149979	5	49	link	plant-derived	742:754	arg1	elicitors					756:764	other plant-derived elicitors	736:764	other plant-derived elicitors	736:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	5	50	theme	relational	617:626	arg1	analysis					628:635	grey relational analysis	612:635	grey relational analysis	612:635	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	6	51	theme	CIPs	805:808	arg1	batches					794:800	19 batches	791:800	19 batches of CIPs	791:808	The results showed that 19 batches of CIPs had definite regional differences in inducing activity and monosaccharide content.
37149979	1	52	theme	plant	181:185	arg1	resistance					194:203	plant immune resistance	181:203	plant immune resistance against pathogens	181:221	Application of elicitors can greatly enhance plant immune resistance against pathogens.
37149979	9	53	theme	CIP	1418:1420	arg1	elicitors					1422:1430	CIP elicitors	1418:1430	CIP elicitors	1418:1430	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	8	54	theme	high	1245:1248	arg1	contents					1250:1257	the high contents	1241:1257	the high contents of Rha, Ara and GalA	1241:1278	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	7	55	theme	Ⅱ	1000:1000	arg1	accumulation					968:979	the accumulation	964:979	the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium	964:1123	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	56	theme	PAL	1076:1078	arg1	genes					1080:1084	PAL genes	1076:1084	PAL genes	1076:1084	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	56	theme	PAL	1076:1078	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	9	57	theme	inducing	1442:1449	arg1	activity					1451:1458	high inducing activity	1437:1458	high inducing activity	1437:1458	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	0	58	from	sources	62:68	arg1	activity					23:30	inducing activity	14:30	inducing activity of CIP elicitors from diverse sources	14:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	0	58	from	sources	62:68	arg1	elicitors					39:47	CIP elicitors	35:47	CIP elicitors from diverse sources	35:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	8	59	with	CIP	1199:1201	arg1	activity					1222:1229	high inducing activity	1208:1229	high inducing activity	1208:1229	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	8	60	theme	inducing	1213:1220	arg1	activity					1222:1229	high inducing activity	1208:1229	high inducing activity	1208:1229	Furthermore, CIP with high inducing activity exhibited the high contents of Rha, Ara and GalA, which might be the main contributor to their high activity.
37149979	7	61	theme	CAT	1066:1068	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	61	theme	CAT	1066:1068	arg1	level					1057:1061	the mRNA relative transcription level	1025:1061	the mRNA relative transcription level of CAT	1025:1068	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	3	62	from	effect	341:346	arg1	resistance					444:453	the disease resistance	432:453	the disease resistance of Atractylodes macrocephala Koidz	432:488	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	5	63	theme	OPLS-DA	603:609	arg1	method					656:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	2	64	theme	elicitor	261:268	arg1	activity					270:277	elicitor activity	261:277	elicitor activity	261:277	However, it is still obscure whether elicitor activity is influenced by diverse sources.
37149979	7	65	theme	mRNA	1029:1032	arg1	Ⅱ					1000:1000	Atractylenolide Ⅱ	984:1000	Atractylenolide Ⅱ	984:1000	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	7	65	theme	mRNA	1029:1032	arg1	level					1057:1061	the mRNA relative transcription level	1025:1061	the mRNA relative transcription level of CAT	1025:1068	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	1	66	theme	elicitors	151:159	arg1	Application					136:146	Application	136:146	Application of elicitors	136:159	Application of elicitors can greatly enhance plant immune resistance against pathogens.
37149979	6	67	contain	had	810:812	arg1	batches					794:800	19 batches	791:800	19 batches of CIPs	791:808	The results showed that 19 batches of CIPs had definite regional differences in inducing activity and monosaccharide content.
37149979	6	67	contain	had	810:812	arg2	differences					832:842	definite regional differences	814:842	definite regional differences	814:842	The results showed that 19 batches of CIPs had definite regional differences in inducing activity and monosaccharide content.
37149979	0	68	from	activity	23:30	arg1	sources					62:68	diverse sources	54:68	diverse sources	54:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	0	69	theme	monosaccharide	79:92	arg1	composition					94:104	monosaccharide composition	79:104	monosaccharide composition	79:104	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	4	70	theme	main	526:529	arg1	reasons					531:537	the main reasons	522:537	the main reasons for the differences of inducing activity of CIP elicitors	522:595	(A. macrocephala) and explored the main reasons for the differences of inducing activity of CIP elicitors.
37149979	7	71	theme	Atractylenolide	1006:1020	arg1	Ⅲ					1022:1022	Atractylenolide Ⅲ	1006:1022	Atractylenolide Ⅲ	1006:1022	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
37149979	3	72	theme	batches	373:379	arg1	spraying					358:365	foliar spraying	351:365	foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs)	351:427	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	0	73	theme	physiological	110:122	arg1	indicators					124:133	physiological indicators	110:133	physiological indicators	110:133	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	5	74	theme	grey	612:615	arg1	analysis					628:635	grey relational analysis	612:635	grey relational analysis	612:635	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	5	75	theme	plant-derived	742:754	arg1	elicitors					756:764	other plant-derived elicitors	736:764	other plant-derived elicitors	736:764	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	3	76	theme	polysaccharides	406:420	arg1	batches					373:379	19 batches	370:379	19 batches of Chrysanthemum indicum polysaccharides (CIPs)	370:427	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	4	77	theme	inducing	562:569	arg1	activity					571:578	inducing activity	562:578	inducing activity of CIP elicitors	562:595	(A. macrocephala) and explored the main reasons for the differences of inducing activity of CIP elicitors.
37149979	3	78	theme	disease	436:442	arg1	resistance					444:453	the disease resistance	432:453	the disease resistance of Atractylodes macrocephala Koidz	432:488	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	0	79	theme	activity	23:30	arg1	Evaluation					0:9	Evaluation	0:9	Evaluation of inducing activity of CIP elicitors from diverse sources	0:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	5	80	theme	PCA	598:600	arg1	method					656:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method	598:661	PCA, OPLS-DA, grey relational analysis and entropy weight method had good predictability for the activity evaluation of CIP elicitors and other plant-derived elicitors.
37149979	9	81	theme	immune	1545:1550	arg1	resistance					1552:1561	plant immune resistance	1539:1561	plant immune resistance	1539:1561	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	3	82	theme	Chrysanthemum	384:396	arg1	CIPs					423:426	CIPs	423:426	CIPs	423:426	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	3	82	theme	Chrysanthemum	384:396	arg1	polysaccharides					406:420	Chrysanthemum indicum polysaccharides	384:420	Chrysanthemum indicum polysaccharides (CIPs)	384:427	This study investigated the effect of foliar spraying of 19 batches of Chrysanthemum indicum polysaccharides (CIPs) on the disease resistance of Atractylodes macrocephala Koidz.
37149979	0	83	theme	CIP	35:37	arg1	elicitors					39:47	CIP elicitors	35:47	CIP elicitors from diverse sources	35:68	Evaluation of inducing activity of CIP elicitors from diverse sources based on monosaccharide composition and physiological indicators.
37149979	9	84	theme	evaluation	1345:1354	arg1	procedure					1356:1364	The evaluation procedure	1341:1364	The evaluation procedure developed in this work	1341:1387	The evaluation procedure developed in this work can be applied for screening CIP elicitors with high inducing activity, and it lays a foundation for identifying more functional elicitors related to plant immune resistance.
37149979	7	85	theme	inducing	917:924	arg1	activity					926:933	high inducing activity	912:933	high inducing activity	912:933	CIP elicitors with high inducing activity could significantly increase the accumulation of Atractylenolide Ⅱ and Atractylenolide Ⅲ, the mRNA relative transcription level of CAT, POD, PAL genes, the amount of pH change in the medium and effectively reduce the disease index of A. macrocephala.
35397464	1	0	theme	compound	302:309	arg1	content					347:353	bioactive compound (BSP, total phenol, and militarine) content	292:353	bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata	292:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	0	theme	compound	302:309	arg1	traits					171:176	the morphological traits	153:176	the morphological traits	153:176	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	4	1	theme	BF	694:695	arg1	treatment					697:705	BF treatment	694:705	BF treatment	694:705	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	5	2	dep	Meanwhile	765:773	arg1	tubers					831:836	tubers	831:836	tubers	831:836	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	5	3	from	contents	808:815	arg1	striata					823:829	B. striata	820:829	B. striata	820:829	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	4	4	from	plants	631:636	arg1	groups					670:675	the RF, YF, and CK treatment groups	641:675	the RF, YF, and CK treatment groups	641:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	1	5	theme	light	136:140	arg1	quality					142:148	light quality	136:148	light quality	136:148	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	5	6	from	phenol	786:791	arg1	striata					823:829	B. striata	820:829	B. striata	820:829	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	1	7	theme	superoxide	230:239	arg1	dismutase					241:249	superoxide dismutase	230:249	superoxide dismutase	230:249	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	0	8	theme	striata	80:86	arg1	composition					56:66	main chemical composition	42:66	main chemical composition	42:66	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	0	8	theme	striata	80:86	arg1	growth					31:36	growth	31:36	growth	31:36	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	0	9	from	Effect	0:5	arg1	composition					56:66	main chemical composition	42:66	main chemical composition	42:66	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	0	9	from	Effect	0:5	arg1	growth					31:36	growth	31:36	growth	31:36	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	4	10	theme	CK	657:658	arg1	groups					670:675	the RF, YF, and CK treatment groups	641:675	the RF, YF, and CK treatment groups	641:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	3	11	theme	red	490:492	arg1	RF					500:501	RF	500:501	RF	500:501	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	3	11	theme	red	490:492	arg1	treatments					474:483	The treatments	470:483	The treatments	470:483	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	3	11	theme	red	490:492	arg1	film					494:497	red film	490:497	red film (RF)	490:502	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	5	12	theme	B.	820:821	arg1	striata					823:829	B. striata	820:829	B. striata	820:829	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	0	13	theme	Bletilla	71:78	arg1	striata					80:86	Bletilla striata	71:86	Bletilla striata	71:86	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	1	14	from	activity	278:285	arg1	striata					367:373	Bletilla striata	358:373	Bletilla striata	358:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	15	theme	total	317:321	arg1	phenol					323:328	total phenol	317:328	total phenol	317:328	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	16	from	effects	125:131	arg1	activity					278:285	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	16	from	effects	125:131	arg1	content					202:208	photosynthetic pigment content	179:208	photosynthetic pigment content	179:208	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	16	from	effects	125:131	arg1	content					347:353	bioactive compound (BSP, total phenol, and militarine) content	292:353	bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata	292:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	16	from	effects	125:131	arg1	traits					171:176	the morphological traits	153:176	the morphological traits	153:176	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	5	17	theme	militarine	797:806	arg1	contents					808:815	militarine contents	797:815	militarine contents in B. striata	797:829	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	1	18	theme	quality	142:148	arg1	effects					125:131	the effects	121:131	the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata	121:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	2	19	theme	colored	455:461	arg1	films					463:467	three differently colored films	437:467	three differently colored films	437:467	Plants of B. striata were grown under light filtered through three differently colored films.
35397464	4	20	theme	treatment	660:668	arg1	groups					670:675	the RF, YF, and CK treatment groups	641:675	the RF, YF, and CK treatment groups	641:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	4	21	theme	striata	623:629	arg1	plants					631:636	striata plants	623:636	the B. striata plants in the RF, YF, and CK treatment groups	616:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	2	22	theme	striata	389:395	arg1	Plants					376:381	Plants	376:381	Plants of B. striata	376:395	Plants of B. striata were grown under light filtered through three differently colored films.
35397464	7	23	theme	plant	1140:1144	arg1	materials					1146:1154	high-quality plant materials	1127:1154	high-quality plant materials	1127:1154	This technique is conducive to achieving large-scale sustainable production of high-quality plant materials.
35397464	1	24	from	content	347:353	arg1	striata					367:373	Bletilla striata	358:373	Bletilla striata	358:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	2	25	theme	B.	386:387	arg1	striata					389:395	B. striata	386:395	B. striata	386:395	Plants of B. striata were grown under light filtered through three differently colored films.
35397464	1	26	theme	morphological	157:169	arg1	activity					278:285	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	26	theme	morphological	157:169	arg1	content					202:208	photosynthetic pigment content	179:208	photosynthetic pigment content	179:208	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	26	theme	morphological	157:169	arg1	content					347:353	bioactive compound (BSP, total phenol, and militarine) content	292:353	bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata	292:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	26	theme	morphological	157:169	arg1	traits					171:176	the morphological traits	153:176	the morphological traits	153:176	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	0	27	theme	quality	16:22	arg1	Effect					0:5	Effect	0:5	Effect of light quality on the growth and main chemical composition of Bletilla striata.	0:87	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	4	28	theme	aerial	751:756	arg1	parts					758:762	the aerial parts	747:762	the aerial parts	747:762	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	6	29	theme	blue	975:978	arg1	film					980:983	blue film	975:983	blue film	975:983	These results show that growing B. striata plants under blue film could be a useful technique to improve quality and production.
35397464	0	30	theme	light	10:14	arg1	quality					16:22	light quality	10:22	light quality	10:22	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	6	31	theme	useful	996:1001	arg1	technique					1003:1011	a useful technique	994:1011	a useful technique to improve quality and production	994:1045	These results show that growing B. striata plants under blue film could be a useful technique to improve quality and production.
35397464	5	32	theme	striata	894:900	arg1	polysaccharides					902:916	B. striata polysaccharides	891:916	B. striata polysaccharides	891:916	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	5	33	theme	total	780:784	arg1	phenol					786:791	the total phenol	776:791	the total phenol	776:791	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	4	34	dep	showed	707:712	arg1	promoted					728:735	promoted	728:735	showed significantly promoted growth of the aerial parts	707:762	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	1	35	dep	compound	302:309	arg1	BSP					312:314	BSP	312:314	BSP	312:314	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	35	dep	compound	302:309	arg1	phenol					323:328	total phenol	317:328	total phenol	317:328	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	35	dep	compound	302:309	arg1	militarine					335:344	militarine	335:344	militarine	335:344	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	36	dep	enzyme	222:227	arg1	peroxidase					252:261	peroxidase	252:261	peroxidase	252:261	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	36	dep	enzyme	222:227	arg1	catalase					268:275	catalase	268:275	catalase	268:275	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	36	dep	enzyme	222:227	arg1	dismutase					241:249	superoxide dismutase	230:249	superoxide dismutase	230:249	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	7	37	theme	materials	1146:1154	arg1	production					1113:1122	large-scale sustainable production	1089:1122	large-scale sustainable production of high-quality plant materials	1089:1154	This technique is conducive to achieving large-scale sustainable production of high-quality plant materials.
35397464	1	38	theme	photosynthetic	179:192	arg1	content					202:208	photosynthetic pigment content	179:208	photosynthetic pigment content	179:208	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	38	theme	photosynthetic	179:192	arg1	traits					171:176	the morphological traits	153:176	the morphological traits	153:176	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	4	39	theme	parts	758:762	arg1	growth					737:742	growth	737:742	growth of the aerial parts	737:762	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	0	40	dep	growth	31:36	arg1	the					27:29	the	27:29	the	27:29	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	1	41	theme	pigment	194:200	arg1	content					202:208	photosynthetic pigment content	179:208	photosynthetic pigment content	179:208	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	41	theme	pigment	194:200	arg1	traits					171:176	the morphological traits	153:176	the morphological traits	153:176	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	3	42	theme	yellow	505:510	arg1	YF					518:519	YF	518:519	YF	518:519	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	3	42	theme	yellow	505:510	arg1	film					512:515	yellow film	505:515	yellow film (YF)	505:520	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	3	43	theme	uncovered	550:558	arg1	control					588:594	a control	586:594	a control (CK)	586:599	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	3	43	theme	uncovered	550:558	arg1	treatment					560:568	an uncovered treatment	547:568	an uncovered treatment	547:568	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	7	44	theme	high-quality	1127:1138	arg1	materials					1146:1154	high-quality plant materials	1127:1154	high-quality plant materials	1127:1154	This technique is conducive to achieving large-scale sustainable production of high-quality plant materials.
35397464	1	45	from	content	202:208	arg1	striata					367:373	Bletilla striata	358:373	Bletilla striata	358:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	46	theme	Bletilla	358:365	arg1	striata					367:373	Bletilla striata	358:373	Bletilla striata	358:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	4	47	theme	YF	649:650	arg1	groups					670:675	the RF, YF, and CK treatment groups	641:675	the RF, YF, and CK treatment groups	641:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	6	48	theme	striata	954:960	arg1	plants					962:967	B. striata plants	951:967	B. striata plants	951:967	These results show that growing B. striata plants under blue film could be a useful technique to improve quality and production.
35397464	3	49	theme	blue	527:530	arg1	BF					538:539	BF	538:539	BF	538:539	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	3	49	theme	blue	527:530	arg1	film					532:535	blue film	527:535	blue film (BF)	527:540	The treatments were red film (RF), yellow film (YF), and blue film (BF), and an uncovered treatment was included as a control (CK).
35397464	5	50	theme	polysaccharides	902:916	arg1	accumulation					875:886	the accumulation	871:886	the accumulation of B. striata polysaccharides	871:916	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	6	51	theme	B.	951:952	arg1	plants					962:967	B. striata plants	951:967	B. striata plants	951:967	These results show that growing B. striata plants under blue film could be a useful technique to improve quality and production.
35397464	5	52	from	Meanwhile	765:773	arg1	striata					823:829	B. striata	820:829	B. striata	820:829	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	7	53	theme	sustainable	1101:1111	arg1	production					1113:1122	large-scale sustainable production	1089:1122	large-scale sustainable production of high-quality plant materials	1089:1154	This technique is conducive to achieving large-scale sustainable production of high-quality plant materials.
35397464	0	54	theme	chemical	47:54	arg1	composition					56:66	main chemical composition	42:66	main chemical composition	42:66	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	5	55	theme	B.	891:892	arg1	polysaccharides					902:916	B. striata polysaccharides	891:916	B. striata polysaccharides	891:916	Meanwhile, the total phenol and militarine contents in B. striata tubers were increased without affecting the accumulation of B. striata polysaccharides.
35397464	4	56	dep	plants	631:636	arg1	B.					620:621	the B. striata plants in the RF, YF, and CK treatment groups	616:675	the B. striata plants in the RF, YF, and CK treatment groups	616:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	1	57	theme	protective	211:220	arg1	enzyme					222:227	protective enzyme	211:227	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	0	58	theme	main	42:45	arg1	composition					56:66	main chemical composition	42:66	main chemical composition	42:66	Effect of light quality on the growth and main chemical composition of Bletilla striata.
35397464	1	59	theme	bioactive	292:300	arg1	compound					302:309	bioactive compound	292:309	bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata	292:373	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	4	60	theme	RF	645:646	arg1	groups					670:675	the RF, YF, and CK treatment groups	641:675	the RF, YF, and CK treatment groups	641:675	Compared with the B. striata plants in the RF, YF, and CK treatment groups, those receiving BF treatment showed significantly promoted growth of the aerial parts.
35397464	7	61	theme	large-scale	1089:1099	arg1	production					1113:1122	large-scale sustainable production	1089:1122	large-scale sustainable production of high-quality plant materials	1089:1154	This technique is conducive to achieving large-scale sustainable production of high-quality plant materials.
35397464	1	62	theme	enzyme	222:227	arg1	activity					278:285	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	protective enzyme (superoxide dismutase, peroxidase, and catalase) activity	211:285	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35397464	1	62	theme	enzyme	222:227	arg1	traits					171:176	the morphological traits	153:176	the morphological traits	153:176	This study aimed to investigate the effects of light quality on the morphological traits, photosynthetic pigment content, protective enzyme (superoxide dismutase, peroxidase, and catalase) activity, and bioactive compound (BSP, total phenol, and militarine) content in Bletilla striata.
35504181	0	0	theme	delivery	109:116	arg1	composites					77:86	hydrogel composites	68:86	hydrogel composites	68:86	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	0	0	theme	delivery	109:116	arg1	system					118:123	a controlled drug delivery system	91:123	a controlled drug delivery system for osteochondral regeneration	91:154	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	6	1	theme	immunomodulation-based	1466:1487	arg1	candidate					1540:1548	a promising candidate	1528:1548	a promising candidate for OC regeneration	1528:1568	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	1	theme	immunomodulation-based	1466:1487	arg1	system					1512:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	2	2	theme	CS	721:722	arg1	microspheres					724:735	the porous CS microspheres	710:735	the porous CS microspheres (CSK-PMS)	710:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	2	theme	CS	721:722	arg1	CSK-PMS					738:744	CSK-PMS	738:744	CSK-PMS	738:744	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	3	3	theme	cartilage	910:918	arg1	regeneration					920:931	cartilage regeneration	910:931	cartilage regeneration	910:931	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	1	4	theme	cartilage	306:314	arg1	degeneration					274:285	degeneration	274:285	degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair	274:373	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	0	5	theme	drug	104:107	arg1	composites					77:86	hydrogel composites	68:86	hydrogel composites	68:86	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	0	5	theme	drug	104:107	arg1	system					118:123	a controlled drug delivery system	91:123	a controlled drug delivery system for osteochondral regeneration	91:154	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	1	6	theme	subchondral	209:219	arg1	bone					221:224	subchondral bone	209:224	subchondral bone of the injured chondral defect	209:255	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	6	7	theme	promising	1530:1538	arg1	candidate					1540:1548	a promising candidate	1528:1548	a promising candidate for OC regeneration	1528:1568	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	7	theme	promising	1530:1538	arg1	system					1512:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	5	8	theme	controlled	1190:1199	arg1	system					1215:1220	a controlled drug delivery system	1188:1220	a controlled drug delivery system	1188:1220	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	5	9	dep	In	1107:1108	arg1	vitro					1110:1114	vitro	1110:1114	vitro	1110:1114	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	4	10	theme	stable	1014:1019	arg1	CSK-PMS					1021:1027	the highly stable CSK-PMS	1003:1027	the highly stable CSK-PMS	1003:1027	The fast-degradable HD favored hyaline cartilage regeneration, while the highly stable CSK-PMS supported the endochondral ossification and regenerated the subchondral bone.
35504181	3	11	theme	defect	842:847	arg1	site					849:852	the defect site	838:852	the defect site	838:852	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	2	12	theme	HPCH	553:556	arg1	hydrogel					559:566	hydroxypropyl chitin (HPCH) hydrogel	531:566	hydroxypropyl chitin (HPCH) hydrogel	531:566	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	1	13	theme	defect	250:255	arg1	cartilage					195:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	1	13	theme	defect	250:255	arg1	bone					221:224	subchondral bone	209:224	subchondral bone of the injured chondral defect	209:255	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	2	14	theme	building	443:450	arg1	block					452:456	a macrophage-modulated and injectable 'building block'	404:457	a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS)	404:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	0	15	theme	osteochondral	129:141	arg1	regeneration					143:154	osteochondral regeneration	129:154	osteochondral regeneration	129:154	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	4	16	theme	endochondral	1043:1054	arg1	ossification					1056:1067	the endochondral ossification	1039:1067	the endochondral ossification	1039:1067	The fast-degradable HD favored hyaline cartilage regeneration, while the highly stable CSK-PMS supported the endochondral ossification and regenerated the subchondral bone.
35504181	4	17	theme	cartilage	973:981	arg1	regeneration					983:994	hyaline cartilage regeneration	965:994	hyaline cartilage regeneration	965:994	The fast-degradable HD favored hyaline cartilage regeneration, while the highly stable CSK-PMS supported the endochondral ossification and regenerated the subchondral bone.
35504181	3	18	theme	HD/CSK-PMS	762:771	arg1	scaffold					783:790	The developed HD/CSK-PMS composite scaffold	748:790	The developed HD/CSK-PMS composite scaffold	748:790	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	0	19	theme	immunomodulation-based	11:32	arg1	chitosan					41:48	Injectable immunomodulation-based porous chitosan	0:48	Injectable immunomodulation-based porous chitosan	0:48	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	5	20	theme	developed	1164:1172	arg1	HD/CSK-PMS					1174:1183	the newly developed HD/CSK-PMS	1154:1183	the newly developed HD/CSK-PMS as a controlled drug delivery system	1154:1220	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	2	21	theme	HPCH	650:653	arg1	HD					665:666	HD	665:666	HD	665:666	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	21	theme	HPCH	650:653	arg1	hydrogel					655:662	the thermosensitive HPCH hydrogel	630:662	the thermosensitive HPCH hydrogel (HD)	630:667	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	22	theme	chitin	545:550	arg1	hydrogel					559:566	hydroxypropyl chitin (HPCH) hydrogel	531:566	hydroxypropyl chitin (HPCH) hydrogel	531:566	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	23	theme	injectable	431:440	arg1	block					452:456	a macrophage-modulated and injectable 'building block'	404:457	a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS)	404:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	0	24	theme	Injectable	0:9	arg1	chitosan					41:48	Injectable immunomodulation-based porous chitosan	0:48	Injectable immunomodulation-based porous chitosan	0:48	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	2	25	theme	thermosensitive	634:648	arg1	HD					665:666	HD	665:666	HD	665:666	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	25	theme	thermosensitive	634:648	arg1	hydrogel					655:662	the thermosensitive HPCH hydrogel	630:662	the thermosensitive HPCH hydrogel (HD)	630:667	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	6	26	theme	high-quality	1422:1433	arg1	repair					1445:1450	high-quality cartilage repair	1422:1450	high-quality cartilage repair	1422:1450	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	1	27	theme	injured	233:239	arg1	defect					250:255	the injured chondral defect	229:255	the injured chondral defect	229:255	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	3	28	theme	developed	752:760	arg1	scaffold					783:790	The developed HD/CSK-PMS composite scaffold	748:790	The developed HD/CSK-PMS composite scaffold	748:790	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	2	29	theme	dimethyloxallyl	579:593	arg1	DMOG					604:607	DMOG	604:607	DMOG	604:607	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	29	theme	dimethyloxallyl	579:593	arg1	glycine					595:601	the dimethyloxallyl glycine	575:601	the dimethyloxallyl glycine (DMOG)	575:608	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	30	theme	delivery	464:471	arg1	system					473:478	a macrophage-modulated and injectable 'building block' drug delivery system	404:478	a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS)	404:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	0	31	theme	porous	34:39	arg1	chitosan					41:48	Injectable immunomodulation-based porous chitosan	0:48	Injectable immunomodulation-based porous chitosan	0:48	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	5	32	theme	M2	1247:1248	arg1	microenvironment					1261:1276	M2 macrophage microenvironment	1247:1276	M2 macrophage microenvironment	1247:1276	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	2	33	theme	macrophage-modulated	406:425	arg1	block					452:456	a macrophage-modulated and injectable 'building block'	404:457	a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS)	404:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	5	34	theme	in	1120:1121	arg1	evaluations					1128:1138	In vitro and in vivo evaluations	1107:1138	In vitro and in vivo evaluations	1107:1138	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	2	35	theme	drug	459:462	arg1	system					473:478	a macrophage-modulated and injectable 'building block' drug delivery system	404:478	a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS)	404:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	0	36	theme	hydrogel	68:75	arg1	composites					77:86	hydrogel composites	68:86	hydrogel composites	68:86	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	0	36	theme	hydrogel	68:75	arg1	system					118:123	a controlled drug delivery system	91:123	a controlled drug delivery system for osteochondral regeneration	91:154	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	5	37	theme	macrophage	1250:1259	arg1	microenvironment					1261:1276	M2 macrophage microenvironment	1247:1276	M2 macrophage microenvironment	1247:1276	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	3	38	from	site	849:852	arg1	microenvironment					818:833	the microenvironment	814:833	the microenvironment at the defect site	814:852	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	6	39	theme	OC	1554:1555	arg1	regeneration					1557:1568	OC regeneration	1554:1568	OC regeneration	1554:1568	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	5	40	theme	drug	1201:1204	arg1	system					1215:1220	a controlled drug delivery system	1188:1220	a controlled drug delivery system	1188:1220	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	4	41	theme	hyaline	965:971	arg1	cartilage					973:981	hyaline cartilage	965:981	hyaline cartilage regeneration	965:994	The fast-degradable HD favored hyaline cartilage regeneration, while the highly stable CSK-PMS supported the endochondral ossification and regenerated the subchondral bone.
35504181	2	42	theme	porous	714:719	arg1	microspheres					724:735	the porous CS microspheres	710:735	the porous CS microspheres (CSK-PMS)	710:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	42	theme	porous	714:719	arg1	CSK-PMS					738:744	CSK-PMS	738:744	CSK-PMS	738:744	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	43	theme	block	452:456	arg1	system					473:478	a macrophage-modulated and injectable 'building block' drug delivery system	404:478	a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS)	404:745	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	1	44	theme	cartilage	358:366	arg1	repair					368:373	cartilage repair	358:373	cartilage repair	358:373	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	6	45	theme	subchondral	1401:1411	arg1	bone					1413:1416	subchondral bone	1401:1416	subchondral bone	1401:1416	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	46	theme	hydrogel/PMS	1489:1500	arg1	candidate					1540:1548	a promising candidate	1528:1548	a promising candidate for OC regeneration	1528:1568	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	46	theme	hydrogel/PMS	1489:1500	arg1	system					1512:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	47	theme	microenvironment	1380:1395	arg1	importance					1355:1364	the importance	1351:1364	the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair	1351:1450	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	2	48	theme	chitosan	500:507	arg1	microspheres					514:525	porous chitosan (CS) microspheres	493:525	porous chitosan (CS) microspheres	493:525	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	1	49	theme	repair	368:373	arg1	failure					347:353	the failure	343:353	the failure of cartilage repair	343:373	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	6	50	theme	cartilage	1435:1443	arg1	repair					1445:1450	high-quality cartilage repair	1422:1450	high-quality cartilage repair	1422:1450	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	3	51	theme	macrophage	870:879	arg1	polarization					884:895	local macrophage M2 polarization	864:895	local macrophage M2 polarization	864:895	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	3	52	theme	composite	773:781	arg1	scaffold					783:790	The developed HD/CSK-PMS composite scaffold	748:790	The developed HD/CSK-PMS composite scaffold	748:790	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	4	53	theme	fast-degradable	938:952	arg1	HD					954:955	The fast-degradable HD	934:955	The fast-degradable HD	934:955	The fast-degradable HD favored hyaline cartilage regeneration, while the highly stable CSK-PMS supported the endochondral ossification and regenerated the subchondral bone.
35504181	5	54	theme	In	1107:1108	arg1	evaluations					1128:1138	In vitro and in vivo evaluations	1107:1138	In vitro and in vivo evaluations	1107:1138	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	5	55	theme	osteochondral	1294:1306	arg1	regeneration					1313:1324	osteochondral (OC) regeneration	1294:1324	osteochondral (OC) regeneration	1294:1324	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	1	56	theme	inappropriate	161:173	arg1	cartilage					195:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	3	57	theme	M2	881:882	arg1	polarization					884:895	local macrophage M2 polarization	864:895	local macrophage M2 polarization	864:895	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	6	58	theme	bone	1413:1416	arg1	importance					1355:1364	the importance	1351:1364	the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair	1351:1450	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	59	theme	immune	1373:1378	arg1	microenvironment					1380:1395	the immune microenvironment	1369:1395	the immune microenvironment	1369:1395	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	60	theme	composite	1502:1510	arg1	candidate					1540:1548	a promising candidate	1528:1548	a promising candidate for OC regeneration	1528:1568	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	6	60	theme	composite	1502:1510	arg1	system					1512:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	the immunomodulation-based hydrogel/PMS composite system	1462:1517	These findings indicate the importance of the immune microenvironment and subchondral bone for high-quality cartilage repair, and thus the immunomodulation-based hydrogel/PMS composite system could be a promising candidate for OC regeneration.
35504181	1	61	theme	regenerated	175:185	arg1	cartilage					195:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	5	62	theme	OC	1309:1310	arg1	regeneration					1313:1324	osteochondral (OC) regeneration	1294:1324	osteochondral (OC) regeneration	1294:1324	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	0	63	theme	controlled	93:102	arg1	composites					77:86	hydrogel composites	68:86	hydrogel composites	68:86	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	0	63	theme	controlled	93:102	arg1	system					118:123	a controlled drug delivery system	91:123	a controlled drug delivery system for osteochondral regeneration	91:154	Injectable immunomodulation-based porous chitosan microspheres/HPCH hydrogel composites as a controlled drug delivery system for osteochondral regeneration.
35504181	1	64	theme	chondral	241:248	arg1	defect					250:255	the injured chondral defect	229:255	the injured chondral defect	229:255	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	1	65	theme	fibrous	187:193	arg1	cartilage					195:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage	157:203	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35504181	3	66	theme	local	864:868	arg1	polarization					884:895	local macrophage M2 polarization	864:895	local macrophage M2 polarization	864:895	The developed HD/CSK-PMS composite scaffold effectively modulated the microenvironment at the defect site, achieved local macrophage M2 polarization and promoted cartilage regeneration.
35504181	5	67	dep	in	1120:1121	arg1	vivo					1123:1126	vivo	1123:1126	vivo	1123:1126	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	2	68	theme	hydroxypropyl	531:543	arg1	hydrogel					559:566	hydroxypropyl chitin (HPCH) hydrogel	531:566	hydroxypropyl chitin (HPCH) hydrogel	531:566	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	5	69	theme	delivery	1206:1213	arg1	system					1215:1220	a controlled drug delivery system	1188:1220	a controlled drug delivery system	1188:1220	In vitro and in vivo evaluations revealed that the newly developed HD/CSK-PMS as a controlled drug delivery system could effectively create M2 macrophage microenvironment and orchestrate osteochondral (OC) regeneration.
35504181	4	70	theme	subchondral	1089:1099	arg1	bone					1101:1104	the subchondral bone	1085:1104	the subchondral bone	1085:1104	The fast-degradable HD favored hyaline cartilage regeneration, while the highly stable CSK-PMS supported the endochondral ossification and regenerated the subchondral bone.
35504181	2	71	theme	porous	493:498	arg1	CS					510:511	CS	510:511	CS	510:511	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	2	71	theme	porous	493:498	arg1	chitosan					500:507	porous chitosan	493:507	porous chitosan (CS) microspheres	493:525	In this study, we developed a macrophage-modulated and injectable 'building block' drug delivery system comprised of porous chitosan (CS) microspheres and hydroxypropyl chitin (HPCH) hydrogel, where the dimethyloxallyl glycine (DMOG) was encapsulated in the thermosensitive HPCH hydrogel (HD) while kartogenin (KGN) was conjugated on the porous CS microspheres (CSK-PMS).
35504181	1	72	theme	regenerated	294:304	arg1	cartilage					306:314	the regenerated cartilage	290:314	the regenerated cartilage	290:314	The inappropriate regenerated fibrous cartilage and subchondral bone of the injured chondral defect ultimately cause degeneration of the regenerated cartilage, which eventually leads to the failure of cartilage repair.
35345778	5	0	theme	Bacteroides	1022:1032	arg1	richness					992:999	the relative richness	979:999	the relative richness of Lactobacillus and Bacteroides	979:1032	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	1	1	theme	quinquefolius	180:192	arg1	ginseng					165:171	American ginseng	156:171	American ginseng (Panax quinquefolius L.)	156:196	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	1	1	theme	quinquefolius	180:192	arg1	L.					194:195	Panax quinquefolius L.	174:195	Panax quinquefolius L.	174:195	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	5	2	theme	inflammatory	710:721	arg1	cells					723:727	inflammatory cells	710:727	inflammatory cells	710:727	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	2	3	theme	quinquefolius	363:375	arg1	polysaccharides					341:355	the polysaccharides	337:355	the polysaccharides of P. quinquefolius (WQP)	337:381	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	2	4	theme	polysaccharides	341:355	arg1	effects					326:332	the effects	322:332	the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride	322:468	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	2	5	from	effects	326:332	arg1	rats					386:389	rats	386:389	rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride	386:468	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	4	6	theme	uronic	587:592	arg1	content					599:605	uronic acid content	587:605	uronic acid content	587:605	The yield, total sugar content, uronic acid content, and protein content were 6.71%, 85.2%, 31.9%, and 2.1%, respectively.
35345778	5	7	theme	relative	983:990	arg1	richness					992:999	the relative richness	979:999	the relative richness of Lactobacillus and Bacteroides	979:1032	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	8	theme	intestinal	1160:1169	arg1	structure					1171:1179	the intestinal structure	1156:1179	the intestinal structure in rats	1156:1187	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	9	dep	enhance	1132:1138	arg1	alleviate					1348:1356	alleviate	1348:1356	alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride	1348:1466	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	9	dep	enhance	1132:1138	arg1	improve					1227:1233	improve	1227:1233	improve short-chain fatty acid (SCFA) levels	1227:1270	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	9	dep	enhance	1132:1138	arg1	reduce					1190:1195	reduce	1190:1195	reduce inflammatory cytokine levels	1190:1224	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	9	dep	enhance	1132:1138	arg1	promote					1273:1279	promote	1273:1279	promote recovery of the gut microbiota and intestinal mucosal barrier	1273:1341	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	10	theme	lincomycin	1443:1452	arg1	hydrochloride					1454:1466	lincomycin hydrochloride	1443:1466	lincomycin hydrochloride	1443:1466	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	0	11	theme	Signaling	136:144	arg1	Pathways					146:153	the MAPK Signaling Pathways	127:153	the MAPK Signaling Pathways	127:153	Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways.
35345778	8	12	theme	inflammatory	1607:1618	arg1	pathway					1630:1636	the MAPK inflammatory signaling pathway	1598:1636	the MAPK inflammatory signaling pathway	1598:1636	In addition, WQP inhibited the MAPK inflammatory signaling pathway to improve the inflammatory status.
35345778	2	13	theme	research	297:304	arg1	purpose					281:287	The purpose	277:287	The purpose of this research	277:304	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	8	14	theme	MAPK	1602:1605	arg1	pathway					1630:1636	the MAPK inflammatory signaling pathway	1598:1636	the MAPK inflammatory signaling pathway	1598:1636	In addition, WQP inhibited the MAPK inflammatory signaling pathway to improve the inflammatory status.
35345778	2	15	theme	antibiotic-associated	396:416	arg1	AAD					429:431	AAD	429:431	AAD	429:431	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	2	15	theme	antibiotic-associated	396:416	arg1	diarrhoea					418:426	antibiotic-associated diarrhoea	396:426	antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride	396:468	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	0	16	theme	MAPK	131:134	arg1	Pathways					146:153	the MAPK Signaling Pathways	127:153	the MAPK Signaling Pathways	127:153	Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways.
35345778	6	17	theme	gut	1297:1299	arg1	microbiota					1301:1310	the gut microbiota	1293:1310	the gut microbiota	1293:1310	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	0	18	theme	Panax	0:4	arg1	Polysaccharides					20:34	Panax quinquefolius Polysaccharides	0:34	Panax quinquefolius Polysaccharides	0:34	Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways.
35345778	6	19	theme	acid	1253:1256	arg1	levels					1265:1270	short-chain fatty acid (SCFA) levels	1235:1270	short-chain fatty acid (SCFA) levels	1235:1270	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	0	20	theme	quinquefolius	6:18	arg1	Polysaccharides					20:34	Panax quinquefolius Polysaccharides	0:34	Panax quinquefolius Polysaccharides	0:34	Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways.
35345778	5	21	theme	Lactobacillus	1004:1016	arg1	richness					992:999	the relative richness	979:999	the relative richness of Lactobacillus and Bacteroides	979:1032	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	8	22	theme	signaling	1620:1628	arg1	pathway					1630:1636	the MAPK inflammatory signaling pathway	1598:1636	the MAPK inflammatory signaling pathway	1598:1636	In addition, WQP inhibited the MAPK inflammatory signaling pathway to improve the inflammatory status.
35345778	2	23	theme	lincomycin	445:454	arg1	hydrochloride					456:468	lincomycin hydrochloride	445:468	lincomycin hydrochloride	445:468	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	5	24	theme	IL-10	839:843	arg1	levels					820:825	the levels	816:825	the levels of IL-4 and IL-10 in colon tissues	816:860	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	25	theme	microbiota	1412:1421	arg1	dysbiosis					1423:1431	microbiota dysbiosis	1412:1431	microbiota dysbiosis	1412:1431	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	1	26	theme	herbal	204:209	arg1	ginseng					165:171	American ginseng	156:171	American ginseng (Panax quinquefolius L.)	156:196	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	1	26	theme	herbal	204:209	arg1	medicine					211:218	an herbal medicine	201:218	an herbal medicine with polysaccharides as its important active ingredient	201:274	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	5	27	theme	Blautia	1072:1078	arg1	richness					1060:1067	the relative richness	1047:1067	the relative richness of Blautia and Coprococcus	1047:1094	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	28	theme	short-chain	1235:1245	arg1	SCFA					1259:1262	SCFA	1259:1262	SCFA	1259:1262	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	28	theme	short-chain	1235:1245	arg1	acid					1253:1256	short-chain fatty acid	1235:1256	short-chain fatty acid (SCFA) levels	1235:1270	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	5	29	from	levels	820:825	arg1	tissues					854:860	colon tissues	848:860	colon tissues	848:860	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	9	30	theme	antibiotic-related	1762:1779	arg1	effects					1786:1792	antibiotic-related side effects	1762:1792	antibiotic-related side effects	1762:1792	This study provides a foundation for the treatment of natural polysaccharides to reduce antibiotic-related side effects.
35345778	6	31	theme	microbiota	1301:1310	arg1	recovery					1281:1288	recovery	1281:1288	recovery of the gut microbiota and intestinal mucosal barrier	1281:1341	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	4	32	theme	total	566:570	arg1	content					578:584	total sugar content	566:584	total sugar content	566:584	The yield, total sugar content, uronic acid content, and protein content were 6.71%, 85.2%, 31.9%, and 2.1%, respectively.
35345778	5	33	theme	colon	848:852	arg1	tissues					854:860	colon tissues	848:860	colon tissues	848:860	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	8	34	theme	inflammatory	1653:1664	arg1	status					1666:1671	the inflammatory status	1649:1671	the inflammatory status	1649:1671	In addition, WQP inhibited the MAPK inflammatory signaling pathway to improve the inflammatory status.
35345778	4	35	theme	protein	612:618	arg1	content					620:626	protein content	612:626	protein content	612:626	The yield, total sugar content, uronic acid content, and protein content were 6.71%, 85.2%, 31.9%, and 2.1%, respectively.
35345778	5	36	theme	cells	723:727	arg1	infiltration					694:705	the infiltration	690:705	the infiltration of inflammatory cells into the ileum and colon	690:752	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	5	37	theme	Coprococcus	1084:1094	arg1	richness					1060:1067	the relative richness	1047:1067	the relative richness of Blautia and Coprococcus	1047:1094	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	1	38	with	medicine	211:218	arg1	polysaccharides					225:239	polysaccharides	225:239	polysaccharides as its important active ingredient	225:274	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	5	39	theme	propionate	902:911	arg1	production					876:885	the production	872:885	the production of acetate and propionate	872:911	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	0	40	theme	Antibiotic-Associated	47:67	arg1	Diarrhoea					69:77	Antibiotic-Associated Diarrhoea	47:77	Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats	47:121	Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways.
35345778	4	41	theme	sugar	572:576	arg1	content					578:584	total sugar content	566:584	total sugar content	566:584	The yield, total sugar content, uronic acid content, and protein content were 6.71%, 85.2%, 31.9%, and 2.1%, respectively.
35345778	6	42	theme	fatty	1247:1251	arg1	SCFA					1259:1262	SCFA	1259:1262	SCFA	1259:1262	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	42	theme	fatty	1247:1251	arg1	acid					1253:1256	short-chain fatty acid	1235:1256	short-chain fatty acid (SCFA) levels	1235:1270	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	43	theme	cytokine	1210:1217	arg1	levels					1219:1224	inflammatory cytokine levels	1197:1224	inflammatory cytokine levels	1197:1224	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	7	44	theme	Claudin-1	1549:1557	arg1	expression					1559:1568	Occludin and Claudin-1 expression	1536:1568	Occludin and Claudin-1 expression	1536:1568	We found that WQP can protect the intestinal barrier by increasing Occludin and Claudin-1 expression.
35345778	6	45	theme	intestinal	1316:1325	arg1	barrier					1335:1341	intestinal mucosal barrier	1316:1341	intestinal mucosal barrier	1316:1341	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	3	46	theme	galacturonic	501:512	arg1	acid					514:517	galacturonic acid	501:517	galacturonic acid	501:517	WQP was primarily composed of galacturonic acid, glucose, galactose, and arabinose.
35345778	4	47	theme	acid	594:597	arg1	content					599:605	uronic acid content	587:605	uronic acid content	587:605	The yield, total sugar content, uronic acid content, and protein content were 6.71%, 85.2%, 31.9%, and 2.1%, respectively.
35345778	5	48	theme	relative	1051:1058	arg1	richness					1060:1067	the relative richness	1047:1067	the relative richness of Blautia and Coprococcus	1047:1094	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	49	theme	inflammatory	1197:1208	arg1	levels					1219:1224	inflammatory cytokine levels	1197:1224	inflammatory cytokine levels	1197:1224	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	5	50	theme	gut	928:930	arg1	diversity					943:951	the gut microbiota diversity	924:951	the gut microbiota diversity	924:951	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	9	51	theme	side	1781:1784	arg1	effects					1786:1792	antibiotic-related side effects	1762:1792	antibiotic-related side effects	1762:1792	This study provides a foundation for the treatment of natural polysaccharides to reduce antibiotic-related side effects.
35345778	7	52	theme	intestinal	1503:1512	arg1	barrier					1514:1520	the intestinal barrier	1499:1520	the intestinal barrier	1499:1520	We found that WQP can protect the intestinal barrier by increasing Occludin and Claudin-1 expression.
35345778	5	53	theme	microbiota	932:941	arg1	diversity					943:951	the gut microbiota diversity	924:951	the gut microbiota diversity	924:951	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	54	theme	mucosal	1327:1333	arg1	barrier					1335:1341	intestinal mucosal barrier	1316:1341	intestinal mucosal barrier	1316:1341	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	1	55	theme	American	156:163	arg1	ginseng					165:171	American ginseng	156:171	American ginseng (Panax quinquefolius L.)	156:196	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	1	55	theme	American	156:163	arg1	medicine					211:218	an herbal medicine	201:218	an herbal medicine with polysaccharides as its important active ingredient	201:274	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	1	55	theme	American	156:163	arg1	L.					194:195	Panax quinquefolius L.	174:195	Panax quinquefolius L.	174:195	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	6	56	from	structure	1171:1179	arg1	rats					1184:1187	rats	1184:1187	rats	1184:1187	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	9	57	theme	polysaccharides	1736:1750	arg1	treatment					1715:1723	the treatment	1711:1723	the treatment of natural polysaccharides	1711:1750	This study provides a foundation for the treatment of natural polysaccharides to reduce antibiotic-related side effects.
35345778	7	58	theme	Occludin	1536:1543	arg1	expression					1559:1568	Occludin and Claudin-1 expression	1536:1568	Occludin and Claudin-1 expression	1536:1568	We found that WQP can protect the intestinal barrier by increasing Occludin and Claudin-1 expression.
35345778	5	59	theme	IL-4	830:833	arg1	levels					820:825	the levels	816:825	the levels of IL-4 and IL-10 in colon tissues	816:860	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	60	theme	side	1377:1380	arg1	effects					1382:1388	antibiotic-related side effects	1358:1388	antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride	1358:1466	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	60	theme	side	1377:1380	arg1	diarrhoea					1398:1406	diarrhoea	1398:1406	diarrhoea	1398:1406	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	60	theme	side	1377:1380	arg1	dysbiosis					1423:1431	microbiota dysbiosis	1412:1431	microbiota dysbiosis	1412:1431	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	1	61	theme	important	248:256	arg1	ingredient					265:274	its important active ingredient	244:274	its important active ingredient	244:274	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	6	62	theme	barrier	1335:1341	arg1	recovery					1281:1288	recovery	1281:1288	recovery of the gut microbiota and intestinal mucosal barrier	1281:1341	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	5	63	theme	acetate	890:896	arg1	production					876:885	the production	872:885	the production of acetate and propionate	872:911	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	5	64	theme	TNF-α	792:796	arg1	levels					798:803	TNF-α levels	792:803	TNF-α levels	792:803	WQP reduced the infiltration of inflammatory cells into the ileum and colon, reduced the IL-1β, IL-6, IL-17A, and TNF-α levels, increased the levels of IL-4 and IL-10 in colon tissues, improved the production of acetate and propionate, regulated the gut microbiota diversity and composition, improved the relative richness of Lactobacillus and Bacteroides, and reduced the relative richness of Blautia and Coprococcus.
35345778	6	65	theme	antibiotic-related	1358:1375	arg1	effects					1382:1388	antibiotic-related side effects	1358:1388	antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride	1358:1466	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	65	theme	antibiotic-related	1358:1375	arg1	diarrhoea					1398:1406	diarrhoea	1398:1406	diarrhoea	1398:1406	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	6	65	theme	antibiotic-related	1358:1375	arg1	dysbiosis					1423:1431	microbiota dysbiosis	1412:1431	microbiota dysbiosis	1412:1431	The results indicated that WQP can enhance the recovery of the intestinal structure in rats, reduce inflammatory cytokine levels, improve short-chain fatty acid (SCFA) levels, promote recovery of the gut microbiota and intestinal mucosal barrier, and alleviate antibiotic-related side effects such as diarrhoea and microbiota dysbiosis caused by lincomycin hydrochloride.
35345778	1	66	theme	active	258:263	arg1	ingredient					265:274	its important active ingredient	244:274	its important active ingredient	244:274	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	0	67	theme	Lincomycin	90:99	arg1	Hydrochloride					101:113	Lincomycin Hydrochloride	90:113	Lincomycin Hydrochloride	90:113	Panax quinquefolius Polysaccharides Ameliorate Antibiotic-Associated Diarrhoea Induced by Lincomycin Hydrochloride in Rats via the MAPK Signaling Pathways.
35345778	2	68	with	rats	386:389	arg1	AAD					429:431	AAD	429:431	AAD	429:431	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	2	68	with	rats	386:389	arg1	diarrhoea					418:426	antibiotic-associated diarrhoea	396:426	antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride	396:468	The purpose of this research was to identify the effects of the polysaccharides of P. quinquefolius (WQP) on rats with antibiotic-associated diarrhoea (AAD) induced by lincomycin hydrochloride.
35345778	9	69	theme	natural	1728:1734	arg1	polysaccharides					1736:1750	natural polysaccharides	1728:1750	natural polysaccharides	1728:1750	This study provides a foundation for the treatment of natural polysaccharides to reduce antibiotic-related side effects.
35345778	1	70	theme	Panax	174:178	arg1	ginseng					165:171	American ginseng	156:171	American ginseng (Panax quinquefolius L.)	156:196	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35345778	1	70	theme	Panax	174:178	arg1	L.					194:195	Panax quinquefolius L.	174:195	Panax quinquefolius L.	174:195	American ginseng (Panax quinquefolius L.) is an herbal medicine with polysaccharides as its important active ingredient.
35566005	8	0	theme	novel	1166:1170	arg1	results					1172:1178	The novel results	1162:1178	The novel results	1162:1178	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	8	1	from	composition	1227:1237	arg1	systems					1266:1272	the studied biochemical systems	1242:1272	the studied biochemical systems using MB dye as a GAG-specific marker	1242:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	1	2	theme	polysaccharides	182:196	arg1	Glycosaminoglycans					117:134	Glycosaminoglycans	117:134	Glycosaminoglycans (GAGs)	117:141	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	1	2	theme	polysaccharides	182:196	arg1	class					149:153	a class	147:153	a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules	147:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	7	3	theme	MB	1103:1104	arg1	binding					1106:1112	MB binding	1103:1112	MB binding	1103:1112	Furthermore, the impact of MB binding on the conformation of GAGs was also evaluated.
35566005	3	4	theme	charged	706:712	arg1	GAGs					714:717	negatively charged GAGs	695:717	negatively charged GAGs	695:717	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	3	5	theme	binding	677:683	arg1	sites					685:689	potential binding sites	667:689	potential binding sites for negatively charged GAGs	667:717	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	2	6	theme	metachromatic	393:405	arg1	methylene					411:419	The metachromatic dye methylene blue	389:424	The metachromatic dye methylene blue (MB)	389:429	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	6	theme	metachromatic	393:405	arg1	MB					427:428	MB	427:428	MB	427:428	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	6	theme	metachromatic	393:405	arg1	agent					448:452	a GAG binding agent	434:452	a GAG binding agent	434:452	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	7	7	from	impact	1093:1098	arg1	conformation					1121:1132	the conformation	1117:1132	the conformation of GAGs	1117:1140	Furthermore, the impact of MB binding on the conformation of GAGs was also evaluated.
35566005	9	8	from	knowledge	1333:1341	arg1	interactions					1365:1376	small molecule-GAG interactions	1346:1376	small molecule-GAG interactions	1346:1376	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	4	9	theme	several	813:819	arg1	types					825:829	several GAG types	813:829	several GAG types	813:829	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	4	9	theme	several	813:819	arg1	sulfates					865:872	heparan and chondroitin sulfates	841:872	heparan and chondroitin sulfates	841:872	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	3	10	theme	terminal	542:549	arg1	groups					558:563	the terminal methyl groups	538:563	the terminal methyl groups attached to the nitrogen atoms	538:594	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	5	11	theme	groups	1001:1006	arg1	role					985:988	the particularly important role	958:988	the particularly important role of sulfate groups	958:1006	We found that GAG-MB interactions are predominantly electrostatically driven, with the particularly important role of sulfate groups.
35566005	5	12	theme	sulfate	993:999	arg1	groups					1001:1006	sulfate groups	993:1006	sulfate groups	993:1006	We found that GAG-MB interactions are predominantly electrostatically driven, with the particularly important role of sulfate groups.
35566005	1	13	theme	various	304:310	arg1	types					312:316	various types	304:316	various types of molecules including proteins, peptides and small organic molecules	304:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	7	14	theme	GAGs	1137:1140	arg1	conformation					1121:1132	the conformation	1117:1132	the conformation of GAGs	1117:1140	Furthermore, the impact of MB binding on the conformation of GAGs was also evaluated.
35566005	2	15	theme	dye	407:409	arg1	methylene					411:419	The metachromatic dye methylene blue	389:424	The metachromatic dye methylene blue (MB)	389:429	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	15	theme	dye	407:409	arg1	MB					427:428	MB	427:428	MB	427:428	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	15	theme	dye	407:409	arg1	agent					448:452	a GAG binding agent	434:452	a GAG binding agent	434:452	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	3	16	theme	ring	519:522	arg1	system					524:529	a tricyclic, monocationic phenothiazine ring system	479:529	a tricyclic, monocationic phenothiazine ring system	479:529	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	8	17	theme	better	1190:1195	arg1	analytics					1210:1218	better quantitative analytics	1190:1218	better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker	1190:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	2	18	theme	binding	440:446	arg1	methylene					411:419	The metachromatic dye methylene blue	389:424	The metachromatic dye methylene blue (MB)	389:429	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	18	theme	binding	440:446	arg1	agent					448:452	a GAG binding agent	434:452	a GAG binding agent	434:452	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	8	19	theme	MB	1280:1281	arg1	marker					1305:1310	a GAG-specific marker	1290:1310	a GAG-specific marker	1290:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	8	19	theme	MB	1280:1281	arg1	dye					1283:1285	MB dye	1280:1285	MB dye	1280:1285	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	9	20	theme	putative	1452:1459	arg1	therapies					1469:1477	putative disease therapies	1452:1477	putative disease therapies	1452:1477	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	6	21	theme	stack	1023:1027	arg1	formation					1029:1037	MB oligomeric stack formation	1009:1037	MB oligomeric stack formation	1009:1037	MB oligomeric stack formation was favored in the presence of GAGs.
35566005	9	22	theme	drug	1436:1439	arg1	design					1441:1446	drug design	1436:1446	drug design	1436:1446	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	4	23	theme	chondroitin	853:863	arg1	types					825:829	several GAG types	813:829	several GAG types	813:829	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	4	23	theme	chondroitin	853:863	arg1	sulfates					865:872	heparan and chondroitin sulfates	841:872	heparan and chondroitin sulfates	841:872	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	8	24	theme	quantitative	1197:1208	arg1	analytics					1210:1218	better quantitative analytics	1190:1218	better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker	1190:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	4	25	dep	types	825:829	arg1	heparin					832:838	heparin	832:838	heparin	832:838	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	0	26	theme	Dynamics	10:17	arg1	Approaches					19:28	Molecular Dynamics Approaches	0:28	Molecular Dynamics Approaches	0:28	Molecular Dynamics Approaches Dissect Molecular Mechanisms Underlying Methylene Blue-Glycosaminoglycan Interactions.
35566005	3	27	theme	methyl	551:556	arg1	groups					558:563	the terminal methyl groups	538:563	the terminal methyl groups attached to the nitrogen atoms	538:594	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	7	28	theme	binding	1106:1112	arg1	impact					1093:1098	the impact	1089:1098	the impact of MB binding on the conformation of GAGs	1089:1140	Furthermore, the impact of MB binding on the conformation of GAGs was also evaluated.
35566005	5	29	theme	important	975:983	arg1	role					985:988	the particularly important role	958:988	the particularly important role of sulfate groups	958:1006	We found that GAG-MB interactions are predominantly electrostatically driven, with the particularly important role of sulfate groups.
35566005	9	30	from	developments	1420:1431	arg1	therapies					1469:1477	putative disease therapies	1452:1477	putative disease therapies	1452:1477	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	9	30	from	developments	1420:1431	arg1	design					1441:1446	drug design	1436:1446	drug design	1436:1446	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	5	31	theme	GAG-MB	889:894	arg1	interactions					896:907	GAG-MB interactions	889:907	GAG-MB interactions	889:907	We found that GAG-MB interactions are predominantly electrostatically driven, with the particularly important role of sulfate groups.
35566005	0	32	theme	Molecular	0:8	arg1	Approaches					19:28	Molecular Dynamics Approaches	0:28	Molecular Dynamics Approaches	0:28	Molecular Dynamics Approaches Dissect Molecular Mechanisms Underlying Methylene Blue-Glycosaminoglycan Interactions.
35566005	6	33	theme	oligomeric	1012:1021	arg1	formation					1029:1037	MB oligomeric stack formation	1009:1037	MB oligomeric stack formation	1009:1037	MB oligomeric stack formation was favored in the presence of GAGs.
35566005	3	34	theme	potential	667:675	arg1	sites					685:689	potential binding sites	667:689	potential binding sites for negatively charged GAGs	667:717	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	8	35	theme	GAG	1223:1225	arg1	composition					1227:1237	GAG composition	1223:1237	GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker	1223:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	1	36	theme	molecules	321:329	arg1	types					312:316	various types	304:316	various types of molecules including proteins, peptides and small organic molecules	304:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	4	37	theme	heparan	841:847	arg1	types					825:829	several GAG types	813:829	several GAG types	813:829	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	4	37	theme	heparan	841:847	arg1	sulfates					865:872	heparan and chondroitin sulfates	841:872	heparan and chondroitin sulfates	841:872	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	3	38	theme	nitrogen	581:588	arg1	atoms					590:594	the nitrogen atoms	577:594	the nitrogen atoms	577:594	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	9	39	theme	molecule-GAG	1352:1363	arg1	interactions					1365:1376	small molecule-GAG interactions	1346:1376	small molecule-GAG interactions	1346:1376	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	2	40	theme	blue	421:424	arg1	methylene					411:419	The metachromatic dye methylene blue	389:424	The metachromatic dye methylene blue (MB)	389:429	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	40	theme	blue	421:424	arg1	MB					427:428	MB	427:428	MB	427:428	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	40	theme	blue	421:424	arg1	agent					448:452	a GAG binding agent	434:452	a GAG binding agent	434:452	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	4	41	theme	molecular	758:766	arg1	mechanisms					768:777	molecular mechanisms	758:777	molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates	758:872	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	3	42	attach	attached	565:572	arg2	groups					558:563	the terminal methyl groups	538:563	the terminal methyl groups attached to the nitrogen atoms	538:594	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	3	42	attach	attached	565:572	arg1	atoms					590:594	the nitrogen atoms	577:594	the nitrogen atoms	577:594	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	1	43	theme	relevant	235:242	arg1	processes					244:252	biologically relevant processes	222:252	biologically relevant processes in the extracellular matrix	222:280	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	3	44	contain	bear	596:599	arg1	groups					558:563	the terminal methyl groups	538:563	the terminal methyl groups attached to the nitrogen atoms	538:594	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	3	44	contain	bear	596:599	arg2	charges					619:625	the most positive charges	601:625	the most positive charges of the cation	601:639	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	1	45	theme	processes	244:252	arg1	number					212:217	a number	210:217	a number of biologically relevant processes in the extracellular matrix	210:280	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	2	46	theme	GAG	436:438	arg1	methylene					411:419	The metachromatic dye methylene blue	389:424	The metachromatic dye methylene blue (MB)	389:429	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	2	46	theme	GAG	436:438	arg1	agent					448:452	a GAG binding agent	434:452	a GAG binding agent	434:452	The metachromatic dye methylene blue (MB) is a GAG binding agent.
35566005	0	47	theme	Molecular	38:46	arg1	Mechanisms					48:57	Molecular Mechanisms	38:57	Molecular Mechanisms Underlying Methylene Blue-Glycosaminoglycan Interactions	38:114	Molecular Dynamics Approaches Dissect Molecular Mechanisms Underlying Methylene Blue-Glycosaminoglycan Interactions.
35566005	8	48	theme	composition	1227:1237	arg1	analytics					1210:1218	better quantitative analytics	1190:1218	better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker	1190:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	8	49	theme	GAG-specific	1292:1303	arg1	marker					1305:1310	a GAG-specific marker	1290:1310	a GAG-specific marker	1290:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	8	49	theme	GAG-specific	1292:1303	arg1	dye					1283:1285	MB dye	1280:1285	MB dye	1280:1285	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	9	50	theme	small	1346:1350	arg1	interactions					1365:1376	small molecule-GAG interactions	1346:1376	small molecule-GAG interactions	1346:1376	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	1	51	from	processes	244:252	arg1	matrix					275:280	the extracellular matrix	257:280	the extracellular matrix	257:280	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	3	52	theme	tricyclic	481:489	arg1	system					524:529	a tricyclic, monocationic phenothiazine ring system	479:529	a tricyclic, monocationic phenothiazine ring system	479:529	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	0	53	theme	Methylene	70:78	arg1	Interactions					103:114	Methylene Blue-Glycosaminoglycan Interactions	70:114	Methylene Blue-Glycosaminoglycan Interactions	70:114	Molecular Dynamics Approaches Dissect Molecular Mechanisms Underlying Methylene Blue-Glycosaminoglycan Interactions.
35566005	9	54	theme	disease	1461:1467	arg1	therapies					1469:1477	putative disease therapies	1452:1477	putative disease therapies	1452:1477	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	1	55	from	matrix	275:280	arg1	number					212:217	a number	210:217	a number of biologically relevant processes in the extracellular matrix	210:280	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	6	56	theme	MB	1009:1010	arg1	formation					1029:1037	MB oligomeric stack formation	1009:1037	MB oligomeric stack formation	1009:1037	MB oligomeric stack formation was favored in the presence of GAGs.
35566005	3	57	theme	most	605:608	arg1	charges					619:625	the most positive charges	601:625	the most positive charges of the cation	601:639	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	3	58	dep	bear	596:599	arg1	represent					657:665	represent	657:665	represent potential binding sites for negatively charged GAGs	657:717	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	8	59	from	analytics	1210:1218	arg1	systems					1266:1272	the studied biochemical systems	1242:1272	the studied biochemical systems using MB dye as a GAG-specific marker	1242:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	3	60	theme	positive	610:617	arg1	charges					619:625	the most positive charges	601:625	the most positive charges of the cation	601:639	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	1	61	with	interactions	286:297	arg1	types					312:316	various types	304:316	various types of molecules including proteins, peptides and small organic molecules	304:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	1	62	theme	small	364:368	arg1	molecules					378:386	small organic molecules	364:386	small organic molecules	364:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	4	63	theme	GAG	821:823	arg1	types					825:829	several GAG types	813:829	several GAG types	813:829	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	4	63	theme	GAG	821:823	arg1	sulfates					865:872	heparan and chondroitin sulfates	841:872	heparan and chondroitin sulfates	841:872	In this study, we rigorously explored molecular mechanisms underlying these interactions for several GAG types: heparin, heparan and chondroitin sulfates.
35566005	3	64	theme	phenothiazine	505:517	arg1	system					524:529	a tricyclic, monocationic phenothiazine ring system	479:529	a tricyclic, monocationic phenothiazine ring system	479:529	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	8	65	from	systems	1266:1272	arg1	analytics					1210:1218	better quantitative analytics	1190:1218	better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker	1190:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	3	66	contain	possesses	469:477	arg1	molecule					460:467	This molecule	455:467	This molecule	455:467	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	3	66	contain	possesses	469:477	arg2	system					524:529	a tricyclic, monocationic phenothiazine ring system	479:529	a tricyclic, monocationic phenothiazine ring system	479:529	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	3	67	dep	tricyclic	481:489	arg1	monocationic					492:503	monocationic	492:503	monocationic	492:503	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	1	68	from	number	212:217	arg1	matrix					275:280	the extracellular matrix	257:280	the extracellular matrix	257:280	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	1	69	theme	periodic	158:165	arg1	polysaccharides					182:196	periodic anionic linear polysaccharides	158:196	periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules	158:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	8	70	theme	studied	1246:1252	arg1	systems					1266:1272	the studied biochemical systems	1242:1272	the studied biochemical systems using MB dye as a GAG-specific marker	1242:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	1	71	theme	extracellular	261:273	arg1	matrix					275:280	the extracellular matrix	257:280	the extracellular matrix	257:280	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	6	72	theme	GAGs	1070:1073	arg1	presence					1058:1065	the presence	1054:1065	the presence of GAGs	1054:1073	MB oligomeric stack formation was favored in the presence of GAGs.
35566005	1	73	theme	anionic	167:173	arg1	polysaccharides					182:196	periodic anionic linear polysaccharides	158:196	periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules	158:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	8	74	theme	biochemical	1254:1264	arg1	systems					1266:1272	the studied biochemical systems	1242:1272	the studied biochemical systems using MB dye as a GAG-specific marker	1242:1310	The novel results allow for better quantitative analytics of GAG composition in the studied biochemical systems using MB dye as a GAG-specific marker.
35566005	9	75	theme	novel	1414:1418	arg1	developments					1420:1431	novel developments	1414:1431	novel developments in drug design and putative disease therapies in which GAGs are involved	1414:1504	Our data add to the knowledge on small molecule-GAG interactions and could be potentially useful for novel developments in drug design and putative disease therapies in which GAGs are involved.
35566005	0	76	theme	Blue-Glycosaminoglycan	80:101	arg1	Interactions					103:114	Methylene Blue-Glycosaminoglycan Interactions	70:114	Methylene Blue-Glycosaminoglycan Interactions	70:114	Molecular Dynamics Approaches Dissect Molecular Mechanisms Underlying Methylene Blue-Glycosaminoglycan Interactions.
35566005	1	77	theme	organic	370:376	arg1	molecules					378:386	small organic molecules	364:386	small organic molecules	364:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
35566005	3	78	theme	cation	634:639	arg1	charges					619:625	the most positive charges	601:625	the most positive charges of the cation	601:639	This molecule possesses a tricyclic, monocationic phenothiazine ring system, while the terminal methyl groups attached to the nitrogen atoms bear the most positive charges of the cation and, therefore, represent potential binding sites for negatively charged GAGs.
35566005	1	79	theme	linear	175:180	arg1	polysaccharides					182:196	periodic anionic linear polysaccharides	158:196	periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules	158:386	Glycosaminoglycans (GAGs) are a class of periodic anionic linear polysaccharides involved in a number of biologically relevant processes in the extracellular matrix via interactions with various types of molecules including proteins, peptides and small organic molecules.
36014526	0	0	theme	Aqueous	103:109	arg1	System					121:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	9	1	dep	Conclusions	1214:1224	arg1	simple					1265:1270	simple	1265:1270	simple	1265:1270	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	1	dep	Conclusions	1214:1224	arg1	has					1313:1315	has	1313:1315	has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds	1313:1442	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	4	2	theme	optimum	749:755	arg1	conditions					757:766	the optimum conditions	745:766	the optimum conditions	745:766	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	2	3	theme	solvents	319:326	arg1	ATPSs					341:345	deep eutectic solvents (DESs)-based ATPSs	305:345	deep eutectic solvents (DESs)-based ATPSs	305:345	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	1	4	theme	bioactive	239:247	arg1	substances					249:258	bioactive substances	239:258	bioactive substances	239:258	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	0	5	theme	Solvents-Based	88:101	arg1	System					121:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	3	6	theme	extraction	587:596	arg1	temperature					598:608	extraction temperature	587:608	extraction temperature	587:608	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	9	7	dep	simple	1265:1270	arg1	low-cost					1299:1306	low-cost	1299:1306	low-cost	1299:1306	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	7	dep	simple	1265:1270	arg1	friendly					1289:1296	friendly	1289:1296	friendly	1289:1296	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	8	8	theme	obtained	1077:1084	arg1	AMP					1086:1088	the obtained AMP	1073:1088	the obtained AMP	1073:1088	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	2	9	theme	eutectic	310:317	arg1	ATPSs					341:345	deep eutectic solvents (DESs)-based ATPSs	305:345	deep eutectic solvents (DESs)-based ATPSs	305:345	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	1	10	theme	substances	249:258	arg1	purification					223:234	purification	223:234	purification	223:234	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	1	10	theme	substances	249:258	arg1	separation					208:217	separation	208:217	separation	208:217	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	3	11	theme	temperature	598:608	arg1	effect					534:539	the effect	530:539	the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP	530:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	2	12	dep	extraction	369:378	arg1	the					365:367	the	365:367	the	365:367	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	1	13	dep	Background	133:142	arg1	used					196:199	used	196:199	have been widely used in the separation and purification of bioactive substances in recent years	179:274	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	1	13	dep	Background	133:142	arg1	1					130:130	1	130:130	1	130:130	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	0	14	theme	Two-Phase	111:119	arg1	System					121:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	9	15	theme	new	1360:1362	arg1	ideas					1364:1368	new ideas	1360:1368	new ideas for the extraction of plant polysaccharides and other bioactive compounds	1360:1442	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	16	theme	plant	1392:1396	arg1	polysaccharides					1398:1412	plant polysaccharides	1392:1412	plant polysaccharides	1392:1412	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	8	17	theme	spectroscopy	1146:1157	arg1	analysis					1159:1166	infrared spectroscopy analysis	1137:1166	infrared spectroscopy analysis	1137:1166	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	9	18	theme	extraction	1322:1331	arg1	efficiency					1333:1342	high extraction efficiency	1317:1342	high extraction efficiency	1317:1342	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	1	19	theme	recent	263:268	arg1	years					270:274	recent years	263:274	recent years	263:274	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	7	20	theme	ATPS	1047:1050	arg1	conditions					1052:1061	the optimum ATPS conditions	1035:1061	the optimum ATPS conditions	1035:1061	The extraction efficiency was 97.85% for AMP under the optimum ATPS conditions.
36014526	2	21	dep	Methods	281:287	arg1	2					278:278	2	278:278	2	278:278	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	2	21	dep	Methods	281:287	arg1	employed					352:359	employed	352:359	were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP)	347:442	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	4	22	theme	141.11	727:732	arg1	mg/g					734:737	141.11 mg/g	727:737	141.11 mg/g	727:737	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	4	22	theme	141.11	727:732	arg1	yield					717:721	The maximum extraction yield	694:721	The maximum extraction yield	694:721	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	6	23	theme	concentration	899:911	arg1	effect					869:874	The effect	865:874	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency	865:964	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	9	24	theme	polysaccharides	1398:1412	arg1	extraction					1378:1387	the extraction	1374:1387	the extraction of plant polysaccharides and other bioactive compounds	1374:1442	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	6	25	theme	extraction	918:927	arg1	temperature					929:939	extraction temperature	918:939	extraction temperature	918:939	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	2	26	theme	membranaceus	409:420	arg1	polysaccharides					422:436	Astragalus membranaceus polysaccharides	398:436	Astragalus membranaceus polysaccharides (AMP)	398:442	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	2	26	theme	membranaceus	409:420	arg1	AMP					439:441	AMP	439:441	AMP	439:441	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	3	27	theme	extraction	615:624	arg1	time					626:629	extraction time	615:629	extraction time	615:629	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	3	28	from	effect	534:539	arg1	yield					649:653	the extraction yield	634:653	the extraction yield of AMP	634:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	4	29	dep	Results	685:691	arg1	mg/g					734:737	141.11 mg/g	727:737	141.11 mg/g	727:737	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	4	29	dep	Results	685:691	arg1	yield					717:721	The maximum extraction yield	694:721	The maximum extraction yield	694:721	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	2	30	theme	Astragalus	398:407	arg1	polysaccharides					422:436	Astragalus membranaceus polysaccharides	398:436	Astragalus membranaceus polysaccharides (AMP)	398:442	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	2	30	theme	Astragalus	398:407	arg1	AMP					439:441	AMP	439:441	AMP	439:441	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	3	31	theme	time	626:629	arg1	effect					534:539	the effect	530:539	the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP	530:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	6	32	from	effect	869:874	arg1	efficiency					955:964	extraction efficiency	944:964	extraction efficiency	944:964	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	3	33	dep	DES	457:459	arg1	=					484:484	=	484:484	=	484:484	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	3	34	theme	choline	462:468	arg1	chloride					470:477	choline chloride	462:477	choline chloride	462:477	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	2	35	theme	-based	334:339	arg1	ATPSs					341:345	deep eutectic solvents (DESs)-based ATPSs	305:345	deep eutectic solvents (DESs)-based ATPSs	305:345	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	7	36	theme	optimum	1039:1045	arg1	conditions					1052:1061	the optimum ATPS conditions	1035:1061	the optimum ATPS conditions	1035:1061	The extraction efficiency was 97.85% for AMP under the optimum ATPS conditions.
36014526	9	37	theme	other	1418:1422	arg1	compounds					1434:1442	other bioactive compounds	1418:1442	other bioactive compounds	1418:1442	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	38	contain	has	1313:1315	arg2	efficiency					1333:1342	high extraction efficiency	1317:1342	high extraction efficiency	1317:1342	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	38	contain	has	1313:1315	arg1	extraction					1237:1246	This ATPS extraction	1227:1246	This ATPS extraction based on DESs	1227:1260	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	39	theme	bioactive	1424:1432	arg1	compounds					1434:1442	other bioactive compounds	1418:1442	other bioactive compounds	1418:1442	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	8	40	theme	weight	1115:1120	arg1	determination					1122:1134	molecular weight determination	1105:1134	molecular weight determination	1105:1134	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	3	41	theme	AMP	658:660	arg1	yield					649:653	the extraction yield	634:653	the extraction yield of AMP	634:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	7	42	theme	extraction	988:997	arg1	%					1019:1019	97.85%	1014:1019	97.85% for AMP	1014:1027	The extraction efficiency was 97.85% for AMP under the optimum ATPS conditions.
36014526	7	42	theme	extraction	988:997	arg1	efficiency					999:1008	The extraction efficiency	984:1008	The extraction efficiency	984:1008	The extraction efficiency was 97.85% for AMP under the optimum ATPS conditions.
36014526	4	43	theme	extraction	706:715	arg1	mg/g					734:737	141.11 mg/g	727:737	141.11 mg/g	727:737	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	4	43	theme	extraction	706:715	arg1	yield					717:721	The maximum extraction yield	694:721	The maximum extraction yield	694:721	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	9	44	theme	compounds	1434:1442	arg1	extraction					1378:1387	the extraction	1374:1387	the extraction of plant polysaccharides and other bioactive compounds	1374:1442	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	9	45	theme	high	1317:1320	arg1	efficiency					1333:1342	high extraction efficiency	1317:1342	high extraction efficiency	1317:1342	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	3	46	theme	extraction	638:647	arg1	yield					649:653	the extraction yield	634:653	the extraction yield of AMP	634:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	6	47	theme	extraction	944:953	arg1	efficiency					955:964	extraction efficiency	944:964	extraction efficiency	944:964	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	2	48	theme	DESs	329:332	arg1	ATPSs					341:345	deep eutectic solvents (DESs)-based ATPSs	305:345	deep eutectic solvents (DESs)-based ATPSs	305:345	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	0	49	theme	membranaceus	42:53	arg1	Polysaccharides					55:69	Astragalus membranaceus Polysaccharides	31:69	Astragalus membranaceus Polysaccharides	31:69	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	3	50	theme	optimal	449:455	arg1	DES					457:459	The optimal DES	445:459	The optimal DES (choline chloride:urea = 1:1)	445:489	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	3	51	theme	solid-liquid	563:574	arg1	ratio					576:580	solid-liquid ratio	563:580	solid-liquid ratio	563:580	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	4	52	theme	maximum	698:704	arg1	mg/g					734:737	141.11 mg/g	727:737	141.11 mg/g	727:737	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	4	52	theme	maximum	698:704	arg1	yield					717:721	The maximum extraction yield	694:721	The maximum extraction yield	694:721	(3) Results: The maximum extraction yield was 141.11 mg/g under the optimum conditions.
36014526	6	53	theme	salt	894:897	arg1	concentration					899:911	salt concentration	894:911	salt concentration	894:911	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	0	54	theme	Astragalus	31:40	arg1	Polysaccharides					55:69	Astragalus membranaceus Polysaccharides	31:69	Astragalus membranaceus Polysaccharides	31:69	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	1	55	dep	separation	208:217	arg1	the					204:206	the	204:206	the	204:206	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	2	56	theme	polysaccharides	422:436	arg1	separation					384:393	separation	384:393	separation	384:393	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	2	56	theme	polysaccharides	422:436	arg1	extraction					369:378	extraction	369:378	extraction	369:378	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	1	57	from	purification	223:234	arg1	years					270:274	recent years	263:274	recent years	263:274	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	3	58	theme	concentration	548:560	arg1	effect					534:539	the effect	530:539	the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP	530:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	1	59	used	used	196:199	arg2	ATPSs					172:176	ATPSs	172:176	ATPSs	172:176	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	1	59	used	used	196:199	arg2	systems					163:169	Aqueous two-phase systems	145:169	Aqueous two-phase systems (ATPSs)	145:177	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	2	60	theme	deep	305:308	arg1	ATPSs					341:345	deep eutectic solvents (DESs)-based ATPSs	305:345	deep eutectic solvents (DESs)-based ATPSs	305:345	(2) Methods: In this study, deep eutectic solvents (DESs)-based ATPSs were employed for the extraction and separation of Astragalus membranaceus polysaccharides (AMP).
36014526	0	61	theme	Polysaccharides	55:69	arg1	Purification					15:26	Purification	15:26	Purification	15:26	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	0	61	theme	Polysaccharides	55:69	arg1	Separation					0:9	Separation	0:9	Separation	0:9	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	9	62	theme	ATPS	1232:1235	arg1	extraction					1237:1246	This ATPS extraction	1227:1246	This ATPS extraction based on DESs	1227:1260	(4) Conclusions: This ATPS extraction based on DESs is simple, environmentally friendly, low-cost, and has high extraction efficiency, which provides new ideas for the extraction of plant polysaccharides and other bioactive compounds.
36014526	3	63	theme	pH	583:584	arg1	effect					534:539	the effect	530:539	the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP	530:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	3	64	theme	extract	513:519	arg1	AMP					521:523	extract AMP	513:523	extract AMP	513:523	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	3	65	theme	DES	544:546	arg1	concentration					548:560	DES concentration	544:560	DES concentration	544:560	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	1	66	from	separation	208:217	arg1	years					270:274	recent years	263:274	recent years	263:274	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	5	67	theme	DES	860:862	arg1	reuse					851:855	reuse	851:855	reuse	851:855	AMP was then preliminarily purified by ATPS, to further realize the recycling and reuse of DES.
36014526	5	67	theme	DES	860:862	arg1	recycling					837:845	recycling	837:845	recycling	837:845	AMP was then preliminarily purified by ATPS, to further realize the recycling and reuse of DES.
36014526	8	68	theme	molecular	1105:1113	arg1	determination					1122:1134	molecular weight determination	1105:1134	molecular weight determination	1105:1134	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	3	69	dep	=	484:484	arg1	chloride					470:477	choline chloride	462:477	choline chloride	462:477	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	6	70	theme	salts	887:891	arg1	concentration					899:911	salt concentration	894:911	salt concentration	894:911	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	6	70	theme	salts	887:891	arg1	type					879:882	type	879:882	type of salts	879:891	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	6	70	theme	salts	887:891	arg1	temperature					929:939	extraction temperature	918:939	extraction temperature	918:939	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	3	71	theme	ratio	576:580	arg1	effect					534:539	the effect	530:539	the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP	530:660	The optimal DES (choline chloride:urea = 1:1) was first screened to extract AMP, and the effect of DES concentration, solid-liquid ratio, pH, extraction temperature, and extraction time on the extraction yield of AMP were investigated.
36014526	8	72	theme	composition	1188:1198	arg1	analysis					1200:1207	monosaccharide composition analysis	1173:1207	monosaccharide composition analysis	1173:1207	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	8	73	theme	monosaccharide	1173:1186	arg1	analysis					1200:1207	monosaccharide composition analysis	1173:1207	monosaccharide composition analysis	1173:1207	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	5	74	dep	recycling	837:845	arg1	the					833:835	the	833:835	the	833:835	AMP was then preliminarily purified by ATPS, to further realize the recycling and reuse of DES.
36014526	0	75	theme	Eutectic	79:86	arg1	System					121:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	1	76	theme	Aqueous	145:151	arg1	ATPSs					172:176	ATPSs	172:176	ATPSs	172:176	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	1	76	theme	Aqueous	145:151	arg1	systems					163:169	Aqueous two-phase systems	145:169	Aqueous two-phase systems (ATPSs)	145:177	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	6	77	theme	temperature	929:939	arg1	effect					869:874	The effect	865:874	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency	865:964	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	6	78	theme	type	879:882	arg1	effect					869:874	The effect	865:874	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency	865:964	The effect of type of salts, salt concentration, and extraction temperature on extraction efficiency was investigated.
36014526	0	79	theme	Deep	74:77	arg1	System					121:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Deep Eutectic Solvents-Based Aqueous Two-Phase System	74:126	Separation and Purification of Astragalus membranaceus Polysaccharides by Deep Eutectic Solvents-Based Aqueous Two-Phase System.
36014526	8	80	theme	infrared	1137:1144	arg1	analysis					1159:1166	infrared spectroscopy analysis	1137:1166	infrared spectroscopy analysis	1137:1166	Finally, the obtained AMP was studied by molecular weight determination, infrared spectroscopy analysis, and monosaccharide composition analysis.
36014526	1	81	theme	two-phase	153:161	arg1	ATPSs					172:176	ATPSs	172:176	ATPSs	172:176	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36014526	1	81	theme	two-phase	153:161	arg1	systems					163:169	Aqueous two-phase systems	145:169	Aqueous two-phase systems (ATPSs)	145:177	(1) Background: Aqueous two-phase systems (ATPSs) have been widely used in the separation and purification of bioactive substances in recent years.
36637177	4	0	contain	contains	905:912	arg1	mucilage					864:871	chia nutlet mucilage	852:871	chia nutlet mucilage	852:871	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	4	0	contain	contains	905:912	arg2	types					930:934	several polymer types	914:934	several polymer types	914:934	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	2	1	theme	Seed/nutlet	305:315	arg1	mucilage					317:324	Seed/nutlet mucilage	305:324	Seed/nutlet mucilage	305:324	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	7	2	from	present	1500:1506	arg1	mucilage					1515:1522	the mucilage	1511:1522	the mucilage	1511:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	4	3	theme	profiling	819:827	arg1	techniques					829:838	profiling techniques	819:838	profiling techniques	819:838	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	7	4	theme	nutlet	1386:1391	arg1	mucilage					1393:1400	chia nutlet mucilage	1381:1400	chia nutlet mucilage	1381:1400	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	6	5	theme	mucilage	1221:1228	arg1	functionality					1192:1204	the dietary fibre functionality	1174:1204	the dietary fibre functionality of chia nutlet mucilage	1174:1228	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	4	6	theme	mass	789:792	arg1	spectrometry					794:805	mass spectrometry	789:805	mass spectrometry	789:805	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	6	7	theme	chia	1209:1212	arg1	mucilage					1221:1228	chia nutlet mucilage	1209:1228	chia nutlet mucilage	1209:1228	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	7	8	theme	complex	1363:1369	arg1	nature					1371:1376	The complex nature	1359:1376	The complex nature of chia nutlet mucilage	1359:1400	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	9	9	theme	nutrients	1853:1861	arg1	bioaccessibility					1829:1844	the bioaccessibility	1825:1844	the bioaccessibility of key nutrients including dietary fibre	1825:1885	Therefore, it is suggested that the benefits of eating chia as a "superfood", could be notably enhanced if the nutlets are ground rather than being consumed whole, improving the bioaccessibility of key nutrients including dietary fibre.
36637177	4	10	dep	complex	883:889	arg1	layered					892:898	layered	892:898	layered	892:898	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	3	11	theme	nutlet	568:573	arg1	mucilage					575:582	chia nutlet mucilage	563:582	chia nutlet mucilage	563:582	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	6	12	dep	in	1234:1235	arg1	vitro					1237:1241	vitro	1237:1241	vitro	1237:1241	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	2	13	from	utility	447:453	arg1	sources					482:488	different sources	472:488	different sources	472:488	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	6	14	theme	fibre	1186:1190	arg1	functionality					1192:1204	the dietary fibre functionality	1174:1204	the dietary fibre functionality of chia nutlet mucilage	1174:1228	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	5	15	theme	modified	1090:1097	arg1	domain					1109:1114	a modified cellulose domain	1088:1114	a modified cellulose domain	1088:1114	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	4	16	theme	chia	852:855	arg1	mucilage					864:871	chia nutlet mucilage	852:871	chia nutlet mucilage	852:871	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	6	17	theme	gas	1254:1256	arg1	technique					1269:1277	an in vitro cumulative gas production technique	1231:1277	an in vitro cumulative gas production technique	1231:1277	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	3	18	theme	gut	730:732	arg1	microbiota					734:743	gut microbiota	730:743	gut microbiota	730:743	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	1	19	theme	dietary	282:288	arg1	content					296:302	their dietary fibre content	276:302	their dietary fibre content	276:302	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	4	20	theme	polymer	922:928	arg1	types					930:934	several polymer types	914:934	several polymer types	914:934	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	6	21	theme	nutlet	1338:1343	arg1	preparations					1345:1356	different chia nutlet preparations	1323:1356	different chia nutlet preparations	1323:1356	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	1	22	theme	content	296:302	arg1	part					268:271	a significant part	254:271	a significant part of their dietary fibre content	254:302	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	6	23	theme	different	1323:1331	arg1	preparations					1345:1356	different chia nutlet preparations	1323:1356	different chia nutlet preparations	1323:1356	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	9	24	theme	superfood	1717:1725	arg1	"					1726:1726	a "superfood"	1714:1726	a "superfood"	1714:1726	Therefore, it is suggested that the benefits of eating chia as a "superfood", could be notably enhanced if the nutlets are ground rather than being consumed whole, improving the bioaccessibility of key nutrients including dietary fibre.
36637177	2	25	theme	texture	345:351	arg1	hydrocolloid					363:374	a texture modifying hydrocolloid	343:374	a texture modifying hydrocolloid	343:374	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	0	26	theme	improved	73:80	arg1	fermentation					91:102	the improved in vitro fermentation	69:102	the improved in vitro fermentation of nutlets when ground	69:125	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	0	27	theme	Novel	0:4	arg1	constituents					6:17	Novel constituents	0:17	Novel constituents of Salvia hispanica L. (chia)	0:47	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	5	28	theme	alcohol-soluble	1130:1144	arg1	oligosaccharides					1146:1161	abundant alcohol-soluble oligosaccharides	1121:1161	abundant alcohol-soluble oligosaccharides	1121:1161	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	8	29	theme	note	1528:1531	arg1	fermented					1566:1574	fermented	1566:1574	fermented	1566:1574	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	3	30	theme	better	609:614	arg1	understanding					616:628	a better understanding	607:628	a better understanding	607:628	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	0	31	theme	hispanica	29:37	arg1	constituents					6:17	Novel constituents	0:17	Novel constituents of Salvia hispanica L. (chia)	0:47	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	1	32	theme	significant	256:266	arg1	part					268:271	a significant part	254:271	a significant part of their dietary fibre content	254:302	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	7	33	theme	present	1500:1506	arg1	substrate					1490:1498	the only fermentable substrate	1469:1498	the only fermentable substrate present in the mucilage	1469:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	33	theme	present	1500:1506	arg1	oligosaccharides					1437:1452	the oligosaccharides	1433:1452	the oligosaccharides	1433:1452	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	2	34	theme	water-binding	413:425	arg1	ability					427:433	its water-binding ability	409:433	its water-binding ability	409:433	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	8	35	theme	ground	1534:1539	arg1	nutlets					1546:1552	ground chia nutlets	1534:1552	ground chia nutlets	1534:1552	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	7	36	theme	fermentable	1478:1488	arg1	substrate					1490:1498	the only fermentable substrate	1469:1498	the only fermentable substrate present in the mucilage	1469:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	36	theme	fermentable	1478:1488	arg1	oligosaccharides					1437:1452	the oligosaccharides	1433:1452	the oligosaccharides	1433:1452	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	0	37	dep	hispanica	29:37	arg1	L					39:39	L	39:39	Salvia hispanica L. (chia)	22:47	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	7	38	attach	present	1500:1506	arg2	substrate					1490:1498	the only fermentable substrate	1469:1498	the only fermentable substrate present in the mucilage	1469:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	38	attach	present	1500:1506	arg2	oligosaccharides					1437:1452	the oligosaccharides	1433:1452	the oligosaccharides	1433:1452	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	38	attach	present	1500:1506	arg1	mucilage					1515:1522	the mucilage	1511:1522	the mucilage	1511:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	1	39	dep	Salvia	148:153	arg1	L.					165:166	Salvia hispanica L.	148:166	Salvia hispanica L.	148:166	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	8	40	theme	short	1616:1620	arg1	acid					1634:1637	short chain fatty acid	1616:1637	short chain fatty acid production	1616:1648	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	3	41	theme	fibre	665:669	arg1	functionality					671:683	its dietary fibre functionality	653:683	its dietary fibre functionality	653:683	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	6	42	theme	cumulative	1243:1252	arg1	technique					1269:1277	an in vitro cumulative gas production technique	1231:1277	an in vitro cumulative gas production technique	1231:1277	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	8	43	theme	fatty	1628:1632	arg1	acid					1634:1637	short chain fatty acid	1616:1637	short chain fatty acid production	1616:1648	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	8	44	theme	whole	1588:1592	arg1	nutlets					1594:1600	intact whole nutlets	1581:1600	intact whole nutlets	1581:1600	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	6	45	theme	in	1234:1235	arg1	technique					1269:1277	an in vitro cumulative gas production technique	1231:1277	an in vitro cumulative gas production technique	1231:1277	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	1	46	theme	polysaccharides	207:221	arg1	capsule					196:202	a gel-like capsule	185:202	a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content	185:302	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	7	47	from	mucilage	1515:1522	arg1	present					1500:1506	present	1500:1506	present	1500:1506	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	48	theme	poor	1409:1412	arg1	fermentation					1414:1425	poor fermentation	1409:1425	poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage	1409:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	49	theme	mucilage	1393:1400	arg1	nature					1371:1376	The complex nature	1359:1376	The complex nature of chia nutlet mucilage	1359:1400	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	6	50	theme	nutlet	1214:1219	arg1	mucilage					1221:1228	chia nutlet mucilage	1209:1228	chia nutlet mucilage	1209:1228	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	1	51	theme	chia	142:145	arg1	nutlets					169:175	chia (Salvia hispanica L.) nutlets	142:175	chia (Salvia hispanica L.) nutlets	142:175	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	7	52	theme	chia	1381:1384	arg1	mucilage					1393:1400	chia nutlet mucilage	1381:1400	chia nutlet mucilage	1381:1400	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	9	53	theme	key	1849:1851	arg1	nutrients					1853:1861	key nutrients	1849:1861	key nutrients	1849:1861	Therefore, it is suggested that the benefits of eating chia as a "superfood", could be notably enhanced if the nutlets are ground rather than being consumed whole, improving the bioaccessibility of key nutrients including dietary fibre.
36637177	4	54	dep	microscopy	761:770	arg1	techniques					829:838	profiling techniques	819:838	profiling techniques	819:838	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	4	55	theme	nutlet	857:862	arg1	mucilage					864:871	chia nutlet mucilage	852:871	chia nutlet mucilage	852:871	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	0	56	theme	nutlets	107:113	arg1	mucilage					56:63	mucilage	56:63	mucilage	56:63	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	0	56	theme	nutlets	107:113	arg1	fermentation					91:102	the improved in vitro fermentation	69:102	the improved in vitro fermentation of nutlets when ground	69:125	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	3	57	theme	chia	563:566	arg1	mucilage					575:582	chia nutlet mucilage	563:582	chia nutlet mucilage	563:582	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	6	58	used	used	1283:1286	arg2	technique					1269:1277	an in vitro cumulative gas production technique	1231:1277	an in vitro cumulative gas production technique	1231:1277	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	5	59	theme	near-linear	1036:1046	arg1	xylan					1048:1052	a near-linear xylan	1034:1052	a near-linear xylan that may be sparsely substituted	1034:1085	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	6	60	theme	dietary	1178:1184	arg1	functionality					1192:1204	the dietary fibre functionality	1174:1204	the dietary fibre functionality of chia nutlet mucilage	1174:1228	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	6	61	theme	production	1258:1267	arg1	technique					1269:1277	an in vitro cumulative gas production technique	1231:1277	an in vitro cumulative gas production technique	1231:1277	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	2	62	from	sources	482:488	arg1	utility					447:453	the utility	443:453	the utility of mucilage from different sources	443:488	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	2	62	from	sources	482:488	arg1	dependent					519:527	dependent	519:527	dependent	519:527	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	2	62	from	sources	482:488	arg1	mucilage					458:465	mucilage	458:465	mucilage from different sources	458:488	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	2	63	used	used	335:338	arg2	mucilage					317:324	Seed/nutlet mucilage	305:324	Seed/nutlet mucilage	305:324	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	3	64	theme	mucilage	575:582	arg1	structure					550:558	structure	550:558	structure	550:558	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	3	64	theme	mucilage	575:582	arg1	composition					534:544	composition	534:544	composition	534:544	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	9	65	theme	eating	1699:1704	arg1	chia					1706:1709	eating chia	1699:1709	eating chia	1699:1709	Therefore, it is suggested that the benefits of eating chia as a "superfood", could be notably enhanced if the nutlets are ground rather than being consumed whole, improving the bioaccessibility of key nutrients including dietary fibre.
36637177	6	66	theme	preparations	1345:1356	arg1	fermentability					1305:1318	the fermentability	1301:1318	the fermentability of different chia nutlet preparations	1301:1356	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	1	67	theme	fibre	290:294	arg1	content					296:302	their dietary fibre content	276:302	their dietary fibre content	276:302	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
36637177	3	68	dep	composition	534:544	arg1	The					530:532	The	530:532	The	530:532	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	4	69	theme	several	914:920	arg1	types					930:934	several polymer types	914:934	several polymer types	914:934	In this study, microscopy, chromatography, mass spectrometry and glycome profiling techniques showed that chia nutlet mucilage is highly complex, layered, and contains several polymer types.
36637177	6	70	theme	chia	1333:1336	arg1	preparations					1345:1356	different chia nutlet preparations	1323:1356	different chia nutlet preparations	1323:1356	To assess the dietary fibre functionality of chia nutlet mucilage, an in vitro cumulative gas production technique was used to determine the fermentability of different chia nutlet preparations.
36637177	0	71	dep	in	82:83	arg1	vitro					85:89	vitro	85:89	vitro	85:89	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	2	72	theme	different	472:480	arg1	sources					482:488	different sources	472:488	different sources	472:488	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	0	73	theme	in	82:83	arg1	fermentation					91:102	the improved in vitro fermentation	69:102	the improved in vitro fermentation of nutlets when ground	69:125	Novel constituents of Salvia hispanica L. (chia) nutlet mucilage and the improved in vitro fermentation of nutlets when ground.
36637177	2	74	theme	mucilage	458:465	arg1	utility					447:453	the utility	443:453	the utility of mucilage from different sources	443:488	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	2	74	theme	mucilage	458:465	arg1	dependent					519:527	dependent	519:527	dependent	519:527	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	5	75	theme	abundant	1121:1128	arg1	oligosaccharides					1146:1161	abundant alcohol-soluble oligosaccharides	1121:1161	abundant alcohol-soluble oligosaccharides	1121:1161	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	8	76	theme	chia	1541:1544	arg1	nutlets					1546:1552	ground chia nutlets	1534:1552	ground chia nutlets	1534:1552	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	2	77	theme	modifying	353:361	arg1	hydrocolloid					363:374	a texture modifying hydrocolloid	343:374	a texture modifying hydrocolloid	343:374	Seed/nutlet mucilage is often used as a texture modifying hydrocolloid and bulking dietary fibre due to its water-binding ability, though the utility of mucilage from different sources is highly structure-function dependent.
36637177	5	78	theme	cellulose	1099:1107	arg1	domain					1109:1114	a modified cellulose domain	1088:1114	a modified cellulose domain	1088:1114	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	79	theme	novel	962:966	arg1	xyloamylose					968:978	a novel xyloamylose	960:978	a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides	960:1161	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	80	contain	containing	980:989	arg2	xylan					1048:1052	a near-linear xylan	1034:1052	a near-linear xylan that may be sparsely substituted	1034:1085	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	80	contain	containing	980:989	arg2	α-linked-glucose					1016:1031	α-linked-glucose	1016:1031	α-linked-glucose	1016:1031	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	80	contain	containing	980:989	arg2	domain					1109:1114	a modified cellulose domain	1088:1114	a modified cellulose domain	1088:1114	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	80	contain	containing	980:989	arg1	xyloamylose					968:978	a novel xyloamylose	960:978	a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides	960:1161	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	80	contain	containing	980:989	arg2	oligosaccharides					1146:1161	abundant alcohol-soluble oligosaccharides	1121:1161	abundant alcohol-soluble oligosaccharides	1121:1161	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	5	80	contain	containing	980:989	arg2	β-linked-xylose					996:1010	β-linked-xylose	996:1010	β-linked-xylose	996:1010	The mucilage comprises a novel xyloamylose containing both β-linked-xylose and α-linked-glucose, a near-linear xylan that may be sparsely substituted, a modified cellulose domain, and abundant alcohol-soluble oligosaccharides.
36637177	9	81	theme	chia	1706:1709	arg1	benefits					1687:1694	the benefits	1683:1694	the benefits	1683:1694	Therefore, it is suggested that the benefits of eating chia as a "superfood", could be notably enhanced if the nutlets are ground rather than being consumed whole, improving the bioaccessibility of key nutrients including dietary fibre.
36637177	8	82	theme	chain	1622:1626	arg1	acid					1634:1637	short chain fatty acid	1616:1637	short chain fatty acid production	1616:1648	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	7	83	theme	only	1473:1476	arg1	substrate					1490:1498	the only fermentable substrate	1469:1498	the only fermentable substrate present in the mucilage	1469:1522	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	7	83	theme	only	1473:1476	arg1	oligosaccharides					1437:1452	the oligosaccharides	1433:1452	the oligosaccharides	1433:1452	The complex nature of chia nutlet mucilage led to poor fermentation where the oligosaccharides appeared to be the only fermentable substrate present in the mucilage.
36637177	8	84	theme	intact	1581:1586	arg1	nutlets					1594:1600	intact whole nutlets	1581:1600	intact whole nutlets	1581:1600	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	3	85	theme	dietary	657:663	arg1	functionality					671:683	its dietary fibre functionality	653:683	its dietary fibre functionality	653:683	The composition and structure of chia nutlet mucilage is poorly defined, and a better understanding will aid in exploiting its dietary fibre functionality, particularly if, and how, it is utilised by gut microbiota.
36637177	8	86	theme	acid	1634:1637	arg1	production					1639:1648	short chain fatty acid production	1616:1648	short chain fatty acid production	1616:1648	Of note, ground chia nutlets were better fermented than intact whole nutlets, as judged by short chain fatty acid production.
36637177	1	87	theme	gel-like	187:194	arg1	capsule					196:202	a gel-like capsule	185:202	a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content	185:302	Upon wetting, chia (Salvia hispanica L.) nutlets produce a gel-like capsule of polysaccharides called mucilage that comprises a significant part of their dietary fibre content.
35395480	8	0	theme	highest	1163:1169	arg1	properties					1183:1192	the highest emulsifying properties	1159:1192	the highest emulsifying properties of its resulting conjugates	1159:1220	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	5	1	theme	molecular	624:632	arg1	weight					634:639	the molecular weight	620:639	the molecular weight	620:639	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	7	2	theme	loosened	977:984	arg1	structure					994:1002	a more loosened protein structure	970:1002	a more loosened protein structure after Maillard reaction	970:1026	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	1	3	theme	isolate	218:224	arg1	properties					192:201	the emulsifying properties	176:201	the emulsifying properties of soy protein isolate (SPI)	176:230	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	6	4	theme	main	800:803	arg1	chains					805:810	less main chains	795:810	less main chains	795:810	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	0	5	theme	structural	65:74	arg1	modification					76:87	structural modification	65:87	structural modification of the grafting polysaccharide	65:118	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	7	6	theme	original	945:952	arg1	SPI					954:956	the original SPI	941:956	the original SPI	941:956	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	5	7	theme	Structural	572:581	arg1	weight					634:639	the molecular weight	620:639	the molecular weight	620:639	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	7	theme	Structural	572:581	arg1	degree					642:647	degree	642:647	degree of methoxylation and acetylation	642:680	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	7	theme	Structural	572:581	arg1	characteristics					583:597	Structural characteristics	572:597	Structural characteristics	572:597	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	7	theme	Structural	572:581	arg1	compositions					702:713	monosaccharide compositions	687:713	monosaccharide compositions	687:713	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	8	8	theme	simple	1125:1130	arg1	procedures					1144:1153	the simple preparation procedures	1121:1153	the simple preparation procedures	1121:1153	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	7	9	theme	surface	871:877	arg1	hydrophobicity					879:892	surface hydrophobicity	871:892	surface hydrophobicity	871:892	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	8	10	theme	emulsifying	1171:1181	arg1	properties					1183:1192	the highest emulsifying properties	1159:1192	the highest emulsifying properties of its resulting conjugates	1159:1220	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	7	11	theme	Fluorescence	844:855	arg1	intensity					857:865	Fluorescence intensity	844:865	Fluorescence intensity	844:865	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	4	12	theme	modified	554:561	arg1	samples					563:569	three modified samples	548:569	three modified samples	548:569	To address this problem, we employed alkaline or/and enzymatic treatments to modify pectin and obtained three modified samples.
35395480	5	13	theme	pectin	602:607	arg1	weight					634:639	the molecular weight	620:639	the molecular weight	620:639	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	13	theme	pectin	602:607	arg1	degree					642:647	degree	642:647	degree of methoxylation and acetylation	642:680	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	13	theme	pectin	602:607	arg1	characteristics					583:597	Structural characteristics	572:597	Structural characteristics	572:597	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	13	theme	pectin	602:607	arg1	compositions					702:713	monosaccharide compositions	687:713	monosaccharide compositions	687:713	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	1	14	theme	great	148:152	arg1	interest					154:161	a great interest	146:161	a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction	146:251	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	0	15	theme	modification	76:87	arg1	effects					54:60	effects	54:60	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.	0:119	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	6	16	theme	molecular	774:782	arg1	weight					784:789	lower molecular weight	768:789	lower molecular weight	768:789	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	8	17	theme	conjugates	1211:1220	arg1	properties					1183:1192	the highest emulsifying properties	1159:1192	the highest emulsifying properties of its resulting conjugates	1159:1220	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	8	17	theme	conjugates	1211:1220	arg1	procedures					1144:1153	the simple preparation procedures	1121:1153	the simple preparation procedures	1121:1153	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	6	18	theme	lower	768:772	arg1	weight					784:789	lower molecular weight	768:789	lower molecular weight	768:789	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	2	19	theme	grafting	273:280	arg1	polysaccharide					282:295	a commonly-used grafting polysaccharide	257:295	a commonly-used grafting polysaccharide	257:295	As a commonly-used grafting polysaccharide, pectin has proved useful in modifying proteins.
35395480	8	20	theme	optimum	1077:1083	arg1	polysaccharide					1094:1107	an optimum grafting polysaccharide	1074:1107	an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates	1074:1220	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	3	21	theme	characteristics	381:395	arg1	effects					355:361	effects	355:361	effects of its structural characteristics on conjugation	355:410	However, effects of its structural characteristics on conjugation are still not fully understood.
35395480	8	22	theme	resulting	1201:1209	arg1	conjugates					1211:1220	its resulting conjugates	1197:1220	its resulting conjugates	1197:1220	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	2	23	theme	commonly-used	259:271	arg1	polysaccharide					282:295	a commonly-used grafting polysaccharide	257:295	a commonly-used grafting polysaccharide	257:295	As a commonly-used grafting polysaccharide, pectin has proved useful in modifying proteins.
35395480	0	24	theme	protein	19:25	arg1	SPI					36:38	SPI	36:38	SPI	36:38	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	0	24	theme	protein	19:25	arg1	isolate					27:33	soy protein isolate	15:33	soy protein isolate (SPI)	15:39	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	1	25	theme	Maillard	235:242	arg1	reaction					244:251	Maillard reaction	235:251	Maillard reaction	235:251	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	0	26	theme	grafting	96:103	arg1	polysaccharide					105:118	the grafting polysaccharide	92:118	the grafting polysaccharide	92:118	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	6	27	with	pectin	756:761	arg1	chains					805:810	less main chains	795:810	less main chains	795:810	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	6	27	with	pectin	756:761	arg1	weight					784:789	lower molecular weight	768:789	lower molecular weight	768:789	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	0	28	theme	soy	15:17	arg1	SPI					36:38	SPI	36:38	SPI	36:38	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	0	28	theme	soy	15:17	arg1	isolate					27:33	soy protein isolate	15:33	soy protein isolate (SPI)	15:39	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	8	29	theme	enzymolysis	1048:1058	arg1	pectin					1060:1065	the enzymolysis pectin	1044:1065	the enzymolysis pectin	1044:1065	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	5	30	theme	monosaccharide	687:700	arg1	compositions					702:713	monosaccharide compositions	687:713	monosaccharide compositions	687:713	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	3	31	theme	structural	370:379	arg1	characteristics					381:395	its structural characteristics	366:395	its structural characteristics	366:395	However, effects of its structural characteristics on conjugation are still not fully understood.
35395480	4	32	theme	or/and	490:495	arg1	treatments					507:516	alkaline or/and enzymatic treatments	481:516	alkaline or/and enzymatic treatments	481:516	To address this problem, we employed alkaline or/and enzymatic treatments to modify pectin and obtained three modified samples.
35395480	0	33	theme	isolate	27:33	arg1	Conjugation					0:10	Conjugation	0:10	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.	0:119	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	1	34	theme	emulsifying	180:190	arg1	properties					192:201	the emulsifying properties	176:201	the emulsifying properties of soy protein isolate (SPI)	176:230	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	4	35	theme	alkaline	481:488	arg1	treatments					507:516	alkaline or/and enzymatic treatments	481:516	alkaline or/and enzymatic treatments	481:516	To address this problem, we employed alkaline or/and enzymatic treatments to modify pectin and obtained three modified samples.
35395480	0	36	theme	polysaccharide	105:118	arg1	modification					76:87	structural modification	65:87	structural modification of the grafting polysaccharide	65:118	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	5	37	theme	methoxylation	652:664	arg1	weight					634:639	the molecular weight	620:639	the molecular weight	620:639	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	37	theme	methoxylation	652:664	arg1	compositions					702:713	monosaccharide compositions	687:713	monosaccharide compositions	687:713	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	37	theme	methoxylation	652:664	arg1	degree					642:647	degree	642:647	degree of methoxylation and acetylation	642:680	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	6	38	theme	conjugate	827:835	arg1	yield					837:841	higher conjugate yield	820:841	higher conjugate yield	820:841	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	4	39	theme	enzymatic	497:505	arg1	treatments					507:516	alkaline or/and enzymatic treatments	481:516	alkaline or/and enzymatic treatments	481:516	To address this problem, we employed alkaline or/and enzymatic treatments to modify pectin and obtained three modified samples.
35395480	8	40	theme	preparation	1132:1142	arg1	procedures					1144:1153	the simple preparation procedures	1121:1153	the simple preparation procedures	1121:1153	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	6	41	theme	higher	820:825	arg1	yield					837:841	higher conjugate yield	820:841	higher conjugate yield	820:841	When conjugated with SPI, pectin with lower molecular weight and less main chains induced higher conjugate yield.
35395480	0	42	with	Conjugation	0:10	arg1	pectin					46:51	pectin	46:51	pectin	46:51	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	5	43	theme	acetylation	670:680	arg1	weight					634:639	the molecular weight	620:639	the molecular weight	620:639	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	43	theme	acetylation	670:680	arg1	compositions					702:713	monosaccharide compositions	687:713	monosaccharide compositions	687:713	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	5	43	theme	acetylation	670:680	arg1	degree					642:647	degree	642:647	degree of methoxylation and acetylation	642:680	Structural characteristics of pectin, including the molecular weight, degree of methoxylation and acetylation, and monosaccharide compositions were measured.
35395480	7	44	theme	protein	986:992	arg1	structure					994:1002	a more loosened protein structure	970:1002	a more loosened protein structure after Maillard reaction	970:1026	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	7	45	theme	Maillard	1010:1017	arg1	reaction					1019:1026	Maillard reaction	1010:1026	Maillard reaction	1010:1026	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	2	46	theme	modifying	326:334	arg1	proteins					336:343	modifying proteins	326:343	modifying proteins	326:343	As a commonly-used grafting polysaccharide, pectin has proved useful in modifying proteins.
35395480	7	47	theme	conjugates	901:910	arg1	hydrophobicity					879:892	surface hydrophobicity	871:892	surface hydrophobicity	871:892	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	7	47	theme	conjugates	901:910	arg1	intensity					857:865	Fluorescence intensity	844:865	Fluorescence intensity	844:865	Fluorescence intensity and surface hydrophobicity of all conjugates markedly reduced compared to the original SPI, suggesting a more loosened protein structure after Maillard reaction.
35395480	1	48	theme	soy	206:208	arg1	SPI					227:229	SPI	227:229	SPI	227:229	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	1	48	theme	soy	206:208	arg1	isolate					218:224	soy protein isolate	206:224	soy protein isolate (SPI)	206:230	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	3	49	from	effects	355:361	arg1	conjugation					400:410	conjugation	400:410	conjugation	400:410	However, effects of its structural characteristics on conjugation are still not fully understood.
35395480	0	50	dep	Conjugation	0:10	arg1	effects					54:60	effects	54:60	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.	0:119	Conjugation of soy protein isolate (SPI) with pectin: effects of structural modification of the grafting polysaccharide.
35395480	8	51	theme	grafting	1085:1092	arg1	polysaccharide					1094:1107	an optimum grafting polysaccharide	1074:1107	an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates	1074:1220	In this study, the enzymolysis pectin proved an optimum grafting polysaccharide considering the simple preparation procedures and the highest emulsifying properties of its resulting conjugates.
35395480	1	52	theme	protein	210:216	arg1	SPI					227:229	SPI	227:229	SPI	227:229	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
35395480	1	52	theme	protein	210:216	arg1	isolate					218:224	soy protein isolate	206:224	soy protein isolate (SPI)	206:230	Recently, there has been a great interest in enhancing the emulsifying properties of soy protein isolate (SPI) by Maillard reaction.
36046862	0	0	theme	Epimedii	95:102	arg1	Folium					104:109	Epimedii Folium	95:109	Epimedii Folium	95:109	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Man					1159:1161	Man	1159:1161	Man	1159:1161	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Gal					1417:1419	Gal	1417:1419	Gal	1417:1419	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Rha					1187:1189	Rha	1187:1189	Rha	1187:1189	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	arabinose					1240:1248	arabinose	1240:1248	arabinose	1240:1248	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Xyl					1422:1424	Xyl	1422:1424	Xyl	1422:1424	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Rha					1359:1361	Rha	1359:1361	Rha	1359:1361	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Xyl					1230:1232	Xyl	1230:1232	Xyl	1230:1232	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	glucose					1193:1199	glucose	1193:1199	glucose(Glc)	1193:1204	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Ara					1431:1433	Ara	1431:1433	Ara	1431:1433	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Fuc					1145:1147	Fuc	1145:1147	Fuc	1145:1147	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Rib					1172:1174	Rib	1172:1174	Rib	1172:1174	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Ara					1250:1252	Ara	1250:1252	Ara	1250:1252	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Glc					1412:1414	Glc	1412:1414	Glc	1412:1414	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Gal					1217:1219	Gal	1217:1219	Gal	1217:1219	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	acid					1375:1378	glucuronic acid	1364:1378	glucuronic acid(GlcA)	1364:1384	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	rhamnose					1178:1185	rhamnose	1178:1185	rhamnose(Rha)	1178:1190	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Glc					1201:1203	Glc	1201:1203	Glc	1201:1203	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	Man					1354:1356	Man	1354:1356	Man	1354:1356	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	mannose					1151:1157	mannose	1151:1157	mannose(Man)	1151:1162	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	xylose					1223:1228	xylose	1223:1228	xylose	1223:1228	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	acid					1400:1403	galacturonic acid	1387:1403	galacturonic acid(GalA)	1387:1409	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	ribose					1165:1170	ribose	1165:1170	ribose(Rib)	1165:1175	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	galactose					1207:1215	galactose	1207:1215	galactose	1207:1215	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	1	from	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	arg1	fructose					1136:1143	fructose	1136:1143	fructose(Fuc)	1136:1148	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	4	2	theme	PMP	771:773	arg1	derivatization					776:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	2	theme	PMP	771:773	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	3	3	theme	present	354:360	arg1	study					362:366	The present study	350:366	The present study	350:366	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	1	4	contain	possesses	129:137	arg2	anti-oxidation					199:212	anti-oxidation	199:212	anti-oxidation	199:212	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	4	contain	possesses	129:137	arg1	Folium					122:127	Epimedii Folium	113:127	Epimedii Folium	113:127	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	4	contain	possesses	129:137	arg2	immunomodulation					181:196	immunomodulation	181:196	immunomodulation	181:196	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	4	contain	possesses	129:137	arg2	anti-tumor					219:228	anti-tumor	219:228	anti-tumor	219:228	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	4	contain	possesses	129:137	arg2	activities					160:169	many pharmacological activities	139:169	many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor	139:228	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	7	5	theme	inflammatory	1652:1663	arg1	IL-12					1681:1685	IL-12	1681:1685	IL-12	1681:1685	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	5	theme	inflammatory	1652:1663	arg1	TNF-α					1692:1696	TNF-α	1692:1696	TNF-α	1692:1696	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	5	theme	inflammatory	1652:1663	arg1	IL-6					1675:1678	IL-6	1675:1678	IL-6	1675:1678	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	5	theme	inflammatory	1652:1663	arg1	cytokines					1665:1673	inflammatory cytokines	1652:1673	inflammatory cytokines(IL-6, IL-12, and TNF-α)	1652:1697	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	6	6	theme	glucuronic	1364:1373	arg1	acid					1375:1378	glucuronic acid	1364:1378	glucuronic acid(GlcA)	1364:1384	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	6	theme	glucuronic	1364:1373	arg1	fructose					1136:1143	fructose	1136:1143	fructose(Fuc)	1136:1148	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	6	theme	glucuronic	1364:1373	arg1	GlcA					1380:1383	GlcA	1380:1383	GlcA	1380:1383	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	7	7	theme	immunomodulatory	1777:1792	arg1	activity					1794:1801	good immunomodulatory activity	1772:1801	good immunomodulatory activity	1772:1801	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	8	theme	cytokines	1665:1673	arg1	levels					1642:1647	the levels	1638:1647	the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity	1638:1801	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	4	9	theme	gel	654:656	arg1	chromatography					669:682	high-performance gel permeation chromatography	637:682	high-performance gel permeation chromatography(HPGPC)	637:689	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	9	theme	gel	654:656	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	9	theme	gel	654:656	arg1	HPGPC					684:688	HPGPC	684:688	HPGPC	684:688	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	5	10	from	effects	942:948	arg1	maturation					957:966	the maturation	953:966	the maturation of bone marrow-derived dendritic cells(BMDCs)	953:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	10	from	effects	942:948	arg1	release					1022:1028	the release	1018:1028	the release of inflammatory cytokines	1018:1054	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	4	11	theme	scanning	792:799	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	11	theme	scanning	792:799	arg1	SEM					821:823	SEM	821:823	SEM	821:823	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	11	theme	scanning	792:799	arg1	microscopy					810:819	scanning electron microscopy	792:819	scanning electron microscopy(SEM)	792:824	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	3	12	theme	DEAE-52	501:507	arg1	chromatography					534:547	DEAE-52 cellulose anion-exchange chromatography	501:547	DEAE-52 cellulose anion-exchange chromatography	501:547	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	6	13	theme	molar	1298:1302	arg1	ratio					1304:1308	molar ratio	1298:1308	molar ratio	1298:1308	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	13	theme	molar	1298:1302	arg1	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37					1258:1296	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37	1258:1296	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	4	14	theme	red	833:835	arg1	test					837:840	Congo red test	827:840	Congo red test	827:840	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	14	theme	red	833:835	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	5	15	theme	marrow-derived	976:989	arg1	BMDCs					1007:1011	BMDCs	1007:1011	BMDCs	1007:1011	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	15	theme	marrow-derived	976:989	arg1	cells					1001:1005	bone marrow-derived dendritic cells	971:1005	bone marrow-derived dendritic cells(BMDCs)	971:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	3	16	theme	neutral	379:385	arg1	EPS-1-1					402:408	EPS-1-1	402:408	EPS-1-1	402:408	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	3	16	theme	neutral	379:385	arg1	polysaccharide					387:400	a neutral polysaccharide	377:400	a neutral polysaccharide(EPS-1-1)	377:409	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	7	17	theme	good	1772:1775	arg1	activity					1794:1801	good immunomodulatory activity	1772:1801	good immunomodulatory activity	1772:1801	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	4	18	theme	Congo	827:831	arg1	test					837:840	Congo red test	827:840	Congo red test	827:840	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	18	theme	Congo	827:831	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	3	19	theme	aqueous	458:464	arg1	extract					466:472	the aqueous extract	454:472	the aqueous extract of Epimedii Folium	454:491	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	5	20	theme	cells	1001:1005	arg1	maturation					957:966	the maturation	953:966	the maturation of bone marrow-derived dendritic cells(BMDCs)	953:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	20	theme	cells	1001:1005	arg1	release					1022:1028	the release	1018:1028	the release of inflammatory cytokines	1018:1054	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	21	theme	immunomodulatory	852:867	arg1	activity					869:876	The immunomodulatory activity	848:876	The immunomodulatory activity of polysaccharides in vitro	848:904	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	4	22	theme	electron	801:808	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	22	theme	electron	801:808	arg1	SEM					821:823	SEM	821:823	SEM	821:823	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	22	theme	electron	801:808	arg1	microscopy					810:819	scanning electron microscopy	792:819	scanning electron microscopy(SEM)	792:824	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	7	23	theme	BMDCs	1548:1552	arg1	function					1536:1543	function	1536:1543	function	1536:1543	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	23	theme	BMDCs	1548:1552	arg1	maturation					1521:1530	the maturation	1517:1530	the maturation	1517:1530	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	24	from	levels	1642:1647	arg1	experiments					1708:1718	vitro experiments	1702:1718	vitro experiments	1702:1718	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	5	25	theme	dendritic	991:999	arg1	BMDCs					1007:1011	BMDCs	1007:1011	BMDCs	1007:1011	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	25	theme	dendritic	991:999	arg1	cells					1001:1005	bone marrow-derived dendritic cells	971:1005	bone marrow-derived dendritic cells(BMDCs)	971:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	3	26	theme	Epimedii	477:484	arg1	Folium					486:491	Epimedii Folium	477:491	Epimedii Folium	477:491	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	0	27	theme	immunomodulatory	17:32	arg1	activity					34:41	immunomodulatory activity	17:41	immunomodulatory activity	17:41	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	4	28	theme	composition	615:625	arg1	etc					843:845	etc	843:845	etc	843:845	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	28	theme	composition	615:625	arg1	derivatization					776:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	28	theme	composition	615:625	arg1	chromatography					669:682	high-performance gel permeation chromatography	637:682	high-performance gel permeation chromatography(HPGPC)	637:689	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	28	theme	composition	615:625	arg1	microscopy					810:819	scanning electron microscopy	792:819	scanning electron microscopy(SEM)	792:824	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	28	theme	composition	615:625	arg1	spectrometry					719:730	Fourier-transform infrared spectrometry	692:730	Fourier-transform infrared spectrometry(FT-IR)	692:737	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	28	theme	composition	615:625	arg1	test					837:840	Congo red test	827:840	Congo red test	827:840	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	28	theme	composition	615:625	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	1	29	theme	Epimedii	113:120	arg1	Folium					122:127	Epimedii Folium	113:127	Epimedii Folium	113:127	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	3	30	theme	Folium	486:491	arg1	extract					466:472	the aqueous extract	454:472	the aqueous extract of Epimedii Folium	454:491	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	0	31	theme	neutral	46:52	arg1	polysaccharides					65:79	neutral and acidic polysaccharides	46:79	neutral and acidic polysaccharides isolated from Epimedii Folium	46:109	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	4	32	theme	chemical	606:613	arg1	etc					843:845	etc	843:845	etc	843:845	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	32	theme	chemical	606:613	arg1	derivatization					776:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	32	theme	chemical	606:613	arg1	chromatography					669:682	high-performance gel permeation chromatography	637:682	high-performance gel permeation chromatography(HPGPC)	637:689	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	32	theme	chemical	606:613	arg1	microscopy					810:819	scanning electron microscopy	792:819	scanning electron microscopy(SEM)	792:824	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	32	theme	chemical	606:613	arg1	spectrometry					719:730	Fourier-transform infrared spectrometry	692:730	Fourier-transform infrared spectrometry(FT-IR)	692:737	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	32	theme	chemical	606:613	arg1	test					837:840	Congo red test	827:840	Congo red test	827:840	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	32	theme	chemical	606:613	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	7	33	theme	MHC-Ⅱ	1594:1598	arg1	expression					1580:1589	the expression	1576:1589	the expression of MHC-Ⅱ, CD86, CD80, and CD40	1576:1620	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	2	34	theme	Epimedii	274:281	arg1	Folium					283:288	Epimedii Folium	274:288	Epimedii Folium	274:288	Polysaccharides are the main components of Epimedii Folium, and their activities are closely related to the structure.
36046862	7	35	dep	cytokines	1665:1673	arg1	IL-12					1681:1685	IL-12	1681:1685	IL-12	1681:1685	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	35	dep	cytokines	1665:1673	arg1	TNF-α					1692:1696	TNF-α	1692:1696	TNF-α	1692:1696	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	35	dep	cytokines	1665:1673	arg1	IL-6					1675:1678	IL-6	1675:1678	IL-6	1675:1678	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	35	dep	cytokines	1665:1673	arg1	cytokines					1665:1673	inflammatory cytokines	1652:1673	inflammatory cytokines(IL-6, IL-12, and TNF-α)	1652:1697	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	4	36	theme	infrared	710:717	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	36	theme	infrared	710:717	arg1	FT-IR					732:736	FT-IR	732:736	FT-IR	732:736	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	36	theme	infrared	710:717	arg1	spectrometry					719:730	Fourier-transform infrared spectrometry	692:730	Fourier-transform infrared spectrometry(FT-IR)	692:737	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	37	theme	1-phenyl-3-methyl-5-pyrazolone	740:769	arg1	derivatization					776:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization	740:789	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	37	theme	1-phenyl-3-methyl-5-pyrazolone	740:769	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	Glc					1412:1414	Glc	1412:1414	Glc	1412:1414	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	Ara					1431:1433	Ara	1431:1433	Ara	1431:1433	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	acid					1375:1378	glucuronic acid	1364:1378	glucuronic acid(GlcA)	1364:1384	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	acid					1400:1403	galacturonic acid	1387:1403	galacturonic acid(GalA)	1387:1409	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	GalA					1405:1408	GalA	1405:1408	GalA	1405:1408	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	Xyl					1422:1424	Xyl	1422:1424	Xyl	1422:1424	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	GlcA					1380:1383	GlcA	1380:1383	GlcA	1380:1383	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	38	from	5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2	1438:1480	arg1	fructose					1136:1143	fructose	1136:1143	fructose(Fuc)	1136:1148	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	5	39	theme	bone	971:974	arg1	BMDCs					1007:1011	BMDCs	1007:1011	BMDCs	1007:1011	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	39	theme	bone	971:974	arg1	cells					1001:1005	bone marrow-derived dendritic cells	971:1005	bone marrow-derived dendritic cells(BMDCs)	971:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	4	40	theme	Fourier-transform	692:708	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	40	theme	Fourier-transform	692:708	arg1	FT-IR					732:736	FT-IR	732:736	FT-IR	732:736	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	40	theme	Fourier-transform	692:708	arg1	spectrometry					719:730	Fourier-transform infrared spectrometry	692:730	Fourier-transform infrared spectrometry(FT-IR)	692:737	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	3	41	theme	acidic	418:423	arg1	polysaccharide					425:438	an acidic polysaccharide	415:438	an acidic polysaccharide(EPS-2-1)	415:447	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	3	41	theme	acidic	418:423	arg1	EPS-2-1					440:446	EPS-2-1	440:446	EPS-2-1	440:446	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	5	42	link	marrow-derived	976:989	arg1	BMDCs					1007:1011	BMDCs	1007:1011	BMDCs	1007:1011	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	42	link	marrow-derived	976:989	arg1	cells					1001:1005	bone marrow-derived dendritic cells	971:1005	bone marrow-derived dendritic cells(BMDCs)	971:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	0	43	theme	polysaccharides	65:79	arg1	[Composition					0:11	[Composition	0:11	[Composition	0:11	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	0	43	theme	polysaccharides	65:79	arg1	activity					34:41	immunomodulatory activity	17:41	immunomodulatory activity	17:41	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	0	44	attach	isolated	81:88	arg2	polysaccharides					65:79	neutral and acidic polysaccharides	46:79	neutral and acidic polysaccharides isolated from Epimedii Folium	46:109	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	0	44	attach	isolated	81:88	arg1	Folium					104:109	Epimedii Folium	95:109	Epimedii Folium	95:109	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	3	45	theme	cellulose	509:517	arg1	chromatography					534:547	DEAE-52 cellulose anion-exchange chromatography	501:547	DEAE-52 cellulose anion-exchange chromatography	501:547	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	2	46	theme	main	255:258	arg1	Polysaccharides					231:245	Polysaccharides	231:245	Polysaccharides	231:245	Polysaccharides are the main components of Epimedii Folium, and their activities are closely related to the structure.
36046862	2	46	theme	main	255:258	arg1	components					260:269	the main components	251:269	the main components of Epimedii Folium	251:288	Polysaccharides are the main components of Epimedii Folium, and their activities are closely related to the structure.
36046862	3	47	theme	anion-exchange	519:532	arg1	chromatography					534:547	DEAE-52 cellulose anion-exchange chromatography	501:547	DEAE-52 cellulose anion-exchange chromatography	501:547	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	6	48	theme	galacturonic	1387:1398	arg1	GalA					1405:1408	GalA	1405:1408	GalA	1405:1408	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	48	theme	galacturonic	1387:1398	arg1	acid					1400:1403	galacturonic acid	1387:1403	galacturonic acid(GalA)	1387:1409	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	6	48	theme	galacturonic	1387:1398	arg1	fructose					1136:1143	fructose	1136:1143	fructose(Fuc)	1136:1148	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	5	49	theme	inflammatory	1033:1044	arg1	cytokines					1046:1054	inflammatory cytokines	1033:1054	inflammatory cytokines	1033:1054	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	6	50	theme	structural	1074:1083	arg1	analysis					1102:1109	the structural characterization analysis	1070:1109	the structural characterization analysis	1070:1109	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	1	51	theme	many	139:142	arg1	anti-oxidation					199:212	anti-oxidation	199:212	anti-oxidation	199:212	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	51	theme	many	139:142	arg1	anti-tumor					219:228	anti-tumor	219:228	anti-tumor	219:228	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	51	theme	many	139:142	arg1	immunomodulation					181:196	immunomodulation	181:196	immunomodulation	181:196	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	51	theme	many	139:142	arg1	activities					160:169	many pharmacological activities	139:169	many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor	139:228	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	7	52	theme	CD40	1617:1620	arg1	expression					1580:1589	the expression	1576:1589	the expression of MHC-Ⅱ, CD86, CD80, and CD40	1576:1620	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	6	53	theme	characterization	1085:1100	arg1	analysis					1102:1109	the structural characterization analysis	1070:1109	the structural characterization analysis	1070:1109	According to the structural characterization analysis, EPS-1-1 was composed of fructose(Fuc), mannose(Man), ribose(Rib), rhamnose(Rha), glucose(Glc), galactose(Gal), xylose(Xyl), and arabinose(Ara) at 1.90∶0.67∶0.05∶0.08∶3.29∶1.51∶0.05∶0.37(molar ratio), while EPS-2-1 was mainly composed of Fuc, Man, Rha, glucuronic acid(GlcA), galacturonic acid(GalA), Glc, Gal, Xyl, and Ara at 5.25∶0.18∶0.32∶0.13∶1.14∶0.16∶0.55∶0.08∶0.2.
36046862	7	54	theme	vitro	1702:1706	arg1	experiments					1708:1718	vitro experiments	1702:1718	vitro experiments	1702:1718	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	5	55	theme	cytokines	1046:1054	arg1	maturation					957:966	the maturation	953:966	the maturation of bone marrow-derived dendritic cells(BMDCs)	953:1012	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	5	55	theme	cytokines	1046:1054	arg1	release					1022:1028	the release	1018:1028	the release of inflammatory cytokines	1018:1054	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	1	56	theme	pharmacological	144:158	arg1	anti-oxidation					199:212	anti-oxidation	199:212	anti-oxidation	199:212	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	56	theme	pharmacological	144:158	arg1	anti-tumor					219:228	anti-tumor	219:228	anti-tumor	219:228	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	56	theme	pharmacological	144:158	arg1	immunomodulation					181:196	immunomodulation	181:196	immunomodulation	181:196	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	1	56	theme	pharmacological	144:158	arg1	activities					160:169	many pharmacological activities	139:169	many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor	139:228	Epimedii Folium possesses many pharmacological activities including immunomodulation, anti-oxidation, and anti-tumor.
36046862	7	57	theme	CD80	1607:1610	arg1	expression					1580:1589	the expression	1576:1589	the expression of MHC-Ⅱ, CD86, CD80, and CD40	1576:1620	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	4	58	theme	permeation	658:667	arg1	chromatography					669:682	high-performance gel permeation chromatography	637:682	high-performance gel permeation chromatography(HPGPC)	637:689	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	58	theme	permeation	658:667	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	58	theme	permeation	658:667	arg1	HPGPC					684:688	HPGPC	684:688	HPGPC	684:688	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	5	59	theme	polysaccharides	881:895	arg1	activity					869:876	The immunomodulatory activity	848:876	The immunomodulatory activity of polysaccharides in vitro	848:904	The immunomodulatory activity of polysaccharides in vitro was determined by investigating the effects on the maturation of bone marrow-derived dendritic cells(BMDCs) and the release of inflammatory cytokines.
36046862	3	60	theme	Sephadex	553:560	arg1	G-100					562:566	Sephadex G-100	553:566	Sephadex G-100	553:566	The present study isolated a neutral polysaccharide(EPS-1-1) and an acidic polysaccharide(EPS-2-1) from the aqueous extract of Epimedii Folium through DEAE-52 cellulose anion-exchange chromatography and Sephadex G-100.
36046862	7	61	contain	possessed	1762:1770	arg2	activity					1794:1801	good immunomodulatory activity	1772:1801	good immunomodulatory activity	1772:1801	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	61	contain	possessed	1762:1770	arg1	EPS-2-1					1754:1760	EPS-2-1	1754:1760	EPS-2-1	1754:1760	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	7	61	contain	possessed	1762:1770	arg1	EPS-1-1					1742:1748	EPS-1-1	1742:1748	EPS-1-1	1742:1748	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36046862	4	62	theme	high-performance	637:652	arg1	chromatography					669:682	high-performance gel permeation chromatography	637:682	high-performance gel permeation chromatography(HPGPC)	637:689	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	62	theme	high-performance	637:652	arg1	analysis					627:634	chemical composition analysis	606:634	chemical composition analysis	606:634	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	4	62	theme	high-performance	637:652	arg1	HPGPC					684:688	HPGPC	684:688	HPGPC	684:688	The structures were characterized by chemical composition analysis, high-performance gel permeation chromatography(HPGPC), Fourier-transform infrared spectrometry(FT-IR), 1-phenyl-3-methyl-5-pyrazolone(PMP) derivatization, scanning electron microscopy(SEM), Congo red test, etc.
36046862	0	63	theme	acidic	58:63	arg1	polysaccharides					65:79	neutral and acidic polysaccharides	46:79	neutral and acidic polysaccharides isolated from Epimedii Folium	46:109	[Composition and immunomodulatory activity of neutral and acidic polysaccharides isolated from Epimedii Folium].
36046862	2	64	theme	Folium	283:288	arg1	Polysaccharides					231:245	Polysaccharides	231:245	Polysaccharides	231:245	Polysaccharides are the main components of Epimedii Folium, and their activities are closely related to the structure.
36046862	2	64	theme	Folium	283:288	arg1	components					260:269	the main components	251:269	the main components of Epimedii Folium	251:288	Polysaccharides are the main components of Epimedii Folium, and their activities are closely related to the structure.
36046862	7	65	theme	CD86	1601:1604	arg1	expression					1580:1589	the expression	1576:1589	the expression of MHC-Ⅱ, CD86, CD80, and CD40	1576:1620	EPS-1-1 and EPS-2-1 could promote the maturation and function of BMDCs through up-regulating the expression of MHC-Ⅱ, CD86, CD80, and CD40, and increasing the levels of inflammatory cytokines(IL-6, IL-12, and TNF-α) in vitro experiments, which suggested that EPS-1-1 and EPS-2-1 possessed good immunomodulatory activity.
36432137	2	0	theme	Mössbauer	414:422	arg1	spectroscopy					424:435	XRD, Mössbauer spectroscopy	409:435	XRD, Mössbauer spectroscopy	409:435	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	4	1	theme	Langmuir	709:716	arg1	pseudo-second-order					719:737	the Langmuir, pseudo-second-order, and pseudo-first-order models	705:768	pseudo-second-order	719:737	The data obtained are in better agreement with the Langmuir, pseudo-second-order, and pseudo-first-order models only for GO-MGH.
36432137	4	2	with	agreement	690:698	arg1	models					763:768	the Langmuir, pseudo-second-order, and pseudo-first-order models	705:768	models	763:768	The data obtained are in better agreement with the Langmuir, pseudo-second-order, and pseudo-first-order models only for GO-MGH.
36432137	4	2	with	agreement	690:698	arg1	pseudo-second-order					719:737	the Langmuir, pseudo-second-order, and pseudo-first-order models	705:768	pseudo-second-order	719:737	The data obtained are in better agreement with the Langmuir, pseudo-second-order, and pseudo-first-order models only for GO-MGH.
36432137	9	3	from	pre-concentration	1335:1351	arg1	waters					1388:1393	natural waters	1380:1393	natural waters	1380:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	0	4	theme	Ions	91:94	arg1	Adsorption					68:77	the Adsorption	64:77	the Adsorption of Europium Ions from Aqueous Solutions	64:117	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36432137	7	5	from	waters	1011:1016	arg1	Tests					976:980	Tests	976:980	Tests of the composites in natural waters	976:1016	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	2	6	theme	morphological	302:314	arg1	characteristics					316:330	The physicochemical and morphological characteristics	278:330	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III	278:388	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	8	7	theme	good	1136:1139	arg1	ability					1152:1158	quite good predictive ability	1130:1158	quite good predictive ability	1130:1158	The ANFIS model has quite good predictive ability, as shown by the values for R2, MSE, SSE, and ARE.
36432137	9	8	from	waters	1388:1393	arg1	pre-concentration					1335:1351	the pre-concentration	1331:1351	the pre-concentration of Pu(IV) and Am(III) from natural waters	1331:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	8	from	waters	1388:1393	arg1	Pu					1356:1357	Pu(IV)	1356:1361	Pu(IV)	1356:1361	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	8	from	waters	1388:1393	arg1	Eu					1319:1320	Eu(III)	1319:1325	Eu(III)	1319:1325	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	8	from	waters	1388:1393	arg1	Am					1367:1368	Am(III)	1367:1373	Am(III)	1367:1373	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	2	9	dep	composites	339:348	arg1	GO-MGH-CS					365:373	GO-MGH-CS I, II, and III	365:388	GO-MGH-CS I, II, and III	365:388	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	2	9	dep	composites	339:348	arg1	GO-CS					358:362	GO-CS	358:362	GO-CS	358:362	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	2	9	dep	composites	339:348	arg1	GO-MGH					350:355	GO-MGH	350:355	GO-MGH	350:355	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	9	10	theme	adsorption	1250:1259	arg1	capacity					1261:1268	the high adsorption capacity	1241:1268	the high adsorption capacity	1241:1268	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	5	11	from	Eu	811:812	arg1	composites					826:835	the composites	822:835	the composites	822:835	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	2	12	theme	Raman	444:448	arg1	spectroscopy					450:461	Raman spectroscopy	444:461	Raman spectroscopy	444:461	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	7	13	theme	high	1027:1030	arg1	efficiency					1040:1049	a high removal efficiency	1025:1049	a high removal efficiency for Eu(III), Pu(IV), and Am(III)	1025:1082	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	5	14	theme	Eu	811:812	arg1	monolayer					855:863	a favourable, monolayer	841:863	monolayer	855:863	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	5	14	theme	Eu	811:812	arg1	adsorption					797:806	the adsorption	793:806	the adsorption of Eu(III) on the composites	793:835	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	9	15	theme	natural	1380:1386	arg1	waters					1388:1393	natural waters	1380:1393	natural waters	1380:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	4	16	theme	better	683:688	arg1	agreement					690:698	better agreement	683:698	better agreement with the Langmuir, pseudo-second-order, and pseudo-first-order models only for GO-MGH	683:784	The data obtained are in better agreement with the Langmuir, pseudo-second-order, and pseudo-first-order models only for GO-MGH.
36432137	5	17	from	composites	826:835	arg1	monolayer					855:863	a favourable, monolayer	841:863	monolayer	855:863	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	5	17	from	composites	826:835	arg1	adsorption					797:806	the adsorption	793:806	the adsorption of Eu(III) on the composites	793:835	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	6	18	theme	GO-MGH	958:963	arg1	case					950:953	the case	946:953	the case of GO-MGH	946:963	The nature of adsorption is chemical and, in the case of GO-MGH, physical.
36432137	9	19	with	composites	1225:1234	arg1	capacity					1261:1268	the high adsorption capacity	1241:1268	the high adsorption capacity	1241:1268	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	7	20	theme	natural	1003:1009	arg1	waters					1011:1016	natural waters	1003:1016	natural waters	1003:1016	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	1	21	theme	graphene	177:184	arg1	oxide					186:190	graphene oxide	177:190	graphene oxide (GO)	177:195	The adsorption of Eu(III) on composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS) has been studied using different approaches.
36432137	8	22	contain	has	1126:1128	arg2	ability					1152:1158	quite good predictive ability	1130:1158	quite good predictive ability	1130:1158	The ANFIS model has quite good predictive ability, as shown by the values for R2, MSE, SSE, and ARE.
36432137	8	22	contain	has	1126:1128	arg1	model					1120:1124	The ANFIS model	1110:1124	The ANFIS model	1110:1124	The ANFIS model has quite good predictive ability, as shown by the values for R2, MSE, SSE, and ARE.
36432137	1	23	from	adsorption	124:133	arg1	composites					149:158	composites	149:158	composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS)	149:231	The adsorption of Eu(III) on composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS) has been studied using different approaches.
36432137	9	24	theme	GO-MGH-CS	1215:1223	arg1	composites					1225:1234	The GO-MGH-CS composites	1211:1234	The GO-MGH-CS composites with the high adsorption capacity	1211:1268	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	24	theme	GO-MGH-CS	1215:1223	arg1	candidates					1289:1298	promising candidates	1279:1298	promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters	1279:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	2	25	theme	composites	339:348	arg1	characteristics					316:330	The physicochemical and morphological characteristics	278:330	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III	278:388	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	0	26	theme	Oxide-Maghemite-Chitosan	24:47	arg1	Composites					49:58	Graphene Oxide-Maghemite-Chitosan Composites	15:58	Graphene Oxide-Maghemite-Chitosan Composites	15:58	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36432137	8	27	theme	predictive	1141:1150	arg1	ability					1152:1158	quite good predictive ability	1130:1158	quite good predictive ability	1130:1158	The ANFIS model has quite good predictive ability, as shown by the values for R2, MSE, SSE, and ARE.
36432137	0	28	theme	Graphene	15:22	arg1	Composites					49:58	Graphene Oxide-Maghemite-Chitosan Composites	15:58	Graphene Oxide-Maghemite-Chitosan Composites	15:58	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36432137	9	29	from	Eu	1319:1320	arg1	waters					1388:1393	natural waters	1380:1393	natural waters	1380:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	7	30	from	Tests	976:980	arg1	waters					1011:1016	natural waters	1003:1016	natural waters	1003:1016	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	3	31	dep	results	490:496	arg1	capacity					556:563	the maximum experimental adsorption capacity	520:563	the maximum experimental adsorption capacity	520:563	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	3	31	dep	results	490:496	arg1	mg/g					594:597	52, 54, 25, 103, and 102 mg/g	569:597	52, 54, 25, 103, and 102 mg/g	569:597	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	7	32	theme	removal	1032:1038	arg1	efficiency					1040:1049	a high removal efficiency	1025:1049	a high removal efficiency for Eu(III), Pu(IV), and Am(III)	1025:1082	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	9	33	theme	pre-concentration	1335:1351	arg1	removal					1308:1314	the removal	1304:1314	the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters	1304:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	5	34	theme	homogeneous	882:892	arg1	sites					894:898	homogeneous sites	882:898	homogeneous sites	882:898	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	3	35	theme	experiments	507:517	arg1	capacity					556:563	the maximum experimental adsorption capacity	520:563	the maximum experimental adsorption capacity	520:563	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	3	35	theme	experiments	507:517	arg1	mg/g					594:597	52, 54, 25, 103, and 102 mg/g	569:597	52, 54, 25, 103, and 102 mg/g	569:597	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	6	36	from	case	950:953	arg1	chemical					929:936	chemical	929:936	chemical	929:936	The nature of adsorption is chemical and, in the case of GO-MGH, physical.
36432137	6	36	from	case	950:953	arg1	nature					905:910	The nature	901:910	The nature of adsorption	901:924	The nature of adsorption is chemical and, in the case of GO-MGH, physical.
36432137	0	37	theme	Composites	49:58	arg1	Preparation					0:10	Preparation	0:10	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.	0:118	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36432137	1	38	dep	oxide	186:190	arg1	GO					193:194	GO	193:194	GO	193:194	The adsorption of Eu(III) on composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS) has been studied using different approaches.
36432137	6	39	from	chemical	929:936	arg1	case					950:953	the case	946:953	the case of GO-MGH	946:963	The nature of adsorption is chemical and, in the case of GO-MGH, physical.
36432137	9	40	theme	Pu	1356:1357	arg1	pre-concentration					1335:1351	the pre-concentration	1331:1351	the pre-concentration of Pu(IV) and Am(III) from natural waters	1331:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	40	theme	Pu	1356:1357	arg1	Eu					1319:1320	Eu(III)	1319:1325	Eu(III)	1319:1325	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	7	41	from	composites	989:998	arg1	waters					1011:1016	natural waters	1003:1016	natural waters	1003:1016	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	5	42	theme	favourable	843:852	arg1	monolayer					855:863	a favourable, monolayer	841:863	monolayer	855:863	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	5	42	theme	favourable	843:852	arg1	adsorption					797:806	the adsorption	793:806	the adsorption of Eu(III) on the composites	793:835	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	1	43	theme	different	256:264	arg1	approaches					266:275	different approaches	256:275	different approaches	256:275	The adsorption of Eu(III) on composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS) has been studied using different approaches.
36432137	3	44	theme	batch	501:505	arg1	experiments					507:517	batch experiments	501:517	batch experiments	501:517	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	7	45	theme	composites	989:998	arg1	Tests					976:980	Tests	976:980	Tests of the composites in natural waters	976:1016	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	2	46	theme	physicochemical	282:296	arg1	characteristics					316:330	The physicochemical and morphological characteristics	278:330	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III	278:388	The physicochemical and morphological characteristics of the composites GO-MGH, GO-CS, GO-MGH-CS I, II, and III were determined by XRD, Mössbauer spectroscopy, FTIR, Raman spectroscopy, and TEM.
36432137	8	47	theme	ANFIS	1114:1118	arg1	model					1120:1124	The ANFIS model	1110:1124	The ANFIS model	1110:1124	The ANFIS model has quite good predictive ability, as shown by the values for R2, MSE, SSE, and ARE.
36432137	3	48	theme	experimental	532:543	arg1	capacity					556:563	the maximum experimental adsorption capacity	520:563	the maximum experimental adsorption capacity	520:563	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	3	48	theme	experimental	532:543	arg1	mg/g					594:597	52, 54, 25, 103, and 102 mg/g	569:597	52, 54, 25, 103, and 102 mg/g	569:597	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	9	49	theme	high	1245:1248	arg1	capacity					1261:1268	the high adsorption capacity	1241:1268	the high adsorption capacity	1241:1268	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	1	50	theme	Eu	138:139	arg1	adsorption					124:133	The adsorption	120:133	The adsorption of Eu(III) on composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS)	120:231	The adsorption of Eu(III) on composites synthesised from graphene oxide (GO), maghemite (MGH), and chitosan (CS) has been studied using different approaches.
36432137	5	51	from	adsorption	797:806	arg1	composites					826:835	the composites	822:835	the composites	822:835	Thus, the adsorption of Eu(III) on the composites was a favourable, monolayer, and occurred at homogeneous sites.
36432137	4	52	theme	pseudo-first-order	744:761	arg1	models					763:768	the Langmuir, pseudo-second-order, and pseudo-first-order models	705:768	models	763:768	The data obtained are in better agreement with the Langmuir, pseudo-second-order, and pseudo-first-order models only for GO-MGH.
36432137	0	53	from	Solutions	109:117	arg1	Adsorption					68:77	the Adsorption	64:77	the Adsorption of Europium Ions from Aqueous Solutions	64:117	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36432137	3	54	theme	adsorption	545:554	arg1	capacity					556:563	the maximum experimental adsorption capacity	520:563	the maximum experimental adsorption capacity	520:563	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	3	54	theme	adsorption	545:554	arg1	mg/g					594:597	52, 54, 25, 103, and 102 mg/g	569:597	52, 54, 25, 103, and 102 mg/g	569:597	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	0	55	theme	Europium	82:89	arg1	Ions					91:94	Europium Ions	82:94	Europium Ions	82:94	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36432137	9	56	theme	promising	1279:1287	arg1	composites					1225:1234	The GO-MGH-CS composites	1211:1234	The GO-MGH-CS composites with the high adsorption capacity	1211:1268	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	56	theme	promising	1279:1287	arg1	candidates					1289:1298	promising candidates	1279:1298	promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters	1279:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	6	57	theme	adsorption	915:924	arg1	chemical					929:936	chemical	929:936	chemical	929:936	The nature of adsorption is chemical and, in the case of GO-MGH, physical.
36432137	6	57	theme	adsorption	915:924	arg1	nature					905:910	The nature	901:910	The nature of adsorption	901:924	The nature of adsorption is chemical and, in the case of GO-MGH, physical.
36432137	9	58	theme	Am	1367:1368	arg1	pre-concentration					1335:1351	the pre-concentration	1331:1351	the pre-concentration of Pu(IV) and Am(III) from natural waters	1331:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	58	theme	Am	1367:1368	arg1	Eu					1319:1320	Eu(III)	1319:1325	Eu(III)	1319:1325	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	9	59	theme	Eu	1319:1320	arg1	removal					1308:1314	the removal	1304:1314	the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters	1304:1393	The GO-MGH-CS composites with the high adsorption capacity could be promising candidates for the removal of Eu(III) and the pre-concentration of Pu(IV) and Am(III) from natural waters.
36432137	3	60	theme	maximum	524:530	arg1	capacity					556:563	the maximum experimental adsorption capacity	520:563	the maximum experimental adsorption capacity	520:563	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	3	60	theme	maximum	524:530	arg1	mg/g					594:597	52, 54, 25, 103, and 102 mg/g	569:597	52, 54, 25, 103, and 102 mg/g	569:597	According to the results of batch experiments, the maximum experimental adsorption capacity was 52, 54, 25, 103, and 102 mg/g for GO-MGH, GO-CS, GO-MGH-CS I, II, and III, respectively.
36432137	7	61	dep	100	1104:1106	arg1	to					1101:1102	to	1101:1102	to	1101:1102	Tests of the composites in natural waters showed a high removal efficiency for Eu(III), Pu(IV), and Am(III), ranging from 74 to 100%.
36432137	0	62	theme	Aqueous	101:107	arg1	Solutions					109:117	Aqueous Solutions	101:117	Aqueous Solutions	101:117	Preparation of Graphene Oxide-Maghemite-Chitosan Composites for the Adsorption of Europium Ions from Aqueous Solutions.
36234960	0	0	theme	Starch	79:84	arg1	Effect					62:67	The Effect	58:67	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.	0:114	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	4	1	theme	adhesion	499:506	arg1	extent					521:526	the extent	517:526	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	1	theme	adhesion	499:506	arg1	number					614:619	the large number	604:619	the large number of OH groups in both reinforcements	604:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	1	theme	adhesion	499:506	arg1	strength					475:482	The strength	471:482	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	1	theme	adhesion	499:506	arg1	similar					549:555	similar	549:555	similar	549:555	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	8	2	theme	larger	1005:1010	arg1	consumption					1019:1029	larger energy consumption	1005:1029	larger energy consumption	1005:1029	The fracture of the bagasse fibers leads to larger energy consumption and to increased impact resistance.
36234960	7	3	theme	composite	941:949	arg1	strength					951:958	thus larger composite strength	929:958	thus larger composite strength	929:958	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	1	4	theme	bagasse	229:235	arg1	fibers					237:242	sugarcane bagasse fibers	219:242	sugarcane bagasse fibers	219:242	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	1	4	theme	bagasse	229:235	arg1	reinforcements					183:196	two natural reinforcements	171:196	two natural reinforcements	171:196	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	0	5	theme	Native	72:77	arg1	Starch					79:84	Native Starch	72:84	Native Starch	72:84	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	2	6	theme	deformation	329:339	arg1	processes					341:349	local deformation processes	323:349	local deformation processes	323:349	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	9	7	theme	biocomposites	1118:1130	arg1	benefit					1094:1100	the environmental benefit	1076:1100	the environmental benefit of the prepared biocomposites	1076:1130	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	9	7	theme	biocomposites	1118:1130	arg1	similar					1135:1141	similar	1135:1141	similar	1135:1141	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	0	8	theme	Sugarcane	90:98	arg1	Fibers					108:113	Sugarcane Bagasse Fibers	90:113	Sugarcane Bagasse Fibers	90:113	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	9	9	theme	prepared	1109:1116	arg1	biocomposites					1118:1130	the prepared biocomposites	1105:1130	the prepared biocomposites	1105:1130	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	2	10	theme	adhesion	273:280	arg1	strength					249:256	The strength	245:256	The strength of interfacial adhesion	245:280	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	5	11	theme	strong	669:674	arg1	adhesion					688:695	Relatively strong interfacial adhesion	658:695	Relatively strong interfacial adhesion	658:695	Relatively strong interfacial adhesion develops between the components, which renders coupling inefficient.
36234960	8	12	theme	increased	1038:1046	arg1	resistance					1055:1064	increased impact resistance	1038:1064	increased impact resistance	1038:1064	The fracture of the bagasse fibers leads to larger energy consumption and to increased impact resistance.
36234960	2	13	theme	interfacial	261:271	arg1	adhesion					273:280	interfacial adhesion	261:280	interfacial adhesion	261:280	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	7	14	theme	debonding	908:916	arg1	stress					918:923	larger debonding stress	901:923	larger debonding stress	901:923	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	7	15	theme	larger	901:906	arg1	stress					918:923	larger debonding stress	901:923	larger debonding stress	901:923	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	0	16	theme	Fibers	108:113	arg1	Effect					62:67	The Effect	58:67	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.	0:114	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	9	17	theme	composites	1204:1213	arg1	better					1218:1223	better	1218:1223	better	1218:1223	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	9	17	theme	composites	1204:1213	arg1	performance					1156:1166	the overall performance	1144:1166	the overall performance of the bagasse fiber reinforced PLA composites	1144:1213	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	0	18	theme	Bagasse	100:106	arg1	Fibers					108:113	Sugarcane Bagasse Fibers	90:113	Sugarcane Bagasse Fibers	90:113	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	4	19	theme	interfacial	487:497	arg1	adhesion					499:506	interfacial adhesion	487:506	interfacial adhesion	487:506	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	20	theme	chemical	584:591	arg1	structure					593:601	chemical structure	584:601	chemical structure	584:601	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	2	21	theme	emission	377:384	arg1	testing					386:392	acoustic emission testing	368:392	acoustic emission testing	368:392	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	4	22	from	similarities	568:579	arg1	structure					593:601	chemical structure	584:601	chemical structure	584:601	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	23	dep	similar	549:555	arg1	extent					521:526	the extent	517:526	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	23	dep	similar	549:555	arg1	number					614:619	the large number	604:619	the large number of OH groups in both reinforcements	604:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	23	dep	similar	549:555	arg1	strength					475:482	The strength	471:482	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	23	dep	similar	549:555	arg1	similar					549:555	similar	549:555	similar	549:555	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	8	24	theme	impact	1048:1053	arg1	resistance					1055:1064	increased impact resistance	1038:1064	increased impact resistance	1038:1064	The fracture of the bagasse fibers leads to larger energy consumption and to increased impact resistance.
36234960	2	25	theme	model	299:303	arg1	calculations					305:316	model calculations	299:316	model calculations	299:316	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	4	26	from	reinforcements	642:655	arg1	extent					521:526	the extent	517:526	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	26	from	reinforcements	642:655	arg1	number					614:619	the large number	604:619	the large number of OH groups in both reinforcements	604:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	26	from	reinforcements	642:655	arg1	strength					475:482	The strength	471:482	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	26	from	reinforcements	642:655	arg1	similar					549:555	similar	549:555	similar	549:555	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	2	27	theme	acoustic	368:375	arg1	testing					386:392	acoustic emission testing	368:392	acoustic emission testing	368:392	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	7	28	theme	smaller	858:864	arg1	size					875:878	The smaller particle size	854:878	The smaller particle size of starch	854:888	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	6	29	theme	deformation	818:828	arg1	processes					830:838	local deformation processes	812:838	local deformation processes	812:838	Dissimilar particle characteristics influence local deformation processes considerably.
36234960	7	30	theme	starch	883:888	arg1	size					875:878	The smaller particle size	854:878	The smaller particle size of starch	854:888	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	7	31	theme	particle	866:873	arg1	size					875:878	The smaller particle size	854:878	The smaller particle size of starch	854:888	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	6	32	theme	local	812:816	arg1	processes					830:838	local deformation processes	812:838	local deformation processes	812:838	Dissimilar particle characteristics influence local deformation processes considerably.
36234960	1	33	theme	natural	175:181	arg1	reinforcements					183:196	two natural reinforcements	171:196	two natural reinforcements	171:196	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	1	33	theme	natural	175:181	arg1	starch					208:213	a native starch	199:213	a native starch	199:213	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	1	33	theme	natural	175:181	arg1	fibers					237:242	sugarcane bagasse fibers	219:242	sugarcane bagasse fibers	219:242	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	0	34	theme	Biocomposites	15:27	arg1	Preparation					0:10	Preparation	0:10	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.	0:114	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	9	35	theme	overall	1148:1154	arg1	better					1218:1223	better	1218:1223	better	1218:1223	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	9	35	theme	overall	1148:1154	arg1	performance					1156:1166	the overall performance	1144:1166	the overall performance of the bagasse fiber reinforced PLA composites	1144:1213	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	8	36	theme	fibers	989:994	arg1	fracture					965:972	The fracture	961:972	The fracture of the bagasse fibers	961:994	The fracture of the bagasse fibers leads to larger energy consumption and to increased impact resistance.
36234960	1	37	theme	lactic	154:159	arg1	poly					149:152	poly	149:152	poly(lactic acid)	149:165	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	1	37	theme	lactic	154:159	arg1	acid					161:164	lactic acid	154:164	lactic acid	154:164	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	4	38	from	groups	627:632	arg1	reinforcements					642:655	both reinforcements	637:655	both reinforcements	637:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	39	theme	OH	624:625	arg1	groups					627:632	OH groups	624:632	OH groups in both reinforcements	624:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	9	40	theme	bagasse	1175:1181	arg1	composites					1204:1213	the bagasse fiber reinforced PLA composites	1171:1213	the bagasse fiber reinforced PLA composites	1171:1213	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	0	41	theme	Natural	34:40	arg1	Reinforcements					42:55	Natural Reinforcements	34:55	Natural Reinforcements	34:55	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	9	42	theme	fiber	1183:1187	arg1	composites					1204:1213	the bagasse fiber reinforced PLA composites	1171:1213	the bagasse fiber reinforced PLA composites	1171:1213	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	5	43	theme	interfacial	676:686	arg1	adhesion					688:695	Relatively strong interfacial adhesion	658:695	Relatively strong interfacial adhesion	658:695	Relatively strong interfacial adhesion develops between the components, which renders coupling inefficient.
36234960	9	44	theme	reinforced	1189:1198	arg1	composites					1204:1213	the bagasse fiber reinforced PLA composites	1171:1213	the bagasse fiber reinforced PLA composites	1171:1213	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	2	45	theme	local	323:327	arg1	processes					341:349	local deformation processes	323:349	local deformation processes	323:349	The strength of interfacial adhesion was estimated by model calculations, and local deformation processes were followed by acoustic emission testing.
36234960	6	46	theme	particle	777:784	arg1	characteristics					786:800	Dissimilar particle characteristics	766:800	Dissimilar particle characteristics	766:800	Dissimilar particle characteristics influence local deformation processes considerably.
36234960	4	47	theme	reinforcement	531:543	arg1	extent					521:526	the extent	517:526	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	47	theme	reinforcement	531:543	arg1	number					614:619	the large number	604:619	the large number of OH groups in both reinforcements	604:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	47	theme	reinforcement	531:543	arg1	strength					475:482	The strength	471:482	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	47	theme	reinforcement	531:543	arg1	similar					549:555	similar	549:555	similar	549:555	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	0	48	with	Preparation	0:10	arg1	Reinforcements					42:55	Natural Reinforcements	34:55	Natural Reinforcements	34:55	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	9	49	theme	environmental	1080:1092	arg1	benefit					1094:1100	the environmental benefit	1076:1100	the environmental benefit of the prepared biocomposites	1076:1130	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	9	49	theme	environmental	1080:1092	arg1	similar					1135:1141	similar	1135:1141	similar	1135:1141	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	1	50	theme	native	201:206	arg1	reinforcements					183:196	two natural reinforcements	171:196	two natural reinforcements	171:196	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	1	50	theme	native	201:206	arg1	starch					208:213	a native starch	199:213	a native starch	199:213	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	6	51	theme	Dissimilar	766:775	arg1	characteristics					786:800	Dissimilar particle characteristics	766:800	Dissimilar particle characteristics	766:800	Dissimilar particle characteristics influence local deformation processes considerably.
36234960	8	52	theme	bagasse	981:987	arg1	fibers					989:994	the bagasse fibers	977:994	the bagasse fibers	977:994	The fracture of the bagasse fibers leads to larger energy consumption and to increased impact resistance.
36234960	9	53	theme	PLA/starch	1250:1259	arg1	composites					1261:1270	the PLA/starch composites	1246:1270	the PLA/starch composites	1246:1270	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	4	54	theme	groups	627:632	arg1	extent					521:526	the extent	517:526	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	54	theme	groups	627:632	arg1	number					614:619	the large number	604:619	the large number of OH groups in both reinforcements	604:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	54	theme	groups	627:632	arg1	strength					475:482	The strength	471:482	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	54	theme	groups	627:632	arg1	similar					549:555	similar	549:555	similar	549:555	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	9	55	theme	PLA	1200:1202	arg1	composites					1204:1213	the bagasse fiber reinforced PLA composites	1171:1213	the bagasse fiber reinforced PLA composites	1171:1213	Although the environmental benefit of the prepared biocomposites is similar, the overall performance of the bagasse fiber reinforced PLA composites is better than that offered by the PLA/starch composites.
36234960	4	56	from	number	614:619	arg1	reinforcements					642:655	both reinforcements	637:655	both reinforcements	637:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	0	57	dep	Preparation	0:10	arg1	Effect					62:67	The Effect	58:67	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.	0:114	Preparation of Biocomposites with Natural Reinforcements: The Effect of Native Starch and Sugarcane Bagasse Fibers.
36234960	8	58	theme	energy	1012:1017	arg1	consumption					1019:1029	larger energy consumption	1005:1029	larger energy consumption	1005:1029	The fracture of the bagasse fibers leads to larger energy consumption and to increased impact resistance.
36234960	4	59	theme	large	608:612	arg1	extent					521:526	the extent	517:526	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	59	theme	large	608:612	arg1	number					614:619	the large number	604:619	the large number of OH groups in both reinforcements	604:655	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	59	theme	large	608:612	arg1	strength					475:482	The strength	471:482	The strength of interfacial adhesion and thus the extent of reinforcement	471:543	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	4	59	theme	large	608:612	arg1	similar					549:555	similar	549:555	similar	549:555	The strength of interfacial adhesion and thus the extent of reinforcement are similar because of similarities in chemical structure, the large number of OH groups in both reinforcements.
36234960	7	60	theme	larger	934:939	arg1	strength					951:958	thus larger composite strength	929:958	thus larger composite strength	929:958	The smaller particle size of starch results in larger debonding stress and thus larger composite strength.
36234960	1	61	theme	sugarcane	219:227	arg1	fibers					237:242	sugarcane bagasse fibers	219:242	sugarcane bagasse fibers	219:242	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
36234960	1	61	theme	sugarcane	219:227	arg1	reinforcements					183:196	two natural reinforcements	171:196	two natural reinforcements	171:196	Biocomposites were prepared from poly(lactic acid) and two natural reinforcements, a native starch and sugarcane bagasse fibers.
35865907	3	0	theme	stereoselective	727:741	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	0	theme	stereoselective	727:741	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	1	theme	remote	1460:1465	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	1	theme	remote	1460:1465	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	2	2	theme	one-pot	393:399	arg1	synthesis					401:409	an efficient, stereoselective and orthogonal one-pot synthesis	348:409	an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide	348:434	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	1	3	theme	challenging	291:301	arg1	task					303:306	a challenging task	289:306	a challenging task in chemical synthesis	289:328	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	5	4	theme	assistance	1478:1487	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	4	theme	assistance	1478:1487	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	3	5	theme	remote	612:617	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	5	theme	remote	612:617	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	5	theme	remote	612:617	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	6	theme	oligosaccharide	1014:1028	arg1	synthesis					1030:1038	oligosaccharide synthesis	1014:1038	oligosaccharide synthesis	1014:1038	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	0	7	theme	Total	0:4	arg1	synthesis					6:14	Total synthesis	0:14	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.	0:155	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	1	8	theme	complex	197:203	arg1	glycans					205:211	long, branched and complex glycans	178:211	long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures	178:279	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	4	9	theme	directed	1373:1380	arg1	α-galactosylation					1382:1398	4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1341:1398	4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1341:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	10	theme	RMRAA	770:774	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	10	theme	RMRAA	770:774	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	11	theme	RMRAA	642:646	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	11	theme	RMRAA	642:646	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	11	theme	RMRAA	642:646	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	12	dep	-glucosylation	799:812	arg1	3					767:767	3	767:767	3	767:767	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	13	theme	assistance	630:639	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	13	theme	assistance	630:639	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	13	theme	assistance	630:639	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	14	dep	-galactosylation	656:671	arg1	1→6					652:654	1→6	652:654	1→6	652:654	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	15	theme	1→6	795:797	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	15	theme	1→6	795:797	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	16	from	[7	1060:1061	arg1	manner					701:706	a highly stereoselective manner	676:706	a highly stereoselective manner	676:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	16	from	[7	1060:1061	arg1	basis					868:872	the basis	864:872	the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation	864:926	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	4	17	theme	RMRAA	1164:1168	arg1	method					1188:1193	this new RMRAA α-galactosylation method	1155:1193	this new RMRAA α-galactosylation method	1155:1193	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	18	theme	α-	792:793	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	18	theme	α-	792:793	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	19	theme	α-	649:650	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	19	theme	α-	649:650	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	19	theme	α-	649:650	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	20	dep	modulation	597:606	arg1	glycosylations					846:859	orthogonal one-pot glycosylations	827:859	merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations	581:859	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	1	21	theme	long	178:181	arg1	glycans					205:211	long, branched and complex glycans	178:211	long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures	178:279	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	5	22	theme	>	1516:1516	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	22	theme	>	1516:1516	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	4	23	with	comparison	1325:1334	arg1	α-galactosylation					1382:1398	4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1341:1398	4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1341:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	24	from	modulation	597:606	arg1	manner					701:706	a highly stereoselective manner	676:706	a highly stereoselective manner	676:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	24	from	modulation	597:606	arg1	basis					868:872	the basis	864:872	the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation	864:926	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	25	theme	orthogonal	827:836	arg1	glycosylations					846:859	orthogonal one-pot glycosylations	827:859	merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations	581:859	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	0	26	theme	stereoselective	76:90	arg1	strategies					145:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	1	27	theme	branched	184:191	arg1	glycans					205:211	long, branched and complex glycans	178:211	long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures	178:279	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	4	28	theme	broad	1225:1229	arg1	scopes					1241:1246	broad substrate scopes	1225:1246	broad substrate scopes	1225:1246	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	29	from	-galactosylation	656:671	arg1	manner					701:706	a highly stereoselective manner	676:706	a highly stereoselective manner	676:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	29	from	-galactosylation	656:671	arg1	basis					868:872	the basis	864:872	the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation	864:926	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	0	30	theme	one-pot	123:129	arg1	strategies					145:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	5	31	theme	>	1506:1506	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	31	theme	>	1506:1506	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	4	32	theme	mild	1199:1202	arg1	conditions					1213:1222	mild reaction conditions	1199:1222	mild reaction conditions	1199:1222	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	33	dep	[7	1060:1061	arg1	5					1046:1046	5	1046:1046	5	1046:1046	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	1	34	theme	chemical	311:318	arg1	synthesis					320:328	chemical synthesis	311:328	chemical synthesis	311:328	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	3	35	theme	ortho-	950:955	arg1	glycosylation					986:998	Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation	929:998	glycosylation	986:998	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	2	36	theme	antitumor	503:511	arg1	activities					513:522	antitumor activities	503:522	antitumor activities	503:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	4	37	from	synthesis	1312:1320	arg1	comparison					1325:1334	comparison	1325:1334	comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1325:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	2	38	theme	Lentinus	463:470	arg1	polysaccharides					482:496	Lentinus giganteus polysaccharides	463:496	Lentinus giganteus polysaccharides with antitumor activities	463:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	0	39	theme	giganteus	28:36	arg1	glycans					38:44	Lentinus giganteus glycans	19:44	Lentinus giganteus glycans with antitumor activities	19:70	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	3	40	theme	benzoate	971:978	arg1	glycosylation					986:998	Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation	929:998	glycosylation	986:998	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	41	theme	stereoselective	685:699	arg1	manner					701:706	a highly stereoselective manner	676:706	a highly stereoselective manner	676:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	2	42	theme	orthogonal	382:391	arg1	synthesis					401:409	an efficient, stereoselective and orthogonal one-pot synthesis	348:409	an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide	348:434	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	3	43	theme	1-phenylvinyl	957:969	arg1	glycosylation					986:998	Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation	929:998	glycosylation	986:998	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	44	theme	acyl	1536:1539	arg1	groups					1541:1546	acyl groups	1536:1546	acyl groups	1536:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	3	45	theme	DMF-modulated	713:725	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	45	theme	DMF-modulated	713:725	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	2	46	theme	stereoselective	362:376	arg1	synthesis					401:409	an efficient, stereoselective and orthogonal one-pot synthesis	348:409	an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide	348:434	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	3	47	theme	tetradecasaccharide	1119:1137	arg1	assembly					1096:1103	the final assembly	1086:1103	the final assembly of the target tetradecasaccharide	1086:1137	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	4	48	theme	step	1276:1279	arg1	counts					1281:1286	significantly shortened step counts	1252:1286	significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1252:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	49	theme	PVB	981:983	arg1	glycosylation					986:998	Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation	929:998	glycosylation	986:998	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	50	theme	1→3	746:748	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	50	theme	1→3	746:748	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	4	51	theme	heptasaccharide	1296:1310	arg1	synthesis					1312:1320	the heptasaccharide synthesis	1292:1320	the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1292:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	52	theme	α-	743:744	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	52	theme	α-	743:744	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	53	theme	anchimeric	1467:1476	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	53	theme	anchimeric	1467:1476	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	4	54	contain	has	1195:1197	arg2	counts					1281:1286	significantly shortened step counts	1252:1286	significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1252:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	4	54	contain	has	1195:1197	arg2	scopes					1241:1246	broad substrate scopes	1225:1246	broad substrate scopes	1225:1246	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	4	54	contain	has	1195:1197	arg1	method					1188:1193	this new RMRAA α-galactosylation method	1155:1193	this new RMRAA α-galactosylation method	1155:1193	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	4	54	contain	has	1195:1197	arg2	conditions					1213:1222	mild reaction conditions	1199:1222	mild reaction conditions	1199:1222	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	5	55	theme	effects	1489:1495	arg1	origins					1449:1455	the origins	1445:1455	the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1445:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	3	56	theme	reagent	589:595	arg1	modulation					597:606	merging reagent modulation	581:606	merging reagent modulation	581:606	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	2	57	with	polysaccharides	482:496	arg1	activities					513:522	antitumor activities	503:522	antitumor activities	503:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	2	58	theme	efficient	351:359	arg1	synthesis					401:409	an efficient, stereoselective and orthogonal one-pot synthesis	348:409	an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide	348:434	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	3	59	theme	stereoselective	776:790	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	59	theme	stereoselective	776:790	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	1	60	from	task	303:306	arg1	synthesis					320:328	chemical synthesis	311:328	chemical synthesis	311:328	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	3	61	theme	anchimeric	619:628	arg1	-galactosylation					656:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation	612:671	remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner	612:706	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	61	theme	anchimeric	619:628	arg1	-glucosylation					799:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	(3) RMRAA stereoselective α-(1→6)-glucosylation	766:812	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	61	theme	anchimeric	619:628	arg1	-glucosylation					750:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	(2) DMF-modulated stereoselective α-(1→3)-glucosylation	709:763	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	1	62	theme	many	224:227	arg1	linkages					248:255	many 1,2-cis glycosidic linkages	224:255	many 1,2-cis glycosidic linkages	224:255	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	1	63	theme	glycosidic	237:246	arg1	linkages					248:255	many 1,2-cis glycosidic linkages	224:255	many 1,2-cis glycosidic linkages	224:255	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	4	64	theme	α-galactosylation	1170:1186	arg1	method					1188:1193	this new RMRAA α-galactosylation method	1155:1193	this new RMRAA α-galactosylation method	1155:1193	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	4	65	theme	new	1160:1162	arg1	method					1188:1193	this new RMRAA α-galactosylation method	1155:1193	this new RMRAA α-galactosylation method	1155:1193	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	0	66	theme	α-glycosylation	92:106	arg1	strategies					145:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	3	67	theme	PTFAI	907:911	arg1	glycosylation					914:926	N-phenyltrifluoroacetimidate (PTFAI) glycosylation	877:926	N-phenyltrifluoroacetimidate (PTFAI) glycosylation	877:926	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	68	theme	4-OBz	1518:1522	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	68	theme	4-OBz	1518:1522	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	4	69	theme	substrate	1231:1239	arg1	scopes					1241:1246	broad substrate scopes	1225:1246	broad substrate scopes	1225:1246	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	70	theme	one-pot	838:844	arg1	glycosylations					846:859	orthogonal one-pot glycosylations	827:859	merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations	581:859	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	0	71	theme	orthogonal	112:121	arg1	strategies					145:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	3	72	theme	convergent	1049:1058	arg1	[7					1060:1061	(5) convergent [7	1045:1061	(5) convergent [7	1045:1061	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	73	theme	N-phenyltrifluoroacetimidate	877:904	arg1	glycosylation					914:926	N-phenyltrifluoroacetimidate (PTFAI) glycosylation	877:926	N-phenyltrifluoroacetimidate (PTFAI) glycosylation	877:926	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	3	74	theme	several	819:825	arg1	modulation					597:606	merging reagent modulation	581:606	merging reagent modulation	581:606	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	0	75	theme	glycosylation	131:143	arg1	strategies					145:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies	76:154	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	1	76	theme	1,2-cis	229:235	arg1	linkages					248:255	many 1,2-cis glycosidic linkages	224:255	many 1,2-cis glycosidic linkages	224:255	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	3	77	theme	Yu	929:930	arg1	glycosylation					932:944	Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation	929:998	glycosylation	932:944	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	78	theme	3,4-OBz	1498:1504	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	78	theme	3,4-OBz	1498:1504	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	4	79	theme	reaction	1204:1211	arg1	conditions					1213:1222	mild reaction conditions	1199:1222	mild reaction conditions	1199:1222	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	2	80	theme	shorter	440:446	arg1	sequences					448:456	shorter sequences	440:456	shorter sequences from Lentinus giganteus polysaccharides with antitumor activities	440:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	3	81	theme	glycosylation	914:926	arg1	basis					868:872	the basis	864:872	the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation	864:926	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	82	theme	3,4-OAc	1508:1514	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	82	theme	3,4-OAc	1508:1514	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	2	83	theme	tetradecasaccharide	416:434	arg1	synthesis					401:409	an efficient, stereoselective and orthogonal one-pot synthesis	348:409	an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide	348:434	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	2	83	theme	tetradecasaccharide	416:434	arg1	sequences					448:456	shorter sequences	440:456	shorter sequences from Lentinus giganteus polysaccharides with antitumor activities	440:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	0	84	theme	Lentinus	19:26	arg1	glycans					38:44	Lentinus giganteus glycans	19:44	Lentinus giganteus glycans with antitumor activities	19:70	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	3	85	dep	developed	571:579	arg1	1					562:562	1	562:562	1	562:562	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	1	86	contain	containing	213:222	arg1	glycans					205:211	long, branched and complex glycans	178:211	long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures	178:279	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	1	86	contain	containing	213:222	arg2	linkages					248:255	many 1,2-cis glycosidic linkages	224:255	many 1,2-cis glycosidic linkages	224:255	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	2	87	theme	giganteus	472:480	arg1	polysaccharides					482:496	Lentinus giganteus polysaccharides	463:496	Lentinus giganteus polysaccharides with antitumor activities	463:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	0	88	theme	glycans	38:44	arg1	synthesis					6:14	Total synthesis	0:14	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.	0:155	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	3	89	theme	final	1090:1094	arg1	assembly					1096:1103	the final assembly	1086:1103	the final assembly of the target tetradecasaccharide	1086:1137	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	5	90	theme	DFT	1414:1416	arg1	calculations					1418:1429	DFT calculations	1414:1429	DFT calculations	1414:1429	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	3	91	theme	synthetic	529:537	arg1	strategy					539:546	The synthetic strategy	525:546	The synthetic strategy	525:546	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	0	92	theme	antitumor	51:59	arg1	activities					61:70	antitumor activities	51:70	antitumor activities	51:70	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	4	93	theme	shortened	1266:1274	arg1	counts					1281:1286	significantly shortened step counts	1252:1286	significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation	1252:1398	In particular, this new RMRAA α-galactosylation method has mild reaction conditions, broad substrate scopes and significantly shortened step counts for the heptasaccharide synthesis in comparison with 4,6-di-tert-butylsilyene (DTBS) directed α-galactosylation.
35865907	3	94	theme	target	1112:1117	arg1	tetradecasaccharide					1119:1137	the target tetradecasaccharide	1108:1137	the target tetradecasaccharide	1108:1137	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35865907	2	95	from	polysaccharides	482:496	arg1	synthesis					401:409	an efficient, stereoselective and orthogonal one-pot synthesis	348:409	an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide	348:434	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	2	95	from	polysaccharides	482:496	arg1	sequences					448:456	shorter sequences	440:456	shorter sequences from Lentinus giganteus polysaccharides with antitumor activities	440:522	Reported here is an efficient, stereoselective and orthogonal one-pot synthesis of a tetradecasaccharide and shorter sequences from Lentinus giganteus polysaccharides with antitumor activities.
35865907	5	96	theme	groups	1541:1546	arg1	>					1524:1524	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz	1498:1530	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	5	96	theme	groups	1541:1546	arg1	effects					1489:1495	remote anchimeric assistance effects	1460:1495	remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups	1460:1546	Furthermore, DFT calculations shed light on the origins of remote anchimeric assistance effects (3,4-OBz > 3,4-OAc > 4-OBz > 3-OBz) of acyl groups.
35865907	1	97	theme	precise	262:268	arg1	structures					270:279	precise structures	262:279	precise structures	262:279	The accessibility to long, branched and complex glycans containing many 1,2-cis glycosidic linkages with precise structures remains a challenging task in chemical synthesis.
35865907	0	98	with	glycans	38:44	arg1	activities					61:70	antitumor activities	51:70	antitumor activities	51:70	Total synthesis of Lentinus giganteus glycans with antitumor activities via stereoselective α-glycosylation and orthogonal one-pot glycosylation strategies.
35865907	3	99	theme	merging	581:587	arg1	modulation					597:606	merging reagent modulation	581:606	merging reagent modulation	581:606	The synthetic strategy consists of: (1) newly developed merging reagent modulation and remote anchimeric assistance (RMRAA) α-(1→6)-galactosylation in a highly stereoselective manner, (2) DMF-modulated stereoselective α-(1→3)-glucosylation, (3) RMRAA stereoselective α-(1→6)-glucosylation, (4) several orthogonal one-pot glycosylations on the basis of N-phenyltrifluoroacetimidate (PTFAI) glycosylation, Yu glycosylation and ortho-(1-phenylvinyl)benzoate (PVB) glycosylation to streamline oligosaccharide synthesis, and (5) convergent [7 + 7] glycosylation for the final assembly of the target tetradecasaccharide.
35121317	1	0	theme	capacity	344:351	arg1	terms					323:327	terms	323:327	terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential	323:440	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	2	1	contain	contained	516:524	arg2	glucuronoxylan					556:569	glucuronoxylan	556:569	glucuronoxylan	556:569	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	2	1	contain	contained	516:524	arg1	extracts					447:454	PHW extracts	443:454	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4)	443:514	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	2	1	contain	contained	516:524	arg2	galactoglucomannan					533:550	galactoglucomannan	533:550	galactoglucomannan	533:550	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	3	2	theme	compounds	685:693	arg1	sources					665:671	rich sources	660:671	rich sources of phenolic compounds	660:693	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	3	2	theme	compounds	685:693	arg1	samples					585:591	samples	585:591	samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark	585:654	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	6	3	theme	human	952:956	arg1	A549					980:983	A549	980:983	A549	980:983	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	3	theme	human	952:956	arg1	IMR90					970:974	IMR90	970:974	IMR90	970:974	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	3	theme	human	952:956	arg1	lines					963:967	human cell lines	952:967	human cell lines (IMR90 and A549)	952:984	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	4	4	theme	α-glucosidase	778:790	arg1	protection					796:805	protection	796:805	protection against stable non-enveloped enteroviruses	796:848	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	4	4	theme	α-glucosidase	778:790	arg1	inhibition					750:759	the highest inhibition	738:759	the highest inhibition of α-amylase and α-glucosidase	738:790	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	1	5	theme	nonconventional	245:259	arg1	sources					261:267	nonconventional sources	245:267	nonconventional sources of functional carbohydrates and phenolic compounds	245:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	1	6	theme	antiviral	354:362	arg1	activity					364:371	antiviral activity	354:371	antiviral activity	354:371	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	6	7	dep	lines	963:967	arg1	A549					980:983	A549	980:983	A549	980:983	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	7	dep	lines	963:967	arg1	IMR90					970:974	IMR90	970:974	IMR90	970:974	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	7	dep	lines	963:967	arg1	lines					963:967	human cell lines	952:967	human cell lines (IMR90 and A549)	952:984	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	8	theme	non-toxicin	1003:1013	arg1	vitroprofile					1015:1026	extracts' non-toxicin vitroprofile	993:1026	extracts' non-toxicin vitroprofile	993:1026	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	9	theme	Cell-based	923:932	arg1	experiments					934:944	Cell-based experiments	923:944	Cell-based experiments using human cell lines (IMR90 and A549)	923:984	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	7	10	theme	polyphenol-rich	1151:1165	arg1	sources					1113:1119	these unconventional sources	1092:1119	these unconventional sources	1092:1119	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	10	theme	polyphenol-rich	1151:1165	arg1	extracts					1167:1174	polyphenol-rich extracts	1151:1174	polyphenol-rich extracts	1151:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	0	11	theme	phenolic-rich	87:99	arg1	extracts					101:108	phenolic-rich extracts	87:108	phenolic-rich extracts from unconventional sources as functional food ingredients	87:167	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	0	12	from	sources	130:136	arg1	extracts					101:108	phenolic-rich extracts	87:108	phenolic-rich extracts from unconventional sources as functional food ingredients	87:167	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	5	13	theme	human	888:892	arg1	erythrocytes					894:905	human erythrocytes	888:905	human erythrocytes	888:905	Additionally, all extracts protected human erythrocytes from hemolysis.
35121317	2	14	theme	Norway	459:464	arg1	spruce					466:471	Norway spruce	459:471	Norway spruce bark (E1 + E2)	459:486	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	1	15	theme	functional	272:281	arg1	carbohydrates					283:295	functional carbohydrates	272:295	functional carbohydrates	272:295	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	3	16	theme	Scots	640:644	arg1	bark					651:654	Scots pine bark	640:654	Scots pine bark	640:654	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	1	17	theme	carbohydrates	283:295	arg1	sources					261:267	nonconventional sources	245:267	nonconventional sources of functional carbohydrates and phenolic compounds	245:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	0	18	theme	unconventional	115:128	arg1	sources					130:136	unconventional sources	115:136	unconventional sources as functional food ingredients	115:167	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	3	19	theme	E5	593:594	arg1	samples					585:591	samples	585:591	samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark	585:654	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	3	19	theme	E5	593:594	arg1	sources					665:671	rich sources	660:671	rich sources of phenolic compounds	660:693	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	4	20	theme	highest	742:748	arg1	inhibition					750:759	the highest inhibition	738:759	the highest inhibition of α-amylase and α-glucosidase	738:790	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	4	21	theme	non-enveloped	822:834	arg1	enteroviruses					836:848	stable non-enveloped enteroviruses	815:848	stable non-enveloped enteroviruses	815:848	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	2	22	theme	PHW	443:445	arg1	extracts					447:454	PHW extracts	443:454	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4)	443:514	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	7	23	theme	functional	1122:1131	arg1	sources					1113:1119	these unconventional sources	1092:1119	these unconventional sources	1092:1119	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	23	theme	functional	1122:1131	arg1	carbohydrates					1133:1145	functional carbohydrates	1122:1145	functional carbohydrates	1122:1145	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	24	theme	extracts	1078:1085	arg1	safety					1068:1073	the relative toxicological safety	1041:1073	the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts	1041:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	6	25	theme	cell	958:961	arg1	A549					980:983	A549	980:983	A549	980:983	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	25	theme	cell	958:961	arg1	IMR90					970:974	IMR90	970:974	IMR90	970:974	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	6	25	theme	cell	958:961	arg1	lines					963:967	human cell lines	952:967	human cell lines (IMR90 and A549)	952:984	Cell-based experiments using human cell lines (IMR90 and A549) showed extracts' non-toxicin vitroprofile.
35121317	1	26	theme	pressurised	203:213	arg1	extracts					231:238	pressurised hot water (PHW) extracts	203:238	pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds	203:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	3	27	from	sources	665:671	arg1	contrast					575:582	contrast	575:582	contrast	575:582	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	1	28	theme	phenolic	301:308	arg1	compounds					310:318	phenolic compounds	301:318	phenolic compounds	301:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	7	29	theme	unconventional	1098:1111	arg1	sources					1113:1119	these unconventional sources	1092:1119	these unconventional sources	1092:1119	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	29	theme	unconventional	1098:1111	arg1	carbohydrates					1133:1145	functional carbohydrates	1122:1145	functional carbohydrates	1122:1145	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	29	theme	unconventional	1098:1111	arg1	extracts					1167:1174	polyphenol-rich extracts	1151:1174	polyphenol-rich extracts	1151:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	1	30	theme	human	388:392	arg1	erythrocytes					394:405	human erythrocytes	388:405	human erythrocytes' protection antidiabetic potential	388:440	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	0	31	dep	Hemicelluloses	31:44	arg1	plate					23:27	the plate	19:27	the plate	19:27	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	1	32	theme	hot	215:217	arg1	extracts					231:238	pressurised hot water (PHW) extracts	203:238	pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds	203:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	7	33	theme	food	1212:1215	arg1	models					1217:1222	food models	1212:1222	food models	1212:1222	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	1	34	theme	compounds	310:318	arg1	sources					261:267	nonconventional sources	245:267	nonconventional sources of functional carbohydrates and phenolic compounds	245:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	7	35	from	sources	1113:1119	arg1	extracts					1078:1085	extracts	1078:1085	extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts	1078:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	35	from	sources	1113:1119	arg1	safety					1068:1073	the relative toxicological safety	1041:1073	the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts	1041:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	4	36	theme	stable	815:820	arg1	enteroviruses					836:848	stable non-enveloped enteroviruses	815:848	stable non-enveloped enteroviruses	815:848	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	7	37	theme	toxicological	1054:1066	arg1	safety					1068:1073	the relative toxicological safety	1041:1073	the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts	1041:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	1	38	theme	water	219:223	arg1	extracts					231:238	pressurised hot water (PHW) extracts	203:238	pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds	203:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	2	39	theme	bark	473:476	arg1	extracts					447:454	PHW extracts	443:454	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4)	443:514	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	0	40	theme	food	152:155	arg1	ingredients					157:167	functional food ingredients	141:167	functional food ingredients	141:167	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	0	41	dep	plate	23:27	arg1	forest					9:14	forest	9:14	forest	9:14	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	0	41	dep	plate	23:27	arg1	the					5:7	the	5:7	the	5:7	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	1	42	from	sources	261:267	arg1	extracts					231:238	pressurised hot water (PHW) extracts	203:238	pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds	203:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	0	43	theme	functional	141:150	arg1	ingredients					157:167	functional food ingredients	141:167	functional food ingredients	141:167	From the forest to the plate - Hemicelluloses, galactoglucomannan, glucuronoxylan, and phenolic-rich extracts from unconventional sources as functional food ingredients.
35121317	1	44	theme	protection	408:417	arg1	potential					432:440	human erythrocytes' protection antidiabetic potential	388:440	human erythrocytes' protection antidiabetic potential	388:440	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	3	45	theme	rich	660:663	arg1	sources					665:671	rich sources	660:671	rich sources of phenolic compounds	660:693	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	3	45	theme	rich	660:663	arg1	samples					585:591	samples	585:591	samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark	585:654	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	3	46	theme	phenolic	676:683	arg1	compounds					685:693	phenolic compounds	676:693	phenolic compounds	676:693	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	1	47	theme	antidiabetic	419:430	arg1	potential					432:440	human erythrocytes' protection antidiabetic potential	388:440	human erythrocytes' protection antidiabetic potential	388:440	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	7	48	theme	relative	1045:1052	arg1	safety					1068:1073	the relative toxicological safety	1041:1073	the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts	1041:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	4	49	theme	phenolic-rich	705:717	arg1	extracts					719:726	phenolic-rich extracts	705:726	phenolic-rich extracts	705:726	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	4	50	theme	α-amylase	764:772	arg1	protection					796:805	protection	796:805	protection against stable non-enveloped enteroviruses	796:848	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	4	50	theme	α-amylase	764:772	arg1	inhibition					750:759	the highest inhibition	738:759	the highest inhibition of α-amylase and α-glucosidase	738:790	Overall, phenolic-rich extracts presented the highest inhibition of α-amylase and α-glucosidase and protection against stable non-enveloped enteroviruses.
35121317	3	51	theme	pine	646:649	arg1	bark					651:654	Scots pine bark	640:654	Scots pine bark	640:654	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	3	52	theme	Norway	621:626	arg1	spruce					628:633	Norway spruce	621:633	Norway spruce	621:633	In contrast, samples E5 to E9 PHW extracted from Norway spruce, and Scots pine bark are rich sources of phenolic compounds.
35121317	2	53	theme	spruce	466:471	arg1	bark					473:476	Norway spruce bark	459:476	Norway spruce bark (E1 + E2)	459:486	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	2	53	theme	spruce	466:471	arg1	E1 + E2					479:485	E1 + E2	479:485	E1 + E2	479:485	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	1	54	theme	PHW	226:228	arg1	extracts					231:238	pressurised hot water (PHW) extracts	203:238	pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds	203:318	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
35121317	2	55	theme	sawdust	498:504	arg1	extracts					447:454	PHW extracts	443:454	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4)	443:514	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	7	56	from	safety	1068:1073	arg1	sources					1113:1119	these unconventional sources	1092:1119	these unconventional sources	1092:1119	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	56	from	safety	1068:1073	arg1	carbohydrates					1133:1145	functional carbohydrates	1122:1145	functional carbohydrates	1122:1145	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	7	56	from	safety	1068:1073	arg1	extracts					1167:1174	polyphenol-rich extracts	1151:1174	polyphenol-rich extracts	1151:1174	Considering the relative toxicological safety of extracts from these unconventional sources, functional carbohydrates and polyphenol-rich extracts can be obtained and further used in food models.
35121317	2	57	theme	Birch	492:496	arg1	E3 + E4					507:513	E3 + E4	507:513	E3 + E4	507:513	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	2	57	theme	Birch	492:496	arg1	sawdust					498:504	Birch sawdust	492:504	Birch sawdust (E3 + E4)	492:514	PHW extracts of Norway spruce bark (E1 + E2) and Birch sawdust (E3 + E4) contained mostly galactoglucomannan and glucuronoxylan.
35121317	1	58	theme	antioxidant	332:342	arg1	capacity					344:351	antioxidant capacity	332:351	antioxidant capacity	332:351	This study aimed to characterise pressurised hot water (PHW) extracts from nonconventional sources of functional carbohydrates and phenolic compounds in terms of antioxidant capacity, antiviral activity, toxicity, and human erythrocytes' protection antidiabetic potential.
36051487	1	0	theme	wound	357:361	arg1	healing					363:369	its potential wound healing	343:369	its potential wound healing activity in alloxan-induced diabetic rats	343:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	7	1	theme	scavenging	1442:1451	arg1	assay					1453:1457	2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay	1405:1457	2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay	1405:1457	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	7	2	theme	DPPH	1436:1439	arg1	assay					1453:1457	2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay	1405:1457	2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay	1405:1457	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	9	3	theme	wound	1639:1643	arg1	%					1678:1678	98 ± 1.11%	1669:1678	98 ± 1.11%	1669:1678	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	9	3	theme	wound	1639:1643	arg1	percentage					1657:1666	wound contraction percentage	1639:1666	wound contraction percentage (98 ± 1.11%)	1639:1679	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	7	4	theme	2,2-diphenyl-1-picrylhydrazyl	1405:1433	arg1	assay					1453:1457	2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay	1405:1457	2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay	1405:1457	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	6	5	theme	1H	1062:1063	arg1	NMR					1065:1067	1H NMR	1062:1067	1H NMR	1062:1067	Results obtained by 1H NMR indicated that PLS consisted of three monosaccharide residues with α and β anomers.
36051487	0	6	theme	Diabetic	134:141	arg1	Rats					143:146	Diabetic Rats	134:146	Diabetic Rats	134:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	1	7	from	determination	255:267	arg1	polysaccharide					204:217	a novel polysaccharide	196:217	a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties	196:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	7	from	determination	255:267	arg1	activity					371:378	its potential wound healing activity	343:378	its potential wound healing activity in alloxan-induced diabetic rats	343:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	7	from	determination	255:267	arg1	extraction					182:191	the extraction	178:191	the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties	178:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	10	8	theme	histological	1727:1738	arg1	assessment					1740:1749	the histological assessment	1723:1749	the histological assessment of the PLS-treated group	1723:1774	Furthermore, the histological assessment of the PLS-treated group demonstrated complete reepithelialized wounds by accelerating collagen synthesis.
36051487	7	9	theme	scavenging	1314:1323	arg1	activity					1325:1332	scavenging activity	1314:1332	three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power	1290:1477	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	11	10	from	closure	1923:1929	arg1	rats					1959:1962	alloxan-induced diabetic rats	1934:1962	alloxan-induced diabetic rats	1934:1962	In general, the findings affirmed that PLS is efficient on wound closure in alloxan-induced diabetic rats.
36051487	1	11	theme	healing	363:369	arg1	activity					371:378	its potential wound healing activity	343:378	its potential wound healing activity in alloxan-induced diabetic rats	343:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	9	12	theme	1.11	1674:1677	arg1	%					1678:1678	98 ± 1.11%	1669:1678	98 ± 1.11%	1669:1678	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	9	12	theme	1.11	1674:1677	arg1	percentage					1657:1666	wound contraction percentage	1639:1666	wound contraction percentage (98 ± 1.11%)	1639:1679	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	3	13	theme	high	708:711	arg1	HPLC					748:751	HPLC	748:751	HPLC	748:751	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	13	theme	high	708:711	arg1	chromatography					732:745	high performance liquid chromatography	708:745	high performance liquid chromatography (HPLC)	708:752	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	10	14	theme	PLS-treated	1758:1768	arg1	group					1770:1774	the PLS-treated group	1754:1774	the PLS-treated group	1754:1774	Furthermore, the histological assessment of the PLS-treated group demonstrated complete reepithelialized wounds by accelerating collagen synthesis.
36051487	1	15	theme	novel	198:202	arg1	polysaccharide					204:217	a novel polysaccharide	196:217	a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties	196:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	16	from	sativum	233:239	arg1	polysaccharide					204:217	a novel polysaccharide	196:217	a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties	196:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	16	from	sativum	233:239	arg1	activity					371:378	its potential wound healing activity	343:378	its potential wound healing activity in alloxan-induced diabetic rats	343:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	16	from	sativum	233:239	arg1	extraction					182:191	the extraction	178:191	the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties	178:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	17	theme	diabetic	399:406	arg1	rats					408:411	alloxan-induced diabetic rats	383:411	alloxan-induced diabetic rats	383:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	18	from	extraction	182:191	arg1	rats					408:411	alloxan-induced diabetic rats	383:411	alloxan-induced diabetic rats	383:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	18	from	extraction	182:191	arg1	sativum					233:239	Lepidium sativum	224:239	Lepidium sativum (PLS)	224:245	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	18	from	extraction	182:191	arg1	determination					255:267	the determination	251:267	the determination of its physicochemical composition and antioxidant properties	251:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	18	from	extraction	182:191	arg1	PLS					242:244	PLS	242:244	PLS	242:244	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	6	19	theme	monosaccharide	1107:1120	arg1	residues					1122:1129	three monosaccharide residues	1101:1129	three monosaccharide residues with α and β anomers	1101:1150	Results obtained by 1H NMR indicated that PLS consisted of three monosaccharide residues with α and β anomers.
36051487	5	20	theme	crude	962:966	arg1	PLS					968:970	the crude PLS	958:970	the crude PLS	958:970	According to HPLC, the crude PLS is a heteropolysaccharide composed of glucose, xylose, and galactose.
36051487	5	20	theme	crude	962:966	arg1	heteropolysaccharide					977:996	a heteropolysaccharide	975:996	a heteropolysaccharide composed of glucose, xylose, and galactose	975:1039	According to HPLC, the crude PLS is a heteropolysaccharide composed of glucose, xylose, and galactose.
36051487	10	21	theme	reepithelialized	1798:1813	arg1	wounds					1815:1820	complete reepithelialized wounds	1789:1820	complete reepithelialized wounds	1789:1820	Furthermore, the histological assessment of the PLS-treated group demonstrated complete reepithelialized wounds by accelerating collagen synthesis.
36051487	6	22	with	residues	1122:1129	arg1	anomers					1144:1150	α and β anomers	1136:1150	α and β anomers	1136:1150	Results obtained by 1H NMR indicated that PLS consisted of three monosaccharide residues with α and β anomers.
36051487	0	23	from	sativum	90:96	arg1	Characterization					12:27	Characterization	12:27	Characterization	12:27	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	23	from	sativum	90:96	arg1	Structure					34:42	Structure	34:42	Structure	34:42	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	23	from	sativum	90:96	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	23	from	sativum	90:96	arg1	Heteropolysaccharide					55:74	a Novel Heteropolysaccharide	47:74	a Novel Heteropolysaccharide from Lepidium sativum	47:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	23	from	sativum	90:96	arg1	Effects					106:112	Its Effects	102:112	Its Effects on Wound Healing in Diabetic Rats	102:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	7	24	theme	antioxidant	1248:1258	arg1	activities					1260:1269	potential antioxidant activities	1238:1269	potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power	1238:1477	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	3	25	theme	liquid	725:730	arg1	HPLC					748:751	HPLC	748:751	HPLC	748:751	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	25	theme	liquid	725:730	arg1	chromatography					732:745	high performance liquid chromatography	708:745	high performance liquid chromatography (HPLC)	708:752	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	0	26	theme	Novel	49:53	arg1	Heteropolysaccharide					55:74	a Novel Heteropolysaccharide	47:74	a Novel Heteropolysaccharide from Lepidium sativum	47:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	1	27	theme	properties	320:329	arg1	PLS					242:244	PLS	242:244	PLS	242:244	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	27	theme	properties	320:329	arg1	sativum					233:239	Lepidium sativum	224:239	Lepidium sativum (PLS)	224:245	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	27	theme	properties	320:329	arg1	determination					255:267	the determination	251:267	the determination of its physicochemical composition and antioxidant properties	251:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	3	28	theme	magnetic	798:805	arg1	resonance					788:796	nuclear resonance magnetic	780:805	nuclear resonance magnetic (NMR)	780:811	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	28	theme	magnetic	798:805	arg1	NMR					808:810	NMR	808:810	NMR	808:810	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	0	29	from	Characterization	12:27	arg1	Healing					123:129	Wound Healing	117:129	Wound Healing in Diabetic Rats	117:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	29	from	Characterization	12:27	arg1	sativum					90:96	Lepidium sativum	81:96	Lepidium sativum	81:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	3	30	theme	gas	755:757	arg1	GC					775:776	GC	775:776	GC	775:776	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	30	theme	gas	755:757	arg1	chromatography					759:772	gas chromatography	755:772	gas chromatography (GC)	755:777	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	31	theme	nuclear	780:786	arg1	resonance					788:796	nuclear resonance magnetic	780:805	nuclear resonance magnetic (NMR)	780:811	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	31	theme	nuclear	780:786	arg1	NMR					808:810	NMR	808:810	NMR	808:810	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	0	32	from	Extraction	0:9	arg1	Healing					123:129	Wound Healing	117:129	Wound Healing in Diabetic Rats	117:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	32	from	Extraction	0:9	arg1	sativum					90:96	Lepidium sativum	81:96	Lepidium sativum	81:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	2	33	theme	red-green	492:500	arg1	a∗					513:514	a∗	513:514	a∗	513:514	This polysaccharide presented a lighter natural color, whose luminosity (L∗), red-green intensity (a∗), and blue-yellow intensity (b∗) were recorded at 63.26, 5.87, and 27.28, respectively.
36051487	2	33	theme	red-green	492:500	arg1	intensity					502:510	red-green intensity	492:510	red-green intensity (a∗)	492:515	This polysaccharide presented a lighter natural color, whose luminosity (L∗), red-green intensity (a∗), and blue-yellow intensity (b∗) were recorded at 63.26, 5.87, and 27.28, respectively.
36051487	1	34	from	activity	371:378	arg1	rats					408:411	alloxan-induced diabetic rats	383:411	alloxan-induced diabetic rats	383:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	34	from	activity	371:378	arg1	sativum					233:239	Lepidium sativum	224:239	Lepidium sativum (PLS)	224:245	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	34	from	activity	371:378	arg1	determination					255:267	the determination	251:267	the determination of its physicochemical composition and antioxidant properties	251:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	34	from	activity	371:378	arg1	PLS					242:244	PLS	242:244	PLS	242:244	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	35	theme	potential	347:355	arg1	healing					363:369	its potential wound healing	343:369	its potential wound healing activity in alloxan-induced diabetic rats	343:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	7	36	theme	potential	1238:1246	arg1	activities					1260:1269	potential antioxidant activities	1238:1269	potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power	1238:1477	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	2	37	theme	lighter	446:452	arg1	color					462:466	a lighter natural color	444:466	a lighter natural color	444:466	This polysaccharide presented a lighter natural color, whose luminosity (L∗), red-green intensity (a∗), and blue-yellow intensity (b∗) were recorded at 63.26, 5.87, and 27.28, respectively.
36051487	3	38	theme	filtration	836:845	arg1	chromatography					847:860	high-pressure gel filtration chromatography	818:860	high-pressure gel filtration chromatography	818:860	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	11	39	theme	diabetic	1950:1957	arg1	rats					1959:1962	alloxan-induced diabetic rats	1934:1962	alloxan-induced diabetic rats	1934:1962	In general, the findings affirmed that PLS is efficient on wound closure in alloxan-induced diabetic rats.
36051487	3	40	theme	high-pressure	818:830	arg1	chromatography					847:860	high-pressure gel filtration chromatography	818:860	high-pressure gel filtration chromatography	818:860	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	10	41	theme	collagen	1838:1845	arg1	synthesis					1847:1855	collagen synthesis	1838:1855	collagen synthesis	1838:1855	Furthermore, the histological assessment of the PLS-treated group demonstrated complete reepithelialized wounds by accelerating collagen synthesis.
36051487	3	42	dep	transform	654:662	arg1	infrared					664:671	infrared	664:671	transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography	654:860	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	7	43	theme	molecular	1194:1202	arg1	weight					1204:1209	an average molecular weight	1183:1209	an average molecular weight of 98.51 kDa	1183:1222	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	4	44	theme	polysaccharides	922:936	arg1	band					914:917	the characteristic band	895:917	the characteristic band of polysaccharides	895:936	The FT-IR and UV spectra showed the characteristic band of polysaccharides.
36051487	1	45	theme	physicochemical	276:290	arg1	composition					292:302	its physicochemical composition	272:302	its physicochemical composition	272:302	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	4	46	theme	UV	877:878	arg1	spectra					880:886	The FT-IR and UV spectra	863:886	spectra	880:886	The FT-IR and UV spectra showed the characteristic band of polysaccharides.
36051487	1	47	theme	polysaccharide	204:217	arg1	activity					371:378	its potential wound healing activity	343:378	its potential wound healing activity in alloxan-induced diabetic rats	343:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	47	theme	polysaccharide	204:217	arg1	extraction					182:191	the extraction	178:191	the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties	178:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	8	48	theme	wound	1559:1563	arg1	healing					1565:1571	wound healing	1559:1571	wound healing	1559:1571	These results strongly support the beneficial effects of the PLS to accelerate wound healing in diabetic rats.
36051487	1	49	theme	Lepidium	224:231	arg1	PLS					242:244	PLS	242:244	PLS	242:244	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	49	theme	Lepidium	224:231	arg1	sativum					233:239	Lepidium sativum	224:239	Lepidium sativum (PLS)	224:245	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	3	50	theme	FT-IR	674:678	arg1	spectroscopy					681:692	(FT-IR) spectroscopy	673:692	(FT-IR) spectroscopy	673:692	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	1	51	theme	present	153:159	arg1	study					161:165	The present study	149:165	The present study	149:165	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	9	52	theme	contraction	1645:1655	arg1	%					1678:1678	98 ± 1.11%	1669:1678	98 ± 1.11%	1669:1678	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	9	52	theme	contraction	1645:1655	arg1	percentage					1657:1666	wound contraction percentage	1639:1666	wound contraction percentage (98 ± 1.11%)	1639:1679	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	7	53	dep	assays	1306:1311	arg1	activity					1325:1332	scavenging activity	1314:1332	three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power	1290:1477	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	6	54	theme	β	1142:1142	arg1	anomers					1144:1150	α and β anomers	1136:1150	α and β anomers	1136:1150	Results obtained by 1H NMR indicated that PLS consisted of three monosaccharide residues with α and β anomers.
36051487	7	55	theme	2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic	1342:1390	arg1	ABTS					1398:1401	ABTS	1398:1401	ABTS	1398:1401	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	7	55	theme	2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic	1342:1390	arg1	acid					1392:1395	2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid	1342:1395	2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS)	1342:1402	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	3	56	theme	UV	695:696	arg1	spectrum					698:705	UV spectrum	695:705	UV spectrum	695:705	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	0	57	theme	Wound	117:121	arg1	Healing					123:129	Wound Healing	117:129	Wound Healing in Diabetic Rats	117:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	9	58	theme	±	1672:1672	arg1	%					1678:1678	98 ± 1.11%	1669:1678	98 ± 1.11%	1669:1678	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	9	58	theme	±	1672:1672	arg1	percentage					1657:1666	wound contraction percentage	1639:1666	wound contraction percentage (98 ± 1.11%)	1639:1679	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	10	59	theme	group	1770:1774	arg1	assessment					1740:1749	the histological assessment	1723:1749	the histological assessment of the PLS-treated group	1723:1774	Furthermore, the histological assessment of the PLS-treated group demonstrated complete reepithelialized wounds by accelerating collagen synthesis.
36051487	6	60	theme	α	1136:1136	arg1	anomers					1144:1150	α and β anomers	1136:1150	α and β anomers	1136:1150	Results obtained by 1H NMR indicated that PLS consisted of three monosaccharide residues with α and β anomers.
36051487	3	61	theme	performance	713:723	arg1	HPLC					748:751	HPLC	748:751	HPLC	748:751	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	61	theme	performance	713:723	arg1	chromatography					732:745	high performance liquid chromatography	708:745	high performance liquid chromatography (HPLC)	708:752	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	1	62	theme	alloxan-induced	383:397	arg1	rats					408:411	alloxan-induced diabetic rats	383:411	alloxan-induced diabetic rats	383:411	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	11	63	theme	wound	1917:1921	arg1	closure					1923:1929	wound closure	1917:1929	wound closure in alloxan-induced diabetic rats	1917:1962	In general, the findings affirmed that PLS is efficient on wound closure in alloxan-induced diabetic rats.
36051487	0	64	from	Effects	106:112	arg1	Healing					123:129	Wound Healing	117:129	Wound Healing in Diabetic Rats	117:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	64	from	Effects	106:112	arg1	sativum					90:96	Lepidium sativum	81:96	Lepidium sativum	81:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	7	65	theme	different	1296:1304	arg1	assays					1306:1311	three different assays	1290:1311	three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power	1290:1477	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	2	66	theme	blue-yellow	522:532	arg1	intensity					534:542	blue-yellow intensity	522:542	blue-yellow intensity	522:542	This polysaccharide presented a lighter natural color, whose luminosity (L∗), red-green intensity (a∗), and blue-yellow intensity (b∗) were recorded at 63.26, 5.87, and 27.28, respectively.
36051487	0	67	theme	Heteropolysaccharide	55:74	arg1	Characterization					12:27	Characterization	12:27	Characterization	12:27	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	67	theme	Heteropolysaccharide	55:74	arg1	Structure					34:42	Structure	34:42	Structure	34:42	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	67	theme	Heteropolysaccharide	55:74	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	67	theme	Heteropolysaccharide	55:74	arg1	Effects					106:112	Its Effects	102:112	Its Effects on Wound Healing in Diabetic Rats	102:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	10	68	theme	complete	1789:1796	arg1	wounds					1815:1820	complete reepithelialized wounds	1789:1820	complete reepithelialized wounds	1789:1820	Furthermore, the histological assessment of the PLS-treated group demonstrated complete reepithelialized wounds by accelerating collagen synthesis.
36051487	9	69	theme	experiment	1698:1707	arg1	days					1690:1693	14 days	1687:1693	14 days of experiment	1687:1707	Indeed, its application significantly increased wound contraction percentage (98 ± 1.11%) after 14 days of experiment.
36051487	0	70	theme	Lepidium	81:88	arg1	sativum					90:96	Lepidium sativum	81:96	Lepidium sativum	81:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	4	71	theme	FT-IR	867:871	arg1	spectra					880:886	The FT-IR and UV spectra	863:886	spectra	880:886	The FT-IR and UV spectra showed the characteristic band of polysaccharides.
36051487	0	72	from	Structure	34:42	arg1	Healing					123:129	Wound Healing	117:129	Wound Healing in Diabetic Rats	117:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	72	from	Structure	34:42	arg1	sativum					90:96	Lepidium sativum	81:96	Lepidium sativum	81:96	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	0	73	from	Healing	123:129	arg1	Rats					143:146	Diabetic Rats	134:146	Diabetic Rats	134:146	Extraction, Characterization, and Structure of a Novel Heteropolysaccharide from Lepidium sativum and Its Effects on Wound Healing in Diabetic Rats.
36051487	7	74	contain	had	1179:1181	arg1	polysaccharide					1164:1177	This novel polysaccharide	1153:1177	This novel polysaccharide	1153:1177	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	7	74	contain	had	1179:1181	arg2	weight					1204:1209	an average molecular weight	1183:1209	an average molecular weight of 98.51 kDa	1183:1222	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	7	75	theme	98.51 kDa	1214:1222	arg1	weight					1204:1209	an average molecular weight	1183:1209	an average molecular weight of 98.51 kDa	1183:1222	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	8	76	theme	beneficial	1515:1524	arg1	effects					1526:1532	the beneficial effects	1511:1532	the beneficial effects of the PLS to accelerate wound healing in diabetic rats	1511:1588	These results strongly support the beneficial effects of the PLS to accelerate wound healing in diabetic rats.
36051487	3	77	dep	Fourier	646:652	arg1	transform					654:662	transform	654:662	transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography	654:860	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	3	78	theme	gel	832:834	arg1	chromatography					847:860	high-pressure gel filtration chromatography	818:860	high-pressure gel filtration chromatography	818:860	The PLS was structurally characterized by Fourier transform infrared (FT-IR) spectroscopy, UV spectrum, high performance liquid chromatography (HPLC), gas chromatography (GC), nuclear resonance magnetic (NMR), and high-pressure gel filtration chromatography.
36051487	7	79	theme	average	1186:1192	arg1	weight					1204:1209	an average molecular weight	1183:1209	an average molecular weight of 98.51 kDa	1183:1222	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	4	80	theme	characteristic	899:912	arg1	band					914:917	the characteristic band	895:917	the characteristic band of polysaccharides	895:936	The FT-IR and UV spectra showed the characteristic band of polysaccharides.
36051487	8	81	theme	PLS	1541:1543	arg1	effects					1526:1532	the beneficial effects	1511:1532	the beneficial effects of the PLS to accelerate wound healing in diabetic rats	1511:1588	These results strongly support the beneficial effects of the PLS to accelerate wound healing in diabetic rats.
36051487	1	82	theme	composition	292:302	arg1	PLS					242:244	PLS	242:244	PLS	242:244	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	82	theme	composition	292:302	arg1	sativum					233:239	Lepidium sativum	224:239	Lepidium sativum (PLS)	224:245	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	1	82	theme	composition	292:302	arg1	determination					255:267	the determination	251:267	the determination of its physicochemical composition and antioxidant properties	251:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	2	83	theme	natural	454:460	arg1	color					462:466	a lighter natural color	444:466	a lighter natural color	444:466	This polysaccharide presented a lighter natural color, whose luminosity (L∗), red-green intensity (a∗), and blue-yellow intensity (b∗) were recorded at 63.26, 5.87, and 27.28, respectively.
36051487	1	84	theme	antioxidant	308:318	arg1	properties					320:329	antioxidant properties	308:329	antioxidant properties	308:329	The present study undertakes the extraction of a novel polysaccharide from Lepidium sativum (PLS) and the determination of its physicochemical composition and antioxidant properties, as well as its potential wound healing activity in alloxan-induced diabetic rats.
36051487	11	85	theme	alloxan-induced	1934:1948	arg1	rats					1959:1962	alloxan-induced diabetic rats	1934:1962	alloxan-induced diabetic rats	1934:1962	In general, the findings affirmed that PLS is efficient on wound closure in alloxan-induced diabetic rats.
36051487	7	86	theme	novel	1158:1162	arg1	polysaccharide					1164:1177	This novel polysaccharide	1153:1177	This novel polysaccharide	1153:1177	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	7	87	theme	reducing	1464:1471	arg1	power					1473:1477	reducing power	1464:1477	reducing power	1464:1477	This novel polysaccharide had an average molecular weight of 98.51 kDa and displayed potential antioxidant activities determined through three different assays: scavenging activity against 2,2'-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging assay, and reducing power.
36051487	8	88	theme	diabetic	1576:1583	arg1	rats					1585:1588	diabetic rats	1576:1588	diabetic rats	1576:1588	These results strongly support the beneficial effects of the PLS to accelerate wound healing in diabetic rats.
37285894	5	0	theme	dielectric	753:762	arg1	properties					779:788	the dielectric energy storage properties	749:788	the dielectric energy storage properties of cellulose films in high humidity environment	749:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	4	1	theme	better	512:517	arg1	effect					519:524	a better effect	510:524	a better effect	510:524	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	1	2	theme	great	190:194	arg1	attention					196:204	great attention	190:204	great attention	190:204	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	6	3	theme	films	1018:1022	arg1	density					976:982	The energy storage density	957:982	The energy storage density of the prepared ternary composite films	957:1022	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	4	4	dep	constant	554:561	arg1	the					539:541	the	539:541	the	539:541	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	4	5	theme	6.2 J/cm3	693:701	arg1	density					682:688	an energy density	672:688	an energy density of 6.2 J/cm3	672:701	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	8	6	theme	materials	1374:1382	arg1	prospect					1348:1355	the application prospect	1332:1355	the application prospect of biomass-based materials	1332:1382	This work broadens the application prospect of biomass-based materials in the field of film dielectric capacitor.
37285894	4	7	theme	composites	593:602	arg1	constant					554:561	dielectric constant	543:561	dielectric constant	543:561	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	4	7	theme	composites	593:602	arg1	strength					577:584	breakdown strength	567:584	breakdown strength	567:584	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	3	8	theme	cellulose	383:391	arg1	films					424:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films were prepared by regeneration, washing and drying.
37285894	5	9	from	properties	779:788	arg1	environment					826:836	high humidity environment	812:836	high humidity environment	812:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	8	10	theme	film	1400:1403	arg1	capacitor					1416:1424	film dielectric capacitor	1400:1424	film dielectric capacitor	1400:1424	This work broadens the application prospect of biomass-based materials in the field of film dielectric capacitor.
37285894	2	11	theme	hydrothermal	320:331	arg1	method					333:338	hydrothermal method	320:338	hydrothermal method	320:338	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	6	12	theme	ternary	1000:1006	arg1	films					1018:1022	the prepared ternary composite films	987:1022	the prepared ternary composite films	987:1022	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	6	13	theme	prepared	991:998	arg1	films					1018:1022	the prepared ternary composite films	987:1022	the prepared ternary composite films	987:1022	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	5	14	theme	composite	940:948	arg1	films					950:954	RC-AONS-PVDF composite films	927:954	RC-AONS-PVDF composite films	927:954	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	4	15	contain	had	506:508	arg2	effect					519:524	a better effect	510:524	a better effect	510:524	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	4	15	contain	had	506:508	arg1	AONS					501:504	The two-dimensional AONS	481:504	The two-dimensional AONS	481:504	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	5	16	theme	films	803:807	arg1	properties					779:788	the dielectric energy storage properties	749:788	the dielectric energy storage properties of cellulose films in high humidity environment	749:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	6	17	theme	416 	1070:1073	arg1	%					1074:1074	%	1074:1074	%	1074:1074	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	5	18	theme	polyvinylidene	855:868	arg1	fluoride					870:877	the hydrophobic polyvinylidene fluoride	839:877	the hydrophobic polyvinylidene fluoride (PVDF)	839:884	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	5	18	theme	polyvinylidene	855:868	arg1	PVDF					880:883	PVDF	880:883	PVDF	880:883	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	3	19	theme	regenerated	371:381	arg1	RC					394:395	RC	394:395	RC	394:395	Then the regenerated cellulose (RC)-AONS dielectric composite films were prepared by regeneration, washing and drying.
37285894	3	19	theme	regenerated	371:381	arg1	cellulose					383:391	Then the regenerated cellulose	362:391	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films were prepared by regeneration, washing and drying.
37285894	5	20	from	films	803:807	arg1	environment					826:836	high humidity environment	812:836	high humidity environment	812:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	0	21	theme	High-performance	0:15	arg1	film					28:31	High-performance dielectric film	0:31	High-performance dielectric film	0:31	High-performance dielectric film capacitors based on cellulose/Al2O3 nanosheets/PVDF composites.
37285894	6	22	theme	%	1074:1074	arg1	improvement					1076:1086	416 % improvement	1070:1086	416 % improvement	1070:1086	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	0	23	theme	dielectric	17:26	arg1	film					28:31	High-performance dielectric film	0:31	High-performance dielectric film	0:31	High-performance dielectric film capacitors based on cellulose/Al2O3 nanosheets/PVDF composites.
37285894	5	24	theme	energy	764:769	arg1	properties					779:788	the dielectric energy storage properties	749:788	the dielectric energy storage properties of cellulose films in high humidity environment	749:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	8	25	theme	biomass-based	1360:1372	arg1	materials					1374:1382	biomass-based materials	1360:1382	biomass-based materials	1360:1382	This work broadens the application prospect of biomass-based materials in the field of film dielectric capacitor.
37285894	4	26	theme	two-dimensional	485:499	arg1	AONS					501:504	The two-dimensional AONS	481:504	The two-dimensional AONS	481:504	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	4	27	theme	energy	675:680	arg1	density					682:688	an energy density	672:688	an energy density of 6.2 J/cm3	672:701	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	3	28	theme	dielectric	403:412	arg1	films					424:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films were prepared by regeneration, washing and drying.
37285894	6	29	theme	storage	968:974	arg1	density					976:982	The energy storage density	957:982	The energy storage density of the prepared ternary composite films	957:1022	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	5	30	theme	high	812:815	arg1	environment					826:836	high humidity environment	812:836	high humidity environment	812:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	4	31	theme	breakdown	567:575	arg1	strength					577:584	breakdown strength	567:584	breakdown strength	567:584	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	7	32	from	absorption	1243:1252	arg1	humidity					1279:1286	humidity	1279:1286	humidity	1279:1286	Concurrently, the water absorption of the composite film in humidity was effectively reduced.
37285894	4	33	theme	5 wt	645:648	arg1	content					656:662	5 wt% AONS content	645:662	5 wt% AONS content	645:662	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	5	34	theme	humidity	817:824	arg1	environment					826:836	high humidity environment	812:836	high humidity environment	812:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	1	35	theme	novel	127:131	arg1	composites					168:177	novel renewable biomass-based dielectric composites	127:177	novel renewable biomass-based dielectric composites	127:177	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	5	36	theme	storage	771:777	arg1	properties					779:788	the dielectric energy storage properties	749:788	the dielectric energy storage properties of cellulose films in high humidity environment	749:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	1	37	dep	design	101:106	arg1	The					97:99	The	97:99	The	97:99	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	6	38	theme	oriented	1131:1138	arg1	2 J/cm3					1155:1161	2 J/cm3	1155:1161	2 J/cm3	1155:1161	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	6	38	theme	oriented	1131:1138	arg1	polypropylene					1140:1152	the commercially biaxially oriented polypropylene	1104:1152	the commercially biaxially oriented polypropylene (2 J/cm3)	1104:1162	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	4	39	with	film	635:638	arg1	content					656:662	5 wt% AONS content	645:662	5 wt% AONS content	645:662	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	4	40	theme	AONS	651:654	arg1	content					656:662	5 wt% AONS content	645:662	5 wt% AONS content	645:662	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	4	41	theme	dielectric	543:552	arg1	constant					554:561	dielectric constant	543:561	dielectric constant	543:561	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	6	42	theme	composite	1008:1016	arg1	films					1018:1022	the prepared ternary composite films	987:1022	the prepared ternary composite films	987:1022	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	4	43	theme	%	649:649	arg1	content					656:662	5 wt% AONS content	645:662	5 wt% AONS content	645:662	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	3	44	theme	composite	414:422	arg1	films					424:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films were prepared by regeneration, washing and drying.
37285894	6	45	theme	energy	961:966	arg1	density					976:982	The energy storage density	957:982	The energy storage density of the prepared ternary composite films	957:1022	The energy storage density of the prepared ternary composite films could reach 8.32 J/cm3 at 400 MV/m, which was 416 % improvement against that of the commercially biaxially oriented polypropylene (2 J/cm3), and could be cycled for >10,000 times under 200 MV/m.
37285894	5	46	theme	cellulose	793:801	arg1	films					803:807	cellulose films	793:807	cellulose films in high humidity environment	793:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	7	47	theme	composite	1261:1269	arg1	film					1271:1274	the composite film	1257:1274	the composite film	1257:1274	Concurrently, the water absorption of the composite film in humidity was effectively reduced.
37285894	2	48	theme	aqueous	259:265	arg1	solution					267:274	NaOH/urea aqueous solution	249:274	NaOH/urea aqueous solution	249:274	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	1	49	theme	renewable	133:141	arg1	composites					168:177	novel renewable biomass-based dielectric composites	127:177	novel renewable biomass-based dielectric composites	127:177	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	0	50	theme	cellulose/Al2O3	53:67	arg1	composites					85:94	cellulose/Al2O3 nanosheets/PVDF composites	53:94	cellulose/Al2O3 nanosheets/PVDF composites	53:94	High-performance dielectric film capacitors based on cellulose/Al2O3 nanosheets/PVDF composites.
37285894	2	51	theme	NaOH/urea	249:257	arg1	solution					267:274	NaOH/urea aqueous solution	249:274	NaOH/urea aqueous solution	249:274	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	5	52	from	environment	826:836	arg1	properties					779:788	the dielectric energy storage properties	749:788	the dielectric energy storage properties of cellulose films in high humidity environment	749:836	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	1	53	theme	biomass-based	143:155	arg1	composites					168:177	novel renewable biomass-based dielectric composites	127:177	novel renewable biomass-based dielectric composites	127:177	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	8	54	theme	capacitor	1416:1424	arg1	field					1391:1395	the field	1387:1395	the field of film dielectric capacitor	1387:1424	This work broadens the application prospect of biomass-based materials in the field of film dielectric capacitor.
37285894	0	55	dep	capacitors	33:42	arg1	based					44:48	based	44:48	capacitors based on cellulose/Al2O3 nanosheets/PVDF composites	33:94	High-performance dielectric film capacitors based on cellulose/Al2O3 nanosheets/PVDF composites.
37285894	1	56	theme	dielectric	157:166	arg1	composites					168:177	novel renewable biomass-based dielectric composites	127:177	novel renewable biomass-based dielectric composites	127:177	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	4	57	theme	RC-AONS	617:623	arg1	film					635:638	the RC-AONS composite film	613:638	the RC-AONS composite film with 5 wt% AONS content	613:662	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
37285894	8	58	theme	application	1336:1346	arg1	prospect					1348:1355	the application prospect	1332:1355	the application prospect of biomass-based materials	1332:1382	This work broadens the application prospect of biomass-based materials in the field of film dielectric capacitor.
37285894	8	59	theme	dielectric	1405:1414	arg1	capacitor					1416:1424	film dielectric capacitor	1400:1424	film dielectric capacitor	1400:1424	This work broadens the application prospect of biomass-based materials in the field of film dielectric capacitor.
37285894	1	60	theme	composites	168:177	arg1	preparation					112:122	preparation	112:122	preparation	112:122	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	1	60	theme	composites	168:177	arg1	design					101:106	design	101:106	design	101:106	The design and preparation of novel renewable biomass-based dielectric composites have drawn great attention recently.
37285894	5	61	theme	RC-AONS-PVDF	927:938	arg1	films					950:954	RC-AONS-PVDF composite films	927:954	RC-AONS-PVDF composite films	927:954	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	5	62	theme	hydrophobic	843:853	arg1	fluoride					870:877	the hydrophobic polyvinylidene fluoride	839:877	the hydrophobic polyvinylidene fluoride (PVDF)	839:884	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	5	62	theme	hydrophobic	843:853	arg1	PVDF					880:883	PVDF	880:883	PVDF	880:883	Furthermore, in order to improve the dielectric energy storage properties of cellulose films in high humidity environment, the hydrophobic polyvinylidene fluoride (PVDF) was innovatively introduced to construct RC-AONS-PVDF composite films.
37285894	2	63	theme	Al2O3	281:285	arg1	AONS					299:302	AONS	299:302	AONS	299:302	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	2	63	theme	Al2O3	281:285	arg1	nanosheets					287:296	Al2O3 nanosheets	281:296	Al2O3 nanosheets (AONS) synthesized by hydrothermal method	281:338	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	2	63	theme	Al2O3	281:285	arg1	fillers					353:359	fillers	353:359	fillers	353:359	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	7	64	theme	water	1237:1241	arg1	absorption					1243:1252	the water absorption	1233:1252	the water absorption of the composite film in humidity	1233:1286	Concurrently, the water absorption of the composite film in humidity was effectively reduced.
37285894	2	65	used	used	345:348	arg2	AONS					299:302	AONS	299:302	AONS	299:302	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	2	65	used	used	345:348	arg2	nanosheets					287:296	Al2O3 nanosheets	281:296	Al2O3 nanosheets (AONS) synthesized by hydrothermal method	281:338	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	2	65	used	used	345:348	arg2	fillers					353:359	fillers	353:359	fillers	353:359	Here, cellulose was dissolved in NaOH/urea aqueous solution, and Al2O3 nanosheets (AONS) synthesized by hydrothermal method were used as fillers.
37285894	0	66	theme	nanosheets/PVDF	69:83	arg1	composites					85:94	cellulose/Al2O3 nanosheets/PVDF composites	53:94	cellulose/Al2O3 nanosheets/PVDF composites	53:94	High-performance dielectric film capacitors based on cellulose/Al2O3 nanosheets/PVDF composites.
37285894	7	67	theme	film	1271:1274	arg1	absorption					1243:1252	the water absorption	1233:1252	the water absorption of the composite film in humidity	1233:1286	Concurrently, the water absorption of the composite film in humidity was effectively reduced.
37285894	3	68	theme	-AONS	397:401	arg1	films					424:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films	362:428	Then the regenerated cellulose (RC)-AONS dielectric composite films were prepared by regeneration, washing and drying.
37285894	4	69	theme	composite	625:633	arg1	film					635:638	the RC-AONS composite film	613:638	the RC-AONS composite film with 5 wt% AONS content	613:662	The two-dimensional AONS had a better effect on improving the dielectric constant and breakdown strength of the composites, so that the RC-AONS composite film with 5 wt% AONS content reached an energy density of 6.2 J/cm3 at 420 MV/m.
35640024	3	0	from	effect	621:626	arg1	interactions					658:669	these interactions	652:669	these interactions	652:669	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	7	1	theme	different	1166:1174	arg1	mechanisms					1176:1185	two different mechanisms	1162:1185	two different mechanisms	1162:1185	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	3	2	theme	salivary	631:638	arg1	proteins					640:647	salivary proteins	631:647	salivary proteins	631:647	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	7	3	theme	flavan-3-ol-SP	1123:1136	arg1	interactions					1138:1149	flavan-3-ol-SP interactions	1123:1149	flavan-3-ol-SP interactions	1123:1149	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	3	4	theme	proteins	640:647	arg1	tannins					541:547	tannins	541:547	tannins	541:547	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	3	4	theme	proteins	640:647	arg1	effect					621:626	the effect	617:626	the effect of salivary proteins on these interactions	617:669	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	7	5	theme	flavan-3-ol-saliva	1298:1315	arg1	interaction					1317:1327	flavan-3-ol-saliva interaction	1298:1327	flavan-3-ol-saliva interaction	1298:1327	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	7	6	theme	SP/MPF/flavan-3-ols	1223:1241	arg1	aggregates					1259:1268	SP/MPF/flavan-3-ols ternary soluble aggregates	1223:1268	SP/MPF/flavan-3-ols ternary soluble aggregates	1223:1268	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	7	7	theme	ternary	1243:1249	arg1	aggregates					1259:1268	SP/MPF/flavan-3-ols ternary soluble aggregates	1223:1268	SP/MPF/flavan-3-ols ternary soluble aggregates	1223:1268	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	8	8	theme	different	1465:1473	arg1	characteristics					1489:1503	different compositional characteristics	1465:1503	different compositional characteristics	1465:1503	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	0	9	from	Interaction	35:45	arg1	Model					106:110	a Cell-Based Model	93:110	a Cell-Based Model of the Oral Epithelium	93:133	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	6	10	theme	most	984:987	arg1	decrease					1001:1008	The most significant decrease	980:1008	The most significant decrease	980:1008	The most significant decrease was obtained in the system containing MPF (38.16%).
35640024	8	11	with	mannoproteins	1446:1458	arg1	characteristics					1489:1503	different compositional characteristics	1465:1503	different compositional characteristics	1465:1503	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	0	12	theme	Cell-Based	95:104	arg1	Model					106:110	a Cell-Based Model	93:110	a Cell-Based Model of the Oral Epithelium	93:133	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	7	13	theme	cell-tannin	1380:1390	arg1	interactions					1392:1403	cell-tannin interactions	1380:1403	cell-tannin interactions	1380:1403	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	4	14	theme	flavan-3-ols	773:784	arg1	content					754:760	the content	750:760	the content of unbound flavan-3-ols after the interactions	750:807	The binding of flavan-3-ols to oral cells was evaluated by DMACA assay, while the content of unbound flavan-3-ols after the interactions was assessed by means of HPLC-DAD-MS.
35640024	2	15	theme	polysaccharides	381:395	arg1	presence					369:376	the presence	365:376	the presence of polysaccharides such as mannoproteins (MP)	365:422	Moreover, astringency development can be affected by the presence of polysaccharides such as mannoproteins (MP).
35640024	8	16	theme	compositional	1475:1487	arg1	characteristics					1489:1503	different compositional characteristics	1465:1503	different compositional characteristics	1465:1503	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	4	17	theme	flavan-3-ols	687:698	arg1	binding					676:682	The binding	672:682	The binding of flavan-3-ols to oral cells	672:712	The binding of flavan-3-ols to oral cells was evaluated by DMACA assay, while the content of unbound flavan-3-ols after the interactions was assessed by means of HPLC-DAD-MS.
35640024	7	18	theme	similar	1406:1412	arg1	mechanism					1346:1354	a competitive mechanism	1332:1354	a competitive mechanism	1332:1354	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	7	19	theme	soluble	1251:1257	arg1	aggregates					1259:1268	SP/MPF/flavan-3-ols ternary soluble aggregates	1223:1268	SP/MPF/flavan-3-ols ternary soluble aggregates	1223:1268	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	7	20	theme	modulating	1102:1111	arg1	effect					1113:1118	modulating effect	1102:1118	modulating effect	1102:1118	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	5	21	theme	cell-tannin	889:899	arg1	interactions					901:912	cell-tannin interactions	889:912	cell-tannin interactions	889:912	Results obtained confirm the existence of cell-tannin interactions, that can be partially inhibited by the presence of SP and/or MP.
35640024	7	22	theme	aggregates	1259:1268	arg1	formation					1210:1218	the formation	1206:1218	the formation of SP/MPF/flavan-3-ols ternary soluble aggregates	1206:1268	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	0	23	theme	Mannoproteins	14:26	arg1	Role					0:3	Role	0:3	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.	0:134	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	1	24	theme	salivary	288:295	arg1	proteins					297:304	salivary proteins	288:304	salivary proteins (SP)	288:309	Astringency is a highly complex sensation which involves multiple mechanisms occurring simultaneously, such as the interaction between flavan-3-ols and salivary proteins (SP).
35640024	1	24	theme	salivary	288:295	arg1	SP					307:308	SP	307:308	SP	307:308	Astringency is a highly complex sensation which involves multiple mechanisms occurring simultaneously, such as the interaction between flavan-3-ols and salivary proteins (SP).
35640024	5	25	theme	MP	976:977	arg1	presence					954:961	the presence	950:961	the presence of SP and/or MP	950:977	Results obtained confirm the existence of cell-tannin interactions, that can be partially inhibited by the presence of SP and/or MP.
35640024	4	26	theme	oral	703:706	arg1	cells					708:712	oral cells	703:712	oral cells	703:712	The binding of flavan-3-ols to oral cells was evaluated by DMACA assay, while the content of unbound flavan-3-ols after the interactions was assessed by means of HPLC-DAD-MS.
35640024	8	27	with	interaction	1532:1542	arg1	families					1570:1577	distinct flavan-3-ol families	1549:1577	distinct flavan-3-ol families	1549:1577	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	3	28	theme	work	441:444	arg1	aim					429:431	The aim	425:431	The aim of this work	425:444	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	0	29	theme	Yeast	8:12	arg1	Mannoproteins					14:26	Yeast Mannoproteins	8:26	Yeast Mannoproteins	8:26	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	5	30	theme	interactions	901:912	arg1	existence					876:884	the existence	872:884	the existence of cell-tannin interactions, that can be partially inhibited by the presence of SP and/or MP	872:977	Results obtained confirm the existence of cell-tannin interactions, that can be partially inhibited by the presence of SP and/or MP.
35640024	1	31	theme	multiple	193:200	arg1	mechanisms					202:211	multiple mechanisms	193:211	multiple mechanisms occurring simultaneously	193:236	Astringency is a highly complex sensation which involves multiple mechanisms occurring simultaneously, such as the interaction between flavan-3-ols and salivary proteins (SP).
35640024	8	32	theme	preferential	1519:1530	arg1	interaction					1532:1542	preferential interaction	1519:1542	preferential interaction with distinct flavan-3-ol families	1519:1577	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	0	33	theme	Epithelium	124:133	arg1	Model					106:110	a Cell-Based Model	93:110	a Cell-Based Model of the Oral Epithelium	93:133	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	7	34	theme	competitive	1334:1344	arg1	mechanism					1346:1354	a competitive mechanism	1332:1354	a competitive mechanism	1332:1354	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	8	35	theme	distinct	1549:1556	arg1	families					1570:1577	distinct flavan-3-ol families	1549:1577	distinct flavan-3-ol families	1549:1577	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	0	36	theme	Oral	119:122	arg1	Epithelium					124:133	the Oral Epithelium	115:133	the Oral Epithelium	115:133	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	3	37	theme	TR146	599:603	arg1	epithelium					587:596	the oral epithelium	578:596	the oral epithelium (TR146 cells)	578:610	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	3	37	theme	TR146	599:603	arg1	cells					605:609	TR146 cells	599:609	TR146 cells	599:609	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	5	38	theme	SP	966:967	arg1	presence					954:961	the presence	950:961	the presence of SP and/or MP	950:977	Results obtained confirm the existence of cell-tannin interactions, that can be partially inhibited by the presence of SP and/or MP.
35640024	8	39	theme	flavan-3-ol	1558:1568	arg1	families					1570:1577	distinct flavan-3-ol families	1549:1577	distinct flavan-3-ol families	1549:1577	This study suggests that mannoproteins with different compositional characteristics could exhibit preferential interaction with distinct flavan-3-ol families.
35640024	4	40	theme	unbound	765:771	arg1	flavan-3-ols					773:784	unbound flavan-3-ols	765:784	unbound flavan-3-ols	765:784	The binding of flavan-3-ols to oral cells was evaluated by DMACA assay, while the content of unbound flavan-3-ols after the interactions was assessed by means of HPLC-DAD-MS.
35640024	0	41	from	Role	0:3	arg1	Interaction					35:45	the Interaction	31:45	the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium	31:133	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	3	42	theme	cell-based	558:567	arg1	model					569:573	a cell-based model	556:573	a cell-based model of the oral epithelium (TR146 cells)	556:610	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	3	43	theme	molecular	466:474	arg1	mechanisms					476:485	the molecular mechanisms	462:485	the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions	462:669	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	7	44	contain	have	1097:1100	arg1	mannoproteins					1067:1079	Both mannoproteins	1062:1079	Both mannoproteins assayed	1062:1087	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	7	44	contain	have	1097:1100	arg2	effect					1113:1118	modulating effect	1102:1118	modulating effect	1102:1118	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	3	45	theme	epithelium	587:596	arg1	model					569:573	a cell-based model	556:573	a cell-based model of the oral epithelium (TR146 cells)	556:610	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	2	46	theme	astringency	322:332	arg1	development					334:344	astringency development	322:344	astringency development	322:344	Moreover, astringency development can be affected by the presence of polysaccharides such as mannoproteins (MP).
35640024	3	47	from	tannins	541:547	arg1	interactions					658:669	these interactions	652:669	these interactions	652:669	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	6	48	contain	containing	1037:1046	arg2	%					1058:1058	38.16%	1053:1058	38.16%	1053:1058	The most significant decrease was obtained in the system containing MPF (38.16%).
35640024	6	48	contain	containing	1037:1046	arg2	MPF					1048:1050	MPF	1048:1050	MPF (38.16%)	1048:1059	The most significant decrease was obtained in the system containing MPF (38.16%).
35640024	6	48	contain	containing	1037:1046	arg1	system					1030:1035	the system	1026:1035	the system containing MPF (38.16%)	1026:1059	The most significant decrease was obtained in the system containing MPF (38.16%).
35640024	4	49	theme	DMACA	731:735	arg1	assay					737:741	DMACA assay	731:741	DMACA assay	731:741	The binding of flavan-3-ols to oral cells was evaluated by DMACA assay, while the content of unbound flavan-3-ols after the interactions was assessed by means of HPLC-DAD-MS.
35640024	7	50	dep	reduce	1373:1378	arg1	i.e.					1357:1360	i.e.	1357:1360	i.e.	1357:1360	Both mannoproteins assayed seem to have modulating effect on flavan-3-ol-SP interactions, acting by two different mechanisms: MPF would lead to the formation of SP/MPF/flavan-3-ols ternary soluble aggregates, while MPL seems to prevent flavan-3-ol-saliva interaction by a competitive mechanism, i.e., MPL would reduce cell-tannin interactions, similar to SP.
35640024	6	51	theme	significant	989:999	arg1	decrease					1001:1008	The most significant decrease	980:1008	The most significant decrease	980:1008	The most significant decrease was obtained in the system containing MPF (38.16%).
35640024	1	52	theme	complex	160:166	arg1	sensation					168:176	a highly complex sensation	151:176	a highly complex sensation which involves multiple mechanisms occurring simultaneously, such as the interaction between flavan-3-ols and salivary proteins (SP)	151:309	Astringency is a highly complex sensation which involves multiple mechanisms occurring simultaneously, such as the interaction between flavan-3-ols and salivary proteins (SP).
35640024	1	52	theme	complex	160:166	arg1	Astringency					136:146	Astringency	136:146	Astringency	136:146	Astringency is a highly complex sensation which involves multiple mechanisms occurring simultaneously, such as the interaction between flavan-3-ols and salivary proteins (SP).
35640024	0	53	theme	Salivary	55:62	arg1	Proteins					64:71	Salivary Proteins	55:71	Salivary Proteins	55:71	Role of Yeast Mannoproteins in the Interaction between Salivary Proteins and Flavan-3-ols in a Cell-Based Model of the Oral Epithelium.
35640024	3	54	theme	oral	582:585	arg1	epithelium					587:596	the oral epithelium	578:596	the oral epithelium (TR146 cells)	578:610	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
35640024	3	54	theme	oral	582:585	arg1	cells					605:609	TR146 cells	599:609	TR146 cells	599:609	The aim of this work was to evaluate the molecular mechanisms whereby MP could modulate the astringency elicited by tannins, using a cell-based model of the oral epithelium (TR146 cells), and the effect of salivary proteins on these interactions.
37054858	2	0	theme	methylation	407:417	arg1	analysis					419:426	methylation analysis	407:426	methylation analysis	407:426	Their chemical structures were characterized by molecular weight distribution, monosaccharide composition, infrared spectrum, methylation analysis, and NMR.
37054858	0	1	from	characterization	11:26	arg1	membranaceus					94:105	Astragalus membranaceus	83:105	Astragalus membranaceus	83:105	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	7	2	theme	MAPK	1037:1040	arg1	pathways					1053:1060	NF-κB and MAPK (ERK, JNK) pathways	1027:1060	NF-κB and MAPK (ERK, JNK) pathways	1027:1060	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	2	3	theme	molecular	329:337	arg1	distribution					346:357	molecular weight distribution	329:357	molecular weight distribution	329:357	Their chemical structures were characterized by molecular weight distribution, monosaccharide composition, infrared spectrum, methylation analysis, and NMR.
37054858	6	4	theme	anti-inflammatory	873:889	arg1	activity					891:898	potential anti-inflammatory activity	863:898	potential anti-inflammatory activity	863:898	Bioactivity assays showed that APS-A1 and APS-B1 had potential anti-inflammatory activity.
37054858	7	5	theme	inflammatory	938:949	arg1	IL-6					967:970	IL-6	967:970	IL-6	967:970	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	5	theme	inflammatory	938:949	arg1	MCP-1					977:981	MCP-1	977:981	MCP-1	977:981	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	5	theme	inflammatory	938:949	arg1	TNF-α					960:964	TNF-α	960:964	TNF-α	960:964	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	5	theme	inflammatory	938:949	arg1	factors					951:957	inflammatory factors	938:957	inflammatory factors (TNF-α, IL-6, and MCP-1)	938:982	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	6	6	theme	potential	863:871	arg1	activity					891:898	potential anti-inflammatory activity	863:898	potential anti-inflammatory activity	863:898	Bioactivity assays showed that APS-A1 and APS-B1 had potential anti-inflammatory activity.
37054858	3	7	dep	branch	537:542	arg1	residues					554:561	every ten residues	544:561	a 1,4,6-α-D-Glcp branch every ten residues	520:561	The results revealed that APS-A1 (2.62 × 106 Da) was a 1,4-α-D-Glcp backbone with a 1,4,6-α-D-Glcp branch every ten residues.
37054858	7	8	theme	factors	951:957	arg1	production					924:933	the production	920:933	the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages	920:1021	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	6	9	contain	had	859:861	arg1	APS-B1					852:857	APS-B1	852:857	APS-B1	852:857	Bioactivity assays showed that APS-A1 and APS-B1 had potential anti-inflammatory activity.
37054858	6	9	contain	had	859:861	arg1	APS-A1					841:846	APS-A1	841:846	APS-A1	841:846	Bioactivity assays showed that APS-A1 and APS-B1 had potential anti-inflammatory activity.
37054858	6	9	contain	had	859:861	arg2	activity					891:898	potential anti-inflammatory activity	863:898	potential anti-inflammatory activity	863:898	Bioactivity assays showed that APS-A1 and APS-B1 had potential anti-inflammatory activity.
37054858	7	10	theme	RAW264.7	1002:1009	arg1	macrophages					1011:1021	LPS-stimulated RAW264.7 macrophages	987:1021	LPS-stimulated RAW264.7 macrophages	987:1021	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	1	11	dep	polysaccharides	139:153	arg1	APS-B1					167:172	APS-B1	167:172	APS-B1	167:172	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	11	dep	polysaccharides	139:153	arg1	APS-A1					156:161	APS-A1	156:161	APS-A1	156:161	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	11	dep	polysaccharides	139:153	arg1	polysaccharides					139:153	two homogeneous polysaccharides	123:153	two homogeneous polysaccharides (APS-A1 and APS-B1)	123:173	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	0	12	from	activity	50:57	arg1	membranaceus					94:105	Astragalus membranaceus	83:105	Astragalus membranaceus	83:105	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	2	13	theme	monosaccharide	360:373	arg1	composition					375:385	monosaccharide composition	360:385	monosaccharide composition	360:385	Their chemical structures were characterized by molecular weight distribution, monosaccharide composition, infrared spectrum, methylation analysis, and NMR.
37054858	1	14	theme	Astragalus	194:203	arg1	membranaceus					205:216	Astragalus membranaceus	194:216	Astragalus membranaceus	194:216	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	0	15	theme	Structural	0:9	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	0	16	theme	anti-inflammatory	32:48	arg1	activity					50:57	anti-inflammatory activity	32:57	anti-inflammatory activity	32:57	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	8	17	theme	anti-inflammatory	1135:1151	arg1	supplements					1153:1163	potential anti-inflammatory supplements	1125:1163	potential anti-inflammatory supplements	1125:1163	These results suggested that the two polysaccharides could be potential anti-inflammatory supplements.
37054858	8	17	theme	anti-inflammatory	1135:1151	arg1	polysaccharides					1100:1114	the two polysaccharides	1092:1114	the two polysaccharides	1092:1114	These results suggested that the two polysaccharides could be potential anti-inflammatory supplements.
37054858	7	18	theme	NF-κB	1027:1031	arg1	pathways					1053:1060	NF-κB and MAPK (ERK, JNK) pathways	1027:1060	NF-κB and MAPK (ERK, JNK) pathways	1027:1060	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	8	19	theme	potential	1125:1133	arg1	supplements					1153:1163	potential anti-inflammatory supplements	1125:1163	potential anti-inflammatory supplements	1125:1163	These results suggested that the two polysaccharides could be potential anti-inflammatory supplements.
37054858	8	19	theme	potential	1125:1133	arg1	polysaccharides					1100:1114	the two polysaccharides	1092:1114	the two polysaccharides	1092:1114	These results suggested that the two polysaccharides could be potential anti-inflammatory supplements.
37054858	2	20	theme	weight	339:344	arg1	distribution					346:357	molecular weight distribution	329:357	molecular weight distribution	329:357	Their chemical structures were characterized by molecular weight distribution, monosaccharide composition, infrared spectrum, methylation analysis, and NMR.
37054858	7	21	dep	pathways	1053:1060	arg1	JNK					1048:1050	JNK	1048:1050	JNK	1048:1050	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	21	dep	pathways	1053:1060	arg1	ERK					1043:1045	ERK	1043:1045	ERK	1043:1045	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	3	22	with	backbone	506:513	arg1	branch					537:542	a 1,4,6-α-D-Glcp branch every ten residues	520:561	a 1,4,6-α-D-Glcp branch every ten residues	520:561	The results revealed that APS-A1 (2.62 × 106 Da) was a 1,4-α-D-Glcp backbone with a 1,4,6-α-D-Glcp branch every ten residues.
37054858	1	23	attach	isolated	180:187	arg2	APS-B1					167:172	APS-B1	167:172	APS-B1	167:172	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	23	attach	isolated	180:187	arg1	membranaceus					205:216	Astragalus membranaceus	194:216	Astragalus membranaceus	194:216	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	23	attach	isolated	180:187	arg2	APS-A1					156:161	APS-A1	156:161	APS-A1	156:161	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	23	attach	isolated	180:187	arg2	polysaccharides					139:153	two homogeneous polysaccharides	123:153	two homogeneous polysaccharides (APS-A1 and APS-B1)	123:173	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	0	24	from	membranaceus	94:105	arg1	polysaccharides					62:76	polysaccharides	62:76	polysaccharides from Astragalus membranaceus	62:105	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	0	24	from	membranaceus	94:105	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	0	24	from	membranaceus	94:105	arg1	activity					50:57	anti-inflammatory activity	32:57	anti-inflammatory activity	32:57	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	3	25	theme	1,4-α-D-Glcp	493:504	arg1	backbone					506:513	a 1,4-α-D-Glcp backbone	491:513	a 1,4-α-D-Glcp backbone with a 1,4,6-α-D-Glcp branch every ten residues	491:561	The results revealed that APS-A1 (2.62 × 106 Da) was a 1,4-α-D-Glcp backbone with a 1,4,6-α-D-Glcp branch every ten residues.
37054858	3	25	theme	1,4-α-D-Glcp	493:504	arg1	APS-A1					464:469	APS-A1	464:469	APS-A1 (2.62 × 106 Da)	464:485	The results revealed that APS-A1 (2.62 × 106 Da) was a 1,4-α-D-Glcp backbone with a 1,4,6-α-D-Glcp branch every ten residues.
37054858	1	26	theme	homogeneous	127:137	arg1	APS-B1					167:172	APS-B1	167:172	APS-B1	167:172	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	26	theme	homogeneous	127:137	arg1	APS-A1					156:161	APS-A1	156:161	APS-A1	156:161	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	26	theme	homogeneous	127:137	arg1	polysaccharides					139:153	two homogeneous polysaccharides	123:153	two homogeneous polysaccharides (APS-A1 and APS-B1)	123:173	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	0	27	theme	polysaccharides	62:76	arg1	characterization					11:26	Structural characterization	0:26	Structural characterization	0:26	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	0	27	theme	polysaccharides	62:76	arg1	activity					50:57	anti-inflammatory activity	32:57	anti-inflammatory activity	32:57	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
37054858	2	28	theme	infrared	388:395	arg1	spectrum					397:404	infrared spectrum	388:404	infrared spectrum	388:404	Their chemical structures were characterized by molecular weight distribution, monosaccharide composition, infrared spectrum, methylation analysis, and NMR.
37054858	7	29	theme	LPS-stimulated	987:1000	arg1	macrophages					1011:1021	LPS-stimulated RAW264.7 macrophages	987:1021	LPS-stimulated RAW264.7 macrophages	987:1021	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	30	from	production	924:933	arg1	macrophages					1011:1021	LPS-stimulated RAW264.7 macrophages	987:1021	LPS-stimulated RAW264.7 macrophages	987:1021	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	6	31	theme	Bioactivity	810:820	arg1	assays					822:827	Bioactivity assays	810:827	Bioactivity assays	810:827	Bioactivity assays showed that APS-A1 and APS-B1 had potential anti-inflammatory activity.
37054858	1	32	theme	Sephadex	243:250	arg1	chromatography					265:278	DEAE-52 cellulose and Sephadex G-100 column chromatography	221:278	chromatography	265:278	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	7	33	dep	factors	951:957	arg1	IL-6					967:970	IL-6	967:970	IL-6	967:970	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	33	dep	factors	951:957	arg1	MCP-1					977:981	MCP-1	977:981	MCP-1	977:981	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	33	dep	factors	951:957	arg1	TNF-α					960:964	TNF-α	960:964	TNF-α	960:964	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	7	33	dep	factors	951:957	arg1	factors					951:957	inflammatory factors	938:957	inflammatory factors (TNF-α, IL-6, and MCP-1)	938:982	They could inhibit the production of inflammatory factors (TNF-α, IL-6, and MCP-1) in LPS-stimulated RAW264.7 macrophages via NF-κB and MAPK (ERK, JNK) pathways.
37054858	2	34	theme	chemical	287:294	arg1	structures					296:305	Their chemical structures	281:305	Their chemical structures	281:305	Their chemical structures were characterized by molecular weight distribution, monosaccharide composition, infrared spectrum, methylation analysis, and NMR.
37054858	3	35	theme	1,4,6-α-D-Glcp	522:535	arg1	branch					537:542	a 1,4,6-α-D-Glcp branch every ten residues	520:561	a 1,4,6-α-D-Glcp branch every ten residues	520:561	The results revealed that APS-A1 (2.62 × 106 Da) was a 1,4-α-D-Glcp backbone with a 1,4,6-α-D-Glcp branch every ten residues.
37054858	1	36	theme	G-100	252:256	arg1	chromatography					265:278	DEAE-52 cellulose and Sephadex G-100 column chromatography	221:278	chromatography	265:278	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	1	37	theme	column	258:263	arg1	chromatography					265:278	DEAE-52 cellulose and Sephadex G-100 column chromatography	221:278	chromatography	265:278	In this study, two homogeneous polysaccharides (APS-A1 and APS-B1) were isolated from Astragalus membranaceus by DEAE-52 cellulose and Sephadex G-100 column chromatography.
37054858	0	38	theme	Astragalus	83:92	arg1	membranaceus					94:105	Astragalus membranaceus	83:105	Astragalus membranaceus	83:105	Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus.
35181327	10	0	theme	environmental	1512:1524	arg1	fields					1537:1542	the food and environmental protection fields	1499:1542	the food and environmental protection fields	1499:1542	These results support its use as an additive in the food and environmental protection fields.
35181327	6	1	theme	metal	1047:1051	arg1	activity					1063:1070	heavy metal chelating activity	1041:1070	heavy metal chelating activity	1041:1070	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	1	2	theme	EPS	238:240	arg1	characteristics					190:204	the preliminary structure characteristics	164:204	the preliminary structure characteristics	164:204	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35181327	1	2	theme	EPS	238:240	arg1	activities					221:230	biological activities	210:230	biological activities	210:230	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35181327	7	3	theme	dextran	1177:1183	arg1	capacity					1161:1168	water holding capacity	1147:1168	water holding capacity	1147:1168	The dissolution percentage and water holding capacity of the dextran were 98.78 ± 1.37% and 426.03 ± 7.26%, respectively.
35181327	7	3	theme	dextran	1177:1183	arg1	percentage					1132:1141	dissolution percentage	1120:1141	dissolution percentage	1120:1141	The dissolution percentage and water holding capacity of the dextran were 98.78 ± 1.37% and 426.03 ± 7.26%, respectively.
35181327	3	4	theme	glycosidic	637:646	arg1	bonds					648:652	α-(1 → 6) glycosidic bonds	627:652	α-(1 → 6) glycosidic bonds	627:652	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	8	5	theme	chelating	1315:1323	arg1	activity					1325:1332	heavy metal chelating activity	1303:1332	heavy metal chelating activity	1303:1332	The dextran exhibited good hydrophilicity, thermal stability and heavy metal chelating activity.
35181327	10	6	from	additive	1487:1494	arg1	fields					1537:1542	the food and environmental protection fields	1499:1542	the food and environmental protection fields	1499:1542	These results support its use as an additive in the food and environmental protection fields.
35181327	2	7	theme	permeation	331:340	arg1	chromatography					342:355	gel permeation chromatography	327:355	gel permeation chromatography (GPC)	327:361	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	2	7	theme	permeation	331:340	arg1	GPC					358:360	GPC	358:360	GPC	358:360	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	7	8	dep	percentage	1132:1141	arg1	The					1116:1118	The	1116:1118	The	1116:1118	The dissolution percentage and water holding capacity of the dextran were 98.78 ± 1.37% and 426.03 ± 7.26%, respectively.
35181327	2	9	theme	purified	275:282	arg1	EPS					287:289	purified H2 EPS	275:289	purified H2 EPS	275:289	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	2	10	theme	H2	284:285	arg1	EPS					287:289	purified H2 EPS	275:289	purified H2 EPS	275:289	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	4	11	theme	force	691:695	arg1	micrograph					697:706	Atomic force micrograph (AFM) and scanning electron microscopy	684:745	micrograph	697:706	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	11	theme	force	691:695	arg1	SEM					748:750	SEM	748:750	SEM	748:750	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	11	theme	force	691:695	arg1	AFM					709:711	AFM	709:711	AFM	709:711	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	8	12	theme	heavy	1303:1307	arg1	activity					1325:1332	heavy metal chelating activity	1303:1332	heavy metal chelating activity	1303:1332	The dextran exhibited good hydrophilicity, thermal stability and heavy metal chelating activity.
35181327	3	13	theme	linear	520:525	arg1	EPS					510:512	the EPS	506:512	the EPS	506:512	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	13	theme	linear	520:525	arg1	homopolysaccharide					527:544	a linear homopolysaccharide	518:544	a linear homopolysaccharide	518:544	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	9	14	theme	metal	1400:1404	arg1	ions					1406:1409	metal ions	1400:1409	metal ions	1400:1409	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	9	14	theme	metal	1400:1404	arg1	speed					1376:1380	speed	1376:1380	speed	1376:1380	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	7	15	theme	water	1147:1151	arg1	capacity					1161:1168	water holding capacity	1147:1168	water holding capacity	1147:1168	The dissolution percentage and water holding capacity of the dextran were 98.78 ± 1.37% and 426.03 ± 7.26%, respectively.
35181327	6	16	theme	H2	1088:1089	arg1	dextran					1091:1097	the purified H2 dextran	1075:1097	the purified H2 dextran	1075:1097	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	1	17	theme	structure	180:188	arg1	characteristics					190:204	the preliminary structure characteristics	164:204	the preliminary structure characteristics	164:204	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35181327	5	18	theme	amorphous	927:935	arg1	nature					937:942	non-crystalline amorphous nature	911:942	non-crystalline amorphous nature	911:942	The XRD pattern reflected non-crystalline amorphous nature.
35181327	6	19	theme	rheological	1016:1026	arg1	property					1028:1035	rheological property	1016:1035	rheological property	1016:1035	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	6	20	theme	thermal	998:1004	arg1	property					1006:1013	thermal property	998:1013	thermal property	998:1013	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	7	21	theme	holding	1153:1159	arg1	capacity					1161:1168	water holding capacity	1147:1168	water holding capacity	1147:1168	The dissolution percentage and water holding capacity of the dextran were 98.78 ± 1.37% and 426.03 ± 7.26%, respectively.
35181327	3	22	theme	few	660:662	arg1	α-					664:665	a few α-	658:665	a few α-(1 → 3) branches	658:681	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	22	theme	few	660:662	arg1	1 → 3					667:671	1 → 3	667:671	1 → 3	667:671	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	23	theme	nuclear	396:402	arg1	NMR					424:426	NMR	424:426	NMR	424:426	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	23	theme	nuclear	396:402	arg1	resonance					413:421	nuclear magnetic resonance	396:421	nuclear magnetic resonance (NMR) spectroscopy spectroscopy	396:453	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	2	24	theme	Molecular	257:265	arg1	mass					267:270	Molecular mass	257:270	Molecular mass of purified H2 EPS	257:289	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	6	25	theme	heavy	1041:1045	arg1	activity					1063:1070	heavy metal chelating activity	1041:1070	heavy metal chelating activity	1041:1070	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	9	26	dep	speed	1376:1380	arg1	solutions					1411:1419	solutions	1411:1419	solutions	1411:1419	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	9	26	dep	speed	1376:1380	arg1	nature					1443:1448	dependent semiviscous nature	1421:1448	rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature	1365:1448	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	3	27	theme	α-	664:665	arg1	branches					674:681	a few α-(1 → 3) branches	658:681	a few α-(1 → 3) branches	658:681	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	28	theme	resonance	413:421	arg1	spectroscopy					429:440	nuclear magnetic resonance (NMR) spectroscopy	396:440	nuclear magnetic resonance (NMR) spectroscopy spectroscopy	396:453	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	6	29	theme	water-holding	974:986	arg1	capacity					988:995	water-holding capacity	974:995	water-holding capacity	974:995	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	4	30	theme	dextran	765:771	arg1	analysis					753:760	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis	684:760	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran	684:771	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	31	theme	micrograph	697:706	arg1	analysis					753:760	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis	684:760	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran	684:771	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	9	32	theme	semiviscous	1431:1441	arg1	nature					1443:1448	dependent semiviscous nature	1421:1448	rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature	1365:1448	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	0	33	theme	structure	16:24	arg1	Analysis					0:7	Analysis	0:7	Analysis of the structure and properties of dextran	0:50	Analysis of the structure and properties of dextran produced by Weissella confusa.
35181327	2	34	theme	EPS	287:289	arg1	mass					267:270	Molecular mass	257:270	Molecular mass of purified H2 EPS	257:289	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	9	35	theme	dependent	1421:1429	arg1	nature					1443:1448	dependent semiviscous nature	1421:1448	rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature	1365:1448	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	1	36	theme	preliminary	168:178	arg1	characteristics					190:204	the preliminary structure characteristics	164:204	the preliminary structure characteristics	164:204	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35181327	7	37	theme	dissolution	1120:1130	arg1	percentage					1132:1141	dissolution percentage	1120:1141	dissolution percentage	1120:1141	The dissolution percentage and water holding capacity of the dextran were 98.78 ± 1.37% and 426.03 ± 7.26%, respectively.
35181327	1	38	theme	Sephadex	144:151	arg1	G-100					153:157	Sephadex G-100	144:157	Sephadex G-100	144:157	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35181327	3	39	with	dextran	614:620	arg1	bonds					648:652	α-(1 → 6) glycosidic bonds	627:652	α-(1 → 6) glycosidic bonds	627:652	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	39	with	dextran	614:620	arg1	branches					674:681	a few α-(1 → 3) branches	658:681	a few α-(1 → 3) branches	658:681	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	40	theme	fourier	459:465	arg1	Composition					364:374	Composition	364:374	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR)	364:492	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	0	41	theme	properties	30:39	arg1	Analysis					0:7	Analysis	0:7	Analysis of the structure and properties of dextran	0:50	Analysis of the structure and properties of dextran produced by Weissella confusa.
35181327	3	42	theme	spectroscopy	429:440	arg1	spectroscopy					442:453	nuclear magnetic resonance (NMR) spectroscopy spectroscopy	396:453	nuclear magnetic resonance (NMR) spectroscopy spectroscopy	396:453	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	43	theme	magnetic	404:411	arg1	NMR					424:426	NMR	424:426	NMR	424:426	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	43	theme	magnetic	404:411	arg1	resonance					413:421	nuclear magnetic resonance	396:421	nuclear magnetic resonance (NMR) spectroscopy spectroscopy	396:453	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	4	44	theme	aqueous	867:873	arg1	solution					875:882	aqueous solution	867:882	aqueous solution	867:882	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	45	theme	microscopy	736:745	arg1	analysis					753:760	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis	684:760	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran	684:771	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	3	46	theme	spectroscopy	442:453	arg1	Composition					364:374	Composition	364:374	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR)	364:492	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	3	47	theme	monosaccharides	379:393	arg1	Composition					364:374	Composition	364:374	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR)	364:492	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	9	48	theme	Rheological	1335:1345	arg1	studies					1347:1353	Rheological studies	1335:1353	Rheological studies	1335:1353	Rheological studies exhibited rotational speed, pH, temperature, metal ions solutions dependent semiviscous nature.
35181327	8	49	theme	metal	1309:1313	arg1	activity					1325:1332	heavy metal chelating activity	1303:1332	heavy metal chelating activity	1303:1332	The dextran exhibited good hydrophilicity, thermal stability and heavy metal chelating activity.
35181327	4	50	from	protuberances	850:862	arg1	solution					875:882	aqueous solution	867:882	aqueous solution	867:882	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	5	51	theme	non-crystalline	911:925	arg1	nature					937:942	non-crystalline amorphous nature	911:942	non-crystalline amorphous nature	911:942	The XRD pattern reflected non-crystalline amorphous nature.
35181327	2	52	theme	gel	327:329	arg1	chromatography					342:355	gel permeation chromatography	327:355	gel permeation chromatography (GPC)	327:361	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	2	52	theme	gel	327:329	arg1	GPC					358:360	GPC	358:360	GPC	358:360	Molecular mass of purified H2 EPS was 2.705 × 106 Da as measured with gel permeation chromatography (GPC).
35181327	5	53	theme	XRD	889:891	arg1	pattern					893:899	The XRD pattern	885:899	The XRD pattern	885:899	The XRD pattern reflected non-crystalline amorphous nature.
35181327	6	54	theme	purified	1079:1086	arg1	dextran					1091:1097	the purified H2 dextran	1075:1097	the purified H2 dextran	1075:1097	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	4	55	theme	scanning	718:725	arg1	microscopy					736:745	Atomic force micrograph (AFM) and scanning electron microscopy	684:745	microscopy	736:745	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	56	theme	irregular	840:848	arg1	protuberances					850:862	many irregular protuberances	835:862	many irregular protuberances in aqueous solution	835:882	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	10	57	from	fields	1537:1542	arg1	use					1477:1479	its use	1473:1479	its use	1473:1479	These results support its use as an additive in the food and environmental protection fields.
35181327	10	57	from	fields	1537:1542	arg1	additive					1487:1494	additive	1487:1494	additive	1487:1494	These results support its use as an additive in the food and environmental protection fields.
35181327	0	58	dep	structure	16:24	arg1	the					12:14	the	12:14	the	12:14	Analysis of the structure and properties of dextran produced by Weissella confusa.
35181327	4	59	theme	Atomic	684:689	arg1	micrograph					697:706	Atomic force micrograph (AFM) and scanning electron microscopy	684:745	micrograph	697:706	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	59	theme	Atomic	684:689	arg1	SEM					748:750	SEM	748:750	SEM	748:750	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	4	59	theme	Atomic	684:689	arg1	AFM					709:711	AFM	709:711	AFM	709:711	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	1	60	theme	biological	210:219	arg1	activities					221:230	biological activities	210:230	biological activities	210:230	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35181327	4	61	theme	many	835:838	arg1	protuberances					850:862	many irregular protuberances	835:862	many irregular protuberances in aqueous solution	835:882	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	3	62	dep	transform	467:475	arg1	infrared					477:484	infrared	477:484	transform infrared	467:484	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	8	63	theme	good	1260:1263	arg1	hydrophilicity					1265:1278	good hydrophilicity	1260:1278	good hydrophilicity	1260:1278	The dextran exhibited good hydrophilicity, thermal stability and heavy metal chelating activity.
35181327	4	64	theme	branched	797:804	arg1	microstructure					806:819	branched microstructure	797:819	sheets branched microstructure anchored with many irregular protuberances in aqueous solution	790:882	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	10	65	theme	protection	1526:1535	arg1	fields					1537:1542	the food and environmental protection fields	1499:1542	the food and environmental protection fields	1499:1542	These results support its use as an additive in the food and environmental protection fields.
35181327	4	66	theme	electron	727:734	arg1	microscopy					736:745	Atomic force micrograph (AFM) and scanning electron microscopy	684:745	microscopy	736:745	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	8	67	theme	thermal	1281:1287	arg1	stability					1289:1297	thermal stability	1281:1297	thermal stability	1281:1297	The dextran exhibited good hydrophilicity, thermal stability and heavy metal chelating activity.
35181327	10	68	theme	food	1503:1506	arg1	fields					1537:1542	the food and environmental protection fields	1499:1542	the food and environmental protection fields	1499:1542	These results support its use as an additive in the food and environmental protection fields.
35181327	0	69	theme	dextran	44:50	arg1	properties					30:39	properties	30:39	properties	30:39	Analysis of the structure and properties of dextran produced by Weissella confusa.
35181327	0	69	theme	dextran	44:50	arg1	structure					16:24	structure	16:24	structure	16:24	Analysis of the structure and properties of dextran produced by Weissella confusa.
35181327	6	70	theme	dextran	1091:1097	arg1	solubility					962:971	solubility	962:971	solubility	962:971	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	6	70	theme	dextran	1091:1097	arg1	capacity					988:995	water-holding capacity	974:995	water-holding capacity	974:995	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	6	70	theme	dextran	1091:1097	arg1	property					1006:1013	thermal property	998:1013	thermal property	998:1013	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	6	70	theme	dextran	1091:1097	arg1	property					1028:1035	rheological property	1016:1035	rheological property	1016:1035	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	6	70	theme	dextran	1091:1097	arg1	activity					1063:1070	heavy metal chelating activity	1041:1070	heavy metal chelating activity	1041:1070	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	3	71	dep	fourier	459:465	arg1	transform					467:475	transform	467:475	transform infrared	467:484	Composition of monosaccharides, nuclear magnetic resonance (NMR) spectroscopy spectroscopy and fourier transform infrared (FT-IR) showed that the EPS was a linear homopolysaccharide, mainly constituted of glucose and it is suggested that the EPS was dextran with α-(1 → 6) glycosidic bonds and a few α-(1 → 3) branches.
35181327	4	72	dep	sheets	790:795	arg1	microstructure					806:819	branched microstructure	797:819	sheets branched microstructure anchored with many irregular protuberances in aqueous solution	790:882	Atomic force micrograph (AFM) and scanning electron microscopy (SEM) analysis of dextran further revealed sheets branched microstructure anchored with many irregular protuberances in aqueous solution.
35181327	6	73	theme	chelating	1053:1061	arg1	activity					1063:1070	heavy metal chelating activity	1041:1070	heavy metal chelating activity	1041:1070	In addition, the solubility, water-holding capacity, thermal property, rheological property and heavy metal chelating activity of the purified H2 dextran were determined.
35181327	1	74	theme	H2	235:236	arg1	EPS					238:240	H2 EPS	235:240	H2 EPS	235:240	An EPS produced by Weissella confusa H2 was purified through Sephadex G-100, and the preliminary structure characteristics and biological activities of H2 EPS were analyzed.
35287912	6	0	contain	containing	981:990	arg2	AH2					992:994	AH2	992:994	AH2	992:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	6	0	contain	containing	981:990	arg1	products					972:979	other products	966:979	other products containing AH2	966:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	6	1	from	application	935:945	arg1	food					957:960	food	957:960	food	957:960	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	6	1	from	application	935:945	arg1	products					972:979	other products	966:979	other products containing AH2	966:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	2	2	theme	OPP	317:319	arg1	viscosity					304:312	the apparent viscosity	291:312	the apparent viscosity of OPP	291:319	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	2	3	theme	H2O2	414:417	arg1	addition					388:395	the addition	384:395	the addition of Fe2+, Cu2+ or H2O2	384:417	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	2	3	theme	H2O2	414:417	arg1	temperature					368:378	high temperature	363:378	high temperature	363:378	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	3	4	theme	OPP	630:632	arg1	effects					522:528	little effects	515:528	little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP	515:632	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	1	5	theme	treatment	126:134	arg1	effects					95:101	effects	95:101	effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP)	95:213	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	5	theme	treatment	126:134	arg1	mechanism					223:231	its mechanism	219:231	its mechanism	219:231	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	6	6	from	products	972:979	arg1	application					935:945	the application	931:945	the application of OPP in food and other products containing AH2	931:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	3	7	theme	AH2	485:487	arg1	concentration					489:501	AH2 concentration	485:501	AH2 concentration	485:501	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	0	8	theme	pectic	41:46	arg1	polysaccharide					48:61	okra pectic polysaccharide	36:61	okra pectic polysaccharide	36:61	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.
35287912	6	9	from	food	957:960	arg1	application					935:945	the application	931:945	the application of OPP in food and other products containing AH2	931:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	5	10	theme	viscosity	786:794	arg1	related					832:838	related	832:838	related	832:838	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	5	10	theme	viscosity	786:794	arg1	reduction					796:804	the viscosity reduction	782:804	the viscosity reduction of OPP induced by AH2	782:826	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	2	11	theme	reducing	330:337	arg1	ability					339:345	the reducing ability	326:345	the reducing ability	326:345	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	1	12	from	effects	95:101	arg1	viscosity					143:151	viscosity	143:151	viscosity	143:151	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	12	from	effects	95:101	arg1	properties					168:177	structural properties	157:177	structural properties	157:177	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	0	13	theme	reduction	23:31	arg1	Mechanism					0:8	Mechanism	0:8	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.	0:79	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.
35287912	6	14	theme	present	883:889	arg1	study					891:895	The present study	879:895	The present study	879:895	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	5	15	from	related	832:838	arg1	summary					773:779	summary	773:779	summary	773:779	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	5	16	theme	hydroxyl	860:867	arg1	radicals					869:876	hydroxyl radicals	860:876	hydroxyl radicals	860:876	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	3	17	from	effects	522:528	arg1	composition					552:562	the monosaccharide composition	533:562	the monosaccharide composition	533:562	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	3	17	from	effects	522:528	arg1	linkages					576:583	glycosidic linkages	565:583	glycosidic linkages	565:583	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	3	17	from	effects	522:528	arg1	characteristics					595:609	infrared characteristics	586:609	infrared characteristics	586:609	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	3	17	from	effects	522:528	arg1	morphology					616:625	morphology	616:625	morphology	616:625	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	1	18	theme	structural	157:166	arg1	properties					168:177	structural properties	157:177	structural properties	157:177	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	0	19	theme	viscosity	13:21	arg1	reduction					23:31	viscosity reduction	13:31	viscosity reduction of okra pectic polysaccharide	13:61	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.
35287912	3	20	contain	had	511:513	arg1	it					508:509	it	508:509	it	508:509	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	3	20	contain	had	511:513	arg2	effects					522:528	little effects	515:528	little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP	515:632	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	1	21	from	mechanism	223:231	arg1	viscosity					143:151	viscosity	143:151	viscosity	143:151	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	21	from	mechanism	223:231	arg1	properties					168:177	structural properties	157:177	structural properties	157:177	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	3	22	theme	infrared	586:593	arg1	characteristics					595:609	infrared characteristics	586:609	infrared characteristics	586:609	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	5	23	theme	radicals	869:876	arg1	formation					847:855	the formation	843:855	the formation of hydroxyl radicals	843:876	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	2	24	theme	high	363:366	arg1	temperature					368:378	high temperature	363:378	high temperature	363:378	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	0	25	theme	okra	36:39	arg1	polysaccharide					48:61	okra pectic polysaccharide	36:61	okra pectic polysaccharide	36:61	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.
35287912	3	26	theme	molecular	424:432	arg1	weight					434:439	The molecular weight	420:439	The molecular weight	420:439	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	1	27	dep	viscosity	143:151	arg1	the					139:141	the	139:141	the	139:141	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	2	28	theme	Cu2+	406:409	arg1	addition					388:395	the addition	384:395	the addition of Fe2+, Cu2+ or H2O2	384:417	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	2	28	theme	Cu2+	406:409	arg1	temperature					368:378	high temperature	363:378	high temperature	363:378	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	5	29	from	summary	773:779	arg1	related					832:838	related	832:838	related	832:838	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	5	29	from	summary	773:779	arg1	reduction					796:804	the viscosity reduction	782:804	the viscosity reduction of OPP induced by AH2	782:826	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	1	30	theme	okra	182:185	arg1	OPP					210:212	OPP	210:212	OPP	210:212	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	30	theme	okra	182:185	arg1	polysaccharide					194:207	okra pectic polysaccharide	182:207	okra pectic polysaccharide (OPP)	182:213	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	0	31	theme	polysaccharide	48:61	arg1	reduction					23:31	viscosity reduction	13:31	viscosity reduction of okra pectic polysaccharide	13:61	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.
35287912	3	32	theme	little	515:520	arg1	effects					522:528	little effects	515:528	little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP	515:632	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	4	33	theme	Hydroxyl	656:663	arg1	radicals					665:672	Hydroxyl radicals	656:672	Hydroxyl radicals	656:672	Hydroxyl radicals were generated during the incubation, which can be activated by introducing Fe2+, Cu2+ or H2O2.
35287912	2	34	theme	Fe2+	400:403	arg1	addition					388:395	the addition	384:395	the addition of Fe2+, Cu2+ or H2O2	384:417	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	2	34	theme	Fe2+	400:403	arg1	temperature					368:378	high temperature	363:378	high temperature	363:378	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	2	35	theme	apparent	295:302	arg1	viscosity					304:312	the apparent viscosity	291:312	the apparent viscosity of OPP	291:319	Results showed that AH2 could decrease the apparent viscosity of OPP, and the reducing ability was promoted by high temperature and the addition of Fe2+, Cu2+ or H2O2.
35287912	1	36	theme	ascorbic	106:113	arg1	AH2					121:123	AH2	121:123	AH2	121:123	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	36	theme	ascorbic	106:113	arg1	acid					115:118	ascorbic acid	106:118	ascorbic acid (AH2) treatment	106:134	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	37	theme	pectic	187:192	arg1	OPP					210:212	OPP	210:212	OPP	210:212	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	37	theme	pectic	187:192	arg1	polysaccharide					194:207	okra pectic polysaccharide	182:207	okra pectic polysaccharide (OPP)	182:213	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	3	38	theme	glycosidic	565:574	arg1	linkages					576:583	glycosidic linkages	565:583	glycosidic linkages	565:583	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	1	39	theme	acid	115:118	arg1	treatment					126:134	ascorbic acid (AH2) treatment	106:134	ascorbic acid (AH2) treatment	106:134	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	40	theme	polysaccharide	194:207	arg1	viscosity					143:151	viscosity	143:151	viscosity	143:151	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	1	40	theme	polysaccharide	194:207	arg1	properties					168:177	structural properties	157:177	structural properties	157:177	In this work, effects of ascorbic acid (AH2) treatment on the viscosity and structural properties of okra pectic polysaccharide (OPP) and its mechanism were investigated.
35287912	0	41	theme	ascorbic	66:73	arg1	acid					75:78	ascorbic acid	66:78	ascorbic acid	66:78	Mechanism of viscosity reduction of okra pectic polysaccharide by ascorbic acid.
35287912	3	42	theme	monosaccharide	537:550	arg1	composition					552:562	the monosaccharide composition	533:562	the monosaccharide composition	533:562	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	6	43	theme	other	966:970	arg1	products					972:979	other products	966:979	other products containing AH2	966:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35287912	5	44	theme	OPP	809:811	arg1	related					832:838	related	832:838	related	832:838	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	5	44	theme	OPP	809:811	arg1	reduction					796:804	the viscosity reduction	782:804	the viscosity reduction of OPP induced by AH2	782:826	In summary, the viscosity reduction of OPP induced by AH2 was related to the formation of hydroxyl radicals.
35287912	3	45	theme	AH2	640:642	arg1	incubation					644:653	AH2 incubation	640:653	AH2 incubation	640:653	The molecular weight was significantly decreased with increasing AH2 concentration, but it had little effects on the monosaccharide composition, glycosidic linkages, infrared characteristics, and morphology of OPP after AH2 incubation.
35287912	6	46	theme	OPP	950:952	arg1	application					935:945	the application	931:945	the application of OPP in food and other products containing AH2	931:994	The present study provides some recommendations for the application of OPP in food and other products containing AH2.
35956761	0	0	theme	Chemical	77:84	arg1	Composition					86:96	Chemical Composition	77:96	Chemical Composition	77:96	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	6	1	theme	PS	849:850	arg1	extracts					852:859	These PS extracts	843:859	These PS extracts	843:859	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	8	2	dep	pomace	1244:1249	arg1	the					1234:1236	the	1234:1236	the	1234:1236	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	5	3	theme	volatile	818:825	arg1	concentrations					827:840	the polysaccharide and volatile concentrations	795:840	the polysaccharide and volatile concentrations	795:840	In general, the use of grape PSs extracted from grape pomace or must improve some characteristics of wine, increasing the polysaccharide and volatile concentrations.
35956761	4	4	theme	different	535:543	arg1	extracts					548:555	four different PS extracts	530:555	four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	530:674	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	7	5	theme	polysaccharides	1112:1126	arg1	effects					1095:1101	the effects	1091:1101	the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines	1091:1197	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	1	6	theme	increasing	154:163	arg1	interest					165:172	an increasing interest	151:172	an increasing interest in the valorization of wine waste by-products	151:218	There is an increasing interest in the valorization of wine waste by-products.
35956761	4	7	from	rich	627:630	arg1	RG-II					635:639	RG-II	635:639	RG-II	635:639	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	3	8	from	pomace	378:383	arg1	extract					355:361	extract	355:361	extract	355:361	Therefore, the aim of this work was to extract PSs from grape pomace and musts and incorporate them into wines to improve their quality and valorize these residues.
35956761	7	9	theme	grape	1106:1110	arg1	polysaccharides					1112:1126	grape polysaccharides	1106:1126	grape polysaccharides	1106:1126	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	7	10	theme	chemical	1135:1142	arg1	composition					1144:1154	chemical composition	1135:1154	chemical composition	1135:1154	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	4	11	theme	PS	545:546	arg1	extracts					548:555	four different PS extracts	530:555	four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	530:674	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	4	12	theme	pomace	583:588	arg1	yeasts					669:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	2	13	theme	polyphenols	269:279	arg1	pomace/marc					227:237	Grape pomace/marc	221:237	Grape pomace/marc	221:237	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	2	13	theme	polyphenols	269:279	arg1	source					259:264	an important source	246:264	an important source of polyphenols but also of polysaccharides (PSs)	246:313	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	5	14	theme	wine	778:781	arg1	characteristics					759:773	some characteristics	754:773	some characteristics of wine	754:781	In general, the use of grape PSs extracted from grape pomace or must improve some characteristics of wine, increasing the polysaccharide and volatile concentrations.
35956761	0	15	theme	Sensory	102:108	arg1	Characteristics					110:124	Sensory Characteristics	102:124	Sensory Characteristics	102:124	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	5	16	theme	grape	700:704	arg1	PSs					706:708	grape PSs	700:708	grape PSs extracted from grape pomace	700:736	In general, the use of grape PSs extracted from grape pomace or must improve some characteristics of wine, increasing the polysaccharide and volatile concentrations.
35956761	8	17	dep	products	1337:1344	arg1	opening					1347:1353	opening	1347:1353	opening	1347:1353	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	0	18	dep	Composition	86:96	arg1	the					73:75	the	73:75	the	73:75	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	5	19	theme	grape	725:729	arg1	pomace					731:736	grape pomace	725:736	grape pomace	725:736	In general, the use of grape PSs extracted from grape pomace or must improve some characteristics of wine, increasing the polysaccharide and volatile concentrations.
35956761	8	20	theme	polysaccharide-rich	1317:1335	arg1	products					1337:1344	polysaccharide-rich products	1317:1344	polysaccharide-rich products	1317:1344	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	6	21	theme	volatile	986:993	arg1	compounds					995:1003	volatile compounds	986:1003	volatile compounds associated with fruity and floral notes	986:1043	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	4	22	theme	purified	610:617	arg1	extract					619:625	a wine purified extract	603:625	a wine purified extract rich in RG-II	603:639	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	7	23	dep	composition	1144:1154	arg1	the					1131:1133	the	1131:1133	the	1131:1133	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	4	24	theme	wine	605:608	arg1	extract					619:625	a wine purified extract	603:625	a wine purified extract rich in RG-II	603:639	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	0	25	theme	Grape	15:19	arg1	Polysaccharides					21:35	Grape Polysaccharides	15:35	Grape Polysaccharides	15:35	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	6	26	theme	taste	892:896	arg1	excess					920:925	an excess	917:925	an excess of acidity and bitterness	917:951	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	6	26	theme	taste	892:896	arg1	attributes					898:907	some taste attributes	887:907	some taste attributes such as an excess of acidity and bitterness	887:951	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	0	27	theme	White	129:133	arg1	Wines					135:139	White Wines	129:139	White Wines	129:139	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	2	28	theme	polysaccharides	293:307	arg1	pomace/marc					227:237	Grape pomace/marc	221:237	Grape pomace/marc	221:237	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	2	28	theme	polysaccharides	293:307	arg1	source					259:264	an important source	246:264	an important source of polyphenols but also of polysaccharides (PSs)	246:313	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	7	29	theme	first	1068:1072	arg1	This					1056:1059	This	1056:1059	This	1056:1059	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	7	29	theme	first	1068:1072	arg1	study					1074:1078	the first study	1064:1078	the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines	1064:1197	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	8	30	theme	valuable	1290:1297	arg1	sources					1299:1305	valuable sources	1290:1305	valuable sources	1290:1305	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	6	31	theme	acidity	930:936	arg1	excess					920:925	an excess	917:925	an excess of acidity and bitterness	917:951	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	8	32	theme	new	1357:1359	arg1	opportunity					1361:1371	a new opportunity	1355:1371	a new opportunity to take advantage of by-products from the wine industry	1355:1427	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	6	33	theme	compounds	995:1003	arg1	loss					978:981	the loss	974:981	the loss of volatile compounds associated with fruity and floral notes	974:1043	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	1	34	theme	wine	197:200	arg1	by-products					208:218	wine waste by-products	197:218	wine waste by-products	197:218	There is an increasing interest in the valorization of wine waste by-products.
35956761	3	35	theme	grape	372:376	arg1	pomace					378:383	grape pomace	372:383	grape pomace	372:383	Therefore, the aim of this work was to extract PSs from grape pomace and musts and incorporate them into wines to improve their quality and valorize these residues.
35956761	8	36	theme	obtained	1216:1223	arg1	results					1225:1231	the obtained results	1212:1231	the obtained results	1212:1231	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	1	37	theme	waste	202:206	arg1	by-products					208:218	wine waste by-products	197:218	wine waste by-products	197:218	There is an increasing interest in the valorization of wine waste by-products.
35956761	0	38	theme	Polysaccharides	21:35	arg1	Effects					4:10	The Effects	0:10	The Effects of Grape Polysaccharides	0:35	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	4	39	theme	white	485:489	arg1	wines					491:495	Two white wines	481:495	Two white wines	481:495	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	0	40	theme	Wines	135:139	arg1	Composition					86:96	Chemical Composition	77:96	Chemical Composition	77:96	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	0	40	theme	Wines	135:139	arg1	Characteristics					110:124	Sensory Characteristics	102:124	Sensory Characteristics	102:124	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	7	41	from	effects	1095:1101	arg1	composition					1144:1154	chemical composition	1135:1154	chemical composition	1135:1154	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	7	41	from	effects	1095:1101	arg1	characteristics					1168:1182	sensory characteristics	1160:1182	sensory characteristics	1160:1182	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	3	42	theme	work	343:346	arg1	aim					331:333	the aim	327:333	the aim of this work	327:346	Therefore, the aim of this work was to extract PSs from grape pomace and musts and incorporate them into wines to improve their quality and valorize these residues.
35956761	1	43	theme	by-products	208:218	arg1	valorization					181:192	the valorization	177:192	the valorization of wine waste by-products	177:218	There is an increasing interest in the valorization of wine waste by-products.
35956761	0	44	theme	Grape	52:56	arg1	By-Products					58:68	Grape By-Products	52:68	Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines	52:139	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	5	45	theme	polysaccharide	799:812	arg1	concentrations					827:840	the polysaccharide and volatile concentrations	795:840	the polysaccharide and volatile concentrations	795:840	In general, the use of grape PSs extracted from grape pomace or must improve some characteristics of wine, increasing the polysaccharide and volatile concentrations.
35956761	0	46	from	By-Products	58:68	arg1	Composition					86:96	Chemical Composition	77:96	Chemical Composition	77:96	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	0	46	from	By-Products	58:68	arg1	Characteristics					110:124	Sensory Characteristics	102:124	Sensory Characteristics	102:124	The Effects of Grape Polysaccharides Extracted from Grape By-Products on the Chemical Composition and Sensory Characteristics of White Wines.
35956761	2	47	theme	Grape	221:225	arg1	pomace/marc					227:237	Grape pomace/marc	221:237	Grape pomace/marc	221:237	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	2	47	theme	Grape	221:225	arg1	source					259:264	an important source	246:264	an important source of polyphenols but also of polysaccharides (PSs)	246:313	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	8	48	theme	musts	1266:1270	arg1	surplus					1255:1261	surplus	1255:1261	surplus	1255:1261	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	8	48	theme	musts	1266:1270	arg1	pomace					1244:1249	pomace	1244:1249	pomace	1244:1249	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	7	49	theme	white	1187:1191	arg1	wines					1193:1197	white wines	1187:1197	white wines	1187:1197	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	8	50	theme	wine	1415:1418	arg1	industry					1420:1427	the wine industry	1411:1427	the wine industry	1411:1427	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	7	51	theme	wines	1193:1197	arg1	composition					1144:1154	chemical composition	1135:1154	chemical composition	1135:1154	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	7	51	theme	wines	1193:1197	arg1	characteristics					1168:1182	sensory characteristics	1160:1182	sensory characteristics	1160:1182	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	4	52	dep	white	591:595	arg1	must					597:600	must	597:600	must	597:600	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	4	53	theme	inactivated	657:667	arg1	yeasts					669:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	6	54	theme	bitterness	942:951	arg1	excess					920:925	an excess	917:925	an excess of acidity and bitterness	917:951	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	8	55	theme	by-products	1394:1404	arg1	advantage					1381:1389	advantage	1381:1389	advantage of by-products	1381:1404	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	2	56	theme	important	249:257	arg1	pomace/marc					227:237	Grape pomace/marc	221:237	Grape pomace/marc	221:237	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	2	56	theme	important	249:257	arg1	source					259:264	an important source	246:264	an important source of polyphenols but also of polysaccharides (PSs)	246:313	Grape pomace/marc can be an important source of polyphenols but also of polysaccharides (PSs).
35956761	4	57	theme	commercial	646:655	arg1	yeasts					669:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	8	58	theme	grape	1238:1242	arg1	pomace					1244:1249	pomace	1244:1249	pomace	1244:1249	Considering the obtained results, the grape pomace and surplus of musts can be considered valuable sources to obtain polysaccharide-rich products, opening a new opportunity to take advantage of by-products from the wine industry.
35956761	6	59	theme	floral	1032:1037	arg1	notes					1039:1043	floral notes	1032:1043	floral notes	1032:1043	These PS extracts can be useful to modulate some taste attributes such as an excess of acidity and bitterness and can also prevent the loss of volatile compounds associated with fruity and floral notes over time.
35956761	4	60	theme	white	591:595	arg1	yeasts					669:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts	571:674	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	3	61	from	musts	389:393	arg1	extract					355:361	extract	355:361	extract	355:361	Therefore, the aim of this work was to extract PSs from grape pomace and musts and incorporate them into wines to improve their quality and valorize these residues.
35956761	4	62	theme	rich	627:630	arg1	extract					619:625	a wine purified extract	603:625	a wine purified extract rich in RG-II	603:639	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	4	63	theme	grape	577:581	arg1	pomace					583:588	white grape pomace	571:588	white grape pomace	571:588	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	5	64	theme	PSs	706:708	arg1	use					693:695	the use	689:695	the use of grape PSs extracted from grape pomace	689:736	In general, the use of grape PSs extracted from grape pomace or must improve some characteristics of wine, increasing the polysaccharide and volatile concentrations.
35956761	1	65	from	interest	165:172	arg1	valorization					181:192	the valorization	177:192	the valorization of wine waste by-products	177:218	There is an increasing interest in the valorization of wine waste by-products.
35956761	7	66	theme	sensory	1160:1166	arg1	characteristics					1168:1182	sensory characteristics	1160:1182	sensory characteristics	1160:1182	This is the first study that shows the effects of grape polysaccharides on the chemical composition and sensory characteristics of white wines.
35956761	4	67	from	RG-II	635:639	arg1	rich					627:630	rich	627:630	rich	627:630	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
35956761	4	68	theme	white	571:575	arg1	pomace					583:588	white grape pomace	571:588	white grape pomace	571:588	Two white wines were elaborated and treated with four different PS extracts obtained from white grape pomace, white must, a wine purified extract rich in RG-II, and commercial inactivated yeasts.
36148891	2	0	theme	HS	321:322	arg1	organization					305:316	domain organization	298:316	domain organization of HS	298:322	There is data to support that domain organization of HS can regulate binding of proteins, however, such model has been difficult to probe.
36148891	5	1	theme	catalyzed	840:848	arg1	cycloaddition					863:875	copper catalyzed alkyne-azide cycloaddition	833:875	copper catalyzed alkyne-azide cycloaddition	833:875	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	4	2	theme	HS	612:613	arg1	oligosaccharide					615:629	a HS oligosaccharide	610:629	a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position	610:754	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	1	3	theme	unmodified	233:242	arg1	fragments					244:252	unmodified fragments	233:252	unmodified fragments (NA domains)	233:265	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	3	theme	unmodified	233:242	arg1	domains					258:264	NA domains	255:264	NA domains	255:264	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	4	contain	has	109:111	arg1	HS					105:106	HS	105:106	HS	105:106	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	4	contain	has	109:111	arg2	structure					122:130	a domain structure	113:130	a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains)	113:265	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	4	contain	has	109:111	arg1	sulfate					96:102	Heparan sulfate	88:102	Heparan sulfate (HS)	88:107	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	5	5	theme	various	902:908	arg1	domains					913:919	various NS domains	902:919	various NS domains separated by unsulfonated regions	902:953	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	5	6	theme	unsulfonated	934:945	arg1	regions					947:953	unsulfonated regions	934:953	unsulfonated regions	934:953	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	5	7	theme	NS	910:911	arg1	domains					913:919	various NS domains	902:919	various NS domains separated by unsulfonated regions	902:953	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	4	8	theme	oligosaccharide	615:629	arg1	synthesis					597:605	the chemical synthesis	584:605	the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position	584:754	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	3	9	theme	HS	469:470	arg1	oligosaccharides					472:487	HS oligosaccharides	469:487	HS oligosaccharides composed of two or more NS domains separated by NA domains of different length	469:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	5	10	theme	alkyne-azide	850:861	arg1	cycloaddition					863:875	copper catalyzed alkyne-azide cycloaddition	833:875	copper catalyzed alkyne-azide cycloaddition	833:875	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	1	11	theme	Heparan	88:94	arg1	HS					105:106	HS	105:106	HS	105:106	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	11	theme	Heparan	88:94	arg1	sulfate					96:102	Heparan sulfate	88:102	Heparan sulfate (HS)	88:107	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	2	12	theme	proteins	348:355	arg1	binding					337:343	binding	337:343	binding of proteins	337:355	There is data to support that domain organization of HS can regulate binding of proteins, however, such model has been difficult to probe.
36148891	5	13	contain	having	777:782	arg2	moiety					804:809	alkyne moiety	797:809	alkyne moiety	797:809	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	5	13	contain	having	777:782	arg1	oligosaccharides					760:775	HS oligosaccharides	757:775	HS oligosaccharides having an azide and alkyne moiety	757:809	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	5	13	contain	having	777:782	arg2	azide					787:791	an azide	784:791	an azide	784:791	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	4	14	theme	various	666:672	arg1	units					686:690	various GlcA-GlcNAc units	666:690	various GlcA-GlcNAc units	666:690	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	5	15	theme	alkyne	797:802	arg1	moiety					804:809	alkyne moiety	797:809	alkyne moiety	797:809	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	0	16	theme	Chemoenzymatic	0:13	arg1	Synthesis					15:23	Chemoenzymatic Synthesis	0:23	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides	0:59	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides having a Domain Structure.
36148891	1	17	theme	NA	255:256	arg1	fragments					244:252	unmodified fragments	233:252	unmodified fragments (NA domains)	233:265	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	17	theme	NA	255:256	arg1	domains					258:264	NA domains	255:264	NA domains	255:264	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	3	18	theme	NS	513:514	arg1	domains					516:522	two or more NS domains	501:522	two or more NS domains separated by NA domains of different length	501:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	5	19	contain	having	895:900	arg1	compounds					885:893	compounds	885:893	compounds having various NS domains separated by unsulfonated regions	885:953	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	5	19	contain	having	895:900	arg2	domains					913:919	various NS domains	902:919	various NS domains separated by unsulfonated regions	902:953	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	4	20	theme	chemical	588:595	arg1	synthesis					597:605	the chemical synthesis	584:605	the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position	584:754	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	0	21	theme	Heparan	28:34	arg1	Oligosaccharides					44:59	Heparan Sulfate Oligosaccharides	28:59	Heparan Sulfate Oligosaccharides	28:59	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides having a Domain Structure.
36148891	5	22	theme	HS	757:758	arg1	oligosaccharides					760:775	HS oligosaccharides	757:775	HS oligosaccharides having an azide and alkyne moiety	757:809	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	4	23	theme	GlcA-GlcNAc	674:684	arg1	units					686:690	various GlcA-GlcNAc units	666:690	various GlcA-GlcNAc units	666:690	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	2	24	theme	such	367:370	arg1	model					372:376	such model	367:376	such model	367:376	There is data to support that domain organization of HS can regulate binding of proteins, however, such model has been difficult to probe.
36148891	0	25	theme	Oligosaccharides	44:59	arg1	Synthesis					15:23	Chemoenzymatic Synthesis	0:23	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides	0:59	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides having a Domain Structure.
36148891	3	26	theme	chemoenzymatic	425:438	arg1	methodology					440:450	a chemoenzymatic methodology	423:450	a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length	423:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	4	27	theme	C-6	743:745	arg1	position					747:754	C-6 position	743:754	C-6 position	743:754	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	0	28	theme	Sulfate	36:42	arg1	Oligosaccharides					44:59	Heparan Sulfate Oligosaccharides	28:59	Heparan Sulfate Oligosaccharides	28:59	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides having a Domain Structure.
36148891	3	29	theme	NA	537:538	arg1	domains					540:546	NA domains	537:546	NA domains of different length	537:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	3	29	theme	NA	537:538	arg1	length					561:566	different length	551:566	different length	551:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	6	30	dep	chemokines	1052:1061	arg1	CCL5					1063:1066	CCL5	1063:1066	CCL5	1063:1066	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	6	30	dep	chemokines	1052:1061	arg1	chemokines					1052:1061	the chemokines CCL5 and CXCL8	1048:1076	the chemokines CCL5 and CXCL8	1048:1076	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	6	30	dep	chemokines	1052:1061	arg1	CXCL8					1072:1076	CXCL8	1072:1076	CXCL8	1072:1076	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	6	31	theme	NA	1013:1014	arg1	domain					1016:1021	an NA domain	1010:1021	an NA domain	1010:1021	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	5	32	theme	copper	833:838	arg1	cycloaddition					863:875	copper catalyzed alkyne-azide cycloaddition	833:875	copper catalyzed alkyne-azide cycloaddition	833:875	HS oligosaccharides having an azide and alkyne moiety could be assembled by copper catalyzed alkyne-azide cycloaddition to give compounds having various NS domains separated by unsulfonated regions.
36148891	2	33	theme	domain	298:303	arg1	organization					305:316	domain organization	298:316	domain organization of HS	298:322	There is data to support that domain organization of HS can regulate binding of proteins, however, such model has been difficult to probe.
36148891	3	34	theme	different	551:559	arg1	length					561:566	different length	551:566	different length	551:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	1	35	theme	domain	115:120	arg1	structure					122:130	a domain structure	113:130	a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains)	113:265	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	3	36	theme	length	561:566	arg1	domains					540:546	NA domains	537:546	NA domains of different length	537:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	3	36	theme	length	561:566	arg1	length					561:566	different length	551:566	different length	551:566	Here, we report a chemoenzymatic methodology that can provide HS oligosaccharides composed of two or more NS domains separated by NA domains of different length.
36148891	6	37	theme	chemokines	1052:1061	arg1	binding					1037:1043	the binding	1033:1043	the binding of the chemokines CCL5 and CXCL8	1033:1076	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	1	38	mod	modified	158:165	arg1	domains					204:210	NS domains	201:210	NS domains	201:210	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	38	mod	modified	158:165	arg1	regions					141:147	regions	141:147	regions that are modified by epimerization and sulfonation (NS domains)	141:211	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	38	mod	modified	158:165	arg3	epimerization					170:182	epimerization	170:182	epimerization	170:182	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	1	38	mod	modified	158:165	arg3	sulfonation					188:198	sulfonation	188:198	sulfonation	188:198	Heparan sulfate (HS) has a domain structure in which regions that are modified by epimerization and sulfonation (NS domains) are interspersed by unmodified fragments (NA domains).
36148891	6	39	theme	domain	1016:1021	arg1	length					1000:1005	the length	996:1005	the length of an NA domain	996:1021	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	6	40	theme	binding	968:974	arg1	studies					976:982	Competition binding studies	956:982	Competition binding studies	956:982	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36148891	0	41	theme	Domain	70:75	arg1	Structure					77:85	a Domain Structure	68:85	a Domain Structure	68:85	Chemoenzymatic Synthesis of Heparan Sulfate Oligosaccharides having a Domain Structure.
36148891	4	42	theme	azido	727:731	arg1	moiety					733:738	an azido moiety	724:738	an azido moiety	724:738	It is based on the chemical synthesis of a HS oligosaccharide that enzymatically was extended by various GlcA-GlcNAc units and terminated in GlcNAc having an azido moiety at C-6 position.
36148891	6	43	theme	Competition	956:966	arg1	studies					976:982	Competition binding studies	956:982	Competition binding studies	956:982	Competition binding studies showed that the length of an NA domain modulates the binding of the chemokines CCL5 and CXCL8.
36099826	0	0	from	characterization	15:30	arg1	peels					88:92	Choerospondias axillaris peels	63:92	Choerospondias axillaris peels	63:92	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	1	1	theme	conventional	177:188	arg1	methods					236:242	conventional thermal and innovative non-thermal extraction methods	177:242	conventional thermal and innovative non-thermal extraction methods	177:242	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	2	theme	pectic	301:306	arg1	polysaccharides					308:322	pectic polysaccharides	301:322	pectic polysaccharides from Choerospondias axillaris peels	301:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	5	3	theme	α-glucosidase	1122:1134	arg1	activity					1147:1154	lower α-glucosidase inhibition activity	1116:1154	lower α-glucosidase inhibition activity	1116:1154	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	5	4	theme	inhibition	1136:1145	arg1	activity					1147:1154	lower α-glucosidase inhibition activity	1116:1154	lower α-glucosidase inhibition activity	1116:1154	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	6	5	theme	extraction	1304:1313	arg1	methods					1315:1321	different extraction methods	1294:1321	different extraction methods	1294:1321	The results indicated that we could obtain polysaccharides with different functional and biological properties by using different extraction methods.
36099826	1	6	theme	thermal	190:196	arg1	methods					236:242	conventional thermal and innovative non-thermal extraction methods	177:242	conventional thermal and innovative non-thermal extraction methods	177:242	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	3	7	theme	abundant	846:853	arg1	monosaccharide					855:868	the most abundant monosaccharide	837:868	the most abundant monosaccharide in UP	837:874	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	3	7	theme	abundant	846:853	arg1	arabinose					815:823	arabinose	815:823	arabinose (67.1%)	815:831	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	1	8	theme	polysaccharides	308:322	arg1	properties					287:296	properties	287:296	properties	287:296	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	8	theme	polysaccharides	308:322	arg1	characteristics					267:281	the physicochemical characteristics	247:281	the physicochemical characteristics	247:281	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	0	9	theme	hot	109:111	arg1	water					113:117	hot water	109:117	hot water	109:117	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	0	10	from	Extraction	0:9	arg1	peels					88:92	Choerospondias axillaris peels	63:92	Choerospondias axillaris peels	63:92	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	6	11	theme	different	1294:1302	arg1	methods					1315:1321	different extraction methods	1294:1321	different extraction methods	1294:1321	The results indicated that we could obtain polysaccharides with different functional and biological properties by using different extraction methods.
36099826	2	12	theme	protein	580:586	arg1	compounds					608:616	phenolic compounds	599:616	phenolic compounds (5.1%)	599:623	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	12	theme	protein	580:586	arg1	%					622:622	5.1%	619:622	5.1%	619:622	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	12	theme	protein	580:586	arg1	%					592:592	4.8%	589:592	4.8%	589:592	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	12	theme	protein	580:586	arg1	contents					568:575	higher contents	561:575	higher contents of protein (4.8%)	561:593	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	3	13	from	monosaccharide	787:800	arg1	HP					805:806	HP	805:806	HP	805:806	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	1	14	from	Influences	163:172	arg1	properties					287:296	properties	287:296	properties	287:296	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	14	from	Influences	163:172	arg1	characteristics					267:281	the physicochemical characteristics	247:281	the physicochemical characteristics	247:281	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	3	15	from	monosaccharide	855:868	arg1	UP					873:874	UP	873:874	UP	873:874	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	4	16	theme	phenolics	994:1002	arg1	degradation					979:989	the thermal degradation	967:989	the thermal degradation of phenolics	967:1002	The ultrasound significantly induced the degradation of polysaccharide chains but reduced the thermal degradation of phenolics.
36099826	1	17	theme	Choerospondias	329:342	arg1	peels					354:358	Choerospondias axillaris peels	329:358	Choerospondias axillaris peels	329:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	5	18	theme	antioxidant	1091:1101	arg1	activity					1103:1110	interfacial, emulsifying and antioxidant activity	1062:1110	interfacial, emulsifying and antioxidant activity	1062:1110	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	2	19	theme	hot	668:670	arg1	HP					679:680	HP	679:680	HP	679:680	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	19	theme	hot	668:670	arg1	water					672:676	hot water	668:676	hot water (HP)	668:681	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	20	theme	lower	482:486	arg1	weight					498:503	lower molecular weight	482:503	lower molecular weight (127.7 kDa)	482:515	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	20	theme	lower	482:486	arg1	127.7 kDa					506:514	127.7 kDa	506:514	127.7 kDa	506:514	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	0	21	theme	water	113:117	arg1	Comparison					95:104	Comparison	95:104	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.	0:161	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	2	22	contain	had	450:452	arg1	polysaccharides					429:443	ultrasound-assisted extracted polysaccharides	399:443	ultrasound-assisted extracted polysaccharides (UP)	399:448	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	22	contain	had	450:452	arg1	UP					446:447	UP	446:447	UP	446:447	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	22	contain	had	450:452	arg2	nature					470:475	a heterogeneous nature	454:475	a heterogeneous nature	454:475	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	1	23	theme	innovative	202:211	arg1	methods					236:242	conventional thermal and innovative non-thermal extraction methods	177:242	conventional thermal and innovative non-thermal extraction methods	177:242	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	2	24	theme	neutral	527:533	arg1	content					541:547	lower neutral sugar content	521:547	lower neutral sugar content (35.1%)	521:555	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	24	theme	neutral	527:533	arg1	%					554:554	35.1%	550:554	35.1%	550:554	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	6	25	theme	biological	1263:1272	arg1	properties					1274:1283	different functional and biological properties	1238:1283	different functional and biological properties	1238:1283	The results indicated that we could obtain polysaccharides with different functional and biological properties by using different extraction methods.
36099826	4	26	theme	thermal	971:977	arg1	degradation					979:989	the thermal degradation	967:989	the thermal degradation of phenolics	967:1002	The ultrasound significantly induced the degradation of polysaccharide chains but reduced the thermal degradation of phenolics.
36099826	1	27	theme	non-thermal	213:223	arg1	methods					236:242	conventional thermal and innovative non-thermal extraction methods	177:242	conventional thermal and innovative non-thermal extraction methods	177:242	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	2	28	theme	lower	521:525	arg1	content					541:547	lower neutral sugar content	521:547	lower neutral sugar content (35.1%)	521:555	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	28	theme	lower	521:525	arg1	%					554:554	35.1%	550:554	35.1%	550:554	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	1	29	theme	axillaris	344:352	arg1	peels					354:358	Choerospondias axillaris peels	329:358	Choerospondias axillaris peels	329:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	30	from	peels	354:358	arg1	properties					287:296	properties	287:296	properties	287:296	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	30	from	peels	354:358	arg1	polysaccharides					308:322	pectic polysaccharides	301:322	pectic polysaccharides from Choerospondias axillaris peels	301:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	30	from	peels	354:358	arg1	characteristics					267:281	the physicochemical characteristics	247:281	the physicochemical characteristics	247:281	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	1	31	theme	extraction	225:234	arg1	methods					236:242	conventional thermal and innovative non-thermal extraction methods	177:242	conventional thermal and innovative non-thermal extraction methods	177:242	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	0	32	theme	extraction	143:152	arg1	methods					154:160	ultrasound-assisted extraction methods	123:160	ultrasound-assisted extraction methods	123:160	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	1	33	theme	methods	236:242	arg1	Influences					163:172	Influences	163:172	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels	163:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	3	34	dep	composition	717:727	arg1	results					729:735	results	729:735	the monosaccharide composition results	698:735	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	0	35	theme	ultrasound-assisted	123:141	arg1	methods					154:160	ultrasound-assisted extraction methods	123:160	ultrasound-assisted extraction methods	123:160	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	0	36	theme	polysaccharides	42:56	arg1	characterization					15:30	characterization	15:30	characterization	15:30	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	0	36	theme	polysaccharides	42:56	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	5	37	theme	interfacial	1062:1072	arg1	activity					1103:1110	interfacial, emulsifying and antioxidant activity	1062:1110	interfacial, emulsifying and antioxidant activity	1062:1110	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	6	38	theme	functional	1248:1257	arg1	properties					1274:1283	different functional and biological properties	1238:1283	different functional and biological properties	1238:1283	The results indicated that we could obtain polysaccharides with different functional and biological properties by using different extraction methods.
36099826	2	39	theme	heterogeneous	456:468	arg1	nature					470:475	a heterogeneous nature	454:475	a heterogeneous nature	454:475	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	0	40	theme	pectic	35:40	arg1	polysaccharides					42:56	pectic polysaccharides	35:56	pectic polysaccharides from Choerospondias axillaris peels	35:92	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	3	41	theme	abundant	778:785	arg1	glucose					749:755	glucose	749:755	glucose (77.8%)	749:763	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	3	41	theme	abundant	778:785	arg1	monosaccharide					787:800	the most abundant monosaccharide	769:800	the most abundant monosaccharide in HP	769:806	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	0	42	theme	methods	154:160	arg1	Comparison					95:104	Comparison	95:104	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.	0:161	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	0	43	from	peels	88:92	arg1	characterization					15:30	characterization	15:30	characterization	15:30	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	0	43	from	peels	88:92	arg1	polysaccharides					42:56	pectic polysaccharides	35:56	pectic polysaccharides from Choerospondias axillaris peels	35:92	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	0	43	from	peels	88:92	arg1	Extraction					0:9	Extraction	0:9	Extraction	0:9	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	6	44	theme	different	1238:1246	arg1	properties					1274:1283	different functional and biological properties	1238:1283	different functional and biological properties	1238:1283	The results indicated that we could obtain polysaccharides with different functional and biological properties by using different extraction methods.
36099826	1	45	theme	physicochemical	251:265	arg1	characteristics					267:281	the physicochemical characteristics	247:281	the physicochemical characteristics	247:281	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	0	46	theme	Choerospondias	63:76	arg1	peels					88:92	Choerospondias axillaris peels	63:92	Choerospondias axillaris peels	63:92	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	4	47	theme	chains	948:953	arg1	degradation					918:928	the degradation	914:928	the degradation of polysaccharide chains	914:953	The ultrasound significantly induced the degradation of polysaccharide chains but reduced the thermal degradation of phenolics.
36099826	1	48	from	properties	287:296	arg1	peels					354:358	Choerospondias axillaris peels	329:358	Choerospondias axillaris peels	329:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	5	49	theme	emulsifying	1075:1085	arg1	activity					1103:1110	interfacial, emulsifying and antioxidant activity	1062:1110	interfacial, emulsifying and antioxidant activity	1062:1110	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	2	50	theme	sugar	535:539	arg1	content					541:547	lower neutral sugar content	521:547	lower neutral sugar content (35.1%)	521:555	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	50	theme	sugar	535:539	arg1	%					554:554	35.1%	550:554	35.1%	550:554	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	5	51	contain	had	1031:1033	arg2	activity					1147:1154	lower α-glucosidase inhibition activity	1116:1154	lower α-glucosidase inhibition activity	1116:1154	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	5	51	contain	had	1031:1033	arg2	activity					1103:1110	interfacial, emulsifying and antioxidant activity	1062:1110	interfacial, emulsifying and antioxidant activity	1062:1110	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	5	51	contain	had	1031:1033	arg2	viscosity					1051:1059	higher apparent viscosity	1035:1059	higher apparent viscosity	1035:1059	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	5	51	contain	had	1031:1033	arg1	UP					1028:1029	UP	1028:1029	UP	1028:1029	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	1	52	from	characteristics	267:281	arg1	peels					354:358	Choerospondias axillaris peels	329:358	Choerospondias axillaris peels	329:358	Influences of conventional thermal and innovative non-thermal extraction methods on the physicochemical characteristics and properties of pectic polysaccharides from Choerospondias axillaris peels were investigated.
36099826	5	53	theme	higher	1035:1040	arg1	viscosity					1051:1059	higher apparent viscosity	1035:1059	higher apparent viscosity	1035:1059	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	2	54	theme	extracted	419:427	arg1	polysaccharides					429:443	ultrasound-assisted extracted polysaccharides	399:443	ultrasound-assisted extracted polysaccharides (UP)	399:448	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	54	theme	extracted	419:427	arg1	UP					446:447	UP	446:447	UP	446:447	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	55	theme	phenolic	599:606	arg1	compounds					608:616	phenolic compounds	599:616	phenolic compounds (5.1%)	599:623	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	55	theme	phenolic	599:606	arg1	%					622:622	5.1%	619:622	5.1%	619:622	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	5	56	theme	apparent	1042:1049	arg1	viscosity					1051:1059	higher apparent viscosity	1035:1059	higher apparent viscosity	1035:1059	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	2	57	theme	ultrasound-assisted	399:417	arg1	polysaccharides					429:443	ultrasound-assisted extracted polysaccharides	399:443	ultrasound-assisted extracted polysaccharides (UP)	399:448	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	57	theme	ultrasound-assisted	399:417	arg1	UP					446:447	UP	446:447	UP	446:447	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	6	58	with	polysaccharides	1217:1231	arg1	properties					1274:1283	different functional and biological properties	1238:1283	different functional and biological properties	1238:1283	The results indicated that we could obtain polysaccharides with different functional and biological properties by using different extraction methods.
36099826	2	59	theme	higher	561:566	arg1	%					592:592	4.8%	589:592	4.8%	589:592	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	59	theme	higher	561:566	arg1	contents					568:575	higher contents	561:575	higher contents of protein (4.8%)	561:593	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	60	theme	molecular	488:496	arg1	weight					498:503	lower molecular weight	482:503	lower molecular weight (127.7 kDa)	482:515	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	2	60	theme	molecular	488:496	arg1	127.7 kDa					506:514	127.7 kDa	506:514	127.7 kDa	506:514	Results showed that ultrasound-assisted extracted polysaccharides (UP) had a heterogeneous nature with lower molecular weight (127.7 kDa) and lower neutral sugar content (35.1%) but higher contents of protein (4.8%) and phenolic compounds (5.1%) than those of polysaccharides extracted by hot water (HP).
36099826	3	61	theme	monosaccharide	702:715	arg1	composition					717:727	the monosaccharide composition results	698:735	the monosaccharide composition results	698:735	Additionally, the monosaccharide composition results showed that glucose (77.8%) was the most abundant monosaccharide in HP, while arabinose (67.1%) was the most abundant monosaccharide in UP.
36099826	0	62	theme	axillaris	78:86	arg1	peels					88:92	Choerospondias axillaris peels	63:92	Choerospondias axillaris peels	63:92	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	5	63	theme	lower	1116:1120	arg1	activity					1147:1154	lower α-glucosidase inhibition activity	1116:1154	lower α-glucosidase inhibition activity	1116:1154	Finally, we found that UP had higher apparent viscosity, interfacial, emulsifying and antioxidant activity but lower α-glucosidase inhibition activity than those of HP.
36099826	0	64	dep	Extraction	0:9	arg1	Comparison					95:104	Comparison	95:104	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.	0:161	Extraction and characterization of pectic polysaccharides from Choerospondias axillaris peels: Comparison of hot water and ultrasound-assisted extraction methods.
36099826	4	65	theme	polysaccharide	933:946	arg1	chains					948:953	polysaccharide chains	933:953	polysaccharide chains	933:953	The ultrasound significantly induced the degradation of polysaccharide chains but reduced the thermal degradation of phenolics.
36641172	0	0	from	dynamics	14:21	arg1	water					87:91	water	87:91	water	87:91	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	7	1	theme	other	1138:1142	arg1	molecules					1144:1152	other molecules	1138:1152	other molecules as well as its reactivity	1138:1178	Composition of mixed solvents thus enables us to modify the interaction of HA with other molecules as well as its reactivity.
36641172	4	2	theme	containing	720:729	arg1	solutions					731:739	tert-butanol containing solutions	707:739	tert-butanol containing solutions	707:739	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	3	3	from	water:1,4-dioxane	537:553	arg1	simulations					499:509	molecular-dynamics (MD) simulations	475:509	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	0	4	theme	shell	78:82	arg1	dynamics					14:21	dynamics	14:21	dynamics	14:21	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	0	4	theme	shell	78:82	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	3	5	from	simulations	499:509	arg1	water					559:563	water	559:563	water	559:563	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	3	5	from	simulations	499:509	arg1	water:1,4-dioxane					537:553	water:1,4-dioxane	537:553	water:1,4-dioxane	537:553	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	4	6	theme	tert-butanol	707:718	arg1	solutions					731:739	tert-butanol containing solutions	707:739	tert-butanol containing solutions	707:739	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	0	7	from	Structure	0:8	arg1	water					87:91	water	87:91	water	87:91	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	7	8	theme	HA	1130:1131	arg1	interaction					1115:1125	the interaction	1111:1125	the interaction of HA with other molecules as well as its reactivity	1111:1178	Composition of mixed solvents thus enables us to modify the interaction of HA with other molecules as well as its reactivity.
36641172	3	9	theme	tert-butanol	565:576	arg1	mixtures					578:585	tert-butanol mixtures	565:585	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	1	10	theme	cosmetic	245:252	arg1	industries					271:280	the cosmetic and pharmaceutic industries	241:280	the cosmetic and pharmaceutic industries	241:280	Hyaluronan (HA) is a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries.
36641172	4	11	theme	solvation	762:770	arg1	shell					772:776	a solvation shell	760:776	a solvation shell enriched by water	760:794	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	6	12	theme	observable	994:1003	arg1	changes					1020:1026	observable conformational changes	994:1026	observable conformational changes of the HA oligosaccharide	994:1052	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	0	13	theme	mixed	102:106	arg1	solvents					108:115	organic mixed solvents	94:115	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.	0:116	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	3	14	from	oligosaccharides	517:532	arg1	water					559:563	water	559:563	water	559:563	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	3	14	from	oligosaccharides	517:532	arg1	water:1,4-dioxane					537:553	water:1,4-dioxane	537:553	water:1,4-dioxane	537:553	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	4	15	from	surroundings	679:690	arg1	separation					635:644	a separation	633:644	a separation of the solvent components in its surroundings	633:690	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	1	16	theme	natural	139:145	arg1	Hyaluronan					118:127	Hyaluronan	118:127	Hyaluronan (HA)	118:132	Hyaluronan (HA) is a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries.
36641172	1	16	theme	natural	139:145	arg1	polysaccharide					147:160	a natural polysaccharide	137:160	a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries	137:280	Hyaluronan (HA) is a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries.
36641172	0	17	theme	organic	94:100	arg1	solvents					108:115	organic mixed solvents	94:115	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.	0:116	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	7	18	with	interaction	1115:1125	arg1	reactivity					1169:1178	its reactivity	1165:1178	other molecules as well as its reactivity	1138:1178	Composition of mixed solvents thus enables us to modify the interaction of HA with other molecules as well as its reactivity.
36641172	7	18	with	interaction	1115:1125	arg1	molecules					1144:1152	other molecules	1138:1152	other molecules as well as its reactivity	1138:1178	Composition of mixed solvents thus enables us to modify the interaction of HA with other molecules as well as its reactivity.
36641172	5	19	with	interactions	810:821	arg1	ions					828:831	ions	828:831	ions	828:831	Furthermore, interactions with ions are stronger than in pure water and depend on the solvent composition.
36641172	4	20	from	separation	635:644	arg1	surroundings					679:690	its surroundings	675:690	its surroundings	675:690	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	3	21	dep	simulations	499:509	arg1	mixtures					578:585	tert-butanol mixtures	565:585	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	5	22	theme	solvent	883:889	arg1	composition					891:901	the solvent composition	879:901	the solvent composition	879:901	Furthermore, interactions with ions are stronger than in pure water and depend on the solvent composition.
36641172	2	23	theme	mixed	446:450	arg1	solvents					452:459	organic mixed solvents	438:459	aqueous solutions, often carried out in water:organic mixed solvents	392:459	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	1	24	theme	pharmaceutic	258:269	arg1	industries					271:280	the cosmetic and pharmaceutic industries	241:280	the cosmetic and pharmaceutic industries	241:280	Hyaluronan (HA) is a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries.
36641172	2	25	theme	HA	308:309	arg1	oligosaccharides					311:326	HA oligosaccharides	308:326	HA oligosaccharides	308:326	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	4	26	from	components	661:670	arg1	surroundings					679:690	its surroundings	675:690	its surroundings	675:690	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	2	27	theme	aqueous	392:398	arg1	solutions					400:408	aqueous solutions	392:408	aqueous solutions	392:408	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	2	28	theme	organic	438:444	arg1	solvents					452:459	organic mixed solvents	438:459	aqueous solutions, often carried out in water:organic mixed solvents	392:459	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	5	29	theme	pure	854:857	arg1	water					859:863	pure water	854:863	pure water	854:863	Furthermore, interactions with ions are stronger than in pure water and depend on the solvent composition.
36641172	2	30	theme	numerous	286:293	arg1	applications					295:306	numerous applications	286:306	numerous applications	286:306	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	0	31	theme	hyaluronan	30:39	arg1	oligosaccharides					41:56	the hyaluronan oligosaccharides	26:56	the hyaluronan oligosaccharides	26:56	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	6	32	theme	solvent	963:969	arg1	composition					971:981	the solvent composition	959:981	the solvent composition	959:981	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	4	33	theme	components	661:670	arg1	separation					635:644	a separation	633:644	a separation of the solvent components in its surroundings	633:690	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	1	34	theme	connective	192:201	arg1	tissues					203:209	the connective tissues	188:209	the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries	188:280	Hyaluronan (HA) is a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries.
36641172	4	35	theme	solvent	653:659	arg1	components					661:670	the solvent components	649:670	the solvent components in its surroundings	649:690	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	3	36	from	water	559:563	arg1	simulations					499:509	molecular-dynamics (MD) simulations	475:509	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	7	37	theme	mixed	1070:1074	arg1	solvents					1076:1083	mixed solvents	1070:1083	mixed solvents	1070:1083	Composition of mixed solvents thus enables us to modify the interaction of HA with other molecules as well as its reactivity.
36641172	3	38	contain	carry	465:469	arg1	We					462:463	We	462:463	We	462:463	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	3	38	contain	carry	465:469	arg2	simulations					499:509	molecular-dynamics (MD) simulations	475:509	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	3	39	theme	different	590:598	arg1	compositions					600:611	different compositions	590:611	different compositions	590:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	3	40	theme	MD	495:496	arg1	simulations					499:509	molecular-dynamics (MD) simulations	475:509	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	0	41	theme	oligosaccharides	41:56	arg1	dynamics					14:21	dynamics	14:21	dynamics	14:21	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	0	41	theme	oligosaccharides	41:56	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	7	42	theme	solvents	1076:1083	arg1	Composition					1055:1065	Composition	1055:1065	Composition of mixed solvents	1055:1083	Composition of mixed solvents thus enables us to modify the interaction of HA with other molecules as well as its reactivity.
36641172	3	43	theme	compositions	600:611	arg1	mixtures					578:585	tert-butanol mixtures	565:585	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	6	44	theme	chain	941:945	arg1	dynamics					922:929	the dynamics	918:929	the dynamics of the HA chain	918:945	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	2	45	dep	solutions	400:408	arg1	solvents					452:459	organic mixed solvents	438:459	aqueous solutions, often carried out in water:organic mixed solvents	392:459	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	6	46	theme	oligosaccharide	1038:1052	arg1	changes					1020:1026	observable conformational changes	994:1026	observable conformational changes of the HA oligosaccharide	994:1052	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	3	47	theme	molecular-dynamics	475:492	arg1	simulations					499:509	molecular-dynamics (MD) simulations	475:509	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	6	48	theme	conformational	1005:1018	arg1	changes					1020:1026	observable conformational changes	994:1026	observable conformational changes of the HA oligosaccharide	994:1052	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	3	49	theme	oligosaccharides	517:532	arg1	simulations					499:509	molecular-dynamics (MD) simulations	475:509	molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions	475:611	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	1	50	theme	vertebrates	214:224	arg1	tissues					203:209	the connective tissues	188:209	the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries	188:280	Hyaluronan (HA) is a natural polysaccharide occurring ubiquitously in the connective tissues of vertebrates widely used in the cosmetic and pharmaceutic industries.
36641172	0	51	theme	solvation	68:76	arg1	shell					78:82	their solvation shell	62:82	their solvation shell	62:82	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	2	52	with	incompatible	374:385	arg1	solutions					400:408	aqueous solutions	392:408	aqueous solutions	392:408	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
36641172	3	53	theme	HA	514:515	arg1	oligosaccharides					517:532	HA oligosaccharides	514:532	HA oligosaccharides in water:1,4-dioxane and water	514:563	We carry out molecular-dynamics (MD) simulations of HA oligosaccharides in water:1,4-dioxane and water:tert-butanol mixtures of different compositions.
36641172	6	54	theme	HA	1035:1036	arg1	oligosaccharide					1038:1052	the HA oligosaccharide	1031:1052	the HA oligosaccharide	1031:1052	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	4	55	theme	HA	614:615	arg1	molecule					617:624	HA molecule	614:624	HA molecule	614:624	HA molecule causes a separation of the solvent components in its surroundings, especially in tert-butanol containing solutions, constituting thus a solvation shell enriched by water.
36641172	6	56	theme	HA	938:939	arg1	chain					941:945	the HA chain	934:945	the HA chain	934:945	Consequently, the dynamics of the HA chain varies with the solvent composition and causes observable conformational changes of the HA oligosaccharide.
36641172	0	57	dep	Structure	0:8	arg1	solvents					108:115	organic mixed solvents	94:115	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.	0:116	Structure and dynamics of the hyaluronan oligosaccharides and their solvation shell in water: organic mixed solvents.
36641172	2	58	theme	incompatible	374:385	arg1	reactions					364:372	reactions	364:372	reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents	364:459	In numerous applications HA oligosaccharides are being chemically modified using reactions incompatible with aqueous solutions, often carried out in water:organic mixed solvents.
35684527	1	0	with	fruit	199:203	arg1	nutritional					215:225	nutritional	215:225	nutritional	215:225	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	1	0	with	fruit	199:203	arg1	value					241:245	high nutritional and medicinal value	210:245	value	241:245	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	0	1	dep	Pleurotus	103:111	arg1	ostreatus					113:121	ostreatus	113:121	ostreatus	113:121	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	3	2	dep	must	640:643	arg1	%					651:651	4%	650:651	4%	650:651	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	3	2	dep	must	640:643	arg1	%					659:659	8%	658:659	8%	658:659	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	3	2	dep	must	640:643	arg1	%					647:647	2%	646:647	2%	646:647	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	0	3	theme	Nutrient	53:60	arg1	Composition					62:72	Nutrient Composition	53:72	Nutrient Composition	53:72	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	6	4	theme	polysaccharide	1134:1147	arg1	content					1149:1155	the crude polysaccharide content	1124:1155	the crude polysaccharide content	1124:1155	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	3	5	theme	crude	469:473	arg1	content					490:496	crude polysaccharide content	469:496	crude polysaccharide content	469:496	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	5	6	theme	crude	915:919	arg1	fiber					921:925	crude fiber	915:925	crude fiber	915:925	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	6	theme	crude	915:919	arg1	substances					889:898	the soluble substances	877:898	the soluble substances	877:898	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	7	theme	crude	984:988	arg1	protein					990:996	the crude protein and total amino acid contents	980:1026	protein	990:996	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	6	8	contain	had	1186:1188	arg2	impact					1193:1198	no impact	1190:1198	no impact	1190:1198	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	6	8	contain	had	1186:1188	arg1	addition					1047:1054	The addition	1043:1054	The addition of R. roxburghii must at low concentrations	1043:1098	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	5	9	theme	R.	828:829	arg1	concentrations					810:823	Low concentrations	806:823	Low concentrations of R. roxburghii	806:840	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	1	10	theme	medicinal	231:239	arg1	value					241:245	high nutritional and medicinal value	210:245	value	241:245	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	3	11	theme	antioxidant	507:517	arg1	activity					519:526	the antioxidant activity	503:526	the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii	503:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	6	12	theme	low	1081:1083	arg1	concentrations					1085:1098	low concentrations	1081:1098	low concentrations	1081:1098	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	1	13	theme	roxburghii	137:146	arg1	plant					166:170	a Rosaceae plant	155:170	a Rosaceae plant endemic to China	155:187	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	1	13	theme	roxburghii	137:146	arg1	Tratt					148:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	3	14	dep	%	647:647	arg1	v/v					662:664	v/v	662:664	v/v	662:664	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	3	15	theme	amino	454:458	arg1	acid					460:463	amino acid	454:463	amino acid	454:463	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	4	16	theme	mycelial	730:737	arg1	growth					739:744	mycelial growth	730:744	mycelial growth	730:744	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	3	17	theme	proximate	431:439	arg1	composition					441:451	proximate composition	431:451	proximate composition	431:451	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	3	18	dep	P.	560:561	arg1	ostreatus					563:571	ostreatus	563:571	ostreatus	563:571	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	0	19	theme	Antioxidant	79:89	arg1	Activity					91:98	Antioxidant Activity	79:98	Antioxidant Activity	79:98	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	4	20	theme	R.	690:691	arg1	concentrations					672:685	Low concentrations	668:685	Low concentrations of R. roxburghii must (2% and 4%)	668:719	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	2	21	theme	Pleurotus	347:355	arg1	mycelia					367:373	Pleurotus ostreatus mycelia	347:373	Pleurotus ostreatus mycelia	347:373	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	6	22	theme	2,2-diphenyl-1-picrylhydrazyl	1243:1271	arg1	scavenging					1207:1216	the scavenging	1203:1216	the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH)	1203:1278	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	5	23	dep	increased	970:978	arg1	p					1029:1029	p	1029:1029	p &lt; 0.05	1029:1039	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	24	theme	Low	806:808	arg1	concentrations					810:823	Low concentrations	806:823	Low concentrations of R. roxburghii	806:840	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	25	from	effects	866:872	arg1	fiber					921:925	crude fiber	915:925	crude fiber	915:925	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	25	from	effects	866:872	arg1	substances					889:898	the soluble substances	877:898	the soluble substances	877:898	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	25	from	effects	866:872	arg1	ash					906:908	ash	906:908	ash	906:908	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	25	from	effects	866:872	arg1	fat					901:903	fat	901:903	fat	901:903	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	1	26	theme	Rosaceae	157:164	arg1	plant					166:170	a Rosaceae plant	155:170	a Rosaceae plant endemic to China	155:187	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	1	26	theme	Rosaceae	157:164	arg1	Tratt					148:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	5	27	theme	acid	1014:1017	arg1	contents					1019:1026	the crude protein and total amino acid contents	980:1026	contents	1019:1026	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	6	28	theme	R.	1059:1060	arg1	addition					1047:1054	The addition	1043:1054	The addition of R. roxburghii must at low concentrations	1043:1098	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	7	29	theme	protein	1404:1410	arg1	contents					1431:1438	the protein and polysaccharide contents	1400:1438	contents	1431:1438	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	3	30	theme	crude	535:539	arg1	polysaccharides					541:555	the crude polysaccharides	531:555	the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii	531:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	5	31	dep	R.	828:829	arg1	roxburghii					831:840	R. roxburghii	828:840	R. roxburghii	828:840	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	4	32	dep	must	704:707	arg1	%					711:711	2%	710:711	2%	710:711	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	4	32	dep	must	704:707	arg1	%					718:718	4%	717:718	4%	717:718	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	0	33	theme	roxburghii	16:25	arg1	Tratt					27:31	Rosa roxburghii Tratt	11:31	Rosa roxburghii Tratt	11:31	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	0	34	theme	Pleurotus	103:111	arg1	Mycelia					123:129	Pleurotus ostreatus Mycelia	103:129	Pleurotus ostreatus Mycelia	103:129	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	4	35	theme	Low	668:670	arg1	concentrations					672:685	Low concentrations	668:685	Low concentrations of R. roxburghii must (2% and 4%)	668:719	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	5	36	theme	soluble	881:887	arg1	fiber					921:925	crude fiber	915:925	crude fiber	915:925	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	36	theme	soluble	881:887	arg1	substances					889:898	the soluble substances	877:898	the soluble substances	877:898	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	36	theme	soluble	881:887	arg1	ash					906:908	ash	906:908	ash	906:908	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	36	theme	soluble	881:887	arg1	fat					901:903	fat	901:903	fat	901:903	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	1	37	theme	endemic	172:178	arg1	plant					166:170	a Rosaceae plant	155:170	a Rosaceae plant endemic to China	155:187	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	1	37	theme	endemic	172:178	arg1	Tratt					148:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	0	38	theme	Rosa	11:14	arg1	Tratt					27:31	Rosa roxburghii Tratt	11:31	Rosa roxburghii Tratt	11:31	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	7	39	dep	R.	1292:1293	arg1	must					1306:1309	must	1306:1309	must	1306:1309	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	3	40	theme	R.	626:627	arg1	roxburghii					629:638	R. roxburghii	626:638	R. roxburghii	626:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	2	41	theme	R.	263:264	arg1	effects					252:258	The effects	248:258	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia	248:373	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	3	42	theme	polysaccharide	475:488	arg1	content					490:496	crude polysaccharide content	469:496	crude polysaccharide content	469:496	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	5	43	contain	had	847:849	arg1	concentrations					810:823	Low concentrations	806:823	Low concentrations of R. roxburghii	806:840	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	5	43	contain	had	847:849	arg2	effects					866:872	no significant effects	851:872	no significant effects on the soluble substances, fat, ash, and crude fiber	851:925	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	0	44	theme	Mycelia	123:129	arg1	Growth					45:50	Growth	45:50	Growth	45:50	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	0	44	theme	Mycelia	123:129	arg1	Composition					62:72	Nutrient Composition	53:72	Nutrient Composition	53:72	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	0	44	theme	Mycelia	123:129	arg1	Activity					91:98	Antioxidant Activity	79:98	Antioxidant Activity	79:98	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	3	45	theme	roxburghii	629:638	arg1	concentrations					608:621	different concentrations	598:621	different concentrations of R. roxburghii	598:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	3	46	theme	P.	560:561	arg1	mycelia					573:579	P. ostreatus mycelia	560:579	P. ostreatus mycelia cultivated under different concentrations of R. roxburghii	560:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	3	47	theme	growth	418:423	arg1	rate					425:428	the mycelial growth rate	405:428	the mycelial growth rate	405:428	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	0	48	theme	Tratt	27:31	arg1	Effects					0:6	Effects	0:6	Effects of Rosa roxburghii Tratt	0:31	Effects of Rosa roxburghii Tratt Must on the Growth, Nutrient Composition, and Antioxidant Activity of Pleurotus ostreatus Mycelia.
35684527	7	49	theme	P.	1363:1364	arg1	cultivation					1376:1386	P. ostreatus cultivation	1363:1386	P. ostreatus cultivation	1363:1386	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	6	50	theme	radicals	1230:1237	arg1	scavenging					1207:1216	the scavenging	1203:1216	the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH)	1203:1278	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	2	51	theme	mycelia	367:373	arg1	activity					335:342	antioxidant activity	323:342	antioxidant activity	323:342	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	2	51	theme	mycelia	367:373	arg1	growth					289:294	growth	289:294	growth	289:294	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	2	51	theme	mycelia	367:373	arg1	composition					306:316	nutrient composition	297:316	nutrient composition	297:316	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	7	52	theme	polysaccharide	1416:1429	arg1	contents					1431:1438	the protein and polysaccharide contents	1400:1438	contents	1431:1438	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	7	53	from	contents	1431:1438	arg1	mycelia					1443:1449	mycelia	1443:1449	mycelia	1443:1449	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	3	54	theme	polysaccharides	541:555	arg1	activity					519:526	the antioxidant activity	503:526	the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii	503:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	2	55	theme	nutrient	297:304	arg1	composition					306:316	nutrient composition	297:316	nutrient composition	297:316	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	5	56	theme	total	1002:1006	arg1	contents					1019:1026	the crude protein and total amino acid contents	980:1026	contents	1019:1026	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	4	57	theme	mycelial	789:796	arg1	growth					798:803	mycelial growth	789:803	mycelial growth	789:803	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	7	58	theme	low	1314:1316	arg1	concentration					1318:1330	low concentration	1314:1330	low concentration	1314:1330	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	5	59	dep	had	847:849	arg1	must					842:845	must	842:845	must	842:845	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	2	60	dep	R.	263:264	arg1	must					277:280	must	277:280	must	277:280	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	5	61	theme	amino	1008:1012	arg1	contents					1019:1026	the crude protein and total amino acid contents	980:1026	contents	1019:1026	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	6	62	theme	crude	1128:1132	arg1	content					1149:1155	the crude polysaccharide content	1124:1155	the crude polysaccharide content	1124:1155	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	5	63	theme	significant	854:864	arg1	effects					866:872	no significant effects	851:872	no significant effects on the soluble substances, fat, ash, and crude fiber	851:925	Low concentrations of R. roxburghii must had no significant effects on the soluble substances, fat, ash, and crude fiber in P. ostreatus mycelia, but significantly increased the crude protein and total amino acid contents (p &lt; 0.05).
35684527	3	64	theme	different	598:606	arg1	concentrations					608:621	different concentrations	598:621	different concentrations of R. roxburghii	598:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	4	65	dep	R.	690:691	arg1	must					704:707	must	704:707	must	704:707	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	4	66	theme	high	755:758	arg1	%					776:776	8%	775:776	8%	775:776	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	4	66	theme	high	755:758	arg1	concentration					760:772	a high concentration	753:772	a high concentration (8%)	753:777	Low concentrations of R. roxburghii must (2% and 4%) promoted mycelial growth, while a high concentration (8%) inhibited mycelial growth.
35684527	6	67	theme	hydroxyl	1221:1228	arg1	radicals					1230:1237	hydroxyl radicals	1221:1237	hydroxyl radicals	1221:1237	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	7	68	dep	P.	1363:1364	arg1	ostreatus					1366:1374	ostreatus	1366:1374	ostreatus	1366:1374	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	3	69	theme	mycelia	573:579	arg1	polysaccharides					541:555	the crude polysaccharides	531:555	the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii	531:638	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	7	70	used	used	1339:1342	arg2	R.					1292:1293	R.	1292:1293	R.	1292:1293	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	7	70	used	used	1339:1342	arg2	substrate					1349:1357	a substrate	1347:1357	a substrate for P. ostreatus cultivation	1347:1386	Therefore, R. roxburghii must at low concentration can be used as a substrate for P. ostreatus cultivation to increase the protein and polysaccharide contents in mycelia.
35684527	2	71	theme	antioxidant	323:333	arg1	activity					335:342	antioxidant activity	323:342	antioxidant activity	323:342	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	3	72	theme	mycelial	409:416	arg1	rate					425:428	the mycelial growth rate	405:428	the mycelial growth rate	405:428	We measured the mycelial growth rate, proximate composition, amino acid and crude polysaccharide content, and the antioxidant activity of the crude polysaccharides of P. ostreatus mycelia cultivated under different concentrations of R. roxburghii must (2%, 4%, and 8%, v/v).
35684527	6	73	dep	R.	1059:1060	arg1	must					1073:1076	must	1073:1076	must	1073:1076	The addition of R. roxburghii must at low concentrations significantly increased the crude polysaccharide content in mycelia (p &lt; 0.05) but had no impact on the scavenging of hydroxyl radicals and 2,2-diphenyl-1-picrylhydrazyl (DPPH).
35684527	2	74	dep	Pleurotus	347:355	arg1	ostreatus					357:365	ostreatus	357:365	ostreatus	357:365	The effects of R. roxburghii must on the growth, nutrient composition, and antioxidant activity of Pleurotus ostreatus mycelia was investigated.
35684527	1	75	theme	Rosa	132:135	arg1	plant					166:170	a Rosaceae plant	155:170	a Rosaceae plant endemic to China	155:187	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
35684527	1	75	theme	Rosa	132:135	arg1	Tratt					148:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt	132:152	Rosa roxburghii Tratt, a Rosaceae plant endemic to China, produces fruit with high nutritional and medicinal value.
36039611	0	0	theme	chloramphenicol	126:140	arg1	detection					113:121	ultrasensitive electrochemical detection	82:121	ultrasensitive electrochemical detection of chloramphenicol	82:140	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	2	1	from	investigations	453:466	arg1	material					499:506	the β-CD@G/Cu-BTC composite material	471:506	the β-CD@G/Cu-BTC composite material	471:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	2	2	from	series	443:448	arg1	material					499:506	the β-CD@G/Cu-BTC composite material	471:506	the β-CD@G/Cu-BTC composite material	471:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	1	3	theme	G	196:196	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	1	4	theme	functionalized	284:297	arg1	graphene					299:306	β-CD functionalized graphene	279:306	β-CD functionalized graphene	279:306	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	1	5	theme	chloramphenicol	380:394	arg1	CAP					397:399	chloramphenicol (CAP)	380:400	chloramphenicol (CAP)	380:400	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	3	6	theme	functionalized	533:546	arg1	solution					557:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	3	7	theme	excellent	573:581	arg1	effect					605:610	an excellent and stable dispersion effect	570:610	an excellent and stable dispersion effect	570:610	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	4	8	theme	catalytic	789:797	arg1	effect					799:804	a synergistic catalytic effect	775:804	a synergistic catalytic effect on the detection of chloramphenicol	775:840	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	1	9	theme	CAP	397:399	arg1	detection					367:375	sensitive detection	357:375	sensitive detection of chloramphenicol (CAP)	357:400	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	4	10	theme	single	720:725	arg1	material					727:734	a single material	718:734	a single material	718:734	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	3	11	theme	β-CD	528:531	arg1	solution					557:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	4	12	theme	material	727:734	arg1	disadvantages					701:713	the disadvantages	697:713	the disadvantages of a single material	697:734	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	4	13	theme	excellent	748:756	arg1	conductivity					758:769	excellent conductivity	748:769	excellent conductivity	748:769	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	5	14	theme	actual	907:912	arg1	sample					914:919	An actual sample	904:919	An actual sample	904:919	An actual sample was also detected using the proposed sensor.
36039611	1	15	theme	/Cu-1,3,5-benzenetricarboxylic	198:227	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	2	16	from	material	499:506	arg1	series					443:448	A series	441:448	A series of investigations on the β-CD@G/Cu-BTC composite material	441:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	4	17	from	effect	799:804	arg1	detection					813:821	the detection	809:821	the detection of chloramphenicol	809:840	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	1	18	theme	acid	229:232	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	0	19	theme	graphene	30:37	arg1	composites					67:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites	0:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.	0:141	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	4	20	theme	synergistic	777:787	arg1	effect					799:804	a synergistic catalytic effect	775:804	a synergistic catalytic effect on the detection of chloramphenicol	775:840	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	0	21	theme	β-Cyclodextrin-functionalized	0:28	arg1	composites					67:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites	0:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.	0:141	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	1	22	theme	Novel	143:147	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	1	23	theme	BTC	235:237	arg1	composites					240:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	0	24	theme	metal-organic	43:55	arg1	composites					67:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites	0:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.	0:141	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	1	25	theme	β-cyclodextrin	149:162	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	2	26	theme	investigations	453:466	arg1	series					443:448	A series	441:448	A series of investigations on the β-CD@G/Cu-BTC composite material	441:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	3	27	theme	dispersion	594:603	arg1	effect					605:610	an excellent and stable dispersion effect	570:610	an excellent and stable dispersion effect	570:610	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	2	28	theme	G/Cu-BTC	480:487	arg1	material					499:506	the β-CD@G/Cu-BTC composite material	471:506	the β-CD@G/Cu-BTC composite material	471:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	3	29	theme	graphene	548:555	arg1	solution					557:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	1	30	theme	new	326:328	arg1	sensor					346:351	a new electrochemical sensor	324:351	a new electrochemical sensor for sensitive detection of chloramphenicol (CAP)	324:400	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	0	31	theme	framework	57:65	arg1	composites					67:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites	0:76	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.	0:141	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	1	32	theme	electrochemical	330:344	arg1	sensor					346:351	a new electrochemical sensor	324:351	a new electrochemical sensor for sensitive detection of chloramphenicol (CAP)	324:400	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	2	33	theme	composite	489:497	arg1	material					499:506	the β-CD@G/Cu-BTC composite material	471:506	the β-CD@G/Cu-BTC composite material	471:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	4	34	theme	electrochemical	849:863	arg1	sensor					865:870	so an electrochemical sensor	843:870	so an electrochemical sensor for CAP detection	843:888	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	0	35	theme	ultrasensitive	82:95	arg1	detection					113:121	ultrasensitive electrochemical detection	82:121	ultrasensitive electrochemical detection of chloramphenicol	82:140	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	3	36	contain	has	566:568	arg2	effect					605:610	an excellent and stable dispersion effect	570:610	an excellent and stable dispersion effect	570:610	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	3	36	contain	has	566:568	arg1	solution					557:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution	524:564	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	4	37	theme	CAP	876:878	arg1	detection					880:888	CAP detection	876:888	CAP detection	876:888	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	1	38	theme	β-CD	165:168	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	2	39	theme	@	479:479	arg1	material					499:506	the β-CD@G/Cu-BTC composite material	471:506	the β-CD@G/Cu-BTC composite material	471:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	1	40	theme	sensitive	357:365	arg1	detection					367:375	sensitive detection	357:375	sensitive detection of chloramphenicol (CAP)	357:400	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	1	41	theme	@	170:170	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	3	42	theme	stable	587:592	arg1	effect					605:610	an excellent and stable dispersion effect	570:610	an excellent and stable dispersion effect	570:610	The β-CD functionalized graphene solution has an excellent and stable dispersion effect.
36039611	5	43	theme	proposed	949:956	arg1	sensor					958:963	the proposed sensor	945:963	the proposed sensor	945:963	An actual sample was also detected using the proposed sensor.
36039611	4	44	theme	chloramphenicol	826:840	arg1	detection					813:821	the detection	809:821	the detection of chloramphenicol	809:840	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	1	45	theme	functionalized	171:184	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	1	46	theme	graphene	186:193	arg1	BTC					235:237	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC)	143:238	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites	143:249	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
36039611	4	47	from	conductivity	758:769	arg1	detection					813:821	the detection	809:821	the detection of chloramphenicol	809:840	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	0	48	theme	electrochemical	97:111	arg1	detection					113:121	ultrasensitive electrochemical detection	82:121	ultrasensitive electrochemical detection of chloramphenicol	82:140	β-Cyclodextrin-functionalized graphene and metal-organic framework composites for ultrasensitive electrochemical detection of chloramphenicol.
36039611	4	49	theme	metal-organic	653:665	arg1	MOFs					679:682	MOFs	679:682	MOFs	679:682	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	4	49	theme	metal-organic	653:665	arg1	frameworks					667:676	metal-organic frameworks	653:676	metal-organic frameworks (MOFs)	653:683	The composite was further combined with metal-organic frameworks (MOFs) to overcome the disadvantages of a single material, displaying excellent conductivity and a synergistic catalytic effect on the detection of chloramphenicol; so an electrochemical sensor for CAP detection is developed.
36039611	2	50	theme	β-CD	475:478	arg1	material					499:506	the β-CD@G/Cu-BTC composite material	471:506	the β-CD@G/Cu-BTC composite material	471:506	A series of investigations on the β-CD@G/Cu-BTC composite material were conducted.
36039611	1	51	theme	β-CD	279:282	arg1	graphene					299:306	β-CD functionalized graphene	279:306	β-CD functionalized graphene	279:306	Novel β-cyclodextrin (β-CD)@functionalized graphene (G)/Cu-1,3,5-benzenetricarboxylic acid (BTC) composites were in situ prepared using β-CD functionalized graphene and Cu-BTC, and a new electrochemical sensor for sensitive detection of chloramphenicol (CAP) was developed based on the composites.
35725209	5	0	dep	hyperproliferation	1100:1117	arg1	the					1096:1098	the	1096:1098	the	1096:1098	These results indicated that LJCP-2b exhibited the activity of inhibiting the hyperproliferation and inflammatory response of RA-FLS, which may be developed for prevention or treatment of RA.
35725209	2	1	theme	glucuronic	546:555	arg1	acid					557:560	glucuronic acid	546:560	glucuronic acid	546:560	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
35725209	4	2	theme	apoptosis	914:922	arg1	rate					924:927	apoptosis rate	914:927	apoptosis rate	914:927	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	3	theme	In	723:724	arg1	experiments					732:742	In vitro experiments	723:742	In vitro experiments	723:742	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	5	4	theme	inflammatory	1123:1134	arg1	response					1136:1143	inflammatory response	1123:1143	inflammatory response	1123:1143	These results indicated that LJCP-2b exhibited the activity of inhibiting the hyperproliferation and inflammatory response of RA-FLS, which may be developed for prevention or treatment of RA.
35725209	4	5	theme	fibroblast-like	828:842	arg1	RA-FLS					858:863	RA-FLS	858:863	RA-FLS	858:863	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	5	theme	fibroblast-like	828:842	arg1	synoviocytes					844:855	TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes	793:855	TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	793:864	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	6	theme	decreased	930:938	arg1	number					950:955	decreased migration number	930:955	decreased migration number	930:955	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	7	theme	TNF-α-induced	793:805	arg1	arthritis					818:826	TNF-α-induced rheumatoid arthritis	793:826	TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	793:864	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	1	8	theme	molecular	260:268	arg1	distribution					277:288	molecular weight distribution	260:288	molecular weight distribution	260:288	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	4	9	dep	In	723:724	arg1	vitro					726:730	vitro	726:730	vitro	726:730	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	1	10	theme	weight	270:275	arg1	distribution					277:288	molecular weight distribution	260:288	molecular weight distribution	260:288	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	0	11	theme	fibroblast-like	104:118	arg1	synoviocytes					120:131	fibroblast-like synoviocytes	104:131	fibroblast-like synoviocytes	104:131	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	0	12	from	Caulis	48:53	arg1	polysaccharide					8:21	A novel polysaccharide	0:21	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.	0:132	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	4	13	theme	arthritis	818:826	arg1	RA-FLS					858:863	RA-FLS	858:863	RA-FLS	858:863	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	13	theme	arthritis	818:826	arg1	synoviocytes					844:855	TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes	793:855	TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	793:864	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	5	14	theme	RA-FLS	1148:1153	arg1	hyperproliferation					1100:1117	hyperproliferation	1100:1117	hyperproliferation	1100:1117	These results indicated that LJCP-2b exhibited the activity of inhibiting the hyperproliferation and inflammatory response of RA-FLS, which may be developed for prevention or treatment of RA.
35725209	5	14	theme	RA-FLS	1148:1153	arg1	response					1136:1143	inflammatory response	1123:1143	inflammatory response	1123:1143	These results indicated that LJCP-2b exhibited the activity of inhibiting the hyperproliferation and inflammatory response of RA-FLS, which may be developed for prevention or treatment of RA.
35725209	4	15	theme	cell	887:890	arg1	viability					892:900	cell viability	887:900	cell viability	887:900	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	16	theme	rheumatoid	807:816	arg1	arthritis					818:826	TNF-α-induced rheumatoid arthritis	793:826	TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	793:864	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	17	theme	IL-6	1006:1009	arg1	levels					996:1001	the levels	992:1001	the levels of IL-6 and IL-1β	992:1019	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	0	18	theme	novel	2:6	arg1	polysaccharide					8:21	A novel polysaccharide	0:21	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.	0:132	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	4	19	theme	migration	940:948	arg1	number					950:955	decreased migration number	930:955	decreased migration number	930:955	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	2	20	theme	homogeneous	382:392	arg1	LJCP-2b					368:374	LJCP-2b	368:374	LJCP-2b	368:374	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
35725209	2	20	theme	homogeneous	382:392	arg1	heteropolysaccharide					394:413	a homogeneous heteropolysaccharide	380:413	a homogeneous heteropolysaccharide	380:413	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
35725209	2	21	theme	7.0 kDa	442:448	arg1	weight					432:437	a molecular weight	420:437	a molecular weight of 7.0 kDa	420:448	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
35725209	1	22	theme	infrared	291:298	arg1	spectrum					300:307	infrared spectrum	291:307	infrared spectrum	291:307	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	0	23	theme	synoviocytes	120:131	arg1	function					92:99	the function	88:99	the function of fibroblast-like synoviocytes	88:131	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	1	24	attach	isolated	171:178	arg1	Caulis					205:210	Caulis	205:210	Caulis	205:210	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	1	24	attach	isolated	171:178	arg2	LJCP-2b					158:164	LJCP-2b	158:164	LJCP-2b	158:164	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	1	24	attach	isolated	171:178	arg2	polysaccharide					142:155	A novel polysaccharide	134:155	A novel polysaccharide (LJCP-2b)	134:165	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	3	25	theme	Structural	563:572	arg1	analysis					574:581	Structural analysis	563:581	Structural analysis	563:581	Structural analysis revealed that LJCP-2b was mainly consisted of 1,3,6-β-D-Galp, 1,4-α-D-Glcp, 1,4,6-α-D-Glcp, 1,4-β-D-Galp, 1,2,4-α-L-Rhap and 1,4-α-D-GalpA.
35725209	0	26	from	effects	77:83	arg1	function					92:99	the function	88:99	the function of fibroblast-like synoviocytes	88:131	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	2	27	theme	molecular	422:430	arg1	weight					432:437	a molecular weight	420:437	a molecular weight of 7.0 kDa	420:448	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
35725209	2	28	theme	galacturonic	475:486	arg1	acid					488:491	galacturonic acid	475:491	galacturonic acid	475:491	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
35725209	1	29	theme	monosaccharide	310:323	arg1	composition					325:335	monosaccharide composition	310:335	monosaccharide composition	310:335	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	0	30	from	Characterization	56:71	arg1	function					92:99	the function	88:99	the function of fibroblast-like synoviocytes	88:131	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	5	31	theme	RA	1210:1211	arg1	treatment					1197:1205	treatment	1197:1205	treatment	1197:1205	These results indicated that LJCP-2b exhibited the activity of inhibiting the hyperproliferation and inflammatory response of RA-FLS, which may be developed for prevention or treatment of RA.
35725209	5	31	theme	RA	1210:1211	arg1	prevention					1183:1192	prevention	1183:1192	prevention	1183:1192	These results indicated that LJCP-2b exhibited the activity of inhibiting the hyperproliferation and inflammatory response of RA-FLS, which may be developed for prevention or treatment of RA.
35725209	1	32	theme	methylation	338:348	arg1	analysis					350:357	methylation analysis	338:357	methylation analysis	338:357	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	4	33	theme	adhesion	961:968	arg1	capacity					970:977	adhesion capacity	961:977	adhesion capacity	961:977	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	4	34	theme	synoviocytes	844:855	arg1	function					781:788	the function	777:788	the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS)	777:864	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	0	35	dep	polysaccharide	8:21	arg1	effects					77:83	effects	77:83	effects on the function of fibroblast-like synoviocytes	77:131	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	0	35	dep	polysaccharide	8:21	arg1	Characterization					56:71	Characterization	56:71	Characterization	56:71	A novel polysaccharide from Lonicerae Japonicae Caulis: Characterization and effects on the function of fibroblast-like synoviocytes.
35725209	1	36	theme	novel	136:140	arg1	LJCP-2b					158:164	LJCP-2b	158:164	LJCP-2b	158:164	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	1	36	theme	novel	136:140	arg1	polysaccharide					142:155	A novel polysaccharide	134:155	A novel polysaccharide (LJCP-2b)	134:165	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	1	37	theme	structural	221:230	arg1	features					232:239	its structural features	217:239	its structural features	217:239	A novel polysaccharide (LJCP-2b) was isolated from Lonicerae Japonicae Caulis, and its structural features were identified by molecular weight distribution, infrared spectrum, monosaccharide composition, methylation analysis and NMR.
35725209	4	38	theme	IL-1β	1015:1019	arg1	levels					996:1001	the levels	992:1001	the levels of IL-6 and IL-1β	992:1019	In vitro experiments showed that LJCP-2b could affect the function of TNF-α-induced rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS), including weakening cell viability, increasing apoptosis rate, decreased migration number and adhesion capacity, and reduced the levels of IL-6 and IL-1β.
35725209	2	39	with	heteropolysaccharide	394:413	arg1	weight					432:437	a molecular weight	420:437	a molecular weight of 7.0 kDa	420:448	LJCP-2b was a homogeneous heteropolysaccharide with a molecular weight of 7.0 kDa and composed of glucose, galacturonic acid, galactose, arabinose, rhamnose, xylose, mannose and glucuronic acid.
37201636	2	0	theme	microbial	483:491	arg1	ecology					493:499	gut microbial ecology	479:499	gut microbial ecology caused by lipopolysaccharide (LPS) exposure	479:543	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	6	1	theme	diversity	1359:1367	arg1	dysbiosis					1319:1327	the gut microbial dysbiosis	1301:1327	the gut microbial dysbiosis	1301:1327	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	6	1	theme	diversity	1359:1367	arg1	loss					1337:1340	the loss	1333:1340	the loss of gut microbial diversity induced by LPS exposure	1333:1391	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	0	2	from	injury	45:50	arg1	mice					109:112	LPS-induced mice	97:112	LPS-induced mice	97:112	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	1	3	theme	common	150:155	arg1	disease					137:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	1	3	theme	common	150:155	arg1	disease					173:179	a common digestive tract disease	148:179	a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized	148:294	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	2	4	theme	gut	479:481	arg1	ecology					493:499	gut microbial ecology	479:499	gut microbial ecology caused by lipopolysaccharide (LPS) exposure	479:543	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	3	5	theme	intestinal	686:695	arg1	disorder					697:704	LPS-induced intestinal disorder	674:704	LPS-induced intestinal disorder	674:704	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	6	6	theme	microbial	1349:1357	arg1	diversity					1359:1367	gut microbial diversity	1345:1367	gut microbial diversity	1345:1367	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	5	7	theme	microbial	929:937	arg1	diversity					939:947	the intestinal microbial diversity	914:947	the intestinal microbial diversity in mice	914:955	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	1	8	theme	digestive	157:165	arg1	disease					137:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	1	8	theme	digestive	157:165	arg1	disease					173:179	a common digestive tract disease	148:179	a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized	148:294	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	6	9	theme	gut	1345:1347	arg1	diversity					1359:1367	gut microbial diversity	1345:1367	gut microbial diversity	1345:1367	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	5	10	from	diversity	939:947	arg1	mice					952:955	mice	952:955	mice	952:955	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	11	theme	intestinal	918:927	arg1	diversity					939:947	the intestinal microbial diversity	914:947	the intestinal microbial diversity in mice	914:955	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	0	12	theme	LPS-induced	97:107	arg1	mice					109:112	LPS-induced mice	97:112	LPS-induced mice	97:112	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	3	13	theme	16S	730:732	arg1	rRNA					734:737	16S rRNA	730:737	16S rRNA	730:737	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	7	14	theme	microecology	1524:1535	arg1	modulation					1499:1508	the modulation	1495:1508	the modulation of intestinal microecology	1495:1535	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	2	15	theme	pharmacological	346:360	arg1	action					423:428	pharmacological action	407:428	pharmacological action	407:428	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	2	15	theme	pharmacological	346:360	arg1	activity					394:401	antioxidant activity	382:401	antioxidant activity	382:401	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	2	15	theme	pharmacological	346:360	arg1	activities					362:371	pharmacological activities	346:371	pharmacological activities	346:371	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	7	16	from	effective	1435:1443	arg1	summary					1397:1403	summary	1397:1403	summary	1397:1403	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	2	17	theme	lipopolysaccharide	511:528	arg1	exposure					536:543	lipopolysaccharide (LPS) exposure	511:543	lipopolysaccharide (LPS) exposure	511:543	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	5	18	theme	several	1146:1152	arg1	Parabacteroides					1218:1232	Parabacteroides	1218:1232	Parabacteroides	1218:1232	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	18	theme	several	1146:1152	arg1	bacteria					1165:1172	several beneficial bacteria	1146:1172	several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides)	1146:1233	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	18	theme	several	1146:1152	arg1	Akkermansia					1202:1212	Akkermansia	1202:1212	Akkermansia	1202:1212	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	18	theme	several	1146:1152	arg1	Lactobacillus					1187:1199	Lactobacillus	1187:1199	Lactobacillus	1187:1199	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	7	19	theme	seaweed	1406:1412	arg1	polysaccharides					1414:1428	seaweed polysaccharides	1406:1428	seaweed polysaccharides	1406:1428	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	1	20	theme	tract	167:171	arg1	disease					137:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	1	20	theme	tract	167:171	arg1	disease					173:179	a common digestive tract disease	148:179	a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized	148:294	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	5	21	theme	beneficial	1154:1163	arg1	Parabacteroides					1218:1232	Parabacteroides	1218:1232	Parabacteroides	1218:1232	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	21	theme	beneficial	1154:1163	arg1	bacteria					1165:1172	several beneficial bacteria	1146:1172	several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides)	1146:1233	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	21	theme	beneficial	1154:1163	arg1	Akkermansia					1202:1212	Akkermansia	1202:1212	Akkermansia	1202:1212	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	21	theme	beneficial	1154:1163	arg1	Lactobacillus					1187:1199	Lactobacillus	1187:1199	Lactobacillus	1187:1199	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	2	22	theme	antioxidant	382:392	arg1	activity					394:401	antioxidant activity	382:401	antioxidant activity	382:401	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	0	23	theme	polysaccharides	8:22	arg1	treatment					24:32	Seaweed polysaccharides treatment	0:32	Seaweed polysaccharides treatment	0:32	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	0	24	theme	barrier	86:92	arg1	injury					45:50	injury	45:50	injury of inflammatory responses and gut barrier in LPS-induced mice	45:112	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	6	25	theme	gut	1305:1307	arg1	dysbiosis					1319:1327	the gut microbial dysbiosis	1301:1327	the gut microbial dysbiosis	1301:1327	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	3	26	from	effects	609:615	arg1	disorder					697:704	LPS-induced intestinal disorder	674:704	LPS-induced intestinal disorder	674:704	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	0	27	theme	Seaweed	0:6	arg1	treatment					24:32	Seaweed polysaccharides treatment	0:32	Seaweed polysaccharides treatment	0:32	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	1	28	theme	intestinal	254:263	arg1	microflora					265:274	intestinal microflora	254:274	intestinal microflora	254:274	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	2	29	theme	Seaweed	297:303	arg1	polysaccharides					305:319	Seaweed polysaccharides	297:319	Seaweed polysaccharides	297:319	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	1	30	theme	microflora	265:274	arg1	role					246:249	the role	242:249	the role of intestinal microflora	242:274	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	7	31	theme	LPS-induced	1453:1463	arg1	damage					1476:1481	LPS-induced intestinal damage	1453:1481	LPS-induced intestinal damage in mice	1453:1489	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	4	32	theme	Histopathological	767:783	arg1	results					785:791	Histopathological results	767:791	Histopathological results	767:791	Histopathological results indicated that the intestinal structure in the LPS-induced group was damaged.
37201636	6	33	theme	microbial	1309:1317	arg1	dysbiosis					1319:1327	the gut microbial dysbiosis	1301:1327	the gut microbial dysbiosis	1301:1327	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	5	34	theme	momentous	974:982	arg1	transformation					984:997	momentous transformation	974:997	momentous transformation	974:997	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	3	35	theme	high-throughput	739:753	arg1	sequencing					755:764	high-throughput sequencing	739:764	high-throughput sequencing	739:764	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	3	36	theme	concentration	630:642	arg1	effects					609:615	the effects	605:615	the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder	605:704	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	1	37	theme	Gastrointestinal	115:130	arg1	disease					137:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease	115:143	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	1	37	theme	Gastrointestinal	115:130	arg1	disease					173:179	a common digestive tract disease	148:179	a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized	148:294	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	1	38	theme	millions	199:206	arg1	health					189:194	health	189:194	health of millions of human	189:215	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	5	39	dep	a	1029:1029	arg1	increased					1045:1053	increased	1045:1053	significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum)	1031:1127	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	39	dep	a	1029:1029	arg1	decreased					1133:1141	decreased	1133:1141	decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides)	1133:1233	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	1	40	dep	effects	181:187	arg1	emphasized					285:294	emphasized	285:294	had been emphasized	276:294	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	7	41	from	damage	1476:1481	arg1	mice					1486:1489	mice	1486:1489	mice	1486:1489	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	2	42	theme	pharmacological	407:421	arg1	action					423:428	pharmacological action	407:428	pharmacological action	407:428	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	5	43	dep	bacteria	1074:1081	arg1	Citrobacter					1098:1108	Citrobacter	1098:1108	Citrobacter	1098:1108	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	43	dep	bacteria	1074:1081	arg1	bacteria					1074:1081	some pathogenic bacteria	1058:1081	some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum)	1058:1127	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	43	dep	bacteria	1074:1081	arg1	Mucispirillum					1114:1126	Mucispirillum	1114:1126	Mucispirillum	1114:1126	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	3	44	dep	microscope	715:724	arg1	sequencing					755:764	high-throughput sequencing	739:764	high-throughput sequencing	739:764	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	4	45	theme	LPS-induced	840:850	arg1	group					852:856	the LPS-induced group	836:856	the LPS-induced group	836:856	Histopathological results indicated that the intestinal structure in the LPS-induced group was damaged.
37201636	5	46	theme	LPS	884:886	arg1	exposure					888:895	LPS exposure	884:895	LPS exposure	884:895	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	1	47	theme	human	211:215	arg1	millions					199:206	millions	199:206	millions of human	199:215	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	0	48	theme	responses	68:76	arg1	injury					45:50	injury	45:50	injury of inflammatory responses and gut barrier in LPS-induced mice	45:112	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	5	49	dep	bacteria	1165:1172	arg1	Parabacteroides					1218:1232	Parabacteroides	1218:1232	Parabacteroides	1218:1232	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	49	dep	bacteria	1165:1172	arg1	Akkermansia					1202:1212	Akkermansia	1202:1212	Akkermansia	1202:1212	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	49	dep	bacteria	1165:1172	arg1	bacteria					1165:1172	several beneficial bacteria	1146:1172	several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides)	1146:1233	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	49	dep	bacteria	1165:1172	arg1	Lactobacillus					1187:1199	Lactobacillus	1187:1199	Lactobacillus	1187:1199	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	3	50	theme	different	620:628	arg1	concentration					630:642	different concentration	620:642	different concentration of seaweed polysaccharides	620:669	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	0	51	theme	inflammatory	55:66	arg1	responses					68:76	inflammatory responses	55:76	inflammatory responses	55:76	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	6	52	theme	LPS	1380:1382	arg1	exposure					1384:1391	LPS exposure	1380:1391	LPS exposure	1380:1391	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	7	53	theme	intestinal	1465:1474	arg1	damage					1476:1481	LPS-induced intestinal damage	1453:1481	LPS-induced intestinal damage in mice	1453:1489	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	1	54	dep	disease	173:179	arg1	effects					181:187	effects	181:187	effects	181:187	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
37201636	2	55	theme	wide	332:335	arg1	activity					394:401	antioxidant activity	382:401	antioxidant activity	382:401	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	2	55	theme	wide	332:335	arg1	range					337:341	a wide range	330:341	a wide range of pharmacological activities, such as antioxidant activity and pharmacological action,	330:429	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	2	55	theme	wide	332:335	arg1	action					423:428	pharmacological action	407:428	pharmacological action	407:428	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	7	56	theme	intestinal	1513:1522	arg1	microecology					1524:1535	intestinal microecology	1513:1535	intestinal microecology	1513:1535	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	3	57	theme	LPS-induced	674:684	arg1	disorder					697:704	LPS-induced intestinal disorder	674:704	LPS-induced intestinal disorder	674:704	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	5	58	theme	pathogenic	1063:1072	arg1	Citrobacter					1098:1108	Citrobacter	1098:1108	Citrobacter	1098:1108	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	58	theme	pathogenic	1063:1072	arg1	bacteria					1074:1081	some pathogenic bacteria	1058:1081	some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum)	1058:1127	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	5	58	theme	pathogenic	1063:1072	arg1	Mucispirillum					1114:1126	Mucispirillum	1114:1126	Mucispirillum	1114:1126	Furthermore, LPS exposure not only reduced the intestinal microbial diversity in mice but also induced momentous transformation in its composition, including a significantly increased in some pathogenic bacteria (Helicobacter, Citrobacter and Mucispirillum) and decreased in several beneficial bacteria (Firmicutes, Lactobacillus, Akkermansia and Parabacteroides).
37201636	7	59	from	summary	1397:1403	arg1	effective					1435:1443	effective	1435:1443	effective	1435:1443	In summary, seaweed polysaccharides were effective against LPS-induced intestinal damage in mice via the modulation of intestinal microecology.
37201636	3	60	theme	seaweed	647:653	arg1	polysaccharides					655:669	seaweed polysaccharides	647:669	seaweed polysaccharides	647:669	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	4	61	theme	intestinal	812:821	arg1	structure					823:831	the intestinal structure	808:831	the intestinal structure in the LPS-induced group	808:856	Histopathological results indicated that the intestinal structure in the LPS-induced group was damaged.
37201636	2	62	theme	activities	362:371	arg1	activity					394:401	antioxidant activity	382:401	antioxidant activity	382:401	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	2	62	theme	activities	362:371	arg1	range					337:341	a wide range	330:341	a wide range of pharmacological activities, such as antioxidant activity and pharmacological action,	330:429	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	2	62	theme	activities	362:371	arg1	action					423:428	pharmacological action	407:428	pharmacological action	407:428	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	0	63	theme	gut	82:84	arg1	barrier					86:92	gut barrier	82:92	gut barrier	82:92	Seaweed polysaccharides treatment alleviates injury of inflammatory responses and gut barrier in LPS-induced mice.
37201636	3	64	theme	polysaccharides	655:669	arg1	concentration					630:642	different concentration	620:642	different concentration of seaweed polysaccharides	620:669	In this study, we investigated the effects of different concentration of seaweed polysaccharides on LPS-induced intestinal disorder by using microscope and 16S rRNA high-throughput sequencing.
37201636	6	65	theme	polysaccharide	1257:1270	arg1	administration					1272:1285	seaweed polysaccharide administration	1249:1285	seaweed polysaccharide administration	1249:1285	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	2	66	theme	ecology	493:499	arg1	dysbiosis					466:474	the dysbiosis	462:474	the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure	462:543	Seaweed polysaccharides featured a wide range of pharmacological activities, such as antioxidant activity and pharmacological action, but whether they can alleviate the dysbiosis of gut microbial ecology caused by lipopolysaccharide (LPS) exposure has not been well conducted.
37201636	6	67	theme	seaweed	1249:1255	arg1	administration					1272:1285	seaweed polysaccharide administration	1249:1285	seaweed polysaccharide administration	1249:1285	Nonetheless, seaweed polysaccharide administration could recover the gut microbial dysbiosis and the loss of gut microbial diversity induced by LPS exposure.
37201636	4	68	from	structure	823:831	arg1	group					852:856	the LPS-induced group	836:856	the LPS-induced group	836:856	Histopathological results indicated that the intestinal structure in the LPS-induced group was damaged.
37201636	1	69	dep	Gastrointestinal	115:130	arg1	GI					133:134	GI	133:134	GI	133:134	Gastrointestinal (GI) disease is a common digestive tract disease effects health of millions of human globally each year, thus the role of intestinal microflora had been emphasized.
36982493	4	0	theme	%	803:803	arg1	increase					805:812	22% increase	801:812	22% increase in yield stress compared to the CS film	801:852	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	1	1	theme	cerium	266:271	arg1	nanoparticles					279:291	cerium oxide nanoparticles	266:291	cerium oxide nanoparticles	266:291	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	7	2	theme	improved	1362:1369	arg1	strength					1326:1333	good mechanical strength	1310:1333	good mechanical strength in dry and swollen states	1310:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	7	2	theme	improved	1362:1369	arg1	biocompatibility					1371:1386	improved biocompatibility	1362:1386	improved biocompatibility in relation to the culture of mesenchymal stem cells	1362:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	3	from	influence	326:334	arg1	features					440:447	the specific features	427:447	the specific features of the intermolecular interactions in the materials	427:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	3	from	influence	326:334	arg1	properties					386:395	properties	386:395	properties	386:395	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	3	from	influence	326:334	arg1	structure					372:380	structure	372:380	structure	372:380	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	3	4	theme	5	699:699	arg1	%					700:700	%	700:700	%	700:700	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	3	5	from	increase	521:528	arg1	stiffness					538:546	film stiffness	533:546	film stiffness	533:546	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	4	6	theme	film	786:789	arg1	strength					791:798	film strength	786:798	film strength (22% increase in yield stress compared to the CS film)	786:853	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	7	7	theme	good	1310:1313	arg1	biocompatibility					1371:1386	improved biocompatibility	1362:1386	improved biocompatibility in relation to the culture of mesenchymal stem cells	1362:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	7	7	theme	good	1310:1313	arg1	strength					1326:1333	good mechanical strength	1310:1333	good mechanical strength in dry and swollen states	1310:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	0	8	theme	Chitosan	0:7	arg1	Composites					9:18	Chitosan Composites	0:18	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.	0:140	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	0	8	theme	Chitosan	0:7	arg1	Characterization					91:106	Characterization	91:106	Characterization	91:106	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	0	8	theme	Chitosan	0:7	arg1	Evaluation					130:139	Cytocompatibility Evaluation	112:139	Cytocompatibility Evaluation	112:139	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	3	9	dep	6.3	666:668	arg1	to					663:664	to	663:664	to	663:664	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	7	10	theme	properties	1298:1307	arg1	number					1278:1283	a number	1276:1283	a number	1276:1283	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	4	11	theme	CS	846:847	arg1	film					849:852	the CS film	842:852	the CS film	842:852	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	3	12	theme	BCd	702:704	arg1	introduction					683:694	the introduction	679:694	the introduction of 5% BCd	679:704	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	6	13	theme	stem	1223:1226	arg1	cells					1228:1232	mesenchymal stem cells	1211:1232	mesenchymal stem cells	1211:1232	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	1	14	theme	disintegrated	211:223	arg1	nanofibers					251:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	5	15	theme	composite	978:986	arg1	structure					961:969	the structure	957:969	the structure of the composite	957:986	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	4	16	from	increase	774:781	arg1	strength					791:798	film strength	786:798	film strength (22% increase in yield stress compared to the CS film)	786:853	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	1	17	theme	cellulose	235:243	arg1	nanofibers					251:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	7	18	from	biocompatibility	1371:1386	arg1	relation					1391:1398	relation	1391:1398	relation to the culture of mesenchymal stem cells	1391:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	1	19	theme	chitosan	298:305	arg1	matrices					312:319	chitosan (CS) matrices	298:319	chitosan (CS) matrices	298:319	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	5	20	theme	ceria	942:946	arg1	amount					922:927	The amount	918:927	The amount of nanosized ceria	918:946	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	5	20	theme	ceria	942:946	arg1	ceria					942:946	nanosized ceria	932:946	nanosized ceria	932:946	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	6	21	theme	nanoceria	1101:1109	arg1	nanoceria					1101:1109	nanoceria	1101:1109	nanoceria	1101:1109	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	6	21	theme	nanoceria	1101:1109	arg1	amount					1091:1096	the amount	1087:1096	the amount of nanoceria	1087:1109	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	7	22	theme	obtained	1239:1246	arg1	films					1262:1266	The obtained nanocomposite films	1235:1266	The obtained nanocomposite films	1235:1266	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	0	23	theme	Nanosized	67:75	arg1	Oxide					84:88	Nanosized Cerium Oxide	67:88	Nanosized Cerium Oxide	67:88	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	3	24	theme	BCd	607:609	arg1	nanofibers					611:620	BCd nanofibers	607:620	BCd nanofibers	607:620	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	1	25	theme	new	156:158	arg1	films					170:174	new composite films	156:174	new composite films	156:174	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	5	26	theme	hydrophilic	1017:1027	arg1	properties					1029:1038	hydrophilic properties	1017:1038	hydrophilic properties	1017:1038	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	7	27	from	strength	1326:1333	arg1	states					1354:1359	dry and swollen states	1338:1359	dry and swollen states	1338:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	28	from	features	440:447	arg1	materials					491:499	the materials	487:499	the materials	487:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	7	29	theme	wound	1552:1556	arg1	dressings					1558:1566	wound dressings	1552:1566	wound dressings	1552:1566	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	3	30	with	matrix	595:600	arg1	nanofibers					611:620	BCd nanofibers	607:620	BCd nanofibers	607:620	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	7	31	theme	cells	1542:1546	arg1	culture					1514:1520	the culture	1510:1520	the culture of mesenchymal stem cells and wound dressings	1510:1566	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	32	from	interactions	471:482	arg1	materials					491:499	the materials	487:499	the materials	487:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	4	33	dep	strength	791:798	arg1	increase					805:812	22% increase	801:812	22% increase in yield stress compared to the CS film	801:852	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	5	34	theme	composite	1059:1067	arg1	films					1069:1073	the composite films	1055:1073	the composite films	1055:1073	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	7	35	theme	mesenchymal	1525:1535	arg1	cells					1542:1546	mesenchymal stem cells	1525:1546	mesenchymal stem cells	1525:1546	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	36	theme	specific	431:438	arg1	features					440:447	the specific features	427:447	the specific features of the intermolecular interactions in the materials	427:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	5	37	dep	properties	1029:1038	arg1	the					1013:1015	the	1013:1015	the	1013:1015	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	4	38	theme	further	709:715	arg1	increase					717:724	A further increase	707:724	A further increase in Young's modulus of 6.7 GPa	707:754	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	7	39	theme	stem	1430:1433	arg1	cells					1435:1439	mesenchymal stem cells	1418:1439	mesenchymal stem cells	1418:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	40	theme	polymer	404:410	arg1	composites					412:421	the polymer composites	400:421	the polymer composites	400:421	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	0	41	theme	Cellulose	35:43	arg1	Nanofibers					45:54	Bacterial Cellulose Nanofibers	25:54	Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide	25:88	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	2	42	theme	intermolecular	456:469	arg1	interactions					471:482	the intermolecular interactions	452:482	the intermolecular interactions in the materials	452:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	43	theme	amount	343:348	arg1	influence					326:334	The influence	322:334	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials	322:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	5	44	theme	nanosized	932:940	arg1	ceria					942:946	nanosized ceria	932:946	nanosized ceria	932:946	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	4	45	theme	GPa	752:754	arg1	modulus					737:743	Young's modulus	729:743	Young's modulus of 6.7 GPa	729:754	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	2	46	theme	nanofillers	353:363	arg1	nanofillers					353:363	nanofillers	353:363	nanofillers	353:363	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	46	theme	nanofillers	353:363	arg1	amount					343:348	the amount	339:348	the amount of nanofillers	339:363	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	4	47	theme	22	801:802	arg1	%					803:803	%	803:803	%	803:803	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	6	48	theme	films	1168:1172	arg1	biocompatibility					1144:1159	the biocompatibility	1140:1159	the biocompatibility of the films	1140:1172	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	6	48	theme	films	1168:1172	arg1	adhesion					1184:1191	their adhesion	1178:1191	their adhesion to the culture of mesenchymal stem cells	1178:1232	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	1	49	theme	oxide	273:277	arg1	nanoparticles					279:291	cerium oxide nanoparticles	266:291	cerium oxide nanoparticles	266:291	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	7	50	theme	swollen	1346:1352	arg1	states					1354:1359	dry and swollen states	1338:1359	dry and swollen states	1338:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	7	51	dep	properties	1298:1307	arg1	biocompatibility					1371:1386	improved biocompatibility	1362:1386	improved biocompatibility in relation to the culture of mesenchymal stem cells	1362:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	7	51	dep	properties	1298:1307	arg1	strength					1326:1333	good mechanical strength	1310:1333	good mechanical strength in dry and swollen states	1310:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	3	52	theme	%	700:700	arg1	BCd					702:704	5% BCd	699:704	5% BCd	699:704	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	3	53	theme	film	533:536	arg1	stiffness					538:546	film stiffness	533:546	film stiffness	533:546	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	7	54	theme	dry	1338:1340	arg1	states					1354:1359	dry and swollen states	1338:1359	dry and swollen states	1338:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	7	55	theme	mechanical	1315:1324	arg1	biocompatibility					1371:1386	improved biocompatibility	1362:1386	improved biocompatibility in relation to the culture of mesenchymal stem cells	1362:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	7	55	theme	mechanical	1315:1324	arg1	strength					1326:1333	good mechanical strength	1310:1333	good mechanical strength in dry and swollen states	1310:1359	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	6	56	theme	cells	1228:1232	arg1	culture					1200:1206	the culture	1196:1206	the culture of mesenchymal stem cells	1196:1232	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	7	57	theme	matrix	1490:1495	arg1	material					1497:1504	a matrix material	1488:1504	a matrix material for the culture of mesenchymal stem cells and wound dressings	1488:1566	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	58	from	materials	491:499	arg1	properties					386:395	properties	386:395	properties	386:395	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	58	from	materials	491:499	arg1	features					440:447	the specific features	427:447	the specific features of the intermolecular interactions in the materials	427:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	58	from	materials	491:499	arg1	structure					372:380	structure	372:380	structure	372:380	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	7	59	theme	favorable	1288:1296	arg1	properties					1298:1307	favorable properties	1288:1307	favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells)	1288:1440	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	6	60	theme	mesenchymal	1211:1221	arg1	cells					1228:1232	mesenchymal stem cells	1211:1232	mesenchymal stem cells	1211:1232	Increasing the amount of nanoceria to 8% significantly improved the biocompatibility of the films and their adhesion to the culture of mesenchymal stem cells.
36982493	3	61	theme	CS	592:593	arg1	matrix					595:600	the CS matrix	588:600	the CS matrix with BCd nanofibers	588:620	An increase in film stiffness was observed as a result of reinforcing the CS matrix with BCd nanofibers: the Young's modulus increased from 4.55 to 6.3 GPa with the introduction of 5% BCd.
36982493	1	62	theme	bacterial	225:233	arg1	nanofibers					251:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	5	63	from	change	1003:1008	arg1	texture					1044:1050	texture	1044:1050	texture	1044:1050	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	5	63	from	change	1003:1008	arg1	properties					1029:1038	hydrophilic properties	1017:1038	hydrophilic properties	1017:1038	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	4	64	theme	yield	817:821	arg1	stress					823:828	yield stress	817:828	yield stress	817:828	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	7	65	theme	nanocomposite	1248:1260	arg1	films					1262:1266	The obtained nanocomposite films	1235:1266	The obtained nanocomposite films	1235:1266	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	0	66	theme	Cerium	77:82	arg1	Oxide					84:88	Nanosized Cerium Oxide	67:88	Nanosized Cerium Oxide	67:88	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	4	67	theme	BCd	878:880	arg1	concentration					882:894	the BCd concentration	874:894	the BCd concentration	874:894	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	4	68	from	increase	805:812	arg1	stress					823:828	yield stress	817:828	yield stress	817:828	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	1	69	theme	composite	160:168	arg1	films					170:174	new composite films	156:174	new composite films	156:174	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	4	70	from	increase	717:724	arg1	strength					791:798	film strength	786:798	film strength (22% increase in yield stress compared to the CS film)	786:853	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	7	71	theme	dressings	1558:1566	arg1	culture					1514:1520	the culture	1510:1520	the culture of mesenchymal stem cells and wound dressings	1510:1566	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	4	72	theme	Young	729:733	arg1	modulus					737:743	Young's modulus	729:743	Young's modulus of 6.7 GPa	729:754	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	0	73	theme	Bacterial	25:33	arg1	Nanofibers					45:54	Bacterial Cellulose Nanofibers	25:54	Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide	25:88	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	5	74	theme	films	1069:1073	arg1	texture					1044:1050	texture	1044:1050	texture	1044:1050	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	5	74	theme	films	1069:1073	arg1	properties					1029:1038	hydrophilic properties	1017:1038	hydrophilic properties	1017:1038	The amount of nanosized ceria affected the structure of the composite, followed by a change in the hydrophilic properties and texture of the composite films.
36982493	7	75	theme	stem	1537:1540	arg1	cells					1542:1546	mesenchymal stem cells	1525:1546	mesenchymal stem cells	1525:1546	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	76	theme	composites	412:421	arg1	properties					386:395	properties	386:395	properties	386:395	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	76	theme	composites	412:421	arg1	features					440:447	the specific features	427:447	the specific features of the intermolecular interactions in the materials	427:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	76	theme	composites	412:421	arg1	structure					372:380	structure	372:380	structure	372:380	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	7	77	theme	cells	1435:1439	arg1	culture					1407:1413	the culture	1403:1413	the culture of mesenchymal stem cells	1403:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	78	theme	interactions	471:482	arg1	properties					386:395	properties	386:395	properties	386:395	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	78	theme	interactions	471:482	arg1	features					440:447	the specific features	427:447	the specific features of the intermolecular interactions in the materials	427:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	78	theme	interactions	471:482	arg1	structure					372:380	structure	372:380	structure	372:380	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	0	79	theme	Cytocompatibility	112:128	arg1	Composites					9:18	Chitosan Composites	0:18	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.	0:140	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	0	79	theme	Cytocompatibility	112:128	arg1	Evaluation					130:139	Cytocompatibility Evaluation	112:139	Cytocompatibility Evaluation	112:139	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	7	80	theme	mesenchymal	1418:1428	arg1	cells					1435:1439	mesenchymal stem cells	1418:1439	mesenchymal stem cells	1418:1439	The obtained nanocomposite films combine a number of favorable properties (good mechanical strength in dry and swollen states, improved biocompatibility in relation to the culture of mesenchymal stem cells), which allows us to recommend them for use as a matrix material for the culture of mesenchymal stem cells and wound dressings.
36982493	2	81	from	structure	372:380	arg1	materials					491:499	the materials	487:499	the materials	487:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	4	82	theme	significant	762:772	arg1	increase					774:781	a significant increase	760:781	a significant increase in film strength (22% increase in yield stress compared to the CS film)	760:853	A further increase in Young's modulus of 6.7 GPa and a significant increase in film strength (22% increase in yield stress compared to the CS film) were observed when the BCd concentration was increased to 20%.
36982493	0	83	with	Composites	9:18	arg1	Nanofibers					45:54	Bacterial Cellulose Nanofibers	25:54	Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide	25:88	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	2	84	from	properties	386:395	arg1	materials					491:499	the materials	487:499	the materials	487:499	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	2	85	dep	structure	372:380	arg1	the					368:370	the	368:370	the	368:370	The influence of the amount of nanofillers on the structure and properties of the polymer composites and the specific features of the intermolecular interactions in the materials were determined.
36982493	1	86	theme	BCd	246:248	arg1	nanofibers					251:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	the disintegrated bacterial cellulose (BCd) nanofibers	207:260	In this work, new composite films were prepared by incorporating the disintegrated bacterial cellulose (BCd) nanofibers and cerium oxide nanoparticles into chitosan (CS) matrices.
36982493	0	87	dep	Composites	9:18	arg1	Composites					9:18	Chitosan Composites	0:18	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.	0:140	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	0	87	dep	Composites	9:18	arg1	Characterization					91:106	Characterization	91:106	Characterization	91:106	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
36982493	0	87	dep	Composites	9:18	arg1	Evaluation					130:139	Cytocompatibility Evaluation	112:139	Cytocompatibility Evaluation	112:139	Chitosan Composites with Bacterial Cellulose Nanofibers Doped with Nanosized Cerium Oxide: Characterization and Cytocompatibility Evaluation.
37047050	2	0	theme	targeted	608:615	arg1	metabolomics					617:628	widely targeted metabolomics	601:628	widely targeted metabolomics	601:628	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	9	1	theme	important	2009:2017	arg1	roles					2019:2023	important roles	2009:2023	important roles	2009:2023	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	2	2	theme	Hua	367:369	arg1	germplasm					386:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	6	3	theme	broad-leaved	1361:1372	arg1	germplasm					1385:1393	the broad-leaved green stem germplasm	1357:1393	the broad-leaved green stem germplasm	1357:1393	Lipids were significantly enriched in the broad-leaved green stem germplasm and the one-year age section.
37047050	5	4	theme	age	1144:1146	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	4	theme	age	1144:1146	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	8	5	dep	acyltransferase	1636:1650	arg1	families					1753:1760	gene families	1748:1760	gene families	1748:1760	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	8	6	theme	gene	1748:1751	arg1	families					1753:1760	gene families	1748:1760	gene families	1748:1760	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	10	7	theme	species	2203:2209	arg1	varieties					2178:2186	new varieties	2174:2186	new varieties of Polygonatum species	2174:2209	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	10	7	theme	species	2203:2209	arg1	species					2203:2209	Polygonatum species	2191:2209	Polygonatum species	2191:2209	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	5	8	from	steroids	1184:1191	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	8	from	steroids	1184:1191	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	4	9	theme	JZ	1082:1083	arg1	germplasm					1086:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	5	10	theme	acid	1301:1304	arg1	metabolites					1306:1316	amino acid metabolites	1295:1316	amino acid metabolites	1295:1316	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	4	11	theme	green	872:876	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	11	theme	green	872:876	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	5	12	from	lipids	1213:1218	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	12	from	lipids	1213:1218	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	1	13	theme	various	194:200	arg1	compounds					202:210	various compounds	194:210	various compounds with many biological activities	194:242	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	4	14	theme	pointed-leaved	1054:1067	arg1	germplasm					1086:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	3	15	theme	age	755:757	arg1	sections					759:766	age sections	755:766	age sections	755:766	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	5	16	contain	contains	1254:1261	arg2	flavonoids					1268:1277	flavonoids	1268:1277	flavonoids	1268:1277	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	16	contain	contains	1254:1261	arg2	alkaloids					1280:1288	alkaloids	1280:1288	alkaloids	1280:1288	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	16	contain	contains	1254:1261	arg2	metabolites					1306:1316	amino acid metabolites	1295:1316	amino acid metabolites	1295:1316	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	16	contain	contains	1254:1261	arg1	section					1246:1252	the three years (CT) age section	1221:1252	the three years (CT) age section	1221:1252	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	8	17	theme	glycerol-3-phosphate	1615:1634	arg1	GPAT					1653:1656	GPAT	1653:1656	GPAT	1653:1656	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	8	17	theme	glycerol-3-phosphate	1615:1634	arg1	acyltransferase					1636:1650	the glycerol-3-phosphate acyltransferase	1611:1650	the glycerol-3-phosphate acyltransferase (GPAT)	1611:1657	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	2	18	from	composition	482:492	arg1	germplasms					540:549	different germplasms	530:549	different germplasms	530:549	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	18	from	composition	482:492	arg1	sections					559:566	age sections	555:566	age sections of P. cyrtonema	555:582	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	4	19	theme	stem	1076:1079	arg1	germplasm					1086:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	0	20	theme	Targeted	129:136	arg1	Analysis					151:158	Widely Targeted Metabolomics Analysis	122:158	Widely Targeted Metabolomics Analysis	122:158	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	1	21	theme	biological	222:231	arg1	activities					233:242	many biological activities	217:242	many biological activities	217:242	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	1	22	theme	pharmaceutical	288:301	arg1	products					303:310	pharmaceutical products	288:310	pharmaceutical products	288:310	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	9	23	theme	real-time	1854:1862	arg1	PCR					1864:1866	The quantitative real-time PCR	1837:1866	The quantitative real-time PCR (qRT-PCR) results	1837:1884	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	9	23	theme	real-time	1854:1862	arg1	qRT-PCR					1869:1875	qRT-PCR	1869:1875	qRT-PCR	1869:1875	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	3	24	theme	cyrtonema	774:782	arg1	rich					789:792	rich	789:792	rich	789:792	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	3	24	theme	cyrtonema	774:782	arg1	germplasms					740:749	the different germplasms	726:749	the different germplasms	726:749	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	3	24	theme	cyrtonema	774:782	arg1	sections					759:766	age sections	755:766	age sections	755:766	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	1	25	from	compounds	202:210	arg1	rich					186:189	rich	186:189	rich	186:189	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	0	26	from	Sections	104:111	arg1	Hua					66:68	Polygonatum cyrtonema Hua	44:68	Polygonatum cyrtonema Hua from Different Germplasms and Age Sections	44:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	26	from	Sections	104:111	arg1	Composition					10:20	Metabolic Composition	0:20	Metabolic Composition	0:20	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	26	from	Sections	104:111	arg1	Traits					34:39	Quality Traits	26:39	Quality Traits	26:39	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	8	27	theme	lysophosphatidic	1660:1675	arg1	LPAT					1699:1702	LPAT	1699:1702	LPAT	1699:1702	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	8	27	theme	lysophosphatidic	1660:1675	arg1	acyltransferase					1682:1696	lysophosphatidic acid acyltransferase	1660:1696	lysophosphatidic acid acyltransferase (LPAT)	1660:1703	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	4	28	from	acids	1037:1041	arg1	rich					997:1000	rich	997:1000	rich	997:1000	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	7	29	theme	lipids	1512:1517	arg1	component					1499:1507	an important component	1486:1507	an important component of lipids	1486:1517	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	29	theme	lipids	1512:1517	arg1	accumulation					1452:1463	the highest accumulation	1440:1463	the highest accumulation of triacylglycerols	1440:1483	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	4	30	theme	green	968:972	arg1	JL					980:981	JL	980:981	JL	980:981	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	30	theme	green	968:972	arg1	stem					974:977	the pointed-leaved green stem	949:977	the pointed-leaved green stem (JL) germplasm	949:992	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	3	31	theme	different	797:805	arg1	components					833:842	different nutritional and medicinal components	797:842	different nutritional and medicinal components	797:842	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	4	32	from	lipids	941:946	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	32	from	lipids	941:946	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	8	33	theme	acyltransferase	1682:1696	arg1	members					1600:1606	Nineteen, 14, and 13 members	1579:1606	Nineteen, 14, and 13 members	1579:1606	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	0	34	theme	Different	75:83	arg1	Germplasms					85:94	Different Germplasms	75:94	Different Germplasms	75:94	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	4	35	from	steroids	1017:1024	arg1	rich					997:1000	rich	997:1000	rich	997:1000	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	2	36	theme	different	530:538	arg1	germplasms					540:549	different germplasms	530:549	different germplasms	530:549	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	3	37	from	rich	789:792	arg1	components					833:842	different nutritional and medicinal components	797:842	different nutritional and medicinal components	797:842	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	5	38	theme	one-year	1130:1137	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	38	theme	one-year	1130:1137	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	7	39	theme	triacylglycerols	1468:1483	arg1	component					1499:1507	an important component	1486:1507	an important component of lipids	1486:1517	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	39	theme	triacylglycerols	1468:1483	arg1	accumulation					1452:1463	the highest accumulation	1440:1463	the highest accumulation of triacylglycerols	1440:1483	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	2	40	theme	rhizomes	516:523	arg1	composition					482:492	metabolic composition	472:492	metabolic composition	472:492	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	40	theme	rhizomes	516:523	arg1	traits					506:511	quality traits	498:511	quality traits	498:511	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	41	theme	molecular	639:647	arg1	mechanism					649:657	the molecular mechanism	635:657	the molecular mechanism of triacylglycerol synthesis	635:686	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	42	theme	metabolic	472:480	arg1	composition					482:492	metabolic composition	472:492	metabolic composition	472:492	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	8	43	theme	diacylglycerol	1710:1723	arg1	DGAT					1742:1745	DGAT	1742:1745	DGAT	1742:1745	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	8	43	theme	diacylglycerol	1710:1723	arg1	acyltransferase					1725:1739	diacylglycerol acyltransferase	1710:1739	diacylglycerol acyltransferase (DGAT)	1710:1746	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	0	44	from	Traits	34:39	arg1	Germplasms					85:94	Different Germplasms	75:94	Different Germplasms	75:94	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	44	from	Traits	34:39	arg1	Sections					104:111	Age Sections	100:111	Age Sections	100:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	45	theme	Metabolic	0:8	arg1	Composition					10:20	Metabolic Composition	0:20	Metabolic Composition	0:20	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	7	46	theme	AT	1563:1564	arg1	section					1570:1576	the AT age section	1559:1576	the AT age section	1559:1576	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	2	47	theme	medicinal	438:446	arg1	values					448:453	the nutritional and medicinal values	418:453	the nutritional and medicinal values of rhizomes	418:465	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	3	48	from	components	833:842	arg1	germplasms					740:749	the different germplasms	726:749	the different germplasms	726:749	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	3	48	from	components	833:842	arg1	rich					789:792	rich	789:792	rich	789:792	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	2	49	theme	synthesis	678:686	arg1	mechanism					649:657	the molecular mechanism	635:657	the molecular mechanism of triacylglycerol synthesis	635:686	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	50	theme	nutritional	422:432	arg1	values					448:453	the nutritional and medicinal values	418:453	the nutritional and medicinal values of rhizomes	418:465	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	7	51	theme	highest	1444:1450	arg1	component					1499:1507	an important component	1486:1507	an important component of lipids	1486:1517	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	51	theme	highest	1444:1450	arg1	accumulation					1452:1463	the highest accumulation	1440:1463	the highest accumulation of triacylglycerols	1440:1483	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	4	52	from	rich	997:1000	arg1	steroids					1017:1024	steroids	1017:1024	steroids	1017:1024	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	52	from	rich	997:1000	arg1	flavonoids					1005:1014	flavonoids	1005:1014	flavonoids	1005:1014	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	52	from	rich	997:1000	arg1	acids					1037:1041	amino acids	1031:1041	amino acids	1031:1041	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	0	53	theme	Hua	66:68	arg1	Composition					10:20	Metabolic Composition	0:20	Metabolic Composition	0:20	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	53	theme	Hua	66:68	arg1	Traits					34:39	Quality Traits	26:39	Quality Traits	26:39	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	2	54	theme	quality	498:504	arg1	traits					506:511	quality traits	498:511	quality traits	498:511	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	4	55	theme	these	848:852	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	55	theme	these	848:852	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	2	56	theme	cyrtonema	357:365	arg1	germplasm					386:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	0	57	theme	Polygonatum	44:54	arg1	Hua					66:68	Polygonatum cyrtonema Hua	44:68	Polygonatum cyrtonema Hua from Different Germplasms and Age Sections	44:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	4	58	contain	contains	1096:1103	arg1	germplasm					1086:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	58	contain	contains	1096:1103	arg2	acids					1119:1123	more phenolic acids	1105:1123	more phenolic acids	1105:1123	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	2	59	dep	germplasm	386:394	arg1	cyrtonema					375:383	P. cyrtonema	372:383	P. cyrtonema	372:383	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	5	60	theme	amino	1295:1299	arg1	metabolites					1306:1316	amino acid metabolites	1295:1316	amino acid metabolites	1295:1316	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	2	61	theme	superior	336:343	arg1	germplasm					386:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	62	from	germplasms	540:549	arg1	rhizomes					516:523	rhizomes	516:523	rhizomes from different germplasms and age sections of P. cyrtonema	516:582	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	62	from	germplasms	540:549	arg1	composition					482:492	metabolic composition	472:492	metabolic composition	472:492	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	62	from	germplasms	540:549	arg1	traits					506:511	quality traits	498:511	quality traits	498:511	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	6	63	theme	green	1374:1378	arg1	germplasm					1385:1393	the broad-leaved green stem germplasm	1357:1393	the broad-leaved green stem germplasm	1357:1393	Lipids were significantly enriched in the broad-leaved green stem germplasm and the one-year age section.
37047050	4	64	theme	stem	878:881	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	64	theme	stem	878:881	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	65	theme	amino	1031:1035	arg1	acids					1037:1041	amino acids	1031:1041	amino acids	1031:1041	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	8	66	theme	acid	1677:1680	arg1	LPAT					1699:1702	LPAT	1699:1702	LPAT	1699:1702	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	8	66	theme	acid	1677:1680	arg1	acyltransferase					1682:1696	lysophosphatidic acid acyltransferase	1660:1696	lysophosphatidic acid acyltransferase (LPAT)	1660:1703	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	1	67	theme	functional	267:276	arg1	foods					278:282	functional foods	267:282	functional foods	267:282	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	4	68	theme	GK	884:885	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	68	theme	GK	884:885	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	5	69	from	acids	1202:1206	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	69	from	acids	1202:1206	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	9	70	theme	triacylglycerol	2028:2042	arg1	synthesis					2044:2052	triacylglycerol synthesis	2028:2052	triacylglycerol synthesis in P. cyrtonema	2028:2068	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	10	71	theme	Polygonatum	2191:2201	arg1	species					2203:2209	Polygonatum species	2191:2209	Polygonatum species	2191:2209	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	3	72	theme	different	730:738	arg1	rich					789:792	rich	789:792	rich	789:792	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	3	72	theme	different	730:738	arg1	germplasms					740:749	the different germplasms	726:749	the different germplasms	726:749	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	2	73	dep	composition	482:492	arg1	the					468:470	the	468:470	the	468:470	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	7	74	theme	GK	1542:1543	arg1	germplasm					1545:1553	the GK germplasm	1538:1553	the GK germplasm	1538:1553	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	4	75	theme	broad-leaved	859:870	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	75	theme	broad-leaved	859:870	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	76	theme	purple	1069:1074	arg1	germplasm					1086:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	the pointed-leaved purple stem (JZ) germplasm	1050:1094	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	8	77	theme	triacylglycerol	1789:1803	arg1	synthesis					1805:1813	triacylglycerol synthesis	1789:1813	triacylglycerol synthesis	1789:1813	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	2	78	theme	age	555:557	arg1	sections					559:566	age sections	555:566	age sections of P. cyrtonema	555:582	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	0	79	from	Germplasms	85:94	arg1	Hua					66:68	Polygonatum cyrtonema Hua	44:68	Polygonatum cyrtonema Hua from Different Germplasms and Age Sections	44:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	79	from	Germplasms	85:94	arg1	Composition					10:20	Metabolic Composition	0:20	Metabolic Composition	0:20	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	79	from	Germplasms	85:94	arg1	Traits					34:39	Quality Traits	26:39	Quality Traits	26:39	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	80	theme	Metabolomics	138:149	arg1	Analysis					151:158	Widely Targeted Metabolomics Analysis	122:158	Widely Targeted Metabolomics Analysis	122:158	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	4	81	from	alkaloids	926:934	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	81	from	alkaloids	926:934	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	6	82	theme	age	1412:1414	arg1	section					1416:1422	the one-year age section	1399:1422	the one-year age section	1399:1422	Lipids were significantly enriched in the broad-leaved green stem germplasm and the one-year age section.
37047050	1	83	theme	many	217:220	arg1	activities					233:242	many biological activities	217:242	many biological activities	217:242	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	2	84	from	traits	506:511	arg1	germplasms					540:549	different germplasms	530:549	different germplasms	530:549	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	84	from	traits	506:511	arg1	sections					559:566	age sections	555:566	age sections of P. cyrtonema	555:582	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	9	85	theme	quantitative	1841:1852	arg1	PCR					1864:1866	The quantitative real-time PCR	1837:1866	The quantitative real-time PCR (qRT-PCR) results	1837:1884	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	9	85	theme	quantitative	1841:1852	arg1	qRT-PCR					1869:1875	qRT-PCR	1869:1875	qRT-PCR	1869:1875	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	5	86	from	polysaccharides	1167:1181	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	86	from	polysaccharides	1167:1181	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	4	87	from	polysaccharides	909:923	arg1	rich					901:904	rich	901:904	rich	901:904	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	87	from	polysaccharides	909:923	arg1	germplasm					888:896	the broad-leaved green stem (GK) germplasm	855:896	the broad-leaved green stem (GK) germplasm	855:896	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	8	88	theme	acyltransferase	1636:1650	arg1	members					1600:1606	Nineteen, 14, and 13 members	1579:1606	Nineteen, 14, and 13 members	1579:1606	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	2	89	theme	cyrtonema	574:582	arg1	germplasms					540:549	different germplasms	530:549	different germplasms	530:549	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	89	theme	cyrtonema	574:582	arg1	sections					559:566	age sections	555:566	age sections of P. cyrtonema	555:582	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	9	90	theme	PCR	1864:1866	arg1	results					1878:1884	The quantitative real-time PCR (qRT-PCR) results	1837:1884	The quantitative real-time PCR (qRT-PCR) results	1837:1884	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	5	91	from	rich	1159:1162	arg1	polysaccharides					1167:1181	polysaccharides	1167:1181	polysaccharides	1167:1181	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	91	from	rich	1159:1162	arg1	steroids					1184:1191	steroids	1184:1191	steroids	1184:1191	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	91	from	rich	1159:1162	arg1	acids					1202:1206	organic acids	1194:1206	organic acids	1194:1206	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	91	from	rich	1159:1162	arg1	lipids					1213:1218	lipids	1213:1218	lipids	1213:1218	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	4	92	from	rich	901:904	arg1	alkaloids					926:934	alkaloids	926:934	alkaloids	926:934	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	92	from	rich	901:904	arg1	lipids					941:946	lipids	941:946	lipids	941:946	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	92	from	rich	901:904	arg1	polysaccharides					909:923	polysaccharides	909:923	polysaccharides	909:923	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	10	93	theme	theoretical	2108:2118	arg1	reference					2120:2128	a new theoretical reference	2102:2128	a new theoretical reference for product development	2102:2152	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	4	94	theme	phenolic	1110:1117	arg1	acids					1119:1123	more phenolic acids	1105:1123	more phenolic acids	1105:1123	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	3	95	theme	medicinal	823:831	arg1	components					833:842	different nutritional and medicinal components	797:842	different nutritional and medicinal components	797:842	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	7	96	theme	important	1489:1497	arg1	component					1499:1507	an important component	1486:1507	an important component of lipids	1486:1517	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	96	theme	important	1489:1497	arg1	accumulation					1452:1463	the highest accumulation	1440:1463	the highest accumulation of triacylglycerols	1440:1483	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	4	97	theme	pointed-leaved	953:966	arg1	JL					980:981	JL	980:981	JL	980:981	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	4	97	theme	pointed-leaved	953:966	arg1	stem					974:977	the pointed-leaved green stem	949:977	the pointed-leaved green stem (JL) germplasm	949:992	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	3	98	theme	nutritional	807:817	arg1	components					833:842	different nutritional and medicinal components	797:842	different nutritional and medicinal components	797:842	The results showed that the different germplasms and age sections of P. cyrtonema were rich in different nutritional and medicinal components.
37047050	1	99	from	rich	186:189	arg1	compounds					202:210	various compounds	194:210	various compounds with many biological activities	194:242	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	1	100	theme	Polygonatum	161:171	arg1	rhizomes					173:180	Polygonatum rhizomes	161:180	Polygonatum rhizomes	161:180	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	4	101	theme	stem	974:977	arg1	germplasm					984:992	the pointed-leaved green stem (JL) germplasm	949:992	the pointed-leaved green stem (JL) germplasm	949:992	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	0	102	from	Composition	10:20	arg1	Germplasms					85:94	Different Germplasms	75:94	Different Germplasms	75:94	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	0	102	from	Composition	10:20	arg1	Sections					104:111	Age Sections	100:111	Age Sections	100:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	2	103	theme	triacylglycerol	662:676	arg1	synthesis					678:686	triacylglycerol synthesis	662:686	triacylglycerol synthesis	662:686	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	5	104	theme	organic	1194:1200	arg1	acids					1202:1206	organic acids	1194:1206	organic acids	1194:1206	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	0	105	theme	Age	100:102	arg1	Sections					104:111	Age Sections	100:111	Age Sections	100:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	7	106	located	found	1529:1533	arg2	accumulation					1452:1463	the highest accumulation	1440:1463	the highest accumulation of triacylglycerols	1440:1483	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	106	located	found	1529:1533	arg2	component					1499:1507	an important component	1486:1507	an important component of lipids	1486:1517	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	106	located	found	1529:1533	arg1	section					1570:1576	the AT age section	1559:1576	the AT age section	1559:1576	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	7	106	located	found	1529:1533	arg1	germplasm					1545:1553	the GK germplasm	1538:1553	the GK germplasm	1538:1553	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	10	107	theme	new	2104:2106	arg1	reference					2120:2128	a new theoretical reference	2102:2128	a new theoretical reference for product development	2102:2152	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	9	108	theme	expressed	1928:1936	arg1	PcDGAT1					1938:1944	the differentially expressed PcDGAT1	1909:1944	the differentially expressed PcDGAT1	1909:1944	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	5	109	theme	age	1242:1244	arg1	section					1246:1252	the three years (CT) age section	1221:1252	the three years (CT) age section	1221:1252	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	9	110	from	synthesis	2044:2052	arg1	cyrtonema					2060:2068	P. cyrtonema	2057:2068	P. cyrtonema	2057:2068	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	10	111	theme	new	2174:2176	arg1	varieties					2178:2186	new varieties	2174:2186	new varieties of Polygonatum species	2174:2209	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	10	111	theme	new	2174:2176	arg1	species					2203:2209	Polygonatum species	2191:2209	Polygonatum species	2191:2209	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	10	112	theme	product	2134:2140	arg1	development					2142:2152	product development	2134:2152	product development	2134:2152	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	0	113	theme	Quality	26:32	arg1	Traits					34:39	Quality Traits	26:39	Quality Traits	26:39	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	4	114	from	flavonoids	1005:1014	arg1	rich					997:1000	rich	997:1000	rich	997:1000	Of these, the broad-leaved green stem (GK) germplasm is rich in polysaccharides, alkaloids, and lipids; the pointed-leaved green stem (JL) germplasm is rich in flavonoids, steroids, and amino acids, while the pointed-leaved purple stem (JZ) germplasm contains more phenolic acids.
37047050	8	115	theme	acyltransferase	1725:1739	arg1	members					1600:1606	Nineteen, 14, and 13 members	1579:1606	Nineteen, 14, and 13 members	1579:1606	Nineteen, 14, and 13 members of the glycerol-3-phosphate acyltransferase (GPAT), lysophosphatidic acid acyltransferase (LPAT), and diacylglycerol acyltransferase (DGAT) gene families, respectively, involved in triacylglycerol synthesis were also identified.
37047050	7	116	theme	age	1566:1568	arg1	section					1570:1576	the AT age section	1559:1576	the AT age section	1559:1576	Interestingly, the highest accumulation of triacylglycerols, an important component of lipids, was also found in the GK germplasm and the AT age section.
37047050	5	117	theme	years	1231:1235	arg1	section					1246:1252	the three years (CT) age section	1221:1252	the three years (CT) age section	1221:1252	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	118	theme	AT	1140:1141	arg1	section					1148:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section	1126:1154	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	5	118	theme	AT	1140:1141	arg1	rich					1159:1162	rich	1159:1162	rich	1159:1162	The one-year (AT) age section is rich in polysaccharides, steroids, organic acids, and lipids; the three years (CT) age section contains more flavonoids, alkaloids, and amino acid metabolites.
37047050	1	119	with	compounds	202:210	arg1	activities					233:242	many biological activities	217:242	many biological activities	217:242	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	0	120	theme	cyrtonema	56:64	arg1	Hua					66:68	Polygonatum cyrtonema Hua	44:68	Polygonatum cyrtonema Hua from Different Germplasms and Age Sections	44:111	Metabolic Composition and Quality Traits of Polygonatum cyrtonema Hua from Different Germplasms and Age Sections Based on Widely Targeted Metabolomics Analysis.
37047050	1	121	used	used	259:262	arg2	rhizomes					173:180	Polygonatum rhizomes	161:180	Polygonatum rhizomes	161:180	Polygonatum rhizomes are rich in various compounds with many biological activities and are widely used in functional foods and pharmaceutical products.
37047050	2	122	theme	rhizomes	458:465	arg1	values					448:453	the nutritional and medicinal values	418:453	the nutritional and medicinal values of rhizomes	418:465	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	123	theme	Polygonatum	345:355	arg1	germplasm					386:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm	336:394	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	6	124	theme	one-year	1403:1410	arg1	section					1416:1422	the one-year age section	1399:1422	the one-year age section	1399:1422	Lipids were significantly enriched in the broad-leaved green stem germplasm and the one-year age section.
37047050	10	125	theme	varieties	2178:2186	arg1	reference					2120:2128	a new theoretical reference	2102:2128	a new theoretical reference for product development	2102:2152	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	10	125	theme	varieties	2178:2186	arg1	breeding					2162:2169	the breeding	2158:2169	the breeding of new varieties of Polygonatum species	2158:2209	Therefore, this study provides a new theoretical reference for product development and the breeding of new varieties of Polygonatum species.
37047050	9	126	theme	PcLPAT4.3	1984:1992	arg1	genes					1994:1998	PcLPAT4.3 genes	1984:1998	PcLPAT4.3 genes	1984:1998	The quantitative real-time PCR (qRT-PCR) results further suggested that the differentially expressed PcDGAT1, PcDGAT2.4, PcGPAT9.1, PcLPAT2.9, and PcLPAT4.3 genes may play important roles in triacylglycerol synthesis in P. cyrtonema.
37047050	2	127	from	sections	559:566	arg1	rhizomes					516:523	rhizomes	516:523	rhizomes from different germplasms and age sections of P. cyrtonema	516:582	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	127	from	sections	559:566	arg1	composition					482:492	metabolic composition	472:492	metabolic composition	472:492	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	2	127	from	sections	559:566	arg1	traits					506:511	quality traits	498:511	quality traits	498:511	In order to screen for superior Polygonatum cyrtonema Hua (P. cyrtonema) germplasm and also to elucidate the nutritional and medicinal values of rhizomes, the metabolic composition and quality traits of rhizomes from different germplasms and age sections of P. cyrtonema were analysed by widely targeted metabolomics, and the molecular mechanism of triacylglycerol synthesis was explored.
37047050	6	128	theme	stem	1380:1383	arg1	germplasm					1385:1393	the broad-leaved green stem germplasm	1357:1393	the broad-leaved green stem germplasm	1357:1393	Lipids were significantly enriched in the broad-leaved green stem germplasm and the one-year age section.
35780917	5	0	from	10-100 μg/mL	958:969	arg1	toxicity					946:953	no toxicity	943:953	no toxicity at 10-100 μg/mL	943:969	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	6	1	theme	Akt1	1025:1028	arg1	phosphorylation					1006:1020	the phosphorylation	1002:1020	the phosphorylation of Akt1 and down-regulated GSK3β	1002:1053	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	4	2	theme	methylation	560:570	arg1	analysis					572:579	methylation analysis	560:579	methylation analysis	560:579	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	2	theme	methylation	560:570	arg1	oxidation					603:611	periodate oxidation	593:611	periodate oxidation	593:611	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	2	theme	methylation	560:570	arg1	FTIR					582:585	FTIR	582:585	FTIR	582:585	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	2	theme	methylation	560:570	arg1	NMR					588:590	NMR	588:590	NMR	588:590	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	2	theme	methylation	560:570	arg1	degradation					620:630	Smith degradation	614:630	Smith degradation	614:630	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	2	theme	methylation	560:570	arg1	ESI-MS					636:641	ESI-MS	636:641	ESI-MS	636:641	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	0	3	theme	sea	76:78	arg1	cucumber					80:87	sea cucumber	76:87	sea cucumber	76:87	Structure and hypoglycemic effect of a neutral polysaccharide isolated from sea cucumber Stichopus japonicus.
35780917	2	4	theme	sea	324:326	arg1	cucumber					328:335	sea cucumber	324:335	sea cucumber	324:335	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	4	5	theme	β-d-glucose	698:708	arg1	branches					714:721	β-d-glucose(1→) branches	698:721	β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses	698:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	6	theme	1→	710:711	arg1	branches					714:721	β-d-glucose(1→) branches	698:721	β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses	698:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	2	7	theme	hyperglycemic	261:273	arg1	activity					275:282	hyperglycemic activity	261:282	hyperglycemic activity	261:282	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	4	8	theme	1 → 4	673:677	arg1	-α-d-glucoses					679:691	(1 → 4)-α-d-glucoses	672:691	(1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses	672:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	5	9	theme	in	779:780	arg1	resistance					796:805	An in vitro insulin resistance	776:805	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	4	10	theme	periodate	593:601	arg1	analysis					572:579	methylation analysis	560:579	methylation analysis	560:579	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	10	theme	periodate	593:601	arg1	oxidation					603:611	periodate oxidation	593:611	periodate oxidation	593:611	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	5	11	theme	significant	887:897	arg1	effect					899:904	significant effect	887:904	significant effect	887:904	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	12	theme	Hep	807:809	arg1	cells					814:818	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	12	theme	Hep	807:809	arg1	model					846:850	a 3 T3-L1 cells model	830:850	a 3 T3-L1 cells model	830:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	12	theme	Hep	807:809	arg1	model					820:824	model	820:824	model	820:824	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	13	theme	insulin	788:794	arg1	resistance					796:805	An in vitro insulin resistance	776:805	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	4	14	theme	analysis	572:579	arg1	analysis					548:555	the analysis	544:555	the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses	544:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	2	15	from	cucumber	328:335	arg1	structure					247:255	structure	247:255	structure	247:255	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	15	from	cucumber	328:335	arg1	activity					275:282	hyperglycemic activity	261:282	hyperglycemic activity	261:282	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	15	from	cucumber	328:335	arg1	NPsj					313:316	NPsj	313:316	NPsj	313:316	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	15	from	cucumber	328:335	arg1	polysaccharide					297:310	a neutral polysaccharide	287:310	a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus	287:355	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	6	16	theme	GS	1096:1097	arg1	phosphorylation					1077:1091	the phosphorylation	1073:1091	the phosphorylation of GS	1073:1097	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	5	17	contain	has	883:885	arg2	effect					899:904	significant effect	887:904	significant effect	887:904	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	17	contain	has	883:885	arg1	NPsj					878:881	the NPsj	874:881	the NPsj	874:881	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	2	18	theme	molecular	364:372	arg1	weight					374:379	weight	374:379	weight	374:379	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	18	theme	molecular	364:372	arg1	301.75 kDa					399:408	301.75 kDa	399:408	301.75 kDa	399:408	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	19	theme	polysaccharide	297:310	arg1	structure					247:255	structure	247:255	structure	247:255	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	19	theme	polysaccharide	297:310	arg1	activity					275:282	hyperglycemic activity	261:282	hyperglycemic activity	261:282	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	4	20	dep	O-6	738:740	arg1	7-9					748:750	7-9	748:750	7-9	748:750	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	2	21	theme	neutral	289:295	arg1	NPsj					313:316	NPsj	313:316	NPsj	313:316	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	2	21	theme	neutral	289:295	arg1	polysaccharide					297:310	a neutral polysaccharide	287:310	a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus	287:355	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	5	22	theme	G2	811:812	arg1	cells					814:818	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	22	theme	G2	811:812	arg1	model					846:850	a 3 T3-L1 cells model	830:850	a 3 T3-L1 cells model	830:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	22	theme	G2	811:812	arg1	model					820:824	model	820:824	model	820:824	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	2	23	theme	HPGPC	413:417	arg1	method					419:424	HPGPC method	413:424	HPGPC method	413:424	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	5	24	dep	cells	814:818	arg1	cells					814:818	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	24	dep	cells	814:818	arg1	model					846:850	a 3 T3-L1 cells model	830:850	a 3 T3-L1 cells model	830:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	24	dep	cells	814:818	arg1	model					820:824	model	820:824	model	820:824	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	6	25	theme	signaling	1177:1185	arg1	pathway					1187:1193	Akt/GSK3β/GS signaling pathway	1164:1193	Akt/GSK3β/GS signaling pathway	1164:1193	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	0	26	theme	hypoglycemic	14:25	arg1	effect					27:32	hypoglycemic effect	14:32	hypoglycemic effect	14:32	Structure and hypoglycemic effect of a neutral polysaccharide isolated from sea cucumber Stichopus japonicus.
35780917	1	27	theme	sea	152:154	arg1	cucumber					156:163	sea cucumber	152:163	sea cucumber	152:163	In addition to its high nutritious value, sea cucumber has been recognized by folk medicine for a long time.
35780917	1	28	theme	folk	188:191	arg1	medicine					193:200	folk medicine	188:200	folk medicine	188:200	In addition to its high nutritious value, sea cucumber has been recognized by folk medicine for a long time.
35780917	4	29	theme	Smith	614:618	arg1	analysis					572:579	methylation analysis	560:579	methylation analysis	560:579	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	29	theme	Smith	614:618	arg1	degradation					620:630	Smith degradation	614:630	Smith degradation	614:630	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	4	30	theme	1,4	755:757	arg1	glucoses					766:773	1,4 linked glucoses	755:773	1,4 linked glucoses	755:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	3	31	theme	Monosaccharide	427:440	arg1	analysis					454:461	Monosaccharide composition analysis	427:461	Monosaccharide composition analysis	427:461	Monosaccharide composition analysis indicated that NPsj is a glucan.
35780917	4	32	theme	NPsj	513:516	arg1	structure					500:508	The structure	496:508	The structure of NPsj	496:516	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	6	33	theme	Akt/GSK3β/GS	1164:1175	arg1	pathway					1187:1193	Akt/GSK3β/GS signaling pathway	1164:1193	Akt/GSK3β/GS signaling pathway	1164:1193	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	3	34	theme	composition	442:452	arg1	analysis					454:461	Monosaccharide composition analysis	427:461	Monosaccharide composition analysis	427:461	Monosaccharide composition analysis indicated that NPsj is a glucan.
35780917	0	35	theme	polysaccharide	47:60	arg1	Structure					0:8	Structure	0:8	Structure	0:8	Structure and hypoglycemic effect of a neutral polysaccharide isolated from sea cucumber Stichopus japonicus.
35780917	0	35	theme	polysaccharide	47:60	arg1	effect					27:32	hypoglycemic effect	14:32	hypoglycemic effect	14:32	Structure and hypoglycemic effect of a neutral polysaccharide isolated from sea cucumber Stichopus japonicus.
35780917	4	36	theme	glucoses	766:773	arg1	O-6					738:740	O-6 every 7-9	738:750	O-6 every 7-9 of 1,4 linked glucoses	738:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	6	37	theme	down-regulated	1034:1047	arg1	GSK3β					1049:1053	down-regulated GSK3β	1034:1053	down-regulated GSK3β	1034:1053	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	5	38	theme	3 T3-L1	832:838	arg1	cells					814:818	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	38	theme	3 T3-L1	832:838	arg1	model					846:850	a 3 T3-L1 cells model	830:850	a 3 T3-L1 cells model	830:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	0	39	theme	neutral	39:45	arg1	polysaccharide					47:60	a neutral polysaccharide	37:60	a neutral polysaccharide	37:60	Structure and hypoglycemic effect of a neutral polysaccharide isolated from sea cucumber Stichopus japonicus.
35780917	4	40	theme	linked	759:764	arg1	glucoses					766:773	1,4 linked glucoses	755:773	1,4 linked glucoses	755:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	5	41	theme	cells	840:844	arg1	cells					814:818	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	41	theme	cells	840:844	arg1	model					846:850	a 3 T3-L1 cells model	830:850	a 3 T3-L1 cells model	830:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	4	42	with	-α-d-glucoses	679:691	arg1	branches					714:721	β-d-glucose(1→) branches	698:721	β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses	698:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	6	43	theme	insulin	1141:1147	arg1	resistance					1149:1158	insulin resistance	1141:1158	insulin resistance	1141:1158	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	5	44	dep	in	779:780	arg1	vitro					782:786	vitro	782:786	vitro	782:786	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	2	45	from	structure	247:255	arg1	cucumber					328:335	sea cucumber	324:335	sea cucumber	324:335	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	1	46	theme	high	129:132	arg1	value					145:149	its high nutritious value	125:149	its high nutritious value	125:149	In addition to its high nutritious value, sea cucumber has been recognized by folk medicine for a long time.
35780917	2	47	from	activity	275:282	arg1	cucumber					328:335	sea cucumber	324:335	sea cucumber	324:335	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
35780917	1	48	theme	long	208:211	arg1	time					213:216	a long time	206:216	a long time	206:216	In addition to its high nutritious value, sea cucumber has been recognized by folk medicine for a long time.
35780917	5	49	theme	glucose	918:924	arg1	consumption					926:936	glucose consumption	918:936	glucose consumption	918:936	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	1	50	theme	nutritious	134:143	arg1	value					145:149	its high nutritious value	125:149	its high nutritious value	125:149	In addition to its high nutritious value, sea cucumber has been recognized by folk medicine for a long time.
35780917	4	51	link	linked	759:764	arg1	glucoses					766:773	1,4 linked glucoses	755:773	1,4 linked glucoses	755:773	The structure of NPsj was obtained by combining the analysis of methylation analysis, FTIR, NMR, periodate oxidation, Smith degradation and ESI-MS, which is mainly composed of (1 → 4)-α-d-glucoses with β-d-glucose(1→) branches substituted at O-6 every 7-9 of 1,4 linked glucoses.
35780917	6	52	theme	GSK3β	1049:1053	arg1	phosphorylation					1006:1020	the phosphorylation	1002:1020	the phosphorylation of Akt1 and down-regulated GSK3β	1002:1053	Furthermore, NPsj upregulates the phosphorylation of Akt1 and down-regulated GSK3β, and then reduces the phosphorylation of GS, indicating its mechanism of ameliorating insulin resistance via Akt/GSK3β/GS signaling pathway.
35780917	5	53	theme	resistance	796:805	arg1	cells					814:818	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model	776:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	53	theme	resistance	796:805	arg1	model					846:850	a 3 T3-L1 cells model	830:850	a 3 T3-L1 cells model	830:850	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	5	53	theme	resistance	796:805	arg1	model					820:824	model	820:824	model	820:824	An in vitro insulin resistance Hep G2 cells model and a 3 T3-L1 cells model were established, and the NPsj has significant effect to increase glucose consumption with no toxicity at 10-100 μg/mL.
35780917	2	54	dep	structure	247:255	arg1	the					243:245	the	243:245	the	243:245	This study investigated the structure and hyperglycemic activity of a neutral polysaccharide (NPsj) from sea cucumber Stichopus japonicus, whose molecular weight was determined as 301.75 kDa by HPGPC method.
36535347	5	0	theme	high	807:810	arg1	content					812:818	a relatively high content	794:818	a relatively high content of uronic acids (11.27 %)	794:844	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	1	1	theme	abundant	198:205	arg1	polysaccharides					217:231	abundant bioactive polysaccharides	198:231	abundant bioactive polysaccharides	198:231	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	9	2	theme	SRP	1355:1357	arg1	treatment					1359:1367	the SRP treatment	1351:1367	the SRP treatment	1351:1367	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	0	3	theme	hypoglycemic	96:107	arg1	activities					130:139	its hypoglycemic and immunomodulatory activities	92:139	its hypoglycemic and immunomodulatory activities	92:139	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis root polysaccharide and its hypoglycemic and immunomodulatory activities.
36535347	5	4	theme	uronic	823:828	arg1	acids					830:834	uronic acids	823:834	uronic acids (11.27 %)	823:844	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	5	4	theme	uronic	823:828	arg1	%					843:843	11.27 %	837:843	11.27 %	837:843	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	1	5	theme	bioactive	207:215	arg1	polysaccharides					217:231	abundant bioactive polysaccharides	198:231	abundant bioactive polysaccharides	198:231	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	9	6	theme	dendritic	1191:1199	arg1	activation					1206:1215	the dendritic cell activation	1187:1215	the dendritic cell activation	1187:1215	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	0	7	theme	immunomodulatory	113:128	arg1	activities					130:139	its hypoglycemic and immunomodulatory activities	92:139	its hypoglycemic and immunomodulatory activities	92:139	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis root polysaccharide and its hypoglycemic and immunomodulatory activities.
36535347	9	8	theme	MHC	1258:1260	arg1	CD86					1272:1275	CD86	1272:1275	CD86	1272:1275	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	9	8	theme	MHC	1258:1260	arg1	CD40					1282:1285	CD40	1282:1285	CD40	1282:1285	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	9	8	theme	MHC	1258:1260	arg1	CD80					1266:1269	CD80	1266:1269	CD80	1266:1269	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	9	8	theme	MHC	1258:1260	arg1	expressions					1243:1253	the expressions	1239:1253	the expressions of MHC II	1239:1263	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	9	9	theme	cell	1201:1204	arg1	activation					1206:1215	the dendritic cell activation	1187:1215	the dendritic cell activation	1187:1215	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	6	10	contain	had	855:857	arg2	weight					871:876	a molecular weight	859:876	a molecular weight of 89.7 kDa	859:888	The SRP had a molecular weight of 89.7 kDa and was composed of eight monosaccharides.
36535347	6	10	contain	had	855:857	arg1	SRP					851:853	The SRP	847:853	The SRP	847:853	The SRP had a molecular weight of 89.7 kDa and was composed of eight monosaccharides.
36535347	1	11	theme	medicinal	171:179	arg1	baicalensis					154:164	Scutellaria baicalensis	142:164	Scutellaria baicalensis	142:164	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	1	11	theme	medicinal	171:179	arg1	plant					181:185	a medicinal plant	169:185	a medicinal plant possessing abundant bioactive polysaccharides	169:231	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	3	12	theme	optimal	422:428	arg1	conditions					441:450	The optimal extraction conditions	418:450	The optimal extraction conditions found in this study	418:470	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	4	13	theme	filtration	680:689	arg1	chromatographies					691:706	The ion exchange and gel filtration chromatographies	655:706	The ion exchange and gel filtration chromatographies	655:706	The ion exchange and gel filtration chromatographies were used to obtain a purified SRP.
36535347	4	14	theme	purified	730:737	arg1	SRP					739:741	a purified SRP	728:741	a purified SRP	728:741	The ion exchange and gel filtration chromatographies were used to obtain a purified SRP.
36535347	3	15	dep	12.27 	646:651	arg1	to					643:644	to	643:644	to	643:644	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	3	16	theme	extraction	430:439	arg1	conditions					441:450	The optimal extraction conditions	418:450	The optimal extraction conditions found in this study	418:470	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	1	17	contain	possessing	187:196	arg2	polysaccharides					217:231	abundant bioactive polysaccharides	198:231	abundant bioactive polysaccharides	198:231	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	1	17	contain	possessing	187:196	arg1	baicalensis					154:164	Scutellaria baicalensis	142:164	Scutellaria baicalensis	142:164	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	1	17	contain	possessing	187:196	arg1	plant					181:185	a medicinal plant	169:185	a medicinal plant possessing abundant bioactive polysaccharides	169:231	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	3	18	dep	follows	480:486	arg1	44.8 mL/g					565:573	liquid-solid ratio 44.8 mL/g	546:573	liquid-solid ratio 44.8 mL/g	546:573	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	3	18	dep	follows	480:486	arg1	50 min					581:586	time 50 min	576:586	time 50 min	576:586	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	3	18	dep	follows	480:486	arg1	225 W					610:614	ultrasonic power 225 W	593:614	ultrasonic power 225 W	593:614	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	3	18	dep	follows	480:486	arg1	57.3 °C					537:543	temperature 57.3 °C	525:543	temperature 57.3 °C	525:543	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	3	18	dep	follows	480:486	arg1	165.6 U/mL					513:522	cellulase concentration 165.6 U/mL	489:522	cellulase concentration 165.6 U/mL	489:522	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	10	19	theme	efficient	1416:1424	arg1	extraction					1426:1435	SRP's efficient extraction	1410:1435	SRP's efficient extraction	1410:1435	This work will provide a foundation for SRP's efficient extraction and utilization for diabetes and immune therapy.
36535347	3	20	theme	temperature	525:535	arg1	57.3 °C					537:543	temperature 57.3 °C	525:543	temperature 57.3 °C	525:543	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	0	21	theme	enzymatic	20:28	arg1	extraction					30:39	Ultrasound-assisted enzymatic extraction	0:39	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis	0:66	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis root polysaccharide and its hypoglycemic and immunomodulatory activities.
36535347	8	22	theme	IC50	1090:1093	arg1	values					1095:1100	IC50 values	1090:1100	IC50 values	1090:1100	It was revealed that SRP could effectively inhibit these two enzymes with IC50 values of 1.23 and 0.63 mg/mL, respectively.
36535347	7	23	theme	SRP	960:962	arg1	activity					948:955	The inhibitory activity	933:955	The inhibitory activity of SRP against α-amylase and α-glucosidase	933:998	The inhibitory activity of SRP against α-amylase and α-glucosidase was determined.
36535347	3	24	theme	concentration	499:511	arg1	165.6 U/mL					513:522	cellulase concentration 165.6 U/mL	489:522	cellulase concentration 165.6 U/mL	489:522	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	0	25	theme	Ultrasound-assisted	0:18	arg1	extraction					30:39	Ultrasound-assisted enzymatic extraction	0:39	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis	0:66	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis root polysaccharide and its hypoglycemic and immunomodulatory activities.
36535347	7	26	theme	inhibitory	937:946	arg1	activity					948:955	The inhibitory activity	933:955	The inhibitory activity of SRP against α-amylase and α-glucosidase	933:998	The inhibitory activity of SRP against α-amylase and α-glucosidase was determined.
36535347	2	27	theme	hypoglycemic	372:383	arg1	activities					406:415	its hypoglycemic and immunomodulatory activities	368:415	its hypoglycemic and immunomodulatory activities	368:415	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	5	28	with	%	786:786	arg1	content					812:818	a relatively high content	794:818	a relatively high content of uronic acids (11.27 %)	794:844	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	3	29	theme	liquid-solid	546:557	arg1	44.8 mL/g					565:573	liquid-solid ratio 44.8 mL/g	546:573	liquid-solid ratio 44.8 mL/g	546:573	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	6	30	theme	89.7 kDa	881:888	arg1	weight					871:876	a molecular weight	859:876	a molecular weight of 89.7 kDa	859:888	The SRP had a molecular weight of 89.7 kDa and was composed of eight monosaccharides.
36535347	1	31	theme	Scutellaria	142:152	arg1	baicalensis					154:164	Scutellaria baicalensis	142:164	Scutellaria baicalensis	142:164	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	1	31	theme	Scutellaria	142:152	arg1	plant					181:185	a medicinal plant	169:185	a medicinal plant possessing abundant bioactive polysaccharides	169:231	Scutellaria baicalensis is a medicinal plant possessing abundant bioactive polysaccharides.
36535347	3	32	theme	ratio	559:563	arg1	44.8 mL/g					565:573	liquid-solid ratio 44.8 mL/g	546:573	liquid-solid ratio 44.8 mL/g	546:573	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	0	33	theme	baicalensis	56:66	arg1	extraction					30:39	Ultrasound-assisted enzymatic extraction	0:39	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis	0:66	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis root polysaccharide and its hypoglycemic and immunomodulatory activities.
36535347	9	34	from	effect	1170:1175	arg1	activation					1206:1215	the dendritic cell activation	1187:1215	the dendritic cell activation	1187:1215	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	5	35	theme	SRP	772:774	arg1	%					786:786	85.09 %	780:786	85.09 %	780:786	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	5	35	theme	SRP	772:774	arg1	content					761:767	The carbohydrate content	744:767	The carbohydrate content of SRP	744:774	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	0	36	theme	Scutellaria	44:54	arg1	baicalensis					56:66	Scutellaria baicalensis	44:66	Scutellaria baicalensis	44:66	Ultrasound-assisted enzymatic extraction of Scutellaria baicalensis root polysaccharide and its hypoglycemic and immunomodulatory activities.
36535347	3	37	theme	cellulase	489:497	arg1	165.6 U/mL					513:522	cellulase concentration 165.6 U/mL	489:522	cellulase concentration 165.6 U/mL	489:522	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	5	38	theme	acids	830:834	arg1	content					812:818	a relatively high content	794:818	a relatively high content of uronic acids (11.27 %)	794:844	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	10	39	theme	immune	1470:1475	arg1	therapy					1477:1483	immune therapy	1470:1483	immune therapy	1470:1483	This work will provide a foundation for SRP's efficient extraction and utilization for diabetes and immune therapy.
36535347	6	40	theme	molecular	861:869	arg1	weight					871:876	a molecular weight	859:876	a molecular weight of 89.7 kDa	859:888	The SRP had a molecular weight of 89.7 kDa and was composed of eight monosaccharides.
36535347	2	41	theme	enzymatic	287:295	arg1	extraction					297:306	the ultrasound-assisted enzymatic extraction	263:306	the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP)	263:350	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	3	42	theme	time	576:579	arg1	50 min					581:586	time 50 min	576:586	time 50 min	576:586	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	8	43	theme	1.23	1105:1108	arg1	values					1095:1100	IC50 values	1090:1100	IC50 values	1090:1100	It was revealed that SRP could effectively inhibit these two enzymes with IC50 values of 1.23 and 0.63 mg/mL, respectively.
36535347	8	44	theme	0.63 mg/mL	1114:1123	arg1	values					1095:1100	IC50 values	1090:1100	IC50 values	1090:1100	It was revealed that SRP could effectively inhibit these two enzymes with IC50 values of 1.23 and 0.63 mg/mL, respectively.
36535347	2	45	theme	ultrasound-assisted	267:285	arg1	extraction					297:306	the ultrasound-assisted enzymatic extraction	263:306	the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP)	263:350	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	2	46	theme	polysaccharide	331:344	arg1	extraction					297:306	the ultrasound-assisted enzymatic extraction	263:306	the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP)	263:350	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	9	47	theme	immunomodulatory	1153:1168	arg1	effect					1170:1175	the immunomodulatory effect	1149:1175	the immunomodulatory effect of SRP on the dendritic cell activation	1149:1215	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	4	48	theme	exchange	663:670	arg1	chromatographies					691:706	The ion exchange and gel filtration chromatographies	655:706	The ion exchange and gel filtration chromatographies	655:706	The ion exchange and gel filtration chromatographies were used to obtain a purified SRP.
36535347	5	49	theme	carbohydrate	748:759	arg1	%					786:786	85.09 %	780:786	85.09 %	780:786	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	5	49	theme	carbohydrate	748:759	arg1	content					761:767	The carbohydrate content	744:767	The carbohydrate content of SRP	744:774	The carbohydrate content of SRP was 85.09 %, with a relatively high content of uronic acids (11.27 %).
36535347	2	50	theme	root	326:329	arg1	SRP					347:349	SRP	347:349	SRP	347:349	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	2	50	theme	root	326:329	arg1	polysaccharide					331:344	S. baicalensis root polysaccharide	311:344	S. baicalensis root polysaccharide (SRP)	311:350	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	2	51	theme	immunomodulatory	389:404	arg1	activities					406:415	its hypoglycemic and immunomodulatory activities	368:415	its hypoglycemic and immunomodulatory activities	368:415	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	4	52	theme	ion	659:661	arg1	exchange					663:670	ion exchange	659:670	ion exchange	659:670	The ion exchange and gel filtration chromatographies were used to obtain a purified SRP.
36535347	2	53	theme	baicalensis	314:324	arg1	SRP					347:349	SRP	347:349	SRP	347:349	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	2	53	theme	baicalensis	314:324	arg1	polysaccharide					331:344	S. baicalensis root polysaccharide	311:344	S. baicalensis root polysaccharide (SRP)	311:350	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	4	54	used	used	713:716	arg2	chromatographies					691:706	The ion exchange and gel filtration chromatographies	655:706	The ion exchange and gel filtration chromatographies	655:706	The ion exchange and gel filtration chromatographies were used to obtain a purified SRP.
36535347	3	55	theme	ultrasonic	593:602	arg1	225 W					610:614	ultrasonic power 225 W	593:614	ultrasonic power 225 W	593:614	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	4	56	theme	gel	676:678	arg1	filtration					680:689	gel filtration	676:689	gel filtration	676:689	The ion exchange and gel filtration chromatographies were used to obtain a purified SRP.
36535347	3	57	located	found	452:456	arg1	study					466:470	this study	461:470	this study	461:470	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	3	57	located	found	452:456	arg2	conditions					441:450	The optimal extraction conditions	418:450	The optimal extraction conditions found in this study	418:470	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
36535347	2	58	theme	S.	311:312	arg1	SRP					347:349	SRP	347:349	SRP	347:349	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	2	58	theme	S.	311:312	arg1	polysaccharide					331:344	S. baicalensis root polysaccharide	311:344	S. baicalensis root polysaccharide (SRP)	311:350	This study aimed to optimize the ultrasound-assisted enzymatic extraction of S. baicalensis root polysaccharide (SRP) and investigate its hypoglycemic and immunomodulatory activities.
36535347	9	59	theme	SRP	1180:1182	arg1	effect					1170:1175	the immunomodulatory effect	1149:1175	the immunomodulatory effect of SRP on the dendritic cell activation	1149:1215	Finally, the immunomodulatory effect of SRP on the dendritic cell activation was investigated, and the expressions of MHC II, CD80, CD86, and CD40 increased by 1.56, 1.96, 1.75, and 1.70 times, respectively, by the SRP treatment.
36535347	3	60	theme	power	604:608	arg1	225 W					610:614	ultrasonic power 225 W	593:614	ultrasonic power 225 W	593:614	The optimal extraction conditions found in this study were as follows: cellulase concentration 165.6 U/mL, temperature 57.3 °C, liquid-solid ratio 44.8 mL/g, time 50 min, and ultrasonic power 225 W; with the yield reached up to 12.27 %.
35045151	4	0	theme	nitric	882:887	arg1	oxide					889:893	nitric oxide	882:893	nitric oxide	882:893	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	5	1	theme	p65	1123:1125	arg1	proteins					1128:1135	phospho-p65 (p65) proteins	1110:1135	phospho-p65 (p65) proteins	1110:1135	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	1	2	theme	monosaccharide	165:178	arg1	compositions					180:191	monosaccharide compositions	165:191	monosaccharide compositions	165:191	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	5	3	theme	Toll-like	1196:1204	arg1	receptor					1206:1213	Toll-like receptor 4	1196:1215	Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities	1196:1288	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	3	theme	Toll-like	1196:1204	arg1	TLR4					1218:1221	TLR4	1218:1221	TLR4	1218:1221	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	0	4	theme	exopolysaccharides	84:101	arg1	activity					63:70	immunomodulatory activity	46:70	immunomodulatory activity	46:70	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	0	4	theme	exopolysaccharides	84:101	arg1	yield					25:29	yield	25:29	yield	25:29	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	0	4	theme	exopolysaccharides	84:101	arg1	structure					32:40	structure	32:40	structure	32:40	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	0	5	from	Role	0:3	arg1	activity					63:70	immunomodulatory activity	46:70	immunomodulatory activity	46:70	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	0	5	from	Role	0:3	arg1	yield					25:29	yield	25:29	yield	25:29	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	0	5	from	Role	0:3	arg1	structure					32:40	structure	32:40	structure	32:40	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	4	6	theme	macrophages	839:849	arg1	activity					818:825	the immunomodulatory activity	797:825	the immunomodulatory activity of RAW264.7 macrophages	797:849	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	5	7	theme	regulated	981:989	arg1	p-ERK					1007:1011	p-ERK	1007:1011	p-ERK	1007:1011	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	7	theme	regulated	981:989	arg1	kinase					999:1004	phospho-extracellular regulated protein kinase	959:1004	phospho-extracellular regulated protein kinase (p-ERK)	959:1012	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	8	theme	pinocytic	1254:1262	arg1	capacities					1279:1288	the pinocytic and phagocytic capacities	1250:1288	the pinocytic and phagocytic capacities	1250:1288	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	0	9	theme	Monascus	75:82	arg1	exopolysaccharides					84:101	Monascus exopolysaccharides	75:101	Monascus exopolysaccharides	75:101	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	4	10	theme	M.	767:768	arg1	purpureus					770:778	genistein-treated M. purpureus	749:778	genistein-treated M. purpureus (G-EMP)	749:786	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	4	10	theme	M.	767:768	arg1	G-EMP					781:785	G-EMP	781:785	G-EMP	781:785	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	3	11	theme	M.	574:575	arg1	biomass					587:593	M. purpureus biomass and EPS yield	574:607	biomass	587:593	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	1	12	theme	physicochemical	133:147	arg1	properties					149:158	physicochemical properties	133:158	physicochemical properties	133:158	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	1	13	theme	biological	285:294	arg1	activities					296:305	their biological activities	279:305	their biological activities	279:305	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	3	14	theme	EPS	715:717	arg1	structures					701:710	structures	701:710	structures	701:710	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	3	14	theme	EPS	715:717	arg1	properties					686:695	the physicochemical properties	666:695	the physicochemical properties	666:695	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	2	15	from	effects	355:361	arg1	amount					412:417	amount	412:417	amount	412:417	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	15	from	effects	355:361	arg1	properties					436:445	physicochemical properties	420:445	physicochemical properties	420:445	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	15	from	effects	355:361	arg1	EPS					481:483	EPS	481:483	EPS secreted by M. purpureus	481:508	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	15	from	effects	355:361	arg1	activity					469:476	immunomodulatory activity	452:476	immunomodulatory activity	452:476	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	16	theme	immunomodulatory	452:467	arg1	activity					469:476	immunomodulatory activity	452:476	immunomodulatory activity	452:476	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	6	17	theme	EPS	1394:1396	arg1	yield					1398:1402	the EPS yield	1390:1402	the EPS yield of M. purpureus	1390:1418	Overall, these findings provide potential rationales for the application of genistein in improving the EPS yield of M. purpureus.
35045151	1	18	theme	exopolysaccharides	196:213	arg1	compositions					180:191	monosaccharide compositions	165:191	monosaccharide compositions	165:191	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	1	18	theme	exopolysaccharides	196:213	arg1	structures					121:130	the structures	117:130	the structures	117:130	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	1	18	theme	exopolysaccharides	196:213	arg1	properties					149:158	physicochemical properties	133:158	physicochemical properties	133:158	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	3	19	theme	EPS	599:601	arg1	yield					603:607	M. purpureus biomass and EPS yield	574:607	yield	603:607	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	2	20	theme	addition	376:383	arg1	effects					355:361	the effects	351:361	the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus	351:508	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	5	21	theme	G-EMP	1168:1172	arg1	stimulation					1174:1184	G-EMP stimulation	1168:1184	G-EMP stimulation	1168:1184	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	22	theme	mitogen-activated	1035:1051	arg1	MAPK					1069:1072	MAPK	1069:1072	MAPK	1069:1072	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	22	theme	mitogen-activated	1035:1051	arg1	kinase					1061:1066	phospho-p38 (p-p38) mitogen-activated protein kinase	1015:1066	phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK)	1015:1073	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	3	23	theme	purpureus	577:585	arg1	biomass					587:593	M. purpureus biomass and EPS yield	574:607	biomass	587:593	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	2	24	theme	physicochemical	420:434	arg1	properties					436:445	physicochemical properties	420:445	physicochemical properties	420:445	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	0	25	theme	genistein	8:16	arg1	Role					0:3	Role	0:3	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.	0:102	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	5	26	theme	phospho-extracellular	959:979	arg1	p-ERK					1007:1011	p-ERK	1007:1011	p-ERK	1007:1011	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	26	theme	phospho-extracellular	959:979	arg1	kinase					999:1004	phospho-extracellular regulated protein kinase	959:1004	phospho-extracellular regulated protein kinase (p-ERK)	959:1012	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	27	theme	protein	991:997	arg1	p-ERK					1007:1011	p-ERK	1007:1011	p-ERK	1007:1011	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	27	theme	protein	991:997	arg1	kinase					999:1004	phospho-extracellular regulated protein kinase	959:1004	phospho-extracellular regulated protein kinase (p-ERK)	959:1012	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	6	28	theme	purpureus	1410:1418	arg1	yield					1398:1402	the EPS yield	1390:1402	the EPS yield of M. purpureus	1390:1418	Overall, these findings provide potential rationales for the application of genistein in improving the EPS yield of M. purpureus.
35045151	6	29	theme	potential	1323:1331	arg1	rationales					1333:1342	potential rationales	1323:1342	potential rationales for the application of genistein in improving the EPS yield of M. purpureus	1323:1418	Overall, these findings provide potential rationales for the application of genistein in improving the EPS yield of M. purpureus.
35045151	2	30	dep	amount	412:417	arg1	the					408:410	the	408:410	the	408:410	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	3	31	dep	g	617:617	arg1	L-1					619:621	L-1	619:621	2.42 g L-1	612:621	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	2	32	theme	EPS	481:483	arg1	amount					412:417	amount	412:417	amount	412:417	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	32	theme	EPS	481:483	arg1	properties					436:445	physicochemical properties	420:445	physicochemical properties	420:445	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	32	theme	EPS	481:483	arg1	EPS					481:483	EPS	481:483	EPS secreted by M. purpureus	481:508	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	2	32	theme	EPS	481:483	arg1	activity					469:476	immunomodulatory activity	452:476	immunomodulatory activity	452:476	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	5	33	theme	nuclear	1079:1085	arg1	NF-κB					1103:1107	NF-κB	1103:1107	NF-κB	1103:1107	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	33	theme	nuclear	1079:1085	arg1	B					1100:1100	nuclear factor-kappa B	1079:1100	nuclear factor-kappa B (NF-κB)	1079:1108	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	3	34	dep	g	632:632	arg1	L-1					634:636	L-1	634:636	6.08 g L-1	627:636	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	6	35	theme	genistein	1367:1375	arg1	application					1352:1362	the application	1348:1362	the application of genistein in improving the EPS yield of M. purpureus	1348:1418	Overall, these findings provide potential rationales for the application of genistein in improving the EPS yield of M. purpureus.
35045151	5	36	theme	factor-kappa	1087:1098	arg1	NF-κB					1103:1107	NF-κB	1103:1107	NF-κB	1103:1107	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	36	theme	factor-kappa	1087:1098	arg1	B					1100:1100	nuclear factor-kappa B	1079:1100	nuclear factor-kappa B (NF-κB)	1079:1108	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	0	37	dep	yield	25:29	arg1	the					21:23	the	21:23	the	21:23	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	5	38	theme	phospho-Jun	920:930	arg1	p-JNK					951:955	p-JNK	951:955	p-JNK	951:955	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	38	theme	phospho-Jun	920:930	arg1	kinase					943:948	phospho-Jun N-terminal kinase	920:948	phospho-Jun N-terminal kinase (p-JNK)	920:956	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	4	39	theme	cytokines	899:907	arg1	secretion					869:877	the secretion	865:877	the secretion of nitric oxide and cytokines	865:907	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	5	40	theme	protein	1053:1059	arg1	MAPK					1069:1072	MAPK	1069:1072	MAPK	1069:1072	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	40	theme	protein	1053:1059	arg1	kinase					1061:1066	phospho-p38 (p-p38) mitogen-activated protein kinase	1015:1066	phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK)	1015:1073	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	4	41	theme	RAW264.7	830:837	arg1	macrophages					839:849	RAW264.7 macrophages	830:849	RAW264.7 macrophages	830:849	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	5	42	theme	N-terminal	932:941	arg1	p-JNK					951:955	p-JNK	951:955	p-JNK	951:955	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	42	theme	N-terminal	932:941	arg1	kinase					943:948	phospho-Jun N-terminal kinase	920:948	phospho-Jun N-terminal kinase (p-JNK)	920:956	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	3	43	theme	physicochemical	670:684	arg1	properties					686:695	the physicochemical properties	666:695	the physicochemical properties	666:695	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
35045151	4	44	theme	genistein-treated	749:765	arg1	purpureus					770:778	genistein-treated M. purpureus	749:778	genistein-treated M. purpureus (G-EMP)	749:786	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	4	44	theme	genistein-treated	749:765	arg1	G-EMP					781:785	G-EMP	781:785	G-EMP	781:785	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	5	45	dep	kinase	943:948	arg1	proteins					1128:1135	phospho-p65 (p65) proteins	1110:1135	phospho-p65 (p65) proteins	1110:1135	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	2	46	theme	work	331:334	arg1	aim					319:321	the aim	315:321	the aim of this work	315:334	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	4	47	theme	oxide	889:893	arg1	secretion					869:877	the secretion	865:877	the secretion of nitric oxide and cytokines	865:907	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	0	48	theme	immunomodulatory	46:61	arg1	activity					63:70	immunomodulatory activity	46:70	immunomodulatory activity	46:70	Role of genistein on the yield, structure and immunomodulatory activity of Monascus exopolysaccharides.
35045151	1	49	attach	isolated	221:228	arg1	microorganisms					235:248	microorganisms	235:248	microorganisms	235:248	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	1	49	attach	isolated	221:228	arg2	EPS					216:218	EPS	216:218	EPS	216:218	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	1	49	attach	isolated	221:228	arg2	exopolysaccharides					196:213	exopolysaccharides	196:213	exopolysaccharides (EPS) isolated from microorganisms	196:248	Manipulating the structures, physicochemical properties, and monosaccharide compositions of exopolysaccharides (EPS) isolated from microorganisms has been reported to enhance their biological activities.
35045151	4	50	theme	immunomodulatory	801:816	arg1	activity					818:825	the immunomodulatory activity	797:825	the immunomodulatory activity of RAW264.7 macrophages	797:849	Furthermore, EPS produced by genistein-treated M. purpureus (G-EMP) improved the immunomodulatory activity of RAW264.7 macrophages by increasing the secretion of nitric oxide and cytokines.
35045151	2	51	theme	genistein	366:374	arg1	addition					376:383	genistein addition	366:383	genistein addition during fermentation	366:403	Hence, the aim of this work was to examine the effects of genistein addition during fermentation on the amount, physicochemical properties, and immunomodulatory activity of EPS secreted by M. purpureus.
35045151	5	52	theme	phagocytic	1268:1277	arg1	capacities					1279:1288	the pinocytic and phagocytic capacities	1250:1288	the pinocytic and phagocytic capacities	1250:1288	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	5	53	theme	phospho-p65	1110:1120	arg1	proteins					1128:1135	phospho-p65 (p65) proteins	1110:1135	phospho-p65 (p65) proteins	1110:1135	Moreover, phospho-Jun N-terminal kinase (p-JNK), phospho-extracellular regulated protein kinase (p-ERK), phospho-p38 (p-p38) mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) phospho-p65 (p65) proteins were remarkably upregulated by G-EMP stimulation, blocking Toll-like receptor 4 (TLR4) that dramatically reduced the pinocytic and phagocytic capacities.
35045151	3	54	theme	genistein	531:539	arg1	addition					541:548	genistein addition	531:548	genistein addition	531:548	Results showed that genistein addition significantly increased M. purpureus biomass and EPS yield to 2.42 g L-1 and 6.08 g L-1, respectively, and affected the physicochemical properties and structures of EPS.
36356874	0	0	theme	drug	109:112	arg1	delivery					114:121	controlled drug delivery	98:121	controlled drug delivery	98:121	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	5	1	theme	composite	829:837	arg1	dressings					845:853	The composite wound dressings	825:853	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs)	825:933	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	7	2	theme	CS-GEL/Thymol-ALG	1112:1128	arg1	MPs					1130:1132	The CS-GEL/Thymol-ALG MPs	1108:1132	The CS-GEL/Thymol-ALG MPs	1108:1132	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	2	3	theme	antimicrobial	391:403	arg1	characteristics					427:441	antimicrobial and anti-inflammatory characteristics	391:441	antimicrobial and anti-inflammatory characteristics	391:441	However, their application has been limited due to their inadequacy of antimicrobial and anti-inflammatory characteristics.
36356874	11	4	theme	present	1686:1692	arg1	film					1718:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	0	5	theme	controlled	98:107	arg1	delivery					114:121	controlled drug delivery	98:121	controlled drug delivery	98:121	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	3	6	with	film	571:574	arg1	capability					585:594	the capability	581:594	the capability of controlled and prolonged release of thymol	581:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	5	7	theme	in	970:971	arg1	evaluations					978:988	in vitro and in vivo evaluations	957:988	in vitro and in vivo evaluations	957:988	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	1	8	theme	wound	290:294	arg1	applications					306:317	wound dressings applications	290:317	wound dressings applications	290:317	Previously, studies have demonstrated the unique characteristics of chitosan-gelatin films as wound dressings applications.
36356874	8	9	from	trend	1289:1293	arg1	MPs					1328:1330	CS-GEL/Thymol-ALG MPs	1310:1330	CS-GEL/Thymol-ALG MPs	1310:1330	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	8	9	from	trend	1289:1293	arg1	MPs					1347:1349	Thymol-ALG MPs	1336:1349	Thymol-ALG MPs	1336:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	10	10	theme	histological	1518:1529	arg1	analysis					1531:1538	the histological analysis	1514:1538	the histological analysis	1514:1538	Also, the histological analysis demonstrated that the CS-GEL/Thymol-ALG MPs could significantly enhance epithelialization, collagen deposition, and induce skin regeneration.
36356874	3	11	theme	controlled	599:608	arg1	release					624:630	controlled and prolonged release	599:630	controlled and prolonged release of thymol	599:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	4	12	theme	chitosan-gelatin	802:817	arg1	film					819:822	the chitosan-gelatin film	798:822	the chitosan-gelatin film	798:822	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	1	13	theme	dressings	296:304	arg1	applications					306:317	wound dressings applications	290:317	wound dressings applications	290:317	Previously, studies have demonstrated the unique characteristics of chitosan-gelatin films as wound dressings applications.
36356874	5	14	dep	in	970:971	arg1	vivo					973:976	vivo	973:976	vivo	973:976	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	11	15	theme	antibacterial	1694:1706	arg1	film					1718:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	3	16	theme	composite	561:569	arg1	film					571:574	a novel composite film	553:574	a novel composite film with the capability of controlled and prolonged release of thymol	553:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	3	16	theme	composite	561:569	arg1	antioxidant					655:665	a natural antioxidant	645:665	a natural antioxidant	645:665	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	6	17	theme	high	1062:1065	arg1	efficiency					1081:1090	high encapsulation efficiency	1062:1090	high encapsulation efficiency (88.9 ± 1.1 %)	1062:1105	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	6	17	theme	high	1062:1065	arg1	%					1104:1104	88.9 ± 1.1 %	1093:1104	88.9 ± 1.1 %	1093:1104	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	8	18	theme	release	1281:1287	arg1	trend					1289:1293	The release trend	1277:1293	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs	1277:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	9	19	theme	wound	1446:1450	arg1	healing					1452:1458	the wound healing	1442:1458	the wound healing process	1442:1466	This wound dressing effectively accelerates the wound healing process at rats' full-thickness skin excisions.
36356874	8	20	theme	diffusion	1377:1385	arg1	mechanism					1387:1395	a pseudo-Fickian diffusion mechanism	1360:1395	a pseudo-Fickian diffusion mechanism	1360:1395	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	8	21	theme	thymol	1298:1303	arg1	trend					1289:1293	The release trend	1277:1293	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs	1277:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	3	22	theme	film	520:523	arg1	characteristics					484:498	the intended multifunctional characteristics	455:498	the intended multifunctional characteristics of chitosan-gelatin film	455:523	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	0	23	theme	antibacterial	124:136	arg1	activity					138:145	antibacterial activity	124:145	antibacterial activity	124:145	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	8	24	from	MPs	1328:1330	arg1	thymol					1298:1303	thymol	1298:1303	thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs	1298:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	8	24	from	MPs	1328:1330	arg1	trend					1289:1293	The release trend	1277:1293	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs	1277:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	7	25	theme	L929	1254:1257	arg1	cells					1270:1274	the L929 fibroblast cells	1250:1274	the L929 fibroblast cells	1250:1274	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	10	26	theme	CS-GEL/Thymol-ALG	1562:1578	arg1	MPs					1580:1582	the CS-GEL/Thymol-ALG MPs	1558:1582	the CS-GEL/Thymol-ALG MPs	1558:1582	Also, the histological analysis demonstrated that the CS-GEL/Thymol-ALG MPs could significantly enhance epithelialization, collagen deposition, and induce skin regeneration.
36356874	6	27	theme	uniform	1037:1043	arg1	morphology					1045:1054	spherical and uniform morphology	1023:1054	spherical and uniform morphology	1023:1054	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	10	28	theme	collagen	1631:1638	arg1	epithelialization					1612:1628	epithelialization	1612:1628	epithelialization	1612:1628	Also, the histological analysis demonstrated that the CS-GEL/Thymol-ALG MPs could significantly enhance epithelialization, collagen deposition, and induce skin regeneration.
36356874	10	28	theme	collagen	1631:1638	arg1	deposition					1640:1649	collagen deposition	1631:1649	collagen deposition	1631:1649	Also, the histological analysis demonstrated that the CS-GEL/Thymol-ALG MPs could significantly enhance epithelialization, collagen deposition, and induce skin regeneration.
36356874	5	29	theme	wound	839:843	arg1	dressings					845:853	The composite wound dressings	825:853	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs)	825:933	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	8	30	from	MPs	1347:1349	arg1	thymol					1298:1303	thymol	1298:1303	thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs	1298:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	8	30	from	MPs	1347:1349	arg1	trend					1289:1293	The release trend	1277:1293	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs	1277:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	11	31	theme	wound	1757:1761	arg1	applications					1773:1784	wound dressings applications	1757:1784	wound dressings applications	1757:1784	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	3	32	theme	intended	459:466	arg1	characteristics					484:498	the intended multifunctional characteristics	455:498	the intended multifunctional characteristics of chitosan-gelatin film	455:523	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	8	33	theme	pseudo-Fickian	1362:1375	arg1	mechanism					1387:1395	a pseudo-Fickian diffusion mechanism	1360:1395	a pseudo-Fickian diffusion mechanism	1360:1395	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	11	34	contain	has	1723:1725	arg1	film					1718:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	11	34	contain	has	1723:1725	arg2	characteristics					1737:1751	promising characteristics	1727:1751	promising characteristics	1727:1751	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	7	35	theme	Gram-positive	1185:1197	arg1	bacteria					1217:1224	both Gram-positive and Gram-negative bacteria	1180:1224	both Gram-positive and Gram-negative bacteria	1180:1224	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	11	36	theme	promising	1727:1735	arg1	characteristics					1737:1751	promising characteristics	1727:1751	promising characteristics	1727:1751	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	3	37	theme	thymol	635:640	arg1	release					624:630	controlled and prolonged release	599:630	controlled and prolonged release of thymol	599:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	9	38	dep	rats	1471:1474	arg1	excisions					1497:1505	full-thickness skin excisions	1477:1505	rats' full-thickness skin excisions	1471:1505	This wound dressing effectively accelerates the wound healing process at rats' full-thickness skin excisions.
36356874	3	39	theme	chitosan-gelatin	503:518	arg1	film					520:523	chitosan-gelatin film	503:523	chitosan-gelatin film	503:523	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	0	40	theme	films	32:36	arg1	Fabrication					0:10	Fabrication	0:10	Fabrication of chitosan-gelatin films	0:36	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	0	41	theme	wound	151:155	arg1	healing					157:163	wound healing	151:163	wound healing	151:163	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	11	42	theme	composite	1708:1716	arg1	film					1718:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film	1682:1721	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	3	43	theme	prolonged	614:622	arg1	release					624:630	controlled and prolonged release	599:630	controlled and prolonged release of thymol	599:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	0	44	theme	chitosan-gelatin	15:30	arg1	films					32:36	chitosan-gelatin films	15:36	chitosan-gelatin films	15:36	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	3	45	theme	release	624:630	arg1	capability					585:594	the capability	581:594	the capability of controlled and prolonged release of thymol	581:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	5	46	theme	CS-GEL/Thymol-ALG	912:928	arg1	MPs					930:932	CS-GEL/Thymol-ALG MPs	912:932	CS-GEL/Thymol-ALG MPs	912:932	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	5	46	theme	CS-GEL/Thymol-ALG	912:928	arg1	film					906:909	chitosan-gelatin film	889:909	chitosan-gelatin film (CS-GEL/Thymol-ALG MPs)	889:933	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	3	47	theme	multifunctional	468:482	arg1	characteristics					484:498	the intended multifunctional characteristics	455:498	the intended multifunctional characteristics of chitosan-gelatin film	455:523	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	4	48	theme	electrospraying	753:767	arg1	method					769:774	electrospraying method	753:774	electrospraying method	753:774	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	7	49	theme	high	1144:1147	arg1	activity					1163:1170	high antibacterial activity	1144:1170	high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells	1144:1274	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	3	50	theme	natural	647:653	arg1	film					571:574	a novel composite film	553:574	a novel composite film with the capability of controlled and prolonged release of thymol	553:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	3	50	theme	natural	647:653	arg1	antioxidant					655:665	a natural antioxidant	645:665	a natural antioxidant	645:665	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	2	51	theme	characteristics	427:441	arg1	inadequacy					377:386	their inadequacy	371:386	their inadequacy of antimicrobial and anti-inflammatory characteristics	371:441	However, their application has been limited due to their inadequacy of antimicrobial and anti-inflammatory characteristics.
36356874	4	52	theme	ALG	711:713	arg1	MPs					715:717	thymol-loaded ALG MPs	697:717	thymol-loaded ALG MPs (Thymol-ALG MPs)	697:734	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	4	52	theme	ALG	711:713	arg1	MPs					731:733	Thymol-ALG MPs	720:733	Thymol-ALG MPs	720:733	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	7	53	theme	fibroblast	1259:1268	arg1	cells					1270:1274	the L929 fibroblast cells	1250:1274	the L929 fibroblast cells	1250:1274	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	9	54	theme	skin	1492:1495	arg1	excisions					1497:1505	full-thickness skin excisions	1477:1505	rats' full-thickness skin excisions	1471:1505	This wound dressing effectively accelerates the wound healing process at rats' full-thickness skin excisions.
36356874	7	55	theme	antibacterial	1149:1161	arg1	activity					1163:1170	high antibacterial activity	1144:1170	high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells	1144:1274	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	5	56	theme	chitosan-gelatin	889:904	arg1	MPs					930:932	CS-GEL/Thymol-ALG MPs	912:932	CS-GEL/Thymol-ALG MPs	912:932	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	5	56	theme	chitosan-gelatin	889:904	arg1	film					906:909	chitosan-gelatin film	889:909	chitosan-gelatin film (CS-GEL/Thymol-ALG MPs)	889:933	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	1	57	theme	unique	238:243	arg1	characteristics					245:259	the unique characteristics	234:259	the unique characteristics of chitosan-gelatin films as wound dressings applications	234:317	Previously, studies have demonstrated the unique characteristics of chitosan-gelatin films as wound dressings applications.
36356874	0	58	theme	alginate	70:77	arg1	microparticles					79:92	thymol-loaded alginate microparticles	56:92	thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing	56:163	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	6	59	theme	spherical	1023:1031	arg1	morphology					1045:1054	spherical and uniform morphology	1023:1054	spherical and uniform morphology	1023:1054	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	5	60	theme	MPs	869:871	arg1	dressings					845:853	The composite wound dressings	825:853	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs)	825:933	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	10	61	theme	skin	1663:1666	arg1	regeneration					1668:1679	skin regeneration	1663:1679	skin regeneration	1663:1679	Also, the histological analysis demonstrated that the CS-GEL/Thymol-ALG MPs could significantly enhance epithelialization, collagen deposition, and induce skin regeneration.
36356874	9	62	theme	healing	1452:1458	arg1	process					1460:1466	the wound healing process	1442:1466	the wound healing process	1442:1466	This wound dressing effectively accelerates the wound healing process at rats' full-thickness skin excisions.
36356874	0	63	theme	thymol-loaded	56:68	arg1	microparticles					79:92	thymol-loaded alginate microparticles	56:92	thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing	56:163	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	0	64	theme	In-vitro	166:173	arg1	microparticles					79:92	thymol-loaded alginate microparticles	56:92	thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing	56:163	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	7	65	theme	Gram-negative	1203:1215	arg1	bacteria					1217:1224	both Gram-positive and Gram-negative bacteria	1180:1224	both Gram-positive and Gram-negative bacteria	1180:1224	The CS-GEL/Thymol-ALG MPs exhibited high antibacterial activity against both Gram-positive and Gram-negative bacteria and no cytotoxicity for the L929 fibroblast cells.
36356874	11	66	theme	dressings	1763:1771	arg1	applications					1773:1784	wound dressings applications	1757:1784	wound dressings applications	1757:1784	The present antibacterial composite film has promising characteristics for wound dressings applications.
36356874	3	67	theme	novel	555:559	arg1	film					571:574	a novel composite film	553:574	a novel composite film with the capability of controlled and prolonged release of thymol	553:640	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	3	67	theme	novel	555:559	arg1	antioxidant					655:665	a natural antioxidant	645:665	a natural antioxidant	645:665	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	4	68	theme	Thymol-ALG	720:729	arg1	MPs					715:717	thymol-loaded ALG MPs	697:717	thymol-loaded ALG MPs (Thymol-ALG MPs)	697:734	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	4	68	theme	Thymol-ALG	720:729	arg1	MPs					731:733	Thymol-ALG MPs	720:733	Thymol-ALG MPs	720:733	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	9	69	theme	full-thickness	1477:1490	arg1	excisions					1497:1505	full-thickness skin excisions	1477:1505	rats' full-thickness skin excisions	1471:1505	This wound dressing effectively accelerates the wound healing process at rats' full-thickness skin excisions.
36356874	5	70	dep	in	957:958	arg1	vitro					960:964	vitro	960:964	vitro	960:964	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	5	71	theme	in	957:958	arg1	evaluations					978:988	in vitro and in vivo evaluations	957:988	in vitro and in vivo evaluations	957:988	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	6	72	theme	encapsulation	1067:1079	arg1	efficiency					1081:1090	high encapsulation efficiency	1062:1090	high encapsulation efficiency (88.9 ± 1.1 %)	1062:1105	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	6	72	theme	encapsulation	1067:1079	arg1	%					1104:1104	88.9 ± 1.1 %	1093:1104	88.9 ± 1.1 %	1093:1104	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	0	73	theme	in-vivo	179:185	arg1	studies					187:193	in-vivo studies	179:193	in-vivo studies	179:193	Fabrication of chitosan-gelatin films incorporated with thymol-loaded alginate microparticles for controlled drug delivery, antibacterial activity and wound healing: In-vitro and in-vivo studies.
36356874	8	74	theme	Thymol-ALG	1336:1345	arg1	MPs					1347:1349	Thymol-ALG MPs	1336:1349	Thymol-ALG MPs	1336:1349	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	8	75	theme	CS-GEL/Thymol-ALG	1310:1326	arg1	MPs					1328:1330	CS-GEL/Thymol-ALG MPs	1310:1330	CS-GEL/Thymol-ALG MPs	1310:1330	The release trend of thymol from CS-GEL/Thymol-ALG MPs and Thymol-ALG MPs followed a pseudo-Fickian diffusion mechanism.
36356874	4	76	theme	thymol-loaded	697:709	arg1	MPs					715:717	thymol-loaded ALG MPs	697:717	thymol-loaded ALG MPs (Thymol-ALG MPs)	697:734	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	4	76	theme	thymol-loaded	697:709	arg1	MPs					731:733	Thymol-ALG MPs	720:733	Thymol-ALG MPs	720:733	Here, thymol-loaded ALG MPs (Thymol-ALG MPs) were prepared by electrospraying method and incorporated into the chitosan-gelatin film.
36356874	2	77	theme	anti-inflammatory	409:425	arg1	characteristics					427:441	antimicrobial and anti-inflammatory characteristics	391:441	antimicrobial and anti-inflammatory characteristics	391:441	However, their application has been limited due to their inadequacy of antimicrobial and anti-inflammatory characteristics.
36356874	1	78	theme	chitosan-gelatin	264:279	arg1	films					281:285	chitosan-gelatin films	264:285	chitosan-gelatin films	264:285	Previously, studies have demonstrated the unique characteristics of chitosan-gelatin films as wound dressings applications.
36356874	5	79	theme	Thymol-ALG	858:867	arg1	MPs					869:871	Thymol-ALG MPs	858:871	Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs)	858:933	The composite wound dressings of Thymol-ALG MPs incorporated in chitosan-gelatin film (CS-GEL/Thymol-ALG MPs) were characterized by in vitro and in vivo evaluations.
36356874	6	80	theme	Thymol-ALG	995:1004	arg1	MPs					1006:1008	The Thymol-ALG MPs	991:1008	The Thymol-ALG MPs	991:1008	The Thymol-ALG MPs demonstrated spherical and uniform morphology, with high encapsulation efficiency (88.9 ± 1.1 %).
36356874	3	81	theme	antimicrobial	671:683	arg1	drug					685:688	antimicrobial drug	671:688	antimicrobial drug	671:688	To improve the intended multifunctional characteristics of chitosan-gelatin film, in this study, we designed a novel composite film with the capability of controlled and prolonged release of thymol as a natural antioxidant and antimicrobial drug.
36356874	9	82	theme	wound	1403:1407	arg1	dressing					1409:1416	This wound dressing	1398:1416	This wound dressing	1398:1416	This wound dressing effectively accelerates the wound healing process at rats' full-thickness skin excisions.
36356874	1	83	theme	films	281:285	arg1	characteristics					245:259	the unique characteristics	234:259	the unique characteristics of chitosan-gelatin films as wound dressings applications	234:317	Previously, studies have demonstrated the unique characteristics of chitosan-gelatin films as wound dressings applications.
36014516	2	0	theme	gray	492:495	arg1	degree					509:514	gray correlation degree	492:514	gray correlation degree with the chromatographic fingerprint as the independent variable	492:579	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	5	1	from	Mongolia	1024:1031	arg1	winter					1040:1045	the winter	1036:1045	the winter	1036:1045	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	1	2	from	Radix	194:198	arg1	polysaccharides					158:172	polysaccharides	158:172	polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	158:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	1	2	from	Radix	194:198	arg1	batches					147:153	10 batches	144:153	10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	144:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	1	3	theme	polysaccharides	158:172	arg1	batches					147:153	10 batches	144:153	10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	144:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	4	4	theme	quality	859:865	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	4	theme	quality	859:865	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	4	theme	quality	859:865	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	4	theme	quality	859:865	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	0	5	from	Fingerprints	9:20	arg1	Radix					94:98	Radix	94:98	Radix	94:98	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	6	6	theme	SPs	1237:1239	arg1	activity					1221:1228	the anti-allergic activity	1203:1228	the anti-allergic activity of the SPs	1203:1239	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	2	7	theme	Radix	374:378	arg1	polysaccharide					380:393	Saposhnikoviae Radix polysaccharide	359:393	Saposhnikoviae Radix polysaccharide (SP)	359:398	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	2	7	theme	Radix	374:378	arg1	SP					396:397	SP	396:397	SP	396:397	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	4	8	dep	=	770:770	arg1	Da					794:795	8.67 × 106~9.56 × 106 Da	772:795	8.67 × 106~9.56 × 106 Da	772:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	5	9	theme	anti-allergic	1060:1072	arg1	activity					1074:1081	the best anti-allergic activity	1051:1081	the best anti-allergic activity	1051:1081	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	2	10	with	degree	509:514	arg1	fingerprint					541:551	the chromatographic fingerprint	521:551	the chromatographic fingerprint as the independent variable	521:579	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	4	11	theme	fragment	758:765	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	11	theme	fragment	758:765	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	11	theme	fragment	758:765	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	11	theme	fragment	758:765	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	7	12	contain	has	1416:1418	arg1	efficacy					1400:1407	efficacy	1400:1407	efficacy	1400:1407	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	7	12	contain	has	1416:1418	arg2	value					1437:1441	more application value	1420:1441	more application value	1420:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	7	12	contain	has	1416:1418	arg1	quality					1388:1394	overall quality	1380:1394	overall quality	1380:1394	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	2	13	theme	chromatographic	525:539	arg1	fingerprint					541:551	the chromatographic fingerprint	521:551	the chromatographic fingerprint as the independent variable	521:579	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	3	14	theme	high	676:679	arg1	similarity					681:690	a high similarity	674:690	a high similarity	674:690	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	4	15	theme	polysaccharide	743:756	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	15	theme	polysaccharide	743:756	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	15	theme	polysaccharide	743:756	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	15	theme	polysaccharide	743:756	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	1	16	from	batches	147:153	arg1	Radix					194:198	Radix	194:198	Radix	194:198	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	2	17	theme	polysaccharide	380:393	arg1	batches					348:354	10 batches	345:354	10 batches of Saposhnikoviae Radix polysaccharide (SP)	345:398	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	1	18	theme	chemometrics	278:289	arg1	analysis					291:298	the chemometrics analysis	274:298	the chemometrics analysis	274:298	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	2	19	theme	Saposhnikoviae	359:372	arg1	polysaccharide					380:393	Saposhnikoviae Radix polysaccharide	359:393	Saposhnikoviae Radix polysaccharide (SP)	359:398	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	2	19	theme	Saposhnikoviae	359:372	arg1	SP					396:397	SP	396:397	SP	396:397	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	4	20	theme	FT-IR	806:810	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	20	theme	FT-IR	806:810	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	20	theme	FT-IR	806:810	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	20	theme	FT-IR	806:810	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	21	theme	=	770:770	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	21	theme	=	770:770	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	21	theme	=	770:770	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	21	theme	=	770:770	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	5	22	theme	Inner	1018:1022	arg1	Mongolia					1024:1031	Inner Mongolia	1018:1031	Inner Mongolia in the winter	1018:1045	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	4	23	used	used	847:850	arg2	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	23	used	used	847:850	arg2	galactose					727:735	galactose	727:735	galactose	727:735	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	23	used	used	847:850	arg2	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	23	used	used	847:850	arg2	rhamnose					714:721	rhamnose	714:721	rhamnose	714:721	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	23	used	used	847:850	arg2	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	23	used	used	847:850	arg2	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	5	24	contain	had	1047:1049	arg2	activity					1074:1081	the best anti-allergic activity	1051:1081	the best anti-allergic activity	1051:1081	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	5	24	contain	had	1047:1049	arg1	polysaccharides					987:1001	the polysaccharides	983:1001	the polysaccharides harvested from Inner Mongolia in the winter	983:1045	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	6	25	theme	anti-allergic	1207:1219	arg1	activity					1221:1228	the anti-allergic activity	1203:1228	the anti-allergic activity of the SPs	1203:1239	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	1	26	theme	PMP-HPLC	101:108	arg1	fingerprints					128:139	PMP-HPLC, FT-IR, and HPSEC fingerprints	101:139	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	101:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	2	27	theme	batches	462:468	arg1	relationship					439:450	the spectrum-effect relationship	419:450	the spectrum-effect relationship of the 10 batches of SP	419:474	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	0	28	from	Relationship	42:53	arg1	Radix					94:98	Radix	94:98	Radix	94:98	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	6	29	theme	spectrum-effect	1088:1102	arg1	model					1117:1121	The spectrum-effect relationship model	1084:1121	The spectrum-effect relationship model	1084:1121	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	7	30	theme	application	1425:1435	arg1	value					1437:1441	more application value	1420:1441	more application value	1420:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	7	31	theme	spectrum-effect	1278:1292	arg1	analysis					1307:1314	spectrum-effect relationship analysis	1278:1314	spectrum-effect relationship analysis	1278:1314	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	0	32	theme	Multiple	0:7	arg1	Fingerprints					9:20	Multiple Fingerprints	0:20	Multiple Fingerprints	0:20	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	6	33	theme	monosaccharide	1139:1152	arg1	composition					1154:1164	the monosaccharide composition	1135:1164	the monosaccharide composition	1135:1164	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	6	33	theme	monosaccharide	1139:1152	arg1	related					1192:1198	related	1192:1198	related	1192:1198	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	4	34	theme	absorption	812:821	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	34	theme	absorption	812:821	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	34	theme	absorption	812:821	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	34	theme	absorption	812:821	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	1	35	theme	FT-IR	111:115	arg1	fingerprints					128:139	PMP-HPLC, FT-IR, and HPSEC fingerprints	101:139	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	101:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	5	36	theme	best	1055:1058	arg1	activity					1074:1081	the best anti-allergic activity	1051:1081	the best anti-allergic activity	1051:1081	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	1	37	theme	different	205:213	arg1	areas					226:230	different production areas	205:230	different production areas	205:230	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	0	38	theme	Spectrum-Effect	26:40	arg1	Relationship					42:53	Spectrum-Effect Relationship	26:53	Spectrum-Effect Relationship	26:53	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	4	39	theme	×	788:788	arg1	Da					794:795	8.67 × 106~9.56 × 106 Da	772:795	8.67 × 106~9.56 × 106 Da	772:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	40	theme	control	867:873	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	40	theme	control	867:873	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	40	theme	control	867:873	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	40	theme	control	867:873	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	6	41	theme	molecular	1170:1178	arg1	weight					1180:1185	molecular weight	1170:1185	molecular weight	1170:1185	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	2	42	theme	anti-allergic	319:331	arg1	activity					333:340	The anti-allergic activity	315:340	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP)	315:398	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	7	43	theme	SPs	1356:1358	arg1	quality					1345:1351	the quality	1341:1351	the quality of SPs from the aspects of overall quality and efficacy, which has more application value	1341:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	1	44	theme	production	215:224	arg1	areas					226:230	different production areas	205:230	different production areas	205:230	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	7	45	theme	overall	1380:1386	arg1	quality					1388:1394	overall quality	1380:1394	overall quality	1380:1394	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	2	46	theme	independent	560:570	arg1	variable					572:579	the independent variable	556:579	the independent variable	556:579	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	4	47	dep	monosaccharides	697:711	arg1	galactose					727:735	galactose	727:735	galactose	727:735	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	47	dep	monosaccharides	697:711	arg1	rhamnose					714:721	rhamnose	714:721	rhamnose	714:721	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	47	dep	monosaccharides	697:711	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	2	48	theme	spectrum-effect	423:437	arg1	relationship					439:450	the spectrum-effect relationship	419:450	the spectrum-effect relationship of the 10 batches of SP	419:474	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	3	49	theme	batches	656:662	arg1	fingerprints					637:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints	606:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP	606:668	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	3	50	theme	PMP-HPLC	610:617	arg1	fingerprints					637:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints	606:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP	606:668	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	3	51	contain	had	670:672	arg1	fingerprints					637:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints	606:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP	606:668	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	3	51	contain	had	670:672	arg2	similarity					681:690	a high similarity	674:690	a high similarity	674:690	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	7	52	theme	Multiple	1242:1249	arg1	fingerprints					1251:1262	Multiple fingerprints	1242:1262	Multiple fingerprints combined with spectrum-effect relationship analysis	1242:1314	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	0	53	from	Radix	94:98	arg1	Polysaccharides					58:72	Polysaccharides	58:72	Polysaccharides from Saposhnikoviae Radix	58:98	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	0	53	from	Radix	94:98	arg1	Fingerprints					9:20	Multiple Fingerprints	0:20	Multiple Fingerprints	0:20	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	0	53	from	Radix	94:98	arg1	Relationship					42:53	Spectrum-Effect Relationship	26:53	Spectrum-Effect Relationship	26:53	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	5	54	theme	β-HEX	955:959	arg1	release					944:950	the release	940:950	the release of β-HEX	940:959	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	1	55	theme	harvest	236:242	arg1	times					244:248	harvest times	236:248	harvest times	236:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	2	56	theme	SP	473:474	arg1	batches					462:468	the 10 batches	455:468	the 10 batches of SP	455:474	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	5	57	theme	SP	909:910	arg1	batches					898:904	All 10 batches	891:904	All 10 batches of SP	891:910	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	1	58	theme	HPSEC	122:126	arg1	fingerprints					128:139	PMP-HPLC, FT-IR, and HPSEC fingerprints	101:139	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	101:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	0	59	theme	Polysaccharides	58:72	arg1	Fingerprints					9:20	Multiple Fingerprints	0:20	Multiple Fingerprints	0:20	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	0	59	theme	Polysaccharides	58:72	arg1	Relationship					42:53	Spectrum-Effect Relationship	26:53	Spectrum-Effect Relationship	26:53	Multiple Fingerprints and Spectrum-Effect Relationship of Polysaccharides from Saposhnikoviae Radix.
36014516	7	60	theme	relationship	1294:1305	arg1	analysis					1307:1314	spectrum-effect relationship analysis	1278:1314	spectrum-effect relationship analysis	1278:1314	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	5	61	theme	RBL-231	964:970	arg1	cells					972:976	RBL-231 cells	964:976	RBL-231 cells	964:976	All 10 batches of SP could significantly inhibit the release of β-HEX in RBL-231 cells, and the polysaccharides harvested from Inner Mongolia in the winter had the best anti-allergic activity.
36014516	7	62	theme	efficacy	1400:1407	arg1	aspects					1369:1375	the aspects	1365:1375	the aspects of overall quality and efficacy, which has more application value	1365:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	4	63	theme	×	777:777	arg1	Da					794:795	8.67 × 106~9.56 × 106 Da	772:795	8.67 × 106~9.56 × 106 Da	772:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	7	64	theme	quality	1388:1394	arg1	aspects					1369:1375	the aspects	1365:1375	the aspects of overall quality and efficacy, which has more application value	1365:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	2	65	theme	batches	348:354	arg1	activity					333:340	The anti-allergic activity	315:340	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP)	315:398	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	7	66	from	aspects	1369:1375	arg1	SPs					1356:1358	SPs	1356:1358	SPs from the aspects of overall quality and efficacy, which has more application value	1356:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	7	66	from	aspects	1369:1375	arg1	quality					1345:1351	the quality	1341:1351	the quality of SPs from the aspects of overall quality and efficacy, which has more application value	1341:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	6	67	theme	relationship	1104:1115	arg1	model					1117:1121	The spectrum-effect relationship model	1084:1121	The spectrum-effect relationship model	1084:1121	The spectrum-effect relationship model showed that the monosaccharide composition and molecular weight were related to the anti-allergic activity of the SPs.
36014516	3	68	theme	FT-IR	631:635	arg1	fingerprints					637:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints	606:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP	606:668	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	7	69	from	quality	1345:1351	arg1	aspects					1369:1375	the aspects	1365:1375	the aspects of overall quality and efficacy, which has more application value	1365:1441	Multiple fingerprints combined with spectrum-effect relationship analysis can evaluate and control the quality of SPs from the aspects of overall quality and efficacy, which has more application value.
36014516	4	70	theme	cm-1	835:838	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	70	theme	cm-1	835:838	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	70	theme	cm-1	835:838	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	70	theme	cm-1	835:838	arg1	galactose					727:735	galactose	727:735	galactose	727:735	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	70	theme	cm-1	835:838	arg1	rhamnose					714:721	rhamnose	714:721	rhamnose	714:721	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	70	theme	cm-1	835:838	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	3	71	theme	SP	667:668	arg1	batches					656:662	10 batches	653:662	10 batches of SP	653:668	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	3	72	theme	HPSEC	620:624	arg1	fingerprints					637:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints	606:648	the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP	606:668	The results showed that the PMP-HPLC, HPSEC, and FT-IR fingerprints of 10 batches of SP had a high similarity.
36014516	1	73	theme	batches	147:153	arg1	fingerprints					128:139	PMP-HPLC, FT-IR, and HPSEC fingerprints	101:139	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times	101:248	PMP-HPLC, FT-IR, and HPSEC fingerprints of 10 batches of polysaccharides from Saposhnikoviae Radix with different production areas and harvest times have been prepared, and the chemometrics analysis was performed.
36014516	2	74	theme	correlation	497:507	arg1	degree					509:514	gray correlation degree	492:514	gray correlation degree with the chromatographic fingerprint as the independent variable	492:579	The anti-allergic activity of 10 batches of Saposhnikoviae Radix polysaccharide (SP) was evaluated, and the spectrum-effect relationship of the 10 batches of SP was analyzed by gray correlation degree with the chromatographic fingerprint as the independent variable.
36014516	4	75	theme	SPs	886:888	arg1	Mn					767:768	the polysaccharide fragment Mn	739:768	the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da	739:795	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	75	theme	SPs	886:888	arg1	peak					823:826	the FT-IR absorption peak	802:826	the FT-IR absorption peak of 892 cm-1	802:838	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	75	theme	SPs	886:888	arg1	markers					875:881	the quality control markers	855:881	the quality control markers of SPs	855:888	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
36014516	4	75	theme	SPs	886:888	arg1	monosaccharides					697:711	Two monosaccharides	693:711	Two monosaccharides (rhamnose and galactose)	693:736	Two monosaccharides (rhamnose and galactose), the polysaccharide fragment Mn = 8.67 × 106~9.56 × 106 Da, and the FT-IR absorption peak of 892 cm-1 can be used as the quality control markers of SPs.
35780667	4	0	theme	swelling	639:646	arg1	%					712:712	28.3% to 40.1%	699:712	28.3% to 40.1%	699:712	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	0	theme	swelling	639:646	arg1	capacity					648:655	a lower swelling capacity	631:655	a lower swelling capacity	631:655	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	7	1	theme	polysaccharides	1091:1105	arg1	extraction					1062:1071	larger scale extraction	1049:1071	larger scale extraction of the date fruit polysaccharides	1049:1105	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	1	2	theme	date	240:243	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	0	3	from	compounds	9:17	arg1	fruit					51:55	the date fruit	42:55	the date fruit	42:55	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	3	4	theme	successive	454:463	arg1	centrifugation					465:478	successive centrifugation	454:478	successive centrifugation	454:478	The decoction and successive centrifugation made it possible to collect two main polysaccharide fractions for all the selected fruits.
35780667	1	5	theme	fruits	245:250	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	2	6	dep	50 mg/100 g	420:430	arg1	to					417:418	to	417:418	to	417:418	The total phenols were in similar amount in the five varieties and ranged from 20 to 50 mg/100 g DW.
35780667	6	7	from	degrees	954:960	arg1	sugars					939:944	neutral sugars	931:944	neutral sugars	931:944	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	4	8	theme	galacturonic	680:691	arg1	acid					693:696	galacturonic acid	680:696	galacturonic acid	680:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	1	9	from	polysaccharides	163:177	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	1	10	theme	Tamr	323:326	arg1	stage					328:332	Tamr stage	323:332	Tamr stage	323:332	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	6	11	from	composition	916:926	arg1	sugars					939:944	neutral sugars	931:944	neutral sugars	931:944	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	5	12	theme	acid	804:807	arg1	content					809:815	an average galacturonic acid content	780:815	an average galacturonic acid content of only 17%	780:827	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	6	13	theme	fractions	880:888	arg1	structure					844:852	The different structure	830:852	The different structure of the two polysaccharide fractions	830:888	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	4	14	theme	lower	633:637	arg1	%					712:712	28.3% to 40.1%	699:712	28.3% to 40.1%	699:712	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	14	theme	lower	633:637	arg1	capacity					648:655	a lower swelling capacity	631:655	a lower swelling capacity	631:655	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	0	15	theme	Comparative	83:93	arg1	study					95:99	Comparative study	83:99	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.	0:142	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	7	16	theme	proposed	998:1005	arg1	procedure					1018:1026	The proposed extraction procedure	994:1026	The proposed extraction procedure	994:1026	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	4	17	theme	%	703:703	arg1	%					712:712	28.3% to 40.1%	699:712	28.3% to 40.1%	699:712	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	17	theme	%	703:703	arg1	capacity					648:655	a lower swelling capacity	631:655	a lower swelling capacity	631:655	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	6	18	theme	acetylation	981:991	arg1	composition					916:926	the composition	912:926	the composition in neutral sugars	912:944	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	6	18	theme	acetylation	981:991	arg1	degrees					954:960	the degrees	950:960	the degrees of methylation and acetylation	950:991	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	6	19	theme	methylation	965:975	arg1	composition					916:926	the composition	912:926	the composition in neutral sugars	912:944	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	6	19	theme	methylation	965:975	arg1	degrees					954:960	the degrees	950:960	the degrees of methylation and acetylation	950:991	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	3	20	theme	polysaccharide	517:530	arg1	fractions					532:540	two main polysaccharide fractions	508:540	two main polysaccharide fractions for all the selected fruits	508:568	The decoction and successive centrifugation made it possible to collect two main polysaccharide fractions for all the selected fruits.
35780667	4	21	dep	%	712:712	arg1	to					705:706	to	705:706	to	705:706	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	0	22	theme	Phenolic	0:7	arg1	compounds					9:17	Phenolic compounds	0:17	Phenolic compounds	0:17	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	0	22	theme	Phenolic	0:7	arg1	Phoenix					58:64	Phoenix	58:64	Phoenix	58:64	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	6	23	theme	polysaccharide	865:878	arg1	fractions					880:888	the two polysaccharide fractions	857:888	the two polysaccharide fractions	857:888	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	2	24	theme	total	339:343	arg1	phenols					345:351	The total phenols	335:351	The total phenols	335:351	The total phenols were in similar amount in the five varieties and ranged from 20 to 50 mg/100 g DW.
35780667	5	25	theme	second	720:725	arg1	fraction					727:734	The second fraction	716:734	The second fraction	716:734	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	5	25	theme	second	720:725	arg1	soluble					745:751	soluble	745:751	soluble	745:751	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	0	26	dep	Phoenix	58:64	arg1	L.					78:79	Phoenix dactylifera L.	58:79	Phoenix dactylifera L.	58:79	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	1	27	theme	phenolic	183:190	arg1	compounds					192:200	phenolic compounds	183:200	phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage	183:332	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	1	27	theme	phenolic	183:190	arg1	Ajwa					279:282	Ajwa	279:282	Ajwa	279:282	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	1	27	theme	phenolic	183:190	arg1	Khalas					303:308	Khalas	303:308	Khalas	303:308	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	1	27	theme	phenolic	183:190	arg1	Barrny					292:297	Barrny	292:297	Barrny	292:297	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	3	28	theme	main	512:515	arg1	fractions					532:540	two main polysaccharide fractions	508:540	two main polysaccharide fractions for all the selected fruits	508:568	The decoction and successive centrifugation made it possible to collect two main polysaccharide fractions for all the selected fruits.
35780667	7	29	theme	larger	1049:1054	arg1	extraction					1062:1071	larger scale extraction	1049:1071	larger scale extraction of the date fruit polysaccharides	1049:1105	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	0	30	theme	consumed	116:123	arg1	varieties					133:141	five widely consumed Arabian varieties	104:141	five widely consumed Arabian varieties	104:141	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	4	31	with	abundant	616:623	arg1	amount					670:675	a higher amount	661:675	a higher amount of galacturonic acid	661:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	31	with	abundant	616:623	arg1	acid					693:696	galacturonic acid	680:696	galacturonic acid	680:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	31	with	abundant	616:623	arg1	%					712:712	28.3% to 40.1%	699:712	28.3% to 40.1%	699:712	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	31	with	abundant	616:623	arg1	capacity					648:655	a lower swelling capacity	631:655	a lower swelling capacity	631:655	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	7	32	theme	scale	1056:1060	arg1	extraction					1062:1071	larger scale extraction	1049:1071	larger scale extraction of the date fruit polysaccharides	1049:1105	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	5	33	with	soluble	745:751	arg1	content					809:815	an average galacturonic acid content	780:815	an average galacturonic acid content of only 17%	780:827	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	3	34	theme	selected	554:561	arg1	fruits					563:568	all the selected fruits	546:568	all the selected fruits	546:568	The decoction and successive centrifugation made it possible to collect two main polysaccharide fractions for all the selected fruits.
35780667	5	35	theme	alkaline	756:763	arg1	solution					765:772	alkaline solution	756:772	alkaline solution	756:772	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	2	36	theme	similar	361:367	arg1	amount					369:374	similar amount	361:374	similar amount in the five varieties	361:396	The total phenols were in similar amount in the five varieties and ranged from 20 to 50 mg/100 g DW.
35780667	6	37	theme	different	834:842	arg1	structure					844:852	The different structure	830:852	The different structure of the two polysaccharide fractions	830:888	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	6	38	theme	neutral	931:937	arg1	sugars					939:944	neutral sugars	931:944	neutral sugars	931:944	The different structure of the two polysaccharide fractions was also confirmed by the composition in neutral sugars and the degrees of methylation and acetylation.
35780667	0	39	theme	date	46:49	arg1	fruit					51:55	the date fruit	42:55	the date fruit	42:55	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	0	40	theme	Arabian	125:131	arg1	varieties					133:141	five widely consumed Arabian varieties	104:141	five widely consumed Arabian varieties	104:141	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	0	41	from	study	95:99	arg1	varieties					133:141	five widely consumed Arabian varieties	104:141	five widely consumed Arabian varieties	104:141	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	7	42	theme	extraction	1007:1016	arg1	procedure					1018:1026	The proposed extraction procedure	994:1026	The proposed extraction procedure	994:1026	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	1	43	from	compounds	192:200	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	4	44	theme	higher	663:668	arg1	amount					670:675	a higher amount	661:675	a higher amount of galacturonic acid	661:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	44	theme	higher	663:668	arg1	acid					693:696	galacturonic acid	680:696	galacturonic acid	680:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	45	theme	acid	693:696	arg1	amount					670:675	a higher amount	661:675	a higher amount of galacturonic acid	661:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	45	theme	acid	693:696	arg1	acid					693:696	galacturonic acid	680:696	galacturonic acid	680:696	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	45	theme	acid	693:696	arg1	%					712:712	28.3% to 40.1%	699:712	28.3% to 40.1%	699:712	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	45	theme	acid	693:696	arg1	capacity					648:655	a lower swelling capacity	631:655	a lower swelling capacity	631:655	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	1	46	theme	consumed	212:219	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	5	47	from	soluble	745:751	arg1	solution					765:772	alkaline solution	756:772	alkaline solution	756:772	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	2	48	from	amount	369:374	arg1	varieties					388:396	the five varieties	379:396	the five varieties	379:396	The total phenols were in similar amount in the five varieties and ranged from 20 to 50 mg/100 g DW.
35780667	5	49	theme	%	827:827	arg1	content					809:815	an average galacturonic acid content	780:815	an average galacturonic acid content of only 17%	780:827	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	4	50	theme	first	592:596	arg1	fraction					598:605	the first fraction	588:605	the first fraction	588:605	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	4	50	theme	first	592:596	arg1	abundant					616:623	abundant	616:623	abundant	616:623	For each variety the first fraction was more abundant, with a lower swelling capacity and a higher amount of galacturonic acid (28.3% to 40.1%).
35780667	0	51	dep	compounds	9:17	arg1	study					95:99	Comparative study	83:99	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.	0:142	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	5	52	theme	average	783:789	arg1	content					809:815	an average galacturonic acid content	780:815	an average galacturonic acid content of only 17%	780:827	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	1	53	theme	little	225:230	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
35780667	7	54	theme	fruit	1085:1089	arg1	polysaccharides					1091:1105	the date fruit polysaccharides	1076:1105	the date fruit polysaccharides	1076:1105	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	0	55	from	polysaccharides	23:37	arg1	fruit					51:55	the date fruit	42:55	the date fruit	42:55	Phenolic compounds and polysaccharides in the date fruit (Phoenix dactylifera L.): Comparative study on five widely consumed Arabian varieties.
35780667	5	56	from	solution	765:772	arg1	fraction					727:734	The second fraction	716:734	The second fraction	716:734	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	5	56	from	solution	765:772	arg1	soluble					745:751	soluble	745:751	soluble	745:751	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	5	57	theme	galacturonic	791:802	arg1	content					809:815	an average galacturonic acid content	780:815	an average galacturonic acid content of only 17%	780:827	The second fraction was only soluble in alkaline solution, with an average galacturonic acid content of only 17%.
35780667	7	58	theme	date	1080:1083	arg1	polysaccharides					1091:1105	the date fruit polysaccharides	1076:1105	the date fruit polysaccharides	1076:1105	The proposed extraction procedure could be applied for larger scale extraction of the date fruit polysaccharides.
35780667	1	59	theme	studied	232:238	arg1	varieties					252:260	widely consumed but little studied date fruits varieties	205:260	widely consumed but little studied date fruits varieties	205:260	The study analysed polysaccharides and phenolic compounds in widely consumed but little studied date fruits varieties such as Sukkari, Ajwa, Segae, Barrny and Khalas harvested at Tamr stage.
36096051	0	0	theme	grape	69:73	arg1	skins					75:79	red and white grape skins	55:79	red and white grape skins	55:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	1	1	theme	unbalanced	290:299	arg1	astringency					301:311	the unbalanced astringency	286:311	the unbalanced astringency of a Tempranillo red wine	286:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	6	2	theme	arabinogalactans	948:963	arg1	presence					936:943	the presence	932:943	the presence of arabinogalactans in the structure	932:980	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	0	3	theme	white	63:67	arg1	skins					75:79	red and white grape skins	55:79	red and white grape skins	55:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	1	4	theme	astringency	301:311	arg1	polysaccharides					170:184	Soluble polysaccharides	162:184	Soluble polysaccharides from white (PSW) and red (PSR) grape skins	162:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	4	theme	astringency	301:311	arg1	modulators					272:281	potential modulators	262:281	potential modulators of the unbalanced astringency of a Tempranillo red wine	262:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	0	5	dep	composition	101:111	arg1	the					84:86	the	84:86	the	84:86	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	1	6	theme	grape	217:221	arg1	skins					223:227	white (PSW) and red (PSR) grape skins	191:227	white (PSW) and red (PSR) grape skins	191:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	0	7	from	Effect	0:5	arg1	composition					101:111	polyphenolic composition	88:111	polyphenolic composition	88:111	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	0	7	from	Effect	0:5	arg1	properties					125:134	sensory properties	117:134	sensory properties	117:134	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	3	8	theme	Titration	486:494	arg1	ITC					509:511	ITC	509:511	ITC	509:511	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	3	8	theme	Titration	486:494	arg1	Calorimetry					496:506	Isothermal Titration Calorimetry	475:506	Isothermal Titration Calorimetry (ITC) studies	475:520	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	2	9	theme	polyphenolic	453:464	arg1	profile					466:472	the polyphenolic profile	449:472	the polyphenolic profile	449:472	The modulation of astringency was evaluated by a sensory panel and it seemed to be related to the changes in the polyphenolic profile.
36096051	3	10	theme	Calorimetry	496:506	arg1	studies					514:520	Isothermal Titration Calorimetry (ITC) studies	475:520	Isothermal Titration Calorimetry (ITC) studies	475:520	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	0	11	theme	polyphenolic	88:99	arg1	composition					101:111	polyphenolic composition	88:111	polyphenolic composition	88:111	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	1	12	theme	Tempranillo	318:328	arg1	wine					334:337	a Tempranillo red wine	316:337	a Tempranillo red wine	316:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	6	13	from	presence	936:943	arg1	structure					972:980	the structure	968:980	the structure	968:980	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	8	14	theme	polysaccharide	1179:1192	arg1	addition					1163:1170	the addition	1159:1170	the addition of any polysaccharide	1159:1192	Furthermore, potential variations of color were also assessed and no deleterious effect was observed after the addition of any polysaccharide.
36096051	1	15	theme	red	330:332	arg1	wine					334:337	a Tempranillo red wine	316:337	a Tempranillo red wine	316:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	4	16	theme	PSW	792:794	arg1	ca					797:798	PSW (ca	792:798	PSW (ca	792:798	ΔGtotal = -2.14 × 104 cal/mol) than PSW (ca.
36096051	3	17	theme	Isothermal	475:484	arg1	ITC					509:511	ITC	509:511	ITC	509:511	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	3	17	theme	Isothermal	475:484	arg1	Calorimetry					496:506	Isothermal Titration Calorimetry	475:506	Isothermal Titration Calorimetry (ITC) studies	475:520	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	1	18	theme	Soluble	162:168	arg1	polysaccharides					170:184	Soluble polysaccharides	162:184	Soluble polysaccharides from white (PSW) and red (PSR) grape skins	162:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	18	theme	Soluble	162:168	arg1	modulators					272:281	potential modulators	262:281	potential modulators of the unbalanced astringency of a Tempranillo red wine	262:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	19	theme	wine	334:337	arg1	astringency					301:311	the unbalanced astringency	286:311	the unbalanced astringency of a Tempranillo red wine	286:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	3	20	theme	flavan-3-ol	659:669	arg1	loss					671:674	a great flavan-3-ol loss	651:674	a great flavan-3-ol loss (ca. 40 %)	651:685	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	3	20	theme	flavan-3-ol	659:669	arg1	%					684:684	ca. 40 %	677:684	ca. 40 %	677:684	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	3	21	theme	great	653:657	arg1	loss					671:674	a great flavan-3-ol loss	651:674	a great flavan-3-ol loss (ca. 40 %)	651:685	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	3	21	theme	great	653:657	arg1	%					684:684	ca. 40 %	677:684	ca. 40 %	677:684	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	7	22	from	effects	1023:1029	arg1	astringency					1039:1049	wine astringency	1034:1049	wine astringency	1034:1049	On the contrary, PSW showed no relevant effects on wine astringency.
36096051	7	23	theme	wine	1034:1037	arg1	astringency					1039:1049	wine astringency	1034:1049	wine astringency	1034:1049	On the contrary, PSW showed no relevant effects on wine astringency.
36096051	0	24	theme	addition	14:21	arg1	Effect					0:5	Effect	0:5	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.	0:160	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	3	25	theme	flavan-3-ol-polysaccharide	548:573	arg1	interactions					575:586	flavan-3-ol-polysaccharide interactions	548:586	flavan-3-ol-polysaccharide interactions	548:586	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	1	26	from	skins	223:227	arg1	polysaccharides					170:184	Soluble polysaccharides	162:184	Soluble polysaccharides from white (PSW) and red (PSR) grape skins	162:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	26	from	skins	223:227	arg1	modulators					272:281	potential modulators	262:281	potential modulators of the unbalanced astringency of a Tempranillo red wine	262:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	27	theme	white	191:195	arg1	skins					223:227	white (PSW) and red (PSR) grape skins	191:227	white (PSW) and red (PSR) grape skins	191:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	7	28	theme	relevant	1014:1021	arg1	effects					1023:1029	no relevant effects	1011:1029	no relevant effects on wine astringency	1011:1049	On the contrary, PSW showed no relevant effects on wine astringency.
36096051	3	29	dep	flavan-3-ols	738:749	arg1	ca					752:753	ca	752:753	ca	752:753	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	8	30	theme	color	1089:1093	arg1	variations					1075:1084	potential variations	1065:1084	potential variations of color	1065:1093	Furthermore, potential variations of color were also assessed and no deleterious effect was observed after the addition of any polysaccharide.
36096051	0	31	theme	soluble	26:32	arg1	polysaccharides					34:48	soluble polysaccharides	26:48	soluble polysaccharides from red and white grape skins	26:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	6	32	theme	molecular	910:918	arg1	size					920:923	the polysaccharide molecular size	891:923	the polysaccharide molecular size	891:923	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	4	33	dep	cal/mol	778:784	arg1	ca					797:798	PSW (ca	792:798	PSW (ca	792:798	ΔGtotal = -2.14 × 104 cal/mol) than PSW (ca.
36096051	6	34	theme	polysaccharide	895:908	arg1	size					920:923	the polysaccharide molecular size	891:923	the polysaccharide molecular size	891:923	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	0	35	theme	sensory	117:123	arg1	properties					125:134	sensory properties	117:134	sensory properties	117:134	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	2	36	from	changes	438:444	arg1	profile					466:472	the polyphenolic profile	449:472	the polyphenolic profile	449:472	The modulation of astringency was evaluated by a sensory panel and it seemed to be related to the changes in the polyphenolic profile.
36096051	2	37	theme	sensory	389:395	arg1	panel					397:401	a sensory panel	387:401	a sensory panel	387:401	The modulation of astringency was evaluated by a sensory panel and it seemed to be related to the changes in the polyphenolic profile.
36096051	2	38	theme	astringency	358:368	arg1	modulation					344:353	The modulation	340:353	The modulation of astringency	340:368	The modulation of astringency was evaluated by a sensory panel and it seemed to be related to the changes in the polyphenolic profile.
36096051	1	39	theme	potential	262:270	arg1	polysaccharides					170:184	Soluble polysaccharides	162:184	Soluble polysaccharides from white (PSW) and red (PSR) grape skins	162:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	39	theme	potential	262:270	arg1	modulators					272:281	potential modulators	262:281	potential modulators of the unbalanced astringency of a Tempranillo red wine	262:337	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	0	40	theme	Tempranillo	139:149	arg1	wines					155:159	Tempranillo red wines	139:159	Tempranillo red wines	139:159	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	8	41	theme	potential	1065:1073	arg1	variations					1075:1084	potential variations	1065:1084	potential variations of color	1065:1093	Furthermore, potential variations of color were also assessed and no deleterious effect was observed after the addition of any polysaccharide.
36096051	0	42	theme	polysaccharides	34:48	arg1	addition					14:21	the addition	10:21	the addition of soluble polysaccharides from red and white grape skins	10:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	0	43	theme	wines	155:159	arg1	composition					101:111	polyphenolic composition	88:111	polyphenolic composition	88:111	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	0	43	theme	wines	155:159	arg1	properties					125:134	sensory properties	117:134	sensory properties	117:134	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	4	44	theme	ΔGtotal = -2.14 × 104	756:776	arg1	cal/mol					778:784	ΔGtotal = -2.14 × 104 cal/mol)	756:785	ΔGtotal = -2.14 × 104 cal/mol)	756:785	ΔGtotal = -2.14 × 104 cal/mol) than PSW (ca.
36096051	6	45	attach	presence	936:943	arg1	structure					972:980	the structure	968:980	the structure	968:980	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	6	45	attach	presence	936:943	arg2	arabinogalactans					948:963	arabinogalactans	948:963	arabinogalactans	948:963	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	0	46	theme	red	151:153	arg1	wines					155:159	Tempranillo red wines	139:159	Tempranillo red wines	139:159	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	3	47	theme	wine	626:629	arg1	astringency					631:641	wine astringency	626:641	wine astringency causing a great flavan-3-ol loss (ca. 40 %)	626:685	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
36096051	8	48	theme	deleterious	1121:1131	arg1	effect					1133:1138	no deleterious effect	1118:1138	no deleterious effect	1118:1138	Furthermore, potential variations of color were also assessed and no deleterious effect was observed after the addition of any polysaccharide.
36096051	1	49	theme	red	207:209	arg1	skins					223:227	white (PSW) and red (PSR) grape skins	191:227	white (PSW) and red (PSR) grape skins	191:227	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	0	50	from	skins	75:79	arg1	addition					14:21	the addition	10:21	the addition of soluble polysaccharides from red and white grape skins	10:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	0	50	from	skins	75:79	arg1	polysaccharides					34:48	soluble polysaccharides	26:48	soluble polysaccharides from red and white grape skins	26:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	1	51	dep	white	191:195	arg1	PSR					212:214	PSR	212:214	PSR	212:214	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	1	51	dep	white	191:195	arg1	PSW					198:200	PSW	198:200	PSW	198:200	Soluble polysaccharides from white (PSW) and red (PSR) grape skins were obtained to be evaluated as potential modulators of the unbalanced astringency of a Tempranillo red wine.
36096051	6	52	theme	interactions	855:866	arg1	related					880:886	related	880:886	related	880:886	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	6	52	theme	interactions	855:866	arg1	strength					837:844	The strength	833:844	The strength of these interactions	833:866	The strength of these interactions seems to be related to the polysaccharide molecular size and to the presence of arabinogalactans in the structure.
36096051	0	53	theme	red	55:57	arg1	skins					75:79	red and white grape skins	55:79	red and white grape skins	55:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	0	54	from	addition	14:21	arg1	skins					75:79	red and white grape skins	55:79	red and white grape skins	55:79	Effect of the addition of soluble polysaccharides from red and white grape skins on the polyphenolic composition and sensory properties of Tempranillo red wines.
36096051	3	55	dep	40 	681:683	arg1	ca.					677:679	ca.	677:679	ca.	677:679	Isothermal Titration Calorimetry (ITC) studies, employed to characterize flavan-3-ol-polysaccharide interactions, showed that PSR decreased noticeably wine astringency causing a great flavan-3-ol loss (ca. 40 %), since they interacted more spontaneously with the flavan-3-ols (ca.
37272940	10	0	theme	lichenase	1400:1408	arg1	efficiency					1386:1395	the hydrolysis efficiency	1371:1395	the hydrolysis efficiency of lichenase	1371:1408	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	3	1	theme	LPMOs	503:507	arg1	stability					490:498	the poor stability	481:498	the poor stability of LPMOs	481:507	However, their practical application was hampered by the complex and costly preparation procedure, as well as the poor stability of LPMOs.
37272940	12	2	theme	insoluble	1596:1604	arg1	lichenan					1606:1613	insoluble lichenan	1596:1613	insoluble lichenan	1596:1613	• The novel function of SpyCatcher in binding to insoluble lichenan was first demonstrated.
37272940	7	3	contain	had	941:943	arg1	SCE					937:939	SCE	937:939	SCE	937:939	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	7	3	contain	had	941:943	arg2	influence					948:956	no influence	945:956	no influence	945:956	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	2	4	theme	lichenases	359:368	arg1	efficiency					345:354	the hydrolysis efficiency	330:354	the hydrolysis efficiency of lichenases	330:368	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	10	5	theme	novel	1312:1316	arg1	protein					1346:1352	A novel self-purification auxiliary protein	1310:1352	A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase	1310:1408	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	10	6	theme	auxiliary	1336:1344	arg1	protein					1346:1352	A novel self-purification auxiliary protein	1310:1352	A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase	1310:1408	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	0	7	theme	biomass	93:99	arg1	degradation					101:111	biomass degradation	93:111	biomass degradation	93:111	A novel self-purified auxiliary protein enhances the lichenase activity towards lichenan for biomass degradation.
37272940	10	8	theme	hydrolysis	1375:1384	arg1	efficiency					1386:1395	the hydrolysis efficiency	1371:1395	the hydrolysis efficiency of lichenase	1371:1408	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	10	9	theme	self-purification	1318:1334	arg1	protein					1346:1352	A novel self-purification auxiliary protein	1310:1352	A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase	1310:1408	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	6	10	theme	boosting	764:771	arg1	degree					773:778	the boosting degree	760:778	the boosting degree for SCE/lichenase	760:796	Under the optimal conditions, the boosting degree for SCE/lichenase was 1.45, and the reducing sugar yield improved by nearly 45%.
37272940	6	10	theme	boosting	764:771	arg1	1.45					802:805	1.45	802:805	1.45	802:805	Under the optimal conditions, the boosting degree for SCE/lichenase was 1.45, and the reducing sugar yield improved by nearly 45%.
37272940	10	11	dep	POINTS	1300:1305	arg1	identified					1419:1428	identified	1419:1428	has been identified	1410:1428	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	3	12	theme	preparation	447:457	arg1	procedure					459:467	the complex and costly preparation procedure	424:467	the complex and costly preparation procedure	424:467	However, their practical application was hampered by the complex and costly preparation procedure, as well as the poor stability of LPMOs.
37272940	9	13	theme	biomass	1259:1265	arg1	degradation					1267:1277	biomass degradation	1259:1277	biomass degradation	1259:1277	These findings endow SC with a novel function in binding to insoluble lichenan, paving the way for biomass degradation and biorefinery.
37272940	7	14	theme	liquid	893:898	arg1	HPLC					916:919	HPLC	916:919	HPLC	916:919	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	7	14	theme	liquid	893:898	arg1	chromatography					900:913	high-performance liquid chromatography	876:913	high-performance liquid chromatography (HPLC)	876:920	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	0	15	theme	novel	2:6	arg1	protein					32:38	A novel self-purified auxiliary protein	0:38	A novel self-purified auxiliary protein	0:38	A novel self-purified auxiliary protein enhances the lichenase activity towards lichenan for biomass degradation.
37272940	7	16	theme	chromatography	900:913	arg1	results					865:871	The results	861:871	The results of high-performance liquid chromatography (HPLC)	861:920	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	4	17	theme	stable	544:549	arg1	protein					561:567	a novel and stable auxiliary protein	532:567	a novel and stable auxiliary protein named SCE	532:577	Herein, we discovered a novel and stable auxiliary protein named SCE to boost the hydrolysis efficiency.
37272940	8	18	theme	experimental	1010:1021	arg1	verification					1023:1034	the experimental verification	1006:1034	the experimental verification	1006:1034	Through the experimental verification and bioinformatics analysis, we proposed the role of SCE in promoting the interaction between the lichenase and substrates.
37272940	12	19	from	function	1559:1566	arg1	binding					1585:1591	binding	1585:1591	binding to insoluble lichenan	1585:1613	• The novel function of SpyCatcher in binding to insoluble lichenan was first demonstrated.
37272940	12	20	theme	novel	1553:1557	arg1	function					1559:1566	• The novel function	1547:1566	• The novel function of SpyCatcher in binding to insoluble lichenan	1547:1613	• The novel function of SpyCatcher in binding to insoluble lichenan was first demonstrated.
37272940	3	21	theme	costly	440:445	arg1	procedure					459:467	the complex and costly preparation procedure	424:467	the complex and costly preparation procedure	424:467	However, their practical application was hampered by the complex and costly preparation procedure, as well as the poor stability of LPMOs.
37272940	0	22	theme	auxiliary	22:30	arg1	protein					32:38	A novel self-purified auxiliary protein	0:38	A novel self-purified auxiliary protein	0:38	A novel self-purified auxiliary protein enhances the lichenase activity towards lichenan for biomass degradation.
37272940	8	23	theme	bioinformatics	1040:1053	arg1	analysis					1055:1062	bioinformatics analysis	1040:1062	bioinformatics analysis	1040:1062	Through the experimental verification and bioinformatics analysis, we proposed the role of SCE in promoting the interaction between the lichenase and substrates.
37272940	6	24	theme	optimal	740:746	arg1	conditions					748:757	the optimal conditions	736:757	the optimal conditions	736:757	Under the optimal conditions, the boosting degree for SCE/lichenase was 1.45, and the reducing sugar yield improved by nearly 45%.
37272940	3	25	theme	practical	386:394	arg1	application					396:406	their practical application	380:406	their practical application	380:406	However, their practical application was hampered by the complex and costly preparation procedure, as well as the poor stability of LPMOs.
37272940	4	26	theme	auxiliary	551:559	arg1	protein					561:567	a novel and stable auxiliary protein	532:567	a novel and stable auxiliary protein named SCE	532:577	Herein, we discovered a novel and stable auxiliary protein named SCE to boost the hydrolysis efficiency.
37272940	6	27	theme	sugar	825:829	arg1	yield					831:835	the reducing sugar yield	812:835	the reducing sugar yield	812:835	Under the optimal conditions, the boosting degree for SCE/lichenase was 1.45, and the reducing sugar yield improved by nearly 45%.
37272940	3	28	theme	complex	428:434	arg1	procedure					459:467	the complex and costly preparation procedure	424:467	the complex and costly preparation procedure	424:467	However, their practical application was hampered by the complex and costly preparation procedure, as well as the poor stability of LPMOs.
37272940	6	29	theme	reducing	816:823	arg1	yield					831:835	the reducing sugar yield	812:835	the reducing sugar yield	812:835	Under the optimal conditions, the boosting degree for SCE/lichenase was 1.45, and the reducing sugar yield improved by nearly 45%.
37272940	12	30	theme	SpyCatcher	1571:1580	arg1	function					1559:1566	• The novel function	1547:1566	• The novel function of SpyCatcher in binding to insoluble lichenan	1547:1613	• The novel function of SpyCatcher in binding to insoluble lichenan was first demonstrated.
37272940	10	31	theme	KEY	1296:1298	arg1	POINTS					1300:1305	KEY POINTS	1296:1305	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.	1296:1429	KEY POINTS: • A novel self-purification auxiliary protein that could boost the hydrolysis efficiency of lichenase has been identified.
37272940	0	32	theme	lichenase	53:61	arg1	activity					63:70	the lichenase activity	49:70	the lichenase activity towards lichenan for biomass degradation	49:111	A novel self-purified auxiliary protein enhances the lichenase activity towards lichenan for biomass degradation.
37272940	7	33	theme	lichenase	987:995	arg1	pattern					976:982	the hydrolysis pattern	961:982	the hydrolysis pattern of lichenase	961:995	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	7	34	theme	hydrolysis	965:974	arg1	pattern					976:982	the hydrolysis pattern	961:982	the hydrolysis pattern of lichenase	961:995	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	4	35	theme	novel	534:538	arg1	protein					561:567	a novel and stable auxiliary protein	532:567	a novel and stable auxiliary protein named SCE	532:577	Herein, we discovered a novel and stable auxiliary protein named SCE to boost the hydrolysis efficiency.
37272940	5	36	theme	elastin-like	655:666	arg1	polypeptides					668:679	elastin-like polypeptides	655:679	elastin-like polypeptides (ELPs)	655:686	SCE was composed of SpyCatcher (SC) and elastin-like polypeptides (ELPs) and could be easily and cheaply prepared.
37272940	5	36	theme	elastin-like	655:666	arg1	ELPs					682:685	ELPs	682:685	ELPs	682:685	SCE was composed of SpyCatcher (SC) and elastin-like polypeptides (ELPs) and could be easily and cheaply prepared.
37272940	2	37	theme	Carbohydrate-binding	214:233	arg1	CBMs					244:247	CBMs	244:247	CBMs	244:247	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	2	37	theme	Carbohydrate-binding	214:233	arg1	modules					235:241	Carbohydrate-binding modules	214:241	Carbohydrate-binding modules (CBMs)	214:248	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	9	38	theme	novel	1191:1195	arg1	function					1197:1204	a novel function	1189:1204	a novel function in binding to insoluble lichenan	1189:1237	These findings endow SC with a novel function in binding to insoluble lichenan, paving the way for biomass degradation and biorefinery.
37272940	7	39	theme	high-performance	876:891	arg1	HPLC					916:919	HPLC	916:919	HPLC	916:919	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	7	39	theme	high-performance	876:891	arg1	chromatography					900:913	high-performance liquid chromatography	876:913	high-performance liquid chromatography (HPLC)	876:920	The results of high-performance liquid chromatography (HPLC) indicated that SCE had no influence on the hydrolysis pattern of lichenase.
37272940	1	40	theme	complex	125:131	arg1	composition					133:143	the complex composition	121:143	the complex composition of lichenan	121:155	Due to the complex composition of lichenan, lichenase alone cannot always hydrolyze it efficiently.
37272940	4	41	theme	hydrolysis	592:601	arg1	efficiency					603:612	the hydrolysis efficiency	588:612	the hydrolysis efficiency	588:612	Herein, we discovered a novel and stable auxiliary protein named SCE to boost the hydrolysis efficiency.
37272940	8	42	dep	lichenase	1134:1142	arg1	the					1130:1132	the	1130:1132	the	1130:1132	Through the experimental verification and bioinformatics analysis, we proposed the role of SCE in promoting the interaction between the lichenase and substrates.
37272940	2	43	theme	polysaccharide	260:273	arg1	LPMOs					291:295	LPMOs	291:295	LPMOs	291:295	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	2	43	theme	polysaccharide	260:273	arg1	monooxygenases					275:288	lytic polysaccharide monooxygenases	254:288	lytic polysaccharide monooxygenases (LPMOs)	254:296	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	3	44	theme	poor	485:488	arg1	stability					490:498	the poor stability	481:498	the poor stability of LPMOs	481:507	However, their practical application was hampered by the complex and costly preparation procedure, as well as the poor stability of LPMOs.
37272940	11	45	theme	•	1431:1431	arg1	protein					1437:1443	• The protein	1431:1443	• The protein	1431:1443	• The protein is highly produced, simple to prepare, well stable, and does not require any external electron donor.
37272940	2	46	theme	hydrolysis	334:343	arg1	efficiency					345:354	the hydrolysis efficiency	330:354	the hydrolysis efficiency of lichenases	330:368	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	8	47	theme	SCE	1089:1091	arg1	role					1081:1084	the role	1077:1084	the role of SCE in promoting the interaction between the lichenase and substrates	1077:1157	Through the experimental verification and bioinformatics analysis, we proposed the role of SCE in promoting the interaction between the lichenase and substrates.
37272940	9	48	theme	insoluble	1220:1228	arg1	lichenan					1230:1237	insoluble lichenan	1220:1237	insoluble lichenan	1220:1237	These findings endow SC with a novel function in binding to insoluble lichenan, paving the way for biomass degradation and biorefinery.
37272940	2	49	theme	lytic	254:258	arg1	LPMOs					291:295	LPMOs	291:295	LPMOs	291:295	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	2	49	theme	lytic	254:258	arg1	monooxygenases					275:288	lytic polysaccharide monooxygenases	254:288	lytic polysaccharide monooxygenases (LPMOs)	254:296	Carbohydrate-binding modules (CBMs) and lytic polysaccharide monooxygenases (LPMOs) have been confirmed to increase the hydrolysis efficiency of lichenases.
37272940	11	50	theme	The	1433:1435	arg1	protein					1437:1443	• The protein	1431:1443	• The protein	1431:1443	• The protein is highly produced, simple to prepare, well stable, and does not require any external electron donor.
37272940	11	51	theme	external	1522:1529	arg1	donor					1540:1544	any external electron donor	1518:1544	any external electron donor	1518:1544	• The protein is highly produced, simple to prepare, well stable, and does not require any external electron donor.
37272940	0	52	theme	self-purified	8:20	arg1	protein					32:38	A novel self-purified auxiliary protein	0:38	A novel self-purified auxiliary protein	0:38	A novel self-purified auxiliary protein enhances the lichenase activity towards lichenan for biomass degradation.
37272940	11	53	theme	electron	1531:1538	arg1	donor					1540:1544	any external electron donor	1518:1544	any external electron donor	1518:1544	• The protein is highly produced, simple to prepare, well stable, and does not require any external electron donor.
37272940	1	54	theme	lichenan	148:155	arg1	composition					133:143	the complex composition	121:143	the complex composition of lichenan	121:155	Due to the complex composition of lichenan, lichenase alone cannot always hydrolyze it efficiently.
37272940	9	55	from	function	1197:1204	arg1	binding					1209:1215	binding	1209:1215	binding to insoluble lichenan	1209:1237	These findings endow SC with a novel function in binding to insoluble lichenan, paving the way for biomass degradation and biorefinery.
36087992	5	0	dep	starch	627:632	arg1	ST					635:636	ST	635:636	ST	635:636	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	7	1	theme	functional	1166:1175	arg1	materials					1177:1185	novel functional materials	1160:1185	novel functional materials	1160:1185	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	5	2	theme	chiroptical	821:831	arg1	activity					833:840	chiroptical activity	821:840	chiroptical activity	821:840	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	4	3	theme	CuO	545:547	arg1	growth					535:540	growth	535:540	growth of CuO	535:547	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	3	4	from	C3	401:402	arg1	poly/oligosaccharides					407:427	poly/oligosaccharides	407:427	poly/oligosaccharides	407:427	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	6	5	theme	form	1021:1024	arg1	architectures					1057:1069	form Cu-Trp metal organic framework architectures	1021:1069	form Cu-Trp metal organic framework architectures	1021:1069	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	3	6	theme	42+	371:373	arg1	ions					375:378	Cu(NH3)42+ ions	364:378	Cu(NH3)42+ ions	364:378	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	5	7	used	used	643:646	arg2	oligosaccharide					729:743	a representative oligosaccharide	712:743	a representative oligosaccharide	712:743	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	7	used	used	643:646	arg2	nanocrystal					605:615	Cellulose nanocrystal	595:615	Cellulose nanocrystal (CNC)	595:621	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	7	used	used	643:646	arg2	starch					627:632	starch	627:632	starch (ST)	627:637	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	7	used	used	643:646	arg2	polysaccharides					666:680	representative polysaccharides	651:680	representative polysaccharides	651:680	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	7	used	used	643:646	arg2	β-cyclodextrin					687:700	β-cyclodextrin	687:700	β-cyclodextrin (β-CD)	687:707	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	7	used	used	643:646	arg2	CNC					618:620	CNC	618:620	CNC	618:620	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	4	8	theme	in	552:553	arg1	transformation					560:573	in situ transformation	552:573	in situ transformation of Cu(NH3)42+ ions	552:592	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	0	9	theme	chiral	98:103	arg1	particles					105:113	chiral particles	98:113	chiral particles	98:113	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	6	10	theme	Cu-Trp	1026:1031	arg1	architectures					1057:1069	form Cu-Trp metal organic framework architectures	1021:1069	form Cu-Trp metal organic framework architectures	1021:1069	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	11	theme	different	1076:1084	arg1	morphologies					1086:1097	different morphologies	1076:1097	different morphologies	1076:1097	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	2	12	theme	chiral	307:312	arg1	inducers					314:321	chiral inducers	307:321	chiral inducers	307:321	Herein, we develop a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates.
36087992	2	12	theme	chiral	307:312	arg1	poly/oligosaccharides					277:297	poly/oligosaccharides	277:297	poly/oligosaccharides	277:297	Herein, we develop a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates.
36087992	5	13	theme	representative	651:664	arg1	starch					627:632	starch	627:632	starch (ST)	627:637	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	13	theme	representative	651:664	arg1	polysaccharides					666:680	representative polysaccharides	651:680	representative polysaccharides	651:680	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	13	theme	representative	651:664	arg1	nanocrystal					605:615	Cellulose nanocrystal	595:615	Cellulose nanocrystal (CNC)	595:621	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	3	14	from	groups	384:389	arg1	C3					401:402	C3	401:402	C3	401:402	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	3	14	from	groups	384:389	arg1	C2					394:395	C2	394:395	C2	394:395	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	1	15	with	resources	160:168	arg1	chirality					184:192	abundant chirality	175:192	abundant chirality	175:192	Poly/oligosaccharides are renewable natural resources with abundant chirality.
36087992	7	16	theme	accessible	1129:1138	arg1	approach					1140:1147	an easily accessible approach	1119:1147	an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications	1119:1278	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	4	17	theme	ions	589:592	arg1	transformation					560:573	in situ transformation	552:573	in situ transformation of Cu(NH3)42+ ions	552:592	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	0	18	theme	cellulose	6:14	arg1	poly/oligosaccharides					43:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	0	18	theme	cellulose	6:14	arg1	inducers					75:82	chiral inducers	68:82	chiral inducers for preparing chiral particles	68:113	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	7	19	from	promise	1249:1255	arg1	applications					1267:1278	chiral applications	1260:1278	chiral applications	1260:1278	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	5	20	theme	chrysanthemum-like	777:794	arg1	particles					806:814	chrysanthemum-like composite particles	777:814	chrysanthemum-like composite particles with chiroptical activity	777:840	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	21	theme	representative	714:727	arg1	oligosaccharide					729:743	a representative oligosaccharide	712:743	a representative oligosaccharide	712:743	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	21	theme	representative	714:727	arg1	starch					627:632	starch	627:632	starch (ST)	627:637	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	21	theme	representative	714:727	arg1	nanocrystal					605:615	Cellulose nanocrystal	595:615	Cellulose nanocrystal (CNC)	595:621	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	22	theme	composite	796:804	arg1	particles					806:814	chrysanthemum-like composite particles	777:814	chrysanthemum-like composite particles with chiroptical activity	777:840	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	0	23	theme	starch	17:22	arg1	poly/oligosaccharides					43:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	0	23	theme	starch	17:22	arg1	inducers					75:82	chiral inducers	68:82	chiral inducers for preparing chiral particles	68:113	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	6	24	theme	saccharide	887:896	arg1	CSP					909:911	CSP	909:911	CSP	909:911	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	24	theme	saccharide	887:896	arg1	particles					898:906	chiral CuO/poly(oligo)saccharide particles	865:906	chiral CuO/poly(oligo)saccharide particles (CSP)	865:912	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	3	25	theme	OH	381:382	arg1	groups					384:389	OH groups	381:389	OH groups on C2 and C3 in poly/oligosaccharides	381:427	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	5	26	with	duchesnea	762:770	arg1	activity					833:840	chiroptical activity	821:840	chiroptical activity	821:840	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	4	27	dep	in	552:553	arg1	situ					555:558	situ	555:558	situ	555:558	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	2	28	theme	growth	327:332	arg1	templates					334:342	growth templates	327:342	growth templates	327:342	Herein, we develop a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates.
36087992	2	28	theme	growth	327:332	arg1	poly/oligosaccharides					277:297	poly/oligosaccharides	277:297	poly/oligosaccharides	277:297	Herein, we develop a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates.
36087992	6	29	theme	tryptophan	988:997	arg1	enantiomers					1005:1015	tryptophan (Trp) enantiomers	988:1015	tryptophan (Trp) enantiomers	988:1015	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	0	30	theme	β-cyclodextrin	28:41	arg1	poly/oligosaccharides					43:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	0	30	theme	β-cyclodextrin	28:41	arg1	inducers					75:82	chiral inducers	68:82	chiral inducers for preparing chiral particles	68:113	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	6	31	theme	oligo	881:885	arg1	CSP					909:911	CSP	909:911	CSP	909:911	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	31	theme	oligo	881:885	arg1	particles					898:906	chiral CuO/poly(oligo)saccharide particles	865:906	chiral CuO/poly(oligo)saccharide particles (CSP)	865:912	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	4	32	theme	42+	585:587	arg1	ions					589:592	Cu(NH3)42+ ions	578:592	Cu(NH3)42+ ions	578:592	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	5	33	with	dandelion	751:759	arg1	activity					833:840	chiroptical activity	821:840	chiroptical activity	821:840	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	2	34	theme	active	251:256	arg1	particles					258:266	optically active particles	241:266	optically active particles	241:266	Herein, we develop a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates.
36087992	6	35	theme	CuO/poly	872:879	arg1	CSP					909:911	CSP	909:911	CSP	909:911	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	35	theme	CuO/poly	872:879	arg1	particles					898:906	chiral CuO/poly(oligo)saccharide particles	865:906	chiral CuO/poly(oligo)saccharide particles (CSP)	865:912	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	7	36	theme	poly/oligosaccharide-based	1190:1215	arg1	induction					1224:1232	poly/oligosaccharide-based chiral induction	1190:1232	poly/oligosaccharide-based chiral induction	1190:1232	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	5	37	with	particles	806:814	arg1	activity					833:840	chiroptical activity	821:840	chiroptical activity	821:840	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	6	38	theme	chiral	865:870	arg1	CSP					909:911	CSP	909:911	CSP	909:911	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	38	theme	chiral	865:870	arg1	particles					898:906	chiral CuO/poly(oligo)saccharide particles	865:906	chiral CuO/poly(oligo)saccharide particles (CSP)	865:912	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	5	39	theme	Cellulose	595:603	arg1	polysaccharides					666:680	representative polysaccharides	651:680	representative polysaccharides	651:680	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	39	theme	Cellulose	595:603	arg1	CNC					618:620	CNC	618:620	CNC	618:620	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	39	theme	Cellulose	595:603	arg1	β-cyclodextrin					687:700	β-cyclodextrin	687:700	β-cyclodextrin (β-CD)	687:707	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	39	theme	Cellulose	595:603	arg1	oligosaccharide					729:743	a representative oligosaccharide	712:743	a representative oligosaccharide	712:743	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	39	theme	Cellulose	595:603	arg1	starch					627:632	starch	627:632	starch (ST)	627:637	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	5	39	theme	Cellulose	595:603	arg1	nanocrystal					605:615	Cellulose nanocrystal	595:615	Cellulose nanocrystal (CNC)	595:621	Cellulose nanocrystal (CNC) and starch (ST) are used as representative polysaccharides, and β-cyclodextrin (β-CD) as a representative oligosaccharide, thus dandelion, duchesnea, and chrysanthemum-like composite particles with chiroptical activity are obtained.
36087992	7	40	theme	novel	1160:1164	arg1	materials					1177:1185	novel functional materials	1160:1185	novel functional materials	1160:1185	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	1	41	theme	renewable	142:150	arg1	resources					160:168	renewable natural resources	142:168	renewable natural resources with abundant chirality	142:192	Poly/oligosaccharides are renewable natural resources with abundant chirality.
36087992	1	41	theme	renewable	142:150	arg1	Poly/oligosaccharides					116:136	Poly/oligosaccharides	116:136	Poly/oligosaccharides	116:136	Poly/oligosaccharides are renewable natural resources with abundant chirality.
36087992	4	42	theme	same	495:498	arg1	time					500:503	the same time	491:503	the same time	491:503	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	6	43	with	coordination	970:981	arg1	architectures					1057:1069	form Cu-Trp metal organic framework architectures	1021:1069	form Cu-Trp metal organic framework architectures	1021:1069	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	43	with	coordination	970:981	arg1	morphologies					1086:1097	different morphologies	1076:1097	different morphologies	1076:1097	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	43	with	coordination	970:981	arg1	enantiomers					1005:1015	tryptophan (Trp) enantiomers	988:1015	tryptophan (Trp) enantiomers	988:1015	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	1	44	theme	natural	152:158	arg1	resources					160:168	renewable natural resources	142:168	renewable natural resources with abundant chirality	142:192	Poly/oligosaccharides are renewable natural resources with abundant chirality.
36087992	1	44	theme	natural	152:158	arg1	Poly/oligosaccharides					116:136	Poly/oligosaccharides	116:136	Poly/oligosaccharides	116:136	Poly/oligosaccharides are renewable natural resources with abundant chirality.
36087992	2	45	theme	general	216:222	arg1	route					224:228	a general route	214:228	a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates	214:342	Herein, we develop a general route to prepare optically active particles by using poly/oligosaccharides as both chiral inducers and growth templates.
36087992	6	46	theme	framework	1047:1055	arg1	architectures					1057:1069	form Cu-Trp metal organic framework architectures	1021:1069	form Cu-Trp metal organic framework architectures	1021:1069	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	7	47	theme	great	1243:1247	arg1	promise					1249:1255	great promise	1243:1255	great promise in chiral applications	1243:1278	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	3	48	theme	Cu	364:365	arg1	ions					375:378	Cu(NH3)42+ ions	364:378	Cu(NH3)42+ ions	364:378	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	6	49	theme	metal	1033:1037	arg1	architectures					1057:1069	form Cu-Trp metal organic framework architectures	1021:1069	form Cu-Trp metal organic framework architectures	1021:1069	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	6	50	theme	organic	1039:1045	arg1	architectures					1057:1069	form Cu-Trp metal organic framework architectures	1021:1069	form Cu-Trp metal organic framework architectures	1021:1069	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36087992	4	51	theme	Cu	578:579	arg1	ions					589:592	Cu(NH3)42+ ions	578:592	Cu(NH3)42+ ions	578:592	At the same time, poly/oligosaccharides direct growth of CuO by in situ transformation of Cu(NH3)42+ ions.
36087992	0	52	theme	chiral	68:73	arg1	poly/oligosaccharides					43:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	cellulose, starch and β-cyclodextrin poly/oligosaccharides	6:63	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	0	52	theme	chiral	68:73	arg1	inducers					75:82	chiral inducers	68:82	chiral inducers for preparing chiral particles	68:113	Using cellulose, starch and β-cyclodextrin poly/oligosaccharides as chiral inducers for preparing chiral particles.
36087992	3	53	from	C2	394:395	arg1	poly/oligosaccharides					407:427	poly/oligosaccharides	407:427	poly/oligosaccharides	407:427	By complexing with Cu(NH3)42+ ions, OH groups on C2 and C3 in poly/oligosaccharides can transfer the chirality to Cu(II) and retain it in CuO.
36087992	7	54	theme	chiral	1260:1265	arg1	applications					1267:1278	chiral applications	1260:1278	chiral applications	1260:1278	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	1	55	theme	abundant	175:182	arg1	chirality					184:192	abundant chirality	175:192	abundant chirality	175:192	Poly/oligosaccharides are renewable natural resources with abundant chirality.
36087992	7	56	theme	chiral	1217:1222	arg1	induction					1224:1232	poly/oligosaccharide-based chiral induction	1190:1232	poly/oligosaccharide-based chiral induction	1190:1232	The study provides an easily accessible approach to prepare novel functional materials by poly/oligosaccharide-based chiral induction and hold great promise in chiral applications.
36087992	6	57	theme	enantioselective	926:941	arg1	ability					943:949	enantioselective ability	926:949	enantioselective ability	926:949	Besides, chiral CuO/poly(oligo)saccharide particles (CSP) demonstrate enantioselective ability by differentiating coordination with tryptophan (Trp) enantiomers and form Cu-Trp metal organic framework architectures with different morphologies.
36334478	4	0	theme	gel	938:940	arg1	fraction					942:949	the gel fraction	934:949	the gel fraction	934:949	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	0	theme	gel	938:940	arg1	ratio					990:994	any PVA/amylose/amylopectin mixing ratio	955:994	any PVA/amylose/amylopectin mixing ratio	955:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	0	theme	gel	938:940	arg1	%					931:931	the G%	926:931	the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio	926:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	5	1	theme	amylopectin	1045:1055	arg1	composition					1057:1067	amylopectin composition	1045:1067	amylopectin composition	1045:1067	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	1	2	theme	amylopectin	154:164	arg1	role					134:137	The role	130:137	The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA)	130:228	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	7	3	theme	botanical	1403:1411	arg1	origin					1413:1418	the starch botanical origin	1392:1418	the starch botanical origin	1392:1418	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	2	4	contain	containing	312:321	arg2	amylopectin					344:354	amylopectin	344:354	amylopectin	344:354	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	2	4	contain	containing	312:321	arg2	amylose					328:334	amylose	328:334	amylose	328:334	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	2	4	contain	containing	312:321	arg2	PVA					323:325	PVA	323:325	PVA	323:325	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	2	4	contain	containing	312:321	arg1	systems					304:310	simplified systems	293:310	simplified systems containing PVA, amylose, and/or amylopectin	293:354	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	4	5	with	fraction	833:840	arg1	compositions					875:886	variable compositions	866:886	variable compositions	866:886	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	3	6	contain	containing	558:567	arg1	solutions					535:543	EXPERIMENTS Pre-gel solutions	515:543	EXPERIMENTS Pre-gel solutions	515:543	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	6	contain	containing	558:567	arg2	PVA/amylose/amylopectin					603:625	PVA/amylose/amylopectin	603:625	PVA/amylose/amylopectin	603:625	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	6	contain	containing	558:567	arg2	PVA/amylopectin					582:596	PVA/amylopectin	582:596	PVA/amylopectin	582:596	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	6	contain	containing	558:567	arg2	PVA/amylose					569:579	PVA/amylose	569:579	PVA/amylose	569:579	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	0	7	theme	phase	101:105	arg1	separation					107:116	liquid-liquid phase separation	87:116	liquid-liquid phase separation	87:116	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	0	8	from	Role	0:3	arg1	cryo-gels					53:61	PVA-starch hybrid cryo-gels	35:61	PVA-starch hybrid cryo-gels	35:61	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	6	9	theme	cryogel	1229:1235	arg1	formation					1237:1245	cryogel formation	1229:1245	cryogel formation	1229:1245	In particular, PVA/amylose and PVA/amylopectin show different behaviors with respect to cryogel formation.
36334478	8	10	theme	positive	1630:1637	arg1	impact					1639:1644	a significantly positive impact	1614:1644	a significantly positive impact on our ecosystem	1614:1661	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	3	11	theme	rheological	799:809	arg1	measurements					811:822	rheological measurements	799:822	rheological measurements	799:822	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	0	12	theme	liquid-liquid	87:99	arg1	separation					107:116	liquid-liquid phase separation	87:116	liquid-liquid phase separation	87:116	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	3	13	theme	scanning	726:733	arg1	CLSM					747:750	CLSM	747:750	CLSM	747:750	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	13	theme	scanning	726:733	arg1	microscopy					735:744	confocal laser scanning microscopy	711:744	confocal laser scanning microscopy (CLSM)	711:751	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	14	theme	EXPERIMENTS	515:525	arg1	solutions					535:543	EXPERIMENTS Pre-gel solutions	515:543	EXPERIMENTS Pre-gel solutions	515:543	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	4	15	theme	G	930:930	arg1	fraction					942:949	the gel fraction	934:949	the gel fraction	934:949	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	15	theme	G	930:930	arg1	ratio					990:994	any PVA/amylose/amylopectin mixing ratio	955:994	any PVA/amylose/amylopectin mixing ratio	955:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	15	theme	G	930:930	arg1	%					931:931	the G%	926:931	the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio	926:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	1	16	dep	HYPOTHESIS	119:128	arg1	role					134:137	The role	130:137	The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA)	130:228	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	3	17	theme	confocal	711:718	arg1	CLSM					747:750	CLSM	747:750	CLSM	747:750	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	17	theme	confocal	711:718	arg1	microscopy					735:744	confocal laser scanning microscopy	711:744	confocal laser scanning microscopy (CLSM)	711:751	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	4	18	theme	gel	829:831	arg1	fraction					833:840	The gel fraction	825:840	The gel fraction (G%) of 23 samples with variable compositions	825:886	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	18	theme	gel	829:831	arg1	%					844:844	G%	843:844	G%	843:844	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	1	19	from	role	134:137	arg1	formation					173:181	the formation	169:181	the formation of cryogels based on Poly(vinyl alcohol) (PVA)	169:228	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	4	20	theme	PVA/amylose/amylopectin	959:981	arg1	ratio					990:994	any PVA/amylose/amylopectin mixing ratio	955:994	any PVA/amylose/amylopectin mixing ratio	955:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	3	21	from	PVA/amylose/amylopectin	603:625	arg1	ratios					639:644	variable ratios	630:644	variable ratios	630:644	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	5	22	theme	final	1098:1102	arg1	blend					1112:1116	the final polymer blend	1094:1116	the final polymer blend	1094:1116	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	2	23	theme	cryogels	422:429	arg1	features					399:406	the final features	389:406	the final features of PVA/starch cryogels	389:429	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	3	24	theme	laser	720:724	arg1	CLSM					747:750	CLSM	747:750	CLSM	747:750	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	24	theme	laser	720:724	arg1	microscopy					735:744	confocal laser scanning microscopy	711:744	confocal laser scanning microscopy (CLSM)	711:751	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	4	25	theme	G	843:843	arg1	fraction					833:840	The gel fraction	825:840	The gel fraction (G%) of 23 samples with variable compositions	825:886	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	25	theme	G	843:843	arg1	%					844:844	G%	843:844	G%	843:844	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	8	26	theme	simple	1488:1493	arg1	tool					1495:1498	a simple tool	1486:1498	a simple tool	1486:1498	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	7	27	theme	PVA/amylose/amylopectin	1343:1365	arg1	ratio					1374:1378	any PVA/amylose/amylopectin mixing ratio	1339:1378	any PVA/amylose/amylopectin mixing ratio	1339:1378	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	8	28	theme	high-quality	1534:1545	arg1	materials					1556:1564	high-quality biobased materials	1534:1564	high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem	1534:1661	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	2	29	theme	PVA/starch	411:420	arg1	cryogels					422:429	PVA/starch cryogels	411:429	PVA/starch cryogels	411:429	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	5	30	theme	blend	1112:1116	arg1	properties					1080:1089	the properties	1076:1089	the properties of the final polymer blend and cryogel formation	1076:1138	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	6	31	theme	different	1193:1201	arg1	behaviors					1203:1211	different behaviors	1193:1211	different behaviors	1193:1211	In particular, PVA/amylose and PVA/amylopectin show different behaviors with respect to cryogel formation.
36334478	7	32	theme	mixing	1367:1372	arg1	ratio					1374:1378	any PVA/amylose/amylopectin mixing ratio	1339:1378	any PVA/amylose/amylopectin mixing ratio	1339:1378	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	1	33	theme	cryogels	186:193	arg1	formation					173:181	the formation	169:181	the formation of cryogels based on Poly(vinyl alcohol) (PVA)	169:228	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	8	34	from	impact	1639:1644	arg1	ecosystem					1653:1661	our ecosystem	1649:1661	our ecosystem	1649:1661	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	2	35	theme	systematic	265:274	arg1	investigation					276:288	A systematic investigation	263:288	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin	263:354	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	3	36	from	PVA/amylose	569:579	arg1	ratios					639:644	variable ratios	630:644	variable ratios	630:644	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	2	37	theme	final	393:397	arg1	features					399:406	the final features	389:406	the final features of PVA/starch cryogels	389:429	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	0	38	theme	amylose	8:14	arg1	Role					0:3	Role	0:3	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels	0:61	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	5	39	theme	cryogel	1122:1128	arg1	formation					1130:1138	cryogel formation	1122:1138	cryogel formation	1122:1138	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	5	40	theme	formation	1130:1138	arg1	properties					1080:1089	the properties	1076:1089	the properties of the final polymer blend and cryogel formation	1076:1138	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	2	41	theme	starches	505:512	arg1	content					477:483	the amylose content	465:483	the amylose content of the employed raw starches	465:512	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	2	41	theme	starches	505:512	arg1	composition					448:458	composition	448:458	composition	448:458	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	7	42	theme	%	1323:1323	arg1	parameter					1325:1333	the simple G% parameter	1311:1333	the simple G% parameter for any PVA/amylose/amylopectin mixing ratio	1311:1378	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	3	43	from	PVA/amylopectin	582:596	arg1	ratios					639:644	variable ratios	630:644	variable ratios	630:644	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	0	44	theme	amylopectin	20:30	arg1	Role					0:3	Role	0:3	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels	0:61	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	2	45	theme	raw	501:503	arg1	starches					505:512	the employed raw starches	488:512	the employed raw starches	488:512	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	3	46	theme	variable	630:637	arg1	ratios					639:644	variable ratios	630:644	variable ratios	630:644	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	7	47	theme	starch	1396:1401	arg1	origin					1413:1418	the starch botanical origin	1392:1418	the starch botanical origin	1392:1418	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	5	48	theme	polymer	1104:1110	arg1	blend					1112:1116	the final polymer blend	1094:1116	the final polymer blend	1094:1116	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	0	49	theme	hybrid	46:51	arg1	cryo-gels					53:61	PVA-starch hybrid cryo-gels	35:61	PVA-starch hybrid cryo-gels	35:61	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	2	50	theme	employed	492:499	arg1	starches					505:512	the employed raw starches	488:512	the employed raw starches	488:512	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	7	51	theme	simple	1315:1320	arg1	parameter					1325:1333	the simple G% parameter	1311:1333	the simple G% parameter for any PVA/amylose/amylopectin mixing ratio	1311:1378	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	0	52	theme	PVA-starch	35:44	arg1	cryo-gels					53:61	PVA-starch hybrid cryo-gels	35:61	PVA-starch hybrid cryo-gels	35:61	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	3	53	theme	differential	754:765	arg1	DSC					789:791	DSC	789:791	DSC	789:791	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	53	theme	differential	754:765	arg1	calorimetry					776:786	differential scanning calorimetry	754:786	differential scanning calorimetry (DSC)	754:792	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	4	54	theme	samples	853:859	arg1	fraction					833:840	The gel fraction	825:840	The gel fraction (G%) of 23 samples with variable compositions	825:886	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	54	theme	samples	853:859	arg1	%					844:844	G%	843:844	G%	843:844	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	3	55	theme	X-ray	686:690	arg1	SAXS					704:707	SAXS	704:707	SAXS	704:707	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	55	theme	X-ray	686:690	arg1	scattering					692:701	small-angle X-ray scattering	674:701	small-angle X-ray scattering (SAXS)	674:708	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	7	56	theme	G	1322:1322	arg1	parameter					1325:1333	the simple G% parameter	1311:1333	the simple G% parameter for any PVA/amylose/amylopectin mixing ratio	1311:1378	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	8	57	theme	synthetic	1589:1597	arg1	materials					1599:1607	fully synthetic materials	1583:1607	fully synthetic materials	1583:1607	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	3	58	theme	scanning	767:774	arg1	DSC					789:791	DSC	789:791	DSC	789:791	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	58	theme	scanning	767:774	arg1	calorimetry					776:786	differential scanning calorimetry	754:786	differential scanning calorimetry (DSC)	754:792	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	8	59	theme	materials	1556:1564	arg1	formation					1521:1529	the formation	1517:1529	the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem	1517:1661	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	0	60	from	separation	107:116	arg1	networks					63:70	networks	63:70	networks	63:70	Role of amylose and amylopectin in PVA-starch hybrid cryo-gels networks formation from liquid-liquid phase separation.
36334478	2	61	theme	systems	304:310	arg1	investigation					276:288	A systematic investigation	263:288	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin	263:354	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	3	62	theme	Pre-gel	527:533	arg1	solutions					535:543	EXPERIMENTS Pre-gel solutions	515:543	EXPERIMENTS Pre-gel solutions	515:543	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	1	63	theme	vinyl	209:213	arg1	Poly					204:207	Poly	204:207	Poly(vinyl alcohol) (PVA)	204:228	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	1	63	theme	vinyl	209:213	arg1	alcohol					215:221	vinyl alcohol	209:221	vinyl alcohol	209:221	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	4	64	theme	variable	866:873	arg1	compositions					875:886	variable compositions	866:886	variable compositions	866:886	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	2	65	theme	simplified	293:302	arg1	systems					304:310	simplified systems	293:310	simplified systems containing PVA, amylose, and/or amylopectin	293:354	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	2	66	theme	amylose	469:475	arg1	content					477:483	the amylose content	465:483	the amylose content of the employed raw starches	465:512	A systematic investigation of simplified systems containing PVA, amylose, and/or amylopectin constitutes the basis to predict the final features of PVA/starch cryogels by knowing their composition, and the amylose content of the employed raw starches.
36334478	3	67	theme	small-angle	674:684	arg1	SAXS					704:707	SAXS	704:707	SAXS	704:707	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	3	67	theme	small-angle	674:684	arg1	scattering					692:701	small-angle X-ray scattering	674:701	small-angle X-ray scattering (SAXS)	674:708	EXPERIMENTS Pre-gel solutions and cryogels containing PVA/amylose, PVA/amylopectin, and PVA/amylose/amylopectin in variable ratios were investigated employing small-angle X-ray scattering (SAXS), confocal laser scanning microscopy (CLSM), differential scanning calorimetry (DSC), and rheological measurements.
36334478	1	68	theme	amylose	142:148	arg1	role					134:137	The role	130:137	The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA)	130:228	HYPOTHESIS The role of amylose and amylopectin in the formation of cryogels based on Poly(vinyl alcohol) (PVA) and starch is poorly understood.
36334478	7	69	theme	cryogel	1284:1290	arg1	formation					1292:1300	cryogel formation	1284:1300	cryogel formation	1284:1300	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	8	70	theme	biobased	1547:1554	arg1	materials					1556:1564	high-quality biobased materials	1534:1564	high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem	1534:1661	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
36334478	5	71	dep	FINDINGS	997:1004	arg1	report					1009:1014	report	1009:1014	report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation	1009:1138	FINDINGS We report on how the PVA, amylose, and amylopectin composition affect the properties of the final polymer blend and cryogel formation.
36334478	7	72	theme	gel	1427:1429	arg1	formation					1431:1439	the gel formation	1423:1439	the gel formation	1423:1439	We show that is possible to predict cryogel formation by using the simple G% parameter for any PVA/amylose/amylopectin mixing ratio, ruling out the starch botanical origin in the gel formation.
36334478	4	73	theme	ratio	990:994	arg1	fraction					942:949	the gel fraction	934:949	the gel fraction	934:949	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	73	theme	ratio	990:994	arg1	ratio					990:994	any PVA/amylose/amylopectin mixing ratio	955:994	any PVA/amylose/amylopectin mixing ratio	955:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	73	theme	ratio	990:994	arg1	%					931:931	the G%	926:931	the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio	926:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	4	74	theme	mixing	983:988	arg1	ratio					990:994	any PVA/amylose/amylopectin mixing ratio	955:994	any PVA/amylose/amylopectin mixing ratio	955:994	The gel fraction (G%) of 23 samples with variable compositions was calculated and plotted to predict the G% (the gel fraction) of any PVA/amylose/amylopectin mixing ratio.
36334478	8	75	theme	able	1501:1504	arg1	tool					1495:1498	a simple tool	1486:1498	a simple tool	1486:1498	The results reported in this work represent a simple tool, able to predict the formation of high-quality biobased materials that can replace fully synthetic materials with a significantly positive impact on our ecosystem.
37119890	0	0	theme	composite	98:106	arg1	films					108:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	7	1	theme	phosphate	942:950	arg1	PBS					967:969	PBS	967:969	PBS	967:969	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	7	1	theme	phosphate	942:950	arg1	saline					959:964	phosphate buffer saline	942:964	phosphate buffer saline (PBS)	942:970	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	3	2	theme	blend	519:523	arg1	films					525:529	ST/PAH blend films	512:529	ST/PAH blend films	512:529	ST/PAH blend films were developed and characterized.
37119890	1	3	theme	biocompatible	276:288	arg1	characteristics					290:304	their remarkable biodegradable and biocompatible characteristics	241:304	their remarkable biodegradable and biocompatible characteristics	241:304	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	0	4	theme	biodegradable	84:96	arg1	films					108:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	8	5	from	%	1100:1100	arg1	110 min					1105:1111	110 min	1105:1111	110 min	1105:1111	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	5	from	%	1100:1100	arg1	case					1014:1017	the case	1010:1017	the case of SGF (pH 1.2)	1010:1033	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	9	6	theme	oral	1311:1314	arg1	administration					1321:1334	oral drug administration	1311:1334	oral drug administration	1311:1334	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	4	7	theme	counterparts	659:670	arg1	involvement					596:606	the involvement	592:606	the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films	592:687	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	9	8	theme	biomedical	1384:1393	arg1	applications					1395:1406	other biomedical applications	1378:1406	other biomedical applications	1378:1406	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	5	9	theme	water	694:698	arg1	WCA					715:717	WCA	715:717	WCA	715:717	The water contact angle (WCA) ranged from 71° to 100° indicating that all the films were hydrophobic.
37119890	5	9	theme	water	694:698	arg1	angle					708:712	The water contact angle	690:712	The water contact angle (WCA)	690:718	The water contact angle (WCA) ranged from 71° to 100° indicating that all the films were hydrophobic.
37119890	2	10	contain	having	385:390	arg2	hydrochloride					415:427	allylamine hydrochloride	404:427	allylamine hydrochloride	404:427	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	10	contain	having	385:390	arg2	Starch/Poly					392:402	Starch/Poly	392:402	Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	392:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	10	contain	having	385:390	arg1	films					379:383	composite films	369:383	composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	369:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	10	contain	having	385:390	arg2	ST/PAH					431:436	ST/PAH	431:436	ST/PAH	431:436	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	5	11	theme	contact	700:706	arg1	WCA					715:717	WCA	715:717	WCA	715:717	The water contact angle (WCA) ranged from 71° to 100° indicating that all the films were hydrophobic.
37119890	5	11	theme	contact	700:706	arg1	angle					708:712	The water contact angle	690:712	The water contact angle (WCA)	690:718	The water contact angle (WCA) ranged from 71° to 100° indicating that all the films were hydrophobic.
37119890	9	12	theme	other	1378:1382	arg1	applications					1395:1406	other biomedical applications	1378:1406	other biomedical applications	1378:1406	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	4	13	theme	H-bonding	626:634	arg1	counterparts					659:670	intermolecular H-bonding between the ST and PAH counterparts	611:670	intermolecular H-bonding between the ST and PAH counterparts	611:670	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	1	14	with	polysaccharides	139:153	arg1	polymers					170:177	synthetic polymers	160:177	synthetic polymers	160:177	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	2	15	theme	different	442:450	arg1	compositions					452:463	different compositions	442:463	different compositions	442:463	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	1	16	theme	much	193:196	arg1	attention					198:206	much attention	193:206	much attention	193:206	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	9	17	theme	drug	1316:1319	arg1	administration					1321:1334	oral drug administration	1311:1334	oral drug administration	1311:1334	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	6	18	theme	drug	859:862	arg1	release					864:870	in vitro controlled drug release	839:870	in vitro controlled drug release (CDR)	839:876	TPH-1 (90 % ST and 10 % PAH) was evaluated for in vitro controlled drug release (CDR) at 37 ± 0.5 °C in a time-dependent fashion.
37119890	6	18	theme	drug	859:862	arg1	CDR					873:875	CDR	873:875	CDR	873:875	TPH-1 (90 % ST and 10 % PAH) was evaluated for in vitro controlled drug release (CDR) at 37 ± 0.5 °C in a time-dependent fashion.
37119890	4	19	theme	intermolecular	611:624	arg1	counterparts					659:670	intermolecular H-bonding between the ST and PAH counterparts	611:670	intermolecular H-bonding between the ST and PAH counterparts	611:670	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	2	20	from	Starch/Poly	392:402	arg1	compositions					452:463	different compositions	442:463	different compositions	442:463	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	9	21	theme	biocompatible	1224:1236	arg1	candidate					1269:1277	a promising candidate	1257:1277	a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications	1257:1406	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	9	21	theme	biocompatible	1224:1236	arg1	films					1244:1248	the fabricated biocompatible blend films	1209:1248	the fabricated biocompatible blend films	1209:1248	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	0	22	theme	drug	11:14	arg1	release					16:22	Controlled drug release	0:22	Controlled drug release	0:22	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	6	23	theme	controlled	848:857	arg1	release					864:870	in vitro controlled drug release	839:870	in vitro controlled drug release (CDR)	839:876	TPH-1 (90 % ST and 10 % PAH) was evaluated for in vitro controlled drug release (CDR) at 37 ± 0.5 °C in a time-dependent fashion.
37119890	6	23	theme	controlled	848:857	arg1	CDR					873:875	CDR	873:875	CDR	873:875	TPH-1 (90 % ST and 10 % PAH) was evaluated for in vitro controlled drug release (CDR) at 37 ± 0.5 °C in a time-dependent fashion.
37119890	0	24	theme	Controlled	0:9	arg1	release					16:22	Controlled drug release	0:22	Controlled drug release	0:22	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	1	25	theme	drug	211:214	arg1	models					225:230	drug delivery models	211:230	drug delivery models owing to their remarkable biodegradable and biocompatible characteristics	211:304	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	8	26	theme	PBS	1157:1159	arg1	solution					1170:1177	PBS (pH 7.4) solution	1157:1177	PBS (pH 7.4) solution	1157:1177	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	27	from	80 min	1147:1152	arg1	solution					1170:1177	PBS (pH 7.4) solution	1157:1177	PBS (pH 7.4) solution	1157:1177	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	6	28	dep	%	802:802	arg1	ST					804:805	ST	804:805	ST	804:805	TPH-1 (90 % ST and 10 % PAH) was evaluated for in vitro controlled drug release (CDR) at 37 ± 0.5 °C in a time-dependent fashion.
37119890	1	29	theme	delivery	216:223	arg1	models					225:230	drug delivery models	211:230	drug delivery models owing to their remarkable biodegradable and biocompatible characteristics	211:304	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	9	30	theme	wound	1357:1361	arg1	dressings					1363:1371	wound dressings	1357:1371	wound dressings	1357:1371	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	2	31	theme	facile	333:338	arg1	preparation					340:350	the facile preparation	329:350	the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	329:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	1	32	theme	synthetic	160:168	arg1	polymers					170:177	synthetic polymers	160:177	synthetic polymers	160:177	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	0	33	theme	starch/poly	46:56	arg1	films					108:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	2	34	theme	composite	369:377	arg1	films					379:383	composite films	369:383	composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	369:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	8	35	theme	SGF	1022:1024	arg1	case					1014:1017	the case	1010:1017	the case of SGF (pH 1.2)	1010:1033	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	36	theme	maximum	1124:1130	arg1	DR					1132:1133	the maximum DR	1120:1133	the maximum DR	1120:1133	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	36	theme	maximum	1124:1130	arg1	%					1142:1142	95 %	1139:1142	95 %	1139:1142	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	9	37	theme	sustained-release	1285:1301	arg1	DDS					1303:1305	a sustained-release DDS	1283:1305	a sustained-release DDS for oral drug administration	1283:1334	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	8	38	theme	drug	1051:1054	arg1	DR					1065:1066	DR	1065:1066	DR	1065:1066	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	38	theme	drug	1051:1054	arg1	release					1056:1062	the percentile drug release	1036:1062	the percentile drug release (DR) for TPH-1	1036:1077	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	38	theme	drug	1051:1054	arg1	%					1100:1100	approximately 91 %	1083:1100	approximately 91 %	1083:1100	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	4	39	theme	PAH	655:657	arg1	counterparts					659:670	intermolecular H-bonding between the ST and PAH counterparts	611:670	intermolecular H-bonding between the ST and PAH counterparts	611:670	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	9	40	theme	promising	1259:1267	arg1	candidate					1269:1277	a promising candidate	1257:1277	a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications	1257:1406	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	9	40	theme	promising	1259:1267	arg1	films					1244:1248	the fabricated biocompatible blend films	1209:1248	the fabricated biocompatible blend films	1209:1248	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	4	41	theme	blended	675:681	arg1	films					683:687	blended films	675:687	blended films	675:687	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	2	42	theme	delivery	489:496	arg1	DDS					506:508	DDS	506:508	DDS	506:508	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	42	theme	delivery	489:496	arg1	system					498:503	a novel drug delivery system	476:503	a novel drug delivery system (DDS)	476:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	6	43	theme	time-dependent	898:911	arg1	fashion					913:919	a time-dependent fashion	896:919	a time-dependent fashion	896:919	TPH-1 (90 % ST and 10 % PAH) was evaluated for in vitro controlled drug release (CDR) at 37 ± 0.5 °C in a time-dependent fashion.
37119890	0	44	theme	hydrochloride	69:81	arg1	films					108:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	7	45	theme	simulated	976:984	arg1	fluid					994:998	simulated gastric fluid	976:998	simulated gastric fluid (SGF)	976:1004	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	7	45	theme	simulated	976:984	arg1	SGF					1001:1003	SGF	1001:1003	SGF	1001:1003	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	2	46	theme	films	379:383	arg1	sequence					357:364	a sequence	355:364	a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	355:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	47	theme	drug	484:487	arg1	DDS					506:508	DDS	506:508	DDS	506:508	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	47	theme	drug	484:487	arg1	system					498:503	a novel drug delivery system	476:503	a novel drug delivery system (DDS)	476:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	4	48	theme	FT-IR	565:569	arg1	evaluation					571:580	FT-IR evaluation	565:580	FT-IR evaluation	565:580	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	4	49	from	involvement	596:606	arg1	films					683:687	blended films	675:687	blended films	675:687	FT-IR evaluation confirmed the involvement of intermolecular H-bonding between the ST and PAH counterparts in blended films.
37119890	1	50	theme	natural	131:137	arg1	polysaccharides					139:153	natural polysaccharides	131:153	natural polysaccharides with synthetic polymers	131:177	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	9	51	theme	blend	1238:1242	arg1	candidate					1269:1277	a promising candidate	1257:1277	a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications	1257:1406	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	9	51	theme	blend	1238:1242	arg1	films					1244:1248	the fabricated biocompatible blend films	1209:1248	the fabricated biocompatible blend films	1209:1248	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	5	52	dep	100°	739:742	arg1	to					736:737	to	736:737	to	736:737	The water contact angle (WCA) ranged from 71° to 100° indicating that all the films were hydrophobic.
37119890	1	53	theme	polysaccharides	139:153	arg1	blending					119:126	The blending	115:126	The blending of natural polysaccharides with synthetic polymers	115:177	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	7	54	theme	gastric	986:992	arg1	fluid					994:998	simulated gastric fluid	976:998	simulated gastric fluid (SGF)	976:1004	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	7	54	theme	gastric	986:992	arg1	SGF					1001:1003	SGF	1001:1003	SGF	1001:1003	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	7	55	theme	buffer	952:957	arg1	PBS					967:969	PBS	967:969	PBS	967:969	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	7	55	theme	buffer	952:957	arg1	saline					959:964	phosphate buffer saline	942:964	phosphate buffer saline (PBS)	942:970	CDR was recorded in phosphate buffer saline (PBS) and simulated gastric fluid (SGF).
37119890	2	56	theme	sequence	357:364	arg1	preparation					340:350	the facile preparation	329:350	the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	329:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	1	57	theme	remarkable	247:256	arg1	characteristics					290:304	their remarkable biodegradable and biocompatible characteristics	241:304	their remarkable biodegradable and biocompatible characteristics	241:304	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	8	58	theme	percentile	1040:1049	arg1	DR					1065:1066	DR	1065:1066	DR	1065:1066	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	58	theme	percentile	1040:1049	arg1	release					1056:1062	the percentile drug release	1036:1062	the percentile drug release (DR) for TPH-1	1036:1077	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	8	58	theme	percentile	1040:1049	arg1	%					1100:1100	approximately 91 %	1083:1100	approximately 91 %	1083:1100	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	9	59	theme	tissue	1337:1342	arg1	engineering					1344:1354	tissue engineering	1337:1354	tissue engineering	1337:1354	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	8	60	from	%	1142:1142	arg1	80 min					1147:1152	80 min	1147:1152	80 min in PBS (pH 7.4) solution	1147:1177	In the case of SGF (pH 1.2), the percentile drug release (DR) for TPH-1 was approximately 91 % in 110 min, while the maximum DR was 95 % in 80 min in PBS (pH 7.4) solution.
37119890	2	61	theme	allylamine	404:413	arg1	Starch/Poly					392:402	Starch/Poly	392:402	Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS)	392:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	61	theme	allylamine	404:413	arg1	hydrochloride					415:427	allylamine hydrochloride	404:427	allylamine hydrochloride	404:427	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	1	62	theme	biodegradable	258:270	arg1	characteristics					290:304	their remarkable biodegradable and biocompatible characteristics	241:304	their remarkable biodegradable and biocompatible characteristics	241:304	The blending of natural polysaccharides with synthetic polymers has attracted much attention in drug delivery models owing to their remarkable biodegradable and biocompatible characteristics.
37119890	0	63	theme	allylamine	58:67	arg1	films					108:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	starch/poly(allylamine hydrochloride) biodegradable composite films	46:112	Controlled drug release contenders comprising starch/poly(allylamine hydrochloride) biodegradable composite films.
37119890	2	64	theme	novel	478:482	arg1	DDS					506:508	DDS	506:508	DDS	506:508	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	2	64	theme	novel	478:482	arg1	system					498:503	a novel drug delivery system	476:503	a novel drug delivery system (DDS)	476:509	This study focuses on the facile preparation of a sequence of composite films having Starch/Poly(allylamine hydrochloride) (ST/PAH) in different compositions to propose a novel drug delivery system (DDS).
37119890	3	65	theme	ST/PAH	512:517	arg1	films					525:529	ST/PAH blend films	512:529	ST/PAH blend films	512:529	ST/PAH blend films were developed and characterized.
37119890	9	66	theme	fabricated	1213:1222	arg1	candidate					1269:1277	a promising candidate	1257:1277	a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications	1257:1406	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
37119890	9	66	theme	fabricated	1213:1222	arg1	films					1244:1248	the fabricated biocompatible blend films	1209:1248	the fabricated biocompatible blend films	1209:1248	Our results demonstrate that the fabricated biocompatible blend films can be a promising candidate for a sustained-release DDS for oral drug administration, tissue engineering, wound dressings, and other biomedical applications.
35773428	2	0	theme	modifications	335:347	arg1	degree					296:301	a high degree	289:301	a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases	289:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	8	1	theme	3→3	1194:1196	arg1	linkages					1198:1205	3→3 linkages	1194:1205	3→3 linkages	1194:1205	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	12	2	theme	mycobacterial	1764:1776	arg1	PG					1778:1779	mycobacterial PG	1764:1779	mycobacterial PG	1764:1779	Collectively, these data report important novel insights into the ultrastructure of mycobacterial PG.
35773428	9	3	from	%	1262:1262	arg1	PG					1288:1289	the PG	1284:1289	the PG of M. smegmatis	1284:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	4	4	theme	high-resolution	675:689	arg1	spectrometry					718:729	high-resolution liquid chromatography-mass spectrometry	675:729	high-resolution liquid chromatography-mass spectrometry	675:729	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	2	5	theme	atypical	260:267	arg1	PG					269:270	an atypical PG	257:270	an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases	257:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	10	6	dep	found	1400:1404	arg1	whereas					1472:1478	whereas	1472:1478	whereas	1472:1478	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	5	7	theme	PG	914:915	arg1	library					917:923	an in silico PG library	901:923	an in silico PG library	901:923	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	9	8	from	PG	1288:1289	arg1	disaccharides					1267:1279	disaccharides	1267:1279	disaccharides in the PG of M. smegmatis	1267:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	9	8	from	PG	1288:1289	arg1	%					1262:1262	Approximately 43%	1246:1262	Approximately 43% of disaccharides in the PG of M. smegmatis	1246:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	4	9	theme	chromatography-mass	698:716	arg1	spectrometry					718:729	high-resolution liquid chromatography-mass spectrometry	675:729	high-resolution liquid chromatography-mass spectrometry	675:729	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	10	10	theme	amu	1427:1429	arg1	loss					1413:1416	a loss	1411:1416	a loss of 41.00 amu that is consistent with N-deacetylation	1411:1469	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	10	10	theme	amu	1427:1429	arg1	consistent					1439:1448	consistent	1439:1448	consistent	1439:1448	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	4	11	from	smegmatis	659:667	arg1	composition					622:632	the chemical composition	609:632	the chemical composition of PG from Mycobacterium smegmatis	609:667	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	11	12	from	regulation	1627:1636	arg1	smegmatis					1669:1677	M. smegmatis	1666:1677	M. smegmatis	1666:1677	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	3	13	theme	molecular	514:522	arg1	architecture					524:535	molecular architecture	514:535	molecular architecture	514:535	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	11	14	from	role	1597:1600	arg1	regulation					1627:1636	the regulation	1623:1636	the regulation of cell wall homeostasis in M. smegmatis	1623:1677	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	6	15	theme	extracted-ion	1006:1018	arg1	chromatogram					1020:1031	the extracted-ion chromatogram	1002:1031	the extracted-ion chromatogram	1002:1031	The relative abundance for each muropeptide ion was measured by integrating the extracted-ion chromatogram.
35773428	3	16	theme	PG	554:555	arg1	composition					498:508	chemical composition	489:508	chemical composition	489:508	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	3	16	theme	PG	554:555	arg1	architecture					524:535	molecular architecture	514:535	molecular architecture	514:535	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	5	17	theme	stationary	761:770	arg1	phase					772:776	the stationary phase	757:776	the stationary phase	757:776	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	5	18	from	phase	772:776	arg1	walls					746:750	Purified cell walls	732:750	Purified cell walls from the stationary phase	732:776	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	2	19	theme	most	221:224	arg1	bacteria					226:233	most bacteria	221:233	most bacteria	221:233	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	5	20	theme	in	904:905	arg1	library					917:923	an in silico PG library	901:923	an in silico PG library	901:923	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	9	21	from	disaccharides	1267:1279	arg1	PG					1288:1289	the PG	1284:1289	the PG of M. smegmatis	1284:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	7	22	theme	PG	1066:1067	arg1	subunit					1069:1075	PG subunit	1066:1075	PG subunit	1066:1075	The percentage of crosslink per PG subunit was measured at 45%.
35773428	12	23	theme	important	1712:1720	arg1	insights					1728:1735	important novel insights	1712:1735	important novel insights into the ultrastructure of mycobacterial PG	1712:1779	Collectively, these data report important novel insights into the ultrastructure of mycobacterial PG.
35773428	5	24	theme	cell	741:744	arg1	walls					746:750	Purified cell walls	732:750	Purified cell walls from the stationary phase	732:776	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	7	25	theme	crosslink	1052:1060	arg1	percentage					1038:1047	The percentage	1034:1047	The percentage of crosslink per PG subunit	1034:1075	The percentage of crosslink per PG subunit was measured at 45%.
35773428	1	26	theme	cells	144:148	arg1	Peptidoglycan					93:105	Peptidoglycan	93:105	Peptidoglycan (PG)	93:110	Peptidoglycan (PG) is the exoskeleton of bacterial cells and is required for their viability, growth, and cell division.
35773428	1	26	theme	cells	144:148	arg1	exoskeleton					119:129	the exoskeleton	115:129	the exoskeleton of bacterial cells	115:148	Peptidoglycan (PG) is the exoskeleton of bacterial cells and is required for their viability, growth, and cell division.
35773428	3	27	theme	important	469:477	arg1	role					479:482	this important role	464:482	this important role	464:482	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	8	28	located	found	1154:1158	arg2	3→3					1109:1111	3→3	1109:1111	3→3	1109:1111	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	8	28	located	found	1154:1158	arg2	cross-linkages					1134:1147	4→3 transpeptide cross-linkages	1117:1147	4→3 transpeptide cross-linkages	1117:1147	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	8	28	located	found	1154:1158	arg1	dimers					1166:1171	PG dimers	1163:1171	PG dimers	1163:1171	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	9	29	theme	smegmatis	1297:1305	arg1	PG					1288:1289	the PG	1284:1289	the PG of M. smegmatis	1284:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	2	30	from	diseases	446:453	arg1	determinants					386:397	important determinants	376:397	important determinants of virulence and pathogenesis in mycobacterial diseases	376:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	30	from	diseases	446:453	arg1	linkages					313:320	unique linkages	306:320	unique linkages	306:320	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	30	from	diseases	446:453	arg1	modifications					335:347	chemical modifications	326:347	chemical modifications	326:347	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	3	31	dep	composition	498:508	arg1	the					485:487	the	485:487	the	485:487	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	0	32	theme	Peptidoglycan	0:12	arg1	analysis					28:35	Peptidoglycan compositional analysis	0:35	Peptidoglycan compositional analysis of Mycobacterium smegmatis	0:62	Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS.
35773428	2	33	theme	mycobacterial	432:444	arg1	diseases					446:453	mycobacterial diseases	432:453	mycobacterial diseases	432:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	10	34	theme	42.01	1506:1510	arg1	amu					1512:1514	42.01 amu	1506:1514	42.01 amu corresponding to O-acetylation of the PG disaccharides	1506:1569	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	2	35	theme	pathogenesis	416:427	arg1	determinants					386:397	important determinants	376:397	important determinants of virulence and pathogenesis in mycobacterial diseases	376:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	35	theme	pathogenesis	416:427	arg1	linkages					313:320	unique linkages	306:320	unique linkages	306:320	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	35	theme	pathogenesis	416:427	arg1	modifications					335:347	chemical modifications	326:347	chemical modifications	326:347	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	8	36	theme	4→3	1117:1119	arg1	cross-linkages					1134:1147	4→3 transpeptide cross-linkages	1117:1147	4→3 transpeptide cross-linkages	1117:1147	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	2	37	theme	virulence	402:410	arg1	determinants					386:397	important determinants	376:397	important determinants of virulence and pathogenesis in mycobacterial diseases	376:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	37	theme	virulence	402:410	arg1	linkages					313:320	unique linkages	306:320	unique linkages	306:320	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	37	theme	virulence	402:410	arg1	modifications					335:347	chemical modifications	326:347	chemical modifications	326:347	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	0	38	theme	Mycobacterium	40:52	arg1	smegmatis					54:62	Mycobacterium smegmatis	40:62	Mycobacterium smegmatis	40:62	Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS.
35773428	11	39	theme	PG	1605:1606	arg1	acetylation					1608:1618	PG acetylation	1605:1618	PG acetylation	1605:1618	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	3	40	theme	chemical	489:496	arg1	composition					498:508	chemical composition	489:508	chemical composition	489:508	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	2	41	from	determinants	386:397	arg1	diseases					446:453	mycobacterial diseases	432:453	mycobacterial diseases	432:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	42	theme	linkages	313:320	arg1	degree					296:301	a high degree	289:301	a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases	289:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	8	43	theme	PG	1163:1164	arg1	dimers					1166:1171	PG dimers	1163:1171	PG dimers	1163:1171	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	2	44	from	virulence	402:410	arg1	diseases					446:453	mycobacterial diseases	432:453	mycobacterial diseases	432:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	10	45	theme	disaccharides	1557:1569	arg1	O-acetylation					1533:1545	O-acetylation	1533:1545	O-acetylation of the PG disaccharides	1533:1569	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	2	46	from	pathogenesis	416:427	arg1	diseases					446:453	mycobacterial diseases	432:453	mycobacterial diseases	432:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	11	47	theme	homeostasis	1651:1661	arg1	regulation					1627:1636	the regulation	1623:1636	the regulation of cell wall homeostasis in M. smegmatis	1623:1677	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	10	48	theme	PG	1385:1386	arg1	trimers					1388:1394	PG trimers	1385:1394	PG trimers	1385:1394	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	8	49	theme	high	1176:1179	arg1	abundance					1181:1189	a high abundance	1174:1189	a high abundance of 3→3 linkages	1174:1205	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	6	50	theme	muropeptide	958:968	arg1	ion					970:972	each muropeptide ion	953:972	each muropeptide ion	953:972	The relative abundance for each muropeptide ion was measured by integrating the extracted-ion chromatogram.
35773428	12	51	theme	PG	1778:1779	arg1	ultrastructure					1746:1759	the ultrastructure	1742:1759	the ultrastructure of mycobacterial PG	1742:1779	Collectively, these data report important novel insights into the ultrastructure of mycobacterial PG.
35773428	11	52	theme	cell	1641:1644	arg1	homeostasis					1651:1661	cell wall homeostasis	1641:1661	cell wall homeostasis	1641:1661	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	2	53	contain	possess	249:255	arg1	mycobacteria					236:247	mycobacteria	236:247	mycobacteria	236:247	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	53	contain	possess	249:255	arg2	PG					269:270	an atypical PG	257:270	an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases	257:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	54	theme	chemical	326:333	arg1	determinants					386:397	important determinants	376:397	important determinants of virulence and pathogenesis in mycobacterial diseases	376:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	54	theme	chemical	326:333	arg1	linkages					313:320	unique linkages	306:320	unique linkages	306:320	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	54	theme	chemical	326:333	arg1	modifications					335:347	chemical modifications	326:347	chemical modifications	326:347	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	3	55	theme	mycobacterial	540:552	arg1	PG					554:555	mycobacterial PG	540:555	mycobacterial PG	540:555	Despite this important role, the chemical composition and molecular architecture of mycobacterial PG have yet to be fully determined.
35773428	8	56	theme	linkages	1198:1205	arg1	abundance					1181:1189	a high abundance	1174:1189	a high abundance of 3→3 linkages	1174:1205	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	6	57	theme	relative	930:937	arg1	abundance					939:947	The relative abundance	926:947	The relative abundance for each muropeptide ion	926:972	The relative abundance for each muropeptide ion was measured by integrating the extracted-ion chromatogram.
35773428	11	58	theme	M.	1666:1667	arg1	smegmatis					1669:1677	M. smegmatis	1666:1677	M. smegmatis	1666:1677	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	4	59	theme	liquid	691:696	arg1	spectrometry					718:729	high-resolution liquid chromatography-mass spectrometry	675:729	high-resolution liquid chromatography-mass spectrometry	675:729	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	2	60	theme	high	291:294	arg1	degree					296:301	a high degree	289:301	a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases	289:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	10	61	theme	significant	1363:1373	arg1	number					1375:1380	A significant number	1361:1380	A significant number of PG trimers	1361:1394	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	4	62	theme	PG	637:638	arg1	composition					622:632	the chemical composition	609:632	the chemical composition of PG from Mycobacterium smegmatis	609:667	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	1	63	theme	cell	199:202	arg1	division					204:211	cell division	199:211	cell division	199:211	Peptidoglycan (PG) is the exoskeleton of bacterial cells and is required for their viability, growth, and cell division.
35773428	4	64	theme	Mycobacterium	645:657	arg1	smegmatis					659:667	Mycobacterium smegmatis	645:667	Mycobacterium smegmatis	645:667	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	5	65	theme	Purified	732:739	arg1	walls					746:750	Purified cell walls	732:750	Purified cell walls from the stationary phase	732:776	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	1	66	theme	bacterial	134:142	arg1	cells					144:148	bacterial cells	134:148	bacterial cells	134:148	Peptidoglycan (PG) is the exoskeleton of bacterial cells and is required for their viability, growth, and cell division.
35773428	9	67	theme	M.	1294:1295	arg1	smegmatis					1297:1305	M. smegmatis	1294:1305	M. smegmatis	1294:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	12	68	theme	novel	1722:1726	arg1	insights					1728:1735	important novel insights	1712:1735	important novel insights into the ultrastructure of mycobacterial PG	1712:1779	Collectively, these data report important novel insights into the ultrastructure of mycobacterial PG.
35773428	5	69	theme	compositional	813:825	arg1	analysis					827:834	compositional analysis	813:834	compositional analysis	813:834	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	8	70	dep	found	1211:1215	arg1	associated					1217:1226	associated	1217:1226	associated with the trimers	1217:1243	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	10	71	with	consistent	1439:1448	arg1	N-deacetylation					1455:1469	N-deacetylation	1455:1469	N-deacetylation	1455:1469	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	2	72	theme	important	376:384	arg1	determinants					386:397	important determinants	376:397	important determinants of virulence and pathogenesis in mycobacterial diseases	376:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	72	theme	important	376:384	arg1	linkages					313:320	unique linkages	306:320	unique linkages	306:320	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	72	theme	important	376:384	arg1	modifications					335:347	chemical modifications	326:347	chemical modifications	326:347	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	0	73	theme	compositional	14:26	arg1	analysis					28:35	Peptidoglycan compositional analysis	0:35	Peptidoglycan compositional analysis of Mycobacterium smegmatis	0:62	Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS.
35773428	8	74	theme	transpeptide	1121:1132	arg1	cross-linkages					1134:1147	4→3 transpeptide cross-linkages	1117:1147	4→3 transpeptide cross-linkages	1117:1147	While both 3→3 and 4→3 transpeptide cross-linkages were found in PG dimers, a high abundance of 3→3 linkages was found associated with the trimers.
35773428	0	75	theme	smegmatis	54:62	arg1	analysis					28:35	Peptidoglycan compositional analysis	0:35	Peptidoglycan compositional analysis of Mycobacterium smegmatis	0:62	Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS.
35773428	0	76	theme	high-resolution	70:84	arg1	LC-MS					86:90	high-resolution LC-MS	70:90	high-resolution LC-MS	70:90	Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS.
35773428	11	77	theme	possible	1588:1595	arg1	role					1597:1600	a possible role	1586:1600	a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis	1586:1677	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	9	78	theme	disaccharides	1267:1279	arg1	disaccharides					1267:1279	disaccharides	1267:1279	disaccharides in the PG of M. smegmatis	1267:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	9	78	theme	disaccharides	1267:1279	arg1	%					1262:1262	Approximately 43%	1246:1262	Approximately 43% of disaccharides in the PG of M. smegmatis	1246:1305	Approximately 43% of disaccharides in the PG of M. smegmatis showed modifications by acetylation or deacetylation.
35773428	11	79	theme	acetylation	1608:1618	arg1	role					1597:1600	a possible role	1586:1600	a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis	1586:1677	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	4	80	theme	chemical	613:620	arg1	composition					622:632	the chemical composition	609:632	the chemical composition of PG from Mycobacterium smegmatis	609:667	Here we determined the chemical composition of PG from Mycobacterium smegmatis using high-resolution liquid chromatography-mass spectrometry.
35773428	10	81	theme	amu	1512:1514	arg1	gain					1498:1501	a gain	1496:1501	a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides	1496:1569	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	5	82	dep	in	904:905	arg1	silico					907:912	silico	907:912	silico	907:912	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
35773428	2	83	theme	unique	306:311	arg1	determinants					386:397	important determinants	376:397	important determinants of virulence and pathogenesis in mycobacterial diseases	376:453	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	83	theme	unique	306:311	arg1	linkages					313:320	unique linkages	306:320	unique linkages	306:320	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	2	83	theme	unique	306:311	arg1	modifications					335:347	chemical modifications	326:347	chemical modifications	326:347	Unlike most bacteria, mycobacteria possess an atypical PG characterized by a high degree of unique linkages and chemical modifications which most likely serve as important determinants of virulence and pathogenesis in mycobacterial diseases.
35773428	10	84	theme	PG	1554:1555	arg1	disaccharides					1557:1569	the PG disaccharides	1550:1569	the PG disaccharides	1550:1569	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	11	85	theme	wall	1646:1649	arg1	homeostasis					1651:1661	cell wall homeostasis	1641:1661	cell wall homeostasis	1641:1661	This suggests a possible role of PG acetylation in the regulation of cell wall homeostasis in M. smegmatis.
35773428	10	86	theme	trimers	1388:1394	arg1	number					1375:1380	A significant number	1361:1380	A significant number of PG trimers	1361:1394	A significant number of PG trimers are found with a loss of 41.00 amu that is consistent with N-deacetylation, whereas the dimers show a gain of 42.01 amu corresponding to O-acetylation of the PG disaccharides.
35773428	5	87	theme	muropeptide	857:867	arg1	ions					869:872	130 muropeptide ions	853:872	130 muropeptide ions that were identified using an in silico PG library	853:923	Purified cell walls from the stationary phase were digested with mutanolysin and compositional analysis was performed on 130 muropeptide ions that were identified using an in silico PG library.
36725234	2	0	theme	alkali-soluble	320:333	arg1	extracts					335:342	The alkali-soluble extracts	316:342	The alkali-soluble extracts of Poria	316:351	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	7	1	theme	Hubei	1415:1419	arg1	province					1421:1428	Hubei province	1415:1428	Hubei province	1415:1428	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	4	2	theme	alkali-soluble	871:884	arg1	extracts					886:893	the alkali-soluble extracts	867:893	the alkali-soluble extracts	867:893	The results showed that the content of the alkali-soluble extracts was in the range of 46.98%-73.86%.
36725234	6	3	theme	samples	1213:1219	arg1	batches					1202:1208	30 batches	1199:1208	30 batches of samples	1199:1219	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	7	4	theme	samples	1402:1408	arg1	content					1391:1397	the content	1387:1397	the content of samples from Hubei province	1387:1428	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	7	4	theme	samples	1402:1408	arg1	higher					1443:1448	higher	1443:1448	higher	1443:1448	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	7	5	theme	-92.57	1374:1379	arg1	%					1373:1373	%	1373:1373	%	1373:1373	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	11	6	theme	Poria	2216:2220	arg1	standards					2203:2211	the quality standards	2191:2211	the quality standards of Poria in Chinese Pharmacopeia	2191:2244	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	3	7	theme	magnetic	695:702	arg1	resonance					704:712	nuclear magnetic resonance	687:712	nuclear magnetic resonance(NMR) spectroscopy	687:730	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	7	theme	magnetic	695:702	arg1	NMR					714:716	NMR	714:716	NMR	714:716	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	7	8	theme	73.70	1368:1372	arg1	%					1373:1373	%	1373:1373	%	1373:1373	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	10	9	theme	alkali-soluble	1880:1893	arg1	extract					1895:1901	alkali-soluble extract	1880:1901	alkali-soluble extract	1880:1901	However, the content determined by HPLC-ELSD was close to that of alkali-soluble extract, which could accurately characterize the content of alkali-soluble polysaccharides in Poria, and the method was simple and repeatable.
36725234	3	10	theme	extracts	554:561	arg1	structure					497:505	structure	497:505	structure	497:505	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	10	theme	extracts	554:561	arg1	composition					520:530	chemical composition	511:530	chemical composition	511:530	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	6	11	theme	UV-Vis	1094:1099	arg1	spectrophotometry					1101:1117	UV-Vis spectrophotometry	1094:1117	UV-Vis spectrophotometry	1094:1117	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	11	12	theme	Chinese	2225:2231	arg1	Pharmacopeia					2233:2244	Chinese Pharmacopeia	2225:2244	Chinese Pharmacopeia	2225:2244	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	3	13	theme	high-performance	584:599	arg1	HPGPC					631:635	HPGPC	631:635	HPGPC	631:635	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	13	theme	high-performance	584:599	arg1	Fourier					639:645	Fourier	639:645	Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	639:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	13	theme	high-performance	584:599	arg1	chromatography					616:629	high-performance gel permeation chromatography	584:629	high-performance gel permeation chromatography(HPGPC)	584:636	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	7	14	from	province	1421:1428	arg1	samples					1402:1408	samples	1402:1408	samples from Hubei province	1402:1428	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	7	14	from	province	1421:1428	arg1	content					1391:1397	the content	1387:1397	the content of samples from Hubei province	1387:1428	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	7	14	from	province	1421:1428	arg1	higher					1443:1448	higher	1443:1448	higher	1443:1448	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	3	15	theme	liquid	753:758	arg1	chromatography					760:773	high-performance liquid chromatography	736:773	high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	736:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	15	theme	liquid	753:758	arg1	HPLC					775:778	HPLC	775:778	HPLC	775:778	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	6	16	theme	detector	1174:1181	arg1	scattering					1163:1172	the evaporative light scattering detector	1141:1181	the evaporative light scattering detector(HPLC-ELSD)	1141:1192	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	6	16	theme	detector	1174:1181	arg1	HPLC-ELSD					1183:1191	HPLC-ELSD	1183:1191	HPLC-ELSD	1183:1191	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	11	17	from	standards	2203:2211	arg1	Pharmacopeia					2233:2244	Chinese Pharmacopeia	2225:2244	Chinese Pharmacopeia	2225:2244	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	1	18	theme	quality	116:122	arg1	methods					132:138	the quality control methods	112:138	the quality control methods of Poria	112:147	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	2	19	theme	samples	468:474	arg1	batches					457:463	30 batches	454:463	30 batches of samples	454:474	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	7	20	theme	polysaccharides	1293:1307	arg1	content					1267:1273	the content	1263:1273	the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry	1263:1346	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	8	21	contain	had	1658:1660	arg1	samples					1630:1636	the samples	1626:1636	the samples from Hunan province	1626:1656	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	8	21	contain	had	1658:1660	arg2	content					1678:1684	slightly higher content	1662:1684	slightly higher content	1662:1684	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	3	22	theme	permeation	605:614	arg1	HPGPC					631:635	HPGPC	631:635	HPGPC	631:635	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	22	theme	permeation	605:614	arg1	Fourier					639:645	Fourier	639:645	Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	639:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	22	theme	permeation	605:614	arg1	chromatography					616:629	high-performance gel permeation chromatography	584:629	high-performance gel permeation chromatography(HPGPC)	584:636	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	11	23	theme	alkali-soluble	2136:2149	arg1	polysaccharides					2151:2165	alkali-soluble polysaccharides	2136:2165	alkali-soluble polysaccharides	2136:2165	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	1	24	theme	Poria	143:147	arg1	methods					132:138	the quality control methods	112:138	the quality control methods of Poria	112:147	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	4	25	theme	%	927:927	arg1	range					906:910	the range	902:910	the range of 46.98%-73.86%	902:927	The results showed that the content of the alkali-soluble extracts was in the range of 46.98%-73.86%.
36725234	10	26	theme	alkali-soluble	1955:1968	arg1	polysaccharides					1970:1984	alkali-soluble polysaccharides	1955:1984	alkali-soluble polysaccharides	1955:1984	However, the content determined by HPLC-ELSD was close to that of alkali-soluble extract, which could accurately characterize the content of alkali-soluble polysaccharides in Poria, and the method was simple and repeatable.
36725234	0	27	theme	extracted	74:82	arg1	polysaccharide					84:97	alkali extracted polysaccharide	67:97	alkali extracted polysaccharide	67:97	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	7	28	theme	alkali-soluble	1278:1291	arg1	polysaccharides					1293:1307	alkali-soluble polysaccharides	1278:1307	alkali-soluble polysaccharides determined by UV-Vis spectrophotometry	1278:1346	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	11	29	theme	analysis	2089:2096	arg1	method					2098:2103	the quantitative analysis method	2072:2103	the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD	2072:2178	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	0	30	theme	[Quality	0:7	arg1	methods					20:26	[Quality evaluation methods	0:26	[Quality evaluation methods of Poria	0:35	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	3	31	dep	FT-IR	679:683	arg1	chromatography					760:773	high-performance liquid chromatography	736:773	high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	736:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	31	dep	FT-IR	679:683	arg1	spectroscopy					719:730	nuclear magnetic resonance(NMR) spectroscopy	687:730	nuclear magnetic resonance(NMR) spectroscopy	687:730	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	31	dep	FT-IR	679:683	arg1	HPLC					775:778	HPLC	775:778	HPLC	775:778	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	6	32	theme	light	1157:1161	arg1	scattering					1163:1172	the evaporative light scattering detector	1141:1181	the evaporative light scattering detector(HPLC-ELSD)	1141:1192	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	6	32	theme	light	1157:1161	arg1	HPLC-ELSD					1183:1191	HPLC-ELSD	1183:1191	HPLC-ELSD	1183:1191	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	2	33	theme	optimum	384:390	arg1	conditions					403:412	the optimum extraction conditions	380:412	the optimum extraction conditions on the basis of single-factor test	380:447	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	0	34	theme	Poria	31:35	arg1	methods					20:26	[Quality evaluation methods	0:26	[Quality evaluation methods of Poria	0:35	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	2	35	theme	test	444:447	arg1	basis					421:425	the basis	417:425	the basis of single-factor test	417:447	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	1	36	theme	alkali-soluble	275:288	arg1	polysaccharides					290:304	alkali-soluble polysaccharides	275:304	alkali-soluble polysaccharides of Poria	275:313	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	1	37	used	used	218:221	arg2	extraction					203:212	alkaline extraction	194:212	alkaline extraction	194:212	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	5	38	theme	molecular	977:985	arg1	mass					987:990	its molecular mass	973:990	its molecular mass	973:990	The main component was β-(1→3)-glucan, and its molecular mass was about 1.093×10~5.
36725234	1	39	theme	alkaline	194:201	arg1	extraction					203:212	alkaline extraction	194:212	alkaline extraction	194:212	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	3	40	theme	infrared	657:664	arg1	FT-IR					679:683	infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	657:825	FT-IR	679:683	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	8	41	from	province	1649:1656	arg1	samples					1630:1636	the samples	1626:1636	the samples from Hunan province	1626:1656	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	2	42	theme	Poria	347:351	arg1	extracts					335:342	The alkali-soluble extracts	316:342	The alkali-soluble extracts of Poria	316:351	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	9	43	theme	UV-Vis	1754:1759	arg1	spectrophotometry					1761:1777	UV-Vis spectrophotometry	1754:1777	UV-Vis spectrophotometry	1754:1777	The content determined by UV-Vis spectrophotometry was higher than that by HPLC-ELSD.
36725234	2	44	from	conditions	403:412	arg1	basis					421:425	the basis	417:425	the basis of single-factor test	417:447	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	6	45	theme	alkali-soluble	1038:1051	arg1	polysaccharides					1053:1067	alkali-soluble polysaccharides	1038:1067	alkali-soluble polysaccharides of Poria	1038:1076	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	8	46	theme	polysaccharides	1547:1561	arg1	content					1521:1527	The content	1517:1527	The content of alkali-soluble polysaccharides determined by HPLC-ELSD	1517:1585	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	3	47	theme	nuclear	687:693	arg1	resonance					704:712	nuclear magnetic resonance	687:712	nuclear magnetic resonance(NMR) spectroscopy	687:730	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	47	theme	nuclear	687:693	arg1	NMR					714:716	NMR	714:716	NMR	714:716	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	48	theme	chemical	511:518	arg1	composition					520:530	chemical composition	511:530	chemical composition	511:530	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	8	49	theme	%	1619:1619	arg1	range					1598:1602	the range	1594:1602	the range of 51.42%-76.69%	1594:1619	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	2	50	theme	single-factor	430:442	arg1	test					444:447	single-factor test	430:447	single-factor test	430:447	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	7	51	theme	%	1380:1380	arg1	range					1359:1363	the range	1355:1363	the range of 73.70%-92.57%	1355:1380	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	11	52	theme	quality	2195:2201	arg1	standards					2203:2211	the quality standards	2191:2211	the quality standards of Poria in Chinese Pharmacopeia	2191:2244	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	3	53	theme	resonance	704:712	arg1	spectroscopy					719:730	nuclear magnetic resonance(NMR) spectroscopy	687:730	nuclear magnetic resonance(NMR) spectroscopy	687:730	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	54	theme	alkali-soluble	539:552	arg1	extracts					554:561	the alkali-soluble extracts	535:561	the alkali-soluble extracts	535:561	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	7	55	from	content	1391:1397	arg1	province					1421:1428	Hubei province	1415:1428	Hubei province	1415:1428	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	3	56	theme	high-performance	736:751	arg1	chromatography					760:773	high-performance liquid chromatography	736:773	high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	736:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	56	theme	high-performance	736:751	arg1	HPLC					775:778	HPLC	775:778	HPLC	775:778	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	4	57	theme	46.98	915:919	arg1	%					920:920	%	920:920	%	920:920	The results showed that the content of the alkali-soluble extracts was in the range of 46.98%-73.86%.
36725234	8	58	theme	higher	1671:1676	arg1	content					1678:1684	slightly higher content	1662:1684	slightly higher content	1662:1684	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	3	59	dep	structure	497:505	arg1	The					493:495	The	493:495	The	493:495	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	4	60	theme	extracts	886:893	arg1	content					856:862	the content	852:862	the content of the alkali-soluble extracts	852:893	The results showed that the content of the alkali-soluble extracts was in the range of 46.98%-73.86%.
36725234	11	61	used	used	2183:2186	arg2	method					2098:2103	the quantitative analysis method	2072:2103	the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD	2072:2178	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	7	62	theme	UV-Vis	1323:1328	arg1	spectrophotometry					1330:1346	UV-Vis spectrophotometry	1323:1346	UV-Vis spectrophotometry	1323:1346	The results indicated that the content of alkali-soluble polysaccharides determined by UV-Vis spectrophotometry was in the range of 73.70%-92.57%, and the content of samples from Hubei province was slightly higher than that from Yunnan province, Anhui province and Hunan province.
36725234	3	63	theme	gel	601:603	arg1	HPGPC					631:635	HPGPC	631:635	HPGPC	631:635	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	63	theme	gel	601:603	arg1	Fourier					639:645	Fourier	639:645	Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	639:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	63	theme	gel	601:603	arg1	chromatography					616:629	high-performance gel permeation chromatography	584:629	high-performance gel permeation chromatography(HPGPC)	584:636	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	1	64	theme	control	124:130	arg1	methods					132:138	the quality control methods	112:138	the quality control methods of Poria	112:147	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	1	65	dep	yield	254:258	arg1	the					250:252	the	250:252	the	250:252	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	6	66	theme	evaporative	1145:1155	arg1	scattering					1163:1172	the evaporative light scattering detector	1141:1181	the evaporative light scattering detector(HPLC-ELSD)	1141:1192	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	6	66	theme	evaporative	1145:1155	arg1	HPLC-ELSD					1183:1191	HPLC-ELSD	1183:1191	HPLC-ELSD	1183:1191	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	0	67	theme	alkali	67:72	arg1	polysaccharide					84:97	alkali extracted polysaccharide	67:97	alkali extracted polysaccharide	67:97	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	1	68	theme	Poria	309:313	arg1	polysaccharides					290:304	alkali-soluble polysaccharides	275:304	alkali-soluble polysaccharides of Poria	275:313	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	8	69	theme	other	1705:1709	arg1	provinces					1717:1725	the other three provinces	1701:1725	the other three provinces	1701:1725	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	10	70	theme	polysaccharides	1970:1984	arg1	content					1944:1950	the content	1940:1950	the content of alkali-soluble polysaccharides in Poria	1940:1993	However, the content determined by HPLC-ELSD was close to that of alkali-soluble extract, which could accurately characterize the content of alkali-soluble polysaccharides in Poria, and the method was simple and repeatable.
36725234	0	71	theme	polysaccharide	84:97	arg1	content					56:62	content	56:62	content	56:62	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	0	71	theme	polysaccharide	84:97	arg1	yield					46:50	yield	46:50	yield	46:50	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	3	72	with	chromatography	760:773	arg1	1-phenyl-3-methyl-5-pyrazolone					786:815	1-phenyl-3-methyl-5-pyrazolone	786:815	1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	786:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	72	with	chromatography	760:773	arg1	PMP-HPLC					817:824	PMP-HPLC	817:824	PMP-HPLC	817:824	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	5	73	theme	main	934:937	arg1	component					939:947	The main component	930:947	The main component	930:947	The main component was β-(1→3)-glucan, and its molecular mass was about 1.093×10~5.
36725234	5	73	theme	main	934:937	arg1	-glucan					960:966	β-(1→3)-glucan	953:966	β-(1→3)-glucan	953:966	The main component was β-(1→3)-glucan, and its molecular mass was about 1.093×10~5.
36725234	4	74	theme	-73.86	921:926	arg1	%					920:920	%	920:920	%	920:920	The results showed that the content of the alkali-soluble extracts was in the range of 46.98%-73.86%.
36725234	0	75	theme	evaluation	9:18	arg1	methods					20:26	[Quality evaluation methods	0:26	[Quality evaluation methods of Poria	0:35	[Quality evaluation methods of Poria based on yield and content of alkali extracted polysaccharide].
36725234	3	76	with	spectroscopy	719:730	arg1	1-phenyl-3-methyl-5-pyrazolone					786:815	1-phenyl-3-methyl-5-pyrazolone	786:815	1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	786:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	3	76	with	spectroscopy	719:730	arg1	PMP-HPLC					817:824	PMP-HPLC	817:824	PMP-HPLC	817:824	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	11	77	theme	quantitative	2076:2087	arg1	method					2098:2103	the quantitative analysis method	2072:2103	the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD	2072:2178	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	2	78	theme	extraction	392:401	arg1	conditions					403:412	the optimum extraction conditions	380:412	the optimum extraction conditions on the basis of single-factor test	380:447	The alkali-soluble extracts of Poria were obtained according to the optimum extraction conditions on the basis of single-factor test, and 30 batches of samples were determined.
36725234	10	79	from	content	1944:1950	arg1	Poria					1989:1993	Poria	1989:1993	Poria	1989:1993	However, the content determined by HPLC-ELSD was close to that of alkali-soluble extract, which could accurately characterize the content of alkali-soluble polysaccharides in Poria, and the method was simple and repeatable.
36725234	11	80	theme	alkali-soluble	2109:2122	arg1	extract					2124:2130	alkali-soluble extract	2109:2130	alkali-soluble extract	2109:2130	Therefore, it is recommended that the quantitative analysis method for alkali-soluble extract and alkali-soluble polysaccharides by HPLC-ELSD be used in the quality standards of Poria in Chinese Pharmacopeia.
36725234	3	81	theme	spectrometry	666:677	arg1	FT-IR					679:683	infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	657:825	FT-IR	679:683	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
36725234	1	82	theme	polysaccharides	290:304	arg1	yield					254:258	yield	254:258	yield	254:258	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	1	82	theme	polysaccharides	290:304	arg1	content					264:270	content	264:270	content	264:270	To improve the quality control methods of Poria and develop and utilize its resources fully, alkaline extraction was used in this study to determine the yield and content of alkali-soluble polysaccharides of Poria.
36725234	6	83	theme	Poria	1072:1076	arg1	polysaccharides					1053:1067	alkali-soluble polysaccharides	1038:1067	alkali-soluble polysaccharides of Poria	1038:1076	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	8	84	theme	alkali-soluble	1532:1545	arg1	polysaccharides					1547:1561	alkali-soluble polysaccharides	1532:1561	alkali-soluble polysaccharides determined by HPLC-ELSD	1532:1585	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	8	85	theme	51.42	1607:1611	arg1	%					1612:1612	%	1612:1612	%	1612:1612	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	6	86	theme	polysaccharides	1053:1067	arg1	content					1027:1033	the content	1023:1033	the content of alkali-soluble polysaccharides of Poria	1023:1076	Further, the content of alkali-soluble polysaccharides of Poria was measured by UV-Vis spectrophotometry and HPLC coupled with the evaporative light scattering detector(HPLC-ELSD), and 30 batches of samples were measured.
36725234	8	87	theme	-76.69	1613:1618	arg1	%					1612:1612	%	1612:1612	%	1612:1612	The content of alkali-soluble polysaccharides determined by HPLC-ELSD was in the range of 51.42%-76.69%, and the samples from Hunan province had slightly higher content than that from the other three provinces.
36725234	3	88	dep	Fourier	639:645	arg1	transform					647:655	transform	647:655	transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC)	647:825	The structure and chemical composition of the alkali-soluble extracts was characterized by high-performance gel permeation chromatography(HPGPC), Fourier transform infrared spectrometry(FT-IR), nuclear magnetic resonance(NMR) spectroscopy and high-performance liquid chromatography(HPLC) with 1-phenyl-3-methyl-5-pyrazolone(PMP-HPLC).
35761706	8	0	theme	wine	1265:1268	arg1	purity					1299:1304	40.6% polysaccharide purity	1278:1304	40.6% polysaccharide purity	1278:1304	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	0	theme	wine	1265:1268	arg1	pomace					1270:1275	the distilled wine pomace	1251:1275	the distilled wine pomace (40.6% polysaccharide purity)	1251:1305	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	1	theme	rich	1086:1089	arg1	Extracts					1077:1084	Extracts	1077:1084	Extracts rich in rhamnogalacturonan type II (RG-II)	1077:1127	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	2	from	rhamnogalacturonan	1094:1111	arg1	rich					1086:1089	rich	1086:1089	rich	1086:1089	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	5	3	theme	glucosyl	891:898	arg1	polysaccharides					900:914	glucosyl polysaccharides	891:914	glucosyl polysaccharides	891:914	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	10	4	theme	finning	1498:1504	arg1	agents					1506:1511	stabilizing or finning agents	1483:1511	stabilizing or finning agents	1483:1511	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	10	5	theme	possible	1517:1524	arg1	solutions					1538:1546	possible alternative solutions	1517:1546	possible alternative solutions	1517:1546	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	3	6	theme	winemaking	575:584	arg1	products					586:593	different grape and winemaking products	555:593	different grape and winemaking products	555:593	This study aimed to recover polysaccharides from different grape and winemaking products and provide information about its composition.
35761706	3	7	theme	different	555:563	arg1	products					586:593	different grape and winemaking products	555:593	different grape and winemaking products	555:593	This study aimed to recover polysaccharides from different grape and winemaking products and provide information about its composition.
35761706	8	8	from	rich	1086:1089	arg1	RG-II					1122:1126	RG-II	1122:1126	RG-II	1122:1126	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	8	from	rich	1086:1089	arg1	rhamnogalacturonan					1094:1111	rhamnogalacturonan	1094:1111	rhamnogalacturonan type II (RG-II)	1094:1127	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	7	9	dep	purity	1037:1042	arg1	%					1049:1049	55.5%	1045:1049	55.5%	1045:1049	Both extracts showed high polysaccharide purity (55.5% and 51.9%, respectively).
35761706	7	9	dep	purity	1037:1042	arg1	%					1059:1059	51.9%	1055:1059	51.9%	1055:1059	Both extracts showed high polysaccharide purity (55.5% and 51.9%, respectively).
35761706	7	10	theme	high	1017:1020	arg1	purity					1037:1042	high polysaccharide purity	1017:1042	high polysaccharide purity (55.5% and 51.9%, respectively)	1017:1074	Both extracts showed high polysaccharide purity (55.5% and 51.9%, respectively).
35761706	4	11	theme	rich	758:761	arg1	extracts					749:756	extracts	749:756	extracts rich in polysaccharides	749:780	The results obtained with the white pomace and white lees revealed its potential to be exploited to obtain extracts rich in polysaccharides.
35761706	9	12	theme	non-available	1397:1409	arg1	composition					1384:1394	different polysaccharide composition	1359:1394	different polysaccharide composition	1359:1394	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	10	13	theme	traditional	1551:1561	arg1	agents					1592:1597	traditional animal-origin protein fining agents	1551:1597	traditional animal-origin protein fining agents	1551:1597	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	9	14	with	extracts	1345:1352	arg1	composition					1384:1394	different polysaccharide composition	1359:1394	different polysaccharide composition	1359:1394	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	4	15	from	rich	758:761	arg1	polysaccharides					766:780	polysaccharides	766:780	polysaccharides	766:780	The results obtained with the white pomace and white lees revealed its potential to be exploited to obtain extracts rich in polysaccharides.
35761706	8	16	theme	polysaccharide	1284:1297	arg1	purity					1299:1304	40.6% polysaccharide purity	1278:1304	40.6% polysaccharide purity	1278:1304	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	16	theme	polysaccharide	1284:1297	arg1	pomace					1270:1275	the distilled wine pomace	1251:1275	the distilled wine pomace (40.6% polysaccharide purity)	1251:1305	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	9	17	theme	different	1359:1367	arg1	composition					1384:1394	different polysaccharide composition	1359:1394	different polysaccharide composition	1359:1394	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	8	18	theme	polysaccharide	1166:1179	arg1	wine					1154:1157	a red wine	1148:1157	a red wine (89.7% polysaccharide purity)	1148:1187	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	18	theme	polysaccharide	1166:1179	arg1	purity					1181:1186	89.7% polysaccharide purity	1160:1186	89.7% polysaccharide purity	1160:1186	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	19	theme	%	1164:1164	arg1	wine					1154:1157	a red wine	1148:1157	a red wine (89.7% polysaccharide purity)	1148:1187	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	19	theme	%	1164:1164	arg1	purity					1181:1186	89.7% polysaccharide purity	1160:1186	89.7% polysaccharide purity	1160:1186	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	20	theme	%	1282:1282	arg1	purity					1299:1304	40.6% polysaccharide purity	1278:1304	40.6% polysaccharide purity	1278:1304	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	20	theme	%	1282:1282	arg1	pomace					1270:1275	the distilled wine pomace	1251:1275	the distilled wine pomace (40.6% polysaccharide purity)	1251:1305	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	2	21	theme	polysaccharides	385:399	arg1	extraction					365:374	the extraction	361:374	the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health	361:503	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	2	22	theme	oenological	440:450	arg1	products					452:459	oenological products	440:459	oenological products	440:459	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	2	23	theme	human	492:496	arg1	health					498:503	human health	492:503	human health	492:503	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	3	24	theme	grape	565:569	arg1	products					586:593	different grape and winemaking products	555:593	different grape and winemaking products	555:593	This study aimed to recover polysaccharides from different grape and winemaking products and provide information about its composition.
35761706	2	25	theme	grape	379:383	arg1	polysaccharides					385:399	grape polysaccharides	379:399	grape polysaccharides	379:399	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	5	26	theme	good	810:813	arg1	source					815:820	a good source	808:820	a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides	808:914	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	10	27	theme	animal-origin	1563:1575	arg1	agents					1592:1597	traditional animal-origin protein fining agents	1551:1597	traditional animal-origin protein fining agents	1551:1597	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	5	28	from	polysaccharides	900:914	arg1	rich					848:851	rich	848:851	rich	848:851	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	8	29	theme	wash	1202:1205	arg1	water					1207:1211	the wash water	1198:1211	the wash water used by the distillery	1198:1234	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	0	30	theme	extracts	35:42	arg1	Characterization					0:15	Characterization	0:15	Characterization of polysaccharide extracts	0:42	Characterization of polysaccharide extracts recovered from different grape and winemaking products.
35761706	2	31	theme	compounds	312:320	arg1	obtention					290:298	the obtention	286:298	the obtention of phenolic compounds	286:320	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	3	32	from	products	586:593	arg1	polysaccharides					534:548	polysaccharides	534:548	polysaccharides from different grape and winemaking products	534:593	This study aimed to recover polysaccharides from different grape and winemaking products and provide information about its composition.
35761706	1	33	theme	valuable	201:208	arg1	compounds					210:218	valuable compounds	201:218	valuable compounds	201:218	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	0	34	theme	polysaccharide	20:33	arg1	extracts					35:42	polysaccharide extracts	20:42	polysaccharide extracts	20:42	Characterization of polysaccharide extracts recovered from different grape and winemaking products.
35761706	9	35	from	market	1418:1423	arg1	non-available					1397:1409	non-available	1397:1409	non-available	1397:1409	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	2	36	theme	phenolic	303:310	arg1	compounds					312:320	phenolic compounds	303:320	phenolic compounds	303:320	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	1	37	theme	compounds	210:218	arg1	valorization					185:196	valorization	185:196	valorization	185:196	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	1	37	theme	compounds	210:218	arg1	recovery					172:179	recovery	172:179	recovery	172:179	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	5	38	theme	White	783:787	arg1	pomace					789:794	White pomace	783:794	White pomace	783:794	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	10	39	theme	Future	1426:1431	arg1	studies					1433:1439	Future studies	1426:1439	Future studies	1426:1439	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	10	40	theme	alternative	1526:1536	arg1	solutions					1538:1546	possible alternative solutions	1517:1546	possible alternative solutions	1517:1546	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	5	41	theme	rich	848:851	arg1	polysaccharides					832:846	polysaccharides	832:846	polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides	832:914	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	10	42	theme	fining	1585:1590	arg1	agents					1592:1597	traditional animal-origin protein fining agents	1551:1597	traditional animal-origin protein fining agents	1551:1597	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	5	43	from	rich	848:851	arg1	PRAG					881:884	PRAG	881:884	PRAG	881:884	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	5	43	from	rich	848:851	arg1	galactose					870:878	galactose	870:878	galactose	870:878	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	5	43	from	rich	848:851	arg1	arabinose					856:864	arabinose	856:864	arabinose	856:864	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	5	43	from	rich	848:851	arg1	polysaccharides					900:914	glucosyl polysaccharides	891:914	glucosyl polysaccharides	891:914	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	8	44	theme	red	1150:1152	arg1	wine					1154:1157	a red wine	1148:1157	a red wine (89.7% polysaccharide purity)	1148:1187	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	44	theme	red	1150:1152	arg1	purity					1181:1186	89.7% polysaccharide purity	1160:1186	89.7% polysaccharide purity	1160:1186	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	0	45	theme	grape	69:73	arg1	products					90:97	different grape and winemaking products	59:97	different grape and winemaking products	59:97	Characterization of polysaccharide extracts recovered from different grape and winemaking products.
35761706	1	46	from	by-products	242:252	arg1	valorization					185:196	valorization	185:196	valorization	185:196	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	1	46	from	by-products	242:252	arg1	recovery					172:179	recovery	172:179	recovery	172:179	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	10	47	theme	stabilizing	1483:1493	arg1	agents					1506:1511	stabilizing or finning agents	1483:1511	stabilizing or finning agents	1483:1511	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	1	48	dep	recovery	172:179	arg1	the					168:170	the	168:170	the	168:170	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	1	49	from	grapes	225:230	arg1	valorization					185:196	valorization	185:196	valorization	185:196	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	1	49	from	grapes	225:230	arg1	recovery					172:179	recovery	172:179	recovery	172:179	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	1	50	theme	important	116:124	arg1	challenges					126:135	the most important challenges	107:135	the most important challenges of the oenological industry	107:163	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	0	51	theme	different	59:67	arg1	products					90:97	different grape and winemaking products	59:97	different grape and winemaking products	59:97	Characterization of polysaccharide extracts recovered from different grape and winemaking products.
35761706	9	52	from	non-available	1397:1409	arg1	market					1418:1423	the market	1414:1423	the market	1414:1423	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	1	53	theme	challenges	126:135	arg1	challenges					126:135	the most important challenges	107:135	the most important challenges of the oenological industry	107:163	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	1	53	theme	challenges	126:135	arg1	One					100:102	One	100:102	One	100:102	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	7	54	theme	polysaccharide	1022:1035	arg1	purity					1037:1042	high polysaccharide purity	1017:1042	high polysaccharide purity (55.5% and 51.9%, respectively)	1017:1074	Both extracts showed high polysaccharide purity (55.5% and 51.9%, respectively).
35761706	4	55	dep	pomace	678:683	arg1	lees					695:698	lees	695:698	lees	695:698	The results obtained with the white pomace and white lees revealed its potential to be exploited to obtain extracts rich in polysaccharides.
35761706	4	55	dep	pomace	678:683	arg1	the					668:670	the	668:670	the	668:670	The results obtained with the white pomace and white lees revealed its potential to be exploited to obtain extracts rich in polysaccharides.
35761706	4	56	from	polysaccharides	766:780	arg1	rich					758:761	rich	758:761	rich	758:761	The results obtained with the white pomace and white lees revealed its potential to be exploited to obtain extracts rich in polysaccharides.
35761706	8	57	dep	rhamnogalacturonan	1094:1111	arg1	type					1113:1116	type II	1113:1119	rhamnogalacturonan type II (RG-II)	1094:1127	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	2	58	contain	have	414:417	arg1	polysaccharides					385:399	grape polysaccharides	379:399	grape polysaccharides	379:399	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	2	58	contain	have	414:417	arg2	potential					427:435	a great potential	419:435	a great potential as oenological products but also for their benefits to human health	419:503	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	8	59	theme	distilled	1255:1263	arg1	purity					1299:1304	40.6% polysaccharide purity	1278:1304	40.6% polysaccharide purity	1278:1304	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	8	59	theme	distilled	1255:1263	arg1	pomace					1270:1275	the distilled wine pomace	1251:1275	the distilled wine pomace (40.6% polysaccharide purity)	1251:1305	Extracts rich in rhamnogalacturonan type II (RG-II) were obtained from a red wine (89.7% polysaccharide purity) and from the wash water used by the distillery after draining the distilled wine pomace (40.6% polysaccharide purity).
35761706	5	60	from	galactose	870:878	arg1	rich					848:851	rich	848:851	rich	848:851	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	2	61	theme	little	327:332	arg1	attention					334:342	little attention	327:342	little attention	327:342	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	1	62	theme	grape	236:240	arg1	by-products					242:252	grape by-products	236:252	grape by-products	236:252	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	0	63	theme	winemaking	79:88	arg1	products					90:97	different grape and winemaking products	59:97	different grape and winemaking products	59:97	Characterization of polysaccharide extracts recovered from different grape and winemaking products.
35761706	2	64	theme	great	421:425	arg1	potential					427:435	a great potential	419:435	a great potential as oenological products but also for their benefits to human health	419:503	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	1	65	theme	oenological	144:154	arg1	industry					156:163	the oenological industry	140:163	the oenological industry	140:163	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35761706	9	66	theme	polysaccharide	1369:1382	arg1	composition					1384:1394	different polysaccharide composition	1359:1394	different polysaccharide composition	1359:1394	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	9	67	theme	new	1325:1327	arg1	lines					1329:1333	new lines	1325:1333	new lines to obtain extracts with different polysaccharide composition, non-available in the market	1325:1423	Our results open new lines to obtain extracts with different polysaccharide composition, non-available in the market.
35761706	10	68	theme	protein	1577:1583	arg1	agents					1592:1597	traditional animal-origin protein fining agents	1551:1597	traditional animal-origin protein fining agents	1551:1597	Future studies are needed to evaluate their potential as stabilizing or finning agents and possible alternative solutions to traditional animal-origin protein fining agents.
35761706	2	69	theme	Recent	255:260	arg1	studies					262:268	Recent studies	255:268	Recent studies	255:268	Recent studies have focused on the obtention of phenolic compounds, but little attention has been paid to the extraction of grape polysaccharides, which could have a great potential as oenological products but also for their benefits to human health.
35761706	5	70	from	arabinose	856:864	arg1	rich					848:851	rich	848:851	rich	848:851	White pomace revealed as a good source to obtain polysaccharides rich in arabinose and galactose (PRAG) and glucosyl polysaccharides.
35761706	1	71	theme	industry	156:163	arg1	challenges					126:135	the most important challenges	107:135	the most important challenges of the oenological industry	107:163	One of the most important challenges of the oenological industry is the recovery and valorization of valuable compounds from grapes and grape by-products.
35038468	1	0	theme	intestinal	373:382	arg1	flora					384:388	intestinal flora	373:388	intestinal flora	373:388	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	1	theme	capsular	174:181	arg1	GLU-CPS-1					213:221	GLU-CPS-1	213:221	GLU-CPS-1	213:221	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	1	theme	capsular	174:181	arg1	WL-CPS-1					200:207	WL-CPS-1	200:207	WL-CPS-1	200:207	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	1	theme	capsular	174:181	arg1	polysaccharides					183:197	Two capsular polysaccharides	170:197	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions	170:305	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	0	2	from	conditions	69:78	arg1	polysaccharides					30:44	Nostoc flagelliforme capsular polysaccharides	0:44	Nostoc flagelliforme capsular polysaccharides from different culture conditions	0:78	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	1	3	theme	mixotrophic	276:286	arg1	conditions					296:305	normal and mixotrophic culture conditions	265:305	normal and mixotrophic culture conditions	265:305	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	4	from	effect	363:368	arg1	flora					384:388	intestinal flora	373:388	intestinal flora	373:388	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	4	from	effect	363:368	arg1	mice					402:405	C57BL/6J mice	393:405	C57BL/6J mice respectively	393:418	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	5	theme	culture	288:294	arg1	conditions					296:305	normal and mixotrophic culture conditions	265:305	normal and mixotrophic culture conditions	265:305	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	3	6	theme	genes	600:604	arg1	expression					569:578	the expression	565:578	the expression of lipid metabolism genes	565:604	They both improved the lipid level by affecting the expression of lipid metabolism genes.
35038468	7	7	dep	higher	1020:1025	arg1	in					1027:1028	in	1027:1028	in	1027:1028	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	0	8	theme	intestinal	116:125	arg1	flora					127:131	intestinal flora	116:131	intestinal flora in C57BL/6J mice to varying degrees	116:167	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	1	9	theme	C57BL/6J	393:400	arg1	mice					402:405	C57BL/6J mice	393:405	C57BL/6J mice respectively	393:418	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	10	from	activity	350:357	arg1	flora					384:388	intestinal flora	373:388	intestinal flora	373:388	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	10	from	activity	350:357	arg1	mice					402:405	C57BL/6J mice	393:405	C57BL/6J mice respectively	393:418	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	0	11	theme	C57BL/6J	136:143	arg1	mice					145:148	C57BL/6J mice	136:148	C57BL/6J mice	136:148	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	7	12	theme	polysaccharides	1181:1195	arg1	bioactivity					1166:1176	the bioactivity	1162:1176	the bioactivity of polysaccharides	1162:1195	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	3	13	theme	lipid	583:587	arg1	genes					600:604	lipid metabolism genes	583:604	lipid metabolism genes	583:604	They both improved the lipid level by affecting the expression of lipid metabolism genes.
35038468	8	14	theme	polysaccharides	1301:1315	arg1	application					1269:1279	application	1269:1279	application of N. flagelliforme polysaccharides with higher activity in hypolipidemia	1269:1353	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	5	15	theme	chain	811:815	arg1	acids					823:827	short chain fatty acids	805:827	the short chain fatty acids (SCFAs) synthesis	801:845	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	5	15	theme	chain	811:815	arg1	SCFAs					830:834	SCFAs	830:834	SCFAs	830:834	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	4	16	dep	down-regulated	612:625	arg1	decreased					730:738	decreased	730:738	decreased the atherosclerosis index and MDA content	730:780	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	4	17	theme	IL-1β	641:645	arg1	levels					647:652	the TNF-α and IL-1β levels	627:652	the TNF-α and IL-1β levels in serum	627:661	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	2	18	theme	previous	499:506	arg1	studies					508:514	previous studies	499:514	previous studies	499:514	Their molecular weight and monosaccharide composition have been determined in previous studies.
35038468	4	19	from	liver	719:723	arg1	activity					684:691	the activity	680:691	the activity of antioxidant enzymes in liver	680:723	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	5	20	theme	short	805:809	arg1	acids					823:827	short chain fatty acids	805:827	the short chain fatty acids (SCFAs) synthesis	801:845	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	5	20	theme	short	805:809	arg1	SCFAs					830:834	SCFAs	830:834	SCFAs	830:834	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	0	21	theme	flagelliforme	7:19	arg1	polysaccharides					30:44	Nostoc flagelliforme capsular polysaccharides	0:44	Nostoc flagelliforme capsular polysaccharides from different culture conditions	0:78	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	1	22	used	used	312:315	arg2	polysaccharides					183:197	Two capsular polysaccharides	170:197	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions	170:305	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	22	used	used	312:315	arg2	GLU-CPS-1					213:221	GLU-CPS-1	213:221	GLU-CPS-1	213:221	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	22	used	used	312:315	arg2	WL-CPS-1					200:207	WL-CPS-1	200:207	WL-CPS-1	200:207	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	7	23	theme	higher	1020:1025	arg1	activity					1035:1042	higher in vivo activity	1020:1042	higher in vivo activity	1020:1042	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	8	24	theme	culture	1368:1374	arg1	conditions					1376:1385	culture conditions	1368:1385	culture conditions	1368:1385	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	2	25	theme	molecular	427:435	arg1	weight					437:442	Their molecular weight	421:442	Their molecular weight	421:442	Their molecular weight and monosaccharide composition have been determined in previous studies.
35038468	0	26	theme	Nostoc	0:5	arg1	polysaccharides					30:44	Nostoc flagelliforme capsular polysaccharides	0:44	Nostoc flagelliforme capsular polysaccharides from different culture conditions	0:78	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	6	27	theme	pathogenic	880:889	arg1	bacteria					891:898	pathogenic bacteria	880:898	pathogenic bacteria	880:898	They decreased the abundance of pathogenic bacteria and increased the abundance of probiotics positively correlated with SCFAs.
35038468	1	28	dep	polysaccharides	183:197	arg1	GLU-CPS-1					213:221	GLU-CPS-1	213:221	GLU-CPS-1	213:221	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	28	dep	polysaccharides	183:197	arg1	WL-CPS-1					200:207	WL-CPS-1	200:207	WL-CPS-1	200:207	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	1	28	dep	polysaccharides	183:197	arg1	polysaccharides					183:197	Two capsular polysaccharides	170:197	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions	170:305	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	4	29	from	enzymes	708:714	arg1	liver					719:723	liver	719:723	liver	719:723	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	7	30	theme	culture	1219:1225	arg1	conditions					1227:1236	culture conditions	1219:1236	culture conditions	1219:1236	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	0	31	theme	capsular	21:28	arg1	polysaccharides					30:44	Nostoc flagelliforme capsular polysaccharides	0:44	Nostoc flagelliforme capsular polysaccharides from different culture conditions	0:78	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	4	32	theme	TNF-α	631:635	arg1	levels					647:652	the TNF-α and IL-1β levels	627:652	the TNF-α and IL-1β levels in serum	627:661	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	6	33	theme	probiotics	931:940	arg1	abundance					918:926	the abundance	914:926	the abundance of probiotics positively correlated with SCFAs	914:973	They decreased the abundance of pathogenic bacteria and increased the abundance of probiotics positively correlated with SCFAs.
35038468	0	34	theme	different	51:59	arg1	conditions					69:78	different culture conditions	51:78	different culture conditions	51:78	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	8	35	from	activity	1329:1336	arg1	hypolipidemia					1341:1353	hypolipidemia	1341:1353	hypolipidemia	1341:1353	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	4	36	theme	antioxidant	696:706	arg1	enzymes					708:714	antioxidant enzymes	696:714	antioxidant enzymes in liver	696:723	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	4	37	from	activity	684:691	arg1	liver					719:723	liver	719:723	liver	719:723	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	4	38	theme	enzymes	708:714	arg1	activity					684:691	the activity	680:691	the activity of antioxidant enzymes in liver	680:723	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	8	39	theme	higher	1322:1327	arg1	activity					1329:1336	higher activity	1322:1336	higher activity in hypolipidemia	1322:1353	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	1	40	theme	hypolipidemic	336:348	arg1	activity					350:357	the hypolipidemic activity	332:357	the hypolipidemic activity	332:357	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	0	41	theme	varying	153:159	arg1	degrees					161:167	varying degrees	153:167	varying degrees	153:167	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	1	42	theme	Nostoc	238:243	arg1	flagelliforme					245:257	Nostoc flagelliforme	238:257	Nostoc flagelliforme	238:257	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	7	43	theme	lipid	1128:1132	arg1	metabolism					1134:1143	lipid metabolism	1128:1143	lipid metabolism	1128:1143	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	7	44	theme	gene	1109:1112	arg1	expression					1114:1123	the gene expression	1105:1123	the gene expression of lipid metabolism	1105:1143	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	0	45	theme	culture	61:67	arg1	conditions					69:78	different culture conditions	51:78	different culture conditions	51:78	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	7	46	theme	metabolism	1134:1143	arg1	expression					1114:1123	the gene expression	1105:1123	the gene expression of lipid metabolism	1105:1143	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	4	47	theme	MDA	770:772	arg1	content					774:780	MDA content	770:780	MDA content	770:780	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	7	48	dep	in	1027:1028	arg1	vivo					1030:1033	vivo	1030:1033	vivo	1030:1033	Compared with WL-CPS-1, GLU-CPS-1 exhibited higher in vivo activity and enriched Odoribacter and Alloprevotella correlating with the gene expression of lipid metabolism, suggesting that the bioactivity of polysaccharides could be regulated by culture conditions.
35038468	3	49	theme	metabolism	589:598	arg1	genes					600:604	lipid metabolism genes	583:604	lipid metabolism genes	583:604	They both improved the lipid level by affecting the expression of lipid metabolism genes.
35038468	0	50	from	flora	127:131	arg1	mice					145:148	C57BL/6J mice	136:148	C57BL/6J mice	136:148	Nostoc flagelliforme capsular polysaccharides from different culture conditions improve hyperlipidemia and regulate intestinal flora in C57BL/6J mice to varying degrees.
35038468	8	51	theme	N.	1284:1285	arg1	polysaccharides					1301:1315	N. flagelliforme polysaccharides	1284:1315	N. flagelliforme polysaccharides with higher activity in hypolipidemia	1284:1353	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	3	52	theme	lipid	540:544	arg1	level					546:550	the lipid level	536:550	the lipid level	536:550	They both improved the lipid level by affecting the expression of lipid metabolism genes.
35038468	5	53	theme	fatty	817:821	arg1	acids					823:827	short chain fatty acids	805:827	the short chain fatty acids (SCFAs) synthesis	801:845	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	5	53	theme	fatty	817:821	arg1	SCFAs					830:834	SCFAs	830:834	SCFAs	830:834	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	2	54	theme	monosaccharide	448:461	arg1	composition					463:473	monosaccharide composition	448:473	monosaccharide composition	448:473	Their molecular weight and monosaccharide composition have been determined in previous studies.
35038468	8	55	with	polysaccharides	1301:1315	arg1	activity					1329:1336	higher activity	1322:1336	higher activity in hypolipidemia	1322:1353	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	6	56	theme	bacteria	891:898	arg1	abundance					867:875	the abundance	863:875	the abundance of pathogenic bacteria	863:898	They decreased the abundance of pathogenic bacteria and increased the abundance of probiotics positively correlated with SCFAs.
35038468	4	57	theme	atherosclerosis	744:758	arg1	index					760:764	the atherosclerosis index	740:764	the atherosclerosis index	740:764	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35038468	1	58	theme	normal	265:270	arg1	conditions					296:305	normal and mixotrophic culture conditions	265:305	normal and mixotrophic culture conditions	265:305	Two capsular polysaccharides (WL-CPS-1 and GLU-CPS-1) purified from Nostoc flagelliforme under normal and mixotrophic culture conditions were used to investigate the hypolipidemic activity and effect on intestinal flora in C57BL/6J mice respectively.
35038468	5	59	theme	acids	823:827	arg1	synthesis					837:845	the short chain fatty acids (SCFAs) synthesis	801:845	the short chain fatty acids (SCFAs) synthesis	801:845	They up-regulated the short chain fatty acids (SCFAs) synthesis.
35038468	3	60	dep	improved	527:534	arg1	both					522:525	both	522:525	both	522:525	They both improved the lipid level by affecting the expression of lipid metabolism genes.
35038468	8	61	theme	flagelliforme	1287:1299	arg1	polysaccharides					1301:1315	N. flagelliforme polysaccharides	1284:1315	N. flagelliforme polysaccharides with higher activity in hypolipidemia	1284:1353	These findings contributed to application of N. flagelliforme polysaccharides with higher activity in hypolipidemia by adjusting culture conditions.
35038468	4	62	from	levels	647:652	arg1	serum					657:661	serum	657:661	serum	657:661	They down-regulated the TNF-α and IL-1β levels in serum and up-regulated the activity of antioxidant enzymes in liver thus decreased the atherosclerosis index and MDA content.
35604046	6	0	from	decrease	898:905	arg1	plasma					880:885	plasma	880:885	plasma	880:885	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	8	1	theme	insulin	1127:1133	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	1	theme	insulin	1127:1133	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	0	2	dep	in	118:119	arg1	vivo					121:124	vivo	121:124	vivo	121:124	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	1	3	theme	accurate	241:248	arg1	release					270:276	accurate and demandable drug release	241:276	accurate and demandable drug release	241:276	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	0	4	theme	composite	82:90	arg1	hydrogel					92:99	electrodeposited chitosan composite hydrogel	56:99	electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	56:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	6	5	theme	glucose	916:922	arg1	decrease					898:905	stable decrease	891:905	stable decrease of blood glucose	891:922	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	6	5	theme	glucose	916:922	arg1	release					869:875	controllable insulin release	848:875	controllable insulin release in plasma	848:885	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	1	6	theme	controlled	151:160	arg1	release					167:173	Electrical signal controlled drug release	133:173	Electrical signal controlled drug release from polymeric drug delivery system	133:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	8	7	from	hydrogel	1168:1175	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	7	from	hydrogel	1168:1175	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	5	8	theme	fast	726:729	arg1	release					749:755	fast responsive pulsed release	726:755	fast responsive pulsed release of insulin	726:766	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	6	9	theme	blood	910:914	arg1	glucose					916:922	blood glucose	910:922	blood glucose	910:922	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	6	10	dep	revealed	839:846	arg1	achieved					931:938	achieved	931:938	can be achieved by using appropriate electrical signal	924:977	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	1	11	theme	demandable	254:263	arg1	release					270:276	accurate and demandable drug release	241:276	accurate and demandable drug release	241:276	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	5	12	theme	responsive	731:740	arg1	release					749:755	fast responsive pulsed release	726:755	fast responsive pulsed release of insulin	726:766	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	0	13	dep	in	105:106	arg1	vitro					108:112	vitro	108:112	vitro	108:112	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	1	14	theme	signal	144:149	arg1	release					167:173	Electrical signal controlled drug release	133:173	Electrical signal controlled drug release from polymeric drug delivery system	133:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	1	15	theme	drug	265:268	arg1	release					270:276	accurate and demandable drug release	241:276	accurate and demandable drug release	241:276	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	5	16	theme	pulsed	742:747	arg1	release					749:755	fast responsive pulsed release	726:755	fast responsive pulsed release of insulin	726:766	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	3	17	theme	formed	441:446	arg1	structure					448:456	The formed structure	437:456	The formed structure in chitosan composite hydrogel	437:487	The formed structure in chitosan composite hydrogel entrapped insulin efficiently, which were proved by various techniques.
35604046	1	18	theme	drug	162:165	arg1	release					167:173	Electrical signal controlled drug release	133:173	Electrical signal controlled drug release from polymeric drug delivery system	133:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	0	19	theme	in	105:106	arg1	study					126:130	An in vitro and in vivo study	102:130	electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	56:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	6	20	theme	stable	891:896	arg1	decrease					898:905	stable decrease	891:905	stable decrease of blood glucose	891:922	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	3	21	from	structure	448:456	arg1	hydrogel					480:487	chitosan composite hydrogel	461:487	chitosan composite hydrogel	461:487	The formed structure in chitosan composite hydrogel entrapped insulin efficiently, which were proved by various techniques.
35604046	8	22	theme	administration	1196:1209	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	22	theme	administration	1196:1209	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	23	theme	promising	1186:1194	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	23	theme	promising	1186:1194	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	6	24	from	release	869:875	arg1	plasma					880:885	plasma	880:885	plasma	880:885	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	6	25	theme	electrical	961:970	arg1	signal					972:977	appropriate electrical signal	949:977	appropriate electrical signal	949:977	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	8	26	theme	chitosan	1148:1155	arg1	hydrogel					1168:1175	chitosan composited hydrogel	1148:1175	chitosan composited hydrogel	1148:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	0	27	dep	hydrogel	92:99	arg1	study					126:130	An in vitro and in vivo study	102:130	electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	56:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	7	28	theme	electrical	1050:1059	arg1	signals					1061:1067	electrical signals	1050:1067	electrical signals	1050:1067	In addition, HE staining suggested negligible effect to the tissue by electrical signals.
35604046	4	29	theme	cell	669:672	arg1	attachment					674:683	cell attachment	669:683	cell attachment	669:683	In addition, the drug loaded chitosan composite hydrogel demonstrated good biocompatibility as suggested by cell attachment.
35604046	0	30	theme	Electrical	0:9	arg1	signals					11:17	Electrical signals	0:17	Electrical signals	0:17	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	6	31	theme	insulin	861:867	arg1	release					869:875	controllable insulin release	848:875	controllable insulin release in plasma	848:885	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	6	32	theme	diabetic	825:832	arg1	rats					834:837	diabetic rats	825:837	diabetic rats	825:837	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	3	33	dep	entrapped	489:497	arg1	proved					531:536	proved	531:536	were proved by various techniques	526:558	The formed structure in chitosan composite hydrogel entrapped insulin efficiently, which were proved by various techniques.
35604046	1	34	theme	polymeric	180:188	arg1	system					204:209	polymeric drug delivery system	180:209	polymeric drug delivery system	180:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	0	35	theme	in	118:119	arg1	study					126:130	An in vitro and in vivo study	102:130	electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	56:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	6	36	theme	in	803:804	arg1	experiment					811:820	The in vivo experiment	799:820	The in vivo experiment in diabetic rats	799:837	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	2	37	dep	nanoplates	325:334	arg1	LDHs					364:367	LDHs	364:367	LDHs	364:367	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	2	37	dep	nanoplates	325:334	arg1	hydroxides					352:361	layered double hydroxides	337:361	layered double hydroxides	337:361	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	6	38	dep	in	803:804	arg1	vivo					806:809	vivo	806:809	vivo	806:809	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	1	39	theme	drug	190:193	arg1	system					204:209	polymeric drug delivery system	180:209	polymeric drug delivery system	180:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	5	40	theme	release	700:706	arg1	experiment					708:717	In vitro drug release experiment	686:717	In vitro drug release experiment	686:717	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	0	41	from	hydrogel	92:99	arg1	release					32:38	the release	28:38	the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	28:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	3	42	theme	various	541:547	arg1	techniques					549:558	various techniques	541:558	various techniques	541:558	The formed structure in chitosan composite hydrogel entrapped insulin efficiently, which were proved by various techniques.
35604046	1	43	theme	delivery	195:202	arg1	system					204:209	polymeric drug delivery system	180:209	polymeric drug delivery system	180:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	5	44	theme	electrical	779:788	arg1	signals					790:796	electrical signals	779:796	electrical signals	779:796	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	3	45	theme	composite	470:478	arg1	hydrogel					480:487	chitosan composite hydrogel	461:487	chitosan composite hydrogel	461:487	The formed structure in chitosan composite hydrogel entrapped insulin efficiently, which were proved by various techniques.
35604046	8	46	theme	electrical	1098:1107	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	46	theme	electrical	1098:1107	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	6	47	from	experiment	811:820	arg1	rats					834:837	diabetic rats	825:837	diabetic rats	825:837	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	6	48	theme	appropriate	949:959	arg1	signal					972:977	appropriate electrical signal	949:977	appropriate electrical signal	949:977	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	8	49	theme	composited	1157:1166	arg1	hydrogel					1168:1175	chitosan composited hydrogel	1148:1175	chitosan composited hydrogel	1148:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	1	50	from	system	204:209	arg1	release					167:173	Electrical signal controlled drug release	133:173	Electrical signal controlled drug release from polymeric drug delivery system	133:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	4	51	theme	good	631:634	arg1	biocompatibility					636:651	good biocompatibility as suggested by cell attachment	631:683	good biocompatibility as suggested by cell attachment	631:683	In addition, the drug loaded chitosan composite hydrogel demonstrated good biocompatibility as suggested by cell attachment.
35604046	5	52	dep	In	686:687	arg1	vitro					689:693	vitro	689:693	vitro	689:693	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	8	53	theme	controlled	1116:1125	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	53	theme	controlled	1116:1125	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	5	54	theme	insulin	760:766	arg1	release					749:755	fast responsive pulsed release	726:755	fast responsive pulsed release of insulin	726:766	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	8	55	theme	signal	1109:1114	arg1	route					1211:1215	a promising administration route	1184:1215	a promising administration route for insulin	1184:1227	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	8	55	theme	signal	1109:1114	arg1	release					1135:1141	the electrical signal controlled insulin release	1094:1141	the electrical signal controlled insulin release from chitosan composited hydrogel	1094:1175	This work suggests that the electrical signal controlled insulin release from chitosan composited hydrogel may be a promising administration route for insulin.
35604046	3	56	theme	chitosan	461:468	arg1	hydrogel					480:487	chitosan composite hydrogel	461:487	chitosan composite hydrogel	461:487	The formed structure in chitosan composite hydrogel entrapped insulin efficiently, which were proved by various techniques.
35604046	0	57	theme	insulin	43:49	arg1	release					32:38	the release	28:38	the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	28:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	5	58	theme	drug	695:698	arg1	experiment					708:717	In vitro drug release experiment	686:717	In vitro drug release experiment	686:717	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	6	59	theme	controllable	848:859	arg1	release					869:875	controllable insulin release	848:875	controllable insulin release in plasma	848:885	The in vivo experiment in diabetic rats revealed controllable insulin release in plasma and stable decrease of blood glucose can be achieved by using appropriate electrical signal.
35604046	2	60	theme	inorganic	315:323	arg1	nanoplates					325:334	inorganic nanoplates	315:334	inorganic nanoplates (layered double hydroxides, LDHs)	315:368	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	5	61	theme	In	686:687	arg1	experiment					708:717	In vitro drug release experiment	686:717	In vitro drug release experiment	686:717	In vitro drug release experiment showed fast responsive pulsed release of insulin by biasing electrical signals.
35604046	2	62	with	co-electrodeposition	401:420	arg1	chitosan					427:434	chitosan	427:434	chitosan	427:434	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	4	63	theme	loaded	583:588	arg1	hydrogel					609:616	loaded chitosan composite hydrogel	583:616	the drug loaded chitosan composite hydrogel	574:616	In addition, the drug loaded chitosan composite hydrogel demonstrated good biocompatibility as suggested by cell attachment.
35604046	7	64	theme	negligible	1015:1024	arg1	effect					1026:1031	negligible effect	1015:1031	negligible effect	1015:1031	In addition, HE staining suggested negligible effect to the tissue by electrical signals.
35604046	7	65	theme	HE	993:994	arg1	staining					996:1003	HE staining	993:1003	HE staining	993:1003	In addition, HE staining suggested negligible effect to the tissue by electrical signals.
35604046	2	66	theme	double	345:350	arg1	LDHs					364:367	LDHs	364:367	LDHs	364:367	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	2	66	theme	double	345:350	arg1	hydroxides					352:361	layered double hydroxides	337:361	layered double hydroxides	337:361	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	1	67	theme	efficient	223:231	arg1	way					233:235	an efficient way	220:235	an efficient way for accurate and demandable drug release	220:276	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	0	68	theme	chitosan	73:80	arg1	hydrogel					92:99	electrodeposited chitosan composite hydrogel	56:99	electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	56:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	4	69	dep	drug	578:581	arg1	hydrogel					609:616	loaded chitosan composite hydrogel	583:616	the drug loaded chitosan composite hydrogel	574:616	In addition, the drug loaded chitosan composite hydrogel demonstrated good biocompatibility as suggested by cell attachment.
35604046	2	70	theme	copper	386:391	arg1	wire					393:396	a copper wire	384:396	a copper wire	384:396	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	2	71	theme	layered	337:343	arg1	LDHs					364:367	LDHs	364:367	LDHs	364:367	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	2	71	theme	layered	337:343	arg1	hydroxides					352:361	layered double hydroxides	337:361	layered double hydroxides	337:361	In this work, insulin was loaded on inorganic nanoplates (layered double hydroxides, LDHs) and coated on a copper wire by co-electrodeposition with chitosan.
35604046	4	72	theme	composite	599:607	arg1	hydrogel					609:616	loaded chitosan composite hydrogel	583:616	the drug loaded chitosan composite hydrogel	574:616	In addition, the drug loaded chitosan composite hydrogel demonstrated good biocompatibility as suggested by cell attachment.
35604046	0	73	theme	electrodeposited	56:71	arg1	hydrogel					92:99	electrodeposited chitosan composite hydrogel	56:99	electrodeposited chitosan composite hydrogel: An in vitro and in vivo study	56:130	Electrical signals regulate the release of insulin from electrodeposited chitosan composite hydrogel: An in vitro and in vivo study.
35604046	1	74	theme	Electrical	133:142	arg1	release					167:173	Electrical signal controlled drug release	133:173	Electrical signal controlled drug release from polymeric drug delivery system	133:209	Electrical signal controlled drug release from polymeric drug delivery system provides an efficient way for accurate and demandable drug release.
35604046	4	75	theme	chitosan	590:597	arg1	hydrogel					609:616	loaded chitosan composite hydrogel	583:616	the drug loaded chitosan composite hydrogel	574:616	In addition, the drug loaded chitosan composite hydrogel demonstrated good biocompatibility as suggested by cell attachment.